Health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
healthcare B-outcome ['Resource-use']
resource I-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
, O
and O
days B-outcome ['Life-Impact']
missed I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
or O
school B-outcome ['Life-Impact']
were O
also O
reported O
. O
['Life-Impact', 'Resource-use', 'Life-Impact', 'Life-Impact']

In O
the O
second O
part O
of O
the O
study O
, O
an O
initial O
infusion O
of O
170 O
ng.kg-1 O
x O
min-1 O
was O
chosen O
, O
followed O
by O
10 O
ng.kg-1 O
x O
min-1 O
for O
maintenance O
. O
[]

Maintenance O
of O
sinus O
rhythm O
after O
conversion O
to O
sinus O
rhythm O
. O
[]

Furthermore O
, O
these O
model O
fits O
were O
improved O
by O
including O
the O
most O
significant O
clinical O
factors O
. O
[]

BACKGROUND O
There O
is O
increasing O
evidence O
that O
dietary O
factors O
may O
play O
a O
role O
in O
the O
production O
, O
metabolism O
, O
and O
bioavailability O
of O
sex O
hormones O
and O
their O
impact O
on O
target O
tissues O
. O
[]

Low O
intensity O
physical O
training O
in O
older O
subjects O
. O
[]

METHODS O
This O
randomized O
study O
compares O
the O
2-year O
follow-up O
results O
after O
102 O
tension-free O
hernioplasties O
with O
implantation O
of O
a O
prolene O
mesh O
in O
all O
groin O
hernias O
to O
53 O
Cooper O
ligament O
repairs O
in O
direct O
hernias O
and O
53 O
abdominal O
ring O
repairs O
in O
indirect O
hernias O
. O
[]

The O
health O
seeking O
behaviour O
outcome O
measure O
included O
knowledge O
regarding O
anaemia O
, O
food O
selection O
ability O
, O
increase O
in O
haemoglobin O
level O
and O
compliance O
to O
iron O
supplementation O
. O
[]

Of O
interest O
, O
wounds O
were O
debrided O
at O
baseline O
followed O
by O
a O
quantitative O
culture O
biopsy O
. O
[]

All O
patients O
were O
instructed O
to O
apply O
compresses O
to O
each O
eye O
for O
5-10 O
minutes O
twice O
daily O
for O
14 O
days O
. O
[]

There O
were O
no O
differences O
among O
groups O
at O
T1 O
and O
T2 O
. O
[]

Subjective O
indicators O
of O
image O
quality O
indicated O
a O
reduction O
in O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effect O
of O
extracorporeal O
shock O
wave O
therapy O
( O
ESWT O
) O
in O
patients O
with O
chronically O
painful O
proximal O
plantar O
fasciitis O
with O
a O
further O
conventional O
conservative O
treatment O
. O
[]

On O
active O
drug O
most O
of O
the O
children O
lost B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
serotonin I-outcome ['Physiological-Clinical']
levels O
fell O
by O
an O
average O
of O
60 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
calcium O
supplementation O
on O
bone O
density O
in O
premenarcheal O
females O
: O
a O
co-twin O
approach O
. O
[]

Galantamine O
and O
risperidone O
were O
both O
safe O
and O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
administered O
either O
alone O
or O
together O
. O
['Life-Impact']

The O
recovery B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
vecuronium I-outcome ['Physiological-Clinical']
after O
stopping O
infusion O
at O
10 O
% O
recovery O
was O
also O
evaluated O
. O
['Physiological-Clinical']

Their O
average O
age O
was O
45 O
years O
, O
91 O
% O
were O
male O
, O
58 O
% O
were O
white O
, O
40 O
% O
served O
in O
Iraq O
or O
Afghanistan O
, O
and O
42 O
% O
served O
in O
Vietnam O
. O
[]

severity B-outcome ['Physiological-Clinical']
, O
duration O
and O
frequency O
. O
['Physiological-Clinical']

Failure O
of O
lithium O
to O
reduce O
period O
of O
neutropenia O
during O
induction O
therapy O
of O
acute O
myeloid O
leukemia O
. O
[]

Therefore O
, O
we O
tested O
the O
hypothesis O
that O
two O
dopaminergic O
( O
DA O
) O
drugs O
have O
a O
similar O
5-HT O
effect O
underlying O
the O
therapeutic O
efficiency O
. O
[]

In O
the O
closure O
group O
, O
the O
incidence O
was O
52 O
% O
( O
16/31 O
) O
, O
but O
in O
the O
no-closure O
group O
it O
was O
only O
23 O
% O
( O
7/30 O
) O
; O
the O
incidence O
in O
the O
no-closure O
group O
was O
significantly O
lower O
( O
P O
< O
0.05 O
) O
. O
[]

METHODS O
Patients O
that O
had O
nonexudative O
age-related O
macular O
degeneration O
( O
AMD O
) O
and O
certain O
hemorheologic O
abnormalities O
were O
randomized O
to O
either O
rheopheresis O
or O
sham O
treatment O
in O
a O
2:1 O
fashion O
. O
[]

Significance O
differences O
of O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
complication B-outcome ['Adverse-effects']
rate O
and O
postoperative B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
between O
those O
groups O
observed O
statistically O
. O
['Life-Impact', 'Adverse-effects', 'Resource-use']

Although O
an O
increasing O
number O
of O
group-based O
programs O
for O
the O
improvement O
of O
social O
skills O
have O
been O
described O
, O
randomized O
controlled O
trials O
are O
needed O
to O
evaluate O
their O
efficacy O
. O
[]

Following O
acid O
infusion O
, O
pain B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
decreased O
( O
17 O
( O
4 O
) O
% O
; O
p=0.01 O
) O
in O
the O
UO O
, O
suggesting O
the O
presence O
of O
secondary O
hyperalgesia O
. O
['Physiological-Clinical']

In O
burned O
areas O
, O
skin B-outcome ['Physiological-Clinical']
contents I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
both I-outcome ['Physiological-Clinical']
selenium I-outcome ['Physiological-Clinical']
( O
P=0.05 O
) O
and O
zinc O
( O
P=0.04 O
) O
increased O
significantly O
by O
day O
20 O
. O
['Physiological-Clinical']

Long-term O
treatment O
with O
atomoxetine O
for O
attention-deficit/hyperactivity B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
children O
and O
adolescents O
with O
autism O
spectrum O
disorder O
: O
an O
open-label O
extension O
study O
. O
['Life-Impact']

Comparison O
of O
prostate-specific O
antigen O
corrected O
for O
total O
prostate O
volume O
and O
transition O
zone O
volume O
in O
a O
population-based O
screening O
study O
. O
[]

The O
6-year O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
EFS O
) O
was O
85 O
% O
+/- O
2 O
% O
for O
dexamethasone O
and O
77 O
% O
+/- O
2 O
% O
for O
prednisone O
( O
P O
=.002 O
) O
. O
['Mortality']

Failure O
increased O
the O
subject O
's O
autonomic B-outcome ['Physiological-Clinical']
arousal I-outcome ['Physiological-Clinical']
, O
as O
measured O
by O
photoplethysmographic O
sensors O
, O
in O
all O
stimulation O
conditions O
, O
but O
only O
the O
condition O
with O
aversive O
stimulation O
increased O
the O
speed B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
clenching I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
The O
proportions O
of O
missing O
values O
per O
patient O
were O
low O
for O
both O
questionnaires O
( O
0.54 O
% O
for O
the O
CRQ O
and O
2 O
% O
for O
the O
SGRQ O
) O
. O
[]

A O
randomised O
, O
double-blind O
, O
parallel O
design O
, O
multi-institutional O
, O
non-inferiority O
phase O
IV O
trial O
of O
imidafenacin O
versus O
fesoterodine O
for O
overactive O
bladder O
. O
[]

The O
authors O
wished O
to O
determine O
the O
safety O
and O
tolerability O
of O
this O
drug O
, O
and O
the O
reduction O
of O
Abeta O
in O
plasma O
and O
cerebrospinal O
fluid O
( O
CSF O
) O
after O
multiple O
doses O
. O
[]

METHODS O
A O
total O
of O
242 O
patients O
with O
type O
III O
prostatitis O
diagnosed O
by O
the O
NIH O
criteria O
were O
randomly O
divided O
into O
an O
experimental O
and O
a O
control O
group O
of O
equal O
number O
, O
the O
former O
treated O
with O
Compound O
Xuanju O
Capsule O
+ O
Tamsulosin O
Hydrochloride O
, O
and O
the O
latter O
with O
Quinolinone O
antibiotics O
+ O
Tamsulosin O
and O
Hydrochloride O
, O
both O
for O
6 O
months O
. O
[]

PURPOSE O
To O
compare O
the O
efficacy O
( O
sustained O
virologic O
suppression O
) O
and O
safety/tolerability O
of O
a O
switch O
to O
lamivudine O
300 O
mg O
once O
daily O
( O
QD O
) O
versus O
continued O
lamivudine O
150 O
mg O
twice O
daily O
( O
BID O
) O
in O
virologically O
suppressed O
patients O
( O
HIV-1 O
RNA O
< O
400 O
copies/mL O
for O
> O
or O
=3 O
months O
) O
on O
stable O
( O
> O
or O
=6 O
months O
) O
therapy O
with O
lamivudine O
150 O
mg O
BID O
plus O
stavudine O
and O
either O
indinavir O
or O
nelfinavir O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
a O
decision O
aid O
( O
DA O
) O
on O
women O
's O
knowledge O
of O
the O
benefits O
and O
harms O
of O
screening O
and O
on O
their O
ability O
to O
make O
an O
informed O
decision O
. O
[]

Blinded O
assessments O
may O
miss O
finer O
nuances O
of O
wound B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
, O
but O
are O
likely O
to O
be O
more O
accurate O
. O
['Physiological-Clinical']

Prospective O
randomized O
controlled O
trial O
comparing O
plasmakinetic O
vaporesection O
and O
conventional O
transurethral O
resection O
of O
the O
prostate O
. O
[]

We O
examined O
the O
influence O
on O
carbohydrate O
and O
lipoprotein O
metabolism O
of O
oral O
contraceptives O
( O
OCs O
) O
containing O
two O
new O
third-generation O
progestogens O
, O
desogestrel O
and O
gestodene O
. O
[]

The O
integration O
and O
control O
of O
systemic O
immune O
responses O
depends O
on O
the O
regulated O
trafficking O
of O
T-lymphocytes O
. O
[]

Electrocardiograms O
for O
signal O
averaging O
were O
recorded O
from O
electrodes O
left O
in O
a O
constant O
location O
. O
[]

Further O
research O
is O
needed O
to O
fully O
elucidate O
the O
role O
of O
lactoferrin O
, O
and O
possible O
benefits O
during O
different O
feeding O
conditions O
or O
milk O
sources O
. O
[]

Analgesia O
was O
initiated O
with O
10 O
ml O
of O
the O
study O
solution O
and O
maintained O
with O
10-ml O
top-ups O
. O
[]

Calves O
were O
housed O
in O
individual O
pens O
in O
either O
an O
open-sided O
barn O
or O
hutches O
. O
[]

While O
the O
efficacy O
index O
of O
the O
two O
drugs O
was O
similar O
( O
approximately O
60 O
% O
) O
, O
they O
differed O
greatly O
in O
their O
profile O
of O
side-effects B-outcome ['Adverse-effects']
. O
['Adverse-effects']

The O
treatment O
condition O
resulted O
in O
significant O
reduction O
in O
hyperactivity/impulsivity B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
early B-outcome ['Life-Impact']
aggressive I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
delinquent I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
, O
as O
well O
as O
significant O
improvement O
in O
several O
other O
functional B-outcome ['Life-Impact']
domains O
. O
['Life-Impact', 'Life-Impact']

Individuals O
living O
in O
better O
housing O
were O
less O
likely O
to O
comply B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
referral I-outcome ['Life-Impact']
( O
OR=0.79 O
; O
CI O
: O
0.65-0.95 O
) O
. O
['Life-Impact']

PURPOSE O
We O
evaluated O
the O
efficacy O
and O
safety O
of O
silodosin O
for O
treatment O
of O
benign O
prostatic O
hyperplasia O
symptoms O
in O
2 O
randomized O
, O
placebo O
controlled O
, O
phase O
3 O
studies O
. O
[]

METHODS O
Fifteen O
white-coat O
hypertensive O
out-patients O
and O
23 O
essential O
hypertensive O
out-patients O
were O
randomly O
assigned O
to O
groups O
A O
or O
B O
. O
[]

Implant B-outcome ['Physiological-Clinical']
stability I-outcome ['Physiological-Clinical']
at O
the O
moment O
of O
implant O
placement O
is O
slightly O
inferior O
in O
the O
immediate O
replacement O
group O
, O
but O
it O
does O
not O
affect O
the O
treatment O
result O
. O
['Physiological-Clinical']

Lithium O
, O
in O
a O
dosage O
yielding O
relatively O
low O
plasma B-outcome ['Physiological-Clinical']
levels O
, O
was O
not O
more O
effective O
than O
placebo O
. O
['Physiological-Clinical']

However O
, O
proton O
pump O
inhibitors O
increase O
the O
local O
concentration O
of O
roxithromycin B-outcome ['Resource-use']
in O
the O
stomach O
which O
may O
contribute O
to O
the O
clinically O
proven O
synergic O
beneficial O
action O
in O
eradication O
therapy O
of O
H. O
pylori O
. O
['Resource-use']

We O
assessed O
treatment O
effect O
on O
LS B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
in O
different O
patient O
subgroups O
at O
month O
12 O
that O
contributed O
to O
the O
risk O
of O
osteoporosis O
in O
addition O
to O
glucocorticoids O
. O
['Physiological-Clinical']

Mucositis B-outcome ['Physiological-Clinical']
, O
the O
inflammation O
and O
necrosis O
of O
mucosal O
membranes O
, O
is O
a O
serious O
and O
debilitating O
consequence O
of O
many O
cancer O
therapies O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
determine O
the O
minimal O
clinically O
important O
difference O
( O
MCID O
) O
of O
warfarin O
therapy O
for O
the O
treatment O
of O
nonvalvular O
atrial O
fibrillation O
from O
the O
perspective O
of O
patients O
using O
2 O
different O
elicitation O
methods O
. O
[]

Daclizumab O
high-yield O
process O
in O
relapsing-remitting B-outcome ['Physiological-Clinical']
multiple I-outcome ['Physiological-Clinical']
sclerosis I-outcome ['Physiological-Clinical']
( O
SELECT O
) O
: O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
['Physiological-Clinical']

RESULTS O
At O
the O
end O
of O
the O
intervention O
, O
JASP/ER O
teachers O
used O
more O
JASP/ER O
strategies O
than O
the O
control O
teachers O
, O
and O
JASP/ER O
preschoolers O
used O
more O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
in O
their O
classroom O
than O
control O
children O
. O
['Life-Impact']

RDT O
introduction O
would O
result O
in O
an O
additional O
2.3 O
% O
and O
9.4 O
% O
of O
patients O
correctly O
treated O
, O
at O
an O
incremental B-outcome ['Resource-use']
cost I-outcome ['Resource-use']
of O
$ O
25 O
and O
$ O
7 O
in O
the O
low O
and O
high O
transmission O
settings O
, O
respectively O
. O
['Resource-use']

Treatment O
was O
repeated O
every O
21 O
days O
in O
both O
arms O
. O
[]

The O
results O
of O
211 O
two-way O
analyses O
of O
variance O
revealed O
that O
age O
and O
age O
and O
sex B-outcome ['Life-Impact']
in O
interaction O
, O
but O
not O
sex O
alone O
, O
significantly O
influenced O
the O
clinical O
ratings O
. O
['Life-Impact']

The O
difference O
was O
not O
statistically O
significant O
( O
chi-square O
= O
0.231 O
, O
p O
> O
0.6 O
) O
. O
[]

Data O
were O
analyzed O
by O
the O
Mann-Whitney O
test O
. O
[]

In O
responders O
, O
the O
dose O
intensity O
of O
Cycles O
3 O
and O
4 O
was O
higher O
in O
the O
PRE O
group O
than O
in O
the O
PERI O
group O
( O
mean O
relative O
dose O
intensity O
of O
90.4 O
% O
versus O
82.6 O
% O
, O
respectively O
; O
p=0.0007 O
) O
. O
[]

[ O
Medical O
safety O
and O
staff O
mental O
health O
] O
. O
[]

Within O
individuals O
, O
the O
presence O
of O
IEDs O
on O
a O
particular O
EEG O
predicted O
, O
on O
average O
, O
a O
27 O
% O
increase O
in O
ADHD B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
severity I-outcome ['Life-Impact']
. O
['Life-Impact']

Ezetimibe O
did O
not O
alter O
the O
serum B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
lipid-soluble B-outcome ['Physiological-Clinical']
vitamins B-outcome ['Physiological-Clinical']
or O
significantly O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

AIMS O
The O
nursing-led O
inpatient O
unit O
is O
designed O
to O
substitute O
for O
a O
period O
of O
care O
in O
acute O
hospital O
wards O
and O
to O
improve O
patient O
outcome O
prior O
to O
discharge O
to O
the O
community O
. O
[]

METHODS O
Twenty-one O
patients O
diagnosed O
with O
posterior O
blepharitis O
were O
randomized O
in O
an O
open-label O
study O
to O
receive O
either O
azithromycin O
plus O
warm O
compresses O
( O
10 O
patients O
) O
, O
or O
compresses O
alone O
( O
11 O
patients O
) O
. O
[]

A O
randomized O
controlled O
trial O
of O
acellular O
diphtheria/pertussis/tetanus O
( O
ADPT O
) O
freeze-dried O
and O
liquid O
vaccines O
in O
infants O
was O
conducted O
in O
a O
peri-urban O
community O
( O
Ashaiman O
) O
in O
southern O
Ghana O
. O
[]

Secondary O
end O
points O
included O
infarct B-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
before O
hospital O
discharge O
and O
short- O
and O
long-term O
outcomes O
. O
['Physiological-Clinical']

PRINCIPAL O
FINDINGS O
We O
randomized O
836 O
cases O
in O
placebo O
and O
835 O
in O
amoxycillin O
group O
. O
[]

[ O
Double-blind O
placebo-controlled O
study O
of O
the O
effectiveness O
and O
tolerability B-outcome ['Life-Impact']
of O
10 O
and O
30 O
mg O
ketorolac O
tromethamine O
suppositories O
in O
post-cholecystectomy O
pain O
] O
. O
['Life-Impact']

The O
LS O
mean O
( O
mm O
) O
changes O
( O
95 O
% O
CI O
) O
over O
12 O
weeks O
for O
etoricoxib O
and O
ibuprofen O
, O
respectively O
, O
compared O
to O
placebo O
were O
given O
as O
follows O
: O
WOMAC-PS O
: O
-11.66 O
( O
-16.31 O
, O
-7.01 O
) O
and O
-7.62 O
( O
-12.30 O
, O
-2.94 O
) O
; O
WOMAC-PFS O
: O
-10.15 O
( O
-14.74 O
, O
-5.57 O
) O
and O
-7.23 O
( O
-11.85 O
, O
-2.61 O
) O
; O
PGADS B-outcome ['Physiological-Clinical']
: O
-11.65 O
( O
-16.81 O
, O
-6.50 O
) O
and O
-8.11 O
( O
-13.30 O
, O
-2.92 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
[]

The O
serum O
analytical O
tests O
included O
: O
calcium B-outcome ['Physiological-Clinical']
corrected O
to O
total O
protein B-outcome ['Physiological-Clinical']
, O
P O
, O
PTH B-outcome ['Physiological-Clinical']
( O
intact B-outcome ['Physiological-Clinical']
molecule I-outcome ['Physiological-Clinical']
) O
and O
bicarbonate B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
the O
patients O
were O
treated O
with O
zidovudine O
and O
were O
randomly O
assigned O
to O
receive O
either O
800 O
mg O
of O
sulfamethoxazole O
and O
160 O
mg O
of O
trimethoprim O
once O
daily O
or O
300 O
mg O
of O
aerosolized O
pentamidine O
administered O
every O
four O
weeks O
by O
jet O
nebulizer O
. O
[]

A O
few O
patent B-outcome ['Physiological-Clinical']
orifices I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
dentinal I-outcome ['Physiological-Clinical']
tubules I-outcome ['Physiological-Clinical']
were O
observed O
in O
dentin O
subjected O
to O
laser O
ablation O
and O
chemo-mechanical O
caries O
removal O
. O
['Physiological-Clinical']

BACKGROUND O
Physical O
activity O
decreases O
risk O
of O
colon O
polyps O
and O
colon O
cancer O
and O
might O
reduce O
risk O
of O
colon O
cancer O
recurrence O
. O
[]

No O
significant O
difference O
was O
observed O
between O
the O
two O
medications O
in O
the O
outcome O
measures O
. O
[]

BALF O
levels O
of O
IL-6 B-outcome ['Physiological-Clinical']
declined O
similarly O
during O
the O
study O
in O
both O
groups O
. O
['Physiological-Clinical']

BACKGROUND O
This O
study O
investigated O
whether O
another O
person O
's O
social O
attention B-outcome ['Life-Impact']
, O
specifically O
the O
direction O
of O
their O
eye O
gaze O
, O
and O
a O
non-social O
directional O
cue O
, O
an O
arrow O
, O
triggered O
reflexive B-outcome ['Life-Impact']
orienting I-outcome ['Life-Impact']
in O
children O
with O
and O
without O
autism O
in O
an O
experimental O
situation O
. O
['Life-Impact', 'Life-Impact']

In O
contrast O
to O
this O
, O
gamma-glutamyl B-outcome ['Physiological-Clinical']
transferase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GGT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
increased O
by O
2,4 O
times O
during O
5-days O
therapy O
with O
the O
lipid O
emulsions O
mentioned O
above O
( O
SMOF O
lipid O
: O
21,9 O
to O
52,9 O
U/L O
, O
Lipofundin O
: O
from O
32,5 O
to O
79,6 O
U/L O
) O
. O
['Physiological-Clinical']

A O
prospective O
, O
randomized O
trial O
of O
clear O
liquids O
versus O
low-fat O
solid O
diet O
as O
the O
initial O
meal O
in O
mild O
acute O
pancreatitis O
. O
[]

Statistical O
analyses O
were O
not O
performed O
due O
to O
the O
low O
number O
of O
subjects O
. O
[]

These O
observing O
responses O
were O
never O
followed O
by O
differential O
consequences O
. O
[]

The O
diagnostic O
yield O
in O
each O
group O
was O
compared O
. O
[]

METHOD O
Eight O
children O
with O
Down O
syndrome O
who O
displayed O
autistic O
features O
were O
compared O
with O
eight O
Down O
syndrome O
children O
without O
autistic O
features O
. O
[]

Seventeen O
patients O
, O
aged O
19 O
to O
48 O
years O
( O
mean O
age O
31 O
) O
, O
were O
given O
fluoxetine O
20 O
mg/day O
plus O
local O
application O
of O
lidocaine O
ointment O
. O
[]

It O
is O
the O
current O
opinion O
that O
an O
ideal O
antihypertensive O
drug O
should O
reduce O
blood O
pressure O
( O
BP O
) O
not O
only O
at O
rest O
but O
also O
during O
stressful O
situations O
. O
[]

No O
effective O
therapy O
is O
known O
. O
[]

This O
report O
summarizes O
the O
demographic O
, O
biochemical B-outcome ['Physiological-Clinical']
, O
and O
clinical B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
of O
the O
randomized O
patients O
at O
the O
time O
of O
entry O
into O
the O
trial O
and O
evaluates O
the O
balance O
between O
the O
treatment O
groups O
within O
each O
population O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Histological O
alterations O
characteristic O
of O
chronic O
rejection O
were O
expressed O
as O
chronic B-outcome ['Resource-use']
allograft I-outcome ['Resource-use']
damage B-outcome ['Physiological-Clinical']
index O
. O
['Resource-use', 'Physiological-Clinical']

G-CSF O
was O
used O
in O
a O
dose O
of O
3 O
microg/kg O
on O
D5-D9 O
during O
each O
cycle O
in O
the O
dose-dense O
group O
. O
[]

The O
relapse B-outcome ['Physiological-Clinical']
rates O
were O
62.5 O
% O
for O
gradual O
placebo O
substitution O
and O
12.5 O
% O
for O
continued O
risperidone O
; O
this O
difference O
was O
statistically O
significant O
. O
['Physiological-Clinical']

Participants O
watched O
a O
dot O
move O
in O
a O
circle O
and O
pressed O
the O
spacebar O
any O
time O
after O
one O
revolution O
. O
[]

Metronidazole O
is O
particularly O
effective O
in O
vitro O
against O
spirochetes O
, O
and O
this O
efficacy O
was O
investigated O
as O
a O
means O
of O
measuring O
patient O
compliance O
with O
metronidazole O
usage O
. O
[]

These O
data O
show O
that O
acute O
nicotine O
administration O
, O
in O
the O
form O
of O
nicotine O
gum O
, O
has O
no O
effect O
on O
cardiovascular B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
stress O
reactivity B-outcome ['Physiological-Clinical']
in O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
groups O
in O
mean O
age O
, O
anaesthetic B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
perioperative B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
, O
or O
['Life-Impact', 'Physiological-Clinical']

Serotonergic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
measured O
by O
the O
neuro-endocrine O
response O
to O
a O
placebo-controlled O
, O
crossover O
challenge O
with O
dexfenfluramine O
. O
['Physiological-Clinical']

5 O
of O
them O
were O
included O
in O
a O
randomized O
trial O
and O
have O
a O
significantly O
different O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
from O
patients O
receiving O
the O
same O
treatment O
but O
without O
BCG O
. O
['Mortality']

Subjects O
received O
15 O
mg O
of O
MTX O
a O
week O
or O
identical O
placebo O
. O
[]

Those O
women O
in O
the O
experimental O
group O
who O
were O
consuming O
soy O
had O
their O
mean O
menstrual B-outcome ['Physiological-Clinical']
cycle O
length B-outcome ['Physiological-Clinical']
increased O
by O
3.52 O
days O
compared O
with O
a O
mean O
decrease O
of O
0.06 O
days O
for O
women O
in O
the O
placebo O
group O
( O
P O
= O
0.04 O
) O
from O
baseline O
to O
the O
third O
menstrual O
cycle O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pre- O
and O
post-course O
tests O
were O
administered O
at O
the O
start O
and O
the O
end O
of O
the O
attachment O
; O
129 O
students O
sat O
both O
tests O
. O
[]

Beta-antagonists O
with O
intrinsic O
sympathomimetic O
or O
cardioselective O
properties O
, O
such O
as O
carteolol O
or O
betaxolol O
, O
may O
cause O
less O
impairment O
. O
[]

A O
single O
levosimendan O
administration O
has O
recently O
been O
shown O
to O
result O
in O
clinical O
and O
hemodynamic O
improvement O
in O
patients O
with O
decompensated O
heart O
failure O
( O
HF O
) O
, O
but O
without O
survival O
benefits O
. O
[]

h O
) O
, O
or O
saline O
for O
85 O
min O
. O
[]

ACE O
inhibition O
significantly O
attenuated O
the O
prostacyclin B-outcome ['Physiological-Clinical']
response O
to O
bradykinin B-outcome ['Physiological-Clinical']
at O
any O
given O
level O
of O
hypotensive O
response O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Intranasal O
recombinant O
alfa-2b O
interferon O
treatment O
of O
naturally B-outcome ['Physiological-Clinical']
occurring I-outcome ['Physiological-Clinical']
common I-outcome ['Physiological-Clinical']
colds I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

2 O
. O
[]

We O
conducted O
a O
single O
and O
repeat O
oral O
dose O
study O
of O
YM17E O
, O
a O
novel O
inhibitor O
of O
acyl O
coenzyme O
A O
( O
CoA O
) O
: O
cholesterol O
acyltransferase O
, O
in O
healthy O
male O
volunteers O
to O
evaluate O
the O
pharmacokinetic B-outcome ['Physiological-Clinical']
profile O
, O
tolerability B-outcome ['Life-Impact']
and O
effect O
of O
the O
drug O
on O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Intraoperative O
microscopy O
of O
bile O
-- O
is O
it O
useful O
? O
[]

Studies O
have O
shown O
that O
half O
of O
patients O
who O
had O
no O
pre-discharge O
contact O
with O
outpatient O
services O
do O
not O
keep O
their O
first O
outpatient O
appointment O
. O
[]

The O
study O
is O
ongoing O
and O
this O
report O
is O
based O
on O
an O
interim O
analysis O
of O
data O
from O
78 O
patients O
. O
[]

The O
ultrasound O
treatment O
was O
easy O
to O
use O
and O
no O
difference O
in O
the O
number O
and O
type O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
between O
the O
two O
treatment O
groups O
was O
noted O
. O
['Adverse-effects']

In O
LPFSTs O
, O
a O
monaural O
, O
low-redundancy O
speech O
sample O
is O
distorted O
by O
using O
filtering O
to O
modify O
its O
frequency O
content O
. O
[]

Since O
exogenous O
somatostatin O
-- O
in O
the O
form O
of O
octreotide O
-- O
fails O
to O
influence O
nocturnal B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
melatonin I-outcome ['Physiological-Clinical']
in O
normal O
subjects O
and O
in O
patients O
with O
primary O
hypothyroidism O
, O
it O
is O
reasonable O
to O
assume O
that O
endogenous O
somatostatin O
may O
not O
be O
an O
important O
regulator O
of O
melatonin O
secretion O
in O
man O
. O
['Physiological-Clinical', 'Physiological-Clinical']

subcutaneously O
( O
n O
= O
103 O
) O
. O
[]

To O
understand O
better O
the O
ability O
of O
these O
pumps O
to O
assist O
women O
in O
the O
maintenance O
of O
lactation O
, O
the O
current O
study O
was O
undertaken O
to O
evaluate O
their O
effects O
on O
milk O
yield O
and O
prolactin O
and O
oxytocin B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
when O
compared O
to O
natural O
infant O
suckling O
. O
['Physiological-Clinical']

Haloperidol O
blood O
levels O
and O
effects O
in O
schizophrenia B-outcome ['Life-Impact']
and O
schizoaffective B-outcome ['Life-Impact']
disorder O
: O
a O
progress O
report O
. O
['Life-Impact', 'Life-Impact']

A O
total O
of O
110 O
patients O
undergoing O
elective O
abdominal O
hysterectomy O
were O
anesthetized O
in O
random O
order O
with O
either O
isoflurane O
in O
nitrous O
oxide O
and O
oxygen O
or O
isoflurane O
in O
air O
and O
oxygen O
. O
[]

RESULTS O
The O
pattern O
of O
autistic O
symptom O
severity O
varied O
over O
time O
by O
domain O
. O
[]

The O
number O
of O
patients O
requiring O
cessation O
of O
feeding B-outcome ['Life-Impact']
because O
of O
pain B-outcome ['Physiological-Clinical']
or O
nausea B-outcome ['Physiological-Clinical']
was O
similar O
in O
both O
groups O
( O
6 O
% O
for O
CLD O
, O
11 O
% O
for O
LFSD O
; O
P O
= O
.51 O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

At O
median O
follow-up O
of O
7.2 O
months O
, O
median O
survival B-outcome ['Mortality']
did O
not O
differ O
significantly O
between O
the O
groups O
in O
the O
overall O
population O
( O
5.6 O
months O
for O
gefitinib O
and O
5.1 O
months O
for O
placebo O
; O
hazard O
ratio O
0.89 O
[ O
95 O
% O
CI O
0.77-1.02 O
] O
, O
p=0.087 O
) O
or O
among O
the O
812 O
patients O
with O
adenocarcinoma O
( O
6.3 O
months O
vs O
5.4 O
months O
; O
0.84 O
[ O
0.68-1.03 O
] O
, O
p=0.089 O
) O
. O
['Mortality']

Fixed-dose O
manidipine/delapril O
versus O
losartan/hydrochlorothiazide O
in O
hypertensive O
patients O
with O
type O
2 O
diabetes O
and O
microalbuminuria O
. O
[]

RESULTS O
Data O
from O
549 O
subjects O
( O
follow-up O
, O
2.7 O
? O
[]

infusion O
, O
followed O
after O
day O
15 O
by O
a O
weekly O
i.v O
. O
[]

C-terminal B-outcome ['Physiological-Clinical']
FGF23 I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
in O
stored O
plasma O
samples O
. O
['Physiological-Clinical']

The O
study O
was O
based O
on O
1292 O
patients O
included O
in O
two O
consecutive O
controlled O
randomized O
trials O
of O
preoperative O
radiotherapy O
in O
operable O
rectal O
carcinoma O
. O
[]

Effects O
of O
intranasal O
oxytocin O
on O
the O
neural O
basis O
of O
face O
processing O
in O
autism O
spectrum O
disorder O
. O
[]

This O
study O
investigated O
the O
relationship O
between O
theory O
of O
mind O
and O
executive O
functioning O
in O
children O
with O
autistic O
spectrum O
disorders O
through O
a O
training O
study O
. O
[]

Cadence B-outcome ['Physiological-Clinical']
, O
recorded O
using O
the O
activPAL? O
activity O
monitor O
, O
was O
used O
to O
measure O
intensity O
. O
['Physiological-Clinical']

A O
randomized O
trial O
of O
a O
brief O
alcohol O
intervention O
for O
needle O
exchangers O
( O
BRAINE O
) O
. O
[]

Recurrences O
and O
complications O
were O
recorded O
at O
follow-up O
visits O
. O
[]

Lung O
injuries O
and O
relevant O
enzymes O
expression O
were O
thus O
assayed O
. O
[]

SETTING O
Community-based O
supervised O
intervention O
. O
[]

The O
treatment O
of O
senile B-outcome ['Physiological-Clinical']
dementia I-outcome ['Physiological-Clinical']
associated O
with O
cerebrovascular O
insufficiency O
: O
a O
comparative O
study O
of O
buflomedil O
and O
dihydrogenated O
ergot O
alkaloids O
. O
['Physiological-Clinical']

Patients O
with O
mild-to-moderate O
heart O
failure O
with O
sinus O
rhythm O
, O
but O
not O
those O
with O
atrial O
fibrillation O
because O
of O
its O
frequent O
induction O
of O
tachycardia O
, O
may O
be O
good O
candidates O
for O
denopamine O
therapy O
. O
[]

Although O
sodium O
nitroprusside O
did O
not O
affect O
plasma B-outcome ['Physiological-Clinical']
t-PA I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
they O
were O
increased O
dose-dependently O
in O
the O
infused O
forearm O
by O
substance O
P O
and O
bradykinin O
infusion O
( O
ANOVA O
, O
p O
< O
0.001 O
for O
both O
) O
. O
['Physiological-Clinical']

Success O
rates O
were O
the O
same O
. O
[]

Antihypertensive O
and O
volume-depleting O
effects O
of O
mild O
exercise O
on O
essential O
hypertension O
. O
[]

Patients O
were O
randomly O
allocated O
to O
piracetam O
+ O
risperidone O
( O
Group O
A O
) O
or O
placebo O
+ O
risperidone O
( O
Group O
B O
) O
for O
a O
10-week O
, O
double-blind O
, O
placebo-controlled O
study O
. O
[]

In O
a O
prospective O
, O
controlled O
, O
randomized O
, O
multicenter O
study O
the O
immunogenicity O
of O
a O
single O
( O
day O
0 O
) O
and O
two O
( O
day O
0 O
, O
28 O
) O
booster O
vaccination O
against O
diphtheria O
were O
compared O
in O
subjects O
who O
had O
received O
their O
last O
diphtheria O
vaccination O
more O
than O
10 O
years O
ago O
. O
[]

METHODS O
Each O
of O
nine O
normal-hearing O
pilot O
subjects O
were O
placed O
in O
an O
environment O
of O
recorded O
helicopter O
noise O
from O
a O
BO-105 O
helicopter O
. O
[]

The O
sibutramine O
group O
was O
given O
sibutramine O
10 O
mg O
daily O
for O
12 O
wk O
. O
[]

By O
contrast O
, O
the O
GH O
group O
increased O
in O
lean B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
( O
1.13 O
+/- O
1.04 O
kg O
) O
and O
had O
a O
positive O
nitrogen B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
( O
1.81 O
+/- O
2.06 O
g/day O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ten-year O
results O
. O
[]

Parent O
Version O
; O
ADIS-P O
) O
pre- O
and O
post-intervention O
condition O
. O
[]

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
impact O
of O
the O
neuromonitoring O
of O
the O
external O
branch O
of O
the O
superior O
laryngeal O
nerve O
( O
EBSLN O
) O
on O
the O
voice B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
after O
mini-incision O
thyroidectomy O
under O
local/regional O
anesthesia O
and O
intravenous O
sedation O
. O
['Physiological-Clinical']

Ranitidine O
premedication O
reduces O
gastric O
volume O
, O
increases O
gastric O
pH O
, O
and O
may O
reduce O
GER B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
compared O
the O
test O
performances O
of O
high-risk O
HPV O
testing O
( O
Hybrid O
Capture O
2 O
) O
using O
self-collected O
and O
clinician-collected O
samples O
as O
well O
as O
cervical O
cytology O
for O
identifying O
cervical O
intraepithelial O
neoplasia O
grades O
2 O
or O
3 O
or O
invasive O
cervical O
cancer O
( O
CIN2+ O
) O
among O
women O
who O
did O
( O
n=812 O
) O
and O
did O
not O
( O
n=1858 O
) O
undergo O
cryotherapy O
in O
a O
South O
African O
screen-and-treat O
trial O
. O
[]

To O
study O
the O
effects O
of O
physical O
exercise O
on O
biochemical B-outcome ['Physiological-Clinical']
risk O
factors B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
ischaemic I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease B-outcome ['Physiological-Clinical']
31 O
healthy O
middle O
aged O
men O
undertook O
regular O
physical O
exercise O
for O
two O
months O
and O
29 O
served O
as O
controls O
in O
a O
randomised O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
evaluated O
a O
5-day O
'live-in O
' O
intervention O
using O
a O
double-blind O
randomized O
control O
trial O
. O
[]

Incidence O
of O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
were O
comparable O
in O
all O
four O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
Stent O
and O
surgery O
for O
symptomatic O
carotid O
stenosis O
. O
[]

The O
triglyceride B-outcome ['Physiological-Clinical']
and O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
corresponded O
to O
4 O
, O
8 O
, O
or O
12 O
kcal/kg O
per O
week O
( O
KKW O
) O
of O
energy O
expenditure O
. O
[]

No O
difference O
in O
species B-outcome ['Physiological-Clinical']
number O
was O
noted O
in O
controls O
. O
['Physiological-Clinical']

Other O
arrhythmias B-outcome ['Physiological-Clinical']
occurred O
in O
1 O
% O
or O
less O
of O
subjects O
by O
treatment O
group O
. O
['Physiological-Clinical']

Fifty-six O
patients O
were O
enrolled O
and O
, O
after O
titration O
of O
the O
placebo O
or O
active O
drug O
, O
they O
were O
followed O
for O
12 O
weeks O
. O
[]

PATIENTS O
AND O
METHODS O
Mucociliary O
clearance O
time O
was O
measured O
using O
the O
saccharine O
clearance O
test O
on O
132 O
adults O
before O
and O
after O
10 O
days O
' O
application O
of O
intranasal O
isotonic O
or O
hypertonic O
saline O
. O
[]

Significant O
differences O
were O
found O
in O
several O
acceptability B-outcome ['Life-Impact']
areas O
with O
respect O
to O
demographics O
and O
quality O
of O
life O
measures O
such O
as O
age O
, O
sex O
, O
and O
severe O
distress O
. O
['Life-Impact']

Fluctuations O
in O
the O
presence O
of O
epileptiform O
discharges O
within O
individual O
children O
with O
a O
developmental O
disability O
syndrome O
may O
be O
associated O
with O
fluctuations O
in O
ADHD O
symptomatology O
, O
even O
in O
the O
absence O
of O
clinical O
seizures O
. O
[]

The O
purpose O
of O
this O
randomized O
, O
double-masked O
, O
placebo-controlled O
study O
was O
to O
determine O
the O
efficacy O
and O
safety O
of O
risedronate B-outcome ['Resource-use']
in O
the O
prevention O
of O
vertebral O
fractures O
in O
postmenopausal O
women O
with O
established O
osteoporosis O
. O
['Resource-use']

Transitions O
during O
effective O
treatment O
for O
cocaine-abusing O
homeless O
persons O
: O
establishing O
abstinence O
, O
lapse O
, O
and O
relapse O
, O
and O
reestablishing O
abstinence O
. O
[]

In O
discrimination O
learning O
paradigm O
, O
children O
receiving O
haloperidol O
learned B-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
discrimination I-outcome ['Life-Impact']
while O
those O
on O
placebo O
did O
not O
. O
['Life-Impact']

BACKGROUND O
In O
patients O
with O
ventricular O
tachycardia O
( O
VT O
) O
and O
a O
history O
of O
myocardial O
infarction O
, O
intervention O
with O
an O
implantable O
cardioverter O
defibrillator O
( O
ICD O
) O
can O
prevent O
sudden O
cardiac O
death O
and O
thereby O
reduce O
total O
mortality O
. O
[]

Adverse O
reactions O
forced O
trial O
termination O
in O
six O
patients O
and O
dose O
reduction O
in O
another O
eight O
, O
and O
consisted O
mainly O
of O
drowsiness B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
anticholinergic B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Five O
hundred O
and O
fifty-nine O
hypertensive O
outpatients O
with O
diastolic O
blood O
pressure O
between O
95 O
and O
110 O
mmHg O
participated O
in O
this O
double-blind O
, O
placebo-controlled O
, O
multicenter O
study O
. O
[]

The O
aim O
of O
the O
present O
study O
protocol O
is O
to O
introduce O
a O
theory-based O
approach O
to O
diagnose O
implementation O
difficulties O
of O
TUPAC O
counselling O
guidelines O
among O
dental O
providers O
. O
[]

Separate O
experiments O
were O
performed O
on O
30 O
women O
( O
mean O
age O
19.6 O
years O
) O
and O
20 O
men O
( O
20.4 O
years O
) O
. O
[]

Thirty-one O
, O
25 O
, O
and O
26 O
% O
more O
HS-60 O
heifers O
were O
pubertal O
( O
P O
< O
0.05 O
) O
on O
May O
1 O
compared O
with O
LS-30 O
, O
HS-30 O
, O
and O
control O
heifers O
, O
respectively O
. O
[]

RESULTS O
Basal B-outcome ['Physiological-Clinical']
echocardiographic I-outcome ['Physiological-Clinical']
and O
hemodynamic B-outcome ['Physiological-Clinical']
data O
were O
similar O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mean O
PNP O
scores O
were O
2.25+/-5.1 O
( O
range O
0-15 O
) O
for O
patients O
in O
Group O
I O
and O
11+/-11.63 O
( O
range O
0-32 O
) O
for O
those O
in O
Group O
II O
( O
P=0.01 O
) O
. O
[]

The O
number O
and O
volume O
of O
injections O
and O
the O
time O
required O
to O
achieve O
complete O
hemostasis O
were O
evaluated O
; O
follow-up O
endoscopy O
was O
performed O
at O
1 O
month O
to O
assess O
gastric O
variceal O
obliteration O
. O
[]

Based O
on O
these O
data O
, O
a O
role O
for O
GHRH O
as O
an O
inducer O
of O
SWS O
was O
proposed O
. O
[]

A O
shift O
from O
a O
right O
hemisphere O
advantage O
to O
a O
left O
hemisphere O
advantage O
across O
blocks O
of O
trials O
was O
also O
found O
. O
[]

Within O
48 O
hours O
of O
administration O
, O
there O
was O
a O
significant O
increase O
in O
the O
circulating B-outcome ['Physiological-Clinical']
absolute I-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( O
ANC B-outcome ['Physiological-Clinical']
) O
at O
5.0 O
micrograms/kg O
twice O
per O
day O
and O
10.0 O
micrograms/kg O
once O
per O
day O
, O
which O
continued O
for O
at O
least O
24 O
hours O
after O
discontinuation O
of O
rhuGM-CSF O
. O
['Physiological-Clinical', 'Physiological-Clinical']

GLP-1 O
dose O
dependently O
diminished O
fundus B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
( O
162.9 O
( O
15.0 O
) O
and O
259.5 O
( O
17.2 O
) O
v O
121.1 O
( O
6.0 O
) O
ml O
with O
saline O
; O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

The O
variables O
for O
safety O
analysis O
were O
adverse O
events O
, O
vital O
signs O
, O
residual O
urine O
volume O
and O
clinical B-outcome ['Physiological-Clinical']
laboratory I-outcome ['Physiological-Clinical']
tests O
. O
['Physiological-Clinical']

The O
trial O
accrued O
patients O
from O
August O
1996 O
to O
October O
2004 O
. O
[]

OBJECTIVE O
The O
vast O
majority O
of O
children O
with O
an O
autism O
spectrum O
disorder O
( O
ASD O
) O
attend O
public O
preschools O
at O
some O
point O
in O
their O
childhood O
. O
[]

By O
random O
, O
15 O
and O
20 O
patients O
were O
provided O
with O
18 O
test O
and O
23 O
control O
implant O
crowns O
, O
respectively O
. O
[]

There O
were O
no O
significant O
differences O
between O
ibuprofen O
and O
ibuprofen-arginate O
in O
PGE2 O
, O
or O
enzymes O
. O
[]

The O
null O
hypothesis O
was O
, O
therefore O
, O
accepted O
. O
[]

Patients O
were O
encouraged O
to O
maintain O
their O
individual O
diet O
and O
exercise O
regimens O
throughout O
the O
study O
. O
[]

The O
urea O
end-product O
method O
suggested O
that O
there O
was O
no O
change O
in O
whole-body B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
after O
surgery O
, O
whether O
or O
not O
insulin O
was O
given O
. O
['Physiological-Clinical']

Participants O
were O
adolescent O
girls O
and O
boys O
( O
N O
= O
878 O
) O
aged O
11-15 O
years O
on O
entry O
. O
[]

We O
hypothesize O
that O
hematogenous O
tumor O
cell O
dissemination O
may O
be O
reduced O
by O
using O
the O
anterior O
approach O
technique O
compared O
to O
conventional O
liver O
resection O
. O
[]

No O
adverse B-outcome ['Physiological-Clinical']
neurologic I-outcome ['Physiological-Clinical']
consequences I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
rHCNTF I-outcome ['Physiological-Clinical']
administration I-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical']

Effects O
of O
alfuzosin O
10 O
mg O
once O
daily O
on O
sexual B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
men O
treated O
for O
symptomatic O
benign O
prostatic O
hyperplasia O
. O
['Life-Impact']

It O
can O
cause O
nausea O
, O
vomiting O
and O
dysphoria O
in O
mothers O
and O
can O
cause O
reduced O
fetal O
heart O
rate O
variability O
and O
accelerations O
. O
[]

No O
significant O
treatment O
effects O
were O
found O
for O
shell O
thickness O
and O
shell O
strength B-outcome ['Life-Impact']
of O
eggs O
( O
P O
> O
0.05 O
) O
. O
['Life-Impact']

DESIGN O
AND O
METHODS O
Twenty-eight O
sedentary O
male O
patients O
with O
angiographically O
documented O
CAD O
and O
average O
pretreatment O
total O
plasma O
cholesterol O
levels O
( O
5.1+/-0.9 O
mmol/l O
) O
aged O
42-75 O
years O
were O
included O
. O
[]

Effects O
of O
monotherapy O
and O
combination O
therapy O
on O
blood O
pressure O
control O
and O
target O
organ O
damage O
: O
a O
randomized O
prospective O
intervention O
study O
in O
a O
large O
population O
of O
hypertensive O
patients O
. O
[]

METHODS O
We O
analyzed O
the O
safety O
of O
rotigotine O
in O
2 O
groups O
of O
patients O
with O
advanced O
stage O
Parkinson O
Disease O
. O
[]

OBJECTIVE O
Autosomal O
dominant O
polycystic O
kidney O
disease O
( O
ADPKD O
) O
is O
progressive O
, O
resulting O
in O
end-stage O
kidney O
failure O
in O
most O
patients O
. O
[]

We O
investigated O
whether O
having O
had O
used O
ROCA O
in O
PLCO O
could O
have O
, O
under O
optimal O
assumptions O
, O
resulted O
in O
a O
significant O
mortality B-outcome ['Mortality']
benefit O
by O
applying O
ROCA O
to O
PLCO O
CA125 O
screening O
values O
. O
['Mortality']

Whether O
baseline O
gene O
expression O
can O
identify O
patients O
who O
will O
benefit O
from O
immunochemotherapy O
over O
chemotherapy O
alone O
has O
not O
been O
determined O
. O
[]

Removing O
bee O
stings O
. O
[]

PARTICIPANTS O
Twenty O
eyes O
of O
20 O
consecutive O
patients O
( O
spherical O
equivalent O
[ O
SE O
] O
, O
-2.01+/-1.36 O
diopters O
[ O
D O
] O
) O
treated O
with O
wavefront-guided O
Zyoptix O
Ablation O
Refinement O
software O
( O
ZAR O
) O
LASIK O
and O
20 O
eyes O
of O
20 O
consecutive O
patients O
( O
SE O
, O
-1.81+/-1.21 O
D O
) O
treated O
with O
standard O
Planoscan O
LASIK O
, O
both O
for O
residual O
refractive O
error O
enhancement O
. O
[]

Teacher O
SE-Restlessness O
and O
initiation B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
in O
the O
clinic O
showed O
a O
trend O
toward O
improvement O
. O
['Life-Impact', 'Life-Impact']

The O
control O
toothpaste O
was O
a O
conventional O
, O
moderately O
abrasive O
paste O
containing O
0.8 O
% O
sodium O
monofluorophosphate O
. O
[]

A O
critical O
step O
in O
biventricular O
pacemaker O
implantation O
is O
coronary O
sinus O
( O
CS O
) O
cannulation O
. O
[]

AIMS O
Diuretic O
therapy O
is O
conventionally O
used O
to O
treat O
oedema O
in O
patients O
with O
hypoxic O
cor O
pulmonale O
. O
[]

This O
study O
examined O
the O
effects O
of O
misoprostol B-outcome ['Physiological-Clinical']
, O
a O
PGE1 O
analog O
with O
antiulcer O
activity O
, O
on O
the O
human O
cardiovascular O
system O
. O
['Physiological-Clinical']

The O
absolute O
risk O
difference O
was O
1.2 O
% O
in O
favor O
of O
warfarin O
( O
Cl O
, O
-7.2 O
% O
to O
4.8 O
% O
) O
. O
[]

OBJECTIVE O
The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
tolerability O
of O
amlodipine O
maleate O
with O
those O
of O
amlodipine O
besylate O
in O
Korean O
patients O
with O
mild O
to O
moderate O
hypertension O
. O
[]

CONCLUSIONS O
Concurrent O
therapy O
with O
cisplatin O
and O
fluorouracil O
and O
radiation O
is O
superior O
to O
radiation O
therapy O
alone O
in O
patients O
with O
localized O
carcinoma O
of O
the O
esophagus O
, O
as O
measured O
by O
control O
of O
local O
tumors O
, O
distant O
metastases O
, O
and O
survival O
, O
but O
at O
the O
cost O
of O
increased O
side O
effects O
. O
[]

The O
main O
variable O
for O
verifying O
the O
efficacy O
of O
the O
treatment O
was O
the O
total O
colonic B-outcome ['Physiological-Clinical']
transit I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
We O
sought O
to O
study O
the O
effect O
of O
probiotic O
and O
prebiotic O
supplementation O
in O
preventing O
allergies O
. O
[]

RESULTS O
Both O
groups O
showed O
a O
significant O
improvement O
during O
observation O
[ O
ISGA O
27.1 O
% O
( O
C/BPO O
) O
and O
24.6 O
% O
( O
C/BPO O
+ O
laser O
) O
, O
total O
lesion B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
9.2 O
% O
and O
9.0 O
% O
, O
['Physiological-Clinical']

A O
baseline O
magnetic O
resonance O
imaging O
examination O
was O
performed O
in O
1999 O
on O
271 O
women O
who O
were O
randomly O
chosen O
from O
a O
larger O
cohort O
of O
women O
having O
cosmetic O
breast O
implants O
for O
a O
median O
period O
of O
12 O
years O
( O
range O
, O
3 O
to O
25 O
years O
) O
. O
[]

After O
behavioral O
control O
by O
the O
previously O
over-selected B-outcome ['Physiological-Clinical']
stimulus I-outcome ['Physiological-Clinical']
was O
extinguished O
, O
behavioral B-outcome ['Life-Impact']
control I-outcome ['Life-Impact']
by O
the O
previously O
under-selected O
cue O
emerged O
without O
direct O
training O
. O
['Physiological-Clinical', 'Life-Impact']

SUBJECTS O
AND O
METHODS O
Thirty O
children O
, O
aged O
2 O
to O
8 O
years O
, O
scheduled O
for O
genitourinary O
surgery O
were O
allocated O
randomly O
to O
receive O
either O
0.25 O
% O
bupivacaine O
0.5 O
ml/kg O
( O
group O
B O
; O
n O
= O
15 O
) O
or O
0.25 O
% O
bupivacaine O
0.5 O
ml/kg O
with O
50 O
microg/kg O
midazolam O
( O
group O
BM O
; O
n O
= O
15 O
) O
by O
the O
caudal O
route O
immediately O
after O
induction O
of O
general O
anesthesia O
. O
[]

STEPP O
analyses O
assessed O
chemotherapy B-outcome ['Resource-use']
effect O
. O
['Resource-use']

The O
azithromycin O
protocols O
used O
here O
were O
therefore O
found O
to O
be O
[]

MAIN O
OUTCOME O
MEASURES O
Primary O
end O
points O
were O
the O
frequency O
and O
severity O
of O
ocular O
and O
systemic O
adverse O
events O
. O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
phase O
I O
study O
of O
MEDI-545 O
, O
an O
anti-interferon-alfa O
monoclonal O
antibody O
, O
in O
subjects O
with O
chronic O
psoriasis O
. O
[]

CONCLUSIONS O
and O
CLINICAL O
IMPLICATIONS O
The O
use O
of O
NovaMin O
powder O
and O
NovaMin-containing O
toothpaste O
for O
hypersensitivity O
reduction O
is O
more O
effective O
than O
the O
use O
of O
a O
desensitizing O
toothpaste O
containing O
potassium O
nitrate O
and O
fluoride O
. O
[]

The O
practice O
of O
routinely O
prehydrating O
patients O
by O
infusing O
a O
crystalloid O
or O
colloid O
solution O
( O
up O
to O
1.0 O
L/70 O
kg O
) O
for O
prevention O
of O
spinal B-outcome ['Physiological-Clinical']
anesthesia-induced I-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
has O
been O
challenged O
recently O
, O
after O
several O
reports O
of O
failure O
to O
demonstrate O
its O
efficacy O
in O
young O
women O
. O
['Physiological-Clinical']

Twenty O
healthy O
subjects O
received O
lorazepam O
0.5 O
mg O
, O
1 O
mg O
and O
2 O
mg O
, O
sertraline O
50 O
mg O
and O
placebo O
in O
a O
balanced O
, O
repeated O
measures O
study O
design O
. O
[]

Milk B-outcome ['Physiological-Clinical']
intolerance I-outcome ['Physiological-Clinical']
in O
children O
with O
persistent O
sleeplessness O
: O
a O
prospective O
double-blind O
crossover O
evaluation O
. O
['Physiological-Clinical']

Each O
maxillary O
tooth O
's O
mesiodistal O
and O
vestibulo-oral O
width O
was O
measured O
using O
a O
dial O
caliper O
on O
each O
dental O
cast O
. O
[]

Ramipril O
reduced O
the O
risk O
for O
any O
progression B-outcome ['Physiological-Clinical']
( O
OR O
, O
0.87 O
; O
95 O
% O
CI O
, O
0.78 O
to O
0.97 O
; O
P O
= O
0.0146 O
) O
. O
['Physiological-Clinical']

Results O
demonstrated O
no O
significant O
differences O
between O
the O
volar O
and O
dorsal O
splints O
in O
reducing O
hypertonus B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
In O
a O
double-blind O
, O
cross-over O
study O
, O
60 O
breast O
cancer O
patients O
experiencing O
HF O
were O
randomized O
to O
8 O
weeks O
venlafaxine O
followed O
by O
2 O
weeks O
wash-out O
, O
and O
8 O
weeks O
clonidine O
or O
vice O
versa O
. O
[]

Older O
men O
in O
the O
ICS O
group O
with O
good O
inhaler O
compliance O
appeared O
to O
be O
at O
the O
greatest O
risk O
of O
bruising B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

3 O
months O
, O
respectively O
; O
P O
: O
=.49 O
) O
. O
[]

Health-education O
package O
to O
prevent O
worm O
infections O
in O
Chinese O
schoolchildren O
. O
[]

Teaching O
children O
with O
autism O
to O
seek O
information O
: O
acquisition O
of O
novel O
information O
and O
generalization O
of O
responding O
. O
[]

There O
was O
no O
effect O
on O
the O
peak O
oxygen O
consumption O
, O
exercise O
time O
, O
ventilation O
to O
carbon O
dioxide O
slope O
, O
or O
anaerobic O
threshold O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
RBC I-outcome ['Physiological-Clinical']
alpha-tocopherol I-outcome ['Physiological-Clinical']
levels O
were O
not O
changed O
by O
the O
intake O
of O
beta-carotene O
. O
['Physiological-Clinical']

Magnesium O
administration O
had O
a O
beneficial O
effect O
on O
clinical O
variables O
assessed O
by O
the O
SK O
score O
( O
change O
: O
4.48 O
points O
after O
magnesium O
compared O
with O
-1.30 O
points O
after O
placebo O
; O
P O
< O
0.001 O
) O
. O
[]

Regression O
analyses O
estimated O
the O
association O
between O
ASD O
diagnosis O
and O
cost B-outcome ['Resource-use']
, O
controlling O
for O
child O
gender O
, O
age O
, O
race/ethnicity O
, O
insurance O
status O
, O
household O
income O
, O
country O
region O
and O
urban/rural O
classification O
, O
and O
non-ASD-related O
illnesses O
. O
['Resource-use']

The O
data O
suggest O
that O
the O
exposure O
time O
of O
saliva O
of O
up O
to O
60 O
min O
has O
no O
effect O
on O
reducing O
the O
eroded B-outcome ['Physiological-Clinical']
dentine I-outcome ['Physiological-Clinical']
wear I-outcome ['Physiological-Clinical']
by O
toothbrushing O
. O
['Physiological-Clinical']

The O
Quality O
of O
Well-Being O
Scale O
( O
QWB O
) O
and O
Current O
Health B-outcome ['Life-Impact']
Desirability I-outcome ['Life-Impact']
Rating O
( O
CHDR O
) O
were O
used O
for O
economic O
evaluation O
, O
supplemented O
by O
the O
arthritis-specific B-outcome ['Physiological-Clinical']
Health I-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
Questionnaire O
( O
HAQ O
) O
, O
Center O
for O
Epidemiologic O
Studies-Depression O
Scale O
( O
CES-D O
) O
, O
and O
Perceived O
Quality O
of O
Life O
Scale O
( O
PQOL O
) O
collected O
at O
baseline O
and O
postclass O
. O
['Life-Impact', 'Physiological-Clinical']

The O
trials O
illustrate O
the O
role O
of O
radiotherapy O
in O
preventing O
[]

Patients O
were O
randomly O
assigned O
to O
two O
equal O
groups O
: O
in O
Group O
I O
, O
blood O
cardioplegia O
was O
administered O
using O
leukocyte O
reduction O
filters O
, O
and O
in O
Group O
II O
, O
leukocyte O
reduction O
filters O
were O
not O
used O
for O
blood O
cardioplegia O
. O
[]

The O
findings O
indicated O
support O
for O
the O
use O
of O
chronic O
aerobic O
exercise O
as O
a O
strategy O
for O
improved O
coping O
with O
acute O
stress O
. O
[]

Results O
of O
endoscopic O
examination O
showed O
greater O
improvement O
in O
patients O
cleared O
of O
C. O
pylori O
than O
in O
those O
with O
persistent O
infection O
. O
[]

During O
the O
study O
a O
register O
of O
patients O
undergoing O
coronary O
arteriography O
at O
the O
fourteen O
participating O
centres O
is O
being O
maintained O
to O
assess O
the O
overall O
context O
of O
patient O
recruitment O
. O
[]

Vaginal O
misoprostol O
should O
be O
the O
regimen O
of O
choice O
but O
sublingual O
misoprostol O
is O
also O
an O
effective O
alternative O
. O
[]

In O
the O
stratum O
1 O
endocrine O
therapy-na?ve O
subset O
( O
n O
= O
158 O
) O
the O
HR B-outcome ['Physiological-Clinical']
was O
0.78 O
( O
95 O
% O
CI O
, O
0.52-1.15 O
) O
, O
and O
the O
prior O
endocrine-treated O
subgroup O
( O
n O
= O
48 O
) O
1.47 O
( O
95 O
% O
CI O
, O
0.63-3.45 O
) O
. O
['Physiological-Clinical']

The O
treatment O
effect O
of O
montelukast O
was O
significantly O
greater O
( O
P O
< O
0.05 O
) O
, O
relative O
to O
placebo O
, O
for O
all O
secondary O
endpoints O
, O
including O
nighttime B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
daytime B-outcome ['Physiological-Clinical']
eye I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
patient O
and O
physician B-outcome ['Physiological-Clinical']
global I-outcome ['Physiological-Clinical']
evaluations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
these O
, O
85 O
patients O
were O
randomized O
to O
the O
treatment O
group O
and O
underwent O
pTBA O
within O
96 O
hours O
after O
subarachnoid O
hemorrhage O
. O
[]

METHODS O
Two O
hundred O
nine O
patients O
with O
acquired O
immunodeficiency O
syndrome O
and O
active O
CMV O
retinitis O
were O
enrolled O
in O
a O
multicenter O
, O
phase O
2/3 O
, O
randomized O
, O
placebo-controlled O
clinical O
trial O
. O
[]

Residential O
school O
children O
( O
N O
= O
18 O
) O
were O
randomly O
assigned O
to O
either O
ascorbate-ascorbate-placebo O
treatment O
order O
group O
or O
ascorbate-placebo-ascorbate O
treatment O
order O
group O
. O
[]

No O
difference O
was O
seen O
between O
study O
arms O
in O
HIV-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality']

All O
patients O
must O
have O
shortness O
of O
breath O
with O
minimal O
exertion O
or O
paroxysmal O
nocturnal O
dyspnea O
, O
a O
left O
ventricular O
internal O
dimension O
( O
LVIDd O
) O
by O
echocardiogram O
of O
> O
or O
= O
55 O
mm O
or O
a O
cardiothoracic O
ratio O
of O
> O
0.5 O
and O
an O
ejection O
fraction O
of O
< O
or O
= O
40 O
% O
. O
[]

Of O
54 O
evaluable O
women O
treated O
with O
tamoxifen O
, O
24 O
% O
had O
an O
objective B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
as O
compared O
with O
21 O
% O
of O
53 O
women O
having O
an O
oophorectomy O
. O
['Physiological-Clinical']

RESULTS O
Demographic O
and O
clinical O
profiles O
of O
both O
groups O
were O
not O
statistically O
different O
. O
[]

Time-concentration O
profiles O
were O
determined O
and O
pharmacokinetic O
parameters O
were O
characterized O
using O
noncompartmental O
methods O
. O
['Physiological-Clinical']

During O
the O
first O
12 O
hours O
of O
hospital O
stay O
by O
sealed O
envelopes O
them O
randomly O
divided O
into O
equal O
groups O
of O
comparison O
, O
given O
3 O
times O
a O
day O
: O
alginate O
product O
-- O
Geviskon O
forte O
dose O
of O
10 O
ml O
and O
aluminum-magnesium O
antacid O
drug O
at O
a O
dose O
of O
1 O
sachet O
. O
[]

Onset O
of O
complete B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
was O
fastest O
and O
the O
degree O
of O
motor B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
was O
most O
profound O
with O
the O
mixture O
containing O
equal O
proportions O
of O
lidocaine O
and O
bupivacaine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
chloroquine O
( O
CQ O
) O
resistance O
was O
first O
reported O
in O
Colombia O
in O
1961 O
and O
sulfadoxine-pyrimethamine O
( O
SP O
) O
resistance O
in O
1981 O
, O
the O
frequency O
of O
treatment O
failures O
to O
these O
drugs O
in O
Colombia O
is O
unclear O
. O
[]

The O
selectivity O
of O
this O
aldosterone O
suppressing O
effect O
of O
ANF O
is O
unclear O
in O
man O
. O
[]

Actigraphy O
data O
were O
collected O
a O
second O
time O
2 O
weeks O
after O
the O
parent O
received O
the O
randomization O
assignment O
and O
analyzed O
by O
using O
Student O
's O
t O
test O
. O
[]

Dental O
study O
casts O
, O
lateral O
and O
postero-anterior O
cephalograms O
were O
taken O
before O
treatment O
, O
after O
the O
distraction O
phase O
and O
at O
12-month O
follow O
up O
. O
[]

In O
the O
first O
part O
, O
patients O
were O
randomly O
assigned O
to O
1 O
of O
2 O
groups O
: O
the O
CRM O
and O
avoidance O
( O
no O
treatment O
) O
. O
[]

No O
alteration O
in O
the O
rate O
of O
BMD B-outcome ['Physiological-Clinical']
change O
was O
observed O
upon O
simplification O
to O
LPV/r O
monotherapy O
. O
['Physiological-Clinical']

DESIGN O
A O
1-year O
randomized O
controlled O
trial O
. O
[]

RESULTS O
The O
five-year O
actuarial O
rates O
of O
cancer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
at O
any O
site O
and O
of O
distant O
metastases O
in O
the O
radiotherapy-first O
group O
and O
the O
chemotherapy-first O
group O
were O
38 O
percent O
and O
31 O
percent O
( O
P O
= O
0.17 O
) O
and O
36 O
percent O
and O
25 O
percent O
( O
P O
= O
0.05 O
) O
, O
respectively O
. O
['Physiological-Clinical']

Acute O
pressor O
and O
hormonal O
effects O
of O
beta-endorphin O
at O
high O
doses O
in O
healthy O
and O
hypertensive O
subjects O
: O
role O
of O
opioid O
receptor O
agonism O
. O
[]

Patterns O
of O
management O
of O
atrial O
fibrillation O
complicating O
coronary O
artery O
bypass O
grafting O
: O
Results O
from O
the O
PRoject O
of O
Ex-vivo O
Vein O
graft O
ENgineering O
via O
Transfection O
IV O
( O
PREVENT-IV O
) O
Trial O
. O
[]

Among O
patients O
on O
vitamin O
A O
for O
at O
least O
2 O
years O
, O
a O
diet O
rich O
in O
omega-3 O
fatty O
acids O
( O
> O
or O
=0.20 O
g/d O
) O
slowed O
the O
decline O
in O
visual O
field O
sensitivity O
. O
[]

METHODS O
From O
January O
2004 O
to O
January O
2006 O
, O
50 O
patients O
( O
pts O
) O
undergoing O
LA O
were O
selected O
and O
randomized O
for O
use O
of O
the O
EBVS O
( O
25 O
pts O
, O
group O
A O
) O
versus O
the O
UltraSonic O
Shears O
( O
USS O
) O
device O
( O
25 O
pts O
, O
group O
B O
) O
. O
[]

Patients O
with O
untreated O
stage O
I O
MM O
( O
defined O
according O
to O
Durie O
and O
Salmon O
) O
were O
randomised O
between O
being O
followed O
without O
cytostatics O
until O
the O
disease O
progressed O
and O
receiving O
six O
courses O
of O
melphalan O
and O
prednisone O
( O
MP-P O
) O
just O
after O
diagnosis O
; O
stage O
II O
patients O
were O
uniformly O
treated O
with O
MPH-P O
and O
stage O
III O
patients O
were O
randomised O
between O
MPH-P O
and O
four O
courses O
of O
combination O
chemotherapy O
with O
Peptichemio O
, O
vincristine O
and O
prednisone O
( O
PTC-VCR-P O
) O
. O
[]

RESULTS O
Total O
knee O
scores O
, O
knee B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
scores O
, O
pain B-outcome ['Physiological-Clinical']
scores O
, O
WOMAC O
scores O
, O
knee B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
, O
and O
activity B-outcome ['Life-Impact']
scores O
did O
not O
show O
statistically O
significant O
differences O
between O
the O
two O
groups O
preoperatively O
or O
at O
the O
time O
of O
the O
final O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Goal B-outcome ['Life-Impact']
attainment I-outcome ['Life-Impact']
scaling I-outcome ['Life-Impact']
as O
an O
outcome O
measure O
in O
randomized O
controlled O
trials O
of O
psychosocial O
interventions O
in O
autism O
. O
['Life-Impact']

We O
studied O
the O
effects O
after O
single O
doses O
of O
niguldipine O
( O
0.3 O
, O
0.6 O
, O
and O
0.9 O
mg O
intravenously O
; O
8 O
and O
16 O
mg O
orally O
) O
and O
nifedipine O
( O
2 O
mg O
intravenously O
; O
20 O
mg O
orally O
) O
in O
healthy O
male O
volunteers O
in O
randomized O
placebo-controlled O
experiments O
. O
[]

STUDY O
DESIGN O
Prospective O
randomized O
double O
masked O
cross-over O
clinical O
trial O
. O
[]

More O
effective O
pain O
relief O
among O
these O
patients O
is O
warranted O
. O
[]

28.20 O
) O
ml/min O
, O
which O
increased O
compared O
with O
that O
before O
the O
treatment O
( O
( O
125.68 O
? O
[]

The O
lower O
97.5 O
% O
confidence O
bound O
of O
this O
difference O
was O
8.6 O
% O
, O
which O
is O
above O
the O
predefined O
noninferiority O
margin O
of O
15 O
% O
. O
[]

PURPOSE O
For O
patients O
with O
advanced O
gastric O
or O
gastroesophageal O
cancer O
( O
AGGEC O
) O
providing O
clinical O
benefit O
with O
improved O
palliation O
is O
highly O
desirable O
. O
[]

Adjuvant O
L-arginine O
treatment O
for O
in-vitro O
fertilization O
in O
poor O
responder O
patients O
. O
[]

INTRODUCTION O
The O
effect O
of O
different O
injection O
temperatures O
on O
carbonated O
anesthetics O
has O
been O
controversial O
since O
1965 O
. O
[]

The O
authors O
conducted O
a O
mail O
and O
telephone O
survey O
of O
49,605 O
registered O
nurses O
for O
the O
2000 O
National O
Sample O
Survey O
of O
Registered O
Nurses O
and O
sent O
an O
extra O
mailing O
to O
a O
random O
subsample O
( O
n O
= O
4,968 O
) O
. O
[]

The O
effects O
of O
encoding O
in O
hypnosis O
and O
post-hypnotic O
suggestion O
on O
academic O
performance O
. O
[]

The O
ketamine O
group O
also O
showed O
a O
statistically O
significant O
difference O
24 O
h O
post O
infusion O
of O
the O
effect O
of O
pain B-outcome ['Physiological-Clinical']
on O
their O
general O
activity O
( O
P=0.03 O
) O
and O
on O
their O
enjoyment O
of O
life O
( O
P=0.004 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Electrical O
cardioversion O
( O
ECV O
) O
of O
atrial O
fibrillation O
( O
AF O
) O
is O
limited O
by O
a O
5-10 O
% O
failure O
rate O
and O
by O
the O
expense O
arising O
from O
a O
perceived O
need O
for O
general O
anesthesia O
. O
[]

The O
cumulative O
lesion B-outcome ['Physiological-Clinical']
area O
for O
all O
lesions O
was O
reduced O
50 O
% O
in O
patients O
receiving O
ME-609 O
compared O
with O
the O
placebo O
group O
( O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical']

INTERVENTION O
Patients O
were O
randomly O
assigned O
to O
1 O
of O
2 O
balance O
rehabilitation O
programs-with O
and O
without O
visual O
cue O
deprivation O
. O
[]

DESIGN O
Healthy O
men O
( O
20-33 O
years O
old O
) O
had O
an O
infusion O
of O
GHRH O
antagonist O
( O
( O
N-Ac-Tyr O
( O
1 O
) O
, O
D-Arg O
( O
2 O
) O
) O
GHRH-29 O
( O
NH O
( O
2 O
) O
) O
) O
or O
saline O
for O
a O
12-h O
period O
, O
between O
2100 O
and O
0900 O
h. O
An O
i.v O
. O
[]

Comparative O
efficacy O
and O
safety O
of O
twice O
daily O
fluticasone O
propionate O
powder O
versus O
placebo O
in O
the O
treatment O
of O
moderate O
asthma O
. O
[]

It O
was O
possible O
to O
differentiate O
between O
: O
( O
1 O
) O
three O
concentrations O
of O
tretinoin O
in O
a O
commercial O
cream O
product O
line O
; O
( O
2 O
) O
two O
concentrations O
of O
tretinoin O
in O
a O
commercial O
gel O
product O
line O
; O
( O
3 O
) O
different O
vehicles O
( O
gel O
vs. O
cream O
) O
containing O
the O
same O
concentration O
of O
tretinoin O
, O
and O
( O
4 O
) O
tretinoin O
and O
adapalene O
at O
the O
same O
concentration O
. O
[]

All O
procedures O
will O
be O
limited O
to O
one O
session O
and O
the O
symptoms O
before O
and O
after O
treatment O
will O
be O
measured O
by O
assessors O
blinded O
to O
treatment O
allocation O
. O
[]

As O
the O
impoverished O
relational-encoding O
account O
suggests O
, O
critical B-outcome ['Physiological-Clinical']
lures I-outcome ['Physiological-Clinical']
appear O
less O
likely O
to O
come O
to O
mind O
after O
picture O
encoding O
than O
they O
do O
after O
word O
encoding O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
effect O
of O
ethinyl O
estradiol O
20 O
microg/drospirenone O
3 O
mg O
( O
EE O
20 O
microg/DRSP O
3 O
mg O
) O
administered O
according O
to O
a O
24/4 O
regimen O
with O
ethinyl O
estradiol O
20 O
microg/desogestrel O
150 O
microg O
( O
EE O
20 O
microg/DSG O
150 O
microg O
) O
administered O
according O
to O
the O
conventional O
21/7 O
regimen O
on O
lipid O
, O
carbohydrate O
and O
hemostatic O
parameters O
. O
[]

The O
[]

One O
subject O
was O
not O
fully O
anaesthetised O
with O
any O
of O
the O
dosages O
used O
. O
[]

Sixty-five O
healthy O
adults O
aged O
18-29yrs O
took O
part O
in O
this O
double-blind O
, O
placebo-controlled O
study O
assessing O
the O
effects O
of O
12 O
weeks O
daily O
dietary O
supplementation O
with O
docosahexaenoic O
acid-rich O
fish O
oil O
( O
1g O
, O
2g O
) O
or O
placebo O
( O
olive O
oil O
) O
. O
[]

METHODS O
Attrition O
( O
dropouts O
) O
and O
compliance O
with O
treatment O
were O
assessed O
in O
a O
25-week O
randomized O
, O
placebo O
controlled O
, O
crossover O
, O
feasibility O
clinical O
trial O
of O
four O
tea O
treatments O
to O
investigate O
the O
effect O
of O
tea O
on O
oral O
cancer O
biomarkers O
. O
[]

Randomized O
clinical O
trial O
of O
cutting O
balloon O
angioplasty O
versus O
high-pressure O
balloon O
angioplasty O
in O
hemodialysis O
arteriovenous O
fistula O
stenoses O
resistant O
to O
conventional O
balloon O
angioplasty O
. O
[]

The O
results O
were O
measured O
after O
3 O
and O
12 O
months O
by O
a O
research O
assistant O
on O
the O
basis O
of O
a O
constructed O
severity O
scale O
, O
an O
incontinence O
diary O
, O
and O
a O
comparison O
by O
the O
patients O
themselves O
of O
their O
previous O
and O
current O
conditions O
. O
[]

In O
a O
randomised O
trial O
comparing O
core O
decompression O
with O
conservative O
treatment O
we O
tested O
the O
hypothesis O
that O
the O
extent O
of O
necrosis O
at O
the O
initial O
MRI O
predicts O
the O
subsequent O
risk O
of O
collapse O
of O
the O
femoral O
head O
. O
[]

RESULTS O
The O
printed O
intervention O
resulted O
in O
a O
higher O
participation B-outcome ['Life-Impact']
rate O
( O
19 O
% O
) O
than O
the O
Web-based O
intervention O
( O
12 O
% O
) O
. O
['Life-Impact']

Side O
effects O
of O
intraperitoneal O
cisplatin O
included O
vomiting B-outcome ['Physiological-Clinical']
[ O
> O
or O
=grade O
2 O
( O
82 O
% O
) O
] O
, O
rise O
in O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
[ O
> O
or O
=grade O
2 O
( O
14 O
% O
) O
] O
, O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
[ O
grade O
1-2 O
( O
38 O
% O
) O
] O
, O
and O
neurotoxicity B-outcome ['Physiological-Clinical']
[ O
grade O
2-3 O
( O
15 O
% O
) O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Twelve O
healthy O
male O
volunteers O
received O
a O
constant O
30-min O
infusion O
of O
either O
1 O
g O
of O
imipenem O
plus O
1 O
g O
of O
cilastatin O
or O
1 O
g O
of O
meropenem O
. O
[]

The O
results O
of O
the O
trial O
indicated O
the O
effectiveness O
of O
the O
vaccine O
in O
decreasing O
the O
incidence O
of O
intrammammary O
infections O
caused O
by O
Staph O
. O
[]

Liver O
cancer O
incidence O
is O
the O
second O
leading O
cancer O
for O
Cambodian O
men O
and O
the O
sixth O
for O
Cambodian O
women O
. O
[]

But O
there O
was O
no O
significant O
improvement O
in O
control O
group O
( O
t O
= O
1.88 O
, O
P O
> O
0.05 O
) O
. O
[]

Pre- O
and O
postoperative O
data O
as O
well O
as O
markers O
for O
myocardial O
damage O
were O
assessed O
. O
[]

METHODS O
After O
randomization O
, O
patients O
were O
premedicated O
with O
clonidine O
or O
flunitrazepam O
( O
control O
) O
. O
[]

Low O
residual O
platelet O
reactivity O
( O
p O
= O
0.001 O
) O
and O
female O
gender O
( O
p O
= O
0.29 O
) O
were O
independent O
predictors O
of O
bleeding O
events O
. O
[]

There O
were O
420 O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
reported O
; O
242 O
in O
152 O
patients O
( O
21.3 O
% O
) O
with O
ferumoxytol O
and O
178 O
in O
119 O
patients O
( O
16.7 O
% O
) O
with O
placebo O
. O
['Adverse-effects']

Systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
3.8+/-1.4 O
mm O
Hg O
lower O
( O
P O
< O
.006 O
) O
and O
diastolic O
blood O
pressure O
( O
DBP O
) O
was O
2.6+/-1.1 O
mm O
Hg O
lower O
( O
P O
< O
.01 O
) O
in O
the O
FO O
group O
compared O
with O
the O
control O
group O
. O
['Physiological-Clinical']

Patients O
were O
evaluated O
clinically O
for O
48 O
weeks O
after O
initiation O
of O
therapy O
. O
[]

VRE O
and O
SE O
were O
essentially O
equivalent O
on O
standardized O
questionnaires O
, O
willingness B-outcome ['Life-Impact']
to O
fly O
, O
anxiety B-outcome ['Life-Impact']
ratings I-outcome ['Life-Impact']
during I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
flight I-outcome ['Life-Impact']
, O
self-ratings O
of O
improvement O
, O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
intervention O
consisted O
of O
a O
paid O
community O
organizer O
in O
each O
neighborhood O
who O
recruited O
a O
group O
of O
residents O
to O
serve O
as O
a O
community O
action O
board O
. O
[]

The O
purpose O
is O
to O
improve O
stone O
fragmentation O
and O
clearance O
rates O
. O
[]

RESULTS O
There O
was O
no O
difference O
between O
patient O
groups O
with O
regard O
to O
sex O
, O
age O
, O
type O
of O
prosthesis O
and O
time O
since O
operation O
, O
though O
anticoagulant O
status O
was O
more O
often O
inadequate O
in O
group O
II O
. O
[]

Twenty O
children O
with O
autism O
spectrum O
disorder O
age O
4-12 O
years O
were O
randomly O
assigned O
for O
14 O
weeks O
to O
placebo O
( O
n=8 O
) O
or O
mecamylamine O
( O
n=12 O
) O
in O
ascending O
fixed O
doses O
: O
0.5 O
mg/day O
for O
6 O
weeks O
, O
2.5 O
mg O
for O
2 O
weeks O
, O
then O
5 O
mg/day O
for O
6 O
weeks O
. O
[]

Paromomycin O
treatment O
resulted O
in O
improvement O
in O
both O
clinical O
and O
parasitologic O
parameters O
in O
cryptosporidiosis O
in O
AIDS O
. O
[]

METHOD O
We O
used O
an O
intervention O
and O
a O
control O
group O
and O
an O
ABA O
design O
to O
compare O
participants O
' O
percentage O
of O
time O
on O
task O
with O
and O
without O
a O
vest O
. O
[]

Then O
multivariate O
analyses O
were O
used O
to O
identify O
factors O
predictive O
of O
prolonged O
air O
leaks O
and O
their O
duration O
. O
[]

METHODS O
One O
hundred O
nine O
consecutive O
patients O
were O
randomly O
assigned O
to O
either O
surgical O
( O
n=57 O
) O
or O
endovascular O
( O
n=52 O
) O
treatment O
. O
[]

Predicted O
plasma B-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
obtained O
by O
developing O
and O
applying O
a O
population O
pharmacokinetic O
model O
using O
nonlinear O
mixed-effects O
modeling O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
more O
research O
is O
needed O
to O
determine O
the O
cost-efficacy O
of O
more O
labor-intensive O
approaches O
to O
registry O
accrual O
. O
[]

These O
data O
may O
have O
relevance O
for O
the O
pathogenesis O
of O
salt-sensitive O
hypertension O
in O
blacks O
. O
[]

Lowering O
the O
triglyceride/high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
is O
associated O
with O
the O
beneficial O
impact O
of O
pioglitazone O
on O
progression O
of O
coronary B-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
in O
diabetic O
patients O
: O
insights O
from O
the O
PERISCOPE O
( O
Pioglitazone O
Effect O
on O
Regression O
of O
Intravascular O
Sonographic O
Coronary O
Obstruction O
Prospective O
Evaluation O
) O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Participants O
were O
randomly O
assigned O
to O
treatment O
and O
control O
groups O
and O
repeated O
measures O
MANCOVA O
was O
used O
to O
detect O
differences O
in O
pain B-outcome ['Physiological-Clinical']
and O
power O
over O
a O
4-day O
period O
of O
time O
. O
['Physiological-Clinical']

to O
facilitate O
tracheal O
intubation O
and O
atracurium O
10 O
to O
20 O
mg O
i.v O
. O
[]

INTERVENTION O
( O
S O
) O
Participants O
were O
randomly O
assigned O
to O
either O
the O
sertraline O
treatment O
group O
or O
to O
the O
placebo O
group O
for O
the O
3-month O
duration O
of O
the O
GnRH O
agonist O
therapy O
. O
[]

0.07 O
% O
vs. O
+0.02 O
? O
[]

Enhancing O
the O
expert O
system O
by O
adding O
proactive O
telephone O
counseling O
or O
a O
stimulus O
control O
computer O
designed O
to O
produce O
nicotine O
fading O
could O
produce O
preventive O
programs O
with O
greater O
population O
impacts O
. O
[]

HBOT O
had O
no O
significant O
effect O
on O
burn O
depth O
. O
[]

The O
first O
consisted O
of O
a O
brochure O
, O
which O
provided O
answers O
to O
the O
questionnaire O
items O
and O
addressed O
the O
issues O
in O
more O
depth O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
the O
use O
of O
the O
PostureJac O
( O
SomatoCentric O
Systems O
, O
Inc. O
, O
Toronto O
, O
Ontario O
, O
Canada O
) O
, O
a O
posture O
support O
and O
exercise O
jacket O
, O
was O
effective O
in O
enhancing O
deep B-outcome ['Physiological-Clinical']
cervical I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Together O
with O
a O
visual O
analog O
scale O
( O
VAS O
, O
range O
0-100 O
) O
on O
overall B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
, O
the O
questionnaire O
was O
applied O
in O
210 O
RA O
patients O
who O
participated O
in O
a O
randomized O
trial O
comparing O
3 O
types O
of O
multidisciplinary O
care O
. O
['Life-Impact']

We O
also O
evaluated O
visit O
satisfaction O
, O
trust O
, O
stress O
, O
and O
mood O
after O
the O
visit O
by O
means O
of O
a O
questionnaire O
. O
[]

A O
randomized O
therapeutic O
trial O
of O
carbenicillin O
( O
CB O
) O
or O
ampicillin O
( O
AMP O
) O
in O
purulent O
meningitis O
was O
performed O
in O
86 O
pediatric O
and O
adult O
patients O
( O
41 O
Haemophilus O
influenzae O
, O
22 O
Streptococcus O
pneumoniae O
, O
13 O
Neisseria O
meningitidis O
, O
and O
10 O
of O
unknown O
etiology O
) O
. O
[]

Behavioural B-outcome ['Life-Impact']
data O
were O
collected O
using O
a O
standardized O
protocol O
. O
['Life-Impact']

The O
improvement O
was O
higher O
during O
the O
peak O
pollen O
season O
( O
28 O
% O
, O
P O
= O
0.001 O
) O
. O
[]

The O
test O
was O
performed O
under O
examination O
conditions O
. O
[]

This O
study O
evaluated O
the O
wide O
range O
of O
effects O
of O
risperidone O
on O
destructive O
behavior O
of O
2 O
persons O
with O
developmental O
disabilities O
using O
weekly O
functional O
analysis O
sessions O
, O
daily O
observations O
, O
hourly O
home O
data O
, O
weekly O
rating O
scales O
, O
and O
monthly O
psychiatric O
impressions O
. O
[]

RESULTS O
After O
6 O
months O
, O
a O
significant O
reduction O
in O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
, O
LDL-cholesterol B-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
and O
triglycerides B-outcome ['Physiological-Clinical']
( O
P O
< O
0.05 O
) O
, O
and O
a O
significant O
increase O
in O
HDL-cholesterol B-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
were O
observed O
in O
the O
group O
treated O
with O
cerivastatin O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

FINDINGS O
Two O
patients O
were O
lost O
to O
follow-up O
, O
but O
were O
included O
in O
analyses O
. O
[]

Although O
adjuvant O
chemotherapy O
was O
well O
tolerated B-outcome ['Life-Impact']
, O
the O
use O
of O
this O
therapeutic O
approach O
in O
patients O
with O
early O
stage O
MZBCL O
did O
not O
offer O
any O
advantage O
over O
radiotherapy O
alone O
as O
the O
initial O
treatment O
. O
['Life-Impact']

The O
total O
medical B-outcome ['Resource-use']
cost I-outcome ['Resource-use']
at O
3 O
months O
was O
the O
primary O
end-point O
. O
['Resource-use']

A O
randomized O
, O
placebo-controlled O
, O
double-blind O
clinical O
trial O
was O
performed O
to O
test O
the O
hypothesis O
that O
a O
2-g O
single O
dose O
of O
metronidazole O
for O
male O
partners O
of O
women O
with O
bacterial O
vaginosis O
was O
more O
effective O
than O
placebo O
in O
improving O
cure O
rate O
and O
decreasing O
recurrence O
rate O
. O
[]

With O
the O
exception O
of O
RTE O
, O
there O
were O
no O
statistically O
significant O
differences O
between O
groups O
in O
any O
other O
measurements O
at O
baseline O
. O
[]

However O
, O
the O
decline O
in O
HIV B-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
in O
the O
SH O
group O
was O
significantly O
more O
than O
that O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

OBJECTIVES O
The O
goal O
of O
this O
study O
was O
to O
assess O
the O
short- O
and O
long-term O
efficacy O
of O
different O
thrombolytic O
therapy O
regimens O
in O
patients O
with O
leg O
or O
pelvic O
deep O
venous O
thrombosis O
( O
DVT O
) O
. O
[]

The O
median O
( O
25th O
and O
75th O
percentiles O
) O
annual O
change O
in O
BMD B-outcome ['Physiological-Clinical']
was O
-0.5 O
( O
-1.8 O
, O
1.3 O
% O
) O
in O
the O
treated O
group O
and O
-1.5 O
( O
-3.8 O
, O
-0.7 O
% O
) O
in O
the O
control O
group O
. O
['Physiological-Clinical']

Both O
proteins O
, O
along O
with O
Ki-67 O
, O
which O
is O
an O
established O
strong O
determinant O
of O
metastasis O
, O
have O
shown O
promise O
in O
predicting O
the O
outcome O
of O
men O
treated O
with O
radiation O
therapy O
( O
RT O
) O
with O
or O
without O
short-term O
androgen O
deprivation O
( O
STAD O
) O
. O
[]

[ O
Neoton O
and O
thrombolytic O
therapy O
of O
myocardial O
infarction O
] O
. O
[]

The O
access O
opening O
was O
filled O
with O
amalgam O
. O
[]

BACKGROUND O
Bevacizumab O
, O
a O
monoclonal O
antibody O
against O
vascular O
endothelial O
growth O
factor O
, O
has O
shown O
promising O
preclinical O
and O
clinical O
activity O
against O
metastatic O
colorectal O
cancer O
, O
particularly O
in O
combination O
with O
chemotherapy O
. O
[]

rHuEPO O
increased O
the O
efficiency O
of O
autologous O
blood O
collections O
, O
as O
predonation O
haematocrit O
values O
could O
be O
preserved O
in O
the O
high-dosage O
groups O
. O
[]

BACKGROUND O
Free O
radical-mediated O
oxidative O
stress O
has O
been O
implicated O
in O
the O
etiopathogenesis O
of O
several O
disorders O
. O
[]

Effect O
of O
pravastatin O
on O
cardiovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
women O
after O
myocardial O
infarction O
: O
the O
cholesterol O
and O
recurrent O
events O
( O
CARE O
) O
trial O
. O
['Physiological-Clinical']

This O
effect O
was O
more O
pronounced O
in O
whites O
( O
-4.1 O
ng/mL O
( O
P O
= O
0.003 O
) O
) O
compared O
with O
African-Americans O
( O
-0.3 O
ng/mL O
( O
P O
= O
0.7 O
) O
, O
P-interaction O
= O
0.03 O
) O
. O
[]

These O
women O
were O
randomized O
1:5:5 O
to O
one O
of O
three O
arms O
: O
800 O
were O
offered O
a O
high-risk O
HPV O
self-test O
, O
4,000 O
were O
randomized O
to O
a O
telephone O
call O
( O
reported O
previously O
) O
and O
4,000 O
constituted O
a O
control O
group O
( O
standard O
screening O
invitation O
routine O
) O
. O
[]

The O
study O
was O
undertaken O
in O
order O
to O
evaluate O
the O
effect O
of O
prednisone- O
and O
triple-treatment O
upon O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
vitamin B-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
endpoint O
was O
the O
incidence O
of O
grade O
2+ B-outcome ['Physiological-Clinical']
sensory I-outcome ['Physiological-Clinical']
neuropathy I-outcome ['Physiological-Clinical']
( O
SN B-outcome ['Physiological-Clinical']
) O
toxicity B-outcome ['Adverse-effects']
( O
CTCAE O
v O
3.0 O
) O
in O
each O
treatment O
arm O
, O
analyzed O
by O
chi-square O
testing O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Proteinuria B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
patients O
receiving O
combined O
therapy O
in O
comparison O
with O
losartan O
treatment O
after O
3 O
months O
of O
therapy O
( O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical']

Correction O
of O
QT B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
was O
calculated O
using O
Bazett O
's O
formula O
( O
QTcb O
) O
, O
Fridericia O
's O
correction O
( O
QTcf O
) O
, O
and O
Framingham O
formula O
( O
QTcF O
) O
. O
['Physiological-Clinical']

The O
median O
neutrophil B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
at O
14 O
days O
was O
significantly O
higher O
in O
the O
GM O
CSF O
group O
( O
1.90 O
vs. O
0.46 O
x O
10 O
( O
9 O
) O
/l O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
Topical O
administration O
of O
diclofenac O
was O
effective O
in O
maintaining B-outcome ['Physiological-Clinical']
mydriasis I-outcome ['Physiological-Clinical']
during O
vitrectomy O
and O
in O
reducing O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
anterior B-outcome ['Physiological-Clinical']
chamber I-outcome ['Physiological-Clinical']
flare I-outcome ['Physiological-Clinical']
as O
determined O
by O
slit-lamp O
evaluations O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
an O
individual O
initial O
visit O
the O
12 O
volunteers O
were O
introduced O
to O
the O
needle O
sensation O
by O
having O
a O
needle O
inserted O
into O
the O
point O
LI O
11 O
. O
[]

The O
maximal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentration O
( O
Cmax O
) O
of O
ropivacaine O
and O
bupivacaine O
were O
964 O
( O
282 O
) O
ng O
ml O
( O
-1 O
) O
and O
638 O
( O
366 O
) O
ng O
ml O
( O
-1 O
) O
, O
respectively O
. O
['Physiological-Clinical']

A O
lens-solution O
interaction O
was O
identified O
, O
with O
LR O
being O
the O
most O
tolerated B-outcome ['Life-Impact']
when O
administered O
with O
the O
MTL O
. O
['Life-Impact']

Ovarian B-outcome ['Physiological-Clinical']
follicular I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
luteal I-outcome ['Physiological-Clinical']
dynamics I-outcome ['Physiological-Clinical']
were O
determined O
using O
ultrasonography O
. O
['Physiological-Clinical']

This O
study O
shows O
final B-outcome ['Physiological-Clinical']
height I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
60 O
girls O
with O
Turner O
syndrome O
treated O
in O
a O
randomized O
dose-response O
trial O
, O
combining O
GH O
treatment O
with O
low O
dose O
estrogens O
at O
a O
relatively O
young O
age O
. O
['Physiological-Clinical']

Caries B-outcome ['Physiological-Clinical']
increments I-outcome ['Physiological-Clinical']
after O
3 O
years O
, O
in O
terms O
of O
DMF O
teeth O
and O
DMF O
surfaces O
, O
showed O
no O
significant O
differences O
between O
the O
MFP O
test O
group O
( O
444 O
children O
) O
and O
the O
MFP O
control O
group O
( O
450 O
children O
) O
. O
['Physiological-Clinical']

The O
average O
hourly O
incidence O
of O
ventricular B-outcome ['Physiological-Clinical']
premature I-outcome ['Physiological-Clinical']
contractions I-outcome ['Physiological-Clinical']
was O
22 O
with O
placebo O
and O
25 O
with O
hydrochlorothiazide O
. O
['Physiological-Clinical']

Hypnosis O
treatment O
for O
severe B-outcome ['Physiological-Clinical']
irritable I-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
: O
investigation O
of O
mechanism O
and O
effects O
on O
symptoms O
. O
['Physiological-Clinical']

In O
patients O
with O
more O
than O
one O
metastatic O
site O
, O
response O
rate O
was O
higher O
in O
the O
combination O
treatment O
, O
and O
only O
in O
this O
arm O
were O
complete O
responses O
observed O
in O
these O
patients O
. O
[]

RESULTS O
12 O
of O
the O
186 O
patients O
included O
discontinued B-outcome ['Life-Impact']
their O
medication O
before O
the O
end O
of O
the O
trial O
due O
to O
side O
effects O
. O
['Life-Impact']

This O
implies O
a O
certain O
need O
for O
maintenance O
where O
a O
one-piece O
single-implant O
protocol O
( O
test O
) O
allows O
both O
for O
a O
simple O
clinical O
procedure O
at O
placement O
without O
cementation O
problems O
, O
as O
well O
as O
for O
an O
easy O
and O
simple O
maintenance O
of O
installed O
single O
implant O
crowns O
in O
long-term O
function O
. O
[]

Levofloxacin O
was O
effective O
therapy O
for O
9 O
of O
15 O
( O
60 O
% O
) O
patients O
. O
[]

In O
experiment O
3d O
, O
a O
four-diameter O
length O
of O
bone O
was O
removed O
. O
( O
[]

MAIN O
RESULTS O
Of O
144 O
patients O
who O
received O
a O
third O
infusion O
, O
138 O
responded O
to O
questions O
on O
bisphosphonate O
preference O
, O
and O
of O
these O
138 O
, O
92 O
% O
( O
127 O
) O
preferred O
Z O
to O
P O
, O
because O
shorter O
infusions O
caused O
less O
disruption B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
day I-outcome ['Life-Impact']
. O
['Life-Impact']

IDACC O
screened O
for O
depression O
in O
patients O
hospitalized O
in O
South O
Australia O
for O
a O
range O
of O
cardiac O
conditions O
, O
with O
outcome O
measures O
monitored O
for O
12 O
months O
after O
discharge O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
use O
of O
pentoxifylline O
to O
treat O
impotence O
in O
men O
with O
mild O
to O
moderate O
penile O
vascular O
insufficiency O
. O
[]

Recruitment O
concluded O
with O
a O
total O
of O
18,113 O
patients O
. O
[]

Hypercholesterolaemic O
, O
postmenopausal O
women O
were O
given O
30 O
mg O
beta-carotene O
per O
day O
( O
n O
= O
15 O
subjects O
) O
or O
placebo O
capsules O
( O
n O
= O
15 O
subjects O
) O
for O
10 O
weeks O
. O
[]

Peer O
support O
has O
been O
used O
effectively O
in O
a O
variety O
of O
patient O
populations O
, O
but O
its O
effectiveness O
in O
improving O
outcomes O
in O
persons O
with O
chronic O
heart O
failure O
has O
not O
been O
explored O
. O
[]

Levocetirizine O
was O
recently O
introduced O
as O
a O
new O
antihistamine O
said O
to O
be O
free O
from O
sedative O
effects O
. O
[]

Metabolic B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
in O
the O
primary O
tumors O
were O
evident O
after O
2 O
wk O
of O
targeted O
therapy O
and O
correlated O
highly O
with O
metabolic O
responses O
at O
week O
6 O
( O
R O
( O
2 O
) O
= O
0.81 O
) O
. O
['Physiological-Clinical']

The O
incidence O
of O
related O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
5.2 O
% O
with O
ferumoxytol O
and O
4.5 O
% O
with O
placebo O
. O
['Adverse-effects']

UNLABELLED O
Propofol O
causes O
pain O
on O
IV B-outcome ['Resource-use']
injection I-outcome ['Resource-use']
in O
28 O
% O
-90 O
% O
of O
patients O
. O
['Resource-use']

The O
concentrations O
of O
two O
pro-inflammatory O
mediators O
, O
high-sensitivity B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( O
hsCRP B-outcome ['Physiological-Clinical']
) O
and O
interleukin B-outcome ['Physiological-Clinical']
( O
IL O
) O
-6 O
, O
decreased O
significantly O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
examine O
how O
nurses O
perform O
with O
regard O
to O
absolute O
10-year O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
assessment O
in O
actual O
practice O
. O
['Physiological-Clinical']

RESULTS O
We O
enrolled O
50 O
patients O
with O
acute O
ischemic O
stroke O
( O
17 O
, O
17 O
, O
and O
16 O
in O
the O
high O
, O
low O
, O
and O
placebo O
groups O
, O
respectively O
) O
. O
[]

OBJECTIVE O
To O
examine O
the O
efficacy O
of O
a O
modular O
cognitive-behavioral O
therapy O
( O
CBT O
) O
protocol O
relative O
to O
treatment O
as O
usual O
( O
TAU O
) O
among O
children O
with O
high-functioning O
autism O
spectrum O
disorders O
( O
ASD O
) O
and O
clinically O
significant O
anxiety O
. O
[]

These O
studies O
suggest O
that O
anaerobic O
bacteria O
are O
the O
major O
contributors O
to O
wound O
infection O
after O
colon O
surgery O
and O
that O
their O
specific O
reduction O
is O
associated O
with O
a O
lower O
incidence O
of O
wound O
infection O
. O
[]

Results O
of O
laboratory O
and O
clinical O
analysis O
indicate O
that O
mechanism O
of O
remaxol O
action O
is O
based O
on O
hepatoprotective B-outcome ['Physiological-Clinical']
, O
antioxidative B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
duration O
of O
postoperative B-outcome ['Resource-use']
anesthesia I-outcome ['Resource-use']
for O
lidocaine O
was O
2.4 O
hours O
( O
range O
, O
1.4 O
to O
4 O
hours O
) O
, O
compared O
with O
21.5 O
hours O
for O
ropivacaine O
and O
less O
requirement O
for O
analgesics O
during O
the O
first O
24 O
postoperative O
hours O
( O
p O
< O
0.05 O
) O
( O
range O
, O
19 O
to O
23 O
hours O
) O
. O
['Resource-use']

Safety O
and O
efficacy O
of O
donepezil O
in O
children O
and O
adolescents O
with O
autism O
: O
neuropsychological O
measures O
. O
[]

In O
a O
pertussis O
vaccine O
efficacy O
trial O
in O
Germany O
we O
collected O
sera O
from O
vaccinees O
( O
DTaP O
or O
DTP O
) O
after O
the O
third O
and O
fourth O
doses O
of O
vaccine O
or O
at O
comparable O
time O
periods O
in O
DT O
vaccine O
recipients O
. O
[]

Participants O
had O
colonoscopy O
after O
3 O
years O
of O
follow-up O
. O
[]

RESULTS O
Based O
on O
biopsy O
results O
, O
the O
sensitivity B-outcome ['Physiological-Clinical']
, O
specificity O
, O
and O
accuracy O
['Physiological-Clinical']

A O
randomized O
comparison O
of O
alternative O
techniques O
to O
achieve O
coronary O
sinus O
cannulation O
during O
biventricular O
implantation O
procedures O
. O
[]

Colorimeter O
data O
for O
deltaE O
immediately O
after O
treatment O
was O
6.77 O
. O
[]

Given O
the O
lack O
of O
randomized O
data O
, O
to O
date O
, O
no O
regimen O
has O
emerged O
as O
standard O
. O
[]

SETTING O
Single O
university O
hospital O
. O
[]

Intervention O
messages O
focused O
on O
self-monitoring O
using O
pedometers O
and O
overcoming O
barriers O
to O
engaging O
in O
physical O
activity O
. O
[]

Thus O
, O
the O
use O
of O
adjuvants O
capable O
of O
inducing O
earlier O
immune O
protection O
would O
be O
highly O
desirable O
. O
[]

OBJECTIVES O
We O
evaluated O
the O
impact O
of O
a O
mailed O
, O
tailored O
intervention O
on O
skin B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
prevention O
and O
skin B-outcome ['Life-Impact']
self-examination I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
of O
adults O
at O
moderate O
and O
high O
risk O
for O
skin O
cancer O
. O
['Physiological-Clinical', 'Life-Impact']

Role O
of O
oxidized O
regenerated O
cellulose O
in O
preventing O
infections O
at O
the O
surgical O
site O
: O
prospective O
, O
randomized O
study O
in O
98 O
patients O
affected O
by O
a O
dirty O
wound O
. O
[]

They O
were O
randomized O
to O
receive O
either O
prednisolone O
or O
dexamethasone O
as O
part O
of O
induction O
of O
remission O
. O
[]

Inhibition O
of O
epidural B-outcome ['Physiological-Clinical']
morphine-induced I-outcome ['Physiological-Clinical']
pruritus I-outcome ['Physiological-Clinical']
by O
intravenous O
droperidol O
. O
['Physiological-Clinical']

Formoterol O
caused O
a O
significantly O
higher O
tremor B-outcome ['Physiological-Clinical']
score O
and O
a O
larger O
drop O
in O
S-potassium B-outcome ['Physiological-Clinical']
than O
salmeterol O
at O
the O
highest O
doses O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Of O
57 O
patients O
for O
whom O
we O
thought O
an O
operative O
intervention O
was O
necessary O
, O
30 O
cases O
in O
the O
first O
group O
had O
a O
TURP O
and O
24 O
cases O
in O
the O
second O
group O
had O
a O
PKRP O
. O
[]

METHODS O
The O
( O
13 O
) O
C-octanoic O
acid B-outcome ['Physiological-Clinical']
breath I-outcome ['Physiological-Clinical']
test I-outcome ['Physiological-Clinical']
was O
performed O
in O
eight O
male O
habitual O
smokers O
on O
two O
randomized O
occasions O
( O
either O
sham O
smoking O
or O
actively O
smoking O
) O
. O
['Physiological-Clinical']

This O
study O
is O
registered O
with O
ClinicalTrials.gov O
, O
number O
NCT00435266 O
. O
[]

The O
primary O
end O
points O
are O
percent O
change O
from O
baseline O
in O
LDL-C B-outcome ['Physiological-Clinical']
and O
the O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
anacetrapib O
. O
['Physiological-Clinical', 'Life-Impact']

At O
baseline O
, O
qDES O
achieved O
stent B-outcome ['Physiological-Clinical']
expansion I-outcome ['Physiological-Clinical']
similar O
to O
BMS O
. O
['Physiological-Clinical']

Patients O
were O
randomly O
assigned O
either O
to O
a O
group O
which O
was O
treated O
topically O
with O
Contractubex O
gel O
( O
Merz O
+ O
Co. O
, O
D-Frankfurt/Main O
) O
, O
containing O
10 O
% O
onion O
extract O
, O
50/U O
of O
sodium O
heparin O
per O
one O
g O
of O
gel O
and O
1 O
% O
allantoin O
, O
or O
to O
a O
group O
receiving O
no O
treatment O
. O
[]

RESULTS O
The O
epidural O
group O
had O
significantly O
lower O
pain B-outcome ['Physiological-Clinical']
scores O
at O
3 O
evaluation O
times O
through O
postoperative O
day O
number O
4 O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

There O
were O
two O
malunions B-outcome ['Physiological-Clinical']
in O
the O
reamed O
group O
and O
four O
malunions B-outcome ['Physiological-Clinical']
in O
the O
unreamed O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
the O
14-day O
event O
rates O
in O
these O
2 O
groups O
showed O
that O
the O
115 O
patients O
with O
electrocardiographic O
evidence O
of O
ischemia O
had O
a O
higher O
frequency O
of O
reinfarction B-outcome ['Physiological-Clinical']
( O
20 O
% O
vs O
5.3 O
% O
, O
p O
less O
than O
0.001 O
) O
, O
more O
extensive B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
as O
assessed O
by O
peak O
MB-creatine B-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
levels O
( O
91 O
+/- O
76 O
vs O
37 O
+/- O
19 O
IU/liter O
, O
p O
= O
0.059 O
[ O
Wilcoxon O
rank O
sum O
] O
) O
and O
a O
higher O
mortality B-outcome ['Mortality']
rate O
( O
11.3 O
% O
vs O
1.5 O
% O
, O
p O
= O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

BACKGROUND O
A O
significant O
decrease O
in O
catheter-related O
infections O
was O
demonstrated O
in O
our O
earlier O
randomized O
controlled O
trial O
of O
central O
venous O
catheter O
( O
CVC O
) O
care O
in O
hematologic O
patients O
. O
[]

The O
subjective O
improvement O
in O
various O
degrees O
and O
the O
shrinkage B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
in O
the O
X-ray O
films O
were O
present O
in O
5/25 O
cases O
who O
received O
preoperative O
chemotherapy O
. O
['Physiological-Clinical']

PURPOSE O
Interferon O
( O
IFN O
) O
-based O
adjuvant O
therapy O
in O
melanoma O
is O
associated O
with O
significant O
side O
effects O
, O
which O
necessitates O
evaluation O
of O
health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
( O
HRQOL O
) O
. O
['Life-Impact']

Eleven O
patients O
complained O
of O
side O
effects O
with O
metoclopramide O
and O
three O
stopped O
therapy O
before O
the O
1-month O
course O
was O
completed O
. O
[]

Late B-outcome ['Adverse-effects']
complication I-outcome ['Adverse-effects']
rates O
in O
the O
weekly O
fractionation O
regimen O
appeared O
to O
be O
lower O
than O
figures O
quoted O
by O
other O
authors O
. O
['Adverse-effects']

Analgesic O
uses O
, O
as O
well O
as O
any O
complications O
, O
were O
also O
noted O
by O
the O
patients O
. O
[]

The O
efficacy O
of O
corticosteroid O
treatment O
in O
the O
prophylaxis O
of O
the O
fat B-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
was O
evaluated O
in O
a O
prospective O
, O
randomized O
, O
double-blind O
study O
of O
high-risk O
patients O
with O
long-bone O
fractures O
. O
['Physiological-Clinical']

Clonidine O
, O
an O
alpha O
2-adrenergic O
receptor O
agonist O
, O
has O
been O
shown O
to O
be O
effective O
in O
reducing O
impulsivity O
, O
inattention O
, O
and O
hyperactivity O
associated O
with O
attention O
deficit O
disorder O
with O
hyperactivity O
. O
[]

Self-reported O
smoking B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
was O
biochemically O
confirmed O
with O
expired O
air B-outcome ['Life-Impact']
carbon I-outcome ['Life-Impact']
monoxide I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

To O
verify O
the O
efficacy O
and O
the O
tolerability B-outcome ['Life-Impact']
of O
local O
immunotherapy O
( O
LI O
) O
by O
inhalation O
of O
a O
powder O
extract O
of O
house O
dust O
mite O
( O
HDM O
) O
, O
in O
comparison O
with O
parenteral O
immunotherapy O
( O
PI O
) O
by O
injection O
, O
10 O
patients O
with O
asthma O
due O
to O
HDM O
were O
studied O
in O
a O
blind O
fashion O
. O
['Life-Impact']

Clinical O
and O
laboratory O
evaluations O
were O
performed O
at O
each O
visit O
. O
[]

RESULTS O
There O
were O
no O
significant O
differences O
in O
the O
incidence O
of O
chronic B-outcome ['Physiological-Clinical']
lung I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( O
28 O
day O
and O
36 O
week O
definitions O
) O
, O
death B-outcome ['Mortality']
, O
pneumothorax O
, O
intraventricular O
haemorrhage O
, O
number O
of O
ventilator B-outcome ['Resource-use']
days I-outcome ['Resource-use']
, O
or O
['Physiological-Clinical', 'Mortality', 'Resource-use']

During O
the O
study O
, O
a O
set O
of O
metabolic B-outcome ['Physiological-Clinical']
and O
non-metabolic B-outcome ['Physiological-Clinical']
parameters O
was O
monitored O
, O
as O
were O
the O
clinostatic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
orthostatic I-outcome ['Physiological-Clinical']
blood O
pressure O
values O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
AND O
METHODS O
The O
European O
Lung O
Cancer O
Working O
Party O
( O
ELCWP O
) O
performed O
a O
randomized O
trial O
with O
the O
primary O
end O
point O
to O
determine O
if O
maintenance O
chemotherapy O
with O
12 O
courses O
of O
etoposide O
( O
120 O
mg/m2 O
on O
days O
1 O
and O
3 O
) O
and O
vindesine O
( O
3 O
mg/m2 O
on O
day O
3 O
) O
could O
improve O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
small-cell O
lung O
cancer O
( O
SCLC O
) O
patients O
who O
responded O
to O
six O
courses O
of O
induction O
chemotherapy O
with O
ifosfamide O
, O
etoposide O
, O
and O
an O
anthracycline O
( O
doxorubicin O
or O
epirubicin O
) O
. O
['Mortality']

Only O
two O
groups O
( O
Optibond O
FL O
and O
G O
Bond O
) O
presented O
equal O
percentages O
of O
marginal B-outcome ['Physiological-Clinical']
adaptation I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
enamel I-outcome ['Physiological-Clinical']
and O
dentin B-outcome ['Physiological-Clinical']
; O
in O
the O
other O
groups O
, O
the O
rate O
of O
degradation B-outcome ['Physiological-Clinical']
was O
product O
dependent O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
was O
conducted O
to O
investigate O
the O
effect O
of O
smoking B-outcome ['Life-Impact']
on O
gastric O
emptying O
of O
solids O
in O
Japanese O
smokers O
. O
['Life-Impact']

Bevacizumab-augmented O
retinal O
laser O
photocoagulation O
in O
proliferative O
diabetic O
retinopathy O
: O
a O
randomized O
double-masked O
clinical O
trial O
. O
[]

Evaluation O
of O
the O
immune O
status O
. O
[]

BACKGROUND O
There O
is O
a O
paucity O
of O
data O
on O
the O
efficacy O
of O
nitrofurantoin O
for O
the O
treatment O
of O
acute O
uncomplicated O
cystitis O
in O
regimens O
shorter O
than O
7 O
days O
. O
[]

Each O
of O
the O
four O
periods O
lasted O
5 O
wk O
and O
was O
followed O
by O
a O
4-wk O
washout O
interval O
. O
[]

Employing O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
design O
, O
95 O
participants O
were O
assigned O
to O
one O
of O
two O
groups O
and O
administered O
a O
single O
dose O
of O
either O
secretin O
or O
placebo O
. O
[]

The O
highest O
rate O
pressure O
product O
during O
the O
cold O
pressor O
test O
was O
about O
109 O
units O
. O
[]

The O
effects O
of O
the O
angiotensin-converting O
enzyme O
inhibitor O
imidapril O
on O
plasma O
plasminogen O
activator O
inhibitor O
activity O
in O
patients O
with O
acute O
myocardial O
infarction O
. O
[]

Gastric O
emptying O
disorders O
may O
play O
a O
role O
in O
the O
development O
of O
these O
upper O
gastrointestinal O
diseases O
. O
[]

Phase O
II O
multi-institutional O
prospective O
randomised O
trial O
comparing O
S-1+paclitaxel O
with O
S-1+cisplatin O
in O
patients O
with O
unresectable O
and/or O
recurrent O
advanced O
gastric O
cancer O
. O
[]

The O
percentage O
of O
heartburn-free B-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
with O
esomeprazole O
40 O
mg O
( O
63 O
% O
, O
66 O
% O
) O
or O
20 O
mg O
( O
63 O
% O
, O
68 O
% O
) O
than O
with O
placebo O
( O
46 O
% O
, O
36 O
% O
; O
P O
< O
or O
= O
0.001 O
) O
in O
each O
of O
the O
two O
studies O
. O
['Physiological-Clinical']

The O
muscles O
surrounding O
the O
hip O
were O
found O
to O
be O
most O
important O
in O
maintaining O
control O
of O
the O
trunk O
and O
preventing B-outcome ['Physiological-Clinical']
collapse I-outcome ['Physiological-Clinical']
in O
response O
to O
the O
FP O
. O
['Physiological-Clinical']

Less O
than O
half O
of O
the O
subjects O
were O
intellectually B-outcome ['Life-Impact']
disabled I-outcome ['Life-Impact']
; O
117 O
( O
78.5 O
% O
) O
were O
rated O
Moderate O
or O
Marked O
on O
the O
Clinical O
Global O
Impression O
for O
Severity O
. O
['Life-Impact']

However O
, O
there O
were O
no O
significant O
differences O
between O
any O
other O
dentin O
surface O
treatment O
groups O
( O
p O
> O
0.05 O
) O
. O
[]

Ovulation O
was O
randomly O
triggered O
( O
hCG O
5000 O
IU O
, O
IM O
) O
when O
the O
leading O
follicle O
diameter O
ranged O
between O
either O
16.0 O
and O
16.9 O
mm O
( O
Early O
hCG O
group O
, O
n=227 O
) O
or O
18.0 O
and O
18.9 O
mm O
( O
Late O
hCG O
group O
, O
n=207 O
) O
and O
IUI O
was O
performed O
approximately O
36 O
h O
later O
. O
[]

The O
current O
study O
sought O
to O
address O
these O
issues O
by O
examining O
how O
individual O
differences O
in O
alcohol O
consequences O
influence O
outcomes O
of O
a O
laboratory-based O
computerized O
intervention O
. O
[]

A O
Scandinavian-Polish O
placebo O
controlled O
, O
randomised O
multicenter O
study O
. O
[]

With O
0.05 O
mg O
propofol/kg O
per O
minute O
all O
patients O
required O
additional O
bolus O
injections O
of O
propofol O
; O
with O
0.10 O
mg O
8 O
patients O
, O
with O
0.15 O
mg O
5 O
patients O
, O
and O
with O
0.20 O
mg O
1 O
patient O
required O
bolus O
injection O
. O
[]

Follow-up O
for O
1 O
to O
9 O
years O
( O
mean O
, O
31/2 O
years O
) O
demonstrated O
durability B-outcome ['Life-Impact']
. O
['Life-Impact']

The O
primary O
end O
point O
was O
the O
American O
College O
of O
Rheumatology B-outcome ['Physiological-Clinical']
20 O
% O
improvement O
criteria O
( O
ACR20 B-outcome ['Physiological-Clinical']
) O
response O
rate O
at O
week O
12 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESEARCH O
DESIGN O
AND O
METHODS O
AND O
RESULTS O
We O
performed O
a O
prospective O
, O
randomized O
, O
double-blind O
study O
on O
patients O
with O
documented O
stable O
coronary O
artery O
disease O
and O
normal O
glucose O
tolerance O
. O
[]

Shear O
bond O
values O
of O
the O
ceramic O
brackets O
were O
higher O
than O
those O
of O
the O
metal O
brackets O
independent O
of O
HFLCS O
application O
( O
P O
< O
0.001 O
) O
. O
[]

The O
beneficial O
effects O
of O
buspirone O
in O
helping O
this O
patient O
with O
autism O
in O
his O
natural O
daily O
settings O
suggest O
that O
buspirone O
may O
be O
an O
alternative O
to O
neuroleptic O
agents O
in O
the O
medical O
therapy O
of O
autism O
; O
further O
study O
in O
other O
patients O
is O
needed O
. O
[]

The O
odds O
ratio O
associated O
with O
the O
fibre O
treatment O
was O
significantly O
higher O
in O
participants O
with O
baseline O
dietary O
calcium O
intake O
above O
the O
median O
than O
in O
those O
with O
intake O
below O
the O
median O
( O
interaction O
test O
, O
p=0.028 O
) O
INTERPRETATION O
Supplementation O
with O
fibre O
as O
ispaghula O
husk O
may O
have O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
['Adverse-effects']

RESULT O
( O
S O
) O
One O
thousand O
five O
hundred O
eighteen O
oocytes O
were O
collected O
in O
106 O
oocyte O
retrievals O
: O
849 O
oocytes O
were O
randomly O
allocated O
to O
ICSI O
, O
of O
which O
761 O
were O
microinjected O
, O
and O
669 O
oocytes O
were O
randomly O
assigned O
to O
IVF O
. O
[]

Their O
combination O
can O
evaluate O
more O
accurately O
the O
efficacy O
of O
antiangiogenic O
therapy O
of O
NSCLC O
. O
[]

METHODS O
The O
study O
was O
conducted O
as O
a O
double-blinded O
, O
randomized O
controlled O
trial O
. O
[]

After O
240 O
min O
, O
nasal B-outcome ['Physiological-Clinical']
airflow I-outcome ['Physiological-Clinical']
was O
increased O
by O
20 O
% O
following O
betamethasone O
( O
P O
< O
0.05 O
) O
and O
by O
19 O
% O
following O
methylprednisolone O
. O
['Physiological-Clinical']

Results O
of O
the O
EICESS-92 O
Study O
: O
two O
randomized O
trials O
of O
Ewing O
's O
sarcoma O
treatment O
-- O
cyclophosphamide O
compared O
with O
ifosfamide O
in O
standard-risk O
patients O
and O
assessment O
of O
benefit O
of O
etoposide O
added O
to O
standard O
treatment O
in O
high-risk O
patients O
. O
[]

In O
total O
, O
87 O
% O
( O
95 O
% O
CI O
, O
74 O
to O
94 O
) O
and O
72 O
% O
( O
95 O
% O
CI O
, O
58 O
to O
84 O
) O
of O
the O
patients O
in O
the O
FIN-RACo O
and O
the O
SINGLE O
treatment O
arms O
, O
respectively O
, O
had O
no O
erosive B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in O
large O
joints O
at O
11 O
years O
. O
['Physiological-Clinical']

Office O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
candesartan O
group O
at O
follow-up O
than O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

The O
combination O
of O
an O
angiotensin-converting O
enzyme O
inhibitor O
and O
an O
angiotensin O
receptor O
blocker O
could O
provide O
a O
higher O
degree O
of O
blockade O
of O
the O
renin-angiotensin O
system O
than O
either O
agent O
alone O
. O
[]

With O
regard O
to O
food O
selection O
ability O
scores O
of O
experimental O
, O
control O
groups O
A O
and O
B O
the O
F O
ratio O
was O
also O
significant O
( O
F O
( O
2,190 O
) O
=20.92 O
, O
p O
< O
0.01 O
) O
. O
[]

With O
respect O
to O
quality O
of O
life O
, O
after O
correcting O
for O
baseline O
imbalances O
, O
there O
were O
no O
significant O
differences O
between O
treatments O
for O
any O
scale O
, O
except O
diarrhea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

After O
2 O
years O
, O
the O
drug-treatment O
strategy O
became O
unrestricted O
, O
but O
still O
targeted O
remission O
. O
[]

The O
number O
of O
treated O
legs O
was O
therefore O
98 O
, O
but O
two O
patients O
were O
lost O
to O
follow-up O
. O
[]

DESIGN/METHODS O
Prospective O
randomized O
, O
controlled O
trial O
. O
[]

The O
use O
of O
psychotropic O
medications O
was O
low O
in O
both O
groups O
( O
approximately O
3 O
% O
) O
. O
[]

CONCLUSIONS O
All O
ZrO O
( O
2 O
) O
copings O
demonstrated O
different O
levels O
of O
light O
transmission O
, O
with O
the O
2 O
Lava O
specimens O
showing O
the O
highest O
values O
. O
[]

Papular O
urticaria O
( O
PU O
) O
is O
among O
the O
commonest O
skin O
ailments O
in O
children O
. O
[]

The O
prevalence O
of O
poor O
diet O
in O
the O
intervention O
group O
was O
lower O
compared O
with O
the O
control O
group O
[ O
relative O
risk O
( O
RR O
) O
= O
0.30 O
; O
95 O
% O
CI O
= O
0.13-0.71 O
) O
. O
[]

CONCLUSIONS O
The O
CBT O
manual O
employed O
in O
this O
study O
is O
one O
of O
the O
first O
adaptations O
of O
an O
evidence-based O
treatment O
for O
children O
with O
autism O
spectrum O
disorders O
. O
[]

The O
average O
analgesic B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
was O
lower O
in O
the O
bupivacaine O
group O
, O
but O
this O
did O
not O
reach O
statistical O
significance O
. O
['Resource-use']

To O
clarify O
the O
influence O
of O
stimulus O
intensity O
and O
choice O
of O
calcium O
blocker O
on O
these O
reported O
differences O
in O
outcome O
, O
we O
performed O
noncumulative O
thermal O
stimulus-response O
curves O
using O
isocapnic O
hyperventilation O
of O
cold O
air O
in O
8 O
asthmatics O
. O
[]

The O
5-year O
actuarial O
survival B-outcome ['Mortality']
was O
78 O
% O
. O
['Mortality']

Gabapentin O
but O
not O
vigabatrin O
is O
effective O
in O
the O
treatment O
of O
acquired O
nystagmus O
in O
multiple O
sclerosis O
: O
How O
valid O
is O
the O
GABAergic O
hypothesis O
? O
[]

This O
report O
examines O
associations O
of O
stages O
of O
change O
with O
diet O
prospectively O
and O
addresses O
whether O
( O
1 O
) O
baseline O
stage O
of O
change O
predicts O
participation O
, O
( O
2 O
) O
forward O
changes O
in O
stage O
movement O
were O
greater O
in O
treatment O
work O
sites O
, O
and O
( O
3 O
) O
change O
in O
stage O
was O
associated O
with O
adoption O
of O
healthful O
diets O
, O
using O
data O
from O
a O
cohort O
of O
11,237 O
employees O
. O
[]

RESULTS O
In O
the O
placebo O
group O
, O
there O
was O
no O
rise O
in O
HR B-outcome ['Physiological-Clinical']
, O
SBP B-outcome ['Physiological-Clinical']
, O
DBP B-outcome ['Physiological-Clinical']
or O
RPP B-outcome ['Physiological-Clinical']
, O
and O
there O
was O
no O
difference O
between O
the O
placebo O
and O
labetalol O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Toxicity B-outcome ['Adverse-effects']
and O
efficacy O
of O
6-thioguanine O
versus O
6-mercaptopurine O
in O
childhood O
lymphoblastic O
leukaemia O
: O
a O
randomised O
trial O
. O
['Adverse-effects']

Phase O
contrast O
and O
scanning O
electron O
microscopes O
were O
used O
to O
score O
cell B-outcome ['Physiological-Clinical']
quantity I-outcome ['Physiological-Clinical']
, O
morphology B-outcome ['Physiological-Clinical']
and O
cell B-outcome ['Physiological-Clinical']
attachment I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Effect O
of O
L-carnitine O
on O
myocardial O
metabolism O
: O
results O
of O
a O
balanced O
, O
placebo-controlled O
, O
double-blind O
study O
in O
patients O
undergoing O
open O
heart O
surgery O
. O
[]

One O
hundred O
and O
eight O
( O
98 O
% O
) O
of O
patients O
were O
followed O
up O
clinically O
after O
a O
median O
of O
five O
months O
( O
range O
1-20 O
) O
. O
[]

These O
findings O
give O
directions O
for O
future O
studies O
investigating O
whether O
deficits O
in O
startle O
pathways O
may O
explain O
the O
prominent O
backward O
instability O
seen O
in O
patients O
with O
Parkinson O
's O
disease O
and O
progressive O
supranuclear O
palsy O
. O
[]

Therefore O
, O
the O
infrared O
LED O
irradiation O
during O
treadmill O
training O
can O
improve O
maximal O
performance O
and O
post-exercise O
recovery O
in O
postmenopausal O
women O
. O
[]

We O
conclude O
that O
Pgp O
has O
prognostic O
relevance O
in O
CML-BP O
but O
that O
the O
modulation O
of O
Pgp O
function O
with O
CsA O
as O
applied O
in O
this O
trial O
is O
ineffective O
. O
[]

Three O
patients O
in O
each O
group O
were O
treated O
for O
croup B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
( O
1.2 O
% O
cuffed O
; O
1.3 O
% O
uncuffed O
) O
. O
['Physiological-Clinical']

Development O
, O
awareness O
and O
inductive O
selectivity O
. O
[]

OBJECTIVE O
To O
compare O
the O
efficacy O
, O
safety O
, O
and O
tolerability B-outcome ['Life-Impact']
of O
6 O
dosages O
of O
oral O
tofacitinib O
( O
CP-690,550 O
) O
with O
placebo O
for O
the O
treatment O
of O
active O
rheumatoid O
arthritis O
( O
RA O
) O
in O
patients O
receiving O
a O
stable O
background O
regimen O
of O
methotrexate O
( O
MTX O
) O
who O
have O
an O
inadequate O
response O
to O
MTX O
monotherapy O
. O
['Life-Impact']

MEASUREMENTS O
After O
4 O
days O
of O
ambulatory O
treatment O
, O
patients O
were O
hospitalized O
, O
and O
IOP B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
were O
obtained O
in O
the O
supine O
and O
sitting O
positions O
with O
a O
handheld O
electronic O
tonometer O
( O
Tono-Pen O
XL O
, O
Bio-Rad O
, O
Glendale O
, O
Calif O
) O
and O
a O
Goldmann O
's O
applanation O
tonometer O
, O
covering O
every O
2-hour O
interval O
, O
around O
the O
clock O
, O
but O
not O
more O
than O
at O
four O
time O
points O
per O
day O
during O
a O
5-day O
period O
. O
['Physiological-Clinical']

This O
study O
examined O
whether O
supervised O
moderate-intensity O
exercise O
could O
mitigate O
the O
complications O
that O
occur O
during O
radiotherapy O
. O
[]

Clinicians O
' O
biases O
about O
the O
medical O
cooperativeness O
of O
blacks O
versus O
whites O
, O
however O
, O
may O
have O
influenced O
treatment O
decisions O
. O
[]

One O
hundred O
seventy-three O
patients O
had O
no O
previous O
history O
of O
variceal O
bleeding O
. O
[]

Children O
with O
Asperger O
's O
syndrome O
show O
deficits O
in O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
while O
their O
intellectual O
and O
language O
development O
is O
intact O
suggesting O
a O
specific O
dysfunction O
in O
mechanisms O
mediating O
social B-outcome ['Life-Impact']
cognition I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Patients O
who O
received O
calcium O
alone O
showed O
a O
decline O
in O
spinal B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
, O
both O
after O
6 O
and O
12 O
months O
( O
P O
< O
.03 O
and O
P O
< O
.005 O
, O
respectively O
) O
; O
femoral O
density O
in O
this O
group O
also O
decreased O
after O
6 O
and O
12 O
months O
( O
P O
< O
.002 O
and O
P O
< O
.05 O
, O
respectively O
) O
. O
['Physiological-Clinical']

This O
phase O
III O
study O
assessed O
the O
impact O
of O
postoperative O
adjuvant O
gefitinib O
on O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality']

CONCLUSION O
Ibuprofen O
is O
a O
potent O
antipyretic B-outcome ['Physiological-Clinical']
agent O
and O
is O
a O
safe O
alternative O
for O
the O
selected O
febrile O
child O
who O
may O
benefit O
from O
antipyretic O
medication O
but O
who O
either O
can O
not O
take O
or O
does O
not O
achieve O
satisfactory O
antipyresis B-outcome ['Physiological-Clinical']
with O
acetaminophen O
. O
['Physiological-Clinical', 'Physiological-Clinical']

IV O
. O
[]

9.6 O
% O
placebo O
) O
, O
face O
numbness O
( O
1.6 O
% O
Cappra O
( O
? O
) O
, O
[]

This O
study O
sought O
to O
determine O
the O
comparative O
effects O
of O
0.05 O
percent O
desonide O
and O
2.5 O
percent O
hydrocortisone O
ointments O
on O
the O
HPA O
axis O
of O
children O
with O
atopic O
dermatitis O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
and O
bacteriological B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
were O
excellent O
, O
with O
netilmicin O
and O
tobramycin O
equally O
effective O
, O
but O
the O
incidences O
of O
nephrotoxicity B-outcome ['Physiological-Clinical']
and O
ototoxicity B-outcome ['Physiological-Clinical']
were O
lower O
in O
patients O
treated O
with O
netilmicin O
than O
those O
receiving O
tobramycin O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

LIMITATIONS O
Small O
sample O
size O
. O
[]

The O
findings O
of O
this O
study O
demonstrated O
that O
the O
Asha-Life O
participants O
significantly O
reduced O
their O
depressive B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
scores O
compared O
to O
the O
Usual O
Care O
participants O
. O
['Life-Impact']

Costs B-outcome ['Resource-use']
were O
calculated O
as O
the O
product O
of O
resources O
used O
and O
unit O
costs O
. O
['Resource-use']

There O
was O
no O
difference O
in O
acceptability B-outcome ['Life-Impact']
of O
['Life-Impact']

Mouth O
closing O
device O
( O
chinstrap O
) O
reduces O
mouth B-outcome ['Physiological-Clinical']
leak I-outcome ['Physiological-Clinical']
during O
nasal O
CPAP O
. O
['Physiological-Clinical']

Propofol O
was O
administered O
after O
release O
of O
venous O
occlusion O
. O
[]

Among O
patients O
who O
achieved O
50 O
% O
improvement O
in O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
according O
to O
the O
American O
College O
of O
Rheumatology O
criteria O
, O
only O
?20 O
% O
required O
a O
reduction O
in O
acute-phase O
reactant O
values O
in O
order O
to O
fulfill O
the O
criteria O
. O
['Physiological-Clinical']

The O
percentage O
reductions O
in O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
in O
the O
infused O
arm O
, O
in O
response O
to O
the O
maximum O
dose O
of O
angiotensin O
II O
( O
50,000 O
fmol O
min-1 O
) O
were O
48.1 O
+/- O
3.6 O
% O
at O
baseline O
, O
57.5 O
+/- O
3.6 O
% O
on O
placebo O
and O
54.5 O
+/- O
4.2 O
% O
on O
enalapril O
. O
['Physiological-Clinical']

The O
findings O
from O
this O
14 O
day O
study O
in O
healthy O
volunteers O
support O
the O
hypothesis O
that O
bisphosphonates O
may O
differ O
from O
one O
another O
in O
their O
potential O
to O
produce O
upper O
GI O
mucosal O
damage O
. O
[]

However O
, O
only O
individuals O
who O
were O
uninformed O
of O
the O
placebo O
condition O
showed O
significant O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
vigor B-outcome ['Physiological-Clinical']
increases O
with O
125 O
mg O
caffeine O
, O
and O
significant O
hand B-outcome ['Physiological-Clinical']
steadiness I-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
and O
vigor B-outcome ['Physiological-Clinical']
increases O
with O
325 O
mg O
caffeine O
compared O
to O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Gastrointestinal O
nematodes O
, O
such O
as O
Ostertagia O
ostertagi O
and O
several O
species O
of O
Cooperia O
, O
are O
ubiquitous O
in O
temperate O
climates O
and O
have O
been O
shown O
to O
have O
detrimental O
effects O
on O
production O
in O
adult O
dairy O
cattle O
. O
[]

METHOD O
This O
multicenter O
, O
double-blind O
, O
randomized O
, O
placebo-controlled O
, O
relapse-prevention O
trial O
enrolled O
patients O
( O
6-17 O
years O
) O
who O
met O
the O
current O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
Fourth O
Edition O
, O
Text O
Revision O
( O
DMS-IV-TR O
) O
criteria O
for O
autistic O
disorder O
and O
who O
also O
had O
serious O
behavioral O
problems O
( O
ie O
, O
tantrums O
, O
aggression O
, O
self-injurious O
behavior O
, O
or O
a O
combination O
of O
these O
behavioral O
problems O
) O
between O
March O
2011 O
and O
June O
2012 O
. O
[]

Efficacy O
and O
safety O
of O
bexarotene O
combined O
with O
psoralen-ultraviolet O
A O
( O
PUVA O
) O
compared O
with O
PUVA O
treatment O
alone O
in O
stage O
IB-IIA O
mycosis O
fungoides O
: O
final O
results O
from O
the O
EORTC O
Cutaneous O
Lymphoma O
Task O
Force O
phase O
III O
randomized O
clinical O
trial O
( O
NCT00056056 O
) O
. O
[]

It O
can O
be O
speculated O
, O
however O
, O
that O
the O
decline O
of O
plasminogen B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
after O
surgery O
in O
patients O
receiving O
this O
drug O
was O
the O
result O
of O
its O
stimulatory O
influence O
on O
the O
conversion O
of O
plasminogen O
into O
plasmin O
. O
['Physiological-Clinical']

Bitewing O
film O
quality O
: O
a O
clinical O
comparison O
of O
the O
loop O
vs. O
holder O
techniques O
. O
[]

No O
differences O
were O
found O
in O
side O
effects O
or O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Life-Impact']

RESULTS O
Of O
538 O
catheters O
randomized O
, O
481 O
( O
89.4 O
% O
) O
produced O
evaluable O
culture B-outcome ['Physiological-Clinical']
results O
. O
['Physiological-Clinical']

Experiments O
with O
guinea O
pigs O
( O
n O
= O
10 O
) O
showed O
that O
pulsed O
low-intensity O
direct O
current O
caused O
a O
rapid B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
flux I-outcome ['Physiological-Clinical']
in O
the O
epidermis O
. O
['Physiological-Clinical']

RESULTS O
Dapsone O
gel-treated O
patients O
achieved O
superior O
results O
in O
terms O
of O
the O
investigator O
's O
global O
acne O
assessment O
( O
P O
< O
.001 O
) O
and O
the O
mean O
percentage O
reduction O
in O
inflammatory B-outcome ['Physiological-Clinical']
, O
noninflammatory B-outcome ['Physiological-Clinical']
, O
and O
total O
['Physiological-Clinical', 'Physiological-Clinical']

The O
irradiation O
parameters O
were O
39 O
mW/cm O
( O
2 O
) O
, O
45 O
min O
and O
108 O
J/cm O
( O
2 O
) O
. O
[]

There O
were O
no O
significant O
changes O
in O
either O
group O
in O
the O
rates O
of O
nasopharyngeal B-outcome ['Physiological-Clinical']
colonization I-outcome ['Physiological-Clinical']
with O
nonsusceptible O
Streptococcus O
pneumoniae O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
short-term O
efficacy O
and O
safety O
of O
methylphenidate O
( O
MPH O
) O
to O
treat O
attention-deficit/hyperactivity O
disorder O
( O
ADHD O
) O
symptoms O
in O
an O
understudied O
population O
of O
preschoolers O
with O
pervasive O
developmental O
disorder O
( O
PDD O
) O
or O
intellectual O
disability O
( O
ID O
) O
. O
[]

The O
second O
study O
utilized O
cisplatin O
and O
5-fluorouracil O
in O
three O
cycles O
prior O
to O
standard O
treatment O
. O
[]

The O
patient O
's O
perspective O
. O
[]

SETTING O
Women O
referred O
to O
routine O
ultrasound O
examination O
at O
Aker O
and O
Ullev?l O
Hospitals O
in O
Norway O
. O
[]

It O
can O
be O
safely O
added O
to O
standard O
heart O
failure O
therapy O
. O
[]

mean O
circular O
resultant O
( O
MCR O
) O
, O
expiration/inspiration O
( O
E/I O
) O
ratio O
] O
. O
[]

The O
therapies O
included O
hydroxyzine O
with O
or O
without O
doxepin O
at O
night O
, O
pentoxifylline O
, O
indomethacin O
and O
topical O
moisturization O
with O
medium-strength O
topical O
steroids O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
linezolid I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
remained O
above O
the O
MIC90 O
for O
susceptible O
target O
pathogens O
( O
4.0 O
mg/L O
) O
for O
the O
majority O
of O
the O
12 O
h O
dosing O
interval O
. O
['Physiological-Clinical']

Among O
all O
patients O
, O
prognostic O
factors O
that O
significantly O
negatively O
impacted O
RFS B-outcome ['Mortality']
and O
OS B-outcome ['Mortality']
included O
ulceration O
, O
recurrent O
disease O
at O
entry O
, O
enrollment O
in O
E1684 O
, O
and O
age O
> O
49 O
years O
. O
['Mortality', 'Mortality']

Attenuation O
of O
hemodynamic O
responses O
to O
laryngoscopy O
and O
tracheal O
intubation O
during O
rapid O
sequence O
induction O
: O
remifentanil O
vs. O
lidocaine O
with O
esmolol O
. O
[]

Although O
the O
mechanism O
of O
action O
of O
L-carnosine O
is O
not O
well O
understood O
, O
it O
may O
enhance O
neurologic O
function O
, O
perhaps O
in O
the O
enterorhinal O
or O
temporal O
cortex O
. O
[]

Small O
but O
important O
errors O
in O
cardiovascular O
risk O
calculation O
by O
practice O
nurses O
: O
a O
cross-sectional O
study O
in O
randomised O
trial O
setting O
. O
[]

RESULTS O
Assessment O
of O
language B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
and O
parents O
' O
behavioral B-outcome ['Life-Impact']
assessments O
revealed O
no O
significant O
differences O
between O
the O
treatment O
and O
placebo O
groups O
. O
['Life-Impact', 'Life-Impact']

Mean O
outcome O
measures O
Balance B-outcome ['Life-Impact']
under O
6 O
sensory O
conditions O
was O
assessed O
by O
computerized O
dynamic O
posturography O
( O
EquiTest O
) O
, O
gait B-outcome ['Life-Impact']
velocity I-outcome ['Life-Impact']
, O
timed B-outcome ['Life-Impact']
stair I-outcome ['Life-Impact']
climbing I-outcome ['Life-Impact']
, O
and O
self-assessment O
of O
ease O
of O
gait B-outcome ['Life-Impact']
before O
and O
after O
program O
completion O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
The O
relative O
risk O
( O
RR O
) O
of O
developing O
a O
follicular O
structure O
greater O
than O
30 O
mm O
in O
diameter O
during O
a O
cycle O
with O
the O
higher-dose O
monophasic O
pill O
was O
0.5 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
0.1-1.9 O
; O
P O
= O
.49 O
) O
compared O
with O
the O
multiphasic O
pill O
. O
[]

This O
study O
sought O
to O
evaluate O
bleeding B-outcome ['Physiological-Clinical']
rates O
and O
adherence O
to O
treatment O
in O
real-world O
patients O
treated O
with O
prasugrel O
. O
['Physiological-Clinical']

Data O
were O
analyzed O
with O
repeated-measures O
ANOVA O
. O
[]

The O
combination O
of O
these O
drugs O
seems O
to O
be O
beneficial O
and O
may O
offer O
an O
additional O
renoprotective O
effect O
. O
[]

RESULTS O
Serum-free B-outcome ['Physiological-Clinical']
estradiol I-outcome ['Physiological-Clinical']
and O
estrone B-outcome ['Physiological-Clinical']
levels O
decreased O
moderately O
in O
the O
experimental O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Group O
100 O
received O
0.3 O
mg O
kg-1 O
diazepam O
orally O
with O
100 O
ml O
of O
water O
2 O
h O
before O
surgery O
. O
[]

A O
considerable O
rise O
in O
omega-3 B-outcome ['Physiological-Clinical']
and O
a O
decrease O
in O
omega-6 B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
occurred O
in O
the O
platelet O
phospholipid O
with O
fish-oil O
consumption O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
exclusion O
criteria O
were O
erectile O
dysfunction O
, O
loss O
of O
libido O
, O
alcohol O
and O
substance O
abuse O
, O
mental O
retardation O
, O
diabetes O
mellitus O
, O
thyroid O
disease O
, O
hypotension O
, O
previous O
use O
of O
these O
drugs O
and O
urogenital O
infections O
. O
[]

Several O
microorganisms O
were O
affected O
by O
both O
treatment O
regimens O
. O
[]

Local O
immunotherapy O
by O
inhalation O
of O
a O
powder O
extract O
in O
asthma O
due O
to O
house O
dust O
mite O
Dermatophagoides O
pteronyssinus O
: O
a O
double-blind O
comparison O
with O
parenteral O
immunotherapy O
. O
[]

RESULTS O
At O
baseline O
, O
circulating O
beta-endorphin O
, O
norepinephrine O
, O
and O
endothelin-1 O
in O
hypertensive O
patients O
were O
significantly O
( O
P O
< O
0.05 O
) O
higher O
than O
in O
controls O
. O
[]

Suture B-outcome ['Physiological-Clinical']
line I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
evaluated I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
4 I-outcome ['Physiological-Clinical']
minutes I-outcome ['Physiological-Clinical']
was O
present O
in O
2 O
( O
4 O
% O
) O
of O
51 O
patients O
in O
the O
BP O
group O
and O
13 O
( O
30 O
% O
) O
of O
44 O
patients O
in O
the O
Dacron O
group O
( O
P O
=.001 O
) O
. O
['Physiological-Clinical']

The O
tension-free O
hernioplasty O
in O
a O
randomized O
trial O
. O
[]

Primary O
end O
points O
were O
death O
from O
atherosclerotic O
vascular O
disease O
plus O
amputation B-outcome ['Resource-use']
of I-outcome ['Resource-use']
the I-outcome ['Resource-use']
opposite I-outcome ['Resource-use']
extremity I-outcome ['Resource-use']
for I-outcome ['Resource-use']
gangrene I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

RESULTS O
There O
was O
continuing O
TBPI B-outcome ['Physiological-Clinical']
improvement O
over O
1 O
month O
in O
patients O
given O
saline O
following O
PTA O
. O
['Physiological-Clinical']

Glycemic O
control O
was O
evaluated O
in O
terms O
of O
glycosylated O
hemoglobin O
( O
HbA O
( O
1c O
) O
) O
values O
and O
fasting O
plasma O
glucose O
( O
FPG O
) O
concentrations O
. O
[]

ILM O
delamination O
shows O
improved O
morphological O
results O
, O
and O
appears O
to O
be O
beneficial O
in O
eyes O
with O
preexisting O
PVD O
. O
[]

SETTING O
Places O
in O
south O
east O
London O
providing O
antenatal O
care O
for O
women O
receiving O
shared O
care O
and O
planning O
to O
deliver O
in O
one O
of O
three O
hospitals O
or O
at O
home O
. O
[]

PARTICIPANTS O
Fifty O
eyes O
among O
50 O
patients O
with O
DME O
, O
retinal O
thickness O
? O
[]

The O
purpose O
of O
this O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
was O
to O
investigate O
the O
efficacy O
and O
tolerability O
of O
the O
active O
combination O
in O
the O
treatment O
of O
post-hemorrhoidectomy O
patients O
. O
[]

RESULTS O
Propofol O
produced O
unconsciousness B-outcome ['Physiological-Clinical']
at O
a O
plasma O
concentration O
of O
3.2 O
+/- O
0.8 O
( O
+/- O
SD O
) O
microgram/ml O
( O
n O
= O
17 O
) O
. O
['Physiological-Clinical']

Patients O
are O
randomized O
to O
2 O
groups O
: O
the O
first O
has O
the O
initial O
2 O
shocks O
for O
ventricular O
fibrillation O
conversion O
programmed O
at O
2 O
energy O
steps O
above O
DFT++ O
( O
typically O
4-6 O
J O
, O
maximum O
10 O
J O
) O
with O
subsequent O
shocks O
at O
maximum O
energy O
, O
and O
the O
second O
has O
all O
shocks O
programmed O
at O
maximum O
energy O
. O
[]

Accuracy O
of O
both O
ECD-based O
and O
TCT-based O
registrations O
was O
assessed O
by O
comparing O
the O
normalisation O
parameter O
values O
and O
regional O
activities O
in O
the O
spatially O
normalised O
ECD O
images O
, O
using O
a O
mixed-model O
analysis O
of O
variance O
( O
ANOVA O
) O
. O
[]

The O
radiotherapy O
was O
performed O
in O
the O
same O
way O
in O
all O
patients O
with O
irradiations O
of O
the O
thoracic O
wall O
and O
the O
regional O
lymph O
nodes O
. O
[]

The O
administration O
of O
propofol O
by O
infusion O
for O
maintenance O
of O
anesthesia O
has O
attracted O
much O
attention O
recently O
. O
[]

Health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
improved O
by O
20 O
% O
in O
patients O
using O
MF-DPI O
once-daily O
in O
the O
evening O
and O
by O
14 O
% O
in O
patients O
using O
MF-DPI O
twice-daily O
. O
['Life-Impact']

CONCLUSION O
The O
KGQG O
could O
effectively O
ameliorate O
liver O
function O
and O
facilitate O
the O
inhibition O
and O
degradation O
of O
liver O
fibrosis O
in O
chronic O
hepatitis O
B O
patients O
, O
which O
may O
be O
developed O
as O
a O
novel O
therapeusis O
to O
treat O
this O
hard-to-cure O
disease O
. O
[]

In O
the O
first O
group O
44 O
patients O
were O
given O
continually O
a O
daily O
dose O
of O
tamoxifen O
( O
TAM O
) O
of O
20 O
mg/m2 O
. O
[]

INTERPRETATION O
Contrary O
to O
previous O
studies O
of O
cemented O
stems O
, O
the O
use O
of O
fluoride O
cement O
did O
not O
influence O
the O
periprosthetic B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
2 O
years O
after O
the O
examination O
. O
['Physiological-Clinical']

An O
individualized O
approach O
was O
applied O
either O
alone O
or O
combined O
with O
the O
commercial O
Weight O
Watchers O
program O
. O
[]

Tests O
were O
: O
modified O
Ashworth O
scale O
( O
MAS O
) O
scoring O
; O
H-reflex O
testing O
with O
and O
without O
Achilles O
tendon O
vibration O
; O
H-reflex O
testing O
with O
and O
without O
dorsiflexor O
contraction O
; O
reflex B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
angle I-outcome ['Physiological-Clinical']
and O
timed B-outcome ['Life-Impact']
toe I-outcome ['Life-Impact']
tapping I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
TTT I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Sympathetic O
nervous O
inhibition O
with O
rilmenidine O
contrasted O
with O
an O
absence O
of O
suppression O
of O
the O
secretion O
of O
adrenaline O
affirming O
that O
here O
, O
as O
elsewhere O
, O
sympathetic B-outcome ['Life-Impact']
nervous I-outcome ['Life-Impact']
and O
adrenal B-outcome ['Physiological-Clinical']
medullary I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
can O
be O
disconnected O
. O
['Life-Impact', 'Physiological-Clinical']

The O
ability O
of O
these O
FE O
models O
to O
predict O
failure B-outcome ['Physiological-Clinical']
load I-outcome ['Physiological-Clinical']
as O
determined O
by O
experimental O
biomechanical O
testing O
was O
evaluated O
and O
compared O
to O
the O
predictive O
ability O
of O
DXA O
. O
['Physiological-Clinical']

However O
, O
the O
dose O
of O
enoxaparin O
must O
be O
adjusted O
to O
the O
patient O
's O
weight O
. O
[]

Overall O
survival B-outcome ['Mortality']
was O
similar O
( O
21 O
and O
22 O
months O
for O
PLD O
and O
doxorubicin O
, O
respectively O
; O
HR=0.94 O
; O
95 O
% O
CI O
0.74-1.19 O
) O
. O
['Mortality']

Blood O
samples O
were O
taken O
at O
intervals O
up O
to O
12 O
hours O
after O
triazolam O
treatment O
. O
[]

Quitting O
a O
weight O
loss O
program O
is O
associated O
with O
anhedonia O
: O
preliminary O
findings O
of O
the O
Lifestyle O
Intervention O
Treatment O
Evaluation O
Study O
in O
northern O
Finland O
. O
[]

In O
the O
second O
study O
we O
used O
a O
naturalistic O
follow-up O
design O
. O
[]

The O
median O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
granulocytes I-outcome ['Physiological-Clinical']
less O
than O
500/cu O
mm O
also O
favored O
the O
lithium O
group O
but O
only O
approached O
statistical O
significance O
: O
14.0 O
days O
versus O
20.5 O
days O
, O
p O
= O
0.054 O
. O
['Physiological-Clinical']

The O
functional O
role O
of O
the O
jejunum O
and O
ileum O
with O
regard O
to O
peripheral O
plasma O
levels O
of O
intact O
neurotensin O
and O
NH2-terminal O
immunoreactivity O
of O
neurotensin O
was O
studied O
by O
using O
jejunoileal O
bypass O
as O
a O
model O
. O
[]

Participants O
accumulated O
more O
moderate-to-vigorous O
physical O
activity O
in O
? O
[]

OBJECTIVE O
To O
determine O
the O
effect O
of O
patient O
position O
on O
the O
reproducibility O
of O
cardiac O
output O
measurements O
. O
[]

METHODS O
Between O
1985 O
and O
1991 O
, O
250 O
children O
with O
institutionally O
classified O
high-grade O
gliomas O
were O
enrolled O
on O
CCG-945 O
. O
[]

RESULTS O
Of O
the O
198 O
patients O
randomized O
to O
dipyridamole O
, O
134 O
completed O
the O
add-on O
and O
only O
12 O
the O
monotherapy O
phase O
. O
[]

After O
bracket O
removal O
, O
professional O
tooth O
cleaning O
and O
drying O
, O
a O
visual O
scoring O
( O
0-4 O
) O
and O
laser O
fluorescence O
( O
LF O
) O
readings O
were O
carried O
out O
. O
[]

OBJECTIVE O
This O
study O
aims O
to O
assess O
the O
efficacy O
of O
a O
cyclooxygenase-2 O
inhibitor O
, O
celecoxib O
, O
as O
adjunctive O
therapy O
in O
the O
treatment O
of O
autism O
METHODS O
In O
a O
10-week O
randomized O
double-blind O
placebo-controlled O
study O
, O
40 O
outpatient O
children O
with O
a O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
fourth O
edition O
, O
text O
revision O
clinical O
diagnosis O
of O
autism O
were O
randomly O
allocated O
to O
celecoxib O
plus O
risperidone O
or O
placebo O
plus O
risperidone O
. O
[]

or O
ranitidine O
150 O
mg O
b.d. O
, O
duodenal O
ulcer O
patients O
to O
nizatidine O
300 O
mg O
nocte O
or O
ranitidine O
300 O
mg O
nocte O
. O
[]

Early O
Treatment O
of O
the O
Atopic O
Child O
. O
[]

In O
a O
subgroup O
, O
anti-CT B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
rose O
( O
> O
or O
=2-folds O
) O
in O
23/30 O
( O
77 O
% O
) O
and O
6/19 O
( O
32 O
% O
) O
in O
vaccine O
and O
placebo O
recipients O
, O
respectively O
. O
['Physiological-Clinical']

Ambulatory O
opioid O
detoxification O
can O
give O
internists O
a O
larger O
role O
in O
initiating O
drug O
treatment O
for O
IDUs O
who O
are O
addicted O
to O
opioids O
. O
[]

46 O
upper O
and O
lower O
molars O
with O
furcation O
grade O
II O
involvement O
were O
selected O
from O
16 O
patients O
with O
periodontal O
disease O
. O
[]

A O
highly O
significant O
difference O
for O
bone B-outcome ['Physiological-Clinical']
flap I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
could O
be O
shown O
with O
0.3 O
% O
in O
the O
cefotiam O
group O
versus O
5.1 O
% O
in O
the O
control O
group O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical']

However O
, O
only O
1 O
of O
11 O
women O
in O
the O
treatment O
group O
versus O
5 O
of O
12 O
in O
the O
control O
group O
delivered O
prior O
to O
33 O
completed O
weeks O
; O
OR O
0.14 O
, O
95 O
% O
CI O
0.02-0.95 O
. O
[]

GHRH-induced O
GH O
peak O
in O
uremics O
( O
22.7 O
+/- O
5.2 O
micrograms/l O
) O
was O
not O
different O
from O
that O
obtained O
in O
control O
subjects O
( O
16.0 O
+/- O
4.3 O
micrograms/l O
) O
. O
[]

Findings O
also O
revealed O
a O
conditional O
effect O
of O
FPI O
on O
children B-outcome ['Physiological-Clinical']
's O
expressive B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
outcomes O
at O
12-month O
follow O
up O
, O
suggesting O
that O
children O
with O
baseline O
language O
skills O
below O
12 O
months O
( O
n O
= O
24 O
) O
are O
most O
likely O
to O
benefit O
from O
FPI O
. O
['Physiological-Clinical', 'Life-Impact']

Patients O
were O
monitored O
daily O
for O
recurrence O
of O
pain B-outcome ['Physiological-Clinical']
, O
need B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
stop I-outcome ['Physiological-Clinical']
feeding I-outcome ['Physiological-Clinical']
, O
post-refeeding B-outcome ['Physiological-Clinical']
LOH I-outcome ['Physiological-Clinical']
( O
primary O
end O
point O
) O
, O
and O
for O
28 O
days O
post-refeeding O
to O
capture O
re-admission B-outcome ['Resource-use']
rates O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

However O
, O
addition O
of O
AMF O
to O
a O
diet O
composed O
of O
dry O
whole-shelled O
corn O
resulted O
in O
an O
improvement O
( O
P O
< O
0.05 O
) O
in O
G B-outcome ['Physiological-Clinical']
: O
F O
( O
0.208 O
vs. O
0.194 O
) O
. O
['Physiological-Clinical']

Furthermore O
, O
we O
investigated O
the O
perfusate O
of O
the O
graft O
liver O
in O
both O
groups O
and O
detected O
signs O
of O
a O
decreased O
t-PA B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
in O
the O
infusion O
group O
. O
['Physiological-Clinical']

MEDI-545 O
was O
nonimmunogenic O
, O
had O
a O
half-life B-outcome ['Physiological-Clinical']
of O
21 O
days O
, O
showed O
no O
significant O
inhibition O
of O
the O
type O
I O
IFN O
gene O
signature O
, O
and O
had O
no O
clinical O
activity O
. O
['Physiological-Clinical']

The O
secondary O
goal O
was O
to O
assess O
the O
predictors O
of O
arterial B-outcome ['Physiological-Clinical']
spasm I-outcome ['Physiological-Clinical']
in O
this O
large O
group O
of O
patients O
. O
['Physiological-Clinical']

The O
day-to-day O
variability O
in O
morning O
USG O
( O
coefficient O
of O
variation O
= O
0.2 O
? O
[]

METHODS O
A O
randomised O
controlled O
trial O
was O
performed O
utilising O
volunteer O
senior O
medical O
students O
. O
[]

The O
images O
were O
further O
converted O
into O
a O
standard O
uniform O
brain O
format O
in O
which O
the O
mean O
data O
of O
all O
11 O
subjects O
were O
obtained O
. O
[]

Though O
in O
the O
stent O
group O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
lower O
and O
target O
lesion O
revascularization B-outcome ['Physiological-Clinical']
rate O
was O
higher O
, O
retroinfusion-supported O
stent O
implantation O
was O
associated O
with O
substantially O
lower O
costs B-outcome ['Resource-use']
and O
might O
be O
considered O
as O
an O
alternative O
treatment O
option O
in O
this O
selected O
group O
of O
high-risk O
patients O
. O
['Mortality', 'Physiological-Clinical', 'Resource-use']

Recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
were O
measured O
from O
the O
date O
of O
randomization O
to O
the O
date O
of O
recurrence O
or O
death O
, O
whichever O
occurred O
first O
. O
['Mortality', 'Mortality']

Of O
36 O
patients O
who O
completed O
treatment O
, O
16 O
( O
44.4 O
% O
) O
experienced O
true O
withdrawal B-outcome ['Life-Impact']
phenomena I-outcome ['Life-Impact']
on O
reducing O
their O
drugs O
, O
but O
8 O
other O
patients O
had O
pseudo-withdrawal B-outcome ['Life-Impact']
reactions I-outcome ['Life-Impact']
at O
a O
time O
when O
their O
drug O
treatment O
was O
unchanged O
. O
['Life-Impact', 'Life-Impact']

In O
the O
therapy O
group O
, O
52 O
% O
of O
all O
specimens O
were O
sterile O
, O
in O
the O
control O
group O
only O
25 O
% O
. O
[]

From O
8 O
to O
12 O
weeks O
of O
age O
total O
tract B-outcome ['Physiological-Clinical']
digestibility I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
decreased O
for O
all O
the O
products O
tested O
. O
( O
['Physiological-Clinical']

During O
synchronise O
, O
correlated B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
was O
observed O
in O
bilateral O
SMA O
, O
more O
caudal O
dorsal O
and O
ventral O
PMC O
, O
right O
DLPFC O
and O
right O
primary O
motor O
cortex O
. O
['Life-Impact']

1981 O
to O
Sep. O
1982 O
by O
preoperative O
chemotherapy O
plus O
surgery O
is O
reported O
. O
[]

CONCLUSIONS O
AND O
IMPLICATIONS O
A O
theory-driven O
approach O
is O
valuable O
in O
improving O
behavior O
to O
promote O
bone O
health O
in O
this O
population O
. O
[]

DESIGN O
A O
prospective O
nonrandomized O
clinical O
trial O
. O
[]

Low O
molecular-weight O
heparin O
versus O
aspirin O
in O
patients O
with O
acute O
ischaemic O
stroke O
and O
atrial O
fibrillation O
: O
a O
double-blind O
randomised O
study O
. O
[]

The O
surfaces O
were O
examined O
using O
SEM O
and O
distinct O
differences O
in O
appearance O
were O
observed O
among O
specimens O
treated O
with O
different O
caries O
removal O
techniques O
. O
[]

Platelet B-outcome ['Physiological-Clinical']
membrane I-outcome ['Physiological-Clinical']
glycoprotein I-outcome ['Physiological-Clinical']
Ib I-outcome ['Physiological-Clinical']
and O
glycoprotein B-outcome ['Physiological-Clinical']
IIb/IIIa I-outcome ['Physiological-Clinical']
, O
P-selectin B-outcome ['Physiological-Clinical']
, O
platelet-derived B-outcome ['Physiological-Clinical']
microparticles I-outcome ['Physiological-Clinical']
, O
leukocyte B-outcome ['Physiological-Clinical']
CD11b/CD18 I-outcome ['Physiological-Clinical']
( O
Mac-1 B-outcome ['Physiological-Clinical']
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Delineation O
of O
cryptogenic O
Lennox-Gastaut O
syndrome O
and O
myoclonic O
astatic O
epilepsy O
using O
multiple O
correspondence O
analysis O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
compare O
postoperative O
pain O
and O
functional O
outcomes O
in O
patients O
undergoing O
inguinal O
herniorrhaphy O
who O
receive O
a O
COX-2 O
selective O
nonsteroidal O
anti-inflammatory O
drug O
( O
COX-2 O
) O
or O
placebo O
preoperatively O
and O
for O
4 O
days O
postoperatively O
. O
[]

Secondary O
analyses O
revealed O
the O
obese O
group O
gained O
more O
weight O
than O
the O
lean O
and O
overweight O
groups O
during O
the O
beverage O
intervention O
( O
P O
= O
0.024 O
) O
. O
[]

Analysis O
of O
mixed O
models O
was O
performed O
with O
R O
2.10.1 O
at O
a O
95 O
% O
confidence O
level O
, O
using O
the O
nonlinear O
mixed O
effects O
( O
NLME O
) O
package O
. O
[]

Platinum-based O
chemotherapy O
is O
often O
a O
first-line O
treatment O
. O
[]

BACKGROUND O
Tamoxifen O
and O
raloxifene O
have O
limited O
patient O
acceptance O
for O
primary O
prevention O
of O
breast O
cancer O
. O
[]

The O
results O
of O
this O
study O
showed O
that O
artificial B-outcome ['Physiological-Clinical']
recurrent I-outcome ['Physiological-Clinical']
caries I-outcome ['Physiological-Clinical']
can O
be O
reduced O
significantly O
( O
P O
< O
0.05 O
) O
with O
a O
glass-ionomer O
liner O
under O
amalgam O
restorations O
. O
['Physiological-Clinical']

Glucosamine B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
of O
patients O
after O
myocardial O
infarction O
subjected O
to O
rehabilitation O
training O
. O
['Physiological-Clinical']

Bumetanide O
reduced O
significantly O
the O
Childhood O
Autism O
Rating O
Scale O
( O
CARS O
) O
( O
D90-D0 O
; O
P O
< O
0.004 O
treated O
vs O
placebo O
) O
, O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions I-outcome ['Physiological-Clinical']
( O
P O
< O
0.017 O
treated O
vs O
placebo O
) O
and O
Autism B-outcome ['Life-Impact']
Diagnostic O
Observation O
Schedule O
values O
when O
the O
most O
severe O
cases O
( O
CARS O
values O
above O
the O
mean O
? O
['Physiological-Clinical', 'Life-Impact']

Differences O
in O
FV O
were O
only O
found O
for O
one O
category O
( O
unsolicited O
information O
) O
( O
p=0.012 O
) O
. O
[]

Forty-two O
diabetic O
patients O
were O
asked O
to O
access O
a O
Web O
site O
by O
using O
a O
cellular O
phone O
or O
wire O
Internet O
and O
input O
their O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
every O
day O
. O
['Physiological-Clinical']

Safety O
of O
intravitreous O
fomivirsen O
for O
treatment O
of O
cytomegalovirus O
retinitis O
in O
patients O
with O
AIDS O
. O
[]

GCV O
was O
taken O
within O
30 O
min O
after O
a O
meal O
. O
[]

Effect O
of O
perception O
of O
mechanical O
loading O
on O
human B-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
regulation O
. O
['Physiological-Clinical']

Data O
are O
reported O
on O
drug O
use O
among O
cocaine-dependent O
homeless O
persons O
who O
participated O
in O
a O
clinical O
trial O
that O
compared O
day O
treatment O
only O
( O
DT O
, O
n O
= O
69 O
) O
with O
day O
treatment O
plus O
abstinent-contingent O
housing O
and O
work O
( O
DT+ O
, O
n O
= O
72 O
) O
. O
[]

The O
spontaneous B-outcome ['Physiological-Clinical']
baroreflex I-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
increased O
in O
the O
PUFA O
( O
from O
8.99 O
+/- O
1.4 O
to O
12.2 O
+/- O
1.2 O
ms O
x O
mm O
Hg O
( O
-1 O
) O
, O
p O
< O
0.02 O
) O
but O
not O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

Breathing B-outcome ['Physiological-Clinical']
frequency O
and O
minute O
ventilation B-outcome ['Physiological-Clinical']
increased O
significantly O
while O
tidal O
volume O
was O
unchanged O
after O
the O
operation O
regardless O
of O
the O
intraoperative O
epidural O
block O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Radiation O
and O
contrast O
agent O
doses O
reductions O
by O
using O
80-kV O
tube O
voltage O
in O
coronary O
computed O
tomographic O
angiography O
: O
a O
comparative O
study O
. O
[]

OUTCOME O
MEASURES O
Weight O
and O
length B-outcome ['Physiological-Clinical']
gains I-outcome ['Physiological-Clinical']
and O
the O
incidences O
of O
severe B-outcome ['Physiological-Clinical']
stunting I-outcome ['Physiological-Clinical']
, O
underweight B-outcome ['Physiological-Clinical']
, O
and O
wasting B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Cognitive O
effects O
of O
risperidone O
in O
children O
with O
autism O
and O
irritable O
behavior O
. O
[]

The O
need O
for O
an O
additional B-outcome ['Resource-use']
antibiotic I-outcome ['Resource-use']
course O
was O
observed O
in O
8 O
patients O
in O
the O
trimethoprim-sulfamethoxazole O
group O
and O
5 O
patients O
in O
the O
ciprofloxacin O
group O
( O
difference O
, O
2.3 O
% O
; O
95 O
% O
CI O
, O
-5.4 O
to O
10.0 O
; O
P O
= O
.549 O
) O
. O
['Resource-use']

Twenty-two O
percent O
of O
patients O
receiving O
droperidol O
became O
sedated B-outcome ['Life-Impact']
. O
['Life-Impact']

The O
rate O
of O
reporting O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
considered O
to O
be O
drug-related O
and O
the O
rate O
of O
withdrawals O
were O
similar O
for O
both O
treatments O
. O
['Adverse-effects']

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
FG B-outcome ['Physiological-Clinical']
, O
and O
lipid B-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
were O
significantly O
correlated O
with O
antioxidant O
enzymes O
activities O
after O
supplementation O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
first O
consecutively O
conducted O
55 O
cases O
, O
both O
techniques O
, O
forceps O
biopsy O
and O
cryobiopsy O
, O
were O
applied O
simultaneously O
. O
[]

Side-effects O
: O
10 O
patients O
had O
salivation O
that O
in O
some O
instances O
lead O
to O
coughing O
, O
9 O
reported O
pain O
at O
the O
injection O
site O
during O
induction O
, O
and O
9 O
reported O
dreams O
of O
a O
pleasant O
nature O
. O
( O
[]

Bulky O
knots O
may O
be O
a O
nidus O
for O
infection O
, O
and O
they O
may O
extrude O
through O
skin O
weeks O
after O
surgery O
. O
[]

[ O
Intraoperative O
continuous O
epidural O
block O
influences O
postoperative O
changes O
in O
breathing O
pattern O
and O
thoracoabdominal O
movement O
associated O
with O
upper O
abdominal O
surgery O
] O
. O
[]

Bradykinin O
increases O
during O
cardiopulmonary O
bypass O
( O
CPB O
) O
and O
stimulates O
the O
release O
of O
nitric B-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
, O
inflammatory O
cytokines O
, O
and O
tissue-type O
plasminogen O
['Physiological-Clinical']

The O
mean O
percentage O
increase O
in O
basal B-outcome ['Physiological-Clinical']
FSH I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
BC O
group O
than O
in O
the O
LS O
group O
at O
both O
3-month O
( O
p O
= O
.023 O
) O
and O
6-month O
follow-up O
( O
p O
= O
.029 O
) O
, O
but O
not O
at O
12-month O
follow-up O
. O
['Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Thirteen O
children O
with O
autism O
between O
the O
ages O
of O
three O
and O
six O
received O
daily O
treatment O
according O
to O
the O
methodology O
for O
5 O
months O
. O
[]

Therefore O
, O
a O
multicenter O
RCT O
was O
proposed O
in O
1998 O
to O
evaluate O
the O
primary O
end O
point O
of O
long-term O
survival O
and O
the O
secondary O
end O
points O
of O
morbidity O
, O
mortality O
and O
quality O
of O
life O
of O
patients O
undergoing O
standard O
versus O
extended O
lymphadenectomy O
in O
radical O
PD O
for O
pancreatic O
cancer O
. O
[]

RESULTS O
Neither O
captopril O
nor O
enalapril O
influenced O
EEG B-outcome ['Resource-use']
and O
cognitive B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
compared O
with O
placebo O
. O
['Resource-use', 'Life-Impact']

AIMS O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
fixed O
combination O
of O
timolol O
and O
dorzolamide O
and O
latanoprost O
plus O
timolol O
on O
retinal B-outcome ['Physiological-Clinical']
, O
choroidal B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
difference O
in O
number O
becoming O
ill B-outcome ['Physiological-Clinical']
( O
133 O
versus O
129 O
) O
, O
number O
of O
episodes B-outcome ['Physiological-Clinical']
( O
166 O
versus O
159 O
) O
or O
mean O
illness B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
( O
5.5 O
versus O
5.8 O
days O
) O
between O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
order O
of O
administration O
was O
randomised O
, O
with O
each O
subject O
acting O
as O
his O
own O
control O
. O
[]

On O
average O
the O
colonic B-outcome ['Physiological-Clinical']
transit I-outcome ['Physiological-Clinical']
of O
130 O
hours O
was O
reduced O
to O
79 O
hours O
. O
['Physiological-Clinical']

During O
the O
study O
, O
the O
horses O
were O
monitored O
for O
general O
health O
, O
lameness O
, O
and O
swelling O
around O
the O
injection O
area O
. O
[]

RESULTS O
No O
significant O
differences O
between O
the O
3 O
groups O
were O
found O
in O
terms O
of O
mental B-outcome ['Life-Impact']
strain I-outcome ['Life-Impact']
, O
concentration-test B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
physical B-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
mental I-outcome ['Life-Impact']
complaints I-outcome ['Life-Impact']
reported O
in O
a O
follow-up O
interview O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
median O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
colds I-outcome ['Physiological-Clinical']
tended O
to O
be O
longer O
in O
the O
20-MU O
group O
( O
10 O
days O
) O
than O
the O
10-MU O
group O
( O
8 O
days O
) O
or O
placebo O
group O
( O
8 O
days O
) O
( O
P O
= O
0.06 O
) O
. O
['Physiological-Clinical']

The O
instructions O
were O
repeated O
every O
six O
months O
. O
[]

As O
compared O
with O
non-diabetic O
patients O
, O
patients O
with O
diabetes O
( O
n=1117 O
) O
showed O
similar O
30-day O
ischemic O
outcomes O
, O
an O
increased O
incidence O
of O
any B-outcome ['Physiological-Clinical']
target I-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
( O
TVR B-outcome ['Physiological-Clinical']
) O
at O
6 O
months O
( O
10.3 O
% O
versus O
7.8 O
% O
; O
P= O
0.008 O
) O
, O
and O
a O
trend O
toward O
higher O
1-year O
mortality B-outcome ['Mortality']
( O
2.5 O
% O
versus O
1.6 O
% O
; O
P=0.056 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Similar O
to O
the O
entire O
group O
of O
patients O
also O
in O
the O
subset O
of O
patients O
with O
nodal O
micrometastases O
the O
type O
of O
lymphadenectomy O
did O
not O
significantly O
influence O
the O
long-term O
survival B-outcome ['Mortality']
( O
P=0.27 O
and O
P=0.39 O
, O
respectively O
) O
. O
['Mortality']

Double-blind O
, O
cross-over O
, O
placebo-controlled O
, O
randomized O
experimental O
study O
. O
[]

Group O
A O
( O
n O
= O
17 O
) O
were O
treated O
by O
warming O
needle O
moxibustion O
, O
group O
B O
( O
n O
= O
12 O
) O
by O
acupuncture O
plus O
auricular O
point O
sticking O
, O
and O
group O
C O
( O
n O
= O
12 O
) O
by O
routine O
acupuncture O
. O
[]

RESULTS O
Cost B-outcome ['Resource-use']
per O
day O
was O
lower O
on O
the O
nursing-led O
inpatient O
unit O
although O
cost O
per O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
higher O
due O
to O
significantly O
increased O
length O
of O
stay O
. O
['Resource-use', 'Resource-use']

However O
, O
when O
comparing O
the O
crown B-outcome ['Physiological-Clinical']
diameters I-outcome ['Physiological-Clinical']
of O
unilaterally- O
and O
bilaterally-affected O
patients O
, O
no O
differences O
in O
tooth-size B-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
these O
decreases O
differed O
significantly O
from O
the O
premedication O
values O
, O
they O
were O
probably O
of O
little O
clinical O
importance O
. O
[]

Children O
in O
the O
community O
treatment O
group O
received O
a O
variety O
of O
services O
averaging O
3.9 O
hours O
per O
week O
. O
[]

RESULTS O
Complete O
data O
on O
96 O
patients O
with O
a O
mean O
age O
+/- O
SD O
of O
69.1 O
+/- O
6.1 O
years O
was O
available O
at O
a O
mean O
followup O
of O
18.3 O
+/- O
6.7 O
months O
( O
range O
12 O
to O
23 O
) O
. O
[]

Updated O
PLCO O
data O
show O
132 O
intervention O
arm O
ovarian O
cancer O
deaths O
versus O
119 O
in O
usual O
care O
( O
relative O
risk O
, O
RR O
= O
1.11 O
) O
. O
[]

RESULTS O
Overall O
84 O
% O
of O
patients O
who O
had O
polyp O
and O
papilla O
removal O
rated O
the O
outcome O
of O
their O
surgery O
as O
excellent O
or O
good O
in O
comparison O
to O
58 O
% O
of O
controls O
. O
[]

Serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
levels O
did O
not O
significantly O
increase O
from O
baseline O
throughout O
the O
study O
. O
['Physiological-Clinical']

AIM O
To O
compare O
clinical B-outcome ['Physiological-Clinical']
and O
radiographic B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
of O
single-implant O
crown O
restorations O
made O
by O
either O
directly O
baked O
porcelain O
to O
custom-made O
TiAdapt O
titanium O
abutments O
( O
Nobel O
Biocare O
AB O
, O
G?teborg O
, O
Sweden O
) O
( O
test O
) O
or O
cement O
crowns O
onto O
CeraOne O
( O
Nobel O
Biocare O
AB O
) O
abutments O
( O
control O
) O
after O
10 O
years O
in O
function O
. O
['Physiological-Clinical', 'Life-Impact']

Fatal O
and O
nonfatal B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
unstable B-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Twelve O
patients O
with O
migraine O
without O
aura O
were O
included O
in O
a O
randomized O
double O
blind O
crossover O
study O
. O
[]

Drift B-outcome ['Physiological-Clinical']
is O
within O
+/- O
0.3 O
kPa O
h-1 O
for O
78 O
% O
of O
monitoring O
time O
. O
['Physiological-Clinical']

Persuasion O
theory O
appears O
useful O
to O
guide O
evaluation O
of O
educational O
interventions O
to O
improve O
attitudes O
towards O
autism B-outcome ['Life-Impact']
. O
['Life-Impact']

IMPORTANCE O
The O
finding O
of O
factors O
that O
differentially O
predict O
the O
likelihood O
of O
response O
to O
placebo O
over O
that O
of O
an O
active O
drug O
could O
have O
a O
significant O
impact O
on O
study O
design O
in O
this O
population O
. O
[]

Additional O
evaluations O
, O
executed O
with O
data O
from O
the O
Symptom-Check-List O
( O
SCL-90R O
) O
and O
with O
other O
scales O
from O
the O
EDI-2 O
also O
showed O
no O
effect O
of O
Spironolactone O
. O
['Life-Impact']

DESIGN O
AND O
SETTING O
A O
prospective O
, O
double-blind O
, O
placebo-controlled O
and O
randomized O
study O
at O
a O
single O
tertiary O
care O
hospital O
. O
[]

These O
results O
reflected O
the O
disease B-outcome ['Mortality']
specific I-outcome ['Mortality']
survival I-outcome ['Mortality']
as O
well O
and O
were O
confirmed O
in O
multivariable O
analyses O
. O
['Mortality']

We O
assessed O
whether O
daclizumab O
high-yield O
process O
( O
HYP O
) O
would O
be O
effective O
when O
given O
as O
monotherapy O
for O
a O
1 O
year O
treatment O
period O
in O
patients O
with O
relapsing-remitting O
multiple O
sclerosis O
. O
[]

Stratified O
analysis O
showed O
that O
in O
the O
Cap-Oxa-CRT O
group O
, O
patients O
with O
AA O
genotype O
showed O
a O
2.34-fold O
increased O
risk O
for O
severe B-outcome ['Physiological-Clinical']
diarrhea I-outcome ['Physiological-Clinical']
( O
95 O
% O
CI O
1.16 O
- O
4.76 O
, O
P O
= O
0.018 O
) O
compared O
with O
those O
with O
GG O
or O
GA O
genotypes O
, O
but O
in O
the O
Cap-CRT O
group O
, O
the O
SNP O
was O
not O
associated O
with O
the O
risk O
of O
severe B-outcome ['Physiological-Clinical']
diarrhea I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
The O
objective O
was O
to O
determine O
whether O
there O
is O
a O
threshold O
beyond O
which O
increasing O
doses O
of O
vitamin O
D O
, O
or O
concentrations O
of O
serum O
25-hydroxyvitamin O
D O
[ O
25 O
( O
OH O
) O
D O
] O
, O
no O
longer O
increase O
calcium B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Nasal B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
was O
also O
beneficially O
affected O
by O
both O
steroids O
150 O
and O
240 O
min O
after O
administration O
compared O
with O
placebo O
( O
P O
< O
0.05 O
for O
both O
time O
points O
following O
betamethasone O
) O
. O
['Physiological-Clinical']

After O
each O
injection O
the O
system O
was O
flushed O
with O
sterile O
saline O
and O
closed O
for O
60 O
min O
before O
opening O
to O
spontaneous O
drainage O
. O
[]

Each O
lasted O
for O
1 O
hour O
and O
was O
implemented O
5 O
days O
a O
week O
for O
4 O
weeks O
. O
[]

However O
, O
the O
presence O
of O
focal B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
TFI B-outcome ['Physiological-Clinical']
and/or O
DFI B-outcome ['Physiological-Clinical']
, O
did O
not O
appear O
to O
interfere O
with O
the O
therapeutic O
activities O
of O
Re O
and/or O
PUVA O
, O
because O
the O
complete B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
rates O
and O
remission B-outcome ['Physiological-Clinical']
periods I-outcome ['Physiological-Clinical']
in O
FI O
( O
+ O
) O
patients O
were O
comparable O
with O
those O
in O
FI O
( O
- O
) O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Role O
of O
memory O
B-cell O
responses O
in O
serum O
and O
mucosal O
fluids O
of O
swine O
for O
protective O
immunity O
against O
pseudorabies O
virus O
. O
[]

During O
the O
ESWL O
session O
the O
patient O
belonging O
to O
the O
second O
group O
received O
i.v O
. O
[]

Controls O
were O
given O
a O
bolus O
dose O
of O
1 O
g O
pralidoxime O
over O
1 O
h O
every O
4 O
h O
for O
48 O
h. O
The O
study O
group O
had O
a O
constant O
infusion O
of O
1 O
g O
over O
an O
hour O
every O
hour O
for O
48 O
h. O
Thereafter O
, O
all O
patients O
were O
given O
1 O
g O
every O
4 O
h O
until O
they O
could O
be O
weaned O
from O
ventilators O
. O
[]

CONCLUSIONS O
There O
is O
strong O
interest O
in O
BRCA1 O
testing O
. O
[]

Fluid-phase O
complement O
activation O
products O
( O
C4b/c O
, O
C3b/c O
) O
and O
activator O
molecules O
were O
determined O
by O
ELISA O
. O
[]

Almost O
half O
as O
many O
relatives O
entered O
nursing O
homes O
in O
the O
counseling O
group O
( O
n O
= O
9 O
vs. O
n O
= O
5 O
) O
but O
these O
compared O
to O
control O
group O
relatives O
had O
greater O
annualized O
per O
person O
expenditures O
for O
health B-outcome ['Resource-use']
and I-outcome ['Resource-use']
social I-outcome ['Resource-use']
services I-outcome ['Resource-use']
( O
Cdn O
$ O
23,437 O
vs. O
Cdn O
$ O
15,151 O
) O
. O
['Resource-use']

BACKGROUND O
Minimally O
invasive O
total O
hip O
arthroplasty O
is O
purported O
to O
allow O
an O
improved O
and O
faster O
rehabilitation B-outcome ['Physiological-Clinical']
in O
the O
immediate O
postoperative O
period O
because O
of O
reduced O
soft-tissue O
damage O
compared O
with O
total O
hip O
arthroplasty O
performed O
with O
use O
of O
a O
standard O
approach O
. O
['Physiological-Clinical']

METHODS O
A O
single-blind O
randomized O
control O
trial O
was O
conducted O
in O
50 O
children O
. O
[]

There O
were O
no O
significant O
differences O
in O
the O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
marker I-outcome ['Physiological-Clinical']
changes O
between O
the O
groups O
. O
['Physiological-Clinical']

Catheter O
ablation O
of O
stable O
ventricular O
tachycardia O
before O
defibrillator O
implantation O
in O
patients O
with O
coronary O
heart O
disease O
( O
VTACH O
) O
: O
a O
multicentre O
randomised O
controlled O
trial O
. O
[]

Compared O
with O
untreated O
children O
, O
treated O
children O
experienced O
significant O
improvement O
of O
their O
sensory B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
( O
p O
< O
0.01 O
) O
, O
and O
demonstrated O
increased O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
( O
p O
< O
0.04 O
) O
and O
basic B-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
( O
p O
< O
0.02 O
) O
on O
standardized O
measures O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Initial O
instruction O
in O
BSE O
group O
would O
include O
demonstration O
of O
proper O
palpation O
techniques O
and O
was O
followed O
by O
2 O
reinforcement O
sessions O
during O
the O
subsequent O
4 O
years O
including O
video O
shows O
, O
BSE O
instruction O
sessions O
and O
BSE O
practice O
under O
medical O
supervision O
. O
[]

The O
impact O
of O
reduced O
drug B-outcome ['Resource-use']
exposure I-outcome ['Resource-use']
( O
expressed O
as O
a O
percentage O
of O
optimal O
) O
on O
EVR O
and O
SVR B-outcome ['Physiological-Clinical']
was O
evaluated O
. O
['Resource-use', 'Physiological-Clinical']

METHODS O
Twelve O
Helicobacter O
pylori O
( O
+ O
) O
patients O
and O
12 O
H. O
pylori O
( O
- O
) O
subjects O
were O
included O
. O
[]

BACKGROUND O
Technological O
innovations O
are O
often O
adopted O
before O
scientific O
comparison O
to O
an O
accepted O
standard O
. O
[]

While O
the O
hormonal O
dynamics O
of O
infant O
suckling O
are O
understood O
, O
little O
is O
known O
about O
the O
effects O
of O
artificial O
methods O
of O
milk B-outcome ['Life-Impact']
expression I-outcome ['Life-Impact']
. O
['Life-Impact']

Response O
to O
ezetimibe O
was O
generally O
consistent O
across O
all O
subgroups O
analyzed O
. O
[]

INTRODUCTION O
Augmented O
reality O
( O
AR O
) O
technologies O
can O
enrich O
the O
real O
environment O
with O
visual O
data O
, O
which O
has O
potential O
benefits O
for O
optimising O
the O
operator O
's O
working O
process O
. O
[]

One O
way O
to O
cope O
with O
chemotherapy-related O
symptom O
distress O
is O
through O
the O
use O
of O
distraction O
. O
[]

During O
cross-clamping O
, O
the O
renal B-outcome ['Physiological-Clinical']
variables I-outcome ['Physiological-Clinical']
were O
not O
markedly O
affected O
in O
either O
group O
and O
remained O
higher O
in O
the O
isoflurane-anesthetized O
patients O
( O
232.9 O
+/- O
47.1 O
and O
49.5 O
+/- O
1.2 O
mL/min O
for O
ERPF O
and O
GFR O
, O
respectively O
) O
than O
in O
the O
halothane-anesthetized O
patients O
( O
132.4 O
+/- O
31.6 O
and O
14.8 O
+/- O
3.7 O
mL/min O
, O
respectively O
) O
( O
P O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

Binary B-outcome ['Physiological-Clinical']
angiographic I-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
( O
> O
50 O
% O
diameter O
stenosis O
) O
was O
seen O
in O
33 O
% O
in O
the O
conventional O
group O
versus O
22 O
% O
in O
the O
stented O
group O
( O
P O
=.137 O
) O
. O
['Physiological-Clinical']

Fifty-one O
patients O
with O
raised O
intraocular O
pressure O
( O
IOP O
) O
were O
treated O
for O
up O
to O
four O
years O
with O
one O
of O
three O
ophthalmic O
solutions O
: O
0.5 O
% O
levobunolol O
, O
1 O
% O
levobunolol O
, O
or O
0.5 O
% O
timolol O
. O
[]

BACKGROUND O
AND O
OBJECTIVES O
Magnesium O
sulphate O
infusion O
during O
general O
anaesthesia O
reduces O
anaesthetic B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
and O
analgesic B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
. O
['Resource-use', 'Resource-use']

To O
examine O
underlying O
mechanisms O
underlying O
the O
effect O
of O
our O
supplementation O
regimen O
, O
we O
examined O
plasma O
levels O
of O
antioxidants O
transferrin O
and O
superoxide O
dismutase O
, O
which O
are O
useful O
markers O
of O
signal O
transduction O
. O
[]

METHODS O
Fifty-six O
male O
patients O
( O
mean O
age O
71.2 O
+/- O
8.2 O
years O
) O
scheduled O
for O
TURP O
were O
enrolled O
in O
the O
study O
. O
[]

Results O
from O
two O
randomized O
trials O
have O
shown O
that O
oral O
beclomethasone O
dipropionate O
( O
BDP O
) O
is O
effective O
for O
treatment O
of O
acute O
gastrointestinal O
graft-versus-host O
disease O
. O
[]

The O
study O
shows O
that O
in O
infants O
with O
atopic O
dermatitis O
, O
raised O
serum B-outcome ['Physiological-Clinical']
total O
IgE B-outcome ['Physiological-Clinical']
has O
significantly O
different O
determinants O
from O
that O
a O
specific O
allergen B-outcome ['Physiological-Clinical']
sensitization I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

By O
contrast O
, O
the O
GH B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
the O
nights O
the O
healthy O
controls O
were O
given O
octreotide O
( O
GH O
AUC O
22.6+/-5.4 O
mU/l O
x O
h O
during O
octreotide O
and O
126.6+/-21.9 O
mU/l O
x O
h O
during O
saline O
; O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

RESULTS O
There O
was O
no O
statistically O
significant O
difference O
in O
terms O
of O
demographic O
data O
, O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
or O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
between O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
standard O
general O
anesthesia O
procedure O
including O
sufentanil O
was O
used O
. O
[]

There O
was O
no O
significant O
difference O
in O
caries B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
among O
the O
three O
groups O
. O
['Physiological-Clinical']

Drugs O
were O
given O
to O
a O
Ramsay O
sedation O
scale O
of O
3 O
. O
[]

Compliance B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
referral I-outcome ['Life-Impact']
was O
analysed O
according O
to O
the O
socio-demographic O
characteristics O
of O
screen-positives O
. O
['Life-Impact']

Patients O
from O
the O
intervention O
wards O
will O
receive O
, O
additionally O
to O
standard O
pain O
treatment O
, O
the O
SCION-PAIN O
program O
consisting O
of O
3 O
modules O
: O
pharmacologic O
pain O
management O
, O
nonpharmacologic O
pain O
management O
and O
discharge O
management O
. O
[]

Patients O
with O
a O
stable O
response O
( O
? O
[]

Various O
ultrasonic O
scalers O
, O
hand O
instruments O
and O
two O
power-driven O
systems O
were O
compared O
by O
assessing O
the O
loss O
of O
tooth B-outcome ['Physiological-Clinical']
substance I-outcome ['Physiological-Clinical']
due O
to O
root O
instrumentation O
. O
['Physiological-Clinical']

Underlying O
dimensions O
of O
DUP O
( O
general O
prodrome O
and O
positive O
, O
negative O
and O
disorganisation O
symptoms O
) O
were O
assessed O
using O
the O
Symptom O
Onset O
in O
Schizophrenia O
( O
SOS O
) O
inventory O
( O
Perkins O
et O
al. O
, O
2000 O
) O
. O
[]

Haloperidol O
was O
shown O
to O
be O
a O
powerful O
therapeutic O
agent O
when O
administered O
for O
4 O
weeks O
and O
free O
of O
side O
effects O
; O
at O
doses O
ranging O
from O
0.25 O
to O
4.0 O
mg/day O
( O
M O
= O
0.844 O
) O
, O
there O
was O
a O
clinically O
and O
statistically O
significant O
reduction O
of O
a O
variety O
of O
symptoms B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Non-haematological B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
was O
mild O
. O
['Adverse-effects']

The O
number O
of O
stereotypic B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
percentage O
of O
on-task B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact']

BACKGROUND O
Creation O
of O
an O
arteriovenous O
fistula O
( O
AVF O
) O
may O
increase O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
hypertrophy I-outcome ['Physiological-Clinical']
in O
the O
hemodialysis O
population O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
work O
was O
to O
measure O
the O
color B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
occurring O
after O
the O
use O
of O
a O
Gantrez-NNP O
combination O
on O
enamel O
tooth O
blocks O
. O
['Physiological-Clinical']

Intermediate O
( O
56 O
patients O
) O
and O
high O
grade O
( O
10 O
patients O
) O
lymphomas O
received O
cyclophosphamide O
, O
vincristine O
, O
adriamycin O
, O
prednisone O
. O
[]

Little O
is O
known O
about O
the O
effects O
of O
bisphosphonates O
on O
bone O
metastases O
from O
other O
tumors O
and O
in O
particular O
from O
tumors O
for O
which O
no O
effective O
treatment O
is O
available O
. O
[]

Mizolastine O
is O
a O
new O
, O
nonsedating O
antihistamine O
providing O
satisfactory O
symptomatic O
relief O
in O
allergic B-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
and O
urticaria B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
treatment O
group O
had O
temperatures B-outcome ['Physiological-Clinical']
that O
were O
significantly O
higher O
than O
those O
of O
the O
control O
group O
30 O
minutes O
after O
arrival O
in O
the O
PACU O
, O
and O
the O
treatment O
group O
experienced O
a O
greater O
['Physiological-Clinical']

1 O
( O
ZJC1 O
) O
on O
morphology O
and O
motility O
of O
sperm O
in O
patients O
with O
oligospermia O
( O
OSM O
) O
. O
[]

The O
two O
preparations O
were O
considered O
bioequivalent O
if O
the O
90 O
% O
confidence O
intervals O
for O
the O
ratio O
of O
geometric B-outcome ['Physiological-Clinical']
means O
['Physiological-Clinical']

Seventeen O
individuals O
had O
approximal O
surfaces O
with O
consistently O
high O
or O
consistently O
low O
S. O
mutans B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

Disability B-outcome ['Life-Impact']
( O
days B-outcome ['Physiological-Clinical']
spent I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
bed I-outcome ['Physiological-Clinical']
) O
and O
quality O
of O
life O
( O
['Life-Impact', 'Physiological-Clinical']

CS O
cannulation O
can O
be O
achieved O
either O
using O
dedicated O
guiding O
catheters O
( O
guiding O
catheter O
alone O
positioning O
strategy O
, O
GCA O
) O
or O
with O
the O
aid O
of O
an O
electrophysiology O
catheter O
advanced O
inside O
the O
guiding O
catheter O
( O
electrophysiology O
catheter O
aided O
positioning O
strategy O
, O
EPA O
) O
. O
[]

The O
control O
group O
received O
only O
the O
usual O
care O
post-diagnosis O
, O
which O
consisted O
of O
a O
1-hour O
consultation O
session O
to O
receive O
the O
results O
of O
diagnostic O
tests O
and O
a O
written O
copy O
of O
the O
recommended O
treatment O
plan O
provided O
by O
a O
developmental O
pediatrician O
and/or O
PNP O
. O
[]

Examining O
the O
temperature O
of O
embryo O
culture O
in O
in O
vitro O
fertilization O
: O
a O
randomized O
controlled O
trial O
comparing O
traditional O
core O
temperature O
( O
37?C O
) O
to O
a O
more O
physiologic O
, O
cooler O
temperature O
( O
36?C O
) O
. O
[]

BACKGROUND O
The O
incidence O
of O
oropharyngeal O
squamous O
cell O
carcinoma O
( O
OPSCC O
) O
has O
markedly O
increased O
over O
the O
last O
three O
decades O
due O
to O
newly O
found O
associations O
with O
human O
papillomavirus O
( O
HPV O
) O
infection O
. O
[]

Furthermore O
, O
the O
direct O
aortic O
cannulation O
technique O
may O
eliminate O
complications B-outcome ['Adverse-effects']
associated O
with O
the O
standard O
femoral O
artery O
cannulation O
. O
['Adverse-effects']

Pathologic O
and O
quantitative O
image O
analyses O
were O
performed O
to O
evaluate O
the O
size O
and O
quality O
of O
the O
obtained O
specimens O
. O
[]

RESULTS O
At O
Months O
12 O
and O
24 O
, O
ranibizumab O
was O
superior O
to O
PDT O
( O
P O
< O
0.0001 O
) O
for O
mean O
changes O
from O
baseline O
in O
total O
area O
of O
lesion B-outcome ['Physiological-Clinical']
, O
CNV B-outcome ['Physiological-Clinical']
area O
, O
and O
total O
area O
CNV B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Focusing O
on O
recent O
calls O
for O
translation O
of O
epidemiologic O
evidence O
into O
clinical O
care O
, O
our O
pilot O
study O
delivered O
an O
evidence-based O
physical O
activity O
intervention O
in O
adults O
with O
polyps O
, O
who O
are O
thus O
at O
elevated O
risk O
of O
developing O
colon O
cancer O
. O
[]

9.2 O
ng/ml O
, O
p O
< O
0.001 O
) O
, O
without O
a O
significant O
reduction O
in O
von O
Willebrand O
factor O
levels O
, O
and O
tended O
to O
prolong O
the O
prothrombin O
and O
partial O
thromboplastin O
times O
. O
[]

BACKGROUND O
Molecular O
markers O
to O
predict O
response O
to O
5-fluorouracil O
( O
FU O
) O
-based O
treatment O
of O
recurrent O
or O
metastasised O
colorectal O
cancer O
( O
mCRC O
) O
are O
not O
established O
. O
[]

Frequent O
treatment-emergent O
grade O
3/4 O
hematologic B-outcome ['Physiological-Clinical']
abnormalities B-outcome ['Physiological-Clinical']
were O
lymphopenia B-outcome ['Physiological-Clinical']
( O
20 O
% O
v O
11 O
% O
) O
, O
anemia B-outcome ['Physiological-Clinical']
( O
9 O
% O
v O
8 O
% O
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Risk O
factors O
retained O
in O
the O
model O
included O
poor B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
absolute B-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
< O
or O
=2.0 O
x O
10 O
( O
9 O
) O
cells/L O
in O
the O
previous O
cycle O
, O
the O
first O
cycle O
of O
chemotherapy B-outcome ['Resource-use']
, O
DOX O
versus O
PLD O
and O
advanced O
age O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

The O
absolute O
risks O
of O
retinopathy B-outcome ['Physiological-Clinical']
and O
nephropathy B-outcome ['Physiological-Clinical']
were O
proportional O
to O
the O
mean O
glycosylated B-outcome ['Physiological-Clinical']
hemoglobin I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HbA I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
level O
over O
the O
follow-up O
period O
preceding O
each O
event O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Most O
patients O
in O
both O
study O
groups O
showed O
high O
adherence O
to O
raloxifene O
at O
the O
3-month O
visit O
: O
56.3 O
% O
vs O
62.7 O
% O
for O
groups O
A O
and O
B O
, O
respectively O
; O
this O
proportion O
at O
the O
12-month O
visit O
was O
47.4 O
% O
( O
P=0.15 O
) O
and O
52.5 O
% O
( O
P=0.02 O
) O
, O
respectively O
. O
[]

Accompanying O
this O
improved O
survival O
, O
the O
ID O
Group O
also O
had O
greater O
white B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
lymphocyte I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
, O
a O
greater O
number O
of O
T O
cells B-outcome ['Physiological-Clinical']
, O
and O
a O
more O
dramatic B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
to O
the O
extracted O
cell O
wall O
polysaccharide O
of O
hemolytic O
streptococcus O
Su-strain O
( O
Su-PS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
all O
doses O
up O
to O
600 O
mg O
, O
Ro O
15-1788 O
demonstrated O
none O
of O
the O
classical O
behavioural B-outcome ['Life-Impact']
effects O
of O
the O
benzodiazepines O
. O
['Life-Impact']

BACKGROUND O
Ageing O
with O
visual O
impairment O
is O
associated O
with O
a O
high O
degree O
of O
disability O
whereby O
age-related O
macular O
degeneration O
in O
particular O
causes O
dependence O
in O
activities O
of O
daily B-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
ADL I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
even O
at O
an O
early O
stage O
. O
['Life-Impact']

CONCLUSIONS O
Parents O
of O
children O
participating O
in O
this O
trial O
were O
highly O
satisfied B-outcome ['Life-Impact']
and O
supportive B-outcome ['Life-Impact']
of O
the O
clinical O
trial O
['Life-Impact']

Consistent O
with O
previous O
research O
, O
increased O
age O
, O
female O
gender O
, O
and O
greater O
sun O
sensitivity O
were O
each O
independently O
associated O
with O
more O
sun B-outcome ['Life-Impact']
protective I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
primary O
outcome O
measure O
was O
pregnancy B-outcome ['Physiological-Clinical']
occurrence I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Durability B-outcome ['Life-Impact']
of O
central O
venous O
catheters O
. O
['Life-Impact']

OBJECTIVE O
To O
assess O
the O
effect O
of O
pain-free O
treadmill O
training O
on O
changes O
of O
plasma O
fibrinogen O
, O
haematocrit O
, O
lipid O
profile O
, O
and O
walking O
ability O
in O
patients O
with O
claudication O
. O
[]

CONCLUSION O
A O
combination O
of O
CRM O
and O
VR O
improves O
BPPV B-outcome ['Physiological-Clinical']
in O
the O
elderly O
. O
['Physiological-Clinical']

Baseline O
measurements O
and O
follow O
up O
measures O
( O
3 O
, O
6 O
, O
9 O
and O
12 O
months O
) O
are O
assessed O
using O
questionnaires O
and O
an O
interview O
. O
[]

There O
was O
a O
statistically O
significant O
difference O
among O
the O
three O
treatment O
groups O
with O
respect O
to O
clinical O
outcome O
; O
more O
patients O
in O
the O
CAE O
group O
( O
62 O
% O
) O
than O
in O
the O
CEC O
group O
( O
46 O
% O
) O
or O
the O
AMX-CL O
group O
( O
52 O
% O
) O
had O
complete O
resolution O
of O
signs B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
AOM I-outcome ['Physiological-Clinical']
( O
including O
effusion B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

An O
open O
, O
multicenter O
study O
investigated O
the O
long-term O
efficacy O
, O
tolerability O
, O
and O
acceptability O
to O
patients O
of O
subcutaneous O
sumatriptan O
6 O
mg O
, O
administered O
using O
a O
novel O
cartridge O
system O
self-injector O
, O
for O
the O
acute O
treatment O
of O
migraine O
. O
[]

beta-Carotene O
appears O
to O
have O
an O
immunostimulatory B-outcome ['Physiological-Clinical']
effect O
in O
HIV-infected O
patients O
. O
['Physiological-Clinical']

METHODS O
Patients O
with O
unresectable O
and/or O
recurrent O
advanced O
gastric O
cancer O
were O
randomly O
assigned O
to O
receive O
one O
of O
the O
two O
regimens O
: O
S-1 O
( O
40 O
mg O
m O
( O
-2 O
) O
twice O
daily O
) O
on O
days O
1-14 O
plus O
paclitaxel O
( O
60 O
mg O
m O
( O
-2 O
) O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
a O
4-week O
cycle O
( O
S-1+paclitaxel O
) O
or O
S-1 O
( O
40 O
mg O
m O
( O
-2 O
) O
twice O
daily O
) O
on O
days O
1-21 O
plus O
cisplatin O
( O
60 O
mg O
m O
( O
-2 O
) O
) O
on O
day O
8 O
of O
a O
5-week O
cycle O
( O
S-1+cisplatin O
) O
. O
[]

They O
were O
randomised O
in O
a O
ratio O
2:1 O
to O
an O
intervention O
group O
( O
133 O
) O
or O
a O
control O
group O
( O
68 O
) O
. O
[]

METHODS O
Two O
hundred O
forty-four O
patients O
with O
stage O
I O
or O
II O
breast O
cancer O
who O
were O
at O
substantial O
risk O
for O
distant O
metastases O
were O
randomly O
assigned O
to O
receive O
a O
12-week O
course O
of O
chemotherapy O
either O
before O
or O
after O
radiation O
therapy O
. O
[]

BACKGROUND O
Acute O
diarrhoea O
is O
a O
frequent O
problem O
in O
children O
with O
heavy O
economic O
burden O
for O
families O
and O
society O
. O
[]

RESULTS O
Plasma B-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GSH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
alpha- B-outcome ['Physiological-Clinical']
and O
gamma-tocopherol B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
decreased O
and O
the O
GSH B-outcome ['Physiological-Clinical']
redox I-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
became O
more O
oxidized O
after O
conditioning O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
randomized O
study O
the O
long-term O
results O
of O
Shouldice O
, O
Lichtenstein O
and O
transabdominal O
preperitoneal O
( O
TAPP O
) O
hernia O
repair O
were O
compared O
. O
[]

In O
conclusion O
, O
atropine O
, O
glycopyrrolate O
, O
and O
scopolamine O
differ O
not O
only O
in O
their O
cardiovascular O
and O
central O
nervous O
system O
effects O
, O
but O
also O
in O
their O
effects O
on O
metabolism O
. O
[]

In O
conclusion O
, O
TEI O
index O
predicted O
outcome O
in O
children O
with O
systemic O
ventricular O
dysfunction O
and O
heart O
failure O
. O
[]

PATIENTS O
120 O
ASA O
physical O
status O
1 O
and O
2 O
patients O
undergoing O
elective O
orthopedic O
surgeries O
. O
[]

Information O
source O
affects O
peers O
' O
initial O
attitudes O
toward O
autism B-outcome ['Life-Impact']
. O
['Life-Impact']

Indicators O
of O
stress O
( O
ie O
, O
alterations O
in O
behavioral B-outcome ['Life-Impact']
, O
neuroendocrine B-outcome ['Physiological-Clinical']
, O
immune B-outcome ['Physiological-Clinical']
, O
and O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
of O
prophylactic O
management O
and O
therapeutics O
on O
hypertensive B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
in O
pregnancy O
: O
preliminary O
studies O
. O
['Physiological-Clinical']

Therefore O
, O
we O
concluded O
that O
the O
ipsilateral B-outcome ['Physiological-Clinical']
arm O
swing B-outcome ['Physiological-Clinical']
may O
partially O
affect O
the O
depression O
of O
the O
soleus B-outcome ['Physiological-Clinical']
H-reflex I-outcome ['Physiological-Clinical']
during O
the O
arm O
swing O
phase O
of O
walking O
but O
is O
not O
responsible O
for O
depression O
of O
the O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
control O
teeth O
received O
SRP O
only O
. O
[]

METHODS O
This O
was O
a O
randomized O
, O
single-blind O
, O
placebo-controlled O
, O
parallel O
study O
. O
[]

The O
2 O
techniques O
were O
evaluated O
with O
respect O
to O
the O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
scores O
, O
complications B-outcome ['Adverse-effects']
, O
day B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
discharge I-outcome ['Life-Impact']
, O
return B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
, O
and O
level O
of O
satisfaction B-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Adverse-effects', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Twenty-five O
were O
treated O
with O
the O
SNRI O
venlafaxine O
SR O
( O
75-150 O
mg/die O
) O
, O
and O
25 O
with O
the O
SSRI O
fluoxetine O
( O
20-40 O
mg/die O
) O
. O
[]

The O
diagnosis O
of O
cortical O
adenoma O
was O
based O
on O
computed O
tomography O
features O
and O
pattern O
of O
uptake O
on O
adrenal O
scintigraphy O
. O
[]

The O
mean O
rates O
of O
bacteremia B-outcome ['Physiological-Clinical']
attributable O
to O
luminal O
colonization O
with O
vancomycin-susceptible O
organisms O
were O
0.6/1000 O
catheter O
days O
in O
the O
heparin O
group O
and O
1.4/1000 O
catheter O
days O
in O
the O
heparin-vancomycin O
group O
( O
p O
= O
0.25 O
) O
. O
['Physiological-Clinical']

During O
Step O
2 O
, O
M O
was O
reduced O
by O
33 O
% O
( O
p O
= O
0.001 O
) O
and O
15 O
% O
( O
p O
= O
0.006 O
) O
for O
25 O
and O
10 O
mg O
prednisone O
compared O
to O
placebo O
; O
and O
M/I O
ratio O
was O
reduced O
by O
31 O
% O
( O
p O
< O
0.001 O
) O
and O
13 O
% O
( O
p O
= O
0.026 O
) O
, O
respectively O
. O
[]

PURPOSE O
The O
maximum O
effect O
of O
midazolam O
injected O
intravenously O
occurs O
in O
about O
3 O
minutes O
. O
[]

RESULTS O
At O
baseline O
, O
the O
mean O
intakes O
for O
macronutrients B-outcome ['Physiological-Clinical']
, O
vitamins O
and O
minerals O
exceeded O
Dietary O
Reference O
Intakes O
( O
DRIs O
) O
. O
['Physiological-Clinical']

Do O
physicians O
' O
implicit O
views O
of O
African O
Americans O
affect O
clinical O
decision O
making O
? O
[]

However O
, O
there O
are O
no O
reports O
regarding O
the O
combined O
effects O
of O
FT O
colon O
operation O
and O
laparoscopic O
technique O
on O
humoral B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
cellular I-outcome ['Physiological-Clinical']
immunity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Accordingly O
, O
tests O
for O
anthelmintic B-outcome ['Physiological-Clinical']
efficacy O
using O
the O
faecal O
egg O
count O
reduction O
test O
( O
FECRT O
) O
on O
the O
range O
of O
drugs O
used O
to O
control O
nematode O
parasites O
were O
carried O
out O
on O
the O
five O
government O
small-ruminant O
breeding O
farms O
in O
Sabah O
. O
['Physiological-Clinical']

Daytime O
frequency O
, O
[]

RESULTS O
The O
markedly O
effective O
rate O
was O
55.0 O
% O
in O
the O
treatment O
group O
and O
15.0 O
% O
in O
the O
control O
group O
with O
a O
very O
significant O
difference O
between O
the O
two O
groups O
( O
P O
< O
0.01 O
) O
; O
the O
differences O
before O
and O
after O
training O
in O
some O
projects O
such O
as O
the O
total O
score O
of O
development O
, O
imitation O
, O
oral O
cognition O
in O
the O
treatment O
group O
were O
very O
significantly O
different O
from O
those O
in O
the O
control O
group O
( O
P O
< O
0.01 O
) O
. O
[]

The O
impact O
of O
fasting O
and O
treatment O
omission O
on O
susceptibility B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
hypoglycaemia I-outcome ['Physiological-Clinical']
in O
children O
and O
adolescents O
with O
GH O
and O
cortisol O
insufficiency O
. O
['Physiological-Clinical']

EXPECTED O
RESULTS O
300 O
patients O
will O
be O
randomized O
with O
a O
statistical O
hypothesis O
of O
a O
progression B-outcome ['Mortality']
free I-outcome ['Mortality']
survival I-outcome ['Mortality']
of O
3 O
months O
in O
the O
control O
arm O
and O
of O
4.5 O
months O
in O
the O
experimental O
arm O
. O
['Mortality']

These O
results O
suggest O
that O
a O
choice O
assessment O
can O
be O
used O
to O
predict O
the O
relative O
reinforcing O
value O
of O
various O
stimuli B-outcome ['Physiological-Clinical']
, O
which O
, O
in O
turn O
, O
may O
help O
to O
improve O
programs O
for O
clients O
with O
severe O
to O
profound O
disabilities O
. O
['Physiological-Clinical']

We O
propose O
a O
systematic O
method O
of O
determining O
the O
index O
of O
the O
necrotic B-outcome ['Physiological-Clinical']
portion I-outcome ['Physiological-Clinical']
which O
may O
be O
clinically O
useful O
in O
the O
management O
of O
early-stage O
ON O
of O
the O
femoral O
head O
. O
['Physiological-Clinical']

Femoral O
neck O
osteoporosis O
with O
low O
ASM B-outcome ['Physiological-Clinical']
predicted O
poor O
chair B-outcome ['Physiological-Clinical']
stand I-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
( O
beta O
-3.3 O
, O
standard O
error O
1.6 O
, O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
previous O
trials O
, O
it O
showed O
a O
higher O
efficacy O
than O
clotrimazole O
in O
the O
treatment O
of O
dermatophytoses O
. O
[]

Based O
on O
the O
results O
of O
a O
literature O
search O
, O
data O
comparing O
the O
effects O
of O
the O
opioids O
are O
lacking O
. O
[]

Febrile B-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
rate O
was O
higher O
in O
the O
VNR/CDDP O
arm O
( O
p=0.02 O
) O
as O
well O
as O
G3-4 O
anemia B-outcome ['Physiological-Clinical']
( O
p=0.005 O
) O
and O
G-CSF/EPO O
use O
( O
p=0.019 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
is O
evidence O
that O
abnormalities O
exist O
in O
the O
serotonin O
( O
5-HT O
) O
system O
in O
autism O
spectrum O
patients O
. O
[]

Our O
results O
support O
the O
view O
that O
the O
treatment O
of O
newly O
detected O
asthma O
should O
be O
started O
with O
a O
high O
dose O
of O
inhaled O
steroid O
. O
[]

Oral O
ciprofloxacin O
vs. O
intramuscular O
ceftriaxone O
as O
empiric O
treatment O
of O
acute O
invasive O
diarrhea O
in O
children O
. O
[]

Amoxicillin/metronidazole/omeprazole/clarithromycin O
: O
a O
new O
, O
short O
quadruple O
therapy O
for O
Helicobacter B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
ventilatory O
and O
MSNA O
responses O
to O
hypoxic O
PECO O
were O
not O
greater O
than O
the O
sum O
of O
the O
responses O
to O
hypoxia O
and O
PECO O
individually O
, O
indicating O
that O
the O
CC O
are O
not O
sensitized O
during O
metaboreflex O
activation O
. O
[]

The O
itching B-outcome ['Physiological-Clinical']
and O
burning B-outcome ['Physiological-Clinical']
symptoms O
were O
not O
severe O
and O
can O
be O
explained O
by O
the O
preservative O
benzyl O
alcohol O
present O
in O
the O
CS O
gel O
. O
['Physiological-Clinical', 'Physiological-Clinical']

226 O
episodes O
were O
included O
in O
the O
primary O
efficacy O
analysis O
of O
fully O
vaccinated O
children O
( O
54 O
among O
1128 O
RRV-TV O
recipients O
, O
172 O
among O
1145 O
placebo O
recipients O
; O
vaccine O
efficacy O
68 O
% O
[ O
57-76 O
] O
) O
. O
[]

RESULTS O
In O
the O
1202 O
men O
studied O
, O
361 O
cases O
of O
prostate O
cancer O
were O
diagnosed O
. O
[]

for O
24 O
months O
) O
or O
no O
intervention O
. O
[]

At O
visit O
2 O
, O
patients O
also O
rated O
their O
degree O
of O
overall B-outcome ['Physiological-Clinical']
symptomatic I-outcome ['Physiological-Clinical']
relief B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Stepwise O
assessment O
tool O
of O
operative O
skills O
( O
SATOS O
) O
: O
validity O
testing O
on O
a O
porcine O
training O
model O
of O
open O
gastrectomy O
. O
[]

Radiotherapy O
and O
CCNU O
in O
the O
treatment O
of O
high-grade O
supratentorial O
astrocytomas O
. O
[]

Prophylaxis O
with O
meropenem O
of O
septic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
in O
acute O
pancreatitis O
: O
a O
randomized O
, O
controlled O
trial O
versus O
imipenem O
. O
['Physiological-Clinical']

Zolmitriptan O
( O
Zomig O
, O
formerly O
311C90 O
) O
is O
a O
selective O
5-hydroxytryptamine O
( O
5-HT O
) O
1B/1D-receptor O
agonist O
with O
central O
and O
peripheral O
activity O
for O
the O
acute O
treatment O
of O
migraine O
. O
[]

[ O
Relationship O
between O
sCD44v6 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
and O
TCM O
differentiation O
type O
of O
gastric O
carcinoma O
patients O
and O
influence O
of O
weitai O
capsule O
on O
the O
expression B-outcome ['Physiological-Clinical']
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Results O
demonstrated O
the O
ability O
to O
recruit O
and O
retain O
53 O
rural O
breast O
cancer O
survivors O
, O
that O
the O
experimental O
arm O
showed O
improvement O
in O
overall B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
( O
P O
= O
.013 O
) O
, O
and O
that O
there O
were O
significant O
differences O
in O
overall B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
between O
the O
experimental O
and O
wait-control O
groups O
at O
both O
months O
3 O
and O
6 O
. O
['Life-Impact', 'Life-Impact']

BACKGROUND O
Improved O
endothelial O
function O
may O
contribute O
to O
the O
beneficial O
effects O
of O
cholesterol O
lowering O
therapy O
in O
patients O
with O
coronary O
artery O
disease O
( O
CAD O
) O
, O
but O
results O
of O
the O
effect O
of O
statin O
therapy O
on O
endothelial O
function O
are O
disparate O
in O
these O
patients O
. O
[]

In O
order O
to O
evaluate O
subtle O
effects O
on O
electroencephalographic O
vigilance O
within O
stage O
A O
, O
also O
the O
anterior-posterior B-outcome ['Physiological-Clinical']
and O
left-right B-outcome ['Physiological-Clinical']
relations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
absolute I-outcome ['Physiological-Clinical']
alpha-power I-outcome ['Physiological-Clinical']
were O
calculated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
month-long O
naltrexone O
( O
NTX O
) O
treatment O
at O
a O
daily O
oral O
dose O
of O
0.5 O
mg/kg/day O
was O
contrasted O
with O
placebo O
( O
PLC O
) O
in O
a O
double-blind O
study O
with O
conjoint O
clinical O
and O
biochemical O
evaluations O
of O
therapeutic O
effects O
. O
[]

PATIENTS O
AND O
METHODS O
Adequate O
tissue O
for O
immunohistochemistry O
was O
available O
for O
p53 O
, O
Ki-67 O
, O
and O
MDM2 O
analyses O
in O
478 O
patient O
cases O
. O
[]

Absolute O
bioavailability O
of O
a O
new O
high O
dose O
methylprednisolone O
tablet O
formulation O
. O
[]

The O
cumulative O
dose O
response O
effect O
of O
eicosapentaenoic O
and O
docosahexaenoic O
acid O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
plasma B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
and O
diet B-outcome ['Life-Impact']
pattern I-outcome ['Life-Impact']
in O
mild O
to O
moderate O
essential O
hypertensive O
black O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
The O
analgesia O
activity O
of O
ketorolac O
tromethamine O
10 O
mg O
and O
30 O
mg O
suppositories O
were O
evaluated O
after O
single O
dose O
administration O
by O
assessing O
pain O
intensity O
and O
pain O
relief O
using O
a O
4 O
point O
scale O
( O
VRS O
) O
. O
[]

METHODS O
Methods O
included O
prospective O
, O
single-hub O
, O
2-spoke O
, O
randomized O
, O
blinded O
, O
controlled O
trial O
of O
a O
2-way O
, O
site-independent O
, O
audiovisual O
telemedicine O
system O
designed O
for O
remote O
examination O
of O
adult O
patients O
with O
acute O
stroke O
versus O
telephone O
consultation O
to O
assess O
eligibility O
for O
treatment O
with O
intravenous O
thrombolysis O
. O
[]

Ridge B-outcome ['Physiological-Clinical']
width I-outcome ['Physiological-Clinical']
and O
height B-outcome ['Physiological-Clinical']
dimensions I-outcome ['Physiological-Clinical']
were O
similarly O
preserved O
with O
both O
graft O
materials O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Randomized O
study O
of O
13-cis O
retinoic O
acid O
v O
placebo O
in O
the O
myelodysplastic O
disorders O
. O
[]

The O
group O
was O
made O
up O
of O
men O
and O
women O
aged O
between O
48 O
and O
73 O
years O
in O
chronic O
treatment O
with O
digitalis O
and O
diuretics O
for O
at O
least O
3 O
months O
and O
who O
still O
displayed O
symptoms O
. O
[]

Patients O
were O
crossed O
over O
to O
the O
other O
technique O
when O
the O
initial O
technique O
was O
a O
failure O
. O
[]

CONCLUSIONS O
Fadrozole O
HCL O
was O
as O
efficacious O
as O
megestrol O
acetate O
in O
postmenopausal O
patients O
with O
metastatic O
breast O
carcinoma O
after O
one O
hormonal O
therapy O
. O
[]

MATERIAL O
AND O
METHODS O
Using O
impressions O
made O
from O
a O
stainless O
steel O
complete-crown O
master O
die O
, O
9 O
stone O
cast O
replicas O
were O
fabricated O
, O
numbered O
, O
and O
distributed O
into O
8 O
ceramic O
ZrO O
( O
2 O
) O
CAD/CAM O
system O
groups O
( O
Lava O
Frame O
0.3 O
and O
0.5 O
, O
IPS O
e.max O
ZirCAD O
, O
VITA O
YZ O
, O
Procera O
AllZircon O
, O
Digizon O
, O
DC O
Zircon O
, O
and O
Cercon O
Base O
) O
and O
to O
a O
lithium O
disilicate O
glass-ceramic O
control O
group O
( O
IPS O
e.max O
Press O
) O
using O
a O
simple O
computer-generated O
randomization O
method O
. O
[]

Duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
chemotherapy I-outcome ['Life-Impact']
in O
small O
cell O
lung O
cancer O
: O
a O
Cancer O
Research O
Campaign O
trial O
. O
['Life-Impact']

Treatment O
of O
severe O
aplastic O
anemia O
with O
antilymphocyte O
globulin O
, O
cyclosporine O
and O
two O
different O
granulocyte O
colony-stimulating O
factor O
regimens O
: O
a O
GITMO O
prospective O
randomized O
study O
. O
[]

The O
main O
assessment O
criteria O
were O
maximum O
diameter B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
resection I-outcome ['Physiological-Clinical']
specimen I-outcome ['Physiological-Clinical']
and O
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
resection I-outcome ['Physiological-Clinical']
area O
, O
and O
the O
complication B-outcome ['Adverse-effects']
rate O
. O
['Physiological-Clinical', 'Adverse-effects']

The O
median O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
95 O
% O
confidence O
interval O
) O
for O
the O
placebo O
group O
was O
48 O
( O
42 O
, O
54 O
) O
hours O
compared O
with O
57 O
( O
38 O
, O
76 O
) O
hours O
in O
the O
dexamethasone O
group O
( O
p O
= O
0.19 O
) O
. O
['Resource-use']

In O
addition O
, O
efficacy O
was O
maintained O
mainly O
between O
days O
2 O
and O
60 O
but O
declined O
slightly O
by O
day O
90 O
. O
[]

Using O
both O
segment- O
and O
patient-based O
analysis O
, O
the O
greatest O
accuracy O
and O
proportion O
of O
interpretable O
images O
were O
obtained O
using O
harmonic O
imaging O
in O
the O
triggered O
mode O
. O
[]

BACKGROUND O
The O
aims O
of O
this O
study O
were O
to O
evaluate O
the O
oral O
health O
impacts O
perceived O
by O
patients O
submitted O
to O
different O
treatments O
of O
chronic O
periodontitis O
and O
their O
association O
with O
clinical O
parameters O
. O
[]

More O
patients O
in O
the O
CRT O
group O
had O
received O
a O
stoma O
( O
73 O
% O
vs. O
52 O
% O
, O
p O
= O
0.09 O
) O
. O
[]

However O
, O
this O
finding O
was O
not O
significant O
. O
[]

Reliability O
analysis O
showed O
Cronbach O
's O
alpha O
of O
the O
questionnaire O
was O
0.91 O
. O
[]

Topically O
applied O
fluorides O
have O
been O
successfully O
used O
to O
inhibit O
the O
formation O
of O
dental O
caries O
in O
this O
population O
. O
[]

RESULTS O
In O
the O
treatment O
group O
( O
n=10 O
) O
, O
the O
mean O
index O
score O
of O
EQ-5D O
and O
VAS O
changed O
significantly O
from O
the O
placebo O
group O
( O
by O
0.299 O
and O
2.61 O
, O
respectively O
) O
from O
day O
2 O
( O
P O
< O
0.01 O
) O
. O
[]

During O
the O
2-year O
period O
after O
therapy O
, O
10 O
% O
in O
MT O
and O
59 O
% O
in O
BT O
required O
no O
further O
sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
due O
to O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

A O
total O
of O
24 O
patients O
were O
recruited O
to O
the O
study O
; O
ten O
received O
cyclosporin O
with O
blood O
transfusions O
( O
BT O
) O
( O
group O
1 O
) O
, O
14 O
received O
BT O
alone O
( O
group O
2 O
) O
. O
[]

Sixty O
healthy O
women O
, O
half O
of O
whom O
had O
been O
using O
OCs O
for O
at O
least O
the O
previous O
6 O
months O
, O
participated O
in O
the O
study O
. O
[]

First-line O
intravenous O
chemotherapy O
( O
CT O
) O
following O
debulking O
surgery O
is O
associated O
with O
prolonged B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
in O
particular O
in O
patients O
who O
achieve O
a O
pathological O
complete O
remission O
( O
pCR O
) O
at O
second-look O
surgery O
but O
in O
whom O
a O
high O
rate O
of O
relapses O
still O
occurs O
. O
['Mortality']

Virtual O
reality O
for O
acute O
pain O
reduction O
in O
adolescents O
undergoing O
burn O
wound O
care O
: O
a O
prospective O
randomized O
controlled O
trial O
. O
[]

Elevated B-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
counts O
, O
elevated B-outcome ['Physiological-Clinical']
platelet I-outcome ['Physiological-Clinical']
counts O
, O
and O
a O
high O
neutrophil-lymphocyte B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
were O
significant O
independent O
predictors O
for O
shorter O
OS O
in O
a O
model O
with O
established O
prognostic O
factors O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
group O
of O
48 O
critically O
injured O
patients O
were O
entered O
into O
a O
prospective O
, O
double-blind O
, O
placebo-controlled O
trial O
to O
evaluate O
the O
efficacy O
of O
early O
infusion O
of O
PGE1 O
for O
reducing O
the O
incidence O
of O
severe B-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

Teaching O
emotion B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
to O
young O
children O
with O
autism O
: O
a O
randomised O
controlled O
trial O
of O
an O
emotion O
training O
programme O
. O
['Life-Impact']

In O
the O
HD1 O
trial O
( O
1983 O
to O
1988 O
) O
, O
146 O
patients O
who O
responded O
to O
chemotherapy O
were O
randomized O
to O
receive O
20 O
Gy O
( O
70 O
patients O
) O
or O
40 O
Gy O
( O
76 O
patients O
) O
of O
EF O
irradiation O
in O
all O
fields O
outside O
bulky O
disease O
sites O
. O
[]

RESULTS O
The O
acupuncture O
group O
experienced O
significantly O
less O
gagging B-outcome ['Physiological-Clinical']
than O
the O
sham O
group O
( O
p O
= O
0.037 O
) O
or O
the O
nonacupuncture O
group O
( O
p O
= O
0.013 O
) O
. O
['Physiological-Clinical']

MK-571 O
provided O
about O
50 O
% O
protection O
during O
maximum O
early O
and O
late O
responses O
compared O
with O
placebo O
( O
p=0.005 O
) O
, O
but O
airway B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
persisted O
8-24 O
hours O
after O
allergen O
on O
both O
treatment O
days O
. O
['Physiological-Clinical']

Only O
1 O
subject O
was O
dropped O
from O
the O
study O
owing O
to O
side O
effects O
, O
notably O
a O
spreading B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
, O
which O
then O
resolved O
spontaneously O
. O
['Physiological-Clinical']

Incomplete B-outcome ['Life-Impact']
colonoscopy I-outcome ['Life-Impact']
occurred O
in O
21 O
( O
2.3 O
% O
) O
cases O
( O
14 O
in O
the O
CF-240I O
group O
and O
seven O
in O
the O
PCF-240L O
group O
, O
P O
> O
0.1 O
) O
. O
['Life-Impact']

Through O
primary O
and O
secondary O
review O
with O
preset O
inclusion O
criteria O
, O
two O
independent O
judges O
identified O
27 O
randomized O
controlled O
trials O
, O
of O
which O
13 O
met O
inclusion O
criteria O
. O
[]

In O
the O
summary O
arm O
, O
54 O
% O
of O
responses O
were O
found O
to O
contain O
falsely B-outcome ['Life-Impact']
recalled I-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
extraneous I-outcome ['Life-Impact']
information I-outcome ['Life-Impact']
versus O
21 O
% O
of O
responses O
in O
the O
narrative O
arm O
( O
difference O
= O
33 O
% O
, O
95 O
% O
CI O
= O
14 O
% O
to O
53 O
% O
) O
. O
['Life-Impact']

In O
contrast O
, O
in O
patients O
with O
a O
negative O
immunohistochemical O
analysis O
systematic O
lymphadenectomy O
resulted O
in O
an O
improved O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P=0.044 O
) O
. O
['Mortality']

A O
randomised O
double-blind O
placebo-controlled O
study O
was O
designed O
to O
evaluate O
the O
effects O
of O
a O
semisynthetic O
macrolide O
antibiotic O
, O
clarithromycin O
, O
on O
bronchial B-outcome ['Physiological-Clinical']
hyperresponsiveness I-outcome ['Physiological-Clinical']
to O
methacholine O
in O
patients O
with O
a O
diagnosis O
of O
asthma O
. O
['Physiological-Clinical']

Beta-carotene B-outcome ['Physiological-Clinical']
and O
vitamin B-outcome ['Physiological-Clinical']
A I-outcome ['Physiological-Clinical']
in O
their O
plasma O
were O
also O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
determine O
the O
effect O
of O
long O
term O
inhaled O
corticosteroids O
on O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
exacerbations B-outcome ['Physiological-Clinical']
, O
and O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
in O
patients O
with O
moderate O
to O
severe O
chronic O
obstructive O
pulmonary O
disease O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
More O
than O
half O
of O
the O
cases O
of O
MPC O
were O
of O
unknown O
etiology O
. O
[]

The O
10-MU O
( O
n O
= O
74 O
) O
, O
20-MU O
( O
n O
= O
74 O
) O
, O
and O
placebo O
( O
n O
= O
72 O
) O
groups O
had O
comparable O
frequencies O
of O
documented O
rhinovirus O
colds O
( O
50 O
to O
65 O
% O
) O
and O
mean O
durations O
of O
pretreatment B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
( O
26 O
to O
27 O
h O
) O
. O
['Physiological-Clinical']

For O
two O
themes O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
recall B-outcome ['Life-Impact']
between O
the O
arms O
. O
['Life-Impact']

Overall O
, O
an O
educational O
program O
developed O
with O
a O
theoretical O
background O
was O
associated O
with O
improvement O
in O
calcium B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
knowledge B-outcome ['Life-Impact']
, O
and O
self-efficacy B-outcome ['Life-Impact']
, O
with O
no O
effect O
on O
most O
health B-outcome ['Life-Impact']
belief I-outcome ['Life-Impact']
subscales O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

CLASSIFICATION O
OF O
EVIDENCE O
This O
study O
provides O
Class O
I O
evidence O
that O
iTBS O
was O
not O
effective O
for O
gait B-outcome ['Life-Impact']
, O
upper B-outcome ['Physiological-Clinical']
extremity I-outcome ['Physiological-Clinical']
bradykinesia I-outcome ['Physiological-Clinical']
, O
or O
other O
motor B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
PD O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Abdominal O
aortic O
surgery O
has O
significant O
effects O
on O
cardiac O
and O
splanchnic O
perfusion O
. O
[]

The O
responses O
to O
acute O
exercise O
were O
more O
pronounced O
than O
responses O
to O
accumulated O
training O
, O
suggesting O
that O
STARS O
signalling O
is O
primarily O
involved O
in O
the O
initial O
phase O
of O
exercise-induced O
muscle O
adaptations O
. O
[]

Effectiveness O
of O
Dader O
Method O
for O
pharmaceutical O
care O
on O
control O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
total O
cholesterol B-outcome ['Physiological-Clinical']
in O
outpatients O
with O
cardiovascular O
disease O
or O
cardiovascular O
risk O
: O
EMDADER-CV O
randomized O
controlled O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Efficacy O
and O
safety O
of O
leuprolide O
acetate O
3-month O
depot O
11.25 O
milligrams O
or O
30 O
milligrams O
for O
the O
treatment O
of O
central O
precocious O
puberty O
. O
[]

The O
purpose O
of O
this O
quasi-experimental O
study O
was O
to O
determine O
the O
effectiveness O
of O
an O
occupation O
based O
health O
and O
fitness O
program O
. O
[]

Split-course B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
resulted O
in O
a O
significantly O
better O
survival O
rate O
in O
cases O
of O
large O
cell O
carcinoma O
but O
the O
number O
of O
cases O
was O
small O
. O
['Resource-use']

After O
insulin O
bolus O
, O
during O
saline O
, O
insulin-induced B-outcome ['Physiological-Clinical']
NOx I-outcome ['Physiological-Clinical']
, O
endothelin-1 B-outcome ['Physiological-Clinical']
, O
and O
forearm B-outcome ['Physiological-Clinical']
cGMP I-outcome ['Physiological-Clinical']
release O
was O
almost O
abolished O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
week O
8 O
, O
losartan O
was O
increased O
to O
50 O
mg O
twice O
daily O
and O
valsartan O
increased O
to O
320 O
mg O
once O
daily O
( O
olmesartan O
remained O
at O
40 O
mg O
once O
daily O
) O
. O
[]

Pharmacokinetics O
and O
pharmacodynamics O
of O
six O
epoetin O
alfa O
dosing O
regimens O
in O
anemic O
critically O
ill O
patients O
without O
acute O
blood O
loss O
. O
[]

Immune O
globulin O
therapy O
had O
no O
effect O
on O
respiratory O
distress O
syndrome O
, O
bronchopulmonary O
dysplasia O
, O
intracranial O
hemorrhage O
, O
the O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
, O
or O
mortality B-outcome ['Mortality']
. O
['Resource-use', 'Mortality']

In O
particular O
, O
the O
role O
of O
adjunctive O
nonpharmacologic O
analgesic O
techniques O
is O
unclear O
. O
[]

The O
mean O
stretching B-outcome ['Physiological-Clinical']
frequency O
decreased O
from O
3.7 O
to O
1.6 O
times O
a O
week O
in O
both O
groups O
. O
['Physiological-Clinical']

The O
primary O
endpoint O
was O
the O
number O
of O
new B-outcome ['Physiological-Clinical']
active I-outcome ['Physiological-Clinical']
MRI-evident I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
over O
24 O
weeks O
of O
treatment O
. O
['Physiological-Clinical']

In O
the O
usual O
care O
group O
11 O
of O
33 O
( O
33 O
% O
) O
patients O
with O
no O
plaques O
suffered O
from O
a O
combined O
end-point O
during O
follow-up O
compared O
with O
11 O
of O
30 O
( O
37 O
% O
) O
in O
the O
intervention O
group O
. O
[]

This O
is O
designed O
to O
provide O
data O
on O
six O
categories O
of O
feelings O
: O
tension O
, O
depression O
, O
anger O
, O
vigor O
, O
fatigue O
, O
and O
confusion O
. O
[]

Thrombin-activatable O
fibrinolysis O
inhibitor O
( O
TAFI O
) O
is O
a O
link O
between O
coagulation O
and O
the O
fibrinolytic O
system O
. O
[]

Intriguing O
evidence O
in O
a O
somatic O
pain O
model O
has O
suggested O
that O
BTX-A O
injection O
may O
have O
an O
antinociceptive O
effect O
on O
both O
acute O
and O
chronic O
( O
inflammatory O
) O
pain O
. O
[]

Stable O
return-to-work O
was O
a O
return-to-work O
lasting O
for O
at O
least O
1 O
month O
from O
the O
start O
of O
follow-up O
. O
[]

RESULTS O
All O
patients O
were O
available O
for O
the O
three O
recall O
appointments O
. O
[]

All O
infants O
received O
a O
0?6 O
mL O
dose O
of O
nevirapine O
at O
birth O
and O
, O
from O
December O
, O
2006 O
, O
4 O
mg/kg O
twice O
daily O
of O
zidovudine O
for O
1 O
week O
after O
birth O
. O
[]

These O
were O
distinguished O
by O
the O
absence O
( O
group O
I O
) O
or O
presence O
( O
group O
II O
) O
of O
supplementation O
with O
0.25 O
mg O
of O
cetrorelix O
. O
[]

Further O
studies O
are O
needed O
to O
assess O
the O
effect O
of O
simultaneous O
delivery O
of O
iron O
and O
vitamin O
A O
for O
the O
treatment O
of O
nightblindness O
. O
[]

Baseline O
tumour O
marker O
levels O
provide O
prognostic O
information O
for O
patients O
with O
UGIA O
on O
palliative O
chemotherapy O
. O
[]

Combination O
chemotherapy O
and O
ALVAC-CEA/B7.1 O
vaccine O
in O
patients O
with O
metastatic O
colorectal O
cancer O
. O
[]

Reduced O
mortality O
among O
children O
in O
southern O
India O
receiving O
a O
small O
weekly O
dose O
of O
vitamin O
A O
. O
[]

We O
hypothesized O
that O
a O
home-based O
, O
simple O
, O
low-intensity O
exercise O
could O
enhance O
back O
extensor O
strength O
and O
improve O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
and/or O
spinal B-outcome ['Physiological-Clinical']
range O
of O
motion B-outcome ['Life-Impact']
in O
postmenopausal O
women O
in O
a O
short-term O
follow-up O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

BACKGROUND O
Pretreatment O
with O
statins O
has O
been O
shown O
to O
reduce O
brain O
injury O
in O
cerebral O
ischemia O
. O
[]

DESIGN O
Randomised O
controlled O
trial O
with O
control O
treatment O
crossover O
after O
the O
first O
follow O
up O
examination O
. O
[]

Doxepin O
produced O
a O
greater O
incidence O
of O
anticholinergic B-outcome ['Physiological-Clinical']
side I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
, O
including O
dry B-outcome ['Physiological-Clinical']
mouth B-outcome ['Physiological-Clinical']
, O
constipation B-outcome ['Physiological-Clinical']
, O
sleepiness B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
( O
LVM B-outcome ['Physiological-Clinical']
) O
and O
ejection B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
evaluated O
by O
echocardiography O
and O
the O
maximal O
working O
capacity O
( O
MWC O
) O
was O
measured O
by O
a O
bicycle O
exercise O
test O
performed O
before O
and O
after O
the O
treatment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
control O
group O
of O
26 O
patients O
was O
also O
evaluated O
to O
determine O
if O
outcome O
variables O
remained O
constant O
from O
baseline O
to O
6 O
months O
. O
[]

There O
were O
11 O
deaths O
because O
of O
heart O
failure O
or O
refractory O
cardiogenic O
shock O
in O
9 O
, O
pulmonary O
embolism O
in O
1 O
, O
and O
cancer O
in O
1 O
. O
[]

Two O
thirds O
of O
the O
patients O
were O
having O
symptoms O
for O
more O
than O
6 O
months O
. O
[]

METHOD O
Forty-nine O
teacher-child O
dyads O
were O
randomized O
into O
1 O
of O
3 O
groups O
: O
( O
1 O
) O
a O
placebo O
control O
( O
PBO O
) O
group O
, O
( O
2 O
) O
COMPASS O
followed O
by O
face-to-face O
( O
FF O
) O
coaching O
sessions O
, O
and O
( O
3 O
) O
COMPASS O
followed O
by O
web-based O
( O
WEB O
) O
coaching O
sessions O
. O
[]

Vilazodone O
lacks O
proarrhythmogenic O
potential O
in O
healthy O
participants O
: O
a O
thorough O
ECG O
study O
. O
[]

Treating O
group O
patients O
received O
three O
times O
Naphcon O
eye O
drops O
during O
15 O
minutes O
before O
surgery O
. O
[]

Although O
SADQ O
scores O
and O
Rand O
definite O
alcoholism B-outcome ['Life-Impact']
were O
in O
general O
agreement O
, O
there O
were O
a O
number O
of O
borderline O
instances O
and O
cases O
of O
disagreement O
, O
and O
neither O
was O
in O
good O
agreement O
with O
estimates O
of O
problem O
duration O
, O
nor O
with O
reports O
of O
recent O
or O
earlier O
attainment O
of O
abstinence O
or O
control O
. O
['Life-Impact']

This O
study O
was O
undertaken O
in O
a O
similar O
way O
to O
compare O
capsular O
contracture O
around O
smooth O
and O
textured O
saline-filled O
prostheses O
with O
pores O
of O
small O
size O
. O
[]

The O
primary O
end-point O
was O
discontinuation B-outcome ['Life-Impact']
due I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
lack I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
heartburn I-outcome ['Life-Impact']
control O
during O
the O
on-demand O
phase B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Thirty-seven O
patients O
from O
5 O
to O
14 O
years O
old O
undergoing O
electrocautery O
tonsillectomy O
were O
randomized O
to O
either O
the O
H2O2 O
mouth O
rinse O
or O
the O
water O
rinse O
( O
control O
) O
group O
. O
[]

METHODS O
An O
internal O
quality O
control O
( O
QC O
) O
program O
was O
developed O
as O
part O
of O
a O
quality O
management O
framework O
for O
the O
trial O
. O
[]

SUBJECTS O
Children O
between O
4 O
and O
18 O
years O
old O
with O
cerebral O
palsy O
. O
[]

OBJECTIVE O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
nutritional O
status O
of O
374 O
surgical O
patients O
with O
gastrointestinal O
disease O
and O
hernias O
of O
the O
abdominal O
wall O
; O
to O
identify O
risk O
factors O
associated O
with O
a O
poorer O
nutritional O
status O
in O
this O
group O
of O
patients O
and O
to O
assess O
awareness O
of O
the O
patient O
's O
nutritional O
status O
by O
medical O
teams O
. O
[]

Treatment O
gains O
were O
maintained O
at O
3-month O
follow-up O
. O
[]

The O
waveform O
was O
much O
more O
successful O
at O
very O
low O
voltages O
( O
less O
than O
or O
equal O
to O
100 O
V O
) O
compared O
with O
the O
conventional O
waveform O
( O
Novel O
: O
82 O
% O
vs O
Conventional O
22 O
% O
, O
P O
= O
0.008 O
) O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
influence O
of O
exteriorization O
of O
uterus O
during O
uterine O
repair O
on O
caesarean O
morbidity O
. O
[]

CONCLUSIONS O
Allopurinol O
treatment O
is O
well O
tolerated O
and O
attenuates O
the O
rise O
in O
intercellular O
adhesion O
molecule-1 O
levels O
seen O
after O
stroke O
. O
[]

BACKGROUND O
The O
efficacy O
of O
nebulized O
corticosteroids O
in O
the O
prevention O
of O
exacerbation O
of O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
has O
been O
poorly O
studied O
. O
[]

The O
subgroup O
identified O
as O
depressed O
was O
entered O
into O
the O
nested O
IDACC O
trial O
, O
which O
tests O
the O
hypothesis O
that O
identifying O
depression O
and O
offering O
an O
evidence-based O
intervention O
to O
general O
practitioners O
, O
incorporating O
multidisciplinary O
telephone O
case O
conferencing O
, O
will O
reduce O
levels O
of O
depression B-outcome ['Life-Impact']
, O
improve O
quality O
of O
life O
, O
and O
reduce O
associated O
economic B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
['Life-Impact', 'Resource-use']

Nifedipine O
therapy O
( O
immediate O
release O
) O
was O
effective O
in O
control O
of O
ischemia B-outcome ['Physiological-Clinical']
only O
when O
both O
ambulatory O
and O
office-measured O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
controlled O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Six O
patients O
died B-outcome ['Mortality']
of I-outcome ['Mortality']
infections I-outcome ['Mortality']
( O
A O
= O
four O
patients O
and O
C O
= O
two O
patients O
) O
. O
['Mortality']

They O
comprised O
the O
intent-to-treat O
population O
. O
[]

A O
comparison O
between O
bupivacaine O
and O
diamorphine O
. O
[]

All O
students O
will O
be O
exposed O
to O
the O
four O
designs O
. O
[]

Push B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
increased O
and O
cycle O
frequency O
decreased O
as O
a O
result O
of O
training O
. O
['Life-Impact']

The O
5 O
alpha-steroid B-outcome ['Physiological-Clinical']
metabolite I-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
in O
the O
MPHs O
was O
compared O
with O
that O
of O
men O
with O
benign O
prostatic O
hyperplasia O
who O
were O
administered O
varying O
doses O
of O
the O
5 O
alpha-reductase O
inhibitor O
finasteride O
. O
['Physiological-Clinical']

BACKGROUND O
Common O
clinical O
risk O
factors O
for O
fracture O
in O
older O
women O
have O
been O
identified O
. O
[]

A1C B-outcome ['Physiological-Clinical']
remained O
stable O
at O
6.4 O
% O
in O
those O
with O
baseline O
A1C O
< O
7.0 O
% O
. O
['Physiological-Clinical']

Few O
randomized O
controlled O
trials O
have O
been O
aimed O
specifically O
at O
lifestyle O
issues O
among O
persons O
with O
a O
psychiatric O
disability O
. O
[]

There O
was O
no O
significant O
carryover B-outcome ['Life-Impact']
or O
period B-outcome ['Physiological-Clinical']
effect O
for O
any O
outcome O
measure O
. O
['Life-Impact', 'Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
LED O
irradiation O
( O
850 O
nm O
) O
applied O
during O
treadmill O
training O
on O
the O
maximal B-outcome ['Physiological-Clinical']
exercise I-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
. O
['Physiological-Clinical']

All O
patients O
received O
the O
same O
cemented O
posterior-stabilized O
implant O
through O
a O
mini-midvastus O
approach O
. O
[]

Prior O
to O
challenge O
, O
patients O
manifested O
some O
subjective B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
but O
few O
objective O
signs O
of O
opioid O
withdrawal O
. O
['Life-Impact']

We O
report O
the O
first O
double O
blind O
randomised O
controlled O
trial O
of O
regular O
opioids O
and O
an O
infusion O
of O
low O
dose O
( O
0.6 O
mg/kg O
) O
intravenous O
ketamine O
compared O
with O
opioids O
and O
placebo O
in O
patients O
with O
allodynia O
, O
hyperalgesia O
and O
hyperpathia O
secondary O
to O
critical O
limb O
ischaemia O
. O
[]

Preoperative O
haemodynamic O
status O
was O
good O
in O
all O
of O
them O
. O
[]

This O
retrospective O
analysis O
of O
data O
from O
that O
study O
was O
undertaken O
to O
determine O
whether O
there O
was O
a O
relationship O
between O
dose O
and O
progression O
rates O
, O
which O
reflects O
the O
amount O
of O
retina O
destroyed O
when O
progression O
occurs O
. O
[]

Antipyrine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
and O
response O
to O
interferon B-outcome ['Physiological-Clinical']
treatment I-outcome ['Physiological-Clinical']
in O
patients O
with O
chronic O
active O
hepatitis O
C. O
To O
determine O
whether O
hepatic O
metabolic O
function O
affects O
the O
response O
to O
interferon B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
, O
we O
measured O
antipyrine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
APC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
85 O
patients O
with O
chronic O
active O
hepatitis O
C O
and O
compared O
the O
results O
with O
treatment O
outcome O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

The O
mean O
follow O
up O
was O
14.1 O
months O
( O
range O
12-23 O
months O
) O
. O
[]

PATIENTS O
Two O
hundred O
and O
one O
functional O
class O
I O
and O
II O
patients O
with O
definite O
or O
classic O
rheumatoid O
arthritis O
, O
previously O
untreated O
with O
disease O
modifying O
antirheumatic O
drugs O
. O
[]

The O
difference O
in O
dropout O
rate O
between O
the O
Web-based O
and O
the O
printed O
intervention O
was O
not O
explained O
by O
user O
characteristics O
. O
[]

CONCLUSION O
Our O
results O
suggest O
that O
central O
effects O
of O
captopril O
and O
enalapril O
were O
minor O
and O
not O
constant O
in O
young O
healthy O
men O
. O
[]

Identifying O
patients O
at O
high O
risk O
for O
neutropenic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
during O
chemotherapy O
for O
metastatic O
breast O
cancer O
with O
doxorubicin O
or O
pegylated O
liposomal O
doxorubicin O
: O
the O
development O
of O
a O
prediction O
model O
. O
['Physiological-Clinical']

Long-term O
effects O
of O
ezetimibe-plus-statin O
therapy O
on O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
levels O
as O
compared O
with O
double-dose O
statin O
therapy O
in O
patients O
with O
coronary O
artery O
disease O
. O
['Physiological-Clinical']

A O
greater O
percentage O
of O
megestrol O
acetate-treated O
patients O
reported O
appetite B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
and O
weight O
gain O
compared O
with O
dronabinol-treated O
patients O
: O
75 O
% O
versus O
49 O
% O
( O
P O
=.0001 O
) O
for O
appetite O
and O
11 O
% O
versus O
3 O
% O
( O
P O
=.02 O
) O
for O
> O
or O
= O
10 O
% O
baseline O
weight O
gain O
. O
['Physiological-Clinical']

Subtraction O
radiography O
showed O
significant O
difference O
in O
bone O
height O
change O
between O
GTR-group O
and O
OFD-group O
( O
-0.14 O
mm O
and O
0.86 O
mm O
, O
respectively O
; O
P O
= O
0.028 O
) O
at O
6 O
months O
. O
[]

MATERIAL/METHODS O
The O
study O
was O
an O
eight-week O
, O
open-label O
trial O
using O
oral O
lipoceutical O
glutathione O
( O
n=13 O
) O
or O
transdermal O
glutathione O
( O
n=13 O
) O
in O
children O
, O
3-13 O
years O
of O
age O
, O
with O
a O
diagnosis O
of O
an O
ASD O
. O
[]

However O
, O
by O
2 O
weeks O
the O
conventional O
group O
reported O
significantly O
higher O
pain B-outcome ['Physiological-Clinical']
scores O
particularly O
on O
passing O
stool O
. O
['Physiological-Clinical']

According O
to O
the O
usual O
approach O
, O
disregarding O
interindividual O
variability O
, O
the O
systolic/diastolic B-outcome ['Physiological-Clinical']
net I-outcome ['Physiological-Clinical']
trough-to-peak I-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
were O
0.46/0.40 O
in O
the O
morning O
and O
0.77/0.99 O
in O
the O
evening O
. O
['Physiological-Clinical']

After O
unilateral O
otoplasty O
no O
patient O
needed O
droperidol B-outcome ['Resource-use']
, O
but O
after O
bilateral O
otoplasty O
, O
12 O
of O
19 O
of O
the O
atropine-treated O
and O
4 O
of O
18 O
( O
P O
< O
.05 O
) O
of O
the O
scopolamine-treated O
patients O
needed O
droperidol O
. O
['Resource-use']

Until O
now O
, O
4 O
patients O
in O
the O
Chinese O
herb O
group O
, O
one O
in O
the O
control O
group O
are O
still O
enjoying O
their O
[]

These O
results O
suggest O
that O
treatment O
and O
follow-up O
to O
prevent O
recolonisation O
in O
pregnant O
women O
with O
group-B O
streptococci O
in O
the O
urine O
may O
reduce O
the O
frequency O
of O
preterm B-outcome ['Physiological-Clinical']
labour I-outcome ['Physiological-Clinical']
in O
these O
patients O
. O
['Physiological-Clinical']

The O
analysis O
was O
adjusted O
for O
other O
patient O
characteristics O
recorded O
on O
the O
uniform O
discharge O
abstract O
. O
[]

This O
result O
could O
be O
assumed O
to O
have O
been O
influenced O
by O
the O
difference O
in O
the O
metastatic O
preponderance O
in O
a O
high O
versus O
low O
sialyl O
Lewis O
( O
a O
) O
expression O
in O
the O
tumor O
cells O
. O
[]

Both O
drugs O
significantly O
reduced O
blood O
pressure O
after O
treatment O
, O
with O
similar O
efficacy O
( O
p O
> O
0.05 O
) O
. O
[]

In O
clinical O
trials O
, O
patches O
were O
applied O
once O
daily O
and O
uptitrated O
to O
the O
individual O
effective O
dose O
in O
increments O
of O
2 O
mg/24 O
h O
every O
week O
. O
[]

Bioavailability B-outcome ['Physiological-Clinical']
of O
omega-3 O
essential O
fatty O
acids O
from O
perilla O
seed O
oil O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
effect O
of O
clinical O
guidelines O
on O
resource O
utilization O
for O
complex O
conditions O
with O
substantial O
barriers O
to O
clinician O
behavior O
change O
has O
not O
been O
well O
studied O
. O
[]

Secondary O
measures O
based O
on O
staff O
ratings O
( O
treatment O
group O
only O
) O
corroborated O
gains O
reported O
by O
parents O
. O
[]

RESULTS O
127 O
patients O
were O
randomised O
to O
a O
nurse O
run O
clinic O
, O
of O
whom O
106 O
( O
83 O
% O
) O
attended O
. O
[]

Parents O
receiving O
P-ESDM O
demonstrated O
significantly O
stronger B-outcome ['Life-Impact']
working O
alliances O
with O
their O
therapists O
than O
did O
the O
community O
group O
. O
['Life-Impact']

METHODS O
A O
prospective O
, O
blinded O
, O
randomized O
study O
was O
undertaken O
involving O
113 O
women O
attending O
a O
university O
hospital O
obstetric O
department O
. O
[]

BACKGROUND O
We O
examined O
the O
impact O
of O
prophylactic O
IABP O
insertion O
in O
EuroSCORE-stratified O
high-risk O
cardiac O
surgery O
patients O
with O
a O
score O
?8 O
. O
[]

Determinants O
of O
improvement O
in O
walking B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
among O
individuals O
with O
chronic O
stroke O
following O
a O
multi-dimensional O
exercise O
program O
. O
['Life-Impact']

METHODS O
Adults O
with O
acute O
leukemia O
undergoing O
remission O
induction O
chemotherapy O
randomly O
were O
assigned O
to O
receive O
antifungal O
prophylaxis O
with O
AMB O
( O
0.5 O
mg/kg O
three O
times O
weekly O
) O
or O
FLU O
( O
400 O
mg O
daily O
) O
. O
[]

As O
many O
of O
these O
patients O
are O
older O
, O
with O
a O
compromised O
cardiovascular O
system O
and O
a O
slow O
response O
of O
the O
erythropoietic O
system O
when O
anemia O
occurs O
, O
the O
feasibility O
and O
benefit O
of O
autologous O
blood O
donation O
is O
often O
limited O
. O
[]

CONCLUSION O
Our O
data O
indicate O
that O
functional O
endoscopic O
sinus O
surgery O
, O
combined O
with O
appropriate O
postoperative O
care O
, O
is O
effective O
at O
maintaining O
a O
significant O
improvement O
in O
the O
overall O
general O
health O
status O
of O
patients O
for O
at O
least O
3 O
years O
after O
surgical O
intervention O
and O
that O
the O
overall O
scores O
return O
to O
a O
range O
of O
normative O
values O
for O
the O
general O
population O
. O
[]

All O
patients O
completed O
the O
program O
. O
[]

Relief O
of O
osteoporotic B-outcome ['Physiological-Clinical']
backache I-outcome ['Physiological-Clinical']
with O
fluoride O
, O
calcium O
, O
and O
calciferol O
. O
['Physiological-Clinical']

or O
placebo O
for O
12 O
weeks O
and O
followed O
to O
Week O
52 O
. O
[]

Generally O
we O
have O
very O
good O
treatment O
results O
. O
[]

The O
exercise O
group O
underwent O
a O
moderate-intensity O
( O
50 O
% O
of O
peak O
oxygen O
uptake O
) O
12-week O
training O
program O
, O
progressing O
to O
100 O
minutes O
per O
week O
of O
step O
aerobics O
and O
50 O
minutes O
per O
week O
of O
cycling O
. O
[]

15 O
vs. O
126 O
? O
[]

Vasopressor O
infusions O
were O
prepared O
either O
by O
diluting O
concentrated O
drugs O
from O
ampoules O
or O
were O
provided O
in O
syringes O
pre-filled O
beforehand O
by O
an O
intensive O
care O
unit O
resident O
. O
[]

Both O
studies O
were O
read O
by O
independent O
investigators O
blinded O
to O
the O
results O
of O
the O
other O
study O
. O
[]

One O
hundred O
nine O
patients O
were O
evaluable O
. O
[]

INTERVENTIONS O
Patients O
received O
epidural O
block O
up O
to O
T10 O
by O
alkalinized O
lidocaine O
2 O
% O
, O
and O
then O
were O
administered O
standard O
general O
anesthesia O
by O
means O
of O
low-flow O
rebreathing O
system O
( O
fresh O
gas O
flow O
= O
1 O
L/min O
) O
. O
[]

INTERPRETATION O
RRV-TV O
vaccine O
was O
highly O
effective O
against O
severe O
rotavirus O
gastroenteritis O
in O
young O
children O
. O
[]

Dexamethasone O
in O
salbutamol-treated O
inpatients O
with O
acute O
bronchiolitis O
: O
a O
randomized O
, O
controlled O
trial O
. O
[]

Complementary O
feeding O
with O
fortified O
spread O
and O
incidence O
of O
severe B-outcome ['Physiological-Clinical']
stunting I-outcome ['Physiological-Clinical']
in O
6- O
to O
18-month-old O
rural O
Malawians O
. O
['Physiological-Clinical']

The O
model O
was O
developed O
using O
training O
data O
sets O
from O
30 O
, O
20 O
, O
15 O
, O
or O
10 O
patients O
at O
one O
or O
two O
time O
points O
. O
[]

Patient-controlled O
sedation O
carried O
out O
with O
1-mg O
increments O
of O
midazolam O
at O
3-minute O
intervals O
provides O
comparable O
conditions O
to O
that O
of O
doctor-controlled O
sedation O
carried O
out O
with O
1-mg O
increments O
at O
1-minute O
intervals O
, O
except O
for O
the O
longer O
duration O
taken O
for O
the O
patients O
to O
achieve O
satisfactory O
sedation O
prior O
to O
surgery O
. O
[]

This O
study O
examined O
the O
extent O
to O
which O
this O
requirement O
can O
be O
supported O
more O
effectively O
through O
informative O
interruption O
cueing O
( O
in O
this O
case O
, O
partial O
information O
about O
the O
nature O
of O
pending O
tasks O
) O
. O
[]

Airway B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
to O
histamine B-outcome ['Physiological-Clinical']
was O
not O
significantly O
attenuated O
at O
24 O
hours O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
additional O
to O
cytoprotective O
action O
, O
the O
use O
of O
mexidor O
in O
complex O
therapy O
of O
CAD O
lowers O
the O
functional B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
thrombocytes I-outcome ['Physiological-Clinical']
, O
eliminates O
high B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
viscosity I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, O
and O
lowers O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Parent O
education O
and O
behaviour O
management O
was O
superior O
to O
parent O
education O
and O
counselling O
. O
[]

METHODS O
This O
multicentre O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
withdrawal O
study O
compared O
6 O
months O
of O
on-demand O
treatment O
with O
rabeprazole O
10 O
mg O
vs. O
placebo O
. O
[]

Hemostatic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
of O
aspirin-treated O
platelets O
vulnerable O
to O
cardiopulmonary O
bypass O
. O
['Physiological-Clinical']

The O
addition O
of O
fentanyl O
may O
be O
effective O
for O
both O
intraoperative O
and O
postoperative O
pain O
relief O
. O
[]

Long-term O
retention O
on O
treatment O
with O
lumiracoxib O
100 O
mg O
once O
or O
twice O
daily O
compared O
with O
celecoxib O
200 O
mg O
once O
daily O
: O
a O
randomised O
controlled O
trial O
in O
patients O
with O
osteoarthritis O
. O
[]

A O
prospective O
randomized O
trial O
. O
[]

All O
subjects O
were O
matched O
at O
baseline O
on O
age O
, O
salivary O
levels O
of O
mutans O
streptococci O
, O
and O
caries O
scores O
. O
[]

Fatty O
acid O
composition O
of O
RBC O
membranes O
was O
quantified O
by O
GC O
. O
[]

It O
is O
therefore O
suggested O
that O
the O
MA-sensitive O
chemotaxis O
plays O
a O
reparative O
role O
in O
the O
inflammatory O
lesions O
of O
rheumatoid O
arthritis O
. O
[]

aureus B-outcome ['Physiological-Clinical']
were O
reduced O
from O
18.8 O
% O
for O
heifers O
in O
the O
control O
group O
to O
6.7 O
and O
6.0 O
% O
for O
heifers O
in O
the O
prepartum O
and O
postpartum O
groups O
, O
respectively O
. O
['Physiological-Clinical']

DESIGN O
Phase O
I O
bicenter O
, O
randomized O
, O
parallel-group O
, O
controlled O
, O
partially O
blinded O
trial O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effects O
of O
a O
combined O
therapy O
consisting O
of O
vaginal O
estriol O
with O
transdermal O
17-beta-estradiol O
( O
50 O
microg/day O
) O
plus O
medroxyprogesterone O
acetate O
( O
5 O
mg/day O
) O
per O
os O
in O
shortening O
the O
period O
of O
uro-genital O
symptoms O
. O
[]

The O
effect O
of O
different O
aprotinin O
applications O
on O
hemostatic O
changes O
and O
blood O
product O
requirements O
in O
orthotopic O
liver O
transplantation O
was O
investigated O
in O
a O
prospective O
, O
open O
, O
and O
randomized O
study O
. O
[]

A O
further O
randomised O
study O
of O
marimastat O
in O
these O
patients O
is O
warranted O
. O
[]

OBJECTIVE O
This O
study O
assessed O
the O
analgesic B-outcome ['Resource-use']
efficacy O
, O
speed B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
onset I-outcome ['Physiological-Clinical']
, O
and O
['Resource-use', 'Physiological-Clinical']

Effective O
response O
rates O
for O
the O
above O
mentioned O
three O
groups O
were O
69.2 O
% O
, O
69.2 O
% O
and O
55.8 O
% O
, O
respectively O
. O
[]

Methamphetamine O
abuse O
and O
dependence O
are O
growing O
problems O
nationally O
and O
worldwide O
. O
[]

METHODS O
Patients O
were O
randomized O
to O
receive O
BB-AVF O
or O
prosthetic O
brachial-antecubital O
forearm O
loop O
access O
. O
[]

Initial O
combination O
therapy O
was O
also O
associated O
with O
higher O
BP B-outcome ['Physiological-Clinical']
control O
rates O
and O
greater O
reductions O
in O
both O
systolic O
and O
diastolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
from O
baseline O
( O
63 O
% O
, O
-27.7+/-13/-15.1+/-8 O
mm O
Hg O
) O
compared O
with O
V-low O
( O
46 O
% O
, O
-21.2+/-13/-11.4+/-8 O
mm O
Hg O
, O
P O
< O
0.0001 O
) O
or O
V-high O
( O
51 O
% O
, O
-24.0+/-13/-12.0+/-10 O
mm O
Hg O
, O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

kg O
( O
-1 O
) O
? O
[]

They O
also O
demonstrate O
that O
oral O
PPS O
is O
beneficial O
to O
microvascular O
sickle O
cell O
blood O
flow O
and O
has O
potential O
as O
an O
efficacious O
agent O
for O
long-term O
prophylactic O
therapy O
of O
SCD O
. O
[]

Samples O
from O
saliva O
, O
dental O
plaque O
and O
faeces O
and O
biopsies O
from O
antrum O
and O
corpus O
were O
analysed O
in O
order O
to O
determine O
the O
ecological O
changes O
in O
the O
normal O
microflora O
. O
[]

Sensory B-outcome ['Resource-use']
anesthesia I-outcome ['Resource-use']
was O
prolonged O
with O
clonidine O
at O
L1 O
( O
51 O
+/- O
23 O
min O
versus O
76 O
+/- O
11 O
min O
; O
P O
= O
0.002 O
) O
, O
as O
was O
complete O
block O
regression O
( O
99 O
+/- O
18 O
min O
versus O
131 O
+/- O
15 O
min O
; O
P O
= O
0.001 O
) O
. O
['Resource-use']

Pharmacologic O
activity O
was O
assessed O
through O
the O
daily O
measurement O
of O
three O
cutaneous O
responses O
intimately O
linked O
to O
retinoid-induced O
changes O
in O
epidermal O
differentiation O
: O
( O
1 O
) O
erythema B-outcome ['Physiological-Clinical']
; O
( O
2 O
) O
exfoliation B-outcome ['Physiological-Clinical']
( O
scaling/peeling B-outcome ['Physiological-Clinical']
) O
, O
and O
( O
3 O
) O
increased O
transepidermal B-outcome ['Physiological-Clinical']
water I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
GH O
response O
to O
bolus O
GHRH O
( O
1-29 O
) O
NH O
( O
2 O
) O
is O
attenuated O
in O
adult O
long-term O
survivors O
of O
childhood O
brain O
tumours O
. O
[]

Amphetamine O
users O
( O
n O
= O
19 O
) O
were O
divided O
into O
two O
groups O
, O
high O
dependence O
( O
n O
= O
10 O
) O
and O
low O
dependence O
( O
n O
= O
10 O
) O
, O
based O
on O
amphetamine O
Severity O
of O
Dependence O
Scale O
scores O
, O
and O
compared O
to O
an O
age-matched O
control O
group O
( O
n O
= O
9 O
) O
. O
[]

Peak O
current O
was O
32 O
% O
higher O
with O
an O
active O
can O
( O
P O
< O
0.01 O
) O
, O
whereas O
shock B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
was O
18 O
% O
lower O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Descriptive O
data O
analysis O
including O
confirmatory O
statements O
found O
delta/theta B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
enhanced O
, O
alpha B-outcome ['Physiological-Clinical']
and O
beta B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
reduced O
, O
total O
power B-outcome ['Physiological-Clinical']
augmented O
, O
and O
the O
centroid B-outcome ['Physiological-Clinical']
slowed O
down O
over O
various O
brain O
regions O
in O
patients O
as O
compared O
with O
controls O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

17.35 O
) O
pg/ml O
, O
ALD O
( O
251.31 O
? O
[]

Delayed-onset B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
soreness I-outcome ['Physiological-Clinical']
was O
induced O
in O
the O
participants O
' O
dominant O
or O
non-dominant O
arm O
using O
two O
sets O
of O
20 O
maximal O
eccentric O
elbow O
flexion O
contractions O
. O
['Physiological-Clinical']

From O
this O
study O
there O
emerged O
the O
value O
of O
combined O
therapy O
using O
doxorubicine O
as O
much O
because O
of O
the O
frequency O
with O
which O
results O
better O
than O
50 O
% O
were O
obtained O
( O
in O
a O
randomised O
trial O
) O
as O
by O
their O
quality B-outcome ['Life-Impact']
, O
which O
was O
made O
clear O
in O
an O
important O
series O
of O
240 O
cases O
. O
['Life-Impact']

We O
conclude O
that O
rhTPO O
can O
safely O
enhance O
mobilization O
of O
PBPC B-outcome ['Physiological-Clinical']
, O
reduce O
the O
number O
of O
leukapheresis B-outcome ['Physiological-Clinical']
, O
and O
allow O
more O
patients O
to O
meet O
minimal O
cell O
yield O
requirements O
to O
receive O
high-dose O
chemotherapy O
with O
PBPC O
transplantation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Important O
racial O
differences O
were O
observed O
in O
demographic O
features O
, O
atherosclerosis O
risk O
factors O
, O
and O
treatment O
strategies B-outcome ['Life-Impact']
; O
however O
, O
despite O
these O
differences O
, O
no O
independent O
difference O
was O
observed O
in O
clinical O
outcomes O
according O
to O
race O
. O
['Life-Impact']

RESULTS O
168 O
patients O
entered O
the O
study O
. O
[]

Liposome-entrapped O
D. O
pteronyssinus O
vaccination O
in O
mild O
asthma O
patients O
: O
effect O
of O
1-year O
double-blind O
, O
placebo-controlled O
trial O
on O
inflammation O
, O
bronchial O
hyperresponsiveness O
and O
immediate O
and O
late O
bronchial O
responses O
to O
the O
allergen O
. O
[]

BACKGROUND O
AND O
OBJECTIVE O
A O
single O
dose O
of O
theophylline O
improves O
hypoglycemia O
unawareness O
in O
type O
1 O
diabetic O
patients O
. O
[]

METHODS/DESIGN O
The O
study O
will O
employ O
a O
cluster O
randomised O
controlled O
trial O
design O
. O
[]

RESULTS O
Children O
took O
more O
steps O
during O
school O
days O
( O
5169 O
steps O
, O
SD O
1641 O
) O
than O
during O
weekend O
days O
( O
4158 O
steps O
, O
SD O
2048 O
; O
p O
< O
0.001 O
) O
. O
[]

Yoga O
can O
be O
used O
as O
an O
auxiliary O
treatment O
with O
traditional O
hospital O
routine O
care O
for O
these O
women O
. O
[]

Acidosis O
was O
defined O
as O
pH O
< O
7.25 O
. O
[]

Changes O
in O
[]

Severe B-outcome ['Life-Impact']
irritative I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
were O
the O
most O
common O
complaints O
after O
PlasmaKinetic O
surgery O
, O
as O
observed O
in O
6 O
cases O
( O
12.2 O
% O
) O
. O
['Life-Impact']

OBJECTIVE O
To O
assess O
the O
effect O
of O
a O
nutritional O
supplement O
containing O
vitamin O
E O
, O
selenium O
, O
vitamin O
C O
and O
coenzyme O
Q10 O
on O
changes O
in O
serum O
levels O
of O
PSA O
in O
patients O
with O
hormonally O
untreated O
carcinoma O
of O
the O
prostate O
and O
rising O
serum B-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

The O
children O
presented O
with O
a O
chief O
complaint O
of O
severely O
disruptive O
symptoms O
related O
to O
autistic O
disorder O
. O
[]

Histologic B-outcome ['Physiological-Clinical']
type O
was O
not O
an O
independent O
predictor O
of O
response O
. O
['Physiological-Clinical']

Results O
of O
the O
present O
study O
demonstrate O
a O
potent O
and O
long-lasting O
analgesic O
effect O
of O
1,2,6-IP3 O
, O
possibly O
related O
to O
its O
antiinflammatory O
properties O
. O
[]

OBJECTIVE O
To O
examine O
how O
improved O
attention O
to O
nutritional B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
and O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
achieved O
through O
the O
employment O
of O
dietetic O
assistants O
( O
DAs O
) O
, O
will O
affect O
postoperative B-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
outcome O
among O
elderly O
women O
with O
hip O
fracture O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Results O
revealed O
that O
children O
randomized O
to O
the O
joint O
attention O
group O
were O
more O
likely O
to O
acknowledge O
the O
probe B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
engage I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
shared I-outcome ['Life-Impact']
interactions I-outcome ['Life-Impact']
between O
intervener O
and O
probe O
upon O
termination O
of O
intervention O
. O
['Life-Impact']

All O
patients O
had O
> O
1 O
mm O
ST-depression O
on O
exercise O
test O
. O
[]

Number O
of O
hospitalizations B-outcome ['Resource-use']
( O
1.3+/-1.7 O
versus O
0.8+/-1.3 O
, O
P O
< O
0.0001 O
) O
, O
total O
hospital B-outcome ['Resource-use']
days I-outcome ['Resource-use']
during O
the O
follow-up O
( O
19.9+/-51 O
versus O
11.1+/-24 O
days O
, O
P O
< O
0.0001 O
) O
, O
and O
the O
need O
for O
emergency B-outcome ['Resource-use']
visits I-outcome ['Resource-use']
( O
4.5+/-10.6 O
versus O
1.6+/-2.4 O
, O
P O
< O
0.0001 O
) O
were O
lower O
in O
the O
intervention O
group O
. O
['Resource-use', 'Resource-use', 'Physiological-Clinical', 'Resource-use']

Noradrenergic O
moderation O
of O
working O
memory O
impairments O
in O
adults O
with O
autism O
spectrum O
disorder O
. O
[]

INTERVENTIONS O
Patients O
were O
randomly O
assigned O
to O
one O
of O
three O
anesthetic O
regimens O
. O
[]

Failure O
of O
naltrexone O
hydrochloride O
to O
reduce O
self-injurious O
and O
autistic O
behavior O
in O
mentally O
retarded O
adults O
. O
[]

Critically O
ill O
patients O
must O
often O
breathe O
spontaneously O
through O
an O
endotracheal O
tube O
that O
acts O
as O
a O
fixed O
inspiratory O
and O
expiratory O
tubular O
airway O
resistor O
. O
[]

A O
second O
aim O
was O
to O
investigate O
whether O
the O
response O
to O
pregnanolone O
was O
associated O
with O
cyclicity O
in O
negative O
mood B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
during O
treatment O
. O
['Life-Impact']

Enrolled O
patients O
received O
trimethoprim-sulfamethoxazole O
( O
n O
= O
85 O
) O
or O
ciprofloxacin O
( O
n O
= O
85 O
) O
for O
10 O
days O
. O
[]

The O
estimates O
( O
with O
relative O
standard O
errors O
expressed O
in O
percentages O
in O
parentheses O
) O
of O
the O
apparent O
zero-order O
rate O
constant B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
flare I-outcome ['Physiological-Clinical']
or O
wheal B-outcome ['Physiological-Clinical']
spontaneous B-outcome ['Physiological-Clinical']
appearance I-outcome ['Physiological-Clinical']
( O
k O
( O
in O
) O
) O
, O
the O
first-order B-outcome ['Physiological-Clinical']
rate O
constant B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
flare I-outcome ['Physiological-Clinical']
or O
wheal B-outcome ['Physiological-Clinical']
disappearance I-outcome ['Physiological-Clinical']
( O
k O
( O
out O
) O
) O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
present O
investigation O
compared O
their O
performance O
in O
a O
randomized O
controlled O
study O
. O
[]

DESIGN O
AND O
SETTING O
Multicentre O
clinical O
trial O
carried O
out O
in O
47 O
Italian O
coronary O
care O
units O
. O
[]

Compared O
to O
placebo O
, O
sumatriptan O
significantly O
lowered O
levels O
of O
plasma B-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
but O
increased O
those O
of O
plasma B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Azimilide O
dihydrochloride O
was O
generally O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
and O
did O
not O
affect O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
or O
minimal O
energy O
requirements O
for O
defibrillation B-outcome ['Resource-use']
or O
pacing O
. O
['Life-Impact', 'Physiological-Clinical', 'Resource-use']

Long-term O
antiarrhythmic O
therapy O
is O
not O
considered O
an O
exclusion O
criterion O
. O
[]

Phosphorus B-outcome ['Physiological-Clinical']
( O
5.8 O
+/- O
1.0 O
vs. O
6 O
+/- O
1.0 O
mg/dl O
, O
p O
= O
0.47 O
) O
and O
calcium B-outcome ['Physiological-Clinical']
( O
1.27 O
+/- O
0.07 O
vs. O
1.23 O
+/- O
0.08 O
mmol/l O
, O
p O
= O
0.68 O
) O
levels O
did O
not O
differ O
between O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
controlled O
crossover O
trial O
of O
fenfluramine O
in O
autism O
. O
[]

The O
treatment O
condition O
included O
15 O
minutes O
of O
running/jogging O
followed O
by O
a O
classroom O
task O
. O
[]

Patients O
were O
followed O
clinically O
for O
a O
minimum O
of O
1 O
year O
. O
[]

79 O
U/L O
vs. O
670 O
? O
[]

BACKGROUND O
The O
impact O
of O
reduced O
drug O
exposure O
on O
outcomes O
in O
patients O
with O
chronic O
hepatitis O
C O
has O
not O
been O
determined O
in O
routine O
clinical O
practice O
. O
[]

These O
data O
demonstrate O
energy O
consumed O
as O
beverages O
may O
be O
especially O
problematic O
for O
weight O
gain O
. O
[]

CONCLUSION O
Zoledronic O
acid O
significantly O
reduced O
skeletal O
complications O
compared O
with O
placebo O
across O
multiple O
end O
points O
in O
Japanese O
women O
with O
bone O
metastases O
from O
breast O
cancer O
. O
[]

Biosafety O
was O
monitored O
during O
the O
4-year O
trial O
to O
determine O
whether O
DHA O
supplementation O
was O
associated O
with O
identifiable O
risks O
. O
[]

Seventy O
percent O
of O
the O
patients O
treated O
with O
LI O
160 O
were O
free O
of O
symptoms B-outcome ['Physiological-Clinical']
after O
4 O
weeks O
. O
['Physiological-Clinical']

Because O
children O
at O
each O
grade O
were O
distributed O
across O
two O
classrooms O
( O
clusters O
) O
and O
were O
homogeneous O
, O
each O
grade O
was O
considered O
to O
consist O
of O
a O
matched O
pair O
. O
[]

Results O
also O
indicated O
that O
children O
reported O
more O
anxiety B-outcome ['Life-Impact']
and O
exhibited O
more O
behavioral B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
in O
the O
CB O
group O
than O
in O
the O
hypnosis O
group O
. O
['Life-Impact', 'Life-Impact']

Total O
costs B-outcome ['Resource-use']
of O
the O
AS O
group O
were O
significantly O
higher O
compared O
to O
the O
regular O
cardiac O
surgery O
group O
[ O
cost O
difference O
bootstrap O
: O
?4,724 O
; O
95 O
% O
uncertainty O
interval O
( O
UI O
) O
, O
?2,770-?6,678 O
] O
. O
['Resource-use']

The O
effect O
of O
weight O
training O
on O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
and O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
in O
postmenopausal O
breast O
cancer O
survivors O
with O
bone O
loss O
: O
a O
24-month O
randomized O
controlled O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
A O
total O
of O
154 O
individuals O
joined O
the O
Cancer O
Genetics O
Network O
. O
[]

Systolic O
Hypertension O
in O
Europe O
( O
SYST-EUR O
) O
Trial O
Investigators O
. O
[]

Wound O
healing O
was O
improved O
in O
the O
TE O
group O
, O
with O
lower O
requirements O
for O
regrafting O
( O
P=0.02 O
) O
. O
[]

A O
cross-over O
study O
with O
prilocaine O
in O
volunteers O
. O
[]

METHODS O
Fifty O
patients O
( O
19 O
males O
and O
31 O
females O
) O
with O
a O
mean O
age O
of O
53.6 O
+/- O
8.9 O
years O
were O
randomly O
assigned O
to O
PH O
or O
ION O
groups O
with O
25 O
patients O
in O
each O
group O
. O
[]

Twelve O
healthy O
males O
with O
a O
mean O
age O
of O
35 O
years O
were O
enrolled O
in O
this O
four-way O
, O
randomized O
, O
crossover O
study O
. O
[]

By O
the O
final O
months O
of O
training O
, O
the O
treatment O
participants O
' O
wet B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
had O
been O
reduced O
by O
0.6 O
episode O
per O
day O
, O
or O
a O
26 O
percent O
reduction O
over O
baseline O
, O
and O
improvement O
was O
maintained O
during O
the O
follow-up O
period O
. O
['Physiological-Clinical']

MEASUREMENTS O
Costs O
of O
initial O
and O
follow-up O
( O
26 O
+/- O
15 O
months O
) O
admissions O
for O
the O
two O
groups O
were O
compared O
. O
[]

Two O
observers O
who O
were O
blinded O
to O
the O
intervention O
recorded O
the O
physiological O
( O
heart O
rate O
and O
oxygen O
saturation O
) O
and O
behavioural O
parameters O
[ O
duration O
of O
crying O
and O
modified O
Neonatal O
Facial O
Coding O
Scores O
( O
NFCS O
) O
] O
after O
the O
venepuncture O
. O
[]

Data O
are O
presented O
to O
the O
dominant O
eye O
on O
a O
semi-transparent O
mirror O
using O
a O
head-mounted O
display O
( O
HMD O
) O
unit O
that O
works O
with O
retinal O
laser O
technology O
. O
[]

OBJECTIVE O
The O
aim O
of O
this O
study O
was O
to O
study O
valproate O
efficacy O
and O
safety O
for O
aggression O
in O
children O
and O
adolescents O
with O
pervasive O
developmental O
disorders O
( O
PDD O
) O
. O
[]

OBJECTIVE O
To O
determine O
whether O
clomipramine O
hydrochloride O
, O
a O
serotonin O
reuptake O
blocker O
with O
unique O
anti-obsessional O
properties O
, O
is O
differentially O
effective O
for O
obsessive-compulsive O
and O
stereotyped O
motor O
behaviors O
in O
autistic O
disorder O
compared O
with O
placebo O
and O
with O
the O
noradrenergic O
tricyclic O
antidepressant O
agent O
, O
desipramine O
hydrochloride O
. O
[]

CONCLUSIONS O
Risperidone O
was O
found O
to O
be O
more O
effective O
than O
haloperidol O
in O
the O
treatment O
of O
behavioral O
symptoms O
, O
impulsivity O
, O
language O
skills O
, O
and O
impaired B-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
relations I-outcome ['Life-Impact']
in O
children O
with O
AD O
. O
['Life-Impact']

For O
those O
patients O
with O
end-stage O
renal O
failure O
, O
GCV B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
fell O
during O
dialysis O
from O
a O
mean O
of O
1.47+/-0.48 O
microg/ml O
before O
dialysis O
to O
0.69+/-0.38 O
microg/ml O
after O
dialysis O
. O
['Physiological-Clinical']

This O
prospective O
study O
evaluated O
the O
effect O
of O
an O
individualized O
, O
comprehensive O
, O
home-based O
cardiac O
rehabilitation O
program O
combining O
exercise O
training O
with O
risk O
factor O
modification O
and O
psychosocial O
counseling O
on O
risk O
factors O
, O
psychological B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
, O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
, O
and O
work B-outcome ['Life-Impact']
resumption I-outcome ['Life-Impact']
in O
99 O
post-percutaneous O
coronary O
interventions O
( O
PCI O
) O
patients O
randomized O
to O
control O
( O
standard O
care O
plus O
telephone O
follow-up O
, O
n=49 O
) O
or O
intervention O
( O
individualized O
, O
comprehensive O
, O
home-based O
cardiac O
rehabilitation O
, O
n=50 O
) O
groups O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
target O
variables O
were O
the O
number O
of O
binges B-outcome ['Life-Impact']
and O
the O
bulimia O
scale O
of O
the O
Eating O
Disorder O
Inventory O
. O
['Life-Impact']

One O
participant O
was O
unable O
to O
tolerate O
persistent O
GI O
discomfort O
. O
[]

BACKGROUND O
This O
randomised O
phase O
III O
trial O
was O
carried O
out O
to O
compare O
the O
efficacy O
and O
safety O
of O
epirubicin O
and O
cyclophosphamide O
( O
EC O
) O
with O
epirubicin O
and O
docetaxel O
( O
Taxotere O
) O
( O
ED O
) O
as O
first-line O
chemotherapy O
for O
metastatic O
breast O
cancer O
. O
[]

Participants O
in O
the O
intervention O
group O
watched O
a O
DVD O
designed O
to O
teach O
emotion O
recognition O
skills O
to O
children O
with O
autism O
( O
the O
Transporters O
) O
, O
whereas O
the O
control O
group O
watched O
a O
DVD O
of O
Thomas O
the O
Tank O
Engine O
. O
[]

After O
remission O
induction O
, O
2027 O
patients O
were O
randomized O
to O
receive O
MP O
( O
n O
= O
1010 O
) O
or O
TG O
( O
n O
= O
1017 O
) O
and O
IT-MTX O
( O
n O
= O
1018 O
) O
or O
ITT O
( O
n O
= O
1009 O
) O
. O
[]

Widening B-outcome ['Physiological-Clinical']
was O
comparable O
at O
canine O
, O
premolar O
and O
molar O
level O
. O
['Physiological-Clinical']

PSK O
has O
been O
supposed O
to O
improve O
survival O
through O
immunological O
mechanisms O
such O
as O
induction O
of O
cytokines O
, O
regulation O
of O
Th1/Th2 O
balance O
, O
and O
inhibition O
of O
immunosuppressive O
molecules O
. O
[]

Identification O
, O
course O
, O
and O
treatment O
of O
depression O
after O
admission O
for O
a O
cardiac O
condition O
: O
rationale O
and O
patient O
characteristics O
for O
the O
Identifying O
Depression O
As O
a O
Comorbid O
Condition O
( O
IDACC O
) O
project O
. O
[]

In O
the O
C O
group O
, O
13 O
% O
received O
no O
chemotherapy O
, O
21 O
% O
one O
or O
two O
cycles O
, O
and O
64 O
% O
all O
three O
cycles O
of O
their O
prescribed O
chemotherapy O
( O
60 O
% O
of O
the O
latter O
with O
no O
delays O
or O
modification O
) O
. O
[]

The O
median O
survival B-outcome ['Mortality']
times I-outcome ['Mortality']
on O
VP O
and O
VIP O
were O
7.3 O
months O
and O
9.0 O
months O
, O
respectively O
( O
P O
= O
.045 O
for O
survival O
curves O
by O
stratified O
log-rank O
test O
) O
with O
2-year O
survival B-outcome ['Mortality']
rates O
of O
5 O
% O
versus O
13 O
% O
, O
respectively O
. O
['Mortality', 'Mortality']

Computer-assisted O
instruction O
: O
an O
effective O
instructional O
method O
for O
HIV B-outcome ['Physiological-Clinical']
prevention I-outcome ['Physiological-Clinical']
education O
? O
['Physiological-Clinical']

The O
baseline O
lysozyme O
content O
of O
patient O
PMN O
's O
relative O
to O
that O
of O
normal O
control O
PMNs O
( O
ratio O
P O
: O
C O
) O
was O
119 O
+/- O
14 O
% O
in O
the O
PGE1 O
group O
. O
[]

min O
( O
-1 O
) O
) O
. O
[]

INTERPRETATION O
Compared O
with O
6-mercaptopurine O
, O
6-thioguanine O
causes O
excess O
toxicity B-outcome ['Adverse-effects']
without O
an O
overall O
benefit O
. O
['Adverse-effects']

Electrocardiogram O
sessions O
that O
lasted O
20 O
hr O
were O
repeated O
up O
to O
three O
times O
among O
49 O
intervention O
and O
70 O
control O
women O
38-84 O
years O
of O
age O
, O
and O
55 O
control O
subjects O
were O
also O
assessed O
after O
receiving O
stoves O
. O
[]

CoQ O
( O
10 O
) O
supplementation O
resulted O
in O
a O
four-fold O
increase O
in O
[]

A O
significant O
difference O
was O
found O
in O
the O
paracetamol O
pharmacokinetic B-outcome ['Physiological-Clinical']
parameter O
oral B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Between O
1987 O
and O
1992 O
, O
945 O
eligible O
men O
with O
locally O
advanced O
prostate O
cancer O
were O
enrolled O
in O
a O
phase O
3 O
trial O
( O
RTOG O
85-31 O
) O
and O
randomized O
to O
RT O
and O
immediate O
goserelin O
or O
RT O
alone O
followed O
by O
goserelin O
at O
recurrence O
. O
[]

RESULTS O
GHB O
was O
more O
effective O
in O
treating O
AWS O
symptoms O
. O
[]

Quality B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
was O
also O
improved O
with O
desmopressin O
versus O
placebo O
( O
statistically O
significant O
for O
one O
of O
the O
two O
parameters O
evaluated O
) O
. O
['Physiological-Clinical']

This O
was O
achieved O
by O
week O
12 O
in O
the O
accelerated O
treatment O
arm O
and O
by O
week O
24 O
in O
the O
standard O
arm O
. O
[]

Follow-up O
lasted O
32 O
days O
. O
[]

UNLABELLED O
Aspiration O
of O
gastric O
contents O
may O
contribute O
to O
pulmonary O
complications O
after O
thoracotomy O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
accuracy O
of O
pelvic O
radiotherapy O
during O
a O
trial O
of O
blocked O
radiotherapy O
at O
the O
Royal O
Marsden O
Hospital O
, O
UK O
. O
[]

Stage O
3 O
: O
finally O
, O
every O
patient O
could O
choose O
his O
treatment O
( O
either O
Polym O
or O
Plc O
) O
for O
the O
rest O
of O
the O
period O
( O
2 O
months O
) O
. O
[]

The O
subjects O
were O
exposed O
to O
170 O
min O
exercise-heat O
stress O
( O
Tdb O
= O
33 O
degrees O
C O
; O
rh O
= O
60 O
% O
) O
consisting O
of O
60 O
min O
in O
a O
sitting O
position O
and O
two O
50-min O
walks O
( O
1.39 O
m.s-1 O
, O
5 O
% O
grade O
) O
separated O
by O
10 O
min O
of O
rest O
. O
[]

METHODS O
Before O
SIT O
, O
thirty-seven O
adult O
patients O
were O
exposed O
for O
eight O
hours O
in O
an O
environmental O
exposure O
chamber O
( O
EEC O
) O
to O
birch O
pollen O
at O
an O
average O
concentration O
of O
3500 O
? O
[]

One O
month O
of O
adjunct O
treatment O
with O
naltrexone O
( O
100 O
mg/day O
) O
was O
compared O
with O
placebo O
in O
a O
double-blind O
, O
randomized O
, O
cross-over O
design O
in O
two O
groups O
of O
patients O
with O
Parkinson O
's O
disease O
. O
[]

Alcohol B-outcome ['Life-Impact']
drinking B-outcome ['Life-Impact']
indices O
and O
craving B-outcome ['Life-Impact']
scores O
were O
not O
significantly O
different O
between O
groups O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

From O
a O
clinical O
perspective O
, O
the O
methods O
are O
to O
be O
considered O
equivalent O
. O
[]

The O
rise O
in O
blood O
glucose O
and O
insulin O
noted O
during O
the O
use O
of O
glucose-based O
solutions O
was O
not O
found O
with O
glycerol O
. O
[]

DESIGN O
Randomised O
trial O
of O
treatment O
of O
operable O
breast O
cancer O
by O
wedge O
mastectomy O
or O
tamoxifen O
, O
with O
median O
follow O
up O
24 O
and O
25 O
months O
respectively O
( O
range O
1-63 O
) O
. O
[]

METHODS O
In O
a O
double-blind O
, O
placebo-controlled O
, O
phase O
1 O
, O
dose-escalation O
study O
, O
15 O
subjects O
with O
inflammatory O
arthritis O
( O
14 O
with O
rheumatoid O
arthritis O
and O
1 O
with O
ankylosing O
spondylitis O
) O
not O
receiving O
tumour O
necrosis O
factor O
alpha O
( O
TNFalpha O
) O
inhibitors O
with O
persistent O
moderate O
( O
grade O
2 O
) O
or O
severe O
( O
grade O
3 O
) O
swelling O
in O
a O
target O
joint O
due O
to O
inflammatory O
arthritis O
received O
a O
single O
intra-articular O
injection O
of O
rAAV2-TNFR O
: O
Fc O
at O
1 O
x O
10 O
( O
10 O
) O
( O
n O
= O
5 O
) O
or O
1 O
x O
10 O
( O
11 O
) O
( O
n O
= O
6 O
) O
DNase O
resistant O
particles O
per O
ml O
joint O
volume O
or O
placebo O
( O
n O
= O
4 O
) O
into O
a O
knee O
( O
n O
= O
14 O
) O
or O
ankle O
( O
n O
= O
1 O
) O
. O
[]

Each O
subject O
received O
a O
total O
of O
four O
treatments O
, O
each O
separated O
by O
one O
week O
. O
[]

Both O
groups O
also O
showed O
significant O
decreases O
in O
drinking B-outcome ['Life-Impact']
days I-outcome ['Life-Impact']
per O
week O
, O
drinks O
per O
drinking B-outcome ['Life-Impact']
day I-outcome ['Life-Impact']
, O
maximum B-outcome ['Life-Impact']
drinks I-outcome ['Life-Impact']
per I-outcome ['Life-Impact']
occasion I-outcome ['Life-Impact']
, O
and O
negative O
consequences B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
drinking I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

After O
14 O
days O
, O
patients O
were O
switched O
to O
the O
other O
treatment O
for O
14 O
additional O
days O
. O
[]

Treatment O
with O
pegvisomant O
had O
no O
additional O
influence O
on O
the O
decline O
of O
free B-outcome ['Physiological-Clinical']
IGF-I I-outcome ['Physiological-Clinical']
induced O
by O
fasting O
. O
['Physiological-Clinical']

Experimental O
and O
clinical O
studies O
have O
shown O
the O
beneficial O
effects O
of O
triiodothyronine O
( O
T3 O
) O
following O
myocardial O
revascularization O
on O
cardiopulmonary O
bypass O
( O
CPB O
) O
. O
[]

Influence O
of O
special-effect O
contact O
lenses O
( O
Crazy O
Lenses O
) O
on O
visual B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Postoperative O
pain O
was O
assessed O
by O
measuring O
morphine B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
and O
visual O
analog O
scale O
['Resource-use']

Evaluation O
of O
the O
effects O
of O
human O
leukocyte O
IFN-alpha O
on O
the O
immune B-outcome ['Physiological-Clinical']
response O
to O
the O
HBV B-outcome ['Physiological-Clinical']
vaccine B-outcome ['Resource-use']
in O
healthy O
unvaccinated O
individuals O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

There O
were O
significantly O
fewer O
women O
in O
the O
vacuum O
extractor O
group O
requiring O
epidural B-outcome ['Resource-use']
or I-outcome ['Resource-use']
spinal I-outcome ['Resource-use']
anaesthetics I-outcome ['Resource-use']
( O
25.4 O
% O
vs O
32.7 O
% O
, O
OR O
0.69 O
; O
95 O
% O
CI O
0.49-0.99 O
) O
or O
general B-outcome ['Resource-use']
anaesthetics I-outcome ['Resource-use']
( O
1 O
% O
vs O
4 O
% O
, O
OR O
0.17 O
; O
95 O
% O
CI O
0.04-0.76 O
) O
. O
['Resource-use', 'Resource-use']

Study O
2 O
was O
a O
randomized O
control O
field O
experiment O
that O
assessed O
a O
team-oriented O
training O
. O
[]

Intensive O
pharmacokinetic O
sampling O
occurred O
after O
4 O
weeks O
of O
therapy O
. O
[]

The O
time B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
locate I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
site I-outcome ['Life-Impact']
and O
direction B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
puncture I-outcome ['Physiological-Clinical']
increased O
with O
technical O
sophistication O
. O
['Life-Impact', 'Physiological-Clinical']

Adherence O
to O
such O
guidelines O
, O
especially O
among O
dental O
providers O
, O
is O
poor O
. O
[]

Patients O
who O
died B-outcome ['Mortality']
or O
experienced O
heart B-outcome ['Resource-use']
failure I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
had O
larger O
antecedent O
increases O
in O
NT-ANP B-outcome ['Physiological-Clinical']
( O
+293.7 O
vs O
-21.5 O
pmol/ml O
, O
p O
= O
0.006 O
) O
and O
lesser O
decreases O
in O
norepinephrine B-outcome ['Physiological-Clinical']
( O
-22.3 O
vs O
-48.5 O
pg/ml O
, O
p O
= O
0.04 O
) O
. O
['Mortality', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
All O
readers O
improved O
analysis O
accuracy O
[]

Effects O
of O
walnut O
consumption O
on O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
type O
2 O
diabetic O
subjects O
: O
a O
randomized O
controlled O
crossover O
trial O
. O
['Physiological-Clinical']

Two O
hundred O
seventy-two O
patients O
received O
standard-timing O
RT O
at O
week O
9 O
and O
thus O
only O
chemotherapy O
during O
induction O
. O
[]

A O
double-blind O
placebo-controlled O
pilot O
study O
of O
olanzapine O
in O
childhood/adolescent O
pervasive O
developmental O
disorder O
. O
[]

Exclusion O
criteria O
included O
active O
bleeding O
or O
chronic O
renal O
failure O
at O
the O
time O
of O
ICU O
admission O
. O
[]

Median O
PFS B-outcome ['Mortality']
was O
13.3 O
( O
95 O
% O
CI O
11.4-15.3 O
) O
and O
9.7 O
( O
95 O
% O
CI O
7.6-11.8 O
) O
months O
for O
the O
beneficial O
and O
unfavorable O
genetic B-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
, O
respectively O
, O
corresponding O
to O
a O
hazards O
ratio O
for O
['Mortality', 'Physiological-Clinical']

A O
simple O
meal O
plan O
of O
'eating O
vegetables O
before O
carbohydrate O
' O
was O
more O
effective O
for O
achieving O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
than O
an O
exchange-based O
meal O
plan O
in O
Japanese O
patients O
with O
type O
2 O
diabetes O
. O
['Physiological-Clinical']

Patients O
in O
the O
WP-IMRT O
arm O
experienced O
significantly O
fewer O
grade O
?2 O
acute O
gastrointestinal O
toxicities O
( O
31.8 O
% O
vs O
63.6 O
% O
, O
P=.034 O
) O
and O
grade O
?3 O
gastrointestinal O
toxicities O
( O
4.5 O
% O
vs O
27.3 O
% O
, O
P=.047 O
) O
than O
did O
patients O
receiving O
WP-CRT O
and O
had O
less O
chronic O
gastrointestinal O
toxicity O
( O
13.6 O
% O
vs O
50 O
% O
, O
P=.011 O
) O
. O
[]

DESIGN O
Randomised O
consent O
design O
for O
clinical O
trials O
according O
to O
Zelen O
. O
[]

Patients O
in O
study O
group O
consumed O
significantly O
less O
morphine O
, O
experienced O
significant O
less O
pain O
scores O
, O
and O
obtained O
significantly O
more O
ROM O
( O
P O
< O
0.01 O
) O
compared O
with O
that O
in O
placebo O
group O
during O
3 O
days O
postoperatively O
. O
[]

There O
was O
no O
statistically O
significant O
difference O
in O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
EFS I-outcome ['Mortality']
) I-outcome ['Mortality']
or I-outcome ['Mortality']
overall I-outcome ['Mortality']
survival I-outcome ['Mortality']
between O
arms O
. O
['Mortality']

Folic O
acid O
combined O
with O
vitamins O
B O
( O
6 O
) O
and O
B O
( O
12 O
) O
is O
effective O
in O
lowering O
homocysteine B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

35.6 O
cm/cm? O
in O
MECC O
group O
; O
P O
= O
.100 O
vs O
T1 O
; O
211.1 O
? O
[]

Seven O
healthy O
, O
untrained O
men O
( O
22.5 O
+/- O
0.9 O
y O
) O
were O
randomly O
assigned O
to O
2 O
cross-over O
experiments O
. O
[]

Brief O
Report O
: O
Randomized O
test O
of O
the O
efficacy O
of O
picture O
exchange O
communication O
system O
on O
highly O
generalized B-outcome ['Life-Impact']
picture I-outcome ['Life-Impact']
exchanges I-outcome ['Life-Impact']
in O
children O
with O
ASD O
. O
['Life-Impact']

Nateglinide O
reduces O
carotid B-outcome ['Physiological-Clinical']
intima-media I-outcome ['Physiological-Clinical']
thickening I-outcome ['Physiological-Clinical']
in O
type O
2 O
diabetic O
patients O
under O
good O
glycemic O
control O
. O
['Physiological-Clinical']

Quality O
of O
life O
as O
measured O
by O
SF-36 O
total O
score O
was O
also O
improved O
in O
both O
treatment O
groups O
, O
with O
a O
trend O
toward O
greater O
improvement O
in O
the O
oxaprozin O
group O
. O
[]

In O
task O
two O
, O
participants O
brought O
their O
outstretched O
hand O
to O
the O
target O
. O
[]

The O
end O
points O
were O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
[ O
OS O
, O
noninferiority O
: O
hazard O
ratio O
( O
preservation/surgery O
) O
? O
['Mortality']

0.3 O
) O
, O
6 O
weeks O
( O
6.3 O
? O
[]

Side O
effects O
were O
negligible O
and O
transient B-outcome ['Physiological-Clinical']
neurological I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
not O
reported O
during O
a O
24-h O
follow-up O
. O
['Physiological-Clinical']

Low-intensity O
exercise O
and O
reduction O
of O
the O
risk O
for O
falls B-outcome ['Life-Impact']
among O
at-risk O
elders O
. O
['Life-Impact']

Isometric B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hip I-outcome ['Physiological-Clinical']
flexors I-outcome ['Physiological-Clinical']
, O
extensors B-outcome ['Physiological-Clinical']
, O
abductors B-outcome ['Physiological-Clinical']
and O
adductors B-outcome ['Physiological-Clinical']
was O
measured O
by O
dynamometer O
and O
expressed O
in O
Newton O
( O
N O
) O
at O
admission B-outcome ['Resource-use']
, O
control O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

METHOD O
Randomized O
controlled O
trial O
. O
[]

RESULTS O
In O
vitro O
: O
the O
cuff B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
exceeded O
50 O
cmH2O O
after O
60 O
min O
without O
CPRV O
, O
but O
did O
not O
exceed O
the O
settings O
with O
CPRV O
. O
['Physiological-Clinical']

The O
study O
was O
planned O
to O
investigate O
the O
effect O
of O
a O
sensory O
integration O
therapy O
program O
on O
sensory B-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
of O
children O
with O
autism O
. O
['Physiological-Clinical']

Group O
A O
( O
19 O
patients O
) O
received O
4 O
mg O
of O
styrene O
maleic O
acid O
neocarzinostatin O
in O
4 O
ml O
of O
Lipiodol O
, O
and O
group O
B O
( O
18 O
patients O
) O
received O
100 O
mg O
of O
epirubicin O
in O
4 O
ml O
of O
Lipiodol O
via O
the O
tumor O
feeding O
arteries O
as O
peripherally O
as O
possible O
. O
[]

However O
, O
Ametop O
gel O
was O
more O
effective O
, O
with O
a O
statistically O
significant O
difference O
in O
the O
pain B-outcome ['Physiological-Clinical']
scores O
of O
the O
two O
groups O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Remission B-outcome ['Physiological-Clinical']
duration O
and O
survival B-outcome ['Mortality']
were O
similar O
when O
induction O
regimens O
were O
compared O
. O
['Physiological-Clinical', 'Mortality']

Protection B-outcome ['Physiological-Clinical']
of O
man O
from O
natural B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
influenza I-outcome ['Physiological-Clinical']
A2 I-outcome ['Physiological-Clinical']
Hong I-outcome ['Physiological-Clinical']
Kong I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
by O
amantadine O
: O
a O
controlled O
field O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
endpoint O
is O
treatment O
discontinuation B-outcome ['Life-Impact']
rate O
for I-outcome ['Life-Impact']
any I-outcome ['Life-Impact']
causes I-outcome ['Life-Impact']
. O
['Life-Impact']

1 O
, O
48 O
Dorset O
? O
[]

Five-year O
survival B-outcome ['Mortality']
and O
cancer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rates O
were O
determined O
, O
with O
special O
emphasis O
on O
the O
location O
of O
recurrence B-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Stent B-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
present O
in O
a O
good O
proportion O
of O
patients O
in O
groups O
1 O
and O
2 O
but O
there O
was O
a O
significant O
difference O
in O
the O
incidence O
of O
urinary B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
( O
11.5 O
% O
versus O
38.1 O
% O
, O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULT O
( O
S O
) O
No O
statistically O
significant O
difference O
was O
detected O
between O
the O
two O
groups O
in O
terms O
of O
survival B-outcome ['Mortality']
rate O
, O
but O
a O
significantly O
higher O
percentage O
of O
detectable B-outcome ['Physiological-Clinical']
spindle I-outcome ['Physiological-Clinical']
was O
observed O
in O
group O
B O
( O
completely O
denuded O
oocytes O
) O
, O
either O
immediately O
after O
warming O
or O
3 O
hours O
after O
incubation O
. O
['Mortality', 'Physiological-Clinical']

METHODS O
We O
used O
a O
randomised O
controlled O
trial O
with O
30 O
clusters O
( O
15 O
in O
each O
arm O
) O
to O
evaluate O
an O
integrated O
, O
scalable O
package O
providing O
two O
pregnancy O
visits O
and O
five O
post-natal O
home O
visits O
delivered O
by O
community O
health O
workers O
in O
Umlazi O
, O
Durban O
, O
South O
Africa O
. O
[]

Horizontal B-outcome ['Physiological-Clinical']
and O
vertical B-outcome ['Physiological-Clinical']
ridge I-outcome ['Physiological-Clinical']
dimensions I-outcome ['Physiological-Clinical']
were O
determined O
using O
a O
digital O
caliper O
and O
a O
template O
. O
['Physiological-Clinical', 'Physiological-Clinical']

U.K. O
Multicentre O
Antifungal O
Prophylaxis O
Study O
Group O
. O
[]

The O
data O
suggest O
that O
inhaled O
heparin O
may O
have O
an O
inhibitory O
effect O
on O
the O
methacholine O
bronchial O
challenge O
, O
and O
thus O
, O
most O
likely O
directs O
its O
effect O
against O
smooth O
muscle O
. O
[]

Therefore O
, O
we O
hypothesized O
that O
enhanced O
mTOR O
signaling O
might O
be O
responsible O
for O
the O
greater O
muscle O
protein O
synthesis O
when O
leucine-enriched O
EAA+CHOs O
are O
ingested O
during O
postexercise O
recovery O
. O
[]

Gastric B-outcome ['Physiological-Clinical']
metaplasia I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
duodenum I-outcome ['Physiological-Clinical']
was O
found O
in O
64 O
or O
87.7 O
% O
of O
the O
73 O
patients O
with O
non-complicated O
DU O
and O
in O
5 O
or O
9.8 O
% O
of O
the O
51 O
patients O
with O
complicated O
DU O
within O
8 O
to O
10 O
years O
of O
observation O
. O
['Physiological-Clinical']

Histological O
diagnosis O
by O
biopsy O
. O
[]

These O
areas O
of O
deficit O
have O
been O
well O
studied O
in O
autism O
but O
have O
rarely O
been O
the O
focus O
of O
treatment O
efforts O
( O
see O
Kasari O
, O
Freeman O
, O
& O
Paparella O
, O
2001 O
) O
. O
[]

The O
impact O
of O
emotional O
distress O
on O
HIV B-outcome ['Physiological-Clinical']
risk O
reduction O
among O
women O
. O
['Physiological-Clinical']

Esmolol O
versus O
verapamil O
in O
the O
acute O
treatment O
of O
atrial O
fibrillation O
or O
atrial O
flutter O
. O
[]

However O
, O
the O
results O
should O
be O
confirmed O
in O
further O
studies O
with O
a O
placebo O
group O
to O
rule O
out O
the O
placebo O
effect O
. O
[]

INTERVENTIONS O
Standard O
sensory O
integration O
therapy O
( O
SI O
) O
was O
compared O
to O
the O
SI O
with O
TTM O
treatments O
. O
[]

However O
, O
it O
included O
many O
small O
trials O
and O
trials O
with O
differing O
eligibility O
criteria O
and O
chemotherapy O
regimens O
. O
[]

The O
presence O
of O
mitral B-outcome ['Physiological-Clinical']
regurgitation I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
CHF I-outcome ['Physiological-Clinical']
was O
associated O
with O
lower O
vWf O
concentrations O
. O
['Physiological-Clinical']

The O
SPEM O
( O
Studio O
Policentrico O
Elettrocateteri O
Membrane O
) O
: O
a O
multicenter O
study O
on O
membrane O
leads O
. O
[]

Fewer O
patients O
received O
rescue B-outcome ['Resource-use']
antiemetics I-outcome ['Resource-use']
in O
the O
granisetron O
groups O
than O
in O
the O
control O
group O
( O
10 O
% O
, O
10 O
% O
, O
and O
43 O
% O
of O
patients O
in O
granisetron O
20 O
micrograms/kg O
and O
40 O
micrograms/kg O
, O
and O
the O
control O
groups O
, O
respectively O
) O
. O
['Resource-use']

There O
was O
only O
a O
suggestion O
that O
naltrexone O
reduced O
fidgety B-outcome ['Life-Impact']
and O
hyperactive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
and O
tended O
to O
alleviate O
overall B-outcome ['Life-Impact']
symptomatology I-outcome ['Life-Impact']
in O
older O
children O
. O
['Life-Impact', 'Life-Impact']

As O
part O
of O
the O
large-scale O
assessment O
of O
sibenadet O
, O
a O
12-month O
safety O
study O
has O
been O
conducted O
. O
[]

METHODS O
The O
study O
was O
carried O
out O
in O
middle-income O
students O
in O
two O
residential O
schools O
that O
catered O
to O
children O
from O
a O
semi-urban O
population O
near O
Hyderabad O
, O
India O
. O
[]

AIM O
This O
study O
investigated O
whether O
pre- O
and O
postmenopausal O
women O
with O
sexual O
arousal O
disorder O
are O
less O
genitally O
responsive O
to O
visual O
sexual O
stimuli O
than O
pre- O
and O
postmenopausal O
women O
without O
sexual O
problems O
. O
[]

Caffeine O
had O
only O
modest O
effects O
on O
nap B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
this O
study O
we O
compared O
data O
obtained O
by O
questionnaires O
to O
that O
obtained O
with O
actigraphy O
. O
[]

In O
study O
2 O
, O
the O
amount O
of O
lansoprazole B-outcome ['Life-Impact']
consumed I-outcome ['Life-Impact']
was O
approximately O
50 O
% O
less O
than O
that O
of O
omeprazole O
, O
and O
this O
translated O
to O
81 O
% O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
with O
lansoprazole O
compared O
with O
only O
9.5 O
% O
for O
omeprazole O
. O
['Life-Impact', 'Life-Impact']

Patencies O
were O
similar O
for O
either O
of O
the O
2 O
conduits O
in O
each O
group O
( O
log O
rank O
analysis O
, O
P O
= O
.06 O
and O
P O
= O
.54 O
, O
respectively O
) O
. O
[]

This O
web-based O
intervention O
will O
be O
evaluated O
in O
a O
2-year O
cluster O
randomised O
controlled O
trial O
( O
c-RCT O
) O
with O
three O
study O
arms O
. O
[]

PARTICIPANTS O
Participants O
( O
N=106 O
) O
were O
randomly O
assigned O
to O
WB O
exercise O
, O
NWB O
exercise O
, O
or O
a O
control O
group O
( O
no O
exercise O
) O
. O
[]

Recent O
animal O
models O
suggest O
that O
enteral O
feeding O
( O
TEN O
) O
compared O
to O
parenteral O
nutrition O
( O
TPN O
) O
improves O
resistance O
to O
infection O
. O
[]

Thirteen O
patients O
( O
45 O
% O
) O
had O
a O
panic O
attack O
during O
epinephrine O
. O
[]

These O
convenient O
, O
low-cost O
interventions O
can O
be O
implemented O
in O
a O
variety O
of O
settings O
and O
should O
be O
tested O
further O
to O
assess O
their O
long-term O
effectiveness O
. O
[]

Both O
doses O
of O
piroxicam O
were O
significantly O
more O
effective O
than O
placebo O
from O
Hours O
2 O
to O
12 O
for O
pain B-outcome ['Physiological-Clinical']
intensity O
difference O
( O
PID B-outcome ['Physiological-Clinical']
) O
and O
relief B-outcome ['Physiological-Clinical']
scores O
, O
as O
well O
as O
for O
SPID O
and O
TOTAL O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

JET O
is O
common O
after O
congenital O
heart O
surgery O
. O
[]

The O
independent O
effect O
of O
fish O
oil O
was O
also O
assessed O
. O
[]

METHODS O
Three O
hundred O
and O
five O
cases O
were O
randomly O
divided O
into O
a O
needle-knife O
group O
of O
153 O
cases O
and O
a O
physiotherapy O
group O
of O
152 O
cases O
. O
[]

CONCLUSIONS O
Administration O
of O
a O
COX-2 O
selective O
nonsteroidal O
anti-inflammatory O
drug O
prior O
to O
and O
following O
outpatient O
inguinal O
herniorrhaphy O
improves O
functional O
outcomes O
when O
compared O
with O
placebo O
and O
increases O
patient O
satisfaction O
. O
[]

Additional O
samples O
were O
obtained O
45 O
min O
after O
the O
start O
of O
surgery O
, O
at O
the O
end O
of O
surgery O
, O
1 O
h O
and O
24 O
h O
after O
the O
end O
of O
surgery O
. O
[]

This O
study O
evaluated O
the O
effect O
of O
food O
on O
the O
pharmacokinetics O
of O
cediranib O
and O
compared O
the O
administration O
of O
continual O
cediranib O
via O
two O
dosing O
strategies O
using O
this O
as O
a O
platform O
to O
investigate O
pharmacodynamic O
imaging O
biomarkers O
. O
[]

Patients O
with O
a O
randomized O
pattern O
of O
CEA B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
after O
tumor O
resection O
should O
be O
regarded O
as O
having O
the O
possibility O
of O
a O
persistent O
CEA O
source O
and O
may O
require O
consideration O
of O
intensive O
follow-up O
or O
adjuvant O
therapy O
. O
['Physiological-Clinical']

In O
the O
fingers O
, O
although O
baseline O
blood B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
was O
lower O
in O
patients O
than O
in O
controls O
, O
both O
groups O
showed O
increases O
with O
application O
of O
active O
gel O
( O
volume O
from O
1100 O
[ O
194 O
] O
to O
3280 O
[ O
672 O
] O
and O
2380 O
[ O
441 O
] O
to O
6160 O
[ O
1160 O
] O
, O
respectively O
; O
flux B-outcome ['Life-Impact']
from O
33,400 O
[ O
4200 O
] O
to O
108,000 O
[ O
13,600 O
] O
and O
52,000 O
[ O
8950 O
] O
to O
185,000 O
[ O
19,500 O
] O
) O
. O
['Physiological-Clinical', 'Life-Impact']

The O
data O
suggest O
that O
a O
5 O
alpha-reductase O
gene O
codes O
for O
an O
enzyme O
with O
affinity O
for O
multiple B-outcome ['Physiological-Clinical']
steroid I-outcome ['Physiological-Clinical']
substrates I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
a O
previous O
prospective O
randomized O
clinical O
study O
comparing O
in O
the O
same O
patient O
textured O
and O
smooth O
saline-filled O
mammary O
implants O
( O
Biocell O
) O
with O
large O
pore O
size O
( O
300 O
to O
600 O
microm O
) O
, O
we O
saw O
no O
difference O
in O
capsular O
contracture O
. O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
in O
45 O
% O
of O
the O
treatment O
group O
and O
in O
18 O
% O
of O
the O
placebo O
group O
( O
relative O
risk O
2.5 O
; O
95 O
% O
CI O
: O
2.1-2.9 O
) O
. O
['Adverse-effects']

[ O
Local O
application O
of O
anti-cancer O
drugs O
for O
the O
treatment O
of O
malignant O
pleural O
and O
pericardial O
effusion O
] O
. O
[]

The O
primary O
endpoints O
studied O
were O
the O
number O
of O
PONV-free B-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
respect I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
PONV I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
Compared O
with O
usual O
care O
, O
peer O
counseling O
reduced O
smoking O
( O
-9.1 O
versus O
-4.5 O
cigarettes O
daily O
, O
P O
=.03 O
) O
, O
but O
did O
not O
affect O
absolute O
quit B-outcome ['Life-Impact']
rates O
( O
24 O
% O
versus O
21 O
% O
) O
at O
36 O
weeks O
' O
gestation O
. O
['Life-Impact']

In O
17 O
patients O
who O
were O
randomly O
allotted O
double-blind O
additional O
dummy O
tablets O
16 O
of O
their O
ulcer O
healed O
completely O
endoscopically O
, O
whereas O
of O
the O
23 O
patients O
given O
additional O
amiloride O
5 O
mg O
three O
times O
a O
day O
only O
14 O
ulcers O
healed O
, O
a O
significant O
reduction O
in O
ulcer O
healing O
. O
[]

Carriers O
of O
HBV O
are O
over O
100 O
times O
more O
likely O
to O
develop O
liver O
cancer O
than O
non-carriers O
. O
[]

Allogeneic O
leucocytes O
are O
assumed O
to O
play O
a O
causal O
role O
. O
[]

Pharmacologic O
treatment O
is O
usually O
begun O
with O
nonopioid O
analgesics O
, O
most O
frequently O
acetaminophen O
. O
[]

Patients O
with O
a O
complete O
response O
, O
partial O
response O
, O
or O
stable O
disease O
after O
four O
cycles O
could O
receive O
cetuximab O
250 O
mg/m O
( O
2 O
) O
/week O
until O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
unacceptable I-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
a O
separate O
cohort O
, O
an O
ascending O
dose O
protocol O
evaluated O
a O
total O
dose O
of O
500 O
mg O
daily O
given O
in O
two O
divided O
doses O
. O
[]

We O
observed O
that O
the O
combined O
administration O
of O
a O
corticosteroid O
drug O
and O
allergen O
extract O
suppressed O
the O
early O
clinical O
and O
immunological O
effects O
of O
SIT O
and O
that O
vitamin O
D O
( O
3 O
) O
prevented O
this O
'adverse O
' O
influence O
of O
steroids O
. O
[]

The O
study O
comprised O
of O
two O
treatments O
. O
[]

The O
quality O
of O
pain B-outcome ['Physiological-Clinical']
control O
, O
the O
amount O
and O
character O
of O
the O
drain O
fluid B-outcome ['Physiological-Clinical']
, O
incidence O
of O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
, O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Although O
several O
SGLT2-selective O
inhibitors O
have O
been O
tested O
in O
large O
phase O
2 O
studies O
, O
dual O
inhibition O
of O
SGLT1 O
and O
SGLT2 O
is O
novel O
at O
this O
stage O
of O
drug O
development O
, O
and O
it O
has O
implications O
for O
clinical-trial O
design O
. O
[]

Although O
out-of-pocket B-outcome ['Resource-use']
expenses I-outcome ['Resource-use']
were O
similar O
for O
both O
cohorts O
, O
combined O
costs B-outcome ['Resource-use']
of I-outcome ['Resource-use']
insurance I-outcome ['Resource-use']
and O
out-of-pocket B-outcome ['Resource-use']
expenses I-outcome ['Resource-use']
were O
27 O
% O
lower O
in O
the O
intervention O
cohort O
( O
$ O
374/year O
per O
farmer O
) O
compared O
to O
the O
control O
cohort O
( O
$ O
512/year O
per O
farmer O
) O
. O
['Resource-use', 'Resource-use', 'Resource-use']

Higher B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
associated O
with O
increased O
prevalence O
of O
female O
gender O
, O
greater O
calcium O
channel O
blocking O
agent O
, O
digoxin O
and O
diuretic O
use O
, O
lower O
heart O
rate O
and O
a O
higher O
rate O
of O
reported O
smoking O
history O
. O
['Physiological-Clinical']

for O
glycerol O
: O
56-81-5 O
, O
lidocaine-HCl O
: O
73-78-9 O
) O
. O
[]

The O
sites O
were O
randomly O
assigned O
to O
either O
the O
experimental O
group O
( O
implemented O
the O
intervention O
) O
or O
the O
control O
group O
( O
continued O
usual O
training O
) O
. O
[]

All O
three O
active O
treatments O
produced O
significant O
antipyresis B-outcome ['Physiological-Clinical']
compared O
with O
placebo O
. O
['Physiological-Clinical']

We O
made O
physical O
examinations O
for O
hydroceles O
and O
leg O
oedema O
and O
investigated O
microfilarial O
densities O
by O
membrane O
filtration O
before O
and O
after O
treatment O
. O
[]

Findings O
suggest O
that O
a O
50 O
mg O
daily O
dose O
of O
diclofensine O
would O
be O
sufficient O
for O
the O
majority O
of O
the O
patients O
. O
[]

RESULTS O
The O
dose O
of O
first O
reported O
nausea B-outcome ['Physiological-Clinical']
and/or O
vomiting B-outcome ['Physiological-Clinical']
was O
8 O
mg/24 O
h O
for O
the O
fast-titration O
group O
and O
4 O
mg/ O
24 O
h O
for O
the O
slow-titration O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
well-controlled O
dietary O
intervention O
studies O
to O
prevent O
minor O
RAS O
are O
very O
rare O
. O
[]

SETTING O
University O
hospital O
. O
[]

This O
multicentre O
study O
was O
designed O
to O
evaluate O
the O
effect O
of O
ibopamine O
versus O
placebo O
in O
double-blind O
conditions O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
rhythm B-outcome ['Physiological-Clinical']
and O
electrical O
safety O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
contrast O
, O
neuroimaging O
studies O
targeting O
the O
representation O
of O
music O
structure O
have O
primarily O
implicated O
regions O
in O
the O
inferior O
frontal O
cortices O
. O
[]

Dogs O
and O
cats O
with O
naturally O
occurring O
flea O
infestations O
, O
some O
of O
which O
also O
had O
signs O
associated O
with O
FAD O
, O
were O
assigned O
randomly O
to O
receive O
three O
months O
of O
topical O
treatment O
with O
selamectin O
( O
220 O
dogs O
, O
189 O
cats O
) O
or O
a O
positive-control O
product O
( O
dogs O
: O
fenthion O
, O
n=81 O
; O
cats O
: O
pyrethrins O
, O
n=66 O
) O
. O
[]

No O
benefit O
of O
preoperative O
enteral O
feeding O
on O
QOL B-outcome ['Life-Impact']
could O
be O
demonstrated O
6 O
months O
after O
surgery O
. O
['Life-Impact']

alone O
and O
another O
10 O
( O
Group O
B O
) O
to O
low-dose O
dopamine O
and O
a O
similar O
diuretic O
regimen O
for O
a O
duration O
of O
5 O
days O
or O
less O
if O
clinical O
edema O
remitted O
. O
[]

The O
essential O
oil O
fraction O
, O
which O
contains O
all O
the O
taste O
and O
odour O
, O
exactly O
duplicated O
the O
[]

RESULTS O
136 O
consecutive O
patients O
were O
enrolled O
into O
the O
study O
. O
[]

RESULTS O
Twenty O
days O
after O
the O
treatment O
, O
in O
ozone O
therapy O
group O
, O
PRA O
was O
( O
1.31 O
? O
[]

RESULTS O
Eighty-two O
patients O
were O
enrolled O
; O
41 O
( O
50 O
% O
) O
patients O
in O
group O
A O
and O
41 O
( O
50 O
% O
) O
patients O
in O
group O
B O
were O
evaluated O
. O
[]

A O
randomized O
double-blind O
, O
placebo-controlled O
crossover O
trial O
of O
CR O
melatonin O
( O
5 O
mg O
) O
followed O
by O
a O
3-month O
open-label O
study O
was O
conducted O
during O
which O
the O
dose O
was O
gradually O
increased O
until O
the O
therapy O
showed O
optimal O
beneficial O
effects O
. O
[]

Overall O
, O
13 O
patients O
( O
46.4 O
% O
) O
had O
detrusor B-outcome ['Physiological-Clinical']
overactivity I-outcome ['Physiological-Clinical']
and O
14 O
( O
50 O
% O
) O
had O
decreased O
bladder B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
the O
management O
of O
CLBP O
, O
trunk O
exercise O
in O
combination O
with O
SMT O
or O
NSAID O
therapy O
seemed O
to O
be O
beneficial O
and O
worthwhile O
. O
[]

PURPOSE O
To O
demonstrate O
the O
application O
of O
mixed O
linear O
modeling O
for O
monitoring O
athletic O
performance O
. O
[]

Another O
1 O
patient O
( O
A O
) O
was O
dead B-outcome ['Mortality']
of O
ileus O
. O
['Mortality']

Data O
justify O
replication O
using O
larger O
samples O
. O
[]

The O
30-day O
mortality B-outcome ['Mortality']
rate O
was O
31 O
% O
in O
patients O
with O
VF O
, O
24 O
% O
in O
those O
with O
VT O
, O
44 O
% O
in O
those O
with O
both O
, O
and O
6 O
% O
in O
those O
with O
neither O
( O
P O
=.001 O
) O
. O
['Mortality']

Among O
the O
study O
participants O
, O
only O
1 O
in O
the O
6-hour O
group O
had O
significant O
bleeding B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
the O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
among O
treatments O
. O
['Adverse-effects']

Lovastatin O
treatment O
was O
associated O
with O
significant O
reductions O
in O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
, O
LDL-cholesterol B-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
and O
apo B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
( O
p O
< O
0.01 O
) O
, O
the O
reductions O
at O
24 O
months O
being O
26 O
, O
30 O
and O
18 O
% O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
determine O
whether O
anabolic O
hormones O
that O
affect O
the O
musculoskeletal O
system O
and O
active O
on O
the O
immune O
cells O
changed O
during O
cyclosporin O
A O
( O
CysA O
) O
therapy O
. O
[]

An O
improvement O
in O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
and O
fundus B-outcome ['Physiological-Clinical']
fluorescein I-outcome ['Physiological-Clinical']
angiographic I-outcome ['Physiological-Clinical']
findings I-outcome ['Physiological-Clinical']
was O
assessed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
At O
baseline O
, O
46.3 O
% O
of O
1455 O
participants O
screened O
were O
classified O
as O
depression B-outcome ['Life-Impact']
cases O
on O
the O
basis O
of O
their O
score O
on O
the O
Center O
for O
Epidemiological O
Studies O
Depression B-outcome ['Life-Impact']
Scale O
( O
> O
or O
=16 O
) O
or O
the O
Hospital O
Anxiety B-outcome ['Life-Impact']
and O
Depression B-outcome ['Life-Impact']
Scale O
( O
> O
or O
=8 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

All O
patients O
had O
failed O
prior O
treatment O
with O
IFN O
or O
peginterferon O
+/- O
RBV O
and O
had O
Ishak O
fibrosis O
scores O
> O
or O
= O
3 O
. O
[]

Management O
of O
the O
thyroid O
isthmus O
in O
tracheostomy O
: O
a O
prospective O
and O
retrospective O
study O
. O
[]

Characterization O
of O
early O
thermal O
burns O
and O
the O
effects O
of O
hyperbaric O
oxygen O
treatment O
: O
a O
pilot O
study O
. O
[]

60 O
% O
) O
were O
randomized O
to O
receive O
PR-STENT O
( O
N=9 O
) O
or O
to O
NO-STENT O
( O
N=9 O
) O
. O
[]

The O
PI B-outcome ['Physiological-Clinical']
, O
mmax O
and O
maximal O
transdiaphragmatic B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

This O
was O
a O
randomized O
, O
controlled O
clinical O
trial O
in O
5- O
to O
11-year-old O
children O
( O
n O
= O
937 O
) O
with O
moderate O
to O
severe O
asthma O
receiving O
health O
care O
in O
hospital- O
and O
community-based O
clinics O
and O
private O
practices O
in O
7 O
inner-city O
urban O
areas O
. O
[]

CONCLUSION O
Despite O
the O
fact O
that O
the O
combination O
of O
anxiolytics O
and O
analgesics O
as O
compared O
with O
analgesics O
alone O
reduced O
anxiety O
and O
the O
requirement O
of O
Morphine O
in O
the O
prehospital O
setting O
of O
acute O
coronary O
syndrome O
, O
this O
strategy O
did O
not O
reduce O
patients O
' O
estimation O
of O
pain O
( O
primary O
endpoint O
) O
. O
[]

BACKGROUND O
AND O
AIMS O
Although O
triple O
combination O
therapy O
containing O
a O
proton O
pump O
inhibitor O
( O
PPI O
) O
and O
two O
antibiotics O
is O
considered O
as O
a O
standard O
regimen O
for O
the O
first-line O
anti-Helicobacter O
pylori O
treatment O
, O
there O
are O
still O
debates O
on O
the O
ideal O
duration O
of O
treatment O
. O
[]

In O
the O
present O
randomized O
, O
double-blind O
, O
split-face O
, O
comparative O
study O
we O
have O
assessed O
efficacy O
, O
tolerability B-outcome ['Life-Impact']
, O
and O
safety O
of O
a O
base O
cream O
containing O
0.5 O
% O
BAs O
as O
compared O
to O
the O
same O
cream O
without O
these O
active O
ingredients O
in O
the O
treatment O
of O
clinical O
manifestations O
of O
photoaging O
of O
facial O
skin O
. O
['Life-Impact']

The O
findings O
suggest O
an O
increase O
in O
bone B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
during O
treatment O
with O
levonorgestrel O
and O
stable O
values O
during O
short-term O
administration O
of O
DMPA O
, O
in O
standard O
clinical O
doses O
for O
contraception O
. O
['Physiological-Clinical']

During O
the O
1-hour O
study O
period O
, O
the O
incidence O
of O
central B-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
side I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
the O
lidocaine O
group O
, O
hypotension B-outcome ['Physiological-Clinical']
occurred O
in O
11 O
patients O
, O
nine O
of O
whom O
had O
received O
lidocaine O
, O
and O
four O
patients O
died B-outcome ['Mortality']
from O
asystole O
, O
three O
of O
whom O
had O
had O
lidocaine O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
5.2 O
months O
( O
95 O
% O
confidence O
interval O
= O
3.3 O
to O
9 O
months O
) O
, O
with O
no O
significant O
difference O
between O
the O
intravenous O
and O
intra-arterial O
arms O
( O
log O
rank O
test O
p O
= O
0.79 O
) O
. O
['Mortality']

All O
groups O
then O
received O
anticoagulation O
and O
compression O
treatment O
for O
one O
year O
. O
[]

BACKGROUND O
Yes-associated B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
YAP1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
frequently O
reported O
to O
function O
as O
an O
oncogene O
in O
many O
types O
of O
cancer O
, O
but O
in O
breast O
cancer O
results O
remain O
controversial O
. O
['Physiological-Clinical']

Sildenafil O
is O
well O
tolerated B-outcome ['Life-Impact']
in O
left O
heart O
failure O
patients O
and O
does O
not O
decrease O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

BACKGROUND O
Much O
of O
China O
lacks O
well-developed O
services O
for O
people O
with O
schizophrenia O
and O
their O
families O
, O
and O
most O
of O
the O
existing O
services O
focus O
on O
hospitals O
. O
[]

In O
this O
severely O
diseased O
population O
of O
patients O
a O
treatment O
period O
limited O
to O
2 O
weeks O
did O
not O
sufficiently O
improve O
ulcer B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Surgery O
remains O
the O
gold O
standard O
in O
treatment O
of O
patients O
with O
symptomatic O
carotid O
artery O
stenosis O
. O
[]

Patients O
were O
randomized O
to O
receive O
MF-DPI O
400 O
microg O
once-daily O
in O
the O
evening O
or O
MF-DPI O
200 O
microg O
twice-daily O
. O
[]

A O
wash-out O
period O
of O
3 O
weeks O
between O
placebo O
and O
lisinopril O
was O
observed O
. O
[]

They O
were O
asked O
to O
record O
their O
pain O
and O
discomfort O
on O
a O
standardised O
visual O
analogue O
scale O
, O
from O
zero O
( O
no O
pain O
) O
to O
10 O
( O
severe O
pain O
) O
. O
[]

Our O
findings O
suggest O
that O
the O
use O
of O
lottery O
tickets O
as O
incentives O
to O
increase O
participation B-outcome ['Life-Impact']
in O
a O
mail O
questionnaire O
among O
parents O
may O
be O
less O
valuable O
or O
even O
harmful O
. O
['Life-Impact']

In O
summary O
, O
we O
found O
that O
the O
addition O
of O
protein O
to O
a O
carbohydrate O
supplement O
enhanced O
aerobic B-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
above O
that O
which O
occurred O
with O
carbohydrate O
alone O
, O
but O
the O
reason O
for O
this O
improvement O
in O
performance O
was O
not O
evident O
. O
['Physiological-Clinical']

Atrophy O
and O
intestinal O
metaplasia O
one O
year O
after O
cure O
of O
H. O
pylori O
infection O
: O
a O
prospective O
, O
randomized O
study O
. O
[]

OBJECTIVES O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
a O
suspension O
formulation O
of O
ciprofloxacin O
in O
the O
treatment O
of O
acute O
invasive O
diarrhea O
in O
infants O
and O
children O
. O
[]

When O
the O
ANC O
was O
normalized O
for O
each O
patient O
's O
first O
ANC O
, O
there O
was O
a O
significant O
increase O
in O
the O
ANC B-outcome ['Physiological-Clinical']
on O
days O
6 O
and O
7 O
at O
each O
dose O
level O
. O
['Physiological-Clinical']

Both O
the O
less O
and O
the O
more O
aggressive O
induction O
policies O
gave O
the O
same O
disease B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Liposomes O
are O
immunological O
adjuvants O
that O
can O
act O
as O
allergen O
carriers O
. O
[]

Onset O
of O
action O
following O
formoterol O
Turbuhaler O
and O
salbutamol O
pMDI O
in O
reversible O
chronic O
airway O
obstruction O
. O
[]

The O
mean O
arterial B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
and O
pulse B-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
were O
not O
significantly O
different O
in O
each O
group O
throughout O
the O
course O
of O
the O
operation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
base-line O
characteristics O
of O
the O
children O
were O
similar O
and O
documented O
a O
high O
prevalence O
of O
vitamin O
A O
deficiency O
and O
undernutrition O
. O
[]

Thus O
, O
and O
as O
predicted O
by O
the O
enhanced O
perceptual O
functioning O
model O
for O
peaks O
of O
ability O
in O
autism O
( O
Mottron O
& O
Burack O
, O
2001 O
) O
, O
autistic O
individuals O
outperform O
typically O
developing O
population O
in O
a O
variety O
of O
low-level O
perceptual O
tasks O
. O
[]

albus O
, O
this O
was O
reduced O
to O
almost O
one O
third O
and O
other O
bacteria O
were O
almost O
eliminated O
in O
the O
group O
receiving O
PVP-I O
. O
[]

Serum B-outcome ['Physiological-Clinical']
TXB2 I-outcome ['Physiological-Clinical']
remained I-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
, O
whereas O
PG B-outcome ['Physiological-Clinical']
synthesis I-outcome ['Physiological-Clinical']
recovered I-outcome ['Physiological-Clinical']
within O
6 O
h. O
3 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
aim O
to O
recruit O
319 O
women O
presenting O
at O
term O
, O
seeking O
analgesia O
for O
continuous O
severe O
lower O
back O
pain O
during O
labour O
. O
[]

After O
8 O
weeks O
of O
treatment O
, O
all O
the O
parameters O
of O
pulse B-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
( O
except O
heart O
rates O
in O
both O
groups O
and O
augmentation O
index O
in O
indapamide O
group O
) O
decreased O
significantly O
. O
['Physiological-Clinical']

Median O
survival B-outcome ['Mortality']
was O
greater O
than O
78 O
months O
in O
stage O
I O
, O
was O
46.3 O
months O
in O
stage O
II O
and O
was O
24.3 O
months O
in O
stage O
III O
patients O
, O
still O
independent O
of O
both O
induction O
and O
post-induction O
policies O
. O
['Mortality']

The O
statistic O
analysis O
pointed O
out O
differences O
only O
in O
Group O
1 O
for O
the O
variables O
percentage O
of O
communicative B-outcome ['Life-Impact']
space I-outcome ['Life-Impact']
used O
and O
use O
of O
the O
mediating O
object O
. O
['Life-Impact']

Demographic O
variables O
included O
age O
, O
education O
, O
ethnicity O
, O
gender O
and O
region O
of O
country O
. O
[]

METHOD O
AND O
MATERIALS O
Ninety-seven O
CP O
and O
AP O
subjects O
underwent O
full-mouth O
SRP O
on O
2 O
consecutive O
days O
. O
[]

HER2 B-outcome ['Physiological-Clinical']
overexpression/amplification I-outcome ['Physiological-Clinical']
was O
observed O
in O
37.3 O
% O
( O
91/244 O
) O
and O
17.9 O
% O
( O
41/229 O
) O
of O
the O
informative O
samples O
in O
the O
local O
and O
central O
evaluations O
, O
respectively O
. O
['Physiological-Clinical']

Mineral O
Trioxide O
Aggregate O
was O
used O
as O
the O
standard O
for O
comparison O
. O
[]

CONCLUSIONS O
Patterns O
of O
antenatal O
care O
involving O
fewer O
routine O
visits O
for O
women O
at O
low O
risk O
may O
lead O
to O
reduced O
psychosocial B-outcome ['Life-Impact']
effectiveness O
and O
dissatisfaction B-outcome ['Life-Impact']
with O
frequency O
of O
visits O
. O
['Life-Impact', 'Life-Impact']

Before O
and O
after O
comparisons O
in O
the O
larger O
sample O
of O
women O
showed O
that O
serial O
CE O
discernibly O
reduced O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
BP O
) O
( O
-8.7 O
% O
and O
-14.0 O
% O
, O
respectively O
) O
, O
increased O
estimated O
[ O
latin O
capital O
V O
with O
dot O
above O
] O
o2max B-outcome ['Physiological-Clinical']
( O
18.9 O
% O
) O
, O
and O
produced O
a O
trend O
( O
0.10 O
> O
p O
> O
0.05 O
) O
toward O
reduced O
resting B-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
( O
-4.9 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
This O
study O
employed O
a O
within-subjects O
crossover O
design O
, O
using O
a O
treatment O
condition O
( O
aerobic O
exercise O
) O
and O
a O
control O
condition O
, O
across O
4 O
classrooms O
. O
[]

In O
both O
groups O
, O
if O
pain O
intensity O
was O
rated O
as O
> O
3 O
on O
the O
VAS O
at O
week O
1 O
or O
2 O
, O
the O
dosage O
was O
doubled O
. O
[]

There O
were O
no O
increases O
in O
frequency O
of O
[]

The O
primary O
measure O
for O
clinical O
benefit O
analysis O
was O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
definitive I-outcome ['Physiological-Clinical']
worsening I-outcome ['Physiological-Clinical']
by O
one O
or O
more O
categories O
of O
Karnofsky O
performance B-outcome ['Physiological-Clinical']
status O
( O
KPS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
order O
to O
prove O
it O
, O
40 O
patients O
admitted O
in O
a O
five-year O
period O
, O
with O
a O
SP O
, O
were O
randomly O
assigned O
to O
be O
treated O
by O
ICT O
or O
VATS O
. O
[]

Ventilatory O
function O
during O
urography O
: O
a O
comparison O
of O
iopamidol O
and O
sodium O
iothalamate O
. O
[]

BACKGROUND O
Iron O
is O
an O
essential O
micronutrient O
that O
can O
have O
carcinogenic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
when O
at O
high O
or O
low O
concentrations O
. O
['Physiological-Clinical']

Exclusion O
criteria O
included O
the O
use O
of O
analgesics O
within O
four O
hours O
of O
the O
study O
. O
[]

All O
children O
received O
0.2 O
mg/kg O
of O
etomidate O
. O
[]

Anesthesia O
was O
standardized O
( O
laryngeal O
mask O
airway O
, O
fentanyl O
, O
propofol O
, O
sevoflurane O
, O
nitrous O
oxide O
, O
and O
oxygen O
) O
. O
[]

All O
patients O
had O
a O
coronary O
spasm O
during O
coronary O
arteriography O
, O
either O
spontaneously O
or O
ergometrine-induced O
. O
[]

Injury B-outcome ['Physiological-Clinical']
and O
illness B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
in O
the O
Certified O
Safe O
Farm O
study O
. O
['Physiological-Clinical', 'Resource-use']

After O
oocyte O
retrieval O
the O
women O
were O
given O
oestradiol O
( O
6 O
mg O
day O
( O
-1 O
) O
) O
and O
progesterone O
administration O
( O
300 O
mg O
day O
( O
-1 O
) O
) O
was O
initiated O
2 O
days O
later O
. O
[]

The O
total O
blood B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
calculated O
at O
T O
= O
10 O
mins O
. O
['Physiological-Clinical']

To O
determine O
the O
efficacy O
and O
safety O
of O
leukocyte-depleted O
reperfusion O
, O
20 O
patients O
were O
enrolled O
in O
a O
randomized O
, O
double-blind O
clinical O
trial O
to O
be O
treated O
with O
either O
warm O
whole O
blood O
reperfusion O
( O
group O
I O
; O
n O
= O
9 O
) O
or O
warm O
leukocyte-depleted O
blood O
reperfusion O
( O
group O
II O
; O
n O
= O
11 O
) O
. O
[]

The O
efficacy O
variable O
was O
determined O
by O
the O
mean O
number O
of O
new O
or O
recurrent O
decayed O
surfaces O
. O
[]

The O
isometric B-outcome ['Physiological-Clinical']
force I-outcome ['Physiological-Clinical']
was O
measured O
, O
and O
the O
time O
for O
the O
force O
to O
drop O
by O
3 O
dB O
( O
fatigue O
time O
) O
and O
the O
normalized O
force-time B-outcome ['Physiological-Clinical']
integral I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FTI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
determined O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Immunomodulatory O
treatment O
with O
immunoglobulin O
is O
effective O
in O
a O
significant O
number O
of O
patients O
with O
CFS O
, O
a O
finding O
that O
supports O
the O
concept O
that O
an O
immunologic O
disturbance O
may O
be O
important O
in O
the O
pathogenesis O
of O
this O
disorder O
. O
[]

BACKGROUND O
There O
is O
a O
paucity O
of O
randomized O
trials O
regarding O
diagnostic O
testing O
in O
women O
with O
suspected O
coronary O
artery O
disease O
( O
CAD O
) O
. O
[]

Eltanolone O
, O
a O
new O
steroid O
hypnotic O
, O
was O
compared O
to O
thiopental O
in O
short O
anaesthesia O
. O
[]

The O
evidence O
that O
breast-feeding O
protects O
against O
obesity O
is O
based O
on O
observational O
studies O
, O
with O
potential O
for O
confounding O
and O
selection O
bias O
. O
[]

The O
overall O
responder B-outcome ['Physiological-Clinical']
rate O
was O
41.3 O
% O
, O
compared O
with O
25 O
% O
for O
the O
control O
group O
( O
P O
= O
0.086 O
) O
. O
['Physiological-Clinical']

A O
single-blind O
study O
compared O
the O
effectiveness O
of O
glutaraldehyde-treated O
polymerized O
ragweed O
with O
nonpolymerized O
monomeric O
ragweed O
. O
[]

Using O
motivational O
interviewing O
with O
this O
population O
holds O
promise O
for O
helping O
prevent O
alcohol-related O
health O
problems O
. O
[]

Topical O
anesthesia O
during O
infant O
eye O
examinations O
: O
does O
it O
reduce O
stress O
? O
[]

In O
this O
model O
, O
medication O
reduces O
tantrums B-outcome ['Life-Impact']
, O
aggression B-outcome ['Life-Impact']
and O
self-injury B-outcome ['Life-Impact']
; O
parent O
training O
promotes O
improvement O
in O
noncompliance B-outcome ['Life-Impact']
and O
adaptive B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

INTERVENTION O
Subjects O
were O
stratified O
by O
baseline O
pain O
intensity O
and O
gender O
and O
randomized O
to O
one O
of O
the O
following O
groups O
: O
evaluation O
of O
efficacy O
( O
heatwrap O
, O
n=95 O
; O
oral O
placebo O
, O
n=96 O
) O
and O
blinding O
( O
oral O
ibuprofen O
, O
n=12 O
; O
unheated O
back O
, O
wrap O
n=16 O
) O
. O
[]

SETTING O
Twenty-four O
hospital-based O
HIV O
clinics O
in O
16 O
Canadian O
cities O
. O
[]

Node O
positive O
patients O
were O
assigned O
to O
CMF- O
( O
cyclophosphamide O
, O
methotrexate O
and O
5-fluorouracil O
) O
chemotherapy O
in O
addition O
to O
endocrine O
therapy O
. O
[]

OBJECTIVE O
To O
assess O
the O
effectiveness O
of O
an O
osteoporosis O
education O
program O
to O
improve O
calcium B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
knowledge B-outcome ['Life-Impact']
, O
and O
self-efficacy B-outcome ['Life-Impact']
in O
community-dwelling O
older O
Black O
adults O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Clonidine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
matures O
rapidly O
during O
the O
early O
postnatal O
period O
: O
a O
population O
pharmacokinetic O
analysis O
in O
newborns O
with O
neonatal O
abstinence O
syndrome O
. O
['Physiological-Clinical']

In O
enalapril O
group O
, O
the O
reduced O
values O
of O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
pulse B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
central I-outcome ['Physiological-Clinical']
aorta I-outcome ['Physiological-Clinical']
were O
significantly O
larger O
than O
those O
in O
brachial O
artery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
followed O
up O
for O
up O
to O
12 O
months O
. O
[]

Given O
that O
poor O
emotion O
regulation O
skills O
have O
been O
found O
to O
predict O
posttreatment O
levels O
of O
alcohol O
use O
, O
and O
that O
several O
defining O
characteristics O
of O
alexithymia O
bear O
similarity O
to O
deficits O
in O
emotion O
regulation O
skills O
, O
it O
is O
possible O
that O
alexithymia O
may O
predict O
poorer O
alcohol O
treatment O
outcomes O
. O
[]

Use O
of O
nerve O
stimulation O
did O
not O
significantly O
alter O
the O
requirements O
for O
analgesia O
although O
there O
was O
a O
reduction O
in O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
in O
the O
nerve O
stimulation O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
cognitive O
group O
treatment O
program O
was O
highly O
acceptable O
among O
the O
participants O
and O
was O
completed O
by O
nearly O
all O
the O
patients O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
GH I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
analyzed O
by O
the O
use O
of O
a O
sensitive O
chemiluminometric O
assay O
. O
['Physiological-Clinical']

OBJECTIVES O
To O
evaluate O
the O
effect O
of O
adaptive O
oral O
hygiene O
devices O
and O
orofacial O
exercise O
to O
improve O
gingival B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
among O
adults O
with O
systemic O
sclerosis O
( O
SSc O
) O
. O
['Physiological-Clinical']

Activation O
and O
intermuscular O
coherence O
of O
distal O
arm O
muscles O
during O
proximal O
muscle O
contraction O
. O
[]

RESULTS O
At O
3.8 O
years O
of O
median O
follow-up O
, O
for O
the O
primary O
end O
point O
, O
recurrence-free B-outcome ['Physiological-Clinical']
survival B-outcome ['Mortality']
( O
RFS B-outcome ['Mortality']
) O
, O
risk O
was O
reduced O
by O
18 O
% O
( O
hazard O
rate O
= O
0.82 O
; O
P O
= O
.01 O
) O
in O
the O
PEG-IFN-alpha-2b O
arm O
compared O
with O
observation O
. O
['Physiological-Clinical', 'Mortality', 'Mortality']

RESULTS O
Significant O
improvements O
were O
observed O
in O
[]

This O
simple O
nonpharmacologic O
method O
was O
effective O
and O
safe O
in O
patients O
with O
very-low- O
and O
low-dose O
heparin O
. O
[]

Additional O
information O
is O
collected O
during O
a O
home O
inspection O
. O
[]

Patients O
appreciation O
for O
information O
on O
anesthesia O
and O
anxiolysis O
in O
dentistry O
. O
[]

Lack O
of O
effect O
of O
food O
on O
the O
steady B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
pharmacokinetics I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
BMS-181101 I-outcome ['Physiological-Clinical']
, O
an O
antidepressant O
, O
in O
healthy O
subjects O
. O
['Physiological-Clinical']

The O
results O
demonstrate O
a O
feasible O
and O
non-threatening O
way O
to O
provide O
women O
with O
important O
personalized O
information O
about O
breast B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
risk O
. O
['Physiological-Clinical']

To O
determine O
the O
efficacy O
of O
intramuscular O
oxytetracycline O
as O
a O
supplemental O
dry O
cow O
treatment O
for O
Staphylococcus O
aureus O
mastitis O
, O
37 O
Holstein O
cows O
were O
randomly O
assigned O
to O
two O
treatment O
groups O
: O
intracisternal O
infusion O
with O
a O
commercial O
preparation O
of O
cephapirin O
benzathine O
at O
drying O
off O
( O
20 O
cows O
) O
and O
infusion O
with O
cephapirin O
benzathine O
at O
drying O
off O
and O
intramuscular O
oxytetracycline O
at O
11 O
mg/kg O
once O
daily O
on O
d O
7 O
, O
8 O
, O
9 O
, O
and O
10 O
after O
drying O
off O
( O
17 O
cows O
) O
. O
[]

Reciprocal O
Imitation O
Training O
( O
RIT O
) O
, O
a O
naturalistic O
imitation O
intervention O
, O
was O
developed O
to O
teach O
young O
children O
with O
autism O
to O
imitate O
during O
play O
. O
[]

Carpal O
tunnel O
release O
by O
limited O
palmar O
incision O
vs O
traditional O
open O
technique O
: O
randomized O
controlled O
trial O
. O
[]

STUDY O
DESIGN O
This O
was O
a O
randomized O
, O
controlled O
, O
parallel-group O
pilot O
study O
designed O
to O
compare O
an O
oat O
cereal O
group O
( O
standardized O
to O
5.52 O
g/day O
beta-glucan O
) O
to O
a O
low-fiber O
cereal O
control O
group O
( O
less O
than O
1.0 O
g/day O
total O
fiber O
) O
over O
6 O
weeks O
. O
[]

Skeletal O
muscle O
total O
creatine O
content O
and O
creatine O
transporter O
gene O
expression O
in O
vegetarians O
prior O
to O
and O
following O
creatine O
supplementation O
. O
[]

A O
prospective O
, O
randomized O
trial O
in O
sixty-two O
patients O
. O
[]

Pilot O
study O
of O
Panax O
quinquefolius O
( O
American O
ginseng O
) O
to O
improve O
cancer-related O
fatigue O
: O
a O
randomized O
, O
double-blind O
, O
dose-finding O
evaluation O
: O
NCCTG O
trial O
N03CA O
. O
[]

Vulvar B-outcome ['Physiological-Clinical']
irritation I-outcome ['Physiological-Clinical']
was O
seen O
in O
seven O
of O
these O
10 O
volunteers O
. O
['Physiological-Clinical']

Finally O
, O
patients O
who O
received O
enflurane O
for O
maintenance O
of O
anesthesia O
had O
a O
significantly O
higher O
frequency O
of O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
than O
the O
propofol O
maintenance O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
More O
than O
50 O
% O
of O
patients O
with O
Crohn O
's O
disease O
become O
either O
steroid O
resistant O
or O
dependent O
. O
[]

Although O
support O
persons O
and O
smokers O
can O
be O
engaged O
in O
this O
type O
of O
outreach O
program O
, O
refinements O
in O
the O
intervention O
approach O
are O
needed O
to O
improve O
the O
smoking B-outcome ['Life-Impact']
outcomes O
. O
['Life-Impact']

SETTING O
Outpatient O
physiotherapy O
departments O
in O
hospital O
and O
university O
settings O
. O
[]

CONCLUSIONS O
It O
is O
suggested O
that O
severely O
dependent O
users O
suffer O
an O
inability O
to O
selectively O
enhance O
the O
sensory O
processing O
of O
relevant O
auditory O
information O
. O
[]

By O
comparison O
of O
3-month O
changes O
between O
randomized O
subgroups O
, O
the O
addition O
of O
low-dose O
flutamide O
was O
found O
to O
have O
consistently O
( O
more O
) O
normalizing O
effects O
on O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
, O
IL-6 B-outcome ['Physiological-Clinical']
, O
and O
adiponectin O
, O
lean O
body O
mass O
, O
total O
and O
abdominal B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
, O
and O
arterial B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
ovaries I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULT O
( O
S O
) O
A O
Hotellings O
T O
( O
2 O
) O
test O
for O
repeated O
measure O
analysis O
indicated O
a O
statistically O
significant O
( O
P O
< O
.05 O
) O
between-group O
difference O
across O
time O
for O
the O
HRSD O
( O
T O
( O
2 O
) O
= O
13.3 O
; O
F O
[ O
3 O
, O
28 O
] O
= O
4.1 O
; O
P=.02 O
) O
with O
the O
sertraline O
treatment O
group O
manifesting O
significantly O
fewer O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
than O
the O
control O
group O
. O
['Life-Impact']

OBJECTIVES O
To O
evaluate O
an O
encounter-based O
immunization O
prompting O
system O
on O
resident O
performance O
in O
administering O
vaccines O
and O
knowledge O
of O
immunization O
guidelines O
. O
[]

A O
combination O
of O
radioiodine O
WBS O
and O
serum O
Tg O
after O
recombinant O
human O
TSH O
stimulation O
detected O
thyroid B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
or O
cancer B-outcome ['Physiological-Clinical']
in O
93 O
% O
of O
patients O
with O
disease O
or O
tissue O
limited O
to O
the O
thyroid O
bed O
and O
100 O
% O
of O
patients O
with O
metastatic O
disease O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Enhancing O
caregiver O
health O
: O
findings O
from O
the O
resources O
for O
enhancing O
Alzheimer O
's O
caregiver O
health O
II O
intervention O
. O
[]

DESIGN O
A O
prospective O
, O
investigator-masked O
, O
randomized O
, O
controlled O
comparative O
study O
involving O
36 O
eyes O
of O
34 O
patients O
with O
functioning O
filtering O
blebs O
who O
were O
to O
undergo O
cataract O
surgery O
. O
[]

Effect O
of O
shearing O
on O
water O
turnover O
and O
thermobiological O
variables O
in O
German O
Blackhead O
mutton O
sheep O
. O
[]

No O
difference O
was O
found O
when O
the O
two O
groups O
were O
compared O
with O
regard O
to O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
P O
= O
0.599 O
) O
. O
['Adverse-effects']

In O
the O
H. O
pylori-infected O
group O
, O
antral O
biopsy O
specimens O
had O
more O
pronounced O
acute B-outcome ['Physiological-Clinical']
gastritis I-outcome ['Physiological-Clinical']
( O
P O
= O
0.01 O
) O
, O
whereas O
corpus O
specimens O
showed O
increased O
acute B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
gastritis I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
and O
a O
marginal O
increase O
in O
GA B-outcome ['Physiological-Clinical']
( O
P O
= O
0.052 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Lossy O
compression O
at O
a O
ratio O
of O
16:1 O
decreased O
the O
sensitivity O
for O
the O
detection O
of O
diagnostic O
features O
( O
76 O
% O
vs. O
80 O
% O
p O
= O
0.004 O
) O
. O
[]

METHODS O
In O
the O
first O
screening O
round O
of O
the O
European O
Randomized O
study O
of O
Screening O
for O
PC O
( O
ERSPC O
) O
Rotterdam O
, O
7,280 O
men O
underwent O
a O
PSA-determination O
and O
DRE O
of O
whom O
2,102 O
underwent O
prostate O
biopsy O
( O
biopsy O
indication O
PSA O
> O
or O
= O
4.0 O
ng/ml O
and/or O
suspicious O
DRE O
and/or O
TRUS O
) O
. O
[]

Delayed O
genomic O
and O
acute O
nongenomic O
action O
of O
glucocorticosteroids O
in O
seasonal O
allergic O
rhinitis O
. O
[]

0 O
% O
placebo O
) O
, O
and O
tachycardia O
( O
1.6 O
% O
Cappra O
( O
? O
) O
, O
[]

Vomiting B-outcome ['Physiological-Clinical']
was O
reduced O
from O
17 O
% O
( O
441/2585 O
) O
to O
11 O
% O
( O
293/2576 O
) O
, O
corresponding O
to O
a O
relative O
risk O
of O
0.67 O
, O
or O
a O
relative O
risk O
reduction O
of O
33 O
% O
. O
['Physiological-Clinical']

Among O
the O
31 O
patients O
, O
17 O
patients O
who O
received O
pirarubicin O
instillation O
had O
fewer O
recurrences B-outcome ['Physiological-Clinical']
when O
compared O
with O
14 O
patients O
who O
received O
control O
treatment O
( O
P O
= O
0.0001 O
) O
. O
['Physiological-Clinical']

In O
case O
of O
progressive O
disease O
( O
PD O
) O
after O
two O
courses O
, O
patients O
were O
operated O
upon O
as O
soon O
as O
possible O
. O
[]

Berries O
were O
homogenised O
in O
hot O
( O
80 O
degrees O
C O
) O
water O
, O
warm O
( O
40 O
degrees O
C O
) O
skimmed O
milk O
and O
hot O
( O
80 O
degrees O
C O
) O
skimmed O
milk O
, O
with O
freeze O
drying O
of O
each O
preparation O
into O
a O
powdered O
form O
. O
[]

Epidemiologic O
and O
experimental O
data O
suggest O
that O
a O
high O
dietary O
intake O
of O
long-chain O
polyunsaturated O
n-3 O
fatty O
acids O
may O
reduce O
the O
risk O
of O
atherothrombotic O
disease O
. O
[]

Multivariable O
survey-logistic O
regression O
analyses O
were O
performed O
to O
assess O
predictors O
and O
probability O
of O
the O
outcome O
. O
[]

A O
study O
realized O
by O
family O
practitioners O
in O
239 O
children O
aged O
4-12 O
years O
old O
. O
[]

5mU/l O
vs O
median O
Controls O
, O
37.4mU/l O
; O
P O
< O
0.01 O
) O
and O
1.0 O
microg/kg O
( O
median O
peak O
Irradiated O
, O
4.8mU/l O
vs O
median O
Controls O
, O
15.2mU/l O
; O
P O
< O
0 O
. O
[]

No O
complication B-outcome ['Adverse-effects']
occurred O
in O
either O
group O
. O
['Adverse-effects']

RESULTS O
Glucocorticoid O
administration O
for O
5 O
weeks O
resulted O
in O
significant O
( O
P O
< O
0.05 O
) O
increases O
in O
BMI O
, O
leptin B-outcome ['Physiological-Clinical']
( O
corrected O
for O
BMI O
) O
and O
the O
leptin B-outcome ['Physiological-Clinical']
: O
SHBG B-outcome ['Physiological-Clinical']
ratio O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Levosulpiride O
in O
functional O
dyspepsia O
: O
a O
multicentric O
, O
double-blind O
, O
controlled O
trial O
. O
[]

OBJECTIVE O
This O
study O
compared O
the O
dynamic O
surface O
electromyographic O
( O
EMG O
) O
activities O
of O
back O
muscles O
and O
pain O
before O
and O
after O
traditional O
bone O
setting O
and O
physical O
therapy O
. O
[]

Chemical B-outcome ['Physiological-Clinical']
cystitis I-outcome ['Physiological-Clinical']
is O
occasionally O
observed O
, O
especially O
if O
multiple O
instillations O
are O
started O
immediately O
after O
TUR O
, O
or O
in O
the O
presence O
of O
additional O
inflammatory O
conditions O
, O
such O
as O
previous O
irradiation O
or O
bacterial O
cystitis O
. O
['Physiological-Clinical']

It O
is O
important O
to O
consider O
dietary O
sodium O
intake O
when O
assessing O
diastolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
between-group O
difference O
in O
SiDBP B-outcome ['Physiological-Clinical']
response O
rate O
( O
the O
proportion O
of O
patients O
who O
experienced O
adequate O
SiDBP O
reductions O
) O
did O
not O
reach O
statistical O
significance O
: O
85.7 O
% O
( O
42/49 O
) O
for O
the O
amlodipine O
maleate O
group O
and O
91.8 O
% O
( O
45/49 O
) O
for O
the O
amlodipine O
besylate O
group O
. O
['Physiological-Clinical']

Their O
pattern O
of O
escaping O
always O
mirrored O
the O
pattern O
of O
their O
primary O
memory O
performance O
across O
serial O
positions O
. O
[]

Risperidone O
dosing O
in O
children O
and O
adolescents O
with O
autistic O
disorder O
: O
a O
double-blind O
, O
placebo-controlled O
study O
. O
[]

Lactational B-outcome ['Physiological-Clinical']
amenorrhea I-outcome ['Physiological-Clinical']
( O
LA O
) O
is O
associated O
with O
postpartum O
infertility O
and O
is O
known O
to O
be O
related O
to O
breast-feeding O
frequency O
and O
duration O
, O
but O
the O
exact O
role O
of O
complementary O
feeding O
of O
the O
infant O
has O
not O
been O
clearly O
defined O
. O
['Physiological-Clinical']

Stroke B-outcome ['Physiological-Clinical']
is O
a O
major O
cause O
of O
death O
and O
disability O
in O
developed O
countries O
. O
['Physiological-Clinical']

$ O
30 O
, O
000/year O
. O
[]

CROP O
( O
cytosine O
arabinoside O
, O
daunorubicin O
, O
vincristine O
, O
prednisolone O
) O
produced O
CR O
in O
41 O
% O
of O
patients O
, O
7 O
and O
3 O
( O
cytosine O
arabinoside O
, O
daunorubicin O
) O
in O
42 O
% O
and O
7 O
and O
3 O
plus O
hydroxyurea O
in O
52 O
% O
. O
[]

The O
magnitudes O
of O
these O
relationships O
were O
similar O
. O
[]

There O
was O
no O
difference O
in O
survival B-outcome ['Mortality']
, O
cause-specific B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
and O
pattern O
of O
relapse B-outcome ['Physiological-Clinical']
between O
both O
groups O
. O
['Mortality', 'Mortality', 'Physiological-Clinical']

All O
of O
the O
bladder B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
rectal I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
needed O
medical O
treatment O
( O
Kottmeier O
's O
grade O
2 O
) O
. O
['Physiological-Clinical']

RESEARCH O
DESIGN O
AND O
METHODS O
We O
conducted O
a O
randomized O
crossover O
trial O
of O
the O
effects O
of O
12 O
g O
decaffeinated O
coffee O
, O
1 O
g O
chlorogenic O
acid O
, O
500 O
mg O
trigonelline O
, O
and O
placebo O
( O
1 O
g O
mannitol O
) O
on O
glucose O
and O
insulin O
concentrations O
during O
a O
2-h O
oral O
glucose O
tolerance O
test O
( O
OGTT O
) O
in O
15 O
overweight O
men O
. O
[]

OBJECTIVE O
Sleep B-outcome ['Physiological-Clinical']
difficulties I-outcome ['Physiological-Clinical']
are O
common O
reasons O
why O
parents O
seek O
medical O
intervention O
in O
children O
with O
autism O
spectrum O
disorders O
( O
ASDs O
) O
. O
['Physiological-Clinical']

A O
close O
correlation O
between O
the O
kinetics O
and O
the O
magnitude O
of O
the O
humoral B-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
observed O
. O
['Physiological-Clinical']

Participants O
in O
the O
CAI O
group O
reviewed O
a O
1-hour O
long O
CAI O
program O
, O
participants O
in O
the O
Lecture O
group O
were O
presented O
with O
a O
1-hour O
long O
lecture O
, O
and O
participants O
in O
the O
No O
Intervention O
group O
received O
no O
intervention O
. O
[]

AIM O
Hydroxyethyl O
starch O
( O
HES O
) O
solutions O
are O
frequently O
used O
for O
perioperative O
volume O
replacement O
. O
[]

We O
conclude O
that O
oral O
ENT O
administration O
did O
not O
affect O
food B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
or O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
in O
subjects O
with O
a O
preference O
for O
a O
high-fat O
diet O
experiencing O
a O
negative O
energy O
and O
fat O
balance O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Genetic O
testing O
for O
BRCA1 O
: O
effects O
of O
a O
randomised O
study O
of O
knowledge O
provision O
on O
interest O
in O
testing O
and O
long O
term O
test O
uptake O
; O
implications O
for O
the O
NICE O
guidelines O
. O
[]

Compared O
with O
povidone-iodine O
, O
the O
chlorhexidine-based O
solution O
was O
associated O
with O
a O
50 O
% O
decrease O
in O
the O
incidence O
of O
catheter B-outcome ['Physiological-Clinical']
colonization I-outcome ['Physiological-Clinical']
( O
11.6 O
% O
vs O
22.2 O
% O
[ O
P O
= O
.002 O
] O
; O
incidence O
density O
, O
9.7 O
vs O
18.3 O
per O
1000 O
catheter-days O
) O
and O
with O
a O
trend O
toward O
lower O
rates O
of O
catheter-related B-outcome ['Physiological-Clinical']
bloodstream I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( O
1.7 O
% O
vs O
4.2 O
% O
[ O
P O
= O
.09 O
] O
; O
incidence O
density O
, O
1.4 O
vs O
3.4 O
per O
1000 O
catheter-days O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

1998 O
) O
with O
two O
important O
new O
contributions O
. O
[]

Burns O
are O
common O
in O
Vietnam O
, O
and O
because O
of O
economic O
constraints O
and O
limited O
resources O
for O
the O
import O
of O
appropriate O
treatments O
, O
the O
health O
authorities O
are O
obliged O
to O
rely O
on O
traditional O
herbal O
remedies O
. O
[]

However O
, O
peptidase B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
for O
placebo O
and O
control O
sites O
increased O
and O
were O
above O
baseline O
values O
on O
week O
9 O
and O
week O
13 O
, O
respectively O
. O
['Physiological-Clinical']

Based O
on O
two-sided O
univariate O
log-rank O
analysis O
of O
pooled O
data O
from O
E1684 O
and O
E1690 O
( O
median O
follow-up O
, O
7.2 O
years O
) O
, O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
RFS I-outcome ['Mortality']
) I-outcome ['Mortality']
-but O
not O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
-was O
significantly O
prolonged O
( O
two-sided O
log-rank O
P O
value O
= O
0.006 O
) O
for O
patients O
treated O
with O
HDI O
versus O
Obs O
. O
['Mortality', 'Mortality']

Perioperative O
data O
, O
as O
well O
as O
symptom O
scores O
, O
Quality O
of O
Life O
( O
QoL O
) O
scores O
, O
and O
maximum O
urinary O
flow O
rates O
( O
Qmax O
) O
were O
obtained O
at O
one O
, O
three O
, O
six,12 O
, O
and O
24 O
months O
. O
[]

METHODS O
In O
this O
double-blind O
, O
randomised O
controlled O
trial O
, O
59 O
newborn O
infants O
at O
University O
College O
Hospital O
( O
London O
, O
UK O
) O
were O
randomly O
assigned O
to O
receive O
0?5 O
mL O
24 O
% O
sucrose O
solution O
or O
0?5 O
mL O
sterile O
water O
2 O
min O
before O
undergoing O
a O
clinically O
required O
heel O
lance O
. O
[]

RESULTS O
Forty-five O
patients O
were O
assessable O
for O
response O
: O
in O
arm O
A O
, O
5 O
patients O
achieved O
a O
partial B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
( O
overall O
response O
, O
25 O
% O
) O
, O
and O
in O
arm O
B O
, O
2 O
patients O
achieved O
a O
complete B-outcome ['Physiological-Clinical']
and O
1 O
a O
partial B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
( O
overall O
response O
, O
12 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
will O
provide O
evidence O
of O
the O
clinical B-outcome ['Physiological-Clinical']
and O
cost-effectiveness O
of O
the O
service O
, O
informing O
its O
longer O
term O
development O
and O
implementation O
of O
the O
model O
in O
other O
centres O
nationally O
and O
internationally O
. O
['Physiological-Clinical', 'Resource-use']

However O
, O
during O
this O
period O
, O
pain O
from O
the O
primary O
surgical O
site O
was O
increased O
compared O
to O
the O
control O
group O
. O
[]

BACKGROUND O
Daclizumab O
, O
a O
humanised O
monoclonal O
antibody O
, O
modulates O
interleukin-2 O
signalling O
by O
blocking O
the O
? O
[]

Measurements O
of O
shoulder B-outcome ['Physiological-Clinical']
and O
hip B-outcome ['Physiological-Clinical']
posture I-outcome ['Physiological-Clinical']
were O
performed O
pre-intervention O
, O
5 O
weeks O
post-intervention O
and O
term O
postmenstrual O
age O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
investigated O
whether O
VK2 O
could O
reduce O
incidence O
of O
tumor O
recurrence O
after O
treatment O
of O
HCC O
. O
[]

In O
both O
groups O
, O
positive O
effects O
on O
patients O
' O
well-being O
were O
found O
to O
a O
similar O
extent O
. O
[]

An O
evaluation O
of O
sealing O
ability O
of O
calcium O
hydroxide O
sealers O
. O
[]

More O
studies O
are O
required O
to O
establish O
the O
bioavailability O
and O
pharmacokinetic O
effects O
of O
purple O
carrot O
anthocyanins O
and O
phenolic O
acids O
prior O
to O
further O
trials O
of O
efficacy O
with O
respect O
to O
treating O
inflammation O
and O
metabolic O
alterations O
. O
[]

Effect O
of O
carbon O
monoxide O
on O
exercise O
performance O
in O
chronic O
obstructive O
pulmonary O
disease O
. O
[]

Fifty-seven O
had O
OG O
and O
64 O
had O
attempted O
PEG O
. O
[]

There O
was O
no O
statistic O
difference O
between O
both O
groups O
( O
p O
= O
0.44 O
) O
. O
[]

A O
randomized O
, O
double-blind O
, O
cross-over O
study O
design O
was O
used O
to O
assess O
the O
in O
vivo O
interaction O
of O
paracetamol B-outcome ['Resource-use']
and O
ferrous O
ion B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

METHODS O
Middle-aged O
working O
men O
with O
recent O
LBP O
but O
without O
severe O
disability O
were O
randomly O
allocated O
to O
either O
a O
training O
( O
TG O
, O
n O
= O
52 O
) O
or O
control O
group O
( O
CG O
, O
n O
= O
54 O
) O
. O
[]

More O
than O
388 O
individuals O
fulfilled O
criteria O
for O
both O
interventions O
and O
188 O
( O
48.5 O
% O
) O
gave O
informed O
consent O
to O
participate O
in O
the O
trials O
. O
[]

Validation O
of O
a O
novel O
satisfaction O
questionnaire O
for O
patients O
with O
rheumatoid O
arthritis O
receiving O
outpatient O
clinical O
nurse O
specialist O
care O
, O
inpatient O
care O
, O
or O
day O
patient O
team O
care O
. O
[]

The O
median O
OS B-outcome ['Mortality']
was O
similar O
in O
the O
S-1+paclitaxel O
and O
S-1+cisplatin O
groups O
( O
16 O
vs O
17 O
months O
; O
P=0.84 O
) O
. O
['Mortality']

Based O
primarily O
on O
the O
beneficial O
effect O
of O
gabapentin O
on O
acquired O
pendular O
nystagmus O
( O
APN O
) O
, O
a O
GABAergic O
mechanism O
in O
controlling O
nystagmus O
has O
been O
hypothesised O
. O
[]

Plaque O
area O
was O
also O
determined O
by O
drawing O
the O
outline O
of O
plaque O
onto O
grids O
. O
[]

8.7 O
) O
] O
were O
all O
significantly O
lower O
than O
those O
in O
the O
6 O
( O
th O
) O
weekend O
of O
treatment O
[ O
( O
14.2 O
? O
[]

More O
proven O
systemic B-outcome ['Physiological-Clinical']
fungal I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
occurred O
in O
flu O
( O
Aspergillus O
four O
, O
Candida O
tropicalis O
one O
, O
C. O
krusei O
one O
) O
than O
itra O
( O
C. O
albicans O
one O
) O
and O
more O
of O
these O
were O
fatal O
( O
four O
versus O
nil O
) O
. O
['Physiological-Clinical']

METHODS O
One O
hundred O
and O
ten O
patients O
with O
a O
femoral O
shaft O
fracture O
were O
enrolled O
in O
a O
prospective O
, O
randomized O
study O
. O
[]

Depression B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
in O
women O
with O
breast O
cancer O
and O
their O
partners O
. O
['Life-Impact', 'Life-Impact']

CONCLUSION O
On O
the O
basis O
of O
diet O
intervention O
, O
electroacupuncture O
plus O
blood-letting O
puncture O
and O
cupping O
is O
a O
better O
therapy O
for O
acute O
gouty O
arthritis O
. O
[]

A O
reversible O
dose-dependent O
elevation O
in O
adrenocorticotrophic B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
generally O
within O
the O
normal O
reference O
range O
, O
was O
observed O
. O
['Physiological-Clinical']

Specifically O
, O
a O
stronger O
bias O
to O
perceive O
auditory B-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
occurring I-outcome ['Physiological-Clinical']
before O
visual O
stimuli O
as O
simultaneous O
was O
associated O
with O
greater O
levels O
of O
autistic O
symptoms O
. O
['Physiological-Clinical']

EXPERIMENTAL O
DESIGN O
Patients O
with O
metastatic O
colorectal O
cancer O
were O
treated O
with O
fluorouracil O
, O
leucovorin O
, O
and O
irinotecan O
and O
were O
also O
given O
ALVAC-CEA/B7.1 O
vaccine O
with O
or O
without O
tetanus O
toxoid O
adjuvant O
. O
[]

PURPOSE O
The O
purpose O
was O
to O
assess O
the O
incidence O
and O
clinical B-outcome ['Physiological-Clinical']
manifestations I-outcome ['Physiological-Clinical']
of O
radiation-induced O
brachial O
plexopathy O
in O
breast O
cancer O
patients O
, O
treated O
according O
to O
the O
Danish O
Breast O
Cancer O
Cooperative O
Group O
protocols O
. O
['Physiological-Clinical']

Differences O
in O
reporting O
levels O
were O
particularly O
striking O
during O
the O
first O
six O
to O
12 O
weeks O
of O
the O
survey O
, O
for O
symptoms O
related O
to O
acute O
, O
transitory O
illness O
, O
and O
among O
minorities O
and O
the O
lower O
socioeconomic O
groups O
. O
[]

At O
the O
end O
of O
each O
treatment O
the O
patients O
underwent O
upright O
bicycle O
exercise O
. O
[]

In O
exercise O
physiology O
, O
it O
has O
been O
traditionally O
assumed O
that O
high-intensity O
aerobic O
exercise O
stops O
at O
the O
point O
commonly O
called O
exhaustion O
because O
fatigued O
subjects O
are O
no O
longer O
able O
to O
generate O
the O
power O
output O
required O
by O
the O
task O
despite O
their O
maximal O
voluntary O
effort O
. O
[]

No O
differences O
were O
seen O
among O
the O
methods O
in O
the O
oxytocin B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
participants O
were O
given O
subcutaneous O
injections O
at O
18:00 O
h O
and O
23:00 O
h O
of O
either O
saline O
or O
octreotide O
( O
Sandostatin O
; O
each O
injection O
50 O
microg O
) O
. O
[]

In O
week O
18 O
, O
the O
median O
relative B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
wart I-outcome ['Physiological-Clinical']
area O
was O
100 O
% O
in O
the O
ALA-PDT O
group O
( O
100 O
% O
, O
57 O
% O
) O
versus O
71 O
% O
( O
100 O
% O
, O
0 O
) O
in O
the O
placebo-PDT O
arm O
( O
p=0.008 O
) O
. O
['Physiological-Clinical']

Secondary O
analyses O
involved O
heat O
and O
cold O
detection O
thresholds O
and O
paradoxical O
heat O
sensations O
. O
[]

The O
patency O
of O
venous O
ACB O
using O
coronary O
DSA O
one O
week O
and O
one O
year O
after O
surgery O
was O
evaluated O
in O
52 O
patients O
divided O
into O
two O
groups O
. O
[]

To O
investigate O
the O
underlying O
causal O
mechanisms O
, O
we O
conducted O
a O
randomized O
clinical O
trial O
of O
an O
experimental O
intervention O
( O
Focused O
Playtime O
Intervention O
, O
FPI O
) O
that O
aims O
to O
enhance O
responsive B-outcome ['Life-Impact']
parental I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
( O
N O
= O
70 O
) O
. O
['Life-Impact']

There O
was O
a O
consistent O
trend O
toward O
improved O
symptoms B-outcome ['Physiological-Clinical']
on O
all O
measures O
48 O
h O
following O
completion O
of O
chemotherapy O
. O
['Physiological-Clinical']

OBJECTIVES O
The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effectiveness O
of O
a O
variety O
of O
tests O
in O
differentiating O
simulating O
test O
performances O
from O
genuine O
memory-impaired B-outcome ['Life-Impact']
and O
normal O
( O
control O
) O
test O
performances O
. O
['Life-Impact']

RESULTS O
Attitudes B-outcome ['Life-Impact']
, O
knowledge B-outcome ['Life-Impact']
, O
and O
application B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
significantly O
improved O
for O
workshop-only O
and O
enriched-model O
nurses O
relative O
to O
controls O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

METHODS O
Of O
420 O
EVS O
patients O
with O
postoperative O
endophthalmitis O
, O
201 O
received O
immediate O
vitreous O
tap O
or O
biopsy O
( O
without O
pars O
plana O
vitrectomy O
) O
by O
random O
assignment O
and O
193 O
completed O
9-12 O
months O
of O
follow-up O
. O
[]

A O
randomized O
study O
. O
[]

Further O
placebo-controlled O
and O
long-term O
studies O
of O
olanzapine O
in O
autistic O
disorder O
are O
required O
. O
[]

METHODS O
Thirty-five O
children O
with O
> O
or O
=40 O
% O
total O
body O
surface O
area O
burns O
were O
randomized O
to O
receive O
either O
placebo O
or O
oxandrolone O
( O
0.1 O
mg/kg O
by O
mouth O
twice O
daily O
) O
from O
postoperative O
day O
5 O
to O
1 O
year O
postburn O
. O
[]

Whether O
heparin O
modulates O
bronchial O
hyperreactivity O
induced O
by O
adenosine O
, O
is O
not O
well O
known O
. O
[]

Headache B-outcome ['Physiological-Clinical']
was O
registered O
for O
12 O
h O
after O
the O
infusion O
and O
headache B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
was O
scored O
on O
a O
scale O
from O
0 O
to O
10 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Other O
methods O
were O
less O
successful O
in O
causing O
prolactin B-outcome ['Physiological-Clinical']
elevations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

All O
subjects O
were O
followed O
up O
for O
a O
period O
of O
four O
weeks O
. O
[]

Comorbidity O
, O
age O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
cetuximab-treated O
patients O
with O
advanced O
colorectal O
cancer O
( O
ACRC O
) O
-- O
results O
from O
NCIC O
CTG O
CO.17 O
: O
a O
phase O
III O
trial O
of O
cetuximab O
versus O
best O
supportive O
care O
. O
['Mortality']

Therefore O
, O
a O
proved O
contact O
allergen O
was O
shown O
to O
be O
required O
for O
therapeutic O
success O
. O
[]

In O
both O
arms O
combined O
, O
declines O
from O
baseline O
to O
3 O
months O
were O
observed O
in O
sexual B-outcome ['Life-Impact']
risk O
behaviors B-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
['Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
The O
mean O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
estimated B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
transfusion B-outcome ['Physiological-Clinical']
rate O
and O
postoperative B-outcome ['Physiological-Clinical']
anemia I-outcome ['Physiological-Clinical']
rate O
were O
significantly O
less O
in O
the O
exteriorized O
group O
than O
the O
intraperitoneal O
group O
( O
p O
= O
0.000 O
, O
0.009,0.048 O
0.038 O
and O
0.028 O
respectively O
) O
, O
but O
not O
in O
other O
outcome O
measures O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Long O
lines O
displayed O
markedly O
prolonged O
survival B-outcome ['Mortality']
times I-outcome ['Mortality']
and O
reduced O
phlebitis B-outcome ['Physiological-Clinical']
compared O
with O
short O
lines O
. O
['Mortality', 'Physiological-Clinical']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Mean O
airway B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
18?3 O
cm O
H2O O
during O
conventional O
mechanical O
ventilation O
and O
was O
increased O
until O
33?3 O
cm O
H2O O
at O
high-frequency O
oscillatory O
ventilation+15 O
. O
['Physiological-Clinical']

There O
are O
three O
critical O
points O
in O
laparoscopic O
hysterectomy O
. O
[]

Serial O
measurements O
of O
these O
neurohormones O
may O
serve O
as O
useful O
surrogate O
markers O
of O
ventricular B-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
and O
prognosticators O
for O
clinical O
risk O
stratification O
. O
['Physiological-Clinical']

The O
purpose O
of O
the O
trial O
was O
to O
test O
the O
effects O
of O
alcohol O
reduction O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Azithromycin O
was O
widely O
distributed O
within O
the O
lower O
respiratory O
tract O
; O
sustained B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
were O
detectable O
at O
the O
last O
sampling O
time O
( O
204 O
h O
) O
in O
lung O
tissue O
and O
bronchial O
washing O
, O
with O
long O
terminal O
half-lives O
of O
132.86 O
and O
74.32 O
h O
at O
500 O
mg O
daily O
and O
133.32 O
and O
70.5 O
h O
at O
1000 O
mg O
daily O
, O
respectively O
. O
['Physiological-Clinical']

Research O
Units O
on O
Pediatric O
Psychopharmacology O
. O
[]

Tramadol O
suppository O
versus O
placebo O
for O
the O
relief O
of O
perineal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
perineorrhaphy O
: O
a O
randomized O
controlled O
trial O
in O
Thailand O
. O
['Physiological-Clinical']

15 O
of O
16 O
patients O
( O
93.8 O
% O
) O
given O
tinidazole O
were O
cured B-outcome ['Physiological-Clinical']
and O
the O
mean O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
was O
4 O
days O
( O
range O
3 O
to O
6 O
days O
) O
. O
['Physiological-Clinical', 'Life-Impact']

It O
is O
suggested O
, O
in O
the O
light O
of O
previous O
findings O
, O
that O
the O
inhibitory O
effect O
of O
ANF O
represents O
a O
non-selective O
action O
of O
ANF O
on O
aldosterone B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
Although O
peripheral O
cryotherapy O
decreases O
the O
incidence O
of O
unfavorable O
anatomic O
outcomes O
in O
threshold O
retinopathy O
of O
prematurity O
( O
ROP O
) O
, O
apnea O
, O
bradycardia O
, O
and O
lid O
edema O
can O
occur O
. O
[]

These O
data O
support O
the O
prophylactic O
value O
of O
corticosteroid O
treatment O
in O
patients O
at O
high O
risk O
for O
the O
fat B-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, O
particularly O
if O
several O
unfavorable O
predictors O
are O
present O
. O
['Physiological-Clinical']

Study O
of O
the O
therapeutic O
effects O
of O
a O
hippotherapy O
simulator O
in O
children O
with O
cerebral O
palsy O
: O
a O
stratified O
single-blind O
randomized O
controlled O
trial O
. O
[]

However O
, O
randomized O
comparisons O
are O
lacking O
. O
[]

METHODS O
We O
conducted O
a O
pilot O
, O
randomized O
, O
open-label O
study O
of O
28-day O
ddI-EC O
capsules O
monotherapy-administered O
in O
a O
fasted O
state O
( O
group O
1 O
, O
n=11 O
) O
or O
with O
food O
( O
group O
2 O
, O
n=10 O
) O
to O
treatment-na?ve O
chronically O
HIV-1-infected O
individuals O
. O
[]

Modulation O
of O
oxidant O
stress O
in O
vivo O
in O
chronic O
cigarette O
smokers O
. O
[]

Overall O
37.7 O
% O
participants O
had O
uncontrolled O
blood O
pressure O
; O
the O
mean O
body O
mass O
index O
( O
BMI O
) O
was O
in O
the O
obese O
range O
( O
32.4 O
) O
and O
21.8 O
% O
had O
diabetes O
. O
[]

OBJECTIVE O
To O
determine O
concentrations O
of O
ofloxacin O
and O
ciprofloxacin O
hydrochloride O
in O
aqueous O
humor O
after O
topical O
or O
combined O
topical O
and O
oral O
administration O
in O
eyes O
with O
filtering O
blebs O
. O
[]

This O
sample O
size O
will O
allow O
for O
the O
detection O
of O
a O
33 O
% O
decrease O
in O
2-year O
mortality B-outcome ['Mortality']
( O
20 O
% O
vs O
30 O
% O
) O
in O
the O
treated O
patients O
compared O
with O
those O
in O
the O
placebo O
group O
, O
with O
a O
power O
of O
0.90 O
and O
a O
2-sided O
alpha O
level O
of O
0.05 O
. O
['Mortality']

Patients O
were O
re-evaluated O
after O
5 O
weeks O
of O
therapy O
and O
at O
the O
end O
of O
therapy O
( O
10 O
weeks O
) O
. O
[]

No O
patients O
were O
excluded O
from O
the O
study O
due O
to O
side O
effects O
. O
[]

Blood B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
for O
cultures O
were O
obtained O
30 O
s O
after O
each O
of O
13 O
dental O
operative O
procedures O
in O
735 O
anesthetized O
children O
aged O
2-16 O
years O
. O
['Physiological-Clinical']

Each O
is O
effective O
for O
post-thoracotomy O
pain B-outcome ['Physiological-Clinical']
relief O
. O
['Physiological-Clinical']

Success O
was O
defined O
as O
> O
or=20 O
% O
reduction O
in O
IOP B-outcome ['Physiological-Clinical']
without O
further O
glaucoma O
intervention O
. O
['Physiological-Clinical']

Many O
patients O
with O
venous O
thromboembolism O
are O
being O
treated O
with O
low O
molecular O
weight O
heparin O
for O
extended O
periods O
of O
time O
. O
[]

The O
same O
group O
of O
30 O
senior O
medical O
students O
used O
in O
the O
first O
study O
was O
used O
as O
novice O
raters O
. O
[]

A O
randomized O
controlled O
trial O
of O
a O
health-promotion O
programme O
and O
its O
effect O
on O
ADL B-outcome ['Life-Impact']
dependence O
and O
self-reported O
health B-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
for O
the O
elderly O
visually O
impaired O
. O
['Life-Impact', 'Physiological-Clinical']

Is O
FlexiT O
non-inferior O
to O
NovaT O
when O
inserted O
immediately O
after O
first-trimester O
abortion O
? O
[]

Participants O
were O
tested O
at O
baseline O
, O
8 O
, O
and O
12 O
months O
. O
[]

The O
changes O
were O
not O
correlated O
with O
stenosis B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
and O
plaque B-outcome ['Physiological-Clinical']
area O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Our O
data O
suggest O
that O
osteocalcin O
, O
a O
useful O
followup O
variable O
of O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
, O
is O
changed O
significantly O
( O
p O
< O
0.02 O
) O
in O
patients O
with O
RA O
regarding O
inflammatory B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

We O
tested O
the O
hypothesis O
that O
gum O
elastic-bougie-guided O
insertion O
of O
the O
ProSeal O
Laryngeal O
Mask O
Airway O
is O
more O
frequently O
successful O
than O
introducer O
tool O
guided O
insertion O
after O
failed O
digital O
insertion O
. O
[]

Seventy-one O
elderly O
volunteers O
, O
aged O
61-89 O
years O
, O
enrolled O
in O
a O
prospective O
randomized O
, O
double-blind O
study O
to O
receive O
either O
DHEA O
( O
50 O
mg O
qd O
p.o O
. O
[]

Two O
days O
later O
, O
the O
intervention O
arms O
were O
crossed O
over O
. O
[]

6 O
. O
[]

Bovine O
carotid O
artery O
heterografts O
versus O
polytetrafluoroethylene O
grafts O
. O
[]

CONCLUSION O
An O
immunization O
prompting O
system O
in O
a O
hospital-based O
pediatric O
resident O
continuity O
clinic O
reduced O
missed O
[]

In O
45 O
young O
men O
carrying O
five O
different O
allele O
combinations O
, O
we O
investigated O
the O
effects O
of O
prolonged O
waking O
and O
2 O
? O
[]

Patients O
were O
more O
likely O
to O
give O
lifestyle B-outcome ['Life-Impact']
information O
and O
approval B-outcome ['Life-Impact']
comments O
on O
the O
telephone O
, O
and O
used O
more O
closed-ended O
questions B-outcome ['Life-Impact']
on O
the O
videophone O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
Most O
measures O
of O
hip O
function O
did O
not O
differ O
between O
the O
two O
groups O
. O
[]

In O
infants O
whose O
mothers O
declared O
they O
intended O
to O
breastfeed O
, O
the O
cumulative O
rate O
of O
HIV O
transmission O
at O
12 O
months O
was O
5?6 O
% O
( O
95 O
% O
CI O
3?4-8?9 O
% O
) O
in O
the O
triple O
antiretroviral O
group O
compared O
with O
10?7 O
% O
( O
7?6-14?8 O
% O
) O
in O
the O
zidovudine O
and O
single-dose O
nevirapine O
group O
( O
p=0?02 O
) O
. O
[]

Age-matched O
typical O
children O
were O
also O
assessed O
. O
[]

CONCLUSIONS O
In O
order O
to O
detect O
95 O
% O
of O
1-cm O
inferolateral O
arthrotomies O
of O
the O
knee O
with O
use O
of O
the O
saline O
solution O
load O
test O
, O
155 O
mL O
must O
be O
injected O
. O
[]

There O
was O
no O
significant O
treatment O
effect O
for O
any O
outcome O
, O
with O
no O
significant O
interactions O
between O
treatment O
and O
demographics O
, O
or O
cytarabine O
randomization O
. O
[]

Thus O
, O
it O
appears O
that O
at O
least O
some O
rural O
breast O
cancer O
survivors O
can O
and O
will O
participate O
in O
a O
larger O
trial O
and O
will O
maintain O
their O
participation O
and O
that O
those O
that O
do O
participate O
experience O
significant O
QOL B-outcome ['Life-Impact']
benefit O
. O
['Life-Impact']

Our O
results O
suggest O
that O
the O
fall O
in O
serum B-outcome ['Physiological-Clinical']
G-CSF I-outcome ['Physiological-Clinical']
levels O
during O
rhG-CSF O
therapy O
may O
result O
from O
increased O
clearance O
and/or O
decreased O
absorption O
of O
rhG-CSF O
, O
two O
processes O
related O
to O
circulating O
neutrophil O
counts O
. O
['Physiological-Clinical']

BACKGROUND O
Acute O
invasive O
diarrhea O
is O
a O
potentially O
serious O
condition O
in O
children O
. O
[]

RESULTS O
Meals O
with O
rye O
bran O
gave O
a O
lower O
postprandial B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
peak I-outcome ['Physiological-Clinical']
when O
compared O
with O
the O
control O
meal O
, O
and O
this O
effect O
was O
more O
pronounced O
in O
women O
compared O
to O
men O
. O
['Physiological-Clinical']

The O
observed B-outcome ['Resource-use']
marginal I-outcome ['Resource-use']
cost I-outcome ['Resource-use']
of O
the O
initial O
conventional O
consultation O
was O
47.13 O
Pounds O
for O
urban O
patients O
and O
48.77 O
Pounds O
for O
rural O
patients O
. O
['Resource-use']

CONCLUSION O
Proactive O
IVR O
outreach O
is O
a O
promising O
tool O
to O
engage O
low O
income O
, O
relapsed O
smokers O
back O
into O
a O
new O
cycle O
of O
treatment O
. O
[]

The O
aim O
of O
the O
trial O
is O
to O
evaluate O
the O
treatment O
of O
depressive O
disorder O
in O
primary O
care O
in O
the O
Netherlands O
by O
means O
of O
an O
adapted O
collaborative O
care O
framework O
, O
including O
contracting O
and O
adherence-improving O
strategies O
, O
combined O
with O
Problem O
Solving O
Treatment O
and O
antidepressant O
medication O
according O
to O
a O
treatment O
algorithm O
. O
[]

METHODS O
One O
hundred O
and O
fifty O
patients O
with O
low O
back O
pain O
for O
at O
least O
eight O
weeks O
and O
referred O
to O
a O
specialized O
secondary O
sector O
outpatient O
back O
pain O
clinic O
are O
included O
in O
the O
study O
. O
[]

However O
, O
this O
difference O
was O
not O
statistically O
significant O
( O
p=0.78 O
) O
. O
[]

These O
differences O
were O
observed O
in O
several O
of O
the O
subjects O
in O
experiment O
I O
. O
[]

The O
patients O
were O
assessed O
before O
and O
after O
Grenz O
ray O
therapy O
and O
were O
followed-up O
for O
6 O
months O
. O
[]

Main O
end O
points O
of O
the O
study O
included O
the O
3-month O
dichotomized O
Glasgow O
Outcome O
Score O
( O
GOS O
) O
, O
development B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
delayed I-outcome ['Physiological-Clinical']
ischemic I-outcome ['Physiological-Clinical']
neurological I-outcome ['Physiological-Clinical']
deficit I-outcome ['Physiological-Clinical']
( O
DIND O
) O
, O
occurrence O
of O
Transcranial B-outcome ['Physiological-Clinical']
Doppler I-outcome ['Physiological-Clinical']
( O
TCD O
) O
vasospasm B-outcome ['Physiological-Clinical']
, O
and O
length O
of O
stay B-outcome ['Resource-use']
in O
the O
ICU B-outcome ['Resource-use']
and O
hospital O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use']

RESULTS O
Of O
the O
60 O
patients O
with O
complete O
data O
, O
none O
had O
acute O
CIN O
( O
increase O
in O
serum O
creatinine O
concentration O
> O
or O
= O
0.044 O
mmol/l O
, O
48 O
h O
after O
administration O
of O
contrast O
agent O
) O
. O
[]

CONCLUSION O
Increased O
baseline O
concentrations B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hsCRP I-outcome ['Physiological-Clinical']
are O
strongly O
associated O
with O
mortality B-outcome ['Mortality']
and O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
across O
the O
ACS O
spectrum O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

Fifteen O
patients O
with O
COPD O
and O
nine O
age-matched O
healthy O
subjects O
performed O
, O
7 O
days O
apart O
, O
two O
CWTs O
up O
to O
exhaustion O
at O
80 O
% O
of O
their O
predetermined O
maximal O
work O
capacity O
. O
[]

Black O
tea O
treatment O
was O
associated O
with O
the O
highest O
rates O
of O
dropout B-outcome ['Life-Impact']
among O
smokers O
( O
37 O
% O
) O
, O
but O
was O
associated O
with O
the O
lowest O
rate O
of O
dropout O
among O
non-smokers O
( O
4 O
% O
) O
. O
['Life-Impact']

Short-term O
intravenous O
antibiotic O
treatment O
of O
acute O
hematogenous O
bone O
and O
joint O
infection O
in O
children O
: O
a O
prospective O
randomized O
trial O
. O
[]

Blinded O
clinical O
judges O
rated O
change O
from O
baseline O
to O
4 O
and O
8 O
weeks O
on O
a O
9-point O
scale O
( O
1 O
= O
normalized O
, O
5 O
= O
unchanged O
, O
9 O
= O
disastrous O
) O
; O
94 O
participants O
had O
usable O
data O
. O
[]

A O
family-based O
, O
cognitive O
behavioural O
treatment O
for O
anxiety O
in O
47 O
children O
with O
comorbid O
anxiety O
disorders O
and O
High O
Functioning O
Autism O
Spectrum O
Disorder O
( O
HFA O
) O
was O
evaluated O
. O
[]

Retrospective O
evaluation O
showed O
that O
the O
volume O
of O
the O
solution O
influenced O
the O
degree O
of O
anesthesia O
. O
[]

DESIGN O
Randomized O
control O
trial O
. O
[]

RESULTS O
In O
an O
intention-to-treat O
analysis O
, O
seizure B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
following I-outcome ['Physiological-Clinical']
CBT I-outcome ['Physiological-Clinical']
was O
superior O
at O
treatment O
end O
( O
group O
x O
time O
interaction O
p O
< O
0.0001 O
; O
large O
to O
medium O
effect O
sizes O
) O
. O
['Physiological-Clinical']

There O
was O
, O
however O
, O
no O
significant O
difference O
in O
distribution O
of O
allele O
genotypes O
between O
all O
lung B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
cases O
and O
the O
controls O
, O
nor O
among O
histological O
types O
for O
the O
cases O
. O
['Physiological-Clinical']

Within O
the O
limitations O
of O
the O
present O
study O
, O
adhesive O
luting O
with O
RXU O
with O
or O
without O
selective O
enamel O
etching O
can O
be O
recommended O
. O
[]

Based O
on O
the O
biochemical O
and O
clinical O
data O
, O
no O
statistically O
significant O
differences O
in O
the O
development O
of O
postoperative B-outcome ['Physiological-Clinical']
hypoparathyroidism I-outcome ['Physiological-Clinical']
in O
relation O
to O
performed O
surgical O
techniques O
were O
observed O
. O
['Physiological-Clinical']

Tests O
were O
done O
on O
T O
cell B-outcome ['Physiological-Clinical']
subpopulations I-outcome ['Physiological-Clinical']
, O
NK B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
humoral B-outcome ['Physiological-Clinical']
immunity I-outcome ['Physiological-Clinical']
and O
leukocyte B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
before O
treatment O
and O
after O
4 O
courses O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
increasing O
the O
doses O
of O
morphine O
and O
of O
droperidol O
. O
[]

AIMS O
To O
assess O
whether O
aerobic O
training O
leads O
to O
a O
more O
active B-outcome ['Life-Impact']
lifestyle I-outcome ['Life-Impact']
and O
improved O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
CHF O
. O
['Life-Impact']

The O
involvement O
of O
neurotransmitters O
such O
as O
5-HT O
has O
been O
suggested O
in O
neuropsychiatric O
disorders O
and O
particularly O
in O
autistic O
disorder O
. O
[]

Effect O
of O
explicit O
instruction O
on O
Japanese O
Verbal O
Learning O
Test O
in O
schizophrenia O
patients O
. O
[]

Nine O
normal O
volunteers O
and O
15 O
patients O
with O
pituitary O
disorders O
were O
given O
a O
combined O
test O
of O
anterior O
pituitary O
function O
using O
four O
hypothalamic O
releasing O
factors O
and O
arginine O
vasopressin O
. O
[]

Syncope O
Evaluation O
in O
the O
Emergency O
Department O
Study O
( O
SEEDS O
) O
: O
a O
multidisciplinary O
approach O
to O
syncope O
management O
. O
[]

One O
hundred O
patients O
received O
1 O
gm O
of O
erythromycin O
base O
by O
mouth O
per O
day O
for O
4 O
weeks O
, O
followed O
by O
333 O
mg/day O
for O
8 O
weeks O
, O
plus O
placebo O
for O
tetracycline O
. O
[]

The O
clinical O
efficacy O
was O
the O
same O
although O
the O
alleviation O
of O
vasomotor B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
was O
somewhat O
slower O
in O
those O
women O
receiving O
preparation O
A O
. O
['Physiological-Clinical']

Oral O
magnesium O
supplementation O
in O
children O
with O
cystic O
fibrosis O
improves O
clinical B-outcome ['Physiological-Clinical']
and O
functional B-outcome ['Physiological-Clinical']
variables O
: O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
crossover O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Heart O
failure O
therapy O
guided O
by O
N-terminal O
BNP O
and O
symptom-guided O
therapy O
resulted O
in O
similar O
rates O
of O
survival B-outcome ['Mortality']
free O
of O
all-cause B-outcome ['Resource-use']
hospitalizations I-outcome ['Resource-use']
( O
41 O
% O
vs O
40 O
% O
, O
respectively O
; O
hazard O
ratio O
[ O
HR O
] O
, O
0.91 O
[ O
95 O
% O
CI O
, O
0.72-1.14 O
] O
; O
P O
= O
.39 O
) O
. O
['Mortality', 'Resource-use']

TRIAL O
REGISTRATION O
Clinicaltrials.gov O
Identifier O
: O
NCT00626587 O
. O
[]

PURPOSE O
This O
study O
was O
undertaken O
with O
the O
null O
hypothesis O
that O
in O
patients O
, O
fully O
denate O
or O
with O
1 O
or O
2 O
teeth O
missing O
and O
older O
than O
25 O
years O
, O
mastication O
does O
not O
affect O
late O
mandibular B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
after O
surgical O
removal O
of O
impacted O
third O
molars O
( O
M3s O
) O
associated O
with O
no O
gross O
pathology O
. O
['Physiological-Clinical']

We O
offered O
2 O
individual O
and O
9 O
group O
DASH O
sessions O
to O
intervention O
participants O
and O
1 O
individual O
session O
and O
printed O
DASH O
educational O
materials O
to O
control O
participants O
. O
[]

BACKGROUND O
AND O
AIMS O
This O
pilot O
study O
tested O
the O
efficacy O
of O
a O
developmentally O
modified O
CBT O
for O
young O
children O
with O
Autism O
Spectrum O
Disorders O
( O
ASD O
) O
to O
teach O
emotion B-outcome ['Life-Impact']
regulation I-outcome ['Life-Impact']
strategies O
for O
reducing O
anger B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
, O
commonly O
noted O
problems O
in O
this O
population O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

We O
performed O
a O
prospective O
randomized O
trial O
to O
evaluate O
the O
optimum B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
stenting I-outcome ['Life-Impact']
after O
endopyelotomy O
. O
['Life-Impact']

The O
rate O
of O
blood O
transfusion O
in O
the O
two O
groups O
was O
similar O
( O
P O
= O
NS O
) O
. O
[]

EXPERIMENTAL O
DESIGN O
Patients O
with O
newly O
metastatic O
disease O
or O
recurred O
after O
adjuvant O
tamoxifen O
( O
stratum O
1 O
) O
, O
or O
recurred O
during/after O
adjuvant O
aromatase O
inhibitor O
( O
AI O
) O
or O
after O
failed O
first-line O
AI O
( O
stratum O
2 O
) O
, O
were O
eligible O
. O
[]

Timing O
of O
antibiotic O
administration O
in O
knee O
replacement O
under O
tourniquet O
. O
[]

Twenty-nine O
patients O
with O
attacks O
of O
distal O
ulcerative O
colitis O
were O
treated O
randomly O
with O
3 O
g O
5-aminosalicylic O
acid O
( O
5-ASA O
) O
or O
30 O
mg O
of O
prednisolone O
phosphate O
sodium O
( O
PP O
) O
enemas O
( O
40 O
ml O
) O
. O
[]

Unique O
attributes O
render O
it O
a O
promising O
candidate O
for O
prophylactic O
mass O
immunization O
, O
even O
in O
subjects O
for O
whom O
conventional O
smallpox O
vaccines O
are O
contraindicated O
. O
[]

The O
results O
indicate O
that O
combined O
stress O
significantly O
( O
p O
< O
0.05 O
) O
reduced O
body B-outcome ['Physiological-Clinical']
weight O
, O
oestrus B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
, O
birth B-outcome ['Physiological-Clinical']
weight O
of O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Anesthesia O
induction O
and O
perioperative O
management O
followed O
the O
same O
protocols O
in O
the O
two O
groups O
, O
and O
in O
UTI O
group O
, O
patients O
received O
5000 O
U/kg O
UTI O
while O
those O
in O
the O
control O
group O
were O
given O
the O
same O
volume O
of O
saline O
. O
[]

Children O
ages O
6-12 O
with O
ASD O
were O
randomly O
assigned O
to O
a O
fine O
motor O
or O
SI O
treatment O
group O
. O
[]

RESULTS O
There O
were O
no O
between O
group O
differences O
in O
mortality B-outcome ['Mortality']
( O
hazard O
ratio O
= O
1.41 O
, O
0.50 O
to O
3.97 O
; O
P O
= O
0.514 O
) O
or O
CHF B-outcome ['Resource-use']
hospitalizations I-outcome ['Resource-use']
( O
incidence O
rate O
ratio O
[ O
IRR O
] O
= O
1.74 O
95 O
% O
CI O
: O
0.85-3.60 O
P O
= O
0.131 O
) O
over O
the O
6 O
month O
follow-up O
period O
. O
['Mortality', 'Resource-use']

Efficacy O
of O
Contractubex O
gel O
in O
the O
treatment O
of O
fresh O
scars O
after O
thoracic O
surgery O
in O
children O
and O
adolescents O
. O
[]

In O
Group O
B O
, O
the O
MMC O
+ O
HCFU O
group O
received O
the O
same O
treatment O
in O
Group O
A O
, O
but O
with O
the O
addition O
of O
600 O
mg/day O
of O
HCFU O
from O
the O
second O
week O
, O
orally O
for O
at O
least O
one O
year O
. O
[]

We O
compared O
the O
effects O
of O
one O
vs O
two O
daily O
bouts O
of O
walking O
on O
aerobic B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
numbers O
of O
deflations O
in O
both O
groups O
were O
noted O
and O
compared O
by O
Mann-Whitney O
U-test O
( O
P O
< O
0.05 O
) O
. O
[]

Modified O
constraint-induced O
movement O
therapy O
improved O
upper O
limb O
function O
in O
subacute O
poststroke O
patients O
: O
a O
small-scale O
clinical O
trial O
. O
[]

Infants O
also O
received O
a O
prebiotic O
galacto-oligosaccharide O
or O
placebo O
. O
[]

Sensitivity O
and O
criterion O
changes O
contributed O
jointly O
to O
the O
slow O
buildup O
of O
perceptual B-outcome ['Life-Impact']
awareness I-outcome ['Life-Impact']
. O
['Life-Impact']

BACKGROUND O
A O
variety O
of O
photorejuvenative O
techniques O
have O
been O
utilized O
to O
reverse O
the O
signs O
of O
cutaneous O
photoaging O
, O
including O
ablative O
and O
nonablative O
laser O
resurfacing O
as O
well O
as O
light-based O
devices O
. O
[]

Scars B-outcome ['Physiological-Clinical']
that O
were O
treated O
with O
garments O
from O
a O
normal O
compression O
class O
did O
score O
significantly O
better O
for O
thickness B-outcome ['Physiological-Clinical']
compared O
to O
the O
low O
compression O
class O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
values O
of O
fingertip O
skin O
temperature O
and O
laser O
Doppler O
flux O
after O
17 O
beta-oestradiol O
tended O
to O
be O
higher O
only O
the O
precooling O
values O
in O
the O
healthy O
subjects O
reached O
significance O
: O
fingertip O
skin O
temperature O
respectively O
with O
placebo O
and O
with O
oestradiol O
( O
mean O
( O
SD O
) O
) O
: O
32.7 O
( O
1.0 O
) O
and O
33.1 O
( O
0.8 O
) O
degrees O
C O
; O
laser O
Doppler O
flux O
with O
placebo O
and O
with O
oestradiol O
: O
33.6 O
( O
11.7 O
) O
and O
42.2 O
( O
9.5 O
) O
perfusion O
units O
; O
both O
P O
< O
0.05 O
) O
. O
( O
[]

RESULTS O
The O
mean O
( O
SD O
) O
exposure B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
N2O I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
sevoflurane I-outcome ['Physiological-Clinical']
in O
the O
group O
without O
an O
extractor O
was O
423 O
( O
290 O
) O
and O
12 O
( O
10.9 O
) O
parts O
per O
million O
( O
ppm O
) O
, O
respectively O
. O
['Physiological-Clinical']

[ O
EMLA O
cream O
( O
lidocaine/prilocaine O
) O
versus O
infiltration O
analgesia O
with O
carbocaine O
( O
mepivacaine O
) O
in O
vasectomy O
] O
. O
[]

Testosterone O
administered O
alone O
or O
in O
combination O
with O
progestogens O
in O
male O
contraception O
induces O
reversible O
oligo-azoospermia O
, O
but O
its O
effects O
on O
body O
composition O
and O
metabolism O
are O
less O
known O
. O
[]

In O
the O
respiration O
chamber O
subjects O
were O
randomly O
assigned O
to O
a O
high-fat O
( O
Hi.F O
) O
diet O
( O
60 O
% O
of O
energy O
( O
En O
% O
) O
fat O
) O
or O
a O
reduced-fat O
( O
Red.F O
) O
diet O
( O
30 O
En O
% O
fat O
) O
. O
[]

The O
results O
also O
showed O
that O
when O
the O
light-cured O
glass-ionomer O
liner O
was O
placed O
0.3 O
mm O
from O
the O
cavosurface O
margin O
under O
composite O
resin O
restoration O
, O
the O
artificial B-outcome ['Physiological-Clinical']
recurrent I-outcome ['Physiological-Clinical']
caries I-outcome ['Physiological-Clinical']
reduced I-outcome ['Physiological-Clinical']
significantly O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
After O
treatment O
, O
the O
amount O
of O
activated B-outcome ['Physiological-Clinical']
CECs I-outcome ['Physiological-Clinical']
decreased O
significantly O
in O
clinical O
benefit O
cases O
( O
P O
= O
0.021 O
in O
chemotherapy O
alone O
, O
P O
= O
0.001 O
in O
chemotherapy O
plus O
Endostar O
) O
, O
increased O
in O
disease B-outcome ['Physiological-Clinical']
progressive I-outcome ['Physiological-Clinical']
cases O
( O
P O
= O
0.015 O
in O
chemotherapy O
alone O
, O
but O
P O
= O
0.293 O
in O
chemotherapy O
with O
Endotatar O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Hematologic B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
was O
greater O
in O
the O
melphalan-platinum O
group O
. O
['Physiological-Clinical']

Three O
upper O
limb O
function O
tests O
, O
developed O
for O
this O
study O
, O
were O
used O
as O
outcome O
measures O
. O
[]

Joint O
engagement O
maintained O
over O
time O
for O
the O
CMM O
group O
, O
and O
initiating O
joint O
attention O
maintained O
for O
both O
groups O
over O
time O
. O
[]

The O
patients O
were O
assessed O
clinically O
and O
radiographically O
with O
the O
rating O
system O
of O
the O
Knee B-outcome ['Physiological-Clinical']
Society O
and O
with O
the O
Western O
Ontario O
and O
McMaster O
Universities O
Osteoarthritis O
Index O
( O
WOMAC O
) O
score O
at O
three O
months O
, O
one O
year O
, O
and O
annually O
thereafter O
. O
['Physiological-Clinical']

INTERVENTIONS O
Neurosurgical O
patients O
' O
hands O
and O
forearms O
were O
covered O
for O
15 O
minutes O
with O
a O
carbon O
fibre O
heating O
mitt O
. O
[]

Experimentally O
, O
two O
slotted O
nails O
, O
the O
Grosse-Kempf O
nail O
and O
the O
AO/ASIF O
universal O
femoral O
nail O
, O
were O
compared O
to O
the O
non-slotted O
Grosse-Kempf O
nail O
and O
control O
bone O
using O
a O
cadaver O
femoral O
osteotomy O
. O
[]

Cyclo-oxygenase O
2 O
inhibitors O
such O
as O
parecoxib O
are O
not O
associated O
with O
a O
bleeding O
risk O
and O
would O
be O
welcome O
analgesics O
if O
shown O
to O
be O
effective O
. O
[]

Two O
rural O
and O
two O
metropolitan O
regions O
were O
randomly O
allocated O
to O
intervention O
groups O
( O
n O
= O
70 O
) O
or O
control O
( O
n O
= O
35 O
) O
. O
[]

When O
subsequently O
asked O
generic O
questions O
about O
real O
nerps O
, O
children O
's O
responses B-outcome ['Life-Impact']
suggested O
that O
they O
had O
learned B-outcome ['Life-Impact']
general I-outcome ['Life-Impact']
facts I-outcome ['Life-Impact']
( O
e.g. O
, O
nerps O
dislike O
carrots O
) O
. O
['Life-Impact', 'Life-Impact']

SD O
120.8? O
? O
[]

At O
the O
completion O
of O
therapy O
, O
the O
disease O
in O
70 O
of O
72 O
patients O
was O
in O
complete O
remission O
( O
one O
failure B-outcome ['Physiological-Clinical']
, O
one O
death B-outcome ['Mortality']
during O
treatment O
) O
. O
['Physiological-Clinical', 'Mortality']

Effect O
of O
marine O
oils O
supplementation O
on O
coagulation O
and O
cellular O
activation O
in O
whole O
blood O
. O
[]

Cross-over O
trial O
of O
intensive O
monotherapy O
with O
atorvastatin O
and O
combined O
therapy O
with O
atorvastatin O
and O
colestimide O
for O
Japanese O
familial O
hypercholesterolemia O
. O
[]

Behavioral O
symptoms O
were O
assessed O
using O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
( O
ABC O
) O
, O
Nisonger O
Child O
Behavior O
Rating O
Form O
, O
and O
Clinical O
Global O
Impression-Change O
. O
['Life-Impact']

RESULTS O
Liver B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
significantly I-outcome ['Physiological-Clinical']
decreased O
from O
1595 O
+/- O
478 O
ml O
to O
1524 O
+/- O
453 O
ml O
with O
octreotide O
whereas O
they O
did O
not O
appreciably O
change O
with O
placebo O
. O
['Physiological-Clinical']

CONCLUSIONS O
This O
project O
provides O
evidence O
that O
a O
community-based O
collaboration O
with O
primary O
care O
providers O
can O
improve O
function B-outcome ['Life-Impact']
and O
reduce O
inpatient B-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
in O
chronically O
ill O
older O
adults O
. O
['Life-Impact', 'Resource-use']

We O
report O
data O
from O
a O
recent O
trial O
, O
which O
, O
for O
the O
first O
time O
, O
assessed O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
lanthanum O
carbonate O
treatment O
, O
compared O
with O
placebo O
, O
in O
Chinese O
patients O
with O
ESRD O
. O
['Life-Impact']

Effects O
of O
a O
leisure O
programme O
on O
quality O
of O
life O
and O
stress O
of O
individuals O
with O
ASD O
. O
[]

Different O
underlying O
mechanisms O
have O
been O
proposed O
, O
and O
allogeneic O
leucocytes O
in O
transfused O
blood O
have O
been O
suggested O
to O
contribute O
to O
this O
phenomenon O
. O
[]

DSM-IV-TR O
) O
criteria O
for O
an O
autism O
spectrum O
disorder O
( O
ASD O
) O
on O
the O
Autism O
Diagnostic O
Interview-Revised O
( O
ADI-R O
) O
and O
the O
Autism O
Diagnostic O
Observation O
Schedule O
( O
ADOS O
) O
, O
and O
had O
significant O
symptoms O
of O
attention-deficit/hyperactivity O
disorder O
( O
ADHD O
) O
. O
[]

Mecamylamine O
appears O
to O
have O
increased O
cigarette O
smoking O
by O
decreasing O
the O
effective O
dose O
level O
of O
nicotine O
available O
from O
cigarette O
smoking O
. O
[]

Approximately O
20 O
% O
of O
patients O
had O
significantly O
increased O
levels O
of O
circulating B-outcome ['Physiological-Clinical']
CD19+ I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
results O
of O
the O
releasing O
factor O
combined O
test O
with O
arginine O
vasopressin O
were O
compared O
in O
the O
same O
subjects O
with O
a O
conventional O
combined O
test O
using O
insulin O
together O
with O
thyrotrophin O
releasing O
hormone O
and O
luteinising O
hormone O
releasing O
hormone O
. O
[]

BACKGROUND O
When O
genital O
atrophy O
exists O
, O
systemic O
hormone O
therapy O
( O
HT O
) O
has O
a O
timing O
until O
to O
induce O
vaginal O
proliferation O
and O
symptomatic O
relieve O
. O
[]

Significant O
correlations O
were O
found O
between O
the O
child B-outcome ['Physiological-Clinical']
's O
['Physiological-Clinical']

clinic O
Main O
outcome O
measures O
were O
the O
numbers O
of O
individuals O
in O
each O
group O
receiving O
immunisation O
, O
and O
practice O
costs B-outcome ['Resource-use']
of O
a O
telephone-appointing O
programme O
. O
['Resource-use']

METHODS O
From O
January O
2002 O
to O
May O
2008 O
, O
168 O
patients O
with O
cervical O
vertigo O
were O
randomly O
divided O
into O
treatment O
group O
( O
84 O
cases O
) O
and O
the O
control O
group O
( O
84 O
cases O
) O
, O
22 O
males O
and O
62 O
females O
in O
treatment O
group O
; O
24 O
males O
and O
60 O
females O
in O
control O
group O
. O
[]

Double O
blockade O
decreased O
R-R B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
and O
variability O
in O
both O
age O
groups O
( O
P O
< O
0.0001 O
) O
, O
but O
R-R O
intervals O
decreased O
less O
in O
older O
than O
in O
young O
subjects O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Venous B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
moved O
parallel O
to O
ascitic B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
, O
and O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
and O
urine B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
all O
improved O
sharply O
; O
then O
, O
as O
ascitic O
fluid O
continued O
to O
form O
, O
reducing O
vascular B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
urine O
flow O
, O
glomerular O
filtration O
rate O
, O
and O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
all O
decreased O
slowly O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Chronological O
age O
at O
onset O
of O
pubertal O
signs O
was O
less O
than O
8 O
yr O
in O
girls O
and O
less O
than O
9 O
yr O
in O
boys O
, O
and O
bone O
age O
was O
advanced O
over O
chronological O
age O
at O
least O
1 O
yr O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
( O
ITT O
) O
. O
[]

Use O
of O
the O
electrothermal O
bipolar O
vessel O
system O
( O
EBVS O
) O
in O
laparoscopic O
adrenalectomy O
: O
a O
prospective O
study O
. O
[]

Participants O
were O
trained O
to O
match O
probes O
to O
targets O
on O
the O
basis O
of O
shape O
or O
color O
with O
the O
relevant O
dimension O
shifting O
according O
to O
item O
context O
. O
[]

A O
phase O
II O
multicenter O
randomized O
clinical O
trial O
was O
subsequently O
designed O
. O
[]

Rectal O
pain O
thresholds O
and O
smooth O
muscle O
tone O
were O
measured O
with O
a O
barostat O
before O
and O
after O
treatment O
in O
18 O
patients O
( O
study O
I O
) O
, O
and O
treatment O
changes O
in O
heart O
rate O
, O
blood O
pressure O
, O
skin O
conductance O
, O
finger O
temperature O
, O
and O
forehead O
electromyographic O
activity O
were O
assessed O
in O
24 O
patients O
( O
study O
II O
) O
. O
[]

Rates O
were O
calculated O
as O
events/patient-year O
( O
based O
on O
total O
cumulative O
reported O
events O
and O
duration O
of O
treatment O
) O
for O
events O
that O
could O
recur O
during O
treatment O
. O
[]

[ O
Acute B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
and O
metabolic B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in O
interval O
and O
endurance O
training O
in O
selected O
patients O
following O
aortocoronary O
bypass O
operation O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
investigate O
the O
effects O
of O
potassium O
and O
calcium O
supplementation O
in O
table O
salt O
on O
reduction O
of O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
sodium B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
adolescents O
with O
higher O
blood O
pressure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Diameters O
of O
wheals O
and O
flares O
were O
measured O
10 O
min O
after O
and O
compared O
with O
control O
sites O
challenged O
with O
20 O
IU O
and O
200 O
IU O
anti-IgE O
in O
a O
5 O
% O
ethanol O
solution O
. O
[]

The O
perioperative O
increase O
in O
cortisol B-outcome ['Physiological-Clinical']
was O
similar O
in O
the O
two O
groups O
, O
despite O
the O
differences O
in O
ACTH O
responses O
. O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
significant O
differences O
within O
, O
or O
between O
, O
the O
control O
and O
test O
groups O
for O
age O
, O
gender O
, O
bone B-outcome ['Physiological-Clinical']
quality B-outcome ['Life-Impact']
or O
quantity O
, O
implant O
stability B-outcome ['Physiological-Clinical']
measurements O
at O
surgery B-outcome ['Resource-use']
, O
or O
implant B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Long-term O
use O
of O
Viozan O
( O
sibenadet O
HCl O
) O
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
: O
results O
of O
a O
1-year O
study O
. O
[]

OBJECTIVE O
To O
assess O
the O
effect O
of O
a O
high-calcium O
, O
fortified O
, O
low-fat O
milk O
drink O
with O
added O
vitamin O
D O
versus O
a O
low-calcium O
placebo O
drink O
on O
anthropometric O
measurements O
of O
postmenopausal O
women O
. O
[]

RESULTS O
The O
TF O
group O
reported O
a O
significantly O
greater O
increase O
in O
fruit B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
( O
0.3 O
serves/d O
P O
= O
0.031 O
) O
in O
comparison O
to O
GE O
and O
the O
C O
group O
. O
['Life-Impact']

Myoclonus B-outcome ['Physiological-Clinical']
occurred O
in O
seven O
patients O
. O
['Physiological-Clinical']

This O
method O
is O
better O
than O
taking O
Alendronate O
. O
[]

Blood O
samples O
were O
collected O
at O
6 O
, O
7 O
, O
and O
12 O
months O
. O
[]

The O
results O
did O
not O
show O
any O
significant O
differences O
among O
the O
groups O
regarding O
the O
main O
parameters O
like O
pH-value B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
different I-outcome ['Physiological-Clinical']
insufflation I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
etc O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVES O
Preoperative O
treatment O
with O
600 O
U/kg O
of O
recombinant O
human O
erythropoietin O
( O
r-HuEPO O
) O
effectively O
increases O
erythropoiesis B-outcome ['Physiological-Clinical']
in O
cancer O
patients O
. O
['Physiological-Clinical']

Urinary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
decreased O
from O
1.8+/-0.6 O
to O
0.8+/-0.4 O
g/day O
, O
( O
P O
< O
0.01 O
) O
in O
this O
group O
, O
and O
urinary B-outcome ['Physiological-Clinical']
podocyte I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
decreased O
from O
1.6+/-0.6 O
to O
0.9+/-0.4 O
cells/ml O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
IL-6 O
, O
IL-8 O
levels O
in O
the O
plasma O
and O
BALF O
collected O
at O
T O
( O
2 O
) O
-T O
( O
4 O
) O
increased O
significantly O
as O
compared O
with O
those O
in O
samples O
collected O
at O
T O
( O
1 O
) O
, O
and O
their O
peak O
concentration O
inplasma B-outcome ['Physiological-Clinical']
and O
BALF B-outcome ['Physiological-Clinical']
samples O
were O
similar O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Diltiazem O
is O
commonly O
used O
to O
treat O
atrial O
fibrillation O
or O
flutter O
( O
AFF O
) O
with O
rapid O
ventricular O
response O
( O
RVR O
) O
. O
[]

The O
results O
were O
, O
briefly O
, O
as O
follows O
: O
The O
incidence O
of O
leukopenia B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
groups O
receiving O
MPA O
in O
patients O
with O
breast O
and O
colorectal O
cancer O
( O
P O
less O
than O
0.02 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
The O
effect O
of O
L-arginine O
and O
L-citrulline O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
right B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
heart O
failure O
patients O
with O
preserved O
ejection O
fraction O
( O
HFpEF O
) O
is O
unknown O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Superior O
performance O
in O
pitch B-outcome ['Life-Impact']
discrimination I-outcome ['Life-Impact']
and O
categorization B-outcome ['Life-Impact']
extends O
previous O
findings O
of O
enhanced O
visual B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
to O
the O
auditory O
domain O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Pre-exposure O
studies O
with O
purified O
chick O
embryo O
cell O
culture O
rabies O
vaccine O
and O
human O
diploid O
cell O
vaccine O
: O
serological O
and O
clinical O
responses O
in O
man O
. O
[]

For O
women O
randomized O
to O
ETT O
, O
ECG O
results O
were O
normal O
in O
64 O
% O
, O
indeterminate O
in O
16 O
% O
, O
and O
abnormal O
in O
20 O
% O
. O
[]

The O
average O
CMV-associated B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
per O
patient O
( O
in O
2001 O
euros O
) O
were O
2,449+/-1,178 O
, O
2,485+/-581 O
, O
and O
4,259+/-4,616 O
in O
the O
GAN O
, O
VAL O
, O
and O
C O
groups O
, O
respectively O
. O
['Resource-use']

The O
possible O
involvement O
of O
endogenous B-outcome ['Physiological-Clinical']
opioids I-outcome ['Physiological-Clinical']
in O
the O
mechanism O
underlying O
the O
abnormal B-outcome ['Physiological-Clinical']
TSH I-outcome ['Physiological-Clinical']
response O
to O
TRH B-outcome ['Physiological-Clinical']
was O
also O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Since O
the O
90 O
% O
confidence O
intervals O
for O
the O
test/reference O
mean O
ratio O
of O
the O
In-transformed O
pharmacokinetic O
variables O
C O
( O
max O
) O
AUC O
( O
0-t O
) O
and O
AUC O
( O
0-infinity O
) O
were O
clearly O
within O
the O
conventional O
bioequivalence O
range O
of O
80 O
% O
to O
125 O
% O
, O
the O
two O
treatments O
were O
considered O
bioequivalent O
. O
[]

Among O
diabetic O
patients O
who O
were O
being O
treated O
with O
insulin O
or O
oral O
hypoglycemic O
agents O
at O
base O
line O
, O
a O
subgroup O
not O
specified O
by O
the O
protocol O
, O
five-year O
survival B-outcome ['Mortality']
was O
80.6 O
percent O
for O
the O
CABG O
group O
as O
compared O
with O
65.5 O
percent O
for O
the O
PTCA O
group O
( O
P O
= O
0.003 O
) O
. O
['Mortality']

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
the O
pulmonary O
abnormalities O
are O
reversible O
and O
whether O
any O
improvements O
lead O
to O
changes O
to O
exercise O
capacity O
or O
symptoms O
. O
[]

Effects O
of O
prelinguistic O
milieu O
teaching O
and O
parent O
responsivity O
education O
on O
dyads O
involving O
children O
with O
intellectual O
disabilities O
. O
[]

Plasma O
ONO-5334 O
concentration O
reached O
steady O
state O
within O
2 O
days O
. O
[]

RESULTS O
The O
odds O
of O
parents O
reporting O
care B-outcome ['Life-Impact']
consistent I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
that I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
medical I-outcome ['Life-Impact']
home I-outcome ['Life-Impact']
were O
less O
likely O
for O
children O
with O
autism O
( O
odds O
ratio O
, O
0.45 O
; O
95 O
% O
confidence O
interval O
, O
0.30-0.66 O
) O
and O
more O
likely O
for O
children O
with O
asthma O
( O
odds O
ratio O
, O
1.17 O
; O
95 O
% O
confidence O
interval O
, O
1.06-1.30 O
) O
compared O
with O
children O
with O
other O
special O
health O
care O
needs O
( O
1 O
[ O
reference O
] O
) O
. O
['Life-Impact']

RESULTS O
In O
no O
patient O
group O
was O
there O
a O
late B-outcome ['Physiological-Clinical']
mandibular I-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
recorded O
. O
['Physiological-Clinical']

High-dose O
thrombolysis O
led O
to O
better O
rates O
of O
complete B-outcome ['Physiological-Clinical']
recanalization I-outcome ['Physiological-Clinical']
after O
seven O
days O
( O
p O
< O
0.01 O
) O
than O
locoregional O
lysis O
. O
['Physiological-Clinical']

In O
the O
present O
study O
we O
evaluated O
the O
effect O
of O
loxiglumide O
, O
a O
specific O
cholecystokininA O
( O
CCKA O
) O
-receptor O
antagonist O
, O
on O
the O
occurrence O
of O
TLESRs O
evoked O
by O
gastric O
distension O
. O
[]

1 O
This O
study O
was O
designed O
to O
compare O
in O
a O
double-blind O
randomized O
crossover O
trial O
, O
atenolol O
, O
labetalol O
, O
metoprolol O
and O
pindolol O
. O
[]

Focal B-outcome ['Physiological-Clinical']
therapeutic O
efficacy O
of O
transcatheter O
arterial O
infusion O
of O
styrene O
maleic O
acid O
neocarzinostatin O
for O
hepatocellular O
carcinoma O
. O
['Physiological-Clinical']

All O
participants O
completed O
a O
battery O
of O
psychosocial B-outcome ['Life-Impact']
questionnaires O
administered O
by O
a O
research O
assistant O
at O
baseline O
, O
immediately O
following O
the O
10-week O
CBSM O
intervention O
period O
, O
and O
at O
a O
6-month O
follow-up O
. O
['Life-Impact']

The O
rationale O
for O
the O
Multicenter O
Acute O
Stroke O
Trial O
( O
MAST O
) O
is O
presented O
in O
a O
companion O
article O
appearing O
in O
this O
issue O
. O
[]

The O
results O
suggest O
that O
PlayWisely O
can O
improve O
recognition B-outcome ['Life-Impact']
, O
brain B-outcome ['Physiological-Clinical']
region I-outcome ['Physiological-Clinical']
agility I-outcome ['Physiological-Clinical']
, O
phonemic B-outcome ['Life-Impact']
awareness I-outcome ['Life-Impact']
, O
letter B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Ganitumab O
with O
either O
exemestane O
or O
fulvestrant O
for O
postmenopausal O
women O
with O
advanced O
, O
hormone-receptor-positive O
breast O
cancer O
: O
a O
randomised O
, O
controlled O
, O
double-blind O
, O
phase O
2 O
trial O
. O
[]

We O
compared O
the O
effects O
of O
a O
16-week O
Cognitive-Behavioral O
Therapy O
( O
CBT O
) O
program O
and O
a O
Social O
Recreational O
( O
SR O
) O
program O
on O
anxiety O
in O
children O
with O
Autism O
Spectrum O
Disorders O
( O
ASD O
) O
. O
[]

However O
, O
subjects O
in O
the O
mCIT+mental O
practice O
group O
exhibited O
significantly O
larger O
changes O
on O
both O
[]

Decreases O
in O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
occurred O
with O
both O
doses O
of O
saralasin O
and O
even O
with O
suppression O
of O
the O
renin-angiotensin O
axis O
. O
['Physiological-Clinical']

Twelve O
autistic O
patients O
ranging O
from O
7 O
to O
15 O
years O
, O
diagnosed O
according O
to O
DSM-III-R O
, O
entered O
a O
double-blind O
crossover O
study O
with O
NAL O
at O
the O
doses O
of O
0.5 O
, O
1.0 O
and O
1.5 O
mg/kg O
every O
48 O
hours O
. O
[]

CONCLUSION O
Compared O
with O
cryotherapy O
, O
the O
diode O
laser O
was O
more O
convenient O
, O
technically O
easier O
to O
administer O
, O
and O
better O
tolerated O
by O
the O
patient O
. O
[]

Blast B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
Pgp I-outcome ['Physiological-Clinical']
( O
63 O
% O
) O
and O
LRP B-outcome ['Physiological-Clinical']
( O
71 O
% O
) O
was O
common O
, O
whereas O
only O
Pgp O
adversely O
impacted O
the O
rate O
of O
CR/CP B-outcome ['Physiological-Clinical']
( O
P O
=.025 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Successful B-outcome ['Life-Impact']
masking I-outcome ['Life-Impact']
of O
an O
intravitreal O
injection O
can O
be O
accomplished O
when O
a O
sham O
injection O
procedure O
carefully O
mimics O
a O
real O
injection O
procedure O
. O
['Life-Impact']

The O
levels O
were O
not O
normalized O
and O
stayed O
higher O
than O
those O
in O
controls O
. O
[]

After O
four O
cycles O
, O
the O
objective O
response O
rate O
( O
ORR O
) O
was O
better O
with O
FEC O
100 O
than O
with O
FEC O
75 O
( O
49.2 O
% O
v O
40 O
% O
, O
respectively O
; O
P O
: O
=.07 O
) O
. O
[]

Mechanical O
efficiency O
, O
oxygen B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
timing B-outcome ['Physiological-Clinical']
parameters O
and O
stroke B-outcome ['Physiological-Clinical']
angles I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

HYPOTHESIS O
There O
will O
be O
a O
detectable O
increase O
in O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
using O
preoperative O
( O
PRE O
) O
as O
opposed O
to O
perioperative O
( O
PERI O
) O
chemotherapy O
in O
resectable O
StageI-II O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O
['Mortality']

METHODS O
AND O
MATERIALS O
Sixty-four O
patients O
were O
randomly O
assigned O
to O
receive O
either O
a O
clinical O
intervention O
including O
an O
information O
session O
, O
the O
use O
of O
a O
pain O
diary O
, O
and O
the O
possibility O
to O
contact O
a O
physician O
to O
adjust O
the O
pain O
medication O
, O
or O
the O
usual O
treatment O
of O
pain O
by O
the O
staff O
radiation O
oncologist O
. O
[]

Some O
of O
these O
studies O
emphasize O
the O
importance O
of O
dealing O
with O
the O
patient O
's O
total O
situation O
in O
comprehensive O
multidisciplinary O
programs O
-- O
the O
bio-psycho-social O
model O
. O
[]

rhTPO O
given O
after O
transplantation O
did O
not O
speed O
platelet B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PVSG-01 O
, O
a O
long-term O
randomized O
controlled O
study O
of O
phlebotomy O
alone O
compared O
with O
the O
myelosuppressive O
agents O
, O
32P O
or O
chlorambucil O
supplemented O
by O
phlebotomy O
, O
continues O
to O
receive O
follow-up O
data O
on O
93 O
% O
of O
surviving O
patients O
18 O
years O
after O
initiation O
of O
the O
study O
. O
[]

The O
10-week O
treatment O
program O
resulted O
in O
satisfactory O
weight O
loss B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Mean O
MVD O
for O
the O
hyperplastic B-outcome ['Physiological-Clinical']
portion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
prostate I-outcome ['Physiological-Clinical']
was O
similar O
for O
the O
finasteride O
and O
control O
groups O
( O
14.21 O
+/- O
7.10 O
and O
19.75 O
+/- O
9.73 O
, O
respectively O
, O
p O
> O
0.05 O
) O
. O
['Physiological-Clinical']

However O
, O
the O
shape O
and O
magnitude O
of O
the O
treatment O
effects O
, O
as O
well O
as O
the O
other O
fixed O
model O
estimates O
, O
were O
very O
similar O
between O
the O
field O
trial O
and O
the O
IPDMA O
suggesting O
that O
any O
bias O
would O
likely O
be O
minimal O
. O
[]

It O
was O
therefore O
hypothesized O
that O
cognitive O
therapy O
not O
only O
reduces O
panic O
but O
also O
agoraphobia O
and O
that O
it O
potentiates O
the O
effects O
of O
exposure O
in O
vivo O
. O
[]

Control O
patients O
required O
ventilatory B-outcome ['Physiological-Clinical']
support I-outcome ['Physiological-Clinical']
for O
longer O
( O
median O
10 O
days O
vs O
5 O
days O
; O
difference O
5 O
days O
[ O
5-6 O
, O
p O
< O
0.0001 O
] O
) O
. O
['Physiological-Clinical']

RESULTS O
A O
significative O
reduction O
of O
angina B-outcome ['Physiological-Clinical']
crisis I-outcome ['Physiological-Clinical']
number O
, O
duration O
, O
intensity O
and O
the O
number O
of O
['Physiological-Clinical']

DISCUSSION O
Greater O
vital B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
fill I-outcome ['Physiological-Clinical']
in O
the O
PUT O
group O
may O
be O
attributable O
to O
earlier O
and O
greater O
vascular O
invasion O
of O
the O
carrier O
material O
. O
['Physiological-Clinical']

There O
was O
a O
trend O
toward O
a O
smaller O
size O
of O
largest O
polyp O
in O
patients O
treated O
with O
aspirin O
versus O
nonaspirin O
-- O
mean O
3.8 O
mm O
versus O
5.5 O
mm O
for O
patients O
treated O
1 O
or O
more O
years O
( O
adjusted O
P O
= O
0.09 O
) O
and O
mean O
3.0 O
mm O
versus O
6.0 O
mm O
for O
patients O
treated O
more O
than O
1 O
year O
( O
P O
= O
0.02 O
) O
; O
there O
were O
similar O
weaker O
trends O
with O
RS O
versus O
non-RS O
. O
[]

Settings O
included O
an O
autism O
clinic O
and O
6 O
community-based O
early O
intervention O
programs O
that O
primarily O
serve O
low-income O
families O
. O
[]

METHODS O
Gainfully O
employed O
( O
?20 O
h/wk O
) O
male O
and O
female O
outpatients O
with O
MDD O
were O
randomly O
assigned O
( O
2:1 O
ratio O
) O
to O
12 O
weeks O
of O
double-blind O
treatment O
with O
desvenlafaxine O
50 O
mg/d O
or O
placebo O
. O
[]

This O
last O
regimen O
was O
repeated O
four O
times O
in O
the O
12-month O
study O
period O
. O
[]

In O
the O
men O
taking O
regular O
exercise O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
increased O
26 O
% O
more O
in O
the O
high B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
subfraction I-outcome ['Physiological-Clinical']
two O
( O
HDL2 B-outcome ['Physiological-Clinical']
) O
and O
decreased O
31 O
% O
more O
in O
the O
subfraction B-outcome ['Physiological-Clinical']
three I-outcome ['Physiological-Clinical']
( O
HDL3 B-outcome ['Physiological-Clinical']
) O
and O
9 O
% O
more O
in O
the O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
than O
in O
the O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
conclude O
that O
75 O
mg O
of O
pure O
liquid O
oral O
histamine O
-- O
a O
dose O
found O
in O
normal O
meals O
-- O
can O
provoke O
immediate O
as O
well O
as O
delayed O
symptoms O
in O
50 O
% O
of O
healthy O
females O
without O
a O
history O
of O
food O
intolerance O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
with O
measurable O
and O
assessable O
disease O
were O
randomized O
to O
receive O
either O
PLD O
50 O
mg/m O
( O
2 O
) O
as O
a O
1-hour O
infusion O
every O
4 O
weeks O
or O
topotecan O
1.5 O
mg/m O
( O
2 O
) O
/d O
for O
5 O
consecutive O
days O
every O
3 O
weeks O
. O
[]

The O
data O
reported O
in O
this O
study O
were O
collected O
at O
baseline O
before O
any O
intervention O
activities O
was O
initiated O
. O
[]

There O
was O
no O
difference O
between O
treatments O
in O
total O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
( O
ENT O
37.1 O
( O
se O
2.6 O
) O
, O
PLA O
35.9 O
( O
se O
3.2 O
) O
MJ O
) O
, O
macronutrient B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
, O
hunger B-outcome ['Physiological-Clinical']
, O
satiety B-outcome ['Physiological-Clinical']
and O
hedonic B-outcome ['Physiological-Clinical']
scores O
during O
the O
4 O
d O
high-fat O
diet O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Only O
12 O
% O
of O
eligible O
patients O
( O
16/138 O
) O
received O
home O
infusions O
, O
but O
13/14 O
questioned O
preferred O
this O
location O
. O
[]

glucose O
, O
between O
the O
three O
groups O
of O
patients O
. O
[]

Risperidone O
has O
antiserotonergic O
and O
antidopaminergic O
properties O
that O
may O
make O
it O
more O
effective O
than O
conventional O
antipsychotic O
agents O
in O
the O
treatment O
of O
the O
negative O
symptoms B-outcome ['Life-Impact']
of O
schizophrenia O
. O
['Life-Impact']

BACKGROUND O
In O
the O
BIGPRO O
1 O
trial O
, O
one O
year O
of O
treatment O
with O
metformin O
in O
non-diabetic O
obese O
subjects O
with O
a O
central O
fat O
distribution O
had O
no O
significant O
effect O
on O
fasting O
plasma O
triglyceride O
concentration O
or O
on O
blood O
pressure O
despite O
a O
decrease O
in O
weight O
, O
fasting O
plasma O
insulin O
and O
glucose O
concentrations O
. O
[]

Serious B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
occurred O
in O
11 O
patients O
taking O
warfarin O
, O
an O
incidence O
of O
0.6 O
% O
per O
year O
. O
['Physiological-Clinical']

Eighty O
depressed O
patients O
undergoing O
standard O
antidepressant O
treatment O
will O
be O
advised O
to O
follow O
four O
additional O
hygienic-dietary O
recommendations O
about O
exercise O
, O
diet O
, O
sunlight O
exposure O
and O
sleep O
. O
[]

SETTING O
Twenty-nine O
primary O
care O
physicians O
in O
Switzerland O
and O
Germany O
coordinated O
by O
the O
University O
Hospital O
Basel O
, O
Switzerland O
. O
[]

Five O
patients O
showed O
allelic B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
at O
least O
one O
genetic O
marker O
in O
the O
metastatic O
tumor O
but O
not O
in O
its O
matched O
primary O
tumor O
. O
['Physiological-Clinical']

CONCLUSION O
These O
results O
suggest O
that O
hCG O
administered O
when O
the O
largest O
follicle O
size O
reaches O
16.0-16.9 O
mm O
leads O
to O
similar O
clinical O
and O
ongoing O
pregnancy O
rates O
as O
when O
it O
reaches O
18.0-18.9 O
mm O
in O
IUI O
cycles O
. O
[]

Changes O
in O
the O
exercise O
leg O
were O
compared O
between O
groups O
using O
ANCOVA O
, O
with O
change O
in O
the O
control O
leg O
and O
baseline O
BMD O
as O
covariates O
. O
[]

Influence O
of O
lime O
juice O
on O
the O
severity O
of O
sickle O
cell O
anemia O
. O
[]

The O
intraoral O
fluoride-releasing O
system O
( O
IFRS O
) O
containing O
a O
sodium O
fluoride O
core O
is O
a O
newly O
developed O
, O
sustained-release O
, O
passive O
drug O
delivery O
system O
that O
does O
not O
require O
patient O
involvement O
except O
for O
periodic O
replacement O
, O
thus O
reducing O
the O
effect O
of O
patient O
compliance O
on O
its O
effectiveness O
in O
dental O
caries O
prevention O
. O
[]

Participants O
in O
the O
MBCT O
group O
had O
more O
imitative B-outcome ['Life-Impact']
attempts I-outcome ['Life-Impact']
( O
p O
= O
.03 O
) O
. O
['Life-Impact']

Exposure B-outcome ['Physiological-Clinical']
to O
the O
['Physiological-Clinical']

These O
interim O
results O
of O
the O
ongoing O
Finnish O
Diabetes O
Prevention O
Study O
demonstrate O
the O
efficacy O
and O
[]

37 O
( O
59 O
% O
) O
patients O
receiving O
eltrombopag O
reduced O
concomitant B-outcome ['Physiological-Clinical']
treatment I-outcome ['Physiological-Clinical']
versus O
ten O
( O
32 O
% O
) O
patients O
receiving O
placebo O
( O
p=0?016 O
) O
. O
['Physiological-Clinical']

Following O
treatment O
, O
71.4 O
% O
of O
the O
treated O
participants O
no O
longer O
fulfilled O
diagnostic O
criteria O
for O
an O
anxiety O
disorder O
. O
[]

At O
the O
end O
of O
the O
study O
the O
changes O
in O
clinic B-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
and O
DBP B-outcome ['Physiological-Clinical']
were O
not O
statistically O
different O
in O
treated O
and O
untreated O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
Effects O
of O
early O
acupuncture O
on O
motor O
function O
of O
the O
limb O
in O
the O
severe O
head O
injury O
patients O
] O
. O
[]

CONCLUSIONS O
This O
is O
the O
first O
ASD O
randomized O
trial O
involving O
toddlers O
to O
identify O
an O
active O
ingredient O
for O
enhancing O
socially O
engaged O
imitation O
. O
[]

It O
has O
been O
confirmed O
that O
angiotensin-converting O
enzyme O
inhibitors O
( O
ACEIs O
) O
and O
angiotensin O
II O
receptor O
blockers O
( O
ARBs O
) O
reduce O
urinary O
protein O
excretion O
and O
attenuate O
the O
development O
of O
renal O
injury O
. O
[]

These O
results O
indicate O
that O
an O
undisturbed O
wound O
healing O
process O
using O
BRG O
together O
with O
tooth O
stability O
is O
beneficial O
to O
overall O
clinical B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSION O
The O
results O
suggest O
that O
combination O
of O
atypical O
antipsychotic O
medications O
and O
pentoxifylline O
might O
have O
synergistic O
effects O
in O
treatment O
of O
behavioral B-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
of O
children O
with O
autism O
. O
['Life-Impact']

Effectiveness O
of O
education O
for O
gastric O
cancer O
patients O
: O
a O
controlled O
prospective O
trial O
comparing O
interactive O
vs. O
lecture-based O
programs O
. O
[]

BACKGROUND O
Remote O
ischaemic O
preconditioning O
attenuates O
cardiac O
injury O
at O
elective O
surgery O
and O
angioplasty O
. O
[]

METHODS O
This O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel-group O
, O
multicenter O
study O
of O
342 O
adolescent O
and O
adult O
patients O
with O
moderate O
asthma O
[ O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
second I-outcome ['Physiological-Clinical']
( O
FEV1 B-outcome ['Physiological-Clinical']
) O
between O
50 O
% O
and O
80 O
% O
of O
predicted O
] O
treated O
previously O
by O
beclomethasone O
dipropionate O
or O
triamcinolone O
acetonide O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Though O
both O
treatments O
reduced O
anxiety B-outcome ['Life-Impact']
, O
FCBT O
outperformed O
ICBT O
for O
children O
with O
moderate O
ASD O
symptoms O
, O
a O
benefit O
potentially O
linked O
to O
more O
at-home O
exposures O
and O
greater O
child O
involvement O
in O
FCBT O
. O
['Life-Impact']

METHODS O
Thirty O
eyes O
of O
30 O
consecutive O
patients O
with O
cystoid O
macular O
edema O
secondary O
to O
nonischemic O
branch O
retinal O
vein O
occlusion O
were O
assigned O
to O
either O
GLP O
group O
or O
to O
intravitreal O
bevacizumab O
( O
IB O
) O
group O
. O
[]

Patients O
in O
group O
I O
( O
n O
= O
23 O
) O
received O
Fansidar O
( O
3 O
tablets O
, O
75 O
mg O
of O
pyrimethamine O
and O
1,500 O
mg O
of O
sulfadoxine O
, O
a O
single O
dose O
on O
the O
first O
day O
) O
, O
group O
II O
( O
n O
= O
23 O
) O
received O
Fansidar O
( O
3 O
tablets O
, O
75 O
mg O
of O
pyrimethamine O
and O
1,500 O
mg O
of O
sulfadoxine O
, O
a O
single O
dose O
on O
the O
first O
day O
) O
and O
then O
received O
primaquine O
( O
30 O
mg O
a O
day O
for O
14 O
days O
) O
, O
group O
III O
( O
n O
= O
23 O
) O
received O
primaquine O
( O
30 O
mg O
a O
day O
for O
14 O
days O
) O
, O
and O
group O
IV O
( O
n O
= O
23 O
) O
received O
artesunate O
( O
200 O
mg O
once O
a O
day O
for O
3 O
days O
) O
and O
then O
primaquine O
( O
30 O
mg O
a O
day O
for O
14 O
days O
) O
. O
[]

INTERVENTION O
Pentoxifylline O
( O
also O
called O
oxpentifylline O
) O
, O
400 O
mg O
3 O
times O
daily O
, O
or O
matching O
placebo O
. O
[]

Initially O
, O
the O
burden B-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
relatives I-outcome ['Life-Impact']
of O
the O
project O
group O
was O
higher O
, O
but O
by O
one O
month O
it O
was O
somewhat O
lower O
and O
by O
four O
months O
it O
was O
significantly O
lower O
than O
the O
burden O
on O
the O
control O
group O
relatives O
. O
['Life-Impact']

No O
significant O
differences O
were O
seen O
in O
the O
amount O
of O
lactobacilli B-outcome ['Physiological-Clinical']
or O
LGG B-outcome ['Physiological-Clinical']
, O
nor O
did O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
defecation B-outcome ['Physiological-Clinical']
frequency O
, O
consistency O
of O
stools B-outcome ['Physiological-Clinical']
or O
ease B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
defecation I-outcome ['Physiological-Clinical']
differ O
between O
the O
two O
study O
periods O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
optimal O
sequencing O
of O
chemotherapy O
and O
radiation O
therapy O
is O
not O
clear O
. O
[]

CONCLUSIONS O
Both O
devices O
provide O
a O
secure O
airway O
, O
are O
similar O
in O
clinical O
utility O
and O
are O
easy O
to O
insert O
. O
[]

Possible O
physiological O
mechanisms O
are O
discussed O
. O
[]

Baseline O
mean O
scores O
and O
rates O
at O
which O
pts O
failed O
to O
complete O
QoL O
assessment O
were O
similar O
in O
the O
two O
arms O
. O
[]

Whether O
either O
scope O
may O
be O
more O
efficient O
in O
any O
subgroups O
was O
also O
investigated O
. O
[]

Azithromycin O
, O
doxycycline O
and O
phenoxymethylpenicillin O
were O
compared O
in O
a O
prospective O
, O
randomized O
study O
of O
64 O
patients O
with O
typical O
erythema O
migrans O
. O
[]

Premature O
infants O
< O
or=32 O
weeks O
, O
< O
or=1850 O
g O
, O
and O
receiving O
parenteral O
amino O
acids O
at O
1.5 O
g/kg/d O
for O
an O
extended O
period O
( O
> O
24 O
hours O
) O
, O
or O
3 O
g/kg/d O
for O
a O
short O
( O
5 O
hour O
) O
, O
extended O
( O
24 O
hour O
) O
, O
or O
prolonged O
( O
3-5 O
days O
) O
duration O
were O
included O
in O
the O
study O
. O
[]

The O
patients O
with O
non-eosinophilic O
asthma O
and O
6 O
different O
patients O
with O
eosinophilic O
asthma O
entered O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
crossover O
study O
in O
which O
the O
effects O
of O
inhaled O
mometasone O
400 O
microg O
once O
daily O
for O
8 O
weeks O
on O
airway B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
and O
asthma B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
were O
investigated O
. O
['Physiological-Clinical', 'Life-Impact']

There O
were O
insignificant O
changes O
in O
the O
parameters O
in O
the O
control O
group O
between O
baseline O
and O
6 O
months O
later O
. O
[]

Age-related O
reductions O
in O
basal O
limb O
blood O
flow O
and O
vascular O
conductance O
are O
associated O
with O
the O
metabolic O
syndrome O
, O
functional O
impairments O
, O
and O
osteoporosis O
. O
[]

A O
total O
of O
3023 O
patients O
were O
enrolled O
at O
130 O
sites O
in O
Canada O
, O
the O
United O
States O
, O
and O
Germany O
between O
October O
2006 O
and O
September O
2007 O
, O
with O
results O
anticipated O
shortly O
after O
completion O
of O
90-day O
follow-up O
in O
March O
2008 O
. O
[]

BACKGROUND O
Midlife O
women O
are O
an O
underserved O
population O
in O
the O
areas O
of O
unintended O
pregnancy O
and O
STI O
prevention O
yet O
remain O
at O
risk O
for O
both O
health O
conditions O
. O
[]

[ O
Study O
on O
treatment O
of O
iron-deficiency O
anemia O
by O
shengxuening O
] O
. O
[]

The O
vascular O
changes O
responsible O
for O
this O
effect O
are O
not O
clear O
. O
[]

An O
important O
finding O
was O
that O
no O
nonspecific O
effects O
of O
EEG-biofeedback O
were O
demonstrated O
. O
[]

Twenty-four O
patients O
with O
malignant O
pericardial O
effusion O
were O
treated O
by O
intrapericardial O
instillation O
of O
anti-cancer O
drugs O
, O
such O
as O
Carbazilquinone O
, O
Mitomycin-C O
or O
ACNU O
, O
with O
pericardial O
drainage O
. O
[]

They O
analyse O
the O
initial O
phases O
, O
which O
correspond O
to O
the O
three O
first O
years O
of O
work O
. O
[]

Further O
, O
indomethacin O
did O
not O
diminish O
the O
need O
for O
invasive B-outcome ['Resource-use']
surgical I-outcome ['Resource-use']
procedures I-outcome ['Resource-use']
for O
relief O
of O
tamponade B-outcome ['Physiological-Clinical']
( O
three O
of O
13 O
placebo O
patients O
, O
two O
of O
11 O
indomethacin O
patients O
) O
or O
result O
in O
decreased O
mortality B-outcome ['Mortality']
rate O
. O
['Resource-use', 'Physiological-Clinical', 'Mortality']

4.8 O
% O
) O
versus O
NHL O
( O
ES O
= O
0.35 O
) O
. O
[]

The O
results O
indicate O
that O
there O
were O
no O
statistically O
significant O
differences O
among O
the O
three O
treatment O
groups O
in O
terms O
of O
clinical O
success O
rates O
, O
but O
that O
clarithromycin O
and O
roxithromycin O
were O
better O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact']

After O
repeated O
oral O
administration O
of O
150 O
mg O
b.d. O
, O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
reached O
steady O
state O
by O
day O
5 O
( O
mean O
Cmin O
48.6 O
ng.ml-1 O
) O
. O
['Physiological-Clinical']

Pegfilgrastim O
for O
peripheral O
CD34+ O
mobilization O
in O
patients O
with O
solid O
tumours O
. O
[]

One O
patient O
in O
the O
placebo O
group O
became O
paradoxically O
more O
tachycardic B-outcome ['Physiological-Clinical']
and O
apneic B-outcome ['Physiological-Clinical']
after O
the O
diltiazem O
infusion O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Compared O
to O
the O
controls O
, O
more O
women O
in O
the O
intervention O
group O
described O
the O
term O
breast B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
correctly O
and O
recognized O
it O
as O
a O
risk O
factor O
for O
breast O
cancer O
. O
['Physiological-Clinical']

Furthermore O
, O
sublingual O
fentanyl O
ODT O
provided O
significant O
improvements O
in O
PID B-outcome ['Physiological-Clinical']
and O
PR O
compared O
to O
placebo O
, O
from O
10 O
min O
post-dose O
( O
p O
= O
0.0055 O
and O
p O
= O
0.049 O
for O
PID O
and O
PR O
, O
respectively O
) O
. O
['Physiological-Clinical']

The O
lunar O
stent O
characteristics O
and O
clinical O
results O
. O
[]

PARTICIPANTS O
111 O
patients O
( O
80 O
women O
and O
31 O
men O
; O
mean O
age O
, O
81 O
years O
) O
admitted O
via O
the O
emergency O
department O
with O
a O
primary O
diagnosis O
of O
fractured O
neck O
of O
femur O
. O
[]

The O
prevention O
effects O
on O
nausea B-outcome ['Physiological-Clinical']
7 O
, O
8 O
and O
10 O
days O
after O
the O
start O
of O
chemotherapy O
, O
on O
appetite B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
2-10 O
days O
after O
it O
, O
and O
2-5 O
days O
after O
its O
completion O
, O
were O
higher O
in O
the O
combination O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
diclofenac O
group O
, O
it O
was O
2.2 O
and O
0.95 O
mg/min O
, O
respectively O
( O
p O
less O
than O
0.01 O
) O
. O
[]

The O
third O
indicator O
, O
training B-outcome ['Life-Impact']
attrition I-outcome ['Life-Impact']
, O
shows O
a O
better O
result O
for O
the O
group O
training O
. O
['Life-Impact']

Validity O
was O
shown O
by O
( O
1 O
) O
the O
ability O
of O
the O
scales O
to O
discriminate O
clearly O
between O
patients O
differing O
in O
clinical O
status O
as O
defined O
by O
pretreatment O
W.H.O O
. O
[]

A O
communication-based O
intervention O
for O
nonverbal O
children O
with O
autism O
: O
what O
changes O
? O
[]

The O
authors O
do O
not O
recommend O
adding O
INB O
for O
patients O
undergoing O
lateral O
thoracotomy O
who O
receive O
0.5 O
mg O
SM O
. O
[]

FINANCIAL O
DISCLOSURE O
( O
S O
) O
Proprietary O
or O
commercial O
disclosure O
may O
be O
found O
after O
the O
references O
. O
[]

Chronology O
of O
panic O
and O
avoidance O
, O
age O
of O
onset O
in O
panic O
disorder O
, O
and O
prediction O
of O
treatment O
response O
. O
[]

There O
was O
no O
significant O
change O
in O
non-trial B-outcome ['Resource-use']
drug I-outcome ['Resource-use']
consumption B-outcome ['Life-Impact']
. O
['Resource-use', 'Life-Impact']

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
behaviour O
alone O
was O
thought O
to O
be O
inadequate O
to O
describe O
the O
response O
pattern O
. O
['Physiological-Clinical']

Effects O
of O
age O
at O
introduction O
of O
complementary O
foods O
to O
breast-fed O
infants O
on O
duration O
of O
lactational O
amenorrhea O
in O
Honduran O
women O
. O
[]

SVR B-outcome ['Physiological-Clinical']
rates O
were O
23 O
% O
, O
17 O
% O
, O
10 O
% O
, O
and O
9 O
% O
in O
groups O
A O
, O
B O
, O
C O
, O
and O
D O
, O
respectively O
( O
P O
< O
.0001 O
for O
trend O
) O
. O
['Physiological-Clinical']

Effects O
of O
nootropic O
therapy O
in O
age-associated O
memory O
impairment O
. O
[]

Data O
were O
submitted O
to O
repeated O
analysis O
of O
variance O
. O
[]

RESULTS O
For O
needle O
insertion O
, O
30 O
% O
of O
the O
subjects O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
lidocaine O
solution O
and O
43 O
% O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
mepivacaine O
solution O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Low O
muscle O
combined O
with O
high O
fat O
mass O
had O
more O
functional O
deficits O
and O
poorer O
bone O
health O
, O
which O
has O
implications O
for O
falls O
risk O
and O
fractures O
. O
[]

RESULTS O
Compared O
with O
children O
who O
received O
community-intervention O
, O
children O
who O
received O
ESDM O
showed O
significant O
improvements O
in O
IQ B-outcome ['Physiological-Clinical']
, O
adaptive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
, O
and O
['Physiological-Clinical', 'Life-Impact']

BACKGROUND O
This O
study O
was O
designed O
to O
examine O
the O
influence O
of O
exercise O
training O
on O
leptin O
levels O
in O
patients O
with O
stable O
coronary O
artery O
disease O
( O
CAD O
) O
. O
[]

Patients O
progressing O
within O
the O
study O
were O
given O
the O
option O
of O
crossover O
to O
the O
other O
treatment O
arm O
; O
time O
to O
second O
progression O
was O
an O
exploratory O
endpoint O
. O
[]

CONCLUSIONS O
This O
randomized O
controlled O
trial O
provides O
promising O
data O
on O
the O
specificity O
and O
generalizability O
of O
joint B-outcome ['Physiological-Clinical']
attention I-outcome ['Physiological-Clinical']
and O
play B-outcome ['Life-Impact']
interventions I-outcome ['Life-Impact']
for O
young O
children O
with O
autism O
. O
['Physiological-Clinical', 'Life-Impact']

Among O
the O
24 O
patients O
with O
angina B-outcome ['Physiological-Clinical']
exclusively O
at O
rest O
, O
nine O
successes O
and O
four O
failures O
were O
observed O
with O
D. O
There O
was O
no O
symptomatic B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
among O
the O
11 O
patients O
treated O
by O
P O
( O
P O
= O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
area O
under O
the O
HIV-1 O
RNA O
curve O
minus O
baseline O
weighted O
by O
time O
( O
AUCMB/day O
) O
was O
calculated O
. O
[]

Folic O
acid-based O
supplementation O
is O
not O
beneficial O
and O
may O
even O
be O
harmful O
in O
the O
secondary O
prevention O
of O
cardiovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
patients O
with O
unstable O
angina O
and O
non-ST-elevation O
myocardial O
infarction O
. O
['Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
between O
the O
2 O
groups O
. O
['Adverse-effects']

The O
current O
study O
involved O
a O
randomized O
controlled O
trial O
of O
Group O
Stepping O
Stones O
Triple O
P O
( O
GSSTP O
) O
for O
a O
mixed-disability O
group O
. O
[]

Butyrate B-outcome ['Physiological-Clinical']
levels O
increased O
in O
response O
to O
RS O
in O
most O
individuals O
but O
often O
decreased O
when O
entry O
levels O
were O
high O
. O
['Physiological-Clinical']

In O
both O
groups O
plasma O
levels O
of O
triglycerides O
, O
very O
low-density B-outcome ['Physiological-Clinical']
lipoprotein B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

for O
7 O
days O
( O
OCT O
) O
or O
identical O
placebos O
. O
[]

74 O
years O
( O
P O
< O
0.05 O
) O
in O
the O
treatment O
and O
65-74 O
years O
( O
P O
= O
0.0008 O
) O
in O
the O
prevention O
subpopulation O
. O
[]

Effect O
of O
diuresis O
on O
extracorporeal O
shockwave O
lithotripsy O
treatment O
of O
ureteric O
calculi O
. O
[]

Clinical O
efficacy O
was O
shown O
in O
76.1 O
% O
of O
patients O
receiving O
eberconazole O
and O
in O
75.0 O
% O
of O
patients O
receiving O
miconazole O
. O
[]

Skin B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SkBF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
evaluated O
by O
laser O
Doppler B-outcome ['Resource-use']
perfusion I-outcome ['Resource-use']
imaging I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

The O
insomniacs O
with O
the O
highest O
screening O
MSLTs O
had O
the O
shortest O
screening O
total O
sleep B-outcome ['Physiological-Clinical']
times O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
methodological O
challenges O
in O
seeking O
to O
identify O
patient O
satisfaction B-outcome ['Life-Impact']
and O
in O
linking O
qualitative O
findings O
with O
trial O
results O
are O
explored O
. O
['Life-Impact']

Medical O
oncology O
represented O
the O
largest O
recruitment O
group O
( O
45.3 O
% O
) O
, O
followed O
by O
stem O
cell O
transplant O
( O
34.5 O
% O
) O
and O
radiation O
oncology O
( O
20.2 O
% O
) O
. O
[]

Ocular B-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
discomfort O
on O
instillation B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
medication I-outcome ['Life-Impact']
were O
measured O
after O
radial O
keratotomy O
with O
a O
visual O
analog O
scale O
and O
a O
questionnaire O
. O
['Physiological-Clinical', 'Life-Impact']

Subjects O
were O
grouped O
according O
to O
their O
drug O
choices O
: O
'non-choosers O
' O
never O
chose O
drug O
, O
whereas O
'choosers O
' O
always O
chose O
drug O
. O
[]

Both O
groups O
experienced O
symptomatic B-outcome ['Physiological-Clinical']
improvement O
with O
treatment O
. O
['Physiological-Clinical']

SETTING O
Five O
community-based O
research O
facilities O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates O
for O
the O
placebo O
and O
treatment O
arms O
were O
extremely O
low O
, O
with O
most O
women O
concluding O
the O
study O
with O
a O
partial O
response O
. O
['Physiological-Clinical']

There O
was O
a O
significant O
reduction O
of O
hand B-outcome ['Physiological-Clinical']
tremor I-outcome ['Physiological-Clinical']
for O
at O
least O
2 O
hours O
as O
measured O
by O
accelerometry O
and O
functional O
tests O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
in O
frequency O
of O
uterine B-outcome ['Physiological-Clinical']
hyperstimulation I-outcome ['Physiological-Clinical']
or O
hypertonus B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
difference O
was O
significant O
( O
P O
= O
0.011 O
) O
. O
[]

Catechol-O-methyltransferase O
( O
COMT O
) O
inhibitors O
may O
be O
useful O
in O
the O
treatment O
of O
Parkinson O
's O
disease O
by O
improving O
the O
bioavailability B-outcome ['Physiological-Clinical']
of O
levodopa O
and O
by O
prolonging O
its O
effects O
. O
['Physiological-Clinical']

1.4 O
years O
) O
from O
three O
Irish O
primary O
schools O
is O
presented O
. O
[]

Comparison O
of O
different O
long-term O
asthma O
treatments O
in O
subjects O
with O
mild-to-moderate O
asthma O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
ranitidine O
or O
omeprazole O
administration O
on O
the O
pharmacokinetics O
and O
pharmacodynamics B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cephalexin I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Patients O
in O
the O
LFSD O
arm O
consumed O
significantly O
more O
calories O
and O
grams B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
than O
those O
in O
the O
CLD O
arm O
during O
their O
first O
meal O
and O
on O
study O
day O
1 O
. O
['Physiological-Clinical']

Cimetidine O
treatment O
shortened O
the O
median O
interval O
until O
the O
first O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
, O
the O
median O
interval O
until O
the O
complete O
resolution B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
promoted O
['Physiological-Clinical', 'Physiological-Clinical']

The O
Km O
values O
for O
theophylline O
metabolism O
to O
3-MX O
, O
1-MU O
and O
DMU O
were O
2.4+/-0.6 O
, O
5.1+/-1.8+/- O
and O
112.3+/-36.8 O
mg/L O
respectively O
and O
the O
Vmax O
values O
were O
3.5+/-0.7 O
, O
7.5+/-2.6 O
and O
112.3+/-36.8 O
mg/hr O
respectively O
. O
[]

0.9 O
years O
) O
participated O
in O
the O
studies O
to O
examine O
( O
a O
) O
the O
day-to-day O
variability O
of O
morning O
urine O
specific O
gravity O
( O
USG O
) O
, O
( O
b O
) O
the O
effects O
of O
consuming O
600 O
ml O
of O
water O
on O
the O
hydration O
status O
of O
HYD O
and O
HYPO O
( O
USG O
> O
1.020 O
) O
subjects O
, O
and O
( O
c O
) O
the O
effects O
of O
consuming O
water O
( O
W O
) O
, O
salt-water O
( O
SW O
, O
40 O
mM O
Na O
) O
, O
a O
carbohydrate-electrolyte O
solution O
with O
3 O
% O
or O
light O
carbohydrate O
( O
CES-L O
, O
20 O
mM O
Na O
) O
or O
a O
CES O
with O
6 O
% O
carbohydrate O
( O
CES O
, O
20 O
mM O
Na O
) O
on O
the O
hydration O
status O
of O
HYPO O
subjects O
. O
[]

Playing O
on O
the O
typewriter O
, O
typing O
on O
the O
piano O
: O
manipulation O
knowledge O
of O
objects O
. O
[]

OBJECTIVE O
Knowledge O
of O
treatment O
response O
for O
alcohol O
and O
drug O
problems O
among O
adults O
is O
mounting O
; O
less O
is O
known O
about O
long-term O
outcome O
for O
adolescents O
who O
receive O
treatment O
for O
alcohol O
and O
drug O
problems O
. O
[]

AIM O
OF O
THE O
STUDY O
Firstly O
, O
to O
evaluate O
the O
bioavailability B-outcome ['Physiological-Clinical']
and O
potential O
antioxidative B-outcome ['Physiological-Clinical']
effects O
in O
humans O
of O
ferulic O
acid O
from O
rye O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Intravenously O
administered O
histamine O
increases O
choroidal O
but O
not O
retinal O
blood O
flow O
. O
[]

Seventeen O
patients O
with O
stable O
congestive O
heart O
failure O
( O
class O
II O
and O
III O
New O
York O
Heart O
Association O
) O
received O
intravenous O
and O
oral O
enoximone O
in O
a O
2-part O
study O
. O
[]

Eight O
patients O
( O
14.4 O
% O
) O
in O
CsA O
group O
required O
a O
drug O
conversion O
but O
none O
in O
FK506 O
group O
. O
[]

The O
patient O
in O
the O
control O
group O
were O
treated O
by O
routine O
treatment O
of O
neurosurgical O
operation O
and O
drug O
treatment O
( O
Mannitol O
, O
Citioline O
Sodium O
, O
Cefeazidime O
, O
etc. O
) O
. O
[]

Hence O
, O
we O
examined O
the O
effect O
of O
inhaled O
LTD4 O
and O
a O
control O
bronchoconstrictor O
agent O
, O
methacholine O
, O
on O
cell B-outcome ['Physiological-Clinical']
differentials I-outcome ['Physiological-Clinical']
in O
hypertonic O
saline-induced O
whole O
sputum O
samples O
of O
12 O
nonsmoking O
atopic O
asthmatic O
subjects O
( O
three O
women O
, O
nine O
men O
; O
21 O
to O
29 O
yr O
of O
age O
; O
FEV1 O
, O
74 O
to O
120 O
% O
pred O
; O
PC20FEV1 O
methacholine O
< O
9.6 O
mg/ml O
) O
. O
['Physiological-Clinical']

MEASUREMENTS O
The O
primary O
end O
point O
was O
the O
incidence O
of O
deep B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
in O
patients O
with O
adequate O
bilateral O
venograms O
; O
the O
secondary O
end O
point O
was O
hemorrhage B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Recent O
studies O
suggest O
that O
beta-carotene O
supplementation O
can O
increase O
CD4 B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
in O
HIV-infected O
patients O
. O
['Physiological-Clinical']

Hence O
it O
is O
recommended O
that O
a O
cuff B-outcome ['Physiological-Clinical']
inflation I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
30 O
cm O
H2O O
( O
22 O
mm O
Hg O
) O
should O
not O
be O
exceeded O
. O
['Physiological-Clinical']

There O
was O
a O
50 O
% O
response O
if O
patients O
had O
thrombocytopenia B-outcome ['Physiological-Clinical']
grade O
3/4 O
( O
versus O
7.1 O
% O
, O
P O
= O
< O
0.01 O
) O
. O
['Physiological-Clinical']

A O
delay O
in O
initiating O
RTX O
treatment O
may O
result O
in O
increased O
PJD O
. O
[]

PURPOSE O
This O
pilot O
trial O
sought O
to O
investigate O
whether O
any O
of O
three O
doses O
of O
American O
ginseng O
( O
Panax O
quinquefolius O
) O
might O
help O
cancer-related O
fatigue O
. O
[]

Men O
responded O
better O
to O
LIS O
than O
to O
HCT O
and O
[]

The O
extract O
from O
Choerospondias O
axillaris O
is O
a O
convenient O
treatment O
for O
second O
degree O
burns O
in O
both O
children O
and O
adults O
. O
[]

The O
study O
employed O
a O
randomised O
crossover O
design O
with O
participants O
receiving O
two O
group O
sessions O
of O
oral O
care O
education O
and O
eight O
of O
acupuncture O
using O
standardised O
methods O
. O
[]

Anti-tetanus B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
anti-diphtheria I-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
levels O
were O
measured O
by O
ELISA O
at O
baseline O
and O
at O
1 O
, O
3 O
, O
7 O
, O
and O
14 O
months O
after O
Td O
vaccination O
. O
['Physiological-Clinical']

Effect O
of O
developmental O
speech O
and O
language O
training O
through O
music O
on O
speech B-outcome ['Life-Impact']
production I-outcome ['Life-Impact']
in O
children O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

Patients O
were O
randomized O
to O
one O
of O
two O
groups O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
investigate O
whether O
such O
lenses O
impair O
visual B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

SUMMARY O
OF O
BACKGROUND O
DATA O
Few O
studies O
have O
evaluated O
deep B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
incidence O
and O
prophylaxis B-outcome ['Physiological-Clinical']
after O
major O
adult O
spinal O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
Oral O
Ganciclovir O
International O
Transplantation O
Study O
Group O
[ O
corrected O
] O
. O
[]

For O
example O
, O
some O
authors O
have O
reported O
deficits O
on O
newly O
developed O
tests O
of O
executive O
function O
sensitive O
to O
rostral O
prefrontal O
function O
, O
despite O
spared O
, O
or O
even O
superior O
, O
performance O
on O
other O
tests O
. O
[]

Those O
infants O
weighing O
1500 O
to O
1999 O
g O
( O
23 O
treated O
, O
9 O
control O
) O
were O
treated O
for O
8 O
days O
. O
[]

RESULTS O
The O
mean O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
using O
the O
logMAR O
crowded O
Kay O
picture O
test O
( O
0.343+/-0.150 O
) O
was O
comparable O
( O
P=0.084 O
) O
with O
the O
mean O
outcome O
using O
the O
crowded O
logMAR O
acuity O
test O
( O
0.402+/-0.188 O
) O
. O
['Physiological-Clinical']

The O
present O
study O
investigated O
the O
effects O
of O
a O
Neurologic O
Music O
Therapy O
( O
NMT O
) O
sensory-motor O
rehabilitation O
technique O
, O
Therapeutic O
Instrumental O
Music O
Performance O
( O
TIMP O
) O
as O
compared O
to O
Traditional O
Occupational O
Therapy O
( O
TOT O
) O
, O
on O
endurance B-outcome ['Physiological-Clinical']
, O
self-perceived B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Intensive O
behavioral O
treatment O
for O
children O
with O
autism B-outcome ['Life-Impact']
: O
four-year O
outcome O
and O
predictors O
. O
['Life-Impact']

After O
an O
initial O
health O
examination O
, O
participants O
in O
the O
I O
group O
were O
counselled O
at O
baseline O
and O
at O
5 O
months O
. O
[]

The O
increase O
in O
protein B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
during O
nutrition O
was O
comparable O
in O
the O
2 O
groups O
( O
P=.07 O
) O
. O
['Physiological-Clinical']

One O
hundred O
seventeen O
patients O
were O
randomized O
to O
usual O
care O
, O
and O
233 O
to O
additional O
intervention O
. O
[]

Mefloquine B-outcome ['Resource-use']
AUC O
was O
reduced O
and O
variable O
in O
the O
presence O
of O
diarrhea O
. O
['Resource-use']

Forty-three O
female O
patients O
were O
randomly O
allocated O
to O
receive O
lidocaine O
( O
1.5 O
mg.kg O
( O
-1 O
) O
) O
or O
placebo O
immediately O
after O
induction O
of O
anaesthesia O
and O
changes O
in O
the O
ECG B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
recorded O
. O
['Physiological-Clinical']

The O
following O
parameters O
were O
evaluated O
on O
the O
first O
, O
second O
and O
seventh O
days O
postsurgery O
: O
trismus B-outcome ['Physiological-Clinical']
, O
facial B-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
, O
lymphadenopathy B-outcome ['Resource-use']
, O
alveolar B-outcome ['Physiological-Clinical']
osteitis I-outcome ['Physiological-Clinical']
and O
subjective O
pain B-outcome ['Physiological-Clinical']
sensations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

We O
compared O
warfarin O
( O
prothrombin O
time O
ratio O
1.3-1.8 O
, O
international O
normalised O
ratio O
2.0-4.5 O
) O
with O
aspirin O
325 O
mg O
daily O
for O
prevention O
of O
ischaemic O
stroke O
and O
systemic O
embolism O
( O
primary O
events O
) O
in O
two O
parallel O
randomised O
trials O
involving O
715 O
patients O
aged O
75 O
years O
or O
less O
and O
385 O
patients O
older O
than O
75 O
; O
we O
sought O
reductions O
in O
the O
absolute O
rate O
of O
primary O
events O
by O
warfarin O
compared O
with O
aspirin O
of O
2 O
% O
per O
year O
and O
4 O
% O
per O
year O
, O
respectively O
. O
[]

A O
randomized O
controlled O
trial O
for O
reducing O
risks O
for O
sexually B-outcome ['Life-Impact']
transmitted I-outcome ['Life-Impact']
infections I-outcome ['Life-Impact']
through O
enhanced O
patient-based O
partner O
notification O
. O
['Life-Impact']

This O
small-scale O
preliminary O
study O
had O
2 O
specific O
aims O
: O
( O
aim O
1 O
) O
establish O
the O
feasibility O
of O
rural O
breast O
cancer O
survivors O
participation O
in O
a O
longitudinal O
quality O
of O
life O
( O
QOL B-outcome ['Life-Impact']
) O
intervention O
trial O
and O
( O
aim O
2 O
) O
determine O
the O
effects O
of O
the O
Breast O
Cancer O
Education O
Intervention O
( O
BCEI O
) O
on O
overall B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Patient O
navigation O
improves O
cancer O
diagnostic O
resolution O
: O
an O
individually O
randomized O
clinical O
trial O
in O
an O
underserved O
population O
. O
[]

Exposure B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
infective I-outcome ['Physiological-Clinical']
third-stage I-outcome ['Physiological-Clinical']
larvae I-outcome ['Physiological-Clinical']
decreased O
in O
all O
monitored O
five O
communities O
. O
['Physiological-Clinical']

A O
prospective O
randomized O
study O
of O
the O
result O
of O
therapy O
in O
inoperable O
patients O
with O
advanced O
disease O
. O
[]

The O
third O
nonunion O
did O
not O
heal B-outcome ['Physiological-Clinical']
despite O
exchange O
reamed O
nailing O
2 O
years O
after O
the O
primary O
surgery O
and O
dynamization O
with O
a O
fibular O
osteotomy O
after O
an O
additional O
1 O
year O
. O
['Physiological-Clinical']

This O
sample O
consisted O
of O
elementary O
school-age O
, O
community-based O
children O
( O
mean O
chronological O
age=8.8 O
years O
, O
SD=1.7 O
; O
mean O
intelligence O
quotient O
[ O
IQ O
] O
=85 O
; O
SD=16.8 O
) O
. O
[]

CONCLUSIONS O
Plasma B-outcome ['Physiological-Clinical']
ADMA I-outcome ['Physiological-Clinical']
levels O
are O
increased O
in O
patients O
with O
CSX O
, O
and O
they O
are O
correlated O
with O
increases O
in O
endothelin-1 B-outcome ['Physiological-Clinical']
and O
reductions O
in O
insulin-induced O
increments O
in O
plasma B-outcome ['Physiological-Clinical']
NOx I-outcome ['Physiological-Clinical']
and O
cGMP B-outcome ['Physiological-Clinical']
, O
effects O
that O
are O
reversed O
by O
intravenous O
L-arginine O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Regression O
of O
ROP B-outcome ['Physiological-Clinical']
occurred O
in O
all O
36 O
eyes O
( O
100 O
% O
) O
in O
both O
groups O
. O
['Physiological-Clinical']

DISCUSSION O
The O
trial O
will O
address O
current O
gaps O
in O
the O
research O
evidence O
base O
and O
contribute O
to O
the O
design O
and O
delivery O
of O
future O
interventions O
promoting O
physical O
activity O
for O
young O
children O
in O
long O
day O
care O
settings O
. O
[]

Lethality B-outcome ['Mortality']
was O
56 O
% O
in O
the O
sepsis B-outcome ['Physiological-Clinical']
group I-outcome ['Physiological-Clinical']
; O
in O
the O
therapy O
group O
lethality B-outcome ['Mortality']
was O
significantly O
lower O
in O
patients O
with O
plasmapheresis B-outcome ['Physiological-Clinical']
, O
even O
though O
in O
this O
population O
the O
organic O
failure O
rate O
was O
higher O
. O
['Mortality', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

BACKGROUND O
AND O
STUDY O
AIM O
As O
for O
any O
manual O
procedure O
, O
the O
learning O
curves O
for O
medical O
interventions O
can O
have O
undesirable O
phases O
, O
occurring O
mostly O
in O
the O
early O
experience O
of O
applying O
a O
technique O
. O
[]

Parenteral O
amino O
acid O
and O
metabolic O
acidosis O
in O
premature O
infants O
. O
[]

Relation O
of O
total O
homocysteine O
and O
lipid O
levels O
in O
children O
to O
premature O
cardiovascular O
death O
in O
male O
relatives O
. O
[]

Regions O
of O
gastric O
metaplasia O
of O
the O
duodenum O
were O
confirmed O
by O
periodic O
acid-Schiff O
and O
alcian O
blue O
( O
Serva O
) O
staining O
( O
pH O
1.0 O
; O
2.5 O
) O
Duodenal O
ulcer O
( O
DU O
) O
complications O
were O
registered O
within O
8 O
to O
10 O
years O
. O
[]

RESULTS O
All O
NT O
201 O
and O
BTXCo O
doses O
achieved O
a O
statistically O
significant O
reduction O
of O
the O
compound B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
M-wave I-outcome ['Physiological-Clinical']
amplitude I-outcome ['Physiological-Clinical']
in O
the O
EDB O
muscle O
. O
['Physiological-Clinical']

One O
group O
received O
2 O
IU/kg O
of O
intravenous O
synthetic O
human O
secretin O
at O
the O
first O
visit O
, O
followed O
by O
an O
equal O
volume O
of O
intravenous O
saline O
placebo O
at O
week O
6 O
. O
[]

They O
all O
received O
the O
same O
theoretical O
study O
package O
and O
the O
training O
group O
practiced O
with O
the O
AccuTouch O
colonoscopy O
simulator O
until O
a O
predefined O
expert O
level O
of O
performance O
was O
reached O
. O
[]

CO B-outcome ['Physiological-Clinical']
inhalation I-outcome ['Physiological-Clinical']
was O
feasible B-outcome ['Life-Impact']
and O
patients O
' O
vital B-outcome ['Physiological-Clinical']
signs B-outcome ['Physiological-Clinical']
were O
unaffected O
; O
2 O
h.day O
( O
-1 O
) O
inhalation O
of O
low-dose O
CO O
on O
4 O
consecutive O
days O
led O
to O
a O
maximal O
individual O
carboxyhaemoglobin B-outcome ['Physiological-Clinical']
level O
of O
4.5 O
% O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
a O
randomized O
double-blind O
crossover O
study O
in O
12 O
patients O
with O
atherosclerotic O
disease O
, O
the O
effect O
of O
2 O
dosages O
( O
100 O
and O
200 O
mg O
twice O
daily O
) O
of O
indobufen O
, O
a O
new O
synthetic O
inhibition O
of O
platelet O
aggregation O
, O
on O
some O
platelet B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
coagulation I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
fibrinolysis I-outcome ['Physiological-Clinical']
tests I-outcome ['Physiological-Clinical']
was O
investigated O
. O
['Physiological-Clinical']

Follow-up O
data O
of O
320 O
multiple O
myeloma O
( O
MM O
) O
patients O
entering O
the O
German O
Myeloma O
Treatment O
Group O
( O
GMTG O
) O
trial O
MM01 O
were O
analysed O
for O
factors O
predicting O
overall B-outcome ['Mortality']
( I-outcome ['Mortality']
OAS O
) I-outcome ['Mortality']
and O
tumour B-outcome ['Mortality']
related I-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
TRS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

The O
Relaxation O
Inventory O
: O
self-report O
scales O
of O
relaxation O
training O
effects O
. O
[]

fractions O
) O
. O
[]

Signal-detection B-outcome ['Physiological-Clinical']
analyses O
confirm O
the O
similarity O
of O
the O
animals O
' O
and O
humans O
' O
performances O
. O
['Physiological-Clinical']

Further O
evaluation O
of O
docosahexaenoic O
acid O
in O
patients O
with O
retinitis O
pigmentosa O
receiving O
vitamin O
A O
treatment O
: O
subgroup O
analyses O
. O
[]

Operating B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
anesthesia I-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
, O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
complications B-outcome ['Adverse-effects']
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
functional B-outcome ['Life-Impact']
index I-outcome ['Life-Impact']
( O
1 O
week O
postoperatively O
) O
, O
sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
, O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
full I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
were O
documented O
. O
['Life-Impact', 'Physiological-Clinical', 'Adverse-effects', 'Resource-use', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Effects O
of O
cognitive O
behavioral O
therapy O
on O
daily B-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
children O
with O
high-functioning O
autism O
and O
concurrent O
anxiety O
disorders O
. O
['Life-Impact']

Single-dose O
antibiotic O
prophylaxis O
proved O
to O
be O
useful O
in O
the O
prevention O
of O
serious B-outcome ['Physiological-Clinical']
infectious I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
after O
transurethral O
prostatectomy O
. O
['Physiological-Clinical']

The O
statistical O
analyses O
demonstrated O
the O
[]

These O
results O
support O
the O
results O
of O
previous O
studies O
and O
suggest O
further O
investigation O
of O
this O
novel O
sleep/pharmacologic O
intervention O
is O
warranted O
. O
[]

METHOD O
Parents O
of O
101 O
children O
with O
autism O
who O
had O
participated O
in O
a O
multi-site O
8-week O
double-blind O
clinical O
trial O
of O
risperidone O
were O
given O
a O
questionnaire O
at O
the O
end O
to O
elicit O
their O
perceptions O
of O
the O
appropriateness O
and O
acceptability O
of O
clinical O
trial O
procedures O
. O
[]

However O
, O
to O
the O
authors O
' O
knowledge O
, O
no O
researchers O
yet O
have O
evaluated O
the O
effectiveness O
of O
100 O
percent O
NovaMin O
powder O
with O
NovaMin-containing O
toothpaste O
in O
reducing O
dentin O
hypersensitivity O
compared O
with O
the O
effectiveness O
of O
NovaMin-containing O
toothpaste O
only O
and O
a O
desensitizing O
toothpaste O
containing O
potassium O
nitrate O
as O
a O
control O
. O
[]

Prospective O
investigation O
of O
body O
mass O
index O
, O
colorectal B-outcome ['Physiological-Clinical']
adenoma I-outcome ['Physiological-Clinical']
, O
and O
colorectal B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
in O
the O
prostate O
, O
lung O
, O
colorectal O
, O
and O
ovarian O
cancer O
screening O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Single-blind O
, O
randomized O
controlled O
trial O
. O
[]

FINDINGS O
The O
frequency O
of O
recurrent B-outcome ['Physiological-Clinical']
ischaemic I-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
during O
the O
first O
14 O
days O
was O
19/244 O
( O
8.5 O
% O
) O
in O
dalteparin-allocated O
patients O
versus O
17/225 O
( O
7.5 O
% O
) O
in O
aspirin-allocated O
patients O
( O
odds O
ratio=1.13 O
, O
95 O
% O
CI O
0.57-2.24 O
) O
. O
['Physiological-Clinical']

This O
difference O
was O
statistically O
significant O
. O
[]

SETTING O
Intensive O
care O
unit O
of O
a O
tertiary O
care O
hospital O
. O
[]

Both O
groups O
improved O
in O
some O
health B-outcome ['Resource-use']
service I-outcome ['Resource-use']
use I-outcome ['Resource-use']
measures O
and O
on O
the O
Work B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
Social I-outcome ['Life-Impact']
Adjustment I-outcome ['Life-Impact']
Scale O
. O
['Resource-use', 'Life-Impact']

The O
program O
consisted O
of O
seven O
units O
passed O
during O
twelve O
weekly O
one-hour O
sessions O
. O
[]

Elevated O
plasma O
homocysteine O
( O
tHcy O
) O
is O
a O
risk O
factor O
for O
Alzheimer O
's O
disease O
( O
AD O
) O
, O
and O
thus O
B O
vitamins O
may O
have O
a O
role O
in O
the O
prevention O
of O
AD O
. O
[]

The O
time O
to O
reach O
peak O
concentration B-outcome ['Physiological-Clinical']
was O
much O
longer O
after O
drug O
administration O
at O
01.00 O
hours O
( O
135 O
+/- O
16.7 O
min O
) O
than O
at O
07.00 O
( O
73.1 O
+/- O
14.1 O
min O
) O
, O
13.00 O
( O
75 O
+/- O
16.5 O
min O
) O
or O
19.00 O
hours O
( O
82.5 O
+/- O
12.7 O
min O
) O
[ O
p O
less O
than O
0.05 O
] O
. O
['Physiological-Clinical']

Remission O
rates O
were O
much O
higher O
using O
the O
DAS28 O
compared O
with O
the O
SDAI O
and O
CDAI O
, O
due O
to O
the O
high O
weight O
of O
the O
ESR O
in O
the O
DAS28 O
and O
the O
effect O
of O
tocilizumab O
on O
the O
ESR O
. O
[]

Indomethacin O
appeared O
to O
inhibit O
augmentation O
of O
natural B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
during O
high O
dose O
induction O
therapy O
. O
['Physiological-Clinical']

Custom O
made O
ear O
plugs O
might O
therefore O
be O
a O
good O
alternative O
to O
other O
forms O
of O
enhanced O
noise O
[]

Results O
of O
neuroleptic O
naive O
and O
neuroleptic O
treated O
patients O
were O
analysed O
separately O
. O
[]

CA O
proved O
superior O
to O
placebo O
on O
the O
evolution O
of O
markers O
of O
alcohol O
ingestion O
at O
three O
months O
, O
in O
this O
large-scale O
multicenter O
study O
. O
[]

All O
urine O
made O
was O
collected O
. O
[]

PATIENTS O
A O
random O
sample O
of O
60 O
eligible O
patients O
with O
back O
pain O
( O
28 O
men O
, O
32 O
women O
) O
were O
recruited O
by O
general O
practitioners O
and O
self-referral O
for O
physiotherapy O
treatment O
and O
randomly O
assigned O
to O
1 O
of O
3 O
groups O
. O
[]

CONCLUSIONS O
Non-eosinophilic O
asthma O
represents O
a O
pathologically O
distinct O
disease O
phenotype O
which O
is O
characterised O
by O
the O
absence O
of O
airway B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
, O
normal O
subepithelial B-outcome ['Physiological-Clinical']
layer I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
and O
a O
poor O
short-term O
response O
to O
['Physiological-Clinical', 'Physiological-Clinical']

To O
compare O
haemodynamic O
responses O
associated O
with O
equipotent O
doses O
of O
neuromuscular O
blockers O
and O
high-dose O
fentanyl O
( O
50 O
micrograms.kg-1 O
) O
, O
40 O
patients O
with O
aortic O
valve O
stenosis O
( O
AS O
) O
and O
20 O
patients O
with O
aortic O
insufficiency O
( O
AI O
) O
were O
randomized O
to O
four O
study O
groups O
to O
receive O
the O
following O
: O
( O
1 O
) O
pancuronium O
0.12 O
mg.kg-1 O
, O
( O
2 O
) O
vecuronium O
0.12 O
mg.kg-1 O
, O
( O
3 O
) O
atracurium O
0.4 O
mg.kg-1 O
, O
or O
( O
4 O
) O
pancuronium-metocurine O
mixture O
( O
0.4 O
mg O
+ O
1.6 O
mg/ml O
) O
: O
1 O
ml/10 O
kg O
) O
. O
[]

Hormones B-outcome ['Physiological-Clinical']
were O
measured O
in O
duplicate O
by O
radioimmunoassay O
. O
['Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
butyrate I-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
in O
the O
LF O
or O
MUFA O
group O
but O
increased O
in O
the O
HF O
group O
( O
from O
2.5 O
+/- O
0.5 O
to O
3.1 O
+/- O
0.6 O
micromol/L O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

The O
in O
vivo O
effects O
of O
oral O
clarithromycin O
administration O
on O
the O
in O
vivo O
activity O
of O
cytochrome O
P450 O
1A2 O
, O
2C9 O
, O
and O
2D6 O
were O
determined O
. O
[]

Participants O
were O
117 O
children O
in O
kindergarten O
through O
6th O
grade O
including O
91 O
children O
( O
78 O
% O
male O
) O
from O
5 O
schools O
who O
were O
consecutively O
referred O
to O
the O
intervention O
program O
and O
26 O
children O
( O
73 O
% O
male O
) O
from O
3 O
schools O
in O
which O
program O
implementation O
was O
delayed O
for O
1 O
year O
. O
[]

Furthermore O
, O
no O
clinically O
significant O
side O
effects O
were O
noted O
during O
HDPM O
administration O
. O
[]

Changes O
in O
family O
communication O
were O
differentially O
associated O
with O
changes O
in O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
adherence B-outcome ['Life-Impact']
, O
and O
family B-outcome ['Life-Impact']
conflict I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

METHODS O
Analyzed O
PRO O
included O
( O
1 O
) O
the O
Medical O
Outcomes O
Study O
Short O
Form O
36 O
, O
version O
2 O
, O
( O
2 O
) O
the O
Surgical O
Pain O
Scale O
, O
( O
3 O
) O
the O
Activities O
Assessment O
Scale O
, O
and O
( O
4 O
) O
patient O
satisfaction O
. O
[]

Depiction O
of O
hypervascular B-outcome ['Physiological-Clinical']
hepatocellular I-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
with O
64-MDCT O
: O
comparison O
of O
moderate- O
and O
high-concentration O
contrast O
material O
with O
and O
without O
saline O
flush O
. O
['Physiological-Clinical']

Thirty O
patients O
received O
0.03 O
% O
flurbiprofen O
6 O
times O
at O
15 O
minute O
intervals O
90 O
minutes O
preoperatively O
in O
addition O
to O
the O
routine O
dilation O
regimen O
. O
[]

Forty-five O
patients O
were O
concurrently O
on O
other O
drug O
treatments O
. O
[]

Epirubicin O
alone O
failed O
to O
induce O
changes O
in O
VEGF B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
( O
P O
= O
0.54 O
) O
, O
while O
the O
addition O
of O
tamoxifen O
to O
epirubicin O
resulted O
in O
a O
significant O
reduction O
in O
VEGF B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIMS O
The O
aim O
was O
to O
explore O
the O
role O
of O
CYP2C19 O
polymorphism O
in O
short-term O
rabeprazole-based O
triple O
therapy O
against O
Helicobacter O
pylori O
infection O
. O
[]

The O
school-age O
children O
were O
randomly O
assigned O
to O
a O
study O
or O
control O
group O
, O
and O
the O
preschool O
children O
served O
as O
their O
own O
controls O
. O
[]

Patients O
were O
monitored O
for O
regimen-related B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
, O
engraftment B-outcome ['Resource-use']
, O
supportive B-outcome ['Resource-use']
care I-outcome ['Resource-use']
, O
response O
and O
['Adverse-effects', 'Resource-use', 'Resource-use']

Operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
fluid B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
were O
significantly O
greater O
in O
group O
A O
than O
in O
group O
B O
( O
23.4 O
+/- O
5.7 O
vs O
16.9 O
+/- O
4.7 O
minutes O
and O
486.4 O
+/- O
170.0 O
vs O
222.1 O
+/- O
104.9 O
mL O
, O
respectively O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Because O
individuals O
with O
autism O
experience O
reduced O
preparatory O
activity O
prior O
to O
a O
voluntary O
movement O
, O
the O
present O
study O
sought O
to O
determine O
whether O
these O
anticipatory O
biases O
are O
exhibited O
by O
persons O
with O
autism O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
whether O
cerivastatin O
, O
a O
newly O
developed O
, O
potent O
synthetic O
statin O
, O
affects O
proteinuria O
and O
urinary O
podocyte O
excretion O
in O
patients O
with O
chronic O
glomerulonephritis O
( O
CGN O
) O
. O
[]

Event-related O
potentials O
and O
monoamines O
in O
autistic O
children O
on O
a O
clinical O
trial O
of O
fenfluramine O
. O
[]

This O
study O
shows O
that O
vitamin O
E O
effectively O
and O
safely O
protects O
patients O
with O
cancer O
from O
the O
occurrence O
of O
paclitaxel-induced B-outcome ['Physiological-Clinical']
peripheral I-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Among O
putative O
variables O
, O
multivariate O
regression O
analysis O
showed O
that O
only O
the O
baseline O
number O
of O
SBIs B-outcome ['Physiological-Clinical']
( O
OR O
= O
6.27 O
, O
95 O
% O
CI O
2.4-16.5 O
) O
and O
simvastatin O
treatment O
( O
OR O
= O
0.09 O
, O
95 O
% O
CI O
0.01-0.82 O
) O
independently O
predicted O
the O
development O
of O
new O
brain O
infarcts O
. O
['Physiological-Clinical']

RESULTS O
ICE O
chemotherapy O
with O
G-CSF O
was O
effective O
in O
mobilizing B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
progenitors I-outcome ['Physiological-Clinical']
( O
median O
, O
120-fold O
) O
. O
['Physiological-Clinical']

One O
hundred O
and O
seventeen O
patients O
formed O
the O
usual O
care O
( O
UC O
) O
group O
. O
[]

RESULTS O
The O
levels O
of O
homocysteine O
markedly O
decreased O
in O
group O
A O
[ O
( O
13 O
+/- O
4 O
) O
micromol/L O
vs O
( O
20 O
+/- O
5 O
) O
micromol/L O
, O
t O
= O
5.3 O
, O
P O
< O
0.01 O
] O
after O
treatment O
, O
whereas O
no O
significant O
changes O
were O
observed O
in O
group O
B O
. O
[]

Compared O
to O
haloperidol O
, O
risperidone O
led O
to O
a O
significantly O
greater O
reduction O
in O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
( O
ABC O
) O
and O
Turgay O
DSM-IV O
Pervasive B-outcome ['Life-Impact']
Developmental I-outcome ['Life-Impact']
Disorder I-outcome ['Life-Impact']
( O
PDD O
) O
scale O
scores O
( O
P O
< O
0.05 O
and O
P O
< O
0.01 O
) O
. O
['Life-Impact']

Raising O
high-density O
lipoprotein O
in O
humans O
through O
inhibition O
of O
cholesteryl O
ester O
transfer O
protein O
: O
an O
initial O
multidose O
study O
of O
torcetrapib O
. O
[]

BACKGROUND O
2-Chloroprocaine O
( O
2-CP O
) O
used O
for O
lumbar O
epidural O
anesthesia O
( O
LEA O
) O
reportedly O
decreases O
the O
efficacy O
of O
epidural O
morphine O
( O
EM O
) O
administered O
for O
post-cesarean O
section O
( O
CS O
) O
analgesia O
. O
[]

INTERVENTIONS O
the O
hospital O
pharmacist O
developed O
discharge O
plans O
which O
gave O
details O
of O
medication O
and O
support O
required O
by O
the O
patient O
. O
[]

Randomization O
was O
made O
at O
the O
time O
of O
diagnosis O
with O
223 O
assigned O
to O
continuing O
CHOP O
and O
234 O
to O
3 O
cycles O
of O
CHOP O
followed O
by O
a O
BEAM O
( O
carmustine O
, O
etoposide O
, O
cytarabine O
, O
melphalan O
) O
autograft O
. O
[]

Earlier O
diagnosis O
and O
appropriate O
treatment O
of O
cardiac O
infarction O
may O
improve O
survival O
of O
hip O
fracture O
patients O
. O
[]

Effect O
sizes O
were O
generally O
large O
( O
60.0 O
% O
of O
discernible O
differences O
) O
. O
[]

Comprehensive O
analysis O
of O
blood O
platelet O
count O
( O
BPC O
) O
, O
fibrin O
degradation O
products O
( O
FDP O
) O
, O
D-dimer O
and O
clinical O
symptoms O
is O
critical O
and O
required O
to O
determine O
the O
coagulation O
status O
to O
select O
an O
anticoagulation O
system O
before O
MARS O
. O
[]

BACKGROUND O
Yoga O
, O
as O
a O
mind-body O
therapy O
, O
is O
effective O
in O
improving O
quality O
of O
life O
for O
patients O
with O
chronic O
diseases O
, O
yet O
little O
is O
known O
about O
its O
effectiveness O
in O
female O
heroin O
addicts O
. O
[]

Patients O
were O
randomly O
allocated O
to O
control O
( O
n O
= O
13 O
) O
or O
treatment O
groups O
( O
n O
= O
12 O
) O
. O
[]

Esophageal O
damage O
during O
radiofrequency O
ablation O
of O
atrial O
fibrillation O
: O
impact O
of O
energy O
settings O
, O
lesion O
sets O
, O
and O
esophageal O
visualization O
. O
[]

Possible O
physiological O
and O
psychological O
mechanisms O
were O
investigated O
in O
two O
studies O
. O
[]

DESIGN O
DELTA-1 O
was O
based O
on O
a O
randomized O
, O
blinded O
, O
crossover O
experimental O
design O
. O
[]

Patients O
who O
enrolled O
in O
the O
study O
were O
significantly O
younger O
than O
those O
who O
did O
not O
( O
p O
< O
0.001 O
) O
. O
[]

The O
efficacy O
of O
etoricoxib O
30 O
mg O
was O
comparable O
to O
ibuprofen O
2400 O
mg. O
All O
treatments O
were O
similarly O
well O
[]

Energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
amount B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
carbohydrate I-outcome ['Life-Impact']
ingested I-outcome ['Life-Impact']
by O
both O
groups O
diminished O
over O
the O
trial O
, O
whereas O
the O
consumption O
of O
protein B-outcome ['Physiological-Clinical']
and O
fibre B-outcome ['Life-Impact']
increased O
and O
lipid O
ingestion O
remained O
unchanged O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Treatment O
groups O
received O
either O
topical O
ofloxacin O
or O
topical O
ciprofloxacin O
( O
instillation O
of O
0.3 O
% O
ophthalmic O
solution O
every O
30 O
minutes O
for O
4 O
hours O
before O
surgery O
) O
, O
or O
a O
combined O
topical O
plus O
oral O
regimen O
( O
ciprofloxacin O
hydrochloride O
, O
four O
100-mg O
tablets O
, O
or O
ofloxacin O
, O
one O
400-mg O
tablet O
, O
administered O
24-26 O
, O
12-14 O
, O
and O
2 O
hours O
preceding O
surgery O
) O
. O
[]

A O
higher O
satisfaction B-outcome ['Life-Impact']
rate O
and O
a O
lower O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
were O
obtained O
in O
the O
normal O
saline O
group O
in O
comparison O
with O
the O
CO O
( O
2 O
) O
group O
. O
['Life-Impact', 'Life-Impact']

These O
children O
were O
randomly O
assigned O
to O
the O
treatment O
group O
with O
tongue O
acupuncture O
( O
40 O
sessions O
over O
8 O
weeks O
) O
or O
the O
control O
group O
( O
sham O
tongue O
acupuncture O
to O
nonacupoints O
in O
the O
tongue O
) O
. O
[]

OBJECTIVE O
To O
observe O
therapeutic O
effect O
of O
small O
needle-knife O
comprehensive O
therapy O
on O
pain B-outcome ['Physiological-Clinical']
and O
lumbar B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
range I-outcome ['Physiological-Clinical']
in O
the O
chronic O
nonspecific O
low O
back O
pain O
patient O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Forty-five O
children O
, O
2.02 O
to O
7.58 O
years O
old O
( O
M O
= O
4.49 O
) O
, O
completed O
this O
crossover O
design O
, O
with O
random O
assignment O
to O
treatment O
sequences O
. O
[]

After O
subjects O
consumed O
fish O
oil O
, O
supplementation O
with O
alpha-tocopheryl O
acetate O
increased O
plasma B-outcome ['Physiological-Clinical']
and O
LDL B-outcome ['Physiological-Clinical']
alpha-tocopherol I-outcome ['Physiological-Clinical']
contents B-outcome ['Physiological-Clinical']
significantly O
and O
lengthened B-outcome ['Physiological-Clinical']
lag O
time O
( O
at O
even O
the O
lowest O
concentration O
) O
but O
had O
no O
significant O
effect O
on O
propagation B-outcome ['Physiological-Clinical']
rate O
or O
maximum B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
compared O
with O
values O
measured O
after O
consumption O
of O
fish O
oil O
alone O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
169 O
evaluable O
IFN/HU-treated O
patients O
( O
75 O
% O
) O
, O
104 O
patients O
( O
62 O
% O
) O
achieved O
a O
cytogenetic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
that O
was O
complete O
in O
12 O
% O
( O
n=21 O
) O
, O
major O
in O
14 O
% O
( O
n=24 O
) O
, O
and O
at O
least O
minimal O
in O
35 O
% O
( O
n=59 O
) O
. O
['Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
number I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
days I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
was O
checked O
monthly O
during O
the O
1-year O
follow-up O
period O
and O
compliance B-outcome ['Life-Impact']
was O
also O
assessed O
. O
['Life-Impact', 'Life-Impact']

Again O
chronic O
renal O
failure O
patients O
showed O
PRL B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
abnormally O
elevated O
till O
the O
end O
of O
the O
test O
. O
['Physiological-Clinical']

The O
vaccine O
Zostavax O
has O
been O
shown O
to O
prevent O
herpes O
zoster O
( O
HZ O
) O
and O
postherpetic O
neuralgia O
and O
is O
recommended O
for O
individuals O
> O
or O
=60 O
years O
of O
age O
. O
[]

Methodological O
challenges O
and O
strategies O
for O
future O
well-designed O
RCTs O
for O
autism O
interventions O
are O
highlighted O
. O
[]

IMPORTANCE O
There O
are O
no O
known O
effective O
treatments O
for O
painful O
chemotherapy-induced O
peripheral O
neuropathy O
. O
[]

RESULTS O
By O
year O
4 O
, O
supplementation O
elevated O
plasma O
and O
red O
blood O
cell-DHA O
4.4- O
and O
3.6-fold O
, O
respectively O
, O
compared O
with O
the O
placebo O
group O
( O
P O
< O
0.00001 O
) O
. O
[]

Retrobulbar O
anesthesia O
consisted O
of O
a O
2.5 O
ml O
injection O
of O
a O
1:1 O
mixture O
of O
2 O
% O
lidocaine O
without O
epinephrine O
and O
0.5 O
% O
bupivacaine O
. O
[]

The O
sway B-outcome ['Life-Impact']
velocity I-outcome ['Life-Impact']
of O
the O
children O
was O
measured O
before O
premedication O
and O
1 O
, O
2 O
and O
3 O
h O
after O
the O
end O
of O
anaesthesia O
. O
['Life-Impact']

The O
mean O
of O
the O
total O
number O
of O
themes O
recalled O
per O
participant O
was O
3.1 O
in O
the O
narrative O
arm O
versus O
2.0 O
in O
the O
summary O
arm O
( O
difference O
= O
1.1 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.6 O
to O
1.7 O
) O
. O
[]

Safety O
analysis O
demonstrated O
no O
dose-dependent O
increase O
in O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
and O
no O
drug-related O
increase O
in O
daytime O
somnolence B-outcome ['Physiological-Clinical']
was O
observed O
. O
['Adverse-effects', 'Physiological-Clinical']

METHODS O
Seventy O
primary O
IgAN O
patients O
were O
equally O
randomized O
into O
two O
groups O
, O
the O
treatment O
group O
and O
the O
control O
group O
, O
they O
were O
orally O
treated O
with O
SYN O
Decoction O
( O
one O
dose O
per O
day O
) O
and O
Losartan O
( O
50 O
mg O
per O
day O
) O
respectively O
for O
1 O
year O
. O
[]

CONCLUSIONS O
The O
consistency O
of O
the O
two O
BIGPRO O
trials O
supports O
the O
conclusion O
that O
metformin O
affects O
several O
cardiovascular O
risk O
factors O
favourably O
in O
non-diabetic O
subjects O
with O
a O
central O
fat O
distribution O
. O
[]

A O
slight O
but O
nonsignificant O
increase O
occurred O
in O
fat B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
in O
the O
milk O
of O
vaccinated O
cows O
. O
['Physiological-Clinical']

This O
difference O
was O
not O
found O
for O
erythema B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Recurrence B-outcome ['Physiological-Clinical']
rate O
of I-outcome ['Physiological-Clinical']
endometriosis I-outcome ['Physiological-Clinical']
was O
6.4 O
% O
in O
group O
1 O
, O
5 O
% O
group O
2 O
and O
5.3 O
% O
in O
group O
3 O
, O
which O
was O
not O
statistically O
significantly O
different O
as O
well O
. O
['Physiological-Clinical']

Six O
patients O
were O
not O
evaluable O
because O
of O
additional O
therapy O
( O
3 O
cases O
) O
or O
decreasing O
tumor O
cell O
markers O
having O
no O
measurable O
lesions O
( O
3 O
cases O
) O
. O
[]

BACKGROUND O
Lead O
systems O
that O
include O
an O
active O
pectoral O
pulse O
generator O
reduce O
defibrillation O
thresholds O
and O
permit O
transvenous O
defibrillation O
in O
nearly O
all O
patients O
. O
[]

Exercise B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
lower O
after O
the O
pindolol/clopamide O
combination O
at O
low O
dose O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
Iron O
deficiency O
may O
limit O
the O
efficacy O
of O
vitamin O
A O
to O
normalize O
dark O
adaptation O
in O
pregnant O
Nepali O
women O
. O
[]

Sublingual O
fentanyl O
ODT O
provided O
significant O
improvements O
in O
SPID O
relative O
to O
placebo O
at O
30 O
min O
( O
49.5 O
vs. O
36.6 O
, O
p O
= O
0.0004 O
) O
and O
60 O
min O
post-administration O
( O
143.0 O
vs. O
104.5 O
, O
p O
= O
0.0002 O
) O
. O
[]

Indices O
of O
snoring B-outcome ['Physiological-Clinical']
and O
OSAS B-outcome ['Physiological-Clinical']
were O
compared O
. O
['Physiological-Clinical', 'Physiological-Clinical']

ACRT O
, O
IQ O
and O
biochemical O
measures O
were O
taken O
after O
5 O
months O
placebo O
and O
5 O
months O
fenfluramine O
treatment O
. O
[]

A O
previous O
study O
showed O
that O
a O
newly O
developed O
thin O
hydrocolloid O
patch O
[ O
Compeed O
cold O
sore O
patch O
( O
CSP O
) O
] O
provided O
multiple O
wound-healing O
benefits O
across O
all O
stages O
of O
a O
herpes O
simplex O
labialis O
( O
HSL O
) O
outbreak O
. O
[]

BACKGROUND O
Endothelial B-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
has O
been O
identified O
as O
an O
independent O
predictor O
of O
cardiovascular O
events O
. O
['Physiological-Clinical']

Administering O
the O
bitter O
tablet O
was O
a O
challenge O
. O
[]

In O
the O
insulin-dependent O
diabetic O
patients O
, O
the O
lower O
dose O
of O
insulin O
infused O
continuously O
did O
not O
alter O
the O
basal B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
arginine-stimulated I-outcome ['Physiological-Clinical']
glucagon I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Double-blind O
, O
randomized O
, O
placebo-controlled O
clinical O
trial O
on O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
a O
physostigmine O
patch O
in O
patients O
with O
senile O
dementia O
of O
the O
Alzheimer O
type O
. O
['Life-Impact']

Intravenous O
adenosine O
in O
normal O
humans O
induces O
counterirritation O
, O
fueling O
the O
notion O
that O
C-fiber O
stimulation O
trigger O
DNICs O
in O
humans O
. O
[]

Induced O
sputum B-outcome ['Physiological-Clinical']
differential I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
were O
obtained O
at O
baseline O
and O
at O
five O
further O
visits O
. O
['Physiological-Clinical']

Evaluation O
of O
a O
new O
computer O
intervention O
to O
teach O
people O
with O
autism O
or O
Asperger O
syndrome O
to O
recognize O
and O
predict O
emotions O
in O
others O
. O
[]

Each O
regimen O
was O
separated O
by O
a O
2-week O
washout O
period O
. O
[]

Oral O
sucrose O
as O
an O
analgesic O
drug O
for O
procedural O
pain O
in O
newborn O
infants O
: O
a O
randomised O
controlled O
trial O
. O
[]

The O
proportion O
of O
patients O
classified O
as O
clinic B-outcome ['Physiological-Clinical']
reactors I-outcome ['Physiological-Clinical']
was O
identical O
using O
the O
HBP O
or O
the O
ABP O
method O
( O
25.9 O
% O
) O
. O
['Physiological-Clinical']

The O
median O
length O
of O
follow-up O
in O
surviving O
patients O
was O
58 O
months O
( O
range O
, O
10 O
to O
124 O
) O
. O
[]

An O
intention-to-treat O
analysis O
yielded O
similar O
results O
. O
[]

Venlafaxine O
induced O
more O
side O
effects O
. O
[]

In O
26 O
of O
the O
106 O
patients O
, O
there O
was O
fertilization O
only O
after O
ICSI O
and O
not O
after O
IVF O
( O
IVF- O
group O
) O
. O
[]

It O
was O
designed O
as O
an O
open-label O
, O
multicenter O
, O
randomized O
, O
comparative O
study O
involving O
104-week O
oral O
treatment O
with O
1 O
of O
the O
3 O
drugs O
( O
aripiprazole O
, O
blonanserin O
, O
and O
paliperidone O
) O
in O
patients O
with O
schizophrenia O
aged O
20 O
years O
or O
over O
who O
required O
antipsychotic O
medication O
or O
switching O
of O
the O
current O
medication O
to O
others O
for O
reasons O
such O
as O
lack O
of O
efficacy O
and O
intolerability O
. O
[]

This O
difference O
between O
the O
tinted O
CL O
could O
suggest O
a O
wavelength O
dependence O
of O
straylight O
values O
, O
although O
this O
should O
be O
investigated O
further O
by O
controlling O
for O
pupil O
size O
and O
subjects O
' O
pigmentation O
, O
as O
well O
as O
by O
using O
neutral O
density O
filters O
. O
[]

Paracetamol O
( O
1.0 O
g O
) O
was O
co-ignested O
alone O
or O
with O
( O
300 O
mg O
) O
ferrous O
sulphate O
by O
ten O
healthy O
male O
volunteers O
, O
using O
saliva O
drug O
levels O
as O
a O
parameter O
. O
[]

300 O
microns O
and O
best-corrected O
visual O
acuity O
( O
BCVA O
) O
20/40 O
to O
20/200 O
. O
[]

Similar O
compliance O
and O
effect O
of O
treatment O
in O
chronic O
hepatitis O
C O
resulting O
from O
intravenous O
drug O
use O
in O
comparison O
with O
other O
infection O
causes O
. O
[]

The O
goals O
of O
the O
study O
were O
to O
evaluate O
the O
efficacy O
and O
reproducibility B-outcome ['Life-Impact']
of O
stapled O
hemorrhoidopexy O
and O
define O
its O
place O
among O
conventional O
techniques O
. O
['Life-Impact']

In O
the O
comparator O
group O
94 O
% O
improved O
clinically O
( O
either O
a O
complete O
or O
partial O
response O
) O
, O
while O
6 O
% O
were O
clinical O
failures O
. O
[]

All O
three O
groups O
were O
administered O
oxygen O
during O
the O
procedures O
. O
[]

Again O
, O
there O
was O
no O
main O
effect O
of O
condition O
on O
heat O
pain O
threshold O
( O
p O
= O
0.17 O
) O
, O
nor O
on O
cold O
pain O
threshold O
( O
p O
= O
0.65 O
) O
, O
nor O
on O
any O
of O
the O
secondary O
measures O
( O
p O
< O
0.56 O
for O
all O
) O
. O
[]

However O
, O
a O
50 O
% O
reduction O
of O
the O
median O
daily B-outcome ['Life-Impact']
ICS I-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
was O
observed O
in O
the O
control O
group O
. O
['Life-Impact']

One O
half O
of O
the O
home O
studies O
were O
randomly O
assigned O
to O
be O
performed O
with O
a O
sleep O
technician O
's O
set O
up O
of O
the O
equipment O
in O
the O
patient O
's O
home O
( O
group O
1 O
) O
, O
and O
the O
other O
half O
with O
the O
patient O
's O
own O
setup O
of O
the O
sleep-recording O
device O
( O
group O
2 O
) O
, O
after O
an O
instruction O
period O
in O
the O
hospital O
. O
[]

Supporting O
interruption O
management O
by O
indicating O
the O
modality O
and O
urgency O
of O
pending O
tasks O
. O
[]

The O
maternal O
primary O
outcomes O
are O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
during O
the O
first O
3 O
hours O
after O
trial O
analgesia B-outcome ['Resource-use']
and O
specifically O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
after O
60 O
minutes O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

OBJECTIVE O
To O
study O
the O
effect O
of O
vitamin O
B O
on O
treatment O
of O
hyperhomocysteinemia O
and O
endothelial O
dysfunction O
in O
renal-transplant O
recipients O
. O
[]

METHODS O
A O
clinic O
that O
provided O
initial O
medical O
evaluation O
, O
methadone O
medication O
, O
and O
AIDS O
education O
, O
but O
did O
not O
include O
formal O
drug O
abuse O
counseling O
or O
other O
social O
support O
services O
was O
established O
in O
New O
York O
City O
. O
[]

The O
study O
evaluated O
the O
efficacy O
a O
parent O
training O
intervention O
for O
children O
with O
autism O
based O
on O
the O
TEACCH O
model O
. O
[]

In O
this O
study O
eicosapentaenoic O
acid O
( O
EPA O
) O
and O
docosahexaenoic O
acid O
( O
DHA O
) O
were O
given O
in O
a O
cumulative O
manner O
, O
every O
6 O
weeks O
, O
starting O
with O
10 O
mg O
, O
then O
100 O
mg O
, O
1000 O
mg O
and O
10,000 O
mg O
EPA O
daily O
to O
mild O
to O
moderate O
essential O
hypertensive O
black O
patients O
. O
[]

Other O
outcomes O
include O
adherence B-outcome ['Life-Impact']
, O
error O
rates O
and O
health B-outcome ['Physiological-Clinical']
outcomes O
. O
['Life-Impact', 'Physiological-Clinical']

RESULTS O
Fecal B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
elastase I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
at O
7 O
, O
14 O
and O
28 O
days O
after O
birth O
were O
significantly O
higher O
than O
those O
at O
1 O
or O
2 O
days O
in O
both O
the O
early O
feeding O
and O
control O
groups O
. O
['Physiological-Clinical']

Comparison O
of O
percutaneous O
transmitral O
commissurotomy O
with O
Inoue O
balloon O
technique O
and O
metallic O
commissurotomy O
: O
immediate O
and O
short-term O
follow-up O
results O
of O
a O
randomized O
study O
. O
[]

A O
patient B-outcome ['Physiological-Clinical']
global I-outcome ['Physiological-Clinical']
rating I-outcome ['Physiological-Clinical']
scale O
showed O
clonidine O
treatment O
resulted O
in O
significant O
improvement O
in O
comparison O
with O
placebo O
. O
['Physiological-Clinical']

IL-6 B-outcome ['Physiological-Clinical']
and O
IL-8 B-outcome ['Physiological-Clinical']
levels O
in O
the O
UTI O
group O
were O
significantly O
lower O
than O
those O
in O
the O
control O
group O
during O
the O
time O
points O
of O
T O
( O
2 O
) O
-T O
( O
4 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
1976 O
we O
initiated O
a O
prospective O
study O
to O
specify O
the O
usefulness O
of O
thyroid O
stimulating O
antibody O
( O
TSAb O
) O
determinations O
in O
predicting O
the O
outcome O
of O
post-antithyroid O
drug O
treatment O
for O
Graves O
' O
disease O
. O
[]

Blinded O
assessors O
collected O
data O
at O
baseline O
and O
3-month O
and O
6-month O
follow-up O
. O
[]

The O
major O
impact O
of O
ASI O
was O
seen O
in O
patients O
with O
stage O
II O
disease O
, O
with O
a O
significantly O
longer O
recurrence-free B-outcome ['Physiological-Clinical']
period I-outcome ['Physiological-Clinical']
( O
p=0.011 O
) O
and O
61 O
% O
( O
18-81 O
) O
risk O
reduction O
for O
recurrences B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ca B-outcome ['Physiological-Clinical']
x I-outcome ['Physiological-Clinical']
P I-outcome ['Physiological-Clinical']
product I-outcome ['Physiological-Clinical']
levels O
were O
also O
significantly O
lower O
in O
the O
lanthanum O
carbonate O
group O
at O
the O
end O
of O
randomized O
treatment O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
differences O
between O
the O
two O
groups O
in O
symptomatic B-outcome ['Physiological-Clinical']
relief B-outcome ['Physiological-Clinical']
and O
electrophysiological B-outcome ['Physiological-Clinical']
parameters O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Ninety-three O
consecutive O
patients O
with O
gynecologic O
pelvic O
malignancies O
who O
underwent O
surgery O
including O
pelvic O
or O
pelvic O
and O
paraaortic O
lymphadenectomy O
were O
randomized O
during O
surgery O
to O
be O
treated O
with O
fibrin O
glue O
or O
not O
. O
[]

CONCLUSIONS O
Combined O
cardiac O
stem O
cell O
delivery O
induces O
a O
moderate O
but O
significant O
improvement O
in O
myocardial B-outcome ['Physiological-Clinical']
infarct I-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

A O
total O
of O
397 O
dogs O
free O
of O
adult O
heartworm O
infection O
from O
four O
heartworm-endemic O
areas O
of O
the O
USA O
were O
allocated O
randomly O
to O
six O
months O
of O
treatment O
with O
selamectin O
( O
n=298 O
) O
or O
ivermectin O
( O
n=99 O
) O
. O
[]

Both O
plasma O
epinephrine O
and O
blood O
lactate O
concentrations O
were O
higher O
in O
the O
PSE O
compared O
with O
the O
PLA O
trials O
, O
and O
preexercise O
and O
postexercise O
urinary O
PSE O
concentrations O
were O
significantly O
higher O
than O
the O
threshold O
( O
150 O
?g?mL O
) O
used O
by O
WADA O
to O
determine O
illicit O
PSE O
use O
. O
[]

PATIENTS O
21 O
ASA O
physical O
status O
I O
, O
II O
, O
and O
III O
patients O
at O
least O
18 O
years O
of O
age O
, O
undergoing O
transurethral O
surgery O
. O
[]

RESULTS O
Across O
studies O
, O
a O
higher O
percentage O
of O
children O
receiving O
LAIV O
had O
a O
? O
[]

The O
exon O
12 O
genotype O
was O
not O
associated O
with O
sex O
or O
age O
. O
[]

Mean O
total O
satisfaction B-outcome ['Life-Impact']
questionnaire O
scores O
were O
72 O
( O
SD O
9 O
) O
, O
76 O
( O
SD O
14 O
) O
, O
and O
78 O
( O
SD O
11 O
) O
, O
in O
the O
nurse O
specialist O
, O
inpatient O
and O
day O
patient O
groups O
, O
respectively O
( O
nurse O
specialist O
versus O
day O
patient O
, O
P O
= O
0.004 O
) O
. O
['Life-Impact']

Additional O
significant B-outcome ['Adverse-effects']
toxic I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
included O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
, O
hypotension B-outcome ['Physiological-Clinical']
, O
leukopenia B-outcome ['Physiological-Clinical']
, O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
primary O
endpoint O
will O
be O
the O
degree O
of O
vascular B-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
as O
obtained O
from O
percutaneous O
biopsy O
of O
gluteal O
subcutaneous O
resistance O
['Physiological-Clinical']

PURPOSE O
This O
study O
examined O
covariation O
among O
changes O
in O
dietary O
, O
physical O
activity O
, O
and O
sedentary O
behaviors O
over O
12 O
months O
among O
adolescents O
participating O
in O
a O
health O
behavior O
intervention O
. O
[]

RESULTS O
On O
postoperative O
day O
( O
POD O
) O
1 O
, O
there O
were O
no O
significant O
differences O
between O
the O
parameters O
of O
the O
two O
groups O
, O
but O
on O
PODs O
2 O
and O
3 O
, O
both O
the O
pain B-outcome ['Physiological-Clinical']
score O
( O
P O
= O
0.033 O
and O
P O
= O
0.011 O
, O
respectively O
) O
and O
the O
number O
of O
patients O
who O
required O
intramuscular B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
injections I-outcome ['Resource-use']
were O
significantly O
less O
in O
group O
1 O
( O
P O
= O
0.022 O
and O
P O
= O
0.007 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Resource-use']

0.1 O
% O
) O
was O
low O
and O
the O
responses O
to O
600 O
ml O
of O
W O
ingestion O
were O
repeatable O
. O
[]

A O
comparative O
study O
of O
the O
safety O
and O
efficacy O
of O
FemCap O
, O
a O
new O
vaginal O
barrier O
contraceptive O
, O
and O
the O
Ortho O
All-Flex O
diaphragm O
. O
[]

METHODS O
52 O
hips O
in O
52 O
patients O
( O
median O
age O
60 O
( O
51-64 O
) O
years O
, O
30 O
women O
) O
were O
randomized O
to O
either O
a O
MOM O
hip O
resurfacing O
system O
( O
ReCap O
) O
or O
a O
standard O
MOP O
total O
hip O
arthoplasty O
( O
Mallory O
Head/Exeter O
) O
. O
[]

PATIENTS O
AND O
METHODS O
Data O
were O
reviewed O
for O
patients O
enrolled O
in O
RECORD-1 O
( O
Renal O
Cell O
Cancer O
Treatment O
With O
Oral O
RAD001 O
Given O
Daily O
) O
at O
French O
sites O
. O
[]

A O
randomized O
controlled O
study O
of O
intrapleural O
instillation O
of O
Adriamycin O
( O
control O
group O
, O
30 O
patients O
) O
and O
Adriamycin O
Nocardia O
rubra O
cell O
wall O
skeleton O
( O
N-CWS O
group O
, O
26 O
patients O
) O
with O
tube O
thoracostomy O
was O
performed O
in O
55 O
patients O
with O
malignant O
pleural O
effusion O
due O
to O
primary O
lung O
cancer O
. O
[]

The O
program O
was O
primarily O
based O
on O
cognitive-behavioral O
modification O
principles O
, O
procedures O
and O
techniques O
. O
[]

METHODS O
We O
measured O
plasma O
norepinephrine O
content O
during O
ischemic O
events O
from O
blood O
obtained O
from O
automatic O
pump O
withdrawal O
with O
the O
assistance O
of O
a O
real-time O
ST O
segment O
depression O
monitor O
. O
[]

Peak O
AT O
force O
was O
significantly O
( O
p O
= O
.024 O
, O
ES O
= O
0.42 O
) O
less O
for O
18HL O
( O
2382 O
? O
[]

The O
results O
in O
diabetic O
patients O
were O
similar O
to O
those O
in O
nondiabetic O
patients O
. O
[]

METHODS O
A O
total O
of O
622 O
men O
and O
women O
with O
radiological O
evidence O
of O
primary O
knee O
OA O
and O
mild O
to O
severe O
symptoms O
were O
randomly O
assigned O
to O
treatment O
with O
a O
topical O
diclofenac O
solution O
plus O
placebo O
oral O
capsules O
, O
or O
placebo O
topical O
solution O
plus O
oral O
diclofenac O
( O
50 O
mg O
) O
capsules O
. O
[]

Persons O
with O
one O
or O
two O
l O
alleles O
or O
higher O
CSF B-outcome ['Physiological-Clinical']
5HIAA I-outcome ['Physiological-Clinical']
levels O
also O
exhibited O
greater O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
a O
mental O
stress O
protocol O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
randomly O
assigned O
to O
one O
of O
three O
groups O
: O
group O
1 O
received O
valsartan O
160 O
mg O
once O
daily O
( O
n O
= O
22 O
) O
; O
group O
2 O
received O
valsartan O
80 O
mg O
once O
daily O
plus O
benazepril O
5 O
or O
10 O
mg O
once O
daily O
( O
n O
= O
42 O
) O
; O
group O
3 O
received O
valsartan O
160 O
mg O
once O
daily O
plus O
benazepril O
5 O
or O
10 O
mg O
once O
daily O
( O
n O
= O
44 O
) O
. O
[]

Effect O
of O
ginseng O
extract O
supplementation O
on O
testicular B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
in O
diabetic O
rats O
. O
['Physiological-Clinical']

METHODS O
Data O
from O
an O
RCT O
( O
Trial O
of O
Etanercept O
and O
Methotrexate O
with O
Radiographic O
Patient O
Outcomes O
[ O
TEMPO O
] O
; O
n=682 O
) O
and O
an O
observational O
registry O
( O
Rheumatoid O
Arthritis O
DMARD O
Intervention O
and O
Utilization O
Study O
[ O
RADIUS O
II O
] O
; O
n=4341 O
) O
were O
used O
to O
evaluate O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
Clinical O
Disease O
Activity O
Index O
[ O
CDAI O
] O
score O
) O
over O
time O
in O
patients O
initiating O
etanercept O
( O
monotherapy O
or O
with O
methotrexate O
) O
. O
['Physiological-Clinical']

RESULTS O
When O
responses O
were O
averaged O
across O
the O
post-dose O
times O
, O
gabapentin O
: O
( O
1 O
) O
significantly O
increased O
the O
temporal O
summation O
pain B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
in O
skin O
compared O
with O
placebo O
( O
P O
= O
.03 O
) O
; O
( O
2 O
) O
significantly O
reduced O
the O
area O
under O
the O
pain B-outcome ['Physiological-Clinical']
intensity O
curve O
to O
hypertonic B-outcome ['Physiological-Clinical']
saline B-outcome ['Resource-use']
injections I-outcome ['Resource-use']
in O
the O
muscle O
( O
P O
= O
.02 O
) O
; O
and O
( O
3 O
) O
significantly O
reduced O
the O
area O
of O
pain B-outcome ['Physiological-Clinical']
evoked O
by O
hypertonic B-outcome ['Resource-use']
saline I-outcome ['Resource-use']
( O
P O
= O
.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Resource-use']

Total O
calcium B-outcome ['Physiological-Clinical']
and O
PTH B-outcome ['Physiological-Clinical']
levels O
were O
evaluated O
pre- O
and O
postoperatively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Side O
effects O
were O
reported O
by O
five O
patients O
receiving O
triple O
therapy O
( O
skin B-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
, O
one O
; O
nausea B-outcome ['Physiological-Clinical']
, O
two O
; O
headache B-outcome ['Physiological-Clinical']
, O
one O
; O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
one O
) O
, O
and O
four O
patients O
receiving O
dual O
therapy O
( O
skin B-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
, O
two O
; O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
one O
; O
diarrhoea B-outcome ['Physiological-Clinical']
, O
one O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
251 O
evaluable O
patients O
, O
three O
induction O
regimens O
achieved O
similar O
complete B-outcome ['Physiological-Clinical']
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
rates O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Development O
of O
the O
WAIS-III O
general O
ability O
index O
estimate O
( O
GAI-E O
) O
. O
[]

bolus O
followed O
by O
continuous O
i.v O
. O
[]

Participants O
were O
selected O
if O
they O
had O
a O
total O
laryngectomy O
and O
complained O
of O
rhinorrhea O
. O
[]

RESULTS O
The O
density O
, O
motility B-outcome ['Physiological-Clinical']
and O
morphology B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sperm I-outcome ['Physiological-Clinical']
were O
improved O
and O
sperm B-outcome ['Physiological-Clinical']
deformity I-outcome ['Physiological-Clinical']
rate O
was O
significantly O
decreased O
after O
treatment O
in O
both O
groups O
( O
P O
< O
0.01 O
) O
, O
but O
the O
effects O
in O
the O
treated O
group O
were O
better O
than O
those O
in O
the O
control O
group O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
3 O
months O
of O
treatment O
, O
the O
patients O
in O
the O
CA O
group O
had O
significantly O
lower B-outcome ['Physiological-Clinical']
GGT I-outcome ['Physiological-Clinical']
( O
1.4 O
+/- O
1.56 O
versus O
2.0 O
+/- O
3.19 O
times O
normal O
, O
P O
= O
0.016 O
) O
. O
['Physiological-Clinical']

The O
study O
was O
conducted O
at O
36 O
centers O
across O
the O
USA O
. O
[]

BACKGROUND O
Migraine O
substantially O
impairs O
HRQoL B-outcome ['Life-Impact']
and O
work B-outcome ['Life-Impact']
productivity I-outcome ['Life-Impact']
before O
, O
during O
, O
and O
after O
attacks O
. O
['Life-Impact', 'Life-Impact']

Teacher O
ratings O
on O
the O
Aberrant O
Behavior O
Checklist O
irritability B-outcome ['Life-Impact']
, O
stereotypy B-outcome ['Life-Impact']
, O
hyperactivity B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Postoperative O
pain O
after O
laparoscopic O
cholecystectomy O
( O
LC O
) O
is O
generally O
less O
than O
open O
cholecystectomy O
; O
however O
, O
the O
postoperative O
shoulder O
and O
abdominal O
pain O
experienced O
by O
patients O
still O
causes O
preventable O
distress O
. O
[]

BACKGROUND O
Sternal B-outcome ['Physiological-Clinical']
dehiscence I-outcome ['Physiological-Clinical']
and O
wound B-outcome ['Physiological-Clinical']
instability I-outcome ['Physiological-Clinical']
are O
troublesome O
complications O
following O
median O
sternotomy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

On O
a O
milligram-to-milligram O
basis O
, O
armodafinil O
200 O
mg O
consistently O
increased O
wakefulness O
more O
than O
modafinil O
200 O
mg O
, O
including O
times O
late O
in O
the O
8-hour O
shift O
. O
[]

Participants O
were O
recruited O
between O
2010 O
and O
2012 O
at O
four O
sites O
, O
had O
completed O
initial O
therapies O
, O
and O
had O
a O
body O
mass O
index O
between O
25 O
and O
45kg/m O
( O
2 O
) O
. O
[]

HPLC B-outcome ['Physiological-Clinical']
measurements O
of O
eicosanoid B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
in O
A23187-stimulated O
neutrophils O
revealed O
a O
considerable O
decrease O
in O
the O
formation O
of O
arachidonic B-outcome ['Physiological-Clinical']
acid-derived I-outcome ['Physiological-Clinical']
leukotriene I-outcome ['Physiological-Clinical']
B4 I-outcome ['Physiological-Clinical']
( O
LTB4 O
) O
, O
by O
41 O
% O
, O
and O
5-HETE B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
5-hydroxyeicosatetraenoic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
by O
30 O
% O
, O
in O
the O
fish-oil O
group O
along O
with O
the O
appearance O
of O
the O
corresponding O
EPA-derived O
products O
[ O
LTB5 O
and O
5-HEPE O
( O
5-hydroxyeicosapentaenoic O
acid O
) O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
analysis O
assessed O
the O
impact O
of O
clindamycin O
phosphate O
1.2 O
% O
-benzoyl O
peroxide O
2.5 O
% O
( O
clindamycin-BPO O
2.5 O
% O
) O
gel O
on O
HRQL O
in O
a O
combined O
study O
population O
( O
N O
= O
2813 O
) O
of O
participants O
with O
moderate O
to O
severe O
acne O
vulgaris O
. O
[]

Side O
effects O
included O
drowsiness B-outcome ['Physiological-Clinical']
and O
weight O
gain O
. O
['Physiological-Clinical']

RESULTS O
The O
AI O
of O
[]

METHODS O
We O
did O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
trial O
at O
76 O
centres O
in O
the O
Czech O
Republic O
, O
Germany O
, O
Hungary O
, O
India O
, O
Poland O
, O
Russia O
, O
Ukraine O
, O
Turkey O
, O
and O
the O
UK O
between O
Feb O
15 O
, O
2008 O
, O
and O
May O
14 O
, O
2010 O
. O
[]

The O
tPA B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
also O
dropped O
, O
both O
before O
and O
after O
VO O
, O
but O
tPA B-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
were O
unchanged O
, O
as O
were O
von B-outcome ['Physiological-Clinical']
Willebrand I-outcome ['Physiological-Clinical']
factor O
( O
vWF O
) O
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
the O
end O
of O
operation O
the O
patients O
were O
allocated O
to O
two O
groups O
. O
[]

A O
possible O
beneficial O
effect O
on O
overall O
survival O
should O
be O
tested O
with O
a O
higher O
statistical O
power O
. O
[]

Data O
were O
analyzed O
in O
2011 O
. O
[]

ISRCTN30249553 O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
compare O
conventional O
coronary O
angiography O
( O
A O
) O
vs O
rotational O
angiography O
( O
B O
) O
, O
focusing O
on O
radiation O
dose O
, O
amount O
of O
contrast O
administered O
, O
and O
total O
procedure O
time O
for O
both O
diagnostic O
and O
therapeutic O
percutaneous O
coronary O
interventions O
. O
[]

The O
DASH O
diet O
did O
not O
affect O
markers O
of O
fibrinolysis O
. O
[]

PATIENTS O
42 O
patients O
with O
coronary O
artery O
disease O
, O
scheduled O
to O
undergo O
coronary O
surgery O
. O
[]

This O
paper O
presents O
the O
protocol O
for O
Phase O
III O
. O
[]

Anesthesia O
was O
induced O
with O
thiopental O
( O
4.0 O
mg/kg O
) O
and O
maintained O
with O
isoflurane O
in O
70 O
% O
nitrous O
oxide O
and O
oxygen O
. O
[]

The O
precision O
of O
maximum O
strength O
assessments O
( O
1 O
repetition O
maximum O
; O
1RM O
) O
is O
important O
to O
evaluate O
the O
functional O
capacity O
and O
to O
prescribe O
and O
monitor O
the O
training O
load O
. O
[]

None O
of O
the O
subjects O
withdrew O
from O
the O
study O
. O
[]

Over O
six O
months O
, O
patients O
developing O
hyperglycemic B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
acetonemia I-outcome ['Physiological-Clinical']
were O
counted O
as O
study O
failures O
. O
['Physiological-Clinical']

RESULTS O
Eleven O
of O
23 O
patients O
( O
48 O
% O
) O
who O
completed O
8 O
weeks O
of O
fluoxetine O
treatment O
showed O
a O
HAM-D O
17 O
reduction O
of O
> O
or O
=50 O
% O
, O
while O
14 O
( O
38 O
% O
) O
of O
all O
treated O
patients O
had O
> O
or O
=50 O
% O
reduction O
in O
baseline O
HAM-D O
17 O
score O
. O
[]

In O
a O
16-week O
, O
double-blind O
, O
randomized O
, O
placebo-controlled O
trial O
, O
we O
evaluated O
the O
efficacy O
of O
supplementation O
with O
large O
doses O
of O
ARA O
added O
to O
DHA O
( O
n O
= O
7 O
) O
or O
placebo O
( O
n O
= O
6 O
) O
in O
13 O
participants O
( O
mean O
age O
, O
14.6 O
[ O
SD O
, O
5.9 O
] O
years O
) O
. O
[]

Here O
, O
we O
hypothesized O
that O
breaking O
down O
a O
complex O
movement O
, O
similar O
to O
a O
tennis O
backhand O
, O
into O
simpler O
parts O
and O
then O
using O
haptic O
feedback O
from O
a O
robotic O
exoskeleton O
would O
help O
the O
motor O
system O
learn O
the O
movement O
. O
[]

RESULTS O
Sixty-three O
volunteers O
were O
recruited O
into O
the O
study O
, O
with O
61 O
entered O
in O
the O
final O
analysis O
. O
[]

Effect O
of O
motivational O
music O
on O
lactate B-outcome ['Physiological-Clinical']
levels O
during O
recovery O
from O
intense O
exercise O
. O
['Physiological-Clinical']

We O
studied O
the O
effect O
of O
an O
angiotensin-converting O
enzyme O
inhibitor O
( O
ACE O
inhibitor O
) O
in O
a O
double-blind O
placebo-controlled O
study O
, O
on O
eight O
volunteers O
undergoing O
physical O
stress O
on O
an O
ergometric O
bicycle O
. O
[]

Abstract O
Tirasemtiv O
is O
a O
fast O
skeletal O
muscle O
activator O
that O
increases O
the O
sensitivity O
of O
the O
sarcomere O
to O
calcium O
, O
increasing O
the O
efficiency O
of O
muscle O
contraction O
when O
the O
muscle O
is O
stimulated O
at O
submaximal O
contraction O
frequencies O
. O
[]

A O
randomized O
, O
placebo-controlled O
trial O
of O
controlled O
release O
melatonin O
treatment O
of O
delayed O
sleep O
phase O
syndrome O
and O
impaired O
sleep O
maintenance O
in O
children O
with O
neurodevelopmental O
disabilities O
. O
[]

Similar O
improvements O
were O
seen O
for O
transcutaneous B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
13 O
[ O
9-17 O
] O
; O
p O
< O
0.0001 O
) O
, O
rest B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
-0.85 O
[ O
-1.6 O
to O
-0.12 O
] O
; O
p=0.025 O
) O
, O
and O
pain-free B-outcome ['Physiological-Clinical']
walking B-outcome ['Life-Impact']
time O
( O
1.2 O
[ O
0.7-1.7 O
] O
; O
p=0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Results O
suggest O
improvements O
in O
core O
autism O
deficits O
of O
joint O
engagement O
, O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
, O
and O
symbolic O
play O
with O
relatively O
brief O
, O
caregiver-mediated O
interventions O
, O
but O
additional O
support O
is O
necessary O
to O
maintain O
and O
generalize O
these O
gains O
over O
time O
. O
['Life-Impact']

For O
the O
mortality O
outcomes O
, O
neither O
of O
the O
supplement O
group O
outcomes O
was O
significantly O
different O
from O
the O
placebo O
group O
outcomes O
. O
[]

Naltrexone O
levels O
measured O
in O
17 O
children O
ranged O
from O
0.12 O
to O
5.60 O
ng/mL O
( O
mean O
= O
0.71 O
, O
standard O
error O
of O
the O
mean O
= O
0.32 O
) O
. O
[]

Treatment O
continued O
for O
a O
four-cycle O
maximum O
. O
[]

Efficacy O
of O
antiemetic O
therapy O
was O
evaluated O
as O
acute O
( O
Day O
1 O
) O
and O
overall O
was O
based O
on O
the O
worst O
day O
during O
the O
chemotherapy O
. O
[]

Gait B-outcome ['Life-Impact']
spatiotemporal I-outcome ['Life-Impact']
parameters O
were O
collected O
by O
use O
of O
the O
Vicon O
system O
at O
JM O
and O
JM O
+ O
30 O
. O
['Life-Impact']

Group O
A O
patients O
showed O
a O
significant O
increase O
in O
[]

The O
objective O
of O
this O
study O
was O
to O
access O
the O
effects O
of O
pentoxifylline O
plus O
risperidone O
in O
the O
treatment O
of O
autistic B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
. O
['Life-Impact']

RESULTS O
No O
significant O
difference O
was O
obtained O
with O
regard O
to O
examination B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
( O
180 O
vs. O
165 O
segments O
free O
from O
stools O
and O
fluid O
, O
p O
> O
0.05 O
) O
and O
overall O
diagnostic B-outcome ['Physiological-Clinical']
accuracy O
( O
16/17 O
colonic O
polyps O
detected O
in O
group O
A O
and O
12/13 O
in O
group O
B O
, O
p O
> O
0.05 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Moreover O
, O
lisinopril O
appeared O
to O
be O
better O
tolerated B-outcome ['Life-Impact']
than O
nifedipine O
in O
our O
study O
population O
. O
['Life-Impact']

CONCLUSIONS O
Haemodynamic O
changes O
following O
PTA O
continue O
for O
at O
least O
1 O
month O
, O
can O
be O
modified O
by O
GTN O
administration O
, O
and O
are O
predictive O
of O
subsequent O
restenosis O
. O
[]

METHODS O
Women O
were O
randomised O
to O
receive O
either O
LLETZ O
or O
NETZ O
. O
[]

Hunter O
DBT O
project O
: O
randomized O
controlled O
trial O
of O
dialectical O
behaviour O
therapy O
in O
women O
with O
borderline O
personality O
disorder O
. O
[]

Left O
ventricular B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
measured O
by O
echocardiography O
on O
day O
1 O
, O
3 O
, O
7 O
, O
14 O
, O
21 O
and O
28 O
; O
arrhythmia B-outcome ['Physiological-Clinical']
was O
analysed O
at O
Holter O
monitoring O
in O
day O
1 O
and O
2 O
of O
MI O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
data O
will O
be O
used O
for O
a O
cost-utility O
analysis O
of O
the O
results O
of O
the O
NMSG O
4/90 O
trial O
. O
[]

Furthermore O
, O
sildenafil O
improved O
exercise B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
( O
peak O
Vo B-outcome ['Physiological-Clinical']
( O
2 O
) O
) O
, O
ventilation B-outcome ['Physiological-Clinical']
efficiency O
( O
ventilation B-outcome ['Physiological-Clinical']
to O
CO B-outcome ['Physiological-Clinical']
( O
2 O
) O
production O
slope O
) O
, O
and O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
degree O
of O
drug-induced O
neutropenia B-outcome ['Physiological-Clinical']
resulting O
from O
a O
controlled O
trial O
( O
UKALL O
I O
) O
of O
treatment O
in O
acute O
lymphoblastic O
leukaemia O
was O
analysed O
. O
['Physiological-Clinical']

OBJECTIVE O
A O
heightened O
inflammatory O
response O
occurs O
after O
cardiac O
surgery O
. O
[]

Postprocedural B-outcome ['Physiological-Clinical']
TIMI I-outcome ['Physiological-Clinical']
3 I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
was O
obtained O
in O
89.7 O
% O
of O
the O
nicorandil O
group O
and O
in O
81.4 O
% O
of O
the O
placebo O
( O
hazard O
ratio O
, O
1.99 O
; O
95 O
% O
CI O
, O
1.09 O
to O
3.65 O
; O
P=0.025 O
) O
. O
['Physiological-Clinical']

Differences O
on O
magnetic B-outcome ['Resource-use']
resonance I-outcome ['Resource-use']
imaging I-outcome ['Resource-use']
( I-outcome ['Resource-use']
MRI I-outcome ['Resource-use']
) I-outcome ['Resource-use']
were O
calculated O
and O
the O
results O
were O
evaluated O
. O
['Resource-use']

Principal O
results O
of O
the O
Japanese O
trial O
to O
assess O
optimal O
systolic O
blood O
pressure O
in O
elderly O
hypertensive O
patients O
( O
JATOS O
) O
. O
[]

OBJECTIVE O
To O
assess O
in O
a O
randomized O
crossover O
trial O
the O
efficacy O
of O
continuous O
subcutaneous O
insulin O
infusion O
in O
improving O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
type O
1 O
diabetic O
patients O
with O
long-standing O
poor O
glycemic O
control O
. O
['Physiological-Clinical', 'Life-Impact']

All O
60 O
patients O
were O
then O
assigned O
to O
1 O
of O
3 O
groups O
according O
to O
demand O
for O
treatment O
. O
[]

Girls O
reported O
a O
higher O
perceived O
susceptibility B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
melanoma I-outcome ['Life-Impact']
than O
did O
boys O
. O
['Life-Impact']

INTERVENTIONS O
Subjects O
received O
riluzole O
( O
titrated O
to O
50 O
or O
100 O
mg/day O
based O
on O
bodyweight O
) O
or O
placebo O
in O
addition O
to O
risperidone O
( O
titrated O
up O
to O
2 O
or O
3 O
mg/day O
based O
on O
bodyweight O
) O
for O
10 O
weeks O
. O
[]

We O
then O
related O
the O
norepinephrine O
content O
to O
ischemic O
episodes O
assessed O
by O
48-h O
Holter O
recording O
, O
blood O
pressure O
reading O
by O
ambulatory O
blood O
pressure O
monitoring O
and O
patients O
' O
diaries O
. O
[]

MATERIAL O
AND O
METHODS O
A O
total O
of O
1195 O
patients O
in O
the O
LIFE-study O
had O
diabetes O
at O
the O
time O
of O
the O
randomisation O
. O
[]

The O
influence O
of O
sequential O
annual O
vaccination O
and O
of O
DHEA O
administration O
on O
the O
efficacy O
of O
the O
immune O
response O
to O
influenza O
vaccine O
in O
the O
elderly O
. O
[]

Subsequent O
dosing O
in O
both O
groups O
was O
based O
upon O
tacrolimus O
trough O
level O
monitoring O
. O
[]

One O
hundred O
and O
twenty O
untreated O
patients O
with O
stage O
III/IV O
bladder O
cancer O
were O
randomized O
to O
receive O
either O
gemcitabine O
( O
250 O
mg/m O
( O
2 O
) O
) O
6-h O
infusion O
on O
days O
1 O
and O
8 O
, O
and O
cisplatin O
( O
70 O
mg/m O
( O
2 O
) O
) O
on O
day O
2 O
every O
21-day O
cycle O
( O
arm O
1 O
) O
or O
gemcitabine O
( O
1,250 O
mg/m O
( O
2 O
) O
) O
30-min O
infusion O
on O
days O
1 O
and O
8 O
, O
with O
the O
same O
dose O
of O
cisplatin O
( O
arm O
2 O
) O
. O
[]

After O
medication O
washout O
, O
patients O
were O
treated O
with O
placebo O
followed O
by O
hydrochlorothiazide O
. O
[]

The O
lengths O
of O
disease-free B-outcome ['Physiological-Clinical']
status B-outcome ['Physiological-Clinical']
and O
survival B-outcome ['Mortality']
of O
patients O
treated O
with O
VAC O
plus O
ADR O
or O
VAC O
plus O
RT O
did O
not O
differ O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Effect O
of O
practice O
on O
laterality O
in O
a O
mental O
rotation O
task O
. O
[]

Atypical O
neuroleptics O
, O
including O
olanzapine O
, O
may O
have O
less O
risk O
for O
dyskinesia O
, O
but O
their O
efficacy O
in O
autistic O
disorder O
is O
not O
established O
. O
[]

The O
mean O
disease O
duration O
was O
64 O
months O
. O
[]

No O
patient O
presented O
additional O
risk O
factors O
for O
increased O
reactive O
oxygen O
species O
levels O
. O
[]

However O
, O
significantly O
greater O
increases O
in O
plasma B-outcome ['Physiological-Clinical']
ALA I-outcome ['Physiological-Clinical']
levels O
from O
baseline O
to O
24h O
were O
observed O
after O
ingestion O
of O
Entrox O
vs. O
non-coated O
product O
, O
suggesting O
a O
possible O
benefit O
of O
Entrox O
with O
long-term O
treatment O
. O
['Physiological-Clinical']

Actual O
market O
input O
and O
output O
prices O
were O
recorded O
. O
[]

It O
is O
a O
transformation O
of O
a O
postal O
mailed O
intervention O
to O
a O
web-based O
intervention O
. O
[]

Anxiety O
was O
reported O
in O
66 O
% O
in O
Mi+Mo O
and O
in O
64 O
% O
in O
Mo O
alone O
at O
randomisation O
( O
NS O
) O
; O
15 O
min O
thereafter O
in O
31 O
% O
and O
39 O
% O
( O
p=0.002 O
) O
and O
finally O
in O
12 O
% O
and O
26 O
% O
respectively O
( O
p O
< O
0.0001 O
) O
. O
[]

More O
than O
50 O
% O
of O
the O
wound B-outcome ['Physiological-Clinical']
area O
had O
closed B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
evaluated O
whether O
exercise O
separately O
or O
in O
combination O
with O
SM O
training O
is O
effective O
at O
increasing O
perceived O
ability O
to O
manage O
stress O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Nasal O
allergic O
inflammation O
enhances O
bone-marrow O
eosinophil O
production O
, O
mainly O
via O
IL-5 O
, O
and O
rhinitis O
patients O
have O
increased O
airway O
inflammation O
during O
the O
pollen O
season O
. O
[]

The O
study O
was O
a O
blinded O
, O
exploratory O
evaluation O
of O
the O
PlayWisely O
program O
on O
autism B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
essential B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
foundation I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
( O
attention B-outcome ['Life-Impact']
, O
recognition B-outcome ['Life-Impact']
, O
and O
memory B-outcome ['Life-Impact']
skills B-outcome ['Life-Impact']
) O
in O
children O
with O
a O
diagnosis O
of O
autism O
, O
autism O
spectrum O
disorder O
( O
ASD O
) O
, O
pervasive O
developmental O
disorder O
- O
not O
otherwise O
specified O
( O
PDD-NOS O
) O
, O
and O
Asperger O
syndrome O
( O
AS O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

AIM O
To O
test O
the O
efficacy O
of O
a O
new O
synbiotic O
formulation O
containing O
Lactobacillus O
paracasei O
B21060 O
, O
arabinogalactan O
and O
xilooligosaccharides O
in O
children O
with O
acute O
diarrhoea O
. O
[]

CONCLUSION O
A O
5-day O
course O
of O
nitrofurantoin O
is O
equivalent O
clinically O
and O
microbiologically O
to O
a O
3-day O
course O
of O
trimethoprim-sulfamethoxazole O
and O
should O
be O
considered O
an O
effective O
fluoroquinolone-sparing O
alternative O
for O
the O
treatment O
of O
acute O
cystitis O
in O
women O
. O
[]

Both O
groups O
had O
the O
leg O
elevated O
30? O
at O
the O
hip O
over O
an O
inactive O
CPM O
for O
72 O
h O
postoperatively O
. O
[]

The O
Aberrant O
Behavior O
Checklist-Community O
Version O
( O
ABC-CV O
) O
and O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions I-outcome ['Physiological-Clinical']
( O
CGI O
) O
scale O
were O
used O
as O
outcome O
variables O
. O
['Life-Impact', 'Physiological-Clinical']

METHODS O
Infants O
born O
to O
mothers O
with O
hemoglobin O
( O
Hb O
) O
< O
100 O
g/L O
were O
randomized O
at O
delivery O
to O
either O
immediate O
cord O
clamping O
( O
early O
group O
) O
or O
cord O
clamping O
delayed O
till O
descent O
of O
placenta O
into O
vagina O
( O
delayed O
group O
) O
. O
[]

42 O
participants O
were O
randomized O
into O
a O
9-week O
MBT-AS O
training O
or O
a O
wait-list O
control O
group O
. O
[]

Clinical O
equivalence O
( O
noninferiority B-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of O
the O
FemCap O
compared O
with O
the O
diaphragm O
, O
as O
defined O
in O
this O
study O
, O
would O
mean O
that O
the O
true O
risk O
of O
pregnancy B-outcome ['Physiological-Clinical']
among O
FemCap O
users O
was O
no O
more O
than O
1.73 O
times O
the O
pregnancy B-outcome ['Physiological-Clinical']
risk O
of O
diaphragm O
users O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Cognitive-behavioral O
therapy O
for O
psychogenic O
nonepileptic O
seizures O
: O
a O
pilot O
RCT O
. O
[]

In O
an O
exploratory O
analysis O
of O
prespecified O
stratification O
factors O
by O
ER O
and O
PR O
expression O
there O
were O
trends O
toward O
improved O
DFS O
for O
AT O
in O
ER/PR-negative O
disease O
. O
[]

RESULTS O
Fifty-eight O
patients O
( O
72.5 O
% O
) O
were O
positive O
for O
hepatitis O
B O
surface O
antibody O
, O
and O
HBV O
DNA O
was O
undetectable O
in O
50 O
patients O
( O
62.5 O
% O
) O
. O
[]

Eligible O
subjects O
were O
randomly O
allocated O
to O
receive O
either O
clonidine O
( O
75 O
micrograms O
twice O
daily O
) O
or O
a O
placebo O
. O
[]

According O
to O
the O
NICE O
guidelines O
regarding O
eligibility O
for O
BRCA1 O
and O
BRCA2 O
testing O
, O
the O
families O
of O
66 O
% O
of O
the O
at O
risk O
group O
and O
13 O
% O
of O
the O
women O
with O
breast O
cancer O
would O
be O
eligible O
for O
testing O
( O
probability O
of O
BRCA1 O
mutation O
> O
or=20 O
% O
) O
. O
[]

In O
the O
vein O
bypass O
group O
, O
patency B-outcome ['Physiological-Clinical']
rate O
was O
unaffected O
( O
75.3 O
% O
in O
the O
WASA O
group O
versus O
74.9 O
% O
in O
the O
ASA O
group O
) O
. O
['Physiological-Clinical']

A O
battery O
of O
non-invasive O
tests O
appears O
useful O
for O
the O
characterization O
of O
cardiovascular O
drugs O
. O
[]

A O
randomized O
trial O
of O
a O
behavioral O
intervention O
for O
black O
MSM O
: O
the O
DiSH O
study O
. O
[]

Patients O
were O
assessed O
on O
days O
1 O
, O
2 O
, O
7 O
, O
14 O
, O
30 O
, O
60 O
, O
and O
90 O
. O
[]

Desmopressin O
in O
the O
treatment O
of O
nocturia O
: O
a O
double-blind O
, O
placebo-controlled O
study O
. O
[]

Two O
studies O
examined O
whether O
adults O
and O
children O
could O
learn O
to O
make O
context-dependent O
inferences O
about O
novel O
stimuli O
and O
the O
role O
of O
awareness O
of O
context O
cues O
in O
such O
learning O
. O
[]

The O
increase O
in O
[]

All O
patients O
underwent O
classical O
radical O
hysterectomy O
. O
[]

A O
morphological O
study O
of O
biopsies O
taken O
via O
a O
gastroscope O
from O
the O
corpus O
mucosa O
showed O
no O
change O
in O
mucosal B-outcome ['Physiological-Clinical']
height I-outcome ['Physiological-Clinical']
, O
parietal B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
unit I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
or O
changes O
in O
cellular B-outcome ['Physiological-Clinical']
infiltration I-outcome ['Physiological-Clinical']
after O
30 O
and O
90 O
days O
treatment O
in O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Linguistic B-outcome ['Life-Impact']
alignment I-outcome ['Life-Impact']
in O
adults O
with O
and O
without O
Asperger O
's O
syndrome O
. O
['Life-Impact']

In O
the O
recovery O
room O
, O
patient-controlled O
analgesia O
i.v O
. O
[]

Double-blind O
, O
placebo-controlled O
, O
dose-ranging O
study O
of O
new O
recombinant O
hypoallergenic O
Bet O
v O
1 O
in O
an O
environmental O
exposure O
chamber O
. O
[]

Steroids O
were O
then O
tapered O
using O
a O
defined O
schedule O
. O
[]

The O
most O
common O
adverse O
events O
included O
, O
grade O
1/2 O
acneiform B-outcome ['Physiological-Clinical']
skin B-outcome ['Physiological-Clinical']
rash B-outcome ['Physiological-Clinical']
( O
86 O
% O
) O
, O
and O
grade O
3 O
radiodermatitis B-outcome ['Physiological-Clinical']
, O
( O
16 O
% O
) O
, O
diarrhea B-outcome ['Physiological-Clinical']
( O
11 O
% O
) O
and O
hypersensitivity B-outcome ['Physiological-Clinical']
( O
5 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Using O
binary O
logistic O
regression O
, O
we O
examined O
the O
effect O
of O
specific O
covariables O
on O
rates O
of O
physician O
counseling O
. O
[]

RESULTS O
The O
pain B-outcome ['Physiological-Clinical']
scores O
were O
comparable O
in O
both O
groups O
at O
all O
times O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
long-term O
efficacy O
of O
hepatitis O
B O
vaccine O
10 O
years O
after O
primary O
immunization O
to O
provide O
scientific O
basis O
for O
the O
time O
of O
revaccination O
. O
[]

There O
was O
no O
blood B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
on O
the O
bougie O
, O
laryngoscope O
or O
introducer O
tool O
at O
removal O
, O
but O
blood B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
was O
more O
common O
on O
the O
ProSeal O
Laryngeal O
Mask O
Airway O
with O
the O
introducer O
tool O
technique O
( O
9/50 O
vs O
2/50 O
, O
P=0.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Marginal O
biotin O
deficiency O
during O
normal O
pregnancy O
. O
[]

BACKGROUND O
Social O
and O
communication O
impairments O
are O
core O
deficits O
and O
prognostic O
indicators O
of O
autism O
. O
[]

Patients O
were O
randomly O
assigned O
to O
receive O
either O
prazosin O
( O
n O
= O
15 O
) O
or O
captopril O
( O
n O
= O
16 O
) O
. O
[]

The O
increase O
in O
the O
number O
of O
decayed B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
filled I-outcome ['Physiological-Clinical']
root I-outcome ['Physiological-Clinical']
surfaces I-outcome ['Physiological-Clinical']
after O
one O
year O
was O
significantly O
lower O
in O
the O
experimental O
groups O
than O
in O
the O
control O
group O
. O
['Physiological-Clinical']

METHODS O
One O
thousand O
patients O
with O
initial O
World O
Federation O
of O
Neurological O
Surgeons O
grades O
of O
I O
to O
III O
undergoing O
clipping O
of O
intracranial O
aneurysms O
after O
subarachnoid O
hemorrhage O
were O
randomized O
to O
intraoperative O
normothermia O
( O
36 O
degrees O
C-37 O
degrees O
C O
) O
or O
hypothermia O
( O
32.5 O
degrees O
C-33.5 O
degrees O
C O
) O
. O
[]

Dietary B-outcome ['Life-Impact']
compensation I-outcome ['Life-Impact']
was O
incomplete O
( O
beverage O
53 O
% O
; O
solid O
78 O
% O
) O
and O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
increased O
after O
the O
beverage O
( O
1.95 O
? O
['Life-Impact', 'Physiological-Clinical']

AIMS O
To O
investigate O
the O
impact O
of O
variations O
in O
clinical O
context O
on O
blood O
pressure O
measurement O
in O
a O
simulator-based O
OSCE O
. O
[]

At O
24 O
h O
and O
7 O
d O
after O
irradiation O
with O
erythemogenic O
doses O
of O
UVB O
to O
the O
backs O
of O
16 O
Japanese O
subjects O
, O
the O
degree O
of O
induced B-outcome ['Physiological-Clinical']
erythema I-outcome ['Physiological-Clinical']
( O
delta O
erythema I-outcome ['Physiological-Clinical']
index O
) O
and O
that O
of O
pigmentation B-outcome ['Physiological-Clinical']
( O
delta O
melanin B-outcome ['Physiological-Clinical']
index O
) O
were O
examined O
by O
an O
image O
analytic O
method O
using O
a O
videomicroscope O
interfaced O
with O
a O
computer O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Primary O
end O
points O
were O
changes O
in O
infarct B-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
and O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
3 O
months O
after O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIM O
To O
compare O
a O
limited O
palmar O
incision O
for O
carpal O
tunnel O
release O
( O
CTR O
) O
with O
a O
traditional O
open O
technique O
, O
which O
is O
still O
considered O
the O
gold O
standard O
. O
[]

CONCLUSIONS O
Salbutamol O
was O
shown O
to O
be O
effective O
and O
safe O
in O
the O
treatment O
of O
acute O
bronchiolitis O
. O
[]

CONCLUSION O
Direct O
patient O
care O
services O
provided O
by O
a O
clinical O
pharmacist O
, O
in O
addition O
to O
routine O
clinical O
services O
, O
have O
a O
positive O
effect O
on O
the O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
African-American O
renal O
transplant O
patients O
. O
['Physiological-Clinical']

SETTING O
University O
research O
laboratory O
. O
[]

METHODS O
In O
this O
phase O
2b O
, O
double-blind O
, O
multicentre O
trial O
, O
patients O
( O
aged O
18-75 O
years O
) O
with O
, O
or O
with O
high O
risk O
of O
, O
coronary O
heart O
disease O
were O
randomly O
assigned O
( O
1:1 O
) O
to O
dalcetrapib O
600 O
mg/day O
or O
placebo O
for O
24 O
months O
. O
[]

CONCLUSIONS O
It O
was O
determined O
that O
injection O
duration O
had O
an O
effect O
on O
bruising O
and O
pain O
following O
the O
subcutaneous O
administration O
of O
heparin O
. O
[]

There O
was O
no O
increase O
in O
suicidal B-outcome ['Life-Impact']
ideation I-outcome ['Life-Impact']
. O
['Life-Impact']

Response O
to O
tubular O
airway O
resistance O
in O
normal O
subjects O
and O
postoperative O
patients O
. O
[]

METHODS O
72 O
patients O
were O
randomized O
to O
either O
ziprasidone O
or O
placebo O
and O
treated O
prospectively O
for O
6 O
weeks O
. O
[]

RESULTS O
Youth O
receiving O
CBT O
showed O
substantial O
improvement O
relative O
to O
TAU O
on O
primary O
anxiety B-outcome ['Life-Impact']
outcomes O
. O
['Life-Impact']

We O
identified O
54 O
patients O
with O
JET O
( O
incidence O
= O
1.4 O
% O
) O
. O
[]

However O
, O
in O
the O
first O
three O
cycles O
, O
serum B-outcome ['Physiological-Clinical']
triglyceride B-outcome ['Physiological-Clinical']
increased O
by O
46 O
% O
and O
40 O
% O
and O
HDL-cholesterol B-outcome ['Physiological-Clinical']
by O
14 O
% O
and O
8 O
% O
in O
the O
GTD B-outcome ['Physiological-Clinical']
and O
DSG B-outcome ['Physiological-Clinical']
groups O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Local O
therapeutic O
drug O
committees O
consider O
the O
approximately O
15 O
% O
overall O
survival B-outcome ['Mortality']
benefit O
seen O
at O
5 O
years O
for O
DLBCL O
when O
rituximab O
is O
added O
to O
combination O
chemotherapy O
as O
too O
marginal O
for O
justifying O
the O
arising O
additional O
expenses O
. O
['Mortality']

RESULTS O
Both O
groups O
exhibited O
significant O
decreases O
in O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
, O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
and O
['Physiological-Clinical', 'Life-Impact']

With O
baseline O
abstinence O
and O
other O
statistically O
important O
covariates O
adjusted O
, O
hierarchical O
logistic O
regression O
analyses O
demonstrated O
that O
the O
associations O
between O
social O
support O
at O
study O
baseline O
and O
biochemically O
confirmed O
abstinence O
3 O
months O
later O
varied O
by O
type O
of O
support O
and O
by O
drug O
. O
[]

RESULTS O
Significant O
differences O
( O
P O
< O
0.05 O
) O
with O
initial O
values O
were O
found O
after O
a O
2 O
mm O
marginal O
bone O
removal O
( O
Osstell/Periotest O
) O
; O
for O
a O
peri-apical B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
, O
after O
removal O
of O
5 O
mm O
( O
Osstell O
) O
or O
8 O
mm O
( O
Periotest O
) O
; O
for O
a O
6-mm-long O
dehiscence O
, O
after O
removal O
up O
to O
180 O
degrees O
of O
the O
implant O
perimeter O
( O
Osstell/Periotest O
) O
; O
for O
a O
3-mm-wide O
dehiscence O
, O
after O
removal O
of O
10 O
mm O
( O
Osstell O
) O
or O
6 O
mm O
( O
Periotest O
) O
. O
['Physiological-Clinical']

The O
study O
is O
registered O
at O
ClinicalTrials.gov O
, O
number O
NCT00626106 O
. O
[]

Under O
there O
conditions O
, O
tobramycin O
could O
not O
be O
measured O
in O
the O
serum O
. O
[]

Monitoring O
of O
CA19-9 O
and O
SPan-1 O
can O
facilitate O
the O
earlier O
confirmation O
of O
progressing O
pancreatic O
cancer O
during O
chemotherapy O
. O
[]

CONCLUSIONS O
During O
the O
first O
6 O
months O
following O
a O
planned O
quit O
attempt O
, O
being O
abstinent O
in O
a O
particular O
week O
appears O
to O
be O
associated O
with O
lower O
levels O
of O
concurrent B-outcome ['Life-Impact']
depressive I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

There O
was O
a O
strong O
correlation O
between O
maximum O
force O
measurements O
and O
stimulation O
order O
, O
which O
was O
not O
apparent O
in O
the O
fatigue B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
or O
FTI B-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
SST-GP O
had O
higher O
efficacy O
than O
the O
LA-GP O
. O
[]

The O
effectiveness O
of O
physical O
activity O
monitoring O
and O
distance O
counselling O
in O
an O
occupational O
health O
setting O
-- O
a O
research O
protocol O
for O
a O
randomised O
controlled O
trial O
( O
CoAct O
) O
. O
[]

Reducing O
breast B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
with O
weight O
loss O
, O
a O
vanguard O
trial O
: O
the O
Exercise O
and O
Nutrition O
to O
Enhance O
Recovery O
and O
Good O
Health O
for O
You O
( O
ENERGY O
) O
Trial O
. O
['Physiological-Clinical']

CONCLUSIONS O
These O
results O
indicate O
that O
E-PEG O
was O
safe O
, O
tolerable B-outcome ['Life-Impact']
and O
speedy O
when O
compared O
ordinary O
pull-method O
PEG O
. O
['Life-Impact']

METHODS O
Thirteen O
patients O
with O
HBeAg-negative O
CHB O
received O
peginterferon O
alfa-2a O
( O
180 O
microg/week O
) O
for O
60 O
wk O
or O
peginterferon O
alfa-2a O
( O
180 O
microg/week O
) O
for O
12 O
wk O
followed O
by O
48 O
wk O
of O
peginterferon O
alfa-2a O
plus O
lamivudine O
. O
[]

In O
the O
92 O
randomized O
patients O
with O
C4 O
disease O
, O
41 O
refused O
postoperative O
AVP O
, O
leaving O
51 O
compliant O
patients O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
outcomes O
within O
6 O
months O
were O
assessed O
. O
['Physiological-Clinical']

The O
effect O
lasted O
for O
the O
entire O
period O
of O
drug O
administration O
and O
in O
50 O
% O
of O
patients O
a O
normal O
platelet O
aggregation O
was O
maintained O
until O
the O
fourth O
day O
after O
discontinuation O
of O
the O
drug O
. O
[]

If O
the O
diastolic O
BP O
stayed O
above O
80 O
mm O
Hg O
, O
the O
physician O
blinded O
to O
randomization O
intensified O
hypertensive O
treatment O
. O
[]

Twenty-seven O
patients O
experienced O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
reported O
as O
drug O
related O
. O
['Adverse-effects']

In O
general O
, O
the O
patients O
were O
eligible O
, O
documentation O
of O
clinical O
data O
was O
fair O
to O
good O
and O
there O
were O
no O
systematic O
major O
protocol O
deviations O
. O
[]

RESULTS O
During O
sitting O
, O
shoulder B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
was O
greater O
for O
both O
groups O
, O
whereas O
shoulder B-outcome ['Physiological-Clinical']
extension I-outcome ['Physiological-Clinical']
and O
elbow B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
, O
part O
of O
the O
flexion O
synergy O
, O
were O
greater O
only O
in O
individuals O
with O
stroke O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Following O
T3 O
therapy O
, O
CPB O
was O
discontinued O
in O
all O
patients O
. O
[]

MEASUREMENTS/MAIN O
RESULTS O
Oral B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
was O
measured O
before O
dosing O
, O
30 O
minutes O
after O
dosing O
, O
and O
hourly O
thereafter O
for O
8 O
hours O
after O
the O
dose O
. O
['Physiological-Clinical']

Intra-articular O
hyaluronic O
acid O
compared O
to O
exercise O
therapy O
in O
osteoarthritis O
of O
the O
ankle O
. O
[]

Continuous O
hemofiltration O
or O
hemodiafiltration O
is O
the O
representative O
technology O
. O
[]

Patients O
not O
fulfilling O
these O
criteria O
should O
have O
primary B-outcome ['Physiological-Clinical']
colostomy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Among O
patients O
enrolled O
in O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
trial O
comparing O
intravenous O
heparin O
, O
aspirin O
, O
both O
treatments O
, O
and O
neither O
during O
the O
acute O
phase O
of O
unstable O
angina O
, O
we O
encountered O
patients O
in O
whom O
unstable O
angina O
was O
reactivated O
after O
heparin O
was O
discontinued O
. O
[]

CONCLUSION O
Thermal O
destruction O
of O
the O
endometrium O
for O
the O
treatment O
of O
menorrhagia O
should O
be O
considered O
an O
effective O
therapeutic O
option O
because O
of O
its O
acceptability B-outcome ['Life-Impact']
among O
patients O
, O
shorter O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
and O
lower O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

However O
, O
the O
mean O
6-month O
change O
in O
central B-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CMT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
the O
combination O
group O
was O
-124 O
?m O
( O
-29.7 O
% O
; O
p O
< O
0.001 O
) O
, O
while O
in O
the O
ranibizumab-only O
group O
, O
the O
change O
was O
-86.9 O
?m O
( O
-19.5 O
% O
; O
p=0.001 O
) O
; O
thus O
, O
the O
combination O
treatment O
resulted O
in O
a O
greater O
reduction O
( O
p=0.003 O
) O
. O
['Physiological-Clinical']

RESULTS O
CS O
gel O
was O
safe O
with O
no O
reported O
severe O
or O
life-threatening B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AE O
) O
. O
['Adverse-effects']

Patients O
were O
evaluated O
for O
PCP B-outcome ['Physiological-Clinical']
, O
mortality B-outcome ['Mortality']
, O
morbidity B-outcome ['Physiological-Clinical']
and O
progression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
HIV I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

An O
analysis O
of O
change O
in O
the O
NYHA O
status O
from O
study O
entry O
to O
study O
end O
showed O
a O
statistically O
significant O
difference O
between O
the O
two O
groups O
( O
p O
= O
0.02 O
) O
in O
favour O
of O
quinapril O
. O
[]

Compared O
with O
baseline O
, O
there O
was O
a O
significant O
reduction O
of O
S. O
mutans O
in O
all O
groups O
. O
[]

A O
blinded O
, O
randomized O
, O
controlled O
trial O
assessing O
conservative O
management O
strategies O
for O
frozen O
shoulder O
. O
[]

Addition O
or O
exclusion O
of O
PAF O
sperm O
treatment O
in O
the O
same O
patients O
did O
not O
significantly O
alter O
the O
outcome O
. O
[]

BACKGROUND O
The O
effects O
of O
short- O
and O
long-term O
risperidone O
treatment O
on O
serum O
prolactin O
were O
assessed O
in O
children O
and O
adolescents O
with O
autism O
. O
[]

These O
findings O
are O
discussed O
in O
relation O
to O
the O
existing O
attitude O
strength O
literature O
. O
[]

Three O
hundred O
and O
forty-seven O
( O
87 O
% O
) O
had O
CIN O
in O
the O
treatment O
specimen O
and O
could O
be O
included O
in O
the O
analysis O
of O
excision O
margins O
. O
[]

INTERVENTIONS O
The O
patients O
slept O
at O
0 O
degrees O
, O
15 O
degrees O
, O
30 O
degrees O
, O
and O
45 O
degrees O
in O
random O
order O
. O
[]

The O
physicians O
were O
asked O
to O
update O
the O
list O
and O
, O
if O
appropriate O
, O
to O
sign O
letters O
to O
potentially O
eligible O
and O
interested O
women O
. O
[]

The O
30 O
heifers O
were O
randomly O
assigned O
to O
three O
groups O
of O
10 O
heifers O
each O
. O
[]

When O
individual O
data O
from O
two O
other O
similar O
studies O
were O
included O
in O
an O
IPDMA O
, O
the O
interaction O
terms O
became O
statistically O
significant O
( O
p=0.009 O
) O
indicating O
that O
there O
is O
a O
beneficial O
treatment O
effect O
when O
ODR O
values O
are O
slightly O
elevated O
. O
[]

OBJECTIVES O
Minimal O
extracorporeal O
circulation O
( O
MECC O
) O
has O
been O
introduced O
in O
coronary O
artery O
bypass O
graft O
( O
CABG O
) O
surgery O
, O
offering O
clinical O
benefits O
owing O
to O
reduced O
hemodilution O
and O
no O
blood-air O
interface O
. O
[]

Yoga O
effects O
on O
mood B-outcome ['Life-Impact']
and O
quality O
of O
life O
in O
Chinese O
women O
undergoing O
heroin O
detoxification O
: O
a O
randomized O
controlled O
trial O
. O
['Life-Impact']

RESULTS O
Comparisons O
between O
naltrexone O
and O
baseline O
, O
but O
not O
naltrexone O
and O
placebo O
, O
on O
parent O
and O
teacher O
ratings O
showed O
statistical O
significance O
. O
[]

One O
hundred O
and O
ten O
patients O
were O
available O
for O
evaluation O
of O
response O
. O
[]

Information O
will O
be O
collected O
on O
specific O
physical O
, O
psychological O
, O
and O
physiological O
factors O
to O
allow O
exploration O
of O
possible O
mechanisms O
of O
action O
through O
which O
yoga O
could O
relieve B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Does O
surface O
preparation O
alter O
ALA B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
in O
superficial O
non-melanoma O
skin O
cancer O
in O
vivo O
? O
['Physiological-Clinical']

RESULTS O
Four O
hundred O
fifty-three O
children O
with O
ASD O
and O
125 O
DD O
children O
were O
included O
. O
[]

Comparable O
clinical B-outcome ['Physiological-Clinical']
benefits O
and O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
noted O
with O
the O
two O
medications O
. O
['Physiological-Clinical', 'Adverse-effects']

CONCLUSIONS O
The O
effect O
of O
latanoprost O
was O
additive O
to O
that O
of O
timolol O
, O
and O
a O
good O
effect O
on O
IOP B-outcome ['Physiological-Clinical']
reduction O
was O
also O
achieved O
by O
switching O
from O
timolol O
to O
latanoprost O
, O
suggesting O
that O
a O
switch O
in O
many O
patients O
is O
an O
effective O
alternative O
to O
combination O
treatment O
. O
['Physiological-Clinical']

Forty-one O
migraine O
subjects O
( O
26 O
males O
, O
15 O
females O
) O
, O
mean O
age O
36 O
+/- O
2 O
years O
( O
range O
36-39 O
years O
) O
, O
and O
20 O
healthy O
control O
subjects O
( O
14 O
males O
, O
six O
females O
) O
, O
mean O
age O
36 O
+/- O
2 O
years O
( O
range O
36-39 O
years O
) O
were O
randomized O
( O
double-blind O
) O
to O
receiving O
sumatriptan O
( O
group O
A O
) O
or O
placebo O
( O
group O
B O
) O
. O
[]

In O
the O
Er O
, O
Cr O
: O
YSGG O
laser O
group O
, O
sensitive O
teeth O
were O
irradiated O
with O
Er O
, O
Cr O
: O
YSGG O
laser O
in O
the O
hard O
tissue O
mode O
using O
a O
none-contact O
probe O
at O
an O
energy O
level O
of O
0.25W O
and O
repetition O
rate O
of O
20Hz O
, O
0 O
% O
water O
and O
10 O
% O
air O
. O
[]

Nonfasting B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
and O
lipoproteins B-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
tHcy I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
cysteine I-outcome ['Physiological-Clinical']
levels O
were O
measured O
in O
the O
children O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
nocturnal B-outcome ['Physiological-Clinical']
IOP I-outcome ['Physiological-Clinical']
reductions I-outcome ['Physiological-Clinical']
were O
statistically O
significant O
( O
P O
< O
.001 O
, O
two-tailed O
paired O
Student O
's O
t O
test O
) O
. O
['Physiological-Clinical']

Hypertension O
is O
associated O
with O
impaired O
fibrinolysis O
. O
[]

CONCLUSIONS O
Immunoenhanced O
enteral O
nutrition O
formulas O
improved O
the O
infection O
rate O
in O
the O
postoperative O
of O
head O
and O
neck O
cancer O
patients O
. O
[]

Similarly O
, O
a O
greater O
proportion O
of O
the O
CBZ O
600 O
group O
required O
a O
change O
in O
dose O
, O
47 O
% O
versus O
20 O
% O
( O
LTG O
100 O
) O
and O
17 O
% O
( O
LTG O
200 O
) O
or O
withdrew O
completely O
due O
to O
adverse B-outcome ['Adverse-effects']
experiences I-outcome ['Adverse-effects']
, O
10.3 O
% O
versus O
4.3 O
% O
( O
LTG O
100 O
) O
and O
4.5 O
% O
( O
LTG O
200 O
) O
. O
['Adverse-effects']

METHODS O
AND O
RESULTS O
this O
is O
a O
secondary O
analysis O
of O
the O
prospective O
randomized O
clinical O
trial O
. O
[]

[ O
Observation O
on O
therapeutic O
effect O
of O
electroacupuncture O
plus O
blood-letting O
puncture O
and O
cupping O
combined O
with O
diet O
intervention O
for O
treatment O
of O
acute O
gouty O
arthritis O
] O
. O
[]

The O
data O
underscore O
the O
magnitude O
of O
error O
present O
in O
such O
a O
test O
setting O
and O
provide O
preliminary O
evidence O
for O
the O
potential O
effect O
of O
this O
problem O
on O
the O
detection O
of O
clinical O
change O
. O
[]

The O
POMS O
data O
were O
reanalyzed O
with O
respect O
to O
sex O
, O
age O
, O
medication O
group O
, O
and O
control O
time O
points O
( O
T1-T4 O
) O
. O
[]

The O
material O
properties O
were O
derived O
from O
the O
homogeneity O
index O
assessed O
by O
texture O
analysis O
of O
the O
radiographs O
, O
with O
focus O
on O
the O
principal O
tensile O
and O
compressive O
trabecular O
systems O
. O
[]

A O
total O
of O
118 O
subjects O
were O
randomly O
allocated O
to O
receive O
SJW O
300 O
mg O
, O
600 O
mg O
, O
or O
a O
matching O
placebo O
tablet O
3 O
times O
a O
day O
combined O
with O
a O
behavioral O
intervention O
for O
12 O
weeks O
. O
[]

Mean O
plasma B-outcome ['Physiological-Clinical']
concentration O
of O
['Physiological-Clinical']

[ O
Clinical O
study O
of O
treating O
knee B-outcome ['Physiological-Clinical']
osteoarthritis I-outcome ['Physiological-Clinical']
( O
Bi O
syndrome O
of O
knee O
) O
by O
massage O
combined O
Chinese O
materia O
medica O
footbath O
fumigation O
and O
washing O
] O
. O
['Physiological-Clinical']

Healthy O
men O
and O
women O
( O
134 O
) O
were O
randomly O
selected O
to O
consume O
15 O
mL/d O
of O
oil O
from O
blubber O
of O
seal O
, O
cod O
liver O
, O
seal/cod O
liver O
, O
blubber O
of O
Minke O
whale O
, O
or O
no O
oil O
for O
ten O
weeks O
. O
[]

Erythromycin O
may O
have O
been O
inactivated O
by O
the O
low O
pH O
in O
the O
areas O
colonized O
with O
C. O
pylori O
. O
[]

RXU+E O
: O
26 O
PCCs O
were O
placed O
in O
molars O
, O
eight O
in O
premolars O
. O
[]

Non-steroidal O
anti-inflammatory O
drugs O
have O
an O
anti-platelet O
action O
and O
carry O
a O
bleeding O
risk O
. O
[]

Investigators O
examined O
the O
6-month O
impact O
of O
three O
cognitive-behavioral O
HIV O
risk-reduction O
programs O
on O
behavioral B-outcome ['Life-Impact']
factors O
( O
substance O
use O
and O
sexual O
risk O
behaviors O
) O
and O
cognitive B-outcome ['Life-Impact']
and O
psychological B-outcome ['Life-Impact']
resources I-outcome ['Life-Impact']
of O
325 O
women O
who O
resided O
in O
emergency O
or O
sober-living O
shelters O
and O
their O
308 O
intimate O
sexual O
partners O
. O
['Life-Impact', 'Life-Impact']

These O
findings O
, O
particularly O
the O
measured O
improvements O
to O
social O
interactions O
in O
a O
natural O
environment O
, O
are O
encouraging O
. O
[]

Among O
participants O
assigned O
to O
medical O
care O
, O
mean O
changes O
[]

In O
our O
study O
, O
we O
assessed O
for O
the O
first O
time O
whether O
simvastatin O
treatment O
affects O
coagulation B-outcome ['Physiological-Clinical']
and O
fibrinolysis B-outcome ['Physiological-Clinical']
in O
patients O
with O
isolated O
hypertriglyceridemia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ten O
patients O
dropped O
out O
of O
the O
transfusion O
group O
, O
and O
two O
patients O
crossed O
over O
from O
the O
standard-care O
group O
to O
the O
transfusion O
group O
. O
[]

It O
is O
suggested O
that O
the O
Hi-Lo-Evac O
tube O
could O
be O
used O
with O
safety O
during O
intranasal O
surgery O
in O
order O
to O
reduce O
[]

We O
compared O
, O
using O
fluoroscopic O
video O
, O
C-spine B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
during O
intubation O
for O
Macintosh O
3 O
blade O
, O
GlideScope O
, O
and O
Intubating O
Lighted O
Stylet O
, O
popularly O
known O
as O
the O
Lightwand O
or O
Trachlight O
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
taken O
up O
to O
120 O
h O
after O
dosing O
. O
['Physiological-Clinical']

The O
fall O
in O
LH B-outcome ['Physiological-Clinical']
lasts O
at O
least O
1 O
week O
and O
may O
be O
explainable O
by O
persistent O
suppression O
of O
endogenous O
GnRH O
by O
LA O
during O
this O
time O
. O
['Physiological-Clinical']

PURPOSE O
To O
prospectively O
study O
the O
effect O
of O
oral O
brovincamine O
, O
a O
relatively O
selective O
cerebral O
vasodilator O
, O
on O
further O
deterioration O
of O
visual O
field O
in O
patients O
with O
normal-tension O
glaucoma O
( O
NTG O
) O
with O
low-normal O
intraocular O
pressure O
( O
IOP O
) O
. O
[]

Repeated O
provocation O
was O
feasible O
in O
the O
majority O
of O
patients O
. O
[]

On O
analyzing O
the O
relationship O
between O
RAS O
polymorphisms O
and O
baseline O
hs-CRP O
or O
TA O
levels O
, O
CC O
genotype O
of O
ATR1 O
showed O
lower O
hs-CRP B-outcome ['Physiological-Clinical']
levels O
( O
P O
= O
.04 O
) O
. O
['Physiological-Clinical']

PARTICIPANTS O
Seventy-two O
drug-free O
children O
, O
aged O
5 O
to O
14 O
years O
, O
with O
pervasive O
developmental O
disorders O
accompanied O
by O
moderate O
to O
severe O
hyperactivity O
. O
[]

Four O
randomized O
cases O
met O
exclusion O
criteria O
: O
penetrating O
trauma O
( O
1 O
) O
, O
cardiac O
arrest O
( O
2 O
) O
, O
and O
fall O
from O
standing O
( O
1 O
) O
. O
[]

The O
time O
between O
first O
bolus O
of O
abciximab O
and O
first O
balloon O
inflation O
of O
pPCI O
was O
83+/-18 O
vs O
21+/-13 O
min O
in O
Group O
1 O
vs O
2 O
. O
[]

Vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and O
blood/ B-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
analysis I-outcome ['Physiological-Clinical']
were O
used O
to O
establish O
safety O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pilot O
results O
agreed O
with O
other O
trials O
published O
in O
the O
literature O
and O
demonstrated O
tamsulone-FS O
efficacy O
and O
safety O
for O
management O
of O
lower O
urinary B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
caused O
by O
prostatic O
adenoma O
. O
['Physiological-Clinical']

METHODS O
One O
hundred O
five O
women O
undergoing O
laparoscopic O
tubal O
sterilization O
with O
silastic O
bands O
were O
randomized O
to O
one O
of O
three O
groups O
: O
one O
received O
intramuscular O
ketorolac O
and O
topical O
placebo O
applied O
to O
the O
fallopian O
tubes O
, O
the O
second O
received O
intramuscular O
placebo O
and O
topical O
bupivacaine O
, O
and O
the O
third O
received O
intramuscular O
placebo O
and O
topical O
placebo O
. O
[]

By O
February O
1998 O
, O
haematoxylin O
and O
eosin O
stained O
sections O
from O
155 O
RP O
specimens O
had O
been O
received O
and O
evaluated O
by O
the O
reviewing O
pathologist O
( O
RM O
) O
. O
[]

Observations O
were O
made O
over O
the O
subsequent O
15-20 O
min O
. O
[]

Thus O
, O
2 O
panels O
of O
25 O
hospital O
nurses O
with O
mild O
signs O
of O
skin O
irritation O
were O
asked O
to O
use O
1 O
of O
the O
test O
products O
provided O
( O
verum O
or O
vehicle O
) O
over O
a O
period O
of O
4 O
weeks O
. O
[]

The O
applied O
intervention O
included O
actions O
related O
to O
change O
of O
positioning O
and O
stimulation O
of O
cough O
. O
[]

OBJECTIVES O
Outdoor O
workers O
are O
at O
high O
risk O
of O
developing O
skin O
cancer O
. O
[]

CONCLUSION O
Preemptive O
epidural O
analgesia O
combined O
with O
postoperative O
epidural O
analgesia O
provides O
more O
satisfactory O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
and O
more O
effectively O
prevents O
IL-6 B-outcome ['Physiological-Clinical']
increment I-outcome ['Physiological-Clinical']
than O
exclusive O
epidural O
analgesia O
or O
intravenous O
analgesia O
after O
gastrectomy O
for O
gastric O
carcinoma O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
only O
one O
report O
of O
[]

The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
4 O
hours O
of O
bed O
rest O
versus O
6 O
hours O
of O
bed O
rest O
on O
patients O
' O
safety O
, O
comfort B-outcome ['Life-Impact']
, O
and O
satisfaction B-outcome ['Life-Impact']
levels O
. O
['Life-Impact']

Each O
child O
received O
20 O
mg O
Org O
2766 O
( O
synthetic O
analog O
of O
ACTH O
4-9 O
) O
/day O
during O
4 O
weeks O
, O
or O
placebo O
in O
a O
randomly O
assigned O
sequence O
. O
[]

Taken O
as O
a O
whole O
, O
the O
group O
showed O
a O
significant O
symptomatic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
all O
three O
treatment O
periods O
( O
p O
less O
than O
0.0001 O
) O
, O
but O
patients O
with O
delayed O
or O
normal O
GE O
did O
not O
differ O
significantly O
in O
their O
symptomatic O
response O
. O
['Physiological-Clinical']

Those O
randomly O
assigned O
to O
the O
experimental O
condition O
watched O
the O
motivational O
interviewing O
videotape O
. O
[]

However O
, O
the O
study O
could O
not O
exclude O
the O
possibility O
of O
smaller O
, O
but O
still O
worthwhile O
, O
effects O
of O
either O
of O
the O
trial O
drugs O
. O
[]

Around-the-clock O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
with O
once-daily O
application O
of O
latanoprost O
by O
itself O
or O
in O
combination O
with O
timolol O
. O
['Physiological-Clinical']

At O
the O
final O
follow-up O
, O
VAS O
score O
was O
significantly O
decreased O
, O
and O
the O
Lysholm O
score O
, O
except O
for O
the O
item O
demanding O
for O
support O
, O
significantly O
increased O
, O
compared O
with O
those O
before O
surgery O
respectively O
in O
both O
groups O
. O
[]

NWB O
exercise O
alone O
may O
be O
sufficient O
enough O
to O
improve O
function B-outcome ['Life-Impact']
and O
muscle B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

During O
Heel O
Stick O
, O
LF B-outcome ['Physiological-Clinical']
and O
HF B-outcome ['Physiological-Clinical']
were O
significantly O
higher O
in O
IC O
than O
in O
KC30 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
We O
concluded O
that O
repeated O
administration O
of O
1 O
g O
of O
intravenous O
paracetamol O
over O
24 O
h O
is O
easy O
, O
effective O
, O
safe O
, O
and O
well O
tolerated O
for O
pain O
management O
in O
patients O
with O
moderate O
to O
severe O
postoperative O
pain O
after O
gasless O
robot-assisted O
endoscopic O
thyroidectomy O
performed O
via O
the O
transaxillary O
approach O
. O
[]

RESULTS O
There O
was O
no O
significant O
difference O
in O
the O
rate O
of O
positive O
response B-outcome ['Life-Impact']
on O
the O
Clinical O
Global O
Impressions O
, O
Improvement O
subscale O
between O
the O
citalopram-treated O
group O
( O
32.9 O
% O
) O
and O
the O
placebo O
group O
( O
34.2 O
% O
) O
( O
relative O
risk O
, O
0.96 O
; O
95 O
% O
confidence O
interval O
, O
0.61-1.51 O
; O
P O
> O
.99 O
) O
. O
['Life-Impact']

The O
study O
included O
100 O
patients O
with O
gastric O
ulcer O
aged O
from O
16 O
to O
60 O
years O
. O
[]

Sivelestat O
sodium O
hydrate O
improves O
septic O
acute O
lung O
injury O
by O
reducing O
alveolar O
dysfunction O
. O
[]

DESIGN O
Randomized O
controlled O
trial O
. O
[]

In O
addition O
, O
functional O
outcomes O
such O
as O
activity B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
return I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
were O
examined O
for O
5 O
postoperative O
days O
. O
['Physiological-Clinical']

The O
primary O
efficacy O
end O
point O
was O
the O
skeletal-related O
event O
( O
SRE O
) O
rate O
ratio O
between O
treatment O
groups O
. O
[]

Chi2 O
and O
Kruskal-Wallis O
tests O
were O
used O
for O
the O
statistical O
analysis O
. O
[]

Ninety-three O
subjects O
were O
randomly O
assigned O
. O
[]

Heparin O
was O
injected O
over O
10 O
seconds O
on O
the O
right O
abdominal O
site O
and O
30 O
seconds O
on O
the O
left O
abdominal O
site O
. O
[]

We O
tested O
memory O
priming O
for O
auditory O
stimuli O
presented O
during O
general O
propofol-sufentanil O
anesthesia O
in O
58 O
patients O
undergoing O
day-case O
arthroscopic O
surgery O
. O
[]

Its O
efficacy O
is O
probably O
lower O
in O
the O
therapy O
of O
multiple O
or O
diffuse O
low O
stage O
transitional O
cell O
carcinoma O
that O
is O
too O
extensive O
to O
be O
completely O
resected O
by O
conventional O
transurethral O
surgery O
. O
[]

Can O
a O
questionnaire O
predict O
vitamin O
D O
status B-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
? O
['Physiological-Clinical']

RESULTS O
The O
study O
involved O
42 O
males O
and O
28 O
females O
( O
median O
age O
, O
7.7 O
years O
) O
with O
a O
median O
follow-up O
of O
10.4 O
years O
. O
[]

[ O
Complication B-outcome ['Adverse-effects']
rate O
after O
gastrectomy O
and O
pouch O
reconstruction O
with O
Longmire O
interposition O
] O
. O
['Adverse-effects']

The O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
each O
active O
treatment O
group O
was O
low O
and O
comparable O
between O
the O
treatments O
. O
['Adverse-effects']

The O
Doppler O
study O
showed O
a O
similarly O
favorable O
hemodynamic B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
regardless O
of O
valve O
orientation O
. O
['Physiological-Clinical']

The O
intent-to-treat O
response O
rate O
was O
19 O
, O
22 O
, O
and O
13 O
% O
respectively O
. O
[]

The O
refrigerated O
( O
n O
= O
182 O
) O
and O
frozen O
( O
n O
= O
185 O
) O
formulations O
induced O
similar O
GMTs B-outcome ['Physiological-Clinical']
( O
727.4 O
and O
834.4 O
gpELISA O
units/ml O
, O
respectively O
) O
; O
the O
estimated B-outcome ['Physiological-Clinical']
GMT I-outcome ['Physiological-Clinical']
ratio O
( O
refrigerated B-outcome ['Physiological-Clinical']
formulation/frozen I-outcome ['Physiological-Clinical']
formulation B-outcome ['Resource-use']
) O
was O
0.87 O
( O
95 O
% O
confidence O
interval O
, O
0.71 O
to O
1.07 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

An O
action O
observation/execution O
matching O
system O
might O
be O
one O
such O
mechanism O
. O
[]

IOPs B-outcome ['Physiological-Clinical']
were O
measured O
at O
3 O
, O
6 O
, O
9 O
, O
and O
24 O
hours O
postoperatively O
. O
['Physiological-Clinical']

This O
research O
explored O
the O
acceptability B-outcome ['Life-Impact']
of O
asking O
symptom O
and O
quality-of-life O
questions O
using O
the O
Electronic O
Self O
Report O
Assessment-Cancer O
program O
on O
wireless O
laptops O
equipped O
with O
touch-screen O
format O
. O
['Life-Impact']

The O
effect O
of O
food O
was O
studied O
in O
an O
open O
crossover O
design O
with O
a O
1-week O
washout O
period O
. O
[]

However O
, O
imiquimod O
was O
well O
tolerated B-outcome ['Life-Impact']
since O
all O
patients O
completed O
the O
12-week O
treatment O
. O
['Life-Impact']

However O
, O
the O
improvement O
found O
is O
limited O
to O
a O
circumscribed O
area O
of O
social-communicative O
function O
and O
generalization O
is O
not O
ensured O
. O
[]

Two O
patients O
sustained O
hip B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
in O
the O
placebo O
group O
, O
and O
no O
hip B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
occurred O
in O
the O
etidronate O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Low-dose O
clonidine O
administration O
in O
the O
treatment O
of O
mild O
or O
moderate O
essential O
hypertension O
: O
results O
from O
a O
double-blind O
placebo-controlled O
study O
( O
Clobass O
) O
. O
[]

The O
rCsA O
with O
sirolimus O
and O
corticosteroid O
regimen O
resulted O
in O
excellent O
12-month O
patient O
and O
graft O
survival O
, O
a O
low O
incidence O
of O
BCAR O
, O
and O
improved O
renal O
function O
in O
renal O
allograft O
recipients O
. O
[]

Participants O
were O
assigned O
to O
either O
a O
target O
treatment O
or O
community O
treatment O
group O
. O
[]

This O
study O
was O
undertaken O
to O
assess O
the O
efficacy O
of O
ketorolac O
compared O
with O
placebo O
when O
delivered O
by O
electromotive O
drug O
administration O
( O
EMDA O
) O
in O
patients O
with O
pain B-outcome ['Physiological-Clinical']
from O
rheumatic O
disease O
. O
['Physiological-Clinical']

There O
was O
no O
difference O
in O
self-timed O
duration O
between O
locations O
. O
[]

Oral O
ganciclovir O
and O
valacyclovir O
reduce O
the O
incidence O
of O
cytomegalovirus B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CMV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
after O
renal O
transplantation O
( O
RTx O
) O
. O
['Physiological-Clinical']

A O
combination O
of O
amoxycillin O
and O
omeprazole O
is O
often O
used O
to O
treat O
Helicobacter O
pylori O
infection O
. O
[]

METHODS O
The O
current O
study O
aimed O
to O
analyze O
alterations O
in O
microvascular B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
at O
4 O
predefined O
time O
points O
( O
T1-T4 O
) O
during O
on-pump O
CABG O
using O
orthogonal O
polarization O
spectral O
imaging O
. O
['Physiological-Clinical']

The O
patients O
were O
given O
placebo O
or O
1 O
g O
of O
paracetamol O
as O
a O
100 O
ml O
solution O
infused O
over O
15 O
min O
1 O
h O
before O
the O
induction O
of O
anesthesia O
, O
and O
then O
at O
6-h O
intervals O
for O
the O
following O
24 O
h. O
RESULTS O
Postoperative O
pain I-outcome ['Physiological-Clinical']
scores O
were O
significantly O
lower O
at O
1 O
, O
3 O
, O
6 O
, O
and O
24 O
h O
after O
surgery O
in O
the O
paracetamol O
group O
than O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
a O
single O
subconjunctival O
( O
SCJ O
) O
or O
intravitreal O
( O
IVT O
) O
injection O
of O
an O
ophthalmic O
sirolimus O
formulation O
in O
eyes O
with O
diabetic O
macular O
edema O
( O
DME O
) O
. O
['Life-Impact']

RESULTS O
The O
trial O
was O
completed O
by O
71 O
% O
and O
77 O
% O
of O
the O
patients O
from O
the O
STG O
and O
the O
CG O
, O
respectively O
. O
[]

Encouraging O
data O
from O
these O
trials O
are O
the O
basis O
for O
phase O
3 O
programs O
in O
this O
area O
( O
MICHELANGELO O
) O
. O
[]

PATIENTS O
The O
patients O
comprised O
some O
randomized O
to O
0 O
vs O
10 O
vs O
36 O
Gy O
of O
radiation O
and O
( O
after O
a O
change O
of O
the O
study O
protocol O
became O
necessary O
) O
others O
who O
participated O
in O
a O
prospective O
, O
controlled O
non-randomized O
pilot O
study O
. O
[]

2 O
Both O
pindolol O
and O
metoprolol O
in O
equipotent O
doses O
lowered O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
to O
the O
same O
extent O
. O
['Physiological-Clinical']

The O
primary O
end O
point O
was O
change O
from O
baseline O
in O
SiDBP B-outcome ['Physiological-Clinical']
at O
week O
8 O
. O
['Physiological-Clinical']

METHODS O
The O
objective O
of O
this O
study O
was O
to O
quantify O
the O
effects O
of O
daily O
10 O
or O
25 O
mg O
prednisone O
administration O
for O
one O
week O
on O
insulin O
sensitivity O
by O
employing O
a O
two-step O
hyperinsulinemic O
euglycemic O
glucose O
clamp O
( O
Step O
1 O
: O
insulin O
infusion O
= O
20 O
mU/m?/min O
; O
Step O
2 O
: O
insulin O
infusion O
= O
80 O
mU/m?/min O
) O
in O
healthy O
, O
lean O
males O
. O
[]

RESULTS O
When O
judged O
on O
the O
last O
month O
of O
IP O
versus O
SC O
periods O
in O
the O
nine O
patients O
who O
completed O
the O
study O
, O
metabolic B-outcome ['Physiological-Clinical']
data O
showed O
better O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
( O
HbA1c O
: O
7.2 O
+/- O
0.2 O
IP O
vs. O
8.5 O
+/- O
0.7 O
% O
SC O
, O
mean O
+/- O
SE O
, O
P O
= O
0.02 O
) O
, O
reduced O
glycemic B-outcome ['Physiological-Clinical']
fluctuations I-outcome ['Physiological-Clinical']
( O
SD O
of O
capillary O
glucose O
values O
: O
3.4 O
+/- O
0.2 O
IP O
vs. O
4.6 O
+/- O
0.2 O
mM O
SC O
, O
P O
< O
0.01 O
) O
, O
and O
fewer O
mild B-outcome ['Physiological-Clinical']
hypoglycemic I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( O
5.7 O
+/- O
2.0 O
IP O
vs. O
10.0 O
+/- O
3.1 O
events/month O
SC O
, O
P O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pravastatin O
improved O
[]

Atrial O
electromechanical O
coupling O
time O
intervals O
showed O
significant O
decreases O
in O
both O
groups O
. O
[]

Other O
measures O
of O
function O
, O
including O
the O
SF-36 O
and O
a O
battery O
of O
physical O
performance O
tests O
, O
did O
not O
change O
with O
the O
intervention O
. O
[]

The O
results O
confirm O
similar O
findings O
of O
other O
authors O
; O
i.e. O
, O
that O
a O
sedating O
antidepressant O
with O
some O
anticholinergic O
effects O
can O
not O
be O
expected O
to O
improve O
cognitive B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
despite O
its O
antidepressant O
effect O
. O
['Life-Impact']

Of O
the O
999 O
trial O
participants O
for O
whom O
follow-up O
data O
were O
available O
, O
135 O
delivered O
by O
Caesarean O
section O
( O
CS O
) O
, O
and O
864 O
had O
a O
vaginal O
birth O
( O
VB O
) O
. O
[]

This O
new O
formulation O
with O
a O
reduced O
pill O
and O
dosing O
burden O
offers O
the O
potential O
to O
improve O
convenience B-outcome ['Life-Impact']
and O
compliance B-outcome ['Life-Impact']
in O
patients O
with O
active O
UC O
. O
['Life-Impact', 'Life-Impact']

P O
= O
0.001 O
and O
P O
= O
0.048 O
, O
respectively O
. O
[]

Symptom O
scores O
, O
peak O
flow O
rates O
, O
spirometry B-outcome ['Resource-use']
, O
and O
beta-agonist B-outcome ['Resource-use']
frequency I-outcome ['Resource-use']
were O
closely O
monitored O
. O
['Resource-use', 'Resource-use']

Developmental O
disabilities O
modification O
of O
the O
Children O
's O
Global O
Assessment O
Scale O
. O
[]

Independent O
predictors O
of O
PFS O
included O
race O
, O
performance B-outcome ['Physiological-Clinical']
status B-outcome ['Physiological-Clinical']
, O
disease B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
all O
measurement O
intervals O
, O
symptoms O
were O
reduced O
for O
both O
EH O
and O
EH O
combined O
with O
CC O
than O
CC O
or O
ATs O
alone O
or O
in O
combination O
( O
P O
< O
0.014 O
) O
. O
[]

Infants O
' O
eyes O
were O
randomly O
dilated O
twice O
with O
both O
regimens O
within O
a O
2-week O
period O
. O
[]

OBJECTIVE O
In O
this O
study O
, O
a O
lentivirus O
delivering O
human O
IL-10 O
( O
LV/hIL-10 O
) O
was O
administered O
intrathecally O
to O
determine O
the O
effects O
of O
IL-10 O
on O
allodynia O
and O
hyperalgesia O
in O
a O
chronic O
constriction O
injury-induced O
( O
CCI O
) O
rat O
model O
of O
neuropathic O
pain O
. O
[]

CONCLUSIONS O
Single-dose O
tranexamic O
acid O
did O
not O
give O
effective O
results O
. O
[]

There O
was O
significant O
improvement O
on O
RF-RLRS O
sensory B-outcome ['Life-Impact']
motor I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
subscale O
and O
ABC O
scores O
in O
risperidone O
group O
. O
['Life-Impact']

Assessment O
of O
safety O
and O
clinical O
efficacy O
over O
a O
1-month O
period O
included O
timed O
tests O
of O
gait B-outcome ['Life-Impact']
and O
bradykinesia B-outcome ['Physiological-Clinical']
, O
Unified O
Parkinson O
's O
Disease O
Rating O
Scale O
( O
UPDRS O
) O
, O
and O
additional O
clinical B-outcome ['Physiological-Clinical']
, O
neuropsychological B-outcome ['Physiological-Clinical']
, O
and O
neurophysiologic B-outcome ['Physiological-Clinical']
measures O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
confirms O
that O
only O
end-treatment O
TSAb O
levels O
are O
predictive O
of O
relapse O
. O
( O
[]

There O
was O
no O
significant O
difference O
in O
the O
percentage O
returning B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
school I-outcome ['Life-Impact']
. O
['Life-Impact']

Sibenadet O
therapy O
was O
generally O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
, O
with O
the O
only O
notable O
differences O
seen O
in O
the O
incidence O
of O
tremor B-outcome ['Physiological-Clinical']
and O
taste B-outcome ['Physiological-Clinical']
of O
treatment B-outcome ['Resource-use']
( O
16.9 O
% O
vs. O
4.1 O
% O
and O
14.5 O
% O
vs. O
4.1 O
% O
in O
the O
sibenadet O
and O
placebo O
groups O
respectively O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

NCX-4016 O
was O
virtually O
devoid O
of O
gastric B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
duodenal I-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
, O
resulting O
in O
a O
total O
gastric B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
duodenal I-outcome ['Physiological-Clinical']
endoscopic I-outcome ['Physiological-Clinical']
score O
of O
1.38 O
+/- O
0.3 O
and O
1.25 O
+/- O
0.5 O
( O
P O
< O
0.0001 O
vs. O
aspirin O
, O
not O
significant O
vs. O
placebo O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
difference O
in O
[]

For O
most O
noncomplicated O
absorption O
models O
, O
the O
AUC O
correlates O
well O
with O
the O
extent O
of O
absorption O
. O
[]

A O
controlled O
trial O
after O
upper O
abdominal O
surgery O
. O
[]

Pilot O
randomized O
controlled O
trial O
of O
Reciprocal O
Imitation O
Training O
for O
teaching O
elicited O
and O
spontaneous B-outcome ['Life-Impact']
imitation I-outcome ['Life-Impact']
to O
children O
with O
autism O
. O
['Life-Impact']

A O
double-blind O
placebo O
controlled O
trial O
of O
Ginkgo O
biloba O
added O
to O
risperidone O
in O
patients O
with O
autistic O
disorders O
. O
[]

Lymphocytes B-outcome ['Physiological-Clinical']
themselves O
may O
be O
important O
in O
this O
host-bacterium O
interaction O
, O
or O
lymphocytopenia B-outcome ['Physiological-Clinical']
may O
be O
the O
marker O
for O
a O
more O
generalized O
deficiency O
in O
host B-outcome ['Physiological-Clinical']
defenses I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Secondary O
outcomes O
were O
bladder B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
, O
incision-to-delivery B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
incision-to-fascial B-outcome ['Physiological-Clinical']
closure I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
estimated B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
postoperative B-outcome ['Physiological-Clinical']
microhematuria I-outcome ['Physiological-Clinical']
, O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
hospital B-outcome ['Resource-use']
days I-outcome ['Resource-use']
, O
endometritis B-outcome ['Physiological-Clinical']
, O
and O
urinary B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

We O
observed O
a O
significant O
interaction O
between O
circulating O
25 O
( O
OH O
) O
D O
levels O
and O
the O
VDR B-outcome ['Physiological-Clinical']
FokI I-outcome ['Physiological-Clinical']
genotype I-outcome ['Physiological-Clinical']
( O
pinteraction O
< O
0.05 O
) O
. O
['Physiological-Clinical']

METHODS O
A O
phase O
III O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
was O
conducted O
in O
patients O
undergoing O
therapy O
with O
neurotoxic O
chemotherapy O
, O
utilizing O
twice O
daily O
dosing O
of O
vitamin O
E O
( O
400 O
mg O
) O
/placebo O
. O
[]

RESULTS O
Compared O
with O
the O
120-kV O
group O
, O
effective O
dose B-outcome ['Life-Impact']
and O
amount O
of O
contrast O
agent B-outcome ['Resource-use']
in O
the O
80-kV O
group O
were O
decreased O
by O
57.8 O
% O
and O
30.5 O
% O
( O
effective O
dose:2.7 O
? O
['Life-Impact', 'Resource-use']

The O
risk O
of O
significant O
neoplasia B-outcome ['Physiological-Clinical']
( O
carcinoma B-outcome ['Physiological-Clinical']
or O
adenoma B-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
villous I-outcome ['Physiological-Clinical']
structure O
, O
severe B-outcome ['Physiological-Clinical']
dysplasia I-outcome ['Physiological-Clinical']
, O
or O
diameter O
> O
10 O
mm O
) O
was O
5.2 O
% O
( O
2.3-8.1 O
% O
) O
and O
8.6 O
% O
( O
3.8-13.3 O
% O
) O
after O
48 O
months O
and O
8.6 O
% O
( O
4.2-13.0 O
% O
) O
and O
17.4 O
% O
( O
7.6-27.2 O
% O
) O
after O
96 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Types O
of O
chronic O
pain O
included O
back O
( O
214 O
; O
45.6 O
% O
) O
, O
arthritic O
( O
145 O
; O
30.9 O
% O
) O
, O
other O
musculoskeletal O
( O
65 O
; O
13.9 O
% O
) O
, O
cancer O
( O
6 O
; O
1.3 O
% O
) O
, O
diabetic O
neuropathic O
( O
3 O
; O
0.6 O
% O
) O
, O
postherpetic O
neuralgic O
( O
5 O
; O
1.1 O
% O
) O
, O
other O
neurologic O
( O
21 O
; O
4.5 O
% O
) O
, O
and O
other O
unclassified O
chronic O
pain O
( O
10 O
; O
2.1 O
% O
) O
. O
[]

Ganciclovir O
and O
valacyclovir O
were O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
, O
with O
ganciclovir O
having O
had O
to O
be O
withdrawn O
shortly O
in O
one O
patient O
only O
because O
of O
thrombocytopenia O
. O
['Life-Impact']

Pegvisomant O
alone O
had O
no O
influence O
on O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
chlorhexidine O
varnish O
was O
then O
painted O
on O
the O
entire O
dentition O
of O
Group O
T O
subjects O
only O
. O
[]

CONCLUSION O
RTX O
re-treatment O
over O
5 O
years O
is O
associated O
with O
maintained O
or O
improved O
efficacy O
, O
continued O
inhibition O
of O
PJD O
, O
and O
a O
safety O
profile O
consistent O
with O
that O
previously O
reported O
. O
[]

In O
both O
groups O
, O
at O
3 O
and O
9 O
months O
80 O
% O
of O
participants O
would O
choose O
to O
have O
an O
X-ray O
if O
the O
choice O
was O
available O
. O
[]

Treatment O
response O
was O
not O
correlated O
with O
age O
level O
of O
autistic O
behavior O
, O
or O
full-scale O
IQ O
. O
[]

For O
those O
who O
reported O
more O
alcohol O
consequences O
at O
baseline O
, O
the O
alcohol O
intervention O
resulted O
in O
significantly O
less O
alcohol O
use O
and O
fewer O
heavy B-outcome ['Life-Impact']
drinking I-outcome ['Life-Impact']
episodes I-outcome ['Life-Impact']
at O
follow-up O
, O
while O
no O
difference O
was O
observed O
between O
intervention O
conditions O
for O
those O
with O
few O
baseline O
consequences O
. O
['Life-Impact']

There O
were O
no O
statistically O
significant O
differences O
among O
these O
survival O
curves O
in O
each O
stage O
. O
[]

CONCLUSIONS O
These O
results O
support O
the O
acceptability O
of O
snowshoeing O
as O
a O
valid O
means O
to O
improve O
or O
maintain O
cardiovascular B-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Nothing O
was O
administered O
to O
the O
Control O
group O
. O
[]

During O
a O
4-year O
period O
of O
clinical O
application O
of O
the O
balloon-expandable O
Palmaz O
stent O
, O
a O
randomized O
trial O
comparing O
stent O
implantation O
and O
traditional O
balloon O
angioplasty O
of O
iliac O
arteries O
in O
arterial O
occlusive O
disease O
was O
started O
. O
[]

Gender O
differences O
were O
considered O
. O
[]

The O
effect O
of O
dose O
is O
more O
prominent O
in O
blacks O
than O
in O
whites O
; O
blacks O
accumulate B-outcome ['Physiological-Clinical']
more I-outcome ['Physiological-Clinical']
Na I-outcome ['Physiological-Clinical']
with O
increasing O
Na O
intake O
than O
whites O
. O
['Physiological-Clinical']

The O
patients O
were O
randomly O
divided O
into O
two O
groups O
: O
in O
the O
test O
group O
patients O
received O
implants O
placed O
and O
restored O
( O
non-occlusal O
loading O
) O
at O
the O
time O
of O
tooth O
extraction O
; O
in O
the O
control O
group O
implants O
were O
placed O
8 O
weeks O
after O
tooth O
extraction O
and O
immediately O
restored O
. O
[]

Patients O
in O
complete O
remission O
( O
CR O
) O
received O
20 O
Gy O
to O
the O
involved O
field O
and O
40 O
Gy O
to O
the O
spleen O
. O
[]

RESULTS O
Among O
patients O
who O
received O
rhNGF O
, O
418 O
( O
83 O
% O
) O
completed O
the O
regimen O
compared O
with O
461 O
( O
90 O
% O
) O
who O
received O
placebo O
. O
[]

The O
interventions O
were O
either O
a O
commercially O
available O
weighted O
blanket O
or O
otherwise O
identical O
usual O
weight O
blanket O
( O
control O
) O
, O
introduced O
at O
bedtime O
; O
each O
was O
used O
for O
a O
2-week O
period O
before O
crossover O
to O
the O
other O
blanket O
. O
[]

AIMS O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
roflumilast O
, O
an O
investigational O
PDE4 O
inhibitor O
for O
the O
treatment O
of O
COPD O
and O
asthma O
, O
on O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
CYP3A I-outcome ['Physiological-Clinical']
probe I-outcome ['Physiological-Clinical']
drug O
midazolam O
and O
its O
major O
metabolites O
. O
['Physiological-Clinical']

Combined O
modality O
therapy O
in O
advanced O
Hodgkin O
's O
disease O
: O
a O
report O
on O
218 O
patients O
with O
a O
median O
follow-up O
of O
eight O
years O
. O
[]

This O
prospective O
, O
randomized O
, O
double-blind O
study O
compares O
the O
digital O
block O
results O
following O
the O
administration O
of O
2.5 O
ml O
of O
0.75 O
% O
ropivacaine O
solution O
and O
2.5 O
ml O
of O
2 O
% O
lidocaine O
solution O
. O
[]

Swallowing O
and O
arousal O
are O
crucial O
to O
prevent O
laryngeal O
chemoreflex O
stimulation O
. O
[]

In O
the O
control O
subjects O
, O
the O
mean O
SVI O
showed O
a O
significant O
reduction O
postoperatively O
( O
p O
= O
0.039 O
) O
. O
[]

Using O
Martha O
Rogers O
' O
science O
of O
unitary O
human O
beings O
, O
changes O
in O
pain B-outcome ['Physiological-Clinical']
and O
power O
among O
42 O
patients O
were O
examined O
in O
relation O
to O
the O
use O
of O
a O
guided O
imagery O
modality O
. O
['Physiological-Clinical']

We O
undertook O
this O
study O
to O
determine O
whether O
these O
results O
could O
be O
replicated O
in O
India O
. O
[]

OBJECTIVE O
To O
determine O
the O
effectiveness O
of O
a O
quality O
improvement O
program O
to O
improve O
pediatricians O
' O
adherence O
to O
existing O
, O
evidence-based O
, O
attention-deficit/hyperactivity O
disorder O
( O
ADHD O
) O
practice O
guidelines O
. O
[]

The O
effect O
of O
venlafaxine O
on O
ongoing O
and O
experimentally O
induced O
pain O
in O
neuropathic O
pain O
patients O
: O
a O
double O
blind O
, O
placebo O
controlled O
study O
. O
[]

These O
data O
suggest O
that O
the O
combination O
of O
verapamil O
and O
warfarin O
, O
in O
the O
absence O
of O
aspirin O
, O
is O
not O
significantly O
better O
than O
verapamil O
alone O
in O
preventing O
symptom O
recurrence O
or O
angiographic B-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
after O
coronary O
angioplasty O
. O
['Physiological-Clinical']

The O
method O
also O
is O
feasible B-outcome ['Life-Impact']
under O
routine O
conditions O
. O
['Life-Impact']

Botulinum O
toxin O
a O
has O
antinociceptive B-outcome ['Physiological-Clinical']
effects O
in O
treating O
interstitial O
cystitis O
. O
['Physiological-Clinical']

Often O
the O
X-ray O
photograph O
leads O
to O
the O
diagnosis O
in O
the O
second O
stage O
( O
ARCO O
1992 O
) O
or O
in O
the O
third O
stage O
, O
when O
the O
femoral O
head O
has O
begun O
to O
collapse O
. O
[]

PATIENTS O
One O
hundred O
seventy O
patients O
with O
bilateral O
obstructive O
or O
minimally O
obstructive O
chronic O
hyperplastic O
sinusitis O
with O
nasal O
polyposis O
. O
[]

The O
bupivacaine O
group O
had O
better O
analgesia B-outcome ['Resource-use']
than O
the O
control O
group O
for O
the O
first O
8 O
hours O
, O
after O
which O
there O
was O
no O
difference O
. O
['Resource-use']

In O
a O
double-blind O
, O
crossover O
design O
, O
7 O
vegetarians O
( O
VEG O
) O
and O
nonvegetarians O
( O
NVEG O
) O
were O
assigned O
Cr O
or O
placebo O
supplements O
for O
5 O
d O
and O
after O
5 O
wk O
, O
received O
the O
alternative O
treatment O
. O
[]

Promoting O
social O
skill O
development O
in O
children O
with O
pervasive O
developmental O
disorders O
: O
a O
feasibility O
and O
efficacy O
study O
. O
[]

Intrathecal O
morphine O
suppresses O
NK B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
following O
abdominal O
surgery O
. O
['Physiological-Clinical']

Rate O
of O
loss O
of O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
evaluated O
objectively O
by O
least-squares O
analyses O
of O
reciprocal B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
, O
was O
reduced-and O
in O
one-third O
of O
the O
patients O
, O
arrested-during O
immunosuppressive O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

COX-2-treated O
patients O
also O
reported O
better O
oral B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
on O
these O
same O
days O
. O
['Life-Impact']

Bridging O
therapy O
with O
LMWHs O
at O
therapeutic O
doses O
in O
HD O
patients O
who O
require O
temporary O
interruption O
of O
warfarin O
therapy O
has O
the O
potential O
for O
complications O
and O
is O
of O
uncertain O
benefit O
. O
[]

Both O
regimens O
were O
followed O
by O
biweekly O
administration O
of O
the O
same O
dose O
of O
dl-LV O
and O
5-FU O
in O
outpatients O
. O
[]

A O
web-based O
approach O
to O
address O
cardiovascular B-outcome ['Physiological-Clinical']
risks O
in O
managers O
: O
results O
of O
a O
randomized O
trial O
. O
['Physiological-Clinical']

METHODS O
Three O
hundred O
twenty-nine O
patients O
were O
evaluated O
. O
[]

Group O
A O
consisted O
of O
three O
men O
and O
13 O
women O
, O
and O
group O
B O
consisted O
of O
four O
men O
and O
eight O
women O
. O
[]

DNA O
samples O
for O
the O
analysis O
of O
allelic B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
pattern O
were O
prepared O
from O
primary O
tumors O
and O
matched O
synchronous O
lymph O
node O
metastases O
by O
tissue O
microdissection O
. O
['Physiological-Clinical']

No O
CsA-specific B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
, O
except O
isometric B-outcome ['Physiological-Clinical']
vacuolation I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
tubuli I-outcome ['Physiological-Clinical']
, O
were O
found O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
examine O
whether O
a O
diagnosis O
for O
major O
depression O
, O
chronic O
depression O
or O
specific O
symptoms O
of O
depression O
is O
associated O
with O
the O
risk O
of O
quitting O
a O
weight O
loss O
program O
. O
[]

This O
paper O
presented O
the O
preliminary O
results O
of O
a O
randomized O
clinical O
trial O
of O
Project O
SEARCH O
plus O
ASD O
Supports O
on O
the O
employment O
outcomes O
for O
youth O
with O
ASD O
between O
the O
ages O
of O
18-21 O
years O
of O
age O
. O
[]

We O
report O
results O
from O
a O
two-stage O
, O
24-month O
, O
randomised O
, O
controlled O
trial O
incorporating O
an O
adaptive O
'catch-up O
' O
design O
and O
interim O
analysis O
. O
[]

The O
primary O
endpoint O
was O
myocardial B-outcome ['Physiological-Clinical']
salvage I-outcome ['Physiological-Clinical']
index O
at O
30 O
days O
after O
primary O
percutaneous O
coronary O
intervention O
, O
measured O
by O
myocardial B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
imaging B-outcome ['Resource-use']
as O
the O
proportion O
of O
the O
area O
at O
risk O
salvaged O
by O
treatment O
; O
analysis O
was O
per O
protocol O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

A O
double O
blind O
randomized O
study O
of O
oral O
clodronate O
in O
the O
treatment O
of O
bone O
metastases O
from O
tumors O
poorly O
responsive O
to O
chemotherapy O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Myocardial B-outcome ['Physiological-Clinical']
ischaemia I-outcome ['Physiological-Clinical']
as O
assessed O
by O
intracoronary B-outcome ['Physiological-Clinical']
( O
i.c O
. O
) O
['Physiological-Clinical', 'Physiological-Clinical']

The O
median O
survival B-outcome ['Mortality']
was O
16 O
months O
for O
the O
traditional O
Chinese O
Kidney-tonifying O
decoction O
group O
, O
and O
10 O
months O
for O
the O
control O
group O
( O
P O
less O
than O
0.05 O
) O
. O
['Mortality']

Performance O
was O
assessed O
by O
postgraduate O
year O
( O
PGY O
) O
according O
to O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
technical B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
using O
a O
23-step O
objective O
structured O
['Life-Impact', 'Life-Impact']

This O
finding O
suggests O
that O
concentration O
of O
local O
anesthetic O
solution O
at O
low O
doses O
is O
a O
primary O
determinant O
of O
motor B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
with O
patient-controlled O
epidural O
analgesia O
after O
lower O
abdominal O
surgery O
. O
['Physiological-Clinical']

Similarly O
, O
the O
rate O
of O
change O
in O
aortic B-outcome ['Physiological-Clinical']
PWV I-outcome ['Physiological-Clinical']
was O
significantly O
decreased O
with O
the O
use O
of O
the O
high-flux O
polyamide O
membrane O
. O
['Physiological-Clinical']

Intermediate-term O
mortality O
and O
cardiac O
transplantation O
in O
infants O
with O
single-ventricle O
lesions O
: O
risk O
factors O
and O
their O
interaction O
with O
shunt O
type O
. O
[]

Subtest O
variables O
included O
vocabulary B-outcome ['Life-Impact']
, O
information O
, O
picture B-outcome ['Life-Impact']
completion I-outcome ['Life-Impact']
, O
and O
matrix B-outcome ['Life-Impact']
reasoning I-outcome ['Life-Impact']
raw O
scores O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

BACKGROUND O
Macrolide O
antibiotics O
are O
active O
in O
vitro O
and O
in O
vivo O
against O
Helicobacter O
pylori O
. O
[]

High-dose O
combinations O
of O
fosamprenavir O
( O
FPV O
) O
and O
ritonavir O
( O
RTV O
) O
were O
evaluated O
in O
healthy O
adult O
subjects O
in O
order O
to O
select O
doses O
for O
further O
study O
in O
multiple O
protease O
inhibitor O
( O
PI O
) O
-experienced O
patients O
infected O
with O
human O
immunodeficiency O
virus O
type O
1 O
. O
[]

A O
randomized O
multicenter O
trial O
comparing O
resection O
and O
radiochemotherapy O
for O
resectable O
locally O
invasive O
pancreatic O
cancer O
. O
[]

The O
end O
points O
for O
the O
study O
were O
the O
clinical O
outcomes O
of O
all O
patients O
, O
and O
the O
results O
of O
histology B-outcome ['Physiological-Clinical']
, O
where O
appropriate O
. O
['Physiological-Clinical']

PURPOSE O
We O
performed O
a O
randomized O
controlled O
study O
to O
examine O
the O
influence O
of O
a O
controlled O
moderate O
exercise O
program O
starting O
parallel O
to O
chemotherapeutic O
conditioning O
and O
total O
body O
irradiation O
on O
the O
patient O
's O
physical O
and O
psychological O
constitution O
. O
[]

Rats O
in O
each O
group O
were O
intrathecally O
delivered O
with O
NS O
, O
LV/control O
, O
or O
recombinant O
vector O
LV/hIL-10 O
in O
a O
total O
volume O
of O
10 O
?l O
. O
[]

Although O
6-thioguanine O
conferred O
a O
significantly O
lower O
risk O
of O
isolated O
CNS B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
than O
did O
6-mercaptopurine O
( O
odds O
ratio O
[ O
OR O
] O
0.53 O
, O
95 O
% O
CI O
0.30-0.92 O
, O
p=0.02 O
) O
, O
the O
benefit O
was O
offset O
by O
an O
increased O
risk O
of O
death B-outcome ['Mortality']
in O
remission O
( O
2.22 O
, O
1.20-4.14 O
, O
p=0.01 O
) O
, O
mainly O
due O
to O
infections O
during O
continuing O
therapy O
. O
['Physiological-Clinical', 'Mortality']

CLINICAL O
RELEVANCE O
It O
seems O
that O
dental O
procedures O
requiring O
profound O
pulpal O
, O
bone O
, O
and O
soft O
tissue O
anesthesia O
could O
be O
effectively O
and O
safely O
obtained O
by O
mentioned O
anesthetic O
protocol O
. O
[]

There O
was O
no O
difference O
in O
VAS O
scores O
the O
evening O
of O
or O
24 O
h O
after O
the O
procedure O
. O
[]

Self-reported O
late O
toxicity O
was O
scored O
according O
to O
the O
LENT O
SOMA O
criteria O
in O
a O
structured O
telephone O
interview O
and O
with O
questionnaires O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
, O
International O
Index O
of O
Erectile O
Function O
( O
IIEF O
) O
, O
and O
sexual O
function-vaginal O
changes O
questionnaire O
( O
SVQ O
) O
. O
[]

The O
POIOPO O
group O
had O
the O
least O
drain B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
( O
303 O
mL O
) O
and O
least O
total O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
( O
688 O
mL O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Standard O
red O
cell O
serological O
techniques O
were O
used O
. O
[]

RESULTS O
A O
dose-dependent O
duration O
of O
pulpal O
and O
soft O
tissue O
anesthesia O
was O
obtained O
only O
by O
the O
ISA O
. O
[]

For O
time O
to O
progression O
a O
significant O
overall O
treatment B-outcome ['Resource-use']
effect O
was O
detected O
dependent O
on O
the O
recurrence O
status O
before O
entry O
into O
the O
study O
( O
p O
= O
0.0059 O
) O
. O
['Resource-use']

CONCLUSION O
This O
study O
demonstrates O
an O
immunostimulatory O
effect O
of O
the O
histamine-2-receptor O
antagonist O
, O
ranitidine O
, O
both O
at O
the O
cellular O
and O
mediator O
levels O
in O
patients O
after O
head O
injury O
. O
[]

In O
the O
POST O
group O
those O
percentages O
were O
83 O
% O
, O
68 O
% O
, O
51 O
% O
and O
51 O
% O
at O
the O
1st O
, O
2nd O
, O
3rd O
and O
4th O
years O
, O
respectively O
( O
p O
= O
0.707 O
) O
. O
[]

The O
results O
of O
the O
aspirin O
trial O
are O
reported O
here O
. O
[]

There O
was O
one O
documented O
case O
of O
osteonecrosis B-outcome ['Physiological-Clinical']
in O
the O
zoledronic O
acid O
group O
. O
['Physiological-Clinical']

CONCLUSIONS O
Thus O
, O
prior O
treatment O
with O
frusemide O
increased O
baseline O
pulmonary B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
and O
significantly O
augmented O
the O
['Physiological-Clinical']

Vi B-outcome ['Physiological-Clinical']
seroprotection I-outcome ['Physiological-Clinical']
rates O
( O
> O
or O
= O
1 O
microg/mL O
) O
of O
85.2 O
% O
and O
84.9 O
% O
after O
28 O
days O
fell O
to O
32.1 O
% O
and O
35.6 O
% O
after O
3 O
years O
, O
increasing O
to O
67.3 O
% O
and O
69.8 O
% O
after O
the O
booster O
dose O
. O
['Physiological-Clinical']

APC O
was O
closely O
associated O
with O
response O
to O
interferon B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Age O
was O
negatively O
associated O
with O
enrollment O
. O
[]

Upon O
validation O
of O
these O
data O
in O
independent O
studies O
, O
stratification O
of O
patients O
using O
these O
markers O
in O
future O
clinical O
trials O
is O
recommended O
. O
[]

Theo-dur O
was O
chosen O
as O
a O
reference O
sustained-release O
formulation O
. O
[]

4.0 O
years O
, O
9 O
females O
, O
[ O
Vdot O
] O
O O
( O
2 O
) O
max O
35.4 O
? O
[]

The O
effect O
on O
coronary B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( O
fatal O
and O
non-fatal O
myocardial O
infarction O
or O
sudden O
death O
) O
was O
a O
47 O
% O
lowering O
of O
the O
5-year O
incidence O
in O
the O
intervention O
group O
compared O
with O
the O
control O
group O
( O
p O
= O
0.02 O
, O
2-sided O
) O
. O
['Physiological-Clinical']

Animal O
studies O
implicate O
the O
AP-1 O
( O
activator O
protein-1 O
) O
pro-inflammatory O
pathway O
as O
a O
promising O
target O
in O
the O
treatment O
of O
atherosclerotic O
disease O
. O
[]

Indications O
of O
more O
absence O
in O
the O
exercise O
therapy O
group O
appeared O
to O
be O
based O
largely O
on O
a O
greater O
number O
of O
patients O
with O
absences O
during O
the O
first O
3 O
months O
. O
[]

There O
is O
a O
need O
for O
culturally O
sensitive O
family O
treatments O
offered O
by O
nurses O
. O
[]

We O
hypothesized O
that O
insulin O
resistance-associated O
hyperinsulinemia O
could O
preferentially O
drive O
endothelin-mediated B-outcome ['Physiological-Clinical']
vasoconstriction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

TREATMENT O
A O
2-day O
PECS O
workshop O
for O
teachers O
plus O
6 O
half-day O
, O
school-based O
training O
sessions O
with O
expert O
consultants O
over O
5 O
months O
. O
[]

All O
patients O
received O
a O
vasodilator O
cocktail O
intra-arterially O
and O
underwent O
cardiac O
catheterization O
using O
a O
5F O
introducer O
sheath O
and O
catheters O
. O
[]

The O
response O
to O
cardiopulmonary O
exercise O
( O
CPX O
) O
in O
patients O
with O
heart O
failure O
( O
HF O
) O
with O
normal O
left O
ventricular O
( O
LV O
) O
ejection O
fractions O
( O
EFs O
) O
is O
not O
well O
characterized O
. O
[]

METHODS/DESIGN O
The O
study O
will O
be O
carried O
out O
at O
a O
tertiary O
level O
maternity O
hospital O
in O
Nepal O
. O
[]

Intraperitoneal O
application O
of O
bupivacaine O
plus O
morphine O
for O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
after O
laparoscopic O
cholecystectomy O
. O
['Physiological-Clinical']

Automated O
ambulatory B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
recordings I-outcome ['Physiological-Clinical']
performed O
in O
221 O
of O
the O
patients O
showed O
that O
the O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
lowered O
evenly O
through O
the O
entire O
24-hour O
dosing O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
subjects O
were O
divided O
into O
two O
groups O
and O
wore O
extended O
wear O
Quantum O
2 O
lenses O
( O
Dk O
= O
120 O
) O
for O
12 O
months O
. O
[]

This O
elevation O
occurs O
in O
patients O
with O
overt O
, O
symptomatic O
heart O
failure O
( O
HF O
) O
and O
in O
patients O
with O
asymptomatic O
left O
ventricular O
dysfunction O
. O
[]

QoL B-outcome ['Life-Impact']
improved O
in O
the O
study O
group O
and O
deteriorated O
in O
the O
control O
one O
. O
['Life-Impact']

There O
were O
no O
accidental B-outcome ['Physiological-Clinical']
needle I-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
noted O
. O
['Physiological-Clinical']

Among O
the O
273 O
children O
who O
were O
seen O
and O
weighed O
at O
the O
one-year O
follow-up O
visit O
, O
the O
rate O
of O
weight O
gain O
was O
8 O
per O
cent O
greater O
for O
those O
receiving O
levamisole O
than O
for O
placebo-treated O
controls O
( O
p O
= O
.06 O
) O
. O
[]

This O
randomized O
controlled O
study O
( O
N O
= O
49 O
) O
indicates O
that O
providing O
children O
with O
low-functioning O
autism O
( O
LFA O
) O
and O
high O
functioning O
autism O
( O
HFA O
) O
opportunities O
to O
practice O
attending O
to O
eye O
gaze O
, O
discriminating O
facial O
expressions O
and O
recognizing O
faces O
and O
emotions O
in O
FaceSay O
's O
structured O
environment O
with O
interactive O
, O
realistic O
avatar O
assistants O
improved O
their O
social O
skills O
abilities O
. O
[]

This O
study O
highlights O
the O
interest O
of O
monitoring O
right O
ventricular O
function O
during O
high-frequency O
oscillatory O
ventilation O
. O
[]

Uterine B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
mean O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
uterine B-outcome ['Physiological-Clinical']
weight O
, O
drop O
in O
hemoglobin B-outcome ['Physiological-Clinical']
, O
intraoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
conversions B-outcome ['Resource-use']
to I-outcome ['Resource-use']
laparotomy I-outcome ['Resource-use']
, O
and O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
were O
recorded O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Resource-use', 'Resource-use']

Guidelines O
on O
the O
management O
of O
low O
back O
pain O
in O
primary O
care O
should O
be O
consistent O
about O
not O
recommending O
lumbar O
spine O
radiography O
in O
patients O
with O
low O
back O
pain O
in O
the O
absence O
of O
red O
flags O
for O
serious O
spinal O
pathology O
, O
even O
if O
the O
pain O
has O
persisted O
for O
at O
least O
6 O
weeks O
. O
[]

The O
difference O
in O
the O
rates O
of O
definite B-outcome ['Physiological-Clinical']
infections B-outcome ['Physiological-Clinical']
was O
greatest O
for O
fungal O
infections O
, O
intermediate O
for O
bacterial O
infections O
, O
and O
lowest O
for O
viral O
infections O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Objective O
responses O
were O
achieved O
in O
> O
50 O
% O
of O
patients O
receiving O
either O
imatinib O
dose O
. O
[]

METHODS O
Fifty O
patients O
, O
demographically O
balanced O
, O
with O
radiographically O
proven O
primary O
hip O
or O
knee O
OA O
completed O
the O
classical O
paper O
and O
the O
new O
computerized O
WOMAC O
version O
. O
[]

Discontinuation O
rates O
due O
to O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
as O
follows O
: O
placebo O
7.7 O
% O
, O
aripiprazole O
5 O
mg/day O
9.4 O
% O
, O
10 O
mg/day O
13.6 O
% O
, O
and O
15 O
mg/day O
7.4 O
% O
. O
['Adverse-effects']

The O
groups O
were O
comparable O
in O
all O
respects O
and O
Pseudomonas O
aeruginosa O
was O
the O
predominant O
sputum O
pathogen O
in O
most O
patients O
. O
[]

Subjects O
receiving O
CM O
( O
behavior O
) O
, O
lost O
a O
mean O
of O
2.54 O
kg O
, O
which O
was O
a O
significant O
weight O
loss O
compared O
to O
the O
control O
period O
. O
[]

The O
utility O
of O
group O
interventions O
for O
spouses O
of O
men O
with O
prostate O
cancer O
is O
discussed O
. O
[]

Venous O
velocities O
were O
monitored O
after O
the O
application O
of O
each O
of O
five O
IPC O
devices O
, O
with O
all O
the O
patients O
in O
the O
supine O
position O
. O
[]

5-FU/FA O
chemotherapy O
for O
the O
treatment O
of O
unresectable O
colorectal O
liver O
metastases O
was O
compared O
in O
a O
prospective O
randomized O
clinical O
trial O
. O
[]

RESULTS O
At O
baseline O
, O
groups O
did O
not O
differ O
in O
clinical O
and O
functional B-outcome ['Life-Impact']
scale O
scores O
. O
['Physiological-Clinical', 'Life-Impact']

Patients O
returned B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
their I-outcome ['Physiological-Clinical']
normal I-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
significantly O
earlier O
after O
RFA O
( O
median O
3 O
( O
2-5 O
) O
versus O
12.5 O
( O
4-21 O
) O
days O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

A O
double-blind O
placebo-controlled O
trial O
of O
zonisamide O
( O
zonegran O
) O
in O
the O
treatment O
of O
essential B-outcome ['Physiological-Clinical']
tremor I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
median O
time B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
surgery I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
was O
3 O
days O
. O
['Physiological-Clinical']

CONCLUSION O
Trichloroacetic O
acid O
20 O
% O
showed O
better O
results O
than O
Jessner O
's O
solution O
as O
peeling O
agent O
and O
hydroquinone O
2 O
% O
with O
kojic O
acid O
as O
a O
topical O
agent O
in O
the O
treatment O
of O
melasma O
. O
[]

Following O
surgery O
, O
patients O
were O
evaluated O
for O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
emergence I-outcome ['Life-Impact']
and O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
meeting I-outcome ['Life-Impact']
discharge I-outcome ['Life-Impact']
criteria O
. O
['Life-Impact']

All O
patients O
were O
managed O
expectantly O
, O
with O
follow-up O
lasting O
1 O
year O
. O
[]

I. O
Predisposition O
to O
methotrexate-induced O
neutropenia O
after O
craniospinal O
irradiation O
. O
[]

In O
a O
pilot O
study O
we O
therefore O
investigated O
the O
effect O
of O
stimulation O
of O
the O
myenteric O
plexus O
by O
cisapride O
. O
[]

Students O
were O
assessed O
pre- O
and O
post-intervention O
using O
facial B-outcome ['Life-Impact']
expression I-outcome ['Life-Impact']
photographs I-outcome ['Life-Impact']
, O
cartoons O
depicting O
emotion-laden O
situations O
, O
and O
non-literal B-outcome ['Life-Impact']
stories I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Both O
carbapenems O
revealed O
high O
SBAs O
against O
clinically B-outcome ['Physiological-Clinical']
important I-outcome ['Physiological-Clinical']
pathogens I-outcome ['Physiological-Clinical']
at O
1 O
h O
; O
meropenem O
had O
a O
higher O
SBA B-outcome ['Physiological-Clinical']
against O
E. O
cloacae O
and O
P. O
mirabilis O
, O
and O
the O
SBA B-outcome ['Physiological-Clinical']
of O
imipenem O
against O
S. O
aureus O
was O
greater O
than O
the O
SBA O
of O
meropenem O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
data O
show O
that O
a O
wider O
variety O
of O
dental O
procedures O
than O
was O
previously O
documented O
cause O
bacteremia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

An O
unpaired O
two-tailed O
t O
test O
was O
carried O
out O
for O
both O
studies O
to O
compare O
the O
average O
weight O
loss O
of O
root B-outcome ['Physiological-Clinical']
substance I-outcome ['Physiological-Clinical']
with O
the O
modes O
of O
instrumentation O
. O
['Physiological-Clinical']

BACKGROUND O
Myoclonic O
movements O
are O
a O
common O
problem O
in O
unpremedicated O
patients O
during O
induction O
of O
anesthesia O
with O
etomidate O
. O
[]

Treatment O
of O
canine O
parvoviral O
enteritis O
with O
interferon-omega O
in O
a O
placebo-controlled O
challenge O
trial O
. O
[]

When O
extrapolated O
up O
to O
3 O
years O
, O
the O
gain O
in O
life O
expectancy O
was O
estimated O
at O
0.35 O
years O
( O
discounted O
at O
3 O
% O
) O
. O
[]

Anaesthesia O
was O
maintained O
with O
either O
a O
propofol O
infusion O
( O
100 O
micrograms O
kg-1 O
min-1 O
) O
or O
sevoflurane O
( O
1 O
% O
end-tidal O
) O
with O
66 O
% O
nitrous O
oxide O
( O
N2O O
) O
, O
n O
= O
15 O
in O
each O
subgroup O
. O
[]

The O
amount O
of O
bilirubin B-outcome ['Physiological-Clinical']
removed I-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
kilogram I-outcome ['Physiological-Clinical']
is O
directly O
correlated O
to O
plasma B-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
r=0.87 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
was O
to O
exercise O
twice O
a O
week O
for O
12 O
months O
, O
once O
guided O
and O
once O
independently O
. O
[]

Our O
study O
supports O
the O
hypothesis O
that O
the O
antimetastatic O
effects O
of O
zoledronic O
acid O
may O
be O
through O
effects O
on O
DTCs O
. O
[]

A O
role O
for O
error O
training O
in O
surgical O
technical O
skill O
instruction O
and O
evaluation O
. O
[]

Effects O
of O
omeprazole O
and O
amoxycillin O
on O
the O
human O
oral O
and O
gastrointestinal O
microflora O
in O
patients O
with O
Helicobacter O
pylori O
infection O
. O
[]

Existing O
studies O
suggest O
that O
inclusion O
of O
physical O
activity O
and O
TAG O
levels O
might O
improve O
the O
performance O
of O
the O
VIDSUN O
questionnaire O
. O
[]

Lisinopril O
has O
been O
compared O
with O
slow-release O
nifedipine O
in O
a O
16-week O
double-blind O
, O
randomized O
, O
parallel-group O
study O
involving O
102 O
patients O
with O
mild O
to O
moderate O
hypertension O
. O
[]

Patients O
were O
randomly O
allocated O
to O
cyproheptadine O
+ O
haloperidol O
( O
Group O
A O
) O
or O
haloperidol O
+ O
placebo O
( O
Group O
B O
) O
for O
an O
8-week O
, O
double-blind O
, O
placebo-controlled O
study O
. O
[]

METHODS O
After O
some O
positive O
results O
with O
prostaglandin O
inhibitors O
, O
we O
undertook O
a O
study O
in O
which O
we O
randomly O
placed O
patients O
on O
four O
different O
forms O
of O
therapy O
for O
their O
pruritus O
. O
[]

A O
subset O
( O
n O
= O
61 O
) O
had O
optical O
coherence O
tomography O
assessments O
. O
[]

340 O
cases O
of O
hookworm O
infection O
, O
196 O
cases O
of O
ascariasis O
and O
178 O
cases O
of O
trichuriasis O
were O
treated O
with O
an O
anthelmintic O
, O
oxibendazole O
, O
15mg/kg.d O
x O
3d O
; O
102 O
, O
70 O
and O
66 O
cases O
of O
respective O
infections O
were O
treated O
with O
pyrantel O
10mg/kg.d O
x O
3d O
and O
108 O
, O
74 O
and O
63 O
cases O
took O
placebo O
for O
comparison O
and O
as O
control O
under O
double-blind O
observations O
. O
[]

VPW B-outcome ['Physiological-Clinical']
and O
central B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CVP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
or O
pulmonary B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
occlusion I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PAOP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
from O
the O
first O
four O
study O
days O
were O
correlated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
study O
was O
strictly O
designed O
with O
randomization O
, O
double-blinding O
, O
and O
placebo-controlled O
method O
to O
observe O
the O
efficacy O
and O
immune B-outcome ['Physiological-Clinical']
memory I-outcome ['Physiological-Clinical']
11 O
years O
following O
hepatitis O
B O
vaccination O
. O
['Physiological-Clinical']

A O
single-center O
prospective O
controlled O
trial O
. O
[]

In O
the O
third O
phase O
, O
the O
adult O
sat O
still O
again O
( O
second O
still-face O
condition O
) O
, O
and O
in O
the O
fourth O
phase O
, O
the O
adult O
engaged O
in O
a O
spontaneous O
interaction O
. O
[]

Predictor O
variables O
were O
coded O
as O
0 O
or O
1 O
to O
represent O
absence O
or O
presence O
, O
respectively O
, O
of O
each O
condition O
and O
were O
included O
as O
fixed O
effects O
. O
[]

Three O
horses O
were O
excluded O
from O
the O
study O
after O
developing O
soft O
tissue O
necrosis O
around O
the O
injection O
site O
, O
septic O
arthritis O
, O
and O
necrotic O
tendinitis O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
immunological O
and O
functional O
effects O
of O
a O
liposome-entrapped O
D. O
pteronyssinus O
vaccine O
on O
mite O
monosensitive O
, O
mild O
asthma O
patients O
. O
[]

METHODS O
We O
carried O
out O
a O
randomized O
study O
of O
patients O
with O
rheumatic O
disease O
attending O
the O
outpatient O
clinic O
for O
rheumatic O
diseases O
. O
[]

Entacapone O
( O
OR-611 O
) O
, O
a O
novel O
COMT O
inhibitor O
, O
which O
does O
not O
cross O
the O
blood O
brain O
barrier O
, O
was O
assessed O
in O
12 O
patients O
with O
Parkinson O
's O
disease O
and O
motor O
fluctuations O
in O
a O
randomised O
, O
double-blind O
, O
cross-over O
, O
single O
dose O
study O
. O
[]

The O
efficacy O
of O
melatonin O
for O
sleep O
problems O
in O
children O
with O
autism O
, O
fragile O
X O
syndrome O
, O
or O
autism O
and O
fragile O
X O
syndrome O
. O
[]

The O
use O
of O
the O
IHC O
based O
TMA O
methodology O
has O
shown O
to O
be O
a O
simple O
, O
cost B-outcome ['Resource-use']
effective O
and O
a O
robust O
alternative O
to O
gene O
expression O
profiling O
( O
GEP O
) O
which O
is O
currently O
regarded O
as O
the O
gold O
standard O
for O
the O
classification O
in O
lymphomas O
. O
['Resource-use']

We O
identified O
three O
risk O
groups O
: O
Group O
1 O
had O
normal O
or O
mildly O
abnormal O
results O
on O
liver-function O
tests O
, O
Group O
2 O
had O
more O
severe O
liver O
dysfunction O
or O
previous O
complications O
, O
and O
Group O
3 O
had O
severe O
prerenal O
azotemia O
without O
kidney O
disease O
. O
[]

For O
children O
beginning O
treatment O
with O
the O
lowest O
language O
levels O
, O
the O
JA O
intervention O
improved O
language B-outcome ['Life-Impact']
outcome O
significantly O
more O
than O
did O
the O
SP O
or O
control O
interventions O
. O
['Life-Impact']

The O
incidence O
of O
postinjection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
temporary B-outcome ['Physiological-Clinical']
numbness/paresthesia I-outcome ['Physiological-Clinical']
, O
and O
incisive B-outcome ['Physiological-Clinical']
papilla I-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
or O
soreness B-outcome ['Physiological-Clinical']
would O
indicate O
that O
some O
pain O
and O
problems O
occur O
with O
the O
P-ASA O
technique O
, O
regardless O
of O
whether O
2 O
% O
lidocaine O
with O
1:100,000 O
epinephrine O
or O
3 O
% O
mepivacaine O
is O
used O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
day O
3 O
, O
patients O
who O
satisfied O
the O
criteria O
for O
switch O
therapy O
were O
randomized O
to O
either O
group O
A O
( O
IV O
ceftriaxone O
) O
or O
group O
B O
( O
oral O
cefditoren O
pivoxil O
400mg O
once O
daily O
) O
. O
[]

The O
cerebellum O
has O
frequently O
been O
reported O
to O
be O
damaged O
by O
prenatal O
alcohol O
exposure O
. O
[]

58 O
% O
of O
the O
patients O
opted O
to O
continuetreatment B-outcome ['Life-Impact']
with O
lansoprazole O
, O
compared O
with O
only O
25 O
% O
in O
the O
case O
of O
esomeprazole O
. O
['Life-Impact']

Seventy-nine O
patients O
with O
an O
histologically O
proven O
disseminated O
breast O
cancer O
, O
never O
treated O
before O
with O
additive O
hormonal O
therapy O
, O
entered O
into O
a O
randomized O
trial O
between O
june O
1981 O
and O
december O
1982 O
. O
[]

Fifty O
patients O
( O
47 O
% O
) O
were O
randomized O
to O
HSD O
and O
56 O
( O
53 O
% O
) O
to O
NS O
. O
[]

The O
side-effects B-outcome ['Adverse-effects']
were O
mild O
and O
tolerable O
. O
['Adverse-effects']

Treatment O
using O
ondansetron O
for O
anti-emetic O
prophylaxis O
did O
not O
provide O
a O
superior O
benefit O
compared O
to O
midazolam O
in O
the O
present O
study O
. O
[]

Serial O
blood O
samples O
were O
drawn O
over O
a O
14-hour O
period O
after O
drug O
administration O
. O
[]

In O
a O
randomized O
, O
double-blind O
, O
crossover O
study O
of O
15 O
aspirin-naive O
patients O
( O
mean O
age O
48.8 O
? O
[]

Treatment O
with O
coumarin O
to O
prevent O
or O
delay O
recurrence O
of O
malignant O
melanoma O
. O
[]

Of O
24 O
informative O
cases O
, O
14 O
patients O
( O
58 O
% O
) O
showed O
the O
same O
pattern O
of O
allelic B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
or O
retention B-outcome ['Physiological-Clinical']
in O
matched O
primary O
and O
metastatic O
tumors O
at O
all O
marker O
locus O
; O
discordant O
allelic B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
observed O
in O
the O
remaining O
10 O
patients O
( O
42 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Compliance B-outcome ['Life-Impact']
was O
above O
90 O
% O
for O
both O
arms O
. O
['Life-Impact']

CONCLUSIONS O
Caudal O
neostigmine O
( O
2 O
, O
3 O
and O
4 O
microg.kg O
( O
-1 O
) O
) O
with O
bupivacaine O
produces O
a O
dose-independent O
analgesic B-outcome ['Resource-use']
effect O
( O
approximately O
16-17 O
hr O
) O
in O
children O
as O
compared O
to O
those O
receiving O
caudal O
bupivacaine O
alone O
( O
approximately O
five O
hours O
) O
and O
a O
reduction O
in O
postoperative B-outcome ['Physiological-Clinical']
rescue I-outcome ['Physiological-Clinical']
analgesic I-outcome ['Physiological-Clinical']
consumption I-outcome ['Physiological-Clinical']
without O
increasing O
the O
incidence O
of O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Resource-use', 'Physiological-Clinical', 'Adverse-effects']

However O
many O
hypercholesterolemic O
patients O
often O
suffer O
from O
arterial O
hypertension O
and O
drugs O
such O
as O
thiazide O
diuretics O
cause O
an O
imbalance O
in O
lipid O
metabolism O
. O
[]

BACKGROUND O
Transbronchial O
lung O
biopsy O
( O
TBLB O
) O
is O
a O
valuable O
procedure O
used O
to O
obtain O
a O
parenchymal B-outcome ['Physiological-Clinical']
specimen I-outcome ['Physiological-Clinical']
in O
the O
evaluation O
of O
diffuse O
lung O
infiltrates O
. O
['Physiological-Clinical']

There O
was O
a O
significant O
improvement O
in O
shoulder B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
on O
Oxford O
and O
Constant O
scores O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

Participants O
were O
randomized O
to O
receive O
a O
standard O
( O
30 O
minutes/day O
) O
or O
high O
( O
60 O
minutes/day O
) O
walking O
program O
. O
[]

OBJECTIVE O
To O
compare O
laparoscopically O
assisted O
vaginal O
hysterectomy O
( O
LAVH O
) O
and O
total O
abdominal O
hysterectomy O
( O
TAH O
) O
in O
patients O
with O
uterine O
fibroids O
. O
[]

Hormone O
replacement O
therapy O
producing O
an O
effect O
equivalent O
to O
higher O
oestradiol O
concentrations O
is O
likely O
to O
increase O
the O
risk O
of O
side O
effects O
without O
conferring O
any O
[]

To O
test O
whether O
the O
leukotriene O
antagonist O
ONO-1078 O
( O
pranlukast O
) O
prevents O
asthma O
exacerbations O
during O
reduction O
of O
high-dose O
inhaled O
corticosteroid O
, O
we O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
in O
79 O
asthma O
patients O
requiring O
high O
doses O
( O
1,500 O
microg/d O
or O
more O
) O
of O
inhaled O
beclomethasone O
dipropionate O
( O
BDI O
) O
for O
clinical O
control O
( O
duration O
of O
asthma O
, O
11.0 O
+/- O
3.1 O
yr O
; O
duration O
of O
BDI O
treatment O
, O
0.5 O
+/- O
0.3 O
yr O
; O
FEV1 O
percentage O
of O
predicted O
, O
80.7 O
+/- O
2.0 O
% O
) O
. O
[]

BACKGROUND O
A O
diagnostic O
hallmark O
of O
autism O
spectrum O
disorders O
is O
a O
qualitative O
impairment O
in O
social O
communication O
and O
interaction O
. O
[]

Transesophageal O
echocardiography O
( O
TEE O
) O
was O
used O
to O
evaluate O
the O
quantity O
and O
quality B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
emboli I-outcome ['Physiological-Clinical']
generated I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
nailing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Hand O
laterality O
recognition O
imparted O
a O
consistent O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
across O
groups O
, O
however O
, O
this O
effect O
was O
limited O
in O
magnitude O
. O
['Physiological-Clinical', 'Life-Impact']

The O
mean O
CYBOCS O
score O
was O
14.4 O
( O
+/- O
3.86 O
) O
with O
excellent O
internal O
consistency O
( O
alpha O
= O
.85 O
) O
. O
[]

This O
telehealth O
intervention O
provides O
support O
and O
education O
to O
patients O
undergoing O
treatment O
for O
head O
and O
neck O
cancers O
. O
[]

However O
, O
after O
10 O
wk O
of O
training O
, O
the O
skeletal O
muscle O
expressed O
a O
higher O
mRNA O
level O
of O
IL-6R O
compared O
with O
before O
training O
. O
[]

INTERVENTION O
Patients O
were O
randomly O
assigned O
to O
receive O
enoxaparin O
( O
30 O
mg O
subcutaneously O
every O
12 O
hours O
) O
or O
adjusted-dose O
warfarin O
( O
international O
normalized O
ratio O
, O
2.0 O
to O
3.0 O
) O
. O
[]

There O
were O
no O
differences O
in O
clinical O
or O
immune O
responses O
between O
the O
treatment O
groups O
. O
[]

Cryotherapy O
for O
Retinopathy O
of O
Prematurity O
Cooperative O
Group O
. O
[]

Intervention O
to O
lower O
household O
wood O
smoke O
exposure O
in O
Guatemala O
reduces O
ST-segment B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
on O
electrocardiograms O
. O
['Physiological-Clinical']

CONCLUSIONS O
In O
the O
absence O
of O
standard O
pharmacological O
treatment O
for O
children O
with O
autistic O
disorder O
, O
a O
placebo-controlled O
study O
remains O
the O
most O
appropriate O
method O
of O
testing O
efficacy O
and O
safety O
. O
[]

Even O
when O
these O
individuals O
were O
excluded O
, O
no O
clinically O
significant O
effect O
of O
gemfibrozil O
on O
kidney B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
observed O
. O
['Physiological-Clinical']

Similarly O
, O
the O
need O
for O
target B-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
was O
reduced O
from O
25.5 O
% O
to O
24.2 O
% O
and O
to O
15.2 O
% O
in O
the O
placebo O
, O
usual-dose O
, O
and O
high-dose O
groups O
, O
respectively O
( O
P=0.08 O
) O
. O
['Physiological-Clinical']

As O
it O
is O
important O
to O
establish O
the O
long-term O
safety O
and O
efficacy O
of O
treatments O
for O
a O
chronic O
disease O
such O
as O
OA O
, O
the O
present O
study O
compared O
the O
effects O
of O
lumiracoxib O
at O
doses O
of O
100 O
mg O
once O
daily O
( O
o.d O
. O
) O
[]

In O
a O
subset O
of O
10 O
participants O
, O
we O
compared O
the O
effects O
of O
4 O
days O
of O
sulfasalazine O
treatment O
( O
n O
= O
5 O
) O
to O
no O
treatment O
( O
n O
= O
5 O
) O
on O
NF?B-regulated O
gene O
expression O
in O
peripheral O
blood O
mononuclear O
cells O
. O
[]

table O
: O
see O
text O
] O
Overall O
, O
side O
effects O
from O
adenosine O
were O
not O
different O
between O
men O
and O
women O
. O
[]

RESULTS O
Of O
2,223 O
eligible O
patients O
, O
562 O
( O
25 O
% O
) O
have O
enrolled O
. O
[]

The O
genotyping O
results O
were O
ranked O
hierarchically O
according O
to O
cancer O
risk O
: O
HPV16 O
> O
other O
carcinogenic O
HPV O
> O
noncarcinogenic O
HPV O
> O
PCR O
negative O
. O
[]

Serum B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
biochemical I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
remained O
unaltered O
. O
['Physiological-Clinical']

Patients O
with O
a O
measured O
leak O
of O
> O
or O
= O
1 O
% O
develop O
mild O
and O
transient O
postoperative O
hypotension O
with O
significantly O
higher O
systemic O
TNF O
levels O
and O
lower O
perfusate O
TNF O
levels O
than O
in O
patients O
without O
leaks O
. O
[]

Ninety O
percent O
of O
the O
patients O
were O
infected O
at O
Thailand-Myanmar O
border O
. O
[]

RESULTS O
Both O
bone B-outcome ['Physiological-Clinical']
dehiscence I-outcome ['Physiological-Clinical']
and O
superficial B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
instability I-outcome ['Physiological-Clinical']
were O
less O
frequent O
in O
the O
PDS O
Group O
( O
4 O
and O
3 O
cases O
in O
the O
SS O
Group O
, O
respectively O
, O
vs. O
no O
cases O
in O
the O
PDS O
Group O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Telephone O
Counselling O
compared O
to O
Usual O
Care O
was O
not O
cost-effective O
( O
$ O
78,489 O
per O
quality O
adjusted O
life O
year O
gained O
) O
. O
['Resource-use']

This O
drug O
can O
be O
recommended O
for O
wide O
clinical O
practice O
in O
[]

We O
studied O
137 O
women O
and O
treatments O
were O
found O
to O
be O
equivalent O
for O
onset O
, O
duration O
and O
quality O
of O
block O
. O
[]

There O
was O
no O
difference O
in O
the O
baseline O
Pap B-outcome ['Resource-use']
smear I-outcome ['Resource-use']
screening-coverage O
rate O
in O
the O
intervention O
vs. O
control O
zones O
( O
36.7 O
vs. O
31.5 O
% O
, O
p=0.339 O
) O
. O
['Resource-use']

Effects O
of O
topical O
and O
systemic O
folic O
acid O
supplementation O
on O
gingivitis B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
an O
intravenous O
human O
monoclonal O
antibody O
to O
cytomegalovirus O
( O
CMV O
) O
, O
MSL-109 O
, O
as O
adjuvant O
treatment O
for O
CMV O
retinitis O
. O
[]

PATIENTS O
A O
total O
of O
1019 O
men O
and O
women O
aged O
18 O
to O
74 O
years O
with O
either O
type O
1 O
or O
type O
2 O
diabetes O
and O
a O
sensory O
polyneuropathy O
attributable O
to O
diabetes O
. O
[]

Histopathology O
was O
reviewed O
centrally O
. O
[]

Further O
studies O
are O
needed O
to O
optimize O
the O
clinical O
practice O
of O
IV O
opioid O
treatment O
to O
prevent O
serious O
complications O
. O
[]

OBJECTIVE O
The O
goal O
of O
this O
study O
has O
been O
to O
determine O
whether O
hyaluronic O
acid O
( O
HA O
) O
or O
exercise O
therapy O
can O
improve O
functional O
parameters O
in O
patients O
with O
osteoarthritis O
( O
OA O
) O
of O
the O
ankle O
. O
[]

Practices O
were O
then O
given O
access O
to O
an O
ADHD O
Internet O
portal O
that O
allowed O
parents O
, O
teachers O
, O
and O
pediatricians O
to O
input O
information O
( O
eg O
, O
rating O
scales O
) O
about O
patients O
, O
after O
which O
information O
was O
scored O
, O
interpreted O
, O
and O
formatted O
in O
a O
report O
style O
that O
was O
helpful O
for O
assessment O
and O
treatment O
of O
patients O
with O
ADHD O
. O
[]

Injection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
propofol O
. O
['Physiological-Clinical']

We O
studied O
500 O
consecutive O
patients O
randomized O
to O
an O
intravenous O
group O
( O
n O
= O
250 O
) O
, O
receiving O
50 O
U/kg O
of O
unfractionated O
heparin O
( O
maximal O
dose O
5,000 O
U O
) O
intravenously O
, O
and O
an O
intra-arterial O
group O
( O
n O
= O
250 O
) O
receiving O
the O
same O
dose O
intra-arterially O
. O
[]

Eighty O
pregnant O
women O
at O
high O
risk O
of O
giving O
birth O
prematurely O
were O
divided O
randomly O
into O
two O
groups O
. O
[]

The O
present O
study O
was O
designed O
as O
a O
12-week O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
pilot O
study O
to O
evaluate O
the O
effectiveness O
and O
safety O
of O
donepezil O
in O
boys O
with O
fragile O
X O
syndrome O
. O
[]

The O
detected O
candidate O
objects O
are O
classified O
using O
all O
features O
and O
a O
k-nearest O
neighbor O
classifier O
. O
[]

A O
controlled O
study O
using O
tetracycline O
. O
[]

Due O
to O
the O
pH-dependent O
solubility O
of O
delavirdine O
, O
the O
buffering O
agents O
in O
didanosine O
formulations O
may O
reduce O
delavirdine O
absorption O
. O
[]

Downstaging O
for O
stages O
I O
+ O
II O
did O
not O
occur O
. O
[]

RESULTS O
Significant O
independent O
predictors O
of O
inhospital O
VF O
were O
higher O
Killip B-outcome ['Physiological-Clinical']
class I-outcome ['Physiological-Clinical']
, O
lower O
baseline O
systolic B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
, O
intravenous O
preenrollment O
lidocaine B-outcome ['Resource-use']
use B-outcome ['Life-Impact']
, O
shorter O
time O
to O
thrombolysis B-outcome ['Physiological-Clinical']
, O
and O
beta-blocker O
use O
< O
2 O
weeks O
before O
enrollment O
; O
independent O
predictors O
of O
inhospital O
VT O
were O
lower O
baseline O
systolic B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
intravenous B-outcome ['Resource-use']
lidocaine I-outcome ['Resource-use']
use O
before O
enrollment O
, O
higher O
Killip O
class O
, O
faster O
baseline O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
advanced O
age O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Whether O
by O
telemedicine O
or O
telephone O
consultative O
modalities O
, O
there O
were O
appropriate O
treatment O
decisions B-outcome ['Life-Impact']
, O
high O
rates O
of O
thrombolysis B-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
improved O
data O
collection B-outcome ['Physiological-Clinical']
, O
low O
rates O
of O
intracerebral B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
, O
and O
equally O
favorable O
time B-outcome ['Life-Impact']
requirements I-outcome ['Life-Impact']
. O
['Life-Impact', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

METHODS O
We O
randomly O
assigned O
129 O
H. O
pylori O
infected O
patients O
with O
severe O
epigastric O
pain O
, O
without O
gastro-oesophageal O
reflux O
symptoms O
, O
to O
receive O
twice O
daily O
treatment O
with O
300 O
mg O
of O
ranitidine O
, O
1000 O
mg O
of O
amoxicillin O
, O
and O
500 O
mg O
of O
clarithromycin O
for O
7 O
days O
and O
124 O
such O
patients O
to O
receive O
identical-appearing O
placebos O
. O
[]

STUDY O
DESIGN O
Male O
and O
female O
immunocompetent O
patients O
applied O
imiquimod O
5 O
% O
cream O
topically O
to O
external O
genital O
warts O
3 O
times O
a O
week O
until O
wart O
clearance O
or O
for O
up O
to O
16 O
weeks O
. O
[]

Although O
the O
flexible O
cryoprobe O
has O
been O
established O
for O
bronchoscopic O
interventions O
in O
malignant O
stenosis O
, O
the O
obtained O
biopsies O
, O
called O
cryobiopsies O
, O
have O
not O
been O
investigated O
in O
a O
large O
cohort O
of O
patients O
. O
[]

Thirty O
six O
patients O
with O
glaucoma O
undergoing O
cataract O
extraction O
and O
posterior O
chamber O
lens O
implantation O
received O
one O
of O
three O
treatments O
. O
[]

The O
most O
common O
adverse O
events O
reported O
were O
worsening B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
UC I-outcome ['Physiological-Clinical']
and O
headache B-outcome ['Physiological-Clinical']
; O
both O
were O
reported O
more O
often O
in O
the O
placebo O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Children O
in O
the O
intervention O
participated O
in O
six O
2-h O
weekly O
sessions O
while O
parents O
participated O
in O
a O
larger O
parent O
group O
. O
[]

OBJECTIVE O
To O
evaluate O
, O
both O
polysomnographically O
and O
by O
subjective O
scales O
, O
the O
efficacy O
and O
safety O
profile O
of O
pramipexole O
for O
restless O
legs O
syndrome O
( O
RLS O
) O
via O
a O
3-week O
, O
double-blind O
, O
placebo-controlled O
, O
parallel-group O
, O
dose-ranging O
study O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
feasibility B-outcome ['Life-Impact']
and O
outcome O
of O
the O
step-down O
approach O
using O
either O
cyclosporin O
A O
( O
CSA O
) O
or O
methotrexate O
( O
MTX O
) O
as O
maintenance O
therapy O
following O
6 O
months O
treatment O
with O
these O
2 O
agents O
in O
combination O
in O
early O
, O
nonerosive O
rheumatoid O
arthritis O
( O
RA O
) O
. O
['Life-Impact']

After O
6 O
months O
, O
47 O
% O
of O
all O
showed O
such O
improvement O
. O
[]

Experiment O
3 O
showed O
that O
increases O
in O
target-distractor B-outcome ['Life-Impact']
similarity O
slowed O
the O
visual B-outcome ['Life-Impact']
search I-outcome ['Life-Impact']
performance B-outcome ['Life-Impact']
of O
the O
control O
group O
significantly O
more O
than O
that O
of O
the O
autism O
group O
, O
suggesting O
that O
the O
adults O
with O
autism O
have O
a O
superior B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
discrimination I-outcome ['Physiological-Clinical']
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

mite O
, O
were O
randomly O
allocated O
to O
two O
treatment O
groups O
in O
Study O
1 O
. O
[]

METHODS O
This O
was O
a O
12-week O
open-label O
study O
designed O
to O
mimic O
an O
actual O
clinical O
setting O
in O
patients O
> O
or=12 O
years O
old O
with O
mild-to-moderate O
persistent O
asthma O
. O
[]

Recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
significantly O
longer O
with O
ASI O
( O
42 O
% O
risk O
reduction O
for O
recurrence O
or O
death O
[ O
0-68 O
] O
, O
p=0.032 O
) O
and O
there O
was O
a O
trend O
towards O
improved O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

Five O
of O
six O
volunteers O
who O
received O
the O
400-mg O
dose O
experienced O
subjective B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
central I-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
side I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
when O
the O
cuff O
was O
released O
. O
['Physiological-Clinical']

Women O
with O
a O
personal O
history O
of O
cancer O
were O
excluded O
. O
[]

The O
treatment O
contact O
time O
varied O
from O
15 O
minutes O
to O
60 O
minutes O
. O
[]

Effect O
of O
intravenous O
fructose-1,6-diphosphate O
on O
myocardial B-outcome ['Physiological-Clinical']
contractility I-outcome ['Physiological-Clinical']
in O
patients O
with O
left O
ventricular O
dysfunction O
. O
['Physiological-Clinical']

Demand O
and O
control B-outcome ['Physiological-Clinical']
were O
measured O
using O
both O
patient- O
and O
caregiver-derived O
measures O
. O
['Physiological-Clinical']

Double O
blind O
comparison O
of O
Iomeprol O
350 O
and O
Iopamidol O
340 O
in O
intravenous O
digital O
subtraction O
angiography O
for O
peripheral O
vascular O
disease O
. O
[]

Relative O
change O
in O
serum B-outcome ['Physiological-Clinical']
retinol I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
among O
the O
Experimental O
group O
, O
with O
one-third O
of O
total O
vitamin O
A O
intake O
coming O
from O
vitamin O
A-fortified O
cooking O
oil O
intake O
, O
than O
in O
the O
Control O
groups O
, O
with O
more O
than O
half O
of O
intake O
from O
other O
vitamin O
A-rich O
foods O
. O
['Physiological-Clinical']

Effects O
of O
iron O
on O
the O
pharmacokinetics O
of O
paracetamol B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
saliva I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
G-CSF I-outcome ['Physiological-Clinical']
levels O
during O
the O
rhG-CSF O
therapy O
greatly O
exceeded O
endogenous B-outcome ['Physiological-Clinical']
G-CSF I-outcome ['Physiological-Clinical']
levels O
and O
were O
mainly O
due O
to O
the O
presence O
of O
exogenous O
rhG-CSF O
rather O
than O
increased O
levels O
of O
endogenous O
G-CSF O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Stool B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
Shigella I-outcome ['Physiological-Clinical']
, O
Salmonella B-outcome ['Physiological-Clinical']
, O
Campylobacter B-outcome ['Physiological-Clinical']
spp I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
impact O
of O
long-term O
, O
heavy O
exercise O
on O
recently O
established O
cardiovascular/thromboembolic O
risk O
factors O
of O
the O
fibrinolytic O
system O
, O
tissue O
plasminogen O
activator O
( O
tPA O
) O
and O
plasminogen O
activator O
inhibitor O
( O
PAI-1 O
) O
in O
relation O
to O
food O
composition O
was O
studied O
. O
[]

After O
16 O
weeks O
, O
the O
TEF B-outcome ['Physiological-Clinical']
was O
not O
reduced O
in O
either O
dietary O
group O
. O
['Physiological-Clinical']

Clinical O
implications O
of O
a O
reduction O
in O
psychological O
distress O
on O
cardiac O
prognosis O
in O
patients O
participating O
in O
a O
psychosocial O
intervention O
program O
. O
[]

Fourteen O
of O
the O
20 O
subjects O
had O
less O
gastric B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
during O
cotherapy O
with O
omeprazole O
. O
['Physiological-Clinical']

Administered O
by O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
, O
it O
is O
the O
first O
trial O
seeking O
to O
demonstrate O
whether O
a O
drug O
, O
tamoxifen O
, O
can O
prevent O
breast O
cancer O
in O
high-risk O
women O
. O
[]

The O
effects O
of O
feeding O
diets O
with O
different O
milliequivalents O
( O
meq O
) O
of O
dietary O
[ O
( O
Na+ O
+ O
K+ O
) O
- O
( O
Cl- O
+ O
SO4= O
) O
] O
to O
dairy O
cows O
during O
the O
last O
seven O
weeks O
of O
pregnancy O
on O
their O
acid-base O
status O
and O
calcium O
mobilisation O
rate O
around O
parturition O
were O
studied O
. O
[]

Twelve O
patients O
were O
randomized O
to O
receive O
5/microg/kg/day O
G-CSF O
and O
14 O
patients O
to O
receive O
5 O
microg/kg/day O
GM-CSF O
, O
both O
administered O
subcutaneously O
starting O
on O
day O
1 O
after O
the O
end O
of O
Dexa-BEAM O
. O
[]

METHODS O
Diabetic O
patients O
with O
de O
novo O
coronary O
lesions O
( O
169 O
patients O
with O
190 O
lesions O
) O
were O
randomly O
assigned O
prospectively O
to O
either O
SES O
or O
PES O
. O
[]

No O
accumulation O
of O
the O
activities O
were O
seen O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
test O
whether O
a O
higher O
dose O
of O
G-CSF O
( O
10 O
micro O
g/kg/day O
) O
would O
reduce O
these O
complications B-outcome ['Adverse-effects']
. O
['Adverse-effects']

Signs O
of O
allergic O
conjunctivitis O
generally O
were O
reduced O
most O
by O
a O
combination O
of O
a O
CC O
in O
combination O
with O
ATs O
or O
EH O
. O
[]

However O
, O
the O
lack O
of O
proarrhythmia O
and O
the O
reduction O
in O
arrhythmic B-outcome ['Mortality']
death I-outcome ['Mortality']
support O
the O
use O
of O
amiodarone O
in O
patients O
for O
whom O
antiarrhythmic O
therapy O
is O
indicated O
. O
['Mortality']

Also O
, O
intensification O
of O
systemic O
induction O
and O
maintenance O
chemotherapy O
was O
given O
. O
[]

Median O
overall O
survival B-outcome ['Mortality']
( O
OS O
) O
was O
similar O
for O
the O
187 O
HLA-A*0201-positive O
[ O
9.3 O
months O
, O
95 O
% O
CI O
( O
confidence O
interval O
) O
7.4-11.5 O
] O
and O
266 O
HLA-A*0201-negative O
patients O
[ O
11.4 O
months O
, O
95 O
% O
CI O
9.3-15.1 O
] O
randomized O
to O
ipilimumab O
at O
all O
doses O
across O
the O
four O
phase O
II O
trials O
. O
['Mortality']

Short-acting O
beta O
( O
2 O
) O
-agonists O
are O
currently O
recommended O
for O
symptom O
relief O
in O
asthma O
and O
the O
treatment O
of O
mild O
, O
acute O
exacerbations O
in O
COPD O
. O
[]

A O
double-blind O
crossover O
design O
was O
used O
to O
assess O
the O
efficacy O
of O
wearing O
ambient O
lenses O
to O
reduce O
the O
behavioral O
symptoms O
of O
autism O
. O
[]

The O
groups O
were O
: O
( O
1 O
) O
the O
LED O
group O
( O
treadmill O
training O
associated O
with O
phototherapy O
, O
n O
= O
10 O
) O
, O
( O
2 O
) O
the O
exercise O
group O
( O
treadmill O
training O
, O
n O
= O
10 O
) O
, O
and O
( O
3 O
) O
the O
sedentary O
group O
( O
neither O
physical O
training O
nor O
phototherapy O
, O
n O
= O
10 O
) O
. O
[]

In O
this O
paper O
, O
we O
present O
data O
to O
illustrate O
that O
adolescents O
with O
traumatic O
brain O
injury O
( O
TBI O
) O
are O
likely O
to O
have O
impairments O
in O
processes B-outcome ['Life-Impact']
such I-outcome ['Life-Impact']
as I-outcome ['Life-Impact']
emotion I-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
and O
mental B-outcome ['Life-Impact']
state I-outcome ['Life-Impact']
attribution I-outcome ['Life-Impact']
, O
and O
that O
these O
might O
not O
be O
identified O
on O
standardised O
tests O
. O
['Life-Impact', 'Life-Impact']

for O
4 O
wk O
, O
followed O
by O
18 O
million O
units O
for O
12 O
wk O
and O
9 O
million O
units O
for O
8 O
wk O
( O
972 O
million O
units O
) O
; O
24 O
( O
C O
) O
received O
2 O
alpha-2a O
IFN O
courses O
( O
9 O
million O
units O
i.m O
. O
[]

Using O
data O
from O
the O
Action O
in O
Diabetes O
and O
Vascular O
disease O
: O
preterAx O
and O
diamicroN-MR O
Controlled O
Evaluation O
study O
, O
we O
assessed O
the O
efficacy O
and O
safety O
of O
routine O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
lowering I-outcome ['Physiological-Clinical']
to O
prevent O
major O
clinical O
outcomes O
in O
elderly O
patients O
with O
type O
2 O
diabetes O
. O
['Physiological-Clinical']

These O
children O
were O
randomly O
selected O
and O
were O
matched O
for O
age O
and O
level O
of O
retardation O
. O
[]

Most O
of O
the O
patients O
enrolled O
were O
elderly O
people O
( O
mean O
age O
, O
71 O
years O
) O
. O
[]

This O
study O
was O
designed O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
BBOS O
1.5 O
% O
for O
reducing O
ocular O
itching O
associated O
with O
AC O
in O
subjects O
enrolled O
in O
a O
natural O
exposure O
trial O
. O
[]

10.2 O
to O
27.4 O
? O
[]

Seventy-five O
percent O
of O
patients O
had O
increased O
norepinephrine B-outcome ['Physiological-Clinical']
after O
nifedipine O
therapy O
. O
['Physiological-Clinical']

It O
is O
known O
that O
cervicogenic O
headache O
sufferers O
present O
with O
several O
musculoskeletal O
changes O
including O
poor O
endurance O
of O
the O
deep O
cervical O
flexor O
muscles O
. O
[]

Tropisetron O
and O
granisetron O
are O
selective O
serotonin O
( O
5-HT3 O
) O
antagonists O
that O
have O
been O
proven O
effective O
in O
the O
prevention O
of O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
in O
adults O
and O
children O
receiving O
cancer O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
results O
show O
that O
in O
both O
active O
groups O
after O
30 O
' O
and O
until O
4 O
hours O
, O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
decreased O
significantly O
with O
respect O
to O
the O
baseline O
. O
['Physiological-Clinical']

were O
given O
until O
discharge O
. O
[]

Results O
suggest O
that O
the O
allocation O
to O
an O
individualized O
, O
comprehensive O
, O
home-based O
cardiac O
rehabilitation O
program O
provided O
more O
advantageous O
outcomes O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
and O
neuropsychological B-outcome ['Physiological-Clinical']
outcome O
was O
assessed O
at O
3 O
and O
12 O
months O
after O
treatment O
; O
MRI O
of O
the O
brain O
was O
performed O
at O
12 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
eyes O
had O
lensectomy O
and O
posterior O
chamber O
intraocular O
lens O
( O
PC O
IOL O
) O
implantation O
. O
[]

Intraperitoneal O
cisplatin O
versus O
no O
further O
treatment O
: O
8-year O
results O
of O
EORTC O
55875 O
, O
a O
randomized O
phase O
III O
study O
in O
ovarian O
cancer O
patients O
with O
a O
pathologically O
complete O
remission O
after O
platinum-based O
intravenous O
chemotherapy O
. O
[]

Dose-response O
relationship O
of O
complementary O
radiotherapy O
following O
four O
cycles O
of O
combination O
chemotherapy O
in O
intermediate-stage O
Hodgkin O
's O
disease O
. O
[]

Analyses O
were O
according O
to O
intention-to-treat O
. O
[]

A O
higher O
number O
of O
fractures B-outcome ['Physiological-Clinical']
occurred O
during O
exemestane O
treatment O
, O
but O
fracture B-outcome ['Physiological-Clinical']
rates O
were O
similar O
after O
treatment O
withdrawal O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SETTING O
Level O
1 O
trauma O
center O
. O
[]

The O
most O
effective O
technique O
to O
administer O
SWI O
is O
yet O
to O
be O
determined O
. O
[]

Effects O
of O
diet O
and O
Aspergillus O
oryzae O
extract O
or O
Saccharomyces O
cervisiae O
on O
growth O
and O
carcass O
characteristics O
of O
lambs O
and O
steers O
fed O
to O
meet O
requirements O
of O
natural O
markets O
. O
[]

CLA O
did O
not O
significantly O
affect O
inflammatory O
markers O
. O
[]

Our O
results O
suggest O
that O
listening O
to O
motivational O
music O
during O
nonstructured O
recovery O
from O
intense O
exercise O
leads O
to O
increased O
activity O
, O
faster O
lactate O
clearance O
, O
and O
reduced O
RPE O
and O
therefore O
may O
be O
used O
by O
athletes O
in O
their O
effort O
to O
enhance O
recovery O
. O
[]

BACKGROUND O
Decreased O
heart O
rate O
variability O
( O
HRV O
) O
is O
associated O
with O
a O
higher O
risk O
of O
mortality O
. O
[]

No O
patient O
in O
either O
group O
experienced O
emesis B-outcome ['Physiological-Clinical']
or O
significant O
dysrhythmias B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
A O
proof-of-concept O
study O
suggested O
that O
combination O
therapy O
with O
commercial O
azelastine O
hydrochloride O
nasal O
spray O
and O
fluticasone O
propionate O
nasal O
spray O
significantly O
improved O
nasal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
seasonal I-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
compared O
with O
either O
agent O
alone O
. O
['Physiological-Clinical']

On O
top O
of O
this O
, O
the O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HOMA-IS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
significantly O
improved O
and O
may O
therefore O
directly O
improve O
the O
impact O
on O
long O
term O
complications O
. O
['Physiological-Clinical']

Acute O
effects O
of O
decaffeinated O
coffee O
and O
the O
major O
coffee O
components O
chlorogenic O
acid O
and O
trigonelline O
on O
glucose B-outcome ['Physiological-Clinical']
tolerance O
. O
['Physiological-Clinical']

In O
group O
A O
( O
50 O
patients O
) O
, O
the O
surgical B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
, O
previous O
site O
of O
the O
stoma O
, O
was O
packed O
with O
ORC O
, O
whereas O
in O
group O
B O
( O
48 O
patients O
) O
gauze O
soaked O
in O
iodine O
was O
used O
. O
['Physiological-Clinical']

Dietary B-outcome ['Life-Impact']
protein I-outcome ['Life-Impact']
content I-outcome ['Life-Impact']
in O
the O
LP O
feed O
after O
weaning O
was O
below O
requirements O
; O
evidenced O
by O
lower O
nitrogen O
retention O
( O
p O
< O
0.001 O
) O
preventing O
LP O
mink O
from O
attaining O
their O
growth O
potential O
( O
p O
< O
0.02 O
) O
. O
['Life-Impact']

In O
contrast O
, O
aortic O
cross-clamping O
during O
isoflurane O
anesthesia O
was O
not O
associated O
with O
renal B-outcome ['Physiological-Clinical']
hemodynamic I-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
We O
selected O
341 O
incident O
gastric O
cancer O
cases O
( O
86 O
cardia O
, O
172 O
noncardia O
, O
and O
83 O
nonspecified O
) O
, O
accrued O
during O
22 O
years O
of O
follow-up O
, O
and O
341 O
individually O
matched O
controls O
. O
[]

Three O
aspects O
of O
students O
' O
knowledge O
were O
assessed O
before O
and O
after O
the O
lesson O
: O
( O
a O
) O
conceptual B-outcome ['Life-Impact']
understanding I-outcome ['Life-Impact']
of O
the O
equal O
sign O
, O
( O
b O
) O
equation B-outcome ['Life-Impact']
encoding I-outcome ['Life-Impact']
, O
and O
( O
c O
) O
problem B-outcome ['Life-Impact']
solving I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Treatment O
continued O
for O
52 O
weeks O
, O
or O
until O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
or O
intolerable B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

The O
individually O
adjusted O
dosage O
of O
rHuEPO O
and O
iron O
supplementation O
merits O
further O
investigation O
. O
[]

This O
group O
was O
randomly O
subdivided O
into O
3 O
groups O
: O
1 O
) O
Intradermal O
group O
( O
ID O
Group O
) O
, O
42 O
patients O
given O
an O
intradermal O
injections O
of O
OK-432 O
. O
[]

Measures O
included O
out-of-pocket B-outcome ['Resource-use']
pharmaceutical I-outcome ['Resource-use']
expenditures I-outcome ['Resource-use']
, O
excess B-outcome ['Life-Impact']
expenditures I-outcome ['Life-Impact']
on O
pads O
or O
tampons O
, O
the O
value O
of O
time B-outcome ['Life-Impact']
missed I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
paid I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
and O
home B-outcome ['Life-Impact']
management I-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
, O
and O
health B-outcome ['Life-Impact']
utility I-outcome ['Life-Impact']
. O
['Resource-use', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
possible O
interaction O
between O
arginine O
vasopressin O
( O
AVP O
) O
and O
atrial O
natriuretic O
factor O
( O
ANF O
) O
in O
the O
control O
of O
urinary O
sodium O
and O
water O
excretion O
was O
investigated O
in O
man O
. O
[]

This O
effect O
was O
also O
shown O
when O
analysis O
was O
restricted O
to O
the O
younger O
participants O
aged O
12 O
to O
15 O
who O
received O
the O
lower O
dose O
. O
[]

Internal B-outcome ['Physiological-Clinical']
consistency O
reliability O
of O
both O
5-items O
questionnaire O
and O
6-items O
clinical O
score O
were O
within O
the O
acceptable O
range O
( O
0.829 O
and O
0.708 O
respectively O
) O
. O
['Physiological-Clinical']

The O
24-gauge O
Gertie O
Marx O
needle O
resulted O
in O
more O
successful B-outcome ['Physiological-Clinical']
location O
of O
the O
['Physiological-Clinical']

Randomized O
clinical O
trial O
of O
behavioral O
intervention O
and O
nutrition O
education O
to O
improve O
caloric O
intake O
and O
weight O
in O
children O
with O
cystic O
fibrosis O
. O
[]

Animals O
were O
sacrificed O
and O
the O
L4-5 O
lumbar O
segment O
of O
the O
spinal O
cord O
was O
removed O
for O
determination O
of O
green O
fluorescent O
protein O
( O
GFP O
) O
expression O
. O
[]

Formoterol O
, O
salmeterol O
, O
or O
oxitropium O
bromide O
elicited O
a O
significant O
increase O
in O
forced O
expiratory B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
one I-outcome ['Physiological-Clinical']
second I-outcome ['Physiological-Clinical']
( O
FEV1 B-outcome ['Physiological-Clinical']
) O
compared O
with O
placebo O
( O
mean O
differences O
( O
L O
) O
= O
placebo O
0.05 O
; O
formoterol O
0.34 O
; O
salmeterol O
0.27 O
; O
oxitropium O
bromide O
0.23 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTRODUCTION O
Laser O
therapy O
is O
clinically O
effective O
in O
hair O
removal O
; O
however O
, O
despite O
the O
development O
of O
various O
strategies O
, O
laser O
procedures O
still O
present O
a O
risk O
of O
adverse O
effects O
due O
to O
the O
overheating O
of O
the O
skin O
. O
[]

The O
median O
length B-outcome ['Physiological-Clinical']
of O
follow-up O
was O
92 O
months O
. O
['Physiological-Clinical']

RESULTS O
The O
percentage O
of O
patients O
with O
endoscopically-verified B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
on O
lansoprazole O
than O
on O
ranitidine O
both O
after O
4 O
weeks O
( O
79 O
% O
vs. O
42 O
% O
) O
and O
8 O
weeks O
( O
91 O
% O
vs. O
66 O
% O
) O
, O
though O
smoking O
had O
a O
negative O
impact O
on O
oesophagitis O
healing O
with O
lansoprazole O
. O
['Physiological-Clinical']

Safety O
and O
immunogenicity B-outcome ['Physiological-Clinical']
of O
a O
cluster O
specific O
immunotherapy O
in O
children O
with O
bronchial O
asthma O
and O
mite O
allergy O
. O
['Physiological-Clinical']

When O
the O
children O
with O
complete O
resolution O
of O
their O
liver O
enlargement O
were O
considered O
separately O
, O
t O
( O
1/2hp O
) O
( O
P=0.0008 O
) O
but O
not O
AUC O
( O
hp O
) O
was O
found O
to O
be O
significantly O
lower O
, O
and O
AUC O
( O
hpFr196 O
) O
( O
P=0.01 O
) O
and O
CL B-outcome ['Physiological-Clinical']
( O
Bhl O
) O
( O
P=0.002 O
) O
were O
found O
to O
be O
significantly O
higher O
in O
the O
CQCP O
group O
than O
in O
the O
other O
groups O
. O
['Physiological-Clinical']

They O
were O
most O
often O
unspecific O
and O
mild O
to O
moderate O
in O
intensity O
. O
[]

Preventive O
programmes O
aimed O
at O
a O
change O
of O
sun O
related O
behaviours O
among O
Swedish O
adolescents O
have O
to O
be O
tailored O
to O
the O
climate O
and O
cultural O
conditions O
and O
must O
take O
into O
account O
that O
having O
a O
tan O
, O
and O
the O
warmth O
of O
the O
sun O
, O
are O
highly O
valued O
by O
most O
adolescents O
. O
[]

CONCLUSIONS O
For O
a O
longer O
follow-up O
period O
than O
in O
previous O
studies O
, O
this O
heart O
failure O
disease O
management O
program O
model O
of O
patients O
under O
the O
supervision O
of O
a O
cardiologist O
is O
associated O
with O
a O
reduction O
in O
unplanned O
hospitalization B-outcome ['Resource-use']
, O
a O
reduction O
of O
total O
['Resource-use']

Diabetic O
nephropathy O
patients O
were O
treated O
with O
either O
B6 O
( O
N.=12 O
) O
( O
250 O
mg/day O
) O
or O
B1+B6 O
( O
N.=15 O
) O
( O
250 O
mg/day O
, O
each O
) O
for O
five O
months O
. O
[]

Age O
, O
double O
blockade O
effects O
, O
the O
age-drug O
interactions O
were O
determined O
by O
analysis O
of O
variance O
for O
repeated O
measures O
. O
[]

Moxifloxacin O
was O
found O
to O
be O
safe O
and O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
. O
['Life-Impact']

INTRODUCTION O
The O
present O
study O
is O
aimed O
at O
investigating O
possible O
predictors O
of O
response O
to O
ziprasidone O
in O
a O
sample O
of O
patients O
with O
mixed O
depressive O
state O
. O
[]

Descriptive O
statistics O
, O
paired O
t-tests O
and O
general O
linear O
models O
adjusted O
for O
baseline O
dietary O
intake O
, O
age O
and O
gender O
were O
used O
to O
examine O
the O
effectiveness O
of O
different O
nutrition O
interventions O
. O
[]

OBJECTIVE O
To O
assess O
critically O
the O
short-term O
efficacy O
and O
safety O
of O
naltrexone O
in O
autistic O
children O
and O
its O
effects O
on O
discrimination O
learning O
in O
the O
laboratory O
. O
[]

Design O
of O
a O
cost-effectiveness O
study O
within O
a O
randomized O
trial O
: O
the O
LIPID O
Trial O
for O
Secondary O
Prevention O
of O
IHD O
. O
[]

Thereafter O
, O
a O
laryngeal O
mask O
airway O
was O
inserted O
and O
, O
with O
spontaneous O
ventilation O
, O
anesthesia O
was O
maintained O
by O
administering O
isoflurane O
( O
end-tidal O
0.7 O
% O
to O
1.2 O
% O
) O
and O
70 O
% O
nitrous O
oxide O
( O
N2O O
) O
in O
oxygen O
. O
[]

This O
study O
examined O
the O
effects O
of O
telephone O
call O
interventions O
by O
a O
collaborative O
team O
on O
patients O
' O
well-being O
. O
[]

A O
multifactorial O
strategy O
of O
pain O
management O
is O
associated O
with O
less O
pain O
in O
scheduled O
vaccination O
of O
children O
. O
[]

Significant O
differences O
in O
neointimal B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
were O
found O
between O
normally O
perfused O
stents O
and O
stents O
with O
artificially O
reduced O
flow O
: O
during O
the O
total O
observation O
period O
of O
6 O
months O
the O
neointimal B-outcome ['Physiological-Clinical']
height I-outcome ['Physiological-Clinical']
was O
up O
to O
200 O
% O
higher O
in O
flow-restricted O
stents O
, O
while O
the O
histological B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
neointima I-outcome ['Physiological-Clinical']
was O
the O
same O
as O
with O
normally O
perfused O
stents O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Altogether O
, O
35 O
consecutive O
patients O
were O
provided O
with O
41 O
turned O
single O
Br?nemark O
System O
implants O
( O
Nobel O
Biocare O
AB O
) O
in O
the O
partially O
edentulous O
upper O
jaw O
. O
[]

The O
proportion O
of O
recurrent B-outcome ['Physiological-Clinical']
tuberculosis I-outcome ['Physiological-Clinical']
cases I-outcome ['Physiological-Clinical']
caused O
by O
reinfection B-outcome ['Physiological-Clinical']
has O
varied O
widely O
in O
previous O
studies O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
Poisson O
regression O
using O
generalized O
estimating O
equations O
( O
GEEs O
) O
was O
used O
to O
estimate O
the O
difference O
in O
overlap O
between O
the O
two O
techniques O
. O
[]

Intervention O
infants O
received O
a O
parent-implemented O
EDI O
delivered O
with O
home O
visits O
by O
parent O
trainers O
every O
other O
week O
for O
3 O
years O
starting O
the O
first O
month O
after O
birth O
. O
[]

Metformin O
does O
not O
enhance O
ovulation O
induction O
in O
clomiphene O
resistant O
polycystic O
ovary O
syndrome O
in O
clinical O
practice O
. O
[]

III O
. O
[]

1.0 O
to O
2.0 O
mg/kg O
for O
induction O
of O
anesthesia O
. O
[]

Families O
in O
the O
target O
treatment O
group O
were O
given O
2 O
hours O
of O
therapy O
and O
coaching O
each O
week O
in O
an O
intervention O
emphasizing O
social-interaction O
and O
the O
parent-child O
relationship O
. O
[]

For O
proper O
positioning O
and O
cone O
cutting O
, O
logistic O
regressions O
using O
GEEs O
were O
used O
. O
[]

In O
all O
six O
cases O
in O
the O
nonstoma O
group O
, O
reoperations B-outcome ['Resource-use']
were O
necessary O
. O
['Resource-use']

Specimens O
were O
stressed O
until O
failure O
occurred O
, O
and O
failure O
modes O
were O
analyzed O
. O
[]

Best O
response O
rates O
during O
follow-up O
were O
identical O
( O
86 O
% O
) O
in O
both O
arms O
. O
[]

However O
, O
predictive O
models O
were O
of O
only O
moderate O
accuracy O
, O
especially O
for O
outcomes O
that O
included O
nonfatal B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

Aspirin O
treatment O
failed O
to O
suppress O
urinary O
levels O
of O
8-epi-PGF2 O
alpha O
despite O
a O
significant O
reduction O
in O
urinary B-outcome ['Physiological-Clinical']
11-dehydro-TxB2 I-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
and O
suppression O
of O
8-epi-PGF2 B-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
and O
TxB2 B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
total O
2-year O
rate O
of O
brain B-outcome ['Physiological-Clinical']
metastasis I-outcome ['Physiological-Clinical']
was O
67 O
% O
and O
40 O
% O
, O
respectively O
( O
relative O
risk O
= O
0.35 O
; O
P O
< O
10 O
( O
-13 O
) O
) O
. O
['Physiological-Clinical']

Examined O
the O
effects O
of O
antecedent O
exercise O
conditions O
on O
maladaptive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
stereotypic I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
6 O
adults O
with O
both O
autism O
and O
moderate O
to O
profound O
mental O
retardation O
. O
['Life-Impact']

Duration O
of O
effect O
was O
dose O
dependent O
. O
[]

However O
, O
the O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
of O
the O
PRE O
group O
were O
higher O
than O
the O
POST O
group O
's O
during O
each O
year O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
higher O
after O
the O
third O
and O
fourth O
years O
. O
['Mortality', 'Mortality']

However O
, O
these O
studies O
did O
not O
control O
for O
nonspecific O
effects O
of O
EEG-biofeedback O
and O
did O
not O
distinguish O
between O
participants O
who O
succeeded O
in O
influencing O
their O
own O
EEG O
activity O
and O
participants O
who O
did O
not O
. O
[]

Subjects O
were O
randomly O
assigned O
to O
two O
groups O
of O
five O
each O
. O
[]

No O
localised B-outcome ['Adverse-effects']
or I-outcome ['Adverse-effects']
systemic I-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
in O
either O
trial O
. O
['Adverse-effects']

CONCLUSIONS O
The O
findings O
imply O
that O
the O
previous O
associations O
of O
lavender O
aroma O
with O
assisted O
relaxation O
may O
have O
been O
influenced O
by O
expectancy O
biases O
, O
and O
that O
the O
relevant O
expectancies O
are O
easily O
manipulable O
. O
[]

Actions O
of O
platelet O
activating O
factor O
( O
PAF O
) O
homologues O
and O
their O
combinations O
on O
neutrophil O
chemokinesis O
and O
cutaneous O
inflammatory O
responses O
in O
man O
. O
[]

Improved O
adherence B-outcome ['Life-Impact']
with O
once-daily O
versus O
twice-daily O
dosing O
of O
mometasone O
furoate O
administered O
via O
a O
dry O
powder O
inhaler O
: O
a O
randomized O
open-label O
study O
. O
['Life-Impact']

In O
aspirin-treated O
platelets O
, O
the O
aggregation O
capacity B-outcome ['Life-Impact']
induced O
by O
adenosine O
diphosphate O
was O
inhibited O
before O
the O
operation O
( O
p O
< O
0.05 O
) O
and O
showed O
substantial O
recovery O
during O
the O
operation O
( O
p O
< O
0.05 O
) O
. O
['Life-Impact']

METHODS O
AND O
RESULTS O
This O
follow-up O
study O
to O
5 O
years O
of O
a O
randomized O
, O
double-blinded O
trial O
was O
conducted O
among O
368 O
patients O
with O
first O
ST-segment-elevation O
myocardial O
infarction O
undergoing O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
[]

STUDY O
OBJECTIVE O
To O
evaluate O
the O
cardiovascular O
changes O
following O
induction O
of O
anesthesia O
, O
laryngoscopy O
, O
and O
intubation O
in O
patients O
receiving O
a O
bolus O
dose O
of O
either O
eltanolone O
or O
propofol O
. O
[]

We O
conducted O
a O
randomized O
controlled O
trial O
among O
African-American O
patients O
attending O
a O
primary-care O
provider O
visit O
to O
compare O
efficacy O
of O
a O
computer-delivered O
tailored O
intervention O
to O
increase O
colorectal B-outcome ['Resource-use']
cancer I-outcome ['Resource-use']
( I-outcome ['Resource-use']
CRC I-outcome ['Resource-use']
) I-outcome ['Resource-use']
screening I-outcome ['Resource-use']
( O
n O
= O
273 O
) O
with O
non-tailored O
print O
material-an O
American O
Cancer O
Society O
brochure O
on O
CRC O
screening O
( O
n O
= O
283 O
) O
. O
['Resource-use']

In O
the O
fennel O
group O
, O
80 O
% O
of O
girls O
and O
in O
the O
mefenamic O
acid O
group O
, O
73 O
% O
of O
girls O
showed O
complete O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
or O
pain B-outcome ['Physiological-Clinical']
decrease O
, O
while O
80 O
% O
in O
the O
fennel O
group O
and O
62 O
% O
in O
the O
mefenamic O
acid O
group O
no O
longer O
needed O
to O
rest O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Postoperative B-outcome ['Physiological-Clinical']
hemodynamics I-outcome ['Physiological-Clinical']
, O
rejection B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

After O
a O
5-day O
placebo O
lead-in O
, O
610 O
patients O
with O
moderate-to-severe O
nasal O
symptoms O
were O
randomized O
to O
treatment O
with O
( O
1 O
) O
azelastine O
nasal O
spray O
, O
( O
2 O
) O
fluticasone O
nasal O
spray O
, O
( O
3 O
) O
combination O
azelastine O
and O
fluticasone O
nasal O
spray O
, O
or O
( O
4 O
) O
placebo O
nasal O
spray O
. O
[]

Patient-controlled O
epidural O
analgesia O
settings O
and O
adjustments O
for O
the O
three O
solutions O
were O
standardized O
to O
deliver O
equivalent O
drug O
doses O
. O
[]

Studies O
have O
previously O
demonstrated O
that O
brief O
( O
4 O
weeks O
) O
passive O
range-of-motion O
exercise O
is O
beneficial O
for O
bone O
development O
in O
very O
low O
birth O
weight O
( O
VLBW O
) O
preterm O
infants O
. O
[]

DISCUSSION O
The O
finding O
of O
high B-outcome ['Physiological-Clinical']
vitamin I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
6 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
is O
consistent O
with O
recent O
reports O
of O
low O
levels O
of O
pyridoxal-5-phosphate B-outcome ['Physiological-Clinical']
and O
low O
activity O
of O
pyridoxal B-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
( O
i.e. O
, O
pyridoxal O
is O
only O
poorly O
converted O
to O
pyridoxal-5-phosphate O
, O
the O
enzymatically O
active O
form O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
received O
TMZ O
200 O
mg/m O
( O
2 O
) O
/day O
orally O
for O
five O
consecutive O
days O
every O
4 O
weeks O
or O
TMZ O
+ O
CDDP O
200 O
mg/m O
( O
2 O
) O
daily O
on O
days O
1-5 O
and O
75 O
mg/m O
( O
2 O
) O
of O
CDDP O
on O
day O
1 O
. O
[]

No O
significant O
changes O
in O
plasma B-outcome ['Physiological-Clinical']
electrolyte I-outcome ['Physiological-Clinical']
levels O
occurred O
. O
['Physiological-Clinical']

In O
doing O
this O
, O
one-third O
of O
the O
total O
length O
of O
the O
bone O
was O
removed O
in O
each O
of O
the O
following O
specimens O
to O
include O
( O
1a O
) O
30 O
percent O
of O
the O
cross-sectional O
area O
of O
the O
total O
bone O
, O
( O
1b O
) O
37 O
percent O
of O
the O
cross-sectional O
area O
of O
the O
total O
bone O
, O
and O
( O
1c O
) O
50 O
percent O
of O
the O
cross-sectional O
area O
of O
the O
total O
bone O
. O
[]

Half O
of O
the O
group O
was O
randomized O
to O
receive O
an O
additional O
program O
in O
their O
homes O
. O
[]

CONCLUSIONS O
The O
sample O
of O
children O
with O
AS O
in O
this O
study O
presented O
with O
a O
profile O
of O
anxiety O
similar O
to O
a O
sample O
of O
clinically O
diagnosed O
anxious O
children O
. O
[]

Before O
the O
target O
appeared O
, O
the O
participant O
's O
attention O
was O
cued O
to O
the O
left O
or O
right O
by O
either O
an O
arrow O
or O
the O
direction O
of O
eye O
gaze O
on O
a O
computerized O
face O
. O
[]

At O
2 O
years O
, O
estimates O
for O
survival B-outcome ['Mortality']
free O
from O
VT B-outcome ['Physiological-Clinical']
or O
VF B-outcome ['Physiological-Clinical']
were O
47 O
% O
in O
the O
ablation O
group O
and O
29 O
% O
in O
the O
control O
group O
( O
hazard O
ratio O
0.61 O
; O
95 O
% O
CI O
0.37-0.99 O
; O
p=0.045 O
) O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Treatment O
by O
continuous O
passive O
movement O
at O
home O
is O
an O
alternative O
to O
immobilisation O
in O
a O
cast O
after O
surgery O
for O
club O
foot O
. O
[]

A O
third O
secondary O
data O
analysis O
from O
that O
study O
suggested O
that O
cocaine B-outcome ['Life-Impact']
abuse I-outcome ['Life-Impact']
acts O
as O
a O
predictor O
of O
poor O
outcome O
for O
both O
depressive O
symptoms O
( O
including O
suicidality O
) O
and O
level O
of O
alcohol O
use O
in O
this O
population O
. O
['Life-Impact']

Samples O
were O
tested O
under O
code O
by O
polymerase O
chain O
reaction O
( O
PCR O
) O
in O
one O
laboratory O
. O
[]

The O
seven O
drugs O
were O
then O
tested O
for O
efficacy O
in O
random O
order O
in O
patients O
who O
were O
eligible O
to O
receive O
them O
. O
[]

We O
report O
a O
randomized O
trial O
of O
a O
revised O
Behavioral O
Family O
Systems O
Therapy O
for O
Diabetes O
( O
BFST-D O
) O
intervention O
. O
[]

Analyzing O
the O
clinically O
significant O
heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
( O
Brooker O
Score O
III O
and O
IV O
) O
there O
was O
no O
significant O
difference O
between O
the O
two O
treatment O
arms O
( O
p O
> O
0.05 O
) O
. O
['Physiological-Clinical']

The O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
PIPN I-outcome ['Physiological-Clinical']
was O
summarized O
by O
means O
of O
a O
modified O
Peripheral B-outcome ['Physiological-Clinical']
Neuropathy I-outcome ['Physiological-Clinical']
( O
PNP O
) O
score O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Critical O
to O
the O
accuracy O
of O
Mohs O
surgery O
is O
the O
ability O
to O
maintain O
proper O
orientation O
of O
excised O
tissue O
with O
respect O
to O
the O
surrounding O
skin O
. O
[]

Effects O
on O
inflammation B-outcome ['Physiological-Clinical']
were O
measured O
in O
induced B-outcome ['Physiological-Clinical']
sputum I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

One O
hundred O
and O
fifty-three O
patients O
( O
all O
of O
whom O
had O
stage O
III O
or O
IV O
unresectable O
disease O
with O
no O
distant O
metastases O
and O
who O
had O
received O
two O
cycles O
of O
taxol O
and O
cisplatin O
chemotherapy O
) O
were O
randomly O
assigned O
to O
receive O
either O
concurrent O
cisplatin O
( O
75 O
mg/m O
( O
2 O
) O
in O
day O
1 O
and O
2 O
) O
and O
5-FU O
( O
750 O
mg/m O
( O
2 O
) O
in O
day O
1 O
, O
2 O
, O
and O
3 O
) O
from O
the O
first O
day O
of O
radiotherapy O
at O
an O
interval O
of O
3 O
weeks O
( O
Arm O
I O
) O
or O
cisplatin O
( O
75 O
mg/m O
( O
2 O
) O
in O
day O
1 O
and O
2 O
) O
and O
capecitabine O
( O
750 O
mg/m O
( O
2 O
) O
in O
two O
divided O
doses O
from O
day O
1-14 O
) O
from O
the O
first O
day O
of O
radiotherapy O
at O
a O
3-week O
interval O
( O
Arm O
II O
) O
. O
[]

RESULTS O
Twelve O
women O
completed O
the O
metformin O
arm O
and O
14 O
the O
placebo O
arm O
. O
[]

1 O
. O
[]

Regimen O
A O
( O
intermittent O
regimen O
) O
consisted O
of O
PRD O
( O
120 O
mg/m2/day O
by O
mouth O
for O
5 O
days O
) O
plus O
6-mercaptopurine O
( O
6MP O
) O
( O
175 O
mg/m2/day O
by O
mouth O
for O
5 O
days O
) O
plus O
VCR O
( O
2.0 O
mg/m2 O
intravenously O
) O
alternating O
biweekly O
with O
MTX O
( O
225 O
mg/m2 O
intravenously O
) O
. O
[]

Analysis O
by O
intention O
to O
treat O
gave O
similar O
results O
( O
17/33 O
v O
9/33 O
patients O
better O
) O
. O
[]

A O
drug O
was O
classified O
as O
being O
effective O
when O
over O
70 O
% O
of O
the O
patients O
taking O
the O
drug O
were O
judged O
as O
success O
in O
all O
3 O
behavioral O
criteria O
: O
( O
1 O
) O
sleeping O
; O
( O
2 O
) O
body O
movement O
; O
and O
( O
3 O
) O
crying O
behaviors O
. O
[]

In O
conclusion O
, O
intra-arterial O
and O
intravenous O
heparin O
administration O
provide O
comparable O
efficacy O
in O
preventing O
RAO O
, O
favoring O
a O
probable O
systemically O
mediated O
mechanism O
of O
action O
, O
rather O
than O
a O
local O
effect O
. O
[]

Mean O
% O
time O
pH O
> O
3 O
and O
> O
4 O
was O
greater O
after O
esomeprazole O
than O
rabeprazole O
during O
0-14 O
h O
( O
P=0.041 O
and O
0.044 O
) O
, O
but O
the O
reverse O
was O
true O
during O
14-24 O
h O
( O
P=0.0005 O
and O
0.001 O
) O
. O
[]

Before O
, O
during O
, O
and O
after O
the O
procedure O
, O
infant O
stress O
was O
evaluated O
by O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
respiration B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
transcutaneous B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Both O
groups O
showed O
significant O
improvements O
in O
mean O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
] O
scores O
for O
pain B-outcome ['Physiological-Clinical']
: O
11 O
( O
7 O
, O
16 O
) O
( O
P O
< O
0.001 O
) O
; O
physical B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
: O
4 O
( O
2 O
, O
5 O
) O
( O
P O
< O
0.001 O
) O
; O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
: O
2 O
( O
0.1 O
, O
4 O
) O
( O
P O
< O
0.02 O
) O
; O
and O
health B-outcome ['Physiological-Clinical']
utility I-outcome ['Physiological-Clinical']
: O
0.11 O
( O
0.07 O
, O
0.16 O
) O
( O
P O
< O
0.001 O
) O
by O
the O
end O
of O
the O
15-month O
period O
of O
the O
study O
, O
but O
there O
was O
no O
significant O
difference O
between O
either O
arm O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

We O
were O
not O
able O
to O
show O
any O
significant O
statistical O
differences O
between O
the O
Spironolactone O
group O
and O
the O
placebo O
group O
. O
[]

Comparison O
of O
tropisetron O
and O
granisetron O
in O
the O
control O
of O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
in O
children O
receiving O
combined O
cancer O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
results O
revealed O
that O
the O
RPMT O
facilitated O
the O
frequency O
of O
generalized B-outcome ['Life-Impact']
turn I-outcome ['Life-Impact']
taking I-outcome ['Life-Impact']
and O
generalized O
initiating O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
more O
than O
did O
the O
PECS O
. O
['Life-Impact', 'Life-Impact']

There O
was O
no O
difference O
in O
the O
probability O
of O
day O
114 O
grades O
2-4 O
acute O
GVHD-free O
survival O
( O
67 O
% O
vs O
62 O
% O
, O
P O
= O
.38 O
) O
. O
[]

Intensive O
induction O
chemotherapy O
for O
small O
cell O
anaplastic O
carcinoma O
of O
the O
lung O
. O
[]

BACKGROUND O
Sitaxsentan O
is O
a O
highly O
selective O
endothelin-A O
receptor O
antagonist O
that O
was O
recently O
withdrawn O
by O
the O
manufacturer O
because O
of O
a O
pattern O
of O
idiosyncratic O
liver O
injury O
. O
[]

Provision O
of O
educational O
information O
did O
not O
affect O
level O
of O
interest B-outcome ['Life-Impact']
. O
['Life-Impact']

1 O
. O
[]

A O
randomized O
double O
blind O
study O
was O
undertaken O
to O
compare O
the O
diagnostic B-outcome ['Life-Impact']
efficacy O
and O
side O
effects O
of O
a O
new O
non-ionic O
contrast O
medium O
Iomeprol O
with O
a O
commonly O
used O
one O
-- O
Iopamidol O
. O
['Life-Impact']

Although O
results O
through O
the O
entire O
blinded O
period O
continued O
to O
show O
that O
selenium O
supplementation O
was O
not O
statistically O
significantly O
associated O
with O
the O
risk O
of O
basal B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
( O
hazard O
ratio O
[ O
HR O
] O
= O
1.09 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.94 O
to O
1.26 O
) O
, O
selenium O
supplementation O
was O
associated O
with O
statistically O
significantly O
elevated O
risk O
of O
squamous B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
carcinoma B-outcome ['Physiological-Clinical']
( O
HR O
= O
1.25 O
, O
95 O
% O
CI O
= O
1.03 O
to O
1.51 O
) O
and O
of O
total O
nonmelanoma B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
( O
HR O
= O
1.17 O
, O
95 O
% O
CI O
= O
1.02 O
to O
1.34 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

INTERVENTION O
CGs O
were O
assigned O
to O
the O
REACH O
intervention O
or O
a O
no-treatment O
control O
group O
. O
[]

A O
clinical O
comparison O
of O
an O
emulsion O
containing O
a O
new O
pilocarpine O
polymer O
( O
Polym O
) O
compound O
to O
that O
of O
a O
traditional O
pilocarpine O
salt O
solution O
( O
Plc O
) O
on O
the O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IOP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
has O
been O
performed O
in O
40 O
open-angle O
patients O
treated O
with O
the O
long O
acting O
pilocarpine-complex O
for O
120 O
days O
. O
['Physiological-Clinical']

She O
reviewed O
the O
subject O
's O
answers O
to O
the O
questionnaire O
items O
correcting O
and/or O
clarifying O
them O
. O
[]

Successful O
production B-outcome ['Physiological-Clinical']
of O
piglets O
derived O
from O
expanded O
blastocysts O
vitrified O
using O
a O
micro O
volume O
air O
cooling O
method O
without O
direct O
exposure O
to O
liquid O
nitrogen O
. O
['Physiological-Clinical']

When O
a O
septic B-outcome ['Physiological-Clinical']
complication I-outcome ['Physiological-Clinical']
of O
pancreatic O
necrosis O
was O
suspected O
, O
fine O
needle O
aspiration O
with O
cultures O
of O
the O
sample O
was O
performed O
. O
['Physiological-Clinical']

Three O
groups O
of O
six O
women O
were O
admitted O
and O
randomly O
assigned O
to O
use O
Acidform O
with O
0 O
% O
, O
2.5 O
% O
, O
and O
5 O
% O
N-9 O
. O
[]

Deficits O
in O
the O
ability O
to O
recognize O
the O
emotions O
of O
others O
are O
believed O
to O
contribute O
to O
this O
. O
[]

In O
each O
subject O
standardized O
finger O
heating O
( O
45 O
degrees O
C O
water O
bath O
, O
10 O
min O
) O
and O
cooling O
tests O
( O
15 O
degrees O
C O
water O
bath O
, O
5 O
min O
and O
20 O
min O
recovery O
) O
were O
performed O
twice O
on O
the O
second O
( O
or O
third O
) O
day O
of O
two O
consecutive O
menstrual O
cycles O
. O
[]

FINDINGS O
A O
total O
of O
232 O
foot O
and O
hand O
warts O
in O
45 O
patients O
were O
entered O
into O
the O
trial O
: O
117 O
warts O
were O
allocated O
to O
ALA-PDT O
and O
115 O
warts O
to O
placebo-PDT O
. O
[]

In O
both O
groups O
, O
minute O
ventilation B-outcome ['Physiological-Clinical']
( O
VE B-outcome ['Physiological-Clinical']
) O
and O
f O
progressively O
decreased O
as O
resistance O
was O
increased O
by O
decreasing O
the O
aperture O
size O
from O
15 O
to O
16 O
mm O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
measured O
the O
accuracy O
and O
precision O
of O
the O
observers O
' O
absolute- O
and O
relative-direction O
judgments O
. O
[]

We O
investigated O
the O
analgesic O
effect O
of O
systemic O
lidocaine O
on O
the O
heat/capsaicin O
sensitization O
model O
of O
experimental O
pain O
in O
24 O
volunteers O
. O
[]

Adults O
with O
ASD O
did O
not O
show O
significantly O
atypical O
processing O
of O
facial B-outcome ['Life-Impact']
familiarity B-outcome ['Life-Impact']
and O
['Life-Impact', 'Life-Impact']

Effects O
of O
cognitive-behavioral O
therapy O
on O
anxiety O
in O
children O
with O
autism O
spectrum O
disorders O
: O
a O
randomized O
controlled O
trial O
. O
[]

The O
MOONLIGHT O
( O
Multicenter O
Objective O
ObservatioNal O
Lunar O
Iridiumoxide O
intimal O
GrowtH O
Trial O
) O
study O
was O
carried O
out O
to O
evaluate O
the O
immediate O
outcome O
and O
long-term O
angiographic O
success O
after O
implantation O
of O
Lunar O
stents O
. O
[]

Eye O
movement O
performance O
during O
the O
tasks O
was O
captured O
using O
an O
infrared O
eye O
tracker O
. O
[]

MAIN O
OUTCOME O
MEASURE O
( O
S O
) O
Utero-ovarian B-outcome ['Physiological-Clinical']
ultrasound I-outcome ['Physiological-Clinical']
analysis I-outcome ['Physiological-Clinical']
and O
color O
Doppler O
evaluation O
of O
uterine B-outcome ['Physiological-Clinical']
and O
stromal B-outcome ['Physiological-Clinical']
ovarian I-outcome ['Physiological-Clinical']
arteries I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Opioid O
doses O
commonly O
prescribed O
in O
IV O
opioid O
treatment O
induce O
marked O
respiratory B-outcome ['Physiological-Clinical']
and O
circulatory B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
, O
as O
well O
as O
occasionally O
irregular B-outcome ['Physiological-Clinical']
paroxysmal I-outcome ['Physiological-Clinical']
EEG I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

pre-treatment O
. O
[]

In O
an O
ethologically O
analyzed O
playroom O
session O
, O
ORG O
2766 O
treatment O
was O
associated O
with O
an O
improvement O
in O
the O
children B-outcome ['Physiological-Clinical']
's O
play B-outcome ['Life-Impact']
behavior B-outcome ['Life-Impact']
and O
a O
significant O
increase O
in O
the O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

We O
examined O
how O
plasma O
Lp O
[ O
a O
] O
in O
healthy O
young O
men O
was O
affected O
by O
fats O
high O
in O
stearic O
( O
C18 O
) O
, O
palmitic O
( O
C16 O
) O
, O
and O
lauric+myristic O
( O
C12+ O
C14 O
) O
acid O
( O
experiment O
I O
, O
15 O
subjects O
) O
, O
and O
by O
fats O
high O
in O
myristic O
( O
C14 O
) O
and O
palmitic O
( O
C16 O
) O
acid O
( O
experiment O
II O
, O
12 O
subjects O
) O
. O
[]

Thirty O
elderly O
, O
mildly O
hypertensive O
patients O
were O
enrolled O
for O
a O
single-blind O
, O
randomised O
cross-over O
placebo O
controlled O
trial O
in O
which O
placebo O
and O
lisinopril O
( O
20 O
mg/day O
before O
breakfast O
) O
were O
given O
for O
4 O
and O
8 O
weeks O
, O
respectively O
. O
[]

Also O
during O
last O
administration O
, O
PMN O
count O
in O
filtered O
blood O
cardioplegic O
solution O
was O
decreased O
compared O
to O
samples O
collected O
before O
filter O
passage O
( O
0.66 O
? O
[]

Mean O
SBP B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
intervention O
group O
at O
the O
second O
( O
137.8 O
+/- O
15.0 O
vs O
168.9 O
+/- O
15.3 O
) O
, O
third O
( O
135.9 O
+/- O
11.7 O
vs O
164.6 O
+/- O
20.1 O
) O
, O
and O
fourth O
( O
145.3 O
+/- O
16.8 O
vs O
175.8 O
+/- O
33.9 O
) O
quarters O
of O
the O
study O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

No O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
reported O
. O
['Adverse-effects']

subunit O
( O
CD25 O
) O
of O
the O
interleukin-2 O
receptor O
. O
[]

Knowledge O
about O
breast B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
susceptibility I-outcome ['Physiological-Clinical']
genes I-outcome ['Physiological-Clinical']
was O
poor O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
objective O
of O
this O
study O
was O
to O
assess O
the O
performance O
of O
three O
staging O
systems O
[ O
Okuda O
, O
Cancer O
of O
the O
Liver O
Italian O
Program O
( O
CLIP O
) O
and O
Barcelona O
Clinic O
Liver O
Cancer O
group O
( O
BCLC O
) O
] O
, O
for O
predicting O
survival B-outcome ['Mortality']
in O
patients O
with O
hepatocellular O
carcinoma O
( O
HCC O
) O
and O
to O
explore O
how O
to O
improve O
prognostic O
classification O
among O
French O
patients O
with O
HCC O
whose O
main O
etiology O
is O
alcoholic O
cirrhosis O
. O
['Mortality']

Baseline O
measurements O
were O
reevaluated O
at O
24 O
, O
48 O
, O
72 O
and O
96 O
h O
after O
the O
induction O
of O
DOMS B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

SBP B-outcome ['Physiological-Clinical']
( O
175 O
+/- O
3.3 O
vs. O
160 O
+/- O
3.0 O
mm O
Hg O
; O
P O
< O
0.001 O
) O
and O
DBP B-outcome ['Physiological-Clinical']
( O
106 O
+/- O
2.3 O
vs. O
95 O
+/- O
2.0 O
mm O
Hg O
; O
P O
< O
0.001 O
) O
were O
significantly O
reduced O
by O
lisinopril O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

On O
the O
whole O
, O
ofloxacin O
was O
well O
tolerated B-outcome ['Life-Impact']
by O
our O
patients O
. O
['Life-Impact']

Results O
were O
also O
pooled O
with O
the O
similarly O
designed O
VACT1 O
trial O
. O
[]

group O
compared O
with O
placebo O
group O
. O
[]

RESULTS O
After O
treatment O
, O
the O
behavioral O
plus O
nutrition O
education O
intervention O
as O
compared O
with O
the O
nutrition O
education O
intervention O
alone O
had O
a O
statistically O
greater O
average O
increase O
on O
the O
primary O
and O
secondary O
outcomes O
of O
caloric B-outcome ['Physiological-Clinical']
intake O
( O
mean O
, O
872 O
vs O
489 O
cal/d O
, O
respectively O
) O
, O
percentage O
of O
the O
estimated O
energy O
requirement O
( O
mean O
, O
148 O
% O
vs O
127 O
% O
, O
respectively O
) O
, O
weight O
gain O
( O
mean O
, O
1.47 O
vs O
0.92 O
kg O
, O
respectively O
) O
, O
and O
body O
mass O
index O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Five O
hundred O
sixty O
patients O
, O
fully O
dentate O
or O
with O
1 O
or O
2 O
teeth O
missing O
and O
older O
than O
25 O
years O
who O
had O
no O
gross O
pathology O
associated O
with O
their O
impacted O
lower O
M3s O
, O
were O
recruited O
in O
this O
study O
. O
[]

The O
results O
show O
that O
, O
in O
both O
groups O
of O
children O
, O
there O
were O
significant O
reductions O
in O
splenomegaly B-outcome ['Physiological-Clinical']
, O
hepatomegaly B-outcome ['Physiological-Clinical']
, O
and O
subjective O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
six O
and O
12 O
months O
after O
initial O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
Expt O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
not O
significantly O
changed O
in O
the O
sitting O
position O
during O
the O
treatment O
period O
, O
and O
the O
majority O
of O
patients O
( O
75 O
percent O
) O
showed O
a O
response O
to O
nifedipine O
doses O
of O
10 O
or O
20 O
mg O
orally O
three O
times O
daily O
in O
the O
capsule O
form O
. O
['Physiological-Clinical']

The O
median O
survival B-outcome ['Mortality']
times O
for O
arms O
A O
, O
B O
, O
and O
C O
were O
similar O
( O
17.9 O
, O
18.9 O
, O
and O
16 O
. O
['Mortality']

Heparin O
in O
Acute O
Embolic O
Stroke O
Trial O
. O
[]

Informed O
consent O
were O
given O
by O
all O
patients O
. O
[]

INTRODUCTION O
A O
significant O
number O
of O
postmenopausal O
women O
suffer O
from O
distressing O
problems O
because O
of O
urogenital O
atrophy O
secondary O
to O
the O
decline O
in O
circulating O
estrogen O
levels O
. O
[]

Long-term O
Intervention O
with O
Pravastatin O
in O
Ischemic O
Heart O
disease O
. O
[]

RESULTS O
Three-hundred O
and O
sixteen O
patients O
were O
included O
in O
the O
study O
. O
[]

Follow-up O
duration O
was O
257?154days O
for O
the O
stroke O
analysis O
and O
222?146days O
for O
the O
bleeding O
analysis O
. O
[]

METHODS O
Changes O
from O
baseline O
to O
week O
54 O
in O
clinical B-outcome ['Physiological-Clinical']
variables O
and O
measures O
of O
radiographic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
were O
compared O
between O
patients O
who O
received O
infliximab O
( O
3 O
mg/kg O
or O
10 O
mg/kg O
every O
4 O
or O
8 O
weeks O
) O
plus O
methotrexate O
( O
MTX O
) O
and O
those O
who O
received O
MTX O
plus O
placebo O
in O
the O
Anti-Tumor O
Necrosis O
Factor O
Trial O
in O
RA O
with O
Concomitant O
Therapy O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Forty-five O
subjects O
diagnosed O
with O
autism O
were O
randomly O
assigned O
to O
receive O
boiled O
CM O
for O
group O
I O
( O
n O
= O
15 O
) O
, O
raw O
CM O
for O
group O
II O
( O
n O
= O
15 O
) O
, O
and O
placebo O
for O
group O
III O
( O
n O
= O
15 O
) O
for O
2 O
wk O
. O
[]

OBJECTIVE O
To O
evaluate O
postoperative O
pain O
relief O
of O
intramuscular O
ketorolac O
, O
topical O
bupivacaine O
, O
and O
placebo O
in O
patients O
undergoing O
laparoscopic O
tubal O
sterilization O
with O
silastic O
bands O
. O
[]

MEASUREMENTS O
Follow-up O
assessments O
were O
made O
at O
6 O
months O
by O
telephone O
interview O
. O
[]

[ O
Therapeutic O
efficacy O
of O
youdujing O
preparation O
in O
treating O
cervical O
high-risk O
human O
papilloma O
virus O
infection O
patients O
] O
. O
['Physiological-Clinical']

Results O
of O
48-hour O
phasing O
at O
the O
end O
of O
one O
month O
's O
treatment O
demonstrated O
a O
significantly O
greater O
fall O
in O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
with O
Ganda O
3.0/0.5 O
( O
9.8 O
mm O
Hg O
) O
than O
with O
Timolol O
0.25 O
per O
cent O
( O
7.67 O
mm O
Hg O
) O
P O
less O
than O
0.001 O
. O
['Physiological-Clinical']

Transient O
or O
final O
side O
branch O
occlusion O
occurred O
less O
frequently O
in O
patients O
receiving O
EES O
compared O
to O
PES O
( O
2.8 O
% O
vs. O
5.2 O
% O
, O
p=0.009 O
) O
, O
contributing O
to O
the O
numerically O
lower O
rates O
of O
in-hospital B-outcome ['Physiological-Clinical']
NQMI I-outcome ['Physiological-Clinical']
with O
EES O
arm O
compared O
to O
PES O
( O
0.7 O
% O
vs. O
2.3 O
% O
, O
p=0.05 O
) O
. O
['Physiological-Clinical']

Some O
evidence O
suggests O
that O
treatment O
with O
ARBs O
could O
increase O
fibrinolysis O
, O
however O
, O
data O
is O
conflicting O
. O
[]

PD O
was O
more O
often O
the O
reason O
for O
not O
completing O
the O
planned O
four O
courses O
than O
toxicity O
. O
[]

After O
eradication O
, O
esophageal B-outcome ['Physiological-Clinical']
variceal I-outcome ['Physiological-Clinical']
recurrence B-outcome ['Physiological-Clinical']
was O
not O
significantly O
different O
in O
patients O
treated O
by O
ligation O
than O
by O
sclerotherapy O
( O
17.4 O
% O
vs. O
10 O
% O
, O
P O
=.67 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Single O
doses O
of O
norfloxacin O
and O
trimethoprim/sulfamethoxazole O
were O
administered O
to O
13 O
and O
5 O
patients O
, O
respectively O
, O
( O
temporal O
profile O
group O
) O
and O
samples O
were O
collected O
at O
0 O
, O
0.5 O
, O
1 O
, O
1.5 O
, O
2 O
, O
4 O
, O
and O
24 O
hours O
. O
[]

Self-reported O
smoking B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
drinking I-outcome ['Life-Impact']
and O
the O
number O
of O
substance O
using O
friends O
were O
assessed O
5 O
times O
over O
3 O
years O
. O
['Life-Impact']

Fentanyl O
was O
used O
as O
an O
adjunct O
to O
isoflurane O
in O
all O
patients O
, O
0.05 O
mg O
every O
45 O
min O
. O
[]

RESULTS O
Significant O
time O
? O
[]

Plasma B-outcome ['Physiological-Clinical']
C-peptide I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
counter-regulatory B-outcome ['Physiological-Clinical']
hormones I-outcome ['Physiological-Clinical']
were O
also O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
trial O
, O
amended O
from O
a O
larger O
factorial O
design O
, O
was O
terminated O
early O
due O
to O
slow O
recruitment O
. O
[]

OBJECTIVE O
To O
examine O
the O
effect O
of O
a O
solution O
of O
nicotine O
on O
sustained B-outcome ['Physiological-Clinical']
resting I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
tone B-outcome ['Physiological-Clinical']
) O
and O
contractile O
activity B-outcome ['Life-Impact']
in O
the O
human O
colon O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Based O
on O
the O
answers O
given O
in O
a O
prior O
assessment O
, O
participants O
received O
tailored O
advice O
on O
3 O
occasions O
: O
( O
1 O
) O
within O
2 O
weeks O
after O
the O
baseline O
, O
( O
2 O
) O
2 O
months O
after O
the O
baseline O
, O
and O
( O
3 O
) O
within O
4 O
months O
after O
the O
baseline O
( O
based O
on O
a O
second O
assessment O
at O
3 O
months O
) O
. O
[]

Airway B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
and O
inflammation B-outcome ['Physiological-Clinical']
in O
subjects O
with O
asthma O
after O
four O
days O
of O
repeated O
high-single-dose O
allergen O
challenge O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Nineteen O
children O
( O
8 O
male O
, O
11 O
female O
) O
with O
a O
median O
age O
5.9 O
years O
( O
range O
2.6-13 O
years O
) O
were O
recruited O
into O
the O
study O
. O
[]

morphine B-outcome ['Resource-use']
used O
in O
the O
first O
24 O
hours B-outcome ['Life-Impact']
as O
well O
as O
the O
amount O
of O
the O
drug B-outcome ['Resource-use']
used I-outcome ['Resource-use']
during O
each O
2-h O
period O
were O
noted O
. O
['Resource-use', 'Life-Impact', 'Resource-use']

Exclusion O
criteria O
included O
comorbid O
history O
of O
epilepsy O
, O
< O
2 O
PNES/month O
, O
and O
IQ O
< O
70 O
. O
[]

The O
first O
group O
( O
n=1,200 O
) O
was O
used O
to O
develop O
the O
formulas O
( O
i.e. O
, O
Development O
group O
) O
and O
the O
second O
( O
n=1,201 O
) O
group O
was O
used O
to O
validate O
the O
prediction O
algorithms O
( O
i.e. O
, O
Validation O
group O
) O
. O
[]

Local B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
, O
consisting O
mostly O
of O
mild O
or O
moderate O
pain B-outcome ['Physiological-Clinical']
, O
were O
least O
frequent O
with O
monovalent O
HA O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
also O
a O
definite O
improvement O
of O
ischemia-caused B-outcome ['Physiological-Clinical']
mitral I-outcome ['Physiological-Clinical']
regurgitation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
a O
randomized O
study O
of O
patients O
undergoing O
Caesarean O
section O
, O
either O
enflurane O
( O
mean O
0.24 O
MAC-h O
) O
or O
halothane O
( O
mean O
0.23 O
MAC-h O
) O
and O
50 O
% O
nitrous O
oxide O
in O
oxygen O
were O
administered O
to O
women O
( O
n O
= O
12 O
) O
with O
severe O
pre-eclampsia-eclampsia O
and O
to O
16 O
healthy O
pregnant O
patients O
with O
normal O
renal O
and O
hepatic O
function O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
2 O
angiotensin O
II O
receptor O
blockers O
( O
olmesartan O
at O
20 O
mg/day O
or O
valsartan O
at O
80 O
mg/day O
) O
on O
coronary O
plaque O
by O
coronary O
intravascular O
ultrasound O
. O
[]

CONCLUSION O
Enteral O
nutrition O
improves O
QOL B-outcome ['Life-Impact']
of O
severely O
malnourished O
head O
and O
neck O
cancer O
patients O
in O
the O
period O
preceding O
surgery O
. O
['Life-Impact']

The O
goal O
of O
the O
current O
study O
was O
to O
measure O
the O
effectiveness O
of O
a O
tailored O
decision O
aid O
designed O
specifically O
to O
assist O
individuals O
to O
make O
informed O
decisions O
regarding O
genetic O
testing O
for O
HNPCC O
risk O
. O
[]

Larger O
studies O
are O
needed O
to O
validate O
these O
findings O
and O
to O
explore O
possible O
mechanisms O
. O
[]

CONCLUSION O
Nonsurgical O
therapy O
resulted O
in O
both O
a O
suppression O
and O
early O
elimination O
of O
single B-outcome ['Physiological-Clinical']
taxa I-outcome ['Physiological-Clinical']
immediately O
after O
completion O
of O
active O
treatment O
. O
['Physiological-Clinical']

Low O
pressure O
cuffs O
, O
however O
, O
may O
easily O
be O
overinflated O
to O
yield O
pressures O
that O
will O
exceed O
capillary O
perfusion O
pressure O
. O
[]

The O
major O
toxicities O
of O
the O
regimen O
were O
fever O
and O
malaise O
. O
( O
[]

In O
some O
situations O
, O
laparoscopic O
instruments O
appear O
to O
amplify O
the O
haptic O
information O
available O
. O
[]

Retaining O
the O
item-of-service O
payments O
to O
practices O
should O
support O
costs O
of O
practice-based O
interventions O
. O
[]

BACKGROUND O
e-learning O
resources O
may O
be O
beneficial O
for O
complex O
or O
conceptually O
difficult O
topics O
. O
[]

Lymphedema B-outcome ['Physiological-Clinical']
was O
assessed O
by O
the O
sum O
of O
differences O
in O
circumference B-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
between I-outcome ['Physiological-Clinical']
affected I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
normal I-outcome ['Physiological-Clinical']
limbs I-outcome ['Physiological-Clinical']
( O
'delta O
' O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Intracellular B-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
molecule I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ICAM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
IL-8 I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
TNF-R I-outcome ['Physiological-Clinical']
levels O
were O
also O
increased O
after O
ILP O
with O
TNF/IFN/M O
. O
['Physiological-Clinical']

However O
, O
the O
weighted O
blanket O
was O
favored O
by O
children O
and O
parents O
, O
and O
blankets O
were O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
over O
this O
period O
. O
['Life-Impact']

The O
main O
beneficial O
effect O
of O
exercise B-outcome ['Life-Impact']
occurred O
in O
the O
first O
4 O
weeks O
of O
the O
intervention O
. O
['Life-Impact']

RESULTS O
The O
results O
of O
this O
study O
indicated O
that O
stimulus B-outcome ['Physiological-Clinical']
over-selectivity I-outcome ['Physiological-Clinical']
was O
present O
in O
a O
group O
of O
patients O
with O
TBI O
. O
['Physiological-Clinical']

The O
treatment O
of O
localized O
non-Hodgkin O
's O
lymphoma O
in O
children O
: O
a O
report O
from O
the O
Children O
's O
Cancer O
Study O
Group O
. O
[]

METHODS O
The O
study O
was O
a O
prospective O
analysis O
of O
95 O
patients O
who O
underwent O
fluoroscopy O
guided O
TBLB O
over O
a O
two O
year O
period O
. O
[]

Operation B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
, O
urethral B-outcome ['Resource-use']
catheterization I-outcome ['Resource-use']
times O
, O
preoperative B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
Hb I-outcome ['Physiological-Clinical']
, O
Htc B-outcome ['Physiological-Clinical']
and O
serum O
Na O
values O
of O
the O
patients O
were O
compared O
and O
the O
complications O
of O
the O
groups O
were O
also O
compared O
. O
['Life-Impact', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

An O
analysis O
after O
adjustment O
for O
these O
variables O
demonstrated O
no O
difference O
in O
survival B-outcome ['Mortality']
comparing O
the O
low O
, O
normal O
and O
high O
magnesium O
groups O
. O
['Mortality']

INTRODUCTION O
Biventricular O
pacing O
system O
implantation O
is O
a O
time-consuming O
and O
challenging O
procedure O
. O
[]

CONCLUSIONS O
Mind-body O
interventions O
had O
no O
statistically O
significant O
impact O
on O
reported O
anxiety B-outcome ['Life-Impact']
, O
perceived B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
or O
satisfaction B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
, O
even O
for O
those O
who O
anticipated O
the O
most O
pain O
or O
started O
with O
high O
anxiety O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

The O
effect O
of O
cisapride O
on O
delayed O
colonic B-outcome ['Physiological-Clinical']
transit I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
in O
patients O
with O
idiopathic O
Parkinson O
's O
disease O
. O
['Physiological-Clinical']

Further O
postsurgical O
follow O
up O
was O
carried O
on O
for O
up O
to O
10 O
years O
. O
[]

However O
, O
the O
improvement O
among O
the O
children O
who O
received O
dimethylglycine O
was O
not O
statistically O
different O
from O
the O
improvement O
observed O
among O
the O
children O
who O
received O
the O
placebo O
. O
[]

Emission O
images O
were O
registered O
to O
an O
ECD O
template O
with O
a O
CD O
cost O
function O
. O
[]

The O
purpose O
of O
this O
trial O
was O
to O
determine O
whether O
adjuvant O
AT O
improved O
disease-free O
survival O
compared O
with O
AC O
in O
operable O
breast B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Patients O
on O
acetazolamide O
showed O
a O
slightly O
better O
improvement O
of O
angiographic B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
( O
at O
least O
by O
one O
grade O
improvement O
) O
over O
that O
of O
placebo O
( O
12 O
vs O
five O
eyes O
) O
. O
['Physiological-Clinical']

After O
6 O
months O
, O
body O
image O
and O
cosmetic O
appearance O
were O
excellent O
for O
both O
groups O
and O
indistinguishable O
by O
most O
measures O
. O
[]

The O
dose O
of O
risperidone O
was O
titrated O
up O
to O
2 O
mg/day O
for O
children O
between O
10 O
and O
40 O
kg O
and O
3 O
mg/day O
for O
children O
weighting O
above O
40 O
kg O
. O
[]

Evaluation O
included O
the O
Structured O
Clinical O
Interview O
for O
DSM-III-R O
, O
administered O
in O
the O
follicular O
phase O
, O
and O
the O
subject O
Penn O
Dally O
Symptoms B-outcome ['Physiological-Clinical']
Report O
( O
DSR O
) O
maintained O
throughout O
the O
study O
. O
['Physiological-Clinical']

One O
of O
the O
points O
was O
to O
reduce O
the O
time B-outcome ['Physiological-Clinical']
without I-outcome ['Physiological-Clinical']
chest I-outcome ['Physiological-Clinical']
compressions I-outcome ['Physiological-Clinical']
in O
the O
first O
phase O
of O
cardiac O
arrest O
. O
['Physiological-Clinical']

Forty-six O
females O
and O
46 O
males O
completed O
four O
blocks O
of O
64 O
trials O
in O
a O
lateralized O
mental O
rotation O
task O
. O
[]

No O
significant O
differences O
between O
Er O
, O
Cr O
: O
YSGG O
and O
GaAlAs O
laser O
groups O
were O
found O
at O
any O
follow-up O
examination O
( O
p O
> O
0.05 O
) O
. O
[]

Multi-arm O
crossover O
tea O
trials O
might O
pose O
a O
higher O
burden O
on O
participants O
and O
research O
is O
needed O
to O
improve O
adherence O
and O
treatment O
compliance O
in O
such O
trials O
. O
[]

Patients O
of O
the O
stent O
group O
and O
the O
bypass O
group O
did O
not O
differ O
in O
baseline O
characteristics O
, O
including O
Parsonnet O
score O
and O
quality-of-life B-outcome ['Life-Impact']
score O
. O
['Life-Impact']

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
clinical O
and O
microbiological O
effects O
of O
subgingival O
application O
of O
25 O
% O
metronidazole O
dental O
gel O
as O
an O
adjunct O
to O
scaling O
and O
root O
planing O
( O
SRP O
) O
in O
the O
treatment O
of O
adult O
periodontitis O
. O
[]

BACKGROUND O
There O
are O
patients O
with O
stage O
I-III O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
who O
are O
not O
suitable O
for O
curative O
radical O
chemoradiation O
therapy O
. O
[]

Adherence B-outcome ['Life-Impact']
was O
assessed O
by O
3-day O
food B-outcome ['Life-Impact']
records O
and O
urine B-outcome ['Physiological-Clinical']
collections O
in O
children O
and O
adults O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Toothbrushes O
were O
air-dried O
( O
25 O
degrees O
C O
) O
for O
four O
or O
24 O
hours O
. O
[]

However O
, O
there O
are O
no O
published O
studies O
comparing O
the O
economic O
costs O
of O
treating O
EVH O
using O
these O
interventions O
. O
[]

Bone O
mineral O
of O
the O
calcaneus O
and O
the O
spine O
correlated O
equally O
to O
body O
weight O
( O
r O
approximately O
0.4 O
, O
p O
< O
0.001 O
) O
, O
whereas O
bone O
mineral O
in O
the O
forearm O
was O
not O
correlated O
to O
body O
weight O
. O
[]

Factor O
VII B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
was O
increased O
in O
both O
groups O
with O
a O
greater O
increase O
in O
the O
DYDR O
group O
. O
['Physiological-Clinical']

In O
patients O
with O
HBe O
antigen-positive O
disease O
acquired O
in O
adult O
life O
the O
response O
rates O
vary O
from O
25-50 O
% O
. O
[]

The O
control O
group O
receives O
treatment O
as O
usual O
with O
no O
additional O
social O
support O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
rate O
of O
Autism B-outcome ['Life-Impact']
Spectrum O
Disorder B-outcome ['Physiological-Clinical']
between O
the O
Regular O
( O
9/1,125 O
, O
0.8 O
% O
) O
and O
Intensive O
( O
7/1,167 O
, O
0.6 O
% O
) O
groups O
, O
nor O
a O
difference O
between O
groups O
in O
the O
level O
of O
['Life-Impact', 'Physiological-Clinical']

However O
, O
transfusion O
rate O
, O
presence O
of O
hepatomegaly O
, O
splenomegaly O
, O
and O
jaundice O
was O
similar O
. O
[]

Optimal O
therapy O
for O
advanced O
chronic O
venous O
insufficiency O
. O
[]

Although O
the O
incidence O
of O
leukopenia O
was O
low O
with O
I-MEC B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
, O
the O
incidence O
of O
thrombocytopenia B-outcome ['Physiological-Clinical']
was O
high O
with O
this O
therapy O
. O
['Resource-use', 'Physiological-Clinical']

The O
overall O
frequency O
of O
paraesthesia B-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
needle-through-needle O
technique O
group O
( O
56.9 O
% O
vs. O
31.6 O
% O
, O
p O
= O
0.011 O
) O
. O
['Physiological-Clinical']

Nine O
male O
and O
six O
female O
healthy O
subjects O
were O
studied O
during O
supine O
bicycle O
exercise O
at O
workloads O
of O
12 O
and O
37 O
W O
; O
pedalling O
rates O
varied O
between O
30 O
and O
50 O
cycles/min O
at O
each O
workload O
. O
[]

METHODS O
Consecutive O
patients O
with O
symptomatic O
varicose O
veins O
due O
to O
isolated O
great O
saphenous O
vein O
( O
GSV O
) O
incompetence O
and O
suitable O
for O
RFA O
were O
randomized O
to O
either O
RFA O
or O
conventional O
surgery O
( O
saphenofemoral O
disconnection O
and O
stripping O
) O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effectiveness O
of O
alpha O
dihidroergocriptine O
in O
patients O
with O
fibrocystic O
mastopathy O
. O
[]

In O
this O
article O
, O
we O
describe O
the O
design O
and O
rationale O
of O
a O
phase O
2 O
, O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
to O
evaluate O
the O
safety O
and O
efficacy O
of O
LX4211 B-outcome ['Physiological-Clinical']
in O
subjects O
with O
type O
2 O
diabetes O
mellitus O
who O
have O
inadequate O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
on O
metformin O
monotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
report O
compares O
the O
utility O
of O
abnormal O
expression O
of O
these O
biomarkers O
in O
estimating O
progression O
in O
a O
cohort O
of O
men O
treated O
on O
RTOG O
92-02 O
. O
[]

Immunization O
triggered O
significant O
increases O
in O
anti-tetanus B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
anti-diphtheria I-outcome ['Physiological-Clinical']
IgG I-outcome ['Physiological-Clinical']
levels O
over O
each O
group O
's O
pre-Td O
baseline O
levels O
and O
those O
of O
an O
unvaccinated O
control O
group O
. O
['Physiological-Clinical']

Parents O
of O
all O
participants O
will O
receive O
three O
sessions O
of O
parent O
counselling O
( O
at O
0 O
, O
2 O
, O
and O
5 O
months O
) O
. O
[]

Effects O
of O
static O
stretching O
on O
repeated B-outcome ['Physiological-Clinical']
sprint I-outcome ['Physiological-Clinical']
and O
change O
of O
direction B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

The O
aim O
of O
this O
study O
was O
to O
pilot O
test O
a O
classroom-based O
intervention O
focused O
on O
facilitating O
play O
and O
joint O
attention O
for O
young O
children O
with O
autism O
in O
self-contained O
special O
education O
classrooms O
. O
[]

Improved O
fibrinolysis O
after O
1-year O
treatment O
with O
HMG O
CoA O
reductase O
inhibitors O
in O
patients O
with O
coronary O
heart O
disease O
. O
[]

A O
16 O
% O
improvement O
in O
ASD B-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
( O
within-group O
effect O
size O
= O
1.18 O
) O
was O
observed O
on O
a O
parent-reported O
scale O
. O
['Life-Impact']

It O
provides O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
measures O
more O
comparable O
with O
the O
gold O
standard O
crowded O
logMAR O
acuity O
test O
than O
the O
uncrowded O
logMAR O
acuity O
test O
. O
['Physiological-Clinical']

Complications O
, O
if O
any O
, O
were O
recorded O
. O
[]

Of O
the O
angioplasty O
group O
, O
9 O
% O
developed O
exercise-induced B-outcome ['Physiological-Clinical']
periinfarct I-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
compared O
with O
60 O
% O
of O
the O
streptokinase O
group O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Testing O
was O
done O
using O
a O
Questionnaire O
in O
a O
True/False O
format O
. O
[]

Univariate O
and O
multivariable O
regression O
analyses O
identified O
variables O
significantly O
associated O
with O
postoperative O
PRO O
. O
[]

OBJECTIVE O
To O
assess O
the O
differential O
implications O
of O
cardiac O
biomarker O
type O
on O
peri-procedural O
myocardial O
infarction O
( O
PMI O
) O
reporting O
. O
[]

Remission O
of O
anxiety B-outcome ['Life-Impact']
disorders O
appears O
to O
be O
an O
achievable O
goal O
among O
high-functioning O
children O
with O
autism O
. O
['Life-Impact']

CONCLUSIONS O
The O
combined O
HA/Vi O
vaccine O
, O
Viatim O
, O
had O
equivalent O
[]

PURPOSE O
This O
trial O
tested O
the O
hypothesis O
that O
combined O
androgen O
suppression O
( O
CAS O
) O
and O
whole-pelvic O
( O
WP O
) O
radiotherapy O
( O
RT O
) O
followed O
by O
a O
boost O
to O
the O
prostate O
improves O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
by O
10 O
% O
compared O
with O
CAS O
and O
prostate-only O
( O
PO O
) O
RT O
. O
['Mortality']

OBJECTIVE O
To O
investigate O
the O
safety O
and O
efficacy O
of O
intermittent O
theta-burst O
stimulation O
( O
iTBS O
) O
in O
the O
treatment O
of O
motor B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
Parkinson O
disease O
( O
PD O
) O
. O
['Life-Impact']

At O
baseline O
, O
mean O
blood O
pressure O
was O
130/78 O
mm O
Hg O
; O
19 O
participants O
used O
antihypertension O
medications O
, O
and O
mean O
body O
mass O
index O
was O
35.9 O
kg/m O
( O
2 O
) O
. O
[]

Younger O
age O
, O
consensus O
histologic O
confirmation O
, O
smoking B-outcome ['Life-Impact']
, O
and O
multiparity B-outcome ['Physiological-Clinical']
increased O
the O
likelihood O
of O
testing B-outcome ['Physiological-Clinical']
HPV I-outcome ['Physiological-Clinical']
16 O
positive O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

2-fold O
increase O
in O
strain-specific O
IgA O
ratio O
compared O
with O
placebo O
recipients O
. O
[]

antibiotics O
and O
hence O
in O
reducing O
the O
subsequent O
phlebitis O
makes O
them O
a O
useful O
alternative O
to O
the O
use O
of O
hep/hc O
. O
[]

Both O
structured O
assessments O
of O
joint O
attention O
and O
play O
skills O
and O
mother-child O
interactions O
were O
collected O
pre O
and O
post O
intervention O
by O
independent O
assessors O
. O
[]

Each O
group O
shall O
be O
scheduled O
to O
meet O
once O
per O
week O
for O
2 O
hours O
for O
8 O
consecutive O
weeks O
. O
[]

INTRODUCTION O
In O
young O
adults O
with O
childhood-onset O
growth O
hormone O
deficiency O
( O
CO O
GHD O
) O
, O
GH O
treatment O
after O
final O
height O
is O
reached O
has O
been O
shown O
to O
have O
beneficial O
effects O
on O
spine O
and O
hip O
bone O
mineral O
density O
. O
[]

SETTING O
Outpatient O
clinics O
. O
[]

The O
frequencies O
of O
predictions O
of O
drug O
efficacy O
and O
of O
adverse O
drug O
effects O
during O
the O
initial O
drug O
titration O
were O
tabulated O
for O
all O
486 O
randomized O
subjects O
. O
[]

METHODS O
Before O
sitaxsentan O
withdrawal O
, O
this O
18-week O
double-blind O
, O
placebo-controlled O
study O
randomized O
patients O
with O
PAH O
to O
receive O
placebo O
or O
sitaxsentan O
50 O
or O
100 O
mg O
once O
daily O
. O
[]

Participants O
were O
seventh- O
, O
eighth- O
and O
ninth-grade O
students O
( O
N O
= O
395 O
) O
from O
regular O
classes O
in O
a O
mainstream O
school O
. O
[]

An O
association O
with O
increased O
prostate B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
risk O
in O
patients O
with O
prior O
benign O
prostate O
hyperplasia O
( O
BPH O
) O
diagnosis O
was O
also O
revealed O
. O
['Physiological-Clinical']

PURPOSE O
To O
compare O
two O
preservative-free O
hydrating O
agents O
, O
in O
multidose O
( O
ABAK O
) O
bottles O
, O
in O
contact O
lens O
wearers O
experiencing O
symptoms O
of O
ocular B-outcome ['Physiological-Clinical']
dryness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
compare O
the O
performance O
of O
high-functioning O
adults O
with O
ASD O
and O
matched O
controls O
on O
a O
naturalistic O
luggage O
screening O
task O
. O
[]

Perioperative O
blood O
transfusions O
, O
with O
or O
without O
allogeneic O
leucocytes O
, O
relate O
to O
survival B-outcome ['Mortality']
, O
not O
to O
cancer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

CONCLUSION O
Among O
the O
children O
studied O
here O
, O
there O
was O
no O
statistically O
significant O
difference O
between O
IMV O
and O
SIMV+PS O
in O
terms O
of O
time O
on O
MV O
, O
duration O
of O
weaning O
or O
time O
spent O
in O
the O
PICU O
. O
[]

While O
in O
the O
heparin-free O
group O
it O
was O
decreased O
gradually O
and O
reached O
a O
ravine O
at O
the O
end O
of O
the O
treatment O
. O
[]

Patients O
were O
asked O
to O
complete O
the O
Medical O
Outcomes O
Study O
36-Item O
Short O
Form O
Health O
Survey O
, O
Migraine-Specific B-outcome ['Life-Impact']
Quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
Life I-outcome ['Life-Impact']
, O
and O
Migraine B-outcome ['Physiological-Clinical']
Disability I-outcome ['Physiological-Clinical']
Assessment O
questionnaires O
before O
treatment O
and O
at O
12- O
and O
60-month O
postoperative O
follow-up O
. O
['Life-Impact', 'Physiological-Clinical']

The O
primary O
end O
point O
was O
the O
change O
in O
A1C B-outcome ['Physiological-Clinical']
at O
study O
end O
. O
['Physiological-Clinical']

Duration O
of O
chronic B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Hazard O
ratio O
( O
HR B-outcome ['Physiological-Clinical']
) O
of O
irregular B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
1.00 O
in O
group O
C O
, O
2.43 O
in O
group O
A O
( O
95 O
% O
CI O
: O
1.08-5.46 O
) O
, O
3.12 O
in O
group O
B O
( O
95 O
% O
CI O
: O
1.42-6.88 O
) O
, O
and O
0.73 O
in O
group O
D O
( O
95 O
% O
CI O
: O
0.26-2.04 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVE O
To O
compare O
dexmedetomidine O
and O
midazolam+fentanyl O
sedation O
primarily O
based O
on O
patient O
satisfaction O
during O
phacoemulsification O
under O
topical O
and O
peribulbar O
anesthesia O
. O
[]

Opiates O
carry O
distinct O
disadvantages O
. O
[]

We O
administered O
morphine O
analgesia O
to O
all O
patients O
by O
patient-controlled O
analgesia O
( O
PCA O
) O
during O
the O
postoperative O
24 O
hours O
. O
[]

RESULTS O
Sixty O
questionnaires O
from O
20 O
patients O
with O
age O
29-73 O
years O
were O
analyzed O
. O
[]

Three O
patients O
in O
group O
B O
were O
converted O
to O
laparotomy O
because O
of O
uterine O
size O
. O
[]

Red B-outcome ['Physiological-Clinical']
man I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
occurred O
in O
7/51 O
( O
13.7 O
% O
) O
and O
5/52 O
( O
9.6 O
% O
) O
in O
od O
and O
bd O
groups O
, O
respectively O
. O
['Physiological-Clinical']

Patients O
who O
did O
not O
improve O
after O
6 O
weeks O
of O
this O
treatment O
were O
randomly O
assigned O
to O
one O
of O
the O
three O
haloperidol O
levels O
for O
another O
6 O
weeks O
. O
[]

Concentrations O
of O
rocuronium O
were O
measured O
using O
high-performance O
liquid O
chromatography O
with O
electrochemical O
detection O
( O
HPLC-EC O
) O
. O
[]

Custom-fit O
minimally O
invasive O
total O
knee O
arthroplasty O
: O
effect O
on O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
early B-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ribavirin O
1000 O
mg/day O
( O
< O
75 O
kg O
) O
or O
1200 O
mg/day O
( O
> O
or=75 O
kg O
) O
and O
peginterferon O
alpha-2a O
180 O
microg/week O
were O
considered O
optimal O
. O
[]

Therefore O
, O
recruitment O
materials O
that O
specifically O
address O
these O
constructs O
have O
the O
potential O
to O
outperform O
traditional O
educational O
brochures O
. O
[]

Throughout O
gestation O
, O
33 O
German O
Landrace O
gilts O
were O
fed O
high O
( O
HP O
, O
30 O
% O
) O
, O
low O
( O
LP O
, O
6.5 O
% O
) O
, O
or O
adequate O
( O
AP O
, O
12.1 O
% O
) O
protein O
diets O
, O
which O
were O
made O
isocaloric O
by O
adjusting O
the O
carbohydrate O
content O
. O
[]

Comparative O
trial O
of O
carbenicillin O
and O
ampicillin O
therapy O
for O
purulent O
meningitis O
. O
[]

The O
outcome O
was O
not O
related O
to O
surgical O
method O
. O
[]

They O
accounted O
for O
60 O
% O
of O
the O
2392 O
children O
( O
aged O
0-7 O
years O
) O
who O
had O
been O
enrolled O
in O
a O
nutrition O
intervention O
study O
during O
1969-77 O
. O
[]

Ambulation O
in O
labour O
. O
[]

[ O
Treatment O
of O
primary O
osteoporosis O
with O
calcium O
and O
salmon O
calcitonin O
] O
. O
[]

The O
overall O
morality O
was O
equivalent O
between O
the O
two O
groups O
-- O
26 O
% O
( O
PGE1 O
) O
versus O
28 O
% O
( O
placebo O
) O
. O
[]

This O
study O
assessed O
the O
effects O
of O
chronic O
treatment O
with O
low O
doses O
of O
aspirin O
( O
100 O
mg/day O
) O
on O
clinic B-outcome ['Resource-use']
and O
ambulatory B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
in O
hypertensives O
on O
chronic O
, O
stable O
antihypertensive O
therapy O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Satisfaction B-outcome ['Life-Impact']
rate O
, O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
discharge B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
complication B-outcome ['Adverse-effects']
rate O
, O
reintervention B-outcome ['Resource-use']
rate O
, O
and O
resumption O
of O
normal B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
evaluated O
in O
each O
group O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Adverse-effects', 'Resource-use', 'Physiological-Clinical']

After O
the O
treatment O
period O
with O
the O
first O
drug O
, O
there O
was O
a O
2 O
week O
wash-out O
period O
on O
placebo O
( O
PL O
) O
before O
the O
second O
drug O
was O
given O
. O
[]

The O
children O
were O
randomly O
assigned O
to O
an O
imitation O
( O
n O
= O
10 O
) O
or O
contingently O
responsive O
( O
n O
= O
10 O
) O
interaction O
group O
based O
on O
a O
stratification O
table O
for O
gender O
and O
developmental O
and O
chronological O
age O
. O
[]

BACKGROUND O
During O
the O
evaluation O
of O
many O
instances O
of O
the O
same O
basic O
surgical O
skill O
, O
we O
observed O
that O
there O
were O
several O
errors O
that O
occurred O
frequently O
. O
[]

A O
second O
injection O
was O
required O
in O
a O
mean O
of O
40 O
% O
of O
attacks O
, O
and O
headache B-outcome ['Physiological-Clinical']
was O
mild O
or O
absent O
1 O
hour O
after O
the O
second O
injection O
in O
a O
mean O
of O
77 O
% O
of O
attacks O
. O
['Physiological-Clinical']

MSL-109 O
adjuvant O
therapy O
for O
cytomegalovirus O
retinitis O
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
: O
the O
Monoclonal O
Antibody O
Cytomegalovirus O
Retinitis O
Trial O
. O
[]

After O
therapy O
, O
the O
expression O
of O
survivin B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
decreased O
in O
clinical O
benefit O
cases O
( O
P O
= O
0.001 O
) O
and O
increased O
in O
disease B-outcome ['Physiological-Clinical']
progressive I-outcome ['Physiological-Clinical']
cases O
( O
P O
= O
0.018 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
. O
[]

Cardiovascular O
safety O
of O
degarelix O
: O
results O
from O
a O
12-month O
, O
comparative O
, O
randomized O
, O
open O
label O
, O
parallel O
group O
phase O
III O
trial O
in O
patients O
with O
prostate O
cancer O
. O
[]

Acute O
exposure O
to O
acid O
fog O
: O
influence O
of O
breathing O
pattern O
on O
effective O
dose B-outcome ['Life-Impact']
. O
['Life-Impact']

METHODS O
In O
this O
study O
, O
we O
investigated O
the O
expression O
of O
sialyl O
Lewis O
( O
a O
) O
antigen O
in O
233 O
colon O
cancer O
specimens O
from O
patients O
who O
were O
registered O
in O
a O
prospective O
adjuvant O
immunochemotherapy O
clinical O
trial O
. O
[]

In O
the O
randomly O
selected O
cases O
presence O
of O
leptin O
protein O
and O
of O
leptin O
receptor O
proteins O
was O
examined O
also O
by O
Western O
blotting O
. O
[]

BACKGROUND O
Total O
knee O
replacement O
( O
TKR O
) O
is O
a O
cost-effective O
treatment O
option O
for O
severe O
osteoarthritis O
( O
OA O
) O
. O
[]

METHODS O
This O
phase O
III O
prospective O
, O
randomized O
, O
and O
stratified O
trial O
was O
undertaken O
to O
evaluate O
the O
efficacy O
of O
four O
courses O
of O
combined O
fluorouracil O
( O
1000 O
mg O
per O
square O
meter O
of O
body-surface O
area O
daily O
for O
four O
days O
) O
and O
cisplatin O
( O
75 O
mg O
per O
square O
meter O
on O
the O
first O
day O
) O
plus O
5000 O
cGy O
of O
radiation O
therapy O
, O
as O
compared O
with O
6400 O
cGy O
of O
radiation O
therapy O
alone O
, O
in O
patients O
with O
squamous-cell O
carcinoma O
or O
adenocarcinoma O
of O
the O
thoracic O
esophagus O
. O
[]

Trimetazidine O
European O
Multicenter O
Study O
Group O
. O
[]

In O
a O
residential O
laboratory O
seven O
non-physically-dependent O
opioid O
abuser O
volunteers O
received O
intramuscular O
buprenorphine O
( O
0.4 O
mg O
or O
0.8 O
mg/70 O
kg O
) O
alone O
and O
in O
combination O
with O
naloxone O
( O
0.4 O
mg O
or O
0.8 O
mg/70 O
kg O
) O
versus O
placebo O
. O
[]

All O
patients O
continued O
to O
receive O
a O
stable O
dosage O
of O
MTX O
. O
[]

One O
hundred O
and O
thirty-two O
patients O
were O
included O
in O
the O
cost-effectiveness O
study O
. O
[]

CPG O
7909 O
did O
not O
increase O
non-7vPnC B-outcome ['Physiological-Clinical']
IgG I-outcome ['Physiological-Clinical']
levels O
after O
PPV-23 O
immunization O
. O
['Physiological-Clinical']

METHODS O
Theories O
of O
behaviour B-outcome ['Life-Impact']
change I-outcome ['Life-Impact']
have O
been O
used O
to O
identify O
key O
theoretical O
domains O
relevant O
to O
the O
behaviours O
of O
healthcare O
providers O
involved O
in O
implementing O
clinical O
guidelines O
. O
['Life-Impact']

Treatment O
with O
simvastatin O
or O
gemfibrozil O
in O
hypertensive O
patients O
in O
hydrochlorothiazide O
monotherapy O
can O
reduce O
total O
cholesterol B-outcome ['Physiological-Clinical']
and O
LDL-cholesterol B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Multicentre O
, O
randomized O
, O
controlled O
clinical O
trial O
of O
group O
vs. O
individual O
care O
in O
the O
routine O
management O
of O
Type O
2 O
diabetes O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
PA I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
28.61 O
+/- O
7.80 O
vs O
39.40 O
+/- O
10.80 O
mm O
Hg O
) O
and O
PA/Ao B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
0.28 O
+/- O
0.08 O
vs O
0.41 O
+/- O
0.11 O
) O
were O
significantly O
lower O
in O
the O
sildenafil O
group O
( O
p O
= O
0.001 O
and O
0.001 O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
localized B-outcome ['Physiological-Clinical']
lymphoblastic I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
were O
uncommon O
. O
['Physiological-Clinical']

The O
intervention O
group O
GPs O
believed B-outcome ['Life-Impact']
they O
were O
more O
involved O
after O
discharge B-outcome ['Life-Impact']
( O
75.0 O
% O
vs O
44.8 O
% O
, O
P O
= O
0.005 O
) O
and O
had O
greater O
understanding B-outcome ['Life-Impact']
of O
their O
patient O
's O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Antioxidant O
supplementation O
and O
exercise-induced O
oxidative O
stress O
in O
the O
60-year-old O
as O
measured O
by O
antipyrine O
hydroxylates O
. O
[]

OBJECTIVE O
To O
define O
the O
most O
effective O
treatment O
for O
severe O
polyarteritis O
nodosa O
( O
PAN O
) O
and O
Churg-Strauss O
syndrome O
( O
CSS O
) O
and O
to O
investigate O
the O
indication O
for O
plasma O
exchange O
treatment O
. O
[]

Post-stroke O
pathological O
crying O
is O
a O
distressing O
condition O
in O
which O
episodes O
occur O
in O
response O
to O
minor O
stimuli O
without O
associated O
mood O
changes O
. O
[]

Both O
drugs O
were O
equally O
effective O
as O
measured O
by O
the O
Hamilton O
Rating O
Scale O
for O
Depression O
, O
the O
overall O
assessment O
of O
efficacy O
and O
the O
Zung O
Self-rating O
Scale O
, O
and O
clearly O
superior O
to O
placebo O
; O
there O
were O
no O
significant O
differences O
between O
the O
2 O
active O
drugs O
. O
[]

At O
follow-up O
, O
the O
CBT O
group O
tended O
to O
be O
more O
likely O
to O
have O
experienced O
3 O
months O
of O
seizure B-outcome ['Physiological-Clinical']
freedom I-outcome ['Physiological-Clinical']
( O
odds O
ratio O
3.125 O
, O
p O
= O
0.086 O
) O
. O
['Physiological-Clinical']

METHODS O
Variations O
in O
SkBF B-outcome ['Physiological-Clinical']
and O
Tsk O
in O
adult O
volunteers O
were O
simultaneously O
recorded O
with O
a O
thermostatic O
laser O
Doppler O
system O
during O
a O
20-minute O
radiofrequency O
exposure O
session O
and O
a O
20-minute O
sham O
session O
. O
['Physiological-Clinical']

Theophylline B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in O
serum O
and O
saliva O
after O
oral O
microcrystalline O
and O
sustained-release O
preparations O
in O
asthmatics O
. O
['Physiological-Clinical']

The O
Cheyne-Stokes O
apnea B-outcome ['Physiological-Clinical']
index O
decreased O
with O
increasing O
sleeping O
angle O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

For O
needle O
placement O
into O
the O
incisive O
canal O
, O
54 O
% O
of O
the O
subjects O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
lidocaine O
solution O
and O
58 O
% O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
mepivacaine O
solution O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
A O
decision O
aid O
for O
individuals O
considering O
genetic O
testing O
for O
HNPCC O
is O
an O
effective O
intervention O
to O
reduce O
uncertainty O
and O
assist O
individuals O
to O
make O
an O
informed O
choice O
regarding O
genetic O
testing O
for O
HNPCC O
after O
genetic O
counseling O
. O
[]

The O
mean O
number/hr O
. O
[]

Impact O
of O
preinduced O
quadriceps O
fatigue O
on O
exercise O
response O
in O
chronic O
obstructive O
pulmonary O
disease O
and O
healthy O
subjects O
. O
[]

Recombinant O
human O
thrombopoietin O
augments O
mobilization O
of O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
progenitor I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
for O
autologous O
transplantation O
. O
['Physiological-Clinical']

CONCLUSIONS O
Larger-scale O
studies O
are O
warranted O
to O
determine O
the O
effectiveness O
and O
usability O
in O
comprehensive O
educational O
programs O
. O
[]

After O
6 O
months O
of O
hearing-aid O
use O
, O
individuals O
experienced O
more O
physical B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
pleasure I-outcome ['Life-Impact']
, O
whereas O
individuals O
using O
hearing O
aids O
for O
long O
periods O
of O
time O
reported O
similar O
levels O
of O
pleasure O
at O
the O
beginning O
and O
at O
the O
end O
of O
a O
6-month O
interval O
. O
['Life-Impact']

The O
psychopharmacology O
of O
saccadic O
distractibility O
is O
less O
well O
understood O
, O
but O
is O
relevant O
both O
to O
interpreting O
patient O
studies O
and O
to O
establishing O
the O
neurological O
basis O
of O
their O
findings O
. O
[]

CONCLUSIONS O
Bilateral O
ultrasound-guided O
TAP O
block O
is O
equivalent O
to O
local O
anesthetic O
infiltration O
of O
trocar O
insertion O
sites O
for O
overall O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
in O
a O
heterogeneous O
group O
of O
patients O
undergoing O
laparoscopic O
cholecystectomy O
. O
['Physiological-Clinical']

Further O
study O
of O
intravenous O
ADP O
blockade O
with O
cangrelor O
may O
be O
warranted O
. O
( O
[]

OBJECTIVE O
To O
explore O
possible O
benefits O
of O
a O
nicotinic O
acetylcholine O
receptor O
( O
nAChR O
) O
agent O
for O
autistic B-outcome ['Life-Impact']
symptoms B-outcome ['Life-Impact']
based O
on O
postmortem O
observation O
of O
nAChR O
abnormalities O
( O
deficient O
?4?2 O
nAChRs O
, O
excess O
?7 O
nAChRs O
) O
in O
brains O
of O
patients O
with O
autism O
. O
['Life-Impact', 'Life-Impact']

Mean O
sexual B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
score O
was O
15 O
points O
lower O
at O
3 O
years O
for O
the O
cryoablation O
group O
and O
13 O
% O
more O
of O
the O
cryoablation O
men O
said O
that O
sexuality O
was O
a O
moderate O
or O
big O
problem O
. O
['Life-Impact']

The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
a O
shortened O
postpartum O
course O
of O
magnesium O
sulphate O
is O
as O
effective O
as O
the O
standard O
Pritchard O
regimen O
in O
controlling O
fits O
in O
eclampsia O
Between O
January O
and O
June O
2011 O
, O
98 O
eclamptic O
mothers O
presenting O
at O
the O
labour O
ward O
of O
the O
University O
of O
Maiduguri O
Teaching O
Hospital O
were O
randomised O
to O
receive O
either O
the O
standard O
Pritchard O
regimen O
of O
magnesium O
sulphate O
or O
a O
shortened O
postpartum O
course O
in O
which O
only O
two O
doses O
of O
intramuscular O
magnesium O
sulphate O
is O
given O
four O
hours O
apart O
. O
[]

Whenever O
possible O
, O
each O
JET O
case O
was O
randomly O
matched O
to O
two O
controls O
on O
the O
basis O
of O
lesion O
, O
repair O
, O
and O
surgical O
period O
. O
[]

The O
pharmacodynamic B-outcome ['Physiological-Clinical']
effects O
and O
acceptability B-outcome ['Life-Impact']
of O
perindopril O
( O
4 O
mg O
daily O
) O
and O
hydrochlorothiazide O
( O
25 O
mg O
daily O
) O
given O
alone O
or O
in O
combination O
for O
1 O
month O
were O
investigated O
in O
a O
double-blind O
, O
placebo O
controlled O
, O
parallel O
group O
study O
. O
['Physiological-Clinical', 'Life-Impact']

Following O
treatment O
withdrawal O
, O
the O
differences O
in O
BMD O
observed O
between O
the O
two O
endocrine O
strategies O
were O
partially O
reversed O
. O
[]

The O
lead O
system O
evaluated O
was O
a O
dual-coil O
transvenous O
defibrillation O
lead O
with O
a O
left O
pectoral O
pulse O
generator O
emulator O
. O
[]

This O
study O
examined O
the O
impact O
of O
esmolol O
pretreatment O
on O
seizure B-outcome ['Physiological-Clinical']
morphology I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Oral O
and O
intravenous O
linezolid O
exhibit O
linear O
pharmacokinetics B-outcome ['Physiological-Clinical']
, O
with O
concentrations O
remaining O
above O
the O
target O
MIC90 O
for O
most O
of O
the O
dosing O
interval O
. O
['Physiological-Clinical']

The O
injection O
time O
of O
fentanyl O
was O
less O
than O
2 O
s O
in O
all O
patients O
. O
[]

However O
, O
because O
intensive O
daily O
self-application O
is O
required O
, O
compliance O
is O
an O
issue O
. O
[]

Not-eradicated O
patients O
underwent O
a O
second O
cycle O
with O
tinidazole O
, O
tetracycline O
, O
bismuth O
and O
rabeprazole O
. O
[]

PURPOSE O
To O
examine O
the O
relationship O
between O
changes O
in O
health-related B-outcome ['Life-Impact']
quality-of-life I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
HRQOL I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
on O
the O
EORTC O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
, O
and O
patients O
' O
perceptions O
of O
HRQOL O
changes O
as O
measured O
by O
the O
Subjective O
Significance O
Questionnaire O
( O
SSQ O
) O
. O
['Life-Impact']

Recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
comparable O
between O
the O
arms O
( O
27 O
events O
in O
the O
fenretinide O
arm O
versus O
21 O
in O
the O
control O
arm O
; O
P O
= O
0.36 O
) O
. O
['Mortality']

Isolated B-outcome ['Physiological-Clinical']
stent I-outcome ['Physiological-Clinical']
edge I-outcome ['Physiological-Clinical']
( O
3.4 O
% O
) O
and O
ribbon B-outcome ['Physiological-Clinical']
edge I-outcome ['Physiological-Clinical']
( O
1.7 O
% O
) O
restenoses B-outcome ['Physiological-Clinical']
were O
infrequent O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
the O
patients O
performed O
isometric O
quadriceps O
femoris O
contraction O
exercise O
and O
knee O
flexion O
and O
extension O
activities O
after O
operation O
. O
[]

Peritonsillar O
infiltration O
with O
bupivacaine O
for O
paediatric O
tonsillectomy O
. O
[]

Comparison O
of O
injection B-outcome ['Life-Impact']
comfort I-outcome ['Life-Impact']
of O
a O
new O
category O
of O
cohesive O
hyaluronic O
acid O
filler O
with O
preincorporated O
lidocaine O
and O
a O
hyaluronic O
acid O
filler O
alone O
. O
['Life-Impact']

INTERVENTIONS O
Total O
laparoscopic O
hysterectomy O
for O
benign O
pathology O
. O
[]

A O
randomized O
study O
was O
performed O
in O
54 O
thrombocytopenic O
patients O
with O
acute O
leukemia O
. O
[]

Participants O
completed O
baseline O
and O
immediate O
follow-up O
surveys O
to O
assess O
the O
intervention O
impact O
on O
study O
outcomes O
. O
[]

METHODS O
We O
randomly O
assigned O
291 O
children O
6 O
to O
23 O
months O
of O
age O
, O
with O
acute O
otitis O
media O
diagnosed O
with O
the O
use O
of O
stringent O
criteria O
, O
to O
receive O
amoxicillin-clavulanate O
or O
placebo O
for O
10 O
days O
. O
[]

The O
interaction O
between O
propofol O
and O
clonidine O
for O
loss O
of O
consciousness O
. O
[]

BACKGROUND O
Current O
practice O
related O
to O
the O
management O
of O
atrial O
fibrillation B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
complicating O
coronary O
artery O
bypass O
grafting O
( O
CABG O
) O
is O
uncertain O
. O
['Physiological-Clinical']

We O
calculated O
odds O
ratios O
( O
ORs B-outcome ['Physiological-Clinical']
) O
and O
95 O
% O
CIs B-outcome ['Physiological-Clinical']
for O
adenoma B-outcome ['Physiological-Clinical']
incidence O
and O
recurrence B-outcome ['Physiological-Clinical']
, O
and O
hazard O
ratios O
( O
HRs B-outcome ['Physiological-Clinical']
) O
and O
95 O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
of O
the O
treatment O
of O
1022 O
ovarian O
cancers O
were O
reviewed O
and O
the O
problems O
of O
prophylactic O
chemotherapy O
, O
a O
second O
look O
operation O
and O
the O
maintenance O
of O
the O
remission O
were O
studied O
. O
[]

PARTICIPANTS O
Parents O
of O
495 O
children O
with O
autism O
, O
parents O
of O
6716 O
children O
with O
asthma O
, O
and O
parents O
of O
11,403 O
children O
with O
other O
special O
health O
care O
needs O
without O
asthma O
. O
[]

Right O
ventricular O
function O
was O
assessed O
using O
transesophageal O
echocardiography O
. O
[]

METHODS O
A O
total O
of O
250 O
patients O
averaging O
40 O
years O
of O
age O
with O
acute O
DVT O
were O
randomized O
into O
five O
groups O
to O
receive O
full O
heparinization O
( O
1,000 O
IU/h O
) O
and O
compression O
treatment O
, O
with O
four O
groups O
also O
administered O
locoregional O
tissue O
plasminogen O
activator O
( O
20 O
mg/day O
) O
or O
urokinase O
( O
100,000 O
IU/day O
) O
or O
systemic O
streptokinase O
( O
3,000,000 O
IU O
daily O
) O
or O
urokinase O
( O
5,000,000 O
IU O
daily O
) O
. O
[]

The O
augmented O
intervention O
consisted O
of O
the O
initial O
e-mail O
reminder O
supplemented O
by O
provider O
prompts O
, O
patient O
education O
material O
, O
and O
clinical O
nurse O
specialist O
outreach O
. O
[]

RESULTS O
Pre-medication O
with O
pronase O
( O
treatment O
C O
) O
significantly O
reduced O
( O
both O
at O
P O
< O
0.05 O
) O
the O
visibility O
score O
( O
score O
4 O
, O
46 O
% O
) O
in O
comparison O
with O
that O
obtained O
for O
pre-medication O
without O
pronase O
( O
10 O
% O
for O
both O
treatments O
A O
and O
B O
) O
. O
[]

The O
incidence O
of O
ICD B-outcome ['Resource-use']
therapies I-outcome ['Resource-use']
per O
patient-year O
among O
the O
placebo O
group O
was O
36 O
, O
and O
it O
was O
10 O
, O
12 O
, O
and O
9 O
among O
35 O
mg O
, O
75 O
mg O
, O
and O
125 O
mg O
AZ O
patients O
, O
respectively O
( O
hazard O
ratio O
= O
0.31 O
, O
p O
= O
0.0001 O
) O
. O
['Resource-use']

RESULTS O
No O
significant O
differences O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
rate-pressure O
product O
, O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
and O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
work I-outcome ['Physiological-Clinical']
index O
were O
observed O
between O
the O
sedated O
and O
non-sedated O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

SETTING O
Level O
1 O
trauma O
center O
. O
[]

Protocol-defined O
cardiotoxicity B-outcome ['Physiological-Clinical']
was O
observed O
in O
13 O
% O
of O
TLC O
D-99 O
patients O
( O
including O
2 O
cases O
of O
CHF O
) O
compared O
to O
29 O
% O
of O
doxorubicin O
patients O
( O
including O
9 O
cases O
of O
CHF O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
These O
data O
indicate O
that O
laparoscopic O
instruments O
do O
, O
in O
fact O
, O
provide O
surgeons O
with O
haptic B-outcome ['Physiological-Clinical']
feedback I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

[ O
Aortofemoral O
bifurcation O
bypass O
. O
[]

One O
sensory O
disturbance O
seen O
in O
ASD O
is O
an O
impaired O
ability O
to O
integrate O
multisensory O
information O
into O
a O
unified O
percept O
. O
[]

Overall O
, O
10.8 O
% O
of O
aripiprazole-treated O
AN O
subjects O
had O
at O
least O
one O
AE O
leading O
to O
discontinuation O
compared O
with O
8.3 O
% O
of O
aripiprazole-treated O
PAE O
subjects O
. O
[]

No O
changes O
occurred O
for O
total O
SRF B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
mean O
daily O
insulin B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
after O
24 O
weeks O
of O
treatment O
was O
16.4 O
+/- O
10.1 O
IU O
in O
the O
acarbose O
group O
and O
22.4 O
+/- O
12.2 O
IU O
in O
the O
placebo O
group O
( O
mean O
+/- O
s.d O
. O
; O
['Life-Impact']

The O
vaccine O
or O
the O
placebo O
was O
administered O
subcutaneously O
in O
the O
brachiocephalicus O
muscle O
of O
the O
neck O
. O
[]

This O
approach O
is O
attractive O
in O
terms O
of O
minimizing O
posttherapeutic B-outcome ['Physiological-Clinical']
restrictions I-outcome ['Physiological-Clinical']
and O
in O
reducing O
the O
potential O
risk O
of O
radiation-induced B-outcome ['Physiological-Clinical']
malignancy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
EC50 B-outcome ['Physiological-Clinical']
in O
the O
2.5 O
and O
5.0 O
microg/kg O
clonidine O
groups O
was O
significantly O
smaller O
than O
that O
in O
the O
Control O
group O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

RESULTS O
( O
PROPOSAL O
) O
: O
At O
baseline O
, O
the O
group O
of O
patients O
showed O
normal B-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
but O
impaired B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
as O
assessed O
with O
conventional O
echocardiographic O
parameters O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
A O
comparison O
of O
clearance B-outcome ['Physiological-Clinical']
and O
peak O
and O
systemic O
exposure B-outcome ['Physiological-Clinical']
to O
midazolam O
following O
administration O
of O
roflumilast O
indicated O
no O
effect O
of O
roflumilast O
dosed O
to O
steady O
state O
on O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
midazolam I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

One O
hundred O
patients O
were O
randomly O
assigned O
to O
the O
control O
group O
; O
the O
study O
group O
consisted O
of O
100 O
patients O
who O
received O
Bioglue O
in O
the O
mucosa O
anastomosis O
area O
. O
[]

Matched-pair O
analysis O
of O
all-polyethylene O
versus O
metal-backed O
tibial O
components O
. O
[]

The O
primary O
efficacy O
endpoint O
of O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
through O
2 O
hours O
demonstrated O
that O
, O
after O
adjustment O
for O
age O
imbalance O
, O
rizatriptan O
10 O
mg O
had O
earlier O
onset O
than O
sumatriptan O
100 O
mg O
( O
P O
= O
0.032 O
; O
hazard O
ratio O
1.21 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVES O
Although O
local O
anesthesia O
has O
been O
demonstrated O
to O
potentiate O
spinal O
morphine O
analgesia O
in O
animal O
studies O
, O
results O
comparing O
epidural O
local O
anesthesia/opioid O
mixtures O
with O
opioid O
alone O
are O
contradictory O
in O
clinical O
studies O
. O
[]

Among O
55 O
patients O
who O
responded O
to O
interferon O
by O
normalization O
of O
alanine O
transaminase O
( O
ALT O
) O
, O
median O
APC O
before O
treatment O
was O
0.47 O
( O
range O
, O
0.12 O
to O
0.98 O
; O
normal O
range O
, O
0.34 O
to O
1.02 O
mL/min/kg O
body O
wt O
) O
, O
a O
value O
that O
was O
significantly O
greater O
than O
in O
30 O
nonresponders O
( O
0.23 O
; O
0.08 O
to O
0.67 O
mL/min/kg O
body O
wt O
, O
P O
< O
.001 O
) O
. O
[]

Twenty-eight O
subacute O
stroke O
patients O
with O
arm O
paresis O
after O
a O
first O
ischemic O
stroke O
in O
the O
middle O
cerebral O
artery O
area O
were O
randomized O
into O
a O
modified O
CIMT O
or O
control O
group O
by O
a O
1:2 O
ratio O
. O
[]

Both O
groups O
completed O
a O
multiple-choice O
test O
based O
on O
the O
aforementioned O
passage O
. O
[]

There O
were O
two O
oesophageal B-outcome ['Resource-use']
intubations I-outcome ['Resource-use']
in O
the O
TAMS O
group O
and O
four O
in O
the O
OSD O
group O
, O
but O
this O
was O
not O
significantly O
different O
( O
P O
= O
0.36 O
) O
. O
['Resource-use']

The O
result O
of O
this O
controlled O
clinical O
study O
confirms O
that O
the O
combination O
Xylometazoline-Dexpanthenol O
is O
an O
enlargement B-outcome ['Physiological-Clinical']
and O
improvement O
of O
effective O
medicinal O
treatment O
of O
rhinitis O
following O
nasal O
operation O
in O
comparison O
to O
therapy O
with O
Xylometazoline O
alone O
. O
['Physiological-Clinical']

Conization O
for O
treatment O
of O
premalignant O
changes O
of O
the O
cervix O
uteri O
will O
probably O
remain O
the O
treatment O
of O
choice O
for O
some O
time O
to O
come O
. O
[]

RESULTS O
Bleeding B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
gums I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
probing I-outcome ['Physiological-Clinical']
( O
BOP B-outcome ['Physiological-Clinical']
) O
and O
pocket B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
( O
PD B-outcome ['Physiological-Clinical']
) O
improved O
at O
the O
treatment O
site O
and O
were O
maintained O
for O
13 O
weeks O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Complication O
rates O
, O
mortality O
, O
and O
hospital O
length O
of O
stay O
were O
similar O
between O
the O
2 O
groups O
; O
however O
, O
administration O
of O
dopexamine O
was O
associated O
with O
earlier O
return O
of O
tolerating O
an O
enteral O
diet O
. O
[]

Presentation O
of O
allergen O
in O
different O
food O
preparations O
affects O
the O
nature O
of O
the O
allergic O
reaction O
-- O
a O
case O
series O
. O
[]

OBJECTIVE O
To O
compare O
the O
effects O
of O
anastrozole O
and O
clomiphene O
citrate O
( O
CC O
) O
on O
follicular B-outcome ['Physiological-Clinical']
development I-outcome ['Physiological-Clinical']
and O
ovulation B-outcome ['Physiological-Clinical']
in O
infertile O
women O
with O
ovulatory O
dysfunction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
explored O
how O
in O
parallel-group O
trials O
interindividual O
variability O
, O
correction O
for O
placebo O
effects O
, O
and O
smoothing O
of O
blood O
pressure O
profiles O
can O
be O
handled O
in O
measuring O
the O
trough-to-peak O
ratio O
in O
244 O
individuals O
with O
isolated O
systolic O
hypertension O
( O
> O
or O
= O
60 O
years O
) O
enrolled O
in O
the O
placebo-controlled O
Systolic O
Hypertension O
in O
europe O
Trial O
. O
[]

Dose-related O
changes O
in O
parameters O
of O
the O
acute-phase B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
were O
noted O
, O
consistent O
with O
the O
relationship O
of O
CNTF O
and O
its O
receptor O
system O
to O
the O
cytokine O
interleukin-6 O
( O
IL-6 O
) O
and O
its O
receptor O
. O
['Physiological-Clinical']

In O
the O
control O
group O
, O
antibiotic O
therapy O
was O
administrated O
for O
2 O
weeks O
, O
or O
antibiotic O
therapy O
was O
continued O
because O
of O
confirmed O
infection O
until O
clinical O
signs O
and O
symptoms O
of O
infection O
disappeared O
over O
3 O
days O
. O
[]

METHODS O
A O
total O
of O
240 O
patients O
with O
severe O
TBI O
( O
GCS O
score O
3-8 O
) O
admitted O
to O
NICU O
were O
prospectively O
enrolled O
and O
randomly O
assigned O
either O
to O
conventional O
insulin O
therapy O
or O
to O
intensive O
insulin O
therapy O
. O
[]

A O
total O
of O
229 O
persons O
were O
randomized O
to O
the O
study O
and O
131 O
( O
57 O
% O
) O
were O
followed O
up O
( O
individual O
intervention O
n=69 O
, O
health-promotion O
programme O
n=62 O
) O
at O
28-month O
. O
[]

METHODS O
Five O
hundred O
seventy-seven O
women O
were O
screened O
for O
MPC O
. O
[]

Effects O
of O
enflurane O
and O
isoflurane O
on O
splanchnic B-outcome ['Physiological-Clinical']
oxygenation I-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical']

The O
use O
of O
?-receptor O
blockers O
in O
peripheral O
arterial O
disease O
is O
controversial O
for O
their O
impact O
on O
vasomotor O
tone O
. O
[]

The O
primary O
endpoint O
was O
average O
leukocyte B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
within O
6 O
weeks O
from O
randomization O
. O
['Physiological-Clinical']

Treatments O
were O
administrated O
on O
days O
1 O
, O
2 O
, O
3 O
, O
and O
4 O
, O
3 O
hours O
before O
the O
start O
of O
the O
laboratory O
test O
battery O
( O
performed O
on O
days O
1 O
and O
4 O
) O
, O
comprising O
a O
word-learning O
test O
, O
the O
Sternberg O
Memory O
Scanning O
Test O
, O
a O
tracking O
test O
( O
easy O
and O
hard O
version O
) O
, O
and O
a O
divided O
attention O
test O
( O
tracking O
and O
memory O
scanning O
simultaneously O
) O
. O
[]

The O
results O
of O
our O
pilot O
study O
suggested O
that O
a O
dose O
of O
5000 O
IU O
administered O
intramuscularly O
three O
times O
per O
week O
for O
four O
weeks O
was O
more O
effective O
than O
the O
lower O
doses O
given O
in O
past O
trials O
. O
[]

Attitudes B-outcome ['Life-Impact']
were O
assessed O
by O
a O
semantic B-outcome ['Life-Impact']
differential I-outcome ['Life-Impact']
questionnaire O
, O
occupational B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
was O
assessed O
by O
the O
Nursing O
Stress O
Scale O
and O
communication B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
were O
assessed O
by O
standardised O
videotaped O
role-playing B-outcome ['Life-Impact']
exercises B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
median O
time O
to O
first O
SRE B-outcome ['Physiological-Clinical']
was O
not O
reached O
in O
the O
intent-to-treat O
population O
. O
['Physiological-Clinical']

The O
following O
were O
measured O
before O
and O
after O
intervention O
: O
strength B-outcome ['Physiological-Clinical']
by O
one O
repetition O
maximum O
, O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
by O
the O
7-d O
accelerometry O
and O
the O
3-d O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
recall O
, O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
by O
3-d O
records O
, O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
by O
dual-energy O
x-ray O
absorptiometry O
( O
DEXA O
) O
, O
glucose/insulin B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
by O
oral O
glucose O
tolerance O
test O
, O
and O
intravenous O
glucose O
tolerance O
test O
with O
minimal O
modeling O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

When O
comparing O
olanzapine O
with O
haloperidol O
, O
cost B-outcome ['Resource-use']
savings O
are O
seen O
throughout O
the O
treatment O
period O
( O
1 O
year O
) O
, O
with O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
most O
highly O
affected O
over O
time O
. O
['Resource-use', 'Life-Impact']

In O
contrast O
, O
13/16 O
patients O
with O
end-treatment B-outcome ['Physiological-Clinical']
TSAb I-outcome ['Physiological-Clinical']
greater O
than O
350 O
% O
relapsed O
. O
['Physiological-Clinical']

The O
neuropeptide O
oxytocin O
has O
recently O
been O
shown O
to O
enhance O
eye B-outcome ['Physiological-Clinical']
gaze I-outcome ['Physiological-Clinical']
and O
emotion B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
in O
healthy O
men O
. O
['Physiological-Clinical', 'Life-Impact']

for O
the O
treatment O
of O
nocturnal O
asthma O
. O
[]

Why O
are O
there O
sometimes O
concreteness B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
for O
prose O
? O
['Life-Impact']

Such O
impairments O
in O
multisensory O
processing O
may O
cascade O
into O
higher-level O
deficits O
, O
impairing O
day-to-day O
functioning O
on O
tasks O
, O
such O
as O
speech O
perception O
. O
[]

In O
the O
SD O
patients O
, O
formation O
of O
alloantibodies B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
mostly I-outcome ['Physiological-Clinical']
anti-HLA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
occurred O
less O
frequently O
( O
p O
less O
than O
0.002 O
) O
, O
after O
a O
longer O
time O
period O
( O
p O
less O
than O
0.002 O
) O
, O
and O
after O
a O
higher O
number O
of O
transfusions O
( O
p O
less O
than O
0.005 O
) O
as O
compared O
to O
MD O
patients O
. O
['Physiological-Clinical']

The O
patients O
were O
randomized O
two O
groups O
before O
surgery O
. O
[]

RESULTS O
There O
was O
no O
effect O
of O
group O
assignment O
on O
parent-child O
interaction O
characteristics O
or O
on O
any O
child O
outcomes O
. O
[]

Sertraline O
had O
no O
effect O
on O
these O
measures O
. O
[]

The O
6-month O
angiographic O
follow-up O
showed O
a O
mean O
minimal B-outcome ['Physiological-Clinical']
luminal I-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
of O
1.57 O
+/- O
0.74 O
mm O
in O
the O
conventional O
group O
versus O
1.93 O
+/- O
0.85 O
mm O
in O
the O
stented O
group O
( O
P O
=.009 O
) O
and O
a O
mean O
diameter B-outcome ['Physiological-Clinical']
stenosis I-outcome ['Physiological-Clinical']
of O
44.7 O
% O
+/- O
25.0 O
% O
versus O
35.5 O
% O
+/- O
26.5 O
% O
( O
P O
=.036 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
670 O
consecutive O
patients O
who O
had O
knee O
arthroplasty O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
and O
total O
tryptophan B-outcome ['Physiological-Clinical']
levels O
were O
obtained O
at O
baseline O
and O
5 O
hours O
after O
the O
drink O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
of O
these O
changes O
in O
flow O
were O
statistically O
more O
common O
for O
the O
circumflex O
coronary O
artery O
and O
early O
treatment O
( O
less O
than O
4 O
h O
) O
, O
but O
did O
not O
differ O
for O
anistreplase O
or O
streptokinase O
. O
[]

In O
contrast O
, O
patients O
with O
AI O
showed O
stable B-outcome ['Physiological-Clinical']
haemodynamics B-outcome ['Physiological-Clinical']
after O
vecuronium O
, O
pancuronium O
and O
the O
pancuronium-metocurine O
mixture O
; O
one O
patient O
became O
tachycardic B-outcome ['Physiological-Clinical']
following O
vecuronium O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Such O
quantitative O
data O
can O
allow O
for O
better O
planning O
and O
selection O
of O
parasiticide O
treatment O
approaches O
at O
the O
farm O
level O
. O
[]

There O
were O
four O
randomised O
treatment O
phases O
, O
each O
of O
4 O
weeks O
duration O
. O
[]

Cardiac B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
investigated O
by O
M-Mode O
and O
2D-echo-cardiography O
. O
['Physiological-Clinical', 'Resource-use']

Actovegin O
is O
a O
protein-free O
metabolically O
active O
hemoderivative O
improving O
oxygen O
and O
glucose O
utilization O
. O
[]

The O
single-item O
Uniscale O
, O
a O
global O
QOL B-outcome ['Life-Impact']
instrument O
, O
found O
comparable O
scores O
. O
['Life-Impact']

INTRODUCTION O
Decreasing O
bone O
density O
and O
muscle O
mass O
and O
increasing O
fat O
mass O
may O
act O
synergistically O
to O
affect O
gait O
and O
balance O
in O
older O
adults O
. O
[]

A O
blind O
, O
randomized O
trial O
of O
antenatal O
glucocorticoid O
treatment O
was O
conducted O
using O
the O
premature O
monkey O
( O
Macaca O
nemestrina O
) O
model O
of O
hyaline O
membrane O
disease O
( O
HMD O
) O
. O
[]

Cases O
were O
followed O
up O
at O
six-monthly O
dermatological O
assessments O
, O
57 O
( O
79 O
% O
) O
for O
18 O
months O
. O
[]

This O
difference O
in O
response O
rate O
was O
also O
confirmed O
by O
survival O
analysis O
. O
[]

The O
starting O
dose O
in O
both O
groups O
was O
20 O
mg/day O
. O
[]

Univariate O
methods O
, O
such O
as O
the O
t O
test O
or O
analysis O
of O
covariance O
, O
can O
not O
evaluate O
the O
efficacy O
of O
interventions O
on O
multiple O
outcomes O
simultaneously O
. O
[]

Thirty-four O
patients O
were O
labeled O
with O
Pervasive O
Developmental O
Disorder O
Not O
Otherwise O
Specified O
, O
and O
22 O
met O
diagnostic O
criteria O
for O
Autistic O
Disorder O
. O
[]

Therefore O
, O
a O
treatment O
with O
Spironolactone O
seems O
to O
have O
no O
effect O
on O
bulimia O
nervosa O
symptoms O
. O
[]

This O
study O
evaluated O
the O
long-term O
effect O
of O
transfusion O
with O
leucocyte-depleted B-outcome ['Physiological-Clinical']
( O
LD O
) O
blood O
in O
patients O
with O
gastrointestinal O
cancer O
. O
['Physiological-Clinical']

At O
baseline O
, O
88 O
% O
of O
the O
patients O
described O
their O
pain O
intensity O
as O
moderate O
; O
12 O
% O
, O
severe O
. O
[]

2 O
. O
[]

Underimmunized O
children O
were O
marginally O
more O
likely O
to O
use O
CAM O
but O
not O
more O
likely O
to O
have O
received O
potentially O
unsafe O
or O
disproven O
CAM O
. O
[]

METHOD O
AND O
RESULTS O
Rates O
of O
virologic B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
were O
similar O
in O
the O
2 O
arms O
at O
week O
16 O
( O
p O
= O
.509 O
) O
. O
['Physiological-Clinical']

At O
3 O
and O
6 O
mo O
, O
the O
cumulative O
percentages O
of O
patients O
with O
recurrence B-outcome ['Physiological-Clinical']
were O
29 O
% O
and O
56 O
% O
after O
antacid O
therapy O
and O
36 O
% O
and O
55 O
% O
after O
cimetidine O
therapy O
. O
['Physiological-Clinical']

About O
40 O
children O
between O
the O
ages O
three O
and O
11 O
years O
( O
inclusive O
) O
with O
a O
DSM O
IV O
clinical O
diagnosis O
of O
autism O
and O
who O
were O
outpatients O
from O
a O
specialty O
clinic O
for O
children O
were O
recruited O
. O
[]

Craniospinal O
irradiation O
consisted O
of O
CRT O
+ O
1400 O
rad O
in O
ten O
fractions O
to O
the O
spine O
. O
[]

These O
include O
infant O
illness O
and O
maternal O
responsibilities O
outside O
the O
home O
, O
both O
requiring O
separation O
from O
the O
mother O
. O
[]

Analgesia O
was O
initiated O
with O
intrathecal O
bupivacaine O
0.25 O
% O
1 O
mL O
+ O
sufentanil O
5 O
microg O
in O
the O
combined O
spinal-epidural O
group O
( O
n O
= O
54 O
) O
, O
and O
with O
bupivacaine O
0.125 O
% O
+ O
epinephrine O
2.5 O
microg O
mL O
( O
-1 O
) O
+ O
sufentanil O
7.5 O
microg O
in O
the O
epidural O
group O
( O
n O
= O
59 O
) O
. O
[]

METHODS O
Patients O
( O
n O
= O
160 O
; O
mean O
age O
, O
21.2 O
years O
; O
63 O
% O
males O
) O
with O
CO O
GHD O
were O
randomised O
2:1 O
to O
GH O
or O
no O
treatment O
for O
24 O
months O
. O
[]

Methotrexate O
in O
the O
treatment O
of O
steroid-dependent O
asthma O
. O
[]

European O
Lung O
Cancer O
Working O
Party O
. O
[]

A O
postablation O
syndrome O
was O
documented O
in O
13 O
patients O
( O
1 O
PLA O
; O
12 O
RFA O
) O
. O
[]

There O
were O
no O
critical O
changes O
in O
heart B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

PURPOSE O
This O
study O
examined O
the O
influence O
of O
preexercise O
food O
intake O
on O
plasma B-outcome ['Physiological-Clinical']
pseudoephedrine I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PSE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
and O
subsequent O
high-intensity B-outcome ['Life-Impact']
exercise I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
Thirty-seven O
patients O
were O
enrolled O
, O
19 O
( O
6 O
females O
, O
median O
age O
43 O
) O
in O
the O
24 O
week O
and O
18 O
( O
5 O
females O
, O
median O
age O
40 O
) O
in O
the O
48 O
week O
treatment O
arm O
. O
[]

Tissue O
samples O
from O
93 O
de O
novo O
diffuse O
large O
B-cell O
lymphoma O
patients O
seen O
between O
1995 O
and O
2009 O
randomly O
receiving O
either O
standard O
combination O
chemotherapy O
( O
CHOP O
, O
n=48 O
) O
or O
the O
identical O
program O
with O
rituximab O
( O
n=45 O
) O
were O
subtyped O
using O
an O
investigational O
immunohistochemical O
( O
IHC O
) O
based O
tissue O
microarray O
( O
TMA O
) O
and O
contrasted O
to O
the O
approximately O
corresponding O
categories O
as O
defined O
either O
by O
Hans O
and O
associates O
using O
a O
three O
marker O
panel O
into O
germinal O
or O
non-germinal O
centre O
subtypes O
or O
by O
Choi O
and O
colleagues O
with O
two O
additional O
antibodies O
into O
germinal O
centre O
( O
GCB O
) O
or O
activated O
B-cells O
( O
ABC O
) O
. O
[]

We O
studied O
whether O
type O
, O
dose O
, O
and O
schedule O
of O
IFN O
, O
and O
type O
and O
frequency O
of O
posttreatment O
monitoring O
, O
influence O
the O
response O
rate O
. O
[]

Of O
the O
47 O
complete O
responders O
, O
7 O
, O
or O
14.9 O
% O
, O
have O
relapsed O
, O
with O
the O
median O
duration O
of O
remission O
of O
44+ O
months O
. O
[]

258 O
patients O
were O
evaluated O
. O
[]

The O
concentration O
of O
PGE-2 O
and O
IL-6 O
of O
joint O
fluid O
in O
study O
group O
are O
significantly O
lower O
than O
that O
in O
placebo O
group O
( O
P O
< O
0.01 O
) O
during O
24 O
h O
postoperatively O
. O
[]

AIM O
To O
assess O
the O
effects O
of O
long-term O
peginterferon O
therapy O
and O
disease O
progression O
on O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
, O
symptoms O
and O
sexual O
health O
in O
HALT-C O
patients O
. O
[]

In O
particular O
, O
41 O
% O
of O
the O
bupivacaine O
group O
complained O
of O
some O
degree O
of O
urinary B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
and O
one O
patient O
required O
temporary B-outcome ['Resource-use']
catheterisation I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

Most O
human B-outcome ['Physiological-Clinical']
biting I-outcome ['Physiological-Clinical']
occurred O
in O
the O
early O
evening O
with O
the O
peak O
biting B-outcome ['Life-Impact']
time O
between O
6 O
pm O
and O
7 O
pm O
( O
35 O
% O
) O
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
Both O
groups O
had O
symptom B-outcome ['Life-Impact']
reduction O
. O
['Life-Impact']

Theorists O
have O
long O
debated O
the O
wisdom O
of O
therapists O
disclosing B-outcome ['Life-Impact']
personal I-outcome ['Life-Impact']
information I-outcome ['Life-Impact']
during O
psychotherapy O
. O
['Life-Impact']

We O
hypothesized O
that O
because O
of O
an O
impaired O
theory-of-mind O
, O
individuals O
with O
AS O
may O
develop O
compensatory O
cognitive O
strategies O
based O
on O
overlearned O
abstract O
knowledge O
about O
normative O
rules O
. O
[]

Patients O
were O
induced O
with O
midazolam O
0.1 O
mg/kg O
, O
fentanyl O
5 O
?g/kg O
, O
propofol O
1-1.5 O
mg/kg O
, O
and O
suxamethonium O
1.5 O
mg/kg O
. O
[]

The O
endurance O
training O
programme O
included O
continuous O
running O
at O
an O
intensity O
corresponding O
to O
75-85 O
% O
of O
maximal O
heart O
rate O
, O
while O
resistance O
training O
consisted O
of O
four O
sets O
of O
circuit O
weight O
training O
for O
11 O
stations O
and O
at O
an O
intensity O
corresponding O
to O
50-60 O
% O
of O
one-repetition O
maximum O
. O
[]

DISCUSSION O
These O
findings O
suggest O
that O
a O
feedback-based O
computerized O
intervention O
that O
includes O
normative O
information O
about O
alcohol O
use O
and O
consequences O
may O
be O
more O
effective O
for O
hazardous O
drinking O
students O
who O
are O
experiencing O
higher O
levels O
of O
alcohol-related O
consequences O
. O
[]

SETTING O
Anaesthesia O
Service O
. O
[]

The O
societal O
costs O
were O
high O
, O
but O
no O
significant O
differences O
in O
resource B-outcome ['Resource-use']
use I-outcome ['Resource-use']
or O
in O
total O
['Resource-use']

Differences O
were O
not O
statistically O
significant O
. O
[]

After O
this O
period O
they O
were O
treated O
using O
the O
protocol O
of O
group O
1 O
. O
[]

Equivocal O
improvement O
also O
occurred O
on O
a O
spatial B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
task I-outcome ['Life-Impact']
. O
['Life-Impact']

Our O
results O
replicated O
Izuma B-outcome ['Physiological-Clinical']
et O
al O
. O
['Physiological-Clinical']

One O
third O
were O
randomly O
assigned O
to O
the O
intervention O
( O
INT O
) O
group O
and O
two O
thirds O
to O
follow-up O
only O
. O
[]

RESULTS O
No O
significant O
between O
group O
differences O
were O
found O
for O
WOMAC O
pain B-outcome ['Physiological-Clinical']
over O
the O
16-month O
follow-up O
. O
['Physiological-Clinical']

Minor B-outcome ['Physiological-Clinical']
omental I-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
occurred O
in O
a O
small O
percentage O
of O
each O
group O
, O
while O
serious O
complications O
occurred O
once O
in O
each O
group O
. O
['Physiological-Clinical']

Between-group O
differences O
on O
the O
SDS O
narrowly O
missed O
statistical O
significance O
in O
the O
ITT O
population O
alone O
, O
but O
the O
totality O
of O
data O
suggests O
functional O
improvements O
with O
active O
treatment O
. O
[]

There O
were O
no O
differences O
in O
uterine B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
Doppler I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
at O
five O
days O
( O
P= O
0.54 O
) O
, O
six O
weeks O
( O
P= O
0.47 O
) O
, O
three O
months O
( O
P= O
0.49 O
) O
and O
at O
six O
months O
( O
P= O
0.18 O
) O
. O
['Physiological-Clinical']

INTERVENTION O
Recombinant O
human O
interferon O
gamma O
, O
100 O
micrograms O
, O
was O
administered O
subcutaneously O
once O
daily O
for O
21 O
days O
( O
or O
until O
patient O
discharge O
if O
prior O
to O
21 O
days O
) O
as O
an O
adjunct O
to O
standard O
antibiotic O
and O
supportive O
therapy O
. O
[]

The O
effect O
of O
surgical O
trauma O
and O
insulin O
on O
whole-body B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
in O
parenterally-fed O
undernourished O
patients O
. O
['Physiological-Clinical']

No O
other O
subject O
characteristics O
were O
correlated O
with O
tidal B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Two O
subjects O
receiving O
VPA O
developed O
increased O
serum B-outcome ['Physiological-Clinical']
ammonia I-outcome ['Physiological-Clinical']
levels O
, O
one O
with O
an O
associated O
parent O
report O
of O
['Physiological-Clinical']

At O
post-testing O
, O
the O
CFT O
group O
was O
superior O
to O
the O
DTC O
group O
on O
parent O
measures O
of O
social B-outcome ['Life-Impact']
skill I-outcome ['Life-Impact']
and O
play B-outcome ['Life-Impact']
date I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
, O
and O
child O
measures O
of O
popularity B-outcome ['Life-Impact']
and O
loneliness B-outcome ['Life-Impact']
, O
At O
3-month O
follow-up O
, O
parent O
measures O
showed O
significant O
improvement O
from O
baseline O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

In O
the O
overall O
sample O
, O
increased O
WMI O
was O
associated O
with O
improved O
scores O
on O
a O
measure O
of O
attention O
and O
improved O
teacher O
ratings O
of O
executive O
function O
. O
[]

Progress O
in O
the O
ability B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
recognize I-outcome ['Life-Impact']
anger I-outcome ['Life-Impact']
in O
the O
SST O
Group O
was O
due O
to O
better O
recognition O
of O
low O
intensity O
stimuli O
on O
adult O
faces O
. O
['Life-Impact']

Variation O
in O
service O
policies O
influenced O
recruitment O
, O
with O
earlier O
assessment O
centres O
seeing O
people O
with O
more O
frequent O
episodes B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
self-harm I-outcome ['Life-Impact']
and O
greater O
parasuicide O
risk O
than O
later O
ones O
. O
['Life-Impact', 'Life-Impact']

CONCLUSIONS O
Desvenlafaxine O
50 O
mg/d O
was O
efficacious O
for O
treating O
MDD O
in O
gainfully O
employed O
adults O
. O
[]

Cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
( O
CO B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
an O
open-labelled O
, O
randomized O
, O
placebo-controlled O
cross-over O
study O
with O
16 O
non-asthmatic O
SAR O
patients O
( O
median O
age O
25 O
years O
, O
56 O
% O
males O
) O
, O
the O
effect O
of O
a O
single O
nasal O
allergen O
challenge O
performed O
out O
of O
season O
on O
induced O
sputum B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
parameters O
was O
evaluated O
. O
['Physiological-Clinical']

Employment O
rates O
are O
reported O
in O
many O
studies O
to O
be O
very O
low O
despite O
many O
years O
of O
intensive O
special O
education O
services O
. O
[]

11.52 O
, O
final O
23.32 O
? O
[]

Torasemide O
versus O
furosemide O
in O
cirrhosis O
: O
a O
long-term O
, O
double-blind O
, O
randomized O
clinical O
study O
. O
[]

[ O
Long-term O
effects O
of O
7-year O
growth O
hormone O
substitution O
on O
bone B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
, O
bone B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
, O
and O
bone B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
in O
growth O
hormone-deficient O
adults O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Need O
the O
thumb O
be O
immobilised O
in O
scaphoid O
fractures O
? O
[]

DESIGN O
Following O
a O
2-week O
, O
single-blind O
placebo O
washout O
phase O
, O
12 O
autistic O
subjects O
completed O
a O
10-week O
, O
double-blind O
, O
crossover O
comparison O
of O
clomipramine O
and O
placebo O
, O
and O
12 O
different O
subjects O
completed O
a O
similar O
comparison O
of O
clomipramine O
and O
desipramine O
. O
[]

The O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hTERT I-outcome ['Physiological-Clinical']
decreased O
in O
the O
two O
groups O
after O
treatment O
, O
showing O
statistical O
difference O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Patients O
with O
essential O
hypertension O
( O
65-85 O
years O
old O
, O
with O
a O
pretreatment O
systolic O
blood O
pressure O
of O
above O
160 O
mmHg O
) O
were O
randomly O
assigned O
to O
receive O
strict O
treatment O
( O
n=2,212 O
) O
or O
mild O
treatment O
( O
n=2,206 O
) O
. O
[]

However O
, O
the O
decreased O
5 O
alpha-reduction O
of O
testosterone O
to O
dihydrotestosterone O
is O
the O
only O
impaired O
steroid O
conversion O
to O
have O
clinical O
consequences O
, O
e.g. O
, O
ambiguous B-outcome ['Physiological-Clinical']
genitalia I-outcome ['Physiological-Clinical']
, O
impaired B-outcome ['Physiological-Clinical']
prostate I-outcome ['Physiological-Clinical']
differentiation I-outcome ['Physiological-Clinical']
and O
development O
, O
and O
decreased O
facial B-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
hair I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Five O
standardised O
, O
superficial O
abrasions O
were O
induced O
on O
their O
forearms O
by O
repeatedly O
scrubbing O
the O
skin O
with O
a O
surgical O
brush O
until O
the O
first O
signs O
of O
uniform O
glistening O
and O
punctuate O
bleeding O
were O
observed O
. O
[]

Perioperative O
antibiotics O
decrease O
surgical B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SWI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
trauma O
patients O
requiring O
abdominal O
exploration O
. O
['Physiological-Clinical']

Ventilation B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
was O
pneumotachy-graphically O
recorded O
. O
['Physiological-Clinical']

The O
baseline O
median O
plasma B-outcome ['Physiological-Clinical']
HIV-1 I-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
level O
was O
4.89 O
log10 O
copies/mL O
( O
44 O
% O
with O
viral O
load O
> O
100,000 O
copies/mL O
) O
, O
and O
the O
median O
CD4 O
cell O
count O
was O
262 O
cells/mm O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
Using O
a O
crossover O
design O
, O
40 O
subjects O
randomly O
received O
, O
in O
a O
double-blind O
manner O
, O
P-ASA O
injections O
of O
1.4 O
mL O
of O
2 O
% O
lidocaine O
with O
1:100,000 O
epinephrine O
and O
1.4 O
mL O
of O
3 O
% O
mepivacaine O
, O
at O
2 O
separate O
appointments O
. O
[]

INTERVENTIONS O
PDT O
with O
the O
Ciaglia O
technique O
using O
the O
Ciaglia O
PDT O
introducer O
set O
and O
the O
Griggs O
technique O
using O
a O
Griggs O
PDT O
kit O
and O
guidewire O
dilating O
forceps O
. O
[]

METHODS O
Thirty O
patients O
undergoing O
primary O
ICD O
implantation O
or O
pulse O
generator O
replacement O
were O
randomly O
assigned O
to O
have O
the O
DFT O
determined O
using O
biphasic O
shocks O
at O
two O
durations O
of O
VF O
each O
( O
5 O
and O
10 O
s O
, O
10 O
and O
20 O
s O
or O
5 O
and O
20 O
s O
) O
. O
[]

SD O
calculated O
GFR O
at O
year O
5 O
was O
55.9 O
? O
[]

Evaluation O
of O
the O
efficacy O
and O
safety O
of O
the O
ophthalmic O
insert O
Mydriasert O
in O
patients O
undergoing O
retinal O
angiography O
. O
[]

At O
15,000 O
PNU O
, O
blocking B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
levels O
were O
not O
statistically O
different O
in O
the O
2 O
groups O
. O
['Physiological-Clinical']

7 O
% O
) O
recipients O
for O
subjects O
receiving O
5 O
?g O
or O
25 O
?g O
of O
VLP O
immunotherapy/dose O
( O
71 O
% O
? O
[]

CONCLUSIONS O
The O
presence O
of O
spotty O
calcification O
is O
associated O
with O
more O
extensive O
and O
diffuse O
coronary O
atherosclerosis O
and O
accelerated O
disease O
progression O
despite O
use O
of O
medical O
therapies O
. O
[]

Low-dose O
oral O
etoposide-based O
induction O
regimen O
for O
children O
with O
acute O
lymphoblastic O
leukemia O
in O
first O
bone O
marrow O
relapse O
. O
[]

Focus O
group O
discussion O
revealed O
unanticipated O
information O
about O
sociocultural B-outcome ['Life-Impact']
influences I-outcome ['Life-Impact']
on O
participants O
' O
understanding B-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
hepatitis I-outcome ['Life-Impact']
B I-outcome ['Life-Impact']
transmission O
, O
disease B-outcome ['Life-Impact']
course O
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Thus O
, O
in O
patients O
with O
IDC O
, O
an O
extensive O
contractile O
reserve O
identified O
by O
high-dose O
dobutamine O
stress O
echocardiography O
is O
associated O
with O
a O
better O
survival B-outcome ['Mortality']
. O
['Mortality']

The O
students O
taught O
on O
an O
integrated O
course O
showed O
a O
much O
greater O
range O
of O
results O
. O
[]

While O
hand-excavated O
, O
bur-excavated O
and O
air-abraded O
carious O
dentin O
surfaces O
were O
covered O
with O
a O
residual O
smear B-outcome ['Physiological-Clinical']
layer I-outcome ['Physiological-Clinical']
, O
sono-abrasion O
with O
patent O
dentinal O
tubules O
completely O
removed O
the O
smear O
layer O
. O
['Physiological-Clinical']

PURPOSE O
The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
enhanced O
milieu O
teaching O
( O
EMT O
) O
implemented O
by O
parents O
and O
therapists O
versus O
therapists O
only O
on O
the O
language O
skills O
of O
preschool O
children O
with O
intellectual O
disabilities O
( O
IDs O
) O
, O
including O
children O
with O
Down O
syndrome O
and O
children O
with O
autism O
spectrum O
disorders O
. O
[]

The O
third O
mother O
was O
taught O
to O
use O
RIT O
to O
target O
both O
object O
and O
gesture O
imitation O
in O
a O
multiple-baseline O
design O
across O
behaviors O
. O
[]

The O
addition O
of O
tamoxifen O
to O
epirubicin O
resulted O
in O
a O
suppression O
of O
a O
key O
angiogenic B-outcome ['Physiological-Clinical']
pathway O
. O
['Physiological-Clinical']

Humoral B-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
tetanus-diphtheria O
vaccine O
given O
during O
extended O
use O
of O
chloroquine O
or O
primaquine O
malaria O
chemoprophylaxis O
. O
['Physiological-Clinical']

Autologous O
cytokine-induced O
killer O
( O
CIK O
) O
cells O
were O
transfused O
via O
hepatic O
artery O
to O
the O
patients O
. O
[]

A O
major O
problem O
in O
the O
interpretation O
of O
the O
results O
was O
the O
use O
of O
semicurative O
radiation O
therapy O
( O
3000 O
to O
4200 O
cGy O
) O
to O
the O
primary O
tumor O
and O
mediastinum O
, O
which O
was O
given O
with O
symptomatic O
intent O
. O
[]

The O
components O
of O
physical O
fitness O
measured O
included O
cardiovascular B-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
, O
muscular B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
and O
endurance B-outcome ['Physiological-Clinical']
and O
flexibility B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

We O
administered O
sivelestat O
to O
patients O
with O
septic O
acute O
lung O
injury O
( O
ALI O
) O
to O
examine O
its O
usefulness O
. O
[]

The O
effect O
of O
phenytoin O
on O
the O
absorption O
of O
synthetic O
folic O
acid O
polyglutamate O
. O
[]

The O
mean O
decrease O
in O
Hb B-outcome ['Physiological-Clinical']
( O
g/L O
) O
at O
3 O
months O
adjusted O
for O
co-variates O
was O
significantly O
less O
in O
the O
delayed O
clamping O
group O
compared O
to O
the O
early O
clamping O
group O
( O
-1.09 O
, O
95 O
% O
CI-1.58 O
to O
-0.62 O
, O
p O
> O
0.001 O
) O
. O
['Physiological-Clinical']

Increased O
fibrinolytic B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
was O
indicated O
by O
elevated O
activity O
and O
reduced O
antigen O
levels O
of O
tissue O
plasminogen O
activator O
and O
reduced O
activity O
and O
concentration O
of O
tissue B-outcome ['Physiological-Clinical']
plasminogen B-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Safety O
and O
tolerability B-outcome ['Life-Impact']
were O
satisfactory O
throughout O
the O
study O
. O
['Life-Impact']

5.0 O
in O
the O
ARB O
group O
vs. O
4.8 O
? O
[]

In O
the O
cross-sectional O
study O
40 O
children O
from O
the O
hypertensive O
subgroup O
and O
40 O
children O
from O
the O
normotensive O
subgroup O
were O
evaluated O
. O
[]

Pharmacogenetic O
interaction O
analysis O
for O
the O
efficacy O
of O
systemic O
treatment O
in O
metastatic O
colorectal O
cancer O
. O
[]

METHODS O
AND O
RESULTS O
Nineteen O
patients O
entered O
the O
study O
. O
[]

Both O
treatments O
significantly O
improved O
airway B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
, O
whereas O
SFC O
generally O
led O
to O
greater O
improvements O
in O
symptom B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
than O
FP/M O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Complaints B-outcome ['Life-Impact']
, O
measured O
as O
percentage O
of O
days O
per O
week O
with O
upper B-outcome ['Physiological-Clinical']
abdominal I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
were O
significantly O
reduced O
in O
both O
groups O
. O
['Life-Impact', 'Physiological-Clinical']

Radiography O
showed O
a O
slow O
progression O
in O
the O
damage B-outcome ['Physiological-Clinical']
score O
and O
number O
of O
eroded B-outcome ['Physiological-Clinical']
joints I-outcome ['Physiological-Clinical']
in O
both O
treatment O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

On O
September O
27 O
, O
2006 O
, O
the O
U.S. O
Food O
and O
Drug O
Administration O
granted O
accelerated O
approval O
to O
panitumumab O
( O
Vectibix O
; O
Amgen O
, O
Inc. O
, O
Thousand O
Oaks O
, O
CA O
) O
for O
the O
treatment O
of O
patients O
with O
epidermal O
growth O
factor O
receptor-expressing O
, O
metastatic O
colorectal O
carcinoma O
with O
disease O
progression O
on O
or O
following O
fluoropyrimidine- O
, O
oxaliplatin- O
, O
and O
irinotecan-containing O
chemotherapy O
regimens O
. O
[]

Recent O
work O
has O
shown O
that O
expectancy O
manipulation O
can O
alter O
perceptions O
of O
aversive O
events O
and O
concomitant O
brain O
activation O
. O
[]

In O
this O
retrospective O
analysis O
, O
pooled O
efficacy O
and O
safety O
data O
are O
presented O
according O
to O
HLA-A*0201 O
status O
and O
dose O
from O
pretreated O
patients O
randomized O
to O
0.3 O
, O
3 O
, O
or O
10 O
mg/kg O
ipilimumab O
in O
four O
phase O
II O
trials O
. O
[]

Overall O
, O
no O
statistically O
significant O
changes O
in O
CRP B-outcome ['Physiological-Clinical']
, O
IL-6 B-outcome ['Physiological-Clinical']
, O
IL-10 B-outcome ['Physiological-Clinical']
, O
and O
sTNF-R2 B-outcome ['Physiological-Clinical']
were O
observed O
after O
the O
vitamin O
D O
supplementation O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

ACE O
inhibitors O
are O
reported O
to O
increase O
prostaglandins O
. O
[]

CONCLUSION O
Vitrectomy O
, O
PVD O
with O
or O
without O
ILM O
removal O
does O
not O
improve O
vision O
in O
patients O
with O
DM O
type O
2 O
and O
cystoid O
diabetic O
macular O
edema O
without O
evident O
vitreoretinal O
traction O
. O
[]

An O
explorative O
study O
on O
the O
clinical O
utility O
of O
baseline O
and O
serial O
serum O
tumour O
marker O
measurements O
in O
advanced O
upper O
gastrointestinal O
cancer O
. O
[]

CONCLUSIONS O
Periodontal O
treatment O
leads O
to O
a O
significant O
reduction O
of O
self-perceived B-outcome ['Life-Impact']
impacts I-outcome ['Life-Impact']
regardless O
of O
the O
non-surgical O
treatment O
protocol O
employed O
. O
['Life-Impact']

The O
main O
safety O
outcomes O
were O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
and O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

OBJECTIVE O
The O
standard O
opioid O
treatment O
for O
postoperative O
pain O
can O
be O
associated O
with O
nausea O
, O
vomiting O
, O
and O
constipation O
. O
[]

The O
data O
were O
registered O
in O
an O
Excel O
spreadsheet O
and O
analysed O
with O
SAS O
. O
[]

METHODS O
1692 O
patients O
who O
were O
refractory O
to O
or O
intolerant O
of O
their O
latest O
chemotherapy O
regimen O
were O
randomly O
assigned O
in O
a O
ratio O
of O
two O
to O
one O
either O
gefitinib O
( O
250 O
mg/day O
) O
or O
placebo O
, O
plus O
best O
supportive O
care O
. O
[]

METHODS/DESIGN O
A O
total O
of O
210 O
participants O
with O
low O
back O
pain O
lasting O
at O
least O
3 O
months O
will O
be O
recruited O
from O
primary O
care O
clinics O
of O
a O
large O
healthcare O
system O
based O
in O
Seattle O
. O
[]

AIM O
To O
determine O
whether O
immunotherapy O
with O
HPV6 O
L1 O
virus O
like O
particles O
( O
VLPs O
) O
without O
adjuvant O
( O
VLP O
immunotherapy O
) O
reduces O
recurrence O
of O
genital B-outcome ['Physiological-Clinical']
warts I-outcome ['Physiological-Clinical']
following O
destructive O
therapy O
. O
['Physiological-Clinical']

Corticosteroids O
may O
interact O
with O
non-depolarizing O
muscle O
relaxants O
both O
in O
prejunctional O
and O
postjunctional O
acetylcholine O
receptors O
by O
several O
mechanisms O
of O
action O
. O
[]

The O
first O
study O
utilized O
bleomycin O
, O
Cytoxan O
, O
methotrexate O
and O
5-fluorouracil O
in O
two O
cycles O
( O
one O
cycle O
if O
no O
tumor O
response O
) O
, O
followed O
by O
standard O
treatment O
which O
consisted O
of O
combined O
irradiation O
and O
surgery O
or O
, O
in O
some O
instances O
, O
primary O
irradiation O
alone O
. O
[]

Predictors O
and O
moderators O
of O
parent O
training O
efficacy O
in O
a O
sample O
of O
children O
with O
autism O
spectrum O
disorders O
and O
serious O
behavioral O
problems O
. O
[]

TRIAL O
REGISTRATION O
NUMBER O
ISRCTN70410203 O
. O
[]

The O
[]

In O
conclusion O
, O
tolrestat O
improved O
autonomic B-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
definite O
DAN O
, O
in O
comparison O
to O
baseline O
and O
placebo O
. O
['Physiological-Clinical']

SUBJECTS O
Randomised O
arm O
: O
421 O
participants O
with O
low O
back O
pain O
, O
with O
median O
duration O
of O
10 O
weeks O
. O
[]

Serum O
samples O
were O
obtained O
at O
Baseline O
and O
Week-8 O
( O
N O
= O
78 O
) O
, O
and O
at O
6-month O
( O
N O
= O
43 O
) O
and O
22-month O
( O
N O
= O
30 O
) O
follow-up O
. O
[]

Oesophageal O
intubation O
can O
be O
undetected O
by O
auscultation O
of O
the O
chest O
. O
[]

The O
effects O
receded O
a O
few O
weeks O
after O
cessation O
of O
the O
endurance O
exercise O
. O
[]

Although O
it O
is O
very O
effective O
for O
rate O
control O
, O
up O
to O
an O
18 O
% O
prevalence O
of O
reported O
diltiazem-induced B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
[ O
defined O
by O
systolic O
blood O
pressure O
( O
SBP O
) O
< O
90 O
mm O
Hg O
] O
, O
and O
a O
mean O
of O
9.7 O
% O
hypotension B-outcome ['Physiological-Clinical']
have O
been O
reported O
from O
several O
studies O
totaling O
over O
450 O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
A O
total O
of O
476 O
patients O
were O
randomly O
assigned O
2:1 O
to O
imatinib O
800 O
mg O
( O
n O
= O
319 O
) O
or O
400 O
mg O
( O
n O
= O
157 O
) O
daily O
. O
[]

Hip O
replacement O
surgery O
is O
associated O
with O
a O
high O
frequency O
of O
postoperative O
deep O
vein O
thrombosis O
. O
[]

In O
this O
clinical O
trial O
, O
90 O
Brazilian O
women O
, O
diagnosed O
to O
CIN2 O
and O
high-risk O
human O
papillomavirus O
infection O
, O
were O
randomized O
into O
two O
groups O
of O
equal O
size O
: O
45 O
women O
whose O
lesions O
were O
excised O
and O
45 O
women O
subjected O
to O
prospective O
follow-up O
at O
3-month O
intervals O
at O
least O
for O
1 O
year O
( O
mean O
6.8 O
months O
) O
. O
[]

METHODS O
In O
this O
52-week O
, O
multicentre O
, O
randomised O
, O
double-blind O
, O
parallel-group O
study O
, O
male O
and O
female O
patients O
( O
aged O
at O
least O
40 O
years O
) O
with O
symptomatic O
primary O
OA O
of O
the O
hip O
, O
knee O
, O
hand O
or O
spine O
were O
randomised O
( O
1:2:1 O
) O
to O
lumiracoxib O
100 O
mg O
o.d O
. O
( O
[]

The O
instilled O
doses O
of O
doxorubicin O
and O
mitoxantrone O
were O
30 O
and O
14 O
mg O
, O
respectively O
. O
[]

TnT B-outcome ['Physiological-Clinical']
elevation I-outcome ['Physiological-Clinical']
was O
observed O
in O
36 O
patients O
( O
51 O
% O
) O
already O
before O
surgery O
. O
['Physiological-Clinical']

The O
control O
group O
consisted O
of O
17 O
patients O
who O
did O
not O
receive O
finasteride O
before O
surgery O
. O
[]

RESULTS O
There O
were O
no O
main O
effects O
of O
the O
HMTW O
intervention O
on O
either O
parental B-outcome ['Life-Impact']
responsivity I-outcome ['Life-Impact']
or O
children B-outcome ['Physiological-Clinical']
's O
communication B-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

[ O
Treatment O
of O
irresectable O
hepatocellular O
carcinoma O
with O
repeated O
transient O
dearterialization O
] O
. O
[]

The O
recent O
availability O
of O
World O
Wide O
Web-based O
directories O
has O
opened O
up O
a O
new O
approach O
for O
tracing O
subjects O
in O
epidemiologic O
studies O
. O
[]

In O
the O
fluoxetine O
group O
, O
8 O
( O
30.8 O
% O
) O
patients O
cured B-outcome ['Physiological-Clinical']
, O
11 O
( O
42.2 O
% O
) O
showed O
improvement O
and O
there O
were O
7 O
failures B-outcome ['Physiological-Clinical']
( O
26.9 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Conflicting O
evidence O
exists O
regarding O
this O
. O
[]

Effects O
of O
supervised O
exercise O
therapy O
in O
patients O
receiving O
radiotherapy O
for O
breast O
cancer O
. O
[]

The O
results O
of O
these O
cultures O
demonstrated O
a O
significant O
bioburden B-outcome ['Physiological-Clinical']
( O
greater O
than O
10 O
( O
5 O
) O
) O
in O
the O
majority O
of O
cases O
, O
despite O
a O
lack O
of O
clinical O
signs O
of O
infection O
. O
['Physiological-Clinical']

In O
the O
intervention O
group O
, O
42 O
women O
( O
33 O
% O
) O
conceived O
, O
of O
which O
29 O
pregnancies O
were O
ongoing O
( O
23 O
% O
) O
. O
[]

The O
levels O
of O
serum B-outcome ['Physiological-Clinical']
MDA I-outcome ['Physiological-Clinical']
and O
SOD B-outcome ['Physiological-Clinical']
activity O
were O
assayed O
by O
chemical O
colorimetry O
, O
and O
other O
indices O
, O
including O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
lipids B-outcome ['Physiological-Clinical']
and O
hepatic/renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
were O
measured O
at O
baseline O
and O
after O
4 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
laparoscopic O
approach O
was O
associated O
with O
a O
longer O
operative O
time O
( O
234.1 O
min O
vs O
137.3 O
min O
) O
but O
was O
less O
painful B-outcome ['Physiological-Clinical']
( O
VAS O
5.3 O
vs O
7.9 O
; O
P O
< O
0.000 O
) O
and O
resulted O
in O
a O
shorter O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
4.4+/-1 O
vs O
7.9+/-1.2 O
days O
; O
P O
< O
0.000 O
) O
. O
['Physiological-Clinical', 'Resource-use']

The O
three O
scales O
, O
Physiological O
Tension O
, O
Physical O
Assessment O
, O
and O
Cognitive O
Tension O
, O
demonstrated O
adequate O
internal O
consistency O
with O
KR20 O
reliability O
coefficients O
of O
.89 O
, O
.95 O
, O
and O
.81 O
, O
respectively O
. O
[]

INTERVENTIONS O
Participants O
were O
initially O
randomized O
to O
either O
wait-list O
control O
( O
WLC O
) O
or O
treatment O
groups O
to O
receive O
either O
individualized O
CHM O
decoctions O
or O
a O
therapeutically O
inert O
placebo O
decoction O
. O
[]

This O
stage O
has O
the O
best O
chances O
for O
a O
drug O
or O
a O
surgical O
therapy O
. O
[]

METHODS O
In O
a O
randomized O
controlled O
study O
, O
20 O
healthy O
women O
( O
median O
age O
33 O
years O
, O
range O
21-47 O
; O
phototype O
I/II O
) O
ingested O
55 O
g O
tomato O
paste O
( O
16 O
mg O
lycopene O
) O
in O
olive O
oil O
, O
or O
olive O
oil O
alone O
, O
daily O
for O
12 O
weeks O
. O
[]

RESULTS O
Pulse B-outcome ['Physiological-Clinical']
and O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
were O
related O
positively O
to O
each O
other O
, O
age O
, O
ejection O
fraction O
and O
prevalence O
of O
diabetes O
and O
hypertension O
and O
inversely O
to O
prior O
myocardial O
infarction O
and O
beta-adrenergic O
blocking O
agent O
use O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
in O
the O
MVPF O
film O
group O
also O
reported O
significantly O
less O
difficulty O
in O
wound B-outcome ['Physiological-Clinical']
care I-outcome ['Physiological-Clinical']
and O
in O
dressing B-outcome ['Life-Impact']
interference I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Cardiovascular O
effects O
of O
non-depolarizing O
neuromuscular O
blockers O
in O
patients O
with O
aortic O
valve O
disease O
. O
[]

RESULTS O
The O
mean O
changes O
in O
AUA O
symptom B-outcome ['Physiological-Clinical']
score O
from O
baseline O
to O
end O
point O
were O
statistically O
significant O
in O
all O
groups O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

2.8 O
) O
, O
( O
12.1 O
? O
[]

OBJECTIVE O
To O
explore O
the O
effect O
of O
Zengjing O
Capsule O
No O
. O
[]

High O
fat O
meals O
induce O
upright B-outcome ['Physiological-Clinical']
GER I-outcome ['Physiological-Clinical']
in O
normals O
, O
but O
do O
not O
significantly O
affect O
the O
abnormal O
amount O
of O
GER O
in O
patients O
. O
['Physiological-Clinical']

In O
contrast O
, O
there O
were O
treatment O
effects O
on O
child O
communication O
gains O
to O
Time O
3 O
that O
were O
moderated O
by O
children O
's O
Time O
1 O
object O
interest O
. O
[]

OBJECTIVES O
Previous O
reports O
, O
involving O
hypercholesterolaemic O
hypertensive O
subjects O
, O
that O
statins O
reduce O
muscle O
sympathetic O
nerve O
activity O
( O
MSNA O
) O
did O
not O
investigate O
potential O
neural O
sites O
of O
such O
sympathoinhibition O
or O
determine O
its O
consequences O
for O
endothelial O
function O
or O
insulin O
resistance O
. O
[]

Differences O
between O
the O
two O
groups O
were O
significant O
( O
p O
less O
than O
0.05 O
) O
. O
[]

Assessing O
drug O
use O
prevalence O
in O
the O
workplace O
: O
a O
comparison O
of O
self-report O
methods O
and O
urinalysis O
. O
[]

Data O
from O
107 O
patients O
were O
included O
in O
the O
intent-to-treat O
( O
ITT O
) O
analysis O
. O
[]

Patients O
were O
randomized O
to O
dual-chamber O
pacemaker O
implant O
( O
paced O
patients O
) O
or O
standard O
treatment O
( O
controls O
) O
. O
[]

YDJ O
external O
lotion O
and O
YDJ O
cream O
were O
applied O
to O
patients O
in O
the O
treatment O
group O
, O
while O
normal O
saline O
was O
applied O
for O
those O
in O
the O
control O
group O
. O
[]

This O
pilot O
, O
randomized O
controlled O
trial O
evaluated O
the O
feasibility B-outcome ['Life-Impact']
and O
preliminary O
outcomes O
of O
the O
Multimodal O
Anxiety O
and O
Social O
Skills O
Intervention O
( O
MASSI O
) O
program O
in O
a O
sample O
of O
30 O
adolescents O
with O
ASD O
and O
anxiety O
symptoms O
of O
moderate O
or O
greater O
severity O
. O
['Life-Impact']

CONCLUSION O
Communication O
skill O
training O
delivered O
in O
a O
computer O
mediated O
format O
had O
a O
positive O
and O
parallel B-outcome ['Physiological-Clinical']
impact I-outcome ['Physiological-Clinical']
on O
both O
patient O
and O
clinician O
reported O
use O
of O
patient-centered B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
and O
in O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

The O
LKSS B-outcome ['Physiological-Clinical']
by O
the O
end O
of O
the O
treatment O
was O
higher O
in O
the O
treatment O
group O
than O
in O
the O
control O
group O
( O
P O
< O
0.05 O
) O
. O
( O
['Physiological-Clinical']

Behavior O
in O
children O
with O
Down O
syndrome O
. O
[]

The O
other O
group O
had O
laparoscopy O
, O
followed O
by O
open O
appendicectomy O
only O
if O
the O
appendix O
was O
seen O
to O
be O
inflamed O
or O
was O
not O
visualized O
. O
[]

Effectiveness O
of O
a O
clinical O
intervention O
in O
improving O
pain O
control O
in O
outpatients O
with O
cancer O
treated O
by O
radiation O
therapy O
. O
[]

LP O
mink O
had O
a O
lower O
liver B-outcome ['Physiological-Clinical']
, O
pancreas B-outcome ['Physiological-Clinical']
and O
kidney B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
as O
well O
as O
lower O
plasma B-outcome ['Physiological-Clinical']
IGF-1 I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
at O
8 O
and O
25 O
( O
p O
< O
0.05 O
) O
weeks O
, O
and O
a O
higher O
incidence O
of O
hepatic B-outcome ['Physiological-Clinical']
lipidosis I-outcome ['Physiological-Clinical']
at O
25 O
weeks O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Further O
studies O
are O
required O
to O
document O
the O
clinical O
consequences O
of O
this O
finding O
, O
for O
example O
in O
severe O
asthmatic O
patients O
. O
[]

The O
final O
results O
. O
[]

RESULTS O
Children O
with O
FASD O
were O
more O
variable O
in O
saccade B-outcome ['Physiological-Clinical']
endpoint O
accuracy B-outcome ['Physiological-Clinical']
, O
which O
was O
reflected O
by O
statistically O
significant O
increases O
in O
the O
error O
of O
the O
initial B-outcome ['Physiological-Clinical']
saccade I-outcome ['Physiological-Clinical']
endpoint O
and O
the O
frequency O
of O
additional O
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
P+EN O
group O
, O
patients O
were O
given O
their O
nutrition O
the O
same O
as O
that O
of O
EN O
, O
and O
also O
probiotics O
( O
bifidobacterium O
, O
4 O
capsules O
every O
12 O
hours O
, O
given O
through O
nasal O
gastric O
tube O
, O
each O
capsule O
weighing O
210 O
mg O
) O
. O
[]

Exposure O
to O
the O
self-face O
facilitates O
identification O
of O
dynamic B-outcome ['Life-Impact']
facial I-outcome ['Life-Impact']
expressions I-outcome ['Life-Impact']
: O
influences O
on O
individual O
differences O
. O
['Life-Impact']

Human O
primary O
visual O
cortex O
( O
V1 O
) O
is O
selective O
for O
second-order O
spatial O
frequency O
. O
[]

After O
LM O
, O
postoperative B-outcome ['Physiological-Clinical']
adhesions I-outcome ['Physiological-Clinical']
were O
evaluated O
by O
second-look B-outcome ['Resource-use']
laparoscopy I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

[ O
Impact O
of O
heparin O
on O
coagulation B-outcome ['Physiological-Clinical']
index O
during O
the O
therapy O
of O
molecular O
adsorbent O
recirculating O
system O
in O
patients O
with O
liver O
failure O
] O
. O
['Physiological-Clinical']

Treatment O
of O
acute O
asthma O
. O
[]

There O
was O
no O
difference O
in O
the O
proportion O
of O
subjects O
achieving O
tacrolimus O
trough O
levels O
?10 O
ng/mL O
( O
82.9 O
% O
Control O
vs O
93.0 O
% O
T2 O
; O
P=0.19 O
) O
or O
between O
10 O
and O
15 O
ng/mL O
( O
41.5 O
% O
Control O
vs O
41.9 O
% O
T2 O
; O
P=0.97 O
) O
at O
day O
3 O
post O
transplant O
. O
[]

All O
assessments O
will O
be O
conducted O
by O
a O
trained O
assessor O
blinded O
to O
treatment O
allocation O
. O
[]

METHODS O
This O
study O
was O
a O
prospective O
clinical O
trial O
that O
compared O
surface B-outcome ['Physiological-Clinical']
EMG I-outcome ['Physiological-Clinical']
dynamic I-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
after O
traditional O
bone O
setting O
and O
physical O
therapy O
. O
['Physiological-Clinical']

Comparison O
of O
the O
Family O
End-of-study O
Up-to-date O
indices O
also O
demonstrated O
that O
families O
of O
patients O
sent O
customized O
letters O
were O
more O
likely O
to O
be O
up-to-date O
than O
families O
not O
sent O
letters O
( O
Kruskal-Wallis O
P O
= O
.0054 O
) O
. O
[]

However O
, O
few O
studies O
have O
shown O
evidence O
for O
their O
effectiveness O
. O
[]

Both O
medications O
were O
well O
tolerated B-outcome ['Life-Impact']
, O
and O
no O
serious O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
during O
the O
study O
. O
['Life-Impact', 'Adverse-effects']

In O
a O
prospective O
, O
randomized O
clinical O
trial O
, O
the O
toxicity O
of O
1 O
mg O
of O
amphotericin O
B O
( O
AmB O
) O
per O
kg O
of O
body O
weight O
per O
day O
infused O
in O
5 O
% O
dextrose O
was O
compared O
with O
that O
of O
AmB O
infused O
in O
lipid O
emulsion O
in O
children O
with O
malignant O
disease O
. O
[]

In O
addition O
, O
there O
was O
statistical O
difference O
in O
the O
accuracy O
of O
prediction O
to O
operative B-outcome ['Resource-use']
procedures I-outcome ['Resource-use']
between O
the O
two O
groups O
( O
94.7 O
% O
vs. O
81.7 O
% O
, O
P O
= O
0.003 O
) O
. O
['Resource-use']

Analysis O
of O
face O
gaze O
in O
autism O
using O
Bubbles O
. O
[]

Patients O
in O
Group O
B O
had O
significantly O
better O
scores O
on O
the O
chair B-outcome ['Life-Impact']
stand I-outcome ['Life-Impact']
test O
( O
13.3 O
compared O
with O
11.1 O
in O
Group O
A O
, O
p O
= O
0.04 O
) O
at O
six O
months O
postoperatively O
, O
but O
there O
was O
no O
difference O
at O
twelve O
months O
( O
14.0 O
compared O
with O
13.6 O
) O
. O
['Life-Impact']

Thirty-six O
patients O
with O
CSX O
were O
randomly O
assigned O
to O
1200 O
mg/d O
of O
Xuezhikang O
or O
placebo O
group O
( O
n=18 O
respectively O
) O
. O
[]

METHODS O
A O
total O
of O
120 O
patients O
, O
American O
Society O
of O
Anesthesiologists O
( O
ASA O
) O
physical O
status O
I-II O
, O
were O
randomized O
into O
two O
equally O
sized O
groups O
( O
n O
= O
60 O
) O
. O
[]

At O
the O
beginning O
of O
the O
study O
, O
45 O
postmenopausal O
women O
were O
assigned O
randomly O
to O
three O
groups O
, O
and O
30 O
women O
completed O
the O
entire O
6 O
months O
of O
the O
study O
. O
[]

The O
other O
intervention O
group O
were O
also O
given O
a O
health O
check O
and O
written O
feedback O
; O
in O
addition O
, O
they O
were O
given O
the O
opportunity O
to O
attend O
their O
general O
practitioner O
to O
discuss O
preventive O
health O
. O
[]

This O
study O
was O
aimed O
at O
assessing O
the O
analgesic O
effect O
of O
the O
intraperitoneal O
administration O
of O
bupivacaine O
and O
morphine O
in O
patients O
undergoing O
laparoscopic O
cholecystectomy O
. O
[]

CONCLUSION O
FZYLG O
can O
increase O
the O
NF-kappa O
B O
expression O
, O
block O
the O
proliferation O
to O
promote O
the O
apoptosis B-outcome ['Physiological-Clinical']
of O
tumor O
cells O
. O
['Physiological-Clinical']

DESIGN O
A O
cohort O
of O
208 O
patients O
with O
retinitis O
pigmentosa O
, O
aged O
18 O
to O
55 O
years O
, O
were O
randomly O
assigned O
to O
1200 O
mg O
of O
docosahexaenoic O
acid O
plus O
15 O
000 O
IU/d O
of O
vitamin O
A O
given O
as O
retinyl O
palmitate O
( O
DHA O
+ O
A O
group O
) O
or O
control O
fatty O
acid O
plus O
15 O
000 O
IU/d O
of O
vitamin O
A O
( O
control O
+ O
A O
group O
) O
and O
followed O
up O
over O
4 O
years O
. O
[]

Terazosin O
and O
enalapril O
had O
a O
comparable O
effect O
on O
resting B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
, O
reducing O
systolic O
( O
SBP B-outcome ['Physiological-Clinical']
) O
and O
diastolic O
( O
DBP B-outcome ['Physiological-Clinical']
) O
blood B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
from O
159.5 O
+/- O
13.9/101.6 O
+/- O
8.8 O
mm O
Hg O
during O
placebo O
by O
7.8 O
% O
/6.7 O
% O
and O
by O
11.3 O
% O
/10.2 O
% O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

To O
assess O
physiologic B-outcome ['Physiological-Clinical']
effects O
, O
practitioners O
and O
subjects O
wore O
cardiorespiratory O
monitors O
to O
assess O
respiratory B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability O
( O
HRV B-outcome ['Physiological-Clinical']
) O
throughout O
the O
4 O
10-minute O
study O
periods O
: O
Baseline O
( O
both O
practitioner O
and O
subjects O
read O
neutral O
material O
) O
; O
non-tactile-LKM O
( O
subjects O
read O
while O
the O
practitioner O
practiced O
LKM O
while O
pretending O
to O
read O
) O
; O
tactile-LKM O
( O
subjects O
rested O
while O
the O
practitioner O
practiced O
LKM O
while O
lightly O
touching O
the O
subject O
on O
arms O
, O
shoulders O
, O
hands O
, O
feet O
, O
and O
legs O
) O
; O
Post-Intervention O
Rest O
( O
subjects O
rested O
; O
the O
practitioner O
read O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Low-dose O
aspirin O
increases O
gastrointestinal B-outcome ['Physiological-Clinical']
losses I-outcome ['Physiological-Clinical']
of O
transfused O
radiolabeled B-outcome ['Physiological-Clinical']
autologous I-outcome ['Physiological-Clinical']
red I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Independent O
prognostic O
information O
provided O
by O
sphygmomanometrically O
determined O
pulse B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
patients O
with O
left O
ventricular O
dysfunction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Nitroglycerin O
was O
infused O
at O
a O
rate O
of O
1-3 O
microg.kg.h-1 O
in O
group O
2 O
, O
and O
sodium O
nitroprusside O
was O
given O
at O
a O
rate O
of O
1-3 O
microg.kg-1.min-1 O
in O
group O
3 O
. O
[]

CONCLUSION O
Prochlorperazine O
was O
statistically O
superior O
to O
octreotide O
in O
clinical B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
rate O
and O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
in O
migraine O
patients O
but O
caused O
more O
restlessness B-outcome ['Life-Impact']
and O
sedation B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

RESULTS O
At O
24 O
hours O
the O
mean O
change O
( O
SD O
) O
from O
baseline O
in O
the O
RDAI B-outcome ['Physiological-Clinical']
score O
was O
1.6 O
( O
2.3 O
) O
in O
the O
placebo O
group O
( O
n O
= O
28 O
) O
and O
1.4 O
( O
2.0 O
) O
in O
the O
dexamethasone O
group O
( O
n O
= O
33 O
; O
p O
= O
0.74 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
Economic B-outcome ['Resource-use']
evaluation O
of O
noninvasive O
( O
suppression O
of O
ventricular O
arrhythmias O
detected O
by O
ambulatory O
monitoring O
) O
and O
invasive O
( O
suppression O
of O
arrhythmias O
induced O
by O
programmed O
stimulation O
) O
approaches O
to O
antiarrhythmic O
drug O
selection O
for O
ventricular O
tachyarrhythmias O
. O
['Resource-use']

each O
trained O
on O
bicycle O
ergometer O
start O
on O
post-operative O
days O
24 O
and O
26 O
, O
resp O
. O
[]

Calcium O
hydroxide O
, O
a O
material O
widely O
used O
for O
the O
treatment O
of O
permanent O
teeth O
has O
not O
been O
used O
frequently O
for O
pulpectomy O
in O
primary O
teeth O
. O
[]

Results O
suggest O
that O
mCPP O
does O
not O
alter O
dopamine B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
lowlanders O
, O
measurements O
were O
performed O
at O
sea O
level O
( O
334 O
m O
) O
and O
between O
days O
3-4 O
( O
acute O
high O
altitude O
) O
and O
12-14 O
( O
chronic O
high O
altitude O
) O
following O
arrival O
to O
5050 O
m. O
Highlanders O
were O
assessed O
once O
at O
5050 O
m. O
Compared O
with O
sea O
level O
, O
acute O
high O
altitude O
reduced O
lowlanders O
' O
FMD O
( O
7.9 O
? O
[]

AIM O
OF O
THE O
STUDY O
To O
evaluate O
whether O
the O
EPA O
technique O
is O
useful O
for O
reducing O
CS B-outcome ['Life-Impact']
cannulation I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
compared O
to O
a O
conventional O
GCA O
technique O
. O
['Life-Impact']

Clinical O
evaluation O
of O
imidapril O
in O
congestive O
heart O
failure O
in O
dogs O
: O
results O
of O
the O
EFFIC O
study O
. O
[]

The O
relative O
risk O
reduction O
was O
however O
similar O
for O
all O
ages O
. O
[]

Gram-positive B-outcome ['Physiological-Clinical']
bacteria I-outcome ['Physiological-Clinical']
were O
isolated O
from O
18 O
patients O
, O
and O
11 O
patients O
were O
cured B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
WL+FAEE O
intervention O
significantly O
reduced O
body O
weight O
( O
-4 O
% O
) O
, O
waist O
circumference O
( O
-4 O
% O
) O
, O
systolic B-outcome ['Physiological-Clinical']
( O
-8 O
% O
) O
and O
diastolic B-outcome ['Physiological-Clinical']
( O
-5 O
% O
) O
blood O
pressures O
, O
pulse B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
-5 O
% O
) O
, O
heart O
rate O
( O
-8 O
% O
) O
, O
plasma B-outcome ['Physiological-Clinical']
TG I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
-36 O
% O
) O
, O
and O
HOMA O
score O
( O
-12 O
% O
) O
and O
increased O
stroke B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( O
+3 O
% O
) O
, O
plasma O
HDL O
cholesterol O
( O
+6 O
% O
) O
and O
adiponectin O
concentrations O
( O
+28 O
% O
) O
, O
and O
C1 O
( O
+20 O
% O
) O
and O
C2 O
( O
+22 O
% O
) O
artery O
elasticity O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Whilst O
azithromycin O
, O
given O
at O
10-15 O
mg/kg O
daily O
for O
3 O
days O
and O
then O
twice O
weekly O
, O
provided O
a O
similar O
, O
rapid O
resolution B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and O
negative O
isolation B-outcome ['Life-Impact']
scores O
as O
doxycycline O
, O
C O
felis O
was O
re-isolated O
in O
four O
out O
of O
the O
five O
cats O
treated O
. O
['Physiological-Clinical', 'Life-Impact']

Randomized O
trial O
of O
combination O
chemotherapy O
in O
hormone-resistant O
metastatic O
prostate O
carcinoma O
. O
[]

They O
were O
treated O
for O
20 O
days O
( O
times O
) O
. O
[]

Finally O
, O
the O
inter-observer O
reliability O
of O
UTC O
was O
determined O
. O
[]

The O
results O
of O
the O
measurement O
of O
aR B-outcome ['Physiological-Clinical']
and O
IOS B-outcome ['Physiological-Clinical']
after O
the O
allergenic O
solution O
showed O
a O
positive O
correlation O
( O
15 O
min O
: O
r O
= O
0,63 O
, O
p O
< O
0,01 O
; O
30 O
min O
: O
r O
= O
0,67 O
, O
p O
< O
0,01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
primary O
focus O
of O
this O
study O
is O
on O
the O
timing O
of O
the O
delivery O
of O
education O
to O
patients O
who O
had O
CABG O
surgery O
. O
[]

for O
8 O
weeks O
, O
arm O
B O
( O
eight O
males/12 O
females O
, O
aged O
42 O
+/- O
12 O
yrs O
) O
clarithromycin O
250 O
mg O
t.id O
. O
[]

The O
use O
of O
monoiodoacetate O
( O
MIA O
) O
for O
arthrodesis O
of O
the O
proximal O
interphalangeal O
joint O
( O
PIJ O
) O
and O
the O
effect O
of O
exercise O
on O
the O
degree O
of O
fusion O
were O
investigated O
. O
[]

Diltiazem O
was O
administered O
as O
an O
intravenous O
bolus O
of O
0.3 O
mg.kg-1 O
within O
5 O
min O
, O
followed O
by O
infusion O
of O
0.1-0.8 O
mg.kg-1.h-1 O
in O
group O
1 O
. O
[]

Randomized O
controlled O
trial O
to O
compare O
the O
dose O
of O
adjuvant O
chemotherapy O
after O
curative O
resection O
of O
hepatocellular O
carcinoma O
. O
[]

Patients O
with O
CSF+/Mass O
had O
a O
nominally O
higher O
treatment O
failure B-outcome ['Physiological-Clinical']
rate O
compared O
with O
patients O
with O
CNS- O
after O
adjusting O
for O
marrow O
status O
and O
lactate O
dehydrogenase O
( O
LDH O
) O
diagnosis O
, O
with O
a O
relative O
failure O
rate O
( O
RFR O
) O
of O
1.52 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.88 O
to O
2.6 O
; O
P O
=.15 O
) O
. O
['Physiological-Clinical']

Fecal B-outcome ['Physiological-Clinical']
butyrate I-outcome ['Physiological-Clinical']
levels O
vary O
widely O
among O
individuals O
but O
are O
usually O
increased O
by O
a O
diet O
high O
in O
resistant O
starch O
. O
['Physiological-Clinical']

Both O
therapy O
groups O
treated O
with O
a O
combination O
of O
glycerol O
and O
lidocaine O
exhibited O
definite O
improvement O
in O
overall B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
after O
seven O
days O
. O
['Physiological-Clinical']

No O
statistical O
differences O
were O
found O
in O
variations O
in O
reserve O
albumin-binding O
capacity O
, O
bilirubin O
, O
albumin O
, O
or O
red O
cell O
bilirubin O
at O
pre O
and O
one-hour O
post O
albumin O
infusion O
in O
the O
primed O
infants O
. O
[]

No O
difference O
in O
cesarean B-outcome ['Physiological-Clinical']
section I-outcome ['Physiological-Clinical']
rate O
or O
in O
the O
indication O
for O
operative B-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
could O
be O
seen O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
comparison O
of O
recombinant O
human O
thyrotropin O
and O
thyroid O
hormone O
withdrawal O
for O
the O
detection O
of O
thyroid O
remnant O
or O
cancer O
. O
[]

Thus O
, O
medication O
and O
parent O
training O
target O
related O
, O
but O
separate O
, O
outcomes O
. O
[]

Postoperative O
analgesia O
by O
D-myo-inositol-1,2,6-trisphosphate O
in O
patients O
undergoing O
cholecystectomy O
. O
[]

By O
subjective O
IRLS O
ratings O
, O
all O
pramipexole O
doses O
were O
significantly O
superior O
to O
placebo O
. O
[]

At O
each O
test O
session O
subjects O
completed O
visual O
analog O
scales O
and O
knee B-outcome ['Physiological-Clinical']
girth I-outcome ['Physiological-Clinical']
was O
measured O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
is O
to O
determine O
effects O
of O
improvisational O
music O
therapy O
on O
social B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
of O
children O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

Significant O
net O
reclassification O
improvement O
was O
achieved O
by O
addition O
of O
BNP O
to O
the O
current O
clinical O
risk O
prediction O
model O
( O
net O
reclassification O
improvement=0.177 O
; O
P O
< O
0.001 O
) O
and O
to O
the O
Mehran O
Risk O
Score O
( O
net O
reclassification O
improvement=0.100 O
; O
P=0.015 O
) O
. O
[]

We O
hypothesized O
that O
there O
would O
be O
improved O
fixation B-outcome ['Physiological-Clinical']
of O
high-porosity O
trabecular O
metal O
( O
TM O
) O
tibial O
components O
compared O
to O
low-porosity O
titanium O
pegged O
porous O
fiber-metal O
( O
Ti O
) O
polyethylene O
metal O
backings O
. O
['Physiological-Clinical']

Objective O
studies O
investigating O
exercise-sleep O
responses O
have O
produced O
mixed O
outcomes O
, O
and O
the O
disparity O
in O
results O
between O
studies O
may O
be O
due O
to O
differences O
in O
individual O
characteristics O
and/or O
exercise O
protocol O
, O
emphasising O
the O
importance O
of O
carefully O
controlled O
trials O
. O
[]

National O
Institute O
of O
Child O
Health O
and O
Human O
Development O
Neonatal O
Research O
Network O
. O
[]

Recovery O
after O
anesthesia O
, O
with O
special O
focus O
on O
postoperative O
nausea O
and O
vomiting O
( O
PONV O
) O
, O
was O
assessed O
. O
[]

This O
study O
examined O
the O
relationship O
between O
proactive O
learning O
in O
hypnosis O
, O
post-hypnotic O
suggestion O
, O
and O
academic O
performance O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
change O
in O
fibularis O
longus O
and O
soleus O
activation O
following O
tibiofibular O
joint O
manipulation O
in O
individuals O
with O
CAI O
. O
[]

On O
the O
other O
hand O
, O
orchiectomy O
has O
few O
, O
if O
any O
, O
complications O
. O
[]

1999 O
WHO/ISH O
Guidelines O
applied O
to O
a O
1999 O
MONICA O
sample O
from O
northern O
Sweden O
. O
[]

Twenty-seven O
stage O
IIID O
and O
thirty-six O
stage O
IV O
were O
treated O
with O
chemotherapy O
alone O
for O
3 O
years O
. O
[]

Transcutaneous O
electrical O
nerve O
stimulation O
in O
the O
treatment O
of O
myofascial O
pain O
dysfunction O
. O
[]

METHODS O
AND O
RESULTS O
Nine O
patients O
with O
CSX O
and O
14 O
control O
subjects O
underwent O
a O
continuous O
infusion O
of O
L-arginine O
( O
0.125 O
g/min O
) O
or O
saline O
for O
120 O
minutes O
. O
[]

The O
authors O
present O
simulations O
that O
establish O
key O
differences O
in O
the O
operating O
characteristics O
of O
the O
hippocampal-recall B-outcome ['Life-Impact']
and O
MTLC-familiarity O
signals O
and O
identify O
several O
manipulations O
( O
e.g. O
, O
target-lure O
similarity O
, O
interference O
) O
that O
differentially O
affect O
the O
2 O
signals O
. O
['Life-Impact', 'Life-Impact']

We O
examined O
the O
effect O
of O
BRAF O
mutation O
on O
survival O
and O
treatment O
efficacy O
in O
patients O
with O
stage O
III O
colon O
cancer O
. O
[]

METHODS O
This O
prospective O
, O
randomized O
, O
controlled O
trial O
was O
designed O
to O
show O
that O
the O
use O
of O
barbed O
suture O
in O
dermal O
closure O
of O
the O
Pfannenstiel O
incision O
during O
nonemergent O
cesarean O
delivery O
surgery O
produces O
scar O
cosmesis O
at O
5 O
weeks O
that O
is O
no O
worse O
than O
that O
observed O
with O
conventional O
closure O
using O
3-0 O
polydioxanone O
suture O
. O
[]

During O
these O
9-h O
study O
periods O
measurements O
were O
also O
made O
of O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
plasma B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
and O
glucagon B-outcome ['Physiological-Clinical']
, O
urinary B-outcome ['Physiological-Clinical']
ammonia I-outcome ['Physiological-Clinical']
, O
nitrogen B-outcome ['Physiological-Clinical']
, O
creatinine B-outcome ['Physiological-Clinical']
and O
3-methylhistidine B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
second O
hygienist O
independently O
assessed O
a O
subset O
of O
areas O
to O
evaluate O
inter-rater O
reliability O
. O
[]

This O
effect O
was O
well O
maintained O
in O
the O
supine O
position O
. O
[]

CONTEXT O
If O
ankle O
joint O
cryotherapy O
impairs O
the O
ability O
of O
the O
ankle O
musculature O
to O
counteract O
potentially O
injurious O
forces O
, O
the O
ankle O
is O
left O
vulnerable O
to O
injury O
. O
[]

There O
were O
significantly O
more O
PONV-free B-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
in O
group O
C O
compared O
with O
group O
P O
( O
20 O
and O
11 O
of O
30 O
, O
respectively O
; O
P O
< O
0.04 O
) O
. O
['Physiological-Clinical']

Efficacy O
and O
tolerance B-outcome ['Life-Impact']
of O
SML O
were O
obviously O
far O
better O
than O
those O
of O
TK O
in O
patients O
with O
nocturnal O
asthma O
. O
['Life-Impact']

The O
maximum B-outcome ['Physiological-Clinical']
pressor I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
observed O
immediately O
after O
intubation O
, O
at O
which O
time O
the O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
change O
from O
baseline O
in O
group O
LE O
( O
29.7 O
% O
) O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
: O
116.1 O
, O
121.9 O
) O
was O
higher O
than O
that O
in O
group O
R O
( O
4.4 O
% O
) O
( O
95 O
% O
CI O
: O
92.9 O
, O
98.5 O
) O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
median O
TTF B-outcome ['Life-Impact']
was O
70 O
days O
in O
the O
mitoxantrone O
group O
and O
104 O
days O
in O
the O
doxorubicin O
group O
( O
P O
= O
.36 O
) O
. O
['Life-Impact']

TSB B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
at O
regular O
intervals O
. O
['Physiological-Clinical']

DESIGN O
A O
randomized O
study O
of O
two O
methods O
of O
endocervical O
sampling O
. O
[]

93 O
patients O
with O
seasonal O
allergic O
rhinitis O
took O
part O
in O
a O
single O
blind O
randomized O
clinical O
comparison O
of O
budesonide O
and O
beclomethasone O
dipropionate O
( O
Becotide O
Nasal O
) O
. O
[]

Values O
are O
given O
as O
median O
( O
range O
) O
. O
( O
[]

METHODS O
One O
hundred O
seventy-six O
patients O
with O
necrotizing O
pancreatitis O
were O
prospectively O
randomized O
to O
prophylactic O
treatment O
with O
0.5 O
g O
meropenem O
t.i.d O
. O
[]

OBJECTIVE O
To O
study O
the O
synergistic B-outcome ['Adverse-effects']
effects O
of O
electroacupuncture O
on O
the O
treatment O
of O
knee O
osteoarthritis O
after O
arthroscopic O
debridement O
. O
['Adverse-effects']

Between O
January O
1996 O
and O
February O
1998 O
, O
259 O
men O
with O
prostate O
cancer O
underwent O
radical O
retropubic O
prostatectomy O
and O
bilateral O
pelvic O
node O
dissection O
in O
the O
26 O
centres O
participating O
in O
the O
Italian O
randomised O
prospective O
PROSIT O
study O
. O
[]

OBJECTIVE O
To O
compare O
the O
impact O
of O
1000-microgram O
self-administered O
vaginal O
misoprostol O
versus O
self-administered O
vaginal O
placebo O
at O
home O
on O
preoperative O
cervical O
ripening O
in O
both O
premenopausal O
and O
postmenopausal O
women O
prior O
to O
outpatient O
resectoscopy O
. O
[]

In O
addition O
, O
the O
introduction O
of O
screening O
programs O
for O
colorectal O
cancer O
will O
also O
increase O
the O
numbers O
of O
procedures O
needed O
. O
[]

BACKGROUND O
A O
hyperglutamatergic O
state O
has O
been O
shown O
to O
play O
a O
possible O
role O
in O
the O
pathophysiology O
of O
autistic O
disorders O
. O
[]

A O
trend O
toward O
a O
longer O
OS B-outcome ['Mortality']
was O
noted O
in O
the O
150 O
mg/m O
( O
2 O
) O
nab-paclitaxel O
arm O
versus O
docetaxel O
arm O
( O
hazard O
ratio O
, O
0.688 O
) O
. O
['Mortality']

Among O
the O
patients O
followed O
up O
for O
12 O
months O
, O
duodenal B-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
recurred I-outcome ['Physiological-Clinical']
in O
4 O
of O
50 O
patients O
given O
antibiotics O
and O
42 O
of O
49 O
given O
placebo O
( O
8 O
percent O
vs. O
86 O
percent O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Silent O
myocardial O
ischemia O
is O
an O
adverse O
prognostic O
marker O
in O
patients O
with O
coronary O
disease O
; O
however O
, O
controlled O
data O
on O
the O
effect O
of O
treatment O
are O
sparse O
and O
contradictory O
, O
and O
the O
relations O
among O
the O
occurrence O
of O
ST B-outcome ['Physiological-Clinical']
segment I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
, O
drug O
efficacy O
, O
and O
heart O
rate O
are O
unclear O
. O
['Physiological-Clinical']

Abomasal B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
rate O
was O
assessed O
by O
acetaminophen B-outcome ['Physiological-Clinical']
and O
glucose B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
blinded O
, O
four-treatment O
crossover O
study O
in O
16 O
normal O
adult O
male O
volunteers O
compared O
plasma O
concentrations O
and O
urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of O
digoxin B-outcome ['Resource-use']
, O
measured O
by O
radioimmunoassay O
, O
after O
oral O
administration O
of O
soft O
gelatin O
capsule O
formulations O
of O
digoxin O
. O
['Physiological-Clinical', 'Resource-use']

Sixteen O
patients O
scheduled O
for O
gastrectomy O
were O
studied O
. O
[]

Among O
the O
45 O
women O
in O
the O
follow-up O
group O
, O
42 O
% O
experienced O
spontaneous O
regression O
, O
11 O
% O
showed O
persistence O
, O
22 O
% O
progressed O
to O
CIN3 O
, O
and O
20 O
% O
had O
partial O
regression O
to O
CIN1 O
or O
ASCUS O
( O
atypical O
squamous O
cell O
undetermined O
signifiance O
) O
. O
[]

Endoscopic B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
was O
defined O
as O
complete B-outcome ['Physiological-Clinical']
epithelialisation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
all I-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Parental O
oversensitivity O
to O
sleep B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
of O
the O
autistic O
children O
may O
explain O
this O
phenomenon O
. O
['Physiological-Clinical']

The O
effects O
of O
therapy O
with O
vitamin O
E O
were O
also O
evaluated O
, O
but O
no O
statistical O
benefits O
were O
shown O
. O
[]

4,724 O
patients O
took O
part O
in O
IES O
, O
and O
206 O
patients O
were O
included O
in O
a O
bone O
sub-study O
. O
[]

Amisulpride O
acts O
preferentially O
on O
specific O
autistic O
symptoms O
whereas O
bromocriptine O
acts O
more O
on O
motor B-outcome ['Physiological-Clinical']
hyperactivity I-outcome ['Physiological-Clinical']
and O
attention B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

The O
decrease O
in O
the O
number O
of O
blood B-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
during O
the O
treatment O
was O
more O
marked O
in O
the O
high O
dose O
budesonide O
group O
( O
P=0.02 O
; O
high O
vs. O
low O
dose O
budesonide O
) O
. O
['Physiological-Clinical']

Functional O
values O
showed O
no O
difference O
in O
terms O
of O
flow B-outcome ['Physiological-Clinical']
rate O
, O
although O
oxitropium O
did O
cause O
a O
significant O
improvement O
in O
the O
['Physiological-Clinical']

RESULTS O
Treatment O
sides O
had O
greater O
decrease O
in O
lesion B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
than O
observation O
sides O
of O
face O
at O
weeks O
2 O
( O
P O
< O
.001 O
) O
and O
5 O
( O
P O
= O
.02 O
) O
. O
['Physiological-Clinical']

These O
principles O
make O
it O
possible O
to O
reduce O
the O
need O
for O
primary B-outcome ['Physiological-Clinical']
colostomy I-outcome ['Physiological-Clinical']
to O
approximately O
50 O
per O
cent O
in O
a O
large O
ongoing O
group O
of O
patients O
with O
colonic O
injury O
. O
['Physiological-Clinical']

Randomised O
controlled O
trial O
of O
graded O
exercise O
in O
patients O
with O
the O
chronic B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
At O
enrollment O
, O
the O
proportion O
of O
women O
in O
the O
intervention O
group O
who O
were O
found O
to O
have O
lesions O
of O
grade O
2 O
or O
3 O
cervical B-outcome ['Physiological-Clinical']
intraepithelial I-outcome ['Physiological-Clinical']
neoplasia I-outcome ['Physiological-Clinical']
or O
cancer B-outcome ['Physiological-Clinical']
was O
51 O
% O
greater O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
13 O
to O
102 O
) O
than O
the O
proportion O
of O
women O
in O
the O
control O
group O
who O
were O
found O
to O
have O
such O
lesions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ezetimibe O
also O
significantly O
improved O
levels O
of O
plasma B-outcome ['Physiological-Clinical']
total O
cholesterol B-outcome ['Physiological-Clinical']
, O
apolipoprotein B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
, O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
( O
2 O
) O
-cholesterol O
and O
lipoprotein B-outcome ['Physiological-Clinical']
( O
a O
) O
, O
and O
elicited O
a O
trend O
toward B-outcome ['Physiological-Clinical']
lower I-outcome ['Physiological-Clinical']
triglyceride I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Negative O
emotional O
experiences O
during O
navigation O
enhance O
parahippocampal O
activity O
during O
recall O
of O
place O
information O
. O
[]

Baseline O
6-minute O
walk O
distance O
was O
306 O
m O
( O
SD O
99 O
) O
. O
[]

A O
significant O
five O
year O
cure B-outcome ['Physiological-Clinical']
rate O
can O
only O
be O
obtained O
if O
the O
uterus O
and O
the O
adnexa O
are O
removed O
. O
['Physiological-Clinical']

CONCLUSIONS O
Locally O
invasive O
pancreatic O
cancer O
without O
distant O
metastases O
and O
major O
arterial O
invasion O
appears O
to O
be O
best O
treated O
by O
surgical O
resection O
. O
[]

The O
cumulative O
HBsAg B-outcome ['Physiological-Clinical']
reverse I-outcome ['Physiological-Clinical']
seroconversion I-outcome ['Physiological-Clinical']
rates O
at O
months O
6 O
, O
12 O
, O
and O
18 O
since O
chemotherapy O
were O
0 O
% O
, O
6.4 O
% O
, O
and O
16.3 O
% O
in O
the O
control O
group O
, O
respectively O
, O
which O
were O
significantly O
higher O
than O
those O
in O
the O
ETV O
prophylactic O
group O
( O
P O
= O
.032 O
) O
. O
['Physiological-Clinical']

Subjects O
were O
randomly O
assigned O
to O
naltrexone O
or O
placebo O
and O
received O
daily O
doses O
over O
a O
period O
of O
21 O
days O
. O
[]

6.90 O
ml/min/1.73 O
m O
( O
2 O
) O
, O
p O
= O
0.0015 O
) O
. O
[]

The O
enhanced O
label O
includes O
a O
universal O
medication O
schedule O
( O
UMS O
) O
that O
standardizes O
the O
directions O
for O
use O
incorporating O
1 O
) O
standard O
time O
periods O
for O
administration O
( O
morning O
, O
noon O
, O
evening O
, O
and O
bedtime O
) O
, O
2 O
) O
numeric O
vs. O
alpha O
characters O
, O
3 O
) O
'carriage O
returns O
' O
to O
separate O
daily O
dose O
and O
4 O
) O
a O
graphic O
aid O
to O
visually O
depict O
dose O
and O
frequency O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
nebulized O
flunisolide O
( O
1 O
mg O
) O
+ O
salbutamol/ipratropium O
bromide O
( O
1,875/375 O
microg O
) O
b.i.d O
. O
['Life-Impact']

Although O
the O
consequences O
of O
HIV B-outcome ['Life-Impact']
stigma I-outcome ['Life-Impact']
have O
been O
documented O
extensively O
, O
efforts O
to O
reduce O
these O
negative O
attitudes O
have O
been O
scarce O
. O
['Life-Impact']

The O
effects O
were O
evaluated O
by O
self-administered O
questionnaires O
at O
3 O
, O
6 O
, O
and O
12 O
months O
after O
baseline O
, O
and O
compared O
between O
the O
groups O
. O
[]

No O
statistically O
significant O
changes O
took O
place O
in O
these O
outcome O
measures O
during O
the O
12-month O
follow-up O
in O
both O
groups O
. O
[]

Thus O
, O
the O
applied O
ISDN O
regimen O
improved O
the O
hemodynamics O
, O
but O
induced O
a O
definite O
, O
partial O
nitrate O
tolerance O
. O
[]

0.4 O
) O
, O
respectively O
, O
was O
similar O
at O
baseline O
yet O
higher O
than O
the O
CT O
group O
( O
3.9 O
? O
[]

METHODS O
In O
a O
randomized O
clinical O
trial O
, O
607 O
subjects O
with O
newly O
diagnosed O
open-angle O
glaucoma O
initially O
were O
treated O
with O
either O
medication O
or O
trabeculectomy O
. O
[]

Treatment O
with O
lime O
did O
not O
cause O
any O
significant O
side-effect O
. O
[]

RESULTS O
A O
total O
of O
596 O
adults O
completed O
the O
trial O
. O
[]

[ O
Intra-uterine O
insemination O
with O
controlled O
ovarian O
hyperstimulation O
compared O
to O
an O
expectant O
management O
in O
couples O
with O
unexplained O
subfertility B-outcome ['Physiological-Clinical']
and O
an O
intermediate O
prognosis O
: O
a O
randomised O
study O
] O
. O
['Physiological-Clinical']

METHODS O
In O
a O
randomized O
double-blind O
crossover O
study O
balanced O
to O
order O
, O
17 O
metabolic O
syndrome O
( O
MetS O
) O
and O
15 O
healthy O
subjects O
inhaled O
filtered O
air O
( O
FA O
) O
or O
DE O
exposure O
in O
two-hour O
sessions O
on O
different O
days O
with O
a O
minimum O
2-week O
washout O
period O
. O
[]

METHODS O
Preoperatively O
bilateral O
VM O
and O
SOL O
H-reflex O
tests O
were O
conducted O
. O
[]

This O
may O
have O
been O
because O
postoperative B-outcome ['Physiological-Clinical']
painful I-outcome ['Physiological-Clinical']
and O
swollen B-outcome ['Physiological-Clinical']
legs I-outcome ['Physiological-Clinical']
effectively O
masked O
any O
signs O
and O
symptoms O
of O
deep O
vein O
thrombosis O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
results O
confirm O
the O
importance O
of O
psychological O
factors O
in O
early O
RA O
and O
their O
relative O
independence O
from O
physical O
findings O
. O
[]

PURPOSE O
This O
paper O
describes O
an O
ongoing O
randomized O
controlled O
trial O
designed O
to O
assess O
the O
impact B-outcome ['Life-Impact']
of O
genetic O
and O
environmental O
risk O
assessment O
( O
GERA O
) O
on O
colorectal O
cancer O
( O
CRC O
) O
screening O
. O
['Life-Impact']

The O
present O
study O
was O
undertaken O
to O
evaluate O
the O
effect O
of O
low-power O
laser O
on O
the O
prevention O
of O
mucositis B-outcome ['Physiological-Clinical']
, O
xerostomia B-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
as O
a O
result O
of O
chemotherapy B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Periinfarct B-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
was O
defined O
as O
a O
reversible O
thallium O
defect O
adjacent O
to O
a O
fixed O
defect O
assessed O
qualitatively O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
comparison O
between O
the O
effect O
of O
oxytocin O
alone O
or O
in O
combination O
with O
propranolol O
on O
labor B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
We O
conducted O
this O
randomized O
controlled O
clinical O
study O
on O
61 O
patients O
. O
[]

Cimetidine O
as O
an O
immunomodulator O
in O
the O
treatment O
of O
herpes O
zoster O
. O
[]

Planned O
sample O
size O
was O
100 O
patients O
per O
arm O
to O
provide O
80 O
% O
power O
to O
detect O
a O
difference O
in O
incidence O
of O
grade O
2+ B-outcome ['Physiological-Clinical']
SN I-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
from O
25 O
% O
in O
the O
placebo O
group O
to O
10 O
% O
in O
the O
vitamin O
E O
group O
. O
['Physiological-Clinical']

The O
5 O
alpha-steroid B-outcome ['Physiological-Clinical']
metabolite I-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
was O
strikingly O
similar O
to O
that O
of O
MPHs O
with O
inherited O
5 O
alpha-reductase O
deficiency O
. O
['Physiological-Clinical']

Paw O
withdrawal O
mechanical O
thresholds O
( O
PWMT O
) O
and O
paw O
withdrawal O
thermal O
latency O
PWTL O
were O
measured O
one O
day O
before O
CCI O
( O
baseline O
) O
and O
0 O
, O
3 O
, O
7 O
, O
14 O
, O
and O
28 O
days O
after O
intrathecal O
administration O
. O
[]

Four O
potential O
determinants O
of O
these O
differences O
were O
explored O
: O
patient O
factors O
; O
therapist O
factors O
; O
patient-therapist O
relationship B-outcome ['Life-Impact']
factors O
; O
and O
therapy B-outcome ['Life-Impact']
factors I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
performance O
of O
children O
with O
and O
without O
autism O
was O
compared O
in O
object-based O
positive O
and O
negative O
priming O
tasks O
within O
a O
visual O
search O
procedure O
. O
[]

This O
study O
describes O
the O
implementation O
of O
a O
nurse O
home O
visiting O
asthma O
education O
program O
for O
low-income O
African O
American O
families O
of O
young O
children O
with O
asthma O
. O
[]

Serial O
measurements O
of O
the O
size O
of O
the O
epithelial O
defects-namely O
, O
two O
maximum O
linear O
dimensions O
perpendicular O
to O
each O
other O
, O
and O
the O
area O
and O
perimeter O
was O
done O
at O
start O
of O
therapy O
and O
follow O
up O
days O
3 O
, O
7 O
, O
14 O
, O
21 O
. O
[]

Subjects O
in O
Group O
1 O
took O
the O
TOVA O
under O
normal O
conditions O
( O
NC O
) O
first O
; O
they O
were O
then O
requested O
to O
subtly O
fake O
bad O
. O
[]

To O
determine O
the O
effect O
of O
intravenous O
porcine O
secretin O
on O
autistic O
behaviours O
in O
children O
aged O
2 O
to O
7 O
years O
, O
the O
effects O
of O
secretin O
on O
( O
1 O
) O
performance O
on O
a O
standardized O
language O
measure O
, O
and O
( O
2 O
) O
autistic O
behaviours O
, O
as O
rated O
by O
parents O
and O
child O
development O
professionals O
was O
examined O
. O
[]

CONCLUSIONS O
A O
prepackaged O
low O
residue O
one-day O
diet O
provided O
cleansing B-outcome ['Physiological-Clinical']
efficacy O
similar O
to O
that O
of O
a O
clear O
liquid O
diet O
and O
offered O
the O
benefit O
of O
improved O
tolerability B-outcome ['Life-Impact']
compared O
to O
the O
conventional O
PEG O
4L O
regimen O
. O
['Physiological-Clinical', 'Life-Impact']

17.1 O
% O
; O
P O
< O
0.05 O
) O
. O
[]

Use O
of O
an O
Internet O
portal O
to O
improve O
community-based O
pediatric O
ADHD O
care O
: O
a O
cluster O
randomized O
trial O
. O
[]

Nine O
patients O
with O
chronic O
renal O
anemia O
on O
maintenance O
hemodialysis O
were O
enrolled O
in O
rHu-EPO O
treatment O
trial O
. O
[]

Expression O
of O
OPN B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
was O
increased O
in O
AML O
patients O
both O
in O
BM O
blasts O
( O
IHC O
) O
and O
in O
BM O
serum O
( O
ELISA O
) O
compared O
with O
healthy O
controls O
. O
['Physiological-Clinical']

The O
systemic B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
local I-outcome ['Life-Impact']
tolerability I-outcome ['Life-Impact']
of O
the O
drug O
was O
good O
. O
['Life-Impact']

BACKGROUND O
Cardioinhibitory O
carotid O
sinus O
syndrome O
causes O
syncope O
, O
and O
symptoms O
respond O
to O
cardiac O
pacing O
. O
[]

RESULTS O
Statistically O
significant O
improvement O
of O
vertigo B-outcome ['Physiological-Clinical']
and O
provoked B-outcome ['Physiological-Clinical']
nystagmus I-outcome ['Physiological-Clinical']
in O
64 O
% O
of O
patients O
in O
the O
CRM O
group O
compared O
with O
the O
no-treatment O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Lomefloxacin O
was O
effective O
therapy O
for O
five O
of O
seven O
( O
71 O
% O
) O
patients O
, O
and O
ciprofloxacin O
was O
effective O
therapy O
for O
two O
of O
five O
patients O
( O
40 O
% O
) O
. O
[]

Regional O
ischemic O
preconditioning O
enhances O
myocardial B-outcome ['Physiological-Clinical']
performance O
in O
off-pump O
coronary O
artery O
bypass O
grafting O
. O
['Physiological-Clinical']

DISCUSSION O
This O
trial O
will O
identify O
whether O
home-based O
pulmonary O
rehabilitation O
can O
deliver O
equivalent O
benefits O
to O
centre-based O
pulmonary O
rehabilitation O
in O
a O
cost O
effective O
manner O
. O
[]

An O
original O
aspect O
of O
the O
intervention O
was O
to O
use O
trained O
clinical O
psychologists O
to O
conduct O
all O
home O
visits O
. O
[]

Vital O
signs O
were O
monitored O
throughout O
the O
study O
period O
. O
[]

Precordial O
echocardiography O
combined O
with O
femoral O
contrast O
delivery O
was O
significantly O
more O
sensitive B-outcome ['Physiological-Clinical']
than O
cardiac O
catheterization O
for O
assessment O
of O
patent B-outcome ['Physiological-Clinical']
foramen I-outcome ['Physiological-Clinical']
ovale I-outcome ['Physiological-Clinical']
( O
8 O
of O
21 O
patients O
vs. O
2 O
of O
21 O
patients O
, O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Our O
results O
suggest O
that O
multilevel O
risk O
factors O
along O
with O
gender O
differences O
should O
be O
considered O
to O
protect O
adolescents O
from O
addictive B-outcome ['Life-Impact']
Internet I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
groups O
did O
not O
differ O
with O
respect O
to O
peroperative O
and O
postoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Monkeys O
and O
humans O
performed O
serial O
probe O
recognition O
tasks O
that O
produced O
differential O
memory O
difficulty O
across O
serial O
positions O
( O
e.g. O
, O
primacy O
and O
recency O
effects O
) O
. O
[]

Incidence O
and O
clinical O
significance O
of O
false-negative O
sextant O
prostate O
biopsies O
. O
[]

Pilot O
study O
of O
imiquimod O
5 O
% O
cream O
as O
adjunctive O
therapy O
to O
curettage O
and O
electrodesiccation O
for O
nodular O
basal O
cell O
carcinoma O
. O
[]

Patients O
were O
randomly O
assigned O
to O
one O
of O
two O
treatment O
groups O
: O
of O
treatment O
group O
A O
: O
Alpha O
dihidroergocriptine O
tablets O
of O
10 O
mg O
, O
group O
B O
: O
Placebo O
, O
during O
6 O
months O
. O
[]

BACKGROUND O
Since O
laparoscopic O
adrenalectomy O
( O
LA O
) O
has O
been O
adopted O
as O
the O
gold O
standard O
for O
the O
treatment O
of O
adrenal O
diseases O
, O
the O
development O
of O
technology O
for O
vascular O
control O
and O
dissection O
manoeuvres O
, O
amongst O
other O
things O
, O
may O
play O
a O
pivotal O
role O
in O
its O
further O
improvement O
. O
[]

Analysis O
of O
469 O
evaluable O
patients O
at O
a O
median O
follow-up O
of O
5.8 O
years O
revealed O
110 O
recurrences O
in O
the O
control O
and O
94 O
recurrences O
in O
the O
infusion O
group O
. O
[]

Approximately O
two O
thirds O
were O
smokers O
and O
were O
randomized O
to O
be O
tested O
after O
either O
a O
12-hr O
nicotine O
deprivation O
or O
administration O
of O
nicotine O
gum O
. O
[]

or O
placebo O
, O
followed O
by O
a O
4-week O
washout O
period O
. O
[]

Patients O
were O
instructed O
to O
maintain O
their O
usual O
dietary O
habits O
. O
[]

Operative O
and O
recovery O
times O
were O
recorded O
. O
[]

The O
two O
capsules O
with O
lowest O
in O
vitro O
burst O
times O
( O
2.9 O
and O
16 O
min O
) O
gave O
comparable O
in O
vivo O
results O
. O
[]

Efficacy O
of O
chlorhexidine O
gluconate O
use O
in O
the O
prevention O
of O
perirectal O
infections O
in O
patients O
with O
acute O
leukemia O
. O
[]

After O
completing O
the O
respective O
interventions O
, O
all O
participants O
completed O
the O
HIV B-outcome ['Physiological-Clinical']
questionnaire O
, O
which O
measured O
selected O
Social O
Cognitive O
Theory O
constructs O
associated O
with O
HIV B-outcome ['Physiological-Clinical']
preventive I-outcome ['Physiological-Clinical']
behaviors I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
purpose O
of O
this O
prospective O
study O
was O
to O
compare O
the O
dental B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
banded O
and O
bonded O
appliances O
. O
['Physiological-Clinical']

Group O
2 O
subjects O
had O
intermediate O
levels O
of O
most O
outcomes O
. O
[]

Additional O
data O
and O
analyses O
confirm O
that O
this O
relationship O
is O
specific O
to O
multisensory B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
and O
symptoms B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
autism I-outcome ['Life-Impact']
. O
['Life-Impact']

DESIGN O
After O
a O
run-in O
of O
3 O
d O
, O
20 O
healthy O
volunteers O
assigned O
to O
2 O
parallel O
dose O
groups O
received O
once O
daily O
oral O
doses O
of O
either O
1 O
mg O
( O
1.76 O
micro O
mol O
) O
or O
10 O
mg O
( O
17.6 O
micro O
mol O
) O
zeaxanthin O
for O
42 O
d. O
Plasma B-outcome ['Physiological-Clinical']
concentration-time I-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
on O
days O
1 O
and O
42 O
, O
concentrations O
immediately O
before O
zeaxanthin O
intake O
during O
the O
dosing O
period O
, O
and O
concentrations O
after O
the O
last O
dose O
until O
day O
76 O
were O
monitored O
. O
['Physiological-Clinical']

Prophylactic O
cranial O
irradiation O
( O
PCI O
) O
was O
administered O
to O
patients O
with O
a O
complete O
response O
. O
[]

Family O
measures O
included O
the O
Caregiver B-outcome ['Life-Impact']
Strain I-outcome ['Life-Impact']
Questionnaire O
. O
['Life-Impact']

[ O
Effects O
of O
an O
intensive O
therapy O
program O
for O
behaviorally O
disordered O
mentally O
handicapped O
patients O
on O
staff O
personnel O
in O
residential O
care O
] O
. O
[]

Effect O
of O
preoperative O
skull O
block O
on O
pediatric O
moyamoya O
disease O
. O
[]

Although O
corticosteroid O
therapy O
might O
be O
clinically O
beneficial O
for O
bronchiectasis O
, O
very O
little O
is O
known O
of O
its O
effects O
on O
the O
inflammatory B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
infective I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
in O
bronchiectasis O
. O
['Physiological-Clinical']

RESULTS O
Roll-off B-outcome ['Physiological-Clinical']
was O
achieved O
in O
all O
10 O
patients O
of O
group O
1 O
, O
indicative O
of O
sufficient O
tumor O
coagulation O
, O
but O
only O
in O
3 O
of O
10 O
patients O
of O
group O
2 O
. O
['Physiological-Clinical']

Sixty O
two O
children O
with O
autism O
( O
aged O
43-103 O
months O
) O
were O
randomly O
allocated O
to O
two O
groups O
: O
group O
1 O
received O
placebo O
, O
followed O
six O
weeks O
later O
by O
secretin O
, O
and O
group O
2 O
received O
secretin O
followed O
by O
placebo O
. O
[]

[ O
Results O
of O
three-year O
clinical O
study O
of O
prostamol O
uno O
efficacy O
and O
safety O
in O
patients O
with O
initial O
symptoms O
of O
prostatic O
adenoma O
and O
risk O
of O
its O
progression O
] O
. O
[]

In O
this O
study O
seven O
patients O
with O
infantile O
autism O
, O
three O
before O
puberty O
and O
four O
after O
puberty O
, O
were O
given O
a O
gluten-free O
diet O
. O
[]

OBJECTIVES O
We O
performed O
a O
deconstruction O
of O
the O
published O
study O
to O
show O
how O
primary O
and O
secondary O
outcome O
analyses O
were O
conflated O
, O
turning O
a O
'negative O
' O
clinical O
trial O
into O
a O
'positive O
' O
study O
- O
with O
conclusions O
and O
recommendations O
that O
could O
adversely O
affect O
patient O
health O
. O
[]

Their O
task O
was O
to O
judge O
the O
pitch O
of O
pure O
tones O
in O
a O
same-different O
discrimination O
task O
and O
in O
a O
high-low O
categorization O
task O
. O
[]

A O
comparison O
between O
an O
angiotensin-converting O
enzyme O
inhibitor O
and O
a O
calcium O
antagonist O
. O
[]

The O
inability O
to O
imitate O
is O
a O
salient O
diagnostic O
marker O
for O
autism O
. O
[]

CONCLUSIONS O
This O
low O
0.3 O
% O
rate O
is O
in O
agreement O
with O
recent O
studies O
that O
focus O
on O
thromboembolic B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Those O
who O
received O
GLY O
received O
standard O
TPN O
, O
isocaloric O
and O
isonitrogenous O
. O
[]

The O
quantified O
version O
of O
the O
Romberg O
test O
performed O
with O
eyes O
open O
or O
closed O
was O
not O
impaired O
after O
anaesthesia O
, O
compared O
with O
the O
control O
values O
, O
indicating O
that O
in O
children O
poor O
equilibrium O
is O
not O
compensated O
by O
vision O
. O
[]

Further O
study O
is O
needed O
to O
assess O
the O
long-term O
safety O
and O
efficacy O
of O
low-dose O
mifepristone O
. O
[]

Angiotensin O
converting O
enzyme O
( O
ACE O
) O
inhibitors O
are O
also O
effective O
as O
sole O
therapy O
in O
many O
patients O
with O
essential O
hypertension O
, O
but O
may O
be O
less O
effective O
in O
those O
with O
low-renin O
hypertension O
. O
[]

The O
folate O
group O
received O
1 O
mg O
folic O
acid O
, O
400 O
microg O
vitamin O
B O
( O
12 O
) O
, O
and O
10 O
mg O
vitamin O
B O
( O
6 O
) O
daily O
. O
[]

No O
exacerbation B-outcome ['Life-Impact']
of O
stereotypies O
was O
noted O
, O
and O
side O
effects O
were O
similar O
to O
those O
seen O
in O
typically O
developing O
children O
with O
ADHD O
. O
['Life-Impact']

At O
baseline O
, O
both O
groups O
had O
low O
BMD B-outcome ['Physiological-Clinical']
with O
high O
levels O
of O
serum O
ionized O
calcium O
and O
urinary B-outcome ['Physiological-Clinical']
deoxypyridinoline I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
no O
case O
were O
any O
undesirable O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
observed O
. O
['Adverse-effects']

RESULTS O
The O
clonidine O
treatment O
showed O
a O
significant O
difference O
from O
placebo O
treatment O
on O
three O
subscales O
of O
the O
Ritvo-Freeman O
Real O
Life O
Rating O
Scale O
( O
i.e. O
, O
social B-outcome ['Life-Impact']
relationship I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
people I-outcome ['Life-Impact']
, O
affectual B-outcome ['Life-Impact']
responses I-outcome ['Life-Impact']
, O
and O
sensory O
responses O
) O
. O
['Life-Impact', 'Life-Impact']

A O
new O
method O
using O
MRI O
. O
[]

The O
primary O
outcome O
measure O
was O
the O
change O
from O
baseline O
in O
the O
RDAI B-outcome ['Physiological-Clinical']
score O
at O
24 O
hours O
. O
['Physiological-Clinical']

CONCLUSIONS O
Both O
teachers O
and O
parents O
were O
able O
to O
provide O
effective O
intervention O
for O
the O
majority O
of O
the O
children O
. O
[]

Both O
modalities O
, O
telephone O
( O
89 O
% O
correct O
) O
and O
telemedicine O
( O
85 O
% O
correct O
) O
, O
performed O
well O
. O
[]

0.9 O
vs. O
14.5 O
? O
[]

Aerobic O
pathogens O
were O
frequently O
isolated O
along O
with O
anaerobes O
from O
the O
infectious O
sites O
in O
this O
series O
; O
their O
susceptibility O
or O
resistance O
to O
clindamycin O
or O
cefoxitin O
did O
not O
influence O
the O
therapeutic O
response O
. O
[]

Design O
of O
the O
DEFINE O
trial O
: O
determining O
the O
EFficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
CETP O
INhibition O
with O
AnacEtrapib O
. O
['Life-Impact']

CONCLUSION O
Nerve O
monitoring O
aids O
in O
the O
visualization O
of O
the O
EBSLN B-outcome ['Physiological-Clinical']
during O
mini-incision O
thyroidectomy O
under O
local/regional O
anesthesia O
and O
leads O
to O
an O
improvement O
in O
patient-assessed O
['Physiological-Clinical']

Plasma O
selective O
delipidation O
converts O
alphaHDL O
to O
prebeta-like O
HDL O
, O
the O
most O
effective O
form O
of O
HDL O
for O
lipid O
removal O
from O
arterial O
plaques O
. O
[]

No O
eyes B-outcome ['Physiological-Clinical']
lost I-outcome ['Physiological-Clinical']
> O
or O
=1 O
line O
of O
BCVA B-outcome ['Physiological-Clinical']
; O
in O
the O
ZAR O
group O
, O
2 O
eyes O
gained O
1 O
line O
and O
6 O
eyes O
gained O
> O
or O
=2 O
lines O
; O
in O
the O
Planoscan O
group O
, O
3 O
eyes O
gained O
1 O
line O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pheasant O
chicks O
( O
approximately O
1 O
day-old O
; O
n O
= O
160 O
) O
were O
randomly O
blocked O
by O
sex O
into O
four O
treatment O
groups O
and O
given O
their O
respective O
diets O
continuously O
for O
6 O
wk O
. O
[]

Dairy O
products O
do O
not O
lead O
to O
alterations O
in O
body B-outcome ['Physiological-Clinical']
weight O
or O
fat B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
young I-outcome ['Physiological-Clinical']
women I-outcome ['Physiological-Clinical']
in O
a O
1-y O
intervention O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
R O
group O
, O
patients O
were O
given O
no O
such O
education O
or O
emphasis O
. O
[]

More O
educated O
women O
and O
those O
with O
higher O
perceived O
risk O
were O
more O
likely O
to O
engage O
in O
leisure B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
, O
and O
married O
women O
were O
less O
likely O
. O
['Life-Impact']

To O
determine O
if O
muscle B-outcome ['Physiological-Clinical']
atrophy I-outcome ['Physiological-Clinical']
could O
be O
minimized O
with O
exercise O
therapy O
, O
30 O
patients O
undergoing O
marrow O
transplantation O
for O
acute O
leukemia O
completed O
a O
prospective O
randomized O
trial O
to O
receive O
: O
( O
1 O
) O
no O
therapy O
( O
controls O
) O
, O
( O
2 O
) O
physical O
therapy O
thrice O
weekly O
( O
PT3 O
) O
, O
or O
( O
3 O
) O
physical O
therapy O
five O
times O
weekly O
( O
PT5 O
) O
. O
['Physiological-Clinical']

The O
present O
study O
aimed O
to O
assess O
the O
effects O
of O
thymostimulin O
in O
patients O
with O
different O
degrees O
of O
immunodepression O
, O
by O
evaluating O
both O
the O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
and O
the O
changes O
induced O
in O
various O
immunological B-outcome ['Physiological-Clinical']
parameters O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Despite O
increases O
having O
been O
found O
in O
straylight O
values O
with O
tinted O
contact O
lenses O
, O
those O
changes O
are O
not O
likely O
to O
induce O
clinically O
significant O
changes O
in O
visual O
function O
under O
photopic O
conditions O
, O
even O
for O
the O
grey-green O
CL O
, O
which O
seems O
to O
increase O
straylight O
values O
more O
significantly O
than O
the O
amber O
CL O
. O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
during O
bronchoscopy O
were O
similar O
in O
both O
groups O
. O
['Adverse-effects']

RESULTS O
Tumors O
with O
high O
EGFr O
( O
84 O
% O
) O
responded O
better O
to O
moderately O
accelerated O
radiotherapy O
, O
than O
carcinomas O
with O
low O
EGFr O
, O
using O
locoregional O
control O
as O
endpoint O
and O
a O
similar O
pattern O
was O
seen O
, O
stratifying O
by O
well/moderate O
vs. O
poor O
tumor B-outcome ['Physiological-Clinical']
differentiation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Mean O
modification B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

RESULTS O
Patients O
classified O
as O
having O
high O
DWMH O
were O
7.14 O
times O
more O
likely O
not O
to O
remit O
following O
antidepressant O
treatment O
compared O
to O
patients O
classified O
as O
having O
low O
DWMH O
( O
p=0.02 O
) O
. O
[]

BACKGROUND O
A O
10-J O
energy O
safety O
margin O
has O
traditionally O
been O
used O
in O
programming O
implantable O
cardioverter O
defibrillators O
( O
ICDs O
) O
. O
[]

The O
patients O
of O
treatment O
group O
and O
control O
group O
were O
respectively O
treated O
with O
fixed-point O
spin O
reduction O
of O
spinal O
manipulation O
therapy O
and O
dialectical O
prescription O
. O
[]

METHODS O
Nineteen O
patients O
using O
a O
MAS O
for O
symptomatic O
OSAS O
underwent O
polysomnography O
, O
with O
MAS O
use O
randomised O
to O
one O
half O
of O
the O
night O
. O
[]

823 O
N O
, O
ES O
= O
0.21 O
) O
. O
[]

Changes O
in O
FCD O
indicate O
a O
faster O
recovery O
of O
the O
microvascular O
perfusion O
in O
MECC O
during O
the O
reperfusion O
period O
. O
[]

Oral O
health O
impacts O
on O
daily O
living O
related O
to O
four O
different O
treatment O
protocols O
for O
chronic O
periodontitis O
. O
[]

In O
an O
efficacy O
trial O
, O
the O
null O
hypothesis O
specifies O
equality O
of O
the O
two O
survival O
distributions O
, O
but O
in O
an O
equivalence O
trial O
, O
a O
null O
hypothesis O
of O
inequivalence O
H0 O
has O
to O
be O
tested O
. O
[]

Both O
vaccines O
were O
otherwise O
well O
tolerated O
. O
[]

RESULTS O
At O
an O
extended O
median O
follow-up O
of O
27.0 O
months O
( O
range O
, O
0-66.9 O
months O
) O
, O
319 O
( O
74.5 O
% O
) O
patients O
in O
the O
fulvestrant O
group O
and O
322 O
( O
76.1 O
% O
) O
patients O
in O
the O
anastrozole O
group O
had O
died B-outcome ['Mortality']
. O
['Mortality']

Tolerability B-outcome ['Life-Impact']
was O
good O
, O
except O
in O
1 O
patient O
on O
placebo O
, O
who O
was O
withdrawn O
from O
the O
study O
because O
of O
severe B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

This O
article O
describes O
details O
of O
the O
study O
and O
presents O
their O
results O
. O
[]

ClinicalTrials.gov O
number O
, O
NCT00100230 O
. O
) O
. O
[]

One O
eye O
had O
to O
be O
excluded O
from O
further O
analysis O
. O
[]

diltiazem O
in O
the O
management O
of O
atrial B-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Other O
side O
effects O
were O
equivalent O
between O
solutions O
and O
mild O
in O
severity O
. O
[]

Behavioral O
ratings O
were O
obtained O
on O
the O
morning O
of O
the O
amino O
acid O
drink O
( O
baseline O
) O
and O
180 O
, O
300 O
, O
and O
420 O
minutes O
after O
the O
drink O
. O
[]

Patients O
aged O
18-80 O
years O
were O
eligible O
for O
enrolment O
if O
they O
had O
stable O
VT O
, O
previous O
myocardial O
infarction O
, O
and O
reduced O
left-ventricular O
ejection O
fraction O
( O
LVEF O
; O
< O
or=50 O
% O
) O
. O
[]

It O
is O
suggested O
that O
addition O
of O
clofibrate O
may O
be O
useful O
in O
maturity-onset O
diabetics O
not O
adequately O
controlled O
by O
diet O
combined O
with O
oral O
hypoglycaemic O
agents O
. O
[]

There O
was O
no O
evidence O
that O
118.5 O
mg/day O
of O
anthocyanins O
and O
259.2 O
mg/day O
of O
phenolic O
acids O
for O
4 O
weeks O
resulted O
in O
statistically O
significant O
changes O
in O
body O
mass O
, O
body O
composition O
, O
appetite O
, O
dietary O
intake O
, O
low O
density O
lipoprotein O
, O
total O
cholesterol O
, O
blood O
pressure O
, O
or O
C-reactive O
protein O
in O
these O
obese O
participants O
at O
the O
dose O
and O
length O
of O
intervention O
used O
in O
this O
trial O
. O
[]

Recurrence O
was O
determined O
by O
two O
consecutive O
21-item O
Hamilton O
Rating O
Scale O
for O
Depression O
( O
HRSD O
) O
scores?15 O
and O
clinician O
interview O
. O
[]

The O
adverse-event O
profile O
of O
risedronate O
, O
including O
gastrointestinal B-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
was O
similar O
to O
that O
of O
control O
. O
['Physiological-Clinical']

Mean O
peak O
FEV1 B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
( O
primary O
endpoint O
) O
was O
maximum O
with O
the O
administration O
of O
the O
combination O
of O
ipratropium O
and O
formoterol O
( O
335.2 O
ml O
, O
SE O
24.6 O
) O
, O
and O
it O
differed O
significantly O
from O
the O
observed O
peak O
changes O
following O
single O
administration O
of O
the O
two O
tested O
doses O
of O
ipratropium O
( O
p O
< O
0.05 O
and O
p O
< O
0.05 O
respectively O
) O
. O
['Physiological-Clinical']

Each O
group O
received O
treatment O
with O
a O
different O
local O
anesthetic O
solution O
containing O
1:200,000 O
epinephrine O
. O
[]

Aripiprazole O
treatment O
of O
irritability O
associated O
with O
autistic O
disorder O
and O
the O
relationship O
between O
prior O
antipsychotic O
exposure O
, O
adverse O
events O
, O
and O
weight O
change O
. O
[]

RESULTS O
All O
samples O
were O
bacterial O
DNA O
negative O
and O
had O
no O
significant O
levels O
of O
lipopolysaccharide O
. O
[]

Protocolization O
of O
the O
training O
program O
, O
in O
conjunction O
with O
skills O
and O
knowledge O
assessment O
, O
may O
improve O
acquisition B-outcome ['Life-Impact']
and O
retention B-outcome ['Life-Impact']
among O
second- O
and O
future-generation O
trainees O
. O
['Life-Impact', 'Life-Impact']

In O
adult O
autistic O
disorders O
, O
severity O
of O
repetitive O
behaviors O
at O
baseline O
, O
as O
measured O
by O
YBOCS-compulsion O
score O
, O
significantly O
positively O
correlated O
with O
both O
peak O
delta O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
area O
under O
the O
curve O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response B-outcome ['Physiological-Clinical']
to O
sumatriptan O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
The O
authors O
compared O
continuous O
epidural O
infusion O
( O
CEI O
) O
with O
continuous O
femoral O
nerve O
block O
( O
CFNB O
) O
regarding O
the O
postoperative B-outcome ['Physiological-Clinical']
analgesic I-outcome ['Physiological-Clinical']
efficacy O
, O
side O
effects O
, O
postoperative B-outcome ['Physiological-Clinical']
knee I-outcome ['Physiological-Clinical']
rehabilitation I-outcome ['Physiological-Clinical']
, O
and O
hospital B-outcome ['Resource-use']
length I-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( I-outcome ['Resource-use']
LOS I-outcome ['Resource-use']
) I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

METHODS O
Year O
1 O
medical O
students O
( O
n O
= O
37 O
) O
were O
randomly O
assigned O
to O
practise O
identifying O
seven O
cardiac O
murmurs O
using O
a O
simulator O
and O
video O
only O
( O
SRL O
group O
) O
or O
a O
simulator O
and O
video O
plus O
the O
booklet O
( O
DSRL O
group O
) O
. O
[]

The O
myocardial B-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ATP I-outcome ['Physiological-Clinical']
and O
creatine B-outcome ['Physiological-Clinical']
phosphate I-outcome ['Physiological-Clinical']
showed O
no O
significant O
differences O
during O
ischemia O
and O
reperfusion O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
evaluated O
the O
concurrent O
validity O
of O
the O
ADS O
as O
a O
general O
measure O
of O
severity O
and O
the O
screening O
accuracy O
of O
the O
total O
score O
and O
subscales O
to O
detect O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
Fourth O
Edition O
( O
DSM-IV O
) O
, O
physiological O
dependence O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Primary O
: O
day O
1 O
mean O
pain O
relief O
( O
0- O
to O
5-point O
verbal O
response O
scale O
) O
. O
[]

In O
a O
rapid O
event-related O
fMRI O
design O
, O
we O
showed O
that O
activations O
in O
the O
rostral O
anterior O
cingulate O
cortex O
( O
rACC O
) O
, O
orbitofrontal O
cortex O
( O
OFC O
) O
, O
and O
dorsolateral O
prefrontal O
cortex O
to O
a O
misleading O
cue O
that O
the O
taste O
would O
be O
mildly O
aversive O
predicted O
decreases O
in O
insula B-outcome ['Physiological-Clinical']
and O
amygdala B-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
to O
the O
highly O
aversive O
taste O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Phosphodiesterase-4 O
inhibitors O
represent O
a O
promising O
new O
class O
of O
substances O
for O
use O
in O
antiinflammatory O
treatment O
of O
this O
disease O
. O
[]

The O
effectiveness O
of O
a O
school-based O
primary O
prevention O
psychological O
program O
is O
assessed O
in O
the O
present O
study O
. O
[]

24 O
gallstone O
patients O
were O
treated O
with O
cicloxilic O
acid O
, O
an O
agent O
endowed O
with O
choleretic O
activity O
, O
at O
the O
dose O
of O
240 O
mg/day O
for O
1 O
month O
. O
[]

Basing O
on O
50 O
posttraumatic O
intensive-care O
patients O
with O
medium O
grade O
lesions O
( O
ISS O
criteria O
) O
, O
the O
prophylactic O
effect O
of O
an O
intravenously O
applicable O
IgM O
preparation O
( O
Pentaglobin O
) O
against O
nosocomial O
infections B-outcome ['Physiological-Clinical']
was O
investigated O
. O
['Physiological-Clinical']

This O
study O
aimed O
to O
evaluate O
the O
Program O
for O
the O
Education O
and O
Enrichment O
of O
Relational O
Skills O
( O
PEERS O
: O
Laugeson O
et O
al O
. O
[]

It O
is O
concluded O
that O
some O
effects O
of O
low B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
provision I-outcome ['Physiological-Clinical']
in O
utero O
can O
be O
alleviated O
by O
an O
adequate O
nutrient B-outcome ['Physiological-Clinical']
supply I-outcome ['Physiological-Clinical']
post-partum I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

4 O
) O
Killing O
the O
birds O
by O
carbon O
dioxide O
inhalation O
and O
bleeding O
led O
to O
slightly O
lower O
ileal B-outcome ['Physiological-Clinical']
digestibility I-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
than O
mechanical O
stunning O
and O
neck O
dislocation O
. O
( O
['Physiological-Clinical']

http O
: O
//www.clinicaltrials.gov/ct2/show/NCT00106210 O
? O
[]

The O
treatment O
group O
participated O
in O
a O
10-week O
( O
30 O
hours O
) O
cognitive O
group O
treatment O
program O
. O
[]

Conversions O
of O
LAVH O
to O
laparotomy O
were O
significantly O
more O
frequent O
in O
Group O
2 O
( O
3/11 O
) O
than O
in O
Group O
1 O
( O
0/20 O
) O
( O
P O
= O
0.04 O
) O
. O
[]

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
full I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
was O
greater O
in O
overweight O
patients O
subjected O
to O
OA O
than O
in O
the O
overweight O
patients O
in O
the O
LA O
group O
( O
22 O
vs O
15 O
days O
, O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
analyse O
the O
influence O
of O
a O
co-administration O
of O
aspirin O
and O
NSAID O
on O
platelet B-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
This O
community-based O
, O
randomized O
trial O
compared O
the O
exercise O
intervention O
with O
a O
no-intervention O
control O
. O
[]

In O
a O
single-center O
, O
open O
, O
randomized O
study O
, O
118 O
postmenopausal O
women O
with O
angiographically O
verified O
coronary O
artery O
disease O
were O
randomized O
to O
hormone O
replacement O
therapy O
, O
given O
as O
long-cycle O
transdermal O
17-beta-estradiol O
( O
50 O
microg/24 O
hour O
) O
for O
3 O
months O
with O
sequential O
medroxy-progesterone O
acetate O
for O
14 O
days O
, O
or O
to O
a O
control O
group O
receiving O
no O
therapy O
. O
[]

SETTING O
Primary O
care O
centre O
. O
[]

Angioplasty O
was O
successful O
in O
95 O
% O
of O
patients O
, O
with O
no O
difference O
in O
placebo O
( O
93 O
% O
) O
and O
streptokinase O
( O
98 O
% O
) O
groups O
. O
[]

Ciaglia O
PDT O
is O
, O
therefore O
, O
the O
preferred O
technique O
for O
percutaneous O
tracheostomy O
in O
critically O
ill O
patients O
. O
[]

Guthrie O
cards O
can O
be O
used O
to O
accurately O
genotype O
CYP21 B-outcome ['Physiological-Clinical']
and O
other O
relevant O
markers B-outcome ['Physiological-Clinical']
, O
potentially O
enhancing O
the O
specificity O
and O
['Physiological-Clinical', 'Physiological-Clinical']

In O
a O
double-blind O
study O
forty-two O
children O
scheduled O
for O
elective O
adenotonsillectomy O
were O
randomized O
to O
receive O
peritonsillar O
infiltration O
, O
following O
induction O
of O
anaesthesia O
, O
with O
either O
0.25 O
% O
plain O
bupivacaine O
or O
0.9 O
% O
saline O
, O
0.5 O
ml/kg O
to O
a O
maximum O
of O
10 O
ml O
. O
[]

The O
effect O
of O
a O
culture-specific O
education O
program O
to O
promote O
breastfeeding O
among O
Vietnamese O
women O
in O
Sydney O
. O
[]

The O
subjective O
global O
assessments O
of O
the O
effect O
of O
the O
treatments O
showed O
a O
significant O
( O
p=0.006 O
) O
linear O
trend O
towards O
a O
better O
effect O
in O
the O
AT O
group O
. O
[]

We O
then O
designed O
a O
4-arm O
clinical O
trial O
in O
patients O
with O
myeloid O
leukemia O
undergoing O
allogeneic O
stem O
cell O
transplantation O
( O
allo-SCT O
) O
. O
[]

METHODS O
Daily O
applications O
of O
products O
containing O
tretinoin O
or O
adapalene O
were O
made O
to O
the O
forearms O
of O
human O
subjects O
for O
up O
to O
21 O
days O
. O
[]

The O
outcome O
measure O
was O
a O
mammogram B-outcome ['Resource-use']
received O
after O
the O
intervention O
period O
and O
within O
2 O
years O
of O
the O
initial O
mammogram O
date O
. O
['Resource-use']

RESULTS O
Twenty O
patients O
were O
assigned O
to O
the O
resection O
group O
and O
22 O
to O
the O
radiochemotherapy O
group O
. O
[]

We O
therefore O
used O
a O
nonparametric O
technique O
to O
calculate O
the O
net O
trough-to-peak O
ratios O
from O
the O
results O
in O
individual O
subjects O
. O
[]

CAC B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( O
35 O
vs. O
24 O
% O
, O
p O
= O
0.94 O
) O
and O
bone B-outcome ['Physiological-Clinical']
histological I-outcome ['Physiological-Clinical']
diagnosis I-outcome ['Physiological-Clinical']
at O
baseline O
and O
12 O
months O
were O
similar O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Preventive O
treatment O
with O
3 O
x O
5 O
mg/day O
of O
Org O
GC O
94 O
for O
a O
period O
of O
3 O
months O
can O
almost O
completely O
eliminate O
migraine B-outcome ['Physiological-Clinical']
attacks O
. O
['Physiological-Clinical']

A O
cross-over O
design O
was O
used O
to O
answer O
the O
following O
research O
questions O
: O
( O
1 O
) O
Is O
virtual O
reality O
an O
effective O
distraction O
intervention O
for O
reducing O
chemotherapy-related O
symptom O
distress O
levels O
in O
older O
women O
with O
breast O
cancer O
? O
( O
[]

Experiment O
3 O
compared O
different O
lengths O
of O
bone O
removed O
in O
the O
osteotomy O
defect O
and O
included O
the O
following O
: O
In O
experiment O
3a O
the O
diameter O
of O
the O
sheep O
tibia O
was O
measured O
at O
the O
incisura O
fibularis O
. O
[]

The O
combination O
did O
not O
offer O
any O
major O
advantage O
over O
conventional O
agents O
. O
[]

Intermittent O
theta-burst O
transcranial O
magnetic O
stimulation O
for O
treatment O
of O
Parkinson B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Gabapentin O
might O
also O
reduce O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

DESIGN O
A O
randomised O
block O
study O
using O
four O
horses O
, O
each O
with O
wounds O
assigned O
to O
four O
treatment O
groups O
. O
[]

The O
aim O
of O
this O
trial O
was O
to O
investigate O
whether O
pre-operative O
chemotherapy O
leads O
to O
a O
15 O
% O
higher O
curative B-outcome ['Physiological-Clinical']
resectability I-outcome ['Physiological-Clinical']
rate O
in O
patients O
with O
operable O
gastric O
cancer O
. O
['Physiological-Clinical']

A O
composite O
of O
in-hospital B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
reinfarction B-outcome ['Physiological-Clinical']
, O
severe B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
failure B-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
, O
and O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
occurred O
in O
15 O
% O
of O
patients O
who O
received O
PCI O
and O
21 O
% O
of O
patients O
who O
received O
SK O
( O
P O
=.4 O
) O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Clinical O
massage O
and O
modified O
Proprioceptive O
Neuromuscular O
Facilitation O
stretching O
in O
males O
with O
latent O
myofascial O
trigger O
points O
. O
[]

All O
patients O
survived B-outcome ['Mortality']
PBSCT O
. O
['Mortality']

Baseline O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
is O
the O
major O
determinant O
of O
the O
rate O
of O
rise O
, O
height O
, O
and O
duration O
of O
Cr O
trajectory O
after O
contrast O
exposure O
. O
['Physiological-Clinical']

The O
steady-state B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of O
distribution O
for O
AmB B-outcome ['Physiological-Clinical']
in O
dextrose O
( O
0.83 O
+/- O
0.33 O
liter O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Seventy O
percent O
of O
blacks O
were O
recruited B-outcome ['Life-Impact']
at O
two O
centers O
; O
the O
one O
with O
the O
major O
special O
recruitment O
effort O
and O
a O
center O
in O
Detroit O
whose O
catchment O
area O
was O
20 O
% O
black O
among O
age-eligibles O
. O
['Life-Impact']

Computed O
tomography O
( O
CT O
) O
, O
electroencephalograms O
( O
EEG O
) O
, O
clinical O
and O
psychometric O
data O
were O
obtained O
in O
96 O
mildly O
to O
moderately O
demented O
patients O
( O
72 O
women O
, O
24 O
men O
) O
, O
aged O
61-96 O
years O
( O
mean O
82 O
) O
, O
diagnosed O
according O
to O
DSM-III O
criteria O
. O
[]

Health-promotion O
interventions O
have O
been O
shown O
to O
reduce O
limitation O
from O
secondary O
conditions O
, O
which O
can O
be O
a O
significant O
barrier O
to O
labor O
force O
participation O
among O
people O
with O
disabilities O
. O
[]

We O
highlight O
considerations O
of O
design O
, O
implementation O
, O
and O
evaluation O
of O
the O
first O
trial O
to O
provide O
rigorous O
evidence O
for O
the O
effectiveness O
of O
current O
Canadian O
IUDs O
when O
inserted O
after O
first-trimester O
abortion O
. O
[]

Correspondingly O
the O
decrease O
of O
plasma B-outcome ['Physiological-Clinical']
renin I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PRA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
prostaglandin I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PGE2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
more O
pronounced O
in O
those O
patients O
treated O
initially O
with O
indomethacin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
odds O
ratio O
( O
OR O
) O
of O
patients O
with O
wounds O
in O
the O
control O
group O
was O
4.1 O
( O
95 O
% O
CI O
is O
1.884 O
, O
8.964 O
) O
more O
likely O
to O
be O
contaminated O
with O
bacteria O
compared O
with O
wounds O
covered O
with O
occlusive O
ionic O
silver-containing O
dressing O
. O
[]

Health B-outcome ['Physiological-Clinical']
outcomes O
were O
measured O
for O
up O
to O
1 O
year O
post-treatment O
. O
['Physiological-Clinical']

The O
effect O
size O
anticipated O
by O
the O
authors O
was O
overestimated O
. O
[]

Twenty-two O
children O
with O
autism O
spectrum O
disorders O
who O
had O
not O
responded O
to O
supported O
behaviour O
management O
strategies O
for O
severe O
dysomnias O
entered O
a O
double O
blind O
, O
randomised O
, O
controlled O
crossover O
trial O
involving O
3 O
months O
of O
placebo O
versus O
3 O
months O
of O
melatonin O
to O
a O
maximum O
dose O
of O
10 O
mg. O
17 O
children O
completed O
the O
study O
. O
[]

Treatment O
with O
topical O
hormones O
may O
provide O
relief O
in O
such O
women O
when O
used O
judiciously O
. O
[]

All O
drugs O
were O
administered O
twice O
daily O
. O
[]

The O
most O
significant O
toxicity B-outcome ['Adverse-effects']
associated O
with O
chemotherapy O
was O
doxorubicin-induced B-outcome ['Physiological-Clinical']
cardiomyopathy I-outcome ['Physiological-Clinical']
, O
which O
resulted O
in O
clinically O
apparent O
congestive B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
in O
five O
patients O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

10 O
ng/mL/cc O
would O
have O
avoided O
28 O
% O
of O
biopsies O
at O
the O
cost O
of O
10 O
% O
of O
detectable O
cancers O
. O
[]

The O
prevalence O
of O
metal B-outcome ['Physiological-Clinical']
allergy I-outcome ['Physiological-Clinical']
was O
similar O
between O
groups O
. O
['Physiological-Clinical']

The O
percentage O
of O
depression B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
ST-segment I-outcome ['Physiological-Clinical']
was O
lower O
for O
diltiazem O
when O
compared O
with O
placebo O
( O
p O
< O
0.05 O
) O
and O
the O
percentage O
of O
patients O
that O
reach O
higher O
stages O
in O
the O
ergometric O
test O
was O
significantly O
better O
for O
diltiazem O
. O
['Physiological-Clinical']

[ O
Comparative O
study O
between O
5 O
% O
prilocaine O
and O
2 O
% O
mepivacaine O
by O
the O
subarachnoid O
route O
in O
transurethral O
resections O
] O
. O
[]

The O
effects O
of O
treatment O
of O
urinary O
incontinence O
in O
general O
practice O
. O
[]

BACKGROUND O
The O
relative O
efficacies O
of O
various O
antiarrhythmic O
drugs O
in O
the O
treatment O
of O
ventricular O
tachyarrhythmias O
are O
not O
well O
known O
. O
[]

Use O
of O
the O
oral O
neuraminidase O
inhibitor O
oseltamivir O
in O
experimental O
human O
influenza O
: O
randomized O
controlled O
trials O
for O
prevention O
and O
treatment O
. O
[]

Comparison O
of O
the O
efficacy O
and O
safety O
of O
faropenem O
daloxate O
and O
cefuroxime O
axetil O
for O
the O
treatment O
of O
acute B-outcome ['Physiological-Clinical']
bacterial I-outcome ['Physiological-Clinical']
maxillary I-outcome ['Physiological-Clinical']
sinusitis I-outcome ['Physiological-Clinical']
in O
adults O
. O
['Physiological-Clinical']

The O
skin O
microvessels O
' O
vasodilatory O
reserve O
was O
assessed O
with O
a O
heat O
challenge O
at O
the O
end O
of O
the O
protocol O
. O
[]

This O
trial O
is O
aimed O
at O
determining O
the O
impact O
of O
activating O
patients O
to O
ask O
providers O
to O
make O
changes O
to O
their O
care O
through O
tailored O
feedback O
. O
[]

Pain B-outcome ['Physiological-Clinical']
and O
fatigue B-outcome ['Physiological-Clinical']
management I-outcome ['Physiological-Clinical']
: O
results O
of O
a O
nursing O
randomized O
clinical O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Post-ERCP B-outcome ['Physiological-Clinical']
pancreatitis I-outcome ['Physiological-Clinical']
was O
the O
primary O
outcome O
of O
interest O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
presence O
of O
brain O
MRI O
abnormalities O
at O
the O
time O
of O
an O
optic O
neuritis O
attack O
is O
a O
strong O
predictor O
of O
the O
15-year O
risk O
[]

Secondary O
outcomes O
were O
changes O
from O
pretreatment O
to O
posttreatment O
in O
percentage O
of O
the O
estimated B-outcome ['Physiological-Clinical']
energy I-outcome ['Physiological-Clinical']
requirement I-outcome ['Physiological-Clinical']
and O
body O
mass O
index O
z O
score O
. O
['Physiological-Clinical']

Predictors O
of O
smoking O
cessation O
among O
cancer O
patients O
enrolled O
in O
a O
smoking O
cessation O
program O
. O
[]

RESULTS O
There O
were O
no O
significant O
differences O
in O
cognitive B-outcome ['Life-Impact']
test O
scores O
between O
the O
off-pump O
and O
on-pump O
groups O
using O
t O
tests O
at O
any O
of O
the O
time O
points O
. O
['Life-Impact']

BACKGROUND O
Patients O
with O
advanced O
cancer O
frequently O
experience O
clinically O
significant O
anemia B-outcome ['Physiological-Clinical']
, O
which O
is O
often O
exacerbated O
by O
myelosuppressive O
chemotherapy O
. O
['Physiological-Clinical']

Effect O
of O
entacapone O
, O
a O
peripherally O
acting O
catechol-O-methyltransferase O
inhibitor O
, O
on O
the O
motor B-outcome ['Physiological-Clinical']
response O
to O
acute O
treatment O
with O
levodopa B-outcome ['Physiological-Clinical']
in O
patients O
with O
Parkinson O
's O
disease O
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
New O
approaches O
to O
evaluation O
of O
nonspecific O
inhalation O
provocation O
( O
dose-response O
relationship O
) O
in O
the O
comparative O
evaluation O
of O
bronchial O
hyperreactivity O
within O
the O
scope O
of O
clinical O
trials O
] O
. O
[]

RESULTS O
There O
was O
a O
high O
rate O
of O
dropout B-outcome ['Life-Impact']
( O
51 O
% O
) O
from O
the O
study O
, O
and O
the O
rates O
were O
significantly O
higher O
among O
smokers O
( O
64 O
% O
) O
than O
non-smokers O
( O
36 O
% O
) O
. O
['Life-Impact']

CONCLUSIONS O
Azimilide O
dihydrochloride O
may O
be O
a O
safe O
and O
effective O
drug O
for O
reducing O
the O
frequency O
of O
VT B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
in O
patients O
with O
implanted O
ICDs O
. O
['Physiological-Clinical']

OBJECTIVE O
Cellulose O
sulfate O
( O
CS O
) O
is O
a O
promising O
vaginal O
microbicide O
. O
[]

No O
statistically O
significant O
difference O
was O
found O
in O
the O
use O
of O
instrumental B-outcome ['Physiological-Clinical']
vaginal I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Each O
received O
the O
30-week O
intervention O
program O
. O
[]

RESULTS O
Infants O
in O
the O
liberal-transfusion O
group O
received O
more O
RBC B-outcome ['Physiological-Clinical']
transfusions I-outcome ['Physiological-Clinical']
( O
5.2 O
+/- O
4.5 O
[ O
mean O
+/- O
SD O
] O
vs O
3.3 O
+/- O
2.9 O
in O
the O
restrictive-transfusion O
group O
) O
. O
['Physiological-Clinical']

Serologically B-outcome ['Physiological-Clinical']
verified I-outcome ['Physiological-Clinical']
influenza I-outcome ['Physiological-Clinical']
, O
as O
measured O
by O
complement B-outcome ['Physiological-Clinical']
fixation I-outcome ['Physiological-Clinical']
and/or I-outcome ['Physiological-Clinical']
haemagglutination I-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
, O
occurred O
in O
27 O
out O
of O
192 O
students O
in O
the O
amantadine O
group O
against O
57 O
out O
of O
199 O
in O
the O
placebo O
group O
, O
giving O
a O
protection O
rate O
of O
52 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Histopathologic B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
eyelid I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
following O
trichloroacetic O
acid O
chemical O
peel O
. O
['Physiological-Clinical']

The O
clinical O
( O
weight O
gain O
and O
oedema B-outcome ['Physiological-Clinical']
) O
and O
metabolic O
( O
hypertension B-outcome ['Physiological-Clinical']
, O
hypokalaemia B-outcome ['Physiological-Clinical']
and O
hypernatraemia B-outcome ['Physiological-Clinical']
) O
side-effects O
were O
reduced O
by O
the O
active O
amiloride O
therapy O
, O
but O
serum B-outcome ['Physiological-Clinical']
carbenoxolone I-outcome ['Physiological-Clinical']
levels O
were O
not O
affected O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

When O
offered O
the O
opportunity O
, O
relapsed O
smokers O
are O
interested O
in O
recycling O
back O
into O
treatment O
for O
a O
new O
, O
assisted O
quit O
attempt O
. O
[]

AIM O
The O
renin-angiotensin-aldosterone O
system O
( O
RAAS O
) O
and O
autonomic O
nervous O
system O
regulate O
the O
cardiovascular O
system O
. O
[]

The O
optimal O
dose O
for O
SIT O
was O
assessed O
using O
efficacy O
results O
from O
the O
EEC O
, O
IgG O
responses O
, O
and O
tolerability O
. O
[]

The O
mean O
[]

In O
order O
to O
examine O
the O
efficacy O
of O
adjuvant O
chemotherapy O
employing O
mitomycin O
C O
( O
MMC O
) O
and O
carmofur O
( O
HCFU O
) O
for O
patients O
with O
noncuratively O
resected O
colorectal O
carcinoma O
, O
a O
cooperative O
study O
was O
performed O
by O
54 O
institutions O
in O
the O
Kyushu O
and O
Chugoku O
areas O
of O
Japan O
. O
[]

This O
is O
a O
preliminary O
report O
on O
18 O
children O
, O
ages O
3.08 O
to O
7.99 O
years O
, O
who O
completed O
this O
ongoing O
study O
. O
[]

plus O
omeprazole O
40 O
mg O
q.d.s. O
, O
or O
dirithromycin O
500 O
mg O
q.d.s O
. O
[]

Low O
FMRP O
levels O
may O
be O
related O
to O
impaired O
neurodevelopmental O
processes O
and O
synaptic O
plasticity O
. O
[]

Long-term O
results O
are O
presented O
from O
two O
randomized O
trials O
of O
RT O
versus O
CT O
in O
pre- O
( O
n O
= O
547 O
) O
and O
postmenopausal O
( O
n O
= O
679 O
) O
patients O
, O
respectively O
, O
with O
node O
positive O
disease O
or O
a O
tumour O
diameter O
> O
30 O
mm O
. O
[]

were O
greater O
than O
0.12 O
. O
[]

These O
studies O
indicate O
that O
children O
with O
autism O
can O
be O
taught O
to O
ask O
questions O
that O
lead O
to O
the O
acquisition O
of O
new O
information O
. O
[]

[ O
Comparison O
of O
the O
efficacy/tolerability O
ratio O
of O
cibenzoline O
and O
propafenone O
in O
the O
treatment O
of O
ventricular O
arrhythmia O
] O
. O
[]

A O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
was O
designed O
to O
compare O
steroid B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
between O
placebo O
and O
methotrexate O
( O
MTX O
) O
treatment O
in O
subjects O
with O
corticosteroid-requiring O
asthma O
. O
['Resource-use']

The O
efficacy O
of O
early O
continuous O
positive O
airway O
pressure O
therapy O
in O
patients O
with O
acute O
cardiogenic O
pulmonary O
edema O
. O
[]

Exclusion O
criteria O
were O
age O
18 O
years O
or O
younger O
and O
90 O
years O
or O
older O
, O
Mini-Mental O
State O
Examination O
score O
of O
21 O
of O
30 O
or O
lower O
, O
no O
ambulating O
order O
, O
advanced O
vision O
impairment O
, O
malignancy O
, O
pneumonia O
, O
or O
heart O
failure O
. O
[]

Pilot O
comparison O
between O
potassium O
titanyl O
phosphate O
laser O
and O
bipolar O
radiofrequency O
in O
paediatric O
tonsillectomy O
. O
[]

More O
patients O
treated O
with O
dexamethasone O
than O
those O
treated O
with O
placebo O
scored O
moderate O
or O
better O
on O
the O
investigator O
's O
global B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
scale O
( O
52 O
% O
versus O
33 O
% O
) O
at O
2 O
days O
, O
but O
the O
difference O
was O
not O
significant O
at O
1 O
month O
( O
54 O
% O
versus O
49 O
% O
) O
. O
['Physiological-Clinical']

Anyway O
controversy O
persists O
regarding O
the O
most O
effective O
inguinal O
hernia O
repair O
. O
[]

INTERPRETATION O
While O
we O
observed O
significantly O
increased O
levels O
of O
metal B-outcome ['Physiological-Clinical']
ions I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
during O
the O
entire O
follow-up O
period O
, O
no O
difference O
in O
prevalence O
of O
metal B-outcome ['Physiological-Clinical']
allergy I-outcome ['Physiological-Clinical']
was O
observed O
in O
the O
MOM O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Four-year O
survival B-outcome ['Mortality']
was O
73.0 O
% O
for O
279 O
high-risk O
patients O
( O
any O
Stage O
IV O
, O
all O
UH O
) O
who O
received O
postoperative O
radiation O
therapy O
( O
RT O
) O
and O
AMD O
+ O
VCR O
+ O
ADR O
+/- O
cyclophosphamide O
( O
CPM O
) O
. O
['Mortality']

The O
interval O
between O
the O
ending O
of O
chemotherapy O
and O
the O
surgical O
resection O
was O
5-6 O
days O
. O
[]

Treatment O
outcome O
was O
measured O
via O
parent O
and O
teacher O
ratings O
of O
child B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
functioning B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

In O
the O
normal O
subjects O
but O
not O
the O
patients O
, O
[]

In O
Phase O
1 O
, O
one O
group O
of O
children O
worked O
with O
teachers O
and O
the O
other O
group O
worked O
with O
parents O
. O
[]

METHODS O
Patients O
with O
IDA O
were O
randomly O
divided O
into O
the O
treated O
group O
and O
the O
control O
group O
, O
50 O
in O
each O
group O
. O
[]

RESULTS O
Significant O
increases O
in O
peak O
oxygen B-outcome ['Physiological-Clinical']
uptake B-outcome ['Physiological-Clinical']
( O
15 O
+/- O
3.4 O
to O
18.5 O
+/- O
2.9mL/kg/min O
; O
p O
= O
.001 O
) O
, O
peak O
workload B-outcome ['Life-Impact']
( O
77 O
+/- O
26 O
to O
99 O
+/- O
31 O
watts O
; O
p O
= O
.000 O
) O
, O
and O
percent O
of O
predicted O
power O
ability B-outcome ['Life-Impact']
( O
43 O
% O
+/- O
10 O
% O
to O
56 O
% O
+/- O
13 O
% O
; O
p O
= O
.000 O
) O
were O
observed O
in O
the O
exercise O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

b O
) O
Advanced O
Intervention O
( O
AI O
) O
. O
[]

Efficacy O
, O
safety O
, O
and O
durability B-outcome ['Life-Impact']
were O
evaluated O
over O
follow-up O
of O
1 O
to O
9 O
years O
( O
mean O
, O
31/2 O
years O
) O
. O
['Life-Impact']

After O
a O
median O
follow-up O
of O
53.9 O
months O
, O
response O
rate O
, O
median O
OS B-outcome ['Mortality']
and O
median O
TFPTD O
were O
14.7 O
% O
( O
6.3 O
% O
CR O
) O
versus O
11.3 O
% O
( O
5.5 O
% O
CR O
) O
, O
14 O
versus O
14 O
months O
, O
6 O
versus O
5 O
months O
, O
in O
arms O
A O
and O
B O
, O
respectively O
with O
no O
significant O
differences O
between O
the O
groups O
. O
['Mortality']

PATIENTS O
AND O
METHODS O
Patients O
with O
diagnosis O
of O
fibrocystic O
breast O
disease O
were O
included O
in O
a O
prospective O
longitudinal O
blind O
double O
, O
controlled O
with O
placebo O
study O
. O
[]

The O
frequency O
of O
pathologic B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
, O
hypercalcemia B-outcome ['Physiological-Clinical']
, O
and O
bone B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
regularly O
assessed O
, O
as O
well O
as O
size O
and O
number O
of O
osteolytic O
lesions O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURE O
The O
Wheelchair O
Use O
Confidence B-outcome ['Life-Impact']
Scale-Manual O
( O
WheelCon-M O
) O
was O
used O
to O
evaluate O
confidence B-outcome ['Life-Impact']
with O
using O
a O
manual O
wheelchair O
. O
['Life-Impact', 'Life-Impact']

In O
those O
patients O
who O
were O
able O
to O
complete O
a O
full O
therapeutic O
trial O
, O
clomipramine O
proved O
comparable O
to O
haloperidol O
in O
terms O
of O
improvement O
compared O
with O
baseline O
. O
[]

Therefore O
, O
our O
particular O
method O
of O
stochastic O
modulation O
of O
the O
stimulation O
parameters O
, O
which O
involved O
moderate O
( O
15 O
% O
) O
variations O
updated O
every O
100 O
ms O
and O
centered O
around O
40 O
Hz O
, O
appeared O
to O
have O
no O
effect O
on O
muscle B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

From O
these O
six O
items O
, O
a O
composite O
score O
of O
? O
[]

We O
conclude O
that O
resource O
utilization O
was O
similar O
between O
treatment O
groups O
and O
that O
the O
choice O
of O
endoscopic O
therapy O
for O
EVH O
must O
still O
rely O
on O
clinical O
grounds O
. O
[]

Changes O
( O
mean O
+/- O
SE O
) O
in O
sitting B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
baseline I-outcome ['Physiological-Clinical']
were O
-8.1 O
+/- O
1.4 O
mm O
Hg O
for O
terazosin O
and O
-5.0 O
+/- O
1.5 O
mm O
Hg O
for O
propranolol O
. O
['Physiological-Clinical']

Infant B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
negatively O
correlated O
with O
cigarettes O
smoked O
per O
day O
( O
r O
= O
-0.29 O
, O
P O
< O
.01 O
) O
and O
expired O
carbon O
monoxide O
( O
r O
= O
-0.39 O
, O
( O
P O
< O
.001 O
) O
at O
delivery O
. O
['Physiological-Clinical']

Measured O
serum B-outcome ['Physiological-Clinical']
propofol I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
equilibrium I-outcome ['Physiological-Clinical']
with O
the O
effect-site O
at O
which O
50 O
% O
of O
the O
patients O
did O
not O
respond O
to O
verbal O
commands O
( O
EC50 O
for O
loss O
of O
consciousness O
) O
were O
determined O
by O
logistic O
regression O
. O
['Physiological-Clinical']

Pioglitazone O
is O
a O
thiazolidinedione O
that O
reduces O
insulin O
resistance O
, O
and O
glimepiride O
is O
a O
sulfonylurea O
insulin O
secretagogue O
. O
[]

The O
clinical O
relevance O
is O
uncertain O
. O
[]

The O
criteria O
for O
patient O
selection O
were O
as O
follows O
: O
1 O
) O
Age O
of O
75 O
years O
or O
less O
and O
not O
accompanied O
by O
any O
serious O
disease O
. O
[]

17.5 O
( O
MI O
) O
, O
59.0 O
? O
[]

They O
were O
aged O
4-10 O
years O
( O
73 O
boys O
) O
. O
[]

No O
significant O
decrease O
in O
total O
respiratory B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
8 I-outcome ['Physiological-Clinical']
Hz I-outcome ['Physiological-Clinical']
( O
Rrs B-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
8 I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
) O
was O
observed O
after O
ipratropium O
, O
whereas O
Rrs O
( O
8 O
) O
decreased O
significantly O
20 O
min O
after O
fenoterol O
and O
40 O
min O
after O
the O
combination O
regimen O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
A O
dose-dependent O
change O
in O
exhaled B-outcome ['Physiological-Clinical']
NO O
during O
graded B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
was O
observed O
( O
p O
= O
0.0012 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Progression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
was O
statistically O
similar O
in O
stage O
I O
patients O
who O
were O
initially O
left O
untreated O
and O
in O
t O
hose O
who O
received O
MPH-P O
just O
after O
diagnosis O
; O
median O
duration O
of O
first O
response O
was O
similar O
in O
stage O
III O
patients O
receiving O
MPH-P O
and O
in O
those O
on O
combination O
chemotherapy O
. O
['Physiological-Clinical']

11.4 O
years O
) O
and O
valsartan O
160 O
mg O
( O
30 O
patients O
; O
21 O
women O
, O
9 O
men O
; O
mean O
age O
49.8 O
? O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

RESULTS O
A O
total O
of O
1,575 O
charts O
from O
14 O
hospitals O
EDs O
were O
abstracted O
. O
[]

Who O
benefits O
? O
[]

Logistic O
regression O
analyses O
showed O
that O
no O
having O
creation O
a O
pleural O
tent O
procedure O
was O
the O
most O
significant O
predictive O
factor O
of O
the O
occurrence O
and O
duration O
of O
prolonged B-outcome ['Physiological-Clinical']
air I-outcome ['Physiological-Clinical']
leaks I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Pazopanib O
in O
locally O
advanced O
or O
metastatic O
renal O
cell O
carcinoma O
: O
results O
of O
a O
randomized O
phase O
III O
trial O
. O
[]

Our O
data O
suggest O
that O
therapeutic O
doses O
of O
glucocorticoids O
induce O
obesity O
mostly O
by O
increasing O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
an O
effect O
which O
may O
be O
related O
to O
the O
ability O
of O
glucocorticoids O
to O
act O
directly O
or O
indirectly O
on O
the O
central O
regulation O
of O
appetite O
. O
['Life-Impact']

GII O
and O
GIV O
ewes O
were O
kept O
in O
climatic O
chamber O
at O
40?C O
and O
55 O
% O
RH O
for O
6 O
h O
a O
day O
between O
10:00 O
and O
16:00 O
hours O
to O
induce O
thermal O
stress O
for O
a O
period O
of O
two O
oestrous O
cycles O
. O
[]

The O
dose O
of O
risperidone O
was O
1-3 O
mg/day O
and O
the O
dose O
of O
Ginko O
T.D O
. O
[]

An O
evaluation O
of O
chemical O
arthrodesis O
of O
the O
proximal O
interphalangeal O
joint O
in O
the O
horse O
by O
using O
monoiodoacetate O
. O
[]

When O
entered O
together O
into O
a O
regression O
analysis O
, O
metrics O
that O
represented O
( O
a O
) O
the O
number O
of O
parent O
utterances O
following O
into O
the O
child O
's O
focus O
of O
attention O
and O
( O
b O
) O
the O
number O
of O
parent B-outcome ['Life-Impact']
utterances I-outcome ['Life-Impact']
responding I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
child I-outcome ['Life-Impact']
verbal I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
acts O
both O
accounted O
for O
unique O
variance O
in O
predicting O
change O
in O
spoken B-outcome ['Life-Impact']
vocabulary I-outcome ['Life-Impact']
from O
Time O
1 O
to O
Time O
2 O
. O
['Life-Impact', 'Life-Impact']

Microbial O
swab O
cultures O
revealed O
significant O
differences O
between O
the O
two O
groups O
( O
p O
< O
0.001 O
, O
mean=1.43?0.63 O
) O
in O
bacterial O
colonisation O
. O
[]

10.9 O
% O
, O
with O
and O
without O
music O
, O
respectively O
, O
p O
? O
[]

The O
treatment O
was O
well O
tolerated O
overall O
. O
[]

In O
a O
randomized O
double-blind O
crossover O
trial O
with O
sequential O
analysis O
, O
the O
effects O
of O
oral O
diuretics O
were O
compared O
with O
the O
effects O
of O
placebo O
on O
pulmonary O
mechanics O
in O
ten O
infants O
with O
bronchopulmonary O
dysplasia O
( O
BPD O
) O
. O
[]

However O
, O
there O
are O
limited O
data O
about O
argatroban O
in O
non-HIT O
patients O
. O
[]

Having O
health B-outcome ['Life-Impact']
insurance I-outcome ['Life-Impact']
( O
odds O
ratio O
= O
7.20 O
, O
P O
= O
.00 O
) O
and O
a O
negative O
urine B-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
screen I-outcome ['Physiological-Clinical']
( O
odds O
ratio O
= O
.56 O
, O
P O
= O
.04 O
) O
were O
significant O
predictors O
of O
being O
in O
HBP O
care O
. O
['Life-Impact', 'Physiological-Clinical']

CBF B-outcome ['Physiological-Clinical']
and O
the O
arteriovenous B-outcome ['Physiological-Clinical']
difference I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
( O
AVDO2 O
) O
were O
measured O
twice O
, O
before O
and O
after O
indomethacin/placebo O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Of O
the O
6 O
CSA O
patients O
who O
completed O
the O
trial O
, O
4 O
( O
66.7 O
% O
) O
were O
ACR O
20 O
% O
responders O
, O
and O
3 O
( O
50 O
% O
) O
were O
both O
ACR O
50 O
% O
and O
ACR O
70 O
% O
responders O
. O
[]

57 O
% O
of O
the O
participants O
with O
pathological O
H2-test O
after O
sorbitol O
and O
56 O
% O
after O
fructose O
reported O
symptoms O
, O
while O
all O
of O
the O
3 O
malabsorbers O
of O
xylitol O
were O
symptomatic O
. O
[]

CONCLUSIONS O
This O
study O
suggests O
that O
for O
patients O
ar O
substantial O
risk O
for O
systemic O
metastases O
, O
it O
is O
preferable O
to O
give O
a O
12-week O
course O
of O
chemotherapy O
followed O
by O
radiation O
therapy O
, O
rather O
than O
radiation O
therapy O
followed O
by O
chemotherapy O
. O
[]

Effect O
of O
phenylephrine O
on O
the O
haemodynamic B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
during O
anaesthesia O
in O
the O
upright O
position O
. O
['Physiological-Clinical']

Pharmacokinetic O
and O
safety O
evaluation O
of O
high-dose O
combinations O
of O
fosamprenavir O
and O
ritonavir O
. O
[]

RESULTS O
Due O
to O
circumstances O
beyond O
the O
researchers O
' O
control O
, O
recruitment O
was O
abandoned O
when O
463 O
women O
had O
been O
enrolled O
. O
[]

As O
compared O
with O
placebo O
, O
secretin O
treatment O
was O
not O
associated O
with O
significant O
improvements O
in O
any O
of O
the O
outcome O
measures O
. O
[]

2 O
. O
[]

The O
clinical O
efficacy O
of O
two O
doses O
of O
mefloquine O
( O
15 O
and O
25 O
mg/kg O
body O
weight O
) O
was O
evaluated O
in O
85 O
children O
suffering O
from O
acute O
symptomatic O
falciparum O
malaria O
. O
[]

Local O
delivery O
of O
a O
recombinant O
adenoassociated O
vector O
containing O
a O
tumour O
necrosis O
factor O
alpha O
antagonist O
gene O
in O
inflammatory O
arthritis O
: O
a O
phase O
1 O
dose-escalation O
safety O
and O
tolerability B-outcome ['Life-Impact']
study O
. O
['Life-Impact']

CONCLUSION O
The O
results O
of O
the O
present O
study O
on O
the O
administration O
of O
GnRH O
analogue O
to O
females O
with O
myomas O
suggest O
that O
no O
direct O
or O
immediate O
inter-relationship O
exists O
between O
expression O
of O
leptin B-outcome ['Physiological-Clinical']
genes I-outcome ['Physiological-Clinical']
in O
uterine O
myomas O
on O
one O
hand O
and O
estrogen O
, O
progesterone O
and O
leptin O
levels O
in O
the O
blood O
on O
the O
other O
. O
['Physiological-Clinical']

Recurrent B-outcome ['Physiological-Clinical']
tuberculosis I-outcome ['Physiological-Clinical']
in O
the O
United O
States O
and O
Canada O
: O
relapse O
or O
reinfection O
? O
['Physiological-Clinical']

The O
mean O
improvement O
rate O
from O
baseline O
at O
month O
12 O
in O
International O
Prostate B-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Score O
and O
the O
maximal B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
similar O
in O
the O
2 O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
use O
of O
lottery O
tickets O
as O
incentives O
in O
an O
epidemiologic O
control O
group O
. O
[]

Patients O
were O
assessed O
for O
response O
to O
treatment O
( O
defined O
as O
a O
platelet O
count O
of O
50,000-400,000 O
per O
?L O
) O
weekly O
during O
the O
first O
6 O
weeks O
and O
at O
least O
once O
every O
4 O
weeks O
thereafter O
; O
the O
primary O
endpoint O
was O
the O
odds O
of O
response B-outcome ['Physiological-Clinical']
to O
eltrombopag O
versus O
placebo O
. O
['Physiological-Clinical']

The O
study O
included O
93 O
patients O
. O
[]

Three O
hundred O
forty-one O
Tanzanian O
preschool O
children O
were O
randomly O
assigned O
to O
levamisole O
or O
placebo O
treatment O
given O
at O
three-month O
intervals O
. O
[]

MEASUREMENTS O
Body B-outcome ['Physiological-Clinical']
weight O
and O
composition B-outcome ['Physiological-Clinical']
, O
TEE B-outcome ['Physiological-Clinical']
, O
REE B-outcome ['Physiological-Clinical']
, O
and O
RQ B-outcome ['Physiological-Clinical']
were O
measured O
at O
baseline O
and O
at O
week O
16 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
determine O
the O
effects O
of O
tocilizumab O
on O
rheumatoid O
arthritis O
( O
RA O
) O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
remission B-outcome ['Physiological-Clinical']
assessment O
, O
using O
measures O
that O
do O
or O
do O
not O
comprise O
acute-phase O
reactants O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Notably O
, O
individuals O
with O
ASD O
showed O
a O
speech-specific B-outcome ['Life-Impact']
deficit I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
multisensory I-outcome ['Life-Impact']
temporal I-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
. O
['Life-Impact']

In O
contrast O
, O
PLCO O
used O
a O
single O
cutoff O
for O
CA125 O
, O
based O
on O
current O
levels O
alone O
. O
[]

The O
treatment O
group O
patients O
received O
a O
preoperative O
NB O
( O
0.25 O
% O
5-8 O
ml O
bupivacaine O
mixed O
with O
20-40 O
mg O
methylprednisolone O
) O
targeting O
the O
supraorbital O
, O
supratrochlear O
, O
auriculotemporal O
, O
and O
posterior O
auricular O
nerves O
. O
[]

RESULTS O
Respiratory B-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
was O
good O
in O
all O
but O
two O
patients O
. O
['Physiological-Clinical']

The O
salivary O
cortisol O
concentrations O
of O
the O
sows O
were O
measured O
in O
the O
course O
of O
the O
gestation O
period O
. O
[]

Cure B-outcome ['Physiological-Clinical']
was O
evaluated O
4 O
months O
postoperatively O
primarily O
by O
fasting O
IGF1 O
less O
than O
or O
equal O
to O
age-adjusted O
upper O
limit O
of O
normal O
. O
['Physiological-Clinical']

The O
minimal O
model O
of O
Bergman O
et O
al O
has O
been O
used O
to O
yield O
estimates O
of O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Si I-outcome ['Physiological-Clinical']
) O
and O
glucose B-outcome ['Physiological-Clinical']
effectiveness O
( O
Sg B-outcome ['Physiological-Clinical']
) O
in O
type O
2 O
diabetes O
by O
incorporating O
exogenous O
insulin O
protocols O
into O
the O
regular O
intravenous O
glucose O
tolerance O
test O
( O
IVGTT O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Nefazodone O
treatment O
resulted O
in O
a O
significant O
reduction O
( O
p O
< O
.01 O
) O
of O
the O
17-item O
Hamilton O
Rating O
Scale O
for O
Depression O
( O
HAM-D-17 O
) O
total O
score O
compared O
with O
placebo O
from O
the O
end O
of O
the O
first O
treatment O
week O
through O
the O
end O
of O
the O
study O
( O
-12.2 O
nefazodone O
vs. O
-7.7 O
placebo O
) O
. O
[]

RESULTS O
At O
week O
24 O
, O
both O
donepezil O
groups O
showed O
significant O
improvement O
in O
cognition B-outcome ['Life-Impact']
versus O
placebo O
on O
the O
Alzheimer B-outcome ['Life-Impact']
's O
Disease O
Assessment O
Scale-cognitive O
subscale O
( O
mean O
change O
from O
baseline O
score O
effect O
size O
: O
donepezil O
5 O
mg/d O
, O
-1.90 O
; O
P=0.001 O
; O
donepezil O
10 O
mg/d O
, O
-2.33 O
; O
P O
< O
0.001 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSION O
Fish O
oil O
improves O
BP B-outcome ['Physiological-Clinical']
in O
normotensive O
and O
normolipidemic O
slightly O
overweight O
adolescent O
boys O
. O
['Physiological-Clinical']

Home O
based O
management O
in O
multiple O
sclerosis O
: O
results O
of O
a O
randomised O
controlled O
trial O
. O
[]

SETTING O
Aberdeen O
Assisted O
Reproduction O
Unit O
. O
[]

The O
main O
intervention O
strategies O
were O
: O
information O
about O
the O
risk O
factor O
concept O
to O
participant O
and O
spouse O
( O
in O
groups O
) O
individual O
diet O
and O
anti-smoking O
counselling O
after O
finishing O
an O
extensive O
clinical O
and O
electrocardiographic O
examination O
, O
including O
exercise-ECG O
basis O
and O
background O
for O
the O
counselling O
strategy O
: O
the O
total O
situation O
of O
the O
participant O
. O
[]

RESULTS O
Symptom B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
pelvic I-outcome ['Physiological-Clinical']
examination I-outcome ['Physiological-Clinical']
scores O
remained O
significantly O
below O
baseline O
for O
at O
least O
8 O
months O
after O
completion O
of O
therapy O
for O
all O
four O
groups O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
statistical O
differences O
between O
the O
two O
treatment O
groups O
for O
the O
parameters O
measured O
with O
one O
exception O
; O
there O
was O
a O
statistically O
significant O
decrease O
in O
discomfort O
levels O
for O
the O
laser O
system O
at O
the O
time O
of O
cavity O
preparation O
for O
subjects O
who O
declined O
to O
receive O
local O
anesthetic O
. O
[]

Time O
to O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
following O
a O
single O
dose O
was O
1.1 O
+/- O
0.8 O
hours O
with O
30 O
mg O
lansoprazole O
, O
3.0 O
+/- O
2.5 O
hours O
with O
20 O
mgomeprazole O
MUPS O
and O
2.1 O
+/- O
1.2 O
hours O
with O
40 O
mg O
esomeprazole O
. O
['Physiological-Clinical']

There O
were O
11 O
treatment O
failures B-outcome ['Physiological-Clinical']
( O
10 O
acute O
and O
one O
relapse O
) O
in O
the O
cefixime O
group O
and O
1 O
acute O
treatment O
['Physiological-Clinical']

RESULTS O
Clinical O
symptoms O
and O
laboratory O
findings O
did O
not O
differ O
significantly O
in O
the O
2 O
groups O
. O
[]

Oscillatory O
potentials O
, O
retinopathy O
, O
and O
long-term O
glucose O
control O
in O
insulin-dependent O
diabetes O
. O
[]

The O
subjective O
and O
objective O
ocular B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
documented O
over O
the O
treatment O
period O
. O
['Physiological-Clinical']

Such O
data O
provide O
evidence O
that O
dietary O
counseling O
for O
mothers O
during O
the O
first O
year O
of O
life O
improves O
the O
overall O
dietary O
quality O
of O
children O
in O
a O
low-income O
population O
. O
[]

METHODS O
In O
all O
, O
24 O
patients O
with O
metastatic O
colorectal O
cancer O
with O
cetuximab O
facial O
rash O
received O
twice O
daily O
pimecrolimus O
application O
for O
5 O
weeks O
to O
half O
of O
the O
face O
. O
[]

Participants O
in O
the O
treatment O
group O
demonstrated O
greater O
play B-outcome ['Life-Impact']
diversity I-outcome ['Life-Impact']
on O
a O
standardized O
assessment O
. O
['Life-Impact']

METHODS O
AND O
RESULTS O
This O
study O
was O
a O
prospective O
, O
randomized O
, O
paired O
comparison O
of O
two O
shock O
configurations O
on O
atrial O
DFTs O
in O
33 O
patients O
. O
[]

Proper O
selection O
of O
patients O
for O
the O
laparoscopic O
procedure O
is O
the O
vital O
step O
in O
achieving O
the O
major O
goals O
of O
this O
approach O
. O
[]

In O
both O
groups O
, O
a O
minimal O
decrease O
in O
the O
erythemal B-outcome ['Physiological-Clinical']
index O
was O
observed O
. O
['Physiological-Clinical']

CONCLUSIONS O
It O
appears O
that O
pimecrolimus O
, O
a O
nonsteroidal O
topical O
treatment O
, O
may O
be O
an O
excellent O
alternative O
therapeutic O
modality O
for O
treating O
seborrhoeic O
dermatitis O
. O
[]

Falls B-outcome ['Life-Impact']
were O
tracked O
for O
1 O
year O
after O
each O
participant O
's O
baseline O
assessment O
. O
['Life-Impact']

BACKGROUND O
Pain B-outcome ['Physiological-Clinical']
after O
craniotomy O
is O
often O
under-treated O
. O
['Physiological-Clinical']

A O
double O
blind O
trial O
of O
terfenadine O
and O
placebo O
in O
hay O
fever O
using O
a O
substitution O
technique O
for O
non-responders O
. O
[]

Depression O
and O
inflammation O
are O
common O
among O
cancer O
patients O
. O
[]

The O
effectiveness O
of O
single-dose O
metronidazole O
therapy O
for O
patients O
and O
their O
partners O
with O
bacterial O
vaginosis O
. O
[]

The O
results O
demonstrated O
significant O
improvements O
in O
parent-reported O
child B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
, O
parenting B-outcome ['Life-Impact']
styles I-outcome ['Life-Impact']
, O
parental B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
, O
and O
conflict B-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
parenting I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Riluzole O
is O
a O
glutamate-modulating O
agent O
with O
neuroprotective O
properties O
, O
which O
has O
been O
shown O
to O
have O
positive O
effects O
in O
many O
neuropsychiatric B-outcome ['Physiological-Clinical']
disorders I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Furthermore O
, O
smokers O
with O
SZ O
demonstrated O
additive O
reductions O
in O
circuit O
strength O
between O
the O
dACC O
and O
insula O
compared O
to O
NC O
smokers O
independent O
of O
smoking O
severity O
. O
[]

Pruritus O
in O
HIV-1 O
disease O
: O
therapy O
with O
drugs O
which O
may O
modulate O
the O
pattern O
of O
immune B-outcome ['Physiological-Clinical']
dysregulation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

No O
significant O
differences O
in O
infection B-outcome ['Physiological-Clinical']
or O
malignancy B-outcome ['Physiological-Clinical']
were O
noted O
between O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Hospital B-outcome ['Resource-use']
admissions I-outcome ['Resource-use']
and O
other O
variables O
were O
assessed O
. O
['Resource-use']

The O
primary O
care O
intervention O
provided O
assistance O
to O
practices O
in O
establishing O
an O
office O
system O
that O
promoted O
sun O
protection O
advice O
to O
children O
and O
their O
parents O
during O
office O
visits O
. O
[]

The O
experimental O
acupuncture O
treatment O
consisted O
of O
specific O
acupuncture O
body O
points O
related O
to O
menopausal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Meal-stimulated O
levels O
of O
intact O
neurotensin O
were O
higher O
after O
1:3 O
than O
3:1 O
jejunoileal O
bypass O
. O
[]

We O
evaluated O
the O
efficacy O
of O
smokeless O
tobacco O
and O
group O
support O
for O
smoking B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
in O
an O
open O
, O
randomized O
study O
that O
compared O
smokeless O
tobacco O
plus O
group O
support O
versus O
group O
support O
only O
. O
['Life-Impact']

Effects O
of O
fatty O
and O
lean O
fish O
intake O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
subjects O
with O
coronary O
heart O
disease O
using O
multiple O
medications O
. O
['Physiological-Clinical']

Complement O
activation O
on O
the O
surface O
of O
cell-derived O
microparticles O
during O
cardiac O
surgery O
with O
cardiopulmonary O
bypass O
- O
is O
retransfusion O
of O
pericardial O
blood O
harmful O
? O
[]

0.2 O
vs. O
6.6 O
? O
[]

This O
study O
evaluates O
the O
effectiveness O
of O
an O
intervention O
package O
including O
a O
discrete O
trial O
program O
( O
Rapid O
Motor O
Imitation O
Antecedent O
Training O
( O
Tsiouri O
and O
Greer O
, O
J O
Behav O
Educat O
12:185-206 O
, O
2003 O
) O
combined O
with O
parent O
education O
for O
eliciting O
first O
words O
in O
children O
with O
ASD O
who O
had O
little O
or O
no O
spoken O
language O
. O
[]

Subjectively O
, O
exercise O
did O
not O
influence O
the O
degree O
of O
cartilage B-outcome ['Physiological-Clinical']
destruction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

[ O
Effect O
of O
acupuncture O
on O
rehabilitation O
training O
of O
child O
's O
autism O
] O
. O
[]

The O
effect O
of O
these O
drugs O
given O
together O
was O
additive O
on O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
synergistic O
on O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
24.5/12.6 O
mm O
Hg O
supine O
) O
taking O
into O
account O
the O
placebo O
response O
. O
['Physiological-Clinical', 'Physiological-Clinical']

prostate O
, O
p O
< O
0.01 O
) O
. O
[]

Two O
randomized O
, O
double-blind O
, O
single-dose O
studies O
were O
conducted O
to O
assess O
the O
analgesic B-outcome ['Resource-use']
efficacy O
and O
safety O
of O
piroxicam O
for O
the O
treatment O
of O
moderate B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
severe I-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

In O
multivariate O
analyses O
, O
the O
best O
predictors O
of O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
were O
fluconazole O
treatment O
( O
P O
= O
0.02 O
; O
relative O
hazard O
, O
13.2 O
) O
, O
a O
lower O
serum O
cryptococcal-antigen O
titer O
( O
P O
= O
0.05 O
; O
relative O
hazard O
, O
1.2 O
) O
, O
and O
more O
prolonged O
primary O
therapy O
with O
flucytosine O
( O
P O
= O
0.09 O
; O
relative O
hazard O
, O
1.1 O
) O
. O
['Mortality']

The O
rate O
of O
breastfeeding O
among O
immigrant O
Vietnamese O
women O
in O
Western O
countries O
is O
low O
compared O
to O
those O
in O
Vietnam O
. O
[]

Visit-to-visit O
intraindividual O
clinic O
SBP O
variability O
was O
only O
slightly O
lower O
on O
calcium O
antagonist O
than O
on O
?-blocker O
treatment O
but O
little O
or O
no O
between-treatment O
difference O
was O
found O
for O
visit-to-visit O
clinic O
DBP O
and O
ambulatory O
SBP/DBP O
particularly O
in O
patients O
under O
monotherapy O
throughout O
the O
study O
. O
[]

Drug O
effects O
were O
monitored O
by O
detailed O
playroom O
observations O
, O
actometers O
, O
and O
parents O
' O
checklist O
ratings O
( O
[]

The O
primary O
aim O
of O
this O
study O
is O
to O
assess O
the O
efficacy O
of O
hyperbaric O
oxygen O
therapy O
plus O
standard O
wound O
care O
compared O
with O
standard O
wound O
care O
alone O
in O
preventing O
the O
need O
for O
major B-outcome ['Resource-use']
amputation I-outcome ['Resource-use']
in O
patients O
with O
diabetes O
mellitus O
and O
chronic O
ulcers O
of O
the O
lower O
limb O
. O
['Resource-use']

Effect O
of O
the O
essential O
oils O
of O
garlic O
and O
onion O
on O
alimentary O
hyperlipemia O
. O
[]

We O
reviewed O
records O
for O
pediatric O
patients O
who O
had O
postoperative O
arrhythmias O
between O
January O
2006 O
and O
June O
2010 O
at O
a O
large O
tertiary-care O
children O
's O
hospital O
. O
[]

Mean O
( O
SD O
) O
SiSBP O
and O
SiDBP B-outcome ['Physiological-Clinical']
were O
significantly O
decreased O
from O
baseline O
in O
both O
groups O
( O
amlodipine O
camsylate O
, O
from O
146.7 O
[ O
12.3 O
] O
/96.6 O
[ O
5.4 O
] O
to O
127.9 O
[ O
14.8 O
] O
/83.4 O
[ O
7.7 O
] O
mm O
Hg O
[ O
both O
, O
P O
< O
0.001 O
] O
; O
amlodipine O
besylate O
, O
from O
146.8 O
[ O
12.8 O
] O
/96.7 O
[ O
5.1 O
] O
to O
128.0 O
[ O
10.1 O
] O
/83.8 O
[ O
7.5 O
] O
mm O
Hg O
[ O
both O
, O
P O
< O
0.001 O
] O
) O
. O
['Physiological-Clinical']

RESULTS O
The O
mean O
number O
of O
sentinel B-outcome ['Physiological-Clinical']
nodes I-outcome ['Physiological-Clinical']
per O
patient O
was O
1.96 O
ranging O
from O
1 O
to O
3 O
nodes O
. O
['Physiological-Clinical']

They O
were O
done O
at O
( O
a O
) O
uncontrolled O
stage O
( O
FBS O
-- O
165 O
+/- O
16.7 O
mg/dl O
, O
PP O
-- O
240 O
+/- O
30.1 O
mg/dl O
and O
HbA1 O
-- O
10.5 O
+/- O
0.9 O
% O
in O
group O
I O
and O
FBS O
-- O
150 O
+/- O
15.8 O
mg/dl O
, O
PP O
-- O
246 O
+/- O
29.1 O
mg/dl O
HbA1 O
10.6 O
+/- O
0.8 O
% O
in O
group O
II O
) O
and O
during O
controlled O
stage O
at O
12 O
weeks O
( O
FBS O
-- O
120 O
+/- O
18.5 O
mg/dl O
, O
PP O
-- O
180 O
+/- O
19.1 O
mg/dl O
and O
HbA1 O
-- O
8.4 O
+/- O
0.29 O
% O
in O
group O
I O
and O
FBS O
-- O
118 O
+/- O
17.6 O
mg/dl O
, O
PP O
-- O
176 O
+/- O
20.1 O
mg/dl O
and O
HbA1 O
-- O
8.5 O
+/- O
0.39 O
% O
in O
group O
II O
patients O
) O
. O
[]

End-expiratory O
lung O
volume O
recovers O
more O
slowly O
after O
closed O
endotracheal B-outcome ['Resource-use']
suctioning O
than O
after O
open O
suctioning O
: O
a O
randomized O
crossover O
study O
. O
['Resource-use']

Concurrent O
doxorubicin O
plus O
docetaxel O
is O
not O
more O
effective O
than O
concurrent O
doxorubicin O
plus O
cyclophosphamide O
in O
operable O
breast O
cancer O
with O
0 O
to O
3 O
positive O
axillary O
nodes O
: O
North O
American O
Breast O
Cancer O
Intergroup O
Trial O
E O
2197 O
. O
[]

Glycerol O
lidocaine O
eardrops O
for O
the O
treatment O
of O
acute B-outcome ['Physiological-Clinical']
abacterial I-outcome ['Physiological-Clinical']
otitis I-outcome ['Physiological-Clinical']
externa I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Treatment O
of O
posterior O
uveitis O
with O
a O
fluocinolone O
acetonide O
implant O
: O
three-year O
clinical O
trial O
results O
. O
[]

The O
endoscopic O
technique O
does O
appear O
to O
have O
[]

Therapeutic O
failures O
were O
crossed O
over O
to O
the O
other O
study O
medication O
. O
[]

Secondary O
outcome O
measures O
included O
the O
American O
Shoulder O
and O
Elbow O
Surgeons O
( O
ASES O
) O
shoulder O
assessment O
form O
and O
a O
count O
of O
revisions B-outcome ['Life-Impact']
required O
in O
each O
group O
. O
['Life-Impact']

A O
coronary O
arteriography O
was O
performed O
on O
study O
entry O
. O
[]

INTERVENTIONS O
Participants O
were O
randomized O
to O
an O
intervention O
( O
simulator O
ON O
) O
or O
control O
( O
simulator O
OFF O
) O
group O
after O
getting O
informed O
consent O
. O
[]

The O
patients O
had O
ECG-verified O
left O
ventricular O
hypertrophy O
, O
mean O
age O
67 O
years O
, O
blood O
pressure O
177/96 O
mmHg O
after O
two O
weeks O
placebo O
run-in O
period O
. O
[]

COX-2 O
was O
higher O
in O
corpus O
than O
antrum O
and O
it O
increased O
after O
ibuprofen O
treatment O
. O
[]

We O
studied O
the O
effect O
of O
warfarin O
plus O
aspirin O
therapy O
( O
WASA O
) O
versus O
aspirin O
therapy O
alone O
( O
ASA O
) O
on O
patient B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
morbidity B-outcome ['Physiological-Clinical']
and O
bypass B-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
rates O
in O
a O
randomized O
clinical O
trial O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Results O
showed O
that O
diphenhydramine O
produced O
a O
significant O
inhibition B-outcome ['Physiological-Clinical']
of O
the O
histamine-induced B-outcome ['Physiological-Clinical']
wheal I-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
at O
1.5 O
h O
which O
lasted O
up O
to O
4 O
h O
after O
drug O
administration O
, O
reaching O
maximum O
inhibition O
at O
2.5 O
h. O
After O
cinnarizine O
treatment O
no O
significant O
decrease O
of O
the O
histamine-induced B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
average O
[]

Ferriman-Gallwey O
scores O
, O
androgen B-outcome ['Physiological-Clinical']
levels O
and O
sex B-outcome ['Physiological-Clinical']
hormone-binding I-outcome ['Physiological-Clinical']
globulin I-outcome ['Physiological-Clinical']
were O
measured O
at O
baseline O
and O
every O
3 O
months O
for O
the O
duration O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Those O
analyzing O
liver B-outcome ['Physiological-Clinical']
and O
kidney B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
were O
blinded O
to O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Budesonide O
was O
administered O
twice O
a O
day O
and O
Becotide O
Nasal O
four O
times O
a O
day O
. O
[]

Levamisole O
appeared O
to O
adversely O
affect O
CR B-outcome ['Physiological-Clinical']
rates O
in O
nodular O
mixed O
and O
nodular O
large-cell O
lymphoma O
and O
CR B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
in O
patients O
with O
unfavorable O
histology O
ML O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Median O
follow-up O
of O
controls O
was O
18.5 O
months O
( O
range O
, O
3.1-32.9 O
months O
) O
. O
[]

Of O
interest O
were O
: O
( O
1 O
) O
the O
number O
of O
overlaps O
and O
the O
percentage O
of O
teeth O
showing O
the O
alveolar O
crest O
; O
( O
2 O
) O
proper O
film O
positioning O
; O
and O
( O
3 O
) O
the O
percentage O
of O
cone O
cutting O
. O
[]

Plasma O
samples O
were O
obtained O
over O
a O
72-h O
interval O
and O
analyzed O
for O
diflunisal B-outcome ['Physiological-Clinical']
and O
naproxen B-outcome ['Physiological-Clinical']
by O
reversed O
phase O
liquid O
chromatography O
with O
UV O
detection O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
frequencies O
of O
QLQ-C30 B-outcome ['Physiological-Clinical']
score O
improvement O
were O
calculated O
and O
mixed O
models O
for O
repeated O
measurements O
were O
applied O
with O
or O
without O
extreme O
poorest O
imputation O
for O
missing O
scores O
. O
['Physiological-Clinical']

The O
objective O
was O
to O
evaluate O
change O
in O
physical O
activity O
, O
measured O
by O
steps O
per O
day O
and O
minutes O
of O
moderate/vigorous B-outcome ['Life-Impact']
physical O
activity O
. O
['Life-Impact']

CONCLUSIONS O
These O
results O
indicate O
that O
cardiac O
output O
measurements O
are O
affected O
by O
alterations O
in O
patient O
position O
. O
[]

All O
eyes O
could O
receive O
treatment O
or O
sham O
as O
often O
as O
every O
4 O
weeks O
. O
[]

The O
ratio O
of O
high- B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
low-frequency I-outcome ['Physiological-Clinical']
power O
of O
the O
diaphragmatic B-outcome ['Physiological-Clinical']
electromyogram I-outcome ['Physiological-Clinical']
( O
EMGdi O
) O
decreased O
during O
loading O
; O
the O
decrease O
was O
less O
with O
fenoterol O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Aggressive O
parenteral O
nutrition O
( O
PN O
) O
including O
amino O
acids O
is O
recommended O
for O
low-birth-weight O
infants O
to O
prevent O
energy O
and O
protein O
deficit O
. O
[]

RESULTS O
One O
hundred O
twenty-four O
patients O
were O
recruited O
over O
a O
23-month O
period O
. O
[]

To O
fill O
this O
gap O
we O
assessed O
magnetoencephalographic B-outcome ['Physiological-Clinical']
Mu-modulations I-outcome ['Physiological-Clinical']
in O
Asperger O
's O
and O
typically O
developed O
children O
, O
while O
observing O
grasping B-outcome ['Life-Impact']
movements I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

METHODS O
In O
a O
prospective O
clinical O
trial O
, O
43 O
ankles O
( O
30 O
patients O
) O
with O
radiographic O
Kellgren O
Lawrence O
grade O
III O
OA O
were O
randomized O
to O
receive O
three O
intra-articular O
HA O
injections O
, O
with O
one-week O
interval O
of O
or O
exercise O
therapy O
for O
six O
weeks O
. O
[]

SETTING O
The O
study O
was O
conducted O
in O
a O
sleep O
center O
. O
[]

An O
exploratory O
, O
pragmatic O
, O
cluster O
randomised O
trial O
of O
practice O
nurse O
training O
in O
the O
use O
of O
asthma O
action O
plans O
. O
[]

Treatment O
of O
recurrent O
chronic O
hyperplastic O
sinusitis O
with O
nasal O
polyposis O
. O
[]

METHODS O
After O
fulfilling O
the O
selection O
criteria O
, O
84 O
patients O
were O
randomly O
allocated O
to O
the O
stapled O
( O
n O
= O
42 O
) O
or O
open O
group O
( O
n O
= O
42 O
) O
. O
[]

Lower O
control O
was O
associated O
with O
higher O
burden O
. O
[]

OBJECTIVE O
To O
compare O
the O
utilization O
of O
conventional O
treatments O
and O
utilization O
of O
complementary O
and O
alternative O
medicine O
in O
preschoolers O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
and O
other O
developmental O
disabilities O
( O
DD O
) O
. O
[]

However O
, O
carotenoid B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
is O
low O
, O
and O
food-based O
products O
with O
enhanced O
bioavailability B-outcome ['Physiological-Clinical']
are O
of O
interest O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Furthermore O
, O
there O
was O
no O
difference O
between O
the O
magnitude O
of O
the O
positive O
nor O
the O
negative O
priming B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
of O
the O
groups O
. O
['Life-Impact']

Primary O
endpoint O
is O
the O
group O
difference O
in O
patient B-outcome ['Life-Impact']
related I-outcome ['Life-Impact']
barriers O
to O
management O
of O
cancer B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
BQII O
) O
, O
7 O
days O
after O
discharge O
. O
['Life-Impact', 'Physiological-Clinical']

Subjects O
then O
rinsed O
their O
mouths O
for O
1 O
minute O
3-times O
a O
day O
with O
15 O
ml O
0.1 O
% O
hexetidine O
or O
placebo O
, O
saliva O
samples O
being O
collected O
at O
2 O
minutes O
, O
30 O
minutes O
, O
1 O
hour O
, O
3 O
hours O
and O
5 O
hours O
post-dosing O
. O
[]

The O
most O
convincing O
neoadjuvant O
trial O
to O
demonstrate O
the O
superiority O
of O
an O
AI O
versus O
tamoxifen O
was O
the O
P024 O
study O
, O
a O
large O
multinational O
double-blind O
trial O
in O
postmenopausal O
women O
with O
HR+ O
breast O
cancer O
ineligible O
for O
breast-conserving O
surgery O
. O
[]

CONCLUSIONS O
Feedback O
based O
on O
one-time O
, O
confidential O
report O
cards O
constructed O
using O
administrative O
data O
is O
not O
an O
effective O
strategy O
for O
quality O
improvement O
regarding O
care O
of O
patients O
with O
AMI O
. O
[]

METHODS O
The O
patients O
were O
24 O
children O
undergoing O
tonsillectomy O
and O
adenoidectomy O
. O
[]

n O
= O
77 O
) O
received O
therapy O
with O
dressing O
changes O
every O
48 O
hours O
. O
[]

To O
investigate O
multisensory O
temporal O
processing O
deficits O
in O
ASD O
and O
their O
links O
to O
speech O
processing O
, O
the O
current O
study O
mapped O
performance O
on O
a O
number O
of O
multisensory O
temporal O
tasks O
( O
with O
both O
simple O
and O
complex O
stimuli O
) O
onto O
the O
ability O
of O
individuals O
with O
ASD O
to O
perceptually O
bind O
audiovisual O
speech O
signals O
. O
[]

These O
findings O
argue O
against O
the O
idea O
that O
elevated O
levels O
of O
total O
factor O
[]

In O
58 O
patients O
, O
traditional O
treatment O
was O
supplemented O
by O
transcranial O
electrotherapy O
using O
a O
TRANSAIR-02 O
apparatus O
. O
[]

The O
more O
effective O
protection O
of O
the O
lower O
airways B-outcome ['Physiological-Clinical']
by O
the O
Hi-Lo-Evac O
tube O
is O
attributed O
to O
the O
facility O
of O
subglottic O
aspiration O
during O
surgery O
. O
['Physiological-Clinical']

CONCLUSION O
Successful O
weight O
management B-outcome ['Physiological-Clinical']
can O
be O
achieved O
in O
a O
pharmacy O
setting O
. O
['Physiological-Clinical']

These O
findings O
suggest O
that O
perceptual B-outcome ['Life-Impact']
awareness I-outcome ['Life-Impact']
emerges O
on O
the O
top O
of O
a O
developing O
or O
even O
mature O
perceptual O
decision O
. O
['Life-Impact']

In O
IC O
, O
LF B-outcome ['Physiological-Clinical']
and O
HF B-outcome ['Physiological-Clinical']
significantly O
increased O
from O
Baseline O
to O
Heel O
Stick O
and O
dropped O
from O
Heel O
Stick O
to O
Recovery O
; O
in O
2 O
KC O
conditions O
, O
no O
changes O
across O
study O
phases O
were O
found O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
apparent O
clinical B-outcome ['Physiological-Clinical']
efficacy O
in O
the O
use O
of O
lithium O
to O
reduce O
the O
period O
of O
neutropenia O
in O
patients O
undergoing O
remission O
induction O
therapy O
for O
acute O
myeloid O
leukemia O
. O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
statistically O
significant O
differences O
between O
the O
two O
groups O
at O
baseline O
. O
[]

The O
antibody B-outcome ['Physiological-Clinical']
level O
in O
either O
group O
were O
low O
throughout O
the O
15-day O
study O
period O
. O
['Physiological-Clinical']

A O
Japanese O
version O
of O
the O
Autism O
Spectrum O
Quotient O
( O
AQ O
) O
, O
AQ-J O
was O
administered O
to O
25 O
normally O
intelligent O
high-functioning O
pervasive O
developmental O
disorder O
( O
HPDD O
) O
patients O
( O
mean O
age O
, O
24.2 O
years O
; O
24 O
male O
, O
one O
female O
) O
and O
215 O
controls O
( O
mean O
age O
, O
30.4 O
years O
; O
86 O
male O
, O
129 O
female O
) O
randomly O
selected O
from O
the O
general O
population O
. O
[]

The O
AUC O
and O
Cmax B-outcome ['Physiological-Clinical']
after O
fasting O
were O
closely O
similar O
to O
those O
after O
a O
meal O
, O
showing O
that O
bioavailability O
was O
not O
affected O
by O
food O
intake O
. O
['Physiological-Clinical']

Can O
incentives O
undermine O
intrinsic B-outcome ['Life-Impact']
motivation I-outcome ['Life-Impact']
to O
participate O
in O
epidemiologic O
surveys O
? O
['Life-Impact']

Best-corrected B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity B-outcome ['Physiological-Clinical']
( O
Early O
Treatment O
Diabetic B-outcome ['Physiological-Clinical']
Retinopathy I-outcome ['Physiological-Clinical']
Study B-outcome ['Life-Impact']
chart O
) O
, O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
measurement O
, O
biomicroscopy B-outcome ['Physiological-Clinical']
, O
funduscopy B-outcome ['Resource-use']
, O
digital B-outcome ['Resource-use']
fluorescein I-outcome ['Resource-use']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use']

METHODS O
In O
a O
prospective O
randomised O
trial O
, O
254 O
patients O
with O
colon O
cancer O
were O
randomly O
assigned O
postoperative O
ASI O
or O
no O
adjuvant O
treatment O
. O
[]

The O
AS O
skin O
test O
and O
intradermal O
histamine-induced O
wheal O
and O
flare O
reaction O
were O
performed O
at O
baseline O
( O
without O
AH O
) O
, O
after O
8 O
and O
16 O
weeks O
( O
under O
AH O
treatment O
) O
. O
[]

Phase O
III O
, O
randomized O
prospective O
study O
] O
. O
[]

In O
the O
present O
study O
we O
subliminally O
primed O
high-functioning O
adults O
with O
ASC O
and O
age- O
and O
IQ-matched O
controls O
with O
either O
a O
pro- O
or O
non- O
social O
attitude O
. O
[]

Secondary O
outcomes O
included O
the O
proportion O
of O
responses B-outcome ['Physiological-Clinical']
in O
each O
study O
arm O
that O
recalled B-outcome ['Life-Impact']
individual I-outcome ['Life-Impact']
themes O
and O
the O
proportion O
of O
responses O
in O
each O
arm O
that O
contained O
falsely B-outcome ['Life-Impact']
recalled I-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
extraneous I-outcome ['Life-Impact']
information I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

This O
may O
reflect O
direct O
pituitary O
damage O
and/or O
the O
loss O
of O
the O
tropic O
effects O
of O
chronic O
GHRH O
deficiency O
. O
[]

Subjects O
were O
unable O
to O
accurately O
guess O
which O
treatment O
they O
had O
received O
. O
[]

METHODS O
Seventy-two O
chronic O
hepatitis O
B O
patients O
who O
did O
not O
use O
any O
anti-HBV O
drugs O
within O
6 O
months O
were O
randomized O
into O
3 O
groups O
( O
90 O
micrograms O
, O
60 O
micrograms O
, O
and O
placebo O
) O
in O
a O
ratio O
of O
1:1:1 O
. O
[]

The O
primary O
end O
point O
was O
the O
frequency O
of O
residual O
tumor O
. O
[]

By O
exploiting O
the O
long O
integration O
time O
of O
noisy O
motion O
stimuli O
, O
and O
by O
forcing O
human O
observers O
to O
make O
difficult O
speeded O
decisions O
-- O
sometimes O
a O
blind O
guess O
-- O
about O
stimulus O
direction O
, O
we O
traced O
the O
temporal O
buildup O
of O
motion O
discrimination O
capability O
and O
perceptual O
awareness O
, O
as O
assessed O
trial O
by O
trial O
through O
direct O
rating O
. O
[]

PURPOSE O
The O
goal O
of O
the O
study O
was O
to O
test O
( O
1 O
) O
whether O
individuals O
in O
an O
RCT O
of O
pharmacotherapy O
and O
counseling O
for O
smoking O
cessation O
differed O
in O
their O
healthcare O
costs O
around O
the O
cessation O
period O
, O
and O
( O
2 O
) O
whether O
the O
healthcare O
costs O
of O
those O
in O
the O
trial O
who O
successfully O
quit O
were O
different O
from O
a O
matched O
sample O
of O
smokers O
in O
the O
community O
. O
[]

Relapse B-outcome ['Physiological-Clinical']
was O
not O
significant O
and O
at O
follow O
up O
the O
significant O
increase O
in O
distance O
was O
sustained O
. O
['Physiological-Clinical']

METHODS O
One O
hundred O
and O
ten O
patients O
with O
CHD O
and O
its O
equivalents O
with O
serum O
total O
cholesterol O
( O
TC O
) O
> O
or O
= O
3.5 O
mmol/L O
were O
randomly O
assigned O
into O
three O
treatment O
groups O
: O
( O
1 O
) O
atorvastatin O
group O
( O
n O
= O
38 O
) O
, O
receiving O
atorvastatin O
10 O
mg/d O
for O
8 O
weeks O
; O
( O
2 O
) O
niacin O
ER O
group O
( O
n O
= O
38 O
) O
, O
given O
niacin O
ER O
500 O
mg/d O
for O
4 O
weeks O
and O
then O
1000 O
mg/d O
for O
4 O
weeks O
; O
( O
3 O
) O
combination O
treatment O
group O
( O
n O
= O
34 O
) O
, O
treated O
with O
atorvastatin O
( O
10 O
mg/d O
) O
plus O
niacin O
ER O
, O
with O
the O
dose O
initiating O
from O
500 O
mg/d O
, O
and O
increasing O
to O
1000 O
mg/d O
after O
4 O
weeks O
, O
for O
8 O
weeks O
. O
[]

Calcium B-outcome ['Physiological-Clinical']
solubility I-outcome ['Physiological-Clinical']
and O
absorption O
across O
Caco-2 B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
were O
studied O
after O
the O
in O
vitro O
digestion O
of O
the O
diets O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Participants O
were O
followed O
up O
for O
1 O
year O
and O
received O
the O
same O
preassigned O
treatment O
for O
every O
new O
episode O
of O
uncomplicated O
malaria O
diagnosed O
during O
follow-up O
. O
[]

A O
14-gauge O
catheter O
was O
used O
for O
endotracheal O
intubation O
, O
and O
anaesthesia O
was O
maintained O
with O
isoflurane O
delivered O
in O
oxygen O
via O
a O
T-piece O
breathing O
system O
. O
[]

BACKGROUND O
A O
phase O
III O
multi-centre O
randomised O
trial O
( O
ROSEL O
) O
has O
been O
initiated O
to O
establish O
the O
role O
of O
stereotactic O
radiotherapy O
in O
patients O
with O
operable O
stage O
IA O
lung O
cancer O
. O
[]

SETTING O
Cystic O
fibrosis O
centers O
in O
the O
eastern O
, O
midwestern O
, O
and O
southern O
United O
States O
. O
[]

Median O
cerebrospinal B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CSF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
antibiotic I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
0.85 O
and O
1.60 O
mug/ml O
for O
CB O
and O
AMP O
, O
respectively O
, O
during O
administration O
of O
daily O
doses O
of O
400 O
mg/kg O
and O
0.65 O
and O
0.45 O
mug/ml O
, O
respectively O
, O
on O
daily O
doses O
of O
200 O
mg/kg O
. O
['Physiological-Clinical']

AIMS O
To O
test O
motivational O
interviewing O
( O
MI O
) O
as O
a O
brief O
intervention O
for O
reducing O
alcohol B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
among O
needle O
exchange O
clients O
. O
['Life-Impact']

The O
REMADHE O
[ O
Repetitive O
Education O
and O
Monitoring O
for O
ADherence O
for O
Heart O
Failure O
] O
trial O
is O
a O
long-term O
randomized O
, O
prospective O
, O
parallel O
trial O
designed O
to O
compare O
intervention O
with O
control O
. O
[]

The O
memory O
support O
system O
for O
mild O
cognitive O
impairment O
: O
randomized O
trial O
of O
a O
cognitive O
rehabilitation O
intervention O
. O
[]

During O
two O
consecutive O
periods O
of O
2 O
days O
, O
patients O
received O
active O
drugs O
or O
placebo O
in O
a O
randomized O
order O
. O
[]

OBJECTIVE O
To O
test O
the O
efficacy O
of O
a O
graded O
aerobic O
exercise O
programme O
in O
the O
chronic B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

All O
trainees O
performed O
their O
first O
ten O
individual O
colonoscopies O
described O
in O
detail O
in O
a O
separate O
protocol O
. O
[]

The O
oats O
group O
experienced O
a O
significant O
reduction O
in O
both O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
9 O
% O
) O
and O
low-density B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Forty-three O
patients O
with O
peripheral O
neuropathic O
pain O
, O
exclusively O
pain O
reduced O
by O
spinal O
cord O
stimulation O
( O
SCS O
) O
, O
were O
switched O
into O
a O
painful O
state O
after O
SCS O
inactivation O
. O
[]

The O
same O
was O
also O
true O
for O
hormonal O
parameters O
as O
STH B-outcome ['Physiological-Clinical']
, O
ACTH B-outcome ['Physiological-Clinical']
, O
cortisol B-outcome ['Physiological-Clinical']
, O
and O
catecholamines B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
EAA+CHO O
group O
ingested O
the O
nutrient O
solution O
1 O
h O
after O
resistance O
exercise O
. O
[]

Recent O
studies O
demonstrated O
a O
reduced O
expression O
of O
Fragile O
X O
Mental O
Retardation O
Protein O
( O
FMRP O
) O
, O
an O
RNA O
binding O
protein O
and O
translation O
regulator O
, O
in O
the O
brain O
and O
peripheral O
lymphocytes O
of O
patients O
with O
schizophrenia O
. O
[]

In O
the O
various O
subgroups O
formed O
for O
different O
primary O
diagnoses O
, O
concomitant O
steroidal O
therapy O
and O
concomitant O
severe O
internal O
medical O
diseases O
cefotiam O
treated O
patients O
and O
controls O
were O
comparable O
as O
well O
. O
[]

Responder O
rates O
were O
analyzed O
according O
to O
patients O
' O
self-reported O
historical O
triptan O
response O
( O
HTR O
[]

Fifty-two O
practices O
recruited O
participants O
to O
the O
trial O
. O
[]

This O
was O
a O
30 O
% O
reduction O
in O
daily B-outcome ['Resource-use']
steroid I-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
( O
p O
less O
than O
0.01 O
) O
. O
['Resource-use']

However O
, O
during O
the O
whole O
12-month O
training O
period O
, O
both O
dynamic B-outcome ['Physiological-Clinical']
and O
isometric B-outcome ['Physiological-Clinical']
back B-outcome ['Physiological-Clinical']
extension I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
objective O
of O
this O
study O
was O
to O
assess O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
and O
total O
treatment O
costs B-outcome ['Resource-use']
of O
retroinfusion-supported O
stenting O
in O
high-risk O
patients O
compared O
to O
bypass O
surgery O
. O
['Mortality', 'Resource-use']

Secondary O
endpoints O
included O
parasitological B-outcome ['Physiological-Clinical']
response O
by O
day O
10 O
and O
mortality O
at O
day O
8 O
. O
['Physiological-Clinical']

Clinical O
Global O
Impressions-Severity O
and O
Children O
's O
Yale-Brown O
Obsessive O
Compulsive O
Scale O
scores O
improved O
significantly O
only O
in O
the O
high-dose O
group O
, O
consistent O
with O
ABC-I O
results O
. O
[]

In O
conclusion O
, O
this O
study O
shows O
that O
a O
2-dimensional O
, O
handheld O
ultrasound O
device O
and O
a O
newly O
developed O
ultrasound O
volume O
scanner O
can O
effectively O
identify O
patients O
with O
AAAs O
confirmed O
by O
CT O
. O
[]

BACKGROUND O
Postoperative O
epidural O
analgesia O
( O
EA O
) O
and O
femoral O
nerve O
block O
( O
FNB O
) O
provided O
effective O
pain O
relief O
However O
, O
EA O
has O
common O
side O
effects O
such O
as O
nausea O
, O
vomiting O
, O
pruritus O
, O
dizziness O
, O
and O
hypotension O
. O
[]

less O
than O
twice O
weekly O
were O
studied O
. O
[]

At O
anaesthesia O
induction O
, O
serum B-outcome ['Physiological-Clinical']
carnitine I-outcome ['Physiological-Clinical']
was O
significantly O
increased O
in O
treated O
patients O
, O
but O
carnitine B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in O
the O
right O
atrial O
biopsy O
obtained O
just O
before O
aortic O
declamping O
were O
similar O
in O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Married O
women O
( O
n O
= O
125,257 O
) O
underwent O
5-week O
surveillance O
for O
pregnancy O
, O
ascertained O
by O
a O
history O
of O
amenorrhea O
and O
confirmed O
by O
urine O
test O
. O
[]

The O
UKEP O
study O
: O
multicentre O
clinical O
trial O
on O
two O
local O
regimens O
of O
urokinase O
in O
massive O
pulmonary O
embolism O
. O
[]

Rapid O
palatal O
expansion O
( O
RPE O
) O
is O
widely O
used O
in O
the O
treatment O
of O
transverse O
maxillary O
deficiencies O
. O
[]

The O
acute B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
of O
baseline O
['Adverse-effects']

There O
was O
no O
difference O
between O
the O
groups O
in O
plasma B-outcome ['Physiological-Clinical']
concentration O
of O
midazolam B-outcome ['Physiological-Clinical']
, O
CBF B-outcome ['Physiological-Clinical']
or O
CMRO2 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Plasma O
levels O
of O
free O
over O
vascular O
endothelial O
growth O
factor-bound O
aflibercept O
were O
adequate O
, O
with O
steady-state O
achieved O
from O
cycle-3 O
. O
[]

RESULTS O
A O
total O
of O
191 O
patients O
with O
superficial O
bladder O
carcinoma O
were O
available O
for O
efficacy O
analysis O
. O
[]

The O
study O
objective O
was O
to O
compare O
whether O
evidence-based O
narrative O
versus O
traditional O
summary O
improved O
recall O
of O
opioid O
prescribing O
guidelines O
from O
the O
American O
College O
of O
Emergency O
Physicians O
( O
ACEP O
) O
. O
[]

AIMS O
To O
present O
the O
concept O
of O
the O
intervention O
studies O
, O
and O
to O
provide O
an O
interim O
report O
of O
the O
recruitment O
procedure O
. O
[]

Secondary O
outcomes O
are O
health O
related O
quality O
of O
life O
, O
specific O
complaints O
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
costs B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

METHODS O
Doses O
of O
febuxostat O
and O
allopurinol O
were O
10 O
and O
100 O
mg/d O
, O
respectively O
, O
during O
a O
12-day O
introduction O
period O
and O
were O
increased O
to O
40 O
and O
200 O
mg/d O
for O
the O
subsequent O
treatment O
period O
of O
44 O
days O
. O
[]

Median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
favored O
the O
high-dose O
paclitaxel O
( O
4.3 O
vs. O
6.4 O
months O
, O
P O
= O
0.044 O
) O
. O
['Physiological-Clinical']

There O
was O
no O
increase O
in O
AE B-outcome ['Adverse-effects']
by O
frequency O
of O
gel O
use O
or O
sexual O
activity O
with O
the O
exception O
of O
abdominal/pelvic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
which O
was O
noted O
more O
frequently O
with O
twice O
daily O
use O
among O
sexually O
abstinent O
women O
. O
['Adverse-effects', 'Physiological-Clinical']

As O
L-ICI B-outcome ['Physiological-Clinical']
can O
be O
influenced O
by O
this O
type O
of O
drug O
, O
it O
may O
be O
an O
interesting O
parameter O
for O
studies O
of O
motor O
learning O
and O
use-dependent O
plasticity O
. O
['Physiological-Clinical']

Randomization O
of O
the O
serotonin-migraine O
cases O
and O
double-blind O
methodology O
were O
applied O
throughout O
the O
trial O
. O
[]

Ciprodex O
treatment O
also O
decreased O
the O
rate O
of O
clinically B-outcome ['Physiological-Clinical']
diagnosed I-outcome ['Physiological-Clinical']
otitis I-outcome ['Physiological-Clinical']
media I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
effusion B-outcome ['Physiological-Clinical']
following O
TT O
placement O
( O
p O
< O
or O
=0.0006 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
At O
week O
12 O
, O
[]

Dose O
distribution O
curves O
in O
cross-section O
and O
midsagittal O
planes O
are O
shown O
and O
calculations O
or O
equivalent O
doses O
at O
various O
selected O
points O
using O
Ellis O
's O
nominal O
single-dose O
formula O
are O
tabulated O
. O
[]

Perioperative O
randomisation O
was O
to O
Ethicon? O
PROXIMATE? O
ILS? O
or O
Autosuture? O
Premium O
Plus O
CEEA? O
. O
[]

Lidocaine O
, O
given O
in O
a O
300 O
mg O
dose O
intramuscularly O
followed O
by O
100 O
mg O
intravenously O
, O
did O
not O
prevent O
sustained B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
, O
although O
there O
was O
a O
significant O
reduction O
in O
the O
number O
of O
patients O
with O
warning B-outcome ['Physiological-Clinical']
arrhythmias I-outcome ['Physiological-Clinical']
between O
15 O
and O
45 O
minutes O
after O
the O
administration O
of O
lidocaine O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
eyes O
were O
divided O
into O
treatment O
( O
non-selective O
beta O
blockers O
or O
selective O
, O
prostaglandin O
analogues O
, O
topical O
carbonic O
anhydrase O
inhibitors O
) O
in O
four O
groups O
. O
[]

The O
incidence O
of O
all O
grade O
neurotoxicity B-outcome ['Physiological-Clinical']
in O
the O
Ca/Mg O
( O
+ O
) O
group O
and O
the O
Ca/Mg O
( O
- O
) O
group O
was O
85 O
% O
and O
92 O
% O
, O
respectively O
( O
p O
= O
0.02 O
) O
, O
and O
the O
incidence O
of O
grade O
? O
['Physiological-Clinical']

Multi-institutional O
randomized O
phase O
II O
trial O
of O
the O
epothilone O
B O
analog O
ixabepilone O
( O
BMS-247550 O
) O
with O
or O
without O
estramustine O
phosphate O
in O
patients O
with O
progressive O
castrate O
metastatic O
prostate O
cancer O
. O
[]

Induction O
of O
anesthesia O
with O
either O
drug O
, O
eltanolone O
or O
propofol O
, O
decreased O
arterial B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
( O
SAP O
) O
and O
diastolic O
( O
DAP O
) O
blood O
pressure O
, O
Q O
, O
and O
stroke B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Long-term O
psychosocial O
and O
health O
economy O
consequences O
of O
ADHD O
, O
autism O
, O
and O
reading-writing O
disorder O
: O
a O
prospective O
service O
evaluation O
project O
. O
[]

Restenosis B-outcome ['Physiological-Clinical']
occurred O
in O
27 O
( O
33 O
% O
) O
patients O
, O
and O
was O
significantly O
more O
frequent O
following O
the O
procedures O
for O
rest O
pain O
or O
ulceration O
, O
or O
where O
a O
TBPI B-outcome ['Physiological-Clinical']
increase O
of O
more O
than O
0.15 O
by O
1 O
week O
was O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
samples O
were O
drawn O
for O
testing O
biochemical O
and O
hormonal O
parameters O
and O
nitrites/nitrates O
. O
['Physiological-Clinical']

INTERVENTION O
Those O
assigned O
to O
a O
brief O
motivational O
intervention O
( O
MI O
) O
condition O
received O
two O
1-hour O
therapist O
sessions O
following O
assessment O
visits O
, O
1 O
month O
apart O
, O
focusing O
on O
alcohol O
use O
and O
HIV O
risk-taking O
. O
[]

The O
aim O
of O
this O
study O
is O
to O
compare O
the O
efficacy O
and O
safety O
of O
these O
two O
treatment O
alternatives O
. O
[]

ASI O
has O
minimal O
adverse O
reactions O
and O
should O
be O
considered O
in O
the O
management O
of O
stage O
II O
colon O
cancer O
. O
[]

First O
, O
delusional O
patients O
were O
significantly O
more O
likely O
than O
non-delusional O
patients O
and O
healthy O
participants O
to O
classify B-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
as I-outcome ['Life-Impact']
unpleasant I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
study O
was O
a O
2 O
X O
2 O
factorial O
experiment O
in O
which O
120 O
patients O
suffering O
from O
pain O
as O
a O
result O
of O
oral O
surgery O
rated O
their O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
for O
up O
to O
5 O
hours O
after O
a O
single O
dose O
of O
one O
of O
: O
1000 O
mg O
acetaminophen O
, O
60 O
mg O
codeine O
, O
1000 O
mg O
acetaminophen O
plus O
60 O
mg O
codeine O
, O
or O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
standard O
inferolateral O
arthroscopic O
portal O
was O
made O
with O
a O
single O
stab O
incision O
with O
use O
of O
a O
number-11 O
blade O
. O
[]

METHODS O
Farms O
( O
316 O
) O
located O
in O
a O
9-county O
area O
of O
northwestern O
Iowa O
were O
recruited O
and O
randomized O
into O
intervention O
and O
control O
cohorts O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
age O
15 O
to O
70 O
years O
with O
untreated O
clinical O
stage O
I/II O
HL O
were O
eligible O
. O
[]

CONCLUSIONS O
& O
IMPLICATIONS O
There O
is O
some O
evidence O
of O
an O
intervention O
effect O
on O
blind O
and O
parent/teacher-reported O
communication O
outcomes O
, O
but O
not O
standardized O
language O
assessment O
outcomes O
, O
for O
6-11-year-old O
children O
who O
have O
pragmatic O
and O
social O
communication O
needs O
. O
[]

RESULTS O
Median O
follow-up O
time O
was O
32 O
months O
for O
all O
patients O
and O
42 O
months O
for O
surviving O
patients O
. O
[]

The O
synergy O
effect O
could O
not O
be O
examined O
for O
dentine O
due O
to O
the O
truncation O
effect O
as O
the O
set O
limit O
of O
the O
profilometer O
was O
exceeded O
. O
[]

Efficacy O
of O
treatment B-outcome ['Resource-use']
, O
Chinese B-outcome ['Physiological-Clinical']
medicine I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
scores O
, O
end-point O
events O
occurrence O
as O
well O
as O
changes O
of O
related O
laboratory B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
were O
observed O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Treatment O
was O
terminated O
when O
there O
was O
no O
response O
with O
maximum O
dose O
of O
CC O
and O
rFSH O
or O
after O
six O
ovulatory O
cycles O
without O
pregnancy O
or O
after O
achieving O
pregnancy O
. O
[]

The O
decrease O
in O
episodes B-outcome ['Life-Impact']
for O
the O
control O
groups O
suggest O
that O
the O
family O
record O
keeping O
required O
of O
all O
subjects O
may O
have O
a O
beneficial O
effect O
, O
a O
phenomenon O
worth O
further O
investigation O
. O
['Life-Impact']

Patients O
achieved O
positive O
nitrogen B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
2 O
days O
earlier O
in O
the O
study O
group O
than O
that O
in O
the O
control O
group O
, O
but O
there O
was O
no O
significant O
difference O
in O
cumulative O
nitrogen B-outcome ['Physiological-Clinical']
balance B-outcome ['Life-Impact']
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

OBJECTIVE O
To O
investigate O
the O
tolerability B-outcome ['Life-Impact']
and O
efficacy O
of O
rizatriptan O
5 O
mg O
in O
adolescent O
migraineurs O
. O
['Life-Impact']

A O
statistically O
significant O
correlation O
was O
observed O
between O
the O
kinetics O
and O
magnitude O
of O
the O
humoral O
immune O
response O
on O
the O
one O
hand O
and O
the O
in O
vitro O
anti-HBs O
response O
on O
the O
other O
hand O
. O
( O
[]

MATERIAL O
AND O
METHODS O
A O
gastric O
electrical O
stimulator O
was O
implanted O
in O
seven O
diabetic O
patients O
with O
medically O
refractory O
gastroparesis O
. O
[]

CONCLUSIONS O
Left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
is O
not O
reduced O
, O
and O
may O
even O
be O
increased O
, O
by O
early O
moderate O
to O
severe O
mitral O
regurgitation O
after O
acute O
myocardial O
infarction O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
mean O
airway O
pressure O
under O
high-frequency O
oscillatory O
ventilation O
on O
right O
ventricular O
function O
. O
[]

In O
the O
ISDN O
group O
less O
events B-outcome ['Physiological-Clinical']
took O
place O
possibly O
due O
to O
the O
longer O
duration O
of O
this O
drug O
. O
['Physiological-Clinical']

The O
ACTH-stimulated B-outcome ['Physiological-Clinical']
mean O
cortisol B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

= O
1 O
, O
P O
= O
0.045 O
respectively O
) O
. O
[]

Relapse O
patterns O
indicate O
that O
patients O
destined O
to O
relapse O
need O
more O
systemic O
, O
rather O
than O
local O
, O
treatment O
. O
[]

The O
first O
study O
involving O
substance-abusing O
suicidal O
patients O
was O
an O
open-label O
trial O
conducted O
in O
the O
early O
1990s O
. O
[]

METHODS O
AND O
RESULTS O
Five O
groups O
of O
8 O
subjects O
each O
were O
randomized O
to O
placebo O
( O
n=2 O
) O
or O
torcetrapib O
( O
n=6 O
) O
at O
10 O
, O
30 O
, O
60 O
, O
and O
120 O
mg O
daily O
and O
120 O
mg O
twice O
daily O
for O
14 O
days O
. O
[]

Psychological O
mediators O
of O
bupropion O
sustained-release O
treatment O
for O
smoking O
cessation O
. O
[]

Seventeen O
sighted O
children O
were O
manually O
guided O
to O
perform O
the O
task O
and O
tactually O
prompted O
during O
imitated O
productions O
of O
novel O
words O
for O
the O
event O
. O
[]

Thus O
, O
in O
order O
to O
obtain O
a O
prompt O
improvement O
, O
the O
association O
of O
local O
therapy O
acting O
on O
the O
genital O
epithelium O
to O
the O
systemic O
treatment O
should O
be O
considered O
. O
[]

The O
Lido O
+ O
Epi O
group O
used O
significantly O
less O
morphine B-outcome ['Resource-use']
( O
P O
= O
0.01 O
) O
compared O
to O
either O
of O
the O
2-CP O
groups O
with O
no O
significant O
difference O
between O
the O
2-CP O
groups O
. O
['Resource-use']

Intubation O
resulted O
in O
significant O
( O
p O
less O
than O
0.01 O
) O
increases O
in O
MAP B-outcome ['Physiological-Clinical']
in O
the O
pancuronium-metocurine O
mixture O
group O
. O
['Physiological-Clinical']

Nicotinic O
acid O
as O
therapy O
for O
dyslipidemia O
in O
non-insulin-dependent O
diabetes O
mellitus O
. O
[]

Patients O
in O
Arm O
II O
had O
a O
significantly O
higher O
quality O
of O
life O
compared O
to O
those O
in O
Arm O
I O
. O
[]

In O
patients O
responding O
to O
initial O
chemotherapy O
the O
disadvantage O
of O
four O
courses O
of O
chemotherapy O
alone O
was O
apparent O
( O
median O
survival O
of O
40 O
weeks O
versus O
49 O
weeks O
, O
P O
= O
0.003 O
) O
but O
not O
if O
drug O
treatment O
was O
given O
on O
relapse O
. O
[]

BACKGROUND O
Promising O
results O
with O
hyperbaric O
therapy O
for O
children O
with O
autism O
have O
been O
reported O
, O
but O
most O
involved O
the O
use O
of O
only O
mild O
pressure O
with O
oxygen O
supplementation O
. O
[]

Statistical O
analyses O
were O
performed O
separately O
for O
days O
1 O
and O
4 O
by O
using O
analysis O
of O
variance O
. O
[]

2003 O
) O
. O
[]

The O
effects O
were O
mild O
in O
both O
groups O
and O
did O
not O
lead O
any O
patient O
to O
stop O
medication O
. O
[]

In O
conclusion O
, O
recombinant O
human O
TSH O
administration O
is O
a O
safe O
and O
effective O
means O
of O
stimulating O
radioiodine O
uptake O
and O
serum O
Tg O
levels O
in O
patients O
undergoing O
evaluation O
for O
thyroid O
cancer O
persistence O
and O
recurrence O
. O
[]

At O
a O
median O
follow O
up O
of O
23 O
months O
of O
all O
patients O
alive O
( O
range O
6-82 O
months O
) O
and O
with O
95/125 O
events O
, O
the O
median O
, O
1 O
, O
2 O
and O
5 O
year O
projected O
survival B-outcome ['Mortality']
was O
7.1 O
months O
, O
32.3 O
% O
, O
22.8 O
% O
and O
13.7 O
% O
vs. O
13.4 O
months O
, O
57.6 O
% O
, O
38.9 O
% O
and O
24.8 O
% O
for O
the O
RT O
and O
CRT O
groups O
, O
respectively O
( O
hazard O
ratio O
0.65 O
, O
95 O
% O
CI O
0.44-0.98 O
, O
P=0.038 O
) O
. O
['Mortality']

METHODS O
Ninety-six O
patients O
were O
randomly O
divided O
into O
an O
observation O
group O
and O
a O
control O
group O
, O
48 O
cases O
in O
each O
group O
. O
[]

International O
Breast O
Cancer O
Study O
Group O
Trials O
VII O
and O
12-93 O
. O
[]

Delayed O
anticancer O
effects O
of O
aspirin O
are O
compatible O
with O
the O
proposed O
mechanism O
, O
as O
continual O
microbleeding B-outcome ['Physiological-Clinical']
has O
a O
gradual O
cumulative O
effect O
on O
stored O
iron O
. O
['Physiological-Clinical']

Half O
received O
a O
training O
intervention O
following O
the O
initial O
interview O
and O
the O
half O
who O
served O
as O
a O
contrast O
group O
did O
not O
. O
[]

Results O
indicated O
statistically O
significant O
differences O
between O
protocols O
, O
while O
post O
hoc O
tests O
indicated O
that O
the O
picture O
task O
card O
condition O
produced O
significantly O
higher O
gross B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
quotient I-outcome ['Physiological-Clinical']
scores O
than O
the O
traditional O
protocol O
and O
the O
picture O
activity O
schedule O
. O
['Physiological-Clinical']

Water O
blankets O
and O
convective O
heating O
devices O
were O
used O
to O
cool O
and O
rewarm O
. O
[]

Sedation B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
during O
spinal O
anesthesia O
and O
survival O
in O
elderly O
patients O
undergoing O
hip O
fracture O
repair O
. O
['Physiological-Clinical']

Inter- O
and O
intra-observer O
variability O
were O
also O
examined O
. O
[]

Forty-three O
subjects O
were O
randomized O
to O
one O
of O
three O
groups O
( O
proximal O
tibiofibular O
manipulation O
, O
distal O
tibiofibular O
manipulation O
, O
or O
control O
) O
. O
[]

Intention B-outcome ['Life-Impact']
to O
treat O
( O
ITT O
) O
and O
per-protocol O
( O
PP O
) O
analyses O
were O
performed O
, O
and O
risk O
ratios O
( O
RR O
) O
adjusted O
by O
age O
, O
gender O
and O
area O
, O
were O
calculated O
. O
['Life-Impact']

Results O
indicate O
that O
at O
the O
amounts O
fed O
, O
AMF O
may O
improve O
[]

Heparin O
plus O
dipyridamole O
in O
childhood O
hemolytic-uremic O
syndrome O
: O
a O
prospective O
, O
randomized O
study O
. O
[]

RESULTS O
The O
lead-in O
that O
described O
the O
highest O
likelihood O
of O
hypertension B-outcome ['Physiological-Clinical']
was O
associated O
with O
significantly O
higher O
reported O
readings O
and O
lower O
accuracy B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
2 O
titration O
schemes O
were O
also O
compared O
with O
each O
other O
. O
[]

We O
prospectively O
evaluated O
90 O
patients O
who O
had O
aortic O
, O
mitral O
, O
and/or O
tricuspid O
valve O
replacement O
with O
Sorin O
Bicarbon O
or O
CarboMedics O
bileaflet O
prostheses O
. O
[]

Risperidone O
, O
an O
atypical O
neuroleptic O
, O
has O
become O
a O
popular O
option O
for O
treating O
destructive O
behaviors O
of O
persons O
with O
developmental O
disabilities O
. O
[]

Enhanced O
baroreceptor O
control O
of O
the O
cardiovascular O
system O
by O
polyunsaturated O
Fatty O
acids O
in O
heart O
failure O
patients O
. O
[]

At O
start O
, O
the O
pulsatility B-outcome ['Physiological-Clinical']
and O
resistance B-outcome ['Physiological-Clinical']
indices O
of O
ovarian O
arteries O
were O
elevated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
significant O
differences O
in O
[]

Progressive O
bone O
disease O
in O
multiple O
myeloma O
frequently O
leads O
to O
osteolysis O
, O
bone O
resorption O
, O
pathologic O
fractures O
, O
vertebral O
compression O
, O
and O
hypercalcemia O
. O
[]

The O
effect O
of O
pain-free O
treadmill O
training O
on O
fibrinogen O
, O
haematocrit O
, O
and O
lipid O
profile O
in O
patients O
with O
claudication O
. O
[]

This O
study O
evaluates O
whether O
comparable O
safety O
and O
efficacy O
continues O
for O
12 O
weeks O
after O
patients O
with O
asthma O
are O
switched O
from O
CFC O
albuterol O
to O
HFA O
albuterol O
. O
[]

This O
prospective O
clinical O
trial O
examined O
the O
impact O
of O
early O
TEN O
vs. O
TPN O
in O
the O
critically O
injured O
. O
[]

Treatment O
of O
hypertensive O
and O
hypercholesterolaemic O
patients O
in O
general O
practice O
. O
[]

The O
response O
rate O
to O
the O
two O
treatments O
was O
approximately O
the O
same O
, O
being O
69 O
% O
and O
75 O
% O
after O
terazosin O
and O
enalapril O
, O
respectively O
. O
[]

Durable O
clinical O
responses O
were O
observed O
in O
some O
patients O
for O
7 O
years O
or O
more O
. O
[]

After O
1 O
year O
, O
four O
patients O
with O
smooth O
prostheses O
and O
one O
with O
a O
textured O
prosthesis O
had O
capsular B-outcome ['Physiological-Clinical']
contracture I-outcome ['Physiological-Clinical']
( O
p O
= O
0.34 O
) O
. O
['Physiological-Clinical']

After O
receiving O
IS-IL-2 O
therapy O
they O
demonstrated O
a O
decrease O
in O
the O
serum O
CEA O
level O
for O
more O
than O
3 O
years O
after O
treatment O
. O
( O
[]

For O
PI O
15/29 O
, O
26/29 O
and O
29/29 O
of O
the O
subjects O
met O
the O
sympathectomy B-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
at O
5 O
, O
10 O
and O
20 O
min O
, O
respectively O
, O
compared O
with O
4/29 O
, O
6/29 O
and O
18/29 O
for O
MAP B-outcome ['Physiological-Clinical']
changes O
and O
3/29 O
, O
8/29 O
and O
14/29 O
for O
toe O
['Physiological-Clinical', 'Physiological-Clinical']

Given O
the O
sensorimotor O
deficits O
in O
most O
children O
with O
autism O
, O
we O
attempted O
to O
translate O
that O
approach O
to O
their O
treatment O
. O
[]

Ten O
of O
the O
forty-five O
women O
treated O
with O
melphalan O
experienced O
severe B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
marrow I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
at O
some O
time O
during O
therapy O
and O
two O
women O
expired B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
leukemia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
aims O
of O
this O
study O
were O
to O
determine O
the O
incidence O
of O
gingival O
overgrowth O
in O
a O
group O
of O
children O
post O
liver O
transplantation O
and O
to O
compare O
gingival O
overgrowth O
in O
children O
receiving O
FK506 O
with O
those O
receiving O
cyclosporin O
. O
[]

Sustained O
oral B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
and O
use O
of O
toothbrushes O
and O
dentifrice O
by O
previous O
users O
of O
traditional O
materials O
in O
a O
rural O
population O
in O
Andhra O
Pradesh O
, O
India O
. O
['Physiological-Clinical']

We O
also O
examined O
how O
the O
particular O
form O
of O
the O
decomposition O
affected O
learning B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
Reductions O
in O
serum O
magnesium O
have O
been O
postulated O
to O
play O
a O
role O
in O
promoting O
arrhythmias O
and O
to O
have O
an O
adverse O
impact O
on O
survival O
in O
congestive O
heart O
failure O
, O
although O
support O
for O
this O
postulate O
is O
lacking O
. O
[]

In O
2 O
patients O
, O
there O
was O
no O
fertilization O
after O
either O
IVF O
( O
0/6 O
oocytes O
) O
or O
ICSI O
( O
0/9 O
oocytes O
) O
. O
[]

BACKGROUND O
The O
relationship O
between O
Helicobacter O
pylori O
infection O
and O
non-ulcer O
dyspepsia O
is O
not O
established O
. O
[]

The O
Study O
of O
Quantitative O
Serial O
Trends O
in O
Lipids O
with O
Apolipoprotein O
A-I O
Stimulation O
( O
SUSTAIN O
, O
NCT01423188 O
) O
study O
aims O
to O
evaluate O
the O
lipid B-outcome ['Physiological-Clinical']
efficacy O
, O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
an O
apoA-I O
inducer O
( O
RVX-208 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

The O
aim O
of O
this O
study O
is O
to O
compare O
the O
open O
technique O
and O
the O
laparoscopic O
approach O
concerning O
: O
complications B-outcome ['Adverse-effects']
, O
recurrences O
, O
recovery O
time O
and O
return O
to O
usual O
activity O
. O
['Adverse-effects']

Participants O
included O
91 O
physicians O
, O
62 O
men O
and O
29 O
women O
; O
median O
age O
was O
38.7 O
years O
. O
[]

The O
30-day O
mortality B-outcome ['Mortality']
rate O
was O
1.4 O
% O
, O
with O
one O
non-procedure-related O
death O
in O
the O
HPBA O
group O
. O
['Mortality']

This O
demonstrates O
that O
suppression O
of O
plasma O
angiotensin O
II O
for O
a O
14 O
day O
period O
does O
not O
enhance O
the O
response O
to O
exogenous O
intra-arterial O
angiotensin O
II O
in O
the O
human O
forearm O
of O
healthy O
salt O
replete O
subjects O
. O
[]

The O
median O
ventilation O
time O
( O
14 O
hours O
versus O
13 O
hours O
) O
, O
median O
catecholamine O
dose O
, O
frequency O
of O
dialysis-dependent O
acute B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
( O
28 O
% O
versus O
18 O
% O
) O
, O
cardiac O
indices O
, O
and O
frequency O
of O
a O
low O
cardiac O
output O
syndrome O
( O
26 O
% O
versus O
25 O
% O
) O
did O
not O
significantly O
differ O
between O
groups O
. O
['Physiological-Clinical']

Human O
nature O
makes O
us O
favour O
novelty O
if O
we O
believe O
it O
is O
going O
to O
be O
better O
. O
[]

DESIGN O
Randomized O
, O
multisite O
clinical O
trial O
. O
[]

However O
, O
a O
head-to-head O
comparison O
of O
the O
lipoprotein O
and O
metabolic O
effects O
of O
these O
two O
medicines O
has O
not O
been O
published O
. O
[]

CYP21 O
PCR O
products O
were O
subjected O
to O
ligase O
detection O
reaction O
, O
simultaneously O
analyzing O
9 O
CYP21 O
mutations O
; O
PCR O
products O
of O
other O
genes O
were O
subjected O
to O
direct O
gel O
analysis O
. O
[]

STUDY O
DESIGN O
This O
was O
a O
10-week O
, O
randomized O
, O
double-blind O
, O
parallel-group O
, O
placebo-controlled O
trial O
. O
[]

OBJECTIVE O
To O
study O
the O
effect O
of O
adapalene O
gel O
comparing O
the O
treatment O
with O
adapalene O
gel O
and O
2 O
% O
ketoconazole O
cream O
in O
pityriasis O
versicolor O
. O
[]

There O
was O
an O
increase O
in O
peak O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
both O
groups O
but O
this O
did O
not O
lead O
to O
an O
increase O
in O
peak O
ventilation B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

1.63 O
?g/mL O
immediately O
after O
aortic O
unclamping O
and O
6.59 O
? O
[]

Patients O
with O
either O
new O
onset O
( O
less O
than O
48 O
hours O
, O
n O
= O
31 O
) O
or O
old O
onset O
( O
greater O
than O
48 O
hours O
, O
n O
= O
14 O
) O
of O
atrial O
fibrillation O
or O
flutter O
with O
rapid O
ventricular O
rate O
were O
stratified O
to O
receive O
esmolol O
( O
n O
= O
21 O
) O
or O
verapamil O
( O
n O
= O
24 O
) O
. O
[]

These O
data O
suggest O
that O
no O
beneficial O
effect O
from O
administration O
of O
antibiotics O
for O
longer O
than O
24 O
hours O
postoperatively O
can O
be O
achieved O
in O
patients O
who O
undergo O
myocutaneous O
flap O
reconstruction O
. O
[]

In O
the O
presence O
of O
leakage B-outcome ['Physiological-Clinical']
( O
settings O
II O
and O
III O
) O
, O
the O
attempt O
to O
compensate O
for O
leak O
was O
only O
evident O
during O
pressure-limited O
NPPV O
, O
since O
inspiratory B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
delivered O
by O
the O
ventilator O
increased O
from O
726+/-129 O
( O
setting O
I O
) O
to O
1104+/-164 O
( O
setting O
II O
) O
, O
and O
to O
1257+/-166 O
( O
setting O
III O
) O
ml O
during O
pressure-limited O
NPPV O
, O
respectively O
( O
all O
p O
< O
0.001 O
) O
; O
however O
, O
they O
remained O
stable O
during O
volume-limited O
NPPV O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Beta-adrenoceptor O
blockade O
and O
cardiovascular B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
the O
cold O
pressor O
test O
. O
['Physiological-Clinical']

The O
overall O
adverse B-outcome ['Adverse-effects']
event O
experience O
was O
similar O
in O
the O
formoterol O
( O
n=26 O
[ O
27 O
% O
] O
) O
and O
placebo O
( O
n=33 O
[ O
31 O
% O
] O
) O
groups O
. O
['Adverse-effects']

OBJECTIVE O
Our O
purpose O
was O
to O
study O
the O
effect O
of O
hematinic O
supplementation O
on O
the O
maternal B-outcome ['Physiological-Clinical']
erythropoietin I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
during O
singleton O
pregnancy O
. O
['Physiological-Clinical']

Consecutive O
2-s O
epochs O
of O
a O
10-min O
EEG O
record O
( O
resting O
conditions O
) O
of O
F3/C3-F4/C4-P3/01-P4/02 O
were O
subjected O
to O
FFT O
( O
Fast O
Fourier O
Transform O
) O
. O
[]

Both O
drugs O
, O
administered O
in O
a O
dose O
of O
one O
suppository O
twice O
a O
day O
for O
7 O
days O
, O
showed O
marked O
anti-inflammatory B-outcome ['Physiological-Clinical']
, O
analgesic B-outcome ['Resource-use']
and O
antipyretic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
produced O
a O
significant O
, O
progressive O
improvement O
in O
the O
typical O
symptoms O
of O
the O
inflammatory B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
up O
to O
their O
complete O
remission O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Intestinal O
absorption O
of O
dietary O
fat O
in O
patients O
with O
multiple O
sclerosis O
. O
[]

Each O
participant O
was O
initially O
given O
a O
saline O
nasal O
spray O
for O
one O
week O
. O
[]

Detailed O
assessment O
of O
drug O
safety O
, O
biochemical B-outcome ['Physiological-Clinical']
and O
haematological B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
, O
and O
efficacy O
was O
made O
at O
these O
dates O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
multicentre O
study O
. O
[]

BACKGROUND O
Psychosocial O
interventions O
can O
improve O
psychological O
quality O
of O
life O
( O
symptoms O
of O
depression O
and O
anxiety O
) O
of O
both O
women O
with O
breast O
cancer O
and O
their O
partners O
, O
but O
are O
not O
offered O
routinely O
to O
women O
and O
their O
partners O
. O
[]

The O
responses O
of O
L. O
rohita O
fingerlings O
to O
dietary O
PN O
were O
assessed O
in O
terms O
of O
growth O
and O
by O
analysing O
some O
hemato-immunological O
parameters O
. O
[]

METHODS O
Sixty-eight O
patients O
with O
peripheral O
obstructive O
arterial O
disease O
and O
intermittent O
claudication O
( O
Fontaine O
stage O
II O
) O
were O
randomly O
assigned O
into O
the O
treadmill O
training O
( O
repetitive O
intervals O
to O
onset O
of O
claudication O
pain O
, O
three O
times O
a O
week O
) O
or O
a O
control O
group O
( O
no O
change O
in O
physical O
activity O
) O
over O
3 O
months O
. O
[]

The O
[]

RESULTS O
Eighty-four O
patients O
were O
randomized O
. O
[]

Significant O
treatment O
differences O
( O
p O
< O
.01 O
) O
in O
favor O
of O
nefazodone O
were O
also O
seen O
in O
the O
Montgomery-Asberg O
Depression O
Rating O
Scale O
; O
the O
HAM-D O
retardation O
, O
anxiety O
, O
and O
sleep O
disturbance O
factors O
; O
and O
HAM-D O
item O
1 O
( O
depressed O
mood O
) O
. O
[]

Treatment-emergent O
adverse O
events O
including O
blood O
chemistry O
metabolites O
were O
recorded O
. O
[]

OBJECTIVES O
Roux-en-Y O
gastric O
bypass O
surgery O
is O
the O
most O
commonly O
performed O
procedure O
for O
the O
treatment O
of O
morbid O
obesity O
. O
[]

Skin B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
with O
two O
different O
oestroprogestins O
in O
patients O
affected O
by O
acne O
and O
polycystic O
ovary O
syndrome O
: O
clinical O
and O
instrumental O
evaluation O
. O
['Physiological-Clinical']

Sixteen O
outpatients O
with O
a O
brain O
injury O
were O
included O
in O
the O
study O
. O
[]

A O
randomized O
breast-feeding O
promotion O
intervention O
did O
not O
reduce O
child O
obesity O
in O
Belarus O
. O
[]

Within-subject O
analyses O
examined O
the O
association O
between O
the O
presence O
of O
IEDs O
and O
changes O
in O
attention-deficit/hyperactivity B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
ADHD I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

Offering O
various O
screening O
options O
can O
be O
a O
successful O
method O
for O
increasing O
participation B-outcome ['Life-Impact']
in O
this O
group O
. O
['Life-Impact']

1.36 O
; O
p O
= O
0.037 O
) O
. O
[]

2 O
. O
[]

This O
number O
declined O
as O
the O
trial O
progressed O
and O
coincided O
with O
investigator O
training O
and O
feedback O
from O
central O
review O
. O
[]

Corneal B-outcome ['Physiological-Clinical']
curvature I-outcome ['Physiological-Clinical']
changed O
as O
predicted O
, O
resulting O
in O
a O
prolate O
aspheric O
shape O
within O
the O
central O
optical O
zone O
. O
['Physiological-Clinical']

We O
hypothesised O
that O
if O
wind-up O
is O
a O
proxy O
for O
central O
sensitisation O
induced O
human O
visceral O
pain O
hypersensitivity O
, O
then O
oesophageal O
wind-up O
should O
be O
enhanced O
by O
secondary O
hyperalgesia O
. O
[]

Fasciculations B-outcome ['Physiological-Clinical']
were O
recorded O
using O
a O
graded O
visual O
scale O
. O
['Physiological-Clinical']

At O
least O
one O
drug-related B-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
was O
reported O
by O
9.5 O
% O
of O
the O
faropenem O
daloxate-treated O
patients O
and O
by O
10.3 O
% O
of O
those O
who O
received O
cefuroxime O
axetil O
. O
['Adverse-effects']

CONCLUSIONS O
Omega-3 O
fatty O
acids O
and O
fenofibrate O
therapy O
promoted O
similar O
changes O
in O
triglycerides B-outcome ['Physiological-Clinical']
and O
endothelium-dependent B-outcome ['Physiological-Clinical']
dilation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
2 O
in-season O
short-term O
sprint O
and O
power O
training O
protocols O
on O
vertical O
countermovement O
jump O
height O
( O
with O
or O
without O
arms O
) O
, O
sprint O
( O
Sprint-15m O
) O
speed O
, O
and O
agility O
( O
Agility-15m O
) O
speed O
in O
male O
elite O
junior O
soccer O
players O
. O
[]

A O
cost-benefit O
comparison O
of O
intensive O
diabetes O
management O
with O
implantable O
pumps O
versus O
multiple O
subcutaneous O
injections O
in O
patients O
with O
type O
I O
diabetes O
. O
['Resource-use']

Under O
short O
general O
anesthesia O
or O
sedation O
, O
100 O
to O
200 O
U O
of O
Dysport O
( O
Polish O
patients O
) O
or O
Botox O
( O
U.S. O
patients O
) O
was O
injected O
through O
a O
cystoscope O
into O
20 O
to O
30 O
sites O
submucosally O
in O
the O
trigone O
and O
floor O
of O
the O
bladder O
. O
[]

Concurrent O
administration O
of O
donepezil O
HCl O
and O
digoxin O
: O
assessment O
of O
pharmacokinetic O
changes O
. O
[]

OBJECTIVES O
The O
objective O
of O
this O
investigation O
was O
to O
evaluate O
the O
changes O
in O
parasympathetic O
tone O
associated O
with O
long-term O
angiotensin-converting O
enzyme O
inhibitor O
therapy O
in O
patients O
with O
congestive O
heart O
failure O
. O
[]

The O
percentage O
of O
oocytes B-outcome ['Physiological-Clinical']
reaching I-outcome ['Physiological-Clinical']
metaphase I-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
( O
P O
< O
0.05 O
) O
in O
the O
FSH-primed O
group O
( O
59 O
% O
, O
92/156 O
) O
compared O
with O
the O
non-primed O
group O
( O
44 O
% O
, O
36/81 O
) O
. O
['Physiological-Clinical']

Cumulative O
amount O
of O
i.v O
. O
[]

RESULTS O
Treatment O
was O
successful O
( O
decrease O
of O
symptoms O
at O
12 O
months O
) O
in O
62 O
% O
of O
patients O
in O
the O
active-treatment O
group O
and O
in O
60 O
% O
of O
the O
placebo O
group O
( O
N.S. O
) O
. O
[]

[ O
Preventive O
use O
of O
Pentaglobin O
in O
intensive O
care O
treatment O
of O
trauma O
patients O
] O
. O
[]

Secondary O
endpoints O
are O
: O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
& O
interference B-outcome ['Life-Impact']
, O
adherence B-outcome ['Life-Impact']
, O
coping B-outcome ['Life-Impact']
and O
HRQoL B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
Over O
the O
2-year O
period O
, O
patients O
treated O
with O
hemiarthroplasty O
gained O
0.15-0.20 O
more O
QALYs O
than O
patients O
treated O
with O
internal O
fixation O
. O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
groups O
, O
dose-ranging O
study O
of O
oral O
, O
human O
immunoglobulin O
( O
IGOH O
140 O
, O
420 O
, O
or O
840 O
mg/day O
) O
was O
utilized O
with O
125 O
children O
( O
ages O
2-17 O
years O
) O
with O
autism O
and O
persistent O
GI O
symptoms O
. O
[]

METHODS O
Fourteen O
preschoolers O
with O
developmental O
disorders O
( O
DD O
, O
n O
= O
14 O
; O
PDD O
, O
n O
= O
12 O
; O
ID O
, O
n O
= O
2 O
) O
underwent O
MPH O
titration O
in O
a O
single-blind O
manner O
followed O
by O
a O
4-week O
double-blind O
crossover O
phase O
. O
[]

Substantial O
evidence O
from O
studies O
in O
animals O
and O
humans O
indicates O
an O
inverse O
relationship O
between O
central O
5-HT O
tonus O
and O
5-HT O
type O
4 O
receptor O
( O
5-HT4R O
) O
density O
, O
suggesting O
that O
5-HT4R O
receptor O
density O
may O
be O
a O
biomarker O
marker O
for O
5-HT O
tonus O
. O
[]

The O
results O
indicate O
that O
desflurane O
is O
associated O
with O
similar O
operating O
conditions O
and O
faster O
postoperative B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
following O
acoustic O
neuroma O
surgery O
. O
['Physiological-Clinical']

Eight O
young O
adults O
who O
were O
diagnosed O
with O
autism O
were O
given O
the O
opiate O
antagonist O
naltrexone O
to O
control O
self-injurious O
behavior O
and O
maladaptive O
idiosyncratic O
mannerisms O
. O
[]

Should O
snacks O
be O
recommended O
in O
obesity O
treatment O
? O
[]

Rapid O
efficacy O
of O
the O
highly O
selective O
alpha1A-adrenoceptor O
antagonist O
silodosin O
in O
men O
with O
signs O
and O
symptoms O
of O
benign O
prostatic O
hyperplasia O
: O
pooled O
results O
of O
2 O
phase O
3 O
studies O
. O
[]

RESULTS O
There O
was O
no O
significant O
difference O
in O
change O
in O
BP B-outcome ['Physiological-Clinical']
between O
intervention O
and O
control O
; O
BP B-outcome ['Physiological-Clinical']
-4.2 O
mmHg O
( O
95 O
% O
CI O
-12.4 O
to O
3.9 O
) O
/-2.6 O
mmHg O
( O
95 O
% O
CI O
-8.4 O
to O
3.3 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
During O
Step O
1 O
of O
the O
clamp O
, O
whole O
body O
glucose O
disposal O
( O
M O
) O
was O
reduced O
by O
35 O
% O
( O
p O
= O
0.003 O
) O
and O
M/I O
was O
reduced O
by O
29 O
% O
( O
p O
= O
0.025 O
) O
for O
25 O
mg O
prednisone O
compared O
to O
placebo O
. O
[]

MATERIALS O
AND O
METHODS O
We O
used O
100 O
ml O
of O
iopamidol O
300 O
at O
an O
injection O
rate O
of O
3.0 O
ml/s O
, O
100 O
ml O
of O
iopamidol O
300 O
at O
an O
injection O
rate O
of O
3.7 O
ml/s O
, O
and O
80 O
ml O
of O
iopamidol O
370 O
at O
an O
injection O
rate O
of O
3.0 O
ml/s O
. O
[]

Recombinant O
murine O
GM-CSF O
administration O
to O
neonatal O
rats O
has O
resulted O
in O
neutrophilia O
, O
increased O
neutrophil O
production O
, O
and O
increased O
survival O
of O
pups O
during O
experimental O
Staphylococcus O
aureus O
sepsis O
. O
[]

RESULTS O
We O
investigated O
26 O
patients O
with O
mild O
to O
moderate O
PD O
: O
13 O
received O
iTBS O
and O
13 O
sham O
stimulation O
. O
[]

The O
mean O
areas O
under O
the O
plasma B-outcome ['Physiological-Clinical']
concentration O
['Physiological-Clinical']

Blood O
samples O
were O
taken O
prior O
to O
operation O
as O
well O
as O
on O
days O
1 O
, O
3 O
, O
and O
5 O
after O
operation O
. O
[]

2 O
. O
[]

The O
secondary O
end O
points O
included O
the O
time O
to O
heal O
and O
cosmetic O
appearance O
. O
[]

RESULTS O
39 O
patients O
with O
alpha O
dihidroergocriptine O
and O
38 O
with O
placebo O
. O
[]

In O
a O
prospective O
, O
randomized O
trial O
, O
we O
compared O
intravenous O
acyclovir O
and O
vidarabine O
in O
the O
treatment O
of O
varicella-zoster O
virus O
infection O
in O
severely O
immunocompromised O
patients O
who O
presented O
within O
72 O
hours O
of O
onset O
of O
the O
infection O
. O
[]

Our O
objective O
was O
to O
explore O
the O
associations O
of O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CrCl I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
with O
outcomes O
in O
a O
trial O
of O
eptifibatide O
therapy O
in O
patients O
who O
underwent O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
['Physiological-Clinical']

The O
aim O
of O
the O
trial O
was O
to O
compare O
the O
efficacy O
and O
morbidity B-outcome ['Physiological-Clinical']
of O
these O
two O
methods O
of O
treatment O
. O
['Physiological-Clinical']

39 O
patients O
with O
marginal O
zone O
B O
cell O
lymphoma O
( O
MZBCL O
) O
of O
the O
parotid O
glands O
( O
stages O
I O
or O
II O
) O
were O
studied O
. O
[]

However O
, O
expenses O
and O
side O
effects O
of O
these O
agents O
have O
also O
been O
a O
concern O
for O
clinical O
doctors O
. O
[]

We O
have O
conducted O
a O
randomised O
trial O
in O
consecutive O
patients O
with O
serious O
infections O
for O
whom O
an O
aminoglycoside O
seemed O
warranted O
. O
[]

CONCLUSION O
NCE O
4D O
MRA O
with O
STAR O
tagging O
and O
VFA O
sampling O
is O
technically O
and O
clinically O
feasible O
and O
represents O
a O
promising O
technique O
for O
assessment O
of O
DAVF O
in O
the O
transverse O
sinus O
. O
[]

Parallel O
to O
the O
clinical O
trials O
, O
experimental O
canine O
artery O
stenting O
was O
performed O
to O
evaluate O
differences O
in O
the O
long-term O
patency O
of O
stents O
exposed O
to O
restricted O
flow O
. O
[]

The O
EDD O
was O
adjusted O
in O
13 O
( O
5.7 O
% O
) O
women O
in O
the O
scan O
group O
and O
in O
2 O
( O
0.9 O
% O
) O
in O
the O
no-scan O
group O
. O
[]

access O
. O
[]

Most O
patients O
( O
54/82 O
) O
delivered O
by O
cesarean B-outcome ['Physiological-Clinical']
section I-outcome ['Physiological-Clinical']
without O
differences O
according O
to O
the O
hysteroscopic O
technique O
used O
for O
metroplasty O
( O
65 O
% O
in O
group O
A O
vs O
67.7 O
% O
in O
group O
B O
) O
or O
to O
the O
gestational O
age O
( O
65.1 O
% O
of O
term O
and O
68.7 O
% O
of O
preterm O
deliveries O
) O
. O
['Physiological-Clinical']

Temporal O
expectation O
in O
focal O
hand O
dystonia O
. O
[]

Delivered B-outcome ['Physiological-Clinical']
energy I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
DFT I-outcome ['Physiological-Clinical']
was O
4.2 O
+/- O
4.1 O
J O
in O
the O
lead O
configuration O
and O
5.0 O
+/- O
3.7 O
J O
in O
the O
active O
can O
configuration O
( O
P O
= O
NS O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Surgical O
hepatic O
resection O
remains O
the O
treatment O
of O
choice O
for O
patients O
with O
liver O
metastases O
from O
colorectal O
cancer O
despite O
the O
use O
of O
alternative O
therapeutic O
strategies O
. O
[]

However O
, O
the O
serum O
levels O
of O
total O
protein O
and O
albumin O
were O
significantly O
higher O
in O
the O
multiple-pass O
hemoconcentration O
group O
as O
compared O
to O
the O
centrifugation O
group O
. O
[]

Lack O
of O
interaction O
between O
pantoprazole O
and O
digoxin O
at O
therapeutic O
doses O
in O
man O
. O
[]

MATERIALS O
AND O
METHODS O
This O
study O
was O
performed O
in O
a O
randomized O
, O
multicenter O
, O
prospective O
manner O
. O
[]

All O
three O
treatments O
generally O
yielded O
comparable O
results O
for O
the O
secondary O
efficacy O
variables O
and O
all O
treatments O
were O
well O
[]

Good O
compliance B-outcome ['Life-Impact']
did O
not O
affect O
the O
results O
. O
['Life-Impact']

In O
the O
EBUS O
conventional O
diagnostic O
procedures O
( O
CDPs O
) O
group O
( O
103 O
patients O
) O
, O
both O
transbronchial O
biopsy O
( O
TBB O
) O
and O
bronchial O
washing O
( O
BW O
) O
were O
performed O
. O
[]

The O
median O
duration O
of O
response O
was O
9?7 O
months O
for O
PUVA O
vs. O
5?8 O
months O
for O
the O
combination O
arm O
( O
P O
= O
0?33 O
) O
. O
[]

The O
purpose O
of O
this O
investigation O
is O
to O
examine O
the O
effects O
of O
long O
term O
exercise O
on O
reversing O
musculoskeletal-related B-outcome ['Physiological-Clinical']
side I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
, O
and O
cardiovascular B-outcome ['Physiological-Clinical']
and O
diabetes B-outcome ['Physiological-Clinical']
risk O
factors O
in O
men O
receiving O
androgen O
deprivation O
for O
their O
prostate O
cancer O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Kaplan-Meier O
survival O
analysis O
comparisons O
were O
made O
between O
respective O
subgroups O
with O
and O
without O
prognostic O
indicators O
for O
filtration O
failures O
using O
a O
relatively O
stringent O
set O
of O
criteria O
for O
filtration O
success O
of O
primary O
glaucoma O
triple O
procedure O
. O
[]

AIM O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
whether O
oxidized B-outcome ['Physiological-Clinical']
regenerated I-outcome ['Physiological-Clinical']
cellulose I-outcome ['Physiological-Clinical']
( O
ORC B-outcome ['Physiological-Clinical']
) O
, O
applied O
to O
dirty O
surgical O
wounds O
, O
is O
able O
to O
reduce O
the O
microbial O
load O
and O
, O
consequently O
, O
the O
infection B-outcome ['Physiological-Clinical']
rate O
as O
compared O
to O
conventional O
local O
wound O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Results O
demonstrated O
that O
typical O
peer O
models O
had O
higher O
social B-outcome ['Life-Impact']
network I-outcome ['Life-Impact']
centrality I-outcome ['Life-Impact']
, O
received O
friendships B-outcome ['Life-Impact']
, O
friendship B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
, O
and O
less O
['Life-Impact', 'Life-Impact', 'Life-Impact']

BACKGROUND O
B-type B-outcome ['Physiological-Clinical']
natriuretic I-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BNP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
are O
reliably O
elevated O
in O
patients O
with O
congestive O
heart O
failure O
( O
CHF O
) O
and O
therefore O
helpful O
in O
its O
diagnosis O
. O
['Physiological-Clinical']

The O
primary O
endpoint O
was O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
VT I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Beta O
radiation O
as O
an O
adjunct O
to O
low-risk O
trabeculectomy O
. O
[]

The O
date O
of O
each O
performance O
test O
was O
included O
as O
a O
continuous O
linear O
fixed O
effect O
and O
interacted O
with O
the O
random O
effect O
for O
the O
athlete O
to O
represent O
individual O
differences O
in O
linear O
trends O
in O
performance O
. O
[]

There O
was O
no O
statistically O
significant O
difference O
between O
the O
means O
or O
medians O
in O
any O
of O
these O
situations O
. O
[]

CONCLUSION O
Proparacaine O
eye O
drops O
offer O
significant O
relief O
of O
pain O
that O
is O
apparently O
short O
lived O
. O
[]

Throughout O
the O
infusion O
, O
changes O
in O
transcutaneous B-outcome ['Physiological-Clinical']
PCO2 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
tcPCO2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
subjective B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
recorded O
continuously O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Group O
I O
( O
25 O
patients O
) O
received O
capsule O
A O
( O
glibenclamide O
) O
while O
Group O
II O
( O
25 O
patients O
) O
received O
capsule O
B O
( O
gliclazide O
) O
. O
[]

OBJECTIVE O
Our O
purpose O
was O
to O
compare O
the O
effect O
of O
vaginal O
administration O
of O
misoprostol O
( O
Cytotec O
) O
with O
that O
of O
dinoprostone O
( O
Cervidil O
) O
on O
cervical B-outcome ['Physiological-Clinical']
ripening I-outcome ['Physiological-Clinical']
and O
labor B-outcome ['Physiological-Clinical']
induction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Adverse O
events O
( O
mostly O
nausea B-outcome ['Physiological-Clinical']
, O
decrease O
in O
['Physiological-Clinical']

The O
results O
suggest O
that O
more O
accurate O
gross O
motor O
quotient O
scores O
on O
the O
TGMD-2 B-outcome ['Physiological-Clinical']
by O
children O
with O
ASD O
can O
be O
elicited O
using O
the O
picture O
task O
card O
protocol O
. O
['Physiological-Clinical']

Four O
parameters O
were O
followed O
: O
serum-specific O
IgE O
against O
antigen O
E O
, O
total O
blocking O
antibody O
against O
antigen O
E O
, O
local O
and O
systemic O
reactions O
to O
injection O
therapy O
, O
and O
symptom O
score O
indices O
. O
[]

Hypothyroidism O
resulted O
in O
hyperfibrinolysis B-outcome ['Physiological-Clinical']
and O
a O
reduced O
TAFIa-dependent B-outcome ['Physiological-Clinical']
prolongation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
clot B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Each O
subject O
took O
element O
calcium O
400 O
mg/d O
and O
vitamin O
D O
200 O
IU/d O
concomitantly O
. O
[]

Our O
task O
was O
divided O
into O
three O
phases O
: O
movement O
selection O
and O
initiation O
( O
initiate O
) O
, O
synchronisation O
of O
finger O
tapping O
with O
an O
external O
auditory O
cue O
( O
synchronise O
) O
, O
and O
continued O
tapping O
in O
absence O
of O
the O
auditory O
pacer O
( O
continue O
) O
. O
[]

While O
the O
patient O
in O
the O
observation O
group O
were O
treated O
by O
the O
routine O
treatment O
and O
acupuncture O
treatment O
48 O
h O
( O
-1 O
) O
week O
after O
operation O
in O
different O
stages O
with O
different O
acupoints O
selected O
when O
the O
situation O
was O
stable O
. O
[]

Statistically O
significant O
improvements O
in O
metabolic O
status O
were O
many O
including O
: O
total O
sulfate B-outcome ['Physiological-Clinical']
( O
+17 O
% O
, O
p O
= O
0.001 O
) O
, O
S-adenosylmethionine B-outcome ['Physiological-Clinical']
( O
SAM O
; O
+6 O
% O
, O
p O
= O
0.003 O
) O
, O
reduced O
glutathione B-outcome ['Physiological-Clinical']
( O
+17 O
% O
, O
p O
= O
0.0008 O
) O
, O
ratio O
of O
oxidized B-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
reduced I-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
( O
GSSG O
: O
GSH O
; O
-27 O
% O
, O
p O
= O
0.002 O
) O
, O
nitrotyrosine B-outcome ['Physiological-Clinical']
( O
-29 O
% O
, O
p O
= O
0.004 O
) O
, O
ATP B-outcome ['Physiological-Clinical']
( O
+25 O
% O
, O
p O
= O
0.000001 O
) O
, O
NADH B-outcome ['Physiological-Clinical']
( O
+28 O
% O
, O
p O
= O
0.0002 O
) O
, O
and O
NADPH B-outcome ['Physiological-Clinical']
( O
+30 O
% O
, O
p O
= O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
of O
candesartan O
on O
diabetes B-outcome ['Physiological-Clinical']
glomerulopathy I-outcome ['Physiological-Clinical']
: O
a O
double-blind O
, O
placebo-controlled O
trial O
. O
['Physiological-Clinical']

Pretests O
and O
posttests O
measured O
social B-outcome ['Life-Impact']
responsiveness I-outcome ['Life-Impact']
, O
sensory B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
, O
functional B-outcome ['Life-Impact']
motor I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact']

MAIN O
OUTCOME O
MEASURES O
Intra-operative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
post-operative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
blood O
transfusion O
rates O
, O
operative B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
, O
uterine B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
ovarian B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
meal O
ingestion O
and O
meal O
composition O
on O
the O
CV O
responses O
to O
orthostasis O
are O
unknown O
. O
[]

Microscopic O
evidence O
of O
residual O
cancer O
was O
obtained O
in O
3 O
cases O
. O
[]

Modified O
Kupperman B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
were O
assessed O
on O
baseline O
and O
every O
3 O
months O
thereafter O
and O
irregular B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
recorded O
on O
menopausal O
diary O
every O
day O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Concurrent O
alcohol O
dependence O
among O
methadone-maintained O
cocaine O
abusers O
is O
associated O
with O
greater O
abstinence B-outcome ['Life-Impact']
. O
['Life-Impact']

Multivariate O
analysis O
showed O
local B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
increased O
with O
age O
( O
P=0.0003 O
) O
. O
['Physiological-Clinical']

We O
performed O
a O
prospective O
, O
single O
institution O
, O
randomized O
trial O
to O
investigate O
whether O
the O
residual O
tumor O
rate O
and O
long-term O
tumor O
recurrence O
can O
be O
decreased O
by O
fluorescence O
diagnosis O
. O
[]

The O
present O
study O
evaluated O
the O
effect O
of O
adjuvant O
immunochemotherapy O
with O
the O
use O
of O
BCG O
( O
bacille O
Calmette-Guerin O
) O
and O
FAM O
( O
5-fluorouracil O
, O
adriamycin O
, O
mitomycin O
C O
) O
chemotherapy O
on O
the O
survival B-outcome ['Mortality']
of I-outcome ['Mortality']
patients I-outcome ['Mortality']
with O
locally O
advanced O
resectable O
gastric O
cancer O
. O
['Mortality']

At O
the O
beginning O
of O
the O
trial O
, O
all O
patients O
were O
also O
randomised O
between O
late O
intensification O
alone O
and O
both O
early O
plus O
late O
blocks O
. O
[]

Gastric O
ulcer O
patients O
who O
satisfied O
all O
criteria O
for O
inclusion O
and O
exclusion O
were O
randomly O
allocated O
to O
nizatidine O
300 O
mg O
nocte O
, O
150 O
mg O
b.d O
. O
[]

Similarly O
, O
Steri-Strip O
S O
versus O
suture O
for O
the O
abdomen O
was O
faster O
( O
p O
< O
0.001 O
; O
4.9 O
minutes O
, O
SD O
= O
2.3 O
versus O
10.1 O
minutes O
, O
SD O
= O
3.4 O
) O
. O
[]

Effect O
of O
total O
androgen O
ablation O
on O
pathologic B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
and O
resection B-outcome ['Physiological-Clinical']
limit I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
prostate I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Postoperative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
aspirin-treated O
patients O
than O
in O
the O
placebo-treated O
patients O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

A O
clinical O
evaluation O
of O
a O
new O
, O
purified O
, O
heat-treated O
equine O
rabies O
immunoglobulin O
( O
PHT-Erig O
) O
, O
F O
( O
ab O
' O
) O
2 O
preparation O
, O
was O
carried O
out O
in O
Thailand O
and O
in O
the O
Philippines-two O
countries O
where O
rabies O
is O
endemic O
. O
[]

Compared O
with O
placebo O
, O
desmopressin O
resulted O
in O
a O
significant O
reduction O
in O
the O
mean O
number O
of O
nocturnal B-outcome ['Physiological-Clinical']
voids I-outcome ['Physiological-Clinical']
( O
39 O
% O
reduction O
with O
desmopressin O
vs. O
15 O
% O
with O
placebo O
; O
absolute O
difference O
-0.84 O
, O
p O
< O
0.0001 O
) O
and O
duration O
of O
the O
first B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
period I-outcome ['Physiological-Clinical']
( O
prolonged O
by O
108 O
min O
with O
desmopressin O
vs. O
41 O
min O
with O
placebo O
; O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
results O
suggest O
a O
possible O
linkage O
between O
abnormal O
plasma O
chemistries O
, O
especially O
those O
related O
to O
the O
pro-opiomelanocortin O
system O
, O
and O
autistic O
symptoms O
. O
[]

Participants O
in O
music O
training O
( O
n O
= O
18 O
) O
watched O
a O
music O
video O
containing O
6 O
songs O
and O
pictures O
of O
the O
36 O
target O
words O
; O
those O
in O
speech O
training O
( O
n O
= O
18 O
) O
watched O
a O
speech O
video O
containing O
6 O
stories O
and O
pictures O
, O
and O
those O
in O
the O
control O
condition O
( O
n O
= O
14 O
) O
received O
no O
treatment O
. O
[]

The O
study O
was O
carried O
out O
in O
30 O
subjects O
using O
the O
controlled O
experiment O
technique O
according O
to O
the O
between O
patient O
pattern O
, O
attributing O
parsalmide O
and O
indomethacin O
at O
random O
to O
two O
groups O
. O
[]

The O
trial O
is O
registered O
with O
ClinicalTrials.gov O
, O
number O
NCT00390221 O
. O
[]

CONCLUSIONS O
The O
rotational O
angiography O
technique O
leads O
to O
a O
significant O
decrease O
in O
[]

Obesity O
and O
mortality O
in O
men O
with O
locally O
advanced O
prostate O
cancer O
: O
analysis O
of O
RTOG O
85-31 O
. O
[]

Higher O
recurrence B-outcome ['Physiological-Clinical']
rates O
were O
found O
for O
Grade O
III O
and O
multiple O
primary O
tumors O
. O
['Physiological-Clinical']

BMD B-outcome ['Physiological-Clinical']
was O
measured O
by O
DXA O
at O
baseline O
and O
after O
6 O
months O
of O
exercise O
. O
['Physiological-Clinical']

The O
matched O
control O
group O
consisted O
of O
26 O
asymptomatic O
tendons O
. O
[]

Pediatricians O
do O
so O
more O
often O
than O
family O
physicians O
. O
[]

3 O
) O
. O
[]

No O
statistically O
significant O
differences O
in O
survival B-outcome ['Mortality']
parameters O
were O
observed O
. O
['Mortality']

CONCLUSION O
Data O
obtained O
from O
gas O
exchange O
analysis O
are O
more O
sensitive O
and O
potentially O
more O
useful O
in O
the O
detection O
of O
short-term O
changes O
in O
exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
than O
data O
obtained O
from O
either O
exercise O
time O
or O
peak O
work O
rate O
, O
indexes O
that O
are O
commonly O
used O
to O
assess O
drug O
therapy O
. O
['Life-Impact']

The O
recurrence O
of O
hepatocellular O
carcinoma O
( O
HCC O
) O
after O
minimally O
invasive O
therapy O
is O
frequent O
. O
[]

On O
Day O
8 O
, O
the O
incidences O
of O
gastric B-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
in O
the O
risedronate O
and O
alendronate O
groups O
were O
3.6 O
% O
and O
6.6 O
% O
, O
respectively O
( O
p O
= O
0.133 O
) O
, O
and O
on O
Day O
15 O
, O
they O
were O
3.3 O
% O
and O
8.7 O
% O
( O
p O
= O
0.008 O
) O
. O
['Physiological-Clinical']

RESULTS O
From O
June O
2008 O
through O
June O
2009 O
, O
we O
enrolled O
178 O
patients O
( O
90 O
midazolam O
, O
88 O
propofol O
) O
. O
[]

This O
difference O
was O
also O
significant O
in O
the O
silicone O
group O
( O
p O
= O
0.041 O
) O
. O
[]

We O
measured O
symptomatic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
rates O
of O
clinical B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Quality O
of O
life O
, O
judged O
by O
Diabetes B-outcome ['Physiological-Clinical']
Control O
and O
Complications B-outcome ['Adverse-effects']
Trial O
questionnaires O
, O
was O
unaffected O
by O
pump O
therapy O
. O
['Physiological-Clinical', 'Adverse-effects']

[ O
Effect O
of O
branch O
chain O
amino O
acid O
enriched O
formula O
on O
postoperative B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
and O
nutritional B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
after O
digestive O
surgery O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

To O
re-evaluate O
the O
effect O
of O
metformin O
on O
fasting O
triglyceride O
concentration O
and O
on O
blood O
pressure O
, O
the O
BIGPRO O
1.2 O
trial O
included O
non-diabetic O
men O
( O
n=168 O
) O
with O
a O
fasting O
plasma O
triglyceride O
concentration O
> O
or O
=1.7 O
and O
< O
or O
=6.5 O
mmol/l O
, O
high O
blood O
pressure O
( O
systolic O
> O
or O
=140 O
and O
< O
or O
=180 O
and/or O
diastolic O
> O
or O
=90 O
and O
< O
or O
=105 O
mmHg O
, O
or O
treatment O
for O
hypertension O
) O
and O
a O
waist-to-hip O
ratio O
> O
or O
=0.95 O
. O
[]

Eighteen O
months O
later O
their O
mean O
weight O
loss B-outcome ['Physiological-Clinical']
was O
10.4 O
kg O
( O
SD=10.8 O
) O
. O
['Physiological-Clinical']

Effect O
of O
supplementary O
antioxidant O
vitamin O
intake O
on O
carotid B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
intima-media I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
in O
a O
controlled O
clinical O
trial O
of O
cholesterol O
lowering O
. O
['Physiological-Clinical']

Furazolidone O
( O
FZ O
) O
has O
been O
used O
in O
China O
as O
a O
treatment O
of O
peptic B-outcome ['Physiological-Clinical']
ulcer O
disease O
for O
about O
20 O
years O
. O
['Physiological-Clinical']

RXU O
: O
25 O
PCCs O
were O
placed O
in O
molars O
, O
nine O
in O
premolars O
. O
[]

METHODS O
We O
performed O
a O
double-blind O
, O
placebo-controlled O
, O
phase O
1b/2a O
trial O
randomizing O
HIV-positive O
patients O
to O
receive O
double O
doses O
of O
7vPnC O
( O
Prevnar O
) O
at O
0 O
and O
3 O
months O
and O
1 O
dose O
of O
23-valent O
pneumococcal O
polysaccharide O
vaccine O
( O
PPV-23 O
; O
Pneumo O
Novum O
) O
at O
9 O
months O
, O
with O
experimental O
patients O
receiving O
1 O
mg O
of O
CPG O
7909 O
added O
to O
each O
of O
their O
3 O
vaccine O
doses O
; O
control O
patients O
had O
phosphate-buffered O
saline O
added O
instead O
. O
[]

The O
primary O
outcome O
was O
change O
in O
body O
mass O
index O
Z-score O
for O
age O
and O
sex O
( O
BMI-Z O
) O
at O
13 O
, O
24 O
, O
and O
36 O
weeks O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
branch O
chain O
amino O
acid O
( O
BCAA O
) O
enriched O
formula O
on O
nutritional B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
and O
postoperative B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
for O
digestive O
surgery O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Spontaneous B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
using I-outcome ['Life-Impact']
picture I-outcome ['Life-Impact']
cards I-outcome ['Life-Impact']
, O
speech B-outcome ['Life-Impact']
, O
or O
both O
increased O
significantly O
following O
training O
( O
rate O
ratio O
[ O
RR O
] O
=1.90 O
, O
95 O
% O
CI O
[ O
1.46 O
, O
2.48 O
] O
, O
p O
< O
.001 O
; O
RR O
= O
1.77 O
, O
95 O
% O
CI O
[ O
1.35 O
, O
2.32 O
] O
, O
p O
< O
.001 O
; O
RR O
= O
3.74 O
, O
95 O
% O
CI O
[ O
2.19 O
, O
6.37 O
] O
, O
p O
< O
.001 O
, O
respectively O
) O
. O
['Life-Impact', 'Life-Impact']

After O
a O
suitable O
infusion O
regimen O
of O
dexmedetomidine O
was O
determined O
according O
to O
hemodynamic O
criteria O
, O
20 O
patients O
were O
included O
in O
a O
double-blind O
, O
randomized O
placebo-controlled O
trial O
( O
10 O
receiving O
dexmedetomidine O
, O
10 O
saline O
solution O
) O
. O
[]

The O
present O
study O
aimed O
to O
examine O
the O
effects O
of O
a O
fixed-dose O
combination O
of O
antihypertensives O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
microalbuminuria B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Resource O
use O
was O
identified O
, O
quantified O
, O
and O
valued O
for O
direct O
and O
indirect O
hospital O
costs O
and O
for O
societal O
costs O
. O
[]

Based O
on O
serial O
electrocardiographic O
data O
, O
115 O
of O
the O
246 O
patients O
with O
angina O
had O
transient O
ST-T B-outcome ['Physiological-Clinical']
changes O
and O
131 O
did O
not O
. O
['Physiological-Clinical']

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
multicenter O
study O
to O
evaluate O
the O
cardioprotective O
effects O
of O
MC-1 O
in O
patients O
undergoing O
high-risk O
coronary O
artery O
bypass O
graft O
surgery O
: O
MC-1 O
to O
Eliminate O
Necrosis O
and O
Damage O
in O
Coronary B-outcome ['Physiological-Clinical']
Artery I-outcome ['Physiological-Clinical']
Bypass O
Graft O
Surgery O
Trial O
( O
MEND-CABG O
) O
II O
-- O
study O
design O
and O
rationale O
. O
['Physiological-Clinical']

This O
study O
investigated O
whether O
sheltered O
workshops O
help O
prepare O
individuals O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
for O
competitive B-outcome ['Life-Impact']
employment I-outcome ['Life-Impact']
within O
the O
community O
. O
['Life-Impact']

The O
long-term O
data O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
values O
in O
the O
survivors O
were O
similar O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

At O
30 O
minutes O
, O
the O
degree O
of O
flexion B-outcome ['Physiological-Clinical']
remaining I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
great I-outcome ['Physiological-Clinical']
toe I-outcome ['Physiological-Clinical']
( O
control O
100 O
% O
) O
was O
4 O
% O
in O
the O
groups O
who O
received O
40 O
ml O
of O
0.5 O
% O
and O
1 O
% O
, O
but O
34 O
% O
in O
those O
who O
received O
20 O
ml O
of O
1 O
% O
respectively O
. O
['Physiological-Clinical']

Changing O
to O
betaxolol O
improved O
mean O
peak O
flow B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
by O
9.1 O
% O
, O
from O
310 O
to O
3411/min O
( O
p O
< O
0.05 O
) O
and O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
1 O
second O
( O
FEV1 O
) O
by O
9.4 O
% O
, O
from O
1.74 O
to O
1.861 O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Plasma O
AT O
, O
lipid-standardized O
AT O
, O
and O
LDL O
AT O
levels O
rose O
in O
a O
dose-dependent O
fashion O
in O
both O
the O
RRR-AT O
and O
all-rac-AT O
groups O
compared O
with O
baseline O
. O
[]

A O
cutoff O
of O
> O
60 O
viral O
copies/100 O
?L O
plasma O
yielded O
96 O
% O
concordance O
with O
EBER-ISH O
. O
[]

Baseline O
tone B-outcome ['Physiological-Clinical']
and O
activity B-outcome ['Life-Impact']
were O
measured O
for O
15 O
min O
prior O
to O
instillation O
of O
20 O
ml O
of O
saline O
alone O
or O
with O
nicotine O
, O
1.2 O
mg O
, O
at O
pH O
4.5 O
. O
['Physiological-Clinical', 'Life-Impact']

Escalation O
and O
reduction O
in O
dose O
was O
mandated O
dependent O
on O
hematotoxicity B-outcome ['Physiological-Clinical']
or O
lack O
thereof O
. O
['Physiological-Clinical']

AIM O
The O
aims O
of O
the O
present O
study O
were O
to O
revise O
the O
Community O
Re-entry O
Program-Japanese O
version O
and O
to O
review O
the O
effectiveness O
of O
the O
revised O
Program O
, O
named O
the O
Discharge O
Preparation O
Program O
. O
[]

The O
main O
outcome O
measure O
of O
parental B-outcome ['Life-Impact']
mental I-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
was O
the O
General B-outcome ['Life-Impact']
Health I-outcome ['Life-Impact']
Questionnaire O
used O
pre- O
and O
postintervention O
and O
at O
6-month O
follow-up O
. O
['Life-Impact', 'Life-Impact']

Early O
weaning O
resulted O
in O
increased O
( O
52-346 O
% O
) O
expression O
of O
genes B-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxidative I-outcome ['Physiological-Clinical']
stress O
and O
immune B-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
but O
decreased O
( O
35-77 O
% O
) O
expression O
of O
genes B-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
macronutrient I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
and O
cell B-outcome ['Physiological-Clinical']
proliferation I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
gut I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

None O
of O
the O
treatments O
affected O
insulin B-outcome ['Resource-use']
or I-outcome ['Resource-use']
glucose I-outcome ['Resource-use']
area O
under O
the O
curve O
values O
during O
the O
OGTT O
compared O
with O
placebo O
. O
['Resource-use']

UVA-control O
sites O
failed O
to O
be O
cleared B-outcome ['Physiological-Clinical']
within O
12 O
weeks O
. O
['Physiological-Clinical']

Protocol O
1 O
: O
96 O
bovine O
incisors O
were O
randomly O
divided O
into O
4 O
groups O
, O
and O
enamel O
surfaces O
were O
bonded O
in O
accordance O
with O
the O
following O
treatments O
: O
( O
1E O
) O
ozone O
+ O
Clearfil O
Protect O
Bond O
; O
( O
2E O
) O
Clearfil O
Protect O
Bond O
( O
control O
) O
; O
( O
3E O
) O
ozone O
+ O
Xeno O
III O
; O
( O
4E O
) O
Xeno O
III O
( O
control O
) O
. O
[]

Twenty O
patients O
subjected O
to O
craniotomy O
for O
supratentorial O
cerebral O
tumors O
were O
anesthetized O
with O
thiopental O
, O
fentanyl O
, O
nitrous O
oxide O
, O
and O
isoflurane O
. O
[]

This O
study O
evaluated O
the O
effect O
of O
a O
calculus O
scaling O
gel O
( O
SofScale O
) O
on O
time B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
ease I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
scaling I-outcome ['Life-Impact']
procedure I-outcome ['Life-Impact']
in O
a O
double-blind O
, O
split-mouth O
clinical O
study O
of O
32 O
subjects O
. O
['Life-Impact']

Covariates O
included O
age O
, O
race O
, O
treatment O
arm O
, O
history O
of O
prostatectomy O
, O
nodal O
involvement O
, O
Gleason O
score O
, O
clinical O
stage O
, O
and O
BMI O
. O
[]

Effectiveness O
of O
once-daily O
monotherapy O
with O
a O
new O
nifedipine O
sustained O
release O
calcium O
antagonist O
. O
[]

Global B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
right I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
were O
collected O
. O
['Physiological-Clinical']

Chemoimmunotherapy O
with O
levamisole O
or O
levamisole-BCG O
offers O
no O
advantage O
in O
terms O
of O
CR B-outcome ['Physiological-Clinical']
rates O
, O
CR B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
, O
or O
survival B-outcome ['Mortality']
compared O
to O
CHOP O
chemotherapy O
alone O
, O
and O
levamisole O
may O
have O
had O
an O
adverse O
impact O
on O
outcome O
in O
certain O
subtypes O
of O
ML O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Accordingly O
, O
it O
would O
be O
anticipated O
that O
angiotensin-converting O
enzyme O
inhibitors O
would O
significantly O
alter O
the O
autonomic O
imbalance O
characteristic O
of O
patients O
with O
congestive O
heart O
failure O
and O
that O
this O
influence O
over O
neural O
mechanisms O
of O
cardiovascular O
control O
may O
significantly O
contribute O
to O
the O
hemodynamic O
benefit O
and O
improved O
survival O
associated O
with O
angiotensin-converting O
enzyme O
inhibitor O
therapy O
. O
[]

METHODS O
Twenty O
moderate O
to O
severe O
persistent O
asthmatics O
completed O
a O
randomized O
double-blind O
crossover O
study O
. O
[]

In O
addition O
, O
a O
planning O
study O
was O
performed O
in O
26 O
stage O
I O
patients O
, O
of O
which O
22 O
were O
stage O
1A O
, O
in O
order O
to O
develop O
and O
evaluate O
the O
planning O
guidelines O
. O
[]

and O
100 O
mg O
twice O
daily O
( O
b.i.d O
. O
) O
[]

The O
incidence O
of O
difficult B-outcome ['Life-Impact']
intubation I-outcome ['Life-Impact']
was O
5.7 O
% O
. O
['Life-Impact']

DESIGN O
Ten O
patients O
( O
mean O
age O
47.7 O
yrs O
) O
with O
cognitive O
deficits O
after O
a O
first-ever O
stroke O
participated O
in O
this O
single-blind O
, O
crossover O
, O
and O
sham-controlled O
experiment O
. O
[]

FloSeal O
hemostatic O
matrix O
in O
persistent O
epistaxis O
: O
prospective O
clinical O
trial O
. O
[]

At O
T3 O
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
group O
2 O
was O
significantly O
higher O
than O
group O
1 O
. O
['Physiological-Clinical']

The O
overall O
difference O
between O
all O
956 O
pairs O
of O
pulse O
oximetry B-outcome ['Physiological-Clinical']
haemoglobin I-outcome ['Physiological-Clinical']
concentration O
and O
true O
haemoglobin O
concentrations O
( O
the O
bias O
) O
averaged O
only O
-0.7 O
g O
l O
whereas O
the O
95 O
% O
prediction O
interval O
was O
wide O
, O
ranging O
from O
-24.9 O
to O
23.7 O
g O
l. O
In O
addition O
to O
the O
choice O
of O
infusion O
fluid O
, O
the O
bias O
was O
strongly O
dependent O
on O
the O
volunteer O
( O
each O
factor O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

There O
was O
no O
evidence O
that O
girls O
and O
boys O
responded O
differently O
to O
the O
intervention O
( O
p O
> O
.05 O
) O
. O
[]

Clinical O
benefit O
assessments O
were O
recorded O
at O
each O
clinic O
visit O
. O
[]

Each O
phase O
lasted O
4 O
weeks O
. O
[]

Cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CBFV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
mean O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
recorded O
before O
anesthesia O
, O
during O
anesthesia O
after O
surgery O
, O
at O
extubation O
, O
and O
5-60 O
min O
after O
extubation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Given O
escalating O
rates O
of O
chronic O
disease O
, O
broad-reach O
and O
cost-effective O
interventions O
to O
increase O
physical O
activity O
and O
improve O
dietary O
intake O
are O
needed O
. O
[]

CONCLUSION O
Based O
on O
our O
data O
, O
combined O
treatment O
with O
prednisone O
, O
cyclophosphamide O
, O
and O
plasma O
exchanges O
is O
not O
superior O
to O
treatment O
with O
prednisone O
and O
cyclophosphamide O
alone O
, O
and O
plasma O
exchanges O
should O
not O
be O
systematically O
proposed O
for O
initial O
treatment O
of O
severe O
PAN O
or O
CSS O
. O
[]

The O
combined O
patient O
population O
treated O
with O
4-8 O
mg/day O
of O
risperidone O
was O
1.43 O
times O
more O
likely O
to O
have O
had O
a O
[]

METHOD O
A O
randomized O
controlled O
trial O
of O
73 O
female O
subjects O
meeting O
criteria O
for O
BPD O
was O
carried O
out O
with O
intention-to-treat O
analyses O
and O
per-protocol O
analyses O
. O
[]

A O
total O
of O
14 O
blood O
and O
4 O
urine O
samples O
were O
taken O
over O
a O
12-hour O
period O
. O
[]

In O
total O
, O
45 O
child O
or O
adolescent O
patients O
with O
ASD O
were O
randomized O
into O
two O
acute O
8-week O
phases O
in O
a O
double-blind O
placebo-controlled O
crossover O
study O
of O
liquid O
fluoxetine O
. O
[]

Results O
Of O
435 O
patients O
enrolled O
, O
233 O
were O
treatment O
naive O
( O
54 O
% O
) O
and O
202 O
were O
cytokine O
pretreated O
( O
46 O
% O
) O
. O
[]

Furthermore O
, O
even O
daily O
administration O
of O
azithromycin O
to O
chronically O
infected O
cats O
was O
ineffective O
in O
clearing B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
33-patient O
group O
was O
divided O
into O
three O
equal O
groups O
. O
[]

The O
response O
rates O
in O
both O
groups O
were O
similar O
: O
three O
of O
25 O
patients O
given O
high-dose O
cytarabine O
and O
three O
of O
23 O
given O
amsacrine O
obtained O
complete B-outcome ['Physiological-Clinical']
remissions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Wild-type O
HBV O
infection O
may O
be O
mild O
and O
respond O
relatively O
well O
to O
interferon O
( O
IFN O
) O
alpha O
therapy O
, O
but O
IFN O
alpha O
is O
not O
an O
effective O
therapeutic O
option O
in O
pre-core O
mutant O
hepatitis O
B O
infection O
and O
new O
therapeutic O
options O
are O
needed O
. O
[]

SETTING O
Two O
University O
teaching O
hospitals O
. O
[]

RESEARCH O
METHODS O
AND O
PROCEDURES O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
human O
trial O
including O
60 O
institutionalized O
volunteers O
aged O
65-85 O
years O
was O
performed O
. O
[]

Intervention O
of O
a O
sleep O
technician O
in O
the O
patient O
's O
home O
was O
the O
least O
expensive B-outcome ['Life-Impact']
strategy O
, O
because O
of O
the O
high O
percentages O
of O
faulty O
studies O
with O
the O
patient O
's O
own O
setup O
of O
the O
equipment O
, O
when O
using O
the O
limited O
sleep-recording O
device O
. O
['Life-Impact']

However O
, O
there O
was O
a O
high O
drop-out O
rate O
and O
intention O
to O
treat O
analysis O
failed O
to O
demonstrate O
statistically O
significant O
differences O
between O
the O
groups O
. O
[]

METHODS O
Patients O
undergoing O
Wise-pattern O
breast O
reduction O
or O
abdominal O
procedures O
had O
paired O
incisions O
randomly O
assigned O
to O
Steri-Strip O
S O
or O
suture O
closure O
. O
[]

Similarly O
, O
this O
study O
supports O
the O
effectiveness O
of O
evaluation O
tests O
based O
on O
[]

Tacrolimus O
monotherapy O
without O
steroids O
after O
liver O
transplantation O
-- O
a O
prospective O
randomized O
double-blinded O
placebo-controlled O
trial O
. O
[]

Patients O
expressing O
high O
levels O
of O
OPN B-outcome ['Physiological-Clinical']
within I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
BM I-outcome ['Physiological-Clinical']
( O
IHC O
) O
experienced O
shortened O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
OS O
; O
P O
= O
.025 O
) O
. O
['Physiological-Clinical', 'Mortality']

The O
interventions O
provided O
identical O
intensity O
( O
10 O
hours O
per O
week O
in O
classroom O
) O
, O
student-to-teacher O
ratio O
, O
schedule O
, O
home-based O
parent O
training O
( O
1.5 O
hours O
per O
month O
) O
, O
parent O
education O
( O
38 O
hours O
) O
, O
and O
instructional O
strategies O
, O
except O
the O
Interpersonal O
Synchrony O
condition O
provided O
a O
supplementary O
curriculum O
targeting O
socially O
engaged O
imitation O
, O
joint O
attention O
, O
and O
affect O
sharing O
; O
measures O
of O
these O
were O
primary O
outcomes O
. O
[]

The O
hypothesis O
that O
sodium O
( O
Na O
) O
kinetics O
are O
not O
a O
first O
order O
process O
was O
tested O
. O
[]

Seventy O
three O
patients O
who O
were O
followed O
up O
for O
2 O
years O
were O
categorized O
into O
two O
groups O
according O
to O
the O
eradication B-outcome ['Physiological-Clinical']
of O
H. O
pylori B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
significant O
predictors O
of O
time O
required O
to O
complete O
PDT O
were O
the O
APACHE O
II O
score O
( O
p O
= O
.041 O
) O
, O
a O
less O
experienced O
operator O
( O
p O
= O
.0001 O
) O
, O
and O
a O
female O
patient O
( O
p O
= O
.013 O
) O
. O
[]

RESPECT-PTSD O
: O
re-engineering O
systems O
for O
the O
primary O
care O
treatment O
of O
PTSD O
, O
a O
randomized O
controlled O
trial O
. O
[]

As O
for O
the O
lipoproteinogram O
, O
a O
tendency O
towards O
a O
decrease O
in O
the O
pre-beta-lipoprotein B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
was O
observed O
and O
so O
was O
a O
non-significant O
tendency O
towards O
an O
increase O
in O
the O
alpha- O
and O
beta-lipoprotein O
fractions O
. O
['Physiological-Clinical']

BACKGROUND O
In O
many O
patients O
, O
ventricular O
arrhythmias O
will O
develop O
early O
after O
acute O
myocardial O
infarction O
. O
[]

RESULTS O
Thirty-nine O
subjects O
completed O
the O
study O
and O
were O
included O
in O
the O
data O
analysis O
. O
[]

Twenty-six O
subjects O
returned O
to O
have O
the O
second O
ankle O
tested O
, O
resulting O
in O
60 O
ankles O
for O
the O
analyses O
. O
[]

Pre- O
and O
post-treatment O
gingival O
and O
stain O
indices O
were O
taken O
. O
[]

Hospital O
course O
is O
longer O
, O
more O
expensive O
, O
and O
more O
complicated O
. O
[]

METHODS O
A O
cost-utility O
analysis O
( O
CUA O
) O
was O
conducted O
alongside O
a O
clinical O
randomized O
controlled O
trial O
at O
a O
university O
hospital O
in O
Norway O
; O
166 O
patients O
, O
124 O
( O
75 O
% O
) O
women O
with O
a O
mean O
age O
of O
82 O
years O
were O
randomized O
to O
either O
internal O
fixation O
( O
n O
= O
86 O
) O
or O
hemiarthroplasty O
( O
n O
= O
80 O
) O
. O
[]

RESULTS O
The O
median O
survival B-outcome ['Mortality']
was O
8.9 O
months O
in O
the O
radiation-treated O
patients O
, O
as O
compared O
with O
12.5 O
months O
in O
the O
patients O
treated O
with O
chemotherapy O
and O
radiation O
therapy O
. O
['Mortality']

RESULTS O
Risperidone O
was O
superior O
to O
placebo O
in O
preventing O
relapse B-outcome ['Life-Impact']
: O
this O
occurred O
in O
3 O
of O
12 O
patients O
continuing O
on O
risperidone O
versus O
8 O
of O
12 O
who O
switched O
to O
placebo O
( O
p O
= O
.049 O
) O
. O
['Life-Impact']

17.6 O
, O
P O
< O
0.02 O
) O
disappeared O
after O
adjustment O
for O
confounding O
factors O
. O
[]

Selamectin O
also O
was O
beneficial O
in O
alleviating O
signs O
in O
dogs O
and O
cats O
diagnosed O
clinically O
with O
FAD O
. O
[]

In O
the O
treatment O
group O
, O
two O
patients O
died O
in O
the O
early O
weeks O
of O
the O
disease O
. O
[]

For O
a O
full O
year O
, O
the O
providers O
of O
intervention O
group O
children O
received O
bimonthly O
computer-generated O
letters O
based O
on O
these O
calls O
summarizing O
the O
child O
's O
asthma O
symptoms O
, O
health O
service O
use O
, O
and O
medication O
use O
with O
a O
corresponding O
recommendation O
to O
step O
up O
or O
step O
down O
medications O
. O
[]

RESULTS O
Mean O
intakes B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
calcium I-outcome ['Life-Impact']
during O
the O
intervention O
were O
742.4 O
+/- O
321.5 O
, O
1026.4 O
+/- O
311.3 O
, O
and O
1131.29 O
+/- O
337.2 O
mg/d O
for O
the O
control O
, O
medium-dairy O
, O
and O
high-dairy O
groups O
, O
respectively O
( O
P O
< O
0.0001 O
) O
. O
['Life-Impact']

In O
only O
4 O
patients O
, O
reaccumulation O
of O
pericardial B-outcome ['Physiological-Clinical']
effusion I-outcome ['Physiological-Clinical']
was O
recognized O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
cardiovascular B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
other O
safety O
and O
efficacy O
parameters O
of O
etoricoxib O
60 O
and O
90 O
mg O
, O
and O
diclofenac O
150 O
mg. O
METHODS O
This O
double-blind O
study O
randomized O
OA O
patients O
to O
etoricoxib O
90 O
mg O
, O
then O
to O
60 O
mg O
once O
daily O
vs O
diclofenac O
75 O
mg O
twice O
daily O
; O
RA O
patients O
were O
randomized O
to O
etoricoxib O
90 O
mg O
once O
daily O
or O
diclofenac O
75 O
mg O
twice O
daily O
. O
['Physiological-Clinical']

For O
the O
valid O
task O
performers O
divided O
attention O
( O
serial B-outcome ['Life-Impact']
search I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
working I-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
) O
was O
shown O
to O
regress O
in O
the O
placebo O
group O
( O
n O
= O
7 O
) O
, O
while O
in O
the O
risperidone O
group O
( O
n O
= O
7 O
) O
there O
was O
further O
improvement O
. O
['Life-Impact']

Satisfaction B-outcome ['Life-Impact']
differed O
significantly O
between O
centres O
for O
4 O
: O
14 O
aspects O
of O
service O
provision O
and O
with O
3 O
: O
17 O
items O
concerning O
communication O
; O
satisfaction O
was O
high O
overall O
. O
['Life-Impact']

Subcutaneous O
sumatriptan O
6 O
mg O
is O
an O
effective O
, O
well O
tolerated O
, O
and O
well O
accepted O
, O
long-term O
, O
acute O
treatment O
for O
migraine O
when O
self-injected O
by O
patients O
using O
the O
novel O
self-injector O
. O
[]

Each O
group O
was O
studied O
in O
regards O
to O
the O
length B-outcome ['Mortality']
of I-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
the O
host B-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
the O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Mortality', 'Physiological-Clinical', 'Adverse-effects']

Hysteroscopic O
transcervical O
endometrial O
resection O
versus O
thermal O
destruction O
for O
menorrhagia O
: O
a O
prospective O
randomized O
trial O
on O
satisfaction O
rate O
. O
[]

Studies O
suggest O
that O
phytoestrogens O
in O
soy O
products O
may O
impart O
hormonal O
effects O
that O
protect O
women O
against O
breast O
cancer O
. O
[]

PURPOSE O
To O
evaluate O
the O
association O
of O
efavirenz O
hypersusceptibility O
( O
EFV-HS O
) O
with O
clinical O
outcome O
in O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
trial O
of O
EFV O
plus O
indinavir O
( O
EFV+IDV O
) O
vs. O
EFV+IDV O
plus O
abacavir O
( O
ABC O
) O
in O
283 O
nucleoside-experienced O
HIV-infected O
patients O
. O
[]

RESULTS O
A O
total O
of O
136 O
patients O
presented O
severe B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
. O
['Adverse-effects']

Four O
conditions O
, O
generated O
by O
the O
combinations O
of O
two O
kinds O
of O
stimulus O
delivered O
to O
the O
subjects O
( O
aversive O
or O
nonaversive O
) O
and O
two O
outcomes O
of O
the O
task O
( O
failure O
or O
success O
) O
, O
were O
investigated O
. O
[]

METHODS O
In O
this O
prospective O
, O
randomized O
, O
double-blind O
study O
, O
90 O
patients O
with O
anal O
fissure O
were O
recruited O
. O
[]

OBJECTIVE O
The O
efficacy O
and O
safety O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
lowering I-outcome ['Physiological-Clinical']
in O
elderly O
patients O
have O
not O
been O
sufficiently O
investigated O
in O
patients O
with O
diabetes O
. O
['Physiological-Clinical']

0.3 O
, O
4.3 O
? O
[]

Performance O
tests O
were O
performed O
without O
splint O
. O
[]

RESULTS O
Thirty-seven O
patients O
completed O
the O
study O
, O
21 O
in O
the O
treatment O
group O
and O
16 O
in O
the O
control O
group O
. O
[]

Only O
49.3 O
% O
( O
37/77 O
) O
of O
surviving O
patients O
consented O
to O
follow-up O
at O
4 O
months O
and O
89 O
% O
( O
33/37 O
) O
completed O
the O
assessment O
. O
[]

CONCLUSION O
Topotecan O
continues O
to O
demonstrate O
comparable O
efficacy O
and O
[]

OBJECTIVES O
To O
compare O
tidal O
volumes O
delivered O
by O
one- O
vs O
two-handed O
compressions O
of O
a O
manual O
resuscitation O
bag O
and O
assess O
the O
effects O
of O
subject O
characteristics O
on O
those O
tidal O
volumes O
. O
[]

In O
a O
double-blind O
study O
, O
24 O
Down O
syndrome O
children O
, O
ages O
6 O
to O
17 O
years O
living O
at O
home O
, O
were O
given O
a O
megadose O
multi-vitamin/mineral O
supplement O
for O
4 O
months O
. O
[]

After O
one O
and O
two O
years O
7 O
% O
and O
8 O
% O
of O
the O
subjects O
had O
diphtheria B-outcome ['Physiological-Clinical']
antitoxin I-outcome ['Physiological-Clinical']
level O
below O
0.01 O
I.U./ml O
. O
['Physiological-Clinical']

After O
acute O
treatment O
phase O
( O
aspiration O
plus O
rtPA O
) O
, O
clot B-outcome ['Physiological-Clinical']
was O
reduced O
an O
average O
of O
46 O
% O
. O
['Physiological-Clinical']

After O
training O
, O
all O
participants O
met O
behavioral B-outcome ['Life-Impact']
criteria O
for O
expertise O
with O
the O
specific O
stimuli O
on O
which O
they O
received O
training O
. O
['Life-Impact']

The O
results O
showed O
that O
adherence O
measures O
varied O
with O
lowest O
adherence B-outcome ['Life-Impact']
from O
two O
items O
of O
['Life-Impact']

The O
utility O
of O
laparoscopy O
in O
the O
diagnosis O
of O
acute O
appendicitis O
in O
women O
of O
reproductive O
age O
. O
[]

Compared O
to O
the O
Placebo O
group O
( O
29 O
% O
) O
, O
the O
group O
receiving O
the O
mixture O
of O
evening O
primrose O
oil O
and O
fish O
oil O
containing O
Gamma-linolenic O
acid O
( O
GLA O
) O
, O
Eicosapentaenoic O
acid O
( O
EPA O
) O
, O
and O
Docosahexaenoic O
acid O
( O
DHA O
) O
had O
a O
significantly O
lower O
incidence O
of O
edema B-outcome ['Physiological-Clinical']
( O
13 O
% O
, O
p O
= O
0.004 O
) O
. O
['Physiological-Clinical']

QoL B-outcome ['Life-Impact']
was O
measured O
with O
the O
St O
George O
's O
Respiratory B-outcome ['Physiological-Clinical']
Questionnaire O
( O
SGRQ O
) O
and O
a O
visual O
analogue O
scale O
( O
VAS O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Adjunctive O
mitomycin O
C O
significantly O
( O
P O
< O
.05 O
) O
improved O
the O
[]

Most O
cases O
initially O
experienced O
bleeding B-outcome ['Physiological-Clinical']
in O
the O
first O
3 O
months O
but O
such O
initiation B-outcome ['Physiological-Clinical']
was O
a O
bit O
later O
in O
group O
C. O
Endometrium B-outcome ['Physiological-Clinical']
, O
as O
detected O
by O
B-mode O
ultrasound O
, O
increased O
approximately O
1 O
mm O
in O
HT O
groups O
, O
while O
it O
was O
a O
bit O
thicker O
in O
group O
C. O
Long O
periods O
in O
reproductive O
age O
and O
short O
time O
since O
menopause O
were O
high O
risk O
factors O
for O
irregular B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Vaccine O
and O
placebo O
effectiveness O
were O
tested O
by O
counting O
active B-outcome ['Physiological-Clinical']
PU I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
, O
and O
IgE B-outcome ['Physiological-Clinical']
, O
before O
and O
after O
4 O
months O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

An O
overall O
improvement O
on O
all O
behavioral B-outcome ['Life-Impact']
measures I-outcome ['Life-Impact']
was O
observed O
for O
both O
the O
placebo O
and O
the O
dimethylglycine O
groups O
. O
['Life-Impact']

METHODS O
From O
December O
1997 O
through O
February O
2003 O
, O
244 O
men O
with O
newly O
diagnosed O
localized O
prostate O
cancer O
were O
randomly O
assigned O
to O
cryoablation O
or O
EBRT O
( O
median O
dose O
68 O
Gy O
) O
. O
[]

Subjects O
will O
be O
randomized O
to O
azelnidipine O
or O
amlodipine O
and O
observed O
for O
48 O
weeks O
. O
[]

In O
Experiment O
1 O
, O
16 O
healthy O
volunteers O
rated O
the O
pain B-outcome ['Physiological-Clinical']
evoked O
by O
noxious O
heat O
stimuli O
( O
5 O
s O
duration O
; O
interstimulus O
interval O
25 O
s O
) O
of O
set O
temperatures O
( O
47? O
, O
48? O
and O
49?C O
) O
during O
the O
rubber O
hand O
illusion O
or O
during O
a O
control O
condition O
. O
['Physiological-Clinical']

Delavirdine B-outcome ['Resource-use']
exposure I-outcome ['Resource-use']
was O
reduced O
by O
concurrent O
administration O
of O
didanosine O
. O
['Resource-use']

Salivary B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
was O
collected O
at O
8 O
am O
, O
1 O
pm O
, O
8 O
pm O
, O
and O
8 O
am O
the O
next O
day O
, O
on O
five O
occasions O
. O
['Physiological-Clinical']

After O
the O
bleeding O
was O
controlled O
we O
continued O
to O
operate O
up O
to O
the O
biopsy O
segment O
. O
[]

Verapamil O
augmentation O
of O
lithium O
treatment O
improves O
outcome O
in O
mania O
unresponsive O
to O
lithium O
alone O
: O
preliminary O
findings O
and O
a O
discussion O
of O
therapeutic O
mechanisms O
. O
[]

An O
objective B-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
chemotherapy O
was O
observed O
in O
68 O
% O
in O
the O
first O
study O
and O
85 O
% O
in O
the O
second O
. O
['Physiological-Clinical']

CONCLUSION O
To O
provide O
a O
new O
stem O
cell O
source O
, O
limbal O
epithelial O
autograft O
transplantation O
, O
for O
an O
injured O
limb O
us O
is O
a O
reasonable O
therapeutic O
method O
for O
the O
treatment O
of O
pterygium O
. O
[]

CONCLUSION O
The O
information O
on O
the O
anxiolytic O
techniques O
, O
loco-regional O
anesthesia O
, O
treatment O
of O
perioperative O
pain O
and O
postoperative O
distress O
was O
enthusiastically O
accepted O
and O
albeit O
initially O
induced O
feelings O
of O
astonishment O
resulted O
to O
be O
appreciated B-outcome ['Life-Impact']
and O
preferred B-outcome ['Life-Impact']
in O
the O
whole O
of O
the O
patients O
. O
['Life-Impact', 'Life-Impact']

Effect O
of O
medical O
ozone O
therapy O
on O
renal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
of O
patients O
with O
chronic O
severe O
hepatitis O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
unsuccessful O
cases O
, O
thrombi O
became O
obstructive O
or O
caused O
stroke B-outcome ['Physiological-Clinical']
during O
heparin O
therapy O
, O
the O
adequate O
duration O
of O
which O
remains O
unclear O
. O
['Physiological-Clinical']

Parents O
were O
randomly O
assigned O
to O
receive O
the O
sleep O
education O
pamphlet O
or O
no O
intervention O
. O
[]

Tamsulosin O
Investigator O
Group O
. O
[]

36.9 O
cm/cm? O
in O
CECC O
group O
; O
P O
= O
.017 O
vs O
T1 O
) O
. O
[]

We O
designed O
a O
randomized O
, O
double O
blind O
, O
dose-assessing O
study O
. O
[]

Neither O
serious O
ocular O
complications O
nor O
systemic B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
were O
noted O
in O
the O
mitomycin O
C O
treated O
group O
. O
['Adverse-effects']

DESIGN O
Single-blind O
, O
randomized O
, O
controlled O
trial O
with O
a O
3-month O
follow-up O
. O
[]

This O
study O
examined O
the O
effects O
of O
ophthalmic O
timolol O
and O
time O
of O
administration O
on O
cardiovascular B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
in O
healthy O
young O
male O
volunteers O
. O
['Physiological-Clinical']

CONCLUSIONS O
Our O
data O
provide O
some O
evidence O
that O
systematic O
lymphadenectomy O
improves O
[]

The O
longest O
individual O
treatment O
was O
8.2 O
years O
, O
with O
3139 O
total O
patient-years O
of O
etanercept O
exposure O
. O
[]

Syncopal B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
also O
reduced O
during O
the O
follow-up O
period O
, O
but O
there O
were O
much O
fewer O
syncopal B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
than O
falls-28 O
episodes O
in O
paced O
patients O
and O
47 O
in O
controls O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
comparison O
of O
the O
effectiveness O
and O
patient O
tolerance O
of O
oral O
sodium O
phosphate O
, O
castor O
oil O
, O
and O
standard O
electrolyte O
lavage O
for O
colonoscopy O
or O
sigmoidoscopy O
preparation O
. O
[]

In O
addition O
, O
targeting O
overall O
dietary O
patterns O
might O
be O
one O
approach O
to O
help O
reduce O
the O
burden O
of O
obesity O
among O
this O
population O
. O
[]

Effect O
of O
a O
dental O
cream O
containing O
amorphous O
cream O
phosphate O
complexes O
on O
white O
spot O
lesion O
regression O
assessed O
by O
laser O
fluorescence O
. O
[]

Patients O
were O
assigned O
at O
random O
to O
group O
1 O
, O
80 O
patients O
undergoing O
total O
arterial O
revascularization O
( O
left O
internal O
thoracic O
artery O
on O
left O
anterior O
descending O
coronary O
artery O
plus O
radial O
artery O
) O
, O
or O
group O
2 O
, O
80 O
patients O
undergoing O
standard O
coronary O
artery O
bypass O
graft O
surgery O
( O
left O
internal O
thoracic O
artery O
on O
left O
anterior O
descending O
coronary O
artery O
plus O
saphenous O
veins O
) O
. O
[]

Treatment O
Group O
participants O
obtained O
significantly O
greater O
improvements O
than O
Control O
Group O
participants O
in O
levels O
of O
disability B-outcome ['Life-Impact']
, O
anxiety B-outcome ['Life-Impact']
, O
depression B-outcome ['Life-Impact']
, O
and O
average O
pain B-outcome ['Physiological-Clinical']
levels O
at O
posttreatment O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

After O
6 O
months O
, O
both O
the O
olmesartan O
and O
the O
valsartan O
groups O
showed O
significant O
reduction O
of O
the O
examined O
coronary B-outcome ['Physiological-Clinical']
plaque I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( O
46.2 O
? O
['Physiological-Clinical']

A O
follow-up O
magnetic O
resonance O
imaging O
examination O
was O
carried O
out O
in O
2001 O
, O
excluding O
women O
who O
underwent O
explantation O
in O
the O
period O
between O
the O
two O
magnetic O
resonance O
imaging O
examinations O
( O
n O
= O
44 O
) O
. O
[]

2.66 O
and O
12.83 O
? O
[]

The O
secondary O
outcome O
is O
participants O
' O
perception B-outcome ['Life-Impact']
of O
improvement O
in O
low O
back B-outcome ['Physiological-Clinical']
symptoms B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
estimate O
cost B-outcome ['Resource-use']
and O
outcomes O
of O
the O
Arthritis O
Foundation O
aquatic O
exercise O
classes O
from O
the O
societal O
perspective O
. O
['Resource-use']

After O
3 O
months O
, O
symptoms O
reduced O
significantly O
in O
all O
treatment O
groups O
, O
while O
PEF O
variability O
improved O
in O
BDP O
and O
BDP O
+ O
S O
groups O
; O
FEV1 O
and O
bronchial O
responsiveness O
to O
methacholine O
were O
significantly O
improved O
in O
comparison O
with O
baseline O
value O
in O
the O
BDP O
+ O
S O
group O
only O
. O
[]

Blood B-outcome ['Physiological-Clinical']
and O
urine B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
collected O
and O
assayed O
for O
each O
of O
the O
compounds O
and O
their O
metabolites O
using O
high-performance O
liquid O
chromatography O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Sun O
exposure O
at O
school O
poses O
a O
significant O
risk O
to O
student O
health O
and O
more O
needs O
to O
be O
carried O
out O
to O
promote O
the O
use O
of O
a O
wide-brimmed O
hat O
and O
limiting O
student B-outcome ['Life-Impact']
sun I-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
. O
['Life-Impact']

No O
patients O
complained O
of O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

We O
examined O
vascular O
function O
and O
structure O
in O
: O
( O
1 O
) O
healthy O
lowlanders O
during O
acute O
hypoxia O
and O
prolonged O
( O
?2 O
weeks O
) O
exposure O
to O
high O
altitude O
, O
and O
( O
2 O
) O
high-altitude O
natives O
at O
5050 O
m O
( O
highlanders O
) O
. O
[]

RESULTS O
The O
percentage O
of O
bruising B-outcome ['Physiological-Clinical']
occurrence O
was O
64 O
% O
with O
the O
injection O
of O
10 O
seconds O
duration O
and O
42 O
% O
in O
the O
30-second O
injection O
. O
['Physiological-Clinical']

The O
Japanese O
Children O
's O
Cancer O
and O
Leukemia O
Study O
Group O
. O
[]

Resistance O
training O
increases O
basal O
limb O
blood O
flow O
and O
vascular O
conductance O
in O
aging O
humans O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
regarding O
the O
development O
of O
ventricular B-outcome ['Physiological-Clinical']
arrhythmia I-outcome ['Physiological-Clinical']
, O
duration O
of O
cardiopulmonary B-outcome ['Physiological-Clinical']
bypass I-outcome ['Physiological-Clinical']
, O
intra-aortic B-outcome ['Physiological-Clinical']
balloon I-outcome ['Physiological-Clinical']
pump I-outcome ['Physiological-Clinical']
and O
inotropic B-outcome ['Physiological-Clinical']
support O
requirement O
, O
duration O
of O
mechanical B-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
, O
duration O
of O
intensive B-outcome ['Resource-use']
care I-outcome ['Resource-use']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use']

No O
statistically O
significant O
differences O
between O
the O
two O
luting O
techniques O
, O
RXU O
and O
RXU+E O
, O
we O
reobserved O
during O
the O
observation O
period O
of O
1 O
year O
. O
[]

Among O
patients O
who O
achieved B-outcome ['Life-Impact']
a O
CR B-outcome ['Physiological-Clinical']
, O
31 O
% O
later O
relapsed B-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

CONCLUSION O
This O
study O
demonstrates O
that O
the O
use O
of O
the O
Ligaclip O
to O
close O
lymphatic O
vessels O
may O
reduce O
the O
incidence O
of O
lymphoceles B-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
laparoscopic O
pelvic O
lymphadenectomy O
. O
['Physiological-Clinical']

BACKGROUND O
The O
tension-free O
hernioplasty O
as O
introduced O
by O
Lichtenstein O
has O
gained O
increasing O
acceptance O
during O
the O
last O
decade O
although O
the O
technique O
has O
not O
been O
evaluated O
in O
a O
randomized O
trial O
. O
[]

METHODS O
Data O
from O
a O
recently O
completed O
trial O
that O
included O
subjects O
with O
IPF O
who O
completed O
the O
6MWT O
, O
Saint O
George O
's O
Respiratory O
Questionnaire O
( O
SGRQ O
) O
and O
forced O
vital O
capacity O
( O
FVC O
) O
at O
6 O
and O
12 O
months O
were O
used O
to O
examine O
longitudinal O
changes O
in O
6MWD O
. O
[]

Parenteral O
analgesia O
with O
Tramal O
was O
performed O
in O
23 O
normal O
deliveries O
. O
[]

The O
changes O
in O
BMD B-outcome ['Physiological-Clinical']
between O
the O
6th O
and O
12th O
months O
were O
0 O
. O
['Physiological-Clinical']

Patients O
were O
randomly O
assigned O
to O
WP O
+ O
NCHT O
, O
PO O
+ O
NCHT O
, O
WP O
+ O
AHT O
, O
or O
PO O
+ O
AHT O
. O
[]

The O
incidence O
of O
CMV B-outcome ['Physiological-Clinical']
viremia I-outcome ['Physiological-Clinical']
was O
30.8 O
% O
, O
50.0 O
% O
, O
and O
91.7 O
% O
in O
the O
GAN O
, O
VAL O
, O
and O
C O
groups O
, O
respectively O
( O
P=0.004 O
, O
GAN O
vs O
C O
; O
P=0.07 O
, O
VAL O
vs O
C O
; O
P=NS O
, O
GAN O
vs O
VAL O
) O
. O
['Physiological-Clinical']

No O
adverse O
effects O
on O
CD4 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
or O
organ B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
occurred O
in O
either O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
approach O
is O
an O
effective O
strategy O
for O
the O
management O
of O
invasive O
aspergillosis O
in O
high-risk O
haematology O
patients O
. O
[]

METHOD O
A O
randomized O
controlled O
trial O
involving O
98 O
children O
and O
families O
was O
carried O
out O
in O
three O
different O
sites O
investigating O
the O
efficacy O
of O
a O
parent O
delivery O
of O
the O
Early O
Start O
Denver O
model O
( O
P-ESDM O
) O
, O
which O
fosters O
parental O
use O
of O
a O
child-centered O
responsive O
interaction O
style O
that O
embeds O
many O
teaching O
opportunities O
into O
play O
, O
compared O
to O
community O
treatment O
as O
usual O
. O
[]

Four O
hundred O
seventy-nine O
smokers O
were O
randomized O
to O
21 O
or O
42 O
mg O
NRT O
, O
initiated O
2 O
wks O
prior O
to O
target O
quit O
dates O
. O
[]

CONCLUSIONS O
In O
subjects O
with O
type O
2 O
diabetes O
, O
changes O
in O
serum B-outcome ['Physiological-Clinical']
SCFAs I-outcome ['Physiological-Clinical']
in O
response O
to O
changes O
in O
['Physiological-Clinical']

Eighty-two O
physicians O
completed O
the O
experiment O
, O
for O
a O
response O
rate O
of O
86 O
% O
. O
[]

The O
cost O
per O
LYS O
using O
levosimendan O
compares O
favourably O
with O
other O
cost-effectiveness O
analyses O
in O
cardiology O
. O
['Resource-use']

The O
5-year O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
71.6 O
% O
for O
the O
CCRT O
group O
compared O
with O
53.0 O
% O
for O
the O
RT-only O
group O
( O
P O
=.0012 O
) O
. O
['Mortality']

All O
subjects O
exhibited O
marked O
reductions O
in O
affected O
arm O
impairment B-outcome ['Life-Impact']
and O
functional B-outcome ['Life-Impact']
limitation I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

LAVH O
, O
when O
compared O
with O
TAH O
in O
the O
two O
weight O
subgroups O
, O
required O
a O
significantly O
longer O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
only O
in O
Group O
2 O
, O
significantly O
reduced O
analgesics B-outcome ['Resource-use']
administration I-outcome ['Resource-use']
only O
in O
Group O
1 O
, O
and O
significantly O
reduced O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
in O
both O
groups O
. O
['Life-Impact', 'Resource-use', 'Resource-use']

Both O
a O
disease-specific O
( O
EORTC O
QLQ-C30 O
) O
and O
a O
generic O
questionnaire O
( O
COOP-WONCA O
) O
were O
used O
. O
[]

A O
carbohydrate O
meal O
attenuates O
the O
forearm O
vasoconstrictor O
response O
to O
lower O
body O
subatmospheric O
pressure O
in O
healthy O
young O
adults O
. O
[]

METHODS O
In O
a O
prospective O
, O
randomized O
trial O
, O
balloon O
angioplasty O
was O
compared O
with O
stent O
implantation O
for O
the O
treatment O
of O
chronic O
total O
occlusions O
. O
[]

Significantly O
fewer O
patients O
in O
the O
paracetamol O
group O
received O
rescue O
analgesics O
compared O
to O
the O
placebo O
group O
( O
9.5 O
% O
vs. O
65.6 O
% O
, O
respectively O
) O
. O
[]

The O
SL O
group O
had O
greater O
12-year O
survival B-outcome ['Mortality']
than O
the O
LAG O
group O
( O
48 O
% O
vs. O
38 O
% O
, O
p O
= O
0.02 O
) O
. O
['Mortality']

Of O
388 O
evaluable O
patients O
with O
unfavorable O
histologic O
types O
of O
ML O
, O
194 O
( O
50 O
% O
) O
achieved O
CR B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Twenty-one O
per O
cent O
of O
those O
allocated O
to O
betaxolol O
showed O
clinically O
significant O
improvement O
in O
FEV1 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
higher O
proportion O
of O
participants O
consulted B-outcome ['Resource-use']
the I-outcome ['Resource-use']
general I-outcome ['Resource-use']
practitioner I-outcome ['Resource-use']
( O
GP O
) O
in O
the O
3 O
months O
following O
an O
X-ray O
( O
OR O
= O
2.72 O
; O
95 O
% O
CI O
, O
1.80 O
to O
4.10 O
) O
. O
['Resource-use']

Links O
between O
multisensory B-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
and O
autism O
. O
['Physiological-Clinical']

fractionation O
during O
a O
prospective O
, O
randomised O
trial O
of O
hyperfractionated O
radiation O
therapy O
( O
HFX O
RT O
) O
to O
a O
total O
dose O
of O
77 O
Gy O
given O
in O
70 O
fractions O
of O
1.1 O
Gy O
b.i.d. O
, O
with O
and O
without O
concurrent O
low-dose O
, O
daily O
cisplatin O
( O
CDDP O
) O
for O
head O
and O
neck O
cancer O
. O
[]

We O
wondered O
whether O
the O
lack O
of O
success B-outcome ['Physiological-Clinical']
with O
pertussis O
immunoglobulins O
might O
be O
attributable O
to O
inadequate O
dose O
, O
so O
we O
designed O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
two O
immunoglobulin O
preparations O
. O
['Physiological-Clinical']

RESULTS O
Both O
topical O
therapies O
were O
equally O
effective O
with O
initial O
response O
rates O
of O
86 O
% O
( O
18/21 O
) O
for O
BCG O
and O
81 O
% O
( O
17/21 O
) O
for O
mitomycin O
C O
plus O
doxorubicin O
, O
irrespective O
of O
the O
tumor O
grade O
. O
[]

The O
primary O
end O
point O
was O
a O
composite O
of O
death B-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
or O
ischemia-driven B-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
48 I-outcome ['Physiological-Clinical']
hours I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Over O
5 O
years O
, O
active O
treatment O
was O
estimated O
to O
prevent O
one O
primary O
outcome O
in O
every O
21 O
, O
71 O
and O
118 O
patients O
of O
at O
least O
75 O
, O
65-74 O
and O
below O
65 O
years O
, O
respectively O
. O
[]

RESULTS O
Mean O
ribavirin B-outcome ['Resource-use']
exposure I-outcome ['Resource-use']
in O
week O
0-12 O
was O
70 O
% O
and O
96 O
% O
in O
patients O
assigned O
to O
ribavirin O
800 O
and O
1000/1200 O
mg/day O
, O
respectively O
. O
['Resource-use']

In O
the O
sivelestat O
group O
, O
the O
duration O
of O
artificial B-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
, O
pulmonary O
oxygenation O
ability O
, O
and O
the O
blood B-outcome ['Physiological-Clinical']
PMN-E B-outcome ['Physiological-Clinical']
, O
SP-D B-outcome ['Physiological-Clinical']
, O
TNF-alpha B-outcome ['Physiological-Clinical']
and O
IL-8 B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
decreased O
significantly O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mother-child O
pairs O
were O
randomized O
either O
to O
intervention O
and O
control O
groups O
and O
dietary O
counseling O
was O
provided O
for O
mothers O
in O
the O
intervention O
group O
during O
10 O
home O
visits O
in O
the O
course O
of O
the O
first O
year O
of O
life O
. O
[]

Hypotension O
that O
required B-outcome ['Resource-use']
vasopressor I-outcome ['Resource-use']
support I-outcome ['Resource-use']
occurred O
in O
six O
of O
six O
patients O
with O
evidence O
of O
a O
leak O
( O
> O
or O
= O
1 O
% O
) O
and O
zero O
of O
six O
patients O
without O
a O
leak O
( O
< O
1 O
% O
) O
. O
['Resource-use']

BACKGROUND O
KC O
11458 O
, O
a O
motilin O
agonist O
without O
antibiotic O
properties O
, O
accelerates O
gastric O
emptying O
in O
animals O
and O
healthy O
humans O
. O
[]

There O
were O
no O
significant O
variations O
in O
implant B-outcome ['Physiological-Clinical']
indications I-outcome ['Physiological-Clinical']
and O
baseline O
antiarrhythmic B-outcome ['Resource-use']
drug I-outcome ['Resource-use']
use I-outcome ['Resource-use']
over O
the O
3-year O
enrollment O
period O
, O
although O
an O
increase O
in O
the O
percentage O
of O
dual-chamber O
ICDs O
implanted O
occurred O
, O
with O
the O
majority O
( O
65 O
% O
) O
of O
implanted O
ICDs O
being O
dual-chamber O
devices O
by O
the O
end O
of O
the O
enrollment O
period O
. O
['Physiological-Clinical', 'Resource-use']

RESULTS O
A O
total O
of O
480 O
patients O
received O
? O
[]

In O
the O
0-24 O
h O
interval O
as O
a O
whole O
, O
there O
was O
no O
difference O
between O
treatments O
in O
mean O
pH O
or O
% O
time O
pH O
> O
3 O
or O
> O
4 O
. O
[]

INTRODUCTION O
Atrioesophageal O
fistula O
is O
an O
uncommon O
but O
often O
lethal O
complication O
of O
atrial O
fibrillation O
( O
AF O
) O
ablation O
. O
[]

Paul O
Ehrlich O
Institute O
) O
( O
tested O
every O
3 O
months O
) O
during O
the O
posttreatment O
follow-up O
. O
[]

Response O
to O
the O
three O
pertussis O
antigens O
ranged O
from O
92-97 O
% O
in O
the O
DTPa-IPV-Hib O
plus O
separate O
HBV O
group O
and O
100 O
% O
in O
the O
DTPa O
HBV-IPV-Hib O
group O
. O
[]

Patients O
will O
be O
entered O
into O
the O
study O
for O
2.5 O
years O
and O
followed O
for O
an O
additional O
2 O
years O
. O
[]

Successful O
difficult O
intubation O
. O
[]

A O
statistically O
higher O
ocular B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
difference I-outcome ['Physiological-Clinical']
was O
seen O
between O
the O
pre- O
and O
postirrigation O
readings O
for O
the O
control O
eye O
in O
volunteers O
irrigated O
with O
MTL O
( O
p O
= O
0.046 O
) O
. O
['Physiological-Clinical']

Importantly O
, O
2D-STE O
analysis O
demonstrated O
the O
presence O
of O
subclinical B-outcome ['Physiological-Clinical']
LV I-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
with O
impaired B-outcome ['Physiological-Clinical']
circumferential I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
longitudinal I-outcome ['Physiological-Clinical']
strain I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
strain I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
at O
the O
isovolumic O
relaxation O
time O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Weight O
loss B-outcome ['Physiological-Clinical']
relative O
to O
control O
was O
statistically O
significant O
in O
the O
comprehensive O
group O
3 O
, O
6 O
, O
and O
12 O
months O
after O
randomization O
, O
whereas O
weight O
loss B-outcome ['Physiological-Clinical']
in O
the O
individualized O
group O
was O
significant O
only O
at O
12 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
A O
longitudinal O
study O
consisting O
of O
three O
phases O
. O
[]

For O
the O
first O
4 O
weeks O
, O
patients O
received O
amlodipine O
5 O
mg O
QD O
( O
morning O
) O
. O
[]

The O
effect O
assessed O
at O
the O
end O
of O
supplementation O
showed O
that O
the O
intervention O
was O
beneficial O
. O
[]

Statistical O
power O
for O
the O
other O
end O
points O
is O
more O
difficult O
to O
estimate O
. O
[]

A O
prospective O
, O
randomized O
, O
comparative O
trial O
of O
a O
COX-2 O
selective O
nonsteroidal O
anti-inflammatory O
drug O
versus O
placebo O
in O
inguinal O
herniorrhaphy O
patients O
. O
[]

Oxytocin O
promotes O
facial B-outcome ['Life-Impact']
emotion I-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
and O
amygdala B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
in O
adults O
with O
asperger O
syndrome O
. O
['Life-Impact', 'Physiological-Clinical']

STUDY O
OBJECTIVE O
To O
evaluate O
whether O
uterine O
shrinkage O
induced O
by O
gonadotropin-releasing O
hormone O
( O
GnRH O
) O
agonists O
in O
women O
with O
a O
large O
uterus O
( O
> O
14 O
wks O
) O
may O
facilitate O
total O
laparoscopic O
hysterectomy O
. O
[]

The O
two O
groups O
were O
not O
significantly O
different O
in O
terms O
of O
surgical B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
. O
['Adverse-effects']

METHODS O
Separate O
patient O
and O
clinician O
web-tools O
comprised O
of O
over O
500 O
, O
10-s O
video O
clips O
demonstrating O
patient-centered B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
various O
ways O
. O
['Life-Impact']

It O
is O
important O
to O
note O
that O
the O
methods O
of O
quantifying O
the O
ODR O
values O
differed O
between O
the O
three O
studies O
in O
the O
IPDMA O
, O
therefore O
some O
caution O
should O
be O
used O
when O
using O
these O
final O
estimated O
values O
. O
[]

SETTING O
Chemotherapy O
clinics O
of O
two O
comprehensive O
and O
two O
community O
cancer O
centers O
. O
[]

All O
patients O
were O
operated O
and O
resected O
without O
difficulty O
. O
[]

Bayesian O
adaptive O
trials O
offer O
advantages O
in O
comparative O
effectiveness O
trials O
: O
an O
example O
in O
status O
epilepticus O
. O
[]

There O
was O
a O
significant O
increase O
in O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
with O
anastrozole O
( O
0.21 O
; O
0.05-0.96 O
; O
P O
= O
0.0436 O
) O
and O
there O
were O
2/48 O
( O
4 O
% O
) O
and O
10/49 O
( O
20 O
% O
) O
deaths O
with O
anastrozole O
and O
tamoxifen O
, O
respectively O
. O
['Mortality']

In O
the O
clinical O
trial O
, O
the O
rate O
of O
ulcer B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
within O
8 O
weeks O
was O
77.9 O
% O
( O
67/86 O
) O
in O
patients O
receiving O
6 O
micrograms O
EGF O
intravenously O
twice O
a O
week O
, O
being O
significantly O
greater O
than O
51.7 O
% O
( O
45/87 O
) O
in O
those O
given O
CH O
. O
['Physiological-Clinical']

The O
observation O
group O
was O
treated O
with O
acupuncture O
and O
moxibustion O
at O
Pishu O
( O
BL O
20 O
) O
, O
Shenshu O
( O
BL O
23 O
) O
, O
Mingmen O
( O
GV O
4 O
) O
, O
Shenque O
( O
CV O
8 O
) O
and O
so O
on O
combined O
with O
taking O
Alendronate O
, O
while O
the O
control O
group O
was O
treated O
with O
taking O
Alendronate O
simply O
. O
[]

They O
received O
either O
levodopa O
SR O
or O
ropinirole O
for O
6 O
weeks O
, O
followed O
by O
a O
washout O
week O
, O
then O
the O
alternate O
treatment O
for O
6 O
weeks O
. O
[]

No O
patient O
treated O
with O
zoledronic O
acid O
had O
grade O
3 O
or O
4 O
serum O
creatinine O
increase O
. O
[]

Clinical O
evaluation O
of O
the O
antihypertensive O
effect O
of O
metoprolol O
in O
combination O
with O
hydrochlorothiazide O
and O
hydralazine O
in O
an O
unselected O
hypertensive O
population O
. O
[]

The O
computerized O
version O
would O
allow O
physicians O
to O
get O
an O
immediate O
result O
and O
if O
present O
a O
direct O
comparison O
with O
a O
previous O
exam O
. O
[]

BACKGROUND O
AND O
AIMS O
The O
multiplicity O
of O
vaccine O
injections O
during O
childhood O
leads O
to O
iterative O
painful O
and O
stressful O
experiences O
which O
may O
lead O
in O
turn O
to O
anticipated O
pain O
and O
then O
possibly O
to O
a O
true O
needle O
phobia O
. O
[]

Clinical O
and O
bacteriological O
responses O
were O
evaluated O
in O
all O
patients O
( O
n O
= O
103 O
) O
. O
[]

For O
the O
primary O
outcome O
of O
methacholine O
PD20 O
, O
this O
amounted O
to O
a O
1.6-fold O
difference O
( O
95 O
% O
CI O
1.1 O
, O
2.5 O
) O
. O
[]

Malnutrition O
and O
immunosupression O
make O
patients O
highly O
susceptible O
to O
postoperative O
infections O
and O
complications O
. O
[]

The O
minimally O
invasive O
Port-Access O
( O
Heartport O
, O
Redwood O
City O
, O
CA O
) O
approach O
in O
mitral-valve O
operations O
originally O
required O
femoral O
arterial O
cannulation O
, O
which O
is O
considered O
a O
disadvantage O
, O
especially O
in O
patients O
with O
peripheral O
vessel O
disease O
. O
[]

RESULTS O
Following O
balloon O
angioplasty O
, O
there O
was O
no O
difference O
in O
CFVR B-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
. O
['Physiological-Clinical']

But O
no O
difference O
was O
found O
in O
the O
sixth O
month O
. O
[]

MATERIALS O
METHODS O
A O
double O
blind O
, O
randomised O
trial O
was O
performed O
on O
102 O
consecutive O
women O
undergoing O
gynaecologic O
cancer O
surgery O
with O
pelvic O
and O
paraaortic O
lymphadenectomy O
. O
[]

AIMS O
To O
determine O
the O
effect O
of O
trophic O
feeding O
on O
clinical O
outcome O
in O
ill O
preterm O
infants O
. O
[]

Beneficial O
effects O
of O
a O
diabetes O
specific O
formula O
on O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
and O
free B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Scaling O
and O
root O
planing O
( O
SRP O
) O
is O
the O
primary O
non-surgical O
treatment O
for O
periodontitis O
, O
but O
its O
effectiveness O
is O
limited O
. O
[]

There O
were O
4 O
cases O
with O
possible O
systemic B-outcome ['Physiological-Clinical']
fungal I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
in O
the O
itraconazole O
group O
, O
and O
there O
were O
8 O
possible O
and O
3 O
probable O
cases O
in O
the O
fluconazole O
group O
. O
['Physiological-Clinical']

Participants O
completed O
tasks O
assessing O
psychomotor B-outcome ['Life-Impact']
vigilance I-outcome ['Life-Impact']
, O
tracking B-outcome ['Life-Impact']
, O
grammatical B-outcome ['Life-Impact']
reasoning I-outcome ['Life-Impact']
, O
alertness B-outcome ['Life-Impact']
and O
sleepiness B-outcome ['Physiological-Clinical']
each O
hour O
across O
the O
night O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Different O
cardiac O
biomarkers O
to O
detect O
peri-procedural O
myocardial O
infarction O
in O
contemporary O
coronary O
stent O
trials O
: O
impact O
on O
outcome O
reporting O
. O
[]

Pilot O
study O
with O
adjuvant O
hormone O
therapy O
in O
FIGO O
stage O
I O
endometrial O
carcinoma O
with O
myometrial O
invasion O
. O
[]

In O
a O
double-blind O
, O
prospective O
, O
randomly O
allocated O
trial O
, O
the O
patients O
were O
given O
increasing O
doses O
of O
captopril O
at O
25-100 O
mg O
twice O
a O
day O
or O
lisinopril O
at O
10-40 O
mg O
once O
a O
day O
until O
a O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
achieved O
or O
the O
highest O
dose O
was O
reached O
. O
['Physiological-Clinical']

The O
patients O
received O
an O
initial O
4-week O
course O
of O
either O
250 O
mg O
acetazolamide O
twice O
daily O
( O
b.i.d O
. O
) O
[]

Plasma B-outcome ['Physiological-Clinical']
clonidine I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
0.8 O
+/- O
0.1 O
and O
1.6 O
+/- O
0.2 O
ng/mL O
on O
the O
small- O
and O
large-dose O
days O
, O
respectively O
. O
['Physiological-Clinical']

Median O
exacerbation B-outcome ['Physiological-Clinical']
rate O
was O
reduced O
by O
25 O
% O
from O
1.32 O
a O
year O
on O
placebo O
to O
0.99 O
a O
year O
on O
with O
fluticasone O
propionate O
( O
P=0.026 O
) O
. O
['Physiological-Clinical']

Six O
children O
were O
randomly O
assigned O
to O
two O
experimental O
groups O
. O
[]

6.8 O
) O
] O
( O
t O
= O
9.60-16.78 O
, O
P O
< O
0.05 O
) O
. O
[]

COMS O
report O
no O
. O
[]

Dose O
modifications O
were O
necessary O
in O
9 O
patients O
, O
4 O
in O
the O
24 O
week O
and O
5 O
in O
the O
48 O
week O
group O
for O
anaemia B-outcome ['Physiological-Clinical']
, O
neutropenia B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

The O
numbers O
of O
patients O
demonstrating O
these O
changes O
for O
each O
test O
were O
compared O
using O
the O
McNemar O
test O
for O
each O
time O
point O
. O
[]

CONCLUSIONS O
DJQ O
showed O
efficiency O
synergism O
and O
toxicity O
reducing O
effects O
, O
but O
with O
no O
effect O
on O
the O
hematopoietic O
function O
of O
the O
bone O
marrow O
. O
[]

Exploratory O
pharmacodynamic O
assessments O
were O
performed O
using O
DCE-MRI O
and O
CT O
enhancing O
fraction O
( O
EnF O
) O
. O
[]

SETTING O
Participant O
enrolment O
and O
baseline O
assessments O
were O
conducted O
remotely O
online O
via O
the O
study O
website O
, O
with O
the O
advice O
reports O
presented O
by O
the O
same O
website O
. O
[]

CaCl O
( O
2 O
) O
seems O
to O
be O
equally O
safe O
compared O
to O
placebo O
as O
a O
pre-treatment O
in O
the O
management O
of O
AFF O
with O
RVR O
, O
we O
were O
unable O
to O
find O
a O
statistically O
significant O
blunting B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
drop I-outcome ['Physiological-Clinical']
with O
CaCl O
( O
2 O
) O
i.v O
. O
['Physiological-Clinical']

CONCLUSIONS O
Video-assisted O
thoracoscopic O
talc O
insufflation O
has O
not O
been O
shown O
to O
be O
a O
superior O
approach O
compared O
with O
talc O
slurry O
in O
our O
study O
. O
[]

Patients O
with O
severe O
dissections O
( O
n O
= O
128 O
) O
or O
without O
available O
reference O
vessel O
CFVR O
( O
n O
= O
139 O
) O
were O
excluded O
. O
[]

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
compare O
the O
short- B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
long-term I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
intravenous O
nitroglycerin O
plus O
placebo O
and O
nitroglycerin O
plus O
N-acetylcysteine O
on O
peripheral O
arteries O
, O
veins O
and O
microcirculation O
in O
humans O
. O
['Physiological-Clinical']

Patients O
were O
treated O
for O
10 O
weeks O
with O
weekly O
injections O
and O
then O
re-exposed O
in O
the O
EEC O
. O
[]

METHODS O
This O
is O
a O
multicentre O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
4-week O
study O
in O
patients O
with O
type O
2 O
diabetes O
with O
suboptimal O
metabolic O
control O
. O
[]

The O
second O
cycle O
of O
concurrent O
chemotherapy O
was O
refused O
by O
nine O
patients O
and O
was O
delayed O
for O
> O
or O
= O
1 O
week O
for O
another O
nine O
patients O
. O
[]

Ninety-five O
percent O
of O
the O
injections O
were O
considered O
easy O
or O
very O
easy O
; O
a O
greater O
percentage O
of O
HA+lidocaine O
injections O
were O
rated O
very O
easy O
. O
[]

Over O
time O
relationships O
between O
early O
adolescent O
and O
peer B-outcome ['Life-Impact']
substance I-outcome ['Life-Impact']
use O
. O
['Life-Impact']

To O
study O
the O
acute O
effects O
of O
acid O
fog O
on O
the O
lung O
, O
the O
authors O
generated O
a O
monodisperse O
10 O
microM O
MMAD O
aerosol O
of O
H2SO4 O
with O
a O
pH O
of O
2.0 O
and O
a O
nominal O
concentration O
of O
500 O
micrograms/m3 O
. O
[]

Response O
to O
primary O
induction O
chemotherapy O
was O
relevant O
for O
prognosis O
if O
a O
limit O
of O
25 O
% O
tumour O
cell O
mass O
( O
TCM O
) O
reduction O
was O
used O
to O
separate O
responders O
from O
non-responders O
. O
[]

Functional O
outcomes O
can O
help O
differentiate O
medications O
and O
can O
be O
used O
to O
help O
demonstrate O
the O
cost B-outcome ['Resource-use']
effectiveness O
of O
atypical O
agents O
. O
['Resource-use']

Orthopnea O
is O
a O
cardinal O
symptom O
of O
heart O
failure O
and O
may O
affect O
the O
patient O
's O
sleeping O
angle O
. O
[]

Recombinant O
human O
GH O
was O
administered O
sc O
daily O
at O
bedtime O
, O
with O
a O
target O
dose O
of O
12 O
micrograms/kg O
x O
day O
. O
[]

RESULTS O
Mucosal B-outcome ['Physiological-Clinical']
endoscopic I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
score O
on O
day O
7 O
was O
0.63 O
+/- O
0.16 O
in O
the O
placebo O
group O
and O
11.0 O
+/- O
3.0 O
and O
16.1 O
+/- O
1.6 O
in O
healthy O
volunteers O
treated O
with O
200 O
and O
420 O
mg O
aspirin O
twice O
daily O
( O
P O
< O
0.0001 O
vs. O
placebo O
) O
. O
['Physiological-Clinical']

RESULTS O
At O
4 O
hours O
, O
the O
INB+ O
group O
demonstrated O
better O
FEV1 B-outcome ['Physiological-Clinical']
( O
56.6 O
% O
vs. O
40.4 O
% O
of O
baseline O
, O
P O
< O
.05 O
) O
and O
FVC B-outcome ['Physiological-Clinical']
values O
( O
54.6 O
% O
vs. O
39.6 O
% O
of O
baseline O
, O
P O
< O
.05 O
) O
and O
less O
resting O
and O
cough O
pain O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Forty-seven O
patients O
with O
confirmed O
palatal O
flutter O
had O
surgery O
and O
all O
of O
them O
had O
a O
preoperative O
and O
postoperative O
objective O
assessment O
of O
their O
snoring B-outcome ['Physiological-Clinical']
loudness I-outcome ['Physiological-Clinical']
and O
duration B-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
home I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Efficacy O
and O
safety O
of O
intraseptal O
and O
periodontal O
ligament O
anesthesia O
achieved O
by O
computer-controlled O
articaine O
+ O
epinephrine O
delivery O
: O
a O
dose-finding O
study O
. O
[]

In O
view O
of O
increasing O
debate O
over O
possible O
benefit O
of O
more O
complete O
surgery O
compared O
to O
conservative O
procedures O
, O
a O
randomized O
controlled O
trial O
contrasting O
the O
then O
standard O
Halsted O
radical O
( O
RDL O
) O
operation O
with O
the O
more O
complete O
extended O
radical O
( O
EXT O
) O
mastectomy O
was O
initiated O
in O
1973 O
. O
[]

PURPOSE O
Our O
purpose O
was O
to O
evaluate O
the O
effects O
of O
prophylactic O
cranial O
irradiation O
on O
brain O
metastasis O
, O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
and O
late-occurring O
toxic B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
in O
patients O
with O
small-cell O
lung O
cancer O
in O
complete O
remission O
. O
['Mortality', 'Adverse-effects']

The O
results O
were O
assessed O
by O
the O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
. O
['Mortality', 'Life-Impact']

The O
insulin B-outcome ['Physiological-Clinical']
antagonistic I-outcome ['Physiological-Clinical']
actions I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
GH I-outcome ['Physiological-Clinical']
are O
important O
in O
preventing O
hypoglycaemia O
. O
['Physiological-Clinical']

A O
single O
endoscopist O
performed O
all O
of O
the O
colonoscopic O
examinations O
under O
sedation O
. O
[]

CALGB O
8642 O
randomizes O
previously O
untreated O
metastatic O
breast O
cancer O
patients O
either O
to O
one O
of O
several O
Phase O
II O
agents O
given O
for O
up O
to O
four O
cycles O
and O
then O
followed O
by O
standard O
cyclophosphamide-doxorubicin-5-fluorouracil O
, O
or O
to O
immediate O
treatment O
with O
standard O
cyclophosphamide-doxorubicin-5-fluorouracil O
. O
[]

We O
conducted O
a O
controlled O
, O
randomized O
trial O
with O
enoxaparin O
in O
the O
treatment O
of O
established O
deep O
vein O
thrombosis O
. O
[]

No O
patient O
suffered O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

OBJECTIVES O
We O
assessed O
the O
short-term O
antihypertensive O
effects O
of O
soluble O
fiber-rich O
whole O
oat O
cereals O
when O
added O
to O
a O
standard O
American O
diet O
. O
[]

Higher O
rates O
were O
also O
found O
for O
general B-outcome ['Physiological-Clinical']
discomfort I-outcome ['Physiological-Clinical']
( O
62 O
% O
vs O
11 O
% O
, O
P=.05 O
) O
, O
nausea B-outcome ['Physiological-Clinical']
( O
62 O
% O
vs O
0 O
% O
, O
P=.009 O
) O
, O
and O
headache B-outcome ['Physiological-Clinical']
( O
62 O
% O
vs O
0 O
% O
, O
P=.009 O
) O
in O
the O
absence O
of O
the O
extractor O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
control O
group O
consisted O
of O
patients O
who O
received O
no O
specific O
training O
. O
[]

Phase O
III O
, O
randomised O
, O
multicentre O
trial O
of O
maintenance O
immunotherapy O
with O
low-dose O
interleukin-2 O
and O
interferon-alpha O
for O
metastatic O
renal O
cell O
cancer O
. O
[]

Treatment O
of O
gastrointestinal B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
: O
the O
Southeastern O
Cancer O
Study O
Group O
experience O
, O
1979 O
to O
1983 O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Between O
January O
1983 O
and O
February O
1989 O
, O
a O
total O
of O
165 O
patients O
with O
carcinoma O
of O
the O
uterine O
cervix O
was O
entered O
in O
a O
prospective O
randomized O
study O
concerning O
the O
point O
A O
dose O
of O
HDR O
therapy O
( O
6 O
Gy/fraction O
vs O
7.5 O
Gy/fraction O
) O
and O
external O
irradiation O
dose O
at O
Department O
of O
Radiation O
Therapy O
, O
The O
Center O
for O
Adult O
Diseases O
, O
Osaka O
. O
[]

DESIGN O
Multicentric O
, O
randomized O
, O
single-blind O
, O
parallel-group O
clinical O
trial O
. O
[]

Using O
baby O
books O
to O
increase O
new B-outcome ['Life-Impact']
mothers I-outcome ['Life-Impact']
' O
safety O
practices B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Rotigotine O
transdermal O
patch O
enables O
rapid O
titration O
to O
effective O
doses O
in O
advanced-stage O
idiopathic O
Parkinson O
disease O
: O
subanalysis O
of O
a O
parallel O
group O
, O
open-label O
, O
dose-escalation O
study O
. O
[]

The O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
effects O
and O
tolerability B-outcome ['Life-Impact']
of O
nebivolol O
in O
comparison O
with O
metoprolol O
in O
these O
patients O
. O
['Life-Impact']

CONCLUSION O
These O
findings O
suggest O
that O
a O
Longmire-Interposition O
with O
or O
without O
a O
pouch O
for O
reconstruction O
after O
total O
gastrectomy O
is O
not O
connected O
with O
a O
higher O
morbidity B-outcome ['Physiological-Clinical']
or O
mortality B-outcome ['Mortality']
in O
comparison O
to O
a O
Roux-en-Y-reconstruction O
. O
['Physiological-Clinical', 'Mortality']

Nonetheless O
, O
the O
relative O
bioavailability B-outcome ['Physiological-Clinical']
of O
93 O
% O
and O
the O
similar O
absorption B-outcome ['Physiological-Clinical']
rates O
suggest O
the O
pharmacokinetic O
profiles O
of O
Erig O
and O
PHT-Erig O
are O
similar O
. O
['Physiological-Clinical', 'Physiological-Clinical']

An O
experimental O
model O
of O
HPAT O
axis O
inhibited O
by O
corticosterone O
( O
CORT O
) O
was O
established O
to O
observe O
the O
effect O
of O
EB O
on O
relevant O
indices O
of O
HPAT O
axis O
. O
[]

RESULTS O
We O
observed O
an O
advantage O
of O
omega-3 O
fatty O
acids O
compared O
with O
placebo O
for O
hyperactivity B-outcome ['Physiological-Clinical']
and O
stereotypy B-outcome ['Physiological-Clinical']
, O
each O
with O
a O
large O
effect O
size O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Clavicular B-outcome ['Physiological-Clinical']
shortening I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
, O
and O
overall B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
was O
higher O
in O
the O
operative O
group O
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
Twenty-nine O
subjects O
had O
photoplethysmography B-outcome ['Physiological-Clinical']
signals I-outcome ['Physiological-Clinical']
that O
met O
a O
priori O
signal O
quality O
criteria O
for O
analysis O
. O
['Physiological-Clinical']

These O
results O
suggest O
that O
end-to-side O
neurorrhaphy O
can O
induce O
the O
functional O
collateral O
sprouting O
of O
both O
motor O
and O
sensory O
axons O
in O
the O
peripheral O
nerve O
. O
[]

After O
12 O
months O
of O
GH O
treatment O
, O
the O
individual O
changes O
in O
BF B-outcome ['Physiological-Clinical']
ranged O
from O
-12.5 O
to O
4.3 O
kg O
and O
from O
-4.5 O
to O
10.1 O
kg O
in O
LBM O
. O
['Physiological-Clinical']

RESULTS O
None O
of O
the O
variables O
under O
investigation O
were O
significantly O
associated O
with O
response O
or O
remission B-outcome ['Physiological-Clinical']
at O
6 O
weeks O
( O
all O
p-values O
> O
0.003 O
, O
respectively O
) O
. O
['Physiological-Clinical']

p16 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
INK4a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
analyzed O
in O
paraffin-embedded O
sections O
using O
immunohistochemical O
staining O
. O
['Physiological-Clinical']

The O
primary O
end O
point O
was O
the O
median O
difference O
in O
FACIT-F O
fatigue O
at O
day O
15 O
. O
[]

Propensity O
scores O
for O
CKD O
were O
calculated O
using O
a O
multivariable O
logistic O
regression O
model O
and O
used O
to O
match O
2399 O
pairs O
of O
patients O
with O
and O
without O
CKD O
. O
[]

For O
the O
detection O
of O
extensive O
defects O
, O
the O
sensitivity B-outcome ['Physiological-Clinical']
varied O
from O
13 O
% O
to O
48 O
% O
, O
with O
specificity O
from O
63 O
% O
to O
100 O
% O
. O
['Physiological-Clinical']

Injections O
areas O
were O
assessed O
for O
the O
presence O
of O
bruising B-outcome ['Physiological-Clinical']
at O
48 O
and O
72 O
hours O
after O
each O
injection O
. O
['Physiological-Clinical']

Using O
the O
demand-control O
model O
of O
job O
strain O
to O
predict O
caregiver B-outcome ['Life-Impact']
burden I-outcome ['Life-Impact']
and O
caregiver B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
in O
the O
informal O
caregivers O
of O
heart O
failure O
patients O
. O
['Life-Impact', 'Life-Impact']

11 O
minutes O
; O
p O
< O
0.01 O
) O
. O
[]

There O
was O
no O
difference O
in O
the O
28-day O
re-admission B-outcome ['Resource-use']
rates O
between O
the O
2 O
arms O
. O
['Resource-use']

A O
randomized O
trial O
comparing O
intravesical O
instillations O
of O
mitoxantrone O
and O
doxorubicin O
in O
patients O
with O
superficial O
bladder O
cancer O
. O
[]

The O
first O
cohort O
included O
30 O
infants O
with O
DS O
( O
17 O
males O
, O
13 O
females O
; O
mean O
age O
10 O
mo O
[ O
SD O
1.9 O
mo O
] O
) O
who O
were O
randomly O
assigned O
to O
either O
a O
lower-intensity-generalized O
( O
LG O
) O
training O
group O
, O
or O
a O
higher-intensity-individualized O
( O
HI O
) O
training O
group O
. O
[]

Six O
of O
the O
seven O
cardiovascular B-outcome ['Mortality']
deaths I-outcome ['Mortality']
in O
the O
control O
group O
were O
caused O
by O
ventricular O
arrhythmias O
. O
['Mortality']

PMN O
activity O
was O
evaluated O
based O
on O
measurements O
of O
plasma O
activity O
of O
granulocyte O
enzymes O
, O
lysozyme O
and O
beta-glucuronidase O
. O
[]

RESULTS O
The O
potassium O
titanyl O
phosphate O
laser O
group O
showed O
a O
slightly O
longer O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
( O
mean O
12 O
minutes O
) O
than O
the O
bipolar O
radiofrequency O
group O
( O
mean O
10 O
minutes O
) O
. O
['Life-Impact']

All O
students O
used O
regulation O
balls O
during O
tournament O
game O
play O
and O
skills O
tests O
. O
[]

A O
controlled O
, O
randomized O
, O
double-blind O
, O
parallel-group O
study O
compared O
the O
effects O
of O
ViviScal O
( O
a O
new O
food O
supplement O
incorporating O
special O
marine O
extracts O
and O
a O
silica O
compound O
) O
with O
those O
of O
a O
fish O
extract O
in O
the O
treatment O
of O
young O
males O
with O
hereditary O
androgenic O
alopecia O
. O
[]

Acetaminophen O
had O
no O
effect O
compared O
with O
placebo O
. O
[]

In O
contrast O
, O
in O
patients O
with O
kidney O
disease O
, O
time O
to O
discharge O
and O
total O
cost O
of O
treatment O
were O
similar O
in O
both O
groups O
. O
[]

METHODS O
Participants O
were O
58 O
children O
with O
autism O
aged O
3 O
and O
4 O
years O
( O
46 O
boys O
) O
. O
[]

After O
a O
pseudo-randomization O
, O
usual O
pain O
management O
( O
n O
= O
132 O
) O
was O
compared O
to O
a O
multifactorial O
strategy O
( O
n O
= O
107 O
) O
associating O
preliminary O
application O
of O
an O
anesthesic O
patch O
, O
preferential O
use O
of O
specified O
vaccines O
, O
child O
education O
by O
the O
parents O
and O
the O
doctor O
, O
parental O
accompaniment O
and O
child O
distraction O
with O
soap O
bubbles O
during O
the O
procedure O
. O
[]

Diameters O
of O
late O
cutaneous O
reactions O
were O
measured O
hourly O
. O
[]

The O
postoperative B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
day I-outcome ['Resource-use']
of O
E-PEG O
was O
within O
two O
days O
except O
for O
the O
two O
complicated O
cases O
. O
['Resource-use']

kg O
( O
-1 O
) O
? O
[]

Activation O
of O
four O
hand O
muscles O
was O
measured O
during O
each O
task O
condition O
using O
surface O
electromyography O
( O
EMG O
) O
. O
[]

DESIGN O
AND O
METHODS O
This O
was O
a O
multicenter O
prospective O
trial O
in O
77 O
SAA O
patients O
treated O
with O
horse O
ALG O
( O
15 O
mg/kg/day O
day1-5 O
) O
and O
CyA O
( O
5 O
mg/kg/day O
day O
1-180 O
) O
. O
[]

Multivariate O
analyses O
compared O
sun B-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
and O
skin B-outcome ['Life-Impact']
self-examination I-outcome ['Life-Impact']
between O
groups O
, O
controlling O
for O
location O
, O
risk O
level O
, O
gender O
, O
and O
age O
. O
['Life-Impact', 'Life-Impact']

CONCLUSIONS O
A O
fixed-dose O
manidipine/delapril O
combination O
represents O
a O
useful O
addition O
to O
the O
treatment O
options O
available O
to O
control O
hypertension O
complicated O
by O
diabetes O
and O
microalbuminuria O
. O
[]

Standardized O
neurologic B-outcome ['Physiological-Clinical']
examinations O
before O
and O
after O
treatment O
on O
33 O
children O
showed O
no O
change O
. O
['Physiological-Clinical']

Efficacy O
and O
safety O
of O
a O
high O
protein O
, O
low O
carbohydrate O
diet O
for O
weight O
loss O
in O
severely O
obese O
adolescents O
. O
[]

BACKGROUND O
Noninvasive O
cortical O
stimulation O
could O
represent O
an O
add-on O
treatment O
to O
enhance O
motor B-outcome ['Life-Impact']
recovery I-outcome ['Life-Impact']
after O
stroke O
. O
['Life-Impact']

The O
purpose O
of O
this O
study O
is O
to O
evaluate O
the O
venous O
velocity O
response O
to O
high-pressure O
, O
rapid-inflation O
compression O
devices O
versus O
standard O
, O
low-pressure O
, O
slow-inflation O
compression O
devices O
in O
healthy O
volunteers O
and O
patients O
with O
severe O
post-thrombotic O
venous O
disease O
. O
[]

Otherwise O
complete O
response O
( O
CR O
) O
partial O
response O
( O
PR O
) O
or O
stable O
disease O
( O
SD O
) O
, O
two O
more O
courses O
were O
scheduled O
. O
[]

This O
RCT O
examined O
the O
efficacy O
of O
a O
manualized O
social O
intervention O
for O
children O
with O
HFASDs O
. O
[]

METHOD O
17 O
patients O
with O
anamnestic O
known O
rhinokonjunktivitis O
( O
6 O
f O
, O
11 O
m O
) O
had O
a O
pricktest O
and O
then O
a O
nasal O
provocation O
testing O
with O
an O
allergen O
which O
provoked O
a O
reaction O
on O
the O
skin O
. O
[]

Standard O
versus O
extended O
lymphadenectomy O
in O
radical O
pancreatoduodenectomy O
for O
ductal O
adenocarcinoma O
of O
the O
head O
of O
the O
pancreas O
: O
long-term O
results O
of O
a O
Japanese O
multicenter O
randomized O
controlled O
trial O
. O
[]

12.5 O
mg/d O
hydrochlorothiazide O
and O
30 O
mg/d O
release-controlling O
tablets O
of O
nifedipine O
were O
orally O
administrated O
as O
basic O
antihypertensive O
medication O
each O
group O
. O
[]

This O
improvement O
differed O
from O
the O
mild O
reduction O
of O
symptoms B-outcome ['Physiological-Clinical']
under O
treatment O
with O
glycerol O
eardrops O
alone O
. O
['Physiological-Clinical']

METHODS O
Psychiatric B-outcome ['Physiological-Clinical']
diagnostic O
assessments O
were O
based O
on O
the O
Structured O
Clinical O
Interview O
for O
DSMIV B-outcome ['Physiological-Clinical']
disorders O
( O
SCID-I O
) O
conducted O
by O
a O
clinical O
psychiatrist O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Lower O
severity O
of O
[]

The O
efficiency O
synergism O
and O
toxicity O
reducing O
effects O
were O
achieved O
by O
regulating O
the O
activities O
of O
MGMT O
gene O
. O
[]

The O
subjects O
were O
randomized O
into O
two O
groups O
, O
After O
surgery O
, O
the O
study O
group O
received O
0.9 O
mg O
of O
atropine O
, O
while O
the O
control O
group O
received O
1.2 O
mg O
of O
atropine O
. O
[]

[ O
Mitomycin O
C O
plus O
HCFU O
adjuvant O
chemotherapy O
for O
noncuratively O
resected O
cases O
of O
colorectal O
carcinoma O
. O
( O
[]

Safety O
, O
tolerability B-outcome ['Life-Impact']
, O
and O
changes O
in O
amyloid B-outcome ['Physiological-Clinical']
beta I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
after O
administration O
of O
a O
gamma-secretase O
inhibitor O
in O
volunteers O
. O
['Life-Impact', 'Physiological-Clinical']

Comparing O
rhTPO O
to O
placebo O
, O
higher O
percentages O
of O
patients O
achieved O
the O
minimum B-outcome ['Physiological-Clinical']
yield I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
CD34+ I-outcome ['Physiological-Clinical']
> O
or O
=2 O
x O
10 O
( O
6 O
) O
/kg O
( O
92 O
% O
v O
75 O
% O
; O
P=.050 O
) O
as O
well O
as O
the O
target O
yield O
of O
CD34+ O
> O
or O
=5 O
x O
10 O
( O
6 O
) O
/kg O
( O
73 O
% O
v O
46 O
% O
; O
P= O
.041 O
) O
. O
['Physiological-Clinical']

There O
were O
29 O
cardiac O
deaths O
. O
[]

RESULTS O
Compared O
with O
systemic O
T1 O
blood O
, O
pericardial O
blood O
contained O
increased O
C4b/c B-outcome ['Physiological-Clinical']
and O
C3b/c B-outcome ['Physiological-Clinical']
, O
and O
increased O
levels O
of O
microparticles B-outcome ['Physiological-Clinical']
with O
bound O
complement O
components O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
lower O
RA O
disease O
activity O
were O
more O
likely O
to O
reach O
remission O
. O
[]

The O
inflammatory B-outcome ['Physiological-Clinical']
response O
( O
interleukin-6 B-outcome ['Physiological-Clinical']
and O
interleukin-8 B-outcome ['Physiological-Clinical']
) O
, O
endothelial B-outcome ['Physiological-Clinical']
( O
soluble B-outcome ['Physiological-Clinical']
E-selectin I-outcome ['Physiological-Clinical']
) O
and O
neutrophil B-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
( O
expression B-outcome ['Physiological-Clinical']
of O
CD11b B-outcome ['Physiological-Clinical']
, O
CD64 B-outcome ['Physiological-Clinical']
) O
, O
and O
antiinflammatory B-outcome ['Physiological-Clinical']
response O
( O
soluble B-outcome ['Physiological-Clinical']
tumor B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor O
receptors B-outcome ['Physiological-Clinical']
I O
and O
II B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
interleukin-10 I-outcome ['Physiological-Clinical']
) O
were O
attenuated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Subjects O
continued O
the O
threshold O
loaded O
breathing O
until O
the O
target O
mouth O
pressure O
could O
no O
longer O
be O
maintained O
( O
endurance O
time O
) O
. O
[]

In O
both O
of O
these O
groups O
of O
patients O
the O
diagnostic O
or O
therapeutic O
radioiodine O
application O
was O
done O
after O
withdrawal O
of O
thyroid O
hormone O
treatment O
. O
[]

INTERPRETATION O
Our O
data O
suggest O
that O
oral O
sucrose O
does O
not O
significantly O
affect O
activity O
in O
neonatal O
brain O
or O
spinal O
cord O
nociceptive O
circuits O
, O
and O
therefore O
might O
not O
be O
an O
effective O
analgesic O
drug O
. O
[]

CONCLUSION O
Once-daily O
latanoprost O
treatment O
provides O
uniform O
circadian O
( O
around-the-clock O
) O
IOP B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
by O
itself O
, O
or O
in O
combination O
with O
timolol O
. O
['Physiological-Clinical']

The O
non-responders O
underwent O
the O
subsequent O
instillation O
of O
the O
other O
intravesical O
therapy O
alternately O
. O
[]

BACKGROUND O
The O
possibility O
of O
additional O
strategies O
to O
enhance O
the O
effectiveness O
of O
specific O
immunotherapy O
( O
SIT O
) O
is O
highly O
attractive O
. O
[]

DESIGN O
Randomized O
, O
prospective O
study O
( O
Canadian O
Task O
Force O
classification O
I O
) O
. O
[]

Proposed O
synergistic O
effect O
of O
calcium O
channel O
blockers O
with O
lipid-lowering O
therapy O
in O
retarding O
progression O
of O
coronary B-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

One O
intervention O
group O
were O
given O
a O
health O
check O
which O
included O
being O
screened O
for O
cardiovascular O
risk O
factors O
, O
lung O
and O
liver O
function O
, O
fitness O
, O
sight O
and O
hearing O
and O
an O
optional O
test O
for O
the O
human O
immunodeficiency O
virus O
( O
HIV O
) O
; O
this O
group O
received O
written O
feedback O
from O
the O
general O
practitioner O
. O
[]

Safety O
and O
tolerability B-outcome ['Life-Impact']
data O
were O
collected O
throughout O
the O
study O
. O
['Life-Impact']

CONCLUSIONS O
This O
study O
found O
that O
interviewer O
body O
mass O
index O
had O
no O
impact O
on O
self-reported O
energy O
intake O
during O
an O
in-person O
MP24R O
, O
and O
that O
telephone O
recall O
data O
were O
comparable O
with O
in-person O
recalls O
. O
[]

Hematologic O
patients O
' O
clinical O
and O
psychosocial O
experiences O
with O
implanted O
long-term O
central O
venous O
catheter O
: O
self-management O
versus O
professionally O
controlled O
care O
. O
[]

The O
other O
group O
received O
treatments O
in O
the O
reverse O
order O
. O
[]

METHODS O
Forty O
children O
between O
the O
ages O
4 O
and O
12 O
years O
with O
a O
DSM O
IV-TR O
clinical O
diagnosis O
of O
autism O
were O
recruited O
. O
[]

Eighteen O
patients O
received O
150 O
IU O
hMG-HP O
( O
150 O
IU O
FSH O
+ O
150 O
IU O
LH-like O
activity O
) O
and O
seventeen O
received O
150IU O
r-hFSH/75IU O
rhLH O
daily O
for O
a O
maximum O
of O
16 O
days O
. O
[]

Etanercept O
treatment O
in O
adults O
with O
established O
rheumatoid O
arthritis O
: O
7 O
years O
of O
clinical O
experience O
. O
[]

CONCLUSIONS O
Tetracycline-containing O
quadruple O
rescue O
therapy O
is O
highly O
effective O
in O
treating O
H. O
pylori O
eradication O
failures O
of O
the O
omeprazole-amoxicillin-clarithromycin O
regimen O
. O
[]

The O
age O
and O
developmental O
stage O
at O
which O
calcium O
supplementation O
produces O
the O
greatest O
bone O
effects O
remain O
controversial O
. O
[]

Conclusions O
This O
post O
hoc O
analysis O
suggests O
that O
zoledronic O
acid O
is O
significantly O
more O
effective O
than O
risedronate O
in O
increasing O
LS O
BMD O
in O
prevention O
and O
treatment O
of O
glucocorticoid-induced O
osteoporosis O
across O
a O
wide O
range O
of O
patients O
. O
[]

The O
purpose O
of O
the O
study O
was O
to O
ascertain O
whether O
the O
prognostic O
significance O
of O
staging O
in O
multiple O
myeloma O
( O
MM O
) O
is O
influenced O
by O
the O
aggressiveness O
of O
effective O
induction O
treatment O
and/or O
by O
continuing O
or O
discontinuing O
maintenance O
chemotherapy O
. O
[]

Three O
patients O
discontinued O
treatment O
early O
( O
two O
due O
to O
moderate O
adverse B-outcome ['Adverse-effects']
events O
, O
one O
due O
to O
non-compliance O
) O
. O
['Adverse-effects']

All O
subjects O
participated O
in O
three O
separate O
experiments O
comparing O
one O
drug O
( O
5 O
mg O
d O
, O
l-amphetamine O
, O
5 O
mg O
diazepam O
or O
10 O
mg O
diazepam O
) O
to O
placebo O
. O
[]

Paracervical O
anesthesia O
for O
routine O
outpatient B-outcome ['Resource-use']
hysteroscopy I-outcome ['Resource-use']
in O
premenopausal O
women O
may O
be O
superfluous O
. O
['Resource-use']

Previous O
research O
has O
suggested O
two O
leading O
hypotheses O
concerning O
which O
excessive O
drinkers O
can O
re-establish O
control O
: O
one O
based O
upon O
level O
of O
dependence O
, O
the O
other O
upon O
the O
client O
's O
personal O
persuasion O
. O
[]

Teaching O
picture-to-object O
relations O
in O
picture-based O
requesting O
by O
children O
with O
autism O
: O
a O
comparison O
between O
error O
prevention O
and O
error O
correction O
teaching O
procedures O
. O
[]

OBJECTIVE O
To O
investigate O
long-term O
safety O
and O
efficacy O
after O
intracoronary O
injection O
of O
autologous O
mononuclear O
bone O
marrow O
cells O
( O
mBMCs O
) O
in O
acute O
myocardial O
infarction O
( O
AMI O
) O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Therefore O
, O
abnormalities O
in O
5-HT O
regulation O
in O
autism O
may O
be O
related O
to O
increased O
sensitivity O
of O
the O
5-HT1d O
inhibitory O
receptor O
in O
autism O
. O
[]

After O
72 O
months O
no O
significant O
difference O
between O
the O
patients O
and O
the O
healthy O
controls O
could O
be O
detected O
. O
[]

METHODS O
Eight O
hundred O
sixty-one O
patients O
with O
severe O
traumatic O
brain O
injury O
who O
were O
admitted O
to O
86 O
centers O
were O
included O
in O
a O
multicenter O
, O
placebo-controlled O
, O
Phase O
III O
trial O
. O
[]

Intervention O
participants O
showed O
improved O
adherence B-outcome ['Life-Impact']
relative O
to O
controls O
on O
all O
three O
outcomes O
: O
doses B-outcome ['Life-Impact']
taken I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
total O
( O
93.4 O
% O
vs. O
79.1 O
% O
) O
, O
days O
on O
which O
correct B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
was O
taken O
( O
88.7 O
% O
vs. O
65.3 O
% O
) O
, O
and O
doses B-outcome ['Life-Impact']
taken I-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
schedule I-outcome ['Life-Impact']
( O
78.8 O
% O
vs. O
55.3 O
% O
) O
( O
P O
< O
0.01 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Mastalgia B-outcome ['Physiological-Clinical']
responded O
in O
100 O
% O
of O
alpha O
dihidroergocriptine O
group O
vs O
64.86 O
% O
of O
placebo O
group O
( O
p O
= O
0.0003 O
) O
. O
['Physiological-Clinical']

Is O
the O
orientation O
of O
the O
apical O
defibrillation O
paddle O
of O
importance O
during O
manual O
external O
defibrillation O
? O
[]

RESULTS O
Rates O
of O
complete B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
of O
fissure B-outcome ['Physiological-Clinical']
were O
similar O
in O
the O
three O
groups O
( O
lignocaine O
alone O
8/27 O
, O
minoxidil O
alone O
10/34 O
, O
combination O
7/22 O
; O
p=ns O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Clinical O
trials O
have O
generally O
failed O
to O
confirm O
benefits O
, O
possibly O
due O
to O
their O
relatively O
short O
duration O
. O
[]

PURPOSE O
Despite O
growing O
concerns O
toward O
maintaining O
participants O
' O
privacy O
, O
individual O
investigators O
collecting O
tissue O
and O
other O
biological O
specimens O
for O
genomic O
analysis O
are O
encouraged O
to O
obtain O
informed O
consent O
for O
broad O
data O
sharing O
. O
[]

Fifty-seven O
patients O
received O
amlodipine O
maleate O
( O
29 O
men O
, O
28 O
women O
; O
mean O
[ O
SD O
] O
age O
, O
49.0 O
[ O
11.4 O
] O
years O
) O
and O
61 O
received O
amlodipine O
besylate O
( O
35 O
men O
, O
26 O
women O
; O
mean O
[ O
SD O
] O
age O
, O
51.6 O
[ O
9.4 O
] O
years O
) O
. O
[]

Incision-to-delivery O
time O
is O
shortened O
but O
total O
operating O
time O
appears O
unchanged O
. O
[]

First-line O
cisplatin O
with O
docetaxel O
or O
vinorelbine O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
: O
a O
quality O
of O
life O
directed O
phase O
II O
randomized O
trial O
of O
Gruppo O
Oncologico O
Italia O
Meridionale O
. O
[]

After O
three O
months O
, O
a O
statistically O
significant O
decrease O
in O
the O
average O
percentage O
of O
sites O
with O
scores O
of O
two O
or O
three O
was O
demonstrated O
in O
the O
T O
group O
( O
0.7 O
+/- O
2.4 O
, O
T O
, O
p O
< O
0.0001 O
; O
1.3 O
+/- O
3.0 O
, O
C O
, O
p O
< O
0.25 O
) O
. O
[]

Each O
dose O
contained O
2.0 O
x O
10 O
( O
10 O
) O
inactivated O
cells O
. O
[]

Mothers O
' O
attachment O
to O
their O
infants O
was O
measured O
at O
6-8 O
weeks O
postpartum O
using O
the O
Maternal B-outcome ['Life-Impact']
Postnatal I-outcome ['Life-Impact']
Attachment I-outcome ['Life-Impact']
Scale O
. O
['Life-Impact']

Observations O
indicate O
that O
rhTSH O
has O
a O
preconditioning O
effect O
beyond O
increasing O
thyroid O
( O
131 O
) O
I O
uptake O
. O
[]

Increased O
appetite B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
drowsiness B-outcome ['Physiological-Clinical']
, O
dizziness B-outcome ['Physiological-Clinical']
, O
and O
drooling B-outcome ['Physiological-Clinical']
were O
more O
common O
in O
the O
risperidone O
group O
than O
in O
the O
placebo O
group O
( O
P O
< O
0.05 O
for O
each O
comparison O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
There O
are O
several O
lines O
of O
evidence O
to O
indicate O
that O
the O
immune O
system O
plays O
an O
important O
role O
in O
the O
pathophysiology O
of O
autism O
. O
[]

Until O
now O
, O
radiotherapy O
was O
considered O
the O
treatment O
of O
choice O
in O
this O
clinical O
setting O
of O
patients O
. O
[]

Study O
follow-up O
was O
completed O
July O
2012 O
. O
[]

Allopurinol O
improves O
endothelial O
function O
and O
reduces O
oxidant-inflammatory O
enzyme O
of O
myeloperoxidase O
in O
metabolic O
syndrome O
. O
[]

Therefore O
, O
since O
the O
relationship O
between O
R-R O
interval O
and O
% O
D O
was O
unaffected O
by O
alinidine O
, O
it O
was O
possible O
to O
hypothesize O
that O
the O
changes O
in O
[]

The O
anesthetic O
and O
recovery O
profile O
of O
two O
doses O
( O
60 O
and O
80 O
mg O
) O
of O
plain O
mepivacaine O
for O
ambulatory O
spinal O
anesthesia O
. O
[]

We O
suggest O
ipratropium O
nasal O
spray O
as O
a O
safe O
, O
effective O
way O
to O
treat O
chronic O
rhinorrhea O
in O
laryngectomized O
patients O
, O
improving O
their O
quality O
of O
life O
. O
[]

In O
the O
final O
analysis O
digital O
images O
were O
randomised O
( O
in O
time O
order O
) O
and O
a O
panel O
of O
nurses O
who O
were O
not O
otherwise O
involved O
in O
the O
research O
project O
graded O
the O
wound O
's O
progress O
. O
[]

Proteus O
mirabilis O
, O
Escherichia O
coli O
and O
micrococci O
. O
[]

The O
clinical O
effects O
of O
SIT O
were O
not O
affected O
in O
the O
steroid+D O
( O
3 O
) O
group O
. O
[]

Subjects O
' O
OAS O
aggression B-outcome ['Life-Impact']
scores O
showed O
significant O
correlation O
with O
the O
already O
validated O
retrospectively O
rated O
Aberrant O
Behavior O
Checklist O
Community O
Scale O
irritability O
subscale O
. O
['Life-Impact']

The O
increase O
of O
hemoglobin B-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
the O
400 O
U/kg O
group O
( O
22.3+/-2.0 O
g/l O
) O
than O
in O
the O
200 O
U/kg O
group O
( O
14.1+/-2.7 O
g/l O
) O
( O
p O
= O
0.017 O
) O
. O
['Physiological-Clinical']

Samples O
were O
taken O
during O
surgery O
for O
lung O
resection O
at O
various O
time O
points O
up O
to O
204 O
h O
after O
the O
last O
drug O
dose O
, O
and O
azithromycin O
levels O
were O
analyzed O
by O
HPLC O
method O
. O
[]

CONCLUSIONS O
On O
each O
POD O
analyzed O
, O
alvimopan O
significantly O
increased O
the O
proportion O
of O
patients O
who O
achieved O
GI-2 B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
and O
DCO O
written O
versus O
placebo O
and O
was O
associated O
with O
relatively O
low O
NNTs O
. O
['Physiological-Clinical']

For O
single O
gram-negative O
bacteremias O
and O
clinically O
documented O
and O
possible O
infections O
the O
response O
rates O
of O
CA O
and O
CAV O
were O
80 O
% O
and O
63 O
% O
( O
P O
= O
.17 O
) O
, O
55 O
% O
and O
75 O
% O
( O
P O
= O
.009 O
) O
, O
and O
74 O
% O
and O
81 O
% O
( O
P O
= O
.16 O
) O
, O
respectively O
. O
[]

There O
was O
no O
effect O
of O
inhaled O
NO O
on O
duration O
of O
mechanical B-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
or O
stay B-outcome ['Resource-use']
at I-outcome ['Resource-use']
the I-outcome ['Resource-use']
intensive I-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit I-outcome ['Resource-use']
. O
['Resource-use', 'Resource-use']

The O
weight O
difference O
between O
the O
treatment O
and O
control O
group O
at O
the O
18-month O
follow-up O
was O
highly O
significant O
( O
p O
< O
0.001 O
) O
. O
[]

The O
rates O
of O
MACEs O
[ O
5.9 O
% O
( O
n O
= O
5 O
) O
in O
the O
SES O
vs. O
9.5 O
% O
( O
n O
= O
8 O
) O
in O
the O
PES O
Group O
, O
P O
= O
0.374 O
] O
and O
definite B-outcome ['Physiological-Clinical']
stent B-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
[ O
1.2 O
% O
( O
n O
= O
1 O
) O
in O
the O
SES O
vs. O
3.6 O
% O
( O
n O
= O
3 O
) O
in O
the O
PES O
Group O
, O
P O
= O
0.368 O
] O
were O
similar O
in O
the O
two O
groups O
during O
the O
three-year O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Antimicrobial O
resistance O
has O
decreased O
eradication O
rates O
for O
Helicobacter O
pylori O
infection O
worldwide O
. O
[]

A O
trend O
towards O
decreased O
plasma B-outcome ['Physiological-Clinical']
TAFI I-outcome ['Physiological-Clinical']
levels O
was O
observed O
in O
healthy O
volunteers O
who O
used O
levothyroxine O
. O
['Physiological-Clinical']

Problem-solving O
counseling O
for O
caregivers O
of O
the O
cognitively O
impaired O
: O
effective O
for O
whom O
? O
[]

The O
research O
obtained O
the O
approval O
of O
the O
Hospital O
Research O
Ethics O
committee O
and O
parents O
signed O
informed O
consent O
. O
[]

Both O
PVP O
and O
NaCl O
improved O
the O
comfort O
of O
contact B-outcome ['Life-Impact']
lens I-outcome ['Life-Impact']
wear I-outcome ['Life-Impact']
( O
P O
= O
0.0003 O
) O
, O
with O
no O
difference O
between O
them O
( O
P O
= O
0.25 O
) O
. O
['Life-Impact']

In O
stratum O
2 O
( O
n O
= O
84 O
) O
, O
CBRs O
were O
29.2 O
% O
with O
gefitinib O
and O
31.4 O
% O
with O
placebo O
. O
[]

Following O
placebo O
run-in O
, O
86 O
patients O
were O
randomised O
to O
receive O
fluvoxamine O
or O
clomipramine O
( O
100-250 O
mg/day O
) O
for O
8 O
weeks O
. O
[]

CONCLUSION O
The O
D-C O
model O
was O
associated O
with O
caregiver O
burden O
, O
but O
not O
satisfaction O
in O
caregivers O
, O
with O
control O
being O
the O
dominant O
predictor O
. O
[]

As O
a O
whole O
group O
, O
a O
significant O
linear O
dose-response O
( O
p O
< O
0.001 O
) O
was O
observed O
and O
a O
significant O
difference O
between O
placebo O
and O
100 O
mg/BID O
was O
observed O
( O
p O
< O
0.001 O
) O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
a O
12-month O
regimen O
of O
rhNGF O
in O
patients O
with O
diabetic O
polyneuropathy O
. O
[]

A O
total O
of O
388 O
patients O
were O
needed O
to O
detect O
a O
50 O
% O
increase O
in O
median O
survival O
from O
14 O
months O
of O
qdRT O
to O
21 O
months O
of O
HART O
; O
accrual O
was O
not O
achieved O
and O
the O
study O
closed O
prematurely O
. O
[]

All O
were O
given O
a O
2 O
g O
loading O
dose O
of O
pralidoxime O
over O
30 O
min O
. O
[]

Repeated O
doses O
of O
porcine O
secretin O
in O
the O
treatment O
of O
autism O
: O
a O
randomized O
, O
placebo-controlled O
trial O
. O
[]

3.6 O
ng/mL O
, O
NS O
) O
, O
they O
did O
increase O
significantly O
in O
the O
control O
group O
( O
8.0 O
? O
[]

Exploratory O
analyses O
indicated O
that O
, O
in O
addition O
to O
verbal O
imitation O
, O
pretreatment O
age O
and O
IQ O
may O
also O
predict O
spoken O
language O
developed O
during O
training O
. O
[]

6 O
. O
[]

OBJECTIVE O
The O
objective O
of O
this O
study O
was O
to O
evaluate O
short-term O
efficacy O
and O
safety O
of O
aripiprazole O
in O
the O
treatment O
of O
irritability B-outcome ['Life-Impact']
in O
children O
and O
adolescents O
with O
autistic O
disorder O
who O
were O
manifesting O
behaviors O
such O
as O
tantrums O
, O
aggression O
, O
self-injurious O
behavior O
, O
or O
a O
combination O
of O
these O
. O
['Life-Impact']

Evaluation O
of O
masking O
study O
participants O
to O
intravitreal O
injections O
in O
a O
randomized O
clinical O
trial O
. O
[]

Despite O
substantial O
overlap O
between O
ASD O
and O
ADHD O
, O
ERP B-outcome ['Life-Impact']
markers I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
face I-outcome ['Life-Impact']
and O
gaze B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
have O
not O
been O
directly O
compared O
across O
pure O
and O
comorbid O
cases O
. O
['Life-Impact', 'Life-Impact']

However O
, O
when O
only O
the O
last O
50 O
patients O
were O
analyzed O
, O
we O
found O
no O
difference O
in O
procedure O
time O
between O
the O
groups O
, O
probably O
related O
to O
the O
learning O
curve O
of O
the O
operators O
. O
[]

Repeated O
triple O
dye O
application O
was O
considered O
least B-outcome ['Physiological-Clinical']
acceptable I-outcome ['Physiological-Clinical']
by O
staff O
and O
parents O
and O
had O
the O
longest O
attachment O
time O
. O
['Physiological-Clinical']

RESULTS O
From O
40 O
general O
practices O
363 O
patients O
who O
were O
gainfully O
employed O
were O
included O
. O
[]

Translucency B-outcome ['Physiological-Clinical']
was O
measured O
by O
the O
direct O
transmission O
method O
with O
a O
digital O
photoradiometer O
mounted O
in O
a O
dark O
chamber O
. O
['Physiological-Clinical']

Second O
report O
) O
: O
5-year O
survival O
rate O
. O
[]

This O
constituted O
part O
of O
a O
wider O
randomized O
controlled O
trial O
( O
RCT O
) O
. O
[]

CONCLUSIONS O
Acupuncture O
of O
CV24 O
is O
an O
easy O
to O
apply O
and O
effective O
method O
to O
reduce O
gag B-outcome ['Physiological-Clinical']
reflex I-outcome ['Physiological-Clinical']
during O
TEE O
. O
['Physiological-Clinical']

Matched B-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
and O
HF B-outcome ['Physiological-Clinical']
hospitalization I-outcome ['Physiological-Clinical']
were O
respectively O
1.17 O
( O
95 O
% O
CI O
, O
1.06-1.28 O
, O
P O
= O
0.002 O
) O
and O
1.28 O
( O
95 O
% O
CI O
, O
1.13-1.45 O
, O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
After O
the O
intervention O
, O
the O
red B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RBC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
content O
of O
eicosapentaenoic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EPA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
docosahexaenoic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DHA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
1.2 O
% O
+/-0.5 O
% O
and O
6.7 O
% O
+/-1.6 O
% O
, O
respectively O
, O
in O
the O
those O
receiving O
fish O
oil O
( O
FO O
group O
) O
, O
compared O
with O
0.6 O
% O
+/-0.3 O
% O
and O
4.1 O
% O
+/-0.9 O
% O
in O
the O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
aimed O
to O
determine O
if O
a O
joint O
attention O
intervention O
would O
result O
in O
greater O
joint O
engagement O
between O
caregivers O
and O
toddlers O
with O
autism O
. O
[]

OBJECTIVES O
To O
compare O
the O
long-term O
effectiveness O
of O
medical O
and O
chiropractic O
care O
for O
low O
back O
pain O
in O
managed O
care O
and O
to O
assess O
the O
effectiveness O
of O
physical O
therapy O
and O
modalities O
among O
patients O
receiving O
medical O
or O
chiropractic O
care O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
inactive O
asthmatic O
patients O
could O
perform O
high-intensity O
physical O
training O
equally O
well O
on O
land O
as O
in O
water O
, O
and O
to O
compare O
the O
effects O
of O
these O
training O
forms O
. O
[]

In O
conclusion O
, O
the O
myocardial O
ECV O
is O
elevated O
in O
patients O
with O
previous O
anthracycline O
treatment O
and O
is O
associated O
with O
the O
diastolic O
function O
and O
increased O
atrial O
volumes O
. O
[]

The O
tolerability B-outcome ['Life-Impact']
of O
the O
tested O
substances O
was O
good O
. O
['Life-Impact']

No O
serious O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
, O
and O
both O
regimens O
were O
equally O
well O
tolerated B-outcome ['Life-Impact']
. O
['Adverse-effects', 'Life-Impact']

CONCLUSIONS O
Results O
suggest O
the O
need O
for O
careful O
examination O
of O
the O
way O
that O
collaborative O
care O
models O
are O
implemented O
for O
treating O
PTSD O
, O
and O
for O
additional O
supports O
to O
encourage O
primary O
care O
providers O
to O
manage O
PTSD O
. O
[]

There O
was O
a O
high O
correlation O
between O
obtained O
and O
predicted O
values O
. O
[]

i.v O
. O
[]

There O
was O
a O
higher O
rate O
of O
severe B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
in O
the O
high-dose O
group O
( O
P O
less O
than O
0.01 O
) O
. O
['Adverse-effects']

Ginger O
has O
shown O
downregulation O
of O
COX O
in O
vitro O
and O
decreased O
incidence/multiplicity O
of O
adenomas O
in O
rats O
. O
[]

No O
significant O
difference O
regarding O
mean O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
noticed O
. O
['Life-Impact']

All O
patients O
in O
both O
groups O
that O
completed O
COMET O
were O
contacted O
3 O
and O
6 O
months O
later O
to O
assess O
whether O
the O
effects O
of O
COMET O
had O
remained O
stable O
. O
[]

adjuvant O
[ O
chemo O
] O
RT O
) O
. O
[]

Mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
recorded O
at O
baseline O
, O
after O
induction O
, O
immediately O
after O
intubation O
and O
every O
minute O
for O
five O
minutes O
after O
intubation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
conclusion O
with O
regard O
to O
the O
differential O
effectiveness O
of O
both O
interventions O
could O
be O
drawn O
. O
[]

RESULTS O
DA-supported O
participants O
were O
less O
likely O
to O
die B-outcome ['Mortality']
in O
the O
acute O
ward O
( O
4.1 O
versus O
10.1 O
% O
, O
P O
= O
0.048 O
) O
. O
['Mortality']

Results O
from O
a O
randomized O
clinical O
trial O
. O
[]

Patients O
did O
not O
practise O
the O
exhalation O
manoeuvre O
prior O
to O
testing O
. O
[]

One O
hundred O
and O
ten O
consecutive O
patients O
were O
evaluated O
. O
[]

Effect O
of O
L-arginine O
or O
L-citrulline O
oral O
supplementation O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
right B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
heart O
failure O
patients O
with O
preserved O
ejection O
fraction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Fifty-seven O
( O
92 O
% O
) O
patients O
completed O
treatment O
. O
[]

Initial O
single-dose O
, O
randomized O
, O
controlled O
trials O
failed O
to O
demonstrate O
any O
therapeutic O
effects O
of O
secretin O
. O
[]

Immunogenicity B-outcome ['Physiological-Clinical']
and O
reactogenicity B-outcome ['Physiological-Clinical']
of O
two O
regimens O
of O
diphtheria-tetanus-acellular O
pertussis-hepatitis O
B-inactivated O
polio O
and O
Haemophilus O
influenzae O
type O
b O
vaccines O
administered O
to O
infants O
primed O
at O
birth O
with O
hepatitis O
B O
vaccine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
results O
showed O
that O
significantly O
fewer O
failures B-outcome ['Physiological-Clinical']
occurred O
when O
preoperative O
antibiotics O
were O
used O
. O
['Physiological-Clinical']

Laser O
treatment O
was O
not O
masked O
. O
[]

Two O
different O
methods O
for O
donor O
hepatic O
transection O
: O
cavitron O
ultrasonic O
surgical O
aspirator O
with O
bipolar O
cautery O
versus O
cavitron O
ultrasonic O
surgical O
aspirator O
with O
radiofrequency O
coagulator-A O
randomized O
controlled O
trial O
. O
[]

Pretreatment O
does O
not O
affect O
surgical B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
or O
duration O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
ClinicalTrials.gov O
number O
, O
NCT00993356 O
) O
. O
['Adverse-effects', 'Resource-use']

CONCLUSION O
These O
results O
demonstrate O
that O
intravenous O
dezocine O
0.1 O
mg/kg O
10 O
min O
prior O
to O
induction O
was O
effective O
in O
suppressing O
fentanyl-induced O
cough O
in O
our O
patients O
. O
[]

These O
findings O
suggest O
that O
individuals O
with O
ASD O
can O
gain O
expertise O
in O
[]

RESULTS O
In O
the O
primary O
analysis O
, O
the O
primary O
end O
point O
occurred O
in O
188 O
patients O
in O
the O
rivaroxaban O
group O
( O
1.7 O
% O
per O
year O
) O
and O
in O
241 O
in O
the O
warfarin O
group O
( O
2.2 O
% O
per O
year O
) O
( O
hazard O
ratio O
in O
the O
rivaroxaban O
group O
, O
0.79 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.66 O
to O
0.96 O
; O
P O
< O
0.001 O
for O
noninferiority O
) O
. O
[]

For O
23 O
patients O
treated O
with O
gentamicin-cefoxitin O
( O
G-C O
) O
, O
the O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
favorable O
in O
20/21 O
( O
95.2 O
% O
) O
evaluable O
cases O
, O
and O
elimination O
or O
marked O
reduction O
of O
33/34 O
( O
97.1 O
% O
) O
organisms O
was O
achieved O
. O
['Physiological-Clinical']

This O
was O
a O
prospective O
randomized O
study O
in O
which O
monophasic O
combinations O
of O
20 O
micrograms O
ethinyl O
estradiol O
( O
E2 O
) O
and O
150 O
micrograms O
desogestrel O
or O
30 O
micrograms O
ethinyl O
E2 O
plus O
75 O
micrograms O
gestodene O
were O
administered O
to O
15 O
and O
19 O
healthy O
women O
, O
respectively O
. O
[]

As O
a O
result O
, O
17 O
% O
of O
those O
taking O
lisinopril O
and O
38 O
% O
of O
those O
taking O
nifedipine O
required O
additional O
therapy O
with O
hydrochlorothiazide B-outcome ['Resource-use']
. O
['Resource-use']

OBJECTIVES O
To O
examine O
the O
relationships O
between O
changes O
from O
baseline O
to O
post-Resources O
for O
Enhancing O
Alzheimer O
's O
Caregiver O
Health O
( O
REACH O
) O
intervention O
in O
caregiver O
( O
CG O
) O
self-reported O
health O
, O
burden O
, O
and O
bother O
. O
[]

It O
is O
often O
suggested O
that O
tumors O
will O
respond O
to O
induction O
chemotherapy O
and O
result O
in O
improved O
survival B-outcome ['Mortality']
for O
patients O
with O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
. O
['Mortality']

DISCUSSION O
The O
program O
was O
successful O
in O
reaching O
smokers O
with O
lower O
levels O
of O
readiness O
to O
quit O
. O
[]

Low O
BMI O
( O
on O
treatment O
) O
and O
young O
age O
( O
off O
treatment O
) O
were O
determinants O
of O
low B-outcome ['Physiological-Clinical']
BG I-outcome ['Physiological-Clinical']
levels O
in O
a O
multiple O
regression O
model O
. O
['Physiological-Clinical']

RESULTS O
CRF B-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
in O
the O
intervention O
group O
, O
corresponding O
to O
a O
Fatigue B-outcome ['Physiological-Clinical']
score O
reduction O
of O
3.04 O
( O
effect O
size O
of O
0.44 O
, O
95 O
% O
CI O
0.17-0.72 O
) O
( O
P O
= O
.002 O
) O
, O
the O
FACT-An B-outcome ['Physiological-Clinical']
score O
by O
5.40 O
( O
P O
= O
.015 O
) O
, O
the O
FACT-An B-outcome ['Physiological-Clinical']
Toi O
score O
by O
5.22 O
( O
P O
= O
.009 O
) O
and O
the O
Anaemia-ANS B-outcome ['Physiological-Clinical']
by O
3.76 O
( O
P O
= O
.002 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Basal B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
homeostasis I-outcome ['Physiological-Clinical']
, O
testosterone B-outcome ['Physiological-Clinical']
in O
men O
, O
and O
free O
['Physiological-Clinical', 'Physiological-Clinical']

0.4 O
; O
p O
= O
0.04 O
) O
and O
SILS O
patients O
reported O
better O
scars O
( O
score O
18.4 O
? O
[]

The O
majority O
of O
men O
had O
severe O
erectile O
dysfunction O
. O
[]

The O
results O
were O
related O
to O
the O
capsulorhexis O
position O
, O
which O
was O
assessed O
with O
a O
retroillumination O
photograph O
. O
[]

Amphotericin O
also O
brought O
about O
quicker O
abatement B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
and O
more O
complete B-outcome ['Physiological-Clinical']
spleen I-outcome ['Physiological-Clinical']
regression I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Netilmicin O
versus O
tobramycin O
in O
multi-centre O
studies O
. O
[]

This O
study O
compared O
the O
learning O
impact O
on O
senior O
medical O
students O
of O
a O
purpose-built O
e-learning O
module O
on O
leukaemia O
, O
compared O
with O
existing O
online O
resources O
. O
[]

0.23 O
( O
SD O
) O
IU/mL O
for O
tinzaparin O
and O
0.62 O
? O
[]

Multivariate O
analysis O
demonstrated O
that O
mesangial B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
proliferation I-outcome ['Physiological-Clinical']
and O
matrix O
scores O
were O
highest O
in O
those O
patients O
with O
more O
rapidly O
progressive O
disease O
. O
['Physiological-Clinical']

Family O
economic O
empowerment O
and O
mental O
health O
among O
AIDS-affected O
children O
living O
in O
AIDS-impacted O
communities O
: O
evidence O
from O
a O
randomised O
evaluation O
in O
southwestern O
Uganda O
. O
[]

A O
total O
of O
256 O
patients O
( O
12 O
% O
) O
in O
the O
placebo O
group O
died B-outcome ['Mortality']
compared O
with O
182 O
( O
8 O
% O
) O
in O
the O
simvastatin O
group O
, O
a O
risk O
reduction O
of O
30 O
% O
( O
p O
= O
0.0003 O
) O
attributable O
to O
a O
42 O
% O
reduction O
in O
the O
risk O
of O
coronary O
death O
. O
['Mortality']

Our O
aim O
was O
to O
compare O
the O
effects O
of O
long O
multidisciplinary O
group O
education O
with O
a O
short O
nurse-based O
group O
education O
with O
regard O
to O
symptoms O
, O
knowledge O
, O
quality O
of O
life O
, O
and O
satisfaction O
with O
the O
intervention O
in O
IBS O
patients O
. O
[]

Nine O
women O
( O
group O
4 O
, O
controls O
) O
underwent O
manual O
removal O
of O
the O
retained O
placenta O
. O
[]

METHODS O
This O
was O
a O
24-week O
, O
randomized O
, O
double-blind O
, O
parallel O
group O
, O
multi-center O
study O
. O
[]

The O
study O
compared O
the O
effect O
of O
music O
training O
, O
speech O
training O
and O
no-training O
on O
the O
verbal O
production O
of O
children O
with O
Autism O
Spectrum O
Disorders O
( O
ASD O
) O
. O
[]

The O
experimental O
group O
was O
significantly O
older O
than O
the O
control O
group O
. O
[]

Nonsteroidal O
antiinflammatory O
drugs O
may O
affect O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
in O
hypertensive O
patients O
receiving O
drug O
treatment O
, O
but O
data O
on O
the O
effects O
of O
low-dose O
aspirin O
are O
scanty O
. O
['Physiological-Clinical']

In O
the O
halothane O
group O
, O
there O
was O
a O
significant O
increase O
of O
the O
mean O
cortisol B-outcome ['Physiological-Clinical']
and O
glucose B-outcome ['Physiological-Clinical']
levels O
after O
the O
start O
of O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Increased O
cortisol B-outcome ['Physiological-Clinical']
levels O
were O
seen O
in O
PHDC+ O
patients O
off O
GH O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Across O
time O
, O
children O
moved O
across O
diagnostic O
boundaries O
both O
in O
terms O
of O
clinical O
diagnosis O
and O
in O
terms O
of O
instrument O
diagnosis O
on O
the O
Autism B-outcome ['Life-Impact']
Diagnostic I-outcome ['Life-Impact']
Interview-Revised O
( O
ADI-R O
) O
. O
['Life-Impact']

PURPOSE O
To O
compare O
the O
microbiologic O
yields O
and O
complication O
rates O
associated O
with O
vitreous O
needle O
tap O
and O
vitreous O
biopsy O
in O
the O
Endophthalmitis O
Vitrectomy O
Study O
( O
EVS O
) O
. O
[]

Activity O
in O
parts O
of O
the O
human B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
has O
been O
shown O
to O
correlate O
with O
the O
complexity O
of O
performed O
motor O
sequences O
in O
terms O
of O
the O
number O
of O
limbs O
moved O
, O
number O
of O
movements O
, O
and O
number O
of O
trajectories O
. O
['Physiological-Clinical']

Practice O
makes O
improvement O
: O
how O
adults O
with O
autism O
out-perform O
others O
in O
a O
naturalistic O
visual O
search O
task O
. O
[]

The O
effects O
of O
desensitizer O
, O
disinfectant O
, O
saliva O
, O
blood O
, O
and O
hydrogen O
peroxide O
on O
the O
tensile B-outcome ['Life-Impact']
bond I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
between O
adhesive O
and O
ceramic O
as O
well O
as O
between O
adhesive O
and O
dentin O
were O
examined O
. O
['Life-Impact']

This O
preliminary O
study O
was O
designed O
to O
a O
) O
test O
the O
feasibility O
of O
two O
strategies O
for O
maintaining O
subject O
blinding O
to O
non-verbal O
communication O
of O
compassion O
( O
NVCC O
) O
, O
and O
b O
) O
determine O
whether O
blinded O
subjects O
would O
experience O
psychophysiologic O
effects O
from O
NVCC O
. O
[]

CONCLUSIONS O
The O
current O
analysis O
showed O
that O
fulvestrant O
was O
similar O
to O
anastrozole O
with O
respect O
to O
overall O
survival O
in O
the O
second-line O
treatment O
of O
postmenopausal O
women O
with O
advanced O
breast O
carcinoma O
. O
[]

When O
participants O
make O
judgments O
about O
the O
onset O
of O
self-initiated O
movements O
they O
typically O
report O
the O
movement O
occurred O
earlier O
than O
it O
had O
[ O
Obhi O
, O
S. O
S. O
, O
& O
Haggard O
, O
P. O
( O
2004 O
) O
. O
[]

The O
trial O
was O
not O
designed O
to O
have O
sufficient O
power O
to O
detect O
a O
difference O
between O
the O
2 O
consultative O
modes O
: O
telemedicine O
and O
telephone-only O
. O
[]

Participants O
were O
randomly O
assigned O
to O
either O
active O
rTMS O
treatment O
or O
wait-list O
( O
WTL O
) O
groups O
. O
[]

Of O
576 O
patients O
with O
non-Q-wave O
acute O
myocardial O
infarction O
enrolled O
in O
the O
Diltiazem O
Reinfarction O
Study O
, O
246 O
( O
43 O
% O
) O
had O
1 O
or O
more O
episodes O
of O
angina O
at O
rest O
or O
with O
minimal O
effort O
during O
10.5 O
days O
of O
treatment O
with O
either O
diltiazem O
( O
90 O
mg O
every O
6 O
hours O
) O
or O
placebo O
. O
[]

The O
effectiveness O
of O
Picture O
Exchange O
Communication O
System O
( O
PECS O
) O
training O
for O
teachers O
of O
children O
with O
autism O
: O
a O
pragmatic O
, O
group O
randomised O
controlled O
trial O
. O
[]

This O
study O
has O
been O
submitted O
for O
registration O
with O
ClinicalTrials.gov O
, O
number O
1839IL/709 O
. O
[]

Four O
patients O
died O
without O
further O
therapy O
for O
HCL B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Position O
of O
anterior O
capsulorhexis O
and O
posterior O
capsule O
opacification O
. O
[]

Fenofibrate O
caused O
a O
significant O
decrease O
in O
serum B-outcome ['Physiological-Clinical']
triglyceride I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
associated O
with O
a O
decrease O
in O
plasma B-outcome ['Physiological-Clinical']
malondialdehyde I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
and O
an O
increase O
in O
plasma B-outcome ['Physiological-Clinical']
PAI-1 I-outcome ['Physiological-Clinical']
( O
P O
< O
0.05 O
) O
and O
P-selectin B-outcome ['Physiological-Clinical']
( O
P O
< O
0.05 O
) O
concentrations O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
, O
prospective O
trial O
was O
designed O
to O
compare O
direct O
trocar O
insertion O
with O
prior O
peritoneal O
insufflation O
with O
a O
Verres O
needle O
for O
laparoscopic O
tubal O
sterilization O
. O
[]

Comparison O
of O
epidural O
tramadol-ropivacaine O
and O
fentanyl-ropivacaine O
for O
labor O
analgesia O
: O
a O
prospective O
randomized O
study O
. O
[]

Each O
time O
period O
was O
tested O
repeatedly O
against O
the O
baseline O
; O
an O
overall O
P O
value O
was O
assigned O
for O
each O
reported O
symptom O
. O
[]

Interventions O
directed O
at O
the O
distal O
tibiofibular O
joint O
acutely O
increase O
soleus B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Between O
baseline O
and O
the O
day O
before O
surgery O
, O
both O
preoperatively O
fed O
groups O
revealed O
a O
positive O
change O
for O
the O
dimensions O
physical O
and O
emotional B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
and O
dyspnea B-outcome ['Physiological-Clinical']
( O
with O
significance O
in O
group O
II O
, O
P=0.050,0.031,0.045 O
respectively O
) O
. O
['Life-Impact', 'Physiological-Clinical']

In O
a O
randomized O
study O
, O
twenty-two O
youth O
, O
ages O
16-19 O
, O
were O
evaluated O
during O
two O
employment O
interviews O
. O
[]

The O
purposes O
include O
also O
analysing O
the O
potential O
effects O
of O
changes O
in O
physical O
activity O
on O
productivity B-outcome ['Life-Impact']
at I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
and O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
, O
and O
healthcare B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
['Life-Impact', 'Life-Impact', 'Resource-use']

Of O
those O
seen O
by O
telemedicine O
, O
61 O
% O
were O
registered O
with O
an O
urban O
practice O
, O
compared O
with O
71 O
% O
of O
those O
seen O
conventionally O
. O
[]

Owing O
to O
its O
efficacy O
, O
added O
to O
high O
availability O
and O
low O
cost O
, O
this O
compound O
should O
be O
considered O
a O
first-line O
treatment O
of O
this O
disorder O
in O
this O
country O
, O
and O
perhaps O
in O
other O
countries O
where O
this O
condition O
presents O
in O
a O
similar O
way O
. O
[]

At O
6 O
months O
, O
3 O
% O
, O
4 O
% O
, O
and O
13 O
% O
of O
patients O
died O
in O
low- O
, O
medium- O
, O
and O
high-risk O
groups O
, O
respectively O
. O
[]

The O
majority O
of O
patients O
had O
a O
history O
of O
documented O
remote O
myocardial O
infarction O
and O
congestive O
heart O
failure O
New O
York O
Heart O
Association O
class O
II O
or O
III O
. O
[]

03 O
; O
tolerated O
full B-outcome ['Life-Impact']
milk I-outcome ['Life-Impact']
feeds I-outcome ['Life-Impact']
( O
165 O
ml/kg/day O
) O
earlier O
, O
mean O
difference O
-11.2 O
( O
CI O
-19 O
, O
-3 O
) O
days O
, O
p O
= O
0.03 O
; O
reduced O
requirement O
for O
supplemental B-outcome ['Resource-use']
oxygen I-outcome ['Resource-use']
, O
mean O
difference O
-22.4 O
( O
CI-41.5 O
, O
-3.3 O
) O
days O
, O
p O
= O
0.02 O
; O
and O
were O
discharged B-outcome ['Life-Impact']
home I-outcome ['Life-Impact']
earlier O
, O
mean O
difference O
-22.1 O
( O
CI O
-42.1 O
, O
-2.2 O
) O
days O
, O
p O
= O
0.04 O
. O
['Life-Impact', 'Resource-use', 'Life-Impact']

During O
the O
1st O
year O
of O
GH O
replacement O
therapy O
BMD B-outcome ['Physiological-Clinical']
decreased O
, O
followed O
by O
a O
continuous O
increase O
in O
BMD B-outcome ['Physiological-Clinical']
( O
about O
12 O
% O
) O
up O
to O
60 O
months O
which O
remained O
unchanged O
thereafter O
, O
building O
up O
a O
plateau O
. O
['Physiological-Clinical', 'Physiological-Clinical']

At O
the O
same O
time O
, O
obvious O
cell B-outcome ['Physiological-Clinical']
apoptosis I-outcome ['Physiological-Clinical']
was O
found O
in O
the O
treated O
group O
, O
the O
apoptosis B-outcome ['Physiological-Clinical']
rate O
of O
which O
was O
significantly O
higher O
than O
that O
in O
the O
control O
group O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
response O
to O
increasing O
doses O
of O
angiotensin O
II O
was O
measured O
using O
venous O
occlusion O
plethysmography O
at O
the O
beginning O
of O
the O
study O
and O
at O
the O
end O
of O
each O
2 O
week O
treatment O
period O
. O
['Physiological-Clinical']

Cost-effectiveness O
data O
are O
similarly O
in O
accord O
with O
giving O
high O
priority O
to O
the O
treatment O
of O
older O
individuals O
with O
hypertension O
. O
['Resource-use']

Three O
patients O
had O
ischemic O
heart O
disease O
, O
13 O
had O
dilated O
cardiomyopathy O
, O
and O
three O
had O
valvular O
disease O
; O
16 O
patients O
were O
in O
New O
York O
Heart O
Association O
class O
II O
, O
and O
three O
patients O
were O
in O
New O
York O
Heart O
Association O
class O
III O
. O
[]

PTF O
administration O
is O
effective O
in O
reducing O
proteinuria B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
NAG I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
in O
these O
patients O
. O
['Physiological-Clinical']

Clonidine O
( O
2.5 O
or O
5.0 O
microg/kg O
) O
was O
administered O
orally O
90 O
min O
before O
the O
induction O
of O
anesthesia O
in O
the O
Clonidine O
groups O
. O
[]

The O
radiographs O
were O
analyzed O
by O
subtraction O
radiography O
. O
[]

In O
the O
event O
of O
an O
adverse O
reaction O
, O
application O
of O
imiquimod O
was O
reduced O
to O
1 O
or O
2 O
times O
per O
week O
. O
[]

METHODS/DESIGN O
This O
study O
is O
a O
multicenter O
, O
randomized O
, O
active-controlled O
trial O
with O
two O
parallel O
arms O
. O
[]

Two O
surgeons O
performed O
all O
operations O
in O
a O
standardized O
way O
. O
[]

Renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
assessed O
by O
measurement O
of O
the O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
single O
bolus O
51Cr-EDTA O
technique O
) O
and O
by O
the O
urinary B-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
radioimmunoassay I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
study O
group O
children O
received O
the O
standard O
school O
dental O
screening O
and O
the O
dental B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
of O
those O
with O
a O
positive O
screening O
result O
was O
assessed O
after O
2 O
months O
by O
means O
of O
a O
questionnaire O
issued O
to O
the O
children O
's O
parents O
. O
['Life-Impact']

vaccination O
with O
0.1 O
ml O
compared O
to O
1.0 O
ml O
i.m O
. O
[]

There O
were O
statistically O
significant O
differences O
in O
terms O
of O
the O
resolution B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
associated I-outcome ['Physiological-Clinical']
local I-outcome ['Physiological-Clinical']
and/or I-outcome ['Physiological-Clinical']
systemic I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Results O
In O
multivariate O
analyses O
that O
adjusted O
for O
all O
markers O
and O
treatment O
covariates O
, O
MDM2 B-outcome ['Physiological-Clinical']
overexpression B-outcome ['Physiological-Clinical']
was O
significantly O
related O
to O
DM B-outcome ['Physiological-Clinical']
( O
P O
= O
.02 O
) O
and O
OM O
( O
P O
= O
.003 O
) O
, O
and O
Ki-67 O
overexpression O
was O
significantly O
related O
to O
DM B-outcome ['Physiological-Clinical']
( O
P O
< O
.0001 O
) O
, O
CSM B-outcome ['Mortality']
( O
P O
= O
.0007 O
) O
, O
and O
OM B-outcome ['Mortality']
( O
P O
= O
.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Mortality']

Patients O
were O
assessed O
at O
baseline O
and O
after O
2 O
, O
4 O
, O
6 O
, O
8 O
and O
10 O
weeks O
of O
starting O
medication O
. O
[]

METHODS O
Prospective O
analyses O
were O
conducted O
with O
baseline O
and O
12-month O
assessments O
from O
a O
randomized O
controlled O
trial O
to O
promote O
improved O
diet B-outcome ['Life-Impact']
, O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
, O
and O
sedentary B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
( O
experimental O
condition O
) O
or O
SUN B-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
( O
comparison O
condition O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSION O
We O
conclude O
that O
CCRT O
is O
superior O
to O
RT O
alone O
for O
patients O
with O
advanced O
NPC O
in O
endemic O
areas O
. O
[]

Four O
of O
the O
six O
patients O
who O
had O
a O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
during O
a O
reactivation O
of O
their O
disease O
were O
in O
the O
heparin O
group O
. O
['Physiological-Clinical']

PATIENTS O
Forty-eight O
patients O
having O
IVF O
for O
the O
first O
time O
were O
randomized O
between O
the O
two O
protocols O
. O
[]

DESIGN O
, O
SETTING O
, O
AND O
PARTICIPANTS O
According O
to O
a O
randomized O
double-blind O
design O
, O
11 O
healthy O
subjects O
( O
controls O
) O
and O
12 O
hypertensive O
inpatients O
( O
mean O
age O
, O
38.9 O
and O
40.4 O
yr O
, O
respectively O
) O
received O
1-h O
iv O
infusion O
of O
beta-endorphin O
( O
250 O
mug/h O
) O
and O
, O
on O
another O
occasion O
, O
the O
same O
infusion O
protocol O
preceded O
by O
the O
opioid O
antagonist O
naloxone O
( O
8 O
mg O
) O
. O
[]

Thus O
, O
greater O
antiarrhythmic B-outcome ['Physiological-Clinical']
efficacy O
can O
be O
achieved O
by O
the O
invasive O
approach O
to O
drug O
selection O
without O
increasing O
total O
hospital B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

We O
conclude O
that O
the O
extent O
of O
the O
necrotic B-outcome ['Physiological-Clinical']
portion I-outcome ['Physiological-Clinical']
ascertain O
by O
this O
method O
is O
a O
major O
predictor O
of O
future O
collapse O
. O
['Physiological-Clinical']

The O
highest O
percentage O
of O
teeth B-outcome ['Physiological-Clinical']
showing I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
alveolar I-outcome ['Physiological-Clinical']
crest I-outcome ['Physiological-Clinical']
by O
the I-outcome ['Physiological-Clinical']
loop O
technique O
was O
97.8 O
% O
in O
the O
mandibular O
second O
premolar O
and O
first O
molar O
. O
['Physiological-Clinical']

It O
has O
been O
suggested O
that O
this O
treatment O
may O
increase O
neuropsychological O
syndromes O
and O
brain O
abnormalities O
indicated O
by O
computed O
tomography O
scans O
. O
[]

Patients O
with O
tobacco-related O
cancers O
and O
female O
patients O
reported O
significantly O
higher O
levels O
of O
depression B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
( O
p O
< O
0.05 O
) O
, O
which O
proved O
predictive O
of O
smoking B-outcome ['Life-Impact']
relapse I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

No O
effect O
of O
beta-carotene O
supplementation O
on O
the O
susceptibility O
of O
low O
density O
lipoprotein O
to O
in O
vitro B-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
among O
hypercholesterolaemic O
, O
postmenopausal O
women O
. O
['Physiological-Clinical']

Breakdown O
of O
disease B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
was O
7.8 O
% O
stage O
III O
, O
22.8 O
% O
stage O
IV O
, O
and O
69.4 O
% O
recurrent O
disease O
. O
['Physiological-Clinical']

We O
propose O
a O
pragmatic O
approach O
to O
the O
correction O
or O
amelioration O
of O
venous O
hypertension O
resulting O
from O
hydrodynamic O
and O
hydrostatic O
venous O
reflux O
. O
[]

In O
response O
to O
the O
therapist O
's O
interpersonal O
demands O
, O
'compliant O
( O
positive O
) O
responses B-outcome ['Physiological-Clinical']
' O
were O
observed O
more O
in O
music O
therapy O
than O
in O
toy O
play O
sessions O
, O
and O
'no O
responses B-outcome ['Physiological-Clinical']
' O
were O
twice O
as O
frequent O
in O
toy O
play O
sessions O
as O
in O
music O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
risperidone O
high-dose O
group O
had O
the O
greatest O
mean O
improvement O
in O
sleep O
visual O
analog O
scale O
( O
24.6 O
) O
. O
[]

The O
control O
condition O
included O
a O
classroom O
task O
not O
preceded O
by O
exercise O
. O
[]

After O
stratification O
according O
to O
staging O
and O
initial O
treatment O
, O
one-third O
of O
the O
patients O
received O
chemotherapy O
for O
2 O
years O
( O
methotrexate O
400 O
mg O
followed O
by O
citrovorum O
factor O
100 O
mg O
+ O
bleomycin O
60 O
mg/week O
, O
during O
the O
first O
15 O
weeks O
) O
, O
one-third O
of O
the O
patients O
received O
immunotherapy O
with O
weekly O
C. O
parvum O
injections O
during O
2 O
years O
, O
while O
the O
remaining O
third O
did O
not O
receive O
any O
treatment O
. O
[]

RESULTS O
Our O
prospective O
cohort O
demonstrated O
significant O
success O
in O
80 O
% O
of O
patients O
with O
persistent O
epistaxis O
, O
who O
would O
have O
otherwise O
been O
taken O
to O
the O
operating O
theatre O
, O
avoiding O
the O
need O
for O
further O
surgical B-outcome ['Resource-use']
intervention I-outcome ['Resource-use']
. O
['Resource-use']

In O
the O
last O
protocol O
including O
56 O
patients O
and O
addressed O
to O
severe O
PAN O
without O
HBV O
markers O
or O
CSS O
we O
have O
shown O
that O
PE O
did O
not O
improve O
the O
prognosis O
and O
control O
of O
the O
disease B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Longitudinal O
follow-up O
of O
children O
with O
autism O
receiving O
targeted O
interventions O
on O
joint O
attention O
and O
play O
. O
[]

CONCLUSIONS O
Adequate O
supplement O
of O
potassium O
and O
calcium O
in O
daily O
table O
salt O
intake O
was O
an O
effective O
way O
to O
prevent O
form O
hypertension B-outcome ['Physiological-Clinical']
and O
could O
promote O
their O
urinary B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
and O
reduction O
of O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
adolescents O
with O
higher O
blood O
pressure O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Counselling O
by O
health O
nurses O
is O
helpful O
in O
managing O
postnatal O
depression O
and O
seems O
to O
work O
well O
within O
the O
Swedish O
Primary O
Health O
Care O
system O
. O
[]

It O
has O
been O
postulated O
that O
RTD O
may O
prevent O
the O
rapid O
development O
of O
collateral O
circulation O
and O
increase O
the O
production O
of O
oxygen-derived B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
radicals I-outcome ['Physiological-Clinical']
, O
which O
may O
be O
the O
responsible O
factors O
for O
the O
ischemic O
treatment O
of O
hepatic O
tumours O
. O
['Physiological-Clinical']

RESULT O
In O
phase O
1 O
, O
compared O
to O
the O
pharmacotherapy B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
of O
patients O
with O
lower O
DA O
scores O
, O
the O
response O
for O
patients O
with O
higher O
DA O
scores O
was O
steeper O
, O
but O
leveled O
off O
toward O
the O
end O
of O
the O
phase O
. O
['Physiological-Clinical']

Measurements O
of O
bone B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
carried O
out O
by O
photon O
absorption O
at O
the O
end O
of O
12 O
months O
showed O
a O
5.5 O
% O
increase O
in O
the O
distal B-outcome ['Physiological-Clinical']
radius I-outcome ['Physiological-Clinical']
in O
group O
2 O
( O
P O
= O
0.0001 O
) O
and O
a O
7.1 O
% O
increase O
in O
group O
3 O
( O
P O
= O
0.0001 O
) O
, O
while O
in O
group O
1 O
mineral O
content O
had O
decreased O
by O
4.3 O
% O
( O
nonsignificant O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

During O
6 O
months O
of O
treatment O
, O
follicular B-outcome ['Physiological-Clinical']
development I-outcome ['Physiological-Clinical']
was O
measured O
by O
vaginal O
ultrasonography O
and O
ovulation B-outcome ['Physiological-Clinical']
was O
indicated O
by O
serum O
progesterone O
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

With O
a O
cosmesis B-outcome ['Life-Impact']
and O
safety O
profile O
that O
is O
similar O
to O
that O
of O
conventional O
suture O
technique O
, O
it O
avoids O
the O
drawbacks O
inherent O
to O
suture O
knots O
. O
['Life-Impact']

High-preference O
stimuli O
consistently O
functioned O
as O
reinforcers O
for O
all O
4 O
clients O
. O
[]

PARTICIPANTS O
37 O
otherwise O
healthy O
children O
aged O
2 O
to O
12 O
years O
with O
acute O
, O
intercurrent O
, O
febrile O
illness O
. O
[]

The O
series O
consisted O
of O
300 O
patients O
with O
C4 O
CVI O
, O
119 O
patients O
with O
C5 O
CVI O
, O
and O
413 O
patients O
with O
C6 O
CVI O
. O
[]

Either O
fenoterol O
( O
5 O
mg O
) O
or O
a O
placebo O
was O
given O
orally O
2 O
h O
before O
loading O
in O
a O
randomized O
double-blind O
crossover O
protocol O
. O
[]

The O
number O
of O
lymphocyte B-outcome ['Physiological-Clinical']
subpopulations I-outcome ['Physiological-Clinical']
was O
determined O
by O
flow O
cytometry O
, O
and O
serum B-outcome ['Physiological-Clinical']
interleukin-6 I-outcome ['Physiological-Clinical']
and O
C-reactive O
protein B-outcome ['Physiological-Clinical']
levels O
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Most O
subjects O
also O
found O
the O
ABAK O
bottles O
convenient O
. O
[]

Patients O
undergoing O
various O
anterior O
segment O
surgery O
were O
randomly O
assigned O
to O
sub-Tenon O
's O
or O
retrobulbar O
anesthesia O
; O
300 O
were O
operated O
with O
1-quadrant O
sub-Tenon O
's O
anesthesia O
( O
1-QST O
) O
and O
the O
results O
were O
compared O
with O
270 O
patients O
operated O
with O
retrobulbar O
anesthesia O
. O
[]

Twelve O
nonsmoking O
healthy O
subjects O
took O
part O
in O
a O
prospective O
double-blind O
placebo O
control O
study O
. O
[]

CONCLUSION O
We O
conclude O
that O
chronic O
allergen O
exposure O
induces O
inflammatory O
changes O
in O
the O
bronchial O
mucosa O
. O
[]

Program O
effects O
for O
positive O
affect O
, O
depression B-outcome ['Life-Impact']
, O
and O
anxiety B-outcome ['Life-Impact']
were O
mediated O
by O
more O
favorable O
change O
over O
time O
in O
social-emotional O
and O
character O
development O
for O
students O
in O
PA O
schools O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
The O
most O
common O
symptoms O
identified O
by O
parents O
were O
tantrums B-outcome ['Life-Impact']
, O
aggression B-outcome ['Life-Impact']
, O
and O
hyperactivity B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Rotational O
angiography O
is O
a O
new O
technique O
which O
involves O
pre-set O
rotation O
of O
the O
X-ray O
tube O
around O
the O
patient O
and O
allows O
visualization O
of O
each O
coronary O
artery O
in O
different O
views O
, O
using O
a O
single O
contrast O
injection O
. O
[]

Nutrient B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
of O
former O
tobacco O
users O
resembled O
that O
of O
nonusers O
rather O
than O
current O
users O
. O
['Life-Impact']

Little O
evidence O
exists O
on O
possible O
predictors O
of O
breastfeeding O
behaviors O
in O
the O
Middle O
East O
. O
[]

Minocycline O
safety O
and O
tolerability B-outcome ['Life-Impact']
in O
Huntington O
disease O
. O
['Life-Impact']

Despite O
this O
expansion O
, O
our O
understanding O
of O
the O
importance O
of O
haptic O
feedback O
during O
laparoscopic O
surgery O
is O
incomplete O
. O
[]

This O
study O
assessed O
the O
effectiveness O
of O
a O
brief O
, O
situation-specific O
, O
group-administered O
preparatory O
intervention O
in O
a O
nonclient O
school O
population O
undergoing O
mass O
inoculation O
against O
rubella O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Arm O
pain B-outcome ['Physiological-Clinical']
measured O
on O
a O
10 O
point B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scale O
. O
['Physiological-Clinical', 'Physiological-Clinical']

UNLABELLED O
Besides O
the O
standard O
method O
of O
anterior O
rhinomanometry O
( O
aR O
) O
, O
the O
impulse-oscillometric O
rhinometry O
( O
IOS O
) O
is O
available O
for O
measurements O
of O
the O
nasal B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PROCEDURES O
Each O
dog O
was O
randomly O
allocated O
to O
receive O
2 O
of O
3 O
treatments O
( O
1-week O
interval O
) O
. O
[]

DESIGN O
Prospective O
, O
randomized O
, O
single-center O
, O
parallel-arm O
, O
controlled O
trial O
. O
[]

In O
the O
AI O
, O
51.9 O
% O
were O
abstinent O
at O
15 O
days O
; O
48.1 O
% O
at O
both O
one O
and O
3 O
months O
; O
25.9 O
% O
at O
6 O
months O
; O
and O
22.2 O
% O
were O
still O
not O
smoking B-outcome ['Life-Impact']
after O
a O
year O
. O
['Life-Impact']

did O
not O
influence O
electrocardiographic O
parameters O
. O
[]

They O
exposed O
participants O
to O
videos O
of O
either O
their O
own O
faces O
( O
self-face O
prime O
) O
or O
faces O
of O
others O
( O
nonself-face O
prime O
) O
prior O
to O
a O
facial O
expression O
judgment O
task O
. O
[]

Between O
February O
2000 O
and O
August O
2004 O
, O
110 O
patients O
after O
LT O
were O
included O
in O
this O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Effect O
of O
vitamin O
D2 O
, O
calcium O
phosphate O
and O
sodium O
fluoride O
administration O
. O
[]

In O
group O
1 O
there O
was O
a O
nonsignificant O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
, O
but O
in O
groups O
2 O
and O
3 O
there O
was O
a O
highly O
significant O
diminution O
in O
pain B-outcome ['Physiological-Clinical']
( O
P O
less O
than O
0.005 O
) O
and O
in O
analgesic B-outcome ['Resource-use']
intake I-outcome ['Resource-use']
( O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

OBJECTIVE O
The O
effects O
of O
a O
6-week O
psychoeducational O
group O
intervention O
on O
the O
distress O
, O
coping O
, O
personal O
growth O
, O
and O
marital O
communication O
of O
wives O
of O
men O
diagnosed O
with O
prostate O
cancer O
were O
evaluated O
using O
a O
randomized O
clinical O
trial O
. O
[]

During O
a O
period O
of O
7.5 O
years O
, O
the O
breast O
hardness O
was O
followed O
up O
, O
and O
at O
the O
end O
of O
the O
study O
patient O
satisfaction O
was O
evaluated O
. O
[]

The O
UKEP O
Study O
Research O
Group O
. O
[]

METHODS O
AND O
RESULTS O
Patients O
with O
ECG O
ST O
segment O
elevation O
who O
presented O
within O
4 O
hours O
of O
symptom O
onset O
, O
had O
no O
contraindication O
to O
thrombolytic O
therapy O
, O
and O
were O
not O
in O
cardiogenic O
shock O
were O
enrolled O
. O
[]

METHODS O
We O
tested O
two O
doses O
of O
the O
CRF O
( O
1 O
) O
antagonist O
R317573 O
for O
effects O
on O
regional B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
rCMglu I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
using O
[ O
( O
18 O
) O
F O
] O
fluoro-2-deoxy-D O
: O
-glucose O
( O
FDG O
) O
positron O
emission O
tomography O
( O
PET O
) O
following O
single-dose O
challenges O
in O
a O
double-blind O
, O
placebo-controlled O
, O
cross-over O
design O
, O
in O
12 O
healthy O
male O
volunteers O
. O
['Physiological-Clinical']

RESULTS O
In O
total O
, O
177 O
( O
out O
of O
755 O
) O
patients O
refused O
randomisation O
, O
including O
31 O
% O
who O
did O
not O
want O
surgery O
and O
22 O
% O
who O
wanted O
surgery O
. O
[]

Post O
hoc O
analysis O
looking O
at O
the O
3 O
core O
symptoms O
of O
autism O
, O
that O
is O
, O
social B-outcome ['Life-Impact']
interaction O
, O
communication B-outcome ['Life-Impact']
, O
and O
stereotyped B-outcome ['Life-Impact']
behaviors B-outcome ['Life-Impact']
, O
revealed O
a O
significant O
improvement O
of O
the O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

BACKGROUND O
Blinding O
trachoma O
, O
caused O
by O
ocular O
infection O
with O
Chlamydia O
trachomatis O
, O
is O
targeted O
for O
global O
elimination O
by O
2020 O
. O
[]

RESULTS O
Relative O
to O
the O
group O
B O
, O
the O
group O
A O
had O
( O
1 O
) O
a O
significant O
decrease O
of O
pain B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
rest I-outcome ['Physiological-Clinical']
at O
the O
end O
of O
8 O
weeks O
of O
the O
treatment O
( O
p O
< O
0.005 O
) O
and O
at O
the O
end O
of O
following O
up O
period O
( O
p O
< O
0.05 O
) O
, O
( O
2 O
) O
a O
significant O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
palpation I-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
isometric I-outcome ['Physiological-Clinical']
testing I-outcome ['Physiological-Clinical']
at O
8 O
weeks O
of O
treatment O
( O
p O
< O
0.05 O
) O
, O
and O
at O
8 O
weeks O
follow-up O
( O
p O
< O
0.001 O
) O
, O
( O
3 O
) O
a O
significant O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
middle I-outcome ['Physiological-Clinical']
finger I-outcome ['Physiological-Clinical']
test I-outcome ['Physiological-Clinical']
at O
the O
end O
of O
8 O
weeks O
of O
treatment O
( O
p O
< O
0.01 O
) O
, O
and O
at O
the O
end O
of O
the O
follow-up O
period O
( O
p O
< O
0.05 O
) O
, O
( O
4 O
) O
a O
significant O
decrease O
of O
pain B-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
grip I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
testing I-outcome ['Physiological-Clinical']
at O
8 O
weeks O
of O
treatment O
( O
p O
< O
0.05 O
) O
, O
and O
at O
8 O
weeks O
follow-up O
( O
p O
< O
0.001 O
) O
, O
( O
5 O
) O
a O
significant O
increase O
in O
the O
wrist B-outcome ['Physiological-Clinical']
range O
of O
motion B-outcome ['Life-Impact']
at O
8 O
weeks O
follow-up O
( O
p O
< O
0.01 O
) O
, O
( O
6 O
) O
an O
increase O
in O
grip B-outcome ['Life-Impact']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

METHODS O
This O
prospective O
study O
was O
performed O
in O
50 O
consecutive O
patients O
. O
[]

RESULTS O
Forty-one O
patients O
were O
entered O
in O
the O
study O
and O
40 O
were O
evaluable O
for O
toxicity B-outcome ['Adverse-effects']
. O
['Adverse-effects']

The O
present O
study O
has O
been O
performed O
to O
assess O
the O
effects O
of O
alinidine O
on O
diastolic O
duration O
during O
exercise O
in O
chronic O
coronary O
artery O
disease O
. O
[]

Usually O
, O
no O
specific O
attention O
is O
given O
to O
them O
and O
they O
are O
considered O
normal O
findings O
. O
[]

Timing O
for O
delivering O
individualized O
patient O
education O
intervention O
to O
Coronary O
Artery O
Bypass O
Graft O
patients O
: O
An O
RCT O
. O
[]

RESULTS O
Median O
PFS B-outcome ['Mortality']
was O
10.9 O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
9.4-12.4 O
] O
months O
. O
['Mortality']

CONCLUSIONS O
Slower O
than O
anticipated O
recruitment O
resulted O
in O
considerably O
fewer O
patients O
than O
planned O
being O
studied O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
assess O
any O
inconsistency O
with O
the O
protocol O
guidelines O
for O
preoperative O
radiotherapy O
for O
rectal O
cancer O
among O
radiotherapy O
institutions O
participating O
in O
the O
framework O
of O
a O
multicentre O
phase-III O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
clinical O
trial O
. O
[]

Leukocyte-depleted O
reperfusion O
has O
been O
shown O
experimentally O
to O
improve O
cardiac B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
after O
cold O
ischemic O
arrest O
. O
['Physiological-Clinical']

All O
drinks O
were O
given O
about O
10 O
min O
before O
the O
start O
of O
the O
procedure O
. O
[]

The O
role O
of O
the O
MA-sensitive O
leukocyte O
chemotaxis O
in O
rheumatoid O
arthritis O
. O
[]

PATIENT O
( O
S O
) O
One O
hundred O
six O
couples O
with O
borderline O
semen O
who O
were O
undergoing O
IVF O
and O
ICSI O
on O
sibling O
oocytes O
. O
[]

In O
all O
individuals O
who O
received O
the O
metronidazole O
, O
there O
was O
a O
significant O
and O
rapid B-outcome ['Physiological-Clinical']
decline I-outcome ['Physiological-Clinical']
and/or I-outcome ['Physiological-Clinical']
disappearance I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
spirochetes I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
plaque I-outcome ['Physiological-Clinical']
during O
the O
time O
interval O
that O
metronidazole O
was O
detectable O
in O
the O
saliva O
. O
['Physiological-Clinical']

CONCLUSIONS O
A O
2-hour O
infusion O
of O
0.1 O
to O
10 O
mg/kg O
ponezumab O
was O
well O
tolerated O
in O
subjects O
with O
mild-to-moderate O
AD O
. O
[]

II O
. O
[]

The O
study O
demonstrated O
a O
cure O
rate O
of O
nearly O
80 O
% O
; O
i.e. O
, O
32 O
% O
of O
the O
women O
could O
restore O
normal O
vaginal O
flora O
and O
47 O
% O
had O
improved O
Nugent O
score O
, O
whereas O
20 O
% O
of O
the O
subjects O
did O
not O
clear O
BV O
in O
the O
first O
follow-up O
( O
after O
8 O
days O
treatment O
) O
. O
[]

The O
primary O
end O
point O
was O
ischemic B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
, O
brain B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
, O
or O
death B-outcome ['Mortality']
from O
vascular O
causes O
other O
than O
stroke B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

No O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
effects O
were O
observed O
related O
to O
['Adverse-effects']

Carotid B-outcome ['Physiological-Clinical']
artery B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
increased O
significantly O
( O
23 O
% O
) O
following O
stretching O
which O
may O
be O
attributed O
to O
a O
reduction O
in O
carotid O
pulse O
pressure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
combination O
treatment O
group O
showed O
a O
trend O
to O
outperform O
other O
active O
treatment O
groups O
, O
with O
fewer O
dropouts O
and O
a O
greater O
proportion O
of O
treatment O
responders O
achieving O
clinically O
significant O
changes O
( O
63.38 O
% O
normative O
sleep O
efficiency O
criterion O
of O
> O
85 O
% O
and O
84.62 O
% O
, O
sleep O
onset O
latency O
< O
30 O
min O
) O
. O
[]

No O
cases O
of O
phase O
separation B-outcome ['Physiological-Clinical']
occurred O
. O
['Physiological-Clinical']

Between O
3 O
and O
6 O
mo O
, O
serum B-outcome ['Physiological-Clinical']
acetate I-outcome ['Physiological-Clinical']
tended O
( O
NS O
) O
to O
decrease O
in O
the O
LF O
group O
( O
from O
69 O
+/- O
4 O
to O
59 O
+/- O
5 O
micromol/L O
) O
and O
increase O
in O
the O
HF O
group O
( O
from O
100 O
+/- O
18 O
to O
107 O
+/- O
17 O
micromol/L O
) O
, O
with O
no O
significant O
change O
in O
the O
MUFA O
group O
. O
['Physiological-Clinical']

OBJECTIVES O
This O
study O
aimed O
to O
determine O
whether O
serial O
autologous O
infusions O
of O
selective O
high-density O
lipoprotein O
( O
HDL O
) O
delipidated O
plasma O
are O
feasible B-outcome ['Life-Impact']
and O
well O
tolerated B-outcome ['Life-Impact']
in O
patients O
with O
acute O
coronary O
syndrome O
( O
ACS O
) O
. O
['Life-Impact', 'Life-Impact']

PFS B-outcome ['Mortality']
was O
significantly O
improved O
in O
the O
sunitinib O
arm O
( O
median O
5.6 O
v O
4.1 O
months O
; O
HR O
, O
0.725 O
; O
95 O
% O
CI O
, O
0.591 O
to O
0.890 O
; O
stratified O
log-rank O
test O
, O
P O
< O
.001 O
) O
. O
['Mortality']

52/36 O
mmHg O
, O
p O
less O
than O
0.001 O
) O
; O
SLN O
was O
able O
to O
reduce O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
90 O
% O
of O
all O
the O
cases O
, O
with O
a O
significant O
reduction O
after O
5 O
min O
. O
( O
['Physiological-Clinical']

Hypericum O
treatment O
of O
mild O
depressions O
with O
somatic O
symptoms O
. O
[]

The O
median O
number O
( O
Q O
( O
1 O
) O
, O
Q O
( O
3 O
) O
range O
) O
of O
active B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
was O
2.0 O
( O
1.38 O
, O
3.96 O
) O
in O
the O
valacyclovir O
treatment O
group O
and O
6.5 O
( O
2.63 O
, O
9.0 O
) O
in O
the O
placebo O
treatment O
group O
. O
['Physiological-Clinical']

Studies O
have O
suggested O
that O
pethidine O
provides O
little O
pain O
relief O
in O
labour O
and O
has O
a O
number O
of O
side O
effects O
affecting O
mother O
and O
neonate O
. O
[]

Effect O
of O
flurbiprofen O
sodium O
on O
pupillary B-outcome ['Physiological-Clinical']
dilatation I-outcome ['Physiological-Clinical']
during O
scleral O
buckling O
surgery O
. O
['Physiological-Clinical']

These O
results O
replicate O
the O
findings O
in O
our O
preliminary O
open-label O
study O
. O
[]

On O
the O
basis O
of O
the O
presence O
and O
dose O
intensity O
of O
the O
included O
agents O
, O
we O
hypothesised O
that O
PELF O
would O
be O
superior O
to O
FAMTX O
. O
[]

Point-prevalence O
abstinence B-outcome ['Life-Impact']
rates O
at O
7 O
weeks O
were O
36.4 O
% O
versus O
20.8 O
% O
( O
OR O
= O
2.52 O
, O
p O
= O
.001 O
) O
, O
respectively O
; O
and O
continuous B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
rates O
from O
weeks O
4 O
to O
7 O
were O
31.5 O
% O
versus O
19.2 O
% O
( O
OR O
= O
1.94 O
, O
p O
= O
.023 O
) O
, O
respectively O
. O
['Life-Impact', 'Life-Impact']

Analyses O
were O
done O
per O
protocol O
. O
[]

A O
detailed O
description O
of O
clinical O
and O
laboratory O
characteristics O
of O
the O
diseases O
is O
presented O
. O
[]

Effect O
of O
the O
dietary O
approaches O
to O
stop O
hypertension O
diet O
and O
reduced O
sodium O
intake O
on O
blood O
pressure O
control O
. O
[]

Thrombin-antithrombin B-outcome ['Physiological-Clinical']
III B-outcome ['Physiological-Clinical']
complex I-outcome ['Physiological-Clinical']
, O
fibrinogen B-outcome ['Physiological-Clinical']
degradation I-outcome ['Physiological-Clinical']
product O
and O
tissue B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Preoperatively O
, O
patients O
were O
provided O
a O
sensory O
impairment O
score O
using O
a O
three-level O
drop-out O
clinical O
neurosensory O
test O
( O
NST O
) O
, O
and O
blind O
comparisons O
were O
made O
with O
the O
surgical O
findings O
postoperatively O
. O
[]

The O
results O
provide O
a O
rationale O
for O
the O
continuing O
use O
of O
risperidone O
beyond O
6 O
months O
, O
although O
considerable O
weight O
gain O
can O
limit O
the O
use O
of O
this O
agent O
. O
[]

Control O
patients O
did O
not O
develop O
cotton B-outcome ['Physiological-Clinical']
wool I-outcome ['Physiological-Clinical']
spots I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Four O
of O
the O
10 O
CAHB O
patients O
received O
combined O
prednisolone/interferon-alpha2b O
( O
IFN-alpha2b O
) O
therapy O
. O
[]

Upregulation O
of O
endogenous O
synthesis O
of O
the O
major O
protein O
on O
HDL O
particles O
, O
apolipoprotein O
A-I O
( O
apoA-I O
) O
, O
represents O
a O
novel O
approach O
to O
generation O
of O
new O
HDL O
particles O
. O
[]

PROCEDURE O
After O
tooth O
scaling O
and O
root O
planing O
, O
2 O
treatment O
, O
1 O
placebo O
, O
and O
1 O
control O
site O
were O
selected O
for O
each O
dog O
. O
[]

[ O
The O
application O
of O
naphcon O
eye O
drops O
during O
Lasik O
surgery O
] O
. O
[]

The O
most O
common O
grade O
3-4 O
toxicities O
were O
infection O
( O
five O
of O
60 O
patients O
in O
the O
zoledronic O
acid O
group O
and O
six O
of O
59 O
in O
the O
control O
group O
) O
and O
thrombosis O
( O
five O
of O
60 O
in O
the O
zoledronic O
acid O
and O
two O
of O
59 O
in O
the O
control O
group O
) O
. O
[]

Antifungal O
prophylaxis O
during O
remission O
induction O
therapy O
for O
acute O
leukemia O
fluconazole O
versus O
intravenous O
amphotericin O
B O
. O
[]

Garlic O
and O
onion O
have O
a O
significant O
protective O
action O
against O
fat-induced B-outcome ['Physiological-Clinical']
increases O
in O
serum O
cholesterol B-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
fibrinogen I-outcome ['Physiological-Clinical']
and O
decreases O
in O
coagulation O
time O
and O
fibrinolytic O
activity O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
patients O
received O
dexamethasone O
24 O
mg O
days O
1-7 O
, O
melphalan O
30 O
mg/m2 O
day O
3 O
, O
BCNU O
60 O
mg/m2 O
day O
3 O
, O
etoposide O
75 O
mg/m2 O
days O
4-7 O
, O
Ara-C O
100 O
mg/m2 O
twice O
daily O
days O
4-7 O
( O
Dexa-BEAM O
) O
. O
[]

Adenosinergic O
mechanisms O
contribute O
to O
individual O
differences O
in O
sleep O
deprivation-induced O
changes O
in O
neurobehavioral O
function O
and O
brain O
rhythmic O
activity O
. O
[]

Naltrexone O
in O
autistic O
children O
: O
behavioral O
symptoms O
and O
attentional O
learning O
. O
[]

Church-based O
programs O
may O
be O
more O
effective O
if O
they O
are O
spiritually O
based O
in O
nature O
. O
[]

We O
recruited O
patients O
from O
primary-care O
practices O
and O
hospitals O
. O
[]

The O
study O
was O
randomized O
and O
double O
blinded O
. O
[]

It O
offers O
the O
possibility O
to O
provide O
context-sensitive O
information O
independently O
of O
the O
user O
's O
location O
and O
position O
. O
[]

CONCLUSIONS O
Long-term O
, O
high-dose O
DHA O
supplementation O
to O
patients O
with O
XLRP O
was O
associated O
with O
limited O
safety O
risks O
in O
this O
4-year O
trial O
. O
[]

OBJECTIVE O
To O
assess O
the O
usefulness B-outcome ['Life-Impact']
of O
the O
ultrashort O
regimen O
of O
gonadotropin-releasing O
hormone O
agonist O
( O
GnRH-a O
) O
in O
ovulation O
induction O
in O
an O
in O
vitro O
fertilization O
( O
IVF O
) O
program O
. O
['Life-Impact']

OBJECTIVE O
The O
primary O
aim O
of O
the O
study O
was O
to O
compare O
the O
effectiveness O
of O
group O
and O
individual O
cognitive O
behaviour O
therapy O
( O
CBT O
) O
for O
obsessive O
compulsive O
disorder O
( O
OCD O
) O
. O
[]

In O
the O
active O
rTMS O
group O
, O
ten O
sessions O
with O
a O
total O
of O
10,000 O
stimuli O
were O
applied O
over O
the O
left O
dorsolateral O
prefrontal O
cortex O
at O
110 O
% O
of O
motor O
threshold O
. O
[]

Pharmacokinetic-pharmacodynamic O
relationship O
of O
rocuronium O
under O
stable O
nitrous O
oxide-fentanyl O
or O
nitrous O
oxide-sevoflurane O
anesthesia O
in O
children O
. O
[]

Keihanshin O
Study O
Group O
of O
Hematological O
Malignancies O
. O
[]

RESULTS O
Thirty O
patients O
started O
with O
venlafaxine O
and O
30 O
with O
clonidine O
. O
[]

Long-term O
effects O
of O
choline O
on O
productive B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
egg I-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
of O
brown-egg O
laying O
hens O
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
bicarbonate I-outcome ['Physiological-Clinical']
levels O
and O
arterial B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
were O
significantly O
higher O
after O
3 O
mo O
of O
bicarbonate B-outcome ['Physiological-Clinical']
PD I-outcome ['Physiological-Clinical']
( O
24.6 O
+/- O
2.3 O
mM O
and O
7.43 O
+/- O
0.06 O
, O
respectively O
) O
, O
compared O
with O
lactate B-outcome ['Physiological-Clinical']
PD I-outcome ['Physiological-Clinical']
( O
22.8 O
+/- O
3.9 O
mM O
and O
7.38 O
+/- O
0.05 O
, O
respectively O
; O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
was O
more O
pronounced O
during O
the O
more O
painful O
second O
pass O
. O
[]

[ O
Evaluating O
an O
interactive O
, O
multi-media O
learning O
system O
for O
the O
study O
of O
primary O
open O
angle O
glaucoma O
] O
. O
[]

Fifty-six O
were O
for O
intermittent O
claudication O
, O
14 O
for O
ischaemic O
rest O
pain O
, O
and O
13 O
for O
non-healing O
ulcers O
. O
[]

While O
prevalence O
of O
OA O
is O
higher O
among O
blacks O
than O
whites O
, O
TKR O
rates O
are O
lower O
among O
blacks O
. O
[]

Mean O
log B-outcome ['Physiological-Clinical']
CFU I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
Gram I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
- I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
bacteria I-outcome ['Physiological-Clinical']
did O
not O
change O
in O
treated O
infants O
weighing O
less O
than O
1500 O
g. O
However O
, O
Gram B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
mean O
log O
CFU B-outcome ['Physiological-Clinical']
showed O
a O
significant O
increase O
on O
day O
21 O
( O
6.1 O
+/- O
0.9 O
) O
compared O
with O
day O
0 O
( O
3.5 O
+/- O
0.9 O
) O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Therapy O
was O
well O
tolerated B-outcome ['Life-Impact']
at O
all O
dose O
levels O
and O
schedules O
, O
with O
most O
patients O
( O
98 O
% O
) O
experiencing O
mild-to-moderate B-outcome ['Physiological-Clinical']
constitutional I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

0.07 O
mg/dl O
, O
P O
< O
0.001 O
) O
, O
and O
creatinine O
clearance O
( O
?SEM O
; O
Nankivell O
method O
) O
was O
significantly O
higher O
( O
57.8 O
? O
[]

The O
difference O
in O
stricture B-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
was O
significant O
in O
small O
as O
well O
as O
large O
esophagi O
. O
['Physiological-Clinical']

A O
low O
remission B-outcome ['Physiological-Clinical']
rate O
was O
observed O
in O
subjects O
who O
had O
previously O
failed O
to O
respond O
to O
an O
antidepressant O
alone O
and O
who O
were O
treated O
with O
olanzapine O
monotherapy O
. O
['Physiological-Clinical']

Atomoxetine O
alone O
or O
combined O
with O
fluoxetine O
for O
treating O
ADHD O
with O
comorbid O
depressive O
or O
anxiety O
symptoms O
. O
[]

[ O
Randomized O
control O
study O
of O
high-dose O
metoclopramide O
in O
the O
prevention O
of O
CDDP-induced B-outcome ['Physiological-Clinical']
emesis I-outcome ['Physiological-Clinical']
] O
. O
['Physiological-Clinical']

The O
percentage O
of O
time O
that O
serum O
concentrations O
remain O
above O
the O
MIC O
( O
90 O
) O
during O
the O
dosing O
interval O
( O
T O
> O
MIC O
( O
90 O
) O
) O
for O
Streptococcus B-outcome ['Physiological-Clinical']
pyogenes I-outcome ['Physiological-Clinical']
and O
Staphylococcus O
aureus O
associated O
with O
the O
pharmacokinetic O
profiles O
was O
calculated O
. O
['Physiological-Clinical']

Gastritis O
resolved O
in O
13 O
( O
81 O
% O
) O
of O
16 O
patients O
treated O
with O
bismuth O
but O
in O
only O
three O
of O
13 O
receiving O
erythromycin O
and O
in O
none O
of O
16 O
patients O
given O
placebo O
. O
[]

BACKGROUND O
AND O
PURPOSE O
Cerebral O
vasospasm O
continues O
to O
be O
a O
major O
cause O
of O
poor O
outcome O
in O
patients O
with O
ruptured O
aneurysms O
. O
[]

Under O
OT O
activation B-outcome ['Life-Impact']
differences O
between O
genotypes O
were O
more O
evident O
( O
though O
not O
statistically O
significantly O
increased O
) O
and O
RT O
were O
accelerated O
in O
homozygotic O
risk O
allele O
carriers O
. O
['Life-Impact']

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
water O
, O
lavender O
, O
or O
rosemary O
scent O
on O
physiology B-outcome ['Physiological-Clinical']
and O
mood B-outcome ['Life-Impact']
state I-outcome ['Life-Impact']
following O
an O
anxiety-provoking O
task O
. O
['Physiological-Clinical', 'Life-Impact']

Platelet O
activation O
was O
evaluated O
by O
measuring O
platelet B-outcome ['Physiological-Clinical']
factor O
4 O
( O
PF-4 B-outcome ['Physiological-Clinical']
) O
, O
beta-thromboglobulin B-outcome ['Physiological-Clinical']
( O
beta-TG B-outcome ['Physiological-Clinical']
) O
, O
the O
ratio O
of O
platelet B-outcome ['Physiological-Clinical']
factor O
4 O
to O
beta-thromboglobulin B-outcome ['Physiological-Clinical']
, O
and O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
by O
measuring O
total O
plasma B-outcome ['Physiological-Clinical']
nitrate B-outcome ['Physiological-Clinical']
levels O
, O
von B-outcome ['Physiological-Clinical']
Willebrand I-outcome ['Physiological-Clinical']
factor O
( O
vWF O
) O
levels O
, O
and O
blood B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
using O
venous B-outcome ['Physiological-Clinical']
occlusive B-outcome ['Physiological-Clinical']
plethysmography I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
incidence O
of O
transient O
( O
10 O
% O
versus O
4 O
% O
; O
P O
= O
0.01 O
) O
, O
but O
not O
sustained O
( O
9 O
% O
versus O
4 O
% O
; O
P O
= O
0.07 O
) O
, O
increases O
in O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
levels O
of O
0.5 O
mg/dL O
or O
greater O
( O
> O
or O
=44 O
micromol/L O
) O
was O
significantly O
greater O
in O
the O
gemfibrozil O
group O
. O
['Physiological-Clinical']

Most O
patients O
in O
groups O
T O
and O
M O
reported O
positive O
changes O
in O
overall B-outcome ['Physiological-Clinical']
subjective I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
this O
trial O
. O
['Physiological-Clinical']

After O
five O
years O
this O
difference O
was O
no O
longer O
statistically O
significant O
and O
children O
who O
presented O
anti-HBsAg B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
below O
10 O
mUI/ml O
received O
an O
additional O
booster O
dose O
which O
stimulated O
the O
antibody B-outcome ['Physiological-Clinical']
concentration O
to O
exceed O
100 O
mIU/ml O
in O
all O
cases O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mortality B-outcome ['Mortality']
was O
higher O
in O
patients O
with O
post-CABG O
AF O
than O
patients O
without O
AF O
at O
30 O
days O
( O
1.5 O
% O
vs O
0.7 O
% O
, O
P O
= O
.01 O
) O
but O
not O
at O
3 O
years O
( O
6.9 O
% O
vs O
4.9 O
% O
, O
P O
= O
.41 O
) O
. O
['Mortality']

The O
primary O
endpoint O
was O
the O
combined O
incidence O
of O
cardiovascular B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
, O
and O
the O
secondary O
endpoints O
were O
total O
deaths B-outcome ['Mortality']
and O
any O
safety O
problems O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Effects O
of O
formoterol O
, O
salmeterol O
or O
oxitropium O
bromide O
on O
airway B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
salbutamol I-outcome ['Physiological-Clinical']
in O
COPD O
. O
['Physiological-Clinical']

Greater O
knowledge B-outcome ['Life-Impact']
gain O
with O
structured O
than O
student-directed O
learning O
in O
Child O
Health O
: O
cluster O
randomized O
trial O
. O
['Life-Impact']

Administering O
naltrexone O
was O
a O
challenge O
. O
[]

Donepezil-treated O
patients O
showed O
significant O
benefits O
in O
activities O
of O
daily B-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
over O
placebo O
on O
the O
['Life-Impact']

Before O
entering O
in O
the O
study O
, O
patients O
were O
asked O
about O
HT O
and O
selected O
for O
inclusion O
. O
[]

There O
were O
significantly O
fewer O
women O
with O
anal B-outcome ['Physiological-Clinical']
sphincter I-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
upper I-outcome ['Physiological-Clinical']
vaginal I-outcome ['Physiological-Clinical']
extensions I-outcome ['Physiological-Clinical']
in O
the O
vacuum O
extractor O
group O
( O
11 O
% O
vs O
17 O
% O
, O
OR O
0.6 O
; O
95 O
% O
CI O
, O
0.38-0.97 O
) O
. O
['Physiological-Clinical']

Linguistic B-outcome ['Physiological-Clinical']
age O
, O
cognitive O
level O
and O
autistic O
symptoms O
were O
analyzed O
, O
respectively O
, O
with O
the O
Peabody O
Picture O
Vocabulary O
Test O
( O
PPVT O
) O
, O
the O
Wechsler O
Intelligence O
Scale O
( O
WISC-R O
or O
WAIS-III O
) O
, O
and O
the O
Autistic O
Behavior O
Checklist O
( O
ABC O
) O
. O
['Physiological-Clinical']

FDRs O
were O
more O
likely O
to O
enroll O
if O
they O
were O
female O
( O
OR=1.77 O
; O
CI=1.1-.85 O
) O
and O
parents O
were O
more O
likely O
to O
enroll O
if O
the O
case O
had O
been O
diagnosed B-outcome ['Physiological-Clinical']
more I-outcome ['Physiological-Clinical']
recently I-outcome ['Physiological-Clinical']
( O
OR=3.3 O
; O
CI=1.9-5.93 O
) O
, O
if O
the O
parent O
was O
partnered O
( O
OR=4.37 O
; O
CI=1.86-10.26 O
) O
, O
and O
if O
the O
parent O
lived O
in O
the O
same O
city O
as O
the O
case O
( O
OR=2.88 O
; O
CI=1.08-7.68 O
) O
. O
['Physiological-Clinical']

Direct O
trocar O
insertion O
vs. O
Verres O
needle O
use O
for O
laparoscopic O
sterilization O
. O
[]

CONCLUSION O
Omission O
of O
the O
bladder O
flap O
at O
primary O
and O
repeat O
cesarean O
deliveries O
does O
not O
increase O
intraoperative O
or O
postoperative O
complications O
. O
[]

The O
incidence O
of O
grade O
3 O
or O
higher O
[]

Intervention O
participants O
attended O
7 O
of O
9 O
group O
sessions O
on O
average O
. O
[]

After O
treatment O
, O
we O
assessed O
the O
therapeutic O
effects O
based O
on O
the O
NIH-CPSI O
scores O
and O
the O
improvement O
of O
relevant O
complications B-outcome ['Adverse-effects']
. O
['Adverse-effects']

However O
, O
an O
increased O
velocity O
response O
to O
the O
high-pressure O
, O
rapid-inflation O
compression O
device O
is O
preserved O
. O
[]

Median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
tracheal I-outcome ['Physiological-Clinical']
extubation I-outcome ['Physiological-Clinical']
was O
similar O
but O
less O
variable O
in O
the O
remifentanil O
group O
( O
remifentanil O
= O
8 O
min O
: O
range O
= O
2-44 O
min O
; O
fentanyl O
= O
8 O
min O
: O
range O
= O
1-732 O
min O
) O
. O
['Physiological-Clinical']

The O
effect O
of O
risedronate O
treatment O
on O
serum O
cytokines O
in O
postmenopausal O
osteoporosis O
: O
a O
6-month O
randomized O
and O
controlled O
study O
. O
[]

TLC O
clinical O
sites O
were O
in O
Baltimore O
, O
Cincinnati O
and O
Columbus O
, O
Newark O
and O
Philadelphia O
. O
[]

Dose O
modifications O
were O
made O
on O
the O
basis O
of O
platelet B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

plus O
metronidazole O
500 O
mg O
t.d.s O
. O
[]

The O
data O
also O
showed O
that O
Xuezhikang O
led O
significantly O
to O
reductions O
in O
median O
and O
log-CRP O
levels O
( O
38 O
% O
and O
44 O
% O
, O
p O
< O
0.01 O
respectively O
) O
, O
IL-6 B-outcome ['Physiological-Clinical']
( O
20 O
% O
, O
p O
< O
0.01 O
) O
, O
and O
ET-1 B-outcome ['Physiological-Clinical']
( O
47 O
% O
, O
p O
< O
0.01 O
) O
compared O
with O
baseline O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
also O
compared O
outcomes O
of O
patients O
who O
developed O
post-CABG O
AF O
( O
663 O
) O
with O
those O
who O
did O
not O
( O
2,131 O
) O
. O
[]

Overall O
frequency O
of O
non-verbal B-outcome ['Life-Impact']
communicative I-outcome ['Life-Impact']
acts B-outcome ['Life-Impact']
did O
not O
change O
between O
the O
two O
assessments O
. O
['Life-Impact', 'Life-Impact']

LEVEL O
OF O
EVIDENCE O
Therapeutic O
study O
, O
Level O
I O
. O
[]

Sustained O
augmentation O
of O
parasympathetic O
tone O
with O
angiotensin-converting O
enzyme O
inhibition O
in O
patients O
with O
congestive O
heart O
failure O
. O
[]

The O
median O
follow-up O
time O
in O
the O
WP-CRT O
arm O
was O
21.7 O
months O
( O
range O
, O
10.7-37.4 O
months O
) O
, O
and O
in O
the O
WP-IMRT O
arm O
it O
was O
21.6 O
months O
( O
range O
, O
7.7-34.4 O
months O
) O
. O
[]

Muscle O
sampling O
occurred O
before O
, O
and O
after O
1 O
and O
5 O
d O
of O
treatment O
ingestion O
. O
[]

Successful O
cardioversion O
improved O
exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
by O
15 O
% O
at O
8 O
weeks O
, O
and O
these O
improvements O
were O
maintained O
throughout O
the O
year O
. O
['Life-Impact']

Residual O
tumor O
diameter O
( O
less O
than O
or O
greater O
than O
2 O
cm O
) O
exerted O
a O
statistically O
significant O
effect O
on O
response O
-- O
47.8 O
vs O
24.4 O
% O
. O
[]

Patients O
of O
the O
IVF+ O
group O
had O
a O
higher O
total O
motile B-outcome ['Physiological-Clinical']
sperm I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
after O
preparation O
than O
did O
those O
of O
the O
IVF- O
group O
. O
['Physiological-Clinical']

Two O
reviewers O
evaluated O
the O
relevance O
of O
each O
candidate O
study O
and O
the O
validity O
of O
eligible O
trials O
. O
[]

Enrollment O
was O
closed O
on O
October O
31 O
, O
1984 O
, O
after O
165 O
patients O
were O
randomized O
to O
mitoxantrone O
and O
160 O
patients O
to O
doxorubicin O
. O
[]

PATIENTS O
AND O
METHODS O
Study O
patients O
included O
472 O
low-income O
, O
predominantly O
female O
Hispanic O
patients O
with O
cancer O
age O
> O
or= O
18 O
years O
with O
major B-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
( O
49 O
% O
) O
, O
dysthymia O
( O
5 O
% O
) O
, O
or O
both O
( O
46 O
% O
) O
. O
['Life-Impact']

Revised O
WHO O
guidelines O
now O
recommend O
antiretroviral O
prophylaxis O
( O
either O
to O
the O
mother O
or O
to O
the O
baby O
) O
during O
breastfeeding O
if O
the O
mother O
is O
not O
already O
receiving O
antiretroviral O
treatment O
for O
her O
own O
health O
. O
[]

Polysomnographic O
measures O
of O
sleep B-outcome ['Physiological-Clinical']
and O
self-report O
indexes O
of O
tobacco O
withdrawal O
were O
collected O
pre- O
and O
postcessation O
from O
an O
active O
nicotine O
patch O
group O
and O
a O
placebo O
patch O
group O
in O
a O
randomized O
, O
double-blind O
clinical O
trial O
( O
N O
= O
34 O
) O
. O
['Physiological-Clinical']

RESULTS O
Eighty-nine O
( O
59.3 O
% O
) O
women O
and O
61 O
( O
40.7 O
% O
) O
men O
were O
included O
in O
the O
study O
. O
[]

Because O
few O
studies O
compare O
methods O
of O
passive O
warming O
, O
we O
used O
an O
unblinded O
, O
prospective O
, O
experimental O
, O
randomized O
design O
to O
compare O
the O
effectiveness O
of O
two O
passive O
methods O
of O
normothermia O
management O
in O
the O
postanesthesia O
care O
unit O
( O
PACU O
) O
. O
[]

RESULTS O
On O
5 O
of O
the O
15 O
tasks O
administered O
, O
simulators O
performed O
significantly O
differently O
from O
normal O
and O
memory-impaired O
participants O
. O
[]

After O
the O
intervention O
and O
at O
follow-up O
, O
three O
vessel O
segments O
were O
individually O
analyzed O
with O
quantitative O
coronary O
angiography O
: O
1 O
) O
the O
stent O
, O
2 O
) O
the O
radiation O
ribbon O
, O
and O
3 O
) O
the O
ribbon+margin O
segment O
( O
including O
5 O
mm O
on O
either O
end O
of O
the O
injured O
or O
radiation-ribbon O
segment O
) O
. O
[]

No O
significant O
difference O
was O
found O
in O
the O
rate O
of O
grade O
3+4 B-outcome ['Physiological-Clinical']
leukocytopenia I-outcome ['Physiological-Clinical']
( O
94 O
% O
vs O
. O
['Physiological-Clinical']

METHODS O
The O
effects O
of O
oral O
administration O
of O
Bifidobacterium O
breve O
( O
B. O
breve O
) O
supplements O
were O
studied O
in O
a O
controlled O
trial O
with O
low O
birth O
weight O
infants O
( O
average O
birth O
weight O
1489 O
g O
) O
. O
[]

Group O
A O
was O
restored O
with O
prefabricated O
glass-fiber O
posts O
and O
Artglass O
polymer O
core O
; O
group O
B O
with O
prefabricated O
glass-fiber O
posts O
and O
Charisma O
composite O
resin O
core O
; O
and O
group O
C O
with O
prefabricated O
glass-fiber O
posts O
and O
AB O
composite O
resin O
core O
. O
[]

In O
the O
study O
, O
a O
set O
of O
informed O
consents O
, O
or O
SmartConsents O
, O
were O
developed O
for O
specific O
diagnoses O
and O
procedures O
, O
enhanced O
with O
graphics O
, O
and O
delivered O
through O
the O
school O
's O
EHR O
. O
[]

Signal-averaged B-outcome ['Physiological-Clinical']
P-wave I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
QRS I-outcome ['Physiological-Clinical']
complex I-outcome ['Physiological-Clinical']
durations I-outcome ['Physiological-Clinical']
did O
not O
significantly O
change O
after O
placebo O
ingestion O
. O
['Physiological-Clinical']

RESULTS O
The O
proportion O
of O
patients O
with O
prolongation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
QTc I-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
was O
the O
same O
for O
placebo O
and O
tegaserod O
, O
as O
was O
the O
frequency O
of O
overall O
electrocardiographic B-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
a O
randomized O
double-blind O
prospective O
study O
80 O
boys O
aged O
two O
to O
eight O
years O
scheduled O
for O
surgical O
repair O
of O
hypospadias O
were O
allocated O
randomly O
to O
one O
of O
four O
groups O
( O
n O
= O
20 O
each O
) O
and O
received O
either O
only O
caudal O
0.25 O
% O
plain O
bupivacaine O
0.5 O
mL.kg O
( O
-1 O
) O
( O
Group O
I O
) O
or O
0.25 O
% O
plain O
bupivacaine O
0.5 O
mL.kg O
( O
-1 O
) O
with O
neostigmine O
( O
Groups O
II-IV O
) O
in O
doses O
of O
2 O
, O
3 O
and O
4 O
microg.kg O
( O
-1 O
) O
respectively O
. O
[]

In O
a O
2 O
week O
randomized O
two-period O
crossover O
trial O
, O
18 O
male O
adolescents O
consumed O
two O
diets O
, O
named O
white O
diet O
( O
WD O
) O
and O
brown O
diet O
( O
BD O
) O
, O
which O
were O
poor O
and O
rich O
in O
MRP O
, O
respectively O
. O
[]

These O
algorithms O
provided O
accurate O
estimates O
of O
GAI O
in O
the O
WAIS-III O
standardization O
sample O
. O
[]

No O
irritation B-outcome ['Physiological-Clinical']
or O
symptom B-outcome ['Physiological-Clinical']
was O
reported O
by O
users O
of O
Acidform O
without O
N-9 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Therefore O
, O
we O
examined O
the O
effects O
of O
a O
modified O
MBT O
protocol O
( O
MBT-AS O
) O
in O
high-functioning O
adults O
with O
ASD O
. O
[]

DISCUSSION O
This O
paper O
highlights O
the O
design O
, O
methods O
and O
operational O
aspects O
of O
a O
significant O
clinical O
trial O
in O
the O
area O
of O
whiplash O
and O
chronic O
pain O
. O
[]

In O
conclusion O
, O
the O
results O
indicated O
that O
supplementation O
with O
beta-carotene O
in O
non-smoking O
, O
hypercholesterolaemic O
, O
postmenopausal O
women O
had O
no O
protective B-outcome ['Physiological-Clinical']
effect O
on O
the O
susceptibility O
of O
LDL O
to O
copper-catalysed O
modification O
in O
vitro O
. O
['Physiological-Clinical']

The O
non-significant O
variables O
were O
excluded O
stepwise O
to O
yield O
models O
comprising O
only O
significant O
factors O
( O
p O
< O
.05 O
) O
. O
[]

CONCLUSIONS O
Naltrexone O
offers O
promise O
as O
an O
agent O
for O
modest O
improvement O
of O
behavior O
and O
social B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
in O
young O
children O
with O
autism O
. O
['Life-Impact']

CONCLUSIONS O
One-year O
clinical O
and O
neuropsychological O
outcomes O
seem O
comparable O
after O
early O
surgical O
and O
endovascular O
treatment O
of O
ruptured O
intracranial O
aneurysms O
. O
[]

Results O
also O
indicated O
that O
both O
high O
and O
low O
functioning O
participants O
improved O
their O
speech B-outcome ['Life-Impact']
production I-outcome ['Life-Impact']
after O
receiving O
either O
music O
or O
speech O
training O
; O
however O
, O
low O
functioning O
participants O
showed O
a O
greater O
improvement O
after O
the O
music O
training O
than O
the O
speech O
training O
. O
['Life-Impact']

Mean O
gestational O
age O
( O
GA O
) O
at O
first O
and O
second O
examinations O
was O
33.3 O
and O
35.3 O
weeks O
, O
respectively O
. O
[]

By O
the O
evaluation O
of O
the O
individual O
data O
, O
it O
became O
apparent O
that O
, O
the O
pains B-outcome ['Physiological-Clinical']
increase O
with O
increasing O
gas O
consumption O
, O
a O
fact O
which O
led O
to O
assumption O
that O
the O
pains B-outcome ['Physiological-Clinical']
are O
caused O
by O
a O
physical O
effect O
such O
as O
the O
cooling O
of O
the O
peritoneum O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Dietary O
patterns O
differ O
between O
urban O
and O
rural O
older O
, O
long-term O
survivors O
of O
breast O
, O
prostate O
, O
and O
colorectal O
cancer O
and O
are O
associated O
with O
body O
mass O
index O
. O
[]

CONCLUSIONS O
Cardiotocography O
is O
not O
useful O
for O
the O
detection O
of O
cord B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULT O
( O
S O
) O
Oocyte O
cumulus O
complexes O
obtained O
from O
the O
IVO O
( O
mean O
, O
8.9 O
) O
and O
IVM O
( O
mean O
, O
6.2 O
) O
groups O
had O
equal O
maturation B-outcome ['Physiological-Clinical']
rates O
. O
['Physiological-Clinical']

Papanicolaou O
smear O
showed O
reactive B-outcome ['Life-Impact']
or O
reparative B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
and O
karyopyknotic B-outcome ['Physiological-Clinical']
index O
exhibited O
a O
significant O
increase O
in O
superficial B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
in O
both O
groups O
and O
at O
the O
end O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Dialectical O
behaviour O
therapy O
( O
DBT O
) O
has O
been O
reported O
to O
be O
effective O
in O
reducing O
DSH O
and O
hospitalization O
. O
[]

Quantitative O
image O
quality O
parameters O
and O
figure O
of O
merit O
( O
FOM O
) O
of O
coronary O
artery O
were O
evaluated O
. O
[]

Dietary O
glutamine O
supplementation O
increased O
intestinal B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
( O
120-124 O
% O
) O
of O
genes B-outcome ['Physiological-Clinical']
that O
are O
necessary O
for O
cell O
growth O
and O
removal O
of O
oxidants O
, O
while O
reducing O
( O
34-75 O
% O
) O
expression O
of O
genes O
that O
promote O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
and O
immune O
activation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Clinical O
and O
experimental O
studies O
suggest O
that O
it O
has O
good O
short-term O
and O
long-term O
effects O
on O
both O
human O
and O
animal B-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Due O
to O
rapid O
changes O
in O
radiotherapy O
technology O
and O
evolving O
techniques O
for O
image-guided O
delivery O
, O
guidelines O
had O
to O
be O
developed O
in O
order O
to O
ensure O
uniformity O
in O
implementation O
of O
stereotactic O
radiotherapy O
in O
this O
multi-centre O
study O
. O
[]

After O
SC O
administration O
, O
time O
to O
maximal O
plasma O
concentration O
was O
1.26 O
+/- O
1.04 O
hours O
and O
maximal O
plasma B-outcome ['Physiological-Clinical']
concentration O
of O
methadone B-outcome ['Physiological-Clinical']
was O
23.9 O
+/- O
14.4 O
ng O
mL O
( O
-1 O
) O
, O
the O
terminal O
half-life O
was O
10.7 O
+/- O
4.3 O
hours O
and O
bioavailability B-outcome ['Physiological-Clinical']
was O
79 O
+/- O
22 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
determine O
whether O
the O
addition O
of O
ifosfamide O
to O
cisplatin O
plus O
etoposide O
improves O
the O
response O
rate O
, O
time O
to O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
, O
or O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
previously O
untreated O
patients O
with O
extensive-stage O
small-cell O
carcinoma O
of O
the O
lung O
( O
SCLC O
) O
. O
['Physiological-Clinical', 'Mortality']

BACKGROUND O
AND O
OBJECTIVE O
The O
aim O
of O
our O
work O
was O
to O
evaluate O
in O
obese O
patients O
with O
an O
indication O
of O
replacement O
surgery O
for O
degenerative O
osteoarthritis O
, O
the O
utility O
of O
a O
hypocaloric O
diet O
with O
Optisource O
vs O
nutritional O
counseling O
. O
[]

A O
Name O
Change O
Work O
group O
, O
appointed O
by O
the O
CFS O
Coordinating O
Committee O
, O
developed O
an O
umbrella O
term O
: O
chronic O
neuroendocrineimmune O
dysfunction O
syndrome O
( O
CNDS O
) O
, O
and O
proposed O
that O
there O
would O
be O
sub-types O
under O
this O
term O
, O
one O
being O
CFS O
. O
[]

In O
normal O
postpartum O
women O
, O
the O
postdelivery O
fall O
in O
serum B-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
levels O
did O
not O
differ O
significantly O
in O
treated O
and O
control O
subjects O
. O
['Physiological-Clinical']

Effects O
of O
propranolol O
on O
bone B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
the O
rat O
. O
['Physiological-Clinical']

Twenty-five O
percent O
of O
patients O
with O
no O
lesions O
on O
baseline O
brain O
MRI O
developed O
MS B-outcome ['Physiological-Clinical']
during O
follow-up O
compared O
with O
72 O
% O
of O
patients O
with O
1 O
or O
more O
lesions O
. O
['Physiological-Clinical']

BACKGROUND O
The O
antifungal O
activity O
of O
coriander O
oil O
has O
already O
been O
demonstrated O
in O
vitro O
. O
[]

METHODS O
AND O
RESULTS O
The O
pharmacokinetics O
and O
pharmacodynamics O
of O
intravenous O
diltiazem O
were O
determined O
in O
32 O
patients O
with O
atrial O
fibrillation O
or O
atrial O
flutter O
( O
mean O
+/- O
SD O
age O
, O
66 O
+/- O
7 O
years O
; O
mean O
baseline O
heart O
rate O
, O
131 O
+/- O
10 O
beats O
per O
minute O
) O
after O
20 O
mg O
or O
20 O
mg O
followed O
by O
25-mg O
bolus O
doses O
and O
a O
10 O
and O
15 O
mg/hr O
infusion O
for O
24 O
hours O
. O
[]

47 O
received O
treatment O
without O
TLT O
and O
neoton O
, O
30 O
patients O
received O
TLT O
with O
streptokinase O
preparations O
, O
29 O
patients O
were O
given O
streptokinase O
preparations O
and O
neoton O
. O
[]

After O
six O
weeks O
, O
biopsies B-outcome ['Resource-use']
were O
taken O
from O
EGCG O
and O
vehicle O
treated O
sites O
. O
['Resource-use']

There O
were O
no O
significant O
differences O
on O
any O
demographic O
or O
general O
clinical O
variables O
between O
the O
rosiglitazone O
group O
( O
n=9 O
) O
and O
the O
placebo O
group O
( O
n=10 O
) O
. O
[]

Fifty O
patients O
completed O
an O
investigator-blind O
trial O
comparing O
bismuth O
subsalicylate O
, O
erythromycin O
ethylsuccinate O
, O
and O
placebo O
matched O
to O
the O
bismuth O
salt O
in O
the O
treatment O
of O
gastritis O
associated O
with O
Campylobacter O
pylori O
. O
[]

In O
addition O
, O
social B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
smiling B-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
seeking I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
play B-outcome ['Life-Impact']
interactions I-outcome ['Life-Impact']
increased O
( O
Leboyer O
, O
Bouvard O
et O
Dugas O
, O
1988 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
animals O
were O
stall O
fed O
with O
a O
diet O
consisting O
of O
60 O
% O
roughage O
and O
40 O
% O
concentrate O
. O
[]

The O
difference O
in O
CR B-outcome ['Physiological-Clinical']
rates O
among O
both O
groups O
was O
not O
statistically O
significant O
even O
when O
calculated O
according O
to O
the O
stage O
or O
histologic O
grouping O
. O
['Physiological-Clinical']

Nineteen O
patients O
received O
iopamidol O
and O
18 O
patients O
received O
sodium O
iothalamate O
. O
[]

Patient B-outcome ['Mortality']
survival I-outcome ['Mortality']
and O
graft O
survival B-outcome ['Mortality']
at O
month O
12 O
was O
similar O
in O
both O
treatment O
groups O
( O
97.4 O
% O
vs. O
96.8 O
% O
and O
92.1 O
% O
vs. O
91.1 O
% O
, O
respectively O
) O
. O
['Mortality', 'Mortality']

METHODS O
A O
total O
of O
700 O
adult O
surgical O
patients O
who O
planned O
to O
have O
surgery O
under O
general O
anesthesia O
were O
enrolled O
in O
this O
double-blinded O
, O
randomized O
and O
placebo-controlled O
study O
. O
[]

The O
antibiotic O
was O
administered O
intravenously O
in O
a O
single O
dose O
of O
2 O
g O
with O
induction O
of O
anaesthesia O
. O
[]

The O
volunteer O
study O
was O
a O
double-blind O
cross-over O
trial O
with O
10 O
volunteers O
. O
[]

Baseline O
leptin B-outcome ['Physiological-Clinical']
levels O
( O
mean O
+/- O
SEM O
: O
12.4 O
+/- O
2.1 O
micrograms/L O
) O
were O
independent O
of O
body O
mass O
index O
( O
25 O
+/- O
1 O
kg/m2 O
) O
, O
insulin O
( O
18.6 O
+/- O
2.9 O
microIU/mL O
) O
, O
cortisol O
( O
504 O
+/- O
43 O
mmol/L O
) O
, O
and O
thyroid O
hormones O
( O
T4 O
: O
63 O
+/- O
5 O
nmol/L O
, O
T3 O
: O
0.72 O
+/- O
0.08 O
nmol/L O
) O
but O
correlated O
positively O
with O
circulating O
levels O
of O
IGF-I O
[ O
86 O
+/- O
6 O
micrograms/L O
, O
determination O
coefficient O
( O
R2 O
) O
= O
0.25 O
] O
and O
ALS O
( O
7.2 O
+/- O
0.6 O
mg/L O
, O
R2 O
= O
0.32 O
) O
. O
['Physiological-Clinical']

There O
were O
associations O
between O
baseline O
exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
and O
measures O
of O
quality B-outcome ['Life-Impact']
of O
life B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
two O
CE O
training O
protocols O
were O
equilibrated O
for O
exercise O
mode O
, O
intensity O
, O
and O
volume O
, O
differing O
only O
in O
the O
timing O
and O
sequence O
of O
exercises O
. O
[]

In O
the O
fish O
oil O
group O
, O
43 O
% O
of O
the O
patients O
had O
> O
or O
[]

Treatment O
included O
4 O
sessions O
of O
manual O
therapy O
and O
stabilizing O
exercises O
aimed O
at O
correcting O
the O
lumbopelvic O
rhythm O
. O
[]

Among O
five O
unsuccessful O
cases O
, O
the O
thrombus B-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
increased O
in O
four O
( O
three O
became O
obstructive O
in O
7-35 O
days O
) O
; O
all O
four O
patients O
were O
switched O
to O
fibrinolysis O
, O
which O
was O
successful O
without O
complications O
in O
12-60 O
h. O
The O
fifth O
patient O
developed O
a O
stroke B-outcome ['Physiological-Clinical']
after O
nine O
days O
of O
heparin O
treatment O
and O
was O
subsequently O
operated O
on O
. O
['Physiological-Clinical', 'Physiological-Clinical']

High-dose O
pyridoxine O
and O
magnesium O
administration O
in O
children O
with O
autistic O
disorder O
: O
an O
absence O
of O
salutary O
effects O
in O
a O
double-blind O
, O
placebo-controlled O
study O
. O
[]

Forty O
patients O
were O
diagnosed O
with O
brucellosis O
based O
on O
clinical O
and O
microbiological O
findings O
. O
[]

Interventions O
in O
the O
initial O
prodromal O
states O
of O
psychosis O
in O
Germany O
: O
concept O
and O
recruitment O
. O
[]

Results O
suggest O
stimulus O
control O
and O
reinforcing O
reduced O
sedentary B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
are O
equivalent O
ways O
to O
decrease O
sedentary B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
and O
behavioral B-outcome ['Life-Impact']
economic I-outcome ['Life-Impact']
relationships I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
eating I-outcome ['Life-Impact']
and O
activity B-outcome ['Life-Impact']
may O
mediate O
the O
effects O
of O
treatment O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
end O
points O
were O
toxicity B-outcome ['Adverse-effects']
and O
PSA B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
both O
groups O
, O
with O
the O
option O
to O
continue O
the O
trial O
as O
a O
Phase O
III O
study O
with O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
and O
survival B-outcome ['Mortality']
as O
end O
points O
, O
if O
sufficient O
responses O
were O
observed O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

CONCLUSIONS O
Esomeprazole O
, O
at O
daily O
doses O
of O
40 O
mg O
or O
20 O
mg O
, O
is O
effective O
and O
safe O
for O
the O
treatment O
of O
chronic B-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
in O
patients O
without O
erosive O
oesophagitis O
. O
['Physiological-Clinical']

However O
, O
one O
patient O
in O
the O
ticlopidine O
group O
was O
withdrawn O
because O
of O
a O
major O
fall O
in O
cyclosporin B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
level O
within O
3 O
days O
of O
treatment O
. O
['Physiological-Clinical']

The O
effect O
of O
the O
presence O
or O
absence O
of O
a O
laryngoscope O
on O
successful O
tube O
placement O
was O
also O
assessed O
. O
[]

The O
median O
PFS O
in O
the O
Ca/Mg O
( O
+ O
) O
versus O
Ca/Mg O
( O
- O
) O
group O
was O
10.1 O
versus O
10.7 O
months O
( O
p O
= O
0.92 O
) O
, O
the O
median O
OS O
was O
19.8 O
versus O
20.7 O
months O
( O
p O
= O
0.10 O
) O
, O
and O
the O
response O
rate O
was O
43.1 O
% O
versus O
50 O
% O
( O
p O
= O
0.11 O
) O
, O
respectively O
. O
[]

METHODS O
A O
randomized O
, O
controlled O
, O
double-masked O
clinical O
trial O
of O
45 O
eyes O
was O
conducted O
. O
[]

Patient O
reports O
of O
relative O
helpfulness O
of O
the O
interventions O
for O
managing O
pain B-outcome ['Physiological-Clinical']
and O
nausea B-outcome ['Physiological-Clinical']
matched O
the O
results O
of O
VAS O
reports O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
significant O
difference O
( O
P O
> O
0.05 O
) O
in O
the O
mean O
parasite B-outcome ['Physiological-Clinical']
and O
fever B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
in O
both O
groups O
( O
48.5 O
+/- O
14.6 O
and O
32.0 O
+/- O
12.7 O
h O
respectively O
for O
the O
25 O
mg/kg O
group O
and O
49.0 O
+/- O
15.1 O
and O
30.0 O
+/- O
13.3 O
h O
respectively O
for O
the O
15 O
mg/kg O
group O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
MCIC O
was O
estimated O
over O
a O
12-week O
period O
, O
and O
three O
different O
methods O
were O
used O
: O
1 O
) O
mean O
change O
scores O
, O
2 O
) O
minimal O
detectable O
change O
, O
and O
3 O
) O
optimal O
cutoff O
point O
in O
receiver O
operant O
curves O
. O
[]

24 O
cases O
of O
major O
primary O
hypercholesterolemia O
] O
. O
[]

Diarrhea B-outcome ['Physiological-Clinical']
, O
stomatitis B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
were O
the O
most O
common O
nonhematologic B-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
in O
both O
arms O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

When O
the O
disease O
progressed O
, O
patients O
in O
Groups O
1 O
and O
2 O
were O
crossed O
over O
to O
receive O
CCNU O
and O
irradiation O
respectively O
. O
[]

The O
specific O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
effectiveness O
of O
supplementing O
a O
group O
of O
premenopausal O
women O
who O
were O
free O
of O
breast O
carcinoma O
with O
a O
dietary O
supplement O
of O
isoflavones O
( O
40 O
mg O
per O
day O
) O
in O
producing O
a O
change O
in O
steroid O
hormones O
and O
menstrual O
cycle O
length O
. O
[]

To O
examine O
the O
effects O
of O
a O
digestive O
enzyme O
supplement O
in O
improving O
expressive B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
, O
behaviour B-outcome ['Life-Impact']
and O
other O
symptoms B-outcome ['Life-Impact']
in O
children O
with O
Autism O
Spectrum O
Disorder O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Doubling O
the O
drug O
dose O
resulted O
in O
a O
remarkable O
increase O
in O
lung B-outcome ['Physiological-Clinical']
area O
under O
the O
curve O
( O
AUC O
, O
1318 O
hx O
microg O
g O
( O
-1 O
) O
vs O
2502 O
hx O
microg O
g O
( O
-1 O
) O
) O
and O
peak O
tissue O
concentration O
( O
9.13+/-0.53 O
microg O
g O
( O
-1 O
) O
vs O
17.85+/-2.4 O
microg O
g O
( O
-1 O
) O
) O
. O
['Physiological-Clinical']

PURPOSE O
Blockage O
of O
long-term O
indwelling O
catheters O
with O
mineral O
deposit O
is O
an O
ongoing O
management O
issue O
, O
but O
evidence O
on O
optimal O
management O
is O
lacking O
. O
[]

Polygraphic O
recordings O
included O
sleep B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
( O
active B-outcome ['Life-Impact']
and O
quiet B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
electroencephalogram I-outcome ['Physiological-Clinical']
, O
eye B-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
, O
breathing B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Data O
analysis O
methods O
used O
would O
include O
Kaplan-Meier O
plots O
, O
log-rank O
test O
and O
Cox O
modeling O
. O
[]

Effects O
of O
radiotherapy O
were O
similar O
irrespective O
of O
the O
type O
of O
surgery O
, O
except O
that O
the O
increase O
in O
postoperative B-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
irradiated O
patients O
was O
greater O
in O
those O
treated O
with O
abdominoperineal O
resection O
. O
['Mortality']

Closure O
of O
the O
femoral O
artery O
after O
cardiac O
catheterization O
: O
a O
comparison O
of O
Angio-Seal O
, O
StarClose O
, O
and O
manual O
compression O
. O
[]

Antibiotic O
elimination O
of O
group-B O
streptococci O
in O
urine O
in O
prevention O
of O
preterm B-outcome ['Physiological-Clinical']
labour I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Epithelial O
defects O
measuring O
at O
least O
2 O
mm O
in O
linear O
dimension O
resistant O
to O
conventional O
medical O
management O
were O
included O
. O
[]

In O
logistic O
regression O
models O
, O
black O
race O
, O
BMI O
, O
suntan O
within O
the O
past O
year O
, O
sun O
exposure O
in O
the O
past O
3 O
months O
, O
sunscreen O
use O
and O
supplemental O
vitamin O
D O
intake O
were O
the O
most O
useful O
questions O
to O
identify O
VDI O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
and O
QT B-outcome ['Physiological-Clinical']
dispersion I-outcome ['Physiological-Clinical']
in O
patients O
with O
subclinical O
hypothyroidism O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
Pakistanis O
also O
had O
a O
lower O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
vitamin I-outcome ['Life-Impact']
D O
than O
that O
of O
the O
Norwegians O
( O
median O
2.2 O
vs O
3.3 O
micrograms/day O
, O
P O
< O
0.05 O
) O
, O
and O
a O
lower O
total O
intake O
, O
including O
supplements O
( O
median O
2.9 O
vs O
7.0 O
micrograms/day O
, O
P O
< O
0.001 O
) O
. O
['Life-Impact']

Trainees O
put O
emphasis O
on O
the O
development O
of O
their O
personal O
relationship O
with O
the O
client O
. O
[]

Neurotransmitter O
replacement O
strategies O
targeting O
the O
dopaminergic O
, O
cholinergic O
, O
and O
serotonergic O
systems O
have O
been O
unsuccessful O
. O
[]

However O
, O
generalisability O
of O
previous O
findings O
has O
been O
restricted O
, O
as O
studies O
were O
limited O
in O
either O
methodological O
accuracy O
or O
the O
clinical O
relevance O
of O
their O
approach O
. O
[]

A O
total O
of O
12 O
EA O
and O
SEA O
sessions O
over O
four O
weeks O
were O
given O
. O
[]

In O
3 O
studies O
, O
the O
authors O
found O
support O
for O
the O
value-congruence O
model O
that O
accounts O
for O
cultural O
variations O
in O
memory O
for O
emotional B-outcome ['Life-Impact']
experiences I-outcome ['Life-Impact']
. O
['Life-Impact']

Oxygen B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
radicals I-outcome ['Physiological-Clinical']
were O
measured O
before O
anesthesia O
in O
arterial O
blood O
, O
before O
cross-clamping O
and O
1 O
and O
10 O
min O
after O
reperfusion O
in O
arterial O
and O
coronary O
sinus O
blood O
. O
['Physiological-Clinical']

Duration O
of O
hospitalization O
was O
more O
than O
1 O
year O
because O
of O
insufficiency O
of O
nursing O
homes O
. O
[]

RESULTS O
Of O
the O
1309 O
patients O
randomized O
, O
842 O
( O
64.3 O
% O
) O
were O
evaluable O
for O
efficacy O
. O
[]

0.11 O
) O
ng?ml???h?? O
, O
AII O
( O
162.21 O
? O
[]

When O
compared O
to O
roxithromycin O
administered O
alone O
, O
its O
combination O
with O
a O
proton O
pump O
inhibitor O
significantly O
increased O
the O
roxithromycin B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
juice I-outcome ['Physiological-Clinical']
( O
3.0-5.0 O
microg/mL O
vs. O
0.3-0.4 O
microg/mL O
) O
and O
gastric B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
( O
antrum O
: O
3.8-4.0 O
vs. O
2.8 O
microg/g O
, O
fundus O
: O
5.9-7.4 O
vs. O
4.2-4.4 O
microg/g O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
The O
aim O
of O
this O
study O
was O
to O
determine O
if O
local O
injection O
of O
bupivacaine O
after O
hemorrhoidal O
banding O
causes O
a O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
and O
in O
the O
incidence O
of O
associated O
symptoms B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Safety O
and O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
hyperimmune O
anti-human O
immunodeficiency O
virus O
( O
HIV O
) O
immunoglobulin O
administered O
to O
HIV-infected O
pregnant O
women O
and O
their O
newborns O
. O
['Physiological-Clinical']

Arterial B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SaO2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
saturation O
and O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
were O
measured O
at O
baseline O
0 O
, O
15 O
and O
30 O
minutes O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Of O
the O
26 O
boys O
with O
occult O
TL O
, O
16 O
( O
62 O
% O
) O
remained O
in O
CCR O
. O
[]

To O
identify O
patients O
with O
type O
II O
diabetes O
mellitus O
for O
whom O
insulin O
therapy O
is O
most O
beneficial O
, O
we O
conducted O
a O
randomized O
controlled O
trial O
in O
the O
general O
medicine O
clinic O
of O
a O
university O
hospital O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

During O
the O
8-week O
acute O
trial O
, O
the O
most O
common O
AEs O
on O
the O
Side O
Effects O
Review O
, O
scored O
as O
moderate O
or O
higher O
, O
were O
as O
follows O
( O
placebo O
and O
risperidone O
, O
respectively O
) O
: O
Somnolence B-outcome ['Physiological-Clinical']
( O
12 O
% O
and O
37 O
% O
) O
, O
enuresis B-outcome ['Physiological-Clinical']
( O
29 O
% O
and O
33 O
% O
) O
, O
excessive B-outcome ['Physiological-Clinical']
appetite I-outcome ['Physiological-Clinical']
( O
10 O
% O
and O
33 O
% O
) O
, O
rhinitis B-outcome ['Physiological-Clinical']
( O
8 O
% O
and O
16 O
% O
) O
, O
difficulty B-outcome ['Life-Impact']
waking I-outcome ['Life-Impact']
( O
8 O
% O
and O
12 O
% O
) O
, O
and O
constipation B-outcome ['Physiological-Clinical']
( O
12 O
% O
and O
10 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

The O
thyroid O
isthmus O
is O
often O
encountered O
while O
a O
tracheostomy O
is O
being O
performed O
. O
[]

LEVEL O
OF O
EVIDENCE O
Prospective O
comparative O
study O
, O
Level O
I O
. O
[]

INTACT O
Investigators O
. O
[]

RESULTS O
Between O
April O
1999 O
and O
December O
2005 O
, O
125 O
patients O
were O
randomised O
to O
a O
RT O
( O
n=60 O
) O
or O
CRT O
group O
( O
n=65 O
) O
. O
[]

The O
findings O
suggest O
that O
alterations O
to O
the O
sensory O
systems O
may O
lead O
to O
behavioral O
change O
in O
some O
children O
. O
[]

The O
intravesical B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
rate O
was O
similar O
in O
the O
2 O
groups O
( O
46 O
% O
and O
45 O
% O
, O
respectively O
) O
. O
['Resource-use']

Further O
work O
will O
monitor O
these O
families O
for O
a O
total O
of O
9 O
months O
to O
determine O
the O
trajectory O
of O
outcomes O
. O
[]

DESIGN O
Stratified O
single-blind O
randomized O
controlled O
trial O
with O
an O
independent O
assessor O
. O
[]

Eight O
( O
12.9 O
% O
) O
( O
2 O
in O
group O
A O
and O
2 O
in O
group O
B O
) O
were O
considered O
to O
be O
in O
clinical B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
and O
required O
a O
maintenance B-outcome ['Life-Impact']
regimen I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
low-dose I-outcome ['Life-Impact']
corticosteroids I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

OBJECTIVE O
To O
compare O
peroneal O
reaction O
to O
sudden O
inversion O
following O
ankle O
joint O
cryotherapy O
. O
[]

The O
patients O
who O
received O
combined O
treatment O
had O
fewer O
local B-outcome ['Physiological-Clinical']
( O
P O
less O
than O
0.02 O
) O
and O
fewer O
distant B-outcome ['Physiological-Clinical']
( O
P O
less O
than O
0.01 O
) O
recurrences B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Forty O
general O
practices O
will O
be O
randomised O
to O
either O
the O
intervention O
group O
or O
the O
control O
group O
. O
[]

SETTING O
Nine O
university-affiliated O
level O
1 O
trauma O
centers O
. O
[]

Oral O
bioavailability O
of O
moxifloxacin O
after O
Roux-en-Y O
gastric O
bypass O
surgery O
. O
[]

After O
a O
run-in O
period O
of O
2 O
weeks O
, O
patients O
received O
treatment O
for O
8 O
weeks O
. O
[]

Pharmacokinetics B-outcome ['Physiological-Clinical']
and O
relative B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
of O
prajmalium O
bitartrate O
after O
single O
oral O
dosing O
. O
['Physiological-Clinical']

RESULTS O
Ecstasy O
users O
showed O
a O
broad O
pattern O
of O
statistically O
significant O
, O
but O
clinically O
small O
, O
impairment B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
and O
prolonged O
reaction B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
fall B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
tcPCO2 I-outcome ['Physiological-Clinical']
was O
predicted O
rather O
by O
the O
frequency O
of O
occurrence O
of O
anxiety-related B-outcome ['Life-Impact']
somatic I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
than O
by O
the O
fear O
of O
these O
symptoms O
. O
['Physiological-Clinical', 'Life-Impact']

When O
histologic O
changes O
were O
compared O
between O
the O
2 O
groups O
, O
decrease O
in O
acute B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
gastritis I-outcome ['Physiological-Clinical']
was O
more O
frequent O
after O
H. O
pylori O
eradication O
( O
P O
< O
0.001 O
) O
but O
changes O
in O
IM B-outcome ['Physiological-Clinical']
were O
similar O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Clinical O
evaluation O
of O
the O
WOMAC O
3.0 O
OA O
Index O
in O
numeric O
rating O
scale O
format O
using O
a O
computerized O
touch O
screen O
version O
. O
[]

CONCLUSIONS O
This O
study O
revealed O
a O
highly O
effective O
tool O
in O
the O
otolaryngologist O
's O
management O
of O
persistent O
epistaxis O
. O
[]

CONCLUSIONS O
In O
this O
study O
, O
we O
have O
proven O
the O
concept O
that O
addition O
of O
an O
NO-donating O
moiety O
to O
aspirin O
results O
in O
a O
new O
chemical O
entity O
that O
maintains O
cyclooxygenase-1 O
and O
platelet O
inhibitory O
activity O
while O
nearly O
avoiding O
[]

Predicting O
the O
costs B-outcome ['Resource-use']
of O
allogeneic O
sibling O
stem-cell O
transplantation O
: O
results O
from O
a O
prospective O
, O
multicenter O
, O
French O
study O
. O
['Resource-use']

Subjects O
made O
a O
fast O
elbow O
extension O
movement O
to O
designated O
target O
in O
response O
to O
a O
go O
signal O
. O
[]

The O
presence O
of O
group-B O
streptococci O
in O
the O
urine O
of O
pregnant O
women O
seems O
to O
be O
associated O
with O
preterm O
labour O
. O
[]

The O
physostigmine O
patch O
application O
in O
doses O
of O
30 O
mg O
and O
60 O
mg O
apparently O
did O
not O
lead O
to O
physostigmine B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
that O
were O
sufficient O
to O
compensate O
for O
cholinergic O
deficiencies O
in O
affected O
brain O
areas O
and O
produce O
clinical O
benefits O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
a O
biopsychosocial O
therapy O
( O
BT O
) O
with O
a O
conventional O
biomedical O
therapy O
( O
MT O
) O
of O
subacute B-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
in O
the O
first O
episode O
of O
sick O
leave O
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

AIMS O
To O
evaluate O
umbilical O
cord O
serum O
therapy O
as O
a O
means O
of O
promoting O
the O
healing O
of O
persistent B-outcome ['Physiological-Clinical']
corneal I-outcome ['Physiological-Clinical']
epithelial I-outcome ['Physiological-Clinical']
defects I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
110 O
+/- O
11 O
before O
and O
106 O
+/- O
13 O
ml/min/1.73 O
m2 O
after O
clonidine O
injection O
. O
['Physiological-Clinical']

In O
line O
with O
behavioral O
data O
that O
show O
decreased O
pain B-outcome ['Physiological-Clinical']
responses O
under O
placebo O
, O
pain-related B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
spinal O
cord O
is O
strongly O
reduced O
under O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Immunogenicity B-outcome ['Physiological-Clinical']
was O
measured O
by O
specific O
IgG O
( O
Mite O
) O
and O
IgG4 O
( O
Mite O
) O
, O
by O
antibody-blocking O
properties O
on O
basophil O
activation O
, O
and O
by O
the O
T O
cell O
subset O
transcription O
factors O
Foxp3 O
, O
T-bet O
, O
and O
GATA-3 O
. O
['Physiological-Clinical']

[ O
Therapeutic O
efficacy O
of O
compound O
Xuanju O
capsule O
on O
type O
III O
prostatitis O
] O
. O
[]

This O
is O
to O
compare O
the O
bioavailability O
of O
diflunisal-naproxen B-outcome ['Physiological-Clinical']
fixed-dose I-outcome ['Physiological-Clinical']
combination I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FDC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
with O
their O
separate O
dosage O
forms O
. O
['Physiological-Clinical']

Human O
papillomavirus O
and O
Papanicolaou O
tests O
to O
screen O
for O
cervical O
cancer O
. O
[]

Changes O
in O
biliary B-outcome ['Physiological-Clinical']
ursodeoxycholic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
correlated O
significantly O
but O
weakly O
with O
the O
changes O
in O
serum B-outcome ['Physiological-Clinical']
alkaline I-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
AST I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
Mayo I-outcome ['Physiological-Clinical']
risk O
score O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
prophylactic O
regimens O
used O
to O
prevent O
CMV O
infection O
and O
disease O
have O
shown O
limited O
benefit O
in O
seronegative O
recipients O
. O
[]

Compared O
with O
historic O
controls O
, O
the O
ALL-2 O
regimen O
was O
superior O
in O
terms O
of O
incidence O
of O
complete O
remission O
, O
failure O
with O
resistant O
disease O
, O
and O
activity O
in O
patients O
with O
Philadelphia O
chromosome O
( O
Ph O
) O
-positive O
ALL O
. O
[]

Both O
the O
feasibility B-outcome ['Life-Impact']
studies O
and O
the O
usability B-outcome ['Life-Impact']
testing O
highlighted O
the O
need O
to O
address O
men O
's O
informed O
decision O
making O
regarding O
screening O
. O
['Life-Impact', 'Life-Impact']

SUBJECTS O
Twenty O
( O
20 O
) O
children O
with O
autistic O
spectrum O
disorder O
, O
ages O
3-8 O
years O
. O
[]

53 O
patients O
with O
primary O
open O
angle O
glaucoma O
, O
capsular O
glaucoma O
, O
or O
ocular O
hypertension O
with O
an O
IOP O
of O
at O
least O
21 O
mmHg O
on O
current O
therapy O
were O
recruited O
. O
[]

During O
the O
placebo O
control O
period O
, O
serum B-outcome ['Physiological-Clinical']
IGF-I I-outcome ['Physiological-Clinical']
, O
LBM B-outcome ['Physiological-Clinical']
, O
and O
TBW B-outcome ['Physiological-Clinical']
increased O
( O
P O
< O
0.001 O
) O
, O
whereas O
BF B-outcome ['Physiological-Clinical']
decreased O
( O
P O
< O
0.001 O
) O
and O
serum B-outcome ['Physiological-Clinical']
GHBP I-outcome ['Physiological-Clinical']
was O
unchanged O
in O
the O
group O
treated O
with O
GH O
compared O
with O
the O
patients O
treated O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Permissive O
hypercapnia O
resulted O
in O
significant O
decreases O
in O
systemic O
vascular O
resistance O
( O
SVR O
) O
and O
increases O
in O
cardiac O
output O
( O
Q O
) O
. O
[]

These O
mental O
practice O
sessions O
required O
daily O
cognitive O
rehearsal O
of O
the O
activities O
of O
daily O
living O
practiced O
during O
mCIT O
clinical O
sessions O
. O
[]

Retapamulin O
was O
well O
tolerated B-outcome ['Life-Impact']
and O
the O
topical O
formulation O
was O
preferred O
over O
the O
oral O
drug O
. O
['Life-Impact']

3 O
) O
Control O
group O
( O
C O
Group O
) O
, O
39 O
patients O
not O
given O
injections O
. O
[]

Supplemental B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
of I-outcome ['Resource-use']
metamizol I-outcome ['Resource-use']
was O
significantly O
lower O
( O
P O
< O
0.05 O
) O
in O
Group O
3 O
than O
in O
Group O
1 O
during O
the O
first O
6 O
h O
after O
surgery O
. O
['Resource-use']

Once O
portal B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
occurred O
, O
all O
subjects O
on O
TG O
were O
changed O
to O
MP O
. O
['Physiological-Clinical']

The O
pattern O
of O
findings O
was O
similar O
for O
most O
subgroups O
defined O
by O
gender O
and O
study O
condition O
. O
[]

CONCLUSION O
Clozapine O
demonstrated O
cost-effectiveness O
on O
some O
but O
not O
all O
measures O
of O
effectiveness O
when O
the O
alternative O
was O
a O
range O
of O
conventional O
antipsychotic O
medications O
. O
['Resource-use']

Partial-area O
method O
in O
bioequivalence O
assessment O
: O
naproxen O
. O
[]

Outcome O
was O
measured O
by O
parents/caregivers O
and O
at O
medical O
follow-up O
using O
three O
established O
tools O
: O
the O
Rett O
Syndrome O
Motor B-outcome ['Life-Impact']
Behavioral I-outcome ['Life-Impact']
Assessment O
, O
the O
Hand B-outcome ['Life-Impact']
Apraxia I-outcome ['Life-Impact']
Scale O
, O
and O
the O
Patient B-outcome ['Life-Impact']
Well-Being I-outcome ['Life-Impact']
Index O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

During O
a O
mean O
followup O
of O
6 O
years O
2 O
patients O
in O
the O
TLA O
group O
had O
a O
late B-outcome ['Adverse-effects']
complication I-outcome ['Adverse-effects']
( O
port O
site O
hernia O
) O
. O
['Adverse-effects']

RESULTS O
There O
were O
102 O
neonates O
randomized O
to O
early O
( O
n O
= O
43 O
) O
or O
delayed O
cord O
clamping O
( O
n O
= O
59 O
) O
. O
[]

CONCLUSION O
This O
prospective O
study O
in O
a O
randomized O
controlled O
trial O
suggests O
that O
sialyl O
Lewis O
( O
a O
) O
expression O
levels O
may O
serve O
as O
an O
indicator O
of O
the O
metastatic O
potential O
of O
colon O
cancer O
cells O
, O
which O
would O
strongly O
predict O
the O
prognosis O
. O
[]

The O
findings O
indicated O
that O
each O
ASD O
intervention O
group O
demonstrated O
significant O
gains O
on O
the O
WMS O
and O
significant O
improvement O
in O
the O
areas O
of O
anxiety B-outcome ['Life-Impact']
management I-outcome ['Life-Impact']
, O
joint B-outcome ['Life-Impact']
attention B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Nasotracheal O
intubation O
under O
curve-tipped O
suction O
catheter O
guidance O
reduces O
epistaxis O
. O
[]

All O
patients O
were O
post-menopausal O
, O
previously O
untreated O
with O
hormone O
therapy O
, O
and O
with O
tumor O
receptor O
status O
determined O
immediately O
before O
randomization O
; O
all O
had O
objectively O
evaluable O
lesions O
. O
[]

No O
significant O
difference O
was O
found O
between O
the O
two O
arms O
for O
the O
end O
points O
of O
local B-outcome ['Physiological-Clinical']
relapse-free I-outcome ['Physiological-Clinical']
rate O
( O
p O
= O
0.91 O
) O
, O
regional B-outcome ['Physiological-Clinical']
relapse-free I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
p O
= O
0.17 O
, O
adjusted O
) O
or O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
p O
= O
0.86 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

The O
women O
were O
separated O
into O
those O
who O
were O
given O
2,500 O
IU O
enoxaparin O
once O
daily O
and O
SH O
in O
a O
dose O
of O
5,000 O
IU O
three O
times O
daily O
. O
[]

PURPOSE O
To O
study O
the O
efficacy O
of O
indirect O
diode O
laser O
photocoagulation O
and O
cryotherapy O
in O
prethreshold B-outcome ['Physiological-Clinical']
retinopathy I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
prematurity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ROP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

DESIGN O
Thirty-one O
men O
and O
women O
, O
age O
19-50 O
y O
and O
body O
mass O
index O
27-33 O
kg/m O
( O
2 O
) O
, O
completed O
this O
randomized O
, O
controlled O
, O
16-week O
weight O
loss O
program O
. O
[]

Tomato O
paste O
rich O
in O
lycopene O
protects O
against O
cutaneous B-outcome ['Physiological-Clinical']
photodamage I-outcome ['Physiological-Clinical']
in O
humans O
in O
vivo O
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

PURPOSE O
To O
determine O
the O
prophylactic O
properties O
of O
amifostine O
against O
acute O
and O
late O
toxicities O
from O
radiochemotherapy O
in O
patients O
with O
head-and-neck O
cancer O
. O
[]

The O
effects O
of O
the O
high O
intake O
of O
Maillard O
reaction O
products O
( O
MRP O
) O
on O
calcium B-outcome ['Physiological-Clinical']
availability I-outcome ['Physiological-Clinical']
in O
adolescents O
and O
across O
Caco-2 O
cell O
monolayers O
were O
examined O
. O
['Physiological-Clinical']

Outcomes O
were O
assessed O
over O
a O
6-year O
period O
of O
program O
implementation O
for O
a O
cohort O
of O
youth O
in O
each O
school O
, O
followed O
from O
grades O
3 O
to O
8 O
. O
[]

Informed O
consents O
are O
routinely O
used O
as O
an O
important O
source O
of O
information O
to O
help O
patients O
make O
appropriate O
clinical O
decisions O
. O
[]

The O
skin B-outcome ['Physiological-Clinical']
microvessels I-outcome ['Physiological-Clinical']
' O
vasodilatory B-outcome ['Physiological-Clinical']
ability B-outcome ['Life-Impact']
was O
found O
to O
be O
greater O
during O
radiofrequency O
exposure O
than O
during O
sham O
exposure O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

In O
this O
randomised O
trial O
, O
patients O
were O
allocated O
to O
receive O
either O
four O
courses O
of O
chemotherapy O
using O
5-fluorouracil O
, O
doxorubicin O
and O
methotrexate O
( O
FAMTX O
) O
prior O
to O
surgery O
or O
to O
undergo O
surgery O
only O
. O
[]

The O
exercise O
duration O
, O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
mm I-outcome ['Physiological-Clinical']
ST-segment I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
was O
significantly O
prolonged O
after O
Xuezhikang O
therapy O
( O
9 O
% O
and O
6 O
% O
, O
p O
< O
0.05 O
respectively O
) O
accompanied O
by O
improvement O
of O
subjective O
feelings B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

DESIGN O
Prospective O
case-control O
study O
with O
intraindividual O
comparison O
of O
myocardial O
ischaemia O
during O
two O
2-min O
coronary O
artery O
balloon O
occlusions O
with O
and O
without O
simultaneous O
iCSO O
by O
a O
balloon-tipped O
catheter O
. O
[]

Intramuscular O
depot O
medroxyprogesterone O
versus O
oral O
megestrol O
for O
the O
control O
of O
postmenopausal O
hot O
flashes O
in O
breast O
cancer O
patients O
: O
a O
randomized O
study O
. O
[]

Circadian O
changes O
in O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
oral O
ketoprofen O
. O
['Physiological-Clinical']

Docosahexaenoic O
acid-rich O
fish O
oil O
modulates O
the O
cerebral B-outcome ['Physiological-Clinical']
hemodynamic I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
cognitive O
tasks O
in O
healthy O
young O
adults O
. O
['Physiological-Clinical']

The O
primary O
end O
point O
, O
sustained B-outcome ['Physiological-Clinical']
virologic I-outcome ['Physiological-Clinical']
response O
( O
SVR O
) O
, O
was O
defined O
as O
a O
reduction O
in O
hepatitis B-outcome ['Physiological-Clinical']
B B-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
deoxyribonucleic I-outcome ['Physiological-Clinical']
acid B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HBV I-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of O
> O
or=2 O
log10 O
copies/mL O
and O
HBV B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
< O
20,000 O
copies/mL O
at O
24 O
wk O
of O
follow-up O
( O
week O
84 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
trial O
showed O
a O
reduction O
in O
mortality B-outcome ['Mortality']
with O
carvedilol O
that O
was O
consistent O
across O
subgroups O
. O
['Mortality']

Cross O
sectionally O
, O
the O
scores O
of O
the O
two O
questionnaires O
were O
moderately O
to O
highly O
correlated O
( O
coefficients O
ranged O
from O
0.35 O
to O
0.72 O
) O
. O
[]

PURPOSE O
Many O
trials O
have O
shown O
that O
calcium O
channel O
blockers O
( O
CCBs O
) O
can O
reduce O
the O
cardiovascular B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
patients O
with O
coronary O
artery O
disease O
( O
CAD O
) O
. O
['Physiological-Clinical']

Glycemia B-outcome ['Physiological-Clinical']
over O
the O
1-year O
study O
was O
largely O
unaffected O
; O
the O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
reduced O
from O
baseline O
with O
manidipine/delapril O
, O
although O
not O
statistically O
significant O
( O
mean O
change O
-0.2 O
mmol/L O
, O
P=0.064 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

7 O
. O
[]

Familial O
adenomatous O
polyposis O
( O
FAP O
) O
strikes O
young O
people O
and O
, O
untreated O
, O
confers O
virtually O
a O
100 O
% O
risk O
of O
colorectal O
cancer O
and O
early O
death O
. O
[]

Post-surgery O
, O
the O
retrained O
persons O
exhibited O
less O
impairment B-outcome ['Life-Impact']
, O
on O
average O
, O
than O
non-retrained O
persons O
only O
in O
two-point O
perception O
( O
P O
< O
0.025 O
) O
, O
suggesting O
that O
retrained O
persons O
experienced O
or O
interpreted O
the O
tactile B-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
differently O
than O
did O
non-retrained O
persons O
. O
['Life-Impact', 'Physiological-Clinical']

Our O
aim O
was O
to O
determine O
the O
effect O
of O
cessation O
of O
raloxifene O
treatment O
on O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
and O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
postmenopausal O
, O
osteopenic O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
present O
investigation O
examined O
the O
effects O
of O
placebo O
( O
P O
) O
, O
low-dose O
( O
LD O
) O
, O
and O
high-dose O
( O
HD O
) O
ethanol O
on O
electroencephalographic B-outcome ['Physiological-Clinical']
( O
EEG O
) O
activity O
in O
21 O
healthy O
, O
adult O
males O
( O
X O
= O
22.7 O
years O
) O
. O
['Physiological-Clinical']

Mitomycin-C O
and O
methyl-CCNU O
were O
administered O
every O
eight O
weeks O
. O
[]

STUDY O
DESIGN O
AND O
SETTING O
The O
trial O
will O
enroll O
720 O
unique O
patients O
in O
emergency O
departments O
and O
uses O
a O
Bayesian O
adaptive O
design O
. O
[]

Few O
studies O
have O
shown O
the O
effectiveness O
of O
counseling O
for O
these O
caregivers O
. O
[]

These O
effects O
are O
not O
evident O
with O
camazepam O
, O
which O
does O
not O
seem O
to O
distort O
the O
normal O
sleep O
pattern O
. O
[]

DESIGN O
Subjects O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O
[]

There O
were O
significant O
( O
P O
< O
0.05 O
) O
reductions O
of O
the O
relative O
amounts O
of O
ET-1 B-outcome ['Physiological-Clinical']
( O
in O
both O
ventricles B-outcome ['Physiological-Clinical']
) O
and O
ET O
( O
A O
) O
R O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Breast O
cancer O
screening O
in O
Sweden O
. O
[]

Barriers O
to O
high B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
HBP O
) O
care O
and O
control O
have O
been O
reported O
in O
the O
literature O
for O
> O
30 O
years O
. O
['Physiological-Clinical']

The O
selective O
5-hydroxytryptamine O
type O
4 O
receptor O
partial O
agonist O
tegaserod O
is O
a O
novel O
promotile O
agent O
developed O
for O
the O
treatment O
of O
functional O
motility O
disorders O
such O
as O
irritable O
bowel O
syndrome O
( O
IBS O
) O
. O
[]

Melatonin O
significantly O
improved O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
( O
by O
an O
average O
of O
47 O
min O
) O
and O
total O
sleep B-outcome ['Physiological-Clinical']
( O
by O
an O
average O
of O
52 O
min O
) O
compared O
to O
placebo O
, O
but O
not O
number O
of O
night O
wakenings O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Amphotericin O
B O
in O
children O
with O
malignant O
disease O
: O
a O
comparison O
of O
the O
toxicities O
and O
pharmacokinetics O
of O
amphotericin O
B O
administered O
in O
dextrose O
versus O
lipid O
emulsion O
. O
[]

Ang O
II O
may O
play O
a O
role O
in O
the O
interaction O
between O
dietary O
sodium O
and O
myocardial B-outcome ['Physiological-Clinical']
relaxation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Further O
increase O
of O
the O
dose O
will O
not O
increase O
the O
duration O
. O
[]

No O
additional O
differences O
were O
found O
between O
treatments O
in O
the O
physiological O
responses O
and O
heat O
balance O
parameters O
at O
the O
end O
of O
exposure O
: O
heart O
rate O
( O
HR O
) O
was O
( O
mean O
+/- O
S.D O
. O
) O
[]

The O
patients O
were O
randomised O
for O
double-blind O
treatment O
with O
losartan O
versus O
atenolol O
. O
[]

Fifteen O
males O
with O
angiographic O
evidence O
of O
coronary O
heart O
disease O
and O
stable O
, O
exercise-induced O
angina O
pectoris O
were O
given O
placebo O
or O
isosorbide O
dinitrate O
( O
ISDN O
) O
in O
a O
dialy O
dose O
of O
30 O
mg O
, O
120 O
mg O
, O
240 O
mg O
and O
480 O
mg O
in O
a O
randomized O
single-blind O
trial O
. O
[]

These O
findings O
should O
be O
regarded O
as O
tentative O
and O
require O
independent O
validation O
in O
similar O
and O
other O
acute O
pain O
models O
. O
[]

Carbon O
dioxide O
versus O
normal O
saline O
as O
a O
uterine O
distension O
medium O
for O
diagnostic O
vaginoscopic O
hysteroscopy O
in O
infertile O
patients O
: O
a O
prospective O
, O
randomized O
, O
multicenter O
study O
. O
[]

MEASUREMENTS O
AND O
RESULTS O
Every O
6 O
months O
, O
a O
structured O
questionnaire O
was O
administered O
to O
elicit O
reports O
of O
any O
bruising B-outcome ['Physiological-Clinical']
and/or I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
rashes I-outcome ['Physiological-Clinical']
, O
slow B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cuts I-outcome ['Physiological-Clinical']
or O
sores B-outcome ['Physiological-Clinical']
, O
or O
other O
skin B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
the O
effectiveness O
of O
oral O
diazepam O
and O
midazolam O
for O
the O
sedation B-outcome ['Physiological-Clinical']
of O
autistic O
patients O
during O
dental O
treatment O
. O
['Physiological-Clinical']

Significant O
relationships O
were O
found O
between O
VAS O
overall O
well-being O
and O
CDI O
( O
r O
= O
0.29 O
, O
p O
= O
0.03 O
) O
, O
CHAQ O
( O
r O
= O
0.37 O
, O
p O
= O
0.000 O
) O
, O
and O
VAS O
pain O
( O
r O
= O
0.41 O
, O
p O
= O
0.000 O
) O
. O
[]

Pemetrexed O
has O
shown O
single-agent O
activity O
in O
SCCHN O
and O
in O
combination O
with O
cisplatin O
for O
other O
tumors O
. O
[]

The O
effectiveness O
of O
educational O
interventions O
to O
enhance O
the O
adoption O
of O
fee-based O
arsenic O
testing O
in O
Bangladesh O
: O
a O
cluster O
randomized O
controlled O
trial O
. O
[]

Methodological O
issues O
in O
designing O
a O
multisite O
trial O
of O
risperidone O
in O
children O
and O
adolescents O
with O
autism O
. O
[]

Treatment O
with O
either O
17 O
alpha-hydroxyprogesterone O
caproate O
, O
250 O
mg O
by O
intramuscular O
injection O
once O
a O
week O
, O
or O
a O
placebo O
was O
given O
in O
a O
double-blind O
fashion O
. O
[]

rHCNTF O
was O
safe O
and O
tolerated B-outcome ['Life-Impact']
within O
acceptable O
limits O
when O
administered O
to O
patients O
with O
ALS O
in O
this O
study O
at O
doses O
of O
up O
to O
30 O
micrograms/kg O
3 O
times O
a O
week O
for O
2 O
weeks O
. O
['Life-Impact']

Subjects O
received O
either O
clonidine O
( O
approximately O
0.005 O
mg/kg/day O
) O
or O
placebo O
by O
a O
weekly O
transdermal O
patch O
. O
[]

Secondary O
clinical O
benefit O
end O
points O
included O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
5 I-outcome ['Physiological-Clinical']
% I-outcome ['Physiological-Clinical']
definitive I-outcome ['Physiological-Clinical']
weight O
loss B-outcome ['Physiological-Clinical']
, O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
definitive I-outcome ['Physiological-Clinical']
worsening I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
appetite I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
one I-outcome ['Physiological-Clinical']
grade O
, O
pain-free B-outcome ['Physiological-Clinical']
survival B-outcome ['Mortality']
( O
defined B-outcome ['Physiological-Clinical']
as O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
appearance I-outcome ['Physiological-Clinical']
of O
pain B-outcome ['Physiological-Clinical']
) O
, O
and O
time O
to O
first O
cancer O
pain-related O
opioid O
intake O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
it O
had O
some O
degree O
of O
face O
validity O
and O
social B-outcome ['Life-Impact']
validity I-outcome ['Life-Impact']
from O
the O
students O
' O
vantage O
point O
. O
['Life-Impact']

These O
results O
show O
that O
in O
hypertensive O
obese O
men O
a O
moderate O
weight O
reducing O
diet O
decreases O
indices O
of O
sympathetic B-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Most O
of O
the O
clinical O
data O
were O
associated O
with O
oral O
health O
impacts O
. O
[]

Outcome O
was O
favourable O
, O
with O
no O
seizures B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
mildly I-outcome ['Physiological-Clinical']
affected I-outcome ['Physiological-Clinical']
cognitive I-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Secretin O
has O
been O
proposed O
as O
a O
treatment O
alternative O
for O
autistic B-outcome ['Life-Impact']
spectrum O
disorders B-outcome ['Life-Impact']
, O
but O
empirical O
support O
is O
lacking O
. O
['Life-Impact', 'Life-Impact']

TRIAL O
REGISTRATION O
clinicaltrials.gov O
Identifier O
: O
NCT00198822 O
. O
[]

Patients O
were O
randomized O
into O
two O
groups O
( O
with O
and O
without O
CPRV O
) O
. O
[]

The O
groups O
' O
diagnostic O
accuracy O
, O
however O
, O
did O
not O
differ O
significantly O
on O
the O
post-test O
, O
retention O
test O
or O
transfer O
test O
items O
( O
p O
> O
0.12 O
) O
. O
[]

A O
clinical O
trial O
using O
prospective O
, O
random O
allocation O
of O
consecutive O
eligible O
patients O
. O
[]

Summing O
scores O
across O
heterogeneous O
symptom O
items O
without O
consideration O
of O
their O
differing O
psychopathological O
significance O
has O
been O
criticized O
as O
producing O
an O
inadequate O
picture O
of O
an O
individual O
's O
clinical O
status O
. O
[]

The O
median O
follow-up O
duration O
is O
6.5 O
years O
. O
[]

BACKGROUND O
Secretin O
is O
a O
peptide O
hormone O
that O
stimulates O
pancreatic O
secretion O
. O
[]

From O
1976 O
to O
1985 O
, O
a O
total O
of O
58 O
infants O
and O
children O
with O
the O
hemolytic-uremic O
syndrome O
were O
randomly O
assigned O
to O
treatment O
either O
with O
heparin O
and O
dipyridamole O
or O
with O
supportive O
management O
only O
. O
[]

They O
are O
proposed O
as O
being O
an O
optimal O
method O
for O
teaching O
clinical O
reasoning O
skills O
. O
[]

Mediation O
analyses O
tested O
whether O
change O
in O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
, O
or O
fatigue B-outcome ['Physiological-Clinical']
predicted O
change O
in O
white B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
neutrophil B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
or O
the O
helper/suppressor B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Recurrences O
of O
arrhythmia O
, O
deaths O
, O
and O
adverse O
drug O
effects O
during O
long-term O
follow-up O
were O
recorded O
for O
the O
296 O
patients O
in O
whom O
an O
antiarrhythmic O
drug O
was O
predicted O
to O
be O
effective O
. O
[]

There O
were O
no O
differences O
in O
the O
quality O
of O
life O
score O
or O
laboratory B-outcome ['Physiological-Clinical']
data O
apart O
from O
increased O
diarrhea B-outcome ['Physiological-Clinical']
after O
surgical O
resection O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
study O
was O
performed O
to O
determine O
the O
sensitivity O
and O
short-term O
and O
day-to-day O
variability O
of O
a O
novel O
technique O
based O
on O
laser O
interferometry O
of O
ocular O
fundus O
pulsations O
and O
of O
non-invasive O
methods O
for O
the O
quantification O
of O
haemodynamic O
drug O
effects O
. O
[]

Fifty-one O
patients O
( O
breast O
, O
n O
= O
24 O
; O
abdomen O
, O
n O
= O
27 O
) O
were O
randomized O
. O
[]

From O
the O
above O
results O
, O
PEB O
seems O
to O
be O
a O
better O
induction O
chemotherapy O
than O
the O
conventional O
one O
for O
advanced O
testicular O
tumors O
. O
[]

The O
influence O
of O
acute O
sleep O
deprivation O
during O
the O
first O
part O
of O
the O
night O
on O
24-h O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
monitoring O
( O
ABPM O
) O
was O
studied O
in O
36 O
never-treated O
mild O
to O
moderate O
hypertensive O
patients O
. O
['Physiological-Clinical']

The O
question O
is O
whether O
there O
is O
a O
necessity O
for O
irradiating O
all O
patients O
. O
[]

PATIENTS O
were O
randomized O
to O
receive O
( O
group O
S O
) O
or O
not O
( O
group O
C O
) O
sevoflurane O
administration O
for O
15 O
min O
just O
before O
coronary O
occlusion O
. O
[]

In O
a O
prospective O
trial O
, O
42 O
medical O
patients O
with O
a O
history O
of O
deep O
vein O
thrombosis O
of O
less O
than O
five O
days O
were O
allocated O
at O
random O
to O
treatment O
with O
streptokinase O
or O
heparin O
. O
[]

Efficacy O
measurements O
were O
comparable O
between O
the O
three O
treatment O
groups O
, O
although O
the O
higher O
lamotrigine O
dose O
was O
possibly O
most O
effective O
, O
with O
60.4 O
% O
completing O
seizure O
free O
compared O
with O
51.3 O
% O
( O
LTG O
100 O
) O
and O
54.7 O
% O
( O
CBZ O
600 O
) O
. O
[]

The O
results O
indicate O
that O
VEG O
have O
a O
lower O
muscle B-outcome ['Physiological-Clinical']
TCr B-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
and O
an O
increased O
['Physiological-Clinical', 'Physiological-Clinical']

Effect O
of O
granulocyte/colony-stimulating O
factor O
on O
the O
onset O
of O
the O
adult O
respiratory O
distress O
syndrome O
. O
[]

It O
may O
predate O
the O
onset O
of O
clinically O
apparent O
hypertension O
. O
[]

Differences O
in O
straylight O
between O
baseline O
( O
without O
CL O
) O
and O
with O
the O
clear O
CL O
in O
place O
were O
neither O
statistically O
significant O
( O
p O
= O
0.066 O
) O
nor O
was O
there O
a O
significant O
difference O
between O
baseline O
and O
the O
amber O
CL O
( O
p O
= O
0.052 O
) O
. O
[]

Within-subject O
variables O
included O
ATC-related B-outcome ['Physiological-Clinical']
workload I-outcome ['Physiological-Clinical']
and O
the O
modality O
, O
frequency O
, O
and O
priority O
of O
interruption O
tasks O
. O
['Physiological-Clinical']

Supplementation O
of O
RPLM O
at O
the O
10 O
g/d O
level O
improved O
gain O
: O
[]

Pain B-outcome ['Physiological-Clinical']
detection O
and O
tolerance O
thresholds O
for O
pressure O
and O
electric B-outcome ['Resource-use']
stimuli I-outcome ['Resource-use']
were O
measured O
in O
six O
selected O
dermatomes O
( O
C5 O
, O
T4 O
, O
T10 O
, O
L1 O
, O
L4 O
and O
T10BACK O
) O
. O
['Physiological-Clinical', 'Resource-use']

However O
, O
the O
levels O
of O
titres O
of O
anti-PT B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
anti-FHA I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
in O
all O
the O
three O
vaccines O
that O
confer O
protection O
are O
not O
known O
. O
['Physiological-Clinical']

Bronchoscopic B-outcome ['Physiological-Clinical']
findings O
in O
patients O
with O
a O
complete O
radiographic O
regression O
of O
small B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
bronchogenic I-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
trial O
group O
was O
treated O
with O
Yufeining O
pills O
taken O
orally O
for O
half O
a O
year O
; O
the O
control O
group O
was O
not O
given O
any O
medicine O
. O
[]

The O
Research O
Units O
on O
Pediatric O
Psychopharmacology O
-- O
Autism O
Network O
reported O
additional O
benefit O
when O
adding O
parent O
training O
( O
PT O
) O
to O
antipsychotic O
medication O
in O
children O
with O
autism O
spectrum O
disorders O
and O
serious O
behavior O
problems O
. O
[]

Seven-star O
needle O
stimulation O
improves O
language B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
interaction I-outcome ['Life-Impact']
of O
children O
with O
autistic O
spectrum O
disorders O
. O
['Life-Impact']

CONCLUSIONS O
The O
epileptic O
pregnant O
patient O
's O
autoimmune O
disease O
( O
probably O
drug-induced O
lupus O
) O
could O
damage O
the O
blood-brain O
barrier O
, O
therefore O
the O
therapeutic O
dose O
( O
> O
or O
=1 O
mg O
) O
of O
folic O
acid O
triggered O
a O
cluster O
of O
seizures B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Each O
mode O
was O
randomly O
sequenced O
. O
[]

Bacteremia B-outcome ['Physiological-Clinical']
with O
Streptococcus O
viridans O
was O
not O
related O
to O
the O
use O
of O
a O
CVC O
. O
['Physiological-Clinical']

The O
influence O
of O
beta-adrenoceptor O
blockade O
on O
left O
ventricular O
function O
. O
[]

Participants O
repeatedly O
practiced O
alphabet O
subtraction O
items O
in O
short O
lag O
and O
long O
lag O
conditions O
. O
[]

There O
was O
a O
concomitant O
significant O
decrease O
in O
depression B-outcome ['Life-Impact']
rating O
from O
HDS O
8.9 O
to O
5.3 O
( O
p O
< O
0.005 O
, O
Wilcoxon O
's O
test O
) O
. O
['Life-Impact']

Sodium-potassium O
pump O
activity O
in O
white O
blood O
cells O
from O
children O
with O
an O
increased O
risk O
of O
developing O
hypertension O
-- O
The O
Odense O
Schoolchild O
Study O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
behavioral B-outcome ['Life-Impact']
effects O
of O
four O
doses O
of O
psychostimulant O
medication O
, O
combining O
extended-release O
methylphenidate O
( O
MPH O
) O
in O
the O
morning O
with O
immediate-release O
MPH O
in O
the O
afternoon O
. O
['Life-Impact']

Evaluation O
of O
oral O
zinc O
sulfate O
effect O
on O
obsessive-compulsive B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
: O
a O
randomized O
placebo-controlled O
clinical O
trial O
. O
['Life-Impact']

Scent O
and O
mood O
state O
following O
an O
anxiety-provoking O
task O
. O
[]

PURPOSE O
The O
occurrence O
of O
choroidal O
detachment O
( O
CD O
) O
in O
eyes O
with O
primary O
rhegmatogenous O
retinal O
detachment O
( O
RRD O
) O
is O
relatively O
uncommon O
( O
2 O
% O
-4.5 O
% O
) O
. O
[]

The O
subjects O
were O
randomised O
to O
an O
intervention O
group O
( O
I O
group O
) O
and O
a O
control O
group O
. O
[]

Proliferation O
was O
further O
evaluated O
by O
immunohistochemical O
Ki-67 O
expression O
. O
[]

Differences O
in O
survival B-outcome ['Mortality']
were O
not O
significant O
in O
sequential O
analysis O
. O
['Mortality']

No O
serious O
ocular O
adverse O
events O
were O
reported O
. O
[]

BACKGROUND O
AND O
PURPOSE O
Telemedicine O
techniques O
can O
be O
used O
to O
address O
the O
rural-metropolitan O
disparity O
in O
acute O
stroke O
care O
. O
[]

The O
validation O
was O
performed O
by O
Kruskal-Wallis O
test O
comparing O
the O
scores O
with O
the O
level O
of O
asthma O
control O
determined O
by O
physicians O
according O
to O
GINA O
guideline O
. O
[]

Children O
's O
Yale-Brown O
Obsessive O
Compulsive O
Scale O
modified O
for O
pervasive O
developmental O
disorders O
. O
[]

Follow-up O
over O
12 O
months O
will O
enhance O
understanding O
of O
the O
natural O
history O
of O
depression O
in O
cardiac O
patients O
, O
while O
the O
nested O
trial O
will O
inform O
on O
effectiveness O
of O
an O
intervention O
involving O
tailored O
advice O
and O
support O
to O
general O
practitioners O
. O
[]

QoL B-outcome ['Life-Impact']
did O
not O
change O
over O
time O
. O
['Life-Impact']

We O
previously O
described O
significant O
reductions O
in O
resting O
energy O
expenditure O
( O
REE O
) O
, O
as O
measured O
by O
indirect O
calorimetry O
, O
over O
the O
course O
of O
HSCT O
. O
[]

We O
evaluated O
change O
over O
time O
in O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
and O
hormones B-outcome ['Physiological-Clinical']
during O
the O
first O
17 O
weeks O
postpartum O
, O
as O
well O
as O
a O
single O
cytokine O
measure O
, O
and O
their O
association O
with O
PPMD O
recurrence O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Primary O
outcome O
measures O
are O
the O
20-item O
Toronto O
Alexithymia O
Scale O
, O
the O
Coping O
Inventory O
for O
Stressful O
Situations O
, O
the O
Motion O
Picture O
Mind-Reading O
task O
, O
and O
an O
ASD O
questionnaire O
. O
[]

OBJECTIVE O
The O
renin-angiotensin O
system O
is O
thought O
to O
be O
involved O
in O
the O
progression O
of O
chronic O
renal O
diseases O
of O
both O
diabetic O
and O
non-diabetic O
origin O
. O
[]

In O
addition O
, O
a O
subjective O
rating O
scale O
was O
used O
. O
[]

Patients O
with O
ventricular O
tachycardia O
also O
had O
either O
syncope O
or O
other O
serious O
cardiac O
symptoms O
, O
along O
with O
a O
left O
ventricular O
ejection O
fraction O
of O
0.40 O
or O
less O
. O
[]

Risperidone-induced O
prolactin B-outcome ['Physiological-Clinical']
elevation I-outcome ['Physiological-Clinical']
in O
a O
prospective O
study O
of O
children O
, O
adolescents O
, O
and O
adults O
with O
mental O
retardation O
and O
pervasive O
developmental O
disorders O
. O
['Physiological-Clinical']

The O
renin O
inhibitor O
provides O
a O
promising O
alternative O
approach O
for O
the O
treatment O
of O
patients O
with O
chronic O
proteinuric O
non-diabetic O
kidney O
disease O
. O
[]

30 O
% O
had O
grade O
3/4 O
toxicity B-outcome ['Adverse-effects']
, O
mainly O
haematological O
, O
nausea/vomiting O
and O
neutropenic O
fever O
, O
and O
six O
patients O
were O
reported O
as O
having O
a O
treatment-related O
death B-outcome ['Mortality']
. O
['Adverse-effects', 'Mortality']

The O
pilot O
study O
demonstrated O
the O
feasibility B-outcome ['Life-Impact']
of O
the O
TAMS O
as O
an O
alternative O
to O
OSD O
. O
['Life-Impact']

METHODS O
We O
performed O
a O
4-week O
randomized O
controlled O
trial O
among O
33 O
RA O
patients O
with O
wrist O
arthritis O
. O
[]

Scanning O
electron O
microscopy O
( O
SEM O
) O
evaluated O
the O
effect O
of O
different O
caries B-outcome ['Resource-use']
removal I-outcome ['Resource-use']
techniques I-outcome ['Resource-use']
on O
human O
dentin O
topography O
. O
['Resource-use']

Treatment O
response O
was O
assessed O
with O
1-week O
actigraphic O
monitoring O
, O
sleep O
diary O
and O
sleep O
questionnaire O
. O
[]

METHODS/DESIGN O
The O
RESPECT O
study O
is O
a O
nationwide O
population-based O
prospective O
, O
controlled O
, O
mixed-methods O
intervention O
study O
looking O
at O
children O
aged O
6-18 O
years O
newly O
diagnosed O
with O
cancer O
in O
eastern O
Denmark O
( O
n=120 O
) O
and O
a O
matched O
control O
group O
in O
western O
Denmark O
( O
n=120 O
) O
. O
[]

The O
dose O
of O
GM-CSF O
was O
increased O
every O
2 O
weeks O
if O
necessary O
to O
keep O
the O
ANC B-outcome ['Physiological-Clinical']
greater O
than O
1,000/microL O
while O
maintaining O
full-dose O
zidovudine O
therapy O
. O
['Physiological-Clinical']

The O
8- O
and O
16-hour O
acid O
challenge O
of O
the O
lesions B-outcome ['Physiological-Clinical']
remineralized I-outcome ['Physiological-Clinical']
with O
the O
control O
gum O
resulted O
in O
65.4 O
and O
88.0 O
% O
reductions O
, O
respectively O
, O
of O
deposited O
mineral O
, O
while O
for O
the O
CPP-ACP-remineralized O
lesions O
the O
corresponding O
reductions O
were O
30.5 O
and O
41.8 O
% O
. O
['Physiological-Clinical']

In-season O
effect O
of O
short-term O
sprint O
and O
power O
training O
programs O
on O
elite O
junior O
soccer O
players O
. O
[]

PURPOSE O
The O
aim O
of O
the O
study O
was O
to O
determine O
the O
accuracy O
of O
non-rigid O
nine-parameter O
image O
registrations O
based O
on O
153Gd O
transmission O
computed O
tomography O
( O
TCT O
) O
images O
as O
compared O
with O
those O
based O
on O
99mTc-ethyl O
cysteinate O
dimer O
( O
ECD O
) O
images O
and O
to O
assess O
whether O
normalised O
mutual O
information O
( O
NMI O
) O
or O
count O
difference O
( O
CD O
) O
should O
be O
used O
. O
[]

MATERIALS O
AND O
METHODS O
HD O
patients O
in O
stage O
I O
to O
IIIA O
with O
a O
large O
mediastinal O
mass O
, O
E O
stage O
, O
or O
massive O
spleen O
involvement O
were O
treated O
with O
two O
double O
cycles O
of O
alternating O
cyclophosphamide O
, O
vincristine O
, O
procarbazine O
, O
and O
prednisone O
( O
COPP O
) O
plus O
doxorubicin O
, O
bleomycin O
, O
vinblastine O
, O
and O
dacarbazine O
( O
ABVD O
) O
followed O
by O
EF O
irradiation O
in O
two O
successive O
trials O
( O
HD1 O
and O
HD5 O
) O
. O
[]

No O
significant O
differences O
were O
found O
for O
WOMAC O
stiffness B-outcome ['Life-Impact']
, O
the O
SF-36 O
subscales O
or O
the O
activity O
scale O
. O
['Life-Impact']

These O
results O
suggest O
that O
impaired O
metabolism O
of O
BK O
induced O
by O
ACE O
inhibitors O
may O
relate O
to O
the O
manifestation O
of O
cough O
in O
hypertensive O
patients O
receiving O
ACE O
inhibitors O
. O
[]

A O
third O
group O
( O
group O
3 O
, O
n=14 O
) O
received O
no O
treatment O
. O
[]

Clinical O
results O
of O
its O
medium-term O
action O
] O
. O
[]

METHODS O
We O
conducted O
two O
feasibility O
studies O
to O
assess O
men O
's O
( O
45-70 O
years O
) O
Internet O
access O
and O
their O
willingness O
to O
use O
a O
web- O
vs. O
a O
print-based O
tool O
. O
[]

From O
November O
1989 O
to O
June O
1990 O
, O
13 O
patients O
received O
aprotinin O
as O
a O
bolus O
of O
0.5 O
Mill O
. O
[]

Enhanced O
vascular O
endothelial O
growth O
factor O
and O
inflammatory O
cytokine O
removal O
with O
online O
hemodiafiltration O
over O
high-flux O
hemodialysis O
in O
sepsis-related O
acute O
kidney O
injury O
patients O
. O
[]

Nausea B-outcome ['Physiological-Clinical']
was O
reduced O
from O
38 O
% O
( O
969/2585 O
) O
in O
the O
control O
to O
28 O
% O
( O
715/2576 O
) O
in O
the O
ondansetron O
group O
, O
corresponding O
to O
a O
relative O
risk O
of O
0.74 O
, O
or O
a O
relative O
risk O
reduction O
of O
26 O
% O
. O
['Physiological-Clinical']

Genotype O
had O
a O
significant O
influence O
on O
both O
behavioral B-outcome ['Life-Impact']
and O
neuronal B-outcome ['Physiological-Clinical']
measures I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
social I-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

The O
IVUS O
data O
demonstrated O
a O
numeric O
trend O
toward O
regression O
in O
the O
total O
atheroma B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of O
-12.18 O
+/- O
36.75 O
mm O
( O
3 O
) O
in O
the O
delipidated O
group O
versus O
an O
increase O
of O
total O
atheroma B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of O
2.80 O
+/- O
21.25 O
mm O
( O
3 O
) O
in O
the O
control O
group O
( O
p O
= O
0.268 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

An O
occupation O
based O
physical O
activity O
intervention O
program O
: O
improving O
fitness B-outcome ['Life-Impact']
and O
decreasing O
obesity B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Ninety O
days O
post O
STZ O
the O
rats O
were O
sacrificed O
, O
and O
testis B-outcome ['Physiological-Clinical']
, O
epididymis B-outcome ['Physiological-Clinical']
, O
prostate B-outcome ['Physiological-Clinical']
, O
and O
seminal B-outcome ['Physiological-Clinical']
vesicles I-outcome ['Physiological-Clinical']
were O
weighed O
and O
subjected O
to O
histological O
examination O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Hemostatic O
parameters O
were O
measured O
at O
baseline O
and O
after O
3 O
and O
12 O
months O
of O
therapy O
. O
[]

A O
significant O
rise O
in O
TnT B-outcome ['Physiological-Clinical']
as O
a O
sign O
of O
myocardial O
infarction O
was O
observed O
in O
71 O
patients O
( O
35.5 O
% O
) O
, O
and O
25 O
of O
them O
had O
a O
TnT B-outcome ['Physiological-Clinical']
elevation I-outcome ['Physiological-Clinical']
exceeding O
five O
times O
the O
upper O
normal O
limit O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Groups O
receiving O
paromomycin O
or O
placebo O
were O
similar O
for O
clinical O
and O
biological O
items O
collected O
initially O
. O
[]

The O
median O
change O
from O
baseline O
in O
the O
percent O
of O
predicted O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
1 O
second O
was O
8.7 O
% O
( O
range O
, O
2.3 O
to O
31.3 O
; O
P=0.008 O
for O
the O
within-subject O
comparison O
, O
P=0.56 O
vs. O
placebo O
) O
. O
['Physiological-Clinical']

While O
, O
in O
the O
ASA O
plus O
dipyridamole-treated O
group O
, O
occlusions B-outcome ['Physiological-Clinical']
were O
found O
in O
11 O
of O
the O
39 O
reconstructions O
( O
28.2 O
% O
) O
, O
the O
proportion O
was O
nine O
out O
of O
37 O
procedures O
( O
24.3 O
% O
) O
in O
the O
indobufen O
group O
. O
['Physiological-Clinical']

This O
multicenter O
, O
double-blind O
, O
parallel-group O
study O
was O
designed O
to O
assess O
the O
efficacy O
and O
the O
safety O
of O
fixed O
low O
dose O
combination O
perindopril O
2 O
mg/indapamide O
0.625 O
mg O
( O
Per/Ind O
) O
versus O
atenolol O
50 O
mg O
( O
Ate O
) O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effectiveness O
of O
school O
dental O
screening O
in O
promoting O
dental B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
among O
children O
with O
a O
treatment O
need O
and O
to O
examine O
the O
relative O
importance O
of O
screening O
, O
social O
class O
and O
other O
factors O
in O
dental B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

OBJECTIVES O
We O
hypothesized O
that O
the O
wakefulness O
promoter O
, O
modafinil O
, O
would O
ameliorate O
this O
decline O
. O
[]

These O
data O
provide O
evidence O
that O
OPN B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
is O
an O
independent O
prognostic O
factor O
in O
AML O
. O
['Physiological-Clinical']

Sinemet O
CR O
in O
Parkinson O
's O
disease O
. O
[]

There O
were O
no O
differences O
in O
scores O
on O
the O
basis O
of O
acromion O
type O
, O
nor O
were O
any O
interaction O
effects O
identified O
between O
group O
and O
acromion O
type O
. O
[]

RESULTS O
Weight O
change O
after O
12 O
months O
of O
intervention O
was O
as O
follows O
( O
mean O
+/- O
SD O
) O
: O
0.85 O
+/- O
6.0 O
kg O
in O
the O
control O
group O
, O
-2.6 O
+/- O
5.9 O
kg O
in O
the O
Weight O
Watchers O
group O
, O
-8.0 O
+/- O
5.5 O
kg O
in O
the O
individualized O
group O
, O
and O
-9.4 O
+/- O
8.6 O
kg O
in O
the O
comprehensive O
group O
that O
used O
both O
individualized O
counseling O
and O
Weight O
Watchers O
. O
[]

Compared O
with O
before O
treatment O
, O
the O
KPS B-outcome ['Physiological-Clinical']
was O
significantly O
improved O
in O
the O
treatment O
group O
after O
treatment O
, O
while O
it O
significantly O
decreased O
in O
the O
control O
group O
after O
treatment O
( O
both O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

METHODS O
Thirty O
patients O
scheduled O
for O
craniotomy O
were O
assigned O
to O
either O
a O
normothermic O
or O
mildly O
hypothermic O
group O
. O
[]

Addition O
of O
fexofenadine O
to O
inhaled O
corticosteroid O
therapy O
to O
reduce O
inflammatory B-outcome ['Physiological-Clinical']
biomarkers I-outcome ['Physiological-Clinical']
in O
atopic O
asthma O
. O
['Physiological-Clinical']

The O
induction O
time B-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
measured I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
onset I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
eyelash I-outcome ['Physiological-Clinical']
reflex I-outcome ['Physiological-Clinical']
was O
shortest O
in O
the O
case O
of O
thiopental O
; O
while O
a O
lower O
frequency O
of O
apnea B-outcome ['Physiological-Clinical']
, O
lesser O
suppression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
circulation I-outcome ['Physiological-Clinical']
, O
and O
lack O
of O
venous B-outcome ['Physiological-Clinical']
irritation I-outcome ['Physiological-Clinical']
were O
points O
favoring O
midazolam O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
determine O
the O
effect O
of O
duloxetine O
, O
60 O
mg O
daily O
, O
on O
average O
pain B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
use O
of O
ozone O
in O
Group O
2 O
resulted O
in O
lower O
values O
of O
?TBS O
in O
all O
conditions O
evaluated O
. O
[]

Olopatadine O
is O
a O
dual O
acting O
H1 O
histamine O
receptor O
antagonist O
and O
a O
mast O
cell O
stabilizer O
, O
shown O
to O
be O
effective O
in O
treating O
allergic O
conjunctivitis O
. O
[]

Secondary O
end O
points O
were O
changes O
in O
BCVA O
and O
retinal O
thickness O
. O
[]

It O
also O
modulates O
individual O
responses O
to O
caffeine O
after O
sleep O
deprivation O
. O
[]

In O
conclusion O
, O
the O
[]

The O
majority O
of O
new B-outcome ['Physiological-Clinical']
IMI I-outcome ['Physiological-Clinical']
was O
caused O
by O
coagulase-negative O
staphylococci O
( O
49 O
% O
) O
and O
environmental O
streptococcal O
organisms O
( O
26.8 O
% O
) O
. O
['Physiological-Clinical']

The O
treated O
skin O
removed O
at O
the O
time O
of O
blepharoplasty O
was O
reviewed O
in O
a O
masked O
fashion O
by O
a O
dermatopathologist O
to O
determine O
the O
depth O
of O
necrosis O
. O
[]

OBJECTIVE O
To O
determine O
whether O
educational O
baby O
books O
are O
an O
effective O
method O
for O
increasing O
low-income O
, O
first-time O
mothers O
' O
safety O
practices O
during O
their O
child O
's O
first O
18 O
months O
. O
[]

RESULTS O
A O
total O
of O
23 O
504 O
patients O
were O
randomized O
with O
mean O
treatment O
duration O
from O
19.4 O
to O
20.8 O
months O
. O
[]

The O
pain O
experienced O
after O
third O
molar O
surgery O
was O
used O
as O
a O
model O
to O
evaluate O
the O
analgesic B-outcome ['Resource-use']
efficacy O
of O
a O
new O
non-steroidal O
anti-inflammatory O
drug O
, O
lornoxicam O
, O
in O
a O
Phase O
II O
study O
. O
['Resource-use']

The O
double-blind O
, O
placebo-controlled O
, O
randomized O
clinical O
trial O
involving O
94 O
patients O
has O
evaluated O
the O
efficacy O
and O
safety O
of O
domestic O
preparation O
afala O
in O
patients O
with O
symptoms O
of O
I-II O
stages O
benign O
prostatic O
hyperplasia O
( O
BPH O
) O
. O
[]

Data O
were O
available O
for O
55 O
children O
given O
risperidone O
( O
n=27 O
) O
or O
placebo O
( O
n=28 O
) O
; O
mean O
baseline O
ABC-I O
( O
+/- O
SD O
) O
was O
20.6 O
( O
8.1 O
) O
and O
21.6 O
( O
10.2 O
) O
. O
[]

IMPLICATIONS O
This O
study O
compared O
the O
use O
of O
a O
desflurane O
general O
anesthetic O
to O
a O
small-dose O
spinal O
anesthetic O
in O
ambulatory O
gynecological O
laparoscopy O
. O
[]

Improvement O
in O
mean O
Ferriman-Gallwey O
score O
was O
35.7 O
+/- O
38.1 O
% O
( O
p O
< O
0.001 O
) O
for O
the O
ethinyl O
estradiol/desogestrel O
arm O
and O
33.4 O
+/- O
27.3 O
% O
( O
p O
< O
0.001 O
) O
for O
the O
ethinyl O
estradiol/levonorgestrel O
arm O
. O
[]

However O
, O
no O
significant O
changes O
in O
resting O
and O
exercise-induced O
mobilizations O
of O
various O
T-lymphocyte O
subsets O
and O
productions O
of O
cytokines O
and O
MPO O
occurred O
following O
the O
N-C O
, O
H-C O
, O
N-T O
, O
and O
H-RT O
interventions O
. O
[]

Multivariate O
analysis O
identified O
karyotype B-outcome ['Physiological-Clinical']
, O
blast B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( O
day O
16 O
) O
, O
and O
the O
level O
of O
OPN B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
as O
independent O
prognostic O
factors O
for O
OS B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Qualitative O
interviews O
are O
conducted O
with O
referring O
and O
non-referring O
health O
care O
professionals O
( O
malignant O
disease O
protocol O
only O
) O
. O
[]

It O
is O
uncertain O
whether O
a O
pulmonary O
rehabilitation O
program O
delivered O
in O
its O
entirety O
at O
home O
is O
cost B-outcome ['Resource-use']
effective O
and O
equally O
capable O
of O
producing O
benefits O
in O
exercise O
capacity O
, O
symptoms O
and O
quality O
of O
life O
as O
a O
hospital-based O
program O
. O
['Resource-use']

RESULTS O
The O
Tecnis O
Z9000 O
intraocular O
lens O
provided O
statistically O
significantly O
better O
contrast O
sensitivity B-outcome ['Physiological-Clinical']
at O
1.5 O
and O
3 O
cycles O
per O
degree O
under O
mesopic O
conditions O
and O
at O
6 O
, O
12 O
and O
18 O
cycles O
per O
degree O
under O
photopic O
conditions O
. O
['Physiological-Clinical']

if O
the O
pre-transplant O
C O
( O
2 O
) O
level O
was O
?20 O
ng/mL O
, O
0.1 O
mg/kg O
b.d O
. O
[]

Immediate O
effects O
of O
a O
tibiofibular O
joint O
manipulation O
on O
lower O
extremity O
H-reflex B-outcome ['Physiological-Clinical']
measurements O
in O
individuals O
with O
chronic O
ankle O
instability O
. O
['Physiological-Clinical']

Leucovorin O
was O
coadministered O
only O
for O
hematologic O
toxicity O
. O
[]

Joint O
mobilization O
has O
been O
shown O
to O
improve O
ankle O
joint O
motion O
, O
but O
effects O
on O
surrounding O
musculature O
is O
unknown O
. O
[]

Web-based O
contraception O
satisfaction O
questionnaires O
, O
clinical O
records O
, O
and O
government-linked O
health O
administrative O
databases O
will O
be O
used O
to O
assess O
primary O
and O
secondary O
outcomes O
. O
[]

The O
discrepancy O
between O
the O
results O
of O
the O
video O
rating O
and O
the O
GDS O
is O
discussed O
. O
- O
[]

The O
upper O
95 O
% O
CL O
for O
the O
differences O
in O
positive O
cultures O
between O
the O
antibiotics O
was O
4.9 O
% O
at O
days O
3-6 O
, O
6.5 O
% O
at O
days O
12-16 O
and O
8.5 O
% O
at O
days O
26-36 O
. O
[]

Factor O
Xa O
inhibition O
is O
a O
targeted O
approach O
to O
anticoagulation O
that O
resulted O
from O
significant O
advances O
in O
our O
understanding O
of O
the O
coagulation O
cascade O
. O
[]

In O
a O
survival O
analysis O
, O
the O
difference O
between O
the O
two O
response O
curves O
was O
significant O
by O
the O
log-rank O
test O
( O
P O
= O
0.04 O
) O
, O
with O
the O
no O
incentive O
group O
having O
a O
shorter O
time O
to O
response O
than O
the O
incentive O
group O
. O
[]

Also O
here O
, O
this O
was O
contrasted O
by O
better O
EFS O
( O
p=0.039 O
) O
in O
the O
LMO2 O
positive O
group O
of O
ABC O
subtypes O
when O
treated O
with O
the O
rituximab O
containing O
regimen O
. O
[]

OBJECTIVE O
To O
describe O
the O
authors O
' O
experience O
of O
conducting O
a O
clinical O
drug O
trial O
in O
children O
with O
Asperger O
Syndrome O
, O
including O
the O
pitfalls O
encountered O
and O
lessons O
learnt O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Medical O
home O
score O
and O
components O
of O
care O
, O
as O
follows O
: O
personal O
provider O
and O
preventive O
; O
family-centered O
, O
compassionate O
, O
and O
culturally O
appropriate O
; O
accessible O
; O
comprehensive O
; O
and O
coordinated O
. O
[]

Blood O
and O
urine O
measurements O
were O
repeated O
after O
each O
treatment O
. O
[]

The O
duration O
of O
each O
level O
of O
embolic O
phenomena O
( O
zero O
, O
moderate O
, O
severe O
) O
was O
used O
to O
determine O
total O
embolic O
load O
with O
various O
steps O
( O
fracture O
manipulation O
, O
proximal O
portal O
opening O
, O
reaming O
, O
and O
nail O
passage O
) O
. O
[]

CONCLUSIONS O
HFLCS O
application O
on O
enamel O
etched O
with O
37 O
% O
phosphoric O
acid O
did O
not O
affect O
the O
bond B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
values O
and O
the O
bond B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
modes I-outcome ['Physiological-Clinical']
of O
metal O
and O
ceramic O
brackets O
bonded O
with O
RMGIC O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
outcome O
measures O
were O
the O
Social O
Responsiveness O
Scale O
and O
the O
Aberrant O
Behavior O
Checklist-Community O
. O
[]

Additionally O
, O
after O
12-hours O
postoperatively O
, O
the O
serum B-outcome ['Physiological-Clinical']
fibrinogen I-outcome ['Physiological-Clinical']
and O
platelet B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
were O
significantly O
higher O
in O
the O
multiple-pass O
hemoconcentration O
group O
as O
compared O
to O
those O
of O
the O
centrifugation O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
190 O
patients O
with O
ICCE O
and O
ACL O
and O
170 O
patients O
with O
ECCE O
and O
PCL O
were O
followed O
up O
for O
2 O
years O
. O
[]

European O
Myocardial O
Infarct O
Amiodarone O
Trial O
Investigators O
. O
[]

The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
influence O
of O
40 O
mg O
of O
the O
beta-blocker O
penbutolol O
( O
Betapressin O
TM O
; O
Hoechst O
Ltd. O
, O
Frankfurt/Main O
) O
in O
comparison O
to O
placebo O
on O
the O
insulin O
consumption O
on O
the O
blood O
sugar O
profile O
in O
twelve O
insulin-dependent O
diabetes O
( O
IDDM O
) O
patients O
. O
[]

RESULTS O
Men O
in O
the O
CBSM O
group O
maintained O
previously O
observed O
effects O
on O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
perceived B-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

However O
, O
there O
was O
no O
relationship O
between O
pre- O
and O
post-treatment O
measures O
of O
negative O
cognitions B-outcome ['Life-Impact']
and O
['Life-Impact']

The O
primary O
contributor O
to O
the O
plasma B-outcome ['Physiological-Clinical']
alkalosis I-outcome ['Physiological-Clinical']
was O
an O
increased O
[ O
SID B-outcome ['Physiological-Clinical']
] O
, O
as O
a O
result O
of O
increased O
plasma O
[ O
Na+ O
] O
and O
decreased O
plasma O
[ O
Cl- O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

AHs O
do O
not O
inhibit O
the O
wheal O
induced O
by O
the O
intradermal O
injection O
of O
AS O
in O
R-CIU O
. O
[]

Group O
A O
patients O
( O
n O
: O
9 O
) O
received O
the O
pill O
at O
8 O
a.m. O
, O
and O
group O
B O
patients O
( O
n O
: O
12 O
) O
received O
the O
pill O
at O
8 O
p.m O
. O
[]

Therapeutic O
recommendations B-outcome ['Life-Impact']
in O
polycythemia O
vera O
based O
on O
Polycythemia O
Vera O
Study O
Group O
protocols O
. O
['Life-Impact']

All O
patients O
also O
received O
bicalutamide O
for O
4 O
weeks O
. O
[]

INTRODUCTION O
The O
aim O
of O
the O
study O
is O
to O
test O
whether O
nizatidine O
delivered O
via O
a O
unique O
bimodal O
pulsatile-controlled O
release O
system O
, O
nizatidine O
controlled O
release O
( O
CR O
) O
, O
accelerates O
gastric B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
in O
patients O
with O
gastroesophageal O
reflux O
disease O
( O
GERD O
) O
. O
['Physiological-Clinical']

Some O
patients O
with O
chronic O
idiopathic O
urticaria O
( O
CIU O
) O
are O
resistant O
to O
conventional O
doses O
of O
antihistamines O
( O
AHs O
) O
. O
[]

All O
teeth O
were O
fully O
covered O
with O
polycarbonate O
resin O
crowns O
. O
[]

OBJECTIVE O
To O
compare O
intermittent O
mandatory O
ventilation O
( O
IMV O
) O
with O
synchronized O
intermittent O
mandatory O
ventilation O
plus O
pressure O
support O
( O
SIMV+PS O
) O
in O
terms O
of O
time B-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
mechanical I-outcome ['Life-Impact']
ventilation I-outcome ['Life-Impact']
, O
duration O
of I-outcome ['Resource-use']
weaning O
and O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
in I-outcome ['Resource-use']
a I-outcome ['Resource-use']
pediatric I-outcome ['Resource-use']
intensive I-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit I-outcome ['Resource-use']
( O
PICU O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Resource-use']

p16 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
INK4a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
Expression I-outcome ['Physiological-Clinical']
does O
not O
predict O
the O
outcome O
of O
cervical O
intraepithelial O
neoplasia O
grade O
2 O
. O
['Physiological-Clinical']

Following O
SRP O
, O
immediate O
elimination O
occurred O
in O
single O
individuals O
of O
all O
three O
treatment O
groups O
at O
day O
2 O
. O
[]

A O
reduction O
of O
plasma B-outcome ['Physiological-Clinical']
nitrite/nitrate I-outcome ['Physiological-Clinical']
indicated O
inhibition O
of O
nitric B-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
and O
correlated O
with O
a O
reduction O
of O
vasopressor B-outcome ['Physiological-Clinical']
support O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Variations O
in O
EEG B-outcome ['Physiological-Clinical']
discharges I-outcome ['Physiological-Clinical']
predict O
ADHD O
severity O
within O
individual O
Smith-Lemli-Opitz O
patients O
. O
['Physiological-Clinical']

The O
effects O
of O
dietary O
supplementation O
with O
coconut O
oil O
on O
the O
biochemical B-outcome ['Physiological-Clinical']
and O
anthropometric B-outcome ['Physiological-Clinical']
profiles O
of O
women O
presenting O
waist O
circumferences O
( O
WC O
) O
> O
88 O
cm O
( O
abdominal O
obesity O
) O
were O
investigated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
3 O
medications O
significantly O
reduced O
mean O
SeDBP B-outcome ['Physiological-Clinical']
from O
baseline O
compared O
with O
placebo O
at O
weeks O
4 O
, O
8 O
, O
and O
12 O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

[ O
Effect O
of O
zengjing O
no O
. O
[]

Reappraisal O
enhanced O
memory O
for O
educational B-outcome ['Life-Impact']
details I-outcome ['Life-Impact']
relative O
to O
no O
instructions O
. O
['Life-Impact']

In O
the O
6- O
to O
< O
16-week O
cohort O
, O
more O
influenza O
vaccine O
, O
recipients O
experienced O
irritability B-outcome ['Life-Impact']
( O
66.7 O
% O
vs O
35.7 O
% O
) O
and O
runny B-outcome ['Physiological-Clinical']
nose I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
nasal I-outcome ['Physiological-Clinical']
congestion I-outcome ['Physiological-Clinical']
( O
63.3 O
% O
vs O
33.3 O
% O
) O
after O
dose O
1 O
but O
not O
dose O
2 O
. O
['Life-Impact', 'Physiological-Clinical']

RESULTS O
At O
12 O
months O
, O
the O
mean O
relative B-outcome ['Physiological-Clinical']
GVR I-outcome ['Physiological-Clinical']
in O
the O
placebo O
and O
the O
rhTSH O
group O
was O
identical O
( O
35+/-3 O
% O
; O
P=0.81 O
) O
. O
['Physiological-Clinical']

The O
calculation O
of O
total O
AUC O
also O
involves O
prolonged O
sampling O
, O
adding O
to O
the O
cost O
and O
risks O
associated O
with O
bioequivalence O
studies O
. O
[]

Analysis O
was O
based O
on O
intention O
to O
treat O
, O
with O
statistical O
adjustment O
for O
clustering O
within O
hospitals/clinics O
to O
permit O
inferences O
at O
the O
individual O
level O
. O
[]

Ten O
ceramic O
blocks O
( O
6x6x6 O
mm O
) O
were O
fabricated O
and O
randomly O
assigned O
to O
2 O
groups O
( O
n=5 O
) O
, O
according O
to O
the O
conditioning O
method O
: O
G1- O
10 O
% O
hydrofluoric O
acid O
application O
for O
2 O
min O
plus O
rinsing O
and O
drying O
, O
followed O
by O
silane O
application O
for O
30 O
s O
; O
G2- O
airborne O
particle O
abrasion O
with O
30 O
microm O
silica O
oxide O
particles O
( O
CoJet-Sand O
) O
for O
20 O
s O
using O
a O
chairside O
air-abrasion O
device O
( O
CoJet O
System O
) O
, O
followed O
by O
silane O
application O
for O
5 O
min O
. O
[]

1.8 O
) O
, O
( O
14.6 O
? O
[]

However O
, O
depression B-outcome ['Life-Impact']
and O
other O
psychopathologies O
decreased O
with O
improvement O
in O
bulimic B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

The O
efficacy O
of O
both O
drugs O
in O
the O
treatment O
of O
interdigital O
tinea O
pedis O
is O
similar O
, O
and O
is O
considerably O
lower O
than O
that O
found O
with O
topical O
imidazole O
preparations O
where O
cure B-outcome ['Physiological-Clinical']
rates O
of O
over O
70 O
% O
are O
generally O
expected O
. O
['Physiological-Clinical']

Early-stage O
squamous O
cell O
carcinoma O
of O
the O
oropharynx O
: O
radiotherapy O
vs. O
trans-oral O
robotic O
surgery O
( O
ORATOR O
) O
-- O
study O
protocol O
for O
a O
randomized O
phase O
II O
trial O
. O
[]

A O
whole-cell O
vaccine O
( O
SsWC O
) O
was O
then O
produced O
by O
formalin O
inactivation O
. O
[]

FINDINGS O
The O
two O
randomised O
groups O
were O
similar O
in O
demographic O
, O
physical O
, O
and O
clinical O
characteristics O
. O
[]

24 O
comparable O
patients O
on O
placebo O
treatment O
acted O
as O
controls O
. O
[]

Sixty O
two O
percent O
( O
n O
= O
26 O
) O
of O
tunnelled O
catheters O
remained B-outcome ['Physiological-Clinical']
within I-outcome ['Physiological-Clinical']
0.5 O
cm O
of O
their O
original O
position O
compared O
to O
38 O
% O
( O
n O
= O
16 O
) O
of O
non-tunnelled O
catheters O
, O
although O
this O
difference O
was O
not O
statistically O
significant O
. O
['Physiological-Clinical']

METHODS O
In O
a O
double-blind O
study O
, O
20 O
patients O
undergoing O
lateral O
thoracotomy O
for O
lung O
resection O
were O
randomized O
to O
receive O
0.5 O
mg O
SM O
preoperatively O
and O
INB O
with O
bupivacaine O
( O
INB+ O
) O
prior O
to O
wound O
closure O
or O
0.5 O
mg O
SM O
with O
INB O
using O
saline O
( O
INB- O
) O
. O
[]

12.4 O
mg/L O
vs. O
103.2 O
? O
[]

PARTICIPANTS O
A O
total O
of O
403 O
adult O
, O
daily O
smokers O
without O
contraindications O
to O
bupropion O
SR O
use O
. O
[]

Key O
outcome O
measures O
were O
closure B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
patient B-outcome ['Life-Impact']
comfort I-outcome ['Life-Impact']
, O
and O
scar B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
at O
6 O
months O
by O
patients O
and O
surgeons O
using O
a O
new O
scar O
evaluation O
tool O
, O
visual O
assessment O
of O
linear O
scars O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

One O
group O
of O
25 O
men O
received O
injection O
papaverine O
initially O
followed O
by O
oral O
sildenafil O
, O
and O
another O
25 O
received O
oral O
sildenafil O
followed O
by O
injection O
papaverine O
. O
[]

Results O
indicate O
that O
aquatic O
exercise O
may O
positively O
impact O
the O
primary B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
secondary I-outcome ['Physiological-Clinical']
physical I-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
caused O
by O
a O
brain O
injury O
. O
['Physiological-Clinical']

A O
longer O
follow-up O
and O
confirmatory O
trials O
are O
needed O
to O
fully O
assess O
late-occurring O
toxic O
effects O
. O
[]

BACKGROUND O
Because O
of O
the O
widespread O
existence O
of O
Neisseria O
gonorrhoeae O
resistant O
to O
penicillin O
or O
tetracycline O
, O
ceftriaxone O
is O
now O
recommended O
for O
the O
treatment O
of O
gonorrhea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Patients O
received O
epoetin O
zeta O
or O
epoetin O
alfa O
intravenously O
, O
1-3 O
times/week O
for O
12 O
weeks O
, O
then O
the O
alternative O
treatment O
for O
12 O
weeks O
, O
in O
this O
double-blind O
, O
crossover O
, O
phase O
III O
trial O
. O
[]

The O
success B-outcome ['Life-Impact']
rate O
for I-outcome ['Life-Impact']
catheter I-outcome ['Life-Impact']
insertion I-outcome ['Life-Impact']
is O
57 O
% O
for O
138 O
standard O
and O
50 O
% O
for O
74 O
laser-cut O
catheters O
studied O
. O
['Life-Impact']

CLO O
was O
given O
orally O
to O
12 O
patients O
in O
a O
dosage O
of O
250 O
mg O
every O
4 O
hours O
as O
a O
liquid O
; O
GHB O
( O
initially O
30 O
mg/kg O
body O
weight O
( O
BW O
) O
followed O
by O
15 O
mg/kg O
BW O
) O
was O
administered O
intravenously O
to O
14 O
patients O
. O
[]

Basal B-outcome ['Physiological-Clinical']
ADMA I-outcome ['Physiological-Clinical']
and O
endothelin-1 B-outcome ['Physiological-Clinical']
levels O
were O
higher O
in O
patients O
with O
CSX O
than O
in O
controls O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
studied O
the O
incidence O
, O
timing O
, O
and O
outcomes O
of O
such O
arrhythmias O
in O
the O
international O
Global O
Utilization O
of O
Streptokinase O
and O
TPA O
( O
alteplase O
) O
for O
Occluded O
Coronary O
Arteries O
( O
GUSTO O
) O
-III O
trial O
. O
[]

The O
incidence O
of O
major B-outcome ['Adverse-effects']
complication I-outcome ['Adverse-effects']
was O
significantly O
lower O
in O
arm O
A O
( O
5.4 O
% O
vs.21.6 O
% O
, O
P O
= O
0.042 O
) O
. O
['Adverse-effects']

The O
patients O
were O
examined O
in O
the O
acute O
state O
and O
after O
treatment O
when O
possible O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
in O
the O
development O
of O
persistent O
AF O
, O
changes O
in O
left O
atrial O
dimension O
, O
occurrence O
of O
cardiovascular O
events O
, O
or O
changes O
in O
QOL O
. O
[]

4 O
out O
of O
10 O
on O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
ESAS O
) O
were O
randomly O
assigned O
to O
one O
of O
the O
following O
four O
groups O
: O
MP+NTI O
, O
PL+NTI O
, O
MP O
+ O
control O
telephone O
intervention O
( O
CTI O
) O
, O
and O
PL+CTI O
. O
[]

RESULTS O
In O
the O
590 O
subjects O
enrolled O
, O
the O
rate O
of O
adherence B-outcome ['Life-Impact']
was O
greater O
in O
the O
3RH O
than O
in O
the O
6H O
arm O
( O
72 O
% O
vs. O
52.4 O
% O
, O
P O
= O
0.001 O
) O
. O
['Life-Impact']

Intraperitoneal O
irrigation O
of O
the O
diaphragmatic O
surface O
and O
gallbladder O
fossa O
using O
normal O
saline O
, O
bupivacaine O
, O
or O
lignocaine O
may O
effectively O
control O
visceral B-outcome ['Physiological-Clinical']
abdominal I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
an O
LC O
. O
['Physiological-Clinical']

CONCLUSIONS O
Our O
data O
demonstrated O
no O
difference O
in O
clinical O
function O
or O
alignment O
and O
survivorship O
of O
the O
components O
between O
the O
knees O
that O
underwent O
computer-navigated O
total O
knee O
arthroplasty O
and O
those O
that O
underwent O
conventional O
total O
knee O
arthroplasty O
. O
[]

Such O
embolic O
signals O
are O
common O
after O
carotid O
endarterectomy O
, O
and O
their O
frequency O
predicts O
risk O
of O
stroke O
recurrence O
. O
[]

Is O
short-term O
, O
intensive O
instillation O
better O
than O
maintenance O
therapy O
? O
[]

The O
administration O
of O
a O
hemolytic O
streptococcus O
preparation O
, O
OK-432 O
, O
is O
thought O
to O
be O
of O
therapeutic O
value O
in O
the O
treatment O
of O
cancer O
patients O
through O
a O
stimulatory O
effect O
on O
the O
immune O
system O
. O
[]

One O
solution O
that O
addresses O
many O
of O
these O
barriers O
is O
the O
adoption O
of O
computerized O
screening O
for O
symptom O
and O
quality-of-life O
information O
. O
[]

For O
postoperative O
analgesia O
, O
0.05 O
mg/kg O
morphine O
was O
administrated O
epidurally O
30 O
min O
before O
the O
end O
of O
the O
operation O
; O
30 O
, O
60 O
, O
90 O
, O
and O
120 O
min O
after O
arriving O
in O
the O
recovery O
room O
, O
vigilance O
was O
assessed O
using O
a O
modified O
Steward O
score O
, O
the O
Trieger O
test O
, O
the O
ability O
to O
recall O
a O
column O
of O
numbers O
( O
KAI O
test O
) O
, O
and O
symbol O
counting O
( O
CI O
test O
) O
. O
[]

Moreover O
, O
BW O
decreased O
both O
linearly O
( O
P O
< O
0.01 O
) O
and O
quadratically O
( O
P O
< O
0.05 O
) O
as O
choline O
increased O
from O
0 O
to O
6,800 O
mg/kg O
. O
[]

21.25 O
) O
ml/min O
) O
and O
was O
higher O
than O
that O
of O
control O
group O
20 O
days O
after O
the O
treatment O
( O
( O
128.59 O
? O
[]

The O
change O
on O
the O
Aberrant O
Behavior O
Checklist O
irritability B-outcome ['Life-Impact']
subscale O
was O
small O
and O
clinically O
insignificant O
. O
['Life-Impact']

It O
was O
concluded O
that O
a O
10-min O
rest O
period O
between O
stimulation O
trials O
was O
insufficient O
to O
allow O
full O
recovery O
of O
muscle B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
To O
estimate O
the O
associations O
between O
autism O
spectrum O
disorder O
( O
ASD O
) O
diagnoses O
and O
service B-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
caregiver B-outcome ['Resource-use']
time I-outcome ['Resource-use']
, O
and O
cost B-outcome ['Resource-use']
outcomes O
. O
['Resource-use', 'Resource-use']

BACKGROUND O
Quality O
of O
life O
( O
QoL B-outcome ['Life-Impact']
) O
has O
gained O
greater O
importance O
in O
the O
management O
of O
metastatic O
non-small-cell O
lung O
cancer O
due O
to O
the O
palliative O
nature O
of O
treatment O
. O
['Life-Impact']

Timing B-outcome ['Mortality']
of I-outcome ['Mortality']
death I-outcome ['Mortality']
and O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
in O
patients O
with O
non-ST O
elevation O
acute O
coronary O
syndromes O
: O
insights O
from O
randomized O
clinical O
trials O
. O
['Mortality', 'Physiological-Clinical']

Nasal B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
and O
concentration O
of O
sICAM-1 O
in O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
were O
assessed O
before O
and O
on O
the O
last O
day O
of O
each O
treatment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

On O
D14 O
, O
100 O
% O
of O
the O
subjects O
had O
protective B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
titers O
( O
anti-rabies O
antibodies O
> O
or O
= O
0.5 O
IU O
ml O
( O
-1 O
) O
, O
which O
is O
the O
WHO-recommended O
level O
of O
seroconversion O
) O
, O
and O
Erig O
PMC O
and O
PHT-Erig O
were O
indistinguishable O
according O
to O
the O
clinical O
definition O
chosen O
. O
['Physiological-Clinical']

SETTING O
Nuclear O
medicine O
laboratory O
in O
a O
university-affiliated O
hospital O
. O
[]

The O
treatment O
group O
also O
showed O
in O
vivo B-outcome ['Physiological-Clinical']
T-cell I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
with O
an O
initial O
lymphopenia O
followed O
by O
a O
rebound B-outcome ['Physiological-Clinical']
lymphocytosis I-outcome ['Physiological-Clinical']
and O
upregulation O
of O
the O
subset B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
CD25 I-outcome ['Physiological-Clinical']
( O
interleukin B-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
) O
and O
CD45RO B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
T-memory I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pooled O
Multiple O
Sleep O
Latency O
Test O
( O
MSLT O
) O
data O
from O
2 O
randomized O
, O
double-blind O
, O
placebo-controlled O
trials O
in O
463 O
patients O
with O
SWD O
, O
1 O
with O
armodafinil O
150 O
mg/d O
and O
1 O
with O
modafinil O
200 O
mg/d O
( O
both O
administered O
around O
2200 O
h O
before O
night O
shifts O
) O
, O
were O
used O
to O
build O
a O
pharmacokinetic/pharmacodynamic B-outcome ['Physiological-Clinical']
model O
. O
['Physiological-Clinical']

DESIGN O
Population-based O
cross-sectional O
study O
. O
[]

For O
statistical O
purposes O
, O
data O
were O
dichotomized O
[ O
( O
0,1 O
) O
( O
2,3 O
) O
] O
for O
the O
gingival O
index O
. O
[]

The O
clinical B-outcome ['Physiological-Clinical']
syndromes I-outcome ['Physiological-Clinical']
and O
the O
index O
of O
the O
transcranial B-outcome ['Physiological-Clinical']
Doppler I-outcome ['Physiological-Clinical']
( O
TCD B-outcome ['Physiological-Clinical']
) O
and O
hemorheology B-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Gains O
were O
generally O
maintained O
at O
3-month O
follow-up O
for O
CBT O
responders O
. O
[]

OBJECTIVES O
The O
main O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
dose-dependent O
anesthetic B-outcome ['Resource-use']
efficacy O
of O
the O
intraseptal O
anesthesia O
( O
ISA O
) O
and O
periodontal O
ligament O
anesthesia O
( O
PLA O
) O
obtained O
with O
different O
volumes O
of O
4 O
% O
articaine O
and O
1:100,000 O
epinephrine O
( O
Ar O
+ O
Ep O
) O
in O
human O
mandibular O
premolars O
, O
using O
a O
computer-controlled O
local O
anesthetic O
delivery O
system O
( O
CCLADS O
) O
. O
['Resource-use']

Secondary O
end-points O
included O
the O
percentage O
of O
heartburn-free B-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
and O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
sustained I-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mecamylamine O
pretreatment O
prevented O
the O
increase O
in O
alpha B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
caused O
by O
the O
4 O
mg O
gum O
dose O
but O
not O
the O
8 O
mg O
dose O
. O
['Physiological-Clinical']

BACKGROUND/PURPOSE O
Photodynamic O
therapy O
( O
PDT O
) O
using O
aminolaevulinic O
acid O
( O
ALA O
) O
is O
widely O
used O
in O
the O
treatment O
of O
non-melanoma O
skin O
cancer O
. O
[]

Adherence O
was O
evaluated O
primarily O
by O
means O
of O
MEMS O
( O
Medication O
Event O
Monitoring B-outcome ['Life-Impact']
System O
, O
Aprex O
Corporation O
, O
Fremont O
, O
California O
) O
an O
electronic O
system O
that O
records O
the O
date O
and O
time O
of O
opening O
of O
the O
study O
medication O
container O
. O
['Life-Impact']

More O
active O
capsacinoids O
might O
be O
tried O
in O
the O
future O
and O
could O
provide O
a O
new O
method O
for O
treating O
migraine O
attacks O
. O
[]

Eighty-two O
patients O
who O
were O
affected O
by O
menorrhagia O
that O
was O
unresponsive O
to O
medical O
treatment O
were O
respectively O
randomized O
to O
transcervical O
hysteroscopic O
endometrial O
resection O
or O
to O
thermal O
destruction O
of O
the O
endometrium O
. O
[]

Furthermore O
, O
the O
dentition O
of O
the O
patients O
in O
the O
two O
experimental O
groups O
was O
treated O
, O
at O
three-month O
intervals O
, O
with O
chlorhexidine O
and O
fluoride O
varnish O
, O
respectively O
. O
[]

Using O
a O
quasi-experimental O
design O
, O
the O
authors O
studied O
118 O
left-heart O
catheterization O
patients O
who O
were O
randomly O
assigned O
to O
4 O
hours O
or O
6 O
hours O
of O
bed O
rest O
. O
[]

The O
use O
of O
adrenocorticotrophic O
hormone O
( O
4-9 O
) O
analog O
ORG O
2766 O
in O
autistic O
children O
: O
effects O
on O
the O
organization O
of O
behavior O
. O
[]

RESULTS O
The O
average O
number O
of O
horizontal B-outcome ['Physiological-Clinical']
overlaps I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
loop I-outcome ['Physiological-Clinical']
and O
holder B-outcome ['Physiological-Clinical']
techniques I-outcome ['Physiological-Clinical']
at O
the O
right O
premolar O
, O
right O
molar O
, O
left O
premolar O
, O
and O
left O
molar O
were O
1.64 O
, O
2.11 O
, O
2.16 O
, O
2.78 O
, O
and O
1.64 O
, O
2.00 O
, O
2.00 O
, O
2.18 O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
influence O
of O
epidermal O
growth O
factor O
receptor O
and O
tumor O
differentiation O
on O
the O
response O
to O
accelerated O
radiotherapy O
of O
squamous O
cell O
carcinomas O
of O
the O
head O
and O
neck O
in O
the O
randomized O
DAHANCA O
6 O
and O
7 O
study O
. O
[]

This O
study O
implemented O
a O
stress O
reduction O
program O
for O
women O
and O
investigated O
its O
ability O
to O
improve O
survival O
in O
women O
coronary O
patients O
. O
[]

Perioperative O
blood O
loss O
, O
hidden O
blood O
loss O
, O
knee O
swelling O
, O
ecchymosis O
, O
analgesia O
requirements O
, O
range O
of O
motion O
( O
ROM O
) O
, O
fixed O
flexion O
deformity O
( O
FFD O
) O
, O
straight-leg O
raising O
action O
, O
and O
postoperative O
complications O
within O
6 O
weeks O
of O
surgery O
were O
measured O
for O
evaluation O
and O
comparison O
. O
[]

RESULTS O
Part O
I O
included O
63 O
children O
. O
[]

OBJECTIVE O
Risperidone O
is O
effective O
for O
short-term O
treatment O
of O
aggression O
, O
temper O
outbursts O
, O
and O
self-injurious O
behavior O
in O
children O
with O
autism O
. O
[]

Most O
adjuvants O
may O
act O
by O
inducing O
cytokines O
, O
and O
among O
them O
, O
type O
I O
interferons O
( O
IFNs O
) O
, O
deserve O
a O
special O
attention O
in O
view O
of O
the O
potent O
immunomostimulatory O
activity O
observed O
in O
mouse O
models O
and O
on O
dendritic O
cell O
functions O
. O
[]

BACKGROUND O
Ulcerative O
colitis O
( O
UC O
) O
is O
a O
chronic O
relapsing O
and O
remitting O
idiopathic O
inflammatory O
bowel O
disorder O
. O
[]

So O
far O
, O
only O
few O
studies O
have O
investigated O
the O
effectiveness O
of O
physical O
activity O
over O
the O
entire O
inpatient O
phase O
of O
an O
allogeneic O
HSCT O
. O
[]

OBJECTIVE O
To O
test O
a O
new O
behavioral O
intervention O
for O
black O
MSM O
in O
reducing O
sexual O
risk O
and O
increasing O
social O
support O
and O
intentions O
to O
use O
condoms O
. O
[]

The O
examining O
physician O
was O
unaware O
of O
the O
treatment O
allocation O
. O
[]

Fine O
texture O
analysis O
with O
either O
a O
conventional O
instrument O
or O
a O
laparoscopic O
instrument O
was O
superior O
to O
direct O
palpation O
( O
p O
< O
0.05 O
) O
. O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
and O
compliance B-outcome ['Life-Impact']
were O
assessed O
at O
the O
6-month O
visit O
. O
['Adverse-effects', 'Life-Impact']

Efficacy O
and O
safety O
of O
routine O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
lowering I-outcome ['Physiological-Clinical']
in O
older O
patients O
with O
diabetes O
: O
results O
from O
the O
ADVANCE O
trial O
. O
['Physiological-Clinical']

Effect O
of O
cervical O
spine O
manipulative O
therapy O
on O
judo O
athletes O
' O
grip O
strength O
. O
[]

Prandial O
insulin O
dose O
was O
reduced O
by O
20 O
% O
. O
[]

An O
objective O
response O
to O
treatment O
was O
observed O
in O
48 O
per O
cent O
of O
the O
patients O
of O
the O
group O
I O
and O
60 O
per O
cent O
of O
the O
group O
II O
. O
[]

Patients O
with O
spotty O
calcification O
were O
identified O
based O
on O
the O
presence O
of O
lesions O
( O
1 O
to O
4 O
mm O
in O
length O
) O
containing O
an O
arc O
of O
calcification O
of O
< O
90? O
. O
[]

All O
measures O
of O
outcome O
were O
worse O
in O
patients O
who O
developed O
fever O
, O
even O
in O
those O
without O
infections B-outcome ['Physiological-Clinical']
or O
who O
were O
World O
Federation O
of O
Neurological O
Surgeons O
grade O
I. O
Logistic O
regression O
analyses O
were O
performed O
to O
adjust O
for O
differences O
in O
preoperative O
factors O
( O
e.g. O
, O
age O
, O
Fisher O
grade O
, O
initial O
neurological O
status O
) O
. O
['Physiological-Clinical']

Clinical O
variables O
were O
compared O
by O
ANCOVA O
and O
paired O
t-tests O
after O
each O
treatment O
interval O
. O
[]

There O
were O
86 O
patients O
( O
31 O
in O
the O
single-dose O
group O
, O
28 O
in O
the O
5-day O
group O
and O
27 O
in O
the O
placebo O
group O
) O
enrolled O
in O
the O
study O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Hemodynamic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
hormonal I-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
were O
performed O
at O
established O
times O
during O
the O
infusion O
protocols O
. O
['Physiological-Clinical']

PURPOSE O
To O
determine O
whether O
the O
effect O
of O
an O
additional O
boost O
radiation O
after O
breast O
conservative O
therapy O
( O
BCT O
) O
on O
local O
control O
depends O
on O
age O
and O
evaluate O
the O
impact O
of O
a O
treatment O
policy O
with O
a O
threshold O
for O
age O
. O
[]

Breast O
cancer O
can O
be O
subdivided O
according O
to O
standard O
pathological O
parameters O
including O
histological O
type O
, O
grade O
, O
and O
assessment O
of O
proliferation O
. O
[]

LDL O
cholesterol-raising O
effect O
of O
low-dose O
docosahexaenoic O
acid O
in O
middle-aged O
men O
and O
women O
. O
[]

All O
children O
had O
access O
to O
picture O
symbols O
during O
assessments O
. O
[]

Use O
of O
PTCA O
was O
similar O
for O
placebo O
( O
92 O
% O
) O
and O
streptokinase O
( O
83 O
% O
) O
groups O
. O
[]

Initial O
head B-outcome ['Physiological-Clinical']
scans B-outcome ['Resource-use']
scored O
3 O
or O
higher O
by O
Marshall O
classification O
for O
12 O
HSD O
and O
11 O
NS O
patients O
. O
['Physiological-Clinical', 'Resource-use']

Analysing O
response O
to O
[]

2004 O
; O
15:440-449 O
) O
. O
[]

Doubling O
the O
dose O
of O
valsartan O
to O
320 O
mg O
incrementally O
lowered O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
by O
-3.8/-3.3 O
mm O
Hg O
( O
P O
= O
not O
significant O
) O
. O
['Physiological-Clinical']

FINDINGS O
2219 O
( O
87.6 O
% O
) O
of O
2534 O
eligible O
people O
received O
treatment O
. O
[]

The O
effects O
of O
haloperidol O
on O
learning B-outcome ['Life-Impact']
and O
behavior B-outcome ['Life-Impact']
in O
autistic O
children O
. O
['Life-Impact', 'Life-Impact']

Results O
indicate O
that O
the O
lag O
effect O
on O
the O
durability O
of O
memory-based B-outcome ['Life-Impact']
automaticity I-outcome ['Life-Impact']
is O
primarily O
due O
to O
interference O
. O
['Life-Impact']

Temporary O
vascular O
access O
catheters O
( O
VACs O
) O
are O
important O
devices O
used O
in O
acute O
blood O
purification O
therapies O
. O
[]

in O
The O
collaborative O
model O
for O
promoting O
competence O
and O
success O
for O
students O
with O
ASD O
. O
[]

METHODS O
A O
randomized O
controlled O
study O
with O
a O
28-month O
follow-up O
. O
[]

Eight-eight O
patients O
had O
attempted O
surgical O
resection O
following O
radiotherapy O
failure O
. O
[]

2 O
. O
[]

An O
existing O
randomised O
controlled O
trial O
was O
used O
to O
investigate O
whether O
multiple O
ultrasound O
scans O
may O
be O
associated O
with O
the O
autism B-outcome ['Life-Impact']
phenotype I-outcome ['Life-Impact']
. O
['Life-Impact']

HPV O
testing O
of O
clinician-collected O
samples O
detected O
the O
most O
cases O
of O
CIN2+ B-outcome ['Physiological-Clinical']
among O
both O
treated O
( O
85 O
% O
) O
and O
untreated O
( O
91 O
% O
) O
women O
( O
p=0.31 O
) O
. O
['Physiological-Clinical']

Patients O
with O
cerebral O
metastases O
were O
included O
. O
[]

Purpose O
of O
our O
present O
prospective O
study O
was O
to O
evaluate O
the O
dose B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
relationship O
of O
paclitaxel O
. O
['Physiological-Clinical']

N-9 O
concentration O
in O
the O
gel O
( O
2.5 O
% O
or O
5.0 O
% O
) O
was O
not O
related O
to O
the O
findings O
. O
[]

The O
goal O
was O
to O
examine O
clozapine O
's O
cost-effectiveness O
in O
routine O
practice O
for O
people O
experiencing O
lengthy O
hospitalizations O
. O
['Resource-use']

The O
primary O
aim O
of O
the O
present O
study O
was O
to O
determine O
whether O
pantoprazole O
modifies O
the O
steady-state O
serum O
concentrations O
of O
orally O
administered O
digoxin O
. O
[]

Regression O
analyses O
revealed O
inverse O
associations O
of O
FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
and O
FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
/FVC O
ratio I-outcome ['Physiological-Clinical']
with O
IL-5 B-outcome ['Physiological-Clinical']
( O
P O
< O
0.05 O
) O
in O
men O
and O
with O
IL-5 B-outcome ['Physiological-Clinical']
( O
P O
= O
0.01 O
) O
, O
IL-6 B-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
, O
IFN-gamma B-outcome ['Physiological-Clinical']
( O
P O
= O
0.034 O
) O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

During O
the O
third O
phase O
( O
the O
second O
still-face O
condition O
) O
, O
the O
children O
in O
the O
imitation O
group O
spent O
less O
time O
in O
gross O
motor O
activity O
and O
more O
time B-outcome ['Physiological-Clinical']
touching I-outcome ['Physiological-Clinical']
the O
adult O
, O
as O
if O
attempting O
to O
initiate O
an O
interaction O
. O
['Physiological-Clinical']

3 O
. O
[]

CONCLUSIONS O
AND O
CLINICAL O
RELEVANCE O
Increased O
[]

Pain B-outcome ['Physiological-Clinical']
intensity O
and O
pain B-outcome ['Physiological-Clinical']
period I-outcome ['Physiological-Clinical']
were O
statistically O
significantly O
lower O
for O
the O
30-second O
injection O
than O
for O
the O
10-second O
injection O
. O
['Physiological-Clinical', 'Physiological-Clinical']

h-1 O
. O
[]

Women O
who O
smoke O
and O
take O
oral O
contraceptives O
( O
OCs O
) O
have O
significantly O
increased O
risk O
of O
cardiovascular O
disease O
, O
but O
the O
exact O
mechanismsfor O
the O
increased O
risk O
are O
not O
known O
. O
[]

Both O
ketorolac O
and O
placebo O
provided O
immediate O
, O
significant O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
when O
delivered O
by O
EMDA O
, O
but O
only O
those O
patients O
receiving O
ketorolac O
experienced O
a O
further O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
7 O
days O
after O
treatment O
; O
those O
receiving O
placebo O
experienced O
a O
slight O
increase O
in O
pain B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Local B-outcome ['Life-Impact']
contextual I-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
in O
major O
depressive O
disorder O
. O
['Life-Impact']

We O
used O
transcranial O
magnetic O
stimulation O
( O
TMS O
) O
to O
evaluate O
the O
effect O
of O
single O
doses O
of O
amantadine O
on O
human O
motor O
cortex B-outcome ['Physiological-Clinical']
excitability O
in O
normal O
subjects O
. O
['Physiological-Clinical']

HR O
patients O
( O
volume O
> O
or=100 O
mL O
or O
metastases O
) O
were O
randomly O
assigned O
to O
receive O
14 O
courses O
of O
either O
VAIA O
or O
VAIA O
plus O
etoposide O
( O
EVAIA O
) O
. O
[]

Thirty-two O
children O
, O
18-60 O
months O
, O
were O
randomly O
assigned O
to O
the O
Picture O
Exchange O
Communication O
System O
( O
PECS O
) O
or O
Responsive O
Education O
and O
Prelinguistic O
Milieu O
Teaching O
( O
RPMT O
) O
condition O
. O
[]

The O
present O
study O
was O
undertaken O
to O
examine O
whether O
the O
effect O
of O
enalapril O
on O
plasma B-outcome ['Physiological-Clinical']
bradykinin I-outcome ['Physiological-Clinical']
( O
BK B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

0.004 O
) O
because O
salt O
or O
CES O
ingestion O
did O
not O
affect O
fluid B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
( O
W O
68 O
% O
, O
SW O
72 O
% O
, O
CES-L O
68 O
% O
, O
CES O
76 O
% O
) O
. O
['Physiological-Clinical']

RESULTS O
Rizatriptan O
5 O
mg O
was O
well O
tolerated O
. O
[]

METHODS O
240 O
patients O
with O
diagnosed O
malignancy O
and O
pain O
> O
3 O
days O
and O
average O
pain O
> O
or= O
3/10 O
will O
participate O
in O
a O
cluster O
randomized O
trial O
on O
18 O
wards O
in O
2 O
German O
university O
hospitals O
. O
[]

METHODS/DESIGN O
A O
randomized O
, O
double O
blind O
, O
placebo-controlled O
, O
superiority O
clinical O
trial O
was O
designed O
to O
assess O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
antazoline O
in O
rapid O
conversion O
of O
AF O
to O
sinus O
rhythm O
. O
['Physiological-Clinical']

No O
significant O
cardiovascular O
changes O
were O
seen O
in O
both O
groups O
. O
[]

SETTING O
Three O
research O
general O
practices O
within O
the O
East O
London O
and O
Essex O
network O
of O
researchers O
( O
ELENoR O
) O
. O
[]

Attendance O
at O
all O
events O
was O
recorded O
. O
[]

A O
double-blind O
, O
placebo-controlled O
study O
of O
risperidone O
in O
adults O
with O
autistic O
disorder O
and O
other O
pervasive O
developmental O
disorders O
. O
[]

Furthermore O
, O
in O
patients O
who O
achieved O
a O
complete O
remission B-outcome ['Physiological-Clinical']
following O
induction O
chemotherapy O
VEGFR-2 B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
levels O
decreased O
into O
the O
normal O
range O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Limitations O
of O
the O
surgical O
correction O
for O
myopia O
include O
inaccuracy O
, O
instability O
, O
treatment O
of O
the O
central O
optical O
zone O
, O
and O
lack O
of O
reversibility O
. O
[]

METHODS O
Forty O
individuals O
with O
single O
domain O
amnestic O
MCI O
and O
their O
program O
partners O
were O
randomized O
to O
receive O
the O
MSS O
, O
either O
with O
training O
or O
without O
( O
controls O
) O
. O
[]

SETTING O
University O
hospital O
. O
[]

ICI B-outcome ['Physiological-Clinical']
was O
slightly O
increased O
after O
amantadine O
intake O
, O
but O
the O
effect O
failed O
to O
be O
significant O
. O
['Physiological-Clinical']

Plasmakinetic O
prostate O
resection O
in O
the O
treatment O
of O
benign O
prostate O
hyperplasia O
: O
results O
of O
1-year O
follow O
up O
. O
[]

CONCLUSIONS O
The O
use O
of O
BNP O
levels O
in O
primary O
care O
did O
not O
reduce O
total O
medical O
cost O
, O
but O
improved O
some O
of O
the O
secondary O
end-points O
including O
diagnostic O
certainty O
and O
time O
to O
initiation O
of O
appropriate O
treatment O
. O
[]

Twenty-two O
maturity-onset O
type O
diabetics O
treated O
with O
oral O
hypoglycaemic O
agents O
entered O
a O
single-blind O
crossover O
study O
using O
placebo O
( O
periods O
A O
and O
C O
, O
2 O
months O
each O
) O
and O
clofibrate O
( O
2 O
g/day O
; O
period O
B O
; O
2 O
months O
) O
. O
[]

OBJECTIVE O
This O
prospective O
randomized O
pilot O
study O
compared O
the O
use O
of O
the O
Ligaclip O
( O
Ethicon O
Endo-Surgery O
, O
Cincinnati O
, O
OH O
) O
with O
bipolar O
coagulation O
in O
preventing O
lymphoceles O
after O
laparoscopic O
pelvic O
lymphadenectomy O
for O
gynecologic O
cancer O
. O
[]

A O
total O
of O
372 O
patients O
were O
randomized O
to O
receive O
alfuzosin O
( O
n=186 O
) O
or O
placebo O
( O
n=186 O
) O
, O
with O
355 O
completing O
the O
study O
. O
[]

RESULTS O
At O
day O
15 O
, O
the O
mean O
changes O
in O
shoulder B-outcome ['Physiological-Clinical']
pain B-outcome ['Physiological-Clinical']
score O
from O
baseline O
in O
the O
oxaprozin O
and O
diclofenac O
groups O
were O
-5.85 O
+/- O
SD O
4.62 O
and O
-5.54 O
+/- O
SD O
4.41 O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Acute O
ischaemic O
stroke O
is O
the O
third O
major O
cause O
of O
death B-outcome ['Mortality']
in O
developed O
countries O
, O
and O
a O
major O
cause O
of O
disability B-outcome ['Life-Impact']
. O
['Mortality', 'Life-Impact']

The O
main O
dependent O
measure O
was O
the O
total O
number O
of O
correct B-outcome ['Life-Impact']
classifications I-outcome ['Life-Impact']
. O
['Life-Impact']

Twenty O
VLBW O
neonates O
( O
500 O
to O
1,500 O
g O
) O
, O
aged O
< O
72 O
hours O
, O
were O
randomized O
to O
receive O
either O
placebo O
( O
n O
= O
5 O
) O
or O
rhuGM-CSF O
at O
5.0 O
micrograms/kg O
once O
per O
day O
( O
n O
= O
5 O
) O
, O
5.0 O
micrograms/kg O
twice O
per O
day O
( O
n O
= O
5 O
) O
, O
or O
10 O
micrograms/kg O
once O
per O
day O
( O
n O
= O
5 O
) O
given O
via O
2-hour O
intravenous O
infusion O
for O
7 O
days O
. O
[]

Evaluation O
of O
postprocedure O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
using O
3 O
distinct O
standard O
sedation O
regimens O
for O
endoscopic O
procedures O
. O
['Life-Impact']

The O
treatment O
group O
participates O
in O
the O
Post-Discharge O
Network O
Coordination O
Program O
. O
[]

A O
total O
of O
920 O
patients O
will O
be O
accrued O
from O
33 O
institutions O
within O
5 O
years O
. O
[]

All O
patients O
had O
histologically O
confirmed O
nonsquamous O
NSCLC O
that O
had O
progressed O
during O
or O
after O
one O
platinum-based O
regimen O
. O
[]

The O
intensity O
of O
the O
IES O
was O
scored O
with O
a O
modified O
Borg O
scale O
. O
[]

Temozolomide O
and O
cisplatin O
versus O
temozolomide O
in O
patients O
with O
advanced O
melanoma O
: O
a O
randomized O
phase O
II O
study O
of O
the O
Hellenic O
Cooperative O
Oncology O
Group O
. O
[]

The O
results O
of O
a O
randomized O
, O
single-blind O
, O
multi-clinic O
study O
comparing O
the O
therapeutic B-outcome ['Physiological-Clinical']
efficacy O
and O
degree O
of O
oral B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
of O
new O
colloidal O
bismuth O
subcitrate O
( O
CBS O
) O
coated O
tablets O
over O
4 O
weeks O
of O
treatment O
in O
patients O
suffering O
from O
duodenal O
ulceration O
are O
reported O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
radioiodine O
accumulated O
metastases O
were O
again O
treated O
with O
radioiodine O
in O
Ostrava O
. O
[]

METHOD O
253 O
couples O
with O
unexplained B-outcome ['Physiological-Clinical']
subfertility I-outcome ['Physiological-Clinical']
and O
a O
probability O
of O
a O
spontaneous O
ongoing O
pregnancy O
of O
30 O
% O
to O
40 O
% O
within O
12 O
months O
, O
were O
randomly O
assigned O
to O
IUI O
with O
COH O
for O
6 O
months O
or O
expectant O
management O
for O
6 O
months O
. O
['Physiological-Clinical']

Following O
induction O
of O
anaesthesia O
with O
propofol O
2.5 O
mg O
kg-1 O
, O
either O
rapacuronium O
1.5 O
mg O
kg-1 O
( O
n O
= O
30 O
) O
or O
rocuronium O
0.6 O
mg O
kg-1 O
( O
n O
= O
30 O
) O
was O
administered O
to O
facilitate O
tracheal O
intubation O
. O
[]

They O
were O
administered O
intravenous O
paracetamol O
( O
APAP O
1 O
g O
) O
or O
saline O
( O
placebo O
, O
pl O
) O
followed O
at O
100 O
min O
with O
IV O
naloxone O
( O
Nal O
8 O
mg O
) O
or O
saline O
, O
every O
week O
for O
4 O
weeks O
. O
[]

The O
plasma O
level O
of O
endotoxin O
, O
TNF-alpha O
, O
IL-1 O
beta O
, O
IL-6 O
and O
IL-8 O
were O
measured O
at O
0 O
, O
1 O
, O
2 O
, O
6 O
, O
12 O
, O
36 O
and O
60 O
h O
after O
CRRT O
initiation O
, O
and O
at O
0 O
, O
12 O
, O
36 O
and O
60 O
h O
after O
the O
patients O
were O
diagnosed O
as O
having O
sepsis O
in O
the O
Control O
group O
. O
[]

No O
significant O
difference O
was O
found O
concerning O
plasma O
levels O
of O
P O
( O
578 O
+/- O
477 O
ng/ml O
compared O
with O
646 O
+/- O
457 O
ng/ml O
, O
p O
greater O
than O
0.05 O
) O
. O
[]

A O
randomised O
controlled O
trial O
comparing O
two O
schedules O
of O
antenatal O
visits O
: O
the O
antenatal O
care O
project O
. O
[]

We O
conducted O
a O
single-blind O
, O
random O
assignment O
, O
placebo-controlled O
, O
12-week O
comparison O
of O
desipramine O
hydrochloride O
and O
amantadine O
hydrochloride O
as O
adjunctive O
treatments O
to O
counseling O
for O
cocaine O
dependence O
. O
[]

Consistent O
with O
previous O
reports O
gadodiamide O
injection O
was O
found O
to O
be O
a O
safe O
and O
effective O
contrast O
medium O
for O
MR O
imaging O
of O
the O
pituitary O
region O
. O
[]

No O
patients O
in O
the O
no-closure O
group O
required O
surgical O
procedures O
such O
as O
needle O
aspiration O
or O
cyst O
drainage O
. O
[]

The O
peak O
plasma B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
twice O
as O
high O
after O
drug O
administration O
at O
07.00 O
hours O
( O
13.4 O
+/- O
1 O
mg/L O
) O
than O
after O
other O
administration O
times O
( O
13.00 O
hours O
: O
6.9 O
+/- O
1 O
; O
19.00 O
hours O
: O
7.2 O
+/- O
0.7 O
; O
01.00 O
hours O
: O
6.3 O
+/- O
0.5 O
mg/L O
) O
[ O
p O
less O
than O
0.001 O
] O
. O
['Physiological-Clinical']

For O
subjects O
receiving O
aripiprazole O
, O
regardless O
of O
PAE O
, O
baseline O
weight O
, O
age O
, O
gender O
, O
and O
symptom O
severity O
were O
evaluated O
in O
a O
regression O
model O
predicting O
body O
weight O
change O
. O
[]

The O
effect O
of O
tunnelling O
on O
epidural B-outcome ['Physiological-Clinical']
catheter I-outcome ['Physiological-Clinical']
migration I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Intervention O
patients O
and O
their O
GPs O
received O
printed O
information O
detailing O
the O
care O
the O
patient O
received O
in O
hospital O
and O
the O
recommended O
postdischarge O
care O
, O
as O
well O
as O
standardized O
educational O
booklets O
about O
asthma O
. O
[]

Losartan O
significantly O
lowered O
t-PA B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
levels O
( O
-1.8 O
ng/mL O
, O
P O
= O
0.045 O
) O
, O
but O
had O
no O
effect O
on O
t-PA B-outcome ['Physiological-Clinical']
or O
PAI-1 B-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Uncuffed O
endotracheal O
tubes O
are O
routinely O
used O
in O
young O
children O
. O
[]

Cognitive-behavioural O
stress O
management O
with O
HIV-positive O
homosexual O
men O
: O
mechanisms O
of O
sustained O
reductions O
in O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
nodules B-outcome ['Physiological-Clinical']
in O
the O
group O
alpha O
dihidroergocriptine O
disappeared O
in O
23.1 O
% O
and O
in O
21.1 O
% O
of O
the O
placebo O
group O
. O
['Physiological-Clinical']

To O
address O
this O
issue O
and O
to O
evaluate O
the O
predictive O
value O
of O
HER2 O
on O
chemotherapy O
, O
we O
investigated O
a O
cohort O
of O
278 O
patients O
from O
the O
GeparTrio O
trial O
, O
a O
prospective O
neoadjuvant O
anthracycline/taxane-based O
multicenter O
study O
. O
[]

Caution O
is O
required O
when O
interpreting O
the O
findings O
from O
assessments O
of O
children O
with O
autism O
at O
age O
2 O
years O
. O
[]

All O
severe O
adverse O
events O
resolved O
without O
the O
discontinuation O
of O
VX-770 O
. O
[]

In O
a O
controlled O
study O
, O
out-patients O
suffering O
from O
moderate O
to O
severe O
depression O
were O
treated O
with O
the O
objective O
of O
assessing O
the O
new O
drug O
's O
therapeutically O
effective O
dose O
range O
. O
[]

Forty O
adult O
patients O
, O
ASA O
I-II O
were O
randomly O
allocated O
to O
receive O
halothane O
or O
isoflurane O
. O
[]

Ca/Mg O
infusions O
did O
not O
affect O
the O
clinical O
efficacy O
of O
treatment O
. O
[]

To O
evaluate O
the O
potential O
interaction O
between O
these O
agents O
, O
12 O
HIV-infected O
patients O
( O
mean O
[ O
+/- O
standard O
deviation O
] O
CD4+ O
cell O
count O
, O
304 O
+/- O
213/mm3 O
) O
were O
enrolled O
in O
a O
three-way O
crossover O
single-dose O
study O
. O
[]

10?/L O
, O
6.3 O
? O
[]

The O
initial O
examination O
and O
the O
follow-up O
evaluation O
were O
performed O
by O
a O
blinded O
observer O
. O
[]

However O
, O
statistical O
significance O
was O
not O
reached O
. O
[]

Depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
biochemically B-outcome ['Physiological-Clinical']
verified I-outcome ['Physiological-Clinical']
abstinence I-outcome ['Physiological-Clinical']
were O
assessed O
1 O
week O
prior O
to O
and O
2 O
, O
8 O
, O
16 O
, O
and O
26 O
weeks O
after O
quit O
date O
. O
['Life-Impact', 'Physiological-Clinical']

RESULTS O
Pattern O
scan O
laser O
and O
GLX O
required O
an O
average O
fluence O
of O
40.33 O
vs O
191 O
J/cm O
( O
2 O
) O
, O
respectively O
. O
[]

Physostigmine O
reverses O
propofol-induced O
unconsciousness O
and O
attenuation O
of O
the O
auditory O
steady O
state O
response O
and O
bispectral O
index O
in O
human O
volunteers O
. O
[]

An O
additional O
aim O
of O
the O
study O
is O
to O
examine O
if O
variation O
in O
dose O
of O
treatment O
( O
i.e. O
, O
number O
of O
music O
therapy O
sessions O
per O
week O
) O
affects O
outcome O
of O
therapy O
, O
and O
to O
determine O
cost-effectiveness O
. O
['Resource-use']

The O
long-term B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
four O
different O
immunosuppressive O
regimens O
on O
renal O
allografts O
have O
been O
investigated O
up O
to O
four O
years O
. O
['Physiological-Clinical']

RESULTS O
The O
median O
percentage O
decrease O
in O
the O
size O
of O
the O
epithelial B-outcome ['Physiological-Clinical']
defect I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
the O
cord O
serum O
group O
at O
days O
7 O
, O
14 O
and O
21 O
( O
p O
< O
0.05 O
) O
when O
measured O
in O
terms O
of O
the O
area O
and O
perimeter O
. O
['Physiological-Clinical']

Niacin O
revisited O
. O
[]

Calcium O
and O
magnesium O
( O
Ca/Mg O
) O
infusions O
are O
frequently O
used O
to O
prevent O
this O
toxicity O
. O
[]

Median O
time-to-progression B-outcome ['Physiological-Clinical']
was O
4.2 O
months O
in O
the O
DCT/CDDP O
arm O
and O
4.5 O
months O
in O
the O
VNR/CDDP O
one O
, O
and O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
12.1 O
( O
range O
1-26+ O
months O
) O
and O
12.5 O
months O
( O
range O
1-28+ O
months O
) O
for O
DCT/CDDP O
and O
VNR/CDDP O
arms O
, O
respectively O
. O
['Physiological-Clinical', 'Mortality']

At O
baseline O
, O
the O
frequency O
of O
AF B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
( O
days/month O
) O
was O
3.8 O
? O
['Physiological-Clinical']

Patients O
also O
received O
consolidation O
, O
maintenance O
therapy O
, O
and O
central O
nervous O
system O
prophylaxis O
. O
[]

Four O
months O
later O
, O
post-intervention O
, O
screening-coverage O
interviews O
were O
again O
performed O
in O
both O
groups O
, O
in O
combination O
with O
the O
same O
health O
education O
for O
100 O
women O
in O
the O
control O
group O
for O
a O
comparison O
. O
[]

Diagnoses O
and O
therapeutic O
decisions O
regarding O
the O
use O
of O
continuous O
positive O
airway O
pressure O
obtained O
from O
the O
home O
and O
laboratory O
studies O
were O
compared O
. O
[]

Transthoracic O
echocardiography O
with O
myocardial O
velocity O
imaging O
and O
right O
heart O
catheterization O
were O
performed O
in O
33 O
patients O
with O
pulmonary O
hypertension O
. O
[]

to O
provide O
adequate O
relaxation O
during O
the O
maintenance O
period O
. O
[]

The O
results O
were O
not O
the O
same O
for O
anti-B/Harbin O
antibodies-repeated O
vaccination O
caused O
a O
non-significant O
increase O
in O
HI O
titer O
in O
previously O
vaccinated O
subjects O
. O
[]

CONCLUSIONS O
There O
were O
no O
statistically O
significant O
differences O
between O
2 O
treatment O
schedules O
in O
survival B-outcome ['Mortality']
rates O
, O
failure B-outcome ['Physiological-Clinical']
patterns O
and O
['Mortality', 'Physiological-Clinical']

Low O
efficacy O
of O
mebendazole O
against O
hookworm B-outcome ['Physiological-Clinical']
in O
Vietnam O
: O
two O
randomized O
controlled O
trials O
. O
['Physiological-Clinical']

In O
previous O
published O
work O
we O
described O
57 O
patients O
undergoing O
emergency O
abdominal O
surgery O
, O
prospectively O
randomised O
to O
receive O
either O
cefotaxime O
or O
cephamandole O
as O
a O
single-antibiotic O
, O
three-dose O
, O
peri-operative O
prophylaxis O
against O
post-operative O
infective O
complications O
. O
[]

The O
aims O
of O
this O
study O
were O
to O
examine O
in O
a O
prospective O
, O
randomized O
trial O
the O
efficacy O
of O
plasmapheresis O
in O
preventing O
irreversible B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
in O
patients O
with O
multiple O
myeloma O
and O
to O
study O
the O
renal O
biopsy O
tissues O
from O
such O
patients O
. O
['Physiological-Clinical']

[ O
Myocardial O
ischemia O
with O
stable O
angina O
pectoris O
: O
clinico-ergometric O
evaluation O
after O
the O
use O
of O
diltiazem O
] O
. O
[]

BACKGROUND O
Previous O
results O
suggested O
that O
increased O
intake O
of O
dairy O
calcium O
is O
associated O
with O
reduced O
weight O
and O
fat B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Major B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
nonmajor I-outcome ['Physiological-Clinical']
clinically I-outcome ['Physiological-Clinical']
relevant I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
occurred O
in O
1475 O
patients O
in O
the O
rivaroxaban O
group O
( O
14.9 O
% O
per O
year O
) O
and O
in O
1449 O
in O
the O
warfarin O
group O
( O
14.5 O
% O
per O
year O
) O
( O
hazard O
ratio O
, O
1.03 O
; O
95 O
% O
CI O
, O
0.96 O
to O
1.11 O
; O
P=0.44 O
) O
, O
with O
significant O
reductions O
in O
intracranial B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
( O
0.5 O
% O
vs. O
0.7 O
% O
, O
P=0.02 O
) O
and O
fatal B-outcome ['Mortality']
bleeding I-outcome ['Mortality']
( O
0.2 O
% O
vs. O
0.5 O
% O
, O
P=0.003 O
) O
in O
the O
rivaroxaban O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

PURPOSE O
To O
study O
the O
effect O
of O
CYP17a O
inhibitor O
, O
ketoconazole O
, O
on O
clomiphene O
responsiveness O
in O
PCOS O
patients O
. O
[]

Energy-matched O
beverage O
or O
solid O
forms O
of O
fruits O
and O
vegetables O
were O
provided O
to O
34 O
, O
lean O
or O
overweight/obese O
adults O
for O
two O
8-week O
periods O
with O
a O
3-week O
washout O
interspersed O
. O
[]

Voice B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
was O
evaluated O
by O
two O
voice O
trainers O
. O
['Physiological-Clinical']

No O
significant O
changes O
in O
total O
cholesterol B-outcome ['Physiological-Clinical']
or O
LDL B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effect O
of O
a O
mixed O
kinesio O
taping-compression O
technique O
on O
quality O
of O
life O
and O
clinical B-outcome ['Physiological-Clinical']
and O
gait B-outcome ['Life-Impact']
parameters I-outcome ['Life-Impact']
in O
postmenopausal O
women O
with O
chronic O
venous O
insufficiency O
: O
double-blinded O
, O
randomized O
controlled O
trial O
. O
['Physiological-Clinical', 'Life-Impact']

In O
the O
indomethacin O
group O
( O
n O
= O
89 O
) O
, O
77 O
patients O
( O
87 O
% O
) O
showed O
no O
HO O
, O
9 O
showed O
HO O
of O
grade O
1 O
and O
3 O
showed O
HO B-outcome ['Physiological-Clinical']
of O
grade O
2 O
according O
to O
the O
Brooker O
classification O
. O
['Physiological-Clinical']

CONCLUSION O
The O
health-promotion O
programme O
seems O
to O
have O
slowed O
down O
the O
disablement B-outcome ['Life-Impact']
process I-outcome ['Life-Impact']
among O
elderly O
with O
decreased O
vision O
by O
enabling O
them O
to O
maintain O
their O
ADL B-outcome ['Physiological-Clinical']
level O
and O
by O
reducing O
self-reported B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
for O
at O
least O
28 O
months O
following O
intervention O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

It O
is O
not O
certain O
if O
it O
is O
necessary O
to O
assess O
anti-Xa B-outcome ['Physiological-Clinical']
levels O
for O
extended O
treatment O
periods O
. O
['Physiological-Clinical']

These O
PSL-LBNP O
exposures O
were O
conducted O
at O
the O
same O
time O
of O
day O
and O
separated O
by O
at O
least O
72 O
h. O
While O
no O
differences O
were O
noted O
in O
either O
the O
response O
pattern O
or O
magnitude O
of O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
or O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
to O
the O
differing O
protocols O
, O
the O
cumulative O
stress O
index O
and O
the O
duration O
of O
negative O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Totally O
HR-HPV O
infection O
70 O
patients O
were O
assigned O
to O
the O
treatment O
group O
and O
the O
control O
group O
using O
random O
single O
blind O
method O
, O
35 O
cases O
in O
each O
group O
. O
[]

METHODS O
A O
group O
of O
children O
with O
FASD O
( O
n O
= O
27 O
) O
between O
the O
ages O
of O
8 O
and O
16 O
and O
typically O
developing O
control O
children O
( O
n O
= O
27 O
) O
matched O
for O
age O
and O
sex O
, O
completed O
3 O
saccadic O
eye O
movement O
tasks O
of O
increasing O
difficulty O
. O
[]

Children O
's O
object O
interest O
, O
a O
putative O
moderator O
, O
was O
measured O
at O
Time O
1 O
. O
[]

RESULTS O
Whereas O
population O
and O
sperm B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
were O
comparable O
in O
both O
groups O
, O
the O
number O
of O
follicles B-outcome ['Physiological-Clinical']
? O
['Physiological-Clinical', 'Physiological-Clinical']

Median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
did O
not O
differ O
significantly O
between O
the O
ganitumab O
and O
placebo O
groups O
( O
3?9 O
months O
, O
80 O
% O
CI O
3?6-5?3 O
vs O
5?7 O
months O
, O
4?4-7?4 O
; O
hazard O
ratio O
[ O
HR O
] O
1?17 O
, O
80 O
% O
CI O
0?91-1?50 O
; O
p=0?44 O
) O
. O
['Mortality']

Successfully O
detoxified O
patients O
were O
referred O
to O
ongoing O
drug O
treatment O
. O
[]

CONCLUSIONS O
Local O
warming O
facilitates O
the O
insertion O
of O
peripheral B-outcome ['Resource-use']
venous I-outcome ['Resource-use']
cannulas I-outcome ['Resource-use']
, O
reducing O
both O
time B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
number I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
attempts I-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
. O
['Resource-use', 'Life-Impact']

The O
Dong O
Nai O
Pediatric O
Center O
Typhoid O
Study O
Group O
. O
[]

Residual O
stenosis O
of O
the O
infarct-related B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
shown I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
predischarge I-outcome ['Physiological-Clinical']
angiography I-outcome ['Physiological-Clinical']
was O
43.8 O
+/- O
31.4 O
% O
for O
the O
angioplasty O
group O
and O
75.0 O
+/- O
15.6 O
% O
for O
the O
streptokinase O
group O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

In O
those O
randomised O
to O
receive O
relapse O
chemotherapy O
the O
response O
rate O
was O
improved O
slightly O
for O
those O
who O
had O
originally O
received O
four O
courses O
of O
chemotherapy O
( O
25.6 O
% O
) O
over O
those O
receiving O
eight O
( O
18.7 O
% O
) O
. O
[]

METHODS O
A O
multi-centre O
randomised O
controlled O
trial O
compared O
the O
combination O
of O
Midazolam O
( O
Mi O
) O
+Morphine O
( O
Mo O
) O
and O
Mo O
alone O
. O
[]

Our O
results O
support O
the O
idea O
that O
each O
of O
these O
two O
biological O
indices O
can O
be O
used O
in O
the O
assessment O
of O
central B-outcome ['Physiological-Clinical']
noradrenergic I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
conclusions O
from O
a O
nonparametric O
repeated-measures O
technique O
indicate O
that O
mean O
night B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
was O
longer O
on O
melatonin O
than O
placebo O
by O
21 O
minutes O
( O
p O
= O
.02 O
) O
, O
mean O
sleep-onset B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
was O
shorter O
by O
28 O
minutes O
( O
p O
= O
.0001 O
) O
, O
and O
mean O
sleep-onset B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
was O
earlier O
by O
42 O
minutes O
( O
p O
= O
.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Randomized O
trial O
of O
recombinant O
alpha O
2b-interferon O
with O
or O
without O
indomethacin O
in O
patients O
with O
metastatic O
malignant O
melanoma O
. O
[]

The O
follow-up O
period O
lasted O
2 O
to O
6 O
yr. O
Renal O
survival O
, O
as O
assessed O
by O
Kaplan-Meier O
analysis O
annually O
to O
5 O
yr O
, O
showed O
significant O
preservation O
of O
function O
from O
3 O
yr O
in O
the O
treatment O
group O
and O
82 O
, O
82 O
, O
72 O
, O
and O
72 O
% O
for O
2 O
, O
3 O
, O
4 O
, O
and O
5 O
yr O
, O
respectively O
, O
compared O
with O
68 O
, O
47 O
, O
26 O
, O
and O
6 O
% O
in O
controls O
. O
[]

A O
randomized O
controlled O
study O
of O
parent-assisted O
Children O
's O
Friendship O
Training O
with O
children O
having O
autism O
spectrum O
disorders O
. O
[]

A O
model O
and O
supporting O
data O
for O
understanding O
and O
treating O
sensory B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
self-regulation I-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
in O
autism O
is O
presented O
. O
['Life-Impact']

The O
training O
targeted O
self-efficacy O
beliefs O
and O
reappraisals O
of O
secondary O
emotions O
( O
emotions O
in O
response O
to O
the O
emotional O
reactions O
elicited O
by O
the O
film O
) O
. O
[]

Secondary O
outcomes O
included O
male B-outcome ['Physiological-Clinical']
ED-specific I-outcome ['Physiological-Clinical']
quality O
of O
life O
( O
MED-QoL O
) O
, O
quality-adjusted O
life O
years O
( O
QALYs O
) O
using O
the O
generic O
Euroqol O
measure O
( O
EQ-5D O
) O
, O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
cardiovascular O
risk O
, O
cholesterol B-outcome ['Physiological-Clinical']
and O
health O
service O
costs O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Losartan O
vs. O
amlodipine O
treatment O
in O
elderly O
oncologic O
hypertensive O
patients O
: O
a O
randomized O
clinical O
trial O
. O
[]

Home O
blood O
pressure O
monitoring O
is O
a O
useful O
tool O
for O
clinical B-outcome ['Physiological-Clinical']
management I-outcome ['Physiological-Clinical']
of O
patients O
with O
hypertension O
. O
['Physiological-Clinical']

In O
patients O
with O
H/A O
, O
pain O
was O
reported O
as O
absent O
or O
mild O
in O
56 O
% O
of O
patients O
at O
the O
starting O
dosage O
of O
25/2500 O
mg/d O
; O
an O
additional O
15 O
% O
of O
the O
patients O
responded O
to O
the O
double O
dosage O
; O
the O
remaining O
29 O
% O
of O
patients O
did O
not O
experience O
any O
pain O
relief O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
erythropoietic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
after O
different O
doses O
of O
r-HuEPO O
in O
order O
to O
find O
the O
minimum O
effective O
dose O
. O
['Physiological-Clinical']

The O
experimental O
groups O
performed O
either O
endurance O
or O
resistance O
training O
3 O
days O
a O
week O
for O
12 O
weeks O
. O
[]

The O
UCAST-FW O
test O
was O
reliable O
over O
repeated O
administrations O
. O
[]

Furthermore O
, O
a O
significantly O
more O
favourable O
effect O
on O
the O
SF-36 O
'mental O
health B-outcome ['Physiological-Clinical']
' O
['Physiological-Clinical']

Postoperative O
analgesia O
with O
preoperative O
oral O
ibuprofen O
or O
acetaminophen O
in O
children O
undergoing O
myringotomy O
. O
[]

No O
adverse O
effects O
were O
reported O
. O
[]

Both O
preparations O
produced O
mean O
serum B-outcome ['Physiological-Clinical']
theophylline I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
within O
the O
10 O
-- O
20 O
mcg/ml O
range O
, O
the O
sustained-release O
tablet O
giving O
higher O
monitoring O
through O
values O
and O
smaller O
through O
to O
peak O
variation O
. O
['Physiological-Clinical']

Concerning O
the O
69-month O
survival B-outcome ['Mortality']
rate O
, O
a O
better O
result O
was O
observed O
in O
the O
MMC O
+ O
HCFU O
group O
than O
in O
the O
MMC O
only O
group O
( O
generalized O
Wilcoxon O
test O
: O
p O
less O
than O
0.05 O
) O
. O
['Mortality']

This O
increase O
was O
mainly O
caused O
by O
a O
decrease O
in O
the O
number O
of O
CD8+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
and O
was O
accompanied O
by O
an O
increase O
in O
serum B-outcome ['Physiological-Clinical']
HBV I-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
levels O
, O
which O
peaked O
during O
the O
latter O
part O
of O
the O
prednisolone O
cycle O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
treatment O
was O
considered O
successful O
if O
sinus B-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
occurred O
within O
1 O
hour O
. O
['Physiological-Clinical']

Children O
from O
a O
hypertensive O
subgroup O
comprising O
the O
upper O
5 O
% O
of O
the O
blood O
pressure O
distribution O
and O
children O
from O
a O
randomly O
selected O
normotensive O
subgroup O
were O
eligible O
for O
the O
study O
. O
[]

2.1 O
cm O
, O
weight O
: O
85.8 O
? O
[]

RESULTS O
No O
serious B-outcome ['Adverse-effects']
toxic O
effects I-outcome ['Adverse-effects']
or O
irritation O
were O
observed O
. O
['Adverse-effects']

LIMITATIONS O
This O
study O
was O
not O
placebo O
controlled O
. O
[]

RESULTS O
When O
compared O
with O
TENS O
, O
the O
combined O
TENS+TRT O
group O
showed O
significantly O
greater O
improvement O
in O
ankle B-outcome ['Physiological-Clinical']
dorsiflexion I-outcome ['Physiological-Clinical']
torque I-outcome ['Physiological-Clinical']
at O
follow-up O
and O
in O
ankle B-outcome ['Physiological-Clinical']
plantarflexion I-outcome ['Physiological-Clinical']
torque I-outcome ['Physiological-Clinical']
at O
week O
2 O
and O
follow-up O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
effectiveness O
of O
inguinal O
herniorrhaphy O
should O
be O
measured O
by O
the O
rate O
of O
recurrence B-outcome ['Physiological-Clinical']
and O
neuralgia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
In O
the O
treated O
group O
, O
28 O
patients O
were O
[]

Mechanomyographic B-outcome ['Physiological-Clinical']
and O
clinical O
evaluation O
by O
single O
twitch O
and O
TOF B-outcome ['Physiological-Clinical']
stimulation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
ulnar I-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
wrist I-outcome ['Physiological-Clinical']
and O
measurement O
of O
the O
concomitant B-outcome ['Physiological-Clinical']
abductor I-outcome ['Physiological-Clinical']
pollicis I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
was O
applied O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
day O
1 O
plasma O
samples O
showed O
significant O
reversal O
of O
plasma B-outcome ['Physiological-Clinical']
suppressive I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
PGE1 O
group O
-- O
ratio O
P O
: O
C O
88 O
+/- O
5 O
% O
versus O
67 O
+/- O
5 O
% O
in O
the O
placebo O
group O
( O
P O
less O
than O
0.02 O
) O
. O
['Physiological-Clinical']

Milk B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
of O
dairy O
cows O
fed O
wet O
corn O
gluten O
feed O
during O
the O
dry O
period O
and O
lactation O
. O
['Physiological-Clinical']

Angiographic O
follow-up O
was O
scheduled O
at O
6 O
months O
, O
and O
clinical O
follow-ups O
performed O
at O
1 O
, O
3 O
and O
6 O
months O
after O
PCI O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
statistically O
benefited O
from O
SRP O
with O
no O
differences O
among O
the O
three O
treatment O
groups O
. O
['Physiological-Clinical']

The O
objective O
of O
this O
study O
was O
to O
assess O
the O
respiratory B-outcome ['Physiological-Clinical']
and O
hemodynamic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
sleeping O
angle O
in O
a O
group O
of O
subjects O
with O
stable O
heart O
failure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
grade O
of O
vomiting B-outcome ['Physiological-Clinical']
was O
mild O
in O
both O
groups O
. O
['Physiological-Clinical']

CONCLUSIONS O
Tailored O
communications O
including O
personalized O
risk O
feedback O
can O
improve O
sun-protection B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
skin B-outcome ['Life-Impact']
self-examination I-outcome ['Life-Impact']
among O
adults O
at O
increased O
risk O
for O
skin O
cancer O
. O
['Life-Impact', 'Life-Impact']

While O
the O
EG O
took O
part O
in O
an O
endurance O
and O
activity O
of O
daily O
living-training O
twice O
a O
day O
, O
the O
CG O
received O
the O
clinic O
's O
standard O
physiotherapy O
program O
once O
a O
day O
. O
[]

CONCLUSIONS O
The O
economic O
analysis O
demonstrated O
that O
clopidogrel O
combination O
therapy O
is O
not O
only O
cost-effective O
as O
antiplatelet O
therapy O
compared O
with O
ASA O
alone O
, O
but O
it O
is O
also O
cost-effective O
compared O
with O
other O
commonly O
used O
and O
openly O
reimbursed O
cardiovascular O
therapies O
in O
the O
Canadian O
health O
care O
system O
. O
[]

Control O
patients O
( O
n O
= O
85 O
) O
received O
standard O
MWT O
. O
[]

In O
comparison O
with O
the O
control O
group O
, O
participants O
receiving O
the O
intervention O
perceived O
that O
having O
a O
spouse O
with O
prostate O
cancer O
had O
made O
positive O
contributions O
to O
their O
lives O
, O
reported O
gains O
in O
the O
use O
of O
positive O
reappraisal B-outcome ['Life-Impact']
coping I-outcome ['Life-Impact']
and O
reductions O
in O
denial B-outcome ['Life-Impact']
coping I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Patients O
of O
the O
sevelamer O
group O
with O
a O
high O
turnover O
at O
baseline O
had O
an O
increase O
in O
bone B-outcome ['Physiological-Clinical']
resorption I-outcome ['Physiological-Clinical']
( O
eroded O
surface O
, O
ES/BS O
= O
9.0 O
+/- O
5.9 O
vs. O
13.1 O
+/- O
9.5 O
% O
, O
p O
= O
0.05 O
) O
, O
whereas O
patients O
of O
both O
groups O
with O
low O
turnover O
at O
baseline O
had O
an O
improvement O
in O
bone B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
rate O
( O
BFR/BS O
= O
0.015 O
+/- O
0.016 O
vs. O
0.062 O
+/- O
0.078 O
, O
p O
= O
0.003 O
for O
calcium O
and O
0.017 O
+/- O
0.016 O
vs. O
0.071 O
+/- O
0.084 O
microm O
( O
3 O
) O
/microm O
( O
2 O
) O
/day O
, O
p O
= O
0.010 O
for O
sevelamer O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Therefore O
, O
the O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
snowshoe O
training O
could O
improve O
fitness B-outcome ['Physiological-Clinical']
measures O
. O
['Physiological-Clinical']

The O
fatty B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
esters I-outcome ['Physiological-Clinical']
was O
determined O
in O
samples O
from O
each O
trial O
period O
to O
measure O
the O
degree O
of O
dietary O
adherence O
. O
['Physiological-Clinical']

The O
HMTW O
intervention O
was O
provided O
over O
3.5 O
months O
. O
[]

RESULTS O
In O
each O
group O
26 O
patients O
were O
available O
for O
evaluation O
. O
[]

CONCLUSION O
Intravenous O
diltiazem O
therapy O
is O
effective O
and O
safe O
for O
patients O
with O
unstable O
angina O
pectoris O
. O
[]

At O
intention-to-treat O
( O
ITT O
) O
and O
per-protocol O
analysis O
( O
PP O
) O
, O
the O
eradication B-outcome ['Physiological-Clinical']
rates O
were O
85.5 O
% O
and O
91.6 O
% O
with O
the O
concomitant O
regimen O
, O
91.1 O
% O
and O
92.1 O
% O
with O
the O
sequential O
therapy O
, O
and O
80 O
% O
and O
85.7 O
% O
with O
the O
hybrid O
regimen O
. O
['Physiological-Clinical']

CONCLUSIONS O
Urinary B-outcome ['Physiological-Clinical']
8-epi-PGF2 I-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
may O
represent O
a O
noninvasive O
, O
quantitative O
index O
of O
oxidant O
stress O
in O
vivo O
. O
['Physiological-Clinical']

The O
results O
obtained O
indicated O
that O
those O
subjects O
with O
the O
highest O
degree O
of O
immunodepression O
( O
hypo-anergic O
) O
benefited O
most O
from O
drug O
therapy O
in O
comparison O
to O
those O
with O
a O
lesser O
degree O
of O
immunodepression O
( O
relatively O
hypo-ergic O
) O
. O
[]

A O
child O
with O
autism O
, O
which O
was O
diagnosed O
by O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
Third O
Edition O
, O
Revised O
, O
criteria O
, O
was O
studied O
. O
[]

Relationship O
between O
subjective O
effects O
and O
drug O
preferences O
: O
ethanol O
and O
diazepam O
. O
[]

Twenty-four O
children O
with O
autism O
were O
randomly O
assigned O
to O
a O
clinic-directed O
group O
, O
replicating O
the O
parameters O
of O
the O
early O
intensive O
behavioral O
treatment O
developed O
at O
UCLA O
, O
or O
to O
a O
parent-directed O
group O
that O
received O
intensive O
hours O
but O
less O
supervision O
by O
equally O
well-trained O
supervisors O
. O
[]

Four O
different O
doses O
of O
labetalol O
( O
150 O
, O
300 O
, O
600 O
and O
900 O
mg/day O
) O
were O
given O
for O
1 O
week O
to O
each O
of O
four O
groups O
of O
patients O
with O
essential O
hypertension O
( O
six O
patients O
for O
each O
group O
) O
. O
[]

METHODS O
Our O
study O
population O
consisted O
of O
242 O
individuals O
recruited O
by O
advertisements O
and O
mailing O
lists O
( O
mean O
[ O
+/- O
SD O
] O
age O
, O
77 O
+/- O
4 O
years O
) O
. O
[]

Eight O
sedentary O
men O
( O
26 O
+/- O
1 O
yr O
, O
77.4 O
+/- O
3.7 O
kg O
) O
were O
studied O
in O
the O
postprandial O
state O
during O
90 O
min O
of O
rest O
and O
60 O
min O
of O
exercise O
twice O
before O
( O
45 O
% O
and O
65 O
% O
V O
( O
O2 O
peak O
) O
) O
and O
twice O
after O
9 O
wk O
of O
endurance O
training O
( O
55 O
% O
and O
65 O
% O
posttraining O
V O
( O
O2 O
peak O
) O
) O
. O
[]

Moreover O
, O
histological O
grading O
would O
be O
clinically O
useful O
in O
defining O
the O
tumor O
characteristics O
and O
behavior O
of O
carcinoma O
in O
situ O
of O
the O
bladder O
. O
[]

IMPLICATIONS O
We O
evaluated O
the O
anesthetic O
and O
recovery O
profiles O
of O
60- O
and O
80-mg O
doses O
of O
plain O
mepivacaine O
for O
ambulatory O
spinal O
anesthesia O
. O
[]

Noradrenaline B-outcome ['Physiological-Clinical']
levels O
were O
reduced O
in O
patients O
with O
PHDC- O
. O
['Physiological-Clinical']

Growth O
hormone O
treatment O
in O
GH-deficient O
adults O
has O
proved O
beneficial O
in O
recent O
short-term O
trials O
, O
but O
long-term O
results O
have O
not O
yet O
been O
reported O
. O
[]

The O
percentage O
variation O
of O
the O
baseline O
value O
of O
MAP B-outcome ['Physiological-Clinical']
after O
30 O
min O
from O
starting O
the O
treatment O
between O
the O
two O
methods O
was O
not O
statistically O
significant O
( O
p O
= O
0.85 O
) O
. O
['Physiological-Clinical']

Refractory B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
epilepticus I-outcome ['Physiological-Clinical']
was O
controlled O
in O
80 O
% O
of O
the O
valproate O
and O
85 O
% O
of O
the O
diazepam O
patients O
. O
['Physiological-Clinical']

At O
60 O
minutes O
, O
rescue B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
was O
required O
by O
48 O
% O
of O
the O
patients O
in O
the O
OC O
group O
, O
whereas O
10 O
% O
of O
the O
PC O
group O
required O
such O
therapy O
( O
P O
< O
.01 O
) O
. O
['Resource-use']

METHODS O
In O
this O
article O
, O
we O
describe O
an O
intervention O
developed O
to O
reduce O
HIV B-outcome ['Life-Impact']
stigma I-outcome ['Life-Impact']
among O
medical O
students O
in O
Puerto O
Rico O
. O
['Life-Impact']

Follow-up O
data O
for O
the O
intervention O
group O
will O
be O
collected O
6 O
months O
after O
the O
interventions O
. O
[]

Reductions O
correlated O
with O
reduced O
anxiety O
severity O
. O
[]

Thus O
, O
50 O
mg O
of O
oral O
SDZ O
ENS-163 O
has O
cholinomimetic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
normal O
men O
, O
but O
this O
dose O
is O
insufficient O
to O
reverse O
the O
muscarinic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
0.4 O
mg O
of O
intravenous O
scopolamine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
patients O
received O
monthly O
0.5-mg O
ranibizumab O
intravitreal O
injections O
for O
3 O
months O
, O
after O
which O
monthly O
injections O
were O
administered O
in O
accordance O
with O
the O
standard O
of O
care O
. O
[]

4 O
. O
[]

Glycaemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
was O
not O
significantly O
different O
on O
the O
two O
treatments O
, O
but O
C-peptide B-outcome ['Physiological-Clinical']
was O
much O
higher O
while O
the O
patients O
were O
on O
glibenclamide O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ropinirole O
was O
superior O
to O
levodopa O
SR O
in O
reducing O
6-item O
IRLS O
scores O
( O
P O
< O
0.001 O
) O
and O
in O
increasing O
sleep B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

This O
study O
demonstrated O
that O
mildly O
HYPO O
subjects O
could O
reach O
euhydration O
within O
45 O
minutes O
of O
the O
ingestion O
of O
600 O
ml O
of O
W O
or O
a O
combination O
of O
salt O
and O
CES O
solutions O
. O
[]

There O
was O
a O
strong O
correlation O
between O
this O
index O
and O
the O
risk O
of O
collapse B-outcome ['Physiological-Clinical']
before O
and O
after O
adjustment O
for O
age O
, O
gender O
, O
stage O
and O
treatment O
group O
. O
['Physiological-Clinical']

Tacrolimus/sirolimus O
vs O
tacrolimus/methotrexate O
as O
GVHD O
prophylaxis O
after O
matched O
, O
related O
donor O
allogeneic O
HCT O
. O
[]

The O
cardiovascular B-outcome ['Physiological-Clinical']
condition I-outcome ['Physiological-Clinical']
improved O
significantly O
and O
similarly O
in O
the O
two O
groups O
. O
['Physiological-Clinical']

RESULTS O
AND O
CONCLUSIONS O
Group O
5 O
showed O
the O
highest O
scores O
which O
was O
significantly O
higher O
than O
all O
other O
groups O
( O
p O
< O
0.05 O
) O
except O
group O
8 O
, O
with O
which O
there O
was O
no O
significant O
difference O
( O
p O
> O
0.05 O
) O
. O
[]

The O
mean O
calcium O
intake O
was O
1142 O
? O
[]

In O
all O
, O
90.5 O
% O
of O
parents O
indicated O
that O
they O
would O
definitely O
recommend O
the O
clinical O
trial O
to O
other O
families O
with O
similar O
children O
. O
[]

Double O
hearing O
protection O
and O
speech O
intelligibility-room O
for O
improvement O
. O
[]

Increased O
loss O
of O
BMD B-outcome ['Physiological-Clinical']
with O
use O
of O
uncemented O
press-fit O
cups O
in O
the O
region O
in O
which O
osteolytic O
lesions O
are O
commonly O
found O
suggests O
that O
stress O
shielding O
may O
initiate O
the O
development O
of O
this O
complication O
. O
['Physiological-Clinical']

Each O
subset O
of O
25 O
was O
displayed O
either O
as O
original O
images O
or O
at O
one O
of O
three O
compression O
ratios O
( O
CRs O
) O
( O
6:1 O
, O
10:1 O
or O
16:1 O
) O
. O
[]

BACKGROUND O
This O
pilot O
study O
evaluated O
an O
intervention O
designed O
to O
enhance O
adherence O
among O
those O
new O
to O
antiretroviral O
therapy O
. O
[]

Eighteen O
children O
with O
ASD O
were O
assessed O
with O
pretreatment O
and O
posttreatment O
measures O
on O
the O
Walker-McConnell O
Scale O
( O
WMS O
) O
and O
the O
MGH O
YouthCare O
Social B-outcome ['Life-Impact']
Competence I-outcome ['Life-Impact']
Development I-outcome ['Life-Impact']
Scale O
. O
['Life-Impact']

METHOD O
All O
general O
practitioners O
from O
the O
four O
practices O
in O
Ebeltoft O
and O
a O
random O
sample O
of O
2000 O
people O
aged O
between O
30 O
and O
50 O
years O
were O
invited O
to O
participate O
. O
[]

Incidence O
of O
infectious B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
after O
radiation O
therapy O
for O
breast O
cancer O
. O
['Physiological-Clinical']

The O
decrease O
in O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
significantly O
less O
in O
the O
300-ml O
h-1 O
group O
at O
the O
end O
of O
induction O
and O
immediately O
after O
induction O
( O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

Baseline O
characteristics O
were O
comparable O
in O
both O
arms O
. O
[]

The O
incidence O
of O
adverse O
events O
was O
similar O
in O
both O
groups O
. O
[]

JET O
remains O
a O
relatively O
common O
postoperative B-outcome ['Physiological-Clinical']
arrhythmia I-outcome ['Physiological-Clinical']
, O
but O
it O
is O
less O
frequent O
than O
previously O
reported O
. O
['Physiological-Clinical']

RESULTS O
There O
was O
no O
significant O
difference O
in O
[]

No O
differences O
favoring O
interferon O
treatment O
were O
found O
in O
respiratory O
symptom O
scores O
or O
resolution O
of O
specific O
symptoms O
. O
[]

An O
exercise O
group O
( O
E O
group O
) O
was O
advised O
to O
take O
up O
aerobics O
exercise O
three O
times/week O
, O
a O
diet O
group O
to O
reduce O
the O
intake O
of O
saturated O
fat O
and O
increase O
fish O
products O
, O
and O
smokers O
to O
stop O
smoking O
. O
[]

These O
patients O
were O
allocated O
to O
one O
of O
two O
groups O
by O
drawing O
lots O
: O
IMV O
group O
( O
IMVG O
; O
n O
= O
35 O
) O
and O
SIMV+PS O
group O
( O
SIMVG O
; O
n O
= O
35 O
) O
. O
[]

The O
post-ischaemic O
functional O
recovery O
of O
the O
heart O
was O
assessed O
by O
clinical O
parameters O
, O
as O
well O
as O
by O
biochemical O
and O
ultrastructure O
evaluations O
on O
biopsy O
specimens O
. O
[]

Bacterial B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
was O
checked O
6 O
weeks O
after O
treatment O
by O
using O
a O
( O
13 O
) O
C-urea O
breath O
test O
. O
['Physiological-Clinical']

Few O
reported O
discomfort B-outcome ['Physiological-Clinical']
or O
pain B-outcome ['Physiological-Clinical']
and O
one O
experienced O
tinnitus B-outcome ['Physiological-Clinical']
during O
real O
stimulation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Changes O
in O
cardiac O
conduction O
parameters O
following O
drug O
administration O
were O
also O
assessed O
. O
[]

Eleven O
( O
47 O
% O
) O
of O
32 O
patients O
taking O
dirithromycin O
alone O
or O
combined O
with O
omeprazole O
reported O
side-effects B-outcome ['Adverse-effects']
, O
but O
only O
two O
( O
6 O
% O
) O
stopped O
therapy O
prematurely O
as O
a O
result O
of O
side-effects B-outcome ['Adverse-effects']
. O
['Adverse-effects', 'Adverse-effects']

Within O
five O
months O
AGE-peptides B-outcome ['Physiological-Clinical']
increased O
in O
the O
diabetic O
group O
without O
nephropathy O
( O
P=0.042 O
) O
but O
not O
in O
the O
group O
with O
nephropathy O
treated O
either O
with O
B1+B6 O
or O
B6 O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVES O
The O
pain O
in O
sickle O
cell O
anemia O
( O
SCA O
) O
is O
often O
triggered O
by O
dehydration O
, O
acidosis O
, O
and O
fever O
that O
are O
usually O
due O
to O
malaria O
. O
[]

Cream O
was O
applied O
5 O
times/d O
for O
5 O
days O
. O
[]

VO B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
2max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
measured O
in O
a O
direct O
maximal O
treadmill O
test O
. O
['Physiological-Clinical']

Antimigraine B-outcome ['Resource-use']
efficacy O
of O
telcagepant O
based O
on O
patient O
's O
historical O
triptan O
response O
. O
['Resource-use']

Supplementary O
motor O
area O
activity O
may O
be O
abnormal O
in O
Parkinson O
's O
disease O
since O
its O
major O
input O
from O
the O
basal O
ganglia O
is O
disrupted O
. O
[]

Further O
, O
physiological B-outcome ['Physiological-Clinical']
scars I-outcome ['Physiological-Clinical']
and O
skin-coloured B-outcome ['Physiological-Clinical']
scars I-outcome ['Physiological-Clinical']
were O
more O
frequent O
in O
the O
treated O
group O
than O
in O
the O
untreated O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Sivelestat O
sodium O
hydrate O
( O
sivelestat O
) O
is O
a O
selective O
inhibitor O
of O
polymorphonuclear O
leukocyte O
elastase O
( O
PMN-E O
) O
. O
[]

The O
mean O
strength B-outcome ['Physiological-Clinical']
training I-outcome ['Physiological-Clinical']
frequency O
decreased O
from O
1.5 O
to O
0.6 O
times O
a O
week O
in O
the O
STG O
during O
the O
intervention O
. O
['Physiological-Clinical']

In O
a O
randomized O
, O
double-blinded O
study O
, O
a O
newly-introduced O
barrier O
cream O
and O
its O
moisturizing O
vehicle O
were O
compared O
regarding O
their O
skin O
compatibility O
, O
efficacy O
and O
resulting O
acceptance O
. O
[]

The O
time O
vs O
( O
13 O
) O
CO O
( O
2 O
) O
excretion B-outcome ['Physiological-Clinical']
rate O
curve O
was O
mathematically O
fitted O
to O
a O
conventional O
formula O
of O
y O
( O
t O
) O
= O
m*k*beta*e O
( O
-k*t O
) O
* O
( O
1 O
- O
e O
( O
-k*t O
) O
) O
( O
beta-1 O
) O
, O
and O
the O
parameters O
of O
k O
and O
beta O
were O
determined O
: O
under O
the O
crossover O
protocol O
, O
a O
larger O
( O
smaller O
) O
beta O
indicates O
slower O
( O
faster O
) O
emptying O
in O
the O
early O
phase O
, O
and O
a O
larger O
( O
smaller O
) O
k O
indicates O
faster O
( O
slower O
) O
emptying O
in O
the O
later O
phase O
. O
['Physiological-Clinical']

Sulfasalazine O
decreases O
acute O
gastrointestinal O
complications O
due O
to O
pelvic O
radiotherapy O
. O
[]

Recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
parasitaemia I-outcome ['Physiological-Clinical']
was O
observed O
after O
day O
30 O
in O
2 O
patients O
in O
the O
15 O
mg/kg O
group O
and O
in O
1 O
patient O
in O
the O
25 O
mg/kg O
group O
. O
['Physiological-Clinical']

The O
warfarin O
( O
n O
= O
56 O
) O
and O
the O
control O
( O
n O
= O
54 O
) O
groups O
were O
not O
different O
in O
terms O
of O
age O
, O
sex O
, O
previous O
coronary O
bypass O
surgery O
or O
coronary O
balloon O
angioplasty O
, O
severity O
of O
symptoms O
, O
and O
frequency O
of O
multivessel O
disease O
or O
of O
total O
coronary O
occlusions O
. O
[]

Influence O
of O
bony O
defects O
on O
implant O
stability O
. O
[]

Buprenorphine O
produced O
dose-related O
opioid O
agonist O
effects O
on O
physiological B-outcome ['Physiological-Clinical']
and O
subjective O
measures O
. O
['Physiological-Clinical']

For O
eyes O
treated O
with O
10 O
Gy O
because O
of O
classic O
CNV O
, O
the O
corresponding O
figures O
were O
33 O
% O
( O
n O
= O
18 O
) O
and O
57 O
% O
( O
n O
= O
14 O
) O
respectively O
. O
[]

Influence O
of O
sentinel O
lymph O
node O
tumor O
burden O
on O
survival O
in O
melanoma O
. O
[]

The O
effects O
of O
some O
oral O
hygiene O
measures O
on O
Streptococcus B-outcome ['Physiological-Clinical']
mutants I-outcome ['Physiological-Clinical']
and O
approximal B-outcome ['Physiological-Clinical']
dental I-outcome ['Physiological-Clinical']
caries I-outcome ['Physiological-Clinical']
were O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
score O
of O
symptoms B-outcome ['Physiological-Clinical']
and O
signs B-outcome ['Physiological-Clinical']
markedly O
decreased O
after O
treatment O
, O
in O
treatment O
group O
: O
vertigo B-outcome ['Physiological-Clinical']
had O
( O
2.75 O
+/- O
1.01 O
) O
scores O
, O
neck-shoulder B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
1.58 O
+/- O
0.36 O
) O
, O
headache B-outcome ['Physiological-Clinical']
( O
0.39 O
+/- O
0.09 O
) O
, O
nausea-vomiting B-outcome ['Physiological-Clinical']
( O
1.58 O
+/- O
1.30 O
) O
, O
ear B-outcome ['Physiological-Clinical']
noises I-outcome ['Physiological-Clinical']
( O
0.48 O
+/- O
0.32 O
) O
, O
positive O
neck B-outcome ['Physiological-Clinical']
rotation O
test O
( O
0.59 O
+/- O
0.21 O
) O
; O
and O
in O
control O
group O
: O
vertigo B-outcome ['Physiological-Clinical']
had O
( O
5.68 O
+/- O
2.02 O
) O
scores O
, O
neck-shoulder B-outcome ['Physiological-Clinical']
pain B-outcome ['Physiological-Clinical']
( O
3.12 O
+/- O
1.82 O
) O
, O
headache B-outcome ['Physiological-Clinical']
( O
1.86 O
+/- O
0.65 O
) O
, O
nausea-vomiting B-outcome ['Physiological-Clinical']
( O
3.25 O
+/- O
0.69 O
) O
, O
ear B-outcome ['Physiological-Clinical']
noises I-outcome ['Physiological-Clinical']
( O
1.64 O
+/- O
0.61 O
) O
, O
positive O
neck B-outcome ['Physiological-Clinical']
rotation O
test O
( O
1.79 O
+/- O
0.67 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

During O
initial O
chemotherapy O
the O
response O
rate O
( O
complete O
and O
partial B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
) O
after O
four O
courses O
of O
treatment O
was O
61 O
% O
with O
no O
significant O
increase O
in O
patients O
receiving O
eight O
courses O
( O
63 O
% O
) O
. O
['Physiological-Clinical']

Five O
hundred O
fifty-three O
patients O
( O
75 O
% O
) O
went O
into O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
63 O
( O
9 O
% O
) O
into O
partial B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
, O
62 O
( O
8 O
% O
) O
failed B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
respond I-outcome ['Physiological-Clinical']
, O
and O
59 O
( O
8 O
% O
) O
died B-outcome ['Mortality']
during O
ACVB O
courses O
, O
17 O
of O
them O
from O
progression O
of O
the O
disease O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Galactorrea B-outcome ['Physiological-Clinical']
responded O
100 O
% O
of O
alpha O
dihidroergocriptine O
group O
vs O
93.33 O
% O
of O
the O
placebo O
. O
['Physiological-Clinical']

Four O
pramipexole O
doses O
were O
evaluated O
: O
0.125 O
, O
0.25 O
, O
0.50 O
, O
and O
0.75mg/d O
. O
[]

Four O
experiments O
explored O
on-line O
encoding O
strategies O
and O
memory O
for O
high O
imagery O
and O
low O
imagery O
texts O
. O
[]

Bone O
marrow-derived O
endothelial O
progenitor O
cells O
( O
EPCs O
) O
improve O
vascular B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
predict O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Video O
rating O
analysis O
of O
effect O
of O
maprotiline O
in O
patients O
with O
dementia O
and O
depression O
. O
[]

Assessment O
of O
elementary O
school O
students O
' O
sun B-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
. O
['Life-Impact']

Six O
subjects O
were O
randomly O
assigned O
to O
receive O
BMS-181101 O
under O
fasted O
conditions O
from O
days O
1 O
to O
6 O
and O
then O
crossed O
over O
to O
fed O
conditions O
from O
days O
7 O
to O
12 O
. O
[]

CONCLUSION O
Both O
groups O
demonstrated O
improvement O
in O
the O
rehabilitation O
unit O
. O
[]

Patients O
were O
assessed O
at O
specified O
times O
throughout O
the O
first O
6 O
months O
after O
surgery O
for O
evidence O
of O
CMV B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
, O
CMV B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
, O
rejection B-outcome ['Physiological-Clinical']
, O
opportunistic B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

One O
year O
after O
surgery O
, O
occlusion B-outcome ['Physiological-Clinical']
was O
found O
in O
14 O
out O
of O
32 O
ACB O
's O
( O
43.7 O
% O
) O
in O
the O
ASA O
plus O
dipyridamole O
group O
compared O
to O
14 O
occlusions O
in O
31 O
ACB O
's O
( O
45.2 O
% O
) O
in O
the O
indobufen O
group O
. O
['Physiological-Clinical']

A O
single-bout O
of O
exercise O
produced O
increases O
in O
STARS B-outcome ['Physiological-Clinical']
and O
SRF B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
and O
decreases O
in O
MRTF-A B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
both I-outcome ['Physiological-Clinical']
ECC I-outcome ['Physiological-Clinical']
and O
CONC B-outcome ['Physiological-Clinical']
exercise I-outcome ['Physiological-Clinical']
, O
but O
with O
an O
enhanced O
response O
occurring O
following O
ECC O
exercise O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Within O
groups O
, O
individuals O
varied O
in O
BP O
response O
to O
sorafenib O
dose O
escalation O
, O
but O
these O
differences O
did O
not O
correlate O
with O
changes O
in O
steady-state O
plasma O
sorafenib O
concentrations O
. O
[]

In O
terms O
of O
open O
infrarenal O
aneurysm O
repair O
, O
no O
randomized O
controlled O
trials O
exist O
to O
introduce O
and O
evaluate O
such O
patient O
care O
programs O
. O
[]

METHODS O
90 O
patients O
with O
IgAN O
of O
deficiency O
of O
Yin O
with O
damp-heat O
symptom O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

SETTING O
Intensive O
Care O
Unit O
of O
the O
Ohio O
State O
University O
Medical O
Center O
. O
[]

OBJECTIVE O
To O
compare O
the O
duration O
of O
spinal O
block O
with O
5 O
% O
prilocaine O
and O
2 O
% O
mepivacaine O
in O
short O
procedures O
for O
transurethral O
resection O
and O
to O
assess O
possible O
complications B-outcome ['Adverse-effects']
in O
the O
immediate O
postoperative O
period O
. O
['Adverse-effects']

In O
B6 O
treated O
group O
a O
substantial O
decrease O
was O
observed O
in O
HbA1c B-outcome ['Physiological-Clinical']
( O
P=0.033 O
) O
. O
['Physiological-Clinical']

Five O
cryotherapy-treated O
eyes O
required O
retreatment B-outcome ['Life-Impact']
because O
of O
persistent O
disease O
with O
adjacent O
skip O
areas O
. O
['Life-Impact']

We O
evaluated O
the O
effects O
of O
spironolactone O
in O
patients O
with O
heart O
failure O
and O
a O
preserved O
left O
ventricular O
ejection O
fraction O
. O
[]

Measured O
IVRTs O
were O
significantly O
longer O
in O
patients O
with O
pulmonary O
hypertension O
than O
in O
control O
subjects O
. O
[]

Average O
time B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
per O
sitting O
was O
1.43 O
minutes O
with O
PASCAL O
and O
4.53 O
minutes O
with O
GLX O
. O
['Life-Impact']

After O
endotracheal O
tube O
placement O
, O
subjects O
were O
ventilated O
for O
5 O
minutes O
with O
1 O
% O
isoflurane O
in O
a O
mixture O
of O
50 O
% O
oxygen/50 O
% O
air O
and O
then O
disconnected O
from O
the O
ventilation O
circuit O
. O
[]

The O
children O
did O
not O
exhibit O
excessive O
carbohydrate O
intake O
. O
[]

This O
is O
the O
very O
first O
study O
, O
based O
on O
estrogen O
intervention O
instead O
of O
physiological O
hormone O
changes O
, O
to O
examine O
the O
association O
between O
estrogen B-outcome ['Physiological-Clinical']
and O
spatial B-outcome ['Physiological-Clinical']
ability I-outcome ['Physiological-Clinical']
in O
women O
with O
schizophrenia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Clay O
modeling O
might O
be O
a O
useful O
self-help O
tool O
to O
help O
manage O
craving B-outcome ['Life-Impact']
for O
chocolate O
, O
snacks O
and O
other O
foods O
. O
['Life-Impact']

The O
1-year O
freedom O
from O
efficacy O
failure B-outcome ['Physiological-Clinical']
in O
Evr O
group O
was O
75 O
% O
versus O
69.2 O
% O
in O
CsA O
group O
, O
p O
= O
0.36 O
. O
['Physiological-Clinical']

No O
differences O
were O
seen O
in O
the O
incidence O
of O
proximal O
venous O
thrombosis O
or O
clinically O
overt O
hemorrhage O
. O
[]

In O
conclusion O
, O
both O
OC O
preparations O
exerted O
small O
and O
probably O
favorable O
effects O
on O
[]

The O
sessions O
consisted O
of O
four O
phases O
, O
with O
each O
phase O
lasting O
3 O
minutes O
. O
[]

Similarly O
, O
in O
a O
fifth O
subject O
, O
who O
was O
not O
restudied O
until O
6 O
months O
of O
androgen O
therapy O
were O
completed O
, O
an O
increase O
in O
RBC B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
was O
associated O
with O
an O
increase O
in O
erythron O
iron O
turnover O
. O
['Physiological-Clinical']

Nausea/vomiting B-outcome ['Physiological-Clinical']
and O
stomatitis B-outcome ['Physiological-Clinical']
were O
significantly O
less O
frequent O
in O
arm O
A O
as O
was O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
decrease O
in O
arm O
C O
( O
A O
= O
six O
patients O
, O
B O
= O
five O
patients O
, O
and O
C O
= O
one O
patient O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
compared O
, O
in O
a O
double-blind O
randomised O
study O
, O
intramuscular O
ketorolac O
30 O
mg O
( O
n O
= O
49 O
) O
and O
intramuscular O
pethidine O
75 O
mg O
( O
n O
= O
51 O
) O
for O
analgesia B-outcome ['Resource-use']
after O
elective O
caesarean O
section O
under O
general O
anaesthesia O
. O
['Resource-use']

The O
relationship O
between O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
sumatriptan O
challenge O
in O
adult O
autistic O
disorder O
. O
['Life-Impact', 'Physiological-Clinical']

OBJECTIVE O
To O
determine O
the O
clinical O
and O
economic O
effects O
of O
granulocyte O
macrophage O
colony-stimulating O
factor O
( O
GM-CSF O
) O
as O
adjunct O
therapy O
in O
relapsed O
or O
refractory O
Hodgkin O
disease O
. O
[]

An O
interaction O
between O
age O
and O
treatment O
for O
the O
primary O
endpoints O
( O
p=0.03 O
) O
was O
seen O
. O
[]

METHOD O
In O
the O
present O
study O
, O
the O
efficacy O
of O
buspirone O
was O
investigated O
in O
patients O
with O
social O
phobia O
using O
a O
12-week O
double-blind O
placebo-controlled O
design O
. O
[]

CONCLUSIONS O
This O
study O
provides O
additional O
support O
for O
an O
early O
intervention O
to O
shorten O
DUP O
to O
facilitate O
a O
better O
outcome O
in O
memory O
and O
attentional O
domains O
of O
FEP O
patients O
. O
[]

CONCLUSION O
Inclusion O
of O
1-10 O
microM O
FF-MAS O
in O
a O
30-hour O
IVM O
protocol O
is O
safe O
. O
[]

Despite O
the O
observed O
cholinomimetic B-outcome ['Physiological-Clinical']
effects O
of O
SDZ O
ENS-163 O
when O
administered O
with O
saline O
, O
the O
changes O
in O
CNTB O
scores O
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
salivation B-outcome ['Physiological-Clinical']
were O
indistinguishable O
between O
placebo/scopolamine O
and O
SDZ O
ENS-163/scopolamine O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Antipyrine O
was O
used O
as O
marker O
for O
oxidative O
stress O
. O
[]

Results O
from O
a O
population-based O
screening O
project O
in O
India O
. O
[]

We O
investigated O
the O
effect O
of O
the O
selective B-outcome ['Physiological-Clinical']
serotonin I-outcome ['Physiological-Clinical']
reuptake I-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
citalopram I-outcome ['Physiological-Clinical']
on O
uncontrolled B-outcome ['Life-Impact']
crying I-outcome ['Life-Impact']
in O
stroke O
patients O
in O
a O
double-blind O
placebo-controlled O
crossover O
study O
. O
['Physiological-Clinical', 'Life-Impact']

On O
achievement O
of O
optimal B-outcome ['Physiological-Clinical']
cosmetic I-outcome ['Physiological-Clinical']
result I-outcome ['Physiological-Clinical']
( O
baseline O
) O
, O
patients O
were O
followed O
up O
for O
6 O
months O
; O
bilateral O
retreatment O
with O
Perlane O
was O
offered O
at O
6 O
or O
9 O
months O
after O
baseline O
. O
['Physiological-Clinical']

After O
fenfluramine O
treatment O
blood O
serotonin O
levels O
fell O
, O
urinary O
catecholamine O
levels O
fell O
and O
the O
HVA/DA O
ratio O
rose O
. O
[]

No O
group O
differences O
were O
found O
for O
cancer-related B-outcome ['Life-Impact']
worry I-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
. O
['Life-Impact']

Participants O
were O
randomly O
assigned O
to O
one O
of O
four O
groups O
: O
( O
a O
) O
disclaimer O
, O
( O
b O
) O
warning O
, O
( O
c O
) O
model O
control O
, O
or O
( O
d O
) O
car O
control O
. O
[]

Activity O
in O
these O
frequencies O
is O
functionally O
related O
to O
sleep O
deprivation O
. O
[]

Image O
noise O
was O
22.7 O
? O
[]

Nineteen O
patients O
with O
normal O
preoperative O
creatinine O
clearances O
who O
were O
scheduled O
for O
reconstructive O
aortic O
surgery O
were O
randomly O
divided O
into O
two O
groups O
: O
halothane O
group O
( O
n O
= O
9 O
) O
and O
isoflurane O
group O
( O
n O
= O
10 O
) O
. O
[]

A O
randomized O
crossover O
design O
was O
used O
. O
[]

RESULTS O
. O
[]

This O
procedure O
can O
result O
in O
logistic O
problems O
, O
if O
there O
is O
a O
great O
distance O
between O
the O
department O
of O
radiotherapy O
and O
the O
orthopedic O
clinic O
. O
[]

Treatment O
did O
not O
improve O
liver O
blood O
tests O
nor O
histological O
appearances O
of O
the O
liver O
, O
but O
there O
was O
a O
trend O
towards O
reduction O
of O
serum B-outcome ['Physiological-Clinical']
titres I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hepatitis I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
night-time B-outcome ['Physiological-Clinical']
systolic/diastolic I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
HCT O
was O
5.0 O
( O
0.6-9.4 O
) O
/2.7 O
[ O
( O
-0.4 O
) O
-5.7 O
] O
mmHg O
for O
men O
and O
11.5 O
( O
7.1-16.0 O
) O
/5.7 O
( O
2.6-8.8 O
) O
mmHg O
for O
women O
, O
and O
to O
LIS O
was O
18.7 O
( O
14.2-22.1 O
) O
/15.4 O
( O
12.4-18.5 O
) O
mmHg O
for O
men O
and O
3.5 O
[ O
( O
-1.0 O
) O
-7.9 O
] O
/2.3 O
[ O
( O
-0.8 O
) O
-5.4 O
] O
mmHg O
for O
women O
. O
['Physiological-Clinical']

arm O
( O
p=0.16 O
) O
. O
[]

They O
were O
randomized O
to O
be O
treated O
with O
either O
radiotherapy O
alone O
( O
extended O
fields O
, O
4500 O
cGy O
) O
or O
radiotherapy O
( O
the O
same O
schedule O
) O
plus O
adjuvant O
chemotherapy O
( O
cyclophosphamide O
, O
vincristine O
and O
prednisone O
) O
. O
[]

From O
the O
ICT O
group O
, O
8 O
( O
53 O
% O
) O
patients O
had O
recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
and O
6 O
( O
40 O
% O
) O
had O
a O
prolonged O
air B-outcome ['Physiological-Clinical']
leak I-outcome ['Physiological-Clinical']
, O
while O
none O
of O
the O
patients O
of O
the O
VATS O
group O
had O
any O
complication B-outcome ['Adverse-effects']
( O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Aspirin O
should O
be O
used O
in O
preference O
to O
warfarin O
for O
patients O
with O
intracranial O
arterial O
stenosis O
. O
[]

The O
patients O
were O
treated O
with O
arthroscopic O
debridement O
combined O
with O
electroacupuncture O
after O
operation O
. O
[]

Calcium O
chloride O
before O
i.v O
. O
[]

Following O
intervention O
, O
the O
behavioral O
plus O
medical O
intervention O
group O
showed O
lower O
levels O
of O
problem B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
and O
completed B-outcome ['Life-Impact']
more I-outcome ['Life-Impact']
academic I-outcome ['Life-Impact']
tasks I-outcome ['Life-Impact']
than O
did O
the O
medical O
intervention O
alone O
group O
. O
['Life-Impact', 'Life-Impact']

Delavirdine O
is O
a O
nonnucleoside O
reverse O
transcriptase O
inhibitor O
with O
in O
vitro O
activity O
against O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
that O
is O
currently O
being O
evaluated O
in O
combination O
regimens O
with O
various O
nucleoside O
analogs O
, O
including O
didanosine O
. O
[]

Upon O
removal O
of O
each O
patch O
, O
skin O
sites O
were O
evaluated O
for O
signs B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
irritation I-outcome ['Physiological-Clinical']
, O
and O
subjective O
complaints B-outcome ['Physiological-Clinical']
such O
as O
itching B-outcome ['Physiological-Clinical']
or O
burning B-outcome ['Physiological-Clinical']
were O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
cases O
of O
bone B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Experiments O
1 O
and O
2 O
showed O
that O
, O
like O
children O
, O
adults O
with O
autism O
were O
superior O
to O
controls O
at O
searching B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
targets I-outcome ['Life-Impact']
. O
['Life-Impact']

CONCLUSIONS O
Although O
deliberate O
mild O
hypothermia O
is O
easily O
achieved O
intraoperatively O
, O
complete O
rewarming O
may O
be O
difficult O
to O
attain O
during O
craniotomy O
with O
current O
methods O
. O
[]

RESULTS O
Follow-up O
was O
complete O
for O
1013 O
patients O
( O
99.7 O
percent O
) O
. O
[]

Fifty O
patients O
with O
alcoholic O
liver O
disease O
( O
27 O
with O
cirrhosis O
, O
23 O
without O
cirrhosis O
) O
were O
randomly O
assigned O
to O
receive O
either O
paromomycin O
sulfate O
( O
3 O
x O
1 O
g/day O
) O
or O
placebo O
in O
a O
double-blind O
fashion O
for O
at O
least O
3 O
weeks O
, O
and O
if O
possible O
4 O
weeks O
. O
[]

The O
effect O
was O
evaluated O
through O
the O
changes O
of O
clinical O
manifestations O
and O
scores O
of O
ABC O
and O
IQ B-outcome ['Life-Impact']
. O
['Life-Impact']

This O
longer-duration O
study O
includes O
a O
broad O
sample O
. O
[]

A O
sham O
and O
an O
active O
ITD O
were O
used O
for O
1 O
min O
each O
in O
a O
randomized O
order O
, O
first O
on O
a O
facemask O
and O
then O
on O
an O
ETT O
. O
[]

Of O
the O
initial O
267 O
HOPE O
centers O
that O
had O
enrolled O
9541 O
patients O
, O
174 O
centers O
participated O
in O
the O
HOPE-TOO O
trial O
. O
[]

Mean O
clearance O
, O
half-life O
and O
volume O
of O
distribution O
were O
similar O
irrespective O
of O
dose O
for O
both O
the O
oral O
and O
intravenous O
routes O
. O
[]

STUDY O
OBJECTIVES O
This O
study O
sought O
to O
establish O
the O
effects O
of O
caffeine O
on O
sleep B-outcome ['Physiological-Clinical']
inertia I-outcome ['Physiological-Clinical']
, O
which O
is O
the O
ubiquitous O
phenomenon O
of O
cognitive O
performance O
impairment O
, O
grogginess O
and O
tendency O
to O
return O
to O
sleep O
immediately O
after O
awakening O
. O
['Physiological-Clinical']

Moxifloxacin B-outcome ['Physiological-Clinical']
accumulated I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
uterine I-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
and O
concentrations B-outcome ['Physiological-Clinical']
were O
highest O
1 O
hour O
after O
infusion O
in O
both O
plasma O
and O
tissue O
. O
['Physiological-Clinical', 'Physiological-Clinical']

They O
were O
both O
perfectly O
homogeneous O
. O
[]

However O
, O
there O
were O
no O
statistically O
significant O
differences O
in O
these O
parameters O
between O
the O
two O
groups O
. O
[]

Of O
the O
158 O
patients O
evaluable O
for O
survival B-outcome ['Mortality']
, O
90 O
patients O
have O
died O
, O
with O
a O
median O
survival O
time O
of O
27.9 O
months O
( O
HAC O
= O
26.4 O
months O
, O
melphalan-platinum O
= O
29.6 O
months O
) O
. O
['Mortality']

Patients O
receiving O
panitumumab O
in O
combination O
with O
bevacizumab O
and O
chemotherapy O
experienced O
a O
higher O
incidence O
of O
death B-outcome ['Mortality']
( O
9 O
% O
versus O
4 O
% O
) O
and O
a O
higher O
risk O
for O
grade O
3 O
and O
4 O
toxicities B-outcome ['Adverse-effects']
than O
patients O
receiving O
bevacizumab O
and O
chemotherapy O
alone O
. O
['Mortality', 'Adverse-effects']

Fifteen O
subjects O
( O
7 O
males O
, O
8 O
females O
) O
with O
mild O
asthma O
were O
included O
in O
the O
study O
. O
[]

BACKGROUND O
AND O
PURPOSE O
Subnormal B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
increased O
fracture B-outcome ['Physiological-Clinical']
risk O
are O
described O
in O
patients O
with O
growth O
hormone O
deficiency O
( O
GHD O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Halothane O
or O
isoflurane O
was O
used O
to O
assess O
the O
influence O
of O
volatile O
anesthesia O
on O
renal B-outcome ['Physiological-Clinical']
hemodynamics I-outcome ['Physiological-Clinical']
during O
aortic O
surgery O
. O
['Physiological-Clinical']

Overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
has O
not O
yet O
been O
reached O
in O
group O
A O
while O
it O
was O
34 O
months O
for O
patients O
of O
group O
B. O
Metrorrhagia B-outcome ['Physiological-Clinical']
was O
observed O
in O
two O
cases O
of O
group O
A O
and O
in O
6 O
of O
group O
B O
, O
and O
thrombophlebitis O
in O
1 O
and O
3 O
cases O
, O
respectively O
. O
['Mortality', 'Physiological-Clinical']

The O
primary O
outcome O
measure O
was O
the O
difference O
in O
the O
change O
in O
the O
ABC-C O
irritability O
subscale O
score O
from O
baseline O
to O
week O
10 O
between O
the O
two O
groups O
. O
[]

Difficulty O
falling O
asleep O
and O
anxiety B-outcome ['Life-Impact']
actually O
favored O
the O
risperidone O
condition O
at O
statistically O
significant O
levels O
. O
['Physiological-Clinical', 'Life-Impact']

However O
, O
the O
total O
metabolic B-outcome ['Physiological-Clinical']
effect O
of O
glibenclamide B-outcome ['Physiological-Clinical']
was O
almost O
identical O
between O
volunteers O
taking O
enalapril O
or O
placebo O
( O
AUC O
GIR O
( O
0-600 O
) O
1267 O
+/- O
334 O
vs O
1286 O
+/- O
249 O
mg O
kg O
( O
-1 O
) O
, O
ns O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
results O
are O
not O
concordant O
with O
the O
view O
that O
intentional O
smoking O
abstinence O
exacerbates O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

In O
contrast O
, O
in O
CYP2C19 O
EMs O
the O
eradication B-outcome ['Physiological-Clinical']
rates O
ranged O
from O
58 O
to O
85 O
% O
. O
['Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
three O
Haemophilus O
influenzae O
type O
b O
( O
Hib O
) O
capsular O
polysaccharide-protein O
conjugate O
vaccine O
( O
PRP-OMP O
, O
PRP-T O
, O
and O
HbOC O
) O
were O
evaluated O
in O
174 O
Philippine O
infants O
after O
a O
primary O
vaccination O
series O
. O
['Physiological-Clinical']

We O
thus O
conclude O
that O
ondansetron O
prevents O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
postoperative B-outcome ['Physiological-Clinical']
vomiting I-outcome ['Physiological-Clinical']
equally O
well O
. O
['Physiological-Clinical', 'Physiological-Clinical']

1 O
. O
[]

An O
operational O
definition O
of O
pedantic O
speech O
was O
formulated O
and O
a O
rating O
scale O
devised O
. O
[]

AIM O
To O
determine O
the O
ability O
of O
parents O
of O
children O
with O
autism B-outcome ['Life-Impact']
to O
guess O
, O
under O
double O
blind O
conditions O
, O
whether O
their O
child O
had O
received O
secretin O
or O
placebo O
. O
['Life-Impact']

Questionnaires O
evaluating O
the O
likelihood O
of O
recommending O
TKR O
, O
perceived O
medical O
cooperativeness O
, O
and O
measures O
of O
implicit O
racial O
bias O
were O
administered O
. O
[]

Children O
with O
persistent O
conduct O
problems O
who O
dropout O
of O
treatment O
. O
[]

RESULTS O
Topical O
antibiotic O
treatment O
yielded O
mean O
concentrations B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ofloxacin I-outcome ['Physiological-Clinical']
, O
0.75 O
microg/mL O
, O
and O
ciprofloxacin O
, O
0.21 O
microg/mL O
, O
in O
aqueous O
. O
['Physiological-Clinical']

The O
mean O
difference O
was O
more O
significant O
when O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
per O
gm O
. O
['Physiological-Clinical']

Patients O
were O
randomised O
to O
receive O
treatment O
with O
a O
4-week O
cycle O
of O
subcutaneous O
low O
doses O
IL-2 O
+ O
IFN O
in O
months O
1 O
, O
3 O
and O
5 O
, O
and O
then O
every O
3 O
months O
until O
the O
first O
documented O
disease O
progression O
( O
arm O
A O
, O
suspension O
) O
, O
or O
the O
same O
regimen O
, O
with O
chronic O
maintenance O
of O
immunotherapy O
, O
regardless O
of O
tumour O
response O
, O
until O
death O
or O
intolerable O
toxicity O
( O
arm O
B O
, O
maintenance O
) O
. O
[]

The O
extent O
and O
severity O
of O
atopic O
eczema O
, O
the O
growth O
and O
nutrition O
of O
infants O
, O
and O
concentrations O
of O
circulating O
cytokines/chemokines O
and O
soluble O
cell O
surface O
adhesion O
molecules O
in O
serum O
and O
methyl-histamine O
and O
eosinophilic O
protein O
X O
in O
urine O
were O
determined O
. O
[]

Further O
, O
donors O
who O
reacted O
were O
less O
likely O
to O
intend O
to O
return O
to O
donate O
. O
[]

Home O
visits O
and O
interviews O
measured O
safety B-outcome ['Life-Impact']
practices I-outcome ['Life-Impact']
when O
women O
were O
in O
their O
third O
trimester O
of O
pregnancy O
( O
baseline O
) O
and O
when O
their O
children O
were O
2 O
, O
4 O
, O
6 O
, O
9 O
, O
12 O
, O
and O
18 O
months O
of O
age O
. O
['Life-Impact']

METHODS O
Eight O
healthy O
subjects O
underwent O
esophageal O
manometry O
using O
a O
10-lumen O
sleeve O
assembly O
during O
placebo O
or O
loxiglumide O
( O
10 O
mg/kg/h O
) O
in O
a O
randomized O
double-blind O
order O
. O
[]

Simultaneously O
there O
was O
a O
significant O
( O
P O
< O
0.001 O
) O
increase O
in O
glutathione B-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
and O
total O
antioxidant B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
, O
and O
significant O
decrease O
( O
P O
< O
0.05 O
) O
in O
malondialdehyde B-outcome ['Physiological-Clinical']
and O
glutathion B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
levels O
in O
the O
serum O
of O
patients O
treated O
with O
chemotherapy O
compared O
to O
the O
patients O
treated O
with O
radiotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Preclinical O
studies O
have O
established O
that O
implantation O
of O
bone O
marrow-mononuclear O
cells O
, O
including O
endothelial O
progenitor O
cells O
, O
into O
ischaemic O
limbs O
increases O
collateral B-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

However O
, O
the O
clinical O
relevance O
of O
these O
findings O
await O
results O
of O
the O
IMPROVE-IT O
trial O
( O
Improved O
Reduction O
of O
Outcomes O
: O
Vytorin O
Efficacy O
International O
Trial O
) O
. O
[]

Physicians O
' O
implicit O
preferences O
might O
explain O
racial O
differences O
in O
TKR O
recommendation O
. O
[]

This O
study O
was O
undertaken O
to O
evaluate O
the O
effect O
of O
ipratropium O
bromide O
( O
IB O
) O
, O
an O
anticholinergic O
nasal O
spray O
, O
on O
rhinorrhea O
in O
these O
patients O
. O
[]

METHODS O
Full-term O
newborns O
and O
children O
( O
n O
= O
488 O
) O
through O
8 O
yr O
of O
age O
who O
required O
general O
anesthesia O
and O
tracheal O
intubation O
were O
assigned O
randomly O
to O
receive O
either O
a O
cuffed O
tube O
sized O
by O
a O
new O
formula O
[ O
size O
( O
mm O
internal O
diameter O
) O
= O
( O
age/4 O
) O
+ O
3 O
] O
, O
or O
an O
uncuffed O
tube O
sized O
by O
the O
modified O
Cole O
's O
formula O
[ O
size O
( O
mm O
internal O
diameter O
) O
= O
( O
age/4 O
) O
+ O
4 O
] O
. O
[]

Ratings O
of O
videotapes B-outcome ['Physiological-Clinical']
significantly O
differed O
from O
live B-outcome ['Physiological-Clinical']
ratings I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Methods O
Seventy-two O
patients O
were O
randomly O
divided O
into O
two O
groups O
, O
the O
36 O
patients O
in O
the O
treated O
group O
were O
treated O
with O
FRCL O
, O
and O
the O
other O
36 O
patients O
in O
the O
control O
group O
simply O
treated O
with O
Western O
medicine O
. O
[]

BACKGROUND O
To O
compare O
the O
combined O
effects O
of O
arteriovenous O
extracorporeal O
lung O
assist O
( O
AV-ECLA O
) O
and O
high-frequency O
oscillatory O
ventilation O
( O
HFOV O
) O
on O
pulmonary B-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
exchange I-outcome ['Physiological-Clinical']
, O
hemodynamics B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
pain B-outcome ['Physiological-Clinical']
scores O
during O
the O
procedure O
favored O
morcellation O
by O
16.1 O
points O
on O
average O
( O
35.9 O
compared O
with O
52.0 O
; O
95 O
% O
CI O
for O
difference O
, O
-24.7 O
to O
-7.6 O
; O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
therapeutic B-outcome ['Physiological-Clinical']
efficacy O
of O
Yinxing O
Damo O
( O
YXDM O
) O
combined O
with O
Betahistine O
Hydrochloride O
Injection O
( O
BHI O
) O
on O
vertebra B-outcome ['Physiological-Clinical']
basilar I-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
ischemic I-outcome ['Physiological-Clinical']
vertigo I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VBIV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
protective O
effects O
by O
increasing O
cumulative O
doses O
of O
formoterol O
( O
12 O
, O
60 O
, O
120 O
micrograms O
) O
and O
salmeterol O
( O
50 O
, O
250 O
, O
500 O
micrograms O
) O
on O
methacholine-induced O
bronchoconstriction O
were O
evaluated O
in O
a O
double-blind O
, O
crossover O
, O
placebo-controlled O
design O
. O
[]

The O
low O
, O
medium O
, O
and O
high O
doses O
of O
methylphenidate O
hydrochloride O
were O
based O
on O
weight O
, O
and O
they O
ranged O
from O
7.5 O
mg/d O
to O
50.0 O
mg/d O
in O
divided O
doses O
. O
[]

Treatment O
was O
continued O
until O
relapse O
or O
up O
to O
16 O
weeks O
. O
[]

The O
prevalences O
of O
PONV O
0 O
to O
24 O
hours O
after O
anesthesia O
were O
28 O
% O
with O
propofol O
( O
P O
= O
0.005 O
) O
, O
32 O
% O
with O
droperidol O
( O
P O
= O
0.011 O
) O
, O
and O
60 O
% O
with O
metoclopramide O
( O
P O
= O
NS O
) O
, O
compared O
with O
placebo O
( O
68 O
% O
) O
. O
[]

MAIN O
OUTCOME O
MEASURE O
[]

There O
was O
a O
1-week O
washout O
period O
prior O
to O
each O
randomized O
treatment O
. O
[]

Paracetamol O
and O
opioid O
pathways O
: O
a O
pilot O
randomized O
clinical O
trial O
. O
[]

Twenty O
patients O
were O
treated O
with O
oral O
azithromycin O
, O
250 O
mg O
bd O
for O
two O
days O
followed O
by O
250 O
mg O
od O
for O
eight O
days O
, O
21 O
patients O
were O
given O
phenoxymethylpenicillin O
1 O
million O
IU O
tds O
for O
14 O
days O
and O
23 O
patients O
received O
doxycycline O
, O
100 O
mg O
bd O
for O
14 O
days O
. O
[]

Population O
pharmacokinetic/pharmacodynamic O
analysis O
of O
the O
DPP-4 O
inhibitor O
linagliptin O
in O
Japanese O
patients O
with O
type O
2 O
diabetes O
mellitus O
. O
[]

Since O
substantial O
proportion O
pneumonias O
have O
a O
viral O
etiology O
, O
where O
children O
are O
more O
likely O
to O
present O
with O
wheeze O
, O
there O
is O
a O
concern O
that O
currently O
antibiotics O
are O
being O
over-prescribed O
for O
it O
. O
[]

A O
prototype O
of O
this O
pneumatic O
sound O
source O
is O
evaluated O
in O
vitro O
and O
in O
six O
laryngectomees O
. O
[]

There O
was O
a O
dose O
related O
reduction O
in O
symptoms B-outcome ['Physiological-Clinical']
, O
plasma B-outcome ['Physiological-Clinical']
follicle I-outcome ['Physiological-Clinical']
stimulating I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
, O
and O
urinary B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
hydroxyproline I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
children O
were O
followed O
up O
for O
one O
or O
two O
rotavirus O
epidemic O
seasons O
. O
[]

A O
hierarchy O
of O
outcomes O
was O
hypothesized O
based O
on O
treatments O
received O
prior O
to O
randomization O
and O
randomized O
treatment O
. O
[]

Infection O
rates O
, O
knowledge O
about O
soil-transmitted B-outcome ['Physiological-Clinical']
helminths I-outcome ['Physiological-Clinical']
( O
as O
assessed O
with O
the O
use O
of O
a O
questionnaire O
['Physiological-Clinical', 'Physiological-Clinical']

STUDY O
DESIGN O
Interdisciplinary O
, O
prospective O
, O
observer-blinded O
, O
randomized O
clinical O
trial O
with O
a O
1-yr O
follow-up O
period O
. O
[]

Both O
groups O
were O
treated O
at O
the O
clinic O
twice O
weekly O
for O
4 O
weeks O
. O
[]

Median O
physostigmine B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
approximately O
100 O
pg/ml O
were O
measured O
, O
showing O
a O
high O
degree O
of O
interindividual O
variability O
and O
no O
linear O
dose O
relationship O
between O
the O
30 O
mg O
and O
60 O
mg O
dosages O
. O
['Physiological-Clinical']

In O
conclusion O
, O
this O
long-term O
study O
did O
not O
show O
any O
serious O
[]

We O
conclude O
that O
fenretinide O
showed O
a O
lack O
of O
effect O
on O
the O
DNA O
content B-outcome ['Physiological-Clinical']
distribution I-outcome ['Physiological-Clinical']
and O
the O
morphology O
of O
urothelial B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
obtained O
in O
serial O
bladder O
washings O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Prior O
to O
and O
following O
the O
4-month O
program O
, O
subjects O
underwent O
comprehensive O
physiological O
and O
psychological O
evaluations O
. O
[]

OBJECTIVE O
To O
assess O
the O
effects O
of O
unilateral O
or O
bilateral O
otoplasty O
on O
bradycardia B-outcome ['Physiological-Clinical']
and O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
vomiting I-outcome ['Physiological-Clinical']
( O
PONV B-outcome ['Physiological-Clinical']
) O
and O
the O
efficiency O
of O
transdermal O
scopolamine O
in O
the O
prophylaxis B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
PONV I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
randomized O
, O
placebo-controlled O
double-blind O
crossover O
trial O
of O
melatonin O
was O
undertaken O
in O
11 O
children O
with O
autistic O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

Oral O
sucrose O
is O
frequently O
given O
to O
relieve O
procedural O
pain O
in O
neonates O
on O
the O
basis O
of O
its O
effect O
on O
behavioural O
and O
physiological O
pain O
scores O
. O
[]

These O
differences O
were O
not O
found O
in O
group O
2 O
eyes O
. O
[]

Outcome O
measures O
included O
the O
Western O
Ontario O
and O
McMaster O
Universities O
( O
WOMAC O
) O
Osteoarthritis O
Index O
hip O
function O
score O
, O
pain O
, O
and O
blinded O
functional O
evaluation O
by O
a O
physical O
therapist O
. O
[]

No O
changes O
in O
B-Hb B-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or O
pulse O
were O
observed O
during O
the O
treatment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Randomised O
controlled O
trial O
( O
RCT O
) O
studies O
in O
this O
area O
have O
been O
rare O
but O
are O
essential O
because O
of O
the O
developmental O
heterogeneity O
of O
the O
disorder O
. O
[]

Forty-four O
children O
, O
ages O
8-11 O
years O
, O
were O
randomly O
assigned O
to O
treatment O
or O
wait O
list O
. O
[]

A O
double-blind O
controlled O
study O
comparing O
the O
effects O
of O
bupropion O
to O
doxepin O
in O
outpatients O
with O
primary O
depression O
was O
conducted O
to O
evaluate O
efficacy O
and O
safety O
differences O
between O
the O
two O
drugs O
. O
[]

On O
the O
whole O
, O
178 O
patients O
( O
89 O
in O
each O
arm O
) O
, O
receiving O
unmanipulated O
HSCT O
from O
either O
a O
relative O
or O
an O
unrelated O
donor O
, O
completed O
the O
study O
. O
[]

Statistical O
differences O
were O
found O
between O
groups O
concerning O
uterine B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
and O
drop O
in O
hemoglobin B-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

The O
purpose O
of O
this O
investigation O
was O
to O
determine O
the O
effect O
of O
unexpected O
forward O
perturbations O
( O
FP O
) O
during O
gait O
on O
lower O
extremity B-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
mechanics I-outcome ['Physiological-Clinical']
and O
muscle B-outcome ['Physiological-Clinical']
Electromyographic I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EMG I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
patterns I-outcome ['Physiological-Clinical']
in O
healthy O
adults O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
bone O
mass O
measurements O
of O
46 O
patients O
participating O
in O
a O
current O
trial O
of O
therapy O
for O
osteoporosis O
were O
reviewed O
. O
[]

Traditional O
nutritional B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
( O
albumin B-outcome ['Physiological-Clinical']
, O
transferrin B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Twenty-one O
women O
died B-outcome ['Mortality']
of O
their O
disease O
. O
['Mortality']

FINDINGS O
From O
June O
, O
2005 O
, O
to O
August O
, O
2008 O
, O
882 O
women O
were O
enrolled O
, O
824 O
of O
whom O
were O
randomised O
and O
gave O
birth O
to O
805 O
singleton O
or O
first O
, O
liveborn O
infants O
. O
[]

The O
present O
study O
investigated O
the O
success B-outcome ['Physiological-Clinical']
rate O
of O
NTI O
and O
frequency O
of O
nasal O
bleeding O
using O
a O
curve-tipped O
suction O
catheter O
( O
CTSC O
) O
to O
guide O
nasotracheal O
tube O
advancement O
. O
['Physiological-Clinical']

Interventions O
involved O
12 O
sessions O
over O
6 O
weeks O
, O
with O
a O
3-month O
follow-up O
. O
[]

OBJECTIVE O
One O
symptom O
common O
to O
many O
persons O
with O
autism O
is O
a O
high O
arousal O
or O
anxiety O
level O
. O
[]

While O
the O
PEP O
scores O
of O
both O
groups O
increased O
, O
and O
the O
score O
of O
trail O
group O
was O
higher O
than O
the O
control O
group O
( O
all O
P O
< O
0.05 O
) O
. O
[]

Of O
436 O
women O
declared O
CIN B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
initially O
, O
26 O
( O
6.0 O
% O
) O
had O
high-grade B-outcome ['Physiological-Clinical']
CIN I-outcome ['Physiological-Clinical']
diagnosed O
on O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical']

injection O
( O
P O
less O
than O
0.005 O
) O
and O
this O
change O
was O
sustained O
for O
60 O
min O
. O
[]

The O
visual O
analogue O
scale O
( O
VAS O
) O
at O
rest B-outcome ['Physiological-Clinical']
and O
coughing B-outcome ['Physiological-Clinical']
and O
the O
respiratory O
functional B-outcome ['Life-Impact']
parameters I-outcome ['Life-Impact']
were O
recorded O
at O
1 O
, O
2 O
, O
4 O
, O
8 O
, O
12 O
, O
24 O
, O
36 O
, O
and O
48 O
h O
after O
the O
start O
of O
PCA O
, O
and O
the O
actual O
and O
effective O
button-pressing O
times O
( O
D O
( O
1 O
) O
/D O
( O
2 O
) O
) O
in O
PCA O
were O
also O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

The O
core O
symptoms O
of O
autism O
are O
abnormalities O
in O
social O
interaction O
, O
communication O
and O
behaviour O
. O
[]

Polydioxanone O
sternal O
sutures O
for O
prevention O
of O
sternal O
dehiscence O
. O
[]

At O
high-frequency O
oscillatory O
ventilation+15 O
, O
15 O
patients O
had O
right O
ventricular O
dysfunction O
and O
nine O
had O
right O
ventricular O
failure O
. O
[]

Mother O
yielded O
more O
persuasive B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
behavioral I-outcome ['Life-Impact']
attitudes I-outcome ['Life-Impact']
for O
third-graders O
versus O
fifth-graders O
. O
['Life-Impact']

RESULTS O
The O
age O
of O
the O
patients O
ranged O
from O
32 O
to O
98 O
years O
( O
mean O
, O
80.8 O
years O
) O
, O
and O
65 O
patients O
had O
a O
history O
of O
coronary O
artery O
disease O
. O
[]

RESULTS O
Greater O
vital B-outcome ['Physiological-Clinical']
force I-outcome ['Physiological-Clinical']
ratings O
( O
mean O
2.9 O
standard O
deviation O
[ O
SD O
] O
0.6 O
) O
correlated O
moderately O
( O
p O
< O
or O
= O
0.005 O
) O
with O
less O
severe O
CGI B-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
ratings O
by O
the O
homeopaths O
( O
r O
=-0.59 O
) O
, O
decreased O
patient-rated O
mental B-outcome ['Life-Impact']
confusion I-outcome ['Life-Impact']
( O
r O
=-0.43 O
) O
, O
higher O
vigor B-outcome ['Life-Impact']
( O
r O
= O
0.38 O
) O
, O
and O
greater O
positive O
states B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
mind I-outcome ['Life-Impact']
( O
r O
= O
0.36 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact']

OBJECTIVE O
The O
study O
aims O
to O
evaluate O
psychosocial O
, O
societal O
, O
and O
family O
cost O
consequences O
of O
a O
psychoeducational O
intervention O
program O
. O
[]

Neuromuscular B-outcome ['Resource-use']
monitoring I-outcome ['Resource-use']
was O
performed O
using O
an O
electromyographic O
( O
EMG O
) O
device O
( O
Datex O
Relaxograph O
) O
. O
['Resource-use']

PATIENTS O
AND O
METHODS O
Between O
November O
2005 O
and O
March O
2006 O
, O
48 O
patients O
were O
randomized O
to O
either O
an O
18F O
Re-entry O
nephrostomy O
tube O
( O
group O
1 O
) O
or O
a O
6F O
Double-J O
stent O
( O
group O
2 O
) O
. O
[]

CONCLUSION O
These O
data O
suggest O
that O
IV O
ceftriaxone O
followed O
by O
oral O
cefditoren O
pivoxil O
is O
highly O
effective O
and O
well-tolerated B-outcome ['Life-Impact']
for O
the O
treatment O
of O
acute O
pyelonephritis O
, O
even O
for O
uropathogens O
with O
a O
high O
proportion O
of O
quinolone-resistant O
strains O
. O
['Life-Impact']

Symptoms O
were O
categorized O
as O
none O
, O
mild O
, O
moderate O
, O
or O
severe O
. O
[]

DESIGN O
Open O
prospective O
randomised O
controlled O
trial O
, O
comparing O
conventional O
nursing O
care O
with O
the O
additional O
nutritional O
support O
provided O
by O
DA O
. O
[]

Women O
have O
low O
coronary B-outcome ['Mortality']
heart I-outcome ['Mortality']
disease I-outcome ['Mortality']
mortality I-outcome ['Mortality']
rates O
, O
which O
do O
not O
correlate O
with O
8-oxo-dG O
. O
['Mortality']

Median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
14.9 O
months O
( O
95 O
% O
CI O
: O
13.7-28.4 O
) O
on O
the O
satraplatin O
plus O
prednisone O
arm O
and O
11.9 O
months O
( O
95 O
% O
CI O
: O
8.4-23.1 O
) O
on O
prednisone O
alone O
( O
hazard O
ratio O
, O
HR O
= O
0.84 O
, O
95 O
% O
CI O
: O
0.46-1.55 O
) O
. O
['Mortality']

Clinical O
and O
prognostic O
significance O
of O
serum O
magnesium O
concentration O
in O
patients O
with O
severe O
chronic O
congestive O
heart O
failure O
: O
the O
PROMISE O
Study O
. O
[]

Significantly O
fewer O
treated O
patients O
worsened O
during O
treatment O
( O
decreased O
[]

In O
spite O
of O
the O
current O
enthusiasm O
, O
there O
remain O
potentially O
serious O
complications O
resulting O
from O
any O
periorbital O
peel O
. O
[]

18 O
patients O
received O
placebo O
and O
23 O
ones O
were O
given O
enalapril O
. O
[]

Is O
adjuvant O
chemotherapy O
of O
benefit O
for O
postmenopausal O
women O
who O
receive O
endocrine O
treatment O
for O
highly O
endocrine-responsive O
, O
node-positive O
breast O
cancer O
? O
[]

ERN O
in O
TMS O
treatment O
group O
became O
significantly O
more O
negative O
. O
[]

The O
propofol-alone O
group O
had O
a O
mean O
TICS O
score O
of O
35.09 O
at O
24 O
hours O
compared O
with O
35.98 O
at O
48 O
hours O
( O
P O
= O
.924 O
) O
. O
[]

0.1 O
% O
bupivacaine O
does O
not O
reduce O
the O
requirement O
for O
epidural O
fentanyl O
infusion O
after O
major O
abdominal O
surgery O
. O
[]

Lambs O
were O
fed O
until O
the O
average O
BW O
of O
each O
pen O
reached O
a O
target O
BW O
( O
55.4 O
kg O
for O
wethers O
and O
50.0 O
kg O
for O
ewes O
) O
, O
at O
which O
time O
the O
entire O
pen O
of O
lambs O
was O
slaughtered O
. O
[]

RESULTS O
Patients O
from O
TEMPO O
and O
RADIUS O
II O
who O
received O
etanercept O
monotherapy O
showed O
similar O
CDAI O
remission O
rates O
( O
39 O
% O
and O
35 O
% O
, O
respectively O
, O
at O
3 O
years O
) O
. O
[]

The O
remaining O
horses O
remained O
healthy O
, O
developed O
a O
grade O
1 O
to O
4 O
lameness O
with O
minimal O
to O
severe O
swelling O
in O
the O
PIJ O
region O
. O
[]

In O
vitro O
determination O
of O
the O
chromatic B-outcome ['Physiological-Clinical']
effect O
of O
a O
silver O
nanoparticles O
solution O
linked O
to O
the O
gantrez O
S-97 O
copolymer O
on O
tooth O
enamel O
. O
['Physiological-Clinical']

CONCLUSION O
Gemfibrozil O
does O
not O
appear O
to O
exert O
a O
clinically O
relevant O
effect O
on O
rates O
of O
kidney B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
loss O
in O
individuals O
with O
moderate O
CRI O
, O
low O
HDL-C O
levels O
, O
and O
concomitant O
coronary O
disease O
. O
['Physiological-Clinical']

No O
correlated O
activity O
was O
observed O
during O
continue O
at O
P O
< O
0.01 O
( O
corrected O
, O
cluster O
level O
) O
, O
though O
left O
angular O
gyrus O
was O
active O
at O
P O
< O
0.05 O
. O
[]

In O
addition O
, O
two O
groups O
of O
8 O
patients O
were O
randomly O
submitted O
to O
a O
desipramine O
150 O
mg/day O
, O
or O
a O
metapramine O
450 O
mg/day O
antidepressant O
treatment O
influencing O
the O
formation O
of O
DOPEG O
and O
MOPEG O
in O
a O
different O
way O
. O
[]

In O
group O
2 O
( O
control O
group O
; O
n O
= O
20 O
) O
patients O
received O
only O
oral O
calcium O
( O
1,000 O
mg/day O
) O
and O
vitamin O
D O
( O
400 O
IU/day O
) O
. O
[]

Therapy B-outcome ['Resource-use']
effect O
of O
either O
paclitaxel O
or O
cyclophosphamide O
combination O
treatment O
in O
patients O
with O
epithelial O
ovarian O
cancer O
and O
relation O
to O
TP53 O
gene O
status O
. O
['Resource-use']

PURPOSE O
To O
determine O
whether O
the O
duration O
and O
the O
dose O
of O
epirubicin O
modify O
the O
long-term O
outcome O
of O
patients O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
[]

These O
results O
can O
improve O
the O
design O
of O
future O
work O
on O
therapeutic O
uses O
of O
TMS O
. O
[]

After O
adding O
exposure O
however O
, O
these O
parameters O
were O
clearly O
and O
significantly O
reduced O
. O
[]

Patients O
received O
one O
of O
three O
different O
protocols O
all O
including O
1 O
Hz O
rTMS O
over O
the O
left O
temporal O
cortex O
. O
[]

Pharmacist O
directed O
home O
medication O
reviews O
in O
patients O
with O
chronic O
heart O
failure O
: O
a O
randomised O
clinical O
trial O
. O
[]

Therefore O
, O
they O
were O
combined O
for O
comparison O
with O
the O
PRN O
group O
. O
[]

This O
order O
effect O
could O
be O
explained O
by O
a O
remanent O
effect O
of O
amisulpride O
after O
6 O
wash-out O
weeks O
. O
( O
[]

PATIENTS O
AND O
METHODS O
Forty O
women O
were O
randomized O
before O
radiotherapy O
after O
various O
operations O
for O
breast O
cancer O
. O
[]

Transient B-outcome ['Physiological-Clinical']
ischaemic I-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
ST I-outcome ['Physiological-Clinical']
segment I-outcome ['Physiological-Clinical']
elevation I-outcome ['Physiological-Clinical']
or O
depression B-outcome ['Life-Impact']
, O
with O
or O
without B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
were O
documented O
by O
continuous B-outcome ['Resource-use']
electrocardiographic I-outcome ['Resource-use']
monitoring I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Resource-use']

The O
trial O
was O
powered O
for O
analyses O
of O
antitumor B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
safety O
. O
['Physiological-Clinical']

CONCLUSIONS O
Pramipexole O
is O
effective O
and O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
in O
RLS O
, O
most O
notably O
among O
objective O
measures O
, O
for O
reducing O
PLM B-outcome ['Physiological-Clinical']
and O
decreasing O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Development O
of O
autistic O
children O
based O
on O
maternal O
responses O
to O
the O
Autism O
Behavior O
Checklist O
. O
[]

In O
all O
other O
respects O
, O
the O
programs O
were O
identical O
. O
[]

An O
18-week O
, O
10-contact O
nursing O
intervention O
utilizing O
problem-solving O
approaches O
to O
symptom O
management O
and O
improving O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
and O
emotional B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
was O
implemented O
. O
['Life-Impact', 'Life-Impact']

The O
posts O
size O
and O
shape O
were O
identical O
in O
the O
3 O
groups O
. O
[]

Pathologic O
high-risk O
features O
will O
be O
used O
to O
determine O
the O
requirement O
for O
adjuvant O
radiotherapy O
+/- O
chemotherapy O
. O
[]

PURPOSE O
To O
compare O
lesion O
anatomical O
responses O
to O
ranibizumab O
versus O
verteporfin O
photodynamic O
therapy O
( O
PDT O
) O
in O
the O
ANCHOR O
( O
Anti-VEGF O
Antibody O
for O
the O
Treatment O
of O
Predominantly O
Classic O
Choroidal O
Neovascularization O
[ O
CNV O
] O
in O
Age-Related O
Macular O
Degeneration O
) O
study O
. O
[]

METHODS O
Totally O
61 O
patients O
with O
grade O
I O
to O
III O
KOA O
were O
randomly O
assigned O
to O
two O
groups O
, O
the O
treatment O
group O
and O
the O
control O
group O
. O
[]

A O
randomised O
controlled O
trial O
comparing O
Drawtex O
with O
standard O
dressings O
for O
exuding O
wounds O
. O
[]

This O
study O
was O
developed O
to O
determine O
if O
5 O
days O
of O
antibiotic B-outcome ['Resource-use']
administration I-outcome ['Resource-use']
would O
be O
more O
effective O
than O
1 O
day O
. O
['Resource-use']

GH B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
GHRH I-outcome ['Physiological-Clinical']
treatment I-outcome ['Physiological-Clinical']
was O
blunted O
in O
patients O
bearing O
adrenal O
incidentaloma O
compared O
with O
controls O
( O
GH O
peak O
, O
5.7 O
+/- O
5.2 O
vs. O
18.0 O
+/- O
7.0 O
microg/L O
; O
P O
< O
0.0001 O
) O
, O
whereas O
GHRH O
plus O
arginine O
was O
able O
to O
elicit O
a O
comparable O
response O
in O
the O
2 O
groups O
( O
GH O
peak O
, O
33.5 O
+/- O
20.3 O
vs. O
33.7 O
+/- O
17.5 O
microg/L O
; O
P O
= O
NS O
) O
. O
['Physiological-Clinical']

Discontinuation B-outcome ['Life-Impact']
due I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
adverse I-outcome ['Life-Impact']
events I-outcome ['Life-Impact']
was O
low O
( O
5 O
% O
vs O
7 O
% O
) O
. O
['Life-Impact']

DESIGN O
A O
controlled O
, O
randomized O
, O
prospective O
study O
. O
[]

rhinorrhea O
and O
itching O
. O
[]

The O
overall O
response O
rate O
across O
the O
three O
groups O
was O
65.3 O
% O
. O
[]

Pioglitazone O
increased O
CD34 B-outcome ['Physiological-Clinical']
( O
+ O
) O
/kinase O
insert I-outcome ['Physiological-Clinical']
domain I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
( O
+ O
) O
EPCs B-outcome ['Physiological-Clinical']
to O
142 O
+/- O
9 O
% O
and O
cultured B-outcome ['Physiological-Clinical']
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled O
acetylated O
LDL O
( O
+ O
) O
/lectin O
( O
+ O
) O
EPCs O
to O
180 O
+/- O
3 O
% O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

But O
these O
patients O
could O
tolerate O
the O
lower O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
very O
well O
in O
the O
diltiazem O
group O
. O
( O
['Physiological-Clinical']

OBJECTIVES O
Attenuation O
of O
protein O
kinase O
C O
( O
PKC O
) O
is O
a O
mechanism O
common O
to O
both O
established O
( O
lithium O
, O
valproate O
) O
and O
some O
novel O
( O
tamoxifen O
) O
antimanic O
agents O
. O
[]

Intragastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
was O
recorded O
continuously O
from O
24 O
h O
before O
to O
24 O
h O
after O
dosing O
. O
['Physiological-Clinical']

Initial O
characteristics O
of O
the O
best O
responders O
were O
mild O
to O
moderate O
symptoms O
of O
autism O
, O
better O
motor O
imitation O
skills O
, O
and O
emerging O
joint O
attention O
skills O
. O
[]

This O
beneficial O
effect O
of O
HBO O
involves O
inhibition O
of O
inducible O
nitric O
oxide O
synthase O
( O
iNOS O
) O
expression O
and O
subsequent O
nitric O
oxide O
( O
NO O
) O
biosynthesis O
. O
[]

The O
duration O
of O
mechanical B-outcome ['Physiological-Clinical']
ventilation B-outcome ['Life-Impact']
, O
the O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
in O
the O
ICU O
, O
and O
the O
use O
of O
inotropic B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
did O
not O
increase O
after O
the O
IP O
protocol O
. O
['Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Resource-use']

infusion O
at O
90 O
mg/h O
for O
24 O
h. O
The O
placebo O
group O
( O
n O
= O
14 O
) O
received O
corresponding O
volumes O
of O
isotonic O
saline O
. O
[]

These O
blinded O
data O
were O
randomised O
, O
and O
outcome O
measures O
were O
determined O
by O
two O
independent O
observers O
. O
[]

Among O
107 O
patients O
who O
presented O
with O
good O
renal O
function O
and O
with O
haemoglobin O
above O
100 O
g/l O
, O
the O
5-year O
survival B-outcome ['Mortality']
was O
43 O
% O
. O
['Mortality']

Spectra O
were O
measured O
( O
a O
) O
before O
and O
( O
b O
) O
after O
surface O
preparation O
, O
( O
c O
) O
immediately O
before O
and O
( O
d O
) O
after O
laser O
irradiation O
at O
630 O
nm O
. O
[]

Elbow B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
also O
induced O
involuntary O
changes O
in O
the O
intrinsic B-outcome ['Physiological-Clinical']
thumb I-outcome ['Physiological-Clinical']
flexor I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
( O
44.6 O
% O
increase O
under O
30 O
% O
elbow O
extensor O
activation O
; O
p O
= O
0.005 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Main O
outcome O
measures O
included O
mean O
change O
from O
baseline O
at O
Months O
12 O
and O
24 O
for O
area O
of O
classic O
CNV O
and O
total O
area O
of O
leakage O
from O
CNV O
. O
[]

The O
rate O
of O
severe B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
( O
final O
acuity O
< O
5/200 O
) O
was O
significantly O
higher O
in O
tap O
eyes O
( O
16 O
eyes O
, O
24 O
% O
) O
compared O
with O
biopsy O
eyes O
( O
13 O
eyes O
, O
11 O
% O
) O
and O
abort O
eyes O
( O
0 O
eyes O
, O
0 O
% O
; O
P O
= O
0.043 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
Metabolic O
disorders O
were O
common O
among O
adult O
Chinese O
in O
both O
rural O
and O
urban O
areas O
in O
Qingdao O
. O
[]

The O
overall O
rate O
of O
encephalopathic B-outcome ['Physiological-Clinical']
syndromes I-outcome ['Physiological-Clinical']
in O
the O
cases O
analysed O
( O
n=34 O
) O
was O
5.8 O
% O
, O
of O
which O
38.2 O
% O
died O
. O
['Physiological-Clinical']

Problem-based O
learning O
: O
is O
anatomy O
a O
casualty O
? O
[]

Patients O
with O
dysthymia B-outcome ['Life-Impact']
in O
addition O
to O
major B-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
also O
showed O
significant O
improvement O
( O
p O
< O
.05 O
) O
when O
treated O
with O
nefazodone O
, O
with O
significant O
differences O
in O
response O
rates O
seen O
as O
early O
as O
week O
2 O
and O
through O
the O
end O
of O
the O
trial O
. O
['Life-Impact', 'Life-Impact']

The O
changes O
in O
amprenavir O
steady-state B-outcome ['Physiological-Clinical']
pharmacokinetic I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
, O
relative O
to O
those O
for O
amprenavir O
alone O
, O
were O
not O
consistent O
among O
protease O
inhibitors O
, O
nor O
were O
the O
changes O
consistent O
with O
potential O
interactions O
in O
CYP3A4 O
metabolism O
or O
P-glycoprotein O
transport O
. O
['Physiological-Clinical']

INTRODUCTION O
It O
has O
been O
reported O
in O
an O
open-label O
study O
that O
the O
combination O
of O
alkalinized O
lidocaine O
and O
heparin O
can O
immediately O
relieve O
the O
symptoms O
of O
urinary B-outcome ['Physiological-Clinical']
urgency I-outcome ['Physiological-Clinical']
, O
frequency O
, O
and O
['Physiological-Clinical']

Compliance O
with O
the O
requirement O
to O
record O
details O
of O
the O
healthcare O
services O
during O
the O
year-long O
study O
was O
high O
. O
[]

This O
individual O
mode O
of O
administration O
allows O
not O
only O
a O
perfect O
dose O
titration O
in O
young O
asthmatics O
, O
but O
is O
also O
helpful O
to O
patients O
who O
have O
difficulty O
in O
swallowing O
large O
dosage O
forms O
. O
[]

INTERPRETATION O
Triple O
antiretroviral O
prophylaxis O
during O
pregnancy O
and O
breastfeeding O
is O
safe O
and O
reduces O
the O
risk O
of O
HIV O
transmission O
to O
infants O
. O
[]

OBJECTIVES O
To O
evaluate O
the O
effectiveness O
of O
a O
back O
support O
plus O
education O
versus O
education O
alone O
in O
promoting O
recovery O
from O
a O
work-related O
low O
back O
disorder O
( O
WR-LBD O
) O
while O
simultaneously O
considering O
personal O
, O
health O
, O
and O
occupational O
factors O
and O
the O
impact O
of O
occupational O
factors O
on O
recovery O
. O
[]

Thirty-five O
( O
49 O
% O
) O
of O
72 O
enrolled O
subjects O
were O
classified O
as O
methylphenidate O
responders O
. O
[]

METHOD O
A O
total O
of O
200 O
neonates O
( O
gestational O
ages O
26.4-41 O
weeks O
) O
treated O
with O
netilmicin O
( O
4-5 O
mg/kg O
in O
extended O
dosing O
intervals O
) O
for O
postnatal O
sepsis O
in O
the O
first O
week O
of O
life O
received O
either O
fluid O
therapy O
or O
parenteral O
nutrition O
. O
[]

ADMA B-outcome ['Physiological-Clinical']
levels O
were O
positively O
correlated O
with O
basal O
endothelin-1 B-outcome ['Physiological-Clinical']
levels O
and O
negatively O
correlated O
with O
insulin-induced B-outcome ['Physiological-Clinical']
incremental I-outcome ['Physiological-Clinical']
levels O
of O
NOx B-outcome ['Physiological-Clinical']
and O
forearm B-outcome ['Physiological-Clinical']
cGMP I-outcome ['Physiological-Clinical']
release B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

A O
total O
of O
227 O
subjects O
were O
randomized O
to O
either O
placebo O
( O
n O
= O
114 O
) O
or O
simvastatin O
20 O
mg O
daily O
( O
n O
= O
113 O
) O
. O
[]

Fifty-seven O
patients O
were O
prospectively O
individually O
randomly O
allocated O
into O
early O
versus O
delayed O
reinfusion O
groups O
prior O
to O
undergoing O
elective O
spinal O
surgery O
by O
a O
single O
surgeon O
. O
[]

In O
light O
of O
these O
findings O
we O
then O
carried O
out O
a O
similar O
randomized O
trial O
comparing O
triple O
dose O
mebendazole O
, O
single O
dose O
albendazole O
, O
and O
triple O
dose O
albendazole O
against O
placebo O
in O
209 O
adults O
in O
the O
same O
area O
. O
[]

RESULTS O
Denosumab O
was O
superior O
to O
zoledronic O
acid O
in O
delaying O
time O
to O
first O
on-study O
SRE O
( O
hazard O
ratio O
, O
0.82 O
; O
95 O
% O
CI O
, O
0.71 O
to O
0.95 O
; O
P O
= O
.01 O
superiority O
) O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
subsequent I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
multiple I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
on-study I-outcome ['Physiological-Clinical']
SREs I-outcome ['Physiological-Clinical']
( O
rate O
ratio O
, O
0.77 O
; O
95 O
% O
CI O
, O
0.66 O
to O
0.89 O
; O
P O
= O
.001 O
) O
. O
['Physiological-Clinical']

We O
chose O
upper-eyelid O
skin O
because O
it O
is O
easier O
to O
obtain O
for O
histopathologic O
study O
than O
lower-eyelid O
skin O
and O
, O
in O
our O
experience O
, O
is O
more O
sensitive O
to O
hypertrophic O
changes O
after O
chemical O
peeling O
or O
carbon O
dioxide O
laser O
resurfacing O
. O
[]

SETTING O
Kinesiology O
laboratory O
. O
[]

Chemotherapy O
with O
cyclophosphamide O
, O
doxorubicin O
, O
vincristine O
, O
and O
prednisone O
alone O
or O
with O
levamisole O
or O
with O
levamisole O
plus O
BCG O
for O
malignant O
lymphoma O
: O
a O
Southwest O
Oncology O
Group O
Study O
. O
[]

METHODS O
During O
phase O
1 O
treatment O
, O
86 O
subjects O
were O
treated O
with O
a O
bionator O
, O
93 O
were O
treated O
with O
headgear/biteplane O
, O
and O
81 O
served O
as O
the O
observation O
group O
. O
[]

In O
addition O
, O
a O
general O
enhancement O
of O
the O
activation B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
lymphocytes I-outcome ['Physiological-Clinical']
was O
observed O
. O
['Physiological-Clinical']

SETTING O
Pediatric O
emergency O
service O
of O
a O
large O
teaching O
hospital O
. O
[]

CONCLUSIONS O
There O
is O
insufficient O
evidence O
to O
indicate O
a O
difference O
in O
language B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
between O
children O
using O
NLFC O
and O
those O
using O
conventional O
amplification O
. O
['Life-Impact']

Survival B-outcome ['Mortality']
was O
significantly O
improved O
with O
an O
increase O
at O
5 O
years O
of O
8 O
% O
, O
from O
79 O
to O
87 O
% O
. O
['Mortality']

Vinorelbine O
is O
an O
important O
chemotherapy O
option O
for O
MBC O
. O
[]

Dexamethasone O
for O
the O
treatment O
of O
depression O
: O
a O
randomized O
, O
placebo-controlled O
, O
double-blind O
trial O
. O
[]

Toxicity B-outcome ['Adverse-effects']
was O
also O
comparable O
, O
with O
the O
exception O
of O
an O
increased O
incidence O
of O
impotence B-outcome ['Physiological-Clinical']
among O
men O
who O
received O
megestrol O
acetate O
. O
['Adverse-effects', 'Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Pain O
relief O
can O
reduce O
hypoxemia B-outcome ['Physiological-Clinical']
in O
distressed O
neonates O
during O
routine O
treatment O
procedures O
. O
['Physiological-Clinical']

The O
three O
groups O
treated O
with O
higher O
dosages O
( O
400 O
to O
800 O
mg O
of O
ebrotidine O
daily O
) O
showed O
an O
endoscopic O
ulcer O
healing O
rate O
of O
90-95 O
% O
, O
significantly O
higher O
than O
55 O
% O
achieved O
with O
placebo O
( O
p O
< O
0.05 O
) O
, O
whilst O
the O
differences O
between O
these O
three O
dosages O
of O
ebrotidine O
were O
not O
statistically O
significant O
. O
[]

In O
conclusion O
, O
it O
is O
suggested O
that O
adaptive O
mechanisms O
, O
which O
would O
functionally O
modify O
the O
reflex O
responses O
, O
are O
also O
continuously O
working O
during O
voluntary O
movements O
in O
response O
to O
sudden O
changes O
in O
environmental O
information O
. O
[]

Comparison O
of O
the O
2 O
groups O
showed O
that O
there O
were O
no O
significant O
differences O
( O
all O
P O
values O
> O
0.05 O
) O
in O
all O
the O
parameters O
of O
pulse O
wave O
except O
that O
the O
central B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
augmentation B-outcome ['Physiological-Clinical']
and O
augmentation B-outcome ['Physiological-Clinical']
index O
were O
significantly O
lower O
in O
enalapril O
group O
than O
in O
indapamide O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
and O
their O
physicians O
selected O
either O
definitive O
radiotherapy O
or O
precystectomy O
radiotherapy O
; O
patients O
were O
then O
randomly O
allocated O
to O
receive O
intravenous O
cisplatin O
100 O
mg/m2 O
at O
2-week O
intervals O
for O
three O
cycles O
concurrent O
with O
pelvic O
radiation O
, O
or O
to O
receive O
radiation O
without O
chemotherapy O
. O
[]

In O
Experiment O
2 O
, O
participants O
' O
eye O
movements O
were O
monitored O
when O
they O
viewed O
a O
visual O
display O
on O
a O
computer O
screen O
while O
listening O
to O
a O
concurrent O
auditory O
input O
. O
[]

Out O
of O
383 O
myocardial O
infarction O
( O
MI O
) O
patients O
aged O
below O
70 O
years O
, O
252 O
( O
66 O
% O
) O
were O
judged O
after O
the O
third O
day O
in O
hospital O
to O
have O
had O
uncomplicated O
infarctions O
. O
[]

Virologic B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
( O
HIV-1 O
RNA O
< O
50 O
copies/mL O
) O
was O
maintained O
at O
week O
96 O
( O
84 O
% O
vs O
82 O
% O
, O
difference O
+2.7 O
% O
, O
95 O
% O
CI O
: O
-2.9 O
% O
to O
8.3 O
% O
) O
. O
['Physiological-Clinical']

Outcomes O
included O
sleep O
quality O
, O
mood O
and O
quality O
of O
life O
questionnaires O
( O
PSQI O
, O
Epworth O
Sleepiness O
Scale O
[ O
ESS O
] O
, O
Short-form O
36 O
[ O
SF-36 O
] O
, O
Center O
for O
Epidemiological O
Studies O
Depression O
Scale O
[ O
CES-D O
] O
) O
. O
[]

Embolization O
results O
were O
evaluated O
by O
a O
central O
laboratory O
. O
[]

Within O
the O
last O
few O
years O
, O
increasing O
evidence O
of O
relative O
adrenal O
insufficiency O
in O
septic O
shock O
evoked O
a O
reassessment O
of O
hydrocortisone O
therapy O
. O
[]

or O
placebo O
for O
two O
weeks O
in O
the O
first O
period O
, O
followed O
by O
one O
week O
washout O
period O
. O
[]

The O
Randomised O
Intervention O
Treatment O
of O
Angina O
( O
RITA O
) O
Trial O
protocol O
: O
a O
long O
term O
study O
of O
coronary O
angioplasty O
and O
coronary O
artery O
bypass O
surgery O
in O
patients O
with O
angina O
. O
[]

Part O
I O
consisted O
of O
4-month O
open-label O
treatment O
with O
risperidone O
, O
starting O
at O
the O
established O
optimal O
dose O
; O
part O
II O
was O
an O
8-week O
randomized O
, O
double-blind O
, O
placebo-substitution O
study O
of O
risperidone O
withdrawal O
. O
[]

RESULTS O
Women O
who O
were O
iron O
deficient O
at O
baseline O
( O
n=38 O
) O
had O
significantly O
greater O
improvement O
in O
PT O
score O
with O
iron B-outcome ['Physiological-Clinical']
and O
riboflavin B-outcome ['Physiological-Clinical']
supplementation I-outcome ['Physiological-Clinical']
than O
without O
( O
P=0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CLINICAL O
TRIAL O
REGISTRATION O
URL O
: O
http O
: O
//www.clinicaltrials.gov O
. O
[]

Sleep B-outcome ['Physiological-Clinical']
normalized O
in O
one O
child O
who O
continued O
to O
receive O
no O
cow O
's O
milk O
only O
after O
the O
hydrolyzed O
hypoallergenic O
diet O
was O
discontinued O
. O
['Physiological-Clinical']

INTERPRETATION O
Because O
LTA O
does O
not O
improve O
survival O
after O
TH O
and O
leads O
to O
increased O
morbidity O
in O
patients O
with O
cancer O
of O
the O
cardia O
or O
subcardia O
, O
LTA O
can O
not O
be O
justified O
to O
treat O
these O
tumours O
. O
[]

OBJECTIVE O
saliva B-outcome ['Physiological-Clinical']
measurements O
were O
also O
carried O
out O
. O
['Physiological-Clinical']

Patients O
also O
received O
a O
low-sodium O
( O
40 O
mmol/day O
) O
diet O
and O
the O
aldosterone O
antagonist O
, O
potassium O
canrenoate O
( O
100 O
mg O
b.i.d. O
) O
. O
[]

This O
economic B-outcome ['Resource-use']
evaluation O
also O
considered O
relative O
efficacies O
of O
the O
approaches O
using O
the O
primary O
outcome O
variable O
of O
symptomatic O
, O
sustained B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
tachyarrhythmia I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
( O
including O
sudden B-outcome ['Mortality']
death I-outcome ['Mortality']
) O
. O
['Resource-use', 'Physiological-Clinical', 'Mortality']

Peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
compared O
pre- O
and O
postoperatively O
in O
the O
two O
groups O
. O
['Physiological-Clinical']

Cambodian O
immigrants O
are O
over O
25 O
times O
more O
likely O
to O
have O
evidence O
of O
chronic O
hepatitis O
B O
infection O
than O
the O
general O
US O
population O
. O
[]

Infants O
of O
dexamethasone-treated O
dams O
had O
significantly O
lower O
incidence O
and O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
HMD I-outcome ['Physiological-Clinical']
than O
did O
infants O
of O
control O
animals O
( O
50 O
versus O
92 O
% O
, O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

In O
total O
, O
we O
found O
2.9 O
% O
of O
patients O
( O
5/175 O
) O
presenting O
ESUL B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Significantly O
lower O
peak O
and O
area O
under O
the O
curve O
( O
AUC O
) O
GH O
concentrations O
occurred O
in O
the O
irradiated O
group O
using O
0.15 O
microg/kg O
( O
median O
peak O
Irradiated O
, O
4 O
. O
[]

At O
the O
end O
of O
the O
treatment O
, O
Z O
scores O
were O
1.8 O
+/- O
0.3 O
for O
Crosslaps O
( O
CTx O
) O
and O
deoxypyridinoline O
( O
D-Pyr O
) O
, O
and O
1.1 O
+/- O
0.2 O
for O
bone B-outcome ['Physiological-Clinical']
alkaline I-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
B-ALP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
osteocalcin B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Divalproex O
has O
been O
shown O
to O
have O
efficacy O
in O
treating O
epilepsy O
, O
bipolar O
disorder O
, O
mood O
lability O
, O
and O
impulsive O
aggression O
. O
[]

CONCLUSION O
An O
initial O
double-dose O
of O
diclofenac-K O
( O
2 O
x O
12.5 O
mg O
) O
or O
paracetamol O
( O
2 O
x O
500 O
mg O
) O
adequately O
relieved O
the O
most O
intense O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
the O
flexible O
multiple O
dose O
regimen O
( O
1 O
or O
2 O
tablets O
) O
maintained O
adequate O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
thereafter O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Niacin O
ER O
has O
a O
favorable O
effect O
in O
modulating O
the O
blood O
lipid O
profile O
, O
especially O
in O
reducing O
TG B-outcome ['Physiological-Clinical']
and O
elevating B-outcome ['Physiological-Clinical']
HDL-C B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

As O
expected O
, O
there O
were O
no O
differences O
in O
clinically O
important O
outcomes O
. O
[]

Our O
aim O
was O
to O
investigate O
the O
clinical O
outcomes O
of O
using O
this O
drug O
in O
patients O
with O
acute O
anterior O
STEMI O
receiving O
thrombolytic O
treatment O
( O
TLT O
) O
. O
[]

In O
this O
study O
, O
the O
efficacy O
and O
safety O
of O
tracheal O
intubation O
with O
the O
LFS O
was O
compared O
with O
that O
of O
the O
Macintosh O
laryngoscope O
utilizing O
manual O
in-line O
stabilization O
( O
MILS O
) O
to O
simulate O
difficult O
airways O
. O
[]

The O
response O
rate O
, O
time O
to O
treatment O
failure B-outcome ['Physiological-Clinical']
( O
TTF O
) O
, O
and O
median O
survival O
time O
were O
superior O
in O
the O
premenopausal O
women O
. O
['Physiological-Clinical']

Due O
to O
its O
higher O
sensitivity O
the O
valid O
limits O
of O
the O
aR O
at O
provocation O
testings O
can O
not O
be O
transferred O
to O
IOS O
to O
avoid O
a O
false O
positive O
reaction B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

At O
baseline O
, O
week O
2 O
, O
and O
week O
5 O
, O
a O
dermatologist O
performed O
facial O
lesion O
counts O
, O
patients O
reported O
perceived O
severity O
of O
rash-related O
symptoms O
, O
and O
standardized O
facial O
photographs O
were O
obtained O
for O
blinded O
evaluation O
of O
global O
rash O
severity O
. O
[]

In O
the O
THP O
group O
, O
30 O
mg O
of O
THP O
dissolved O
in O
50 O
ml O
saline O
was O
administered O
4 O
times O
intravesically O
for O
4 O
consecutive O
days O
before O
TUR O
. O
[]

METHODS O
We O
used O
a O
prospective O
study O
that O
utilized O
the O
Short-Form O
36 O
Survey O
at O
baseline O
presentation O
and O
at O
a O
mean O
time O
of O
3 O
years O
post-functional O
endoscopic O
sinus O
surgery O
to O
assess O
the O
general O
health O
status O
of O
patients O
who O
presented O
for O
their O
initial O
visitfrom O
1996 O
to O
1998 O
. O
[]

The O
change O
in O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
was O
significantly O
better O
in O
the O
sodium O
bicarbonate O
group O
than O
other O
2 O
groups O
( O
P O
= O
.007 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Recommendations O
vary O
regarding O
immediate O
antimicrobial O
treatment O
versus O
watchful O
waiting O
for O
children O
younger O
than O
2 O
years O
of O
age O
with O
acute O
otitis O
media O
. O
[]

A O
comparative O
trial O
of O
fixed O
ratio O
beta-adrenoceptor O
blocker O
and O
diuretic O
combination O
products O
in O
moderate O
hypertension O
. O
[]

Most O
importantly O
, O
the O
experiments O
clarified O
apparently O
contradictory O
results O
of O
previous O
studies O
by O
indicating O
that O
concreteness B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
generally O
do O
not O
occur O
in O
memory O
for O
prose O
when O
imageability O
is O
manipulated O
between-subjects O
, O
and O
that O
their O
occurrence O
when O
imageability O
is O
manipulated O
within-subjects O
depends O
on O
the O
order O
occurrence O
when O
imageability O
is O
manipulated O
within-subjects O
depends O
on O
the O
order O
of O
presentation O
. O
['Life-Impact']

Outcome O
measures O
were O
the O
DSRs O
and O
the O
17-item O
Hamilton O
Depression O
Rating O
Scale O
( O
HAM-D17 O
) O
. O
[]

RESULTS O
Intervention O
patients O
reported O
using O
more O
skills B-outcome ['Life-Impact']
than O
controls O
in O
five O
of O
six O
skill O
areas O
, O
including O
identification O
of O
problems/concerns B-outcome ['Life-Impact']
, O
information O
exchange B-outcome ['Life-Impact']
, O
treatment O
adherence B-outcome ['Life-Impact']
, O
shared O
decision-making B-outcome ['Life-Impact']
and O
interpersonal B-outcome ['Life-Impact']
rapport I-outcome ['Life-Impact']
( O
all O
p O
< O
.05 O
) O
; O
post O
intervention O
, O
physicians O
reported O
using O
more O
skills O
in O
the O
same O
5 O
areas O
( O
all O
p O
< O
.01 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
primary O
outcome O
- O
death B-outcome ['Mortality']
or I-outcome ['Mortality']
chronic I-outcome ['Mortality']
lung I-outcome ['Mortality']
disease I-outcome ['Mortality']
at O
36 O
weeks O
' O
postmenstrual O
age O
- O
occurred O
in O
significantly O
fewer O
infants O
in O
the O
vitamin O
A O
group O
than O
in O
the O
control O
group O
( O
55 O
percent O
vs. O
62 O
percent O
; O
relative O
risk O
, O
0.89 O
; O
95 O
percent O
confidence O
interval O
, O
0.80 O
to O
0.99 O
) O
. O
['Mortality']

For O
total O
stone O
capture O
( O
all O
sizes O
) O
the O
Sacred O
Heart O
Halo O
resulted O
in O
the O
most O
rapid B-outcome ['Physiological-Clinical']
stone I-outcome ['Physiological-Clinical']
extraction I-outcome ['Physiological-Clinical']
( O
17 O
+/- O
14 O
seconds O
) O
by O
novices O
and O
experts O
, O
while O
the O
Sur-Catch O
NT O
resulted O
in O
the O
slowest O
stone O
extraction O
( O
78 O
+/- O
90 O
, O
seconds O
, O
p O
= O
0.001 O
) O
. O
['Physiological-Clinical']

ANIMALS O
Eighteen O
mallard O
ducks O
were O
included O
for O
the O
LD O
( O
50 O
) O
study O
and O
28 O
for O
the O
fluid O
resuscitation O
study O
. O
[]

The O
recruitment B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
children I-outcome ['Life-Impact']
is O
often O
the O
major O
barrier O
to O
the O
progress O
of O
a O
successful O
clinical O
trial O
. O
['Life-Impact']

Enhancing O
the O
working B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
of O
stroke O
patients O
using O
tDCS O
. O
['Life-Impact']

At O
six O
months O
follow-up O
, O
25 O
( O
69 O
% O
) O
interferon O
and O
27 O
( O
73 O
% O
) O
placebo O
recipients O
experienced O
recurrences B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Doppler O
ultrasound O
can O
detect O
cerebral O
emboli O
noninvasively O
. O
[]

There O
was O
no O
significant O
difference O
in O
average O
leukocyte B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

5-FU/FA O
. O
[]

CONCLUSIONS O
The O
use O
of O
large O
amounts O
of O
urea O
fertiliser O
during O
spring O
and O
the O
consequent O
increases O
in O
concentrations O
of O
CP O
in O
pasture O
and O
urea B-outcome ['Physiological-Clinical']
in O
['Physiological-Clinical']

However O
, O
compared O
with O
standard O
care O
, O
performing O
a O
pre-transplant O
tacrolimus O
C O
( O
2 O
) O
does O
lead O
to O
patients O
achieving O
a O
whole-blood O
concentration O
of O
?10 O
ng/mL O
sooner O
. O
[]

Sixty-eight O
evaluable O
patients O
with O
MDS O
were O
randomized O
to O
receive O
a O
single O
, O
daily O
oral O
dose O
of O
either O
13-cis O
retinoic O
acid O
( O
13-CRA O
, O
100 O
mg/m2 O
) O
or O
matching O
placebo O
. O
[]

Prolactin B-outcome ['Physiological-Clinical']
levels O
showed O
a O
decrease O
in O
the O
group O
treated O
with O
alpha O
dihidroergocriptine O
with O
an O
important O
difference O
between O
both O
groups O
at O
the O
end O
of O
the O
6 O
months O
study O
period O
. O
['Physiological-Clinical']

Among O
those O
with O
complete O
resolution O
, O
however O
, O
the O
times O
to O
resolution O
of O
50 O
% O
( O
HR50 O
) O
or O
90 O
% O
( O
HR90 O
) O
of O
the O
liver O
enlargement O
were O
similar O
in O
all O
the O
treatment O
groups O
. O
[]

No O
significant O
difference O
was O
found O
in O
the O
ability B-outcome ['Life-Impact']
to O
climb B-outcome ['Physiological-Clinical']
stairs I-outcome ['Physiological-Clinical']
but O
there O
was O
a O
marked O
improvement O
in O
the O
symptomatic B-outcome ['Physiological-Clinical']
questionnaire O
score O
, O
19 O
+/- O
5 O
in O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Of O
the O
714 O
patients O
enrolled O
in O
the O
initial O
trials O
, O
581 O
( O
81 O
% O
) O
enrolled O
in O
the O
extension O
, O
and O
388 O
( O
54 O
% O
) O
patients O
are O
continuing O
to O
receive O
etanercept O
therapy O
. O
[]

A O
novel O
aspect O
of O
the O
design O
is O
the O
use O
of O
a O
preliminary O
cost-effectiveness O
analysis O
, O
based O
on O
best-guess O
values O
, O
and O
a O
sensitivity O
analysis O
over O
plausible O
ranges O
to O
guide O
the O
choice O
of O
subsample O
size O
. O
[]

CONCLUSION O
The O
effect O
of O
acupuncture O
combined O
with O
drug O
for O
treatment O
of O
male O
osteoporosis O
is O
good O
with O
little O
adverse O
reaction O
. O
[]

Trimetazidine O
: O
a O
new O
concept O
in O
the O
treatment O
of O
angina O
. O
[]

Biopsies O
were O
taken O
from O
the O
gastric O
antrum O
and O
corpus O
for O
determination O
of O
prostaglandin O
E2 O
( O
PGE2 O
) O
by O
ELISA O
and O
cyclooxygenase O
( O
COX-1 O
and O
COX-2 O
) O
and O
nitric O
oxide O
synthase O
( O
eNOS O
and O
iNOS O
) O
by O
western O
blot O
. O
[]

In O
comparison O
, O
it O
was O
only O
47.10 O
% O
( O
57/121 O
) O
in O
the O
control O
group O
, O
31.78 O
% O
( O
34/107 O
) O
in O
those O
with O
complications O
. O
[]

Patients O
were O
then O
given O
a O
daily O
infusion O
of O
1,000 O
ml O
of O
fresh O
frozen O
plasma O
for O
seven O
to O
18 O
days O
to O
expand O
the O
blood O
volume O
to O
supranormal O
levels O
as O
assayed O
by O
serial O
measurement O
of O
blood O
volume O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
efficacy O
of O
controlled-release O
( O
CR O
) O
melatonin O
in O
the O
treatment O
of O
delayed O
sleep O
phase O
syndrome O
and O
impaired O
sleep O
maintenance O
of O
children O
with O
neurodevelopmental O
disabilities O
including O
autistic O
spectrum O
disorders O
. O
[]

The O
area O
under O
the O
receiver O
operating O
characteristic O
curve O
( O
AUC O
) O
was O
used O
to O
compare O
the O
discriminating O
ability O
of O
all O
fits O
. O
[]

To O
examine O
whether O
the O
addition O
of O
robot-assisted O
training O
out O
of O
the O
horizontal O
plane O
leads O
to O
improved O
outcomes O
. O
[]

Randomized O
controlled O
trial O
evaluating O
the O
clinical O
benefit O
of O
montelukast O
for O
treating O
spring B-outcome ['Physiological-Clinical']
seasonal I-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Salvage O
treatments O
mainly O
with O
surgical O
resection O
of O
residual O
tumors O
after O
the O
chemotherapy O
, O
however O
, O
were O
more O
successful O
in O
group O
B O
( O
88 O
% O
) O
than O
group O
A O
( O
61 O
% O
) O
. O
[]

The O
intervention O
group O
received O
family O
education O
, O
and O
data O
on O
their O
knowledge O
about O
schizophrenia B-outcome ['Life-Impact']
, O
symptoms B-outcome ['Life-Impact']
, O
functioning B-outcome ['Life-Impact']
, O
psychosocial B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
, O
relapse B-outcome ['Life-Impact']
and O
medication B-outcome ['Life-Impact']
adherence I-outcome ['Life-Impact']
were O
collected O
and O
compared O
with O
the O
control O
group O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

BACKGROUND O
Medical O
ozone O
therapy O
system O
was O
reported O
to O
have O
certain O
effects O
on O
the O
treatment O
of O
severe B-outcome ['Physiological-Clinical']
hepatitis I-outcome ['Physiological-Clinical']
, O
but O
its O
mechanism O
is O
not O
very O
clear O
. O
['Physiological-Clinical']

We O
investigated O
the O
role O
of O
exercise O
on O
the O
sleep O
need O
of O
sedentary O
adults O
, O
after O
controlling O
for O
exercise O
mode O
, O
timing O
and O
duration O
. O
[]

There O
was O
no O
statistically O
significant O
difference O
in O
patient B-outcome ['Mortality']
survival I-outcome ['Mortality']
between O
the O
two O
groups O
. O
['Mortality']

CONCLUSION O
When O
one O
treatment O
is O
superior O
to O
the O
other O
two O
, O
the O
trial O
design O
provides O
better O
patient B-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
, O
higher O
power B-outcome ['Life-Impact']
, O
and O
a O
lower O
expected O
sample O
['Life-Impact', 'Life-Impact']

There O
was O
a O
trend O
( O
p O
= O
.06 O
) O
for O
children O
receiving O
naltrexone O
in O
the O
highest O
weight O
percentile O
( O
> O
or O
= O
90th O
) O
to O
lose O
weight O
( O
mean O
= O
-0.42 O
kg O
) O
but O
this O
was O
not O
the O
case O
for O
those O
in O
the O
lower O
weight O
percentiles O
( O
mean O
= O
+0.03 O
kg O
) O
. O
[]

Alpha O
interferon O
has O
shown O
initial O
promise O
in O
the O
treatment O
of O
low-grade O
non-Hodgkin O
's O
lymphoma O
( O
NHL O
) O
, O
especially O
with O
the O
nodular O
form O
of O
the O
disease O
. O
[]

MEASUREMENTS O
Ecological O
momentary O
assessment O
ratings O
of O
smoking B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
and O
putative O
mediators O
were O
collected O
pre- O
and O
post-quit O
. O
['Life-Impact']

Hypoglycemia-induced O
responses O
of O
epinephrine O
, O
norepinephrine O
, O
and O
cortisol O
were O
not O
enhanced O
by O
theophylline O
. O
[]

The O
prevalence O
of O
moderate B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
severe I-outcome ['Physiological-Clinical']
mitral I-outcome ['Physiological-Clinical']
regurgitation I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
colour I-outcome ['Physiological-Clinical']
Doppler I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
S1 I-outcome ['Physiological-Clinical']
was O
greater O
in O
patients O
who O
had O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
at O
any O
time O
( O
10.2 O
% O
v O
4.2 O
% O
, O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Topical O
administration O
of O
diclofenac O
( O
1 O
% O
) O
in O
the O
prevention O
of O
miosis B-outcome ['Physiological-Clinical']
during O
vitrectomy O
. O
['Physiological-Clinical']

Interactive O
effects O
between O
source O
, O
and O
sex O
and O
grade O
were O
found O
for O
cognitive O
and O
behavioral O
attitudes O
. O
[]

There O
was O
no O
change O
in O
pulse B-outcome ['Physiological-Clinical']
or O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
when O
carteolol O
was O
substituted O
for O
timolol O
but O
an O
increase O
of O
10 O
beats O
per O
minute O
( O
p O
< O
0.05 O
) O
in O
mean O
resting B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
in O
the O
betaxolol O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
total O
effective O
rate O
was O
86.7 O
% O
in O
the O
EA O
plus O
behavior O
therapy O
group O
which O
was O
better O
than O
56.7 O
% O
of O
the O
behavior O
therapy O
group O
, O
and O
had O
significant O
enhancement O
in O
sensation O
, O
association O
, O
body O
, O
and O
ability B-outcome ['Life-Impact']
of O
self-care B-outcome ['Life-Impact']
( O
P O
< O
0.05 O
) O
and O
was O
better O
than O
the O
behavior O
therapy O
group O
in O
sensation B-outcome ['Life-Impact']
, O
['Life-Impact', 'Life-Impact', 'Life-Impact']

During O
continuous O
administration O
of O
propofol O
, O
reversal B-outcome ['Physiological-Clinical']
of O
unconsciousness B-outcome ['Physiological-Clinical']
produced O
by O
physostigmine O
( O
28 O
microgram/kg O
) O
and O
block O
of O
this O
reversal B-outcome ['Physiological-Clinical']
by O
scopolamine O
( O
8.6 O
microgram/kg O
) O
were O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Analgesia O
lasted O
longer O
in O
the O
bupivacaine-clonidine O
group O
( O
139.4 O
+/- O
31 O
min O
) O
compared O
with O
the O
bupivacaine-fentanyl O
group O
( O
127.9 O
+/- O
48 O
min O
) O
( O
P O
= O
0.42 O
) O
. O
[]

METHODS O
One O
hundred O
patients O
were O
randomized O
to O
receive O
inferior-superior O
or O
inferior-medial O
injections O
in O
a O
study O
in O
which O
injectate O
, O
injectate O
volumes O
, O
5-min O
ocular O
akinesia O
scoring O
( O
0-8 O
) O
, O
lid O
scoring O
( O
0-2 O
) O
and O
supplemental O
injection O
protocols O
were O
standardized O
. O
[]

Preservative-free O
2-chloroprocaine O
( O
2-CP O
) O
is O
being O
investigated O
for O
short-acting O
spinal O
anesthesia O
. O
[]

Under O
these O
circumstances O
, O
acute B-outcome ['Physiological-Clinical']
maternal I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
infusion I-outcome ['Physiological-Clinical']
may O
further O
contribute O
to O
fetal B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
acidosis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
SLT O
patients O
were O
treated O
with O
a O
frequency-doubled O
q-switched O
neodymium O
: O
yytrium-aluminum-garnet O
laser O
( O
wavelength O
532 O
nm O
) O
. O
[]

No O
concomitant O
anti-inflammatory O
or O
antirheumatic O
drug O
therapy O
was O
permitted O
during O
the O
study O
. O
[]

Results O
show O
that O
participants O
were O
significantly O
more O
accurate B-outcome ['Physiological-Clinical']
when O
binocular O
information O
was O
['Physiological-Clinical']

Antipyrine O
reacts O
quickly O
with O
hydroxyl O
radicals O
to O
form O
para- O
and O
ortho-hydroxyantipyrine O
. O
[]

Treated O
patients O
underwent O
surgical O
deactivation O
of O
trigger O
site O
( O
s O
) O
. O
[]

Subfoveal O
and O
pulsatile O
choroidal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow O
were O
measured O
with O
laser O
Doppler O
flowmetry O
and O
laser O
interferometry O
, O
respectively O
. O
['Physiological-Clinical']

One O
hundred O
sixty-three O
colon O
cancer O
patients O
underwent O
the O
traditional O
protocol O
and O
open O
operation O
( O
traditional O
open O
group O
, O
n=42 O
) O
, O
the O
traditional O
protocol O
and O
laparoscopic O
operation O
( O
traditional O
laparoscopic O
group O
, O
n=40 O
) O
, O
the O
FT O
protocol O
and O
open O
operation O
( O
FT O
open O
group O
, O
n=41 O
) O
, O
or O
the O
FT O
protocol O
and O
laparoscopic O
operation O
( O
FT O
laparoscopic O
group O
, O
n=40 O
) O
. O
[]

INTRODUCTION O
We O
compared O
arch O
dimension O
changes O
in O
1-phase O
and O
2-phase O
treatment O
of O
Class O
II O
malocclusion O
. O
[]

This O
study O
examines O
immune B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
populations I-outcome ['Physiological-Clinical']
of O
infants O
fed O
soy O
protein O
isolate O
formulas O
with O
and O
without O
added O
nucleotides O
for O
1 O
year O
. O
['Physiological-Clinical']

At O
two O
weeks O
each O
treatment O
was O
associated O
with O
a O
significant O
degree O
of O
improvement O
; O
however O
, O
pharmacological O
ionisation O
produced O
a O
significantly O
higher O
improvement O
in O
symptoms B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
In O
1996 O
, O
survival O
data O
were O
updated O
from O
three O
prospective O
, O
randomized O
comparisons O
of O
idarubicin O
and O
daunorubicin O
that O
began O
in O
1984 O
and O
1985 O
. O
[]

Gender O
differences O
may O
not O
pose O
a O
relevant O
problem O
for O
the O
study O
of O
acute O
haemodynamic O
effects O
of O
cardiovascular O
drugs O
. O
[]

There O
were O
no O
significant O
changes O
in O
blood B-outcome ['Physiological-Clinical']
chemistry I-outcome ['Physiological-Clinical']
, O
including O
lipoprotein B-outcome ['Physiological-Clinical']
classes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
endpoint O
was O
posttraumatic B-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
within O
48 O
hours O
; O
secondary O
endpoints O
were O
survival O
and O
neurologic O
outcome O
30 O
days O
after O
injury O
. O
['Physiological-Clinical']

We O
therefore O
investigated O
the O
time O
course O
of O
subjective O
and O
objective O
measures O
of O
nasal B-outcome ['Physiological-Clinical']
affection I-outcome ['Physiological-Clinical']
after O
steroid O
administration O
in O
patients O
with O
allergic O
rhinitis O
following O
specific O
allergen O
challenge O
. O
['Physiological-Clinical']

The O
EC50 B-outcome ['Physiological-Clinical']
+/- O
SE O
values O
in O
the O
Control O
, O
2.5 O
microg/kg O
Clonidine O
, O
and O
5.0 O
microg/kg O
Clonidine O
groups O
were O
2.67 O
+/- O
0.18 O
, O
1.31 O
+/- O
0.12 O
, O
and O
0.91 O
+/- O
0.13 O
microg/mL O
, O
respectively O
. O
['Physiological-Clinical']

In O
the O
propranolol O
group O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
reduced O
markedly O
. O
['Physiological-Clinical']

No O
unexpected O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
noted O
. O
['Adverse-effects']

CONCLUSION O
A O
substantial O
beneficial O
effect O
of O
IUI O
with O
COH O
in O
couples O
with O
unexplained B-outcome ['Physiological-Clinical']
subfertility I-outcome ['Physiological-Clinical']
and O
an O
intermediate O
prognosis O
can O
be O
excluded O
. O
['Physiological-Clinical']

All O
other O
parameters O
of O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
were O
not O
affected O
by O
either O
treatment O
. O
['Life-Impact']

Physiotherapy O
included O
exercise O
, O
massage O
, O
taping O
, O
and O
mobilisation O
, O
followed O
by O
12 O
weeks O
of O
self O
management O
. O
[]

AIMS O
Supraphysiologic O
glucocorticoid O
activity O
is O
well O
established O
to O
cause O
impaired O
glucose B-outcome ['Physiological-Clinical']
tolerance O
and O
insulin B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
, O
yet O
no O
study O
has O
evaluated O
dose-dependent O
effects O
of O
low-dose O
prednisone O
during O
short-term O
oral O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Clinical O
outcomes O
and O
complications B-outcome ['Adverse-effects']
were O
compared O
for O
1 O
year O
of O
follow-up O
. O
['Adverse-effects']

Metallic O
commissurotomy O
is O
reported O
to O
be O
a O
cheaper O
and O
effective O
alternative O
to O
balloon O
mitral O
commissurotomy O
. O
[]

CONCLUSION O
The O
treatment O
with O
rhGH O
of O
adult O
chronic O
hemodialysis O
patients O
for O
6 O
months O
increased O
the O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
significantly O
, O
but O
without O
any O
effect O
on O
ejection O
fraction O
or O
maximal O
working O
capacity O
. O
['Physiological-Clinical']

The O
PCT O
composite O
definition O
of O
clinical O
outcome O
( O
i.e. O
, O
worsened O
, O
improved O
, O
or O
unchanged O
) O
was O
used O
. O
[]

DESIGN O
The O
NORwegian O
study O
on O
DIstrict O
treatment O
of O
STEMI O
( O
NORDISTEMI O
) O
is O
an O
open O
, O
prospective O
, O
randomized O
controlled O
trial O
in O
patients O
with O
STEMI O
of O
less O
than O
6 O
hours O
of O
duration O
and O
more O
than O
90 O
minutes O
expected O
time O
delay O
to O
PCI O
. O
[]

Cardiopulmonary O
exercise O
variables O
in O
diastolic O
versus O
systolic O
heart O
failure O
. O
[]

BACKGROUND O
Clinical O
vitamin O
A O
deficiency O
affects O
millions O
of O
children O
worldwide O
, O
and O
subclinical O
deficiency O
is O
even O
more O
common O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
use O
structural O
equation O
modeling O
( O
SEM O
) O
to O
re-analyze O
a O
RCT O
, O
comparing O
the O
effects O
of O
pre-curved O
interdental O
brushes O
and O
flossing O
on O
probing O
pocket O
depth O
( O
PPD O
) O
, O
plaque O
indices O
, O
and O
bleeding O
on O
probing O
( O
BOP O
) O
measured O
at O
baseline O
, O
intermediate O
, O
and O
final O
examinations O
. O
[]

METHODS O
In O
two O
crossover O
studies O
omeprazole O
20 O
mg O
b.d. O
, O
lansoprazole O
30 O
mg O
b.d. O
, O
roxithromycin O
300 O
mg O
b.d. O
, O
and O
the O
combination O
of O
roxithromycin O
with O
either O
omeprazole O
or O
lansoprazole O
were O
administered O
to O
12 O
healthy O
volunteers O
over O
6 O
days O
. O
[]

71.9 O
mm O
( O
3 O
) O
vs. O
133.9 O
? O
[]

An O
international O
multi-clinic O
study O
comparing O
the O
therapeutic O
efficacy O
of O
colloidal O
bismuth O
subcitrate O
coated O
tablets O
with O
chewing O
tablets O
in O
the O
treatment O
of O
duodenal O
ulceration O
. O
[]

Exclusion O
criteria O
included O
peritonsillar O
abscess O
history O
, O
bleeding O
disorders O
, O
and O
any O
other O
procedure O
together O
with O
tonsillectomy O
. O
[]

Thus O
, O
188 O
patients O
were O
treated O
and O
included O
in O
the O
ITT O
analysis O
( O
94 O
patients O
per O
treatment O
group O
; O
ITT O
analysis O
) O
; O
161 O
patients O
were O
included O
in O
the O
perprotocol O
( O
PP O
) O
analysis O
( O
n O
= O
80 O
for O
amlodipine O
camsylate O
, O
n O
= O
81 O
for O
amlodipine O
besylate O
) O
( O
14 O
patients O
in O
the O
amlodipine O
camsylate O
group O
and O
13 O
patients O
in O
the O
amlodipine O
besylate O
group O
were O
excluded O
from O
the O
PP O
analysis O
due O
to O
consistent O
withdrawal O
or O
protocol O
violation O
) O
. O
[]

AIMS O
To O
evaluate O
whether O
ketorolac O
eyedrops O
and O
ranibizumab O
intravitreal O
injections O
would O
provide O
additional O
benefit O
over O
ranibizumab O
alone O
in O
the O
treatment O
of O
choroidal O
neovascularisation O
( O
CNV O
) O
. O
[]

SETTING O
Department O
of O
Obstetric O
and O
Gynecology O
2nd O
Medical O
Faculty O
Charles O
University O
and O
Teaching O
Hospital O
Motol O
, O
Prague O
, O
and O
Department O
of O
Obstetric O
and O
Gynecology O
1st O
Medical O
Faculty O
and O
Teaching O
Hospital O
Bulovka O
, O
Prague O
. O
[]

Effects O
of O
both O
types O
of O
preparations O
were O
studied O
weekly O
by O
clinical O
examination O
and O
the O
instrumental O
assessment O
of O
bioengineering O
parameters O
. O
[]

In O
counterbalanced O
order O
, O
25 O
couples O
were O
exposed O
to O
couple-responsible O
and O
therapist-responsible O
episodes O
during O
one O
therapy O
session O
. O
[]

A O
double O
blind O
randomized O
trial O
to O
compare O
the O
effects O
of O
eprosartan O
and O
enalapril O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
platelets B-outcome ['Physiological-Clinical']
, O
and O
endothelium B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
essential O
hypertension O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Participants O
were O
randomly O
divided O
over O
an O
experimental O
group O
( O
n=14 O
) O
and O
a O
control O
group O
( O
n=7 O
) O
. O
[]

This O
difference O
is O
not O
significant O
( O
X2 O
= O
1,05 O
) O
. O
[]

Double-blind O
placebo-controlled O
comparison O
of O
the O
analgesic B-outcome ['Resource-use']
effects O
of O
single O
doses O
of O
lornoxicam O
and O
aspirin O
in O
patients O
with O
postoperative O
dental O
pain O
. O
['Resource-use']

Overall O
, O
the O
clinician O
spent O
a O
total O
mean O
time O
of O
81.54 O
minutes O
( O
SD O
30.91 O
minutes O
) O
contacting O
participants O
during O
the O
program O
. O
[]

A O
double-blind O
, O
placebo-controlled O
crossover O
study O
investigating O
the O
effect O
of O
porcine O
secretin O
in O
children O
with O
autism O
. O
[]

The O
aim O
of O
our O
study O
was O
to O
compare O
laparoscopy O
with O
laparotomy O
for O
the O
removal O
of O
ovarian O
dermoid O
cysts O
. O
[]

The O
horses O
were O
euthanized O
at O
24 O
weeks O
. O
[]

After O
nicorandil O
, O
the O
tests O
were O
negative O
in O
nine O
patients O
and O
positive O
for O
a O
higher O
or O
lower O
dose O
of O
ergometrine O
in O
three O
and O
one O
patient O
, O
respectively O
( O
p O
= O
0.0034 O
vs. O
placebo O
) O
. O
[]

There O
were O
no O
incidences O
of O
febrile B-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
during O
the O
study O
. O
['Physiological-Clinical']

Median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
estimated O
with O
4.0 O
, O
5.6 O
, O
and O
6.0 O
months O
( O
P=0.21 O
) O
. O
['Mortality']

A O
control O
group O
practiced O
the O
same O
number O
of O
movements B-outcome ['Physiological-Clinical']
, O
but O
experienced O
the O
target B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
only O
, O
achieving O
eight O
times O
more O
direct B-outcome ['Physiological-Clinical']
practice I-outcome ['Physiological-Clinical']
with O
this O
motion O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Analysis O
of O
interviews O
identified O
a O
complex O
picture O
concerning O
expectations O
These O
could O
be O
classified O
as O
ideal O
, O
realistic O
, O
normative O
and O
unformed O
. O
[]

CONCLUSION O
Neoton O
given O
to O
MI O
patients O
receiving O
TLT O
prevents O
progression O
of O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
and O
establishment O
of O
predictors O
of O
unfavourable O
outcome O
. O
['Physiological-Clinical']

Patients O
were O
evaluated O
at O
study O
initiation O
( O
visit O
1 O
) O
and O
at O
end O
of O
treatment O
( O
visit O
2 O
) O
for O
the O
severity O
of O
five O
clinical O
signs O
: O
eyelid B-outcome ['Physiological-Clinical']
debris I-outcome ['Physiological-Clinical']
, O
eyelid B-outcome ['Physiological-Clinical']
redness I-outcome ['Physiological-Clinical']
, O
eyelid B-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
, O
meibomian B-outcome ['Physiological-Clinical']
gland I-outcome ['Physiological-Clinical']
( O
MG B-outcome ['Physiological-Clinical']
) O
plugging B-outcome ['Physiological-Clinical']
, O
and O
the O
quality O
of O
MG B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
new O
sound O
source O
consists O
of O
a O
single O
silicone O
lip O
, O
which O
performs O
an O
oscillatory O
movement O
driven O
by O
expired O
pulmonary O
air O
flowing O
along O
the O
outward-striking O
lip O
through O
the O
TE O
shunt O
valve O
. O
[]

YAP1 O
downregulation O
resulted O
in O
increased O
progesterone O
receptor O
( O
PgR O
) O
expression O
and O
a O
delayed O
and O
weaker O
tamoxifen O
in O
support O
of O
the O
clinical O
data O
. O
[]

CONCLUSIONS O
The O
good O
efficacy O
and O
tolerability O
of O
a O
topical O
therapeutic O
preparation O
in O
first O
and O
second O
degree O
hemorrhoids O
have O
been O
convincingly O
demonstrated O
. O
[]

However O
, O
failure B-outcome ['Physiological-Clinical']
to O
respond O
, O
delayed B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
, O
partial B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
, O
relapses B-outcome ['Physiological-Clinical']
and O
early B-outcome ['Mortality']
deaths I-outcome ['Mortality']
remain O
significant O
problems O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Higher O
weekly B-outcome ['Physiological-Clinical']
contact I-outcome ['Physiological-Clinical']
hours I-outcome ['Physiological-Clinical']
and O
patient O
ratings O
of O
expressed O
emotion B-outcome ['Life-Impact']
( O
EE O
) O
predicted O
a O
negative O
experience O
of O
caregiving O
. O
['Physiological-Clinical', 'Life-Impact']

Pilot O
study O
of O
a O
moderate O
dose O
multivitamin/mineral O
supplement O
for O
children O
with O
autistic O
spectrum O
disorder O
. O
[]

Consideration O
should O
be O
given O
to O
restoring O
EELV O
after O
either O
suction O
method O
via O
a O
recruitment O
maneuver O
. O
[]

Participants O
were O
randomly O
assigned O
to O
1 O
of O
3 O
groups O
: O
control O
( O
usual O
care O
, O
no O
washout O
) O
, O
saline O
washout O
, O
or O
commercially O
available O
acidic O
washout O
solution O
( O
Contisol O
Maelor O
Pharmaceuticals O
Ltd O
, O
Wrexham O
, O
UK O
) O
. O
[]

We O
compared O
iron O
intake O
and O
iron O
nutritional O
status O
of O
two O
groups O
of O
healthy O
term O
infants O
who O
received O
meat-containing O
baby O
foods O
fortified O
with O
ferrous O
sulphate O
( O
2 O
mg O
Fe/100 O
g O
) O
. O
[]

One O
group O
received O
a O
night O
splint O
in O
addition O
to O
eccentric O
exercises O
. O
[]

There O
were O
no O
group O
differences O
in O
any O
other O
objective O
or O
subjective O
measure O
of O
sleep B-outcome ['Physiological-Clinical']
, O
including O
behavioral O
outcomes O
. O
['Physiological-Clinical']

In O
the O
placebo O
group O
, O
mannitol O
supplemented O
with O
hypocapnia O
was O
applied O
in O
five O
patients O
. O
[]

SUMMARY O
OBJECTIVE O
To O
determine O
the O
effectiveness O
of O
green O
banana O
in O
the O
home O
management O
of O
acute O
( O
< O
7 O
days O
) O
or O
prolonged O
( O
? O
[]

Men O
with O
the O
less O
functional O
FokI O
ff O
genotype O
( O
14 O
% O
in O
the O
European-descent O
population O
of O
this O
cohort O
) O
are O
more O
susceptible O
to O
this O
cancer O
in O
the O
presence O
of O
low O
25 O
( O
OH O
) O
D O
status O
. O
[]

OBJECTIVES O
To O
study O
the O
relative O
efficacy O
of O
three O
different O
treatment O
for O
chronic O
low O
back O
pain O
( O
CLBP O
) O
. O
[]

The O
study O
was O
performed O
at O
a O
single O
centre O
as O
an O
open O
randomised O
parallel-group O
study O
, O
patients O
being O
selected O
for O
inclusion O
from O
the O
outpatient O
population O
. O
[]

48 O
healthy O
adults O
were O
also O
studied O
as O
normal O
control O
group O
. O
[]

INTERVENTIONS O
A O
total O
of O
43 O
of O
67 O
evaluable O
patients O
randomly O
received O
either O
EPA+GLA O
or O
an O
isonitrogenous O
, O
isocaloric O
standard O
diet O
that O
was O
tube O
fed O
at O
a O
minimum O
caloric O
delivery O
of O
75 O
% O
of O
basal O
energy O
expenditure O
times O
1.33 O
for O
at O
least O
4 O
to O
7 O
days O
. O
[]

RESEARCH O
METHODS O
AND O
PROCEDURES O
Eighty-eight O
overweight O
and O
obese O
women O
participated O
in O
this O
study O
. O
[]

METHOD O
From O
an O
obesity O
unit O
's O
waiting O
list O
, O
the O
patients O
were O
randomly O
assigned O
to O
either O
a O
treatment O
group O
or O
remained O
in O
the O
waiting O
list O
to O
serve O
as O
a O
control O
group O
. O
[]

Comparison O
of O
nicardipine O
and O
propranolol O
in O
the O
treatment O
of O
mild O
and O
moderate O
hypertension O
. O
[]

One O
week O
later O
, O
patients O
received O
the O
same O
battery O
after O
being O
randomized O
to O
a O
single O
dose O
of O
40 O
IU O
intranasal O
oxytocin O
or O
placebo O
. O
[]

The O
interobserver O
variability O
of O
digital O
rectal O
examination O
in O
a O
large O
randomized O
trial O
for O
the O
screening O
of O
prostate O
cancer O
. O
[]

A O
functional O
gamma-secretase O
inhibitor O
, O
LY450139 O
, O
was O
developed O
that O
inhibits O
Abeta O
formation O
in O
whole O
cell O
assays O
, O
transgenic O
mice O
, O
and O
beagle O
dogs O
. O
[]

We O
evaluated O
the O
effects O
of O
extended-release O
alfuzosin O
HCl O
10 O
mg O
once O
daily O
( O
q.d O
. O
) O
[]

Hence O
the O
park O
environment O
better O
facilitated O
the O
achievement O
of O
current O
physical O
activity O
guidelines O
. O
[]

The O
clinical O
course O
and O
the O
prognosis O
of O
the O
patients O
were O
evaluated O
after O
all O
the O
immunohistochemical O
analyses O
had O
been O
performed O
. O
[]

FINDINGS O
240 O
eligible O
patients O
were O
recruited O
from O
six O
Australian O
centres O
between O
Sept O
30 O
, O
2005 O
, O
and O
Nov O
19 O
, O
2009 O
. O
[]

1.74 O
mm O
; O
p O
= O
0.008 O
) O
was O
observed O
but O
remained O
larger O
than O
in O
the O
CIU O
( O
2.31 O
? O
[]

Among O
rural O
survivors O
, O
greater O
adherence O
to O
the O
high O
reduced-fat O
dairy O
, O
cereal O
, O
nuts O
, O
and O
fruits O
pattern O
was O
positively O
associated O
with O
lower O
BMI O
( O
P O
trend O
< O
0.05 O
) O
, O
whereas O
higher O
scores O
on O
the O
mixed O
pattern O
was O
associated O
with O
greater O
BMI O
( O
P O
trend O
< O
0.05 O
) O
. O
[]

RESULTS O
A O
total O
of O
79 O
subjects O
( O
28 O
males O
and O
51 O
females O
) O
were O
enrolled O
and O
completed O
the O
study O
. O
[]

regimen O
of O
lamivudine O
( O
3TC O
) O
versus O
a O
150-mg O
twice-daily O
( O
b.i.d O
. O
) O
[]

Intraoperative O
parameters O
differed O
significantly O
between O
the O
groups O
with O
respect O
to O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
fluoroscopy B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
and O
incision B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
, O
with O
the O
difference O
favoring O
Group O
B O
for O
each O
parameter O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Some O
changes O
could O
be O
ascribed O
to O
trauma O
, O
but O
others O
seemed O
spontaneous O
. O
[]

The O
use O
of O
stimulant O
therapy O
continued O
unchanged O
. O
[]

It O
was O
therefore O
sought O
to O
determine O
whether O
regular O
intake O
of O
lime O
juice O
will O
ameliorate O
crisis O
, O
especially O
recurrent B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
primary O
outcome O
was O
the O
change O
on O
the O
Brief O
Agitation O
Rating O
Scale O
( O
BARS O
) O
. O
[]

The O
63 O
hypertensive O
women O
had O
a O
high O
incidence O
of O
diabetes B-outcome ['Physiological-Clinical']
mellitus I-outcome ['Physiological-Clinical']
diagnosed O
during O
pregnancy O
( O
49.2 O
% O
) O
as O
compared O
to O
the O
authors O
' O
general O
obstetric O
population O
( O
8.1 O
% O
) O
. O
['Physiological-Clinical']

The O
active O
treatment O
group O
showed O
significant O
improvement O
compared O
with O
controls O
on O
the O
primary O
outcome O
measure O
-- O
Autism B-outcome ['Life-Impact']
Diagnostic I-outcome ['Life-Impact']
Observation O
Schedule O
( O
ADOS O
) O
total O
score O
, O
particularly O
in O
reciprocal B-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
interaction O
-- O
and O
on O
secondary O
measures O
of O
expressive B-outcome ['Life-Impact']
language B-outcome ['Life-Impact']
, O
communicative B-outcome ['Life-Impact']
initiation I-outcome ['Life-Impact']
and O
parent-child B-outcome ['Life-Impact']
interaction O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

RFA O
took O
longer O
than O
conventional O
surgery O
: O
median O
interquartile O
range O
76 O
( O
67-84 O
) O
versus O
48 O
( O
39-54 O
) O
min O
; O
P O
< O
0.001 O
. O
[]

CONCLUSION O
Compound O
Xuanju O
Capsule O
has O
a O
good O
therapeutic O
effect O
on O
type O
III O
prostatitis O
. O
[]

Retransfusion O
of O
pericardial O
blood O
, O
however O
, O
does O
not O
contribute O
to O
systemic B-outcome ['Physiological-Clinical']
complement I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
To O
assess O
the O
extent O
to O
which O
parents O
of O
children O
with O
autism O
compared O
with O
parents O
of O
children O
with O
asthma O
or O
other O
special O
health O
care O
needs O
report O
receiving O
primary O
care O
for O
their O
child O
consistent O
with O
the O
American O
Academy O
of O
Pediatrics O
medical O
home O
model O
. O
[]

Forty-two O
children O
with O
the O
diagnosis O
of O
autism O
were O
randomized O
to O
one O
of O
two O
groups O
in O
this O
double-blind O
cross-over O
trial O
. O
[]

Probiotics O
could O
affect O
disease B-outcome ['Physiological-Clinical']
risk O
either O
directly O
through O
colonization O
or O
indirectly O
by O
promoting O
changes O
in O
gut O
microbial O
ecology O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
present O
study O
suggests O
that O
amantadine O
may O
be O
a O
potential O
adjunctive O
treatment O
strategy O
for O
autism O
and O
it O
was O
generally O
well O
tolerated O
. O
[]

The O
hypothesis O
that O
the O
cognitive-behavioral O
skills O
package O
would O
have O
an O
additive O
effect O
beyond O
relaxation O
and O
imagery O
alone O
was O
not O
confirmed O
. O
[]

Recently O
, O
Competitive B-outcome ['Life-Impact']
Memory I-outcome ['Life-Impact']
Training O
( O
COMET O
) O
has O
shown O
to O
be O
effective O
for O
the O
enhancement O
of O
self-esteem O
in O
several O
psychopathological O
conditions O
. O
['Life-Impact']

The O
amount O
of O
necessary O
oxytocin B-outcome ['Resource-use']
for O
the O
first O
day O
of O
induction O
was O
less O
in O
the O
propranolol O
group O
. O
['Resource-use']

Intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
alterations I-outcome ['Physiological-Clinical']
were O
similar O
between O
groups O
. O
['Physiological-Clinical']

No O
effect O
of O
Na O
intake O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
identified O
in O
either O
whites O
or O
blacks O
. O
['Physiological-Clinical']

Endobronchial O
ultrasonography-guided O
transbronchial O
needle O
aspiration O
increases O
the O
diagnostic B-outcome ['Life-Impact']
yield I-outcome ['Life-Impact']
of O
peripheral O
pulmonary O
lesions O
: O
a O
randomized O
trial O
. O
['Life-Impact']

Subjects O
scheduled O
for O
colonoscopies O
were O
approached O
for O
enrollment O
the O
day O
of O
their O
procedure O
. O
[]

BACKGROUND O
The O
benefits O
of O
the O
long-term O
administration O
of O
oral O
anticoagulant O
therapy O
remain O
unclear O
in O
patients O
with O
lower O
extremity O
arterial O
bypass O
surgery O
. O
[]

When O
PAN O
is O
not O
related O
to O
HBV O
and O
in O
CSS O
, O
even O
in O
severe O
cases O
, O
there O
is O
presently O
no O
argument O
supporting O
systematic O
administration O
of O
PE O
at O
the O
time O
of O
diagnosis O
. O
[]

As O
adjuvant O
therapy O
, O
5Fu O
or O
derivatives O
were O
administered O
to O
all O
cases O
from O
the O
beginning O
of O
the O
treatment O
period O
to O
one O
year O
after O
the O
basic O
therapy O
, O
with O
the O
exception O
of O
cases O
in O
whom O
side O
effects O
were O
serious O
enough O
to O
contraindicate O
use O
of O
the O
drug O
. O
[]

METHODS O
Thirty O
six O
NPC O
patients O
underwent O
head O
and O
neck O
CT O
, O
Tc-MIBI O
SPECT O
, O
and O
FDG-PET O
four O
months O
after O
radiotherapy O
to O
differentiate O
recurrent O
or O
residual O
NPC O
from O
benign O
lesions O
. O
[]

The O
present O
study O
examined O
the O
effects O
of O
oxytocin O
on O
the O
neural O
basis O
of O
face O
processing O
in O
adults O
with O
Asperger O
syndrome O
( O
AS O
) O
. O
[]

BACKGROUND O
We O
evaluated O
the O
antithrombotic O
effects O
of O
statins O
and O
angiotensin-converting O
enzyme O
inhibitor O
( O
ACEI O
) O
drugs O
in O
patients O
with O
coronary O
artery O
disease O
( O
CAD O
) O
. O
[]

KEY O
FINDINGS O
Examination O
of O
the O
erythema B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
course I-outcome ['Physiological-Clinical']
by O
a O
sensitive O
spectrophotometric O
reflectance O
method O
showed O
a O
significant O
increase O
of O
skin B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
in O
the O
non-treated O
group O
after O
the O
second O
week O
of O
treatment O
and O
maximal O
alterations O
between O
the O
fourth O
and O
sixth O
week O
. O
['Physiological-Clinical', 'Physiological-Clinical']

is O
more O
effective O
than O
high-dose O
ranitidine O
( O
300 O
mg O
b.d O
. O
) O
[]

As O
well O
, O
anxiety B-outcome ['Life-Impact']
levels O
were O
found O
to O
be O
significantly O
higher O
in O
the O
pre-discharge O
group O
than O
the O
post-discharge O
group O
. O
['Life-Impact']

Symptom B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
was O
recorded O
24 O
hours O
, O
6 O
days O
and O
12 O
days O
after O
PPH O
, O
urine B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
24h O
after O
PPH O
, O
first B-outcome ['Physiological-Clinical']
stool I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
mean O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
were O
also O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

STUDY O
OBJECTIVES O
To O
determine O
the O
effects O
of O
enflurane O
and O
isoflurane O
on O
hepatic B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation O
( O
ShvO2 B-outcome ['Physiological-Clinical']
) O
and O
splanchnic B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
( O
O2 B-outcome ['Physiological-Clinical']
) O
extraction B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Using O
the O
Brief O
Pain O
Inventory O
, O
the O
% O
pain O
relief O
that O
the O
patients O
in O
the O
ketamine O
group O
attributed O
to O
their O
medication O
improved O
significantly O
from O
50 O
% O
immediately O
pre-infusion O
to O
65 O
% O
24 O
h O
post-infusion O
and O
69 O
% O
5 O
days O
post O
infusion O
. O
[]

Hypotension B-outcome ['Physiological-Clinical']
immediately O
after O
administration O
of O
metoclopramide O
was O
observed O
in O
two O
patients O
and O
four O
patients O
given O
ondansetron O
developed O
profound O
systolic O
hypotension O
at O
induction O
of O
anesthesia O
. O
['Physiological-Clinical']

Low-dose O
growth O
hormone O
treatment O
with O
diet O
restriction O
accelerates B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
exerts O
anabolic O
effect O
and O
improves B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
secretory I-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
in O
obese O
adults O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
discriminatory O
power O
of O
the O
predictive O
model O
was O
0.75 O
and O
that O
of O
the O
simplified O
score O
was O
0.72 O
. O
[]

The O
orthopedic O
prophylactic O
and O
nonorthopedic O
clinical O
programs O
for O
fondaparinux O
in O
the O
management O
of O
thrombosis O
support O
the O
concept O
that O
targeted B-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
coagulation I-outcome ['Physiological-Clinical']
is O
an O
effective O
advance O
in O
antithrombotic O
therapy O
. O
['Physiological-Clinical']

This O
procedure O
was O
repeated O
7 O
days O
after O
changing O
the O
drug O
from O
4 O
degrees O
C O
to O
30 O
degrees O
C O
or O
vice O
versa O
, O
and O
application O
to O
the O
left O
eye O
for O
3 O
days O
. O
[]

For O
the O
performance O
of O
clinical O
drug O
trials O
in O
the O
therapy O
for O
bronchial O
hyperresponsiveness O
, O
unspecific O
inhalatory O
provocation O
tests O
are O
generally O
employed O
to O
judge O
therapeutic O
success O
. O
[]

DESIGN O
, O
SETTING O
, O
PARTICIPANTS O
, O
& O
MEASUREMENTS O
In O
this O
secondary O
, O
post O
hoc O
analysis O
of O
the O
above O
study O
, O
octreotide-induced O
changes O
in O
liver B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
compared O
with O
placebo O
and O
the O
relationship O
between O
concomitant O
changes O
in O
liver O
and O
kidney O
volumes O
were O
evaluated O
. O
['Physiological-Clinical']

We O
studied O
599 O
evaluable O
patients O
with O
benign O
prostatic O
hypertrophy O
at O
7 O
urological O
units O
. O
[]

No O
other O
plasma B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
essential I-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
changed O
during O
the O
trial O
, O
although O
the O
HDL B-outcome ['Physiological-Clinical']
: O
cholesterol B-outcome ['Physiological-Clinical']
increased O
slightly O
but O
non-significantly O
with O
an O
increase O
in O
EPA B-outcome ['Physiological-Clinical']
and O
DHA B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
In O
this O
study O
, O
cetirizine/PSE O
relieved O
nasal B-outcome ['Physiological-Clinical']
congestion I-outcome ['Physiological-Clinical']
and O
other O
objective O
and O
subjective O
symptoms B-outcome ['Physiological-Clinical']
to O
a O
significantly O
greater O
extent O
than O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
a O
second O
study O
of O
predictive O
validity O
, O
40 O
individuals O
were O
randomly O
assigned O
to O
one O
of O
four O
conditions O
: O
relaxation O
training O
, O
tension O
inducement O
, O
pre-postcontrol O
, O
or O
postcontrol O
. O
[]

OBJECTIVE O
The O
objective O
of O
the O
study O
was O
to O
examine O
the O
effects O
of O
DPP-4 B-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
fasting I-outcome ['Physiological-Clinical']
islet I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

When O
patients O
were O
reviewed O
four O
months O
after O
treatment O
, O
only O
4 O
of O
44 O
patients O
( O
9 O
% O
) O
who O
used O
a O
dilator O
had O
not O
been O
improved O
and O
required O
additional O
therapy O
, O
compared O
with O
15 O
of O
42 O
patients O
( O
36 O
% O
) O
who O
had O
anal O
stretch O
alone O
( O
P O
less O
than O
0.02 O
) O
. O
[]

IIT O
did O
not O
increase O
the O
anabolic O
hormone O
IGF-I O
in O
critically O
ill O
adults O
, O
but O
feeding O
in O
critically O
ill O
children O
and O
pediatric O
hormonal O
responses O
may O
differ O
. O
[]

Outcomes O
of O
Japanese O
breast O
cancer O
patients O
treated O
with O
pre-operative O
and O
post-operative O
anastrozole O
or O
tamoxifen O
. O
[]

We O
studied O
the O
effect O
on O
microcirculation O
of O
a O
nitric-oxide-generating O
system O
applied O
topically O
to O
the O
finger O
and O
forearm O
of O
healthy O
volunteers O
and O
patients O
with O
primary O
Raynaud O
's O
syndrome O
. O
[]

RESULTS O
The O
amount O
of O
urethral B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
slight O
and O
similar O
in O
the O
2 O
groups O
. O
['Physiological-Clinical']

Prospective O
, O
randomized O
comparison O
of O
transperitoneal O
versus O
retroperitoneal O
laparoscopic O
adrenalectomy O
. O
[]

RESPECT O
includes O
Danish-speaking O
children O
diagnosed O
with O
cancer O
and O
treated O
at O
pediatric O
oncology O
units O
in O
Denmark O
. O
[]

Secondary O
variables O
included O
changes O
in O
other O
lipid B-outcome ['Physiological-Clinical']
, O
hemostatic B-outcome ['Physiological-Clinical']
and O
carbohydrate B-outcome ['Life-Impact']
parameters O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

[ O
Pharmacokinetics O
of O
theophylline O
in O
sustained-release O
formulation O
in O
young O
asthmatics O
] O
. O
[]

TRIAL O
DESIGN O
A O
randomized O
placebo O
controlled O
blinded O
study O
of O
treatment O
of O
recurrent O
genital O
warts O
amenable O
to O
destructive O
therapy O
, O
conducted O
independently O
in O
Australia O
and O
China O
. O
[]

RESULTS O
No O
statistically O
significant O
difference O
in O
baseline O
characteristics O
between O
randomized O
groups O
was O
found O
. O
[]

Results O
showed O
that O
triacylglycerol-rich B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
zeaxanthin I-outcome ['Physiological-Clinical']
peaked O
at O
6 O
h O
post-ingestion O
for O
all O
formulations O
. O
['Physiological-Clinical']

After O
either O
treatment O
, O
the O
recurrence-free B-outcome ['Physiological-Clinical']
rate O
['Physiological-Clinical']

The O
retentive O
effect O
of O
labetalol O
on O
sodium O
was O
directly O
related O
to O
the O
decrease O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
the O
successive B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
escape I-outcome ['Physiological-Clinical']
might O
be O
explained O
either O
by O
the O
observed O
increase O
of O
plasma O
volume O
( O
indirectly O
measured O
by O
packed O
cell O
volume O
) O
or O
by O
aldosterone O
inhibition O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Perceptual O
wind-up O
( O
increased O
pain O
perception O
to O
constant O
intensity O
sensory O
stimuli O
at O
frequencies O
> O
or=0.3 O
Hz O
) O
is O
used O
as O
a O
proxy O
for O
central O
sensitisation O
to O
investigate O
pain O
syndromes O
where O
pain O
hypersensitivity O
is O
important O
( O
for O
example O
, O
fibromyalgia O
) O
. O
[]

The O
alteration O
of O
levels O
of O
lymphocyte O
subsets O
in O
peripheral O
blood O
of O
patients O
was O
examined O
by O
flow O
cytometry O
. O
[]

RESULTS O
Using O
an O
intention O
to O
treat O
analysis O
, O
physiotherapy O
and O
placebo O
groups O
showed O
similar O
pain B-outcome ['Physiological-Clinical']
reductions O
at O
12 O
weeks O
: O
-2.2 O
cm O
( O
95 O
% O
CI O
, O
-2.6 O
to O
-1.7 O
) O
and O
-2.0 O
cm O
( O
-2.5 O
to O
-1.5 O
) O
, O
respectively O
. O
['Physiological-Clinical']

CONCLUSIONS O
Breast-milk O
contains O
significant O
numbers O
of O
bifidobacteria O
and O
the O
maternal O
allergic O
status O
further O
deranges O
the O
counts O
of O
bifidobacteria O
in O
breast-milk O
. O
[]

IOP B-outcome ['Physiological-Clinical']
rises I-outcome ['Physiological-Clinical']
of O
> O
6 O
mm O
Hg O
were O
seen O
in O
7 O
% O
of O
patients O
( O
one O
of O
15 O
) O
in O
the O
combined O
treatment O
group O
, O
45 O
% O
( O
five O
of O
11 O
) O
of O
the O
acetylcholine O
group O
, O
and O
70 O
% O
( O
seven O
of O
10 O
) O
of O
the O
acetazolamide O
group O
. O
['Physiological-Clinical']

A O
nationwide O
sample O
of O
129 O
clinicians O
rated O
the O
pathological O
significance O
of O
221 O
symptom O
items O
in O
a O
design O
such O
that O
every O
rater O
rated O
121 O
items O
, O
21 O
of O
which O
were O
rated O
by O
all O
raters O
and O
100 O
of O
which O
were O
rated O
only O
by O
the O
A O
or O
B O
subgroup O
to O
which O
each O
rater O
was O
randomly O
assigned O
. O
[]

To O
investigate O
treatment O
outcome O
beyond O
the O
6-week O
end-of-treatment O
point O
, O
the O
present O
study O
examined O
characteristics O
associated O
with O
more O
clinically O
relevant O
smoking O
endpoints O
following O
treatment O
with O
bupropion O
SR O
in O
a O
large O
health O
care O
system O
. O
[]

No O
patient O
had O
[]

A O
larger O
, O
longer O
duration O
study O
using O
a O
higher O
dose O
of O
a O
more O
potent O
statin O
is O
required O
. O
[]

This O
study O
examined O
the O
effect O
of O
pairing O
inpatient O
alcoholics O
with O
nursing O
home O
residents O
( O
NHRs O
) O
on O
the O
alcoholics B-outcome ['Life-Impact']
' O
self-esteem B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Iobitridol O
300 O
compared O
to O
iopromide O
300 O
-- O
a O
double-blind O
randomized O
phase-III O
study O
of O
clinical O
tolerance O
in O
total O
body O
CT. O
UNLABELLED O
PURPOSE O
, O
MATERIAL O
AND O
METHODS O
: O
The O
clinical O
safety O
of O
iobitriodol O
300 O
mg O
I/ml O
and O
iopromide O
300 O
mg O
I/ml O
were O
compared O
in O
a O
randomized O
double O
blind O
phase-III O
study O
conducted O
on O
60 O
patients O
undergoing O
abdominal O
CT O
for O
a O
variety O
of O
indications O
. O
[]

Groups O
1 O
and O
2 O
received O
high-frequency/low-volume O
ventilation O
with O
100 O
% O
( O
group O
1 O
) O
or O
21 O
% O
oxygen O
( O
group O
2 O
) O
. O
[]

Total O
cholesterol B-outcome ['Physiological-Clinical']
, O
triglycerides B-outcome ['Physiological-Clinical']
, O
HDL B-outcome ['Physiological-Clinical']
and O
LDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
fractions I-outcome ['Physiological-Clinical']
were O
determined O
twice O
during O
an O
initial O
4-week O
washout O
phase O
, O
and O
after O
a O
1- O
, O
3- O
and O
6-month O
active O
hypotensive O
drug O
phase O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
value O
was O
then O
lower O
than O
expected O
in O
group O
2 O
, O
corresponding O
to O
a O
loss O
of O
plasma B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of O
> O
3 O
mL/kg O
. O
['Physiological-Clinical']

We O
measured O
ventilatory O
variables O
and O
end-tidal O
CO2 O
tension O
, O
dyspnea O
intensity O
by O
visual O
analog O
scale O
, O
and O
the O
intensity O
of O
putative O
chest O
pain O
. O
[]

Burn B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
, O
measured O
by O
laser O
Doppler O
imaging O
( O
LDI O
) O
and O
histologically O
, O
white B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
WBC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
cytokine I-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
were O
assessed O
at O
24 O
h O
( O
pre O
HBOT O
) O
and O
48 O
h O
( O
post O
HBOT O
) O
post O
burn O
, O
as O
were O
immunohistochemistry O
and O
microbiology O
of O
burns O
tissue O
samples O
at O
48 O
h O
post O
burn O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
comparisons O
of O
TORS O
and O
RT O
in O
a O
non-randomized O
fashion O
are O
susceptible O
to O
bias O
. O
[]

UNLABELLED O
The O
synthetic O
arginine-derived O
direct O
thrombin O
inhibitor O
argatroban O
is O
an O
attractive O
anticoagulant O
for O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
, O
because O
of O
its O
rapid O
onset O
and O
offset O
, O
and O
its O
hepatic O
elimination O
. O
[]

In O
accordance O
, O
calcium B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
in O
adolescents O
did O
not O
vary O
between O
the O
diets O
( O
% O
WD O
= O
40.4 O
+/- O
5.1 O
, O
% O
BD O
= O
38.2 O
+/- O
3.6 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Whiplash-associated O
disorder O
( O
or O
whiplash O
) O
is O
a O
common O
condition O
incurring O
considerable O
expense O
in O
social O
and O
economic O
terms O
. O
[]

We O
compared O
TTI O
with O
the O
apical O
paddle O
in O
both O
a O
transverse O
and O
longitudinal O
orientation O
. O
[]

No O
late B-outcome ['Physiological-Clinical']
rebleedings I-outcome ['Physiological-Clinical']
have O
occurred O
. O
['Physiological-Clinical']

Immune O
response O
was O
similar O
following O
the O
two O
regimens O
with O
100 O
% O
of O
the O
vaccinees O
seroprotected O
for O
HBV O
, O
diphtheria O
, O
tetanus O
, O
Hib O
and O
poliovirus O
types O
2 O
and O
3 O
diseases O
after O
the O
full O
vaccination O
course O
. O
[]

RESULTS O
In O
the O
midazolam+fentanyl O
groups O
, O
better O
patient B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
surgeon I-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
scores O
were O
obtained O
( O
P O
< O
.005 O
) O
, O
verbal O
pain B-outcome ['Physiological-Clinical']
scale O
scores O
were O
significantly O
lower O
( O
P O
< O
.001 O
) O
, O
and O
patients O
needed O
less O
postoperative B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
. O
['Life-Impact', 'Physiological-Clinical', 'Resource-use']

Effects O
of O
a O
single O
intravenous O
dose O
of O
aspirin O
( O
600 O
mg O
) O
on O
bradykinin-stimulated O
prostaglandin O
( O
PG O
) O
and O
on O
thromboxane O
( O
TX O
) O
biosynthesis O
were O
determined O
in O
nine O
healthy O
male O
volunteers O
. O
[]

This O
is O
the O
first O
report O
of O
the O
measurement O
of O
health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
a O
prospective O
clinical O
trial O
in O
multiple O
myeloma O
. O
['Life-Impact']

At O
week O
18 O
, O
WHO O
functional O
class O
was O
improved O
or O
maintained O
in O
more O
patients O
receiving O
sitaxsentan O
100 O
mg O
than O
placebo O
( O
P O
= O
0.038 O
) O
; O
0 O
% O
versus O
12 O
% O
of O
patients O
deteriorated O
, O
respectively O
. O
[]

CONCLUSIONS O
Further O
investigations O
are O
warranted O
due O
to O
clear O
limitations O
, O
mostly O
small O
sample O
size O
and O
use O
of O
concomitant O
medications O
. O
[]

Exercise B-outcome ['Life-Impact']
tolerance I-outcome ['Life-Impact']
was O
improved O
by O
40-74 O
% O
and O
exercise B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
before I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
angina I-outcome ['Life-Impact']
by O
61-94 O
% O
( O
P O
less O
than O
0.01 O
) O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
In O
group O
C O
a O
significant O
reduction O
of O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
intramyocardial I-outcome ['Physiological-Clinical']
velocities I-outcome ['Physiological-Clinical']
was O
found O
during O
myocardial O
ischemia O
due O
to O
coronary O
occlusion O
. O
['Physiological-Clinical']

CONCLUSION O
AT O
did O
not O
improve O
DFS O
or O
overall O
survival O
in O
this O
population O
, O
and O
was O
associated O
with O
more O
toxicity O
. O
[]

patient-controlled B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
( I-outcome ['Resource-use']
PCA I-outcome ['Resource-use']
) I-outcome ['Resource-use']
device O
. O
['Resource-use']

A O
randomized O
, O
dose-escalation O
study O
of O
subconjunctival O
and O
intravitreal O
injections O
of O
sirolimus O
in O
patients O
with O
diabetic O
macular O
edema O
. O
[]

The O
implications O
of O
these O
findings O
are O
discussed O
. O
[]

To O
assess O
the O
need O
for O
this O
, O
we O
randomly O
allocated O
392 O
fresh O
fractures O
for O
treatment O
by O
either O
a O
forearm O
gauntlet O
( O
Colles O
' O
) O
cast O
, O
leaving O
the O
thumb O
free O
, O
or O
by O
a O
conventional O
'scaphoid O
' O
plaster O
incorporating O
the O
thumb O
as O
far O
as O
its O
interphalangeal O
joint O
. O
[]

In O
a O
comparative O
study O
, O
we O
examined O
the O
regulation O
of O
the O
STARS O
signalling O
pathway O
in O
response O
to O
unilateral O
resistance O
exercise O
performed O
as O
either O
eccentric O
( O
ECC O
) O
or O
concentric O
( O
CONC O
) O
contractions O
as O
well O
as O
prolonged O
training O
; O
with O
and O
without O
whey O
protein O
supplementation O
. O
[]

Results O
from O
a O
prospective O
randomized O
trial O
. O
[]

MATERIALS O
AND O
METHODS O
For O
both O
studies O
, O
two O
types O
of O
rater O
training O
videotapes O
were O
developed O
. O
[]

Of O
the O
remaining O
50 O
patients O
, O
42 O
( O
84.0 O
% O
) O
were O
American O
College O
of O
Rheumatology O
( O
ACR O
) O
20 O
% O
responders O
, O
30 O
( O
60.0 O
% O
) O
were O
ACR O
50 O
% O
responders O
, O
and O
23 O
( O
46.0 O
% O
) O
were O
ACR O
70 O
% O
responders O
. O
[]

RESULTS O
RFA O
resulted O
in O
successful O
obliteration O
of O
the O
GSV O
in O
all O
47 O
patients O
. O
[]

Low O
pre-course O
scores O
or O
gender O
did O
not O
affect O
knowledge B-outcome ['Life-Impact']
gain O
. O
['Life-Impact']

METHODS O
This O
was O
a O
randomized O
placebo O
controlled O
double-blind O
crossover O
study O
of O
3 O
months O
metformin O
( O
1500 O
mg O
day-1 O
) O
/placebo O
, O
followed O
by O
3 O
months O
metformin/placebo O
together O
with O
clomiphene O
( O
50-100 O
mg O
for O
5 O
days O
) O
for O
three O
cycles O
in O
clomiphene O
resistant O
women O
with O
PCOS O
. O
[]

Dose O
increments O
were O
given O
at O
20 O
min O
intervals O
with O
measurements O
being O
made O
15 O
min O
after O
each O
dose O
. O
[]

RESULTS O
Both O
MDD O
patients O
and O
age-matched O
controls O
demonstrated O
a O
significant O
reaction O
time O
( O
RT O
) O
and O
P3b B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
differences O
between O
predicted O
and O
random O
targets O
. O
['Physiological-Clinical']

The O
treated O
area O
was O
sampled O
by O
the O
scrub-wash O
method O
immediately O
before O
treatment O
began O
and O
after O
2 O
and O
4 O
weeks O
, O
and O
microorganisms O
were O
enumerated O
and O
identified O
. O
[]

Adequacy O
of O
hot O
biopsy O
for O
the O
treatment O
of O
diminutive O
polyps O
: O
a O
prospective O
randomized O
trial O
. O
[]

However O
, O
it O
is O
unlikely O
this O
plays O
a O
major O
role O
in O
the O
mechanism O
by O
which O
iTFA O
increase O
the O
risk O
of O
CVD O
. O
[]

METHODS O
For O
this O
purpose O
, O
we O
carried O
out O
a O
40 O
weeks O
, O
prospective O
, O
experimental O
, O
epidemiological-operational O
and O
randomized O
study O
enrolling O
18 O
patients O
( O
36 O
eyes O
) O
with O
recently O
primary O
open O
angle O
glaucoma O
. O
[]

Twenty O
six O
postmenopausal O
women O
with O
climacteric O
symptoms O
were O
administered O
HRT O
in O
a O
randomized O
, O
double O
blinded O
, O
placebo-controlled O
, O
crossover O
study O
. O
[]

Overall O
, O
in O
children O
with O
complete B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
partial I-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of O
their O
enlarged O
livers O
, O
the O
area O
produced O
by O
plotting O
liver O
size O
against O
time O
( O
i.e O
. O
['Physiological-Clinical']

The O
clinical O
evaluation O
and O
laboratory O
tests O
were O
performed O
before O
treatment O
( O
baseline O
) O
and O
after O
3 O
and O
9 O
months O
of O
therapy O
. O
[]

METHODS O
Thirty-six O
stable O
hyperhomocysteinemic O
renal-transplant O
recipients O
were O
randomly O
assigned O
to O
vitamin O
treatment O
( O
group O
A O
, O
n O
= O
18 O
, O
folic O
acid O
5 O
mg/d O
, O
vitamin O
B O
( O
6 O
) O
50 O
mg/d O
, O
B O
( O
12 O
) O
1000 O
microg/d O
) O
or O
controlled O
group O
( O
group O
B O
, O
n O
= O
18 O
) O
for O
6 O
months O
. O
[]

All O
these O
changes O
were O
maximal O
1 O
to O
2 O
hours O
after O
infusion O
and O
lasted O
8 O
hours O
at O
least O
. O
[]

PLP O
normalized O
thyroid B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
at O
6 O
and O
30 O
weeks O
after O
treatment O
. O
['Physiological-Clinical']

Amphotericin O
versus O
pentamidine O
in O
antimony-unresponsive O
kala-azar O
. O
[]

All O
patients O
on O
oral O
therapy O
overall O
had O
greater O
relief O
than O
patients O
using O
topical O
steroids O
. O
[]

Secondary O
end O
points O
were O
survival B-outcome ['Mortality']
, O
tumor B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
safety O
, O
and O
quality O
of O
life O
. O
['Mortality', 'Physiological-Clinical']

It O
's O
an O
( O
eyes O
) O
open O
and O
shut O
case O
. O
[]

Effects O
of O
remaxol O
vs O
placebo O
on O
the O
functional B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
of O
affected O
liver O
are O
discussed O
. O
['Life-Impact']

Eight O
side-effects O
were O
observed O
over O
the O
trial O
, O
out O
of O
the O
25 O
side-effects O
that O
the O
checklist O
included O
. O
[]

RESULTS O
Of O
the O
47 O
women O
enrolled O
, O
24 O
were O
randomized O
to O
ethinyl O
estradiol/desogestrel O
and O
23 O
were O
randomized O
to O
ethinyl O
estradiol/levonorgestrel O
. O
[]

Examination B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
, O
diagnostic B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
patient B-outcome ['Life-Impact']
acceptability I-outcome ['Life-Impact']
( O
rated O
with O
a O
self-completed O
questionnaire O
) O
in O
the O
two O
groups O
of O
patients O
were O
compared O
by O
using O
the O
McNemar O
test O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Eight O
patients O
relapsed B-outcome ['Physiological-Clinical']
( O
in O
situ O
, O
1 O
; O
marginal O
, O
1 O
; O
nonirradiated O
subdiaphragmatic O
area O
, O
6 O
) O
after O
three O
to O
57 O
months O
of O
complete O
remission O
( O
median O
20 O
months O
) O
; O
one O
patient O
died O
after O
relapse O
. O
['Physiological-Clinical']

BACKGROUND O
The O
increasing O
prevalence O
of O
type O
2 O
diabetes O
poses O
a O
major O
public O
health O
challenge O
. O
[]

AIM O
AND O
DESIGN O
To O
evaluate O
the O
biocompatibility O
of O
glass O
ionomer O
cement O
( O
GIC O
) O
impregnated O
with O
collagen O
or O
bioactive O
glass O
to O
BHK-21 O
fibroblasts O
in O
vitro O
. O
[]

Independent O
clinical O
evaluators O
, O
blind O
to O
condition O
, O
completed O
structured O
interviews O
( O
Anxiety O
Disorders O
Interview O
Schedule O
? O
[]

RESULTS O
Response O
rate O
for O
the O
entire O
cohort O
at O
week O
8 O
was O
77 O
% O
( O
95 O
% O
CI O
, O
73 O
% O
to O
81 O
% O
; O
complete O
response O
[ O
CR B-outcome ['Physiological-Clinical']
] O
, O
21 O
% O
; O
partial O
response O
[ O
PR O
] O
, O
56 O
% O
) O
but O
response O
had O
no O
influence O
on O
FFS B-outcome ['Mortality']
( O
P O
= O
.57 O
) O
. O
['Physiological-Clinical', 'Mortality']

RESULTS O
Large O
and O
stable O
pre-post O
effect O
sizes O
were O
found O
for O
both O
treatment O
conditions O
in O
the O
study O
( O
d O
= O
1.06-1.24 O
on O
the O
Yale-Brown O
Obsessive B-outcome ['Life-Impact']
Compulsive I-outcome ['Life-Impact']
Scale O
) O
. O
['Life-Impact']

Cystoscopy O
and O
bladder O
washing O
for O
DNA O
flow O
cytometry O
end O
points O
( O
proportion O
of O
DNA O
aneuploid O
histograms O
, O
hyperdiploid O
fraction O
, O
and O
percentage O
of O
apoptotic O
cells O
) O
and O
proportion O
of O
abnormal B-outcome ['Physiological-Clinical']
cytological I-outcome ['Physiological-Clinical']
examinations I-outcome ['Physiological-Clinical']
were O
repeated O
every O
4 O
months O
for O
up O
to O
36 O
months O
. O
['Physiological-Clinical']

Anesthesia O
for O
in O
vitro O
fertilization O
: O
the O
addition O
of O
fentanyl O
to O
1.5 O
% O
lidocaine O
. O
[]

The O
platelet B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
was O
dependent O
on O
the O
minimum O
rectal O
temperature O
during O
CPB B-outcome ['Physiological-Clinical']
, O
the O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
and O
the O
CPB B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

However O
, O
there O
was O
a O
significantly O
higher O
incidence O
of O
varus O
angulation O
by O
10 O
degrees O
or O
more O
by O
the O
completion O
of O
healing O
among O
fractures O
treated O
with O
the O
sliding O
hip O
screw O
( O
p O
= O
0.04 O
) O
. O
[]

Propofol O
and O
midazolam O
act O
synergistically O
in O
combination O
. O
[]

Randomised O
placebo-controlled O
trial O
of O
rhesus-human O
reassortant O
rotavirus O
vaccine O
for O
prevention O
of O
severe B-outcome ['Physiological-Clinical']
rotavirus I-outcome ['Physiological-Clinical']
gastroenteritis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
source O
of O
this O
eye-position O
information O
, O
particularly O
during O
monocular O
viewing O
, O
is O
a O
matter O
of O
debate O
. O
[]

OBJECTIVE O
The O
authors O
examine O
whether O
an O
innovative O
family O
economic O
empowerment O
intervention O
addresses O
mental O
health O
functioning O
of O
AIDS-affected O
children O
in O
communities O
heavily O
impacted O
by O
HIV/AIDS O
in O
Uganda O
. O
[]

Clearance B-outcome ['Physiological-Clinical']
was O
histologically O
confirmed O
2 O
weeks O
after O
the O
last O
application O
of O
imiquimod O
in O
all O
patients O
clinically O
diagnosed O
as O
lesion O
free O
. O
['Physiological-Clinical']

3.0 O
? O
[]

Low O
power O
laser O
therapy O
of O
shoulder O
tendonitis O
. O
[]

Comparison O
of O
alfentanil O
, O
fentanyl O
and O
sufentanil O
for O
total O
intravenous O
anaesthesia O
with O
propofol O
in O
patients O
undergoing O
coronary O
artery O
bypass O
surgery O
. O
[]

The O
long-term O
efficacy O
of O
endovascular O
treatment O
in O
preventing O
rebleeding B-outcome ['Physiological-Clinical']
remains O
open O
. O
['Physiological-Clinical']

The O
occurrence O
of O
anti-IgG B-outcome ['Physiological-Clinical']
antibodies B-outcome ['Resource-use']
did O
no O
correlate O
with O
symptoms B-outcome ['Physiological-Clinical']
, O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
or O
the O
level O
of O
allergen-specific B-outcome ['Physiological-Clinical']
IgG B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Likewise O
, O
anthelmintic O
treated O
sheep O
performed B-outcome ['Life-Impact']
significantly O
better O
than O
their O
non-treated O
contemporaries O
( O
MP=ETB O
28 O
vs. O
8 O
) O
. O
['Life-Impact']

Forty O
three O
ASA O
I O
or O
II O
children O
age O
six O
months O
or O
older O
scheduled O
for O
elective O
BM O
& O
T O
were O
randomized O
to O
receive O
acetaminophen O
( O
paracetamol O
) O
15 O
mg.kg-1 O
, O
ibuprofen O
10 O
mg.kg-1 O
, O
or O
placebo O
. O
[]

Body O
mass O
index O
, O
fasting B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
electrolyte I-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
, O
uric B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
, O
white B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
lipid B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
as O
well O
as O
hepatic B-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
parameters O
remained O
unaltered O
throughout O
the O
observation O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
article O
begins O
with O
a O
brief O
overview O
of O
the O
historical O
origins O
of O
games O
, O
along O
with O
their O
advantages O
and O
disadvantages O
as O
educational O
strategies O
. O
[]

After O
50 O
randomized O
patients O
, O
the O
trial O
was O
closed O
to O
further O
accrual O
by O
the O
sponsoring O
company O
. O
[]

Three O
attempts O
per O
nurse O
were O
allowed O
. O
[]

Supportive-expressive O
group O
therapy O
for O
primary O
breast B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
patients O
: O
a O
randomized O
prospective O
multicenter O
trial O
. O
['Physiological-Clinical']

Oils O
were O
consumed O
at O
a O
level O
of O
approximately O
12 O
% O
of O
the O
subjects O
' O
prescribed O
energy O
intakes O
in O
the O
form O
of O
muffins O
and O
liquid O
oil O
. O
[]

[ O
Treatment O
of O
essential B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
in O
developmental O
age O
with O
L-5-HTP O
( O
cross O
over O
double-blind O
study O
versus O
placebo O
) O
] O
. O
['Physiological-Clinical']

Eighty O
teeth O
in O
18 O
patients O
were O
evaluated O
using O
a O
split O
mouth O
design O
. O
[]

Nine O
children O
, O
aged O
from O
4 O
to O
13 O
years O
, O
according O
to O
the O
DSM O
III O
for O
infantile O
autism O
, O
received O
either O
drug O
in O
a O
random O
order O
during O
four O
weeks O
with O
an O
in-between O
placebo O
period O
of O
six O
weeks O
. O
[]

Duodenal O
bulb O
deformity O
significantly O
affected O
healing O
in O
both O
groups O
, O
and O
was O
the O
only O
offsetting O
factor O
identifiable O
for O
sucralfate O
out O
of O
46 O
factors O
examined O
. O
[]

The O
objective O
response O
rate O
was O
30 O
% O
with O
pazopanib O
compared O
with O
3 O
% O
with O
placebo O
( O
P O
< O
.001 O
) O
. O
[]

Cardiovascular B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate O
and O
arterial B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Specifically O
, O
attentional B-outcome ['Life-Impact']
capture I-outcome ['Life-Impact']
was O
larger O
when O
visual O
or O
spatial O
working O
memory O
was O
loaded O
, O
but O
phonological O
working O
memory O
load O
did O
not O
affect O
['Life-Impact']

007 O
) O
and O
willingness B-outcome ['Life-Impact']
to O
take O
the O
drug O
again O
( O
90 O
vs. O
80 O
% O
, O
p O
= O
0.043 O
) O
. O
['Life-Impact']

SETTING O
Teaching O
hospital O
. O
[]

Equivalent O
efficacy O
of O
mitomycin O
C O
plus O
doxorubicin O
instillation O
to O
bacillus O
Calmette-Guerin O
therapy O
for O
carcinoma O
in O
situ O
of O
the O
bladder O
. O
[]

Lisinopril O
administration O
improves O
insulin B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
in O
aged O
patients O
with O
hypertension O
. O
['Physiological-Clinical']

In O
all O
four O
groups O
, O
the O
plasma B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
levels O
increased O
after O
surgery O
, O
on O
postoperative O
days O
1 O
and O
2 O
. O
['Physiological-Clinical']

Ibuprofen O
arginate O
and O
dexibuprofen O
showed O
similar O
bioavailability O
for O
S O
( O
+ O
) O
-ibuprofen O
. O
[]

In O
the O
VNR/CDDP O
arm O
12 O
pts O
( O
27 O
% O
) O
achieved O
PR B-outcome ['Physiological-Clinical']
, O
18 O
( O
41 O
% O
) O
SD O
a O
68 O
% O
TGCR O
. O
['Physiological-Clinical']

Single O
nucleotide O
polymorphism O
in O
the O
hypoxia-inducible O
factor-1alpha O
gene O
in O
colorectal O
carcinoma O
. O
[]

1-year O
results O
. O
[]

The O
achievement O
of O
pneumoperitoneum B-outcome ['Physiological-Clinical']
required O
4.5+/-0.4 O
min O
in O
the O
V O
group O
and O
3.2+/-0.2 O
min O
in O
the O
H O
group O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

METHODS O
We O
studied O
244 O
subjects O
with O
prehypertension O
, O
43.0 O
+/- O
13.0 O
years O
of O
age O
, O
randomly O
divided O
in O
three O
groups O
: O
nonpharmacological O
hygienic-dietary O
recommendations O
; O
the O
same O
recommendations O
and O
aspirin O
( O
100 O
mg/day O
) O
on O
awakening O
; O
or O
the O
same O
recommendations O
and O
aspirin O
at O
bedtime O
. O
[]

Paired O
comparisons O
revealed O
a O
significant O
difference O
in O
efficacy O
between O
CAE O
and O
CEC O
and O
a O
nearly O
significant O
difference O
between O
AMX-CL O
and O
CEC O
. O
[]

Secondary O
end O
points O
included O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
tumor B-outcome ['Physiological-Clinical']
response O
rate O
( O
Response O
Evaluation O
Criteria O
in O
Solid B-outcome ['Physiological-Clinical']
Tumors B-outcome ['Physiological-Clinical']
) O
, O
and O
safety O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Similar O
patterns O
of O
benefits O
were O
observed O
for O
secondary O
outcomes O
. O
[]

Sixty-one O
percent O
of O
patients O
failed O
to O
manifest O
clinically O
significant O
changes O
in O
subjective B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
and O
74 O
% O
of O
patients O
failed O
to O
manifest O
clinically O
significant O
changes O
in O
objective B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
opioid I-outcome ['Physiological-Clinical']
withdrawal I-outcome ['Physiological-Clinical']
following O
naloxone O
administration O
. O
['Life-Impact', 'Physiological-Clinical']

The O
more O
anxious O
group O
rated O
their O
perceived B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
level O
lower O
, O
despite O
the O
fact O
that O
both O
groups O
had O
similar O
scores O
in O
actual B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Statistical O
aspects O
of O
early O
termination O
in O
the O
beta-blocker O
heart O
attack O
trial O
. O
[]

For O
efficacy O
analysis O
only O
those O
patients O
were O
considered O
in O
whom O
treatment O
with O
the O
aminoglycoside O
was O
not O
stopped O
within O
72 O
h O
( O
n O
= O
67 O
) O
; O
toxicity O
was O
analysed O
on O
patients O
receiving O
aminoglycosides O
for O
more O
than O
48 O
h O
and O
not O
using O
other O
nephrotoxic O
medication O
( O
n O
= O
85 O
) O
. O
[]

We O
aimed O
to O
design O
and O
validate O
a O
dietary O
strategy O
of O
increasing O
flavonoid-rich O
versus O
flavonoid-poor O
F B-outcome ['Life-Impact']
& I-outcome ['Life-Impact']
V I-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
on O
nutrient O
biomarker O
profile O
. O
['Life-Impact']

There O
were O
no O
significant O
relationships O
between O
the O
serum O
of O
TARC B-outcome ['Physiological-Clinical']
level O
and O
the O
CARS O
score O
, O
age O
, O
or O
gender O
for O
any O
group O
. O
['Physiological-Clinical']

BACKGROUND O
This O
placebo-controlled O
phase O
III O
study O
investigated O
the O
effect O
on O
survival B-outcome ['Mortality']
of O
gefitinib O
as O
second-line O
or O
third-line O
treatment O
for O
patients O
with O
locally O
advanced O
or O
metastatic O
non-small-cell O
lung O
cancer O
. O
['Mortality']

After O
the O
follow-up O
period O
, O
MASI O
score O
was O
statistically O
significantly O
lower O
in O
group O
A O
than O
group O
C O
( O
P O
< O
0.001 O
) O
, O
statistically O
significantly O
lower O
in O
group O
B O
than O
group O
C O
( O
P O
< O
0.001 O
) O
, O
and O
statistically O
significantly O
lower O
in O
group O
B O
than O
group O
A O
( O
P O
= O
0.035 O
) O
. O
[]

Statistically O
significant O
differences O
were O
found O
for O
placebo O
in O
3 O
out O
of O
6 O
children O
and O
for O
secretin O
in O
one O
child O
, O
using O
parental O
ratings O
only O
( O
VAS O
scores O
) O
. O
[]

OBJECTIVE O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
clinical O
performance O
of O
four O
denture O
soft O
liners O
up O
to O
12 O
months O
. O
[]

INTERPRETATION O
Zoledronic O
acid O
administered O
with O
chemotherapy O
resulted O
in O
a O
decreased O
proportion O
of O
patients O
with O
DTCs O
detected O
in O
the O
bone O
marrow O
at O
the O
time O
of O
surgery O
. O
[]

If O
indicated O
, O
external O
radiation O
therapy O
targeted O
on O
the O
neck O
and O
upper O
mediastinum O
was O
performed O
in O
the O
Slovak O
Republic O
, O
in O
the O
University O
Hospital O
in O
Martin O
. O
[]

METHODS O
A O
total O
of O
41 O
chronic O
stroke O
patients O
received O
excitatory O
TBS O
to O
the O
ipsilesional O
hemisphere O
or O
inhibitory O
TBS O
to O
the O
contralesional O
hemisphere O
in O
2 O
centers O
; O
each O
active O
group O
was O
compared O
with O
a O
group O
receiving O
sham O
TBS O
. O
[]

It O
is O
concluded O
that O
an O
addition O
of O
SH O
herbs O
to O
two O
nucleoside O
reverse O
transcriptase O
inhibitors O
has O
greater O
antiviral B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
than O
antiretrovirals O
only O
. O
['Physiological-Clinical']

Osteopontin B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OPN I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
a O
glycoprotein O
that O
is O
secreted O
by O
osteoblasts O
and O
hematopoietic O
cells O
. O
['Physiological-Clinical']

On O
admission O
to O
a O
hospital O
nausea B-outcome ['Physiological-Clinical']
or O
vomiting B-outcome ['Physiological-Clinical']
was O
reported O
in O
9 O
% O
in O
Mi+Mo O
and O
in O
13 O
% O
in O
Mo O
alone O
( O
p=0.003 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
improvement O
was O
observed O
both O
among O
those O
who O
maintained O
SR O
and O
those O
with O
intermittent O
AF O
. O
[]

These O
changes O
contribute O
to O
functional B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
of O
['Life-Impact']

After O
4 O
weeks O
ISDN O
treatment O
, O
mean O
exercise B-outcome ['Physiological-Clinical']
PAWP I-outcome ['Physiological-Clinical']
and O
MAP B-outcome ['Physiological-Clinical']
, O
3 O
h O
after O
morning O
dose O
, O
were O
reduced O
to O
22.4 O
+/- O
7.09 O
mmHg O
and O
127 O
+/- O
18.2 O
mmHg O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SETTING O
Travis O
Pharmacy O
in O
Shenandoah O
, O
Iowa O
. O
[]

CONCLUSIONS O
Risperidone O
was O
effective O
and O
well O
tolerated O
for O
the O
treatment O
of O
tantrums O
, O
aggression O
, O
or O
self-injurious O
behavior O
in O
children O
with O
autistic O
disorder O
. O
[]

METHODS O
A O
randomized O
comparative O
study O
of O
136 O
women O
undergoing O
primary O
caesarean O
delivery O
at O
Havana O
Specialist O
Hospital O
Lagos O
Nigeria O
. O
[]

This O
prospective O
study O
assesses O
the O
effect O
of O
2.5 O
, O
4 O
, O
and O
10 O
mg O
of O
pyridoxine O
supplementation O
during O
pregnancy O
on O
maternal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
fetal I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
levels O
of I-outcome ['Physiological-Clinical']
pyridoxal I-outcome ['Physiological-Clinical']
5'-phosphate O
( O
PLP O
) O
and O
on O
the O
degree O
of O
coenzyme B-outcome ['Physiological-Clinical']
saturation O
( O
activation O
factor O
) O
of O
aspartate B-outcome ['Physiological-Clinical']
aminotransferase I-outcome ['Physiological-Clinical']
and O
alanine O
aminotransferase O
( O
alphaEGOT O
and O
alphaEGPT O
) O
in O
maternal O
erythrocytes O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Antenatal O
dexamethasone O
treatment O
was O
successful O
in O
reducing O
the O
incidence O
and O
severity O
of O
experimental B-outcome ['Resource-use']
HMD I-outcome ['Resource-use']
in O
this O
animal O
model O
; O
the O
beneficial O
effects O
of O
treatment O
were O
associated O
with O
accelerated O
maturation O
of O
fetal B-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
, O
including O
, O
but O
not O
limited O
to O
, O
synthetic B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
SAM I-outcome ['Physiological-Clinical']
phospholipid I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

On O
multivariate O
analysis O
, O
antiretroviral O
therapy O
was O
not O
an O
independent O
predictor O
of O
mortality B-outcome ['Mortality']
, O
and O
previous O
rifabutin O
prophylaxis O
was O
independently O
associated O
with O
poor O
survival O
outcomes O
, O
a O
result O
consistent O
across O
study O
treatment O
. O
['Mortality']

PURPOSE O
The O
chronic O
fatigue O
syndrome O
( O
CFS O
) O
is O
characterized O
by O
profound O
fatigue O
, O
neuropsychiatric O
dysfunction O
, O
and O
frequent O
abnormalities O
in O
cell-mediated O
immunity O
. O
[]

In O
the O
timolol O
and O
carteolol O
groups O
there O
were O
no O
significant O
changes O
in O
mean O
spirometric B-outcome ['Physiological-Clinical']
values O
. O
['Physiological-Clinical']

Cytosine O
arabinoside O
( O
CA O
) O
was O
utilized O
in O
efforts O
to O
synchronize O
leukemic O
cells O
in O
DNA O
synthesis O
for O
treatment O
with O
vincristine O
, O
prednisone O
, O
and O
L-asparaginase O
in O
children O
with O
acute O
leukemia O
in O
relapse O
. O
[]

5.2 O
ng/mL O
, O
p O
< O
0.02 O
) O
. O
[]

BACKGROUND O
Radiation-induced O
gastrointestinal O
toxicity O
is O
a O
significant O
concern O
for O
patients O
who O
are O
treated O
with O
this O
modality O
for O
pelvic O
malignancies O
. O
[]

All O
nifedipine-SR O
doses O
reduced O
supine B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
significantly O
more O
than O
placebo O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical']

METHODS O
Tumour O
tissue O
was O
obtained O
from O
168 O
patients O
with O
mCRC O
for O
relative O
thymidylate O
synthase B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
mRNA O
quantitation O
. O
['Physiological-Clinical']

During O
mental O
arithmetic O
, O
from O
an O
average O
of O
181.6 O
+/- O
17.8/118.6 O
+/- O
11.5 O
mm O
Hg O
during O
placebo O
, O
BP B-outcome ['Physiological-Clinical']
was O
reduced O
by O
11.5 O
% O
/7.9 O
% O
after O
terazosin O
and O
by O
13.6 O
% O
/8.5 O
% O
after O
enalapril O
; O
during O
handgrip O
test O
, O
['Physiological-Clinical']

2.78 O
) O
were O
significantly O
lower O
than O
those O
at O
baseline O
( O
13.9 O
? O
[]

Clonidine O
, O
as O
compared O
with O
placebo O
, O
was O
associated O
with O
an O
increased O
rate O
of O
nonfatal B-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
arrest I-outcome ['Physiological-Clinical']
( O
0.3 O
% O
[ O
16 O
patients O
] O
vs. O
0.1 O
% O
[ O
5 O
patients O
] O
; O
hazard O
ratio O
, O
3.20 O
; O
95 O
% O
CI O
, O
1.17 O
to O
8.73 O
; O
P=0.02 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Children O
who O
have O
a O
combination O
of O
language O
and O
developmental O
disabilities O
with O
autism O
often O
experience O
major O
difficulties O
in O
learning O
relations O
between O
objects O
and O
their O
graphic O
representations O
. O
[]

PURPOSE O
Quadriceps O
weakness O
following O
anterior O
cruciate O
ligament O
reconstruction O
( O
ACLR O
) O
is O
prevalent O
despite O
intensive O
rehabilitation O
. O
[]

In O
one O
patient O
this O
was O
incapacitating B-outcome ['Physiological-Clinical']
after O
10 O
mg O
and O
precluded O
exposure O
to O
20 O
mg O
. O
['Physiological-Clinical']

All O
participants O
completed O
baseline O
and O
follow-up O
self-report O
measures O
of O
visit O
communication B-outcome ['Life-Impact']
and O
satisfaction B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

EL O
and O
ES O
had O
similar O
cost/variceal O
rebleeding O
prevented O
( O
$ O
28,678 O
vs. O
$ O
29,093 O
) O
and O
cost/survival O
( O
$ O
27,313 O
vs. O
$ O
23,804 O
) O
. O
['Mortality', 'Resource-use']

METHODS O
To O
assess O
the O
efficacy O
of O
nitrofurantoin O
vs O
trimethoprim-sulfamethoxazole O
, O
338 O
women O
aged O
18 O
to O
45 O
years O
with O
acute O
uncomplicated O
cystitis O
were O
randomized O
to O
open-label O
treatment O
with O
either O
trimethoprim-sulfamethoxazole O
, O
1 O
double-strength O
tablet O
twice O
daily O
for O
3 O
days O
, O
or O
nitrofurantoin O
, O
100 O
mg O
twice O
daily O
for O
5 O
days O
. O
[]

Anxiety O
is O
common O
among O
adolescents O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
and O
may O
amplify O
the O
core O
social O
disability O
, O
thus O
necessitating O
combined O
treatment O
approaches O
. O
[]

DATA O
COLLECTION O
At O
each O
home O
health O
visit O
provided O
by O
a O
study O
nurse O
to O
an O
eligible O
HF O
patient O
during O
the O
45-day O
follow-up O
period O
, O
a O
structured O
chart O
abstraction O
tool O
was O
used O
to O
collect O
information O
on O
whether O
the O
nurse O
provided O
the O
care O
practices O
highlighted O
in O
the O
e-mail O
reminder O
. O
[]

We O
collected O
data O
on O
anesthetic B-outcome ['Resource-use']
technique I-outcome ['Resource-use']
, O
levels O
of I-outcome ['Physiological-Clinical']
extension B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
sensory I-outcome ['Physiological-Clinical']
blockades I-outcome ['Physiological-Clinical']
, O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
blockades I-outcome ['Physiological-Clinical']
and O
complications O
within O
the O
first B-outcome ['Physiological-Clinical']
24 I-outcome ['Physiological-Clinical']
hours I-outcome ['Physiological-Clinical']
after O
surgery O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Only O
topical O
bupivacaine O
was O
found O
to O
decrease O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scores O
significantly O
over O
those O
with O
placebo O
, O
at O
30 O
minutes O
postoperatively O
( O
median O
score O
2 O
compared O
with O
4 O
, O
P O
= O
.002 O
) O
and O
at O
discharge O
from O
the O
recovery O
room O
( O
median O
score O
2 O
compared O
with O
3 O
, O
P O
= O
.03 O
) O
. O
['Physiological-Clinical']

The O
treatment O
group O
self-administered O
fusidic O
acid O
viscous O
eye O
drops O
four O
times O
daily O
for O
seven O
days O
before O
surgery O
; O
the O
placebo O
group O
received O
inert O
ophthalmic O
drops O
. O
[]

AIM O
To O
evaluate O
the O
acute O
effects O
of O
KC O
11458 O
on O
gastric O
emptying O
in O
diabetic O
gastroparesis O
. O
[]

The O
use O
of O
antioxidant O
agents O
neutralizes O
the O
free O
oxygen O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
long-term O
increases O
in O
consumption O
of O
dairy O
calcium O
alter O
body B-outcome ['Physiological-Clinical']
weight O
and O
fat B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
young I-outcome ['Physiological-Clinical']
, O
healthy B-outcome ['Physiological-Clinical']
women I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
large O
randomized O
controlled O
trial O
is O
warranted O
to O
further O
evaluate O
the O
efficacy O
of O
this O
regimen O
. O
[]

AIM O
To O
study O
the O
effect O
of O
acetazolamide O
on O
cystoid O
macular O
oedema O
( O
CMO O
) O
in O
patients O
with O
Behcet O
's O
disease O
. O
[]

When O
considered O
in O
combination O
, O
the O
overexpression O
of O
both O
Ki-67 B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

Lung O
function O
and O
respiratory O
symptoms O
in O
a O
1-year O
randomized O
smoking O
cessation O
trial O
of O
varenicline O
in O
COPD O
patients O
. O
[]

catheters O
( O
short O
lines O
) O
versus O
long O
( O
30 O
cm O
) O
i.v O
. O
[]

High-frequency O
oscillatory O
ventilation+10 O
and O
+15 O
further O
worsened O
right O
ventricular O
function O
, O
resulting O
in O
about O
a O
40 O
% O
increase O
in O
right O
ventricular O
end-diastolic O
area/left O
ventricular O
end-diastolic O
area O
ratio O
and O
a O
30 O
% O
increase O
in O
end-diastolic O
eccentricity O
index O
when O
compared O
with O
conventional O
mechanical O
ventilation O
or O
high-frequency O
oscillatory O
ventilation+5 O
periods O
. O
[]

Correlation O
analysis O
revealed O
significant O
relationships O
between O
BALF O
neutrophil B-outcome ['Physiological-Clinical']
counts O
and O
indices O
of O
alveolar-capillary O
membrane O
protein O
permeability O
, O
IL-8 O
, O
and O
leukotriene B-outcome ['Physiological-Clinical']
B4 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Cemented O
CeraOne O
and O
porcelain O
fused O
to O
TiAdapt O
abutment O
single-implant O
crown O
restorations O
: O
a O
10-year O
comparative O
follow-up O
study O
. O
[]

Breast-milk O
bacteria O
should O
thus O
be O
considered O
an O
important O
source O
of O
bacteria O
in O
the O
establishment O
of O
infantile O
intestinal O
microbiota O
. O
[]

Second O
, O
to O
study O
the O
effect O
of O
oral O
omeprazole O
20 O
mg O
given O
once O
or O
twice O
daily O
up O
to O
day O
10 O
, O
after O
cessation O
of O
a O
3-day O
intravenous O
infusion O
( O
80 O
mg O
+ O
8 O
mg/h O
) O
. O
[]

Outward B-outcome ['Physiological-Clinical']
catheter I-outcome ['Physiological-Clinical']
migration I-outcome ['Physiological-Clinical']
was O
not O
reduced O
by O
subcutaneous O
tunnelling O
. O
['Physiological-Clinical']

METHODS O
In O
a O
randomized O
, O
double-blind O
, O
four-arm O
study O
with O
placebo O
run-in O
phase O
conducted O
at O
travel O
clinics O
in O
Switzerland O
, O
Germany O
, O
and O
Israel O
, O
we O
compared O
moods O
and O
feelings O
in O
chemoprophylaxis O
users O
( O
n= O
547 O
) O
by O
administering O
the O
standardized O
Profile O
of O
Mood O
States O
( O
POMS O
) O
questionnaire O
. O
[]

The O
primary O
outcomes O
of O
this O
study O
are O
change O
in O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
measured O
in O
MET O
minutes O
per O
week O
, O
work B-outcome ['Life-Impact']
productivity I-outcome ['Life-Impact']
and O
['Life-Impact', 'Life-Impact']

The O
following O
variables O
contributed O
significantly O
to O
predicting O
FH B-outcome ['Physiological-Clinical']
SD I-outcome ['Physiological-Clinical']
score O
: O
GH B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
, O
height B-outcome ['Physiological-Clinical']
SD I-outcome ['Physiological-Clinical']
score I-outcome ['Physiological-Clinical']
( O
ref O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

From O
July O
1996 O
to O
July O
1998 O
, O
61 O
patients O
with O
clinical O
stage O
I O
endometrial O
cancer O
were O
treated O
at O
the O
Gynaecology O
Oncology O
Unit O
at O
the O
Royal O
North O
Shore O
of O
Sydney O
, O
Australia O
. O
[]

Two O
open-label O
, O
controlled O
, O
multicenter O
, O
intergroup O
, O
international O
, O
randomized O
phase O
III O
studies O
were O
submitted O
-- O
one O
conducted O
by O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer B-outcome ['Physiological-Clinical']
( O
n O
= O
946 O
) O
and O
the O
other O
by O
the O
Southwest O
Oncology O
Group O
( O
n O
= O
746 O
) O
. O
['Physiological-Clinical']

However O
, O
there O
is O
a O
lack O
of O
information O
regarding O
patient O
's O
adherence B-outcome ['Life-Impact']
to O
these O
recommendations O
in O
daily O
clinical O
practice O
. O
['Life-Impact']

Estradiol O
and O
the O
addition O
of O
progesterone O
increase O
the O
sensitivity O
to O
a O
neurosteroid O
in O
postmenopausal O
women O
. O
[]

and O
salbutamol O
200 O
microg O
p.r.n O
. O
[]

Fifty-four O
patients O
were O
randomized O
to O
Group O
A O
( O
piriformis O
fossa O
portal O
) O
and O
fifty-six O
to O
Group O
B O
( O
trochanteric O
portal O
) O
. O
[]

Supervisor O
tolerance-responsiveness O
to O
substance O
abuse O
and O
workplace O
prevention O
training O
: O
use O
of O
a O
cognitive O
mapping O
tool O
. O
[]

SUBJECTS O
A O
total O
of O
sixty-five O
middle-aged O
women O
who O
participated O
in O
a O
randomized O
clinical O
trial O
. O
[]

All O
intervention O
groups O
received O
modified O
carbohydrate O
nutrition O
classes O
( O
once O
a O
week O
) O
, O
whereas O
the O
N O
+ O
ST O
also O
received O
strength O
training O
( O
twice O
a O
week O
) O
and O
the O
N O
+ O
CAST O
received O
a O
combination O
of O
strength O
and O
aerobic O
training O
( O
twice O
a O
week O
) O
. O
[]

Unique O
identifier O
: O
NCT00282711 O
. O
[]

29.2 O
mg/L O
; O
lipase O
: O
269 O
? O
[]

The O
reocclusion B-outcome ['Physiological-Clinical']
rates O
were O
7.3 O
% O
and O
8.2 O
% O
, O
respectively O
( O
P O
= O
1.00 O
) O
. O
['Physiological-Clinical']

Four O
hundred O
two O
patients O
with O
suspected O
myocardial O
infarction O
seen O
within O
6 O
hours O
of O
the O
onset O
of O
symptoms O
entered O
a O
double-blind O
randomized O
trial O
of O
lidocaine O
vs O
placebo O
. O
[]

Patients O
and O
surgeon O
did O
not O
know O
which O
medications O
were O
used O
. O
[]

OBJECTIVES O
The O
intention O
of O
this O
study O
was O
to O
test O
the O
hypothesis O
that O
, O
in O
heart O
failure O
patients O
, O
dietary O
supplementation O
of O
polyunsaturated O
fatty O
acids O
( O
PUFA O
) O
enhances O
arterial O
baroreceptor O
control O
of O
the O
cardiovascular O
system O
. O
[]

UNLABELLED O
Ultrasonically O
guided O
transvaginal O
oocyte O
retrieval O
is O
relatively O
short O
procedure O
that O
is O
performed O
on O
an O
out-patient O
basis O
. O
[]

Our O
findings O
provide O
a O
clear O
demonstration O
in O
man O
of O
the O
important O
homeostatic B-outcome ['Physiological-Clinical']
role I-outcome ['Physiological-Clinical']
of O
renal O
prostaglandins O
in O
preserving O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
particularly O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
, O
under O
conditions O
of O
elevated O
circulating O
angiotensin O
II O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Follow-up O
endoscopy O
is O
scheduled O
3 O
months O
after O
therapy O
, O
and O
thereafter O
in O
one-year O
intervals O
. O
[]

The O
child O
's O
initial O
sleep O
difficulties O
were O
retrospectively O
attributed O
to O
inappropriate O
sleep O
habits O
. O
( O
[]

Continued O
remission O
appeared O
more O
likely O
in O
patients O
achieving O
remission O
earlier O
in O
the O
course O
of O
their O
therapy O
( O
0-6 O
months O
) O
. O
[]

Using O
an O
optimal O
cut-off O
value O
of O
> O
56 O
ml O
, O
defined O
by O
receiver-operating O
characteristic O
curve O
analysis O
, O
sensitivity O
, O
specificity O
, O
and O
the O
positive O
and O
negative O
predictive O
values O
of O
the O
volume O
scanner O
for O
detecting O
AAA O
were O
90 O
% O
, O
90 O
% O
, O
97 O
% O
, O
and O
71 O
% O
, O
respectively O
. O
[]

PURPOSE O
To O
compare O
the O
recovery B-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
, O
efficacy O
and O
safety O
of O
remifentanil O
and O
morphine O
for O
transitional O
analgesia O
with O
fentanyl O
in O
patients O
undergoing O
elective O
craniotomy O
for O
supratentorial O
mass O
lesions O
. O
['Physiological-Clinical']

Younger O
children O
had O
more O
severe B-outcome ['Physiological-Clinical']
diarrhea I-outcome ['Physiological-Clinical']
( O
P O
=.002 O
) O
, O
whereas O
older O
children O
had O
worse O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
( O
P O
=.01 O
) O
after O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
the O
494 O
boys O
entered O
on O
study O
, O
255 O
( O
51.6 O
% O
) O
were O
in O
complete O
continuous O
remission O
( O
CCR O
) O
3 O
years O
after O
entering O
remission O
and O
an O
additional O
eight O
were O
in O
CCR O
3 O
years O
after O
localized O
extramedullary O
relapse O
and O
retreatment O
; O
263 O
boys O
were O
eligible O
for O
testicular O
biopsy O
. O
[]

[ O
4 O
years O
' O
experience O
with O
a O
balloon-expandable O
endoprosthesis O
. O
[]

Modulation O
of O
human B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
cortex I-outcome ['Physiological-Clinical']
excitability I-outcome ['Physiological-Clinical']
by O
single O
doses O
of O
amantadine O
. O
['Physiological-Clinical']

In O
this O
cohort O
, O
quantitative O
image O
analysis O
showed O
significantly O
larger O
biopsies O
regarding O
size O
and O
artifact-free B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
sections I-outcome ['Physiological-Clinical']
for O
cryobiopsy O
compared O
with O
forceps O
biopsy O
( O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical']

The O
faster O
recovery B-outcome ['Physiological-Clinical']
following O
desflurane O
may O
be O
desirable O
after O
long O
surgical O
procedures O
, O
enabling O
the O
patient O
's O
full O
cooperation O
and O
facilitating O
early O
diagnosis O
of O
any O
potential O
neurological O
deficit O
. O
['Physiological-Clinical']

GH O
treatment O
was O
well B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

The O
pioglitazone O
group O
had O
significantly O
higher O
HbA B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
values O
compared O
with O
the O
glimepiride O
group O
after O
12 O
weeks O
of O
therapy O
( O
8.66 O
% O
vs O
7.80 O
% O
; O
P O
= O
0.007 O
) O
but O
had O
significantly O
lower O
values O
after O
52 O
weeks O
( O
7.46 O
% O
vs O
7.77 O
% O
; O
P O
= O
0.027 O
) O
. O
['Physiological-Clinical']

INTERVENTIONS O
100 O
patients O
with O
anterior O
wall O
ST-elevation O
myocardial O
infarction O
treated O
with O
acute O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
were O
randomised O
to O
receive O
intracoronary O
injection O
of O
mBMCs O
( O
n O
= O
50 O
) O
or O
not O
( O
n O
= O
50 O
) O
. O
[]

Therefore O
, O
it O
is O
of O
interest O
to O
assess O
the O
efficacy O
of O
cyproheptadine O
, O
a O
5-HT2 O
antagonist O
in O
the O
treatment O
of O
autistic O
disorder O
. O
[]

However O
significantly O
less O
frequent O
dosing O
was O
necessary O
with O
Sinemet O
CR O
. O
[]

Since O
the O
beginning O
of O
1995 O
the O
new O
hydrostatic O
dual-switch O
valve O
( O
DSV O
) O
was O
implanted O
in O
35 O
adult O
patients O
with O
hydrocephalus O
of O
different O
etiology O
. O
[]

We O
evaluated O
the O
hypothesis O
that O
net O
leg B-outcome ['Physiological-Clinical']
total O
FFA B-outcome ['Physiological-Clinical']
, O
LDL-C B-outcome ['Physiological-Clinical']
, O
and O
TG B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
and O
HDL-C B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
during O
moderate-intensity O
cycling O
exercise O
would O
be O
increased O
following O
endurance O
training O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Data O
were O
collected O
during O
the O
experimental O
period O
( O
for O
10 O
months O
from O
approximately O
1 O
year O
of O
age O
) O
on O
feed B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
live B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
eggs O
per O
gram B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EPG I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
faeces I-outcome ['Physiological-Clinical']
, O
packed-cell B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PCV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
wool O
weight O
, O
and O
adult-worm B-outcome ['Physiological-Clinical']
burden I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Broccoli O
intake O
did O
not O
modify O
[]

Guided O
imagery O
appeared O
to O
have O
potential O
as O
a O
useful O
nursing O
modality O
for O
chronic O
pain O
sufferers O
. O
[]

CONCLUSION O
Denosumab O
was O
superior O
to O
zoledronic O
acid O
in O
delaying O
or O
preventing O
SREs O
in O
patients O
with O
breast O
cancer O
metastatic O
to O
bone O
and O
was O
generally O
well O
tolerated O
. O
[]

A O
randomized O
controlled O
trial O
was O
conducted O
to O
compare O
the O
efficacy O
of O
clinical O
hypnosis O
versus O
cognitive O
behavioral O
( O
CB O
) O
coping O
skills O
training O
in O
alleviating O
the O
pain B-outcome ['Physiological-Clinical']
and O
distress B-outcome ['Life-Impact']
of O
30 O
pediatric O
cancer O
patients O
( O
age O
5 O
to O
15 O
years O
) O
undergoing O
bone O
marrow O
aspirations O
. O
['Physiological-Clinical', 'Life-Impact']

Effects O
of O
nicotine O
on O
regional B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
awake O
resting O
tobacco O
smokers O
. O
['Physiological-Clinical']

[ O
Long-term O
treatment O
of O
cerebrovascular O
changes O
in O
the O
elderly O
( O
author O
's O
transl O
) O
] O
. O
[]

We O
aimed O
to O
assess O
the O
efficacy O
and O
safety O
of O
concurrent O
capecitabine O
and O
cisplatin O
over O
concurrent O
cisplatin O
and O
5-flurouracil O
( O
5-FU O
) O
in O
locally O
advanced O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
. O
[]

On O
multivariate O
analysis O
, O
pirarubicin O
instillation O
was O
an O
independent O
predictor O
of O
better O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
in O
the O
patients O
with O
positive O
urine O
cytology O
( O
hazard O
ratio O
, O
0.02 O
; O
95 O
% O
confidence O
interval O
, O
0.00-0.53 O
; O
P O
= O
0.018 O
) O
. O
['Mortality']

RESULTS O
Participants O
in O
both O
arms O
significantly O
increased O
objectively O
measured O
minutes O
of O
moderate/vigorous B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
over O
the O
course O
of O
the O
intervention O
. O
['Life-Impact']

The O
38 O
encephalopathy O
cases O
were O
classified O
into O
three O
types O
according O
to O
the O
leading O
clinical O
picture O
: O
coma O
type O
, O
convulsion O
type O
and O
psychotic O
reactions O
. O
[]

Two O
groups O
of O
high-school O
girls O
( O
mean O
age O
13 O
years O
) O
suffering O
dysmenorrhoea O
were O
randomized O
to O
receive O
fennel O
extract O
( O
n O
= O
55 O
) O
or O
mefenamic O
acid O
( O
n O
= O
55 O
) O
for O
2 O
months O
. O
[]

Data O
were O
analysed O
per O
protocol O
. O
[]

RESULTS O
The O
postoperative O
hidden O
blood O
loss O
, O
knee O
swelling O
, O
and O
scope O
of O
ecchymosis O
were O
significantly O
lower O
in O
the O
flexion O
group O
than O
in O
the O
extension O
group O
, O
and O
ROM O
and O
straight-leg O
raising O
action O
were O
significantly O
higher O
during O
the O
early O
period O
after O
operation O
. O
[]

RESULTS O
Of O
33 O
protocol O
compliant O
Brisbane O
recipients O
of O
placebo O
immunotherapy O
, O
11 O
were O
disease O
free O
at O
two O
months O
, O
and O
a O
further O
9 O
demonstrated O
reduction O
of O
> O
50 O
% O
in O
total O
wart O
area O
. O
[]

METHODS O
We O
present O
1 O
year O
of O
follow-up O
information O
on O
95 O
subjects O
enrolled O
in O
the O
United O
States O
Food O
and O
Drug O
Administration O
Phase O
III O
clinical O
trials O
. O
[]

Limited O
research O
suggests O
that O
intake O
of O
soy O
products O
high O
in O
isoflavonoid O
phytoestrogens O
affects O
sex B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
, O
but O
it O
is O
unknown O
whether O
phytoestrogens O
in O
soy O
have O
any O
effect O
on O
menstrual O
function O
or O
serum O
sex O
hormones O
in O
women O
on O
common O
hormone O
therapies O
, O
such O
as O
oral O
contraceptives O
( O
OC O
) O
. O
['Physiological-Clinical']

Statistical O
analysis O
was O
performed O
using O
paired O
t O
tests O
, O
chi O
( O
2 O
) O
analysis O
, O
Fisher O
exact O
test O
, O
or O
multiple O
linear O
regression O
as O
appropriate O
. O
[]

Asthma O
: O
communication O
between O
hospital O
and O
general O
practitioners O
. O
[]

RESULTS O
The O
2-year O
patient/graft B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
86.0 O
% O
/73.7 O
% O
and O
94.2 O
% O
/90.3 O
% O
in O
CsA O
and O
FK506 O
groups O
, O
respectively O
( O
P O
< O
0.05 O
) O
, O
with O
incidence O
of O
acute B-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
of O
10.5 O
% O
and O
9.6 O
% O
( O
P O
> O
0.05 O
) O
, O
and O
rate O
of O
abnormal B-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
of O
26.3 O
% O
and O
15.4 O
% O
( O
P O
< O
0.05 O
) O
, O
respectively O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

INTERVENTION O
Four O
locomotor O
imagery O
trainings O
on O
walking O
performance O
: O
visual O
locomotor O
imagery O
training O
, O
kinesthetic O
locomotor O
imagery O
training O
, O
visual O
locomotor O
imagery O
training O
with O
auditory O
step O
rhythm O
and O
kinesthetic O
locomotor O
imagery O
training O
with O
auditory O
step O
rhythm O
. O
[]

An O
exposure O
period O
of O
36 O
hours O
doubled O
the O
aneuploidy B-outcome ['Physiological-Clinical']
rate O
, O
but O
this O
was O
significant O
only O
for O
the O
20-muM O
dose O
of O
FF-MAS O
. O
['Physiological-Clinical']

Evaluation O
of O
lidocaine O
in O
human O
inferior O
alveolar O
nerve O
block O
. O
[]

Comparative O
speed O
of O
kill O
of O
selamectin O
, O
imidacloprid O
, O
and O
fipronil- O
( O
S O
) O
-methoprene O
spot-on O
formulations O
against O
fleas B-outcome ['Physiological-Clinical']
on O
cats O
. O
['Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

CONCLUSIONS O
The O
clinical O
assessment O
agrees O
with O
the O
fluorescence O
data O
as O
no O
significant O
difference O
was O
seen O
between O
prepared O
and O
unprepared O
halves O
of O
the O
lesion O
12 O
months O
after O
PDT O
. O
[]

Remodeling O
of O
small O
resistance O
vessels O
may O
be O
the O
earliest O
pathologic O
finding O
associated O
with O
hypertension O
. O
[]

CONCLUSIONS O
The O
primary O
endpoint O
achievement O
did O
not O
correlate O
with O
PR O
. O
[]

Statistical O
analysis O
was O
performed O
using O
repeated O
measures O
ANOVA O
and O
Fisher O
's O
pairwise O
comparisons O
. O
[]

The O
multicenter O
trial O
did O
not O
evaluate O
early O
callus O
formation O
. O
[]

The O
overall O
incidence O
of O
PONV O
was O
low O
and O
was O
not O
significantly O
different O
between O
the O
two O
groups O
. O
[]

METHODS O
An O
assessment O
of O
CSP O
efficacy O
and O
safety O
was O
conducted O
in O
an O
international O
, O
multicentre O
, O
assessor-blinded O
study O
, O
which O
enrolled O
728 O
subjects O
with O
a O
history O
of O
recurrent O
HSL O
. O
[]

Post-hoc O
analysis O
indicated O
more O
than O
87 O
% O
of O
children O
receiving O
CFT O
showed O
reliable O
change O
on O
at O
least O
one O
measure O
at O
post-test O
and O
66.7 O
% O
after O
3 O
months O
follow-up O
. O
[]

MAIN O
OUTCOME O
MEASUREMENTS O
Nonunions B-outcome ['Physiological-Clinical']
, O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
, O
and O
rate O
of O
malunions B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
latest O
research O
into O
the O
prevention O
of O
peri- B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
thromboembolic I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
has O
found O
orthopaedic O
surgery O
patients O
to O
be O
most O
at O
risk O
. O
['Physiological-Clinical']

METHODS O
One O
hundred O
and O
twenty O
consecutive O
patients O
with O
a O
BMI O
< O
23.0 O
kg/m O
( O
2 O
) O
and O
a O
low O
calcium O
load O
undergoing O
retrospective O
electrocardiogram O
( O
ECG O
) O
-gated O
dual-source O
CCTA O
were O
randomized O
into O
two O
groups O
[ O
standard-tube O
voltage O
( O
120-kV O
) O
vs. O
low-tube O
voltage O
( O
80-kV O
) O
] O
. O
[]

These O
observations O
led O
to O
a O
proposed O
model O
of O
the O
interaction O
between O
the O
basal O
ganglia O
and O
the O
supplementary O
motor O
area O
, O
involving O
the O
temporal O
organization O
of O
voluntary O
and O
internally O
determined O
sequential O
movements O
. O
[]

It O
is O
an O
acute O
febrile O
illness O
that O
may O
cause O
coronary O
artery O
aneurysm O
formation O
in O
infected O
children O
. O
[]

Monotherapy O
of O
mild O
hypertension B-outcome ['Physiological-Clinical']
with O
nifedipine O
. O
['Physiological-Clinical']

These O
changes O
persisted O
at O
days O
12-14 O
, O
and O
after O
allometrically O
scaling O
FMD O
to O
adjust O
for O
altered O
baseline O
diameter O
. O
[]

These O
findings O
raise O
the O
specificity O
of O
these O
two O
drugs O
which O
appear O
to O
act O
preferentially O
on O
some O
target O
symptoms O
and O
are O
consistent O
with O
some O
clinical O
and O
pharmacological O
observations O
showing O
a O
sedative B-outcome ['Resource-use']
effect O
with O
low O
doses O
of O
DA O
agonists O
and O
a O
stimulant B-outcome ['Physiological-Clinical']
effect O
with O
low O
doses O
of O
DA O
antagonists O
such O
as O
the O
benzamides O
. O
['Resource-use', 'Physiological-Clinical']

A O
there- O
to O
five-year O
follow-up O
examined O
their O
course O
after O
release O
from O
the O
hospital O
. O
[]

No O
morphologic B-outcome ['Physiological-Clinical']
variable O
or O
residual O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
predicted O
response O
to O
immunosuppressive O
therapy O
at O
entry O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
sham O
group O
received O
corresponding O
sham O
stimulation O
. O
[]

RESULTS O
Of O
60 O
epileptic O
women O
with O
periconceptional O
folic O
acid O
( O
0.8 O
mg O
) O
-containing O
multivitamin O
supplementation O
, O
no O
one O
developed O
epilepsy-related O
side O
effects O
during O
the O
periconception O
period O
. O
[]

A O
symptom O
based O
questionnaire O
was O
administered O
to O
all O
patients O
at O
stent O
removal O
. O
[]

Tachycardia B-outcome ['Physiological-Clinical']
and O
palpitations B-outcome ['Physiological-Clinical']
were O
more O
frequent O
following O
isoproterenol O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
data O
on O
the O
safety O
and O
efficacy O
of O
atypical O
antipsychotic O
agents O
in O
children O
are O
limited O
. O
[]

Before O
PTCA O
, O
19 O
ischemic O
episodes O
were O
present O
in O
10 O
( O
33 O
% O
) O
of O
30 O
patients O
. O
[]

Measurements O
were O
taken O
during O
the O
placebo O
period O
and O
immediate-release O
nifedipine O
therapy O
in O
30 O
hypertensive O
patients O
( O
20 O
with O
and O
10 O
without O
stable O
angina O
) O
. O
[]

SETTING O
A O
teaching O
hospital O
and O
tertiary O
medical O
center O
. O
[]

Primary O
outcome O
measures O
were O
tests O
of O
attention O
( O
Digit O
Span O
, O
Trail O
Making O
Test O
, O
and O
Symbol O
Digit O
Modalities O
Test O
) O
, O
verbal O
memory O
( O
Selective O
Reminding O
Test O
) O
, O
nonverbal O
memory O
( O
Benton O
Visual O
Retention O
Test O
) O
, O
and O
motor O
speed O
( O
Finger O
Tapping O
Test O
) O
. O
[]

The O
effects O
of O
haloperidol O
on O
discrimination B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
autistic O
children O
. O
['Life-Impact', 'Life-Impact']

Based O
on O
these O
early O
data O
, O
further O
study O
of O
inhaled O
treprostinil O
appears O
warranted O
in O
pediatric O
patients O
with O
PAH O
. O
[]

Also O
, O
plyometric O
exercises O
was O
recommended O
for O
the O
treatment O
of O
the O
tendinopathy O
. O
[]

RESULTS O
The O
level O
of O
ACTH B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
CORT I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
decreased O
and O
lymphocyte B-outcome ['Physiological-Clinical']
proliferative I-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
reduced O
in O
patients O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
Thirty-two O
patients O
with O
left O
anterior O
descending O
coronary O
artery O
( O
LAD O
) O
or O
two-vessel O
heart O
disease O
( O
including O
LAD O
) O
who O
were O
to O
undergo O
off-pump O
CABG O
were O
randomized O
into O
an O
IP O
group O
and O
a O
control O
group O
. O
[]

This O
leads O
to O
a O
higher O
peak O
bone O
mass O
and O
may O
reduce O
the O
risk O
of O
cortical O
bone O
fragility O
later O
in O
life O
. O
[]

BACKGROUND O
Treating O
hypertension O
with O
drugs O
is O
so O
far O
the O
most O
cost-effective O
way O
to O
reduce O
this O
important O
risk O
factor O
for O
cardiovascular O
disease O
( O
CVD O
) O
. O
[]

In O
summary O
, O
flecainide O
is O
an O
effective O
and O
safe O
drug O
for O
conversion O
of O
paroxysmal O
AF O
to O
sinus O
rhythm O
, O
but O
ineffective O
for O
AFI B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Our O
aim O
was O
to O
examine O
these O
reflexes B-outcome ['Physiological-Clinical']
and O
breathing B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
in O
healthy O
neonates O
after O
pharyngeal O
infusion O
of O
water O
in O
the O
supine O
versus O
the O
prone O
position O
, O
controlling O
for O
sleep O
state O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Rofecoxib O
25 O
mg O
provided O
greater O
response O
( O
p O
< O
0.05 O
) O
than O
celecoxib O
on O
WOMAC O
subscales O
. O
[]

MATERIALS O
AND O
METHODS O
A O
multisite O
, O
randomized O
, O
prospective O
, O
blinded O
, O
clinical O
trial O
was O
conducted O
on O
130 O
patients O
with O
inferior O
alveolar O
nerve O
( O
IAN O
) O
and O
lingual O
nerve O
( O
LN O
) O
injuries O
. O
[]

No O
differences O
were O
found O
between O
the O
naltrexone O
and O
placebo O
conditions O
in O
any O
of O
the O
measures O
of O
children B-outcome ['Physiological-Clinical']
or O
parents O
' O
communication B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Average O
LV B-outcome ['Physiological-Clinical']
posterior I-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
was O
15 O
+/- O
1.1 O
mm O
, O
septum O
16 O
+/- O
2 O
mm O
, O
LV O
mass O
420 O
+/- O
90 O
g O
, O
and O
LV O
mass O
index O
212 O
= O
51 O
g/m2 O
. O
['Physiological-Clinical']

Disease O
activity O
states O
, O
including O
remission O
, O
were O
defined O
using O
established O
cut O
points O
; O
for O
the O
DAS28 O
, O
an O
alternative O
cut O
point O
of O
< O
2.4 O
was O
also O
used O
. O
[]

CONCLUSIONS O
The O
increased O
VM B-outcome ['Physiological-Clinical']
H-reflex I-outcome ['Physiological-Clinical']
amplitude I-outcome ['Physiological-Clinical']
at O
3 O
months O
following O
HS O
autograft O
ACLR O
demonstrates O
an O
increase O
in O
VM B-outcome ['Physiological-Clinical']
neuromuscular I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

We O
conclude O
that O
operative O
laparoscopy O
is O
a O
safe O
procedure O
for O
the O
removal O
of O
dermoid O
ovarian O
cysts O
and O
is O
as O
effective O
as O
laparotomy O
. O
[]

ICT O
patients O
required O
analgesic B-outcome ['Resource-use']
drugs I-outcome ['Resource-use']
during O
76.8 O
+/- O
31 O
hours O
and O
VATS O
patients O
38.4 O
+/- O
13 O
hours O
( O
p O
< O
.05 O
) O
. O
['Resource-use']

Two O
fluorescent O
tracers O
( O
true O
blue O
and O
diamidino O
yellow O
) O
were O
applied O
to O
the O
proximal O
ends O
of O
tibial O
and O
common O
peroneal O
nerves O
, O
respectively O
after O
four O
or O
six O
months O
of O
nerve O
coaptation O
. O
[]

Doxepin O
differed O
from O
bupropion O
mainly O
on O
the O
sleep B-outcome ['Physiological-Clinical']
factor O
of O
the O
Hamilton O
Depression B-outcome ['Life-Impact']
Scale O
, O
with O
doxepin O
improving O
sleep O
to O
a O
greater O
extent O
than O
bupropion O
. O
['Physiological-Clinical', 'Life-Impact']

Prospective O
analyses O
using O
data O
for O
all O
participants O
will O
provide O
more O
definitive O
information O
on O
GERA O
uptake O
and O
the O
impact O
of O
GERA O
feedback O
. O
[]

The O
overt O
aggression O
scale O
for O
rating O
aggression O
in O
outpatient O
youth O
with O
autistic O
disorder O
: O
preliminary O
findings O
. O
[]

Comparison O
of O
5-aminosalicylic O
acid O
( O
3 O
g O
) O
and O
prednisolone O
phosphate O
sodium O
enemas O
( O
30 O
mg O
) O
in O
the O
treatment O
of O
distal B-outcome ['Physiological-Clinical']
ulcerative I-outcome ['Physiological-Clinical']
colitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Conversely O
, O
neither O
PaO2 B-outcome ['Physiological-Clinical']
nor O
intrapulmonary O
shunt O
( O
or O
AaDO2 O
) O
in O
the O
control O
group O
demonstrated O
any O
significant O
beneficial O
changes O
. O
['Physiological-Clinical']

Due O
to O
marked O
hepatic O
transaminase O
elevations O
, O
predominantly O
with O
FPV O
1,400 O
mg O
BID O
plus O
RTV O
200 O
mg O
BID O
, O
the O
study O
was O
terminated O
prematurely O
. O
[]

0.05 O
) O
. O
[]

Comparison O
of O
the O
time B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
to O
administer O
three O
different O
fluke O
and O
worm O
combination O
products O
to O
commercial O
beef O
cattle O
at O
housing O
. O
['Life-Impact']

Aerobic O
fitness O
is O
associated O
with O
white B-outcome ['Physiological-Clinical']
matter I-outcome ['Physiological-Clinical']
integrity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
WMI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
adults O
as O
measured O
by O
diffusion B-outcome ['Physiological-Clinical']
tensor I-outcome ['Physiological-Clinical']
imaging I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DTI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
previously O
found O
that O
91 O
% O
of O
the O
ischemic O
episodes O
in O
our O
hypertensive O
patients O
with O
stable O
angina O
were O
silent O
. O
[]

METHODS O
After O
a O
3-14-day O
run-in O
, O
204 O
patients O
were O
randomized O
to O
receive O
formoterol O
12 O
microg O
dry O
powder O
inhalation O
or O
matching O
placebo O
twice O
daily O
for O
8 O
weeks O
. O
[]

Effects O
of O
temafloxacin O
and O
ciprofloxacin O
on O
the O
pharmacokinetics O
of O
caffeine O
. O
[]

Moderate-to-severe B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
requiring O
treatment O
( O
Kottmeier O
's O
grade O
2 O
or O
more O
) O
were O
noted O
in O
6 O
patients O
( O
7 O
% O
) O
in O
group O
A O
and O
6 O
patients O
( O
7 O
% O
) O
in O
group O
B O
. O
['Physiological-Clinical']

RESULTS O
Treatment O
with O
nab-paclitaxel O
150 O
mg/m O
( O
2 O
) O
qw O
3/4 O
resulted O
in O
a O
median O
overall O
survival B-outcome ['Mortality']
( O
OS O
) O
of O
33.8 O
months O
compared O
with O
22.2 O
, O
27.7 O
, O
and O
26.6 O
months O
for O
nab-paclitaxel O
100 O
mg/m O
( O
2 O
) O
qw O
3/4 O
, O
nab-paclitaxel O
300 O
mg/m O
( O
2 O
) O
q3w O
, O
and O
docetaxel O
, O
respectively O
( O
overall O
P O
= O
.047 O
) O
. O
['Mortality']

OBJECTIVE O
Deliberate O
self-harm O
( O
DSH O
) O
, O
general O
hospital O
admission O
and O
psychiatric O
hospital O
admission O
are O
common O
in O
women O
meeting O
criteria O
for O
borderline O
personality O
disorder O
( O
BPD O
) O
. O
[]

RESULTS O
The O
average O
cancer B-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
rate O
was O
3.5 O
% O
, O
3.2 O
% O
and O
3.5 O
% O
for O
the O
completed O
rounds O
1 O
, O
2 O
and O
3 O
, O
respectively O
, O
in O
all O
five O
centres O
. O
['Physiological-Clinical']

This O
article O
summarizes O
a O
previously O
published O
study O
in O
which O
we O
assessed O
whether O
an O
intervention O
designed O
to O
promote O
exclusive O
and O
prolonged O
breast-feeding O
affects O
children O
's O
height O
, O
weight O
, O
adiposity O
, O
and O
blood O
pressure O
( O
BP O
) O
at O
age O
6.5 O
y O
. O
[]

There O
is O
controversy O
about O
efficacy O
of O
intraarticular O
morphine O
after O
shoulder O
arthroscopy O
. O
[]

During O
each O
10-day O
study O
period O
, O
subjects O
wore O
from O
0900 O
to O
1700 O
h O
an O
upper O
removable O
acrylic O
appliance O
holding O
one O
polished O
enamel O
and O
one O
polished O
dentine O
specimen O
. O
[]

Treatment O
predictor O
variables O
from O
47 O
teachers O
and O
children O
who O
were O
randomized O
to O
receive O
the O
COMPASS O
intervention O
( O
Ruble O
et O
al O
. O
[]

Concomitant O
medication O
usage O
was O
significantly O
greater O
on O
5-FU/LV O
( O
P O
=.010 O
) O
. O
[]

Thus O
it O
does O
not O
appear O
that O
postexercise B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
is O
dependent O
on O
increased O
production O
of O
nitric B-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Blood B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
levels O
were O
not O
significantly O
different O
between O
groups O
at O
any O
point O
in O
time O
; O
and O
there O
were O
no O
significant O
associations O
between O
blood B-outcome ['Physiological-Clinical']
isoflavones I-outcome ['Physiological-Clinical']
and O
lipid B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

[ O
Intravesical O
instillation O
of O
doxorubicin O
or O
epirubicin O
for O
chemoprophylaxis O
of O
superficial O
bladder O
cancer O
-- O
the O
fifth O
study O
of O
the O
Japanese O
Urological O
Cancer O
Research O
Group O
for O
Adriamycin/Farumorubicin O
] O
. O
[]

In O
the O
untreated O
control O
group O
, O
no O
positive O
[]

However O
, O
the O
DBP B-outcome ['Physiological-Clinical']
decline O
was O
significantly O
greater O
in O
the O
intervention O
than O
control O
groups O
, O
which O
showed O
a O
mean O
decrease O
of O
2.8 O
mm O
Hg O
( O
confidence O
interval O
: O
-5.5 O
to O
-0.1 O
; O
P O
= O
0.04 O
) O
. O
['Physiological-Clinical']

More O
S/CC O
patients O
enrolled O
on O
trials O
with O
advanced O
stage O
( O
III-IV O
) O
disease O
( O
as O
opposed O
to O
recurrent O
disease O
) O
compared O
to O
E O
patients O
( O
45 O
% O
vs. O
24 O
% O
, O
p O
< O
0.05 O
) O
. O
[]

Flea B-outcome ['Physiological-Clinical']
burdens I-outcome ['Physiological-Clinical']
were O
assessed O
by O
flea O
comb O
counts O
and O
clinical O
evaluations O
of O
FAD O
were O
performed O
before O
treatment O
, O
and O
on O
days O
14 O
, O
30 O
, O
60 O
, O
and O
90 O
. O
['Physiological-Clinical']

Each O
subject O
underwent O
an O
initial O
isoglycemic/hyperinsulinemic O
clamp O
after O
1-wk O
dietary O
control O
and O
a O
second O
clamp O
after O
completing O
the O
study O
. O
[]

On O
the O
AVP O
+ O
ANF O
study O
day O
, O
UNaV B-outcome ['Physiological-Clinical']
increased O
( O
+64 O
% O
) O
as O
with O
P B-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
ANF I-outcome ['Physiological-Clinical']
, O
but O
V B-outcome ['Physiological-Clinical']
( O
-44 O
% O
) O
and O
CH2O B-outcome ['Physiological-Clinical']
( O
-52 O
% O
) O
continued O
to O
decrease O
below O
baseline O
levels O
; O
analysis O
of O
variance O
showed O
this O
antidiuresis O
reflected O
the O
prevalent O
effect O
of O
AVP O
rather O
than O
any O
specific O
interaction O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Conversion B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
sinus I-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
was O
achieved O
in O
19 O
of O
22 O
patients O
( O
86 O
% O
) O
when O
AF O
lasted O
less O
than O
24 O
hours O
and O
in O
4 O
of O
10 O
( O
40 O
% O
) O
when O
the O
arrhythmia O
lasted O
greater O
than O
24 O
hours O
. O
['Physiological-Clinical']

To O
define O
the O
most O
effective O
treatment O
for O
polyarteritis O
nodosa O
( O
PAN O
) O
and O
Churg-Strauss O
syndrome O
( O
CSS O
) O
, O
we O
undertook O
4 O
consecutive O
prospective O
therapeutic O
trials O
including O
236 O
patients O
and O
tried O
to O
answer O
several O
important O
questions O
: O
Should O
cyclophosphamide O
( O
CYC O
) O
be O
given O
as O
the O
first-line O
treatment O
? O
[]

RESULTS O
There O
were O
no O
differences O
on O
climacteric B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
. O
['Physiological-Clinical']

Levels O
of O
recombinant B-outcome ['Physiological-Clinical']
human I-outcome ['Physiological-Clinical']
granulocyte I-outcome ['Physiological-Clinical']
colony-stimulating I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
in O
serum O
are O
inversely O
correlated O
with O
circulating O
neutrophil O
counts O
. O
['Physiological-Clinical']

Cell O
death O
after O
treatment O
with O
chemotherapy O
is O
exerted O
by O
activation O
of O
apoptosis O
, O
and O
the O
p53 O
protein O
has O
been O
shown O
to O
actively O
participate O
in O
this O
process O
. O
[]

The O
trial O
is O
expected O
to O
start O
at O
the O
beginning O
of O
next O
year O
. O
[]

The O
pre-dosing O
oral O
flora O
of O
the O
subjects O
was O
assessed O
from O
saliva O
samples O
cultured O
for O
aerobic O
and O
anaerobic O
bacteria O
, O
as O
well O
as O
Candida O
albicans O
. O
[]

Despite O
considerable O
efforts O
, O
it O
is O
sometimes O
hard O
to O
reach O
treatment O
goals O
for O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
with O
classical O
treatment O
options O
. O
['Physiological-Clinical']

Nifedipine O
therapy O
controlled O
measured O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
but O
not O
24-h B-outcome ['Physiological-Clinical']
ambulatory I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Biological O
osteosynthesis O
using O
dynamic O
condylar O
screw O
( O
DCS O
) O
and O
retrograde O
intramedullary O
supracondylar O
nail O
( O
RIMSN O
) O
preserve O
the O
blood O
supply O
and O
limit O
the O
need O
for O
bone O
grafting O
. O
[]

Non-Hodgkin O
's O
Lymphoma O
Cooperative O
Study O
Group O
. O
[]

We O
investigated O
the O
effect O
of O
cholesterol-lowering O
therapy O
on O
the O
progression O
of O
diabetic O
nephropathy O
in O
34 O
patients O
with O
non-insulin-dependent O
diabetes O
mellitus O
. O
[]

Subjects O
could O
sometimes O
completely O
inhibit O
initiation O
of O
the O
movements O
when O
the O
ISI O
was O
0 O
ms O
, O
but O
could O
rarely O
do O
so O
when O
the O
ISI O
exceeded O
100 O
ms. O
For O
responses O
that O
were O
initiated O
but O
stopped O
on O
the O
way O
, O
the O
amplitude O
of O
the O
movement B-outcome ['Life-Impact']
decreased O
linearly O
as O
the O
time O
interval O
( O
=modification O
time O
) O
from O
the O
stop O
signal O
to O
EMG O
onset O
increased O
. O
['Life-Impact']

In O
SH O
patients O
, O
the O
standard O
deviation O
of O
N-Ns B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SDNN I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
negatively O
related O
to O
TSH O
( O
r=-0.42 O
, O
P=0.006 O
) O
, O
while O
low O
frequency O
( O
LF B-outcome ['Physiological-Clinical']
) O
/high O
frequency O
( O
HF B-outcome ['Physiological-Clinical']
) O
ratio O
was O
positively O
related O
to O
TSH O
( O
r=0.42 O
, O
P=0.006 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Physical O
activity O
level O
and O
energy O
expenditure O
were O
assessed O
with O
a O
1-day O
activity O
diary O
. O
[]

Of O
10,001 O
TNT O
participants O
, O
9,376 O
had O
estimated O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
eGFR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
measurements O
at O
baseline O
and O
1 O
year O
and O
were O
included O
in O
this O
analysis O
. O
['Physiological-Clinical']

All O
the O
patients O
received O
oxygen O
, O
nebulized O
salbutamol O
, O
i.v O
. O
[]

of O
units O
) O
were O
lower O
in O
patients O
treated O
with O
somatostatin O
than O
in O
those O
treated O
with O
ranitidine O
, O
this O
was O
not O
statistically O
significant O
( O
mean O
+/- O
SD O
: O
2.56 O
+/- O
3.05 O
vs. O
5.17 O
+/- O
4.96 O
, O
respectively O
; O
P O
> O
0.05 O
) O
; O
the O
time B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
stop I-outcome ['Physiological-Clinical']
was O
shorter O
in O
the O
somatostatin O
group O
than O
in O
the O
ranitidine O
group O
( O
mean O
+/- O
SD O
: O
3.24 O
+/- O
2.45 O
vs. O
11.25 O
+/- O
11.63 O
, O
respectively O
; O
P O
= O
0.0383 O
) O
. O
['Physiological-Clinical']

Isoflurane O
was O
administered O
according O
to O
predetermined O
hemodynamic O
criteria O
. O
[]

CONCLUSION O
Aromatherapy O
massage O
does O
not O
appear O
to O
confer O
benefit O
on O
cancer O
patients O
' O
anxiety B-outcome ['Life-Impact']
and/or O
depression B-outcome ['Life-Impact']
in O
the O
long-term O
, O
but O
is O
associated O
with O
clinically O
important O
benefit O
up O
to O
2 O
weeks O
after O
the O
intervention O
. O
['Life-Impact', 'Life-Impact']

We O
tested O
the O
hypothesis O
that O
a O
strength O
training O
program O
would O
increase O
basal B-outcome ['Physiological-Clinical']
femoral I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
in O
aging O
adults O
. O
['Physiological-Clinical']

Tackling O
default O
will O
require O
development O
of O
targeted O
strategies O
to O
encourage O
attendance O
and O
research O
to O
better O
understand O
the O
reasons O
underpinning O
default O
. O
[]

[ O
The O
equipotency O
of O
ropivacaine O
, O
bupivacaine O
and O
etidocaine O
] O
. O
[]

The O
end O
points O
were O
survival O
and O
time O
to O
treatment O
failure O
( O
TTF O
) O
. O
[]

[ O
Effects O
of O
shuxuening O
injection O
on O
the O
levels O
of O
serum B-outcome ['Physiological-Clinical']
matrix I-outcome ['Physiological-Clinical']
metalloproteinase-9 I-outcome ['Physiological-Clinical']
and O
tissue B-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
metalloproteinase-1 I-outcome ['Physiological-Clinical']
in O
acute O
exacerbated O
chronic O
obstructive O
pulmonary O
disease O
patients O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
value O
for O
the O
area O
under O
the O
concentration-time B-outcome ['Physiological-Clinical']
curve O
of O
rhG-CSF B-outcome ['Physiological-Clinical']
on O
the O
day O
of O
neutrophilia O
was O
lower O
than O
that O
on O
the O
day O
of O
neutropenia O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
of O
enterostatin O
intake O
on O
food B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Using O
a O
double-blind O
protocol O
, O
55 O
premature O
infants O
weighing O
less O
than O
1501 O
g O
at O
birth O
were O
selected O
randomly O
to O
receive O
normal O
saline O
or O
proparacaine O
HCl O
0.5 O
% O
eye O
drops O
as O
a O
corneal O
wetting O
agent O
at O
their O
initial O
eye O
examination O
. O
[]

In O
contrast O
, O
the O
inflammatory B-outcome ['Physiological-Clinical']
response O
to O
O O
( O
3 O
) O
inhalation O
, O
as O
represented O
by O
the O
['Physiological-Clinical']

PURPOSE O
To O
compare O
the O
role O
of O
an O
aromatase O
inhibitor O
( O
letrozole O
) O
with O
a O
GnRH O
agonist O
( O
triptorelin O
) O
versus O
case O
control O
on O
the O
pregnancy B-outcome ['Physiological-Clinical']
rate O
and O
recurrence O
of O
symptoms B-outcome ['Physiological-Clinical']
and O
signs B-outcome ['Physiological-Clinical']
in O
patients O
with O
endometriosis O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
overall O
response O
rate O
was O
26 O
% O
in O
both O
treatment O
groups O
. O
[]

Patients O
were O
treated O
for O
as O
long O
as O
was O
tolerable O
. O
[]

The O
proportion O
of O
suture O
line O
sites O
that O
achieved O
immediate B-outcome ['Physiological-Clinical']
sealing I-outcome ['Physiological-Clinical']
and O
the O
proportion O
sealed O
within O
5 O
minutes O
were O
determined O
among O
37 O
experimental O
( O
59 O
sites O
) O
and O
17 O
control O
subjects O
( O
27 O
sites O
) O
. O
['Physiological-Clinical']

Microbial O
protein O
synthesis O
, O
nitrogen O
capture O
efficiency O
and O
nutrient O
utilisation O
in O
sheep O
fed O
on O
finger O
millet O
straw O
( O
Eleucine O
coracana O
) O
-based O
diet O
with O
different O
rumen-degradable O
nitrogen O
levels O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
Active O
controlled O
, O
double-blind O
, O
randomized O
, O
parallel O
group O
, O
multi-center O
clinical O
trial O
in O
ear O
, O
nose O
, O
and O
throat O
( O
ENT O
) O
specialist O
practices O
with O
a O
planned O
interim O
analysis O
for O
sample O
size O
adaptation O
. O
[]

Diastolic B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
was O
calculated O
by O
subtracting O
the O
electromechanical O
systole O
from O
the O
R-R O
interval O
and O
expressed O
as O
a O
percentage O
of O
the O
cardiac O
cycle O
( O
% O
D O
) O
. O
['Physiological-Clinical']

METHODS O
Review O
the O
design O
considerations O
for O
clinical O
trials O
in O
children O
with O
autistic O
disorder O
accompanied O
by O
severe O
tantrums O
, O
aggressive O
and/or O
self-injurious O
behaviors O
. O
[]

Anxiety O
was O
rated O
after O
2 O
and O
4 O
weeks O
with O
the O
Italian O
HAM-A O
scale O
and O
with O
a O
4-point O
scale O
( O
patient O
's O
assessment O
) O
. O
[]

This O
tendency O
was O
similar O
to O
those O
previously O
reported O
in O
step-tracking O
movements O
with O
various O
amplitudes O
. O
[]

Dietary O
intake O
was O
correlated O
with O
descriptors O
of O
stool O
consistency O
using O
cumulative O
logistic O
regression O
methods O
. O
[]

Plasma O
levels O
, O
areas O
under O
24-hour O
plasma O
concentration O
curves O
and O
urinary O
excretion O
were O
similar O
by O
both O
formulations O
in O
steady O
state O
. O
[]

Multivariable O
logistic O
regression O
was O
used O
for O
analysis O
. O
[]

Here O
, O
the O
screw/neck O
angle O
deviation O
has O
had O
the O
strongest O
significance O
for O
prediction O
of O
fixation O
failure O
. O
[]

Proportions O
of O
all O
TLV O
categories O
were O
higher O
in O
the O
CRM-training O
group O
( O
p O
< O
0.001 O
) O
. O
[]

Noncardiovascular O
causes O
accounted O
for O
49 O
and O
46 O
deaths B-outcome ['Mortality']
in O
the O
placebo O
and O
simvastatin O
groups O
, O
respectively O
. O
['Mortality']

Combined O
delivery O
approach O
of O
bone O
marrow O
mononuclear O
stem O
cells O
early O
and O
late O
after O
myocardial O
infarction O
: O
the O
MYSTAR O
prospective O
, O
randomized O
study O
. O
[]

METHODS/DESIGN O
CoAct O
is O
a O
randomised O
controlled O
trial O
with O
two O
arms O
: O
a O
control O
group O
and O
intervention O
group O
with O
daily O
activity O
monitoring O
and O
distance O
counselling O
. O
[]

Three O
patients O
showed O
liver B-outcome ['Physiological-Clinical']
involvement I-outcome ['Physiological-Clinical']
secondary O
to O
cryoglobulinemia O
and O
an O
improvement O
of O
histological B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
after O
the O
induction O
with O
combined O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
potent O
oral O
P-selectin O
blocking O
agent O
improves O
microcirculatory B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
a O
marker O
of O
endothelial B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
in O
patients O
with O
sickle O
cell O
disease O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Safety O
assessment O
of O
docosahexaenoic O
acid O
in O
X-linked O
retinitis O
pigmentosa O
: O
the O
4-year O
DHAX O
trial O
. O
[]

RESULTS O
No O
statistically O
significant O
differences O
were O
found O
in O
any O
of O
the O
studied O
parameters O
between O
the O
test O
and O
the O
control O
groups O
( O
P O
> O
0.05 O
) O
. O
[]

We O
report O
our O
experience O
with O
the O
electrothermal O
bipolar O
vessel O
sealing O
( O
EBVS O
) O
device O
for O
LA O
. O
[]

A O
randomized O
controlled O
trial O
assessing O
the O
health B-outcome ['Resource-use']
economics I-outcome ['Resource-use']
of O
realtime O
teledermatology O
compared O
with O
conventional O
care O
: O
an O
urban O
versus O
rural O
perspective O
. O
['Resource-use']

OBJECTIVE O
To O
study O
the O
efficacy O
, O
safety O
, O
and O
compliance O
of O
short-term O
electro-acupuncture O
for O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

Hydrofluoroalkane-134a O
( O
HFA O
) O
, O
a O
non-ozone-depleting O
propellant O
, O
has O
been O
used O
to O
reformulate O
albuterol O
( O
HFA O
albuterol O
) O
. O
[]

RESULTS O
At O
admission O
, O
several O
variables O
of O
coagulation B-outcome ['Physiological-Clinical']
and O
fibrinolysis B-outcome ['Physiological-Clinical']
were O
elevated O
and O
correlated O
well O
with O
clinical O
status O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Participants O
with O
acute O
low O
back O
pain O
and O
severe O
functional O
disability O
, O
defined O
as O
an O
Oswestry O
Disability O
Index O
( O
ODI O
) O
value O
> O
60 O
% O
, O
will O
be O
randomly O
allocated O
to O
the O
acupuncture O
group O
and O
the O
nonsteroidal O
anti-inflammatory O
drug O
( O
NSAID O
) O
injection O
group O
. O
[]

METHODS O
Consecutively O
scheduled O
central O
venous O
catheters O
inserted O
into O
jugular O
or O
subclavian O
veins O
were O
randomly O
assigned O
to O
be O
disinfected O
with O
5 O
% O
povidone-iodine O
in O
70 O
% O
ethanol O
or O
with O
a O
combination O
of O
0.25 O
% O
chlorhexidine O
gluconate O
, O
0.025 O
% O
benzalkonium O
chloride O
, O
and O
4 O
% O
benzylic O
alcohol O
. O
[]

The O
grade O
of O
Lipiodol O
accumulation O
and O
the O
tumor O
regression O
rate O
were O
determined O
2 O
weeks O
after O
TAI O
by O
computerized O
tomography O
. O
[]

Intravenous O
levosimendan O
treatment O
is O
cost-effective O
compared O
with O
dobutamine O
in O
severe O
low-output O
heart O
failure O
: O
an O
analysis O
based O
on O
the O
international O
LIDO O
trial O
. O
[]

At O
baseline O
, O
we O
observed O
no O
significant O
differences O
in O
HRV B-outcome ['Physiological-Clinical']
or O
hormone B-outcome ['Physiological-Clinical']
replacement O
use O
between O
treatment O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
determine O
whether O
the O
use O
of O
a O
recombinant O
human O
granulocyte O
colony-stimulating O
factor O
( O
[ O
G-CSF O
] O
lenogastrim O
) O
can O
increase O
the O
chemotherapy O
dose-intensity O
( O
CDI O
) O
delivered O
during O
consolidation O
chemotherapy O
of O
childhood O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
. O
[]

Self-reported O
ratings O
of O
the O
strength B-outcome ['Physiological-Clinical']
of O
the O
gum O
were O
significantly O
diminished O
by O
mecamylamine O
pretreatment O
. O
['Physiological-Clinical']

In O
experiment O
3c O
, O
a O
three-diameter O
length O
of O
bone O
was O
removed O
. O
[]

Preschoolers O
acquire O
general O
knowledge O
by O
sharing O
in O
pretense O
. O
[]

The O
carotid O
artery O
was O
cannulated O
to O
monitor O
the O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
to O
take O
samples O
for O
arterial B-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
observe O
the O
Chinese O
herbal O
medicine O
Selaginella-induced O
radiosensitization O
of O
terminal O
nasopharyngeal O
carcinoma O
( O
NPC O
) O
. O
[]

The O
optimal O
duration O
of O
NHT O
is O
unknown O
. O
[]

Furthermore O
, O
the O
platelet B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
increased O
22 O
hrs O
after O
DE O
exposure O
in O
healthy O
, O
but O
not O
in O
MetS O
subjects O
[ O
DE O
: O
16.6 O
( O
95 O
% O
CI O
: O
10.2 O
to O
23 O
) O
thousand O
platelets/mL O
versus O
[ O
FA O
: O
3.4 O
( O
95 O
% O
CI O
: O
-9.5 O
to O
16.3 O
) O
thousand O
platelets/mL O
) O
] O
; O
p=0.04 O
. O
['Physiological-Clinical']

Experiment O
4 O
reveals O
that O
these O
constructs O
each O
play B-outcome ['Life-Impact']
an I-outcome ['Life-Impact']
independent I-outcome ['Life-Impact']
role I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
persuasion I-outcome ['Life-Impact']
and O
resistance B-outcome ['Life-Impact']
situations I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

To O
minimize O
the O
consequence O
of O
haemorrhage O
, O
we O
performed O
every O
rigid O
bronchoscopy O
, O
placing O
a O
non O
inflated O
Fogarty O
balloon O
and O
a O
rigid O
aspirator O
( O
diameter O
4 O
mm O
) O
in O
lobar O
bronchus O
near O
the O
biopsy O
segment O
. O
[]

Secondary O
end O
points O
included O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
, O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
, O
and O
safety O
. O
['Mortality', 'Mortality']

The O
groups O
were O
balanced O
at O
baseline O
. O
[]

[ O
Encephalopathy O
therapeutic O
tongue O
acupoint O
apparatus O
( O
ETTAA O
) O
for O
42 O
cases O
of O
autism O
] O
. O
[]

Few O
studies O
have O
evaluated O
the O
impact O
of O
maintenance O
immunosuppression O
on O
blood O
humoral O
parameters O
. O
[]

In O
summary O
, O
the O
present O
data O
suggest O
that O
in O
patients O
with O
incidental O
adrenal O
adenomas O
the O
GH B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
GHRH O
is O
blunted O
due O
to O
increased O
somatostatinergic B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
, O
as O
it O
can O
be O
restored O
to O
normal O
by O
pretreatment O
with O
the O
functional O
somatostatin O
antagonist O
arginine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Forty-nine O
patients O
( O
40 O
with O
abnormal O
cell-mediated O
immunity O
) O
participated O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
to O
determine O
the O
effectiveness O
of O
high-dose O
intravenously O
administered O
immunoglobulin O
G. O
The O
patients O
received O
three O
intravenous O
infusions O
of O
a O
placebo O
solution O
or O
immunoglobulin O
at O
a O
dose O
of O
2 O
g/kg/month O
. O
[]

No O
significant O
differences O
between O
the O
two O
treatment O
groups O
were O
observed O
for O
the O
coagulation B-outcome ['Resource-use']
products I-outcome ['Resource-use']
prothrombin B-outcome ['Physiological-Clinical']
fragment O
1+2 O
or O
thrombin-antithrombin B-outcome ['Physiological-Clinical']
complex I-outcome ['Physiological-Clinical']
or O
for O
D-dimer B-outcome ['Physiological-Clinical']
, O
although O
there O
were O
significant O
decreases O
in O
the O
levels O
within O
the O
hormone O
replacement O
therapy O
group O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
long-term O
results O
of O
a O
randomized O
clinical O
trial O
evaluating O
the O
effect O
of O
postoperative O
radiotherapy O
as O
an O
adjuvant O
to O
radical O
mastectomy O
are O
presented O
. O
[]

A O
replication O
on O
a O
French O
sample O
. O
[]

RESULTS O
Back B-outcome ['Physiological-Clinical']
extensor I-outcome ['Physiological-Clinical']
strength B-outcome ['Physiological-Clinical']
significantly I-outcome ['Physiological-Clinical']
increased O
both O
in O
the O
exercise O
group O
( O
26 O
% O
) O
and O
in O
the O
control O
group O
( O
11 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Triglyceride B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
levels O
were O
unchanged O
. O
['Physiological-Clinical', 'Physiological-Clinical']

With O
a O
median O
follow-up O
of O
23 O
months O
, O
the O
estimated O
2-year O
overall O
survival O
time O
to O
failure O
( O
TTF O
) O
, O
and O
time B-outcome ['Mortality']
to I-outcome ['Mortality']
relapse I-outcome ['Mortality']
( I-outcome ['Mortality']
TTR I-outcome ['Mortality']
) I-outcome ['Mortality']
survival I-outcome ['Mortality']
are O
67 O
% O
, O
56 O
% O
, O
and O
67 O
% O
, O
respectively O
. O
['Mortality']

MAIN O
RESULTS O
Of O
132 O
eligible O
patients O
, O
113 O
were O
randomized O
. O
[]

Stress O
measures O
were O
administered O
3 O
months O
after O
surgery O
and O
at O
the O
first O
visit O
after O
the O
visual O
acuity O
( O
VA O
) O
assessment O
done O
at O
12 O
months O
of O
age O
. O
[]

A O
double-blind O
, O
placebo-controlled O
, O
parallel O
groups O
design O
with O
fixed O
dose O
was O
used O
, O
with O
random O
assignment O
to O
naltrexone O
or O
placebo O
. O
[]

These O
results O
suggest O
a O
differential O
responsivity O
of O
both O
cortical B-outcome ['Physiological-Clinical']
region I-outcome ['Physiological-Clinical']
and O
EEG O
frequency O
['Physiological-Clinical']

Sustained O
effect O
of O
SQ-standardized O
grass O
allergy O
immunotherapy O
tablet O
on O
rhinoconjunctivitis O
quality O
of O
life O
. O
[]

and O
in O
transfusion O
requirements O
( O
7.5 O
% O
vs. O
10 O
% O
; O
n.s. O
) O
. O
[]

FINDINGS O
Weal B-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
, O
and O
thus O
envenomisation O
, O
increased O
as O
the O
time B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
stinging I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
removal I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
sting I-outcome ['Physiological-Clinical']
increased O
, O
even O
within O
a O
few O
seconds O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
age- O
and O
weight-adjusted O
infusions O
( O
determined O
with O
STANPUMP O
, O
a O
computer O
modeling O
software O
package O
) O
were O
given O
to O
achieve O
three O
predicted O
constant O
plasma O
levels O
for O
40 O
min O
each O
of O
remifentanil O
( O
0.75 O
, O
1.5 O
, O
and O
3 O
ng/ml O
) O
and O
alfentanil O
( O
16 O
, O
32 O
, O
and O
64 O
ng/ml O
) O
. O
[]

It O
is O
well-known O
that O
many O
athletes O
experience O
some O
form O
of O
precompetition O
stress O
that O
may O
result O
in O
insomnia O
during O
the O
night O
before O
their O
competition O
. O
[]

We O
collected O
the O
following O
measures O
of O
safety O
and O
tolerability B-outcome ['Life-Impact']
: O
( O
1 O
) O
laboratory B-outcome ['Physiological-Clinical']
blood B-outcome ['Physiological-Clinical']
assessments O
( O
CBC O
with O
differential O
, O
electrolytes O
, O
and O
liver O
function O
tests O
) O
and O
urinalyses O
, O
( O
2 O
) O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
, O
( O
3 O
) O
Side B-outcome ['Adverse-effects']
Effects I-outcome ['Adverse-effects']
Review O
of O
AEs O
thought O
to O
be O
associated O
with O
risperidone O
, O
( O
4 O
) O
sleep B-outcome ['Physiological-Clinical']
records I-outcome ['Physiological-Clinical']
, O
( O
5 O
) O
Simpson O
Angus O
Neurological O
Rating O
Scale O
( O
SARS O
) O
, O
( O
6 O
) O
Abnormal O
Involuntary O
Movement O
Scale O
( O
AIMS O
) O
, O
and O
( O
7 O
) O
height B-outcome ['Physiological-Clinical']
and O
weight B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

was O
given O
on O
all O
study O
days O
and O
each O
volunteer O
was O
randomised O
to O
receive O
45 O
min O
infusion O
of O
either O
5 O
% O
D-glucose O
( O
placebo O
) O
or O
ANF O
( O
99-126 O
) O
3 O
or O
15 O
pmol O
kg-1 O
min-1 O
. O
[]

Prevention O
of O
bone O
loss O
in O
survivors O
of O
breast O
cancer O
: O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
clinical O
trial O
. O
[]

Assessment O
in O
multisite O
randomized O
clinical O
trials O
of O
patients O
with O
autistic B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
: O
the O
Autism O
RUPP O
Network O
. O
['Life-Impact']

6.1 O
mL O
; O
both O
p O
< O
0.0001 O
) O
, O
respectively O
. O
[]

[ O
Obstetrical O
analgesia O
with O
tramadol O
] O
. O
[]

CONCLUSION O
Ciprodex O
reduced O
early B-outcome ['Physiological-Clinical']
post-operative I-outcome ['Physiological-Clinical']
otorrhea I-outcome ['Physiological-Clinical']
, O
clinically B-outcome ['Physiological-Clinical']
diagnosed I-outcome ['Physiological-Clinical']
OM I-outcome ['Physiological-Clinical']
and O
effusion B-outcome ['Physiological-Clinical']
following O
TT O
insertion O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
ETT O
with O
selective O
follow-up O
testing O
should O
be O
considered O
as O
the O
initial O
diagnostic O
strategy O
in O
symptomatic O
women O
with O
suspected O
CAD O
. O
[]

Efficacy O
and O
safety O
of O
zidovudine O
and O
zalcitabine O
combined O
with O
a O
combination O
of O
herbs O
in O
the O
treatment O
of O
HIV-infected O
Thai O
patients O
. O
[]

There O
were O
not O
significant O
effects O
on O
ODD B-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
stereotyped I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
repetitive I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
. O
['Life-Impact']

Eligibility O
criteria O
included O
( O
1 O
) O
primary O
PBSCT O
, O
( O
2 O
) O
chemotherapy-responsive O
disease O
, O
and O
( O
3 O
) O
collected O
cell O
number O
> O
1 O
x O
10 O
( O
5 O
) O
colony-forming O
unit-granulocyte-macrophage O
( O
CFU-GM O
) O
/kg O
and O
> O
1 O
x O
10 O
( O
6 O
) O
CD34 O
( O
+ O
) O
cells/kg O
patient O
's O
body O
weight O
. O
[]

Silver O
nanoparticles O
( O
NNPs O
) O
, O
alone O
or O
in O
combination O
with O
the O
bioadhesive O
Gantrez O
S-97 O
, O
have O
demonstrated O
their O
efficacy O
against O
Streptococcus O
mutans O
; O
however O
, O
it O
is O
not O
known O
if O
this O
combination O
changes O
the O
color B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
teeth I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
authors O
discuss O
the O
supported O
psychological O
process O
as O
a O
potential O
explanation O
for O
several O
well-established O
findings O
reported O
in O
the O
literature O
on O
confessions O
. O
[]

One O
important O
pathogenic O
factor O
in O
dialysis O
hypotension O
is O
the O
drop O
in O
plasma O
osmolality O
. O
[]

Significant O
errors O
of O
recalibration B-outcome ['Physiological-Clinical']
occur O
in O
6 O
% O
of O
calibrations O
. O
['Physiological-Clinical']

Thiopental O
0.5 O
mg/kg O
was O
the O
most O
effective O
treatment O
. O
[]

INTERVENTIONS O
Random O
allocation O
to O
12 O
weeks O
of O
either O
graded O
aerobic O
exercise O
or O
flexibility O
exercises O
and O
relaxation O
therapy O
. O
[]

SUBJECTS O
Eleven O
healthy O
male O
volunteers O
. O
[]

PATIENTS O
99 O
patients O
with O
severe O
pain O
following O
surgery O
. O
[]

BACKGROUND O
Low-dose O
dopamine O
, O
a O
renal O
vasodilator O
, O
has O
been O
used O
empirically O
to O
improve O
renal O
function O
or O
outcome O
in O
critically O
ill O
patients O
with O
oliguria O
or O
acute O
renal O
failure O
. O
[]

CBR B-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
20 O
mg O
arm O
according O
to O
the O
investigator O
( O
64.3 O
% O
versus O
61.4 O
% O
) O
and O
the O
independent O
review O
panel O
( O
59.5 O
% O
versus O
47.7 O
% O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
Results O
support O
the O
use O
of O
interventions O
early O
in O
treatment O
to O
provide O
information O
and O
social O
support O
to O
establish O
long-term O
healthy O
adherence O
behaviors O
. O
[]

Measures O
, O
blind O
to O
treatment O
order O
, O
included O
parent O
and O
teacher O
ratings O
of O
behavior B-outcome ['Life-Impact']
, O
direct B-outcome ['Physiological-Clinical']
observational I-outcome ['Physiological-Clinical']
recordings I-outcome ['Physiological-Clinical']
, O
IQ B-outcome ['Life-Impact']
, O
language B-outcome ['Life-Impact']
, O
and O
social/adaptive B-outcome ['Life-Impact']
tests O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
effect O
of O
HCG O
supplementation O
after O
combined O
GnRH O
agonist/HMG O
treatment O
in O
an O
IVF O
programme O
. O
[]

To O
develop O
a O
minimal O
disturbance O
approach O
in O
estimating O
Si O
and O
[]

The O
primary O
endpoint O
was O
30-day O
mortality O
. O
[]

1 O
days O
) O
. O
[]

The O
mean O
DFT B-outcome ['Resource-use']
significantly O
increased O
from O
10.9+/-6.1 O
J O
at O
10 O
s O
of O
VF O
to O
12.6+/-5.6 O
J O
( O
p=0.03 O
) O
at O
20 O
s O
of O
VF O
, O
and O
from O
7.0+/-3.5 O
J O
at O
5 O
s O
of O
VF O
to O
10.5+/-6.3 O
J O
( O
p=0.04 O
) O
at O
20 O
s O
of O
VF O
. O
['Resource-use']

Overall O
, O
individual O
or O
total O
lignans O
or O
proanthocyanidins O
were O
not O
associated O
with O
colorectal B-outcome ['Physiological-Clinical']
adenoma I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Due O
to O
the O
richness O
of O
the O
neural O
pathways O
in O
the O
auditory O
system O
and O
the O
redundancy O
of O
acoustic O
information O
in O
spoken O
language O
, O
a O
normal O
listener O
is O
able O
to O
recognize O
speech O
even O
when O
parts O
of O
the O
signal O
are O
missing O
, O
whereas O
this O
ability O
is O
often O
impaired O
in O
listeners O
with O
APD O
. O
[]

The O
calculated O
maximal B-outcome ['Life-Impact']
tolerable I-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
was O
substantially O
greater O
in O
the O
presence O
of O
pyridostigmine O
: O
355 O
+/- O
90 O
versus O
260 O
+/- O
115 O
mg O
every O
6 O
hours O
( O
p O
less O
than O
0.001 O
) O
. O
['Life-Impact']

We O
believe O
that O
the O
video O
assisted O
thoracoscopy O
( O
VATS O
) O
is O
the O
best O
treatment O
possible O
because O
it O
allows O
us O
to O
treat O
the O
ruptured O
bleb O
radically O
avoiding O
any O
recurrence O
. O
[]

Blood O
samples O
were O
taken O
via O
a O
venous O
cannula O
immediately O
before O
( O
fasting O
) O
and O
2 O
, O
4 O
, O
6 O
, O
7 O
, O
8 O
and O
10 O
h O
post-ingestion O
. O
[]

If O
yoga O
is O
found O
effective O
, O
further O
analyses O
will O
explore O
whether O
yoga O
's O
benefits O
are O
attributable O
to O
physical O
, O
psychological O
and/or O
physiological O
factors O
. O
[]

The O
use O
of O
this O
scoring O
system O
in O
choosing O
the O
route O
of O
antibiotic O
administration O
is O
recommended O
. O
[]

Finally O
, O
these O
data O
challenge O
any O
claim O
that O
drospirenone O
, O
as O
currently O
used O
in O
a O
contraceptive O
, O
is O
a O
clinically O
significant O
antiandrogen O
. O
[]

We O
evaluated O
the O
efficacy O
and O
safety O
of O
conatumumab O
( O
an O
agonistic O
monoclonal O
antibody O
against O
human O
death O
receptor O
5 O
) O
and O
ganitumab O
( O
a O
monoclonal O
antibody O
against O
the O
type O
1 O
insulin-like O
growth O
factor O
receptor O
) O
combined O
with O
standard O
FOLFIRI O
chemotherapy O
as O
a O
second-line O
treatment O
in O
patients O
with O
mutant O
KRAS O
mCRC O
. O
[]

In O
the O
RTD O
group O
, O
the O
effective O
rate O
was O
70 O
% O
, O
the O
mean O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
was O
8.2 O
months O
, O
and O
the O
6-month O
survival B-outcome ['Mortality']
rate O
was O
79.7 O
% O
. O
['Mortality', 'Mortality']

Once O
enrolled O
, O
patients O
are O
given O
a O
trial O
of O
intranasal O
FloSeal O
hemostatic O
matrix O
to O
abort O
the O
epistaxis O
. O
[]

This O
double-blind O
, O
placebo-controlled O
, O
randomized O
multicenter O
study O
evaluated O
the O
antihypertensive B-outcome ['Resource-use']
efficacy O
and O
safety O
of O
cetamolol O
hydrochloride O
in O
108 O
patients O
diagnosed O
as O
having O
mild O
to O
moderate O
hypertension O
. O
['Resource-use']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
During O
CPAP O
withdrawal O
, O
severe B-outcome ['Physiological-Clinical']
sleep-disordered I-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
was O
evident O
and O
administration O
of O
modafinil O
improved O
simulated O
driving O
performance B-outcome ['Life-Impact']
( O
steering B-outcome ['Life-Impact']
variability I-outcome ['Life-Impact']
, O
P O
< O
0.0001 O
; O
mean O
reaction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
P O
< O
or= O
0.0002 O
; O
lapses B-outcome ['Life-Impact']
, O
P O
< O
or= O
0.01 O
on O
a O
concurrent O
task O
) O
, O
psychomotor B-outcome ['Life-Impact']
vigilance I-outcome ['Life-Impact']
task O
( O
mean O
1/reaction O
time O
and O
lapses O
, O
both O
P O
< O
or= O
0.0002 O
) O
, O
and O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Groups O
3 O
and O
4 O
received O
continuous O
positive O
airway O
pressure O
of O
5 O
cm O
H O
( O
2 O
) O
O O
with O
100 O
% O
( O
group O
3 O
) O
or O
21 O
% O
oxygen O
( O
group O
4 O
) O
; O
and O
in O
group O
5 O
, O
each O
patient O
's O
airway O
was O
disconnected O
from O
the O
ventilator O
( O
passive O
deflation O
) O
. O
[]

With O
the O
comparable O
relaxivities O
of O
gadodiamide O
injection O
and O
gadopentetate O
dimeglumine O
, O
similarities O
in O
results O
have O
to O
be O
expected O
when O
using O
these O
media O
for O
MR O
image O
enhancement O
. O
[]

Tailored O
materials O
appeared O
to O
have O
no O
effect O
but O
were O
highly O
regarded O
. O
[]

For O
example O
, O
the O
[]

In O
addition O
, O
response O
to O
treatment O
was O
positively O
correlated O
with O
plasma O
levels O
of O
ADA O
only O
in O
the O
clozapine O
group O
( O
r O
= O
0.46 O
and O
p O
= O
0.04 O
) O
. O
[]

There O
were O
no O
differences O
in O
maternal B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
, O
fetal B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FHR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
Apgar I-outcome ['Physiological-Clinical']
scores O
between O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
statistically O
significant O
differences O
in O
the O
amount O
of O
increase O
between O
women O
who O
underwent O
different O
interventions O
. O
[]

PURPOSE O
To O
compare O
the O
effectiveness O
of O
diclofenac O
and O
ketorolac O
in O
relieving B-outcome ['Physiological-Clinical']
corneal I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
refractive O
surgery O
, O
and O
determine O
if O
there O
is O
a O
difference O
in O
stinging O
on O
instillation O
. O
['Physiological-Clinical']

METHODS O
409 O
patients O
with O
malignant O
pleural O
mesothelioma O
, O
from O
76 O
centres O
in O
the O
UK O
and O
two O
in O
Australia O
, O
were O
randomly O
assigned O
to O
ASC O
alone O
( O
treatment O
could O
include O
steroids O
, O
analgesic O
drugs O
, O
bronchodilators O
, O
palliative O
radiotherapy O
[ O
n=136 O
] O
) O
; O
to O
ASC O
plus O
MVP O
( O
four O
cycles O
of O
mitomycin O
6 O
mg/m2 O
, O
vinblastine O
6 O
mg/m2 O
, O
and O
cisplatin O
50 O
mg/m2 O
every O
3 O
weeks O
[ O
n=137 O
] O
) O
; O
or O
to O
ASC O
plus O
vinorelbine O
( O
one O
injection O
of O
vinorelbine O
30 O
mg/m2 O
every O
week O
for O
12 O
weeks O
[ O
n=136 O
] O
) O
. O
[]

Preparing O
and O
treating O
the O
enamel O
surface O
exclusively O
by O
Er O
: O
YAG O
laser O
resulted O
in O
the O
highest O
degree O
of O
leakage B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
frequencies O
of O
intramammary B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
caused I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
Staph I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
5-mg O
dose O
of O
droperidol O
had O
no O
inhibitory B-outcome ['Physiological-Clinical']
effect O
. O
['Physiological-Clinical']

Doxorubicin O
and O
docetaxel O
( O
AT O
) O
is O
one O
of O
the O
most O
active O
cytotoxic O
regimens O
for O
metastatic B-outcome ['Physiological-Clinical']
breast I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BIS O
delivers O
a O
complex O
intervention O
( O
of O
non-pharmacological O
and O
pharmacological O
treatments O
) O
via O
a O
multi-professional O
team O
. O
[]

Arthroscopic O
rotator O
cuff O
repair O
with O
and O
without O
acromioplasty O
in O
the O
treatment O
of O
full-thickness O
rotator O
cuff O
tears O
: O
a O
multicenter O
, O
randomized O
controlled O
trial O
. O
[]

The O
absolute O
mean O
decrease O
in O
delta O
value O
was O
1.9 O
+/- O
3.7 O
cm O
in O
the O
PC O
group O
and O
0.5 O
+/- O
3.3 O
cm O
in O
the O
control O
group O
. O
[]

Its O
protective O
effect O
is O
related O
to O
cardiac O
cooling O
and O
metabolism O
reduction O
, O
oxygen O
supply O
from O
erythrocytes O
, O
and O
reactive O
oxygen O
species O
scavenging O
. O
[]

CONCLUSION O
Patients O
receiving O
higher O
doses O
of O
foscarnet O
have O
slower O
rates O
of O
progression O
and O
therefore O
less O
retinal O
tissue O
damage O
during O
maintenance O
therapy O
. O
[]

The O
thermoregulatory B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
clonidine O
thus O
resemble O
those O
of O
volatile O
anesthetics O
, O
opioids O
, O
and O
propofol O
. O
['Physiological-Clinical']

We O
conclude O
that O
serotoninergic O
neurotransmission O
plays O
an O
important O
part O
in O
post-stroke O
pathological O
crying O
and O
that O
citalopram O
is O
an O
effective O
and O
well-tolerated O
treatment O
. O
[]

On O
the O
telephone O
interview O
, O
100 O
% O
of O
patients O
expressed O
satisfaction O
for O
the O
experienced O
intraoperative B-outcome ['Physiological-Clinical']
tranquillity I-outcome ['Physiological-Clinical']
, O
91.3 O
% O
complained O
for O
not O
having O
received O
in O
the O
past O
a O
similar O
preoperative O
visit O
, O
99.3 O
% O
wished O
a O
diffused B-outcome ['Physiological-Clinical']
application I-outcome ['Physiological-Clinical']
of O
the O
information O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Participants O
allocated O
to O
the O
control O
group O
will O
receive O
arm O
therapy O
in O
accordance O
with O
usual O
care O
. O
[]

The O
group O
receiving O
bevacizumab O
had O
better O
BCVA B-outcome ['Physiological-Clinical']
and O
lower O
CMT B-outcome ['Physiological-Clinical']
values O
at O
all O
time O
points O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Veterans O
Administration O
Cooperative O
Study O
on O
antiplatelet O
agents O
in O
diabetic O
patients O
after O
amputation O
for O
gangrene O
: O
II O
. O
[]

The O
mean O
increase O
was O
402 O
% O
( O
41 O
+/- O
20 O
sec O
to O
169 O
+/- O
66 O
sec O
) O
for O
the O
placebo O
group O
and O
286 O
% O
( O
42 O
+/- O
16 O
to O
120 O
+/- O
57 O
sec O
) O
in O
the O
antacid O
group O
. O
[]

The O
results O
revealed O
that O
55 O
% O
of O
women O
were O
regularly O
active O
. O
[]

Those O
who O
flared O
were O
randomly O
assigned O
to O
amiprilose O
HCl O
, O
6 O
g/d O
, O
or O
placebo O
for O
12 O
weeks O
. O
[]

The O
treatment O
effect O
of O
grass O
AIT O
during O
the O
follow-up O
year O
and O
the O
previous O
three O
treatment O
years O
was O
similar O
. O
[]

1 O
Increases O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
following O
graded O
intravenous O
bolus O
injections O
of O
isoprenaline O
sulphate O
, O
were O
measured O
in O
a O
double-blind O
randomised O
study O
of O
six O
subjects O
who O
received O
either O
placebo O
, O
practolol O
50 O
mg O
, O
practolol O
200 O
mg O
, O
propranolol O
10 O
mg O
or O
propranolol O
40 O
mg. O
2 O
Dose O
related O
increases O
in O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
were O
produced O
by O
the O
graded O
boluses O
of O
isoprenaline O
sulphate O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Incidence O
of O
major B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
, O
death B-outcome ['Mortality']
related O
to O
infection B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

Because O
our O
data O
are O
hampered O
by O
the O
lack O
of O
predictivity O
of O
the O
selected O
biomarkers O
, O
additional O
studies O
are O
necessary O
to O
assess O
the O
activity O
of O
fenretinide O
in O
preventing O
bladder O
cancer O
. O
[]

HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
change O
differed O
among O
groups O
but O
without O
significant O
post O
hoc O
differences O
. O
['Physiological-Clinical']

The O
effectiveness O
of O
Interceed B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TC7 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
evaluated O
at O
laparoscopy O
10-98 O
days O
after O
laparotomy O
. O
['Physiological-Clinical']

A O
1-month O
washout O
period O
was O
completed O
before O
the O
crossover O
trial O
. O
[]

Important O
demographic O
and O
skin O
cancer O
risk O
factor O
differences O
in O
sun O
protective O
behaviors O
and O
stages O
of O
change O
for O
sun O
protection O
were O
found O
, O
especially O
differences O
based O
on O
age O
, O
gender O
, O
and O
degree O
of O
sun O
sensitivity O
. O
[]

Nasal O
oxytocin O
for O
social O
deficits O
in O
childhood O
autism O
: O
a O
randomized O
controlled O
trial O
. O
[]

Ozone O
gas O
was O
applied O
for O
80 O
s. O
Shear O
bond O
strength O
was O
measured O
with O
a O
universal O
testing O
machine O
. O
[]

Predictive O
validity O
of O
a O
medication O
adherence O
measure O
in O
an O
outpatient O
setting O
. O
[]

We O
evaluated O
the O
effects O
of O
RRR-alpha-tocpheryl O
acetate O
( O
alpha-tocopheryl O
acetate O
) O
and O
hormone-replacement O
therapy O
( O
HRT O
) O
on O
the O
oxidative O
susceptibility O
of O
low-density O
lipoprotein O
( O
LDL O
) O
in O
postmenopausal O
women O
consuming O
a O
fish O
oil O
supplement O
. O
[]

Two O
out O
of O
three O
of O
those O
offered O
a O
health O
talk O
with O
the O
general O
practitioner O
appeared O
willing O
to O
make O
relevant O
lifestyle O
changes O
. O
[]

No O
such O
disturbances O
were O
observed O
in O
the O
present O
study O
. O
[]

Moreover O
, O
86 O
% O
of O
support O
persons O
in O
the O
intervention O
group O
completed O
all O
five O
telephone O
sessions O
. O
[]

Compared O
to O
caregivers O
and O
toddlers O
randomized O
to O
the O
waitlist O
control O
group O
the O
immediate O
treatment O
( O
IT O
) O
group O
made O
significant O
improvements O
in O
targeted O
areas O
of O
joint B-outcome ['Life-Impact']
engagement I-outcome ['Life-Impact']
. O
['Life-Impact']

Reductions O
in O
BMI B-outcome ['Physiological-Clinical']
were O
observed O
in O
both O
groups O
at O
T2 O
( O
P O
< O
0.05 O
) O
, O
but O
only O
group O
C O
exhibited O
a O
reduction O
in O
WC B-outcome ['Physiological-Clinical']
( O
P O
= O
0.005 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SAR O
patients O
were O
identified O
by O
history O
, O
skin-prick O
test O
and O
specific O
IgE O
. O
[]

Efficacy O
was O
measured O
through O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
scores O
, O
number O
of O
daily B-outcome ['Life-Impact']
doses I-outcome ['Life-Impact']
of O
study O
medication B-outcome ['Resource-use']
, O
number O
of O
daily O
doses B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
supplemental I-outcome ['Life-Impact']
analgesics I-outcome ['Life-Impact']
, O
number O
of O
patients O
who O
discontinued B-outcome ['Life-Impact']
therapy B-outcome ['Resource-use']
due O
to O
an O
unsatisfactory B-outcome ['Life-Impact']
analgesic I-outcome ['Life-Impact']
response I-outcome ['Life-Impact']
, O
and O
global O
assessment O
scores O
. O
['Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Life-Impact', 'Life-Impact', 'Resource-use', 'Life-Impact']

Evidence-based O
treatments O
for O
depressive O
disorder O
are O
already O
available O
, O
but O
these O
are O
used O
insufficiently O
, O
and O
with O
less O
positive O
results O
than O
possible O
. O
[]

The O
probability O
that O
phenytoin O
has O
any O
prophylactic B-outcome ['Resource-use']
efficacy O
is O
0.383 O
. O
['Resource-use']

Despite O
intriguing O
results O
from O
laboratory O
studies O
, O
previous O
epidemiological O
studies O
showed O
inconsistent O
associations O
of O
circulating O
levels O
of O
25 O
( O
OH O
) O
D O
, O
1,25 O
( O
OH O
) O
2D O
, O
and O
several O
VDR O
polymorphisms O
with O
prostate O
cancer O
risk O
. O
[]

Large O
bleeding O
gastric O
varices O
in O
20 O
heparinized O
dogs O
were O
randomized O
to O
endoscopic O
injection O
treatment O
with O
one O
of O
the O
following O
agents O
: O
cyanoacrylate O
; O
a O
1:1:1 O
mixture O
of O
sodium O
tetradecyl O
sulfate O
3 O
% O
, O
ethanol O
98 O
% O
, O
and O
normal O
saline O
solution O
; O
ethanolamine O
oleate O
5 O
% O
; O
sodium O
morrhuate O
5 O
% O
; O
sodium O
tetradecyl O
sulfate O
1.5 O
% O
; O
polidocanol O
1 O
% O
; O
normal O
saline O
solution O
with O
epinephrine O
1:10,000 O
; O
or O
normal O
saline O
solution O
( O
control O
) O
. O
[]

Thirty O
patients O
scheduled O
for O
aortic O
valve O
replacement O
were O
included O
. O
[]

METHODS O
58 O
growth-retarded O
SGA O
children O
aged O
2-5 O
years O
were O
randomized O
to O
a O
TOTO O
regimen O
( O
4 O
years O
alternating O
treatment O
( O
T O
) O
and O
observation O
( O
O O
) O
, O
n O
= O
30 O
) O
or O
a O
TTOO O
regimen O
( O
2 O
years O
' O
treatment O
, O
followed O
by O
2 O
years O
' O
observation O
, O
n O
= O
28 O
) O
. O
[]

This O
metabolite B-outcome ['Physiological-Clinical']
is O
detected O
in O
plasma O
in O
concentrations O
ten O
times O
lower O
than O
the O
parent O
compound O
. O
['Physiological-Clinical']

Randomized O
, O
placebo-controlled O
, O
phase O
III O
trial O
of O
sunitinib O
plus O
prednisone O
versus O
prednisone O
alone O
in O
progressive O
, O
metastatic O
, O
castration-resistant O
prostate O
cancer O
. O
[]

CONCLUSIONS O
This O
study O
demonstrates O
a O
clinically O
small O
but O
statistically O
significant O
value O
to O
customizing O
reminder O
letters O
. O
[]

Patients O
with O
solid O
malignancies O
( O
n O
= O
23 O
) O
received O
AUTO O
. O
[]

Fellow O
eyes O
of O
both O
groups O
remained O
untreated O
as O
a O
natural O
control O
. O
[]

Of O
720 O
patients O
screened O
, O
306 O
eligible O
patients O
were O
enrolled O
. O
[]

We O
analysed O
data O
from O
5161 O
patients O
undergoing O
general O
anaesthesia O
who O
were O
randomly O
stratified O
to O
receive O
a O
combination O
of O
six O
interventions O
, O
one O
of O
which O
was O
4 O
mg O
ondansetron O
vs O
placebo O
. O
[]

The O
major O
trial O
end O
points O
include O
death B-outcome ['Mortality']
, O
new B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
and O
new B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
angioplasty I-outcome ['Physiological-Clinical']
or O
coronary B-outcome ['Resource-use']
artery I-outcome ['Resource-use']
bypass I-outcome ['Resource-use']
procedures I-outcome ['Resource-use']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

OBJECTIVE O
Parameters O
of O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
were O
quantitated O
in O
50 O
patients O
with O
type O
2 O
diabetes O
mellitus O
in O
uncontrolled O
state O
and O
after O
control O
using O
oral O
glibenclamide O
or O
gliclazide O
. O
['Physiological-Clinical']

Prolonged O
GnRH O
agonist O
and O
add-back O
therapy O
for O
symptomatic B-outcome ['Physiological-Clinical']
endometriosis I-outcome ['Physiological-Clinical']
: O
long-term O
follow-up O
. O
['Physiological-Clinical']

The O
patients O
were O
treated O
with O
penbutolol O
and O
placebo O
for O
a O
period O
of O
three O
days O
, O
and O
then O
were O
examined O
with O
the O
help O
of O
the O
glucose-controlled O
insulin O
infusion O
system O
. O
[]

Immunoresponsiveness B-outcome ['Physiological-Clinical']
to O
both O
vaccines O
increased O
with O
age O
. O
['Physiological-Clinical']

The O
percentage O
mean O
treatment O
difference O
between O
Abalon O
and O
placebo O
demonstrated O
significantly O
lower O
mean O
values O
after O
Abalon O
for O
LDL B-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
( O
10 O
+/- O
15 O
% O
, O
P O
< O
0.05 O
) O
, O
LDL/UHDL B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
( O
12 O
+/- O
18 O
% O
, O
P O
< O
0.05 O
) O
, O
apolipoprotein B-outcome ['Physiological-Clinical']
( O
apo O
) O
B100 O
( O
30 O
+/- O
38 O
% O
, O
P O
< O
0.01 O
) O
, O
triglycerides B-outcome ['Physiological-Clinical']
( O
22 O
+/- O
10 O
% O
, O
P O
< O
0.05 O
) O
, O
and O
homocysteine B-outcome ['Physiological-Clinical']
( O
14 O
+/- O
21 O
% O
, O
P O
< O
0.01 O
) O
, O
whereas O
the O
total O
cholesterol B-outcome ['Physiological-Clinical']
value O
tended O
to O
be O
less O
significant O
but O
still O
lower O
( O
8 O
+/- O
15 O
% O
, O
P O
< O
0.08 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Fifty O
alcoholic O
inpatients O
were O
randomly O
assigned O
to O
the O
PALS O
program O
( O
n O
= O
25 O
) O
or O
to O
the O
library O
for O
free O
reading O
time O
( O
n O
= O
25 O
) O
. O
[]

CONCLUSIONS O
Simple O
drainage O
with O
continuous O
irrigation O
of O
the O
presacral O
space O
, O
in O
patients O
with O
abdominoperineal O
resection O
or O
proctocolectomy O
, O
could O
significantly O
lower O
the O
incidence O
of O
major O
complication O
and O
improve O
wound O
healing O
for O
perineal O
wound O
when O
compared O
with O
simple O
drainage O
only O
. O
[]

A O
psychological O
intervention O
reduces O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
by O
alleviating O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
: O
secondary O
analysis O
of O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical', 'Life-Impact']

We O
used O
mixed O
linear O
modeling O
of O
log-transformed O
swim O
time O
to O
quantify O
effects O
on O
performance B-outcome ['Life-Impact']
in O
training O
versus O
competition O
, O
in O
morning O
versus O
evening O
swims O
, O
and O
with O
use O
of O
caffeine O
. O
['Life-Impact']

Follow-up O
data O
was O
available O
on O
14 O
subjects O
in O
the O
NAC O
group O
and O
15 O
in O
the O
placebo O
group O
. O
[]

There O
was O
an O
increase O
in O
fasting B-outcome ['Physiological-Clinical']
and O
glucagon-stimulated B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
C-peptide I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
during O
propranolol O
therapy O
compared O
with O
placebo O
( O
p O
= O
0.037 O
and O
p O
= O
0.030 O
, O
respectively O
) O
, O
although O
this O
was O
not O
reflected O
by O
a O
significant O
change O
in O
serum B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Long-term O
efficacy O
of O
subcutaneous O
sumatriptan O
using O
a O
novel O
self-injector O
. O
[]

Highly O
significant O
differences O
between O
brushing O
and O
no O
brushing O
plaque B-outcome ['Physiological-Clinical']
indices O
and O
areas O
were O
determined O
. O
['Physiological-Clinical']

Pathological O
features O
and O
inhaled O
corticosteroid O
response O
of O
eosinophilic O
and O
non-eosinophilic O
asthma O
. O
[]

RESULTS O
For O
the O
204 O
patients O
evaluable O
for O
response O
assessment O
, O
the O
response O
rates O
were O
48.6 O
% O
for O
GP1 O
, O
52.2 O
% O
for O
GP2 O
, O
and O
52.3 O
% O
for O
GD O
. O
[]

Long-term O
follow-up O
of O
three O
randomized O
trials O
comparing O
idarubicin O
and O
daunorubicin O
as O
induction O
therapies O
for O
patients O
with O
untreated O
acute O
myeloid O
leukemia O
. O
[]

Their O
median O
age O
was O
31 O
years O
( O
range O
, O
22-59 O
) O
and O
14 O
patients O
were O
males O
and O
12 O
were O
females O
. O
[]

The O
primary O
end O
point O
was O
response O
to O
treatment B-outcome ['Resource-use']
: O
at O
least O
20 O
% O
improvement O
from O
basal O
conditions O
on O
clinical O
, O
laboratory O
, O
or O
specific O
neurological O
testing O
variables O
. O
['Resource-use']

METHODS O
Fifty-eight O
patients O
with O
posterior O
benign O
paroxysmal O
positional O
vertigo O
were O
randomly O
assigned O
to O
treatment O
and O
control O
groups O
using O
a O
block O
of O
four O
. O
[]

52 O
U/L O
vs. O
298 O
? O
[]

Fat B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
was O
studied O
in O
24 O
patients O
with O
clinically O
definite O
multiple O
sclerosis O
and O
in O
36 O
healthy O
control O
subjects O
. O
['Physiological-Clinical']

Measurements O
across O
an O
exercising O
leg O
were O
taken O
to O
be O
a O
surrogate O
for O
active O
skeletal O
muscle O
. O
[]

Significantly O
lower O
( O
p O
< O
0.02 O
) O
plasma O
beta-glucuronidase O
levels O
were O
found O
in O
arterial O
blood O
samples O
in O
Group O
I O
compared O
to O
Group O
II O
( O
5.59 O
? O
[]

SUMMARY O
OF O
BACKGROUND O
DATA O
Improving O
the O
control O
of O
lumbar O
NZ O
and O
enhancing O
muscle O
activation O
patterns O
ensuring O
spinal O
stability O
have O
been O
proposed O
as O
means O
for O
secondary O
prevention O
of O
LBP B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Reactive O
balance O
adjustments O
to O
unexpected O
perturbations O
during O
human O
walking O
. O
[]

However O
, O
there O
were O
no O
significant O
differences O
in O
patients O
' O
assessment O
of O
symptoms O
and O
in O
review O
of O
facial O
photographs O
for O
rash B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
between O
treatment O
and O
observation O
sides O
. O
['Physiological-Clinical']

RESULTS O
In O
segments O
with O
diagnostic O
MCE O
, O
the O
segmental B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
ranged O
from O
14 O
% O
to O
65 O
% O
, O
and O
the O
specificity O
varied O
from O
78 O
% O
to O
95 O
% O
, O
depending O
on O
the O
dose O
of O
contrast O
agent O
. O
['Physiological-Clinical']

OBJECTIVES O
The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
factors O
associated O
with O
the O
favorable O
effect O
of O
pioglitazone O
on O
atheroma O
progression O
. O
[]

Clinical O
trial O
: O
marine O
lipid O
suppositories O
as O
laxatives O
. O
[]

Complication B-outcome ['Resource-use']
rates O
were O
similar O
for O
the O
two O
groups O
. O
['Resource-use']

Major B-outcome ['Physiological-Clinical']
hemorrhagic I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
occurred O
more O
frequently O
in O
the O
WASA O
group O
( O
WASA O
, O
n O
= O
35 O
; O
ASA O
, O
n O
= O
15 O
; O
P O
=.02 O
) O
. O
['Physiological-Clinical']

Radioiodine O
WBS O
and O
serum O
Tg O
measurements O
were O
performed O
after O
administration O
of O
recombinant O
human O
TSH O
and O
again O
after O
thyroid O
hormone O
withdrawal O
in O
each O
patient O
. O
[]

The O
mean O
+/- O
SD O
pain O
score O
was O
4.5 O
+/- O
2.0 O
at O
hysteroscopy O
and O
5.2 O
+/- O
2.1 O
at O
endometrial O
biopsy O
in O
the O
87 O
subjects O
given O
a O
paracervical O
block O
versus O
4.9 O
+/- O
2.2 O
and O
5.7 O
+/- O
2.4 O
in O
the O
90 O
women O
not O
given O
local O
anesthesia O
, O
without O
statistically O
significant O
differences O
. O
[]

Virological O
response O
was O
evaluated O
by O
HCV O
RNA O
PCR O
at O
week O
10 O
( O
initial O
response O
) O
, O
at O
the O
end O
of O
treatment O
( O
end O
of- O
treatment O
response O
) O
and O
at O
the O
end O
of O
24 O
weeks O
follow-up O
( O
sustained O
response O
) O
. O
[]

In O
the O
present O
study O
, O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
study O
was O
conducted O
to O
examine O
whether O
the O
Chinese O
medicinal O
herb O
complex O
, O
RG-CMH O
, O
which O
represents O
a O
mixture O
of O
rose O
geranium O
and O
extracts O
of O
G. O
tsugae O
, O
C. O
pilosula O
and O
A. O
sinensis O
, O
can O
improve O
the O
immune O
cell O
count O
of O
cancer O
patients O
receiving O
chemotherapy O
and/or O
radiotherapy O
to O
prevent O
leucopenia O
and O
immune O
impairment O
that O
usually O
occurs O
during O
cancer O
therapy O
. O
[]

No O
significant O
benefit O
was O
seen O
from O
18 O
agents O
, O
and O
one O
agent O
is O
still O
under O
evaluation O
. O
[]

A O
tone O
either O
followed O
the O
participants O
' O
voluntary O
movement O
or O
was O
computer O
generated O
. O
[]

The O
qualified O
success B-outcome ['Physiological-Clinical']
rate O
in O
the O
DSMMC O
group O
was O
statistically O
significant O
when O
compared O
with O
that O
in O
the O
DS O
group O
. O
['Physiological-Clinical']

CONTEXT O
GnRH O
agonist O
( O
GnRHa O
) O
monthly O
injections O
are O
frequently O
used O
in O
the O
treatment O
of O
central O
precocious O
puberty O
( O
CPP O
) O
. O
[]

P O
values O
less O
than O
0.05 O
were O
considered O
statistically O
significant O
. O
[]

Persistence O
of O
these O
structures O
leaves O
behind O
a O
sense O
of O
incomplete O
treatment O
, O
reducing O
the O
overall B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
on O
the O
part O
of O
the O
patient O
. O
['Life-Impact']

Patients O
in O
the O
placebo O
group O
required O
higher O
heparin O
doses O
( O
P O
< O
0.005 O
) O
for O
anticoagulation O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
total O
factor O
VII B-outcome ['Physiological-Clinical']
was O
measured O
by O
use O
of O
a O
chromogenic O
assay O
; O
plasma O
active O
FVII O
by O
a O
recently O
developed O
method O
using O
truncated O
tissue O
factor O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Evaluation O
of O
the O
effect O
of O
topical O
agents O
on O
radiation-induced B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
by O
reflectance O
spectrophotometry O
. O
['Physiological-Clinical']

Only O
a O
small O
percentage O
of O
students O
wore O
long B-outcome ['Physiological-Clinical']
sleeves I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
hat I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
brim I-outcome ['Physiological-Clinical']
before O
leaving O
for O
school O
. O
['Physiological-Clinical']

Determination O
of O
response O
to O
treatment O
was O
based O
on O
clinical O
course O
, O
repeat O
bone O
marrow O
biopsies O
, O
and O
aspirates B-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
( O
CBC O
) O
with O
WBC O
differential O
, O
platelet B-outcome ['Physiological-Clinical']
, O
and O
reticulocyte B-outcome ['Physiological-Clinical']
numbers O
at O
specified O
intervals O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
tested O
the O
validity O
of O
this O
assumption O
by O
measuring O
maximal B-outcome ['Physiological-Clinical']
voluntary I-outcome ['Physiological-Clinical']
cycling I-outcome ['Physiological-Clinical']
power I-outcome ['Physiological-Clinical']
before O
( O
mean O
+/- O
SD O
, O
1,075 O
+/- O
214 O
W O
) O
and O
immediately O
after O
( O
731 O
+/- O
206 O
W O
) O
( O
P O
< O
0.001 O
) O
exhaustive O
cycling O
exercise O
at O
242 O
+/- O
24 O
W O
( O
80 O
% O
of O
peak O
aerobic O
power O
measured O
during O
a O
preliminary O
incremental O
exercise O
test O
) O
in O
ten O
fit O
male O
human O
subjects O
. O
['Physiological-Clinical']

We O
examined O
the O
production O
of O
8-epi-prostaglandin O
( O
PG O
) O
F2 O
alpha O
, O
a O
stable O
product O
of O
lipid O
peroxidation O
in O
vivo O
, O
and O
its O
modulation O
by O
aspirin O
and O
antioxidant O
vitamins O
in O
chronic O
cigarette O
smokers O
. O
[]

CONCLUSIONS O
A O
postoperative O
, O
fixed-dose O
enoxaparin O
regimen O
is O
more O
effective O
than O
adjusted-dose O
warfarin O
in O
preventing O
deep O
venous O
thrombosis O
after O
knee O
arthroplasty O
. O
[]

Following O
initial O
application O
only O
imidacloprid O
had O
caused O
a O
significant O
reduction O
in O
adult B-outcome ['Physiological-Clinical']
fleas I-outcome ['Physiological-Clinical']
on O
treated O
cats O
within O
6 O
hours O
, O
but O
by O
24 O
hours O
all O
three O
formulations O
had O
killed O
96.7 O
% O
of O
the O
fleas O
. O
['Physiological-Clinical']

Effects O
of O
frusemide O
and O
hypoxia O
on O
the O
pulmonary O
vascular O
bed O
in O
man O
. O
[]

Maintenance O
of O
sinus O
rhythm O
is O
better O
than O
maintenance O
of O
fixed O
ventricular O
rate O
in O
atrial O
fibrillation O
( O
AF O
) O
especially O
in O
the O
presence O
of O
irritable O
left O
or O
right O
atrium O
because O
of O
enlargement O
. O
[]

Women O
in O
the O
intervention O
arm O
were O
also O
more O
likely O
to O
[]

OBJECTIVE O
Depression O
after O
hip O
fracture O
surgery O
is O
prevalent O
and O
associated O
with O
increased O
mortality O
rates O
and O
impaired O
functional O
recovery O
. O
[]

0.82 O
hours O
, O
respectively O
( O
p O
= O
0.051 O
) O
. O
[]

The O
risk O
of O
nonvertebral B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
was O
reduced O
by O
33 O
% O
compared O
with O
control O
over O
3 O
years O
( O
p O
= O
0.06 O
) O
. O
['Physiological-Clinical']

The O
implications O
of O
these O
findings O
are O
discussed O
further O
. O
[]

It O
is O
uncertain O
whether O
irinotecan O
is O
better O
administered O
with O
5-fluorouracil O
or O
alone O
in O
patients O
previously O
treated O
with O
a O
fluoropyrimidine O
. O
[]

Release B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
but O
not O
of O
prolactin B-outcome ['Physiological-Clinical']
after O
dexfenfluramine O
administration O
was O
significantly O
reduced O
in O
both O
groups O
of O
ecstasy O
users O
compared O
with O
the O
controls O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Nine O
women O
( O
18.4 O
% O
) O
from O
group O
B O
and O
8 O
women O
( O
16 O
% O
) O
from O
group O
B O
experienced O
spontaneous B-outcome ['Mortality']
abortions I-outcome ['Mortality']
. O
['Mortality']

Aerobic O
exercise O
improves O
self-reported O
sleep B-outcome ['Physiological-Clinical']
and O
quality O
of O
life O
in O
older O
adults O
with O
insomnia O
. O
['Physiological-Clinical']

BACKGROUND O
It O
has O
been O
postulated O
from O
virologic O
studies O
that O
herpesvirus O
infection O
could O
play O
a O
role O
in O
the O
progression O
of O
MS. O
METHODS O
Patients O
were O
eligible O
for O
the O
study O
if O
they O
had O
had O
two O
or O
more O
MS O
relapses O
in O
the O
2-year O
period O
before O
enrollment O
. O
[]

0.9 O
years O
) O
were O
analyzed O
. O
[]

Acetabular B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
was O
measured O
with O
dual-energy O
X-ray O
absorptiometry O
( O
DXA O
) O
1 O
week O
postoperatively O
, O
and O
after O
12 O
and O
24 O
months O
. O
['Physiological-Clinical']

Six O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
in O
two O
subjects O
( O
diffuse B-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
in O
one O
subject O
and O
five O
incidents O
of O
elevated O
blood B-outcome ['Physiological-Clinical']
and O
urine B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
in O
one O
subject O
with O
diabetes B-outcome ['Physiological-Clinical']
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Tumor-liver B-outcome ['Physiological-Clinical']
contrast I-outcome ['Physiological-Clinical']
was O
significantly O
different O
between O
protocols O
A O
and O
B O
( O
p O
= O
0.03 O
, O
p O
= O
0.02 O
) O
and O
protocols O
B O
and O
C O
( O
p O
= O
0.03 O
, O
p O
= O
0.04 O
) O
in O
the O
first O
and O
second O
phases O
but O
not O
between O
protocols O
A O
and O
C. O
There O
was O
no O
significant O
difference O
in O
hepatic B-outcome ['Physiological-Clinical']
enhancement I-outcome ['Physiological-Clinical']
among O
the O
three O
protocols O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
cases O
of O
perinatal B-outcome ['Mortality']
death I-outcome ['Mortality']
or O
fetal B-outcome ['Physiological-Clinical']
malformations I-outcome ['Physiological-Clinical']
in O
either O
group O
. O
['Mortality', 'Physiological-Clinical']

In O
addition O
, O
the O
LDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
: O
apolipoprotein B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
ratio O
was O
3.1 O
% O
higher O
with O
DHA O
treatment O
than O
with O
placebo O
( O
P O
= O
0.04 O
) O
, O
which O
suggested O
an O
increase O
in O
LDL B-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Ginkgo O
biloba O
has O
been O
reported O
to O
affect O
the O
neurotransmitter O
system O
and O
to O
have O
antioxidant O
properties O
that O
could O
impact O
the O
pathogenesis O
of O
Autism O
Spectrum O
Disorder O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Binary O
choices O
and O
ordinal O
visual O
analogue O
scores O
from O
a O
validated O
questionnaire O
on O
self O
reported O
measures O
: O
patient B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
and O
preference B-outcome ['Life-Impact']
to O
speak O
to O
receptionists O
and O
disclose O
confidential O
information O
without O
being O
overhead O
and O
concern B-outcome ['Life-Impact']
about O
disclosure O
of O
items O
of O
confidential O
personal O
information B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Primary O
capsulectomy O
, O
anterior O
vitrectomy O
, O
lensectomy O
, O
and O
posterior O
chamber O
lens O
implantation O
in O
children O
: O
limbal O
versus O
pars O
plana O
. O
[]

Response O
was O
assessed O
every O
8 O
weeks O
. O
[]

There O
were O
no O
deaths B-outcome ['Mortality']
or O
bile-duct B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
in O
either O
group O
, O
but O
the O
postoperative B-outcome ['Adverse-effects']
complication I-outcome ['Adverse-effects']
rate O
was O
significantly O
( O
p=0.0048 O
) O
higher O
in O
the O
OC O
than O
in O
the O
LC O
group O
: O
seven O
( O
23 O
% O
) O
patients O
had O
major O
and O
six O
( O
19 O
% O
) O
minor B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
after O
OC O
, O
whereas O
only O
one O
( O
3 O
% O
) O
minor O
complication O
occurred O
after O
LC O
. O
['Mortality', 'Physiological-Clinical', 'Adverse-effects', 'Adverse-effects']

In O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
Phase O
I O
study O
, O
10 O
evaluable O
subjects O
received O
either O
three O
doses O
of O
SsWC O
on O
Days O
0 O
, O
14 O
, O
and O
28 O
( O
N O
= O
3 O
) O
; O
five O
doses O
of O
SsWC O
on O
Days O
0 O
, O
2 O
, O
4 O
, O
6 O
, O
and O
28 O
( O
N O
= O
4 O
) O
; O
or O
placebo O
( O
N O
= O
3 O
) O
. O
[]

Nelfinavir O
significantly O
increased O
amprenavir B-outcome ['Physiological-Clinical']
minimum I-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
at O
steady O
state O
( O
by O
189 O
% O
) O
but O
did O
not O
affect O
amprenavir O
AUC O
( O
ss O
) O
or O
C O
( O
max O
, O
ss O
) O
. O
['Physiological-Clinical']

PATIENTS O
Twenty-six O
tendons O
from O
patients O
with O
chronic O
midportion O
Achilles O
tendinopathy O
were O
included O
. O
[]

At O
endpoint O
, O
subjects O
assigned O
to O
ZNS O
were O
taking O
a O
mean O
dosage O
of O
160 O
+/- O
50 O
mg/day O
. O
[]

The O
time B-outcome ['Physiological-Clinical']
required I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
capillary I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation O
( O
SaO2 O
) O
, O
as O
measured O
by O
pulse O
oximeter O
, O
to O
decline O
from O
100 O
% O
to O
92 O
% O
was O
noted O
and O
identified O
as O
the O
safe O
apnea B-outcome ['Physiological-Clinical']
period O
( O
SAP O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

STUDY O
SAMPLE O
Participants O
were O
44 O
of O
the O
450 O
children O
in O
the O
LOCHI O
cohort O
. O
[]

Middle B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
and O
hemodynamics B-outcome ['Physiological-Clinical']
in O
heart O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
individual O
differences O
in O
response O
to O
antecedent O
exercise O
. O
[]

In O
an O
analysis O
of O
82 O
children O
who O
received O
a O
full O
course O
of O
6 O
days O
or O
more O
of O
AmB O
( O
117 O
courses O
) O
, O
it O
was O
shown O
that O
there O
were O
significant O
increases O
in O
plasma O
urea O
and O
creatinine O
concentrations O
and O
in O
potassium O
requirement O
after O
6 O
days O
of O
therapy O
with O
both O
AmB O
infused O
in O
dextrose O
and O
AmB O
infused O
in O
lipid O
emulsion O
, O
with O
there O
being O
no O
difference O
between O
the O
two O
methods O
of O
AmB O
administration O
. O
[]

Interrater O
reliability O
was O
somewhat O
lower O
for O
the O
correct O
only O
and O
error O
only O
training O
groups O
in O
both O
the O
student O
and O
faculty O
studies O
. O
[]

We O
investigated O
long-term O
effects O
of O
calcium O
and O
vitamin O
D O
on O
falls B-outcome ['Life-Impact']
and O
parameters O
of O
muscle B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
community-dwelling O
elderly O
women O
and O
men O
. O
['Life-Impact', 'Life-Impact']

Approximately O
one O
half O
of O
patients O
enrolled O
in O
these O
studies O
showed O
statistically O
significant O
improvement O
in O
balance B-outcome ['Life-Impact']
and O
manual B-outcome ['Life-Impact']
dexterity I-outcome ['Life-Impact']
while O
taking O
IDA O
compared O
to O
placebo O
. O
['Life-Impact', 'Life-Impact']

Further O
study O
of O
the O
OAS O
in O
outpatients O
with O
aggression O
and O
developmental O
disabilities O
is O
warranted O
. O
[]

OBJECTIVE O
Although O
many O
centers O
have O
introduced O
more O
restrictive O
transfusion O
policies O
for O
preterm O
infants O
in O
recent O
years O
, O
the O
benefits O
and O
adverse O
consequences O
of O
allowing O
lower O
hematocrit O
levels O
have O
not O
been O
systematically O
evaluated O
. O
[]

Both O
groups O
of O
parents O
improved O
interaction O
skills B-outcome ['Life-Impact']
, O
and O
both O
groups O
of O
children O
demonstrated O
progress B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

The O
most O
important O
critical O
point O
is O
to O
identify O
uterine O
arteries O
from O
the O
ureter O
in O
the O
paracervical O
area O
. O
[]

[ O
Sentinel B-outcome ['Physiological-Clinical']
lymph I-outcome ['Physiological-Clinical']
node I-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
in O
colorectal O
cancer O
: O
importance O
, O
techniques O
and O
results O
] O
. O
['Physiological-Clinical']

Multilevel O
Poisson O
regression O
was O
used O
to O
test O
for O
intervention O
effects O
and O
outcome O
predictors O
. O
[]

CONCLUSION O
Stapled O
hemorrhoidopexy O
causes O
significantly O
less O
[]

The O
mean O
foot B-outcome ['Physiological-Clinical']
ulcer B-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
area O
decreased O
from O
46.88 O
+/- O
9.28 O
mm O
( O
2 O
) O
to O
35.09 O
+/- O
4.09 O
mm O
( O
2 O
) O
in O
the O
experimental O
group O
( O
p O
= O
0.006 O
) O
and O
from O
46.62 O
+/- O
10.03 O
mm O
( O
2 O
) O
to O
42.89 O
+/- O
8.1 O
mm O
( O
2 O
) O
in O
the O
control O
group O
( O
p O
= O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Diet O
and O
vitamin O
D O
status O
among O
pregnant O
Pakistani O
women O
in O
Oslo O
. O
[]

Despite O
numerous O
publications O
and O
clinical O
trials O
, O
the O
results O
of O
treatment O
of O
recalcitrant O
chronic O
plantar O
fasciitis O
with O
extracorporeal O
shockwave O
therapy O
( O
ESWT O
) O
still O
remain O
equivocal O
as O
to O
whether O
or O
not O
this O
treatment O
provides O
relief B-outcome ['Physiological-Clinical']
from O
the O
pain B-outcome ['Physiological-Clinical']
associated O
with O
this O
condition O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
CRT O
group O
received O
identical O
radiotherapy O
with O
concurrent O
weekly O
cisplatin O
at O
35 O
mg/m O
( O
2 O
) O
for O
6-7 O
cycles O
. O
[]

The O
neurologic O
outcome O
according O
to O
Glasgow O
Outcome O
Score O
( O
GOS O
) O
at O
6 O
months O
( O
GOS O
5 O
and O
4 O
) O
was O
better O
in O
the O
intensive O
insulin O
therapy O
group O
( O
34 O
of O
117 O
, O
29.1 O
% O
) O
than O
that O
in O
the O
conventional O
therapy O
group O
( O
26 O
of O
116 O
, O
22.4 O
% O
, O
P O
< O
0.05 O
) O
. O
[]

Good O
grade O
patients O
had O
absolute O
and O
relative O
risk O
reductions O
of O
respectively O
9.5 O
and O
29.4 O
% O
( O
P=0.73 O
) O
. O
[]

First-intron O
polymorphisms O
with O
greater O
numbers O
of O
CA O
dinucleotide O
repeats O
tend O
to O
downregulate O
EGFR O
expression O
, O
which O
suggests O
that O
this O
polymorphism O
may O
modulate O
susceptibility O
to O
lung O
cancer O
. O
[]

GH B-outcome ['Physiological-Clinical']
was O
measured O
before O
stimulation O
, O
every O
2min O
for O
the O
first O
hour O
and O
every O
5min O
for O
the O
second O
hour O
. O
['Physiological-Clinical']

The O
RCT O
evaluated O
the O
effects O
of O
the O
parent-delivered O
component O
of O
the O
intervention O
. O
[]

Correlation O
between O
the O
IFN-? O
ELISPOT O
and O
gpELISA O
assays O
was O
poor O
. O
[]

Using O
a O
multiple O
baseline O
design O
across O
subjects O
, O
the O
purpose O
of O
this O
research O
was O
to O
determine O
if O
two O
interventions O
, O
reciprocal O
imitation O
training O
and O
video O
modeling O
were O
effective O
in O
promoting B-outcome ['Life-Impact']
imitation I-outcome ['Life-Impact']
acquisition I-outcome ['Life-Impact']
in O
young O
children O
with O
autism O
. O
['Life-Impact']

OBJECTIVE O
Vilazodone O
is O
a O
potent O
serotonin O
reuptake O
inhibitor O
and O
5-HT1A O
receptor O
partial O
agonist O
approved O
for O
the O
treatment O
of O
major O
depressive O
disorder O
( O
MDD O
) O
in O
adults O
. O
[]

For O
the O
320 O
patients O
who O
completed O
the O
DAN-PSSsex O
, O
alfuzosin O
treatment O
was O
associated O
with O
a O
significant O
improvement O
in O
the O
mean O
change O
from O
baseline O
in O
erectile B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
on O
day O
29 O
compared O
with O
placebo O
( O
P=0.02 O
) O
. O
['Physiological-Clinical']

The O
results O
demonstrated O
no O
differences O
between O
the O
emergence O
or O
discharge O
times O
following O
desflurane O
or O
isoflurane O
. O
[]

DISCUSSION O
This O
study O
will O
determine O
the O
acceptability B-outcome ['Life-Impact']
of O
the O
intervention O
, O
the O
characteristics O
of O
the O
population O
recruited O
, O
recruitment O
and O
retention O
rates O
, O
descriptive O
statistics O
of O
outcomes O
, O
and O
incidence O
of O
AEs O
. O
['Life-Impact']

Anatomical O
landmarks O
( O
group O
I O
) O
are O
normally O
used O
for O
localization O
of O
the O
IJV O
. O
[]

A O
total O
of O
5469 O
patients O
in O
16 O
countries O
were O
randomised O
by O
198 O
mobile O
emergency O
units O
to O
receive O
either O
pre-hospital O
treatment O
with O
anistreplase O
, O
the O
thrombolytic O
agent O
used O
, O
followed O
by O
placebo O
after O
hospital O
admission O
( O
pre-hospital O
group O
; O
2750 O
patients O
) O
, O
or O
placebo O
followed O
by O
anistreplase O
( O
hospital O
group O
; O
2719 O
patients O
) O
. O
[]

The O
design O
of O
these O
and O
similar O
drug O
trials O
in O
children O
with O
autistic O
disorder O
must O
take O
into O
account O
the O
possibility O
of O
a O
large O
placebo O
response O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

Lactated O
Ringer O
's O
solution O
( O
4 O
degrees O
C O
) O
was O
infused O
via O
a O
central O
venous O
catheter O
over O
a O
period O
of O
approximately O
2 O
h O
to O
decrease O
tympanic B-outcome ['Physiological-Clinical']
membrane I-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
by O
approximately O
1.5 O
degrees O
C O
h O
( O
-1 O
) O
. O
['Physiological-Clinical']

Hodgkin O
's O
disease O
in O
childhood O
and O
adolescence O
: O
results O
of O
chemotherapy-radiotherapy O
in O
clinical O
stages O
IA-IIB O
. O
[]

Hepatitis B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
surface B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HBsAg I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
were O
analyzed O
and O
compared O
to O
changes O
in O
HBV B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
assessed O
objectively O
( O
employing O
National O
Prostate O
Cancer O
Project O
criteria O
) O
and O
subjectively O
( O
using O
a O
numerical O
scoring O
scheme O
) O
. O
[]

Because O
persons O
whose O
urine O
contains O
low O
proportions O
of O
DMA O
and O
high O
proportions O
of O
MMA O
and O
InAs O
have O
been O
reported O
to O
be O
at O
greater O
risk O
of O
skin O
and O
bladder O
cancers O
and O
peripheral O
vascular O
disease O
, O
these O
results O
suggest O
that O
folic O
acid O
supplementation O
may O
reduce O
the O
risk O
of O
arsenic-related O
health O
outcomes O
. O
[]

Safety O
and O
efficacy O
of O
a O
low O
molecular O
weight O
heparin O
( O
Logiparin O
) O
versus O
dextran O
as O
prophylaxis O
against O
thrombosis O
after O
total O
hip O
replacement O
. O
[]

METHOD O
Thirteen O
patients O
received O
early O
conventional O
therapy O
, O
and O
13 O
received O
therapy O
combined O
with O
standing O
balance O
training O
by O
biofeedback O
( O
BPM O
Monitor O
) O
. O
[]

Generalizability O
and O
durability B-outcome ['Life-Impact']
of O
treatment O
effects O
in O
an O
intervention O
program O
for O
coronary-prone O
( O
Type O
A O
) O
managers O
. O
['Life-Impact']

Cox O
regression O
models O
were O
used O
to O
estimate O
overall B-outcome ['Mortality']
mortality I-outcome ['Mortality']
( O
OM O
) O
, O
and O
Fine O
and O
Gray O
's O
regressions O
were O
applied O
to O
the O
end O
points O
of O
distant B-outcome ['Physiological-Clinical']
metastasis I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
cause-specific B-outcome ['Mortality']
mortality I-outcome ['Mortality']
( O
CSM B-outcome ['Mortality']
) O
. O
['Mortality', 'Physiological-Clinical', 'Mortality', 'Mortality']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Patients O
in O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
were O
further O
randomly O
assigned O
to O
receive O
either O
consolidation O
procedure O
. O
['Physiological-Clinical']

Anesthesia O
was O
induced O
with O
thiopental O
and O
remifentanil O
( O
1.0 O
micro O
g O
x O
kg O
( O
-1 O
) O
bolus O
and O
a O
1 O
micro O
g O
x O
kg O
( O
-1 O
) O
x O
min O
( O
-1 O
) O
infusion O
) O
or O
fentanyl O
( O
1 O
micro O
g O
x O
kg O
( O
-1 O
) O
bolus O
and O
a O
1.0 O
micro O
g O
x O
kg O
( O
-1 O
) O
x O
min O
( O
-1 O
) O
infusion O
) O
. O
[]

METHODS O
Four O
children O
with O
autism O
participated O
in O
a O
multiple-baseline O
, O
single-subject O
study O
. O
[]

AIMS O
To O
investigate O
whether O
metoprolol O
controlled O
release/extended O
release O
( O
CR/XL O
) O
once O
daily O
would O
improve O
diastolic B-outcome ['Physiological-Clinical']
and O
systolic B-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
chronic O
heart O
failure O
and O
decreased O
ejection O
fraction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

26 O
patients O
suffered O
from O
normotensive O
hydrocephalus O
( O
10 O
idiopathic O
and O
16 O
symptomatic O
) O
, O
and O
9 O
patients O
from O
hypertensive O
hydrocephalus O
of O
various O
origin O
. O
[]

The O
JIA O
group O
had O
significantly O
less O
time O
in O
physical O
activity O
( O
p O
= O
0.000 O
) O
, O
decrease O
in O
energy O
expenditure O
( O
p O
= O
0.04 O
) O
, O
and O
higher O
CHAQ O
scores O
( O
p O
= O
0.000 O
) O
compared O
with O
the O
control O
group O
. O
[]

CONCLUSIONS O
Although O
the O
study O
was O
small O
owing O
to O
recruitment O
difficulties O
, O
it O
still O
provides O
evidence O
of O
effectiveness O
of O
melatonin O
in O
children O
with O
sleep O
difficulties O
and O
ASD O
, O
which O
we O
predict O
a O
larger O
study O
would O
confirm O
. O
[]

This O
demonstrated O
that O
fever B-outcome ['Physiological-Clinical']
continued O
to O
be O
significantly O
associated O
with O
most O
outcome O
measures O
, O
even O
when O
infection B-outcome ['Physiological-Clinical']
was O
added O
to O
the O
model O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
a O
randomized O
single-blind O
crossover O
experiment O
data O
were O
obtained O
from O
16 O
( O
8 O
women O
) O
nonsmoking O
adults O
at O
baseline O
and O
at O
0 O
, O
1 O
, O
and O
3 O
hours O
after O
a O
1-hour O
SHS O
exposure O
set O
at O
bar/restaurant O
SHS O
levels O
. O
[]

Participating O
EDs O
were O
randomized O
to O
one O
of O
three O
intervention O
groups O
: O
no O
intervention O
, O
partial O
intervention O
, O
or O
full O
intervention O
. O
[]

Preoperative B-outcome ['Physiological-Clinical']
intraocular I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
were O
8.7 O
+/- O
3.0 O
mmHg O
in O
the O
retrobulbar O
and O
9.2 O
+/- O
3.2 O
mmHg O
in O
1-QST O
patients O
. O
['Physiological-Clinical']

The O
inferior-medial O
combination O
achieved O
greater O
ocular B-outcome ['Physiological-Clinical']
akinesia I-outcome ['Physiological-Clinical']
than O
the O
inferior-superior O
combination O
5 O
min O
after O
the O
initial O
injections O
( O
mean O
score O
+/- O
standard O
deviation O
of O
1.74 O
+/- O
1.86 O
vs. O
2.66 O
+/- O
2.39 O
; O
P O
< O
0.05 O
) O
, O
with O
a O
reduced O
requirement O
for O
supplementary O
injections O
( O
3 O
vs. O
23 O
supplementary O
injections O
; O
P O
< O
0.025 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
soy O
isoflavones O
on O
menopausal O
symptoms O
in O
women O
who O
do O
and O
who O
do O
not O
produce O
equol O
, O
a O
daidzein O
metabolite O
. O
[]

Medication O
and O
parent O
training O
in O
children O
with O
pervasive O
developmental O
disorders O
and O
serious O
behavior O
problems O
: O
results O
from O
a O
randomized O
clinical O
trial O
. O
[]

The O
MBCT O
group O
progressed O
significantly O
in O
number O
of O
verbal B-outcome ['Life-Impact']
attempts I-outcome ['Life-Impact']
after O
weeks O
1 O
through O
4 O
and O
number O
of O
correct B-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
after O
weeks O
1 O
and O
3 O
, O
while O
the O
traditional O
group O
progressed O
significantly O
after O
weeks O
4 O
and O
5 O
. O
['Life-Impact', 'Life-Impact']

Referring O
to O
overall O
and O
to O
clinically O
relevant O
heterotopic B-outcome ['Physiological-Clinical']
ossification B-outcome ['Physiological-Clinical']
the O
incidence O
of O
['Physiological-Clinical', 'Physiological-Clinical']

They O
were O
all O
affected O
by O
cardiac O
, O
respiratory O
or O
infective O
pathology O
, O
all O
of O
them O
intubated O
and O
on O
artificial O
respiratory O
support O
, O
sedated O
and O
infused O
with O
dopamine O
. O
[]

CONCLUSIONS O
Findings O
suggest O
that O
teachers O
were O
able O
to O
improve O
a O
core B-outcome ['Life-Impact']
deficit I-outcome ['Life-Impact']
of O
children B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
ASD I-outcome ['Life-Impact']
in O
a O
public O
preschool O
context O
. O
['Life-Impact', 'Life-Impact']

The O
latter O
was O
measured O
using O
the O
Disabilities O
of O
the O
Arm O
, O
Shoulder O
, O
and O
Hand O
questionnaire O
and O
the O
short O
version O
of O
the O
Sequential O
Occupational O
Dexterity O
Assessment O
. O
[]

BACKGROUND O
Despite O
the O
known O
health O
risks O
of O
hypertension O
, O
many O
hypertensive O
patients O
still O
have O
uncontrolled O
blood O
pressure O
. O
[]

However O
, O
the O
high O
incidence O
of O
severe O
, O
life-threatening B-outcome ['Physiological-Clinical']
, O
or O
['Physiological-Clinical']

PURPOSE O
Temozolomide O
( O
TMZ O
) O
is O
an O
oral O
alkylating O
agent O
that O
produces O
methyl O
adducts O
at O
the O
0.6 O
position O
of O
guanine O
. O
[]

Local B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
such O
as O
swelling B-outcome ['Physiological-Clinical']
and O
redness B-outcome ['Physiological-Clinical']
were O
observed O
in O
2 O
% O
( O
8/399 O
) O
to O
2.3 O
% O
( O
9/385 O
) O
of O
the O
acellular O
vaccine O
recipients O
as O
against O
31 O
% O
( O
122/394 O
) O
in O
the O
whole-cell O
vaccine O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
hypotheses O
to O
be O
tested O
are O
1 O
) O
. O
[]

There O
was O
a O
significant O
difference O
between O
the O
two O
groups O
favouring O
home O
based O
management O
in O
four O
SF-36 O
[]

In O
one O
study O
arm O
, O
patients O
with O
bulimia O
nervosa O
were O
treated O
with O
150 O
mg O
Spironolactone O
per O
day O
; O
in O
the O
other O
arm O
, O
patients O
received O
a O
placebo O
for O
a O
total O
of O
8 O
weeks O
. O
[]

The O
PMS O
leuprolide O
subjects O
improved O
significantly O
compared O
with O
the O
PMS O
placebo O
and O
PME O
leuprolide O
groups O
. O
[]

CONCLUSIONS O
Our O
results O
suggest O
that O
calcitriol O
can O
prevent O
bone B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
, O
therefore O
, O
may O
be O
useful O
for O
the O
treatment O
of O
bone O
disease O
in O
patients O
with O
cirrhosis O
of O
the O
liver O
. O
['Physiological-Clinical']

The O
serum O
values O
of O
soluble O
transferrin O
receptors O
and O
ferritin O
were O
observed O
as O
markers O
of O
iron B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
reserves I-outcome ['Physiological-Clinical']
, O
too O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Thirty-eight O
percent O
were O
in O
the O
precontemplation O
stage O
, O
45 O
% O
in O
the O
contemplation O
stage O
, O
and O
only O
17 O
% O
in O
the O
preparation O
stage O
. O
[]

Cases O
with O
cord O
complications O
and O
controls O
were O
paired O
by O
parity O
, O
gestational O
age O
, O
maternal O
age O
and O
mode O
of O
delivery O
. O
[]

End O
points O
were O
changes O
in O
ankle-brachial O
index O
, O
initial O
and O
absolute O
claudication O
distance O
, O
endothelial O
function O
assessed O
by O
flow-mediated O
dilatation O
of O
the O
brachial O
artery O
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
quality O
of O
life O
using O
the O
claudication B-outcome ['Physiological-Clinical']
scale O
questionnaire O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Our O
objective O
was O
to O
determine O
the O
impact O
of O
carbohydrate O
and/or O
protein O
ingestion O
before O
and O
after O
exercise O
on O
ribosomal O
protein O
S6 O
kinase O
( O
S6K1 O
) O
and O
S6 O
phosphorylation O
status O
in O
human O
skeletal O
muscle O
tissue O
. O
[]

In O
this O
PALS O
program O
, O
the O
alcoholic O
inpatients O
assumed O
a O
helping-companion O
relationship O
with O
the O
NHRs O
for O
2 O
hr O
per O
day O
during O
their O
last O
2 O
weeks O
of O
treatment O
. O
[]

We O
studied O
the O
safety O
and O
efficacy O
of O
oral O
ganciclovir O
in O
the O
prevention O
of O
CMV O
disease O
following O
orthotopic O
liver O
transplantation O
. O
[]

This O
may O
reflect O
improved O
availability O
of O
cognitive O
processing O
resources O
in O
the O
parietal O
cortex O
, O
an O
area O
that O
on O
the O
one O
hand O
plays O
an O
important O
role O
in O
fundamental O
aspects O
of O
attention O
and O
on O
the O
other O
hand O
has O
been O
found O
to O
be O
functionally O
impaired O
in O
dementia O
. O
[]

Aspirin-associated O
iron O
loss O
as O
an O
anticancer O
mechanism O
. O
[]

After O
4 O
weeks O
, O
if O
either O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
> O
or O
=140/ O
> O
or O
=90 O
mm O
Hg O
or O
SiDBP O
had O
not O
decreased O
by O
> O
or O
=10 O
mm O
Hg O
from O
baseline O
, O
the O
dose O
of O
amlodipine O
was O
increased O
to O
10 O
mg O
QD O
for O
4 O
weeks O
. O
['Physiological-Clinical']

Patient O
information O
, O
shared O
care O
and O
decision-making O
are O
recognised O
as O
beneficial O
to O
chronic O
disease O
management O
. O
[]

For O
the O
other O
three O
assessment O
tools O
the O
difference O
between O
treatment O
group O
and O
placebo O
group O
was O
not O
statistically O
significant.Regression O
analysis O
revealed O
that O
the O
degree O
of O
improvement O
on O
the O
Average O
Change O
of O
the O
PGI-R B-outcome ['Physiological-Clinical']
was O
strongly O
associated O
with O
several O
biomarkers O
( O
adj O
. O
['Physiological-Clinical']

During O
the O
ensuing O
two O
months O
either O
clofibrate O
or O
niceritrol O
, O
a O
nicotinic O
acid O
ester O
, O
was O
added O
in O
a O
randomized O
order O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Surgical O
time O
, O
difficulties O
, O
and O
surgical O
and O
anesthesia O
complications O
were O
measured O
at O
0-2 O
hrs O
, O
24 O
hrs O
, O
and O
7 O
days O
postprocedure O
. O
[]

The O
predictive O
value O
of O
gastric O
metaplasia O
in O
the O
duodenal O
mucosa O
in O
patients O
Helicobacter O
pylori-positive O
patients O
with O
duodenal O
bulb O
ulcer O
( O
DBU O
) O
was O
investigated O
. O
[]

RESULTS O
Mammographic B-outcome ['Physiological-Clinical']
densities I-outcome ['Physiological-Clinical']
increased O
compared O
with O
baseline O
values O
in O
73 O
% O
of O
subjects O
( O
mean O
increase O
, O
6.7 O
% O
; O
95 O
% O
confidence O
interval O
, O
2.5 O
% O
, O
11.0 O
% O
; O
P O
= O
.003 O
) O
. O
['Physiological-Clinical']

Therefore O
, O
our O
main O
outcomes O
and O
measures O
were O
the O
frequency O
of O
the O
nonverbal B-outcome ['Life-Impact']
information-based I-outcome ['Life-Impact']
judgments I-outcome ['Life-Impact']
( O
NVJs O
) O
, O
the O
response O
time O
for O
NVJs O
, O
and O
brain B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
of O
the O
medial O
prefrontal O
cortex O
during O
NVJs O
. O
['Life-Impact', 'Physiological-Clinical']

In O
the O
first O
study O
, O
heifers O
receiving O
the O
SG+IVPO O
had O
fewer O
( O
P O
= O
0.02 O
) O
cattle O
retreated O
for O
disease O
and O
73 O
% O
fewer O
( O
P O
= O
0.06 O
) O
worm O
eggs O
per O
fecal O
sample O
98 O
d O
after O
treatment O
than O
heifers O
treated O
with O
IVPO O
. O
[]

BACKGROUND O
Poor O
sleep O
quality O
, O
dysregulation O
of O
hormones O
and O
increased O
inflammatory O
cytokines O
are O
all O
associated O
with O
the O
risk O
for O
postpartum O
major O
depression O
( O
PPMD O
) O
. O
[]

Our O
data O
suggest O
that O
global B-outcome ['Physiological-Clinical']
contour I-outcome ['Physiological-Clinical']
integration I-outcome ['Physiological-Clinical']
is O
based O
on O
mechanisms O
of O
limited O
spatial O
extent O
, O
comparable O
to O
the O
interactions O
observed O
in O
V1 O
. O
['Physiological-Clinical']

Comparison O
of O
individual B-outcome ['Physiological-Clinical']
active I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
readings O
from O
separate O
transducers O
revealed O
good O
agreement O
whether O
the O
catheters O
were O
tied O
together O
or O
were O
separate O
. O
['Physiological-Clinical']

In O
addition O
, O
the O
TEF O
to O
an O
HP O
or O
LP O
meal O
was O
determined O
for O
3 O
h O
, O
at O
baseline O
and O
at O
week O
16 O
. O
[]

Overall O
improvement O
of O
symptoms O
, O
expressed O
by O
the O
area O
under O
the O
curve O
of O
the O
baseline-adjusted O
symptom O
sum O
score O
, O
yielded O
a O
mean O
value O
of O
10.95 O
( O
standard O
deviation O
27.4 O
) O
for O
the O
morning O
survey O
of O
the O
groups O
receiving O
eardrops O
containing O
only O
glycerol O
; O
in O
comparison O
, O
for O
eardrops O
containing O
glycerol O
and O
2 O
% O
lidocaine O
it O
was O
15.71 O
( O
+/- O
23.6 O
) O
and O
for O
glycerol O
with O
0.5 O
% O
lidocaine O
, O
23.16 O
( O
+/- O
19.4 O
) O
. O
[]

No O
differences O
were O
found O
between O
the O
groups O
in O
their O
demographic O
characteristics O
, O
immunosuppressive O
protocols O
, O
or O
donor O
and O
recipient O
CMV O
serology O
. O
[]

CONCLUSIONS O
This O
study O
provides O
evidence O
that O
the O
increased O
excretion B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
3-HIA I-outcome ['Physiological-Clinical']
seen O
frequently O
in O
normal O
pregnancy O
reflects O
reduced O
biotin B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
213 O
eligible O
patients O
were O
enrolled O
. O
[]

Naltrexone O
in O
autistic O
children O
: O
a O
double-blind O
and O
placebo-controlled O
study O
. O
[]

AIM O
This O
study O
was O
designed O
to O
compare O
the O
effectiveness O
of O
remifentanil O
vs. O
a O
lidocaine-esmolol O
combination O
in O
blunting O
the O
hemodynamic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
laryngoscopy O
and O
intubation O
during O
rapid O
sequence O
induction O
using O
thiopental O
and O
rocuronium O
in O
normotensive O
patients O
. O
['Physiological-Clinical']

No O
significant O
treatment O
effects O
were O
found O
for O
the O
Matching O
Familiar O
Figures O
Test O
, O
short-term O
recognition O
memory O
and O
concept B-outcome ['Life-Impact']
attainment I-outcome ['Life-Impact']
tasks O
, O
or O
the O
Stroop O
Test O
. O
['Life-Impact']

Thus O
, O
increased O
adenosine O
in O
the O
brain O
upon O
awakening O
may O
be O
the O
cause O
of O
sleep B-outcome ['Physiological-Clinical']
inertia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

[ O
Erythropoietin O
therapy O
during O
frequent O
autologous O
blood O
donations O
. O
[]

The O
ability O
of O
three O
listeners O
to O
perform O
these O
two O
tasks O
was O
measured O
at O
six O
frequencies O
( O
from O
0.25 O
to O
8 O
kHz O
) O
. O
[]

A O
randomised O
prospective O
trial O
. O
[]

masticatory B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
, O
and O
the O
subjective O
chewing B-outcome ['Physiological-Clinical']
experience O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
observed O
behavioural O
effects O
of O
methadone O
were O
decreased O
licking B-outcome ['Life-Impact']
and O
swallowing B-outcome ['Life-Impact']
and O
an O
increase O
in O
whining B-outcome ['Life-Impact']
after O
SC O
administration O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Stress O
reduction O
prolongs O
life O
in O
women O
with O
coronary O
disease O
: O
the O
Stockholm O
Women O
's O
Intervention O
Trial O
for O
Coronary O
Heart O
Disease O
( O
SWITCHD O
) O
. O
[]

The O
primary O
outcome O
, O
knowledge B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
benefits I-outcome ['Life-Impact']
and O
harms B-outcome ['Adverse-effects']
of I-outcome ['Adverse-effects']
screening I-outcome ['Adverse-effects']
, O
and O
secondary O
outcomes O
, O
['Life-Impact', 'Adverse-effects']

Sevoflurane O
reduced O
rocuronium O
requirements O
as O
well O
as O
decreased O
EC50 O
relevant O
to O
inhibition O
of O
T1 O
and O
rocuronium B-outcome ['Physiological-Clinical']
transfer I-outcome ['Physiological-Clinical']
to O
effect O
compartment O
. O
['Physiological-Clinical']

Standardized O
preoperative O
corticosteroid O
treatment O
in O
neonates O
undergoing O
cardiac O
surgery O
: O
results O
from O
a O
randomized O
trial O
. O
[]

However O
, O
at O
week O
16 O
, O
PDR B-outcome ['Physiological-Clinical']
recurred O
in O
a O
sizable O
number O
of O
the O
Avastin-treated O
eyes O
, O
and O
the O
complete B-outcome ['Physiological-Clinical']
regression O
rate O
in O
the O
two O
groups O
became O
identical O
( O
25 O
% O
; O
p=1.000 O
) O
; O
partial O
regression O
rates O
were O
70 O
% O
vs O
65 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical']

At O
1 O
wk O
, O
subjects O
were O
exposed O
to O
filtered O
air O
for O
2 O
h O
while O
exercising O
( O
20 O
L/min/m O
( O
2 O
) O
) O
, O
and O
then O
underwent O
bronchoalveolar O
lavage O
( O
BAL O
) O
and O
were O
randomly O
assigned O
to O
receive O
either O
a O
placebo O
or O
250 O
mg O
of O
vitamin O
C O
, O
50 O
IU O
of O
alpha-tocopherol O
, O
and O
12 O
oz O
of O
vegetable O
cocktail O
daily O
for O
2 O
wk O
. O
[]

Changes O
of O
RPF O
induced O
by O
treatment O
correlated O
with O
the O
L-NMMA O
induced O
decrease O
in O
RPF B-outcome ['Physiological-Clinical']
in O
the O
combination O
( O
r O
= O
0.70 O
, O
P O
< O
0.01 O
) O
and O
eprosartan O
phase O
( O
r O
= O
0.86 O
, O
P O
< O
0.001 O
) O
, O
but O
not O
in O
the O
enalapril O
phase O
( O
r O
= O
-0.44 O
, O
P O
= O
0.10 O
) O
. O
['Physiological-Clinical']

The O
clinical O
significance O
of O
the O
CEE O
effect O
on O
mammographic B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
remains O
to O
be O
determined O
. O
['Physiological-Clinical']

The O
use O
of O
flurbiprofen O
did O
not O
affect O
the O
mean O
pupillary B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
for O
any O
of O
these O
groups O
. O
['Physiological-Clinical']

METHODS O
A O
group O
of O
106 O
patients O
with O
a O
body O
mass O
index O
( O
BMI O
) O
> O
26.4 O
, O
representing O
the O
upper O
quintile O
of O
500 O
prospectively O
randomized O
patients O
, O
were O
included O
in O
the O
study O
. O
[]

All O
tests O
administered O
pre-intervention O
, O
following O
the O
intervention O
and O
12 O
months O
later O
. O
[]

RESULT O
( O
S O
) O
Both O
treatments O
improved O
hirsutism B-outcome ['Physiological-Clinical']
, O
hyperandrogenemia B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Sixty-eight O
patients O
with O
unresectable O
HCC O
were O
randomized O
into O
2 O
age O
, O
tumor O
size O
, O
TNM O
stages O
, O
and O
liver O
function O
grade-matched O
groups O
: O
TACE O
group O
( O
n=30 O
) O
undergoing O
TACE O
and O
TACE+HIFU O
group O
( O
n=38 O
) O
undergoing O
2-3 O
weeks O
after O
TACE O
. O
[]

Respiratory B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
and O
presence O
of O
cyanosis B-outcome ['Physiological-Clinical']
, O
wheezing B-outcome ['Physiological-Clinical']
, O
retractions B-outcome ['Physiological-Clinical']
were O
recorded O
before O
and O
after O
each O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
97 O
patients O
with O
recurrent O
condylomata O
acuminata O
. O
[]

Physiological O
dose O
( O
< O
1 O
mg O
) O
of O
folic O
acid O
both O
in O
healthy O
and O
60 O
epileptic O
women O
, O
all O
without O
any O
autoimmune O
disease O
, O
did O
not O
increase O
the O
risk O
for O
epileptic B-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Equal O
numbers O
of O
subjects O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
: O
a O
physician-pharmacist O
intervention O
group O
( O
n O
= O
66 O
) O
and O
a O
control O
group O
( O
n O
= O
66 O
) O
. O
[]

A O
controlled O
trial O
of O
extended O
radical O
versus O
radical O
mastectomy O
. O
[]

Additional O
research O
is O
needed O
to O
fully O
understand O
whether O
this O
role O
is O
primarily O
causal O
or O
compensatory O
in O
nature O
. O
[]

During O
maintenance O
therapy O
with O
interferon O
alfa-2b O
, O
no O
significant O
differences O
in O
the O
occurrence O
of O
relapse B-outcome ['Physiological-Clinical']
have O
yet O
been O
seen O
compared O
to O
patients O
on O
no O
maintenance O
therapy O
. O
['Physiological-Clinical']

People O
aged O
5 O
years O
or O
older O
in O
seven O
communities O
received O
randomly O
assigned O
diethylcarbamazine O
6 O
mg/kg O
and O
people O
in O
the O
other O
seven O
communities O
received O
diethylcarbamazine O
6 O
mg/kg O
plus O
ivermectin O
400 O
micrograms/kg O
. O
[]

No O
significant O
effect O
on O
idiopathic B-outcome ['Physiological-Clinical']
pneumonitis I-outcome ['Physiological-Clinical']
or O
survival B-outcome ['Mortality']
was O
observed O
. O
['Physiological-Clinical', 'Mortality']

Study O
participants O
were O
randomized O
for O
time O
of O
tissue O
sampling O
, O
which O
was O
performed O
1 O
, O
2 O
, O
4 O
, O
7 O
, O
or O
24 O
hours O
following O
the O
moxifloxacin O
infusion O
. O
[]

Except O
for O
delta-sleep O
time O
and O
awakenings/arousals O
, O
sleep O
parameters O
remained O
unchanged O
or O
favored O
pramipexole O
. O
[]

CONCLUSIONS O
In O
patients O
with O
paroxysmal O
AF O
and O
hypertension O
, O
treatment O
of O
hypertension O
by O
candesartan O
did O
not O
have O
an O
advantage O
over O
amlodipine O
in O
the O
reduction O
in O
the O
frequency O
of O
paroxysmal O
AF O
( O
umin O
CTR O
C000000427 O
) O
. O
[]

OBJECTIVE O
The O
potential O
of O
probiotics O
to O
control O
allergic B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
at O
an O
early O
age O
was O
assessed O
in O
a O
randomized O
double-blind O
placebo-controlled O
study O
. O
['Physiological-Clinical']

Smokers O
were O
contacted O
at O
home O
via O
telephone O
or O
mail O
. O
[]

The O
independent O
data O
monitoring O
committee O
stopped O
the O
study O
for O
futility O
after O
the O
second O
interim O
analysis O
. O
[]

Lorazepam O
also O
was O
not O
particularly O
liked O
and O
was O
not O
different O
from O
placebo O
on O
most O
subjective O
abuse-relevant O
measures O
. O
[]

However O
, O
no O
significant O
differences O
in O
these O
parameters O
between O
the O
female O
subjects O
in O
the O
two O
groups O
were O
observed O
. O
[]

The O
PD O
effects O
were O
assessed O
by O
vasodilator-stimulated O
phosphoprotein O
phosphorylation O
assay O
, O
light B-outcome ['Resource-use']
transmittance I-outcome ['Resource-use']
aggregometry I-outcome ['Resource-use']
, O
VerifyNow B-outcome ['Resource-use']
P2Y12 I-outcome ['Resource-use']
assay I-outcome ['Resource-use']
( O
Accumetric O
, O
Inc. O
, O
San O
Diego O
, O
California O
) O
, O
and O
multiple B-outcome ['Resource-use']
electrode I-outcome ['Resource-use']
aggregometry I-outcome ['Resource-use']
at O
baseline O
and O
14 O
days O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']

We O
conducted O
a O
randomized O
controlled O
study O
of O
streptococcal O
preparation O
OK-432 O
on O
120 O
newly O
identified O
cases O
of O
laryngeal O
squamous O
cell O
carcinoma O
who O
were O
registered O
at O
10 O
participating O
institutions O
between O
November O
1984 O
and O
October O
1989 O
. O
[]

After O
every O
2nd O
course O
the O
patients O
were O
crossed O
over O
to O
the O
other O
regimen O
. O
[]

Half O
of O
these O
patients O
ultimately O
developed O
complete O
loss B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
at O
the O
study O
endpoint O
. O
['Physiological-Clinical']

infusion O
at O
a O
rate O
of O
6 O
mg/d O
for O
72 O
h O
, O
or O
2 O
) O
ranitidine O
300 O
mg/d O
by O
continuous O
i.v O
. O
[]

Treatment O
of O
hepatitis O
B O
virus O
infection O
with O
interferon O
. O
[]

chest O
wall O
RT O
schedule O
( O
72 O
Gy O
in O
1.2-Gy O
b.i.d O
. O
[]

A O
demethylated O
product O
of O
C O
exhibits O
only O
minor O
beta-blocking B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
earlier O
work O
suggested O
that O
cefotaxime O
might O
be O
more O
effective O
than O
cephamandole O
in O
preventing O
wound O
sepsis O
in O
emergency O
abdominal O
surgery O
. O
[]

16.4 O
( O
CsA O
) O
mL/min/1.73 O
m O
( O
2 O
) O
. O
[]

A O
phase O
III O
clinical O
trial O
of O
exercise O
modalities O
on O
treatment O
side-effects O
in O
men O
receiving O
therapy O
for O
prostate O
cancer O
. O
[]

Whether O
this O
is O
true O
for O
the O
subpopulation O
of O
patients O
with O
a O
mixed O
index O
episode O
is O
not O
known O
. O
[]

Ten O
minutes O
later O
the O
variables O
were O
measured O
again O
. O
[]

OBJECTIVES O
To O
describe O
current O
primary O
care O
sun O
protection O
advice O
for O
children O
and O
assess O
the O
effect O
on O
clinicians O
of O
an O
intervention O
to O
enhance O
their O
sun B-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
advocacy I-outcome ['Life-Impact']
. O
['Life-Impact']

CONCLUSIONS O
Greater O
baseline O
BMI B-outcome ['Physiological-Clinical']
is O
independently O
associated O
with O
higher O
PCSM B-outcome ['Mortality']
in O
men O
with O
locally O
advanced O
prostate O
cancer O
. O
['Physiological-Clinical', 'Mortality']

SUBJECTS O
Postmenopausal O
women O
. O
[]

CONCLUSION O
Thermal O
welding O
tonsillectomy O
procedure O
provides O
sufficient O
hemostasis B-outcome ['Physiological-Clinical']
, O
lower O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
quick O
return B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
normal I-outcome ['Life-Impact']
diet I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Even O
among O
the O
26 O
charts O
in O
which O
the O
possibility O
of O
physical O
abuse O
was O
noted O
, O
documentation O
remained O
variable O
. O
[]

A O
Phase O
II O
clinical O
study O
that O
was O
not O
completed O
documented O
that O
daily O
oral O
doses O
of O
PPS O
administered O
for O
8 O
weeks O
lowered O
plasma O
levels O
of O
sVCAM-1 O
and O
tended O
to O
improve O
microvascular O
blood O
flow O
in O
patients O
with O
SCD O
. O
[]

The O
antiproteinuric O
effect O
is O
probably O
similar O
to O
that O
of O
perindopril O
, O
for O
equivalent O
hypotensive O
dosages O
. O
[]

There O
were O
no O
significant O
differences O
between O
sleep B-outcome ['Physiological-Clinical']
variables I-outcome ['Physiological-Clinical']
at O
baseline O
. O
['Physiological-Clinical']

Results O
showed O
that O
the O
LEGO O
therapy O
group O
improved O
more O
than O
the O
other O
groups O
on O
autism-specific O
social O
interaction O
scores O
( O
Gilliam O
Autism O
Rating O
Scale O
) O
. O
[]

Active O
treatment O
was O
first O
a O
single O
100-mg O
dose O
of O
naltrexone O
hydrochloride O
. O
[]

Antibody O
kinetics O
, O
height O
of O
the O
response O
and O
persistence O
of O
antibody B-outcome ['Physiological-Clinical']
over O
two O
years O
were O
virtually O
identical O
after O
PCECV O
and O
HDCSV O
. O
['Physiological-Clinical']

The O
valve O
's O
hemodynamic B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
was O
investigated O
through O
Doppler O
study O
. O
['Physiological-Clinical']

Anaesthesia O
and O
postoperative O
analgesia O
were O
standardized O
and O
the O
same O
surgeon O
performed O
all O
the O
operations O
. O
[]

METHODS O
In O
this O
multi-center O
, O
randomized O
, O
double-masked O
, O
placebo-controlled O
parallel-group O
comparison O
, O
the O
change O
of O
signs O
and O
symptoms O
( O
sum O
score O
) O
of O
blepharitis O
in O
197 O
patients O
( O
ITT O
( O
intention-to-treat-group O
) O
; O
mean O
age O
56 O
? O
[]

The O
recurrence B-outcome ['Physiological-Clinical']
rate O
was O
3.2 O
% O
both O
in O
1 O
year O
and O
2 O
years O
later O
in O
the O
former O
group-one O
consisting O
of O
31 O
patients O
with O
H. O
pylori O
eradicated O
, O
while O
the O
recurrence B-outcome ['Physiological-Clinical']
rate O
was O
57.1 O
% O
in O
1 O
year O
and O
78.6 O
% O
in O
2 O
years O
later O
, O
in O
the O
latter O
group-the O
other O
of O
42 O
patients O
with O
H. O
pylori O
not O
eradicated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

To O
establish O
a O
dose-response O
curve O
for O
the O
effects O
of O
isocapnic O
hypoxemia O
on O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CO I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
we O
studied O
20 O
healthy O
men O
, O
aged O
20 O
to O
34 O
years O
, O
using O
a O
tight-fitting O
face O
mask O
and O
an O
isocapnic O
partial O
rebreathing O
system O
( O
a O
modified O
anesthesia O
machine O
) O
. O
['Physiological-Clinical']

Biochemical O
and O
functional O
effects O
of O
creatine O
phosphate O
in O
cardioplegic O
solution O
during O
aortic O
valve O
surgery O
-- O
a O
clinical O
study O
. O
[]

In O
patients O
with O
a O
high O
risk O
of O
bleeding O
, O
conventional O
doses O
of O
heparin O
given O
continuously O
can O
reduce O
the O
rate O
of O
hemorrhagic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
but O
will O
result O
in O
more O
recurrences O
. O
['Physiological-Clinical']

The O
posts O
used O
for O
luting O
were O
duplicated O
with O
dual O
resin O
cement O
( O
Duo-link O
) O
inside O
Aestheti O
Plus O
# O
2 O
molds O
. O
[]

These O
data O
suggest O
that O
pressure O
garments O
that O
deliver O
a O
pressure O
of O
at O
least O
15 O
mmHg O
pressure O
tend O
to O
accelerate O
scar B-outcome ['Physiological-Clinical']
maturation I-outcome ['Physiological-Clinical']
and O
that O
measurements O
of O
the O
pattern O
of O
change O
of O
the O
erythema O
can O
be O
used O
to O
predict O
changes O
in O
scar O
thickness O
and O
vice O
versa O
. O
['Physiological-Clinical']

s.d O
. O
; O
[]

This O
led O
to O
reliable O
selective O
induction O
in O
a O
majority O
of O
adults O
and O
a O
sizeable O
proportion O
of O
4- O
to O
6-year-olds O
. O
[]

OBJECTIVE O
We O
sought O
to O
determine O
the O
clinical O
safety O
and O
efficacy O
of O
topical O
retapamulin O
ointment O
1 O
% O
versus O
oral O
cephalexin O
for O
the O
treatment O
of O
SID O
. O
[]

The O
in O
vitro B-outcome ['Physiological-Clinical']
cellular I-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
measured O
using O
an O
HBsAg-specific O
lymphoproliferation O
assay O
. O
['Physiological-Clinical']

CONCLUSION O
The O
study O
demonstrated O
that O
the O
midazolam+fentanyl O
combination O
provided O
high-level O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
scores O
, O
low-level O
pain B-outcome ['Physiological-Clinical']
scores O
, O
and O
shorter O
recovery B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
findings O
of O
the O
present O
study O
support O
the O
effective O
role O
of O
losartan O
compared O
to O
amlodipine O
in O
treating O
hypertension O
and O
hyperuricemia O
in O
elderly O
patients O
under O
chemotherapeutic O
treatment O
. O
[]

One O
patient O
on O
amiprilose O
developed O
thrombocytopenia B-outcome ['Physiological-Clinical']
of O
unknown O
cause O
; O
no O
other O
reported O
adverse O
effects O
were O
serious O
. O
['Physiological-Clinical']

The O
loss O
of O
HBsAg B-outcome ['Physiological-Clinical']
in O
addition O
to O
HBeAg B-outcome ['Physiological-Clinical']
and O
hepatitis B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
was O
more O
likely O
to O
occur O
in O
patients O
with O
chronic O
infection O
of O
less O
than O
2 O
years O
duration O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
study O
was O
double-blind O
, O
in O
a O
random O
order O
, O
10 O
days O
separating O
each O
session O
. O
[]

There O
was O
a O
trend O
toward O
the O
reduction O
in O
mean O
units O
of O
blood B-outcome ['Resource-use']
transfused I-outcome ['Resource-use']
per O
patient O
during O
months O
2 O
and O
3 O
of O
therapy O
combined O
in O
rHuEPO-treated O
patients O
compared O
with O
placebo-treated O
patients O
( O
0.91 O
U O
versus O
1.65 O
U O
; O
P O
= O
.056 O
) O
. O
['Resource-use']

Esmolol O
was O
associated O
with O
a O
decrease O
in O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
from O
6.2 O
+/- O
1.3 O
to O
3.8 O
+/- O
0.8 O
L/min O
, O
which O
, O
because O
of O
a O
22 O
% O
increase O
in O
systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
, O
far O
exceeded O
the O
reduction O
in O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Crucially O
, O
in O
both O
age O
groups O
, O
selective B-outcome ['Life-Impact']
induction I-outcome ['Life-Impact']
was O
dependent O
on O
awareness O
of O
context O
. O
['Life-Impact']

BACKGROUND O
AND O
OBJECTIVE O
Many O
treatment O
options O
, O
including O
non-pharmacological O
and O
pharmacological O
measures O
, O
have O
been O
recommended O
in O
the O
management O
of O
osteoarthritis O
( O
OA O
) O
. O
[]

Relative O
increases O
in O
rCMglu B-outcome ['Physiological-Clinical']
were O
observed O
in O
frontal O
cortical O
regions O
while O
relative O
decreases O
occurred O
in O
the O
putamen O
and O
right O
amygdala O
after O
both O
doses O
. O
['Physiological-Clinical']

When O
the O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
profiles O
were O
smoothed O
by O
substituting O
the O
1-hour O
averages O
by O
moving O
or O
fixed O
2-hour O
averages O
or O
by O
Fourier O
modeling O
, O
the O
trough-to-peak O
ratios O
remained O
unchanged O
after O
the O
morning O
dose O
( O
0.20/0.13 O
, O
0.20/0.14 O
, O
and O
0.16/0.21 O
, O
respectively O
) O
but O
tended O
to O
increase O
in O
the O
evening O
( O
0.32/0.38 O
, O
0.28/0.40 O
, O
and O
0.48/0.49 O
) O
. O
['Physiological-Clinical']

Children O
are O
sensitive O
to O
the O
inflammatory O
side O
effects O
of O
cardiopulmonary O
bypass O
( O
CPB O
) O
. O
[]

Tone B-outcome ['Physiological-Clinical']
in O
all O
17 O
subjects O
was O
reduced O
significantly O
at O
3 O
min O
after O
nicotine O
( O
P O
= O
0.000015 O
, O
sign O
test O
) O
; O
the O
rate O
of O
['Physiological-Clinical']

Outpatients O
with O
cancer O
were O
eligible O
for O
the O
study O
if O
they O
were O
aged O
> O
-18 O
years O
and O
had O
chronic O
( O
duration O
, O
> O
/= O
3 O
months O
) O
moderate O
to O
severe O
cancer-related O
pain O
( O
score O
on O
10-cm O
visual O
analog O
scale O
[ O
VAS O
] O
, O
> O
3 O
cm O
[ O
moderate O
] O
; O
score O
on O
a O
4-point O
verbal O
pain-intensity O
scale O
, O
> O
1 O
[ O
moderate O
] O
) O
. O
[]

The O
combination O
of O
dietary O
sodium O
restriction O
with O
blockade O
of O
the O
renin O
system O
by O
an O
ACE O
inhibitor O
is O
a O
particularly O
effective O
way O
to O
improve O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control O
. O
['Physiological-Clinical']

S-phase O
kinase-associated O
protein O
2 O
expression O
in O
laryngeal O
squamous O
cell O
carcinomas O
and O
its O
prognostic O
implications O
. O
[]

The O
experimental O
group O
made O
gains O
relative O
to O
the O
control O
group O
on O
all O
three O
measures O
. O
[]

A O
predefined O
subset O
of O
women O
( O
n=1,455 O
) O
had O
extended O
follow-up O
with O
colposcopy/biopsy O
at O
12 O
months O
. O
[]

Secondary O
efficacy O
endpoints O
included O
E O
2 O
levels/follicle O
at O
mid-cycle O
, O
number O
of O
follicles O
at O
mid-cycle O
and O
pregnancy O
rate O
( O
PR O
) O
. O
[]

Armodafinil O
200 O
mg O
produced O
a O
plasma B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
above O
the O
EC O
( O
50 O
) O
( O
4.6 O
?g/mL O
) O
for O
9 O
hours O
, O
whereas O
modafinil O
200 O
mg O
did O
not O
exceed O
the O
EC O
( O
50 O
) O
. O
['Physiological-Clinical']

Such O
behavior O
can O
compromise O
school O
performance O
. O
[]

In O
contrast O
, O
analogous O
slopes O
were O
steeper O
in O
the O
RPMT O
group O
than O
in O
the O
PECS O
group O
for O
children O
who O
began O
treatment O
with O
relatively O
low O
object O
exploration O
. O
[]

A O
comparison O
of O
Villalta-Prandoni O
scale O
and O
venous O
clinical O
severity O
score O
in O
the O
assessment O
of O
post B-outcome ['Physiological-Clinical']
thrombotic I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
were O
no O
differences O
in O
overall O
change O
across O
goal O
domains O
between O
the O
FF O
and O
WEB O
groups O
, O
suggesting O
the O
efficacy O
of O
videoconferencing O
technology O
. O
[]

METHODS O
A O
randomised O
, O
double-blind O
, O
crossover O
trial O
was O
performed O
in O
14 O
patients O
with O
nondiabetic O
chronic O
kidney O
disease O
with O
24-h O
mean O
proteinuria O
of O
2.01 O
g O
( O
95 O
% O
CI O
, O
1.36?2.66 O
) O
and O
estimated O
creatinine O
clearance O
of O
93?6.8 O
ml/min O
. O
[]

OBJECTIVE O
To O
determine O
whether O
interferon O
alpha-2a O
, O
when O
utilised O
as O
adjuvant O
chemotherapy O
following O
ablation O
of O
condylomata O
acuminata O
( O
genital O
warts O
) O
by O
cryotherapy O
, O
is O
effective O
in O
the O
prevention O
of O
recurrences O
. O
[]

Finally O
, O
the O
three O
methods O
of O
analysis O
were O
comparable O
for O
consistency O
analysis O
. O
[]

METHODS O
Ten O
healthy O
volunteers O
were O
enrolled O
in O
a O
randomized O
, O
double-blinded O
, O
placebo-controlled O
, O
crossover O
trial O
in O
which O
they O
received O
an O
infusion O
of O
saline O
, O
remifentanil O
, O
or O
alfentanil O
for O
120 O
min O
. O
[]

In O
a O
previously O
reported O
trial O
to O
prevent O
delirium O
, O
we O
randomized O
patients O
undergoing O
hip B-outcome ['Physiological-Clinical']
fracture B-outcome ['Physiological-Clinical']
repair B-outcome ['Physiological-Clinical']
under O
spinal O
anesthesia O
to O
light O
( O
BIS O
> O
80 O
) O
or O
deep O
( O
BIS O
approximately O
50 O
) O
sedation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Stress O
response B-outcome ['Physiological-Clinical']
was O
assessed O
during O
and O
after O
surgery O
by O
determining O
the O
plasma B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Stage O
1 O
of O
the O
trial O
saw O
72 O
Danish O
children O
( O
aged O
4 O
years O
to O
10 O
years O
11 O
months O
) O
assigned O
to O
diet O
( O
A O
) O
or O
non-diet O
( O
B O
) O
groups O
by O
stratified O
randomisation O
. O
[]

Treatment O
was O
then O
randomized O
in O
each O
group O
. O
[]

OBJECTIVES O
Compare O
two O
immunoenhanced O
enteral O
nutritions O
with O
a O
control O
diet O
, O
and O
evaluate O
the O
effect O
in O
postoperative B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
, O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
and O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

In O
Parkinson O
's O
disease O
, O
however O
, O
the O
supplementary O
motor O
area O
was O
only O
involved O
in O
movements O
which O
must O
be O
internally O
determined O
( O
non-cued O
movements O
, O
but O
not O
externally O
cued O
movements O
) O
; O
therefore O
impaired O
internal O
control O
mechanisms O
, O
operating O
via O
the O
supplementary O
motor O
area O
, O
are O
bypassed O
when O
external O
cues O
are O
given O
. O
[]

The O
temporal O
dynamics O
of O
adenosine-induced O
dyspnea O
and O
RIII O
inhibition O
differed O
( O
immediate O
onset O
followed O
by O
a O
slow O
decrease O
for O
dyspnea O
, O
slower O
onset O
for O
RIII O
inhibition O
) O
. O
[]

No O
atypical B-outcome ['Physiological-Clinical']
hyperplasia I-outcome ['Physiological-Clinical']
was O
noted O
. O
['Physiological-Clinical']

Results O
of O
electrodiagnostic O
studies O
did O
not O
add O
to O
the O
clinical O
examination O
results O
. O
[]

Surgical O
faculty O
served O
as O
expert O
raters O
in O
this O
study O
and O
were O
randomly O
assigned O
to O
receive O
either O
error O
training O
or O
no O
training O
. O
[]

METHODS O
We O
randomly O
assigned O
40 O
normotensive O
hypercholesterolemic O
patients O
with O
CGN O
to O
receive O
either O
cerivastatin O
0.15 O
mg/day O
( O
n=20 O
) O
or O
placebo O
( O
n=20 O
) O
. O
[]

There O
were O
no O
effects O
of O
any O
dose O
of O
ascorbic O
acid O
on O
[]

Comparing O
length O
of O
attachment O
, O
microbial O
control O
, O
and O
satisfaction O
. O
[]

However O
, O
at O
the O
8-year O
follow-up O
examination O
, O
substantial O
[]

However O
, O
there O
were O
significantly O
more O
cardiovascular B-outcome ['Physiological-Clinical']
deaths I-outcome ['Physiological-Clinical']
with O
losartan O
( O
420 O
, O
15 O
% O
) O
than O
with O
captopril O
( O
363 O
, O
13 O
% O
; O
p O
= O
0.03 O
) O
. O
['Physiological-Clinical']

In O
addition O
, O
a O
significantly O
higher O
proportion O
of O
patients O
receiving O
lanthanum O
carbonate O
had O
controlled O
serum B-outcome ['Physiological-Clinical']
phosphorus I-outcome ['Physiological-Clinical']
levels O
( O
60 O
% O
) O
compared O
with O
the O
placebo O
group O
( O
10 O
% O
; O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

The O
three O
levels O
correspond O
to O
a O
simplified O
hierarchy O
of O
controls O
. O
[]

PATIENTS O
AND O
METHODS O
Between O
January O
1995 O
and O
April O
1996 O
, O
414 O
patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
were O
randomized O
to O
received O
either O
a O
control O
arm O
of O
high-dose O
cisplatin O
( O
100 O
mg/m O
( O
2 O
) O
) O
or O
a O
combination O
of O
paclitaxel O
( O
175 O
mg/m O
( O
2 O
) O
, O
3-hour O
infusion O
) O
and O
cisplatin O
( O
80 O
mg/m O
( O
2 O
) O
) O
every O
21 O
days O
. O
[]

We O
examined O
the O
effect O
of O
ABC O
on O
health O
outcomes O
and O
behavioral O
risk O
factors O
when O
participants O
were O
aged O
21 O
years O
, O
and O
then O
explored O
the O
mediators O
of O
this O
relationship O
. O
[]

The O
presence O
of O
root-surface O
caries O
was O
scored O
at O
baseline O
and O
after O
one O
year O
. O
[]

CONCLUSIONS O
Early O
death B-outcome ['Mortality']
or O
neurologic B-outcome ['Physiological-Clinical']
deterioration I-outcome ['Physiological-Clinical']
, O
deterioration B-outcome ['Physiological-Clinical']
, O
and O
recurrent B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
are O
associated O
independently O
with O
high B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
, O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
pulse B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
BP B-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
led O
to O
the O
discontinuation O
of O
study O
medication O
in O
13 O
( O
18 O
% O
) O
of O
72 O
subjects O
. O
['Adverse-effects']

Diclofenac O
sodium O
and O
5-Fluorouracil O
are O
effective O
, O
non-invasive O
and O
easy-to-apply O
topical O
treatment O
options O
. O
[]

Drug O
effects O
were O
monitored O
with O
behavior O
checklists O
rated O
by O
parents O
and O
teachers O
, O
and O
ethological O
playroom O
observations O
. O
[]

OBJECTIVE O
The O
Pirarubicin O
Monotherapy O
Study O
Group O
trial O
was O
a O
randomized O
Phase O
II O
study O
that O
evaluated O
the O
efficacy O
of O
intravesical O
instillation O
of O
pirarubicin O
in O
the O
prevention O
of O
bladder O
recurrence O
after O
nephroureterectomy O
for O
upper O
urinary O
tract O
urothelial O
carcinoma O
. O
[]

rHuEPO O
ameliorates O
the O
preoperative O
decrease O
of O
haemoglobin B-outcome ['Physiological-Clinical']
and O
haematocrit O
values O
due O
to O
autologous O
blood O
donations O
in O
a O
dose-related O
fashion O
. O
['Physiological-Clinical']

Initiation B-outcome ['Life-Impact']
['Life-Impact']

METHOD O
Seventy-seven O
consecutively O
admitted O
, O
drug-na?ve O
patients O
with O
FEP O
were O
assessed O
at O
baseline O
and O
at O
1month O
and O
6months O
. O
[]

CONCLUSION O
Although O
we O
could O
not O
evaluate O
the O
reasons O
why O
, O
a O
large O
percentage O
of O
children O
with O
autism O
do O
not O
receive O
primary B-outcome ['Resource-use']
care I-outcome ['Resource-use']
consistent I-outcome ['Resource-use']
with I-outcome ['Resource-use']
that I-outcome ['Resource-use']
in I-outcome ['Resource-use']
a I-outcome ['Resource-use']
medical I-outcome ['Resource-use']
home I-outcome ['Resource-use']
. O
['Resource-use']

Plasma B-outcome ['Physiological-Clinical']
catecholamine I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
remained O
within O
the O
normal O
range O
during O
the O
investigation O
in O
patients O
subjected O
to O
general O
anaesthesia O
( O
Groups O
1-3 O
) O
. O
['Physiological-Clinical']

71.5 O
to O
498 O
? O
[]

In O
isolated O
animal O
lungs O
the O
amount O
of O
exhaled O
NO O
is O
decreased O
during O
hypoxia O
. O
[]

DESIGN O
Randomized O
controlled O
trial O
( O
Canadian O
Task O
Force O
classification O
I O
) O
. O
[]

We O
excluded O
patients O
with O
infantile O
spasms O
or O
typical O
absences O
. O
[]

There O
were O
no O
significant O
differences O
( O
P O
> O
.05 O
) O
between O
the O
lidocaine O
and O
mepivacaine O
solutions O
. O
[]

Expression O
seems O
to O
be O
of O
a O
more O
durable O
nature O
but O
factors O
that O
induce O
such O
expression O
remain O
unknown O
. O
[]

Of O
the O
45 O
patients O
with O
ALL O
in O
first O
bone O
marrow O
relapse O
enrolled O
on O
the O
ALL O
R15 O
protocol O
, O
44 O
had O
received O
epipodophyllotoxins O
during O
frontline O
therapy O
. O
[]

Clobazam O
completely O
prevented O
seizures B-outcome ['Physiological-Clinical']
in O
most O
of O
the O
patients O
, O
and O
toxic O
effects O
were O
of O
low O
frequency O
and O
severity O
. O
['Physiological-Clinical']

METHODS O
A O
total O
of O
1,347 O
stable O
patients O
with O
angiographic O
coronary O
artery O
disease O
underwent O
serial O
evaluation O
of O
atheroma B-outcome ['Physiological-Clinical']
burden I-outcome ['Physiological-Clinical']
with O
intravascular O
ultrasound O
imaging O
. O
['Physiological-Clinical']

These O
results O
suggest O
that O
the O
major O
benefit O
of O
TENS O
in O
the O
postappendicectomy O
patient O
is O
due O
to O
its O
'placebo O
effect O
' O
and O
its O
use O
in O
this O
situation O
can O
not O
be O
recommended O
. O
[]

Patients O
receiving O
6 O
and O
9 O
g/night O
doses O
were O
titrated O
to O
their O
final O
dose O
in O
weekly O
1.5 O
g O
increments O
, O
while O
patients O
receiving O
placebo O
were O
randomized O
to O
undergo O
a O
similar O
mock O
dose O
titration O
. O
[]

Consequently O
, O
folate O
nutritional O
status O
may O
influence O
arsenic B-outcome ['Physiological-Clinical']
methylation I-outcome ['Physiological-Clinical']
and O
toxicity O
. O
['Physiological-Clinical']

The O
effects O
of O
strength O
training O
on O
central B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
in O
middle-aged O
and O
older O
adults O
. O
['Physiological-Clinical']

We O
conducted O
a O
controlled O
, O
double-blind O
trial O
to O
evaluate O
the O
efficacy O
of O
maintenance O
therapy O
with O
fluconazole O
. O
[]

RESULTS O
Effectiveness O
of O
the O
GHRH O
antagonist O
was O
validated O
in O
all O
subjects O
by O
demonstrating O
93+/-1.8 O
% O
( O
P=0.012 O
) O
suppression O
of O
GH B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
a O
GHRH O
bolus O
. O
['Physiological-Clinical']

For O
quantitative O
analysis O
of O
this O
prostaglandin O
metabolite O
and O
the O
stable-isotope O
dilution O
techniqe O
of O
selected O
ion O
monitoring O
( O
SIM O
) O
is O
employed O
using O
gas-liquid O
chromatography-mass O
spectrometry O
. O
[]

OBJECTIVE O
To O
compare O
a O
meal O
replacement O
( O
MR O
) O
program O
with O
a O
conventional O
reduced-calorie O
diet O
( O
RCD O
) O
for O
weight O
management B-outcome ['Physiological-Clinical']
using O
the O
pharmacy O
as O
the O
setting O
and O
the O
pharmacist O
as O
the O
point O
of O
contact O
for O
dietary O
advice O
. O
['Physiological-Clinical']

Administration O
of O
rhNGF O
was O
safe O
, O
with O
few O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
attributed O
to O
treatment O
apart O
from O
injection O
site B-outcome ['Physiological-Clinical']
pain/hyperalgesia I-outcome ['Physiological-Clinical']
and O
['Adverse-effects', 'Physiological-Clinical']

In O
contrast O
, O
therapy O
with O
zofenopril O
was O
associated O
with O
a O
50 O
% O
increase O
in O
total O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
( O
p O
= O
0.09 O
) O
and O
a O
significant O
( O
p O
= O
0.03 O
) O
twofold O
increase O
in O
['Physiological-Clinical']

MATERIAL O
AND O
METHODS O
A O
randomized O
trial O
with O
104 O
patients O
either O
without O
prophylactic O
IABP O
insertion O
( O
group O
A O
, O
n=52 O
) O
or O
with O
IABP O
( O
group O
B O
, O
n=52 O
) O
was O
conducted O
. O
[]

Thus O
, O
high O
dosages O
of O
IVIG O
are O
not O
conferring O
better O
protection O
against O
infections O
in O
such O
patients O
. O
[]

Given O
its O
efficacy O
when O
combined O
with O
other O
therapy O
regimens O
, O
the O
current O
study O
examined O
the O
efficacy O
of O
mental O
practice O
when O
combined O
with O
mCIT O
versus O
mCIT O
only O
using O
randomized O
, O
controlled O
methods O
. O
[]

Extrapyramidal B-outcome ['Physiological-Clinical']
effects O
were O
evident O
for O
all O
doses O
of O
haloperidol O
, O
but O
absent O
for O
the O
lower O
doses O
of O
sertindole O
. O
['Physiological-Clinical']

In O
addition O
, O
children O
with O
ASD O
demonstrated O
altered O
response O
to O
gaze B-outcome ['Life-Impact']
direction I-outcome ['Life-Impact']
on O
P1 O
latency O
and O
no O
sensitivity B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
gaze I-outcome ['Life-Impact']
direction I-outcome ['Life-Impact']
on O
midline-N170 O
amplitude O
compared O
to O
TD O
and O
ADHD O
. O
['Life-Impact', 'Life-Impact']

10.7? O
) O
and O
mild O
PFOA O
( O
mean O
? O
[]

These O
data O
suggest O
that O
the O
secondary O
metabolic O
changes O
, O
e.g O
. O
[]

Significant O
treatment O
effects O
were O
found O
for O
five O
of O
seven O
primary O
outcome O
measures O
( O
parent O
ratings O
and O
direct O
child O
measures O
) O
. O
[]

RESULTS O
Compared O
with O
sixteen O
control O
participants O
, O
patients O
with O
CSX O
had O
significantly O
higher O
activity B-outcome ['Life-Impact']
of O
MPO B-outcome ['Physiological-Clinical']
and O
levels O
of O
MDA B-outcome ['Physiological-Clinical']
, O
but O
significantly O
lower B-outcome ['Physiological-Clinical']
SOD I-outcome ['Physiological-Clinical']
activity B-outcome ['Life-Impact']
and O
levels O
of O
NOx B-outcome ['Physiological-Clinical']
before O
treatment O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Thirty-two O
patients O
awaiting O
a O
total O
hip O
arthroplasty O
were O
randomly O
allocated O
to O
either O
the O
experimental O
group O
, O
( O
A O
) O
, O
to O
have O
six O
sessions O
of O
acupuncture O
each O
lasting O
up O
to O
25 O
minutes O
, O
or O
the O
control O
group O
, O
( O
B O
) O
, O
to O
be O
given O
advice O
and O
exercises O
for O
their O
hip O
over O
a O
six O
week O
period O
. O
[]

With O
the O
control O
group O
it O
continued O
until O
discharge O
( O
usually O
on O
the O
15th O
day O
) O
and O
at O
home O
for O
about O
three O
weeks O
until O
the O
completion O
of O
the O
physiotherapy O
cycle O
. O
[]

infusion O
to O
maintain O
blood O
glucose O
in O
the O
range O
5.5-11.1 O
mmol O
litre O
( O
-1 O
) O
. O
[]

Translucency O
of O
zirconia O
copings O
made O
with O
different O
CAD/CAM O
systems O
. O
[]

However O
, O
in O
sex-specific O
analyses O
, O
total O
lignan O
intake O
was O
positively O
associated O
with O
any O
adenoma B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
in O
women O
( O
highest O
vs. O
lowest O
lignan O
intake O
quartile O
OR O
= O
2.07 O
, O
95 O
% O
CI O
: O
1.22-3.52 O
, O
p O
trend O
= O
0.004 O
) O
but O
not O
in O
men O
( O
p O
interaction O
= O
0.04 O
) O
. O
['Physiological-Clinical']

Large B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
C1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
small B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
elasticity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
C2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
measured O
by O
pulse O
contour O
analysis O
of O
the O
radial O
artery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
was O
possible O
to O
define O
good O
, O
intermediate O
and O
poor O
renal-function O
groups O
which O
were O
highly O
correlated O
with O
prognosis O
( O
X2 O
for O
trend O
= O
62.6 O
) O
. O
[]

Nifedipine O
( O
10 O
mg O
) O
and O
nicorandil O
( O
30 O
mg O
) O
were O
equally O
effective O
in O
eight O
patients O
; O
in O
the O
remaining O
five O
patients O
, O
nicorandil O
had O
better O
results O
( O
p O
= O
0.06 O
) O
. O
[]

We O
studied O
the O
antiproteinuric B-outcome ['Physiological-Clinical']
effect O
of O
such O
a O
treatment O
in O
a O
double-blind O
study O
. O
['Physiological-Clinical']

Virtual O
reality O
colonoscopy O
simulation O
: O
a O
compulsory O
practice O
for O
the O
future O
colonoscopist O
? O
[]

No O
evidence O
of O
nephrotoxicity B-outcome ['Physiological-Clinical']
was O
found O
in O
any O
pre-eclamptic O
or O
normal O
patient O
. O
['Physiological-Clinical']

These O
results O
overall O
suggested O
that O
Re-PUVA O
is O
the O
most O
effective O
treatment O
for O
PPP O
. O
[]

BACKGROUND O
Changes O
in O
gait O
patterns O
due O
to O
a O
simultaneously O
performed O
cognitive O
task O
have O
been O
reported O
previously O
and O
associated O
with O
an O
increased O
falling O
risk O
among O
older O
adults O
. O
[]

In O
patients O
using O
opioid O
PCA O
, O
but O
with O
no O
other O
high O
risk O
factors O
for O
PONV B-outcome ['Physiological-Clinical']
, O
prophylactic O
ondansetron O
does O
not O
have O
any O
clinical O
benefit O
. O
['Physiological-Clinical']

Clonidine O
in O
patients O
undergoing O
noncardiac O
surgery O
. O
[]

Methandienone O
caused O
many O
side O
effects O
, O
and O
three O
men O
had O
to O
withdraw O
because O
of O
them O
. O
[]

Incidence O
of O
puberty B-outcome ['Physiological-Clinical']
in O
beef O
heifers O
fed O
high- O
or O
low-starch O
diets O
for O
different O
periods O
before O
breeding O
. O
['Physiological-Clinical']

A O
randomized O
controlled O
trial O
of O
COMPASS O
web-based O
and O
face-to-face O
teacher O
coaching O
in O
autism O
. O
[]

Brain B-outcome ['Physiological-Clinical']
5-HT4R I-outcome ['Physiological-Clinical']
binding I-outcome ['Physiological-Clinical']
was O
quantified O
at O
baseline O
and O
at O
follow-up O
with O
[ O
( O
11 O
) O
C O
] O
SB207145 O
positron B-outcome ['Resource-use']
emission I-outcome ['Resource-use']
tomography I-outcome ['Resource-use']
( O
PET O
) O
. O
['Physiological-Clinical', 'Resource-use']

METHOD O
In O
a O
quasi-randomized O
trial O
over O
the O
course O
of O
? O
[]

The O
delay O
in O
setting O
up O
the O
infusion O
system O
and O
the O
short O
time O
between O
requesting O
analgesia B-outcome ['Resource-use']
and O
vaginal O
delivery B-outcome ['Physiological-Clinical']
were O
limitations O
with O
self-administration O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

22 O
patients O
received O
immunotherapy O
10 O
days O
before O
surgery O
, O
whereas O
the O
remaining O
21 O
control O
patients O
received O
no O
immune O
stimulation O
. O
[]

Human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
testing O
is O
an O
essential O
part O
of O
pathological O
assessment O
in O
breast O
cancer O
patients O
, O
as O
HER2 O
provides O
not O
only O
prognostic O
but O
also O
predictive O
information O
on O
response O
to O
targeted O
therapy O
. O
[]

RESULTS O
Twenty-seven O
patients O
have O
died B-outcome ['Mortality']
; O
6 O
deaths B-outcome ['Mortality']
were O
reported O
by O
the O
clinical O
center O
as O
due O
to O
metastatic B-outcome ['Physiological-Clinical']
melanoma I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Mortality', 'Physiological-Clinical']

Chalazion B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
, O
satisfaction B-outcome ['Life-Impact']
and O
inconvenience B-outcome ['Life-Impact']
experienced O
because O
of O
treatments O
were O
the O
outcomes O
assessed O
via O
a O
telephone O
interview O
at O
3 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

BACKGROUND O
The O
results O
of O
open O
pilot O
studies O
suggest O
that O
the O
serotonin-1A O
( O
5-HT1A O
) O
receptor O
agonist O
buspirone O
might O
be O
effective O
in O
social O
phobia O
. O
[]

Nitrogen B-outcome ['Physiological-Clinical']
and O
magnesium B-outcome ['Physiological-Clinical']
balances I-outcome ['Physiological-Clinical']
were O
similar O
during O
both O
feeds O
, O
and O
met O
estimated O
fetal O
requirements O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
trial O
of O
the O
canalith O
repositioning O
procedure O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Third O
, O
the O
curriculum O
is O
briefly O
described O
, O
and O
finally O
, O
the O
role O
of O
the O
students O
and O
community O
in O
the O
video O
production O
is O
described O
. O
[]

For O
this O
reason O
, O
the O
direction O
of O
the O
IJV O
was O
classified O
as O
typical O
in O
80 O
% O
of O
group O
I O
, O
in O
85 O
% O
of O
group O
II O
, O
but O
in O
only O
45 O
% O
of O
group O
III O
. O
[]

Sixty O
women O
were O
qualified O
to O
participate O
in O
the O
study O
. O
[]

Number O
of O
presentations O
of O
the O
standard O
never O
affected O
the O
proportion O
of O
identifications O
of O
the O
standard O
when O
it O
was O
presented O
, O
nor O
other O
features O
of O
the O
temporal O
generalization O
gradients O
observed O
. O
[]

Sequential O
therapy O
includes O
one O
additional O
antibiotic O
( O
tinidazole O
) O
that O
is O
not O
contained O
in O
standard O
therapy O
. O
[]

Significantly O
higher O
dietary O
intakes O
of O
folate O
( O
P O
= O
0.035 O
) O
, O
non-starch O
polysaccharides O
( O
P O
= O
0.001 O
) O
, O
vitamin O
C O
( O
P O
= O
0.0001 O
) O
and O
carotenoids O
( O
P O
= O
0.0001 O
) O
were O
observed O
in O
both O
intervention O
groups O
compared O
with O
CT O
, O
which O
were O
broadly O
supported O
by O
nutrient O
biomarker O
analysis O
. O
[]

RESEARCH O
METHOD/DESIGN O
A O
total O
of O
297 O
VR O
clients O
participated O
in O
a O
randomized O
trial O
of O
the O
Working O
Well O
health O
promotion O
program O
. O
[]

A O
100-mg O
dose O
of O
caffeine O
enhanced O
performance O
in O
training B-outcome ['Life-Impact']
and O
competition B-outcome ['Life-Impact']
by O
approximately O
1.3 O
% O
. O
['Life-Impact', 'Life-Impact']

adjuvant O
[ O
chemo O
] O
RT O
) O
in O
patients O
with O
OPSCC O
. O
[]

Verapamil O
afforded O
no O
consistent O
protection O
against O
the O
thermal O
challenges O
, O
whereas O
nifedipine O
significantly O
blunted O
the O
bronchoconstrictor B-outcome ['Physiological-Clinical']
response O
to O
stimuli B-outcome ['Physiological-Clinical']
of O
low O
( O
p O
less O
than O
0.02 O
) O
and O
middle O
( O
p O
less O
than O
0.03 O
) O
intensity O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
drawback O
to O
this O
therapeutic O
approach O
is O
the O
relatively O
long O
and O
complex O
management O
of O
the O
induction O
phase O
. O
[]

In O
addition O
, O
the O
pattern O
of O
the O
results O
supported O
the O
use O
of O
rational-emotive O
imagery O
as O
a O
component O
of O
rational-emotive O
therapy O
. O
[]

Forty-five O
patients O
reaching O
maintenance O
therapy O
were O
randomised O
to O
either O
chemo-immunotherapy O
( O
BCG O
plus O
intradermal O
leukaemic O
blast O
cells O
) O
or O
chemotherapy O
alone O
. O
[]

The O
cancer B-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
rate O
in O
the O
first O
re-biopsy O
after O
the O
diagnosis O
of O
high O
grade O
PIN O
was O
12.9 O
% O
. O
['Physiological-Clinical']

RESULTS O
At O
any O
time O
point O
, O
independent O
of O
the O
diet O
consumed O
, O
the O
24 O
h B-outcome ['Physiological-Clinical']
carbohydrate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CHO I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
balances I-outcome ['Physiological-Clinical']
in O
the O
chamber O
were O
mostly O
negative O
( O
means O
ranging O
from O
+31 O
to O
-98 O
g/d O
) O
and O
the O
fat B-outcome ['Physiological-Clinical']
balances I-outcome ['Physiological-Clinical']
mostly O
positive O
( O
means O
ranging O
from O
-26 O
to O
+38 O
g/d O
) O
for O
the O
obese O
a O
well O
as O
for O
the O
lean O
, O
well-trained O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
determine O
if O
any O
differences O
exist O
in O
healing B-outcome ['Physiological-Clinical']
and O
complications O
between O
reamed O
and O
unreamed O
nailing O
in O
patients O
with O
tibial O
shaft O
fractures O
. O
['Physiological-Clinical']

Included O
will O
be O
patients O
who O
are O
diagnosed O
with O
moderate O
to O
severe O
depression O
, O
based O
on O
DSM-IV O
criteria O
, O
and O
stratified O
according O
to O
comorbid O
chronic O
physical O
illness O
. O
[]

Blood O
was O
drawn O
at O
-20 O
, O
0 O
, O
5 O
, O
10 O
, O
20 O
, O
45 O
, O
and O
90 O
min O
following O
the O
infusions O
, O
and O
assayed O
for O
norepinephrine O
( O
NE O
) O
and O
3-methoxy-4-hydroxy-phenyl O
glycol O
( O
MHPG O
) O
. O
[]

A O
Pediatric O
Oncology O
Group O
study O
. O
[]

Coronary O
arteriography O
was O
performed O
at O
baseline O
and O
at O
15 O
, O
30 O
, O
45 O
, O
60 O
, O
75 O
, O
and O
90 O
minutes O
after O
drug O
infusion O
. O
[]

36 O
months O
. O
[]

Results O
of O
this O
study O
suggested O
that O
only O
saliva O
, O
blood O
, O
and O
hydrogen O
peroxide O
influenced O
the O
tensile B-outcome ['Life-Impact']
bond I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
between O
dentin O
and O
ceramic O
. O
['Life-Impact']

Thus O
it O
was O
concluded O
that O
a O
single O
dose O
of O
cefotiam O
significantly O
reduces O
post-operative B-outcome ['Physiological-Clinical']
deep I-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PURPOSE O
A O
prospective O
, O
randomized O
clinical O
trial O
was O
conducted O
to O
assess O
the O
usefulness O
of O
preoperative O
diclofenac O
eye O
drops O
in O
maintaining O
mydriasis B-outcome ['Physiological-Clinical']
during O
vitrectomy O
and O
in O
reducing O
postoperative B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

176 O
eligible O
patients O
with O
advanced O
suboptimally O
operated O
ovarian O
carcinoma O
were O
randomly O
allocated O
to O
receive O
either O
cisplatin O
75 O
mg/m2 O
or O
cisplatin O
50 O
mg/m2 O
and O
cyclophosphamide O
500 O
mg/m2 O
( O
CP O
) O
every O
28 O
days O
for O
six O
courses O
. O
[]

An O
exploratory O
study O
. O
[]

Pain B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
was O
assessed O
using O
the O
Brief O
Pain B-outcome ['Physiological-Clinical']
Inventory-Short O
Form O
average O
pain B-outcome ['Physiological-Clinical']
item O
with O
0 O
representing O
no O
pain B-outcome ['Physiological-Clinical']
and O
10 O
representing O
as O
bad O
as O
can O
be O
imagined O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Since O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
is O
characterised O
by O
inflammation O
and O
oxidative O
stress O
, O
low-dose O
CO O
could O
be O
of O
therapeutic O
use O
. O
[]

Postmenopausal O
women O
( O
n O
= O
1226 O
) O
with O
two O
or O
more O
prevalent O
vertebral B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
received O
risedronate O
2.5 O
or O
5 O
mg/day O
or O
placebo O
; O
all O
subjects O
also O
received O
elemental O
calcium O
1000 O
mg/day O
, O
and O
up O
to O
500 O
IU/day O
vitamin O
D O
if O
baseline O
levels O
were O
low O
. O
['Physiological-Clinical']

This O
study O
involves O
118 O
evaluable O
patients O
: O
32 O
in O
the O
laser-CO2 O
group O
, O
34 O
in O
the O
5-fluorouracil O
group O
and O
52 O
in O
the O
interferon O
group O
. O
[]

Combined O
descriptive O
and O
explanatory O
information O
improves O
peers O
' O
perceptions B-outcome ['Life-Impact']
of O
autism B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
spontaneous O
bone O
loss O
was O
similar O
at O
all O
the O
skeletal O
sites O
measured O
, O
with O
a O
mean O
spontaneous O
loss O
in O
calcanean O
BMD O
of O
1.6 O
% O
over O
one O
year O
. O
[]

The O
goal O
of O
this O
study O
was O
to O
analyze O
regression O
of O
left O
ventricular O
hypertrophy O
after O
randomization O
to O
conventional O
biological O
versus O
stentless O
aortic O
valve O
replacement O
. O
[]

Identification O
of O
a O
biomarker O
that O
can O
inform O
on O
extracellular O
serotonin O
( O
5-HT O
) O
levels O
in O
the O
brains O
of O
living O
humans O
would O
enable O
greater O
understanding O
of O
the O
way O
brain O
circuits O
are O
modulated O
by O
serotonergic O
neurotransmission O
. O
[]

Two O
groups O
of O
11 O
children O
( O
age O
12-18 O
) O
with O
autism O
or O
Asperger O
syndrome O
at O
two O
special O
schools O
participated O
: O
one O
group O
used O
the O
computer O
program O
for O
10 O
half-hour O
sessions O
over O
2 O
weeks O
. O
[]

Episodes O
of O
asymptomatic B-outcome ['Physiological-Clinical']
ST I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
decreased O
by O
50 O
% O
or O
more O
in O
70 O
% O
of O
the O
patients O
from O
a O
median O
number O
of O
4.5 O
( O
range O
, O
0-19 O
) O
to O
1.5 O
( O
range O
, O
0-13 O
) O
( O
p O
= O
0.0001 O
) O
; O
their O
cumulative O
duration O
also O
decreased O
from O
78.5 O
( O
range O
, O
0-60 O
) O
to O
24.5 O
( O
range O
, O
0-411 O
) O
minutes O
( O
p O
= O
0.001 O
) O
. O
['Physiological-Clinical']

No O
complications B-outcome ['Adverse-effects']
were O
reported O
in O
either O
group O
. O
['Adverse-effects']

These O
are O
the O
socio-cultural O
priority O
problems O
that O
demand O
immediate O
attention O
by O
the O
policy O
makers O
and O
health O
professionals O
. O
[]

PATIENTS O
AND O
METHODS O
In O
a O
phase O
III O
study O
, O
SCLC O
patients O
with O
brain O
metastases O
were O
randomized O
to O
receive O
teniposide O
with O
or O
without O
WBRT O
. O
[]

However O
, O
cellular B-outcome ['Physiological-Clinical']
aspects I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
immunologic I-outcome ['Physiological-Clinical']
development I-outcome ['Physiological-Clinical']
of O
soy-fed O
infants O
have O
not O
been O
studied O
extensively O
. O
['Physiological-Clinical']

The O
Home B-outcome ['Life-Impact']
Situations I-outcome ['Life-Impact']
Questionnaire O
( O
HSQ O
) O
and O
the O
Hyperactivity/Noncompliance O
subscale O
of O
the O
Aberrant O
Behavior B-outcome ['Life-Impact']
Checklist O
were O
used O
as O
outcome O
measures O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Effects O
of O
insufficient O
sleep O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
hypertensive O
patients O
: O
a O
24-h O
study O
. O
['Physiological-Clinical']

IL-1 B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
on O
day O
15 O
did O
not O
significantly O
differ O
from O
day O
1 O
in O
both O
D53-treated O
and O
placebo O
groups O
either O
when O
AMs O
were O
unstimulated O
or O
were O
stimulated O
with O
concentrations O
of O
LPS O
resulting O
in O
maximal O
IL-1 B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pathophysiological O
implications O
. O
[]

Flumazenil O
had O
no O
effect O
on O
CBF B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

OBJECTIVE O
The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
safety O
and O
efficacy O
of O
leuprolide O
acetate O
3-month O
depot O
formulations O
for O
the O
treatment O
of O
CPP O
in O
children O
. O
[]

The O
risk-benefit O
ratio O
for O
estrogen O
therapy O
of O
depression B-outcome ['Life-Impact']
in O
these O
patients O
was O
judged O
to O
be O
favorable O
. O
['Life-Impact']

They O
were O
asked O
to O
rate O
the O
severity B-outcome ['Physiological-Clinical']
and O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
their I-outcome ['Physiological-Clinical']
rhinorrhea I-outcome ['Physiological-Clinical']
each O
day O
throughout O
the O
study O
on O
a O
scale O
from O
zero O
to O
six O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
comparison O
of O
different O
antipyretics O
in O
children O
with O
malaria O
showed O
a O
small O
effect O
of O
naproxen O
, O
but O
not O
of O
metamizol O
, O
on O
the O
reduction O
of O
fever B-outcome ['Physiological-Clinical']
peaks O
. O
['Physiological-Clinical']

CONCLUSION O
The O
quality O
of O
bitewing O
films O
taken O
by O
the O
loop O
and O
holder O
techniques O
was O
not O
significantly O
different O
. O
[]

BACKGROUND O
Pulmonary O
rehabilitation O
is O
widely O
advocated O
for O
people O
with O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
to O
improve O
exercise O
capacity O
, O
symptoms O
and O
quality O
of O
life O
, O
however O
only O
a O
minority O
of O
individuals O
with O
COPD O
are O
able O
to O
participate O
. O
[]

Perceived B-outcome ['Life-Impact']
exertion I-outcome ['Life-Impact']
during O
exhaustive O
cycling O
exercise O
was O
strongly O
correlated O
( O
r O
= O
-0.82 O
, O
P O
= O
0.003 O
) O
with O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
exhaustion I-outcome ['Physiological-Clinical']
( O
10.5 O
+/- O
2.1 O
min O
) O
. O
['Life-Impact', 'Physiological-Clinical']

OBJECTIVE O
The O
aim O
of O
the O
present O
randomized O
, O
double-blind O
study O
was O
to O
evaluate O
the O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
of O
proximal O
furcations O
treated O
with O
enamel O
matrix O
derivative O
proteins O
( O
EMD O
) O
. O
['Physiological-Clinical']

The O
primary O
outcome O
was O
sustained B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
, O
defined O
as O
a O
Birmingham O
Vasculitis O
Activity O
Score O
for O
Wegener O
's O
Granulomatosis O
of O
0 O
for O
at O
least O
six O
months O
( O
scores O
can O
range O
from O
0 O
to O
67 O
, O
with O
higher O
scores O
indicating O
more O
active O
disease O
) O
. O
['Physiological-Clinical']

Effect O
of O
intestinal O
production O
of O
equol O
on O
menopausal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
women O
treated O
with O
soy O
isoflavones O
. O
['Physiological-Clinical']

The O
results O
indicated O
that O
short-term O
treatment O
with O
the O
alkaloid O
improved O
memory B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
. O
['Life-Impact']

In O
addition O
, O
sildenafil-treated O
subjects O
were O
more O
satisfied O
with O
treatment O
and O
had O
a O
higher O
intercourse B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
rate O
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
samples O
were O
obtained O
for O
the O
measurement O
of O
ionized O
calcium B-outcome ['Physiological-Clinical']
, O
ionized O
['Physiological-Clinical', 'Physiological-Clinical']

The O
results O
showed O
a O
highly O
significant O
diagnosisxdrugxtime B-outcome ['Physiological-Clinical']
interaction I-outcome ['Physiological-Clinical']
on O
repeated O
measure O
analysis O
covaried O
for O
baseline O
. O
['Physiological-Clinical']

A O
total O
of O
94 O
patients O
completed O
the O
study O
which O
involved O
two O
training O
sessions O
prior O
to O
treatment O
and O
twice O
a O
week O
'booster O
' O
sessions O
during O
the O
first O
5 O
weeks O
of O
treatment O
. O
[]

Bronchodilatory B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
formoterol O
, O
ipratropium O
, O
and O
their O
combination O
in O
patients O
with O
stable O
COPD O
. O
['Physiological-Clinical']

RESULTS O
The O
mean O
total O
operating B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
( O
standard O
error O
of O
the O
mean O
) O
when O
the O
hand-sewn O
and O
the O
stapled O
methods O
were O
used O
were O
214 O
( O
4 O
) O
minutes O
and O
217 O
( O
3.4 O
) O
minutes O
, O
respectively O
( O
p O
= O
not O
significant O
[ O
NS O
] O
) O
. O
['Life-Impact']

PATIENTS O
Individuals O
with O
New O
York O
Heart O
Association O
functional O
class O
II-III O
heart O
failure O
( O
mild O
to O
moderate O
) O
. O
[]

Elevated O
scores O
were O
associated O
with O
being O
younger O
, O
female O
, O
divorced O
or O
separated O
, O
not O
employed O
, O
living O
alone O
, O
having O
a O
lower O
level O
of O
education O
, O
and O
having O
poorer O
health O
and O
quality O
of O
life O
. O
[]

Thus O
, O
both O
the O
degenerative O
and O
vascular O
type O
of O
dementia O
exhibited O
a O
therapeutic O
benefit O
that O
could O
be O
objectified O
at O
the O
neurophysiological O
level O
by O
EEG O
mapping O
in O
an O
improvement O
of O
vigilance O
. O
[]

The O
correlation O
coefficient O
between O
the O
volume O
scanner O
and O
CT O
was O
0.86 O
, O
with O
agreement O
of O
90 O
% O
and O
kappa O
value O
of O
0.73 O
. O
[]

The O
stone B-outcome ['Physiological-Clinical']
fragmentation I-outcome ['Physiological-Clinical']
and O
3-month O
clearance B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
) O
rates O
were O
clearly O
higher O
: O
93.8 O
% O
and O
87.5 O
% O
respectively O
for O
ESWL O
with O
diuresis O
compared O
with O
70.6 O
% O
( O
for O
both O
fragmentation O
and O
clearance O
) O
with O
standard O
ESWL O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pharmacokinetics B-outcome ['Physiological-Clinical']
of O
carvedilol O
( O
C O
) O
have O
been O
studied O
in O
healthy O
volunteers O
after O
a O
single O
i.v O
. O
['Physiological-Clinical']

A O
Pediatric O
Oncology O
Group O
study O
. O
[]

In O
vitro-in O
vivo O
correlations O
were O
obtained O
by O
comparing O
the O
logarithm O
of O
the O
in O
vitro O
burst O
time O
with O
time O
to O
peak O
plasma B-outcome ['Physiological-Clinical']
level I-outcome ['Physiological-Clinical']
and O
the O
time O
to O
the O
first O
measurable O
['Physiological-Clinical']

Baseline O
evaluations O
were O
performed O
on O
31 O
patients O
after O
a O
four-week O
placebo O
washout O
period O
. O
[]

There O
was O
no O
significant O
difference O
in O
discomfort B-outcome ['Physiological-Clinical']
scores O
between O
the O
two O
groups O
; O
however O
, O
all O
discomfort B-outcome ['Physiological-Clinical']
scores O
decreased O
over O
time O
( O
p O
= O
0.008 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
P-113 O
, O
a O
12 O
amino O
acid O
histatin-based O
peptide O
, O
was O
evaluated O
in O
a O
mouthrinse O
formulation O
for O
safety O
, O
prevention O
of O
the O
development O
of O
experimental O
gingivitis O
, O
and O
for O
its O
effects O
on O
periodontal O
flora O
. O
[]

INTERVENTIONS O
Phlebotomy O
was O
performed O
during O
both O
the O
LD O
( O
50 O
) O
and O
fluid O
resuscitation O
studies O
. O
[]

In O
contrast O
, O
with O
sodium O
nitroprusside O
or O
isoflurane O
, O
the O
decrease O
in O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
associated O
with O
decreases O
in O
systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
of O
similar O
magnitude O
, O
with O
no O
change O
in O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
To O
test O
the O
hypothesis O
that O
5 O
mg/mL O
tramadol O
is O
superior O
to O
3 O
? O
[]

Perineal O
wound O
healing O
was O
taken O
as O
endpoint O
of O
this O
study O
. O
[]

RESULTS O
714 O
patients O
were O
included O
in O
the O
study O
( O
356 O
intervention O
, O
358 O
control O
) O
, O
and O
the O
mean O
[ O
SD O
] O
age O
was O
62.8 O
[ O
8.1 O
] O
years O
. O
[]

The O
advantage O
for O
women O
receiving O
CMFVP O
was O
seen O
for O
all O
subsets O
regardless O
of O
menopausal O
status O
except O
among O
women O
who O
were O
premenopausal O
and O
had O
1-3 O
positive O
nodes O
. O
[]

BACKGROUND O
Back B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
one O
of O
the O
most O
prevalent O
conditions O
afflicting O
American O
adults O
, O
is O
the O
leading O
reason O
for O
using O
complementary O
and O
alternative O
medicine O
( O
CAM O
) O
therapies O
. O
['Physiological-Clinical']

Obesity O
is O
a O
major O
risk O
factor O
for O
breast O
cancer O
recurrence O
and O
mortality O
in O
both O
pre- O
and O
postmenopausal O
women O
. O
[]

Indicators O
of O
personal B-outcome ['Life-Impact']
persuasion I-outcome ['Life-Impact']
were O
more O
consistent O
. O
['Life-Impact']

Further O
replication O
and O
long-term O
maintenance O
trials O
are O
needed O
. O
[]

110 O
patients O
were O
randomly O
allocated O
in O
a O
1:1 O
ratio O
to O
receive O
catheter O
ablation O
and O
an O
ICD O
( O
ablation O
group O
, O
n=54 O
) O
or O
ICD O
alone O
( O
control O
group O
, O
n=56 O
) O
. O
[]

The O
stone B-outcome ['Physiological-Clinical']
fragmentation I-outcome ['Physiological-Clinical']
and O
clearance B-outcome ['Physiological-Clinical']
rates O
were O
the O
two O
end O
points O
for O
evaluation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

MPA-Hematology O
Italian O
Cooperative O
Group O
. O
[]

Clinical O
impact O
of O
leak O
compensation O
during O
non-invasive O
ventilation O
. O
[]

Patients O
were O
monitored O
for O
adverse O
events O
. O
[]

RESULTS O
The O
mean O
age O
of O
the O
patients O
was O
44 O
years O
, O
86 O
were O
males O
and O
16 O
were O
females O
. O
[]

OBJECTIVE O
To O
compare O
the O
effects O
of O
a O
single O
dose O
of O
biologic O
and O
synthetic O
porcine O
secretin O
to O
placebo O
on O
a O
variety O
of O
autism O
symptoms O
. O
[]

METHODS O
Thirty O
three O
patients O
with O
Huntington O
's O
disease O
participated O
in O
a O
double O
blind O
randomised O
trial O
. O
[]

A O
second O
goal O
was O
to O
identify O
the O
optimal O
route O
for O
administration O
. O
[]

RESULTS O
All O
12 O
volunteers O
completed O
the O
study O
without O
incident O
. O
[]

OBJECTIVE O
The O
objective O
of O
this O
study O
was O
to O
perform O
an O
investigation O
evaluating O
if O
cervical O
spinal O
manipulative O
therapy O
( O
SMT O
) O
can O
increase O
grip O
strength O
on O
judo O
athletes O
in O
a O
top O
10 O
national-ranked O
team O
. O
[]

RESULTS O
Of O
96,517 O
eligible O
subjects O
, O
87,655 O
were O
screened O
, O
8688 O
individuals O
never O
received O
the O
invitation O
and O
174 O
refused O
screening O
. O
[]

There O
was O
no O
significant O
difference O
found O
in O
analgesic B-outcome ['Resource-use']
use I-outcome ['Resource-use']
during O
the O
first O
24 O
hrs O
after O
surgery O
. O
['Resource-use']

Patients O
were O
randomly O
assigned O
after O
surgery O
to O
receive O
doxorubicin O
( O
60 O
mg/m O
( O
2 O
) O
) O
plus O
either O
cyclophosphamide O
( O
600 O
mg/m O
( O
2 O
) O
; O
AC O
) O
or O
docetaxel O
( O
60 O
mg/m O
( O
2 O
) O
; O
AT O
) O
given O
every O
3 O
weeks O
for O
four O
cycles O
, O
followed O
by O
hormone O
therapy O
for O
patients O
with O
estrogen O
receptor O
( O
ER O
) O
and/or O
progesterone O
receptor O
( O
PR O
) O
-positive O
tumors O
. O
[]

The O
adjuvant O
use O
of O
aromatase O
inhibitors O
in O
breast O
cancer O
is O
associated O
with O
adverse O
effects O
on O
bone O
health O
. O
[]

[ O
Effects O
of O
parecoxib O
on O
morphine O
dosage O
in O
postoperative O
patient-controlled O
analgesia O
following O
thoracoscope-assisted O
thoracotomy O
] O
. O
[]

CONCLUSION O
Loss O
of O
LH O
after O
stopping O
LA O
is O
likely O
to O
be O
clinically O
important O
in O
ovarian O
stimulation O
regimens O
that O
use O
pure O
FSH O
with O
LA O
in O
ultrashort O
protocols O
. O
[]

Compared O
to O
IVO O
, O
exposure O
of O
germinal-vesicle O
oocytes O
for O
a O
maturation O
period O
of O
30 O
hours O
did O
not O
increase O
aneuploidy B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Rilmenidine O
left O
adrenaline B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
untouched O
under O
all O
conditions O
. O
['Physiological-Clinical']

METHODS O
From O
1991 O
to O
1995 O
, O
89 O
patients O
with O
T3b O
, O
T4 O
or O
metastatic O
urothelial O
carcinoma O
were O
randomly O
allocated O
to O
a O
methotrexate O
, O
epirubicin O
and O
cisplatin O
chemotherapy O
group O
( O
arm O
1 O
: O
S-MEC O
therapy O
; O
n O
= O
29 O
) O
, O
a O
dose-intensified O
MEC O
therapy O
combined O
with O
G-CSF O
group O
( O
arm O
2 O
: O
I-MEC O
therapy O
; O
n O
= O
30 O
) O
or O
a O
methotrexate O
, O
vinblastine O
, O
doxorubicin O
and O
cisplatin O
chemotherapy O
( O
arm O
3 O
: O
M-VAC O
therapy O
; O
n O
= O
30 O
) O
. O
[]

OBJECTIVE O
Intraoperative O
comfort O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
during O
surgical O
procedures O
under O
regional O
anaesthesia O
can O
be O
improved O
with O
the O
use O
of O
supplemental O
intravenous O
sedation O
. O
['Life-Impact']

CONCLUSIONS O
Application O
of O
R-salbutamol O
cream O
0.5 O
% O
was O
safe O
and O
well O
tolerated O
. O
[]

The O
mechanism O
behind O
this O
phenomenon O
remains O
to O
be O
elucidated O
. O
[]

PURPOSE O
To O
evaluate O
the O
treatment O
outcomes O
after O
guided O
tissue O
regeneration O
( O
GTR O
) O
with O
a O
bioabsorbable O
membrane O
in O
Class O
II O
furcation O
defects O
in O
mandibular O
molars O
. O
[]

The O
dosage O
of O
CC O
was O
fixed O
at O
3.0 O
g/day O
for O
the O
12-week O
study O
. O
[]

Evaluation O
of O
the O
intervention O
indicated O
that O
women O
thought O
the O
head O
mounted O
device O
was O
easy O
to O
use O
, O
they O
experienced O
no O
cybersickness B-outcome ['Physiological-Clinical']
, O
and O
100 O
% O
would O
use O
VR O
again O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
results O
suggest O
that O
short-term O
treatment O
with O
donepezil O
may O
have O
limited O
impact O
on O
cognitive O
functioning O
in O
ASD O
. O
[]

Patients O
with O
hematologic O
malignancies O
received O
high-dose O
chemotherapy O
, O
total O
body O
irradiation O
, O
and O
either O
allogeneic O
( O
ALLO O
) O
BMT O
( O
n O
= O
18 O
) O
or O
autologous O
( O
AUTO O
) O
stem O
cell O
transplantation O
( O
n O
= O
25 O
) O
. O
[]

Survival B-outcome ['Mortality']
curve O
( O
Kaplan-meire O
's O
) O
of O
the O
Chinese O
herb O
group O
was O
better O
than O
that O
of O
the O
control O
group O
. O
['Mortality']

Subjects O
were O
evaluated O
every O
2 O
weeks O
by O
clinician O
raters O
and O
weekly O
by O
parents O
. O
[]

An O
exploratory O
study O
: O
the O
use O
of O
paroxetine O
for O
methamphetamine B-outcome ['Physiological-Clinical']
craving I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Patients O
were O
randomly O
assigned O
to O
take O
the O
drug O
along O
with O
a O
high-fat O
, O
high-calorie O
breakfast O
for O
the O
administration O
at O
day O
1 O
of O
the O
first O
or O
second O
cycle O
. O
[]

The O
primary O
end O
point O
was O
objective O
response O
rate O
( O
ORR O
) O
. O
[]

Conjugated O
equine O
estrogen O
influence O
on O
mammographic B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
in O
a O
substudy O
of O
the O
women O
's O
health O
initiative O
randomized O
trial O
. O
['Physiological-Clinical']

Heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
was O
scored O
according O
to O
the O
Brooker O
Grading O
system O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Adult O
patients O
with O
measurable O
, O
locally O
advanced O
, O
and/or O
metastatic O
RCC O
were O
randomly O
assigned O
2:1 O
to O
receive O
oral O
pazopanib O
or O
placebo O
. O
[]

A O
double-blind O
multicentre O
study O
. O
[]

BCG O
+ O
FAM O
significantly O
improved O
the O
survival B-outcome ['Mortality']
of I-outcome ['Mortality']
patients I-outcome ['Mortality']
with O
intestinal-type O
but O
not O
diffuse-type O
cancer O
. O
['Mortality']

Transcutaneous O
electrical O
nerve O
stimulation O
( O
TENS O
) O
has O
been O
used O
to O
treat O
chronic O
pain O
syndromes O
and O
has O
been O
reported O
to O
be O
of O
some O
utility O
in O
the O
treatment O
of O
postsurgical O
pain O
. O
[]

Patients O
in O
group O
A O
had O
a O
more O
rapid O
increase O
in O
WBC B-outcome ['Physiological-Clinical']
than O
those O
in O
group O
B O
; O
however O
, O
by O
week O
8 O
, O
the O
WBC B-outcome ['Physiological-Clinical']
in O
each O
group O
was O
essentially O
equal O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
AND O
DESIGN O
In O
a O
double-blinded O
setup O
, O
90 O
patients O
( O
78 O
women O
; O
median O
age O
, O
52 O
yr O
; O
range O
, O
22-83 O
) O
with O
a O
nontoxic O
nodular O
goiter O
( O
median O
size O
, O
63 O
ml O
; O
range O
, O
25-379 O
ml O
) O
were O
randomized O
to O
either O
0.1 O
mg O
rhTSH O
( O
n=60 O
) O
followed O
by O
a O
thyroid O
dose O
of O
50 O
Gy O
or O
placebo O
followed O
by O
100 O
Gy O
( O
n=30 O
) O
. O
[]

The O
method O
of O
Hills O
and O
Armitage O
was O
used O
, O
reducing O
ethanol O
in O
daily O
alcohol O
consumption O
by O
28 O
ml O
. O
[]

[ O
Local O
therapy O
of O
grade O
1 O
and O
2 O
hemorrhoids O
. O
[]

Five O
participants O
met O
diagnostic O
criteria O
for O
ASD O
, O
3 O
for O
FXS O
alone O
, O
3 O
for O
FXS O
and O
ASD O
, O
and O
1 O
for O
fragile O
X O
premutation O
. O
[]

Maternal B-outcome ['Physiological-Clinical']
oversedation I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
did O
not O
occur O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
AND O
METHODS O
218 O
patients O
with O
previously O
untreated O
HD O
entered O
this O
study O
: O
106 O
patients O
in O
arm O
A O
( O
ABVD/MOPP O
) O
and O
112 O
in O
arm O
B O
( O
ABVD/OPP O
) O
. O
[]

CONCLUSIONS O
The O
results O
suggest O
that O
increased O
neural B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
at O
the O
time O
of O
the O
ischemic O
event O
may O
play O
a O
role O
in O
reducing O
coronary O
perfusion O
leading O
to O
silent O
ischemia O
. O
['Physiological-Clinical']

In O
the O
computed O
version O
cartoons O
, O
written O
and O
audio O
instruments O
were O
included O
in O
order O
facilitate O
application O
. O
[]

The O
efficacy O
and O
safety O
of O
the O
11betaHSD1 O
inhibitor O
INCB13739 O
were O
assessed O
when O
added O
to O
ongoing O
metformin O
monotherapy O
in O
patients O
with O
type O
2 O
diabetes O
exhibiting O
inadequate O
glycemic O
control O
( O
A1C O
7-11 O
% O
) O
. O
[]

OBJECTIVE O
To O
study O
the O
effect O
of O
ursodeoxycholic O
acid O
( O
UDCA O
) O
on O
serum O
liver O
enzyme O
levels O
[ O
alanine O
aminotransferase O
( O
ALT O
) O
and O
gamma-glutamyl O
transferase O
( O
GGT O
) O
] O
in O
101 O
patients O
with O
hepatitis O
C O
virus-related O
chronic O
liver O
disease O
. O
[]

Nurses O
and O
physician O
assistants O
( O
PAs O
) O
were O
presented O
a O
case O
study O
of O
a O
patient O
with O
symptoms O
of O
CFS O
. O
[]

Regardless O
of O
the O
dosage O
used O
, O
indobufen O
was O
shown O
to O
induce O
a O
prompt O
normalization O
of O
the O
enhanced B-outcome ['Physiological-Clinical']
platelet I-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
of O
these O
patients O
. O
['Physiological-Clinical']

16 O
consecutive O
patients O
( O
median O
age O
58.5 O
years O
, O
range O
40-83 O
) O
entered O
the O
9-week O
study O
a O
median O
of O
168 O
days O
( O
range O
6-913 O
) O
post O
stroke O
and O
were O
treated O
with O
citalopram O
10-20 O
mg O
daily O
for O
3 O
weeks O
. O
[]

ETAC O
( O
Early O
Treatment O
of O
the O
Atopic O
Child O
) O
, O
a O
multi-centre O
predominantly O
European O
study O
to O
investigate O
the O
potential O
for O
cetirizine O
to O
prevent O
the O
development O
of O
asthma O
in O
infants O
with O
atopic O
dermatitis O
has O
completed O
enrollment O
: O
817 O
children O
have O
been O
randomised O
to O
18 O
months O
' O
treatment O
with O
either O
active O
or O
placebo O
and O
a O
subsequent O
18 O
months O
of O
post-treatment O
follow-up O
. O
[]

The O
primary O
end O
point O
was O
the O
major B-outcome ['Physiological-Clinical']
molecular I-outcome ['Physiological-Clinical']
response O
( O
MMR O
) O
rate O
at O
12 O
months O
. O
['Physiological-Clinical']

Severe B-outcome ['Physiological-Clinical']
late I-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
bladder I-outcome ['Physiological-Clinical']
were O
seen O
in O
58.5 O
% O
of O
patients O
after O
neutron O
therapy O
and O
in O
40.5 O
% O
after O
photon O
therapy O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

Subjects O
randomly O
assigned O
to O
the O
mCIT+mental O
practice O
experimental O
condition O
also O
received O
30-minute O
mental O
practice O
sessions O
provided O
directly O
after O
therapy O
sessions O
. O
[]

Pain O
and O
overall O
well-being O
were O
measured O
using O
a O
visual O
analog O
scale O
( O
VAS O
) O
. O
[]

A O
non-intervention O
group O
of O
consenting O
women O
choosing O
a O
range O
of O
other O
post-abortion O
contraception O
methods O
, O
including O
no O
contraception O
, O
will O
be O
included O
for O
comparison O
of O
secondary O
outcomes O
. O
[]

Bifidobacteria B-outcome ['Physiological-Clinical']
were O
analysed O
by O
a O
direct O
PCR O
method O
in O
fecal O
samples O
from O
mothers O
at O
30-35 O
weeks O
of O
gestation O
and O
from O
infants O
at O
1 O
month O
of O
age O
and O
from O
breast-milk O
samples O
1 O
month O
post-partum O
. O
['Physiological-Clinical']

In O
the O
etidronate O
group O
, O
serum B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
deoxypyridinoline I-outcome ['Physiological-Clinical']
levels O
decreased O
significantly O
during O
the O
study O
period O
, O
whereas O
the O
levels O
in O
the O
placebo O
group O
were O
increased O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Porfimer O
sodium O
exhibited O
a O
longer O
elimination O
half-life B-outcome ['Physiological-Clinical']
( O
175.3 O
hr O
) O
, O
slower O
clearance O
( O
0.0028 O
L/kg/hr O
) O
, O
and O
a O
larger O
area O
under O
the O
curve O
( O
1075 O
microg/g/hr O
) O
in O
tumors O
than O
did O
tin O
ethyl O
etiopurpurin O
or O
aluminum O
chlorophthalocyanine O
. O
['Physiological-Clinical']

In O
the O
well-trained O
group O
the O
24h B-outcome ['Physiological-Clinical']
CHO I-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
was O
even O
more O
negative O
for O
both O
types O
of O
diet O
( O
-103 O
to O
-185 O
g/d O
for O
the O
Red.F O
and O
Hi.F O
diet O
, O
respectively O
) O
under O
similar O
conditions O
compared O
with O
the O
trained O
obese O
group O
. O
['Physiological-Clinical']

The O
means O
, O
95 O
% O
confidence O
intervals O
[ O
95 O
% O
CI O
] O
, O
incremental B-outcome ['Resource-use']
cost-effectiveness O
graphic O
and O
acceptability O
curve O
were O
obtained O
from O
1,000 O
bootstrap O
replications O
. O
['Life-Impact', 'Resource-use']

Most O
subjects O
required O
[]

All O
efficacy O
measures O
were O
obtained O
by O
an O
independent O
evaluator O
blinded O
to O
randomization O
condition O
and O
side O
effects O
. O
[]

We O
analyzed O
48-hour O
and O
30-day O
outcomes O
of O
patients O
enrolled O
in O
the O
Enhanced O
Suppression O
of O
the O
Platelet O
IIb/IIIa O
Receptor O
with O
Integrilin O
Therapy O
( O
ESPRIT O
) O
trial O
. O
[]

BP B-outcome ['Physiological-Clinical']
became O
['Physiological-Clinical']

The O
bupivacaine O
group O
( O
n=30 O
) O
received O
20cc O
of O
0.5 O
% O
bupivacaine O
in O
at O
the O
same O
surgical O
site O
. O
[]

Fondaparinux O
combined O
with O
intermittent O
pneumatic O
compression O
vs. O
intermittent O
pneumatic O
compression O
alone O
for O
prevention O
of O
venous O
thromboembolism O
after O
abdominal O
surgery O
: O
a O
randomized O
, O
double-blind O
comparison O
. O
[]

Scoring O
of O
neurologic B-outcome ['Physiological-Clinical']
disability I-outcome ['Physiological-Clinical']
was O
performed O
at O
the O
start O
and O
end O
of O
the O
treatment O
period O
. O
['Physiological-Clinical']

Group O
I O
consisted O
of O
15 O
infants O
who O
were O
given O
intravenously O
1 O
gm/kg O
of O
salt-poor O
human O
serum O
albumin O
one O
hour O
before O
the O
exchanges O
. O
[]

PATIENTS O
Forty-five O
patients O
with O
displaced O
closed O
and O
open O
Gustilo O
type O
I-IIIA O
fractures O
of O
the O
central O
two O
thirds O
of O
the O
tibia O
. O
[]

End-treatment B-outcome ['Physiological-Clinical']
TSAb I-outcome ['Physiological-Clinical']
values O
, O
when O
low O
( O
less O
than O
350 O
% O
) O
or O
negative O
did O
not O
correlate O
with O
later O
evolution O
: O
in O
these O
39 O
patients O
, O
relapse B-outcome ['Physiological-Clinical']
rate O
was O
41 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
relevance O
of O
the O
chronology O
between O
panic O
disorder O
and O
avoidance O
behavior O
and O
of O
an O
early O
, O
medium O
or O
late O
onset O
of O
panic O
disorder O
was O
tested O
. O
[]

The O
authors O
conclude O
that O
the O
use O
of O
the O
MTL O
for O
ocular O
irrigation O
is O
well O
tolerated O
and O
recommend O
using O
LR O
as O
the O
irrigation O
solution O
for O
maximal O
patient O
comfort O
. O
[]

Both O
dosage O
regimens O
of O
lamotrigine O
were O
well O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact']

CONCLUSIONS O
Proton O
pump O
inhibitors O
and O
roxithromycin O
do O
not O
alter O
the O
systemic O
bioavailability O
of O
each O
other O
. O
[]

Cox O
proportional O
hazards O
model O
was O
used O
to O
assess O
the O
prognostic O
role O
of O
BRAF O
mutation O
, O
adjusting O
for O
clinical O
features O
, O
adjuvant O
chemotherapy O
arm O
, O
and O
MSI O
status O
. O
[]

However O
, O
application O
of O
the O
technique O
may O
be O
limited O
by O
the O
magnitude O
of O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
response O
and O
by O
the O
short-lived O
nature O
of O
the O
increase O
in O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Report O
to O
the O
Medical O
Research O
Council O
of O
the O
Working O
Party O
on O
Leukaemia O
in O
Childhood O
. O
[]

AIM O
To O
evaluate O
the O
efficacy O
of O
on-demand O
rabeprazole O
maintenance O
therapy O
in O
patients O
with O
non-erosive O
reflux O
disease O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
with O
surgically O
resected O
locally O
advanced O
( O
T3-4 O
or O
N1-2 O
) O
or O
metastatic O
RCC O
were O
randomly O
assigned O
to O
1 O
of O
4 O
treatment O
groups O
that O
received O
different O
dose O
levels O
and O
schedules O
of O
subcutaneous O
IL-2 O
as O
follows O
: O
dose O
level O
1 O
, O
4 O
MIU/m2 O
per O
day O
, O
every O
other O
week O
for O
24 O
weeks O
( O
n O
= O
10 O
) O
; O
dose O
level O
2 O
, O
8 O
MIU/m2 O
per O
day O
, O
every O
other O
week O
for O
24 O
weeks O
( O
n O
= O
9 O
) O
; O
dose O
level O
3 O
, O
4 O
MIU/m2 O
per O
day O
, O
weeks O
1-4 O
, O
9-12 O
, O
and O
17-20 O
( O
n O
= O
11 O
) O
; O
and O
dose O
level O
4 O
, O
8 O
MIU/m2 O
per O
day O
, O
weeks O
1-4 O
, O
9-12 O
, O
and O
17-20 O
( O
n O
= O
10 O
) O
. O
[]

Total O
bacterial B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
decreased O
by O
90 O
% O
for O
treatment O
sites O
and O
remained O
at O
that O
value O
for O
13 O
weeks O
. O
['Physiological-Clinical']

Scopolamine O
significantly O
decreased O
both O
VO2 B-outcome ['Physiological-Clinical']
and O
EE B-outcome ['Physiological-Clinical']
, O
whereas O
glycopyrrolate O
increased O
VO2 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Although O
maternal O
attachment O
is O
an O
important O
predictor O
of O
infant O
attachment O
security O
and O
other O
developmental O
outcomes O
, O
little O
is O
known O
about O
the O
formation O
of O
maternal O
attachment O
in O
the O
first O
few O
months O
of O
the O
infant O
's O
life O
, O
particularly O
among O
ethnic O
minority O
mothers O
. O
[]

Assessment O
of O
autistic B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
( O
autism B-outcome ['Life-Impact']
) O
symptoms B-outcome ['Physiological-Clinical']
, O
primary O
and O
secondary B-outcome ['Physiological-Clinical']
, O
poses O
more O
challenging O
problems O
than O
ordinarily O
found O
in O
multisite O
randomized O
clinical O
trial O
( O
RCT O
) O
assessments O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Response O
rate O
( O
complete O
+ O
partial O
remission O
) O
at O
week O
10 O
was O
78 O
% O
( O
95 O
% O
confidence O
interval O
( O
CI O
) O
64-88 O
% O
) O
in O
Arm O
A O
and O
68 O
% O
( O
95 O
% O
CI O
54-80 O
% O
) O
in O
Arm O
B O
( O
p O
= O
0.13 O
) O
. O
[]

OBJECTIVES O
To O
evaluate O
triple O
tourniquets O
in O
controlled O
conditions O
and O
for O
the O
first O
time O
to O
investigate O
the O
hypothesis O
that O
leaving O
a O
semi-permanent O
tourniquet O
around O
the O
uterine O
artery O
reduces O
post-operative O
bleeding O
from O
the O
uterine O
incisions O
. O
[]

METHODS O
A O
total O
of O
1,256 O
patients O
with O
stage O
III O
melanoma O
were O
randomly O
assigned O
after O
full O
lymphadenectomy O
to O
receive O
either O
observation O
( O
n O
= O
629 O
) O
or O
PEG-IFN-alpha-2b O
( O
n O
= O
627 O
) O
: O
induction O
6 O
micrograms/kg/wk O
[ O
DOSAGE O
ERROR O
CORRECTED O
] O
for O
8 O
weeks O
then O
maintenance O
3 O
micrograms/kg/wk O
[ O
DOSAGE O
ERROR O
CORRECTED O
] O
for O
an O
intended O
total O
duration O
of O
5 O
years O
. O
[]

The O
promoter O
methylation O
of O
the O
MGMT O
gene O
in O
the O
plasma O
DNA O
samples O
form O
middle-and-late O
stage O
tumor O
patients O
receiving O
chemotherapy O
was O
detected O
before O
and O
after O
treatment O
using O
nested O
methylation-specific O
polymerase O
chain O
reaction O
( O
MSP O
) O
. O
[]

In O
phase O
2 O
, O
49 O
participants O
were O
randomly O
assigned O
in O
a O
double-blind O
design O
to O
receive O
an O
additional O
6 O
rounds O
of O
either O
DMSA O
or O
placebo O
. O
[]

Few O
studies O
have O
explored O
the O
joint O
association O
of O
circulating O
vitamin O
D O
levels O
with O
VDR O
polymorphisms O
. O
[]

The O
results O
are O
discussed O
in O
relation O
to O
the O
cognitive O
effects O
of O
nicotine O
. O
[]

We O
evaluated O
a O
strategy O
of O
balloon O
dissection O
, O
subfascial O
endoscopic O
perforating O
vein O
surgery O
( O
SEPS O
) O
with O
routine O
posterior O
deep O
compartment O
fasciotomy O
, O
including O
ligation O
and O
stripping O
of O
the O
superficial O
system O
, O
for O
use O
when O
reflux O
is O
documented O
at O
duplex O
ultrasound O
( O
US O
) O
scanning O
. O
[]

Baseline O
subjective O
and O
blinded O
physician O
dyschromia B-outcome ['Physiological-Clinical']
and O
rhytid B-outcome ['Physiological-Clinical']
scores O
revealed O
no O
significant O
difference O
between O
the O
IPL O
and O
Er O
: O
YAG O
randomly O
assigned O
sides O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
This O
double-blind O
, O
randomized O
, O
placebo-controlled O
crossover O
study O
included O
44 O
CF O
patients O
( O
aged O
7-19 O
y O
; O
20 O
males O
) O
who O
were O
randomly O
assigned O
to O
receive O
magnesium O
( O
n O
= O
22 O
; O
300 O
mg/d O
) O
or O
placebo O
( O
n O
= O
22 O
) O
for O
8 O
wk O
with O
a O
4-wk O
washout O
period O
between O
trials O
. O
[]

Elective O
testicular O
biopsy O
was O
performed O
on O
235 O
( O
89.4 O
% O
) O
boys O
. O
[]

These O
effects O
were O
in O
excess O
of O
actual O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
differences O
. O
['Physiological-Clinical']

Several O
new O
studies O
have O
indicated O
that O
an O
active O
approach O
to O
patients O
with O
chronic O
disabling O
low O
back O
pain O
( O
LBP O
) O
seems O
effective O
. O
[]

We O
hypothesized O
that O
this O
was O
due O
to O
differences O
in O
the O
composition O
of O
the O
challenge O
vehicle O
. O
[]

On O
the O
basis O
of O
recovery O
assessed O
by O
postural O
stability O
, O
propofol/alfentanil/N2O O
anaesthesia O
was O
not O
preferable O
to O
thiopentone/halothane/N2O O
anaesthesia O
after O
minor O
paediatric O
otolaryngological O
surgery O
. O
[]

The O
primary O
outcome O
was O
defined O
as O
an O
improvement O
of O
2 O
points O
in O
error O
rates O
for O
facial B-outcome ['Life-Impact']
emotion I-outcome ['Life-Impact']
labeling I-outcome ['Life-Impact']
( O
DANVA2 O
) O
from O
baseline O
. O
['Life-Impact']

Infant O
attention O
was O
defined O
as O
duration O
of O
time O
spent O
examining O
objects O
. O
[]

In O
PAN O
related O
to O
HBV O
: O
The O
first-line O
treatment O
should O
be O
the O
association O
of O
anti-viral O
agents O
and O
PE O
. O
[]

These O
results O
provide O
preliminary O
evidence O
that O
CBT O
may O
yield O
increased O
independence O
and O
daily B-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
among O
children O
with O
ASD O
. O
['Life-Impact']

The O
arousal B-outcome ['Physiological-Clinical']
index O
was O
significantly O
higher O
during O
leak O
periods O
, O
and O
its O
changes O
correlated O
positively O
with O
changes O
in O
mouth B-outcome ['Physiological-Clinical']
leak I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
single- O
and O
dual-coil O
active O
pectoral O
defibrillation O
lead O
systems O
. O
[]

OS B-outcome ['Mortality']
rates O
were O
also O
different O
: O
54 O
percent O
( O
95 O
percent O
CI O
: O
48-57 O
percent O
) O
vs O
70 O
percent O
( O
95 O
percent O
CI O
: O
65-76 O
percent O
) O
, O
respectively O
( O
p O
< O
0.01 O
) O
. O
['Mortality']

FINDINGS O
We O
randomised O
44 O
patients O
to O
combination O
and O
45 O
to O
single O
agent O
. O
[]

The O
authors O
conducted O
a O
study O
to O
compare O
two O
sedation O
techniques O
for O
surgical O
procedures O
performed O
under O
regional O
anaesthesia O
, O
i.e. O
, O
midazolam O
and O
pethidine O
combination O
compared O
with O
midazolam O
and O
tramadol O
combination O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
assessed O
at O
regular O
intervals O
for O
12 O
hours O
using O
an O
objective O
pain B-outcome ['Physiological-Clinical']
score O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
No O
significant O
improvement O
in O
objective O
outcome O
variables O
was O
observed O
in O
the O
population O
treated O
with O
ES O
compared O
with O
the O
population O
treated O
with O
KE O
( O
with O
29.2 O
% O
vs. O
36.4 O
% O
of O
the O
women O
showing O
objective O
improvement O
in O
measured O
urinary B-outcome ['Physiological-Clinical']
leakage I-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical']

Tumors O
of O
the O
lung B-outcome ['Physiological-Clinical']
and O
other B-outcome ['Physiological-Clinical']
solid I-outcome ['Physiological-Clinical']
forms I-outcome ['Physiological-Clinical']
showed O
no O
such O
difference O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
misoprostol B-outcome ['Physiological-Clinical']
on O
human O
circulation O
. O
['Physiological-Clinical']

These O
findings O
reveal O
statistically O
significant O
relationships O
of O
low O
to O
moderate O
strength O
among O
potential B-outcome ['Physiological-Clinical']
quantitative I-outcome ['Physiological-Clinical']
spasticity I-outcome ['Physiological-Clinical']
measures O
, O
a O
traditional B-outcome ['Physiological-Clinical']
qualitative I-outcome ['Physiological-Clinical']
spasticity I-outcome ['Physiological-Clinical']
scale O
and O
a O
simple B-outcome ['Physiological-Clinical']
measure I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
voluntary I-outcome ['Physiological-Clinical']
ankle I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Exercise O
with O
or O
without O
CLA O
supplementation O
decreased O
insulin B-outcome ['Resource-use']
levels O
and O
increased O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Captopril O
and O
quinapril O
doses O
were O
titrated O
to O
lower O
pressure O
similarly O
. O
[]

It O
may O
be O
either O
binocular O
eye O
position O
, O
or O
the O
position O
of O
the O
viewing-eye O
only O
, O
that O
is O
crucial O
. O
[]

Diabetic O
patients O
were O
older O
; O
were O
more O
likely O
to O
be O
female O
; O
had O
a O
higher O
proportion O
of O
congestive B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
, O
hypertension B-outcome ['Physiological-Clinical']
, O
prior B-outcome ['Physiological-Clinical']
CABG I-outcome ['Physiological-Clinical']
, O
and O
unstable B-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
; O
and O
had O
higher O
body O
mass O
index O
and O
lower O
ejection B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
than O
nondiabetic O
patients O
( O
P O
< O
0.01 O
for O
all O
comparisons O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Reciprocal O
imitation O
training O
( O
RIT O
) O
is O
a O
naturalistic O
imitation O
intervention O
designed O
to O
teach O
spontaneous B-outcome ['Life-Impact']
imitation I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
during O
play O
. O
['Life-Impact']

BACKGROUND O
Magnesium O
is O
one O
of O
the O
most O
important O
minerals O
in O
the O
body O
. O
[]

Patients O
were O
assessed O
on O
entry O
and O
after O
three O
months O
treatment O
. O
[]

However O
, O
median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TTP I-outcome ['Physiological-Clinical']
) O
and O
overall O
survival B-outcome ['Mortality']
( O
OS B-outcome ['Mortality']
) O
were O
significantly O
longer O
in O
patients O
treated O
with O
concomitant O
chemoradiotherapy O
. O
['Physiological-Clinical', 'Mortality', 'Mortality']

BACKGROUND O
Blood O
pressure O
measurement O
is O
an O
essential O
clinical O
skill O
that O
can O
readily O
be O
assessed O
in O
objective O
structured O
clinical O
examination O
( O
OSCE O
) O
. O
[]

These O
preliminary O
findings O
suggest O
that O
VRH O
analgesia O
is O
a O
novel O
technology O
worthy O
of O
further O
study O
, O
both O
to O
improve O
pain B-outcome ['Resource-use']
management I-outcome ['Resource-use']
and O
to O
increase O
availability O
of O
hypnotic O
analgesia O
to O
populations O
without O
access O
to O
therapist-provided O
hypnosis O
and O
suggestion O
. O
['Resource-use']

The O
net O
change O
in O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
was O
-1.2 O
kg O
( O
95 O
% O
CI-1.9 O
, O
-0.5 O
) O
in O
Group O
S1 O
and O
-1.1 O
kg O
( O
95 O
% O
CI O
-1.8 O
, O
-0.4 O
) O
in O
Group O
S2 O
. O
['Physiological-Clinical']

They O
were O
randomized O
to O
either O
operative O
or O
nonoperative O
treatment O
with O
a O
2-year O
follow-up O
. O
[]

At O
each O
of O
three O
60-min O
intervals O
after O
the O
capsule O
was O
ingested O
, O
the O
subjects O
chewed O
two O
pieces O
of O
gum O
containing O
a O
total O
of O
0 O
, O
4 O
or O
8 O
mg O
of O
nicotine O
. O
[]

The O
seven-day O
course O
of O
metronidazole O
was O
superior O
to O
the O
single-dose O
regimen O
in O
the O
percentage O
of O
patients O
with O
clue O
cells O
and O
the O
percentage O
of O
patients O
with O
a O
positive O
sniff O
test O
at O
the O
first O
follow-up O
visit O
; O
however O
, O
differences O
in O
the O
initial B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
assessed I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
and O
Gram-stained B-outcome ['Physiological-Clinical']
smear I-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
were O
not O
statistically O
significant O
between O
the O
two O
patient O
treatment O
regimens O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Forty-two O
patients O
with O
carcinoma O
in O
situ O
of O
the O
bladder O
were O
randomized O
to O
intravesical O
BCG O
( O
21 O
patients O
) O
or O
mitomycin O
C O
plus O
doxorubicin O
sequential O
therapy O
( O
21 O
patients O
) O
as O
first O
line O
treatment O
. O
[]

caused O
significant O
sedation B-outcome ['Physiological-Clinical']
, O
but O
did O
not O
alter O
the O
effects O
of O
morphine O
5 O
mg O
on O
pain B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
or O
ventilatory B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
carbon O
dioxide O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Topical O
application O
of O
TGF-beta O
1 O
at O
the O
two O
concentrations O
studied O
had O
no O
significant O
effect O
on O
the O
total O
area O
of O
wounds B-outcome ['Physiological-Clinical']
( O
P O
= O
0.7 O
) O
, O
the O
area O
of O
granulation B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
( O
P O
= O
0.78 O
) O
, O
the O
area O
of O
epithelialisation B-outcome ['Physiological-Clinical']
( O
P O
= O
0.92 O
) O
, O
histological O
assessment O
or O
subjective O
clinical B-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
wounds I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Anti-Xa B-outcome ['Physiological-Clinical']
levels O
were O
assessed O
at O
the O
end O
of O
weeks O
1 O
and O
4,4-6 O
hours O
after O
injection O
of O
dalteparin O
. O
['Physiological-Clinical']

Hence O
, O
previous O
trials O
on O
therapy O
with O
inhaled O
NO O
in O
ARDS O
should O
be O
carefully O
interpreted O
, O
as O
they O
used O
constant O
NO O
concentrations O
, O
which O
may O
have O
become O
overdoses O
leading O
to O
deterioration O
of O
oxygenation B-outcome ['Physiological-Clinical']
after O
several O
days O
. O
['Physiological-Clinical']

Improving O
immunisation B-outcome ['Resource-use']
rates O
will O
require O
a O
sustained O
public O
health O
campaign O
. O
['Resource-use']

The O
incidence O
and O
predictive O
value O
of O
high O
grade O
PIN O
and O
LSPC O
for O
prostate O
cancer O
in O
subsequent O
biopsy O
following O
these O
diagnoses O
were O
evaluated O
. O
[]

METHODS O
Twenty O
heart-transplant O
recipients O
were O
randomised O
into O
either O
a O
treated O
or O
a O
placebo O
group O
. O
[]

The O
current O
intervention O
, O
unlike O
many O
others O
for O
the O
same O
or O
similar O
difficulties O
proposed O
in O
the O
past O
, O
was O
successful O
without O
requiring O
extensive O
time O
, O
training O
, O
or O
effort O
on O
the O
part O
of O
providers O
and O
parents O
or O
their O
children O
, O
nor O
did O
it O
require O
large-scale O
institutional O
changes O
. O
[]

Dabigatran O
etexilate O
is O
a O
prodrug O
that O
is O
rapidly O
converted O
to O
the O
active O
direct O
thrombin O
inhibitor O
dabigatran O
. O
[]

In O
a O
trial O
of O
CBT O
for O
anxiety O
in O
ASD O
( O
Wood O
et O
al O
. O
[]

Although O
slightly O
elevated O
in O
both O
groups O
, O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
C-peptide B-outcome ['Physiological-Clinical']
levels O
measured O
during O
oral O
glucose O
tolerance O
tests O
were O
within O
normal O
reference O
ranges O
at O
cycle O
7 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
needs O
to O
be O
confirmed O
in O
a O
study O
with O
a O
larger O
sample O
size O
. O
[]

Secondary O
end-points O
were O
diagnostic B-outcome ['Life-Impact']
certainty I-outcome ['Life-Impact']
, O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
appropriate I-outcome ['Life-Impact']
therapy I-outcome ['Life-Impact']
, O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
, O
hospitalization B-outcome ['Resource-use']
and O
mortality B-outcome ['Mortality']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Resource-use', 'Mortality']

When O
accounting O
for O
increased O
hospital B-outcome ['Resource-use']
activity I-outcome ['Resource-use']
in O
HBI O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
during O
follow-up O
for O
2 O
years O
, O
post O
hoc O
analyses O
showed O
that O
HBI O
reduced O
readmissions B-outcome ['Resource-use']
by O
14 O
% O
within O
2 O
years O
in O
patients O
without O
this O
condition O
( O
mean O
+/- O
SD O
rate O
, O
0.54 O
+/- O
0.72 O
vs O
0.63 O
+/- O
0.88 O
readmission/patient O
per O
year O
; O
P O
= O
.04 O
) O
and O
by O
21 O
% O
in O
all O
surviving O
patients O
within O
3 O
to O
8 O
years O
( O
mean O
+/- O
SD O
rate O
, O
0.64 O
+/- O
1.26 O
vs O
0.81 O
+/- O
1.61 O
readmissions/patient O
per O
year O
; O
P O
= O
.03 O
) O
. O
['Resource-use', 'Resource-use']

The O
acid O
challenge O
after O
in O
situ O
remineralization O
for O
both O
control O
and O
CPP-ACP-treated O
lesions O
resulted O
in O
demineralization B-outcome ['Physiological-Clinical']
underneath O
the O
remineralized O
zone O
, O
indicating O
that O
the O
remineralized O
mineral O
was O
more O
resistant O
to O
subsequent O
acid O
challenge O
. O
['Physiological-Clinical']

Discharge B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
complication B-outcome ['Adverse-effects']
rate O
, O
and O
resumption O
of O
normal B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
not O
significantly O
different O
between O
the O
two O
groups O
. O
['Life-Impact', 'Adverse-effects', 'Physiological-Clinical']

Major B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
experienced O
by O
622 O
patients O
( O
28 O
% O
) O
in O
the O
placebo O
group O
and O
431 O
patients O
( O
19 O
% O
) O
in O
the O
simvastatin O
group O
, O
corresponding O
to O
a O
risk O
reduction O
of O
34 O
% O
( O
p O
< O
0.00001 O
) O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Thirty-two O
implants O
were O
randomly O
allocated O
to O
one O
of O
the O
four O
types O
of O
bone O
defects O
: O
marginal O
bone O
loss O
, O
peri-apical O
bone O
defect O
, O
constant O
width O
dehiscence O
and O
constant O
length O
dehiscences O
. O
[]

STUDY O
DESIGN O
AND O
METHODS O
In O
a O
randomized O
, O
controlled O
trial O
, O
477 O
women O
with O
anemia O
, O
iron O
deficiency O
, O
and O
heavy O
uterine O
bleeding O
were O
assigned O
to O
receive O
either O
IV O
ferric O
carboxymaltose O
( O
< O
or=1000 O
mg O
over O
15 O
min O
, O
repeated O
weekly O
to O
achieve O
a O
total O
calculated O
replacement O
dose O
) O
or O
325 O
mg O
of O
ferrous O
sulfate O
( O
65 O
mg O
elemental O
iron O
) O
prescribed O
orally O
thrice O
daily O
for O
6 O
weeks O
. O
[]

The O
experience O
of O
aversion O
is O
shaped O
by O
multiple O
physiological O
and O
psychological O
factors O
including O
one O
's O
expectations O
. O
[]

Pain B-outcome ['Physiological-Clinical']
was O
assessed O
with O
a O
four-point O
scale O
: O
0 O
= O
no O
pain O
, O
1 O
= O
mild O
pain O
, O
2 O
= O
moderate O
pain O
, O
and O
3 O
= O
severe O
pain O
at O
the O
time O
of O
propofol O
injection O
. O
['Physiological-Clinical']

Two O
reviewers O
independently O
scored O
the O
responses O
to O
assess O
recall B-outcome ['Life-Impact']
of O
the O
six O
themes O
. O
['Life-Impact']

Evaluating O
erectile O
dysfunction O
: O
oral O
sildenafil O
versus O
intracavernosal O
injection O
of O
papaverine O
. O
[]

One O
construct O
thought O
to O
impede O
the O
regulation O
of O
emotion O
is O
alexithymia O
. O
[]

Patients O
with O
severe B-outcome ['Physiological-Clinical']
LV I-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
on O
two O
dimensional O
echocardiography O
and O
low O
fractional O
shortening O
also O
had O
significantly O
higher O
vWf B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
than O
those O
with O
no O
LV O
dysfunction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
changes O
in O
infarct B-outcome ['Physiological-Clinical']
size O
at O
3 O
months O
were O
-3.5 O
+/- O
5.1 O
% O
( O
95 O
% O
CI O
-5.5 O
% O
to O
-1.5 O
% O
, O
P O
= O
0.001 O
) O
in O
the O
early O
group O
and O
-3.9 O
+/- O
5.6 O
% O
( O
95 O
% O
CI O
-6.1 O
% O
to O
-1.6 O
% O
, O
P O
= O
0.002 O
) O
in O
the O
late O
group O
, O
and O
changes O
in O
ejection B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
were O
3.5 O
+/- O
5.6 O
% O
( O
95 O
% O
CI O
1.3-5.6 O
% O
, O
P O
= O
0.003 O
) O
and O
3.4 O
+/- O
7.0 O
% O
( O
95 O
% O
CI O
0.7-6.1 O
% O
, O
P O
= O
0.017 O
) O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

One O
urban O
and O
one O
rural O
health O
centre O
were O
linked O
to O
a O
regional O
hospital O
in O
Northern O
Ireland O
by O
ISDN O
at O
128 O
kbit/s O
. O
[]

We O
report O
follow-up O
information O
on O
69 O
hairy B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
leukemia I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HCL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
patients O
treated O
with O
interferon O
alfa-2b O
( O
IFN O
) O
as O
primary O
treatment O
from O
1983 O
to O
1986 O
. O
['Physiological-Clinical']

Fistula O
rates O
were O
not O
improved O
in O
the O
enhanced O
diet O
groups O
. O
[]

Pre-core O
mutant O
chronic O
hepatitis O
B O
infection O
usually O
proceeds O
to O
serious O
liver O
disease O
. O
[]

RESULTS O
Forty-six O
subjects O
( O
24 O
HPLC O
, O
22 O
in O
low O
fat O
) O
initiated O
and O
33 O
subjects O
completed O
the O
intervention O
; O
follow-up O
data O
were O
available O
on O
approximately O
half O
of O
the O
subjects O
. O
[]

We O
studied O
17 O
patients O
with O
AS O
( O
ICD-10 O
; O
14 O
male O
, O
3 O
female O
; O
mean O
age O
16.4 O
years O
, O
mean O
full-scale O
IQ O
97 O
) O
and O
compared O
them O
with O
a O
control O
group O
of O
13 O
patients O
with O
normal-intelligence O
autism O
or O
high-functioning O
autism O
( O
HFA O
) O
( O
ICD-10/DSM-III-R O
; O
12 O
male O
, O
1 O
female O
; O
mean O
age O
15.5 O
years O
, O
mean O
full-scale O
IQ O
81.2 O
) O
. O
[]

The O
data O
from O
the O
cardiac O
magnetic O
resonance O
study O
were O
compared O
to O
those O
from O
healthy O
volunteers O
. O
[]

Nelfinavir O
and O
saquinavir O
steady-state B-outcome ['Physiological-Clinical']
pharmacokinetics I-outcome ['Physiological-Clinical']
were O
unchanged O
by O
coadministration O
with O
amprenavir O
compared O
with O
the O
historical O
monotherapy O
data O
. O
['Physiological-Clinical']

Low-dose O
angiotensin O
II O
receptor O
antagonists O
and O
angiotensin O
II-converting O
enzyme O
inhibitors O
alone O
or O
in O
combination O
for O
treatment O
of O
primary O
glomerulonephritis O
. O
[]

There O
was O
a O
trend O
for O
prolonged O
progression-free B-outcome ['Physiological-Clinical']
survival B-outcome ['Mortality']
( O
PFS O
; O
median O
241 O
days O
for O
CAF O
v O
366 O
days O
for O
dofequidar O
+ O
CAF O
; O
P O
= O
.145 O
) O
. O
['Physiological-Clinical', 'Mortality']

Safety O
, O
pharmacokinetics O
and O
pharmacodynamics O
of O
GS-9620 O
, O
an O
oral O
Toll-like O
receptor O
7 O
agonist O
. O
[]

RESULTS O
The O
incidence O
of O
inversion O
ankle B-outcome ['Physiological-Clinical']
sprains I-outcome ['Physiological-Clinical']
was O
1.9 O
% O
in O
non-brace-wearers O
and O
0.3 O
% O
in O
brace-wearers O
( O
risk O
ratio O
, O
6.9 O
; O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical']

Results O
were O
consistent O
when O
restricted O
to O
patients O
with O
normal O
karyotype O
. O
[]

PARTICIPANTS O
Between O
2/98 O
and O
10/99 O
, O
we O
recruited O
187 O
AUDIT-positive O
( O
> O
8 O
) O
active O
injection O
drug O
users O
. O
[]

DESIGN O
AND O
METHODS O
The O
Migraine-Specific B-outcome ['Physiological-Clinical']
Questionnaire O
( O
MSQ B-outcome ['Physiological-Clinical']
, O
version O
2.1 O
) O
was O
used O
to O
assess O
the O
effect O
of O
TPM O
100 O
mg/d O
on O
the O
functionality O
and O
HRQoL O
of O
randomized O
intent-to-treat O
( O
ITT O
) O
and O
study-completer O
populations O
pooled O
from O
three O
randomized O
, O
double-blind O
, O
placebo-controlled O
trials O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Fifty-seven O
patients O
younger O
than O
65 O
years O
with O
early O
, O
nonerosive O
RA O
were O
first O
treated O
with O
CSA O
and O
MTX O
in O
combination O
for O
6 O
months O
. O
[]

Hospital B-outcome ['Mortality']
death I-outcome ['Mortality']
occurred O
in O
7 O
patients O
( O
8.2 O
% O
) O
receiving O
trimethoprim-sulfamethoxazole O
and O
8 O
patients O
( O
9.4 O
% O
) O
receiving O
ciprofloxacin O
( O
difference O
, O
-1.2 O
% O
; O
95 O
% O
CI O
, O
-9.7 O
to O
7.3 O
; O
P O
= O
.90 O
) O
. O
['Mortality']

METHODS O
Eighteen O
HTs O
aged O
65.7 O
? O
[]

Factors O
predicting O
response O
to O
interferon O
. O
[]

20 O
mm O
, O
in O
view O
of O
the O
lower O
incidence O
of O
complications O
. O
[]

Primary O
outcome O
is O
the O
composite O
event O
of O
vascular B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
stroke B-outcome ['Physiological-Clinical']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
or O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
ADA I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
measured O
at O
baseline O
and O
week O
8 O
. O
['Physiological-Clinical']

METHODS O
Electro-acupuncture O
was O
added O
for O
patients O
undergoing O
chemotherapy O
. O
[]

The O
haemostatic O
effect O
of O
desmopressin O
has O
been O
attributed O
to O
the O
release O
of O
von O
Willebrand O
factor O
( O
vWF O
) O
and O
a O
reduced O
bleeding B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

With O
the O
rigid O
fixation O
of O
the O
distal O
femoral O
fractures O
, O
bone O
grafting O
is O
frequently O
needed O
. O
[]

Clinical O
effects O
of O
naltrexone O
on O
autistic O
behavior O
. O
[]

Both O
types O
of O
radiation O
techniques O
lowered O
the O
incidence O
of O
loco-regional B-outcome ['Physiological-Clinical']
recurrences I-outcome ['Physiological-Clinical']
significantly O
, O
but O
had O
no O
significant O
influence O
on O
the O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

Captopril O
, O
but O
not O
quinapril O
, O
increased O
excretion O
of O
prostacyclin B-outcome ['Physiological-Clinical']
metabolite I-outcome ['Physiological-Clinical']
( O
217 O
+/- O
50 O
vs. O
135 O
+/- O
21 O
pg/mg O
Cr O
base O
line O
, O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

PURPOSE O
High-dose O
rate O
( O
HDR O
) O
remote O
afterloading O
intracavitary O
therapy O
has O
been O
recognized O
as O
an O
effective O
and O
safe O
treatment O
modality O
for O
carcinoma O
of O
the O
uterine O
cervix O
. O
[]

In O
a O
double-blind O
procedure O
half O
the O
patients O
began O
withdrawal O
immediately O
and O
half O
after O
8 O
weeks O
. O
[]

METHODS O
Patients O
with O
pancreatic O
cancer O
who O
met O
our O
preoperative O
criteria O
for O
inclusion O
( O
pancreatic O
cancer O
invading O
the O
pancreatic O
capsule O
without O
involvement O
of O
the O
superior O
mesenteric O
artery O
or O
the O
common O
hepatic O
artery O
, O
or O
without O
distant O
metastasis O
) O
underwent O
laparotomy O
. O
[]

The O
5-year O
survival B-outcome ['Mortality']
rate O
and O
the O
5-year O
recurrence-free B-outcome ['Physiological-Clinical']
rate O
were O
76 O
% O
and O
84 O
% O
, O
respectively O
, O
in O
the O
immunized O
groups O
( O
both O
the O
early O
and O
advanced O
groups O
) O
, O
whereas O
the O
same O
rates O
for O
the O
control O
groups O
were O
78 O
% O
and O
75 O
% O
. O
['Mortality', 'Physiological-Clinical']

Several O
factors O
can O
affect O
the O
precision O
of O
1RM O
tests O
, O
including O
the O
warm-up O
procedure O
. O
[]

Based O
on O
a O
definition O
of O
lactate B-outcome ['Physiological-Clinical']
steady I-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LSS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
as O
less O
than O
a O
0.5 O
mmol.l-1 O
increase O
, O
this O
value O
signified O
LSS O
. O
['Physiological-Clinical']

The O
primary O
end O
point O
is O
the O
occurrence O
of O
cardiovascular B-outcome ['Mortality']
death I-outcome ['Mortality']
or O
nonfatal B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
through O
postoperative O
day O
30 O
. O
['Mortality', 'Physiological-Clinical']

One O
patient O
died O
before O
treatment O
, O
which O
left O
30 O
patients O
in O
each O
group O
. O
[]

The O
Autism B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
( O
Krug O
et O
al. O
, O
1993 O
) O
was O
used O
, O
adapted O
to O
the O
Portuguese O
language O
by O
Marteleto O
( O
2003 O
) O
. O
['Life-Impact']

Changes O
in O
performance O
were O
compared O
by O
repeated O
measures O
ANOVA O
. O
[]

In O
an O
attempt O
to O
reduce O
the O
incidence O
of O
lethal O
cytomegalovirus B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CMV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
interstitial I-outcome ['Physiological-Clinical']
pneumonitis I-outcome ['Physiological-Clinical']
after O
allogenic O
bone O
marrow O
transplantation O
49 O
patients O
were O
randomized O
in O
a O
multicenter O
controlled O
study O
to O
receive O
either O
CMV-hyperimmune O
globulin O
or O
a O
control O
immune O
globulin O
with O
low O
anticytomegalovirus O
titer O
. O
['Physiological-Clinical']

The O
peroxide O
strip O
group O
demonstrated O
95 O
% O
+ O
color B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
( O
Deltab* O
& O
DeltaL* O
) O
at O
Week O
12 O
, O
differing O
significantly O
( O
P O
< O
0.0001 O
) O
versus O
either O
of O
the O
continuously O
used O
whitening O
dentifrices O
. O
['Physiological-Clinical']

Post-immunization B-outcome ['Physiological-Clinical']
titers I-outcome ['Physiological-Clinical']
against O
influenza O
A O
strains O
were O
significantly O
higher O
in O
those O
subjects O
who O
were O
never O
immunized O
before O
. O
['Physiological-Clinical']

Assessments O
of O
JA O
skills O
, O
SP O
skills O
, O
mother-child B-outcome ['Life-Impact']
interactions I-outcome ['Life-Impact']
, O
and O
language B-outcome ['Life-Impact']
development I-outcome ['Life-Impact']
were O
collected O
at O
4 O
time O
points O
: O
pre- O
and O
postintervention O
and O
6 O
and O
12 O
months O
postintervention O
by O
independent O
testers O
. O
['Life-Impact', 'Life-Impact']

These O
results O
underline O
the O
rapid B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
autonomy I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
stay I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
medical I-outcome ['Physiological-Clinical']
ICU I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
was O
significantly O
more O
grade O
3 O
and O
4 O
emesis B-outcome ['Physiological-Clinical']
in O
the O
combination O
arm O
. O
['Physiological-Clinical']

The O
observed O
mean O
difference O
in O
the O
average O
pain B-outcome ['Physiological-Clinical']
score O
between O
duloxetine O
and O
placebo O
was O
0.73 O
( O
95 O
% O
CI O
, O
0.26-1.20 O
) O
. O
['Physiological-Clinical']

These O
included O
sex O
, O
pain O
frequency O
, O
smoking O
, O
disease O
duration O
, O
and O
acid O
secretion O
. O
[]

CONCLUSIONS O
Balsalazide O
disodium O
1.1 O
g O
tablets O
administered O
as O
3.3 O
g O
twice O
daily O
are O
effective O
, O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
and O
significantly O
better O
than O
placebo O
for O
improving O
signs B-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
mild-to-moderately-active I-outcome ['Physiological-Clinical']
UC I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Clindamycin O
vaginal O
cream O
therapy O
was O
associated O
with O
significantly O
prolonged O
gestation O
and O
reduced O
cost O
of O
neonatal O
care O
in O
women O
with O
BV O
. O
[]

Similar O
odds O
ratios O
were O
obtained O
for O
PVH O
( O
OR=4.17 O
, O
p=0.16 O
) O
and O
total O
volumes O
( O
OR=5.00 O
, O
p=0.05 O
) O
. O
[]

However O
, O
when O
subjects O
were O
examined O
individually O
both O
the O
GHRH- B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
TRH-induced I-outcome ['Physiological-Clinical']
hormonal I-outcome ['Physiological-Clinical']
peaks I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
subsequent I-outcome ['Physiological-Clinical']
fall I-outcome ['Physiological-Clinical']
were O
not O
different O
in O
both O
groups O
. O
['Physiological-Clinical']

BACKGROUND O
Blood O
transfusions O
prevent O
recurrent O
stroke O
in O
children O
with O
sickle O
cell O
anemia O
, O
but O
the O
value O
of O
transfusions O
in O
preventing O
a O
first O
stroke O
is O
unknown O
. O
[]

Sixteen O
percent O
of O
the O
home O
study O
findings O
were O
inconclusive O
. O
[]

SUMMARY O
BACKGROUND O
DATA O
Malnutrition O
is O
prevalent O
among O
surgical O
patients O
and O
is O
associated O
with O
higher O
surgical O
complication O
rates O
and O
mortality O
. O
[]

Prehydration O
alone O
is O
sufficient O
to O
prevent O
contrast-induced O
nephropathy O
after O
day-only O
angiography O
procedures O
-- O
a O
randomised O
controlled O
trial O
. O
[]

In O
patients O
remaining O
in O
SR O
for O
15 O
days O
after O
from O
the O
start O
of O
follow-up O
, O
freedom B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
was O
significantly O
more O
prevalent O
in O
the O
aprindine O
group O
than O
in O
the O
placebo O
group O
( O
p=0.0414 O
) O
, O
but O
there O
was O
no O
significant O
difference O
between O
the O
digoxin O
and O
placebo O
groups O
. O
['Physiological-Clinical']

After O
the O
procedure O
the O
mean O
minimal B-outcome ['Physiological-Clinical']
luminal I-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
in O
the O
conventional O
group O
was O
2.34 O
+/- O
0.46 O
mm O
versus O
2.90 O
+/- O
0.41 O
mm O
in O
the O
stented O
group O
( O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical']

Aspirin-induced O
loss O
of O
stored O
iron O
from O
chronic O
gastrointestinal O
bleeding O
is O
proposed O
as O
a O
mechanism O
underlying O
this O
beneficial O
effect O
. O
[]

Both O
drugs O
induced O
a O
similar O
pronounced O
decreased O
in O
TRP B-outcome ['Physiological-Clinical']
, O
indicating O
peripheral O
vasodilation O
, O
followed O
by O
increasing O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
cardiac B-outcome ['Physiological-Clinical']
output B-outcome ['Physiological-Clinical']
, O
a O
decrease O
in O
diastolic O
blood O
pressure O
, O
and O
a O
shortening O
of O
the O
PEPc O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
variety O
of O
predictors O
of O
early O
attachment O
were O
explored O
including O
: O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
during I-outcome ['Life-Impact']
pregnancy I-outcome ['Life-Impact']
, O
pregnancy B-outcome ['Life-Impact']
intention I-outcome ['Life-Impact']
, O
feelings B-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
pregnancy I-outcome ['Life-Impact']
, O
and O
the I-outcome ['Life-Impact']
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
partner I-outcome ['Life-Impact']
relationship I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Beneficial O
effects O
of O
intranasal O
beclomethasone O
dipropionate O
( O
Bdp O
) O
in O
patients O
with O
nasal O
polyposis O
have O
been O
reported O
earlier O
. O
[]

Almost O
all O
of O
the O
456 O
participants O
( O
96 O
% O
) O
who O
were O
offered O
the O
opportunity O
of O
discussing O
their O
health O
with O
their O
general O
practitioner O
took O
up O
the O
offer O
; O
64 O
% O
of O
the O
456 O
participants O
reported O
that O
they O
had O
decided O
to O
undertake B-outcome ['Life-Impact']
lifestyle I-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
. O
['Life-Impact']

Infected O
subjects O
were O
randomized O
to O
receive O
omeprazole O
20 O
mg O
b.d. O
, O
clarithromycin O
250 O
mg O
b.d O
. O
[]

Central O
independent O
review O
by O
5 O
neuropathologists O
led O
to O
a O
reclassification O
of O
low-grade O
glioma O
in O
70 O
patients O
, O
who O
were O
the O
focus O
of O
the O
current O
study O
. O
[]

Forty-five O
patients O
with O
cured O
or O
possibly O
cured O
HCC O
were O
randomly O
selected O
, O
assigning O
patients O
to O
treatment O
( O
n=21 O
) O
or O
control O
group O
( O
n=24 O
) O
with O
randomization O
list O
. O
[]

OBJECTIVES O
The O
study O
was O
done O
to O
investigate O
the O
relationship O
between O
clinical O
restenosis O
and O
the O
relative O
angiographic O
location O
of O
the O
recurrent O
restenotic O
lesion O
, O
after O
treatment O
of O
in-stent O
restenosis O
with O
vascular O
brachytherapy O
in O
the O
Washington O
Radiation O
for O
In-Stent O
Restenosis O
Trial O
( O
WRIST O
) O
. O
[]

Statistical O
analyses O
were O
performed O
using O
2-tailed O
McNemar O
tests O
, O
Pearson O
chi-square O
tests O
, O
and O
Student O
's O
t-tests O
; O
P O
< O
0.05 O
was O
considered O
statistically O
significant O
. O
[]

Evaluation O
of O
electrofunctional O
data O
following O
argon-laser O
trabeculoplasty O
in O
primary O
open-angle O
glaucoma O
. O
[]

The O
magnitude O
and O
duration O
of O
the O
therapeutic O
response O
to O
a O
single O
dose O
of O
200 O
mg O
levodopa/50 O
mg O
carbidopa O
was O
evaluated O
after O
concomitant O
placebo O
, O
or O
200 O
or O
800 O
mg O
entacapone O
. O
[]

In O
conclusion O
, O
dose-dense O
FEC O
( O
75 O
) O
and O
FEC O
( O
90 O
) O
are O
feasible O
with O
pegfilgrastim O
support O
. O
[]

Despite O
this O
fact O
, O
this O
intervention O
remains O
controversial O
. O
[]

METHODS O
A O
prospective O
study O
was O
carried O
out O
on O
51 O
participants O
with O
amblyopia O
( O
strabismic O
n=17 O
; O
anisometropic O
n=10 O
; O
combined O
n=24 O
) O
, O
mean O
age O
10 O
years O
8 O
months O
. O
[]

Each O
treatment O
arm O
was O
given O
as O
six O
monthly O
cycles O
, O
followed O
by O
three O
bimonthly O
cycles O
. O
[]

The O
addition O
of O
a O
phone O
call O
did O
not O
further O
increase O
screening O
rates O
. O
[]

Eighty-three O
patients O
with O
advanced O
disease O
were O
entered O
into O
the O
first O
study O
( O
43/chemotherapy O
; O
40/control O
) O
, O
and O
60 O
into O
the O
second O
( O
27/chemotherapy O
; O
33/control O
) O
. O
[]

The O
energy O
balance O
group O
consumed O
an O
isocaloric O
diet O
consisting O
of O
50 O
% O
carbohydrate O
, O
30 O
% O
fat O
, O
and O
20 O
% O
protein O
for O
15 O
d. O
The O
energy O
balance O
plus O
exercise O
group O
consumed O
a O
similar O
diet O
over O
the O
15 O
d O
and O
performed O
50-min O
of O
treadmill O
walking O
at O
70 O
% O
of O
maximum O
oxygen O
consumption O
maximum O
during O
the O
second O
7 O
d O
of O
the O
15-d O
study O
period O
. O
[]

Yet O
subjective O
measures O
were O
better O
in O
the O
cisapride O
group O
; O
they O
rated O
themselves O
as O
more O
hungry B-outcome ['Life-Impact']
( O
p O
= O
.02 O
) O
and O
more O
improved O
on O
the O
global O
measure O
of O
change O
in O
symptoms B-outcome ['Physiological-Clinical']
( O
p O
= O
.02 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

New O
therapies O
to O
raise O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HDL-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
are O
currently O
being O
investigated O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Mammograms O
of O
41 O
postmenopausal O
women O
obtained O
before O
and O
1 O
year O
after O
the O
initiation O
of O
HRT O
were O
evaluated O
blindly O
according O
to O
the O
quantitative O
density O
percentage O
method O
and O
the O
Wolfe O
classification O
system O
. O
[]

The O
cefoxitin O
patients O
with O
colon O
injuries O
were O
analyzed O
( O
p O
< O
0.007 O
) O
. O
[]

OBJECTIVE O
To O
study O
the O
effect O
of O
medical O
ozone O
in O
the O
treatment O
of O
chronic O
hepatitis O
B O
. O
[]

METHODS O
We O
conducted O
a O
comparative O
, O
open-label O
trial O
in O
310 O
adults O
with O
AIDS O
who O
had O
recently O
recovered O
from O
an O
initial O
episode O
of O
PCP O
and O
had O
no O
treatment-limiting O
toxic O
effects O
of O
trimethoprim-sulfamethoxazole O
or O
pentamidine O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
treatment O
groups O
in O
survival B-outcome ['Mortality']
or O
neurologic B-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
after O
30 O
days O
. O
['Mortality', 'Physiological-Clinical']

Men O
between O
55 O
and O
65 O
years O
of O
age O
with O
a O
gastric O
cancer O
phenotype O
of O
Helicobacter O
pylori O
gastritis O
are O
randomized O
to O
receive O
a O
7 O
day O
course O
of O
omeprazole O
2 O
X O
20mg O
, O
clarithromycin O
2 O
X O
500mg O
, O
and O
amoxicillin O
2 O
X O
1g O
for O
7 O
days O
, O
or O
omeprazole O
2 O
X O
20mg O
plus O
placebo O
. O
[]

A O
total O
of O
128 O
patients O
with O
intermittent O
claudication O
and O
essential O
hypertension O
were O
included O
and O
double-blind O
randomized O
to O
receive O
5 O
mg O
of O
nebivolol O
( O
N=65 O
) O
or O
95 O
mg O
of O
metoprolol O
( O
N=63 O
) O
once O
daily O
. O
[]

Further O
study O
will O
be O
needed O
to O
determine O
its O
ability O
to O
reduce O
clinical B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Treatment O
of O
anal O
fissures O
using O
a O
combination O
of O
minoxidil O
and O
lignocaine O
: O
a O
randomized O
, O
double-blind O
trial O
. O
[]

Physicians O
were O
seen O
to O
be O
the O
most O
common O
source O
of O
care O
for O
patients O
with O
COPD O
and O
more O
of O
the O
patients O
with O
severe O
COPD O
( O
stage O
III O
) O
than O
mild O
( O
stage O
I O
) O
were O
seen O
to O
utilize O
the O
most O
expensive O
resources O
( O
e.g O
. O
[]

The O
response O
rate O
for O
the O
HAC O
group O
was O
31 O
% O
and O
for O
the O
melphalan-platinum O
group O
was O
37.8 O
% O
. O
[]

Univariate O
and O
multiple O
regression O
analysis O
demonstrated O
discarded O
blood B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
to O
be O
a O
significant O
and O
independent O
predictor O
of O
the O
decline O
in O
hemoglobin O
concentration O
. O
['Physiological-Clinical']

Postoperative B-outcome ['Resource-use']
morphine I-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
, O
measured O
using O
a O
patient-controlled O
system O
, O
was O
similar O
to O
that O
in O
patients O
in O
the O
bupivacaine O
only O
group O
( O
pethidine-clonidine O
: O
median O
39 O
mg/24 O
h O
; O
bupivacaine O
: O
median O
34 O
mg/24 O
h O
) O
but O
greater O
than O
that O
in O
the O
bupivacaine-morphine O
group O
( O
median O
8 O
mg/24 O
h O
) O
( O
P O
< O
0.001 O
) O
. O
['Resource-use']

Administrative O
Data O
Feedback O
for O
Effective O
Cardiac O
Treatment O
: O
AFFECT O
, O
a O
cluster O
randomized O
trial O
. O
[]

All O
patients O
had O
complete O
resection O
of O
gross O
tumor O
and O
underwent O
postoperative O
radiotherapy O
( O
6000-6300 O
rads O
over O
7-8 O
weeks O
) O
. O
[]

A O
total O
of O
10,010 O
patients O
at O
135 O
centers O
in O
23 O
countries O
were O
enrolled O
. O
[]

The O
ET-1 B-outcome ['Physiological-Clinical']
and O
its O
receptor B-outcome ['Physiological-Clinical']
genes I-outcome ['Physiological-Clinical']
were O
expressed O
in O
the O
right O
and O
left O
ventricles O
of O
control O
and O
T O
( O
3 O
) O
-treated O
broilers O
at O
12 O
, O
28 O
and O
49 O
days O
of O
age O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Because O
most O
NSAIDs O
are O
weak O
acids O
( O
pKa O
3-5 O
) O
and O
become O
concentrated O
in O
acidic O
tissues O
, O
such O
as O
injured O
and O
inflamed O
tissues O
, O
we O
hypothesized O
that O
local O
administration O
may O
enhance O
its O
analgesic O
efficacy O
while O
lowering O
the O
potential O
for O
systemic O
complications O
. O
[]

The O
volume O
in O
the O
drain O
bottles O
was O
recorded O
after O
48 O
h. O
Hb B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
estimated O
by O
subtracting O
the O
postoperative O
from O
the O
preoperative O
Hb O
level O
. O
['Physiological-Clinical']

These O
23 O
patients O
were O
randomly O
allocated O
to O
an O
antibiotic O
group O
or O
a O
control O
group O
; O
there O
was O
one O
wound O
infection O
in O
the O
antibiotic O
group O
and O
two O
in O
the O
control O
group O
. O
[]

Each O
circuit O
consisted O
of O
three O
20 O
s O
work O
intervals O
at O
each O
station O
with O
a O
1:1 O
work O
: O
rest O
ratio O
. O
[]

Biventricular O
pacing O
improves O
cardiac B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
prevents O
further O
left B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
in O
patients O
with O
symptomatic O
atrial O
fibrillation O
after O
atrioventricular O
node O
ablation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
There O
was O
a O
decrease O
in O
MASI O
score O
in O
all O
three O
groups O
after O
treatment O
and O
after O
follow-up O
period O
but O
after O
treatment O
MASI O
score O
was O
statistically O
significantly O
lower O
in O
group O
A O
than O
group O
C O
( O
P O
= O
0.01 O
) O
, O
and O
it O
was O
also O
statistically O
significantly O
lower O
in O
group O
B O
than O
group O
C O
( O
P O
< O
0.001 O
) O
but O
there O
was O
no O
statistically O
significant O
difference O
between O
groups O
A O
and O
B O
. O
[]

RESULTS O
At O
1 O
year O
, O
99 O
% O
of O
patients O
( O
89 O
of O
90 O
) O
had O
20/40 O
uncorrected O
vision O
or O
better O
. O
[]

The O
provocative O
concentration O
of O
AMP O
producing O
a O
20 O
% O
fall O
in O
FEV1 O
( O
PC20 O
) O
was O
measured O
after O
each O
washout O
at O
baseline O
and O
at O
4-6 O
h O
following O
the O
first O
and O
last O
doses O
of O
each O
randomized O
treatment O
. O
[]

Pyrimethamine O
, O
25 O
mg O
thrice O
weekly O
, O
was O
evaluated O
as O
primary O
prophylaxis O
for O
toxoplasmic O
encephalitis O
( O
TE O
) O
in O
a O
double-blind O
, O
randomized O
clinical O
trial O
in O
patients O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
disease O
, O
absolute O
CD4 O
lymphocyte O
count O
of O
< O
200/microL O
( O
or O
prior O
AIDS-defining O
opportunistic O
infection O
) O
, O
and O
the O
presence O
of O
serum O
IgG O
to O
Toxoplasma O
gondii O
. O
[]

Pre-incisionally O
, O
IL-2 B-outcome ['Physiological-Clinical']
increased O
in O
the O
halothane O
group O
( O
p O
< O
0.01 O
) O
, O
whereas O
it O
decreased O
significantly O
in O
the O
isoflurane O
group O
( O
p O
< O
0.001 O
) O
compared O
with O
the O
pre-induction O
level O
. O
['Physiological-Clinical']

Treating O
elderly O
women O
with O
vaginal O
ES O
of O
the O
pelvic O
floor O
has O
a O
high O
physical O
and O
emotional O
cost O
for O
the O
individual O
. O
[]

In O
conclusion O
, O
both O
surface O
conditioning O
methods O
provided O
similar O
microtensile O
bond O
strengths O
between O
the O
repair O
composite O
resin O
and O
the O
ceramic O
. O
[]

Magnesium O
is O
an O
attractive O
anti-shivering O
agent O
because O
it O
is O
used O
for O
treatment O
of O
postoperative O
shivering O
and O
provides O
protection O
against O
ischaemic O
injury O
in O
animal O
models O
. O
[]

The O
present O
study O
demonstrates O
that O
DEX O
is O
less O
inhibitory B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
phytohemagglutinin I-outcome ['Physiological-Clinical']
( O
PHA O
) O
-induced O
T O
cell O
proliferation O
in O
AD O
patients O
as O
compared O
to O
age-matched O
controls O
. O
['Physiological-Clinical']

In O
contrast O
, O
the O
DASH O
diet O
had O
no O
significant O
effect O
on O
markers B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
fibrinolysis I-outcome ['Physiological-Clinical']
in O
whites O
or O
African-Americans O
. O
['Physiological-Clinical']

As O
expected O
, O
no O
significant O
differences O
were O
found O
in O
the O
sedentary O
group O
( O
p O
? O
[]

The O
results O
of O
experimental O
and O
clinical O
studies O
support O
the O
hypothesis O
that O
gut-derived O
endotoxins O
might O
be O
of O
relevance O
for O
the O
development O
and O
course O
of O
alcoholic O
liver O
disease O
. O
[]

Daily O
doses O
were O
titrated O
as O
follows O
: O
for O
prazosin O
, O
1 O
mg O
two O
times O
daily O
to O
maximum O
of O
20 O
mg O
per O
day O
; O
for O
captopril O
, O
25 O
mg O
three O
times O
daily O
to O
a O
maximum O
of O
450 O
mg O
per O
day O
. O
[]

Comparison O
between O
intermittent O
mandatory O
ventilation O
and O
synchronized O
intermittent O
mandatory O
ventilation O
with O
pressure O
support O
in O
children O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
TDM O
and O
control O
groups O
in O
the O
outcome O
measures O
, O
except O
for O
the O
incidence O
of O
nephrotoxicity B-outcome ['Physiological-Clinical']
: O
the O
rates O
of O
minor B-outcome ['Physiological-Clinical']
nephrotoxicity I-outcome ['Physiological-Clinical']
were O
33.3 O
% O
and O
13.5 O
% O
in O
the O
control O
and O
TDM O
groups O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

intervals O
for O
1 O
hour O
prior O
to O
drug O
administration O
, O
to O
permit O
calculating O
baseline O
values O
. O
[]

Toxicity B-outcome ['Adverse-effects']
was O
generally O
minimal O
in O
both O
arms O
. O
['Adverse-effects']

Administration O
of O
intramammary O
tilmicosin O
appears O
to O
be O
an O
efficacious O
therapy O
for O
prevention O
of O
[]

RESULTS O
Both O
medications O
were O
highly O
effective O
in O
relieving O
pain B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Performances O
of O
Okuda O
, O
CLIP O
and O
BCLC O
scores O
have O
been O
compared O
using O
Akaike O
information O
criterion O
, O
discriminatory O
ability O
( O
Harrell O
's O
C O
and O
the O
Royston O
's O
D O
statistics O
) O
, O
monotonicity O
of O
gradients O
and O
predictive O
accuracy O
( O
Schemper O
statistics O
Vs O
) O
. O
[]

We O
conducted O
a O
prospective O
randomized O
trial O
of O
PBSC O
mobilization O
using O
etoposide O
and O
G-CSF O
with O
or O
without O
rituximab O
to O
determine O
whether O
its O
addition O
would O
adversely O
affect O
CD34+ B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
yield I-outcome ['Physiological-Clinical']
in O
patients O
with O
non-Hodgkin O
's O
lymphoma O
. O
['Physiological-Clinical']

RESULTS O
40 O
participants O
( O
mean O
age O
52.5 O
years O
, O
60 O
% O
male O
) O
were O
included O
in O
the O
study O
. O
[]

The O
average O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
procedure I-outcome ['Life-Impact']
was O
31.9 O
minutes O
. O
['Life-Impact']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Increased O
FSR B-outcome ['Physiological-Clinical']
was O
associated O
with O
enhanced O
phosphorylation O
of O
mTOR O
and O
S6K1 O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
baseline O
parameters O
of O
22 O
preexisting O
stenoses O
progressing B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
occlusions I-outcome ['Physiological-Clinical']
differed O
from O
those O
remaining B-outcome ['Physiological-Clinical']
patent I-outcome ['Physiological-Clinical']
only O
with O
regard O
to O
the O
% B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
stenosis I-outcome ['Physiological-Clinical']
( O
43 O
+/- O
9 O
% O
vs O
39 O
+/- O
11 O
% O
; O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Absence O
of O
rebound O
pulmonary B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
, O
availability O
, O
and O
low O
cost O
of O
the O
drug O
are O
considered O
as O
its O
major O
advantages O
. O
['Physiological-Clinical']

Few O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
noted O
. O
['Adverse-effects']

OBJECTIVE O
To O
observe O
therapeutic O
effects O
of O
acupuncture O
at O
different O
opportunities O
on O
peripheral O
facial O
paralysis O
. O
[]

At O
subsequent O
screening O
examinations O
, O
the O
proportion O
of O
women O
in O
the O
intervention O
group O
who O
were O
found O
to O
have O
grade O
2 O
or O
3 O
lesions B-outcome ['Physiological-Clinical']
or O
cancer B-outcome ['Physiological-Clinical']
was O
42 O
% O
less O
( O
95 O
% O
CI O
, O
4 O
to O
64 O
) O
and O
the O
proportion O
with O
grade O
3 O
lesions O
or O
cancer O
was O
47 O
% O
less O
( O
95 O
% O
CI O
, O
2 O
to O
71 O
) O
than O
the O
proportions O
of O
control O
women O
who O
were O
found O
to O
have O
such O
lesions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Students O
in O
PA O
schools O
, O
compared O
with O
those O
in O
control O
schools O
, O
had O
more O
favorable O
change O
over O
the O
course O
of O
the O
study O
in O
positive O
affect O
( O
standardized O
mean O
difference O
effect O
size O
[ O
ES O
] O
= O
.17 O
) O
and O
life B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
( O
ES O
= O
.13 O
) O
as O
well O
as O
significantly O
lower O
depression B-outcome ['Life-Impact']
( O
ES O
= O
-.14 O
) O
and O
anxiety B-outcome ['Life-Impact']
( O
ES O
= O
-.26 O
) O
at O
study O
end O
point O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

General O
anesthesia O
and O
higher O
costs O
are O
reasonable O
compromises O
for O
a O
shorter O
period O
of O
discomfort B-outcome ['Physiological-Clinical']
in O
patients O
with O
a O
low O
ASA O
index O
and O
busy O
job/sport O
activity O
. O
['Physiological-Clinical']

CONCLUSIONS O
Mixed O
linear O
modeling O
can O
be O
applied O
successfully O
to O
monitor O
factors O
affecting O
performance O
in O
a O
squad O
of O
elite O
athletes O
. O
[]

In O
a O
prospective O
cohort O
study O
in O
which O
the O
choice O
of O
prophylactic O
therapy O
was O
left O
to O
each O
practitioner O
, O
we O
followed O
cirrhotic O
patients O
with O
medium/large O
varices O
to O
determine O
factors O
predictive O
of O
bleeding O
and O
death O
. O
[]

H. O
pylori O
status O
was O
checked O
by O
13C O
urea B-outcome ['Physiological-Clinical']
breath O
test O
before O
and O
after O
four O
weeks O
of O
therapy O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Twenty O
sequential O
anaesthetised O
patients O
were O
studied O
. O
[]

Antazoline O
is O
a O
first O
generation O
antihistaminic O
agent O
with O
chinidin-like O
properties O
. O
[]

This O
investigation O
was O
conducted O
to O
determine O
if O
pyridostigmine O
affects O
various O
physiological O
and O
biophysical O
parameters O
of O
human O
temperature O
regulation O
in O
subjects O
wearing O
CW O
protective O
clothing O
. O
[]

Evaluation O
of O
mood O
profiles O
during O
malaria O
chemoprophylaxis O
: O
a O
randomized O
, O
double-blind O
, O
four-arm O
study O
. O
[]

RESULTS O
In O
the O
UDCA O
group O
, O
serum B-outcome ['Physiological-Clinical']
ALT I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
GGT I-outcome ['Physiological-Clinical']
levels O
significantly O
improved O
. O
['Physiological-Clinical']

AIMS O
To O
assess O
the O
effects O
of O
synthetic O
GLP-1 O
on O
fundus B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
and O
volume B-outcome ['Physiological-Clinical']
waves I-outcome ['Physiological-Clinical']
, O
gastric B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
, O
and O
perception O
of O
gastric B-outcome ['Physiological-Clinical']
distension I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Despite O
hyperinsulinemia O
, O
blood O
glucose O
was O
kept O
close O
to O
its O
basal O
value O
by O
the O
glucose O
clamp O
technique O
. O
[]

INTRODUCTION O
Randomized O
trials O
have O
demonstrated O
the O
effectiveness O
of O
the O
Dietary O
Approaches O
to O
Stop O
Hypertension O
( O
DASH O
) O
program O
for O
lowering O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
; O
however O
, O
program O
participation O
has O
been O
limited O
in O
some O
populations O
. O
['Physiological-Clinical']

Ovulation O
was O
induced O
by O
a O
single O
administration O
of O
hCG O
on O
the O
day O
after O
the O
last O
hMG-HP O
or O
r-hFSH/r-hLH O
. O
[]

The O
project O
group O
patients O
were O
not O
admitted O
if O
this O
could O
be O
avoided O
; O
instead O
they O
were O
taken O
back O
to O
the O
community O
by O
the O
project O
team O
who O
provided O
them O
and O
their O
relatives O
with O
comprehensive O
, O
assertive O
and O
prolonged O
follow-up O
treatment O
backed O
by O
a O
24-hour O
crisis O
service O
. O
[]

Accordingly O
, O
demonstration O
that O
a O
specific O
molecular O
subtype O
accounts O
for O
superior O
outcome O
, O
when O
using O
these O
regimens O
, O
is O
needed O
. O
[]

Ten O
monozygotic O
twin O
pairs O
of O
pregnant O
cows O
( O
five O
pairs O
of O
parity O
1 O
or O
2 O
, O
and O
five O
pairs O
of O
parity O
3 O
or O
more O
) O
were O
allocated O
to O
two O
diets O
which O
were O
formulated O
to O
provide O
either O
-4 O
meq O
( O
anion O
diet O
) O
or O
+572.5 O
meq O
( O
cation O
diet O
) O
of O
[ O
( O
Na+ O
+ O
K+ O
) O
- O
( O
Cl- O
+ O
SO4= O
) O
] O
kg-1 O
dietary O
dry O
matter O
( O
DM O
) O
. O
[]

METHODS O
The O
main O
outcome O
measure O
was O
the O
accuracy O
of O
risk O
assessments O
, O
defined O
as O
( O
1 O
) O
the O
difference O
between O
the O
10-year O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
percentage O
calculated O
by O
nurses O
and O
an O
independent O
assessor O
, O
and O
( O
2 O
) O
the O
agreement O
between O
the O
treatment O
['Physiological-Clinical']

Larger O
trials O
are O
warranted O
to O
better O
determine O
the O
population O
best O
suited O
for O
this O
treatment O
. O
[]

Of O
the O
141 O
patients O
from O
36 O
participating O
centers O
, O
47 O
were O
given O
aprindine O
, O
47 O
digoxin O
, O
and O
47 O
were O
on O
placebo O
. O
[]

There O
was O
significant O
improvement O
in O
creatinine B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

The O
use O
of O
desflurane O
as O
part O
of O
a O
balanced O
anesthetic O
technique O
did O
not O
speed O
the O
emergence O
or O
discharge B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
when O
compared O
with O
isoflurane O
. O
['Life-Impact']

Absence O
of O
cervical B-outcome ['Physiological-Clinical']
radiation I-outcome ['Physiological-Clinical']
myelitis I-outcome ['Physiological-Clinical']
after O
hyperfractionated O
radiation O
therapy O
with O
and O
without O
concurrent O
chemotherapy O
for O
locally O
advanced O
, O
unresectable O
, O
nonmetastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
. O
['Physiological-Clinical']

DESIGN O
A O
single O
blind O
randomised O
controlled O
trial O
created O
from O
the O
two O
week O
placebo O
run-in O
periods O
for O
two O
nested O
trials O
that O
compared O
acupuncture O
and O
amitriptyline O
with O
their O
respective O
placebo O
controls O
. O
[]

There O
was O
a O
wide O
variability O
( O
up O
to O
ten-fold O
) O
in O
the O
pharmacokinetic O
parameters O
within O
each O
dose O
group O
. O
[]

Hence O
the O
current O
trial O
was O
conducted O
with O
the O
objective O
to O
show O
the O
therapeutic O
equivalence O
of O
two O
treatments O
( O
placebo O
and O
amoxycillin O
) O
for O
children O
presenting O
with O
non-severe O
pneumonia O
with O
wheeze O
, O
who O
have O
persistent O
fast O
breathing O
after O
nebulisation O
with O
salbutamol O
, O
and O
have O
normal O
chest O
radiograph O
. O
[]

The O
objective O
of O
the O
present O
study O
was O
to O
investigate O
whether O
variants O
in O
presumed O
nutrient-sensitive O
genes O
involved O
in O
lipid O
metabolism O
modified O
lipid B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
after O
weight O
loss O
and O
in O
response O
to O
a O
given O
diet O
, O
among O
overweight O
European O
adults O
participating O
in O
the O
Diet O
Obesity O
and O
Genes O
study O
. O
['Physiological-Clinical']

PURPOSE O
The O
purpose O
of O
this O
in O
vitro O
study O
was O
to O
evaluate O
the O
translucency B-outcome ['Physiological-Clinical']
of O
zirconia O
copings O
for O
single O
crowns O
fabricated O
using O
different O
CAD/CAM O
systems O
, O
using O
lithium O
disilicate O
glass O
ceramic O
as O
a O
control O
. O
['Physiological-Clinical']

There O
was O
no O
statistically O
significant O
difference O
in O
baseline O
characteristics O
between O
the O
two O
groups O
. O
[]

Since O
left O
heart O
failure O
may O
be O
associated O
with O
pulmonary O
hypertension O
out O
of O
proportion O
to O
left O
heart O
disease O
, O
sildenafil O
may O
have O
beneficial O
effect O
in O
such O
patients O
. O
[]

OBJECTIVE O
Lowering O
of O
the O
central B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
PP O
) O
has O
been O
shown O
to O
contribute O
to O
an O
improvement O
of O
the O
cardiac O
damage O
beyond O
that O
of O
lowering O
the O
brachial O
PP O
. O
['Physiological-Clinical']

Analysis O
of O
the O
two O
endpoints O
for O
conventional O
short O
i.v O
. O
[]

Recommendations O
were O
made O
for O
future O
research O
on O
the O
inventory O
. O
[]

Two O
studies O
used O
a O
thrice-weekly O
dosing O
regimen O
and O
1 O
study O
used O
a O
once-daily O
dosing O
regimen O
for O
24 O
weeks O
. O
[]

The O
anti-inflammatory O
, O
analgesic O
and O
tranquillizing O
activity O
of O
a O
synthetic O
compound O
called O
parsalmide O
was O
investigated O
in O
patients O
suffering O
from O
inflammatory O
and O
degenerative O
rheumatic O
arthropathies O
. O
[]

METHODS O
In O
a O
prospective O
, O
observer-blinded O
fashion O
, O
40 O
ASA O
1 O
paediatric O
patients O
undergoing O
subumbilical O
surgery O
were O
randomly O
allocated O
to O
receive O
a O
caudal O
injection O
of O
either O
plain O
ropivacaine O
0.2 O
% O
( O
1 O
ml/kg O
) O
( O
R0.2 O
) O
or O
a O
mixture O
of O
ropivacaine O
0.1 O
% O
with O
clonidine O
2 O
microg/kg O
( O
1 O
ml/kg O
) O
( O
R0.1C O
) O
. O
[]

[ O
Effects O
of O
dujieqing O
oral O
liquid O
on O
the O
promoter O
methylation O
of O
the O
MGMT O
gene O
in O
middle-and-late O
stage O
tumor O
patients O
receiving O
chemotherapy O
] O
. O
[]

Thus O
60 O
attacks O
were O
treated O
. O
[]

METHODS O
We O
randomized O
258 O
women O
undergoing O
primary O
and O
repeat O
cesarean O
deliveries O
at O
32 O
weeks O
of O
gestation O
or O
more O
to O
creation O
( O
n=131 O
) O
or O
omission O
( O
n=127 O
) O
of O
the O
bladder O
flap O
. O
[]

The O
most O
frequently O
noted O
reason O
for O
refusal B-outcome ['Life-Impact']
was O
being O
too O
busy O
or O
having O
no O
time O
. O
['Life-Impact']

END O
POINT O
Treatment O
efficacy O
was O
assessed O
by O
local B-outcome ['Physiological-Clinical']
control O
of O
disease B-outcome ['Physiological-Clinical']
and O
by O
survival B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

A O
lack O
of O
research O
on O
effective O
therapy O
for O
patients O
with O
chronic O
whiplash O
associated O
disorders O
prompted O
the O
design O
of O
the O
current O
study O
. O
[]

While O
the O
surgery O
was O
stressful O
, O
no O
unexpected O
complications B-outcome ['Adverse-effects']
occurred O
during O
or O
following O
treatment O
. O
['Adverse-effects']

0.5 O
Nm/body O
weight O
[ O
BW O
] O
) O
compared O
to O
no O
PFOA O
( O
mean O
? O
[]

2 O
) O
In O
addition O
, O
the O
effect O
of O
killing O
technique O
on O
apparent O
ileal O
protein O
digestibility O
values O
obtained O
by O
a O
slaughter O
method O
and O
effect O
of O
rapeseed O
feeding O
on O
size O
of O
specific O
organs O
were O
studied O
. O
( O
[]

Crown O
lengthening O
with O
a O
2.0 O
mm O
apical O
extended O
ferrule O
resulted O
in O
reduced O
fracture B-outcome ['Physiological-Clinical']
strengths I-outcome ['Physiological-Clinical']
for O
endodontically-treated O
teeth O
restored O
using O
two O
dowel-core O
systems O
and O
cast O
metal O
crowns O
. O
['Physiological-Clinical']

The O
study O
primarily O
assessed O
risperidone O
's O
safety O
; O
efficacy O
was O
assessed O
as O
a O
secondary O
end-point O
. O
[]

An O
analysis O
of O
the O
mortality O
effect O
in O
a O
breast O
cancer O
screening O
study O
. O
[]

In O
a O
subgroup O
of O
patients O
with O
high O
levels O
of O
disease O
activity O
who O
had O
more O
than O
one O
active O
MRI-evident O
lesion O
during O
4 O
weeks O
, O
valacyclovir O
treatment O
was O
associated O
with O
a O
reduced O
number O
of O
new B-outcome ['Physiological-Clinical']
active I-outcome ['Physiological-Clinical']
MRI-evident I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
and O
with O
an O
increase O
in O
the O
number O
of O
scans O
free O
of O
new B-outcome ['Physiological-Clinical']
active I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
conclude O
that O
cisapride O
is O
effective O
in O
the O
treatment O
of O
constipation O
in O
idiopathic O
PD O
. O
[]

Several O
indicators B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oxidative I-outcome ['Physiological-Clinical']
stress O
, O
immunity B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Forty-nine O
community-based O
pediatricians O
at O
8 O
practices O
participated O
in O
a O
cluster-randomized O
trial O
. O
[]

INTERVENTION O
( O
S O
) O
Outpatient O
hysteroscopy O
was O
performed O
with O
CO O
( O
2 O
) O
( O
group O
A O
) O
or O
normal O
saline O
( O
group O
B O
) O
and O
with O
endometrial O
biopsy O
when O
indicated O
. O
[]

Cyanoacrylate O
was O
the O
best O
agent O
overall O
in O
terms O
of O
immediate O
efficacy O
, O
low B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
requirement I-outcome ['Physiological-Clinical']
, O
time B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
initial I-outcome ['Life-Impact']
hemostasis I-outcome ['Life-Impact']
, O
and O
reduction O
of O
gastric B-outcome ['Physiological-Clinical']
variceal I-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

There O
was O
a O
strong O
inverse O
association O
between O
the O
level O
of O
CD19 B-outcome ['Physiological-Clinical']
values O
at O
diagnosis O
and O
infections O
within O
the O
first O
2 O
months O
of O
diagnosis O
. O
['Physiological-Clinical']

VARIABLES O
Pain B-outcome ['Physiological-Clinical']
and O
fatigue B-outcome ['Physiological-Clinical']
, O
numbers O
of O
other O
symptoms B-outcome ['Physiological-Clinical']
, O
and O
physical B-outcome ['Life-Impact']
role I-outcome ['Life-Impact']
impact I-outcome ['Life-Impact']
and O
social-functioning B-outcome ['Life-Impact']
subscales O
from O
the O
Medical O
Outcomes O
Study O
36 O
Short O
Form O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

CONCLUSION O
TGF-beta O
1 O
had O
no O
beneficial O
effects O
on O
wound B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
An O
active O
and O
sham O
ITD O
were O
randomly O
applied O
first O
to O
a O
facemask O
and O
then O
to O
an O
ETT O
during O
active O
compression-decompression O
cardiopulmonary O
resuscitation O
in O
13 O
out-of-hospital O
cardiac O
arrest O
patients O
in O
a O
randomized O
, O
double-blinded O
, O
prospective O
clinical O
trial O
. O
[]

METHODS O
Sixty O
lower O
rectal O
cancer O
patients O
were O
divided O
randomly O
into O
two O
groups O
. O
[]

We O
recorded O
Visual O
Analogue O
Scale O
( O
VAS O
) O
, O
satisfaction B-outcome ['Life-Impact']
scores O
, O
morphine B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
and O
side O
effects O
during O
postoperative O
24 O
hours O
. O
['Life-Impact', 'Resource-use']

However O
, O
because O
cryotherapy O
is O
not O
100 O
% O
effective O
, O
follow-up O
is O
needed O
after O
treatment O
to O
detect O
post-treatment O
failures O
. O
[]

Activity B-outcome ['Life-Impact']
in O
premotor O
regions O
, O
IPL B-outcome ['Physiological-Clinical']
and O
MOTG O
correlated O
positively O
with O
social B-outcome ['Life-Impact']
competence I-outcome ['Life-Impact']
, O
whereas O
prefrontal O
Mu-sources O
correlated O
negatively O
with O
social B-outcome ['Life-Impact']
competence I-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Apolipoprotein B-outcome ['Physiological-Clinical']
A-I I-outcome ['Physiological-Clinical']
and O
E B-outcome ['Physiological-Clinical']
were O
elevated O
27 O
% O
and O
66 O
% O
, O
respectively O
, O
and O
apoB B-outcome ['Physiological-Clinical']
was O
reduced O
26 O
% O
with O
120 O
mg O
twice O
daily O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
were O
observed O
in O
dissociation O
with O
effects O
of O
articulatory O
suppression O
and O
matrix O
tapping O
, O
so O
that O
the O
locus O
of O
the O
effects O
of O
the O
new O
task O
is O
not O
due O
to O
the O
slave O
systems O
. O
[]

METHOD O
Sixty-four O
children O
with O
autism O
( O
ages O
2-7 O
years O
; O
55 O
boys O
and O
9 O
girls O
) O
with O
a O
range O
of O
intelligence O
quotient O
and O
verbal O
ability O
were O
randomly O
assigned O
, O
in O
a O
double-blind O
manner O
, O
to O
secretin O
or O
placebo O
groups O
. O
[]

CONCLUSIONS O
Although O
probably O
not O
arrhythmogenic O
in O
normal O
subjects O
, O
moderate O
caffeine O
ingestion O
does O
produce O
a O
small O
but O
statistically O
significant O
prolongation O
of O
signal-averaged B-outcome ['Physiological-Clinical']
QRS I-outcome ['Physiological-Clinical']
complexes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Effects O
of O
cooking O
plant O
oils O
on O
recurrent O
aphthous O
stomatitis O
: O
a O
randomized O
, O
placebo-controlled O
, O
double-blind O
trial O
. O
[]

The O
combined O
acupuncture O
and O
medication O
group O
was O
treated O
with O
acupuncture O
at O
Baihui O
( O
GV O
20 O
) O
, O
Sishencong O
( O
EX-HN O
1 O
) O
, O
Dazhui O
( O
GV O
14 O
) O
, O
Guanyuan O
( O
CV O
4 O
) O
, O
etc O
. O
[]

Clinical O
evaluation O
of O
the O
intraoral O
fluoride O
releasing O
system O
in O
radiation-induced O
xerostomic O
subjects O
. O
[]

RESULTS O
Among O
235 O
eligible O
patients O
initially O
registered O
, O
91 O
were O
randomized O
to O
receive O
maintenance O
therapy O
, O
including O
seven O
patients O
who O
were O
no O
longer O
responding O
. O
[]

Her O
pregnancy O
ended O
with O
stillbirth B-outcome ['Mortality']
. O
['Mortality']

All O
groups O
were O
comparable O
at O
baseline O
. O
[]

Caudal O
analgesia O
for O
perianal O
surgery O
. O
[]

METHODS O
Nasal O
IgA O
responses O
were O
assessed O
using O
data O
from O
3 O
prospective O
, O
2-year O
, O
randomized O
studies O
comparing O
LAIV O
with O
placebo O
in O
children O
6-36 O
months O
of O
age O
. O
[]

Arterial B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
was O
measured O
noninvasively O
in O
the O
left O
common O
carotid O
artery O
with O
color O
Doppler O
ultrasound O
. O
['Physiological-Clinical']

Subjects O
took O
one O
tablet O
daily O
and O
rinsed O
twice O
daily O
for O
1 O
min O
with O
the O
mouthwash O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
groups O
when O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
episode I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bacteremia I-outcome ['Physiological-Clinical']
attributable O
to O
luminal O
colonization O
with O
a O
vancomycin-susceptible O
organism O
was O
compared O
by O
means O
of O
Kaplan-Meier O
survival O
estimates O
. O
['Physiological-Clinical']

One O
hundred O
twenty-eight O
patients O
were O
treated O
with O
postoperative O
radiotherapy O
with O
50 O
Gy O
in O
25 O
daily O
fractions O
over O
5 O
weeks O
. O
[]

In O
adults O
, O
mean O
age O
of O
35.3 O
years O
, O
prolactin B-outcome ['Physiological-Clinical']
increased O
more O
markedly O
from O
11.6+/-7.4 O
baseline O
( O
n=11 O
) O
to O
93.3+/-54.2 O
acutely O
but O
decreased O
to O
67.8+/-62.9 O
in O
maintenance O
( O
n=7 O
) O
. O
['Physiological-Clinical']

RESULTS O
Adrenaline O
significantly O
decreased O
surgeons O
' O
subjective O
estimate O
of O
the O
amount O
of O
intraoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
( O
proportion O
of O
patients O
with O
significant O
decrease O
67 O
versus O
21 O
% O
, O
P O
< O
0.001 O
) O
, O
reduced O
the O
mean O
number O
of O
packings B-outcome ['Physiological-Clinical']
needed O
( O
0.6 O
versus O
1.2 O
, O
P O
< O
0.001 O
) O
and O
use B-outcome ['Life-Impact']
of O
electrocautery B-outcome ['Resource-use']
( O
22 O
versus O
45 O
% O
, O
P O
= O
0.015 O
) O
, O
and O
shortened O
the O
mean O
duration O
of O
the O
procedure B-outcome ['Resource-use']
( O
13 O
versus O
18 O
min O
, O
P O
= O
0.043 O
) O
and O
the O
mean O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Resource-use']

This O
pilot O
study O
was O
designed O
to O
test O
the O
efficacy O
of O
adding O
home-based O
Developmental O
, O
Individual-Difference O
, O
Relationship-Based O
( O
DIR O
) O
/Floortime? O
intervention O
to O
the O
routine O
care O
of O
preschool O
children O
with O
autistic O
spectrum O
disorder O
. O
[]

CONCLUSIONS O
CYP2C19 O
genotypes O
play O
a O
role O
in O
H. O
pylori O
eradication O
therapy O
. O
[]

The O
analysis O
of O
individual O
target O
symptoms O
and O
the O
parents O
' O
treatment O
preferences O
substantiated O
the O
beneficial O
effects O
of O
ORG O
2766 O
. O
[]

Incidence O
and O
pattern O
of O
myocardial O
ischemia O
during O
the O
peri-PTCA O
( O
percutaneous O
transluminal O
coronary O
angioplasty O
) O
period O
and O
the O
possible O
role O
of O
continuous O
intravenous O
isosorbide O
dinitrate O
in O
its O
prevention O
were O
examined O
prospectively O
in O
30 O
patients O
. O
[]

High-intensity O
physical O
training O
in O
adults O
with O
asthma O
. O
[]

Heart O
rate O
and O
the O
total O
dose O
of O
exercise O
correlated O
with O
WMI O
changes O
in O
the O
exercise O
group O
. O
[]

Therefore O
, O
it O
was O
of O
interest O
to O
assess O
the O
efficacy O
of O
piracetam O
, O
a O
positive O
modulator O
of O
AMPA-sensitive O
glutamate O
receptors O
in O
autistic O
disorder O
. O
[]

for O
8 O
days O
, O
does O
not O
accelerate O
gastric B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
in O
patients O
with O
diabetic O
gastroparesis O
. O
['Physiological-Clinical']

Regression O
analysis O
demonstrated O
a O
significant O
correlation O
of O
the O
changes O
in O
minimal B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
with O
baseline O
% B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
stenosis I-outcome ['Physiological-Clinical']
( O
r O
= O
0.30 O
; O
P O
< O
0.001 O
) O
, O
minimal B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
( O
r O
= O
-0.28 O
; O
P O
< O
0.001 O
) O
and O
reference B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
stenoses I-outcome ['Physiological-Clinical']
( O
r O
= O
-0.14 O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Training O
referential O
communicative O
skills O
to O
individuals O
with O
autism O
spectrum O
disorder O
: O
a O
pilot O
study O
. O
[]

Using O
this O
technique O
, O
vasculature B-outcome ['Physiological-Clinical']
and O
red B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
are O
separated O
from O
the O
background O
of O
the O
image O
. O
['Physiological-Clinical']

CONCLUSIONS O
Individual O
assessments O
of O
obesity O
and O
overweight O
should O
also O
include O
an O
assessment O
for O
subthreshold O
depression O
, O
mainly O
anhedonia O
. O
[]

This O
single O
subject O
design O
study O
examined O
two O
models O
of O
intervention O
: O
Denver O
Model O
( O
which O
merges O
behavioral O
, O
developmental O
, O
and O
relationship-oriented O
intervention O
) O
, O
and O
PROMPT O
( O
a O
neuro-developmental O
approach O
for O
speech O
production O
disorders O
) O
. O
[]

Complete B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
( O
grade O
2 O
or O
3 O
to O
grade O
0 O
or O
1 O
) O
occurred O
in O
35 O
% O
of O
all O
reperfused O
patients O
. O
['Physiological-Clinical']

Subjects O
who O
were O
> O
or O
=50 O
% O
adherent O
to O
exercise O
had O
no O
improvement O
in O
BMD B-outcome ['Physiological-Clinical']
but O
were O
less O
likely O
to O
lose O
BMD B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Teacher-implemented O
joint O
attention O
intervention O
: O
pilot O
randomized O
controlled O
study O
for O
preschoolers O
with O
autism O
. O
[]

The O
study O
is O
powered O
to O
detect O
differences O
in O
the O
primary O
efficacy O
end O
point O
of O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
heart B-outcome ['Resource-use']
failure I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
and O
2 O
safety O
end O
points O
. O
['Mortality', 'Resource-use']

OBJECTIVE O
Medical O
procedures O
, O
particularly O
venipuncture O
( O
the O
puncture O
of O
a O
vein O
especially O
for O
the O
withdrawal O
of O
blood O
) O
, O
can O
cause O
serious O
distress O
and O
behavior B-outcome ['Life-Impact']
disturbance I-outcome ['Life-Impact']
for O
many O
children O
. O
['Life-Impact']

Records O
of O
plaque O
index O
, O
gingival O
index O
, O
bleeding O
on O
probing O
, O
probing O
depth O
, O
probing O
attachment O
level O
and O
microscopic O
counts O
were O
obtained O
at O
0 O
, O
4 O
, O
6 O
and O
8 O
weeks O
. O
[]

BACKGROUND O
Rye O
bread O
contributes O
an O
important O
part O
of O
the O
whole O
grain O
intake O
in O
the O
Scandinavian O
diet O
. O
[]

Implanted O
eyes O
had O
higher O
incidences O
of O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
elevation B-outcome ['Physiological-Clinical']
( O
> O
or O
= O
10 O
mm O
Hg O
) O
than O
nonimplanted O
eyes O
( O
P O
< O
.01 O
) O
, O
and O
glaucoma B-outcome ['Physiological-Clinical']
surgery B-outcome ['Resource-use']
was O
required O
in O
40 O
% O
of O
implanted O
eyes O
vs O
2 O
% O
of O
nonimplanted O
eyes O
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Twenty O
boys O
with O
fragile O
X O
syndrome O
were O
randomized O
to O
receive O
12 O
weeks O
of O
treatment O
with O
either O
placebo O
or O
donepezil O
( O
2.5 O
mg O
daily O
for O
initial O
4 O
weeks O
followed O
by O
5 O
mg O
daily O
for O
next O
8 O
weeks O
) O
. O
[]

Using O
the O
multiplex O
assay O
, O
small O
borderline O
significant O
increases O
in O
matrix B-outcome ['Physiological-Clinical']
metalloproteinase-9 I-outcome ['Physiological-Clinical']
, O
interleukins B-outcome ['Physiological-Clinical']
( O
IL B-outcome ['Physiological-Clinical']
) O
-1 O
beta B-outcome ['Physiological-Clinical']
, O
6 O
and O
10 O
occurred O
7 O
hrs O
post O
exposure O
initiation O
, O
whereas O
E-selectin O
, O
intercellular O
adhesion O
molecule-1 O
, O
and O
vascular B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
adhesion B-outcome ['Physiological-Clinical']
molecule B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
20 O
ASA O
physical O
status O
I O
, O
II O
, O
and O
III O
adults O
, O
who O
underwent O
major O
abdominal O
surgery O
requiring O
mechanical O
ventilation O
a O
few O
hours O
postoperatively O
. O
[]

Patients O
were O
randomly O
allocated O
( O
in O
a O
2:1 O
ratio O
) O
treatment O
with O
local O
standard O
of O
care O
plus O
50 O
mg O
eltrombopag O
or O
matching O
placebo O
once O
daily O
for O
6 O
months O
. O
[]

The O
three O
experiments O
varied O
the O
experimental O
design O
( O
between O
or O
within O
subjects O
) O
, O
task B-outcome ['Life-Impact']
difficulty I-outcome ['Life-Impact']
( O
how O
closely O
the O
comparison O
stimuli O
were O
spaced O
around O
the O
standards O
) O
, O
and O
presence O
or O
absence O
of O
feedback B-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
accuracy O
. O
['Life-Impact', 'Life-Impact']

Mean O
bone B-outcome ['Physiological-Clinical']
mineral O
density O
values O
remained O
at O
or O
above O
baseline O
in O
all O
add-back O
groups O
. O
['Physiological-Clinical']

CONCLUSIONS O
These O
results O
suggest O
that O
the O
test O
protocol O
accurately O
predicted O
the O
MLSS B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
Pneumatic O
compression O
is O
a O
frequently O
prescribed O
physical O
therapy O
for O
patients O
affected O
by O
postmastectomy O
lymphedema O
but O
, O
despite O
its O
wide O
use O
, O
its O
efficacy O
has O
not O
been O
demonstrated O
in O
phase O
III O
studies O
. O
[]

Early O
ambulation O
in O
patients O
with O
a O
closure O
device O
is O
safe O
. O
[]

A O
study O
with O
pulsed O
Doppler O
echocardiography O
] O
. O
[]

RESULTS O
Those O
students O
taught O
on O
a O
traditional O
course O
exhibited O
a O
significantly O
higher O
level O
of O
basic B-outcome ['Life-Impact']
anatomical I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
( O
p O
< O
0.001 O
) O
than O
those O
taught O
on O
an O
integrated O
course O
. O
['Life-Impact']

RESULTS O
After O
treatment O
, O
the O
serum O
iron O
level O
significantly O
rose O
in O
both O
groups O
. O
[]

Intravenous O
fentanyl O
100 O
micrograms O
was O
given O
after O
delivery O
of O
the O
neonate O
. O
[]

Increasing O
N-stage O
was O
also O
associated O
with O
the O
progression O
of O
proliferation O
pattern O
from O
marginal O
to O
random O
( O
P O
< O
0.001 O
) O
. O
[]

METHODS O
Placebo O
or O
RRV-TV O
( O
titre O
4x10 O
( O
5 O
) O
plaque-forming O
units O
) O
was O
given O
to O
infants O
at O
ages O
2 O
, O
3 O
, O
and O
5 O
months O
. O
[]

RESULTS O
After O
6 O
and O
12 O
months O
, O
whereas O
patients O
treated O
only O
with O
calcium O
and O
cholecalciferol O
( O
group O
A O
) O
showed O
a O
marked B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
with O
increased O
levels O
of O
DPD B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
BALP I-outcome ['Physiological-Clinical']
compared O
with O
baseline O
values O
, O
patients O
treated O
also O
with O
neridronate O
( O
group O
B O
) O
had O
substantially O
unchanged O
levels O
of O
these O
markers O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Both O
the O
cytology O
and O
the O
conjunctival O
biopsy O
specimens O
were O
investigated O
by O
histological O
exams O
and O
immunohistochemistry O
using O
different O
monoclonal O
antibodies O
. O
[]

CONCLUSION O
Procalcitonin O
is O
a O
helpful O
and O
safe O
tool O
for O
guiding O
duration O
of O
antibiotic O
treatment O
in O
patients O
with O
severe O
acute O
pancreatitis O
. O
[]

This O
pilot O
study O
was O
conducted O
to O
assure O
a O
high O
response O
rate O
and O
to O
keep O
respondents O
' O
privacy O
confidential O
by O
using O
an O
anonymous O
questionnaire O
survey O
technique O
. O
[]

After O
unilateral O
otoplasty O
, O
none O
of O
the O
TTS-scopolamine-treated O
patients O
and O
50 O
% O
of O
the O
atropine-treated O
patients O
suffered O
from O
PONV B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

kg-1 O
) O
was O
significantly O
lower O
( O
P O
< O
0.005 O
) O
than O
the O
CL O
of O
AmB O
in O
lipid O
emulsion O
( O
0.062 O
+/- O
0 O
. O
[]

OBJECTIVE O
To O
study O
the O
effectiveness O
of O
a O
training O
intervention O
with O
emphases O
on O
the O
control O
of O
lumbar O
neutral O
zone O
( O
NZ O
) O
and O
behavior O
modeling O
as O
secondary O
prevention O
of O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
LBP O
) O
and O
disability B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

CONCLUSION O
The O
potential O
role O
of O
finasteride O
on O
hematuria O
related O
to O
BPH O
may O
be O
the O
suppressive O
effect O
on O
MVD B-outcome ['Physiological-Clinical']
in O
the O
suburethral O
tissue O
of O
prostate O
. O
['Physiological-Clinical']

Subsequent O
surgical O
resection O
data O
were O
recorded O
. O
[]

RESULTS O
Fibrinogen O
was O
reduced O
in O
both O
groups O
but O
more O
markedly O
in O
the O
DYDR O
group O
. O
[]

Chinese O
Clinical O
Trial O
Registry O
; O
Registration O
No O
. O
: O
[]

CONCLUSIONS O
In O
this O
group O
of O
Benelux O
patients O
, O
IVDUs O
showed O
similar O
compliance B-outcome ['Life-Impact']
and O
response O
to O
treatment O
with O
interferon O
and O
ribavirin O
compared O
with O
other O
patients O
with O
CHC O
infection O
. O
['Life-Impact']

Complications O
were O
not O
different O
for O
the O
two O
groups O
. O
[]

Subjective O
rating O
scores O
coincided O
with O
these O
findings O
. O
[]

Our O
study O
showed O
that O
immobilization-induced O
hypercalcemia O
and O
25-hydroxyvitamin O
D O
deficiency O
contribute O
to O
reduced O
bone O
mineral O
density O
( O
BMD O
) O
. O
[]

A O
randomized O
clinical O
trial O
of O
the O
efficacy O
of O
scheduled O
dosing O
of O
acetaminophen O
and O
hydrocodone O
for O
the O
management O
of O
postoperative O
pain O
in O
children O
after O
tonsillectomy O
. O
[]

Effect O
of O
nimodipine O
upon O
electroencephalographic B-outcome ['Physiological-Clinical']
vigilance I-outcome ['Physiological-Clinical']
in O
elderly O
persons O
with O
minor O
impairment O
of O
brain O
functions O
. O
['Physiological-Clinical']

This O
study O
is O
registered O
as O
an O
International O
Standard O
Randomised O
Controlled O
Trial O
, O
number O
ISRCTN O
NCT00174993 O
. O
[]

Data O
suggested O
that O
the O
benefit O
of O
Xuezhikang O
resulted O
in O
significant O
modification O
vascular B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
by O
reduction O
of O
ET-1 O
, O
inflammatory O
markers O
and O
LDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
, O
which O
may O
be O
clinically O
important O
for O
patients O
with O
CSX O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
investigate O
the O
efficacy O
of O
wrist O
working O
splints O
after O
a O
period O
of O
splinting O
in O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
. O
[]

CONCLUSION O
Pretreatment O
with O
minidose O
succinylcholine O
causes O
no O
greater O
incidence O
of O
fasciculations B-outcome ['Physiological-Clinical']
than O
pancuronium O
in O
rapid-sequence O
intubation O
of O
head O
trauma O
patients O
in O
an O
ED O
setting O
. O
['Physiological-Clinical']

The O
cure B-outcome ['Physiological-Clinical']
rates O
were O
similar O
in O
men O
and O
women O
, O
and O
pharyngeal B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
eradicated O
in O
20 O
of O
22 O
patients O
( O
91 O
percent O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Accordingly O
, O
220 O
inpatients O
( O
26 O
% O
chronic O
active O
hepatitis O
, O
68 O
% O
cirrhosis O
, O
6 O
% O
primary O
biliary O
cirrhosis O
) O
with O
stable O
( O
1 O
month O
or O
more O
) O
at O
least O
twofold O
increases O
in O
serum B-outcome ['Physiological-Clinical']
total O
and O
conjugated B-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
alkaline I-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
volunteered O
for O
the O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
control O
group O
did O
not O
perform O
a O
training O
program O
. O
[]

All O
patients O
transplanted O
with O
more O
than O
5 O
x O
10 O
( O
6 O
) O
CD34+ O
cells/kg O
had O
a O
rapid O
platelet B-outcome ['Physiological-Clinical']
recovery B-outcome ['Physiological-Clinical']
( O
20 O
x O
10 O
( O
9 O
) O
/l O
) O
between O
6 O
and O
11 O
days O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Normal O
individuals O
who O
evenly O
matched O
with O
the O
study O
group O
were O
assessed O
for O
normal O
respiratory O
function O
parameters O
. O
[]

Six-month O
trial O
of O
on-demand O
rabeprazole O
10 O
mg O
maintains O
symptom B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
patients O
with O
non-erosive O
reflux B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
15-year O
actuarial O
locoregional B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rate O
was O
7 O
% O
for O
the O
q.d O
. O
['Physiological-Clinical']

The O
different O
parameters O
were O
compared O
by O
analysis O
of O
variance O
( O
ANOVA O
) O
. O
[]

Since O
FGF23 O
shares O
structural O
features O
with O
FGF19 O
subfamily O
members O
that O
exert O
hormonal O
control O
of O
fat O
mass O
, O
we O
hypothesized O
that O
high O
circulating O
FGF23 O
concentrations O
would O
be O
associated O
with O
the O
development O
of O
a O
uremic O
lipid O
profile O
and O
lower O
body O
mass O
index O
( O
BMI O
) O
. O
[]

Young O
injection O
drug O
users O
( O
IDUs O
) O
who O
are O
not O
infected O
with O
HIV O
or O
hepatitis O
C O
virus O
are O
at O
great O
risk O
of O
acquiring O
one O
or O
both O
of O
these O
infections O
through O
their O
sexual O
or O
injection O
behaviors O
. O
[]

To O
avoid O
the O
errors O
associated O
with O
the O
measurement O
of O
spinal O
bone O
density O
the O
total O
hip O
has O
been O
accepted O
as O
the O
standard O
measurement O
site O
. O
[]

Terfenadine O
was O
demonstrated O
to O
be O
an O
effective O
drug O
in O
hay O
fever O
and O
produced O
no O
more O
drowsiness B-outcome ['Life-Impact']
than O
placebo O
. O
['Life-Impact']

The O
frequency O
of O
postoperative B-outcome ['Physiological-Clinical']
adhesions I-outcome ['Physiological-Clinical']
was O
the O
main O
outcome O
. O
['Physiological-Clinical']

SUBJECTS O
AND O
METHODS O
In O
a O
randomized O
, O
double O
blind O
, O
controlled O
with O
placebo O
study O
, O
27 O
women O
with O
climacteric O
symptoms O
and O
atrophic O
vaginitis O
were O
treated O
for O
4 O
months O
with O
HT O
plus O
vaginal O
estriol O
0.5 O
mg/day O
( O
group O
E O
) O
or O
placebo O
( O
group O
P O
) O
. O
[]

The O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
safety O
, O
pharmacokinetics O
and O
pharmacodynamics O
of O
recombinant O
human O
porphobilinogen O
deaminase O
( O
P O
9808 O
) O
, O
administered O
to O
healthy O
subjects O
and O
asymptomatic O
porphobilinogen O
deaminase-deficient O
subjects O
with O
high O
concentrations O
of O
porphobilinogen O
, O
the O
substrate O
of O
porphobilinogen O
deaminase O
. O
[]

Haloperidol O
( O
mean O
dose O
, O
2.95 O
mg/day O
) O
caused O
significant O
decreases O
in O
Porteus O
Maze O
test O
quotient O
scores O
and O
a O
slowing O
of O
reaction O
time O
( O
RT O
) O
on O
a O
simple O
RT O
task O
. O
[]

The O
adrenocorticotrophic O
hormone O
( O
4-9 O
) O
analog O
ORG O
2766 O
benefits O
autistic O
children O
: O
report O
on O
a O
second O
controlled O
clinical O
trial O
. O
[]

PURPOSE O
To O
evaluate O
the O
toxicity B-outcome ['Adverse-effects']
and O
clinical B-outcome ['Physiological-Clinical']
outcome O
in O
patients O
with O
locally O
advanced O
cervical O
cancer O
( O
LACC O
) O
treated O
with O
whole O
pelvic O
conventional O
radiation O
therapy O
( O
WP-CRT O
) O
versus O
intensity O
modulated O
radiation O
therapy O
( O
WP-IMRT O
) O
. O
['Adverse-effects', 'Physiological-Clinical']

However O
, O
concerns O
about O
a O
negative O
impact O
of O
Ca/Mg O
infusions O
on O
outcome O
have O
been O
raised O
. O
[]

This O
difference O
may O
reflect O
changes O
in O
the O
source O
of O
rhGM-CSF O
or O
in O
the O
infusion O
schedule O
. O
[]

The O
1 O
% O
and O
2 O
% O
concentrations O
decreased O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
significantly O
from O
baseline O
compared O
to O
placebo O
at O
one O
, O
two O
, O
four O
, O
six O
, O
eight O
, O
and O
12 O
hours O
after O
administration O
. O
['Physiological-Clinical']

Secondary O
outcomes O
included O
the O
mean O
changes O
in O
logarithm O
of I-outcome ['Physiological-Clinical']
the O
minimum B-outcome ['Physiological-Clinical']
angle I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
best-corrected B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BCVA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
central B-outcome ['Physiological-Clinical']
retinal B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
( O
CRT B-outcome ['Physiological-Clinical']
) O
, O
and O
angiographic B-outcome ['Physiological-Clinical']
findings I-outcome ['Physiological-Clinical']
from O
baseline O
to O
12 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
these O
, O
351 O
experienced O
an O
HSL O
outbreak O
and O
were O
randomized O
to O
use O
CSP O
( O
n O
= O
179 O
) O
or O
acyclovir O
cream O
5 O
% O
( O
n O
= O
172 O
) O
at O
the O
onset O
of O
symptoms O
until O
the O
lesion O
healed O
, O
for O
a O
maximum O
of O
10 O
days O
. O
[]

After O
a O
washout O
period O
of O
2 O
weeks O
, O
patients O
were O
randomized O
to O
amlodipine O
maleate O
or O
amlodipine O
besylate O
for O
8 O
weeks O
. O
[]

Treatments O
were O
1 O
) O
0.9 O
kg O
( O
as-fed O
basis O
) O
of O
a O
42 O
% O
CP O
supplement/d O
and O
pasture O
( O
control O
) O
; O
2 O
) O
a O
high-starch O
( O
HS O
) O
diet O
( O
73 O
% O
corn O
; O
53 O
% O
starch O
) O
fed O
in O
a O
drylot O
for O
60 O
d O
( O
HS-60 O
) O
; O
3 O
) O
a O
HS O
diet O
fed O
in O
drylot O
for O
30 O
d O
( O
HS-30 O
) O
; O
or O
4 O
) O
a O
low-starch O
( O
LS O
) O
diet O
( O
49 O
% O
corn O
; O
37 O
% O
starch O
) O
self-fed O
on O
pasture O
for O
30 O
d O
( O
LS-30 O
) O
. O
[]

RESULTS O
Treatment O
with O
both O
doses O
of O
exenatide O
versus O
insulin O
monotherapy O
significantly O
reduced O
glucose B-outcome ['Physiological-Clinical']
excursions I-outcome ['Physiological-Clinical']
over O
300 O
min O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

88 O
( O
88 O
% O
) O
and O
64 O
( O
64 O
% O
) O
of O
controls O
and O
high-dose O
patients O
, O
respectively O
, O
needed O
intubation O
during O
admission B-outcome ['Resource-use']
to I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
( O
relative O
risk=0.72 O
, O
0.62-0.86 O
, O
p=0.0001 O
) O
. O
['Resource-use']

In O
conclusion O
, O
heart B-outcome ['Physiological-Clinical']
rate O
, O
respiration B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
phase O
III O
study O
evaluated O
efficacy O
and O
safety O
of O
pazopanib O
monotherapy O
in O
treatment-naive O
and O
cytokine-pretreated O
patients O
with O
advanced O
renal O
cell O
carcinoma O
( O
RCC O
) O
. O
[]

Comparison O
of O
the O
hypotensive O
effects O
of O
bendrofluazide O
, O
bumetanide O
and O
xipamide O
. O
[]

Final O
analysis O
of O
the O
UKLG O
LY02 O
trial O
comparing O
6-8 O
cycles O
of O
CHOP O
with O
3 O
cycles O
of O
CHOP O
followed O
by O
a O
BEAM O
autograft O
in O
patients O
< O
65 O
years O
with O
poor O
prognosis O
histologically O
aggressive O
NHL O
. O
[]

With O
the O
exception O
of O
hyperglycaemia O
, O
adverse O
events O
were O
generally O
similar O
between O
groups O
. O
[]

Quantitative O
monitoring O
of O
serum B-outcome ['Physiological-Clinical']
hepatitis I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
lymphocyte I-outcome ['Physiological-Clinical']
subsets I-outcome ['Physiological-Clinical']
during O
combined O
prednisolone O
and O
interferon-alpha O
therapy O
in O
patients O
with O
chronic O
hepatitis O
B O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
scales O
were O
found O
to O
be O
valid O
instruments O
. O
[]

The O
remaining O
174 O
patients O
were O
included O
in O
the O
analysis O
. O
[]

The O
recently O
published O
Ongoing O
Telmisartan O
Alone O
and O
in O
Combination O
With O
Ramipril O
Global O
Endpoint O
Trial O
( O
ONTARGET O
) O
in O
patients O
with O
vascular O
disease O
or O
high-risk O
diabetes O
, O
as O
the O
largest O
published O
comparative O
trial O
of O
these O
agent O
classes O
, O
provides O
further O
evidence O
concerning O
the O
comparison O
between O
the O
angiotensin-receptor O
blockers O
( O
ARBs O
) O
and O
the O
angiotensin-converting O
enzyme O
inhibitors O
( O
ACEIs O
) O
. O
[]

The O
aim O
was O
a O
ringing B-outcome ['Life-Impact']
voice I-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
with O
strong O
overtones O
at O
3-5 O
kHz O
. O
['Life-Impact']

RESULTS O
The O
characteristics O
of O
the O
population O
studied O
were O
similar O
to O
those O
reported O
in O
previous O
trials O
of O
beta-blockers O
. O
[]

Protocol O
for O
the O
Multicenter O
Acute O
Stroke O
Trial O
-- O
thrombolysis O
study O
. O
[]

We O
report O
the O
results O
of O
a O
randomized O
multicenter O
clinical O
trial O
on O
the O
effects O
of O
aspirin O
plus O
dipyridamole O
versus O
placebo O
on O
major O
vascular B-outcome ['Physiological-Clinical']
end I-outcome ['Physiological-Clinical']
points I-outcome ['Physiological-Clinical']
in O
231 O
non-insulin-dependent O
diabetic O
men O
with O
either O
a O
recent O
amputation O
for O
gangrene O
or O
active O
gangrene O
. O
['Physiological-Clinical']

Three O
high-pressure O
, O
rapid-compression O
devices O
and O
two O
standard O
, O
low-pressure O
, O
slow-inflation O
compression O
devices O
were O
applied O
in O
a O
random O
sequence O
. O
[]

A O
double-blind O
crossover O
comparison O
of O
pindolol O
, O
metoprolol O
, O
atenolol O
and O
labetalol O
in O
mild O
to O
moderate O
hypertension O
. O
[]

After O
six O
months O
, O
there O
were O
no O
differences O
among O
the O
three O
groups O
regarding O
these O
variables O
. O
[]

PURPOSE O
Pemetrexed O
has O
shown O
varied O
response O
rates O
in O
advanced O
breast O
cancer O
. O
[]

HBOT O
may O
possibly O
have O
a O
broad-spectrum O
antimicrobial O
effect O
worthy O
of O
further O
study O
. O
[]

A O
maximum O
of O
4 O
IUI O
cycles O
per O
couple O
with O
or O
without O
exogenous O
PAF O
treatment O
were O
performed O
and O
the O
main O
outcome O
measure O
was O
the O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate O
( O
pregnancies O
confirmed O
by O
ultrasonography O
per O
100 O
cycles O
) O
. O
['Physiological-Clinical']

MEASUREMENTS O
Main O
outcomes O
were O
12-month O
changes O
from O
baseline O
in O
bone B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
and O
resorption B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
and O
bone B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
measured O
according O
to O
quantitative O
ultrasound O
scanning O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Group O
A O
was O
expected O
to O
give O
more O
correct O
answers O
to O
questions O
about O
the O
common O
facts O
than O
Group O
B O
, O
when O
tested O
postoperatively O
, O
and O
Group O
B O
to O
attribute O
more O
fame O
to O
presented O
names O
than O
Group O
A O
( O
famous O
names O
test O
) O
. O
[]

Significantly O
more O
women O
in O
the O
sublingual O
group O
preferred O
the O
route O
to O
which O
they O
were O
assigned O
when O
compared O
with O
the O
vaginal O
group O
. O
[]

The O
mean O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
83 O
ml O
( O
group O
A O
) O
and O
210 O
ml O
( O
group O
B O
) O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Given O
the O
necessarily O
invasive O
nature O
of O
caudal O
block O
, O
we O
suggest O
the O
combined O
use O
of O
diclofenac O
suppository O
with O
local O
anesthetic O
infiltration O
at O
port O
sites O
as O
a O
useful O
and O
more O
economical O
alternative O
for O
analgesia O
following O
pediatric O
laparoscopy O
. O
[]

This O
may O
partially O
explain O
the O
protective O
effect O
of O
D53 O
immunostimulant O
against O
respiratory B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHOD O
The O
surgical O
sites O
from O
both O
groups O
were O
swabbed O
and O
sent O
for O
culture O
and O
sensitivity O
upon O
wound O
closure O
( O
superficial O
incisional O
skin O
surface O
) O
in O
the O
operating O
theatre O
, O
as O
a O
baseline O
for O
bacterial O
colonisation O
. O
[]

A O
group O
of O
older O
adults O
were O
prepared O
as O
peer O
mentors O
through O
a O
30-week O
preparation O
program O
. O
[]

Significantly O
more O
patients O
treated O
with O
nefazodone O
( O
36 O
% O
) O
than O
placebo-treated O
patients O
( O
14 O
% O
) O
had O
a O
HAM-D-17 O
score O
< O
or O
= O
10 O
at O
the O
end O
of O
treatment O
( O
p O
= O
.004 O
) O
. O
[]

Selamectin O
was O
administered O
on O
days O
0 O
, O
30 O
, O
and O
60 O
. O
[]

METHOD O
Fifty-nine O
full O
term O
parturients O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
in O
active O
labor O
. O
[]

The O
IVR O
intervention O
consists O
of O
automated O
questions O
to O
identify O
and O
address O
barriers O
to O
re-cycling O
in O
QL O
support O
, O
followed O
by O
an O
offer O
to O
be O
transferred O
to O
the O
QL O
and O
reinitiate O
treatment O
. O
[]

A O
randomized O
, O
double-blind O
, O
phase O
II O
study O
of O
two O
doses O
of O
pemetrexed O
as O
first-line O
chemotherapy O
for O
advanced O
breast O
cancer O
. O
[]

METHODS O
The O
study O
was O
designed O
as O
a O
prospective O
randomized O
study O
. O
[]

For O
neonates O
< O
32 O
weeks O
this O
comparison O
was O
not O
feasible O
as O
the O
majority O
were O
parenterally O
fed O
. O
[]

METHODS O
ACS O
patients O
undergoing O
cardiac O
catheterization O
with O
> O
or=1 O
nonobstructive O
native O
coronary O
artery O
atheroma O
were O
randomized O
to O
either O
7 O
weekly O
HDL O
selective O
delipidated O
or O
control O
plasma O
apheresis/reinfusions O
. O
[]

It O
was O
organized O
according O
to O
the O
Coordinated O
School O
Health O
Program O
and O
included O
a O
PE O
component O
with O
core O
objectives O
of O
promoting O
enjoyment O
of O
PE O
, O
physical O
activity O
enjoyment O
, O
and O
self-efficacy O
. O
[]

At O
review O
2-7 O
years O
after O
the O
accidents O
, O
the O
two O
groups O
were O
compared O
with O
reference O
to O
symptoms B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
range O
of O
motion B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
wrist I-outcome ['Physiological-Clinical']
, O
power O
of O
first B-outcome ['Physiological-Clinical']
closure I-outcome ['Physiological-Clinical']
and O
radiographic B-outcome ['Physiological-Clinical']
appearance B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Control O
subjects O
received O
two O
brief O
check-in O
telephone O
calls O
during O
this O
6-month O
period O
. O
[]

INTERVENTIONS O
A O
physician O
intervention O
served O
the O
dual O
function O
of O
1 O
) O
providing O
an O
educational O
demonstration O
of O
anxiety O
in O
the O
primary O
care O
setting O
and O
2 O
) O
providing O
a O
reporting O
system O
for O
summarizing O
the O
anxiety O
symptom O
levels O
and O
functioning O
status O
of O
the O
patients O
enrolled O
in O
the O
study O
. O
[]

Is O
a O
2-week O
duration O
sufficient O
for O
stenting O
in O
endopyelotomy O
? O
[]

CONCLUSION O
Although O
the O
sample O
size O
of O
this O
study O
was O
small O
, O
we O
found O
no O
evidence O
that O
this O
hyperfractionation O
schedule O
of O
postmastectomy O
RT O
offered O
a O
clinical O
advantage O
. O
[]

Patients O
were O
randomly O
assigned O
into O
2 O
groups O
including O
a O
PCT-guided O
group O
( O
study O
group O
) O
and O
a O
prophylactic O
antibiotic O
therapy O
( O
control O
group O
) O
. O
[]

METHODS O
One O
hundred O
forty-two O
pregnant O
, O
predominantly O
Hispanic O
women O
were O
assigned O
to O
a O
peer-led O
smoking O
cessation O
program O
or O
to O
usual O
care O
. O
[]

Partial O
response O
( O
PR O
) O
was O
observed O
in O
one O
unresectable B-outcome ['Physiological-Clinical']
hepatoma I-outcome ['Physiological-Clinical']
and O
11 O
demonstrated O
no O
change O
( O
NC O
) O
or O
progressive B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Avastin-assigned O
eyes O
received O
1.25 O
mg O
intravitreal O
bevacizumab O
( O
Genentech O
Inc. O
, O
San O
Francisco O
, O
CA O
) O
on O
the O
first O
session O
of O
their O
laser O
treatments O
. O
[]

During O
the O
one O
year O
therapy O
the O
levels O
of O
serum B-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
, O
uric B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
and O
triglycerides B-outcome ['Physiological-Clinical']
were O
significantly O
increased O
in O
all O
groups O
but O
the O
group O
treated O
with O
metoprolol O
and O
hydralazine O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
took O
on O
average O
7 O
s O
and O
at O
most O
21 O
s O
to O
return O
to O
baseline O
level O
after O
stopping O
cuff O
inflation O
. O
['Physiological-Clinical']

Memory B-outcome ['Life-Impact']
benefits O
of O
effective O
instructions O
were O
pronounced B-outcome ['Life-Impact']
for O
children O
with O
poorer O
emotion B-outcome ['Life-Impact']
regulation I-outcome ['Life-Impact']
skill I-outcome ['Life-Impact']
, O
suggesting O
the O
utility O
of O
reappraisal O
in O
learning O
contexts O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Exemestane O
for O
breast-cancer O
prevention O
in O
postmenopausal O
women O
. O
[]

The O
effect O
of O
hydrochlorothiazide O
therapy O
on O
ventricular B-outcome ['Physiological-Clinical']
arrhythmias I-outcome ['Physiological-Clinical']
was O
studied O
in O
45 O
hypertensive O
African-American O
men O
with O
moderate O
to O
severe O
left O
ventricular O
( O
LV O
) O
hypertrophy O
. O
['Physiological-Clinical']

The O
primary O
endpoint O
of O
A O
placebo-controlled O
, O
double-blind O
, O
parallel-arm O
Trial O
to O
assess O
the O
efficacy O
of O
dronedarone O
400 O
mg O
bid O
for O
the O
prevention O
of O
cardiovascular B-outcome ['Resource-use']
Hospitalization I-outcome ['Resource-use']
or O
death B-outcome ['Mortality']
from O
any O
cause O
in O
patiENTs O
with O
Atrial O
fibrillation/atrial O
flutter O
( O
ATHENA O
) O
, O
a O
composite O
of O
first O
CV O
hospitalization O
or O
death O
from O
any O
cause O
, O
was O
significantly O
reduced O
by O
dronedarone O
. O
['Resource-use', 'Mortality']

At O
baseline O
, O
the O
resting O
and O
stimulated O
salivary O
flow O
rates O
( O
g/5min O
) O
were O
significantly O
greater O
in O
the O
control O
group O
than O
in O
the O
study O
group O
( O
p O
< O
0.05 O
) O
. O
[]

Examination O
of O
subjects O
by O
treatment O
interaction O
effects O
indicated O
that O
risk O
counseling O
did O
not O
produce O
improved O
comprehension B-outcome ['Life-Impact']
among O
the O
large O
proportion O
of O
women O
who O
had O
high O
levels O
of O
anxious O
preoccupation O
with O
breast O
cancer O
at O
base O
line O
( O
P O
= O
.02 O
) O
. O
['Life-Impact']

CONCLUSION O
In O
this O
placebo-controlled O
study O
, O
multiple O
doses O
of O
secretin O
did O
not O
produce O
any O
symptomatic O
improvement O
. O
[]

Considering O
the O
entire O
group O
of O
57 O
patients O
, O
follow-up O
ranged O
from O
10 O
to O
86 O
months O
( O
median O
, O
35 O
months O
) O
. O
[]

A O
prospective O
randomized O
study O
. O
[]

Holter O
electrocardiographic O
monitoring O
was O
performed O
for O
21 O
+/- O
3 O
h O
before O
PTCA O
and O
continued O
during O
and O
for O
41 O
+/- O
8 O
h O
after O
the O
procedure O
. O
[]

No O
significant O
difference O
was O
found O
between O
the O
in-person O
and O
telephone O
recalls O
for O
rEI B-outcome ['Physiological-Clinical']
and O
misreporting O
. O
['Physiological-Clinical']

For O
all O
the O
groups O
combined O
, O
the O
median O
time O
to O
the O
resolution O
of O
ascites O
was O
5.4 O
weeks O
for O
medical O
patients O
and O
3.0 O
weeks O
for O
surgical O
patients O
( O
P O
less O
than O
0.01 O
) O
. O
[]

Randomized O
trial O
of O
daily O
versus O
weekly O
administration O
of O
2-chlorodeoxyadenosine O
in O
patients O
with O
hairy O
cell O
leukemia O
: O
a O
multicenter O
phase O
III O
trial O
( O
SAKK O
32/98 O
) O
. O
[]

The O
aim O
of O
the O
study O
was O
to O
determine O
a O
possible O
interaction O
between O
a O
corticosteroid O
( O
betamethasone O
) O
and O
vecuronium O
, O
a O
nondepolarizing O
muscle O
relaxant O
. O
[]

CONCLUSIONS O
Both O
medications O
decreased O
NRS O
pain B-outcome ['Physiological-Clinical']
scores O
by O
approximately O
50 O
% O
. O
['Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
the O
incidence O
of O
congestive B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
between O
propranolol- O
and O
placebo-treated O
groups O
. O
['Physiological-Clinical']

Group O
I O
showed O
a O
significant O
immediate O
reduction O
of O
S. O
mutans O
in O
saliva O
as O
well O
as O
an O
approximal O
tooth O
surfaces O
. O
[]

The O
main O
outcomes O
studied O
were O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Resource-use']
transfusion I-outcome ['Resource-use']
, O
intraoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
duration O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
number O
of O
lymph B-outcome ['Physiological-Clinical']
nodes I-outcome ['Physiological-Clinical']
obtained O
. O
['Life-Impact', 'Physiological-Clinical', 'Resource-use', 'Adverse-effects', 'Adverse-effects', 'Resource-use', 'Physiological-Clinical']

Two O
weeks O
following O
SRP O
, O
mean O
PPD B-outcome ['Physiological-Clinical']
significantly O
decreased O
from O
baseline O
by O
0.65 O
mm O
for O
the O
test O
group O
and O
0.17 O
mm O
for O
the O
control O
; O
mean O
BI O
significantly O
dropped O
by O
0.17 O
for O
the O
test O
group O
and O
0.05 O
for O
the O
control O
. O
['Physiological-Clinical']

Results O
of O
a O
multicenter O
, O
8-week O
, O
parallel-group O
, O
randomized O
, O
double-blind O
, O
double-dummy O
, O
Phase O
III O
clinical O
trial O
to O
evaluate O
the O
efficacy O
and O
tolerability O
of O
amlodipine O
maleate O
versus O
amlodipine O
besylate O
in O
Korean O
patients O
with O
mild O
to O
moderate O
hypertension O
. O
[]

BACKGROUND O
Children O
with O
Developmental O
Coordination O
Disorder O
( O
DCD O
) O
are O
a O
heterogeneous O
group O
who O
have O
a O
marked O
impairment O
in O
the O
performance O
of O
functional O
skills O
. O
[]

The O
most O
frequently O
reported O
cardiac O
disorder O
was O
ischemic B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
, O
which O
occurred O
in O
4 O
% O
of O
subjects O
treated O
with O
degarelix O
and O
10 O
% O
of O
those O
on O
leuprolide O
. O
['Physiological-Clinical']

During O
myocardial O
ischemia O
there O
is O
a O
drop O
in O
high-energy B-outcome ['Physiological-Clinical']
phosphates I-outcome ['Physiological-Clinical']
in O
the O
myocardium O
. O
['Physiological-Clinical']

Outcome O
measures O
included O
the O
Autism B-outcome ['Life-Impact']
Diagnostic I-outcome ['Life-Impact']
Observation I-outcome ['Life-Impact']
Schedule O
, O
Ritvo-Freeman O
Real O
Life O
Rating O
Scale O
, O
Symbolic B-outcome ['Life-Impact']
Play I-outcome ['Life-Impact']
Test O
, O
and O
Parenting B-outcome ['Life-Impact']
Stress O
['Life-Impact', 'Life-Impact', 'Life-Impact']

To O
test O
the O
reliability O
and O
durability B-outcome ['Life-Impact']
of O
positive O
treatment O
effects O
obtained O
in O
a O
type O
A O
intervention O
project O
for O
healthy O
managers O
, O
the O
analysis O
was O
extended O
to O
data O
available O
from O
a O
third O
treatment O
group O
( O
a O
special O
behavior O
therapy O
group O
for O
participants O
eliminated O
from O
the O
main O
sample O
because O
of O
manifestations O
of O
clinical O
CHD O
) O
and O
to O
measures O
obtained O
6 O
months O
following O
the O
end O
of O
treatment O
. O
['Life-Impact']

Temporal B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
renin I-outcome ['Physiological-Clinical']
, O
angiotensin-II B-outcome ['Physiological-Clinical']
, O
aldosterone B-outcome ['Physiological-Clinical']
, O
epinephrine B-outcome ['Physiological-Clinical']
, O
norepinephrine B-outcome ['Physiological-Clinical']
, O
B-type B-outcome ['Physiological-Clinical']
natriuretic I-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BNP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
N-terminal B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
natriuretic I-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NT-ANP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
768 O
treated O
patients O
with O
heart O
failure O
measured O
at O
baseline O
and O
17 O
and O
43 O
weeks O
after O
randomization O
were O
examined O
for O
their O
relations O
with O
concurrent O
changes O
in O
the O
EF B-outcome ['Physiological-Clinical']
, O
cardiac B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
, O
and O
risk O
for O
subsequent O
adverse O
clinical O
outcomes O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

UNLABELLED O
There O
is O
a O
need O
for O
a O
sophisticated O
approach O
to O
track O
athletic O
performance O
and O
to O
quantify O
factors O
affecting O
it O
in O
practical O
settings O
. O
[]

Disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
statistically O
significant O
, O
with O
38 O
% O
for O
the O
SL O
group O
vs. O
26 O
% O
for O
the O
LAG O
group O
( O
p O
= O
0.003 O
) O
. O
['Mortality']

However O
, O
its O
reliability O
in O
routine O
practice O
is O
unclear O
. O
[]

Similar O
compensatory B-outcome ['Life-Impact']
effect O
was O
also O
demonstrable O
in O
cerebral B-outcome ['Physiological-Clinical']
haemodynamics I-outcome ['Physiological-Clinical']
: O
in O
the O
placebo O
group O
there O
was O
a O
progressive B-outcome ['Physiological-Clinical']
increase O
in O
cerebral B-outcome ['Physiological-Clinical']
circulation I-outcome ['Physiological-Clinical']
time O
, O
an O
expression O
of O
decreased O
cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow B-outcome ['Physiological-Clinical']
, O
while O
with O
Hydergine O
cerebral O
circulation O
time O
was O
shortened O
and O
stabilized O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Group O
1 O
consisted O
of O
27 O
patients O
who O
received O
room O
temperature O
irrigation O
fluid O
( O
70 O
degrees O
F O
) O
throughout O
TURP O
; O
group O
2 O
consisted O
of O
29 O
patients O
whose O
procedure O
was O
performed O
with O
warmed O
irrigation O
fluid O
( O
91.5 O
degrees O
F O
) O
. O
[]

Incidence O
of O
the O
primary O
endpoint O
( O
biopsy-proven O
acute O
rejection O
, O
BPAR O
; O
graft O
loss O
, O
death O
, O
DGF O
, O
wound O
healing O
complications O
related O
to O
transplant O
surgery O
or O
loss O
to O
follow-up O
) O
was O
64.6 O
% O
and O
66.2 O
% O
in O
the O
IE O
and O
DE O
groups O
, O
respectively O
, O
at O
month O
12 O
( O
P O
= O
0.860 O
) O
. O
[]

Despite O
an O
observed O
association O
between O
colonic O
inflammation O
and O
grade O
2 O
or O
higher O
diarrhea O
, O
no O
baseline O
biomarkers O
could O
reliably O
predict O
development O
of O
gastrointestinal O
toxicity O
. O
[]

CONCLUSIONS O
We O
conclude O
that O
the O
use O
of O
heparin-coated O
circuits O
was O
safe O
and O
imparted O
protection O
from O
reoperations O
for O
bleeding O
and O
major O
bleeding O
episodes O
. O
[]

The O
infusion O
was O
titrated O
for O
each O
patient O
to O
the O
rate O
required O
for O
pain O
relief O
during O
forced O
inspiration O
( O
pain O
score O
< O
or O
= O
2 O
, O
maximum O
10 O
) O
. O
[]

CONCLUSIONS O
Despite O
superior O
results O
of O
induction O
therapy O
with O
the O
ALL-2 O
regimen O
, O
this O
treatment O
did O
not O
improve O
long-term O
outcomes O
. O
[]

Zoledronic O
acid O
is O
significantly O
more O
effective O
than O
risedronate O
in O
increasing O
lumbar B-outcome ['Physiological-Clinical']
spine I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
both O
prevention O
and O
treatment O
of O
glucocorticoid-induced O
osteoporosis O
. O
['Physiological-Clinical']

P53 B-outcome ['Physiological-Clinical']
overexpression B-outcome ['Physiological-Clinical']
was O
significantly O
related O
to O
OM B-outcome ['Mortality']
( O
P O
= O
.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Comparison O
of O
propofol O
, O
droperidol O
, O
and O
metoclopramide O
for O
prophylaxis O
of O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
after O
breast O
cancer O
surgery O
: O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
in O
Japanese O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

At O
3 O
yr O
follow-up O
, O
17.5 O
% O
of O
patients O
in O
group O
A O
were O
alive B-outcome ['Mortality']
compared O
to O
52 O
% O
in O
group O
B O
and O
42 O
% O
in O
group O
C O
( O
p O
< O
0.001 O
) O
. O
['Mortality']

PATIENTS O
AND O
METHODS O
Four O
hundred O
sixty-nine O
assessable O
advanced O
cancer O
patients O
were O
randomized O
to O
( O
1 O
) O
oral O
megestrol O
acetate O
800 O
mg/d O
liquid O
suspension O
plus O
placebo O
, O
( O
2 O
) O
oral O
dronabinol O
2.5 O
mg O
twice O
a O
day O
plus O
placebo O
, O
or O
( O
3 O
) O
both O
agents O
. O
[]

150.6 O
steps O
, O
with O
and O
without O
music O
, O
respectively O
; O
p O
? O
[]

OBJECTIVES O
To O
determine O
the O
immediate O
effects O
of O
modified O
Proprioceptive O
Neuromuscular O
Facilitation O
( O
PNF O
) O
stretching O
( O
group O
I O
) O
versus O
Myofascial O
Trigger O
Point O
( O
MTrP O
) O
therapy O
plus O
modified O
PNF O
stretching O
( O
group O
II O
) O
in O
comparison O
to O
a O
control O
group O
receiving O
no O
treatment O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
FVIII I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
vs. O
time O
curves O
was O
characterized O
for O
a O
standard O
set O
of O
PK O
parameter O
estimates O
. O
['Physiological-Clinical']

CONCLUSIONS O
Informed O
decision O
making O
for O
PCa O
screening O
is O
crucial O
at O
present O
and O
may O
be O
important O
for O
some O
time O
, O
particularly O
if O
a O
definitive O
recommendation O
either O
for O
or O
against O
screening O
does O
not O
emerge O
from O
ongoing O
prostate O
cancer O
screening O
trials O
. O
[]

MATERIALS O
AND O
METHODS O
A O
total O
of O
57 O
consecutive O
patients O
with O
primary O
ureteropelvic O
junction O
obstruction O
were O
randomized O
to O
undergo O
7/14Fr O
internal O
endopyelotomy O
stent O
placement O
for O
2 O
( O
group O
1 O
) O
and O
4 O
( O
group O
2 O
) O
weeks O
. O
[]

In O
the O
total O
population O
, O
improved O
fibrinolytic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
observed O
after O
1 O
year O
with O
increased O
levels O
of O
serum B-outcome ['Physiological-Clinical']
D-dimer I-outcome ['Physiological-Clinical']
( O
P=.001 O
) O
and O
tPA B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
P=.024 O
) O
and O
a O
reduction O
in O
tPA B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
( O
P=.048 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
rare O
non-targets O
N1 B-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
Fz I-outcome ['Physiological-Clinical']
decreased O
but O
P3 B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
of O
hypertensive O
subjects O
with O
lower O
plasma O
cholesterol O
tested O
the O
hypotheses O
that O
lipophilic O
simvastatin O
would O
attenuate O
resting O
sympathoexcitation O
and O
augment O
baroreflex O
modulation O
of O
MSNA O
and O
heart O
rate O
( O
HR O
) O
, O
flow-mediated O
vasodilation O
and O
insulin O
sensitivity O
. O
[]

Participants O
were O
assessed O
on O
their O
ability O
to O
complete O
basic B-outcome ['Life-Impact']
emotion I-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
tasks I-outcome ['Life-Impact']
, O
mindreading B-outcome ['Life-Impact']
and O
theory O
of O
mind B-outcome ['Life-Impact']
( O
TOM O
) O
tasks O
before O
and O
after O
the O
4-week O
intervention O
period O
, O
and O
at O
3-month O
follow-up O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

After O
17 O
d O
of O
dosing O
, O
> O
90 O
% O
of O
steady O
state O
concentrations B-outcome ['Physiological-Clinical']
were O
reached O
, O
which O
was O
compatible O
with O
an O
effective O
half-life O
for O
accumulation O
of O
5 O
d. O
The O
terminal B-outcome ['Physiological-Clinical']
elimination O
half-life B-outcome ['Physiological-Clinical']
was O
12 O
+/- O
7 O
d O
( O
n O
= O
20 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
first O
study O
assessed O
the O
effects O
of O
incremental O
doses O
of O
GH O
( O
0.5 O
, O
1.0 O
, O
2.0 O
IU/day O
for O
1 O
wk O
each O
) O
on O
insulin-like O
growth O
factor O
I O
( O
IGF-I O
) O
levels O
during O
each O
estrogen O
treatment O
phase O
. O
[]

Among O
112 O
participants O
with O
2 O
study O
eyes O
, O
the O
correct B-outcome ['Life-Impact']
assignment I-outcome ['Life-Impact']
was O
stated O
for O
24.1 O
% O
of O
the O
sham O
plus O
prompt O
laser O
eyes O
. O
['Life-Impact']

These O
were O
poured O
in O
orthodontic O
stone O
, O
trimmed O
, O
and O
photocopied O
from O
the O
occlusal O
aspect O
. O
[]

A O
significantly O
larger O
proportion O
of O
patients O
achieved O
clinical B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
and O
improvement O
in O
rectal B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
in O
the O
balsalazide O
group O
vs. O
the O
placebo O
group O
( O
55 O
vs. O
40 O
% O
, O
P=0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
differences O
in O
HIV B-outcome ['Life-Impact']
stigma I-outcome ['Life-Impact']
levels O
between O
the O
groups O
were O
sustained O
for O
a O
12-month O
period O
. O
['Life-Impact']

RESULTS O
Updated O
analysis O
of O
E1684 O
, O
E1690 O
, O
and O
E1694 O
confirmed O
their O
original O
conclusions O
, O
now O
at O
median O
follow-up O
intervals O
of O
2.1-12.6 O
years O
. O
[]

It O
is O
concluded O
that O
once-daily O
administration O
of O
enalapril O
or O
lisinopril O
was O
generally O
effective O
and O
well-tolerated O
in O
the O
management O
of O
mild O
to O
moderate O
uncomplicated O
essential O
hypertension O
. O
[]

SIGNIFICANCE O
These O
findings O
suggest O
that O
although O
CRM O
is O
more O
effective O
than O
no O
treatment O
, O
VR O
can O
be O
added O
to O
improve O
the O
results O
in O
the O
treatment O
of O
BPPV O
. O
[]

These O
include O
first-order O
cues O
such O
as O
luminance O
modulations O
and O
second-order O
cues O
involving O
modulations O
of O
orientation O
and O
contrast O
. O
[]

After O
randomization O
, O
24-hour B-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
measurement I-outcome ['Physiological-Clinical']
, O
BP B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Sinus B-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
was O
restored O
in O
29/30 O
patients O
( O
97 O
% O
) O
in O
each O
group O
using O
a O
similar O
number O
of O
shocks O
for O
both O
groups O
( O
1.3 O
+/- O
0.6 O
transesophageal O
vs O
1.4 O
+/- O
0.7 O
transthoracic O
, O
P O
= O
NS O
) O
with O
a O
similar O
procedure O
duration O
( O
14.1 O
+/- O
8.2 O
minutes O
vs O
13.8 O
+/- O
7.5 O
minutes O
, O
P O
= O
NS O
) O
. O
['Physiological-Clinical']

Mecamylamine O
also O
produced O
modest O
, O
dose-related O
decreases O
in O
standing O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
increases O
in O
standing B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
matched O
group O
of O
23 O
children O
received O
a O
placebo O
in O
identical O
form O
. O
[]

BACKGROUND O
Infants O
fed O
a O
soy O
protein O
isolate-based O
formula O
have O
immunization B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
similar O
to O
breast-fed O
infants O
. O
['Physiological-Clinical']

In O
addition O
, O
in O
spite O
of O
improvements O
in O
accurate O
diagnosis O
of O
autism O
spectrum O
disorder O
( O
ASD O
) O
at O
increasingly O
earlier O
ages O
and O
proliferation O
of O
interventions O
, O
research O
associated O
with O
leisure O
and O
quality O
of O
life O
for O
people O
with O
ASD O
is O
lacking O
. O
[]

Compared O
with O
the O
remaining O
693 O
patients O
, O
subjects O
with O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
were O
older O
( O
mean O
( O
SD O
) O
age O
: O
64.6 O
( O
13.0 O
) O
v O
59.8 O
( O
11.7 O
) O
years O
, O
p O
< O
0.005 O
) O
, O
and O
had O
larger B-outcome ['Physiological-Clinical']
infarcts I-outcome ['Physiological-Clinical']
( O
extent O
of O
wall O
motion O
asynergy O
: O
40.9 O
( O
11.5 O
) O
% O
v O
24.9 O
( O
14 O
) O
% O
, O
p O
< O
0.001 O
) O
, O
greater O
depression O
of O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
at O
S1 O
( O
43.3 O
( O
6.9 O
) O
% O
v O
48.1 O
( O
6.8 O
) O
% O
, O
p O
< O
0.001 O
) O
, O
and O
greater O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
at O
S1 O
( O
end O
diastolic O
volume O
: O
87 O
( O
22 O
) O
v O
78 O
( O
18 O
) O
ml/m O
( O
2 O
) O
, O
p O
< O
0.001 O
; O
end O
systolic O
volume O
: O
50 O
( O
17 O
) O
v O
41 O
( O
14 O
) O
ml/m O
( O
2 O
) O
, O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Sodium O
kinetics O
in O
white O
and O
black O
normotensive O
subjects O
: O
possible O
relevance O
to O
salt-sensitive O
hypertension O
. O
[]

We O
examined O
the O
associations O
of O
prediagnostic O
plasma O
levels O
of O
25 O
( O
OH O
) O
D O
and O
1,25 O
( O
OH O
) O
2D O
, O
individually O
and O
jointly O
, O
with O
total O
and O
aggressive O
disease O
, O
and O
explored O
whether O
relations O
between O
vitamin O
D O
metabolites O
and O
prostate O
cancer O
were O
modified O
by O
the O
functional O
VDR O
FokI O
polymorphism O
, O
using O
conditional O
logistic O
regression O
. O
[]

It O
is O
unclear O
whether O
ACEi O
provide O
additional O
benefit O
when O
added O
to O
a O
standard O
exercise O
training O
program O
. O
[]

RESULTS O
The O
occurrence O
of O
distant B-outcome ['Physiological-Clinical']
metastases I-outcome ['Physiological-Clinical']
was O
the O
same O
in O
both O
study O
arms O
. O
['Physiological-Clinical']

PegIFNalpha O
2a O
was O
administered O
subcutaneously O
at O
a O
dose O
of O
180 O
microg O
once O
weekly O
for O
48 O
weeks O
; O
and O
IFNalpha O
2b/RBV O
at O
doses O
of O
3 O
MU O
thrice O
weekly O
subcutaneously O
and O
1000-1200 O
mg/day O
orally O
. O
[]

In O
a O
prospective O
double-blind O
clinical O
study O
, O
single-dose O
lumbar O
epidural O
blockade O
was O
instituted O
in O
60 O
healthy O
patients O
undergoing O
lower O
abdominal O
surgery O
. O
[]

Fundamental O
frequency O
( O
F0 O
) O
, O
sound O
pressure O
level O
( O
SPL O
) O
and O
long-term-average O
spectrum O
( O
LTAS O
) O
analyses O
were O
made O
. O
[]

Analysis O
of O
treatment O
effects O
versus O
observation O
( O
Obs O
) O
was O
based O
on O
data O
from O
713 O
patients O
randomized O
to O
high-dose O
IFN-alpha O
2b O
( O
HDI O
) O
or O
Obs O
in O
Trials O
E1684 O
and O
E1690 O
. O
[]

FINDINGS O
23 O
patients O
in O
the O
AT O
group O
and O
four O
in O
the O
PT O
group O
returned O
to O
sports O
without O
groin B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
odds O
ratio O
, O
multiple-logistic-regression O
analysis O
, O
12.7 O
[ O
95 O
% O
CI O
3.4-47.2 O
] O
) O
. O
['Physiological-Clinical']

The O
incidence O
of O
stroke O
( O
cerebral O
infarction O
or O
intracranial O
hemorrhage O
) O
was O
compared O
between O
the O
two O
groups O
. O
[]

OBJECTIVE O
African O
Americans O
have O
a O
much O
higher O
risk O
of O
major O
( O
above- O
or O
below-knee O
) O
lower O
extremity O
amputation O
and O
a O
lower O
rate O
of O
limb-preserving B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
surgery I-outcome ['Physiological-Clinical']
or O
angioplasty O
than O
white O
patients O
. O
['Physiological-Clinical']

The O
objective O
of O
this O
study O
was O
to O
determine O
the O
negative O
and O
positive O
outcomes O
of O
providing O
mammographic O
breast O
density O
( O
MBD O
) O
information O
to O
participants O
of O
a O
screening O
program O
. O
[]

The O
48 O
participants O
performed O
a O
visually O
demanding O
air O
traffic O
control O
( O
ATC O
) O
task O
. O
[]

In O
our O
previous O
study O
on O
individuals O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
( O
Sokhadze O
et O
al. O
, O
Appl O
Psychophysiol O
Biofeedback O
34:37-51 O
, O
2009a O
) O
we O
reported O
abnormalities O
in O
the O
attention-orienting O
frontal O
event-related O
potentials O
( O
ERP O
) O
and O
the O
sustained-attention O
centro-parietal O
ERPs O
in O
a O
visual O
oddball O
experiment O
. O
[]

The O
primary O
end-point O
was O
an O
increase O
in O
pain-free B-outcome ['Physiological-Clinical']
walking I-outcome ['Physiological-Clinical']
distance I-outcome ['Physiological-Clinical']
[ O
initial O
claudication B-outcome ['Physiological-Clinical']
distance O
( O
ICD O
) O
] O
during O
the O
24 O
weeks O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OUTCOMES O
Cognitive O
development O
( O
Stanford-Binet O
Intelligence O
Scale O
) O
, O
behavioral B-outcome ['Life-Impact']
competence I-outcome ['Life-Impact']
( O
Achebach O
Child O
Behavior O
Checklist O
) O
, O
and O
health O
status O
( O
indexes O
summarizing O
reported O
morbidity O
, O
the O
Functional O
Status O
II O
( O
R O
) O
Scale O
, O
and O
General O
Health O
Ratings O
Index O
) O
. O
['Life-Impact']

The O
remote O
possible O
risk O
of O
the O
late B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
shown O
in O
our O
patients O
indicates O
the O
need O
for O
no O
special O
precautions O
. O
['Physiological-Clinical']

Once O
they O
had O
been O
fitted O
with O
hearing O
aids O
, O
the O
participants O
reported O
lower O
levels O
of O
[]

The O
overall O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
and O
subsequent O
downtime B-outcome ['Life-Impact']
was O
increased O
for O
Er O
: O
YAG O
( O
1/10 O
patients O
experienced O
hyperpigmentation B-outcome ['Physiological-Clinical']
, O
3/10 O
exfoliation B-outcome ['Physiological-Clinical']
, O
1/10 O
['Adverse-effects', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
assessed O
the O
ability O
of O
various O
schedules O
of O
recombinant O
human O
thrombopoietin O
( O
rhTPO O
) O
to O
enhance O
mobilization O
of O
peripheral O
blood O
progenitor O
cells O
( O
PBPCs O
) O
in O
134 O
patients O
with O
cancer O
undergoing O
high-dose O
chemotherapy O
and O
autologous O
PBPC O
transplantation O
. O
[]

RESULTS O
The O
number O
of O
patients O
who O
delivered B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
day I-outcome ['Physiological-Clinical']
showed O
no O
difference O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
observe O
the O
effect O
difference O
of O
behavior O
training O
with O
head O
needling O
retention O
and O
behavior O
training O
after O
acupuncture O
for O
autism O
children O
. O
[]

Laparoscopy O
was O
associated O
with O
no O
added O
complications B-outcome ['Adverse-effects']
, O
no O
increase O
in O
hospital B-outcome ['Resource-use']
stay B-outcome ['Resource-use']
in O
patients O
who O
went O
on O
to O
appendicectomy O
, O
and O
a O
reduction O
in O
['Adverse-effects', 'Resource-use', 'Resource-use']

BACKGROUND O
First-generation O
drug-eluting O
stents O
have O
reduced O
angiographic O
and O
clinical O
restenosis O
, O
but O
long-term O
safety O
remains O
controversial O
. O
[]

For O
6 O
% O
coriander O
oil O
in O
unguentum O
leniens O
, O
a O
highly O
significant O
improvement O
of O
the O
clinical B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
( O
p O
< O
0.0001 O
) O
was O
observed O
during O
the O
entire O
observation O
period O
; O
the O
number O
of O
positive O
fungal B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
also O
tended O
to O
decrease O
( O
p O
= O
0.0654 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Parenteral O
nutrition O
and O
protein O
sparing O
after O
surgery O
: O
do O
we O
need O
glucose O
? O
[]

At O
6 O
months O
after O
enrolment O
( O
and O
after O
cryotherapy O
, O
if O
performed O
) O
, O
women O
were O
tested O
using O
all O
three O
screening O
methods O
and O
then O
underwent O
colposcopy/biopsy O
. O
[]

We O
evaluated O
Interceed O
( O
TC7 O
) O
in O
a O
randomized O
, O
multicenter O
clinical O
study O
. O
[]

Their O
satisfaction O
with O
the O
intervention O
was O
also O
assessed O
. O
[]

ChiCTR-TRC-12002561 O
; O
URL O
: O
www.chictr.org O
. O
[]

Circulating O
25-hydroxyvitamin O
D3 O
( O
25 O
[ O
OH O
] O
D O
) O
, O
the O
most O
commonly O
used O
index O
of O
vitamin O
D O
status O
, O
is O
converted O
to O
the O
active O
hormone O
1,25 O
dihydroxyvitamin O
D3 O
( O
1,25 O
[ O
OH O
] O
2D O
) O
, O
which O
, O
operating O
through O
the O
vitamin O
D O
receptor O
( O
VDR O
) O
, O
inhibits O
in O
vitro O
cell O
proliferation O
, O
induces O
differentiation O
and O
apoptosis O
, O
and O
may O
protect O
against O
prostate O
cancer O
. O
[]

Short-term O
studies O
on O
the O
use O
of O
glycerol O
as O
an O
osmotic O
agent O
in O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
CAPD O
) O
. O
[]

RESULTS O
Children O
with O
parent-reported O
ASD O
had O
higher O
levels O
of O
health O
care O
office O
visits O
and O
prescription O
drug O
use O
compared O
with O
children O
without O
ASD O
( O
P O
< O
.05 O
) O
. O
[]

The O
WheelCon-M O
is O
a O
self-report O
questionnaire O
that O
comprises O
65 O
items O
in O
6 O
conceptual O
areas O
. O
[]

METHODS O
We O
conducted O
a O
randomized O
, O
blinded O
, O
placebo-controlled O
, O
three-arm O
, O
dose-ranging O
clinical O
trial O
. O
[]

A O
paired O
analysis O
compared O
the O
effect O
of O
DE O
and O
FA O
exposures O
for O
the O
change O
from O
pre-exposure O
to O
the O
subsequent O
time O
points O
. O
[]

This O
is O
the O
first O
report O
of O
a O
direct O
comparison O
between O
propofol O
and O
isoflurane O
. O
[]

Anthropometric O
indices O
were O
measured O
at O
baseline O
and O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical']

propofol O
and O
midazolam O
for O
induction O
of O
anaesthesia O
in O
200 O
unpremedicated O
female O
patients O
undergoing O
elective O
gynaecological O
surgery O
. O
[]

Planning O
for O
closeout O
of O
the O
study O
began O
a O
year O
prior O
to O
the O
common O
end O
date O
of O
December O
31 O
, O
1995 O
and O
included O
plans O
for O
obtaining O
vital O
status O
on O
December O
31 O
, O
1995 O
. O
[]

All O
had O
had O
breast-conserving O
surgery O
. O
[]

Nineteen O
eligible O
patients O
were O
missed O
because O
of O
lack O
of O
time O
( O
9 O
[ O
22 O
% O
] O
) O
, O
paramedic O
discretion O
( O
3 O
[ O
7 O
% O
] O
) O
, O
the O
paramedic O
forgot O
( O
6 O
[ O
15 O
% O
] O
) O
, O
and O
the O
paramedic O
refused O
( O
1 O
[ O
2 O
% O
] O
) O
. O
[]

Forty-six O
eyes O
( O
20 O
% O
) O
had O
undergone O
no O
previous O
vitrectomy O
( O
group O
1 O
) O
; O
71 O
eyes O
( O
42 O
% O
) O
had O
undergone O
previous O
vitrectomy O
( O
group O
2 O
) O
with O
intraocular O
gas O
tamponade O
( O
P O
< O
.001 O
) O
. O
[]

Two O
high-dose O
regimens O
, O
FPV O
1,400 O
mg O
twice O
a O
day O
( O
BID O
) O
plus O
RTV O
100 O
mg O
BID O
and O
FPV O
1,400 O
mg O
BID O
plus O
RTV O
200 O
mg O
BID O
, O
were O
planned O
to O
be O
compared O
to O
the O
approved O
regimen O
, O
FPV O
700 O
mg O
BID O
plus O
RTV O
100 O
mg O
BID O
, O
in O
a O
randomized O
three-period O
crossover O
study O
. O
[]

Total O
plasma B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
because O
of O
a O
reduction O
in O
nonHDL-C B-outcome ['Physiological-Clinical']
, O
including O
a O
21 O
% O
to O
42 O
% O
lowering O
of O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
at O
the O
higher O
doses O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
summarizes O
the O
treatment O
effect O
of O
zoledronic O
acid O
infusion O
on O
lumbar B-outcome ['Physiological-Clinical']
spine I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
in O
different O
subgroups O
with O
glucocorticoid-induced O
osteoporosis O
. O
['Physiological-Clinical']

RESULTS O
Preoperative O
characteristics O
and O
risk O
factors O
( O
EuroSCORE O
: O
group O
1 O
= O
7.9 O
vs O
group O
2 O
= O
8.1 O
) O
, O
number O
of O
grafted B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
vessels I-outcome ['Physiological-Clinical']
( O
group O
1 O
= O
2.4 O
vs O
group O
2 O
= O
2.5 O
) O
, O
aortic B-outcome ['Physiological-Clinical']
crossclamping I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
( O
group O
1 O
= O
37 O
+/- O
7 O
minutes O
vs O
group O
2 O
= O
38 O
+/- O
7 O
minutes O
) O
, O
ventilation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
( O
group O
1 O
= O
22 O
+/- O
12 O
hours O
vs O
group O
2 O
= O
23 O
+/- O
11 O
hours O
) O
, O
intensive B-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
group O
1 O
= O
39 O
+/- O
10 O
hours O
vs O
group O
2 O
= O
40 O
+/- O
9 O
hours O
) O
, O
and O
hospital B-outcome ['Mortality']
mortality I-outcome ['Mortality']
( O
group O
1 O
= O
3.8 O
% O
vs O
group O
2 O
= O
5 O
% O
) O
were O
comparable O
between O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Mortality']

Of O
these O
, O
136 O
patients O
were O
eligible O
for O
the O
according-to-protocol O
analysis O
of O
efficacy O
, O
167 O
subjects O
for O
the O
intention-to-treat O
analysis O
of O
efficacy O
, O
and O
181 O
patients O
were O
included O
in O
the O
safety O
analysis O
. O
[]

We O
assessed O
the O
effect O
of O
adding O
fentanyl O
to O
1.5 O
% O
lidocaine O
in O
women O
undergoing O
ultrasonically O
guided O
oocyte O
retrieval O
. O
[]

Each O
treatment O
phase O
lasted O
10 O
weeks O
and O
behaviors O
were O
rated O
weekly O
using O
the O
Ritvo-Freeman O
scale O
. O
[]

However O
, O
the O
present O
data O
can O
not O
exclude O
the O
possibility O
that O
the O
neuroendocrine O
changes O
reflect O
nonspecific O
stress O
responses O
or O
changes O
in O
pituitary O
blood O
flow O
. O
[]

METHODS O
Eligible O
children O
between O
6 O
and O
18 O
years O
of O
age O
( O
N O
= O
240 O
) O
presenting O
to O
the O
ED O
for O
laceration O
repair O
were O
randomly O
assigned O
to O
an O
intervention O
or O
control O
arm O
. O
[]

Maximal O
bioavailability B-outcome ['Physiological-Clinical']
of O
digoxin O
from O
tablets O
and O
oral O
solution O
in O
steady O
state O
. O
['Physiological-Clinical']

DISCUSSION O
Data O
suggest O
that O
PDS O
suture O
can O
protect O
against O
development O
of O
aseptic B-outcome ['Physiological-Clinical']
sternal I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
following O
median O
sternotomy O
in O
high-risk O
patients O
with O
little O
body O
mass O
. O
['Physiological-Clinical']

This O
study O
investigated O
the O
effects O
of O
deep O
pressure O
on O
arousal O
and O
anxiety O
reduction O
in O
autism O
with O
Grandin O
's O
Hug O
Machine O
, O
a O
device O
that O
allows O
self-administration O
of O
lateral O
body O
pressure O
. O
[]

An O
analysis O
of O
available O
space O
was O
made O
by O
evaluating O
the O
pre-treatment O
dental O
casts O
of O
all O
patients O
included O
in O
the O
study O
. O
[]

Secondary B-outcome ['Physiological-Clinical']
target I-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
at O
6 O
months O
were O
96.5 O
% O
for O
CBA O
and O
80.0 O
% O
for O
HPBA O
( O
P O
= O
.03 O
) O
. O
['Physiological-Clinical']

The O
postoperative O
analgesic O
requirement O
was O
assessed O
by O
the O
total O
dose O
of O
metamizol B-outcome ['Physiological-Clinical']
administered O
by O
an O
i.v O
. O
['Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
, O
glucose B-outcome ['Physiological-Clinical']
homeostasis I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
and O
hemostasic B-outcome ['Physiological-Clinical']
variables O
were O
assessed O
at O
baseline O
and O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
this O
randomized O
, O
controlled O
, O
double-blind O
, O
split O
mouth O
, O
clinical O
study O
was O
to O
evaluate O
and O
compare O
the O
desensitizing O
effects O
of O
erbium O
, O
chromium-doped O
: O
yttrium O
, O
scandium O
, O
gallium O
and O
garnet O
( O
Er O
, O
Cr O
: O
YSGG O
) O
to O
galium-aluminium-arsenide O
( O
GaAlAs O
) O
laser O
on O
DH O
. O
[]

BACKGROUND O
Corticotropin-releasing O
factor O
receptor O
type O
1 O
( O
CRF O
( O
1 O
) O
) O
antagonists O
have O
been O
proposed O
as O
therapeutic O
agents O
in O
the O
treatment O
of O
mood O
and O
anxiety O
disorders O
although O
clinical O
evidence O
supporting O
their O
development O
and O
understanding O
of O
a O
dose-response O
relationship O
has O
been O
lacking O
. O
[]

After O
equilibration O
between O
the O
blood O
and O
effect-site O
for O
15 O
min O
, O
a O
verbal O
command O
to O
open O
their O
eyes O
was O
given O
two O
times O
to O
the O
patients O
. O
[]

Whether O
body O
mass O
index O
( O
BMI O
) O
differentially O
influences O
the O
risk O
across O
the O
stages O
of O
colorectal O
cancer O
development O
remains O
unclear O
. O
[]

METHODS O
Patients O
with O
IBS O
according O
to O
the O
Rome O
II O
criteria O
were O
randomized O
to O
either O
short O
nurse-based O
or O
a O
long O
multidisciplinary-based O
education O
. O
[]

Gastric B-outcome ['Physiological-Clinical']
irritation I-outcome ['Physiological-Clinical']
was O
noted O
only O
once O
. O
['Physiological-Clinical']

increase O
of O
A O
beta O
40 O
was O
7.0 O
pg/ml O
( O
8.4 O
) O
in O
the O
vitamin O
group O
( O
4.9 O
% O
) O
, O
and O
26.8 O
pg/ml O
( O
7.7 O
) O
( O
18.5 O
% O
) O
in O
the O
placebo O
group O
. O
[]

CONCLUSIONS O
In O
contrast O
to O
the O
effects O
of O
either O
substance O
alone O
, O
a O
combination O
of O
half O
the O
dose O
of O
eprosartan O
with O
half O
the O
dose O
of O
enalapril O
had O
a O
prominent O
effect O
on O
renal B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PATIENTS O
Endocrinologically O
normal O
women O
with O
a O
medical O
indication O
for O
IVF O
or O
intracytoplasmic O
sperm O
injection O
, O
or O
healthy O
volunteers O
. O
[]

These O
results O
demonstrate O
that O
guar O
exerts O
its O
cholesterol-lowering O
effect O
in O
addition O
to O
that O
of O
bezafibrate O
. O
[]

A O
two-way O
mixed O
model O
ANOVA O
was O
used O
to O
compare O
changes O
in O
the O
ratio O
of O
the O
maximum B-outcome ['Physiological-Clinical']
H-reflex I-outcome ['Physiological-Clinical']
and O
maximum B-outcome ['Physiological-Clinical']
M-wave I-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
( O
H/M O
ratio O
) O
of O
the O
fibularis O
longus O
and O
soleus O
between O
groups O
over O
time O
( O
pre O
, O
post O
0 O
, O
10 O
, O
20 O
, O
30 O
min O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
Efficacy O
observation O
on O
chronic B-outcome ['Physiological-Clinical']
tension-type I-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
treated O
with O
acupuncture O
at O
galea O
tendon-muscle O
node O
] O
. O
['Physiological-Clinical']

Animal O
studies O
suggest O
this O
response O
is O
mediated O
by O
increased O
production O
of O
nitric O
oxide O
. O
[]

BACKGROUND O
We O
previously O
showed O
that O
H1-antihistamines O
may O
shift O
the O
PC20 O
( O
provocation O
concentration O
that O
caused O
a O
decrease O
in O
forced O
expiratory O
volume O
in O
1 O
second O
of O
20 O
% O
) O
threshold O
to O
adenosine O
monophosphate O
( O
AMP O
) O
challenge O
but O
may O
paradoxically O
prolong O
recovery O
. O
[]

METHODS O
In O
a O
prospective O
trial O
450 O
patients O
were O
randomized O
to O
AS O
, O
SC O
, O
or O
MC O
. O
[]

Fifty-six O
subjects O
with O
autistic O
disorder O
received O
either O
a O
secretin O
or O
placebo O
infusion O
at O
baseline O
and O
the O
other O
substance O
at O
week O
4 O
. O
[]

The O
present O
prospective O
, O
randomized O
study O
was O
conducted O
with O
50 O
patients O
submitted O
to O
curative O
adjuvant O
irradiation O
following O
surgery O
for O
mammary O
carcinoma O
. O
[]

OBJECTIVES O
So O
far O
it O
has O
not O
clearly O
been O
demonstrated O
that O
systematic O
mediastinal O
lymphadenectomy O
improves O
survival B-outcome ['Mortality']
in O
patients O
with O
non-small O
cell O
lung O
cancer O
. O
['Mortality']

There O
were O
no O
significant O
differences O
in O
the O
quality B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
analgesia I-outcome ['Physiological-Clinical']
, O
as O
assessed O
by O
the O
investigators O
. O
['Physiological-Clinical']

RESULTS O
MgSO4 O
group O
showed O
early O
and O
significant O
improvement O
as O
compared O
to O
placebo O
group O
in O
PEFR B-outcome ['Physiological-Clinical']
and O
SaO2 B-outcome ['Physiological-Clinical']
at O
30 O
min O
and O
1 O
, O
2 O
, O
3 O
and O
7 O
hours O
after O
stopping O
the O
infusion O
( O
p O
ranging O
from O
< O
0.05 O
to O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Tensile B-outcome ['Life-Impact']
bond I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
of O
a O
lithium-disilicate O
pressed O
glass O
ceramic O
to O
dentin O
of O
different O
surface O
treatments O
. O
['Life-Impact']

The O
cumulative O
gastrointestinal B-outcome ['Physiological-Clinical']
( O
GI B-outcome ['Physiological-Clinical']
) O
/liver O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs B-outcome ['Adverse-effects']
) O
discontinuation B-outcome ['Life-Impact']
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Adverse-effects', 'Life-Impact']

Animal O
data O
indicate O
that O
this O
stems O
from O
supraspinal B-outcome ['Physiological-Clinical']
diffuse I-outcome ['Physiological-Clinical']
noxious I-outcome ['Physiological-Clinical']
inhibitory I-outcome ['Physiological-Clinical']
controls I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DNICs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
triggered O
by O
C O
and O
A? O
fibers O
. O
['Physiological-Clinical']

Thirty-nine O
patients O
with O
unilateral O
lung O
pathology O
were O
positioned O
on O
their O
sides O
with O
the O
unaffected O
lung O
down O
, O
on O
their O
sides O
with O
the O
affected O
lung O
down O
, O
and O
also O
in O
semi-Fowler O
's O
position O
. O
[]

The O
sample O
size O
was O
22 O
. O
[]

DESIGN O
A O
prospective O
randomised O
controlled O
trial O
. O
[]

In O
both O
groups O
, O
the O
medications O
were O
initiated O
at O
5 O
mg O
QD O
. O
[]

Twenty-nine O
patients O
were O
treated O
with O
laparoscopic O
assisted O
vaginal O
hysterectomy O
( O
LAVH O
) O
and O
bilateral O
salpingo-oophrectomy O
( O
BSO O
) O
plus O
minus O
laparoscopic O
pelvic O
lymphadenectomy O
( O
LPLA O
) O
, O
while O
32 O
patients O
were O
treated O
with O
the O
traditional O
laparotomy O
and O
underwent O
total O
abdominal O
hysterectomy O
( O
TAH O
) O
and O
BSO O
plus O
minus O
pelvic O
lymphadenectomy O
( O
PLA O
) O
. O
[]

Orlistat O
was O
safe O
and O
well O
tolerated O
. O
[]

The O
main O
outcome O
measures O
included O
TKR O
recommendation O
, O
implicit O
racial O
preference O
, O
and O
medical O
cooperativeness O
stereotypes O
measured O
with O
implicit O
association O
tests O
. O
[]

This O
study O
is O
registered O
ClinicalTrials.gov O
, O
number O
NCT00000922 O
. O
[]

There O
were O
no O
differences O
in O
the O
tolerability B-outcome ['Life-Impact']
between O
randomized O
allocations O
across O
age O
groups O
( O
all O
P O
heterogeneity O
> O
0.6 O
) O
CONCLUSION O
Routine O
administration O
of O
perindopril-indapamide O
lowers O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
safely O
and O
reduces O
the O
risk O
of O
major O
clinical O
outcomes O
in O
patients O
of O
at O
least O
75 O
years O
with O
type O
2 O
diabetes O
. O
['Life-Impact', 'Physiological-Clinical']

Pelvic O
lymphadenectomy O
for O
cervical O
carcinoma O
: O
laparotomy O
extraperitoneal O
, O
transperitoneal O
or O
laparoscopic O
approach O
? O
[]

Is O
periprostatic O
local O
anesthesia O
for O
transrectal O
ultrasound O
guided O
prostate O
biopsy O
associated O
with O
increased O
infectious B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
hemorrhagic I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
? O
['Physiological-Clinical']

Forty-three O
normal-weight O
healthy O
volunteers O
were O
recruited O
( O
mean O
age O
29 O
years O
; O
18 O
women O
) O
. O
[]

Effect O
of O
micronutrient O
supplement O
on O
health B-outcome ['Physiological-Clinical']
and O
nutritional B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
of O
schoolchildren O
: O
study O
design O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
seek O
more O
potent O
evidences O
of O
collateral O
sprouting O
for O
both O
motor O
and O
sensory O
nerve O
fibres O
after O
end-to-side O
neurorrhaphy O
using O
a O
modified O
double-labelling O
retrograde O
tracing O
method O
and O
to O
investigate O
the O
function O
of O
regenerated O
motor O
axons O
with O
electrophysiological O
evaluation O
. O
[]

In O
a O
placebo O
controlled O
, O
partially O
double-blinded O
, O
clinical O
trial O
, O
a O
combination O
of O
evening O
primrose O
oil O
and O
fish O
oil O
was O
compared O
to O
Magnesium O
Oxide O
, O
and O
to O
a O
Placebo O
in O
preventing O
Pre-Eclampsia B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
Pregnancy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Hypotension B-outcome ['Physiological-Clinical']
induced O
by O
prostaglandin O
E1 O
( O
PGE1 O
) O
infusion O
( O
100-150 O
ng/kg/minute O
) O
during O
halothane O
anaesthesia O
to O
reduce O
operative O
blood O
loss O
during O
mastectomy O
was O
investigated O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
complications B-outcome ['Adverse-effects']
associated O
with O
the O
laser-aided O
drainage O
procedures O
( O
25 O
eyes O
) O
. O
['Adverse-effects']

CONCLUSION O
This O
unique O
study O
suggests O
that O
a O
nonspecific O
HBI O
provides O
long-term O
cost O
benefits O
in O
a O
range O
of O
chronic O
illnesses O
, O
except O
for O
chronic O
obstructive O
pulmonary O
disease O
. O
[]

METHODS O
AND O
RESULTS O
ATHENA O
was O
a O
double-blind O
, O
parallel O
group O
study O
in O
4628 O
patients O
with O
a O
history O
of O
paroxysmal/persistent O
AF O
and O
additional O
risk O
factors O
, O
treated O
with O
placebo O
or O
dronedarone O
. O
[]

OBJECTIVE O
The O
objective O
of O
this O
study O
was O
to O
test O
the O
hypothesis O
that O
folic O
acid O
supplementation O
of O
arsenic-exposed O
adults O
would O
increase O
arsenic O
methylation O
. O
[]

Prostamol O
Uno O
( O
PU O
) O
efficacy O
and O
safety O
were O
studied O
in O
a O
multicenter O
, O
open-population O
, O
randomized O
and O
comparative O
trial O
. O
[]

Following O
this O
study O
epidural O
anesthesia O
was O
carried O
out O
with O
20 O
ml O
etidocaine O
1 O
% O
( O
n O
= O
20 O
) O
in O
an O
open O
study O
. O
[]

In O
addition O
, O
progressive O
increases O
in O
acid B-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
were O
found O
over O
the O
3 O
postprandial O
hours O
in O
GER O
patients O
in O
a O
recumbent O
position O
. O
['Physiological-Clinical']

The O
treatment O
response O
was O
similar O
in O
the O
groups O
with O
early B-outcome ['Life-Impact']
, I-outcome ['Life-Impact']
medium I-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
late I-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
panic I-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
in O
vivo B-outcome ['Physiological-Clinical']
anti-HBs I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
measured O
using O
commercially O
available O
immunoradiometric O
assays O
. O
['Physiological-Clinical']

RESULTS O
Standard O
histopathological O
analysis O
revealed O
no O
lymph B-outcome ['Physiological-Clinical']
node I-outcome ['Physiological-Clinical']
involvement I-outcome ['Physiological-Clinical']
( O
pN0 O
) O
in O
61 O
patients O
, O
pN1 O
disease O
in O
13 O
patients O
and O
pN2 O
disease O
in O
20 O
patients O
without O
significant O
differences O
between O
LA O
and O
LS O
with O
respect O
to O
T-stage O
, O
N-stage O
or O
age O
and O
sex O
of O
the O
patients O
. O
['Physiological-Clinical']

Stage B-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
and O
the O
frequency O
of O
nocturnal B-outcome ['Physiological-Clinical']
awakenings B-outcome ['Physiological-Clinical']
were O
each O
significantly O
decreased O
at O
the O
6 O
and O
9 O
g/night O
doses O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

AIMS O
Adenosine O
monophosphate O
( O
AMP O
) O
acts O
indirectly O
via O
primed O
airway O
mast O
cells O
to O
induce O
bronchial O
hyper-responsiveness O
, O
which O
in O
turn O
correlates O
with O
eosinophilic B-outcome ['Physiological-Clinical']
asthmatic I-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
atopic I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

These O
findings O
in O
normotensive O
patients O
suggest O
BP O
is O
a O
complex O
pharmacodynamic O
biomarker O
of O
VEGF O
inhibition O
. O
[]

These O
findings O
have O
important O
clinical O
significance O
, O
and O
potentially O
lead O
to O
a O
therapeutic O
breakthrough O
for O
the O
treatment O
of O
CA O
. O
[]

The O
main O
clinical O
purpose O
of O
N7-GP O
is O
to O
provide O
safe O
and O
effective O
prophylaxis O
to O
patients O
with O
hemophilia O
and O
inhibitors O
. O
[]

The O
cytokine O
interleukin-6 O
( O
IL-6 O
) O
exerts O
it O
actions O
via O
the O
IL-6 O
receptor O
( O
IL-6R O
) O
in O
conjunction O
with O
the O
ubiquitously O
expressed O
gp130 O
receptor O
. O
[]

OBJECTIVE O
The O
aims O
of O
the O
present O
study O
were O
to O
implement O
and O
provide O
an O
initial O
evaluation O
of O
a O
spiritually O
based O
prostate O
cancer O
screening O
informed O
decision O
making O
intervention O
for O
African-American O
men O
who O
attend O
church O
, O
and O
determine O
its O
efficacy O
for O
increasing O
informed O
decision O
making O
. O
[]

In O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
4-week O
trial O
, O
59 O
patients O
with O
moderate O
to O
severe O
atopic O
dermatitis O
were O
treated O
orally O
with O
10 O
mg O
of O
the O
leukotriene O
antagonist O
montelukast O
. O
[]

AUCMB/day O
values O
were O
0.775 O
log O
( O
10 O
) O
copies/mL O
( O
95 O
% O
CI O
0.33-1.22 O
) O
and O
0.774 O
log O
( O
10 O
) O
copies/mL O
( O
95 O
% O
CI O
0.48-1.07 O
) O
, O
respectively O
, O
showing O
no O
difference O
in O
the O
rate O
of O
decrease O
of O
HIV-1 O
RNA O
( O
P=0.995 O
) O
. O
[]

Drug O
administration O
sequence O
was O
randomly O
assigned O
in O
a O
double-blind O
crossover O
method O
, O
with O
1 O
week O
between O
drugs O
. O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
comparison O
of O
the O
analgesic B-outcome ['Resource-use']
efficacy O
, O
onset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
, O
and O
tolerability B-outcome ['Life-Impact']
of O
ibuprofen O
arginate O
and O
ibuprofen O
in O
postoperative O
dental O
pain O
. O
['Resource-use', 'Physiological-Clinical', 'Life-Impact']

CONCLUSIONS O
This O
study O
shows O
that O
triple O
rabeprazole-based O
eradicating O
regimens O
are O
effective O
and O
safe O
. O
[]

Finally O
, O
both O
lisinopril O
and O
nifedipine O
showed O
a O
similar O
antihypertensive B-outcome ['Resource-use']
effect O
in O
these O
patients O
which O
was O
not O
associated O
with O
significant O
differences O
in O
plasma O
glucose O
, O
insulin O
or O
lipid O
concentrations O
. O
['Resource-use']

Drug O
effects O
were O
monitored O
by O
ethological B-outcome ['Life-Impact']
playroom I-outcome ['Life-Impact']
observation O
and O
by O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
ratings O
by O
parents O
and O
teachers O
. O
['Life-Impact', 'Life-Impact']

OBJECTIVE O
To O
assess O
disease B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
to O
compare O
the O
response O
rates O
of O
patients O
treated O
with O
PUVA O
alone O
or O
PUVA O
and O
bexarotene O
. O
['Physiological-Clinical']

The O
objective O
of O
this O
study O
was O
to O
examine O
the O
influence O
of O
MTX O
on O
infliximab O
exposure O
in O
patients O
with O
AS O
. O
[]

Twelve O
control O
animals O
received O
saline O
. O
[]

We O
report O
the O
results O
of O
chemotherapy O
treatment O
in O
82 O
patients O
presenting O
with O
primary O
digestive O
lymphoma O
and O
included O
in O
a O
study O
conducted O
between O
October O
1977 O
and O
October O
1985 O
. O
[]

CONCLUSIONS O
A O
program O
of O
cooperation O
between O
physician O
and O
pharmacist O
was O
successful O
in O
reducing O
cardiovascular O
risk O
factors O
in O
patients O
with O
mild O
to O
moderate O
hypertension O
by O
promoting O
better O
blood O
pressure O
( O
BP O
) O
control O
, O
appropriate O
changes O
in O
antihypertensive O
medications O
, O
and O
beneficial O
changes O
in O
lifestyle O
. O
[]

hemoglobin O
per O
gm O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
determine O
whether O
extracorporeal O
shock O
wave O
therapy O
can O
safely O
and O
effectively O
relieve O
the O
pain B-outcome ['Physiological-Clinical']
associated O
with O
chronic O
plantar O
fasciitis O
compared O
to O
placebo O
treatment O
, O
as O
demonstrated O
by O
pain O
with O
walking O
in O
the O
morning O
. O
['Physiological-Clinical']

and O
diarrheagenic B-outcome ['Physiological-Clinical']
Escherichia I-outcome ['Physiological-Clinical']
coli I-outcome ['Physiological-Clinical']
were O
obtained O
on O
Days O
1 O
, O
3 O
, O
4 O
to O
5 O
and O
21 O
+/- O
5 O
. O
['Physiological-Clinical']

Most O
notably O
, O
occlusion O
of O
flow O
in O
the O
microvasculature O
causes O
the O
acute O
pain O
crises O
[ O
3 O
] O
that O
are O
the O
commonest O
cause O
for O
patients O
with O
SCD O
to O
seek O
medical O
attention O
[ O
4 O
] O
and O
major O
determinants O
of O
their O
quality O
of O
life O
[ O
5 O
] O
. O
[]

A O
randomized O
, O
blinded O
, O
placebo-controlled O
trial O
was O
designed O
to O
evaluate O
the O
utility O
of O
TENS O
after O
total O
knee O
arthroplasty O
. O
[]

The O
circuits O
were O
equipped O
with O
an O
airway O
pressure-limiting O
valve O
to O
allow O
connection O
to O
an O
anesthetic O
gas O
extractor O
. O
[]

The O
incidence O
of O
the O
primary O
endpoint O
in O
these O
patients O
was O
compared O
to O
that O
in O
178 O
patients O
out O
of O
the O
initial O
256 O
rate-control O
patients O
of O
RACE O
who O
were O
in O
AF O
and O
using O
oral O
anticoagulation O
continuously O
. O
[]

Comparison O
was O
made O
against O
conventional O
insulin O
therapy O
using O
a O
randomized O
trial O
design O
. O
[]

PARTICIPANTS O
Thirty-four O
eyes O
of O
32 O
patients O
with O
chronic O
CSC O
with O
> O
6 O
months O
' O
duration O
of O
symptoms O
or O
recurrent O
CSC O
were O
randomly O
placed O
into O
the O
low-fluence O
PDT O
group O
( O
n O
= O
18 O
) O
or O
the O
ranibizumab O
group O
( O
n O
= O
16 O
) O
. O
[]

METHODS O
This O
study O
was O
a O
randomized O
controlled O
trial O
( O
RCT O
) O
. O
[]

MEASUREMENTS O
The O
specific O
objectives O
were O
to O
assess O
protocol-related O
logistical O
issues O
, O
randomization O
, O
HSD B-outcome ['Physiological-Clinical']
safety I-outcome ['Physiological-Clinical']
, O
and O
follow B-outcome ['Life-Impact']
up I-outcome ['Life-Impact']
rates O
and O
to O
obtain O
survival B-outcome ['Mortality']
and O
neurocognitive B-outcome ['Physiological-Clinical']
end O
point O
estimates O
. O
['Physiological-Clinical', 'Life-Impact', 'Mortality', 'Physiological-Clinical']

Forty O
unpremedicated O
female O
patients O
aged O
18-59 O
, O
scheduled O
for O
minor O
gynecological O
procedures O
, O
were O
randomly O
assigned O
to O
four O
groups O
. O
[]

However O
, O
donepezil O
appeared O
to O
be O
safe O
and O
well O
tolerated O
. O
[]

Those O
with O
significant O
improvement O
of O
urticaria O
activity O
score O
under O
fexofenadine O
at O
180 O
mg O
were O
included O
in O
the O
CIU O
group O
. O
[]

The O
study O
encompasses O
a O
wide O
range O
of O
COPD O
patients O
, O
e.g O
. O
[]

The O
Functional O
Assessment O
of O
Anorexia/Cachexia O
Therapy O
questionnaire O
, O
which O
emphasizes O
anorexia-related O
questions O
, O
demonstrated O
an O
improvement O
in O
quality O
of O
life O
( O
QOL B-outcome ['Life-Impact']
) O
among O
megestrol O
acetate-treated O
and O
combination-treated O
patients O
. O
['Life-Impact']

The O
patients O
were O
randomly O
assigned O
to O
the O
control O
( O
levamlodipine O
besylate O
2.5 O
mg/d O
plus O
benazepril O
10 O
mg/d O
, O
n=20 O
) O
or O
probucol O
group O
( O
levamlodipine O
besylate O
2.5 O
mg/d O
plus O
benazepril O
10 O
mg/d O
plus O
probucol O
500 O
mg/d O
, O
n=20 O
) O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
compare O
side O
effects O
and O
bone O
turnover O
markers O
in O
postmenopausal O
women O
who O
had O
received O
alendronate O
daily O
or O
weekly O
in O
tablets O
with O
or O
without O
enteric O
coating O
. O
[]

METHOD O
Sixty-two O
children O
with O
spastic O
CP O
( O
39 O
males O
, O
23 O
females O
; O
mean O
age O
10y O
1mo O
, O
SD O
1y O
8mo O
; O
age O
range O
7-13y O
) O
, O
classified O
as O
Gross O
Motor O
Function O
Classification O
System O
( O
GMFCS O
) O
levels O
I O
to O
III O
, O
participated O
. O
[]

Viozan O
( O
sibenadet O
HCl O
, O
AR-C68397AA O
) O
is O
a O
novel O
dual O
D2 O
dopamine O
receptor O
, O
beta2-adrenoceptor O
agonist O
that O
has O
been O
investigated O
for O
efficacy O
in O
alleviating O
the O
symptoms O
of O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
. O
[]

Complications O
were O
categorized O
by O
( O
1 O
) O
hematoma/seroma B-outcome ['Physiological-Clinical']
, O
( O
2 O
) O
orchitis B-outcome ['Physiological-Clinical']
, O
( O
3 O
) O
neuralgia B-outcome ['Physiological-Clinical']
, O
and O
( O
4 O
) O
other O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
no O
long-term O
advantages O
have O
been O
shown O
. O
[]

Prostaglandin O
F2 O
alpha O
, O
20 O
mg O
, O
diluted O
to O
20 O
ml O
in O
normal O
saline O
solution O
( O
10 O
women O
, O
group O
1 O
) O
, O
30 O
IU O
of O
oxytocin O
, O
diluted O
to O
20 O
ml O
in O
normal O
saline O
solution O
( O
11 O
women O
, O
group O
2 O
) O
, O
or O
20 O
ml O
of O
normal O
saline O
solution O
alone O
( O
7 O
women O
, O
group O
3 O
) O
, O
were O
injected O
into O
the O
umbilical O
vein O
1 O
h O
after O
delivery O
. O
[]

Five O
outcomes O
related O
to O
wrist O
band O
efficacy O
( O
acute B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
, O
delayed B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
, O
vomiting B-outcome ['Physiological-Clinical']
, O
QOL B-outcome ['Life-Impact']
, O
and O
total O
amount O
of O
antiemetic B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
used I-outcome ['Resource-use']
) O
were O
examined O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

The O
purpose O
of O
this O
study O
was O
to O
investigate O
whether O
combining O
electrically O
induced O
sensory O
inputs O
through O
transcutaneous O
electrical O
nerve O
stimulation O
( O
TENS O
) O
with O
task-related O
training O
( O
TRT O
) O
in O
a O
home-based O
program O
would O
augment O
voluntary B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
in O
chronic O
stroke O
survivors O
better O
than O
either O
treatment O
alone O
or O
no O
treatment O
. O
['Physiological-Clinical']

DESIGN O
Randomised O
controlled O
trial O
. O
[]

The O
primary O
outcome O
measure O
was O
recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
fits I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
elimination O
of O
postoperative O
complications O
in O
this O
method O
is O
more O
difficult O
. O
[]

Sentinel O
lymph O
node O
study O
is O
progressively O
being O
popularized O
as O
a O
method O
that O
increases O
sensibility O
in O
detect O
positive O
nodes B-outcome ['Physiological-Clinical']
to O
reveal O
a O
more O
accurate O
stage B-outcome ['Physiological-Clinical']
and O
prognosis O
in O
colorectal O
cancer O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Forty O
times O
less O
erythema B-outcome ['Physiological-Clinical']
and O
15 O
times O
less O
induration B-outcome ['Physiological-Clinical']
were O
found O
with O
polymerized O
ragweed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
those O
patients O
who O
experienced O
an O
exacerbation O
during O
the O
trial O
( O
irrespective O
of O
treatment O
group O
) O
, O
resource B-outcome ['Resource-use']
use I-outcome ['Resource-use']
was O
increased O
during O
the O
periods O
when O
an O
exacerbation O
was O
reported O
when O
compared O
with O
the O
periods O
before O
or O
after O
an O
exacerbation O
. O
['Resource-use']

Stress O
scores O
did O
not O
change O
differentially O
for O
participants O
assigned O
to O
IOL O
versus O
CL O
treatments O
. O
[]

CONCLUSIONS O
Isoflavone O
supplementation O
improves O
menopausal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
only O
in O
women O
with O
the O
ability O
to O
produce O
equol O
. O
['Physiological-Clinical']

In O
addition O
, O
cognitive O
behavior O
interventions O
have O
been O
shown O
to O
lower O
the O
risk O
of O
recurrence O
of O
LBP B-outcome ['Physiological-Clinical']
and O
long-term B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Changes O
in O
calcanean O
bone O
mineral O
occurring O
spontaneously O
and O
during O
hormone O
replacement O
therapy O
in O
early O
post-menopausal O
women O
. O
[]

The O
exercising O
participants O
were O
instructed O
during O
a O
single O
physiotherapy O
visit O
and O
subsequently O
exercised O
four O
days O
or O
more O
per O
week O
; O
training O
and O
step-count O
goals O
were O
advanced O
during O
bimonthly O
telephone O
calls O
. O
[]

RESULTS O
With O
the O
chinstrap O
, O
both O
mouth B-outcome ['Physiological-Clinical']
leak I-outcome ['Physiological-Clinical']
and O
the O
arousal B-outcome ['Physiological-Clinical']
index O
decreased O
significantly O
, O
from O
( O
mean+/-SD O
) O
42.9+/-23.5 O
to O
23.8+/-13.3 O
% O
of O
total O
sleep B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
( O
TST O
) O
, O
and O
from O
33.4+/-18.6 O
to O
23.6+/-9.3/sleep O
hour O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Inadequate O
maternal O
nutrition O
during O
gestation O
may O
cause O
an O
adverse O
environment O
for O
the O
fetus O
leading O
to O
alterations O
of O
the O
hypothalamic-pituitary-adrenal O
( O
HPA O
) O
and O
sympatho-adrenomedullary O
( O
SAM O
) O
systems O
later O
in O
life O
. O
[]

Bevacizumab O
compared O
with O
macular O
laser O
grid O
photocoagulation O
for O
cystoid O
macular O
edema O
in O
branch O
retinal O
vein O
occlusion O
. O
[]

BACKGROUND O
The O
objective O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
toxicity O
of O
the O
liposome-encapsulated O
doxorubicin O
, O
TLC O
D-99 O
( O
Myocet O
, O
Elan O
Pharmaceuticals O
, O
Princeton O
, O
NJ O
) O
, O
and O
conventional O
doxorubicin O
in O
first-line O
treatment O
of O
metastatic O
breast O
carcinoma O
( O
MBC O
) O
. O
[]

No O
significant O
difference O
was O
observed O
in O
overall O
survival B-outcome ['Mortality']
, O
with O
a O
median O
of O
19.4 O
and O
21.5 O
months O
for O
CP O
and O
cisplatin O
, O
respectively O
. O
['Mortality']

All O
patients O
received O
therapy O
with O
salbutamol O
delivered O
with O
metered-dose O
inhaler O
( O
MDI O
) O
into O
a O
spacer O
device O
( O
Volumatic O
) O
in O
four O
puffs O
( O
400 O
micrograms O
) O
at O
10-min O
interval O
, O
and O
intravenous O
hydrocortisone O
( O
500 O
mg O
) O
. O
[]

BACKGROUND O
AND O
AIMS O
NCX-4016 O
is O
a O
nitric O
oxide-releasing O
derivative O
of O
aspirin O
with O
antiplatelet B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

or O
to O
a O
waiting O
list O
period O
. O
[]

We O
are O
performing O
a O
randomized O
controlled O
trial O
of O
parenteral O
nutrition O
among O
children O
undergoing O
allogeneic O
HSCT O
. O
[]

Drinking O
orange O
juice O
and O
brushing O
with O
toothpaste O
B O
. O
[]

The O
low O
rate O
of O
recorded O
complications O
showed O
that O
both O
techniques O
cause O
little O
damage O
to O
the O
tonsillar O
bed O
during O
dissection O
, O
thus O
minimising O
complications O
. O
[]

On O
the O
basis O
of O
these O
results O
, O
it O
seems O
that O
ginger O
has O
the O
potential O
to O
decrease O
eicosanoid O
levels O
, O
perhaps O
by O
inhibiting O
their O
synthesis O
from O
arachidonic O
acid O
. O
[]

Anxiety O
can O
adversely O
impact O
functioning O
across O
school O
, O
home O
and O
community O
environments O
. O
[]

Predictors O
of O
incident B-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
after O
hip O
fracture O
surgery O
. O
['Life-Impact']

Fourteen O
patients O
( O
4.7 O
% O
) O
temporarily O
discontinued O
prasugrel O
( O
average O
6.5 O
days O
) O
mainly O
because O
of O
surgical O
procedures O
. O
[]

Cardiovascular B-outcome ['Life-Impact']
mortality I-outcome ['Life-Impact']
was O
reduced O
by O
37 O
% O
in O
favour O
of O
losartan O
( O
p O
< O
0.028 O
) O
, O
and O
all O
cause O
mortality B-outcome ['Mortality']
by O
39 O
% O
( O
p O
< O
0.002 O
) O
. O
['Life-Impact', 'Mortality']

Major B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
occurred O
in O
3/75 O
( O
4 O
% O
) O
patients O
of O
the O
V O
group O
and O
in O
1/75 O
( O
1.3 O
% O
) O
patient O
of O
the O
H O
group O
( O
p O
< O
0.05 O
) O
. O
['Adverse-effects']

CONCLUSIONS O
The O
results O
suggest O
that O
coadministration O
of O
nitroglycerin O
and O
N-acetylcysteine O
in O
humans O
1 O
) O
potentiates O
and O
preserves O
nitroglycerin-induced B-outcome ['Physiological-Clinical']
venodilation I-outcome ['Physiological-Clinical']
and O
2 O
) O
augments O
the O
effect O
of O
nitroglycerin O
on O
small B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
vessels I-outcome ['Physiological-Clinical']
( O
regulating O
subcutaneous B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
) O
without O
affecting O
the O
response O
to O
nitroglycerin B-outcome ['Resource-use']
in O
middle-sized O
arteries B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

SETTING O
Participating O
general O
practices O
and O
a O
district O
general O
teaching O
hospital O
. O
[]

Gastrointestinal O
side O
effects O
and O
hand-foot B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
were O
more O
common O
with O
combination O
therapy O
, O
whereas O
myalgia B-outcome ['Physiological-Clinical']
, O
arthralgia B-outcome ['Physiological-Clinical']
, O
and O
neutropenic B-outcome ['Physiological-Clinical']
fever/sepsis B-outcome ['Physiological-Clinical']
were O
more O
common O
with O
single-agent O
docetaxel O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
incidence O
of O
initial B-outcome ['Physiological-Clinical']
RAO I-outcome ['Physiological-Clinical']
was O
5.9 O
% O
in O
the O
2,000-IU O
group O
and O
2.9 O
% O
in O
the O
5,000-IU O
group O
( O
p O
= O
0.17 O
) O
, O
with O
a O
compression O
time O
of O
2.10 O
? O
['Physiological-Clinical']

Participants O
spent O
a O
greater O
proportion O
of O
sleep O
in O
light B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
( O
stage O
1 O
+ O
stage O
2 O
) O
after O
exercise O
at O
both O
65 O
% O
and O
75 O
% O
[ O
Vdot O
] O
O O
( O
2 O
) O
max O
( O
P O
< O
0.05 O
) O
than O
the O
no-exercise O
condition O
. O
['Physiological-Clinical']

Variability O
of O
thrombolytic O
coronary O
reperfusion O
: O
an O
angiographic O
study O
of O
streptokinase O
and O
anistreplase O
. O
[]

In O
the O
12 O
( O
th O
) O
weekend O
of O
treatment O
, O
the O
factors O
and O
total O
scores O
of O
PANSS O
in O
study O
group O
[ O
( O
12.0 O
? O
[]

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
was O
3.5 O
months O
( O
range O
, O
1-38 O
) O
in O
patients O
treated O
with O
5-FU O
plus O
FA O
, O
and O
3 O
months O
( O
range O
, O
1-21 O
) O
in O
patients O
treated O
with O
the O
IFO O
combination O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVES O
Thoracotomy O
is O
associated O
with O
pain O
and O
compromised O
pulmonary O
function O
. O
[]

SSA O
patients O
had O
significantly O
less O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
than O
DES O
patients O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

After O
12 O
weeks O
of O
the O
treatment O
we O
observed O
in O
these O
patients O
decreases O
in O
CD3 B-outcome ['Physiological-Clinical']
, O
CD4 B-outcome ['Physiological-Clinical']
, O
CD8 B-outcome ['Physiological-Clinical']
and O
CD16 B-outcome ['Physiological-Clinical']
cell O
numbers O
and O
elevation O
of O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
treatment O
decision O
must O
be O
based O
on O
repeated O
clinic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
readings O
. O
['Physiological-Clinical']

Hyperglycemia B-outcome ['Physiological-Clinical']
worsened O
in O
insulin-withdrawal O
patients O
who O
did O
not O
meet O
study O
failure O
criteria O
, O
but O
it O
improved O
in O
control O
patients O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
efficacy O
of O
a O
behavioral O
plus O
nutrition O
education O
intervention O
, O
Be O
In O
CHARGE O
! O
, O
[]

At O
12 O
months O
follow O
up O
, O
a O
higher O
rate O
of O
major B-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
was O
observed O
overall O
in O
group O
A O
than O
in O
group O
B O
( O
10 O
( O
22 O
% O
) O
v O
23 O
( O
11 O
% O
) O
, O
p O
= O
0.041 O
) O
. O
['Physiological-Clinical']

We O
recorded O
side O
effects O
, O
C-telopeptide B-outcome ['Physiological-Clinical']
, O
osteocalcin B-outcome ['Physiological-Clinical']
and O
urine B-outcome ['Physiological-Clinical']
hydroxyproline I-outcome ['Physiological-Clinical']
at O
the O
start O
of O
the O
study O
and O
at O
3 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
After O
12 O
weeks O
, O
200 O
mg O
of O
INCB13739 O
resulted O
in O
significant O
reductions O
in O
A1C O
( O
-0.6 O
% O
) O
, O
fasting B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
( O
-24 O
mg/dl O
) O
, O
and O
homeostasis B-outcome ['Physiological-Clinical']
model O
assessment-insulin O
resistance B-outcome ['Physiological-Clinical']
( O
HOMA-IR O
) O
( O
-24 O
% O
) O
compared O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
clinical O
implications O
of O
these O
findings O
are O
discussed O
. O
[]

Reduced O
rsFC B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
between O
the O
insula O
, O
dACC O
and O
striatum O
is O
associated O
with O
nicotine O
addiction O
severity O
in O
both O
non-psychiatrically O
ill O
and O
in O
SZ O
smokers O
. O
['Physiological-Clinical']

Consistency O
of O
results O
was O
found O
across O
trials O
( O
P O
> O
0.10 O
, O
heterogeneity O
value O
) O
for O
all O
comparisons O
. O
[]

DESIGN O
Randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Clindamycin O
was O
found O
to O
be O
more O
effective O
than O
cefoxitin O
in O
eradicating O
the O
offending O
anaerobic O
pathogens O
from O
the O
site O
of O
infection O
. O
[]

Nausea B-outcome ['Physiological-Clinical']
was O
noted O
in O
71.4 O
% O
and O
46.2 O
% O
, O
respectively O
, O
and O
the O
inhibitory O
effect O
tended O
to O
be O
higher O
in O
the O
combination O
group O
. O
['Physiological-Clinical']

New O
combination O
regimen O
with O
higher O
efficacy O
should O
be O
developed O
as O
a O
first-line O
eradication O
therapy O
for O
H. O
pylori O
in O
Korea O
. O
[]

CONCLUSIONS O
Decreased O
YAP1 O
expression O
is O
an O
independent O
prognostic O
factor O
for O
recurrence O
in O
the O
less O
aggressive O
luminal O
A O
breast O
cancer O
subgroup O
, O
likely O
due O
to O
the O
decreased O
tamoxifen O
sensitivity O
conferred O
by O
YAP1 O
downregulation O
. O
[]

SUBJECTS O
AND O
METHODS O
Twenty-six O
patients O
with O
knee O
disorders O
requiring O
arthroscopy O
were O
randomly O
assigned O
to O
1 O
of O
3 O
groups O
. O
[]

The O
effects O
of O
dried O
purple O
carrot O
on O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
lipids B-outcome ['Physiological-Clinical']
, O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
, O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
tests O
, O
and O
appetite B-outcome ['Physiological-Clinical']
were O
investigated O
in O
16 O
males O
( O
aged O
53.1 O
? O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Diet O
design O
for O
a O
multicenter O
controlled O
feeding O
trial O
: O
the O
DELTA O
program O
. O
[]

However O
, O
PVP O
use O
led O
to O
more O
favorable O
evolution O
of O
fluorescein-staining B-outcome ['Physiological-Clinical']
corneal I-outcome ['Physiological-Clinical']
punctuations I-outcome ['Physiological-Clinical']
( O
P O
= O
0.028 O
) O
. O
['Physiological-Clinical']

To O
address O
the O
need O
for O
improved O
educational O
outcomes O
, O
a O
previously O
tested O
consultation O
intervention O
called O
the O
Collaborative O
Model O
for O
Promoting O
Competence O
and O
Success O
( O
COMPASS O
; O
Ruble O
, O
Dalrymple O
, O
& O
McGrew O
, O
2010 O
; O
Ruble O
, O
Dalrymple O
, O
& O
McGrew O
, O
2012 O
) O
was O
evaluated O
in O
a O
2nd O
randomized O
controlled O
trial O
, O
with O
the O
addition O
of O
a O
web-based O
group O
. O
[]

There O
were O
substantial O
but O
unclear O
individual O
responses O
to O
training O
and O
caffeine O
( O
SD O
of O
0.3 O
% O
and O
0.8 O
% O
, O
respectively O
) O
. O
[]

The O
number O
of O
hospitalizations B-outcome ['Resource-use']
, O
functional B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
and O
total O
medical B-outcome ['Resource-use']
cost I-outcome ['Resource-use']
at O
3 O
months O
[ O
median O
$ O
1655 O
, O
interquartile O
range O
( O
IQR O
) O
, O
850-3331 O
vs. O
$ O
1541 O
, O
IQR O
859-2827 O
; O
P O
= O
0.68 O
] O
were O
similar O
in O
both O
groups O
. O
['Resource-use', 'Life-Impact', 'Resource-use']

Plaque O
indices O
have O
largely O
been O
developed O
for O
buccal O
and O
lingual O
tooth O
surfaces O
. O
[]

MAIN O
OUTCOME O
MEASURE O
( O
S O
) O
Peak O
E O
( O
2 O
) O
levels O
, O
days O
of O
stimulation O
with O
rFSH O
, O
total O
rFSH O
dosage O
, O
total O
number O
of O
oocytes B-outcome ['Physiological-Clinical']
retrieved B-outcome ['Physiological-Clinical']
, O
M2 O
oocytes B-outcome ['Physiological-Clinical']
retrieved I-outcome ['Physiological-Clinical']
, O
total O
number O
of O
embryos B-outcome ['Physiological-Clinical']
, O
number O
of O
embryos B-outcome ['Physiological-Clinical']
transferred O
, O
number O
of O
Grade-1 O
embryos B-outcome ['Physiological-Clinical']
transferred O
, O
clinical O
pregnancy O
rate O
( O
positive O
fetal O
cardiac O
activity O
) O
, O
and O
cancellation O
rates O
of O
stimulation O
and O
embryo O
transfer O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Increasing O
the O
dialysate O
Na+ O
concentration O
decreases O
hypotensive O
episodes O
. O
[]

Blood O
samples O
were O
collected O
at O
0 O
, O
10 O
, O
30 O
, O
and O
40 O
days O
and O
used O
for O
the O
evaluation O
of O
DNA B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
, O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-I I-outcome ['Physiological-Clinical']
( O
IGF-I B-outcome ['Physiological-Clinical']
) O
and O
histone B-outcome ['Physiological-Clinical']
deacetylase I-outcome ['Physiological-Clinical']
( O
HDAC B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
No O
statistically O
significant O
differences O
were O
observed O
between O
the O
two O
arms O
in O
terms O
of O
CR B-outcome ['Physiological-Clinical']
rate O
and O
toxicity B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

Alertness B-outcome ['Life-Impact']
and O
cognitive B-outcome ['Life-Impact']
performance B-outcome ['Life-Impact']
amongst O
the O
chewing O
condition O
did O
not O
differ O
or O
were O
in O
fact O
worse O
when O
compared O
with O
placebo O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Total O
of O
225 O
cases O
with O
rectal O
cancer O
were O
enrolled O
in O
this O
study O
. O
[]

Evaluations O
were O
carried O
out O
before O
and O
12 O
weeks O
after O
treatment O
with O
either O
100 O
mg O
denbufylline O
BID O
or O
placebo O
and O
included O
EEG O
mapping O
, O
the O
Sandoz O
Clinical O
Assessment O
Geriatric O
( O
SCAG O
) O
score/factors O
, O
the O
Clinical O
Global O
Impression O
( O
CGI O
) O
, O
the O
Digit O
Symbol O
Substitution O
Test O
( O
DSST O
) O
, O
the O
Trail-Making O
Test O
( O
TMT O
) O
and O
the O
Digit O
Span O
Test O
( O
DS O
) O
. O
[]

The O
first O
and O
last O
classes O
were O
for O
one O
or O
both O
parents O
only O
, O
and O
the O
middle O
four O
sessions O
were O
for O
the O
child O
and O
parent O
( O
s O
) O
. O
[]

PATIENTS O
Consecutive O
patients O
who O
were O
referred O
for O
evaluation O
of O
known O
or O
suspected O
coronary O
artery O
disease O
. O
[]

The O
parent O
education O
and O
behavior O
management O
intervention O
was O
effective O
in O
alleviating O
a O
greater O
percentage O
of O
anxiety B-outcome ['Life-Impact']
, O
insomnia B-outcome ['Physiological-Clinical']
, O
and O
['Life-Impact', 'Physiological-Clinical']

In O
a O
randomized O
, O
placebo-controlled O
, O
multicenter O
trial O
of O
60 O
patients O
with O
documented O
coronary O
disease O
, O
positive O
exercise O
tests O
, O
and O
ischemic O
episodes O
on O
Holter O
monitoring O
, O
long-acting O
diltiazem O
reduced O
ischemic B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
by O
50 O
% O
compared O
to O
placebo O
, O
from O
a O
mean O
of O
5.6 O
to O
2.8 O
( O
p O
less O
than O
0.0001 O
) O
. O
['Physiological-Clinical']

Uremic O
patients O
showed O
PRL B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
higher O
than O
in O
controls O
, O
however O
their O
TRH-induced B-outcome ['Physiological-Clinical']
PRL I-outcome ['Physiological-Clinical']
peak I-outcome ['Physiological-Clinical']
( O
20.6 O
+/- O
6.6 O
micrograms/l O
) O
was O
not O
different O
from O
that O
of O
controls O
( O
26.5 O
+/- O
3.0 O
micrograms/l O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Force O
measurements O
were O
obtained O
by O
a O
hydraulic O
dynamometer O
immediately O
before O
and O
after O
each O
intervention O
at O
the O
same O
period O
before O
training O
up O
to O
3 O
weeks O
with O
at O
least O
36 O
hours O
between O
interventions O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
recorded O
and O
blood B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
for O
measurement O
of O
plasma B-outcome ['Physiological-Clinical']
cyclic I-outcome ['Physiological-Clinical']
AMP I-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
, O
C-peptide B-outcome ['Physiological-Clinical']
, O
glucose B-outcome ['Physiological-Clinical']
, O
lactate B-outcome ['Physiological-Clinical']
, O
glycerol B-outcome ['Physiological-Clinical']
, O
non-esterified B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
( O
NEFA B-outcome ['Physiological-Clinical']
) O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Thus O
, O
PCR B-outcome ['Physiological-Clinical']
viremia I-outcome ['Physiological-Clinical']
provides O
prognostic O
information O
about O
CMV O
disease O
in O
AIDS O
patients O
, O
and O
valaciclovir O
showed O
activity O
as O
both O
a O
preemptive O
and O
prophylactic O
agent O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Patients O
with O
monolateral O
postmastectomy O
lymphedema O
were O
randomized O
to O
receive O
two O
cycles O
of O
intermittent O
pneumatic O
compression O
( O
PC O
group O
) O
, O
i.e. O
, O
five O
two-hour O
sessions O
per O
week O
for O
two O
weeks O
, O
to O
be O
repeated O
after O
a O
five-week O
interval O
, O
or O
to O
no O
treatment O
( O
control O
group O
) O
. O
[]

This O
study O
compares O
the O
influence O
of O
intravenous O
ibutilide O
, O
a O
class O
III O
antiarrhythmic O
agent O
, O
with O
procainamide O
, O
a O
class O
IA O
antiarrhythmic O
agent O
, O
and O
with O
placebo O
on O
its O
ability O
to O
terminate O
atrial O
flutter O
using O
rapid O
atrial O
pacing O
. O
[]

Because O
of O
the O
absence O
of O
differences O
in O
outcome O
among O
the O
four O
randomization O
groups O
, O
cost B-outcome ['Resource-use']
data O
for O
all O
patients O
were O
pooled O
. O
['Resource-use']

Differential O
effects O
on O
bone B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
of O
progestogen-only O
methods O
for O
contraception O
in O
premenopausal O
women O
. O
['Physiological-Clinical']

JET O
occurs O
more O
commonly O
in O
smaller O
patients O
with O
longer O
CPB O
runs O
and O
significant O
postoperative B-outcome ['Physiological-Clinical']
lactic I-outcome ['Physiological-Clinical']
acidosis I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

Baseline O
IOP B-outcome ['Physiological-Clinical']
, O
whether O
adjusted O
for O
CCT O
or O
not O
, O
was O
statistically O
significant O
in O
all O
models O
including O
those O
with O
CCT O
in O
the O
same O
model O
. O
['Physiological-Clinical']

When O
the O
adaptor O
and O
probe O
were O
spectrally O
the O
same O
, O
the O
MAE B-outcome ['Physiological-Clinical']
was O
greater O
than O
when O
they O
were O
from O
different O
spectral O
regions O
; O
the O
magnitude O
of O
this O
difference O
depended O
on O
adaptor O
speed O
and O
was O
subject-dependent O
. O
['Physiological-Clinical']

BACKGROUND/AIM O
Traumas O
and O
war O
injuries O
, O
next O
to O
chronic O
occlusive O
artery O
disease O
and O
diabetes O
mellitus-derived O
complications O
, O
are O
the O
most O
frequent O
cause O
of O
the O
lower O
limbs O
amputation O
. O
[]

OBJECTIVE O
To O
test O
the O
hypothesis O
that O
supplemental O
oxygen O
reduces O
infection O
risk O
in O
patients O
following O
colorectal O
surgery O
. O
[]

Rates O
were O
calculated O
as O
patients O
with O
events/person-year O
for O
the O
following O
events O
: O
retinal O
detachment O
, O
cataract O
, O
visual O
field O
disturbance O
, O
and O
retinal O
pigment O
epitheliopathy O
. O
[]

Such O
alterations O
were O
not O
observed O
in O
group O
C. O
It O
appears O
that O
dietetic O
supplementation O
with O
coconut O
oil O
does O
not O
cause O
dyslipidemia O
and O
seems O
to O
promote O
a O
reduction O
in O
[]

Both O
groups O
lost B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
but O
there O
was O
no O
significant O
difference O
in O
weight O
loss B-outcome ['Physiological-Clinical']
after O
1 O
year O
of O
treatment O
( O
3M O
vs O
3+3M=-4.1+/-6.1 O
vs O
-5.9+/-9.4 O
kg O
; O
P=0.31 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Both O
arms O
exceeded O
the O
intervention O
goal O
, O
but O
there O
was O
not O
a O
significant O
difference O
between O
arms O
at O
follow-up O
. O
[]

OBJECTIVES O
The O
aims O
of O
this O
study O
were O
to O
test O
the O
feasibility O
of O
a O
novel O
methodology O
for O
investigating O
individualized O
decoctions O
of O
CHM O
rigorously O
and O
to O
gather O
preliminary O
data O
on O
the O
treatment O
effect O
of O
CHM O
for O
a O
larger O
definitive O
trial O
. O
[]

We O
now O
report O
influences O
of O
v1.0 O
quit-success B-outcome ['Physiological-Clinical']
genotype I-outcome ['Physiological-Clinical']
score O
, O
level O
of O
dependence O
and O
precessation O
smoking O
reduction O
in O
a O
smoking O
cessation O
trial O
that O
examined O
effects O
of O
21 O
versus O
42 O
mg/24 O
h O
precessation O
NRT O
. O
['Physiological-Clinical']

The O
oat O
powder O
also O
influenced O
the O
effects O
of O
the O
mixed O
meal O
, O
diminishing O
the O
glucose-lowering B-outcome ['Physiological-Clinical']
effects O
. O
['Physiological-Clinical']

Following O
a O
4-week O
treatment O
with O
open-label O
TIO O
18 O
mcg O
once O
daily O
, O
subjects O
were O
randomized O
in O
a O
double-blind O
fashion O
to O
either O
the O
addition O
of O
FSC O
250/50 O
DISKUS O
twice O
daily O
or O
matching O
placebo O
. O
[]

Statistical O
analysis O
of O
survival B-outcome ['Mortality']
and O
RFS B-outcome ['Mortality']
experience O
shows O
that O
the O
less O
intensive O
therapy O
does O
not O
worsen O
results O
for O
low-risk O
patients O
and O
CPM O
does O
not O
benefit O
those O
at O
high O
risk O
. O
['Mortality', 'Mortality']

Cardiac B-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
right B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RVEF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
improved O
by O
ischaemic O
preconditioning O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
differences O
in O
the O
percentage O
changes O
of O
the O
FEV1 B-outcome ['Physiological-Clinical']
and O
FVC B-outcome ['Physiological-Clinical']
in O
the O
iopamidol O
and O
the O
sodium O
iothalamate O
groups O
were O
not O
statistically O
significant O
( O
P O
greater O
than O
0.5 O
and O
P O
greater O
than O
0.1 O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
148 O
organisms O
was O
obtained O
in O
136 O
microbiologically O
valid O
patients O
( O
30.1 O
% O
) O
. O
[]

Efficacy O
and O
safety O
of O
a O
very-low-protein O
diet O
when O
postponing O
dialysis O
in O
the O
elderly O
: O
a O
prospective O
randomized O
multicenter O
controlled O
study O
. O
[]

PARTICIPANTS O
Healthy O
male O
and O
female O
volunteers O
aged O
18-75 O
years O
were O
included O
. O
[]

This O
trial O
initiates O
the O
effort O
to O
establish O
weight O
loss O
support O
for O
overweight O
or O
obese O
breast O
cancer O
survivors O
as O
a O
new O
standard O
of O
clinical O
care O
. O
[]

PARTICIPANTS O
Male O
adults O
with O
complete O
SCI O
at O
or O
below O
the O
fifth O
thoracic O
level O
( O
T5 O
) O
( O
N=17 O
) O
volunteered O
for O
this O
study O
. O
[]

Our O
aim O
was O
to O
evaluate O
enteral O
and O
parenteral O
glutamine O
in O
patients O
undergoing O
BMT O
. O
[]

90 O
% O
of O
the O
IM O
Group O
developed O
fever B-outcome ['Physiological-Clinical']
but O
abscess B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
was O
absent O
in O
all O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Plasma O
levels O
of O
acute O
phase O
reactants O
, O
interleukins B-outcome ['Physiological-Clinical']
, O
granulocytic B-outcome ['Physiological-Clinical']
proteins I-outcome ['Physiological-Clinical']
and O
complement B-outcome ['Physiological-Clinical']
factors I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Intraoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
complication B-outcome ['Adverse-effects']
rates O
, O
and O
return B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
normal I-outcome ['Life-Impact']
diet I-outcome ['Life-Impact']
were O
evaluated O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Adverse-effects', 'Life-Impact']

A O
total O
of O
269 O
patients O
, O
who O
presented O
with O
symptoms O
and O
electrocardiographic O
signs O
suggesting O
acute O
myocardial O
infarction O
were O
randomized O
to O
acute O
intravenous O
and O
subsequent O
oral O
therapy O
with O
propranolol O
( O
n O
= O
134 O
) O
or O
placebo O
( O
n O
= O
135 O
) O
. O
[]

Previous O
studies O
have O
indicated O
that O
neuroinflammation O
in O
the O
spinal O
cord O
is O
an O
important O
contributor O
to O
neuropathological O
and O
behavioral O
abnormalities O
. O
[]

One O
involved O
the O
use O
of O
examples O
of O
common O
errors O
( O
error O
) O
and O
the O
other O
demonstrated O
the O
skill O
being O
performed O
correctly O
( O
correct O
) O
. O
[]

BACKGROUND O
Persistent O
infection O
with O
Helicobacter O
pylori O
is O
associated O
with O
the O
recurrence O
of O
duodenal O
ulcer O
. O
[]

Carvedilol O
may O
have O
a O
beneficial O
effect O
on O
reversal O
of O
left O
ventricular O
remodeling O
and O
global O
ventricular O
function O
in O
pediatric O
heart O
failure O
. O
[]

Decoding O
was O
done O
at O
the O
completion O
of O
the O
study O
. O
[]

In O
comparison O
to O
the O
Ca O
( O
++ O
) O
-blocker O
Gallopamil O
the O
antiischemic B-outcome ['Physiological-Clinical']
effects O
of O
Enoximone O
were O
more O
pronounced O
, O
a O
synergistic B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
was O
, O
however O
, O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Studies O
concerning O
the O
treatment O
of O
substance-abusing O
suicidal O
patients O
are O
scarce O
despite O
the O
frequent O
presence O
of O
suicidal O
behavior O
among O
this O
population O
. O
[]

RESULTS O
The O
treatment O
duration O
was O
significantly O
shorter O
in O
the O
amifostine-treated O
group O
( O
p O
= O
0.013 O
) O
, O
because O
treatment O
interruptions O
were O
more O
frequent O
in O
the O
control O
group O
. O
[]

There O
were O
no O
changes O
in O
anthropometry B-outcome ['Physiological-Clinical']
for O
either O
group O
. O
['Physiological-Clinical']

No O
other O
measures O
reached O
statistical O
significance O
. O
[]

RESULTS O
Treatment O
with O
100 O
, O
200 O
or O
400 O
mg O
of O
PHX1149 O
significantly O
decreased O
postprandial B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
area O
under O
the O
curve O
AUC O
( O
0-2 O
h O
) O
by O
approximately O
20 O
% O
( O
+0.11 O
+/- O
0.50 O
, O
-2.08 O
+/- O
0.51 O
, O
-1.73 O
+/- O
0.49 O
and O
-1.88 O
+/- O
0.48 O
mmol/l O
x O
h O
, O
respectively O
, O
for O
placebo O
and O
100 O
, O
200 O
and O
400 O
mg O
( O
p O
= O
0.002 O
, O
0.008 O
and O
0.004 O
vs. O
placebo O
) O
. O
['Physiological-Clinical']

RESULTS O
The O
study O
groups O
were O
similar O
with O
respect O
to O
their O
baseline O
characteristics O
and O
pain O
levels O
at O
randomization O
. O
[]

RESULTS O
Among O
the O
52 O
patients O
given O
antibiotics O
, O
H. O
pylori O
was O
eradicated B-outcome ['Physiological-Clinical']
in O
46 O
, O
as O
compared O
with O
1 O
of O
the O
52 O
given O
placebo O
( O
89 O
percent O
vs. O
2 O
percent O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
Disturbances O
in O
body O
weight O
regulation O
are O
often O
encountered O
during O
glucocorticoid O
treatment O
and O
are O
associated O
with O
increased O
insulin O
resistance O
and O
truncal O
fat O
accumulation O
. O
[]

One O
event O
, O
mild O
knee O
pruritus O
, O
was O
considered O
probably O
related O
. O
[]

During O
hyposensitization O
IgG B-outcome ['Physiological-Clinical']
anti-IgG I-outcome ['Physiological-Clinical']
titres I-outcome ['Physiological-Clinical']
showed O
a O
slight O
initial O
increase O
followed O
by O
a O
decrease O
below O
pretreatment O
level O
. O
['Physiological-Clinical']

WL O
alone O
reduced O
( O
P O
< O
0.05 O
in O
all O
) O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
( O
-3 O
% O
) O
, O
waist O
circumference O
( O
-4 O
% O
) O
, O
systolic O
( O
-3 O
% O
) O
and O
diastolic O
( O
-3 O
% O
) O
blood O
pressures O
, O
cardiac O
output O
( O
-4 O
% O
) O
, O
plasma O
TG O
concentration O
( O
-25 O
% O
) O
, O
and O
the O
homeostasis O
model O
assessment O
( O
HOMA O
) O
score O
( O
-12 O
% O
) O
and O
increased O
plasma B-outcome ['Physiological-Clinical']
HDL I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
+9 O
% O
) O
and O
adiponectin O
( O
+18 O
% O
) O
concentrations O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
cangrelor O
group O
, O
as O
compared O
with O
the O
placebo O
group O
, O
two O
prespecified O
secondary O
end O
points O
were O
significantly O
reduced O
at O
48 O
hours O
: O
the O
rate O
of O
stent B-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
, O
from O
0.6 O
% O
to O
0.2 O
% O
( O
odds O
ratio O
, O
0.31 O
; O
95 O
% O
CI O
, O
0.11 O
to O
0.85 O
; O
P=0.02 O
) O
, O
and O
the O
rate O
of O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
any I-outcome ['Mortality']
cause I-outcome ['Mortality']
, O
from O
0.7 O
% O
to O
0.2 O
% O
( O
odds O
ratio O
, O
0.33 O
; O
95 O
% O
CI O
, O
0.13 O
to O
0.83 O
; O
P=0.02 O
) O
. O
['Physiological-Clinical', 'Mortality']

The O
Toronto O
prehospital O
hypertonic O
resuscitation O
-- O
head O
injury O
and O
multiorgan O
dysfunction O
trial O
: O
feasibility O
study O
of O
a O
randomized O
controlled O
trial O
. O
[]

METHOD O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
clinical O
trial O
was O
conducted O
over O
6 O
months O
with O
96 O
healthy O
menopausal O
women O
. O
[]

However O
, O
a O
nonsignificant O
increase O
( O
OR O
1.25 O
; O
0.87 O
, O
1.79 O
, O
p O
= O
0.221 O
) O
in O
Pap B-outcome ['Life-Impact']
test I-outcome ['Life-Impact']
completion I-outcome ['Life-Impact']
was O
demonstrated O
in O
women O
categorized O
as O
low O
risk O
for O
cervical O
cancer O
. O
['Life-Impact']

This O
showed O
that O
a O
low-level O
dietary O
intervention O
could O
achieve O
modest O
dietary O
behaviour O
changes O
that O
are O
of O
public O
health O
significance O
. O
[]

Baseline O
characteristics O
were O
well O
balanced O
between O
the O
two O
treatment O
arms O
. O
[]

CONCLUSION O
Our O
results O
indicate O
that O
CLIP O
staging O
seems O
to O
be O
most O
adapted O
to O
palliative O
setting O
and O
that O
it O
could O
be O
better O
by O
associating O
WHO O
PS O
. O
[]

BACKGROUND O
An O
open-label O
, O
randomized O
controlled O
trial O
compared O
clozapine O
with O
physicians'-choice O
medications O
among O
long-term O
state O
hospital O
inpatients O
in O
Connecticut O
. O
[]

In O
no O
patient O
group O
was O
there O
a O
statistically O
significant O
difference O
in O
relation O
to O
gender O
( O
P O
= O
.735 O
) O
, O
site O
of O
surgery O
( O
P O
= O
.552 O
) O
, O
class O
horizontal O
space O
available O
( O
P O
= O
.427 O
) O
, O
class O
highest O
portion O
of O
the O
M3 O
crown O
( O
P O
= O
.424 O
) O
, O
angulations O
of O
the O
teeth O
( O
P O
= O
.925 O
) O
, O
and O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
impaction I-outcome ['Physiological-Clinical']
( O
P O
= O
.445 O
) O
. O
['Physiological-Clinical']

Measurement O
of O
repeatability O
and O
plaque O
removal O
. O
[]

This O
study O
investigated O
acute O
effects O
of O
caffeine O
ingestion O
on O
signal-averaged B-outcome ['Physiological-Clinical']
P-wave I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
QRS I-outcome ['Physiological-Clinical']
complexes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Patient O
preference O
arm O
: O
55 O
participants O
with O
low O
back O
pain O
, O
with O
median O
duration O
of O
11 O
weeks O
. O
[]

Three O
of O
35 O
patients O
on O
tolrestat O
( O
8.6 O
% O
) O
developed O
high B-outcome ['Physiological-Clinical']
transaminases I-outcome ['Physiological-Clinical']
levels O
( O
more O
than O
threefold O
the O
upper O
normal O
limit O
) O
and O
were O
withdrawn O
from O
the O
study O
. O
['Physiological-Clinical']

A O
randomized O
double-blind O
comparison O
of O
coformulated O
elvitegravir/cobicistat/emtricitabine/tenofovir O
disoproxil O
fumarate O
versus O
efavirenz/emtricitabine/tenofovir O
disoproxil O
fumarate O
for O
initial O
treatment O
of O
HIV-1 O
infection O
: O
analysis O
of O
week O
96 O
results O
. O
[]

RESULTS O
The O
median O
interval O
from O
randomization O
to O
delivery B-outcome ['Physiological-Clinical']
was O
4 O
days O
in O
the O
prostaglandin O
E2 O
group O
( O
range O
0 O
to O
28 O
days O
) O
versus O
10 O
days O
in O
the O
placebo O
group O
( O
range O
0 O
to O
26 O
days O
, O
p O
= O
0.002 O
) O
. O
['Physiological-Clinical']

Psychiatric O
treatment O
of O
eczema O
: O
a O
controlled O
trial O
. O
[]

As O
a O
group O
, O
participants O
in O
the O
self-face O
prime O
condition O
recognized B-outcome ['Life-Impact']
expressions I-outcome ['Life-Impact']
earlier O
( O
when O
less O
affective O
perceptual O
information O
was O
available O
) O
compared O
to O
participants O
in O
the O
nonself-face O
prime O
condition O
. O
['Life-Impact']

The O
antihypertensive O
effect O
of O
the O
peripheral O
vasodilator O
diazoxide O
in O
13 O
patients O
and O
the O
alpha-beta O
adrenoceptor O
blocking O
agent O
labetalol O
in O
12 O
patients O
were O
compared O
in O
46 O
severe O
acute O
hypertensive B-outcome ['Physiological-Clinical']
episodes O
during O
haemodialysis O
. O
['Physiological-Clinical']

Therefore O
, O
we O
prospectively O
randomized O
122 O
patients O
with O
evolving O
MI O
to O
PTCA O
therapy O
with O
or O
without O
adjunctive O
intravenous O
streptokinase O
therapy O
. O
[]

Of O
these O
, O
18 O
were O
not O
included O
in O
the O
vision B-outcome ['Physiological-Clinical']
or O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
evaluation O
because O
they O
did O
not O
complete O
one O
treatment O
. O
['Physiological-Clinical', 'Adverse-effects']

CONCLUSION O
It O
is O
indicated O
that O
sensory O
stimulation O
( O
acupunctura O
) O
in O
healthy O
persons O
is O
associated O
with O
changed O
activity O
in O
the O
sympathetic O
and O
parasympathetic O
nervous O
system O
depending O
on O
site O
of O
stimulation O
and O
period O
of O
observation O
. O
[]

MF101 O
, O
a O
selective O
estrogen O
receptor O
beta O
modulator O
for O
the O
treatment O
of O
menopausal O
hot O
flushes O
: O
a O
phase O
II O
clinical O
trial O
. O
[]

With O
the O
Ciaglia O
PDT O
kit O
, O
both O
intraoperative O
and O
at O
2 O
and O
24 O
hrs O
, O
surgical B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
were O
less O
common O
( O
p O
= O
.023 O
) O
and O
the O
procedure O
was O
more O
often O
completed O
without O
expert O
assistance O
( O
p O
= O
.013 O
) O
. O
['Adverse-effects']

The O
purpose O
of O
the O
present O
application O
was O
to O
fulfill O
a O
postmarketing O
commitment O
to O
provide O
long-term O
efficacy O
and O
safety O
data O
on O
treatment O
with O
imatinib B-outcome ['Resource-use']
mesylate I-outcome ['Resource-use']
( O
Gleevec O
; O
Novartis O
Pharmaceuticals O
, O
East O
Hanover O
, O
NJ O
) O
in O
patients O
with O
CD117 O
( O
+ O
) O
unresectable O
and/or O
metastatic O
malignant O
gastrointestinal O
stromal O
tumors O
( O
GISTs O
) O
. O
['Resource-use']

CONCLUSION O
Two O
1-hour O
WSTP O
sessions O
improve O
confidence O
with O
using O
a O
manual O
wheelchair O
among O
older O
adults O
who O
are O
inexperienced O
wheelchair O
users O
. O
[]

Thirty-four O
patients O
were O
treated O
with O
D O
( O
282 O
+/- O
102 O
mg/day O
) O
and O
36 O
with O
P O
( O
158 O
+/- O
81 O
mg/day O
) O
. O
[]

BACKGROUND O
Colon O
cancer O
is O
curable O
by O
surgery O
, O
but O
cure O
rate O
depends O
on O
the O
extent O
of O
disease O
. O
[]

METHODS O
In O
this O
2-year O
, O
Phase O
III O
, O
randomized O
, O
multicenter O
, O
double-masked O
trial O
, O
423 O
patients O
received O
ranibizumab O
( O
0.3 O
or O
0.5 O
mg O
) O
monthly O
+ O
sham O
PDT O
or O
PDT O
+ O
monthly O
sham O
injection O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
CPB O
in O
both O
groups O
greatly O
increased O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor O
alpha B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TNF-alpha I-outcome ['Physiological-Clinical']
) O
, O
interleukin B-outcome ['Physiological-Clinical']
( O
IL B-outcome ['Physiological-Clinical']
) O
-1beta O
, O
IL-1beta B-outcome ['Physiological-Clinical']
receptor B-outcome ['Physiological-Clinical']
antagonist B-outcome ['Physiological-Clinical']
, O
IL-6 B-outcome ['Physiological-Clinical']
, O
IL-10 B-outcome ['Physiological-Clinical']
, O
and O
N-terminal B-outcome ['Physiological-Clinical']
probrain I-outcome ['Physiological-Clinical']
natriuretic B-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
( O
NT-proBNP B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Success O
rate O
, O
onset O
, O
and O
duration O
of O
profound O
pulpal O
anesthesia O
were O
evaluated O
by O
the O
electrical O
pulp O
tester O
, O
while O
the O
width O
of O
the O
anesthetic O
field O
and O
duration O
of O
soft O
tissue O
anesthesia O
were O
recorded O
using O
the O
pinprick O
testing O
. O
[]

The O
PCCs O
were O
CAD/CAM O
fabricated O
using O
the O
Cerec O
3 O
system O
. O
[]

In O
the O
human O
upper O
extremity O
( O
UE O
) O
, O
unintended O
effects O
of O
proximal O
muscle O
activation O
on O
muscles O
controlling O
the O
hand O
could O
be O
an O
important O
aspect O
of O
motor O
control O
due O
to O
the O
necessary O
coordination O
of O
distal O
and O
proximal O
segments O
during O
functional O
activities O
. O
[]

All O
patients O
had O
carcinoma O
confined O
to O
the O
cervix O
, O
the O
upper O
part O
of O
the O
vagina O
or O
the O
parametrial O
region O
. O
[]

Ciprofloxacin/dexamethasone O
drops O
decrease O
the O
incidence O
of O
physician O
and O
patient O
outcomes O
of O
otorrhea B-outcome ['Physiological-Clinical']
after O
tube O
placement O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
incidence O
of O
tissue O
orientation O
loss O
resulting O
from O
inability O
to O
identify O
skin O
score O
marks O
with O
that O
occurring O
from O
failure O
to O
identify O
marks O
made O
using O
a O
gentian O
violet O
marker O
during O
Mohs O
micrographic O
surgery O
( O
MMS O
) O
. O
[]

Expanded O
blastocysts O
were O
vitrified O
in O
a O
solution O
containing O
6 O
M O
ethylene O
glycol O
, O
0.6 O
M O
trehalose O
and O
2 O
% O
( O
wt/vol O
) O
polyethylene O
glycol O
in O
10 O
% O
HEPES-buffered O
PZM-5 O
. O
[]

BACKGROUND O
Malignant O
pleural O
mesothelioma O
is O
almost O
always O
fatal O
, O
and O
few O
treatment O
options O
are O
available O
. O
[]

Experiment O
3 O
confirmed O
this O
finding O
, O
further O
demonstrating O
that O
observation O
of O
DTkid O
training O
trials O
alone O
was O
sufficient O
to O
enhance O
participants O
' O
declarative B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
procedural I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
of O
DTT O
. O
['Life-Impact']

However O
, O
the O
hazard O
ratio O
and O
95 O
% O
confidence O
intervals O
are O
consistent O
with O
the O
previously O
reported O
meta-analysis O
and O
two O
large O
recently O
reported O
trials O
, O
which O
suggest O
a O
small O
survival O
benefit O
with O
cisplatin-based O
chemotherapy O
. O
[]

The O
pharmacokinetics O
of O
epoetin O
alfa O
did O
not O
predict O
pharmacodynamic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
anemic O
critically O
ill O
patients O
. O
['Physiological-Clinical']

The O
primary O
outcome O
was O
a O
composite O
of O
death B-outcome ['Mortality']
or O
nonfatal B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
at O
30 O
days O
. O
['Mortality', 'Physiological-Clinical']

Effect O
of O
a O
high-protein O
, O
energy-restricted O
diet O
on O
weight O
loss B-outcome ['Physiological-Clinical']
and O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
after O
weight O
stabilization O
in O
hyperinsulinemic O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
increases O
were O
maintained O
after O
1 O
week O
of O
intermittent O
but O
not O
continuous O
treatment O
. O
[]

The O
incidence O
of O
tracheal B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
aspiration B-outcome ['Physiological-Clinical']
in O
the O
placebo O
and O
ranitidine O
groups O
was O
7.7 O
% O
and O
2.5 O
% O
, O
respectively O
( O
not O
significant O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SETTING O
An O
obstetrics/gynecological O
office O
specializing O
in O
infertility O
in O
an O
academic O
environment O
. O
[]

BACKGROUND O
Symptoms O
suggestive O
of O
functional O
dyspepsia O
( O
FD O
) O
and O
irritable O
bowel O
syndrome O
( O
IBS O
) O
frequently O
overlap O
with O
those O
of O
gastroesophageal O
reflux O
disease O
. O
[]

INTERVENTIONS O
Problem-solving O
education O
is O
a O
brief O
, O
cognitive O
intervention O
delivered O
in O
six O
30-minute O
individualized O
sessions O
by O
existing O
staff O
( O
early O
intervention O
programs O
) O
or O
research O
staff O
without O
formal O
mental O
health O
training O
( O
autism O
clinic O
) O
. O
[]

The O
techniques O
are O
described O
. O
[]

All O
participants O
had O
been O
thoroughly O
assessed O
for O
ASD O
and O
also O
had O
DNA O
testing O
for O
the O
diagnosis O
of O
FXS O
. O
[]

METHODS O
Primiparous O
women O
( O
n O
= O
167 O
) O
were O
randomly O
assigned O
to O
1 O
of O
3 O
groups O
: O
an O
educational O
book O
group O
, O
a O
noneducational O
book O
group O
, O
or O
a O
no-book O
group O
. O
[]

If O
so O
administered O
it O
would O
not O
increase O
bodily O
sodium O
load O
and O
unlike O
isotonic O
crystalloid O
solution O
it O
dose O
not O
cause O
accumulation O
of O
water O
in O
the O
body O
on O
equipollent O
basis O
. O
[]

Each O
group O
was O
offered O
an O
instructor-led O
after-school O
program O
every O
school O
day O
for O
approximately O
8 O
months O
. O
[]

A O
second O
objective O
is O
to O
determine O
which O
subgroups O
within O
the O
autism O
spectrum O
profit O
most O
from O
the O
intervention O
. O
[]

Cognitive O
behavioral O
therapy O
for O
anxiety B-outcome ['Life-Impact']
in O
children O
with O
autism O
spectrum O
disorders O
: O
a O
randomized O
, O
controlled O
trial O
. O
['Life-Impact']

There O
were O
no O
significant O
differences O
between O
the O
three O
groups O
with O
respect O
to O
requirements O
for O
supplemental B-outcome ['Resource-use']
pain I-outcome ['Resource-use']
medications I-outcome ['Resource-use']
in O
the O
recovery O
room O
, O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
vomiting I-outcome ['Physiological-Clinical']
, O
or O
length O
of O
time O
spent O
in O
the O
recovery O
room O
. O
['Resource-use', 'Physiological-Clinical']

CONCLUSIONS O
Although O
MCE O
is O
specific O
, O
it O
has O
limited O
sensitivity O
for O
detection O
of O
moderate B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
severe I-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
defects I-outcome ['Physiological-Clinical']
, O
and O
it O
underestimates O
the O
extent O
of O
SPECT B-outcome ['Physiological-Clinical']
defects I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Dropout O
from O
the O
trial O
and O
compliance O
( O
consumption O
of O
?85 O
% O
of O
the O
prescribed O
treatment O
packets O
) O
are O
the O
main O
outcome O
measures O
reported O
. O
[]

Simultaneous B-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
from O
systemic O
haemodynamics O
, O
laser O
interferometry O
of O
ocular O
fundus O
pulsations O
, O
systolic O
time O
intervals O
from O
mechanocardiography O
, O
a/b O
ratio O
from O
oxymetric O
fingerplethysmography O
and O
Doppler O
sonography O
of O
the O
radial O
artery O
were O
used O
to O
describe O
the O
haemodynamic O
effects O
of O
cumulative O
, O
stepwise O
increasing O
intravenous O
doses O
of O
phenylephrine O
, O
isoprenaline O
, O
sodium O
nitroprusside O
and O
of O
placebo O
. O
['Physiological-Clinical']

Estradiol B-outcome ['Physiological-Clinical']
, O
prolactin B-outcome ['Physiological-Clinical']
and O
cortisol B-outcome ['Physiological-Clinical']
, O
and O
a O
single O
measure O
of O
IL-6 B-outcome ['Physiological-Clinical']
were O
assayed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Side O
effects O
were O
few O
and O
under O
tocainide O
only O
2 O
pts O
. O
[]

All O
patients O
were O
assessable O
for O
survival B-outcome ['Mortality']
; O
163 O
were O
fully O
assessable O
for O
response O
and O
162 O
for O
toxicity B-outcome ['Adverse-effects']
. O
['Mortality', 'Adverse-effects']

Histological O
material O
from O
402 O
patients O
was O
collected O
and O
stained O
for O
the O
presence O
and O
pattern O
of O
Ki-67 O
staining O
. O
[]

METHODS O
Sixty-six O
patients O
with O
American O
Society O
of O
Anesthesiologists O
( O
ASA O
) O
physical O
status O
class O
I O
who O
required O
tracheal O
intubation O
for O
elective O
surgery O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O
[]

In O
conclusion O
, O
lamivudine O
is O
suitable O
for O
treatment O
of O
a O
wide O
range O
of O
patients O
with O
chronic O
hepatitis O
B O
, O
including O
those O
with O
pre-core O
mutant O
HBV O
infection O
. O
[]

METHODS O
Thirty-seven O
women O
with O
CC-resistant O
PCOS O
were O
randomly O
assigned O
to O
be O
pretreated O
with O
500 O
mg O
of O
metformin O
or O
placebo O
3 O
times O
per O
day O
for O
2 O
cycles O
, O
and O
100 O
mg O
of O
CC O
was O
given O
on O
days O
5 O
through O
9 O
of O
the O
second O
cycle O
in O
both O
groups O
. O
[]

Therefore O
, O
we O
prospectively O
studied O
the O
synthesis O
of O
IL-1 B-outcome ['Physiological-Clinical']
beta I-outcome ['Physiological-Clinical']
by O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
from O
42 O
patients O
with O
PBC O
entered O
into O
a O
randomized O
, O
double-blind O
, O
double-dummy O
controlled O
trial O
of O
colchicine O
and O
methotrexate O
. O
['Physiological-Clinical']

Household O
presence O
of O
children O
was O
associated O
with O
bednet O
use O
, O
but O
not O
household O
income O
or O
education O
, O
suggesting O
that O
distribution O
to O
priority O
groups O
may O
help O
overcome O
traditional O
barriers O
to O
adoption O
in O
some O
settings O
. O
[]

The O
school-age O
SCRPA O
curriculum O
( O
ages O
6-14 O
) O
consisted O
of O
eight O
90-minute O
classes O
for O
both O
child O
and O
parent O
( O
s O
) O
scheduled O
twice O
a O
week O
for O
4 O
weeks O
. O
[]

One O
limitation O
of O
the O
various O
versions O
of O
the O
LPFST O
is O
that O
they O
are O
carried O
out O
using O
a O
constant O
level O
of O
low-pass O
filtering O
( O
e.g O
. O
[]

After O
intravenous O
dosing O
, O
C O
( O
max O
) O
and O
T O
( O
max O
) O
were O
4.53 O
? O
[]

Secondary O
measures O
included O
change O
in O
biochemical O
parameters O
[ O
e.g O
. O
[]

In O
the O
placebo O
group O
FEV1 B-outcome ['Physiological-Clinical']
decreased O
by O
0.33 O
+/- O
0.20 O
L O
after O
6 O
wk O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

We O
used O
this O
situation O
to O
determine O
the O
antiplatelet B-outcome ['Physiological-Clinical']
efficacy O
of O
L-arginine O
and O
S-nitrosoglutathione O
( O
GSNO O
) O
, O
a O
physiological O
nitric O
oxide O
donor O
with O
possible O
platelet O
specificity O
. O
['Physiological-Clinical']

Swine O
influenza O
( O
SI O
) O
is O
a O
disease O
of O
significance O
for O
the O
swine O
industry O
, O
and O
vaccination O
is O
often O
recommended O
as O
a O
way O
to O
reduce O
its O
impact O
on O
production O
. O
[]

METHOD O
This O
study O
was O
a O
randomized O
controlled O
trial O
. O
[]

The O
primary O
objective O
is O
to O
compare O
the O
anterior O
approach O
with O
the O
conventional O
liver O
resection O
technique O
with O
regard O
to O
intraoperative O
haematogenous O
tumor O
cell O
dissemination O
. O
[]

Logistic B-outcome ['Life-Impact']
regression O
analyses O
were O
performed O
on O
baseline O
and O
nine-month O
follow-up O
data O
. O
['Life-Impact']

Patients O
who O
viewed O
the O
tape O
that O
portrayed O
the O
recovery O
period O
as O
consisting O
of O
ups O
and O
downs O
also O
reported O
significantly O
more O
frequent O
moderate B-outcome ['Life-Impact']
exercise I-outcome ['Life-Impact']
at O
1 O
month O
and O
more O
frequent O
['Life-Impact']

At O
20 O
months O
of O
age O
, O
all O
children O
but O
one O
had O
detectable O
antibodies O
to O
all O
three O
poliovirus O
types O
. O
[]

After O
an O
initial O
baseline O
, O
mothers O
were O
taught O
to O
implement O
RIT O
techniques O
with O
their O
child O
twice O
a O
week O
for O
10 O
weeks O
in O
a O
clinic O
setting O
. O
[]

In O
every O
child O
, O
a O
double-blind O
crossover O
challenge O
was O
conducted O
involving O
a O
control O
diet O
containing O
no O
cow O
's O
milk O
and O
a O
diet O
containing O
cow O
's O
milk O
. O
[]

schedule O
( O
60 O
Gy O
in O
2-Gy O
q.d O
. O
[]

The O
high O
risk O
of O
complications O
associated O
with O
estrogens O
and O
radiotherapy O
has O
to O
be O
taken O
into O
consideration O
in O
the O
selection O
of O
treatment O
. O
[]

Secondary O
end O
points O
were O
early B-outcome ['Mortality']
deaths I-outcome ['Mortality']
, O
blood B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
at O
day O
+120 O
, O
and O
survival B-outcome ['Mortality']
. O
['Mortality', 'Physiological-Clinical', 'Mortality']

Patients O
were O
pretreated O
with O
a O
median O
of O
eight O
cycles O
of O
cytotoxic O
chemotherapy O
, O
while O
18 O
patients O
had O
undergone O
extended O
field O
irradiation O
. O
[]

A O
double-blind O
randomly O
controlled O
trial O
of O
one O
particular O
laxative O
, O
Senokot O
, O
used O
in O
moderate O
dosage O
, O
was O
carried O
out O
on O
a O
group O
of O
40 O
children O
with O
severe O
and O
persistent O
soiling O
and O
often O
with O
a O
history O
of O
faecal O
retention O
. O
[]

At O
baseline O
, O
most O
participants O
had O
some O
knowledge O
of O
CRC B-outcome ['Resource-use']
screening I-outcome ['Resource-use']
and O
GERA O
, O
viewed O
CRC O
screening O
favorably O
, O
and O
reported O
that O
they O
had O
decided O
to O
do O
screening O
. O
['Resource-use']

Response O
to O
treatment B-outcome ['Resource-use']
was O
assessed O
by O
periodic B-outcome ['Physiological-Clinical']
mite I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
and O
skin B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
scored I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
and O
fecal B-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
against I-outcome ['Physiological-Clinical']
SsWC I-outcome ['Physiological-Clinical']
, O
LPS B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Excluding O
37 O
% O
of O
the O
treated O
patients O
and O
29 O
% O
of O
the O
placebo O
data O
from O
the O
analysis O
, O
there O
appeared O
to O
be O
statistically O
significant O
improvement O
in O
the O
treated O
patients O
compared O
to O
the O
control O
patients O
at O
1 O
year O
with O
a O
P O
value O
of O
.001 O
( O
repeated O
measures O
P O
value O
= O
.01 O
) O
. O
[]

The O
effect O
of O
the O
PostureJac O
on O
deep B-outcome ['Physiological-Clinical']
cervical I-outcome ['Physiological-Clinical']
flexor I-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
: O
implications O
in O
the O
management O
of O
cervicogenic B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
and O
mechanical B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mean O
VPA B-outcome ['Physiological-Clinical']
trough O
blood B-outcome ['Physiological-Clinical']
levels O
were O
75.5 O
mcg/mL O
at O
week O
4 O
and O
77.8 O
mcg/mL O
at O
week O
8 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

administration O
of O
each O
of O
the O
FVIII O
preparations O
. O
[]

[ O
Treatment O
of O
hyperhomocysteinemia O
and O
endothelial O
dysfunction O
in O
renal-transplant O
recipients O
with O
vitamin O
B O
] O
. O
[]

Drug O
effects O
were O
evaluated O
on O
children O
's O
attention B-outcome ['Life-Impact']
during I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
game I-outcome ['Life-Impact']
, O
as O
indicated O
by O
their O
on-task O
behavior O
on O
the O
field O
and O
their O
ability B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
answer I-outcome ['Life-Impact']
questions I-outcome ['Life-Impact']
about O
the O
status O
of O
the O
game O
at O
all O
times O
. O
['Life-Impact', 'Life-Impact']

METHODS O
In O
an O
echocardiographic O
substudy O
to O
the O
Metoprolol O
CR/XL O
Randomized O
Intervention O
Trial O
in O
Heart O
Failure O
( O
MERIT-HF O
) O
, O
66 O
patients O
were O
examined O
three O
times O
during O
a O
12-month O
period O
blinded O
to O
treatment O
group O
, O
assessing O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
dimensions I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
, O
and I-outcome ['Physiological-Clinical']
Doppler O
mitral B-outcome ['Physiological-Clinical']
inflow I-outcome ['Physiological-Clinical']
parameters O
, O
all O
measured O
in O
a O
core O
laboratory O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
At O
enrollment O
, O
minority O
patients O
had O
significantly O
more O
pain B-outcome ['Physiological-Clinical']
than O
their O
white O
counterparts O
( O
6.0 O
vs O
5.0 O
, O
P O
= O
0.05 O
) O
. O
['Physiological-Clinical']

Event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
after O
1 O
year O
was O
higher O
in O
the O
bypass O
group O
( O
71.4 O
% O
vs. O
52.3 O
% O
; O
P O
= O
0.02 O
) O
due O
to O
a O
lower O
target O
lesion O
revascularization O
rate O
. O
['Mortality']

Expression O
of O
HMGB1 O
, O
RAGE O
, O
and O
pAkt O
were O
lower O
in O
CCI-induced O
rats O
treated O
with O
LV/hIL-10 O
than O
in O
those O
treated O
with O
LV/control O
( O
vector O
) O
or O
saline O
( O
NS O
) O
. O
[]

One O
hour O
after O
drug O
intake O
, O
patients O
underwent O
an O
ergometrine O
test O
with O
increasing O
doses O
of O
Methergin O
( O
ergometrine O
) O
( O
0.05 O
, O
0.10 O
, O
0.20 O
, O
and O
0.40 O
mg O
every O
5 O
min O
) O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
acid-base I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
were O
not O
affected O
by O
dietary O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Similarly O
, O
levels O
of O
neutrophils O
significantly O
decreased O
from O
35?6 O
% O
for O
the O
placebo O
group O
to O
11?0 O
% O
for O
the O
RG-CMH O
group O
. O
[]

A O
comparison O
of O
acupuncture O
with O
advice O
and O
exercises O
on O
the O
symptomatic B-outcome ['Physiological-Clinical']
treatment I-outcome ['Physiological-Clinical']
of O
osteoarthritis O
of O
the O
hip O
-- O
a O
randomised O
controlled O
trial O
. O
['Physiological-Clinical']

A O
significant O
increase O
in O
aortic B-outcome ['Physiological-Clinical']
PWV I-outcome ['Physiological-Clinical']
, O
a O
marker O
of O
aortic B-outcome ['Physiological-Clinical']
stiffness I-outcome ['Physiological-Clinical']
, O
was O
noted O
after O
patients O
switched O
from O
high-flux O
to O
low-flux O
polyamide O
membranes O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
A O
variety O
of O
different O
endoscopic O
resection O
techniques O
for O
early O
stage O
cancer O
of O
the O
upper O
GI O
tract O
have O
been O
described O
that O
are O
more O
effective O
than O
strip O
biopsy O
. O
[]

Neither O
total O
deaths B-outcome ['Mortality']
nor O
hospitalizations B-outcome ['Resource-use']
for O
any O
reason O
were O
significantly O
reduced O
by O
spironolactone O
. O
['Mortality', 'Resource-use']

We O
compared O
three O
practice O
conditions O
, O
one O
with O
reading O
and O
two O
with O
spelling O
, O
in O
order O
to O
test O
whether O
computer-based O
reading O
and O
spelling O
practice O
has O
an O
influence O
on O
the O
development O
of O
reading O
and O
spelling O
ability O
in O
children O
with O
LD O
. O
[]

Outcome O
was O
assessed O
at O
3 O
and O
6 O
months O
postinjury O
using O
the O
extended O
Glasgow O
Outcome O
Scale O
; O
standardized O
assessment O
was O
facilitated O
by O
the O
use O
of O
a O
structured O
interview O
. O
[]

There O
were O
no O
differences O
in O
the O
degree O
of O
dysphagia B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
, O
number O
of O
endoscopic B-outcome ['Resource-use']
procedures I-outcome ['Resource-use']
or O
survival B-outcome ['Mortality']
times I-outcome ['Mortality']
. O
['Physiological-Clinical', 'Resource-use', 'Mortality']

In O
the O
control O
group O
no O
treatment O
was O
performed O
. O
[]

Liver-only O
disease O
( O
47 O
% O
vs. O
25 O
% O
; O
P=0.0012 O
) O
and O
absence O
of O
previous O
weight O
loss O
( O
38 O
% O
vs. O
20 O
% O
; O
P=0.0189 O
) O
were O
significantly O
associated O
with O
a O
higher O
ORR O
on O
the O
multivariate O
analysis O
. O
[]

The O
response O
rate O
was O
highest O
in O
the O
no O
incentive O
group O
( O
69.3 O
% O
) O
and O
lowest O
in O
the O
one O
plus O
one O
lottery O
ticket O
group O
( O
62.0 O
% O
) O
. O
[]

To O
assess O
the O
effect O
of O
Entrox O
coating O
on O
the O
short-term O
bioavailability O
of O
ALA O
administered O
in O
the O
form O
of O
ALA-rich O
Perilla O
seed O
oil O
, O
12 O
healthy O
subjects O
( O
6 O
males O
and O
6 O
females O
) O
received O
in O
a O
random O
order O
Entrox-coated O
and O
non-coated O
ALA O
formulations O
, O
each O
as O
a O
single O
6g O
dose O
separated O
by O
a O
3-week O
washout O
period O
. O
[]

It O
is O
not O
, O
however O
, O
clear O
whether O
the O
treatment O
should O
be O
started O
with O
a O
high O
or O
a O
low O
dose O
of O
the O
inhaled O
steroid O
. O
[]

The O
results O
of O
our O
current O
study O
validate O
the O
use O
of O
low-frequency O
rTMS O
as O
a O
modulatory O
tool O
that O
altered O
the O
disrupted O
ratio O
of O
cortical O
excitation O
to O
inhibition O
in O
autism O
. O
[]

Teacher-report O
data O
also O
confirmed O
that O
children O
receiving O
the O
intervention O
made O
significant O
improvements O
in O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
from O
pre- O
to O
post-treatment O
. O
['Life-Impact']

After O
completion O
of O
the O
standard O
back O
centre O
treatment O
patients O
are O
randomized O
into O
one O
of O
three O
groups O
: O
A O
) O
Nordic O
Walking O
twice O
a O
week O
for O
eight O
weeks O
under O
supervision O
of O
a O
specially O
trained O
instructor O
; O
B O
) O
Unsupervised O
Nordic O
Walking O
for O
eight O
weeks O
after O
one O
training O
session O
with O
an O
instructor O
; O
C O
) O
A O
one O
hour O
motivational O
talk O
including O
advice O
to O
stay O
active O
. O
[]

The O
use O
of O
sedation O
of O
moderate O
depth O
renders O
cardioversion O
by O
either O
approach O
acceptable O
. O
[]

No O
significant O
difference O
was O
recorded O
between O
the O
sucrose O
and O
sterile O
water O
groups O
in O
the O
magnitude O
or O
latency O
of O
the O
spinal O
nociceptive O
reflex O
withdrawal O
recorded O
from O
the O
biceps O
femoris O
of O
the O
stimulated O
leg O
. O
[]

Three O
patients O
on O
placebo O
also O
complained O
of O
important O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

High-dose O
specific O
pertussis O
immunoglobulin O
with O
a O
high O
antitoxin O
concentration O
has O
a O
beneficial O
effect O
in O
the O
treatment O
of O
whooping O
cough O
. O
[]

We O
evaluated O
the O
impact O
of O
supplementing O
a O
comprehensive O
intervention O
with O
a O
curriculum O
targeting O
socially O
synchronous O
behavior O
on O
social O
outcomes O
of O
toddlers O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
. O
[]

Erythron B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
, O
an O
index O
of O
RBC O
production O
, O
increased O
in O
the O
one O
responder O
studied O
but O
not O
in O
the O
two O
nonresponders O
. O
['Physiological-Clinical']

For O
the O
subsequent O
operative O
procedure O
, O
the O
median O
score O
was O
1 O
for O
1-QST O
and O
2 O
for O
the O
retrobulbar O
patients O
. O
[]

In O
addition O
, O
trough O
blood O
samples O
were O
collected O
on O
days O
4 O
, O
5 O
, O
10 O
, O
and O
11 O
prior O
to O
the O
morning O
dose O
. O
[]

Sixty O
women O
with O
climacteric O
complaints O
who O
had O
not O
menstruated O
for O
at O
least O
1 O
year O
were O
randomly O
allocated O
to O
receive O
one O
of O
four O
hormonal O
replacement O
regimens O
. O
[]

Expectant B-outcome ['Life-Impact']
management I-outcome ['Life-Impact']
for O
a O
period O
of O
6 O
months O
therefore O
appears O
justified O
in O
these O
couples O
. O
['Life-Impact']

MATERIALS O
AND O
METHODS O
A O
total O
of O
100 O
consecutive O
patients O
with O
sterile O
urine O
cultures O
underwent O
transrectal O
ultrasound O
guided O
prostate O
biopsy O
. O
[]

6.0 O
years O
, O
were O
randomized O
either O
to O
six O
weeks O
of O
aerobic O
training O
, O
three O
times O
a O
week O
, O
at O
60-80 O
% O
of O
maximal O
heart O
rate O
( O
training O
group O
, O
Ex O
, O
n O
= O
32 O
) O
or O
to O
a O
control O
group O
( O
n O
= O
32 O
) O
. O
[]

Linear O
and O
angular O
displacements O
of O
the O
major O
fragments O
and O
implant B-outcome ['Physiological-Clinical']
migration I-outcome ['Physiological-Clinical']
into I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
femoral I-outcome ['Physiological-Clinical']
head I-outcome ['Physiological-Clinical']
during O
healing O
were O
assessed O
. O
['Physiological-Clinical']

There O
were O
452 O
women O
( O
904 O
knees O
) O
and O
sixty-eight O
men O
( O
136 O
knees O
) O
with O
a O
mean O
age O
of O
sixty-eight O
years O
( O
range O
, O
forty-nine O
to O
eighty-eight O
years O
) O
at O
the O
time O
of O
the O
index O
arthroplasty O
. O
[]

Six O
months O
later O
, O
the O
children O
in O
group O
A O
were O
re-treated O
with O
the O
same O
dose O
of O
praziquantel O
, O
while O
the O
children O
in O
group O
B O
were O
given O
placebos O
. O
[]

Between O
1 O
year O
and O
7.5 O
years O
, O
three O
breasts O
with O
smooth O
and O
textured B-outcome ['Life-Impact']
implants I-outcome ['Life-Impact']
contracted I-outcome ['Life-Impact']
and O
one O
with O
a O
textured O
implant O
softened.The O
patients O
reported O
on O
a O
Visual O
Analogue O
Scale O
( O
1 O
to O
10 O
) O
the O
impact O
of O
the O
augmentation O
on O
their O
quality O
of O
life O
to O
be O
9 O
+/- O
1 O
. O
['Life-Impact']

Because O
of O
the O
longer O
half-life O
of O
6.4 O
h O
after O
oral O
administration O
in O
contrast O
to O
2.4 O
h O
after O
i.v O
. O
[]

Patients O
self O
management O
skills O
are O
affected O
by O
the O
patients O
' O
knowledge O
, O
activities O
and O
attitude O
to O
pain O
management O
. O
[]

After O
7 O
days O
' O
treatment O
( O
400 O
mg O
b.i.d O
. O
) O
, O
[]

CONCLUSION O
Distinct O
improvement B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
patients O
following O
nasal O
operations O
underlines O
the O
efficacy O
of O
both O
medications O
. O
['Physiological-Clinical']

Cost-effectiveness O
of O
clopidogrel O
in O
acute O
coronary O
syndromes O
in O
Canada O
: O
a O
long-term O
analysis O
based O
on O
the O
CURE O
trial O
. O
[]

Effects O
also O
generalized O
to O
the O
classroom O
, O
where O
participants O
in O
the O
treatment O
group O
initiated O
more O
gestures O
and O
spent O
less O
time O
unengaged O
. O
[]

The O
2-year O
cumulative O
rate O
of O
brain B-outcome ['Physiological-Clinical']
metastasis I-outcome ['Physiological-Clinical']
as O
an O
isolated O
first O
site O
of O
relapse B-outcome ['Life-Impact']
was O
45 O
% O
in O
the O
control O
group O
and O
19 O
% O
in O
the O
treatment O
group O
( O
P O
< O
10 O
( O
-6 O
) O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Further O
validation O
of O
the O
alcohol O
dependence O
scale O
as O
an O
index O
of O
severity O
. O
[]

A O
hot B-outcome ['Physiological-Clinical']
flash I-outcome ['Physiological-Clinical']
score O
was O
calculated O
at O
each O
time O
point O
. O
['Physiological-Clinical']

with O
those O
of O
celecoxib O
200 O
mg O
o.d O
. O
[]

Forty-one O
consecutive O
patients O
with O
supratentorial O
primary O
brain O
tumors O
( O
38 O
Grade O
III O
and O
IV O
astrocytomas O
, O
one O
giant-cell O
astrocytoma O
, O
and O
two O
cases O
with O
insufficient O
tissue O
for O
diagnosis O
) O
were O
randomly O
allocated O
within O
2 O
weeks O
of O
surgery O
to O
one O
of O
three O
therapeutic O
groups O
. O
[]

Acidform O
without O
N-9 O
was O
well O
tolerated O
by O
volunteers O
, O
but O
it O
was O
unable O
to O
protect O
the O
cervix O
, O
vagina O
, O
and O
vulva O
from O
the O
N-9 O
effects O
. O
[]

Our O
results O
encourage O
the O
usage O
of O
shorter O
induction O
regimens O
, O
which O
produce O
better O
compliance O
with O
this O
therapy O
. O
[]

SAM O
participate O
in O
the O
development O
of O
diabetic O
macroangiopathy O
and O
microangiopathy O
. O
[]

How O
well O
do O
blood B-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
predict O
dietary O
folate O
intakes O
in O
a O
sample O
of O
Canadian O
lactating O
women O
exposed O
to O
high O
levels O
of O
folate O
? O
['Physiological-Clinical']

Sera O
obtained O
from O
439 O
children O
at O
two O
, O
four O
, O
and O
six O
months O
of O
age O
and O
from O
85 O
children O
at O
18 O
and O
20 O
months O
of O
age O
were O
examined O
for O
neutralizing B-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Efficacy O
was O
measured O
from O
standardized O
digital O
images O
of O
the O
maxillary O
facial O
tooth O
surfaces O
, O
while O
safety O
was O
evaluated O
from O
oral O
examination O
and O
interview O
. O
[]

The O
substrate O
for O
contour O
integration O
may O
be O
based O
on O
contextual O
interactions O
and O
intrinsic O
horizontal O
connections O
seen O
in O
primary O
visual O
cortex O
( O
V1 O
) O
. O
[]

The O
A-V O
Impulse O
System O
appears O
to O
be O
a O
safe O
and O
effective O
method O
of O
reducing O
the O
incidence O
of O
proximal B-outcome ['Physiological-Clinical']
deep-vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
, O
and O
of O
postoperative B-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
a O
prospective O
, O
parallel-group O
, O
randomized O
unblinded O
clinical O
trial O
, O
we O
compared O
cementless O
tibial O
components O
in O
patients O
aged O
70 O
years O
and O
younger O
with O
osteoarthritis O
. O
[]

Changes O
in O
ovarian B-outcome ['Physiological-Clinical']
reserve I-outcome ['Physiological-Clinical']
were O
investigated O
by O
measuring O
the O
levels O
of O
anti-Mullerian B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AMH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
basal B-outcome ['Physiological-Clinical']
follicle-stimulating I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FSH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
before O
surgery O
and O
at O
3 O
, O
6 O
and O
12 O
months O
from O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
differences O
emerged O
between O
the O
TMI O
and O
the O
IMZ O
group O
. O
[]

Sub-Tenon O
's O
capsule O
anesthesia O
for O
anterior O
segment O
surgery O
avoids O
the O
risks O
of O
retrobulbar O
and O
peribulbar O
injections O
. O
[]

Fasting B-outcome ['Physiological-Clinical']
and O
post-prandial B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
glycosylated B-outcome ['Physiological-Clinical']
haemoglobin I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
appeared O
to O
be O
unaffected O
by O
either O
agent O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Whether O
the O
efficacy O
of O
bismuth O
therapy O
in O
reducing O
the O
rate O
of O
recurrence O
of O
duodenal O
ulcer O
is O
due O
to O
its O
antimicrobial O
effects O
on O
H. O
pylori O
or O
to O
a O
direct O
protective O
action O
on O
the O
mucosa O
is O
still O
a O
matter O
of O
debate O
. O
[]

About O
30 O
% O
of O
patients O
in O
each O
active O
treatment O
group O
took O
rescue B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
during O
the O
study O
, O
compared O
to O
78 O
% O
on O
placebo O
. O
['Resource-use']

RESULTS O
There O
were O
2,882 O
eligible O
patients O
enrolled O
. O
[]

The O
Pakistani O
women O
had O
a O
lower O
intake O
of O
calcium O
than O
the O
Norwegians O
( O
median O
793 O
vs O
1134 O
mg/day O
, O
P O
< O
0.001 O
) O
. O
[]

Blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
levels O
were O
elevated O
above O
placebo O
during O
carbohydrate O
and O
carbohydrate-protein O
supplementation O
, O
but O
no O
differences O
were O
found O
between O
the O
carbohydrate O
and O
carbohydrate-protein O
treatments O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Exploring O
effects O
of O
different O
treadmill O
interventions O
on O
walking B-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
and O
gait B-outcome ['Life-Impact']
patterns I-outcome ['Life-Impact']
in O
infants O
with O
Down O
syndrome O
. O
['Life-Impact', 'Life-Impact']

We O
reviewed O
neoadjuvant O
biopsy O
tissue O
and O
gastric O
cancer O
tissue O
delivered O
by O
operation O
in O
these O
cases O
. O
[]

In O
the O
placebo O
group O
, O
none O
of O
the O
patients O
showed O
undetectable B-outcome ['Physiological-Clinical']
HBV I-outcome ['Physiological-Clinical']
DNA B-outcome ['Physiological-Clinical']
, O
HBeAg/Anti-HBe B-outcome ['Physiological-Clinical']
seroconversion B-outcome ['Physiological-Clinical']
or O
HBeAg B-outcome ['Physiological-Clinical']
disappearance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Although O
SILS O
is O
technically O
even O
more O
challenging O
than O
conventional O
laparoscopy O
, O
published O
data O
of O
first O
clinical O
series O
seem O
to O
demonstrate O
the O
feasibility O
of O
these O
approaches O
. O
[]

Individuals O
whose O
BP B-outcome ['Physiological-Clinical']
was O
controlled O
continued O
on O
the O
protocol O
for O
six O
months O
. O
['Physiological-Clinical']

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

The O
effects O
of O
SQ29,852 O
( O
n O
= O
24 O
) O
, O
a O
new O
angiotensin O
converting O
enzyme O
inhibitor O
, O
and O
atenolol O
( O
n O
= O
22 O
) O
, O
monotherapies O
were O
compared O
in O
46 O
patients O
with O
mild O
to O
moderate O
essential O
hypertension O
. O
[]

Peptide O
infusions O
were O
started O
after O
a O
1-microgram/kg O
bolus O
at O
0900 O
h O
and O
infused O
( O
1 O
microgram/kg.h O
) O
until O
0600 O
h O
the O
next O
morning O
. O
[]

After O
9.5 O
? O
[]

Vascular O
pedicle O
width O
in O
acute O
lung O
injury O
: O
correlation O
with O
intravascular O
pressures O
and O
ability O
to O
discriminate O
fluid O
status O
. O
[]

Both O
arms O
exhibited O
minimal O
toxicity B-outcome ['Adverse-effects']
( O
grade O
3/4 O
neutropenia B-outcome ['Physiological-Clinical']
< O
20 O
% O
, O
leukopenia B-outcome ['Physiological-Clinical']
< O
9 O
% O
, O
and O
other O
toxicities B-outcome ['Adverse-effects']
< O
5 O
% O
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Alopecia B-outcome ['Physiological-Clinical']
( O
overall O
, O
66 O
% O
versus O
20 O
% O
; O
pronounced O
, O
54 O
% O
versus O
7 O
% O
) O
, O
nausea B-outcome ['Physiological-Clinical']
( O
53 O
% O
versus O
37 O
% O
) O
, O
vomiting B-outcome ['Physiological-Clinical']
( O
31 O
% O
versus O
19 O
% O
) O
and O
neutropenia B-outcome ['Physiological-Clinical']
( O
10 O
% O
versus O
4 O
% O
) O
were O
more O
often O
associated O
with O
doxorubicin O
than O
PLD O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

From O
March O
1998 O
to O
June O
2000 O
, O
a O
total O
of O
28 O
women O
underwent O
36 O
completed O
treatment O
cycles O
, O
randomized O
sequentially O
in O
one O
of O
two O
groups O
. O
[]

Circulating O
blood O
B O
cells O
in O
multiple O
myeloma O
: O
analysis O
and O
relationship O
to O
circulating O
clonal O
cells O
and O
clinical O
parameters O
in O
a O
cohort O
of O
patients O
entered O
on O
the O
Eastern O
Cooperative O
Oncology O
Group O
phase O
III O
E9486 O
clinical O
trial O
. O
[]

Development O
of O
an O
adaptive O
low-pass O
filtered O
speech O
test O
for O
the O
identification O
of O
auditory B-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
disorders I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Radial O
artery O
occlusion O
( O
RAO O
) O
can O
result O
from O
transradial O
catheterization O
. O
[]

Parenting B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
in O
the O
infant O
aphakia O
treatment O
study O
. O
['Life-Impact']

Automatic O
detection O
of O
red O
lesions O
in O
digital O
color O
fundus O
photographs O
. O
[]

Seventy-two O
patients O
with O
eczema O
were O
randomly O
allotted O
to O
one O
of O
two O
treatment O
groups O
: O
A O
, O
those O
receiving O
dermatological O
treatment O
only O
, O
and O
B O
, O
those O
receiving O
the O
same O
dermatological O
treatment O
plus O
psychiatric O
treatment O
, O
limited O
where O
possible O
to O
four O
months O
. O
[]

This O
was O
a O
12-month O
randomized O
, O
prospective O
, O
multicenter O
, O
double-masked O
, O
placebo-controlled O
, O
Food O
and O
Drug O
Administration O
approved O
clinical O
trial O
designed O
to O
compare O
rheopheresis O
treatment O
with O
placebo-control O
treatment O
. O
[]

The O
primary O
parameter O
was O
the O
diagnostic B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of O
the O
6 O
min O
film O
, O
assessed O
in O
a O
blinded O
fashion O
, O
by O
consensus O
, O
by O
four O
radiologists O
. O
['Life-Impact']

The O
two O
lower O
doses O
of O
lornoxicam O
and O
aspirin O
all O
showed O
apparent O
degrees O
of O
efficacy O
intermediate O
between O
that O
of O
placebo O
and O
lornoxicam O
8 O
mg O
, O
although O
the O
trial O
proved O
to O
have O
inadequate O
power O
to O
show O
significant O
differences O
between O
these O
three O
treatments O
. O
[]

Preplanned O
subgroup O
analyses O
showed O
significantly O
longer O
survival B-outcome ['Mortality']
in O
the O
gefitinib O
group O
than O
the O
placebo O
group O
for O
never-smokers O
( O
n=375 O
; O
0.67 O
[ O
0.49-0.92 O
] O
, O
p=0.012 O
; O
median O
survival B-outcome ['Mortality']
8.9 O
vs O
6.1 O
months O
) O
and O
patients O
of O
Asian O
origin O
( O
n=342 O
; O
0.66 O
[ O
0.48-0.91 O
] O
, O
p=0.01 O
; O
median O
survival B-outcome ['Mortality']
9.5 O
vs O
5.5 O
months O
) O
. O
['Mortality', 'Mortality', 'Mortality']

CONCLUSION O
Combined O
preoperative O
xeloda O
and O
radiotherapy O
for O
lower O
rectal O
cancer O
is O
able O
to O
significantly O
improve O
the O
operative O
resection O
, O
anal O
preservation O
and O
decrease O
the O
local O
recurrence O
rates O
. O
[]

Natural O
coral O
calcium O
BRG O
was O
utilised O
in O
33 O
patients O
. O
[]

A O
randomized O
clinical O
trial O
of O
treatment O
of O
clomiphene O
citrate-resistant O
anovulation O
with O
the O
use O
of O
oral O
contraceptive O
pill O
suppression O
and O
repeat O
clomiphene O
citrate O
treatment O
. O
[]

As O
parameters O
for O
the O
determination O
of O
the O
validity O
of O
fetal O
monitoring O
the O
reliability O
, O
positive O
( O
ppv O
) O
and O
negative O
predictive O
value O
( O
npv O
) O
, O
sensitivity O
and O
specificity O
were O
used O
. O
[]

One O
patient O
( O
group O
I O
) O
displayed O
a O
hematoma B-outcome ['Physiological-Clinical']
following O
inadvertent O
puncture O
of O
the O
CA O
. O
['Physiological-Clinical']

SESSION O
B O
An O
acupuncture O
needle O
( O
Hwato O
, O
& O
emptyv O
; O
0.30x30 O
mm O
) O
was O
inserted O
perpendicular O
into O
the O
Hegu O
point O
( O
LI O
4 O
) O
in O
the O
middle O
of O
the O
right O
dorsal O
thenar O
muscle O
. O
[]

Calf O
and O
thigh O
circumferences O
were O
measured O
in O
both O
groups O
at O
seven O
to O
ten O
days O
after O
operation O
. O
[]

No O
significant O
changes O
in O
diet B-outcome ['Life-Impact']
pattern I-outcome ['Life-Impact']
or O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
was O
observed O
. O
['Life-Impact', 'Physiological-Clinical']

The O
amount O
of O
fibrinolytic O
activity O
in O
the O
thyroid O
gland O
equals O
that O
of O
the O
prostate O
. O
[]

The O
total O
hip B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
as O
directly O
measured O
was O
compared O
with O
that O
obtained O
from O
the O
formula O
: O
Total O
hip B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
= O
0.48 O
x O
Neck B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
+ O
0.62 O
x O
Trochanteric B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
+ O
0.03 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Tromethamine O
buffer O
modifies O
the O
depressant B-outcome ['Resource-use']
effect O
of O
permissive O
hypercapnia O
on O
myocardial O
contractility O
in O
patients O
with O
acute O
respiratory O
distress O
syndrome O
. O
['Resource-use']

The O
hemostatic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
of O
platelets O
comprises O
two O
mechanisms O
: O
the O
shear-induced O
and O
the O
cyclooxygenase O
pathways O
. O
['Physiological-Clinical']

During O
the O
1-year O
follow-up O
period O
, O
three O
( O
15 O
% O
) O
patients O
in O
group O
2 O
and O
two O
( O
10 O
% O
) O
patients O
in O
group O
1 O
had O
clinical O
relapses B-outcome ['Physiological-Clinical']
; O
these O
rates O
were O
not O
significantly O
different O
. O
['Physiological-Clinical']

Participants O
were O
randomly O
assigned O
to O
either O
the O
80-mg O
valsartan O
( O
n O
= O
52 O
) O
or O
5-mg O
amlodipine O
( O
n O
= O
52 O
) O
group O
and O
were O
treated O
for O
eight O
months O
. O
[]

OBJECTIVE O
To O
study O
whether O
an O
intravenous O
infusion O
dose O
of O
omeprazole O
( O
80 O
mg O
+ O
8 O
mg/h O
) O
during O
24 O
h O
can O
be O
subsequently O
reduced O
with O
maintained O
effect O
. O
[]

RESULTS O
At O
day O
28 O
, O
in O
the O
group O
of O
subjects O
who O
received O
150 O
mg O
of O
VX-770 O
, O
the O
median O
change O
in O
the O
nasal B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
difference I-outcome ['Physiological-Clinical']
( O
in O
response O
to O
the O
administration O
of O
a O
chloride-free O
isoproterenol O
solution O
) O
from O
baseline O
was O
-3.5 O
mV O
( O
range O
, O
-8.3 O
to O
0.5 O
; O
P=0.02 O
for O
the O
within-subject O
comparison O
, O
P=0.13 O
vs. O
placebo O
) O
, O
and O
the O
median O
change O
in O
the O
level O
of O
sweat B-outcome ['Physiological-Clinical']
chloride I-outcome ['Physiological-Clinical']
was O
-59.5 O
mmol O
per O
liter O
( O
range O
, O
-66.0 O
to O
-19.0 O
; O
P=0.008 O
within-subject O
, O
P=0.02 O
vs. O
placebo O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Groups O
were O
divided O
according O
to O
whether O
they O
would O
receive O
the O
Ivanissevich O
technique O
( O
n O
= O
55 O
) O
, O
Tauber O
's O
technique O
( O
n O
= O
51 O
) O
or O
subinguinal O
sclerotherapy O
( O
n O
= O
49 O
) O
. O
[]

There O
seemed O
to O
be O
a O
sustained O
reduction O
in O
medication B-outcome ['Resource-use']
use I-outcome ['Resource-use']
at O
the O
1-yr O
follow-up O
. O
['Resource-use']

The O
same O
registration O
parameters O
were O
applied O
to O
the O
transmission O
images O
to O
create O
a O
TCT O
template O
. O
[]

RESULTS O
WBC O
count O
and O
serum O
interleukin O
( O
IL O
) O
-1? O
, O
IL-4 O
, O
IL-6 O
, O
IL-10 O
and O
interferon-? O
were O
significantly O
elevated O
24 O
h O
after O
burn O
, O
but O
no O
significant O
changes O
in O
any O
of O
these O
parameters O
were O
found O
with O
HBOT O
. O
[]

Two O
hundred O
one O
male O
and O
female O
subjects O
, O
aged O
20 O
to O
70 O
years O
, O
with O
elevated O
low-density O
lipoprotein O
cholesterol O
values O
( O
in O
the O
75th O
to O
95th O
percentiles O
) O
, O
participated O
in O
a O
randomized O
, O
controlled O
, O
double-blind O
study O
using O
a O
new O
form O
of O
niacin O
( O
Enduracin O
) O
, O
which O
employs O
a O
wax-matrix O
vehicle O
for O
sustained O
release O
. O
[]

The O
primary O
efficacy O
outcome O
was O
the O
change O
of O
the O
size O
of O
the O
thrombus B-outcome ['Physiological-Clinical']
assessed O
by O
repeated O
venograms O
between O
day O
0 O
and O
day O
10 O
. O
['Physiological-Clinical']

4.9 O
y O
completed O
the O
study O
. O
[]

RESULTS O
The O
cured B-outcome ['Physiological-Clinical']
rate O
of O
78.6 O
% O
in O
the O
treatment O
group O
was O
significantly O
higher O
than O
50.0 O
% O
in O
the O
control O
group O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

We O
did O
not O
find O
any O
significant O
differences O
in O
improvements O
between O
lamotrigine O
or O
placebo O
groups O
on O
the O
Autism O
Behavior O
Checklist O
, O
the O
Aberrant O
Behavior O
Checklist O
, O
the O
Vineland O
Adaptive O
Behavior O
scales O
, O
the O
PL-ADOS O
, O
or O
the O
CARS O
. O
[]

This O
study O
offers O
a O
paradigm O
for O
exploring O
the O
instructional O
advantage O
of O
enhanced O
participatory O
experience O
. O
[]

METHODS O
Patients O
( O
n O
= O
32 O
) O
were O
randomized O
to O
receive O
one O
of O
two O
treatment O
regimens O
: O
8 O
weeks O
of O
treatment O
with O
once-daily O
dosing O
for O
alternate O
weeks O
( O
R1 O
) O
and O
5 O
weeks O
of O
once-daily O
dosing O
with O
a O
1-week O
interval O
in O
the O
middle O
of O
the O
course O
( O
R2 O
) O
. O
[]

The O
effects O
of O
a O
specific O
warm-up O
have O
already O
been O
acknowledged O
in O
improving O
performance O
. O
[]

No O
significant O
difference O
in O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
occurred O
among O
groups O
after O
the O
first-line O
regimens O
: O
48 O
% O
in O
group O
A O
, O
44 O
% O
in O
group O
B O
and O
46 O
% O
in O
group O
C. O
Twenty-two O
out O
of O
the O
193 O
enrolled O
subjects O
( O
11 O
% O
) O
were O
not O
eradicated B-outcome ['Physiological-Clinical']
after O
the O
first-line O
therapy O
. O
['Adverse-effects', 'Physiological-Clinical']

The O
findings O
of O
this O
study O
suggest O
that O
sibutramine O
treatment O
promotes O
thermogenesis B-outcome ['Physiological-Clinical']
, O
thus O
facilitating O
weight O
loss B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
A O
better O
treatment O
modality O
is O
needed O
to O
control O
the O
pain B-outcome ['Physiological-Clinical']
of O
medial B-outcome ['Physiological-Clinical']
or O
lateral B-outcome ['Physiological-Clinical']
epicondylitis I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
tennis I-outcome ['Physiological-Clinical']
elbow I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Theophylline B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in O
saliva O
have O
been O
compared O
with O
those O
in O
serum O
in O
13 O
asthmatic O
patients O
after O
single O
and O
multiple O
oral O
dosage O
of O
a O
microcrystalline O
theophylline O
tablet O
( O
Nuelin O
) O
and O
a O
sustained-release O
preparation O
( O
Nuelin O
Retard O
) O
. O
['Physiological-Clinical']

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
for O
single O
and O
grade O
1+2 O
tumors B-outcome ['Physiological-Clinical']
tended O
to O
be O
longer O
in O
the O
THP O
group O
( O
P O
= O
0.09 O
, O
P O
= O
0.079 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

TEN O
was O
delivered O
via O
a O
needle O
catheter O
jejunostomy O
. O
[]

Recombinant O
human O
erythropoietin O
( O
rHuEPO O
) O
has O
been O
used O
safely O
and O
effectively O
to O
treat O
anemia O
in O
AIDS O
patients O
receiving O
zidovudine O
( O
AZT O
) O
and O
in O
patients O
with O
chronic O
renal O
failure O
. O
[]

SIGNIFICANCE O
These O
findings O
suggest O
that O
patients O
with O
major O
depression O
have O
altered B-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
local I-outcome ['Physiological-Clinical']
contextual I-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
are O
no O
controlled O
studies O
evaluating O
these O
interventions O
as O
adjuncts O
to O
facilitate O
completion O
of O
painful O
procedures O
in O
the O
pediatric O
emergency O
department O
( O
ED O
) O
. O
[]

RESULTS O
There O
was O
a O
notable O
reduction O
in O
intimal B-outcome ['Physiological-Clinical']
layer I-outcome ['Physiological-Clinical']
macrophages I-outcome ['Physiological-Clinical']
and O
subintimal B-outcome ['Physiological-Clinical']
macrophages I-outcome ['Physiological-Clinical']
and O
lymphocytes B-outcome ['Physiological-Clinical']
after O
treatment O
with O
IL-1Ra O
at O
150 O
mg/day O
( O
n=3 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
aging O
motor O
system O
as O
a O
model O
for O
plastic O
changes O
of O
GABA-mediated O
intracortical O
inhibition O
and O
their O
behavioral O
relevance O
. O
[]

Peak O
plasma B-outcome ['Physiological-Clinical']
nicotine I-outcome ['Physiological-Clinical']
levels O
varied O
three-fold O
and O
the O
areas O
under O
the O
curve O
( O
0-30min O
) O
varied O
seven-fold O
among O
the O
individual O
subjects O
. O
['Physiological-Clinical']

Mean O
postoperative B-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
were O
10.3 O
and O
8.3 O
, O
respectively O
, O
and O
differed O
significantly O
( O
p O
= O
.008 O
) O
. O
['Physiological-Clinical']

Efficacy O
measures O
were O
tumour B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
at O
weeks O
19 O
and O
52 O
and O
measures O
of O
patients O
' O
acceptability B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

The O
current O
study O
asked O
: O
does O
regular O
antacid O
therapy O
have O
a O
favorable O
influence O
on O
the O
natural O
history O
of O
symptomatic B-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
esophagitis I-outcome ['Physiological-Clinical']
, O
ie O
, O
does O
therapy O
heal O
or O
otherwise O
change O
esophagitis O
so O
that O
painful O
episodes O
are O
either O
less O
frequent O
, O
less O
severe O
, O
or O
both O
? O
['Physiological-Clinical']

Proportion O
of O
titers O
of O
more O
than O
100 O
mIU/ml O
for O
four O
kinds O
HepB O
were O
79.0 O
% O
, O
85.7 O
% O
, O
88.2 O
% O
and O
84.6 O
% O
respectively O
, O
and O
there O
was O
no O
significant O
difference O
( O
chi2 O
= O
0.75 O
, O
0.05 O
) O
. O
[]

Representative O
samples O
of O
fractured O
specimens O
were O
observed O
by O
SEM O
( O
scanning O
electron O
microscopy O
) O
. O
[]

Patients O
with O
premature B-outcome ['Physiological-Clinical']
LH I-outcome ['Physiological-Clinical']
surge I-outcome ['Physiological-Clinical']
had O
a O
statistically O
significantly O
lower O
pregnancy B-outcome ['Physiological-Clinical']
rate O
( O
21.4 O
% O
[ O
9/42 O
] O
vs. O
0 O
[ O
0/18 O
] O
) O
relative O
to O
their O
unaffected O
counterparts O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
changes O
were O
found O
in O
SDS B-outcome ['Physiological-Clinical']
or O
PFS O
values O
. O
['Physiological-Clinical']

The O
onset B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
of O
vecuronium O
after O
a O
single O
bolus O
dose O
of O
0.08 O
mg/kg O
, O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
to O
10 O
% O
single B-outcome ['Physiological-Clinical']
twitch I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
, O
duration O
of O
continuous O
infusion O
of O
0.4-0.5 O
micrograms/kg/min O
of O
vecuronium O
started O
at O
10 O
% O
single B-outcome ['Physiological-Clinical']
twitch I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
, O
and O
the O
effects O
of O
0.1 O
mg/kg O
betamethasone O
administration O
10 O
min O
after O
continuous O
infusion O
were O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Recent O
analyses O
of O
circulating O
blood O
B O
cells O
in O
myeloma O
have O
generated O
controversy O
concerning O
the O
exact O
levels O
of O
these O
cells O
and O
whether O
they O
may O
represent O
circulating O
clonal O
tumor O
B O
cells O
. O
[]

Radial B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
ulnar I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flows I-outcome ['Physiological-Clinical']
were O
assessed O
using O
Doppler B-outcome ['Resource-use']
probe I-outcome ['Resource-use']
and O
pulse B-outcome ['Resource-use']
oximetry I-outcome ['Resource-use']
before O
, O
just O
after O
, O
and O
24 O
h O
after O
decannulation B-outcome ['Resource-use']
by O
the O
same O
investigator O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use', 'Resource-use']

Multimodal O
therapy O
for O
the O
management O
of O
primary O
, O
nonmetastatic O
Ewing O
's O
sarcoma O
of O
bone O
: O
an O
Intergroup O
Study O
. O
[]

Preliminary O
evidence O
suggests O
Chinese O
herbal O
medicine O
( O
CHM O
) O
may O
contribute O
to O
the O
treatment O
of O
endometriosis O
. O
[]

Both O
MR O
and O
RCD O
programs O
were O
effective O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
utility O
of O
a O
surgical O
adhesive O
, O
the O
biological O
albumin-glutaraldehyde O
glue O
Bioglue O
, O
in O
reduction O
of O
these O
postoperative O
complications O
. O
[]

Many O
who O
have O
had O
a O
total O
laryngectomy O
complain O
of O
unrelenting O
rhinorrhea O
that O
is O
often O
very O
difficult O
to O
control O
. O
[]

CONCLUSIONS O
Primary O
and O
secondary O
target O
lesion O
patency O
rates O
of O
CBA O
were O
statistically O
superior O
to O
those O
of O
HPBA O
following O
suboptimal O
conventional O
PTA O
. O
[]

A O
comparison O
of O
antiarrhythmic-drug O
therapy O
with O
implantable O
defibrillators O
in O
patients O
resuscitated O
from O
near-fatal O
ventricular O
arrhythmias O
. O
[]

[ O
Limbal O
epithelial O
autograft O
transplantation O
in O
treatment O
of O
pterygium O
] O
. O
[]

B O
( O
RANK O
) O
ligand O
, O
with O
zoledronic O
acid O
in O
delaying O
or O
preventing O
skeletal-related O
events O
( O
SREs O
) O
in O
patients O
with O
breast O
cancer O
with O
bone O
metastases O
. O
[]

In O
peripheral O
blood O
monocytes O
, O
human B-outcome ['Physiological-Clinical']
leukocyte I-outcome ['Physiological-Clinical']
antigen-DR I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
only O
slightly O
depressed O
, O
whereas O
in O
vitro B-outcome ['Physiological-Clinical']
phagocytosis I-outcome ['Physiological-Clinical']
and O
the O
monocyte-activating B-outcome ['Physiological-Clinical']
cytokine I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Although O
amantadine O
has O
several O
mechanisms O
of O
action O
, O
the O
NMDA-receptor O
antagonism O
seems O
to O
be O
the O
most O
relevant O
effect O
on O
cortical B-outcome ['Physiological-Clinical']
excitability I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Past O
research O
has O
shown O
a O
superiority O
of O
participants O
with O
high-functioning O
autism O
over O
comparison O
groups O
in O
memorizing O
picture-pitch O
associations O
and O
in O
detecting O
pitch O
changes O
in O
melodies O
. O
[]

Combined O
therapy O
in O
the O
treatment O
of O
primary O
mediastinal O
B-cell O
lymphoma O
: O
conventional O
versus O
escalated O
chemotherapy O
. O
[]

Among O
102 O
protocol O
compliant O
Brisbane O
recipients O
of O
VLP O
immunotherapy O
, O
disease O
reduction O
was O
significantly O
greater O
than O
among O
the O
placebo O
immunotherapy O
( O
50 O
% O
? O
[]

PURPOSE O
The O
Providing O
Assistance O
to O
Caregivers O
in O
Transition O
( O
PACT O
) O
program O
offers O
nursing O
home O
discharge O
planning O
and O
case O
management O
for O
individuals O
in O
the O
transitional O
period O
following O
a O
return O
to O
the O
community O
. O
[]

Frusemide O
administration O
at O
the O
midpoint O
of O
each O
study O
limb O
resulted O
in O
each O
case O
in O
a O
prompt O
15 O
to O
20 O
fold O
increase O
in O
natriuresis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
is O
to O
compare O
the O
costs O
and O
benefits O
of O
home-based O
and O
hospital-based O
pulmonary O
rehabilitation O
for O
people O
with O
COPD O
. O
[]

METHODS O
Sixty-two O
children O
( O
51 O
boys O
and O
11 O
girls O
; O
M O
age O
= O
20 O
months O
; O
SD O
= O
2.6 O
) O
who O
met O
criteria O
for O
autism O
spectrum O
disorders O
( O
ASD O
) O
and O
their O
parents O
participated O
in O
the O
study O
. O
[]

Overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
also O
better O
with O
CT O
( O
cumulative O
survival O
at O
15 O
years O
: O
50 O
% O
and O
44 O
% O
in O
the O
CT O
and O
RT O
groups O
, O
respectively O
) O
but O
the O
difference O
was O
not O
statistically O
significant O
. O
['Mortality']

The O
area O
of O
each O
wart O
compared O
with O
entry O
area O
was O
the O
primary O
outcome O
variable O
, O
measured O
from O
photographs O
by O
an O
evaluator O
unaware O
of O
treatment O
allocation O
for O
intervention O
. O
[]

The O
sternal O
paddle O
was O
placed O
in O
a O
longitudinal O
orientation O
for O
all O
measurements O
. O
[]

A O
total O
of O
17,046 O
healthy O
breast-fed O
infants O
were O
enrolled O
from O
31 O
Belarussian O
maternity O
hospitals O
and O
affiliated O
clinics O
, O
of O
whom O
13,889 O
( O
81.5 O
% O
) O
were O
followed O
up O
at O
6.5 O
y O
with O
duplicate O
measurements O
of O
height O
, O
weight O
, O
waist O
circumference O
, O
triceps O
and O
subscapular O
skinfold O
thicknesses O
, O
systolic O
and O
diastolic O
BP O
. O
[]

Low O
doses O
of O
oral O
sildenafil O
appear O
to O
be O
effective O
and O
safe O
to O
control O
postoperative O
PA O
pressure O
in O
children O
. O
[]

Postexercise B-outcome ['Physiological-Clinical']
FSR I-outcome ['Physiological-Clinical']
was O
elevated O
above O
baseline O
in O
both O
groups O
at O
1 O
h O
but O
was O
even O
further O
elevated O
in O
the O
EAA+CHO O
group O
at O
2 O
h O
postexercise O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Primary B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
occurred O
in O
1 O
subject O
of O
the O
BET O
group O
. O
['Physiological-Clinical']

Amino O
acids O
derived O
from O
ingested O
protein O
are O
potential O
substrates O
for O
gluconeogenesis O
. O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
did O
not O
significantly O
differ O
in O
the O
2 O
groups O
. O
['Adverse-effects']

All O
patients O
underwent O
duplex O
US O
scanning O
to O
document O
reflux O
in O
the O
deep O
, O
superficial O
, O
and O
perforating O
venous O
systems O
. O
[]

Forty-eight O
horses O
subjected O
to O
elective O
surgery O
were O
randomly O
assigned O
to O
three O
groups O
of O
16 O
horses O
. O
[]

SETTING O
Surgical O
intensive O
care O
unit O
of O
a O
university O
Level O
I O
trauma O
center O
. O
[]

Training O
groups O
participated O
in O
a O
9 O
wk O
program O
, O
3 O
d.wk-1 O
. O
[]

BACKGROUND O
AND O
AIMS O
We O
undertook O
this O
study O
to O
determine O
the O
efficacy O
of O
oral O
magnesium O
supplementation O
in O
the O
improvement O
of O
the O
metabolic B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
metabolically O
obese O
, O
normal-weight O
( O
MONW O
) O
individuals O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Those O
who O
were O
least O
satisfied O
with O
themselves O
used B-outcome ['Life-Impact']
sunbeds I-outcome ['Life-Impact']
most O
frequently O
. O
['Life-Impact']

A O
randomised O
trial O
comparing O
holmium O
laser O
enucleation O
versus O
transurethral O
resection O
in O
the O
treatment O
of O
prostates O
larger O
than O
40 O
grams O
: O
results O
at O
2 O
years O
. O
[]

The O
stratum O
corneum O
was O
painlessly O
ablated O
with O
a O
low-fluence O
Er O
: O
YAG O
laser O
on O
half O
of O
the O
face O
, O
then O
the O
whole O
face O
was O
covered O
with O
ELA-Max O
cream O
for O
60 O
minutes O
. O
[]

Patients O
were O
randomised O
to O
receive O
either O
5-FU/folinic O
acid O
( O
FA O
, O
FUFA O
) O
alone O
or O
in O
combination O
with O
irinotecan O
5-fluorouracil/folinic O
acid O
and O
irinotecan O
( O
FOLFIRI O
) O
stratified O
by O
TS O
( O
low O
versus O
high O
) O
. O
[]

The O
different O
effects O
on O
serum O
lipoprotein O
( O
a O
) O
[ O
Lp O
( O
a O
) O
] O
levels O
by O
administering O
estrogens O
at O
different O
times O
of O
the O
day O
( O
8 O
a.m. O
and O
8 O
p.m. O
) O
were O
evaluated O
in O
twenty-four O
post-menopausal O
women O
. O
[]

Intention-to-treat O
analysis O
showed O
significant O
decreases O
in O
all O
three O
groups O
in O
mean O
( O
+/- O
SEM O
) O
supine B-outcome ['Physiological-Clinical']
DBP I-outcome ['Physiological-Clinical']
throughout O
the O
study O
, O
with O
no O
significant O
differences O
at O
week O
16 O
between O
trandolapril O
( O
-10.6 O
+/- O
1.3 O
mm O
Hg O
) O
and O
HCTZ O
( O
-10.9 O
+/- O
1.3 O
mm O
Hg O
) O
. O
['Physiological-Clinical']

All O
of O
the O
children O
learned O
to O
ask O
the O
question O
within O
the O
instructional O
context O
, O
while O
on O
a O
walk O
in O
the O
school O
building O
, O
and O
to O
request O
information O
about O
three-dimensional O
objects O
. O
[]

The O
results O
suggested O
that O
such O
combined O
modality O
is O
worth O
further O
study O
. O
[]

The O
most O
prevalent O
[]

Clinical O
significance O
and O
prognostic O
importance O
of O
left O
ventricular O
hypertrophy O
in O
non-Q-wave O
acute O
myocardial O
infarction O
. O
[]

Among O
the O
patients O
that O
responded O
to O
combined O
therapy O
, O
nine O
of O
them O
had O
a O
complete O
response O
, O
four O
a O
partial O
response O
, O
and O
two O
a O
minor O
response O
. O
[]

A O
randomized O
double-blind O
casein-controlled O
trial O
. O
[]

PURPOSE O
To O
evaluate O
the O
analgesic B-outcome ['Resource-use']
efficacy O
and O
duration O
of O
varying O
doses O
of O
caudal O
neostigmine O
with O
plain O
bupivacaine O
and O
its O
side O
effects O
in O
children O
undergoing O
genito-urinary O
surgery O
. O
['Resource-use']

The O
consecutive O
sessions O
were O
at O
least O
1 O
wk O
apart O
for O
each O
subject O
. O
[]

On O
the O
contrary O
, O
naltrexone O
increased O
the O
incidence O
of O
stereotypic B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
on O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
, O
and O
the O
care O
staff O
evaluated O
the O
effect O
of O
the O
50-mg/d O
treatment O
as O
being O
significantly O
worse O
than O
that O
of O
the O
placebo O
treatment O
as O
measured O
by O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
Scale O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Methods O
in O
situ O
are O
recently O
available O
to O
study O
separately O
erosion B-outcome ['Physiological-Clinical']
and O
abrasion B-outcome ['Physiological-Clinical']
of O
dental B-outcome ['Physiological-Clinical']
tissues I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Travel O
and O
transport O
are O
frequently O
cited O
as O
barriers O
to O
uptake O
of O
centre-based O
programs O
. O
[]

In O
the O
eastern O
Malaysian O
state O
of O
Sabah O
, O
high-level O
stock O
losses O
have O
been O
recorded O
on O
these O
farms O
for O
several O
years O
, O
frequently O
accompanied O
by O
clinical O
signs O
indicating O
pathogenic O
levels O
of O
infections O
with O
the O
nematode O
parasite O
Haemonchus O
contortus O
. O
[]

Although O
many O
nonrandomized O
studies O
have O
reported O
tumor O
responses O
to O
anticancer O
chemotherapy O
, O
few O
have O
studied O
palliation O
and O
it O
is O
not O
known O
whether O
chemotherapy O
prolongs O
survival O
or O
provides O
clinically O
worthwhile O
palliation O
with O
acceptable O
toxicity O
when O
given O
in O
addition O
to O
ASC O
. O
[]

Peptidase B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
clinical O
and O
microbiologic O
effects O
were O
evaluated O
and O
compared O
among O
sites O
for O
17 O
weeks O
. O
['Physiological-Clinical']

BACKGROUND O
Long-term O
data O
from O
randomised O
trials O
on O
the O
consequences O
of O
treatment O
with O
a O
protease O
inhibitor O
( O
PI O
) O
, O
non-nucleoside O
reverse O
transcriptase O
inhibitor O
( O
NNRTI O
) O
, O
or O
both O
are O
lacking O
. O
[]

CONCLUSION O
CSP O
using O
hydrocolloid O
technology O
provides O
an O
efficacious O
and O
safe O
alternative O
to O
topical O
antivirals O
in O
treating O
HSL O
as O
a O
wound O
while O
affording O
additional O
immediate O
benefits O
of O
wound O
protection O
, O
discretion O
and O
relief O
of O
social O
embarrassment O
. O
[]

This O
study O
examined O
the O
efficacy O
and O
safety O
of O
nifedipine O
sustained O
release O
( O
nifedipine O
SR O
) O
compared O
with O
Ginkgo O
biloba O
extract O
as O
treatment O
for O
primary O
Raynaud O
's O
phenomenon O
( O
RP O
) O
in O
Korea O
. O
[]

The O
effect O
of O
vaccination B-outcome ['Resource-use']
on O
pig B-outcome ['Physiological-Clinical']
['Resource-use', 'Physiological-Clinical']

Enzyme-linked O
immunosorbent O
assays O
( O
ELISAs O
) O
have O
the O
ability O
to O
quantify O
nematode O
infections O
in O
cattle O
, O
and O
thus O
, O
could O
be O
used O
to O
estimate O
the O
amount O
of O
milk O
production O
loss O
due O
to O
differing O
levels O
of O
parasitism O
at O
the O
individual O
cow O
level O
. O
[]

Since O
1983 O
, O
a O
prospective O
randomized O
study O
was O
started O
in O
order O
to O
investigate O
the O
more O
advantageous O
treatment O
schedule O
with O
keeping O
the O
local O
control O
rate O
. O
[]

BACKGROUND O
A O
supplemented O
very-low-protein O
diet O
( O
sVLPD O
) O
seems O
to O
be O
safe O
when O
postponing O
dialysis O
therapy O
. O
[]

In O
addition O
, O
costs O
for O
hemiarthroplasty O
were O
lower O
. O
[]

Atrial O
fibrillation O
and O
ventricular O
tachycardia O
have O
been O
associated O
with O
prolongation O
of O
P-wave B-outcome ['Physiological-Clinical']
and O
QRS B-outcome ['Physiological-Clinical']
complex I-outcome ['Physiological-Clinical']
durations I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
signal-averaged I-outcome ['Physiological-Clinical']
electrocardiograms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Both O
placebo O
and O
treatment O
groups O
were O
balanced O
at O
baseline O
study O
in O
terms O
of O
functional O
class O
, O
ventricular O
performance O
and O
autonomic O
tone O
. O
[]

Ponezumab O
was O
well O
tolerated O
with O
no O
drug-attributed O
serious O
adverse O
events O
. O
[]

In O
the O
same O
groups O
bacterial B-outcome ['Physiological-Clinical']
cystitis I-outcome ['Physiological-Clinical']
occurred O
in O
17 O
( O
21.8 O
% O
) O
patients O
and O
in O
16 O
( O
18.4 O
% O
) O
patients O
, O
respectively O
. O
['Physiological-Clinical']

DESIGN O
This O
was O
a O
randomized O
controlled O
trial O
study O
. O
[]

Patients O
( O
15-65 O
years O
old O
) O
were O
assigned O
to O
1 O
of O
4 O
treatments O
regimens O
in O
a O
serial O
order O
. O
[]

Results O
showed O
that O
participants O
in O
both O
music O
and O
speech O
training O
significantly O
increased O
their O
pre O
to O
posttest O
verbal B-outcome ['Life-Impact']
production I-outcome ['Life-Impact']
. O
['Life-Impact']

Hematomas O
> O
15 O
cm O
( O
2 O
) O
were O
also O
assessed O
. O
[]

We O
have O
therefore O
studied O
the O
immunological O
effects O
of O
low-dose O
recombinant O
interleukin O
2 O
given O
to O
patients O
undergoing O
surgery O
for O
colorectal O
cancer O
to O
determine O
whether O
this O
agent O
has O
potential O
in O
perioperative O
adjuvant O
immunotherapy O
. O
[]

Data O
obtained O
were O
analyzed O
using O
1-way O
ANOVA O
and O
the O
Bonferroni O
multiple O
comparison O
test O
( O
alpha=.05 O
) O
. O
[]

Of O
the O
200 O
randomly O
selected O
patients O
, O
150 O
respondents O
completed O
follow-up O
surveys O
( O
a O
75 O
% O
response O
rate O
) O
. O
[]

METHODS O
Three O
hundred O
fifty O
patients O
who O
had O
reoperation O
with O
CABG O
only O
( O
58 O
% O
) O
, O
or O
with O
valve O
operations O
( O
42 O
% O
) O
were O
randomly O
assigned O
to O
receive O
either O
a O
heparin-coated O
( O
Duraflo O
II O
; O
study O
group O
) O
or O
uncoated O
( O
control O
group O
) O
circuit O
. O
[]

METHODS O
After O
a O
4-week O
washout O
period O
, O
patients O
whose O
untreated O
daytime O
diastolic O
ambulatory O
BP O
averaged O
> O
or O
= O
85 O
mm O
Hg O
were O
randomized O
to O
be O
treated O
according O
to O
their O
ambulatory O
or O
home O
BP O
. O
[]

An O
open O
, O
parallel O
group O
comparison O
of O
quinapril O
and O
captopril O
, O
when O
added O
to O
diuretic O
therapy O
, O
in O
the O
treatment O
of O
elderly O
patients O
with O
heart O
failure O
. O
[]

Systolic B-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
sphericity I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
( O
SI O
; O
n O
= O
110 O
) O
, O
TEI O
index O
( O
n O
= O
145 O
) O
, O
and O
systemic O
ventricular O
dP/dt O
( O
n O
= O
70 O
) O
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mean O
response O
time O
evaluated O
using O
the O
psychomotor O
vigilance O
task O
test O
( O
PVT O
) O
showed O
significant O
improvement O
in O
the O
BL O
periods O
compared O
with O
the O
non-BL O
periods O
. O
[]

Ebrotidine O
( O
N- O
[ O
( O
E O
) O
- O
[ O
[ O
2- O
[ O
[ O
[ O
2- O
[ O
( O
diaminomethylene O
) O
amino O
] O
-4 O
-thiazoly O
] O
methyl O
] O
thio O
] O
ethyl O
] O
amino O
] O
methylene O
] O
-4-bromo-benzenesulfon O
amide O
, O
CAS O
100981-43-9 O
, O
FI-3542 O
) O
is O
a O
new O
H2-receptor O
antagonist O
characterized O
by O
its O
high O
receptor O
affinity O
and O
gastroprotective O
effect O
. O
[]

Changes O
in O
continuously O
recorded O
'Finapres O
' O
finger B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
ten O
normotensive O
and O
seven O
hypertensive O
subjects O
induced O
by O
self-inflation O
of O
the O
cuff O
or O
just O
wearing O
the O
inflated O
cuff O
were O
studied O
. O
['Physiological-Clinical']

Among O
the O
552 O
participants O
who O
completed O
the O
follow-up O
examination O
, O
94 O
stopped O
treatment O
early O
. O
[]

The O
treatment O
effect O
by O
these O
measures O
was O
-0.5 O
and O
-0.4 O
units O
in O
favor O
of O
LE O
( O
P O
< O
or O
= O
0.008 O
) O
. O
[]

Change O
in O
cardiovascular B-outcome ['Physiological-Clinical']
autonomic I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

The O
5 O
FU-mitomycin O
combination O
produced O
a O
14 O
% O
and O
22 O
% O
response O
rate O
in O
disseminated O
stomach O
and O
pancreatic O
carcinoma O
, O
respectively O
. O
[]

Peak O
and O
mean O
power O
output B-outcome ['Physiological-Clinical']
measured O
during O
the O
Wingate O
test O
were O
also O
improved O
by O
a O
similar O
magnitude O
after O
SP O
( O
21+/-5 O
% O
) O
and O
MX O
( O
15+/-6 O
% O
) O
. O
['Physiological-Clinical']

The O
overall O
cure B-outcome ['Physiological-Clinical']
rates O
were O
96 O
percent O
for O
the O
400-mg O
dose O
of O
cefixime O
( O
89 O
of O
93 O
patients O
) O
( O
95 O
percent O
confidence O
interval O
, O
93.5 O
percent O
to O
97.8 O
percent O
) O
; O
98 O
percent O
for O
the O
800-mg O
dose O
of O
cefixime O
( O
86 O
of O
88 O
patients O
) O
( O
95 O
percent O
confidence O
interval O
, O
94.6 O
percent O
to O
100 O
percent O
) O
; O
and O
98 O
percent O
for O
ceftriaxone O
( O
92 O
of O
94 O
patients O
) O
( O
95 O
percent O
confidence O
interval O
, O
94.9 O
to O
100 O
percent O
) O
. O
['Physiological-Clinical']

A O
quality O
improvement O
process O
cycle O
will O
introduce O
the O
neonatal O
resuscitation O
protocol O
. O
[]

Two O
CMZ O
patients O
and O
one O
morphine O
patient O
showed O
complete O
pain B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

The O
A-V O
Impulse O
System O
reduces O
deep-vein O
thrombosis O
and O
swelling O
after O
hemiarthroplasty O
for O
hip O
fracture O
. O
[]

CONCLUSIONS O
Conscious O
sedation O
with O
midazolam O
does O
not O
reduce O
the O
cardiac O
stress O
during O
UGIE O
. O
[]

Efficacy O
of O
dose-intensified O
MEC O
( O
methotrexate O
, O
epirubicin O
and O
cisplatin O
) O
chemotherapy O
for O
advanced O
urothelial O
carcinoma O
: O
a O
prospective O
randomized O
trial O
comparing O
MEC O
and O
M-VAC O
( O
methotrexate O
, O
vinblastine O
, O
doxorubicin O
and O
cisplatin O
) O
. O
[]

Twelve O
normotensive O
white O
and O
12 O
normotensive O
black O
men O
were O
given O
10 O
, O
200 O
, O
and O
400 O
mmol/d O
Na O
as O
the O
chloride O
salt O
for O
7 O
days O
in O
random O
order O
. O
[]

A O
10-week O
double-blind O
, O
placebo-controlled O
trial O
was O
undertaken O
to O
examine O
both O
the O
efficacy O
and O
safety O
of O
HDPM O
in O
autism O
. O
[]

A O
randomized O
trial O
in O
children O
with O
malignant O
diseases O
. O
[]

Patients O
received O
3 O
to O
9 O
breaths O
( O
6 O
?g/breath O
) O
of O
inhaled O
treprostinil O
4 O
times/day O
. O
[]

Controlling O
for O
all O
other O
factors O
, O
individuals O
older O
than O
44 O
, O
and O
those O
with O
more O
advanced O
lesions O
were O
more O
likely O
to O
comply O
with O
referral B-outcome ['Life-Impact']
( O
p O
< O
0.001 O
) O
. O
['Life-Impact']

To O
investigate O
the O
effect O
of O
these O
COX-2 O
selective O
NSAIDs B-outcome ['Resource-use']
on O
heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
( O
HO O
) O
after O
primary O
total O
hip O
arthroplasty O
( O
THA O
) O
, O
we O
conducted O
a O
randomized O
controlled O
trial O
using O
either O
indomethacin O
or O
rofecoxib O
for O
7 O
days O
. O
['Resource-use', 'Physiological-Clinical']

The O
score O
on O
the O
quality O
of O
life O
of O
transhiatal O
patients O
was O
significantly O
higher O
than O
that O
of O
transthoracic O
patients O
in O
the O
third O
, O
sixth O
and O
twelfth O
month O
. O
[]

According O
to O
current O
British O
Thoracic O
Society O
( O
BTS O
) O
guidelines O
, O
patients O
should O
be O
treated O
with O
active O
symptom O
control O
( O
ASC O
) O
, O
involving O
( O
1 O
) O
regular O
follow-up O
in O
a O
specialist O
clinic O
; O
( O
2 O
) O
structured O
assessments O
of O
physical O
, O
psychological O
and O
social O
problems O
with O
appropriate O
action O
; O
( O
3 O
) O
rapid O
involvement O
of O
additional O
specialists O
; O
and O
( O
4 O
) O
parallel O
nursing O
support O
. O
[]

After O
the O
conventional O
treatment O
, O
patients O
were O
randomly O
allocated O
to O
adjuvant O
hormone O
therapy O
or O
no O
further O
treatment O
. O
[]

The O
results O
obtained O
in O
111 O
patients O
do O
not O
support O
any O
consistent O
relationship O
between O
plasma O
level O
of O
haloperidol O
and O
clinical B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
prevalence O
of O
myxedema B-outcome ['Physiological-Clinical']
( O
10 O
% O
) O
did O
not O
differ O
among O
groups O
. O
['Physiological-Clinical']

Analgesics B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
increased O
in O
both O
groups O
, O
but O
significantly O
more O
in O
patients O
receiving O
placebo O
( O
p O
= O
0.042 O
) O
, O
in O
whom O
increase O
in O
opioid O
requirements O
was O
particularly O
evident O
. O
['Resource-use']

The O
patients O
were O
breathing O
N2O/O2 O
with O
FIO2 O
33 O
% O
. O
[]

On O
the O
ACRT B-outcome ['Physiological-Clinical']
subjects O
were O
asked O
to O
press O
a O
button O
to O
a O
rare O
target O
( O
500 O
Hz O
, O
P O
= O
0.14 O
) O
and O
to O
ignore O
higher O
pitched O
rare O
( O
2,000 O
Hz O
, O
P O
= O
0.14 O
) O
and O
frequent O
non-targets O
( O
1,000 O
Hz O
) O
. O
['Physiological-Clinical']

Except O
for O
initial O
clinical O
stage O
, O
no O
differences O
were O
noted O
in O
the O
clinical B-outcome ['Physiological-Clinical']
or O
pathological B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
, O
or O
prostate B-outcome ['Physiological-Clinical']
specific I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
in O
patients O
with O
negative O
versus O
positive O
repeat O
biopsies O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Participants O
completed O
an O
interview O
at O
baseline O
, O
1 O
month O
, O
and O
6 O
months O
and O
were O
checked O
at O
6 O
months O
for O
gonorrhea O
or O
chlamydial O
infection O
via O
nucleic O
acid O
amplification O
testing O
of O
urine O
. O
[]

RESULTS O
Mean O
weight O
and O
length B-outcome ['Physiological-Clinical']
gains I-outcome ['Physiological-Clinical']
in O
the O
LP O
, O
FS50 O
, O
and O
FS25 O
groups O
were O
2.37 O
, O
2.47 O
, O
and O
2.37 O
kg O
( O
P O
= O
.66 O
) O
and O
12.7 O
, O
13.5 O
, O
and O
13.2 O
cm O
( O
P O
= O
.23 O
) O
, O
respectively O
. O
['Physiological-Clinical']

Although O
a O
combination O
of O
i.v O
. O
[]

Concomitant O
use O
of O
an O
anticholinergic O
agent O
increases O
the O
duration O
of O
antacid B-outcome ['Resource-use']
action O
. O
['Resource-use']

RESULTS O
Patients O
became O
significantly O
more O
depressed B-outcome ['Life-Impact']
over O
time O
. O
['Life-Impact']

Following O
strength O
training O
, O
MVC O
of O
the O
plantar B-outcome ['Physiological-Clinical']
flexors I-outcome ['Physiological-Clinical']
increased O
by O
14.4 O
? O
['Physiological-Clinical']

Perioperative O
blood O
transfusions O
are O
associated O
with O
impaired O
survival O
, O
but O
not O
with O
cancer O
recurrence O
. O
[]

The O
associations O
between O
the O
SNP O
and O
acute B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
were O
indicated O
by O
odds O
ratios O
( O
ORs O
) O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
, O
which O
were O
computed O
with O
logistic O
regression O
model O
. O
['Adverse-effects']

Change O
in O
leptin B-outcome ['Physiological-Clinical']
levels O
after O
2 O
months O
of O
treatment O
( O
mean=-0.3 O
ng/ml O
, O
SD=6.2 O
) O
( O
N=48 O
) O
did O
not O
predict O
final O
weight O
['Physiological-Clinical']

These O
results O
suggested O
the O
need O
for O
further O
study O
of O
energy O
expenditure O
, O
body O
composition O
and O
nutritional O
intake O
in O
this O
group O
of O
high O
risk O
patients O
. O
[]

RESULTS O
Thirty-seven O
patients O
were O
eligible O
for O
safety O
and O
efficacy O
. O
[]

Survival B-outcome ['Mortality']
is O
also O
not O
signigicantly O
modified O
by O
adjuvant O
treatment O
and O
was O
better O
for O
patients O
with O
small O
tumors O
. O
['Mortality']

Visible B-outcome ['Physiological-Clinical']
re-epithelialisation I-outcome ['Physiological-Clinical']
was O
recorded O
on O
days O
5 O
and O
8 O
. O
['Physiological-Clinical']

BACKGROUND O
Subclinical B-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
infarct I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
associated O
with O
subsequent O
stroke O
and O
cognitive O
decline O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
addition O
of O
a O
TLR9 O
agonist O
to O
7vPnC O
significantly O
enhanced O
the O
proportion O
of O
vaccine B-outcome ['Resource-use']
high O
responders O
. O
['Resource-use']

A O
prospective O
randomized O
trial O
. O
[]

We O
found O
that O
( O
a O
) O
relative-direction O
judgments O
were O
precise O
and O
independent O
of O
phoria O
, O
and O
( O
b O
) O
monocular O
absolute-direction O
judgments O
were O
inaccurate O
, O
and O
the O
magnitude O
of O
the O
inaccuracy B-outcome ['Life-Impact']
was O
predictable O
from O
the O
magnitude O
of O
phoria O
. O
['Life-Impact']

Mean O
differences O
were O
2.6 O
( O
95 O
% O
CI O
, O
0.93-4.22 O
; O
P O
= O
0.002 O
) O
on O
the O
HAM-D?? O
and O
2.1 O
( O
95 O
% O
CI O
, O
0.36-3.76 O
; O
P O
= O
0.017 O
) O
on O
the O
SDS O
. O
[]

Five O
of O
eight O
patients O
in O
group O
A O
and O
seven O
of O
nine O
in O
group O
B O
had O
a O
history O
of O
Pneumocystis O
carinii O
pneumonia O
( O
PCP O
) O
. O
[]

A O
total O
of O
34 O
patients O
have O
been O
included O
( O
with O
glutamine O
: O
n O
= O
18 O
; O
without O
glutamine O
: O
n O
= O
16 O
) O
. O
[]

Self-adhesive O
patches O
which O
release O
glyceryl O
trinitrate O
at O
a O
slow O
continuous O
rate O
or O
placebo O
patches O
were O
applied O
to O
the O
skin O
of O
patients O
distal O
to O
intravenous O
infusion O
sites O
in O
a O
double-blind O
manner O
. O
[]

CONCLUSION O
Feeding O
5 O
ml O
of O
EBM O
before O
venepuncture O
is O
effective O
in O
reducing O
symptoms B-outcome ['Physiological-Clinical']
due O
to O
pain O
in O
term O
neonates O
. O
['Physiological-Clinical']

The O
second O
study O
involved O
two O
treatment O
groups O
, O
ultrasonic O
scaler O
alone O
and O
hand O
instruments O
, O
each O
allocated O
with O
20 O
teeth O
( O
small O
root O
fragments O
) O
. O
[]

The O
overall O
rate O
of O
post-operative B-outcome ['Physiological-Clinical']
deep I-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
including I-outcome ['Physiological-Clinical']
meningitis I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
abscesses I-outcome ['Physiological-Clinical']
was O
also O
significantly O
( O
p O
less O
than O
0.005 O
) O
different O
with O
3.1 O
% O
in O
the O
cefotiam O
versus O
9.0 O
% O
in O
the O
control O
group O
. O
['Physiological-Clinical']

Argatroban O
was O
approved O
for O
PCI O
in O
patients O
with O
heparin-induced O
thrombocytopenia O
( O
HIT O
) O
. O
[]

Participants O
were O
randomized O
to O
receive O
either O
4 O
mg O
perindopril O
or O
matching O
placebo O
daily O
for O
20 O
weeks O
. O
[]

Prophylactic O
administration O
of O
antihistamines O
, O
antidopaminergics O
, O
anticholinergics O
, O
phenothiazines O
, O
serotonin O
antagonist O
, O
steroids O
and O
even O
acupuncture O
has O
been O
shown O
to O
be O
effective O
. O
[]

CONCLUSIONS O
For O
most O
benign O
adrenal O
lesions O
requiring O
surgery O
laparoscopic O
adrenalectomy O
can O
be O
performed O
safely O
and O
effectively O
by O
the O
transperitoneal O
or O
the O
retroperitoneal O
approach O
. O
[]

12 O
micrograms O
formoterol O
fumarate O
( O
Foradil O
MDI O
, O
12 O
micrograms/puff O
) O
plus O
3 O
puffs O
placebo O
; O
C. O
80 O
micrograms O
ipratropium O
; O
D. O
24 O
micrograms O
formoterol O
plus O
2 O
puffs O
placebo O
; O
E. O
12 O
micrograms O
formoterol O
plus O
40 O
micrograms O
ipratropium O
plus O
1 O
puff O
placebo O
; O
F. O
4 O
puffs O
placebo O
. O
[]

Both O
groups O
received O
conventional O
therapy O
after O
admission O
. O
[]

OBJECTIVE O
To O
investigate O
the O
effect O
of O
an O
exercise O
program O
, O
including O
specific O
stabilizing O
exercises O
, O
on O
pain O
intensity O
and O
functional O
ability O
in O
women O
with O
pregnancy-related O
low O
back O
pain O
. O
[]

Clearfil O
Protect O
Bond O
showed O
higher O
bond B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
to O
enamel O
than O
Xeno O
III O
, O
irrespective O
of O
the O
ozone O
treatment O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
results O
suggested O
that O
Seven-star O
Needle O
Stimulation O
might O
be O
an O
effective O
intervention O
to O
improve O
language B-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
of O
children O
with O
ASD O
. O
['Life-Impact', 'Life-Impact']

As O
to O
the O
neuroendocrinological B-outcome ['Physiological-Clinical']
effect O
, O
cyproheptadine O
augmentation O
did O
not O
reduce O
the O
plasma B-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
level O
but O
did O
induce O
a O
decrease O
in O
the O
plasma B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Nine O
( O
7 O
% O
) O
eltrombopag-treated O
patients O
and O
two O
( O
3 O
% O
) O
in O
the O
placebo O
group O
had O
mild O
increases O
in O
alanine O
aminotransferase O
concentration O
, O
and O
five O
( O
4 O
% O
) O
eltrombopag-treated O
patients O
( O
vs O
none O
allocated O
to O
placebo O
) O
had O
increases O
in O
total O
bilirubin O
. O
[]

Here O
, O
we O
studied O
the O
relationship O
between O
peripheral O
FMRP O
level O
, O
visual B-outcome ['Physiological-Clinical']
perception I-outcome ['Physiological-Clinical']
( O
contrast O
sensitivity B-outcome ['Physiological-Clinical']
, O
perceptual B-outcome ['Physiological-Clinical']
integration I-outcome ['Physiological-Clinical']
, O
motion/form B-outcome ['Physiological-Clinical']
perception I-outcome ['Physiological-Clinical']
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
outcome O
measure O
was O
self-reported O
3 O
months O
prolonged B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
, O
and O
secondary O
outcomes O
were O
1 O
month O
prolonged O
abstinence O
, O
7-day O
and O
24-hour O
point O
prevalence O
abstinence O
. O
['Life-Impact']

A O
very O
short O
lead-time O
may O
indicate O
poor O
sensitivity O
of O
the O
screening O
test O
, O
while O
a O
very O
long O
lead-time O
suggests O
overdiagnosis O
. O
[]

The O
primary O
efficacy O
endpoint O
was O
AM O
pre-dose O
FEV O
( O
1 O
) O
and O
secondary O
endpoints O
included O
other O
measures O
of O
lung O
function O
, O
rescue O
albuterol O
use O
, O
health O
status O
and O
exacerbations O
. O
[]

DESIGN O
A O
prospective O
, O
randomized O
, O
double-blind O
study O
. O
[]

Randomized O
controlled O
study O
of O
customized O
preventive O
medicine O
reminder O
letters O
in O
a O
community O
practice O
. O
[]

These O
results O
appear O
to O
warrant O
prospective O
randomized O
trials O
to O
determine O
in O
a O
more O
definitive O
manner O
the O
merits O
of O
this O
combination O
in O
the O
prevention O
of O
progression O
of O
coronary B-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
two-year O
prospective O
cohort O
study O
. O
[]

A O
self-administered O
questionnaire O
was O
sent O
to O
parents O
in O
the O
municipality O
of O
Stockholm O
, O
Sweden O
, O
who O
were O
to O
be O
used O
as O
a O
control O
group O
in O
a O
study O
addressing O
stress O
in O
parents O
of O
children O
with O
cancer O
. O
[]

Efficacy O
of O
selamectin O
was O
studied O
in O
naturally O
acquired O
S. O
muris O
infections O
in O
rats O
. O
[]

25.1 O
U/L O
, O
P O
< O
0.05 O
or O
P O
< O
0.01 O
) O
. O
[]

The O
PACT O
program O
targeted O
individuals O
newly O
admitted O
to O
nursing O
homes O
and O
worked O
with O
a O
family O
caregiver O
to O
develop O
and O
implement O
a O
nursing O
home O
discharge O
plan O
. O
[]

The O
median O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
prolonged O
by O
14 O
months O
in O
patients O
treated O
with O
AVCMF O
( O
chi2 O
1 O
= O
11.7 O
; O
P O
= O
0.0006 O
) O
. O
['Mortality']

HYPOTHESIS O
Prevention O
of O
fasciculations B-outcome ['Physiological-Clinical']
during O
rapid-sequence O
intubation O
of O
head O
trauma O
patients O
can O
be O
accomplished O
as O
safely O
and O
effectively O
with O
minidose O
succinylcholine O
as O
with O
a O
defasciculating O
dose O
of O
pancuronium O
. O
['Physiological-Clinical']

Symptom B-outcome ['Physiological-Clinical']
and O
medication O
scores O
, O
skin B-outcome ['Physiological-Clinical']
test O
results O
and O
( O
in O
asthmatic O
patients O
) O
FEV1 O
values O
were O
monitored O
for O
two O
years O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
conclude O
that O
amonafide O
is O
somewhat O
active O
in O
previously O
untreated O
breast O
cancer O
patients O
. O
[]

Treatments O
were O
administered O
using O
a O
double-blind O
randomized O
design O
. O
[]

Alkalinized O
lidocaine O
and O
heparin O
provide O
immediate O
relief O
of O
pain B-outcome ['Physiological-Clinical']
and O
urgency O
in O
patients O
with O
interstitial O
cystitis O
. O
['Physiological-Clinical']

One O
to O
2 O
weeks O
after O
induction O
chemotherapy O
, O
45 O
Gy/30 O
Fx/19 O
d O
TRT O
was O
administered O
concurrently O
with O
the O
third O
cycle O
of O
EP O
regimen O
. O
[]

Toxicity B-outcome ['Adverse-effects']
and O
early B-outcome ['Mortality']
death I-outcome ['Mortality']
were O
particularly O
frequent O
in O
Procarbazine O
treated O
patients O
, O
whereas O
most O
patients O
progressed O
in O
both O
treatment O
groups O
. O
['Adverse-effects', 'Mortality']

Patient O
randomization O
was O
stratified O
by O
stage O
( O
III/IV O
) O
and O
site O
( O
oral O
cavity O
, O
oropharynx O
, O
nasopharynx O
, O
hypopharynx O
, O
larynx O
, O
paranasal O
sinuses O
) O
. O
[]

Control-group O
participants O
also O
experienced O
significantly O
lower O
rates O
of O
limitation B-outcome ['Life-Impact']
, O
but O
pre- O
to O
postdifferences O
were O
less O
dramatic O
, O
F O
( O
1 O
, O
308 O
) O
= O
4.19 O
, O
p O
= O
.006 O
. O
['Life-Impact']

The O
analysis O
of O
normalisation O
parameters O
indicated O
that O
z-scaling O
is O
underestimated O
and O
yz-rotation O
overestimated O
with O
TCT/NMI O
registration O
. O
[]

RESULTS O
Although O
no O
significant O
changes O
were O
noted O
for O
the O
control O
brochure O
, O
after O
reading O
the O
new O
brochure O
participants O
reported O
significant O
improvements O
in O
attitude B-outcome ['Life-Impact']
, O
anxiety B-outcome ['Life-Impact']
, O
self-efficacy B-outcome ['Life-Impact']
, O
and O
donation B-outcome ['Life-Impact']
intention I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

We O
also O
prospected O
an O
oral O
use O
of O
EGF O
on O
the O
basis O
of O
our O
experimental O
evidence O
. O
[]

Leukopenia B-outcome ['Physiological-Clinical']
was O
greater O
for O
the O
first O
course O
on O
the O
mitomycin O
limb O
. O
['Physiological-Clinical']

Double-blind O
, O
placebo-controlled O
trial O
of O
risperidone O
plus O
topiramate O
in O
children O
with O
autistic O
disorder O
. O
[]

Thirty-five O
healthy O
adults O
age O
35-69 O
years O
were O
enrolled O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
8 O
weeks O
' O
duration O
. O
[]

A O
randomized O
controlled O
trial O
of O
Hanen O
's O
'More O
Than O
Words O
' O
in O
toddlers O
with O
early O
autism O
symptoms O
. O
[]

OBJECTIVE O
The O
aim O
of O
this O
study O
was O
to O
assess O
renal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
of O
aerosolized O
tobramycin O
in O
intubated O
and O
mechanically O
ventilated O
patients O
with O
nosocomial O
pneumonia O
. O
['Physiological-Clinical']

Both O
groups O
recorded O
the O
daily B-outcome ['Physiological-Clinical']
grading I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
the O
amount O
of O
anti-vertiginous B-outcome ['Physiological-Clinical']
drugs I-outcome ['Physiological-Clinical']
( O
cinnarizine B-outcome ['Resource-use']
) O
taken O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Effective O
teaching O
strategies O
that O
seek O
to O
promote O
health O
and O
wellness O
in O
children O
need O
to O
be O
developed O
and O
empirically O
evaluated O
. O
[]

BACKGROUND O
Calm O
, O
compassionate O
clinicians O
comfort O
others O
. O
[]

The O
effect O
of O
acebutolol O
on O
left O
ventricular O
performance O
was O
examined O
by O
various O
noninvasive O
means O
in O
three O
studies O
. O
[]

No O
significant O
changes O
were O
seen O
in O
the O
placebo O
group O
regarding O
any O
of O
these O
variables O
. O
[]

The O
incidence O
of O
new-onset O
depressive O
symptoms O
in O
patients O
initially O
not O
depressed O
after O
hip O
fracture O
surgery O
and O
their O
relationship O
with O
functional O
recovery O
is O
unknown O
. O
[]

Overall O
, O
62.5 O
% O
of O
divalproex O
subjects O
vs O
9 O
% O
of O
placebo O
subjects O
were O
responders B-outcome ['Life-Impact']
( O
CGI-irritability O
OR O
: O
16.7 O
, O
Fisher O
's O
exact O
p=0.008 O
) O
. O
['Life-Impact']

METHODS O
AND O
RESULTS O
Following O
dietary O
stabilization O
, O
a O
2-12-week O
washout O
period O
, O
and O
a O
4-week O
, O
single-blind O
, O
placebo O
lead-in O
period O
, O
827 O
patients O
with O
baseline O
low-density O
lipoprotein O
cholesterol O
( O
LDL-C O
) O
> O
or O
=3.36 O
mmol/l O
( O
130 O
mg/dl O
) O
to O
< O
or O
=6.47 O
mmol/l O
( O
250 O
mg/dl O
) O
and O
triglycerides O
< O
or O
=3.95 O
mmol/l O
( O
350 O
mg/dl O
) O
were O
randomized O
3:1 O
to O
receive O
ezetimibe O
10 O
mg O
or O
placebo O
orally O
once O
daily O
in O
the O
morning O
for O
12 O
weeks O
. O
[]

CONCLUSIONS O
Titanoreine O
can O
effectively O
relieve B-outcome ['Physiological-Clinical']
the O
early O
postoperative O
symptoms O
after O
PPH O
. O
['Physiological-Clinical']

Ratings O
were O
collinear O
with O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression-Improvement O
and O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
Irritability O
subscale O
( O
primary O
dimensional O
measure O
) O
. O
['Physiological-Clinical', 'Life-Impact']

The O
prevalence O
of O
minor B-outcome ['Physiological-Clinical']
RAS I-outcome ['Physiological-Clinical']
in O
the O
experimental O
phase O
decreased O
['Physiological-Clinical']

Ratings O
from O
a O
blinded O
peer O
review O
panel O
indicated O
significant O
improvement O
in O
the O
appropriateness O
of O
the O
blood O
pressure O
regimen O
, O
going O
from O
8.7 O
+/- O
4.7 O
to O
10.9 O
+/- O
4.5 O
in O
the O
study O
group O
( O
p O
< O
0.01 O
) O
, O
but O
they O
did O
not O
change O
in O
the O
control O
group O
. O
[]

Efficacy O
of O
porcine O
secretin O
in O
children O
with O
autism O
and O
pervasive O
developmental O
disorder O
. O
[]

Entry O
criteria O
included O
the O
presence O
of O
symptomatic O
gastroesophageal O
reflux O
confirmed O
by O
both O
an O
acid O
perfusion O
( O
Bernstein O
) O
test O
and O
by O
intraesophageal O
pH O
probe O
. O
[]

Patients O
with O
ASA O
I O
or O
II O
were O
enrolled O
in O
the O
study O
. O
[]

UNLABELLED O
Randomized O
controlled O
study O
in O
80 O
postmenopausal O
women O
with O
osteoporosis O
was O
conducted O
to O
investigate O
the O
effect O
of O
a O
home-based O
, O
simple O
, O
low-intensity O
exercise O
. O
[]

through O
reintervention B-outcome ['Resource-use']
surgery I-outcome ['Resource-use']
, O
haemorrhage B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
or O
extensive B-outcome ['Resource-use']
diagnostic I-outcome ['Resource-use']
interventions I-outcome ['Resource-use']
. O
['Resource-use', 'Physiological-Clinical', 'Resource-use']

After O
12 O
weeks O
, O
we O
observed O
significant O
increases O
in O
fruit B-outcome ['Life-Impact']
and O
vegetable B-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
and O
increases O
in O
participants O
' O
confidence B-outcome ['Life-Impact']
in O
their O
ability O
to O
reduce O
salt B-outcome ['Life-Impact']
and O
fat B-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
and O
eat B-outcome ['Life-Impact']
healthier O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

YM617 O
Clinical O
Study O
Group O
. O
[]

Analyses O
were O
by O
intention O
to O
treat O
. O
[]

Inclusion O
criteria O
were O
known O
vascular O
disease O
or O
diabetes O
plus O
one O
other O
cardiovascular O
risk O
factor O
, O
exclusion O
criteria O
included O
heart O
failure O
or O
known O
impaired O
left O
ventricular O
function O
, O
dipstick-positive O
proteinuria O
( O
> O
1+ O
) O
, O
and O
serum O
creatinine O
> O
2.3 O
mg/dl O
( O
200 O
microM O
) O
. O
[]

METHODS O
Methadone O
hydrochloride O
, O
0.4 O
mg O
kg O
( O
-1 O
) O
, O
was O
administered O
intravenously O
( O
IV O
) O
and O
subcutaneously O
( O
SC O
) O
with O
a O
crossover O
design O
. O
[]

TS B-outcome ['Physiological-Clinical']
levels O
were O
available O
for O
147 O
patients O
( O
87.5 O
% O
) O
. O
['Physiological-Clinical']

Participants O
were O
randomly O
assigned O
to O
receive O
the O
VR O
distraction O
intervention O
during O
one O
chemotherapy O
treatment O
and O
received O
no O
distraction O
intervention O
( O
control O
condition O
) O
during O
an O
alternate O
chemotherapy O
treatment O
. O
[]

METHODS O
This O
randomized O
clinical O
study O
assessed O
27 O
subjects O
( O
12 O
men O
and O
15 O
women O
) O
with O
lateral O
epicondylitis O
and O
were O
divided O
randomly O
into O
2 O
groups O
. O
[]

A O
randomised O
study O
was O
therefore O
planned O
to O
compare O
postural O
stability O
measured O
by O
computerised O
posturography O
in O
31 O
oral O
midazolam-atropine O
premedicated O
children O
aged O
6.9 O
( O
s.e O
. O
[]

Days B-outcome ['Life-Impact']
lost I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
per O
patient O
per O
month O
was O
zero O
on O
three O
times O
12 O
U/kg O
, O
0.4 O
day O
on O
twice O
18 O
U/kg O
and O
once O
36 O
U/kg O
, O
while O
it O
had O
been O
five O
days O
in O
the O
pre-trial O
period O
. O
['Life-Impact']

16.9 O
to O
112.5 O
? O
[]

RAST B-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
showed O
that O
neither O
recipe O
altered O
epitope B-outcome ['Physiological-Clinical']
recognition I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Angioplasty B-outcome ['Physiological-Clinical']
was O
performed O
in O
29 O
patients O
in O
group O
A O
and O
28 O
patients O
in O
group O
B O
. O
['Physiological-Clinical']

Specifically O
, O
in O
the O
phase O
2 O
medication O
only O
condition O
, O
patients O
with O
higher O
DA O
improved O
while O
those O
with O
lower O
DA O
scores O
did O
not O
. O
[]

STUDY O
OBJECTIVE O
To O
determine O
the O
efficacy O
of O
melatonin O
on O
sleep O
problems O
in O
children O
with O
autistic O
spectrum O
disorder O
( O
ASD O
) O
and O
fragile O
X O
syndrome O
( O
FXS O
) O
. O
[]

Cold O
potassium O
cardioplegia O
decreases O
but O
does O
not O
altogether O
prevent O
this O
reduction O
. O
[]

Overall O
, O
the O
cumulative O
diagnostic O
cost O
savings O
was O
48 O
% O
for O
ETT O
compared O
with O
exercise O
MPI O
( O
P O
< O
0.001 O
) O
. O
[]

0.78 O
hours O
and O
2.25 O
? O
[]

Patients O
with O
T18N0M0 O
( O
A2 O
) O
or O
T2N0M0 O
( O
B O
) O
disease O
after O
lymphangiogram O
( O
LAG O
) O
or O
staging O
laparotomy O
( O
SL O
) O
were O
randomized O
between O
prophylactic O
radiation O
to O
the O
pelvic O
lymph O
nodes O
and O
prostatic O
bed O
vs. O
prostatic O
bed O
alone O
. O
[]

The O
other O
20 O
subjects O
, O
the O
experimental O
group O
, O
were O
treated O
using O
plastic O
curettes O
during O
a O
similar O
SPT O
visit O
. O
[]

The O
beneficial O
effect O
on O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
of O
96 O
weeks O
of O
raloxifene O
was O
lost O
6 O
months O
after O
cessation O
of O
treatment O
. O
['Physiological-Clinical']

Primary O
prevention O
in O
this O
group O
can O
potentially O
reduce O
the O
incidence O
of O
skin O
cancer O
, O
and O
also O
potentiates O
the O
spontaneous O
remission O
of O
existing O
solar O
keratoses O
. O
[]

The O
authors O
describe O
for O
the O
first O
time O
that O
dietary O
sodium O
modulates O
myocardial B-outcome ['Physiological-Clinical']
relaxation I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
to O
Ang O
II O
. O
['Physiological-Clinical']

CONCLUSION O
This O
painless O
methodology O
can O
be O
used O
to O
investigate O
, O
in O
vivo O
, O
human O
muscle O
RNA O
and O
DNA O
adaptations O
in O
response O
to O
either O
physiological O
and/or O
pharmacological O
stimuli O
. O
[]

In O
the O
HR O
group O
, O
the O
EFS B-outcome ['Physiological-Clinical']
and O
OS B-outcome ['Physiological-Clinical']
hazard O
ratios O
( O
EVAIA O
v O
VAIA O
) O
indicated O
a O
17 O
% O
reduction O
in O
the O
risk O
of O
an O
event O
( O
95 O
% O
CI O
, O
-35 O
% O
to O
5 O
% O
; O
P O
= O
.12 O
) O
and O
15 O
% O
reduction O
in O
dying O
( O
95 O
% O
CI O
, O
-34 O
% O
to O
10 O
% O
) O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
crossover O
study O
measured O
the O
effect O
of O
a O
single O
dose O
of O
oral O
gabapentin O
( O
900 O
mg O
) O
on O
pain B-outcome ['Physiological-Clinical']
and O
allodynia B-outcome ['Physiological-Clinical']
associated I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
herpes I-outcome ['Physiological-Clinical']
zoster I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

First O
, O
100 O
women O
in O
the O
intervention O
group O
were O
visited O
in O
their O
homes O
by O
one O
of O
the O
researchers O
, O
who O
provided O
culturally-sensitive O
health O
education O
that O
emphasized O
the O
need O
for O
screening O
. O
[]

A O
follow-up O
was O
conducted O
12 O
months O
later O
( O
mean O
age O
= O
35 O
months O
) O
. O
[]

CONCLUSIONS O
The O
NO O
concentration B-outcome ['Physiological-Clinical']
in O
exhaled O
air O
in O
healthy O
humans O
is O
dependent O
on O
oxygen O
tension O
. O
['Physiological-Clinical']

Dronedarone O
treatment O
significantly O
reduced O
the O
risk O
of O
first O
CV O
hospitalization B-outcome ['Resource-use']
( O
P O
< O
0.0001 O
vs. O
placebo O
) O
, O
while O
the O
risk O
of O
first O
non-CV B-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
was O
similar O
in O
both O
groups O
( O
P O
= O
0.77 O
) O
. O
['Resource-use', 'Resource-use']

A O
highly O
significant O
effect O
was O
seen O
for O
time O
( O
F O
= O
4.80 O
, O
P O
= O
0.0003 O
) O
but O
not O
for O
TENS O
. O
[]

CONTEXT O
Intensive O
insulin O
therapy O
( O
IIT O
) O
improved O
outcome O
in O
the O
adult O
and O
pediatric O
intensive O
care O
unit O
( O
PICU O
) O
compared O
with O
conventional O
insulin O
therapy O
( O
CIT O
) O
. O
[]

Many O
women O
overestimate O
their O
percentage O
risk O
of O
breast O
cancer O
, O
even O
after O
they O
have O
received O
careful O
estimates O
from O
health O
professionals O
. O
[]

Plasma O
Epstein-Barr O
virus O
DNA O
predicts O
outcome O
in O
advanced O
Hodgkin O
lymphoma O
: O
correlative O
analysis O
from O
a O
large O
North O
American O
cooperative O
group O
trial O
. O
[]

After O
induction O
, O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
decreased O
by O
systolic/diastolic O
20/10-15 O
mmHg O
. O
['Physiological-Clinical']

Flurbiprofen O
did O
not O
affect O
the O
pupillary B-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
at O
any O
step O
of O
the O
surgery O
. O
['Physiological-Clinical']

RESULTS O
Clopidogrel O
was O
shown O
to O
be O
cost-effective O
, O
with O
incremental O
cost-effectiveness O
ratios O
less O
than O
$ O
10,000 O
per O
event O
prevented B-outcome ['Physiological-Clinical']
and O
less O
than O
$ O
4,000 O
per O
life-year O
gained O
. O
['Resource-use', 'Resource-use', 'Physiological-Clinical']

It O
thus O
has O
made O
it O
possible O
to O
pose O
the O
next O
series O
of O
therapeutic O
questions O
that O
must O
be O
addressed O
in O
this O
disorder O
with O
a O
greater O
degree O
of O
sophistication O
than O
was O
previously O
possible O
. O
[]

Midazolam O
as O
a O
main O
anesthesia O
induction O
agent O
-- O
a O
comparison O
with O
thiopental O
and O
diazepam O
. O
[]

Moreover O
, O
the O
incidence O
of O
overall B-outcome ['Physiological-Clinical']
recurrent I-outcome ['Physiological-Clinical']
thromboembolic I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

METHODS O
Eighty-six O
patients O
consented O
and O
were O
randomly O
assigned O
intraoperatively O
to O
one O
of O
two O
study O
groups O
, O
and O
sixty-eight O
of O
them O
completed O
the O
study O
. O
[]

Efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
antibiotics O
in O
patients O
undergoing O
H. O
pylori O
eradication O
. O
['Life-Impact']

The O
doses O
that O
were O
effective O
and O
associated O
with O
the O
fewest O
adverse O
reactions O
were O
20 O
mg O
and O
50 O
mg O
once O
daily O
. O
[]

In O
a O
recent O
clinical O
trial O
, O
postmenopausal O
estrogen-progestin O
therapy O
was O
shown O
to O
increase O
the O
risk O
of O
early B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
among O
women O
with O
a O
history O
of O
coronary O
heart O
disease O
( O
CHD O
) O
. O
['Physiological-Clinical']

It O
is O
unique O
because O
it O
includes O
equal O
numbers O
of O
VKA-experienced O
and O
naive O
patients O
and O
evaluates O
2 O
different O
dosages O
of O
dabigatran O
, O
which O
may O
allow O
tailoring O
of O
dosing O
to O
individual O
patient O
needs O
. O
[]

Reduction O
of O
stimulus B-outcome ['Life-Impact']
overselectivity I-outcome ['Life-Impact']
with O
nonverbal O
differential O
observing O
responses O
. O
['Life-Impact']

OBJECTIVE O
To O
explore O
the O
efficacy O
of O
paliperidone O
extended-release O
tablets O
in O
the O
improvement O
of O
social B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
in O
schizophrenics O
. O
['Life-Impact']

METHODS O
A O
sample O
of O
2985 O
previous O
QL O
callers O
were O
randomized O
to O
either O
receive O
IVR O
screening O
for O
current O
smoking O
( O
control O
group O
) O
or O
IVR O
screening O
plus O
an O
IVR O
intervention O
. O
[]

Ro O
15-1788 O
, O
an O
imidazodiazepine O
derivative O
, O
exhibits O
marked O
antagonism O
of O
the O
behavioural O
and O
biochemical O
effects O
of O
the O
benzodiazepines O
in O
animals O
and O
man O
. O
[]

The O
median O
observation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
longer O
than O
5 O
years O
and O
follow-up O
data O
were O
available O
from O
all O
94 O
patients O
. O
['Life-Impact']

Outcome O
measures O
included O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions I-outcome ['Physiological-Clinical']
( O
CGI O
) O
and O
the O
Children O
's O
Psychiatric O
Rating O
Scale O
( O
CPRS O
) O
. O
['Physiological-Clinical']

Interviews O
were O
performed O
at O
baseline O
and O
6 O
months O
. O
[]

Twenty-one O
patients O
with O
active O
myeloma O
and O
progressive O
renal O
failure O
were O
randomized O
to O
one O
of O
two O
groups O
: O
group O
1 O
, O
forced O
diuresis O
and O
chemotherapy O
( O
10 O
patients O
) O
, O
and O
group O
2 O
, O
forced O
diuresis O
, O
chemotherapy O
, O
and O
plasmapheresis O
( O
11 O
patients O
) O
. O
[]

Our O
results O
show O
that O
deep B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
during O
the O
first O
week O
after O
hip O
replacement O
surgery O
can O
not O
be O
discovered O
by O
clinical O
diagnostics O
. O
['Physiological-Clinical']

CONCLUSIONS O
ZV O
was O
generally O
well-tolerated O
and O
immunogenic O
in O
adults O
?60 O
years O
old O
. O
[]

VAS O
scores O
decreased O
significantly O
compared O
to O
the O
baseline O
measurements O
in O
all O
groups O
. O
[]

The O
incidence O
of O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
was O
not O
different O
from O
placebo O
. O
['Adverse-effects']

During O
treatment O
either O
with O
placebo O
or O
oxitropium O
, O
there O
was O
a O
statistically O
significant O
decrease O
in O
clinical B-outcome ['Physiological-Clinical']
scores O
. O
['Physiological-Clinical']

Variables O
of O
interest O
were O
number O
and O
intensity O
of O
problem O
behaviours B-outcome ['Life-Impact']
, O
and O
parent O
evaluation O
of O
social B-outcome ['Life-Impact']
interaction O
skills B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Patients O
with O
poor O
initial O
performance O
status O
or O
liver O
involvement O
had O
significantly O
lower O
response O
rates O
and O
reduced O
survival B-outcome ['Mortality']
. O
['Mortality']

Fatigue B-outcome ['Physiological-Clinical']
, O
stress O
and O
storage B-outcome ['Life-Impact']
conditions I-outcome ['Life-Impact']
had O
significant O
effects O
on O
the O
marginal O
adaptation B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

The O
following O
parameters O
were O
measured O
before O
and O
at O
the O
end O
of O
the O
study O
: O
aortic O
and O
large-artery O
compliance O
and O
arterial B-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
reflections I-outcome ['Physiological-Clinical']
[ O
pulse B-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PWV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
augmentation B-outcome ['Physiological-Clinical']
index O
( O
AI O
) O
application O
tonometry O
] O
and O
cardiac B-outcome ['Physiological-Clinical']
echocardiography I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
outcome O
was O
assessed O
by O
an O
independent O
data O
review O
committee O
from O
which O
the O
study O
allocations O
were O
masked O
. O
[]

Statistically O
significant O
changes O
in O
fatigue B-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
, O
appetite B-outcome ['Physiological-Clinical']
, O
diarrhea B-outcome ['Physiological-Clinical']
, O
and O
global B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
scores O
were O
detected O
during O
RT O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

In O
this O
study O
we O
evaluated O
the O
efficacy O
and O
safety O
of O
fluticasone/salmeterol O
( O
FSC O
) O
( O
250/50 O
mcg O
twice O
daily O
) O
when O
added O
to O
tiotropium O
( O
18 O
mcg O
once O
daily O
) O
( O
TIO O
) O
in O
subjects O
with O
symptomatic O
moderate O
to O
severe O
COPD O
. O
[]

The O
time B-outcome ['Life-Impact']
interval I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
anesthesia I-outcome ['Life-Impact']
start I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
surgery I-outcome ['Life-Impact']
start I-outcome ['Life-Impact']
was O
greater O
in O
group O
T O
than O
group O
I O
( O
48 O
vs O
35 O
mins O
, O
P O
< O
0.001 O
) O
. O
['Life-Impact']

Some O
of O
these O
complications O
may O
be O
a O
result O
of O
providing O
PN O
in O
excess O
of O
nutrient O
requirements O
. O
[]

Following O
resistance O
exercise O
, O
4E-BP1 B-outcome ['Physiological-Clinical']
phosphorylation I-outcome ['Physiological-Clinical']
was O
reduced O
to O
a O
greater O
extent O
in O
the O
CHO O
treatment O
( O
-48 O
+/- O
7 O
% O
) O
than O
in O
the O
CHO+PRO O
treatment O
( O
-15 O
+/- O
14 O
% O
, O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

We O
report O
on O
the O
quality O
of O
life O
( O
QOL B-outcome ['Life-Impact']
) O
outcomes O
for O
this O
trial O
. O
['Life-Impact']

Everyone O
has O
autistic O
characteristics O
to O
a O
greater O
or O
lesser O
degree O
, O
encapsulated O
in O
the O
Autism B-outcome ['Life-Impact']
Spectrum O
Quotient B-outcome ['Physiological-Clinical']
, O
a O
scale O
that O
measures O
the O
degree O
to O
which O
an O
adult O
of O
normal O
intelligence O
displays O
traits O
associated O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact', 'Physiological-Clinical']

Analgesia O
was O
determined O
by O
the O
pin-prick O
method O
and O
motor O
blockade O
was O
assessed O
according O
to O
the O
Bromage O
scale O
. O
[]

Misoprostol O
( O
400 O
mcg O
) O
or O
its O
matching O
placebo O
were O
administered O
orally O
, O
and O
the O
measurements O
were O
repeated O
at O
10 O
min O
. O
[]

CONCLUSION O
During O
3-min O
periods O
of O
mask O
ventilation O
on O
a O
manikin O
, O
VDMV O
produced O
the O
least O
variation O
in O
delivered O
ventilation B-outcome ['Resource-use']
. O
['Resource-use']

In O
everyday O
adolescent O
communication O
, O
the O
ability O
to O
empathise O
with O
the O
mental O
state O
of O
others O
, O
recognise O
or O
infer O
intentions O
, O
or O
make O
judgements O
about O
emotional O
state O
, O
is O
a O
non-conscious O
but O
vital O
prerequisite O
of O
relating O
. O
[]

The O
MIC O
and O
50 O
% O
, O
90 O
% O
and O
99 O
% O
inhibitory O
concentrations O
were O
200.8 O
, O
6.27 O
, O
31.7 O
and O
119.6 O
nM/litre O
respectively O
. O
[]

OBJECTIVE O
To O
investigate O
the O
short-term O
effect O
of O
a O
mixed O
Kinesio O
taping O
( O
KT O
) O
model O
on O
range O
of O
ankle B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
( O
ROAM B-outcome ['Physiological-Clinical']
) O
, O
gait B-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
, O
perimeter O
of O
lower O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Comparison O
of O
warfarin O
and O
aspirin O
for O
symptomatic O
intracranial O
arterial O
stenosis O
. O
[]

At O
each O
age O
symptom B-outcome ['Life-Impact']
severity I-outcome ['Life-Impact']
, O
cognitive B-outcome ['Life-Impact']
and O
language B-outcome ['Life-Impact']
assessments O
were O
completed O
. O
['Life-Impact', 'Life-Impact']

To O
our O
knowledge O
, O
we O
have O
provided O
the O
first O
experimental O
evidence O
from O
a O
randomized O
controlled O
trial O
linking O
increased O
enjoyment O
with O
increased O
physical O
activity O
among O
black O
and O
white O
adolescent O
girls O
. O
[]

The O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
for O
the O
experimental O
arm O
was O
193 O
v O
182 O
days O
for O
the O
control O
arm O
( O
P O
=.75 O
) O
; O
6-month O
and O
1-year O
survival B-outcome ['Mortality']
rates O
were O
53 O
% O
and O
27 O
% O
v O
49 O
% O
and O
24 O
% O
for O
the O
control O
arm O
, O
respectively O
; O
median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
112 O
v O
109 O
days O
for O
the O
control O
arm O
. O
['Mortality', 'Mortality', 'Mortality']

BACKGROUND O
A O
psychological O
disorder O
called O
'Internet O
addiction O
' O
has O
newly O
emerged O
along O
with O
a O
dramatic O
increase O
of O
worldwide O
Internet O
use O
. O
[]

Using O
the O
LTS-D O
significantly O
reduced O
NFT O
compared O
to O
ET O
and O
the O
BMV O
( O
125 O
s O
vs. O
207 O
s O
vs. O
160 O
s O
; O
p O
< O
0.01 O
) O
. O
[]

Double-blind O
, O
placebo-controlled O
study O
of O
L-carnosine O
supplementation O
in O
children O
with O
autistic O
spectrum O
disorders O
. O
[]

No O
differences O
between O
the O
two O
arms O
, O
either O
as O
regards O
the O
duration O
of O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
or O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
were O
noted O
in O
the O
group O
with O
more O
than O
one O
invaded O
lymph O
node O
whatever O
the O
number O
of O
invaded O
lymph O
nodes O
. O
['Mortality', 'Mortality']

Furthermore O
, O
temperature O
elevation O
is O
dependent O
on O
both O
the O
duration O
and O
the O
intensity O
of O
the O
activity O
, O
which O
may O
eventually O
affect O
1RM O
performance O
. O
[]

Dose-response O
characteristics O
during O
long-term O
inhalation O
of O
nitric O
oxide O
in O
patients O
with O
severe O
acute O
respiratory O
distress O
syndrome O
: O
a O
prospective O
, O
randomized O
, O
controlled O
study O
. O
[]

The O
results O
are O
discussed O
in O
terms O
of O
the O
impact O
of O
learning O
processes O
specific O
to O
the O
roles O
of O
the O
staff O
members O
and O
motivational O
factors O
on O
learning O
and O
therapy O
outcome O
, O
along O
with O
institutional O
conditions O
influencing O
successful O
learning O
. O
[]

The O
purpose O
of O
this O
randomized O
pilot O
study O
is O
to O
conduct O
an O
intervention O
with O
68 O
rural O
women O
living O
with O
AIDS O
to O
compare O
the O
effectiveness O
of O
two O
different O
programs O
on O
depressive O
symptoms O
. O
[]

Temporal O
judgements O
of O
internal O
and O
external O
events O
in O
persons O
with O
and O
without O
autism O
. O
[]

When O
compared O
against O
the O
control O
, O
this O
regimen O
produced O
reduction O
of O
drain B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
total O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
whereas O
the O
IOPO O
regimen O
did O
not O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Outcome O
at O
7 O
years O
of O
children O
diagnosed O
with O
autism O
at O
age O
2 O
: O
predictive O
validity O
of O
assessments O
conducted O
at O
2 O
and O
3 O
years O
of O
age O
and O
pattern O
of O
symptom O
change O
over O
time O
. O
[]

[ O
Evaluation O
on O
the O
effect O
of O
intervention O
regarding O
breast O
self-examination O
for O
decreasing O
breast O
cancer O
mortality O
] O
. O
[]

In O
the O
108 O
patients O
treated O
with O
Defibrotide O
only O
one O
case O
of O
DVT B-outcome ['Physiological-Clinical']
was O
reported O
and O
in O
none O
of O
these O
patients O
were O
symptoms B-outcome ['Physiological-Clinical']
or O
signs B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
encountered O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
increase O
accrual O
among O
Hispanics O
to O
the O
Cancer O
Genetics O
Network O
national O
cancer O
genetics O
registry O
. O
[]

The O
5-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
72.3 O
% O
for O
the O
CCRT O
arm O
and O
54.2 O
% O
for O
the O
RT-only O
arm O
( O
P O
=.0022 O
) O
. O
['Mortality']

SUBJECTS O
A O
total O
of O
60 O
autistic O
children O
between O
the O
ages O
of O
3 O
and O
10 O
completed O
this O
study O
. O
[]

OUTCOMES O
the O
primary O
outcome O
was O
re-admission B-outcome ['Resource-use']
to I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
within O
6 O
months O
. O
['Resource-use']

H. O
pylori-infected O
subjects O
were O
randomized O
to O
receive O
either O
a O
1-week O
course O
of O
omeprazole O
, O
amoxicillin O
, O
and O
clarithromycin O
( O
OAC O
) O
or O
placebo O
. O
[]

The O
degree O
of O
esophageal B-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
was O
determined O
during O
endoscopy O
before O
the O
study O
. O
['Physiological-Clinical']

Pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
were O
evaluated O
at O
half O
hour O
and O
hourly O
intervals O
for O
4 O
hours O
. O
['Physiological-Clinical', 'Physiological-Clinical']

At O
the O
end O
of O
treatment O
86 O
% O
of O
patients O
in O
the O
CHOP O
arm O
had O
responded O
with O
58 O
% O
in O
CR O
. O
[]

In O
the O
pretreatment O
state O
there O
was O
good O
agreement O
between O
the O
two O
measures O
( O
r2 O
= O
0.96 O
, O
SEE O
0.012 O
g/cm2 O
) O
. O
[]

In O
a O
randomized O
, O
double-blind O
, O
controlled O
study O
, O
we O
compared O
heparinized O
and O
nonheparinized O
infusions O
for O
the O
maintenance O
of O
perioperative B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
catheter I-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
and O
the O
incidence O
of O
subsequent B-outcome ['Physiological-Clinical']
radial I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
occlusion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
this O
pilot O
study O
, O
we O
tested O
the O
effects O
of O
a O
novel O
intervention O
( O
JASPER O
, O
Joint O
Attention O
Symbolic O
Play O
Engagement O
and O
Regulation O
) O
on O
3 O
to O
5 O
year O
old O
, O
minimally O
verbal O
children O
with O
autism O
who O
were O
attending O
a O
non-public O
preschool O
. O
[]

UNLABELLED O
30 O
children O
between O
7 O
and O
17 O
years O
suffering O
from O
at O
least O
2 O
attacks/month O
of O
common O
or O
classical O
migraine O
since O
more O
than O
1 O
year O
were O
studied O
. O
[]

Variables O
of O
signal-averaged B-outcome ['Physiological-Clinical']
electrocardiography I-outcome ['Physiological-Clinical']
did O
not O
differ O
between O
the O
2 O
treatments O
. O
['Physiological-Clinical']

Fulfillment O
of O
IHS O
criteria O
was O
recorded O
for O
24 O
h. O
The O
middle B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
arteries I-outcome ['Physiological-Clinical']
were O
evaluated O
by O
transcranial B-outcome ['Physiological-Clinical']
Doppler I-outcome ['Physiological-Clinical']
and O
the O
diameter O
of O
the O
superficial B-outcome ['Physiological-Clinical']
temporal I-outcome ['Physiological-Clinical']
and O
radial B-outcome ['Physiological-Clinical']
arteries I-outcome ['Physiological-Clinical']
were O
measured O
with O
high O
frequency O
ultrasound B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
a O
measure O
of O
rate O
of O
non-verbal B-outcome ['Life-Impact']
communicative I-outcome ['Life-Impact']
acts I-outcome ['Life-Impact']
taken O
from O
an O
interactive O
play-based O
assessment O
at O
age O
2 O
was O
significantly O
associated O
with O
language B-outcome ['Life-Impact']
, O
communication B-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
outcomes I-outcome ['Life-Impact']
at O
age O
7 O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

4 O
There O
was O
a O
significantly O
greater O
fall B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

The O
suppressive O
activity O
of O
the O
patient O
plasma O
was O
assayed O
by O
measurement O
of O
normal O
PMN O
superoxide O
production O
relative O
to O
normal O
control O
plasma O
( O
ratio O
P O
: O
C O
) O
. O
[]

The O
study O
design O
was O
a O
prospective O
randomised O
controlled O
clinical O
trial O
. O
[]

Among O
patients O
with O
BRAF-mutated O
tumors O
, O
a O
nonsignificant O
trend O
toward O
improved O
OS B-outcome ['Physiological-Clinical']
was O
observed O
for O
IFL O
versus O
FU/LV O
arm O
( O
multivariate O
HR O
= O
0.52 O
; O
95 O
% O
CI O
: O
0.25-1.10 O
) O
. O
['Physiological-Clinical']

METHODS O
In O
this O
web-based O
study O
, O
543 O
family O
and O
internal O
medicine O
physicians O
were O
given O
a O
scenario O
describing O
either O
a O
black O
or O
white O
patient O
with O
severe O
OA O
refractory O
to O
medical O
treatment O
. O
[]

Regarding O
the O
immediate O
pattern O
response O
to O
loading O
, O
there O
was O
a O
tendency O
for O
increased O
qualitative B-outcome ['Physiological-Clinical']
variation I-outcome ['Physiological-Clinical']
across O
subjects O
as O
the O
load O
size O
increased O
, O
but O
the O
within-subject O
variability O
( O
coefficient O
of O
variation O
) O
was O
unaffected O
. O
['Physiological-Clinical']

This O
question O
arose O
when O
performing O
an O
investigation O
about O
the O
effect O
of O
Esberitox O
in O
a O
combined O
chemo-radiotherapy O
. O
[]

BACKGROUND O
AND O
PURPOSE O
Mouth O
leak O
occasionally O
complicates O
continuous O
positive O
airway O
pressure O
( O
CPAP O
) O
therapy O
, O
which O
leads O
to O
discomfort O
. O
[]

METHOD O
A O
double-blind O
, O
multicentre O
study O
was O
conducted O
in O
86 O
severely O
depressed O
inpatients O
( O
> O
or= O
25 O
on O
the O
17-item O
Hamilton O
depression O
rating O
scale O
[ O
HAMD O
] O
total O
score O
) O
to O
compare O
the O
efficacy O
and O
safety O
of O
fluvoxamine O
with O
that O
of O
clomipramine O
. O
[]

An O
intent-to-treat O
comparison O
of O
the O
numbers O
of O
courses O
affected O
by O
acute O
toxicity O
( O
fever O
, O
rigors O
) O
and O
chronic O
toxicity O
( O
nephrotoxicity O
) O
also O
indicated O
that O
there O
was O
no O
significant O
difference O
between O
AmB O
infused O
in O
dextrose O
( O
78 O
courses O
) O
and O
AmB O
infused O
in O
lipid O
emulsion O
( O
84 O
courses O
) O
. O
[]

Adding O
a O
saline O
flush O
to O
the O
high-concentration O
protocol O
eliminated O
the O
difference O
in O
depiction O
of O
hepatocellular B-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
between O
the O
moderate- O
and O
high-concentration O
protocols O
. O
['Physiological-Clinical']

The O
pharmacokinetic B-outcome ['Physiological-Clinical']
parameters O
used O
for O
the O
bioequivalence O
assessment O
( O
AUClast O
, O
AUCinf O
and O
Cmax B-outcome ['Physiological-Clinical']
) O
were O
determined O
from O
the O
terbinafine O
concentration O
data O
using O
non-compartmental O
analysis O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
adjusting O
for O
multiple O
testing O
, O
a O
SNP-dietary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
interaction O
effect O
on O
TAG B-outcome ['Physiological-Clinical']
was O
identified O
for O
lipin O
1 O
( O
LPIN1 O
) O
rs4315495 O
, O
with O
a O
decrease O
in O
TAG B-outcome ['Physiological-Clinical']
of O
20.26 O
mmol/l O
per O
A-allele/protein O
unit O
( O
95 O
% O
CI O
20.38 O
, O
20.14 O
, O
P=0.000043 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Prolonged B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
observed O
with O
both O
drugs O
, O
with O
10-20 O
% O
of O
patients O
still O
alive B-outcome ['Mortality']
> O
5 O
years O
after O
randomization O
. O
['Mortality', 'Mortality']

Measurements O
were O
performed O
in O
plasma O
of O
arterial O
and O
coronary O
sinus O
blood O
samples O
collected O
before O
aortic O
clamping O
, O
immediately O
after O
unclamping O
, O
and O
after O
25 O
min O
of O
reperfusion O
. O
[]

METHODS O
523 O
patients O
undergoing O
balloon O
angioplasty O
and O
sequential O
intracoronary O
Doppler O
measurements O
were O
examined O
as O
part O
of O
the O
DEBATE O
II O
trial O
( O
Doppler O
endpoints O
balloon O
angioplasty O
trial O
Europe O
) O
. O
[]

OBJECTIVES O
To O
evaluate O
the O
effect O
of O
eradication B-outcome ['Physiological-Clinical']
of O
Helicobacter O
pylori O
( O
H.pylori O
) O
in O
the O
patients O
with O
duodenal O
ulcer O
( O
Du O
) O
upon O
the O
DU B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

They O
analyzed O
data O
by O
using O
Friedman O
and O
Wilcoxon O
signed-rank O
tests O
for O
within-group O
comparison O
. O
[]

We O
tested O
assumptions O
of O
equality O
between O
GAS O
descriptions O
for O
outcome O
measurement O
in O
a O
randomized O
trial O
( O
i.e. O
, O
measurability O
, O
equidistance O
, O
level O
of O
difficulty O
, O
comparability O
of O
behavior O
samples O
collected O
from O
teachers O
vs. O
researchers O
and O
live O
vs. O
videotape O
) O
. O
[]

rhTPO-treated O
patients O
required O
fewer O
phereses O
to O
achieve O
minimum O
( O
P= O
.011 O
) O
and O
target O
( O
P= O
.015 O
) O
CD34+ B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
values O
. O
['Physiological-Clinical']

Effect O
of O
interferon O
gamma O
on O
infection-related O
death O
in O
patients O
with O
severe O
injuries O
. O
[]

A O
follow-up O
of O
212 O
randomized O
patients O
. O
[]

Clinical O
and O
endoscopic O
controls O
were O
performed O
4 O
, O
6 O
and O
8 O
weeks O
after O
the O
onset O
of O
the O
treatment O
. O
[]

Measurements O
of O
exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
, O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
, O
symptoms B-outcome ['Physiological-Clinical']
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
will O
be O
taken O
at O
baseline O
, O
immediately O
following O
the O
intervention O
and O
at O
12 O
months O
, O
by O
a O
blinded O
assessor O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Isotonic O
training O
in O
addition O
, O
improved O
ventilatory B-outcome ['Physiological-Clinical']
efficiency O
. O
['Physiological-Clinical']

The O
infection B-outcome ['Physiological-Clinical']
rate O
during O
the O
study O
was O
significantly O
higher O
in O
patients O
who O
received O
conventional O
insulin O
therapy O
than O
that O
in O
patients O
who O
received O
intensive O
insulin O
therapy O
( O
46.2 O
% O
vs. O
31.4 O
% O
; O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
run-in O
clinical O
score O
was O
high O
. O
[]

METHODS O
Men O
were O
randomized O
to O
either O
a O
10-week O
, O
group-based O
CBSM O
intervention O
( O
n O
= O
83 O
) O
or O
a O
psychoeducational O
seminar O
group O
( O
n O
= O
46 O
) O
. O
[]

The O
mean O
MSLT B-outcome ['Physiological-Clinical']
score O
of O
the O
zolpidem O
group O
did O
not O
differ O
from O
that O
of O
the O
placebo O
group O
, O
and O
the O
stability O
within O
treatment O
groups O
also O
did O
not O
differ O
. O
['Physiological-Clinical']

CONCLUSION O
Small O
needle-knife O
comprehensive O
therapy O
can O
significantly O
improve O
pain B-outcome ['Physiological-Clinical']
and O
lumbar B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
range I-outcome ['Physiological-Clinical']
in O
the O
chronic O
nonspecific O
low O
back O
pain O
patient O
, O
with O
a O
stable O
long-term O
therapeutic O
effect O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
CoAct O
( O
Cocreating O
Activity O
) O
study O
is O
investigating O
a O
novel O
lifestyle O
intervention O
, O
aimed O
at O
the O
working O
population O
, O
with O
daily O
activity O
monitoring O
and O
distance O
counselling O
via O
telephone O
and O
secure O
web O
messages O
. O
[]

In O
a O
randomized O
study O
of O
24 O
children O
with O
severe O
head O
injury O
, O
urinary O
free O
cortisol O
was O
measured O
by O
radioimmunoassay O
. O
[]

3 O
) O
After O
treatment O
, O
the O
onsets O
of O
refractory B-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
pectoris I-outcome ['Physiological-Clinical']
were O
reduced O
more O
significantly O
in O
the O
diltiazem O
group O
than O
in O
nitroglycerin O
group O
[ O
4 O
( O
3.8 O
% O
) O
vs O
13 O
( O
11.9 O
% O
) O
, O
RR O
0.32 O
( O
95 O
% O
CI O
0.11 O
- O
0.96 O
) O
, O
P O
< O
0.05 O
] O
. O
( O
['Physiological-Clinical']

One-quarter O
of O
the O
patients O
reported O
urinary O
incontinence O
. O
[]

Differences O
were O
small O
and O
lacked O
clinical O
significance O
, O
which O
was O
in O
accordance O
with O
the O
overall O
impression O
of O
the O
parents O
and O
teachers O
and O
visual O
inspection O
of O
graphs O
. O
[]

In O
conclusion O
, O
a O
single O
dose O
of O
misoprostol O
( O
400 O
mcg O
) O
has O
no O
clinically O
significant O
vasoconstrictive B-outcome ['Physiological-Clinical']
or O
vasodilative B-outcome ['Physiological-Clinical']
properties O
in O
man O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
obtained O
toxicity B-outcome ['Adverse-effects']
data O
using O
an O
adverse-event O
reporting O
system O
, O
with O
follow-up O
questionnaires O
to O
seek O
detailed O
information O
for O
specific O
toxicities O
. O
['Adverse-effects']

Primary O
biliary O
cirrhosis O
( O
PBC O
) O
is O
a O
chronic O
, O
progressive O
, O
cholestatic O
liver O
disease O
. O
[]

OBJECTIVE O
To O
determine O
if O
early O
developmental O
intervention O
( O
EDI O
) O
improves O
developmental O
abilities O
in O
resuscitated O
children O
. O
[]

A O
randomized O
clinical O
trial O
of O
St. O
John O
's O
wort O
for O
smoking B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
. O
['Life-Impact']

RESULTS O
In O
group O
A O
with O
90 O
evaluable O
patients O
, O
the O
response O
rate O
was O
25.6 O
% O
( O
6 O
CR O
, O
17 O
PR O
) O
whereas O
in O
group O
B O
with O
88 O
evaluable O
patients O
, O
the O
response O
rate O
was O
31.8 O
% O
( O
3 O
CR O
, O
25 O
PR O
) O
, O
P O
= O
0.733 O
. O
[]

Tegaserod O
, O
a O
5-hydroxytryptamine O
type O
4 O
receptor O
partial O
agonist O
, O
is O
devoid O
of O
electrocardiographic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Over-all O
, O
empiric O
antibiotic O
trials O
were O
more O
often O
successful B-outcome ['Physiological-Clinical']
( O
P O
= O
0.004 O
) O
in O
group O
1 O
( O
55 O
of O
62 O
patients O
or O
89 O
per O
cent O
) O
than O
in O
group O
2 O
( O
42 O
of O
64 O
patients O
, O
66 O
per O
cent O
) O
mwithin O
group O
1 O
, O
there O
was O
a O
favorable O
outcome O
in O
30 O
of O
32 O
( O
94 O
per O
cent O
) O
C-T/S O
trials O
and O
in O
25 O
of O
30 O
( O
83 O
per O
cent O
) O
C-G O
trials O
( O
P O
= O
0.25 O
) O
; O
within O
group O
2 O
, O
there O
was O
a O
favorable O
outcome O
in O
23 O
of O
30 O
( O
77 O
per O
cent O
) O
C-T/S O
trials O
and O
in O
19 O
of O
34 O
( O
56 O
per O
cent O
) O
C-G O
trials O
( O
P O
= O
0.14 O
) O
, O
Combined O
results O
in O
both O
groups O
indicated O
a O
higher O
proportion O
of O
favorable O
outcome O
in O
C-T/S O
trials O
( O
53 O
of O
62 O
, O
85 O
per O
cent O
) O
than O
in O
C-G O
trials O
( O
44 O
of O
64 O
, O
69 O
per O
cent O
) O
. O
['Physiological-Clinical']

acetaminophen O
pretreatment O
on O
the O
propofol O
injection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Control O
and O
experimental O
tests O
were O
also O
performed O
in O
seven O
male O
patients O
with O
subclinical O
hypothyroidism O
and O
were O
repeated O
in O
the O
same O
obese O
subjects O
after O
substantial O
weight O
loss O
. O
[]

Effect O
of O
protein O
ingestion O
on O
the O
glucose B-outcome ['Physiological-Clinical']
appearance I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
people O
with O
type O
2 O
diabetes O
. O
['Physiological-Clinical']

The O
use O
of O
concurrent O
cisplatin O
had O
no O
detectable O
effect O
on O
distant O
metastases O
. O
[]

Feasibility O
of O
an O
obesity O
intervention O
for O
paediatric O
primary O
care O
targeting O
parenting O
and O
children O
: O
Helping O
HAND O
. O
[]

There O
is O
no O
consistently O
safe O
, O
effective O
treatment O
for O
the O
maintenance O
of O
remission O
. O
[]

The O
two O
subtypes O
of O
dementia O
could O
be O
differentiated O
in O
some O
conventional O
EEG O
variables O
but O
mostly O
by O
means O
of O
power O
asymmetry O
indices O
. O
[]

We O
performed O
a O
randomized O
trial O
comparing O
the O
use O
of O
quantitative O
DNAemia O
versus O
positive O
antigenemia O
for O
starting O
preemptive O
antihuman O
cytomegalovirus O
( O
HCMV O
) O
therapy O
in O
hematopoietic O
stem-cell O
transplantation O
( O
HSCT O
) O
recipients O
. O
[]

Systemic O
oxytetracycline O
, O
in O
combination O
with O
intramammary O
dry O
cow O
treatment O
, O
did O
not O
improve O
the O
rate O
of O
cure B-outcome ['Physiological-Clinical']
for O
S. O
aureus O
mastitis O
. O
['Physiological-Clinical']

Just O
before O
surgery O
, O
phonophoresis O
of O
a O
ketoprofen O
gel O
( O
Fastum O
gel O
) O
was O
given O
to O
group O
A O
using O
continuous O
ultrasound O
( O
1 O
MHz O
, O
1.5 O
W/cm2 O
, O
for O
5 O
minutes O
) O
. O
[]

We O
also O
monitored O
the O
effect O
of O
enoxaparin O
on O
activation O
of O
coagulation B-outcome ['Physiological-Clinical']
and O
fibrinolysis B-outcome ['Physiological-Clinical']
after O
closure O
of O
the O
ruptured O
aneurysm O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
staff O
members O
rated O
their O
professional O
competence O
, O
quality O
of O
interaction O
with O
the O
client O
, O
team O
culture O
and O
work O
satisfaction O
before O
and O
after O
being O
engaged O
in O
the O
program O
, O
with O
additional O
ratings O
of O
their O
personal O
aims O
at O
the O
beginning O
of O
the O
program O
. O
[]

OBJECTIVE O
We O
tested O
the O
hypothesis O
that O
supplementation O
with O
a O
micronutrient-fortified O
beverage O
improves O
micronutrient O
status O
and O
physical O
and O
mental O
development O
in O
apparently O
healthy O
schoolchildren O
. O
[]

PATIENTS O
AND O
METHODS O
A O
total O
of O
67 O
eyes O
of O
35 O
Behcet O
's O
patients O
with O
chronic O
, O
but O
well-controlled O
uveitis O
, O
and O
CMO O
were O
randomised O
into O
a O
double-masked O
, O
crossover O
trial O
comparing O
the O
effect O
of O
acetazolamide O
vs O
placebo O
. O
[]

PM O
presented O
a O
superior O
ICER B-outcome ['Physiological-Clinical']
, O
suggesting O
that O
it O
may O
be O
a O
promising O
treatment O
option O
to O
implement O
in O
EDs O
. O
['Physiological-Clinical']

The O
Zerotip O
functioned O
well O
for O
2 O
mm O
calculi O
in O
the O
hands O
of O
expert O
operators O
( O
15 O
+/- O
9 O
seconds O
) O
but O
not O
novice O
operators O
( O
94 O
+/- O
95 O
seconds O
) O
. O
[]

Although O
some O
studies O
reported O
that O
patients O
with O
cystic O
fibrosis O
( O
CF O
) O
lack O
magnesium O
, O
no O
international O
study O
has O
assessed O
the O
importance O
of O
oral O
magnesium O
supplementation O
in O
CF O
patients O
. O
[]

In O
contrast O
, O
lathosterol/TC O
unchanged O
and O
campesterol/TC O
increased O
, O
increasing O
campesterol/lathosterol O
ratio O
for O
52 O
weeks O
in O
double-dose O
statin O
. O
[]

During O
this O
time O
, O
the O
children O
received O
120 O
% O
of O
estimated O
energy O
requirements O
( O
either O
3.75 O
% O
or O
22.5 O
% O
as O
lipid O
) O
and O
amino O
acids O
2.5 O
gm/120 O
kcal O
by O
central O
venous O
catheter O
, O
plus O
as O
much O
of O
their O
usual O
diet O
as O
desired O
. O
[]

Despite O
improvement O
on O
a O
number O
of O
EF O
measures O
, O
no O
statistically O
significant O
between-group O
differences O
were O
found O
( O
with O
gains O
observed O
for O
both O
the O
placebo O
and O
donepezil O
groups O
) O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Bulbar B-outcome ['Physiological-Clinical']
conjunctival I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
( O
primary B-outcome ['Physiological-Clinical']
sign I-outcome ['Physiological-Clinical']
) O
and O
itching B-outcome ['Physiological-Clinical']
( O
primary O
symptom B-outcome ['Physiological-Clinical']
) O
over O
the O
first O
2 O
weeks O
of O
treatment O
was O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
a O
subsequent O
study O
did O
not O
find O
evidence O
for O
a O
drug O
effect O
. O
[]

Adherence O
rates O
were O
lower O
in O
adolescents O
( O
12-17 O
years O
old O
) O
. O
['Life-Impact']

Linear O
regression O
analyses O
showed O
that O
gender O
is O
an O
independent O
predictor O
of O
the O
ABP O
responses B-outcome ['Physiological-Clinical']
to O
HCT O
and O
to O
LIS O
. O
['Physiological-Clinical']

Race O
remained O
a O
significant O
independent O
risk O
factor O
even O
after O
controlling O
for O
the O
higher O
severity O
of O
illness O
, O
greater O
disability O
, O
and O
more O
complex O
presentation O
of O
African O
American O
amputees O
. O
[]

Ten O
patients O
showed O
anti-HCV B-outcome ['Physiological-Clinical']
positivity O
which O
remained O
unchanged O
after O
the O
treatment O
. O
['Physiological-Clinical']

Adverse O
events O
were O
documented O
. O
[]

However O
, O
no O
study O
has O
led O
to O
the O
Food O
and O
Drug O
Administration O
's O
approval O
of O
n-BCA O
for O
intravascular O
use O
. O
[]

All O
patients O
also O
underwent O
digital O
subtraction O
angiography O
( O
DSA O
) O
and/or O
contrast-enhanced O
magnetic O
resonance O
angiography O
( O
CEMRA O
) O
. O
[]

Ambulatory B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
was O
performed O
in O
the O
final O
week O
of O
each O
phase O
. O
['Physiological-Clinical']

SETTING O
Primary O
care O
practices O
caring O
for O
children O
in O
New O
Hampshire O
with O
special O
attention O
to O
clinicians O
serving O
10 O
towns O
that O
were O
involved O
in O
a O
randomized O
controlled O
trial O
of O
the O
multicomponent O
SunSafe O
intervention O
involving O
schools O
, O
recreation O
areas O
, O
and O
primary O
care O
practices O
. O
[]

No O
collective B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
was O
found O
in O
these O
groups O
. O
['Physiological-Clinical']

After O
the O
change O
to O
flecainide O
, O
9 O
of O
15 O
patients O
( O
60 O
% O
) O
with O
AF O
still O
converted B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Ambulatory B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
was O
unchanged O
in O
subjects O
randomized O
to O
either O
nonpharmacological O
intervention O
or O
aspirin O
on O
awakening O
. O
['Physiological-Clinical']

Neither O
increase O
nor O
decrease O
was O
statistically O
significant O
. O
[]

Groups O
from O
the O
sample O
of O
the O
cross-national O
collaborative O
panic O
study O
( O
CNCPS O
) O
were O
compared O
for O
differences O
in O
basic O
characteristics O
and O
for O
the O
ability O
to O
predict O
treatment O
response O
. O
[]

There O
were O
no O
maternal O
or O
[]

The O
difference O
between O
the O
acetylcholine O
group O
and O
the O
combined O
group O
for O
rises O
> O
6 O
mm O
Hg O
was O
significant O
using O
the O
chi O
2 O
test O
while O
the O
acetazolamide O
group O
showed O
a O
significant O
difference O
for O
rises O
> O
[]

The O
success B-outcome ['Physiological-Clinical']
rate O
of O
second-line O
levofloxacin-based O
triple O
therapy O
is O
decreasing O
. O
['Physiological-Clinical']

Pulmonary B-outcome ['Physiological-Clinical']
hypertensive I-outcome ['Physiological-Clinical']
crisis I-outcome ['Physiological-Clinical']
was O
detected O
in O
4 O
patients O
in O
the O
control O
group O
, O
but O
none O
in O
the O
sildenafil O
group O
( O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical']

The O
SPLS-ps O
group O
showed O
a O
tendency O
toward O
better O
performances B-outcome ['Life-Impact']
than O
the O
SPLS-pp O
group O
, O
but O
the O
difference O
was O
not O
significant O
. O
['Life-Impact']

Non-attendance O
for O
the O
second O
test O
was O
also O
significantly O
higher O
among O
women O
who O
were O
younger O
, O
smokers O
and O
had O
negative O
cytology O
on O
the O
first O
surveillance O
test O
. O
[]

The O
AI B-outcome ['Physiological-Clinical']
of O
gastric B-outcome ['Physiological-Clinical']
cancer B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
in O
Group O
FC O
was O
significantly O
higher O
than O
in O
the O
other O
groups O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Reflecting O
the O
hierarchy O
of O
controls O
, O
material O
factors O
were O
weighted O
highest O
, O
followed O
by O
process O
, O
and O
then O
human O
interface O
. O
[]

However O
, O
the O
sensitivity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
HPV I-outcome ['Physiological-Clinical']
testing I-outcome ['Physiological-Clinical']
using O
self-collected O
samples O
was O
significantly O
lower O
among O
treated O
versus O
untreated O
women O
( O
55 O
% O
vs. O
78 O
% O
, O
p=0.01 O
) O
. O
['Physiological-Clinical']

Relatively O
few O
studies O
have O
been O
conducted O
on O
the O
frequency O
of O
paraesthesia O
during O
combined O
spinal O
epidural O
anaesthesia O
. O
[]

Despite O
the O
relatively O
small O
sample O
size O
our O
results O
seem O
to O
exclude O
any O
significant O
influence O
of O
low-dose O
aspirin O
on O
BP B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
in O
hypertensives O
under O
treatment O
. O
['Physiological-Clinical']

Preventing O
disability B-outcome ['Life-Impact']
and O
falls O
in O
older O
adults O
: O
a O
population-based O
randomized O
trial O
. O
['Life-Impact']

Comparative O
effectiveness O
of O
exercise O
electrocardiography O
with O
or O
without O
myocardial O
perfusion O
single O
photon O
emission O
computed O
tomography O
in O
women O
with O
suspected O
coronary O
artery O
disease O
: O
results O
from O
the O
What O
Is O
the O
Optimal O
Method O
for O
Ischemia O
Evaluation O
in O
Women O
( O
WOMEN O
) O
trial O
. O
[]

Outpatients O
were O
excluded O
due O
to O
difficulties O
in O
obtaining O
sufficient O
clinical O
information O
. O
[]

Several O
studies O
have O
reported O
that O
most O
adverse O
events O
are O
due O
to O
errors O
of O
hospital O
staff O
, O
and O
emphasized O
the O
necessity O
of O
promoting O
countermeasures O
against O
medical O
errors O
. O
[]

Schizophrenia O
( O
SZ O
) O
is O
associated O
with O
high O
rates O
of O
smoking O
. O
[]

The O
global O
impression O
, O
evaluated O
by O
video O
rating O
, O
gave O
no O
indication O
as O
to O
a O
beneficial O
effect O
of O
the O
treatment O
. O
- O
[]

Early O
changes O
generally O
failed O
to O
provide O
accurate O
information O
for O
tumour O
response O
and O
survival O
. O
[]

DESIGN O
Prospective O
, O
pseudorandomised O
, O
controlled O
trial O
. O
[]

We O
evaluated O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
quality O
of O
life O
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
, O
and O
satisfaction B-outcome ['Life-Impact']
of O
patients O
who O
were O
monitored O
by O
specially O
trained O
community O
pharmacists O
in O
a O
group O
medical O
practice O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Using O
baseline O
and O
follow-up O
photographs O
and O
pre-established O
definitions O
and O
methodology O
in O
a O
masked O
analysis O
, O
posterior O
progression O
rates O
and O
foveal O
proximity O
rates O
for O
individual O
lesions O
, O
selected O
by O
prospectively O
defined O
criteria O
, O
were O
calculated O
in O
each O
patient O
. O
[]

A O
further O
15 O
patients O
with O
more O
advanced O
malignancies O
were O
added O
to O
our O
studies O
. O
[]

All O
patients O
developed O
antibody B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
against I-outcome ['Physiological-Clinical']
ALVAC I-outcome ['Physiological-Clinical']
, O
but O
increased O
anti-CEA B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
titers I-outcome ['Physiological-Clinical']
were O
detected O
in O
only O
three O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
difference O
was O
maintained O
at O
the O
6- O
and O
12-months O
follow-ups O
. O
[]

Fluvoxamine O
as O
effective O
as O
clomipramine O
against O
symptoms O
of O
severe B-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
: O
results O
from O
a O
multicentre O
, O
double-blind O
study O
. O
['Life-Impact']

The O
rebleeding B-outcome ['Physiological-Clinical']
rate O
was O
significantly O
higher O
in O
the O
sclerotherapy O
group O
( O
25 O
% O
vs. O
4 O
% O
, O
P O
=.049 O
) O
, O
as O
was O
the O
rate O
of O
major O
complications B-outcome ['Adverse-effects']
( O
25 O
% O
vs. O
4 O
% O
, O
P O
=.049 O
) O
. O
['Physiological-Clinical', 'Adverse-effects']

All O
groups O
showed O
significant O
improvement O
in O
6-minute B-outcome ['Life-Impact']
walk I-outcome ['Life-Impact']
distance I-outcome ['Life-Impact']
, O
quality-of-life B-outcome ['Life-Impact']
score O
, O
and O
New O
York O
Heart O
Association O
class O
. O
['Life-Impact', 'Life-Impact']

There O
was O
no O
increase O
in O
serious O
adverse O
events O
associated O
with O
rhAT O
. O
[]

Symptomatic B-outcome ['Physiological-Clinical']
vasospasm I-outcome ['Physiological-Clinical']
( O
OR O
2.47 O
; O
95 O
% O
CI O
1.45 O
to O
4.19 O
; O
P O
< O
0.001 O
) O
, O
poorer O
Hunt O
and O
Hess B-outcome ['Physiological-Clinical']
grade I-outcome ['Physiological-Clinical']
( O
OR O
2.50 O
; O
95 O
% O
CI O
1.31 O
to O
4.75 O
; O
P=0.005 O
) O
, O
need O
for O
permanent B-outcome ['Physiological-Clinical']
shunt I-outcome ['Physiological-Clinical']
( O
OR O
8.90 O
; O
95 O
% O
CI O
1.80 O
to O
44.15 O
; O
P=0.008 O
) O
, O
and O
larger O
size O
of O
the O
aneurysm B-outcome ['Physiological-Clinical']
( O
OR O
1 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Venlafaxine O
versus O
clonidine O
for O
the O
treatment O
of O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
in O
breast O
cancer O
patients O
: O
a O
double-blind O
, O
randomized O
cross-over O
study O
. O
['Physiological-Clinical']

Secondary O
outcome O
measures O
were O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
, O
respiratory B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
RDAI B-outcome ['Physiological-Clinical']
measurement I-outcome ['Physiological-Clinical']
twice I-outcome ['Physiological-Clinical']
daily I-outcome ['Physiological-Clinical']
for O
the O
first O
4 O
days O
, O
and O
the O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

PARTICIPANTS O
Consisted O
of O
61 O
consecutive O
male O
and O
female O
patients O
from O
ages O
40 O
to O
80 O
who O
were O
scheduled O
for O
cardiac O
surgery O
with O
cardiopulmonary O
bypass O
. O
[]

The O
placebo O
group O
received O
daily O
injections O
of O
saline O
without O
IFN O
. O
[]

Results O
showed O
increased O
opportunities B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
respond I-outcome ['Life-Impact']
, O
increased O
levels O
of O
responding B-outcome ['Life-Impact']
and O
academic B-outcome ['Life-Impact']
engagement I-outcome ['Life-Impact']
, O
higher O
gains O
on O
weekly O
criterion-referenced O
pre- O
and O
posttests O
, O
and O
decreased O
passive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
inappropriate I-outcome ['Life-Impact']
student I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
during O
interventions O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Both O
groups O
had O
an O
appropriate O
response O
with O
regard O
to O
H. O
influenzae O
type O
b O
polysaccharide O
polyribosylribitol O
phosphate O
, O
but O
the O
dynamics O
of O
the O
response O
were O
significantly O
different O
: O
geometric O
mean O
concentrations B-outcome ['Physiological-Clinical']
( O
micrograms O
per O
ml O
) O
after O
the O
second O
, O
third O
and O
booster O
doses O
were O
1.27 O
, O
5.06 O
and O
23.12 O
in O
the O
Pa O
group O
and O
2.72 O
, O
6.66 O
and O
13.59 O
in O
the O
Pw O
group O
, O
respectively O
( O
P O
= O
0.0002 O
after O
second O
dose O
; O
P O
= O
0.0005 O
after O
booster O
) O
. O
['Physiological-Clinical']

Gastric B-outcome ['Physiological-Clinical']
emptying B-outcome ['Physiological-Clinical']
improved O
significantly O
but O
equally O
in O
both O
groups O
over O
the O
study O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
end O
point O
was O
early B-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
measured O
by O
opiate O
usage O
and O
pain O
score O
in O
the O
first O
12 O
hours O
) O
. O
['Physiological-Clinical']

CONCLUSION O
( O
S O
) O
The O
results O
indicate O
that O
sertraline O
is O
an O
effective O
option O
in O
the O
management O
of O
depressive O
mood O
symptoms O
associated O
with O
ovarian O
suppression O
during O
GnRH O
agonist O
therapy O
. O
[]

Phenobarbitone O
was O
rapidly O
absorbed O
, O
reaching O
a O
mean O
( O
range O
) O
peak O
concentration O
of O
34.2 O
[ O
29.3-42.6 O
] O
mumol.l-1 O
in O
a O
median O
( O
range O
) O
of O
4 O
( O
2.5-12 O
) O
h. O
These O
values O
are O
comparable O
to O
those O
previously O
reported O
in O
healthy O
children O
and O
in O
children O
with O
febrile B-outcome ['Physiological-Clinical']
convulsions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Auditory O
evoked O
potential O
modifications O
according O
to O
clinical O
and O
biochemical O
responsiveness O
to O
fenfluramine O
treatment O
in O
children O
with O
autistic O
behavior O
. O
[]

A O
prospective O
, O
randomized O
comparison O
of O
BCAH O
and O
PTFE O
vascular O
access O
grafts O
resulted O
in O
no O
statistically O
significant O
difference O
when O
analyzed O
for O
survival O
rates O
of O
complications B-outcome ['Adverse-effects']
, O
types O
of O
complications B-outcome ['Adverse-effects']
, O
reasons B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
failure I-outcome ['Life-Impact']
, O
and O
clot B-outcome ['Physiological-Clinical']
salvageability I-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Adverse-effects', 'Life-Impact', 'Physiological-Clinical']

A O
20-gauge O
catheter O
was O
inserted O
into O
a O
superficial O
radial O
vein O
of O
the O
left O
hand O
, O
and O
after O
the O
occlusion O
of O
venous O
drainage O
, O
Groups O
I O
, O
II O
, O
and O
III O
were O
pretreated O
with O
40 O
mg O
of O
lidocaine O
in O
saline O
, O
50 O
mg O
of O
i.v O
. O
[]

CONCLUSIONS O
In O
patients O
with O
ISR O
, O
an O
oral O
adjunctive O
sirolimus O
treatment O
with O
an O
intensified O
loading O
regimen O
before O
coronary O
intervention O
resulted O
in O
a O
significant O
improvement O
in O
the O
angiographic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
eradication O
rates O
of O
the O
PAC7 O
group O
were O
not O
inferior O
to O
those O
of O
the O
PAC14 O
group O
in O
both O
intention-to-treat O
analysis O
( O
71.2 O
% O
vs. O
75.5 O
% O
) O
and O
per-protocol O
analysis O
( O
83.6 O
% O
vs. O
86.6 O
% O
) O
. O
[]

METHODS O
Out-patients O
scheduled O
for O
endoscopic O
ultrasonography O
were O
randomly O
assigned O
to O
oral O
pre-medication O
with O
the O
anti-foam O
agent O
, O
dimethylpolysiloxane O
, O
alone O
( O
treatment O
A O
; O
n O
= O
29 O
) O
, O
with O
dimethylpolysiloxane O
plus O
sodium O
bicarbonate O
( O
treatment O
B O
; O
n O
= O
29 O
) O
or O
with O
dimethylpolysiloxane O
, O
sodium O
bicarbonate O
and O
pronase O
( O
treatment O
C O
; O
n O
= O
29 O
) O
. O
[]

OBJECTIVE O
This O
study O
tested O
the O
hypotheses O
that O
intermittent O
coronary O
sinus O
occlusion O
( O
iCSO O
) O
reduces O
myocardial B-outcome ['Physiological-Clinical']
ischaemia I-outcome ['Physiological-Clinical']
, O
and O
that O
the O
amount O
of O
ischaemia B-outcome ['Physiological-Clinical']
reduction O
is O
related O
to O
coronary O
collateral O
function O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subjects O
were O
recruited O
at O
10 O
U.S. O
centers O
between O
1993 O
and O
2001 O
. O
[]

Two O
high O
prevalence O
HIV/AIDS O
villages O
in O
rural O
Andhra O
Pradesh O
, O
which O
were O
demographically O
alike O
and O
served O
by O
distinct O
Public O
Health O
Centers O
, O
were O
selected O
randomly O
from O
a O
total O
of O
16 O
villages O
. O
[]

Systemic B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
is O
virtually O
absent O
, O
and O
no O
severe B-outcome ['Adverse-effects']
drug-related I-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
have O
ever O
been O
reported O
. O
['Physiological-Clinical', 'Adverse-effects']

The O
efficacy O
of O
audiotapes O
in O
promoting B-outcome ['Life-Impact']
psychological I-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
in O
cancer O
patients O
: O
a O
randomised O
, O
controlled O
trial O
. O
['Life-Impact']

Of O
85 O
patients O
having O
a O
positive O
culture O
after O
completing O
treatment O
, O
6 O
( O
7.1 O
% O
) O
were O
classified O
as O
false-positive O
cultures O
by O
a O
review O
committee O
blinded O
to O
treatment O
assignment O
. O
[]

INTERPRETATION O
Annual O
single-dose O
community-wide O
treatment O
with O
diethylcarbamazine O
alone O
or O
with O
ivermectin O
is O
effective O
for O
the O
control O
of O
lymphatic O
filariasis O
in O
highly O
endemic O
areas O
, O
but O
combination O
therapy O
brings O
about O
greater O
decreases O
in O
rates O
and O
intensity O
of O
[]

CrCl B-outcome ['Physiological-Clinical']
was O
calculated O
using O
the O
Cockcroft O
and O
Gault O
formula O
, O
and O
the O
associations O
of O
CrCl B-outcome ['Physiological-Clinical']
with O
outcomes O
were O
evaluated O
using O
logistic O
regression O
models O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Behaviour B-outcome ['Life-Impact']
was O
registered O
before O
, O
during O
and O
after O
the O
period O
with O
a O
gluten-free O
diet O
. O
['Life-Impact']

Changes O
in O
skin B-outcome ['Physiological-Clinical']
microcirculatory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
flux B-outcome ['Physiological-Clinical']
were O
measured O
bilaterally O
by O
infrared O
photoplethysmography O
and O
laser O
doppler O
fluxmetry O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

WOMAC O
response B-outcome ['Physiological-Clinical']
over O
the O
first O
6 O
days O
was O
greater O
( O
p O
< O
0.05 O
) O
with O
both O
rofecoxib O
doses O
than O
acetaminophen O
and O
celecoxib O
. O
['Physiological-Clinical']

RLS O
is O
present O
in O
20-40 O
% O
of O
patients O
with O
renal O
failure O
. O
[]

More O
than O
4 O
mg O
of O
pyridoxine O
supplementation O
daily O
was O
required O
for O
most O
pregnancies O
to O
maintain O
maternal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
PLP I-outcome ['Physiological-Clinical']
levels O
within O
the O
range O
observed O
during O
the O
first O
trimester O
and O
in O
the O
nonpregnant O
state O
. O
['Physiological-Clinical']

Nonanimal O
stabilized O
hyaluronic O
acid O
has O
reduced O
potential O
for O
immunogenicity O
and O
hypersensitivity O
and O
may O
provide O
a O
more O
durable O
aesthetic O
result O
. O
[]

Final O
survival B-outcome ['Mortality']
analyses O
and O
updated O
safety O
results O
are O
reported O
. O
['Mortality']

METHODS O
AND O
RESULTS O
A O
total O
of O
122 O
( O
qDES O
66 O
, O
BMS O
56 O
) O
patients O
were O
enrolled O
into O
the O
IVUS O
substudy O
. O
[]

Despite O
a O
significant O
decline O
in O
symptoms O
of O
emotional O
distress O
during O
the O
study O
period O
, O
the O
women O
in O
this O
sample O
reported O
high O
levels O
of O
depressive B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
at O
baseline O
and O
6-month O
follow-up O
. O
['Life-Impact']

Reduction O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
to O
the O
normotensive O
range O
was O
observed O
only O
when O
there O
was O
a O
concomitant O
restriction O
of O
sodium O
intake O
. O
['Physiological-Clinical']

A O
randomized O
double-blind O
clinical O
trial O
compared O
the O
efficacy O
and O
safety O
of O
600 O
mg O
of O
ABC O
administered O
once O
daily O
( O
n O
= O
384 O
) O
versus O
300 O
mg O
of O
ABC O
administered O
twice O
daily O
( O
n O
= O
386 O
) O
in O
combination O
with O
300 O
mg O
of O
lamivudine O
( O
3TC O
) O
and O
600 O
mg O
of O
efavirenz O
( O
EFV O
) O
administered O
once O
daily O
in O
antiretroviral-naive O
patients O
over O
48 O
weeks O
. O
[]

[ O
Safety O
of O
adjuvant O
dose-dense O
chemotherapy O
with O
paclitaxel O
and O
epirubicin O
for O
high-risk O
breast O
cancer O
] O
. O
[]

In O
contrast O
, O
fasting B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
, O
and O
hemoglobin B-outcome ['Physiological-Clinical']
A1C I-outcome ['Physiological-Clinical']
were O
lowered O
and O
insulin O
sensitivity O
increased O
with O
estradiol O
therapy O
, O
but O
the O
changes O
were O
not O
related O
to O
carotid O
IMT O
progression O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Only O
a O
formal O
trial O
of O
fever B-outcome ['Physiological-Clinical']
treatment O
or O
prevention O
can O
address O
this O
issue O
. O
['Physiological-Clinical']

RESULTS O
Dexamethasone O
produced O
a O
significant O
23-mm O
improvement O
on O
the O
100-mm O
patient O
visual O
analog O
scale O
ratings O
, O
compared O
with O
14 O
mm O
for O
placebo O
at O
2 O
days O
and O
24 O
mm O
compared O
with O
19 O
mm O
at O
1 O
month O
. O
[]

Collectively O
, O
these O
data O
convincingly O
demonstrate O
the O
benefits O
of O
eye-closure O
as O
an O
aid O
to O
retrieval O
, O
and O
offer O
insight O
into O
why O
hypnosis O
, O
which O
usually O
involves O
eye-closure O
, O
may O
facilitate O
eyewitness O
recall O
. O
[]

We O
studied O
if O
H. O
pylori O
eradication O
would O
alter O
the O
course O
of O
premalignant O
histologic O
changes O
in O
the O
stomach O
. O
[]

METHODS O
A O
pragmatic O
, O
cluster O
randomised O
trial O
with O
an O
intervention O
( O
an O
interactive O
seminar O
) O
delivered O
at O
practice O
level O
( O
n=13 O
practices O
; O
6=intervention O
, O
7=control O
) O
. O
[]

T O
lymphocyte O
subsets O
and O
NK O
cell O
cytotoxicity O
in O
chronic O
hemodialysis O
patients O
. O
[]

METHOD O
A O
cohort O
of O
youth O
( O
N O
= O
162 O
, O
60 O
% O
male O
) O
treated O
during O
adolescence O
( O
mean O
age O
= O
16 O
years O
) O
was O
followed O
into O
young O
adulthood O
, O
a O
period O
associated O
with O
stabilization O
of O
alcohol O
use O
patterns O
and O
elevated O
risk O
for O
life O
problems O
secondary O
to O
both O
alcohol O
and O
drug O
use O
. O
[]

Due O
to O
PD O
and/or O
toxicity B-outcome ['Adverse-effects']
, O
12 O
patients O
( O
44 O
% O
) O
could O
not O
complete O
the O
planned O
four O
courses O
of O
FAMTX O
. O
['Adverse-effects']

The O
cured B-outcome ['Physiological-Clinical']
rate O
was O
100.0 O
% O
and O
the O
therapeutic B-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
was O
( O
7.24 O
+/- O
3.87 O
) O
in O
the O
group O
A O
, O
66.7 O
% O
, O
( O
9.83 O
+/- O
4.60 O
) O
times O
in O
the O
group O
B O
and O
75.0 O
% O
, O
( O
15.25 O
+/- O
3.81 O
) O
times O
in O
the O
group O
C O
, O
with O
significant O
differences O
in O
the O
cured B-outcome ['Physiological-Clinical']
rate O
and O
the O
therapeutic B-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
among O
the O
3 O
groups O
( O
P O
< O
0.05 O
, O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Impact O
of O
antisecretory O
treatment O
on O
respiratory B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
gastroesophageal I-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
in O
children O
. O
['Physiological-Clinical']

In O
patients O
receiving O
no O
maintenance O
therapy O
, O
those O
who O
received O
interferon O
alfa-2b O
during O
the O
induction O
phase O
showed O
a O
favourable O
trend O
in O
terms O
of O
incidence O
of O
relapse B-outcome ['Physiological-Clinical']
compared O
to O
those O
who O
had O
received O
chlorambucil O
alone O
. O
['Physiological-Clinical']

Plots O
of O
differences O
of O
IOP O
as O
a O
function O
of O
the O
mean O
for O
each O
pair O
of O
instruments O
were O
obtained O
. O
[]

Analysis O
of O
outcome O
events O
was O
performed O
according O
to O
the O
intention O
to O
treat O
. O
[]

Patients O
with O
and O
without O
LV O
hypertrophy O
did O
not O
differ O
significantly O
in O
acute O
mortality B-outcome ['Mortality']
during O
hospitalization B-outcome ['Resource-use']
, O
progression B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
Q I-outcome ['Physiological-Clinical']
waves I-outcome ['Physiological-Clinical']
, O
reinfarction O
by O
CK-MB B-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
or O
angina B-outcome ['Physiological-Clinical']
associated O
with O
transient O
electrocardiographic O
changes O
. O
['Mortality', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
patients O
completed O
measures O
of O
anxiety B-outcome ['Life-Impact']
and O
self-efficacy B-outcome ['Life-Impact']
at O
discharge O
, O
1 O
month O
and O
3 O
months O
after O
discharge O
from O
the O
hospital O
. O
['Life-Impact', 'Life-Impact']

SETTING O
Conducted O
at O
a O
western O
Canadian O
tertiary O
care O
hospital O
. O
[]

Children O
with O
ASD+ADHD O
are O
an O
additive O
co-occurrence O
with O
deficits O
of O
both O
disorders O
. O
[]

Before O
, O
immediately O
after O
, O
and O
1 O
h O
after O
a O
single O
bout O
of O
resistance O
exercise O
, O
subjects O
consumed O
0.3 O
g O
x O
kg O
( O
-1 O
) O
carbohydrate O
with O
or O
without O
0.3 O
g O
x O
kg O
( O
-1 O
) O
protein O
hydrolysate O
( O
CHO+PRO O
and O
CHO O
, O
respectively O
) O
. O
[]

METHODS O
138 O
cases O
of O
senile O
hypertension O
complicating O
with O
depression O
were O
studied O
. O
[]

CONCLUSION O
Our O
results O
indicated O
that O
early O
EN O
with O
addition O
of O
probiotics O
( O
bifidobacterium O
) O
resulted O
in O
significant O
lowering O
of O
the O
level O
of O
pro-inflammatory O
cytokines O
, O
earlier O
restoration O
of O
gastrointestinal O
function O
, O
decrease O
of O
complications O
such O
as O
infection O
, O
and O
shortening O
of O
hospital O
day O
in O
patients O
with O
SAP O
. O
[]

LEGO O
therapy O
and O
the O
Social O
Use O
of O
Language O
Programme O
( O
SULP O
) O
were O
evaluated O
as O
social O
skills O
interventions O
for O
6-11 O
year O
olds O
with O
high O
functioning O
autism O
and O
Asperger O
Syndrome O
. O
[]

Studies O
on O
section B-outcome ['Physiological-Clinical']
2D1 I-outcome ['Physiological-Clinical']
monoclonal I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
etiology O
and O
functional O
significance O
of O
plasma O
carnitine O
deficiency O
seen O
in O
some O
patients O
with O
Rett O
syndrome O
is O
unknown O
. O
[]

Finasteride O
Urodynamics O
Study O
Group O
. O
[]

The O
objective O
was O
to O
assess O
clinical O
efficacy O
of O
3 O
dosages O
of O
intravenous O
gammaglobulins O
to O
prevent O
infectious O
episodes O
in O
adult O
common O
variable O
immunodeficiency O
. O
[]

Patients O
were O
randomly O
allocated O
to O
topiramate+risperidone O
( O
Group O
A O
) O
or O
placebo+risperidone O
( O
Group O
B O
) O
for O
an O
8-week O
, O
double-blind O
, O
placebo-controlled O
study O
. O
[]

OUTCOMES O
The O
primary O
outcome O
was O
predialysis O
anti-Xa O
levels O
20 O
to O
24 O
hours O
after O
the O
third O
LMWH O
dose O
( O
therapeutic O
target O
, O
< O
0.2 O
IU/mL O
) O
. O
[]

RESULTS O
Women O
treated O
with O
pravastatin O
had O
a O
risk O
reduction O
of O
43 O
% O
for O
the O
primary O
end O
point O
( O
p O
= O
0.035 O
) O
, O
46 O
% O
for O
combined O
coronary O
events O
( O
p O
= O
0.001 O
) O
, O
48 O
% O
for O
PTCA O
( O
p O
= O
0.025 O
) O
, O
40 O
% O
for O
CABG O
( O
p O
= O
0.14 O
) O
and O
56 O
% O
for O
stroke O
( O
p O
= O
0.07 O
) O
. O
[]

Following O
resection O
of O
the O
apical O
3mm O
, O
root O
end O
cavities O
were O
prepared O
and O
restored O
with O
conventional O
GIC O
( O
group O
1 O
) O
or O
GIC O
with O
0.01 O
% O
, O
0.1 O
% O
or O
1 O
% O
collagen O
( O
groups O
2 O
, O
3 O
, O
4 O
respectively O
) O
or O
, O
10 O
% O
, O
30 O
% O
or O
50 O
% O
bioactive O
glass O
( O
groups O
5 O
, O
6 O
, O
7 O
respectively O
) O
, O
or O
Mineral O
Trioxide O
Aggregate O
( O
group O
8 O
) O
. O
[]

These O
results O
demonstrated O
simultaneous O
inhibition O
of O
cholesterol O
absorption O
and O
synthesis O
provides O
stable O
and O
greater O
decrease O
in O
LDL-C O
levels O
. O
[]

[ O
The O
comparison O
of O
the O
effect O
of O
enalapril O
and O
indapamide O
on O
the O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
central B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
through O
pulse O
wave O
analysis O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
received O
24 O
weeks O
' O
treatment O
with O
oral O
lamotrigine O
100 O
mg O
( O
LTG O
100 O
, O
n O
= O
115 O
) O
or O
200 O
mg O
( O
LTG O
200 O
, O
n O
= O
111 O
) O
or O
carbamazepine O
600 O
mg O
( O
CBZ O
600 O
, O
n O
= O
117 O
) O
. O
[]

All O
sheep O
were O
exposed O
to O
natural O
sub-clinical O
helminthosis O
challenge O
. O
[]

METHODS O
Women O
with O
hirsutism O
, O
as O
defined O
by O
a O
minimum O
Ferriman-Gallwey O
score O
of O
10 O
, O
were O
randomized O
in O
a O
double-blind O
fashion O
to O
receive O
an O
OC O
containing O
either O
ethinyl O
estradiol/desogestrel O
or O
ethinyl O
estradiol/levonorgestrel O
for O
9 O
months O
of O
treatment O
. O
[]

Sixteen O
volunteers O
completed O
the O
two O
treatment O
phases O
. O
[]

49 O
patients O
( O
22 O
women O
, O
27 O
men O
, O
mean O
age O
43.7 O
[ O
21-65 O
] O
years O
) O
with O
Hodgkin O
's O
disease O
were O
examined O
by O
Doppler O
echocardiography O
a O
median O
of O
5.37 O
( O
2-10 O
) O
years O
after O
the O
end O
of O
chemotherapy O
( O
given O
according O
to O
the O
COPP/ABVD O
scheme O
, O
with O
or O
without O
mediastinal O
irradiation O
) O
for O
possible O
chronic B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
myocardium I-outcome ['Physiological-Clinical']
, O
pericardium B-outcome ['Physiological-Clinical']
or O
cardiac B-outcome ['Physiological-Clinical']
valves I-outcome ['Physiological-Clinical']
, O
as O
well O
as O
for O
any O
haemodynamic B-outcome ['Physiological-Clinical']
sequelae I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Nifedipine O
did O
not O
affect O
basal O
or O
Oxo B-outcome ['Physiological-Clinical']
meal I-outcome ['Physiological-Clinical']
stimulated I-outcome ['Physiological-Clinical']
gastrin I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in O
normal O
volunteers O
nor O
did O
it O
affect O
resting B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
gastrin I-outcome ['Physiological-Clinical']
or O
calcium B-outcome ['Physiological-Clinical']
stimulated I-outcome ['Physiological-Clinical']
increase O
in O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
total O
of O
47 O
MONW O
individuals O
with O
hypomagnesemia O
were O
enrolled O
in O
clinical O
a O
randomized O
double-blind O
placebo-controlled O
trial O
. O
[]

Intermittent O
recombinant O
growth O
hormone O
treatment O
in O
short O
children O
born O
small O
for O
gestational O
age O
: O
four-year O
results O
of O
a O
randomized O
trial O
of O
two O
different O
treatment O
regimens O
. O
[]

In O
the O
L-arginine O
treated O
group O
a O
lower O
cancellation B-outcome ['Life-Impact']
rate O
, O
an O
increased O
number O
of O
oocytes O
collected O
, O
and O
embryos B-outcome ['Physiological-Clinical']
transferred B-outcome ['Physiological-Clinical']
were O
observed O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
study O
, O
the O
hypothesis O
tested O
was O
that O
low O
doses O
of O
propranolol O
could O
alter O
bone B-outcome ['Physiological-Clinical']
properties I-outcome ['Physiological-Clinical']
and O
enhance O
orthotopic B-outcome ['Physiological-Clinical']
endochondral I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Further O
studies O
are O
required O
to O
assess O
neonatal O
morbidity O
adequately O
. O
[]

Green O
banana-supplemented O
diet O
in O
the O
home O
management O
of O
acute O
and O
prolonged B-outcome ['Physiological-Clinical']
diarrhoea I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
children I-outcome ['Physiological-Clinical']
: O
a O
community-based O
trial O
in O
rural O
Bangladesh O
. O
['Physiological-Clinical']

Effectiveness O
of O
norgestimate O
and O
ethinyl O
estradiol O
in O
treating O
moderate O
acne O
vulgaris O
. O
[]

Sixty O
unpremedicated O
, O
Asa O
1-2 O
women O
were O
randomized O
to O
receive O
eltanolone O
0.6 O
( O
group O
E1 O
) O
or O
0.8 O
mg.kg-1 O
( O
group O
E2 O
) O
or O
thiopental O
4 O
mg.kg-1 O
( O
group O
T O
) O
for O
induction O
of O
anaesthesia O
. O
[]

Two O
accounts O
explain O
why O
studying O
pictures O
reduces O
false B-outcome ['Life-Impact']
memories I-outcome ['Life-Impact']
within O
the O
Deese-Roediger-McDermott O
paradigm O
( O
J. O
Deese O
, O
1959 O
; O
H. O
L. O
Roediger O
& O
K. O
B. O
McDermott O
, O
1995 O
) O
. O
['Life-Impact']

CONCLUSION O
In O
comparison O
to O
electrosurgical O
resection O
during O
hysteroscopic O
polypectomy O
, O
morcellation O
was O
significantly O
quicker O
, O
less O
painful B-outcome ['Physiological-Clinical']
, O
more O
acceptable B-outcome ['Life-Impact']
to O
women O
, O
and O
more O
likely O
to O
completely B-outcome ['Physiological-Clinical']
remove I-outcome ['Physiological-Clinical']
endometrial I-outcome ['Physiological-Clinical']
polyps I-outcome ['Physiological-Clinical']
compared O
with O
electrosurgical O
resection O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

MEASUREMENTS O
AND O
RESULTS O
In O
the O
placebo O
condition O
, O
sleep B-outcome ['Physiological-Clinical']
inertia I-outcome ['Physiological-Clinical']
was O
manifested O
as O
significantly O
impaired O
psychomotor B-outcome ['Life-Impact']
vigilance I-outcome ['Life-Impact']
upon O
awakening O
from O
the O
naps O
. O
['Physiological-Clinical', 'Life-Impact']

Brain O
Cognition O
, O
52 O
( O
3 O
) O
, O
285-294. O
) O
. O
[]

CONCLUSIONS O
Caffeine O
was O
efficacious O
in O
overcoming O
sleep B-outcome ['Physiological-Clinical']
inertia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Six O
subjects O
( O
86 O
% O
) O
completed O
the O
study O
; O
one O
was O
removed O
due O
to O
the O
development O
of O
a O
rash O
. O
[]

However O
, O
little O
is O
known O
about O
the O
impact O
of O
prior O
treatment O
on O
the O
outcome O
of O
major O
depression O
with O
psychotic O
features O
( O
MDpsy O
) O
. O
[]

The O
early O
metabolic B-outcome ['Physiological-Clinical']
effects O
of O
the O
anti-HER2 O
therapies O
on O
the O
primary O
tumors O
and O
their O
predictive O
values O
for O
pCR O
were O
assessed O
in O
a O
subset O
of O
patients O
. O
['Physiological-Clinical']

All O
patients O
had O
received O
monthly O
leuprolide O
acetate O
and O
were O
randomized O
to O
one O
of O
four O
groups O
: O
A-daily O
placebo O
; O
B-daily O
norethindrone O
acetate O
5 O
mg O
; O
C-daily O
norethindrone O
acetate O
5 O
mg O
and O
conjugated O
equine O
estrogens O
0.625 O
mg O
; O
and O
D-daily O
norethindrone O
acetate O
5 O
mg O
and O
conjugated O
equine O
estrogens O
1.25 O
mg. O
Of O
201 O
patients O
enrolled O
in O
the O
initial O
trial O
, O
123 O
completed O
at O
least O
280 O
days O
of O
therapy O
and O
entered O
the O
follow-up O
period O
. O
[]

The O
results O
indicate O
that O
individuals O
with O
ASDs O
, O
like O
controls O
, O
experience B-outcome ['Life-Impact']
interference I-outcome ['Life-Impact']
from O
facial O
features O
that O
they O
are O
told O
to O
ignore O
. O
['Life-Impact']

BACKGROUND O
It O
is O
postulated O
that O
alteration O
of O
central O
cholinergic O
transmission O
plays O
an O
important O
role O
in O
the O
mechanism O
by O
which O
anesthetics O
produce O
unconsciousness O
. O
[]

Adjuvant O
immunochemotherapy O
using O
the O
antitumour O
polysaccharide O
sizofiran O
( O
SPG O
) O
, O
an O
extract O
from O
the O
culture O
broth O
of O
Schizophyllum O
commune O
Fries O
, O
was O
prescribed O
randomly O
for O
386 O
Japanese O
patients O
with O
resectable O
gastric O
cancer O
. O
[]

Each O
patient O
received O
up O
to O
2 O
doses O
of O
analgesic O
medication O
when O
necessary O
. O
[]

As O
expected O
, O
reaction B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
on O
both O
the O
incongruent O
and O
congruent O
trials O
decreased O
significantly O
after O
stimulation O
, O
and O
there O
was O
no O
difference O
with O
regard O
to O
the O
Stroop B-outcome ['Physiological-Clinical']
interference I-outcome ['Physiological-Clinical']
effect O
. O
['Physiological-Clinical', 'Physiological-Clinical']

They O
were O
operated O
on O
under O
local O
anesthesia O
using O
a O
standard O
technique O
and O
randomly O
assigned O
into O
2 O
groups O
for O
nonroutine O
( O
NR O
group O
) O
and O
routine O
( O
R O
group O
) O
postoperative O
instructions O
. O
[]

No O
phlebographically B-outcome ['Physiological-Clinical']
verified I-outcome ['Physiological-Clinical']
thrombi I-outcome ['Physiological-Clinical']
or O
any O
bleeding B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
were O
registered O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Providing O
drug O
infusions O
in O
syringes O
pre-filled O
by O
pharmacists O
or O
pharmaceutical O
companies O
would O
reduce O
medication B-outcome ['Resource-use']
errors B-outcome ['Life-Impact']
and O
treatment O
['Resource-use', 'Life-Impact']

Sixty O
patients O
with O
bilaterally O
symmetrical O
proliferative O
diabetic O
retinopathy O
or O
severe O
nonproliferative O
diabetic O
retinopathy O
participated O
. O
[]

Patients O
in O
the O
electrocoagulation O
( O
EC O
) O
group O
experienced O
more O
pain B-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
procedure I-outcome ['Physiological-Clinical']
than O
the O
injection O
sclerotherapy O
( O
IS O
) O
group O
( O
P O
< O
0.000 O
) O
, O
but O
EC O
was O
significantly O
more O
effective O
than O
IS O
in O
terms O
of O
reducing O
the O
bleeding B-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
rectum I-outcome ['Physiological-Clinical']
( O
P O
= O
0.039 O
) O
, O
and O
also O
significantly O
higher O
number O
of O
patients O
were O
fully O
satisfied B-outcome ['Life-Impact']
with O
EC O
than O
with O
IS O
( O
P O
< O
0.04 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Parents O
of O
381 O
girls O
and O
375 O
boys O
age O
8-12 O
y O
completed O
family O
history O
questionnaires O
. O
[]

The O
difference O
between O
treatment O
groups O
was O
maintained O
after O
5 O
minutes O
with O
approximately O
85 O
per O
cent O
( O
50 O
of O
59 O
) O
of O
CoSeal O
sites O
compared O
to O
just O
over O
one-half O
( O
14 O
of O
27 O
) O
of O
control O
sites O
demonstrating O
ultimate B-outcome ['Physiological-Clinical']
sealing I-outcome ['Physiological-Clinical']
( O
P O
= O
0.01 O
) O
. O
['Physiological-Clinical']

Twenty O
( O
29 O
percent O
) O
reported O
complete O
elimination O
of O
migraine B-outcome ['Physiological-Clinical']
headache B-outcome ['Physiological-Clinical']
, O
41 O
( O
59 O
percent O
) O
noticed O
a O
significant O
decrease O
, O
and O
eight O
( O
12 O
percent O
) O
experienced O
no O
significant O
change O
. O
['Physiological-Clinical', 'Physiological-Clinical']

ANIMALS O
Five O
male O
Holstein-Friesian O
calves O
( O
8-15 O
days O
of O
age O
) O
. O
[]

METHODS O
A O
total O
of O
156 O
patients O
with O
stage O
III O
or O
IV O
gastric O
cancer O
who O
had O
undergone O
curative O
resection O
were O
randomly O
assigned O
to O
three O
treatment O
groups O
: O
BCG O
+ O
FAM O
( O
immunochemotherapy O
) O
, O
FAM O
( O
chemotherapy O
) O
, O
and O
control O
( O
surgery O
only O
) O
. O
[]

The O
study O
was O
conducted O
in O
pharmacies O
operated O
by O
the O
Southern O
California O
region O
Kaiser O
Permanente O
Medical O
Care O
Program O
. O
[]

OBJECTIVE O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
riluzole O
as O
an O
adjunctive O
to O
risperidone O
in O
the O
treatment O
of O
irritability O
in O
autistic O
children O
who O
were O
not O
optimally O
responding O
to O
previous O
medications O
. O
['Life-Impact']

This O
study O
investigates O
the O
effect O
of O
systemic O
lidocaine O
on O
experimental-induced B-outcome ['Physiological-Clinical']
hyperalgesia I-outcome ['Physiological-Clinical']
in O
25 O
volunteers O
. O
['Physiological-Clinical']

Ordinary O
least O
squares O
regressions O
were O
used O
to O
estimate O
the O
effect O
of O
the O
program O
on O
costs O
for O
Medicaid B-outcome ['Resource-use']
PCS/waiver I-outcome ['Resource-use']
services I-outcome ['Resource-use']
and O
other O
Medicaid B-outcome ['Resource-use']
services I-outcome ['Resource-use']
, O
while O
controlling O
for O
consumers O
' O
preenrollment O
characteristics O
and O
preenrollment O
Medicaid O
spending O
. O
['Resource-use', 'Resource-use']

Predictors O
of O
stable O
return-to-work O
in O
non-acute O
, O
non-specific O
spinal O
pain O
: O
low O
total O
prior O
sick-listing O
, O
high O
self O
prediction O
and O
young O
age O
. O
[]

BACKGROUND O
Substantial O
, O
but O
indirect O
, O
evidence O
suggests O
that O
improving O
nutrition O
in O
early O
childhood O
in O
developing O
countries O
is O
a O
long-term O
economic O
investment O
. O
[]

Clinical O
toxicities B-outcome ['Adverse-effects']
, O
commonly O
associated O
with O
doxorubicin O
, O
appeared O
less O
common O
with O
TLC O
D-99 O
, O
although O
the O
difference O
was O
not O
statistically O
significant O
. O
['Adverse-effects']

Menopausal O
symptoms O
were O
evaluated O
using O
a O
modified O
Kupperman O
Index O
. O
[]

BACKGROUND O
As O
renin-angiotensin O
system O
( O
RAS O
) O
activity O
may O
affect O
the O
severity O
of O
oxidative O
stress O
and O
inflammatory O
markers O
, O
we O
assessed O
the O
effects O
of O
enalapril O
( O
E O
) O
and/or O
losartan O
( O
L O
) O
on O
these O
markers O
in O
renal O
transplant O
recipients O
with O
RAS O
polymorphisms O
. O
[]

A O
randomized O
controlled O
trial O
investigating O
the O
safety O
and O
efficacy O
of O
aripiprazole O
in O
the O
long-term O
maintenance O
treatment O
of O
pediatric O
patients O
with O
irritability O
associated O
with O
autistic O
disorder O
. O
[]

A O
subjective O
and O
clinically O
relevant O
improvement O
was O
reported O
by O
4 O
patients O
( O
27 O
% O
) O
on O
buspirone O
and O
2 O
patients O
( O
13 O
% O
) O
on O
placebo O
. O
[]

Slab O
sections O
of O
the O
PIJ O
were O
evaluated O
grossly O
and O
radiographically O
for O
bony O
fusion O
. O
[]

Onset O
and O
complete B-outcome ['Physiological-Clinical']
spread O
of O
sensory B-outcome ['Resource-use']
blockade I-outcome ['Resource-use']
were O
similar O
in O
all O
five O
groups O
. O
['Physiological-Clinical', 'Resource-use']

However O
, O
quinolone-resistant O
strains O
of O
Salmonella O
typhi O
have O
recently O
been O
reported O
from O
Vietnam O
; O
and O
if O
quinolone O
resistance O
becomes O
established O
, O
alternative O
oral O
treatment O
options O
will O
be O
needed O
. O
[]

The O
pattern O
was O
similar O
in O
the O
control O
group O
. O
[]

CONTEXT O
Measurement O
of O
blood O
haemoglobin B-outcome ['Physiological-Clinical']
concentration O
by O
pulse O
oximetry O
could O
be O
of O
value O
in O
determining O
when O
erythrocytes O
should O
be O
transfused O
during O
surgery O
, O
but O
the O
effect O
of O
infusion O
fluids O
on O
the O
results O
is O
unclear O
. O
['Physiological-Clinical']

There O
is O
evidence O
that O
abnormalities O
exist O
in O
peptide O
systems O
, O
particularly O
the O
oxytocin O
system O
, O
in O
autism O
spectrum O
patients O
. O
[]

METHODS O
To O
study O
the O
effect O
of O
the O
eradication O
of O
H. O
pylori B-outcome ['Physiological-Clinical']
on O
the O
recurrence O
of O
duodenal O
ulcer O
, O
we O
treated O
104 O
patients O
with O
H. O
pylori O
infection O
and O
recurrent O
duodenal O
ulcer O
with O
either O
amoxicillin O
( O
750 O
mg O
three O
times O
daily O
) O
plus O
metronidazole O
( O
500 O
mg O
three O
times O
daily O
) O
or O
identical-appearing O
placebos O
, O
given O
orally O
for O
12 O
days O
. O
['Physiological-Clinical']

Fifty-one O
communities O
of O
38 O
families O
each O
were O
randomized O
to O
receive O
the O
intervention O
or O
no O
intervention O
. O
[]

A O
multicenter O
, O
double-blind O
, O
between-patient O
trial O
comparing O
two O
doses O
of O
ketazolam O
( O
15 O
and O
30 O
mg O
) O
with O
placebo O
, O
each O
given O
once O
daily O
, O
in O
the O
evening O
, O
to O
92 O
outpatients O
affected O
by O
generalized O
anxiety O
disorders O
for O
at O
least O
1 O
month O
, O
was O
carried O
out O
. O
[]

Increasing O
BNP B-outcome ['Physiological-Clinical']
( O
p O
< O
0.0001 O
) O
and O
NT-ANP B-outcome ['Physiological-Clinical']
( O
p O
= O
0.01 O
) O
over O
time O
were O
associated O
with O
a O
concurrent O
decreasing O
EF B-outcome ['Physiological-Clinical']
, O
increasing O
end-diastolic B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EDV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
increasing O
end-systolic B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( O
ESV O
; O
all O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
of O
the O
mothers O
were O
unwed O
, O
on O
Medicaid O
, O
and O
black O
. O
[]

The O
rationale O
for O
this O
is O
the O
finding O
that O
in O
geriatric O
patients O
two O
electroencephalographically O
distinguishable O
forms O
of O
dissolution O
can O
be O
observed O
. O
[]

No O
endodontic O
treatment O
was O
performed O
. O
[]

BACKGROUND O
To O
evaluate O
the O
effect O
of O
a O
7-week O
low-intensity O
hand O
rim O
wheelchair O
training O
on O
the O
submaximal O
metabolic O
cost O
, O
mechanical O
efficiency O
and O
propulsion O
technique O
in O
able-bodied O
participants O
. O
[]

28 O
kg/m O
( O
2 O
) O
) O
were O
randomized O
to O
one O
of O
three O
conditions O
: O
i O
) O
The O
combination O
of O
a O
standardized O
lifestyle O
modification O
( O
LM O
) O
program O
for O
individuals O
with O
SMI O
and O
payment O
for O
group O
attendance O
( O
CM O
( O
attendance O
) O
) O
, O
ii O
) O
The O
combination O
of O
LM O
and O
payment O
for O
weight O
loss O
( O
CM O
( O
weight O
) O
) O
, O
and O
iii O
) O
waitlist O
control O
( O
CON O
) O
. O
[]

Nineteen O
ragweed-sensitive O
patients O
were O
randomized O
into O
2 O
groups O
; O
10 O
received O
the O
polymerized O
form O
and O
9 O
received O
the O
monomeric O
form O
. O
[]

INTERPRETATION O
Combination O
treatment O
compared O
with O
single-agent O
irinotecan O
reduces O
alopecia B-outcome ['Physiological-Clinical']
and O
diarrhoea B-outcome ['Physiological-Clinical']
without O
compromising O
efficacy O
on O
clinical B-outcome ['Physiological-Clinical']
outcomes O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

1 O
RTX O
course O
. O
[]

Do O
colonic O
short-chain O
fatty O
acids O
contribute O
to O
the O
long-term B-outcome ['Physiological-Clinical']
adaptation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
in O
subjects O
with O
type O
2 O
diabetes O
consuming O
a O
high-fiber O
diet O
? O
['Physiological-Clinical']

Measuring O
the O
impact O
of O
patient O
counseling O
in O
the O
outpatient O
pharmacy O
setting O
: O
the O
research O
design O
of O
the O
Kaiser O
Permanente/USC O
patient O
consultation O
study O
. O
[]

After O
a O
median O
overall O
follow-up O
of O
8.7 O
months O
, O
median O
OS B-outcome ['Mortality']
was O
13.1 O
months O
and O
11.8 O
months O
for O
sunitinib O
and O
placebo O
, O
respectively O
( O
hazard O
ratio O
[ O
HR O
] O
, O
0.914 O
; O
95 O
% O
CI O
, O
0.762 O
to O
1.097 O
; O
stratified O
log-rank O
test O
, O
P O
= O
.168 O
) O
. O
['Mortality']

Patients O
who O
received O
COX-2 O
demonstrated O
improved O
bowel B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
as O
reflected O
by O
more O
bowel O
movements O
on O
postoperative O
day O
2 O
and O
postoperative O
day O
3 O
. O
['Physiological-Clinical']

RESULTS O
On O
the O
primary O
efficacy O
endpoint O
, O
sildenafil-treated O
subjects O
had O
significantly O
better O
scores O
on O
the O
International O
Index O
of O
Erectile B-outcome ['Physiological-Clinical']
Function I-outcome ['Physiological-Clinical']
( O
IIEF O
) O
questions O
3 O
and O
4 O
than O
placebo O
( O
p O
< O
0.001 O
, O
both O
questions O
) O
. O
['Physiological-Clinical']

CONCLUSION O
A O
larger O
study O
investigating O
the O
same O
hypothesis O
is O
warranted O
to O
detect O
difference O
in O
the O
effects O
of O
these O
treatments O
strategies O
. O
[]

METHODS O
At O
baseline O
visit O
, O
the O
catheter O
was O
changed O
and O
participants O
were O
followed O
weekly O
for O
8 O
weeks O
, O
with O
checks O
for O
catheter B-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
and O
urine B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
was O
the O
final O
diagnosis O
in O
34 O
% O
of O
patients O
. O
['Physiological-Clinical']

Baseline O
factors O
predicting O
placebo O
response O
to O
treatment O
in O
children O
and O
adolescents O
with O
autism O
spectrum O
disorders O
: O
a O
multisite O
randomized O
clinical O
trial O
. O
[]

PURPOSE O
To O
compare O
the O
efficacy O
and O
safety O
of O
cutting O
balloon O
angioplasty O
( O
CBA O
) O
versus O
high-pressure O
balloon O
angioplasty O
( O
HPBA O
) O
for O
the O
treatment O
of O
hemodialysis O
autogenous O
fistula O
stenoses O
resistant O
to O
conventional O
percutaneous O
transluminal O
angioplasty O
( O
PTA O
) O
. O
[]

Platelets O
and O
leukocytes O
were O
enumerated O
. O
[]

We O
studied O
41 O
pregnant O
women O
. O
[]

A O
decrease O
was O
found O
in O
the O
number O
of O
blood B-outcome ['Physiological-Clinical']
monocytes I-outcome ['Physiological-Clinical']
and O
the O
number O
of I-outcome ['Physiological-Clinical']
monocytes B-outcome ['Physiological-Clinical']
capable I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
transforming I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

The O
addition O
of O
chronic O
vasodilator O
therapy O
with O
flosequinan O
to O
standard O
digitalis-diuretic O
regimens O
is O
capable O
of O
inducing O
clinical O
improvement O
in O
patients O
with O
moderate O
to O
severe O
chronic O
heart O
failure O
. O
[]

There O
was O
no O
other O
evidence O
of O
toxicity B-outcome ['Adverse-effects']
with O
butorphanol O
. O
['Adverse-effects']

Continuous O
chemotherapy O
in O
biochemically O
defined O
responders O
was O
associated O
with O
a O
significant O
lengthening B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
and O
an O
improved O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
and O
survival B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Life-Impact', 'Mortality']

Effects O
of O
large O
doses O
of O
arachidonic O
acid O
added O
to O
docosahexaenoic O
acid O
on O
social O
impairment O
in O
individuals O
with O
autism O
spectrum O
disorders O
: O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
trial O
. O
[]

The O
fentanyl O
patients O
required O
a O
longer O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
achieve I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
normal I-outcome ['Physiological-Clinical']
neurological I-outcome ['Physiological-Clinical']
score O
( O
fentanyl O
= O
38.0 O
min O
; O
remifentanil O
= O
26.0 O
min O
; O
P O
= O
0.035 O
) O
. O
['Physiological-Clinical']

Additionally O
a O
15-item O
self-reported O
evaluation O
is O
completed O
for O
each O
VP O
, O
based O
on O
a O
widely O
used O
EViP O
tool O
. O
[]

Given O
the O
potential O
barrier O
that O
anxiety O
can O
pose O
for O
patient O
learning O
, O
nurses O
need O
to O
adapt O
their O
interventions O
to O
deal O
with O
the O
patients O
' O
feelings O
of O
anxiety B-outcome ['Life-Impact']
that O
accompany O
cardiac O
surgery O
to O
make O
the O
learning O
process O
effective O
. O
['Life-Impact']

S6 B-outcome ['Physiological-Clinical']
phosphorylation I-outcome ['Physiological-Clinical']
was O
substantially O
higher O
following O
exercise O
in O
the O
CHO+PRO O
( O
1.69 O
+/- O
0.35 O
) O
than O
in O
the O
CHO O
experiment O
( O
0.45 O
+/- O
0.07 O
, O
P O
< O
0.01 O
) O
and O
remained O
elevated O
during O
recovery O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
control O
group O
consisted O
of O
sex- O
and O
age-matched O
patents O
with O
allergic O
rhinitis O
. O
[]

The O
objective O
of O
the O
present O
study O
was O
to O
investigate O
whether O
the O
prevalence O
of O
RAS O
decreased O
with O
perilla O
oil O
( O
rich O
in O
alpha-linolenic O
acid O
) O
. O
[]

A O
statistically O
significant O
decrease O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
between O
the O
two O
treatment O
groups O
was O
also O
noted O
. O
['Physiological-Clinical']

Modest O
clinical O
benefits O
were O
achieved O
with O
both O
PLC O
and O
NTX O
, O
with O
marginally O
better O
overall O
results O
following O
NTX O
, O
and O
degree O
of O
improvement O
appeared O
to O
be O
related O
to O
plasma O
chemical O
profiles O
. O
[]

Using B-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
upper I-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
limit I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
4 I-outcome ['Physiological-Clinical']
ng/ml I-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
for O
prostate O
cancer O
in O
men O
receiving O
dutasteride O
vs O
placebo O
was O
0.737 O
vs O
0.804 O
, O
while O
specificity O
was O
0.671 O
vs O
0.578 O
. O
['Physiological-Clinical']

A O
doubling O
of O
the O
area O
under O
the O
plasma B-outcome ['Physiological-Clinical']
concentration-time O
curve O
( O
77.8 O
vs O
31.8 O
mg/L.h O
) O
and O
terminal-phase B-outcome ['Life-Impact']
half-life I-outcome ['Life-Impact']
( O
9.7 O
vs O
4.5h O
) O
of O
caffeine O
were O
observed O
in O
the O
presence O
of O
ciprofloxacin O
. O
['Physiological-Clinical', 'Life-Impact']

OBJECTIVE O
The O
aim O
is O
to O
evaluate O
the O
effectiveness O
of O
a O
manualized O
12-week O
supportive-expressive O
group O
therapy O
program O
among O
primary O
breast B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
patients O
treated O
in O
community O
settings O
, O
to O
determine O
whether O
highly O
distressed O
patients O
were O
most O
likely O
to O
benefit O
and O
whether O
therapist O
's O
training O
or O
experience O
was O
related O
to O
outcome O
. O
['Physiological-Clinical']

RESULTS O
Non-compliance O
( O
8.2 O
% O
) O
in O
IVDUs O
was O
not O
different O
from O
non-IVDUs O
( O
6.8 O
% O
) O
( O
relative O
risk=1.20 O
; O
95 O
% O
confidence O
interval=0.55-2.62 O
) O
. O
[]

Only O
minor B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
in O
this O
study O
. O
['Adverse-effects']

Racial O
differences O
in O
primary O
and O
repeat O
lower O
extremity O
amputation O
: O
results O
from O
a O
multihospital O
study O
. O
[]

Risperidone O
in O
children O
with O
autism O
and O
serious O
behavioral O
problems O
. O
[]

RESULTS O
The O
high-dependence O
group O
showed O
slowed O
reaction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
reduced O
early B-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
negativity O
and O
peak O
N1 B-outcome ['Physiological-Clinical']
amplitude I-outcome ['Physiological-Clinical']
to O
location-relevant O
nontarget O
stimuli O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
CNS O
metastases O
were O
eligible O
and O
received O
concurrent O
whole-brain O
radiotherapy O
. O
[]

Early O
identification O
and O
timely O
transfer O
of O
patients O
requiring O
mechanical O
ventilation O
to O
such O
hospitals O
may O
improve O
the O
efficiency O
of O
inpatient O
care O
. O
[]

The O
present O
study O
examined O
the O
emotional B-outcome ['Life-Impact']
reactivity I-outcome ['Life-Impact']
of O
persons O
with O
heightened O
borderline O
personality O
( O
BP O
) O
features O
to O
social O
rejection O
and O
negative O
evaluation O
in O
the O
laboratory O
. O
['Life-Impact']

OBJECTIVES O
To O
examine O
changes O
over O
time O
in O
distance O
walked B-outcome ['Life-Impact']
( O
ie O
, O
6MWD O
) O
during O
the O
6MWT O
and O
to O
estimate O
the O
change O
in O
distance O
that O
constitutes O
the O
MID O
in O
patients O
with O
IPF O
. O
['Life-Impact']

The O
decrease O
in O
group O
I O
was O
significantly O
higher O
than O
in O
the O
other O
groups O
. O
[]

In O
this O
study O
of O
hepatic O
amoebiasis O
in O
Bangladesh O
, O
tinidazole O
was O
found O
to O
be O
superior O
to O
metronidazole O
in O
overall O
efficacy O
because O
a O
shorter O
course O
of O
treatment O
was O
necessary O
and O
it O
caused O
fewer O
side-effects B-outcome ['Adverse-effects']
. O
['Adverse-effects']

CONCLUSIONS O
Hypertensive O
patients O
of O
African O
descent O
responded O
better O
to O
LIS O
than O
to O
HCT O
. O
[]

No O
significant O
differences O
in O
mortality B-outcome ['Mortality']
, O
morbidity B-outcome ['Physiological-Clinical']
or O
incapacity B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
could O
be O
detected O
during O
the O
three-month O
period O
of O
follow-up O
. O
['Mortality', 'Physiological-Clinical', 'Life-Impact']

The O
changes O
in O
RBC B-outcome ['Physiological-Clinical']
EPA I-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
were O
inversely O
correlated O
with O
the O
changes O
in O
SBP B-outcome ['Physiological-Clinical']
and O
DBP B-outcome ['Physiological-Clinical']
and O
directly O
correlated O
with O
the O
increases O
in O
HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
and O
non-HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Four-year O
outcomes O
from O
adolescent O
alcohol O
and O
drug O
treatment O
. O
[]

Both O
medication O
adherence O
and O
AA O
meeting O
attendance O
evidenced O
direct O
and O
independent O
influences O
on O
abstinent O
outcome O
: O
medication O
adherence O
showed O
a O
small O
direct O
influence O
, O
and O
AA O
meeting O
attendance O
showed O
a O
much O
larger O
, O
independent O
influence O
. O
[]

The O
treatment O
was O
not O
responsible O
for O
severe O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

We O
postulated O
that O
this O
drug O
might O
reduce O
mortality O
in O
patients O
at O
high O
risk O
of O
death O
after O
myocardial O
infarction O
because O
of O
impaired O
ventricular O
function O
, O
irrespective O
of O
whether O
they O
had O
ventricular O
arrhythmias O
. O
[]

Atypical O
antipsychotics O
have O
been O
shown O
to O
improve O
disruptive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
repetitive I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
pervasive O
developmental O
disorders O
( O
PDDs O
) O
, O
but O
they O
require O
assessment O
of O
potential O
side O
effects O
. O
['Life-Impact']

These O
findings O
demonstrate O
that O
a O
local B-outcome ['Resource-use']
injection I-outcome ['Resource-use']
of I-outcome ['Resource-use']
5 I-outcome ['Resource-use']
mg I-outcome ['Resource-use']
tropisetron I-outcome ['Resource-use']
does O
represent O
an O
alternative O
to O
the O
local O
treatment O
with O
corticosteriods O
plus O
local O
anesthetics O
. O
['Resource-use']

It O
has O
been O
shown O
previously O
that O
alopecia O
areata O
can O
be O
treated O
with O
dinitrochlorobenzene O
( O
DNCB O
) O
and O
other O
contact O
allergens O
. O
[]

The O
primary O
efficacy O
end-point O
was O
the O
difference O
in O
DMVF O
at O
12 O
weeks O
. O
[]

Secondary O
outcome O
measures O
consisted O
of O
Aberrant O
Behavior O
Checklist O
( O
ABC O
) O
, O
Ritvo-Freeman O
Real O
Life O
Scale O
( O
RFRLS O
) O
, O
Reynell O
Developmental O
Language O
Scale O
( O
RDLS O
) O
, O
and O
a O
standardized O
parental B-outcome ['Life-Impact']
report I-outcome ['Life-Impact']
. O
['Life-Impact']

There O
were O
no O
significant O
differences O
in O
clinical B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
or O
in O
frequency O
of O
complications B-outcome ['Adverse-effects']
, O
except O
for O
mild B-outcome ['Physiological-Clinical']
diarrhoea I-outcome ['Physiological-Clinical']
, O
which O
occurred O
in O
16 O
ceftriaxone O
patients O
and O
in O
8 O
in O
the O
other O
group O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical']

83 O
% O
of O
the O
combined O
therapy O
patients O
responded O
as O
opposed O
to O
27 O
% O
of O
the O
prednisone O
treated O
patients O
. O
[]

Sixty O
patients O
were O
later O
included O
in O
this O
study O
. O
[]

Intraglomerular O
metastases O
are O
therefore O
an O
indicator O
of O
malignant O
dissemination O
which O
in O
turn O
should O
be O
associated O
with O
a O
poor O
prognosis O
. O
[]

A O
total O
of O
569 O
patients O
with O
cancer O
of O
the O
breast O
and O
involvement O
of O
axillary O
lymph O
nodes O
were O
randomised O
, O
after O
simple O
mastectomy O
with O
axillary O
sampling O
, O
to O
receive O
either O
no O
adjuvant O
treatment O
or O
intravenous O
adriamycin O
50 O
mg O
, O
vincristine O
1 O
mg O
, O
cyclophosphamide O
250 O
mg O
, O
methotrexate O
150 O
mg O
and O
fluorouracil O
250 O
mg O
( O
AVCMF O
) O
every O
21 O
days O
for O
eight O
cycles O
. O
[]

Absolute B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
, O
for O
the O
nine O
patients O
so O
analyzed O
, O
was O
7.2+/-2.4 O
% O
. O
['Physiological-Clinical']

This O
study O
followed O
the O
previous O
Phase O
II O
study O
to O
confirm O
the O
safety O
of O
laparoscopy-assisted O
distal O
gastrectomy O
( O
JCOG0703 O
) O
and O
began O
in O
March O
2010 O
. O
[]

It O
was O
demonstrated O
that O
retention B-outcome ['Life-Impact']
on O
treatment O
with O
lumiracoxib O
at O
either O
dose O
was O
non-inferior O
to O
celecoxib O
200 O
mg O
o.d O
. O
['Life-Impact']

These O
results O
were O
accomplished O
by O
two O
applications O
per O
day O
as O
compared O
to O
the O
four O
necessary O
applications O
of O
Plc O
, O
on O
a O
half O
daily O
pilocarpine O
dose O
with O
Polym O
. O
[]

5 O
. O
[]

Therefore O
, O
the O
use O
of O
CS O
can O
not O
be O
assumed O
to O
be O
protective O
of O
lung O
volumes O
postsuctioning O
. O
[]

Between-group O
differences O
from O
baseline O
in O
mean O
MSQ B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Comparison O
of O
intravenous O
and O
intra-arterial O
urokinase O
thrombolysis O
for O
acute O
ischaemic O
stroke O
. O
[]

Nitrogen B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
remained O
equivalent O
throughout O
the O
study O
period O
, O
at O
day O
5 O
TEN O
= O
-0.3 O
+/- O
1.0 O
vs. O
TPN O
0.1 O
+/- O
0.8 O
gm/day O
. O
['Physiological-Clinical']

The O
treated O
patients O
had O
a O
logMAR B-outcome ['Physiological-Clinical']
vision I-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
of O
0.02 O
+/- O
0.213 O
, O
and O
the O
placebo O
patients O
had O
a O
vision B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
of O
0.02 O
+/- O
0.20 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
strong O
association O
existed O
between O
WCE B-outcome ['Physiological-Clinical']
calculated O
using O
the O
HBP B-outcome ['Physiological-Clinical']
or O
the O
ABP O
method O
( O
r O
= O
0.64/0.59 O
systolic/diastolic O
, O
P O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Forty-eight O
children O
diagnosed O
with O
ASD O
between O
18 O
and O
30 O
months O
of O
age O
were O
randomly O
assigned O
to O
1 O
of O
2 O
groups O
: O
( O
1 O
) O
ESDM O
intervention O
, O
which O
is O
based O
on O
developmental O
and O
applied O
behavioral O
analytic O
principles O
and O
delivered O
by O
trained O
therapists O
and O
parents O
for O
2 O
years O
; O
or O
( O
2 O
) O
referral O
to O
community O
providers O
for O
intervention O
commonly O
available O
in O
the O
community O
. O
[]

CONCLUSIONS O
Ocular O
hydration O
improves O
comfort B-outcome ['Life-Impact']
in O
contact O
lens O
wearers O
. O
['Life-Impact']

METHOD O
The O
Identifying O
Depression O
As O
a O
Comorbid O
Condition O
( O
IDACC O
) O
study O
employed O
a O
hybrid O
design O
, O
incorporating O
a O
randomized O
controlled O
trial O
nested O
within O
a O
prospective O
cohort O
study O
. O
[]

Twenty-four-hour O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
significantly O
lowered O
in O
all O
treatment O
groups O
. O
['Physiological-Clinical']

Risedronate O
5 O
mg O
provides O
effective O
and O
well-tolerated O
therapy O
for O
severe O
postmenopausal O
osteoporosis O
, O
reducing O
the O
incidence O
of O
vertebral O
fractures O
and O
improving O
bone O
density O
in O
women O
with O
established O
disease O
. O
[]

CONCLUSION O
Use O
of O
weekly O
vitamin O
A O
or O
beta O
carotene O
in O
pregnant O
women O
in O
Bangladesh O
, O
compared O
with O
placebo O
, O
did O
not O
reduce O
all-cause O
maternal O
, O
fetal O
, O
or O
infant O
mortality O
. O
[]

We O
conducted O
a O
double-blind O
study O
in O
173 O
newly O
diagnosed O
multiple O
myeloma O
patients O
of O
etidronate O
disodium O
( O
EHDP O
) O
, O
a O
diphosphonate O
compound O
that O
reduces O
bone O
resorption O
by O
inhibiting O
osteoclastic O
activity O
. O
[]

Each O
volunteer O
received O
183mg O
once-daily O
doses O
of O
caffeine O
in O
conjunction O
with O
twice-daily O
placebo O
, O
temafloxacin O
600mg O
and O
ciprofloxacin O
750mg O
in O
3 O
separate O
phases O
according O
to O
a O
randomised O
sequence O
. O
[]

METHODS O
Eighty-six O
patients O
underwent O
( O
18 O
) O
F-FDG O
PET/CT O
at O
baseline O
and O
weeks O
2 O
and O
6 O
of O
anti-HER2 O
treatment O
. O
[]

It O
is O
difficult O
to O
determine O
the O
best O
method O
when O
only O
considering O
the O
[]

Low O
calcium O
intake O
has O
been O
identified O
as O
a O
potential O
contributing O
factor O
to O
overweight O
and O
obesity O
. O
[]

We O
used O
transcranial O
Doppler O
ultrasonography O
to O
identify O
children O
with O
sickle O
cell O
anemia O
who O
were O
at O
high O
risk O
for O
stroke O
and O
then O
randomly O
assigned O
them O
to O
receive O
standard O
care O
or O
transfusions O
to O
prevent O
a O
first O
stroke O
. O
[]

Children O
were O
matched O
on O
CA O
, O
IQ O
, O
and O
autistic O
symptoms O
before O
being O
randomly O
assigned O
to O
LEGO O
or O
SULP O
. O
[]

Secondary O
endpoints O
included O
response O
rates O
, O
other O
acute B-outcome ['Physiological-Clinical']
hematotoxicity I-outcome ['Physiological-Clinical']
, O
acute B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
hospital B-outcome ['Resource-use']
admission I-outcome ['Resource-use']
, O
remission B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
, O
event-free B-outcome ['Mortality']
, O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Mortality', 'Mortality']

Trials O
with O
higher O
doses O
are O
planned O
. O
[]

Microbiologic O
yields O
and O
complication O
rates O
of O
vitreous O
needle O
aspiration O
versus O
mechanized O
vitreous O
biopsy O
in O
the O
Endophthalmitis O
Vitrectomy O
Study O
. O
[]

The O
median O
total O
sum O
of O
vitagram O
points O
was O
28.1 O
for O
radiotherapy O
, O
20.7 O
for O
cyclophosphamide O
and O
6.8 O
for O
placebo O
. O
[]

Here O
we O
report O
effects O
of O
endocrine O
treatment O
withdrawal O
on O
BMD O
, O
bone O
turnover O
markers O
( O
BTM O
) O
and O
fracture O
rates O
. O
[]

The O
maximum B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
control O
rate O
( O
84 O
% O
) O
was O
achieved O
with O
the O
DASH/lower O
sodium O
diet O
. O
['Physiological-Clinical']

Randomised O
trial O
of O
efficacy O
and O
safety O
of O
oral O
ganciclovir O
in O
the O
prevention O
of O
cytomegalovirus O
disease O
in O
liver-transplant O
recipients O
. O
[]

No O
differences O
in O
behavior B-outcome ['Life-Impact']
, O
serious B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
, O
functional B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
, O
or O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Of O
the O
patients O
with O
healed O
ulcers O
, O
238 O
participated O
in O
a O
24-mo O
follow-up O
study O
consisting O
of O
interviews O
at O
2-mo O
intervals O
and O
endoscopy O
at O
4-mo O
intervals O
or O
whenever O
symptoms O
recurred O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
the O
use O
of O
a O
whey-predominant O
, O
50 O
% O
medium O
chain O
triglyceride O
formula O
with O
relatively O
high O
concentrations O
of O
zinc O
and O
copper O
would O
promote O
the O
achievement O
of O
the O
in O
utero B-outcome ['Physiological-Clinical']
accretion I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
zinc I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
copper I-outcome ['Physiological-Clinical']
in O
the O
preterm O
infant O
. O
['Physiological-Clinical']

The O
primary O
end O
point O
was O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality']

Prosthodontic B-outcome ['Physiological-Clinical']
and O
aesthetic B-outcome ['Life-Impact']
outcomes O
were O
assessed O
using O
established O
criteria O
. O
['Physiological-Clinical', 'Life-Impact']

In O
each O
school O
one O
class O
was O
randomly O
assigned O
as O
the O
intervention O
group O
and O
another O
as O
controls O
. O
[]

CI-AKI B-outcome ['Physiological-Clinical']
was O
defined O
as O
a O
relative O
increase O
in O
serum O
creatinine O
of O
?25 O
% O
, O
or O
an O
absolute O
increase O
of O
?0.5 O
mg/dL O
, O
occurring O
within O
48 O
hours O
after O
contrast O
administration O
. O
['Physiological-Clinical']

It O
is O
concluded O
that O
in O
elderly O
patients O
undergoing O
upper O
abdominal O
surgery O
the O
risks O
related O
to O
the O
use O
of O
morphine O
by O
the O
epidural O
route O
outweigh O
the O
marginal O
advantages O
it O
may O
offer O
over O
conventional O
analgesic O
techniques O
. O
[]

Patients O
of O
both O
groups O
received O
0.625 O
mg O
conjugated O
equine O
estrogens O
daily O
per O
os O
for O
21 O
days O
. O
[]

Across O
species O
, O
across O
tasks O
, O
and O
even O
across O
conspecifics O
with O
sharper O
or O
duller O
memories O
, O
monkeys O
and O
humans O
used O
the O
escape B-outcome ['Life-Impact']
option I-outcome ['Life-Impact']
selectively O
when O
more O
indeterminate O
memory O
traces O
were O
probed O
. O
['Life-Impact']

Comparison O
of O
comfort B-outcome ['Life-Impact']
and O
local B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
after O
cardiac O
catheterization O
. O
['Life-Impact', 'Adverse-effects']

A O
comparative O
evaluation O
of O
calcium O
hydroxide O
and O
zinc O
oxide O
eugenol O
used O
as O
root B-outcome ['Physiological-Clinical']
canal I-outcome ['Physiological-Clinical']
filling I-outcome ['Physiological-Clinical']
materials I-outcome ['Physiological-Clinical']
in O
primary O
molars O
is O
presented O
. O
['Physiological-Clinical']

LEGO O
therapy O
and O
the O
social O
use O
of O
language O
programme O
: O
an O
evaluation O
of O
two O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
interventions O
for O
children O
with O
high O
functioning O
autism O
and O
Asperger O
Syndrome O
. O
['Life-Impact']

There O
was O
no O
difference O
in O
the O
magnitude O
of O
WCE B-outcome ['Physiological-Clinical']
assessed O
using O
the O
ABP O
or O
the O
HBP B-outcome ['Physiological-Clinical']
method O
( O
mean O
discrepancy O
, O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
: O
-1.5 O
+/- O
11.7 O
mm O
Hg O
, O
95 O
% O
CI O
-3.2 O
, O
0.2 O
; O
diastolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
: O
0.9 O
+/- O
7.0 O
, O
95 O
% O
CI O
-0.1 O
, O
1.9 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

To O
evaluate O
the O
role O
of O
hydroxyurea O
( O
HU O
) O
for O
the O
outcome O
of O
IFN O
therapy O
, O
we O
conducted O
a O
randomized O
trial O
to O
compare O
the O
combination O
of O
IFN O
and O
HU O
vs O
HU O
monotherapy O
( O
CML-study O
II O
) O
. O
[]

Our O
data O
indicate O
that O
aztreonam O
is O
safe O
and O
effective O
for O
the O
prevention O
of O
infections O
following O
biliary O
and O
gastric O
surgery O
. O
[]

In O
the O
exercise O
therapy O
group O
the O
percentage O
of O
patients O
with O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
was O
higher O
and O
the O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
was O
longer O
than O
in O
the O
placebo O
and O
usual O
care O
groups O
, O
but O
these O
differences O
were O
not O
significant O
. O
['Life-Impact', 'Life-Impact']

Direct O
and O
indirect O
effects O
of O
interdental O
hygiene O
in O
a O
clinical O
trial O
. O
[]

Since O
1977 O
, O
31 O
patients O
were O
entered O
in O
a O
randomized O
, O
prospective O
study O
testing O
the O
efficacy O
of O
adjuvant O
chemotherapy O
after O
aggressive O
local O
treatment O
of O
high-grade O
sarcomas O
of O
the O
head O
, O
neck O
, O
breast O
, O
and O
trunk O
( O
excluding O
retroperitoneal O
sarcomas O
) O
. O
[]

We O
conclude O
that O
such O
automatic B-outcome ['Physiological-Clinical']
enhancement I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
place I-outcome ['Physiological-Clinical']
representations I-outcome ['Physiological-Clinical']
by O
aversive O
emotional O
events O
serves O
as O
an O
important O
adaptive O
mechanism O
for O
avoiding O
future O
threats O
. O
['Physiological-Clinical']

2 O
) O
The O
rate O
of O
achieving O
the O
LDL-C B-outcome ['Physiological-Clinical']
goal O
of O
The O
National O
Cholesterol O
Education O
Program O
( O
NCEP O
) O
in O
Adult O
Treatment O
Panel O
III O
( O
ATP O
III O
) O
in O
the O
combination O
therapy O
group O
was O
73.5 O
% O
, O
significantly O
higher O
than O
those O
of O
the O
atorvastatin O
and O
niacin O
groups O
( O
47.7 O
% O
and O
42.1 O
% O
respectively O
, O
both O
P O
< O
0.05 O
) O
. O
( O
['Physiological-Clinical']

CONCLUSION O
No O
differences O
were O
found O
in O
between O
Tramadol O
and O
placebo O
in O
relief O
perineal O
pain O
after O
perineorrhaphy O
[]

Consecutive O
patients O
undergoing O
emergency O
appendicectomy O
were O
randomised O
into O
control O
, O
sham O
TENS O
and O
active O
TENS O
groups O
. O
[]

METHODS O
A O
double-blind O
, O
placebo O
controlled O
trial O
was O
performed O
to O
evaluate O
the O
clinical O
response O
to O
nebulized O
salbutamol O
. O
[]

After O
total O
mastectomy O
and O
axillary O
node O
sampling O
, O
high-risk O
patients O
were O
randomized O
to O
adjuvant O
therapy O
. O
[]

Effect O
of O
home-based O
nursing O
pulmonary O
rehabilitation O
on O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
: O
a O
randomised O
clinical O
trial O
. O
[]

Pre-transplant O
pharmacokinetic O
profiling O
and O
tacrolimus B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
post-transplant I-outcome ['Resource-use']
. O
['Resource-use']

BACKGROUND O
The O
efficacy O
, O
safety O
and O
tolerability O
of O
lumiracoxib O
, O
a O
novel O
selective O
cyclooxygenase-2 O
( O
COX-2 O
) O
inhibitor O
, O
has O
been O
demonstrated O
in O
previous O
studies O
of O
patients O
with O
osteoarthritis O
( O
OA O
) O
. O
[]

Superior O
modulation O
of O
activation O
levels O
of O
stimulus O
representations O
does O
not O
underlie O
superior O
discrimination O
in O
autism O
. O
[]

All O
participants O
took O
three O
gelcaps O
per O
day O
, O
one O
at O
each O
meal O
. O
[]

The O
intervention O
consisted O
of O
reporting O
the O
presence O
of O
MBD O
in O
the O
screening O
mammography O
results O
letter O
that O
was O
sent O
along O
with O
an O
information O
pamphlet O
. O
[]

A O
literature O
search O
( O
MEDLINE O
database O
) O
revealed O
wide O
variations O
in O
IDI O
techniques O
without O
a O
basis O
for O
comparison O
. O
[]

A O
total O
of O
507 O
medical O
students O
were O
randomly O
introduced O
into O
our O
intervention O
and O
control O
conditions O
. O
[]

When O
designing O
a O
clinical O
trial O
, O
selecting O
volunteers O
, O
or O
judging O
the O
tolerance O
of O
a O
new O
drug O
, O
the O
rise O
in O
TSB B-outcome ['Physiological-Clinical']
caused O
by O
fasting O
must O
therefore O
be O
taken O
into O
account O
, O
particularly O
in O
trials O
where O
volunteers O
or O
patients O
fast O
before O
entering O
the O
study O
. O
['Physiological-Clinical']

Both O
PSA-D O
and O
PSA-T O
showed O
a O
significantly O
higher O
area O
under O
the O
ROC O
curve O
( O
0.77 O
and O
0.79 O
, O
respectively O
) O
than O
PSA O
alone O
( O
area O
0.65 O
) O
. O
[]

The O
differences O
in O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
imply O
that O
fluorescence O
diagnosis O
is O
a O
clinically O
relevant O
procedure O
for O
decreasing O
the O
number O
of O
tumor B-outcome ['Physiological-Clinical']
recurrences I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

To O
determine O
whether O
Pgp O
inhibition O
improves O
treatment O
outcome O
in O
CML-BP O
, O
the O
Southwest O
Oncology O
Group O
performed O
a O
randomized O
, O
controlled O
trial O
testing O
the O
benefit O
of O
the O
Pgp O
modulator O
, O
cyclosporin O
A O
( O
CsA O
) O
. O
[]

METHODS O
Fecal B-outcome ['Physiological-Clinical']
elastase I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
secretin I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
at O
four O
different O
periods O
during O
the O
first O
28 O
days O
of O
life O
in O
VLBW O
infants O
, O
with O
extremely O
early O
enteral O
feeding O
starting O
within O
24 O
h O
of O
birth O
, O
as O
well O
as O
in O
control O
infants O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Therefore O
, O
the O
potentiating O
effect O
of O
sevoflurane O
seems O
to O
be O
mainly O
of O
PD O
origin O
, O
probably O
due O
to O
an O
increased O
sensitivity O
of O
the O
neuromuscular O
junction O
. O
[]

In O
comparison O
, O
a O
schedule O
of O
immunization O
on O
days O
0 O
, O
28 O
and O
56 O
ultimately O
evoked O
the O
highest O
titres O
21 O
days O
after O
the O
final O
injection O
, O
but O
antibody O
persisted O
equally O
well O
over O
two O
years O
with O
either O
schedule O
. O
[]

There O
were O
no O
complications B-outcome ['Adverse-effects']
during O
the O
study O
period O
. O
['Adverse-effects']

RESULTS O
After O
12 O
months O
, O
median O
CGM O
use O
was O
6.8 O
days O
per O
week O
. O
[]

The O
main O
outcome O
measures O
were O
HIV-RNA B-outcome ['Physiological-Clinical']
, O
CD4 B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
and O
blood B-outcome ['Physiological-Clinical']
chemistry I-outcome ['Physiological-Clinical']
profiles O
prior O
to O
the O
treatment O
and O
then O
every O
4 O
weeks O
for O
24 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OUTCOME O
Eradication B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
GABHS I-outcome ['Physiological-Clinical']
, O
determined O
with O
follow-up O
throat O
cultures O
on O
days O
3-6 O
, O
12-16 O
and O
26-36 O
. O
['Physiological-Clinical']

Complete B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
enlarged I-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
within O
168 O
h O
was O
associated O
with O
a O
sensitive O
response O
to O
each O
treatment O
. O
['Physiological-Clinical']

Maternal O
breast-milk O
and O
intestinal O
bifidobacteria O
guide O
the O
compositional O
development O
of O
the O
Bifidobacterium O
microbiota O
in O
infants O
at O
risk O
of O
allergic O
disease O
. O
[]

METHODS O
Forty-two O
patients O
scheduled O
for O
elective O
CS O
were O
randomly O
divided O
into O
3 O
equal O
groups O
, O
and O
received O
2-CP O
, O
2-CP O
+ O
epinephrine O
( O
Epi O
, O
5 O
micrograms.ml-1 O
) O
or O
2 O
% O
lidocaine O
( O
Lido O
) O
with O
Epi O
for O
LEA O
. O
[]

Mortality B-outcome ['Mortality']
was O
not O
significantly O
different O
in O
the O
AR-R15896AR O
group O
compared O
with O
the O
placebo O
group O
( O
10 O
% O
vs. O
6 O
% O
) O
. O
['Mortality']

RESULTS O
The O
comparative O
results O
were O
very O
close O
; O
mean O
difference O
( O
bias O
) O
+/- O
standard O
deviation O
( O
precision O
) O
was O
0.05 O
( O
0.84 O
) O
mmol/min/kPa O
. O
[]

The O
clinical O
effectiveness O
of O
treatments O
was O
not O
significantly O
related O
to O
changes O
in O
cortical B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Induced O
specific O
desensitization O
to O
insect O
bites O
is O
theoretically O
an O
effective O
means O
of O
prevention O
of O
PU O
. O
[]

In O
a O
small O
trial O
, O
arbitrary O
lower O
doses O
of O
heparin O
given O
intermittently O
similar O
to O
the O
doses O
of O
heparin O
given O
continuously O
resulted O
in O
fewer O
bleeding B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
and O
more O
recurrences B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
results O
suggest O
that O
12 O
g O
RDN O
kg?? O
DOMI O
or O
19 O
g O
RDN O
kg?? O
DOMR O
may O
be O
adequate O
for O
optimum O
MPS O
, O
NCE O
and O
digestibility O
of O
nutrients O
in O
sheep O
fed O
on O
an O
FMS-based O
diet O
. O
[]

BACKGROUND O
AND O
PURPOSE O
Modified O
constraint-induced O
therapy O
( O
mCIT O
) O
is O
an O
outpatient O
therapy O
encouraging O
repetitive O
, O
task-specific O
practice O
with O
the O
affected O
arm O
. O
[]

Female O
smokers O
had O
higher O
serum O
low-density O
lipoprotein O
( O
LDL O
) O
/high-density O
lipoprotein O
( O
HDL O
) O
ratios O
and O
triglycerides O
. O
[]

CIMT O
may O
facilitate O
functional O
improvement O
of O
a O
plegic O
hand O
. O
[]

Children O
with O
no O
GI O
problems O
are O
unaffected O
by O
either O
secretin O
or O
placebo O
. O
[]

Codeine O
60 O
mg O
was O
significantly O
superior O
to O
placebo O
for O
percent O
SPID O
and O
some O
hourly O
measures O
. O
[]

Results O
showed O
that O
the O
maximal O
administered O
dose O
of O
disopyramide O
was O
greater O
with O
active O
pyridostigmine O
than O
with O
placebo O
: O
295 O
+/- O
75 O
versus O
245 O
+/- O
100 O
mg O
every O
6 O
hours O
( O
p O
less O
than O
0.05 O
) O
. O
[]

CONCLUSIONS O
A O
targeted O
e-learning O
module O
on O
leukaemia O
had O
a O
significant O
effect O
on O
learning B-outcome ['Life-Impact']
in O
this O
cohort O
, O
compared O
with O
existing O
online O
resources O
. O
['Life-Impact']

In O
Group O
A O
( O
January O
2006-October O
2007 O
) O
, O
we O
analyzed O
the O
fluctuation O
[]

Briefly O
, O
arginine O
( O
30 O
g O
) O
was O
infused O
from O
-30 O
to O
0 O
min O
, O
and O
GHRH O
( O
100 O
microg O
) O
was O
injected O
as O
a O
bolus O
at O
0 O
min O
, O
with O
measurement O
of O
serum O
GH O
[ O
immunoradiometric O
assay O
( O
IRMA O
) O
] O
every O
15 O
min O
for O
150 O
min O
. O
[]

In O
all O
protocols O
, O
the O
same O
iodine O
load O
per O
kilogram O
of O
body O
weight O
( O
516 O
mg/kg O
) O
was O
administered O
for O
the O
same O
injection O
duration O
( O
30 O
seconds O
) O
. O
[]

Additionally O
, O
children O
in O
the O
experimental O
group O
, O
whose O
GSR B-outcome ['Life-Impact']
measures O
decreased O
, O
on O
average O
, O
after O
deep O
pressure O
, O
were O
somewhat O
more O
likely O
to O
have O
higher O
GSR B-outcome ['Life-Impact']
arousal I-outcome ['Life-Impact']
a O
priori O
. O
['Life-Impact', 'Life-Impact']

There O
appears O
no O
obvious O
adverse O
effect O
on O
uterine B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
or O
ovarian B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

No O
significant O
variations O
in O
maximum B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
ibopamine O
117.7 O
+/- O
20.9 O
; O
placebo O
118.1 O
+/- O
20.7 O
) O
, O
medium O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
ibopamine O
71.8 O
+/- O
10.2 O
; O
placebo O
72.6 O
+/- O
10.1 O
) O
or O
minimum B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
ibopamine O
55.3 O
+/- O
11.7 O
; O
placebo O
54.6 O
+/- O
10.6 O
) O
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHOD O
159 O
periodontally O
healthy O
subjects O
abstained O
from O
oral O
hygiene O
procedures O
and O
self-administered O
either O
0.005 O
% O
, O
0.01 O
% O
, O
0.05 O
% O
P-113 O
or O
placebo O
mouthrinse O
formulations O
twice O
daily O
over O
a O
four O
week O
treatment O
period O
. O
[]

Forty-three O
variables O
( O
including O
in-hospital O
and O
post-hospital O
data O
) O
were O
evaluated O
using O
stepwise O
logistic O
regression O
. O
[]

BACKGROUND O
Chemoprevention O
crossover O
trials O
of O
tea O
can O
be O
more O
efficient O
than O
parallel O
designs O
but O
the O
attrition O
and O
compliance O
rates O
with O
such O
trials O
are O
unknown O
. O
[]

0.03 O
vs O
0.28 O
? O
[]

Loss O
of O
tooth O
substance O
during O
root O
planing O
with O
various O
periodontal O
instruments O
: O
an O
in O
vitro O
study O
. O
[]

In O
patients O
with O
chlorpromazine-induced O
hyperprolactinaemia O
and O
galactorrhoea O
, O
pyridoxine O
did O
not O
reduce O
the O
elevated O
levels O
. O
[]

Overall O
response O
rate O
was O
42 O
% O
( O
E=44 O
% O
, O
S=44 O
% O
, O
CC=32 O
% O
) O
. O
[]

Increased O
repetitive O
behaviours O
and O
prolactin O
responsivity O
to O
oral O
m-chlorophenylpiperazine O
in O
adults O
with O
autism O
spectrum O
disorders O
. O
[]

RESULTS O
The O
total O
effective O
rate O
was O
80 O
. O
[]

These O
findings O
suggest O
that O
increases O
in O
RBC B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
during O
nandrolone O
decanoate O
therapy O
result O
from O
two O
mechanisms O
: O
increased O
erythropoiesis O
( O
shown O
by O
simultaneous O
increases O
in O
RBC B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
and O
erythron B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
) O
and O
increased O
RBC B-outcome ['Physiological-Clinical']
survival I-outcome ['Physiological-Clinical']
( O
indirectly O
shown O
by O
increases O
in O
RBC B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
without O
increases O
in O
erythron B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
randomized O
for O
conventional O
therapy O
( O
control O
) O
or O
continuous O
treatment O
with O
10 O
parts O
per O
million O
( O
ppm O
) O
inhaled O
NO O
until O
weaning O
was O
initiated O
. O
[]

Arm O
B O
: O
86 O
patients O
were O
included O
, O
80 O
were O
evaluable O
for O
activity O
; O
RESPONSE O
CR B-outcome ['Physiological-Clinical']
7 O
( O
9 O
% O
) O
, O
PR B-outcome ['Physiological-Clinical']
29 O
( O
36 O
% O
) O
, O
SD O
10 O
( O
12.5 O
% O
) O
, O
PD B-outcome ['Physiological-Clinical']
34 O
( O
42.5 O
% O
) O
; O
The O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Clozapine O
versus O
placebo O
in O
Huntington O
's O
disease O
: O
a O
double O
blind O
randomised O
comparative O
study O
. O
[]

Computer O
Assisted O
Instruction O
( O
CAI O
) O
has O
shown O
increased O
popularity O
recently O
and O
there O
are O
many O
studies O
showing O
promise O
for O
this O
approach O
for O
children O
with O
Autism O
Spectrum O
Disorders O
( O
ASD O
) O
. O
[]

For O
Intergroup O
Rhabdomyosarcoma O
Study O
( O
IRS O
) O
IV O
patients O
with O
group O
III O
rhabdomyosarcoma O
, O
we O
assessed O
whether O
reported O
response O
assessed O
by O
anatomic O
imaging O
at O
week O
8 O
predicted O
FFS O
. O
[]

RESULTS O
Mean O
age O
of O
the O
study O
participants O
was O
37.6 O
+/- O
12.4 O
years O
; O
they O
smoked O
an O
average O
of O
20.0 O
+/- O
6.6 O
cigarettes O
per O
day O
for O
20 O
+/- O
12.1 O
years O
. O
[]

RESULTS O
In O
total O
, O
29 O
patients O
( O
55 O
eyes O
) O
completed O
the O
trial O
and O
were O
available O
for O
analysis O
. O
[]

The O
genotype O
of O
CCND1 O
A870G O
in O
the O
patients O
was O
detected O
by O
polymerase O
chain O
reaction-based O
restriction O
fragment O
length O
polymorphism O
( O
PCR-RFLP O
) O
analysis O
. O
[]

Patients O
of O
the O
NLA O
group O
showed O
no O
hyperglycaemia O
and O
only O
mild O
elevations O
of O
the O
cortisol O
levels O
during O
the O
intraoperative O
period O
. O
( O
[]

Seventy-three O
patients O
with O
advanced O
UGIA O
were O
randomised O
to O
receive O
45 O
mg/m2 O
docetaxel O
or O
180 O
mg/m2 O
irinotecan O
with O
5-FU/leucovorin O
. O
[]

This O
study O
details O
retrospective O
and O
prospective O
comparison O
of O
electrocautery O
division O
of O
the O
isthmus O
with O
older O
techniques O
. O
[]

RESULTS O
A O
total O
of O
2,757 O
patients O
were O
screened O
at O
153 O
centers O
in O
20 O
countries O
, O
and O
1,623 O
patients O
were O
randomized O
into O
the O
trial O
. O
[]

The O
Nutritional O
Prevention O
of O
Cancer O
Trial O
was O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
clinical O
trial O
designed O
to O
test O
whether O
selenium O
as O
selenized O
yeast O
( O
200 O
microg O
daily O
) O
could O
prevent O
nonmelanoma O
skin O
cancer O
among O
1312 O
patients O
from O
the O
Eastern O
United O
States O
who O
had O
previously O
had O
this O
disease O
. O
[]

RESULTS O
For O
the O
primary O
efficacy O
analysis O
, O
change O
of O
[]

French O
Multicentre O
Study O
Group O
. O
[]

The O
use O
of O
a O
simple O
tele-messaging O
device O
as O
an O
adjunct O
to O
symptom O
management O
is O
feasible B-outcome ['Life-Impact']
, O
affordable B-outcome ['Life-Impact']
, O
and O
acceptable B-outcome ['Life-Impact']
to O
patients O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Left O
ventricular O
mass O
regression O
in O
elderly O
hypertensives O
. O
[]

The O
women O
were O
assigned O
to O
two O
study O
groups O
. O
[]

No O
bilateral B-outcome ['Physiological-Clinical']
adnexal I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

The O
effect O
was O
not O
seen O
with O
regard O
to O
self-reported O
relaxation B-outcome ['Life-Impact']
( O
as O
represented O
by O
changes O
in O
state O
anxiety O
) O
and O
was O
independent O
of O
ratings O
of O
attitudes B-outcome ['Life-Impact']
towards O
aromatherapy O
. O
['Life-Impact', 'Life-Impact']

This O
randomized O
and O
controlled O
trial O
aimed O
to O
assess O
the O
effect O
of O
ischemic B-outcome ['Physiological-Clinical']
postconditioning I-outcome ['Physiological-Clinical']
on O
protection O
against O
myocardial B-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
reperfusion O
injury O
in O
TOF O
patients O
receiving O
cardioplegia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

As O
expected O
, O
initial B-outcome ['Physiological-Clinical']
TSAb I-outcome ['Physiological-Clinical']
levels O
had O
no O
predictive O
value O
. O
['Physiological-Clinical']

These O
trials O
were O
registered O
at O
www.clinicaltrials.gov O
as O
# O
NCT00090051 O
( O
REACH O
) O
and O
# O
NCT00281918 O
( O
CLL8 O
) O
. O
[]

Piroxicam O
20 O
mg O
was O
significantly O
more O
effective O
than O
codeine O
60 O
mg O
for O
percent O
SPID O
and O
a O
few O
hourly O
measures O
including O
time O
to O
remedication O
. O
[]

The O
total O
incidence O
of O
PONV B-outcome ['Physiological-Clinical']
in O
the O
desflurane-only O
group O
was O
80 O
% O
( O
P O
< O
0.01 O
) O
, O
compared O
to O
40 O
% O
and O
20 O
% O
in O
the O
desflurane O
group O
receiving O
ondansetron O
and O
the O
propofol O
group O
, O
respectively O
. O
['Physiological-Clinical']

In O
the O
present O
study O
we O
examine O
the O
effects O
of O
low-frequency O
, O
repetitive O
Transcranial O
Magnetic O
Stimulation O
( O
rTMS O
) O
on O
novelty O
processing O
as O
well O
as O
behavior O
and O
social O
functioning O
in O
13 O
individuals O
with O
ASD O
. O
[]

Ventilation O
( O
Ve O
) O
, O
heart O
rate O
( O
HR O
) O
, O
blood O
pressure O
, O
and O
muscle O
sympathetic O
nervous O
activity O
( O
MSNA O
) O
data O
were O
continuously O
obtained O
. O
[]

Therapists O
worked O
with O
individual O
families O
. O
[]

PURPOSE O
Initial O
response O
to O
induction O
chemotherapy O
predicts O
failure-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
FFS I-outcome ['Mortality']
) I-outcome ['Mortality']
in O
osteosarcoma O
and O
Ewing O
's O
sarcoma O
. O
['Mortality']

Forty-three O
patients O
were O
selected O
for O
the O
experimental O
group O
, O
and O
31 O
control O
subjects O
used O
the O
sham O
instrument O
( O
placebo O
group O
) O
. O
[]

A O
double-blind O
, O
placebo-controlled O
trial O
of O
nefazodone O
in O
the O
treatment O
of O
patients O
hospitalized O
for O
major O
depression O
. O
[]

Children O
in O
the O
treatment O
group O
underwent O
30 O
sessions O
of O
stimulation O
over O
6 O
weeks O
, O
while O
children O
in O
the O
control O
group O
were O
on O
a O
waiting O
list O
and O
did O
not O
receive O
treatment O
during O
this O
period O
of O
time O
. O
[]

CONCLUSIONS O
These O
findings O
support O
those O
of O
neuroimaging O
studies O
implicating O
the O
basal O
ganglia O
in O
depression O
and O
geriatric O
depression O
. O
[]

RESULTS O
A O
pathologic O
result O
was O
found O
in O
90 O
% O
of O
the O
patients O
. O
[]

RESULTS O
In O
the O
IV O
group O
there O
was O
a O
slight O
but O
significant O
increase O
in O
p O
( O
a O
) O
CO2 O
after O
5 O
, O
10 O
, O
and O
15 O
min O
compared O
with O
the O
IM O
group O
( O
5.2 O
vs. O
4.8 O
, O
5.4 O
, O
vs. O
5.0 O
and O
5.5 O
vs. O
5.1 O
kPa O
, O
respectively O
) O
. O
[]

CONCLUSIONS O
Serum O
magnesium O
does O
not O
appear O
to O
be O
an O
independent O
risk O
factor O
for O
either O
[]

The O
addition O
of O
rituximab O
to O
the O
uniform O
drug O
regimen O
did O
not O
show O
any O
significant O
improvement O
in O
5 O
years O
overall O
( O
63 O
% O
versus O
59 O
% O
, O
p O
0.68 O
) O
or O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
42 O
% O
versus O
39 O
% O
, O
p O
0.94 O
) O
, O
for O
CHOP O
versus O
R-CHOP O
comparisons O
. O
['Mortality']

CONCLUSIONS O
This O
study O
confirms O
the O
findings O
in O
a O
previous O
open O
label O
trial O
that O
administration O
of O
VLP O
immunotherapy O
may O
assist O
in O
clearance O
of O
recurrent O
genital O
warts O
in O
patients O
for O
whom O
destructive O
therapy O
is O
unsuccessful O
and O
that O
unsuccessful O
destructive O
therapy O
is O
more O
common O
with O
increasing O
prior O
disease O
duration O
. O
[]

Weight O
loss B-outcome ['Physiological-Clinical']
was O
higher O
in O
group O
I O
than O
II O
( O
7,7 O
[ O
4,7 O
] O
vs O
3,92 O
[ O
3,32 O
] O
kg O
; O
P=.05 O
) O
, O
with O
a O
significant O
decrease O
of O
HOMA B-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
group O
I. O
Decreases O
of O
body O
mass O
index O
( O
-2,9 O
[ O
1,8 O
] O
vs O
-1,4 O
[ O
0,9 O
] O
; O
P=.05 O
) O
, O
fat B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
( O
-3,8 O
[ O
3,4 O
] O
vs O
-2,3 O
[ O
1,7 O
] O
kg O
; O
P=.0,05 O
) O
and O
HOMA B-outcome ['Physiological-Clinical']
( O
-2,0 O
[ O
2,2 O
] O
vs O
-0,4 O
[ O
1,82 O
] O
; O
P=.05 O
) O
were O
higher O
in O
group O
I O
than O
II O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Coronary O
artery O
disease O
patients O
whose O
LDL-C O
? O
[]

On O
day O
15 O
, O
a O
second O
BAL O
was O
done O
and O
AM O
IL-1 B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
was O
again O
tested O
. O
['Physiological-Clinical']

Mean O
run-in O
postprandial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
also O
reduced O
upon O
ACE-inhibition O
( O
9 O
a.m. O
: O
12.7 O
+/- O
0.4 O
vs. O
11.1 O
+/- O
0.4 O
mmol/l O
; O
1 O
p.m. O
: O
11.0 O
+/- O
0.3 O
vs. O
8.9 O
+/- O
0.3 O
mmol/l O
; O
P O
less O
than O
0.05 O
) O
, O
while O
blood B-outcome ['Physiological-Clinical']
kinin I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
( O
40.0 O
+/- O
2.5 O
pmol/l O
) O
were O
approximately O
doubled O
( O
108.8 O
+/- O
23.5 O
pmol/l O
; O
P O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Our O
purpose O
was O
to O
evaluate O
the O
safety O
of O
marine O
lipid O
suppositories O
and O
ointment O
in O
healthy O
volunteers O
and O
to O
explore O
the O
laxative B-outcome ['Physiological-Clinical']
effect O
of O
the O
suppositories O
. O
['Physiological-Clinical']

Most O
effective O
regimen O
of O
tranexamic O
acid O
in O
knee O
arthroplasty O
: O
a O
prospective O
randomized O
controlled O
study O
in O
240 O
patients O
. O
[]

The O
effect O
of O
orally O
administered O
ranitidine O
on O
the O
pharmacokinetic B-outcome ['Physiological-Clinical']
properties O
of O
orally O
and O
intravenously O
administered O
triazolam O
was O
determined O
. O
['Physiological-Clinical']

A O
randomized O
prospective O
controlled O
trial O
of O
oral O
ganciclovir O
versus O
oral O
valacyclovir O
for O
prophylaxis O
of O
cytomegalovirus B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
after O
renal O
transplantation O
. O
['Physiological-Clinical']

The O
modalities O
of O
definitive O
treatment O
( O
radiotherapy O
+/- O
surgery O
) O
were O
chosen O
prior O
to O
randomization O
. O
[]

RESULTS O
DELTA-1 O
was O
able O
to O
provide O
a O
standardized O
diet O
that O
met O
nutrient B-outcome ['Physiological-Clinical']
specifications I-outcome ['Physiological-Clinical']
across O
4 O
field O
centers O
over O
24 O
weeks O
of O
participant O
feeding O
spanning O
a O
total O
of O
8 O
months O
. O
['Physiological-Clinical']

BACKGROUND O
Atherosclerotic O
intracranial O
arterial O
stenosis O
is O
an O
important O
cause O
of O
stroke O
. O
[]

Adjuvant O
therapy O
with O
pegylated O
interferon O
alfa-2b O
versus O
observation O
in O
resected O
stage O
III O
melanoma O
: O
a O
phase O
III O
randomized O
controlled O
trial O
of O
health-related O
quality O
of O
life O
and O
symptoms O
by O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Melanoma O
Group O
. O
[]

Beside O
, O
the O
occurrence O
of O
end-point O
events O
in O
the O
treatment O
group O
was O
slightly O
lower O
than O
that O
in O
the O
control O
group O
, O
though O
showed O
no O
statistical O
difference O
between O
them O
. O
[]

Moreover O
, O
the O
incidence O
of O
newly O
detected O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
elevation O
was O
high O
. O
['Physiological-Clinical']

Index O
finger O
flow O
was O
assessed O
at O
baseline O
and O
after O
ischemia O
every O
30 O
s O
by O
maximum O
amplitude O
time O
( O
MAT O
) O
, O
total O
time O
of O
the O
curve O
( O
TT O
) O
and O
the O
index O
of O
the O
two O
( O
MAT/TT O
< O
30 O
= O
normal O
) O
before O
and O
after O
the O
administration O
of O
L-arginine O
( O
8 O
g/day O
in O
two O
doses O
, O
n O
= O
15 O
) O
or O
citrulline O
( O
3 O
g/day O
in O
one O
dose O
, O
n O
= O
15 O
) O
for O
60 O
days O
in O
addition O
to O
optimal O
pharmacological O
treatment O
. O
[]

There O
was O
no O
significant O
reduction O
in O
the O
requirement O
for O
patient-controlled B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
with O
or O
without O
TENS O
. O
['Resource-use']

RESULTS O
The O
ICS O
of O
two O
groups O
after O
treatment O
both O
decreased O
significantly O
( O
both O
P O
< O
0.001 O
) O
, O
and O
the O
decreasing O
degree O
in O
observation O
group O
was O
more O
significant O
than O
that O
in O
control O
group O
( O
P O
< O
0.001 O
) O
. O
[]

DESIGN O
A O
randomized O
controlled O
trial O
. O
[]

We O
can O
not O
advocate O
the O
administration O
of O
lidocaine O
prophylactically O
in O
the O
early O
hours O
of O
suspected O
myocardial O
infarction O
. O
[]

STUDY O
NUMBER O
: O
SAM40030 O
( O
SOLTA O
) O
. O
[]

Preoperatively O
there O
were O
no O
differences O
with O
regard O
to O
aortic B-outcome ['Physiological-Clinical']
valve I-outcome ['Physiological-Clinical']
pathology I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
gradients I-outcome ['Physiological-Clinical']
between O
the O
two O
patient O
groups O
. O
['Physiological-Clinical']

In O
retrospectively O
defined O
subgroups O
, O
significant O
improvement O
in O
[]

RESULTS O
Oestrogen B-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
positive O
ductal B-outcome ['Physiological-Clinical']
carcinomas B-outcome ['Physiological-Clinical']
responded O
as O
expected O
to O
tamoxifen O
, O
whereas O
the O
difference O
in O
recurrence B-outcome ['Physiological-Clinical']
free O
survival B-outcome ['Mortality']
between O
control O
and O
tamoxifen O
treated O
patients O
was O
less O
apparent O
in O
the O
relatively O
few O
lobular O
carcinomas O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

METHOD O
This O
study O
is O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
three O
month O
vitamin/mineral O
treatment O
study O
. O
[]

RESULTS O
( O
1 O
) O
After O
8 O
weeks O
of O
treatment O
, O
the O
serum O
level O
of O
triglyceride O
( O
TG O
) O
and O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HDL-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
reduced O
by O
30 O
% O
and O
16 O
% O
respectively O
in O
the O
niacin O
ER O
group O
compared O
with O
the O
baseline O
values O
( O
both O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Identifying O
the O
indications O
for O
laparoscopically O
assisted O
vaginal O
hysterectomy O
: O
a O
prospective O
, O
randomised O
comparison O
with O
abdominal O
hysterectomy O
in O
patients O
with O
symptomatic O
uterine O
fibroids O
. O
[]

Risperidone O
in O
the O
treatment O
of O
disruptive O
behavioral O
symptoms O
in O
children O
with O
autistic O
and O
other O
pervasive O
developmental O
disorders O
. O
[]

Half O
the O
patients O
receiving O
continuous O
infusion O
and O
multiple O
injections O
developed O
retinal B-outcome ['Physiological-Clinical']
cotton I-outcome ['Physiological-Clinical']
wool I-outcome ['Physiological-Clinical']
spots I-outcome ['Physiological-Clinical']
after O
three O
to O
six O
months O
. O
['Physiological-Clinical']

Components O
of O
working O
memory O
and O
visual O
selective O
attention O
. O
[]

Gain O
was O
defined O
by O
the O
adjusted O
core B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
increase O
required O
to O
augment O
sweating O
from O
100 O
to O
300 O
g.m-2.h-1 O
. O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
significant O
( O
p O
> O
0.05 O
) O
changes O
in O
markers O
of O
kidney B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
or O
urinary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
between O
groups O
over O
the O
2 O
years O
despite O
a O
significant O
fall O
in O
total O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
in O
pravastatin-treated O
patients O
( O
p O
= O
0.029 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
This O
study O
aimed O
to O
investigate O
the O
course O
of O
depression B-outcome ['Life-Impact']
for O
patients O
with O
recently O
diagnosed O
rheumatoid O
arthritis O
( O
RA O
) O
and O
to O
investigate O
predictors O
of O
depression O
. O
['Life-Impact']

In O
contrast O
, O
children O
with O
ADHD O
( O
ADHD/ASD+ADHD O
) O
exhibited O
a O
reduced O
face B-outcome ['Life-Impact']
inversion I-outcome ['Life-Impact']
effect O
on O
P1 O
latency O
compared O
to O
TD O
and O
ASD O
. O
['Life-Impact']

A O
clinical O
trial O
was O
designed O
to O
evaluate O
the O
efficacy O
of O
azithromycin O
for O
the O
treatment O
of O
chlamydia O
( O
Chlamydophila O
felis O
) O
infection O
in O
cats O
. O
[]

Comparison O
of O
endocrine O
and O
radiation O
therapy O
in O
locally O
advanced O
prostatic O
cancer O
. O
[]

Adult O
participants O
performed O
significantly O
better O
on O
the O
UCAST-FW O
in O
comparison O
to O
the O
child O
participants O
. O
[]

Condylomata O
acuminata O
( O
CA O
) O
caused O
by O
human O
papillomavirus O
( O
HPV O
) O
is O
a O
common O
sexually O
transmitted O
disease O
with O
half O
a O
million O
new O
cases O
diagnosed O
in O
the O
United O
States O
per O
year O
and O
the O
annual O
increase O
in O
incidence O
in O
China O
. O
[]

OBJECTIVE O
A O
randomized O
phase O
II O
trial O
was O
conducted O
to O
test O
whether O
the O
addition O
of O
gemcitabine O
to O
weekly O
docetaxel O
could O
improve O
the O
objective O
response O
rate O
and O
survival B-outcome ['Mortality']
outcomes O
as O
second-line O
chemotherapy O
in O
patients O
with O
metastatic O
breast O
cancer O
who O
have O
failed O
a O
paclitaxel-containing O
regimen O
. O
['Mortality']

Haemodynamic O
and O
left O
ventricular O
variables O
were O
determined O
by O
M-mode O
echocardiography O
in O
21 O
normotensive O
and O
36 O
hypertensive O
patients O
during O
the O
last O
trimester O
of O
pregnancy O
. O
[]

Determinants O
of O
serum O
creatinine O
trajectory O
in O
acute O
contrast O
nephropathy O
. O
[]

The O
pharmacokinetic B-outcome ['Physiological-Clinical']
profile O
of O
bilastine O
was O
investigated O
using O
a O
simultaneous O
analysis O
of O
all O
concentration-time O
data O
by O
means O
of O
nonlinear O
mixed-effects O
modelling O
population O
pharmacokinetic O
software O
NONMEM O
version O
6.1 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
subgroup O
of O
active O
bleeders O
, O
ES O
had O
a O
substantially O
lower O
cost/survival O
( O
$ O
28,523 O
vs. O
$ O
51,696 O
) O
. O
[]

We O
found O
that O
, O
among O
healthy O
sedentary O
menopausal O
women O
, O
yoga O
appears O
to O
improve O
menopausal O
quality O
of O
life O
; O
the O
clinical O
significance O
of O
our O
finding O
is O
uncertain O
because O
of O
the O
modest O
effect O
. O
[]

CONCLUSIONS O
This O
study O
shows O
the O
influence O
of O
some O
communication O
skills O
on O
the O
evolution O
of O
[]

BACKGROUND O
This O
study O
compared O
two O
interventions O
for O
improving O
the O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
of O
high O
functioning O
children O
with O
autism O
spectrum O
disorders O
in O
general O
education O
classrooms O
. O
['Life-Impact']

The O
study O
was O
conducted O
in O
the O
operation O
room O
, O
post-anesthesia O
care O
unit O
, O
and O
inpatient O
clinic O
. O
[]

After O
high-dose O
chemotherapy O
and O
PBPC O
transplantation O
, O
groups O
1 O
through O
4 O
received O
rhTPO O
1.5 O
microg/kg O
days O
0 O
, O
+2 O
, O
+4 O
, O
and O
+6 O
with O
either O
G-CSF O
5 O
microg/kg/day O
( O
groups O
1-3 O
) O
or O
granulocyte-macrophage O
colony-stimulating O
factor O
250 O
microg/m O
( O
2 O
) O
/day O
( O
group O
4 O
) O
. O
[]

At O
week O
4 O
, O
doses O
were O
titrated O
to O
40 O
, O
100 O
, O
and O
160 O
mg O
once O
daily O
for O
olmesartan O
, O
losartan O
, O
and O
valsartan O
, O
respectively O
. O
[]

RESULTS O
Glucagon O
elicited O
hyperglycemia B-outcome ['Physiological-Clinical']
whereas O
hyoscine O
N-butyl O
bromide O
manifested O
an O
anticholinergic B-outcome ['Physiological-Clinical']
effect O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
median O
numbers O
of O
transfused B-outcome ['Physiological-Clinical']
mononuclear I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MNC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
CD34 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
and O
CFU-GM B-outcome ['Physiological-Clinical']
were O
, O
respectively O
, O
4.5 O
( O
range O
, O
1 O
to O
19 O
) O
x O
10 O
( O
8 O
) O
/kg O
, O
8.0 O
( O
1.1 O
to O
25 O
) O
x O
10 O
( O
6 O
) O
/kg O
, O
and O
3.7 O
( O
1.2 O
to O
23 O
) O
x O
10 O
( O
5 O
) O
/kg O
in O
the O
treatment O
group O
( O
n O
= O
30 O
) O
and O
2.9 O
( O
0.8 O
to O
21 O
) O
x O
10 O
( O
8 O
) O
/kg O
, O
6.3 O
( O
1.1 O
to O
34 O
) O
x O
10 O
( O
6 O
) O
/kg O
, O
and O
5.5 O
( O
1.3 O
to O
37 O
) O
x O
10 O
( O
5 O
) O
/kg O
, O
respectively O
, O
in O
the O
control O
group O
( O
n O
= O
28 O
) O
, O
with O
no O
significant O
difference O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Braced O
for O
impact O
: O
reducing O
military O
paratroopers O
' O
ankle O
sprains O
using O
outside-the-boot O
braces O
. O
[]

To O
examine O
whether O
it O
is O
possible O
to O
evaluate O
the O
degree O
of O
ultraviolet O
B O
( O
UVB O
) O
-induced O
inflammation O
by O
measuring O
the O
degree O
of O
hyperpigmentation B-outcome ['Physiological-Clinical']
, O
we O
investigated O
the O
relationship O
between O
UVB-induced O
erythema O
and O
the O
subsequent B-outcome ['Physiological-Clinical']
pigmentation I-outcome ['Physiological-Clinical']
quantitatively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
has O
been O
reported O
that O
autism O
is O
a O
hypoglutamatergic O
disorder O
. O
[]

This O
study O
reports O
results O
of O
a O
randomized O
controlled O
trial O
aimed O
at O
joint O
attention O
( O
JA O
) O
and O
symbolic O
play O
( O
SP O
) O
in O
preschool O
children O
with O
autism O
, O
with O
prediction O
to O
language B-outcome ['Life-Impact']
outcome I-outcome ['Life-Impact']
12 O
months O
later O
. O
['Life-Impact']

RESULTS O
All O
children O
demonstrated O
statistically O
significant O
improvements O
in O
contextual B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
and O
cognitive B-outcome ['Life-Impact']
flexibility I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Basal O
L-arginine O
group O
= O
38.75 O
? O
[]

Their O
diet O
and O
serum O
phospholipid O
fatty O
acid O
profiles O
were O
monitored O
. O
[]

Marbling O
scores O
and O
the O
percentage O
of O
carcasses O
grading O
USDA O
Choice O
and O
Prime O
were O
greater O
in O
TT O
than O
CC O
steers O
when O
fed O
diets O
devoid O
of O
ZH O
, O
but O
both O
marbling O
and O
quality O
grades O
did O
not O
differ O
among O
leptin O
genotypes O
when O
fed O
ZH O
for O
21 O
d O
( O
leptin O
genotype O
? O
[]

Patients O
on O
nasal O
continuous O
positive O
airway O
pressure O
desiring O
a O
cool O
bedroom O
temperature O
could O
benefit O
from O
controlled O
heated O
breathing O
tube O
humidification O
technology O
( O
with O
inputs O
from O
ambient O
temperature O
, O
set O
pressure O
and O
flow O
) O
. O
[]

GM-CSF B-outcome ['Physiological-Clinical']
levels O
were O
measured O
by O
a O
sandwich O
enzyme-linked O
immunosorbent O
assay O
at O
2 O
, O
4 O
, O
6 O
, O
12 O
, O
and O
24 O
hours O
after O
the O
first O
dose O
of O
rhuGM-CSF O
. O
['Physiological-Clinical']

The O
adverse B-outcome ['Adverse-effects']
reactions B-outcome ['Adverse-effects']
were O
few O
and O
mild O
. O
['Adverse-effects', 'Adverse-effects']

Left O
internal O
thoracic O
artery-radial O
artery O
composite O
grafts O
as O
the O
technique O
of O
choice O
for O
myocardial O
revascularization O
in O
elderly O
patients O
: O
a O
prospective O
randomized O
evaluation O
. O
[]

This O
study O
also O
suggests O
that O
earlier O
use O
of O
pump O
therapy O
might O
help O
to O
preserve O
residual O
?-cell O
function O
, O
although O
a O
larger O
clinical O
trial O
would O
be O
required O
to O
confirm O
this O
. O
[]

kg-1 O
) O
was O
also O
significantly O
lower O
( O
P O
< O
0.005 O
) O
than O
that O
for O
AmB O
in O
lipid O
emulsion O
( O
1.47 O
+/- O
0.77 O
liter O
. O
[]

Within O
the O
cohort O
of O
intervention O
farmers O
, O
annual O
occupational B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
and O
illness O
cost B-outcome ['Resource-use']
savings B-outcome ['Life-Impact']
were O
directly O
associated O
with O
on-farm O
safety O
review O
scores O
. O
['Physiological-Clinical', 'Resource-use', 'Life-Impact']

Seven O
paraplegic O
subjects O
participated O
in O
this O
study O
. O
[]

Central O
side O
effects O
or O
a O
worsening O
of O
Parkinsonian B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
not O
found O
. O
['Physiological-Clinical']

Children O
with O
high O
plasma O
ascorbic O
acid O
concentrations O
had O
longer O
mean O
illness B-outcome ['Physiological-Clinical']
( O
6.8 O
versus O
4.0 O
days O
, O
P O
less O
than O
0.05 O
) O
than O
those O
with O
low O
levels O
. O
['Physiological-Clinical']

RESULTS O
Thirty-nine O
subjects O
were O
enrolled O
( O
23 O
PVP O
; O
16 O
NaCl O
) O
. O
[]

There O
were O
11 O
proven O
mucosal B-outcome ['Physiological-Clinical']
candidal I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
flu O
and O
four O
in O
itra O
. O
['Physiological-Clinical']

Homozygotic O
risk O
allele O
carriers O
showed O
slower O
reaction O
times O
( O
RT O
) O
and O
higher O
activation O
of O
left B-outcome ['Physiological-Clinical']
fusiform I-outcome ['Physiological-Clinical']
gyrus I-outcome ['Physiological-Clinical']
during O
visual O
processing O
of O
social B-outcome ['Life-Impact']
stimuli I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Four O
months O
after O
surgery O
, O
the O
motor B-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
conduction I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
end-to-side I-outcome ['Physiological-Clinical']
coaptation O
was O
significantly O
slower O
than O
in O
the O
normal O
control O
. O
['Physiological-Clinical']

FT O
surgery O
had O
a O
better O
protective O
role O
with O
respect O
to O
the O
post-operative O
immune O
system O
compared O
with O
traditional O
peri-operative O
care O
. O
[]

Diesel O
Exhaust O
( O
DE O
) O
is O
a O
major O
contributor O
to O
TRAP O
in O
the O
world O
. O
[]

Simple O
clinical O
tests O
can O
be O
used O
to O
rapidly O
distinguish O
between O
toxic O
effects O
due O
either O
to O
vincristine O
or O
corticosteroids O
, O
and O
routine O
implementation O
of O
these O
tests O
can O
prevent O
inappropriate O
dose O
attenuation O
of O
these O
agents O
. O
[]

Qigong O
massage O
treatment O
for O
sensory B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
self-regulation I-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
in O
young O
children O
with O
autism O
: O
a O
randomized O
controlled O
trial O
. O
['Life-Impact']

The O
immediate O
efficacy O
of O
adjunctive O
doxycycline O
in O
treatment O
of O
localized O
juvenile O
periodontitis O
. O
[]

The O
primary O
endpoint O
was O
the O
number O
of O
patients O
with O
detectable B-outcome ['Physiological-Clinical']
DTCs I-outcome ['Physiological-Clinical']
at O
3 O
months O
. O
['Physiological-Clinical']

Adverse O
experiences O
were O
mild O
with O
both O
therapies O
, O
but O
megestrol O
acetate O
was O
associated O
wiht O
a O
higher O
frequency O
of O
weight O
[]

Gamma O
aminobutyric O
acid O
( O
GABA O
) O
-mediated O
synapses O
and O
the O
oscillations O
they O
orchestrate O
are O
altered O
in O
autism O
. O
[]

A O
randomized O
comparison O
of O
the O
Endeavor O
zotarolimus-eluting O
stent O
versus O
the O
TAXUS O
paclitaxel-eluting O
stent O
in O
de O
novo O
native O
coronary O
lesions O
12-month O
outcomes O
from O
the O
ENDEAVOR O
IV O
trial O
. O
[]

Colchicine O
or O
methotrexate O
has O
some O
beneficial O
effects O
in O
the O
treatment O
of O
PBC O
, O
and O
also O
affects O
interleukin-1 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IL-1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Two O
groups O
of O
21 O
males O
with O
moderate O
and O
heavy O
recreational O
use O
of O
MDMA O
, O
respectively O
, O
and O
a O
control O
group O
of O
20 O
males O
without O
use O
of O
MDMA O
were O
compared O
. O
[]

We O
used O
fixed O
effects O
models O
to O
evaluate O
associations O
with O
measures O
of O
temperature O
that O
were O
adjusted O
for O
time-varying O
covariates O
. O
[]

Autism O
is O
heterogeneous O
with O
respect O
to O
clinical O
symptoms O
and O
etiology O
. O
[]

Carotid O
sinus O
syndrome O
: O
a O
modifiable O
risk O
factor O
for O
nonaccidental B-outcome ['Physiological-Clinical']
falls I-outcome ['Physiological-Clinical']
in O
older O
adults O
( O
SAFE O
PACE O
) O
. O
['Physiological-Clinical']

Glasgow O
Outcome O
Scale O
scores O
were O
not O
significantly O
different O
between O
the O
two O
groups O
before O
treatment O
, O
after O
embolization O
, O
or O
after O
resection O
. O
[]

BACKGROUND O
Pain O
is O
one O
of O
the O
most O
frequent O
and O
distressing O
symptoms O
in O
cancer O
patients O
. O
[]

Animal O
studies O
have O
suggested O
interspecies O
differences O
in O
brain O
norepinephrine O
( O
NE O
) O
metabolism O
, O
especially O
with O
regard O
to O
the O
relative O
proportions O
of O
3,4-dihydroxyphenylethyleneglycol O
( O
DOPEG O
) O
compared O
to O
3-methoxy-4-hydroxyphenylethyleneglycol O
( O
MOPEG O
) O
. O
[]

To O
various O
degrees O
, O
ingested O
inorganic O
arsenic O
( O
InAs O
) O
is O
methylated O
to O
monomethylarsonic O
acid O
( O
MMA O
) O
and O
dimethylarsinic O
acid O
( O
DMA O
) O
via O
folate-dependent O
one-carbon O
metabolism O
; O
impaired O
methylation O
is O
associated O
with O
adverse O
health O
outcomes O
. O
[]

DISCUSSION O
Because O
this O
study O
is O
expected O
to O
yield O
evidence O
regarding O
the O
selection O
of O
antipsychotics O
for O
facilitating O
the O
recovery O
of O
social O
activity O
in O
patients O
with O
schizophrenia O
, O
it O
is O
considered O
highly O
valuable O
to O
perform O
this O
effectiveness O
study O
under O
ordinary O
healthcare O
setting O
in O
Japan O
. O
[]

INTERVENTION O
Lumbar O
spine O
radiography O
and O
usual O
care O
versus O
usual O
care O
without O
radiography O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
and O
homocysteine B-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
arsenic I-outcome ['Physiological-Clinical']
metabolites I-outcome ['Physiological-Clinical']
were O
analyzed O
at O
baseline O
and O
after O
12 O
wk O
of O
supplementation O
with O
folic O
acid O
at O
a O
dose O
of O
400 O
microg/d O
or O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Exercise O
has O
been O
recommended O
for O
enhancing O
sleep O
; O
a O
claim O
linked O
to O
the O
belief O
that O
sleep O
need O
- O
defined O
by O
sleep O
duration O
and O
depth O
- O
is O
increased O
post-exercise O
to O
allow O
tissue O
recovery O
. O
[]

BACKGROUND O
AND O
PURPOSE O
A O
low-affinity O
, O
use-dependent O
N-Methyl-D-Aspartate O
( O
NMDA O
) O
antagonist O
AR-R15896AR O
has O
neuroprotective O
properties O
in O
animal O
models O
of O
ischaemic O
stroke O
. O
[]

RESULTS O
The O
baseline O
data O
on O
the O
anthropometric B-outcome ['Physiological-Clinical']
, O
bone B-outcome ['Physiological-Clinical']
densitometry I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effectiveness O
of O
omeprazole O
, O
clarithromycin O
and O
tinidazole O
in O
eradicating B-outcome ['Physiological-Clinical']
Helicobacter I-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
in O
a O
community O
screen O
and O
treat O
programme O
. O
['Physiological-Clinical']

The O
second O
intervention O
was O
an O
educational O
conversation O
with O
a O
specially O
trained O
mammography O
technologist O
. O
[]

A O
joint O
ear O
, O
nose O
and O
throat O
( O
ENT O
) O
oncological O
committee O
performed O
the O
selection O
. O
[]

In O
all O
, O
340 O
patients O
were O
Ph/BCR-ABL O
positive O
and O
evaluable O
. O
[]

These O
benefits O
should O
be O
balanced O
with O
the O
potential O
risks O
associated O
with O
eltrombopag O
treatment O
. O
[]

The O
lowest O
SaO2 B-outcome ['Physiological-Clinical']
after O
resuming O
ventilation O
and O
the O
time O
from O
that O
nadir O
to O
an O
SaO2 O
of O
97 O
% O
were O
also O
recorded O
. O
['Physiological-Clinical']

Secondary O
outcome O
measures O
were O
analgesic O
onset O
time O
, O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
after O
the O
operation B-outcome ['Resource-use']
and O
residual O
motor B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

METHODS O
Children O
with O
cryptosporidial O
diarrhoea O
who O
were O
admitted O
to O
the O
University O
Teaching O
Hospital O
, O
Lusaka O
, O
Zambia O
, O
between O
November O
, O
2000 O
, O
and O
July O
, O
2001 O
, O
and O
whose O
parents O
consented O
to O
their O
having O
an O
HIV O
test O
were O
randomly O
assigned O
nitazoxanide O
( O
100 O
mg O
twice O
daily O
orally O
for O
3 O
days O
) O
or O
placebo O
. O
[]

Data O
from O
two O
groups O
of O
children O
who O
were O
randomly O
allocated O
to O
those O
groups O
showed O
that O
the O
ability O
of O
children O
with O
ASD O
to O
identify B-outcome ['Life-Impact']
and O
label B-outcome ['Life-Impact']
basic I-outcome ['Life-Impact']
and O
complex B-outcome ['Life-Impact']
facial I-outcome ['Life-Impact']
expressions I-outcome ['Life-Impact']
following O
a O
3-week O
home O
based O
DVD O
intervention O
significantly O
improved O
when O
viewing O
The O
Transporters O
DVD O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Currently O
, O
many O
rehabilitation O
protocols O
for O
total O
hip O
replacements O
( O
THRs O
) O
include O
activity O
restrictions O
to O
prevent O
postoperative O
dislocation O
. O
[]

Preliminary O
analysis O
of O
the O
final O
multicenter O
investigation O
of O
rheopheresis O
for O
age O
related O
macular O
degeneration O
( O
AMD O
) O
trial O
( O
MIRA-1 O
) O
results O
. O
[]

[ O
Clinical O
trial O
of O
2 O
tobacco O
use O
cessation O
interventions O
in O
primary O
care O
] O
. O
[]

BACKGROUND O
We O
performed O
short-term O
neoadjuvant O
chemotherapy O
( O
s-NAC O
) O
to O
examine O
whether O
anticancer O
drugs O
can O
change O
the O
proliferative O
ability O
of O
cancer O
cells O
in O
gastric O
cancer O
patients O
. O
[]

Muscle B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
and O
turnover B-outcome ['Physiological-Clinical']
was O
assessed O
by O
weekly B-outcome ['Physiological-Clinical']
nitrogen I-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
, O
and O
creatinine B-outcome ['Physiological-Clinical']
and O
3-methylhistidine B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Both O
regimens O
were O
started O
after O
surgery O
. O
[]

An O
alternative O
nitrate O
, O
isosorbide O
dinitrate O
( O
ISDN O
) O
is O
now O
available O
as O
an O
intravenous O
preparation O
, O
and O
may O
offer O
technical O
advantages O
, O
both O
due O
to O
its O
stability O
in O
solution O
and O
also O
its O
longer O
in O
vivo O
half-life O
. O
[]

The O
endotracheal O
route O
of O
adrenaline O
administration O
is O
not O
reliable O
in O
out-of-hospital O
cardiac O
arrest O
. O
[]

Analysis O
of O
variance O
compared O
BP O
and O
GFR O
values O
changes O
from O
baseline O
to O
the O
follow-up O
; O
differences O
for O
continuous O
variables O
were O
evaluated O
between O
groups O
with O
the O
Tukey O
's O
post O
hoc O
test O
after O
adjustment O
for O
age O
, O
change O
of O
BP O
between O
baseline O
and O
at O
the O
follow-up O
, O
GFR O
and O
body O
mass O
index O
( O
BMI O
) O
. O
[]

There O
were O
10 O
patients O
in O
each O
group O
. O
[]

Uterine O
incision O
closure O
at O
caesarean O
section O
: O
a O
randomised O
comparative O
study O
of O
intraperitoneal O
closure O
and O
closure O
after O
temporary O
exteriorisation O
. O
[]

Cost O
of O
ICT B-outcome ['Physiological-Clinical']
and O
VATS O
were O
$ O
850 O
and O
$ O
1730 O
, O
respectively O
. O
['Physiological-Clinical']

RESULTS O
The O
following O
parameters O
displayed O
a O
statistically O
significant O
difference O
( O
P O
< O
0.05 O
) O
. O
[]

Sixty O
7x3 O
mm O
pressed O
ceramic O
discs O
of O
IPS O
e.max O
were O
fabricated O
and O
randomly O
assigned O
to O
six O
groups O
of O
different O
dentin O
surface O
treatments O
( O
control O
, O
desensitizer O
, O
disinfectant O
, O
saliva O
, O
blood O
, O
and O
hydrogen O
peroxide O
) O
. O
[]

A O
double-blind O
, O
placebo-controlled O
study O
of O
the O
efficacy O
of O
transdermal O
clonidine O
in O
autism O
. O
[]

Twenty-four O
vs. O
forty-eight O
weeks O
of O
re-therapy O
with O
interferon O
alpha O
2b O
and O
ribavirin O
in O
interferon O
alpha O
monotherapy O
relapsers O
with O
chronic O
hepatitis O
C. O
BACKGROUND/AIM O
Roughly O
50 O
% O
of O
patients O
with O
chronic O
hepatitis O
C O
, O
who O
relapsed O
after O
a O
previous O
monotherapy O
with O
interferon O
alpha O
, O
will O
respond O
in O
a O
sustained O
fashion O
to O
24 O
weeks O
of O
re-therapy O
with O
the O
combination O
of O
interferon O
alpha O
plus O
ribavirin O
. O
[]

DESIGN O
Case-control O
study O
. O
[]

However O
, O
experimental O
studies O
in O
which O
human O
volunteers O
were O
exposed O
acutely O
to O
moderate O
levels O
of O
NO2 O
( O
0.5-2.0 O
ppm O
) O
have O
shown O
little O
evidence O
of O
lung O
inflammation O
or O
decreased O
host O
resistance O
capacity O
. O
[]

CONCLUSION O
No O
statistical O
difference O
was O
found O
between O
the O
survival B-outcome ['Mortality']
rates O
of O
the O
rectal O
carcinoma O
patients O
receiving O
radiotherapy O
either O
pre-operatively O
or O
postoperatively O
. O
['Mortality']

Other O
core O
features O
of O
the O
quality O
of O
service O
, O
e.g O
. O
[]

Randomization O
was O
achieved O
by O
the O
envelope O
method O
. O
[]

The O
lean O
group O
had O
the O
highest O
dietary O
compensation O
( O
119 O
% O
) O
and O
no O
significant O
weight O
change O
( O
0.84 O
? O
[]

METHODS O
Three O
hundred O
and O
eighty O
six O
preterm O
infants O
with O
birthweights O
from O
1000 O
to O
2000 O
g O
, O
and O
requiring O
ventilation O
for O
respiratory O
distress O
syndrome O
within O
24 O
hours O
of O
birth O
, O
were O
randomised O
to O
receive O
either O
conventional O
or O
trigger O
ventilation O
with O
the O
SLE O
2000 O
ventilator O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
evaluate O
whether O
the O
magnitude O
of O
implicit O
racial O
bias O
predicts O
physician O
recommendation O
of O
TKR O
for O
black O
and O
white O
patients O
with O
OA O
and O
to O
assess O
the O
effectiveness O
of O
a O
web-based O
instrument O
as O
an O
intervention O
to O
decrease O
the O
effect O
of O
implicit O
racial O
bias O
on O
physician O
recommendation O
of O
TKR O
. O
[]

A O
gender O
effect O
was O
seen O
on O
bone O
width O
( O
p O
< O
0.0001 O
) O
, O
endosteal O
diameter O
( O
p O
< O
0.01 O
) O
and O
cortical O
thickness O
( O
p O
< O
0.01 O
) O
, O
but O
not O
with O
MCI O
( O
NS O
) O
. O
[]

Ethnic O
minority O
subjects O
were O
more O
satisfied O
than O
white O
participants O
with O
the O
use O
of O
learning O
tests O
. O
[]

AIM O
To O
compare O
the O
analgesic B-outcome ['Resource-use']
efficacy O
of O
caudal O
block O
with O
diclofenac O
suppository O
and O
local O
anesthetic O
infiltration O
in O
children O
undergoing O
laparoscopy O
. O
['Resource-use']

Outcomes O
and O
biochemical O
parameters O
following O
cardiac O
surgery O
: O
effects O
of O
transfusion O
of O
residual O
blood O
using O
centrifugation O
and O
multiple-pass O
hemoconcentration O
. O
[]

PURPOSE O
Increased O
growth O
factor O
signaling O
may O
contribute O
to O
tamoxifen O
resistance O
. O
[]

Morphine O
sulfate O
and O
naltrexone O
hydrochloride O
extended O
release O
capsules O
( O
MS-sNT O
) O
, O
which O
contain O
naltrexone O
sequestered O
in O
each O
pellet O
core O
, O
are O
indicated O
for O
management O
of O
chronic O
, O
moderate O
to O
severe O
pain O
. O
[]

The O
primary O
end O
point O
was O
1-year O
graft B-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
, O
which O
was O
assessed O
by O
angiography O
in O
95 O
% O
of O
patients O
. O
['Physiological-Clinical']

The O
mean O
value O
of O
dye B-outcome ['Physiological-Clinical']
penetration I-outcome ['Physiological-Clinical']
for O
AH O
plus O
was O
2.87 O
+/- O
0.43 O
mm O
, O
while O
that O
of O
EndoRez O
was O
4.54 O
+/- O
0.36 O
mm O
. O
['Physiological-Clinical']

These O
data O
provide O
novel O
evidence O
for O
the O
unique O
association O
between O
AS O
of O
the O
development O
of O
anxiety O
symptoms O
. O
[]

The O
intervention O
process O
was O
conducted O
by O
speech-language O
pathologists O
who O
were O
part O
of O
a O
graduate O
program O
in O
this O
area O
. O
[]

CONCLUSION O
The O
results O
of O
the O
present O
study O
suggest O
that O
immediate O
replacement O
without O
functional O
loading O
may O
be O
considered O
a O
valuable O
therapeutic O
option O
for O
selected O
cases O
of O
single-tooth O
replacement O
in O
the O
esthetic O
area O
when O
TE O
implants O
are O
used O
. O
[]

There O
was O
a O
significant O
difference O
in O
the O
change O
in O
plasma B-outcome ['Physiological-Clinical']
transferrin I-outcome ['Physiological-Clinical']
levels O
and O
a O
trend O
toward O
a O
significant O
difference O
in O
the O
change O
in O
plasma B-outcome ['Physiological-Clinical']
superoxide I-outcome ['Physiological-Clinical']
dismutase I-outcome ['Physiological-Clinical']
levels O
between O
the O
2 O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Phase O
3 O
, O
prospective O
, O
randomized O
, O
double-blind O
, O
multicenter O
study O
to O
compare O
TISSEEL O
VH O
S/D O
to O
TISSEEL O
VH O
during O
cardiac O
surgery O
. O
[]

Following O
consecutive O
administration O
of O
the O
drugs O
the O
effects O
of O
atropine O
predominated O
. O
[]

Models O
of O
couple-responsible O
and O
therapist-responsible O
process O
in O
couple O
therapy O
were O
developed O
. O
[]

Thirteen O
experienced O
male O
weightlifters O
taking O
high-protein O
diets O
and O
regular O
exercise O
took O
part O
in O
a O
double-blind O
crossover O
trial O
of O
methandienone O
10 O
or O
25 O
mg/day O
to O
seeif O
the O
drug O
improved O
athletic B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Life-Impact']

Twenty-five O
per O
cent O
recovery B-outcome ['Physiological-Clinical']
was O
shorter O
with O
rapacuronium O
than O
rocuronium O
during O
propofol O
( O
15.0 O
( O
3.2 O
) O
vs O
39.1 O
( O
14.2 O
) O
min O
, O
P O
< O
0.001 O
) O
and O
sevoflurane O
( O
15.1 O
( O
4.2 O
) O
vs O
47.8 O
( O
19.0 O
) O
min O
, O
P O
< O
0.001 O
) O
anaesthesia O
. O
['Physiological-Clinical']

RESULTS O
Magnesium O
reduced O
the O
shivering B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
( O
36.3 O
[ O
SD O
0.4 O
] O
degrees O
C O
vs O
36.6 O
[ O
0.3 O
] O
degrees O
C O
, O
P O
= O
0.040 O
) O
. O
['Physiological-Clinical']

RESULTS O
Vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
were O
stable O
during O
spinal O
anaesthesia O
and O
postoperative O
period O
. O
['Physiological-Clinical']

In O
cycle O
0 O
, O
a O
14-day O
prechemotherapy O
cycle O
, O
patients O
( O
N=61 O
) O
were O
randomized O
open-label O
to O
single O
doses O
of O
pegfilgrastim O
( O
6 O
, O
12 O
or O
18 O
mg O
) O
on O
day O
1 O
, O
or O
daily O
filgrastim O
( O
10 O
microg/kg O
) O
for O
< O
or O
=7 O
days O
. O
[]

RESULTS O
The O
satisfaction B-outcome ['Life-Impact']
rate O
was O
significantly O
higher O
in O
the O
thermal O
destruction O
group O
. O
['Life-Impact']

A O
high O
dose O
of O
primaquine O
is O
safe O
and O
effective O
in O
the O
treatment O
of O
P. O
vivax O
malaria O
during O
the O
28-day O
follow-up O
period O
. O
[]

Twelve O
patients O
were O
enrolled O
, O
and O
10 O
patients O
( O
mean O
age O
6 O
years O
3 O
months O
) O
were O
able O
to O
complete O
the O
study O
. O
[]

Satraplatin O
is O
a O
novel O
oral O
platinum O
( O
IV O
) O
complex O
that O
shows O
activity O
against O
hormone-refractory O
prostate O
cancer O
( O
HRPC O
) O
in O
cisplatin-resistant O
human O
tumor O
lines O
in O
phase O
I O
and O
phase O
II O
trials O
. O
[]

Of O
the O
total O
number O
of O
cases O
, O
59 O
% O
were O
aged O
60 O
to O
89 O
years O
, O
and O
55 O
% O
were O
men O
. O
[]

A O
comparative O
study O
on O
control O
subjects O
and O
depressed O
patients O
. O
[]

DESIGN O
A O
single-blind O
randomized O
AB/BA O
crossover O
design O
. O
[]

The O
study O
was O
planned O
on O
a O
hypothesis O
of O
equivalence O
between O
the O
two O
study O
drugs O
. O
[]

Although O
the O
mean O
endotoxin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
lower O
in O
the O
verum O
group O
after O
1 O
week O
( O
paromomycin O
, O
8.0 O
+/- O
1.9 O
pg/ml O
; O
placebo O
, O
14.6 O
+/- O
3.5 O
pg/ml O
; O
p O
> O
0.05 O
) O
, O
paromomycin O
treatment O
had O
no O
significant O
effect O
on O
endotoxin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
or O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
tests O
during O
the O
4-week O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
of O
the O
multiple O
baseline O
design O
showed O
robust O
support O
for O
improvement O
in O
child O
and O
parent B-outcome ['Physiological-Clinical']
behavior I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
findings O
provide O
insight O
into O
those O
messages O
that O
could O
be O
communicated O
via O
the O
mass O
media O
or O
in O
targeted O
communications O
to O
retain O
first-time O
donors O
who O
have O
experienced O
a O
mild O
vasovagal O
reaction O
. O
[]

Alinidine O
increased O
both O
total O
exercise O
duration O
from O
246.7 O
+/- O
120.7 O
to O
346.6 O
+/- O
114.1 O
s O
( O
p O
less O
than O
0.05 O
) O
and O
time O
to O
0.1-mV O
ST O
segment O
depression O
from O
98.3 O
+/- O
53 O
to O
187.2 O
+/- O
105 O
s O
( O
p O
less O
than O
0.05 O
) O
. O
[]

[ O
Rilmenidine O
sympatholytic O
activity O
preserves O
mental B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
orthostatic I-outcome ['Physiological-Clinical']
sympathetic I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
epinephrine B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
double-blind O
, O
placebo-controlled O
study O
examined O
the O
effects O
of O
6 O
weeks O
of O
treatment O
with O
the O
adrenocorticotropin4-9 O
analogue O
ORG-2766 O
( O
40 O
mg/day O
) O
on O
brain O
event-related O
potentials O
( O
ERPs O
) O
of O
autistic O
children O
. O
[]

This O
article O
describes O
the O
research O
method O
used O
to O
measure O
the O
impact O
of O
three O
alternative O
models O
of O
patient O
counseling O
in O
the O
outpatient O
pharmacy O
setting O
. O
[]

CONCLUSIONS O
These O
effects O
of O
CETP O
inhibition O
resemble O
those O
observed O
in O
partial O
CETP O
deficiency O
. O
[]

Uniformity O
was O
attempted O
by O
adoption O
of O
the O
senior O
author O
's O
protocol O
and O
technique O
through O
on-site O
preceptorship O
in O
each O
surgeon O
's O
operative O
theater O
. O
[]

A O
secondary O
objective O
was O
to O
identify O
molecular O
biomarkers O
correlating O
with O
response O
and O
toxicity B-outcome ['Adverse-effects']
. O
['Adverse-effects']

An O
increase O
in O
anxiety O
was O
linked O
with O
breaking O
bad O
news O
( O
P O
= O
0.050 O
) O
and O
with O
supportive O
skills O
( O
P O
= O
0.013 O
) O
. O
[]

A O
higher O
percentage O
of O
the O
experimental O
group O
were O
in O
treatment O
at O
16-month O
follow-up O
( O
72 O
% O
vs O
56 O
% O
) O
. O
[]

Self-management O
improvement O
program O
combined O
with O
community O
involvement O
in O
Thai O
hypertensive O
population O
: O
an O
action O
research O
. O
[]

Our O
hypothesis O
was O
that O
low-frequency O
rTMS O
application O
to O
dorsolateral O
prefrontal O
cortex O
( O
DLFPC O
) O
would O
result O
in O
an O
alteration O
of O
the O
cortical O
excitatory/inhibitory O
balance O
through O
the O
activation O
of O
inhibitory O
GABAergic O
double O
bouquet O
interneurons O
. O
[]

BACKGROUND O
Imbalance O
between O
the O
parasympathetic O
and O
sympathetic O
nervous O
systems O
is O
a O
recognized O
contributor O
to O
progression O
of O
chronic O
heart O
failure O
. O
[]

We O
designed O
a O
randomized O
trial O
to O
assess O
whether O
the O
early O
withdrawal O
of O
cyclosporine O
( O
CsA O
) O
followed O
by O
the O
initiation O
of O
everolimus O
( O
Evr O
) O
monotherapy O
in O
de O
novo O
liver O
transplantation O
( O
LT O
) O
patients O
would O
result O
in O
superior O
renal O
function O
compared O
to O
a O
CsA-based O
immunosuppression O
protocol O
. O
[]

To O
test O
this O
hypothesis O
, O
we O
have O
performed O
the O
corollary O
experiment O
whereby O
the O
action O
of O
endogenous O
GHRH O
has O
been O
antagonized O
. O
[]

Increase O
in O
mean O
weight O
( O
11-15 O
% O
) O
and O
body O
mass O
index O
( O
5-10 O
% O
) O
occurred O
; O
one O
patient O
discontinued O
because O
of O
weight O
increase O
. O
[]

The O
presence O
of O
a O
laryngoscope B-outcome ['Resource-use']
in O
the O
mouth O
while O
rail-roading O
a O
tube O
over O
the O
bougie O
also O
made O
a O
significant O
difference O
to O
the O
rate O
of O
successful B-outcome ['Life-Impact']
first-time I-outcome ['Life-Impact']
intubations I-outcome ['Life-Impact']
. O
['Resource-use', 'Life-Impact']

No O
significant O
enhancing O
effect O
on O
the O
antibody B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
observed O
, O
in O
spite O
of O
an O
early O
and O
transient O
upregulation O
of O
costimulatory O
molecule O
expression O
on O
['Physiological-Clinical']

CRT O
+ O
ITC O
was O
given O
as O
CRT O
, O
2400 O
rad O
in O
12 O
fractions O
followed O
by O
ITC O
maintenance O
bimonthly O
for O
2 O
years O
. O
[]

Patients O
undergoing O
thoracotomy O
are O
therefore O
at O
high O
risk O
of O
acid B-outcome ['Physiological-Clinical']
GER I-outcome ['Physiological-Clinical']
, O
which O
may O
lead O
to O
tracheal B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
aspiration I-outcome ['Physiological-Clinical']
in O
an O
appreciable O
proportion O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
significant O
changes O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Injection O
sites O
were O
randomized O
to O
either O
a O
superomedial O
or O
inferomedial O
location O
. O
[]

Ameliorating B-outcome ['Physiological-Clinical']
intrusive I-outcome ['Physiological-Clinical']
memories I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
distressing I-outcome ['Physiological-Clinical']
experiences I-outcome ['Physiological-Clinical']
using O
computerized O
reappraisal O
training O
. O
['Physiological-Clinical']

Injection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
postinjection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
of O
the O
palatal-anterior O
superior O
alveolar O
injection O
, O
administered O
with O
the O
Wand O
Plus O
system O
, O
comparing O
2 O
% O
lidocaine O
with O
1:100,000 O
epinephrine O
to O
3 O
% O
mepivacaine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
results O
show O
that O
sugar-free O
gum O
containing O
CPP-ACP O
is O
superior O
to O
an O
equivalent O
gum O
not O
containing O
CPP-ACP O
in O
remineralization O
of O
enamel O
subsurface O
lesions O
in O
situ O
with O
mineral O
that O
is O
more O
resistant B-outcome ['Physiological-Clinical']
to O
subsequent O
acid O
challenge O
. O
['Physiological-Clinical']

Comprehensive O
metabolic O
analyses O
were O
assessed O
for O
group O
differences O
. O
[]

They O
were O
randomly O
assigned O
to O
receive O
12 O
mg O
of O
nicorandil O
or O
a O
placebo O
intravenously O
just O
before O
reperfusion O
. O
[]

Because O
the O
alcoholic O
inpatients O
in O
the O
PALS O
group O
engaged O
in O
[]

Effect O
of O
VX-770 O
in O
persons O
with O
cystic O
fibrosis O
and O
the O
G551D-CFTR O
mutation O
. O
[]

A O
total O
of O
516 O
patients O
consented O
to O
participate O
in O
the O
study O
from O
October O
2008 O
to O
September O
2011 O
, O
85 O
% O
of O
whom O
( O
n O
= O
439 O
) O
had O
technically O
successful O
conventional O
PTA O
. O
[]

Allocation O
was O
concealed O
with O
opaque O
sealed O
envelopes O
. O
[]

Levels O
of O
serum B-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
were O
measured O
before O
therapy O
and O
after O
three O
and O
6 O
months O
. O
['Physiological-Clinical']

Again O
, O
there O
were O
no O
significant O
differences O
in O
the O
lag O
phase O
of O
oxidation B-outcome ['Physiological-Clinical']
at O
each O
dose O
for O
RRR-AT O
when O
compared O
with O
all-rac-AT O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
changes O
in O
serum B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
, O
apolipoproteins B-outcome ['Physiological-Clinical']
, O
lipoproteins B-outcome ['Physiological-Clinical']
or O
atherosclerotic B-outcome ['Physiological-Clinical']
indices O
after O
both O
SQ29,852 O
and O
atenolol O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
single-blinded O
, O
prospective O
, O
comparative O
, O
pilot O
, O
randomized O
, O
clinical O
trial O
was O
performed O
with O
18 O
athletes O
of O
both O
sexes O
from O
a O
judo O
team O
currently O
competing O
on O
a O
national O
level O
. O
[]

A O
comparison O
of O
urinary B-outcome ['Physiological-Clinical']
and O
sexual B-outcome ['Physiological-Clinical']
outcomes O
in O
women O
experiencing O
vaginal O
and O
Caesarean O
births O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
may O
enhance O
the O
effects O
of O
endothelin O
, O
as O
these O
patients O
also O
had O
elevated O
endothelin O
levels O
. O
[]

Drug O
and O
hormone O
analyses O
in O
plasma O
were O
performed O
using O
Liquid O
Chromatography-Electrospray O
Ionization-Tandem O
Mass O
Spectrometry O
and O
radioimmunoassay O
respectively O
. O
[]

OBJECTIVE O
Assess O
the O
effectiveness O
of O
sildenafil O
in O
Asian O
males O
with O
erectile O
dysfunction O
( O
ED O
) O
and O
one O
or O
more O
of O
the O
co-morbidities O
, O
mild-to-moderate O
hypertension O
, O
dyslipidemia O
, O
and O
diabetes O
. O
[]

In O
22 O
patients O
plasmapheresis O
in O
combination O
with O
continuous O
venovenous O
hemofiltration O
( O
CVVHF O
) O
was O
administered O
. O
[]

A O
web-based O
patient O
activation O
intervention O
to O
improve O
hypertension O
care O
: O
study O
design O
and O
baseline O
characteristics O
in O
the O
web O
hypertension O
study O
. O
[]

With O
the O
exclusion O
of O
those O
whose O
menses O
returned O
before O
18 O
wk O
postpartum O
( O
which O
could O
not O
have O
been O
due O
to O
the O
intervention O
) O
, O
the O
proportion O
of O
women O
who O
were O
amenorrheic B-outcome ['Physiological-Clinical']
at O
6 O
mo O
was O
64.5 O
% O
in O
the O
SF O
group O
, O
80.0 O
% O
in O
the O
FBF O
group O
, O
and O
85.7 O
% O
in O
the O
SF-M O
group O
( O
chi-square O
test O
= O
4.13 O
, O
P O
= O
0.02 O
; O
one-tailed O
test O
with O
the O
latter O
two O
groups O
combined O
) O
. O
['Physiological-Clinical']

In O
an O
additional O
manipulation O
, O
for O
half O
of O
the O
participants O
, O
the O
observer O
was O
also O
the O
recipient O
of O
their O
donations O
, O
and O
participants O
were O
told O
that O
this O
observer O
would O
subsequently O
have O
the O
opportunity O
to O
donate O
to O
them O
( O
motivation O
condition O
) O
. O
[]

The O
H-AT O
for O
4 O
weeks O
up-regulated O
co-stimulatory O
molecule O
CD28 O
expression O
and O
was O
accompanied O
by O
depressed O
KLRG1 O
level O
on O
CD3 O
, O
CD4 O
, O
CD8 O
, O
or O
CD8 O
( O
bright O
) O
lymphocytes O
at O
rest O
or O
following O
exercise O
. O
[]

Comparison O
between O
the O
central O
effects O
of O
camazepam O
and O
temazepam O
. O
[]

In O
the O
capillary O
blood O
samples O
indices O
of O
acid-base B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
, O
lactate B-outcome ['Physiological-Clinical']
level O
, O
and O
glucose B-outcome ['Physiological-Clinical']
level O
were O
determined O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pathological O
complete O
response O
was O
observed O
in O
22 O
( O
8.2 O
% O
) O
and O
16 O
patients O
( O
6.1 O
% O
) O
, O
respectively O
. O
[]

The O
Candidas O
were O
cultured O
. O
[]

The O
pharmacokinetics B-outcome ['Physiological-Clinical']
and O
serum B-outcome ['Physiological-Clinical']
bactericidal I-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBAs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of O
imipenem O
and O
meropenem O
were O
investigated O
in O
a O
randomized O
crossover O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effectiveness O
of O
aromatherapy O
massage O
in O
the O
management O
of O
anxiety B-outcome ['Life-Impact']
and O
depression B-outcome ['Life-Impact']
in O
patients O
with O
cancer O
: O
a O
multicenter O
randomized O
controlled O
trial O
. O
['Life-Impact', 'Life-Impact']

Calf O
birth O
weight O
( O
39 O
+/- O
2 O
kg O
) O
, O
weaning B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
( O
225 O
+/- O
7 O
kg O
) O
, O
and O
age-adjusted B-outcome ['Physiological-Clinical']
weaning I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
( O
234 O
+/- O
8 O
kg O
) O
did O
not O
differ O
because O
of O
dam O
supplementation O
regimen O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Forty-six O
patients O
with O
systemic O
poisoning O
by O
this O
snake O
were O
given O
echis O
antivenom O
made O
either O
by O
the O
South O
African O
Institute O
for O
Medical O
Research O
( O
S.A.I.M.R O
. O
) O
[]

These O
results O
suggest O
that O
naftopidil O
improves O
storage O
symptoms O
as O
well O
as O
voiding O
symptoms O
regardless O
of O
timing O
of O
administration O
. O
[]

In O
2 O
out O
of O
24 O
patients O
, O
colonic B-outcome ['Physiological-Clinical']
transit I-outcome ['Physiological-Clinical']
was O
prolonged O
up O
to O
the O
limit O
, O
both O
with O
and O
without O
therapy O
. O
['Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
the O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
on O
the O
above O
3 O
dosages O
, O
and O
no O
difference O
in O
the O
duration O
of O
infection-free B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

When O
the O
pattern O
of O
cognitive B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
over I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
was O
compared O
using O
sophisticated O
modeling O
techniques O
, O
the O
two O
groups O
were O
again O
comparable O
, O
except O
for O
results O
on O
the O
test O
of O
verbal B-outcome ['Life-Impact']
fluency I-outcome ['Life-Impact']
, O
in O
which O
the O
off-pump O
group O
showed O
more O
rapid O
postsurgical O
cognitive B-outcome ['Life-Impact']
gains I-outcome ['Life-Impact']
than O
the O
on-pump O
group O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

RESULTS O
The O
complete B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
showed O
neither O
in O
the O
basic O
measurement O
( O
aR O
0,38 O
+/- O
0,14 O
kPa/l/s O
; O
IOS O
0,38 O
+/- O
0,11 O
kPa/l/s O
) O
nor O
in O
the O
control O
solution O
( O
aR O
0,38 O
+/- O
0,14 O
; O
IOS O
0,39 O
+/- O
0,14 O
) O
nor O
after O
application O
of O
the O
allergenic O
solution O
( O
15 O
min O
: O
aR O
0,69 O
+/- O
0,27 O
; O
IOS O
0,77 O
+/- O
0,42 O
; O
30 O
min O
: O
aR O
0,65 O
+/- O
0,29 O
; O
IOS O
0,6 O
+/- O
0,38 O
) O
a O
significant O
difference O
between O
the O
two O
methods O
. O
['Physiological-Clinical']

133 O
patients O
were O
included O
in O
this O
trial O
: O
two O
patients O
died B-outcome ['Mortality']
before O
treatment O
and O
two O
were O
excluded O
retrospectively O
, O
leaving O
129 O
patients O
for O
final O
analysis O
( O
67 O
: O
UK O
2000 O
+ O
heparin O
; O
62 O
: O
UK O
4400 O
) O
. O
['Mortality']

n O
= O
755 O
) O
, O
lumiracoxib O
100 O
mg O
b.i.d O
. O
( O
[]

CONCLUSIONS O
HFLCS O
application O
on O
enamel O
etched O
with O
37 O
% O
phosphoric O
acid O
did O
not O
affect O
the O
bond O
strength O
values O
and O
the O
bond O
failure O
modes O
of O
metal O
and O
ceramic O
brackets O
bonded O
with O
RMGIC O
. O
[]

Ten O
subjects O
completed O
the O
9 O
months O
of O
treatment O
in O
the O
levonorgestrel O
group O
and O
11 O
completed O
the O
study O
in O
the O
desogestrel O
group O
. O
[]

Polycystic O
ovary O
syndrome O
and O
cardiovascular O
risk O
in O
young O
patients O
treated O
with O
drospirenone-ethinylestradiol O
or O
contraceptive O
vaginal O
ring O
. O
[]

METHODS O
A O
cross-sectional O
and O
prospective O
study O
was O
performed O
. O
[]

Studies O
predicting O
mortality O
after O
myocardial O
infarction O
( O
MI O
) O
usually O
rely O
on O
in-hospital O
data O
, O
and O
combine O
patients O
admitted O
for O
the O
first O
MI O
with O
recurrent O
MI O
patients O
. O
[]

One O
group O
received O
risperidone O
plus O
Ginko O
T.D O
and O
the O
other O
received O
risperidone O
plus O
placebo O
. O
[]

Rioprostil O
given O
600 O
micrograms O
daily O
in O
the O
evening O
is O
a O
highly O
effective O
treatment O
for O
the O
prevention O
of O
duodenal O
ulcer O
relapse O
, O
the O
efficacy O
not O
being O
significantly O
different O
from O
ranitidine O
150 O
mg O
. O
[]

Six O
couples O
did O
not O
attempt B-outcome ['Life-Impact']
intercourse I-outcome ['Life-Impact']
despite O
a O
professed O
interest O
in O
sexual B-outcome ['Life-Impact']
['Life-Impact', 'Life-Impact']

We O
studied O
101 O
adult O
patients O
with O
newly O
detected O
bronchial O
asthma O
who O
were O
without O
inhaled O
steroid O
or O
any O
regular O
pharmacological O
treatment O
for O
their O
asthma O
. O
[]

OBJECTIVE O
To O
test O
the O
hypothesis O
that O
balance O
rehabilitation O
with O
visual O
cue O
deprivation O
improves O
balance B-outcome ['Life-Impact']
more O
effectively O
than O
rehabilitation O
with O
free O
vision O
. O
['Life-Impact']

RESULTS O
The O
results O
of O
logistic O
regression O
analysis O
showed O
that O
women O
who O
received O
risk O
counseling O
were O
significantly O
more O
likely O
to O
improve O
their O
risk O
comprehension B-outcome ['Life-Impact']
, O
compared O
with O
women O
in O
the O
control O
condition O
( O
odds O
ratio O
[ O
OR O
] O
= O
3.5 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
1.3-9.5 O
; O
P O
= O
.01 O
) O
. O
['Life-Impact']

The O
comparative O
safety O
and O
diagnostic B-outcome ['Life-Impact']
accuracy I-outcome ['Life-Impact']
of O
adenosine O
myocardial O
perfusion O
imaging O
in O
women O
versus O
men O
. O
['Life-Impact']

This O
study O
provides O
the O
first O
independent O
replication O
and O
extension O
of O
the O
empirically-supported O
PEERS O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
intervention O
for O
adolescents O
with O
ASD O
. O
['Life-Impact']

Acebutolol O
at O
effective O
antianginal O
doses O
modestly O
improved O
resting B-outcome ['Physiological-Clinical']
global I-outcome ['Physiological-Clinical']
and O
regional B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thus O
, O
these O
data O
call O
for O
continuous O
surveillance O
for O
these O
events O
and O
efforts O
beyond O
the O
acute O
phase O
at O
increasing O
adherence O
to O
evidence-based O
therapies O
to O
improve O
the O
outcomes O
of O
these O
patients O
. O
[]

The O
clinically B-outcome ['Physiological-Clinical']
proven O
efficacy O
is O
emphasized O
by O
good O
tolerability B-outcome ['Life-Impact']
of O
both O
treatments O
. O
['Physiological-Clinical', 'Life-Impact']

Sleep-anticipating B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
melatonin O
in O
the O
human O
brain O
. O
['Physiological-Clinical']

In O
order O
to O
determine O
whether O
this O
assumption O
was O
correct O
or O
not O
, O
we O
carried O
out O
a O
clinical O
trial O
on O
26 O
type O
II O
( O
non-insulin-dependent O
) O
diabetics O
, O
in O
fairly O
good O
metabolic O
control O
and O
with O
moderate O
hypertension O
( O
orthostatic O
diastolic O
pressure O
from O
100 O
to O
115 O
mmHg O
) O
, O
comparing O
the O
effect O
of O
MZ O
with O
those O
of O
chlorthalidone O
( O
CL O
) O
. O
[]

Histologically O
demonstrable O
signs O
of O
inflammation B-outcome ['Physiological-Clinical']
were O
more O
clearly O
improved O
in O
the O
preparation O
group O
than O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

Compared O
with O
the O
treatment O
group O
, O
( O
1 O
) O
control O
group O
members O
were O
less O
likely O
to O
receive B-outcome ['Life-Impact']
any I-outcome ['Life-Impact']
services I-outcome ['Life-Impact']
at O
all O
( O
despite O
being O
authorized O
for O
them O
) O
, O
and O
( O
2 O
) O
service O
recipients O
received O
a O
lower O
proportion O
of O
the O
amount O
of O
['Life-Impact']

Although O
mexiletine O
, O
an O
antiarrhythmic O
with O
local O
anesthetic O
properties O
, O
has O
been O
reported O
to O
relieve O
discomfort O
in O
diabetic O
neuropathy O
, O
its O
usefulness O
in O
the O
treatment O
of O
HIV-related O
painful O
peripheral O
neuropathy O
( O
PPN O
) O
has O
not O
been O
determined O
. O
[]

Individuals O
in O
one O
group O
were O
fitted O
with O
dorsal O
splints O
, O
and O
individuals O
in O
a O
second O
group O
with O
volar O
splints O
. O
[]

Local B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
was O
achieved O
in O
46 O
patients O
( O
81 O
% O
) O
; O
3-year O
actuarial O
disease-free B-outcome ['Mortality']
and I-outcome ['Mortality']
overall I-outcome ['Mortality']
survivals I-outcome ['Mortality']
were O
67 O
% O
and O
77 O
% O
, O
respectively O
. O
['Physiological-Clinical', 'Mortality']

It O
has O
been O
shown O
that O
RTD O
is O
superior O
to O
HAL O
in O
terms O
of O
the O
objective O
response O
to O
the O
therapy O
, O
reduction O
of O
tumor B-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
, O
patient O
's O
symptom B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
, O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
AFP B-outcome ['Physiological-Clinical']
changes O
and O
patient O
's O
survival B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

All O
side O
effects O
disappeared O
after O
the O
drug O
was O
stopped O
. O
[]

INTERVENTION O
2-min O
iCSO O
. O
[]

Thirty-six O
children O
were O
randomly O
assigned O
to O
one O
of O
two O
treatment O
conditions O
, O
one O
of O
which O
was O
the O
Picture O
Exchange O
Communication O
System O
( O
PECS O
) O
. O
[]

UNLABELLED O
The O
aim O
of O
our O
study O
is O
to O
evaluate O
the O
safety O
, O
efficacy O
and O
also O
the O
maximum O
duration O
of O
effect O
of O
the O
pleural B-outcome ['Physiological-Clinical']
tent I-outcome ['Physiological-Clinical']
in O
reducing O
the O
incidence O
of O
air O
leak O
after O
upper O
lobectomy O
. O
['Physiological-Clinical']

The O
experimental O
group O
attended O
a O
program O
to O
improve O
self-management O
methods O
based O
on O
social O
cognitive O
theory O
( O
SCT O
) O
. O
[]

In O
addition O
, O
urinary O
PSE O
concentrations O
were O
measured O
under O
the O
same O
conditions O
and O
compared O
with O
the O
present O
threshold O
of O
the O
World O
Anti-Doping O
Agency O
( O
WADA O
) O
. O
[]

The O
exercise O
intervention O
incorporated O
50 O
multidirectional O
hops O
on O
one O
randomly O
selected O
leg O
. O
[]

The O
optimal O
management O
of O
severe O
ascites O
in O
patients O
with O
alcoholic O
cirrhosis O
has O
not O
been O
defined O
. O
[]

Gastroesophageal O
reflux O
and O
tracheal O
aspiration O
in O
the O
thoracotomy O
position O
: O
should O
ranitidine O
premedication O
be O
routine O
? O
[]

RESULTS O
ORR B-outcome ['Physiological-Clinical']
was O
42.6 O
% O
for O
CAF O
compared O
with O
53.1 O
% O
for O
dofequidar O
+ O
CAF O
, O
a O
24.6 O
% O
relative O
improvement O
and O
10.5 O
% O
absolute O
increase O
( O
P O
= O
.077 O
) O
. O
['Physiological-Clinical']

The O
EMGdi O
also O
decreased O
with O
loading O
; O
the O
decrease O
was O
greater O
on O
fenoterol O
treatment O
( O
P O
< O
0.01 O
) O
. O
[]

The O
Tokyo O
Joshi-Idai O
Asthma O
Research O
Group O
. O
[]

The O
mean O
( O
SE O
) O
exhaled B-outcome ['Physiological-Clinical']
NO I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
31 O
( O
3 O
) O
ppb O
at O
baseline O
, O
39 O
( O
4 O
) O
ppb O
at O
an O
FiO2 O
of O
1.0 O
, O
and O
26 O
( O
3 O
) O
ppb O
at O
an O
FiO2 O
of O
0.1 O
. O
['Physiological-Clinical']

Cardiovascular O
complications O
categorized O
as O
impaired O
arterial O
circulation O
including O
ischemic B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
, O
venous B-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
, O
cardiac B-outcome ['Physiological-Clinical']
incompensation I-outcome ['Physiological-Clinical']
and O
cerebral B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
were O
found O
to O
be O
equally O
frequent O
following O
the O
two O
different O
forms O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
authors O
' O
objective O
was O
to O
document O
the O
dynamic O
changes O
in O
systolic O
function O
of O
both O
ventricles O
during O
acute O
HF O
and O
after O
a O
3-month O
follow-up O
period O
, O
and O
to O
identify O
factors O
associated O
with O
ventricular O
improvement O
. O
[]

Ovulation O
and O
follicular O
development O
associated O
with O
three O
low-dose O
oral O
contraceptives O
: O
a O
randomized O
controlled O
trial O
. O
[]

9.30 O
?g/L O
; O
TNF-? O
: O
44.3 O
? O
[]

Patients O
receiving O
BCT O
and O
50Gy O
whole O
breast O
irradiation O
were O
randomized O
to O
no O
boost O
and O
16Gy O
boost O
( O
N=5318 O
) O
. O
[]

METHODS O
Monitoring O
of O
serum B-outcome ['Physiological-Clinical']
TMs I-outcome ['Physiological-Clinical']
and O
computed B-outcome ['Resource-use']
tomography I-outcome ['Resource-use']
were O
performed O
every O
4 O
weeks O
until O
progression O
of O
disease O
in O
90 O
patients O
with O
PC O
undergoing O
gemcitabine O
therapy O
. O
['Physiological-Clinical', 'Resource-use']

Rapid-sequence O
intubation O
of O
head O
trauma O
patients O
: O
prevention O
of O
fasciculations B-outcome ['Physiological-Clinical']
with O
pancuronium O
versus O
minidose O
succinylcholine O
. O
['Physiological-Clinical']

Zeaxanthin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
in O
the O
triacylglycerol-rich O
lipoprotein O
fraction O
of O
plasma O
was O
measured O
by O
HPLC B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Enhancing O
HIV O
medication O
adherence B-outcome ['Life-Impact']
in O
India O
. O
['Life-Impact']

No O
significant O
difference O
in O
efficiency O
on O
bilirubin B-outcome ['Physiological-Clinical']
removal I-outcome ['Physiological-Clinical']
was O
seen O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

The O
safety O
profiles O
of O
both O
the O
test O
and O
reference O
formulations O
were O
comparable O
. O
[]

A O
biochemical O
response O
index O
comprising O
ESR O
, O
CEA O
and O
CA O
15.3 O
was O
evaluated O
in O
67 O
patients O
with O
systemic O
breast O
cancer O
treated O
by O
chemotherapy O
; O
55 O
were O
assessable O
by O
UICC O
criteria O
and O
the O
response O
index O
( O
96 O
% O
of O
all O
UICC O
assessable O
patients O
) O
. O
[]

RESULTS O
After O
96 O
weeks O
, O
the O
mean O
percent O
change O
from O
baseline O
in O
total O
BMD B-outcome ['Physiological-Clinical']
was O
-2.5 O
% O
( O
LPV/r O
) O
and O
-2.3 O
% O
( O
EFV O
) O
( O
P O
< O
0.01 O
for O
within-group O
changes O
in O
either O
arm O
; O
P O
= O
0.86 O
for O
between-group O
differences O
) O
. O
['Physiological-Clinical']

5.0 O
) O
, O
( O
50.2 O
? O
[]

Cox O
proportional O
hazards O
regression O
model O
in O
the O
whole O
study O
population O
identified O
female O
sex B-outcome ['Physiological-Clinical']
, O
chronic B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
insufficiency I-outcome ['Physiological-Clinical']
, O
diabetes B-outcome ['Physiological-Clinical']
, O
advanced O
age O
, O
lower O
sternal B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
, O
osteoporosis B-outcome ['Physiological-Clinical']
, O
corticosteroid B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
, O
and O
prolonged B-outcome ['Life-Impact']
CPB I-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
ventilation I-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
as O
predisposing O
factors O
to O
any O
of O
the O
two O
studied O
sternal O
complications O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Life-Impact']

Do O
ACE O
inhibitors O
improve O
the O
response O
to O
exercise B-outcome ['Life-Impact']
training I-outcome ['Life-Impact']
in O
functionally O
impaired O
older O
adults O
? O
['Life-Impact']

From O
8 O
to O
18 O
h O
postoperatively O
the O
temperatures B-outcome ['Physiological-Clinical']
of O
the O
two O
groups O
were O
similar O
except O
for O
a O
slightly O
greater O
temperature B-outcome ['Life-Impact']
in O
the O
hypothermic O
patients O
at O
12 O
h O
( O
37.6 O
+/- O
0.5 O
vs. O
37.3 O
+/- O
0.4 O
degrees O
C O
, O
P O
= O
.029 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

This O
model O
provides O
very O
promising O
results O
in O
that O
the O
employment B-outcome ['Life-Impact']
outcomes O
for O
youth O
in O
the O
treatment O
group O
were O
much O
higher O
in O
non-traditional O
jobs O
with O
higher O
than O
minimum O
wage O
incomes O
than O
for O
youth O
in O
the O
control O
condition O
. O
['Life-Impact']

Obesity O
is O
associated O
with O
a O
number O
of O
chronic O
diseases O
, O
including O
cardiovascular O
disease O
, O
hypertension O
, O
and O
diabetes O
. O
[]

RESULTS O
Qualitative O
assessment O
was O
subtle O
among O
the O
three O
protocols O
. O
[]

In O
the O
liver O
, O
they O
were O
marginally O
higher O
in O
the O
LBW O
group O
than O
in O
the O
BV O
group O
( O
P O
= O
.03 O
) O
. O
[]

METHODS O
In O
a O
double-blind O
, O
placebo-controlled O
6-month O
study O
comprising O
20 O
adult O
enfeebled O
hemodialysis O
patients O
, O
9 O
patients O
were O
treated O
with O
a O
single O
daily O
subcutaneous O
injection O
of O
recombinant O
human O
growth O
hormone O
( O
rhGH O
) O
4 O
IU/m2 O
and O
11 O
with O
placebo O
injections O
. O
[]

The O
criteria O
for O
a O
successful O
priming O
session O
were O
a O
patient-assessed O
instantaneous O
total O
nasal B-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
score O
of O
at O
least O
6 O
( O
of O
a O
possible O
12 O
) O
and O
a O
nasal B-outcome ['Physiological-Clinical']
congestion I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
rhinorrhea I-outcome ['Physiological-Clinical']
score O
of O
at O
least O
2 O
( O
of O
a O
possible O
3 O
) O
90 O
minutes O
after O
allergen O
exposure O
during O
at O
least O
two O
consecutive O
priming O
sessions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Adjvant O
treatment O
of O
tongue O
and O
floor O
of O
the O
mouth O
cancers O
. O
[]

Interventions O
were O
conducted O
30 O
min O
daily O
for O
5-6 O
weeks O
. O
[]

One O
hundred O
children O
with O
ASD O
, O
aged O
7 O
to O
12 O
years O
will O
be O
randomly O
assigned O
to O
an O
intervention O
or O
a O
waiting O
list O
control O
group O
. O
[]

SECONDARY O
: O
time B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
successful I-outcome ['Life-Impact']
cannulation I-outcome ['Life-Impact']
. O
['Life-Impact']

Baseline O
data O
at O
study O
entry O
were O
examined O
with O
respect O
to O
final O
outcome O
to O
determine O
if O
response O
predictors O
could O
be O
identified O
. O
[]

RESULTS O
Both O
groups O
showed O
a O
reduction O
in O
DSH B-outcome ['Physiological-Clinical']
and O
hospitalizations B-outcome ['Resource-use']
, O
but O
there O
were O
no O
significant O
differences O
in O
DSH O
, O
hospital B-outcome ['Resource-use']
admissions I-outcome ['Resource-use']
or O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
in O
hospital O
between O
groups O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use', 'Resource-use']

Although O
candidiasis O
is O
the O
most O
common O
infection O
, O
mold O
infections O
are O
increasing O
in O
frequency O
. O
[]

The O
patients O
were O
randomized O
in O
six O
groups O
to O
receive O
either O
0.5 O
% O
bupivacaine-CO2 O
or O
0.5 O
% O
bupivacaine-HCl O
at O
temperatures O
of O
4 O
degrees O
, O
20 O
degrees O
, O
or O
36 O
degrees O
C. O
The O
six O
groups O
were O
comparable O
in O
age O
, O
height O
, O
and O
weight O
. O
[]

The O
proportion O
of O
subjects O
with O
negative O
expectations B-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
future I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
ability B-outcome ['Life-Impact']
decreased O
in O
both O
groups O
at O
6 O
and O
12 O
months O
; O
however O
, O
the O
proportion O
was O
significantly O
bigger O
in O
TG O
compared O
with O
CG O
( O
P O
= O
0.028 O
) O
. O
['Life-Impact', 'Life-Impact']

BACKGROUND O
Children O
undergoing O
hematopoietic O
stem O
cell O
transplantation O
( O
HSCT O
) O
frequently O
require O
prolonged O
courses O
of O
parenteral O
nutrition O
( O
PN O
) O
as O
a O
consequence O
of O
gastrointestinal O
dysfunction O
related O
to O
preparative O
chemotherapy O
and O
radiation O
. O
[]

Women O
were O
assigned O
randomly O
to O
receive O
: O
( O
a O
) O
alendronate O
10mg/day O
: O
( O
b O
) O
alendronate O
70 O
mg O
once O
a O
week O
: O
or O
( O
c O
) O
enteric O
alendronate O
70 O
mg O
per O
week O
. O
[]

METHODS/DESIGN O
This O
is O
a O
multi-centre O
randomised O
2 O
x O
2 O
factorial O
design O
study O
evaluating O
two O
independent O
variables O
of O
VP O
design O
, O
branching O
( O
present O
or O
absent O
) O
, O
and O
structured O
clinical O
reasoning O
feedback O
( O
present O
or O
absent O
) O
.The O
study O
will O
be O
carried O
out O
in O
medical O
student O
volunteers O
in O
one O
year O
group O
from O
three O
university O
medical O
schools O
in O
the O
United O
Kingdom O
, O
Warwick O
, O
Keele O
and O
Birmingham O
. O
[]

They O
received O
alinidine O
or O
placebo O
in O
a O
double-blind O
randomized O
crossover O
trial O
for O
3 O
days O
after O
a O
wash-out O
period O
of O
4 O
days O
. O
[]

Walking B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
, O
cardiorespiratory B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
, O
isometric B-outcome ['Physiological-Clinical']
knee I-outcome ['Physiological-Clinical']
extensor I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
, O
balance B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

The O
processing O
of O
time-dependent O
features O
of O
movement O
has O
a O
crucial O
role O
in O
predicting O
whether O
the O
outcome O
of O
a O
complex O
motor O
sequence O
, O
such O
as O
handwriting O
or O
playing O
a O
musical O
passage O
, O
will O
be O
consistent O
with O
its O
ultimate O
goal O
, O
or O
results O
instead O
in O
an O
execution O
error O
. O
[]

This O
open-label O
, O
single-dose O
, O
4-way O
crossover O
, O
pharmacokinetic O
drug O
interaction O
study O
compared O
the O
relative O
bioavailability B-outcome ['Physiological-Clinical']
of O
morphine B-outcome ['Resource-use']
and O
naltrexone B-outcome ['Physiological-Clinical']
when O
MS-sNT O
is O
administered O
( O
under O
fasting O
conditions O
) O
with O
increasing O
doses B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
alcohol I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Life-Impact']

Perioperative O
enteral O
nutrition O
and O
quality O
of O
life O
of O
severely O
malnourished O
head O
and O
neck O
cancer O
patients O
: O
a O
randomized O
clinical O
trial O
. O
[]

Fifteen O
of O
18 O
( O
83.3 O
% O
) O
evaluated O
episodes O
in O
the O
od O
and O
12/16 O
( O
75.0 O
% O
) O
evaluated O
episodes O
in O
the O
bd O
group O
showed O
a O
favourable O
bacteriological B-outcome ['Physiological-Clinical']
response O
. O
['Physiological-Clinical']

Cumulative O
active B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
very O
similar O
when O
assessed O
by O
each O
catheter O
in O
the O
same O
uterus O
. O
['Physiological-Clinical']

A O
water-perfused O
manometry O
catheter O
, O
with O
openings O
at O
5 O
, O
10 O
and O
15 O
cm O
from O
the O
tip O
, O
was O
placed O
by O
rigid O
sigmoidoscopy O
in O
the O
recto-sigmoid O
region O
. O
[]

CONCLUSIONS O
Excellent O
results O
are O
achieved O
if O
ROP O
is O
treated O
at O
the O
prethreshold O
stage O
with O
both O
indirect O
laser O
photocoagulation O
and O
cryotherapy O
. O
[]

One O
important O
executive O
function O
known O
to O
be O
compromised O
in O
autism O
spectrum O
disorder O
( O
ASD O
) O
is O
related O
to O
response O
error O
monitoring B-outcome ['Life-Impact']
and O
post-error O
response O
correction B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

In O
the O
whole O
study O
196 O
( O
32.1 O
% O
) O
had O
limited O
disease O
and O
414 O
( O
67.9 O
% O
) O
extensive O
disease O
. O
[]

RESULTS O
The O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
reduction O
rate O
was O
similar O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

A O
single O
dose O
of O
enoxaparin O
suppressed O
early B-outcome ['Physiological-Clinical']
coagulation I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
but O
thrombin B-outcome ['Physiological-Clinical']
generation I-outcome ['Physiological-Clinical']
was O
not O
inhibited B-outcome ['Physiological-Clinical']
during O
thromboprophylaxis O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
6-month O
intervention O
trial O
was O
conducted O
among O
542 O
Filipino O
children O
aged O
4 O
to O
7 O
years O
to O
determine O
the O
effect O
of O
vitamin O
A-fortified O
coconut O
cooking O
oil O
intake O
on O
their O
vitamin O
A O
status O
and O
to O
identify O
factors O
that O
influence O
this O
. O
[]

RESULTS O
All O
110 O
prophylaxis O
study O
group O
patients O
were O
clinically O
asymptomatic B-outcome ['Physiological-Clinical']
and O
109 O
duplex B-outcome ['Resource-use']
scans I-outcome ['Resource-use']
were O
normal O
. O
['Physiological-Clinical', 'Resource-use']

vs. O
11 O
% O
for O
b.i.d. O
, O
p=0.54 O
) O
. O
[]

In O
Group O
D O
, O
patients O
were O
pretreated O
with O
normal O
saline O
followed O
by O
propofol O
2.0 O
mg/kg O
at O
50 O
mg/sec O
. O
[]

We O
evaluated O
the O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
low-dose O
etoposide O
in O
relapsed O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
. O
['Physiological-Clinical']

A O
significantly O
greater O
improvement O
in O
the O
study O
primary O
outcome O
( O
the O
ABC-C O
irritability O
subscale O
score O
) O
was O
achieved O
by O
the O
riluzole-treated O
children O
compared O
with O
the O
placebo O
group O
( O
P O
= O
0.03 O
) O
. O
[]

Intraabdominal O
structures O
may O
be O
damaged O
during O
blind O
introduction O
of O
the O
first O
trocar O
for O
laparoscopic O
operations O
. O
[]

RESULT O
There O
were O
no O
statistical O
differences O
in O
the O
discharge B-outcome ['Life-Impact']
rate O
( O
84 O
% O
treatment O
vs O
76 O
% O
controls O
) O
or O
in O
the O
median O
length O
of O
['Life-Impact']

regimen O
of O
3TC O
, O
combined O
with O
zidovudine O
( O
300 O
mg O
b.i.d O
. O
) O
[]

There O
were O
minimal O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
no O
significant O
changes O
in O
safety O
parameters O
, O
and O
no O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects', 'Adverse-effects']

In O
this O
study O
, O
we O
examined O
whether O
azelnidipine O
addition O
could O
have O
renoprotective O
properties O
in O
hypertensive O
CKD O
patients O
by O
reducing O
serum O
levels O
of O
AGE O
and O
soluble O
form O
of O
RAGE O
( O
sRAGE O
) O
. O
[]

We O
performed O
two O
hundred O
and O
thirty O
laparoscopic O
hysterectomies O
during O
the O
period O
from O
March O
1991 O
to O
October O
1993 O
. O
[]

In O
contrast O
to O
the O
hypothesis O
to O
be O
tested O
, O
the O
efficacy O
of O
physostigmine O
was O
not O
superior O
to O
that O
of O
placebo O
after O
a O
treatment O
period O
of O
24 O
weeks O
. O
[]

UNLABELLED O
There O
are O
few O
data O
concerning O
changes O
in O
lung O
function O
and O
respiratory O
symptoms O
in O
smokers O
with O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
weeks O
to O
months O
after O
quitting O
smoking O
. O
[]

In O
vivo O
assessment O
of O
catheter-tip O
PO2 O
sensor O
: O
sampling O
lumen O
fabrication O
. O
[]

PURPOSE O
The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
, O
collateral O
damage O
, O
and O
convenience O
of O
panretinal O
photocoagulation O
for O
proliferative O
diabetic O
retinopathy O
or O
severe O
nonproliferative O
diabetic O
retinopathy O
using O
a O
532-nm O
solid-state O
green O
laser O
( O
GLX O
) O
versus O
a O
multispot O
532-nm O
pattern O
scan O
laser O
( O
PASCAL O
) O
. O
[]

The O
mean O
adherence B-outcome ['Life-Impact']
rates O
, O
as O
measured O
by O
the O
automatic O
dose O
counter O
, O
were O
significantly O
better O
( O
P O
< O
0.001 O
) O
with O
MF-DPI O
400 O
microg O
once-daily O
in O
the O
evening O
( O
93.3 O
% O
) O
than O
with O
MF-DPI O
200 O
microg O
twice-daily O
( O
89.5 O
% O
) O
. O
['Life-Impact']

All O
patients O
achieved O
small O
sustainable O
improvements B-outcome ['Physiological-Clinical']
-- I-outcome ['Physiological-Clinical']
9HPT I-outcome ['Physiological-Clinical']
, O
5 O
% O
of O
maximum O
( O
confidence O
interval O
[ O
CI O
] O
= O
3 O
% O
-7 O
% O
) O
; O
JTT B-outcome ['Physiological-Clinical']
, O
5.7 O
% O
( O
CI O
= O
3 O
% O
-8 O
% O
) O
; O
and O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
, O
6 O
% O
( O
CI O
= O
2 O
% O
-10 O
% O
) O
-- O
all O
below O
the O
defined O
clinically O
important O
level O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Many O
people O
relapse O
after O
weight O
restoration O
. O
[]

Human O
interferon-?2a O
( O
huIFN-?2a O
) O
and O
3'-azido-2',3'-dideoxythymidine O
( O
AZT O
) O
have O
been O
proven O
to O
decrease O
antigenaemia O
in O
cats O
infected O
experimentally O
with O
FeLV O
. O
[]

Fifty-one O
patients O
have O
been O
enrolled O
with O
a O
minimum O
follow-up O
exceeding O
100 O
days O
. O
[]

GH O
has O
an O
anabolic O
effect O
by O
increasing O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor O
( O
IGF B-outcome ['Physiological-Clinical']
) O
-I O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
This O
study O
shows O
that O
finasteride O
given O
for O
2 O
weeks O
preoperatively O
decreases O
bleeding B-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
transurethral O
prostate O
resection O
. O
['Physiological-Clinical']

In O
phase O
2 O
, O
the O
control O
group O
was O
subsequently O
randomized O
into O
2 O
groups O
with O
alternate O
weight-placement O
. O
[]

The O
effect O
of O
hypothyroidism O
on O
TAFI O
was O
studied O
in O
a O
multicentre O
observational O
cohort O
study O
. O
[]

The O
data O
show O
no O
significant O
difference O
in O
toxicity B-outcome ['Adverse-effects']
and O
suggest O
that O
netilmicin O
and O
gentamicin O
are O
both O
highly O
effective O
in O
combination O
with O
cefoxitin O
in O
patients O
who O
have O
serious O
infections O
after O
surgery O
. O
['Adverse-effects']

Training O
included O
five O
sessions O
per O
week O
( O
100-120 O
min O
each O
) O
and O
was O
performed O
for O
4 O
weeks O
. O
[]

There O
was O
no O
statistically O
significant O
difference O
in O
pain B-outcome ['Physiological-Clinical']
scores O
on O
the O
numeric O
analog O
scale O
( O
0-10 O
) O
between O
the O
groups O
at O
4 O
hrs O
after O
surgery O
( O
P O
= O
0.18 O
) O
or O
during O
the O
24 O
hrs O
after O
surgery O
( O
P O
= O
0.23 O
) O
. O
['Physiological-Clinical']

RESULTS O
Retapamulin O
was O
as O
effective O
as O
cephalexin O
( O
clinical O
success O
rates O
at O
follow-up O
: O
85.9 O
% O
and O
89.7 O
% O
, O
respectively O
) O
. O
[]

In O
the O
entire O
sample O
studied O
, O
the O
mean O
pupillary B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
was O
greater O
in O
the O
eyedrops O
group O
after O
20 O
and O
40 O
minutes O
, O
while O
mydriasis B-outcome ['Physiological-Clinical']
was O
similar O
in O
the O
2 O
groups O
after O
60 O
minutes O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Field O
trials O
of O
a O
vaccine O
against O
bovine O
mastitis O
. O
[]

Of O
16 O
polyuric O
patients O
, O
5 O
in O
group O
1 O
and O
7 O
in O
group O
2 O
showed O
improvement O
in O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
In O
a O
randomized O
controlled O
trial O
, O
73 O
patients O
were O
assigned O
to O
CT O
angiography O
, O
and O
72 O
were O
assigned O
to O
DSA O
. O
[]

METHODS O
Patients O
aged O
25 O
to O
74 O
years O
attending O
community O
pharmacies O
with O
a O
prescription O
for O
at O
least O
1 O
drug O
indicated O
for O
CVD O
or O
CV O
risk O
factors O
were O
randomized O
to O
2 O
groups O
: O
an O
intervention O
group O
that O
received O
pharmaceutical O
care O
, O
which O
was O
provided O
by O
specially O
trained O
pharmacists O
working O
in O
collaboration O
with O
physicians O
, O
and O
a O
control O
group O
that O
received O
usual O
care O
( O
routine O
dispensing O
counseling O
) O
and O
verbal O
and O
written O
counseling O
regarding O
CVD O
prevention O
. O
[]

The O
visual O
analogue O
and O
verbal O
rating O
pain B-outcome ['Physiological-Clinical']
scores O
at O
0 O
, O
4 O
, O
8 O
, O
12 O
and O
24 O
hours O
for O
both O
shoulder O
and O
abdominal O
pain O
were O
recorded O
in O
a O
prospective O
double-blind O
fashion O
at O
four O
points O
during O
the O
first O
24 O
postoperative O
hours O
. O
['Physiological-Clinical']

In O
103 O
non-and-low O
response O
children O
, O
proportion O
of O
titers O
of O
more O
than O
100 O
mIU/ml O
of O
group O
B O
and O
group O
C O
were O
61.2 O
% O
and O
84.5 O
% O
, O
and O
there O
was O
statistical O
significant O
difference O
( O
chi2 O
= O
14.13 O
, O
P O
< O
0.01 O
) O
. O
[]

Its O
beneficial O
results O
have O
been O
reported O
in O
patients O
suffering O
from O
hypotension O
during O
spinal O
anesthesia O
. O
[]

In O
this O
first O
randomized O
study O
in O
high-risk O
patients O
for O
stent O
implantation O
and O
bypass O
surgery O
, O
patients O
with O
retroinfusion-supported O
stent O
implantation O
had O
a O
similar O
1-year O
outcome O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
compared O
to O
patients O
with O
bypass O
surgery O
. O
['Life-Impact']

A O
six-month O
crossover O
chemoprevention O
clinical O
trial O
of O
tea O
in O
smokers O
and O
non-smokers O
: O
methodological O
issues O
in O
a O
feasibility O
study O
. O
[]

There O
was O
a O
similar O
and O
highly O
significant O
degree O
of O
beta B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
and O
amelioration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of O
thyrotoxicosis B-outcome ['Physiological-Clinical']
at O
the O
end O
of O
the O
dosage O
interval O
( O
trough O
) O
, O
i.e. O
, O
24 O
hours O
after O
nadolol O
or O
6 O
to O
8 O
hours O
after O
propranolol O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Premixed O
70 O
% O
NPH/30 O
% O
Regular O
insulin O
was O
taken O
before O
supper O
, O
and O
the O
dosage O
was O
adjusted O
weekly O
by O
an O
algorithm O
seeking O
nearly O
normal O
fasting O
glycemia O
. O
[]

DESIGN O
The O
Administrative O
Data O
Feedback O
for O
Effective O
Cardiac O
Treatment O
( O
AFFECT O
) O
study O
, O
a O
cluster O
randomized O
trial O
. O
[]

The O
effect O
of O
nebivolol O
treatment O
on O
oxidative B-outcome ['Physiological-Clinical']
stress O
and O
antioxidant B-outcome ['Physiological-Clinical']
status B-outcome ['Physiological-Clinical']
in O
patients O
with O
cardiac O
syndrome-X O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

It O
has O
been O
used O
for O
many O
years O
in O
the O
Vietnam-Sweden O
hospital O
at O
Uong O
Bi O
in O
northern O
Vietnam O
. O
[]

The O
radiographs B-outcome ['Physiological-Clinical']
of O
hands O
and O
feet O
were O
analyzed O
by O
using O
the O
Larsen O
score O
at O
baseline O
, O
2 O
, O
5 O
, O
and O
11 O
years O
, O
and O
the O
radiographs O
of O
large O
joints O
, O
at O
11 O
years O
. O
['Physiological-Clinical']

Subjects O
underwent O
pre- O
and O
post-treatment O
lab O
testing O
to O
evaluate O
plasma B-outcome ['Physiological-Clinical']
reduced I-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
oxidized I-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
cysteine I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
taurine I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
total O
sulfate B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
whole-blood I-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

STUDY O
DESIGN O
Prospective O
randomized O
trial O
. O
[]

Prediction O
linear O
equations O
for O
the O
main O
variables O
of O
clinical O
interest O
were O
established O
by O
backward O
stepwise O
regression O
analysis O
including O
: O
sex O
, O
age O
, O
knee O
extensor O
peak O
torque O
, O
bone-free O
lean O
leg O
mass O
, O
total O
and O
lean O
body O
mass O
, O
height O
, O
and O
physical O
activity O
scores O
. O
[]

Using O
double-blind O
sham-controlled O
parallel O
design O
, O
we O
evaluated O
the O
effect O
of O
HF-rTMS O
over O
the O
left O
dorsolateral O
prefrontal O
cortex O
( O
DLPFC O
) O
on O
negative O
symptoms O
in O
patients O
with O
schizophrenia O
. O
[]

OBJECTIVE O
The O
aim O
of O
the O
study O
was O
to O
assess O
the O
effects O
of O
two O
estroprogestins O
( O
EPs O
) O
, O
ethinyl-estradiol O
( O
EE O
) O
30 O
mcg/drospirenone O
( O
DRSP O
) O
3 O
mg O
, O
and O
ethinyl-estradiol O
( O
EE O
) O
30 O
mcg/chlormadinone O
acetate O
( O
CMA O
) O
2 O
mg O
, O
both O
on O
increased O
serum B-outcome ['Physiological-Clinical']
androgen I-outcome ['Physiological-Clinical']
levels O
and O
on O
several O
skin B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
in O
women O
affected O
by O
mild O
to O
severe O
acne O
and O
polycystic O
ovary O
syndrome O
( O
PCOS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

The O
[]

Given O
the O
low O
incidence O
, O
routine O
screening O
for O
asymptomatic O
thrombi O
appears O
unwarranted O
. O
[]

On O
intention-to-treat O
analysis O
, O
eradication B-outcome ['Physiological-Clinical']
was O
achieved O
in O
41 O
of O
the O
49 O
patients O
( O
84 O
% O
; O
95 O
% O
confidence O
interval O
, O
70.4-92.7 O
% O
) O
and O
27 O
of O
the O
46 O
patients O
( O
59 O
% O
; O
95 O
% O
confidence O
interval O
, O
43.3-73.0 O
% O
) O
of O
the O
tetracycline- O
and O
clarithromycin-containing O
groups O
, O
respectively O
( O
P=0.007 O
) O
. O
['Physiological-Clinical']

Endoscopic O
ligation O
, O
a O
new O
form O
of O
endoscopic O
treatment O
for O
bleeding O
varices O
, O
has O
been O
shown O
to O
be O
superior O
to O
sclerotherapy O
in O
adult O
patients O
with O
cirrhosis O
. O
[]

Additionally O
, O
in O
early O
stage O
( O
I O
, O
II O
) O
cases O
, O
Skp2 O
expression O
was O
also O
revealed O
to O
possess O
a O
significant O
prognostic O
factor O
in O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
p=0.0234 O
) O
, O
but O
not O
in O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
p=0.2055 O
) O
. O
['Mortality', 'Mortality']

Their O
performance O
pre O
and O
post O
intervention O
was O
assessed O
by O
four O
independent O
raters O
using O
a O
scale O
that O
included O
evaluation O
of O
both O
Content O
and O
Delivery B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
Patients O
with O
chronic O
kidney O
disease O
, O
including O
kidney O
transplant O
recipients O
, O
are O
at O
high O
risk O
for O
cardiovascular B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CVD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Complete B-outcome ['Physiological-Clinical']
relaxation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cords I-outcome ['Physiological-Clinical']
was O
present O
in O
all O
but O
two O
patients O
, O
one O
in O
each O
group O
. O
['Physiological-Clinical']

The O
authors O
studied O
the O
Overt O
Aggression O
Scale O
( O
OAS O
) O
in O
a O
preliminary O
sample O
of O
eight O
outpatients O
who O
participated O
in O
an O
ongoing O
placebo-controlled O
study O
of O
valproate O
for O
aggression O
in O
autism O
. O
[]

METHODS O
After O
informed O
consent O
, O
46 O
healthy O
adults O
were O
randomly O
assigned O
to O
one O
of O
three O
strip O
+ O
dentifrice O
treatment O
groups O
. O
[]

Bacterial B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
fungal I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
( O
considered O
life-threatening O
or O
fatal O
) O
occurred O
in O
17 O
children O
with O
ALL O
and O
in O
7 O
with O
ANLL O
. O
['Physiological-Clinical']

Two O
studies O
were O
undertaken O
to O
examine O
the O
use O
of O
these O
errors O
for O
improving O
the O
instruction O
and O
evaluation O
of O
the O
skill O
. O
[]

In O
the O
late O
phase O
of O
the O
ECC O
( O
T3 O
) O
, O
FCD O
in O
the O
MECC O
group O
was O
already O
recovered O
, O
whereas O
FCD O
in O
the O
CECC O
group O
was O
still O
significantly O
depressed O
( O
223.1 O
? O
[]

RESULTS O
Use O
of O
CEE O
resulted O
in O
mean O
increase O
in O
mammographic B-outcome ['Physiological-Clinical']
percent I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
of O
1.6 O
percentage O
points O
( O
95 O
% O
CI O
, O
0.8 O
to O
2.4 O
) O
at O
year O
1 O
compared O
with O
a O
mean O
decrease O
of O
1.0 O
percentage O
point O
( O
95 O
% O
CI O
, O
-1.7 O
to O
-0.4 O
) O
in O
the O
placebo O
group O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

Prospective O
randomized O
trials O
seem O
warranted O
to O
determine O
the O
optimum O
antibiotic O
prophylaxis O
regimen O
in O
patients O
undergoing O
biopsy O
with O
a O
periprostatic O
nerve O
block O
. O
[]

Government-owned O
small-ruminant O
breeding O
farms O
in O
Malaysia O
provide O
the O
source O
of O
sheep O
and O
goats O
to O
smallholder O
farmers O
in O
the O
country O
. O
[]

For O
identified O
cases O
, O
rosters O
were O
prepared O
and O
sent O
to O
the O
physician O
with O
a O
cover O
letter O
and O
study O
description O
. O
[]

Three O
patients O
experienced O
an O
acute B-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
episode O
( O
n O
= O
2 O
MI O
; O
n O
= O
1 O
LI O
) O
. O
['Physiological-Clinical']

The O
patients O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

Study O
drug O
( O
BDP O
or O
placebo O
) O
was O
administered O
as O
1-mg O
immediate-release O
formulation O
plus O
1-mg O
delayed-release O
formulation O
orally O
four O
times O
daily O
. O
[]

Main O
study O
outcome O
is O
daily B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
during O
the O
first O
year O
after O
the O
treatment O
, O
assessed O
on O
the O
Health O
Assessment O
Questionnaire O
. O
['Life-Impact']

The O
low O
, O
relatively O
safe O
level O
of O
hookworm O
infection O
used O
in O
this O
study O
was O
immunogenic O
, O
inducing O
eosinophilia B-outcome ['Physiological-Clinical']
and O
a O
significant O
specific B-outcome ['Physiological-Clinical']
IgG I-outcome ['Physiological-Clinical']
response O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
double-blind O
, O
placebo-controlled O
trial O
of O
oral O
human O
immunoglobulin O
for O
gastrointestinal O
dysfunction O
in O
children O
with O
autistic O
disorder O
. O
[]

This O
compound O
exhibits O
antioxidant B-outcome ['Physiological-Clinical']
, O
immunomodulatory B-outcome ['Physiological-Clinical']
, O
photoprotective B-outcome ['Physiological-Clinical']
, O
anti-angiogenic B-outcome ['Physiological-Clinical']
, O
and O
anti-inflammatory B-outcome ['Physiological-Clinical']
properties O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Sirolimus O
administered O
with O
rCsA O
and O
corticosteroids O
provided O
adequate O
immunosuppression O
while O
reducing O
the O
potential O
for O
the O
nephrotoxic O
effects O
of O
cyclosporine O
. O
[]

Dogs O
of O
various O
breed O
, O
age O
and O
weight O
were O
included O
in O
the O
study O
. O
[]

Influence O
of O
glyceryl O
trinitrate O
on O
venous O
and O
arterial O
effects O
of O
chronic O
, O
asymmetric O
isosorbide O
dinitrate O
treatment O
in O
patients O
with O
ischemic O
heart O
disease O
. O
[]

Results O
showed O
that O
there O
were O
no O
differences O
in O
rates O
of O
employment B-outcome ['Life-Impact']
between O
these O
two O
groups O
. O
['Life-Impact']

The O
annual O
financial O
burden O
was O
estimated O
. O
[]

SETTING O
Research O
setting O
in O
a O
large O
medical O
center O
. O
[]

Osteonecrosis O
of O
the O
jaw O
occurred O
infrequently O
( O
2.0 O
% O
, O
denosumab O
; O
1.4 O
% O
, O
zoledronic O
acid O
; O
P O
= O
.39 O
) O
. O
[]

CONCLUSIONS O
Amoxicillin B-outcome ['Resource-use']
was O
as O
efficacious O
as O
erythromycin O
in O
the O
treatment O
of O
severe B-outcome ['Physiological-Clinical']
pyoderma I-outcome ['Physiological-Clinical']
in O
Mali O
. O
['Resource-use', 'Physiological-Clinical']

In O
addition O
, O
the O
new O
test O
( O
but O
not O
the O
classical O
test O
) O
provided O
evidence O
for O
[]

CONCLUSIONS O
The O
interventions O
conducted O
by O
a O
robot O
and O
a O
human O
trainer O
were O
both O
effective O
in O
promoting O
self-initiated O
questions O
in O
children O
with O
ASD O
. O
[]

Two O
experiments O
examined O
whether O
over-selectivity O
is O
the O
product O
of O
a O
post-acquisition B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
deficit O
, O
rather O
than O
an O
attention O
problem O
. O
['Life-Impact']

PATIENTS O
Twenty-six O
patients O
( O
22 O
men O
, O
4 O
women O
; O
mean O
+/- O
SD O
age O
, O
54 O
+/- O
9yrs O
) O
with O
a O
history O
of O
severe O
chronic O
heart O
failure O
( O
left O
ventricular O
ejection O
fraction O
of O
18 O
% O
+/- O
8 O
% O
) O
. O
[]

TLA O
was O
comparable O
to O
RLA O
in O
terms O
of O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
( O
130 O
vs O
126.5 O
minutes O
, O
p O
= O
0.64 O
) O
, O
estimated B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
( O
p O
= O
0.92 O
) O
, O
specimen B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
( O
p O
= O
0.81 O
) O
, O
analgesic B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
( O
p O
= O
0.25 O
) O
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
p O
= O
0.56 O
) O
and O
the O
complication B-outcome ['Adverse-effects']
rate O
( O
p O
= O
0.58 O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Adverse-effects']

Both O
groups O
were O
considered O
homogeneous O
in O
the O
preoperative O
assessment O
. O
[]

OBJECTIVE O
The O
authors O
examined O
the O
developmental O
impact O
and O
temporal O
characteristics O
of O
risperidone-associated O
weight O
change O
. O
[]

Data O
obtained O
by O
such O
analyses O
allow O
simulation O
of O
the O
dilution O
of O
the O
plasma B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
during O
infusion O
of O
the O
solution O
at O
different O
rates O
. O
['Physiological-Clinical']

Further O
study O
is O
needed O
to O
test O
this O
hypothesis O
. O
[]

Injection O
of O
known O
quantities O
of O
venom O
showed O
that O
this O
measurement O
is O
a O
good O
indicator O
of O
envenomisation O
. O
[]

Similarly O
, O
Ganoderma O
tsugae O
( O
Ganodermataceae O
) O
, O
Codonopsis O
pilosula O
( O
Campanulaceae O
) O
and O
Angelica O
sinensis O
( O
Apiaceae O
) O
are O
traditional O
Chinese O
herbs O
associated O
with O
immunomodulatory O
functions O
. O
[]

RESULTS O
Reliability O
52 O
% O
, O
ppv B-outcome ['Physiological-Clinical']
52 O
% O
, O
npv B-outcome ['Physiological-Clinical']
52 O
% O
, O
sensitivity B-outcome ['Physiological-Clinical']
46 O
% O
, O
specificity O
58 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
zeaxanthin-standardised O
dose O
( O
15 O
mg O
) O
of O
each O
was O
consumed O
, O
in O
randomised O
order O
, O
together O
with O
a O
standardised O
breakfast O
by O
twelve O
healthy O
, O
consenting O
subjects O
in O
a O
cross-over O
trial O
, O
with O
a O
3-5-week O
washout O
period O
between O
treatments O
. O
[]

RESULTS O
The O
oral O
formulation O
of O
cetirizine/PSE O
was O
significantly O
( O
P O
< O
0.001 O
) O
superior O
to O
placebo O
in O
improving O
nasal B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
during O
both O
challenges O
. O
['Physiological-Clinical']

Personalized O
smoking O
cessation O
: O
interactions O
between O
nicotine O
dose O
, O
dependence O
and O
quit-success O
genotype O
score O
. O
[]

The O
aims O
of O
this O
study O
were O
to O
evaluate O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
bowel O
preparation O
protocols O
based O
on O
a O
low O
residue O
diet O
and O
4L O
polyethylene O
glycol O
( O
PEG O
) O
solution O
, O
and O
to O
compare O
these O
new O
options O
with O
the O
traditional O
liquid O
diet O
and O
the O
PEG O
4L O
lavage O
. O
['Life-Impact']

RESULTS O
Seven O
hundred O
and O
thirty O
two O
patients O
were O
evaluable O
for O
this O
analysis O
. O
[]

BACKGROUND O
Previous O
studies O
have O
shown O
that O
, O
in O
patients O
receiving O
DAPT O
, O
the O
adjunctive O
use O
of O
a O
PDE O
inhibitor O
enhances O
platelet B-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
, O
particularly O
in O
those O
presenting O
with O
diabetes O
mellitus O
( O
DM O
) O
. O
['Physiological-Clinical']

The O
experimental O
group O
was O
treated O
with O
VCT O
in O
addition O
to O
conventional B-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
for O
10 O
sessions O
. O
['Physiological-Clinical']

Initial O
control O
of O
the O
disease O
was O
similar O
in O
both O
groups O
. O
[]

UNLABELLED O
Molecular O
imaging O
receives O
increased O
attention O
for O
selecting O
patients O
who O
will O
benefit O
from O
targeted O
anticancer O
therapies O
. O
[]

PARTICIPANTS O
Nine O
hundred O
and O
thirty O
patients O
presenting O
to O
hospital O
within O
12 O
hours O
of O
the O
onset O
of O
septic O
shock O
. O
[]

Patients O
without O
postoperative O
complications O
showed O
no O
significant O
differences O
in O
postoperative O
immunosuppression B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

All O
patients O
received O
RT O
to O
the O
primary O
lesion O
, O
and O
the O
survival B-outcome ['Mortality']
rate O
after O
3 O
years O
was O
65 O
% O
. O
['Mortality']

CONCLUSION O
ILP O
with O
TNF/IFN/M O
can O
be O
safely O
performed O
, O
as O
I131 O
albumin O
provides O
a O
sensitive O
measure O
of O
systemic O
leakage O
from O
the O
perfusion O
circuit O
. O
[]

Heartburn O
, O
retrosternal O
pain O
and O
belching O
improved O
significantly O
better O
with O
lansoprazole O
than O
with O
ranitidine O
, O
as O
did O
the O
patient-rated O
overall O
symptom O
severity O
. O
[]

A O
randomised O
non-inferiority O
controlled O
trial O
of O
a O
single O
versus O
a O
four O
intradermal O
sterile O
water O
injection O
technique O
for O
relief O
of O
continuous O
lower O
back O
pain O
during O
labour O
. O
[]

SUMMARY O
OF O
BACKGROUND O
DATA O
MCIC O
can O
provide O
valuable O
information O
for O
researchers O
, O
healthcare O
providers O
, O
and O
policymakers O
. O
[]

Auditory O
integration O
training O
and O
a O
control O
treatment O
were O
provided O
for O
16 O
children O
with O
autism B-outcome ['Life-Impact']
in O
a O
crossover O
experimental O
design O
. O
['Life-Impact']

To O
determine O
the O
efficacy O
of O
cisapride O
, O
10 O
mg O
three O
times O
daily O
, O
in O
improving O
gastric B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
, O
reducing O
distress B-outcome ['Life-Impact']
during I-outcome ['Life-Impact']
meals I-outcome ['Life-Impact']
, O
and O
facilitating O
weight O
gain O
in O
anorexia O
nervosa O
, O
we O
conducted O
an O
8-week O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
on O
29 O
inpatients O
. O
['Physiological-Clinical', 'Life-Impact']

Children O
on O
placebo O
did O
not O
show O
statistically O
significant O
changes O
. O
[]

Prevention O
of O
postoperative O
hypocalcemia O
with O
routine O
oral O
calcium O
and O
vitamin O
D O
supplements O
in O
patients O
with O
differentiated O
papillary O
thyroid O
carcinoma O
undergoing O
total O
thyroidectomy O
plus O
central O
neck O
dissection O
. O
[]

Comparing O
the O
placebo O
to O
the O
treatment O
period O
, O
subjective O
symptoms O
, O
such O
as O
nocturia B-outcome ['Physiological-Clinical']
and O
urgency B-outcome ['Physiological-Clinical']
, O
were O
significantly O
decreased O
in O
group O
H O
( O
p O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Compared O
with O
TAH O
, O
LAVH O
has O
advantages O
in O
removing O
uteri O
weighing O
< O
or O
= O
500 O
g O
, O
with O
comparable O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
less O
post-operative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
shorter O
recovery B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
anesthesia O
and O
operating O
times O
were O
significantly O
longer O
in O
LA O
for O
both O
overweight O
patients O
and O
those O
with O
a O
normal O
BMI O
. O
[]

Patients O
underwent O
concealed O
random O
allocation O
to O
a O
target O
glucose O
range O
of O
5 O
to O
7 O
or O
8 O
to O
10 O
mmol/L O
using O
pretested O
algorithms O
of O
insulin O
infusions O
. O
[]

Most O
modern O
defibrillators O
used O
for O
the O
cardioversion O
of O
atrial O
fibrillation O
( O
AF O
) O
employ O
high-tilt O
, O
capacitor-based O
biphasic O
waveforms O
. O
[]

Many O
kinds O
of O
blood O
purifying O
technologies O
have O
been O
applied O
to O
the O
treatment O
of O
critically O
ill O
patients O
since O
1979 O
when O
plasma O
exchange O
with O
hollow-fiber O
membranes O
was O
developed O
. O
[]

212 O
TKA O
patients O
were O
enrolled O
in O
a O
double O
blind O
randomized O
controlled O
trial O
to O
receive O
either O
a O
traditional O
implant O
or O
one O
which O
incorporated O
new O
design O
features O
. O
[]

MATERIAL O
AND O
METHODS O
Fifteen O
patients O
, O
each O
with O
a O
pair O
of O
contralateral O
class-II O
proximal O
furcation O
involvements O
, O
presenting O
probing O
depths O
( O
PDs O
) O
> O
/=5 O
mm O
and O
bleeding O
on O
probing O
( O
BOP O
) O
were O
selected O
. O
[]

A O
total O
of O
91 O
patients O
showing O
a O
minimal O
myoma O
> O
5 O
cm O
, O
excluding O
pedunculated O
myomas O
, O
underwent O
LM O
alone O
: O
32 O
patients O
in O
the O
control O
group O
, O
29 O
in O
the O
fibrin O
gel O
group O
and O
30 O
patients O
in O
the O
fibrin O
sheet O
group O
. O
[]

a O
traditional O
herbal O
medicine O
which O
was O
used O
in O
Thailand O
for O
decades O
, O
for O
the O
treatment O
of O
mild O
and O
mild O
to O
moderate O
ED O
in O
Thai O
patients O
. O
[]

Significant O
parameters O
for O
survival O
prediction O
at O
univariate O
analysis O
are O
: O
DeltaWMSI O
( O
chi-square O
20.1 O
; O
p O
< O
0.0000 O
) O
, O
New O
York O
Heart O
Association O
( O
NYHA O
) O
class O
( O
chi-square O
17.57 O
; O
p O
< O
0.0000 O
) O
, O
rest O
ejection O
fraction O
( O
chi-square O
10.41 O
; O
p O
= O
0.0013 O
) O
, O
angiotensin-converting O
enzyme O
inhibitors O
( O
chi-square O
8.23 O
; O
p O
= O
0.0041 O
) O
, O
and O
hypertension O
( O
chi-square O
8.08 O
, O
p O
= O
0.0045 O
) O
. O
[]

METHODS O
A O
total O
of O
120 O
patients O
hospitalised O
for O
CHF O
were O
randomised O
to O
receive O
a O
pharmacist O
directed O
post-discharge O
home O
medication O
review O
( O
n O
= O
64 O
, O
53.3 O
% O
) O
or O
standard O
care O
( O
n O
= O
56 O
, O
46.7 O
% O
) O
. O
[]

The O
number O
of O
daytime B-outcome ['Physiological-Clinical']
and O
nighttime B-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
the O
use B-outcome ['Resource-use']
of I-outcome ['Resource-use']
beta2-agonist I-outcome ['Resource-use']
increased O
in O
the O
placebo O
group O
, O
whereas O
they O
remained O
unchanged O
in O
the O
ONO-1078 O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

In O
general O
, O
the O
Pakistanis O
avoided O
any O
direct O
sunshine O
exposure O
, O
and O
no O
relation O
between O
outdoor O
activity O
and O
serum O
level O
of O
25-hydroxyvitamin O
D3 O
was O
found O
. O
[]

Twenty O
surgeons O
were O
presented O
objects O
in O
a O
random O
order O
, O
with O
participants O
blinded O
as O
to O
their O
identity O
. O
[]

Tolfenamic O
acid O
is O
a O
potent O
inhibitor O
of O
prostaglandin O
biosynthesis O
, O
which O
has O
been O
proved O
effective O
in O
the O
treatment O
of O
acute B-outcome ['Physiological-Clinical']
migraine I-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
aim O
of O
this O
double-blind O
study O
was O
to O
evaluate O
the O
effect O
of O
low O
power O
Ga-Al-As O
laser O
treatment O
on O
chronic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
related O
to O
osteoarthritis O
of O
the O
knee O
with O
periarticular O
tender O
points O
. O
['Physiological-Clinical']

We O
compared O
the O
impact O
of O
an O
interactive O
, O
patient-oriented O
group O
program O
to O
a O
lecture-based O
, O
information-only O
program O
in O
gastric O
cancer O
patients O
. O
[]

RESULTS O
Fresh-start B-outcome ['Life-Impact']
experiences I-outcome ['Life-Impact']
and O
a O
standard B-outcome ['Life-Impact']
attachment I-outcome ['Life-Impact']
style I-outcome ['Life-Impact']
were O
found O
to O
enhance O
chances O
of O
remission B-outcome ['Physiological-Clinical']
, O
with O
new O
severe O
stressors O
and O
markedly O
poor O
coping O
strategies O
liable O
to O
prevent O
it O
, O
with O
volunteer O
befriending O
continuing O
to O
play O
a O
role O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Dentine O
is O
considerably O
more O
susceptible O
than O
enamel O
to O
erosion B-outcome ['Physiological-Clinical']
and O
abrasion B-outcome ['Physiological-Clinical']
alone O
or O
combined O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Vitality B-outcome ['Physiological-Clinical']
scores O
were O
lower O
in O
those O
with O
cirrhosis O
, O
and O
treated O
patients O
experienced O
a O
greater O
decline O
over O
time O
than O
untreated O
patients O
; O
HRQOL O
rebounded O
after O
treatment O
ended O
. O
['Physiological-Clinical']

Overall O
, O
Skp2 B-outcome ['Physiological-Clinical']
overexpression I-outcome ['Physiological-Clinical']
was O
observed O
in O
36.7 O
% O
( O
37 O
of O
102 O
) O
patients O
and O
was O
significantly O
associated O
with O
lymph O
node O
metastasis O
( O
p=0.002 O
) O
and O
was O
inversely O
associated O
with O
p27kip1 O
expression O
( O
p=0.026 O
) O
. O
['Physiological-Clinical']

Participants O
were O
randomly O
allocated O
to O
Study O
and O
Control O
groups O
. O
[]

MEG B-outcome ['Physiological-Clinical']
premotor I-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
in O
children O
with O
Asperger O
's O
syndrome O
: O
determinants O
of O
social B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
? O
['Physiological-Clinical', 'Life-Impact']

The O
combined O
orange O
juice O
and O
toothpaste O
effects O
were O
directional O
for O
synergy O
but O
did O
not O
reach O
significance O
. O
[]

Measurement O
of O
7alpha-hydroxy-5,11-diketotetranoprostane-1,16-dioic O
acid O
, O
( O
PGE-M O
) O
, O
the O
major O
urinary O
metabolite O
of O
prostaglandin O
E1 O
and O
E2 O
in O
man O
provides O
a O
useful O
indicator O
to O
monitor O
prostaglandin O
biosynthesis O
. O
[]

Buprenorphine O
alone O
and O
in O
combination O
with O
naloxone O
in O
non-dependent O
humans O
. O
[]

We O
conclude O
that O
though O
CLA O
supplementation O
and O
exercise O
can O
affect O
these O
parameters O
, O
CLA O
is O
not O
more O
effective O
than O
exercise O
alone O
. O
[]

The O
lag O
phases B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
were O
significantly O
prolonged O
with O
doses O
> O
or O
= O
400 O
IU/d O
of O
RRR-AT O
and O
all-rac-AT O
, O
as O
measured O
by O
conjugated-dienes O
assay O
and O
at O
400 O
IU/d O
of O
RRR-AT O
and O
800 O
IU/d O
of O
both O
forms O
of O
AT O
by O
lipid O
peroxide O
assay O
. O
['Physiological-Clinical']

Iron O
in O
relation O
to O
gastric O
cancer O
in O
the O
Alpha-tocopherol O
, O
Beta-carotene O
Cancer O
Prevention O
Study O
. O
[]

Prior O
observations O
suggested O
potential O
advantages O
for O
dexamethasone O
over O
prednisone O
and O
for O
intravenous O
( O
IV O
) O
over O
oral O
6-mercaptopurine O
, O
which O
remain O
to O
be O
validated O
. O
[]

Randomized O
controlled O
trial O
of O
entecavir O
prophylaxis O
for O
rituximab-associated O
hepatitis O
B O
virus O
reactivation O
in O
patients O
with O
lymphoma O
and O
resolved O
hepatitis O
B O
. O
[]

METHODS O
A O
single-centre O
, O
double-blind O
, O
randomized O
, O
placebo-controlled O
study O
was O
performed O
in O
48 O
type O
2 O
diabetic O
patients O
with O
late-term O
failure O
following O
at O
least O
3 O
years O
of O
sulphonylurea O
therapy O
requiring O
additional O
insulin O
therapy O
to O
determine O
the O
impact O
of O
acarbose O
on O
glycaemic O
control O
and O
insulin O
requirements O
. O
[]

All O
12 O
departments O
participated O
. O
[]

There O
was O
a O
significant O
dose O
related O
decrease O
in O
the O
fractional O
recovery O
of O
3-MX O
and O
1-MU O
( O
p O
< O
0.001 O
) O
and O
a O
dose O
related O
increase O
in O
fractional B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
DMU I-outcome ['Physiological-Clinical']
and O
unchanged O
theophylline O
( O
p O
< O
0.01 O
and O
p O
< O
0.001 O
respectively O
) O
. O
['Physiological-Clinical']

Caregivers O
reported O
on O
the O
frequency O
of O
troublesome B-outcome ['Life-Impact']
patient I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
their O
reactions B-outcome ['Life-Impact']
to O
them O
at O
baseline O
and O
at O
regular O
follow-up O
interviews O
. O
['Life-Impact']

In O
arm O
B O
, O
8 O
patients O
suffered O
major O
complications O
, O
3 O
patients O
incurred O
with O
minor O
complications O
and O
26 O
patients O
got O
primary O
healing O
of O
the O
perineal O
wounds O
. O
[]

For O
patients O
with O
CrCl O
between O
10 O
and O
50 O
ml/min O
, O
the O
levels O
achieved O
were O
low O
and O
these O
patients O
would O
likely O
benefit O
from O
increased O
doses O
. O
[]

METHOD O
We O
investigated O
the O
effects O
of O
risperidone O
( O
N=16 O
) O
, O
olanzapine O
( O
N=18 O
) O
and O
low O
doses O
of O
haloperidol O
( O
N=18 O
) O
in O
cortical O
thickness O
changes O
during O
1-year O
follow-up O
period O
in O
a O
large O
and O
heterogeneous O
sample O
of O
schizophrenia O
spectrum O
patients O
. O
[]

Acupuncture O
versus O
venlafaxine O
for O
the O
management O
of O
vasomotor B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
patients O
with O
hormone O
receptor-positive O
breast O
cancer O
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

In O
part O
I O
the O
patients O
received O
omeprazole O
, O
80 O
mg O
+ O
8 O
mg/h O
, O
during O
24 O
h O
followed O
by O
8 O
, O
4 O
or O
2 O
mg/h O
. O
[]

General O
practitioners O
are O
required O
to O
offer O
regular O
health O
checks O
to O
healthy O
people O
, O
in O
spite O
of O
the O
lack O
of O
scientific O
evidence O
for O
the O
universal O
need O
, O
usefulness O
and O
side O
effects O
of O
such O
an O
intervention O
. O
[]

A O
randomized O
, O
controlled O
trial O
. O
[]

The O
study O
implies O
that O
economic O
empowerment O
; O
strengthening O
health O
literacy O
through O
planned O
educational O
programs O
will O
definitely O
improve O
the O
health O
behaviour O
of O
individual O
and O
community O
at O
large O
. O
[]

The O
data O
were O
statistically O
analyzed O
by O
one O
way O
ANOVA O
with O
Post O
Hoc O
Tukey O
HSD O
test O
( O
p O
= O
0.05 O
) O
. O
[]

Although O
statistical O
analysis O
was O
not O
conducted O
because O
of O
the O
small O
number O
of O
subjects O
, O
all O
subjects O
receiving O
repeated O
oral O
administration O
of O
300 O
mg O
twice O
daily O
showed O
a O
25 O
% O
decrease O
in O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
level O
on O
day O
7 O
, O
but O
also O
the O
simultaneous O
occurrence O
of O
diarrhoea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHOD O
Mecamylamine O
, O
because O
of O
its O
safety O
record O
in O
children O
with O
other O
disorders O
, O
was O
chosen O
for O
this O
first O
exploration O
. O
[]

In O
the O
present O
study O
we O
observed O
a O
tendency O
of O
the O
lower O
recurrence O
rate O
in O
the O
immunized O
group O
, O
and O
we O
hypothesize O
that O
OK-432 O
is O
effective O
in O
extending O
the O
recurrence-free O
period O
. O
[]

In O
the O
first O
Stroke O
Prevention O
in O
Atrial O
Fibrillation O
( O
SPAF-I O
) O
study O
, O
direct O
comparison O
of O
warfarin O
with O
aspirin O
was O
limited O
by O
the O
small O
number O
of O
thromboembolic O
events O
. O
[]

The O
effect O
of O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
GM-CSF O
) O
on O
the O
serological B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
at O
influenza O
vaccination O
was O
studied O
in O
117 O
patients O
who O
had O
undergone O
stem O
cell O
transplantation O
( O
SCT O
) O
. O
['Physiological-Clinical']

There O
was O
a O
significant O
interaction O
between O
baseline O
length O
and O
intervention O
( O
P O
= O
.04 O
) O
; O
in O
children O
with O
below-median O
length O
at O
enrollment O
, O
those O
given O
FS50 O
gained O
a O
mean O
of O
1.9 O
cm O
more O
than O
individuals O
receiving O
LP O
. O
[]

RESULTS O
After O
16 O
weeks O
, O
weight O
loss B-outcome ['Physiological-Clinical']
was O
similar O
in O
response O
to O
each O
diet O
; O
the O
overall O
decrease O
was O
7.9+/-0.6 O
kg O
( O
P O
< O
0.001 O
) O
, O
of O
which O
6.8+/-0.5 O
kg O
was O
fat O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

METHODS O
The O
study O
was O
performed O
on O
16 O
lesions O
, O
either O
superficial O
basal O
cell O
carcinoma O
( O
BCC O
) O
or O
Bowen O
's O
disease O
( O
BD O
) O
. O
[]

Fifty O
percent O
of O
esmolol-treated O
patients O
with O
new O
onset O
of O
arrhythmias O
converted B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
sinus I-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
, O
whereas O
only O
12 O
% O
of O
those O
who O
received O
verapamil O
converted O
( O
p O
less O
than O
0.03 O
) O
. O
['Physiological-Clinical']

Since O
previous O
findings O
suggested O
that O
a O
nimodipine O
effect O
can O
only O
be O
demonstrated O
when O
individual O
differences O
in O
the O
baseline-EEG O
are O
considered O
, O
the O
subjects O
were O
subdivided O
in O
equal O
subgroups O
according O
to O
the O
number O
of O
non-A O
epochs O
under O
placebo O
. O
[]

The O
antihypertensive O
treatment O
decreased O
serum O
MDA O
levels O
but O
increased O
SOD O
content O
, O
and O
probucol O
treatment O
exaggerated O
these O
effects O
, O
with O
greater O
reduction O
of O
serum B-outcome ['Physiological-Clinical']
MDA I-outcome ['Physiological-Clinical']
levels O
and O
greater O
increase O
of O
SOD B-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
gradual O
increase O
of O
AP-1 O
activation O
was O
found O
in O
non-progressive O
and O
progressive O
phases O
of O
atherosclerosis O
respectively O
( O
P O
< O
0.044 O
) O
. O
[]

The O
colon B-outcome ['Physiological-Clinical']
cleansing I-outcome ['Physiological-Clinical']
efficacy O
of O
the O
different O
preparations O
was O
rated O
using O
the O
Ottawa B-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
preparation I-outcome ['Physiological-Clinical']
scale O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
hyperthyroxinemia O
on O
TAFI O
was O
studied O
in O
healthy O
volunteers O
who O
were O
randomised O
to O
receive O
levothyroxine O
or O
no O
medication O
for O
14 O
days O
in O
a O
crossover O
design O
. O
[]

Twelve O
years O
after O
the O
beginning O
of O
the O
trials O
on O
PAN O
and O
CSS O
patients O
, O
we O
think O
that O
the O
therapeutic O
strategy O
should O
be O
as O
follows O
: O
In O
PAN O
without O
HBV O
and O
CSS O
: O
prednisone O
in O
association O
with O
CYC O
improves O
the O
control O
of O
the O
disease B-outcome ['Physiological-Clinical']
despite O
infectious B-outcome ['Physiological-Clinical']
side I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
which O
may O
be O
reduced O
by O
better O
CYC O
dose O
adaptation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
maternal O
and O
fetal O
outcomes O
were O
compared O
. O
[]

It O
is O
of O
utmost O
importance O
to O
identify O
patients O
at O
risk O
for O
malnutrition O
in O
order O
to O
prevent O
related O
complications O
. O
[]

However O
, O
no O
data O
are O
available O
on O
the O
characteristics O
of O
GH O
secretion O
in O
patients O
with O
incidentally O
discovered O
adrenal O
adenomas O
. O
[]

DESIGN O
Prospective O
controlled O
study O
. O
[]

In O
experiment O
3b O
, O
a O
two-diameter O
length O
of O
bone O
was O
removed O
. O
[]

Serum O
specimens O
( O
or O
plasma O
from O
patients O
on O
hemodialysis O
) O
obtained O
at O
steady O
state O
were O
analyzed O
for O
GCV O
concentrations O
by O
high-performance O
liquid O
chromatography O
. O
[]

CONCLUSIONS O
In O
our O
manikin O
study O
, O
NFT O
was O
reduced O
significantly O
when O
the O
LTS-D O
was O
used O
when O
compared O
to O
ET O
and O
BMV O
. O
[]

Determinants O
of O
total O
and O
specific O
IgE O
in O
infants O
with O
atopic O
dermatitis O
. O
[]

This O
study O
suggested O
a O
beneficial O
influence O
of O
normothermic O
CPB O
on O
postoperative B-outcome ['Physiological-Clinical']
hemodynamics I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVES O
To O
evaluate O
the O
efficacy O
of O
isoniazid O
for O
the O
prevention O
of O
tuberculosis O
in O
tuberculin O
skin O
test-positive O
and O
negative O
individuals O
with O
HIV O
infection O
. O
[]

1 O
year O
. O
[]

Beat-to-beat O
heart O
rate O
( O
HR O
) O
and O
spectral O
power O
analysis O
of O
heart O
rate O
variability O
, O
low O
frequency O
power O
( O
LF O
) O
, O
high O
frequency O
power O
( O
HF O
) O
, O
and O
LF/HF O
ratio O
were O
measured O
in O
26 O
infants O
. O
[]

Increasing O
NT-ANP B-outcome ['Physiological-Clinical']
( O
hazard O
ratio O
[ O
HR O
] O
3.45 O
, O
p O
= O
0.009 O
) O
and O
norepinephrine O
( O
HR O
2.04 O
, O
p O
= O
0.02 O
) O
over O
time O
independently O
predicted O
increased O
risk O
for O
subsequent O
death B-outcome ['Mortality']
or O
heart B-outcome ['Resource-use']
failure I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Mortality', 'Resource-use']

Nicotine O
caused O
a O
small O
overall O
reduction O
in O
global B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
but O
, O
when O
the O
data O
were O
normalized O
, O
several O
brain O
regions O
showed O
relative O
increases O
in O
activity O
. O
['Physiological-Clinical']

Recently O
, O
we O
demonstrated O
that O
FOXP3 O
( O
+ O
) O
regulatory O
T O
( O
Treg O
) O
cells O
mediate O
the O
immunosuppression O
in O
large O
genital O
warts O
. O
[]

Baseline O
patient O
characteristics O
, O
anesthetic O
treatment O
, O
and O
potential O
confounding O
factors O
were O
recorded O
. O
[]

Thirty O
patients O
undergoing O
elective O
cholecystectomy O
were O
allocated O
randomly O
to O
receive O
an O
infusion O
of O
morphine O
or O
an O
infusion O
of O
placebo O
( O
control O
group O
) O
for O
24 O
hours O
. O
[]

Detection O
of O
traumatic O
arthrotomy O
of O
the O
knee O
using O
the O
saline O
solution O
load O
test O
. O
[]

4 O
. O
[]

In O
order O
to O
identify O
healthcare B-outcome ['Resource-use']
resource I-outcome ['Resource-use']
use I-outcome ['Resource-use']
patterns I-outcome ['Resource-use']
associated O
with O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
, O
resource O
utilization O
( O
RU O
) O
data O
collection O
was O
integrated O
into O
a O
randomized O
, O
double-blind O
placebo-controlled O
study O
of O
Viozan O
( O
sibenadet O
HCl O
) O
. O
['Resource-use']

Blood O
pressure O
control O
during O
weight O
reduction O
in O
obese O
hypertensive O
men O
: O
separate O
effects O
of O
sodium O
and O
energy O
restriction O
. O
[]

0.4 O
and O
8.1 O
? O
[]

Of O
the O
patients O
with O
previous O
CABG O
, O
those O
who O
had O
undergone O
?1 O
saphenous O
vein O
graft O
intervention O
had O
significantly O
higher O
adjusted O
risks O
of O
cardiac O
death O
( O
hazard O
ratio O
2.21 O
, O
95 O
% O
confidence O
interval O
1.26 O
to O
3.76 O
, O
p O
= O
0.01 O
) O
, O
myocardial O
infarction O
( O
hazard O
ratio O
2.56 O
, O
95 O
% O
confidence O
interval O
1.10 O
to O
5.60 O
, O
p O
= O
0.03 O
) O
, O
target O
lesion O
revascularization O
( O
hazard O
ratio O
2.65 O
, O
95 O
% O
confidence O
interval O
1.82 O
to O
3.81 O
, O
p O
< O
0.001 O
) O
, O
and O
definite O
stent O
thrombosis O
( O
hazard O
ratio O
7.70 O
, O
95 O
% O
confidence O
interval O
1.99 O
to O
29.1 O
, O
p O
= O
0.004 O
) O
compared O
with O
those O
who O
underwent O
percutaneous O
coronary O
intervention O
only O
for O
the O
native O
coronary O
artery O
. O
[]

A O
decrease O
in O
collagen-induced B-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
by O
using O
washed O
platelet O
suspensions O
was O
found O
in O
both O
groups O
after O
nutritional O
supplementation O
. O
['Physiological-Clinical']

Therefore O
, O
we O
conclude O
that O
4-week O
H-AT O
intervention O
reduced O
senescent O
T-lymphocyte O
subsets O
with O
increasing O
IFN-? O
level O
in O
blood O
, O
which O
responses O
are O
accompanied O
by O
depressed O
oxidative O
stress O
and O
pro-inflammatory O
cytokine O
production O
. O
[]

Primary O
end O
point O
will O
be O
the O
conversion O
of O
[]

CONCLUSIONS O
A O
walnut-enriched O
ad O
libitum O
diet O
improves O
endothelium-dependent O
vasodilatation O
in O
type O
2 O
diabetic O
individuals O
, O
suggesting O
a O
potential O
reduction O
in O
overall O
[]

PTCA O
also O
resulted O
in O
lower O
rates O
of O
death B-outcome ['Mortality']
or O
reinfarction B-outcome ['Physiological-Clinical']
( O
1.4 O
% O
vs O
18.0 O
% O
, O
p O
= O
0.0009 O
) O
, O
recurrent B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
( O
11.3 O
% O
vs O
28.4 O
% O
, O
p O
= O
0.01 O
) O
, O
and O
stroke B-outcome ['Physiological-Clinical']
( O
0.0 O
% O
vs O
6.0 O
% O
, O
p O
= O
0.037 O
) O
in O
anterior O
wall O
AMI O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Medical O
students O
on O
these O
integrated O
courses O
have O
reported O
a O
lack O
of O
confidence O
in O
their O
basic O
science O
knowledge O
, O
especially O
concerning O
anatomy O
. O
[]

BACKGROUND O
Although O
collaborative O
care O
is O
effective O
for O
treating O
depression O
and O
other O
mental O
disorders O
in O
primary O
care O
, O
there O
have O
been O
no O
randomized O
trials O
of O
collaborative O
care O
specifically O
for O
patients O
with O
Posttraumatic O
stress O
disorder O
( O
PTSD O
) O
. O
[]

Women O
were O
randomly O
assigned O
to O
1 O
of O
3 O
groups O
: O
1 O
) O
control O
: O
continue O
established O
dietary O
intake O
; O
2 O
) O
medium O
dairy O
: O
substitute O
dairy O
products O
to O
achieve O
intake O
of O
calcium O
of O
approximately O
1000-1100 O
mg/d O
and O
maintain O
isocaloric O
intake O
; O
3 O
) O
high O
dairy O
: O
substitute O
dairy O
products O
to O
achieve O
intake O
of O
calcium O
of O
1300-1400 O
mg/d O
and O
maintain O
isocaloric O
intake O
. O
[]

More O
patients O
on O
the O
L-20 O
arm O
failed O
with O
resistant B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( O
21 O
% O
vs O
8 O
% O
; O
P O
= O
.02 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
Our O
purpose O
was O
to O
evaluate O
the O
efficacy O
of O
a O
triphasic O
, O
combination O
OC O
( O
ORTHO O
TRI-CYCLEN O
[ O
Ortho-McNeil O
Pharmaceutical O
, O
Raritan O
, O
N.J. O
] O
, O
norgestimate/ethinyl O
estradiol O
) O
compared O
with O
placebo O
in O
the O
treatment O
of O
moderate O
acne O
vulgaris O
. O
[]

In O
the O
group O
followed O
for O
3 O
to O
15 O
months O
, O
1 O
cryotherapy-treated O
eye O
and O
1 O
diode O
laser-treated O
eye O
progressed B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
5 I-outcome ['Physiological-Clinical']
retinal I-outcome ['Physiological-Clinical']
detachment I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

These O
design O
considerations O
include O
the O
definition O
of O
inclusion O
criteria O
that O
are O
relevant O
to O
clinical O
practice O
and O
matching O
study O
design O
to O
the O
goal O
of O
evaluating O
short- O
and O
long-term O
effects O
. O
[]

This O
disease O
can O
greatly O
reduce O
the O
affected O
individual O
's O
walking O
capacity O
and O
can O
seriously O
affect O
daily O
life O
activities O
. O
[]

Urine B-outcome ['Physiological-Clinical']
samples O
were O
collected O
before O
and O
after O
14 O
d O
of O
supplementation O
with O
300 O
microg O
( O
1.2 O
micromol O
) O
biotin/d O
or O
placebo O
. O
['Physiological-Clinical']

All O
patients O
received O
total O
abdominal O
hysterectomy O
and O
bilateral O
salpingo-oophorectomy O
plus O
complementary O
radium O
therapy O
on O
the O
vaginal O
stump O
. O
[]

Mean O
hemoglobin B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
compared O
on O
ICU O
admission O
and O
at O
12-hr O
intervals O
. O
['Physiological-Clinical']

BACKGROUND O
There O
is O
a O
growing O
body O
of O
evidence O
that O
advanced O
glycation O
end O
products O
( O
AGE O
) O
and O
their O
receptor O
( O
RAGE O
) O
system O
are O
implicated O
in O
chronic O
kidney O
disease O
( O
CKD O
) O
. O
[]

An O
experimental O
design O
was O
used O
to O
test O
the O
effectiveness O
of O
this O
program O
. O
[]

Sixty O
patients O
undergoing O
ambulatory O
anterior O
cruciate O
ligament O
repair O
of O
the O
knee O
under O
spinal O
anesthesia O
were O
randomized O
into O
two O
groups O
; O
Group O
1 O
( O
29 O
patients O
) O
received O
4 O
mL O
of O
1.5 O
% O
( O
60-mg O
dose O
) O
and O
Group O
2 O
( O
31 O
patients O
) O
received O
4 O
mL O
of O
2 O
% O
( O
80-mg O
dose O
) O
of O
plain O
mepivacaine O
. O
[]

Hypothermia O
is O
a O
common O
problem O
for O
surgical O
patients O
and O
can O
result O
in O
many O
complications O
. O
[]

After O
ovarian O
stimulation O
with O
clomiphene O
and O
human O
menopausal O
gonadotrophin O
( O
HMG O
) O
, O
the O
beneficial O
effect O
of O
supporting O
the O
luteal O
phase O
has O
never O
been O
scientifically O
demonstrated O
. O
[]

The O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
was O
a O
stronger O
predictor O
of O
the O
success O
of O
treatment O
than O
was O
the O
assigned O
agent O
. O
['Physiological-Clinical']

Any O
airway B-outcome ['Physiological-Clinical']
difficulties I-outcome ['Physiological-Clinical']
were O
noted O
. O
['Physiological-Clinical']

Two O
exacerbations B-outcome ['Physiological-Clinical']
occurred O
in O
the O
CO O
period O
. O
['Physiological-Clinical']

The O
maximal O
administered O
dose O
for O
each O
regimen O
was O
used O
in O
conjunction O
with O
corresponding O
questionnaire O
scores O
to O
calculate O
an O
index O
or O
estimate O
of O
the O
maximal B-outcome ['Life-Impact']
tolerable I-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
of O
disopyramide O
. O
['Life-Impact']

Dietary O
sodium O
restriction O
alone O
is O
effective O
in O
lowering O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
some O
, O
but O
not O
all O
, O
patients O
with O
essential O
hypertension O
. O
['Physiological-Clinical']

Patients O
' O
postoperative O
pain B-outcome ['Physiological-Clinical']
, O
anxiety B-outcome ['Life-Impact']
, O
blood B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Synthetic O
intakes O
> O
151-410 O
microg/d O
in O
these O
women O
produced O
little O
additional O
benefit O
in O
terms O
of O
maximizing O
RBC O
content O
. O
[]

A O
total O
of O
288 O
parasitologically O
proved O
patients O
of O
kala-azar O
were O
randomly O
allocated O
to O
three O
treatment O
groups O
. O
[]

A O
comparison O
of O
continuous O
femoral O
nerve O
block O
( O
CFNB O
) O
and O
continuous O
epidural O
infusion O
( O
CEI O
) O
in O
postoperative B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
and O
knee B-outcome ['Physiological-Clinical']
rehabilitation I-outcome ['Physiological-Clinical']
after O
total O
knee O
arthroplasty O
( O
TKA O
) O
. O
['Resource-use', 'Physiological-Clinical']

Both O
techniques O
have O
similar O
procedural O
success O
, O
complication O
rates O
, O
and O
follow-up O
events O
. O
[]

STATISTICAL O
ANALYSES O
Means O
( O
+/- O
standard O
error O
) O
were O
calculated O
and O
compared O
with O
target O
nutrient O
specifications O
. O
[]

Treatment O
of O
adults O
with O
acute O
lymphoblastic O
leukemia O
: O
do O
the O
specifics O
of O
the O
regimen O
matter O
? O
: O
[]

Seventy O
patients O
with O
Expanded O
Disability O
Status O
Scale O
scores O
of O
0 O
to O
5.5 O
were O
randomly O
assigned O
to O
receive O
1 O
gram O
of O
valacyclovir O
( O
n O
= O
36 O
) O
or O
placebo O
( O
n O
= O
34 O
) O
three O
times O
daily O
for O
24 O
weeks O
. O
[]

UNLABELLED O
Although O
effective O
in O
neuropathic O
pain O
, O
the O
efficacy O
of O
systemic O
lidocaine O
in O
non-neuropathic O
pain O
remains O
uncertain O
. O
[]

Our O
objective O
was O
to O
study O
the O
effects O
of O
candesartan O
on O
diabetic B-outcome ['Physiological-Clinical']
glomerulopathy I-outcome ['Physiological-Clinical']
in O
young O
normoalbuminuric O
and O
normotensive O
patients O
with O
type O
1 O
diabetes O
in O
a O
double-blind O
, O
placebo-controlled O
trial O
. O
['Physiological-Clinical']

Under O
AH O
therapy O
, O
the O
skin B-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
intradermal I-outcome ['Physiological-Clinical']
histamine I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
was O
significantly O
diminished O
in O
all O
study O
groups O
. O
['Physiological-Clinical']

On O
day O
14 O
of O
Study O
2 O
, O
there O
was O
a O
statistically O
significant O
reduction O
in O
mite B-outcome ['Physiological-Clinical']
counts O
( O
P O
< O
0.008 O
) O
and O
the O
mite B-outcome ['Physiological-Clinical']
counts O
remained O
very O
low O
throughout O
the O
remainder O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Alginate O
impressions O
were O
taken O
of O
each O
dental O
arch O
at O
each O
data O
collection O
point O
. O
[]

Eradication O
of O
H. O
pylori B-outcome ['Physiological-Clinical']
was O
seen O
in O
one O
of O
seven O
patients O
taking O
dirithromycin O
plus O
metronidazole O
. O
['Physiological-Clinical']

However O
, O
MMR O
occurred O
faster O
among O
patients O
randomly O
assigned O
to O
imatinib O
800 O
mg/d O
, O
who O
had O
higher O
rates O
of O
MMR O
at O
3 O
and O
6 O
months O
compared O
with O
those O
in O
the O
imatinib O
400-mg/d O
arm O
( O
P O
= O
.0035 O
by O
log-rank O
test O
) O
. O
[]

Do O
sheltered O
workshops O
enhance O
employment B-outcome ['Life-Impact']
outcomes O
for O
adults O
with O
autism O
spectrum O
disorder O
? O
['Life-Impact']

This O
study O
applied O
a O
12-week O
educational O
intervention O
that O
used O
both O
the O
cellular O
phone O
and O
the O
Internet O
to O
send O
short O
message O
service O
. O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
mostly O
gastrointestinal O
, O
caused O
discontinuation O
of O
treatment O
in O
3.4 O
% O
of O
the O
patients O
in O
the O
clarithromycin O
group O
, O
in O
6.6 O
% O
of O
the O
patients O
in O
the O
roxithromycin O
group O
, O
and O
in O
18.5 O
% O
of O
the O
patients O
in O
the O
erythromycin O
stearate O
group O
. O
['Adverse-effects']

Fluconazole O
is O
widely O
used O
as O
antifungal B-outcome ['Resource-use']
prophylaxis I-outcome ['Resource-use']
but O
it O
is O
ineffective O
against O
Aspergillus O
. O
['Resource-use']

CONCLUSIONS O
Alcohol O
and O
drug O
use O
patterns O
during O
the O
4 O
years O
following O
treatment O
highlight O
both O
changes O
and O
diversity O
in O
substance O
involvement O
as O
youth O
make O
the O
transitions O
from O
middle O
to O
late O
adolescence O
and O
into O
young O
adulthood O
. O
[]

METHODS O
Seventy-one O
children O
aged O
ten O
to O
twelve O
years O
were O
recruited O
to O
participate O
in O
the O
anxiety O
programme O
. O
[]

Previous O
reports O
suggested O
that O
CD19+ B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
are O
markedly O
increased O
in O
myeloma O
patients O
and O
that O
this O
population O
shares O
clonotypic O
rearrangements O
with O
the O
malignant O
plasma O
cell O
. O
['Physiological-Clinical']

Lapatinib O
plus O
vinorelbine O
offers O
an O
effective O
treatment O
option O
for O
patients O
with O
HER2-overexpressing O
MBC O
, O
having O
displayed O
comparable O
efficacy O
and O
tolerability O
rates O
to O
lapatinib O
plus O
capecitabine O
. O
[]

Differences O
in O
treatment O
efficacy O
were O
assessed O
by O
ANCOVA O
. O
[]

In O
both O
experiments O
, O
children O
with O
Autistic O
Spectrum O
Disorder O
were O
presented O
with O
a O
trial-and-error O
discrimination O
task O
using O
two O
, O
two-element O
stimuli O
and O
over-selected O
in O
both O
studies O
. O
[]

Of O
the O
bacteriologically O
evaluable O
patients O
19 O
of O
20 O
showed O
a O
satisfactory B-outcome ['Physiological-Clinical']
bacteriological I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
the O
ofloxacin O
treated O
group O
, O
while O
in O
the O
comparator O
group O
the O
bacteriological O
response O
was O
judged O
satisfactory O
in O
14 O
of O
17 O
patients O
. O
['Physiological-Clinical']

Nevertheless O
, O
GI O
symptoms O
should O
be O
monitored O
in O
all O
patients O
taking O
high O
dose O
DHA O
especially O
those O
with O
personal O
or O
family O
history O
of O
GI O
disturbances O
. O
( O
[]

Results O
show O
a O
lower O
proportion O
of O
video-trained O
teachers O
implemented O
the O
curriculum O
, O
but O
overall O
completeness O
and O
fidelity B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
implementation I-outcome ['Life-Impact']
for O
those O
teachers O
who O
did O
teach O
the O
curriculum O
were O
comparable O
for O
the O
two O
groups O
. O
['Life-Impact']

Marimastat O
treatment O
was O
associated O
with O
the O
development O
of O
musculoskeletal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
inflammation B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eighty-two O
patients O
were O
included O
, O
of O
whom O
16 O
were O
included O
with O
both O
of O
their O
legs O
. O
[]

Median O
( O
95 O
% O
confidence O
interval O
, O
range O
) O
fever B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
were O
4.4 O
( O
4 O
to O
5.2 O
, O
0.2 O
to O
9.9 O
) O
days O
for O
ofloxacin O
recipients O
and O
8.5 O
( O
4.2 O
to O
9 O
, O
1.8 O
to O
15.2 O
) O
days O
for O
cefixime-treated O
patients O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
The O
Sixth O
National O
Nutrition O
Survey O
2003 O
revealed O
that O
the O
highest O
prevalence O
of O
overweight O
and O
obesity O
among O
Filipino O
female O
adults O
( O
30.8 O
% O
) O
was O
found O
in O
the O
age O
group O
from O
40 O
to O
59 O
years O
. O
[]

CONCLUSION O
During O
sub-umbilical O
surgery O
, O
caudal O
levobupivacaine O
, O
ropivacaine O
and O
bupivacaine O
provided O
comparable O
[]

BACKGROUND O
Commonly O
used O
dosage O
protocols O
for O
antimicrobial O
agents O
may O
alter O
the O
rate O
of O
gastric B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Additional O
ethical O
and O
scientific O
issues O
concern O
the O
length O
of O
trial O
and O
sample O
size O
. O
[]

10.9 O
d O
on O
feed O
) O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
and O
RBC O
folate O
values O
at O
16-wk O
postpartum O
correctly O
identified O
the O
quartile O
of O
folate O
intake O
of O
only O
26 O
of O
55 O
( O
47 O
% O
) O
and O
18 O
of O
55 O
( O
33 O
% O
) O
of O
subjects O
, O
respectively O
. O
['Physiological-Clinical']

Reductions O
in O
SVR B-outcome ['Physiological-Clinical']
after O
atracurium O
allowed O
small O
but O
significant O
( O
p O
less O
than O
0.01 O
) O
decreases O
in O
MAP B-outcome ['Physiological-Clinical']
which O
were O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
; O
one O
patient O
, O
however O
, O
did O
develop O
severe O
hypotension B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

This O
randomized O
controlled O
study O
was O
designed O
to O
test O
the O
efficacy O
and O
safety O
of O
percutaneous O
ultrasound O
( O
US O
) O
-guided O
laser O
photocoagulation O
( O
PLP O
) O
for O
treatment O
of O
subjects O
with O
compressive O
symptoms O
due O
to O
benign B-outcome ['Physiological-Clinical']
thyroid I-outcome ['Physiological-Clinical']
nodules I-outcome ['Physiological-Clinical']
and/or O
at O
high O
surgical O
risk O
. O
['Physiological-Clinical']

The O
data O
have O
to O
be O
confirmed O
with O
a O
large-scale O
trial O
. O
[]

RESULTS O
Nonlinear O
PK O
of O
linagliptin O
in O
T2DM O
patients O
were O
well O
described O
by O
a O
2-compartment O
model O
assuming O
concentration-dependent O
binding O
to O
DPP-4 O
in O
the O
central O
and O
peripheral O
compartment O
. O
[]

These O
theoretical O
domains O
will O
inform O
the O
development O
of O
a O
questionnaire O
aimed O
at O
assessing O
the O
implementation O
of O
the O
TUPAC O
counselling O
guidelines O
among O
Finnish O
municipal O
dental O
providers O
. O
[]

CONCLUSION O
Folate B-outcome ['Life-Impact']
intakes I-outcome ['Life-Impact']
, O
estimated O
by O
food O
composition O
tables O
, O
and O
blood B-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
are O
not O
predictive O
of O
each O
other O
in O
Canadian O
lactating O
women O
exposed O
to O
high O
levels O
of O
folate B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
pindolol O
and O
clopamide O
on O
blood B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
in O
arterial O
hypertensive O
patients O
. O
['Physiological-Clinical']

The O
sequence O
of O
test O
conditions O
was O
randomized O
and O
double-blind O
. O
[]

BACKGROUND O
A O
previous O
clinical O
trial O
evaluating O
autologous O
fibroblasts O
( O
human O
dermal O
) O
injections O
for O
the O
treatment O
of O
facial O
contour O
deformities O
found O
significantly O
greater O
improvements O
in O
wrinkle B-outcome ['Physiological-Clinical']
and O
acne B-outcome ['Physiological-Clinical']
scar I-outcome ['Physiological-Clinical']
appearance I-outcome ['Physiological-Clinical']
than O
with O
placebo O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Despite O
less O
experience O
with O
the O
target O
motion O
, O
part O
training O
was O
better O
, O
but O
only O
when O
the O
arm O
trajectory O
was O
decomposed O
into O
anatomical O
components O
. O
[]

The O
protocol O
criteria O
for O
overall B-outcome ['Physiological-Clinical']
therapeutic I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
were O
satisfied O
by O
41 O
% O
of O
the O
amiprilose O
patients O
, O
compared O
with O
21 O
% O
of O
the O
placebo O
group O
( O
P O
= O
0.003 O
) O
. O
['Physiological-Clinical']

Stage O
II O
carcinoma O
of O
the O
ovary O
: O
an O
analysis O
of O
survival B-outcome ['Mortality']
after O
comprehensive O
surgical O
staging O
and O
adjuvant O
therapy O
. O
['Mortality']

There O
were O
no O
differences O
for O
all O
other O
outcome O
measurements O
. O
[]

Clinical O
outcomes O
were O
compared O
and O
the O
variables O
were O
analyzed O
using O
the O
following O
three O
groups O
: O
entire O
populations O
of O
study O
group O
and O
control O
group O
, O
subgroup O
of O
patients O
who O
had O
CABG O
reoperation O
only O
, O
and O
a O
subgroup O
who O
had O
valve O
reoperation O
or O
combined O
valve O
and O
CABG O
reoperation O
. O
[]

There O
was O
no O
statistically O
significant O
difference O
in O
the O
third B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
the O
two O
groups O
. O
['Physiological-Clinical']

During O
maintenance O
, O
5 O
days O
of O
the O
randomized O
steroid O
was O
given O
monthly O
, O
at O
the O
same O
dose O
, O
and O
all O
patients O
received O
daily O
oral O
6-mercaptopurine O
. O
[]

Indobufen O
was O
also O
able O
to O
reduce O
platelet B-outcome ['Physiological-Clinical']
adhesiveness I-outcome ['Physiological-Clinical']
and O
to O
lengthen O
bleeding B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
especially O
when O
the O
higher O
dosage O
was O
used O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Change O
in O
CPSD B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

BACKGROUND O
The O
host O
inflammatory O
response O
has O
a O
vital O
role O
in O
carcinogenesis O
and O
tumour O
progression O
. O
[]

Similarly O
, O
significant O
improvement O
was O
observed O
in O
clinician O
and O
parent O
ratings O
. O
[]

We O
investigated O
the O
feasibility O
of O
two O
intermediate O
dose-dense O
FEC O
regimens O
. O
[]

Reduction O
in O
[]

The O
randomized O
controlled O
study O
( O
n O
= O
10 O
) O
employed O
a O
single O
subject O
comparison O
design O
in O
two O
different O
conditions O
, O
improvisational O
music O
therapy O
and O
toy O
play O
sessions O
, O
and O
DVD O
analysis O
of O
sessions O
. O
[]

The O
study O
was O
conducted O
on O
44 O
patients O
, O
both O
male O
and O
female O
, O
classified O
as O
ASA O
II O
and O
III O
. O
[]

CONCLUSIONS O
The O
addition O
of O
FSC O
to O
subjects O
with O
COPD O
treated O
with O
TIO O
significantly O
improves O
lung O
function O
without O
increasing O
the O
risk O
of O
adverse O
events O
. O
[]

Patient O
navigation O
improved O
diagnostic B-outcome ['Life-Impact']
resolution I-outcome ['Life-Impact']
for O
patients O
presenting O
with O
mammographic O
BIRADS O
3 O
( O
P O
= O
0.0003 O
) O
and O
BIRADS O
0 O
( O
P O
= O
0.09 O
) O
, O
but O
not O
BIRADS O
4/5 O
or O
abnormal O
breast O
examinations O
. O
['Life-Impact']

METHODS O
Oxytocin O
and O
placebo O
challenges O
were O
administered O
to O
15 O
adult O
subjects O
diagnosed O
with O
autism O
or O
Asperger O
's O
disorder O
, O
and O
comprehension O
of O
affective O
speech O
( O
happy O
, O
indifferent O
, O
angry O
, O
and O
sad O
) O
in O
neutral O
content O
sentences O
was O
tested O
. O
[]

21 O
were O
assigned O
at O
random O
to O
the O
MI O
group O
and O
27 O
to O
the O
AI O
group O
. O
[]

STUDY O
DESIGN O
AND O
METHODS O
A O
total O
of O
108 O
iron-deficient O
patients O
were O
randomly O
assigned O
to O
two O
groups O
: O
Group O
C O
( O
control O
) O
or O
Group O
IE O
( O
200 O
mg O
of O
iron O
sucrose O
intravenously O
over O
1 O
hr O
and O
3000 O
IU O
of O
rHuEPO-? O
subcutaneously O
during O
the O
operation O
and O
during O
the O
postoperative O
period O
if O
the O
hemoglobin O
[ O
Hb O
] O
level O
was O
70-80 O
g/L O
) O
. O
[]

METHODS O
Patients O
with O
stage O
I/II O
melanoma O
, O
consecutively O
submitted O
to O
a O
SLN O
procedure O
by O
the O
same O
surgeon O
from O
2000 O
to O
2006 O
, O
were O
evaluated O
. O
[]

Theory O
of O
Mind O
training O
in O
children O
with O
autism B-outcome ['Life-Impact']
: O
a O
randomized O
controlled O
trial O
. O
['Life-Impact']

Patient O
demographics O
, O
indications O
for O
surgery O
, O
preoperative O
and O
postoperative O
International O
Prostate O
Symptom O
Score O
, O
uroflowmetry B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
, O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
catheterization B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
and O
complication B-outcome ['Adverse-effects']
rates O
were O
compared O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Resource-use', 'Adverse-effects']

Blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
during O
surgery O
was O
significantly O
decreased O
. O
['Physiological-Clinical']

The O
results O
suggest O
that O
a O
combination O
of O
atypical O
antipsychotic O
medications O
and O
a O
glutamate O
agent O
such O
as O
piracetam O
, O
might O
have O
increase O
synergistic O
effects O
in O
the O
treatment O
of O
autism O
. O
[]

The O
incidence O
of O
steroid-sensitive B-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
rejections I-outcome ['Physiological-Clinical']
was O
7.9 O
% O
( O
induction O
) O
and O
22.2 O
% O
( O
noninduction O
) O
( O
P=0.001 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
study O
the O
mechanism O
of O
Tongbu O
No O
. O
[]

BACKGROUND O
Oral O
dipyridamole O
induces O
accumulation O
of O
endogenous O
adenosine O
, O
which O
in O
a O
hypoxic O
milieu O
exerts O
experimentally O
an O
angiogenic O
effect O
on O
coronary O
collateral O
circulation O
. O
[]

On O
the O
other O
hand O
, O
gagging B-outcome ['Physiological-Clinical']
occurred O
more O
frequently O
during O
oral O
endoscopy O
( O
6/9 O
vs O
1/9 O
, O
p O
= O
0.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
Preoperative O
clinical O
data O
such O
as O
mean O
age O
, O
lens O
status O
, O
Snellen O
visual O
acuity O
, O
duration O
of O
macular O
detachment O
, O
CD O
( O
size O
and O
extent O
) O
, O
and O
retinal O
detachment O
characteristics O
( O
e.g. O
, O
extent O
, O
number O
of O
retinal O
breaks O
, O
atrophic O
or O
tractional O
retinal O
break O
, O
size O
of O
retinal O
break O
, O
and O
location O
of O
retinal O
break O
) O
were O
similarly O
distributed O
in O
both O
groups O
. O
[]

Topical O
antibiotics O
have O
demonstrated O
varying O
degrees O
of O
success O
in O
the O
management O
of O
discharging O
ears O
. O
[]

Significant O
negative O
correlations O
between O
smoking B-outcome ['Life-Impact']
severity I-outcome ['Life-Impact']
and O
rsFC B-outcome ['Physiological-Clinical']
between I-outcome ['Physiological-Clinical']
insula I-outcome ['Physiological-Clinical']
, O
dACC O
and O
striatum O
were O
found O
for O
both O
groups O
. O
['Life-Impact', 'Physiological-Clinical']

We O
studied O
anthropometric B-outcome ['Physiological-Clinical']
, O
biochemical B-outcome ['Physiological-Clinical']
and O
antioxidant B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
in O
62 O
subjects O
aged O
65-96 O
years O
after O
a O
6-week O
daily O
intake O
of O
polyphenol-rich O
EVOO O
with O
high O
oleuropein O
derivative O
contents O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

UNLABELLED O
It O
has O
been O
postulated O
that O
sensory O
stimulation O
( O
acupuncture O
) O
affects O
the O
cardiovascular O
system O
via O
the O
autonomic O
nervous O
system O
. O
[]

RESULTS O
Results O
indicated O
no O
statistically O
significant O
difference O
in O
outcomes O
between O
the O
two O
time O
points O
. O
[]

METHODS O
A O
randomised O
double-blind O
trial O
comparing O
metformin O
treatment O
( O
850 O
mg O
bid O
) O
with O
placebo O
. O
[]

RESULTS O
At O
week O
6 O
, O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
were O
reduced O
by O
86 O
% O
on O
average O
in O
the O
whole O
group O
of O
patients O
, O
without O
significant O
differences O
between O
the O
two O
progestins O
. O
['Physiological-Clinical']

The O
mean O
age O
, O
baseline O
serum B-outcome ['Physiological-Clinical']
Cr I-outcome ['Physiological-Clinical']
, O
and O
Cr B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CrCl I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
69.3 O
+/- O
10.8 O
years O
, O
2.5 O
+/- O
0.9 O
mg/dL O
, O
and O
31.4 O
+/- O
12.1 O
mL/min O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mastodinia B-outcome ['Physiological-Clinical']
, O
a O
satisfactory O
response O
was O
observed O
in O
100 O
% O
of O
alpha O
dihidroergocriptine O
group O
vs O
61.11 O
% O
of O
placebo O
group O
( O
p O
= O
0.0002 O
) O
. O
['Physiological-Clinical']

METHODS O
Seventy-two O
consecutive O
anti-HBe-positive O
chronic O
hepatitis O
B O
patients O
( O
59 O
male O
and O
13 O
female O
, O
median O
age O
41 O
yr O
) O
stratified O
by O
sex O
and O
histology O
were O
randomly O
allocated O
to O
three O
treatment O
arms O
. O
[]

Risperidone O
[ O
mean O
dose O
( O
+/- O
SD O
) O
: O
1.37 O
mg/day O
( O
0.7 O
) O
] O
resulted O
in O
significantly O
greater O
reduction O
from O
baseline O
to O
endpoint O
in O
ABC-I O
versus O
placebo O
[ O
mean O
change O
( O
+/- O
SD O
) O
: O
-13.4 O
( O
1.5 O
) O
vs. O
-7.2 O
( O
1.4 O
) O
, O
P O
< O
0.05 O
; O
ES=-0.7 O
] O
. O
[]

METHODS O
The O
concentrations O
of O
recombinant B-outcome ['Physiological-Clinical']
human I-outcome ['Physiological-Clinical']
porphobilinogen I-outcome ['Physiological-Clinical']
deaminase B-outcome ['Physiological-Clinical']
and O
titres B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
against I-outcome ['Physiological-Clinical']
recombinant I-outcome ['Physiological-Clinical']
human I-outcome ['Physiological-Clinical']
porphobilinogen B-outcome ['Physiological-Clinical']
deaminase I-outcome ['Physiological-Clinical']
were O
analysed O
by O
ELISA O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Radiation-induced O
brachial O
plexopathy O
: O
neurological O
follow-up O
in O
161 O
recurrence-free O
breast O
cancer O
patients O
. O
[]

Investigator-rated O
pain B-outcome ['Physiological-Clinical']
and O
tenderness B-outcome ['Physiological-Clinical']
scores O
favored O
dexamethasone O
over O
placebo O
at O
2 O
days O
. O
['Physiological-Clinical', 'Physiological-Clinical']

in O
J O
Child O
Psychol O
Psychiatry O
50:224-234 O
, O
2009 O
) O
, O
children O
's O
daily O
living O
skills O
and O
related O
parental B-outcome ['Life-Impact']
intrusiveness I-outcome ['Life-Impact']
were O
assessed O
. O
['Life-Impact']

CONCLUSION O
CM O
administered O
for O
2 O
wk O
significantly O
improved O
clinical O
measurements O
of O
autism O
severity O
and O
decreased O
serum O
level O
of O
TARC O
in O
autistic O
children O
, O
but O
subsequent O
studies O
are O
recommended O
. O
[]

Primary O
outcome O
measures O
for O
assessment O
of O
arm O
function B-outcome ['Life-Impact']
are O
the O
Action O
Research O
Arm O
Test O
( O
ARAT O
) O
and O
Wolf O
Motor O
Function O
Test O
( O
WMFT O
) O
. O
['Life-Impact']

BACKGROUND O
The O
purpose O
of O
this O
study O
was O
to O
compare O
home O
and O
ambulatory O
blood O
pressure O
( O
BP O
) O
in O
the O
adjustment O
of O
antihypertensive O
treatment O
. O
[]

BACKGROUND O
In O
older O
people O
, O
undernutrition O
is O
associated O
with O
increased O
hospitalization B-outcome ['Resource-use']
rates O
and O
mortality B-outcome ['Mortality']
. O
['Resource-use', 'Mortality']

RESULTS O
Sialyl O
Lewis O
( O
a O
) O
expression O
levels O
were O
correlated O
with O
both O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
= O
0.0006 O
) O
and O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
= O
0.004 O
) O
in O
all O
patients O
with O
the O
log-rank O
test O
. O
['Mortality', 'Mortality']

We O
recently O
assessed O
efficacy O
of O
high-dose O
DHA O
supplementation O
to O
slow O
vision B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
patients O
with O
X-linked O
retinitis O
pigmentosa O
( O
XLRP O
) O
in O
a O
randomized O
clinical O
trial O
. O
['Physiological-Clinical']

Mean O
baseline O
vasomotor O
symptoms O
frequency O
was O
7.6/day O
, O
and O
the O
mean O
baseline O
total O
MENQOL O
score O
was O
3.8 O
( O
range O
, O
1-8 O
from O
better O
to O
worse O
) O
with O
no O
between-group O
differences O
. O
[]

RESULTS O
Fifty-four O
( O
51 O
% O
) O
of O
the O
105 O
eyes O
in O
the O
5-fluorouracil O
group O
and O
80 O
( O
74 O
% O
) O
of O
the O
108 O
eyes O
in O
the O
standard O
filtering O
surgery O
group O
were O
classified O
as O
failures O
( O
P O
< O
.001 O
, O
Mantel-Cox O
survival O
analysis O
) O
. O
[]

OBJECTIVE O
In O
an O
attempt O
to O
investigate O
the O
prophylactic O
effect O
of O
a O
thromboxane O
A2 O
( O
TXA2 O
) O
synthetase O
inhibitor O
on O
pregnant O
women O
with O
a O
high O
risk O
of O
preeclampsia O
, O
the O
following O
clinical O
study O
was O
undertaken O
. O
[]

A O
randomized O
double-blind O
placebo-controlled O
study O
of O
the O
long-term O
efficacy O
and O
safety O
of O
diethylpropion O
in O
the O
treatment O
of O
obese O
subjects O
. O
[]

group O
2 O
-- O
203 O
patients O
given O
160/800 O
mg. O
trimethoprimsulfamethoxazole O
and O
group O
3 O
-- O
199 O
controls O
given O
no O
antimicrobial O
prophylaxis O
. O
[]

These O
findings O
were O
not O
as O
evident O
when O
outcomes O
where O
clozapine O
was O
not O
clearly O
superior O
( O
psychotic B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
weight O
gain O
) O
were O
examined O
. O
['Physiological-Clinical']

There O
were O
no O
differences O
in O
postoperative B-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
nor O
in O
the O
amount O
of O
pain B-outcome ['Physiological-Clinical']
or O
discomfort B-outcome ['Physiological-Clinical']
between O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Seventy-nine O
patients O
with O
history O
and O
physical O
findings O
characteristic O
of O
antenatal O
DES O
exposure O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

The O
results O
showed O
that O
risperidone O
, O
when O
administered O
with O
galantamine O
, O
did O
not O
change O
the O
bioavailability B-outcome ['Physiological-Clinical']
of O
galantamine O
at O
steady O
state O
. O
['Physiological-Clinical']

BACKGROUND O
GS-9620 O
is O
a O
novel O
oral O
agonist O
of O
Toll-like O
receptor O
7 O
( O
TLR7 O
) O
in O
development O
for O
the O
treatment O
of O
chronic O
viral O
hepatitis O
. O
[]

[ O
Profiles O
of O
irregular B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
induced O
by O
low-dose O
hormone O
therapy O
and O
Chinese O
formulated O
herbs O
products O
] O
. O
['Physiological-Clinical']

Secondary O
prevention O
of O
macrovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
patients O
with O
type O
2 O
diabetes O
in O
the O
PROactive O
Study O
( O
PROspective O
pioglitAzone O
Clinical O
Trial O
In O
macroVascular O
Events O
) O
: O
a O
randomised O
controlled O
trial O
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
isoflavone I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical']

Acute O
reduction O
of O
arterial O
blood O
pressure O
reduces O
urinary B-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
in O
type O
1 O
( O
insulin-dependent O
) O
diabetic O
patients O
with O
incipient O
nephropathy O
. O
['Physiological-Clinical']

The O
90 O
% O
confidence O
intervals O
for O
the O
ratio O
of O
log O
transformed O
values O
of O
Cmax O
, O
AUC0-t O
, O
and O
AUCt-? O
of O
the O
2 O
treatments O
were O
within O
the O
acceptable O
range O
( O
0.8-1.25 O
) O
for O
bioequivalence O
. O
[]

BACKGROUND O
Although O
no O
randomized O
controlled O
trial O
has O
assessed O
the O
effects O
of O
either O
compression O
sclerotherapy O
or O
ambulatory O
phlebectomy O
, O
both O
techniques O
are O
used O
to O
treat O
varicose O
veins O
worldwide O
. O
[]

METHODS O
To O
further O
investigate O
the O
importance O
of O
G84E O
in O
the O
Finns O
, O
we O
determined O
its O
frequency O
in O
more O
than O
4,000 O
prostate O
cancer O
cases O
and O
5,000 O
controls O
. O
[]

Whether O
regression O
of O
LV O
mass O
by O
ARBs O
is O
correlated O
to O
ROS O
formation O
by O
monocytes O
and O
CRP O
is O
not O
fully O
understood O
yet O
. O
[]

There O
were O
no O
serious O
complications O
with O
this O
procedure O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
elucidate O
the O
effect O
of O
treatment O
with O
nebivolol O
on O
the O
metabolic B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oxidative I-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
, O
and O
antioxidant O
status O
markers O
in O
patients O
with O
cardiac O
syndrome-X O
( O
CSX O
) O
, O
additionally O
, O
to O
compare O
with O
the O
effect O
of O
metoprolol O
treatment O
. O
['Physiological-Clinical']

Children B-outcome ['Physiological-Clinical']
's O
IQs B-outcome ['Life-Impact']
and O
language B-outcome ['Life-Impact']
comprehension I-outcome ['Life-Impact']
did O
not O
increase O
, O
but O
adaptive/social B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
scores O
and O
expressive B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
quotients O
decreased O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSIONS O
Oral O
desmopressin O
tablets O
provide O
an O
effective O
and O
well-tolerated O
treatment O
for O
nocturia O
. O
[]

Counselling O
of O
postnatal O
depression O
: O
a O
controlled O
study O
on O
a O
population O
based O
Swedish O
sample O
. O
[]

We O
have O
therefore O
performed O
a O
double-blind O
, O
placebo-controlled O
study O
to O
evaluate O
the O
effects O
of O
a O
4-wk O
administration O
of O
inhaled O
fluticasone O
in O
bronchiectasis O
. O
[]

OBJECTIVE O
To O
perform O
a O
comparative O
assessment O
of O
the O
efficacy O
of O
total O
occlusive O
ionic O
silver-containing O
dressing O
( O
TOISD O
) O
combination O
vs O
no O
dressing O
after O
colorectal O
surgery O
. O
[]

The O
hazard O
reduction O
was O
similar O
for O
both O
radiation O
plans O
. O
[]

METHODS O
Randomisation O
between O
LAVH O
and O
TAH O
. O
[]

The O
sample O
( O
360 O
potential O
respondents O
) O
was O
selected O
randomly O
from O
basic O
resident O
registers O
in O
two O
geographically O
different O
areas O
. O
[]

Seven O
CSA O
recipients O
became O
hypertensive B-outcome ['Physiological-Clinical']
and O
four O
required O
anti-hypertensive B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

In O
the O
diode O
laser O
group O
, O
sensitive O
teeth O
were O
irradiated O
with O
the O
GaAlAs O
laser O
at O
8.5J/cm O
( O
2 O
) O
energy O
density O
. O
[]

But O
, O
infants O
receiving O
diuretics O
not O
only O
had O
significantly O
increased O
urine B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
, O
osmolal B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
, O
and O
potassium B-outcome ['Physiological-Clinical']
and O
phosphorus B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
, O
but O
these O
infants O
also O
retained B-outcome ['Physiological-Clinical']
less I-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
, O
and O
, O
in O
addition O
, O
excreted B-outcome ['Physiological-Clinical']
less I-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
than O
infants O
receiving O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

EPC B-outcome ['Physiological-Clinical']
numbers O
were O
not O
changed O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
safety O
of O
oral O
misoprostol O
400 O
mug O
with O
intramuscular O
syntometrine O
in O
the O
management O
of O
the O
third O
stage O
of O
labor O
. O
[]

Evaluation O
of O
asthma O
knowledge O
and O
quality O
of O
life O
in O
Hungarian O
asthmatics O
. O
[]

Effects O
of O
self-directed O
stress O
management O
training O
and O
home-based O
exercise O
on O
stress O
management B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
cancer O
patients O
receiving O
chemotherapy O
. O
['Life-Impact']

OBJECTIVE O
To O
compare O
the O
long-term O
effect O
and O
safety O
of O
tacrolimus O
( O
FK506 O
) O
and O
cyclosporine O
( O
CsA O
) O
in O
kidney O
transplant O
( O
KT O
) O
recipients O
carrying O
hepatitis O
B O
Virus O
( O
HBV O
) O
. O
[]

These O
results O
indicate O
that O
HBP B-outcome ['Physiological-Clinical']
is O
not O
appropriate O
as O
an O
alternative O
to O
ABP O
diagnostic O
testing O
in O
the O
detection O
of O
WCE O
. O
['Physiological-Clinical']

Probiotics O
in O
the O
management O
of O
atopic O
eczema O
. O
[]

In O
the O
ofloxacin O
treated O
group O
all O
patients O
showed O
clinical B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
median O
survival O
time O
in O
these O
groups O
was O
188 O
, O
259 O
, O
and O
252 O
days O
, O
and O
the O
mean O
survival B-outcome ['Mortality']
263 O
, O
262 O
, O
and O
329 O
days O
. O
['Mortality']

We O
have O
assessed O
nasal B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
and O
serum B-outcome ['Physiological-Clinical']
soluble I-outcome ['Physiological-Clinical']
ICAM-1 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
sICAM-1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in O
relation O
to O
nasal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
patients O
with O
persistent O
allergic O
rhinitis O
( O
AR O
) O
treated O
for O
6 O
weeks O
with O
either O
desloratadine O
, O
levocetirizine O
, O
montelukast O
alone O
, O
or O
in O
combination O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
selected O
five O
communities O
for O
monthly O
entomological O
surveys O
between O
September O
, O
1993 O
, O
and O
September O
, O
1995 O
. O
[]

Research O
participants O
for O
the O
ESRA-C O
study O
were O
recruited O
from O
the O
Seattle O
Cancer O
Care O
Alliance O
, O
a O
consortium O
among O
the O
University O
of O
Washington O
Medical O
Center O
, O
Fred O
Hutchinson O
Cancer O
Research O
Center O
, O
and O
Children O
's O
Hospital O
and O
Regional O
Medical O
Center O
in O
Seattle O
, O
WA O
. O
[]

METHODS O
Eighty O
freshly O
extracted O
maxillary O
premolars O
were O
randomly O
divided O
into O
4 O
groups O
( O
20 O
in O
each O
group O
) O
. O
[]

BACKGROUND O
An O
excess O
of O
androgen O
is O
believed O
to O
contribute O
to O
development O
of O
acne O
in O
some O
patients O
. O
[]

Peak O
oxygen B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
, O
maximal O
achieved O
workload B-outcome ['Life-Impact']
and O
exercise B-outcome ['Life-Impact']
duration B-outcome ['Life-Impact']
tended O
to O
improve O
in O
the O
exercise O
training O
group O
but O
remained O
unchanged O
in O
the O
pravastatin-treated O
group O
. O
['Resource-use', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Among O
subjects O
with O
hypertension O
at O
baseline O
, O
at O
higher O
sodium O
intake O
the O
DASH O
diet O
increased O
BP B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
two-fold O
over O
control O
( O
63 O
% O
vs. O
32 O
% O
; O
95 O
% O
confidence O
interval O
, O
1.4-2.9 O
) O
. O
['Physiological-Clinical']

White O
coat O
effect O
detected O
using O
self-monitoring O
of O
blood O
pressure O
at O
home O
: O
comparison O
with O
ambulatory O
blood O
pressure O
. O
[]

Recent O
research O
also O
suggests O
that O
adults O
with O
ASD O
are O
unable O
to O
understand O
their O
own O
mental O
states O
, O
which O
could O
lead O
to O
difficulties O
in O
emotion-regulation O
. O
[]

SETTING O
University O
teaching O
hospital O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
groups O
regarding O
pain B-outcome ['Physiological-Clinical']
intensity O
and O
escape B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

BACKGROUND O
Oxytocin O
dysfunction O
might O
contribute O
to O
the O
development O
of O
social O
deficits O
in O
autism O
, O
a O
core O
symptom O
domain O
and O
potential O
target O
for O
intervention O
. O
[]

Group O
I O
received O
normal O
saline O
, O
group O
II O
received O
lidocaine O
2 O
% O
( O
40 O
mg O
) O
, O
and O
groups O
III O
and O
IV O
received O
thiopental O
0.25 O
mg/kg O
and O
0.5 O
mg/kg O
, O
respectively O
. O
[]

during O
anesthesia O
appears O
to O
be O
a O
simple O
, O
effective O
, O
and O
[]

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
halothane O
vs. O
isoflurane O
on O
cytokine B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
during O
minor O
elective O
surgery O
. O
['Physiological-Clinical']

Analyses O
revealed O
that O
clients O
receiving O
psychotherapy O
under O
conditions O
of O
heightened O
therapist O
disclosure O
not O
only O
reported O
lower O
levels O
of O
symptom O
distress O
but O
also O
liked B-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
therapist I-outcome ['Life-Impact']
more O
. O
['Life-Impact']

We O
assessed O
the O
correlation O
of O
symptomatic B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
and O
health-related B-outcome ['Physiological-Clinical']
quality O
of O
life O
['Physiological-Clinical', 'Physiological-Clinical']

Pulse O
oximeter O
perfusion O
index O
as O
an O
early O
indicator O
of O
sympathectomy O
after O
epidural O
anesthesia O
. O
[]

A O
randomized O
prospective O
single-center O
controlled O
trial O
. O
[]

BACKGROUND O
The O
study O
aimed O
to O
investigate O
the O
effectiveness O
of O
a O
new O
multi-component O
social O
skills O
intervention O
for O
children O
with O
Asperger O
syndrome O
( O
AS O
) O
: O
The O
Junior O
Detective O
Training O
Program O
. O
[]

A O
prospective O
study O
over O
15 O
months O
in O
100 O
elderly O
patients O
with O
signs O
of O
cerebro-vascular O
impairment O
demonstrated O
by O
psychometric O
testing O
that O
Hydergine O
( O
an O
ergot O
alkaloid O
preparation O
: O
4.5 O
mg O
daily O
) O
compensated O
the O
signs O
of O
dementia O
, O
present O
in O
the O
placebo O
group O
, O
and O
in O
some O
patients O
actually O
brought O
about O
a O
significant O
improvement O
in O
mental B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
diagnosis O
of O
left O
ventricular O
thrombosis O
was O
based O
on O
the O
detection O
of O
an O
echo O
dense O
mass O
with O
defined O
margins O
visible O
throughout O
the O
cardiac O
cycle O
in O
at O
least O
two O
orthogonal O
views O
. O
[]

PARTICIPANTS O
One O
hundred O
forty-nine O
volunteers O
5 O
to O
17 O
years O
old O
( O
mean O
[ O
SD O
] O
age O
, O
9.4 O
[ O
3.1 O
] O
years O
) O
were O
randomized O
to O
receive O
citalopram O
( O
n O
= O
73 O
) O
or O
placebo O
( O
n O
= O
76 O
) O
. O
[]

Secondary O
endpoints O
included O
other O
MRI O
measures O
and O
clinical O
endpoints O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Sun B-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
promotion I-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
of O
primary O
care O
clinicians O
as O
determined O
by O
their O
self O
report O
, O
research O
assistant O
observation O
, O
and O
parent O
interviews O
. O
['Life-Impact']

DESIGN O
This O
was O
a O
prospective O
, O
randomized O
, O
placebo-controlled O
trial O
in O
21 O
patients O
aged O
35 O
+/- O
11 O
y O
( O
x O
+/- O
SD O
) O
with O
burns O
on O
45 O
+/- O
21 O
% O
of O
their O
body O
surface O
area O
. O
[]

BEACOPP O
, O
a O
new O
dose-escalated O
and O
accelerated O
regimen O
, O
is O
at O
least O
as O
effective O
as O
COPP/ABVD O
in O
patients O
with O
advanced-stage O
Hodgkin O
's O
lymphoma O
: O
interim O
report O
from O
a O
trial O
of O
the O
German O
Hodgkin O
's O
Lymphoma O
Study O
Group O
. O
[]

A O
prospective O
study O
. O
[]

Patients O
received O
the O
study O
drug O
on O
days O
1 O
, O
3 O
, O
and O
5 O
before O
initiation O
of O
granulocyte O
colony-stimulating O
factor O
( O
G-CSF O
) O
10 O
microg/kg/day O
on O
day O
5 O
and O
pheresis O
starting O
on O
day O
9 O
. O
[]

The O
effects O
of O
hypoxemia O
on O
cardiac O
output O
. O
[]

MATERIALS O
AND O
METHODS O
The O
root O
canals O
of O
30 O
human O
incisors O
and O
canines O
were O
instrumented O
and O
prepared O
with O
burs O
. O
[]

Population-based O
screening O
and O
early O
treatment O
for O
type O
2 O
diabetes O
could O
reduce O
this O
growing O
burden O
. O
[]

BACKGROUND O
The O
objective O
was O
to O
develop O
an O
educational O
instrument O
, O
to O
assess O
its O
impact O
as O
an O
intervention O
instrument O
and O
to O
examine O
quality O
of O
life O
( O
QoL O
) O
. O
[]

Ulcers B-outcome ['Physiological-Clinical']
recurred I-outcome ['Physiological-Clinical']
in O
1 O
of O
46 O
patients O
in O
whom O
H. O
pylori O
had O
been O
eradicated O
, O
as O
compared O
with O
45 O
of O
53 O
in O
whom O
H. O
pylori O
persisted O
( O
2 O
percent O
vs. O
85 O
percent O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Evolution O
of O
neuropathy O
and O
myopathy O
during O
intensive O
vincristine/corticosteroid O
chemotherapy O
for O
non-Hodgkin O
's O
lymphoma O
. O
[]

Corneal B-outcome ['Physiological-Clinical']
epithelial I-outcome ['Physiological-Clinical']
defects I-outcome ['Physiological-Clinical']
were O
as O
common O
with O
a O
low O
dose O
as O
with O
higher O
doses O
previously O
described O
. O
['Physiological-Clinical']

Efficacy O
of O
intravenous O
granisetron O
to O
control O
nausea O
and O
vomiting O
during O
multiple O
cycles O
of O
cisplatin-based O
chemotherapy O
. O
[]

No O
differences O
in O
6-month O
values O
were O
present O
( O
58 O
+/- O
15 O
% O
versus O
62 O
+/- O
15 O
% O
, O
p O
= O
NS O
) O
for O
placebo O
and O
streptokinase O
groups O
, O
respectively O
. O
[]

Change O
from O
baseline O
in O
post-bronchodilator O
FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
was O
significantly O
improved O
in O
continuous O
abstainers O
( O
121.8 O
mL O
) O
vs. O
continuous O
smokers O
( O
37.9 O
mL O
) O
at O
Week O
12 O
( O
P O
= O
0.0069 O
) O
, O
but O
not O
at O
Weeks O
24 O
or O
52 O
. O
['Physiological-Clinical']

Growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
GH-releasing O
hormone O
alone O
or O
combined O
with O
arginine O
in O
patients O
with O
adrenal O
incidentaloma O
: O
evidence O
for O
enhanced O
somatostatinergic O
tone O
. O
['Physiological-Clinical']

The O
interesting O
feature O
of O
the O
Lunar O
stent O
from O
Inflow O
Dynamics O
is O
that O
it O
is O
coated O
with O
a O
layer O
of O
iridium O
oxide O
. O
[]

Endoscopy O
was O
performed O
at O
4 O
and O
, O
if O
not O
healed O
, O
at O
8 O
weeks O
. O
[]

Sixty-seven O
patients O
with O
bacterial O
vaginosis O
( O
BV O
) O
, O
50 O
with O
intermediate O
flora O
and O
42 O
with O
normal O
vaginal O
flora O
were O
enrolled O
in O
this O
double-blind O
study O
. O
[]

Consistent O
with O
this O
mechanism O
of O
action O
, O
DPP-4 O
inhibitors O
improve O
glucose O
tolerance O
after O
meals O
by O
increasing O
insulin O
and O
reducing O
glucagon O
levels O
in O
the O
plasma O
. O
[]

Video O
microscope O
images O
support O
these O
findings O
. O
[]

PARTICIPANTS O
Thirty O
physically O
active O
males O
with O
tight O
hamstrings O
and O
at O
least O
one O
latent O
MTrP O
on O
muscles O
innervated O
by O
the O
lumbosacral O
, O
sciatic O
, O
tibial O
and O
common O
peroneal O
nerves O
. O
[]

BACKGROUND O
Although O
indomethacin O
is O
effective O
in O
preventing O
heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
( O
HO O
) O
after O
primary O
total O
hip O
arthroplasty O
, O
side O
effects O
are O
frequently O
observed O
. O
['Physiological-Clinical']

Both O
support O
persons O
and O
smokers O
completed O
assessments O
separately O
by O
mail O
at O
baseline O
and O
at O
weeks O
6 O
( O
end O
of O
treatment O
) O
and O
26 O
. O
[]

SETTING O
Two O
university O
hospitals O
in O
Oslo O
, O
Norway O
. O
[]

8-epi-PGF2 B-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
( O
in O
pmol/mmol O
, O
mean O
+/- O
SEM O
) O
was O
176.5+/-30.6 O
in O
heavy O
smokers O
, O
92.7+/-4.8 O
( O
P O
< O
.05 O
) O
in O
moderate O
smokers O
, O
and O
54.1+/-2.7 O
( O
P O
< O
.005 O
) O
in O
nonsmokers O
. O
['Physiological-Clinical']

Non-responders O
were O
given O
15 O
mg O
chlorthalidone O
and O
were O
also O
checked O
for O
a O
further O
3 O
months O
. O
[]

The O
number O
of O
patients O
who O
required O
additional B-outcome ['Resource-use']
surgery I-outcome ['Resource-use']
was O
greater O
( O
p O
= O
0.05 O
) O
in O
the O
group O
that O
had O
arthroscopic O
cuff O
repair O
alone O
than O
in O
the O
group O
that O
had O
arthroscopic O
cuff O
repair O
and O
acromioplasty O
. O
['Resource-use']

In O
61 O
acceptable O
patients O
, O
there O
was O
no O
significant O
difference O
in O
terms O
of O
response O
rate O
, O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
, O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
and O
survival B-outcome ['Mortality']
rate O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

The O
two O
groups O
had O
similar O
pretreatment O
clinical O
, O
haemodynamic O
and O
angiographic O
characteristics O
: O
the O
Miller O
angiographic B-outcome ['Physiological-Clinical']
index O
of O
severity O
averaged O
22.6 O
+/- O
3.7 O
for O
patients O
in O
the O
UK O
2000 O
group O
, O
and O
22.6 O
+/- O
3.4 O
for O
patients O
in O
the O
UK O
4400 O
group O
( O
average O
filling O
defect O
of O
66 O
% O
on O
pulmonary O
angiograms O
) O
. O
['Physiological-Clinical']

30 O
patients O
were O
randomized O
to O
receive O
one O
of O
two O
treatments O
: O
troxerutin O
150 O
mg O
and O
carbazochrome O
1.5 O
mg O
, O
or O
placebo O
, O
i.m O
. O
[]

CONCLUSIONS O
Mortality B-outcome ['Mortality']
rates O
at O
6 O
months O
follow-up O
are O
not O
affected O
by O
intensive O
glucose O
control O
in O
patients O
with O
severe O
TBI O
. O
['Mortality']

Children O
with O
ASD O
and O
typically O
developing O
( O
TD O
) O
children O
viewed O
randomly O
presented O
digital O
morphs O
between O
their O
own O
face O
and O
a O
gender-matched O
other O
face O
, O
and O
made O
self/other O
judgments O
. O
[]

OBJECTIVE O
We O
investigated O
the O
use O
of O
the O
bispectral O
index O
for O
monitoring O
sedation O
during O
cardiac B-outcome ['Physiological-Clinical']
catheterization I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Mean O
final O
dosages O
were O
7.9+/-2.5 O
mg/day O
for O
olanzapine O
and O
1.4+/-0.7 O
mg/day O
for O
haloperidol O
. O
[]

Cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
rose O
in O
two O
of O
these O
, O
but O
it O
dropped O
in O
all O
others O
. O
['Physiological-Clinical']

TXB2 B-outcome ['Physiological-Clinical']
was O
measured O
in O
serum O
from O
blood O
allowed O
to O
clot O
at O
37 O
degrees O
C. O
2 O
. O
['Physiological-Clinical']

BACKGROUND O
Few O
investigations O
include O
both O
subjective O
and O
objective O
measurements O
of O
the O
effectiveness O
of O
treatments O
for O
osteoarthritis O
of O
the O
knee O
. O
[]

CONCLUSIONS O
The O
ECC.O O
system O
can O
be O
safely O
used O
in O
CABG O
patients O
and O
it O
maintains O
haemoglobin O
level O
better O
than O
conventional O
CPB O
. O
[]

The O
hypothesis O
that O
the O
cytodiagnostic O
results O
on O
endoscopic O
brushings O
obtained O
before O
biopsy O
may O
be O
superior O
to O
those O
brushings O
obtained O
after O
biopsy O
, O
but O
with O
the O
accuracy O
of O
the O
subsequent O
biopsy O
reduced O
, O
was O
examined O
for O
300 O
consecutive O
patients O
, O
including O
256 O
with O
esophageal O
or O
gastric O
carcinomas O
. O
[]

Using B-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
increase O
from O
nadir O
of O
0.8 O
ng/ml O
the O
sensitivity B-outcome ['Physiological-Clinical']
of O
dutasteride O
was O
0.548 O
and O
its O
specificity O
was O
0.795 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

On O
days O
5 O
and O
7 O
, O
nasal O
washings O
from O
compliant O
subjects O
with O
proven O
rhinovirus O
colds O
yielded O
rhinoviruses O
more O
often O
in O
placebo O
( O
47 O
and O
48 O
% O
, O
respectively O
) O
than O
in O
interferon O
( O
15 O
and O
16 O
% O
, O
respectively O
) O
recipients O
( O
P O
less O
than O
0.02 O
) O
, O
but O
no O
differences O
in O
new O
respiratory B-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
occurrence I-outcome ['Physiological-Clinical']
were O
observed O
in O
household O
contacts O
. O
['Physiological-Clinical']

The O
same O
enzyme O
dosages O
were O
administered O
as O
divided O
doses O
every O
12 O
hours O
for O
4 O
consecutive O
days O
in O
a O
randomised O
, O
double-blinded O
, O
placebo-controlled O
design O
. O
[]

In O
Exp O
. O
[]

INTERVENTION O
Aerobic O
exercise O
training O
was O
performed O
for O
7 O
d. O
MAIN O
OUTCOME O
MEASURES O
Whole-body O
, O
peripheral B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Endoscopic O
sphincterotomy O
by O
using O
pure-cut O
electrosurgical O
current O
and O
the O
risk O
of O
post-ERCP O
pancreatitis O
: O
a O
prospective O
randomized O
trial O
. O
[]

Although O
many O
surgeons O
believe O
that O
the O
use O
of O
minimally O
invasive O
techniques O
eliminates O
force O
feedback B-outcome ['Life-Impact']
and O
tactile B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
haptics I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
the O
importance O
of O
haptics O
in O
MIS O
has O
not O
been O
fully O
evaluated O
. O
['Life-Impact', 'Physiological-Clinical']

METHODS O
Sixty O
cases O
were O
randomly O
divided O
into O
an O
observation O
group O
and O
a O
control O
group O
, O
30 O
cases O
in O
eachgroup O
. O
[]

RESULTS O
Seizures B-outcome ['Physiological-Clinical']
were O
controlled O
in O
13 O
of O
the O
30 O
neonates O
assigned O
to O
receive O
phenobarbital O
( O
43 O
percent O
) O
and O
13 O
of O
the O
29 O
neonates O
assigned O
to O
receive O
phenytoin O
( O
45 O
percent O
; O
P=1.00 O
) O
. O
['Physiological-Clinical']

The O
patients O
were O
randomized O
to O
intravenous O
indomethacin O
50 O
mg O
or O
placebo O
administrated O
after O
exposure O
of O
the O
dura O
. O
[]

BACKGROUND O
Vitamin/mineral O
supplements O
are O
among O
the O
most O
commonly O
used O
treatments O
for O
autism O
, O
but O
the O
research O
on O
their O
use O
for O
treating O
autism O
has O
been O
limited O
. O
[]

The O
use O
of O
filters O
in O
this O
patient O
group O
may O
offer O
advantages O
in O
terms O
of O
ease O
of O
use O
and O
a O
possible O
decrease O
in O
hep/hc-related B-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Research O
shows O
that O
depression O
and O
anxiety O
disorders O
are O
the O
most O
common O
psychiatric O
concern O
in O
autism O
spectrum O
disorders O
( O
ASD O
) O
. O
[]

The O
development O
of O
a O
web- O
and O
a O
print-based O
decision O
aid O
for O
prostate B-outcome ['Resource-use']
cancer I-outcome ['Resource-use']
screening I-outcome ['Resource-use']
. O
['Resource-use']

Both O
drugs O
were O
administered O
in O
association O
with O
spironolactone O
( O
200 O
mg/day O
) O
in O
28 O
nonazotemic O
cirrhotic O
patients O
with O
controlled O
ascites O
. O
[]

Naltrexone O
did O
not O
appear O
to O
affect O
discrimination B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
. O
['Life-Impact']

Patients O
were O
monitored O
for O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
during O
the O
study O
and O
24 O
hours O
after O
administration O
of O
the O
assigned O
drug O
. O
['Adverse-effects']

General O
anesthesia O
with O
sevoflurane O
was O
induced O
in O
both O
groups O
. O
[]

SUBJECT O
2794 O
women O
at O
low O
risk O
fulfilling O
the O
trial O
's O
inclusion O
criteria O
between O
June O
1993 O
and O
July O
1994 O
. O
[]

In O
the O
present O
study O
, O
we O
analyzed O
the O
prognostic O
impact O
of O
OPN O
in O
AML O
by O
investigating O
the O
expression B-outcome ['Physiological-Clinical']
and B-outcome ['Physiological-Clinical']
relevance I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
OPN I-outcome ['Physiological-Clinical']
in O
newly O
diagnosed O
AML O
patients O
from O
2 O
large O
study O
groups O
( O
the O
German O
AML O
Cooperative O
Group O
and O
the O
Dutch-Belgian O
Hematology O
Oncology O
Cooperative O
group O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

4 O
In O
comparison O
to O
metoprolol O
, O
pindolol O
produced O
less O
reduction O
in O
resting B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate O
, O
cardiac B-outcome ['Physiological-Clinical']
index O
and O
ejection B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
reflecting O
the O
intrinsic O
sympathomimetic O
activity O
of O
the O
drug O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Evaluation O
of O
a O
preventive O
intervention O
for O
child O
anxiety O
in O
two O
randomized O
attention-control O
school O
trials O
. O
[]

Analysis O
was O
carried O
out O
according O
to O
the O
intention O
to O
treat O
principle O
. O
[]

Homeostasis O
and O
oxygen O
transport O
] O
. O
[]

A O
series O
of O
25 O
patients O
with O
advanced O
esophageal O
cancer O
treated O
from O
Mar O
. O
[]

Patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
scores O
were O
consistently O
higher O
in O
the O
study O
group O
at O
the O
end O
of O
the O
study O
. O
['Life-Impact']

METHODS O
Women O
who O
were O
at O
least O
5 O
years O
postmenopausal O
were O
invited O
to O
participate O
in O
the O
study O
. O
[]

A O
prospective O
randomised O
comparison O
of O
sublingual O
and O
vaginal O
misoprostol O
in O
second O
trimester O
termination O
of O
pregnancy O
. O
[]

This O
study O
describes O
the O
need O
to O
control O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
with O
two O
or O
more O
drugs O
in O
most O
hypertensive O
patients O
and O
illustrates O
good O
clinical O
outcomes O
, O
independent O
of O
blood O
pressure O
lowering O
, O
using O
combination O
therapy O
with O
losartan O
, O
low-dose O
thiazide O
, O
and O
amlodipine O
. O
['Physiological-Clinical']

The O
most O
beneficial O
timing O
for O
autologous O
reinfusion O
of O
predonated O
blood O
remains O
unknown O
. O
[]

RESULTS O
Incidence O
of O
heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
was O
47.8 O
% O
in O
the O
7 O
Gy O
preoperative O
group O
( O
Brooker O
Score O
I O
: O
36.9 O
% O
; O
II O
: O
8.7 O
% O
; O
III O
: O
2.2 O
% O
; O
IV O
: O
0 O
% O
) O
and O
11.1 O
% O
in O
the O
NSAID O
group O
( O
Brooker O
Score O
I O
: O
9.3 O
% O
; O
II O
: O
1.8 O
% O
; O
III O
: O
0 O
% O
; O
IV O
: O
0 O
% O
) O
. O
['Physiological-Clinical']

Moreover O
, O
they O
show O
that O
binocular O
eye-position O
information O
is O
crucial O
when O
judging O
the O
absolute O
direction O
of O
both O
monocular O
and O
binocular O
targets O
. O
[]

Cephamandole O
levels O
in O
serum O
and O
drain O
fluid O
were O
measured O
in O
32 O
knee O
replacement O
operations O
to O
determine O
the O
benefit O
of O
an O
intravenous O
dose O
of O
antibiotic O
at O
the O
time O
of O
tourniquet O
deflation O
. O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
crossover O
study O
of O
Cappra? O
for O
the O
treatment O
of O
mild O
or O
mild O
to O
moderate O
erectile O
dysfunction O
in O
Thai O
male O
. O
[]

This O
study O
's O
purpose O
was O
to O
determine O
whether O
using O
chlorhexidine O
gluconate O
( O
CHG O
) O
in O
a O
prophylactic O
perirectal O
skin-care O
regimen O
decreases O
perirectal O
infections O
and O
whether O
it O
produces O
more O
skin O
irritation O
than O
a O
nonmedicated O
skin O
cleanser O
. O
[]

The O
same O
phenomenon O
was O
also O
noted O
in O
the O
8-to-24-hour O
interval O
( O
PONV O
4 O
% O
vs. O
12 O
% O
, O
p O
< O
0.05 O
and O
rescue O
anti-emetic O
3 O
% O
vs. O
9 O
% O
, O
p O
< O
0.05 O
in O
Group O
D O
vs. O
Group O
P O
, O
respectively O
. O
) O
[]

After O
a O
run-in O
period O
of O
at O
least O
2 O
weeks O
on O
timolol O
, O
5 O
mg/ml O
twice O
daily O
, O
patients O
were O
randomised O
to O
one O
of O
three O
groups O
. O
[]

Improved O
selectivity O
in O
early O
cortical O
responses O
lead O
to O
better B-outcome ['Physiological-Clinical']
stimulus I-outcome ['Physiological-Clinical']
differentiation I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
later-stage I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
as O
was O
made O
evident O
by O
our O
P3b O
and O
P3a O
component O
findings O
. O
['Physiological-Clinical']

METHODS O
AND O
RESULTS O
Two O
hundred O
thirty-seven O
consecutive O
women O
patients O
, O
aged O
75 O
years O
or O
younger O
, O
hospitalized O
for O
acute O
myocardial O
infarction O
, O
coronary O
artery O
bypass O
grafting O
, O
or O
percutaneous O
coronary O
intervention O
were O
randomized O
to O
a O
group-based O
psychosocial O
intervention O
program O
or O
usual O
care O
. O
[]

RESULTS O
Thirty-eight O
children O
participated O
. O
[]

Likewise O
, O
all O
H. O
pylori O
( O
- O
) O
subjects O
showed O
a O
rapid O
and O
sustained O
reduction O
of O
intragastric B-outcome ['Physiological-Clinical']
acidity I-outcome ['Physiological-Clinical']
during O
the O
infusion O
. O
['Physiological-Clinical']

The O
implications O
of O
these O
findings O
for O
understanding O
the O
role O
of O
discrete O
trial O
approaches O
to O
language O
intervention O
are O
discussed O
. O
[]

Blood O
pressure I-outcome ['Physiological-Clinical']
reduction O
was O
significant O
in O
these O
all O
groups O
and O
no O
differences O
were O
observed O
in O
blood O
pressure O
reduction O
among O
the O
groups O
. O
['Physiological-Clinical']

A O
prospective O
randomized O
trial O
of O
two O
different O
endoscopic O
resection O
techniques O
for O
early O
stage O
cancer O
of O
the O
esophagus O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
efficiency O
, O
safety O
and O
advantages O
of O
PKVP O
compared O
with O
standard O
transurethral O
resection O
of O
the O
prostate O
( O
TURP O
) O
at O
a O
regional O
acute O
hospital O
. O
[]

Subjects O
experienced O
the O
five O
SaO2 O
measurements O
in O
random O
order O
. O
[]

Although O
the O
mean O
hemoglobin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
blood O
conservation O
group O
after O
6 O
days O
, O
statistical O
significance O
was O
not O
reached O
until O
9.5 O
days O
of O
ICU O
care O
. O
['Physiological-Clinical']

Median O
age O
( O
interquartile O
range O
) O
was O
68 O
( O
58 O
, O
75 O
) O
years O
, O
29 O
% O
were O
women O
, O
and O
78 O
% O
of O
the O
patients O
met O
at O
least O
one O
criterion O
for O
not O
low O
risk O
AMI O
( O
anterior O
location O
, O
age O
> O
70 O
years O
old O
, O
previous O
MI O
, O
systolic O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
< O
100 O
mm O
Hg O
, O
and/or O
heart O
rate O
> O
100 O
bpm O
) O
. O
['Physiological-Clinical']

The O
strength O
training O
group O
increased O
maximal B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
in O
all O
the O
major O
muscle O
groups O
tested O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

In O
a O
multicenter O
, O
controlled O
, O
randomized O
trial O
, O
49 O
patients O
scheduled O
for O
orthopaedic O
or O
vascular O
surgery O
received O
0 O
( O
control O
group O
, O
n O
= O
9 O
) O
, O
200 O
( O
n O
= O
10 O
) O
, O
300 O
( O
n O
= O
11 O
) O
, O
400 O
( O
n O
= O
10 O
) O
or O
500 O
( O
n O
= O
9 O
) O
U/kg O
rHuEPO O
( O
Erypo O
, O
Cilag O
, O
Sulzbach O
, O
distributor O
Fresenius O
, O
Oberursel O
, O
Germany O
) O
subcutaneously O
twice O
a O
week O
for O
3 O
weeks O
while O
every O
week O
450 O
ml O
blood O
was O
collected O
. O
[]

Because O
the O
observed O
upper O
95 O
% O
confidence O
limit O
( O
and O
even O
the O
point O
estimate O
) O
exceeded O
1.73 O
, O
the O
probability O
of O
pregnancy B-outcome ['Physiological-Clinical']
among I-outcome ['Physiological-Clinical']
FemCap I-outcome ['Physiological-Clinical']
users O
, O
compared O
with O
that O
among O
diaphragm O
users O
, O
did O
not O
meet O
the O
definition O
of O
clinical B-outcome ['Physiological-Clinical']
equivalence O
used O
in O
this O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

11.3 O
years O
) O
. O
[]

Nimesulide O
evidenced O
greater O
speed B-outcome ['Physiological-Clinical']
and O
duration O
of O
therapeutic O
action O
. O
['Physiological-Clinical']

An O
emergency O
clinical O
pathway O
for O
stroke O
patients O
-- O
results O
of O
a O
cluster O
randomised O
trial O
( O
isrctn41456865 O
) O
. O
[]

CONCLUSIONS O
Since O
the O
results O
were O
essentially O
identical O
between O
the O
techniques O
, O
it O
seems O
that O
[]

There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
. O
[]

Effect O
of O
enamel O
preparation O
method O
on O
in O
vitro O
marginal B-outcome ['Physiological-Clinical']
microleakage I-outcome ['Physiological-Clinical']
of O
a O
flowable O
composite O
used O
as O
pit O
and O
fissure O
sealant O
. O
['Physiological-Clinical']

Controls O
were O
performed O
at O
baseline O
and O
every O
two O
weeks O
at O
four O
follow-up O
visits O
unless O
ulcer O
healed O
before O
. O
[]

Brain O
mechanisms O
of O
expectation O
associated O
with O
insula O
and O
amygdala O
response O
to O
aversive O
taste O
: O
implications O
for O
placebo O
. O
[]

Our O
data O
indicate O
that O
the O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
in O
Chinese O
CAHB O
patients O
do O
not O
differ O
from O
those O
of O
Caucasian O
patients O
with O
CAHB O
, O
when O
analysed O
using O
similar O
methods O
for O
the O
enumeration O
of O
lymphocyte O
subsets O
. O
['Physiological-Clinical']

Beverage O
consumption O
has O
been O
implicated O
in O
weight O
gain O
, O
but O
questions O
remain O
about O
the O
veracity O
of O
the O
association O
, O
whether O
the O
relationship O
is O
causal O
and O
what O
property O
of O
beverages O
is O
responsible O
. O
[]

A O
double-blind O
placebo-controlled O
study O
. O
[]

Other O
benefits O
of O
treatment O
included O
a O
37 O
% O
reduction O
( O
p O
< O
0.00001 O
) O
in O
the O
risk O
of O
undergoing O
myocardial B-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
procedures I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Influence O
of O
phase-related O
variability O
in O
premenstrual B-outcome ['Physiological-Clinical']
symptomatology I-outcome ['Physiological-Clinical']
, O
mood B-outcome ['Life-Impact']
, O
smoking B-outcome ['Life-Impact']
withdrawal I-outcome ['Life-Impact']
, O
and O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

BACKGROUND O
In O
1998 O
, O
mandatory O
folic O
acid O
fortification O
of O
white O
flour O
and O
select O
cereal O
grain O
products O
was O
implemented O
in O
Canada O
with O
the O
intention O
to O
increase O
dietary O
folate O
intakes O
of O
reproducing O
women O
. O
[]

World O
Health O
Organization O
functional O
class O
improved O
in O
19 O
and O
was O
unchanged O
in O
10 O
; O
exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
significantly O
improved O
with O
the O
6-minute O
walk O
distance O
, O
improving O
on O
follow-up O
from O
455.7 O
? O
['Life-Impact']

Need O
for O
insulin O
therapy O
in O
type O
II O
diabetes O
mellitus O
. O
[]

In O
phase O
1 O
, O
36 O
participants O
were O
randomly O
assigned O
to O
experimental O
and O
control O
groups O
. O
[]

CCR O
was O
sustained O
in O
25 O
% O
of O
patients O
regardless O
of O
therapy O
. O
[]

BACKGROUND O
Ropivacaine O
, O
0.2 O
% O
, O
is O
a O
new O
local O
anesthetic O
approved O
for O
epidural O
analgesia O
. O
[]

The O
relation B-outcome ['Physiological-Clinical']
was O
equally O
strong O
in O
patients O
with O
severe O
pulmonary O
disease O
; O
for O
patients O
with O
FEV1 O
< O
1.51 O
the O
mean O
difference O
was O
0.21 O
( O
0.80 O
) O
mmol/min/kPa O
. O
['Physiological-Clinical']

Children O
were O
randomly O
assigned O
to O
haloperidol-placebo-haloperidol O
or O
placebo-haloperidol-placebo O
treatment O
sequences O
. O
[]

Children O
with O
autism O
's O
response O
to O
novel B-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
while O
participating O
in O
interventions O
targeting O
joint O
attention O
or O
symbolic O
play O
skills O
. O
['Physiological-Clinical']

Intravenous O
regional O
anaesthesia O
below O
the O
knee O
. O
[]

Cibenzoline O
( O
C O
) O
was O
compared O
with O
propafenone O
( O
P O
) O
in O
18 O
adult O
patients O
( O
7 O
women O
and O
11 O
men O
) O
aged O
50 O
+/- O
7 O
in O
double-blind O
, O
placebo-controlled O
crossover O
trial O
. O
[]

Students O
in O
the O
comparing O
symbols O
group O
showed O
greater O
gains O
in O
conceptual B-outcome ['Life-Impact']
understanding I-outcome ['Life-Impact']
from O
pretest O
to O
posttest O
than O
students O
in O
the O
other O
two O
groups O
, O
and O
students O
in O
the O
comparing O
symbols O
group O
also O
scored O
higher O
on O
a O
posttest O
that O
assessed O
knowledge O
about O
inequality O
symbols O
and O
inequality B-outcome ['Life-Impact']
problem I-outcome ['Life-Impact']
solving I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Parent O
and O
teacher O
measures O
can O
be O
useful O
in O
outpatient O
trials O
to O
evaluate O
change O
. O
[]

This O
randomized O
, O
placebo-controlled O
, O
crossover O
study O
investigated O
the O
effects O
of O
fluoxetine O
administration O
on O
the O
pharmacokinetics O
and O
pharmacodynamics B-outcome ['Physiological-Clinical']
of O
zolmitriptan O
. O
['Physiological-Clinical']

At O
one O
and O
six O
weeks O
after O
bleaching B-outcome ['Physiological-Clinical']
, O
there O
were O
51 O
% O
and O
65 O
% O
reductions O
in O
deltaE O
, O
respectively O
. O
['Physiological-Clinical']

CONCLUSION O
Patients O
who O
experience O
virologic B-outcome ['Physiological-Clinical']
suppression I-outcome ['Physiological-Clinical']
with O
a O
regimen O
of O
lamivudine O
150 O
mg O
BID O
in O
combination O
with O
stavudine/PI O
can O
maintain O
that O
suppression B-outcome ['Physiological-Clinical']
by O
continuing O
their O
regimen O
or O
switching O
to O
lamivudine O
300 O
mg O
QD O
and O
continuing O
the O
other O
components O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
brachial O
plexus O
is O
more O
vulnerable O
to O
large O
fraction O
size O
. O
[]

The O
trial O
is O
designed O
to O
provide O
a O
definitive O
QOL O
comparison O
between O
the O
two O
arms O
, O
and O
to O
inform O
the O
design O
of O
an O
eventual O
phase O
III O
trial O
for O
survival O
outcomes O
. O
[]

The O
total O
observed B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
of O
teledermatology O
were O
higher O
than O
the O
costs O
of O
conventional O
care O
in O
both O
urban O
and O
rural O
areas O
, O
mainly O
because O
of O
the O
fixed O
equipment O
costs O
. O
['Resource-use']

Local O
warming O
and O
insertion O
of O
peripheral O
venous O
cannulas O
: O
single O
blinded O
prospective O
randomised O
controlled O
trial O
and O
single O
blinded O
randomised O
crossover O
trial O
. O
[]

There O
were O
no O
differences O
among O
the O
three O
groups O
with O
respect O
to O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
or O
analgesic O
requirements O
. O
['Physiological-Clinical']

Potential O
explanations O
for O
the O
pattern O
of O
results O
are O
evaluated O
, O
and O
implications O
for O
theories O
of O
mental O
imagery O
and O
memory O
are O
considered O
. O
[]

The O
pulsatility B-outcome ['Physiological-Clinical']
index O
and O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
naltrexone O
on O
communication O
skills O
of O
young O
children O
with O
autism O
. O
[]

METHODS O
The O
relationship O
between O
baseline O
BP O
, O
heart O
rate O
, O
and O
other O
hemodynamic O
parameters O
, O
and O
early O
outcomes O
were O
assessed O
using O
data O
from O
TAIST O
trial O
. O
[]

Treatment O
was O
continued O
, O
when O
possible O
, O
for O
a O
period O
of O
6 O
months O
. O
[]

CONCLUSIONS O
A O
single O
dose O
of O
intravenous O
human O
secretin O
is O
not O
effective O
in O
changing O
behaviour O
and O
communication O
in O
children O
with O
ASD O
when O
compared O
to O
placebo O
. O
[]

RESULTS O
Laparoscopic O
assessment O
was O
correct O
in O
all O
cases O
in O
which O
the O
appendix O
was O
visualized O
. O
[]

Omitting O
the O
instruction O
and O
using O
off-line O
blink O
subtraction O
procedures O
seems O
a O
viable O
alternative O
. O
[]

RESULTS O
At O
the O
interview O
conducted O
by O
the O
physician O
3 O
months O
after O
the O
final O
infusion O
, O
10 O
of O
23 O
( O
43 O
% O
) O
immunoglobulin O
recipients O
and O
three O
of O
the O
26 O
( O
12 O
% O
) O
placebo O
recipients O
were O
assessed O
as O
having O
responded O
with O
a O
substantial O
reduction O
in O
their O
symptoms O
and O
recommencement B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
, O
leisure B-outcome ['Life-Impact']
, O
and O
social B-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

HAEST O
Study O
Group O
. O
[]

As O
part O
of O
the O
comprehensive O
Dental O
Implant O
Clinical O
Research O
Group O
clinical O
implant O
study O
, O
the O
preoperative O
or O
postoperative O
use O
of O
antibiotics O
, O
the O
type O
used O
, O
and O
the O
duration O
of O
coverage O
was O
left O
to O
the O
discretion O
of O
the O
surgeon O
. O
[]

Three O
groups O
of O
young O
patients O
with O
borderline O
hypertension O
were O
studied O
for O
a O
12 O
months O
period O
. O
[]

In O
15 O
hypertensive O
patients O
, O
noradrenaline B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
adrenaline I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
kinetics I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
intra-arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
were O
performed O
at O
rest O
, O
after O
mental O
stress O
( O
difficult O
mental O
arithmetic O
) O
and O
during O
head-up O
tilting O
, O
at O
the O
end O
of O
the O
2-week O
dosing O
periods O
. O
['Physiological-Clinical']

The O
proportion O
of O
infants O
with O
serum O
retinol O
values O
below O
20 O
microg O
per O
deciliter O
( O
0.70 O
micromol O
per O
liter O
) O
was O
lower O
in O
the O
vitamin O
A O
group O
than O
in O
the O
control O
group O
( O
25 O
percent O
vs. O
54 O
percent O
, O
P O
< O
0.001 O
) O
. O
[]

CONCLUSIONS O
We O
advocate O
that O
to O
maintain O
optimal B-outcome ['Physiological-Clinical']
lens I-outcome ['Physiological-Clinical']
integrity I-outcome ['Physiological-Clinical']
and O
ocular B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
, O
RGP O
lenses O
used O
for O
extended O
wear O
should O
be O
replaced O
every O
3 O
to O
6 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Patients O
in O
CC O
were O
more O
likely O
to O
receive O
adequate B-outcome ['Life-Impact']
( O
type O
, O
['Life-Impact']

Pethidine O
versus O
tramadol O
for O
pain O
relief O
during O
labor O
. O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Postoperative O
neuralgias O
have O
a O
deleterious O
effect O
on O
all O
patient-reported O
outcomes O
. O
[]

Long-term O
results O
after O
intracoronary O
injection O
of O
autologous O
mononuclear O
bone O
marrow O
cells O
in O
acute O
myocardial O
infarction O
: O
the O
ASTAMI O
randomised O
, O
controlled O
study O
. O
[]

Significantly O
poorer O
5-year O
PFS B-outcome ['Mortality']
was O
seen O
in O
children O
younger O
than O
24 O
months O
, O
those O
with O
fibrillary O
astrocytoma O
, O
and O
those O
with O
posterior O
fossa O
tumors O
. O
['Mortality']

Immunological O
studies O
of O
both O
lymphocyte B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
subset O
number O
were O
performed O
preoperatively O
and O
on O
Days O
1 O
, O
4 O
, O
7 O
, O
and O
10 O
. O
['Physiological-Clinical']

Acute O
and O
long-term O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
risperidone O
in O
children O
with O
autism O
. O
['Life-Impact']

No O
differences O
between O
the O
2 O
groups O
were O
noted O
in O
the O
rates O
of O
increase O
in O
retinal B-outcome ['Physiological-Clinical']
area O
involved O
by O
CMV B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

Moreover O
, O
it O
suggests O
a O
close O
relationship O
between O
the O
ability O
of O
listeners O
to O
perform O
frequency O
discrimination O
of O
simple O
tones O
and O
spectral-shape O
discrimination O
of O
two-tone O
complexes O
. O
[]

METHODS O
Sixty-six O
children O
( O
mean O
age O
7.5 O
y O
) O
with O
autistic O
disorder O
, O
Asperger O
's O
disorder O
, O
and O
PDD O
not O
otherwise O
specified O
, O
were O
randomized O
to O
varying O
sequences O
of O
placebo O
and O
three O
different O
doses O
of O
methylphenidate O
during O
a O
4-week O
blinded O
, O
crossover O
study O
. O
[]

There O
were O
no O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
reported O
. O
['Adverse-effects']

Additionally O
, O
adequacy O
of O
the O
reduction O
and O
the O
location O
of O
the O
implant O
within O
the O
femoral O
head O
as O
predictors O
of O
fixation O
failure O
were O
evaluated O
. O
[]

The O
subgroup O
of O
patients O
with O
sarcomas O
of O
the O
trunk O
( O
39 O
patients O
) O
demonstrated O
the O
greatest O
benefit O
from O
chemotherapy O
, O
with O
regard O
to O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
less O
than O
or O
equal O
to O
0.001 O
) O
. O
['Mortality']

Among O
the O
postmenopausal O
patients O
there O
were O
no O
substantial O
differences O
in O
terms O
of O
recurrence-free B-outcome ['Mortality']
or I-outcome ['Mortality']
overall I-outcome ['Mortality']
survival I-outcome ['Mortality']
between O
the O
treatment O
groups O
. O
['Mortality']

Fluorescein B-outcome ['Physiological-Clinical']
angiographic I-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
classic I-outcome ['Physiological-Clinical']
and O
occult B-outcome ['Physiological-Clinical']
CNV I-outcome ['Physiological-Clinical']
could O
not O
be O
halted O
by O
10 O
Gy O
, O
while O
a O
temporary B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
retardation I-outcome ['Physiological-Clinical']
was O
observed O
in O
cases O
irradiated O
with O
36 O
Gy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Data O
on O
the O
long-term O
benefits O
of O
nonspecific O
disease O
management O
programs O
are O
limited O
. O
[]

Amlodipine O
camsylate O
is O
a O
newer O
formulation O
developed O
for O
generic O
use O
. O
[]

Secondly O
, O
to O
evaluate O
urine O
levels O
of O
ferulic O
acid O
as O
a O
possible O
biomarker O
of O
the O
ordinary O
dietary O
intake O
of O
ferulic O
acid O
. O
[]

This O
paper O
presents O
results O
of O
3 O
weeks O
physical O
training O
on O
glucosamine O
level O
in O
serum O
of O
male O
patients O
after O
myocardial O
infarction O
( O
MI O
) O
aged O
between O
38 O
and O
61 O
. O
[]

The O
benefit O
of O
randomization O
to O
TG O
over O
MP O
, O
as O
measured O
by O
EFS O
, O
was O
evident O
primarily O
in O
boys O
who O
began O
TG O
at O
60 O
mg/m O
( O
2 O
) O
( O
relative O
hazard O
rate O
[ O
RHR O
] O
0.65 O
, O
P O
= O
.002 O
) O
. O
[]

Frequency O
of O
side O
effects O
was O
similar O
between O
the O
two O
groups O
. O
[]

Dose O
dependent O
pharmacokinetics O
of O
theophylline O
: O
Michaelis-Menten O
parameters O
for O
its O
major O
metabolic O
pathways O
. O
[]

Forty-one O
children O
, O
all O
inpatients O
, O
ages O
2.9 O
to O
7.8 O
years O
, O
completed O
the O
study O
. O
[]

At O
this O
time O
, O
patency O
at O
the O
PTA O
site O
was O
determined O
by O
arteriography O
. O
[]

BACKGROUND O
Patients O
with O
Raynaud O
's O
syndrome O
have O
abnormal O
digital O
vasoconstriction O
, O
which O
may O
be O
secondary O
to O
impaired O
synthesis O
of O
, O
or O
impaired O
sensitivity O
to O
, O
nitric O
oxide O
. O
[]

UNLABELLED O
Bone O
, O
muscle O
, O
and O
fat O
may O
affect O
gait O
and O
balance O
in O
older O
adults O
. O
[]

OBJECTIVE O
To O
assess O
the O
impact O
of O
nasal O
allergy O
on O
sputum B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
results O
indicated O
that O
self-reports O
and O
urinalysis O
are O
complementary O
methods O
of O
[]

A O
twice-daily O
0.1 O
mg O
imidafenacin O
with O
placebo O
, O
or O
once-daily O
4 O
mg O
fesoterodine O
with O
placebo O
were O
administered O
for O
12 O
weeks O
. O
[]

The O
questionnaire O
was O
filled O
in O
during O
an O
interview O
on O
three O
occasions O
: O
at O
the O
beginning O
of O
intervention O
, O
after O
six O
months O
and O
at O
the O
end O
of O
12 O
months O
. O
[]

The O
present O
study O
evaluated O
the O
efficacy O
of O
a O
clinician-guided O
Internet-delivered O
cognitive O
behaviour O
therapy O
( O
iCBT O
) O
program O
, O
the O
Pain O
Course O
, O
to O
reduce O
disability B-outcome ['Life-Impact']
, O
anxiety B-outcome ['Life-Impact']
, O
and O
depression B-outcome ['Life-Impact']
associated O
with O
chronic O
pain O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
times O
were O
60 O
weeks O
for O
PLD O
and O
56.7 O
weeks O
for O
topotecan O
. O
['Mortality']

METHODS O
Participants O
included O
112 O
families O
of O
a O
child O
who O
had O
Autism O
Spectrum O
Disorder O
who O
met O
criteria O
for O
being O
low-resourced O
and O
who O
were O
randomly O
assigned O
to O
1 O
of O
2 O
3-month O
interventions O
, O
group O
caregiver O
education O
or O
individualized O
caregiver-mediated O
intervention O
( O
CMM O
) O
. O
[]

An O
explanation O
for O
the O
increased O
morbidity B-outcome ['Physiological-Clinical']
seems O
to O
be O
that O
the O
volume O
of O
lung O
tissue O
, O
encompassed O
within O
the O
full-dose O
target O
volume O
, O
is O
the O
crucial O
factor O
. O
['Physiological-Clinical']

AIMS O
Testing O
the O
effectiveness O
of O
a O
topical O
combination O
preparation O
containing O
standardized O
leech O
extract O
, O
polidocanol O
and O
allantoin O
. O
[]

The O
main O
findings O
of O
this O
study O
show O
that O
before O
the O
intervention O
, O
no O
significant O
difference O
was O
observed O
in O
the O
health O
status O
of O
the O
children O
. O
[]

Patients O
randomized O
to O
CM O
achieved O
better O
outcomes O
than O
those O
randomized O
to O
SC O
, O
but O
there O
was O
no O
interaction O
between O
treatment O
condition O
and O
AD O
status O
. O
[]

There O
were O
2 O
cases O
of O
severe O
bleeding O
after O
MARS O
was O
finished O
in O
the O
heparin O
group O
, O
and O
1 O
was O
terminated O
because O
of O
degree O
III O
clotting O
in O
the O
heparin-free O
group O
. O
[]

These O
could O
be O
shown O
to O
be O
of O
younger O
mental O
age O
and O
less O
adaptive O
as O
measured O
by O
the O
Vineland O
Behavior B-outcome ['Life-Impact']
Scales O
. O
['Life-Impact']

Participants O
of O
the O
Web-based O
intervention O
were O
significantly O
younger O
( O
P O
< O
.001 O
) O
, O
more O
often O
men O
( O
P=.01 O
) O
, O
had O
a O
higher O
body O
mass O
index O
( O
BMI O
) O
( O
P=.001 O
) O
and O
a O
lower O
intention O
to O
be O
physically O
active O
( O
P=.03 O
) O
than O
participants O
of O
the O
printed O
intervention O
. O
[]

Patients O
who O
received O
this O
drug O
also O
showed O
a O
reduced O
number O
of O
dysrhythmic B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
24-hour I-outcome ['Physiological-Clinical']
ECG I-outcome ['Physiological-Clinical']
recordings I-outcome ['Physiological-Clinical']
, O
but O
this O
trend O
did O
not O
achieve O
statistical O
significance O
. O
['Physiological-Clinical']

Most O
had O
used O
heroin O
by O
injection O
. O
[]

All O
relevant O
prognostic O
factors O
were O
balanced O
, O
with O
the O
exception O
that O
there O
were O
significantly O
more O
progesterone O
receptor O
positive O
patients O
in O
the O
doxorubicin-treated O
group O
. O
[]

2 O
. O
[]

Comparison O
of O
high O
and O
low O
dose O
of O
the O
inhaled O
steroid O
, O
budesonide O
, O
as O
an O
initial O
treatment O
in O
newly O
detected O
asthma O
. O
[]

RESULTS O
At O
6 O
months O
, O
the O
RVCAL B-outcome ['Physiological-Clinical']
gains O
of O
the O
control O
and O
test O
group O
were O
0.39 O
+/- O
1.00 O
and O
0.54 O
+/- O
0.95 O
mm O
, O
while O
the O
RHCAL B-outcome ['Physiological-Clinical']
gains O
were O
1.21 O
+/- O
2.28 O
and O
1.36 O
+/- O
1.26 O
mm O
( O
p O
> O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
importance O
of O
the O
dual-switch O
valve O
for O
the O
treatment O
of O
adult O
normotensive O
or O
hypertensive O
hydrocephalus O
. O
[]

CONCLUSIONS O
We O
found O
little O
evidence O
for O
the O
involvement O
of O
iron O
exposure O
in O
the O
pathogenesis O
of O
GCC B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Consecutive O
patients O
affected O
by O
stage O
IB-IIB O
cervical O
carcinoma O
scheduled O
for O
radical O
surgery O
entered O
the O
study O
. O
[]

Compared O
with O
placebo O
, O
analysis O
of O
variance O
( O
ANOVA O
) O
of O
the O
change O
from O
baseline O
showed O
that O
cilomilast O
did O
not O
alter O
any O
sputum B-outcome ['Physiological-Clinical']
endpoint O
or O
FEV1 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

As O
with O
RU O
486 O
, O
the O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
metabolites I-outcome ['Physiological-Clinical']
were O
maintained O
at O
high O
levels O
for O
up O
to O
48-72 O
h O
after O
dosing O
. O
['Physiological-Clinical']

[ O
Effects O
of O
small O
needle-knife O
comprehensive O
therapy O
on O
pain O
and O
lumbar O
flexion O
range O
in O
the O
chronic O
nonspecific O
low O
back O
pain O
patient O
] O
. O
[]

The O
greatest O
benefit O
was O
observed O
in O
patients O
who O
had O
previously O
received O
chemotherapy O
. O
[]

A O
prospective O
and O
randomized O
study O
was O
performed O
to O
compare O
the O
treatment O
effect O
of O
3 O
day O
miconazole O
( O
400 O
mg/d O
) O
, O
6 O
day O
miconazole O
( O
400 O
mg/d O
) O
, O
and O
7 O
day O
miconazole O
( O
200 O
mg/d O
) O
for O
uncomplicated O
and O
complicated O
VVC O
. O
[]

Marginal O
zone O
B O
cell O
lymphoma O
of O
the O
parotid O
glands O
: O
results O
of O
a O
randomised O
trial O
comparing O
radiotherapy O
to O
combined O
therapy O
. O
[]

PURPOSE O
To O
analyze O
and O
compare O
the O
extension B-outcome ['Physiological-Clinical']
and O
the O
speed O
of O
the O
evolutional O
process O
of O
children O
with O
Autism O
Spectrum O
Disorders O
in O
direct O
and O
indirect O
interventions O
as O
opposed O
to O
only O
indirect O
intervention O
. O
['Physiological-Clinical']

PATIENT O
( O
S O
) O
Infertile O
women O
at O
their O
first O
visit O
to O
a O
tertiary O
referral O
infertility O
clinic O
( O
n O
= O
94 O
) O
and O
new O
patients O
seeking O
pre-natal O
care O
( O
n O
= O
110 O
) O
who O
had O
smoked O
> O
/= O
3 O
cigarettes O
in O
the O
past O
six O
months O
. O
[]

BACKGROUND O
Although O
physical O
therapy O
and O
falls O
prevention O
education O
are O
argued O
to O
reduce O
falls B-outcome ['Life-Impact']
and O
disability B-outcome ['Life-Impact']
in O
people O
with O
idiopathic O
Parkinson O
's O
disease O
, O
this O
has O
not O
yet O
been O
confirmed O
with O
a O
large O
scale O
randomised O
controlled O
clinical O
trial O
. O
['Life-Impact', 'Life-Impact']

CONCLUSION O
Skills O
acquired O
using O
the O
AccuTouch O
simulator O
transfer O
well O
into O
the O
clinical O
colonoscopy O
environment O
. O
[]

It O
has O
been O
proposed O
that O
women O
who O
have O
a O
negative O
colposcopic O
examination O
or O
who O
have O
no O
cervical O
intraepithelial O
neoplasia O
( O
CIN O
) O
on O
colposcopic O
biopsy O
can O
be O
safely O
returned O
to O
routine O
screening O
with O
the O
next O
visit O
being O
three O
or O
five O
years O
later O
. O
[]

Children O
from O
highly O
stressed O
families O
appeared O
to O
benefit O
most O
, O
reinforcing O
the O
importance O
of O
involving O
families O
in O
early O
childhood O
intervention O
programmes O
. O
[]

RESULTS O
Significant O
differences O
( O
P O
< O
0.05 O
) O
from O
control O
or O
placebo O
were O
found O
for O
ESWS O
, O
mean O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
cardiac B-outcome ['Physiological-Clinical']
output O
, O
SVR O
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
P O
wave O
duration O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
exercise O
in O
preventing O
falls B-outcome ['Life-Impact']
varied O
significantly O
by O
baseline O
physical O
function O
level O
( O
p O
< O
or O
=.002 O
) O
. O
['Life-Impact']

19 O
% O
higher O
after O
methylprednisolone O
and O
betamethasone O
( O
P O
< O
0.05 O
) O
compared O
with O
placebo O
. O
[]

A O
proposed O
method O
to O
derive O
systolic O
PAP O
should O
be O
used O
while O
screening O
the O
patients O
at O
risk O
for O
pulmonary O
hypertension O
, O
monitoring O
the O
disease O
progression O
and O
the O
effect O
of O
treatment O
. O
[]

The O
core O
temperature O
triggering O
sweating B-outcome ['Physiological-Clinical']
, O
adjusted O
to O
a O
designated O
mean O
skin O
temperature O
of O
34 O
degrees O
C O
, O
identified O
the O
threshold O
for O
this O
response O
. O
['Physiological-Clinical']

PH-LPL B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
increased O
significantly O
in O
both O
groups O
, O
displaying O
increased O
fatty O
acid O
mobilization O
. O
['Physiological-Clinical']

Effect O
of O
duloxetine O
on O
pain B-outcome ['Physiological-Clinical']
, O
function B-outcome ['Life-Impact']
, O
and O
quality O
of O
life O
among O
patients O
with O
chemotherapy-induced O
painful O
peripheral O
neuropathy O
: O
a O
randomized O
clinical O
trial O
. O
['Physiological-Clinical', 'Life-Impact']

The O
duration O
of O
[]

RESULTS O
The O
median O
skin B-outcome ['Life-Impact']
incision I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
delivery I-outcome ['Life-Impact']
interval I-outcome ['Life-Impact']
was O
shorter O
with O
omission O
of O
the O
bladder O
flap O
( O
9 O
[ O
range O
1-43 O
] O
compared O
with O
10 O
[ O
range O
2-70 O
] O
minutes O
; O
P=.04 O
) O
, O
but O
there O
was O
no O
difference O
in O
total O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
( O
51 O
[ O
range O
18-124 O
] O
minutes O
compared O
with O
51 O
[ O
range O
16-178 O
] O
; O
P=.10 O
) O
. O
['Life-Impact', 'Life-Impact']

After O
6-months O
of O
exercise O
intervention O
, O
we O
observed O
a O
dose O
dependent O
increase O
in O
all O
parasympathetically O
derived O
time O
and O
frequency O
domain O
measurements O
across O
exercise O
groups O
after O
adjustment O
for O
age O
, O
ethnicity O
, O
antidepressants B-outcome ['Resource-use']
, O
and O
baseline O
rMSSD O
( O
all O
, O
P O
< O
0.001 O
) O
. O
['Resource-use']

The O
pilot O
study O
attempted O
to O
make O
a O
comparison O
between O
the O
human O
radius O
and O
the O
sheep O
tibia O
for O
experimental O
purposes O
. O
[]

RESULTS O
One O
hundred O
eighteen O
patients O
were O
enrolled O
. O
[]

CONCLUSIONS O
The O
plasma O
concentrations O
of O
VLDL B-outcome ['Physiological-Clinical']
particles I-outcome ['Physiological-Clinical']
and O
apoCIII O
in O
VLDL B-outcome ['Physiological-Clinical']
and O
LDL B-outcome ['Physiological-Clinical']
are O
more O
specific O
measures O
of O
coronary O
heart O
disease O
risk O
than O
plasma O
triglycerides O
perhaps O
because O
their O
known O
metabolic O
properties O
link O
them O
more O
closely O
to O
atherosclerosis O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Double-blinded O
, O
prospective O
, O
randomized O
, O
controlled O
clinical O
trial O
. O
[]

Our O
findings O
show O
that O
the O
influenza O
vaccine O
alone O
as O
well O
as O
the O
combination O
of O
the O
influenza O
and O
pneumococcal O
vaccine O
increases O
CRP-levels O
with O
a O
peak O
2 O
days O
after O
vaccination O
. O
['Physiological-Clinical']

The O
weight O
reduction O
was O
greater O
( O
-4.6 O
kg O
) O
at O
1 O
year O
in O
the O
intervention O
group O
( O
n O
= O
152 O
) O
than O
in O
the O
control O
group O
( O
n O
= O
143 O
, O
-0.9 O
kg O
, O
P O
< O
0.0001 O
) O
, O
and O
this O
difference O
was O
sustained O
in O
the O
second O
year O
of O
follow-up O
. O
[]

In O
the O
investigator O
's O
global B-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
, O
93.7 O
% O
of O
the O
active O
treatment O
group O
versus O
65.4 O
% O
of O
the O
placebo O
group O
were O
rated O
as O
improved O
at O
the O
end O
of O
the O
study O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Within O
each O
diet O
, O
individuals O
were O
randomly O
assigned O
to O
receive O
losartan O
or O
placebo O
for O
4 O
weeks O
in O
double-blind O
, O
cross-over O
fashion O
. O
[]

One O
epileptic O
woman O
delivered O
a O
newborn O
with O
cleft O
lip O
and O
palate O
. O
[]

After O
6 O
months O
' O
treatment O
, O
patients O
receiving O
ViviScal O
showed O
a O
mean O
increase O
in O
non-vellus B-outcome ['Physiological-Clinical']
hair I-outcome ['Physiological-Clinical']
of O
38 O
% O
compared O
with O
a O
2 O
% O
increase O
in O
the O
fish O
extract O
treatment O
group O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Ketorolac O
30 O
mg O
and O
pethidine O
75 O
mg O
provided O
similar O
but O
variable O
quality O
of O
analgesia O
after O
caesarean O
section O
. O
[]

Our O
hypothesis O
is O
that O
coinduction O
with O
clonidine O
reduces O
the O
incidence O
of O
PONV O
in O
adult O
patients O
undergoing O
breast O
cancer O
surgery O
. O
[]

BACKGROUND O
Prior O
pilot O
studies O
support O
the O
use O
of O
antiviral O
medications O
with O
topical O
corticosteroids O
for O
herpes O
simplex O
labialis O
( O
HSL O
) O
. O
[]

In O
classrooms O
with O
either O
low O
or O
high O
program O
fidelity O
, O
students O
in O
Strategies O
for O
Teaching O
based O
on O
Autism O
Research O
experienced O
a O
greater O
gain O
in O
Differential O
Ability B-outcome ['Life-Impact']
Scales O
score O
than O
students O
in O
Structured O
Teaching O
( O
11.2 O
vs. O
5.5 O
points O
and O
11.3 O
vs. O
8.9 O
points O
, O
respectively O
) O
. O
['Life-Impact']

Both O
random O
assignment O
and O
large-scale O
geographic O
area O
research O
designs O
were O
used O
. O
[]

preoperatively O
, O
2x0.5 O
mg O
digoxin O
intravenously O
on O
the O
operating O
day O
and O
digoxin O
0.25 O
mg O
P.O.+metoprolol O
100 O
mg O
P.O O
. O
[]

CLINICAL O
TRIALS O
REGISTRY O
This O
phase-4 O
study O
is O
registered O
at O
ClinicalTrials.gov O
( O
NCT00576732 O
) O
. O
[]

SETTING O
The O
medical O
intensive O
care O
unit O
( O
ICU O
) O
of O
a O
university O
hospital O
located O
in O
a O
large O
metropolitan O
area O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
association O
between O
estrogen B-outcome ['Physiological-Clinical']
and O
spatial B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
tasks O
in O
women O
suffering O
from O
schizophrenia O
. O
['Physiological-Clinical', 'Life-Impact']

Conservative O
treatment O
of O
plantar O
fasciitis O
. O
[]

Multivariate O
regression O
analysis O
revealed O
that O
the O
relative O
risk O
of O
death B-outcome ['Mortality']
and O
reinfarction B-outcome ['Physiological-Clinical']
during O
the O
initial O
year O
after O
AMI O
was O
increased O
by O
a O
factor O
of O
1.7 O
and O
2.1 O
among O
patients O
with O
LV O
hypertrophy O
, O
respectively O
. O
['Mortality', 'Physiological-Clinical']

Frequency O
and O
percentage O
of O
responses O
to O
different O
measures O
of O
adherence O
were O
carried O
out O
as O
well O
as O
correlation O
between O
the O
measures O
. O
[]

Twenty-six O
patients O
in O
the O
ketorolac O
group O
and O
17 O
patients O
in O
the O
pethidine O
group O
requested O
further O
analgesia B-outcome ['Resource-use']
by O
90 O
minutes O
. O
['Resource-use']

Treatment O
discontinuations B-outcome ['Life-Impact']
were O
more O
common O
in O
the O
ABC O
arm O
( O
p O
= O
.001 O
) O
. O
['Life-Impact']

BACKGROUND O
Although O
dental O
care O
settings O
provide O
an O
exceptional O
opportunity O
to O
reach O
smokers O
and O
provide O
brief O
cessation O
advice O
and O
treatment O
to O
reduce O
oral O
and O
other O
tobacco-related O
health O
conditions O
, O
dental O
care O
providers O
demonstrate O
limited O
adherence O
to O
evidence-based O
guidelines O
for O
treatment O
of O
tobacco O
use O
and O
dependence O
. O
[]

This O
may O
theoretically O
result O
in O
a O
higher O
TTI O
than O
a O
longitudinal O
orientation O
because O
of O
poorer O
contact O
at O
the O
lateral O
paddle O
edges O
. O
[]

Correcting O
for O
body O
height O
decreased O
the O
association O
with O
age O
. O
[]

Because O
of O
slow O
accrual O
, O
the O
two O
chemotherapy O
groups O
were O
combined O
and O
compared O
with O
ASC O
alone O
for O
the O
primary O
outcome O
of O
overall O
survival O
. O
[]

The O
combination O
treatment O
had O
no O
adverse O
effects O
. O
[]

Findings O
showed O
the O
significant O
decrease O
in O
the O
mean O
scores O
of O
fatigue B-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
and O
significant O
improvement O
in O
mean O
scores O
of O
ADL B-outcome ['Life-Impact']
( O
p O
< O
0.001 O
) O
and O
QOL B-outcome ['Life-Impact']
( O
p O
< O
0.001 O
) O
after O
home-based O
nursing O
pulmonary O
rehabilitation O
in O
the O
case O
group O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Multichannel O
urodynamic O
studies O
were O
completed O
with O
and O
without O
rectal O
balloon O
distension O
. O
[]

A O
comparison O
of O
local O
anaesthetics O
for O
venepuncture O
. O
[]

After O
6 O
months O
, O
body B-outcome ['Life-Impact']
image I-outcome ['Life-Impact']
and O
cosmetic B-outcome ['Life-Impact']
appearance I-outcome ['Life-Impact']
were O
assessed O
using O
a O
validated O
survey O
. O
['Life-Impact', 'Life-Impact']

For O
some O
guidelines O
there O
were O
no O
group O
differences O
. O
[]

Six O
hundred O
and O
twelve O
infertile O
women O
candidates O
for O
intrauterine O
insemination O
( O
IUI O
) O
received O
HP-hMG O
75 O
IU/day O
SC O
from O
cycle O
days O
4 O
to O
8 O
and O
then O
as O
per O
ovarian O
response O
. O
[]

The O
GH O
response O
to O
low-dose O
bolus O
growth O
hormone-releasing O
hormone O
( O
GHRH O
( O
1-29 O
) O
NH2 O
) O
is O
attenuated O
in O
patients O
with O
longstanding O
post-irradiation O
GH O
insufficiency O
. O
[]

OBJECTIVE O
Safety O
and O
efficacy O
of O
botulinum O
neurotoxin O
type O
A O
preparation O
NT O
201 O
( O
Xeomin O
, O
Merz O
Pharmaceuticals O
GmbH O
, O
Frankfurt O
am O
Main O
, O
Germany O
) O
were O
investigated O
over O
52 O
weeks O
in O
a O
double-blind O
, O
randomized O
trial O
with O
32 O
male O
volunteers O
. O
[]

Fifty-four O
patients O
treated O
with O
daunorubicin O
, O
cytosine O
arabinoside O
and O
thioquanine O
for O
acute O
myeloid O
leukemia O
were O
randomly O
assigned O
to O
receive O
oral O
lithium O
carbonate O
1200 O
mg O
daily O
or O
no O
lithium O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
of O
meropenem O
, O
a O
new O
carbapenem O
antibiotic O
, O
with O
that O
of O
imipenem O
, O
which O
is O
the O
standard O
prophylactic O
treatment O
in O
patients O
with O
severe O
acute O
pancreatitis O
. O
[]

Other O
injuries O
appeared O
unaffected O
by O
the O
brace O
. O
[]

Thirteen O
individuals O
with O
ASD O
participated O
in O
an O
8-wk O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
divalproex O
sodium O
vs. O
placebo O
. O
[]

STUDY O
DESIGN O
A O
total O
of O
78 O
boys O
age O
13-15 O
years O
with O
a O
mean O
body O
fat O
percentage O
of O
30 O
% O
+/-9 O
% O
were O
randomly O
assigned O
to O
consume O
fish O
oil O
( O
providing O
1.5 O
g O
of O
n-3 O
long-chain O
polyunsaturated O
fatty O
acid/day O
) O
or O
vegetable O
oil O
( O
control O
) O
for O
16 O
weeks O
. O
[]

A O
multi-institutional O
prospective O
randomized O
double-blind O
study O
was O
designed O
. O
[]

There O
were O
not O
differences O
in O
the O
presence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
between O
groups O
. O
['Adverse-effects']

For O
instrumentation O
prior O
to O
each O
treatment O
, O
each O
dog O
was O
anesthetized O
with O
isoflurane O
. O
[]

METHODS/DESIGN O
The O
trial O
protocol O
was O
developed O
in O
consultation O
with O
an O
interdisciplinary O
team O
of O
clinical O
researchers O
. O
[]

METHOD O
In O
this O
relatively O
long-term O
study O
of O
risperidone O
efficacy O
and O
safety O
for O
aggression O
and O
self-injury O
in O
children O
, O
adolescents O
, O
and O
adults O
with O
MR O
and O
PDDs O
, O
serum B-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
was O
measured O
in O
a O
21-subject O
subset O
during O
the O
course O
of O
a O
double-blind O
, O
placebo-controlled O
trial O
. O
['Physiological-Clinical']

The O
interstimulus O
interval O
( O
ISI O
) O
, O
or O
time O
interval O
between O
the O
go O
and O
stop O
signals O
, O
was O
randomly O
varied O
between O
0 O
and O
200 O
ms. O
Electromyographic B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EMG I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
recorded O
from O
biceps O
brachii O
and O
triceps O
brachii O
. O
['Physiological-Clinical']

RATIONALE O
AND O
OBJECTIVE O
Depression O
is O
a O
significant O
complication O
of O
stroke O
. O
[]

RESULTS O
A O
total O
of O
200 O
patients O
were O
enrolled O
. O
[]

Patients O
will O
be O
assigned O
to O
receive O
either O
amiodarone O
or O
placebo O
. O
[]

Process O
evaluation O
of O
Healthy O
Bodies O
, O
Healthy O
Souls O
: O
a O
church-based O
health O
intervention O
program O
in O
Baltimore O
City O
. O
[]

Patients O
were O
randomized O
to O
receive O
cisplatin O
( O
20 O
mg/m2 O
) O
plus O
etoposide O
( O
100 O
mg/m2 O
) O
( O
VP O
) O
both O
given O
intravenously O
( O
i.v O
. O
) O
[]

The O
active O
treatment O
groups O
all O
resulted O
in O
improvements O
across O
all O
outcome O
measures O
, O
with O
moderate-to-large O
effect O
sizes O
from O
baseline O
to O
a O
12-week O
assessment O
. O
[]

Patients O
performed O
under O
general O
anesthesia O
( O
n O
= O
35 O
) O
were O
separated O
as O
a O
nasogastric O
tube O
for O
visualization O
of O
the O
esophagus O
was O
used O
. O
[]

The O
volunteer O
study O
did O
not O
confirm O
this O
finding O
in O
man O
. O
[]

The O
primary O
endpoint O
was O
the O
difference O
in O
AF B-outcome ['Physiological-Clinical']
frequency O
between O
the O
pre-treatment O
period O
and O
the O
final O
month O
of O
the O
follow-up O
. O
['Physiological-Clinical']

INTERVENTIONS O
Sixty O
minutes O
, O
3 O
times O
a O
week O
for O
6 O
weeks O
of O
robot-assisted O
planar O
reaching O
( O
gravity O
compensated O
) O
, O
combined O
planar O
with O
vertical O
robot-assisted O
reaching O
, O
or O
intensive O
conventional O
arm O
exercise O
program O
. O
[]

However O
, O
DPP-4 O
inhibitors O
also O
reduce O
fasting O
blood O
glucose O
, O
an O
unexpected O
effect O
because O
circulating O
levels O
of O
active O
GIP O
and O
GLP-1 O
are O
low O
in O
the O
postabsorptive O
state O
. O
[]

The O
contribution O
of O
salvage O
surgery O
to O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
similar O
for O
both O
arms O
of O
the O
study O
as O
was O
the O
surgical B-outcome ['Adverse-effects']
complication I-outcome ['Adverse-effects']
rate O
. O
['Mortality', 'Adverse-effects']

Individuals O
with O
high O
levels O
of O
BP O
features O
( O
n O
= O
30 O
) O
and O
controls O
with O
low O
levels O
of O
BP O
features O
( O
n O
= O
44 O
) O
were O
randomly O
assigned O
to O
a O
condition O
involving O
negative O
evaluation O
based O
on O
writing B-outcome ['Life-Impact']
( O
negative O
evaluation/academic O
) O
, O
or O
a O
condition O
involving O
negative O
evaluation O
based O
on O
personal B-outcome ['Life-Impact']
characteristics I-outcome ['Life-Impact']
as O
well O
as O
social B-outcome ['Life-Impact']
rejection I-outcome ['Life-Impact']
( O
negative O
evaluation/social O
rejection I-outcome ['Life-Impact']
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

OBJECTIVE O
To O
investigate O
whether O
4-month O
preoperative O
lanreotide O
treatment O
would O
improve O
the O
surgical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rate O
of O
newly O
diagnosed O
acromegalic O
patients O
with O
macroadenomas O
. O
['Physiological-Clinical']

Improvement O
of O
pain O
related O
self O
management O
for O
oncologic O
patients O
through O
a O
trans O
institutional O
modular O
nursing O
intervention O
: O
protocol O
of O
a O
cluster O
randomized O
multicenter O
trial O
. O
[]

The O
incidence O
of O
severe B-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
was O
lower O
in O
the O
PGE1 O
group O
-- O
13 O
% O
versus O
32 O
% O
, O
but O
this O
did O
not O
reach O
significance O
. O
['Physiological-Clinical']

High B-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
( O
greater O
than O
37.8C O
) O
was O
more O
frequent O
in O
the O
nerve O
block O
group O
and O
2 O
patients O
in O
this O
group O
required O
rehospitalization O
. O
['Physiological-Clinical']

The O
time B-outcome ['Resource-use']
to I-outcome ['Resource-use']
discharge I-outcome ['Resource-use']
with O
M O
, O
almost O
six O
hours O
, O
was O
significantly O
longer O
than O
with O
C O
or O
L. O
There O
was O
a O
trend O
to O
an O
increasing O
rate O
of O
unplanned B-outcome ['Resource-use']
overnight I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
admission I-outcome ['Resource-use']
with O
increasing O
duration O
of O
the O
local O
anesthetic O
drug O
employed O
. O
['Resource-use', 'Resource-use']

Effects O
of O
tryptophan O
depletion O
in O
drug-free O
adults O
with O
autistic O
disorder O
. O
[]

Patient O
compliance O
with O
the O
unsupervised O
usage O
of O
prescription O
medication O
can O
be O
poor O
. O
[]

CatD B-outcome ['Physiological-Clinical']
and O
TAG-72 B-outcome ['Physiological-Clinical']
were O
quantified O
with O
immunoradiometric B-outcome ['Physiological-Clinical']
( O
IRMA O
) O
methods O
, O
and O
EGFR B-outcome ['Physiological-Clinical']
were O
studied O
by O
radioimmunoassay B-outcome ['Resource-use']
( O
RIA O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Continuous O
and O
cyclical O
clodronate O
therapies O
and O
bone O
density O
in O
postmenopausal O
bone O
loss O
. O
[]

Most O
men O
randomised O
to O
conservative O
management O
were O
willing O
to O
undertake O
it O
as O
part O
of O
a O
trial O
but O
at O
the O
end O
of O
the O
trial O
they O
were O
divided O
between O
those O
who O
wanted O
to O
continue O
with O
it O
and O
those O
who O
expected O
surgery O
. O
[]

AIMS O
To O
determine O
whether O
web-based O
tailored O
cessation O
advice O
, O
based O
on O
social O
cognitive O
theory O
and O
the O
perspectives O
on O
change O
model O
, O
was O
more O
effective O
in O
aiding O
a O
quit O
attempt O
than O
broadly O
similar O
web-based O
advice O
that O
was O
not O
tailored O
. O
[]

The O
steepness O
parameter O
was O
somewhat O
higher O
in O
the O
logistic O
model O
, O
also O
resulting O
in O
a O
slightly O
lower O
D O
( O
50 O
) O
. O
[]

METHODS O
Type O
2 O
diabetic O
patients O
( O
N.=57 O
) O
were O
divided O
into O
two O
groups O
as O
with O
nephropathy O
( O
N.=27 O
) O
and O
without O
nephropathy O
( O
N.=30 O
) O
. O
[]

Occasionally O
, O
some O
restorations O
presented O
loose O
abutment O
screws O
and/or O
fistulas O
during O
follow-up O
. O
[]

nifedipine O
SR O
was O
more O
effective O
than O
Ginkgo O
biloba O
extract O
for O
treatment O
of O
primary O
RP O
in O
Korean O
patients O
. O
[]

A O
pilot O
study O
on O
the O
efficacy O
of O
melodic O
based O
communication O
therapy O
for O
eliciting B-outcome ['Life-Impact']
speech I-outcome ['Life-Impact']
in O
nonverbal O
children O
with O
autism O
. O
['Life-Impact']

RESULTS O
The O
exercise O
class O
group O
improved O
from O
a O
mean O
Constant O
score O
of O
39.8 O
at O
baseline O
to O
71.4 O
at O
6 O
weeks O
and O
88.1 O
at O
1 O
year O
. O
[]

Children O
were O
assessed O
at O
the O
end O
of O
a O
two-week O
placebo-baseline O
period O
and O
again O
after O
four O
weeks O
of O
treatment O
. O
[]

The O
impact O
of O
daily O
sodium O
intake O
on O
posttransplant B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
in O
kidney O
allograft O
recipients O
. O
['Physiological-Clinical']

Therefore O
we O
evaluated O
the O
profile O
of O
AP-1 O
activation O
through O
histological O
analysis O
and O
tested O
the O
potential O
benefit O
of O
AP-1 O
inhibition O
in O
a O
clinical O
trial O
. O
[]

Following O
a O
2-day O
workshop O
, O
13 O
clinicians O
received O
live O
supervision O
via O
telephone O
during O
5 O
counseling O
sessions O
conducted O
at O
their O
community O
treatment O
facilities O
. O
[]

SETTING O
Trauma O
and O
general O
intensive O
care O
units O
of O
a O
university O
tertiary O
teaching O
hospital O
, O
which O
is O
also O
a O
level O
1 O
trauma O
center O
. O
[]

Intravenous O
platelet O
blockade O
with O
cangrelor O
during O
PCI O
. O
[]

Secondary O
endpoints O
include O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
development O
of O
renal B-outcome ['Physiological-Clinical']
and O
visual B-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
, O
peripheral B-outcome ['Physiological-Clinical']
neuropathy I-outcome ['Physiological-Clinical']
, O
health B-outcome ['Physiological-Clinical']
service B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
, O
self-reported B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of O
life O
, O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Life-Impact']

CSF B-outcome ['Physiological-Clinical']
Abeta O
concentrations B-outcome ['Physiological-Clinical']
were O
unchanged O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Intervention O
group O
viewed O
14.9 O
( O
SE O
2.3 O
) O
h/week O
of O
TV O
post O
intervention O
versus O
control O
group O
23.3 O
( O
SE O
2.4 O
) O
h/week O
( O
P O
< O
0.05 O
) O
. O
[]

PATIENTS O
AND O
METHODS O
comorbidity O
was O
independently O
evaluated O
using O
the O
Charlson O
Comorbidity O
Index O
( O
CCI B-outcome ['Physiological-Clinical']
) O
, O
a O
validated O
measure O
of O
comorbidity O
based O
on O
the O
presence O
of O
medical O
conditions O
weighted O
according O
to O
their O
effect O
on O
mortality O
. O
['Physiological-Clinical']

VLDL-cholesterol B-outcome ['Physiological-Clinical']
, O
VLDL-triglyceride B-outcome ['Physiological-Clinical']
, O
VLDL-apoB B-outcome ['Physiological-Clinical']
, O
apoCIII B-outcome ['Physiological-Clinical']
and O
apoE B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
VLDL+LDL I-outcome ['Physiological-Clinical']
and O
apoE B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
HDL I-outcome ['Physiological-Clinical']
were O
all O
interrelated O
, O
and O
each O
was O
a O
univariate O
predictor O
of O
subsequent O
coronary O
events O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
One-year-long O
complementary O
feeding O
with O
FS O
does O
not O
have O
a O
significantly O
larger O
effect O
than O
LP O
on O
mean O
weight O
gain O
in O
all O
infants O
, O
but O
it O
is O
likely O
to O
boost O
linear B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
in O
the O
most O
disadvantaged O
individuals O
and O
, O
hence O
, O
decrease O
the O
incidence O
of O
severe B-outcome ['Physiological-Clinical']
stunting I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
plasma O
levels O
of O
epinephrine O
, O
norepinephrine O
, O
glucose O
, O
lactate O
and O
free O
glycerol O
were O
measured O
in O
addition O
to O
mean O
arterial O
pressure O
( O
MAP O
) O
and O
heart O
rate O
( O
HR O
) O
immediately O
before O
anaesthesia O
, O
10 O
minutes O
after O
skin O
incision O
, O
10 O
minutes O
after O
having O
started O
bone O
drilling O
, O
at O
the O
end O
of O
the O
operation O
and O
3 O
hours O
after O
operation O
. O
[]

Isoflavone B-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
were O
inversely O
associated O
with O
risk O
of O
fibroadenomas B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
nifedipine O
on O
gastric B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
and O
gastrin B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
in O
man O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Whereas O
the O
clinical O
and O
CRP O
changes O
among O
ACR20 O
nonresponders O
to O
infliximab O
plus O
MTX O
were O
small O
and O
much O
lower O
than O
among O
ACR20 O
responders O
to O
this O
treatment O
, O
radiographic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
among O
ACR20 O
nonresponders O
to O
infliximab O
plus O
MTX O
was O
significantly O
inhibited O
( O
P O
< O
0.001 O
) O
compared O
with O
ACR20 O
nonresponders O
to O
MTX O
plus O
placebo O
. O
['Physiological-Clinical']

The O
urinary O
metabolites O
consist O
of O
carvedilol O
glucuronide O
( O
5.2 O
% O
of O
the O
dose O
) O
, O
cleavage O
products O
of O
the O
beta-blocking O
side O
chain O
( O
2.1 O
% O
) O
, O
and O
ring-hydroxylated O
forms O
( O
2.9 O
% O
) O
. O
[]

We O
attempted O
to O
assess O
whether O
retroperitoneal O
partial O
no-closure O
reduces O
the O
incidence O
of O
lymphocyst B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
following O
retroperitoneal O
lymphadenectomy O
. O
['Physiological-Clinical']

Further O
results O
of O
the O
study O
and O
the O
clinical O
implications O
are O
discussed O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
mean O
percentage O
decrease O
of O
AMH B-outcome ['Physiological-Clinical']
levels O
in O
the O
BC O
group O
and O
LS O
group O
at O
3- O
, O
6- O
, O
and O
12-month O
follow-up O
. O
['Physiological-Clinical']

All O
children O
were O
diagnosed O
with O
AS O
and O
the O
presence O
of O
anxiety O
symptoms O
was O
accepted O
on O
parent O
report O
via O
brief O
interview O
. O
[]

PATIENTS O
AND O
METHODS O
Enrolled O
in O
the O
study O
were O
184 O
patients O
, O
and O
all O
received O
initial O
infusions O
of O
Z O
( O
so O
any O
first O
infusion O
reactions O
did O
not O
confound O
preferences O
for O
P O
) O
. O
[]

METHODS O
Forty O
type-2 O
diabetic O
patients O
with O
never-treated O
hypertension O
were O
randomly O
assigned O
to O
two O
groups O
. O
[]

Two O
patients O
in O
each O
group O
had O
elevated O
triglyceride B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

There O
was O
less O
intraoperative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
a O
lower O
rate O
of O
wound B-outcome ['Physiological-Clinical']
complications B-outcome ['Resource-use']
in O
the O
patients O
treated O
by O
the O
Gamma O
nail O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

The O
effects O
of O
music O
played O
during O
an O
exercise O
task O
on O
athletic O
performance O
have O
been O
previously O
studied O
. O
[]

Controlled O
clinical O
trial O
of O
IV O
cyclophosphamide O
versus O
IV O
methylprednisolone O
in O
severe O
neurological O
manifestations O
in O
systemic O
lupus O
erythematosus O
. O
[]

METHODS O
In O
vitro O
: O
the O
PRV O
was O
set O
to O
10 O
, O
15 O
, O
20 O
or O
25 O
cmH2O O
release O
pressure O
and O
connected O
to O
a O
cuffed O
tube O
placed O
into O
a O
box O
flushed O
with O
66 O
% O
N2O O
in O
O2 O
. O
[]

DISCUSSION O
Findings O
from O
this O
study O
support O
that O
these O
telephone-delivered O
psychosocial O
interventions O
were O
effective O
for O
decreasing O
symptoms O
of O
[]

Thus O
, O
studies O
examining O
a O
link O
between O
smoking O
and O
gastric O
emptying O
disorders O
have O
clinical O
relevance O
. O
[]

Furthermore O
, O
in O
cimetidine- O
but O
not O
sucralfate-healed O
patients O
, O
early O
ulcer O
relapse O
( O
within O
6 O
mo O
) O
was O
associated O
with O
short O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
, O
short O
remission B-outcome ['Physiological-Clinical']
period O
, O
long B-outcome ['Physiological-Clinical']
symptomatic I-outcome ['Physiological-Clinical']
spell I-outcome ['Physiological-Clinical']
, O
and O
reluctance O
to O
give O
up O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Plasma O
norepinephrine O
levels O
, O
which O
reflect O
sympathetic O
nervous O
system O
activity O
, O
are O
almost O
universally O
elevated O
in O
patients O
with O
left O
ventricular O
dysfunction O
. O
[]

We O
developed O
a O
telemedicine O
system O
for O
remote O
guidance O
of O
emergency O
airway O
management O
called O
the O
Tele-Airway O
Management O
System O
( O
TAMS O
) O
. O
[]

RESPIRE O
( O
Randomized O
Exposure O
Study O
of O
Pollution O
Indoors O
and O
Respiratory O
Effects O
) O
was O
a O
randomized O
trial O
of O
a O
chimney O
woodstove O
that O
reduces O
wood O
smoke O
exposure O
. O
[]

A O
total O
of O
388 O
participants O
developed O
the O
composite O
endpoint O
, O
302 O
developed O
AIDS O
or O
died O
, O
and O
188 O
died O
. O
[]

These O
findings O
localize O
abnormal B-outcome ['Physiological-Clinical']
Mu-activity I-outcome ['Physiological-Clinical']
in O
the O
brain O
of O
Asperger O
children O
providing O
evidence O
which O
associates O
motor-system O
abnormalities O
with O
social-function B-outcome ['Life-Impact']
deficits I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Allergic O
children O
have O
a O
different O
fecal O
microflora O
, O
with O
less O
lactobacilli O
and O
bifidobacteria O
. O
[]

BACKGROUND O
Controlling O
alloimmune O
humoral O
response O
is O
a O
challenge O
in O
transplantation O
. O
[]

Several O
observations O
suggest O
a O
beneficial O
effect O
of O
melatonin O
antagonism O
for O
Parkinson O
's O
disease O
( O
PD O
) O
. O
[]

Analysis O
of O
covariance O
was O
used O
to O
compare O
differences O
in O
week O
12 O
adjusted O
mean O
changes O
from O
baseline O
on O
the O
17-item O
Hamilton O
Depression O
Rating O
Scale O
( O
HAM-D?? O
) O
( O
primary O
outcome O
) O
and O
Sheehan O
Disability O
Scale O
( O
SDS O
) O
( O
key O
secondary O
outcome O
) O
in O
the O
intent-to-treat O
( O
ITT O
) O
population O
. O
[]

Subjects O
in O
all O
three O
groups O
chose O
5 O
mg O
diazepam O
as O
often O
as O
placebo O
but O
preferred O
placebo O
to O
10 O
mg O
diazepam O
. O
[]

The O
following O
differences O
were O
significant O
: O
group O
CTR O
versus O
groups O
S O
, O
M O
, O
and O
S+M O
with O
values O
of O
p O
= O
0.002 O
, O
p O
= O
0.007 O
and O
p O
< O
0.0001 O
, O
respectively O
; O
and O
group O
S+M O
versus O
groups O
S O
and O
M O
with O
p O
= O
0.04 O
and O
p O
= O
0.01 O
, O
respectively O
. O
[]

RESULTS O
Seven O
( O
37 O
% O
) O
of O
the O
19 O
patients O
given O
dexamethasone O
but O
only O
one O
( O
6 O
% O
) O
of O
the O
18 O
patients O
given O
placebo O
responded O
positively O
. O
[]

RESULTS O
Physician B-outcome ['Life-Impact']
prompting I-outcome ['Life-Impact']
, O
dependent B-outcome ['Life-Impact']
drinking I-outcome ['Life-Impact']
, O
and O
recent B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
were O
significant O
correlates O
of O
physician O
counseling O
( O
P O
< O
.05 O
) O
, O
while O
male O
gender O
was O
a O
marginally O
significant O
correlate O
( O
P O
= O
.08 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Thus O
, O
a O
randomized O
controlled O
trial O
of O
food O
form O
was O
conducted O
. O
[]

METHODS O
A O
single-blinded O
randomized O
controlled O
trial O
was O
conducted O
at O
the O
Loewenstein O
Rehabilitation O
Hospital O
, O
Israel O
. O
[]

METHODS O
In O
a O
randomized O
population-based O
screening O
study O
( O
Rotterdam O
section O
of O
the O
European O
Randomized O
Study O
of O
Screening O
for O
Prostate O
Cancer O
) O
, O
in O
which O
10,865 O
men O
have O
been O
screened O
, O
the O
biopsy O
results O
of O
1202 O
men O
with O
PSA O
levels O
of O
4 O
ng/mL O
or O
more O
were O
evaluated O
. O
[]

In O
the O
normal O
men O
, O
saline O
or O
continuous O
( O
0.8 O
mU O
kg-1 O
min-1 O
) O
or O
pulsatile O
( O
5.2 O
mU O
kg-1 O
min-1 O
, O
with O
a O
switching O
on/off O
length O
of O
2/11 O
min O
) O
human O
insulin O
were O
delivered O
on O
different O
days O
and O
in O
random O
order O
. O
[]

The O
combination O
regimen O
produced O
significantly O
greater O
ofloxacin B-outcome ['Physiological-Clinical']
levels O
than O
did O
topical O
therapy O
alone O
( O
P O
=.007 O
) O
. O
['Physiological-Clinical']

An O
empirical O
comparison O
of O
the O
St O
George O
's O
Respiratory O
Questionnaire O
( O
SGRQ O
) O
and O
the O
Chronic O
Respiratory O
Disease O
Questionnaire O
( O
CRQ O
) O
in O
a O
clinical O
trial O
setting O
. O
[]

INTERVENTION O
The O
nutrition O
goals O
for O
women O
randomly O
assigned O
to O
the O
low-fat O
intervention O
were O
to O
reduce O
total O
fat O
intake O
to O
20 O
% O
or O
less O
of O
energy O
from O
fat O
and O
to O
consume O
5 O
or O
more O
fruit/vegetable O
servings O
daily O
and O
6 O
or O
more O
grain O
servings O
daily O
. O
[]

The O
children O
and O
their O
caregivers O
are O
participants O
in O
the O
ongoing O
Seattle-King O
County O
Healthy O
Homes O
Project O
, O
a O
randomized O
controlled O
trial O
of O
an O
intervention O
to O
empower O
low-income O
families O
to O
reduce O
exposure O
to O
indoor O
asthma O
triggers O
. O
[]

American O
College O
of O
Cardiology/European O
Society O
of O
Cardiology O
International O
Study O
of O
Angiographic O
Data O
Compression O
Phase O
I O
: O
The O
effect O
of O
lossy O
data O
compression O
on O
recognition O
of O
diagnostic O
features O
in O
digital O
coronary O
angiography O
. O
[]

BACKGROUND O
Practice O
nurses O
play O
an O
increasingly O
important O
role O
in O
the O
prevention O
of O
cardiovascular O
diseases O
but O
we O
do O
not O
have O
evidence O
about O
the O
accuracy O
of O
their O
cardiovascular O
risk O
assessments O
during O
real O
practice O
consultations O
. O
[]

The O
treatment O
group O
consisted O
of O
13 O
patients O
who O
were O
given O
5 O
mg O
finasteride O
daily O
for O
4 O
weeks O
before O
surgery O
. O
[]

BACKGROUND O
Acupuncture O
is O
widely-used O
to O
treat O
patients O
with O
low O
back O
pain O
, O
despite O
insufficient O
evidence O
of O
the O
technique O
's O
efficacy O
for O
acute O
back O
pain O
. O
[]

Reference B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
( O
95 O
% O
confidence O
limits O
) O
were O
calculated O
: O
some O
of O
these O
values O
differed O
markedly O
from O
those O
formerly O
recommended O
. O
['Physiological-Clinical']

Cough B-outcome ['Physiological-Clinical']
was O
more O
often O
reported O
with O
lisinopril O
and O
headache B-outcome ['Physiological-Clinical']
, O
sweating B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
combined O
analysis O
of O
the O
two O
studies O
was O
prospectively O
defined O
and O
agreed O
to O
by O
both O
groups O
. O
[]

Overall O
the O
mean O
postoperative B-outcome ['Physiological-Clinical']
Snore I-outcome ['Physiological-Clinical']
Index O
( O
SI O
) O
was O
less O
than O
the O
preoperative O
SI O
( O
P O
< O
0.0001 O
) O
, O
the O
average O
difference O
being O
78.2 O
snores/h O
. O
['Physiological-Clinical']

Daily O
drug O
doses O
were O
adjusted O
progressively O
to O
attain O
optimal O
hypotensive O
effects O
. O
[]

CONTEXT O
Influenza O
virus O
neuraminidase O
is O
thought O
to O
be O
essential O
for O
virus O
replication O
in O
humans O
; O
however O
, O
to O
date O
, O
available O
neuraminidase O
inhibitors O
are O
limited O
to O
zanamivir O
, O
which O
is O
topically O
administered O
. O
[]

RESULTS O
All O
reinfusion O
sessions O
were O
tolerated B-outcome ['Life-Impact']
well O
by O
all O
patients O
. O
['Life-Impact']

This O
is O
an O
important O
intermediate O
step O
in O
object B-outcome ['Physiological-Clinical']
recognition I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
study O
evaluated O
the O
efficacy O
of O
TKI O
re-treatment O
in O
patients O
with O
disease O
progression O
after O
a O
TKI-everolimus O
sequence O
. O
[]

Increased O
cellular B-outcome ['Physiological-Clinical']
infiltration I-outcome ['Physiological-Clinical']
was O
observed O
in O
all O
patients O
receiving O
placebo O
( O
n=3 O
) O
; O
variable O
changes O
were O
observed O
after O
IL-1Ra O
30 O
mg/day O
( O
n=6 O
) O
. O
['Physiological-Clinical']

The O
primary O
endpoint O
was O
adenoma O
recurrence O
. O
[]

CONCLUSION O
Cyclophosphamide O
seemed O
to O
have O
a O
similar O
effect O
on O
EFS B-outcome ['Physiological-Clinical']
and O
OS B-outcome ['Physiological-Clinical']
as O
ifosfamide O
in O
SR O
patients O
but O
was O
associated O
with O
increased O
['Physiological-Clinical', 'Physiological-Clinical']

Discrete-trial O
training O
( O
DTT O
) O
relies O
critically O
on O
implementation O
by O
trained O
tutors O
. O
[]

More O
than O
one O
adenoma O
at O
first O
examination O
was O
associated O
with O
higher O
risk O
[]

It O
has O
become O
evident O
that O
elevated O
plasma O
norepinephrine O
levels O
are O
directly O
related O
to O
prognosis O
; O
patients O
with O
levels O
> O
900 O
pg/ml O
have O
a O
poor O
prognosis O
and O
shortened O
life O
expectancy O
. O
[]

BACKGROUND/OBJECTIVES O
Studies O
suggest O
that O
excessive O
sun O
exposure O
in O
childhood O
contributes O
to O
the O
development O
of O
skin O
cancer O
later O
in O
life O
. O
[]

METHODS O
The O
design O
of O
the O
study O
was O
a O
three-wave O
repeated O
measures O
with O
a O
between-subjects O
factor O
( O
treatment O
group O
) O
. O
[]

RESULTS O
After O
the O
interventions O
, O
significant O
differences O
were O
found O
in O
the O
[]

Patients O
of O
resectable O
esophageal O
cancer O
of O
comparable O
stage O
were O
allocated O
to O
undergo O
the O
transthoracic O
or O
transhiatal O
procedure O
in O
turn O
. O
[]

The O
number O
of O
patients O
who O
needed O
a O
second O
blood B-outcome ['Resource-use']
patch I-outcome ['Resource-use']
did O
not O
differ O
significantly O
between O
the O
two O
groups O
: O
6 O
( O
10.0 O
% O
) O
for O
prophylactic O
epidural O
blood O
patch O
and O
4 O
( O
11.1 O
% O
) O
for O
therapeutic O
epidural O
blood O
patch O
. O
['Resource-use']

The O
occurrence O
of O
infection B-outcome ['Physiological-Clinical']
of O
pancreatic I-outcome ['Physiological-Clinical']
necrosis B-outcome ['Physiological-Clinical']
, O
rate O
of O
extrapancreatic B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
, O
systemic B-outcome ['Physiological-Clinical']
and O
local O
complications B-outcome ['Adverse-effects']
, O
need O
for O
surgery B-outcome ['Resource-use']
, O
mortality B-outcome ['Mortality']
rate O
, O
and O
length O
of O
hospitalization B-outcome ['Resource-use']
were O
recorded O
for O
each O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Resource-use', 'Mortality', 'Resource-use']

Despite O
this O
, O
this O
underserved O
population O
has O
received O
very O
little O
attention O
from O
health O
disparities O
researchers O
. O
[]

The O
study O
was O
prematurely O
ended O
due O
to O
insufficient O
recruitment O
flow O
. O
[]

Impact O
of O
triiodothyronine O
on O
the O
survival O
of O
high-risk O
patients O
undergoing O
open O
heart O
surgery O
. O
[]

OBJECTIVES O
Recent O
studies O
on O
tinnitus O
have O
focused O
on O
the O
efficacy O
of O
Internet-based O
interventions O
. O
[]

Indeed O
, O
suicidality O
( O
ideation O
or O
behavior O
) O
is O
generally O
an O
exclusion O
criterion O
for O
participation O
in O
treatment O
studies O
of O
subjects O
with O
alcohol O
or O
drug O
abuse O
. O
[]

Therapeutic B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
in O
the O
CQ-treated O
group O
was O
associated O
with O
an O
age O
< O
15 O
years O
old O
( O
P O
< O
0.01 O
) O
, O
but O
was O
not O
associated O
with O
initial O
parasite O
density O
, O
the O
presence O
of O
CQ O
or O
sulfa-containing O
drugs O
in O
urine O
, O
or O
a O
history O
of O
malaria O
. O
['Physiological-Clinical']

A O
prospective O
randomized O
study O
was O
conducted O
to O
determine O
the O
ablation B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
of O
mitoxantrone O
in O
Ta-T1 O
superficial O
bladder O
tumors O
versus O
mitomycin O
C O
, O
a O
drug O
whose O
intravesical O
ablation O
properties O
are O
well-known O
. O
['Physiological-Clinical']

21 O
mm O
( O
p O
= O
0.0081 O
) O
. O
[]

The O
effect O
of O
high-dose O
metoclopramide O
( O
2 O
mg/kg O
, O
4 O
times O
every O
2 O
hours O
) O
on O
the O
emesis B-outcome ['Physiological-Clinical']
of O
patients O
treated O
with O
CDDP O
( O
80 O
mg/m2 O
) O
was O
examined O
by O
randomized O
control O
trial O
. O
['Physiological-Clinical']

Arousal B-outcome ['Life-Impact']
was O
measured O
behaviorally O
with O
the O
Conners O
Parent O
Rating O
Scale O
and O
physiologically O
with O
galvanic O
skin O
response O
( O
GSR O
) O
readings O
. O
['Life-Impact']

This O
study O
was O
set O
up O
to O
examine O
whether O
an O
influenza O
vaccine O
or O
an O
influenza O
vaccine O
in O
combination O
with O
pneumococcal O
vaccine O
can O
be O
used O
as O
a O
model O
to O
study O
responses O
to O
mild O
stimulation O
of O
the O
inflammatory O
system O
. O
[]

INTRODUCTION O
St. O
John O
's O
wort O
( O
SJW O
) O
is O
a O
widely O
used O
herbal O
supplement O
. O
[]

Women O
( O
8,800 O
) O
, O
aged O
30-62 O
, O
were O
randomly O
selected O
among O
women O
without O
a O
registered O
Pap O
smear O
in O
the O
two O
latest O
screening O
rounds O
. O
[]

Outcomes O
of O
interest O
were O
death B-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
death B-outcome ['Mortality']
or O
MI O
at O
180 O
days O
. O
['Mortality', 'Physiological-Clinical', 'Mortality']

Pharmacokinetic-pharmacodynamic B-outcome ['Physiological-Clinical']
modelling O
of O
the O
antihistaminic O
( O
H1 O
) O
effect O
of O
bilastine O
. O
['Physiological-Clinical']

The O
usefulness O
of O
OK-432 O
was O
studied O
using O
the O
sealed O
envelope O
method O
. O
[]

Patients O
were O
assigned O
to O
each O
of O
the O
following O
treatments O
: O
oral O
CoQ O
( O
10 O
) O
( O
100 O
mg O
tid O
) O
, O
CoQ O
( O
10 O
) O
plus O
supervised O
exercise O
training O
( O
ET O
) O
( O
60 O
% O
of O
peak O
VO O
( O
2 O
) O
, O
five O
times O
a O
week O
) O
, O
placebo O
, O
and O
placebo O
plus O
ET O
. O
[]

is O
effective O
and O
well-tolerated O
and O
can O
be O
used O
as O
alternative O
therapy O
for O
mild O
and O
mild O
to O
moderate O
ED O
. O
[]

The O
efficacy O
of O
sublingual O
immunotherapy O
for O
respiratory O
allergy O
is O
not O
affected O
by O
different O
dosage O
regimens O
in O
the O
induction O
phase O
. O
[]

To O
counteract O
this O
trend O
, O
a O
language O
and O
culture O
specific O
education O
program O
was O
developed O
. O
[]

Infective B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
occurred O
in O
12/32 O
( O
37 O
per O
cent O
) O
of O
the O
cefotaxime O
group O
and O
15/31 O
( O
48 O
per O
cent O
) O
of O
the O
cephamandole O
group O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
in O
vivo O
bitewing O
film O
quality O
using O
the O
holder O
versus O
the O
paper O
loop O
technique O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
etanercept O
and O
control O
groups O
in O
the O
relative O
risk O
of O
disease B-outcome ['Physiological-Clinical']
flares I-outcome ['Physiological-Clinical']
per O
100 O
person-years O
of O
follow-up O
( O
0.89 O
, O
P=0.54 O
) O
. O
['Physiological-Clinical']

The O
main O
purpose O
of O
this O
study O
is O
to O
evaluate O
the O
effectiveness O
of O
lifestyle O
counselling O
on O
the O
level O
of O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
in O
an O
occupational O
health O
setting O
. O
['Life-Impact']

Uncertainty O
remains O
as O
to O
the O
clinical O
effectiveness O
of O
reduced O
visit O
schedules O
for O
rare O
pregnancy O
problems O
. O
[]

At O
the O
last O
assessment O
, O
41 O
% O
of O
the O
patients O
had O
recovered O
their O
previous O
autonomy O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Serum O
levels O
of O
N-acetylcysteine O
were O
measured O
every O
30 O
minutes O
for O
six O
hours O
. O
[]

There O
was O
no O
significant O
pharmacokinetic B-outcome ['Physiological-Clinical']
and O
pharmacodynamic B-outcome ['Physiological-Clinical']
difference O
between O
plain O
bupivacaine O
and O
ropivacaine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

GIR O
during O
the O
last O
hour O
of O
the O
insulin O
clamp O
was O
3.7 O
+/- O
0.6 O
vs O
3.6 O
+/- O
0.6 O
mg/kg O
x O
min O
( O
ns O
) O
. O
[]

This O
study O
assessed O
the O
efficacy O
of O
FaceSay O
, O
a O
computer-based O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
training O
program O
for O
children O
with O
Autism O
Spectrum O
Disorders O
( O
ASD O
) O
. O
['Life-Impact']

Exposure O
reduced O
agoraphobia O
but O
not O
panic O
, O
and O
cognitive O
therapy O
reduced O
panic O
but O
not O
agoraphobia O
. O
[]

Since O
this O
new O
technique O
is O
based O
solely O
upon O
exhalation O
, O
anomalies O
associated O
with O
inspiration O
and O
breath O
holding O
do O
not O
affect O
results O
. O
[]

Topical O
tetracaine O
was O
not O
associated O
with O
a O
significant O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
score O
, O
although O
it O
did O
lead O
to O
faster O
recovery B-outcome ['Physiological-Clinical']
times O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
was O
effective O
even O
though O
most O
of O
the O
individualized O
contacts O
were O
by O
telephone O
. O
[]

INTERPRETATION O
Improving O
nutrition O
in O
early O
childhood O
led O
to O
substantial O
increases O
in O
wage O
[]

Patients O
were O
allocated O
to O
a O
single O
agent O
: O
carvedilol O
25 O
mg O
, O
amlodipine O
10 O
mg O
, O
enalapril O
20 O
mg O
, O
or O
losartan O
50 O
mg O
( O
groups O
C O
, O
A O
, O
E O
, O
and O
L O
, O
respectively O
) O
. O
[]

[ O
Validity O
of O
cardiotocography O
in O
the O
detection O
of O
umbilical B-outcome ['Physiological-Clinical']
cord I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
] O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
Cohort O
study O
( O
diagnosis O
) O
; O
Level O
of O
evidence O
, O
2 O
. O
[]

METHODS O
Eighty-five O
cases O
with O
chronic O
severe O
hepatitis O
were O
randomly O
divided O
into O
ozone O
therapy O
group O
( O
43 O
cases O
) O
and O
control O
group O
( O
42 O
cases O
) O
. O
[]

BACKGROUND O
Breathlessness O
in O
advanced O
disease O
causes O
significant O
distress B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
and O
carers O
and O
presents O
management O
challenges O
to O
health O
care O
professionals O
. O
['Physiological-Clinical']

As O
the O
coefficient O
of O
variation O
( O
VC O
) O
of O
measured O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
continuously O
increased O
the O
best O
time O
of O
a O
steady O
state O
was O
between O
90 O
and O
130 O
min O
after O
beginning O
the O
infusion O
( O
mean O
VC O
8.9 O
% O
) O
. O
['Physiological-Clinical']

This O
may O
result O
from O
local O
differences O
in O
the O
receptor O
distribution O
in O
the O
posterior O
part O
of O
the O
eye O
. O
[]

It O
is O
not O
known O
whether O
more O
potent O
suppression O
of O
acid O
can O
prevent O
NSAID O
damage O
. O
[]

The O
authors O
analyze O
their O
experience O
in O
the O
application O
of O
mexicor O
, O
a O
Russian O
cytoprotector O
, O
in O
50patients O
with O
chronic O
coronary O
artery O
disease O
( O
CAD O
) O
and O
51 O
patients O
with O
acute O
coronary O
syndrome O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
determine O
whether O
a O
pharmacist O
directed O
home O
medication O
review O
intervention O
had O
positive O
effects O
on O
CHF O
patient O
outcomes O
. O
[]

Moreover O
, O
the O
differences O
between O
before O
and O
after O
training O
( O
delta O
values O
) O
for O
the O
Tlim O
, O
METs O
and O
HR O
at O
isotime O
were O
greater O
in O
the O
LED O
group O
than O
in O
the O
exercise O
group O
with O
a O
significant O
intergroup O
difference O
( O
p O
< O
0.05 O
) O
. O
[]

The O
mean O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
at O
0 O
degrees O
was O
found O
to O
be O
statistically O
significant O
higher O
( O
p O
= O
0.0083 O
) O
than O
the O
mean O
cardiac O
output O
at O
45 O
degrees O
. O
['Physiological-Clinical']

Results O
are O
reported O
as O
mean O
? O
[]

The O
baseline O
drug O
was O
efonidipine O
hydrochloride O
, O
a O
long-acting O
calcium O
antagonist O
. O
[]

This O
study O
is O
registered O
with O
, O
number O
NCT00149266 O
. O
[]

METHODS O
Participants O
were O
enrolled O
in O
a O
controlled O
, O
randomised O
clinical O
trial O
in O
Barcelona O
, O
Spain O
, O
from O
April O
2001 O
to O
April O
2005 O
. O
[]

In O
the O
radiotherapy O
group O
, O
19 O
of O
45 O
patients O
had O
bowel B-outcome ['Physiological-Clinical']
or O
bladder B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
patients O
treated O
with O
venlafaxine O
had O
a O
greater O
improvement O
on O
alexithymia B-outcome ['Life-Impact']
severity I-outcome ['Life-Impact']
than O
those O
treated O
with O
fluoxetine O
. O
['Life-Impact']

RESULTS O
Of O
the O
vacuum O
extractor O
group O
, O
85 O
% O
were O
delivered O
by O
the O
allocated O
instrument O
compared O
to O
90 O
% O
in O
the O
forceps O
group O
( O
odds O
ratio O
( O
OR O
) O
0.64 O
; O
95 O
% O
confidence O
intervals O
( O
CI O
) O
0.4-1.04 O
) O
. O
[]

Ranitidine O
pretreatment O
had O
no O
effect O
on O
triazolam B-outcome ['Physiological-Clinical']
's O
terminal B-outcome ['Physiological-Clinical']
elimination O
rate O
constant O
or O
on O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
reach I-outcome ['Physiological-Clinical']
maximum I-outcome ['Physiological-Clinical']
serum B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Reinfarction B-outcome ['Physiological-Clinical']
( O
12.2 O
% O
vs O
3.6 O
% O
, O
p O
less O
than O
0.0001 O
) O
or O
death B-outcome ['Mortality']
( O
6.1 O
% O
vs O
1.5 O
% O
, O
p O
= O
0.003 O
) O
was O
more O
likely O
to O
occur O
within O
2 O
weeks O
of O
randomization O
in O
patients O
with O
postinfarction O
angina O
than O
in O
those O
without O
angina O
. O
['Physiological-Clinical', 'Mortality']

Grade O
III B-outcome ['Physiological-Clinical']
or O
IV B-outcome ['Physiological-Clinical']
hemorrhoids I-outcome ['Physiological-Clinical']
were O
more O
common O
in O
men O
( O
ie O
, O
80.9 O
% O
and O
85.7 O
% O
in O
the O
stapled O
and O
open O
group O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effect O
of O
a O
vitamin/mineral O
supplement O
on O
children O
and O
adults O
with O
autism O
. O
[]

We O
hypothesized O
that O
aging O
would O
be O
associated O
with O
a O
diminished O
proinflammatory O
cytokine O
response O
to O
sepsis O
. O
[]

On O
days O
1 O
and O
7 O
, O
the O
subjects O
received O
YM17E O
once O
a O
day O
( O
after O
breakfast O
) O
for O
evaluation O
of O
pharmacokinetic O
properties O
. O
[]

A O
randomized O
controlled O
trial O
to O
improve O
colon O
cancer O
screening O
in O
rural O
family O
medicine O
: O
an O
Iowa O
Research O
Network O
( O
IRENE O
) O
study O
. O
[]

Three O
to O
10 O
days O
later O
, O
subjects O
received O
in O
a O
single-blind O
, O
randomized O
, O
crossover O
fashion O
oral O
beta-acetyldigoxin O
( O
0.2 O
mg O
) O
twice O
daily O
and O
concomitant O
oral O
pantoprazole O
( O
40 O
mg O
) O
or O
placebo O
once O
daily O
for O
5 O
days O
. O
[]

Of O
the O
initial O
120 O
cases O
, O
11 O
cases O
were O
disqualified O
( O
3 O
cases O
of O
double O
cancer O
and O
8 O
of O
incomplete O
primary O
therapy O
) O
and O
the O
remaining O
109 O
were O
used O
for O
evaluation O
. O
[]

RESULTS O
When O
LA O
was O
stopped O
after O
5 O
days O
of O
administration O
, O
LH B-outcome ['Physiological-Clinical']
levels O
fell O
profoundly O
when O
compared O
with O
levels O
when O
LA O
was O
continued O
. O
['Physiological-Clinical']

Selection O
criteria O
were O
: O
infertility O
> O
1 O
year O
, O
subnormal O
semen O
, O
sonographic O
diameter O
of O
veins O
> O
3 O
mm O
and O
time O
of O
regurge O
> O
2 O
s. O
Patients O
were O
randomly O
assigned O
to O
the O
groups O
of O
treatment O
, O
with O
follow-up O
every O
3 O
months O
for O
1 O
year O
. O
[]

The O
education O
instrument O
was O
developed O
based O
on O
the O
EuroPharm-Forum O
Guidelines O
and O
its O
impact O
assessed O
by O
a O
self-developed O
questionnaire O
. O
[]

There O
were O
28 O
males O
and O
6 O
females O
; O
the O
mean O
age O
was O
30.3 O
years O
. O
[]

All O
measures O
took O
part O
: O
Prior O
to O
randomisation O
, O
15 O
min O
thereafter O
and O
on O
admission O
to O
a O
hospital O
. O
[]

CONCLUSIONS O
These O
data O
suggest O
that O
long-term O
treatment O
with O
pioglitazone O
enhances O
insulin O
sensitivity O
relative O
to O
glimepiride O
in O
Mexican O
patients O
with O
type O
2 O
diabetes O
and O
that O
pioglitazone O
may O
have O
a O
more O
sustained O
antihyperglycemic O
effect O
. O
[]

[ O
One-year O
effect O
of O
health O
counseling O
on O
life O
style O
and O
risk O
factors O
of O
heart O
disease O
] O
. O
[]

BACKGROUND O
The O
objectives O
of O
the O
current O
study O
were O
to O
determine O
the O
outcome O
of O
children O
who O
were O
treated O
with O
chemotherapy O
and O
radiotherapy O
on O
the O
Children O
's O
Cancer O
Group O
( O
CCG O
) O
high-grade O
glioma O
protocol O
( O
CCG-945 O
) O
who O
were O
diagnosed O
with O
low-grade O
gliomas O
on O
post O
hoc O
central O
pathologic O
review O
and O
to O
identify O
clinical B-outcome ['Physiological-Clinical']
and O
biologic O
features O
associated O
with O
prognosis O
. O
['Physiological-Clinical']

Interleukin-8 B-outcome ['Physiological-Clinical']
and O
neutrophil B-outcome ['Physiological-Clinical']
elastase I-outcome ['Physiological-Clinical']
were O
measured O
in O
sputum O
supernatant O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
obtained O
economic O
data O
from O
1424 O
Guatemalan O
individuals O
( O
aged O
25-42 O
years O
) O
between O
2002 O
and O
2004 O
. O
[]

The O
number O
of O
mild B-outcome ['Physiological-Clinical']
hypoglycemic I-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
per O
patient-week O
was O
0.99 O
( O
95 O
% O
CI O
0.11-1.87 O
) O
higher O
in O
the O
insulin O
pump O
group O
( O
P O
= O
0.028 O
) O
. O
['Physiological-Clinical']

DESIGN O
Prospective O
, O
randomized O
clinical O
trial O
. O
[]

The O
eligible O
subjects O
were O
HIV-infected O
Thai O
adults O
who O
had O
never O
received O
anti-retrovirals O
, O
had O
a O
Karnofski O
Performance O
Score O
( O
KPS O
) O
of O
> O
or O
= O
70 O
, O
and O
had O
no O
opportunistic O
infections O
. O
[]

Changes O
in O
the O
minimal B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
of O
the O
1063 O
preexisting O
coronary O
stenoses O
compared O
between O
both O
angiograms O
were O
set O
in O
relation O
to O
a O
number O
of O
conventional B-outcome ['Physiological-Clinical']
stenosis I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
at O
baseline O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
authors O
conclude O
that O
0.9 O
mg O
of O
atropine O
with O
2.5 O
mg O
neostigmine O
can O
be O
safely O
used O
as O
the O
reversal O
agent O
for O
a O
non-depolarizing O
muscle O
relaxant O
, O
particularly O
in O
patients O
for O
whom O
any O
increase O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
would O
be O
harmful O
. O
['Physiological-Clinical']

However O
, O
feedlot B-outcome ['Physiological-Clinical']
performance O
for O
the O
whole O
trial O
and O
carcass O
characteristics O
( O
except O
for O
fat B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
) O
were O
not O
affected O
( O
P O
> O
.10 O
) O
by O
the O
source O
of O
dietary O
CP O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
40 O
highly O
functioning O
men O
with O
ASD O
participated O
and O
were O
randomized O
in O
the O
trial O
. O
[]

CONCLUSIONS O
Mydriasert O
assures O
an O
adequate O
degree O
of O
mydriasis O
for O
retinal O
angiography O
in O
both O
diabetic O
and O
nondiabetic O
patients O
. O
[]

Consequently O
, O
the O
PostureJac O
may O
be O
a O
useful O
therapeutic O
tool O
in O
the O
management O
of O
cervicogenic B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
and O
mechanical B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
Structural O
and O
immunohistochemical O
changes O
of O
conjunctiva O
induced O
by O
topical O
glaucoma O
medication O
] O
. O
[]

Histamine O
intolerance-like O
symptoms O
in O
healthy O
volunteers O
after O
oral O
provocation O
with O
liquid O
histamine O
. O
[]

Ibopamine O
was O
employed O
at O
a O
dose O
of O
100 O
mg O
t.i.d O
. O
[]

BACKGROUND O
This O
study O
was O
designed O
to O
evaluate O
the O
effects O
of O
a O
low O
intensity O
general O
training O
program O
( O
< O
50 O
% O
of O
heart O
rate O
reserve O
) O
on O
physical O
fitness O
of O
healthy O
older O
subjects O
, O
by O
comparing O
maximal O
and O
submaximal O
indices O
of O
training O
response O
. O
[]

Heparin O
treatment O
was O
successful O
in O
about O
one-half O
of O
our O
cases O
in O
the O
presence O
of O
sessile O
or O
small O
thrombi O
and O
inadequate O
anticoagulant O
status O
. O
[]

OBJECTIVE O
To O
assess O
the O
adherence O
to O
and O
effects O
of O
a O
12-month O
combined O
strength O
and O
stretching O
home O
exercise O
regimen O
versus O
stretching O
alone O
, O
on O
patient O
outcome O
after O
lumbar O
disk O
surgery O
. O
[]

CONCLUSIONS O
Although O
mechanisms O
remain O
unclear O
, O
a O
group-based O
psychosocial O
intervention O
program O
for O
women O
with O
coronary O
heart O
disease O
may O
prolong O
lives O
independent O
of O
other O
prognostic O
factors O
. O
[]

Three O
patients O
experienced O
symptomatic B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

No O
preoperative O
differences O
between O
the O
two O
groups O
were O
encountered O
with O
respect O
to O
the O
side O
effects O
of O
the O
premedication O
. O
[]

The O
population O
PK O
model O
of O
clonidine B-outcome ['Resource-use']
was O
developed O
by O
NONMEM O
, O
and O
significant O
covariates O
were O
identified O
, O
followed O
by O
nonparametric O
bootstraps O
( O
2000 O
replicates O
) O
and O
simulation O
experiments O
. O
['Resource-use']

The O
ORR B-outcome ['Physiological-Clinical']
was O
better O
with O
the O
longer O
regimens O
( O
arm O
A O
, O
56.9 O
% O
; O
B O
, O
64 O
% O
; O
and O
C O
, O
47.6 O
% O
; O
P O
: O
=.06 O
) O
and O
was O
41 O
% O
after O
second-line O
FEC O
100 O
. O
['Physiological-Clinical']

During O
the O
cardiac O
arrest O
simulation O
, O
establishing O
and O
performing O
ventilation B-outcome ['Resource-use']
took O
an O
average O
of O
57 O
s O
with O
the O
LTS-D O
compared O
to O
116 O
s O
with O
ET O
and O
111 O
s O
with O
the O
BMV O
. O
['Resource-use']

Whether O
this O
action O
affects O
the O
final O
outcome O
is O
not O
yet O
determined O
. O
[]

BACKGROUNDS/AIMS O
Elevated O
triglyceride O
levels O
seem O
to O
predispose O
to O
the O
earlier O
development O
and O
accelerated O
progression O
of O
coronary O
artery O
disease O
. O
[]

The O
effect O
of O
glucocorticoid O
administration O
on O
energy B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
and O
food B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
was O
studied O
in O
20 O
healthy O
, O
nondiabetic O
Caucasian O
male O
volunteers O
[ O
27 O
+/- O
5 O
( O
SD O
) O
yr O
, O
72 O
+/- O
9 O
kg O
, O
20 O
+/- O
7 O
% O
body O
fat O
] O
randomly O
and O
blindly O
assigned O
to O
glucocorticoid O
( O
methylprednisolone O
, O
METH O
; O
n O
= O
10 O
) O
or O
placebo O
( O
PLAC O
; O
n O
= O
10 O
) O
treatment O
. O
['Physiological-Clinical', 'Life-Impact']

Of O
1016 O
patients O
( O
45 O
percent O
of O
whom O
had O
ventricular O
fibrillation O
, O
and O
55 O
percent O
ventricular O
tachycardia O
) O
, O
507 O
were O
randomly O
assigned O
to O
treatment O
with O
implantable O
cardioverter-defibrillators O
and O
509 O
to O
antiarrhythmic-drug O
therapy O
. O
[]

BIS O
is O
being O
continuously O
developed O
and O
its O
impact O
evaluated O
using O
the O
MRC O
's O
framework O
for O
complex O
interventions O
( O
PreClinical O
, O
Phase O
I O
and O
Phase O
II O
completed O
) O
. O
[]

All O
patients O
were O
divided O
according O
to O
disease O
location O
( O
colon O
or O
rectum O
) O
and O
received O
one O
of O
two O
chemotherapeutic O
regimens O
after O
surgery O
( O
Regimen O
C O
: O
MMC O
12 O
mg/m2 O
i.v O
. O
[]

PURPOSE O
For O
the O
majority O
of O
children O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
CNS O
prophylaxis O
consists O
of O
either O
intrathecal O
( O
IT O
) O
methotrexate O
or O
triple O
IT O
therapy O
( O
ie O
, O
methotrexate O
with O
both O
cytarabine O
and O
hydrocortisone O
) O
. O
[]

Under O
fasting O
conditions O
, O
24 O
healthy O
Egyptian O
male O
volunteers O
were O
randomly O
allocated O
to O
receive O
a O
single O
oral O
dose O
of O
either O
one O
FDC O
tablet O
or O
co-administration O
of O
two O
separate O
diflunisal O
and O
naproxen O
marketed O
tablets O
. O
[]

BACKGROUND O
The O
laparoscopic O
treatment O
of O
rectal O
cancer O
is O
controversial O
. O
[]

It O
is O
generally O
agreed O
that O
absolute-direction O
judgments O
require O
information O
about O
eye O
position O
, O
whereas O
relative-direction O
judgments O
do O
not O
. O
[]

Earlier O
research O
in O
the O
USA O
has O
shown O
good O
results O
in O
the O
treatment O
of O
depressive O
disorder O
based O
on O
a O
collaborative O
care O
approach O
with O
Problem B-outcome ['Resource-use']
Solving I-outcome ['Resource-use']
Treatment I-outcome ['Resource-use']
and O
an O
antidepressant O
treatment O
algorithm O
, O
and O
research O
in O
the O
UK O
has O
also O
shown O
good O
results O
with O
Problem O
Solving O
Treatment O
. O
['Resource-use']

The O
levels O
of O
prebeta-like B-outcome ['Physiological-Clinical']
HDL I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
alphaHDL I-outcome ['Physiological-Clinical']
in O
the O
delipidated O
plasma O
converted O
from O
5.6 O
% O
to O
79.1 O
% O
and O
92.8 O
% O
to O
20.9 O
% O
, O
respectively O
. O
['Physiological-Clinical']

PATIENTS O
A O
population O
of O
44 O
patients O
with O
oral O
and O
laryngeal O
cancer O
was O
enrolled O
in O
a O
randomized O
trial O
. O
[]

The O
patients O
' O
diary O
cards O
revealed O
that O
both O
drugs O
had O
a O
beneficial O
therapeutic O
effect O
, O
and O
that O
budesonide O
was O
significantly O
more O
active O
than O
Becotide O
Nasal O
. O
[]

Both O
biochemical O
and O
electrophysiological O
results O
argued O
for O
an O
amphetamine-like O
action O
of O
fenfluramine O
in O
those O
autistic O
children O
whose O
attention O
deficits O
are O
associated O
with O
motor O
disturbances O
including O
hyperactivity O
. O
[]

CONCLUSION O
The O
results O
demonstrated O
that O
chemotherapy O
but O
not O
radiotherapy O
results O
in O
significant O
increase O
in O
the O
trace O
elements O
levels O
and O
antioxidant O
activities O
in O
blood O
serum O
of O
cervical O
cancer O
patients O
. O
[]

The O
authors O
hypothesized O
that O
a O
similar O
relationship O
would O
exist O
in O
the O
heart O
, O
and O
that O
the O
pattern O
of O
responses O
would O
be O
qualitatively O
similar O
to O
the O
renal O
vasculature O
. O
[]

The O
best O
prognostic O
factor O
for O
one-year O
survival B-outcome ['Mortality']
was O
the O
response O
rate O
( O
P O
< O
0.0001 O
) O
. O
['Mortality']

They O
all O
had O
a O
DSM-III O
diagnosis O
of O
conduct O
disorder O
-- O
undersocialized O
, O
aggressive O
, O
with O
a O
profile O
of O
highly O
explosive O
and O
aggressive O
behavior O
. O
[]

Two O
hundred O
and O
thirty-seven O
students O
, O
drawn O
from O
six O
homeroom O
grade O
eight O
classes O
were O
randomly O
assigned O
to O
experimental O
and O
control O
( O
no O
intervention O
) O
conditions O
. O
[]

Tumor B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
assessed O
using O
World O
Health O
Organization O
criteria O
. O
['Physiological-Clinical']

This O
study O
evaluated O
the O
feasibility O
of O
using O
CM O
to O
promote O
weight O
loss O
in O
individuals O
with O
SMI O
over O
8 O
weeks O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
investigate O
to O
what O
extent O
acupuncture O
applied O
into O
the O
thenar O
muscle O
and O
into O
the O
cavum O
concha O
of O
the O
ear O
induced O
changes O
in O
the O
sympathetic O
and/or O
parasympathetic O
nervous O
system O
in O
healthy O
subjects O
. O
[]

[ O
Mitoxantrone O
( O
MTX O
) O
versus O
mitomycin O
C O
( O
MMC O
) O
in O
the O
ablative O
treatment O
of O
Ta O
, O
T1 O
superficial O
bladder O
tumors O
. O
[]

Monitoring O
was O
continued O
during O
the O
recovery O
room O
stay O
. O
[]

The O
investigational O
arm O
received O
two O
cycles O
of O
concurrent O
chemotherapy O
with O
cisplatin O
20 O
mg/m O
( O
2 O
) O
/d O
plus O
fluorouracil O
400 O
mg/m O
( O
2 O
) O
/d O
by O
96-hour O
continuous O
infusion O
during O
the O
weeks O
1 O
and O
5 O
of O
RT O
. O
[]

During O
the O
1 O
hour O
after O
administration O
of O
the O
drug O
the O
incidence O
of O
ventricular B-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
or O
sustained B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
among O
the O
204 O
patients O
with O
acute O
myocardial O
infarction O
was O
low O
, O
1.5 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Hospital O
programs O
will O
follow O
the O
traditional O
outpatient O
model O
consisting O
of O
twice O
weekly O
supervised O
exercise O
training O
and O
education O
for O
eight O
weeks O
. O
[]

OBJECTIVE O
This O
study O
aimed O
to O
compare O
the O
haemorrhagic O
complications O
and O
efficacy O
of O
enoxaparin O
, O
a O
low O
molecular O
weight O
heparin O
( O
LMWH O
) O
, O
and O
conventional O
standard O
heparin O
( O
SH O
) O
in O
gynaecological O
oncologic O
surgery O
. O
[]

The O
gum O
containing O
CPP-ACP O
produced O
approximately O
twice O
the O
level O
of O
remineralization B-outcome ['Physiological-Clinical']
as O
the O
control O
sugar-free O
gum O
. O
['Physiological-Clinical']

Mediterranean O
diet O
and O
high O
dietary O
acid O
load O
associated O
with O
mixed O
nuts O
: O
effect O
on O
bone B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
elderly O
subjects O
. O
['Physiological-Clinical']

The O
study O
enrolled O
263 O
healthy O
smokers O
( O
M O
( O
age O
) O
= O
49 O
years O
) O
who O
smoked O
a O
mean O
of O
24 O
cigarettes/day O
, O
with O
a O
mean O
of O
31 O
pack-years O
. O
[]

OBJECTIVE O
To O
explore O
associations O
between O
a O
global O
rating O
for O
the O
classical O
homeopathic O
construct O
of O
vital O
force O
and O
clinician O
and O
patient O
ratings O
on O
previously O
validated O
bio-psycho-social-spiritual O
questionnaires O
. O
[]

We O
conclude O
that O
inability O
to O
determine O
ER O
status O
should O
not O
prejudice O
against O
the O
use O
of O
tamoxifen O
in O
postmenopausal O
patients O
with O
advanced O
breast O
cancer O
. O
[]

The O
average O
number O
of O
dressing B-outcome ['Resource-use']
changes I-outcome ['Resource-use']
performed O
per O
patient O
was O
118.0 O
( O
range O
12-226 O
) O
for O
MWT O
versus O
41 O
( O
6-140 O
) O
for O
NPWT O
( O
P O
= O
.0001 O
) O
. O
['Resource-use']

Soluble O
intercellular O
adhesion O
molecule-1 O
in O
primary O
biliary O
cirrhosis O
: O
effect O
of O
ursodeoxycholic O
acid O
and O
immunosuppressive O
therapy O
. O
[]

CONCLUSIONS O
Although O
the O
present O
validation O
study O
was O
undertaken O
among O
middle-aged O
women O
with O
low O
consumption O
of O
marine O
food O
products O
( O
< O
3 O
servings/week O
) O
, O
our O
FFQ O
provided O
estimates O
of O
EPA O
and O
DHA O
intakes O
that O
correlated O
fairly O
well O
with O
their O
RBC O
concentrations O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
veno-venous O
continuous O
renal O
replacement O
therapy O
( O
CRRT O
) O
on O
the O
plasma O
levels O
of O
endotoxin O
and O
cytokines O
in O
severely O
burned O
patients O
with O
sepsis O
. O
[]

DESIGN O
Subjects O
in O
the O
Optic O
Neuritis O
Treatment O
Trial O
, O
who O
were O
enrolled O
between O
July O
1 O
, O
1988 O
, O
and O
June O
30 O
, O
1991 O
, O
were O
followed O
up O
prospectively O
for O
15 O
years O
, O
with O
the O
final O
examination O
in O
2006 O
. O
[]

Rizatriptan O
10 O
mg O
was O
also O
superior O
to O
sumatriptan O
on O
pain-free O
response O
( O
P O
= O
0.032 O
) O
, O
reduction O
in O
functional B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
( O
P O
= O
0.015 O
) O
, O
and O
relief B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
at O
2 O
hours O
( O
P O
= O
0.010 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

SETTING O
Referral O
clinics O
in O
27 O
academic O
centers O
. O
[]

It O
is O
possible O
that O
interventions O
aimed O
at O
the O
progressive O
neurohormonal O
activation O
that O
occurs O
in O
HF O
may O
improve O
the O
course O
of O
illness O
. O
[]

For O
356 O
patients O
who O
completed O
6 O
years O
of O
etanercept O
treatment O
, O
response O
rates O
were O
ACR20=73 O
% O
, O
ACR50=52 O
% O
, O
ACR70=27 O
% O
, O
DAS28 O
CRP O
good O
response=52 O
% O
, O
and O
DAS28 O
CRP O
remission=37 O
% O
of O
patients O
. O
[]

CONCLUSIONS O
Urban O
and O
rural O
differences O
in O
dietary O
intake O
behavior O
should O
be O
considered O
in O
designing O
public O
health O
interventions O
among O
the O
increasing O
population O
of O
older O
cancer O
survivors O
. O
[]

[ O
Cooperative O
study O
of O
surgical O
adjuvant O
chemotherapy O
of O
colorectal O
carcinoma O
( O
second O
study O
) O
: O
3-year O
survival O
after O
surgery O
of O
non-curatively O
resected O
patients O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

There O
was O
no O
significant O
difference O
in O
the O
rate O
of O
recommendation B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
TKR I-outcome ['Physiological-Clinical']
when O
the O
patient O
was O
black O
( O
47 O
% O
) O
versus O
white O
( O
38 O
% O
) O
( O
P O
= O
.439 O
) O
, O
and O
neither O
implicit O
nor O
explicit O
racial O
biases O
predicted O
differential O
treatment O
recommendations O
by O
race O
( O
all O
P O
> O
.06 O
) O
. O
['Physiological-Clinical']

There O
are O
conflicting O
data O
on O
the O
effect O
of O
adding O
a O
heated O
humidifier O
to O
nasal O
continuous O
positive O
airway O
pressure O
( O
CPAP O
) O
therapy O
for O
patients O
with O
obstructive O
sleep O
apnoea O
syndrome O
( O
OSAS O
) O
. O
[]

Osteosynthesis O
of O
femoral O
shaft O
fractures O
using O
slotted O
nails O
has O
not O
resulted O
in O
healing O
disturbances O
, O
which O
could O
be O
accounted O
for O
by O
the O
high O
torsional O
elasticity O
of O
the O
nail O
; O
there O
seems O
to O
be O
no O
indication O
for O
high-stiffness O
nails O
in O
femoral O
fractures O
. O
[]

As O
a O
conclusion O
, O
the O
present O
study O
does O
not O
provide O
evidence O
in O
favour O
of O
the O
routine O
use O
of O
adjunctive O
metronidazole B-outcome ['Resource-use']
dental I-outcome ['Resource-use']
gel I-outcome ['Resource-use']
in O
the O
treatment O
of O
adult B-outcome ['Physiological-Clinical']
periodontitis I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

RESULTS O
There O
were O
no O
differences O
in O
AI B-outcome ['Physiological-Clinical']
or O
MI B-outcome ['Physiological-Clinical']
in O
biopsy O
tissue O
between O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
feasibility O
studies O
confirmed O
that O
the O
Internet B-outcome ['Life-Impact']
was O
a O
viable O
medium O
, O
as O
the O
majority O
of O
men O
used B-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
computer I-outcome ['Life-Impact']
, O
had O
access B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
Internet I-outcome ['Life-Impact']
, O
and O
Internet B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
increased O
over O
time O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Children O
received O
2 O
doses O
of O
placebo O
or O
porcine O
secretin O
, O
6 O
weeks O
apart O
. O
[]

RESULTS O
We O
undertook O
a O
short-term O
, O
placebo-controlled O
study O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
risperidone O
in O
children O
and O
adolescents O
with O
autistic O
disorder O
. O
[]

Also O
the O
demographic O
data O
, O
operative O
results O
and O
survival B-outcome ['Mortality']
were O
recorded O
. O
['Mortality']

They O
also O
drove B-outcome ['Life-Impact']
earlier O
( O
P=.02 O
) O
. O
['Life-Impact']

Two O
hundred O
and O
nine O
of O
the O
212 O
patients O
randomized O
were O
included O
in O
the O
analyses O
. O
[]

RESULTS O
VO2max B-outcome ['Physiological-Clinical']
improved O
significantly O
in O
both O
running O
and O
snowshoeing O
groups O
, O
6.3 O
and O
8.5 O
% O
, O
respectively O
. O
['Physiological-Clinical']

All O
but O
one O
of O
the O
scales O
met O
the O
minimum O
criteria O
of O
reliability O
( O
Cronbach O
's O
alpha O
> O
/ O
0.70 O
) O
. O
[]

Subtotal O
, O
bilateral O
strumectomies O
were O
performed O
according O
to O
Rothmund O
's O
suggestions O
. O
[]

The O
purpose O
of O
this O
trial O
is O
to O
explore O
the O
effect O
of O
two O
different O
potentially O
important O
design O
features O
on O
clinical B-outcome ['Life-Impact']
reasoning I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
and O
the O
student B-outcome ['Life-Impact']
experience I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

BACKGROUND O
Diabetes O
mellitus O
is O
associated O
with O
accelerated O
coronary O
atheroma O
progression O
. O
[]

RESULTS O
Group O
B O
patients O
showed O
a O
significant O
improvement O
in O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
: O
serum B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
urea I-outcome ['Physiological-Clinical']
nitrogen B-outcome ['Physiological-Clinical']
48.9 O
+/- O
10.3 O
to O
32.1 O
+/- O
14.4 O
mg/dl O
( O
p O
< O
0.05 O
) O
; O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
1.97 O
+/- O
0.24 O
to O
1.49 O
+/- O
0.39 O
mg/dl O
( O
p O
< O
0.05 O
) O
; O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
35.6 O
+/- O
11.6 O
to O
48.8 O
+/- O
12.3 O
ml/min O
( O
p O
< O
0.05 O
) O
; O
and O
indexed B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
0.56 O
+/- O
0.16 O
to O
2.02 O
+/- O
0.72 O
ml/kg/h O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
patients O
admitted O
to O
the O
hospital O
with O
acute O
HF O
, O
both O
ventricles O
were O
evaluated O
by O
echocardiography O
on O
admission O
, O
at O
discharge O
, O
and O
at O
3 O
months O
. O
[]

Induction O
chemotherapy O
was O
generally O
followed O
by O
radiation O
therapy O
( O
RT O
) O
starting O
after O
week O
9 O
. O
[]

METHODS O
Fifty O
ASA O
I-II O
patients O
were O
included O
in O
the O
randomized O
double O
blind O
study O
. O
[]

CONCLUSIONS O
Low O
doses O
of O
haloperidol O
, O
risperidone O
, O
and O
olanzapine O
seem O
to O
equally O
affect O
gray B-outcome ['Physiological-Clinical']
matter I-outcome ['Physiological-Clinical']
cortical I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
overall I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
lobes I-outcome ['Physiological-Clinical']
, O
at O
the O
medium-term O
( O
1 O
year O
) O
. O
['Physiological-Clinical']

In O
the O
intention-to-treat O
analysis O
, O
the O
primary O
end O
point O
occurred O
in O
269 O
patients O
in O
the O
rivaroxaban O
group O
( O
2.1 O
% O
per O
year O
) O
and O
in O
306 O
patients O
in O
the O
warfarin O
group O
( O
2.4 O
% O
per O
year O
) O
( O
hazard O
ratio O
, O
0.88 O
; O
95 O
% O
CI O
, O
0.74 O
to O
1.03 O
; O
P O
< O
0.001 O
for O
noninferiority O
; O
P=0.12 O
for O
superiority O
) O
. O
[]

INTRODUCTION O
Most O
pharmacological O
treatments O
that O
are O
currently O
being O
developed O
for O
women O
with O
sexual O
arousal O
disorder O
are O
aimed O
at O
remedying O
a O
vasculogenic O
deficit O
. O
[]

METHODS O
AND O
RESULTS O
Forty-eight O
patients O
with O
unexplained O
syncope O
and O
negative O
passive O
head-up O
tilt O
at O
70 O
degrees O
for O
40 O
min O
, O
and O
14 O
healthy O
controls O
underwent O
glyceryl O
trinitrate O
head-up O
tilt O
and O
isoprenaline O
head-up O
tilt O
( O
maximum O
dose O
5 O
microg O
x O
min O
( O
-1 O
) O
) O
one O
week O
apart O
in O
random O
order O
. O
[]

The O
duration O
of O
diarrhoea B-outcome ['Physiological-Clinical']
significantly O
reduced O
in O
the O
S. O
boulardii O
group O
compared O
with O
the O
placebo O
group O
( O
4.7 O
vs O
5.5 O
d O
, O
p O
= O
0.03 O
) O
. O
['Physiological-Clinical']

Patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
was O
greater O
with O
the O
CFNB O
group O
although O
postoperative B-outcome ['Physiological-Clinical']
knee I-outcome ['Physiological-Clinical']
rehabilitation I-outcome ['Physiological-Clinical']
and O
the O
hospital B-outcome ['Resource-use']
LOS I-outcome ['Resource-use']
were O
not O
different O
. O
['Life-Impact', 'Physiological-Clinical', 'Resource-use']

In O
both O
cases O
, O
alkaline B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
showed O
no O
significant O
differences O
. O
['Physiological-Clinical']

The O
blood O
samples O
were O
collected O
for O
e O
same O
measurements O
of O
interleukin-8 O
( O
IL-8 O
) O
and O
tumor O
necrosis O
factor O
( O
TNF-? O
) O
by O
enzyme O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
and O
for O
the O
C-reactive O
protein O
( O
CRP O
) O
, O
lactic O
acid O
dehydrogenase O
( O
LDH O
) O
, O
white O
blood O
cell O
( O
WBC O
) O
count O
, O
amylase O
and O
lipase O
by O
biochemistry O
assay O
1 O
day O
before O
intervention O
of O
nutrition O
, O
and O
7 O
days O
and O
14 O
days O
after O
intervention O
. O
[]

At O
week O
8 O
compared O
with O
week O
4 O
, O
the O
concentration O
of O
P B-outcome ['Physiological-Clinical']
increased O
from O
5.7+/-1.4 O
to O
6.4+/-1.7 O
mg/dL O
in O
group O
A O
, O
and O
decreased O
significantly O
in O
groups O
B O
and O
C O
, O
and O
in O
group O
B O
compared O
with O
groups O
A O
and O
C O
; O
groups O
A O
and O
C O
had O
similar O
concentrations O
at O
week O
8 O
. O
['Physiological-Clinical']

Lamotrigine O
therapy O
for O
autistic O
disorder O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Tonsillar B-outcome ['Physiological-Clinical']
focal I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TFI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
dental B-outcome ['Physiological-Clinical']
focal I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DFI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
found O
in O
6/20 O
and O
17/20 O
patients O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

By O
24 O
h O
postoperatively O
in O
both O
groups O
, O
IL-1beta B-outcome ['Physiological-Clinical']
had O
decreased O
significantly O
( O
p O
< O
0.05 O
) O
, O
whereas O
IFN-gamma B-outcome ['Physiological-Clinical']
had O
increased O
significantly O
( O
p O
< O
0.05 O
) O
compared O
with O
the O
end O
of O
anaesthesia O
and O
surgery O
level O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subjects O
were O
randomly O
assigned O
to O
either O
an O
experimental O
or O
a O
control O
group O
. O
[]

In O
patients O
given O
GTN O
, O
peak O
TBPI B-outcome ['Physiological-Clinical']
was O
achieved O
by O
1 O
week O
, O
and O
corresponded O
with O
the O
TBPI B-outcome ['Physiological-Clinical']
observed O
immediately O
following O
GTN O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eleven O
healthy O
subjects O
performed O
precision O
grip O
tasks O
while O
a O
constant O
extension O
or O
flexion O
moment O
was O
applied O
to O
their O
elbow O
joints O
, O
inducing O
a O
sustained O
submaximal O
contraction O
of O
elbow O
muscles O
to O
counter O
the O
applied O
torque O
. O
[]

There O
was O
no O
significant O
between-group O
difference O
in O
the O
risk O
of O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
although O
intracranial O
and O
fatal B-outcome ['Mortality']
bleeding I-outcome ['Mortality']
occurred O
less O
frequently O
in O
the O
rivaroxaban O
group O
. O
( O
['Physiological-Clinical', 'Mortality']

Metal B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
and O
metal B-outcome ['Physiological-Clinical']
allergy I-outcome ['Physiological-Clinical']
after O
total O
hip O
replacement O
with O
resurfacing O
versus O
conventional O
hybrid O
prosthesis O
. O
['Physiological-Clinical', 'Physiological-Clinical']

0.4 O
vs. O
6.8 O
? O
[]

Response O
rate O
was O
65 O
% O
( O
95 O
% O
CI O
, O
57 O
% O
to O
73 O
% O
; O
CR B-outcome ['Physiological-Clinical']
, O
12 O
% O
; O
['Physiological-Clinical']

General O
anaesthesia O
was O
administered O
using O
laryngeal O
airway O
masks O
following O
neural O
blockade O
in O
both O
groups O
. O
[]

The O
results O
of O
this O
study O
show O
that O
sodium O
cromoglycate O
delivered O
by O
pressurized O
aerosol O
was O
significantly O
superior O
to O
placebo O
, O
not O
only O
in O
improving O
[]

During O
the O
'dark O
' O
interval O
, O
subjects O
were O
asked O
to O
indicate O
when O
the O
movement O
represented O
in O
the O
video O
reached O
its O
end O
by O
clicking O
on O
the O
space O
bar O
of O
the O
keyboard O
. O
[]

Recurrence O
of O
condylomata B-outcome ['Physiological-Clinical']
acuminata I-outcome ['Physiological-Clinical']
following O
cryotherapy O
is O
not O
prevented O
by O
systemically O
administered O
interferon O
. O
['Physiological-Clinical']

The O
participants O
were O
requested O
to O
limit O
their O
daily O
alcohol O
consumption O
to O
zero O
or O
reduce O
it O
as O
much O
as O
possible O
for O
the O
reduced O
alcohol O
consumption O
period O
. O
[]

Of O
the O
179 O
patients O
treated O
with O
mastectomy O
after O
neoadjuvant O
chemotherapy O
, O
108 O
participated O
in O
a O
randomized O
component O
of O
the O
trial O
that O
compared O
a O
dose-escalated O
, O
hyperfractionated O
( O
twice-daily O
, O
b.i.d O
. O
) O
[]

The O
remaining O
participants O
were O
told O
that O
the O
person O
watching O
was O
just O
observing O
the O
procedure O
( O
no O
motivation O
condition O
) O
. O
[]

Participants O
were O
interviewed O
at O
baseline O
, O
post-intervention O
and O
at O
6-month O
follow-up O
with O
a O
structured O
questionnaire O
including O
information O
on O
sociodemographics O
, O
sexual O
and O
drug-using O
behavior O
, O
and O
psychosocial O
characteristics O
. O
[]

mean O
diastolic O
BP O
( O
DBP O
) O
increased O
in O
both O
study O
groups O
. O
[]

Although O
absolute B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
readings I-outcome ['Physiological-Clinical']
were O
significantly O
higher O
in O
the O
colloid O
group O
between O
6 O
and O
30 O
min O
( O
P O
< O
0.05 O
) O
, O
the O
incidence O
of O
hypotension B-outcome ['Physiological-Clinical']
was O
not O
significantly O
different O
between O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Treatment O
was O
repeated O
with O
the O
same O
agent O
after O
30 O
min O
if O
the O
respiratory O
score O
was O
5 O
or O
more O
. O
[]

In O
the O
clopamide O
monotherapy O
group O
, O
total O
cholesterol B-outcome ['Physiological-Clinical']
increased O
significantly O
( O
p O
less O
than O
0.05 O
) O
; O
triglycerides B-outcome ['Physiological-Clinical']
and O
LDL B-outcome ['Physiological-Clinical']
showed O
a O
tendency O
to O
increase O
while O
for O
HDL B-outcome ['Physiological-Clinical']
a O
tendency O
to O
decrease O
was O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Prolactin B-outcome ['Physiological-Clinical']
was O
measured O
in O
ng/mL O
at O
baseline O
, O
once O
during O
acute O
treatment O
, O
and O
once O
during O
maintenance O
. O
['Physiological-Clinical']

Cardiovascular O
risk O
is O
increased O
in O
GH O
deficiency O
( O
GHD O
) O
. O
[]

Results O
indicated O
that O
the O
hypnosis O
sessions O
predicted O
significantly O
impaired B-outcome ['Life-Impact']
test I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Life-Impact']

Changes O
in O
the O
PSA B-outcome ['Physiological-Clinical']
were O
not O
seen O
and O
were O
insignificant O
, O
respectively O
. O
['Physiological-Clinical']

The O
effect O
of O
topical O
nasal O
fluticasone O
on O
objective B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
testing I-outcome ['Physiological-Clinical']
and O
the O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
22 O
patients O
constituted O
the O
control O
group O
of O
a O
controlled O
trial O
and O
received O
standard O
outpatient O
clinic O
treatment O
during O
follow-up O
. O
[]

Finally O
, O
1 O
patient O
was O
in O
first O
CRp O
. O
[]

Results O
suggest O
that O
RMIA O
, O
with O
parent O
training O
, O
catalyzes O
development O
of O
verbal B-outcome ['Life-Impact']
imitation I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
production I-outcome ['Life-Impact']
for O
some O
children O
. O
['Life-Impact']

CONCLUSIONS O
It O
appears O
that O
patients O
can O
[]

We O
examined O
whether O
a O
pretreatment O
with O
formoterol O
, O
oxitropium O
bromide O
, O
or O
salmeterol O
might O
modify O
the O
dose-response B-outcome ['Physiological-Clinical']
curves O
to I-outcome ['Physiological-Clinical']
inhaled I-outcome ['Physiological-Clinical']
salbutamol I-outcome ['Physiological-Clinical']
in O
patients O
with O
stable O
and O
partially O
reversible O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
. O
['Physiological-Clinical']

Ambulation O
in O
labour O
should O
be O
encouraged O
: O
it O
may O
bring O
human O
benefits O
while O
allowing O
the O
advantages O
of O
hospital O
supervision O
. O
[]

Diclofenac O
did O
not O
significantly O
increase O
creatinine B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

If O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
is O
not O
achieved O
, O
the O
so-called O
weak O
opioids O
, O
such O
as O
codeine O
and O
hydrocodone O
, O
may O
be O
used O
in O
combination O
with O
acetaminophen O
. O
['Physiological-Clinical']

Terazosin O
had O
a O
favorable O
effect O
on O
serum B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
levels O
and O
appeared O
to O
compensate O
for O
the O
negative O
lipid O
effects O
associated O
with O
diuretics O
and O
beta-blockers O
when O
used O
in O
combination O
with O
these O
agents O
. O
['Physiological-Clinical']

Patients O
were O
mobilized O
1 O
to O
2 O
hr O
after O
device O
placement O
, O
and O
6 O
hr O
after O
MC O
. O
[]

Rhinocort O
Study O
Group O
. O
[]

Nine O
healthy O
volunteers O
( O
age O
, O
23.4 O
+/- O
0.2 O
years O
; O
body O
mas O
index O
[ O
BMI O
] O
, O
23.5 O
+/- O
1.6 O
kg/m O
( O
2 O
) O
) O
were O
fed O
, O
in O
random O
order O
, O
with O
a O
high-fat O
diet O
( O
HFD O
) O
( O
65 O
% O
of O
energy O
content O
fat O
, O
15 O
% O
protein O
, O
20 O
% O
carbohydrate O
) O
or O
a O
high-carbohydrate O
diet O
( O
HCD O
) O
( O
70 O
% O
carbohydrate O
, O
15 O
% O
protein O
, O
15 O
% O
fat O
) O
for O
5 O
days O
, O
with O
a O
washout O
period O
of O
10 O
days O
between O
the O
diets O
. O
[]

One O
hundred O
and O
fifty O
patients O
with O
documented O
AF O
were O
randomly O
assigned O
to O
undergo O
cardiac O
surgery O
with O
or O
without O
AS O
. O
[]

CONCLUSIONS O
In O
patients O
with O
AIDS O
who O
are O
receiving O
zidovudine O
, O
trimethoprim-sulfamethoxazole O
is O
more O
effective O
than O
aerosolized O
pentamidine O
in O
conventional O
doses O
for O
the O
prevention O
of O
recurrent B-outcome ['Physiological-Clinical']
pneumocystis I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
Warfarin O
Re-Infarction O
Study O
( O
WARIS O
) O
studied O
the O
effect O
of O
warfarin O
in O
survivors O
of O
acute O
myocardial O
infarction O
. O
[]

TeachTown O
: O
Basics O
, O
a O
CAI O
program O
which O
also O
includes O
supplementary O
off-computer O
activities O
, O
was O
implemented O
over O
3 O
months O
for O
approximately O
20 O
minutes O
per O
day O
on O
the O
computer O
and O
20 O
minutes O
per O
day O
in O
supplementary O
TeachTown O
: O
Basics O
activities O
. O
[]

Overall O
, O
the O
results O
support O
the O
effectiveness O
of O
highly O
organized O
and O
structured O
stroke O
telemedicine O
networks O
for O
extending O
expert O
stroke O
care O
into O
rural O
remote O
communities O
lacking O
sufficient O
neurological O
expertise O
. O
[]

A O
complete B-outcome ['Physiological-Clinical']
response O
, O
defined O
as O
no B-outcome ['Physiological-Clinical']
emesis I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
no B-outcome ['Physiological-Clinical']
need I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
another I-outcome ['Physiological-Clinical']
rescue I-outcome ['Physiological-Clinical']
antiemetic I-outcome ['Physiological-Clinical']
, O
during O
the O
first O
3 O
h O
( O
0-3 O
h O
) O
after O
anesthesia B-outcome ['Resource-use']
was O
87 O
% O
with O
granisetron O
and O
78 O
% O
with O
perphenazine O
( O
P O
= O
0.204 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Ultrasound O
waves O
of O
1 O
MHz O
frequency O
was O
applied O
for O
5 O
minutes O
to O
the O
target O
knee O
, O
so O
also O
was O
the O
direct O
current O
for O
10 O
minutes O
for O
10 O
sessions O
treatment O
period O
. O
[]

The O
present O
study O
was O
designed O
to O
assess O
the O
efficacy O
of O
PDT O
as O
an O
alternative O
treatment O
approach O
. O
[]

The O
main O
outcome O
measure O
was O
the O
change O
in O
documentation O
from O
baseline O
. O
[]

The O
difference O
between O
treatment O
arms O
regarding O
objective O
response O
rates O
, O
TTP O
and O
OS O
were O
not O
statistically O
significant O
. O
[]

D O
was O
increased O
by O
alinidine O
both O
at O
rest O
and O
during O
exercise O
. O
[]

RESULTS O
The O
mean O
symptom B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
during O
the O
placebo O
period O
in O
the O
groups O
given O
lansoprazole O
first O
and O
placebo O
first O
were O
as O
follows O
: O
reflux B-outcome ['Physiological-Clinical']
score O
, O
21.5 O
and O
17.6 O
, O
respectively O
( O
not O
significant O
) O
; O
total O
score O
, O
11.2 O
and O
10.3 O
, O
respectively O
( O
not O
significant O
) O
; O
and O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
same O
group O
, O
PPD O
and O
tooth B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
were O
significantly O
reduced O
compared O
to O
nonsplint O
teeth O
. O
['Physiological-Clinical']

METHODS O
As O
part O
of O
a O
randomized O
clinical O
trial O
, O
newly O
diagnosed O
breast O
cancer O
patients O
( O
n O
= O
45 O
) O
with O
clinically O
significant O
depressive O
symptoms O
were O
evaluated O
and O
randomized O
to O
psychological O
intervention O
with O
assessment O
or O
assessment O
only O
study O
arms O
. O
[]

Influenza O
vaccination O
increased O
CRP B-outcome ['Physiological-Clinical']
by O
0.20 O
mg/L O
, O
and O
influenza O
in O
combination O
with O
pneumococcal O
vaccine O
increased O
CRP B-outcome ['Physiological-Clinical']
by O
0.60 O
mg/L O
. O
['Physiological-Clinical', 'Physiological-Clinical']

19 O
patients O
finished O
the O
study O
in O
group O
I O
and O
14 O
in O
group O
II O
. O
[]

These O
data O
suggest O
that O
increased O
ADMA B-outcome ['Physiological-Clinical']
levels O
play O
a O
role O
in O
the O
abnormal O
vascular O
reactivity O
that O
is O
observed O
in O
patients O
with O
CSX O
. O
['Physiological-Clinical']

The O
Collaborative O
Ocular O
Melanoma O
Study O
Group O
. O
[]

Implant O
rupture O
is O
a O
well-known O
complication O
of O
breast O
implant O
surgery O
that O
can O
pass O
unnoticed O
by O
both O
patient O
and O
physician O
. O
[]

Patients O
were O
randomized O
to O
valsartan O
80 O
mg O
( O
V-low O
) O
, O
valsartan O
160 O
mg O
( O
V-high O
) O
or O
valsartan/HCTZ O
160/12.5 O
mg O
( O
V/HCTZ O
) O
, O
and O
electively O
titrated O
after O
weeks O
2 O
and O
4 O
to O
the O
next O
dosage O
level O
( O
maximum O
dose O
valsartan/HCTZ O
160/25 O
mg O
) O
if O
BP O
remained O
> O
140/90 O
mm O
Hg O
. O
[]

When O
Skp2 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
and O
p27kip1 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
were O
combined O
, O
patients O
with O
both O
Skp2 O
overexpression O
and O
reduced O
expression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
p27kip1 I-outcome ['Physiological-Clinical']
revealed O
poorest O
disease-free B-outcome ['Physiological-Clinical']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
as O
compared O
to O
the O
other O
cases O
( O
p=0.0017 O
and O
p O
< O
0.0001 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

In O
premenopausal O
women O
, O
in O
both O
subpopulations O
, O
zoledronic O
acid O
significantly O
increased O
total O
hip O
BMD O
( O
all O
P O
< O
0.05 O
) O
versus O
risedronate O
at O
month O
12 O
but O
not O
LS O
BMD O
. O
[]

Dacarbazine O
versus O
dacarbazine-vindesine O
in O
disseminated O
malignant O
melanoma O
: O
a O
randomized O
phase O
II O
study O
. O
[]

The O
first O
vaccinations O
contained O
10 O
( O
7 O
) O
BCG O
organisms O
. O
[]

BACKGROUND O
To O
understand O
better O
the O
genetic O
basis O
of O
the O
clonal O
evolution O
of O
prostate O
carcinoma O
, O
the O
authors O
analyzed O
the O
pattern O
of O
allelic B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
25 O
matched O
primary O
and O
metastatic O
prostate O
tumors O
. O
['Physiological-Clinical']

Radiation-induced B-outcome ['Physiological-Clinical']
brachial I-outcome ['Physiological-Clinical']
plexopathy I-outcome ['Physiological-Clinical']
was O
more O
frequent O
in O
patients O
receiving O
cytotoxic O
therapy O
( O
p O
= O
0.04 O
) O
and O
in O
younger O
patients O
( O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical']

In O
addition O
to O
freedom B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
and O
no O
lost B-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
from O
work O
, O
there O
was O
increased O
mobility B-outcome ['Life-Impact']
and O
physical B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Comparison O
was O
made O
with O
standard O
screening O
invitation O
routine O
or O
standard O
routine O
plus O
a O
telephone O
call O
. O
[]

These O
improvements O
were O
sustained O
at O
24 O
weeks O
. O
[]

A O
home O
visiting O
asthma O
education O
program O
: O
challenges O
to O
program O
implementation O
. O
[]

METHODS O
The O
paroxetine O
352 O
study O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
19-site O
trial O
comparing O
paroxetine O
and O
imipramine O
in O
117 O
patients O
with O
bipolar B-outcome ['Life-Impact']
type O
I O
major B-outcome ['Life-Impact']
depressive I-outcome ['Life-Impact']
episode B-outcome ['Life-Impact']
which O
was O
unresponsive O
to O
prior O
lithium O
carbonate O
therapy O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

However O
, O
there O
was O
a O
trend O
towards O
fewer O
PUVA O
sessions O
and O
lower O
UVA O
dose O
required O
to O
achieve O
CCR O
in O
the O
combination O
arm O
( O
PUVA O
+ O
bexarotene O
) O
but O
this O
did O
not O
achieve O
statistical O
significance O
due O
to O
insufficient O
power O
. O
[]

In O
a O
multivariate O
analysis O
adjusting O
for O
the O
above O
covariates O
and O
treatment O
assignment O
, O
higher O
pulse B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
remained O
an O
independent O
predictor O
of O
total O
and O
cardiovascular B-outcome ['Mortality']
mortality I-outcome ['Mortality']
( O
total O
mortality O
relative O
risk O
, O
1.05 O
per O
10 O
mm O
Hg O
increment O
; O
95 O
% O
confidence O
interval O
, O
1.01 O
to O
1.10 O
; O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Mortality']

Screening O
for O
abdominal O
aortic O
aneurysms O
( O
AAAs O
) O
in O
patients O
at O
risk O
will O
become O
more O
cost O
effective O
if O
a O
simple O
, O
inexpensive O
, O
and O
reliable O
ultrasound O
device O
is O
available O
. O
[]

All O
patients O
also O
received O
sirolimus O
and O
corticosteroids O
. O
[]

RESULT O
( O
S O
) O
[]

OBJECTIVE O
To O
assess O
the O
efficacy O
of O
moderate O
aerobic O
physical O
activity O
with O
sleep O
hygiene O
education O
to O
improve O
sleep O
, O
mood O
and O
quality O
of O
life O
in O
older O
adults O
with O
chronic O
insomnia O
. O
[]

Cure B-outcome ['Physiological-Clinical']
rates O
on O
day O
28 O
of O
follow-up O
were O
40 O
% O
, O
100 O
% O
, O
100 O
% O
, O
and O
100 O
% O
in O
groups O
I O
, O
II O
, O
II O
, O
and O
IV O
, O
respectively O
. O
['Physiological-Clinical']

CONCLUSION O
Profiles O
of O
irregular B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
in O
3 O
commonly O
used O
types O
of O
low-dose O
HT O
are O
different O
and O
some O
factors O
such O
as O
long O
period O
in O
reproductive O
age O
and O
short O
time O
since O
menopause O
may O
contribute O
to O
bleeding O
initiation O
. O
['Physiological-Clinical']

Symptoms O
were O
common O
in O
both O
groups O
. O
[]

In O
the O
diazoxide-treated O
patients O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
fell O
from O
192 O
+/- O
3/115 O
+/- O
4 O
mmHg O
to O
141 O
+/- O
8/85 O
+/- O
4 O
mmHg O
2 O
h O
after O
injection O
. O
['Physiological-Clinical']

Overall O
, O
the O
rate O
of O
new B-outcome ['Physiological-Clinical']
IMI I-outcome ['Physiological-Clinical']
during O
the O
dry O
period O
was O
16.7 O
% O
of O
quarters O
. O
['Physiological-Clinical']

Two O
hundred O
children O
undergoing O
bilateral O
TT O
placement O
were O
categorized O
as O
having O
unilateral O
( O
wet/dry O
) O
, O
bilateral O
( O
wet/wet O
) O
, O
or O
no O
( O
dry/dry O
) O
effusion O
at O
the O
time O
of O
surgery O
. O
[]

Although O
postoperative B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
and O
in-hospital B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
were O
the O
same O
, O
patients O
from O
the O
stapled O
group O
reported O
significantly O
more O
pain O
at O
discharge O
. O
['Resource-use', 'Resource-use']

The O
Dutch O
Gastric O
Cancer O
Group O
( O
DGCG O
) O
. O
[]

Inhibition O
of O
spontaneous O
platelet B-outcome ['Physiological-Clinical']
aggregation O
and O
adhesion B-outcome ['Physiological-Clinical']
by O
indobufen O
( O
K O
3920 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
objectives O
of O
this O
pilot O
trial O
were O
to O
evaluate O
the O
feasibility O
of O
a O
randomized O
trial O
of O
intensive O
insulin O
therapy O
with O
respect O
to O
( O
a O
) O
achieving O
target O
glucose O
values O
in O
the O
2 O
ranges O
of O
5 O
to O
7 O
and O
8 O
to O
10 O
mmol/L O
and O
( O
b O
) O
uncovering O
problems O
with O
the O
protocol O
in O
anticipation O
of O
a O
larger O
trial O
. O
[]

These O
differences O
ceased O
, O
however O
, O
to O
be O
statistically O
significant O
in O
logistic O
models O
. O
[]

Patients O
were O
assessed O
at O
baseline O
and O
after O
2 O
, O
4 O
, O
6 O
, O
and O
10 O
weeks O
of O
starting O
medication O
using O
the O
Aberrant O
Behavior O
Checklist-Community O
( O
ABC-C O
) O
Rating O
Scale O
. O
['Life-Impact']

These O
markers O
did O
not O
change O
much O
at O
different O
time O
points O
within O
72 O
h. O
In O
stroke O
group O
, O
P-selectin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
highly O
correlated O
to O
PAI-1 B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
r O
= O
0.8433 O
, O
p O
< O
0.001 O
) O
, O
but O
not O
to O
tPA B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
( O
r O
= O
-0.1752 O
, O
p O
> O
0.05 O
) O
, O
and O
tPA B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
r O
= O
0.2465 O
, O
p O
> O
0.05 O
) O
, O
which O
was O
further O
confirmed O
in O
the O
multiple O
linear O
regression O
analysis O
( O
F O
= O
47.052 O
, O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Notably O
, O
most O
SRL O
participants O
used O
that O
same O
approach O
spontaneously O
. O
[]

RESULTS O
Baseline O
HAM-D?? O
scores O
for O
desvenlafaxine O
( O
n O
= O
285 O
) O
and O
placebo O
( O
n O
= O
142 O
) O
were O
22.0 O
and O
21.8 O
, O
whereas O
baseline O
SDS O
scores O
were O
19.8 O
and O
20.4 O
. O
[]

We O
are O
now O
using O
the O
index O
to O
routinely O
direct O
chemotherapy O
and O
select O
out O
true O
responders O
for O
maintenance O
chemotherapy O
. O
[]

The O
aims O
of O
this O
study O
were O
, O
therefore O
, O
to O
compare O
the O
effects O
of O
root O
instrumentation O
using O
plastic O
curettes O
( O
Universal O
Perio O
Soft O
Scaler O
, O
Hawe-Neos O
Dental O
, O
Bioggio O
, O
TI O
, O
Switzerland O
) O
versus O
conventional O
steel O
curettes O
on O
the O
periodontal O
conditions O
during O
supportive O
periodontal O
therapy O
. O
[]

No O
significant O
difference O
was O
seen O
in O
the O
occurrence O
of O
perirectal B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
( O
p O
= O
0.35 O
) O
or O
skin B-outcome ['Physiological-Clinical']
breakdown I-outcome ['Physiological-Clinical']
( O
p O
= O
0.18 O
) O
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Local O
institutions O
coded O
response O
. O
[]

OBJECTIVE O
To O
compare O
the O
clinical O
efficacy O
of O
alginate O
drug O
Geviskon O
and O
aluminum-magnesium O
antacids O
to O
relieve O
symptoms O
of O
esophageal O
, O
extraesophageal O
syndrome O
and O
functional O
dyspepsia O
at O
3 O
and O
7 O
days O
of O
study O
in O
patients O
with O
GERD O
elderly O
. O
[]

48 O
( O
80 O
% O
) O
patients O
given O
pentamidine O
showed O
initial O
cure B-outcome ['Physiological-Clinical']
and O
46 O
( O
77 O
% O
) O
showed O
definitive B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
compared O
with O
60 O
( O
100 O
% O
) O
and O
59 O
( O
98 O
% O
) O
cases O
, O
respectively O
, O
on O
amphotericin O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
patients O
with O
dementia O
and O
mild O
depression O
( O
DSM-III-R O
290.21 O
) O
, O
the O
effect O
of O
low O
doses O
of O
the O
antidepressant O
maprotiline O
( O
up O
to O
75 O
mg/d O
) O
was O
examined O
. O
[]

The O
percentage O
of O
patients O
achieving O
serum B-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
levels O
6.0 O
mg/dL O
or O
less O
after O
8 O
weeks O
was O
82.0 O
% O
for O
the O
febuxostat O
group O
and O
70.0 O
% O
for O
the O
allopurinol O
group O
( O
P O
= O
0.019 O
, O
logistic O
regression O
analysis O
) O
. O
['Physiological-Clinical']

Standardized O
ginseng O
extract O
( O
Dansk O
Droge O
A/S O
, O
Copenhagen O
, O
Denmark O
) O
was O
administered O
per O
os O
( O
100 O
mg/kg O
BW O
) O
by O
stomach O
tube O
daily O
for O
90 O
days O
starting O
one O
week O
after O
STZ O
. O
[]

Hypercytokinemia O
plays O
a O
central O
role O
in O
pathogenesis O
and O
is O
related O
to O
the O
high O
mortality O
in O
sepsis-related O
acute O
kidney O
injury O
( O
AKI O
) O
. O
[]

The O
implementation O
intention O
intervention O
may O
be O
an O
easy-to-administer O
and O
effective O
means O
of O
promoting O
AED O
adherence O
. O
[]

All O
were O
followed O
regularly O
by O
clinical O
evaluation O
, O
plain O
radiography O
and O
MRI O
at O
intervals O
of O
three O
months O
. O
[]

Both O
the O
ionic O
and O
the O
non-ionic O
contrast O
media O
produced O
a O
measurable O
but O
asymptomatic O
and O
biologically O
insignificant O
fall O
in O
static B-outcome ['Physiological-Clinical']
ventilatory I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
use O
of O
anaferon O
in O
complex O
therapy O
reduced O
the O
duration O
of O
intoxication B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
local B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
shortened O
the O
duration O
of O
the O
relapse B-outcome ['Physiological-Clinical']
, O
activated B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of O
IFN-gamma B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
, O
and O
improved O
IFN-gamma-producing B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Histological B-outcome ['Physiological-Clinical']
examination I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
biopsies B-outcome ['Resource-use']
taken O
from O
the O
abrasions O
of O
two O
volunteers O
showed O
the O
dermis B-outcome ['Physiological-Clinical']
remained B-outcome ['Physiological-Clinical']
intact I-outcome ['Physiological-Clinical']
, O
making O
the O
model O
highly O
suitable O
for O
the O
study O
of O
superficial O
wounds O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
We O
previously O
reported O
urinary O
podocytes O
to O
be O
a O
marker O
of O
glomerular O
injury O
. O
[]

The O
effect O
of O
metformin O
and O
insulin O
on O
sympathetic O
nerve O
activity O
, O
norepinephrine O
spillover O
and O
blood O
pressure O
in O
obese O
, O
insulin O
resistant O
, O
normoglycemic O
, O
hypertensive O
men O
. O
[]

The O
difference O
was O
most O
striking O
for O
CD4 B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( O
about O
4-fold O
higher O
counts O
for O
CD45RA O
( O
high O
) O
CD4 O
T O
cells O
and O
about O
2-fold O
higher O
counts O
for O
CD45RA B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
low/- I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
CD4 I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
; O
P O
< O
.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

typewriter O
) O
related O
to O
a O
target O
word O
( O
e.g O
. O
[]

Both O
the O
RET O
and O
REI O
groups O
yielded O
greater O
reductions O
in O
irrational B-outcome ['Life-Impact']
thinking I-outcome ['Life-Impact']
than O
did O
the O
ROC O
and O
WLC O
groups O
. O
['Life-Impact']

Specific O
items O
will O
be O
drawn O
from O
the O
guidelines O
and O
the O
literature O
on O
TUPAC O
studies O
. O
[]

Logistic O
regression O
analysis O
failed O
to O
show O
a O
significant O
effect O
on O
postintervention O
benzodiazepine O
on/off O
status O
between O
study O
groups O
, O
when O
controlling O
for O
preintervention O
on/off O
status O
, O
PPGP-member O
age O
, O
PPGP-member O
gender O
, O
and O
all O
possible O
interactions O
. O
['Resource-use']

RESULTS O
For O
men O
, O
the O
mean O
annual O
change O
in O
BMD B-outcome ['Physiological-Clinical']
was O
1.1 O
% O
in O
the O
treated O
group O
and O
-0.4 O
% O
in O
the O
control O
group O
. O
['Physiological-Clinical']

Suggestive O
but O
non-significant O
results O
were O
found O
in O
[]

The O
rate O
of O
surgical B-outcome ['Physiological-Clinical']
reattachment I-outcome ['Physiological-Clinical']
of O
the O
['Physiological-Clinical']

Statistically O
the O
results O
give O
no O
reason O
to O
believe O
that O
placebo O
is O
better O
than O
radiotherapy O
, O
but O
it O
can O
not O
be O
excluded O
that O
radiotherapy O
patients O
could O
have O
a O
much O
longer O
survival B-outcome ['Mortality']
. O
['Mortality']

Ten O
patients O
, O
5 O
in O
each O
group O
, O
had O
exercise-induced B-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
at O
the O
start O
of O
the O
rehabilitation O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
incremental O
cost-effectiveness O
ratios O
( O
ICERs O
) O
of O
two O
brief O
cognitive-behavioral O
therapy O
( O
CBT O
) O
-based O
interventions O
and O
a O
pharmacological O
treatment O
, O
compared O
with O
usual O
care O
, O
initiated O
in O
the O
emergency O
department O
( O
ED O
) O
for O
individuals O
with O
panic B-outcome ['Physiological-Clinical']
disorder I-outcome ['Physiological-Clinical']
( O
PD O
) O
with O
a O
chief O
complaint O
of O
noncardiac O
chest O
pain O
. O
['Resource-use', 'Physiological-Clinical']

SUBJECTS O
AND O
METHODS O
Children O
with O
ASD O
were O
randomly O
assigned O
to O
an O
electro-acupuncture O
( O
EA O
) O
group O
( O
n=30 O
) O
or O
a O
sham O
electro-acupuncture O
( O
SEA O
) O
group O
( O
n=25 O
) O
matched O
by O
age O
and O
severity O
of O
autism O
. O
[]

Hypnosis O
and O
CB O
were O
similarly O
effective O
in O
the O
relief B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

During O
radiotherapy O
, O
grade O
I O
, O
II B-outcome ['Physiological-Clinical']
weight O
loss B-outcome ['Physiological-Clinical']
was O
observed O
in O
29.4 O
% O
, O
5.9 O
% O
and O
56.4 O
% O
, O
7.7 O
% O
patients O
respectively O
( O
P O
= O
0.04 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
microprecipitate O
developed O
in O
media O
supplemented O
with O
lot O
1 O
after O
several O
days O
of O
culture O
. O
[]

Endovascular O
aneurysm O
repair O
and O
outcome O
in O
patients O
unfit O
for O
open O
repair O
of O
abdominal O
aortic O
aneurysm O
( O
EVAR O
trial O
2 O
) O
: O
randomised O
controlled O
trial O
. O
[]

In O
conclusion O
, O
pantoprazole O
and O
digoxin O
may O
be O
administered O
concomitantly O
without O
the O
need O
for O
dose O
adjustment O
. O
[]

The O
intra-assay O
coefficient O
of O
variation O
of O
this O
SIM O
method O
ranged O
between O
4.0 O
to O
6.7 O
percent O
. O
[]

Neuromuscular O
transmission O
was O
monitored O
electromyographically O
. O
[]

There O
was O
no O
difference O
in O
the O
number O
of O
children O
receiving O
rescue B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
. O
['Resource-use']

CONCLUSION O
iTBS O
of O
the O
motor O
and O
prefrontal O
cortices O
appears O
safe O
and O
improves O
mood B-outcome ['Life-Impact']
, O
but O
failed O
to O
improve O
motor B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
functional B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
in O
PD O
. O
['Life-Impact', 'Life-Impact']

Initial O
bolus O
dose O
of O
rocuronium O
, O
0.6 O
mg O
x O
kg O
( O
-1 O
) O
was O
followed O
by O
continuous O
infusion O
, O
targeting O
at O
steady-state O
95 O
% O
T1 O
depression O
. O
[]

Effect O
of O
cicloxilic O
acid O
on O
bile B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
in O
patients O
with O
gallstones O
: O
a O
multicenter O
trial O
. O
['Physiological-Clinical']

Experiment O
2 O
( O
N O
= O
143 O
) O
yielded O
the O
same O
pattern O
, O
but O
with O
a O
procedure O
that O
reversed O
the O
order O
of O
the O
proximal B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
distal I-outcome ['Life-Impact']
consequences I-outcome ['Life-Impact']
, O
thereby O
ruling O
out O
the O
possibility O
that O
it O
was O
the O
unique O
characteristics O
of O
the O
consequences O
rather O
than O
their O
proximity O
that O
influenced O
the O
admission B-outcome ['Resource-use']
rate O
. O
['Life-Impact', 'Resource-use']

Additional O
findings O
included O
that O
a O
10 O
% O
increase O
in O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
increased O
session B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
by O
0.4 O
% O
( O
P O
< O
.001 O
) O
and O
a O
10 O
% O
increase O
in O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
predicted O
a O
decrease O
in O
percent O
energy O
from O
fat O
of O
0.3 O
% O
( O
P O
< O
.001 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

After O
the O
10 O
and O
15 O
mg/hr O
infusions O
of O
diltiazem O
, O
mean O
+/- O
SD O
elimination O
half-life O
was O
6.8 O
+/- O
1.8 O
and O
6.9 O
+/- O
1.5 O
hours O
, O
volume O
of O
distribution O
was O
411 O
+/- O
151.8 O
and O
299 O
+/- O
70.8 O
I O
, O
and O
systemic O
clearance O
was O
42 O
+/- O
12.4 O
and O
31 O
+/- O
8.3 O
l/hr O
, O
respectively O
. O
[]

Further O
elucidation O
of O
potential O
mechanisms O
is O
warranted O
. O
[]

PRINCIPAL O
FINDINGS O
Survey O
results O
showed O
that O
mobilization B-outcome ['Life-Impact']
increased O
to O
the O
same O
degree O
in O
both O
intervention O
and O
control O
neighborhoods O
with O
no O
evidence O
of O
an O
overall O
intervention O
effect O
. O
['Life-Impact']

The O
risk O
ratio O
for O
injured B-outcome ['Physiological-Clinical']
individuals O
was O
1.2:1 O
( O
non-brace O
to O
brace O
groups O
; O
p O
= O
0.65 O
) O
. O
['Physiological-Clinical']

Fecal B-outcome ['Physiological-Clinical']
elastase I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
levels O
in O
the O
early O
feeding O
group O
were O
significantly O
higher O
than O
those O
in O
the O
control O
group O
at O
7 O
and O
14 O
days O
after O
birth O
. O
['Physiological-Clinical']

Three O
different O
spatial O
ability O
tasks O
- O
spatial B-outcome ['Life-Impact']
orientation I-outcome ['Life-Impact']
, O
spatial B-outcome ['Life-Impact']
visualization I-outcome ['Life-Impact']
, O
and O
flexibility B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
closure I-outcome ['Life-Impact']
- O
were O
measured O
by O
a O
paper-and-pencil O
test O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Primary O
outcome O
measures O
were O
Aberrant O
Behavior O
Checklist-Irritability O
subscale O
and O
Clinical O
Global O
Impression-Improvement O
, O
which O
focused O
on O
irritability O
. O
['Physiological-Clinical', 'Life-Impact']

Enhanced O
induction O
of O
apoptosis O
in O
lung O
adenocarcinoma O
after O
preoperative O
chemotherapy O
with O
tegafur O
and O
uracil O
( O
UFT O
) O
. O
[]

infusion O
for O
72 O
h. O
RESULTS O
In O
Group O
I O
, O
although O
mean O
blood O
transfusion O
requirements O
( O
no O
. O
[]

The O
results O
did O
not O
indicate O
any O
therapeutic O
advantage O
for O
patients O
treated O
with O
this O
combination O
compared O
to O
those O
treated O
without O
any O
attempt O
at O
CA O
synchronization O
. O
[]

The O
patients O
receiving O
acipimox O
showed O
a O
fall O
in O
the O
mean O
concentration O
of O
plasma B-outcome ['Physiological-Clinical']
triglyceride I-outcome ['Physiological-Clinical']
compared O
to O
placebo O
( O
0.74 O
mmol/l O
) O
and O
this O
was O
most O
marked O
in O
patients O
whose O
initial O
plasma B-outcome ['Physiological-Clinical']
triglyceride I-outcome ['Physiological-Clinical']
levels O
were O
greater O
than O
3 O
mmol/l O
( O
1.0 O
mmol/l O
, O
confidence O
limits O
0.18 O
, O
1.82 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
requirements O
for O
respiratory B-outcome ['Physiological-Clinical']
support I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
also O
significantly O
lower O
when O
using O
the O
bispectral O
index O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Adverse-effects']

The O
concentrations O
of O
the O
drugs B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
and O
urine B-outcome ['Physiological-Clinical']
were O
determined O
by O
bioassay O
and O
high-pressure B-outcome ['Resource-use']
liquid I-outcome ['Resource-use']
chromatography I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

It O
improved O
the O
clinical O
outcome O
, O
providing O
a O
significantly O
higher O
graft O
patency O
rate O
and O
a O
lower O
incidence O
of O
late O
cardiac O
events O
. O
[]

After O
treatment O
initiation O
and O
early O
follow-up O
, O
subjects O
were O
evaluated O
clinically O
at O
6-month O
intervals O
. O
[]

Patients O
with O
a O
low O
magnesium O
level O
( O
defined O
as O
< O
or O
= O
1.5 O
mEq/liter O
, O
n O
= O
199 O
) O
had O
no O
difference O
in O
survival B-outcome ['Mortality']
compared O
with O
the O
group O
with O
a O
normal O
magnesium O
level O
( O
p O
= O
NS O
, O
risk O
ratio O
= O
0.89 O
) O
. O
['Mortality']

Histologic O
analysis O
revealed O
vital B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
in O
the O
PUT O
group O
of O
about O
61 O
% O
+/-9 O
% O
versus O
26 O
% O
+/-20 O
% O
for O
the O
BDX O
group O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

Bonded O
beams O
( O
1.0 O
mm O
( O
2 O
) O
) O
were O
tested O
under O
tension O
( O
0.5 O
mm O
min O
( O
-1 O
) O
) O
. O
[]

There O
was O
a O
similar O
and O
significant O
degree O
of O
resolution B-outcome ['Physiological-Clinical']
in O
the O
two O
groups O
: O
26 O
% O
and O
20 O
% O
, O
respectively O
. O
['Physiological-Clinical']

Calibration O
chi-square O
was O
acceptable O
for O
all O
models O
. O
[]

MI O
areas O
were O
evaluated O
with O
the O
ECG-54 O
criteria/32 O
system O
and O
myocardial B-outcome ['Physiological-Clinical']
blush I-outcome ['Physiological-Clinical']
grade O
( O
MBG O
) O
was O
measured O
. O
['Physiological-Clinical']

At O
the O
end O
of O
CPB O
, O
increased O
C3b/c B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
but I-outcome ['Physiological-Clinical']
not I-outcome ['Physiological-Clinical']
C4b/c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
present O
in O
systemic O
T2 O
blood O
compared O
with O
T1 O
, O
while O
concentrations O
of O
microparticles O
binding O
complement O
components O
and O
of O
those O
binding O
complement O
activator O
molecules O
were O
similar O
. O
['Physiological-Clinical']

on O
day O
1 O
and O
etoposide O
at O
100 O
mg/m2 O
i.v O
. O
[]

After O
0.5 O
week O
( O
range O
3 O
to O
4 O
days O
) O
of O
treatment O
patients O
receiving O
silodosin O
vs O
placebo O
achieved O
significant O
improvement O
in O
total O
International O
Prostate B-outcome ['Physiological-Clinical']
Symptom B-outcome ['Physiological-Clinical']
Score O
( O
difference O
-1.9 O
, O
p O
< O
0.0001 O
) O
and O
irritative B-outcome ['Physiological-Clinical']
( O
-0.5 O
, O
p O
= O
0.0002 O
) O
and O
obstructive B-outcome ['Physiological-Clinical']
( O
-1.4 O
, O
p O
< O
0.0001 O
) O
subscores O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
iridium O
oxide O
coating O
is O
believed O
to O
reduce O
restenosis B-outcome ['Physiological-Clinical']
by O
decreasing O
the O
inflammatory B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
the O
stent O
via O
its O
antioxidant O
action O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Its O
effects O
on O
bone B-outcome ['Physiological-Clinical']
in O
vivo O
are O
unknown O
, O
although O
beta O
receptor O
sites O
have O
been O
found O
on O
osteoblasts O
. O
['Physiological-Clinical']

RESULTS O
The O
cumulative O
probability O
of O
developing B-outcome ['Physiological-Clinical']
MS I-outcome ['Physiological-Clinical']
by O
15 O
years O
after O
onset O
of O
optic O
neuritis B-outcome ['Physiological-Clinical']
was O
50 O
% O
( O
95 O
% O
confidence O
interval O
, O
44 O
% O
-56 O
% O
) O
and O
strongly O
related O
to O
presence O
of O
lesions O
on O
a O
baseline O
non-contrast-enhanced O
magnetic O
resonance O
imaging O
( O
MRI O
) O
of O
the O
brain O
. O
['Physiological-Clinical', 'Physiological-Clinical']

FINDINGS O
In O
the O
forearm O
, O
blood B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
increased O
significantly O
after O
application O
of O
the O
active O
gel O
both O
in O
patients O
with O
Raynaud O
's O
syndrome O
( O
microcirculatory O
volume O
from O
mean O
area O
under O
the O
curve O
98 O
[ O
SE O
14 O
] O
to O
1024 O
[ O
130 O
] O
; O
microcirculatory O
flux O
from O
5060 O
[ O
462 O
] O
to O
74,800 O
[ O
3940 O
] O
) O
and O
in O
healthy O
controls O
( O
volume O
from O
85 O
[ O
19 O
] O
to O
1020 O
[ O
60 O
] O
; O
flux O
from O
4420 O
[ O
435 O
] O
to O
84,500 O
[ O
7000 O
] O
) O
. O
['Physiological-Clinical']

Aggression O
is O
a O
common O
and O
costly O
problem O
in O
youth O
with O
developmental O
disabilities O
. O
[]

METHODS O
This O
study O
was O
conducted O
among O
654 O
patients O
receiving O
chronic O
hemodialysis O
. O
[]

Patients O
applied O
50 O
drops O
of O
study O
solution O
and O
took O
1 O
study O
capsule O
3 O
times O
daily O
for O
12 O
weeks O
. O
[]

Hospital O
and O
demographic O
characteristics O
were O
similar O
across O
intervention O
groups O
. O
[]

OBJECTIVE O
To O
examine O
the O
efficacy O
of O
intravenous O
porcine O
secretin O
for O
the O
treatment O
of O
autistic B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
. O
['Life-Impact']

Prognosis O
of O
advanced O
hepatocellular O
carcinoma O
: O
comparison O
of O
three O
staging O
systems O
in O
two O
French O
clinical O
trials O
. O
[]

The O
specimens O
were O
stored O
in O
distilled O
water O
at O
room O
temperature O
for O
24 O
hours O
and O
subsequently O
tested O
in O
shear O
mode O
with O
a O
universal O
testing O
machine O
. O
[]

Colony O
forming O
units O
of O
Porphyromonas O
gingivalis O
and O
Prevotella O
intermedia O
/ O
Prevotella O
nigrescens O
were O
determined O
. O
[]

Therefore O
, O
we O
studied O
whether O
iTFA O
and O
conjugated O
linoleic O
acid O
( O
CLA O
) O
affect O
markers O
of O
inflammation B-outcome ['Physiological-Clinical']
and O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Efficacy O
of O
prepackaged O
, O
low O
residual O
test O
meals O
with O
4L O
polyethylene O
glycol O
versus O
a O
clear O
liquid O
diet O
with O
4L O
polyethylene O
glycol O
bowel O
preparation O
: O
a O
randomized O
trial O
. O
[]

Antibiotic-associated B-outcome ['Physiological-Clinical']
nephrotoxicity I-outcome ['Physiological-Clinical']
was O
more O
frequent O
in O
patients O
treated O
with O
vancomycin O
( O
6 O
% O
vs. O
2 O
% O
, O
P O
= O
.02 O
) O
. O
['Physiological-Clinical']

Clinical B-outcome ['Physiological-Clinical']
pharmacology I-outcome ['Physiological-Clinical']
of O
methadone O
in O
dogs O
. O
['Physiological-Clinical']

However O
, O
four O
patients O
in O
the O
ketorolac O
group O
and O
six O
patients O
in O
the O
pethidine O
group O
requested O
no O
further B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
within O
24 O
hours O
. O
['Resource-use']

three O
times O
daily O
for O
6 O
days O
) O
. O
[]

Having O
failed O
to O
respond O
to O
an O
adequate O
antidepressant O
treatment O
course O
predicts O
poorer O
treatment O
outcomes O
in O
patients O
with O
major O
depression O
. O
[]

The O
equations O
describing O
the O
models O
for O
AUC O
using O
two O
time O
points O
( O
3 O
and O
24h O
) O
and O
Cmax O
for O
the O
training O
data O
set O
of O
30 O
subjects O
were O
AUCpredicted O
= O
11.1 O
C3h O
+ O
121.4 O
C24h O
- O
157 O
( O
r O
= O
0.80 O
) O
Cmax O
( O
predicted O
) O
= O
0.036 O
AUC O
+ O
42.9 O
( O
r O
= O
0.74 O
) O
The O
model O
was O
validated O
on O
64 O
patients O
who O
received O
flunarizine O
orally O
. O
[]

The O
main O
surgical O
parameters O
collected O
for O
each O
patient O
( O
pt O
) O
concerned O
operative O
time O
, O
major O
and O
minor O
complications O
, O
conversion O
rate O
, O
blood O
loss O
, O
hospital O
stay O
and O
histology O
. O
[]

METHODS O
This O
was O
a O
single-blind O
, O
prospective O
, O
single O
centre O
, O
randomised O
controlled O
trial O
set O
in O
the O
Sports O
Medical O
Department O
, O
The O
Hague O
Medical O
Centre O
, O
The O
Netherlands O
. O
[]

In O
the O
arm O
A O
, O
2 O
patients O
developed O
major O
complications O
, O
3 O
patients O
incurred O
with O
minor O
complications O
and O
32 O
patients O
got O
primary O
healing B-outcome ['Physiological-Clinical']
of O
the O
perineal O
wounds O
. O
['Physiological-Clinical']

Incidence O
of O
high O
grade O
PIN B-outcome ['Physiological-Clinical']
increased O
from O
1.5 O
% O
in O
the O
first O
round O
to O
5.0 O
% O
in O
the O
third O
round O
, O
varying O
among O
centres O
in O
the O
first O
round O
between O
0.8 O
% O
and O
7.6 O
% O
. O
['Physiological-Clinical']

Participants O
were O
12 O
nonverbal O
children O
with O
autism O
ages O
5 O
through O
7 O
randomly O
assigned O
to O
either O
treatment O
group O
. O
[]

The O
patients O
were O
randomized O
to O
receive O
1 O
g O
of O
aztreonam O
or O
80 O
mg O
of O
gentamicin O
intravenously O
30 O
minutes O
before O
surgery O
and O
8 O
and O
16 O
hours O
after O
surgery O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bupivacaine I-outcome ['Physiological-Clinical']
were O
measured O
also O
in O
the O
extradural O
group O
at O
each O
sampling O
time O
. O
['Physiological-Clinical']

Arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
waveforms I-outcome ['Physiological-Clinical']
were O
recorded O
and O
inspected O
for O
dampening O
or O
other O
deformation O
. O
['Physiological-Clinical']

The O
magnitude O
of O
the O
change O
in O
solid B-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
correlated O
with O
the O
change O
in O
the O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
r O
= O
0.49 O
; O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
average O
number O
of O
days B-outcome ['Physiological-Clinical']
without I-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
was O
lower O
in O
group O
2 O
patients O
than O
in O
group O
1 O
patients O
( O
mean+/-SD O
: O
3.85+/-1.98 O
for O
group O
1 O
vs. O
2.78+/-1.03 O
for O
group O
2 O
, O
P=0.044 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Barriers O
to O
hypertension O
care O
and O
control O
in O
young O
urban O
black O
men O
. O
[]

Patients O
and O
investigators O
provided O
favorable O
tolerability B-outcome ['Life-Impact']
ratings O
preferring O
bibrocathol O
over O
placebo O
. O
['Life-Impact']

CONCLUSIONS O
In O
moderate O
persistent O
asthmatics O
switched O
from O
taking O
ICS O
to O
salmeterol O
alone O
, O
adding O
montelukast O
conferred O
significant O
benefits O
on O
all O
parameters O
of O
asthma O
control O
. O
[]

It O
was O
found O
that O
parasites O
play O
an O
important O
role O
in O
the O
multifactorial O
etiology O
of O
this O
condition O
and O
their O
eradication B-outcome ['Physiological-Clinical']
by O
deworming O
drugs O
gives O
better O
results O
than O
the O
traditional O
therapies O
. O
['Physiological-Clinical']

Participants O
EEG O
was O
recorded O
and O
an O
engagement B-outcome ['Life-Impact']
index O
( O
EI O
= O
20 O
x O
beta/ O
( O
alpha O
+ O
theta O
) O
) O
was O
derived O
. O
['Life-Impact']

During O
the O
fifth O
and O
sixth O
cycles O
of O
combination O
therapy O
94 O
% O
of O
cycles O
were O
free B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
flushing I-outcome ['Physiological-Clinical']
( O
vs. O
31 O
% O
for O
control O
, O
P O
< O
0.01 O
) O
, O
64 O
% O
of O
cycles O
were O
free B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
spotting I-outcome ['Physiological-Clinical']
not O
requiring B-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
( O
control O
75 O
% O
) O
, O
96 O
% O
of O
cycles O
were O
free B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
vaginal I-outcome ['Physiological-Clinical']
bleeding B-outcome ['Physiological-Clinical']
( O
control O
100 O
% O
) O
, O
endometrial O
biopsy O
showed O
inactive B-outcome ['Physiological-Clinical']
endometrium I-outcome ['Physiological-Clinical']
in O
nine O
of O
the O
10 O
subjects O
re-biopsied O
, O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Objective O
outcome O
variables O
were O
: O
( O
1 O
) O
Urinary B-outcome ['Physiological-Clinical']
leakage I-outcome ['Physiological-Clinical']
( O
during O
a O
standardized O
PAD O
test O
) O
, O
( O
2 O
) O
pelvic B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
( O
measured O
by O
a O
perineometer O
) O
, O
and O
( O
3 O
) O
detrusor B-outcome ['Physiological-Clinical']
instability I-outcome ['Physiological-Clinical']
( O
on O
ambulant B-outcome ['Physiological-Clinical']
urodynamic I-outcome ['Physiological-Clinical']
registration I-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
comparison O
, O
toothbrushing O
alone O
caused O
a O
bacteremia B-outcome ['Physiological-Clinical']
on O
38.5 O
% O
of O
occasions O
. O
['Physiological-Clinical']

[ O
A O
multicenter O
, O
randomized O
clinical O
trial O
of O
intravenous O
diltiazem O
in O
treatment O
of O
unstable O
angina O
] O
. O
[]

Generally O
speaking O
, O
buspirone O
was O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
. O
['Life-Impact']

FINDINGS O
Study O
retention O
was O
96.8 O
% O
at O
6 O
months O
. O
[]

of O
4.6 O
Gy O
. O
[]

These O
significant O
differences O
were O
not O
consistent O
across O
the O
centres O
, O
therefore O
, O
differences O
could O
not O
be O
linked O
to O
specific O
aspects O
of O
service O
provision O
. O
[]

Subjects O
underwent O
endothelial O
function O
testing O
( O
measured O
as O
flow-mediated O
dilatation O
[ O
FMD O
] O
) O
and O
assessment O
of O
cardiovascular O
biomarkers O
before O
and O
after O
each O
8-week O
treatment O
phase O
. O
[]

RESULTS O
Relapses B-outcome ['Physiological-Clinical']
occurred O
in O
21 O
( O
43 O
% O
) O
of O
49 O
patients O
, O
predominantly O
in O
the O
CNS O
( O
71 O
% O
) O
and O
bone O
marrow O
( O
52 O
% O
) O
. O
['Physiological-Clinical']

METHODS O
In O
an O
open O
, O
randomized O
( O
for O
midazolam O
treatment O
sequence O
) O
study O
, O
18 O
healthy O
male O
subjects O
received O
single O
doses O
of O
midazolam O
( O
2 O
mg O
oral O
and O
1 O
mg O
i.v. O
, O
1 O
day O
apart O
) O
alone O
, O
repeated O
doses O
of O
roflumilast O
( O
500 O
microg O
once O
daily O
for O
14 O
days O
) O
alone O
, O
and O
repeated O
doses O
of O
roflumilast O
together O
with O
single O
doses O
of O
midazolam O
( O
2 O
mg O
oral O
and O
1 O
mg O
i.v. O
, O
1 O
day O
apart O
) O
. O
[]

The O
purpose O
of O
this O
pilot O
study O
was O
to O
evaluate O
whether O
a O
modified O
version O
of O
the O
Coping O
Cat O
program O
could O
be O
effective O
in O
reducing O
anxiety B-outcome ['Life-Impact']
in O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
['Life-Impact']

The O
tumor O
growth O
pattern O
according O
to O
Jass O
and O
the O
extent O
of O
tumor O
budding O
were O
analyzed O
in O
patients O
with O
American O
Joint O
Committee O
on O
Cancer/Union O
for O
International O
Cancer O
Control O
( O
AJCC/UICC O
) O
stage O
II O
disease O
. O
[]

The O
reliability O
of O
the O
overall O
exposure O
prevention O
ratings O
was O
excellent O
( O
weighted O
kappa O
= O
0.84 O
) O
. O
[]

BACKGROUND O
Effective O
pain O
management O
remains O
a O
challenge O
for O
adolescents O
during O
conscious O
burn O
wound O
care O
procedures O
. O
[]

SETTING O
Department O
of O
rehabilitation O
. O
[]

CONCLUSIONS O
GM-CSF O
priming O
from O
days O
5 O
to O
1 O
before O
doxorubicin O
and O
cyclophosphamide O
chemotherapy O
was O
associated O
with O
an O
earlier O
neutrophil B-outcome ['Physiological-Clinical']
and O
platelet B-outcome ['Physiological-Clinical']
nadir I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Overall O
, O
there O
was O
no O
significant O
difference O
in O
[]

Early O
combination O
disease-modifying O
antirheumatic O
drug O
therapy O
and O
tight O
disease O
control O
improve O
long-term O
radiologic B-outcome ['Physiological-Clinical']
outcome O
in O
patients O
with O
early O
rheumatoid O
arthritis O
: O
the O
11-year O
results O
of O
the O
Finnish O
Rheumatoid O
Arthritis O
Combination O
Therapy O
trial O
. O
['Physiological-Clinical']

infusion O
of O
Ringer O
's O
acetate O
solution O
have O
been O
analysed O
recently O
using O
mathematical O
models O
. O
[]

Mail O
reminders O
were O
no O
more O
effective O
than O
a O
routine O
publicity O
campaign O
. O
[]

Women O
's O
responses O
to O
information O
on O
mammographic O
breast O
density O
. O
[]

This O
report O
is O
an O
analysis O
of O
the O
morbidity B-outcome ['Physiological-Clinical']
in O
the O
bladder O
and O
bowel O
observed O
in O
a O
randomized O
trial O
of O
d O
( O
15 O
) O
+Be O
neutrons O
versus O
megavoltage O
photons O
in O
the O
treatment O
of O
bladder O
cancer O
. O
['Physiological-Clinical']

Since O
fever B-outcome ['Physiological-Clinical']
is O
rarely O
the O
dose-limiting O
toxicity O
of O
interferon O
, O
indomethacin O
is O
of O
marginal O
benefit O
to O
patients O
with O
malignant O
melanoma O
receiving O
interferon O
at O
the O
doses O
outlined O
in O
this O
study O
. O
['Physiological-Clinical']

The O
change O
in O
the O
children B-outcome ['Physiological-Clinical']
's O
behavior B-outcome ['Life-Impact']
was O
evaluated O
using O
parents O
' O
report O
and O
neurophysiological O
changes O
were O
measured O
by O
quantitative O
EEG O
( O
qEEG O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Peak O
ejection B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
peak B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
filling I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
reports O
on O
the O
results O
of O
a O
randomized O
controlled O
trial O
that O
evaluated O
a O
caregiver-based O
intervention O
program O
for O
children O
with O
autism O
in O
community O
day-care O
centers O
. O
[]

METHODS O
The O
pharmacokinetic O
model O
was O
developed O
from O
different O
single-dose O
and O
multiple-dose O
studies O
. O
[]

A O
trial O
comparing O
two O
different O
radiotherapy O
techniques O
and O
schedules O
in O
the O
treatment O
of O
83 O
patients O
with O
advanced O
cancer O
of O
the O
uterine O
cervix O
( O
stage O
IIIB O
) O
employing O
external O
irradiation O
alone O
is O
described O
. O
[]

Patients O
were O
selected O
on O
the O
basis O
of O
: O
a O
) O
occurrence O
in O
the O
last O
4 O
weeks O
of O
at O
least O
5/10 O
selected O
symptoms O
( O
anorexia B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
vomiting B-outcome ['Physiological-Clinical']
, O
upper B-outcome ['Physiological-Clinical']
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
postprandial B-outcome ['Physiological-Clinical']
bloating I-outcome ['Physiological-Clinical']
, O
abdominal B-outcome ['Physiological-Clinical']
fullness I-outcome ['Physiological-Clinical']
, O
early B-outcome ['Physiological-Clinical']
satiety I-outcome ['Physiological-Clinical']
, O
belching B-outcome ['Physiological-Clinical']
, O
heartburn B-outcome ['Physiological-Clinical']
, O
regurgitation B-outcome ['Physiological-Clinical']
) O
, O
severity O
of O
which O
should O
reach/exceed O
a O
total O
score O
of O
8 O
, O
as O
assessed O
by O
a O
specific O
scale O
ranging O
from O
0 O
( O
absent O
) O
to O
3 O
( O
severe O
) O
; O
b O
) O
normal O
results O
of O
routine O
biochemical O
, O
ultrasound O
and O
endoscopic O
examinations O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

4.5 O
mL?kg?min O
; O
mean O
? O
[]

The O
introduction O
was O
followed O
by O
three O
test O
sessions O
. O
[]

Clozapine O
was O
more O
effective O
than O
usual O
care O
on O
many O
but O
not O
all O
measures O
. O
[]

Intervention O
patients O
had O
access O
for O
up O
to O
12 O
months O
to O
a O
depression O
clinical O
specialist O
( O
supervised O
by O
a O
psychiatrist O
) O
who O
offered O
education O
, O
structured O
psychotherapy O
, O
and O
maintenance/relapse O
prevention O
support O
. O
[]

The O
Dutch O
Lansoprazole O
Study O
Group O
. O
[]

A O
randomized O
, O
prospective O
study O
was O
conducted O
to O
compare O
the O
individual O
effectiveness O
of O
three O
types O
of O
conservative O
therapy O
in O
the O
treatment O
of O
plantar O
fasciitis O
. O
[]

Patients O
?75 O
years O
old O
and O
with O
body O
weight O
?60 O
kg O
received O
a O
maintenance O
dose O
of O
5 O
mg/day O
( O
10 O
mg/day O
for O
all O
the O
other O
patients O
) O
. O
[]

Our O
results O
suggest O
that O
single O
dose O
oral O
mebendazole O
has O
low O
efficacy O
against O
hookworm O
[]

PARTICIPANTS O
A O
total O
of O
302 O
patients O
aged O
over O
15 O
years O
. O
[]

Resting B-outcome ['Physiological-Clinical']
MSA I-outcome ['Physiological-Clinical']
, O
total O
body B-outcome ['Physiological-Clinical']
and O
right B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
NE I-outcome ['Physiological-Clinical']
spillover I-outcome ['Physiological-Clinical']
did O
not O
differ O
significantly O
after O
placebo O
and O
metformin O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
investigate O
the O
efficacy O
and O
safety O
of O
zoledronic O
acid O
for O
the O
treatment O
of O
bone O
metastases O
from O
breast O
cancer O
. O
[]

The O
geometric O
means O
of O
AUCi.v O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
if O
a O
dietary O
supplement O
of O
soy O
protein O
, O
isoflavones O
, O
and O
cotyledon O
fiber O
( O
Abalon O
) O
affects O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
markers B-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
and O
insulin B-outcome ['Resource-use']
levels O
in O
type O
2 O
diabetic O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

RESULTS O
Mizolastine O
and O
loratadine O
both O
relieved B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
CIU I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
problem O
of O
measurement O
error O
in O
multisite O
clinical O
trials O
. O
[]

Intra-operative O
antibiotic O
prophylaxis O
in O
neurosurgery O
. O
[]

Although O
gains O
in O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
were O
associated O
with O
treatment O
, O
a O
mediation O
analysis O
did O
not O
support O
imitation O
as O
the O
mechanism O
of O
action O
. O
['Life-Impact']

Combination O
therapy O
, O
( O
CT O
) O
conventionally O
employed O
for O
the O
various O
types O
of O
tumor O
involved O
, O
was O
associated O
with O
MPA O
( O
117 O
patients O
) O
or O
placebo O
( O
110 O
patients O
) O
. O
[]

This O
suggests O
TC O
information O
is O
not O
anxiogenic O
, O
but O
inclusion O
of O
TSE O
information O
may O
improve O
acceptance O
of O
disease O
awareness O
information O
. O
[]

Among O
them O
the O
frequencies O
of O
the O
three O
genotypes O
GG O
, O
GA O
and O
AA O
were O
16.9 O
% O
, O
50.7 O
% O
and O
32.4 O
% O
, O
compared O
with O
24.6 O
% O
, O
48.1 O
% O
and O
27.3 O
% O
, O
respectively O
, O
among O
the O
patients O
without O
severe B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
. O
['Adverse-effects']

METHODS O
68 O
athletes O
with O
long-standing O
( O
median O
40 O
weeks O
) O
adductor-related O
groin O
pain O
-- O
after O
examination O
according O
to O
a O
standardised O
protocol O
-- O
were O
randomly O
assigned O
to O
AT O
or O
PT O
. O
[]

Subjects O
were O
randomly O
divided O
in O
two O
groups O
: O
supplementation O
( O
n O
11 O
) O
with O
100 O
mg O
dl-alpha-tocopheryl O
acetate O
, O
200 O
mg O
ascorbic O
acid O
, O
and O
2 O
mg O
beta-carotene O
, O
and O
placebo O
( O
n O
9 O
) O
. O
[]

CONCLUSION O
AND O
CLINICAL O
RELEVANCE O
When O
methadone O
was O
administered O
by O
the O
SC O
route O
, O
the O
half-life O
was O
longer O
, O
but O
the O
individual O
variation O
in O
[]

In O
order O
to O
evaluate O
the O
effect O
of O
local O
treatment O
on O
urinary O
and O
genital O
symptoms O
, O
a O
score O
for O
genital O
, O
urinary O
and O
colposcopic O
complaints O
( O
0 O
minimum-100 O
maximum O
) O
was O
developed O
. O
[]

CONCLUSIONS O
Amiprilose O
HCl O
has O
significant O
anti-inflammatory B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
a O
favorable O
safety O
profile O
when O
used O
as O
the O
sole O
antirheumatic O
therapy O
in O
patients O
with O
active O
rheumatoid O
arthritis O
. O
['Physiological-Clinical']

There O
was O
no O
difference O
in O
the O
performance O
of O
individuals O
with O
AS O
and O
matched O
controls O
and O
both O
groups O
showed O
significant O
alignment O
with O
the O
confederate O
at O
all O
three O
levels O
. O
[]

It O
markedly O
improves O
the O
results O
of O
ESWL O
treatment O
of O
distal O
ureteric O
stones O
compared O
with O
standard O
ESWL O
. O
[]

Satisfaction O
was O
associated O
with O
meeting O
participants O
' O
information O
needs O
and O
reduced O
belief O
in O
the O
necessity O
for O
investigations O
for O
low O
back O
pain O
, O
including O
X-rays O
and O
blood O
tests O
. O
[]

An O
inverse O
correlation O
between O
changes O
in O
BNP B-outcome ['Physiological-Clinical']
and O
changes O
in O
dP/dt B-outcome ['Physiological-Clinical']
( O
r O
= O
-0.45 O
, O
P O
= O
0.04 O
) O
was O
found O
only O
in O
the O
carvedilol O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
treatment O
should O
only O
be O
applied O
when O
there O
is O
a O
realistic O
increase O
in O
chance O
of O
pregnancy B-outcome ['Physiological-Clinical']
, O
particularly O
because O
it O
carries O
the O
increased O
risk O
of O
multiple O
pregnancies O
. O
['Physiological-Clinical']

In O
conclusion O
, O
CUSA O
with O
TL O
is O
superior O
to O
CUSA O
with O
BP O
for O
donor O
hepatectomy O
in O
terms O
of O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
speed B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
transection I-outcome ['Life-Impact']
with O
no O
increase O
in O
morbidity B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Analyses O
of O
variance O
tested O
differences O
between O
ADS O
quartiles O
on O
alcohol- O
related O
measures O
. O
[]

MAIN O
OUTCOME O
MEASURES O
PRIMARY O
: O
success B-outcome ['Life-Impact']
rate O
for I-outcome ['Life-Impact']
insertion I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
18 I-outcome ['Life-Impact']
gauge I-outcome ['Life-Impact']
cannula I-outcome ['Life-Impact']
into I-outcome ['Life-Impact']
vein I-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
back I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
hand I-outcome ['Life-Impact']
. O
['Life-Impact']

EEG-biofeedback O
has O
been O
reported O
to O
reduce O
symptoms O
of O
autism O
spectrum O
disorders O
( O
ASD O
) O
in O
several O
studies O
. O
[]

In O
patients O
with O
severe O
pre-eclampsia O
there O
appears O
no O
contraindication O
to O
enflurane B-outcome ['Physiological-Clinical']
or O
, O
probably O
, O
halothane O
as O
volatile O
supplements O
during O
general O
anaesthesia O
. O
['Physiological-Clinical']

Central O
neuronal O
mechanisms O
of O
gastric O
electrical O
stimulation O
in O
diabetic O
gastroparesis O
. O
[]

A O
second O
dose O
of O
CaCl O
( O
2 O
) O
pre-treatment O
or O
placebo O
and O
diltiazem O
was O
given O
if O
clinically O
indicated O
for O
additional O
rate O
control O
. O
[]

Epstein-Barr O
virus O
( O
EBV O
) O
is O
associated O
with O
Hodgkin O
lymphoma O
( O
HL O
) O
and O
can O
be O
detected O
by O
in O
situ O
hybridization O
( O
ISH O
) O
of O
viral O
nucleic O
acid O
( O
EBER O
) O
in O
tumor O
cells O
. O
[]

The O
better O
scores O
observed O
for O
the O
TG O
is O
probably O
related O
to O
the O
effectiveness O
of O
direct O
intervention O
, O
and O
not O
to O
the O
lack O
of O
attention O
of O
parents O
in O
the O
OG O
in O
recognizing O
behavioral O
changes O
in O
their O
children O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

The O
effects O
of O
long-term O
therapy O
( O
70 O
days O
) O
with O
torasemide O
( O
20 O
mg/day O
) O
, O
a O
new O
loop O
diuretic O
, O
were O
compared O
with O
those O
of O
furosemide O
( O
50 O
mg/day O
) O
in O
a O
randomized O
double-blind O
trial O
. O
[]

Bone O
mineral O
density O
( O
BMD O
) O
of O
lumbar O
spine O
( O
L1-L4 O
) O
and O
proximal O
femur O
were O
determined O
using O
dual O
X-ray O
absorptiometry O
at O
baseline O
and O
after O
one O
year O
. O
[]

Seven O
patients O
( O
10 O
% O
) O
had O
ST O
elevation O
myocardial O
infarction O
, O
23 O
patients O
( O
32 O
% O
) O
had O
new B-outcome ['Physiological-Clinical']
ST I-outcome ['Physiological-Clinical']
depressions I-outcome ['Physiological-Clinical']
, O
and O
21 O
patients O
( O
30 O
% O
) O
had O
no O
new O
ST O
segment O
changes O
in O
the O
serial O
electrocardiographic O
recordings O
. O
['Physiological-Clinical']

CONCLUSION O
Application O
of O
this O
topical O
diclofenac O
solution O
to O
the O
knee O
of O
patients O
with O
OA O
produced O
relief B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
equivalent O
to O
oral O
diclofenac O
, O
with O
minor O
local O
skin O
irritation O
, O
but O
significantly O
reduced O
incidence O
of O
diclofenac-related B-outcome ['Physiological-Clinical']
GI I-outcome ['Physiological-Clinical']
complaints I-outcome ['Physiological-Clinical']
and O
abnormal B-outcome ['Physiological-Clinical']
laboratory I-outcome ['Physiological-Clinical']
values O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
the O
end O
of O
the O
first O
hour O
of O
infusion O
, O
compared O
with O
saline O
, O
L-arginine O
infusion O
increased O
basal B-outcome ['Physiological-Clinical']
forearm I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
nitrite B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
nitrate I-outcome ['Physiological-Clinical']
( O
NOx B-outcome ['Physiological-Clinical']
) O
, O
and O
forearm B-outcome ['Physiological-Clinical']
cGMP I-outcome ['Physiological-Clinical']
release O
and O
decreased O
endothelin-1 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Efficacy O
and O
safety O
of O
two O
different O
testosterone O
undecanoate O
formulations O
in O
hypogonadal O
men O
with O
metabolic O
syndrome O
. O
[]

Both O
anchor- O
and O
distribution-based O
approaches O
as O
well O
as O
linear O
regression O
analyses O
were O
used O
to O
determine O
the O
MID O
for O
6MWD O
. O
[]

65 O
mg/m O
( O
2 O
) O
and O
a O
mean O
left O
ventricular O
ejection O
fraction O
of O
52 O
? O
[]

Symptomatic O
treatment O
versus O
combination O
chemotherapy O
for O
patients O
with O
extensive O
non-small O
cell O
lung O
cancer O
. O
[]

The O
mean O
required O
post-operative B-outcome ['Resource-use']
fentanyl I-outcome ['Resource-use']
infusion I-outcome ['Resource-use']
rate O
( O
57.7 O
+/- O
19.5 O
micrograms/h O
) O
and O
the O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
( O
0.84 O
+/- O
0.36 O
ng/mL O
) O
in O
the O
fentanyl O
group O
were O
comparable O
to O
the O
infusion B-outcome ['Physiological-Clinical']
rate O
( O
54.4 O
+/- O
19.2 O
micrograms/h O
) O
and O
the O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
( O
0.86 O
+/- O
0.36 O
ng/mL O
) O
in O
the O
fentanyl/bupivacaine O
group O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Both O
regimens O
were O
essentially O
identical O
with O
respect O
to O
the O
clinical O
and O
bacteriological O
results O
they O
produced O
. O
[]

There O
were O
a O
total O
of O
79 O
patients O
with O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
SAEs O
) O
, O
43 O
( O
14.8 O
% O
) O
in O
the O
sibenadet O
pMDI O
group O
and O
36 O
( O
24.8 O
% O
) O
in O
the O
placebo O
group O
. O
['Adverse-effects']

The O
two-year O
actuarial O
probability O
of O
a O
recurrent O
, O
sustained O
, O
symptomatic B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
tachyarrhythmia I-outcome ['Physiological-Clinical']
was O
greater O
in O
noninvasive O
( O
0.50 O
+/- O
0.10 O
) O
than O
in O
invasive O
( O
0.20 O
+/- O
0.08 O
) O
approach O
patients O
( O
P O
= O
0.02 O
) O
. O
['Physiological-Clinical']

A O
large O
randomized O
trial O
of O
glycemic O
control O
is O
feasible O
in O
this O
population O
to O
examine O
clinically O
important O
outcomes O
, O
but O
will O
require O
refined O
insulin O
algorithms O
and O
more O
comprehensive O
behavior O
change O
strategies O
to O
achieve O
target O
values O
. O
[]

Bone B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
defects I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Randomized O
trial O
of O
an O
allogeneic O
melanoma O
lysate O
vaccine O
with O
low-dose O
interferon O
Alfa-2b O
compared O
with O
high-dose O
interferon O
Alfa-2b O
for O
Resected O
stage O
III O
cutaneous O
melanoma O
. O
[]

According O
to O
these O
results O
, O
VATS O
should O
be O
the O
treatment O
of O
choice O
in O
SP O
patients O
. O
[]

The O
average O
reconstruction B-outcome ['Physiological-Clinical']
error I-outcome ['Physiological-Clinical']
of O
the O
3D O
models O
was O
1.77 O
mm O
( O
?1.17 O
mm O
) O
, O
with O
the O
error O
being O
smallest O
in O
the O
femoral O
head O
and O
neck O
, O
and O
greatest O
in O
the O
trochanter O
. O
['Physiological-Clinical']

From O
February O
1991 O
to O
December O
1994 O
, O
376 O
patients O
with O
newly O
diagnosed O
CML O
in O
chronic O
phase O
were O
randomized O
. O
[]

Vitamin O
A O
supplementation O
for O
extremely-low-birth-weight O
infants O
. O
[]

PURPOSE O
This O
study O
examined O
whether O
safe O
and O
effective O
mydriasis O
can O
be O
achieved O
in O
premature O
infants O
with O
heavily O
pigmented O
irides O
using O
combination O
cyclopentolate O
0.2 O
% O
and O
phenylephrine O
1 O
% O
eyedrops O
. O
[]

[ O
Value O
of O
absorbable O
clips O
in O
laparoscopic O
cholecystectomy O
. O
[]

The O
GMC O
after O
3 O
doses O
revaccination O
with O
four O
kinds O
of O
HepB O
, O
included O
5 O
microg O
HepB-Y O
, O
10 O
microg O
HepB-Y O
, O
l0 O
microg O
HepB-CHO O
, O
10 O
microg O
HepB-HY O
were O
168.8 O
mJU/ml O
, O
174.7 O
mIU/ml O
, O
184.9 O
mIU/ml O
, O
182.9 O
mIU/ml O
respectively O
. O
[]

Dark-phase O
light O
contamination O
can O
significantly O
disrupt O
chronobiologic B-outcome ['Physiological-Clinical']
rhythms I-outcome ['Physiological-Clinical']
, O
thereby O
potentially O
altering O
the O
endocrine O
physiology O
and O
metabolism O
of O
experimental O
animals O
and O
influencing O
the O
outcome O
of O
scientific O
investigations O
. O
['Physiological-Clinical']

a O
fixed O
1kHz O
corner O
frequency O
) O
which O
makes O
them O
prone O
to O
ceiling O
and O
floor O
effects O
. O
[]

Complete O
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
rates O
were O
not O
statistically O
different O
: O
64 O
% O
[ O
95 O
percent O
confidence O
interval O
( O
CI O
) O
: O
58 O
percent O
to O
70 O
percent O
] O
for O
conventional O
arm O
vs O
81 O
percent O
( O
95 O
CI O
: O
77-86 O
percent O
) O
in O
the O
intensive O
group O
( O
p=0.2 O
) O
. O
['Physiological-Clinical']

The O
peanut O
content O
of O
the O
two O
recipes O
was O
analysed O
using O
RAST O
inhibition O
studies O
and O
ELISA O
tests O
. O
[]

dosing O
. O
[]

Dust-trapping O
reservoirs O
were O
common O
; O
76.8 O
% O
of O
children O
's O
bedrooms O
had O
carpeting O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
a O
classroom-based O
activity O
break O
on O
in-school B-outcome ['Life-Impact']
step I-outcome ['Life-Impact']
counts I-outcome ['Life-Impact']
of O
primary O
school O
children O
. O
['Life-Impact']

Basal O
R-R O
intervals O
were O
unaffected O
by O
age O
. O
[]

The O
feasibility B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
procedures I-outcome ['Life-Impact']
, O
analyzed O
on O
an O
intention-to-treat O
basis O
, O
was O
96 O
% O
, O
93 O
% O
and O
95 O
% O
for O
TPL O
, O
EPL O
and O
LPL O
group O
respectively O
( O
P=ns O
) O
. O
['Life-Impact']

The O
area O
under O
the O
receiver-operating O
characteristics O
curve O
for O
BNP O
to O
identify O
heart O
failure O
was O
0.87 O
( O
95 O
% O
confidence O
interval O
, O
0.81-0.93 O
) O
. O
[]

The O
predictors O
of O
higher O
costs O
( O
adding O
an O
average O
20,000 O
Euros/patient O
) O
were O
the O
occurrence O
of O
transplant-related B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
: O
graft-versus-host O
disease O
and O
repeated B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
that O
were O
unpredictable O
before O
transplant O
in O
this O
homogeneous O
group O
of O
patients O
. O
['Adverse-effects', 'Physiological-Clinical']

The O
objective O
of O
this O
overview O
was O
to O
critically O
evaluate O
published O
randomized O
controlled O
trials O
on O
treatments O
in O
preterm O
premature O
rupture O
of O
the O
membranes O
. O
[]

CONCLUSION O
Although O
the O
CF O
method O
provided O
a O
product O
in O
a O
shorter O
turnaround O
time O
, O
with O
consistent O
clearance O
of O
heparin O
, O
the O
MPH O
method O
trended O
towards O
enhanced B-outcome ['Physiological-Clinical']
biochemical I-outcome ['Physiological-Clinical']
and O
clinical B-outcome ['Physiological-Clinical']
patient O
outcomes O
over O
the O
12-hour O
postoperative O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mean O
IGF-I O
level O
was O
significantly O
lower O
during O
oral O
estrogen O
treatment O
( O
P O
< O
0.05 O
) O
and O
rose O
dose B-outcome ['Life-Impact']
dependently O
during O
GH O
administration O
by O
a O
lesser O
magnitude O
( O
P O
< O
0.05 O
) O
compared O
with O
transdermal O
treatment O
. O
['Life-Impact']

The O
children O
with O
HFA O
demonstrated O
improvements O
in O
all O
three O
areas O
: O
facial O
recognition O
, O
emotion O
recognition O
, O
and O
social O
interactions O
. O
[]

METHODS O
Muscle B-outcome ['Physiological-Clinical']
sympathetic I-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
BP B-outcome ['Physiological-Clinical']
, O
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of O
medically O
treated O
HF O
patients O
( O
EF O
< O
45 O
% O
) O
and O
OSA O
( O
apnea-hypopnea B-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
> O
or O
=20/h O
of O
sleep O
) O
were O
recorded O
on O
the O
morning O
after O
overnight O
polysomnography O
, O
and O
again O
one O
month O
after O
patients O
were O
randomly O
allocated O
nocturnal O
CPAP O
treatment O
or O
no O
CPAP O
( O
control O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

1.428 O
, O
one-sided O
? O
[]

Scores O
for O
taste B-outcome ['Life-Impact']
and O
symptom O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
similar O
for O
each O
preparation O
. O
['Life-Impact', 'Adverse-effects']

BACKGROUND O
The O
efficacy O
of O
angiotensin-converting O
enzyme O
( O
ACE O
) O
inhibitors O
in O
decreasing O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
African O
patients O
is O
controversial O
. O
['Physiological-Clinical']

INTERVENTION O
WB O
exercise O
and O
NWB O
exercise O
groups O
underwent O
an O
8-week O
knee O
extension-flexion O
exercise O
program O
. O
[]

increased O
their O
daily O
dose O
of O
AH O
to O
4 O
tablets O
daily O
. O
[]

Among O
the O
125 O
patients O
who O
enrolled O
in O
the O
study O
, O
57 O
selected O
clonidine O
and O
68 O
selected O
clonidine/naltrexone O
. O
[]

Randomised O
clinical O
trial O
of O
physiotherapy O
after O
open O
abdominal O
surgery O
in O
high O
risk O
patients O
. O
[]

The O
growth O
of O
fibroblasts O
and O
keratinocytes O
may O
be O
enhanced O
by O
pulsed O
low-intensity O
direct O
current O
due O
to O
changes O
in O
calcium B-outcome ['Physiological-Clinical']
homeostasis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

All O
rectal O
medications O
were O
very O
well O
accepted O
, O
but O
mask B-outcome ['Life-Impact']
acceptance I-outcome ['Life-Impact']
, O
improvement O
in O
anxiety B-outcome ['Life-Impact']
, O
and O
sedation B-outcome ['Physiological-Clinical']
were O
best O
in O
the O
midazolam O
group O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

This O
study O
evaluated O
the O
effectiveness O
of O
rational-emotive O
therapy O
and O
rational-emotive O
imagery O
. O
[]

OBJECTIVES O
To O
conduct O
an O
adequately O
powered O
trial O
of O
a O
home-based O
exercise O
intervention O
that O
can O
be O
facilely O
integrated O
into O
established O
delivery O
and O
reimbursement O
structures O
. O
[]

Grade O
3 O
burns O
with O
a O
200-mum O
spot O
size O
were O
placed O
with O
both O
modalities O
. O
[]

DESIGN O
Prospective O
, O
randomized O
, O
single-blind O
, O
parallel O
study O
. O
[]

Removal O
of O
hypertrophied O
anal O
papillae O
and O
fibrous O
anal O
polyps O
increases O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
after O
anal O
fissure O
surgery O
. O
['Life-Impact']

Comparison O
of O
fluid O
types O
for O
resuscitation O
after O
acute B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
mallard O
ducks O
( O
Anas O
platyrhynchos O
) O
. O
['Physiological-Clinical']

Thirty O
nondiabetic O
stage O
I O
or O
II O
CKD O
patients O
who O
had O
already O
been O
treated O
with O
angiotensin O
II O
receptor O
blockers O
were O
enrolled O
in O
this O
study O
. O
[]

In O
patients O
with O
advanced O
atherosclerosis O
manifested O
by O
arterial O
occlusion O
in O
the O
lower O
extremities O
without O
a O
baseline O
blood O
lipid O
disorder O
statin O
treatment O
caused O
improvement O
of O
the O
efficiency O
, O
i.e O
. O
[]

The O
treatment O
period O
was O
8-12 O
weeks O
. O
[]

Continued O
improvement O
in O
pressure-flow B-outcome ['Physiological-Clinical']
parameters O
in O
men O
receiving O
finasteride O
for O
2 O
years O
. O
['Physiological-Clinical']

Treatment O
of O
adult O
asthma O
: O
controlled O
double-blind O
clinical O
trial O
of O
oxitropium O
bromide O
. O
[]

It O
is O
two-pronged O
: O
Trainers O
work O
with O
children O
directly O
20 O
times O
over O
5 O
months O
, O
and O
parents O
give O
the O
massage O
daily O
to O
their O
children O
. O
[]

Mean O
+/- O
SD O
Emax O
( O
maximum O
percent O
reduction O
in O
heart O
rate O
from O
baseline O
) O
and O
EC50 B-outcome ['Physiological-Clinical']
( O
plasma O
diltiazem O
concentration O
that O
achieves O
half O
Emax O
) O
were O
52 O
+/- O
17 O
% O
and O
110 O
+/- O
84 O
ng/ml O
, O
respectively O
. O
['Physiological-Clinical']

Pre- O
, O
midterm- O
and O
post-training O
assessments O
of O
fitness O
were O
completed O
and O
rates O
of O
participation O
and O
retention O
were O
documented O
. O
[]

Median O
scores O
( O
min O
, O
max O
) O
were O
0 O
( O
0 O
, O
5 O
) O
, O
2 O
( O
0 O
, O
6 O
) O
, O
4 O
( O
0 O
, O
12 O
) O
respectively O
, O
( O
5-items O
, O
p O
< O
0.001 O
) O
and O
2 O
( O
0 O
, O
7 O
) O
, O
3 O
( O
1 O
, O
7 O
) O
, O
6 O
( O
2,15 O
) O
respectively O
, O
( O
6-items O
, O
p O
< O
0.001 O
) O
. O
[]

These O
patients O
were O
allocated O
at O
random O
to O
two O
groups O
, O
one O
of O
which O
was O
given O
treatment O
for O
8 O
days O
and O
the O
other O
for O
15 O
days O
. O
[]

Subjects/Study O
interventions O
: O
Forty-one O
( O
41 O
) O
patients O
were O
studied O
. O
[]

Group O
A O
received O
placebo O
mouthwash O
and O
tablets O
; O
Group O
B O
; O
placebo O
mouthwash O
and O
5 O
mg O
folate O
tablets O
; O
Group O
C O
: O
folate O
mouthwash O
and O
placebo O
tablets O
. O
[]

Follow O
up O
was O
incomplete O
in O
3.3 O
% O
and O
4.7 O
% O
patients O
in O
standard O
and O
sequential O
therapy O
groups O
, O
respectively O
. O
[]

OBJECTIVE O
It O
was O
aimed O
to O
investigate O
the O
effect O
of O
standardized O
ginseng O
extract O
on O
fertility B-outcome ['Physiological-Clinical']
parameters O
in O
diabetic O
rats O
. O
['Physiological-Clinical']

Effects O
of O
treatment O
were O
evaluated O
on O
the O
basis O
of O
the O
presence O
of O
exuberant O
granulation O
tissue O
requiring O
excision O
, O
number O
of O
times O
excision O
was O
required O
, O
total O
wound O
area O
, O
area O
of O
epithelialisation O
, O
area O
of O
granulation O
, O
and O
histological O
evaluation O
of O
biopsy O
samples O
of O
wounds O
on O
day O
8 O
and O
excised O
wounds O
on O
day O
21 O
. O
[]

The O
results O
can O
be O
considered O
representative O
, O
therefore O
, O
of O
clinical B-outcome ['Physiological-Clinical']
beta-blockade I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Avoidance O
of O
homologous O
blood O
products O
and O
patients O
' O
demand O
for O
preoperative O
autologous O
blood O
donation O
programs O
are O
increasing O
. O
[]

Children O
were O
randomly O
assigned O
to O
an O
experimental O
or O
delayed-treatment O
control O
group O
. O
[]

Registration O
, O
www.irct.ir O
; O
IRCT138711091556N2 O
) O
. O
[]

Statistical O
analysis O
, O
based O
on O
surface O
area O
and O
ulcer B-outcome ['Physiological-Clinical']
depth O
before O
and O
after O
treatment O
, O
showed O
that O
low-intensity O
direct O
current O
had O
a O
significant O
influence O
on O
the O
healing B-outcome ['Physiological-Clinical']
rates O
for O
these O
ulcers O
( O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
additional O
subsamples O
for O
the O
cost-effectiveness O
study O
will O
include O
information O
on O
quality O
of O
life O
, O
time B-outcome ['Life-Impact']
off I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
, O
and O
resources B-outcome ['Resource-use']
used I-outcome ['Resource-use']
, O
such O
as O
time B-outcome ['Resource-use']
in I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
, O
procedures B-outcome ['Resource-use']
, O
and O
medications B-outcome ['Resource-use']
taken O
. O
['Resource-use', 'Life-Impact', 'Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']

Analysis O
of O
all O
data O
revealed O
that O
there O
was O
no O
or O
reduced O
bacterial B-outcome ['Physiological-Clinical']
contamination I-outcome ['Physiological-Clinical']
in O
the O
second O
and O
third O
swab O
in O
33 O
patients O
( O
66 O
% O
) O
of O
Group O
A O
versus O
12 O
patients O
( O
25 O
% O
) O
of O
Group O
B O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
30 O
patients O
who O
were O
candidates O
for O
BPH O
surgery O
were O
prospectively O
included O
in O
the O
study O
. O
[]

0.003 O
, O
SW O
1.013 O
? O
[]

Nine O
gastrointestinal O
symptoms O
were O
assessed O
for O
frequency O
and O
severity O
before O
treatment O
. O
[]

METHODS O
Stable O
return-to-work O
was O
the O
outcome O
variable O
, O
the O
above-mentioned O
factors O
were O
the O
predictive O
variables O
in O
multiple-logistic O
regression O
models O
, O
one O
per O
follow-up O
at O
6 O
, O
12 O
, O
18 O
and O
24 O
months O
after O
baseline O
. O
[]

Previous O
studies O
have O
shown O
over O
70 O
% O
of O
children O
require O
analgesics O
following O
bilateral O
myringotomy O
and O
tube O
placement O
( O
BM O
& O
T O
) O
. O
[]

Four O
groups O
( O
n=4 O
for O
each O
group O
) O
were O
used O
: O
end-to-end O
coaptation O
( O
six O
months O
postoperatively O
) O
, O
end-to-side O
coaptation O
( O
four O
months O
and O
six O
months O
postoperatively O
) O
and O
normal O
control O
. O
[]

The O
aim O
of O
the O
present O
trial O
was O
to O
evaluate O
the O
effects O
of O
IFN-alpha O
administered O
as O
an O
adjuvant O
of O
HBV O
vaccine O
in O
healthy O
unvaccinated O
individuals O
. O
[]

CONCLUSIONS O
Moderately O
accelerated O
fractionation O
is O
superior O
to O
conventional O
treatment O
in O
HNSCC O
but O
the O
response O
is O
heterogeneous O
and O
may O
be O
predicted O
by O
high O
expression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
EGFr I-outcome ['Physiological-Clinical']
and O
well/moderate O
tumor B-outcome ['Physiological-Clinical']
differentiation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Placebo-corrected O
time-matched O
analysis O
of O
the O
QTcI B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
for O
the O
vilazodone O
treatment O
effect O
indicated O
that O
no O
vilazodone O
dose O
had O
an O
upper O
bound O
that O
approached O
or O
exceeded O
10 O
ms O
, O
demonstrating O
no O
signal O
for O
a O
significant O
vilazodone O
effect O
on O
cardiac B-outcome ['Physiological-Clinical']
repolarization I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
purpose O
of O
this O
randomised O
clinical O
trial O
was O
to O
compare O
an O
active O
training O
programme O
( O
AT O
) O
with O
a O
physiotherapy O
treatment O
without O
active O
training O
( O
PT O
) O
in O
the O
treatment O
of O
adductor-related O
groin O
pain O
in O
athletes O
. O
[]

The O
efficacy O
of O
transcutaneous O
electrical O
nerve O
stimulation O
( O
TENS O
) O
as O
an O
adjunct O
to O
narcotic O
medications O
for O
the O
management O
of O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
assessed O
in O
a O
prospective O
, O
randomized O
, O
controlled O
study O
of O
patients O
following O
coronary O
artery O
bypass O
graft O
( O
CABG O
) O
surgery O
with O
the O
right O
or O
left O
internal O
thoracic O
artery O
( O
ITA O
) O
. O
['Physiological-Clinical']

We O
did O
not O
find O
evidence O
for O
fat O
malabsorption O
in O
multiple O
sclerosis O
. O
[]

The O
impact O
on O
guideline O
adherence O
and O
resource O
utilization O
was O
evaluated O
during O
the O
12-month O
period O
before O
and O
after O
implementation O
. O
[]

Because O
oral O
contraceptives O
( O
OCs O
) O
may O
reduce O
the O
active B-outcome ['Physiological-Clinical']
androgen I-outcome ['Physiological-Clinical']
level O
, O
hormonal O
therapy O
with O
OCs O
has O
been O
used O
successfully O
to O
treat O
patients O
with O
acne O
, O
although O
this O
treatment O
has O
previously O
not O
been O
studied O
in O
placebo-controlled O
trials O
. O
['Physiological-Clinical']

Both O
self-report O
and O
sociometric B-outcome ['Life-Impact']
measures O
were O
used O
to O
evaluate O
treatment O
outcome O
. O
['Life-Impact']

Patterning O
of O
pain B-outcome ['Physiological-Clinical']
and O
power O
with O
guided O
imagery O
. O
['Physiological-Clinical']

Primary O
end-point O
was O
overall O
response O
to O
first-line B-outcome ['Physiological-Clinical']
treatment B-outcome ['Resource-use']
among O
TS O
high O
patients O
. O
['Physiological-Clinical', 'Resource-use']

PURPOSE O
To O
assess O
the O
optimal O
scan O
delays O
and O
contrast O
injection O
durations O
for O
contrast-enhanced O
whole-body O
computed O
tomography O
( O
CT O
) O
. O
[]

The O
efficacy O
and O
the O
tolerability B-outcome ['Life-Impact']
of O
simvastatin O
( O
a O
inhibitor O
of O
HGM-CoA O
reductase O
) O
with O
that O
of O
gemfibrozil O
( O
a O
fibric O
acid O
derivative O
, O
which O
can O
reduce O
the O
VLDL O
level O
) O
were O
compared O
in O
a O
placebo-controlled O
study O
in O
2 O
groups O
of O
patients O
with O
primary O
hypercholesterolemia O
and O
mild-to-moderate O
essential O
hypertension O
treated O
with O
hydrochlorothiazide O
. O
['Life-Impact']

Efficacy O
of O
amantadine O
on O
quality O
of O
life O
in O
patients O
with O
chronic O
hepatitis O
C O
treated O
with O
interferon-alpha O
and O
ribavirin O
: O
results O
from O
a O
randomized O
, O
placebo-controlled O
, O
double-blind O
trial O
. O
[]

CONCLUSIONS O
KeraVision O
Intacs O
are O
effective O
, O
predictable O
, O
stable B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical']

Baseline O
symptom B-outcome ['Physiological-Clinical']
prevalence O
ranged O
from O
2 O
% O
( O
vaginal O
bleeding O
) O
to O
60 O
% O
to O
70 O
% O
( O
bone/muscle B-outcome ['Physiological-Clinical']
aches I-outcome ['Physiological-Clinical']
and O
low B-outcome ['Physiological-Clinical']
energy I-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Risperidone O
and O
adaptive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
children O
with O
autism O
. O
['Life-Impact']

A O
double-blind O
placebo-controlled O
parallel O
groups O
design O
was O
used O
. O
[]

The O
training O
group O
performed O
exercises O
every O
day O
: O
on O
bicycle O
ergometer O
during O
30 O
minutes O
( O
5 O
times O
a O
week O
) O
, O
overall-conditioning O
exercises O
for O
30 O
minutes O
daily O
and O
30 O
to O
60 O
minutes O
of O
walking O
each O
day O
. O
[]

Noradrenaline B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
decreased O
to O
less O
than O
baseline O
values O
in O
the O
extradural O
group O
and O
were O
significantly O
less O
than O
in O
the O
opioid O
group O
. O
['Physiological-Clinical']

Fentanyl O
supplementation O
to O
inhalation O
anaesthesia O
. O
[]

Mass O
inoculation O
in O
a O
community O
: O
the O
effect O
of O
primary O
prevention O
of O
stress O
reactions B-outcome ['Life-Impact']
. O
['Life-Impact']

METHODS O
A O
single-blinded O
, O
randomized O
controlled O
trial O
was O
conducted O
with O
323 O
eligible O
adult O
participants O
being O
recruited O
into O
one O
of O
six O
genome O
studies O
at O
Baylor O
College O
of O
Medicine O
in O
Houston O
, O
Texas O
, O
between O
January O
2008 O
and O
August O
2009 O
. O
[]

Anhedonia B-outcome ['Life-Impact']
put O
individuals O
at O
risk O
of O
quitting O
the O
weight O
loss O
program O
( O
bivariate O
analysis O
OR O
3.1 O
, O
95 O
% O
CI O
0.8-11.6 O
, O
p=0.091 O
, O
multivariate O
analysis O
OR O
6.5 O
, O
95 O
% O
CI O
1.1-38.2 O
, O
p=0.038 O
) O
. O
['Life-Impact']

Subjects O
are O
randomized O
to O
receive O
PN O
designed O
to O
provide O
100 O
% O
of O
measured O
REE O
, O
or O
standard O
PN O
, O
i.e. O
, O
140 O
% O
of O
estimated O
energy O
expenditure O
. O
[]

After O
the O
first O
4 O
weeks O
all O
subjects O
were O
changed O
from O
CC O
to O
sevelamer O
3.0 O
g/day O
for O
another O
4 O
weeks O
, O
then O
allocated O
randomly O
to O
three O
groups O
for O
the O
final O
4 O
weeks O
: O
group O
A O
, O
sevelamer O
6.0 O
g/day O
; O
group O
B O
, O
sevelamer O
3.0 O
g/day O
and O
CC O
3.0 O
g/day O
; O
group O
C O
, O
CC O
3.0 O
g/day O
. O
[]

The O
18HL O
reduced O
[]

Hypertension O
and O
non-insulin-dependent O
diabetes O
. O
[]

RESULTS O
Of O
152 O
potential O
participants O
, O
25 O
were O
randomly O
assigned O
to O
either O
the O
intervention O
( O
n O
= O
14 O
) O
or O
the O
control O
( O
n O
= O
11 O
) O
group O
; O
22 O
were O
women O
, O
and O
21 O
were O
educated O
beyond O
high O
school O
. O
[]

CONCLUSION O
A O
specific O
exercise O
program O
decreased O
back O
pain O
intensity O
and O
increased O
functional O
ability O
during O
pregnancy O
in O
South O
African O
women O
with O
lumbar O
and O
pelvic O
girdle O
pain O
. O
[]

Patients O
with O
a O
recurrence O
after O
open O
repair O
had O
more O
pain B-outcome ['Physiological-Clinical']
than O
those O
with O
a O
recurrence O
after O
laparoscopic O
repair O
( O
P O
= O
.0001 O
) O
. O
['Physiological-Clinical']

Effect O
of O
reduced O
alcohol O
consumption O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
untreated O
hypertensive O
men O
. O
['Physiological-Clinical']

METHODS O
Twenty-two O
volunteers O
over O
60 O
years O
of O
age O
participated O
in O
the O
present O
study O
. O
[]

At O
present O
no O
study O
of O
gastric O
dysrhythmia O
, O
measured O
with O
epigastric B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
, O
has O
been O
presented O
, O
and O
the O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
gastric O
rhythms O
by O
means O
of O
impedance O
gastrography O
in O
control O
infants O
, O
compared O
to O
infants O
with O
different O
gastrointestinal O
diseases O
, O
before O
and O
after O
treatment O
of O
their O
disease O
. O
['Physiological-Clinical']

Patients O
referred O
for O
coronary O
angiography O
were O
randomized O
to O
very-low-dose O
heparin O
( O
2,000 O
IU O
) O
or O
low-dose O
heparin O
( O
5,000 O
IU O
) O
. O
[]

Patients O
treated O
with O
allopurinol O
showed O
less O
myocardial B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
radicals I-outcome ['Physiological-Clinical']
, O
indicating O
that O
its O
protective O
effect O
may O
be O
due O
to O
its O
antioxidative O
properties O
. O
['Physiological-Clinical']

Tubeless O
percutaneous O
nephrolithotomy O
: O
safe O
even O
in O
supracostal O
access O
. O
[]

From O
the O
present O
findings O
tocainide O
and O
prajmalium O
bitartrate O
have O
the O
same O
efficient O
antiarrhythmic B-outcome ['Physiological-Clinical']
effects O
in O
the O
majority O
of O
patients O
. O
['Physiological-Clinical']

The O
effect O
of O
prophylactic O
fentanyl O
on O
shivering O
in O
elective B-outcome ['Resource-use']
caesarean I-outcome ['Resource-use']
section I-outcome ['Resource-use']
under O
epidural O
analgesia O
. O
['Resource-use']

MATERIALS O
AND O
METHODS O
A O
total O
of O
118 O
patients O
with O
biopsy O
proved O
prostate O
cancer O
underwent O
repeat O
sextant O
prostate O
biopsy O
before O
enrollment O
in O
a O
prospective O
randomized O
trial O
of O
radical O
prostatectomy O
with O
or O
without O
neoadjuvant O
hormonal O
therapy O
. O
[]

DESIGN O
Reanalysis O
of O
the O
baseline O
prediction O
model O
for O
the O
development O
of O
POAG O
from O
the O
Ocular O
Hypertension O
Treatment O
Study O
( O
OHTS O
) O
substituting O
IOP O
adjusted O
for O
CCT O
using O
5 O
different O
correction O
formulae O
for O
unadjusted O
IOP O
. O
[]

Half O
of O
the O
participants O
heard O
their O
heart O
sounds O
first O
via O
headphones O
and O
then O
via O
loudspeakers O
which O
were O
also O
audible O
to O
observers O
. O
[]

Our O
data O
indicate O
that O
the O
functional O
hip O
outcome O
of O
femoral O
intramedullary O
nailing O
performed O
through O
the O
greater O
trochanter O
is O
equal O
to O
that O
of O
intramedullary O
nailing O
performed O
through O
the O
piriformis O
fossa O
. O
[]

METHODS O
We O
conducted O
a O
randomized O
, O
controlled O
, O
masked O
clinical O
trial O
for O
one O
year O
in O
southern O
India O
involving O
15,419 O
preschool-age O
children O
who O
received O
either O
8.7 O
mumol O
( O
8333 O
IU O
) O
of O
vitamin O
A O
and O
46 O
mumol O
( O
20 O
mg O
) O
of O
vitamin O
E O
( O
the O
treated O
group O
) O
or O
vitamin O
E O
alone O
( O
the O
control O
group O
) O
. O
[]

The O
EA O
group O
received O
electro-acupuncture O
for O
selected O
acupoints O
while O
the O
SEA O
group O
received O
sham O
electro-acupuncture O
to O
sham O
acupoints O
. O
[]

RESULTS O
PRIMARY O
MEASUREMENTS O
3-monthly O
HbA1c B-outcome ['Physiological-Clinical']
, O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
waist-hip B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
yearly B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
, O
and O
bi-yearly O
assessment O
of I-outcome ['Life-Impact']
knowledge B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
diabetes I-outcome ['Life-Impact']
, O
health B-outcome ['Life-Impact']
behaviours I-outcome ['Life-Impact']
and O
quality O
of O
life O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Accuracy O
of O
pelvic O
radiotherapy O
: O
prospective O
analysis O
of O
90 O
patients O
in O
a O
randomised O
trial O
of O
blocked O
versus O
standard O
radiotherapy O
. O
[]

DESIGN O
Prospective O
, O
randomized O
study O
. O
[]

If O
the O
pertactin O
value O
was O
> O
or O
= O
7 O
EU O
ml-1 O
and O
the O
PT O
value O
> O
or O
= O
66 O
EU O
ml-1 O
all O
subjects O
were O
non-cases O
. O
[]

Each O
subjects-either O
inactive O
or O
active-performed O
two O
treadmill O
tests O
at O
two-days O
interval O
, O
to O
measure O
maximal O
and O
submaximal O
responses O
to O
exercise O
, O
respectively O
. O
[]

BACKGROUND O
In O
the O
treatment O
of O
reflux O
oesophagitis O
, O
H2-receptor O
antagonists O
are O
still O
widely O
used O
in O
spite O
of O
the O
apparent O
higher O
efficacy O
of O
proton O
pump O
inhibitors O
. O
[]

Movement-related O
potentials O
in O
Parkinson O
's O
disease O
. O
[]

We O
found O
that O
superficial B-outcome ['Physiological-Clinical']
peels I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
involving O
30 O
% O
of O
the O
epidermis O
were O
produced O
by O
the O
lowest-concentration O
combination O
of O
TCA O
applied B-outcome ['Life-Impact']
( O
20 O
% O
followed O
by O
0 O
% O
) O
. O
['Physiological-Clinical', 'Life-Impact']

The O
Sur-Catch O
NT O
had O
the O
slowest O
stone B-outcome ['Physiological-Clinical']
capture I-outcome ['Physiological-Clinical']
rate O
for O
all O
stone O
sizes O
. O
['Physiological-Clinical']

When O
compared O
with O
high-flux O
HD O
, O
online O
HDF O
provided O
significantly O
greater O
percentages O
of O
the O
reduction O
ratio O
in O
plasma B-outcome ['Physiological-Clinical']
cytokine I-outcome ['Physiological-Clinical']
levels O
, O
including O
VEGF B-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
, O
IL-6 O
( O
P O
= O
0.001 O
) O
, O
IL-8 O
( O
P O
= O
0.021 O
) O
, O
IL-10 O
( O
P O
= O
0.011 O
) O
, O
and O
tumor O
necrosis O
factor-? O
( O
P O
= O
0.029 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Fifty O
consecutive O
patients O
entered O
the O
myocardial O
contrast O
echocardiography O
( O
MCE O
) O
substudy O
of O
the O
REMEDIA O
( O
Randomized O
Evaluation O
of O
the O
Effect O
of O
Mechanical O
Reduction O
of O
Distal O
Embolization O
by O
Thrombus O
Aspiration O
in O
Primary O
and O
Rescue O
Angioplasty O
) O
trial O
, O
which O
defined O
the O
role O
of O
a O
new O
thrombus-aspirating O
device O
in O
preventing O
distal O
microembolization B-outcome ['Physiological-Clinical']
after O
PCI O
. O
['Physiological-Clinical']

The O
participants O
were O
randomly O
assigned O
to O
one O
of O
four O
groups O
: O
1 O
) O
Copy O
the O
target O
word O
from O
the O
computer O
screen O
( O
n=22 O
) O
, O
2 O
) O
Memorize O
the O
target O
word O
and O
write O
it O
from O
memory O
( O
n=21 O
) O
, O
3 O
) O
Word O
reading O
( O
n=21 O
) O
, O
and O
4 O
) O
the O
untrained O
control O
group O
( O
n=21 O
) O
. O
[]

The O
incremental O
cost-effectiveness O
ratio O
is O
?73,359 O
per O
QALY O
. O
[]

INTERVENTION O
( O
S O
) O
Mature O
oocytes O
obtained O
from O
a O
single O
cohort O
of O
oocytes O
were O
randomly O
divided O
into O
two O
groups O
; O
one O
was O
cultured O
at O
37?C O
and O
the O
other O
at O
36?C O
from O
the O
time O
of O
ICSI O
to O
the O
time O
of O
embryo O
transfer O
or O
vitrification O
. O
[]

A O
total O
of O
45 O
children O
diagnosed O
with O
Autism O
Spectrum O
Disorder O
( O
ASD O
) O
ages O
7-14 O
were O
randomly O
assigned O
to O
standard O
, O
directive O
, O
or O
control O
story O
conditions O
. O
[]

In O
weeks O
4 O
, O
5 O
and O
6 O
the O
patients O
received O
a O
total O
of O
nine O
treatments O
, O
each O
of O
15 O
min O
and O
administered O
to O
periarticular O
tender O
points O
. O
[]

Twenty-four O
children O
meeting O
ICD-10 O
criteria O
for O
childhood O
autism O
( O
mean O
age O
= O
23 O
months O
) O
were O
identified O
using O
the O
CHAT O
screen O
and O
randomised O
to O
the O
parent O
training O
group O
or O
to O
local O
services O
only O
. O
[]

Comparison O
of O
increasing O
doses O
of O
olmesartan O
medoxomil O
, O
losartan O
potassium O
, O
and O
valsartan O
in O
patients O
with O
essential O
hypertension O
. O
[]

Capsaicin O
is O
an O
agonist O
of O
the O
transient O
receptor O
potential O
vanilloid O
type O
1 O
. O
[]

An O
exposure O
prevention O
rating O
method O
for O
intervention O
needs O
assessment O
and O
effectiveness O
evaluation O
. O
[]

Plasminogen O
levels O
were O
also O
increased O
in O
both O
groups O
with O
a O
greater O
increase O
in O
the O
T-group O
. O
[]

Primary O
deep O
sclerectomy O
versus O
primary O
deep O
sclerectomy O
with O
the O
use O
of O
mitomycin O
C O
in O
primary O
open-angle O
glaucoma O
. O
[]

OBJECTIVE O
. O
[]

This O
study O
was O
actually O
motivated O
by O
discrepant O
findings O
on O
the O
effects O
of O
the O
preceding O
tone O
sequence O
on O
P3 O
. O
[]

The O
median O
time B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
diagnosis I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
crossover I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Groups I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( O
Group O
3 O
) O
was O
163 O
, O
99 O
, O
and O
220 O
days O
, O
and O
the O
mean O
time O
was O
172 O
, O
108 O
, O
and O
231 O
days O
. O
['Physiological-Clinical']

When O
concurrent O
activation O
of O
elbow O
muscles O
was O
induced O
, O
significant O
changes O
in O
the O
activation O
levels O
of O
the O
hand O
muscles O
were O
observed O
, O
with O
greater O
effects O
on O
the O
extrinsic O
finger O
extensor O
( O
23.2 O
% O
increase O
under O
30 O
% O
elbow O
extensor O
activation O
; O
p O
= O
0.003 O
) O
than O
extrinsic O
finger O
flexor O
( O
14.2 O
% O
increase O
under O
30 O
% O
elbow O
flexor O
activation O
; O
p O
= O
0.130 O
) O
. O
[]

[ O
No O
better O
vigilance B-outcome ['Physiological-Clinical']
after O
general O
anesthesia O
with O
propofol O
in O
colonic O
surgery O
. O
['Physiological-Clinical']

Combined O
hospital B-outcome ['Mortality']
death I-outcome ['Mortality']
and O
additional O
antibiotic B-outcome ['Resource-use']
prescription I-outcome ['Resource-use']
rates O
were O
similar O
in O
the O
2 O
groups O
( O
16.4 O
% O
vs O
15.3 O
% O
for O
trimethoprim-sulfamethoxazole O
group O
vs O
ciprofloxacin O
group O
; O
difference O
, O
1.1 O
% O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
-9.8 O
% O
to O
12.0 O
% O
; O
P O
= O
.832 O
) O
. O
['Mortality', 'Resource-use']

MAIN O
OUTCOME O
MEASURES O
The O
main O
outcome O
measures O
were O
survival B-outcome ['Mortality']
and O
bacteriologic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
defined O
by O
consecutive O
negative O
blood B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
for O
MAC B-outcome ['Physiological-Clinical']
at O
least O
2 O
weeks O
apart O
within O
16 O
weeks O
of O
study O
entry O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

INTERVENTION O
Twelve O
weeks O
of O
treatment O
with O
placebo O
or O
400 O
mg O
tid O
of O
pentoxifylline O
. O
[]

Cohort O
2 O
( O
n O
= O
7 O
) O
was O
treated O
every O
2 O
weeks O
, O
with O
leukapheresis O
on O
day O
1 O
of O
the O
next O
cycle O
and O
storage O
of O
the O
leukapheresis O
product O
at O
4 O
degrees O
C. O
Cohort O
3 O
( O
n O
= O
12 O
) O
was O
treated O
every O
2 O
weeks O
, O
with O
500 O
to O
750 O
mL O
of O
blood O
drawn O
by O
venesection O
on O
day O
1 O
of O
the O
next O
cycle O
and O
stored O
at O
4 O
degrees O
C. O
In O
cohorts O
2 O
and O
3 O
, O
chemotherapy O
was O
given O
if O
the O
WBC O
count O
was O
> O
or O
= O
3 O
x O
10 O
( O
9 O
) O
/L O
and O
platelet O
count O
> O
or O
= O
30 O
x O
10 O
( O
9 O
) O
/L O
. O
[]

Both O
protocols O
included O
adjuvant O
medications O
for O
muscle O
cramps O
, O
insomnia O
, O
and O
vomiting O
. O
[]

The O
implications O
for O
these O
findings O
are O
discussed O
. O
[]

We O
employed O
an O
ultrasound O
Doppler O
device O
in O
group O
II O
and O
a O
real-time O
ultrasonograph O
in O
group O
III O
. O
[]

Argatroban O
for O
elective O
percutaneous O
coronary O
intervention O
: O
the O
ARG-E04 O
multi-center O
study O
. O
[]

METHODS O
The O
design O
of O
this O
study O
is O
a O
clinical O
trial O
. O
[]

Mean O
number O
of O
whoops B-outcome ['Physiological-Clinical']
during O
the O
first O
week O
of O
follow-up O
was O
also O
significantly O
reduced O
( O
p O
= O
0.0196 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Rheumatic O
fever O
is O
a O
preventable O
chronic O
disease O
preceded O
by O
group O
A O
beta-haemolytic O
streptococcal O
( O
GABHS O
) O
pharyngitis O
. O
[]

Median O
back B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
leg I-outcome ['Physiological-Clinical']
pain B-outcome ['Physiological-Clinical']
varied O
between O
17 O
and O
23 O
mm O
( O
VAS O
) O
, O
and O
the O
Million O
and O
Oswestry B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
varied O
between O
14 O
and O
23 O
points O
2 O
months O
postoperatively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
percentage O
of O
children B-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
detectable I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
and O
the O
reciprocal O
geometric O
mean O
titers O
were O
similar O
for O
both O
groups O
at O
two O
months O
of O
age O
for O
antibodies O
to O
all O
three O
poliovirus O
types O
. O
['Physiological-Clinical']

Additionally O
, O
our O
data O
demonstrated O
an O
even O
more O
rapid O
induction O
of O
[]

Effect O
of O
a O
nutrition O
intervention O
during O
early O
childhood O
on O
economic B-outcome ['Resource-use']
productivity I-outcome ['Resource-use']
in O
Guatemalan O
adults O
. O
['Resource-use']

No O
difference O
was O
observed O
with O
respect O
to O
the O
median O
yield O
of O
CFU-GM B-outcome ['Physiological-Clinical']
and O
CD34+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
: O
32.5 O
x O
10 O
( O
4 O
) O
/kg O
vs O
31.3 O
x O
10 O
( O
4 O
) O
/kg O
CFU-GM O
, O
and O
7.6 O
x O
10 O
( O
6 O
) O
/kg O
vs O
5.6 O
x O
10 O
( O
6 O
) O
/kg O
CD34+ O
cells O
, O
for O
G-CSF O
and O
GM-CSF B-outcome ['Physiological-Clinical']
, O
respectively O
( O
U O
test O
, O
P= O
0.837 O
and O
0.696 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
conducted O
a O
randomized O
prospective O
study O
on O
30 O
patients O
with O
lung O
adenocarcinoma O
, O
divided O
into O
two O
groups O
of O
15 O
patients O
each O
. O
[]

STATEMENT O
OF O
PROBLEMS O
Postoperative O
cold O
sensitivity O
after O
the O
cementation O
of O
indirect O
restorations O
with O
composite O
cements O
has O
been O
reported O
frequently O
but O
not O
scientifically O
documented O
. O
[]

A O
significant O
increase O
in O
the O
postoperative O
day O
# O
1 O
, O
2 O
and O
3 O
hemoglobin B-outcome ['Physiological-Clinical']
was O
seen O
in O
the O
early O
reinfusion O
group O
, O
while O
there O
was O
no O
significant O
difference O
seen O
in O
the O
postoperative O
day O
# O
7 O
hemoglobin O
between O
the O
early O
versus O
delayed O
reinfusion O
group O
. O
['Physiological-Clinical']

Forty-seven O
patients O
completed O
the O
study O
. O
[]

The O
fatty B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
esters I-outcome ['Physiological-Clinical']
has O
been O
studied O
during O
lipid-lowering O
treatment O
of O
95 O
patients O
with O
atherosclerotic O
disease O
. O
['Physiological-Clinical']

The O
pharmacokinetics O
and O
pharmacodynamics O
of O
enalapril O
, O
an O
angiotensin O
converting O
enzyme O
inhibitor O
, O
are O
reported O
to O
vary O
with O
the O
time O
of O
administration O
. O
[]

Lorazepam O
increased O
direction B-outcome ['Life-Impact']
errors I-outcome ['Life-Impact']
in O
the O
antisaccade O
and O
no-saccade O
tasks O
in O
a O
dose-dependent O
manner O
. O
['Life-Impact']

European O
Cancer O
Prevention O
Organisation O
Study O
Group O
. O
[]

Following O
priming O
, O
an O
automatic O
imitation O
paradigm O
was O
used O
to O
acquire O
an O
index O
of O
imitation B-outcome ['Life-Impact']
. O
['Life-Impact']

Final O
BW O
of O
steers O
fed O
ZH O
was O
6.0 O
kg O
heavier O
( O
P O
= O
0.008 O
) O
, O
and O
ZH-fed O
steers O
had O
greater O
( O
P O
= O
0.003 O
) O
ADG O
than O
steers O
not O
fed O
ZH O
. O
[]

CLINICAL O
IMPLICATIONS O
The O
results O
of O
this O
study O
suggest O
that O
women O
who O
exercised O
regularly O
before O
receiving O
a O
breast O
cancer O
diagnosis O
attempted O
to O
maintain O
their O
exercise O
programs O
. O
[]

OUTCOME O
Patients O
were O
assessed O
at O
baseline O
, O
week O
5 O
, O
and O
week O
10 O
. O
[]

Tinzaparin O
versus O
dalteparin O
for O
periprocedure O
prophylaxis O
of O
thromboembolic O
events O
in O
hemodialysis O
patients O
: O
a O
randomized O
trial O
. O
[]

The O
effects O
of O
ezetimibe/simvastatin O
versus O
simvastatin O
monotherapy O
on O
platelet B-outcome ['Physiological-Clinical']
and O
inflammatory B-outcome ['Physiological-Clinical']
biomarkers I-outcome ['Physiological-Clinical']
in O
patients O
with O
metabolic O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
1-week O
washout O
period O
47 O
patients O
were O
randomized O
to O
ketazolam O
15 O
mg O
, O
and O
45 O
to O
placebo O
for O
15 O
days O
( O
first O
period O
) O
. O
[]

A O
European O
multicenter O
study O
has O
examined O
the O
use O
of O
dopexamine O
in O
patients O
undergoing O
major O
abdominal O
surgery O
, O
showing O
a O
trend O
toward O
improved O
survival B-outcome ['Mortality']
and O
reduced O
complications B-outcome ['Adverse-effects']
in O
high-risk O
patients O
when O
receiving O
low-dose O
dopexamine O
( O
0.5 O
?g O
? O
['Mortality', 'Adverse-effects']

SETTING O
A O
gynaecological O
oncology O
centre O
and O
a O
teaching O
hospital O
in O
West O
London O
. O
[]

Participants O
were O
also O
surveyed O
about O
the O
effectiveness O
of O
the O
education O
materials O
and O
the O
phone O
contact O
. O
[]

CONTEXT O
Simulation-based O
medical O
education O
allows O
trainees O
to O
engage O
in O
self-regulated O
learning O
( O
SRL O
) O
, O
yet O
research O
aimed O
at O
elucidating O
the O
mechanisms O
of O
SRL O
in O
this O
context O
is O
relatively O
absent O
. O
[]

MRI O
signal O
hyperintensities O
in O
geriatric O
depression O
. O
[]

Three O
interventions O
were O
performed O
on O
each O
of O
the O
athletes O
at O
different O
time O
points O
. O
[]

RESULTS O
The O
oral O
treatment O
group O
showed O
significant O
increases O
in O
plasma B-outcome ['Physiological-Clinical']
reduced I-outcome ['Physiological-Clinical']
glutathione B-outcome ['Physiological-Clinical']
, O
but O
not O
whole-blood O
glutathione B-outcome ['Physiological-Clinical']
levels O
following O
supplementation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Doses O
were O
titrated O
( O
maximal O
doses O
: O
pioglitazone O
45 O
mg O
, O
glimepiride O
8 O
mg O
) O
to O
achieve O
glycemic O
targets O
( O
fasting O
blood O
glucose O
< O
or O
=7 O
mmol/L O
and O
1-hour O
postprandial O
blood O
glucose O
< O
or O
=10 O
mmol/L O
) O
. O
[]

Controlled O
study O
on O
the O
therapeutic B-outcome ['Physiological-Clinical']
efficacy O
of O
propionyl-L-carnitine O
in O
patients O
with O
congestive O
heart O
failure O
. O
['Physiological-Clinical']

Six O
hundred O
eighteen O
volunteers O
were O
screened O
; O
306 O
were O
randomized O
. O
[]

Twenty-six O
were O
assigned O
to O
the O
PRE O
group O
and O
were O
operated O
on O
5 O
to O
8 O
weeks O
after O
the O
completion O
of O
radiotherapy O
. O
[]

Visualization O
of O
the O
esophageal O
course O
by O
barium O
contrast O
was O
not O
able O
to O
prevent O
ESUL B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Therefore O
, O
comparison O
might O
be O
biased O
. O
[]

Further O
outcome O
variables O
include O
: O
social B-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
, O
change O
in O
psychiatric B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
quality O
of O
life O
, O
and O
independence O
in O
daily B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Children O
with O
ALL O
were O
randomized O
between O
Regimens O
I O
and O
II O
( O
31 O
and O
36 O
evaluable O
patients O
, O
respectively O
) O
. O
[]

BACKGROUND O
Though O
the O
outcome O
of O
resection O
for O
locally O
invasive O
pancreatic O
cancer O
is O
still O
poor O
, O
it O
has O
gradually O
improved O
in O
Japan O
, O
and O
the O
5-year O
survival B-outcome ['Mortality']
is O
now O
about O
10 O
% O
. O
['Mortality']

Regulatory O
authorities O
require O
demonstration O
of O
bioequivalence O
through O
comparisons O
of O
different O
pharmacokinetic O
parameters O
, O
the O
area O
under O
the O
plasma B-outcome ['Physiological-Clinical']
concentration-time O
curve O
( O
AUC O
) O
, O
the O
maximum O
plasma B-outcome ['Physiological-Clinical']
concentration O
( O
Cmax B-outcome ['Physiological-Clinical']
) O
, O
and O
the O
time O
to O
reach O
peak O
concentration B-outcome ['Physiological-Clinical']
( O
Tmax B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
this O
approach O
can O
not O
account O
for O
potential O
third O
variables O
between O
participants O
that O
may O
affect O
both O
smoking O
and O
depression O
. O
[]

For O
patients O
who O
achieved O
a O
stable B-outcome ['Physiological-Clinical']
PT I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
( O
defined O
as O
a O
PT O
ratio O
between O
1.3 O
and O
2.5 O
that O
varied O
by O
less O
than O
0.05 O
on O
two O
consecutive O
days O
or O
by O
less O
than O
0.1 O
on O
three O
consecutive O
days O
without O
a O
dosage O
change O
) O
before O
discharge O
, O
the O
number O
of O
days O
( O
time O
to O
stabilization O
) O
from O
administration O
of O
the O
first O
warfarin O
dose O
to O
achievement O
of O
the O
warfarin O
dosage O
that O
produced O
a O
stable B-outcome ['Physiological-Clinical']
PT I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
( O
stabilization B-outcome ['Life-Impact']
dosage I-outcome ['Life-Impact']
) O
was O
compared O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Genetic B-outcome ['Physiological-Clinical']
linkage O
disequilibrium B-outcome ['Physiological-Clinical']
was O
found O
between O
two O
CYP21 O
mutations O
and O
chromosome O
6p O
markers O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
apical O
sealing O
ability O
and O
adaptation O
to O
dentine O
of O
two O
resin-based O
root O
canal O
sealers O
. O
[]

These O
observations O
were O
compiled O
in O
detailed O
daily O
notes O
. O
[]

The O
venous B-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
rate O
was O
1.7 O
% O
( O
7/424 O
) O
in O
the O
fondaparinux-treated O
patients O
and O
5.3 O
% O
( O
22/418 O
) O
in O
the O
placebo-treated O
patients O
( O
odds O
ratio O
reduction O
69.8 O
% O
; O
95 O
% O
confidence O
interval O
27.9-87.3 O
; O
P O
= O
0.004 O
) O
. O
['Physiological-Clinical']

The O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
rate O
was O
68 O
% O
with O
complete O
remission O
with O
incomplete O
count O
recovery O
in O
an O
additional O
16 O
% O
; O
8-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
32 O
% O
. O
['Physiological-Clinical', 'Mortality']

Consecutive O
consenting O
patients O
from O
one O
center O
in O
a O
multicenter O
trial O
that O
compared O
6 O
months O
of O
low O
molecular O
weight O
heparin O
with O
oral O
anticoagulant O
therapy O
were O
treated O
with O
therapeutic O
doses O
of O
dalteparin O
( O
200 O
IU O
per O
kilogram O
) O
subcutaneously O
daily O
. O
[]

BACKGROUND O
AND O
PURPOSE O
Reduction O
of O
the O
overall O
treatment O
time O
of O
radiotherapy O
has O
increased O
locoregional B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
disease B-outcome ['Mortality']
specific I-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
squamous O
cell O
carcinomas O
of O
the O
head O
and O
neck O
( O
HNSCC O
) O
, O
but O
the O
response O
is O
heterogeneous O
. O
['Physiological-Clinical', 'Mortality']

CONCLUSIONS O
Psychosocial O
therapy O
significantly O
reduced O
the O
risk O
of O
cardiovascular B-outcome ['Mortality']
death I-outcome ['Mortality']
in O
sudden O
cardiac O
arrest O
survivors O
. O
['Mortality']

For O
the O
hemiarthroplasty O
group O
, O
the O
direct B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
, O
total O
hospital B-outcome ['Resource-use']
['Resource-use', 'Resource-use']

Hispanic O
families O
in O
both O
groups O
used O
CAM B-outcome ['Physiological-Clinical']
less O
often O
than O
non-Hispanic O
families O
. O
['Physiological-Clinical']

Independent O
and O
paired O
t-tests O
, O
chi-squared O
tests O
and O
covariance O
analysis O
were O
used O
to O
analysing O
data O
. O
[]

Children O
in O
the O
community O
group O
received O
significantly O
more O
intervention B-outcome ['Life-Impact']
hours I-outcome ['Life-Impact']
than O
those O
in O
the O
P-ESDM O
group O
. O
['Life-Impact']

BACKGROUND O
Aspirin O
has O
been O
found O
to O
prevent O
angiotensin O
II-induced O
hypertension O
and O
to O
induce O
nitric O
oxide O
( O
NO O
) O
release O
from O
vascular O
endothelium O
. O
[]

BACKGROUND O
Oesophageal O
acid O
infusion O
induces O
enhanced O
pain O
hypersensitivity O
in O
non-acid O
exposed O
upper O
oesophagus O
( O
secondary O
hyperalgesia O
) O
in O
patients O
with O
non-cardiac O
chest O
pain O
, O
thus O
suggesting O
central O
sensitisation O
contributes O
to O
visceral O
pain O
hypersensitivity O
in O
functional O
gut O
disorders O
( O
FGD O
) O
. O
[]

Effect O
size O
d O
was O
1.4 O
, O
compared O
to O
1.2 O
on O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
Irritability O
subscale O
. O
['Life-Impact']

Systolic O
time O
intervals O
were O
sensitive O
and O
specific O
for O
isoprenaline-induced O
effects O
, O
PEP O
and O
QS2c-measurements O
had O
high O
reproducibility O
. O
[]

There O
was O
no O
difference O
between O
the O
groups O
in O
blood O
and O
platelet O
transfusions O
. O
[]

RESULTS O
Among O
312 O
patients O
enrolled O
, O
30 O
% O
experienced O
at O
least O
one O
SRE B-outcome ['Physiological-Clinical']
during O
the O
12-month O
study O
, O
and O
22 O
% O
experienced O
only O
one O
SRE B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Our O
studies O
do O
not O
characterize O
AP-1 O
as O
a O
therapeutic O
target O
for O
progressive O
human O
atherosclerotic O
disease O
. O
[]

In O
a O
randomized O
controlled O
trial O
, O
3-12 O
year-old O
children O
with O
autism O
were O
assigned O
to O
either O
a O
sensorimotor O
enrichment O
group O
, O
which O
received O
daily O
olfactory/tactile O
stimulation O
along O
with O
exercises O
that O
stimulated O
other O
paired O
sensory O
modalities O
, O
or O
to O
a O
control O
group O
. O
[]

Graphical O
plots O
revealed O
trends O
towards O
higher O
Escort B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
as O
mean O
values O
rose O
compared O
with O
both O
mini-Wright O
and O
turbine O
readings O
for O
peak O
expiratory I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
one I-outcome ['Physiological-Clinical']
second I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
24 O
patients O
who O
had O
anti-Xa B-outcome ['Physiological-Clinical']
levels O
measured O
at O
weeks O
1 O
and O
4 O
. O
['Physiological-Clinical']

In O
Phase O
2 O
, O
the O
trend O
observed O
with O
morphine O
was O
insignificant O
( O
P O
= O
0.41 O
) O
. O
[]

Twenty-one O
consecutive O
obese O
patients O
with O
heart O
failure O
were O
recruited O
. O
[]

In O
12 O
patients O
with O
ARDS O
, O
permissive O
hypercapnia O
was O
implemented O
for O
2 O
h O
with O
a O
target O
Pa O
( O
CO O
( O
2 O
) O
) O
of O
80 O
mm O
Hg O
. O
[]

All O
drugs O
produced O
a O
drug O
effect O
, O
however O
, O
buspirone O
20 O
mg O
was O
significantly O
less O
liked O
than O
were O
lorazepam O
, O
secobarbital O
, O
or O
buspirone O
10 O
mg O
( O
p O
less O
than O
.05 O
) O
but O
not O
placebo O
. O
[]

A O
meta-analysis O
of O
the O
available O
data O
confirmed O
the O
value O
of O
a O
protective O
ostomy O
for O
patients O
undergoing O
low O
anterior O
resection O
. O
[]

DESIGN O
This O
randomized O
double-blind O
phase O
I O
study O
assessed O
the O
safety O
and O
acceptability B-outcome ['Life-Impact']
of O
seven O
consecutive O
daily O
doses O
of O
CS O
versus O
KY O
Jelly O
in O
36 O
HIV-positive O
men O
. O
['Life-Impact']

CONCLUSION O
The O
warming O
needle O
moxibustion O
is O
the O
best O
method O
for O
PGS O
, O
with O
less O
therapeutic B-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
, O
high O
cured B-outcome ['Physiological-Clinical']
rate O
and O
rapid O
effect O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
total O
of O
162 O
diabetic O
patients O
with O
post-amputation O
wounds O
( O
up O
to O
the O
trans-metatarsal O
level O
) O
entered O
a O
16-week O
, O
randomized O
clinical O
trial O
. O
[]

Both O
drugs O
induced O
a O
reduction O
in O
the O
albumin B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AER I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Session B-outcome ['Life-Impact']
completion I-outcome ['Life-Impact']
, O
participant B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
, O
child B-outcome ['Physiological-Clinical']
anthropometrics I-outcome ['Physiological-Clinical']
, O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
, O
TV B-outcome ['Life-Impact']
viewing I-outcome ['Life-Impact']
and O
behaviour-specific B-outcome ['Life-Impact']
parenting I-outcome ['Life-Impact']
practices I-outcome ['Life-Impact']
were O
measured O
pre O
and O
post O
intervention O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Placebos O
were O
administered O
for O
a O
comparable O
period O
to O
17 O
similar O
patients O
. O
[]

Patients O
were O
adaptively O
randomized O
as O
follows O
: O
Arm O
I-Clo O
: O
Flu O
10:30 O
mg/m O
( O
2 O
) O
, O
Arm O
II-20:20 O
mg/m O
( O
2 O
) O
, O
Arm O
III-30:10 O
mg/m O
( O
2 O
) O
, O
and O
Arm O
IV-single-agent O
Clo O
at O
40 O
mg/m O
( O
2 O
) O
. O
[]

HLA O
typing O
was O
also O
performed O
prospectively O
in O
several O
phase O
II O
trials O
and O
was O
available O
for O
93.5 O
% O
of O
patients O
. O
[]

Patients O
with O
glutamine O
substitution O
showed O
decreased O
systemic B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
, O
significant O
faster O
compensation O
for O
postoperative B-outcome ['Physiological-Clinical']
immunosuppression I-outcome ['Physiological-Clinical']
and O
a O
lower O
incidence O
of O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

The O
age O
of O
the O
patients O
varied O
from O
38 O
till O
60 O
. O
[]

After O
5 O
years O
, O
hypersensitivity B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
metals I-outcome ['Physiological-Clinical']
was O
evaluated O
by O
patch O
testing O
and O
lymphocyte O
transformation O
assay O
. O
['Physiological-Clinical']

CONCLUSIONS O
Estrogen O
may O
affect O
the O
concentration O
of O
[]

The O
mean O
patient O
age O
and O
mean O
duration O
and O
severity O
of O
baldness O
compared O
well O
between O
the O
two O
groups O
. O
[]

Our O
primary O
endpoint O
was O
the O
composite O
of O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
non B-outcome ['Physiological-Clinical']
fatal I-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
( O
including O
silent B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
) O
, O
stroke B-outcome ['Physiological-Clinical']
, O
acute B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, O
endovascular B-outcome ['Resource-use']
or O
surgical B-outcome ['Resource-use']
intervention I-outcome ['Resource-use']
in I-outcome ['Resource-use']
the I-outcome ['Resource-use']
coronary I-outcome ['Resource-use']
or O
leg B-outcome ['Physiological-Clinical']
arteries I-outcome ['Physiological-Clinical']
, O
and O
amputation B-outcome ['Resource-use']
above I-outcome ['Resource-use']
the I-outcome ['Resource-use']
ankle I-outcome ['Resource-use']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Physiological-Clinical', 'Resource-use']

Patients O
with O
severe O
irritable O
bowel O
syndrome O
received O
seven O
biweekly O
hypnosis O
sessions O
and O
used O
hypnosis O
audiotapes O
at O
home O
. O
[]

From O
February O
1 O
, O
1997 O
, O
to O
October O
1 O
, O
1999 O
, O
186 O
patients O
( O
131 O
men O
and O
55 O
women O
, O
mean O
age O
56 O
+/- O
12 O
years O
) O
with O
IDC O
, O
ejection O
fraction O
< O
35 O
% O
, O
and O
angiographically O
normal O
coronary O
arteries O
were O
studied O
by O
high-dose O
( O
up O
to O
40 O
micro/kg/min O
) O
dobutamine O
echo O
in O
6 O
centers O
, O
all O
quality O
controlled O
for O
stress O
echo O
reading O
. O
[]

The O
possible O
effect O
on O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
needs O
to O
be O
evaluated O
with O
a O
larger O
number O
of O
patients O
in O
complete O
remission O
, O
and O
a O
meta-analysis O
of O
similar O
trials O
is O
recommended O
. O
['Mortality']

Intraoperative B-outcome ['Physiological-Clinical']
hyphema I-outcome ['Physiological-Clinical']
occurred O
in O
2 O
tap O
eyes O
( O
3 O
% O
) O
, O
3 O
biopsy O
eyes O
( O
2 O
% O
) O
, O
and O
0 O
( O
0 O
% O
) O
abort O
eyes O
. O
['Physiological-Clinical']

Depressive O
symptoms O
were O
assessed O
by O
the O
Children O
's O
Depression O
Inventory O
( O
CDI O
) O
. O
[]

We O
found O
no O
significant O
differences O
between O
the O
two O
groups O
regarding O
incidence O
of O
perineal B-outcome ['Physiological-Clinical']
tears I-outcome ['Physiological-Clinical']
, O
duration O
of O
second B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
of O
labour B-outcome ['Physiological-Clinical']
, O
use O
of O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
and O
rate O
of O
vaginal B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Randomized O
verum O
controlled O
parallel-group-comparison O
of O
two O
weeks O
treatment O
of O
a O
nasal-spray O
. O
[]

During O
the O
break O
between O
sets O
, O
the O
participants O
either O
rested O
( O
control O
[ O
CON O
] O
) O
or O
completed O
a O
static O
stretching O
protocol O
( O
static O
stretch O
[ O
SS O
] O
) O
. O
[]

The O
conflicting O
results O
could O
be O
explained O
by O
the O
fact O
that O
patients O
were O
included O
with O
different O
prognostic O
factors O
. O
[]

RESULTS O
There O
was O
significantly O
less O
blood B-outcome ['Physiological-Clinical']
lost I-outcome ['Physiological-Clinical']
in O
the O
tourniquet O
group O
than O
in O
the O
control O
group O
( O
difference O
between O
means O
1870 O
mL O
, O
95 O
% O
CI O
1159-2580 O
mL O
, O
P O
< O
0.0001 O
; O
transfusion O
rates O
of O
7 O
% O
and O
79 O
% O
, O
P= O
0.0003 O
) O
. O
['Physiological-Clinical']

Laryngoscopy O
with O
GlideScope O
took O
62 O
% O
longer O
than O
with O
the O
Macintosh O
blade O
( O
P O
< O
0.01 O
) O
. O
[]

In O
Study O
2 O
, O
the O
authors O
demonstrated O
that O
value O
orientation O
mediates O
the O
CulturexType O
of O
Event O
congruence B-outcome ['Life-Impact']
effect O
. O
['Life-Impact']

METHOD O
In O
the O
Research O
Units O
on O
Pediatric O
Psychopharmacology O
( O
RUPP O
) O
Autism O
Network O
8-week O
double-blind O
trial O
of O
risperidone O
versus O
placebo O
, O
the O
chief O
concerns O
of O
parents O
were O
collected O
at O
0 O
, O
4 O
, O
and O
8 O
weeks O
( O
endpoint O
) O
, O
in O
addition O
to O
standardized O
primary O
measures O
. O
[]

RESULTS O
The O
positive O
predictive O
and O
negative O
predictive O
values O
for O
LN-injured O
patients O
were O
95 O
% O
and O
100 O
% O
, O
respectively O
. O
[]

The O
MSKCC O
trial O
revealed O
a O
significant O
advantage O
of O
idarubicin O
compared O
with O
daunorubicin O
in O
both O
the O
original O
and O
the O
updated O
analyses O
. O
[]

Primary O
outcomes O
were O
exclusive B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
appropriate I-outcome ['Physiological-Clinical']
infant I-outcome ['Physiological-Clinical']
feeding I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
12 I-outcome ['Physiological-Clinical']
weeks I-outcome ['Physiological-Clinical']
post-natally I-outcome ['Physiological-Clinical']
and O
HIV-free B-outcome ['Physiological-Clinical']
infant I-outcome ['Physiological-Clinical']
survival B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

The O
dose O
of O
piracetam O
was O
titrated O
up O
to O
800 O
mg/day O
. O
[]

BACKGROUND O
There O
is O
accumulating O
experimental O
, O
epidemiological O
, O
and O
clinical O
evidence O
of O
an O
association O
between O
anti-oxidant O
vitamin O
intake O
and O
reduced O
risk O
of O
coronary O
heart O
disease O
. O
[]

The O
positive O
predictive O
and O
negative O
predictive O
values O
for O
IAN O
patients O
were O
77 O
% O
and O
60 O
% O
, O
respectively O
. O
[]

SETTING O
Outpatient O
physical O
therapy O
department O
of O
a O
large O
military O
medical O
center O
. O
[]

18 O
months O
, O
58 O
of O
210 O
families O
with O
children O
with O
autism O
spectrum O
disorders O
participating O
in O
a O
larger O
study O
of O
phenotypic O
and O
genotypic O
factors O
reported O
significant O
concerns O
about O
blood O
draws O
and O
elected O
to O
use O
the O
Blood O
Draw O
Intervention O
Program O
. O
[]

Three O
educational O
interventions O
were O
tested O
in O
this O
study O
. O
[]

medroxyprogesterone O
acetate O
( O
MPA O
) O
for O
the O
control O
of O
hot O
flashes O
in O
postmenopausal O
patients O
with O
a O
history O
of O
breast O
cancer O
. O
[]

Noncompliance O
to O
blood O
draws O
can O
have O
significant O
ramifications O
in O
both O
research O
and O
clinical O
settings O
. O
[]

BACKGROUND O
Recent O
studies O
have O
suggested O
that O
exposure O
to O
air O
pollutants O
may O
enhance O
the O
airway O
responsiveness O
of O
susceptible O
individuals O
to O
inhaled O
allergen O
. O
[]

RESULTS O
Four O
patients O
receiving O
exercise O
and O
three O
receiving O
flexibility O
treatment O
dropped O
out O
before O
completion O
. O
[]

Overall O
, O
the O
LNG/EE O
group O
achieved O
a O
consistently O
higher O
percentage O
of O
normal B-outcome ['Physiological-Clinical']
menstrual I-outcome ['Physiological-Clinical']
cycles I-outcome ['Physiological-Clinical']
as O
well O
as O
a O
lower O
rate O
of O
intermenstrual B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
and O
amenorrhea B-outcome ['Physiological-Clinical']
than O
the O
NETA/EE O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
suggest O
that O
NTX O
only O
benefits O
a O
subgroup O
of O
autistic O
children O
, O
who O
may O
be O
identified O
by O
the O
presence O
of O
certain O
plasma O
abnormalities O
. O
[]

Dipyridamole O
in O
chronic O
stable O
angina O
pectoris O
; O
a O
randomized O
, O
double O
blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
. O
[]

Results O
are O
expressed O
as O
lag O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
in O
minutes O
. O
['Physiological-Clinical']

These O
results O
suggest O
that O
new O
therapies O
that O
target O
structures O
outside O
of O
the O
basal O
ganglia O
may O
be O
useful O
for O
symptomatic B-outcome ['Physiological-Clinical']
treatment O
of O
['Physiological-Clinical']

Topical O
PUVA O
, O
etretinate O
, O
and O
combined O
PUVA O
and O
etretinate O
for O
palmoplantar O
pustulosis O
: O
comparison O
of O
therapeutic B-outcome ['Physiological-Clinical']
efficacy O
and O
the O
influences O
of O
tonsillar B-outcome ['Physiological-Clinical']
and O
dental O
focal O
infections O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effect O
of O
low-intensity O
back O
exercise O
on O
quality O
of O
life O
and O
back B-outcome ['Physiological-Clinical']
extensor I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
in O
patients O
with O
osteoporosis O
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

One O
group O
received O
computer-generated O
, O
customized O
letters O
explaining O
recommended O
preventive O
procedures O
for O
each O
family O
member O
. O
[]

OBJECTIVE O
The O
ability O
of O
the O
potent O
cholesteryl O
ester O
transfer O
protein O
( O
CETP O
) O
inhibitor O
torcetrapib O
( O
CP-529,414 O
) O
to O
raise O
high-density O
lipoprotein O
cholesterol O
( O
HDL-C O
) O
levels O
in O
healthy O
young O
subjects O
was O
tested O
in O
this O
initial O
phase O
1 O
multidose O
study O
. O
[]

Participants O
were O
randomly O
assigned O
to O
treatment O
or O
wait-list O
conditions O
. O
[]

We O
registered O
a O
significant O
improvement O
of O
tactile O
roughness O
and O
fine O
lines O
in O
the O
half O
side O
of O
the O
face O
treated O
with O
BAs O
; O
noninvasive O
instrumental O
diagnostic O
investigations O
showed O
an O
improvement O
of O
elasticity B-outcome ['Physiological-Clinical']
, O
a O
decrease O
of O
sebum B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
, O
and O
a O
change O
of O
echographic B-outcome ['Physiological-Clinical']
parameters O
suggesting O
a O
reshaping O
of O
dermal B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

3.6 O
) O
, O
( O
26.2 O
? O
[]

All O
four O
formulations O
were O
administered O
daily O
and O
continuously O
and O
each O
contained O
2 O
mg O
of O
micronized O
oestradiol-17 O
beta O
in O
combination O
with O
either O
norethisterone O
acetate O
1 O
mg O
( O
group O
A O
) O
or O
0.5 O
mg O
( O
group O
B O
) O
or O
megestrol O
acetate O
5 O
mg O
( O
group O
C O
) O
or O
2.5 O
mg O
( O
group O
D O
) O
. O
[]

After O
the O
intervention O
, O
the O
MAT/TT O
index O
of O
all O
patients O
normalized O
in O
each O
evaluation O
period O
with O
statistically O
significant O
differences O
. O
[]

The O
raltegravir O
group O
had O
a O
significant O
increase O
in O
the O
level O
of O
2-LTR B-outcome ['Physiological-Clinical']
circles I-outcome ['Physiological-Clinical']
, O
compared O
to O
the O
placebo O
group O
. O
['Physiological-Clinical']

Thus O
the O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
could O
be O
extended O
. O
['Mortality']

There O
was O
no O
bias O
between O
home O
and O
polysomnography O
studies O
in O
the O
Bland-Altman O
plot O
. O
[]

Randomization O
was O
stratified O
according O
to O
whether O
CNS O
leukemia O
occurred O
at O
initial O
diagnosis O
of O
acute O
lymphocytic O
leukemia O
( O
ALL O
) O
( O
Stratum O
I O
, O
15 O
patients O
) O
, O
during O
first O
bone O
marrow O
( O
BM O
) O
remission O
( O
Stratum O
II O
, O
49 O
patients O
) O
, O
simultaneous O
with O
first O
BM O
relapse O
( O
Stratum O
III O
, O
12 O
patients O
) O
, O
or O
during O
second O
BM O
remission O
( O
Stratum O
IV O
, O
11 O
patients O
) O
. O
[]

Also O
, O
the O
results O
from O
further O
efficacy O
assessments O
improvement O
of O
single O
symptoms O
and O
ocular O
discomfort O
measured O
by O
a O
VAS O
( O
visual O
analogue O
scale O
) O
supported O
treatment O
with O
bibrocathol O
. O
[]

Using O
the O
serial O
anticipation O
method O
under O
double-blind O
conditions O
it O
was O
found O
that O
PRL-8-53 O
causes O
slight O
improvement O
of O
acquisition B-outcome ['Life-Impact']
. O
['Life-Impact']

The O
temporal O
dissociation O
between O
adenosine-induced O
dyspnea O
and O
RIII O
inhibition O
suggests O
that O
C O
fibers O
other O
than O
pulmonary O
ones O
might O
be O
involved O
. O
[]

After O
1 O
year O
of O
treatment O
, O
no O
consistent O
decrease O
in O
postseasonal B-outcome ['Physiological-Clinical']
specific I-outcome ['Physiological-Clinical']
IgE I-outcome ['Physiological-Clinical']
rise I-outcome ['Physiological-Clinical']
could O
be O
shown O
in O
either O
group O
. O
['Physiological-Clinical']

OBJECTIVES O
The O
aim O
of O
the O
present O
study O
was O
to O
determine O
the O
effect O
of O
angiotensin-converting O
enzyme O
( O
ACE O
) O
inhibition O
on O
the O
local O
stimulated O
release O
of O
tissue O
plasminogen O
activator O
( O
t-PA O
) O
from O
the O
endothelium O
. O
[]

Because O
the O
former O
demands O
more O
resources O
, O
we O
advocate O
that O
talc O
slurry O
should O
be O
considered O
as O
the O
procedure O
of O
choice O
in O
the O
treatment O
of O
symptomatic O
malignant O
pleural O
effusion O
in O
patients O
who O
do O
not O
have O
trapped O
lungs O
. O
[]

We O
conclude O
that O
, O
at O
infusion O
rates O
in O
the O
low- O
to O
mid-antiarrhythmic O
range O
, O
lidocaine O
has O
no O
effect O
on O
acute B-outcome ['Physiological-Clinical']
nociceptive I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
but O
does O
have O
a O
limited O
and O
selective O
effect O
on O
secondary B-outcome ['Physiological-Clinical']
hyperalgesia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
patients O
designated O
as O
having O
responded O
had O
improvement O
in O
physical O
, O
psychologic O
, O
and O
immunologic O
measures O
( O
p O
less O
than O
0.01 O
for O
each O
) O
. O
[]

Prompt O
detection O
of O
oesophageal O
intubation O
is O
a O
primary O
concern O
in O
anaesthetic O
practice O
. O
[]

None O
of O
the O
children O
had O
[]

CONCLUSION O
Treatment O
of O
RA O
with O
IL-1Ra O
resulted O
in O
reduced O
mononuclear O
cell O
infiltration O
of O
synovial O
membrane O
, O
which O
may O
represent O
the O
in O
vivo O
inhibition O
of O
biologically O
relevant O
IL-1ss-mediated O
pathogenic O
effects O
. O
[]

Autism O
is O
a O
chronic O
pervasive O
neurodevelopmental O
disorder O
characterized O
by O
the O
early O
onset O
of O
social O
and O
communicative O
impairments O
as O
well O
as O
restricted O
, O
ritualized O
, O
stereotypic O
behavior O
. O
[]

MATERIALS O
AND O
METHODS O
Ten O
subjects O
( O
ages O
35-63 O
) O
with O
facial O
dyschromia O
and O
rhytides O
were O
enrolled O
. O
[]

Change O
from O
baseline O
in O
the O
vitality B-outcome ['Physiological-Clinical']
subscale O
of O
the O
SF-36 O
was O
7.3-7.8 O
in O
the O
placebo O
and O
the O
750-mg/day O
arm O
, O
versus O
10.5-14.6 O
in O
the O
1,000- O
and O
2,000-mg/day O
arms O
. O
['Physiological-Clinical']

Informed O
consentwas O
obtained O
from O
the O
parents O
of O
each O
participant O
. O
[]

During O
the O
nights O
when O
the O
healthy O
volunteers O
were O
given O
octreotide O
, O
melatonin B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
was O
similar O
to O
that O
recorded O
during O
administration O
of O
saline O
. O
['Physiological-Clinical']

The O
prophylactic O
use O
of O
intravesical O
instillation O
of O
Adriamycin O
has O
been O
studied O
more O
extensively O
. O
[]

CGI O
scale O
ratings O
were O
higher O
in O
the O
amantadine O
group O
: O
53 O
% O
improved O
versus O
25 O
% O
( O
p O
= O
.076 O
) O
. O
[]

Significantly O
more O
deaths O
of O
presumed O
fungal B-outcome ['Physiological-Clinical']
origin O
occurred O
in O
flu O
than O
itra O
( O
seven O
versus O
nil O
, O
P O
= O
0.024 O
) O
. O
['Physiological-Clinical']

A O
5?C O
change O
in O
the O
4-day O
moving O
average O
of O
apparent O
temperature O
was O
associated O
with O
21.6 O
% O
( O
95 O
% O
CI O
: O
2.5 O
, O
44.2 O
; O
p O
= O
0.03 O
) O
higher O
CRP O
. O
[]

DESIGN O
Randomized O
, O
controlled O
study O
. O
[]

RATIONALE O
AND O
OBJECTIVES O
The O
specific O
aim O
of O
the O
study O
was O
to O
determine O
which O
of O
several O
cost-effective O
interventions O
is O
best O
able O
to O
improve O
the O
breast B-outcome ['Life-Impact']
cancer I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
of O
women O
who O
present O
for O
screening O
mammography O
. O
['Life-Impact']

Future O
adjuvant O
trials O
in O
this O
setting O
are O
not O
likely O
to O
include O
IL-2 O
in O
view O
of O
the O
clinical B-outcome ['Physiological-Clinical']
efficacy O
and O
favorable O
['Physiological-Clinical']

The O
subject O
's O
fist B-outcome ['Life-Impact']
clenching I-outcome ['Life-Impact']
was O
used O
as O
an O
indicator O
of O
aggression B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Enterostatin O
( O
ENT O
) O
has O
been O
found O
to O
inhibit O
food O
intake O
and O
selectively O
inhibit O
fat O
intake O
in O
rats O
. O
[]

Tumor B-outcome ['Physiological-Clinical']
budding I-outcome ['Physiological-Clinical']
is O
an O
independent O
predictor O
of O
outcome O
in O
AJCC/UICC O
stage O
II O
colorectal O
cancer O
. O
['Physiological-Clinical']

Similarly O
, O
no O
effects O
were O
seen O
on O
secondary B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
end I-outcome ['Physiological-Clinical']
points I-outcome ['Physiological-Clinical']
, O
except O
for O
a O
suggestion O
of O
protection B-outcome ['Physiological-Clinical']
versus I-outcome ['Physiological-Clinical']
strokes I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
transient I-outcome ['Physiological-Clinical']
ischemic I-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
Intramuscular O
Diamorphine O
versus O
Intramuscular O
Pethidine O
( O
IDvIP O
) O
trial O
is O
a O
randomised O
double-blind O
two O
centre O
controlled O
trial O
comparing O
intramuscular O
diamorphine O
and O
pethidine O
regarding O
their O
analgesic O
efficacy O
in O
labour O
and O
their O
side O
effects O
in O
mother O
, O
fetus O
and O
neonate O
. O
[]

Secondary O
parameters O
assessed O
included O
postprandial B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
and O
C-peptide B-outcome ['Physiological-Clinical']
during O
the O
treatment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Data O
for O
prostate O
cancer O
were O
obtained O
from O
the O
ERSPC O
central O
database O
. O
[]

Dronedarone O
treatment O
reduced O
total O
hospitalizations B-outcome ['Resource-use']
for O
acute O
coronary O
syndrome O
( O
P O
= O
0.0105 O
) O
and O
the O
time O
between O
the O
first B-outcome ['Physiological-Clinical']
AF/atrial I-outcome ['Physiological-Clinical']
flutter B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
and O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Additionally O
, O
there O
was O
a O
significantly O
shorter O
procedure B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
less O
patient O
discomfort B-outcome ['Life-Impact']
in O
the O
hands O
of O
the O
simulator-trained O
group O
. O
['Life-Impact', 'Life-Impact']

METHODS O
Drawing O
from O
South O
Texas O
cancer O
registries O
, O
444 O
Hispanic O
men O
and O
women O
were O
randomly O
assigned O
to O
one O
of O
three O
experimental O
conditions O
: O
standard O
direct-mailed O
procedures O
( O
X1 O
) O
, O
X1 O
plus O
culturally O
tailored O
materials O
( O
X2 O
) O
, O
and O
X2 O
plus O
interpersonal O
phone O
contact O
( O
X3 O
) O
. O
[]

A O
multi-component O
social O
skills O
intervention O
for O
children O
with O
Asperger O
syndrome O
: O
the O
Junior O
Detective O
Training O
Program O
. O
[]

500 O
grains/m O
( O
3 O
) O
, O
then O
randomized O
to O
four O
maintenance O
dose O
groups O
of O
rBet O
v O
1-FV O
and O
one O
placebo O
group O
: O
20 O
?g O
( O
n O
= O
7 O
) O
, O
80 O
?g O
( O
n O
= O
8 O
) O
, O
160 O
?g O
( O
n O
= O
7 O
) O
, O
320 O
?g O
( O
n O
= O
8 O
) O
, O
and O
placebo O
( O
n O
= O
7 O
) O
. O
[]

Short-term O
antibiotic O
prophylaxis O
was O
studied O
in O
80 O
patients O
undergoing O
biliary O
or O
gastric O
surgery O
. O
[]

In O
a O
randomized O
order O
, O
one O
test O
was O
performed O
with O
preinduced O
quadriceps O
fatigue O
and O
the O
other O
in O
a O
fresh O
state O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

Chi-squared O
analyses O
suggested O
educators O
' O
conceptions O
for O
organising O
murmurs O
differed O
significantly O
from O
students O
' O
conceptions O
. O
[]

RESULTS O
Median O
LVM B-outcome ['Physiological-Clinical']
increased O
significantly O
from O
172 O
to O
220 O
g O
( O
p O
= O
0.03 O
) O
in O
the O
rhGH-treated O
group O
, O
while O
an O
insignificant O
decrease O
was O
observed O
in O
the O
placebo O
group O
from O
281 O
to O
200 O
g O
( O
p O
= O
0.3 O
) O
. O
['Physiological-Clinical']

The O
primary O
outcome O
measure O
is O
'patient O
distress O
due O
to O
breathlessness O
' O
measured O
on O
a O
numerical O
rating O
scale O
( O
0-10 O
) O
. O
[]

First O
, O
an O
overview O
of O
the O
Ho'ouna O
Pono O
research O
results O
to O
date O
( O
2007-2013 O
) O
is O
provided O
. O
[]

Serial O
venous O
blood O
samples O
were O
drawn O
up O
to O
72 O
h O
after O
dosing O
and O
moxifloxacin B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
levels O
were O
measured O
by O
a O
validated O
HPLC O
method O
with O
fluorescence O
detection O
. O
[ O
['Physiological-Clinical']

Six O
of O
23 O
patients O
in O
the O
control O
group O
versus O
1 O
of O
26 O
in O
the O
CMV O
hyperimmune O
globulin O
group O
died O
of O
CMV B-outcome ['Physiological-Clinical']
interstitial I-outcome ['Physiological-Clinical']
pneumonitis I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

Each O
participant O
received O
160 O
perturbations O
, O
25 O
% O
of O
which O
were O
combined O
with O
a O
SAS O
. O
[]

Our O
results O
indicate O
, O
however O
, O
that O
the O
prophylactic O
use O
those O
patients O
who O
are O
at O
particularly O
high O
infection O
exposure O
risk O
, O
e.g O
. O
[]

Influence O
of O
ball O
weight O
on O
junior O
high O
school O
girls O
' O
volleyball O
performance B-outcome ['Life-Impact']
. O
['Life-Impact']

The O
role O
of O
medical O
therapy O
for O
silent O
ischemia O
will O
be O
clarified O
only O
when O
its O
effect O
upon O
morbidity O
and O
mortality O
are O
determined O
. O
[]

CONCLUSION O
Argatroban O
dose-dependently O
increases O
coagulation O
parameters O
and O
, O
compared O
to O
UFH O
, O
demonstrates O
a O
superior O
predictable O
anticoagulant O
effect O
in O
patients O
undergoing O
elective O
PCI O
. O
[]

The O
primary O
end O
point O
was O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
both O
groups O
, O
there O
were O
no O
significant O
changes O
in O
brachial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
plasma B-outcome ['Physiological-Clinical']
endothelin-1 I-outcome ['Physiological-Clinical']
and O
angiotensin B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
femoral B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
, O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
, O
and O
systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Forty-eight O
hours O
, O
2 O
weeks O
and O
3 O
months O
after O
PCNL O
, O
plain O
X-ray O
abdomen O
, O
ultrasonography O
and O
IVP O
were O
performed O
for O
each O
case O
. O
[]

Patients O
received O
long-term O
treatment O
with O
the O
first O
antiarrhythmic O
drug O
that O
was O
predicted O
to O
be O
effective O
on O
the O
basis O
of O
drug O
testing O
. O
[]

High O
versus O
low O
total O
, O
DWMH B-outcome ['Physiological-Clinical']
, O
and O
PVH B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
were O
defined O
based O
on O
the O
highest O
quartile O
of O
their O
respective O
distributions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
significance O
was O
lost O
with O
adjustments O
for O
differences O
in O
baseline O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
( O
p O
= O
0.09 O
) O
. O
['Physiological-Clinical']

ABC O
administered O
once O
daily O
was O
non-inferior O
to O
the O
twice-daily O
regimen O
, O
with O
66 O
% O
and O
68 O
% O
of O
patients O
in O
these O
respective O
treatment O
arms O
achieving O
a O
confirmed O
plasma B-outcome ['Physiological-Clinical']
HIV-1 I-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
level O
< O
50 O
copies/mL O
( O
95 O
% O
confidence O
interval O
: O
-8.4 O
% O
, O
4.9 O
% O
) O
. O
['Physiological-Clinical']

In O
Experiment O
1 O
, O
twenty-two O
3- O
to O
4-year-olds O
watched O
pretense O
in O
which O
a O
puppet O
represented O
a O
nerp O
( O
an O
unfamiliar O
kind O
of O
animal O
) O
. O
[]

The O
largest O
increase O
in O
exercise B-outcome ['Life-Impact']
tolerance I-outcome ['Life-Impact']
was O
obtained O
during O
treatment O
with O
50 O
mg O
once O
daily O
. O
['Life-Impact']

PD O
fluids O
with O
neutral O
pH O
and O
reduced O
glucose O
degradation O
product O
contents O
are O
considered O
more O
biocompatible O
, O
because O
they O
preserve O
peritoneal O
cell O
functions O
in O
vitro O
. O
[]

This O
prolongation O
was O
not O
associated O
with O
a O
significant O
reduction O
in O
the O
total O
cost B-outcome ['Resource-use']
per O
surviving O
infant O
( O
tocolysis O
, O
$ O
38,593 O
+/- O
$ O
40,887 O
versus O
bed O
rest O
, O
$ O
43,158 O
+/- O
$ O
37,116 O
; O
p O
= O
0.445 O
) O
. O
['Resource-use']

The O
authors O
prospectively O
monitored O
the O
evolution O
of O
neuropathy O
and O
myopathy O
during O
an O
intensive O
12-week O
chemotherapy O
program O
for O
patients O
with O
intermediate O
and O
high-grade O
non-Hodgkin O
's O
lymphoma O
. O
[]

The O
two O
treatments O
did O
not O
show O
significant O
differences O
in O
terms O
of O
the O
number O
of O
ranibizumab B-outcome ['Resource-use']
injections I-outcome ['Resource-use']
required O
. O
['Resource-use']

There O
were O
no O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
the O
calcium O
pre-treatment O
study O
arm O
. O
['Adverse-effects']

Randomized O
, O
double-blind O
placebo-controlled O
trial O
using O
crossover O
design O
over O
6 O
months O
for O
43 O
children O
, O
aged O
3-8 O
years O
. O
[]

In O
Study O
1 O
, O
each O
of O
the O
following O
explanations O
was O
unrelated O
to O
persistence B-outcome ['Life-Impact']
: O
public O
commitment O
, O
self-consistency O
, O
and O
unique O
causal O
risk O
models O
. O
['Life-Impact']

Pre-bent O
instruments O
used O
in O
single-port O
laparoscopic O
surgery O
versus O
conventional O
laparoscopic O
surgery O
: O
comparative O
study O
of O
performance O
in O
a O
dry O
lab O
. O
[]

These O
visits O
were O
carried O
out O
by O
fieldworkers O
who O
counseled O
the O
mothers O
about O
the O
Ten O
Steps O
for O
Healthy O
Feeding O
from O
Birth O
to O
Two O
Years O
of O
Age O
, O
based O
on O
the O
WHO O
guidelines O
. O
[]

Of O
the O
discordant O
scans O
, O
8 O
( O
4 O
% O
) O
had O
superior O
scans O
after O
recombinant O
human O
TSH O
administration O
, O
and O
17 O
( O
8 O
% O
) O
had O
superior O
scans O
after O
thyroid O
hormone O
withdrawal O
( O
P O
= O
0.108 O
) O
. O
[]

These O
reactivations B-outcome ['Physiological-Clinical']
required O
urgent O
intervention O
( O
thrombolysis O
, O
angioplasty O
, O
or O
coronary-bypass O
surgery O
) O
in O
11 O
patients O
treated O
with O
heparin O
alone O
, O
but O
in O
only O
2 O
patients O
in O
the O
other O
groups O
combined O
( O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

Patients O
were O
stratified O
by O
sex O
and O
number O
of O
nodes O
and O
were O
randomly O
assigned O
to O
receive O
either O
2 O
years O
of O
treatment O
with O
active O
specific O
immunotherapy O
with O
allogeneic O
melanoma O
lysates O
and O
low-dose O
IFN-alpha-2b O
( O
arm O
1 O
) O
or O
high-dose O
IFN-alpha-2b O
alone O
for O
1 O
year O
( O
arm O
2 O
) O
. O
[]

which O
produced O
a O
95 O
% O
confidence O
interval O
from O
-0.539 O
to O
-0.083 O
. O
[]

Increased O
platelet B-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
may O
be O
correlated O
with O
decreased O
fibrinolysis O
. O
['Physiological-Clinical']

Neuromuscular O
excitability O
changes O
in O
the O
vastus O
medialis O
following O
anterior O
cruciate O
ligament O
reconstruction O
. O
[]

At O
24 O
weeks O
, O
American O
College O
of O
Rheumatology O
20/50/70 O
responses O
were O
62.0 O
% O
, O
30.8 O
% O
, O
and O
13.0 O
% O
, O
respectively O
at O
course O
1 O
( O
n O
= O
400 O
) O
and O
70.3 O
% O
, O
41.8 O
% O
, O
and O
22.0 O
% O
at O
course O
5 O
( O
n O
= O
91 O
) O
. O
[]

OBJECTIVES O
This O
study O
evaluated O
the O
effects O
of O
azimilide O
dihydrochloride O
( O
AZ O
) O
on O
anti-tachycardia B-outcome ['Physiological-Clinical']
pacing I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ATP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
shock-terminated B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
patients O
with O
implantable O
cardioverter O
defibrillators O
( O
ICDs O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
A O
statistically O
significant O
10- O
to O
20-fold O
increase O
in O
urinary O
levels O
of O
cobalt O
and O
chromium O
was O
observed O
throughout O
the O
entire O
follow-up O
in O
the O
MOM O
group O
. O
[]

In O
an O
open-label O
, O
three-way O
crossover O
study O
, O
24 O
healthy O
men O
were O
randomly O
assigned O
to O
receive O
0.5 O
mg O
of O
risperidone O
twice O
daily O
, O
5 O
mg O
of O
donepezil O
once O
daily O
, O
or O
both O
drugs O
for O
14 O
consecutive O
days O
, O
followed O
by O
a O
21-day O
washout O
period O
. O
[]

49 O
U/L O
, O
236 O
? O
[]

METHOD O
Forty-eight O
children O
( O
5 O
years O
to O
16 O
years O
, O
5 O
months O
) O
who O
showed O
behavioral O
improvement O
during O
acute O
treatment O
with O
risperidone O
were O
followed O
for O
6 O
months O
and O
assessed O
with O
the O
Vineland O
Scales O
. O
[]

Total O
iron-binding B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TIBC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
transferrin O
saturation O
were O
estimated O
from O
these O
metrics O
. O
['Physiological-Clinical']

Patients O
were O
eligible O
for O
treatment O
with O
the O
alternate O
therapy O
at O
third O
line O
. O
[]

This O
study O
, O
which O
included O
adverse O
event O
monitoring O
, O
physical O
examinations O
, O
and O
extensive O
hematological O
and O
biochemical O
assessments O
, O
showed O
that O
anti-CD O
WPC O
is O
safe O
to O
consume O
by O
patients O
with O
CDAD O
. O
[]

OBJECTIVE O
To O
assess O
the O
association O
between O
maternal O
breast-milk O
and O
fecal O
bifidobacteria O
and O
infants O
' O
fecal O
bifidobacteria O
. O
[]

CONCLUSION O
The O
results O
suggest O
that O
the O
combination O
of O
cyproheptadine O
with O
a O
conventional O
antipsychotic O
may O
be O
superior O
to O
conventional O
antipsychotic O
alone O
for O
children O
with O
autistic O
disorder O
. O
[]

The O
sample O
consisted O
of O
342 O
adult O
participants O
who O
completed O
both O
baseline O
and O
follow-up O
survey O
sessions O
. O
[]

METHODS O
Twenty O
male O
, O
white O
patients O
( O
27 O
+/- O
1 O
years O
) O
with O
mild O
essential O
hypertension O
( O
143 O
+/- O
11/95 O
+/- O
6 O
mm O
Hg O
) O
were O
included O
in O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
, O
fourfold O
cross-over O
study O
with O
placebo O
, O
enalapril O
( O
20 O
mg/day O
) O
, O
eprosartan O
( O
600 O
mg/day O
) O
, O
or O
combination O
of O
both O
drugs O
( O
10 O
and O
300 O
mg/day O
, O
respectively O
) O
each O
over O
a O
one O
week O
period O
followed O
by O
a O
two-week O
washout O
phase O
. O
[]

The O
most O
common O
reasons O
for O
delay O
were O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
and O
personal/logistical O
reasons O
. O
['Adverse-effects']

The O
magnitude O
of O
nonspecific O
therapeutic O
( O
placebo O
) O
effects O
, O
cost-effectiveness O
and O
relative O
risks O
of O
side O
effects O
associated O
with O
these O
types O
of O
therapy O
need O
to O
be O
addressed O
in O
future O
studies O
. O
[]

There O
was O
no O
significant O
difference O
in O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
intubate I-outcome ['Life-Impact']
between O
the O
Lightwand O
and O
the O
Macintosh O
blade O
. O
['Life-Impact']

Endoscopic B-outcome ['Resource-use']
examination I-outcome ['Resource-use']
as O
well O
as O
urinary B-outcome ['Physiological-Clinical']
cytology I-outcome ['Physiological-Clinical']
was O
performed O
in O
each O
case O
every O
three O
months O
. O
['Resource-use', 'Physiological-Clinical']

The O
proportions O
of O
depressed B-outcome ['Life-Impact']
( O
p O
< O
0.01 O
) O
and O
anxious B-outcome ['Life-Impact']
( O
p=0.04 O
) O
patients O
were O
also O
smaller O
in O
the O
group O
who O
were O
operated O
on O
. O
['Life-Impact', 'Life-Impact']

The O
association O
of O
treatment O
with O
measures O
of O
cognitive B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
was O
not O
modified O
by O
sex O
or O
age O
at O
diagnosis O
. O
['Life-Impact']

Intravesical O
seeding O
of O
upper O
urinary O
tract O
urothelial O
carcinoma O
cells O
during O
nephroureterectomy O
: O
an O
exploratory O
analysis O
from O
the O
THPMG O
trial O
. O
[]

INTRODUCTION O
To O
investigate O
the O
feasibility B-outcome ['Life-Impact']
of O
improving O
asthma O
management O
- O
in O
particular O
, O
the O
implementation O
of O
individualised O
asthma O
action O
plans O
( O
AAPs O
) O
for O
poorly-controlled O
adult O
asthma O
patients O
- O
by O
providing O
training O
in O
asthma-focused O
clinical O
and O
communication O
skills O
for O
practice O
nurses O
who O
deliver O
asthma O
clinics O
. O
['Life-Impact']

Reduction O
of O
isoflurane O
MAC O
by O
fentanyl O
or O
remifentanil O
in O
rats O
. O
[]

The O
pharmacological O
and O
CBT O
interventions O
were O
associated O
with O
a O
greater O
clinical B-outcome ['Physiological-Clinical']
improvement O
compared O
with O
usual O
care O
at O
posttest O
. O
['Physiological-Clinical']

At O
the O
onset O
of O
the O
study O
as O
well O
as O
after O
2 O
and O
4 O
weeks O
, O
the O
following O
criteria O
were O
analyzed O
: O
HAMD O
, O
B-L O
, O
CGI O
, O
and O
vegetative O
symptoms O
. O
[]

Reaction O
time O
, O
direct O
recall O
, O
and O
recognition B-outcome ['Life-Impact']
were O
assessed O
. O
['Life-Impact']

METHODS O
Physiological O
, O
plasma O
beta-endorphin O
, O
cortisol O
, O
and O
glucose O
responses O
to O
routine O
treatment O
procedures O
were O
studied O
in O
84 O
mechanically O
ventilated O
distressed O
neonates O
randomized O
into O
groups O
receiving O
1 O
mg/kg O
meperidine O
or O
0.9 O
% O
saline O
15 O
minutes O
before O
tracheal O
suction O
or O
routine O
nursing O
care O
. O
[]

However O
, O
a O
trend O
toward O
a O
higher O
rate O
of O
permanent B-outcome ['Life-Impact']
discontinuation I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
study I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
was O
noted O
among O
children O
assigned O
to O
NFV O
+ O
NVP O
+ O
d4T O
compared O
with O
NFV O
+ O
RTV O
+ O
ddI O
[ O
7 O
of O
20 O
( O
35 O
% O
) O
versus O
2 O
of O
21 O
( O
10 O
% O
) O
; O
P O
= O
0.12 O
] O
. O
['Life-Impact']

Wind-up O
may O
offer O
new O
opportunities O
to O
investigate O
the O
contribution O
of O
central O
neuronal O
changes O
to O
symptoms O
in O
FGD O
. O
[]

OBJECTIVE O
This O
study O
aimed O
to O
( O
1 O
) O
investigate O
whether O
provision O
of O
a O
home-based O
program O
in O
addition O
to O
a O
center-based O
program O
improves O
development O
in O
young O
children O
with O
disabilities O
and O
coping O
abilities O
of O
their O
families O
and O
( O
2 O
) O
describe O
the O
characteristics O
of O
children O
and O
families O
who O
benefit O
most O
from O
the O
intervention O
. O
[]

Most O
patients O
were O
unable O
to O
tolerate B-outcome ['Life-Impact']
metronidazole I-outcome ['Life-Impact']
because O
of O
side O
effects O
or O
lack O
of O
efficacy O
, O
with O
only O
five O
( O
21 O
% O
) O
continuing O
to O
take O
the O
drug O
at O
24 O
weeks O
. O
['Life-Impact']

BACKGROUND O
Nicotine O
may O
be O
of O
therapeutic O
value O
in O
ulcerative O
colitis O
( O
UC O
) O
, O
although O
its O
mechanism O
of O
action O
has O
not O
been O
established O
. O
[]

The O
animal O
used O
for O
these O
studies O
was O
the O
greyhound O
, O
which O
has O
thin O
skin O
, O
angular O
conformation O
, O
limited O
body O
fat O
and O
is O
predisposed O
to O
pressure O
ulcers O
similar O
to O
those O
occurring O
in O
humans O
. O
[]

The O
two O
treatment O
groups O
were O
matched O
for O
age O
, O
sex O
, O
drinking O
and O
smoking O
habits O
, O
and O
drug O
use O
. O
[]

Cytotoxic O
therapy O
adds O
to O
the O
damaging O
effect O
of O
radiotherapy O
. O
[]

In O
addition O
, O
alcohol O
has O
been O
shown O
to O
disrupt O
the O
extended-release O
characteristics O
of O
certain O
extended-release O
opioid O
formulations O
, O
releasing O
a O
hazardous O
amount O
of O
opioid O
over O
a O
short O
time O
period O
. O
[]

Between O
day O
30 O
and O
365 O
after O
transplantation O
, O
counts O
of O
most B-outcome ['Physiological-Clinical']
lymphocyte I-outcome ['Physiological-Clinical']
subsets I-outcome ['Physiological-Clinical']
were O
higher O
in O
the O
blood O
stem O
cell O
recipients O
. O
['Physiological-Clinical']

Thirty O
minutes O
after O
rectal O
administration O
of O
midazolam O
, O
patients O
showed O
a O
decrease O
in O
both O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Longer O
follow O
up O
time O
may O
be O
needed O
to O
explore O
the O
long O
term O
effects O
of O
different O
vascular O
accesses O
on O
cardiac B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Daily O
diary O
records O
were O
kept O
by O
patients O
of O
the O
number O
of O
night-time O
awakenings O
due O
to O
pain O
, O
pain O
severity O
at O
awakening O
in O
the O
morning O
and O
the O
duration O
of O
early O
morning O
stiffness O
. O
[]

Conduit O
artery O
structure O
and O
function O
in O
lowlanders O
and O
native O
highlanders O
: O
relationships O
with O
oxidative O
stress O
and O
role O
of O
sympathoexcitation O
. O
[]

In O
an O
ongoing O
study O
that O
used O
a O
double-blind O
placebo-controlled O
food O
challenge O
to O
investigate O
peanut O
allergy O
and O
clinical O
symptoms O
, O
the O
observed O
reaction O
severity O
in O
four O
of O
the O
first O
six O
subjects O
was O
greater O
than O
anticipated O
. O
[]

Further O
research O
is O
necessary O
to O
determine O
long-term O
gains O
in O
rates O
of O
physician O
counseling O
and O
improvements O
in O
the O
course O
of O
these O
patients O
. O
[]

The O
pharmacokinetic B-outcome ['Physiological-Clinical']
parameters O
of O
zolmitriptan O
and O
its O
metabolites O
were O
not O
significantly O
affected O
by O
fluoxetine O
pretreatment O
. O
['Physiological-Clinical']

The O
feasibility O
of O
the O
intervention O
was O
demonstrated O
by O
successfully O
implementing O
it O
with O
33 O
sexually-active O
, O
single O
girls O
. O
[]

The O
present O
study O
evaluated O
5-year O
survival O
and O
cancer O
recurrence O
among O
512 O
patients O
with O
gastrointestinal O
cancer O
included O
in O
the O
TACTIC O
study O
. O
[]

INTERVENTION O
( O
S O
) O
Subjects O
were O
randomized O
at O
a O
ratio O
1 O
to O
6 O
into O
either O
conventional O
GnRH-agonist O
and O
recombinant O
FSH O
stimulation O
( O
IVO O
) O
for O
oocyte O
retrieval O
, O
or O
minimally O
stimulated O
in O
vitro O
maturation O
( O
IVM O
) O
with O
the O
use O
of O
recombinant O
FSH O
. O
[]

The O
infants O
' O
rate O
of O
weight O
gain O
decreased O
on O
the O
first O
three O
days O
of O
diuretic O
treatment O
, O
but O
was O
thereafter O
comparable O
with O
weight O
gain O
during O
treatment O
with O
placebo O
. O
[]

Large O
volume O
, O
low O
pressure O
endotracheal O
tube O
cuffs O
are O
claimed O
to O
have O
less O
deleterious O
effect O
on O
tracheal B-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
than O
high O
pressure O
, O
low O
volume O
cuffs O
. O
['Physiological-Clinical']

Although O
intensive O
low-density O
lipoprotein O
cholesterol O
and O
blood O
pressure O
lowering O
therapy O
slowed O
disease O
progression O
, O
these O
efficacies O
were O
attenuated O
in O
patients O
with O
spotty O
calcification O
. O
[]

Evaluation O
of O
reducing O
postoperative O
hip O
precautions O
in O
total O
hip O
replacement O
: O
a O
randomized O
prospective O
study O
. O
[]

OBJECTIVES O
To O
test O
experimentally O
whether O
a O
psychological O
intervention O
reduces O
depression-related O
symptoms O
and O
markers O
of O
inflammation O
among O
cancer O
patients O
and O
to O
test O
one O
mechanism O
for O
the O
intervention O
effects O
. O
[]

The O
most O
common O
adverse O
events O
were O
[]

A O
comparison O
between O
training O
on O
land O
and O
in O
water O
. O
[]

Participatory O
action O
research O
and O
a O
review O
of O
the O
literature O
were O
used O
to O
develop O
electronically O
administered O
symptom O
management O
algorithms O
addressing O
all O
major O
symptoms O
experienced O
by O
patients O
undergoing O
treatment O
for O
head O
and O
neck O
cancers O
. O
[]

followed O
by O
0.5 O
% O
to O
1.5 O
% O
enflurane O
and O
67 O
% O
N2O O
in O
oxygen O
( O
O2 O
) O
. O
[]

When O
administered O
intravenously O
, O
antazoline O
exerts O
a O
strong B-outcome ['Physiological-Clinical']
antiarrhythmic I-outcome ['Physiological-Clinical']
effect O
on O
supraventricular B-outcome ['Physiological-Clinical']
arrhythmia B-outcome ['Physiological-Clinical']
, O
especially O
on O
AF B-outcome ['Physiological-Clinical']
, O
facilitating O
rapid B-outcome ['Physiological-Clinical']
conversion I-outcome ['Physiological-Clinical']
to O
sinus B-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
scores O
for O
the O
Mini-Mental O
State O
Examination O
( O
MMSE O
) O
, O
Ability O
of O
Daily B-outcome ['Life-Impact']
Life I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
ADL I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
and O
the O
therapeutic B-outcome ['Physiological-Clinical']
effects O
were O
assessed O
and O
compared O
before O
treatment O
and O
after O
treatment O
for O
12 O
weeks O
among O
the O
groups O
. O
['Life-Impact', 'Physiological-Clinical']

In O
patients O
, O
CCM O
therapy O
increased O
LV B-outcome ['Physiological-Clinical']
peak O
+dP/dt O
by O
10.1 O
+/- O
1.5 O
% O
. O
['Physiological-Clinical']

Patients O
with O
close O
surgical O
margins O
, O
longer O
interval O
between O
surgery O
and O
radiation O
, O
high O
level O
of O
hemoglobin O
, O
T4 O
had O
benefit O
from O
accelerated O
radiotherapy O
. O
[]

Using O
the O
belief O
basis O
of O
the O
theory O
of O
planned O
behavior O
( O
TPB O
) O
, O
the O
current O
study O
explored O
the O
rate O
of O
mild B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
reported O
by O
donors O
in O
relation O
to O
their O
first O
donation O
and O
the O
intention O
and O
beliefs O
of O
those O
donors O
with O
regard O
to O
returning O
to O
donate O
again O
. O
['Physiological-Clinical']

Impact O
of O
interviewer O
's O
body O
mass O
index O
on O
underreporting O
energy O
intake O
in O
overweight O
and O
obese O
women O
. O
[]

BACKGROUND O
Effective O
pharmacotherapies O
to O
treat O
methamphetamine O
( O
MA O
) O
dependence O
have O
not O
been O
identified O
, O
and O
behavioral O
therapies O
are O
marginally O
effective O
. O
[]

In O
visual O
and O
auditory O
oddball O
paradigms O
( O
with O
task O
and O
nontask O
conditions O
) O
, O
standard O
( O
80 O
% O
) O
, O
target O
( O
10 O
% O
) O
, O
and O
unexpected O
novel O
stimuli O
( O
10 O
% O
) O
were O
presented O
. O
[]

At O
3 O
months O
both O
clodronate O
and O
placebo-treated O
patients O
had O
a O
decrease O
in O
Karnofsky O
performance B-outcome ['Physiological-Clinical']
status O
, O
with O
the O
decrease O
being O
more O
evident O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

PRIMARY O
OUTCOME O
MEASURE O
Postoperative B-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
the O
acute O
trauma O
unit O
. O
['Mortality']

For O
anxiety O
, O
women O
's O
symptoms B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
decreased O
in O
the O
TIP-C O
and O
exercise O
groups O
over O
time O
, O
but O
not O
in O
the O
AC O
group O
. O
['Life-Impact']

METHODOLOGY O
Randomized O
controlled O
trial O
involving O
60 O
patients O
admitted O
to O
the O
Royal O
Children O
's O
Hospital O
, O
Melbourne O
, O
with O
acute O
asthma O
and O
an O
identifiable O
GP O
. O
[]

Resource O
utilization O
and O
economic O
costs O
of O
care O
based O
on O
a O
randomized O
trial O
of O
vacuum-assisted O
closure O
therapy O
in O
the O
treatment O
of O
diabetic O
foot O
wounds O
. O
[]

A O
randomised O
study O
was O
conducted O
in O
62 O
patients O
with O
advanced O
breast O
cancer O
to O
assess O
whether O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
GM-CSF O
) O
would O
yield O
an O
increase O
in O
the O
dose O
intensity O
of O
a O
standard-dose O
CEF O
regimen O
through O
an O
acceleration O
of O
chemotherapy O
administration O
. O
[]

Under O
both O
40 O
mg O
and O
60 O
mg O
nimodipine O
the O
subgroup O
with O
a O
prevalence O
of O
non-A B-outcome ['Physiological-Clinical']
epochs I-outcome ['Physiological-Clinical']
( O
poor O
alpha-activity O
) O
showed O
a O
decrease O
of O
non-A B-outcome ['Physiological-Clinical']
epochs I-outcome ['Physiological-Clinical']
; O
the O
subgroup O
with O
a O
prevalence O
of O
A-epochs B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
abundant I-outcome ['Physiological-Clinical']
alpha-activity I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
an O
increase O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PARTICIPANTS O
Fourteen O
physician O
groups O
with O
120 O
primary O
care O
physician O
and O
associate O
practitioners O
from O
2 O
group O
model O
HMO O
practices O
. O
[]

Altogether O
, O
results O
indicate O
that O
the O
TOM O
test O
is O
a O
reliable O
and O
valid O
instrument O
that O
can O
be O
employed O
to O
measure O
various O
aspects O
of O
theory O
of O
mind O
. O
[]

SETTING O
AND O
PATIENTS O
Patients O
with O
AMI O
who O
were O
admitted O
to O
76 O
acute O
care O
hospitals O
in O
Quebec O
that O
treated O
at O
least O
30 O
AMI O
patients O
per O
year O
between O
April O
1 O
, O
1999 O
, O
and O
March O
31 O
, O
2003 O
. O
[]

Examination O
of O
PTK2 O
gene O
expression O
in O
CLL8 O
patients O
yielded O
similar O
results O
. O
[]

albus O
and O
Staph O
. O
[]

[ O
Comparative O
effects O
of O
nebivolol O
and O
valsartan O
on O
atrial O
electromechanical B-outcome ['Physiological-Clinical']
coupling I-outcome ['Physiological-Clinical']
in O
newly O
diagnosed O
stage O
1 O
hypertensive O
patients O
] O
. O
['Physiological-Clinical']

tmax B-outcome ['Physiological-Clinical']
was O
prolonged O
after O
administration O
of O
the O
tablets O
. O
['Physiological-Clinical']

In O
particularly O
, O
ARA O
is O
important O
in O
signal O
transduction O
related O
to O
neuronal O
maturation O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Recurrence B-outcome ['Physiological-Clinical']
rate O
, O
vision B-outcome ['Physiological-Clinical']
, O
and O
complications B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

AIM O
To O
assess O
, O
in O
a O
randomized O
controlled O
trial O
, O
the O
efficacy O
of O
therapy O
in O
eradicating O
H. O
pylori O
as O
part O
of O
a O
screening O
programme O
, O
and O
to O
report O
the O
adverse O
events O
associated O
with O
this O
strategy O
. O
[]

The O
occurrence O
of O
AV B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
in O
the O
atrial O
group O
was O
recorded O
. O
['Physiological-Clinical']

1 O
. O
[]

Five O
hundred O
thirty-seven O
Hispanics O
were O
randomly O
assigned O
to O
brief O
intervention O
or O
treatment O
as O
usual O
. O
[]

The O
patients O
were O
randomized O
to O
receive O
nebivolol O
5 O
mg O
( O
30 O
patients O
; O
21 O
women O
, O
9 O
men O
; O
mean O
age O
48.4 O
? O
[]

Thus O
, O
23 O
of O
32 O
patients O
( O
72 O
% O
) O
with O
AF O
and O
none O
of O
7 O
with O
AFI O
converted O
to O
sinus B-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
after O
treatment O
with O
flecainide O
. O
['Physiological-Clinical']

Analgesic B-outcome ['Resource-use']
efficacy O
, O
maternal B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
changes O
in O
the O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
labor I-outcome ['Physiological-Clinical']
were O
assessed O
. O
['Resource-use', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
laparoscopic O
group O
, O
however O
, O
there O
were O
no O
differences O
between O
the O
overweight O
and O
normal-weight O
patients O
. O
[]

Randomised O
, O
placebo-controlled O
, O
double-blind O
clinical O
trial O
of O
beta-sitosterol O
in O
patients O
with O
benign O
prostatic O
hyperplasia O
. O
[]

Sixty O
adult O
patients O
, O
ASA O
Classes O
I O
& O
II O
, O
were O
involved O
in O
a O
study O
to O
compare O
the O
effectiveness O
of O
Mallinckrodt O
Hi-Lo-Evac O
tube O
and O
Portex O
blue O
line O
tube O
in O
preventing O
soiling O
of O
the O
lower O
airways O
during O
intranasal O
surgery O
. O
[]

RESULTS O
The O
three O
methods O
of O
evaluation O
showed O
no O
significant O
difference O
between O
Groups O
A O
vs. O
B O
, O
and O
C O
vs. O
D O
, O
while O
statistically O
significant O
differences O
were O
observed O
between O
Groups O
A O
vs. O
C O
, O
A O
vs. O
D O
, O
B O
vs. O
C O
and O
B O
vs. O
D. O
Based O
on O
the O
results O
of O
this O
study O
, O
the O
size O
of O
occlusal O
access O
significantly O
affected O
the O
efficacy O
of O
demineralized B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
removal I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
bone B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
episodes B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hypercalcemia I-outcome ['Physiological-Clinical']
, O
or O
['Physiological-Clinical', 'Physiological-Clinical']

0.3 O
, O
4.6 O
? O
[]

A O
randomized O
parallel O
study O
to O
assess O
the O
safety O
and O
efficacy O
of O
two O
different O
dosing O
regimens O
of O
5 O
% O
imiquimod O
in O
the O
treatment O
of O
superficial O
basal O
cell O
carcinoma O
. O
[]

Safety O
trial O
of O
the O
vaginal O
microbicide O
cellulose O
sulfate O
gel O
in O
HIV-positive O
men O
. O
[]

Of O
these O
patients O
, O
five O
had O
reported O
cough O
with O
ACE O
inhibitors O
. O
[]

This O
model O
reproduced O
the O
effects O
observed O
in O
postmenopausal O
women O
with O
high O
bone O
turnover O
treated O
with O
HRT O
. O
[]

Furthermore O
, O
5-HT O
is O
known O
to O
play O
a O
role O
in O
repetitive O
and O
social O
behaviours O
. O
[]

To O
detect O
trends O
in O
additional O
imaging O
recommendations O
, O
logistic O
regression O
analysis O
was O
used O
. O
[]

Celecoxib O
as O
adjunctive O
treatment O
to O
risperidone O
in O
children O
with O
autistic O
disorder O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

In O
particular O
, O
no O
immediate O
( O
anaphylactic B-outcome ['Physiological-Clinical']
type O
) O
or O
delayed O
( O
serum B-outcome ['Physiological-Clinical']
sickness I-outcome ['Physiological-Clinical']
) O
allergic B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Increases O
in O
blood B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
with O
placebo O
gel O
were O
not O
significant O
. O
['Physiological-Clinical']

RESULTS O
The O
71 O
patients O
who O
concluded O
the O
study O
had O
similar O
baseline O
characteristics O
. O
[]

Three O
dose O
levels O
of O
once-daily O
mizolastine O
( O
5 O
mg O
, O
10 O
mg O
, O
and O
15 O
mg O
) O
were O
compared O
with O
placebo O
during O
5-day O
dose O
periods O
. O
[]

CONCLUSIONS O
Etomidate O
resulted O
in O
stable O
hemodynamic B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
and O
relatively O
less O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
and O
flumazenil O
antagonized O
the O
anesthetic B-outcome ['Resource-use']
effect O
of O
etomidate O
; O
thus O
, O
etomidate O
with O
flumazenil O
is O
suitable O
for O
performing O
stem O
cell O
transplantation O
in O
autistic O
children O
. O
['Physiological-Clinical', 'Adverse-effects', 'Resource-use']

A O
prospective O
randomized O
study O
has O
been O
carried O
out O
in O
order O
to O
compare O
three O
different O
treatment O
modalities O
for O
symptomatic O
metastatic O
hormone-resistant O
prostatic O
cancer O
. O
[]

A O
generalized B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
intense I-outcome ['Physiological-Clinical']
erythema I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
cervix I-outcome ['Physiological-Clinical']
was O
observed O
in O
10 O
of O
12 O
Acidform/N-9 O
users O
and O
abrasion O
occurred O
in O
nine O
of O
them O
. O
['Physiological-Clinical']

For O
pediatric O
patients O
with O
asymptomatic O
low-stage O
and O
intermediate-stage O
Hodgkin O
disease O
, O
chemotherapy O
and O
chemoradiotherapy O
both O
resulted O
in O
3-year O
EFS B-outcome ['Mortality']
of O
approximately O
90 O
% O
and O
statistically O
indistinguishable O
8-year O
EFS B-outcome ['Physiological-Clinical']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
without O
significant O
long-term O
toxicity B-outcome ['Adverse-effects']
. O
['Mortality', 'Physiological-Clinical', 'Mortality', 'Adverse-effects']

However O
, O
it O
must O
be O
considered O
that O
these O
provocation O
doses O
are O
not O
equally O
calculable O
for O
every O
patient O
in O
the O
same O
way O
and O
at O
any O
examination O
time O
. O
[]

RESULTS O
Overall O
10-year O
survival B-outcome ['Mortality']
was O
47.1 O
% O
for O
the O
immunochemotherapy O
group O
( O
P O
< O
0.037 O
vs O
FAM O
and O
P O
< O
0.0006 O
vs O
control O
) O
, O
30 O
% O
for O
the O
chemotherapy O
group O
( O
vs O
control O
, O
NS O
) O
, O
and O
15.2 O
% O
for O
the O
control O
group O
. O
['Mortality']

The O
group O
treated O
by O
a O
medical O
nurse O
without O
training O
in O
psychotherapy O
experienced O
sustained O
relief O
of O
dyspnoea B-outcome ['Physiological-Clinical']
but O
tended O
to O
undergo O
less O
psychodynamic B-outcome ['Life-Impact']
change I-outcome ['Life-Impact']
; O
psychiatric B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Argon O
laser O
trabeculoplasty O
in O
primary O
open-angle O
glaucoma O
-- O
results O
in O
black O
Jamaican O
population O
. O
[]

After O
discharge O
LS O
received O
6 O
months O
home O
care O
, O
but O
without O
supplementation O
. O
[]

The O
treatment O
of O
ED O
by O
the O
first-line O
drugs O
is O
limited O
to O
a O
certain O
group O
of O
patients O
due O
to O
their O
side O
effects O
and O
costs O
. O
[]

Low-fluence O
photodynamic O
therapy O
versus O
ranibizumab O
for O
chronic O
central O
serous O
chorioretinopathy O
: O
one-year O
results O
of O
a O
randomized O
trial O
. O
[]

Specific O
exercises O
to O
treat O
pregnancy-related O
low O
back O
pain O
in O
a O
South O
African O
population O
. O
[]

Does O
aerobic O
training O
lead O
to O
a O
more O
active B-outcome ['Life-Impact']
lifestyle I-outcome ['Life-Impact']
and O
improved O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
patients O
with O
chronic O
heart O
failure O
? O
['Life-Impact', 'Life-Impact']

Patients O
in O
group O
2 O
( O
n=10 O
) O
terminated O
their O
timolol O
treatment O
3 O
weeks O
before O
the O
beginning O
of O
the O
study O
. O
[]

Dietary O
outcome O
measures O
in O
the O
areas O
of O
saturated B-outcome ['Life-Impact']
fat I-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
( O
g O
) O
, O
and O
the O
intake O
of O
fruit B-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
serves I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
, O
vegetables B-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
serves I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
, O
grain B-outcome ['Life-Impact']
and O
cereals B-outcome ['Life-Impact']
as O
total O
and O
wholegrain B-outcome ['Life-Impact']
( O
serves O
) O
were O
collected O
using O
7-day O
estimated O
dietary O
records O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

An O
experimental O
design O
with O
random O
assignment O
of O
subjects O
to O
treatment O
and O
control O
groups O
was O
used O
to O
demonstrate O
the O
impact B-outcome ['Life-Impact']
of O
this O
peer-mediated O
intervention O
. O
['Life-Impact']

RESULTS O
No O
statistical O
differences O
were O
found O
between O
ozone O
treated O
specimens O
and O
controls O
, O
neither O
on O
enamel B-outcome ['Physiological-Clinical']
nor O
on O
dentin B-outcome ['Physiological-Clinical']
irrespective O
of O
the O
tested O
adhesive O
. O
['Physiological-Clinical', 'Physiological-Clinical']

0.3 O
) O
and O
18 O
weeks O
( O
7.6 O
? O
[]

MATERIAL O
AND O
METHOD O
In O
this O
prospective O
, O
randomized O
controlled O
study O
, O
61 O
ASA O
physical O
status O
I-III O
patients O
scheduled O
for O
elective O
unilateral O
total O
knee O
arthroplasty O
( O
TKA O
) O
under O
spinal O
anesthesia O
( O
SA O
) O
participated O
. O
[]

RESULTS O
One O
hundred O
forty-one O
patients O
were O
evaluable O
. O
[]

[ O
Clinical O
diagnosis O
of O
deep O
venous O
thrombosis O
after O
hip O
replacement O
surgery O
] O
. O
[]

We O
conclude O
that O
both O
drugs O
are O
effective O
and O
useful O
in O
treating O
hypertensive B-outcome ['Physiological-Clinical']
emergencies I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
138 O
patients O
with O
anterior O
wall O
AMI O
, O
in-hospital B-outcome ['Mortality']
mortality I-outcome ['Mortality']
was O
significantly O
reduced O
by O
treatment O
with O
PTCA O
compared O
with O
tPA O
( O
1.4 O
% O
vs O
11.9 O
% O
, O
p O
= O
0.01 O
) O
. O
['Mortality']

Sensory B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
regression I-outcome ['Physiological-Clinical']
and O
ambulatory O
milestones O
were O
20-30 O
min O
longer O
with O
the O
80-mg O
dose O
. O
['Physiological-Clinical']

The O
present O
study O
was O
designed O
to O
assess O
the O
antithrombotic O
effect O
of O
both O
dual O
antiplatelet O
regimens O
using O
a O
human O
ex O
vivo O
model O
of O
arterial O
thrombosis O
. O
[]

RESULTS O
At O
month O
12 O
, O
16 O
eyes O
( O
88.9 O
% O
) O
of O
the O
low-fluence O
PDT O
group O
maintained O
complete O
resolution O
of O
[]

Patients O
were O
randomised O
to O
six O
cycles O
of O
FEC O
( O
75 O
) O
or O
FEC O
( O
90 O
) O
, O
with O
all O
three O
drugs O
given O
on O
day O
1 O
of O
each O
14-day O
cycle O
. O
[]

Even O
so O
, O
because O
of O
a O
small O
risk O
of O
silicone O
spread O
, O
the O
authors O
suggest O
that O
women O
with O
implant O
ruptures O
be O
followed O
clinically O
, O
if O
not O
operated O
on O
. O
[]

If O
prescribers O
complied O
with O
current O
guidelines O
, O
microscopy O
would O
give O
rise O
to O
lower O
average O
costs B-outcome ['Resource-use']
per O
patient O
correctly O
treated O
than O
RDTs O
in O
areas O
of O
both O
high O
and O
low O
transmission O
. O
['Resource-use']

RESULTS O
Mean O
baseline O
HIV-1 O
RNA O
was O
4.2 O
log O
( O
10 O
) O
copies/mL O
in O
group O
1 O
and O
3.8 O
log O
( O
10 O
) O
copies/mL O
in O
group O
2 O
. O
[]

OBJECTIVE O
To O
examine O
the O
effect O
of O
early O
educational O
intervention O
after O
discharge O
from O
the O
hospital O
on O
the O
health O
and O
developmental O
status O
of O
very O
low O
birth O
weight O
( O
< O
or O
= O
1500 O
gm O
) O
infants O
. O
[]

Exercise O
training O
did O
not O
significantly O
modify O
the O
lipid B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Intention-to-treat O
eradication O
rates O
were O
88.2 O
% O
( O
95 O
% O
CI O
80.9-93.0 O
% O
) O
vs. O
79.1 O
% O
( O
95 O
% O
CI O
71.1-85.4 O
% O
) O
, O
p O
= O
0.029 O
, O
respectively O
. O
[]

One O
of O
the O
2 O
controlled O
preventive O
trials O
within O
the O
Oslo O
Study O
was O
a O
non-drug O
trial O
on O
the O
effect O
of O
diet B-outcome ['Life-Impact']
and O
smoking B-outcome ['Resource-use']
intervention I-outcome ['Resource-use']
on O
coronary O
heart O
disease O
in O
1232 O
middleaged O
, O
normotensive O
, O
healthy O
men O
. O
['Life-Impact', 'Resource-use']

Assisted O
exercise O
and O
bone O
strength O
in O
preterm O
infants O
. O
[]

Temporal O
variation O
in O
the O
effects O
of O
ophthalmic O
timolol O
on O
cardiovascular B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
in O
healthy O
men O
. O
['Physiological-Clinical']

The O
Pittsburgh O
Sleep B-outcome ['Physiological-Clinical']
Quality I-outcome ['Physiological-Clinical']
Index O
( O
PSQI O
) O
and O
blood O
samples O
were O
collected O
8 O
times O
during O
the O
first O
17 O
weeks O
postpartum O
. O
['Physiological-Clinical']

This O
study O
was O
a O
14-week O
open O
, O
randomized O
, O
crossover O
trial O
of O
ropinirole O
vs. O
levodopa O
sustained O
release O
( O
SR O
) O
in O
11 O
patients O
with O
RLS O
on O
chronic O
hemodialysis O
. O
[]

Locomoting-to-reach O
is O
a O
basic O
perception/action O
behavior O
that O
requires O
visual O
information O
for O
the O
control O
of O
both O
locomotion O
and O
reaching O
components O
. O
[]

Concurrent O
training O
enhances O
athletes O
' O
cardiovascular O
and O
cardiorespiratory O
measures O
. O
[]

RESULTS O
Principal O
components O
analysis O
identified O
three O
primary O
dietary O
patterns O
among O
rural O
dwellers O
( O
high O
sweets O
and O
starches O
, O
high O
reduced-fat O
dairy O
, O
cereal O
, O
nuts O
, O
and O
fruits O
, O
and O
mixed O
) O
and O
three O
among O
urban O
dwellers O
( O
high O
fruits O
and O
vegetables O
, O
high O
meat O
and O
refined O
grains O
, O
and O
high O
sugar-sweetened O
beverages O
) O
. O
[]

A O
placebo O
controlled O
study O
. O
[]

METHODS O
This O
was O
a O
single O
centre O
randomized O
treatment O
study O
. O
[]

We O
compared O
itraconazole O
oral O
solution O
( O
which O
has O
an O
improved O
pharmacokinetic O
profile O
) O
with O
fluconazole O
for O
antifungal O
prophylaxis O
. O
[]

RESULTS O
In O
neurosurgical O
patients O
, O
it O
took O
36 O
seconds O
( O
95 O
% O
confidence O
interval O
31 O
to O
40 O
seconds O
) O
to O
insert O
a O
cannula B-outcome ['Resource-use']
in O
the O
active O
warming O
group O
and O
62 O
( O
50 O
to O
74 O
) O
seconds O
in O
the O
passive O
insulation O
group O
( O
P=0.002 O
) O
. O
['Resource-use']

Rapid O
release O
of O
cardiac B-outcome ['Physiological-Clinical']
enzymes I-outcome ['Physiological-Clinical']
was O
observed O
in O
Group O
1 O
as O
compared O
with O
Group O
2 O
: O
rate O
of O
rise O
of O
CK B-outcome ['Physiological-Clinical']
was O
210+/-209 O
vs O
97+/-95 O
U/l/h O
( O
p=0.015 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
patients O
with O
hypothyroidism O
also O
showed O
similar O
nocturnal B-outcome ['Physiological-Clinical']
melatonin I-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
during O
octreotide O
and O
saline O
. O
['Physiological-Clinical']

All O
patients O
will O
receive O
vasodilator O
therapy O
, O
unless O
they O
find O
it O
intolerable O
. O
[]

Treatment O
with O
BBOS O
1.5 O
% O
significantly O
reduced O
instantaneous B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
reflective I-outcome ['Physiological-Clinical']
ocular I-outcome ['Physiological-Clinical']
itching I-outcome ['Physiological-Clinical']
scores O
from O
baseline O
compared O
with O
placebo O
over O
the O
2-week O
study O
period O
( O
p O
= O
0.007 O
and O
p O
= O
0.005 O
, O
respectively O
) O
. O
['Physiological-Clinical']

Intraperitoneal B-outcome ['Physiological-Clinical']
distribution I-outcome ['Physiological-Clinical']
imaging O
prior O
to O
chromic O
phosphate O
( O
P-32 O
) O
therapy O
in O
ovarian O
cancer O
patients O
. O
['Physiological-Clinical']

METHODS O
One O
hundred O
and O
seventy O
patients O
with O
Fisher O
Grade O
III O
subarachnoid O
hemorrhage O
were O
enrolled O
in O
the O
study O
. O
[]

Each O
patient O
received O
6 O
cycles O
of O
chemotherapy O
with O
intravenous O
administration O
of O
paclitaxel O
( O
175 O
mg/m2 O
, O
on O
D3 O
) O
and O
epirubicin O
( O
60 O
mg/m2 O
, O
on O
Dl O
and O
D2 O
) O
. O
[]

The O
substantial O
overlap O
between O
the O
presence O
of O
PLI O
and O
ASD O
( O
75 O
% O
) O
across O
the O
whole O
cohort O
suggests O
that O
the O
intervention O
may O
also O
be O
applicable O
to O
some O
verbally O
able O
children O
with O
ASD O
who O
have O
pragmatic O
communication O
needs O
. O
[]

The O
first O
study O
included O
32 O
children O
and O
used O
a O
randomised O
controlled O
treatment O
design O
comparing O
a O
CBT O
approach O
with O
conjoint O
family O
therapy O
and O
an O
eclectic O
approach O
. O
[]

Program O
participation O
had O
a O
marked O
effect O
on O
dietary B-outcome ['Life-Impact']
adherence I-outcome ['Life-Impact']
: O
a O
10 O
% O
increase O
in O
session B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
predicted O
a O
1.2 O
% O
decrease O
in O
percent O
energy O
from O
fat O
( O
P O
< O
.001 O
) O
. O
['Life-Impact', 'Life-Impact']

Clinical O
parameters O
and O
standardized O
radiographs O
were O
obtained O
at O
baseline O
and O
6 O
months O
after O
the O
surgeries O
. O
[]

Data O
for O
90 O
children O
( O
49 O
boys O
, O
41 O
girls O
, O
9.3 O
? O
[]

This O
difference O
in O
the O
pattern O
of O
recurrence B-outcome ['Physiological-Clinical']
was O
of O
borderline O
statistical O
significance O
( O
P O
= O
0.07 O
) O
. O
['Physiological-Clinical']

Neuroimaging O
studies O
have O
shown O
the O
engagement O
of O
the O
left O
dorsolateral O
prefrontal O
cortex O
( O
DLPFC O
) O
in O
executive O
functioning O
, O
and O
more O
specifically O
during O
selective O
attention O
. O
[]

In O
the O
intervention O
group O
, O
plasma O
levels O
of O
vitamin O
E O
, O
selenium O
and O
coenzyme O
Q10 O
increased O
significantly O
over O
the O
21 O
weeks O
study O
period O
. O
[]

The O
lavage O
was O
divided O
into O
a O
predominantly O
bronchial O
washing O
( O
first O
20 O
ml O
of O
lavage O
; O
BL O
) O
and O
a O
predominantly O
alveolar O
washing O
( O
BAL O
) O
. O
[]

40 O
% O
) O
, O
hospitalization B-outcome ['Resource-use']
( O
38 O
% O
vs O
. O
['Resource-use']

RESULTS O
Of O
the O
88 O
eligible O
patients O
, O
four O
treated O
with O
S-MEC O
therapy O
and O
two O
treated O
with O
I-MEC O
therapy O
showed O
CR O
. O
[]

METHODS O
Data O
analyzed O
was O
from O
a O
phase O
III O
, O
randomized O
clinical O
trial O
of O
DOX O
( O
60 O
mg/m O
( O
2 O
) O
every O
3 O
weeks O
) O
or O
PLD O
( O
50 O
mg/m O
( O
2 O
) O
every O
4 O
weeks O
) O
for O
the O
first O
line O
therapy O
for O
MBC O
( O
n O
= O
509 O
) O
( O
O'Brien O
et O
al O
, O
Ann O
Oncol O
. O
[]

The O
intervention O
consisted O
of O
11 O
individual O
sessions O
, O
implementing O
three O
components O
: O
physiologic O
relaxation O
with O
biofeedback O
training O
focused O
on O
altering O
autonomic O
tone O
; O
cognitive O
behavioral O
therapy O
aimed O
at O
self-management O
and O
coping O
strategies O
for O
depression O
, O
anxiety O
, O
and O
anger O
; O
and O
cardiovascular O
health O
education O
. O
[]

Increases O
in O
CEA-specific B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
were O
detected O
in O
50 O
% O
, O
37 O
% O
, O
and O
30 O
% O
of O
patients O
in O
groups O
1 O
, O
2 O
, O
and O
3 O
, O
respectively O
. O
['Physiological-Clinical']

The O
response O
time O
was O
not O
significantly O
different O
in O
the O
anodal O
and O
sham O
stimulation O
groups O
. O
[]

Postoperative O
pain O
was O
assessed O
using O
the O
Children O
's O
Hospital O
of O
Eastern O
Ontario O
Pain O
Scale O
( O
CHEOPS O
) O
upon O
arrival O
to O
the O
PACU O
and O
at O
5 O
, O
10 O
, O
15 O
, O
30 O
, O
45 O
, O
and O
60 O
min O
. O
[]

This O
subgroup O
specificity O
led O
us O
to O
hypothesize O
that O
YAP1 O
may O
be O
important O
for O
response O
to O
endocrine O
therapies O
, O
such O
as O
tamoxifen O
, O
extensively O
used O
for O
luminal O
A O
breast O
cancers O
. O
[]

A O
tested O
curriculum O
was O
adapted O
to O
meet O
the O
needs O
of O
the O
target O
population O
. O
[]

PATIENTS O
Of O
124 O
consecutive O
patients O
referred O
for O
treatment O
of O
symptomatic O
ventricular O
tachyarrhythmias O
, O
57 O
consenting O
patients O
were O
eligible O
to O
have O
drug O
therapy O
selected O
by O
either O
noninvasive O
or O
invasive O
approaches O
. O
[]

Two O
of O
these O
fractures O
healed O
after O
dynamization O
by O
removing O
static O
interlocking O
screws O
. O
[]

The O
physiotherapy O
group O
were O
treated O
with O
ultra-short O
wave O
, O
modulated O
medium O
frequency O
current O
, O
massage O
and O
functional O
training O
. O
[]

Only O
one O
case O
in O
arm O
A O
was O
complicated O
by O
local B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
around O
35 O
months O
after O
operation O
. O
['Physiological-Clinical']

As O
a O
result O
of O
our O
study O
, O
caution O
seems O
to O
be O
necessary O
if O
acylaminopenicillins O
are O
administered O
in O
the O
early O
postoperative O
period O
. O
[]

Drug O
preference O
in O
normal O
volunteers O
: O
effects O
of O
age O
and O
time O
of O
day O
. O
[]

METHODS O
AND O
RESULTS O
Fifty-five O
patients O
with O
STEMI O
were O
randomized O
either O
to O
start O
abciximab O
( O
0.25 O
mg/kg O
bolus O
followed O
by O
10 O
microg/min O
infusion O
) O
during O
the O
organization O
phase O
for O
pPCI O
( O
Group O
1 O
, O
n=28 O
) O
or O
immediately O
before O
pPCI O
( O
Group O
2 O
, O
n=27 O
) O
. O
[]

METHOD O
12 O
endoscopy O
trainees O
, O
10 O
surgeons O
and O
two O
medical O
gastroenterologists O
, O
all O
with O
experience O
in O
gastroscopy O
but O
with O
no O
specific O
colonoscopy O
experience O
, O
were O
randomly O
assigned O
to O
either O
simulator O
training O
or O
to O
a O
control O
group O
. O
[]

Accounting O
for O
interindividual O
variability O
reduces O
the O
trough-to-peak O
ratio O
. O
[]

The O
slowly O
progressive O
nature O
of O
this O
disease O
means O
that O
patients O
will O
require O
ongoing O
therapeutic O
management O
for O
many O
years O
, O
or O
even O
decades O
. O
[]

Extracorporeal O
shock O
wave O
therapy O
( O
ESWT O
) O
in O
patients O
with O
chronic O
proximal O
plantar O
fasciitis O
: O
a O
2-year O
follow-up O
. O
[]

DESIGN O
, O
SETTING O
, O
AND O
PARTICIPANTS O
A O
randomized O
clinical O
trial O
compared O
6 O
sessions O
of O
PSE O
with O
usual O
care O
. O
[]

70.1 O
kg O
; O
p O
= O
0.01 O
) O
, O
compared O
with O
the O
other O
4 O
conditions O
. O
[]

The O
primary O
efficacy O
endpoint O
was O
met O
for O
the O
concurrent O
arm O
only O
. O
[]

BACKGROUND O
Although O
different O
methods O
to O
prevent O
bruising O
and O
pain O
following O
the O
subcutaneous O
injection O
of O
heparin O
have O
been O
widely O
studied O
and O
described O
, O
the O
effect O
of O
injection O
duration O
on O
the O
occurrence O
of O
bruising O
and O
pain O
is O
little O
documented O
. O
[]

Both O
doses O
produced O
comparable O
sensory O
and O
motor O
block O
. O
[]

A O
pragmatic O
study O
was O
conducted O
in O
two O
phases O
during O
routine O
surgeries O
at O
Aldermoor O
Health O
Centre O
, O
Southampton O
. O
[]

We O
previously O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
conducted O
from O
2000 O
to O
2003 O
of O
palifermin O
, O
a O
recombinant O
human O
keratinocyte O
growth O
factor O
, O
dosed O
from O
240 O
microg/kg O
to O
720 O
microg/kg O
, O
in O
100 O
allogeneic O
hematopoietic O
stem O
cell O
transplantation O
( O
HCT O
) O
recipients O
. O
[]

Results O
showed O
that O
patient O
characteristics O
within O
each O
case O
load O
( O
after O
random O
assignments O
) O
were O
similar O
and O
disclosed O
no O
differences O
that O
would O
have O
explained O
the O
differences O
in O
success O
; O
therapist O
's O
personal B-outcome ['Life-Impact']
qualities I-outcome ['Life-Impact']
were O
correlated O
with O
outcomes O
but O
not O
significantly O
( O
mean O
r O
= O
.32 O
) O
; O
an O
early-in-treatment O
measure O
of O
the O
patient-therapist O
['Life-Impact']

Clinical O
hypnosis O
versus O
cognitive O
behavioral O
training O
for O
pain B-outcome ['Resource-use']
management I-outcome ['Resource-use']
with O
pediatric O
cancer O
patients O
undergoing O
bone O
marrow O
aspirations O
. O
['Resource-use']

The O
total O
duration O
of O
sensory B-outcome ['Resource-use']
anesthesia I-outcome ['Resource-use']
was O
133 O
+/- O
28 O
minutes O
( O
C O
) O
, O
182 O
+/- O
38 O
( O
L O
) O
, O
and O
247 O
+/- O
42 O
( O
M O
) O
( O
p O
less O
than O
0.05 O
) O
. O
['Resource-use']

Until O
definitive O
level O
I O
evidence O
is O
available O
, O
this O
operative O
technique O
is O
advocated O
as O
optimal O
therapy O
for O
CVI O
. O
[]

AIMS O
To O
examine O
the O
effect O
of O
a O
single O
dose O
of O
human O
synthetic O
secretin O
( O
HSS O
) O
on O
behaviour O
and O
communication O
in O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
using O
an O
objective O
measure O
of O
communication O
and O
social O
reciprocity O
and O
standardised O
rating O
scales O
. O
[]

DESIGN O
Randomized O
prospective O
controlled O
study O
. O
[]

Thirty-eight O
participants O
were O
randomly O
allocated O
to O
the O
EEG-biofeedback O
, O
skin O
conductance O
( O
SC O
) O
-biofeedback O
or O
waiting O
list O
group O
. O
[]

LEVEL O
OF O
EVIDENCE O
I O
. O
[]

The O
subjects O
walked O
5 O
d/week O
for O
15 O
weeks O
at O
65 O
% O
of O
their O
maximal O
aerobic O
power O
expending O
300 O
kcal O
( O
1255 O
kJ O
) O
in O
exercise O
in O
one O
( O
Group O
S1 O
) O
or O
two O
daily O
sessions O
( O
Group O
S2 O
) O
. O
[]

were O
cultured O
on O
various O
selective O
and O
non-selective O
media O
. O
[]

The O
measured O
volumes O
were O
compared O
with O
the O
volumes O
of O
57 O
radical O
prostatectomy O
specimens O
through O
Spearman O
's O
rank O
correlation O
coefficient O
and O
agreement O
tests O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
relative O
risk O
of O
any O
complication B-outcome ['Adverse-effects']
. O
['Adverse-effects']

Both O
the O
sodium O
iothalamate O
and O
the O
iopamidol O
groups O
showed O
a O
significant O
fall O
in O
FEV1 B-outcome ['Physiological-Clinical']
and O
FVC B-outcome ['Physiological-Clinical']
( O
P O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
crossover O
study O
, O
6 O
months O
of O
octreotide O
( O
40 O
mg O
every O
28 O
days O
) O
therapy O
limited O
kidney O
volume O
growth O
more O
effectively O
than O
placebo O
in O
12 O
patients O
with O
ADPKD O
. O
[]

BACKGROUND O
Extreme O
temperatures O
have O
been O
associated O
with O
hospitalization O
and O
death O
among O
individuals O
with O
heart O
failure O
, O
but O
few O
studies O
have O
explored O
the O
underlying O
mechanisms O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
use O
inhibition O
of O
wheal O
and O
flare O
formation O
after O
2-mu O
g O
intradermal O
histamine O
injections O
as O
a O
measure O
of O
the O
antihistamine O
effect O
of O
repeated O
doses O
of O
mizolastine O
. O
[]

Treatment O
included O
instruction O
and O
therapeutic O
activities O
targeting O
social O
skills O
, O
face-emotion O
recognition O
, O
interest O
expansion O
, O
and O
interpretation O
of O
non-literal O
language O
. O
[]

Vein B-outcome ['Physiological-Clinical']
graft I-outcome ['Physiological-Clinical']
occlusion I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
distal I-outcome ['Physiological-Clinical']
anastomoses I-outcome ['Physiological-Clinical']
were O
27 O
% O
in O
the O
fish O
oil O
group O
and O
33 O
% O
in O
the O
control O
group O
( O
odds O
ratio O
0.77 O
, O
95 O
% O
confidence O
interval O
, O
0.60 O
to O
0.99 O
, O
p O
= O
0.034 O
) O
. O
['Physiological-Clinical']

In O
cases O
of O
intolerable B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
the O
patients O
were O
authorized O
to O
reactivate O
their O
SCS O
. O
['Physiological-Clinical']

The O
dose O
of O
oral O
famotidine O
was O
2 O
mg/kg/day O
( O
given O
in O
two O
divided O
doses O
) O
; O
the O
maximum O
total O
daily O
dose O
was O
100 O
mg O
. O
[]

Basic O
autohemotherapy B-outcome ['Resource-use']
was O
used O
. O
['Resource-use']

CONTEXT O
Nerve O
growth O
factor O
is O
a O
neurotrophic O
factor O
that O
promotes O
the O
survival O
of O
small O
fiber O
sensory O
neurons O
and O
sympathetic O
neurons O
in O
the O
peripheral O
nervous O
system O
. O
[]

Ultrasound O
evaluation O
of O
the O
nodules O
did O
not O
show O
significant O
differences O
between O
both O
groups O
. O
[]

A O
controlled O
, O
randomised O
, O
prospective O
trial O
of O
Argon O
laser O
trabeculoplasty O
( O
ALT O
) O
was O
carried O
out O
on O
48 O
eyes O
of O
30 O
black O
Jamaican O
patients O
with O
primary O
open-angle O
glaucoma O
. O
[]

Subjects O
participating O
in O
the O
study O
were O
randomly O
allocated O
to O
control O
( O
C O
) O
and O
treatment O
( O
T O
) O
groups O
, O
n O
= O
53 O
and O
n O
= O
57 O
, O
respectively O
. O
[]

PURPOSE O
This O
phase O
III O
study O
compared O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TTP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of O
an O
oral O
regimen O
of O
dihydropyrimidine O
dehydrogenase O
inhibitory O
fluoropyrimidine O
composed O
of O
a O
fixed O
combination O
of O
tegafur O
and O
uracil O
in O
a O
1:4 O
molar O
ratio O
( O
UFT O
) O
and O
leucovorin O
( O
LV O
) O
to O
intravenous O
( O
IV O
) O
fluorouracil O
( O
5-FU O
) O
and O
LV O
in O
previously O
untreated O
metastatic O
colorectal O
carcinoma O
( O
CRC O
) O
patients O
. O
['Physiological-Clinical']

Further O
analysis O
revealed O
cutoff O
point O
at O
2.5 O
to O
separate O
uncontrolled O
from O
controlled O
or O
partly O
controlled O
patient O
with O
sensitivity B-outcome ['Physiological-Clinical']
76.9 O
% O
and O
specificity O
89.4 O
% O
and O
cutoff O
point O
at O
1.5 O
to O
separate O
uncontrolled O
or O
partly O
controlled O
from O
controlled O
patient O
with O
['Physiological-Clinical']

However O
, O
the O
retrospective O
and O
qualitative O
nature O
of O
RCA O
is O
a O
limitation O
in O
scientific O
analyses O
examining O
causal O
relationships O
. O
[]

Changes O
in O
serum B-outcome ['Physiological-Clinical']
acetate I-outcome ['Physiological-Clinical']
from O
0 O
to O
3 O
mo O
were O
not O
related O
to O
changes O
in O
lipids B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
have O
examined O
the O
clearance O
rates O
for O
subgroups O
based O
on O
variables O
of O
gender O
, O
baseline O
wart B-outcome ['Physiological-Clinical']
area O
, O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
current I-outcome ['Physiological-Clinical']
outbreak I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
warts I-outcome ['Physiological-Clinical']
, O
previous B-outcome ['Physiological-Clinical']
wart I-outcome ['Physiological-Clinical']
treatment O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

AIMS O
To O
investigate O
the O
effect O
of O
rectal O
distension O
on O
bladder B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
and O
the O
number O
of O
detrusor B-outcome ['Physiological-Clinical']
contractions I-outcome ['Physiological-Clinical']
in O
patients O
with O
overactive O
bladder O
( O
OAB O
) O
symptoms O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
examined O
the O
effect O
of O
prior O
treatment O
history O
on O
the O
outcome O
of O
pharmacotherapy B-outcome ['Physiological-Clinical']
of O
MDpsy O
in O
patients O
who O
participated O
in O
the O
STOPD-PD O
study O
, O
a O
randomized O
, O
double-blind O
, O
clinical O
trial O
comparing O
a O
combination O
of O
olanzapine O
plus O
sertraline O
vs. O
olanzapine O
plus O
placebo O
. O
['Physiological-Clinical']

The O
COF O
chemotherapy O
consisted O
of O
Vincristine O
1 O
mg O
, O
cyclophosphamide O
600 O
mg O
and O
5-fluorouracil O
500 O
mg O
IV O
on O
days O
1 O
and O
8 O
with O
or O
without O
the O
addition O
of O
Pingyangmycin O
, O
a O
drug O
equivalent O
to O
Bleomycin O
A5 O
, O
at O
the O
dose O
of O
10 O
mg O
IM O
on O
days O
1 O
, O
3 O
, O
6 O
and O
8 O
. O
[]

Cough O
responses O
to O
citric O
acid O
were O
similar O
between O
patients O
with O
and O
without O
cough O
, O
and O
SP O
up O
to O
10 O
( O
-5 O
) O
M O
did O
not O
cause O
cough O
in O
any O
of O
the O
subjects O
. O
[]

This O
method O
has O
major O
clinical O
relevance O
, O
such O
as O
its O
application O
in O
clarifying O
the O
mechanisms O
underling O
metabolic O
and O
systemic O
disorders O
. O
[]

DESIGN O
, O
SETTING O
, O
AND O
PARTICIPANTS O
Cluster O
randomized O
, O
double-masked O
, O
placebo-controlled O
trial O
among O
pregnant O
women O
13 O
to O
45 O
years O
of O
age O
and O
their O
live-born O
infants O
to O
12 O
weeks O
( O
84 O
days O
) O
postpartum O
in O
rural O
northern O
Bangladesh O
between O
2001 O
and O
2007 O
. O
[]

No O
drug B-outcome ['Physiological-Clinical']
interaction I-outcome ['Physiological-Clinical']
was O
found O
between O
morphine O
in O
MS-sNT O
and O
4 O
% O
or O
20 O
% O
alcohol O
. O
['Physiological-Clinical']

BACKGROUND O
In O
stressful O
conditions O
, O
increasing O
blood O
glucose O
concentrations O
are O
closely O
related O
to O
an O
increase O
in O
catecholamines O
and O
cortisol O
release O
. O
[]

Twenty-seven O
patients O
were O
fully O
evaluable O
. O
[]

Short-term O
pulmonary O
effects O
of O
total O
parenteral O
nutrition O
in O
children O
with O
cystic O
fibrosis O
. O
[]

However O
, O
we O
found O
that O
there O
were O
significant O
differences O
among O
the O
groups O
in O
terms O
of O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates O
( O
75 O
% O
for O
clarithromycin O
, O
64 O
% O
for O
roxithromycin O
, O
and O
41 O
% O
for O
erythromycin O
stearate O
, O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical']

The O
study O
was O
focused O
on O
aseptic O
sternal O
complications O
, O
namely O
bone B-outcome ['Physiological-Clinical']
dehiscence I-outcome ['Physiological-Clinical']
and O
superficial B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
instability I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Gastrointestinal B-outcome ['Physiological-Clinical']
safety I-outcome ['Physiological-Clinical']
of O
NO-aspirin O
( O
NCX-4016 O
) O
in O
healthy O
human O
volunteers O
: O
a O
proof O
of O
concept O
endoscopic O
study O
. O
['Physiological-Clinical']

BACKGROUND O
Laser O
systems O
have O
been O
developed O
for O
the O
cutting O
of O
dental O
hard O
tissues O
. O
[]

Response O
rates O
to O
platinum O
second-line O
therapy O
were O
6 O
and O
50 O
% O
for O
resistant O
and O
sensitive O
tumours O
, O
respectively O
( O
P O
< O
0.001 O
) O
. O
[]

During O
the O
course O
of O
therapy O
, O
a O
modest O
improvement O
in O
the O
symptom B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
and O
functional B-outcome ['Life-Impact']
classification I-outcome ['Life-Impact']
of O
the O
flosequinan-treated O
patients O
was O
observed O
. O
['Physiological-Clinical', 'Life-Impact']

The O
intervention O
was O
DBT O
and O
the O
control O
condition O
was O
treatment O
as O
usual O
plus O
waiting O
list O
for O
DBT O
( O
TAU+WL O
) O
, O
with O
outcomes O
measured O
after O
6 O
months O
. O
[]

The O
median O
proportion O
of O
utterances B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
echolalia I-outcome ['Life-Impact']
was O
0.16 O
. O
['Life-Impact']

Univariate O
analysis O
revealed O
that O
the O
Ligaclip O
's O
use O
compared O
with O
electrocoagulation O
in O
the O
laparoscopic O
pelvic O
lymphadenectomy O
is O
an O
independent O
predictive O
factor O
for O
development O
of O
lymphocele B-outcome ['Physiological-Clinical']
( O
P O
= O
.006 O
) O
. O
['Physiological-Clinical']

Ongoing O
monitoring O
of O
BMD O
is O
therefore O
not O
routinely O
required O
. O
[]

The O
mean O
arterial B-outcome ['Physiological-Clinical']
carboxyhemoglobin I-outcome ['Physiological-Clinical']
was O
1.48 O
per O
cent O
in O
the O
carbon O
monoxide O
control O
period O
and O
increased O
from O
1.43 O
to O
4.08 O
per O
cent O
after O
breathing O
carbon O
monoxide O
( O
P O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical']

Mean O
absolute B-outcome ['Physiological-Clinical']
reticulocyte I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
peaked O
at O
day O
11 O
or O
15 O
in O
each O
group O
and O
appeared O
to O
be O
greater O
for O
subcutaneous O
dosing O
( O
mean O
peak O
response O
149-169 O
x O
10 O
( O
9 O
) O
/L O
) O
compared O
with O
IV O
dosing O
( O
mean O
peak O
response O
138-147 O
x O
10 O
( O
9 O
) O
/L O
) O
at O
most O
visits O
. O
['Physiological-Clinical']

Effects O
of O
early O
enteral O
feeding O
on O
fecal B-outcome ['Physiological-Clinical']
elastase I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
secretin I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
increase O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
were O
compared O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Secondary B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
were I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
measured I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
Levine I-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
scale O
, O
function O
measured O
by O
Pransky O
's O
upper O
extremity O
function O
scale O
, O
and O
grip O
strength O
. O
['Physiological-Clinical']

BACKGROUND O
The O
overall O
effect O
of O
prophylactic O
tamoxifen O
in O
women O
depends O
on O
the O
balance O
between O
the O
effects O
of O
the O
drug O
, O
which O
include O
preventing B-outcome ['Physiological-Clinical']
breast I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
and O
altering O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
contrast O
, O
beta-blockers O
reliably O
reduce O
ischemic B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
This O
study O
was O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
clinical O
trial O
. O
[]

Because O
of O
some O
benefits O
of O
indobufen O
compared O
to O
ASA O
( O
shorter O
time O
of O
effect O
, O
superior O
tolerance O
in O
patients O
with O
ulceration O
) O
, O
the O
former O
drug O
can O
be O
recommended O
for O
use O
in O
some O
indicated O
cases O
. O
[]

no O
droperidol O
) O
was O
compared O
with O
the O
group O
that O
received O
2.5 O
mg O
droperidol O
, O
both O
when O
2 O
mg O
and O
when O
4 O
mg O
morphine O
was O
used O
. O
[]

If O
so O
, O
this O
would O
be O
a O
great O
support O
for O
doctors O
who O
might O
systematically O
recommend O
these O
simple O
and O
costless O
measures O
, O
especially O
in O
primary O
care O
. O
[]

Further O
, O
in O
ONTARGET O
, O
the O
ACEI O
was O
not O
titrated O
to O
the O
maximum O
dose O
and O
patients O
with O
heart O
failure O
were O
excluded O
. O
[]

The O
subjects O
received O
a O
histamine-free O
diet O
also O
low O
in O
allergen O
24 O
hours O
before O
hospitalization O
and O
over O
the O
whole O
observation O
period O
. O
[]

MATERIALS O
AND O
METHODS O
A O
total O
of O
118 O
lesions O
in O
lung O
, O
liver O
and O
lymph O
nodes O
were O
selected O
from O
30 O
patients O
enrolled O
in O
early O
phase O
clinical O
trials O
. O
[]

Effects O
of O
supplementation O
of O
whole O
corn O
germ O
on O
reproductive B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
, O
calf O
performance O
, O
and O
leptin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
in O
primiparous O
and O
mature O
beef O
cows O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Risperidone O
elevates O
prolactin B-outcome ['Physiological-Clinical']
more O
than O
other O
atypical O
antipsychotic O
medications O
. O
['Physiological-Clinical']

RESULTS O
Analysis O
of O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
data O
revealed O
a O
statistically O
significant O
increase O
in O
strength B-outcome ['Life-Impact']
within O
the O
treatment O
group O
after O
the O
first O
intervention O
( O
6.95 O
% O
right O
, O
12.61 O
% O
left O
) O
as O
compared O
with O
the O
second O
( O
11.53 O
% O
right O
, O
17.02 O
% O
left O
) O
and O
the O
third O
interventions O
( O
10.53 O
% O
right O
, O
16.81 O
% O
left O
) O
. O
['Life-Impact', 'Life-Impact']

In O
the O
GHB O
group O
, O
AWS B-outcome ['Physiological-Clinical']
score O
dropped O
from O
6.6 O
+/- O
2.6 O
to O
1.8 O
+/- O
2.1 O
( O
p O
< O
.01 O
) O
, O
while O
in O
the O
CLO O
group O
, O
the O
score O
dropped O
from O
6 O
+/- O
2.5 O
to O
4.1 O
+/- O
2.4 O
( O
n. O
s. O
) O
. O
['Physiological-Clinical']

The O
endoscopic B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
rates O
at O
4 O
wk O
were O
76 O
% O
and O
79 O
% O
, O
respectively O
, O
and O
cross-over O
treatment O
of O
the O
failures O
for O
a O
further O
4 O
wk O
resulted O
in O
68 O
% O
healing O
with O
cimetidine O
and O
69 O
% O
healing O
with O
sucralfate O
, O
both O
differences O
being O
not O
statistically O
different O
. O
['Physiological-Clinical']

ANIMALS O
Four O
adult O
Standardbred O
geldings O
. O
[]

A O
comparative O
study O
of O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
ibuprofen O
arginate O
versus O
dexibuprofen O
in O
healthy O
volunteers O
. O
['Physiological-Clinical']

The O
Symptom O
Distress O
Scale O
( O
SDS O
) O
, O
Revised O
Piper O
Fatigue O
Scale O
( O
PFS O
) O
, O
and O
the O
State B-outcome ['Life-Impact']
Anxiety I-outcome ['Life-Impact']
Inventory O
( O
SAI O
) O
were O
used O
to O
measure O
symptom O
distress O
. O
['Life-Impact']

CONCLUSION O
The O
longitudinal O
orientation O
of O
a O
rectangular O
defibrillation O
paddle O
provides O
a O
lower O
TTI O
than O
orientation O
horizontally O
. O
[]

Surgery O
was O
performed O
in O
cases O
of O
verified O
infected O
necrosis O
. O
[]

Comparison O
of O
hand-sewn O
and O
stapled O
esophagogastric O
anastomosis O
after O
esophageal O
resection O
for O
cancer O
: O
a O
prospective O
randomized O
controlled O
trial O
. O
[]

The O
two O
groups O
were O
comparable O
at O
entry O
and O
no O
significant O
differences O
between O
the O
groups O
developed O
at O
any O
time O
during O
the O
treatment O
period O
. O
[]

A O
further O
4 O
weeks O
of O
combined O
therapy O
enhanced O
most O
anticoagulant B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
only O
when O
atorvastatin O
was O
added O
to O
quinapril O
. O
['Physiological-Clinical']

Four O
procedures O
used O
for O
conservative O
dentistry O
caused O
bacteremias B-outcome ['Physiological-Clinical']
significantly O
more O
often O
than O
the O
baseline O
value O
of O
9.4 O
% O
: O
polishing O
teeth O
24.5 O
% O
, O
intraligamental O
injection O
96.6 O
% O
, O
rubber O
dam O
placement O
29.4 O
% O
, O
and O
matrix O
band O
with O
wedge O
placement O
32.1 O
% O
. O
['Physiological-Clinical']

Run O
time O
to O
exhaustion O
also O
improved O
significantly O
in O
both O
groups O
, O
23.3 O
and O
33.5 O
% O
, O
respectively O
. O
[]

RESULTS O
Parents O
in O
the O
parent O
+ O
therapist O
group O
demonstrated O
greater O
use O
of O
EMT B-outcome ['Physiological-Clinical']
strategies I-outcome ['Physiological-Clinical']
at O
home O
than O
untrained O
parents O
in O
the O
therapist-only O
group O
, O
and O
these O
effects O
maintained O
over O
time O
. O
['Physiological-Clinical']

After O
a O
2-week O
placebo O
baseline O
period O
, O
children O
were O
randomly O
assigned O
either O
to O
naltrexone O
or O
to O
placebo O
for O
a O
period O
of O
3 O
weeks O
followed O
by O
a O
one-week O
posttreatment O
placebo O
period O
. O
[]

The O
overall O
second O
response O
rate O
was O
28.5 O
% O
( O
34.0 O
% O
to O
MPH-P O
and O
25.3 O
% O
to O
combination O
chemotherapy O
, O
P O
= O
NS O
) O
. O
[]

The O
main O
objective O
of O
the O
STRokE O
DOC O
Arizona O
TIME O
( O
The O
Initial O
Mayo O
Clinic O
Experience O
) O
trial O
was O
to O
determine O
the O
feasibility O
of O
establishing O
, O
de O
novo O
, O
a O
single-hub O
, O
multirural O
spoke O
hospital O
telestroke O
research O
network O
across O
a O
large O
geographical O
area O
in O
Arizona O
by O
replicating O
the O
STRokE O
DOC O
protocol O
. O
[]

Although O
soluble O
tumor O
necrosis O
factor-alpha O
receptor O
II O
concentrations O
at O
baseline O
and O
24 O
weeks O
were O
at O
least O
marginally O
associated O
with O
subsequent O
changes O
in O
BMD B-outcome ['Physiological-Clinical']
( O
P O
= O
0.06 O
and O
P O
= O
0.028 O
, O
respectively O
) O
, O
these O
associations O
were O
no O
longer O
significant O
after O
adjustment O
for O
CD4 O
T O
cell O
count O
. O
['Physiological-Clinical']

Additionally O
, O
discharged O
patients O
who O
are O
not O
well O
linked O
to O
their O
outpatient O
care O
networks O
are O
at O
twice O
the O
risk O
of O
re-hospitalization O
. O
[]

In O
our O
previous O
case-control O
study O
using O
the O
same O
psychological O
task O
, O
when O
making O
decisions O
about O
social O
information O
with O
conflicting O
verbal O
and O
nonverbal O
contents O
, O
participants O
with O
ASD O
made O
judgments O
based O
on O
nonverbal O
contents O
less O
frequently O
with O
longer O
time O
and O
could O
not O
induce O
enough O
activation O
in O
the O
medial O
prefrontal O
cortex O
. O
[]

The O
present O
article O
describes O
the O
first O
home-visiting O
program O
in O
France O
to O
specifically O
target O
mental O
health O
questions O
in O
families O
living O
in O
vulnerable O
contexts O
. O
[]

This O
trial O
involved O
457 O
patients O
and O
sought O
to O
assess O
the O
value O
of O
early O
intensification O
with O
autologous O
transplantation O
in O
patients O
with O
poor O
prognosis O
histologically O
aggressive O
non-Hodgkin O
lymphoma O
( O
NHL O
) O
showing O
a O
response O
to O
initial O
CHOP O
( O
cyclophosphamide O
, O
doxorubicin O
, O
vincristine O
, O
prednisolone O
) O
chemotherapy O
. O
[]

Thirty O
of O
these O
applied O
the O
technique O
of O
dissecting O
the O
ureter O
at O
the O
initiation O
of O
laparoscopic O
hysterectomy O
. O
[]

Completion B-outcome ['Physiological-Clinical']
rates O
will O
be O
compared O
between O
programs O
. O
['Physiological-Clinical']

Among O
the O
cases O
treated O
with O
pyrantel O
, O
the O
egg B-outcome ['Physiological-Clinical']
negative O
conversion B-outcome ['Life-Impact']
['Physiological-Clinical', 'Life-Impact']

Our O
study O
provides O
no O
support O
for O
a O
role O
for O
error O
training O
in O
improving O
skill O
evaluation O
. O
[]

AIM O
To O
compare O
the O
long-term O
effect O
of O
treatment O
with O
a O
stabilization O
appliance O
( O
group O
T O
) O
and O
treatment O
with O
a O
control O
appliance O
( O
group O
C O
) O
in O
temporomandibular O
disorder O
( O
TMD O
) O
patients O
with O
myofascial O
pain O
. O
[]

A O
significant O
difference O
in O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
favour O
of O
paclitaxel/cisplatin O
chemotherapy O
was O
found O
( O
P O
= O
0.001 O
) O
. O
['Mortality']

The O
amount O
of O
activated O
CECs O
was O
detected O
by O
flow O
cytometry O
, O
and O
the O
expression O
of O
survivin O
mRNA O
was O
determined O
by O
real-time O
polymerase O
chain O
reaction O
( O
PCR O
) O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
aldosterone I-outcome ['Physiological-Clinical']
levels O
decreased O
to O
a O
normal O
range O
, O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
both O
increased O
, O
and O
urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
and O
potassium B-outcome ['Physiological-Clinical']
both O
returned O
toward O
normal O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
No O
pre-existing O
differences O
were O
found O
between O
groups O
on O
any O
demographic O
variable O
or O
movement O
scale O
. O
[]

METHODS O
Prospective O
analysis O
was O
employed O
with O
the O
setup O
at O
Alexandria O
IVF/ICSI O
center O
. O
[]

Despite O
ongoing O
allergen O
exposure O
, O
inhaled O
steroids O
reduced O
the O
numbers O
of O
mucosal B-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
, O
neutrophils B-outcome ['Physiological-Clinical']
and O
T B-outcome ['Physiological-Clinical']
lymphocytes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
findings O
indicate O
that O
children O
with O
poor O
mental O
health O
functioning O
living O
in O
communities O
affected O
by O
HIV/AIDS O
may O
benefit O
from O
innovative O
family O
economic O
empowerment O
interventions O
. O
[]

Three O
of O
11 O
subjects O
improved O
in O
two O
or O
more O
settings O
. O
[]

CONCLUSIONS O
Magnesium O
sulphate O
infusion O
may O
be O
used O
as O
an O
adjunct O
for O
reducing O
analgesic B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
after O
spinal O
anaesthesia O
. O
['Resource-use']

The O
second O
group O
was O
composed O
of O
eight O
patients O
with O
L-dopa-induced O
peak-dose O
dyskinesia O
. O
[]

The O
two O
groups O
also O
did O
not O
differ O
on O
the O
muscle B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
testing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Three O
groups O
of O
subjects O
were O
tested O
: O
i O
) O
a O
group O
of O
40-55-year-old O
subjects O
( O
AGE O
group O
; O
N O
= O
11 O
) O
who O
were O
tested O
in O
the O
morning O
, O
ii O
) O
a O
group O
of O
21-35-year-old O
subjects O
( O
CTL O
group O
; O
N O
= O
12 O
) O
who O
were O
also O
tested O
in O
the O
morning O
, O
and O
iii O
) O
a O
group O
of O
21-35-year-olds O
who O
were O
tested O
in O
the O
late O
afternoon O
( O
AFT O
group O
; O
N O
= O
13 O
) O
. O
[]

Non-eosinophilic O
and O
eosinophilic O
asthma O
groups O
had O
increased O
mast B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
numbers I-outcome ['Physiological-Clinical']
in O
the O
airway O
smooth O
muscle O
compared O
with O
normal O
controls O
( O
9 O
vs O
8 O
vs O
0 O
cells/mm O
( O
2 O
) O
, O
p O
= O
0.016 O
) O
. O
['Physiological-Clinical']

Ropivacaine O
, O
congenerate O
to O
bupivacaine O
and O
mepivacaine O
has O
been O
widely O
studied O
in O
laboratory O
animals O
, O
but O
there O
have O
been O
few O
investigations O
of O
its O
efficacy O
in O
human O
epidural O
anesthesia O
and O
peripheral O
nerve O
blocks O
. O
[]

RESULTS O
The O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
significantly O
decreased O
by O
7.13 O
mm O
Hg O
or O
27.59 O
% O
in O
the O
DS O
group O
and O
by O
11.68 O
mm O
Hg O
or O
42.25 O
% O
in O
the O
DSMMC O
group O
at O
the O
end O
of O
the O
follow-up O
period O
. O
['Physiological-Clinical']

Patients O
were O
randomly O
assigned O
to O
receive O
telmisartan O
at O
80 O
mg O
day O
( O
-1 O
) O
( O
n O
= O
15 O
) O
or O
enalapril O
at O
10 O
mg O
day O
( O
-1 O
) O
( O
n O
= O
15 O
) O
. O
[]

A O
lower O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
was O
seen O
with O
both O
PRP O
( O
15 O
% O
) O
and O
PRP-P O
( O
20 O
% O
) O
than O
with O
DTP O
( O
56 O
% O
) O
. O
['Adverse-effects']

In O
the O
present O
study O
the O
effects O
of O
single O
rising O
oral O
doses O
of O
Ro O
15-1788 O
on O
cognitive B-outcome ['Life-Impact']
, O
psychomotor B-outcome ['Life-Impact']
and O
subjective B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
man O
have O
been O
assessed O
using O
a O
battery O
of O
psychometric B-outcome ['Life-Impact']
tests O
designed O
to O
identify O
the O
sedative B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of O
the O
benzodiazepines O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Comparison O
of O
maintenance O
treatment O
regimens O
for O
first O
central O
nervous O
system O
relapse O
in O
children O
with O
acute O
lymphocytic O
leukemia O
. O
[]

In O
addition O
, O
the O
total O
sleep O
time O
, O
time O
spent O
in O
sleep O
stages O
3 O
and O
4 O
, O
and O
rapid O
eye O
movement O
sleep O
phases O
were O
significantly O
longer O
and O
the O
overall O
side-effect B-outcome ['Adverse-effects']
score O
was O
lower O
than O
with O
conventional O
heated O
humidification O
. O
['Adverse-effects']

However O
, O
clearance B-outcome ['Physiological-Clinical']
rates O
at O
week O
52 O
were O
significantly O
different O
: O
43 O
% O
for O
R1 O
and O
88 O
% O
for O
R2 O
( O
95 O
% O
CI O
for O
difference O
: O
11 O
% O
to O
68 O
% O
, O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical']

No O
evidence O
of O
new O
microhemorrhage O
, O
vasogenic O
edema O
, O
or O
meningoencephalitis B-outcome ['Physiological-Clinical']
was O
noted O
. O
['Physiological-Clinical']

Effects O
of O
extended O
release O
methylphenidate O
treatment O
on O
ratings O
of O
attention-deficit/hyperactivity B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
ADHD I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
and O
associated O
behavior B-outcome ['Life-Impact']
in O
children O
with O
autism O
spectrum O
disorders O
and O
ADHD O
symptoms O
. O
['Life-Impact', 'Life-Impact']

Esmolol O
blunts O
the O
cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
increase O
during O
emergence O
from O
anesthesia O
in O
neurosurgical O
patients O
. O
['Physiological-Clinical']

After O
5 O
years O
of O
median O
follow-up O
, O
the O
cumulative O
incidence O
of O
IBR B-outcome ['Physiological-Clinical']
was O
2.5 O
% O
in O
the O
surgery-only O
arm O
and O
0.7 O
% O
in O
the O
surgery O
plus O
RT O
arm O
. O
['Physiological-Clinical']

Intra-articular O
hyaluronic O
acid O
compared O
to O
intra-articular O
triamcinolone O
hexacetonide O
in O
inflammatory O
knee O
osteoarthritis O
. O
[]

P B-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
and O
QRS B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
were O
measured O
from O
SAECG O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
Group O
Spinal O
( O
S O
) O
, O
10 O
mg O
of O
hyperbaric O
tetracaine O
was O
administered O
intrathecally O
. O
[]

The O
side O
effects O
of O
most O
concern O
were O
somnolence B-outcome ['Physiological-Clinical']
and O
weight O
gain O
. O
['Physiological-Clinical']

RESULTS O
Eight O
( O
53 O
% O
) O
of O
15 O
patients O
in O
the O
fluvoxamine-treated O
group O
were O
categorized O
as O
responders O
compared O
with O
none O
of O
15 O
in O
the O
placebo O
group O
( O
P O
= O
.001 O
) O
. O
[]

Neither O
enalapril O
alone O
( O
-2 O
+/- O
2/1 O
+/- O
2 O
mm O
Hg O
, O
NS O
vs. O
placebo O
) O
nor O
eprosartan O
alone O
( O
-1 O
+/- O
1/0 O
+/- O
2 O
mm O
Hg O
, O
NS O
vs. O
placebo O
) O
had O
a O
clear-cut O
significant O
effect O
on O
casual B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
tested O
the O
extent O
to O
which O
systemic O
nitric O
oxide O
synthase O
inhibition O
[ O
N O
( O
G O
) O
-monomethyl-L-arginine O
( O
L-NMMA O
) O
] O
can O
reverse O
the O
drop O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
that O
occurs O
after O
exercise O
in O
humans O
. O
['Physiological-Clinical']

RESULTS O
The O
median O
follow-up O
period O
was O
36 O
months O
. O
[]

In O
humans O
, O
standard O
doses O
of O
H2-receptor O
antagonists O
prevent O
only O
duodenal O
injury O
and O
provide O
no O
protection O
for O
the O
gastric O
mucosa O
. O
[]

The O
primary O
efficacy O
endpoint O
was O
the O
proportion O
of O
subjects O
receiving O
> O
or O
=85 O
% O
relative O
dose O
intensity O
and O
was O
achieved O
by O
96 O
% O
and O
88 O
% O
of O
patients O
in O
the O
FEC O
( O
75 O
) O
and O
FEC O
( O
90 O
) O
arms O
, O
respectively O
. O
[]

The O
safety O
profile O
of O
TISSEEL O
VH O
S/D O
was O
very O
similar O
to O
that O
of O
currently O
licensed O
TISSEEL O
VH O
as O
assessed O
by O
the O
safety O
endpoints O
. O
[]

Active O
treatments O
and O
placebo O
were O
comparable O
as O
far O
as O
concerns O
occurrence O
of O
side-effects O
( O
12-20 O
% O
) O
including O
galactorrhoea B-outcome ['Physiological-Clinical']
, O
breast B-outcome ['Physiological-Clinical']
tenderness I-outcome ['Physiological-Clinical']
and O
menstrual B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
neonates O
were O
randomly O
assigned O
to O
receive O
either O
phenobarbital O
or O
phenytoin O
intravenously O
, O
at O
doses O
sufficient O
to O
achieve O
free O
plasma O
concentrations O
of O
25 O
microg O
per O
milliliter O
for O
phenobarbital O
and O
3 O
microg O
per O
milliliter O
for O
phenytoin O
. O
[]

The O
first O
study O
was O
designed O
to O
assess O
the O
impact O
of O
error O
instruction O
on O
skill B-outcome ['Life-Impact']
acquisition I-outcome ['Life-Impact']
. O
['Life-Impact']

Grade O
> O
or O
[]

No O
differences O
were O
detected O
in O
surgical B-outcome ['Life-Impact']
resection I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
number O
of O
patients O
who O
required O
transfusion B-outcome ['Resource-use']
, O
volume O
and O
number O
of O
transfusion B-outcome ['Resource-use']
units I-outcome ['Resource-use']
, O
or O
type O
and O
volume O
of O
fluid B-outcome ['Physiological-Clinical']
replacement I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Resource-use', 'Resource-use', 'Physiological-Clinical']

The O
patients O
were O
switched O
to O
the O
alternative O
treatment O
in O
the O
second O
period O
. O
[]

No O
significant O
changes O
in O
lipids B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
levels O
were O
observed O
. O
['Physiological-Clinical']

Adjuvant O
portal O
therapy O
of O
the O
liver O
with O
resection O
of O
the O
colorectal O
primary O
malignancy O
seems O
to O
be O
advantageous O
for O
advanced O
tumors O
. O
[]

The O
Low O
Energy O
Safety O
Study O
( O
LESS O
) O
: O
rationale O
, O
design O
, O
patient O
characteristics O
, O
and O
device O
utilization O
. O
[]

Post O
hoc O
analysis O
of O
a O
single O
IV O
infusion O
of O
zoledronic O
acid O
versus O
daily O
oral O
risedronate O
on O
lumbar O
spine O
bone O
mineral O
density O
in O
different O
subgroups O
with O
glucocorticoid-induced O
osteoporosis O
. O
[]

Diastolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
improved O
significantly O
in O
group O
L O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

The O
two-segment O
regression O
time O
was O
199 O
+/- O
80 O
min O
for O
bupivacaine O
, O
201 O
+/- O
52 O
min O
for O
ropivacaine O
, O
and O
174 O
+/- O
81 O
min O
for O
etidocaine O
. O
[]

Changing O
Childbirth O
: O
a O
pilot O
project O
. O
[]

A O
phase O
II O
study O
of O
cetuximab O
, O
capecitabine O
and O
radiotherapy O
in O
neoadjuvant O
treatment O
of O
patients O
with O
locally O
advanced O
resectable O
rectal O
cancer O
. O
[]

Insulin O
sensitivity O
( O
primary O
end O
point O
) O
was O
evaluated O
in O
terms O
of O
the O
Homeostasis O
Model O
Assessment O
for O
Insulin O
Sensitivity O
( O
HOMA-S O
) O
, O
the O
Quantitative O
Insulin O
Sensitivity O
Check O
Index O
( O
QUICKI O
) O
, O
and O
fasting O
serum O
insulin O
( O
FSI O
) O
concentrations O
. O
[]

AIMS O
This O
study O
assessed O
off-the-shelf O
VR O
for O
( O
1 O
) O
its O
effect O
on O
reducing O
acute O
pain O
intensity O
during O
adolescent O
burn O
wound O
care O
, O
and O
( O
2 O
) O
its O
clinical O
utility O
in O
a O
busy O
hospital O
setting O
. O
[]

Forty-two O
healthy O
adult O
subjects O
were O
enrolled O
, O
and O
39 O
subjects O
completed O
period O
1 O
. O
[]

To O
explore O
the O
steady-state O
pharmacokinetic O
profile O
after O
coadministration O
of O
galantamine O
and O
risperidone O
, O
an O
open-label O
, O
randomized O
, O
single-center O
, O
two-way O
crossover O
drug-drug O
interaction O
study O
was O
conducted O
in O
16 O
healthy O
elderly O
subjects O
, O
ages O
60 O
years O
and O
older O
. O
[]

In O
Regimen O
B O
, O
CNS B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
testicular I-outcome ['Physiological-Clinical']
relapses I-outcome ['Physiological-Clinical']
increased O
after O
3 O
years O
of O
CCR O
. O
['Physiological-Clinical']

OBJECTIVE O
This O
is O
the O
first O
study O
to O
assess O
the O
efficacy O
of O
desvenlafaxine O
( O
administered O
as O
desvenlafaxine O
succinate O
) O
for O
improving O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
functioning B-outcome ['Life-Impact']
exclusively O
in O
employed O
patients O
with O
major O
depressive O
disorder O
( O
MDD O
) O
. O
['Life-Impact', 'Life-Impact']

Parents O
completed O
an O
interview O
on O
past O
and O
current O
services O
. O
[]

There O
was O
a O
significant O
sex O
difference O
for O
several O
of O
the O
haemodynamic O
parameters O
under O
baseline O
conditions O
; O
however O
, O
the O
responsiveness O
to O
the O
drugs O
under O
study O
was O
not O
different O
, O
when O
drug O
effects O
were O
expressed O
as O
% O
-change O
from O
the O
baseline O
. O
[]

OBJECTIVE O
Radial O
artery O
spasm O
remains O
a O
major O
complication O
of O
transradial O
coronary O
interventions O
. O
[]

At O
follow-up O
, O
39 O
% O
of O
conservative O
management O
patients O
requested O
surgery O
, O
and O
interference O
of O
symptoms B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

RESULTS O
Interaction O
between O
HFLCS O
and O
bracket O
type O
was O
not O
statistically O
significant O
( O
P O
= O
0.15 O
) O
. O
[]

The O
composite O
endpoint O
of O
death B-outcome ['Mortality']
, O
nonfatal B-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, O
and O
serious B-outcome ['Resource-use']
re-hospitalization I-outcome ['Resource-use']
was O
significantly O
higher O
in O
the O
folate O
group O
; O
serious O
re-hospitalization O
alone O
was O
significantly O
higher O
in O
this O
group O
. O
['Mortality', 'Physiological-Clinical', 'Resource-use']

INTERVENTIONS O
Blood O
samples O
for O
creatine O
kinase O
( O
CK O
) O
, O
CK-myoband O
( O
CK-MB O
) O
mass O
or O
cardiac O
troponin O
( O
cTn O
) O
( O
optional O
) O
were O
collected O
before O
and O
at O
6 O
, O
12 O
and O
18 O
h O
after O
the O
assigned O
percutaneous O
coronary O
intervention O
or O
at O
discharge O
. O
[]

OCT O
revealed O
a O
significantly O
greater O
reduction O
of O
foveal B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
following O
PVD O
with O
ILM O
removal O
[ O
group O
I O
: O
mean O
change O
: O
95 O
% O
CI O
( O
-208.95 O
?m O
; O
-78.05 O
?m O
) O
, O
group O
II O
: O
( O
-80.90 O
?m O
: O
+59.17 O
?m O
) O
] O
. O
['Physiological-Clinical']

The O
response O
to O
chemotherapy O
was O
evaluated O
after O
two O
and O
four O
courses O
. O
[]

injection O
of O
streptozotocin O
( O
STZ O
; O
50 O
mg/kg O
) O
. O
[]

In O
conclusion O
, O
AH O
plus O
sealer O
has O
better O
apical B-outcome ['Physiological-Clinical']
sealing I-outcome ['Physiological-Clinical']
ability I-outcome ['Physiological-Clinical']
and O
adaptation O
to O
dentine O
than O
EndoRez O
sealer O
. O
['Physiological-Clinical']

The O
preoperative O
, O
operative O
, O
and O
postoperative O
characteristics O
of O
both O
groups O
were O
compared O
. O
[]

Local O
injection-site O
reactions B-outcome ['Adverse-effects']
( O
redness B-outcome ['Physiological-Clinical']
, O
swelling B-outcome ['Physiological-Clinical']
, O
pruritus B-outcome ['Physiological-Clinical']
, O
and O
induration B-outcome ['Physiological-Clinical']
) O
were O
less O
frequent O
with O
Perlane O
than O
with O
Zyplast O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
cumulative O
incidence O
at O
20 O
years O
was O
estimated O
at O
0.3 O
% O
and O
3.7 O
% O
in O
the O
CT O
and O
RT O
groups O
, O
respectively O
. O
[]

Large O
randomized O
controlled O
investigations O
are O
warranted O
. O
[]

Blood O
samples O
also O
were O
collected O
to O
determine O
whether O
ketoprofen B-outcome ['Resource-use']
entered O
the O
systemic B-outcome ['Physiological-Clinical']
circulation I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

METHODS O
This O
was O
a O
2-phase O
randomized O
clinical O
trial O
. O
[]

Five O
subjects O
exhibited O
paroxysmal B-outcome ['Physiological-Clinical']
EEG I-outcome ['Physiological-Clinical']
patterns I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
dependent O
variables O
were O
DSM-IV O
Criteria O
for O
Pathological O
Gambling B-outcome ['Life-Impact']
, O
Money B-outcome ['Life-Impact']
Spent I-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
Gambling I-outcome ['Life-Impact']
During O
the O
Last O
Week O
and O
Gamblers B-outcome ['Life-Impact']
Inventory O
of O
Negative O
Consequences B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

CONCLUSIONS O
Otherwise O
healthy O
patients O
, O
average O
age O
of O
60 O
years O
, O
without O
a O
previous O
diagnosis O
of O
malignant O
disease O
who O
have O
small O
choroidal B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
judged O
to O
be O
melanoma O
have O
a O
low O
risk O
of O
dying O
within O
5 O
years O
. O
['Physiological-Clinical']

The O
results O
showed O
that O
the O
complexity O
of O
emitted B-outcome ['Physiological-Clinical']
messages I-outcome ['Physiological-Clinical']
had O
improved O
statistically O
significantly O
in O
the O
trained O
group O
as O
an O
effect O
of O
training O
. O
['Physiological-Clinical']

PURPOSE O
To O
test O
the O
effectiveness O
of O
supplementing O
usual O
supportive O
care O
with O
aromatherapy O
massage O
in O
the O
management O
of O
anxiety O
and O
depression O
in O
cancer O
patients O
through O
a O
pragmatic O
two-arm O
randomized O
controlled O
trial O
in O
four O
United O
Kingdom O
cancer O
centers O
and O
a O
hospice O
. O
[]

[ O
Clinical O
application O
of O
irradiated O
drug-containing O
porcine-cornea O
to O
patients O
with O
ocular O
burns O
] O
. O
[]

Dietary O
intake O
was O
assessed O
at O
3-4 O
y O
of O
age O
for O
345 O
children O
using O
two O
24-h O
food O
recalls O
. O
[]

We O
used O
a O
partial-budget O
analysis O
to O
evaluate O
profitability B-outcome ['Life-Impact']
of O
different O
management O
strategies O
of O
three O
genotypes O
of O
sheep O
in O
a O
2 O
x O
2 O
x O
3 O
factorial O
experiment O
conducted O
at O
Debre O
Berhan O
research O
station O
in O
the O
central O
highlands O
of O
Ethiopia O
. O
['Life-Impact']

OBJECTIVE O
To O
test O
the O
effectiveness O
of O
two O
interventions O
designed O
to O
improve O
the O
adoption O
of O
evidence-based O
practices O
by O
home O
health O
nurses O
caring O
for O
heart O
failure O
( O
HF O
) O
patients O
. O
[]

Plasma O
samples O
were O
collected O
at O
the O
moment O
of O
discontinuation O
of O
infusion O
, O
and O
10 O
, O
20 O
, O
30 O
, O
50 O
, O
60 O
and O
75 O
min O
afterwards O
. O
[]

Effects O
of O
three O
oral O
analgesics O
on O
postoperative O
pain O
following O
root O
canal O
preparation O
: O
a O
controlled O
clinical O
trial O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

CONCLUSIONS O
These O
results O
provide O
further O
evidence O
that O
use O
of O
ecstasy O
may O
be O
associated O
with O
impairment O
of O
memory B-outcome ['Life-Impact']
and O
of O
serotonergic B-outcome ['Physiological-Clinical']
['Life-Impact', 'Physiological-Clinical']

To O
further O
unravel O
this O
paradoxical O
metabolic O
condition O
, O
and O
in O
search O
of O
potential O
therapeutic O
strategies O
, O
we O
measured O
serum O
concentrations O
of O
leptin O
; O
studied O
the O
relationship O
with O
body O
mass O
index O
, O
insulin O
, O
cortisol O
, O
thyroid O
hormones O
, O
and O
somatomedins O
; O
and O
documented O
the O
effects O
of O
hypothalamic O
releasing O
factors O
, O
in O
particular O
, O
GH-secretagogues O
and O
TRH O
. O
[]

Baseline O
clinical O
characteristics O
and O
infarct O
location O
were O
well O
balanced O
in O
both O
groups O
. O
[]

Acid-base O
balance O
and O
peritoneal O
membrane O
longevity O
are O
of O
utmost O
relevance O
for O
pediatric O
patients O
undergoing O
peritoneal O
dialysis O
( O
PD O
) O
. O
[]

There O
have O
been O
impressive O
advances O
in O
endoscopic O
procedures O
during O
recent O
years O
, O
and O
there O
is O
an O
emerging O
trend O
that O
the O
number O
of O
procedures O
is O
increasing O
in O
parallel O
with O
these O
. O
[]

Primary O
efficacy O
criteria O
included O
the O
change O
after O
one O
year O
in O
the O
number O
of O
closed B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
segments I-outcome ['Physiological-Clinical']
and O
the O
occurrence O
of O
postthrombotic O
syndrome O
. O
['Physiological-Clinical']

No O
interactions O
( O
P O
> O
.10 O
) O
between O
source O
of O
dietary O
CP O
and O
level O
of O
RPLM O
were O
observed O
for O
feedlot O
performance O
or O
carcass O
characteristics O
. O
[]

Nine O
( O
16 O
% O
) O
patients O
in O
the O
treatment O
group O
and O
19 O
( O
35 O
% O
) O
in O
the O
placebo O
group O
developed O
deep B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
, O
diagnosed O
by O
the O
125I-fibrinogen O
uptake O
test O
( O
p O
< O
0.02 O
) O
. O
['Physiological-Clinical']

This O
randomized O
controlled O
trial O
compared O
results O
obtained O
after O
12 O
months O
of O
nonintensive O
parent O
training O
plus O
care-as-usual O
and O
care-as-usual O
alone O
. O
[]

However O
, O
in O
attributing O
intentions O
to O
their O
classmates O
, O
older O
children O
and O
girls O
gave O
lower O
ratings O
to O
the O
child O
in O
the O
autism O
conditions O
. O
[]

RESULTS O
Patients O
placed O
on O
indomethacin O
obtained O
relief B-outcome ['Physiological-Clinical']
more O
consistently O
and O
more O
completely O
. O
['Physiological-Clinical']

BACKGROUND O
Endometriosis O
is O
a O
common O
and O
disabling O
gynecologic O
condition O
affecting O
between O
5 O
% O
and O
15 O
% O
of O
women O
of O
childbearing O
age O
. O
[]

Efficacy O
results O
are O
reported O
for O
581 O
patients O
who O
enrolled O
in O
the O
extension O
. O
[]

No O
change O
or O
reduction O
in O
HOA B-outcome ['Physiological-Clinical']
RMS B-outcome ['Physiological-Clinical']
was O
found O
in O
the O
ZAR O
group O
( O
factor O
of O
0.96 O
; O
P O
> O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
returning O
to O
baseline O
, O
Abeta B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
transiently O
increased O
. O
['Physiological-Clinical']

In O
each O
study O
, O
samples O
were O
collected O
in O
a O
subset O
of O
patients O
; O
a O
new O
cohort O
was O
enrolled O
each O
year O
. O
[]

However O
, O
for O
patients O
with O
gram-positive O
bacteremia O
and O
for O
all O
other O
patients O
, O
there O
were O
no O
differences O
by O
treatment O
regimens O
in O
the O
proportion O
of O
febrile B-outcome ['Physiological-Clinical']
patients O
on O
each O
trial O
day O
( O
P O
= O
.85 O
, O
P O
= O
.82 O
, O
respectively O
) O
or O
in O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
( O
P O
= O
.22 O
, O
P O
= O
.93 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
There O
was O
no O
difference O
in O
CAC B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
or O
changes O
in O
bone B-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
between O
the O
calcium O
and O
the O
sevelamer O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

METHODS O
The O
subjects O
were O
112 O
consecutive O
patients O
randomly O
assigned O
either O
to O
receive O
MFF O
( O
group O
1 O
) O
for O
1 O
week O
or O
not O
to O
receive O
MFF O
, O
as O
a O
control O
( O
group O
2 O
) O
, O
after O
hemorrhoidectomy O
, O
The O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
the O
number O
of O
intramuscular B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
injections I-outcome ['Resource-use']
required O
were O
recorded O
for O
the O
first O
3 O
days O
, O
then O
1 O
week O
after O
hemorrhoidectomy O
. O
['Physiological-Clinical', 'Resource-use']

BACKGROUND O
Breastfeeding O
is O
essential O
for O
child O
health O
and O
development O
in O
low-resource O
settings O
but O
carries O
a O
significant O
risk O
of O
transmission O
of O
HIV-1 O
, O
especially O
in O
late O
stages O
of O
maternal O
disease O
. O
[]

We O
tested O
the O
hypothesis O
that O
magnesium O
reduces O
the O
threshold O
( O
triggering O
core O
temperature O
) O
and O
gain O
of O
shivering B-outcome ['Physiological-Clinical']
without O
substantial O
sedation B-outcome ['Physiological-Clinical']
or O
muscle O
weakness O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
the O
efficacy O
and O
safety O
of O
esmolol O
, O
a O
short-acting O
beta O
blocker O
, O
with O
placebo O
in O
the O
treatment O
of O
supraventricular O
tachyarrhythmias O
. O
[]

All O
patients O
had O
paroxysmal O
( O
seven O
patients O
) O
or O
chronic O
( O
three O
patients O
) O
atrial O
fibrillation O
and O
were O
referred O
for O
catheter O
ablation O
of O
the O
atrioventricular O
junction O
. O
[]

By O
the O
end O
of O
anaesthesia O
and O
surgery O
and O
by O
24 O
h O
postoperatively O
, O
IL-2 B-outcome ['Physiological-Clinical']
had O
decreased O
significantly O
in O
the O
halothane O
group O
( O
p O
< O
0.001 O
) O
, O
whereas O
it O
increased O
significantly O
in O
the O
isoflurane O
group O
( O
p O
< O
0.001 O
) O
compared O
with O
pre-incision O
and O
end O
of O
anaesthesia O
and O
surgery O
levels O
, O
respectively O
. O
['Physiological-Clinical']

BACKGROUND O
The O
prehospital O
treatment O
of O
pain O
and O
discomfort O
among O
patients O
who O
suffer O
from O
acute O
coronary O
syndrome O
( O
ACS O
) O
needs O
a O
treatment O
strategy O
which O
combines O
relief O
of O
pain O
with O
relief O
of O
anxiety O
. O
[]

The O
lipid O
profile O
improved O
. O
[]

METHODS O
A O
total O
of O
27 O
infants O
, O
mean O
age O
4.6 O
months O
, O
who O
manifested O
atopic O
eczema O
during O
exclusive O
breast-feeding O
and O
who O
have O
had O
no O
exposure O
to O
any O
infant O
or O
substitute O
formula O
were O
weaned O
to O
probiotic-supplemented O
, O
Bifidobacterium O
lactis O
Bb-12 O
or O
Lactobacillus O
strain O
GG O
( O
ATCC O
53103 O
) O
, O
extensively O
hydrolysed O
whey O
formulas O
or O
to O
the O
same O
formula O
without O
probiotics O
. O
[]

Subsequently O
90 O
% O
in O
the O
study O
group O
defecated B-outcome ['Physiological-Clinical']
, O
compared O
to O
33 O
% O
in O
the O
control O
group O
( O
P O
= O
0.001 O
) O
. O
['Physiological-Clinical']

METHODS O
Long-term O
intraindividual O
BP O
variability O
was O
defined O
as O
the O
coefficient O
of O
variation O
of O
the O
average O
systolic O
or O
diastolic O
values O
of O
clinic O
and O
24-h O
BP O
measured O
at O
each O
visit O
throughout O
the O
treatment O
period O
. O
[]

Data O
on O
average O
pain B-outcome ['Physiological-Clinical']
( O
0-10 O
scale O
) O
were O
collected O
at O
enrollment O
and O
2-week O
follow-up O
. O
['Physiological-Clinical']

Of O
these O
, O
53 O
completed O
the O
full O
8 O
weeks O
of O
data O
collection O
; O
16 O
terminated O
early O
because O
of O
3 O
catheter O
changes O
or O
self-reported O
'UTI O
' O
. O
[]

Baseline O
measures O
included O
demographic O
( O
sex O
, O
age O
, O
weight O
, O
and O
pubertal O
status O
) O
, O
clinical O
, O
and O
family O
measures O
. O
[]

The O
carbon O
fiber-reinforced O
dowel-resin O
core O
system O
reduced O
the O
severity O
of O
the O
root O
fractures O
. O
[]

Assessment O
instructions O
included O
the O
Chinese O
State-Trait O
Anxiety B-outcome ['Life-Impact']
Inventory O
( O
C-STAI O
) O
, O
the O
Quality O
of O
Life O
Index O
for O
Colostomy B-outcome ['Resource-use']
( O
QoL-Colostomy O
) O
and O
the O
Hong O
Kong O
Chinese O
version O
of O
the O
World O
Health O
Organisation O
Quality O
of O
Life O
Scale O
( O
WHOQoL O
['Life-Impact', 'Life-Impact', 'Resource-use', 'Life-Impact']

General O
and O
specific O
warm-up O
routines O
are O
recommended O
to O
enhance O
performance O
. O
[]

RESULTS O
Seven O
percent O
of O
the O
home O
studies O
in O
group O
1 O
, O
and O
33 O
% O
in O
group O
2 O
produced O
no O
interpretable O
data O
because O
of O
artifacts O
( O
p O
< O
0.05 O
) O
. O
[]

This O
study O
's O
objective O
was O
to O
determine O
the O
efficacy O
of O
FloSeal O
hemostatic O
matrix O
( O
Baxter O
Healthcare O
Corporation O
, O
Hayward O
, O
CA O
) O
in O
epistaxis O
refractory O
to O
nasal O
packing O
. O
[]

Pain B-outcome ['Physiological-Clinical']
was O
measured O
on O
a O
valid O
and O
reproducible O
verbal O
numeric O
rating O
scale O
( O
NRS O
) O
ranging O
from O
0 O
to O
10 O
, O
and O
patients O
were O
contacted O
by O
telephone O
approximately O
24 O
hours O
after O
being O
discharged O
. O
['Physiological-Clinical']

Study O
endpoints O
were O
morbidity B-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
, O
need O
for O
postoperative B-outcome ['Resource-use']
mechanical I-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
, O
and O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( I-outcome ['Resource-use']
LOS I-outcome ['Resource-use']
) I-outcome ['Resource-use']
on I-outcome ['Resource-use']
intensive I-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit I-outcome ['Resource-use']
( I-outcome ['Resource-use']
ICU I-outcome ['Resource-use']
) I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Mortality', 'Resource-use', 'Resource-use']

Aerosolized O
pentamidine O
as O
primary O
prophylaxis O
for O
Pneumocystis B-outcome ['Physiological-Clinical']
carinii I-outcome ['Physiological-Clinical']
pneumonia I-outcome ['Physiological-Clinical']
: O
efficacy O
, O
mortality O
and O
morbidity O
. O
['Physiological-Clinical']

After O
a O
mean O
follow-up O
of O
47 O
months O
, O
five O
patients O
( O
12 O
% O
) O
developed O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Abnormalities O
in O
gastrointestinal O
motility O
have O
been O
reported O
in O
a O
substantial O
proportion O
of O
patients O
with O
functional O
dyspepsia O
, O
supporting O
the O
use O
of O
prokinetic O
drugs O
for O
treatment O
of O
dyspeptic O
symptoms O
. O
[]

Group O
1 O
( O
control O
) O
received O
thiopental O
sodium O
4 O
mg/kg O
intravenously O
( O
i.v O
. O
) O
, O
[]

RESULTS O
Only O
19 O
% O
of O
patients O
in O
the O
rhAT O
group O
received O
fresh O
frozen O
plasma O
, O
compared O
with O
81 O
% O
of O
patients O
in O
the O
placebo O
group O
( O
P O
< O
0.001 O
) O
. O
[]

Group O
IV O
) O
. O
[]

There O
was O
no O
difference O
in O
the O
incidence O
of O
grade O
2+ B-outcome ['Physiological-Clinical']
SN I-outcome ['Physiological-Clinical']
between O
the O
two O
arms O
( O
34 O
% O
-vitamin O
E O
, O
29 O
% O
-placebo O
; O
P O
= O
0.43 O
) O
. O
['Physiological-Clinical']

There O
were O
24 O
atherosclerotic B-outcome ['Mortality']
deaths I-outcome ['Mortality']
in O
the O
drug O
treatment O
group O
( O
21.8 O
% O
) O
and O
23 O
in O
the O
placebo O
group O
( O
19.0 O
% O
) O
. O
['Mortality']

Eligible O
patients O
will O
present O
AF O
lasting O
less O
than O
43 O
hours O
, O
will O
be O
in O
stable O
cardio-pulmonary O
condition O
and O
will O
have O
no O
prior O
history O
of O
advanced O
heart O
failure O
or O
significant O
valvular O
disease O
. O
[]

The O
incidence O
of O
neurotoxicity B-outcome ['Physiological-Clinical']
differed O
significantly O
between O
groups O
, O
occurring O
in O
3/16 O
( O
18.7 O
% O
) O
patients O
assigned O
to O
the O
vitamin O
E O
supplementation O
group O
and O
in O
10/16 O
( O
62.5 O
% O
) O
controls O
( O
P=0.03 O
) O
. O
['Physiological-Clinical']

No O
effect O
of O
vitamin B-outcome ['Physiological-Clinical']
E O
within O
the O
drug O
group O
was O
found O
. O
['Physiological-Clinical']

Vincristine O
typically O
impaired O
fine-motor B-outcome ['Physiological-Clinical']
coordination I-outcome ['Physiological-Clinical']
initially O
, O
whereas O
corticosteroids O
were O
associated O
with O
delayed O
development O
of O
proximal B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
weakness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
D-C O
model O
accounted O
for O
15 O
and O
19 O
% O
of O
the O
variance O
in O
caregiver B-outcome ['Life-Impact']
burden I-outcome ['Life-Impact']
, O
after O
controlling O
for O
age O
, O
gender O
and O
relationship O
to O
the O
patient O
. O
['Life-Impact']

Serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
the O
two O
groups O
were O
not O
observed O
. O
['Adverse-effects']

BACKGROUND O
We O
compared O
the O
safety O
and O
immunogenicity O
of O
two O
combined O
diphtheria-tetanus-pertussis-inactivated O
poliovirus O
vaccines O
containing O
either O
acellular O
( O
Pa O
, O
SmithKline O
Beecham O
Biologicals O
) O
or O
whole O
cell O
( O
Pw O
, O
Pasteur O
Merieux O
Connaught O
) O
pertussis O
components O
, O
mixed O
with O
a O
Haemophilus O
influenzae O
type O
b O
polysaccharide O
polyribosylribitol O
phosphate-tetanus O
conjugate O
vaccine O
in O
an O
open O
, O
randomized O
study O
in O
healthy O
infants O
. O
[]

Of O
993 O
eligible O
subjects O
with O
abnormal O
screening O
tests O
randomized O
to O
navigation O
and O
no-navigation O
( O
control O
) O
arms O
and O
analyzed O
, O
628 O
had O
abnormal O
breast O
screens O
( O
66 O
abnormal O
clinical O
breast O
examinations O
, O
304 O
BIRADS O
0 O
, O
200 O
BIRADS O
3 O
, O
58 O
BIRADS O
4 O
or O
5 O
) O
whereas O
235 O
had O
abnormal O
colorectal O
and O
130 O
had O
abnormal O
prostate O
screens O
. O
[]

The O
primary O
end O
point O
was O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
there O
were O
499 O
( O
18 O
% O
) O
and O
447 O
( O
16 O
% O
) O
deaths B-outcome ['Mortality']
in O
the O
losartan O
and O
captopril O
group O
, O
respectively O
( O
p O
= O
0.07 O
) O
. O
['Mortality', 'Mortality']

Each O
patient O
was O
randomly O
assigned O
to O
undergo O
two O
transcranial O
direct O
current O
stimulation O
sessions O
: O
anodal O
dorsolateral O
prefrontal O
cortex O
and O
sham O
stimulation O
within O
48 O
hrs O
of O
a O
washout O
period O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
combined O
preoperative O
xeloda O
and O
pelvic O
radiotherapy O
on O
locally O
advanced O
lower O
rectal O
cancer O
. O
[]

MAIN O
MEASURES O
Gross B-outcome ['Physiological-Clinical']
Motor I-outcome ['Physiological-Clinical']
Function I-outcome ['Physiological-Clinical']
Measure O
( O
dimension O
B O
for O
balance B-outcome ['Physiological-Clinical']
and O
the O
Total O
Score O
) O
and O
Sitting B-outcome ['Life-Impact']
Assessment O
Scale O
were O
carried O
out O
at O
baseline O
( O
prior O
to O
randomization O
) O
, O
end O
of O
intervention O
and O
12 O
weeks O
after O
completing O
the O
intervention O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Approximately O
50 O
adjacent O
, O
but O
not O
overlapping O
, O
laser O
spots O
were O
distributed O
over O
180 O
degrees O
of O
the O
trabecular O
meshwork O
, O
using O
an O
energy O
level O
ranging O
from O
0.7 O
to O
1.0 O
mJ O
per O
pulse O
. O
[]

DESIGN O
, O
SETTING O
, O
AND O
PARTICIPANTS O
Women O
with O
urodynamic O
SUI O
were O
enrolled O
in O
this O
12-mo O
multicenter O
randomized O
study O
. O
[]

At O
M12 O
, O
although O
peripheral O
B-cell O
counts O
did O
not O
differ O
between O
the O
groups O
, O
Tac/MMF O
regimen O
was O
associated O
with O
lower O
IgG O
, O
IgA O
, O
and O
IgM O
levels O
than O
CsA/AZA O
( O
?5.9 O
% O
, O
?14.6 O
% O
, O
and O
?34 O
% O
, O
respectively O
) O
. O
[]

CONCLUSIONS O
Combined O
use O
of O
a O
postural O
support O
roll O
and O
a O
postural O
support O
nappy O
while O
very O
preterm O
infants O
are O
nursed O
prone O
improves O
hip B-outcome ['Physiological-Clinical']
posture I-outcome ['Physiological-Clinical']
up O
to O
term O
postmenstrual O
age O
. O
['Physiological-Clinical']

Three O
hundred O
twenty-five O
women O
with O
metastatic O
adenocarcinoma O
of O
the O
breast O
who O
had O
failed O
one O
prior O
chemotherapeutic O
regimen O
for O
advanced O
disease O
were O
randomized O
to O
receive O
14 O
mg/m2 O
of O
mitoxantrone O
or O
75 O
mg/m2 O
of O
doxorubicin O
intravenously O
( O
IV O
) O
every O
3 O
weeks O
. O
[]

The O
efficacy O
and O
safety O
of O
amlodipine O
( O
5-10 O
mg O
) O
once O
daily O
were O
studied O
in O
an O
open O
study O
in O
patients O
with O
symptomatic O
myocardial O
ischemia O
. O
[]

OBJECTIVE O
To O
investigate O
the O
optimum O
conduit O
for O
coronary O
targets O
other O
than O
the O
left O
anterior O
descending O
artery O
, O
we O
evaluated O
long-term O
patencies O
and O
clinical O
outcomes O
of O
the O
radial O
artery O
, O
right O
internal O
thoracic O
artery O
, O
and O
saphenous O
vein O
through O
the O
Radial O
Artery O
Patency O
and O
Clinical O
Outcomes O
trial O
. O
[]

Olanzapine O
was O
associated O
with O
significant O
weight O
gain O
( O
7.5 O
+/- O
4.8 O
lbs O
vs. O
1.5 O
+/- O
1.5 O
lbs O
on O
placebo O
) O
. O
[]

Results O
revealed O
a O
significant O
interaction O
between O
group O
and O
time O
, O
whereby O
only O
the O
car O
control O
group O
reported O
a O
significant O
change O
( O
i.e. O
, O
decrease O
) O
in O
body B-outcome ['Life-Impact']
dissatisfaction I-outcome ['Life-Impact']
over O
time O
. O
['Life-Impact']

The O
overall B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
rate O
( O
ORR O
) O
was O
55 O
% O
for O
letrozole O
and O
36 O
% O
for O
tamoxifen O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

The O
secondary O
efficacy O
endpoints O
showed O
no O
statistically O
significant O
differences O
between O
the O
two O
arms O
. O
[]

However O
, O
there O
is O
no O
report O
of O
a O
prospective O
randomized O
comparison O
of O
different O
techniques O
. O
[]

Primary B-outcome ['Physiological-Clinical']
target I-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
at O
6 O
months O
were O
66.4 O
% O
and O
39.9 O
% O
for O
CBA O
and O
HPBA O
, O
respectively O
( O
P O
= O
.01 O
) O
. O
['Physiological-Clinical']

Outcome O
measures O
were O
administered O
before O
and O
after O
treatment O
, O
as O
well O
as O
at O
6- O
and O
12-month O
follow-ups O
. O
[]

Intervals B-outcome ['Life-Impact']
between I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
operation I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
return I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
( O
median O
5 O
days O
, O
range O
2-15 O
) O
were O
shorter O
in O
the O
trial O
group O
than O
in O
the O
control O
group O
( O
median O
10 O
days O
, O
range O
2-21 O
; O
p O
< O
0.001 O
) O
, O
as O
well O
as O
the O
intervals O
between O
the O
['Life-Impact']

the O
AQ-J O
score O
was O
significantly O
higher O
in O
the O
HPDD O
( O
mean O
, O
29.6 O
) O
than O
controls O
( O
mean O
, O
22.2 O
) O
] O
. O
[]

METHODS O
We O
conducted O
a O
randomized O
, O
placebo-controlled O
trial O
at O
eight O
centers O
to O
evaluate O
etanercept O
for O
the O
maintenance O
of O
remission O
in O
180 O
patients O
with O
Wegener O
's O
granulomatosis O
. O
[]

Larger O
, O
confirmatory O
studies O
are O
now O
needed O
. O
[]

Other O
randomized O
clinical O
trials O
of O
intraperitoneal O
CT O
are O
reviewed O
and O
briefly O
discussed O
. O
[]

Each O
patient O
was O
randomly O
assigned O
to O
a O
normal O
or O
lower O
compression O
class O
treatment O
, O
with O
respectively O
mean O
values O
of O
15 O
and O
10 O
mmHg O
pressure O
after O
wearing O
the O
garment O
for O
1 O
month O
. O
[]

Lowering O
of O
the O
preoperative O
haematocrit B-outcome ['Physiological-Clinical']
jeopardizes O
the O
aim O
of O
avoidance O
of O
homologous O
blood O
transfusions O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
The O
study O
employed O
a O
randomized O
design O
with O
nurses O
assigned O
to O
usual O
care O
or O
one O
of O
two O
intervention O
groups O
upon O
identification O
of O
an O
eligible O
patient O
. O
[]

Current O
therapy O
with O
beta O
adrenergic O
antagonists O
is O
designed O
to O
moderate O
the O
up-regulation O
of O
norepinephrine O
and O
sympathetic O
effects O
; O
however O
, O
to O
date O
, O
there O
are O
no O
therapies O
that O
specifically O
address O
the O
withdrawal O
of O
parasympathetic O
influences O
on O
cardiac O
function O
and O
structure O
. O
[]

Lung O
function O
measurement O
in O
general O
practice O
: O
a O
comparison O
of O
the O
Escort O
spirometer O
with O
the O
Micromed O
turbine O
spirometer O
and O
the O
mini-Wright O
peak O
flow O
meter O
. O
[]

PATIENTS O
40 O
ASA O
status O
I O
and O
II O
patients O
scheduled O
for O
elective O
surgery O
. O
[]

For O
17 O
children O
( O
11.6 O
% O
) O
, O
no O
explanation O
was O
found O
for O
the O
sleep O
difficulties O
in O
spite O
of O
an O
extensive O
workup O
. O
[]

The O
ongoing B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
transfer I-outcome ['Physiological-Clinical']
cycle I-outcome ['Physiological-Clinical']
was O
significantly O
better O
with O
HCG O
( O
18.7 O
versus O
9.3 O
) O
. O
['Physiological-Clinical']

IFN-beta O
was O
injected O
intramuscularly O
three O
times O
weekly O
at O
9 O
M O
IU O
. O
[]

Leukaemia O
is O
one O
such O
topic O
, O
yet O
there O
are O
no O
reports O
on O
the O
efficacy O
of O
e-learning O
for O
leukaemia O
. O
[]

Medial B-outcome ['Physiological-Clinical']
nail I-outcome ['Physiological-Clinical']
protrusion I-outcome ['Physiological-Clinical']
occurred O
in O
7 O
cases O
in O
the O
operative O
group O
. O
['Physiological-Clinical']

Male O
pseudohermaphrodites O
( O
MPHs O
) O
with O
inherited O
5 O
alpha-reductase O
deficiency O
and O
decreased O
dihydrotestosterone O
production O
have O
a O
global O
defect O
in O
5 O
alpha-metabolism O
affecting O
both O
C19 O
androgen O
metabolism O
and O
C21 O
steroid O
metabolism O
. O
[]

Patients O
were O
retrospectively O
divided O
into O
two O
groups O
: O
patients O
in O
the O
Ca/Mg O
( O
+ O
) O
group O
received O
Ca/Mg O
at O
least O
during O
their O
first O
treatment O
cycle O
, O
and O
patients O
in O
the O
Ca/Mg O
( O
- O
) O
group O
did O
not O
. O
[]

The O
aim O
of O
this O
substudy O
of O
an O
existing O
randomized O
controlled O
trial O
, O
with O
post O
hoc O
analyses O
, O
was O
to O
determine O
the O
impact O
of O
lifestyle O
changes O
aimed O
at O
weight O
reduction O
on O
inflammatory O
biomarkers O
in O
overweight O
patients O
with O
mild O
OSA O
. O
[]

Supplementary O
motor O
area O
involvement O
also O
relied O
on O
the O
predictability O
( O
in O
controls O
) O
or O
presence O
( O
in O
Parkinson O
's O
disease O
) O
of O
timing O
cues O
and O
not O
spatial O
cues O
, O
indicating O
a O
role O
of O
the O
supplementary O
motor O
area O
and O
basal O
ganglia O
in O
the O
temporal O
organizations O
of O
sequential O
movement O
rather O
than O
the O
programming O
of O
specific O
movements O
. O
[]

During O
year O
1 O
, O
total O
Medicaid B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
were O
generally O
higher O
for O
the O
treatment O
group O
than O
for O
the O
control O
group O
, O
with O
treatment-control O
cost O
differences O
ranging O
from O
1 O
percent O
( O
and O
statistically O
insignificant O
) O
for O
the O
elderly O
in O
Florida O
to O
17 O
percent O
for O
the O
elderly O
in O
Arkansas O
. O
['Resource-use']

RESULTS O
Substantial O
observer O
variation O
was O
found O
in O
the O
rating O
of O
sample O
cases O
( O
weighted O
kappa O
, O
0.72 O
; O
confidence O
interval O
, O
0.68-0.75 O
) O
and O
in O
assigning O
outcome O
based O
on O
completed O
structured O
interviews O
( O
weighted O
kappa O
, O
0.61 O
; O
confidence O
interval O
, O
0.57-0.64 O
) O
. O
[]

METHODS O
Safety O
results O
are O
reported O
for O
714 O
patients O
who O
received O
etanercept O
in O
one O
of O
7 O
initial O
trials O
or O
a O
longterm O
extension O
. O
[]

The O
effect O
of O
an O
acute O
reduction O
in O
arterial O
blood O
pressure O
upon O
kidney B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
studied O
in O
12 O
patients O
with O
Type O
1 O
( O
insulin-dependent O
) O
diabetes O
and O
incipient O
nephropathy O
( O
persistent O
microalbuminuria O
) O
. O
['Physiological-Clinical']

Rectal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
thresholds I-outcome ['Physiological-Clinical']
, O
rectal B-outcome ['Physiological-Clinical']
smooth I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
, O
and O
autonomic B-outcome ['Physiological-Clinical']
functioning I-outcome ['Physiological-Clinical']
( O
except O
sweat B-outcome ['Physiological-Clinical']
gland I-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
) O
were O
unaffected O
by O
hypnosis O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
screening O
procedure O
appears O
to O
be O
feasible B-outcome ['Life-Impact']
and O
trial O
participation B-outcome ['Life-Impact']
seems O
to O
be O
acceptable O
to O
a O
relevant O
proportion O
of O
people O
at O
increased O
risk O
of O
developing O
psychosis O
. O
['Life-Impact', 'Life-Impact']

The O
Ca B-outcome ['Physiological-Clinical']
concentration B-outcome ['Physiological-Clinical']
decreased O
significantly O
from O
9.7+/-1.0 O
to O
9.1+/-0.7 O
mg/dL O
after O
the O
change O
to O
sevelamer O
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
is O
understood O
that O
PONV O
is O
a O
multi-factorial O
outcome O
and O
occurs O
more O
often O
with O
general O
anesthesia O
than O
with O
other O
anesthetic O
methods O
. O
[]

Our O
results O
demonstrate O
an O
advantage O
of O
aprotinin O
given O
as O
continuous O
infusion O
over O
bolus O
application O
in O
OLT O
. O
[]

In O
the O
pindolol O
monotherapy O
group O
, O
a O
significant O
reduction O
of O
triglycerides B-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.01 O
) O
and O
a O
significant O
increase O
of O
HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.05 O
) O
were O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
Group O
A O
a O
significant O
decrease O
in O
symptoms B-outcome ['Physiological-Clinical']
score O
and O
in O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( O
PEF B-outcome ['Physiological-Clinical']
) O
-derived O
parameters O
was O
observed O
already O
after O
3 O
months O
of O
treatment O
, O
and O
2 O
patients O
lost O
the O
late B-outcome ['Physiological-Clinical']
component I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
bronchial I-outcome ['Physiological-Clinical']
response O
to O
the O
challenge O
with O
HDM O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Methods O
of O
CVC O
care O
have O
different O
influences O
on O
the O
patients O
' O
clinical B-outcome ['Physiological-Clinical']
and O
psychosocial O
outcomes O
, O
depending O
on O
whether O
they O
were O
hospitalized O
or O
outpatients O
. O
['Physiological-Clinical']

[ O
A O
randomized O
comparative O
study O
of O
surgical O
adjuvant O
chemotherapy O
using O
5-fluorouracil O
and O
dl-leucovorin O
with O
CDDP O
5-FU O
and O
dl-leucovorin O
for O
colorectal O
cancer O
] O
. O
[]

The O
primary O
end O
points O
were O
glycaemic B-outcome ['Physiological-Clinical']
response O
rate O
( O
responders O
being O
predefined O
as O
patients O
who O
achieve O
a O
decrease O
in O
HbA1c O
to O
less O
than O
8 O
% O
or O
a O
reduction O
by O
at O
least O
15 O
% O
as O
compared O
to O
the O
baseline O
values O
) O
and O
the O
daily B-outcome ['Life-Impact']
insulin I-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
at O
6 O
months O
. O
['Physiological-Clinical', 'Life-Impact']

BACKGROUND O
Starvation O
is O
associated O
with O
a O
blunted B-outcome ['Physiological-Clinical']
TSH I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
thyrotropin-releasing B-outcome ['Physiological-Clinical']
hormone B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TRH I-outcome ['Physiological-Clinical']
) O
( O
peak O
minus O
baseline O
< O
5 O
mIU/L O
) O
, O
despite O
basal O
TSH O
and O
thyroid O
hormone O
levels O
within O
the O
normal O
range O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
tumor O
size O
( O
P O
= O
0.07 O
) O
, O
TNM O
stage O
( O
P O
= O
0.39 O
) O
and O
cumulative O
breast B-outcome ['Mortality']
cancer I-outcome ['Mortality']
mortality I-outcome ['Mortality']
rate O
( O
P O
= O
0.72 O
) O
were O
not O
significantly O
different O
between O
the O
2 O
groups O
. O
['Mortality']

RESULTS O
Enrollment O
is O
complete O
( O
702 O
patients O
) O
, O
but O
follow-up O
results O
are O
pending O
. O
[]

The O
cytotoxic B-outcome ['Physiological-Clinical']
dose-intensity I-outcome ['Physiological-Clinical']
of O
standard O
every-4-weeks O
ICE O
is O
100 O
% O
. O
['Physiological-Clinical']

The O
results O
suggest O
that O
zidovudine O
but O
not O
didanosine O
reduces O
intrathecal B-outcome ['Physiological-Clinical']
immunoactivation I-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
HIV-1 I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Each O
of O
the O
subjects O
in O
the O
supplementary O
group O
and O
their O
family O
members O
was O
given O
10 O
mmol O
of O
potassium O
and O
10 O
mmol O
of O
calcium O
mixed O
in O
their O
table O
salt O
daily O
for O
24 O
months O
. O
[]

Limited O
sensory O
blockade O
was O
achieved O
in O
the O
groups O
with O
40 O
ml O
0.5 O
% O
and O
20 O
ml O
1 O
% O
during O
the O
30-minute O
test O
period O
. O
[]

The O
national O
anaemia O
control O
programme O
focuses O
on O
iron O
supplementation O
, O
but O
nutritional O
education O
and O
supervision O
of O
iron O
supplementation O
has O
failed O
in O
different O
regions O
. O
[]

RESULTS O
There O
was O
no O
difference O
in O
the O
baseline O
characteristics O
of O
the O
neonates O
in O
the O
two O
groups O
. O
[]

Primary O
variables O
were O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
PFS O
; O
stratum O
1 O
) O
and O
clinical O
benefit O
rate O
( O
CBR O
; O
stratum O
2 O
) O
. O
['Mortality']

The O
rate O
of O
visualized B-outcome ['Physiological-Clinical']
EBSLN I-outcome ['Physiological-Clinical']
was O
higher O
in O
group O
1 O
( O
66 O
% O
vs O
21 O
% O
; O
P O
= O
.003 O
) O
. O
['Physiological-Clinical']

In O
addition O
, O
the O
patients O
in O
Regimen O
B O
had O
a O
much O
higher O
incidence O
of O
infections B-outcome ['Physiological-Clinical']
than O
Regimen O
A O
. O
['Physiological-Clinical']

BACKGROUND O
This O
randomized O
, O
double-blind O
, O
phase O
II O
study O
assessed O
two O
doses O
of O
the O
selective O
estrogen O
receptor O
modulator O
arzoxifene O
in O
women O
with O
advanced O
breast O
cancer O
. O
[]

Saccade B-outcome ['Physiological-Clinical']
metrics I-outcome ['Physiological-Clinical']
( O
e.g. O
, O
velocity B-outcome ['Physiological-Clinical']
, O
amplitude O
, O
accuracy O
) O
were O
quantified O
and O
compared O
between O
the O
2 O
groups O
for O
the O
3 O
different O
tasks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
trial O
is O
registered O
with O
Current O
Controlled O
Trials O
, O
ISRCTN71468401 O
. O
[]

The O
egg B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hookworm I-outcome ['Physiological-Clinical']
were O
98.1-98.6 O
% O
. O
['Physiological-Clinical']

and O
tinidazole O
500 O
mg O
b.d O
. O
[]

Effect O
of O
sulfasalazine O
on O
inflammation B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
endothelial I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
established O
coronary O
artery O
disease O
. O
['Physiological-Clinical']

The O
rates O
of O
recurrence B-outcome ['Physiological-Clinical']
, O
disease-free B-outcome ['Physiological-Clinical']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
were O
compared O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

The O
primary O
end O
point O
was O
to O
choose O
the O
best O
of O
two O
doses O
of O
arzoxifene O
based O
on O
the O
response O
rate O
or O
the O
clinical O
benefit O
rate O
( O
CBR B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical']

Supplemented O
sheep O
had O
significantly O
higher O
marginal O
profit B-outcome ['Resource-use']
( O
MP O
) O
per O
sheep O
than O
non-supplemented O
sheep O
( O
ETB O
33 O
vs. O
4 O
) O
. O
['Resource-use']

In O
the O
other O
10 O
patients O
the O
second O
flow O
measurement O
was O
performed O
before O
the O
administration O
of O
flumazenil O
. O
[]

Logistic O
regression O
[]

[ O
Effect O
of O
ulinastatin O
on O
inflammatory B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
induced O
by O
oesophagectomy O
] O
. O
['Physiological-Clinical']

Efficacy O
of O
ebrotidine O
and O
ranitidine O
combined O
with O
amoxicillin O
and O
metronidazole O
in O
the O
eradication B-outcome ['Physiological-Clinical']
of O
Helicobacter O
pylori O
in O
patients O
with O
duodenal O
ulcer O
. O
['Physiological-Clinical']

RESULTS O
29 O
% O
of O
the O
study O
participants O
reported O
a O
fall B-outcome ['Life-Impact']
during O
the O
study O
period O
. O
['Life-Impact']

After O
1 O
wk O
, O
a O
similar O
procedure O
with O
the O
other O
drug O
was O
performed O
. O
[]

The O
changes O
induced O
by O
the O
cold O
stress O
in O
the O
cardiovascular B-outcome ['Physiological-Clinical']
variables O
in O
the O
placebo O
and O
propranolol O
experiments O
were O
not O
statistically O
different O
. O
['Physiological-Clinical']

Dose O
response O
effect O
of O
cyclical O
medroxyprogesterone O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
. O
['Physiological-Clinical']

It O
provides O
a O
useful O
prognostic O
tool O
in O
stratifying O
DLBCL O
or O
other O
entities O
in O
future O
, O
even O
when O
frozen O
tissue O
samples O
are O
not O
available O
for O
GEP O
analysis O
. O
[]

Results O
The O
daytime B-outcome ['Physiological-Clinical']
systolic/diastolic I-outcome ['Physiological-Clinical']
ABP I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
HCT O
was O
4.9 O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
1.2-8.6 O
] O
/3.6 O
( O
1.0-6.2 O
) O
mmHg O
for O
men O
and O
12.9 O
( O
9.2-16.6 O
) O
/6.3 O
( O
3.7-8.8 O
) O
mmHg O
for O
women O
. O
['Physiological-Clinical']

The O
remaining O
26 O
subjects O
were O
randomized O
to O
placebo O
or O
treatment O
. O
[]

Thus O
the O
program O
facilitates O
the O
professional O
and O
interpersonal O
learning O
process O
of O
staff O
members O
in O
a O
specific O
way O
with O
success O
as O
well O
as O
with O
limitations O
. O
[]

We O
therefore O
plan O
to O
conduct O
a O
multicenter O
randomized O
controlled O
trial O
comparing O
( O
1 O
) O
ASC O
alone O
, O
( O
2 O
) O
ASC O
plus O
mitomycin O
vinblastine O
and O
cisplatin O
( O
MVP O
) O
, O
and O
( O
3 O
) O
ASC O
plus O
vinorelbine O
( O
N O
; O
Navelbine O
, O
Pierre O
Fabre O
Oncology O
, O
Winchester O
, O
UK O
) O
. O
[]

No O
statistically O
significant O
differences O
were O
found O
between O
the O
powder O
and O
aerosol O
formulations O
with O
respect O
to O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
length O
of O
time O
mean O
FEV1 O
remained O
greater O
than O
or O
equal O
to O
15 O
% O
above O
baseline O
, O
physicians O
' O
assessments O
of O
patients O
' O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
or O
patients O
' O
subjective O
symptom B-outcome ['Physiological-Clinical']
scores O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
urinary B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
was O
markedly O
higher O
and O
['Physiological-Clinical']

The O
authors O
have O
compared O
the O
effects O
of O
oral O
temazepam O
, O
a O
medium O
half-life O
benzodiazepine O
vs O
oral O
zolpidem O
, O
a O
short O
half-life O
non-benzodiazepine O
drug O
, O
vs O
placebo O
. O
[]

The O
patients O
in O
the O
SH O
group O
experienced O
less O
postoperative B-outcome ['Physiological-Clinical']
pain/discomfort I-outcome ['Physiological-Clinical']
as O
scored O
by O
pain O
during O
bowel B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
, O
total O
analgesic B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
over O
the O
first O
3 O
days O
( O
according O
to O
the O
World O
Health O
Organization O
[ O
WHO O
] O
class O
II O
analgesics O
[ O
P O
= O
0.002 O
] O
; O
class O
III O
[ O
P O
= O
0.066 O
] O
) O
, O
and O
per-patient O
consumption O
frequency O
of O
class O
III O
analgesics O
( O
P O
= O
0.089 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

The O
assessment O
of O
nasal-breathing-resistance B-outcome ['Physiological-Clinical']
according O
to O
scores O
was O
defined O
as O
target-parameter O
. O
['Physiological-Clinical']

During O
a O
mean O
follow-up O
period O
of O
1.8 O
years O
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
the O
two O
groups O
included O
death B-outcome ['Mortality']
( O
4.3 O
percent O
in O
the O
aspirin O
group O
vs. O
9.7 O
percent O
in O
the O
warfarin O
group O
; O
hazard O
ratio O
for O
aspirin O
relative O
to O
warfarin O
, O
0.46 O
; O
95 O
percent O
confidence O
interval O
, O
0.23 O
to O
0.90 O
; O
P=0.02 O
) O
, O
major B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
( O
3.2 O
percent O
vs. O
8.3 O
percent O
, O
respectively O
; O
hazard O
ratio O
, O
0.39 O
; O
95 O
percent O
confidence O
interval O
, O
0.18 O
to O
0.84 O
; O
P=0.01 O
) O
, O
and O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
or O
sudden B-outcome ['Mortality']
death I-outcome ['Mortality']
( O
2.9 O
percent O
vs. O
7.3 O
percent O
, O
respectively O
; O
hazard O
ratio O
, O
0.40 O
; O
95 O
percent O
confidence O
interval O
, O
0.18 O
to O
0.91 O
; O
P=0.02 O
) O
. O
['Adverse-effects', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

This O
study O
assessed O
the O
effectiveness O
of O
parent-implemented O
RIT O
using O
a O
multiple-baseline O
design O
across O
three O
young O
children O
with O
autism O
and O
their O
mothers O
. O
[]

Each O
day O
subjects O
completed O
self-report O
diary O
forms O
that O
elicited O
information O
about O
activity O
levels O
, O
and O
the O
occurrence O
of O
symptoms O
and O
side O
effects O
during O
cancer O
treatment O
. O
[]

Both O
groups O
had O
patients O
with O
severe B-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
3 O
each O
) O
and O
fecal B-outcome ['Physiological-Clinical']
incontinence I-outcome ['Physiological-Clinical']
( O
1 O
patient O
each O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
data O
from O
the O
MEND-CABG O
II O
trial O
will O
establish O
whether O
peri- O
and O
postoperative O
treatment O
with O
MC-1 O
can O
decrease O
the O
short- B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
intermediate-term I-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
of O
high-risk O
patients O
undergoing O
CABG O
surgery O
. O
['Physiological-Clinical', 'Mortality']

CONCLUSION O
Early O
acupuncture O
can O
improve O
the O
limb O
motor O
function O
in O
the O
severe O
head O
injury O
patients O
. O
[]

No O
significant O
difference O
in O
the O
rate O
of O
catheter-related B-outcome ['Physiological-Clinical']
bloodstream I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
was O
observed O
between O
the O
groups O
( O
2.1 O
% O
vs O
4.8 O
% O
, O
P O
= O
0.5967 O
) O
. O
['Physiological-Clinical']

Rivaroxaban O
versus O
warfarin O
in O
nonvalvular O
atrial O
fibrillation O
. O
[]

Drugs O
derived O
from O
plants O
, O
for O
which O
no O
precise O
mechanism O
of O
action O
has O
been O
described O
, O
are O
widely O
used O
for O
this O
purpose O
in O
Europe O
. O
[]

Acyclovir O
also O
shortened O
the O
median O
interval O
until O
the O
first O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
( O
4 O
vs. O
7 O
days O
, O
P O
= O
0.005 O
) O
, O
the O
['Physiological-Clinical']

A O
trend O
toward O
a O
reduction O
in O
BALF O
tumor B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor-alpha I-outcome ['Physiological-Clinical']
was O
observed O
on O
study O
day O
7 O
in O
the O
EPA+GLA O
group O
as O
compared O
with O
control O
patients O
. O
['Physiological-Clinical']

METHODS O
Prospective O
study O
of O
104 O
consecutive O
patients O
undergoing O
coronary O
angiography O
who O
were O
randomized O
to O
one O
of O
these O
techniques O
. O
[]

Prediction O
of O
the O
response O
to O
citalopram O
and O
reboxetine O
in O
post-stroke O
depressed O
patients O
. O
[]

Patients O
in O
Group O
D O
also O
requested O
less O
rescue O
anti-emetic O
( O
17 O
% O
) O
than O
those O
in O
Group O
P O
( O
30 O
% O
, O
p O
< O
0.05 O
) O
. O
[]

A O
monitor O
was O
used O
for O
the O
measurement O
of O
cardiovascular O
parameters O
. O
[]

The O
subjects O
were O
randomized O
to O
receive O
either O
a O
combination O
of O
ZDV O
200 O
mg O
three O
times O
per O
day O
, O
ddC O
0.75 O
mg O
three O
times O
per O
day O
, O
and O
SH O
2.5 O
g O
three O
times O
per O
day O
or O
a O
combination O
of O
ZDV O
200 O
mg O
three O
times O
per O
day O
, O
ddC O
0.75 O
mg O
three O
times O
per O
day O
, O
and O
placebo O
2.5 O
g O
three O
times O
per O
day O
for O
24 O
weeks O
. O
[]

BACKGROUND O
Although O
chlorhexidine-based O
solutions O
and O
alcohol-based O
povidone-iodine O
have O
been O
shown O
to O
be O
more O
efficient O
than O
aqueous O
povidone-iodine O
for O
skin O
disinfection O
at O
catheter O
insertion O
sites O
, O
their O
abilities O
to O
reduce O
catheter-related B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
have O
never O
been O
compared O
. O
['Physiological-Clinical']

DESIGN O
the O
study O
was O
conceptualized O
based O
on O
Rosenstock O
and O
Becker O
's O
health O
belief O
model O
. O
[]

15 O
patients O
received O
metronidazole O
and O
16 O
tinidazole O
, O
in O
random O
order O
. O
[]

The O
authors O
have O
studied O
indices O
of O
natriuretic O
peptide O
and O
oxidative O
stress O
in O
patients O
with O
chronic O
heart O
failure O
( O
CHF O
) O
. O
[]

Patients O
undergoing O
various O
anterior O
segment O
surgery O
procedures O
were O
randomly O
assigned O
to O
1-QST O
or O
retrobulbar O
anesthesia O
; O
300 O
patients O
were O
operated O
with O
1-QST O
and O
the O
results O
were O
compared O
with O
270 O
patients O
operated O
with O
retrobulbar O
anesthesia O
. O
[]

OBJECTIVE O
Several O
experimental O
and O
clinical O
studies O
indicate O
that O
the O
renin O
system O
may O
play O
a O
pivotal O
role O
in O
progressing O
renal O
disease O
. O
[]

The O
women O
in O
study O
group O
1 O
received O
local O
estrogen O
cream O
; O
study O
group O
2 O
received O
local O
estrogen O
and O
testosterone O
cream O
; O
the O
control O
group O
received O
nonhormonal O
lubricant O
KY O
gel O
for O
12 O
weeks O
. O
[]

Randomized O
controlled O
trial O
of O
electro-acupuncture O
for O
autism O
spectrum O
disorder O
. O
[]

Losartan O
was O
better O
tolerated B-outcome ['Life-Impact']
than O
captopril O
with O
fewer O
patients O
discontinuing B-outcome ['Life-Impact']
medication I-outcome ['Life-Impact']
( O
17 O
versus O
23 O
% O
for O
losartan O
and O
captopril O
, O
respectively O
) O
. O
['Life-Impact', 'Life-Impact']

6 O
. O
[]

Also O
, O
the O
upper O
95 O
% O
confidence O
limit O
of O
5 O
inflammatory O
lesions O
has O
satisfied O
the O
noninferiority O
criterion O
. O
[]

48/50 O
patients O
have O
progressed B-outcome ['Physiological-Clinical']
and O
42 O
have O
died B-outcome ['Mortality']
, O
mostly O
due O
to O
prostate O
cancer O
. O
['Physiological-Clinical', 'Mortality']

0.28 O
mm O
) O
and O
least O
( O
P O
= O
0.003 O
) O
for O
CC O
steers O
( O
11.0 O
? O
[]

Except O
for O
Anopheles O
annularis O
, O
which O
showed O
no O
apparent O
preference B-outcome ['Life-Impact']
( O
51 O
% O
outdoor O
biting O
) O
, O
all O
major O
species O
showed O
a O
strong O
preference B-outcome ['Physiological-Clinical']
for O
outdoor B-outcome ['Physiological-Clinical']
biting I-outcome ['Physiological-Clinical']
; O
Anopheles O
epiroticus O
( O
79 O
% O
) O
, O
Anopheles O
subpictus O
( O
72 O
% O
) O
, O
Anopheles O
maculatus O
( O
92 O
% O
) O
, O
Anopheles O
aconitus O
( O
85 O
% O
) O
and O
Anopheles O
vagus O
( O
72 O
% O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Only O
the O
glucose B-outcome ['Physiological-Clinical']
levels O
of O
patients O
who O
received O
no O
carbohydrate-containing O
infusion O
fluids O
were O
used O
for O
evaluation O
of O
the O
stress O
response O
. O
['Physiological-Clinical']

Women O
categorized O
in O
the O
high-risk O
group O
for O
developing O
cervical O
cancer O
( O
> O
2 O
sexual O
partners O
, O
age O
< O
18 O
years O
at O
first O
sexual O
intercourse O
, O
smoker O
; O
treated O
for O
sexually O
transmitted O
disease O
[ O
STD O
] O
or O
partner O
with O
treated O
STD O
) O
significantly O
( O
OR O
1.88 O
; O
1.54 O
, O
2.28 O
, O
p O
< O
0.001 O
) O
increased O
Pap B-outcome ['Life-Impact']
test I-outcome ['Life-Impact']
completion I-outcome ['Life-Impact']
. O
['Life-Impact']

Using O
a O
novel O
wound O
model O
to O
investigate O
the O
healing B-outcome ['Physiological-Clinical']
properties I-outcome ['Physiological-Clinical']
of O
products O
for O
superficial O
wounds O
. O
['Physiological-Clinical']

Effects O
of O
a O
caregiver O
intervention O
on O
negative O
caregiver O
appraisals O
of O
behavior O
problems O
in O
patients O
with O
Alzheimer O
's O
disease O
: O
results O
of O
a O
randomized O
trial O
. O
[]

The O
volume O
in O
the O
pelvic B-outcome ['Physiological-Clinical']
drain I-outcome ['Physiological-Clinical']
20 O
min O
post-operatively O
and O
after O
48 O
hours O
failed O
to O
reach O
statistical O
significance O
between O
the O
two O
groups O
( O
P= O
0.10 O
and O
P= O
0.165 O
) O
. O
['Physiological-Clinical']

RESULTS O
The O
incidence O
of O
DIND O
was O
lower O
in O
the O
pTBA O
group O
( O
P=0.30 O
) O
and O
fewer O
patients O
required O
therapeutic O
angioplasty O
to O
treat O
DIND O
( O
P=0.03 O
) O
. O
[]

Genital B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
in O
healthy O
women O
with O
and O
without O
sexual O
arousal O
disorder O
. O
['Physiological-Clinical']

The O
results O
are O
discussed O
in O
terms O
of O
their O
implications O
for O
the O
need O
for O
more O
effective O
treatments O
in O
general O
, O
and O
the O
role O
of O
individual O
differences O
in O
the O
likelihood O
of O
returning B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
smoking I-outcome ['Life-Impact']
following I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
for O
quitting O
. O
['Life-Impact']

Data O
were O
obtained O
from O
health O
plan O
administrative O
data O
files O
supplemented O
by O
medical O
chart O
review O
. O
[]

METHODS O
Patients O
above O
18 O
years O
with O
a O
rectal O
cancer O
, O
able O
to O
give O
informed O
consent O
, O
and O
scheduled O
for O
an O
anterior O
resection O
were O
eligible O
for O
the O
study O
. O
[]

For O
treated O
diabetics O
, O
five-year O
survival B-outcome ['Mortality']
was O
significantly O
better O
after O
CABG O
than O
after O
PTCA O
. O
['Mortality']

METHOD O
Caregivers O
( O
n O
= O
77 O
) O
of O
the O
cognitively O
impaired O
living O
at O
home O
were O
randomized O
to O
receive O
nurse O
counseling O
or O
not O
. O
[]

Parameters O
studied O
were O
body O
weight O
, O
oestrus O
incidences O
, O
plasma O
oestradiol O
17-? O
, O
plasma O
progesterone O
, O
conception O
rate O
, O
gestation O
period O
, O
lambing O
rate O
, O
and O
birth O
weight O
of O
lambs O
. O
[]

Current O
treatment O
is O
based O
on O
glucose O
loading O
and O
parenteral O
haem O
replenishment O
, O
which O
reduce O
the O
accumulation O
of O
5-aminolevulinic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
and O
porphobilinogen B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Clinical B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
was O
associated O
with O
( O
i O
) O
placebo O
treatment O
( O
adjusted O
OR O
= O
1.28 O
, O
95 O
% O
CI O
: O
1.01 O
to1.62 O
) O
, O
( O
ii O
) O
excess B-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
of O
> O
10 O
breaths B-outcome ['Physiological-Clinical']
per O
minute O
( O
adjusted O
OR O
= O
1.51 O
, O
95 O
% O
CI O
: O
1.19 O
, O
1.92 O
) O
, O
( O
iii O
) O
vomiting B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
enrolment I-outcome ['Physiological-Clinical']
( O
adjusted O
OR O
= O
1.49 O
, O
95 O
% O
CI O
: O
1.13 O
, O
1.96 O
) O
, O
( O
iv O
) O
history O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
significant O
differences O
among O
the O
groups O
in O
terms O
of O
clinical B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
rates O
( O
clinical O
cure O
or O
improvement O
: O
89 O
% O
for O
clarithromycin O
, O
82 O
% O
for O
roxithromycin O
, O
and O
73 O
% O
for O
erythromycin O
stearate O
, O
p O
= O
0.32 O
) O
. O
['Physiological-Clinical']

Compared O
to O
effects O
of O
oral O
intake O
of O
oxibutinin O
, O
such O
method O
was O
two O
times O
more O
effective O
in O
relation O
to O
overactive B-outcome ['Physiological-Clinical']
bladder I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
shorter O
duration O
of O
the O
treatment O
and O
reduced O
side O
effects O
. O
['Physiological-Clinical']

The O
role O
of O
the O
MA-sensitive O
chemotaxis O
in O
rheumatoid O
arthritis O
could O
thus O
be O
elucidated O
by O
a O
clinical O
trial O
of O
griseofulvin O
treatment O
. O
[]

There O
was O
significantly O
less O
severe O
and O
less O
frequent O
toxicity B-outcome ['Adverse-effects']
with O
mitoxantrone O
administration O
. O
['Adverse-effects']

15 O
of O
29 O
patients O
rated O
themselves O
as O
better O
after O
completing O
exercise O
treatment O
compared O
with O
eight O
of O
30 O
patients O
who O
completed O
flexibility O
treatment O
. O
[]

14.7 O
% O
with O
and O
without O
music O
, O
respectively O
; O
p O
? O
[]

Severe B-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
were O
observed O
in O
8.5 O
% O
of O
the O
patients O
after O
photon O
therapy O
compared O
with O
3.8 O
% O
after O
neutron O
therapy O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
growth B-outcome ['Physiological-Clinical']
and O
incidence O
of O
malnutrition B-outcome ['Physiological-Clinical']
in O
infants O
receiving O
long-term O
dietary O
supplementation O
with O
ready-to-use O
fortified O
spread O
( O
FS O
) O
or O
micronutrient-fortified O
maize-soy O
flour O
( O
likuni O
phala O
[ O
LP O
] O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
this O
randomized O
, O
double-blind O
trial O
, O
we O
assigned O
3445 O
patients O
with O
symptomatic O
heart O
failure O
and O
a O
left O
ventricular O
ejection O
fraction O
of O
45 O
% O
or O
more O
to O
receive O
either O
spironolactone O
( O
15 O
to O
45 O
mg O
daily O
) O
or O
placebo O
. O
[]

It O
is O
concluded O
that O
oral O
diuretics O
improve O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
infants O
with O
chronic O
bronchopulmonary O
dysplasia O
; O
however O
, O
potassium O
and O
phosphorus O
depletion O
are O
potential O
complications O
of O
treatment O
. O
['Physiological-Clinical']

The O
diltiazem O
was O
administered O
from O
100 O
microg/min O
at O
the O
initiation O
of O
treatment O
, O
the O
largest O
dosage O
was O
200 O
- O
300 O
microg/min O
; O
the O
nitroglycerin O
was O
administered O
from O
20 O
microg/min O
at O
the O
initiation O
of O
treatment O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
three O
hypotensive O
techniques O
in O
their O
effects O
on O
the O
hormonal O
and O
metabolic O
response O
, O
although O
the O
increase O
in O
[]

Two O
cohorts O
of O
participants O
were O
included O
to O
investigate O
the O
effects O
of O
different O
treadmill O
interventions O
on O
walking B-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
and O
gait B-outcome ['Life-Impact']
patterns I-outcome ['Life-Impact']
in O
infants O
with O
Down O
syndrome O
( O
DS O
) O
. O
['Life-Impact', 'Life-Impact']

In O
addition O
, O
roxithromycin B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
also O
determined O
in O
gastric O
juice O
and O
gastric O
tissue O
obtained O
during O
endoscopy O
. O
['Physiological-Clinical']

RESULTS O
Patients O
in O
the O
fluticasone O
propionate O
groups O
experienced O
a O
mean O
increase O
from O
baseline O
to O
endpoint O
in O
FEV1 B-outcome ['Physiological-Clinical']
ranging O
from O
0.43 O
L O
to O
0.47 O
L. O
Patients O
in O
the O
placebo O
group O
experienced O
a O
mean O
decrease O
from O
baseline O
of O
0.22 O
L O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

PATIENTS O
83 O
patients O
with O
osteoarthritis O
of O
the O
knee O
who O
were O
randomly O
assigned O
to O
receive O
treatment O
( O
n O
= O
42 O
; O
15 O
men O
and O
27 O
women O
[ O
mean O
age O
, O
60 O
+/- O
11 O
years O
] O
) O
or O
placebo O
( O
n O
= O
41 O
; O
19 O
men O
and O
22 O
women O
[ O
mean O
age O
, O
62 O
+/- O
10 O
years O
] O
) O
. O
[]

The O
estimation O
of O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
is O
important O
for O
the O
medical O
treatment O
of O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
. O
['Physiological-Clinical']

In O
one O
, O
saline O
was O
administered O
; O
in O
another O
, O
a O
2-micrograms/kg O
bolus O
of O
clonidine O
was O
followed O
by O
an O
infusion O
at O
2 O
micrograms.kg-1.h-1 O
, O
and O
on O
a O
third O
day O
, O
a O
4-micrograms/kg O
bolus O
was O
followed O
by O
an O
infusion O
at O
4 O
micrograms.kg-1.h-1 O
. O
[]

RESULTS O
The O
median O
follow-up O
for O
survivors B-outcome ['Mortality']
was O
7 O
years O
, O
and O
the O
median O
patient O
age O
was O
43 O
years O
. O
['Mortality']

Because O
the O
aim O
of O
prostate O
cancer O
detection O
is O
to O
find O
cancers O
at O
an O
early O
, O
potentially O
curable O
stage O
, O
it O
is O
of O
major O
interest O
that O
71.8 O
% O
of O
evaluable O
cancers O
were O
clinical O
stage O
B O
; O
8.4 O
% O
and O
10.7 O
% O
were O
stages O
C1 O
and O
C2 O
, O
respectively O
; O
only O
9.2 O
% O
were O
stage O
D O
( O
metastatic O
) O
at O
first O
visit O
while O
none O
was O
at O
stage O
D O
at O
follow-up O
visits O
. O
[]

A O
limited O
sampling O
model O
has O
been O
developed O
for O
flunarizine O
following O
a O
30 O
mg O
oral O
dose O
in O
epileptic O
patients O
who O
were O
receiving O
phenytoin O
or O
carbamazepine O
or O
both O
, O
to O
estimate O
the O
area O
under O
the O
curve O
( O
AUC O
) O
and O
maximum O
plasma O
concentration O
( O
Cmax B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
directly O
examine O
whether O
oxytocin O
has O
beneficial O
effects O
on O
the O
sociocommunicational O
deficits O
of O
ASD O
using O
both O
behavioral O
and O
neural O
measures O
. O
[]

Patients O
who O
were O
nonadherent O
to O
medication O
regimens O
were O
more O
likely O
to O
relapse B-outcome ['Life-Impact']
. O
['Life-Impact']

Analyzed O
on O
an O
intention-to-treat O
basis O
, O
123 O
( O
20 O
% O
) O
in O
the O
placebo O
group O
died B-outcome ['Mortality']
, O
versus O
94 O
( O
15 O
% O
) O
in O
the O
warfarin O
group O
, O
a O
risk O
reduction O
of O
24 O
% O
( O
P O
= O
0.026 O
) O
. O
['Mortality']

Optimized O
strategy O
for O
detection O
of O
early O
stage O
, O
curable O
prostate O
cancer O
: O
role O
of O
prescreening O
with O
prostate-specific O
antigen O
. O
[]

To O
confirm O
this O
hypothesis O
, O
a O
multicenter O
randomized O
trial O
of O
CCBs O
treatment O
with O
azelnidipine O
or O
amlodipine O
will O
be O
conducted O
in O
hypertensive O
CAD O
patients O
undergoing O
elective O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
[]

Unpacking O
attitude O
certainty O
: O
attitude O
clarity O
and O
attitude O
correctness O
. O
[]

The O
most O
effective O
treatment O
regimen O
was O
VAC O
plus O
ADR O
; O
74 O
% O
of O
the O
patients O
were O
free O
of O
disease O
at O
2 O
years O
. O
[]

The O
sound O
, O
either O
a O
500-Hz O
low-pass O
noise O
or O
a O
6300-Hz O
high-pass O
noise O
, O
repeatedly O
traversed O
a O
semicircular O
arc O
in O
the O
observer O
's O
front O
hemifield O
at O
ear O
level O
( O
distance O
: O
1.5 O
m O
) O
. O
[]

This O
prospective O
, O
randomized O
study O
comprised O
120 O
patients O
who O
had O
ST-elevation O
myocardial O
infarction O
that O
was O
treated O
within O
12 O
hours O
from O
symptom O
onset O
with O
a O
high O
dose O
of O
GIK O
( O
25 O
% O
glucose O
, O
50 O
IU O
of O
soluble O
insulin O
per O
liter O
, O
and O
80 O
mmol O
of O
potassium O
chloride O
per O
liter O
at O
1 O
ml/kg/hour O
over O
24 O
hours O
) O
as O
adjunct O
to O
thrombolytic O
therapy O
( O
1.5 O
MU O
of O
streptokinase/30 O
to O
60 O
minutes O
; O
GIK O
group O
) O
or O
thrombolytic O
therapy O
alone O
( O
control O
group O
) O
. O
[]

The O
most O
common O
laboratory O
abnormality O
was O
anemia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

During O
the O
trial O
no O
evidence O
of O
renal B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical']

Similar O
decreases O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
seen O
24 O
h O
after O
the O
last O
dose O
of O
perindopril O
or O
hydrochlorothiazide O
( O
11/7 O
mm O
Hg O
supine O
) O
given O
alone O
at O
these O
doses O
. O
['Physiological-Clinical']

After O
medical O
screening O
all O
participants O
were O
evaluated O
before O
and O
after O
12 O
weeks O
in O
which O
the O
experimental O
subjects O
underwent O
a O
low O
intensity O
training O
. O
[]

during O
a O
48-week O
period O
. O
[]

The O
FLT3ITD O
mRNA O
level O
has O
a O
high O
prognostic O
impact O
in O
NPM1 O
mutated O
, O
but O
not O
in O
NPM1 O
unmutated O
, O
AML O
with O
a O
normal O
karyotype O
. O
[]

Change O
in O
behavioral O
ratings O
from O
pretest O
to O
post-test O
showed O
significant O
differences O
in O
motivational O
interviewing O
skills O
between O
the O
experimental O
and O
control O
groups O
. O
[]

FUNDING O
Australian O
National O
Health O
and O
Medical O
Research O
Council O
, O
Cancer O
Council O
New O
South O
Wales O
, O
Pfizer O
, O
Merck O
, O
Gilead O
Sciences O
. O
[]

For O
14 O
days O
, O
patients O
recorded O
pain O
levels O
twice O
daily O
using O
a O
visual O
analogue O
scale O
. O
[]

Thirty-two O
patients O
with O
impingement O
syndrome O
underwent O
subacromial O
decompression O
in O
the O
course O
of O
arthroscopic O
shoulder O
surgery O
. O
[]

Few O
reports O
on O
barriers O
, O
however O
, O
have O
focused O
on O
the O
young O
black O
man O
with O
HBP O
, O
the O
age/sex/race O
group O
with O
the O
highest O
rates O
of O
early O
severe O
and O
complicated O
HBP O
and O
the O
lowest O
rates O
of O
awareness O
, O
treatment O
, O
and O
control O
. O
[]

The O
present O
submission O
summarizes O
a O
second O
clinical O
trial O
, O
to O
be O
included O
in O
the O
panitumumab O
package O
insert O
in O
June O
2008 O
, O
of O
chemotherapy O
and O
bevacizumab O
with O
and O
without O
panitumumab O
in O
the O
first-line O
treatment O
of O
patients O
with O
metastatic O
colorectal O
cancer O
. O
[]

RESULTS O
A O
pool O
of O
108 O
patients O
was O
randomly O
divided O
into O
two O
groups O
. O
[]

Excess O
pharmaceutical O
and O
pad O
and O
tampon O
costs B-outcome ['Resource-use']
were O
$ O
333 O
per O
patient O
per O
year O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
$ O
263- O
$ O
403 O
) O
. O
['Resource-use']

RESULTS O
Twenty-seven O
patients O
participated O
in O
the O
study O
. O
[]

Effect O
of O
esomeprazole O
on O
nighttime O
heartburn O
and O
sleep O
quality O
in O
patients O
with O
GERD O
: O
a O
randomized O
, O
placebo-controlled O
trial O
. O
[]

Best O
results O
were O
obtained O
for O
the O
polyurethane O
and O
hydrocolloid O
products O
, O
which O
had O
high O
mean O
scores O
close O
to O
the O
maximum O
of O
10 O
. O
[]

After O
six O
months O
there O
was O
already O
a O
significant O
difference O
in O
favour O
of O
the O
group O
treated O
with O
intranasal O
Bdp O
. O
[]

INTERVENTION O
Patients O
were O
randomised O
to O
receive O
topical O
gauze O
sponges O
soaked O
in O
either O
1:500 O
RA O
or O
0.9 O
% O
sodium O
chloride O
( O
physiological O
saline O
) O
for O
3 O
min O
after O
adenoidectomy O
. O
[]

A O
comparison O
of O
the O
upper O
lip O
bite O
test O
( O
a O
simple O
new O
technique O
) O
with O
modified O
Mallampati O
classification O
in O
predicting O
difficulty O
in O
endotracheal B-outcome ['Resource-use']
intubation I-outcome ['Resource-use']
: O
a O
prospective O
blinded O
study O
. O
['Resource-use']

Beta-blockers O
with O
less O
cardiodepressive O
effect O
than O
traditional O
nonselective O
beta O
( O
1+2 O
) O
-blocking O
agents O
could O
be O
useful O
in O
the O
treatment O
of O
hypertension O
, O
provided O
the O
reduction O
in O
blood O
pressure O
was O
satisfactory O
. O
[]

RESULTS O
After O
the O
first O
2-tablet O
dose O
, O
patients O
took O
on O
average O
2.5 O
additional O
tablets O
of O
diclofenac-K O
or O
2.4 O
tablets O
of O
paracetamol O
, O
almost O
all O
as O
1-tablet O
doses O
. O
[]

METHODS O
Fifty O
toddlers O
with O
ASD O
, O
ages O
21 O
to O
33 O
months O
, O
were O
randomized O
to O
one O
of O
two O
six-month O
interventions O
: O
Interpersonal O
Synchrony O
or O
Non-Interpersonal O
Synchrony O
. O
[]

The O
primary O
outcome O
measure O
was O
gain O
in O
knowledge B-outcome ['Life-Impact']
of O
the O
Child O
Health O
core O
curriculum O
that O
is O
covered O
in O
the O
outpatient O
setting O
. O
['Life-Impact']

Long-term O
exposure O
to O
belatacept O
in O
recipients O
of O
extended O
criteria O
donor O
kidneys O
. O
[]

The O
main O
outcome O
was O
the O
frequency O
of O
severe B-outcome ['Physiological-Clinical']
exacerbations I-outcome ['Physiological-Clinical']
over O
a O
6-month O
period O
. O
['Physiological-Clinical']

Intra-luminal O
nicotine O
reduces O
smooth O
muscle O
tone O
and O
contractile O
activity O
in O
the O
distal O
large O
bowel O
. O
[]

Patients O
in O
both O
arms O
were O
well O
balanced O
with O
regard O
to O
clinical O
variables O
. O
[]

The O
IFN O
group O
received O
daily O
intravenous O
injections O
of O
rFeIFN-omega O
( O
2.5 O
MU/kg O
) O
for O
three O
consecutive O
days O
. O
[]

A O
double-blind O
, O
placebo-controlled O
study O
was O
designed O
to O
assess O
critically O
the O
effects O
of O
naltrexone O
on O
behavioral B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
learning B-outcome ['Life-Impact']
in O
autistic O
children O
, O
and O
its O
safety O
. O
['Life-Impact', 'Life-Impact']

DESIGN O
Randomized O
, O
controlled O
, O
blind O
, O
prospective O
clinical O
study O
. O
[]

Using O
a O
visual O
analogue O
pain B-outcome ['Physiological-Clinical']
scale O
, O
patients O
reported O
that O
significantly O
reduced O
pain B-outcome ['Physiological-Clinical']
was O
experienced O
over O
the O
first O
4 O
days O
postoperatively O
with O
the O
diflunisal/bupivacaine O
treatment O
and O
patient B-outcome ['Life-Impact']
preference I-outcome ['Life-Impact']
for O
this O
treatment O
was O
highly O
significant O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

STUDY O
DESIGN O
Sixty O
subjects O
with O
autism O
were O
randomly O
selected O
and O
assigned O
to O
either O
treatment O
or O
placebo O
group O
. O
[]

CONCLUSION O
Home O
sleep O
studies O
are O
a O
viable O
form O
of O
diagnosing O
SAHS O
, O
and O
are O
less O
expensive B-outcome ['Life-Impact']
than O
polysomnography O
. O
['Life-Impact']

In O
the O
original O
study O
280 O
patients O
in O
the O
white O
light O
cystoscopy O
group O
and O
271 O
in O
the O
fluorescence O
cystoscopy O
group O
were O
followed O
with O
cystoscopy O
for O
3 O
, O
6 O
and O
9 O
months O
after O
initial O
resection O
or O
until O
recurrence O
. O
[]

Mild B-outcome ['Physiological-Clinical']
genital I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
reported O
in O
42 O
% O
of O
CS O
users O
( O
itching B-outcome ['Physiological-Clinical']
, O
burning B-outcome ['Physiological-Clinical']
, O
tingling B-outcome ['Physiological-Clinical']
, O
testicular B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
dysuria B-outcome ['Physiological-Clinical']
, O
and O
warm B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
cold I-outcome ['Physiological-Clinical']
feeling I-outcome ['Physiological-Clinical']
) O
and O
8 O
% O
of O
KY O
Jelly O
users O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
tested O
whether O
providing O
physicians O
with O
their O
patients O
' O
results O
on O
the O
alcohol O
module O
of O
the O
Diagnostic O
Interview O
Schedule O
and O
counseling O
directives O
would O
prompt O
them O
to O
counsel O
these O
patients O
. O
[]

DESIGN O
A O
longitudinal O
study O
design O
where O
a O
cohort O
was O
followed O
for O
3 O
years O
. O
[]

There O
is O
preliminary O
evidence O
of O
disturbed O
serotoninergic O
neurotransmission O
in O
such O
cases O
. O
[]

Multiple O
doses O
of O
secretin O
in O
the O
treatment O
of O
autism O
: O
a O
controlled O
study O
. O
[]

Factors O
predicting O
poor O
prognosis O
were O
renal O
symptoms O
, O
gastrointestinal O
tract O
involvement O
, O
cardiomyopathy O
, O
central O
nervous O
system O
involvement O
, O
weight O
loss O
> O
10 O
% O
of O
body O
weight O
, O
and O
age O
> O
50 O
years O
old O
. O
[]

This O
study O
evaluated O
stability O
, O
tipping O
and O
relapse O
after O
surgically O
assisted O
rapid O
maxillary O
expansion O
( O
SARME O
) O
, O
comparing O
bone-borne O
and O
tooth-borne O
devices O
, O
in O
skeletally O
matured O
non-syndromal O
patients O
with O
transverse O
maxillary O
hypoplasia O
. O
[]

INTERVENTIONS O
Single-dose O
intranasal O
administration O
of O
oxytocin O
( O
24 O
IU O
) O
and O
placebo O
. O
[]

All O
subjects O
were O
requested O
to O
consume O
25-30 O
g O
of O
the O
oils O
daily O
and O
maintain O
a O
fixed O
level O
of O
energy O
intake O
and O
exercise O
. O
[]

The O
frequency O
of O
paraesthesia B-outcome ['Physiological-Clinical']
at O
spinal O
needle O
insertion O
was O
20.7 O
% O
in O
the O
needle-through-needle O
technique O
group O
and O
8.8 O
% O
in O
the O
double O
segment O
technique O
group O
; O
whereas O
the O
frequency O
of O
['Physiological-Clinical']

In O
the O
single-dose O
studies O
, O
a O
total O
of O
183 O
subjects O
received O
oral O
doses O
of O
bilastine O
2.5 O
, O
5 O
, O
10 O
, O
20 O
, O
50 O
, O
100 O
, O
120 O
, O
160 O
, O
200 O
and O
220 O
mg O
. O
[]

Validation O
of O
an O
FFQ O
for O
evaluation O
of O
EPA O
and O
DHA B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
. O
['Life-Impact']

During O
hypoxia B-outcome ['Physiological-Clinical']
, O
7 O
of O
the O
16 O
subjects O
experienced O
intermittent O
and O
somewhat O
severe O
bradycardia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Neither O
basal O
values O
nor O
changes O
of O
renin O
and O
aldosterone B-outcome ['Physiological-Clinical']
were O
related O
to O
the O
hypotensive O
effect O
of O
labetalol O
. O
['Physiological-Clinical']

METHODS O
In O
ten O
paired O
biopsies O
, O
crystallinity B-outcome ['Physiological-Clinical']
, O
apparent B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
and O
width/thickness B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
crystals I-outcome ['Physiological-Clinical']
, O
interplanar B-outcome ['Physiological-Clinical']
distances I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
purpose O
of O
this O
investigation O
was O
to O
evaluate O
postprocedure O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
associated O
with O
3 O
distinct O
standard O
sedation O
regimens O
used O
for O
endoscopic O
procedures O
. O
['Life-Impact']

In O
92 O
% O
ulcers B-outcome ['Physiological-Clinical']
healed I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
were I-outcome ['Physiological-Clinical']
significantly I-outcome ['Physiological-Clinical']
improved I-outcome ['Physiological-Clinical']
within O
4 O
to O
14 O
weeks O
. O
['Physiological-Clinical']

Colposcopic O
evaluation O
for O
vulvar O
, O
vaginal O
, O
and O
cervical O
signs O
of O
irritation O
was O
performed O
and O
photographs O
were O
taken O
, O
following O
a O
specific O
World O
Health O
Organization O
protocol O
, O
at O
time O
0 O
, O
and O
after O
24 O
h O
and O
6 O
days O
of O
application O
of O
the O
gel O
. O
[]

All O
scores O
were O
in O
the O
normal O
range O
, O
and O
no O
means O
were O
more O
than O
1 O
SD O
from O
the O
norm O
. O
[]

METHODS O
Post-hoc O
analyses O
were O
conducted O
on O
data O
from O
patients O
presenting O
with O
a O
mixed O
index O
episode O
who O
were O
enrolled O
in O
a O
larger O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

RESULTS O
Plasma B-outcome ['Physiological-Clinical']
renin I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PRA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
significantly O
( O
P O
< O
0.01 O
) O
increased O
after O
prior O
treatment O
with O
frusemide O
compared O
with O
placebo O
at O
all O
time O
points O
. O
['Physiological-Clinical']

Both O
longer O
and O
shorter O
KC O
before O
and O
throughout O
heel O
stick O
can O
stabilize O
HR B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
preterm O
infants O
, O
and O
longer O
KC O
significantly O
affected O
infants O
' O
sympathetic O
and O
parasympathetic O
responses O
during O
heel O
stick O
compared O
with O
incubator O
care O
. O
['Physiological-Clinical']

BACKGROUND O
The O
sliding O
hip O
screw O
has O
gained O
considerable O
acceptance O
in O
the O
treatment O
of O
unstable O
trochanteric O
fractures O
. O
[]

RESULTS O
Nasal O
allergen O
challenge O
led O
to O
an O
increase O
in O
sputum B-outcome ['Physiological-Clinical']
ECP I-outcome ['Physiological-Clinical']
( O
pre O
= O
60 O
+/- O
12 O
, O
post O
= O
212 O
+/- O
63 O
micro O
g/L O
, O
P O
= O
0.02 O
vs. O
placebo O
) O
, O
and O
sICAM B-outcome ['Physiological-Clinical']
( O
4.8 O
+/- O
2.7 O
to O
6.5 O
+/- O
2.9 O
ng/mL O
, O
P O
= O
0.02 O
vs. O
placebo O
) O
, O
whereas O
IL-10 B-outcome ['Physiological-Clinical']
decreased O
after O
provocation O
( O
44 O
+/- O
11 O
to O
29 O
+/- O
6 O
pg/mL O
, O
P O
= O
0.06 O
vs. O
placebo O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
presents O
the O
preliminary O
results O
of O
a O
randomized O
prospective O
two-arm O
study O
in O
which O
bacillus O
Calmette-Gu?rin O
( O
BCG O
) O
RIVM O
, O
a O
Dutch O
BCG O
preparation O
, O
is O
compared O
with O
mitomycin O
C O
( O
MMC O
) O
in O
patients O
with O
primary O
or O
recurrent O
superficial O
bladder O
tumors O
, O
including O
carcinoma O
in O
situ O
( O
CIS O
) O
. O
[]

The O
amount O
of O
PGE-M O
excreted O
decreased O
significantly O
after O
administration O
of O
indomethacin O
or O
acetyl O
salicylic O
acid O
in O
therapeutic O
doses O
. O
[]

Steward B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
were O
also O
better O
during O
the O
first O
postoperative O
hour O
in O
the O
D O
group O
( O
D O
: O
40 O
min O
vs O
I O
: O
90 O
min O
, O
P O
< O
0.005 O
for O
100 O
% O
of O
patients O
with O
Steward O
score O
of O
6 O
) O
. O
['Physiological-Clinical']

Changes O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
hemodynamics B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

The O
communication O
subscale O
of O
the O
CSBS O
, O
specifying O
communication O
function O
, O
reciprocity O
, O
and O
social-affective O
signalling O
was O
videotaped O
and O
scored O
by O
a O
blinded O
, O
trained O
observer O
. O
[]

CONCLUSIONS O
Although O
both O
methods O
were O
associated O
with O
layering B-outcome ['Physiological-Clinical']
out I-outcome ['Physiological-Clinical']
, O
agglutination B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
In O
the O
uncemented O
sockets O
, O
the O
BMD B-outcome ['Physiological-Clinical']
had O
decreased O
proximally O
and O
medially O
to O
the O
cup O
after O
2 O
years O
. O
['Physiological-Clinical']

There O
was O
no O
difference O
in O
the O
incidence O
of O
pruritus B-outcome ['Physiological-Clinical']
between O
use O
of O
2 O
mg O
and O
4 O
mg O
morphine O
. O
['Physiological-Clinical']

Nineteen O
incidents O
of O
PCP O
and O
13 O
deaths B-outcome ['Mortality']
, O
of O
which O
one O
was O
related O
to O
an O
acute O
episode O
of O
PCP O
, O
were O
noted O
in O
the O
control O
group O
. O
['Mortality']

Slotted O
versus O
non-slotted O
locked O
intramedullary O
nailing O
for O
femoral O
shaft O
fractures O
. O
[]

A O
phase O
II O
, O
randomized O
, O
multicenter O
study O
evaluating O
the O
combination O
of O
lapatinib O
and O
vinorelbine O
in O
women O
with O
ErbB2 O
overexpressing O
metastatic O
breast O
cancer O
. O
[]

Fifty-nine O
ascitic O
fluid O
samples O
were O
obtained O
. O
[]

There O
was O
no O
difference O
in O
clinical O
or O
objective O
improvement O
in O
the O
two O
groups O
. O
[]

Subjects O
completed O
1-week O
diet O
sheets O
which O
were O
analysed O
for O
dietary B-outcome ['Life-Impact']
folate B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

The O
findings O
will O
improve O
knowledge O
pertinent O
to O
the O
implementation O
, O
dissemination O
, O
and O
sustained O
utilization O
of O
evidence-based O
tobacco O
use O
treatment O
in O
dental O
practices O
. O
[]

However O
, O
pressure-limited O
-- O
but O
not O
volume-limited O
-- O
NPPV O
results O
in O
a O
clinically-important O
leak O
compensation O
in O
vivo O
. O
[]

RESULTS O
The O
difference O
between O
the O
two O
protocols O
was O
significant O
as O
the O
group O
that O
received O
pentoxifylline O
had O
greater O
reduction O
in O
ABC-C O
subscale O
scores O
for O
Irritability O
, O
Lethargy/Social O
Withdrawal O
, O
Stereotypic O
Behavior O
, O
Hyperactivity/Noncompliance O
and O
Inappropriate O
Speech O
. O
[]

TK O
; O
T O
300 O
mg+K O
1 O
mg O
b.i.d O
. O
) O
[]

Comparison O
of O
the O
effectiveness O
of O
fennel O
and O
mefenamic B-outcome ['Resource-use']
acid I-outcome ['Resource-use']
on O
pain O
intensity O
in O
dysmenorrhoea O
. O
['Resource-use']

No O
case O
of O
reactionary B-outcome ['Physiological-Clinical']
post-tonsillectomy I-outcome ['Physiological-Clinical']
haemorrhage I-outcome ['Physiological-Clinical']
was O
recorded O
in O
either O
group O
. O
['Physiological-Clinical']

The O
platelet O
response O
was O
related O
to O
plasma O
ASA O
and O
salicyclic O
acid O
determined O
by O
high-pressure O
liquid O
chromatography O
. O
[]

Beta-glucuronidase O
levels O
in O
coronary O
sinus O
blood O
samples O
collected O
after O
aortic O
unclamping O
and O
at O
the O
end O
of O
reperfusion O
were O
significantly O
higher O
in O
Group O
II O
compared O
to O
Group O
I O
( O
p O
< O
0.04 O
) O
. O
[]

GNCC B-outcome ['Physiological-Clinical']
was O
associated O
with O
an O
iron O
profile O
similar O
to O
that O
of O
iron O
deficiency O
. O
['Physiological-Clinical']

The O
primary O
outcome O
is O
the O
change O
in O
self-reported O
pain B-outcome ['Physiological-Clinical']
measured O
by O
visual O
analogue O
scale O
at O
baseline O
and O
thirty O
minutes O
post O
intervention O
. O
['Physiological-Clinical']

Prevention O
of O
a O
first O
stroke O
by O
transfusions O
in O
children O
with O
sickle O
cell O
anemia O
and O
abnormal O
results O
on O
transcranial O
Doppler O
ultrasonography O
. O
[]

Both O
groups O
of O
children O
activated O
a O
right B-outcome ['Physiological-Clinical']
premotor/prefrontal I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
when O
identifying O
images O
containing O
a O
greater O
percentage O
of O
the O
self O
face O
. O
['Physiological-Clinical']

Although O
dietary O
sodium O
restriction O
is O
a O
widely O
recommended O
nonpharmacological O
measure O
for O
control O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
no O
detailed O
investigation O
has O
been O
conducted O
regarding O
the O
impact O
of O
dietary O
sodium O
restriction O
on O
this O
condition O
. O
['Physiological-Clinical']

The O
present O
hospital-based O
case-control O
study O
evaluated O
the O
possible O
association O
of O
CA B-outcome ['Physiological-Clinical']
repeat I-outcome ['Physiological-Clinical']
polymorphism I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
EGFR I-outcome ['Physiological-Clinical']
gene I-outcome ['Physiological-Clinical']
with O
risk O
of O
lung B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
in O
a O
Korean O
population O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
response O
to O
these O
concerns O
, O
we O
developed O
and O
evaluated O
the O
Blood O
Draw O
Intervention O
Program O
. O
[]

INTERVENTIONS O
Twelve O
weeks O
of O
citalopram O
hydrobromide O
( O
10 O
mg/5 O
mL O
) O
or O
placebo O
. O
[]

Only O
those O
with O
unequivocal O
clinical O
, O
radiological O
and O
laboratory O
evidence O
of O
hepatic O
amoebiasis O
were O
included O
; O
diagnostic O
and O
therapeutic O
aspiration O
was O
performed O
where O
necessary O
. O
[]

Comparison O
of O
long-term O
efficacy O
and O
safety O
of O
risperidone O
and O
haloperidol O
in O
children O
and O
adolescents O
with O
autistic O
disorder O
. O
[]

We O
conducted O
this O
study O
to O
determine O
whether O
gemfibrozil O
reduced O
rates O
of O
renal O
function O
loss O
in O
people O
with O
moderate O
CRI O
. O
[]

1 O
, O
heifers O
( O
205 O
+/- O
5 O
kg O
; O
n O
= O
68 O
) O
grazing O
dormant O
native O
pasture O
were O
fed O
0.9 O
kg/d O
( O
as-fed O
basis O
) O
of O
a O
42 O
% O
CP O
supplement O
from O
November O
until O
February O
14 O
. O
[]

The O
duration O
of O
crying O
was O
significantly O
shorter O
in O
babies O
fed O
EBM O
[ O
median O
38.5 O
s O
, O
interquartile O
range O
( O
IQR O
) O
9.5-57.5 O
s O
] O
than O
in O
those O
fed O
DW O
( O
median O
90 O
s O
, O
IQR O
28-210 O
s O
) O
. O
[]

In O
group O
2 O
the O
wrist O
was O
dorsiflexed O
20 O
degrees O
, O
while O
the O
carpus O
was O
pushed O
in O
a O
volar O
direction O
by O
an O
impression O
in O
the O
plaster O
cast O
. O
[]

Subsequent O
HF O
was O
preceded O
by O
a O
decrease O
in O
eGFR B-outcome ['Physiological-Clinical']
over O
1 O
year O
compared O
to O
modest O
improvement O
in O
those O
without O
subsequent O
HF O
( O
-0.09 O
? O
['Physiological-Clinical']

RESULTS O
The O
intervention O
reduced O
significantly O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
inflammation B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Change O
in O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
( O
primary O
) O
. O
['Physiological-Clinical']

The O
study O
had O
a O
cross-over O
, O
placebo-controlled O
design O
consisting O
of O
4 O
d O
separated O
by O
> O
or O
= O
1 O
wk O
. O
[]

Extensor B-outcome ['Physiological-Clinical']
mechanism I-outcome ['Physiological-Clinical']
power O
output B-outcome ['Physiological-Clinical']
and O
physical O
performance O
on O
a O
battery O
of O
timed O
functional O
activities O
was O
assessed O
pre-operatively O
and O
then O
at O
6 O
, O
26 O
, O
and O
52 O
weeks O
post-operatively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
randomized O
, O
double-blind O
, O
controlled O
clinical O
trial O
including O
159 O
subjects O
. O
[]

Peri-implant B-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
response O
and O
papilla B-outcome ['Physiological-Clinical']
index O
were O
recorded O
4 O
weeks O
after O
definitive O
crown O
placement O
to O
allow O
for O
mucosal O
maturation O
and O
at O
1 O
year O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
, O
SETTING O
, O
AND O
PARTICIPANTS O
At O
the O
University O
of O
Tokyo O
Hospital O
, O
we O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
within-subject-crossover O
, O
single-site O
experimental O
trial O
in O
which O
intranasal O
oxytocin O
and O
placebo O
were O
administered O
. O
[]

Load O
theory O
( O
Lavie O
, O
N. O
, O
Hirst O
, O
A. O
, O
De O
Fockert O
, O
J. O
W. O
, O
& O
Viding O
, O
E. O
[ O
2004 O
] O
. O
[]

The O
primary O
outcome O
will O
be O
changes O
in O
7-day O
average O
total O
nasal B-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
score O
. O
['Physiological-Clinical']

Using O
a O
sigmoidal O
Emax O
pharmacodynamic O
model O
, O
a O
strong O
relation O
( O
mean O
+/- O
SD O
r2 O
, O
0.78 O
+/- O
0.2 O
) O
was O
observed O
between O
plasma B-outcome ['Physiological-Clinical']
diltiazem I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
percent O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHOD O
Forty-eight O
18- O
to O
30-month-old O
children O
with O
autism O
spectrum O
disorder O
were O
randomized O
to O
receive O
the O
ESDM O
or O
referral O
to O
community O
intervention O
for O
2 O
years O
. O
[]

METHODS O
AND O
RESULTS O
Six O
dogs O
with O
microembolizations-induced O
HF O
and O
9 O
HF O
patients O
underwent O
CCM O
leads O
and O
generator O
( O
OPTIMIZER O
II O
) O
implantation O
. O
[]

METHODS O
Heparin O
in O
Acute O
Embolic O
Stroke O
Trial O
( O
HAEST O
) O
was O
a O
multicentre O
, O
randomised O
, O
double-blind O
, O
and O
double-dummy O
trial O
on O
the O
effect O
of O
low-molecular-weight O
heparin O
( O
LMWH O
, O
dalteparin O
100 O
IU/kg O
subcutaneously O
twice O
a O
day O
) O
or O
aspirin O
( O
160 O
mg O
every O
day O
) O
for O
the O
treatment O
of O
449 O
patients O
with O
acute O
ischaemic O
stroke O
and O
atrial O
fibrillation O
. O
[]

No O
significant O
differences O
in O
safety O
or O
tolerability B-outcome ['Life-Impact']
between O
children O
randomized O
to O
NFV O
+ O
RTV O
+ O
ddI O
versus O
NFV O
+ O
NVP O
+ O
d4T O
were O
identified O
. O
['Life-Impact']

However O
, O
changes O
in O
serum B-outcome ['Physiological-Clinical']
acetate I-outcome ['Physiological-Clinical']
from O
3 O
to O
6 O
mo O
were O
positively O
related O
to O
changes O
in O
the O
ratio O
of O
total O
to O
HDL B-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
( O
P O
= O
0.041 O
) O
and O
in O
fasting O
( O
P O
= O
0.013 O
) O
and O
postprandial B-outcome ['Physiological-Clinical']
( O
P B-outcome ['Physiological-Clinical']
= O
0.016 O
) O
triacylglycerols B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
first O
study O
compared O
ondansetron O
1 O
, O
8 O
and O
16 O
mg O
to O
placebo O
, O
and O
the O
second O
study O
compared O
8 O
mg O
ondansetron O
to O
placebo O
. O
[]

The O
need O
for O
improved O
health O
care O
provider O
education O
in O
child O
abuse O
identification O
and O
documentation O
remains O
. O
[]

OBJECTIVE O
To O
assess O
the O
importance O
of O
baseline O
characteristics O
including O
medical O
history O
, O
indicators O
of O
current B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
therapeutic B-outcome ['Resource-use']
drug I-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
in O
vitro B-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
susceptibility I-outcome ['Physiological-Clinical']
, O
immune B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
and O
mycobacterial B-outcome ['Physiological-Clinical']
load I-outcome ['Physiological-Clinical']
on O
bacteriologic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
survival B-outcome ['Mortality']
in O
HIV-positive O
patients O
with O
Mycobacterium O
avium O
complex O
( O
MAC O
) O
bacteremia O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

During O
the O
5-8 O
week O
treatment O
, O
three O
novel O
probes O
were O
administered O
to O
determine O
mastery O
of O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact']

CP O
13.0 O
months O
+/- O
7.0 O
( O
P O
less O
than O
0.05 O
) O
. O
[]

At O
27 O
months O
, O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
79.4 O
% O
in O
the O
WP-CRT O
group O
versus O
60 O
% O
in O
the O
WP-IMRT O
group O
( O
P=.651 O
) O
, O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
76 O
% O
in O
the O
WP-CRT O
group O
versus O
85.7 O
% O
in O
the O
WP-IMRT O
group O
( O
P=.645 O
) O
. O
['Mortality', 'Mortality']

METHODS O
Patients O
were O
enrolled O
under O
a O
prospective O
, O
randomized O
protocol O
. O
[]

All O
patients O
received O
antithrombotic O
treatment O
, O
either O
aspirin O
or O
warfarin O
. O
[]

Covariation O
of O
adolescent B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
and O
dietary B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
over O
12 O
months O
. O
['Life-Impact', 'Life-Impact']

GH O
treatment O
caused O
a O
1.6-fold O
increase O
in O
the O
fraction O
of O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
lost O
as O
fat O
and O
a O
greater O
loss B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
visceral I-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
area O
than O
placebo O
treatment O
( O
35.3 O
vs. O
28.5 O
% O
, O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Tinidazole O
and O
metronidazole O
in O
hepatic O
amoebiasis O
. O
[]

RESULTS O
Histological B-outcome ['Physiological-Clinical']
analysis I-outcome ['Physiological-Clinical']
, O
PMNs/alveoli B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
and O
wet/dry B-outcome ['Physiological-Clinical']
weight O
ratio O
measurements O
demonstrated O
that O
LPS O
caused O
significant O
lung O
injury O
and O
HBO O
and/or O
hemin O
significantly O
attenuated O
this O
LPS-induced O
lung O
injury O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Comparing O
the O
effectiveness O
of O
copper O
intrauterine O
devices O
available O
in O
Canada O
. O
[]

Proteinuria B-outcome ['Physiological-Clinical']
, O
present O
in O
all O
patients O
at O
the O
time O
of O
entry O
into O
the O
trial O
, O
was O
reduced O
by O
treatment O
from O
12 O
mo O
, O
compared O
with O
pretreatment O
levels O
or O
controls O
; O
erythrocyturia B-outcome ['Physiological-Clinical']
was O
reduced O
from O
6 O
mo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
labour I-outcome ['Life-Impact']
was O
significantly O
shorter O
, O
the O
need B-outcome ['Resource-use']
for I-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
significantly O
less O
, O
and O
the O
incidence O
of O
fetal B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
significantly O
smaller O
in O
the O
ambulant O
group O
than O
in O
the O
recumbent O
group O
. O
['Life-Impact', 'Resource-use', 'Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
comparative O
efficacy O
and O
safety O
of O
intra-articular O
( O
i/a O
) O
triamcinolone O
. O
[]

CONCLUSION O
Use O
of O
CAM O
is O
common O
in O
families O
of O
young O
children O
with O
neurodevelopmental O
disorders O
, O
and O
it O
is O
predicted O
by O
higher O
parental O
education O
and O
non-Hispanic O
ethnicity O
but O
not O
developmental O
characteristics O
. O
[]

Eye O
movements O
affirm O
: O
automatic B-outcome ['Physiological-Clinical']
overt I-outcome ['Physiological-Clinical']
gaze I-outcome ['Physiological-Clinical']
and O
arrow B-outcome ['Life-Impact']
cueing I-outcome ['Life-Impact']
for O
typical O
adults O
and O
adults O
with O
autism O
spectrum O
disorder O
. O
['Physiological-Clinical', 'Life-Impact']

There O
were O
no O
significant O
differences O
between O
amantadine O
, O
pemoline O
, O
and O
placebo O
. O
[]

Dynamic O
surface B-outcome ['Physiological-Clinical']
electromyographic I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
in O
chronic O
low O
back O
pain O
treated O
by O
traditional O
bone O
setting O
and O
conventional O
physical O
therapy O
. O
['Physiological-Clinical']

Intake O
was O
adequate O
for O
calories O
and O
carbohydrates O
and O
increased O
for O
protein O
. O
[]

For O
delirious B-outcome ['Physiological-Clinical']
awakening I-outcome ['Physiological-Clinical']
, O
the O
odds O
ratio O
in O
the O
control O
group O
was O
4.9 O
compared O
with O
the O
NB O
group O
. O
['Physiological-Clinical']

The O
rate O
of O
continuation B-outcome ['Physiological-Clinical']
and O
the O
rate O
of O
on-time B-outcome ['Life-Impact']
injections I-outcome ['Life-Impact']
did O
not O
differ O
between O
groups O
. O
['Physiological-Clinical', 'Life-Impact']

However O
, O
the O
HR O
and O
NNT O
suggest O
some O
patients O
will O
benefit O
from O
maintenance O
treatment O
. O
[]

Primary O
end O
point O
was O
overall O
response O
rate O
( O
ORR O
; O
partial B-outcome ['Physiological-Clinical']
or O
complete B-outcome ['Physiological-Clinical']
response O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
On O
day O
1 O
, O
diphenhydramine O
significantly O
impaired O
tracking B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
( O
easy O
: O
F O
( O
1,90 O
) O
= O
25.9 O
, O
P O
< O
.0001 O
; O
hard O
: O
F O
( O
1,90 O
) O
= O
20.5 O
, O
P O
< O
.0001 O
) O
and O
divided O
attention O
( O
tracking O
: O
F O
( O
1,90 O
) O
= O
23.8 O
, O
P O
< O
.0001 O
; O
memory B-outcome ['Physiological-Clinical']
scanning I-outcome ['Physiological-Clinical']
: O
F O
( O
1,90 O
) O
= O
22.0 O
, O
P O
< O
.0001 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

A O
prospective O
, O
randomized O
, O
double-blind O
study O
. O
[]

There O
appeared O
to O
be O
patients O
entered O
into O
the O
study O
that O
did O
not O
meet O
inclusion O
criteria O
. O
[]

Terazosin O
, O
alone O
and O
combined O
with O
other O
antihypertensive O
agents O
, O
was O
well O
tolerated B-outcome ['Life-Impact']
with O
minimal O
side O
effects O
in O
black O
hypertensive O
patients O
. O
['Life-Impact']

The O
significant O
increase O
in O
plasma B-outcome ['Physiological-Clinical']
renin I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
produced O
by O
perindopril O
alone O
was O
potentiated O
by O
concurrent O
administration O
of O
hydrochlorothiazide O
. O
['Physiological-Clinical']

RESULTS O
Including O
clinical O
factors O
significantly O
increased O
the O
predictive O
power O
of O
the O
models O
for O
all O
end O
points O
. O
[]

CONCLUSION O
Treatment O
with O
75 O
U/kg O
rhAT O
is O
effective O
in O
restoring O
heparin B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
and O
promoting O
therapeutic B-outcome ['Physiological-Clinical']
anticoagulation I-outcome ['Physiological-Clinical']
in O
the O
majority O
of O
heparin-resistant O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
healthy O
subjects O
, O
there O
was O
no O
significant O
difference O
in O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
with O
the O
different O
doses O
but O
in O
duodenal O
ulcer O
patients O
a O
tenfold O
increase O
of O
the O
antacid O
dose O
resulted O
in O
a O
doubling O
of O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Overall O
response O
rate O
was O
18 O
% O
. O
[]

To O
date O
, O
only O
one O
study O
has O
been O
published O
on O
individual O
characteristics O
associated O
with O
outcome O
following O
standard O
treatment O
with O
bupropion O
SR O
for O
smoking O
cessation O
. O
[]

MEASURES O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
early I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
velocities I-outcome ['Physiological-Clinical']
were O
registered O
by O
Tissue O
Doppler O
from O
a O
long-axis O
view O
of O
the O
interventricular O
septum O
or O
the O
anterior O
wall O
of O
the O
left O
ventricle O
. O
['Physiological-Clinical']

All O
the O
patients O
treated O
with O
placebo O
suppositories O
required O
another O
rescue B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
drug I-outcome ['Resource-use']
and O
withdrew O
from O
the O
trial O
. O
['Resource-use']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
The O
LD O
( O
50 O
) O
for O
acute B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
60 O
% O
of O
total O
blood B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Nitrous O
oxide O
does O
not O
increase O
the O
incidence O
of O
nausea O
and O
vomiting O
after O
isoflurane O
anesthesia O
. O
[]

Antibiotic-use B-outcome ['Resource-use']
rates O
at O
baseline O
were O
2.8 O
, O
1.7 O
, O
and O
1.4 O
antibiotics O
per O
person-year O
among O
those O
aged O
3 O
to O
< O
24 O
, O
24 O
to O
< O
48 O
, O
and O
48 O
to O
< O
72 O
months O
, O
respectively O
. O
['Resource-use']

Prospective O
randomized O
trial O
of O
short-term O
neoadjuvant O
chemotherapy O
for O
advanced O
gastric O
cancer O
. O
[]

Older O
, O
married O
, O
and O
employed O
women O
were O
more O
likely O
to O
engage O
in O
household/occupational B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
, O
whereas O
women O
who O
perceived O
their O
risk O
for O
breast O
cancer O
as O
high O
were O
less O
likely O
. O
['Life-Impact']

Why O
the O
prone O
position O
is O
a O
risk O
factor O
for O
sudden O
infant O
death O
syndrome O
. O
[]

These O
10 O
patients O
experienced O
a O
significantly O
greater O
benefit O
from O
the O
metronidazole B-outcome ['Resource-use']
than O
did O
the O
8 O
patients O
who O
were O
considered O
noncompliant O
, O
i.e. O
, O
a O
reduction O
of O
['Resource-use']

Subjects O
chewed O
nicotine O
gum O
( O
4 O
mg O
) O
or O
placebo O
. O
[]

Apgar B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
at O
one O
and O
five O
minutes O
were O
also O
significantly O
greater O
in O
the O
ambulant O
group O
. O
['Physiological-Clinical']

Seventy-eight O
patients O
completed O
the O
first O
period O
and O
75 O
the O
whole O
study O
. O
[]

Following O
a O
successful O
pilot O
study O
, O
( O
1 O
) O
we O
have O
now O
performed O
a O
double-blind O
clinical O
trial O
using O
the O
diuretic O
, O
chloride-importer O
antagonist O
bumetanide O
that O
reduces O
intracellular O
chloride O
reinforcing O
GABAergic O
inhibition O
. O
[]

Relaxing O
retinotomy O
with O
silicone O
oil O
or O
long-acting O
gas O
in O
eyes O
with O
severe O
proliferative O
vitreoretinopathy O
. O
[]

Healthway O
provides O
sponsorships O
for O
the O
arts O
and O
racing O
and O
sporting O
events O
to O
replace O
funds O
previously O
provided O
by O
tobacco O
companies O
. O
[]

They O
wore O
a O
wrist-watch-like O
actimetry O
sensor O
to O
measure O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
and O
sun B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
24 O
hours O
a O
day O
. O
['Life-Impact', 'Life-Impact']

A O
six-session O
higher-functioning O
autism O
anti-stigma O
program O
incorporating O
descriptive O
, O
explanatory O
and O
directive O
information O
was O
delivered O
to O
adolescent O
boys O
and O
the O
impact O
upon O
knowledge B-outcome ['Life-Impact']
, O
attitudes B-outcome ['Life-Impact']
and O
behavioural B-outcome ['Life-Impact']
intentions I-outcome ['Life-Impact']
towards O
peers O
with O
autism O
was O
evaluated O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Primary O
response O
was O
defined O
by O
normal B-outcome ['Physiological-Clinical']
ALT I-outcome ['Physiological-Clinical']
and O
serum B-outcome ['Physiological-Clinical']
HBV-DNA I-outcome ['Physiological-Clinical']
levels O
below O
10 O
pg/ml O
at O
the O
end O
of O
therapy O
and O
sustained O
response O
by O
normal B-outcome ['Physiological-Clinical']
ALT I-outcome ['Physiological-Clinical']
( O
tested O
monthly O
) O
, O
undetectable B-outcome ['Physiological-Clinical']
HBV-DNA I-outcome ['Physiological-Clinical']
and O
IgM O
anti-HBc O
( O
< O
7 O
I.U O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Effectiveness O
of O
the O
school O
dental O
screening O
programme O
in O
stimulating O
dental B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
for O
children O
in O
need O
of O
treatment O
in O
Northern O
Ireland O
. O
['Life-Impact']

Morbidity B-outcome ['Physiological-Clinical']
was O
worse O
after O
LTA O
than O
after O
TH O
. O
['Physiological-Clinical']

The O
rapid O
initial O
treatment O
response O
of O
GHB O
in O
contrast O
to O
CLO O
has O
no O
influence O
on O
duration O
of O
patient B-outcome ['Physiological-Clinical']
withdrawal I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PURPOSE O
The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
outcome O
of O
stapled B-outcome ['Resource-use']
hemorrhoidopexy I-outcome ['Resource-use']
( O
SH O
group O
) O
performed O
using O
a O
circular O
stapler O
with O
that O
of O
the O
Milligan-Morgan O
technique O
( O
MM O
group O
) O
. O
['Resource-use']

The O
primary O
outcome O
, O
Fatigue B-outcome ['Physiological-Clinical']
score O
( O
CRF O
) O
, O
was O
evaluated O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anaemia O
Questionnaire O
( O
FACT-An- O
) O
( O
FACT-G O
score O
& O
FACT-An O
Anemia O
subscale O
) O
. O
['Physiological-Clinical']

Pioglitazone O
significantly O
reduced O
FPG B-outcome ['Physiological-Clinical']
compared O
with O
glimepiride O
( O
-0.6 O
vs O
0.6 O
mmol/L O
; O
P O
= O
0.01 O
) O
. O
['Physiological-Clinical']

Apneic B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
requiring I-outcome ['Physiological-Clinical']
intubation I-outcome ['Physiological-Clinical']
resulted O
from O
two O
cryotherapy O
sessions O
but O
no O
diode O
laser O
sessions O
. O
['Physiological-Clinical']

Neutrophil O
C3bi O
receptor O
expression O
was O
measured O
at O
0 O
and O
24 O
hours O
. O
[]

[ O
Dose-reduced O
antihypertensive O
agents O
-- O
use O
in O
complex O
nonmedicamentous O
therapy O
of O
hypertension O
] O
. O
[]

Efficacy O
of O
wrist O
working O
splints O
in O
patients O
with O
rheumatoid O
arthritis O
: O
a O
randomized O
controlled O
study O
. O
[]

CONCLUSION O
GHB O
effectively O
controls O
AWS B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
medical O
ICU O
patients O
. O
['Physiological-Clinical']

Ischemic B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
were O
reduced O
only O
in O
patients O
whose O
ambulatory O
blood O
pressure O
was O
controlled O
. O
['Physiological-Clinical']

Survival O
of O
the O
embryos O
was O
assessed O
by O
in O
vitro O
culture O
( O
Experiment O
1 O
) O
and O
by O
embryo O
transfer O
to O
recipients O
( O
Experiment O
2 O
) O
. O
[]

In O
a O
prospective O
randomized O
clinical O
trial O
comprising O
22 O
postmenopausal O
women O
with O
backache O
and O
a O
halisteretic O
spine O
with O
crush O
fracture O
( O
s O
) O
, O
12 O
women O
completed O
a O
12-week O
therapy O
with O
sodium O
fluoride O
, O
calcium O
and O
calciferol O
and O
10 O
with O
placebo O
. O
[]

RESULTS O
About O
half O
of O
the O
clinical O
responders O
did O
not O
produce O
valid B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
measures O
. O
['Life-Impact']

Safety O
and O
efficacy O
of O
oral O
DMSA O
therapy O
for O
children O
with O
autism O
spectrum O
disorders O
: O
Part O
A O
-- O
medical O
results O
. O
[]

As O
a O
conducting O
medium O
, O
1 O
% O
indomethacin O
cream O
was O
used O
for O
the O
experimental O
group O
and O
placebo O
cream O
for O
the O
control O
group O
respectively O
. O
[]

OBJECTIVE O
To O
evaluate O
whether O
hysteroscopic O
morcellation O
or O
bipolar O
electrosurgical O
resection O
is O
more O
favorable O
for O
removing O
endometrial B-outcome ['Physiological-Clinical']
polyps I-outcome ['Physiological-Clinical']
in O
an O
office O
setting O
in O
terms O
of O
feasibility B-outcome ['Life-Impact']
, O
speed B-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
, O
and O
acceptability B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

For O
those O
with O
an O
oral O
aperture O
of O
less O
than O
40 O
mm O
, O
orofacial O
exercises O
were O
taught O
. O
[]

METHODS O
This O
investigation O
assesses O
the O
validity O
of O
the O
Lactate O
Minimum O
Test O
( O
LMT O
) O
, O
which O
consists O
of O
inducing O
lactic O
acidosis O
through O
a O
VO2peak O
test O
, O
followed O
by O
an O
eight-minute O
walking O
recovery O
and O
an O
incremental O
exercise O
test O
, O
to O
determine O
if O
the O
running O
velocity O
associated O
with O
the O
minimum O
lactate O
value O
predicts O
the O
MLSS O
velocity O
. O
[]

Opioid B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
was O
measured O
during O
the O
initial O
24 O
hours O
after O
the O
operation O
. O
['Life-Impact']

The O
aim O
was O
to O
investigate O
which O
baseline O
variables O
predict O
a O
stable O
return-to-work O
during O
a O
2-year O
period O
after O
baseline O
: O
objective O
variables O
from O
function O
tests O
, O
socioeconomic O
, O
subjective O
and/or O
treatment O
variables O
. O
[]

Mode O
of O
education O
did O
not O
affect O
outcomes O
. O
[]

Children O
participating O
in O
a O
daily O
10 O
min O
classroom-based O
activity O
break O
undertake O
more O
physical O
activity O
during O
school O
hours O
than O
controls O
. O
[]

The O
results O
showed O
that O
low-power O
laser O
was O
able O
to O
decrease O
the O
effect O
of O
chemotherapy O
on O
oral B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
, O
xerostomia B-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
in O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effect O
of O
amlodipine O
and O
enalapril O
on O
platelet B-outcome ['Physiological-Clinical']
aggregation O
, O
and O
['Physiological-Clinical']

The O
tolerance O
and O
effectiveness O
of O
mexiletine O
in O
HIV-related O
PPN O
were O
assessed O
in O
22 O
patients O
who O
were O
randomized O
to O
receive O
mexiletine O
( O
maximum O
dose O
, O
600 O
mg/day O
) O
or O
placebo O
for O
6 O
weeks O
, O
followed O
by O
the O
alternative O
intervention O
for O
6 O
weeks O
after O
a O
1-week O
washout O
period O
. O
[]

The O
calorific B-outcome ['Life-Impact']
value I-outcome ['Life-Impact']
of O
the O
absorbed O
osmotic O
agent O
was O
lower O
, O
by O
19 O
% O
with O
isotonic O
and O
22 O
% O
with O
hypertonic O
solutions O
, O
when O
glycerol O
was O
used O
in O
place O
of O
glucose O
. O
['Life-Impact']

There O
was O
increased O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
12 O
h O
postoperatively O
( O
P O
= O
0.05 O
) O
with O
a O
trend O
toward O
increased O
24-h B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
in O
the O
rhAT O
group O
( O
P O
= O
0.06 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
single O
dose O
of O
sirolimus O
administered O
SCJ O
( O
220 O
, O
440 O
, O
880 O
, O
1320 O
, O
or O
1760 O
?g O
) O
or O
IVT O
( O
44 O
, O
110 O
, O
176 O
, O
264 O
, O
or O
352 O
?g O
) O
on O
day O
0 O
; O
observation O
through O
day O
90 O
. O
[]

Outcome O
measures O
included O
self O
, O
peer O
and O
teacher O
reports O
of O
social O
skills O
and O
independent O
weekly O
observations O
of O
children O
on O
their O
school O
playground O
over O
the O
course O
of O
the O
intervention O
. O
[]

The O
intensity O
of O
pain B-outcome ['Physiological-Clinical']
was O
scored O
based O
on O
10-point O
VAS O
before O
and O
after O
treatment O
for O
up O
to O
24 O
h O
postoperatively O
. O
['Physiological-Clinical']

OBJECTIVE O
In O
a O
double-blind O
, O
vehicle-controlled O
study O
, O
the O
administration O
of O
imiquimod O
after O
C O
& O
D O
was O
investigated O
to O
determine O
if O
the O
combination O
regimen O
would O
reduce O
the O
frequency O
of O
residual O
tumor O
compared O
with O
C O
& O
D O
alone O
in O
patients O
with O
nodular O
BCC O
. O
[]

Retinoids O
have O
shown O
a O
potential O
activity O
in O
preventing O
tumor O
recurrence O
in O
superficial O
bladder O
cancer O
. O
[]

For O
this O
study O
, O
a O
head-mounted O
display O
( O
Sony O
PC O
Glasstron O
PLM O
- O
S700 O
) O
was O
used O
to O
display O
encompassing O
images O
and O
block O
competing O
stimuli O
during O
chemotherapy O
infusions O
. O
[]

SETTING O
A O
university O
hospital O
. O
[]

In O
3 O
out O
of O
8 O
patients O
who O
underwent O
a O
further O
bronchoscopy B-outcome ['Physiological-Clinical']
after O
18 O
months O
of O
treatment O
, O
disappearance O
of O
nodules B-outcome ['Physiological-Clinical']
was O
noted O
at O
the O
later O
examination O
. O
['Physiological-Clinical', 'Physiological-Clinical']

They O
were O
subjected O
to O
the O
following O
assessments O
: O
1 O
) O
oropharyngeal O
class O
according O
to O
the O
modified O
Mallampati O
criteria O
; O
2 O
) O
the O
new O
, O
upper O
lip O
bite O
criteria-class O
I O
= O
lower O
incisors O
can O
bite O
the O
upper O
lip O
above O
the O
vermilion O
line O
, O
class O
II O
= O
lower O
incisors O
can O
bite O
the O
upper O
lip O
below O
the O
vermilion O
line O
, O
and O
class O
III O
= O
lower O
incisors O
can O
not O
bite O
the O
upper O
lip O
; O
and O
3 O
) O
laryngeal O
view O
grading O
according O
to O
Cormack O
's O
criteria O
. O
[]

RESULTS O
Fifty-six O
chronically O
constipated O
children O
were O
randomly O
assigned O
into O
the O
study O
, O
but O
only O
48 O
children O
completed O
it O
. O
[]

Perioperative O
fever O
and O
outcome O
in O
surgical O
patients O
with O
aneurysmal O
subarachnoid O
hemorrhage O
. O
[]

The O
mean O
daily O
duration O
of O
lens O
wear O
and O
the O
daily O
number O
of O
instillations O
to O
relieve O
discomfort O
( O
4.2 O
+/- O
2.0 O
for O
PVP O
ABAK O
; O
4.6 O
+/- O
1.9 O
for O
NaCl O
ABAK O
) O
were O
comparable O
. O
[]

CONCLUSION O
Uptake O
of O
influenza O
immunisation B-outcome ['Physiological-Clinical']
among O
the O
low-risk O
older O
population O
in O
inner-city O
areas O
can O
be O
boosted O
by O
around O
6 O
% O
using O
a O
simple O
intervention O
by O
receptionists O
. O
['Physiological-Clinical']

2 O
) O
Intramuscular O
group O
( O
IM O
Group O
) O
, O
40 O
patients O
given O
an O
intramuscular O
injections O
of O
OK-432 O
. O
[]

METHOD O
Seventy-five O
patients O
undergoing O
open O
hernia O
repair O
as O
day O
care O
surgery O
were O
randomly O
allocated O
to O
three O
groups O
: O
intraoperative O
music O
, O
postoperative O
music O
and O
silence O
( O
control O
group O
) O
. O
[]

METHODS O
Among O
134 O
eligible O
patients O
, O
QLQ-C30 B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
were O
collected O
and O
described O
at O
each O
2 O
monthly O
follow-up O
visit O
during O
6 O
months O
. O
['Physiological-Clinical']

Bradykinin-induced O
release O
of O
active B-outcome ['Physiological-Clinical']
t-PA I-outcome ['Physiological-Clinical']
was O
more O
than O
doubled O
during O
treatment O
with O
quinapril O
in O
comparison O
to O
placebo O
or O
losartan O
( O
two-way O
ANOVA O
: O
p O
< O
0.003 O
for O
treatment O
group O
, O
p O
< O
0.001 O
for O
t-PA O
response O
and O
p O
= O
ns O
for O
interaction O
) O
, O
whereas O
the O
substance B-outcome ['Physiological-Clinical']
P I-outcome ['Physiological-Clinical']
response O
was O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
assessed O
by O
a O
third-year O
resident O
of O
psychiatry O
at O
baseline O
and O
after O
2 O
, O
4 O
, O
6 O
and O
8 O
weeks O
of O
starting O
medication O
. O
[]

Sitting B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
were O
reduced O
6 O
and O
5 O
mmHg O
more O
by O
lisinopril O
than O
by O
nifedipine O
over O
12 O
weeks O
monotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Four O
patients O
( O
6 O
% O
) O
converted O
to O
normal B-outcome ['Physiological-Clinical']
sinus B-outcome ['Physiological-Clinical']
rhythm B-outcome ['Physiological-Clinical']
during O
esmolol O
infusion O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Sensory B-outcome ['Life-Impact']
motor I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
( O
subscale O
I O
) O
and O
language B-outcome ['Life-Impact']
at O
the O
end O
of O
the O
12th O
week O
, O
RF-RLRS O
sensory O
motor O
and O
language O
subscale O
scores O
decreased O
in O
the O
risperidone O
group O
further O
than O
the O
other O
group O
( O
P O
< O
0.05 O
) O
. O
['Life-Impact', 'Life-Impact']

We O
studied O
200 O
women O
aged O
35 O
years O
and O
older O
who O
had O
a O
family O
history O
of O
breast O
cancer O
in O
a O
first-degree O
relative O
. O
[]

Correlation O
between O
CHAQ O
and O
CDI O
( O
r O
= O
0.34 O
, O
p O
= O
0.01 O
) O
was O
significant O
. O
[]

RESULT O
At O
30 O
and O
60 O
min O
after O
drug O
administration O
, O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
was O
greater O
in O
the O
pethidine O
group O
than O
in O
tramadol O
group O
. O
['Physiological-Clinical']

Failure O
was O
defined O
as O
a O
reoperation O
to O
control O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or O
an O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
greater O
than O
21 O
mm O
Hg O
at O
or O
after O
the O
first-year O
examination O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Kaplan-Meier O
relapse O
rates O
at O
week O
16 O
were O
35 O
% O
for O
aripiprazole O
and O
52 O
% O
for O
placebo O
( O
hazard O
ratio O
[ O
HR O
] O
= O
0.57 O
; O
number O
needed O
to O
treat O
[ O
NNT O
] O
= O
6 O
) O
. O
[]

Clinical O
check-ups O
and O
treatment O
of O
acute O
PCP O
could O
be O
a O
justifiable O
alternative O
to O
drug O
prophylaxis O
with O
aerosolized O
pentamidine O
in O
selected O
patients O
. O
[]

HI2 O
was O
more O
effective O
than O
HI1 O
and O
CA O
as O
measured O
by O
[]

In O
contrast O
, O
symptom O
and O
skin O
test O
scores O
did O
not O
significantly O
change O
in O
controls O
. O
[]

No O
differences O
were O
found O
between O
CER O
group O
and O
UC O
group O
at O
6 O
weeks O
. O
[]

The O
Clobass O
Study O
Group O
. O
[]

SETTING O
CG O
and O
care O
recipient O
( O
CR O
) O
homes O
in O
five O
U.S. O
cities O
. O
[]

Nebulized O
bitolterol O
solution O
and O
isoproterenol O
solution O
were O
compared O
when O
used O
on O
a O
regular O
basis O
, O
2.5 O
mg O
three O
times O
a O
day O
for O
1 O
month O
by O
patients O
with O
chronic O
asthma O
. O
[]

OBJECTIVE O
To O
investigate O
the O
impact O
of O
coagulative O
parameters O
on O
different O
anticoagulation B-outcome ['Physiological-Clinical']
systems O
in O
molecular O
adsorbent O
recirculating O
system O
( O
MARS O
) O
in O
subjects O
with O
liver O
failure O
, O
and O
to O
evaluate O
the O
safety O
of O
different O
anticoagulation B-outcome ['Physiological-Clinical']
methods O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
result O
was O
robust O
in O
the O
sensitivity O
analysis O
. O
[]

We O
investigated O
whether O
5 O
to O
20mg O
per O
week O
oral O
methotrexate O
could O
slow O
down O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
in O
44 O
patients O
with O
inclusion O
body O
myositis O
in O
a O
randomized O
double-blind O
placebo-controlled O
study O
over O
48 O
weeks O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Patients O
with O
mutant O
KRAS O
metastatic O
adenocarcinoma O
of O
the O
colon O
or O
rectum O
refractory O
to O
fluoropyrimidine- O
and O
oxaliplatin-based O
chemotherapy O
were O
randomized O
1 O
: O
1 O
: O
1 O
to O
receive O
intravenous O
FOLFIRI O
plus O
conatumumab O
10 O
mg/kg O
( O
Arm O
A O
) O
, O
ganitumab O
12 O
mg/kg O
( O
Arm O
B O
) O
, O
or O
placebo O
( O
Arm O
C O
) O
Q2W O
. O
[]

Plasma O
level O
variations O
of O
TAM O
, O
N-desmethyl O
TAM O
and O
MPA O
were O
checked O
at O
various O
intervals O
on O
3 O
patients O
of O
group O
B O
, O
and O
confirmed O
that O
our O
schedule O
is O
able O
to O
produce O
a O
drug O
wash-out O
period O
for O
tumor O
cells O
. O
[]

RESULTS O
Physical O
capacity O
increased O
significantly O
only O
in O
Ex O
patients O
( O
max O
workload O
in O
METs O
from O
7.7 O
? O
[]

The O
purpose O
of O
this O
study O
was O
to O
assess O
stability O
of O
fixation O
and O
analyze O
modes O
of O
failure O
in O
unstable O
trochanteric O
hip O
fractures O
treated O
with O
these O
devices O
. O
[]

MIP B-outcome ['Physiological-Clinical']
was O
the O
primary O
outcome O
. O
['Physiological-Clinical']

CONCLUSION O
VIP O
combination O
chemotherapy O
is O
associated O
with O
an O
improved O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
over O
VP O
therapy O
in O
patients O
with O
extensive O
SCLC O
. O
['Physiological-Clinical', 'Mortality']

VAS O
values O
differed O
significantly O
between O
the O
two O
groups O
. O
[]

RESULTS O
Mean O
+/- O
SD O
baseline O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
TC B-outcome ['Physiological-Clinical']
) O
and O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LDL-C B-outcome ['Physiological-Clinical']
) O
levels O
were O
233+/-20 O
and O
153+21 O
mg+/-dL O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Altering O
expectancies O
of O
upcoming O
aversive O
events O
are O
shown O
here O
to O
depend O
on O
robust O
functional O
associations O
among O
brain O
regions O
implicated O
in O
prior O
work O
on O
the O
placebo O
effect O
. O
[]

Intercellular B-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
molecule-1 I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
ng/mL O
) O
rose O
by O
51.2 O
in O
the O
placebo O
group O
, O
rose O
slightly O
( O
by O
10.6 O
) O
in O
the O
low-dose O
allopurinol O
group O
, O
but O
fell O
in O
the O
high-dose O
group O
( O
by O
2.6 O
; O
difference O
between O
groups O
P=0.012 O
, O
Kruskal-Wallis O
test O
) O
. O
['Physiological-Clinical']

Aromatase O
inhibitors O
prevent O
more O
contralateral O
breast O
cancers O
and O
cause O
fewer O
side O
effects O
than O
tamoxifen O
in O
patients O
with O
early-stage O
breast O
cancer O
. O
[]

Responders O
tended O
to O
have O
ADHD B-outcome ['Life-Impact']
inattentive O
subtype O
and O
comorbid O
neurodevelopmental O
disorders O
. O
['Life-Impact']

RESULTS O
The O
QoL B-outcome ['Life-Impact']
questionnaires O
were O
completed O
by O
37 O
pts O
( O
88 O
% O
) O
in O
the O
DCT/CDDP O
arm O
and O
39 O
pts O
( O
87 O
% O
) O
in O
the O
VNR/CDDP O
one O
. O
['Life-Impact']

None O
of O
the O
women O
had O
been O
treated O
with O
beta-sympathomimetic O
drugs O
earlier O
in O
their O
pregnancy O
. O
[]

INTRODUCTION O
The O
purpose O
of O
this O
study O
was O
to O
analyze O
the O
evolution O
of O
implant O
mechanical O
stability O
in O
different O
types/sizes O
of O
bony O
defects O
using O
both O
Periotest O
and O
Osstell O
devices O
as O
objective O
tools O
. O
[]

Baseline O
characteristics O
of O
both O
groups O
were O
not O
different O
. O
[]

In O
group O
1 O
( O
n O
= O
15 O
) O
a O
basal O
period O
with O
no O
dietary O
restriction O
was O
followed O
by O
a O
period O
taking O
an O
energy O
reduced O
diet O
( O
5.1 O
MJ O
; O
1230 O
kcal O
) O
, O
the O
sodium O
intake O
being O
supplemented O
and O
hence O
unchanged O
( O
1 O
: O
ErSn O
) O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effectiveness O
of O
lactobacilli O
on O
vaginal B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
proinflammatory I-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
characteristics O
of O
the O
VACs O
, O
including O
the O
sites O
, O
procedures O
, O
and O
lengths O
, O
were O
similar O
in O
both O
groups O
. O
[]

Clinical O
and O
microbiological O
examinations O
were O
carried O
out O
before O
treatment O
and O
on O
weeks O
1 O
, O
3 O
, O
7 O
, O
13 O
, O
26 O
, O
38 O
and O
52 O
of O
the O
experimental O
period O
. O
[]

Human O
recombinant O
GM-CSF O
in O
allogeneic O
bone O
marrow O
transplantation O
for O
leukaemia O
: O
double-blind O
placebo O
controlled O
trial O
. O
[]

Small O
group O
meetings O
may O
be O
less O
intrusive O
and O
more O
desirable O
for O
this O
patient O
population O
. O
[]

The O
physical O
activity O
intervention O
will O
consist O
of O
a O
number O
of O
strategies O
including O
: O
delivering O
structured O
fundamental O
movement O
skill O
activities O
, O
increasing O
physical O
activity O
opportunities O
, O
increasing O
staff O
role O
modelling O
, O
providing O
children O
with O
a O
physical O
activity O
promoting O
indoor O
and O
outdoor O
environment O
and O
limiting O
children O
's O
small O
screen O
recreation O
and O
sedentary O
behaviours O
. O
[]

The O
cognitive B-outcome ['Life-Impact']
, O
subjective O
, O
and O
['Life-Impact']

The O
maximal B-outcome ['Physiological-Clinical']
moments I-outcome ['Physiological-Clinical']
were O
14-18 O
% O
and O
48 O
% O
, O
respectively O
. O
['Physiological-Clinical']

Two O
additional O
assessments O
of O
treatment O
status O
and O
mortality B-outcome ['Mortality']
were O
conducted O
in O
1993-1994 O
and O
1995-1996 O
. O
['Mortality']

METHODS O
Over O
a O
6-year O
period O
, O
patients O
with O
persistent O
H. O
pylori O
infection O
following O
omeprazole-clarithromycin-amoxicillin O
eradication O
therapy O
were O
randomized O
to O
receive O
omeprazole O
, O
20 O
mg O
twice O
daily O
, O
bismuth O
, O
120 O
mg O
four O
times O
daily O
, O
metronidazole O
, O
500 O
mg O
twice O
daily O
, O
and O
either O
tetracycline O
, O
500 O
mg O
four O
times O
daily O
, O
or O
clarithromycin O
, O
500 O
mg O
twice O
daily O
, O
given O
for O
7 O
days O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Efficacy O
, O
safety O
, O
predictability O
, O
stability B-outcome ['Physiological-Clinical']
, O
HOAs B-outcome ['Physiological-Clinical']
, O
and O
CS O
were O
evaluated O
before O
and O
after O
enhancement O
at O
6 O
months O
' O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
study O
the O
specific B-outcome ['Physiological-Clinical']
cellular I-outcome ['Physiological-Clinical']
immunoresponse I-outcome ['Physiological-Clinical']
of O
peripheral O
blood O
lymphocytes O
in O
the O
chronic O
hepatitis O
B O
patients O
treated O
with O
different O
doses O
of O
recombinant O
hepatitis O
B O
vaccine O
. O
['Physiological-Clinical']

Patients O
were O
randomly O
assigned O
to O
receive O
either O
orally O
administered O
dexamethasone O
with O
0.5 O
mg/kg O
as O
the O
first O
dose O
and O
0.3 O
mg/kg O
for O
the O
next O
2 O
mornings O
, O
or O
an O
equal O
volume O
of O
an O
orally O
administered O
placebo O
with O
an O
identical O
appearance O
. O
[]

A O
second O
interest O
was O
to O
evaluate O
whether O
more O
intensive O
parent O
involvement O
would O
increase O
the O
child O
's O
ability O
to O
manage O
anxiety O
outside O
of O
the O
clinic O
setting O
. O
[]

MEASUREMENTS O
Self-reported O
Physical O
function O
, O
physical O
performance O
tests O
, O
health B-outcome ['Resource-use']
care I-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
, O
and O
health O
behaviors O
. O
['Resource-use']

The O
groups O
were O
prospectively O
followed O
for O
2 O
years O
with O
visual O
field O
examinations O
every O
4 O
months O
, O
using O
the O
30-2 O
Humphrey O
perimeter O
program O
. O
[]

CONCLUSIONS O
The O
trajectory O
of O
autism O
symptoms O
over O
time O
differed O
in O
different O
domains O
, O
suggesting O
that O
they O
may O
be O
, O
at O
least O
in O
part O
, O
separable O
. O
[]

Efficacy O
of O
nebulized O
flunisolide O
combined O
with O
salbutamol O
and O
ipratropium O
bromide O
in O
stable O
patients O
with O
moderate-to-severe O
chronic O
obstructive O
pulmonary O
disease O
. O
[]

Re-enrollment O
in O
QL O
services O
for O
both O
groups O
was O
documented O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Roland O
adaptation O
of O
the O
Sickness O
Impact O
Profile O
, O
visual O
analogue O
pain B-outcome ['Physiological-Clinical']
scale O
, O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
scale O
, O
EuroQol O
, O
use O
of O
primary O
and O
secondary B-outcome ['Resource-use']
care I-outcome ['Resource-use']
services I-outcome ['Resource-use']
, O
and O
physical B-outcome ['Resource-use']
and I-outcome ['Resource-use']
complementary I-outcome ['Resource-use']
therapies I-outcome ['Resource-use']
, O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
, O
medication B-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
, O
reassurance B-outcome ['Life-Impact']
and O
belief O
in O
value O
of O
radiography O
at O
3 O
and O
9 O
months O
post-randomisation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Life-Impact', 'Resource-use', 'Life-Impact', 'Life-Impact']

We O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
to O
determine O
if O
intravenous O
aminophylline O
adds O
any O
benefit O
to O
high O
doses O
of O
inhaled O
salbutamol O
in O
patients O
who O
presented O
for O
treatment O
of O
acute O
asthma O
. O
[]

INTERVENTION O
Participants O
randomly O
assigned O
to O
either O
of O
2 O
groups O
: O
Group O
1 O
( O
experimental O
group O
) O
or O
Group O
2 O
( O
wait-list O
control O
group O
) O
. O
[]

Adverse O
events O
were O
also O
recorded O
. O
[]

OBJECTIVE O
This O
study O
evaluates O
the O
cost-effectiveness O
of O
vancomycin O
serum O
concentration O
monitoring O
in O
patients O
with O
hematologic O
malignancies O
. O
[]

Reproducibility O
of O
exercise O
performance O
was O
verified O
during O
a O
3 O
week O
run-in O
placebo O
washout O
period O
. O
[]

In O
particular O
, O
the O
incidence O
and O
magnitude O
of O
febrile B-outcome ['Physiological-Clinical']
temperatures I-outcome ['Physiological-Clinical']
were O
significantly O
lower O
between O
the O
4th O
and O
8th O
days O
of O
treatment O
. O
['Physiological-Clinical']

Sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
was O
2.6 O
h O
[ O
95 O
% O
confidence O
intervals O
( O
CI O
) O
2.28-2.93 O
] O
baseline O
, O
1.91 O
h O
( O
95 O
% O
CI O
1.78-2.03 O
) O
with O
placebo O
and O
1.06 O
h O
( O
95 O
% O
CI O
0.98-1.13 O
) O
with O
melatonin O
. O
['Physiological-Clinical']

Comparative O
in O
vitro O
dissolution O
and O
in O
vivo O
bioavailability O
of O
diflunisal/naproxen O
fixed-dose O
combination O
tablets O
and O
concomitant O
administration O
of O
diflunisal O
and O
naproxen O
in O
healthy O
adult O
subjects O
. O
[]

For O
instance O
, O
in O
one O
scenario O
, O
the O
nerp O
ate O
and O
disliked O
a O
carrot O
. O
[]

had O
to O
discontinue O
the O
therapy O
. O
[]

Either O
bezafibrate O
alone O
or O
bezafibrate O
in O
combination O
with O
guar O
was O
administered O
in O
a O
cross-over O
study O
for O
3 O
months O
. O
[]

Serotonergic O
control O
of O
TSH B-outcome ['Physiological-Clinical']
and O
PRL B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
obese O
men O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Both O
the O
workshop-only O
and O
the O
enriched-model O
nurses O
relative O
to O
controls O
had O
significantly O
improved O
knowledge O
and O
changed O
attitudes O
towards O
optimal O
pain O
management O
. O
[]

Does O
an O
educational O
leaflet O
improve O
self-reported O
adherence B-outcome ['Life-Impact']
to O
therapy O
in O
osteoporosis O
? O
['Life-Impact']

Patients O
with O
a O
baseline O
haemoglobin O
A O
( O
1c O
) O
( O
HbA O
( O
1c O
) O
) O
of O
7.3 O
to O
11.0 O
% O
were O
randomized O
1 O
: O
1 O
: O
1 O
: O
1 O
to O
receive O
once-daily O
oral O
therapy O
with O
either O
PHX1149 O
( O
100 O
, O
200 O
or O
400 O
mg O
) O
or O
placebo O
; O
patients O
were O
on O
a O
constant O
background O
therapy O
of O
either O
metformin O
alone O
or O
metformin O
plus O
a O
glitazone O
. O
[]

Patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
was O
greatest O
after O
laparoscopic O
TAPP O
repair O
. O
['Life-Impact']

Usefulness O
of O
temporal O
changes O
in O
neurohormones O
as O
markers O
of O
ventricular O
remodeling O
and O
prognosis O
in O
patients O
with O
left O
ventricular O
systolic O
dysfunction O
and O
heart O
failure O
receiving O
either O
candesartan O
or O
enalapril O
or O
both O
. O
[]

Further O
, O
sprint B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
again O
tended O
to O
be O
slower O
in O
the O
CODS-SS O
trial O
compared O
with O
the O
CODS-CON O
across O
all O
sprint O
variables O
, O
with O
a O
significantly O
slower O
( O
P O
< O
0.05 O
) O
BST O
recorded O
for O
set O
3 O
after O
static O
stretching O
. O
['Life-Impact']

METHODS O
A O
randomized O
, O
placebo-controlled O
, O
dose-escalation O
trial O
with O
five O
cohorts O
( O
N7-GP O
dose O
of O
12.5-100 O
?g O
kg O
( O
-1 O
) O
) O
was O
performed O
. O
[]

Those O
who O
showed O
a O
positive O
MR O
angiogram O
for O
the O
supply O
vein O
were O
randomly O
allocated O
to O
one O
of O
two O
groups O
, O
using O
the O
sealed O
envelope O
method O
, O
and O
underwent O
either O
EIS O
or O
EVL O
. O
[]

At O
the O
conclusion O
of O
the O
study O
, O
parents O
were O
asked O
to O
guess O
their O
child O
's O
group O
assignment O
. O
[]

We O
measured O
the O
number O
and O
proportion O
of O
scheduled O
visits O
resulting O
in O
stepping O
up O
of O
medications O
, O
asthma O
symptoms O
( O
2-week O
recall O
) O
, O
and O
health O
care O
use O
( O
2-month O
recall O
) O
. O
[]

Hence O
it O
is O
important O
for O
professionals O
to O
consider O
the O
possibility O
of O
a O
dual O
diagnosis O
which O
will O
entitle O
the O
child O
to O
a O
more O
specialized O
and O
effective O
educational O
and O
intervention O
services O
. O
[]

AX-CPT B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
was O
assessed O
following O
administration O
of O
a O
single O
dose O
of O
propranolol O
( O
a O
beta O
adrenergic O
antagonist O
) O
and O
following O
placebo O
( O
sugar O
pill O
) O
administration O
. O
['Physiological-Clinical']

Operative O
time O
for O
SILS O
averaged O
40 O
% O
longer O
( O
54 O
? O
[]

OBJECTIVES O
We O
examined O
the O
effects O
of O
a O
high O
fat O
diet O
rich O
in O
monounsaturated O
fat O
( O
MUFA-diet O
) O
and O
a O
moderate O
fat O
diet O
rich O
in O
polyunsaturated O
fat O
( O
PUFA-diet O
) O
on O
the O
susceptibility O
of O
LDL B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
visual O
supports O
on O
the O
performance O
of O
the O
Test O
of O
Gross O
Motor O
Development O
( O
TGMD-2 O
) O
for O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

Piperacillin/tazobactam O
plus O
tobramycin O
versus O
ceftazidime O
plus O
tobramycin O
as O
empiric O
therapy O
for O
fever B-outcome ['Physiological-Clinical']
in O
severely O
neutropenic O
patients O
. O
['Physiological-Clinical']

Sensitivity O
to O
DEX O
was O
negatively O
correlated O
with O
the O
ability B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
produce I-outcome ['Physiological-Clinical']
IL-2 I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
IL-4 I-outcome ['Physiological-Clinical']
in O
the O
controls O
but O
not O
in O
AD O
patients O
. O
['Physiological-Clinical']

Comparison O
of O
dual-axis O
rotational O
coronary O
angiography O
( O
XPERSWING O
) O
versus O
conventional O
technique O
in O
routine O
practice O
. O
[]

RESULTS O
At O
12-month O
follow-up O
, O
seven O
( O
35 O
% O
) O
patients O
who O
underwent O
optical O
urethrotomy O
and O
21 O
( O
70 O
% O
) O
in O
the O
VLASU O
group O
did O
not O
require O
repetition O
of O
the O
procedure O
. O
[]

The O
morbidity B-outcome ['Physiological-Clinical']
rates O
were O
similar O
for O
the O
2 O
groups O
. O
['Physiological-Clinical']

METHODS O
This O
8-week O
, O
double-blind O
, O
randomized O
, O
placebo-controlled O
, O
parallel-group O
study O
was O
conducted O
of O
children O
and O
adolescents O
( O
aged O
6-17 O
years O
) O
with O
autistic O
disorder O
. O
[]

At O
the O
end O
of O
follow-up O
, O
changes O
in O
the O
mean O
of O
systolic O
( O
-2.1 O
vs. O
3.9 O
% O
mmHg O
, O
p O
< O
0.05 O
) O
and O
diastolic O
( O
-3.8 O
vs. O
7.5 O
% O
mmHg O
, O
p O
< O
0.05 O
) O
blood O
pressures O
, O
HOMA-IR O
index O
( O
-46.5 O
vs. O
-5.4 O
% O
, O
p O
< O
0.0001 O
) O
, O
fasting O
glucose O
( O
-12.3 O
vs. O
-1.8 O
% O
mg/dL O
, O
p O
< O
0.05 O
) O
and O
triglyceride O
levels O
( O
-47.4 O
% O
vs. O
10.1 O
% O
mg/dL O
, O
p O
< O
0.0001 O
) O
were O
significantly O
lower O
in O
the O
subjects O
who O
received O
MgCl2 O
compared O
with O
individuals O
in O
the O
control O
group O
. O
[]

Vitamin O
A O
compared O
with O
either O
placebo O
or O
beta O
carotene O
supplementation O
increased O
plasma O
retinol O
concentrations O
by O
end O
of O
study O
( O
1.46 O
[ O
95 O
% O
CI O
, O
1.42-1.50 O
] O
?mol/L O
vs O
1.13 O
[ O
95 O
% O
CI O
, O
1.09-1.17 O
] O
?mol/L O
and O
1.18 O
[ O
95 O
% O
CI O
, O
1.14-1.22 O
] O
?mol/L O
, O
respectively O
; O
P O
< O
.001 O
) O
and O
reduced O
, O
but O
did O
not O
eliminate O
, O
gestational O
night O
blindness O
( O
7.1 O
% O
for O
vitamin O
A O
vs O
9.2 O
% O
for O
placebo O
and O
8.9 O
% O
for O
beta O
carotene O
[ O
P O
< O
.001 O
for O
both O
] O
) O
. O
[]

Therefore O
, O
reduced O
resting-state O
inhibition O
might O
lead O
to O
a O
subsequent O
loss O
of O
modulatory O
capacity O
, O
possibly O
reflecting O
malfunctioning O
precision O
in O
GABAAergic O
neurotransmission O
; O
the O
consequence O
is O
an O
inevitable O
decline O
in O
motor O
function O
. O
[]

There O
was O
a O
trend O
for O
responders O
to O
have O
higher O
valproate B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
levels O
compared O
with O
nonresponders O
. O
['Physiological-Clinical']

Subjects O
who O
tolerated O
the O
test O
dose O
( O
n O
= O
66 O
) O
were O
assigned O
to O
receive O
placebo O
for O
1 O
week O
and O
then O
3 O
methylphenidate O
doses O
in O
random O
order O
during O
a O
double-blind O
, O
crossover O
phase O
. O
[]

METHODS O
The O
women O
were O
randomised O
to O
either O
1000 O
micrograms O
of O
self-administered O
vaginal O
misoprostol O
or O
self-administered O
vaginal O
placebo O
the O
evening O
before O
outpatient O
resectoscopy O
. O
[]

The O
incidence O
of O
apnoea B-outcome ['Physiological-Clinical']
was O
also O
significantly O
less O
in O
the O
slower O
infusion O
group O
. O
['Physiological-Clinical']

Effects O
of O
gabapentin O
on O
experimental O
somatic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
temporal B-outcome ['Physiological-Clinical']
summation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
combined O
effects O
may O
have O
important O
consequences O
in O
controlling O
metastatic O
dissemination O
of O
tumor O
during O
the O
vulnerable O
perioperative O
period O
. O
[]

Implementation O
barriers O
could O
limit O
the O
utility O
of O
this O
approach O
in O
usual O
care O
settings O
. O
[]

Three O
patients O
dropped O
out O
of O
the O
trial O
, O
1 O
with O
each O
active O
drug O
( O
for O
epigastric B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
) O
and O
1 O
with O
dummy O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURE O
The O
superiority O
of O
the O
combination O
of O
Xylometazoline-Dexpanthenol O
nasal-spray O
versus O
Xylometazoline O
nasal O
spray O
could O
be O
proven O
for O
the O
target-parameter O
as O
clinically O
relevant O
and O
statistically O
significant O
. O
[]

Patients O
receiving O
chemotherapy O
( O
N O
= O
391 O
) O
were O
randomized O
to O
receive O
usual O
care O
only O
( O
UCO O
) O
, O
SM O
, O
exercise O
( O
EX O
) O
, O
or O
stress O
management O
and O
exercise O
( O
SMEX O
) O
. O
[]

The O
IDvIP O
trial O
: O
a O
two-centre O
randomised O
double-blind O
controlled O
trial O
comparing O
intramuscular O
diamorphine O
and O
intramuscular O
pethidine O
for O
labour O
analgesia O
. O
[]

With O
the O
low O
infusion O
rate O
, O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
increased O
to O
its O
control O
value O
during O
operation O
; O
it O
remained O
at O
the O
postinduction O
value O
with O
high O
infusion O
rates O
. O
['Physiological-Clinical']

The O
efficacy O
was O
assessed O
by O
the O
International O
Index O
of O
Erectile O
Function O
( O
IIEF O
) O
questionnaire O
and O
adverse O
events O
. O
[]

Readings O
taken O
with O
these O
different O
types O
of O
meter O
can O
not O
be O
interchanged O
with O
confidence O
in O
clinical O
practice O
. O
[]

Fenfluramine O
may O
have O
a O
limited O
place O
in O
the O
management O
of O
some O
patients O
with O
autistic O
disorder O
. O
[]

Compared O
to O
the O
students O
in O
the O
control O
group O
, O
the O
TeachTown O
: O
Basics O
students O
showed O
more O
improvement O
overall B-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
cognitive I-outcome ['Life-Impact']
outcome O
measures O
. O
['Life-Impact']

Changes O
in O
beta-carotene O
levels O
by O
long-term O
administration O
of O
natural O
beta-carotene O
derived O
from O
Dunaliella O
bardawil O
in O
humans O
. O
[]

[ O
Randomized O
study O
on O
the O
long-term O
adjuvant O
chemotherapy O
with O
ftorafur O
and O
mitomycin O
C O
for O
stomach O
cancer O
: O
second O
report O
] O
. O
[]

In O
controls O
GH B-outcome ['Physiological-Clinical']
and O
PRL B-outcome ['Physiological-Clinical']
peaks O
clustered O
around O
15-30 O
min O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SUMMARY O
OF O
BACKGROUND O
DATA O
No O
randomized O
studies O
of O
active O
industrial O
workers O
with O
low O
back O
disorders O
exist O
regarding O
the O
effectiveness O
of O
back O
supports O
plus O
education O
. O
[]

Naltrexone O
, O
1.0 O
mg/kg O
, O
was O
given O
daily O
in O
a O
randomized O
, O
double-blind O
, O
crossover O
design O
. O
[]

BP B-outcome ['Physiological-Clinical']
was O
assessed O
manually O
by O
the O
pharmacist O
after O
a O
10-minute O
rest O
in O
the O
supine O
position O
. O
['Physiological-Clinical']

We O
hypothesized O
that O
the O
administration O
of O
tromethamine O
( O
THAM O
) O
, O
a O
buffer O
which O
does O
not O
increase O
carbon O
dioxide O
production O
, O
would O
modify O
these O
changes O
. O
[]

METHODS O
Developmental O
disabilities-relevant O
descriptors O
were O
developed O
for O
the O
DD-CGAS O
, O
and O
administration O
procedures O
were O
established O
to O
enhance O
rater O
consistency O
. O
[]

Prior O
treatment O
with O
frusemide O
significantly O
( O
P O
< O
0.05 O
) O
increased O
PVR B-outcome ['Physiological-Clinical']
compared O
with O
placebo O
at O
baseline O
: O
185 O
+/- O
17 O
vs O
132 O
+/- O
10 O
dyn O
s O
cm-5 O
at O
an O
SaO2 O
of O
85-90 O
% O
: O
291 O
+/- O
18 O
vs O
229 O
+/- O
16 O
dyn O
s O
cm-5 O
and O
at O
SaO2 O
of O
75-80 O
% O
: O
356 O
+/- O
12 O
vs O
296 O
+/- O
17 O
dyn O
s O
cm-5 O
respectively O
. O
['Physiological-Clinical']

Modulation O
of O
the O
NO O
system O
with O
these O
agents O
may O
have O
applications O
in O
the O
treatment O
of O
thromboembolic O
disease O
. O
[]

Overall O
, O
the O
procedure O
was O
associated O
with O
minimal O
pain B-outcome ['Physiological-Clinical']
and O
discomfort B-outcome ['Physiological-Clinical']
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
3- O
( O
2-benzylmethylaminoethyl O
) O
benzoic O
acid O
methyl O
ester O
hydrochloride O
( O
PRL-8-53 O
) O
on O
learning B-outcome ['Life-Impact']
and O
on O
retention O
of O
verbal B-outcome ['Life-Impact']
information I-outcome ['Life-Impact']
in O
human O
subjects O
was O
investigated O
. O
['Life-Impact', 'Life-Impact']

Flexible B-outcome ['Resource-use']
sigmoidoscopy I-outcome ['Resource-use']
at O
baseline O
and O
day O
28 O
was O
used O
to O
obtain O
colon O
biopsies O
. O
['Resource-use']

METHODS O
Single O
blind O
study O
in O
120 O
children O
. O
[]

Finally O
, O
once O
values O
of O
the O
concentration O
that O
produced O
50 O
% O
inhibition B-outcome ['Physiological-Clinical']
( O
IC B-outcome ['Physiological-Clinical']
( O
50 O
) O
) O
had O
been O
estimated O
for O
wheal O
and O
flare O
effects O
, O
simulations O
were O
carried O
out O
to O
predict O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
for O
the O
doses O
of O
bilastine O
5 O
, O
10 O
and O
20 O
mg O
at O
steady O
state O
( O
72-96 O
hours O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
the O
remaining O
61 O
patients O
, O
10 O
of O
27 O
assigned O
to O
placebo O
( O
37 O
percent O
) O
and O
1 O
of O
34 O
assigned O
to O
fluconazole O
( O
3 O
percent O
) O
had O
a O
recurrence O
of O
cryptococcal B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
any I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
( O
difference O
in O
risk O
, O
34 O
percent O
; O
95 O
percent O
confidence O
interval O
, O
15 O
to O
53 O
) O
. O
['Physiological-Clinical']

This O
study O
has O
2 O
parts O
. O
[]

The O
first O
48 O
hours O
, O
four O
times O
daily O
, O
clinical O
evaluation O
, O
CKMB B-outcome ['Physiological-Clinical']
data O
, O
ECG B-outcome ['Resource-use']
were O
obtained O
and O
two O
times O
daily O
until O
7th O
day O
. O
['Physiological-Clinical', 'Resource-use']

Here O
we O
investigated O
the O
effects O
of O
the O
serotoninergic O
and O
noradrenergic O
reuptake O
inhibitor O
( O
SNRI O
) O
venlafaxine O
in O
comparison O
with O
the O
SSRI O
fluoxetine O
on O
alexithymia B-outcome ['Life-Impact']
severity O
in O
patients O
with O
DSM-IV O
post-stroke O
major O
depressive-like O
episode O
( O
PSD O
) O
. O
['Life-Impact']

PARTICIPANTS O
751 O
men O
and O
women O
aged O
between O
40 O
and O
75 O
years O
with O
mean O
forced O
expiratory O
volume O
in O
one O
second O
( O
FEV O
( O
1 O
) O
) O
50 O
% O
of O
predicted O
normal O
. O
[]

MDM2 O
and O
Ki-67 O
predict O
for O
distant B-outcome ['Physiological-Clinical']
metastasis I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
in O
men O
treated O
with O
radiotherapy O
and O
androgen O
deprivation O
for O
prostate O
cancer O
: O
RTOG O
92-02 O
. O
['Physiological-Clinical', 'Mortality']

The O
children O
ingested O
daily O
65 O
ml O
of O
milk-based O
fruit O
juice O
containing O
either O
LGG O
alone O
( O
6.5 O
x O
10 O
( O
9 O
) O
CFU O
) O
or O
LGG O
plus O
2 O
g O
of O
GOS O
. O
[]

Effects O
of O
application O
in O
spring O
of O
urea O
fertiliser O
on O
aspects O
of O
reproductive O
performance O
of O
pasture-fed O
dairy O
cows O
. O
[]

The O
airway B-outcome ['Physiological-Clinical']
of O
one O
patient O
in O
each O
group O
could O
not O
be O
managed O
with O
these O
devices O
after O
three O
attempts O
. O
['Physiological-Clinical']

Following O
a O
non-randomized O
study O
suggesting O
that O
desmopressin O
acetate O
( O
desmopressin O
) O
reduced O
blood O
product O
requirements O
in O
these O
patients O
, O
we O
conducted O
a O
double-blind O
, O
placebo-controlled O
randomized O
trial O
of O
desmopressin O
( O
0.3 O
micrograms/kg O
, O
i. O
v. O
) O
in O
92 O
patients O
with O
overt O
bleeding O
and O
a O
prolonged O
bleeding O
time O
. O
[]

MATERIAL O
AND O
METHODS O
From O
September O
1991 O
to O
October O
2005 O
in O
the O
Department O
of O
Nuclear O
Medicine O
in O
Ostrava O
357 O
patients O
from O
the O
Slovak O
Republic O
with O
differentiated O
thyroid O
cancers O
( O
follicular O
and O
papillary O
) O
underwent O
complex O
therapy O
. O
[]

Group O
B O
patients O
received O
full-dose O
zidovudine O
concurrently O
with O
GM-CSF O
administration O
. O
[]

RESULTS O
Among O
the O
children O
who O
received O
amoxicillin-clavulanate O
, O
35 O
% O
had O
initial B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
by O
day O
2 O
, O
61 O
% O
by O
day O
4 O
, O
and O
80 O
% O
by O
day O
7 O
; O
among O
children O
who O
received O
placebo O
, O
28 O
% O
had O
initial O
resolution O
of O
symptoms O
by O
day O
2 O
, O
54 O
% O
by O
day O
4 O
, O
and O
74 O
% O
by O
day O
7 O
( O
P=0.14 O
for O
the O
overall O
comparison O
) O
. O
['Physiological-Clinical']

Creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
and O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
were O
stable O
during O
the O
entire O
study O
period O
in O
all O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

GHD O
adults O
are O
frequently O
abdominally O
obese O
and O
display O
features O
of O
the O
metabolic O
syndrome O
. O
[]

Another O
patient O
exhibited O
with O
a O
cluster O
of O
seizures B-outcome ['Physiological-Clinical']
after O
the O
periconception O
period O
using O
another O
multivitamin O
. O
['Physiological-Clinical']

Ninety-eight O
patients O
completed O
the O
chemotherapy O
as O
planed O
. O
[]

Analysis O
of O
relapse B-outcome ['Physiological-Clinical']
patterns I-outcome ['Physiological-Clinical']
showed O
that O
18 O
of O
26 O
relapsing O
patients O
either O
failed O
to O
respond O
in O
initial O
bulky O
sites O
( O
n O
= O
5 O
) O
or O
had O
an O
extranodal O
relapse O
( O
n O
= O
9 O
) O
or O
both O
( O
n O
= O
4 O
) O
. O
['Physiological-Clinical']

C-spine O
motion O
using O
the O
Lightwand O
was O
less O
than O
during O
Macintosh O
laryngoscopy O
, O
averaging O
57 O
% O
less O
at O
the O
four O
motion O
segments O
studied O
( O
P O
< O
0.03 O
) O
. O
[]

PMIs O
were O
adjudicated O
using O
either O
the O
2007 O
universal O
definition O
of O
MI O
( O
type-4a O
) O
or O
the O
extended O
historical O
definition O
of O
MI O
. O
[]

Maternal B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical']

Citalopram O
for O
post-stroke O
pathological O
crying O
. O
[]

Although O
considered O
a O
benign O
condition O
, O
fibroadenomas O
utilize O
substantial O
resources O
for O
management O
and O
treatment O
to O
rule O
out O
potential O
malignancies O
. O
[]

MATERIALS O
AND O
METHODS O
Three O
hundred O
consecutive O
patients O
scheduled O
for O
US-guided O
TPB O
were O
randomized O
1:1:1 O
to O
receive O
PI O
administration O
of O
5 O
g O
2.5 O
% O
lidocaine O
gel O
10 O
minutes O
before O
TPB O
( O
Group O
1 O
) O
, O
or O
a O
mixture O
of O
5 O
g O
2.5 O
% O
lidocaine O
gel O
and O
0.3 O
% O
ketorolac O
tromethamine O
solution O
1 O
hour O
before O
TPB O
( O
Group O
2 O
) O
, O
or O
5 O
g O
2.5 O
% O
lidocaine O
and O
2.5 O
% O
prilocaine O
cream O
20 O
minutes O
before O
TPB O
( O
Group O
3 O
) O
. O
[]

Although O
final O
blood B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
systolic/diastolic I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
significantly O
lower O
in O
the O
strict-treatment O
group O
compared O
with O
the O
mild-treatment O
group O
( O
135.9/74.8 O
vs. O
145.6/78.1 O
mmHg O
; O
p O
< O
0.001 O
) O
, O
the O
incidence O
of O
the O
primary O
endpoint O
was O
similar O
in O
the O
two O
groups O
( O
86 O
patients O
in O
each O
group O
; O
p=0.99 O
) O
. O
['Physiological-Clinical']

A O
randomized O
, O
controlled O
trial O
of O
a O
home-based O
intervention O
program O
for O
children O
with O
autism O
and O
developmental O
delay O
. O
[]

3 O
. O
[]

Rivaroxaban O
, O
an O
oral O
factor O
Xa O
inhibitor O
, O
may O
provide O
more O
consistent O
and O
predictable O
anticoagulation O
than O
warfarin O
. O
[]

10 O
( O
p O
= O
0.04 O
) O
. O
[]

CONCLUSION O
Both O
spinal O
and O
general O
anesthesia O
induced O
a O
significant O
decrease O
in O
intraabdominal O
pressure O
. O
[]

In O
a O
subgroup O
of O
diabetic O
patients O
with O
DGE O
( O
n O
= O
10 O
) O
, O
the O
CFB O
with O
nizatidine O
CR O
( O
300 O
mg O
) O
was O
significant O
( O
P O
< O
0.05 O
) O
at O
3- O
and O
4-hour O
postmeal O
. O
[]

A O
significant O
improvement O
in O
the O
gingival B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
could O
not O
be O
demonstrated O
in O
the O
C O
group O
. O
['Physiological-Clinical']

Lipiodol B-outcome ['Physiological-Clinical']
accumulation I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
group O
A O
( O
12/19 O
; O
63.2 O
% O
showing O
grade O
IV O
Lipiodol O
accumulation O
) O
than O
in O
group O
B O
( O
3/18 O
; O
16.7 O
% O
showing O
grade O
IV O
) O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

As O
interactions O
between O
metaboreceptors O
and O
chemoreceptors O
have O
been O
previously O
observed O
, O
the O
purpose O
of O
this O
study O
was O
to O
isolate O
the O
metaboreflex O
while O
acutely O
stimulating O
or O
inhibiting O
the O
CC O
to O
determine O
whether O
the O
metaboreflex O
increased O
CC O
activity/sensitivity O
. O
[]

There O
were O
no O
complications O
related O
to O
corticosteroid O
treatment O
. O
[]

Subjects O
had O
not O
tolerated O
or O
responded O
to O
other O
psychopharmacologic O
treatments O
( O
neuroleptics O
, O
methylphenidate O
, O
or O
desipramine O
) O
. O
[]

Consequently O
, O
to O
date O
, O
little O
is O
known O
about O
the O
optimal O
treatment O
of O
this O
population O
. O
[]

Hemoglobin B-outcome ['Physiological-Clinical']
levels O
increased O
by O
2.5 O
g/dL O
in O
anemic O
subjects O
. O
['Physiological-Clinical']

A O
marked O
decrease O
in O
viral B-outcome ['Physiological-Clinical']
load I-outcome ['Physiological-Clinical']
was O
observed O
, O
during O
treatment O
with O
IFN-alpha2b O
, O
in O
patients O
with O
HBV O
DNA O
levels O
below O
10 O
000 O
pg O
ml-1 O
. O
['Physiological-Clinical']

Trials O
involving O
larger O
patient O
populations O
will O
be O
necessary O
to O
confirm O
the O
results O
of O
this O
preliminary O
study O
and O
to O
determine O
the O
extent O
of O
clinical O
improvement O
, O
subpopulations O
benefited O
, O
role O
in O
heart O
failure O
therapeutics O
, O
and O
so O
forth O
. O
[]

METHODS O
In O
two O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
dose-escalating O
trials O
, O
subjects O
were O
exposed O
either O
to O
oral O
( O
375 O
, O
500 O
or O
625 O
mg O
) O
or O
intravenous O
( O
500 O
or O
625 O
mg O
) O
linezolid O
or O
placebo O
twice O
daily O
. O
[]

In O
light O
of O
recent O
data O
on O
the O
mutagenicity O
of O
DNCB O
to O
bacteria O
, O
other O
contact O
allergens O
for O
topical O
immunotherapy O
are O
being O
sought O
. O
[]

Stimulus B-outcome ['Physiological-Clinical']
over-selectivity I-outcome ['Physiological-Clinical']
in O
temporal O
brain O
injury O
: O
mindfulness O
as O
a O
potential O
intervention O
. O
['Physiological-Clinical']

Fasting O
and O
meal-stimulated O
plasma O
levels O
of O
neurotensin O
in O
obese O
patients O
after O
jejunoileal O
bypass O
with O
3:1 O
or O
1:3 O
jejunoileal O
ratio O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Year O
1 O
program O
participation O
( O
degree O
of O
attending O
group O
sessions O
and O
submitting O
fat O
scores O
) O
and O
adherence B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
low-fat I-outcome ['Life-Impact']
dietary I-outcome ['Life-Impact']
pattern I-outcome ['Life-Impact']
( O
percent B-outcome ['Life-Impact']
energy I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
fat I-outcome ['Life-Impact']
) O
as O
predicted O
by O
baseline O
physical O
and O
emotional O
status O
( O
eight O
SF-36 O
Health O
Survey O
subscales O
) O
. O
['Life-Impact', 'Life-Impact']

Therefore O
, O
85 O
HCC O
patients O
after O
transcatheter O
arterial O
chemoembolization O
and O
radiofrequency O
ablation O
therapy O
were O
randomized O
to O
immunotherapy O
group O
and O
no O
adjuvant O
therapy O
group O
. O
[]

Improvement O
in O
sensory O
impairment O
and O
social O
interaction O
in O
young O
children O
with O
autism O
following O
treatment O
with O
an O
original O
Qigong O
massage O
methodology O
. O
[]

RESULTS O
The O
mean O
number O
of O
new B-outcome ['Physiological-Clinical']
active I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
+/- O
SD O
per O
patient O
during O
24 O
weeks O
of O
treatment O
with O
valacyclovir O
was O
11.9 O
+/- O
17.6 O
and O
that O
during O
placebo O
treatment O
was O
14.5 O
+/- O
21.4 O
. O
['Physiological-Clinical']

Patients O
with O
a O
lung O
mass O
or O
solitary O
lung O
nodule O
undergoing O
TBLB O
were O
excluded O
. O
[]

The O
main O
parameter O
was O
a O
video O
rating O
of O
global O
impression O
. O
[]

The O
CPRS-R-DSM-IV-ADHD O
subscale O
was O
significant O
for O
the O
PDD O
subgroup O
( O
p O
= O
0.005 O
, O
Cohen O
d O
= O
0.97 O
) O
and O
marginally O
significant O
for O
the O
entire O
DD O
sample O
( O
p O
= O
0.08 O
, O
Cohen O
d O
= O
0.50 O
) O
. O
['Life-Impact']

These O
latter O
( O
control O
) O
patients O
received O
COMET O
after O
their O
TAU O
only O
period O
. O
[]

t O
( O
max O
) O
was O
significantly O
prolonged O
when O
cephalexin O
was O
administered O
with O
ranitidine O
or O
omeprazole O
. O
[]

METHODS O
In O
all O
, O
153 O
individuals O
were O
randomized O
to O
receive O
the O
decision O
aid O
or O
a O
control O
pamphlet O
at O
the O
end O
of O
their O
first O
genetic O
counseling O
consultation O
. O
[]

Comparison O
of O
ketazolam O
given O
once-a-day O
with O
diazepam O
given O
three O
times O
a O
day O
and O
placebo O
given O
either O
once O
or O
3 O
times O
a O
day O
in O
101 O
anxious O
outpatients O
showed O
ketazolam O
to O
be O
significantly O
better O
than O
placebo O
in O
alleviating O
the O
symptoms O
of O
anxiety O
and O
, O
on O
several O
measures O
of O
efficacy O
, O
better O
than O
diazepam O
as O
well O
. O
[]

The O
effects O
of O
adult O
intervention O
on O
infants O
' O
level O
of O
attention B-outcome ['Life-Impact']
to O
objects O
were O
studied O
with O
10-month-old O
infants O
. O
['Life-Impact']

Participants O
were O
tested O
at O
baseline O
and O
again O
with O
weights O
placed O
according O
to O
group O
membership O
. O
[]

Oestrous O
behaviour O
and O
the O
number O
, O
time O
and O
outcome O
of O
inseminations O
were O
also O
recorded O
. O
[]

Notably O
, O
low O
YAP1 O
mRNA O
was O
independently O
associated O
with O
decreased O
recurrence-free O
survival O
in O
the O
gene O
expression O
dataset O
, O
specifically O
for O
the O
luminal O
A O
subgroup O
( O
p O
< O
0.001 O
) O
which O
includes O
low O
proliferating O
tumours O
of O
lower O
grade O
, O
usually O
associated O
with O
a O
good O
prognosis O
. O
[]

BACKGROUND O
Extensive O
research O
is O
currently O
ongoing O
to O
prolong O
the O
half-life O
of O
coagulation O
factors O
. O
[]

Two O
hundred O
cases O
of O
cervical O
spondylosis O
were O
studied O
for O
1 O
to O
4 O
average O
( O
2 O
1/2 O
) O
years O
. O
[]

It O
is O
concluded O
that O
the O
myocardial O
protection O
during O
ischemia O
was O
sufficient O
to O
prevent O
significant O
reductions O
of O
myocardial B-outcome ['Physiological-Clinical']
ATP I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
creatine I-outcome ['Physiological-Clinical']
phosphate I-outcome ['Physiological-Clinical']
irrespective O
of O
supplementation O
with O
CP O
. O
['Physiological-Clinical']

The O
total O
effectiveness O
rate O
was O
77.69 O
% O
( O
94/121 O
) O
in O
the O
experimental O
group O
, O
71.56 O
% O
( O
78/109 O
) O
in O
those O
with O
complications O
. O
[]

Both O
ACE O
inhibitors O
dramatically O
, O
equally O
potentiated O
the O
vasodepressor B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
bradykinin O
; O
the O
bradykinin O
dose O
required O
to O
decrease O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
15 O
mm O
Hg O
or O
increase O
pulse O
20 O
bpm O
was O
50-fold O
lower O
in O
ACEI-treated O
than O
in O
placebo-treated O
subjects O
( O
10 O
+/- O
0 O
and O
12.1 O
+/- O
2.1 O
ng/kg/min O
in O
captopril O
and O
quinapril O
groups O
vs. O
567 O
+/- O
109 O
ng/kg/min O
in O
the O
placebo O
group O
; O
P O
< O
.005 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
EFS O
for O
those O
who O
achieved O
an O
early O
complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
than O
for O
those O
who O
did O
not O
. O
['Physiological-Clinical']

Laser O
conization O
versus O
cold O
knife O
conization O
. O
[]

Cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
COe I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
estimated O
by O
using O
an O
esophageal O
Doppler O
from O
anesthesia O
to O
60 O
min O
after O
extubation O
. O
['Physiological-Clinical']

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
were O
monitored O
throughout O
the O
study O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
value O
of O
P O
less O
than O
.05 O
was O
considered O
statistically O
significant O
. O
[]

It O
is O
concluded O
that O
the O
immunity B-outcome ['Physiological-Clinical']
is O
disturbed O
in O
patients O
with O
laryngo-pharyngeal O
cancer O
, O
but O
that O
this O
disturbance O
does O
not O
clearly O
correlate O
with O
the O
clinical O
state O
of O
the O
disease O
. O
['Physiological-Clinical']

DFS O
after O
testicular B-outcome ['Resource-use']
biopsy I-outcome ['Resource-use']
was O
significantly O
better O
in O
boys O
without O
occult O
TL O
( O
P O
= O
.001 O
) O
. O
['Resource-use']

Effect O
of O
increasing O
doses O
of O
labetalol O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
plasma B-outcome ['Physiological-Clinical']
renin I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
aldosterone B-outcome ['Physiological-Clinical']
in O
hypertensive O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
LIT O
did O
not O
seem O
to O
have O
important O
effects O
on O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
CCR I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Economic O
burden O
of O
childhood O
autism O
spectrum O
disorders O
. O
[]

This O
trial O
was O
registered O
before O
commencement O
at O
clinical O
trials.gov O
as O
NCT00117000 O
. O
[]

After O
cholestyramine O
treatment O
alone O
for O
12 O
weeks O
, O
serum B-outcome ['Physiological-Clinical']
total O
and O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
decreased O
by O
20 O
percent O
and O
29 O
percent O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Two O
of O
the O
3 O
subjects O
in O
the O
MCT O
oil O
group O
with O
evidence O
of O
the O
metabolic O
syndrome O
at O
baseline O
did O
not O
have O
metabolic O
syndrome O
at O
endpoint O
. O
[]

This O
endothelial O
dysfunction O
is O
regarded O
as O
an O
early O
feature O
of O
atherosclerosis O
. O
[]

The O
results O
demonstrate O
significant O
improvements O
in O
parental B-outcome ['Life-Impact']
reports I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
child I-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
and O
parenting B-outcome ['Life-Impact']
styles I-outcome ['Life-Impact']
with O
the O
treatment O
effects O
for O
child O
behaviour B-outcome ['Life-Impact']
, O
parental B-outcome ['Life-Impact']
over B-outcome ['Life-Impact']
reactivity I-outcome ['Life-Impact']
and O
parental B-outcome ['Life-Impact']
verbosity I-outcome ['Life-Impact']
being O
maintained O
at O
follow-up O
6 O
months O
later O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

After O
controlling O
for O
potential O
confounding O
variables O
, O
the O
average O
distance O
walked B-outcome ['Life-Impact']
in O
6 O
minutes O
at O
8 O
weeks O
among O
patients O
in O
the O
treatment O
group O
was O
170 O
m O
( O
95 O
% O
CI O
, O
71 O
to O
270 O
m O
) O
more O
than O
that O
in O
the O
placebo O
group O
and O
the O
average O
WOMAC O
scores O
were O
599 O
mm O
higher O
( O
95 O
% O
CI O
, O
197 O
to O
1002 O
mm O
) O
. O
['Life-Impact']

There O
were O
no O
other O
statistically O
significant O
differences O
between O
the O
groups O
. O
[]

Allergic O
conjunctivitis O
( O
AC O
) O
affects O
an O
estimated O
20 O
% O
of O
the O
population O
in O
the O
Western O
world O
, O
with O
a O
large O
fraction O
suffering O
due O
to O
seasonal O
or O
perennial O
allergen O
exposures O
. O
[]

The O
mean O
age O
was O
67 O
years O
and O
mean O
BMI O
was O
28.3 O
kg/m O
( O
2 O
) O
. O
[]

The O
interventions O
consisted O
of O
packets O
of O
green O
tea O
, O
black O
tea O
, O
caffeinated O
water O
, O
or O
placebo O
. O
[]

Valsartan O
alone O
or O
with O
a O
diuretic O
or O
ACE O
inhibitor O
as O
treatment O
for O
African O
American O
hypertensives O
: O
relation O
to O
salt O
intake O
. O
[]

BACKGROUND O
NovaMin O
( O
NovaMin O
Technology O
, O
Alachua O
, O
Fla. O
) O
was O
introduced O
into O
the O
dental O
market O
as O
a O
desensitizer O
in O
December O
2004 O
. O
[]

BACKGROUND O
Few O
data O
are O
available O
on O
the O
safety O
and O
efficacy O
of O
once-weekly O
oral O
bisphosphonate O
therapy O
in O
breast O
cancer O
survivors O
. O
[]

Patients O
most O
frequently O
complain O
of O
dysphagia O
and O
therapy O
resistant O
constipation O
, O
as O
far O
as O
the O
gastrointestinal O
tract O
is O
concerned O
. O
[]

Experiment O
1 O
uses O
factor O
analysis O
and O
correlational O
data O
to O
provide O
evidence O
for O
viewing O
attitude B-outcome ['Life-Impact']
clarity I-outcome ['Life-Impact']
and O
attitude B-outcome ['Life-Impact']
correctness I-outcome ['Life-Impact']
as O
separate O
constructs O
. O
['Life-Impact', 'Life-Impact']

In O
Study O
1 O
, O
27 O
healthy O
, O
Thai O
adults O
received O
a O
40 O
IU O
kg O
( O
-1 O
) O
dose O
of O
either O
Erig O
PMC O
( O
n O
= O
12 O
) O
or O
PHT-Erig O
( O
n O
= O
15 O
) O
via O
the O
intramuscular O
( O
i.m O
. O
) O
[]

The O
infusions O
were O
Ringer O
's O
acetate O
( O
20 O
ml O
kg O
) O
, O
hydroxyethyl O
starch O
130/0.4 O
( O
10 O
ml O
kg O
) O
and O
a O
combination O
of O
both O
. O
[]

The O
main O
toxic B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
in O
both O
arms O
were O
fever B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
anorexia B-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
randomized O
clinical O
trial O
included O
obese O
patients O
with O
ejection O
fractions O
< O
or O
=40 O
% O
. O
[]

An O
idea O
that O
is O
rapidly O
gaining O
popularity O
in O
clinical O
pain O
medicine O
is O
that O
body O
ownership O
illusions O
can O
be O
used O
to O
modify O
pathological O
pain O
sensations O
and O
induce O
analgesia O
. O
[]

Adherence O
to O
moderate-intensity O
exercise O
during O
breast O
cancer O
therapy O
. O
[]

No O
viable B-outcome ['Physiological-Clinical']
H. O
['Physiological-Clinical']

Combining O
afferent O
stimulation O
and O
mirror O
therapy O
for O
rehabilitating O
motor B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
motor B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
ambulation B-outcome ['Life-Impact']
, O
and O
daily B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
after O
stroke O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

The O
total O
[]

Response O
of O
pre-core O
mutant O
chronic O
hepatitis O
B O
infection O
to O
lamivudine O
. O
[]

In O
Study O
3 O
( O
a O
daily O
event O
sampling O
study O
) O
, O
the O
authors O
showed O
that O
the O
[]

The O
current O
study O
has O
been O
designed O
to O
compare O
the O
classical O
mono O
chemotherapy O
docetaxel O
with O
a O
docetaxel O
cisplatin O
doublet O
. O
[]

The O
levels O
of O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
about O
2 O
weeks O
after O
admission O
were O
significantly O
higher O
in O
the O
imidapril O
group O
than O
in O
the O
placebo O
group O
( O
65.9 O
% O
+/- O
2.5 O
% O
vs O
49.1 O
% O
+/- O
4.4 O
% O
; O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Moreover O
, O
teriparatide O
appeared O
to O
improve O
early O
callus O
formation O
in O
distal O
radial O
fractures O
. O
[]

BACKGROUND O
Interim O
methadone O
maintenance O
has O
been O
proposed O
as O
a O
method O
of O
providing O
clinically O
effective O
services O
to O
heroin O
addicts O
waiting O
for O
treatment O
in O
standard O
comprehensive O
methadone O
maintenance O
programs O
. O
[]

The O
efficacy O
of O
these O
methods O
has O
been O
established O
, O
but O
several O
issues O
remain O
unresolved O
. O
[]

The O
additional O
benefit O
of O
WB O
exercise O
was O
improved O
position O
sense B-outcome ['Physiological-Clinical']
, O
which O
may O
enhance O
complex B-outcome ['Life-Impact']
walking I-outcome ['Life-Impact']
tasks O
( O
walking O
on O
figure O
of O
8 O
route O
and O
spongy O
surface O
) O
. O
['Physiological-Clinical', 'Life-Impact']

The O
study O
was O
divided O
into O
the O
following O
periods O
: O
P0 O
: O
baseline O
measurements O
; O
P1 O
: O
washout O
( O
withdrawal O
of O
AH O
for O
15 O
days O
) O
; O
P2 O
: O
random O
allocation O
to O
CA O
and O
CC O
treatment O
at O
doses O
equivalent O
to O
75 O
mEq O
of O
elemental O
calcium O
, O
stratified O
according O
to O
previous O
doses O
of O
AH O
( O
2 O
months O
) O
; O
P3 O
: O
adjustment O
of O
doses O
until O
control O
P O
( O
2 O
months O
) O
. O
[]

The O
study O
further O
suggests O
that O
these O
changes O
, O
i.e O
. O
[]

The O
100 O
sequences O
were O
divided O
into O
four O
, O
25-sequence O
subsets O
. O
[]

RATIONAL O
Autism O
is O
associated O
with O
activation O
of O
the O
inflammatory O
response O
system O
. O
[]

Recombinant O
human O
erythropoietin O
therapy O
for O
anemic O
cancer O
patients O
on O
combination O
chemotherapy O
. O
[]

Neonates O
whose O
seizures O
were O
not O
controlled O
by O
the O
assigned O
drug O
were O
then O
treated O
with O
both O
drugs O
. O
[]

CEE O
0.625 O
mg O
was O
also O
administered O
once O
daily O
as O
open O
labelled O
tablets O
to O
all O
subjects O
throughout O
the O
study O
. O
[]

Over O
90 O
% O
of O
referring O
doctors O
were O
moderately/very O
satisfied O
with O
the O
service O
, O
but O
23 O
% O
were O
dissatisfied O
with O
waiting O
times O
and O
19 O
% O
with O
access O
to O
preventive O
treatment O
. O
[]

In O
total O
218 O
participants O
developed O
subsequent O
HF O
hospitalization O
. O
[]

SETTING O
The O
study O
was O
performed O
at O
Ohio O
State O
University O
's O
General O
Clinical O
Research O
Center O
. O
[]

The O
larval B-outcome ['Physiological-Clinical']
negative O
conversion B-outcome ['Physiological-Clinical']
rates O
of O
Ancylostoma B-outcome ['Physiological-Clinical']
duodenale I-outcome ['Physiological-Clinical']
and O
Necator B-outcome ['Physiological-Clinical']
americanus I-outcome ['Physiological-Clinical']
were O
77.7 O
and O
83.2 O
% O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pain O
scores O
were O
higher O
in O
the O
surgical O
treatment O
group O
compared O
with O
the O
triamcinolone O
injection O
group O
( O
P O
< O
0.003 O
) O
. O
['Physiological-Clinical']

METHOD O
Thirty-six O
children O
with O
an O
autism O
spectrum O
disorder O
( O
5-17 O
years O
old O
) O
accompanied O
by O
severe O
tantrums O
, O
aggression O
, O
or O
self-injurious O
behavior O
, O
started O
8-week O
open-label O
treatment O
with O
risperidone O
. O
[]

Especially O
, O
nonresponders O
in O
the O
amantadine O
group O
showed O
significantly O
lower O
deterioration O
of O
depression B-outcome ['Life-Impact']
, O
['Life-Impact']

However O
, O
these O
solutions O
should O
be O
selectively O
prescribed O
rather O
than O
used O
based O
on O
anecdotal O
evidence O
. O
[]

Fluid O
retention O
events O
and O
skin O
rash O
were O
numerically O
reported O
more O
often O
in O
the O
800-mg/day O
treatment O
cohort O
of O
patients O
. O
[]

The O
repeatability O
of O
a O
single O
examiner O
in O
scoring O
the O
index O
was O
performed O
using O
4 O
groups O
of O
10 O
subjects O
. O
[]

IMPLICATIONS O
Gastroesophageal B-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
( O
GER O
) O
and O
['Physiological-Clinical']

A O
final O
patient O
population O
of O
149 O
subjects O
rated O
pain B-outcome ['Physiological-Clinical']
intensity O
and O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
at O
one O
half O
hour O
and O
one O
hour O
following O
treatment O
and O
then O
hourly O
for O
six O
hours O
, O
with O
a O
global O
assessment O
made O
at O
the O
completion O
of O
24 O
hours O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Similar O
to O
the O
women O
, O
partners O
' O
symptoms B-outcome ['Life-Impact']
of O
anxiety B-outcome ['Life-Impact']
decreased O
significantly O
in O
the O
TIP-C O
and O
exercise O
groups O
, O
but O
not O
in O
the O
AC O
group O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Some O
89.2 O
per O
cent O
of O
patients O
had O
a O
primary O
tumour O
and O
79.7 O
per O
cent O
underwent O
surgery O
with O
curative O
intent O
; O
243 O
patients O
received O
perioperative B-outcome ['Physiological-Clinical']
RBC I-outcome ['Physiological-Clinical']
transfusion I-outcome ['Physiological-Clinical']
( O
median O
3 O
units O
) O
. O
['Physiological-Clinical']

Patients O
were O
randomized O
to O
receive O
monotherapy O
with O
either O
glimepiride O
( O
2 O
mg O
QD O
initially O
) O
or O
pioglitazone O
( O
15 O
mg O
QD O
initially O
) O
. O
[]

These O
results O
obtained O
with O
the O
LNH-84 O
regimen O
demonstrate O
that O
this O
therapeutic O
scheme O
is O
an O
effective O
treatment O
for O
aggressive O
ML O
. O
[]

Continuous O
intraoperative O
monitoring O
( O
CIM O
) O
for O
systemic O
leak O
from O
the O
perfusion O
circuit O
was O
performed O
using O
radioactive O
iodine-131 O
albumin O
. O
[]

DESIGN O
Randomized O
, O
controlled O
, O
open-label O
trial O
. O
[]

1 O
. O
[]

The O
eradication B-outcome ['Physiological-Clinical']
rate O
of O
H. O
pylori O
for O
patients O
under O
quadruple O
treatment O
, O
without O
vs. O
with O
previous O
dual O
therapy O
, O
were O
96 O
% O
vs. O
92 O
% O
( O
42/44 O
vs. O
22/24 O
) O
by O
per O
protocol O
and O
91 O
% O
vs. O
88 O
% O
( O
42/46 O
vs. O
22/25 O
) O
by O
intention O
to O
treat O
analysis O
( O
comparisons O
not O
significant O
) O
. O
['Physiological-Clinical']

The O
results O
were O
similar O
when O
the O
patients O
were O
divided O
in O
accord O
with O
the O
degree O
of O
respiratory B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
( O
baseline O
FEV1 O
< O
30 O
percent O
of O
predicted O
) O
and O
theophylline B-outcome ['Physiological-Clinical']
level O
at O
30 O
min O
of O
treatment O
( O
placebo O
group O
patients O
with O
theophylline O
level O
< O
10 O
mg/L O
vs O
aminophylline O
group O
patients O
with O
theophylline O
level O
> O
or O
= O
10 O
mg/L O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
There O
is O
some O
reluctance O
to O
treat O
intravenous O
drug O
users O
( O
IVDUs O
) O
with O
chronic O
hepatitis O
C O
( O
CHC O
) O
because O
of O
presumed O
lower O
compliance O
and O
response O
to O
antiviral O
therapy O
. O
[]

No O
difference O
in O
cooperation B-outcome ['Life-Impact']
was O
found O
. O
['Life-Impact']

AIM O
to O
evaluate O
the O
development O
process O
of O
autistic O
children O
, O
in O
a O
direct O
and O
indirect O
intervention O
context O
based O
on O
the O
responses O
of O
mothers O
to O
the O
Autism O
Behavior O
Checklist O
. O
[]

A O
2-yr O
study O
using O
primiparous O
and O
multiparous O
, O
spring-calving O
, O
crossbred O
beef O
cows O
was O
conducted O
to O
evaluate O
the O
effects O
of O
supplemental O
whole O
corn O
germ O
on O
reproductive B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
, O
calf O
performance O
, O
and O
serum B-outcome ['Physiological-Clinical']
leptin I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
a O
chalazion O
underwent O
either O
of O
the O
three O
treatment O
options O
. O
[]

Effects O
of O
low O
and O
high O
protein B-outcome ['Physiological-Clinical']
: O
carbohydrate B-outcome ['Life-Impact']
ratios O
in O
the O
diet O
of O
pregnant O
gilts O
on O
maternal B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
and O
the O
adrenocortical B-outcome ['Physiological-Clinical']
and O
sympathoadrenal B-outcome ['Physiological-Clinical']
reactivity B-outcome ['Physiological-Clinical']
in O
their O
offspring O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
a O
randomized O
, O
double-blind O
study O
design O
, O
group O
1 O
( O
12 O
patients O
; O
7 O
males O
, O
5 O
females O
) O
with O
serum B-outcome ['Physiological-Clinical']
LDL-C I-outcome ['Physiological-Clinical']
levels O
higher O
than O
170 O
mg/dL O
and O
without O
any O
other O
risk O
factor O
for O
atherosclerosis O
received O
three O
months O
of O
20 O
mg/day O
atorvastatin O
treatment O
while O
group O
11 O
( O
8 O
males O
, O
4 O
females O
) O
with O
the O
same O
characteristics O
received O
80 O
mg/day O
. O
['Physiological-Clinical']

Pacing B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
values O
both O
at O
implant O
( O
unipolar O
571 O
+/- O
165 O
omega O
; O
bipolar O
605 O
+/- O
123 O
omega O
) O
and O
at O
follow-ups O
( O
unipolar O
480 O
+/- O
72 O
omega O
; O
bipolar O
518 O
+/- O
75 O
omega O
) O
are O
slightly O
lower O
in O
the O
unipolar O
configuration O
. O
['Physiological-Clinical']

Pubertal B-outcome ['Physiological-Clinical']
BW I-outcome ['Physiological-Clinical']
( O
313 O
+/- O
6 O
kg O
) O
was O
not O
influenced O
by O
treatment O
, O
but O
HS O
and O
LS O
heifers O
were O
younger O
( O
P O
< O
0.03 O
) O
than O
control O
heifers O
at O
puberty O
. O
['Physiological-Clinical']

Based O
on O
the O
discussions O
of O
the O
Joint O
Federal O
Committee O
( O
G-BA O
) O
and O
the O
conceptual O
work O
of O
the O
MDS O
, O
the O
Competence O
Centre O
Oncology O
of O
the O
MDK O
, O
the O
IQWIG O
and O
the O
National O
Association O
of O
Statutory O
Health O
Insurance O
Funds O
( O
GKV-Spitzenverband O
) O
, O
a O
prospective O
randomised O
multicentre O
trial O
was O
developed O
comparing O
the O
four O
treatments O
actually O
recommended O
by O
the O
German O
and O
European O
guidelines O
for O
localised O
prostate O
cancer O
( O
radical B-outcome ['Resource-use']
prostatectomy I-outcome ['Resource-use']
, O
percutaneous B-outcome ['Resource-use']
radiotherapy I-outcome ['Resource-use']
and O
permanent B-outcome ['Physiological-Clinical']
seed I-outcome ['Physiological-Clinical']
implantation I-outcome ['Physiological-Clinical']
and O
active O
surveillance O
) O
allowing O
a O
rejection O
of O
one O
or O
two O
treatment O
options O
. O
['Resource-use', 'Resource-use', 'Physiological-Clinical']

BACKGROUND O
AND O
PURPOSE O
Liquid O
N-butyl O
cyanoacrylate O
( O
n-BCA O
) O
use O
for O
the O
treatment O
of O
arteriovenous O
malformations O
( O
AVM O
) O
in O
the O
brain O
has O
become O
part O
of O
medical O
practice O
. O
[]

Measuring O
acute O
effects O
on O
rCMglu O
with O
FDG-PET O
may O
offer O
a O
method O
for O
defining O
pharmacologically O
active O
doses O
for O
central O
nervous O
system O
targets O
for O
which O
selective O
radiotracers O
are O
lacking O
. O
[]

AIM O
The O
objective O
of O
this O
study O
was O
to O
explore O
the O
result O
of O
pretreatment O
and O
concomitant O
use O
of O
metformin O
with O
clomiphene O
citrate O
( O
CC O
) O
and O
rFSH O
for O
ovulation O
induction O
in O
clomiphene-citrate-resistant O
polycystic O
ovary O
syndrome O
( O
PCOS O
) O
. O
[]

PURPOSE O
To O
examine O
the O
impact O
of O
initial O
CNS O
involvement O
on O
outcome O
and O
patterns O
of O
failure O
in O
patients O
with O
disseminated O
small O
noncleaved-cell O
lymphoma O
and O
B-cell O
leukemia O
who O
were O
treated O
in O
four O
successive O
Children O
's O
Cancer O
Group O
trials O
. O
[]

We O
examined O
weather O
the O
resistance-measurement O
by O
means O
of O
IOS O
in O
comparison O
to O
the O
aR O
is O
a O
more O
suitable O
method O
for O
nasal B-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
provocation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
gender O
effect O
persisted O
after O
adjustment O
for O
a O
number O
of O
potential O
mediators O
. O
[]

In O
the O
multivariate O
stepwise O
analysis O
only O
DeltaWMSI O
and O
NYHA O
were O
independent O
predictors O
of O
outcome O
( O
DeltaWMSI O
= O
hazard O
ratio O
0.02 O
, O
p O
< O
0.0000 O
; O
NYHA O
class O
= O
hazard O
ratio O
3.83 O
, O
p O
< O
0.0000 O
) O
. O
[]

The O
ion O
exchange O
membrane O
is O
effective O
in O
reducing O
the O
chronic B-outcome ['Physiological-Clinical']
pacing I-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
like O
acute O
steroid O
elution O
at O
low O
doses O
, O
but O
membrane O
alone O
does O
not O
prevent O
an O
acute B-outcome ['Physiological-Clinical']
pacing I-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
increase O
through O
the O
first O
month O
postimplant O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
bronchoalveoar O
lavage O
fluid O
( O
BAFL O
) O
was O
also O
collected O
at O
T O
( O
1 O
) O
and O
T O
( O
2 O
) O
for O
IL-6 O
and O
IL-8 O
detection O
. O
[]

CONCLUSION O
Recurrence B-outcome ['Physiological-Clinical']
rate O
is O
reduced O
to O
one-third O
after O
tension-free O
herniotomies O
as O
compared O
with O
the O
conventionel O
herniotomies O
without O
increase O
in O
complication B-outcome ['Adverse-effects']
rate O
. O
['Physiological-Clinical', 'Adverse-effects']

Pregabalin O
( O
PRE O
) O
acts O
as O
a O
presynaptic O
inhibitor O
of O
the O
release O
of O
excessive O
levels O
of O
excitatory O
neurotransmitters O
by O
selectively O
binding O
to O
the O
alpha O
( O
2 O
) O
-delta O
subunit O
of O
voltage-gated O
calcium O
channels O
. O
[]

Each O
non-pregnant O
subject O
took O
an O
oral O
dose O
of O
RU O
486 O
( O
25 O
, O
100 O
, O
400 O
and O
600 O
mg O
consecutively O
) O
once O
per O
menstrual O
cycle O
. O
[]

Quality O
of O
life O
was O
measured O
at O
baseline O
and O
after O
12 O
weeks O
of O
treatment O
. O
[]

A O
placebo-controlled O
trial O
of O
maintenance O
therapy O
with O
fluconazole O
after O
treatment O
of O
cryptococcal O
meningitis O
in O
the O
acquired O
immunodeficiency O
syndrome O
. O
[]

Fewer O
women O
( O
62 O
% O
) O
who O
used O
CS O
experienced O
urogenital B-outcome ['Physiological-Clinical']
AE I-outcome ['Physiological-Clinical']
than O
those O
assigned O
to O
placebo O
gel O
( O
70 O
% O
) O
( O
P O
= O
0.59 O
) O
. O
['Physiological-Clinical']

Anti-emetic B-outcome ['Resource-use']
efficacy O
of O
prophylactic O
granisetron O
compared O
with O
perphenazine O
for O
the O
prevention O
of O
post-operative B-outcome ['Physiological-Clinical']
vomiting I-outcome ['Physiological-Clinical']
in O
children O
. O
['Resource-use', 'Physiological-Clinical']

With O
respect O
to O
total O
, O
partial B-outcome ['Physiological-Clinical']
colon I-outcome ['Physiological-Clinical']
, O
and I-outcome ['Physiological-Clinical']
rectum I-outcome ['Physiological-Clinical']
transit I-outcome ['Physiological-Clinical']
time O
, O
there O
seemed O
to O
be O
a O
trend O
, O
although O
statistically O
nonsignificant O
, O
toward O
faster O
transit B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
in O
the O
cocoa O
husk O
group O
than O
in O
the O
placebo O
group O
. O
['Physiological-Clinical', 'Life-Impact']

No O
significant O
difference O
in O
excretion O
of O
PGE-M O
between O
the O
sexes O
was O
observed O
in O
the O
pre-pubertal O
age-grou O
( O
male O
: O
2.9 O
+/- O
0.8 O
mug/24 O
hours O
, O
n=5 O
; O
female O
: O
3.1 O
+/- O
0.9 O
mug/24 O
hours O
, O
n=5 O
) O
or O
in O
the O
age-group O
of O
45-80 O
years O
( O
male O
: O
9.3 O
+/- O
1.1 O
mug/24 O
hours O
, O
n=21 O
; O
female O
: O
7.3 O
+/- O
0.9 O
mug/24 O
hours O
, O
n=12 O
) O
. O
[]

CONCLUSION O
Topical O
bupivacaine O
decreases O
postoperative O
pain O
scores O
significantly O
compared O
with O
placebo O
in O
women O
undergoing O
laparoscopic O
tubal O
sterilization O
with O
silastic O
bands O
. O
[]

No O
side-effects B-outcome ['Adverse-effects']
were O
reported O
. O
['Adverse-effects']

For O
the O
diagnosis O
of O
sepsis O
, O
patients O
were O
randomly O
divided O
into O
CRRT O
( O
n=10 O
) O
and O
Control O
( O
n=10 O
) O
. O
[]

BACKGROUND O
A O
recently O
identified O
germline O
mutation O
G84E O
in O
HOXB13 O
was O
shown O
to O
increase O
the O
risk O
of O
prostate O
cancer O
. O
[]

METHODS O
Patients O
with O
mild O
pancreatitis O
were O
randomized O
to O
a O
CLD O
or O
LFSD O
when O
they O
were O
ready O
to O
resume O
oral O
nutrition O
. O
[]

Perioperative O
immunotherapy O
with O
recombinant O
interleukin O
2 O
in O
patients O
undergoing O
surgery O
for O
colorectal O
cancer O
. O
[]

Ingestion O
of O
LGG O
combined O
with O
2 O
g O
of O
GOS O
increased O
the O
bifidobacteria B-outcome ['Physiological-Clinical']
more O
than O
LGG O
on O
its O
own O
and O
thus O
GOS O
clearly O
has O
a O
prebiotic O
effect O
in O
children O
. O
['Physiological-Clinical']

Following O
drug O
administration O
the O
decrease O
in O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
the O
increase O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
statistically O
significant O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
statistically O
significant O
treatment O
effects O
were O
observed O
between O
groups O
for O
the O
secondary O
outcomes O
. O
[]

Parent-defined O
target O
symptoms O
respond O
to O
risperidone O
in O
RUPP O
autism O
study O
: O
customer O
approach O
to O
clinical O
trials O
. O
[]

There O
were O
no O
differences O
between O
2 O
groups O
in O
postoperative B-outcome ['Physiological-Clinical']
hepatic I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
, O
changes O
in O
oxygen B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
, O
arterial-venous B-outcome ['Physiological-Clinical']
PCO2 I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
arterial-venous I-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
gradient I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Preliminary O
results O
of O
a O
prospective O
randomized O
study O
] O
. O
[]

These O
results O
suggest O
that O
generalization O
of O
joint O
attention O
skills O
to O
a O
novel O
probe O
did O
occur O
for O
the O
group O
targeting O
joint O
attention O
and O
provides O
further O
evidence O
of O
the O
effectiveness O
of O
the O
joint O
attention O
intervention O
. O
[]

In O
addition O
, O
co-administration O
produced O
no O
changes O
in O
cardiac O
conduction O
parameters O
during O
the O
24 O
h O
of O
telemetry O
monitoring O
following O
drug O
administration O
. O
[]

CONCLUSIONS O
Enalapril O
and O
indapamide O
are O
both O
similarly O
effective O
in O
reducing O
peripheral B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

These O
findings O
provide O
limited O
support O
for O
the O
efficacy O
of O
the O
Transporters O
programme O
for O
young O
children O
with O
autism O
of O
a O
lower O
cognitive O
range O
. O
[]

It O
is O
currently O
unknown O
whether O
migraine O
patients O
who O
can O
not O
be O
adequately O
helped O
with O
triptans O
might O
benefit O
from O
treatment O
with O
telcagepant O
. O
[]

The O
corresponding B-outcome ['Physiological-Clinical']
incidence I-outcome ['Physiological-Clinical']
during O
the O
next O
21 O
h O
( O
3-24 O
h O
) O
after O
anaesthesia O
was O
87 O
% O
and O
62 O
% O
( O
P O
= O
0.007 O
) O
. O
['Physiological-Clinical']

Therapeutic B-outcome ['Physiological-Clinical']
angiogenesis I-outcome ['Physiological-Clinical']
for O
patients O
with O
limb O
ischaemia O
by O
autologous O
transplantation O
of O
bone-marrow O
cells O
: O
a O
pilot O
study O
and O
a O
randomised O
controlled O
trial O
. O
['Physiological-Clinical']

DESIGN O
Randomized O
, O
double-blind O
, O
placebo-controlled O
3-month O
study O
. O
[]

Variations O
in O
construct O
design O
should O
be O
further O
explored O
to O
enhance O
the O
training O
and O
assessment O
of O
clinical O
competence O
that O
reflects O
the O
unpredictability O
encountered O
in O
daily O
clinical O
practice O
. O
[]

In O
addition O
, O
we O
surveyed O
clinical O
educators O
( O
n O
= O
17 O
) O
to O
find O
out O
how O
they O
would O
sequence O
their O
teaching O
of O
these O
murmurs O
. O
[]

METHODS O
Eighty O
patients O
were O
randomised O
to O
receive O
a O
daily O
supplement O
with O
either O
vitamin O
E O
, O
selenium O
, O
vitamin O
C O
, O
coenzyme O
Q10 O
( O
intervention O
group O
) O
or O
placebo O
over O
21 O
weeks O
. O
[]

OBJECTIVE O
We O
compared O
the O
efficacy O
of O
etoricoxib O
30 O
mg O
to O
placebo O
and O
ibuprofen O
2400 O
mg O
for O
the O
treatment O
of O
osteoarthritis O
( O
OA O
) O
of O
the O
hip O
and O
knee O
. O
[]

Patients O
were O
also O
given O
hydrocodone O
bitartrate O
for O
use O
as O
needed O
in O
the O
postoperative O
period O
. O
[]

The O
oxytocin O
or O
placebo O
was O
administered O
during O
parent-child O
interaction O
training O
sessions O
. O
[]

METHODS O
Outdoor O
workers O
were O
randomly O
allocated O
to O
an O
intervention O
( O
n O
= O
65 O
) O
or O
control O
group O
( O
n O
= O
77 O
) O
. O
[]

Effect O
of O
L-ornithine-L-aspartate O
on O
patients O
with O
and O
without O
TIPS O
undergoing O
glutamine O
challenge O
: O
a O
double O
blind O
, O
placebo O
controlled O
trial O
. O
[]

Diet O
and O
tobacco O
use O
: O
analysis O
of O
data O
from O
the O
diabetic O
control O
and O
complications O
trial O
, O
a O
randomized O
study O
. O
[]

The O
recurrence B-outcome ['Physiological-Clinical']
rate O
after I-outcome ['Physiological-Clinical']
tension-free I-outcome ['Physiological-Clinical']
repairs I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
primary I-outcome ['Physiological-Clinical']
direct I-outcome ['Physiological-Clinical']
inguinal I-outcome ['Physiological-Clinical']
hernias I-outcome ['Physiological-Clinical']
was O
7 O
% O
as O
compared O
with O
30 O
% O
after O
Cooper O
ligament O
repair O
( O
P O
= O
0.0081 O
) O
. O
['Physiological-Clinical']

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

MEASUREMENTS O
Following O
a O
2-week O
screening O
period O
, O
69 O
obese O
healthy O
adults O
received O
a O
hypocaloric O
diet O
and O
were O
randomized O
to O
diethylpropion O
50 O
mg O
BID O
( O
n=37 O
) O
or O
placebo O
( O
n=32 O
) O
for O
6 O
months O
. O
[]

However O
, O
it O
has O
never O
been O
used O
for O
digital O
blocks O
. O
[]

L-Carnosine O
, O
a O
dipeptide O
, O
can O
enhance O
frontal O
lobe O
function O
or O
be O
neuroprotective O
. O
[]

Remote O
ischaemic O
conditioning O
before O
hospital O
admission O
, O
as O
a O
complement O
to O
angioplasty O
, O
and O
effect O
on O
myocardial B-outcome ['Physiological-Clinical']
salvage I-outcome ['Physiological-Clinical']
in O
patients O
with O
acute O
myocardial O
infarction O
: O
a O
randomised O
trial O
. O
['Physiological-Clinical']

The O
impoverished O
relational-encoding O
account O
suggests O
that O
studying B-outcome ['Life-Impact']
pictures I-outcome ['Life-Impact']
interferes O
with O
the O
encoding O
of O
relational O
information O
, O
which O
is O
the O
primary O
basis O
for O
false O
memories O
in O
this O
paradigm O
. O
['Life-Impact']

Journal O
of O
Autism O
and O
Developmental O
Disorders O
, O
29 O
, O
407-418 O
) O
. O
[]

SETTING O
Tertiary O
referral O
unit O
and O
a O
teaching O
hospital O
. O
[]

in O
14 O
randomized O
patients O
with O
stable O
ischemic O
heart O
disease O
in O
a O
double-blinded O
study O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
with O
advanced O
cancer O
with O
a O
fatigue O
score O
of O
? O
[]

The O
overall O
median O
survival B-outcome ['Mortality']
was O
not O
improved O
( O
36 O
weeks O
for O
the O
high-dose O
group O
vs O
43 O
weeks O
for O
the O
standard-dose O
group O
) O
; O
however O
, O
the O
median O
survival B-outcome ['Mortality']
in O
patients O
achieving O
CR O
was O
prolonged O
( O
92 O
weeks O
for O
the O
high-dose O
group O
vs O
50 O
weeks O
for O
the O
standard-dose O
group O
) O
. O
['Mortality', 'Mortality']

The O
study O
was O
registered O
at O
ClinicalTrials.gov O
: O
NCT00399009 O
. O
[]

BACKGROUND O
Low-molecular-weight O
heparin O
( O
LMWH O
) O
is O
cleared O
predominantly O
by O
the O
kidneys O
and O
hence O
there O
is O
uncertainty O
about O
the O
safety O
of O
its O
use O
in O
hemodialysis O
( O
HD O
) O
patients O
. O
[]

5.5 O
mo O
) O
. O
[]

BACKGROUND O
Neuropathic O
pain O
is O
a O
complex O
state O
of O
chronic O
pain O
that O
is O
usually O
accompanied O
by O
peripheral O
and O
central O
nervous O
system O
damage O
or O
dysfunction O
. O
[]

Nicotine O
and O
mecamylamine O
dose O
combinations O
were O
randomized O
across O
subjects O
. O
[]

The O
EF B-outcome ['Physiological-Clinical']
showed O
no O
significant O
changes O
in O
the O
two O
groups O
. O
['Physiological-Clinical']

The O
baseline O
ratio O
P O
: O
C O
was O
62 O
+/- O
5 O
% O
in O
the O
PGE1 O
group O
versus O
60 O
+/- O
5 O
% O
in O
the O
placebo O
group O
. O
[]

Group O
1 O
received O
a O
weekly O
session O
of O
posterior O
tibial O
nerve O
stimulation O
for O
12 O
weeks O
and O
group O
2 O
was O
the O
placebo O
group O
. O
[]

Stage O
2 O
is O
a O
medium O
term O
study O
were O
the O
12 O
patients O
used O
in O
Stage O
1 O
were O
added O
to O
another O
28 O
patients O
. O
[]

There O
was O
a O
trend O
for O
subjects O
treated O
with O
desipramine O
to O
maintain O
longer O
periods O
of O
cocaine B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
. O
['Life-Impact']

CHEOP O
scores O
did O
not O
differ O
between O
the O
groups O
at O
any O
time O
. O
[]

They O
were O
randomly O
assigned O
to O
1 O
of O
3 O
experimental O
groups O
that O
differed O
in O
the O
availability O
of O
information O
( O
not O
available O
, O
available O
upon O
request O
, O
available O
automatically O
) O
about O
the O
urgency O
and O
modality O
of O
pending O
interruption O
tasks O
. O
[]

OBJECTIVES O
To O
develop O
a O
predictive O
model O
and O
a O
simplified O
score O
for O
use O
on O
day O
7 O
of O
hospitalization O
to O
assess O
whether O
a O
patient O
receiving O
mechanical O
ventilation O
is O
likely O
to O
require O
an O
additional O
25 O
days O
of O
hospitalization O
( O
ie O
, O
would O
qualify O
for O
transfer O
to O
a O
long-term O
care O
hospital O
) O
. O
[]

Baseline O
tear O
and O
saliva O
production O
was O
significantly O
reduced O
during O
disopyramide O
therapy O
, O
but O
was O
restored O
toward O
normal O
by O
the O
addition O
of O
pyridostigmine O
. O
( O
[]

CONCLUSION O
Premature O
treatment O
discontinuations B-outcome ['Life-Impact']
in O
the O
ABC O
arm O
and O
the O
presence O
of O
EFV-HS O
HIV O
variants O
in O
this O
patient O
population O
likely O
made O
it O
difficult O
to O
detect O
a O
benefit O
of O
adding O
ABC O
to O
EFV+IDV O
. O
['Life-Impact']

One O
dose O
reduction O
occurred O
during O
the O
study O
( O
FEC O
( O
90 O
) O
) O
, O
related O
to O
diarrhoea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Compared O
to O
ten O
IQ- O
and O
age-matched O
healthy O
controls O
, O
eight O
participants O
with O
autism O
showed O
less O
fixation B-outcome ['Life-Impact']
specificity O
to O
the O
eyes O
and O
mouth O
, O
a O
greater O
tendency O
to O
saccade O
away O
from O
the O
eyes O
when O
information O
was O
present O
in O
those O
regions O
, O
and O
abnormal O
directionality O
of O
saccades O
. O
['Life-Impact']

Both O
antibiotics O
were O
well O
tolerated O
in O
this O
single-dose O
administration O
study O
. O
[]

Before O
administering O
of O
the O
therapy O
and O
3 O
weeks O
later O
all O
MI O
patients O
performed O
the O
bicycle O
ergometer O
exercise O
test O
until O
the O
ventilatory B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
was O
reached O
. O
['Physiological-Clinical']

METHODOLOGY O
In O
this O
double-blind O
clinical O
trial O
, O
100 O
patients O
who O
had O
anterior O
or O
premolar O
teeth O
with O
irreversible O
pulpitis O
without O
any O
signs O
and O
symptoms O
of O
acute O
or O
chronic O
apical O
periodontitis O
and O
moderate O
to O
severe O
pain O
were O
divided O
by O
balanced O
block O
random O
allocation O
into O
four O
groups O
of O
25 O
each O
, O
a O
control O
group O
receiving O
a O
placebo O
medication O
, O
and O
three O
experimental O
groups O
receiving O
a O
single O
dose O
of O
either O
Tramadol O
( O
100 O
mg O
) O
, O
Novafen O
( O
325 O
mg O
of O
paracetamol O
, O
200 O
mg O
ibuprofen O
and O
40 O
mg O
caffeine O
anhydrous O
) O
or O
Naproxen O
( O
500 O
mg O
) O
immediately O
after O
the O
first O
appointment O
where O
the O
pulp O
was O
removed O
, O
and O
the O
canals O
were O
fully O
prepared O
. O
[]

Vaginal O
tolerance O
tests O
were O
performed O
with O
a O
new O
potential O
microbicidal O
and O
spermicidal O
product O
, O
an O
acid-buffering O
vaginal O
gel O
( O
Acidform O
) O
without O
or O
with O
nonoxynol-9 O
( O
N-9 O
) O
. O
[]

Data O
from O
this O
study O
indicate O
that O
consumption O
of O
medium-and O
long-chain O
triglycerides O
can O
reduce O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Clonidine O
increased O
tourniquet B-outcome ['Life-Impact']
tolerance I-outcome ['Life-Impact']
from O
33 O
to O
45 O
min O
( O
P O
= O
0.06 O
) O
and O
increased O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
ambulation I-outcome ['Life-Impact']
, O
spontaneous B-outcome ['Physiological-Clinical']
voiding I-outcome ['Physiological-Clinical']
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Whether O
medical O
therapy O
for O
silent O
ischemia O
improves O
prognosis O
is O
not O
known O
. O
[]

Hemoglobin B-outcome ['Physiological-Clinical']
, O
erythrocyte B-outcome ['Physiological-Clinical']
riboflavin I-outcome ['Physiological-Clinical']
, O
and O
plasma B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
and O
retinol B-outcome ['Physiological-Clinical']
were O
measured O
before O
and O
after O
the O
intervention O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
patients O
met O
the O
major O
characteristics O
of O
Lennox-Gastaut O
syndrome O
. O
[]

DESIGN O
Randomised O
, O
controlled O
trial O
. O
[]

On O
multivariate O
regression O
analysis O
, O
the O
sensitivity B-outcome ['Physiological-Clinical']
of O
H. O
pylori O
to O
metronidazole O
had O
a O
likelihood O
ratio O
of O
5.2 O
( O
P=0.022 O
) O
, O
followed O
by O
the O
type O
of O
quadruple O
therapy O
( O
likelihood O
ratio O
, O
4.4 O
; O
P=0.036 O
) O
. O
['Physiological-Clinical']

The O
effectiveness O
of O
the O
Cignolini O
methodology O
, O
an O
original O
Qigong O
massage O
methodology O
, O
in O
treating O
sensory O
impairment O
in O
young O
children O
with O
autism O
was O
evaluated O
in O
a O
small O
, O
controlled O
study O
. O
[]

This O
concept O
is O
based O
primarily O
on O
informal O
observations O
or O
studies O
conducted O
with O
questionnaires O
. O
[]

Oat O
ingestion O
reduces O
systolic O
and O
diastolic O
blood O
pressure O
in O
patients O
with O
mild O
or O
borderline O
hypertension O
: O
a O
pilot O
trial O
. O
[]

INTERVENTION O
( O
S O
) O
A O
three O
to O
five O
minute O
scripted O
intervention O
and O
booklet O
specific O
to O
the O
woman O
's O
stage-of-change O
in O
the O
smoking O
continuum O
, O
versus O
standard O
of O
care O
. O
[]

RESULTS O
When O
including O
all O
follow-up O
variables O
, O
there O
were O
three O
groups O
: O
( O
1 O
) O
Thirty-seven O
children O
with O
male O
predominance O
, O
familial O
history O
of O
epilepsy O
, O
simple O
febrile O
convulsions O
, O
massive O
myoclonus O
, O
tonic-clonic O
fits O
. O
[]

The O
lack O
of O
statistical O
power O
limits O
the O
external O
validity O
of O
these O
findings O
. O
[]

Acute O
stress O
consisted O
of O
losing O
against O
a O
competitor O
of O
the O
opposite O
sex O
on O
the O
criterion O
motor O
task O
while O
receiving O
unpleasant O
information O
about O
their O
performance O
over O
30 O
preintervention O
and O
30 O
postintervention O
trials O
. O
[]

No O
significant O
differences O
were O
found O
in O
perioperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
between O
patients O
in O
the O
treatment O
group O
( O
n O
= O
39 O
) O
and O
control O
group O
( O
n O
= O
37 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Three-year O
follow-up O
of O
major B-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
event O
( O
MACE B-outcome ['Physiological-Clinical']
) O
( O
death O
, O
nonfatal O
myocardial O
infarction O
, O
target O
lesion O
revascularization O
) O
and O
the O
predictors O
of O
MACEs O
in O
diabetic O
patients O
after O
sirolimus-eluting O
stent O
( O
SES O
) O
or O
paclitaxel-eluting O
stent O
( O
PES O
) O
implantation O
have O
not O
been O
reported O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
In O
the O
present O
study O
, O
naltrexone O
significantly O
reduced O
only O
hyperactivity B-outcome ['Physiological-Clinical']
, O
and O
no O
serious B-outcome ['Adverse-effects']
untoward I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
. O
['Physiological-Clinical', 'Adverse-effects']

The O
present O
research O
examined O
the O
effectiveness O
of O
a O
cognitive-behavioral B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
( O
CBT O
) O
based O
intervention O
program O
, O
FRIENDS O
, O
for O
children O
from O
grades O
4 O
to O
6 O
, O
using O
random O
assignment O
at O
the O
school-level O
and O
an O
attention-control O
design O
in O
two O
longitudinal O
studies O
. O
['Resource-use']

OBJECTIVE O
To O
evaluate O
safety O
and O
efficacy O
of O
longterm O
etanercept O
treatment O
in O
patients O
with O
disease O
modifying O
antirheumatic O
drug O
( O
DMARD O
) O
refractory O
rheumatoid O
arthritis O
( O
RA O
) O
. O
[]

We O
examined O
the O
effect O
of O
CEE O
alone O
on O
mammographic B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
in O
a O
subsample O
of O
the O
Women O
's O
Health O
Initiative O
( O
WHI O
) O
clinical O
trial O
participants O
. O
['Physiological-Clinical']

No O
pregnancies B-outcome ['Physiological-Clinical']
were O
obtained O
in O
group O
1 O
( O
0 O
% O
, O
0/12 O
) O
, O
whereas O
seven O
clinical B-outcome ['Physiological-Clinical']
pregnancies I-outcome ['Physiological-Clinical']
were O
obtained O
in O
group O
2 O
( O
29 O
% O
, O
7/24 O
) O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
changes O
between O
pre-treatment O
and O
the O
eight-week O
follow-up O
also O
showed O
a O
significant O
improvement O
in O
group O
A O
compared O
with O
group O
B O
( O
p=0.03 O
) O
. O
[]

For O
the O
coprimary O
MRI O
and O
PET/CT O
endpoints O
, O
CIs O
were O
below O
the O
no-harm O
boundary O
or O
the O
adverse O
change O
was O
numerically O
lower O
in O
the O
dalcetrapib O
group O
than O
in O
the O
placebo O
group O
. O
[]

The O
frequency O
of O
thromboembolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
other I-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
was O
highest O
in O
the O
estrogen O
group O
( O
13/50 O
patients O
) O
. O
['Physiological-Clinical']

STATISTICAL O
ANALYSES O
PERFORMED O
Descriptive O
and O
inferential O
statistical O
analyses O
were O
performed O
. O
[]

Success B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
valvotomy I-outcome ['Physiological-Clinical']
, O
procedure-related B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
and O
follow-up O
events B-outcome ['Physiological-Clinical']
of O
the O
2 O
techniques O
were O
compared O
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical']

They O
point O
out O
the O
conditions O
required O
to O
initiate O
the O
place O
of O
such O
a O
scheme O
in O
all O
complex O
therapy O
which O
aims O
as O
much O
at O
palliation O
as O
at O
cure O
, O
and O
point O
out O
how O
important O
it O
is O
to O
be O
methodical O
in O
the O
application O
of O
chemotherapy O
in O
order O
to O
ensure O
its O
development O
as O
an O
anticancer O
therapy O
. O
[]

In O
the O
placebo O
group O
, O
there O
was O
a O
loss O
in O
lean B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
mass B-outcome ['Physiological-Clinical']
( O
-2.62 O
+/- O
1.51 O
kg O
) O
and O
a O
negative O
nitrogen B-outcome ['Physiological-Clinical']
balance B-outcome ['Life-Impact']
( O
-4.52 O
+/- O
3.51 O
g/day O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Complications O
associated O
with O
rectal O
lesions O
may O
be O
severe O
enough O
to O
cause O
life-threatening O
septicemia O
. O
[]

Mean O
delta O
stage-of-change O
declined O
by O
-0.62 O
. O
[]

Nimesulide O
have O
been O
studied O
in O
a O
double O
blind O
study O
compared O
with O
flurbiprofen O
, O
in O
98 O
patients O
aged O
between O
18 O
and O
75 O
suffering O
from O
pain-inflammatory O
pathologies O
of O
ENT O
nature O
. O
[]

ST-segment B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
> O
50 O
% O
was O
observed O
in O
79.5 O
% O
and O
61.2 O
% O
of O
the O
nicorandil O
and O
placebo O
groups O
, O
respectively O
( O
hazard O
ratio O
, O
2.45 O
; O
95 O
% O
CI O
, O
1.54 O
to O
3.90 O
; O
P=0.0002 O
) O
. O
['Physiological-Clinical']

We O
studied O
the O
phospholipid O
composition O
of O
high-density O
lipoproteins O
in O
patients O
with O
coronary O
heart O
disease O
and O
hypercholesterolemia O
treated O
with O
simvastatin O
( O
Zocor O
, O
inhibitor O
of O
the O
key O
enzyme O
of O
cholesterol O
synthesis O
) O
and O
preparation O
of O
polyunsaturated O
phospholipids O
( O
lipostabil O
forte O
) O
. O
[]

They O
were O
questioned O
on O
the O
topics O
of O
( O
i O
) O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
( O
ii O
) O
ease B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
swallowing I-outcome ['Physiological-Clinical']
, O
( O
iii O
) O
satisfaction O
of O
daily B-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
, O
( O
iv O
) O
dependence O
on O
medications B-outcome ['Resource-use']
, O
( O
v O
) O
working B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
, O
( O
vi O
) O
fatigue B-outcome ['Physiological-Clinical']
, O
( O
vii O
) O
appetite B-outcome ['Physiological-Clinical']
, O
( O
viii O
) O
sociality B-outcome ['Life-Impact']
, O
( O
ix O
) O
happiness O
and O
( O
x O
) O
self O
respect O
, O
in O
the O
third O
, O
sixth O
and O
twelfth O
month O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

No O
significant O
difference O
was O
found O
between O
the O
groups O
when O
compared O
for O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
labor I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
Apgar I-outcome ['Physiological-Clinical']
scores O
. O
['Physiological-Clinical']

This O
study O
investigated O
differences O
between O
the O
symptoms O
associated O
with O
either O
adjuvant O
tamoxifen O
or O
exemestane O
. O
[]

This O
clinical O
study O
suggests O
that O
non-root O
substance O
removing O
curettes O
may O
be O
valuable O
instruments O
for O
periodontally O
treated O
patients O
during O
maintenance O
care O
, O
thus O
minimizing O
trauma O
on O
the O
hard O
structures O
of O
the O
teeth O
. O
[]

Limited O
effects O
of O
micronutrient O
supplementation O
on O
strength B-outcome ['Physiological-Clinical']
and O
physical O
function O
after O
abdominal B-outcome ['Physiological-Clinical']
aortic O
aneurysmectomy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
estimated O
means O
[ O
95 O
% O
CI O
] O
of O
direct B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
and O
reduction O
of O
fear B-outcome ['Life-Impact']
of O
progression B-outcome ['Physiological-Clinical']
were O
< O
euro O
> O
9,045.03 O
[ O
6,359.07 O
; O
12,091.87 O
] O
and O
1.41 O
[ O
0.93 O
; O
1.92 O
] O
for O
patients O
in O
the O
SET O
and O
< O
euro O
> O
6,682.78 O
[ O
4,998.09 O
; O
8,440.95 O
] O
and O
1.44 O
[ O
1.02 O
; O
1.09 O
] O
for O
patients O
in O
the O
CBT O
. O
['Resource-use', 'Life-Impact', 'Physiological-Clinical']

Genotyping O
used O
Affymetrix B-outcome ['Resource-use']
arrays I-outcome ['Resource-use']
( O
Santa O
Clara O
, O
CA O
, O
USA O
) O
. O
['Resource-use']

RESULTS O
During O
trial O
1 O
, O
there O
was O
a O
-0.6 O
+/- O
0.3 O
mmol O
l-1 O
( O
mean O
+/- O
SE O
) O
change O
in O
lactate B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Ninety O
patients O
were O
recruited O
, O
of O
which O
84 O
were O
included O
in O
the O
analysis O
( O
control O
group O
n=43 O
; O
T2 O
group O
n=41 O
) O
. O
[]

Addition O
of O
LEV O
to O
high-concentrate O
, O
corn-based O
diets O
did O
not O
improve O
( O
P O
> O
0.10 O
) O
growth B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
of O
feedlot O
steers O
. O
['Physiological-Clinical']

No O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
or I-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
reported O
, O
and O
all O
patients O
who O
entered O
the O
study O
completed O
it O
. O
['Adverse-effects']

Significant O
reduction O
in O
( O
BMI-Z O
) O
was O
achieved O
in O
both O
groups O
during O
intervention O
and O
was O
significantly O
greater O
for O
the O
HPLC O
group O
( O
P O
= O
.03 O
) O
. O
['Physiological-Clinical']

The O
Breast O
Cancer O
Prevention O
Trial O
is O
the O
largest O
breast O
cancer O
prevention O
study O
ever O
undertaken O
. O
[]

Jejunal O
feeding O
was O
tolerated B-outcome ['Life-Impact']
unconditionally O
in O
25 O
( O
86 O
% O
) O
of O
the O
TEN O
group O
. O
['Life-Impact']

Hyperactivity B-outcome ['Life-Impact']
and O
impulsivity B-outcome ['Life-Impact']
improved O
more O
than O
inattention B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

No O
subjects O
developed O
systemic B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
prospective O
randomised O
comparison O
of O
the O
dynamic O
hip O
screw O
and O
the O
gamma O
locking O
nail O
. O
[]

CONCLUSION O
This O
study O
for O
the O
first O
time O
shows O
rapid O
in O
vivo O
effects O
of O
external O
glucocorticosteroids O
in O
humans O
. O
[]

CONCLUSIONS O
Omeprazole O
given O
as O
a O
continuous O
infusion O
of O
80 O
mg O
+ O
8 O
mg/h O
for O
72 O
h O
followed O
by O
omeprazole O
20 O
mg O
once O
daily O
raised O
the O
[]

Significant O
differences O
tended O
to O
show O
that O
the O
control O
condition O
was O
superior O
on O
parent-rated O
measures O
of O
hyperactivity B-outcome ['Life-Impact']
and O
on O
direct O
observational O
measures O
of O
ear-occlusion B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Eight O
percent O
of O
patients O
were O
treated O
at O
the O
time O
of O
study O
enrollment O
and O
an O
additional O
33 O
% O
were O
treated O
during O
follow-up O
. O
[]

BACKGROUND O
Tibial B-outcome ['Physiological-Clinical']
tubercle-trochlear I-outcome ['Physiological-Clinical']
groove I-outcome ['Physiological-Clinical']
distance O
( O
TT-TG O
) O
is O
a O
commonly O
used O
measurement O
for O
surgical O
decision O
making O
in O
patients O
with O
patellofemoral O
malalignment O
and O
instability O
. O
['Physiological-Clinical']

The O
study O
is O
aimed O
at O
assessing O
the O
structural O
and O
immunohistochemical O
changes O
of O
conjunctiva O
induced O
by O
topical O
glaucoma O
medication O
. O
[]

CONCLUSIONS O
The O
results O
of O
this O
study O
suggest O
that O
MPH O
formulations O
are O
efficacious O
and O
well-tolerated B-outcome ['Life-Impact']
for O
children O
with O
ASD O
and O
significant O
ADHD O
symptoms O
. O
['Life-Impact']

OBJECTIVE O
To O
test O
the O
effect O
of O
a O
consumer-directed O
model O
( O
Cash O
and O
Counseling O
) O
of O
Medicaid O
personal O
care O
services O
( O
PCS O
) O
or O
home- O
and O
community-based O
waiver O
services O
( O
HCBS O
) O
on O
the O
cost O
of O
Medicaid O
services O
. O
[]

No O
adverse B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
with O
Tramal O
concerning O
the O
follow-up O
of O
labour O
or O
the O
newborn O
. O
['Adverse-effects']

The O
technique O
of O
dual O
isotopes O
of O
stable O
calcium O
was O
used O
with O
a O
calcium O
carrier O
to O
measure O
calcium O
absorption O
at O
baseline O
and O
after O
8 O
wk O
. O
[]

This O
study O
aims O
to O
investigate O
the O
oral O
bioavailability O
of O
moxifloxacin O
in O
12 O
healthy O
volunteers O
who O
underwent O
gastric O
bypass O
surgery O
. O
[]

Between O
the O
third O
and O
sixth O
cycle O
, O
no O
further O
significant O
changes O
were O
observed O
, O
nor O
did O
these O
changes O
differ O
significantly O
between O
the O
two O
groups O
. O
[]

Prothrombin O
fragments O
1+2 O
and O
urinary O
11-dehydro-thromboxane O
B2 O
( O
TXB2 O
) O
were O
additionally O
measured O
in O
60 O
of O
100 O
patients O
( O
30 O
of O
whom O
were O
smokers O
) O
and O
in O
24 O
healthy O
controls O
. O
[]

The O
longer O
patients O
waited O
in O
the O
clinic O
to O
see O
their O
providers O
, O
the O
less O
satisfied B-outcome ['Life-Impact']
they O
were O
with O
the O
clinic O
visit O
. O
['Life-Impact']

The O
Antiarrhythmics O
versus O
Implantable O
Defibrillators O
( O
AVID O
) O
Investigators O
. O
[]

A O
large O
and O
rapid O
fall O
in O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
may O
promote O
transient O
deterioration O
of O
diabetic O
retinopathy O
. O
['Physiological-Clinical']

Baseline O
QOL B-outcome ['Life-Impact']
scores O
indicated O
significant O
differences O
between O
patients O
with O
CRS O
and O
published O
norms O
in O
6/8 O
subscale O
parameters O
( O
role O
physical O
, O
bodily B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
general B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
, O
social B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
vitality B-outcome ['Physiological-Clinical']
, O
and O
mental O
health O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

This O
double-blind O
, O
randomized O
, O
phase O
III O
clinical O
trial O
was O
carried O
out O
in O
two O
parallel O
groups O
to O
assess O
the O
efficacy O
of O
ebrotidine O
( O
N- O
[ O
( O
E O
) O
- O
[ O
[ O
2- O
[ O
[ O
[ O
2- O
[ O
( O
diaminomethylene O
) O
amino O
] O
-4-thiazolyl O
] O
methyl O
] O
thio O
] O
ethyl O
] O
amino O
] O
methylene O
] O
-4-bromo-benzenesulfonamide O
, O
CAS O
100981-43-9 O
, O
FI-3542 O
) O
400 O
mg O
and O
ranitidine O
300 O
mg O
given O
in O
single O
evening O
dose O
, O
combined O
with O
amoxicillin O
750 O
mg O
and O
metronidazole O
500 O
mg O
three O
times O
daily O
for O
14 O
days O
, O
in O
the O
eradication B-outcome ['Physiological-Clinical']
of O
Helicobacter O
pylori O
in O
patients O
with O
duodenal O
ulcer O
. O
['Physiological-Clinical']

CA B-outcome ['Physiological-Clinical']
was O
['Physiological-Clinical']

Atropine O
had O
no O
significant O
effect O
on O
metabolic B-outcome ['Physiological-Clinical']
variables O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
assess O
the O
effectiveness O
of O
expert O
training O
and O
consultancy O
for O
teachers O
of O
children O
with O
autism O
spectrum O
disorder O
in O
the O
use O
of O
the O
Picture O
Exchange O
Communication O
System O
( O
PECS O
) O
. O
[]

CRP B-outcome ['Physiological-Clinical']
and O
prothrombin B-outcome ['Physiological-Clinical']
fragment I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
( O
F1+2 O
) O
were O
measured O
at O
baseline O
, O
and O
two O
times O
after O
vaccination O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Behavioral B-outcome ['Life-Impact']
effects O
of O
Org O
2766 O
, O
a O
synthetic O
analog O
of O
the O
adrenocorticotrophic O
hormone O
( O
4-9 O
) O
, O
in O
14 O
outpatient O
autistic O
children O
. O
['Life-Impact']

The O
combination O
of O
wall O
motion O
and O
MCE O
assessment O
gave O
the O
best O
balance O
of O
sensitivity O
( O
46 O
% O
to O
55 O
% O
) O
and O
specificity O
( O
82 O
% O
to O
83 O
% O
) O
. O
[]

Immunotherapy O
maintenance O
in O
acute O
non-lymphocytic O
leukaemia O
. O
[]

Both O
the O
oral O
and O
transdermal O
treatment O
groups O
showed O
significant O
increases O
in O
[]

Near O
normoglycaemia O
was O
achieved O
with O
continuous O
infusion O
and O
multiple O
injections O
but O
not O
with O
conventional O
treatment O
. O
[]

The O
mean O
apical B-outcome ['Physiological-Clinical']
leakage I-outcome ['Physiological-Clinical']
of O
six O
groups O
was O
as O
follows O
: O
I O
= O
0.45 O
mm O
, O
II O
= O
0.277 O
mm O
, O
III O
= O
0.343 O
mm O
, O
IV O
= O
0.263 O
mm O
, O
V O
= O
0.336 O
mm O
, O
and O
VI O
= O
2.310 O
mm O
. O
['Physiological-Clinical']

At O
6 O
months O
, O
the O
UC O
group O
showed O
QoL O
improvement O
and O
less O
anxiety B-outcome ['Life-Impact']
compared O
to O
the O
CER O
group O
. O
['Life-Impact', 'Life-Impact']

Forty-five O
( O
45 O
) O
female O
subjects O
, O
between O
the O
ages O
of O
18 O
and O
40 O
years O
, O
were O
randomly O
assigned O
to O
three O
groups O
consisting O
of O
the O
no-treatment O
control O
, O
the O
treatment-control O
( O
table O
stabilization O
) O
, O
and O
the O
experimental O
( O
PostureJac O
) O
group O
. O
[]

Zoledronic O
acid O
significantly O
reduces O
skeletal O
complications O
compared O
with O
placebo O
in O
Japanese O
women O
with O
bone O
metastases O
from O
breast O
cancer O
: O
a O
randomized O
, O
placebo-controlled O
trial O
. O
[]

Analysis O
of O
drainage O
fluids O
showed O
a O
higher B-outcome ['Physiological-Clinical']
contamination I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
15/18 O
= O
83 O
% O
) O
in O
the O
control O
group O
as O
compared O
to O
the O
prophylaxis O
arm O
( O
2/20 O
= O
10 O
% O
) O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Regarding O
survival B-outcome ['Mortality']
, O
Stage O
II O
patients O
with O
medially O
located O
tumors O
seemed O
to O
benefit O
more O
from O
60Co O
radiation O
than O
those O
with O
lateral O
tumors O
. O
['Mortality']

METHODS O
The O
Prostate O
, O
Colorectal O
, O
Lung O
and O
Ovarian O
( O
PLCO O
) O
Cancer O
Screening O
Trial O
is O
a O
multicenter O
randomized O
trial O
designed O
to O
evaluate O
the O
effectiveness O
of O
screening O
for O
the O
PLCO O
cancers O
. O
[]

The O
correlation O
with O
the O
central O
PP O
was O
stronger O
than O
with O
the O
brachial B-outcome ['Physiological-Clinical']
PP I-outcome ['Physiological-Clinical']
( O
P O
= O
0.018 O
) O
or O
central B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
P O
= O
0.002 O
) O
, O
and O
these O
relationships O
were O
essentially O
the O
same O
even O
after O
adjustment O
for O
the O
use O
of O
atenolol O
or O
the O
change O
in O
heart O
rate O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pars O
plana O
vitrectomy O
for O
diabetic O
macular O
edema O
. O
[]

However O
, O
BOP B-outcome ['Physiological-Clinical']
and O
PD B-outcome ['Physiological-Clinical']
in O
placebo O
and O
control O
sites O
increased O
from O
weeks O
9 O
to O
17 O
Peptidase B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
periodontal O
pocket O
decreased O
noticeably O
from O
week O
1 O
to O
17 O
, O
compared O
with O
baseline O
values O
for O
the O
treatment O
site O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Our O
double-blind O
, O
placebo-controlled O
clinical O
trial O
was O
designed O
to O
test O
the O
efficacy O
of O
beta-carotene O
in O
raising O
CD4 O
counts O
in O
HIV-infected O
patients O
. O
[]

Using O
an O
imaging O
genetics O
approach O
, O
we O
studied O
differential O
effects O
of O
an O
intranasal O
OT O
application O
on O
neural B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
stimuli I-outcome ['Life-Impact']
in O
55 O
healthy O
young O
men O
depending O
on O
their O
CD38 O
gene O
variant O
in O
a O
double-blind O
placebo-controlled O
crossover O
design O
. O
['Life-Impact']

Treatments O
were O
considered O
equivalent O
if O
the O
95 O
% O
confidence O
interval O
( O
CI B-outcome ['Physiological-Clinical']
) O
for O
the O
difference O
in O
proportions O
of O
patients O
achieving B-outcome ['Life-Impact']
an O
HIV-1 O
RNA O
level O
of O
< O
400 O
copies/mL O
was O
within O
the O
bound O
of O
-12 O
% O
to O
12 O
% O
. O
['Physiological-Clinical', 'Life-Impact']

A O
preliminary O
study O
of O
the O
optimal O
anesthesia O
positioning O
for O
the O
morbidly O
obese O
patient O
. O
[]

Only O
a O
few O
, O
mild O
adverse O
reactions O
to O
the O
vehicle O
cream O
were O
reported O
. O
[]

Intervention O
components O
with O
the O
greatest O
dose O
received O
were O
giveaways O
( O
42.0-61.7 O
% O
) O
, O
followed O
by O
taste B-outcome ['Life-Impact']
tests O
( O
48.7-53.7 O
% O
) O
and O
posters O
( O
34.3-65.0 O
% O
) O
. O
['Life-Impact']

A O
comparison O
of O
the O
effect O
of O
short-term O
aromatase O
inhibitor O
( O
letrozole O
) O
and O
GnRH O
agonist O
( O
triptorelin O
) O
versus O
case O
control O
on O
pregnancy B-outcome ['Physiological-Clinical']
rate O
and O
symptom B-outcome ['Physiological-Clinical']
and O
sign B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
after O
laparoscopic O
treatment O
of O
endometriosis O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Environmental O
enrichment O
therefore O
appears O
to O
be O
effective O
in O
ameliorating O
some O
of O
the O
symptoms O
of O
autism O
in O
children O
. O
[]

CONCLUSION O
Aerosolized O
tobramycin O
was O
well O
tolerated O
in O
ventilated O
patients O
with O
documented O
nosocomial O
pneumonia O
. O
[]

OBJECTIVES O
The O
aims O
of O
this O
study O
were O
1 O
) O
to O
evaluate O
the O
role O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
associated O
neural B-outcome ['Physiological-Clinical']
tonicity I-outcome ['Physiological-Clinical']
in O
ambient O
ischemia O
of O
a O
group O
of O
hypertensive O
patients O
with O
stable O
angina O
, O
and O
2 O
) O
to O
determine O
the O
efficacy O
of O
immediate O
release O
nifedipine O
therapy O
in O
controlling O
the O
total O
ischemic O
burden O
in O
both O
office-measured O
and O
ambulatory O
blood O
pressure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
, O
the O
largest O
ever O
study O
of O
nutritional O
support O
after O
hip O
fracture O
, O
shows O
that O
their O
employment O
significantly O
reduced O
patients O
' O
risk O
[]

This O
inhibition O
was O
incomplete O
because O
AII O
levels O
increased O
markedly O
when O
captopril O
was O
given O
( O
no O
treatment O
effect O
: O
p O
< O
0.37 O
) O
. O
[]

The O
thrombotic B-outcome ['Physiological-Clinical']
CV I-outcome ['Physiological-Clinical']
risk O
hazard O
ratio O
( O
HR O
) O
( O
etoricoxib O
to O
diclofenac O
) O
was O
0.96 O
( O
95 O
% O
CI O
0.81 O
, O
1.15 O
) O
, O
consistent O
with O
non-inferiority O
of O
etoricoxib O
to O
diclofenac O
. O
['Physiological-Clinical']

All O
cumulus-enclosed O
oocytes O
of O
healthy O
appearance O
were O
matured O
in O
culture O
medium O
( O
TCM-199 O
) O
in O
vitro O
for O
28-36 O
h O
before O
intracytoplasmic O
sperm O
injection O
( O
ICSI O
) O
. O
[]

TRIAL O
REGISTRATION O
Dutch O
Trial O
Register O
( O
NTR O
) O
: O
2297 O
: O
http O
: O
//www.trialregister.nl/trialreg/admin/rctview.asp O
? O
[]

Before O
treatment O
there O
was O
no O
statistical O
difference O
in O
the O
pathological B-outcome ['Physiological-Clinical']
results I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cervix I-outcome ['Physiological-Clinical']
and O
the O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hTERT I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Perioperative B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
, O
including O
cervical B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
hematoma I-outcome ['Physiological-Clinical']
, O
transient B-outcome ['Physiological-Clinical']
ischemic I-outcome ['Physiological-Clinical']
attack I-outcome ['Physiological-Clinical']
, O
and O
stroke B-outcome ['Physiological-Clinical']
, O
and O
perioperative B-outcome ['Mortality']
mortality I-outcome ['Mortality']
were O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Consumer-directed O
care O
for O
beneficiaries O
with O
mental O
illness O
: O
lessons O
from O
New O
Jersey O
's O
Cash O
and O
Counseling O
program O
. O
[]

The O
use O
of O
topical O
anesthetic O
did O
not O
significantly O
reduce O
pain B-outcome ['Physiological-Clinical']
of O
needle O
insertion O
when O
compared O
to O
a O
placebo O
. O
['Physiological-Clinical']

Pharmacokinetic O
studies O
suggest O
that O
armodafinil O
achieves O
higher O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
than O
modafinil O
late O
in O
a O
dose O
interval O
following O
equal O
oral O
doses O
. O
['Physiological-Clinical']

High B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
remained O
unchanged O
. O
['Physiological-Clinical']

The O
efficacy O
of O
prophylactic O
ondansetron O
, O
droperidol O
, O
perphenazine O
, O
and O
metoclopramide O
in O
the O
prevention O
of O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
after O
major O
gynecologic O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pathology O
parameters O
and O
adjuvant B-outcome ['Physiological-Clinical']
tamoxifen I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
a O
randomised O
premenopausal O
breast O
cancer O
trial O
. O
['Physiological-Clinical']

Possible O
mechanisms O
to O
explain O
this O
finding O
are O
discussed O
. O
[]

Results O
revealed O
, O
in O
comparison O
to O
the O
waitlist O
group O
, O
that O
the O
experimental O
treatment O
group O
significantly O
improved O
their O
knowledge O
of O
PEERS O
concepts O
and O
friendship B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
increased O
in O
their O
amount B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
get-togethers I-outcome ['Life-Impact']
, O
and O
decreased O
in O
their O
levels O
of O
social B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
, O
core B-outcome ['Life-Impact']
autistic I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
and O
problem B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
from O
pre-to O
post-PEERS O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Skeletal-related B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SREs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
defined O
as O
pathologic O
bone O
fractures O
, O
spinal O
cord O
compression O
, O
surgery O
to O
bone O
, O
radiation O
therapy O
to O
bone O
, O
and O
hypercalcemia O
of O
malignancy O
. O
['Physiological-Clinical']

After O
identifying O
potential O
implementation O
difficulties O
, O
we O
will O
design O
two O
interventions O
using O
theories O
of O
behaviour O
change O
to O
link O
them O
with O
relevant O
behaviour O
change O
techniques O
aiming O
to O
improve O
guideline O
adherence O
. O
[]

Participants O
assigned O
to O
3CM O
were O
more O
likely O
to O
have O
a O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
visit I-outcome ['Life-Impact']
, O
fill O
an O
antidepressant O
prescription O
, O
and O
have O
adequate B-outcome ['Life-Impact']
antidepressant I-outcome ['Life-Impact']
refills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

METHODS O
In O
a O
multicenter O
, O
prospective O
, O
nonmasked O
clinical O
trial O
, O
831 O
patients O
who O
underwent O
peripheral O
arterial O
bypass O
surgery O
were O
compared O
in O
a O
long-term O
treatment O
program O
of O
WASA O
( O
target O
international O
normalized O
ratio O
of O
1.4 O
to O
2.8 O
; O
325 O
mg/day O
) O
with O
ASA O
( O
325 O
mg/day O
) O
. O
[]

In O
the O
BDP O
+ O
S O
group O
, O
the O
improvement O
in O
symptoms B-outcome ['Physiological-Clinical']
and O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
persisted O
until O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Those O
in O
the O
motivation O
intervention O
arm O
experienced O
a O
greater O
reduction O
in O
[]

Median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
PFS B-outcome ['Physiological-Clinical']
, O
months O
) O
was O
similar O
in O
both O
treatment O
arms O
( O
pemetrexed-cisplatin O
, O
3.6 O
; O
placebo-cisplatin O
, O
2.8 O
; O
HR O
, O
0.88 O
; O
95 O
% O
CI O
, O
0.76-1.03 O
; O
P O
= O
.166 O
) O
. O
['Mortality', 'Physiological-Clinical']

After O
a O
2-week O
complete O
pharmacological O
washout O
, O
clinical O
examination O
, O
electrocardiogram O
, O
and O
Doppler O
echocardiography O
were O
performed O
at O
baseline O
, O
15 O
, O
30 O
, O
45 O
, O
and O
60 O
min O
after O
sumatriptan O
or O
placebo O
administration O
. O
[]

Effects O
of O
water O
extracts O
of O
Graptopetalum O
paraguayense O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
fasting B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
and O
lipid B-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
of O
subjects O
with O
metabolic O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Twenty O
patients O
with O
seborrhoeic O
dermatitis O
were O
included O
in O
this O
study O
, O
11 O
patients O
in O
the O
pimecrolimus O
1 O
% O
cream O
group O
and O
nine O
patients O
in O
the O
betamethasone O
17-valerate O
0.1 O
% O
cream O
group O
. O
[]

A O
comparison O
between O
the O
effect O
of O
oxytocin O
only O
and O
oxytocin O
plus O
propranolol O
on O
the O
labor B-outcome ['Physiological-Clinical']
( O
a O
double O
blind O
randomized O
trial O
) O
. O
['Physiological-Clinical']

Genotyping O
was O
conducted O
using O
TaqMan O
, O
MassARRAY O
iPLEX O
, O
and O
sequencing O
. O
[]

Similar O
relationships O
were O
noted O
for O
deterioration B-outcome ['Physiological-Clinical']
alone I-outcome ['Physiological-Clinical']
, O
and O
recurrent B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
median O
survival O
was O
5.3 O
months O
( O
95 O
% O
confidence O
interval O
4.6-6.2 O
) O
. O
[]

Comparison O
of O
split-course O
radiation O
therapy O
and O
continuous O
radiation O
therapy O
for O
unresectable O
bronchogenic O
carcinoma O
: O
5 O
year O
results O
. O
[]

A O
priori O
stopping O
rules O
were O
defined O
for O
early O
termination O
of O
the O
trial O
. O
[]

There O
were O
no O
significant O
changes O
in O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
after O
HSS O
or O
saline O
placebo O
. O
['Physiological-Clinical']

The O
augmentation O
with O
safe O
supplementation O
of O
medication O
, O
such O
as O
with O
trace O
elements O
, O
may O
be O
a O
solution O
to O
some O
of O
these O
problems O
. O
[]

Interleukin-6 O
receptor O
inhibition O
with O
tocilizumab O
and O
attainment O
of O
disease O
remission O
in O
rheumatoid O
arthritis O
: O
the O
role O
of O
acute-phase O
reactants O
. O
[]

[ O
A O
clinical O
study O
on O
the O
effect O
of O
Yinxing O
Damo O
combined O
with O
betahistine O
hydrochloride O
injection O
on O
vertebral B-outcome ['Physiological-Clinical']
basilar I-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
ischemic I-outcome ['Physiological-Clinical']
vertigo I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
were O
no O
other O
statistically O
significant O
differences O
between O
the O
groups O
. O
[]

Metabolic O
and O
circulatory O
effects O
of O
oral O
salbutamol O
in O
the O
third O
trimester O
of O
pregnancy O
in O
diabetic O
and O
non-diabetic O
women O
. O
[]

Thirty-one O
patients O
scheduled O
for O
long-term O
( O
24 O
weeks O
) O
treatment O
with O
prednisone O
in O
comparatively O
high O
doses O
were O
randomly O
allocated O
to O
two O
further O
treatment O
groups O
. O
[]

SETTING O
University O
Hospital O
, O
cardiac O
surgical O
operative O
theatre O
. O
[]

A O
decrease O
in O
temperature B-outcome ['Physiological-Clinical']
was O
observed O
in O
21 O
( O
72.4 O
% O
) O
of O
the O
29 O
patients O
who O
received O
warm O
irrigation B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
Evaluation O
of O
Stepping O
Stones O
Triple O
P O
: O
Interims O
analysis O
of O
the O
Stepping-Stones-SPC-Multicentric O
Study O
] O
. O
[]

RESULTS O
Twenty O
participants O
( O
24.4 O
% O
) O
quit O
during O
the O
6-month O
intervention O
period O
. O
[]

OBJECTIVE O
To O
compare O
the O
effects O
of O
presacral O
irrigation O
and O
simple O
drainage O
on O
the O
perineal O
wound O
healing O
in O
patients O
after O
abdominoperineal O
resection O
( O
APR O
) O
. O
[]

Gemcitabine O
and O
split-dose O
paclitaxel O
or O
docetaxel O
in O
metastatic O
breast O
cancer O
: O
a O
randomised O
phase O
II O
study O
. O
[]

METHODS O
A O
randomized O
controlled O
trial O
of O
an O
Internet-based O
multimedia O
program O
to O
reduce O
risk O
of O
unintended O
pregnancy O
and O
STIs O
among O
midlife O
women O
was O
conducted O
with O
164 O
women O
ages O
40-55 O
years O
of O
age O
. O
[]

IMg2+ O
values O
correlated O
with O
TMg O
values O
in O
both O
hemodialysis O
( O
r O
= O
0.93 O
; O
p O
< O
0.0001 O
) O
and O
CAPD O
( O
r O
= O
0.92 O
; O
p O
< O
0.0001 O
) O
patients O
did O
not O
correlate O
with O
age O
, O
time O
on O
dialysis O
, O
weight O
, O
fasting O
cholesterol O
or O
triglyceride O
, O
albumin O
, O
blood O
urea O
nitrogen O
( O
BUN O
) O
, O
creatinine O
, O
hematocrit O
, O
phosphate O
, O
or O
PTH O
values O
. O
( O
[]

Although O
the O
median O
duration O
of O
response O
was O
long O
in O
both O
treatment O
arms O
( O
combination O
, O
19 O
months O
versus O
alternating O
, O
21 O
months O
) O
, O
the O
median O
[]

The O
training O
was O
conducted O
for O
five O
weeks O
, O
consisting O
of O
two O
hours O
training O
a O
week O
. O
[]

CONCLUSIONS O
Ofloxacin O
penetrates O
better O
than O
ciprofloxacin B-outcome ['Physiological-Clinical']
into O
the O
aqueous O
of O
eyes O
with O
filtering O
blebs O
, O
particularly O
after O
combined O
topical O
and O
oral O
administration O
, O
by O
which O
ofloxacin O
reaches O
more O
than O
a O
10-fold O
greater O
concentration O
than O
does O
ciprofloxacin O
. O
['Physiological-Clinical']

The O
suppression O
of O
1,25 O
( O
OH O
) O
2D O
may O
be O
an O
effect O
of O
raised O
25OHD2 O
alone O
, O
or O
in O
combination O
with O
corticosteroid O
excess O
. O
[]

A O
total O
of O
204 O
patients O
were O
enrolled O
in O
the O
study O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
similar O
between O
groups O
. O
['Physiological-Clinical']

The O
presence O
of O
shock O
on O
arrival O
, O
which O
was O
found O
to O
increase O
the O
risk O
of O
infection B-outcome ['Physiological-Clinical']
when O
this O
factor O
was O
analyzed O
individually O
, O
did O
not O
add O
predictive O
power O
. O
['Physiological-Clinical']

In O
addition O
, O
the O
degree O
of O
the O
temporal B-outcome ['Physiological-Clinical']
summation I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
electrical I-outcome ['Physiological-Clinical']
and O
heat B-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
decreased O
significantly O
following O
treatment O
in O
both O
venlafaxine O
groups O
compared O
to O
the O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
follow-up O
study O
16 O
months O
later O
evaluated O
the O
extent O
to O
which O
the O
skills O
and O
equipment O
necessary O
for O
CPAP O
use O
have O
been O
maintained O
. O
[]

CONCLUSION O
To O
our O
knowledge O
, O
this O
trial O
is O
the O
first O
to O
evaluate O
the O
effect O
of O
prescription O
label O
improvement O
on O
understanding B-outcome ['Life-Impact']
, O
medication B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
and O
outcomes O
in O
a O
clinical O
setting O
. O
['Life-Impact', 'Life-Impact']

They O
then O
received O
a O
4-week O
course O
of O
the O
reverse O
study O
medication O
. O
[]

CONCLUSION O
The O
results O
provide O
the O
first O
clinical O
demonstration O
of O
specific O
probiotic O
strains O
modifying O
the O
changes O
related O
to O
allergic B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
When O
compared O
with O
baseline O
results O
, O
maximum B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
consumption B-outcome ['Resource-use']
was O
significantly O
increased O
( O
P=.031 O
) O
, O
suggesting O
an O
improvement O
in O
physical B-outcome ['Life-Impact']
fitness I-outcome ['Life-Impact']
in O
the O
intervention O
group O
. O
['Physiological-Clinical', 'Resource-use', 'Life-Impact']

However O
, O
this O
approach O
presents O
several O
barriers O
, O
including O
delays O
in O
receiving O
information O
, O
difficulty O
in O
integrating O
responses O
with O
electronic O
records O
, O
and O
the O
time O
required O
to O
manually O
score O
questionnaires O
for O
measurement O
purposes O
. O
[]

This O
study O
was O
funded O
by O
the O
National O
Heart O
, O
Lung O
, O
and O
Blood O
Institute O
and O
the O
National O
Cancer O
Institute O
; O
and O
the O
trial O
was O
registered O
at O
www.clinicaltrials.gov O
as O
# O
NCT00406393 O
. O
[]

CONCLUSION O
The O
effect O
of O
behavior O
training O
with O
head O
needle O
retention O
on O
autism O
children O
is O
better O
than O
behavior O
training O
after O
acupuncture O
treatment O
, O
especially O
in O
enhancing O
cognition B-outcome ['Life-Impact']
understanding I-outcome ['Life-Impact']
and O
cognition B-outcome ['Life-Impact']
expression I-outcome ['Life-Impact']
. O
['Life-Impact']

In O
summary O
, O
excluding O
glucose O
from O
a O
short-term O
feeding O
protocol O
does O
not O
diminish O
the O
protein-sparing B-outcome ['Physiological-Clinical']
effect O
of O
amino O
acids O
and O
avoids O
hyperglycemia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Authors O
examined O
the O
combined O
effects O
of O
descriptive O
and O
explanatory O
information O
on O
peers O
' O
perceptions B-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
intentions I-outcome ['Life-Impact']
toward O
an O
unfamiliar O
child O
with O
autism O
. O
['Life-Impact', 'Life-Impact']

Sigmoidoscopy O
was O
performed O
4 O
wk O
after O
treatment O
to O
determine O
the O
adequacy O
of O
polyp O
eradication O
. O
[]

Silent O
myocardial O
ischemia O
is O
a O
frequent O
finding O
when O
Holter O
monitoring O
is O
done O
in O
patients O
with O
advanced O
coronary O
disease O
. O
[]

The O
statistical O
analysis O
was O
done O
through O
one-way O
anova O
followed O
by O
least O
significant O
difference O
( O
LSD O
) O
. O
[]

Following O
the O
seminar O
, O
physicians O
were O
presented O
with O
4 O
clinical O
vignettes O
and O
asked O
to O
describe O
what O
tests O
, O
treatments O
, O
counseling O
, O
or O
referrals O
they O
would O
recommend O
. O
[]

It O
is O
concluded O
that O
patients O
with O
early O
postinfarction O
angina O
are O
at O
increased O
risk O
of O
reinfarction B-outcome ['Physiological-Clinical']
and O
death B-outcome ['Mortality']
, O
and O
angina B-outcome ['Physiological-Clinical']
associated O
with O
transient B-outcome ['Physiological-Clinical']
electrocardiographic I-outcome ['Physiological-Clinical']
changes O
identified O
a O
very O
high O
risk O
subset O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Quantitative O
analysis O
of O
this O
effect O
of O
the O
instruments O
used O
was O
performed O
on O
20 O
freshly O
extracted O
, O
non-periodontally O
involved O
, O
large O
human O
molars O
. O
[]

A O
trend O
is O
developing O
for O
greater O
reduction O
of O
depressive B-outcome ['Life-Impact']
symptomatology I-outcome ['Life-Impact']
in O
the O
group O
treated O
with O
self-disclosure O
. O
['Life-Impact']

In O
cancer O
research O
we O
are O
more O
often O
concerned O
with O
survival B-outcome ['Mortality']
. O
['Mortality']

CONCLUSIONS O
All O
three O
interventions O
resulted O
in O
increased O
knowledge B-outcome ['Life-Impact']
about O
breast O
cancer O
and O
screening O
. O
['Life-Impact']

3.0 O
; O
p O
< O
0.01 O
) O
. O
[]

No O
patient O
experienced O
virologic O
failure O
, O
clinical O
disease O
progression O
, O
or O
a O
drug-related B-outcome ['Adverse-effects']
serious I-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
during O
the O
trial O
. O
['Adverse-effects']

It O
is O
uncertain O
whether O
administration O
of O
intravenous O
( O
IV O
) O
anti-oxidant O
, O
N-acetylcysteine O
( O
NAC O
) O
, O
can O
prevent O
reduction O
in O
renal O
function O
and O
whether O
this O
is O
a O
cost-effective O
approach O
. O
[]

MET O
treatment O
was O
associated O
with O
a O
decreased O
BMI O
( O
p O
= O
0.02 O
) O
as O
well O
as O
with O
a O
reduction O
in O
subcutaneous B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
( O
p O
= O
0.03 O
) O
, O
particularly O
the O
deep B-outcome ['Physiological-Clinical']
subcutaneous I-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
( O
p O
= O
0.04 O
) O
as O
assessed O
by O
magnetic O
resonance O
imaging O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Before O
treatment O
, O
IL-1 O
beta O
production O
did O
not O
relate O
to O
severity O
of O
disease O
except O
in O
response O
to O
S O
epidermidis O
. O
( O
[]

The O
intra-arterial O
chemotherapy O
represents O
an O
expensive O
, O
but O
effective O
method O
of O
treatment O
of O
advanced O
ovarian O
carcinomas O
. O
[]

Effect O
of O
ischemic B-outcome ['Physiological-Clinical']
postconditioning I-outcome ['Physiological-Clinical']
in O
correction O
of O
tetralogy O
of O
Fallot O
. O
['Physiological-Clinical']

PATIENTS O
Women O
undergoing O
controlled O
ovarian O
stimulation O
for O
assisted O
conception O
were O
randomized O
to O
receive O
LA O
according O
to O
short O
or O
ultrashort O
protocols O
. O
[]

Markers O
of O
systemic B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
predict O
survival O
in O
patients O
with O
advanced O
renal O
cell O
cancer O
. O
['Physiological-Clinical']

Gender O
, O
mood O
disorder O
, O
and O
antiseizure O
medications O
did O
not O
alter O
response O
. O
[]

CONCLUSION O
The O
marine O
lipid O
suppositories O
and O
ointment O
were O
well O
tolerated O
with O
no O
significant O
toxic B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
observed O
during O
the O
study O
period O
. O
['Adverse-effects']

BACKGROUND O
Tubulointerstitial O
injury O
is O
a O
major O
feature O
of O
diabetic O
nephropathy O
and O
an O
important O
predictor O
of O
renal O
dysfunction O
. O
[]

PATIENTS O
AND O
METHODS O
In O
this O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
, O
patients O
were O
treated O
with O
six O
cycles O
of O
CAF O
therapy O
: O
28 O
days/cycle O
, O
with O
doxorubicin O
( O
25 O
mg/m2 O
) O
and O
fluorouracil O
( O
500 O
mg/m2 O
) O
administered O
on O
days O
1 O
and O
8 O
and O
cyclophosphamide O
( O
100 O
mg O
orally O
[ O
PO O
] O
) O
administered O
on O
day O
1 O
through O
14 O
. O
[]

Patients O
able O
to O
sit O
in O
a O
chair O
( O
n O
= O
65 O
) O
, O
who O
mostly O
had O
less O
severe O
strokes O
, O
had O
a O
significantly O
higher O
mean O
SaO B-outcome ['Physiological-Clinical']
( O
2 O
) O
and O
heart B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

This O
modulation O
was O
stronger O
in O
typical O
than O
in O
Asperger O
children O
. O
[]

The O
effects O
of O
active O
treatment O
on O
outcomes O
were O
estimated O
in O
subgroups O
according O
to O
age O
: O
below O
65 O
, O
65-74 O
and O
at O
least O
75 O
years O
. O
[]

2 O
trial O
, O
confirming O
most O
of O
the O
previous O
results O
of O
the O
BIGPRO O
1 O
trial O
. O
[]

A O
prospective O
, O
randomized O
study O
] O
. O
[]

OBJECTIVE O
To O
compare O
the O
efficacy O
( O
maintenance O
of O
remission B-outcome ['Physiological-Clinical']
) O
, O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
cyclosporin O
( O
CsA O
) O
with O
those O
of O
cyclophosphamide O
in O
patients O
with O
steroid-dependent O
or O
frequently O
relapsing O
nephrotic O
syndrome O
( O
NS O
) O
. O
['Physiological-Clinical', 'Life-Impact']

MAIN O
OUTCOME O
MEASURES O
Primary O
outcomes O
were O
changes O
from O
pretreatment O
to O
posttreatment O
in O
caloric B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
weight O
gain O
. O
['Life-Impact']

Psychological O
theory O
suggests O
that O
if O
threat O
( O
eg O
, O
TC O
) O
information O
is O
accompanied O
with O
threat O
control O
strategies O
( O
eg O
, O
testicular O
self-examination O
; O
TSE O
) O
anxiety O
is O
less O
likely O
. O
[]

SD O
125.8? O
? O
[]

Predictors O
of O
mental O
health O
problems O
and O
negative O
caregiving O
experiences O
in O
carers O
of O
adolescents O
with O
bulimia O
nervosa O
. O
[]

RESULTS O
A O
total O
of O
100 O
women O
( O
mean O
[ O
SD O
] O
age O
, O
52 O
[ O
7 O
] O
years O
; O
height O
, O
154 O
[ O
6 O
] O
cm O
; O
weight O
, O
54 O
[ O
7 O
] O
kg O
) O
were O
included O
in O
the O
study O
. O
[]

Full B-outcome ['Life-Impact']
compliance I-outcome ['Life-Impact']
was O
achieved O
in O
93 O
% O
( O
122 O
of O
131 O
) O
. O
['Life-Impact']

CONCLUSION O
Tension-free O
repair O
was O
superior O
to O
the O
non-mesh O
Shouldice O
technique O
. O
[]

Seventy-eight O
patients O
with O
AFF O
and O
a O
ventricular O
rate O
of O
> O
/= O
120 O
beats O
per O
minute O
were O
enrolled O
. O
[]

Results O
held O
for O
men O
and O
women O
and O
were O
not O
altered O
by O
controlling O
for O
potential O
confounders O
. O
[]

Eighty-six O
male O
mink O
were O
exposed O
to O
low O
( O
19 O
% O
of O
ME O
from O
CP O
; O
crude O
protein O
) O
or O
adequate O
( O
31 O
% O
of O
ME O
from O
CP O
) O
protein O
provision O
in O
utero O
, O
and O
to O
LP O
( O
~20 O
% O
of O
ME O
from O
CP O
) O
or O
AP O
( O
30-42 O
% O
of O
ME O
from O
CP O
) O
provision O
post-weaning O
. O
[]

Treatments O
were O
administered O
during O
one O
month O
, O
then O
cross-overed O
again O
during O
4 O
weeks O
. O
[]

CONCLUSIONS O
From O
the O
results O
obtained O
, O
we O
observed O
that O
application O
of O
topical O
agents O
used O
in O
radio-induced O
skin O
disease O
were O
able O
to O
significantly O
reduce O
the O
erythema B-outcome ['Physiological-Clinical']
extent O
compared O
to O
the O
non-treated O
group O
. O
['Physiological-Clinical']

The O
study O
duration O
was O
3 O
years O
; O
however O
, O
the O
2.5 O
mg O
group O
was O
discontinued O
by O
protocol O
amendment O
after O
2 O
years O
. O
[]

PARTICIPANTS O
Seventy-nine O
children O
aged O
4 O
to O
12 O
years O
below O
the O
40th O
percentile O
for O
weight O
for O
age O
were O
recruited O
. O
[]

Low-dose O
versus O
standard-dose O
gemcitabine O
infusion O
and O
cisplatin O
for O
patients O
with O
advanced O
bladder O
cancer O
: O
a O
randomized O
phase O
II O
trial-an O
update O
. O
[]

In O
the O
majority O
of O
patients O
( O
80 O
% O
) O
, O
therapeutic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
lost O
within O
30 O
minutes O
following O
discontinuation O
of O
esmolol O
infusion O
, O
a O
finding O
indicative O
of O
rapid O
reversal O
of O
beta-adrenoceptor O
blockade O
. O
['Physiological-Clinical']

OBJECTIVE O
Many O
children O
with O
pervasive O
developmental O
disorders O
( O
PDDs O
) O
have O
serious O
, O
functionally B-outcome ['Life-Impact']
impairing I-outcome ['Life-Impact']
behavioral I-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
. O
['Life-Impact']

Few O
side O
effects O
were O
reported O
and O
there O
were O
no O
abnormal O
laboratory O
findings O
during O
treatment O
. O
[]

Using O
the O
transporters O
DVD O
as O
a O
learning O
tool O
for O
children O
with O
Autism O
Spectrum O
Disorders O
( O
ASD O
) O
. O
[]

BACKGROUND O
Mucopurulent O
cervicitis O
( O
MPC O
) O
is O
a O
clinical O
syndrome O
characterized O
by O
mucopurulent O
discharge O
from O
the O
cervix O
and O
other O
signs O
of O
inflammation O
. O
[]

Exemestane O
patients O
reported O
more O
bone/muscle B-outcome ['Physiological-Clinical']
aches I-outcome ['Physiological-Clinical']
( O
P O
< O
.0001 O
) O
, O
vaginal B-outcome ['Physiological-Clinical']
dryness I-outcome ['Physiological-Clinical']
( O
P O
= O
.0004 O
) O
, O
and O
difficulty B-outcome ['Physiological-Clinical']
sleeping I-outcome ['Physiological-Clinical']
( O
P O
= O
.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
an O
educational O
leaflet O
on O
adherence B-outcome ['Life-Impact']
to O
medication O
and O
to O
assess O
the O
association O
between O
adherence B-outcome ['Life-Impact']
and O
health-related B-outcome ['Physiological-Clinical']
quality O
of O
life O
( O
HRQOL O
) O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Before O
initiation O
of O
trial O
centers O
, O
outcome O
ratings O
were O
obtained O
for O
sample O
cases O
to O
establish O
initial O
levels O
of O
agreement O
. O
[]

METHODS O
AND O
RESULTS O
Out O
of O
the O
266 O
AF O
patients O
randomized O
to O
rhythm O
control O
in O
the O
RACE O
study O
, O
49 O
patients O
turned O
to O
long-term O
sinus O
rhythm O
and O
were O
continuously O
treated O
with O
oral O
anticoagulation O
. O
[]

The O
subjects O
of O
the O
control O
group O
( O
n O
= O
12 O
) O
received O
advice O
on O
the O
natural O
evolution O
of O
lateral O
epicondylitis O
, O
computer O
ergonomics O
, O
and O
stretching O
exercises O
. O
[]

Twelve O
student O
actors O
( O
6 O
males O
, O
6 O
females O
) O
were O
given O
voice O
training O
for O
two O
months O
. O
[]

This O
therapy O
has O
iatrogenic O
complications O
, O
such O
as O
osteoporosis O
. O
[]

EPOCH O
consisted O
of O
a O
96-hour O
intravenous O
infusion O
of O
etoposide O
, O
doxorubicin O
, O
and O
vincristine O
plus O
oral O
prednisone O
followed O
by O
intravenous O
bolus O
cyclophosphamide O
given O
every O
21 O
days O
for O
4 O
to O
6 O
cycles O
. O
[]

In O
a O
prospective O
non-randomized O
trial O
, O
59 O
patients O
with O
sepsis O
( O
n O
= O
43 O
) O
and O
SIRS O
( O
n O
= O
16 O
) O
were O
treated O
on O
a O
surgical O
intensive O
care O
unit O
. O
[]

Adjudication O
of O
type-4a B-outcome ['Physiological-Clinical']
MI I-outcome ['Physiological-Clinical']
in O
patients O
with O
an O
ACS O
was O
problematic O
with O
< O
10 O
% O
of O
the O
potential O
type-4a O
MI O
being O
confirmed O
as O
an O
event O
, O
as O
compared O
with O
approximately O
95 O
% O
in O
stable O
patients O
undergoing O
elective O
PCI O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Predictive O
accuracy O
of O
each O
Cox O
proportional O
hazards O
model O
was O
assessed O
using O
the O
c-statistic O
and O
calibration O
chi-square O
. O
[]

Conventional O
medical O
intervention O
has O
unpleasant O
side-effects O
, O
and O
symptoms O
frequently O
return O
after O
treatment O
. O
[]

At O
baseline O
no O
difference O
between O
physical B-outcome ['Physiological-Clinical']
test I-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
was O
evident O
between O
the O
2 O
groups O
( O
p O
> O
0.05 O
) O
. O
['Physiological-Clinical']

5 O
. O
[]

In O
thyrotoxicosis O
, O
trough O
levels O
of O
propranolol B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
nadolol I-outcome ['Physiological-Clinical']
were O
significantly O
inversely O
correlated O
with O
derived O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
values O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
athletes O
were O
randomly O
assigned O
to O
2 O
groups O
: O
chiropractic O
SMT O
and O
sham O
. O
[]

Results O
consistently O
indicated O
that O
concreteness B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
text I-outcome ['Life-Impact']
depend O
on O
how O
materials O
are O
presented O
in O
several O
different O
respects O
. O
['Life-Impact']

CONCLUSIONS O
Oral O
vitamin/mineral O
supplementation O
is O
beneficial O
in O
improving O
the O
nutritional O
and O
metabolic O
status O
of O
children O
with O
autism O
, O
including O
improvements O
in O
methylation O
, O
glutathione O
, O
oxidative O
stress O
, O
sulfation O
, O
ATP O
, O
NADH O
, O
and O
NADPH O
. O
[]

The O
effect O
was O
found O
to O
be O
significant O
among O
the O
high O
employed O
group O
( O
P O
< O
0.01 O
) O
and O
the O
unemployed O
group O
( O
P O
< O
0.05 O
) O
. O
[]

Further O
studies O
are O
warranted O
to O
investigate O
the O
potential O
for O
NFlB O
inhibition O
to O
reduce O
cardiovascular O
risk O
. O
[]

Differences O
in O
change O
scores O
between O
the O
splinting O
and O
the O
control O
group O
were O
analyzed O
using O
analysis O
of O
covariance O
. O
[]

Boswellic O
acids O
( O
BAs O
) O
are O
pentacyclic O
triterpenes O
with O
strong O
anti-inflammatory O
activity O
; O
their O
most O
important O
source O
is O
the O
extract O
of O
the O
gum O
resin O
of O
Boswellia O
serrata O
, O
a O
tropical O
tree O
that O
grows O
in O
India O
and O
Africa O
. O
[]

There O
were O
no O
adverse O
events O
related O
to O
the O
use O
of O
the O
polymeric O
sealant O
in O
this O
study O
. O
[]

MAIN O
OUTCOME O
MEASURE O
The O
self O
rated O
clinical B-outcome ['Physiological-Clinical']
global I-outcome ['Physiological-Clinical']
impression I-outcome ['Physiological-Clinical']
change O
score O
, O
very O
much O
better O
or O
much O
better O
being O
considered O
as O
clinically O
important O
. O
['Physiological-Clinical']

Interindividual O
variability O
showed O
the O
highest O
values O
for O
the O
reactance O
before O
oscillatory B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
and O
Raw O
. O
['Physiological-Clinical']

Data O
on O
36 O
subjects O
were O
analyzed O
and O
taken O
together O
; O
the O
results O
favored O
haloperidol O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effects O
of O
amantadine O
and O
pemoline O
on O
cognitive O
functioning O
in O
MS. O
METHODS O
A O
total O
of O
45 O
ambulatory O
patients O
with O
MS O
and O
severe O
fatigue O
were O
treated O
for O
6 O
weeks O
with O
amantadine O
, O
pemoline O
, O
or O
placebo O
using O
a O
parallel O
group O
design O
. O
[]

Group O
1 O
= O
patients O
were O
prehydrated O
with O
isotonic O
lactated O
Ringer O
's O
solution O
at O
7 O
mg/kg O
( O
n O
= O
30 O
) O
; O
Group O
2 O
= O
patients O
were O
given O
prehydration O
with O
3 O
% O
hypertonic O
saline O
at O
7 O
ml/kg O
( O
n O
= O
30 O
) O
. O
[]

RESULTS O
Mean O
daily B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
on O
the O
screening O
MSLT O
of O
insomniacs O
was O
normally O
distributed O
across O
the O
full O
range O
of O
MSLT O
scores O
and O
significantly O
higher O
than O
those O
of O
a O
population-based O
representative O
control O
sample O
( O
P O
< O
0.006 O
) O
. O
['Physiological-Clinical']

2 O
. O
[]

The O
target O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
140/90 O
mmHg O
or O
lower O
in O
both O
groups O
. O
['Physiological-Clinical']

However O
, O
a O
moderately O
high O
conversion O
rate O
must O
be O
accepted O
. O
[]

PURPOSE O
Hormonal O
breast O
cancer O
treatment O
increases O
menopausal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
women O
. O
['Physiological-Clinical']

The O
control O
group O
showed O
the O
highest O
levels O
of O
TNFalpha B-outcome ['Physiological-Clinical']
at O
the O
fourteenth O
postoperative O
day O
. O
['Physiological-Clinical']

CONCLUSION O
In O
the O
study O
presented O
, O
the O
natural O
course O
of O
occult O
CNV O
could O
not O
be O
improved O
by O
irradiation O
with O
10 O
or O
36 O
Gy O
. O
[]

Following O
randomization O
and O
prior O
to O
any O
intervention O
, O
baseline O
discomfort B-outcome ['Physiological-Clinical']
scores O
were O
obtained O
by O
means O
of O
a O
verbally O
administered O
, O
horizontal O
, O
100-mm O
, O
unnumbered O
analog O
discomfort O
scale O
. O
['Physiological-Clinical']

Triple O
therapy O
with O
metronidazole O
, O
amoxycillin O
, O
and O
omeprazole O
was O
significantly O
more O
effective O
for O
the O
eradication O
of O
H. O
pylori O
than O
dual O
therapy O
with O
amoxycillin O
and O
omeprazole O
alone O
. O
[]

Both O
the O
median O
number O
of O
angina B-outcome ['Physiological-Clinical']
attacks B-outcome ['Physiological-Clinical']
per O
week O
and O
the O
median O
number O
of O
nitroglycerin B-outcome ['Physiological-Clinical']
( O
NTG B-outcome ['Physiological-Clinical']
) O
tablets B-outcome ['Resource-use']
consumed/week I-outcome ['Resource-use']
were O
significantly O
reduced O
after O
amlodipine O
( O
mean O
daily O
dose O
of O
8.6 O
mg O
) O
when O
compared O
with O
baseline O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Functional O
outcome O
following O
intramedullary O
nailing O
of O
the O
femur O
: O
a O
prospective O
randomized O
comparison O
of O
piriformis O
fossa O
and O
greater O
trochanteric O
entry O
portals O
. O
[]

Forty O
patients O
in O
the O
diet O
group O
started O
dialysis O
treatment O
because O
of O
either O
fluid B-outcome ['Physiological-Clinical']
overload I-outcome ['Physiological-Clinical']
or O
hyperkalemia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
coexisting O
variables O
was O
analyzed O
with O
the O
Kruskal-Wallis O
. O
[]

EVR O
and O
SVR B-outcome ['Physiological-Clinical']
rates O
were O
lower O
in O
patients O
assigned O
to O
ribavirin O
800 O
than O
1000/1200 O
mg/day O
( O
EVR O
, O
75 O
% O
vs. O
84 O
% O
, O
respectively O
, O
P O
< O
0.001 O
; O
SVR O
, O
45 O
% O
vs. O
54 O
% O
, O
respectively O
, O
P O
= O
0.011 O
) O
. O
['Physiological-Clinical']

The O
lowering O
effect O
of O
reduced O
alcohol O
consumption O
on O
blood O
pressure O
was O
independent O
of O
changes O
in O
salt O
consumption O
, O
which O
were O
estimated O
by O
24-hour O
urine O
collection O
and O
body O
weight O
. O
( O
[]

RESULTS O
There O
were O
no O
significant O
differences O
with O
respect O
to O
overall O
mood B-outcome ['Life-Impact']
impact O
between O
the O
medication O
arms O
. O
['Life-Impact']

METHODS O
AND O
RESULTS O
Patients O
were O
randomized O
to O
supervised O
intensive O
lifestyle O
intervention O
group O
( O
N=28 O
) O
or O
to O
control O
group O
( O
N=31 O
) O
, O
which O
received O
routine O
lifestyle O
advices O
. O
[]

CONCLUSION O
The O
use O
of O
vaginal O
misoprostol O
for O
second O
trimester O
medical O
abortion O
resulted O
in O
a O
higher O
success B-outcome ['Physiological-Clinical']
rate O
than O
sublingual O
misoprostol O
at O
24 O
hours O
but O
the O
abortion B-outcome ['Mortality']
rate O
was O
similar O
at O
48 O
hours O
. O
['Physiological-Clinical', 'Mortality']

Effect O
of O
two O
monophasic O
oral O
contraceptives O
containing O
gestodene O
or O
desogestrel O
on O
serum O
lipoprotein O
lipid O
levels O
. O
[]

METHODS O
Linagliptin O
plasma O
concentration O
and O
DPP-4 O
inhibition O
measurements O
from O
a O
placebo-controlled O
, O
parallel O
group O
multiple O
( O
28 O
days O
) O
dose O
trial O
that O
included O
36 O
T2DM O
patients O
( O
18 O
patients O
each O
in O
2.5 O
mg O
and O
10 O
mg O
dose O
group O
) O
were O
used O
for O
analysis O
. O
[]

Bepotastine O
besilate O
ophthalmic O
solution O
( O
BBOS O
) O
1.5 O
% O
, O
a O
dual-acting O
histamine O
( O
H O
( O
1 O
) O
) O
receptor O
antagonist O
and O
mast O
cell O
stabilizer O
, O
is O
indicated O
for O
itching O
associated O
with O
AC O
. O
[]

DESIGN O
A O
prospective O
, O
randomised O
study O
. O
[]

Prosthesis O
orientation O
crucially O
affects O
the O
rate O
of O
success B-outcome ['Physiological-Clinical']
of O
the O
fluoroscopic O
evaluation O
. O
['Physiological-Clinical']

Complete B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
partial I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
occurred O
in O
25.0 O
% O
( O
SE O
= O
8.8 O
% O
) O
, O
28.1 O
% O
( O
SE O
= O
8.0 O
% O
) O
, O
and O
25.9 O
% O
( O
SE O
= O
8.4 O
% O
) O
of O
evaluable O
patients O
on O
ALL O
Regimen O
I O
, O
ALL O
Regimen O
II O
, O
and O
ANLL O
, O
respectively O
. O
['Physiological-Clinical']

SETTING O
Eighteen O
UK O
hospitals O
. O
[]

Two O
hundred O
and O
thirty-one O
patients O
with O
dyspepsia O
were O
randomized O
to O
a O
10-day O
sequential O
regimen O
( O
40 O
mg O
of O
pantoprazole O
, O
1 O
g O
of O
amoxicillin O
, O
each O
administered O
twice O
daily O
for O
the O
first O
5 O
days O
, O
followed O
by O
40 O
mg O
of O
pantoprazole O
, O
500 O
mg O
of O
clarithromycin O
, O
and O
500 O
mg O
of O
tinidazole O
, O
each O
administered O
twice O
daily O
for O
the O
remaining O
5 O
days O
) O
or O
to O
standard O
14-day O
therapy O
( O
40 O
mg O
of O
pantoprazole O
, O
500 O
mg O
of O
clarithromycin O
, O
and O
1 O
g O
of O
amoxicillin O
, O
each O
administered O
twice O
daily O
) O
. O
[]

Gefitinib O
plus O
best O
supportive O
care O
in O
previously O
treated O
patients O
with O
refractory O
advanced O
non-small-cell O
lung O
cancer O
: O
results O
from O
a O
randomised O
, O
placebo-controlled O
, O
multicentre O
study O
( O
Iressa O
Survival O
Evaluation O
in O
Lung O
Cancer O
) O
. O
[]

Fatigue O
( O
P O
< O
.001 O
) O
, O
nausea O
( O
P O
= O
.01 O
) O
, O
depression O
( O
P O
= O
.02 O
) O
, O
anxiety O
( O
P O
= O
.01 O
) O
, O
drowsiness O
( O
P O
< O
.001 O
) O
, O
appetite O
( O
P O
= O
.009 O
) O
, O
sleep O
( O
P O
< O
.001 O
) O
, O
and O
feeling O
of O
well-being O
( O
P O
< O
.001 O
) O
, O
as O
measured O
by O
the O
ESAS O
, O
significantly O
improved O
in O
patients O
who O
received O
NTI O
. O
[]

The O
effect O
of O
adjuvant O
immunotherapy O
with O
a O
single O
neighbourhood O
injection O
of O
2 O
mg O
C. O
parvum O
( O
CP O
) O
was O
investigated O
in O
a O
randomized O
study O
involving O
43 O
patients O
with O
carcinoma O
of O
the O
cervix O
uteri O
, O
all O
of O
whom O
were O
treated O
by O
radical O
surgery O
. O
[]

[ O
Prevention O
of O
pneumonia B-outcome ['Physiological-Clinical']
by O
endotracheal O
micronebulization O
of O
tobramycin O
] O
. O
['Physiological-Clinical']

The O
increase O
from O
two O
to O
four O
preoperative O
chemotherapy O
cycles O
did O
not O
increase O
the O
pathological O
response O
rate O
. O
[]

The O
median O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
was O
longer O
in O
medical O
patients O
than O
in O
surgical O
patients O
( O
6.1 O
vs. O
2.4 O
weeks O
in O
Group O
1 O
[ O
P O
less O
than O
0.001 O
] O
and O
5.0 O
vs. O
3.1 O
weeks O
in O
Group O
2 O
[ O
P O
less O
than O
0.01 O
] O
) O
. O
['Resource-use']

The O
XaI O
activity O
was O
less O
than O
or O
equal O
to O
0.24 O
XaI O
units/ml O
and O
the O
IIaI O
activity O
less O
than O
or O
equal O
to O
0.043 O
IIaI O
mu/ml O
. O
[]

If O
induction O
failed O
, O
additional O
boluses O
of O
the O
test O
drug O
were O
given O
. O
[]

Suitable O
embryos O
( O
maximum O
two O
embryos O
) O
were O
transferred O
on O
day O
3 O
after O
ICSI O
. O
[]

Participants O
were O
instructed O
to O
simply O
identify O
the O
auditory O
input O
and O
touch O
the O
corresponding O
object O
on O
the O
computer O
display O
. O
[]

A O
convenience O
sample O
of O
96 O
subjects O
was O
randomly O
assigned O
. O
[]

Science O
to O
practice O
in O
underserved O
communities O
: O
the O
effectiveness O
of O
school O
mental O
health O
programming O
. O
[]

Responses O
were O
assessed O
using O
World O
Health O
Organization O
criteria O
and O
were O
required O
to O
be O
of O
at O
least O
6 O
weeks O
' O
duration O
. O
[]

A O
drug O
interaction O
study O
between O
ticlopidine O
and O
cyclosporin O
in O
heart O
transplant O
recipients O
. O
[]

Hypnosis O
improves O
irritable B-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
( O
IBS O
) O
, O
but O
the O
mechanism O
is O
unknown O
. O
['Physiological-Clinical']

A O
relation O
between O
plasma O
diltiazem O
concentration O
and O
percent O
change O
in O
[]

Encephalopathies O
are O
the O
most O
feared O
complications O
of O
sleeping O
sickness O
treatment O
with O
melarsoprol O
. O
[]

Funded O
by O
Johnson O
& O
Johnson O
and O
Bayer O
; O
ROCKET O
AF O
ClinicalTrials.gov O
number O
, O
NCT00403767 O
. O
) O
. O
[]

Effects O
of O
guided O
imagery O
with O
relaxation O
training O
on O
anxiety B-outcome ['Life-Impact']
and O
quality O
of O
life O
among O
patients O
with O
inflammatory O
bowel O
disease O
. O
['Life-Impact']

Inherent O
stent O
related O
problems O
warrant O
a O
minimum O
possible O
duration O
of O
stenting O
without O
compromising O
the O
results O
of O
endopyelotomy O
. O
[]

At O
T12 O
, O
before O
the O
allergen O
challenge O
, O
serum B-outcome ['Physiological-Clinical']
ECP I-outcome ['Physiological-Clinical']
levels O
increased O
in O
the O
placebo O
group O
and O
blood O
eosinophils O
showed O
a O
trend O
towards O
lower O
numbers O
in O
the O
active O
one O
. O
['Physiological-Clinical']

BACKGROUND O
In O
a O
preliminary O
dose-finding O
study O
, O
D-cycloserine O
, O
a O
partial O
agonist O
at O
the O
glycine O
modulatory O
site O
of O
the O
glutamatergic O
N-methyl-D-aspartate O
( O
NMDA O
) O
receptor O
, O
improved O
negative O
symptoms O
and O
cognitive O
function O
when O
added O
to O
conventional O
neuroleptics O
at O
a O
dose O
of O
50 O
mg/d O
. O
[]

INTERVENTIONS O
N/A O
. O
[]

Neuroleptic O
naive O
patients O
reported O
aggravation O
of O
functional B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
, O
possibly O
reflecting O
the O
frequent O
occurrence O
of O
side O
effects O
. O
['Life-Impact']

As O
we O
disclosed O
no O
toxic B-outcome ['Adverse-effects']
or I-outcome ['Adverse-effects']
allergic I-outcome ['Adverse-effects']
reaction I-outcome ['Adverse-effects']
post-operatively I-outcome ['Adverse-effects']
which O
could O
be O
related O
to O
the O
use O
of O
PVP-I O
as O
a O
disinfectant O
, O
this O
agent O
seems O
to O
constitute O
an O
effective O
pre-operative B-outcome ['Resource-use']
antimicrobial I-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
, O
taking O
into O
consideration O
the O
broad O
antimicrobial O
spectrum O
of O
PVP-I O
shown O
by O
other O
authors O
. O
['Adverse-effects', 'Resource-use']

40 O
% O
were O
randomly O
divided O
into O
2 O
groups O
: O
92 O
MARS O
treatment O
sessions O
in O
the O
heparin-free O
group O
and O
82 O
in O
the O
low-dose O
heparin O
group O
. O
[]

Collectively O
, O
the O
results O
represent O
the O
first O
to O
illustrate O
links O
between O
multisensory O
temporal O
function O
and O
speech O
processing O
in O
ASD O
, O
strongly O
suggesting O
that O
deficits O
in O
low-level O
sensory O
processing O
may O
cascade O
into O
higher-order O
domains O
, O
such O
as O
language B-outcome ['Life-Impact']
and O
['Life-Impact']

GABA-acting O
benzodiazepines O
exert O
in O
some O
patients O
with O
autism O
paradoxical O
effects O
, O
raising O
the O
possibility O
that O
like O
in O
epilepsies O
, O
GABA O
excites O
neurons O
because O
of O
elevated O
intracellular O
concentrations O
of O
chloride O
. O
[]

A O
sample O
of O
406 O
spouses-caregivers O
of O
patients O
with O
Alzheimer O
's O
disease O
was O
randomized O
to O
an O
active O
multicomponent O
counseling O
and O
support O
intervention O
condition O
or O
to O
a O
usual O
care O
condition O
. O
[]

Dis O
. O
[]

The O
mean O
RBC B-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
of O
women O
consuming O
151-410 O
microg/d O
of O
synthetic O
folate O
( O
2nd O
quartile O
of O
intake O
) O
did O
not O
differ O
from O
that O
of O
women O
consuming O
> O
410 O
microg/d O
( O
3rd O
and O
4th O
quartile O
) O
. O
['Physiological-Clinical']

Although O
not O
eradicating B-outcome ['Physiological-Clinical']
completely I-outcome ['Physiological-Clinical']
aerobic I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
anaerobic I-outcome ['Physiological-Clinical']
bacteria I-outcome ['Physiological-Clinical']
, O
it O
is O
concluded O
that O
the O
substantial O
reduction O
in O
their O
numbers O
should O
prove O
clinically O
useful O
. O
['Physiological-Clinical']

In O
a O
randomized O
clinical O
trial O
, O
87 O
patients O
with O
inoperable O
, O
extensive O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
were O
randomized O
to O
receive O
either O
combination O
chemotherapy O
( O
cisplatin O
at O
70 O
mg/m2 O
intravenously O
[ O
i.v O
. O
] O
[]

DESIGN O
Subjects O
( O
108 O
healthcare O
providers O
from O
a O
500-bed O
teaching O
hospital O
) O
were O
assigned O
randomly O
to O
one O
of O
two O
procedures O
: O
one- O
followed O
by O
two-handed O
compression O
or O
two- O
followed O
by O
one-handed O
compression O
. O
[]

It O
can O
be O
used O
in O
cases O
in O
which O
introduction O
of O
a O
22 O
Char O
optical O
urethrotome O
into O
the O
stricture O
site O
is O
impossible O
, O
as O
well O
as O
for O
treatment O
of O
multiple O
strictures O
during O
one O
procedure O
. O
[]

METHODOLOGY/PRINCIPAL O
FINDINGS O
Our O
primary O
aim O
was O
to O
measure O
HRV O
in O
post-menopausal O
women O
following O
6-months O
of O
exercise O
training O
. O
[]

Participants O
were O
randomly O
assigned O
to O
fitting O
with O
NLFC O
( O
Phonak O
Naida O
V O
SP O
or O
UP O
) O
or O
with O
conventional O
processing O
in O
hearing O
aids O
, O
prescribed O
by O
using O
either O
the O
NAL O
or O
the O
DSL O
formula O
. O
[]

No O
significant O
difference O
was O
observed O
between O
the O
two O
groups O
in O
terms O
of O
extrapyramidal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
( O
P O
= O
0.23 O
) O
. O
['Physiological-Clinical']

INTERVENTIONS O
Patients O
were O
premedicated O
with O
oral O
temazepam O
20 O
mg. O
Anesthesia O
was O
induced O
with O
either O
eltanolone O
0.58 O
mg/kg O
or O
propofol O
1.7 O
mg/kg O
, O
neuromuscular O
blockade O
was O
achieved O
with O
vecuronium O
0.1 O
mg/kg O
, O
and O
anesthesia O
was O
maintained O
with O
enflurane O
0.5 O
% O
to O
1.0 O
% O
in O
nitrous O
oxide O
( O
67 O
% O
) O
. O
[]

Comparison O
of O
three-year O
clinical O
outcomes O
between O
sirolimus-versus O
paclitaxel-eluting O
stents O
in O
diabetic O
patients O
: O
prospective O
randomized O
multicenter O
trial O
. O
[]

We O
have O
previously O
found O
that O
a O
long-acting O
calcium O
channel O
blocker O
, O
azelnidipine O
, O
but O
not O
amlodipine O
, O
improves O
renal B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
in O
CKD O
patients O
. O
['Physiological-Clinical']

The O
parameters O
studied O
included O
: O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
, O
contrast O
sensitivity O
( O
with O
and O
without O
glare O
) O
, O
visual B-outcome ['Physiological-Clinical']
field I-outcome ['Physiological-Clinical']
, O
and O
mesopic O
vision O
( O
with O
and O
without O
glare O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
After O
deconvolution O
of O
the O
data O
, O
the O
subjective O
( O
nurse O
perception O
) O
method O
of O
evaluation O
determined O
that O
the O
new O
dressing O
resulted O
in O
wound B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
in O
12.7 O
% O
more O
patients O
than O
did O
routine O
practice O
, O
but O
the O
blinded O
assessment O
method O
( O
based O
on O
the O
digital O
images O
) O
showed O
that O
routine O
practice O
was O
better O
by O
6.6 O
% O
. O
['Physiological-Clinical']

We O
have O
developed O
and O
validated O
a O
group O
care O
approach O
that O
is O
applicable O
to O
everyday O
clinical O
practice O
and O
cost-effective O
in O
improving O
metabolic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
knowledge B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
, O
health B-outcome ['Life-Impact']
behaviours I-outcome ['Life-Impact']
, O
and O
quality O
of O
life O
in O
Type O
2 O
diabetes O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

BACKGROUND O
A O
24-week O
phase O
II O
trial O
has O
shown O
that O
0.3 O
mg O
of O
laquinimod O
given O
daily O
to O
patients O
with O
relapsing-remitting O
multiple O
sclerosis O
was O
well O
tolerated O
and O
reduced O
the O
formation O
of O
active B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Mortality O
risk O
was O
characterized O
by O
early O
and O
constant O
phases O
; O
transplant O
was O
characterized O
by O
only O
a O
constant O
phase O
. O
[]

At O
a O
mean O
follow-up O
of O
16 O
+/- O
3 O
months O
, O
patients O
in O
group O
1 O
showed O
superior O
clinical O
results O
with O
a O
lower O
incidence O
of O
graft B-outcome ['Physiological-Clinical']
occlusion I-outcome ['Physiological-Clinical']
( O
group O
1 O
= O
2 O
vs O
group O
2 O
= O
11 O
; O
P O
=.06 O
) O
and O
angina B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
( O
group O
1 O
= O
2 O
patients O
vs O
group O
2 O
= O
12 O
patients O
; O
P O
=.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
data O
should O
be O
considered O
in O
treatment O
decision-making O
for O
pts O
with O
advanced O
non-small-cell O
lung O
cancer O
and O
for O
the O
design O
of O
future O
trials O
with O
chemotherapy O
plus O
biologics O
. O
[]

CONCLUSION O
Single-dose O
rabeprazole O
20 O
mg O
was O
as O
effective O
as O
esomeprazole O
40 O
mg O
in O
increasing O
intragastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
and O
maintaining O
pH B-outcome ['Physiological-Clinical']
> O
3 O
and O
> O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
Silicone O
Study O
, O
117 O
of O
404 O
eyes O
( O
29 O
% O
) O
with O
severe O
proliferative O
vitreoretinopathy O
( O
> O
or O
= O
C-3 O
, O
full-thickness O
retinal O
folds O
in O
three O
or O
more O
quadrants O
) O
enrolled O
in O
the O
study O
were O
treated O
with O
vitrectomy O
, O
underwent O
a O
relaxing O
retinotomy O
, O
and O
were O
randomly O
assigned O
to O
treatment O
with O
long-acting O
gas O
or O
silicone O
oil O
. O
[]

In O
controls O
, O
MRPs O
revealed O
involvement O
of O
the O
supplementary O
motor O
area O
in O
movements O
which O
can O
be O
internally O
determined O
( O
non-cued O
and O
externally O
cued O
, O
predictable O
movements O
, O
but O
not O
unpredictable O
movements O
) O
. O
[]

It O
was O
established O
that O
CHF O
patients O
with O
progression O
of O
the O
disease O
had O
worsening O
of O
their O
clinical B-outcome ['Physiological-Clinical']
condition I-outcome ['Physiological-Clinical']
together O
with O
an O
increase O
of O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
which O
was O
characterized O
through O
decrease O
of O
NO O
metabolites B-outcome ['Physiological-Clinical']
, O
NADPH B-outcome ['Physiological-Clinical']
-- I-outcome ['Physiological-Clinical']
diaphorase I-outcome ['Physiological-Clinical']
( O
eNOS B-outcome ['Physiological-Clinical']
) O
, O
increase O
of O
nitrite B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
iNOS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
peroxinitrite B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ONOO I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
correlative O
increase O
the O
level O
of O
brain B-outcome ['Physiological-Clinical']
natriuretic I-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
plazma I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Is O
a O
calculated O
total O
hip O
BMD O
of O
clinical B-outcome ['Physiological-Clinical']
use I-outcome ['Physiological-Clinical']
? O
['Physiological-Clinical']

The O
primary O
end O
point O
occurred O
in O
22.1 O
percent O
of O
the O
patients O
in O
the O
aspirin O
group O
and O
21.8 O
percent O
of O
those O
in O
the O
warfarin O
group O
( O
hazard O
ratio O
, O
1.04 O
; O
95 O
percent O
confidence O
interval O
, O
0.73 O
to O
1.48 O
; O
P=0.83 O
) O
. O
[]

Biochemical B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
were O
measured O
at O
enrollment O
and O
after O
8 O
weeks O
. O
['Physiological-Clinical']

There O
is O
evidence O
to O
suggest O
accelerated O
bone B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
following O
estrogen O
cessation O
. O
['Physiological-Clinical']

METHODS/DESIGN O
The O
target O
patient O
population O
comprises O
OPSCC O
patients O
who O
would O
be O
unlikely O
to O
require O
chemotherapy O
post-resection O
: O
Tumor O
stage O
T1-T2 O
with O
likely O
negative O
margins O
at O
surgery O
; O
Nodal O
stage O
N0-2 O
, O
?3 O
cm O
in O
size O
, O
with O
no O
evidence O
of O
extranodal O
extension O
on O
imaging O
. O
[]

METHODS O
We O
investigated O
the O
difference O
between O
surgical O
intervention O
plus O
rtPA O
and O
standard O
medical O
management O
for O
ICH O
. O
[]

AIDS O
Clinical O
Trials O
Group O
Protocol O
204/Glaxo O
Wellcome O
123-014 O
International O
CMV O
Prophylaxis O
Study O
Group O
. O
[]

The O
findings O
suggest O
that O
individual O
telephone O
support O
may O
provide O
an O
effective O
alternative O
to O
in-person O
support O
groups O
. O
[]

Patients O
were O
randomly O
divided O
in O
two O
groups O
: O
In O
group O
1 O
( O
n O
= O
41 O
) O
postmenopausal O
women O
received O
oral O
risedronate O
( O
35 O
mg/week O
) O
, O
calcium O
( O
1,000 O
mg/day O
) O
, O
and O
vitamin O
D O
( O
400 O
IU/day O
) O
for O
12 O
months O
. O
[]

One O
of O
the O
components O
of O
abnormal O
social O
functioning O
in O
autism O
is O
an O
impaired O
ability O
to O
direct O
eye O
gaze O
onto O
other O
people O
's O
faces O
in O
social O
situations O
. O
[]

Levels O
were O
measured O
as O
relative O
concentrations O
by O
the O
electron O
spin O
resonance O
method O
. O
[]

The O
injection O
regimen O
was O
changed O
in O
every O
patient O
every O
two O
months O
, O
from O
36 O
U/kg O
once O
to O
18 O
U/kg O
twice O
and O
12 O
U/kg O
three O
times O
, O
intravenously O
. O
[]

METHODS O
Calves O
received O
each O
of O
the O
following O
4 O
IM O
treatments O
in O
random O
order O
: O
control O
, O
2 O
mL O
of O
0.9 O
% O
NaCl O
; O
erythromycin O
, O
8.8 O
mg/kg O
; O
low-dose O
gentamicin O
, O
4.4 O
mg/kg O
; O
high-dose O
gentamicin O
, O
6.6 O
mg/kg O
. O
[]

METHODS O
Between O
December O
, O
1993 O
, O
and O
April O
, O
1995 O
, O
304 O
liver-transplant O
recipients O
were O
randomised O
to O
receive O
oral O
ganciclovir O
1000 O
mg O
or O
matching O
placebo O
three O
times O
a O
day O
. O
[]

CONCLUSION O
CS O
gel O
applied O
to O
the O
penis O
was O
well O
tolerated B-outcome ['Life-Impact']
in O
this O
HIV-positive O
male O
population O
. O
['Life-Impact']

Effect O
of O
a O
multi-faceted O
intervention O
on O
gingival B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
among O
adults O
with O
systemic O
sclerosis O
. O
['Physiological-Clinical']

Three O
cases O
of O
catheter B-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
sepsis I-outcome ['Physiological-Clinical']
, O
two O
in O
the O
tunnelled O
group O
and O
one O
in O
the O
conventional O
group O
, O
were O
registered O
. O
['Physiological-Clinical']

BACKGROUND O
Parkinson O
's O
disease O
( O
PD O
) O
is O
a O
chronic O
neurodegenerative O
disorder O
with O
limited O
knowledge O
about O
the O
normal O
function O
and O
effects O
of O
non-pharmacological O
therapies O
on O
the O
hypothalamic-pituitary-adrenal B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HPA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
axis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Pharmacokinetics O
and O
pharmacodynamics O
of O
the O
monoamine O
oxidase O
B O
inhibitor O
mofegiline O
assessed O
during O
a O
phase O
I O
dose O
tolerance O
trial O
. O
[]

These O
data O
were O
confirmed O
by O
blocking O
CD63 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
as O
well O
as O
release O
of O
cysteinyl O
leukotrienes O
after O
in O
vitro O
basophil O
stimulation O
. O
['Physiological-Clinical']

The O
remaining O
27 O
practices O
were O
randomly O
allocated O
to O
IT O
and O
RC O
. O
[]

INTERPRETATION O
In O
primary O
Raynaud O
's O
syndrome O
, O
topical O
application O
of O
a O
nitric-oxide-generating O
system O
can O
stimulate O
an O
increase O
in O
both O
microcirculatory B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
flux B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
prospective O
, O
fellow-eye O
sham O
controlled O
clinical O
trial O
was O
conducted O
on O
80 O
eyes O
of O
40 O
high-risk O
characteristic O
proliferative O
diabetic O
retinopathy O
type O
II O
diabetics O
. O
[]

A O
central O
reading O
center O
assessed O
fundus O
photography O
and O
fluorescein O
angiography O
images O
. O
[]

Mutans B-outcome ['Physiological-Clinical']
streptococci I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
root I-outcome ['Physiological-Clinical']
surfaces I-outcome ['Physiological-Clinical']
were I-outcome ['Physiological-Clinical']
suppressed I-outcome ['Physiological-Clinical']
significantly O
( O
p O
less O
than O
0.05 O
) O
during O
the O
whole O
experimental O
period O
in O
the O
chlorhexidine O
varnish O
group O
, O
but O
not O
in O
the O
fluoride O
varnish O
group O
. O
['Physiological-Clinical']

Recovery B-outcome ['Physiological-Clinical']
after O
a O
predetermined O
AMP O
PC20 O
challenge O
was O
measured O
( O
primary O
outcome O
) O
, O
along O
with O
exhaled B-outcome ['Physiological-Clinical']
nitric I-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
levels O
, O
plasma B-outcome ['Physiological-Clinical']
eosinophil I-outcome ['Physiological-Clinical']
cationic I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
levels O
, O
peripheral B-outcome ['Physiological-Clinical']
eosinophil I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
, O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
diary O
card O
outcomes O
, O
and O
quality O
of O
life O
( O
all O
secondary O
outcomes O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Little O
is O
known O
whether O
the O
type O
of O
cognitive O
task O
performed O
while O
walking O
is O
important O
concerning O
possible O
gait O
interference O
in O
older O
fall-prone O
individuals O
. O
[]

6.4 O
) O
] O
( O
t O
= O
2.58-4.26 O
, O
P O
< O
0.05 O
) O
. O
[]

Nasal B-outcome ['Physiological-Clinical']
airflow I-outcome ['Physiological-Clinical']
and O
nasal B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
were O
not O
significantly O
altered O
by O
steroids O
during O
the O
first O
2 O
h O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Angiotensin-converting O
enzyme O
inhibitors O
provide O
hemodynamic O
and O
symptomatic O
benefit O
and O
are O
associated O
with O
improved O
survival O
in O
patients O
with O
congestive O
heart O
failure O
. O
[]

We O
prospectively O
compared O
the O
oral O
and O
nasal O
routes O
in O
volunteers O
, O
using O
a O
thin O
prototype O
video O
endoscope O
. O
[]

Including O
additionally O
3 O
patients O
on O
placebo O
and O
1 O
patient O
on O
valproate O
who O
felt O
they O
had O
suffered O
a O
migraine B-outcome ['Physiological-Clinical']
attack B-outcome ['Physiological-Clinical']
, O
but O
who O
had O
as O
associated O
symptoms O
only O
photophobia B-outcome ['Physiological-Clinical']
or O
phonophobia B-outcome ['Physiological-Clinical']
, O
a O
significant O
reduction O
in O
the O
number O
of O
patients O
with O
induced B-outcome ['Resource-use']
migraine B-outcome ['Physiological-Clinical']
after O
valproate O
was O
seen O
( O
P O
= O
0.031 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Humoral O
immunity O
after O
kidney O
transplantation O
: O
impact O
of O
two O
randomized O
immunosuppressive O
protocols O
. O
[]

Addictive B-outcome ['Life-Impact']
internet I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
among O
Korean O
adolescents O
: O
a O
national O
survey O
. O
['Life-Impact']

The O
duration O
of O
induced O
hypotension O
was O
about O
75 O
minutes O
. O
[]

Concerning O
spectral O
analysis O
, O
temazepam B-outcome ['Resource-use']
induces O
a O
light O
increase O
of O
the O
relative O
power O
of O
the O
slowest O
frequencies O
, O
paralleled O
by O
an O
increase O
of O
the O
fast O
bands O
, O
while O
major O
effects O
are O
found O
on O
the O
characteristic O
periodicity O
of O
delta O
activities O
, O
which O
appear O
disrupted O
by O
the O
drug O
. O
['Resource-use']

Application O
of O
either O
cream O
produced O
a O
very O
slight O
increase O
( O
less O
than O
or O
equal O
to O
0.5 O
log O
cycle O
) O
in O
the O
skin B-outcome ['Physiological-Clinical']
flora I-outcome ['Physiological-Clinical']
during O
the O
first O
2 O
weeks O
of O
treatment O
. O
['Physiological-Clinical']

ACE O
inhibitor O
administration O
does O
not O
modify O
the O
physical O
performance O
of O
nonathletic O
subjects O
; O
AII O
is O
significantly O
increased O
with O
exercise O
despite O
captopril O
treatment O
; O
ACE O
inhibitor O
decreases O
GFR B-outcome ['Physiological-Clinical']
significantly O
but O
does O
not O
influence O
MA O
with O
prolonged O
physical O
effort O
. O
['Physiological-Clinical']

After O
a O
median O
follow-up O
of O
24 O
months O
, O
the O
median O
DFS B-outcome ['Physiological-Clinical']
and O
OS B-outcome ['Physiological-Clinical']
were O
not O
reached O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Seventy O
SAP O
cases O
admitted O
from O
January O
2005 O
to O
October O
2012 O
were O
randomly O
assigned O
into O
parenteral O
nutrition O
( O
PN O
) O
group O
( O
n=22 O
) O
, O
EN O
group O
( O
n=25 O
) O
and O
bifidobacterium O
added O
EN O
( O
P+EN O
) O
group O
( O
n=23 O
) O
. O
[]

Simvastatin O
was O
beneficial O
regardless O
of O
whether O
patients O
had O
a O
history O
of O
myocardial O
infarction O
or O
whether O
they O
were O
smokers O
or O
had O
hypertension O
. O
( O
[]

Both O
treatments O
provided O
significant O
improvements O
in O
all O
the O
clinical B-outcome ['Physiological-Clinical']
and O
microbiological B-outcome ['Physiological-Clinical']
parameters O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Long-term O
follow-up O
of O
a O
phase O
I/II O
randomized O
, O
placebo-controlled O
trial O
of O
palifermin O
to O
prevent O
graft-versus-host O
disease O
( O
GVHD O
) O
after O
related O
donor O
allogeneic O
hematopoietic O
cell O
transplantation O
( O
HCT O
) O
. O
[]

Therefore O
, O
bumetanide O
is O
a O
promising O
novel O
therapeutic O
agent O
to O
treat O
autism O
. O
[]

Allergen O
bronchial O
challenge O
was O
made O
at O
the O
beginning O
( O
T0 O
) O
and O
after O
1 O
year O
of O
treatment O
( O
T12 O
) O
. O
[]

The O
incidence O
of O
cerebrovascular B-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
was O
lower O
in O
the O
warfarin O
group O
( O
16 O
patients O
) O
than O
the O
placebo O
group O
( O
41 O
patients O
) O
, O
a O
highly O
significant O
reduction O
of O
61 O
% O
( O
P O
= O
0.0003 O
) O
. O
['Physiological-Clinical']

Multiple O
episodes B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
GER I-outcome ['Physiological-Clinical']
occurred O
in O
some O
patients O
in O
the O
placebo O
group O
only O
. O
['Physiological-Clinical']

METHODS O
From O
September O
1996 O
to O
October O
1998 O
, O
we O
randomly O
allocated O
49 O
legs O
to O
compression O
sclerotherapy O
and O
49 O
legs O
to O
ambulatory O
phlebectomy O
. O
[]

Female O
patients O
between O
16 O
and O
45 O
years O
were O
eligible O
for O
inclusion O
once O
a O
clinical O
decision O
had O
been O
made O
to O
perform O
an O
appendicectomy O
for O
suspected O
acute O
appendicitis O
. O
[]

There O
was O
no O
relationship O
between O
the O
kind O
of O
G-CSF O
and O
the O
incidence O
of O
ARDS O
due O
to O
pulmonary B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( O
per O
chemotherapy O
session O
; O
p O
> O
0.10 O
, O
per O
case O
; O
p O
> O
0.30 O
, O
chi2 O
test O
) O
. O
['Physiological-Clinical']

Efficacy O
was O
determined O
based O
on O
daytime O
intraocular O
pressure O
curve O
and O
safety O
by O
examining O
visual O
fields O
, O
visual O
acuity O
, O
optic O
discs O
, O
by O
determining O
blood O
pressure O
and O
pulse O
rate O
, O
and O
by O
performing O
Schirmer O
and O
fluorescein O
tests O
. O
[]

Of O
the O
534 O
patients O
, O
105 O
( O
20 O
% O
) O
underwent O
allogeneic O
stem O
cell O
transplantation O
in O
first O
chronic O
phase O
. O
[]

CONCLUSION O
Our O
results O
show O
that O
FDTV O
produces O
a O
greater O
reduction O
of O
VCAM-1 O
circulating O
levels O
than O
trandolapril O
alone O
. O
[]

Patients O
randomized O
to O
the O
two O
treatment O
groups O
were O
compared O
for O
response O
rate O
, O
duration O
of O
response O
, O
time O
to O
progression O
or O
death B-outcome ['Mortality']
, O
time O
to O
treatment O
failure B-outcome ['Physiological-Clinical']
( O
TTF O
) O
, O
and O
survival B-outcome ['Mortality']
. O
['Mortality', 'Physiological-Clinical', 'Mortality']

INTERVENTIONS O
53 O
women O
were O
randomized O
to O
have O
endocervical O
sampling O
with O
the O
Kevorkian O
curette O
and O
47 O
to O
have O
sampling O
with O
the O
Medscand O
endocervical O
brush O
. O
[]

CONCLUSION O
EE O
20 O
microg/DRSP O
3 O
mg O
has O
a O
good O
safety O
profile O
comparable O
with O
EE O
20 O
microg/DSG O
150 O
microg O
. O
[]

Therefore O
, O
the O
leukotriene O
antagonist O
ONO-1078 O
prevents O
the O
asthma O
deterioration O
provoked O
by O
a O
6-wk O
reduction O
of O
the O
dose O
of O
inhaled O
BDI O
into O
half O
. O
[]

METHODS O
Adult O
patients O
who O
underwent O
laparotomy O
for O
bowel O
resection O
scheduled O
for O
opioid-based O
intravenous O
patient-controlled O
analgesia O
received O
oral O
alvimopan O
or O
placebo O
preoperatively O
and O
twice O
daily O
postoperatively O
until O
hospital O
discharge O
or O
for O
7 O
postoperative O
days O
. O
[]

The O
[]

The O
number O
needed O
to O
treat O
was O
3.3 O
( O
95 O
% O
confidence O
interval O
, O
1.8 O
, O
16.9 O
) O
. O
[]

Iron O
and O
riboflavin O
affect O
vitamin O
A O
utilization O
and O
photoreceptor O
function O
, O
respectively O
, O
and O
pilot O
data O
in O
the O
study O
population O
showed O
a O
high O
prevalence O
of O
iron O
and O
riboflavin O
deficiencies O
. O
[]

However O
, O
while O
there O
is O
much O
anecdotal O
evidence O
to O
that O
effect O
, O
the O
empirical O
literature O
is O
very O
inconsistent O
. O
[]

A O
significant O
increase O
of O
the O
percent O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
and O
sleep B-outcome ['Physiological-Clinical']
efficiency I-outcome ['Physiological-Clinical']
was O
also O
found O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
intervention O
consisted O
of O
44 O
home O
visits O
from O
the O
third O
trimester O
of O
pregnancy O
through O
to O
the O
child O
's O
second O
birthday O
. O
[]

Adjusted O
OR O
( O
95 O
% O
CI B-outcome ['Physiological-Clinical']
) O
for O
the O
highest O
versus O
the O
lowest O
quartile O
of O
plasma O
concentration O
were O
0.36 O
( O
0.16-0.79 O
; O
P-trend O
< O
0.001 O
) O
for O
daidzein O
and O
0.39 O
( O
0.19-0.84 O
; O
P-trend O
= O
0.010 O
) O
for O
genistein O
. O
['Physiological-Clinical']

However O
, O
this O
finding O
must O
be O
interpreted O
with O
caution O
, O
since O
it O
is O
a O
secondary O
end O
point O
and O
was O
found O
only O
after O
multiple O
analyses O
of O
the O
data O
. O
[]

However O
, O
the O
advantage O
of O
resection O
over O
radiochemotherapy O
has O
not O
yet O
been O
confirmed O
by O
a O
randomized O
trial O
. O
[]

The O
risk O
of O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
was O
reduced O
by O
62 O
% O
in O
the O
therapy O
group O
, O
p O
= O
.13 O
. O
['Mortality']

An O
additional O
examination O
was O
performed O
at O
34 O
weeks O
if O
the O
fetal O
weight O
in O
the O
32nd O
week O
was O
estimated O
to O
be O
less O
than O
95 O
% O
of O
the O
expected O
mean O
weight O
. O
[]

Randomized O
evaluation O
of O
octreotide O
vs O
prochlorperazine O
for O
ED O
treatment O
of O
migraine B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
in O
vivo O
pilot O
study O
evaluated O
eight O
products O
with O
hydrogen O
peroxide O
( O
HP O
) O
concentrations O
ranging O
from O
15 O
% O
to O
35 O
% O
. O
[]

The O
frequency O
of O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
for O
the O
ALL-2 O
regimen O
versus O
the O
L-20 O
regimen O
was O
83 O
% O
versus O
71 O
% O
( O
P O
= O
.06 O
) O
. O
['Physiological-Clinical']

The O
evolution O
of O
the O
New O
York O
Heart O
Association O
stage B-outcome ['Physiological-Clinical']
and O
the O
functional B-outcome ['Life-Impact']
signs I-outcome ['Life-Impact']
score O
were O
evaluated O
as O
primary O
efficacy O
criteria O
. O
['Physiological-Clinical', 'Life-Impact']

A O
randomized O
comparison O
of O
the O
effect O
of O
two O
prelinguistic O
communication O
interventions O
on O
the O
acquisition O
of O
spoken O
communication O
in O
preschoolers O
with O
ASD O
. O
[]

Significant O
improvement O
of O
active O
over O
dummy O
laser O
was O
noted O
for O
all O
seven O
assessments O
. O
[]

None O
of O
three O
patients O
treated O
with O
LSA2-L2 O
relapsed O
compared O
with O
three O
of O
nine O
treated O
with O
COMP O
. O
[]

METHODS O
Twenty-six O
alcoholic O
patients O
with O
severe O
AWS B-outcome ['Physiological-Clinical']
and O
concomitant O
medical O
diseases O
were O
randomally O
enrolled O
in O
the O
study O
. O
['Physiological-Clinical']

Topical O
retapamulin O
ointment O
( O
1 O
% O
, O
wt/wt O
) O
twice O
daily O
for O
5 O
days O
versus O
oral O
cephalexin O
twice O
daily O
for O
10 O
days O
in O
the O
treatment O
of O
secondarily O
infected O
dermatitis O
: O
results O
of O
a O
randomized O
controlled O
trial O
. O
[]

Atrial O
natriuretic O
factor O
inhibits O
metoclopramide O
stimulated O
aldosterone B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
in O
man O
. O
['Physiological-Clinical']

Bizzy O
Break O
! O
[]

When O
calculated O
per O
month O
, O
the O
median O
sum O
of O
vitagram O
points O
was O
5.9 O
for O
radiotherapy O
, O
5.7 O
for O
cyclophosphamide O
and O
4.8 O
for O
placebo O
. O
[]

Heart O
rate O
( O
HR O
) O
, O
oxygen B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VO2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
pulmonary B-outcome ['Physiological-Clinical']
ventilation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
measured O
using O
a O
telemetric O
apparatus O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Feedlot O
performance O
and O
carcass O
characteristics O
of O
Holstein O
steers O
as O
affected O
by O
source O
of O
dietary O
protein O
and O
level O
of O
ruminally O
protected O
lysine O
and O
methionine O
. O
[]

CONCLUSIONS O
Cy O
seems O
to O
be O
more O
effective O
than O
MP O
in O
the O
treatment O
of O
acute O
, O
severe O
NPSLE O
. O
[]

METHODS O
This O
was O
a O
multicenter O
, O
randomized O
, O
open-label O
clinical O
trial O
with O
initial O
and O
on-demand O
therapy O
. O
[]

CONCLUSION O
Cluster O
SIT O
is O
safe O
in O
children O
. O
[]

METHODS O
Pericardial O
blood O
of O
13 O
patients O
was O
retransfused O
in O
9 O
and O
discarded O
in O
4 O
cases O
. O
[]

FUNDING O
Research O
grant O
( O
Pfizer O
) O
. O
[]

CONCLUSIONS O
The O
barbed O
suture O
represents O
an O
innovative O
option O
for O
wound O
closure O
. O
[]

OBJECTIVE O
To O
study O
the O
efficacy O
of O
two O
types O
of O
intervention O
to O
stop O
tobacco B-outcome ['Life-Impact']
dependency O
. O
['Life-Impact']

The O
prespecified O
secondary O
end O
points O
of O
stent O
thrombosis O
and O
death O
were O
lower O
in O
the O
cangrelor O
group O
, O
with O
no O
significant O
increase O
in O
the O
rate O
of O
transfusion O
. O
[]

Complete B-outcome ['Physiological-Clinical']
ophthalmologic I-outcome ['Physiological-Clinical']
examinations I-outcome ['Physiological-Clinical']
were O
performed O
just O
before O
GLP O
and O
IB O
injection O
at O
1 O
, O
3 O
, O
6 O
, O
and O
12 O
months O
after O
treatment O
. O
['Physiological-Clinical']

The O
most O
common O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
infections B-outcome ['Physiological-Clinical']
and O
respiratory B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
were O
expected O
for O
this O
patient O
population O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Startle O
pathways O
may O
contribute O
to O
rapid O
accomplishment O
of O
postural O
stability O
. O
[]

RESULTS O
In O
total O
, O
155 O
patients O
were O
randomized O
. O
[]

BACKGROUND O
Although O
antiangiogenesis O
therapy O
plays O
an O
important O
role O
in O
anti-neoplastic O
treatment O
with O
its O
recognized O
efficacy O
and O
slight O
adverse O
effect O
, O
there O
is O
no O
prospective O
clinical O
trial O
to O
define O
ideal O
markers O
for O
predicting O
efficacy O
of O
antiangiogenic O
therapy O
. O
[]

In O
two O
thirds O
of O
the O
children O
with O
a O
positive O
response O
to O
risperidone O
at O
eight O
weeks O
( O
23 O
of O
34 O
) O
, O
the O
benefit O
was O
maintained O
at O
six O
months O
. O
[]

The O
frequency O
of O
perceived O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
and O
near B-outcome ['Physiological-Clinical']
misses I-outcome ['Physiological-Clinical']
was O
also O
lower O
in O
the O
BL O
than O
in O
the O
non-BL O
periods O
, O
but O
not O
significantly O
so O
, O
possibly O
indicating O
that O
the O
one-month O
observation O
period O
was O
too O
short O
to O
achieve O
any O
significant O
success O
. O
['Adverse-effects', 'Physiological-Clinical']

The O
effect O
of O
S. O
boulardii O
on O
watery B-outcome ['Physiological-Clinical']
diarrhoea I-outcome ['Physiological-Clinical']
became O
apparent O
after O
the O
second O
day O
of O
the O
treatment O
. O
['Physiological-Clinical']

After O
2 O
wk O
, O
rats O
underwent O
6 O
low-volume O
blood O
draws O
at O
4-h O
intervals O
( O
beginning O
at O
0400 O
) O
during O
both O
the O
light O
and O
dark O
phases O
. O
[]

A O
randomized O
control O
trial O
comparing O
two O
social O
communication O
treatments O
for O
children O
with O
autism O
spectrum O
disorder O
examined O
the O
effect O
of O
treatment O
on O
object O
interest O
. O
[]

The O
rate O
of O
death B-outcome ['Mortality']
from O
vascular O
causes O
was O
3.2 O
percent O
in O
the O
aspirin O
group O
and O
5.9 O
percent O
in O
the O
warfarin O
group O
( O
P=0.16 O
) O
; O
the O
rate O
of O
death B-outcome ['Mortality']
from O
nonvascular O
causes O
was O
1.1 O
percent O
and O
3.8 O
percent O
, O
respectively O
( O
P=0.05 O
) O
. O
['Mortality', 'Mortality']

Measurements O
were O
performed O
at O
baseline O
and O
after O
4 O
weeks O
. O
[]

Initial O
substance O
use O
predicted O
an O
increase O
in O
the O
number O
of O
substance B-outcome ['Life-Impact']
using I-outcome ['Life-Impact']
friends I-outcome ['Life-Impact']
over I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
indicating O
an O
effect O
of O
selection O
, O
and O
the O
initial O
number O
of O
substance O
using O
friends O
predicted O
substance B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
progression O
, O
providing O
evidence O
of O
socialization O
. O
['Life-Impact', 'Life-Impact']

Groups O
were O
similar O
regarding O
patient O
characteristics O
, O
depth O
of O
anaesthesia O
, O
sufentanil O
total O
dose O
, O
anaesthesia O
duration O
( O
D O
: O
349.1 O
+/- O
19.1 O
min O
; O
I O
: O
349.2 O
+/- O
22.9 O
min O
) O
, O
haemodynamic/respiratory O
parameters O
, O
and O
surgical O
conditions O
( O
assessed O
by O
a O
bleeding O
score O
) O
. O
[]

BMD B-outcome ['Physiological-Clinical']
was O
measured O
at O
the O
lumbar O
spine O
by O
dual-photon O
absorptiometry O
( O
DPA O
) O
and O
at O
the O
forearm O
by O
single-photon O
absorptiometry O
( O
SPA O
) O
. O
['Physiological-Clinical']

The O
parameters O
studied O
were O
Superoxide B-outcome ['Physiological-Clinical']
dismutase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SOD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
malonyl-dialdehyde B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MDA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
reduced O
glutathione B-outcome ['Physiological-Clinical']
( O
GSH B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Subjects O
applied O
study O
cream O
to O
one O
biopsy-confirmed O
basal O
cell O
carcinoma O
tumor O
5 O
x/week O
for O
2 O
, O
4 O
, O
or O
6 O
weeks O
in O
this O
vehicle-controlled O
, O
double-blind O
study O
. O
[]

Moreover O
they O
suggest O
a O
dose O
dependence O
of O
the O
effect O
, O
i.e. O
, O
at O
higher O
doses O
nimodipine O
seems O
to O
act O
as O
a O
sedative O
. O
[]

Ischemic B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
peaked O
in O
the O
early O
morning O
, O
and O
55 O
% O
occurred O
during O
routine O
sedentary O
activities O
. O
['Physiological-Clinical']

CONCLUSIONS O
Levels O
of O
socio-communicative O
ability O
in O
children O
with O
ASD O
were O
related O
to O
gaze B-outcome ['Life-Impact']
patterns I-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
unfamiliar I-outcome ['Life-Impact']
and O
Self O
Faces O
, O
but O
not O
familiar O
faces O
. O
['Life-Impact']

RESULTS O
From O
the O
control O
group O
( O
no O
Bioglue O
application O
) O
, O
two O
patients O
presented O
with O
anal B-outcome ['Physiological-Clinical']
stenosis I-outcome ['Physiological-Clinical']
, O
two O
with O
hemorrhage B-outcome ['Physiological-Clinical']
, O
three O
had O
anastomosis B-outcome ['Physiological-Clinical']
leak I-outcome ['Physiological-Clinical']
and O
one O
had O
thrombosis B-outcome ['Physiological-Clinical']
, O
whereas O
none O
of O
the O
patients O
from O
the O
Bioglue O
group O
had O
any O
of O
these O
complications B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Listening O
to O
motivational O
music O
during O
the O
recovery O
was O
associated O
with O
increased O
voluntary O
activity O
of O
the O
participants O
, O
determined O
by O
increased O
number O
of O
steps O
( O
499.4 O
? O
[]

Participants O
will O
be O
assessed O
at O
baseline O
, O
and O
then O
electronically O
randomized O
and O
allocated O
to O
group O
by O
minimization O
, O
based O
on O
the O
time O
post-stroke O
and O
extent O
of O
upper-limb O
impairment O
. O
[]

The O
primary O
endpoint O
was O
a O
composite O
of O
major B-outcome ['Physiological-Clinical']
macrovascular I-outcome ['Physiological-Clinical']
and O
microvascular B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Participant O
satisfaction O
is O
seldom O
assessed O
in O
pharmacological O
research O
. O
[]

They O
were O
consecutive O
admissions O
to O
a O
pilot O
study O
of O
clomipramine O
( O
n O
= O
4 O
) O
or O
a O
double-blind O
, O
placebo O
controlled O
study O
of O
haloperidol O
( O
n O
= O
4 O
) O
. O
[]

For O
both O
couple-responsible O
and O
therapist-responsible O
episodes O
, O
cooperation B-outcome ['Life-Impact']
was O
negatively O
affected O
by O
a O
shift O
from O
the O
prior O
, O
opposite O
therapist O
process O
. O
['Life-Impact']

STUDY O
DESIGN O
AND O
SETTING O
We O
conducted O
a O
prospective O
, O
randomized O
, O
crossover O
surgical O
trial O
at O
a O
university O
hospital O
. O
[]

A O
2-week O
baseline O
period O
in O
which O
patients O
maintained O
their O
current O
antianginal O
therapy O
was O
followed O
by O
a O
10-week O
treatment O
period O
with O
5-10 O
mg O
of O
amlodipine/day O
. O
[]

The O
biocompatibility O
of O
collagen B-outcome ['Physiological-Clinical']
and O
bioactive B-outcome ['Resource-use']
glass I-outcome ['Resource-use']
was O
concentration O
dependent O
. O
['Physiological-Clinical', 'Resource-use']

METHODS O
Data O
for O
this O
longitudinal O
study O
is O
nested O
within O
a O
randomized O
controlled O
trial O
( O
RCT O
) O
assessing O
the O
impact O
of O
a O
24-hour O
hotline O
and O
postpartum O
support O
film O
on O
postpartum O
stress O
. O
[]

There O
was O
no O
statistically O
significant O
relationship O
between O
oxygenation O
level O
or O
systolic O
blood O
pressure O
. O
[]

Abnormal O
cardiac O
contractility O
in O
long-term O
exogenous O
subclinical O
hyperthyroid O
patients O
as O
demonstrated O
by O
two-dimensional O
echocardiography O
speckle O
tracking O
imaging O
. O
[]

A O
comparison O
of O
the O
serologic O
responses O
to O
oral O
and O
injectable O
trivalent O
poliovirus O
vaccines O
. O
[]

Effect O
of O
simultaneous O
didanosine O
administration O
on O
itraconazole B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
in O
healthy O
volunteers O
. O
['Physiological-Clinical']

The O
antihypertensive B-outcome ['Resource-use']
efficacies O
of O
lisinopril O
and O
captopril O
were O
compared O
using O
office O
sphygmomanometry O
and O
24-h O
ambulatory O
blood O
pressure O
monitoring O
. O
['Resource-use']

Seven O
patients O
were O
studied O
before O
bypass O
surgery O
and O
28 O
were O
examined O
after O
end-to-side O
jejunoileal O
bypass O
with O
50 O
cm O
intestine O
in O
continuity O
and O
a O
3:1 O
or O
1:3 O
ratio O
between O
the O
length O
of O
the O
jejunal O
and O
ileal O
segments O
. O
[]

Active O
back O
exercise O
at O
home O
together O
with O
rehabilitation O
treatments O
might O
be O
effective O
and O
improve O
function O
for O
patients O
with O
chronic O
low O
back O
pain O
. O
[]

Is O
chronic O
sildenafil O
therapy O
safe O
and O
clinically O
beneficial O
in O
patients O
with O
systolic O
heart O
failure O
? O
[]

SETTING O
N/A O
. O
[]

RESULTS O
All O
children O
improved O
in O
joint B-outcome ['Life-Impact']
engagement I-outcome ['Life-Impact']
and O
initiating B-outcome ['Life-Impact']
joint I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
, O
with O
significantly O
greater O
improvement O
by O
the O
CMM O
group O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Mean O
waiting B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
were O
43 O
days O
( O
sigma O
= O
+/-16 O
) O
and O
105 O
days O
( O
sigma O
= O
+/-51 O
) O
for O
'fast O
track O
' O
and O
'ordinary O
' O
appointments O
, O
respectively O
. O
['Life-Impact']

All O
patients O
received O
a O
standardized O
preventive O
treatment O
. O
[]

The O
fall B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
tcPCO2 I-outcome ['Physiological-Clinical']
and O
the O
cardiovascular B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
greater O
in O
panicking O
patients O
than O
patients O
who O
did O
not O
panic O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Improving O
the O
transition O
from O
residential O
to O
outpatient O
addiction O
treatment O
: O
gender O
differences O
in O
response O
to O
supportive O
telephone O
calls O
. O
[]

The O
subjects O
were O
seen O
for O
efficacy O
evaluations O
at O
the O
end O
of O
each O
cycle O
. O
[]

We O
conclude O
that O
hot O
biopsy O
treatment O
for O
diminutive O
polyps O
is O
significantly O
more O
effective O
when O
visible O
necrosis O
is O
achieved O
during O
cautery O
. O
[]

A O
significant O
decrease O
in O
frequency O
and O
intensity O
of O
myofascial B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
found O
in O
group O
T O
at O
the O
follow-ups O
. O
['Physiological-Clinical']

Several O
racial O
and O
ethnic O
group O
differences O
existed O
in O
physical B-outcome ['Physiological-Clinical']
and O
emotional B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
, O
as O
well O
as O
in O
total O
frustration B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
caregiving I-outcome ['Life-Impact']
, O
emotional B-outcome ['Life-Impact']
burden I-outcome ['Life-Impact']
, O
and O
CG-rated O
bother O
with O
CR O
's O
activities O
of O
daily O
living O
and O
instrumental O
activities O
of O
daily O
living O
at O
baseline O
and O
at O
follow-up O
, O
although O
differences O
between O
baseline O
and O
posttest O
did O
not O
vary O
according O
to O
race O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact']

BACKGROUND O
Prophylactic O
cranial O
irradiation O
in O
patients O
with O
small-cell O
lung O
cancer O
decreases O
the O
overall O
rate O
of O
brain O
metastases O
without O
an O
effect O
on O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality']

Randomized O
, O
double-blind O
, O
phase O
III O
, O
controlled O
trial O
comparing O
levobupivacaine O
0.25 O
% O
, O
ropivacaine O
0.25 O
% O
and O
bupivacaine O
0.25 O
% O
by O
the O
caudal O
route O
in O
children O
. O
[]

The O
worldwide O
site O
distribution O
and O
broad O
range O
of O
stroke O
risk O
further O
increase O
the O
general O
applicability O
of O
the O
trial O
. O
[]

A O
second-generation O
drug-eluting O
stent O
, O
which O
delivers O
zotarolimus O
, O
a O
potent O
antiproliferative O
agent O
, O
via O
a O
biocompatible O
phosphorylcholine O
polymer O
on O
a O
cobalt O
alloy O
thin-strut O
stent O
has O
shown O
promising O
experimental O
and O
early O
clinical O
results O
. O
[]

0.05 O
) O
. O
[]

Differences O
in O
the O
[]

Patient-reported O
outcomes O
after O
inguinal O
herniorrhaphy O
. O
[]

In O
both O
groups O
each O
inhalation O
was O
preceded O
by O
premedication O
with O
disodium O
cromoglycate O
( O
DSCG O
) O
( O
40 O
mg O
) O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
of O
a O
new O
therapeutic O
ointment O
( O
MEBO O
) O
in O
the O
treatment O
of O
partial O
thickness O
burns O
. O
[]

There O
was O
no O
observable O
toxicity B-outcome ['Adverse-effects']
, O
but O
phenobarbitone O
recipients O
had O
a O
significant O
tendency O
to O
deepen O
in O
their O
level O
of O
coma B-outcome ['Physiological-Clinical']
or O
to O
become B-outcome ['Physiological-Clinical']
sleepy I-outcome ['Physiological-Clinical']
within O
the O
4 O
h O
after O
drug O
administration O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Twenty O
adults O
, O
critically O
ill O
for O
several O
weeks O
and O
supported O
with O
normocaloric O
, O
continuously O
administered O
parenteral O
and/or O
enteral O
feeding O
, O
were O
studied O
for O
45 O
h. O
They O
had O
been O
randomized O
to O
receive O
one O
of O
three O
combinations O
of O
peptide O
infusions O
, O
in O
random O
order O
: O
TRH O
( O
one O
day O
) O
and O
placebo O
( O
other O
day O
) O
; O
TRH O
+ O
GH-releasing O
peptide O
( O
GHRP O
) O
-2 O
and O
GHRP-2 O
; O
TRH O
+ O
GHRH O
+ O
GHRP-2 O
and O
GHRH O
+ O
GHRP-2 O
. O
[]

Cancers O
are O
discovered O
by O
the O
present O
approach O
at O
an O
estimated O
cost B-outcome ['Resource-use']
of O
$ O
2,665 O
per O
cancer O
. O
['Resource-use']

Treatment O
of O
varicella-zoster O
virus O
infection O
in O
severely O
immunocompromised O
patients O
. O
[]

METHODS O
One O
hundred O
eighty-three O
older O
adults O
( O
age O
72.7 O
+/- O
6 O
years O
, O
range O
56-93 O
; O
body O
mass O
index O
28.2 O
+/- O
4.9 O
, O
range O
16.6-46.0 O
) O
were O
recruited O
from O
a O
New O
Zealand O
falls O
prevention O
intervention O
trial O
. O
[]

Somatostatin O
has O
been O
found O
in O
the O
pineal O
gland O
of O
several O
animal O
species O
, O
which O
suggests O
that O
it O
may O
be O
involved O
in O
the O
regulation O
of O
melatonin B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Aim O
of O
the O
study O
was O
to O
assess O
the O
effectiveness O
and O
tolerability B-outcome ['Life-Impact']
of O
sublingual O
captopril O
( O
SLC O
) O
versus O
sublingual O
nifedipine O
( O
SLN O
) O
in O
treating O
hypertensive O
emergencies O
. O
['Life-Impact']

Noninfiltrative O
anesthesia O
therefore O
represents O
an O
attractive O
alternative O
to O
periprostatic O
infiltration O
. O
[]

We O
investigated O
the O
feasibility B-outcome ['Life-Impact']
and O
diagnostic B-outcome ['Life-Impact']
utility I-outcome ['Life-Impact']
of O
genotyping O
9 O
CYP21 O
mutations O
, O
linked O
chromosome O
6p O
markers O
, O
and O
a O
dimorphic O
X-Y O
marker O
from O
neonatal O
screening O
samples O
. O
['Life-Impact']

It O
does O
not O
increase O
the O
mortality B-outcome ['Mortality']
rate O
, O
and O
the O
morbidity B-outcome ['Physiological-Clinical']
rate O
seems O
to O
be O
even O
lower O
than O
that O
in O
OC O
. O
['Mortality', 'Physiological-Clinical']

Optimal O
dose O
analyses O
suggested O
significant O
interindividual O
variability O
in O
dose O
response O
. O
[]

PARTICIPANTS O
A O
total O
of O
201 O
chronically O
ill O
older O
adults O
seniors O
aged O
70 O
and O
older O
recruited O
through O
medical O
practices O
. O
[]

RESULTS O
A O
significantly O
higher O
number O
of O
patients O
in O
the O
R0.1C O
group O
( O
18/20 O
) O
could O
be O
managed O
without O
supplemental B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
during O
the O
first O
24 O
h O
postoperatively O
compared O
to O
the O
R0.2 O
group O
( O
11/20 O
) O
( O
P=0.034 O
) O
. O
['Resource-use']

Dexmedetomidine O
use O
allows O
keeping O
optimal O
type O
of O
haemodynamics O
and O
vegetative O
nervous O
system O
parameters O
on O
first O
day O
of O
postoperative O
period O
. O
[]

Both O
drugs O
were O
tolerable B-outcome ['Life-Impact']
with O
primary O
RP O
patients O
. O
['Life-Impact']

Serum O
samples O
were O
obtained O
frequently O
for O
12 O
hours O
after O
the O
dose O
. O
[]

SETTINGS/LOCATION O
The O
study O
was O
conducted O
at O
the O
Rehabilitation O
Centre O
of O
the O
Thai O
Red O
Cross O
Society O
. O
[]

The O
Aberrant O
Behavior O
Checklist O
-- O
Community O
Scale O
( O
ABC-C O
) O
Irritability O
subscale O
was O
the O
primary O
outcome O
measure O
( O
p O
= O
0.65 O
) O
, O
and O
CGI O
-- O
Improvement O
( O
p O
= O
0.16 O
) O
and O
OAS O
( O
p O
= O
0.96 O
) O
were O
secondary O
outcome O
measures O
. O
[]

RESULTS O
Findings O
on O
the O
University O
of O
Canterbury O
Adaptive O
Speech O
Test-Filtered O
Words O
( O
UCAST-FW O
) O
indicated O
a O
significant O
maturational B-outcome ['Physiological-Clinical']
effect O
. O
['Physiological-Clinical']

The O
patients O
were O
evaluated O
after O
laboratory O
tests O
and O
clinical-ergometric O
examinations O
. O
[]

Ten O
undernourished O
patients O
receiving O
total O
parenteral O
nutrition O
and O
undergoing O
major O
intestinal O
surgery O
were O
restarted O
on O
intravenous O
feeds O
identical O
to O
their O
pre-operative O
regimens O
within O
24 O
h O
of O
their O
operation O
. O
[]

The O
women O
received O
2 O
mg O
oral O
estradiol O
( O
E O
( O
2 O
) O
) O
continuously O
during O
two O
28-day O
cycles O
and O
800 O
mg O
of O
vaginal O
progesterone O
or O
placebo O
sequentially O
for O
the O
last O
14 O
days O
of O
each O
treatment O
cycle O
. O
[]

Longitudinal O
regression O
analyses O
that O
followed O
participants O
throughout O
the O
treatment O
period O
showed O
significantly O
greater O
downward O
slopes O
per O
week O
on O
the O
10 O
point O
arm O
pain B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

These O
treatment O
strategies O
may O
also O
work O
very O
well O
in O
the O
Netherlands O
too O
, O
even O
though O
health O
care O
systems O
differ O
between O
countries O
. O
[]

Effect O
of O
thermal O
stress O
, O
restricted O
feeding O
and O
combined O
stresses O
( O
thermal O
stress O
and O
restricted O
feeding O
) O
on O
growth O
and O
plasma O
reproductive O
hormone O
levels O
of O
Malpura O
ewes O
under O
semi-arid O
tropical O
environment O
. O
[]

All O
products O
were O
administered O
by O
an O
authorized O
person O
, O
blinded O
to O
both O
the O
investigating O
physician O
and O
the O
biologist O
. O
[]

Alendronate O
daily O
, O
weekly O
in O
conventional O
tablets O
and O
weekly O
in O
enteric O
tablets O
: O
preliminary O
study O
on O
the O
effects O
in O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
and O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

Tramadol O
was O
significantly O
less O
effective O
( O
P O
< O
0.05 O
) O
than O
Naproxen O
, O
and O
Novafen O
that O
were O
similar O
to O
each O
other O
( O
P O
> O
0.05 O
) O
. O
[]

PURPOSE O
We O
evaluated O
angiogenesis-targeted B-outcome ['Physiological-Clinical']
sunitinib I-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
in O
a O
randomized O
, O
double-blind O
trial O
of O
metastatic O
castration-resistant O
prostate O
cancer O
( O
mCRPC O
) O
. O
['Physiological-Clinical']

Early O
HBOT O
had O
no O
apparent O
effects O
on O
any O
of O
the O
parameters O
measured O
in O
this O
small O
pilot O
study O
. O
[]

arm O
and O
12 O
% O
for O
the O
b.i.d O
. O
[]

Bacteria O
were O
identified O
in O
23 O
patients O
, O
11 O
of O
83 O
undergoing O
cholecystectomy O
alone O
and O
12 O
of O
28 O
undergoing O
exploration O
of O
the O
common O
bile O
duct O
( O
P O
less O
than O
0.01 O
) O
. O
[]

PURPOSE O
Docetaxel O
and O
capecitabine O
, O
a O
tumor-activated O
oral O
fluoropyrimidine O
, O
show O
high O
single-agent O
efficacy O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
and O
synergy O
in O
preclinical O
studies O
. O
[]

Nitrogen B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
total O
protein B-outcome ['Physiological-Clinical']
, O
albumin B-outcome ['Physiological-Clinical']
, O
prealbumin B-outcome ['Physiological-Clinical']
, O
transferrin B-outcome ['Physiological-Clinical']
, O
retinol B-outcome ['Physiological-Clinical']
binding B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
and O
postoperative B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
score O
were O
monitored O
during O
the O
postoperative O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
peak O
velocity B-outcome ['Physiological-Clinical']
increased O
linearly O
as O
the O
movement O
amplitude O
increased O
. O
['Physiological-Clinical']

INTERVENTION O
Hospitals O
were O
randomly O
assigned O
to O
receive O
rapid O
( O
immediate O
; O
n O
= O
38 O
hospitals O
and O
2533 O
patients O
) O
or O
delayed O
( O
14 O
months O
; O
n O
= O
38 O
hospitals O
and O
3142 O
patients O
) O
confidential O
feedback O
on O
quality O
indicators O
constructed O
using O
administrative O
data O
. O
[]

Median O
survival B-outcome ['Mortality']
was O
7.6 O
months O
in O
the O
ASC O
alone O
group O
and O
8.5 O
months O
in O
the O
ASC O
plus O
chemotherapy O
group O
. O
['Mortality']

CONCLUSION O
It O
is O
obvious O
that O
PKRP O
is O
as O
efficient O
as O
TURP O
and O
it O
has O
a O
similar O
morbidity O
. O
[]

We O
intend O
to O
build O
on O
our O
work O
by O
using O
the O
survey O
platform O
in O
other O
modalities O
while O
ensuring O
that O
the O
patient O
's O
preferences O
are O
considered O
at O
all O
times O
. O
[]

Analysis O
of O
the O
data O
showed O
no O
significant O
differences O
between O
groups O
in O
anxiety B-outcome ['Life-Impact']
, O
severity O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
helpfulness O
of O
self-care B-outcome ['Life-Impact']
strategies I-outcome ['Life-Impact']
, O
and O
coping B-outcome ['Life-Impact']
strategies I-outcome ['Life-Impact']
. O
['Life-Impact', 'Adverse-effects', 'Life-Impact', 'Life-Impact']

4.2 O
% O
) O
( O
p O
= O
.029 O
, O
effect O
size O
[ O
ES O
] O
= O
0.44 O
) O
but O
not O
for O
12HL O
( O
5.8 O
? O
[]

After O
taking O
take O
135 O
mg O
of O
isoflavones O
daily O
for O
1 O
week O
, O
the O
women O
in O
the O
study O
group O
were O
assigned O
to O
the O
equol-producing O
( O
EP O
) O
or O
the O
non-EP O
group O
according O
to O
the O
presence O
or O
absence O
of O
equol O
in O
their O
urine O
. O
[]

PURPOSE O
Bleeding O
associated O
with O
transurethral O
prostate O
resection O
can O
often O
be O
significant O
and O
lead O
to O
increased O
morbidity O
and O
occasionally O
mortality O
. O
[]

METHODS O
This O
was O
a O
6-week O
, O
double-masked O
, O
randomised O
multi-centre O
study O
. O
[]

A O
crossover O
study O
. O
[]

Heparin O
caused O
less O
attenuation O
of O
a O
challenge O
with O
adenosine O
and O
probably O
does O
not O
affect O
mast O
cell O
degranulation O
. O
[]

Pharmacokinetic B-outcome ['Physiological-Clinical']
study O
of O
human O
immunodeficiency O
virus O
protease O
inhibitors O
used O
in O
combination O
with O
amprenavir O
. O
['Physiological-Clinical']

In O
each O
arm O
, O
two O
or O
more O
courses O
of O
chemotherapy O
( O
4-week O
cycles O
) O
were O
performed O
. O
[]

There O
was O
a O
reduction O
of O
ST-depression B-outcome ['Physiological-Clinical']
both O
at O
spontaneously O
occurring O
ischemic O
episodes O
and O
during O
exercise O
, O
in O
the O
number O
and O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
silent I-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
, O
particularly O
, O
however O
, O
a O
decrease O
in O
symptomatic B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
the O
duration B-outcome ['Mortality']
of I-outcome ['Mortality']
survival I-outcome ['Mortality']
from O
treatment O
start O
for O
the O
two O
ALL O
regimens O
( O
P O
= O
0.46 O
) O
. O
['Mortality']

INTERVENTIONS O
All O
children O
received O
intensive O
pediatric O
and O
developmental O
surveillance O
. O
[]

The O
corresponding O
1-year O
mortality B-outcome ['Mortality']
['Mortality']

Use O
of O
ampicillin/sulbactam O
results O
in O
a O
significantly O
lower O
SWI B-outcome ['Physiological-Clinical']
rate O
than O
use O
of O
cefoxitin O
, O
which O
may O
be O
a O
result O
of O
improved O
enterococcal B-outcome ['Physiological-Clinical']
and O
Bacteroides B-outcome ['Physiological-Clinical']
coverage O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
observational O
analysis O
showed O
a O
significant O
difference O
in O
survival B-outcome ['Mortality']
between O
transfused O
and O
non-transfused O
patients O
( O
59.6 O
versus O
72.9 O
per O
cent O
; O
P O
< O
0.001 O
) O
. O
['Mortality']

BACKGROUND O
Rapid B-outcome ['Physiological-Clinical']
conversion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
( O
AF B-outcome ['Physiological-Clinical']
) O
to O
sinus B-outcome ['Physiological-Clinical']
rhythm B-outcome ['Physiological-Clinical']
may O
be O
achieved O
by O
the O
administration O
of O
class O
IA O
, O
IC O
and O
III O
antiarrhythmic O
drugs O
or O
vernakalant O
hydrochloride O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
assigned O
patients O
to O
oral O
pioglitazone O
titrated O
from O
15 O
mg O
to O
45 O
mg O
( O
n=2605 O
) O
or O
matching O
placebo O
( O
n=2633 O
) O
, O
to O
be O
taken O
in O
addition O
to O
their O
glucose-lowering O
drugs O
and O
other O
medications O
. O
[]

BACKGROUND O
The O
World O
Helath O
Organization O
( O
WHO O
) O
Group O
I O
anovulation O
, O
or O
hypogonadotropic O
hypogonadism O
( O
HH O
) O
, O
is O
characterized O
by O
reduced O
hypothalamic/pituitary O
activity O
which O
results O
in O
abnormally O
low O
serum O
FSH O
and O
LH O
levels O
and O
negligible O
estrogen O
activity O
. O
[]

Since O
the O
conventional O
angiographic O
parameters O
analysed O
in O
this O
study O
failed O
to O
identify O
individual O
arterial O
sites O
with O
an O
increased O
risk O
for O
progression O
, O
definition O
of O
new O
angiographic O
parameters O
or O
application O
of O
new O
techniques O
seem O
mandatory O
to O
this O
end O
. O
[]

Some O
of O
these O
women O
had O
personal O
or O
family O
histories O
of O
hypertension O
( O
21 O
% O
) O
. O
[]

Already O
after O
the O
first O
week O
of O
the O
skiing O
tour O
there O
were O
significant O
drops O
in O
PAI-1 B-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
, O
cholesterol B-outcome ['Physiological-Clinical']
and O
triglycerides B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
pilot O
study O
in O
an O
academic O
medical O
center-based O
infectious O
disease O
clinic O
, O
11 O
clinically O
stable O
, O
HIV-infected O
adults O
had O
been O
treated O
with O
highly O
active O
, O
antiretroviral O
therapy O
and O
had O
HIV O
plasma O
RNA O
levels O
of O
less O
than O
10 O
000 O
copies/mL O
. O
[]

Thus O
, O
the O
higher O
concentration O
of O
glycerol O
required O
to O
provide O
equal O
ultrafiltration O
may O
offset O
any O
calorific O
advantage O
. O
[]

It O
is O
not O
reasonable O
to O
advise O
elderly O
women O
with O
urinary O
incontinence O
to O
undertake O
this O
treatment O
procedure O
. O
[]

Comparison O
with O
propranolol O
in O
patients O
with O
stable O
angina O
. O
[]

FINDINGS O
107 O
patients O
were O
included O
in O
the O
ITT O
population O
( O
ablation O
group O
, O
n=52 O
; O
control O
group O
, O
n=55 O
) O
. O
[]

Torcetrapib O
was O
well O
tolerated B-outcome ['Life-Impact']
, O
with O
all O
treated O
subjects O
completing O
the O
study O
. O
['Life-Impact']

Some O
reports O
have O
suggested O
that O
rituximab O
administration O
before O
PBSC O
mobilization O
may O
adversely O
affect O
PBSC O
yield O
. O
[]

HBV B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
turned O
negative O
in O
6/24 O
of O
the O
patients O
treated O
with O
recombinant O
hepatitis O
B O
vaccine O
( O
at O
both O
the O
doses O
of O
90 O
micrograms O
and O
60 O
micrograms O
) O
, O
and O
HBeAg/Anti-HBe B-outcome ['Physiological-Clinical']
seroconversion B-outcome ['Physiological-Clinical']
or O
HBeAg B-outcome ['Physiological-Clinical']
became O
negative O
in O
7/24 O
of O
them O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
conclude O
that O
eyes O
undergoing O
a O
vitreous O
operation O
for O
the O
first O
time O
for O
the O
treatment O
of O
proliferative B-outcome ['Physiological-Clinical']
vitreoretinopathy I-outcome ['Physiological-Clinical']
can O
in O
most O
instances O
be O
successfully O
treated O
by O
conventional O
techniques O
without O
the O
need O
for O
relaxing O
retinotomy O
. O
['Physiological-Clinical']

Subjects O
40 O
years O
or O
older O
with O
cigarette O
smoking O
history O
?10 O
pack-years O
and O
with O
the O
diagnosis O
of O
COPD O
and O
post-bronchodilator O
FEV O
( O
1 O
) O
?40 O
to O
? O
[]

The O
results O
suggest O
that O
a O
substantial O
subgroup O
of O
heroin O
addicts O
are O
able O
to O
use O
opioids O
regularly O
while O
maintaining O
relatively O
low O
levels O
of O
physical O
dependence O
. O
[]

Healing B-outcome ['Physiological-Clinical']
rates O
after O
4 O
weeks O
of O
therapy O
appeared O
to O
be O
76 O
% O
for O
CBS O
coated O
tablets O
and O
72 O
% O
for O
CBS O
chewing O
tablets O
, O
so O
no O
statistically O
significant O
difference O
in O
therapeutic O
efficacy O
was O
seen O
. O
['Physiological-Clinical']

Four O
hundred O
sixty-seven O
members O
of O
an O
occupational O
cohort O
( O
total O
N O
= O
573 O
) O
were O
examined O
via O
questionnaires O
and O
B-mode O
ultrasound O
. O
[]

Up O
to O
three O
IPL O
or O
Er O
: O
YAG O
treatments O
did O
not O
result O
in O
a O
significant O
improvement O
in O
rhytid O
scores O
. O
[]

Changes O
in O
their O
knowledge O
and O
perceptions O
of O
breast B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
were O
measured O
and O
compared O
. O
['Physiological-Clinical']

Laser O
interferometry O
detected O
the O
isoprenaline-effects O
at O
the O
lowest O
dose O
level O
of O
0.1 O
micrograms O
min-1 O
with O
a O
high O
signal-to-noise O
ratio O
. O
[]

CONCLUSION O
Irrespective O
of O
the O
preexercise O
meal O
, O
cycling O
TT O
performance O
of O
approximately O
30 O
min O
was O
not O
improved O
after O
PSE O
supplementation O
. O
[]

Concentrations O
of O
indinavir B-outcome ['Physiological-Clinical']
, O
coadministered O
with O
amprenavir B-outcome ['Physiological-Clinical']
, O
in O
plasma B-outcome ['Physiological-Clinical']
decreased O
in O
both O
single-dose O
and O
steady-state O
evaluations O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
a O
3-6 O
week O
placebo O
washout O
period O
, O
the O
patients O
were O
randomized O
to O
receive O
either O
placebo O
or O
nifedipine O
SR-20 O
mg O
( O
study O
I O
only O
) O
, O
50 O
mg O
, O
100 O
mg O
, O
or O
150 O
mg O
( O
study O
II O
only O
) O
. O
[]

The O
main O
outcomes O
were O
: O
diet B-outcome ['Life-Impact']
, O
based O
on O
multiple O
24-hour O
recalls O
( O
total O
fat O
, O
grams O
of O
fiber O
, O
servings O
of O
fruit O
and O
vegetables O
, O
total O
calories O
) O
; O
average O
daily B-outcome ['Life-Impact']
energy I-outcome ['Life-Impact']
expenditure I-outcome ['Life-Impact']
( O
kcals/kg O
) O
based O
on O
7-day O
physical O
activity O
recall O
interviews O
; O
daily B-outcome ['Life-Impact']
minutes I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
moderate-vigorous I-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
minutes O
from O
accelerometery O
; O
and O
self-reported O
daily B-outcome ['Life-Impact']
hours I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
sedentary I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Comparison O
of O
regimens O
of O
amphotericin O
B O
deoxycholate O
in O
kala-azar O
. O
[]

METHOD O
Forty O
children O
( O
7-11 O
years O
old O
) O
were O
randomly O
assigned O
to O
16 O
sessions O
of O
CBT O
or O
a O
3-month O
waitlist O
( O
36 O
completed O
treatment O
or O
waitlist O
) O
. O
[]

Short-term O
sulfasalazine O
inhibited O
NFlB O
activity O
; O
however O
, O
long-term O
treatment O
was O
poorly O
tolerated O
and O
did O
not O
improve O
endothelial O
function O
. O
[]

Additional O
propofol O
was O
administered O
as O
a O
bolus O
of O
10 O
to O
20 O
mg O
when O
the O
patients O
moved O
. O
[]

Sulfadoxine/pyrimethamine O
alone O
or O
with O
amodiaquine O
or O
artesunate O
for O
treatment O
of O
uncomplicated B-outcome ['Physiological-Clinical']
malaria I-outcome ['Physiological-Clinical']
: O
a O
longitudinal O
randomised O
trial O
. O
['Physiological-Clinical']

A O
copy O
was O
given O
to O
the O
patient O
and O
to O
all O
relevant O
professionals O
and O
carers O
. O
[]

Recombinant O
human O
nerve O
growth O
factor O
( O
rhNGF O
) O
has O
demonstrated O
efficacy O
as O
treatment O
for O
peripheral O
neuropathy O
in O
experimental O
models O
and O
phase O
2 O
clinical O
trials O
. O
[]

RESULTS O
A O
total O
of O
1905 O
of O
the O
randomized O
subjects O
( O
91.6 O
percent O
) O
completed O
the O
study O
. O
[]

CONCLUSIONS O
DCCT O
intensive O
therapy O
is O
more O
expensive O
than O
conventional O
therapy O
, O
but O
it O
offers O
the O
hope O
of O
cost O
savings O
as O
a O
result O
of O
averted O
complications O
. O
[]

The O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
were O
significantly O
reduced O
( O
P O
< O
0.01 O
) O
in O
the O
10 O
patients O
with O
chronic O
hepatitis O
B O
, O
compared O
with O
those O
of O
the O
controls O
, O
owing O
to O
a O
significant O
increase O
in O
the O
number O
of O
CD8+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( O
P O
< O
0.005 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Immunodepression O
is O
a O
common O
condition O
in O
patients O
undergoing O
elective O
operations O
and O
it O
constitutes O
a O
high O
risk O
for O
the O
onset O
of O
postoperative O
infective O
complications O
. O
[]

mCPP O
( O
0.35 O
mg/kg O
) O
and O
placebo O
were O
administered O
orally O
to O
10 O
healthy O
men O
in O
a O
randomized O
double-blind O
design O
. O
[]

The O
outcomes O
of O
interest O
were O
the O
rapidity O
of O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
achieved O
with O
a O
single B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
, O
effectiveness O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
with O
on O
demand O
therapy O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Each O
patient O
participated O
in O
the O
study O
for O
9 O
weeks O
and O
registered O
daily O
level O
of O
pain O
and O
consumption B-outcome ['Resource-use']
of I-outcome ['Resource-use']
analgesics I-outcome ['Resource-use']
. O
['Resource-use']

The O
primary O
endpoints O
were O
HIV-free O
infant O
survival O
at O
6 O
weeks O
and O
12 O
months O
; O
HIV-free O
survival O
at O
12 O
months O
in O
infants O
who O
were O
ever O
breastfed O
; O
AIDS-free O
survival O
in O
mothers O
at O
18 O
months O
; O
and O
serious O
adverse O
events O
in O
mothers O
and O
babies O
. O
[]

Ten O
interventions O
were O
given O
during O
8 O
weeks O
followed O
by O
a O
26 O
weeks O
of O
follow O
up O
. O
[]

This O
volume O
was O
considerable O
in O
the O
preoperatively O
treated O
patients O
but O
kept O
at O
a O
minimum O
in O
the O
postoperative O
group O
. O
[]

Cells O
expressing O
the O
genes O
for O
interleukin-8 B-outcome ['Physiological-Clinical']
and O
tumor B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor-alpha I-outcome ['Physiological-Clinical']
were O
identified O
by O
in O
situ O
hybridization O
and O
quantified O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subjects O
in O
Group O
I O
replaced O
lenses O
every O
3 O
months O
, O
whereas O
those O
in O
Group O
II O
were O
not O
scheduled O
to O
replace O
their O
lenses O
. O
[]

A O
superiority O
of O
CM O
over O
EC O
was O
observed O
for O
both O
treated O
attacks O
for O
the O
main O
endpoint O
: O
success O
in O
54 O
versus O
36 O
% O
, O
p O
= O
0.003 O
for O
the O
first O
attack O
and O
60 O
versus O
44 O
% O
, O
p O
= O
0.02 O
for O
the O
second O
attack O
. O
[]

Overall O
, O
increased O
appetite O
occurred O
most O
frequently O
. O
[]

The O
shear-induced B-outcome ['Physiological-Clinical']
pathway I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
aspirin-treated I-outcome ['Physiological-Clinical']
platelets I-outcome ['Physiological-Clinical']
was O
not O
affected O
before O
cardiopulmonary O
bypass O
, O
but O
it O
was O
impaired O
more O
during O
the O
operation O
( O
p O
< O
0.01 O
) O
and O
remained O
worse O
afterward O
( O
p O
< O
0.05 O
) O
, O
compared O
with O
that O
of O
placebo-treated O
platelets O
. O
['Physiological-Clinical']

The O
effect O
of O
levetiracetam O
on O
essential B-outcome ['Physiological-Clinical']
tremor I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Results O
of O
the O
Third O
National O
Wilms O
' O
Tumor O
Study O
. O
[]

The O
main O
outcome O
measure O
was O
antibiotic B-outcome ['Resource-use']
concentration I-outcome ['Resource-use']
measured O
by O
chromatographic O
separation O
and O
mass O
spectrometry O
of O
aqueous O
samples O
obtained O
during O
surgery O
. O
['Resource-use']

Cohort O
1 O
( O
n O
= O
6 O
) O
was O
treated O
every O
3 O
weeks O
, O
with O
leukapheresis O
after O
2 O
weeks O
and O
cryopreservation O
of O
the O
leukapheresis O
product O
. O
[]

Later O
, O
patients O
were O
randomly O
assigned O
to O
receive O
cefoperazone O
sodium O
for O
either O
24 O
hours O
or O
120 O
hours O
. O
[]

Results O
of O
the O
therapeutic O
effects O
will O
not O
be O
available O
for O
some O
time O
, O
but O
the O
study O
has O
provided O
an O
opportunity O
to O
investigate O
influences O
on O
sensitization B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
allergens I-outcome ['Physiological-Clinical']
in O
a O
large O
cohort O
of O
1-2 O
years O
olds O
with O
already O
established O
atopic O
dermatitis O
, O
resident O
in O
different O
countries O
and O
in O
different O
environments O
. O
['Physiological-Clinical']

The O
setting O
was O
in O
nephrological O
departments O
in O
Italy O
. O
[]

METHODS O
Thirteen O
emmetropic O
subjects O
were O
randomly O
fitted O
with O
two O
different O
tinted O
Nike O
Maxsight O
( O
Bausch O
& O
Lomb O
, O
Rochester O
, O
NY O
, O
USA O
) O
CL O
in O
one O
eye O
, O
while O
the O
contralateral O
eye O
was O
fitted O
with O
a O
clear O
lens O
made O
of O
the O
same O
material O
( O
Optima O
38 O
, O
Bausch O
& O
Lomb O
) O
. O
[]

Vibriocidal B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
developed O
in O
105/186 O
( O
57 O
% O
) O
and O
5/116 O
( O
4 O
% O
) O
in O
vaccine O
and O
placebo O
recipients O
, O
respectively O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
on O
other O
behavioural B-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
psychological I-outcome ['Life-Impact']
measures I-outcome ['Life-Impact']
, O
although O
at O
the O
4-week O
follow-up O
the O
control O
group O
perceived O
their O
risk O
for O
breast O
cancer O
, O
relative O
to O
other O
women O
their O
age O
, O
as O
a O
lot O
lower O
than O
did O
women O
in O
the O
intervention O
group O
. O
['Life-Impact']

FINDINGS O
After O
a O
median O
follow O
up O
of O
6 O
years O
, O
there O
was O
no O
difference O
in O
event-free B-outcome ['Mortality']
or O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
between O
the O
two O
treatment O
groups O
. O
['Mortality', 'Mortality']

Whether O
prolonging O
treatment O
duration O
to O
48 O
weeks O
will O
further O
increase O
sustained O
response O
rates O
remains O
ill O
defined O
. O
[]

Brief O
report O
: O
effect O
of O
a O
focused O
imitation O
intervention O
on O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
in O
children O
with O
autism O
. O
['Life-Impact']

2.4 O
) O
, O
( O
56.5 O
? O
[]

Other O
clinical B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
were O
determined O
as O
secondary O
outcomes O
. O
['Physiological-Clinical']

INTERVENTION O
Patients O
were O
randomized O
to O
an O
MR O
plan O
or O
a O
traditional O
RCD O
plan O
. O
[]

The O
additive O
effects O
of O
low-dose O
flutamide O
( O
62.5 O
mg/d O
) O
were O
assessed O
over O
3 O
months O
in O
young O
patients O
with O
hyperinsulinemic O
ovarian O
hyperandrogenism O
( O
n O
= O
40 O
; O
age O
, O
approximately O
17 O
yr O
; O
body O
mass O
index O
, O
approximately O
22 O
kg/m O
( O
2 O
) O
) O
; O
all O
participants O
started O
on O
metformin O
( O
850 O
mg/d O
) O
and O
a O
fourth-generation O
contraceptive O
( O
ethinylestradiol O
30 O
microg O
plus O
drospirenone O
3 O
mg O
, O
21 O
d/month O
) O
, O
and O
they O
were O
randomized O
to O
receive O
flutamide O
in O
addition O
( O
n O
= O
20 O
) O
or O
not O
( O
n O
= O
20 O
) O
. O
[]

Group O
2 O
( O
13 O
patients O
) O
received O
1- O
( O
2-chloroethyl O
) O
-3-cyclohexyl-1-nitrosourea O
CCNU O
) O
130 O
mg/sq O
m O
orally O
every O
6 O
weeks O
. O
[]

CONCLUSIONS O
Somatostatin O
is O
more O
effective O
than O
ranitidine O
in O
controlling O
acute B-outcome ['Physiological-Clinical']
non-variceal I-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
in O
patients O
with O
Forrest O
IB O
bleeding O
activity O
. O
['Physiological-Clinical']

The O
sensation O
of O
incomplete B-outcome ['Physiological-Clinical']
voiding I-outcome ['Physiological-Clinical']
was O
significantly O
improved O
in O
groups O
M O
and O
H O
( O
p O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

Pre- O
and O
postintervention B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
scores O
were O
similar O
: O
intervention O
group O
( O
75.5 O
% O
vs O
80.7 O
% O
, O
control O
group O
; O
76.5 O
% O
vs O
81.3 O
% O
) O
. O
['Life-Impact']

morphine O
5 O
mg O
as O
required O
and O
regular O
acetaminophen O
was O
prescribed O
. O
[]

Glucose O
tolerance O
was O
normalized O
in O
greater O
than O
50 O
% O
of O
subjects O
with O
impaired O
glucose O
tolerance O
, O
the O
accumulated O
incidence O
of O
diabetes O
was O
10.6 O
% O
, O
and O
more O
than O
50 O
% O
of O
the O
diabetic O
patients O
were O
in O
remission O
after O
a O
mean O
follow-up O
of O
6 O
years O
. O
[]

METHODS O
This O
study O
evaluated O
patients O
with O
and O
without O
kidney O
disease O
[ O
glomerular O
filtration O
rate O
( O
GFR O
) O
less O
than O
60 O
mL/min/1.73 O
m O
( O
2 O
) O
) O
presenting O
with O
acute O
dyspnea O
. O
[]

No O
differences O
in O
chronic B-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
were O
detected O
for O
the O
two O
treatment O
groups O
. O
['Physiological-Clinical']

10 O
minute O
bouts O
during O
park O
walks O
: O
25.5 O
( O
9.6 O
) O
[ O
median O
( O
interquartile O
range O
) O
] O
vs. O
14.0 O
( O
20.3 O
) O
min O
. O
[]

As O
a O
marker O
of O
oxidative O
stress O
, O
allopurinol O
significantly O
reduced O
malondialdehyde B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Four O
hundred O
forty-two O
patients O
had O
intermediate-grade O
ML O
, O
221 O
highgrade O
ML O
, O
and O
74 O
unclassified O
ML O
. O
[]

There O
were O
no O
differences O
among O
groups O
in O
the O
number O
of O
patients O
with O
positive O
herpes O
simplex O
virus O
cultures O
. O
[]

RESULTS O
When O
being O
treated O
with O
combination O
therapy O
, O
7 O
of O
the O
57 O
patients O
( O
12.3 O
% O
) O
withdrew O
because O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

As O
there O
is O
evidence O
of O
a O
possible O
immunoregulatory O
role O
for O
H2-histamine O
receptor O
antagonists O
, O
we O
carried O
out O
a O
prospective O
randomized O
trial O
to O
evaluate O
the O
in O
vivo O
and O
in O
vitro O
effect O
of O
cimetidine O
, O
an O
H2-blocker O
, O
in O
the O
treatment O
of O
herpes O
zoster O
infection O
. O
[]

Median O
survival B-outcome ['Mortality']
was O
20.3 O
and O
14.9 O
months O
for O
HART O
and O
qdRT O
, O
respectively O
( O
P O
= O
.28 O
) O
. O
['Mortality']

A O
total O
of O
33 O
and O
91 O
cases O
of O
CIN2+ O
were O
detected O
among O
treated O
and O
untreated O
women O
, O
respectively O
. O
[]

Infants O
with O
large O
patent O
ductus O
arteriosus O
( O
PDA O
) O
exhibited O
significantly O
( O
p O
< O
.05 O
) O
lower B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
early O
, O
had O
higher O
blood B-outcome ['Physiological-Clinical']
urea I-outcome ['Physiological-Clinical']
nitrogen I-outcome ['Physiological-Clinical']
levels O
( O
26 O
+/- O
9 O
vs O
18 O
+ O
8 O
mg/dL O
; O
p O
< O
.05 O
) O
, O
and O
had O
greater O
weight O
loss B-outcome ['Physiological-Clinical']
( O
approximately O
17 O
% O
of O
birth O
weight O
) O
when O
compared O
with O
infants O
without O
PDA O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
significant O
difference O
was O
found O
in O
the O
range O
of O
[]

The O
purpose O
of O
this O
study O
was O
to O
test O
in O
vivo O
biofilm O
formation O
on O
polymethyl O
methacrylate O
( O
PMMA O
) O
self-cured O
acrylic O
resin O
provisional O
crowns O
. O
[]

AIM O
To O
evaluate O
once-daily O
mesalamine O
( O
mesalazine O
) O
granules O
( O
MG O
) O
for O
maintenance O
of O
remission O
of O
UC O
. O
[]

The O
incidence O
of O
preeclampsia B-outcome ['Physiological-Clinical']
in O
the O
randomized O
prophylactic O
antihypertensive O
group O
was O
statistically O
lower O
than O
that O
in O
the O
nonrandomized O
group O
( O
8.7 O
versus O
32.5 O
% O
; O
P O
less O
than O
.01 O
) O
. O
['Physiological-Clinical']

Oral O
fluoroquinolones O
can O
be O
safe O
, O
effective O
therapy O
if O
they O
are O
given O
for O
a O
prolonged O
course O
as O
treatment O
for O
infections O
caused O
by O
susceptible O
gram-positive O
as O
well O
as O
gram-negative O
organisms O
and O
in O
combination O
with O
adequate O
surgical O
debridement O
. O
[]

Of O
the O
CNS+ O
patients O
, O
28 O
had O
M2 O
( O
5 O
% O
to O
25 O
% O
blasts O
) O
or O
M3 O
( O
> O
25 O
% O
blasts O
) O
bone O
marrow O
involvement O
. O
[]

Live O
ratings O
were O
performed O
by O
two O
raters O
at O
the O
end O
of O
the O
pre-treatment O
placebo O
baseline O
period O
and O
at O
the O
end O
of O
the O
drug O
treatment O
period O
on O
the O
CPRS O
and O
the O
CGI O
and O
were O
videotaped O
. O
[]

Circulating O
concentrations O
of O
carotenoids B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical']

Participants O
made O
a O
significantly O
faster O
decision B-outcome ['Life-Impact']
about O
the O
target O
word O
( O
e.g O
. O
['Life-Impact']

Transmission O
was O
almost O
interrupted O
in O
two O
communities O
treated O
with O
combined O
therapy O
. O
[]

Zolmitriptan O
was O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
when O
given O
alone O
or O
concomitantly O
with O
fluoxetine O
. O
['Life-Impact']

Group O
C O
received O
5 O
minutes O
of O
sham O
ultrasound O
with O
the O
ketoprofen O
gel O
. O
[]

General O
variables O
: O
age O
, O
sex O
, O
marital O
status O
, O
educational O
level O
, O
work O
situation O
, O
cohabitation O
with O
children O
, O
smokers O
at O
home O
, O
number O
of O
years O
smoking O
, O
type O
of O
tobacco O
. O
[]

CONCLUSIONS O
Pulsed O
low-intensity O
direct O
current O
represents O
a O
useful O
approach O
for O
the O
treatment O
of O
stage B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
III I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
decubitus I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
by O
increasing O
the O
healing O
rate O
. O
['Physiological-Clinical']

Scanning O
electron O
micrographs O
demonstrate O
a O
much O
smaller O
sampling O
lumen O
in O
the O
laser-cut O
group O
, O
but O
no O
reduction O
in O
fibrin B-outcome ['Physiological-Clinical']
deposition I-outcome ['Physiological-Clinical']
at O
the O
site O
of O
the O
sampling O
hole O
. O
['Physiological-Clinical']

The O
shortened O
postpartum O
course O
of O
magnesium O
sulphate B-outcome ['Physiological-Clinical']
is O
as O
effective O
as O
the O
standard O
Pritchard O
regimen O
in O
the O
management B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
eclampsia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Complete B-outcome ['Physiological-Clinical']
hematologic I-outcome ['Physiological-Clinical']
response O
rates O
were O
higher O
in O
IFN/HU-treated O
patients O
( O
59 O
vs O
32 O
% O
) O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effect O
of O
trandolapril O
( O
T O
) O
and O
its O
fixed-dose O
combination O
with O
verapamil O
( O
FDTV O
) O
on O
SAM O
levels O
in O
hypertensive O
type-2 O
diabetic O
patients O
. O
[]

AMP O
and O
CB O
are O
equivalent O
for O
the O
treatment O
of O
bacterial O
meningitis O
due O
to O
susceptible O
organisms O
. O
[]

Presented O
results O
indicate O
that O
chronic O
hemodialysis O
patients O
have O
significantly O
diminished O
lymphocyte B-outcome ['Physiological-Clinical']
number I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
study O
demonstrates O
the O
importance O
of O
conducting O
rigorous O
trials O
in O
children O
with O
autism O
and O
casts O
doubt O
on O
one O
GI O
mechanism O
presumed O
to O
exert O
etiological O
and/or O
symptomatic O
effects O
in O
this O
population O
. O
[]

The O
improvement O
in O
nasal B-outcome ['Physiological-Clinical']
airflow I-outcome ['Physiological-Clinical']
and O
nasal B-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
with O
cetirizine/PSE O
than O
with O
placebo O
( O
P O
< O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
63 O
patients O
with O
mild O
or O
mild O
to O
moderate O
ED O
were O
randomized O
to O
receive O
Cappra O
( O
? O
) O
[]

INTERVENTION O
The O
MgSO4 O
group O
received O
0.2 O
ml/kg O
of O
50 O
% O
MgSO4 O
as O
intravenous O
( O
i.v O
. O
) O
[]

1.1 O
mo O
) O
than O
in O
Brisbane O
subjects O
( O
53.7 O
? O
[]

CONCLUSIONS O
The O
positive O
result O
reported O
in O
the O
preceding O
paper O
is O
unlikely O
to O
be O
an O
artefact O
. O
[]

A O
phase O
III O
study O
of O
belatacept-based O
immunosuppression O
regimens O
versus O
cyclosporine O
in O
renal O
transplant O
recipients O
( O
BENEFIT O
study O
) O
. O
[]

Body O
composition O
was O
measured O
by O
dual-energy O
X-ray O
absorptiometry O
and O
abdominal O
computed O
tomographic O
scans O
. O
[]

EIS O
was O
done O
to O
embolize O
esophageal O
varices O
as O
well O
as O
their O
feeders O
by O
intravariceal O
injection O
of O
sclerosant O
under O
fluoroscopic O
guidance O
. O
[]

Both O
SQ29,852 O
( O
mean O
dose O
15.0 O
+/- O
5.1 O
mg/day O
) O
and O
atenolol O
( O
mean O
dose O
37.5 O
+/- O
18.5 O
mg/day O
) O
significantly O
decreased O
both O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
authors O
therefore O
prospectively O
evaluated O
the O
clinical O
usefulness O
of O
routine O
oral O
calcium O
and O
vitamin O
D O
supplementation O
for O
prevention O
of O
hypocalcemia O
after O
total O
thyroidectomy O
and O
CND O
. O
[]

METHODS O
Fifty-nine O
women O
were O
randomized O
to O
receive O
EE/DRSP O
( O
n O
= O
32 O
) O
or O
EE/CMA O
( O
n O
= O
27 O
) O
for O
six O
months O
. O
[]

Recently O
, O
compression O
devices O
have O
been O
designed O
that O
produce O
high O
pressure O
and O
rapid O
inflation O
of O
air O
cuffs O
on O
the O
plantar O
plexus O
of O
the O
foot O
and O
the O
calf O
. O
[]

These O
results O
suggest O
that O
the O
elimination O
kinetics O
of O
theophylline O
is O
nonlinear O
in O
the O
human O
in O
the O
therapeutic O
range O
of O
serum B-outcome ['Physiological-Clinical']
concenntrations I-outcome ['Physiological-Clinical']
and O
can O
be O
explained O
by O
saturable O
formation O
kinetics O
of O
3-MX O
and O
1-MU O
. O
['Physiological-Clinical']

DISCUSSION O
The O
study O
will O
determine O
if O
the O
acquired O
self O
management O
skills O
of O
the O
patients O
continue O
to O
be O
used O
after O
discharge O
from O
hospital O
. O
[]

Patients O
receiving O
150 O
mg/m O
( O
2 O
) O
nab-paclitaxel O
had O
prolonged O
median O
OS B-outcome ['Mortality']
compared O
with O
those O
in O
the O
100 O
mg/m O
( O
2 O
) O
nab-paclitaxel O
arm O
( O
hazard O
ratio O
, O
0.575 O
; O
P O
= O
.008 O
) O
. O
['Mortality']

METHODS O
In O
a O
16-wk O
randomized O
trial O
, O
41 O
overweight O
Latina O
girls O
( O
15.2 O
+/- O
1.1 O
yr O
) O
were O
randomly O
assigned O
to O
C O
( O
n O
= O
7 O
) O
, O
N O
( O
n O
= O
10 O
) O
, O
N O
+ O
ST O
( O
n O
= O
9 O
) O
, O
or O
N O
+ O
CAST O
( O
n O
= O
15 O
) O
. O
[]

A O
double-blind O
, O
randomized O
, O
controlled O
, O
multicenter O
safety O
and O
immunogenicity O
study O
of O
a O
refrigerator-stable O
formulation O
of O
Zostavax O
. O
[]

Effects O
of O
low-level O
laser O
and O
plyometric O
exercises O
in O
the O
treatment O
of O
lateral O
epicondylitis O
. O
[]

Occlusion O
of O
side O
branches O
may O
be O
an O
important O
factor O
contributing O
to O
periprocedural O
MIs O
. O
[]

Emotional B-outcome ['Life-Impact']
reactivity I-outcome ['Life-Impact']
to O
social O
rejection O
and O
negative O
evaluation O
among O
persons O
with O
borderline O
personality O
features O
. O
['Life-Impact']

Both O
protocols O
allowed O
patients O
randomized O
to O
the O
400-mg/day O
imatinib O
arm O
to O
cross O
over O
to O
800 O
mg/day O
imatinib B-outcome ['Resource-use']
at O
progression O
. O
['Resource-use']

For O
the O
remaining O
women O
( O
no-scan O
group O
) O
, O
gestation O
was O
determined O
using O
the O
LMP O
. O
[]

CONCLUSIONS O
: O
Transurethral O
surgery O
with O
PlasmaKinetic O
bipolar O
energy O
seems O
to O
be O
a O
promising O
alternative O
to O
prostatic O
tissue O
removal O
with O
shorter O
operative O
, O
catheterization O
and O
hospitalization O
times O
, O
although O
increased O
rates O
of O
postoperative B-outcome ['Physiological-Clinical']
irritative I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
urethral B-outcome ['Physiological-Clinical']
stricture I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
must O
be O
further O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
judged O
not O
to O
be O
able O
to O
exercise O
adequately O
. O
[]

RESULTS O
The O
two O
intervention O
groups O
demonstrated O
significant O
decreases O
in O
parent-reported O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
at O
follow-up O
and O
a O
significant O
increase O
in O
the O
child O
's O
ability O
to O
generate O
positive O
strategies O
in O
an O
anxiety-provoking O
situation O
. O
['Life-Impact']

Five O
hundred O
ninety-two O
patients O
were O
evaluated O
: O
283 O
received O
ampicillin/sulbactam O
and O
309 O
received O
cefoxitin O
. O
[]

POPULATION O
A O
total O
of O
9025 O
women O
were O
screened O
in O
early O
pregnancy O
. O
[]

The O
drug O
had O
demonstrated O
significant O
activity O
in O
preclinical O
studies O
and O
some O
activity O
in O
Phase O
I O
trials O
. O
[]

The O
ABCD O
( O
Appropriate O
Blood O
Pressure O
Control O
in O
Diabetes O
) O
trial O
is O
a O
large O
, O
prospective O
, O
randomized O
clinical O
trial O
designed O
to O
compare O
the O
effects O
of O
intensive O
with O
moderate O
blood O
pressure O
control O
on O
the O
prevention O
and O
progression O
of O
diabetic O
nephropathy O
, O
retinopathy O
, O
cardiovascular O
disease O
, O
and O
neuropathy O
in O
non-insulin-dependent O
diabetes O
( O
NIDDM O
) O
. O
[]

Intervention O
was O
a O
validated O
planned O
educational O
programme O
with O
visual O
aids O
and O
iron O
supplementation O
. O
[]

The O
outcome O
measure O
was O
frequency O
of O
stereotypic B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
, O
which O
was O
evaluated O
for O
5 O
min O
before O
and O
after O
standing O
on O
the O
vibration O
platform O
. O
['Life-Impact']

Can O
a O
home-visit O
invitation O
increase O
Pap O
smear O
screening O
in O
Samliem O
, O
Khon O
Kaen O
, O
Thailand O
? O
[]

At O
base O
line O
, O
the O
transfusion O
group O
had O
a O
slightly O
lower O
mean O
hemoglobin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
7.2 O
vs. O
7.6 O
g O
per O
deciliter O
, O
P=0.001 O
) O
and O
hematocrit B-outcome ['Physiological-Clinical']
( O
20.4 O
vs. O
21.7 O
percent O
, O
P=0.002 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Supplementary O
electrocardiography B-outcome ['Resource-use']
( I-outcome ['Resource-use']
ECG I-outcome ['Resource-use']
) I-outcome ['Resource-use']
was O
performed O
before O
and O
after O
6-month O
treatment O
. O
['Resource-use']

Also O
, O
serum B-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
, O
globulin B-outcome ['Physiological-Clinical']
and O
lysozyme B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
found O
significantly O
( O
p O
< O
0.05 O
) O
higher O
in O
PN-fed O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

and O
, O
in O
18 O
cases O
, O
up O
to O
the O
8th O
hour O
from O
the O
administration O
. O
[]

There O
was O
no O
increase O
in O
levels O
of O
autoantibodies B-outcome ['Physiological-Clinical']
during O
the O
study O
period O
in O
either O
study O
group O
. O
['Physiological-Clinical']

Pre- O
, O
post- O
and O
one-year O
follow-up O
tests O
were O
administered O
. O
[]

Factor O
VIIc O
activity O
levels O
decreased O
in O
both O
groups O
with O
a O
greater O
change O
in O
the O
T-group O
. O
[]

Intranasal O
oxytocin O
improves O
emotion B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
for O
youth O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

Patients O
were O
monitored O
for O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
throughout O
the O
study O
period O
and O
up O
to O
30 O
days O
following O
administration O
of O
the O
last O
study O
medication O
. O
['Adverse-effects']

These O
findings O
may O
help O
to O
improve O
long-term O
renal O
allograft O
outcomes O
. O
[]

Effect O
of O
esomeprazole O
triple O
therapy O
on O
eradication B-outcome ['Physiological-Clinical']
rates O
of I-outcome ['Physiological-Clinical']
Helicobacter I-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical']

One-half O
of O
the O
150 O
healthy O
, O
full-term O
infants O
received O
a O
DTPa O
HBV-IPV-Hib O
vaccine O
at O
1 O
1/2 O
, O
3 O
and O
5 O
months O
of O
age O
; O
the O
other O
received O
a O
DTPa-IPV-Hib O
vaccine O
at O
1 O
1/2 O
, O
3 O
and O
5 O
months O
of O
age O
with O
separate O
HBV O
vaccine O
at O
1 O
and O
5 O
months O
of O
age O
. O
[]

b O
) O
. O
[]

RESULTS O
After O
the O
program O
, O
the O
mean O
rank O
of O
the O
perceived B-outcome ['Life-Impact']
self-efficacy I-outcome ['Life-Impact']
for O
the O
self-management B-outcome ['Life-Impact']
strategies I-outcome ['Life-Impact']
was O
statistically O
different O
between O
the O
two O
groups O
( O
p O
= O
0.023 O
) O
. O
['Life-Impact', 'Life-Impact']

Endothelin O
antagonism O
augmented O
insulin-stimulated B-outcome ['Physiological-Clinical']
NO I-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
and O
NOx B-outcome ['Physiological-Clinical']
flux I-outcome ['Physiological-Clinical']
, O
but O
not O
differently O
between O
groups O
and O
not O
proportional O
to O
hyperinsulinemia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
the O
mean O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
respond I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
verbal I-outcome ['Physiological-Clinical']
commands I-outcome ['Physiological-Clinical']
was O
significantly O
shorter O
in O
the O
propofol O
induction O
groups O
compared O
with O
the O
thiopental O
induction O
group O
. O
['Physiological-Clinical']

Effect O
of O
acarbose O
on O
additional O
insulin O
therapy O
in O
type O
2 O
diabetic O
patients O
with O
late O
failure O
of O
sulphonylurea O
therapy O
. O
[]

A O
variety O
of O
cues O
can O
differentiate O
objects O
from O
their O
surrounds O
. O
[]

MPA O
: O
in O
this O
group O
, O
89 O
% O
of O
responders O
still O
showed O
a O
benefit O
at O
week O
24 O
, O
compared O
with O
45 O
% O
in O
the O
megestrol O
group O
( O
P O
= O
0.03 O
) O
. O
[]

Racemic O
epinephrine O
was O
significantly O
more O
effective O
than O
saline O
at O
10 O
( O
P O
less O
than O
.01 O
) O
and O
30 O
minutes O
( O
P O
less O
than O
.05 O
) O
but O
not O
at O
120 O
minutes O
after O
the O
treatment O
. O
[]

Antifibrinolytic O
therapy O
for O
prevention O
of O
hemorrhage O
during O
surgery O
of O
the O
thyroid O
gland O
. O
[]

Both O
toxicities B-outcome ['Adverse-effects']
were O
seen O
more O
in O
arm O
A O
than O
in O
arm O
B O
, O
showing O
complete O
recovery O
in O
all O
cases O
. O
['Adverse-effects']

RESULTS O
Patients O
receiving O
bibrocathol O
2 O
% O
showed O
greater O
improvement O
in O
the O
sum O
score O
than O
the O
placebo O
patients O
( O
p O
< O
0.0001 O
, O
Cohen O
's O
effect O
size O
d O
= O
0.73 O
) O
. O
[]

The O
effect O
of O
the O
micronutrients O
on O
the O
outcome O
variables O
growth O
, O
biochemical O
status O
, O
mental B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
and O
bone B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
were O
assessed O
. O
['Life-Impact', 'Physiological-Clinical']

Seronegative O
recipients O
of O
seronegative O
livers O
were O
excluded O
. O
[]

Secondary O
analyses O
examined O
gains O
in O
expressive B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
and O
nonverbal B-outcome ['Life-Impact']
cognition I-outcome ['Life-Impact']
, O
and O
time O
effects O
during O
the O
intervention O
and O
follow-up O
periods O
. O
['Life-Impact', 'Life-Impact']

In O
12 O
healthy O
lowlanders O
( O
aged O
32 O
? O
[]

RESULTS O
Thirty-three O
subjects O
( O
31 O
male O
subjects O
, O
2 O
female O
subjects O
; O
aged O
3.2-10.7 O
years O
) O
were O
randomized O
in O
the O
study O
. O
[]

PATIENTS O
AND O
METHODS O
Physicians O
, O
after O
attending O
the O
BT O
, O
were O
randomly O
assigned O
to O
CW O
or O
to O
a O
waiting O
list O
. O
[]

Patients O
with O
ischemic O
chest O
pain O
with O
duration O
< O
or O
=12 O
hours O
and O
no O
contraindication O
for O
thrombolytic O
therapy O
were O
included O
. O
[]

In O
a O
cohort O
of O
systolic O
HF O
patients O
, O
we O
tested O
the O
effects O
of O
PDE5 O
inhibition O
( O
sildenafil O
) O
on O
LV O
ejection O
fraction O
, O
diastolic O
function O
, O
cardiac O
geometry O
, O
and O
clinical O
status O
. O
[]

Gemfibrozil O
induced O
a O
20 O
% O
reduction O
in O
plasma B-outcome ['Physiological-Clinical']
triglycerides I-outcome ['Physiological-Clinical']
and O
a O
13 O
% O
decrease O
in O
plasma B-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
, O
with O
a O
significant O
19 O
% O
increase O
in O
HDL B-outcome ['Physiological-Clinical']
and O
a O
11 O
% O
reduction O
in O
LDL B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
rate O
of O
a O
positive O
response O
, O
defined O
as O
at O
least O
a O
25 O
percent O
decrease O
in O
the O
Irritability B-outcome ['Life-Impact']
score O
and O
a O
rating O
of O
much O
improved O
or O
very O
much O
improved O
on O
the O
CGI-I O
scale O
, O
was O
69 O
percent O
in O
the O
risperidone O
group O
( O
34 O
of O
49 O
children O
had O
a O
positive O
response O
) O
and O
12 O
percent O
in O
the O
placebo O
group O
( O
6 O
of O
52 O
, O
P O
< O
0.001 O
) O
. O
['Life-Impact']

Peak O
N-acetylcysteine B-outcome ['Physiological-Clinical']
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
peak I-outcome ['Physiological-Clinical']
were O
not O
significantly O
different O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
incidence O
of O
first-dose O
hypotension O
with O
quinapril O
in O
patients O
with O
mild O
to O
moderate O
hypertension O
. O
[]

a O
measure O
of O
cardiac O
autonomic O
modulation O
, O
in O
SH O
patients O
. O
[]

BACKGROUND O
The O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
effectiveness O
of O
a O
brief O
CBT O
intervention O
for O
anxiety O
with O
children O
diagnosed O
with O
Asperger O
syndrome O
( O
AS O
) O
. O
[]

CONCLUSION O
IOS O
is O
a O
suitable O
procedure O
for O
nasal O
provocation O
testing O
and O
provides O
results O
similar O
to O
the O
aR O
. O
[]

The O
dosages O
of O
platelet O
5-HT O
and O
serum O
prolactin O
were O
carried O
out O
at O
the O
beginning O
and O
at O
the O
end O
of O
every O
phase O
of O
treatment O
( O
active O
or O
placebo O
) O
with O
radioenzymology O
and O
radioimmunoassay O
methods O
respectively O
. O
[]

At O
week O
48 O
of O
the O
study O
, O
an O
intent-to-treat O
analysis O
in O
which O
patients O
with O
missing O
data O
were O
considered O
to O
have O
experienced O
treatment O
failure B-outcome ['Physiological-Clinical']
showed O
that O
the O
3TC O
q.d O
. O
['Physiological-Clinical']

CT B-outcome ['Physiological-Clinical']
and O
MRI O
measurements O
of O
tibial B-outcome ['Physiological-Clinical']
tubercle-trochlear I-outcome ['Physiological-Clinical']
groove I-outcome ['Physiological-Clinical']
distances I-outcome ['Physiological-Clinical']
are O
not O
equivalent O
in O
patients O
with O
patellar O
instability O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
conclusion O
cuffed O
, O
tunnelled O
central O
venous O
catheters O
are O
less O
prone O
to O
displacement B-outcome ['Life-Impact']
than O
traditional O
percutaneous O
central O
venous O
catheters O
when O
used O
in O
children O
with O
malignant O
diseases O
. O
['Life-Impact']

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
dopexamine O
, O
an O
inodilator O
drug O
, O
on O
hemodynamic O
and O
splanchnic O
perfusion O
with O
measurement O
of O
gastric O
intramucosal O
pH O
, O
by O
the O
method O
of O
gastric O
tonometry O
, O
during O
abdominal O
aneurysm O
resection O
. O
[]

CT O
had O
a O
lower O
confidence B-outcome ['Life-Impact']
score O
than O
did O
DSA O
( O
7.2 O
vs O
8.2 O
, O
P O
< O
.001 O
) O
. O
['Life-Impact']

MATERIALS O
AND O
METHODS O
Participants O
( O
mean O
age O
: O
43.25 O
years O
; O
range O
: O
23-71 O
years O
) O
satisfying O
specified O
inclusion O
criteria O
were O
randomly O
allocated O
to O
conventional O
two-stage O
restoration O
( O
control O
group O
; O
n=14 O
) O
and O
immediate O
restoration O
groups O
( O
test O
group O
; O
n O
=14 O
) O
in O
a O
randomized O
controlled O
clinical O
trial O
. O
[]

The O
Ca/Mg O
( O
+ O
) O
group O
consisted O
of O
551 O
patients O
, O
the O
Ca/Mg O
( O
- O
) O
group O
consisted O
of O
181 O
patients O
. O
[]

The O
mean O
clinic O
time O
taken O
to O
receive O
Z O
and O
any O
concomitant O
therapy O
was O
about O
half O
that O
for O
P O
( O
78 O
vs O
161 O
min O
) O
. O
[]

AIM O
To O
evaluate O
the O
proteinuria-lowering B-outcome ['Physiological-Clinical']
effect O
of O
a O
renin O
inhibitor O
( O
aliskiren O
) O
, O
compared O
to O
placebo O
and O
to O
an O
angiotensin-converting O
enzyme O
inhibitor O
( O
perindopril O
) O
, O
in O
patients O
with O
non-diabetic O
chronic O
kidney O
disease O
. O
['Physiological-Clinical']

TPM O
is O
an O
effective O
and O
generally O
well-tolerated B-outcome ['Life-Impact']
migraine O
prophylactic O
( O
preventive O
) O
therapy O
for O
adults O
, O
as O
demonstrated O
in O
several O
randomized O
, O
double-blind O
, O
placebo-controlled O
trials O
. O
['Life-Impact']

Almost O
all O
patients O
were O
receiving O
diuretics O
and O
ACE O
inhibitors O
with O
few O
patients O
taking O
angiotensin O
receptor O
blockers O
. O
[]

However O
, O
there O
is O
a O
lack O
of O
randomized O
studies O
comparing O
conventional O
bypass O
surgery O
with O
stent O
implantation O
, O
particularly O
in O
patients O
with O
high O
risk O
for O
both O
treatments O
. O
[]

This O
protective B-outcome ['Physiological-Clinical']
effect O
was O
maintained O
for O
at O
least O
6 O
mo O
. O
['Physiological-Clinical']

The O
effects O
of O
delay O
in O
standard O
treatment O
due O
to O
induction O
chemotherapy O
in O
two O
randomized O
prospective O
studies O
. O
[]

The O
trial O
evaluated O
therapies O
in O
combination O
only O
and O
was O
not O
designed O
to O
test O
the O
individual O
treatment O
components O
. O
[]

Initial O
results O
of O
the O
Italian O
PROSIT O
study O
. O
[]

Hip B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
was O
decreased O
by O
2 O
% O
at O
192 O
weeks O
compared O
to O
baseline O
. O
['Physiological-Clinical']

Efficacy O
and O
long-term O
tolerability O
of O
sublingual O
fentanyl O
orally O
disintegrating O
tablet O
in O
the O
treatment O
of O
breakthrough O
cancer O
pain O
. O
[]

Dental B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
was O
reported O
among O
45.5 O
% O
of O
the O
study O
group O
( O
n=352 O
) O
in O
the O
2 O
months O
following O
screening O
. O
['Life-Impact']

Mixed O
method O
interviews O
are O
conducted O
with O
patients O
and O
their O
lay O
carers O
at O
three O
to O
five O
measurement O
points O
depending O
on O
randomisation O
and O
sub-protocol O
. O
[]

Bond B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
data O
were O
analyzed O
with O
two-way O
repeated O
measures O
ANOVA O
and O
Tukey O
's O
test O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Custom O
tray O
application O
of O
peroxide O
gel O
as O
an O
adjunct O
to O
scaling O
and O
root O
planing O
in O
the O
treatment O
of O
periodontitis O
: O
results O
of O
a O
randomized O
controlled O
trial O
after O
six O
months O
. O
[]

PATIENTS O
AND O
METHODS O
Four O
hundred O
seventeen O
anthracycline-naive O
MBC O
patients O
were O
randomized O
to O
receive O
one O
of O
the O
following O
regimens O
: O
arm O
A O
: O
11 O
cycles O
of O
fluorouracil O
500 O
mg/m O
( O
2 O
) O
, O
epirubicin O
75 O
mg/m O
( O
2 O
) O
, O
and O
cyclophosphamide O
500 O
mg/m O
( O
2 O
) O
( O
FEC O
75 O
) O
every O
21 O
days O
; O
arm O
B O
: O
four O
cycles O
of O
FEC O
100 O
( O
same O
regimen O
but O
with O
epirubicin O
100 O
mg/m O
( O
2 O
) O
) O
then O
eight O
cycles O
of O
FEC O
50 O
( O
epirubicin O
50 O
mg/m O
( O
2 O
) O
) O
; O
and O
arm O
C O
: O
four O
cycles O
of O
FEC O
100 O
then O
restart O
the O
same O
regimen O
at O
disease O
progression O
in O
case O
of O
prior O
response O
or O
stabilization O
. O
[]

20 O
subjects O
served O
as O
a O
control O
group O
and O
were O
treated O
with O
conventional O
steel O
curettes O
during O
a O
supportive O
periodontal O
care O
visit O
( O
SPT O
) O
. O
[]

OBJECTIVES O
To O
determine O
the O
effect O
irrigation O
fluid O
temperature O
has O
on O
core O
body O
temperature O
changes O
in O
patients O
undergoing O
transurethral O
resection O
of O
the O
prostate O
( O
TURP O
) O
. O
[]

Thyroid O
stimulating O
antibodies O
: O
an O
aid O
to O
the O
strategy O
of O
treatment O
of O
Graves O
' O
disease O
? O
[]

The O
most O
frequently O
reported O
post-vaccination O
symptoms O
were O
irritability B-outcome ['Life-Impact']
in O
the O
DTPa-IPV-Hib O
plus O
separate O
HBV O
group O
( O
49 O
% O
of O
vaccinees O
) O
and O
fever B-outcome ['Physiological-Clinical']
, O
defined O
as O
axillary O
temperature O
> O
or O
=37.5 O
degrees O
C O
, O
in O
the O
DTPa O
HBV- O
IPV-Hib O
group O
( O
50 O
% O
of O
vaccinees O
) O
. O
['Life-Impact', 'Physiological-Clinical']

The O
protracted O
anti-anginal B-outcome ['Physiological-Clinical']
effect O
of O
ISDN O
is O
largely O
due O
to O
its O
metabolites O
. O
['Physiological-Clinical']

A O
20-min O
set O
of O
audiotaped O
instructions O
on O
progressive O
muscle O
relaxation O
training O
( O
PMRT O
) O
was O
given O
to O
the O
patients O
in O
the O
experimental O
group O
for O
home O
practice O
. O
[]

A O
study O
with O
non-invasive O
automated O
cardiac O
flow O
measurement O
by O
color O
Doppler O
echocardiography O
. O
[]

However O
, O
patients O
with O
nephropathy O
treated O
with O
B1+B6 O
or O
B6 O
did O
not O
display O
any O
further O
increase O
in O
AGE-peptides B-outcome ['Physiological-Clinical']
within O
five O
months O
. O
['Physiological-Clinical']

Investigator-assessed O
shoulder B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
improved O
in O
both O
groups O
but O
more O
so O
in O
the O
oxaprozin O
group O
( O
p O
= O
0.028 O
at O
day O
15 O
) O
. O
['Physiological-Clinical']

A O
trend O
toward O
improvement O
in O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
was O
noted O
in O
myoblast-treated O
groups O
( O
?6-minute O
walk O
test O
of O
-3.6 O
vs O
+95.6 O
vs O
+85.5 O
m O
[ O
placebo O
vs O
low O
dose O
vs O
high O
dose O
; O
P O
= O
.50 O
] O
) O
without O
significant O
changes O
in O
Minnesota O
Living O
With O
HF O
scores O
. O
['Life-Impact']

The O
data O
were O
collected O
from O
9 O
clinics O
in O
the O
Netherlands O
, O
Belgium O
, O
Ireland O
, O
the O
United O
Kingdom O
, O
and O
Italy O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Fructose-1,6-diphosphate O
resulted O
in O
a O
modest O
7 O
% O
increase O
in O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Fibroblast O
growth O
factor O
23 O
( O
FGF23 O
) O
has O
been O
associated O
with O
death O
in O
dialysis O
patients O
. O
[]

Failure O
for O
PFS B-outcome ['Mortality']
was O
defined O
as O
the O
first O
occurrence O
of O
local B-outcome ['Physiological-Clinical']
, O
regional B-outcome ['Physiological-Clinical']
, O
or O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

A O
statistically O
significant O
difference O
was O
also O
observed O
for O
bleeding B-outcome ['Physiological-Clinical']
and O
pruritus B-outcome ['Physiological-Clinical']
at O
T3 O
and O
for O
these O
two O
parameters O
and O
both O
inflammation B-outcome ['Physiological-Clinical']
and O
edema B-outcome ['Physiological-Clinical']
at O
T4 O
( O
p O
< O
0.001 O
) O
in O
favor O
of O
the O
active O
combination O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
new O
technique O
of O
circular O
stapler O
for O
the O
treatment O
of O
hemorrhoids O
has O
shown O
early O
promise O
in O
terms O
of O
minimal O
or O
no O
postoperative O
pain O
, O
early O
discharge O
from O
hospital O
, O
and O
quick O
return O
to O
work O
. O
[]

METHOD O
the O
research O
sample O
consisted O
of O
11 O
mothers O
of O
children O
diagnosed O
, O
according O
to O
the O
criteria O
established O
by O
the O
DSM O
IVtr O
( O
APA O
, O
2002 O
) O
, O
with O
autism O
( O
six O
) O
and O
with O
Asperger O
Syndrome O
( O
five O
) O
and O
who O
were O
seen O
at O
the O
Investigation O
Laboratory O
of O
Global O
Developmental O
Disorders O
of O
the O
Federal O
University O
of O
S?o O
Paulo O
. O
[]

Effect O
sizes B-outcome ['Physiological-Clinical']
varied O
twofold O
by O
symptom O
category O
, O
largest O
for O
self-injury O
( O
2.11 O
) O
and O
tantrums O
( O
1.95 O
) O
. O
['Physiological-Clinical']

Early O
immunisation O
with O
hepatitis O
B O
vaccine O
: O
a O
five-year O
study O
. O
[]

OBJECTIVE O
This O
study O
was O
designed O
to O
determine O
the O
effectiveness O
and O
tolerability B-outcome ['Life-Impact']
of O
amlodipine O
camsylate O
compared O
with O
amlodipine O
besylate O
in O
Korean O
patients O
with O
mild O
to O
moderate O
hypertension O
. O
['Life-Impact']

The O
diagnostic B-outcome ['Life-Impact']
yield I-outcome ['Life-Impact']
of O
the O
biopsy B-outcome ['Resource-use']
was O
not O
significantly O
different O
whether O
the O
lesions O
were O
brushed O
before O
or O
after O
the O
biopsy O
( O
92.7 O
% O
versus O
93.2 O
% O
; O
P O
less O
than O
.5 O
) O
. O
['Life-Impact', 'Resource-use']

The O
significant O
decrease O
in O
serum B-outcome ['Physiological-Clinical']
total O
and O
LDL-cholesterol B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
caused O
by O
simvastatin O
was O
associated O
with O
an O
increase O
in O
serum B-outcome ['Physiological-Clinical']
N-acetyl-beta-glucosaminidase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
, O
ascorbic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
, O
plasminogen B-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
( O
PAI-1 O
) O
( O
P O
< O
0.01 O
) O
, O
vonWillebrand B-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
( O
P O
< O
0.05 O
) O
, O
E-selectin B-outcome ['Physiological-Clinical']
( O
P O
< O
0.01 O
) O
and O
vascular B-outcome ['Physiological-Clinical']
endothelial I-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
( O
P O
< O
0.05 O
) O
concentrations O
and O
with O
a O
decrease O
in O
plasma B-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
( O
P O
< O
0.01 O
) O
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
series O
of O
134 O
patients O
were O
included O
at O
7 O
hospital O
centers O
. O
[]

A O
prospective O
randomized O
study O
was O
carried O
out O
at O
the O
Detroit O
General O
Hospital O
over O
a O
two O
year O
period O
to O
evaluate O
methods O
of O
management O
in O
165 O
patients O
with O
colonic O
injuries O
. O
[]

BACKGROUND O
Effective O
new O
strategies O
that O
complement O
primary O
care O
are O
needed O
to O
reduce O
disability O
risks O
and O
improve O
self-management O
of O
chronic B-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
in O
frail O
older O
people O
living O
in O
the O
community O
. O
['Physiological-Clinical']

CONCLUSION O
Use O
of O
moderate O
concentration O
was O
more O
effective O
than O
use O
of O
a O
high O
concentration O
of O
contrast O
material O
for O
depiction O
of O
hepatocellular O
carcinoma O
. O
[]

However O
, O
the O
influence O
of O
pH O
on O
cerebral O
lactate O
uptake O
and O
, O
in O
turn O
, O
on O
the O
cerebral O
metabolic O
ratio O
during O
exercise O
is O
not O
known O
. O
[]

The O
investigators O
believe O
that O
collaboration O
, O
caring O
, O
and O
communication O
are O
the O
essence O
of O
exemplary O
health O
care O
. O
[]

CONCLUSION O
The O
RAB-plate O
provided O
a O
more O
stable O
fixation O
, O
especially O
with O
regard O
to O
maintained O
postoperative O
alignment O
. O
[]

OBJECTIVE O
To O
identify O
factors O
associated O
with O
completion O
of O
care O
among O
foreign-born O
adolescents O
treated O
for O
latent O
tuberculosis O
infection O
( O
LTBI O
) O
. O
[]

HR B-outcome ['Physiological-Clinical']
increased O
. O
['Physiological-Clinical']

BACKGROUND O
Although O
some O
studies O
have O
demonstrated O
that O
pharmacist O
intervention O
can O
improve O
drug O
therapy O
among O
patients O
with O
cardiovascular O
disease O
( O
CVD O
) O
, O
more O
evidence O
derived O
from O
randomized O
controlled O
trials O
( O
RCTs O
) O
is O
needed O
, O
including O
assessment O
of O
the O
effect O
of O
community O
pharmacist O
interventions O
in O
patients O
with O
CVD O
. O
[]

The O
present O
study O
examined O
attributions O
of O
this O
new O
umbrella O
term O
when O
compared O
with O
CFS O
. O
[]

Absorption O
of O
intramuscular B-outcome ['Resource-use']
phenobarbitone I-outcome ['Resource-use']
in O
children O
with O
severe O
falciparum O
malaria O
. O
['Resource-use']

After O
remission O
, O
standard O
medications O
were O
tapered O
according O
to O
the O
protocol O
. O
[]

CONCLUSION O
Periotest O
and O
Osstell B-outcome ['Physiological-Clinical']
are O
in O
general O
not O
very O
sensitive O
in O
the O
identification O
of O
peri-implant O
bone O
destruction O
, O
except O
for O
marginal O
bone O
loss O
. O
['Physiological-Clinical']

Only O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
end-diastolic I-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
tended O
to O
be O
of O
significance O
. O
['Physiological-Clinical']

Spoken O
communication O
was O
assessed O
in O
a O
rigorous O
test O
of O
generalization O
at O
pretreatment O
, O
posttreatment O
, O
and O
6-month O
follow-up O
periods O
. O
[]

After O
recent O
publicity O
about O
a O
child O
with O
autism O
whose O
condition O
markedly O
improved O
after O
a O
single O
dose O
of O
secretin O
, O
thousands O
of O
children O
with O
autistic O
disorders O
may O
have O
received O
secretin O
injections O
. O
[]

CONCLUSIONS O
Our O
study O
provides O
important O
insights O
into O
the O
timing O
of O
adverse O
events O
and O
suggests O
that O
the O
substantial O
proportion O
of O
patients O
suffer O
subsequent O
adverse O
events O
after O
their O
index O
NSTE O
ACS O
. O
[]

This O
index O
was O
then O
used O
to O
select O
out O
truly O
responsive O
patients O
and O
to O
prospectively O
direct O
their O
chemotherapy O
. O
[]

The O
following O
assessments O
were O
carried O
out O
: O
mechanical O
, O
thermal O
and O
electrical O
stimulations O
with O
sensory O
recordings O
in O
the O
esophagus O
and O
duodenum O
, O
and O
standardized O
, O
self-administered O
, O
daily O
symptom O
questionnaires O
. O
[]

Enhancing O
antiepileptic O
drug O
adherence O
: O
a O
randomized O
controlled O
trial O
. O
[]

Ninety-seven O
women O
with O
moderate O
to O
severe O
preeclampsia O
( O
PE O
) O
were O
allocated O
at O
random O
to O
labetalol O
or O
hydralazine O
treatment O
. O
[]

Seventy-seven O
consecutive O
biopsies O
were O
performed O
by O
a O
single O
operator O
. O
[]

Secondary O
end O
points O
were O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
the O
response O
rate O
, O
the O
duration O
of O
the O
response B-outcome ['Physiological-Clinical']
, O
safety O
, O
and O
the O
quality O
of O
life O
. O
['Mortality', 'Physiological-Clinical']

Changes O
in O
severity O
scores O
for O
arm O
symptoms O
and O
grip O
strength O
were O
similar O
between O
groups O
, O
but O
arm O
function O
improved O
more O
in O
the O
placebo O
pill O
group O
( O
2.0 O
, O
0.06 O
to O
3.92 O
, O
P O
= O
0.04 O
) O
. O
[]

The O
first O
group O
was O
composed O
of O
10 O
patients O
with O
a O
moderate O
motor B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
insufficiently O
controlled O
by O
monotherapy O
with O
bromocriptine O
. O
['Life-Impact']

A O
questionnaire O
establishing O
typical O
pre-trial O
, O
COPD-related B-outcome ['Physiological-Clinical']
RU I-outcome ['Physiological-Clinical']
was O
completed O
by O
each O
patient O
. O
['Physiological-Clinical']

One O
infusion O
prepared O
from O
ampoules O
contained O
one-fifth O
of O
the O
expected O
concentration O
of O
epinephrine O
; O
another O
contained O
none O
at O
all O
. O
[]

In O
addition O
, O
systemic O
exposure O
of O
risperidone O
active O
moiety O
( O
risperidone O
plus O
9-hydroxyrisperidone O
) O
, O
the O
most O
clinically O
relevant O
component O
of O
risperidone O
treatment O
, O
was O
not O
affected O
by O
galantamine O
coadministration O
, O
while O
systemic B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
was O
increased O
by O
approximately O
10 O
% O
for O
risperidone O
and O
decreased O
by O
about O
10 O
% O
for O
9-hydroxyrisperidone O
( O
active O
metabolite O
of O
risperidone O
) O
. O
['Life-Impact']

Exhaled B-outcome ['Physiological-Clinical']
NO O
was O
measured O
with O
a O
chemiluminescence O
detector O
from O
end O
expiratory O
single O
breath O
exhalation O
. O
['Physiological-Clinical']

Group O
B O
received O
three O
subcutaneous O
administrations O
at O
14 O
days O
interval O
of O
a O
1 O
% O
formulation O
of O
ivermectin O
at O
the O
dose O
rate O
of O
400mug/kg O
. O
[]

The O
low O
pressure O
suction O
drain O
removed O
an O
intraperitoneal O
marker O
, O
gentamicin O
, O
more O
effectively O
than O
the O
high O
pressure O
suction O
drain O
, O
but O
not O
more O
effectively O
than O
the O
passive O
drain O
. O
[]

We O
performed O
a O
long-term O
follow-up O
of O
a O
previously O
published O
randomized O
trial O
. O
[]

The O
safety O
of O
anti-C. O
difficile O
whey O
protein O
concentrate O
( O
anti-CD O
WPC O
) O
is O
supported O
by O
analytical O
data O
comparing O
the O
composition O
of O
raw O
milk O
from O
immunized O
cows O
versus O
that O
from O
non-immunized O
cows O
, O
and O
the O
composition O
of O
anti-CD O
WPC O
versus O
that O
of O
regular O
whey O
protein O
concentrate O
. O
[]

OBJECTIVES O
To O
determine O
the O
efficacy O
and O
safety O
of O
methylphenidate O
hydrochloride O
in O
children O
with O
pervasive O
developmental O
disorders O
and O
hyperactivity O
. O
[]

Moreover O
, O
pruritus B-outcome ['Physiological-Clinical']
was O
not O
observed O
after O
discontinuation O
of O
treatment O
from O
day O
15 O
and O
beyond O
in O
the O
pimecrolimus O
group O
, O
whereas O
it O
was O
reported O
in O
most O
patients O
of O
the O
betamethasone O
group O
. O
['Physiological-Clinical']

The O
treatment O
was O
always O
well O
tolerated B-outcome ['Life-Impact']
without O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Life-Impact', 'Adverse-effects']

Clinically O
significant O
depressive O
symptoms O
were O
defined O
as O
a O
score O
of O
7 O
or O
more O
on O
the O
15-item O
Geriatric O
Depression B-outcome ['Life-Impact']
Scale O
. O
['Life-Impact']

Elevated O
thromboxane O
levels O
are O
associated O
with O
a O
number O
of O
disease O
states O
, O
including O
dermal O
pressure O
ulcers O
. O
[]

Two O
wound O
infections O
occurred O
in O
the O
metronidazole O
group O
( O
5 O
% O
) O
and O
in O
both O
cases O
the O
organisms O
recovered O
were O
staphylococci O
of O
presumed B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
origin I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

To O
indicate O
the O
magnitude O
of O
the O
treatment O
effects O
, O
effect O
sizes O
were O
calculated O
. O
[]

The O
situation O
was O
then O
reversed O
for O
the O
next O
3 O
weeks O
( O
experimental O
period O
2 O
) O
. O
[]

With O
regard O
to O
total O
treatment O
costs B-outcome ['Resource-use']
, O
however O
, O
the O
stent O
group O
compared O
favorably O
to O
the O
bypass O
group O
( O
9,346 O
+/- O
807 O
vs. O
26,874 O
+/- O
3,985 O
euro O
) O
, O
predominantly O
as O
a O
result O
of O
a O
shorter O
intensive O
care O
and O
hospital O
stay O
. O
['Resource-use']

Comparison O
of O
quality O
of O
life O
, O
work B-outcome ['Life-Impact']
productivity I-outcome ['Life-Impact']
and O
medical B-outcome ['Resource-use']
resource I-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
of O
peginterferon O
alpha O
2a O
vs O
the O
combination O
of O
interferon O
alpha O
2b O
plus O
ribavirin O
as O
initial O
treatment O
in O
patients O
with O
chronic O
hepatitis O
C. O
The O
on-treatment O
impact O
of O
interferon-based O
therapies O
on O
quality O
of O
life O
( O
QOL B-outcome ['Life-Impact']
) O
, O
work B-outcome ['Life-Impact']
productivity I-outcome ['Life-Impact']
, O
and O
medical B-outcome ['Resource-use']
resource I-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
has O
not O
been O
systematically O
studied O
. O
['Life-Impact', 'Resource-use', 'Life-Impact', 'Life-Impact', 'Resource-use']

In O
the O
case O
of O
CYP2D6 O
, O
the O
dextromethorphan B-outcome ['Physiological-Clinical']
to O
dextrorphan B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
was O
not O
['Physiological-Clinical', 'Physiological-Clinical']

Reduction O
with O
aspiration O
of O
blood O
. O
[]

Group O
III O
was O
maintained O
in O
the O
preventive O
program O
provided O
by O
the O
local O
Dental O
Health O
Office O
, O
based O
on O
mechanical O
plaque O
control O
and O
topical O
use O
of O
fluorides O
and O
chlorhexidine O
at O
individualized O
intervals O
. O
[]

Shocks O
were O
delivered O
between O
the O
right O
ventricular O
coil O
and O
either O
an O
active O
can O
alone O
( O
single O
coil O
) O
or O
an O
active O
can O
with O
the O
proximal O
atrial O
coil O
( O
dual O
coil O
) O
. O
[]

The O
AV O
Node O
Ablation O
with O
CLS O
and O
CRT O
Pacing O
Therapies O
for O
Treatment O
of O
AF O
trial O
( O
AVAIL O
CLS/CRT O
) O
was O
designed O
to O
demonstrate O
superiority O
of O
BiV O
pacing O
in O
patients O
with O
AF O
after O
AV O
node O
ablation O
, O
to O
evaluate O
its O
effects O
on O
cardiac O
structure O
and O
function O
, O
and O
to O
investigate O
additional O
benefits O
of O
Closed O
Loop O
Stimulation O
( O
CLS O
) O
( O
BIOTRONIK O
, O
Berlin O
, O
Germany O
) O
. O
[]

The O
main O
agent O
associated O
with O
severe O
neutropenia O
was O
methotrexate O
, O
and O
methotrexate-induced B-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
patients O
who O
had O
received O
craniospinal O
irradiation O
. O
['Physiological-Clinical']

Fifty-six O
outpatients O
were O
randomly O
chosen O
and O
allocated O
to O
a O
treatment O
group O
or O
a O
waiting-list O
control O
group O
. O
[]

Denbufylline O
induced O
a O
statistically O
significant O
and O
clinically O
relevant O
improvement O
in O
both O
SDAT O
and O
MID O
patients O
, O
whereas O
after O
placebo O
this O
was O
not O
the O
case O
in O
CGI O
, O
the O
TMT O
, O
and O
the O
DS O
, O
with O
interdrug O
differences O
being O
significant O
in O
all O
primary O
target O
variables O
such O
as O
the O
CGI O
, O
MMS O
, O
SCAG O
, O
and O
DSST O
. O
[]

METHODS O
In O
SUSTAIN O
, O
172 O
patients O
with O
low O
levels O
of O
HDL-C O
will O
be O
randomized O
to O
receive O
RVX-208 O
100 O
mg O
bid O
or O
placebo O
for O
24 O
weeks O
. O
[]

RESULTS O
Colonization O
with O
LGG B-outcome ['Physiological-Clinical']
occurred O
in O
5 O
of O
24 O
( O
21 O
% O
) O
infants O
who O
weighed O
less O
than O
1500 O
g O
versus O
11 O
of O
23 O
( O
47 O
% O
) O
in O
larger O
infants O
. O
['Physiological-Clinical']

Changes O
in O
hemodynamic B-outcome ['Physiological-Clinical']
response O
to O
tasks O
were O
not O
accompanied O
by O
consistent O
changes O
in O
cognitive B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

PURPOSE O
To O
evaluate O
the O
effects O
of O
diltiazem O
and O
propranolol O
in O
patients O
with O
unstable O
angina O
. O
[]

0.30 O
kg O
) O
( O
85 O
% O
fat O
mass O
) O
treatments O
( O
both O
P O
< O
0.0005 O
) O
. O
[]

The O
k O
( O
eo O
) O
values O
were O
lower O
in O
CYP2C19 O
PMs O
than O
in O
EMs O
on O
day O
1 O
( O
0.012 O
vs. O
0.017 O
x O
10 O
( O
-4 O
) O
l O
min O
( O
-1 O
) O
) O
, O
and O
higher O
than O
in O
EMs O
on O
day O
4 O
( O
0.804 O
vs. O
0.169 O
x O
10 O
( O
-4 O
) O
l O
min O
( O
-1 O
) O
) O
of O
rabeprazole O
treatment O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
microtensile O
bond O
strength O
of O
a O
repair O
composite O
resin O
to O
a O
leucite-reinforced O
feldspathic O
ceramic O
( O
Omega O
900 O
, O
VITA O
) O
submitted O
to O
two O
surface O
conditionings O
methods O
: O
1 O
) O
etching O
with O
hydrofluoric O
acid O
+ O
silane O
application O
or O
2 O
) O
tribochemical O
silica O
coating O
. O
[]

CONCLUSIONS O
A O
doubling O
factor O
is O
effective O
for O
maintaining O
the O
sensitivity O
and O
specificity O
of O
PSA B-outcome ['Physiological-Clinical']
for O
prostate O
cancer O
detection O
in O
men O
on O
dutasteride O
. O
['Physiological-Clinical']

Eighteen O
patients O
who O
had O
undergone O
stoma O
surgery O
were O
assessed O
with O
respect O
to O
their O
anxiety B-outcome ['Life-Impact']
level O
and O
self-reported O
quality O
of O
life O
( O
QoL O
) O
on O
three O
occasions O
; O
namely O
, O
immediately O
after O
surgery O
, O
5 O
weeks O
after O
surgery O
, O
and O
10 O
weeks O
after O
surgery O
. O
['Life-Impact']

Subjects O
were O
assigned O
to O
gain O
weight O
( O
approximately O
4 O
kg O
) O
( O
n=35 O
) O
or O
to O
maintain O
weight O
( O
n=8 O
) O
. O
[]

METHODS O
Patients O
with O
stage O
IC-IV O
OC O
were O
randomized O
to O
either O
GC O
( O
gemcitabine O
1,000 O
mg/m O
( O
2 O
) O
, O
days O
1 O
and O
8 O
, O
plus O
carboplatin O
area O
under O
the O
curve O
[ O
AUC O
] O
5 O
, O
day O
1 O
) O
or O
TC O
( O
paclitaxel O
175 O
mg/m O
( O
2 O
) O
plus O
carboplatin O
AUC O
6 O
, O
day O
1 O
) O
every O
21 O
days O
for O
up O
to O
six O
cycles O
. O
[]

1 O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Resting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
BP B-outcome ['Physiological-Clinical']
) O
, O
HR O
, O
MSNA O
, O
spontaneous O
arterial O
baroreflex O
MSNA O
and O
HR O
modulation O
, O
endothelium-dependent O
and O
endothelium-independent O
vasodilation O
, O
and O
the O
homoeostatic O
model O
assessment O
of O
insulin O
resistance O
( O
HOMA-IR O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

100 O
episodes O
were O
severe O
, O
eight O
in O
RRV-TV O
recipients O
and O
92 O
in O
placebo O
recipients O
( O
vaccine O
efficacy O
91 O
% O
[ O
82-96 O
] O
) O
. O
[]

Therefore O
, O
we O
have O
concluded O
that O
it O
should O
not O
be O
further O
studied O
in O
this O
cohort O
of O
patients O
. O
[]

Cutaneous B-outcome ['Physiological-Clinical']
dissemination I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
occurred O
in O
none O
of O
the O
10 O
acyclovir O
recipients O
and O
in O
5 O
of O
the O
10 O
vidarabine O
recipients O
who O
had O
presented O
with O
localized O
dermatomal O
disease O
( O
P O
= O
0.016 O
) O
. O
['Physiological-Clinical']

Group O
data O
indicated O
no O
statistically O
significant O
findings O
even O
though O
several O
parents O
reported O
improvement O
in O
their O
children O
. O
[]

Aim O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
a O
brachial-basilic O
( O
BB O
) O
AVF O
and O
the O
prosthetic O
brachial-antecubital O
forearm O
loop O
access O
( O
PTFE O
) O
on O
cardiac B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Perindopril O
, O
whether O
given O
alone O
or O
in O
combination O
with O
hydrochlorothiazide O
, O
was O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
and O
produced O
no O
clinically O
significant O
change O
in O
routine O
haematology B-outcome ['Physiological-Clinical']
or O
serum B-outcome ['Physiological-Clinical']
biochemistry I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
rates O
of O
adverse B-outcome ['Adverse-effects']
clinical I-outcome ['Adverse-effects']
events O
in O
the O
groups O
were O
low O
and O
equal O
. O
['Adverse-effects']

At O
the O
end O
of O
the O
3 O
wk O
, O
we O
measured O
plasma O
inflammatory O
markers O
IL-6 O
, O
C-reactive O
protein O
, O
tumor O
necrosis O
factor O
receptors O
I O
and O
II O
( O
TNF-RI O
and O
-RII O
) O
, O
monocyte O
chemotactic O
protein-1 O
and O
E-selectin O
, O
and O
urinary O
8-iso-PGF O
( O
2? O
) O
, O
a O
marker O
of O
lipid O
peroxidation O
. O
[]

After O
a O
50 O
mg O
oral O
dose O
, O
maximum O
concentrations O
of O
66 O
micrograms/l O
are O
achieved O
within O
1.2 O
h. O
C O
is O
extensively O
distributed O
to O
the O
tissues O
( O
Vz O
= O
132 O
l O
) O
and O
eliminated O
primarily O
by O
hepatic O
metabolism O
( O
total O
clearance O
590 O
ml/min O
, O
renal O
clearance O
4 O
ml/min O
) O
. O
[]

Both O
ecASA O
and O
cASA O
inhibited O
14C-serotonin O
release O
; O
no O
significant O
difference O
was O
observed O
in O
the O
maximum O
effect O
between O
these O
two O
products O
( O
p O
less O
than O
0.05 O
) O
. O
[]

Participants O
receiving O
X-rays O
are O
more O
satisfied O
with O
their O
care O
, O
but O
are O
not O
less O
worried O
or O
more O
reassured O
about O
serious O
disease O
causing O
their O
low O
back O
pain O
. O
[]

Researchers O
evaluated O
whether O
a O
new O
device O
might O
decrease O
the O
time B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
catheter I-outcome ['Life-Impact']
insertion I-outcome ['Life-Impact']
, O
increase O
the O
likelihood O
of O
inserting O
the O
catheter B-outcome ['Resource-use']
on O
the O
first O
attempt O
( O
improved O
accuracy O
) O
, O
and O
['Life-Impact', 'Resource-use']

RESULTS O
Lesions O
treated O
with O
5 O
% O
imiquimod O
cream O
were O
clinically B-outcome ['Physiological-Clinical']
cleared I-outcome ['Physiological-Clinical']
in O
21 O
( O
84 O
% O
) O
of O
25 O
patients O
and O
partially B-outcome ['Physiological-Clinical']
cleared I-outcome ['Physiological-Clinical']
in O
2 O
( O
8 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

To O
assess O
the O
risks O
associated O
with O
inadvertent O
exposure O
of O
infants O
to O
vaccine O
viruses O
from O
vaccinated O
contacts O
, O
this O
study O
was O
designed O
to O
evaluate O
the O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
cold-adapted O
influenza O
vaccine O
, O
trivalent O
, O
administered O
intranasally O
to O
healthy O
children O
6 O
to O
< O
24 O
weeks O
of O
age O
. O
['Life-Impact']

OBJECTIVE O
To O
study O
the O
immunomodulatory O
effect O
of O
the O
histamine O
receptor O
antagonist O
, O
ranitidine O
, O
in O
patients O
admitted O
to O
the O
intensive O
care O
unit O
after O
severe O
head O
injury O
. O
[]

JobTIPS O
: O
a O
transition O
to O
employment O
program O
for O
individuals O
with O
autism O
spectrum O
disorders O
. O
[]

CONCLUSIONS O
A O
web-based O
intervention O
that O
tailored O
content O
according O
to O
smoking-related O
beliefs O
, O
personal O
characteristics O
and O
smoking O
patterns O
, O
self-efficacy O
and O
outcome O
expectations O
, O
was O
not O
more O
effective O
than O
web-based O
materials O
presenting O
broadly O
similar O
non-tailored O
information O
. O
[]

Bone B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
in O
the O
controls O
( O
group O
3 O
) O
remained O
at O
the O
upper O
limit O
of O
the O
reference O
range O
throughout O
, O
with O
decreases O
in O
BMD B-outcome ['Physiological-Clinical']
of O
2.3 O
% O
( O
spine O
) O
and O
2.8 O
% O
( O
hip O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Co-administration O
of O
single O
doses O
of O
donepezil O
HCl O
( O
5 O
mg O
) O
and O
digoxin O
( O
0.25 O
mg O
) O
produced O
no O
changes O
in O
the O
pharmacokinetic O
profile O
of O
either O
drug O
. O
[]

Analysis O
of O
trends O
demonstrated O
increasing O
( O
but O
not O
statistically O
significant O
) O
confidence B-outcome ['Life-Impact']
in O
CT O
and O
stable O
['Life-Impact']

The O
greatest O
prevalence O
reduction O
occurred O
for O
stimulants O
; O
modest O
changes O
were O
evident O
in O
alcohol O
and O
marijuana O
use O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
rate O
of O
blood O
transfusion O
( O
1.0 O
% O
in O
the O
cangrelor O
group O
and O
0.6 O
% O
in O
the O
placebo O
group O
, O
P=0.13 O
) O
, O
though O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
on O
one O
scale O
was O
increased O
in O
the O
cangrelor O
group O
, O
from O
3.5 O
% O
to O
5.5 O
% O
( O
P O
< O
0.001 O
) O
, O
because O
of O
more O
groin B-outcome ['Physiological-Clinical']
hematomas I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
This O
randomized O
controlled O
trial O
compared O
Hanen O
's O
'More O
than O
Words O
' O
( O
HMTW O
) O
, O
a O
parent-implemented O
intervention O
, O
to O
a O
'business O
as O
usual O
' O
control O
group O
. O
[]

RESULTS O
Ninety-five O
physicians O
were O
randomized O
. O
[]

Safety O
and O
acceptability O
of O
cellulose O
sulfate O
as O
a O
vaginal O
microbicide O
in O
HIV-infected O
women O
. O
[]

Effects O
of O
dietary O
pyridoxine O
on O
haemato-immunological B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
of O
Labeo O
rohita O
fingerlings O
reared O
at O
higher O
water O
temperature O
. O
['Physiological-Clinical']

In O
the O
present O
study O
, O
while O
initial O
benefits O
were O
observed O
to O
be O
independent O
of O
dental O
prophylaxis O
, O
significant O
reductions O
in O
periodontal B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
were O
sustained O
by O
a O
combination O
of O
dental O
prophylaxis O
and O
swabbing O
protocol O
, O
at O
reduced O
frequency O
of O
application O
and O
over O
prolonged O
time O
. O
['Physiological-Clinical']

METHOD O
Thirteen O
children O
with O
autistic O
disorder O
, O
aged O
3.4 O
to O
8.3 O
years O
( O
mean O
5.4 O
) O
, O
were O
studied O
in O
home O
, O
school O
, O
and O
outpatient O
laboratory O
. O
[]

From O
a O
previously O
reported O
5-year O
screening O
programme O
of O
6,956 O
47-49-year-old O
Malm? O
males O
, O
a O
series O
of O
41 O
subjects O
with O
early-stage O
Type O
2 O
( O
non-insulin-dependent O
) O
diabetes O
mellitus O
and O
181 O
subjects O
with O
impaired O
glucose O
tolerance O
were O
selected O
for O
prospective O
study O
and O
to O
test O
the O
feasibility O
aspect O
of O
long-term O
intervention O
with O
an O
emphasis O
on O
life-style O
changes O
. O
[]

SUBJECTS O
AND O
SETTINGS O
we O
randomized O
patients O
aged O
75 O
years O
and O
older O
on O
four O
or O
more O
medicines O
who O
had O
been O
discharged O
from O
three O
acute O
general O
and O
one O
long-stay O
hospital O
to O
a O
pharmacy O
intervention O
or O
usual O
care O
. O
[]

CONCLUSIONS O
Initiation O
of O
insulin O
pump O
therapy O
at O
diagnosis O
improved O
glycemic O
control O
, O
was O
well O
tolerated O
, O
and O
contributed O
to O
improved O
patient O
satisfaction O
with O
treatment O
. O
[]

The O
dropout O
rate O
in O
the O
experimental O
group O
( O
60 O
% O
) O
was O
significantly O
less O
after O
18 O
months O
than O
the O
control O
group O
( O
82 O
% O
) O
. O
[]

K. O
A. O
Perkins O
( O
1996 O
) O
recently O
proposed O
that O
nicotine O
reinforcement O
controls O
smoking O
to O
a O
greater O
degree O
among O
men O
than O
women O
and O
that O
consequently O
, O
nicotine O
replacement O
therapy O
( O
NRT O
) O
during O
smoking O
cessation O
should O
benefit O
men O
more O
than O
women O
. O
[]

OBJECT O
Stable O
hemodynamics O
, O
normocapnia O
, O
and O
adequate O
pain O
relief O
are O
considered O
important O
factors O
in O
the O
reduction O
of O
neurological O
complications O
in O
pediatric O
patients O
undergoing O
encephaloduroarteriomyosynangiosis O
( O
EDAMS O
) O
operations O
for O
the O
treatment O
of O
moyamoya O
disease O
. O
[]

The O
results O
indicate O
that O
the O
drugs O
promote O
a O
profibrinolytic O
profile O
, O
and O
may O
in O
part O
explain O
the O
benefit O
of O
statin O
treatment O
rendered O
in O
the O
prevention O
of O
CHD O
. O
[]

inpatient B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
care B-outcome ['Life-Impact']
) O
. O
['Resource-use', 'Life-Impact']

This O
novel O
method O
for O
automatically O
constructing O
a O
patient-specific O
3D O
finite O
element O
model O
from O
standard O
2D O
radiographs O
shows O
encouraging O
results O
in O
estimating O
patient-specific O
failure O
loads O
. O
[]

Secondary O
outcomes O
will O
be O
measured O
at O
30 O
minutes O
after O
treatment O
using O
the O
NRS O
of O
leg B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
ODI B-outcome ['Physiological-Clinical']
, O
patient B-outcome ['Physiological-Clinical']
global I-outcome ['Physiological-Clinical']
impression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
, O
range O
of O
motion B-outcome ['Physiological-Clinical']
( O
ROM B-outcome ['Physiological-Clinical']
) O
of O
the O
lumbar B-outcome ['Physiological-Clinical']
spine I-outcome ['Physiological-Clinical']
, O
and O
degrees O
of O
straight B-outcome ['Physiological-Clinical']
leg B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
10 O
years O
, O
the O
risk O
of O
developing O
MS B-outcome ['Physiological-Clinical']
was O
very O
low O
for O
patients O
without O
baseline O
lesions O
but O
remained O
substantial O
for O
those O
with O
lesions O
. O
['Physiological-Clinical']

We O
studied O
the O
effects O
of O
angiotensin O
converting O
enzyme O
( O
ACE O
) O
inhibitors O
on O
cough B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
bradykinin O
( O
BK O
) O
, O
substance O
P O
( O
SP O
) O
and O
citric O
acid O
in O
a O
double O
blind O
, O
random O
study O
on O
10 O
hypertensive O
patients O
receiving O
ACE O
inhibitors O
. O
['Physiological-Clinical']

Adequacy O
of O
vitamin O
B6 O
supplementation O
during O
pregnancy O
: O
a O
prospective O
study O
. O
[]

The O
more O
robust O
impact O
among O
Medicaid-insured O
children O
and O
for O
specific O
medication O
classes O
provides O
an O
argument O
for O
specific O
targeting O
of O
resources O
for O
patient O
and O
physician O
behavior O
change O
. O
[]

The O
control O
group O
received O
a O
single O
socialization O
contact O
. O
[]

The O
absolute O
number O
of O
blood B-outcome ['Physiological-Clinical']
and O
sputum B-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
after O
allergen O
or O
placebo O
challenge O
( O
P O
> O
0.07 O
, O
both O
comparisons O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
To O
analyze O
to O
what O
extent O
the O
percentage O
of O
suspicious O
digital O
rectal O
examination O
( O
DRE O
) O
findings O
vary O
between O
examiners O
and O
to O
what O
extent O
the O
percentage O
of O
prostate O
cancers O
( O
PCs O
) O
detected O
in O
men O
with O
these O
suspicious O
findings O
varies O
between O
examiners O
. O
[]

Those O
with O
poor O
logical O
analysis O
coping O
skills O
at O
baseline O
had O
decreased O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
( O
F O
( O
1,53 O
) O
= O
9.7 O
, O
p O
= O
.003 O
) O
and O
improved O
psychosocial B-outcome ['Life-Impact']
adjustment I-outcome ['Life-Impact']
( O
F O
( O
1,53 O
) O
= O
4.7 O
, O
p O
= O
.035 O
) O
after O
1 O
year O
. O
['Life-Impact', 'Life-Impact']

This O
study O
thus O
examined O
( O
1 O
) O
the O
effectiveness O
of O
different O
weekly O
frequencies O
of O
exercise O
on O
femoral B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
and O
( O
2 O
) O
whether O
BMD B-outcome ['Physiological-Clinical']
change O
differed O
between O
hip O
sites O
using O
a O
high-impact O
, O
unilateral O
intervention O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Functional O
outcomes O
can O
therefore O
serve O
2 O
purposes O
: O
to O
enhance O
compliance O
by O
improving O
health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
and O
to O
assist O
in O
making O
both O
treatment O
and O
formulary O
decisions O
. O
['Life-Impact']

ORG-2766 O
( O
a O
) O
increased O
the I-outcome ['Physiological-Clinical']
occipital B-outcome ['Physiological-Clinical']
P3 I-outcome ['Physiological-Clinical']
component I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
ERP I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
targets I-outcome ['Physiological-Clinical']
, O
( O
b O
) O
decreased O
the I-outcome ['Physiological-Clinical']
occipital B-outcome ['Physiological-Clinical']
P3 I-outcome ['Physiological-Clinical']
component I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
ERP I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
auditory I-outcome ['Physiological-Clinical']
targets B-outcome ['Physiological-Clinical']
, O
( O
c O
) O
did O
not O
affect O
visual B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
auditory I-outcome ['Physiological-Clinical']
parietal I-outcome ['Physiological-Clinical']
target I-outcome ['Physiological-Clinical']
P3 B-outcome ['Physiological-Clinical']
components I-outcome ['Physiological-Clinical']
, O
and O
( O
d O
) O
also O
did O
not O
affect O
the O
A/Pcz/300 O
to O
auditory O
novel O
stimuli O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Four O
population-based O
breast O
cancer O
screening O
projects O
are O
in O
progress O
in O
Sweden O
, O
three O
of O
which O
are O
randomized O
studies O
. O
[]

RESULTS O
Sixty-five O
patients O
in O
the O
FIN-RACo O
and O
65 O
in O
the O
SINGLE O
group O
had O
radiographs O
of O
hands O
and O
feet O
available O
at O
baseline O
and O
at O
11 O
years O
. O
[]

A O
whey O
protein O
concentrate O
prepared O
from O
the O
milk O
of O
cows O
that O
have O
been O
immunized O
against O
Clostridium O
difficile O
( O
C. O
difficile O
) O
and O
its O
toxins O
, O
toxin O
A O
and O
toxin O
B O
, O
is O
produced O
for O
use O
as O
a O
medical O
food O
for O
the O
dietary O
management O
of O
patients O
with O
C. O
difficile-associated O
diarrhea O
( O
CDAD O
) O
to O
prevent O
a O
relapse O
of O
the O
infection O
. O
[]

Should O
this O
fail O
, O
patients O
then O
proceed O
with O
surgical O
clipping O
. O
[]

No O
significant O
differences O
were O
found O
between O
the O
two O
groups O
regarding O
Doppler O
echocardiographic O
parameters O
( O
aortic B-outcome ['Physiological-Clinical']
integral I-outcome ['Physiological-Clinical']
, O
pulmonary B-outcome ['Physiological-Clinical']
integral I-outcome ['Physiological-Clinical']
, O
end-systolic B-outcome ['Physiological-Clinical']
and O
end-diastolic B-outcome ['Physiological-Clinical']
diameters I-outcome ['Physiological-Clinical']
) O
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
; O
only O
a O
slight O
but O
not O
significant O
increase O
in O
arterial O
blood O
pressure O
was O
observed O
in O
group O
A O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Twenty O
teeth O
from O
each O
group O
were O
used O
for O
the O
apical O
leakage O
test O
and O
the O
remaining O
five O
teeth O
from O
each O
group O
were O
used O
for O
examination O
under O
the O
scanning O
electron O
microscope O
( O
SEM O
) O
. O
[]

RESULTS O
Seventy-four O
ulcers O
were O
treated O
in O
four O
centers O
. O
[]

INTERVENTION O
( O
S O
) O
Metaphase O
II O
oocytes O
were O
divided O
into O
groups O
A O
and O
B O
, O
vitrified O
with O
and O
without O
cumulus O
cells O
, O
respectively O
. O
[]

Naltrexone B-outcome ['Physiological-Clinical']
sequestering I-outcome ['Physiological-Clinical']
was O
successful O
in O
all O
treatment O
arms O
and O
not O
affected O
by O
coadministration O
with O
alcohol O
over O
the O
dose O
range O
tested O
. O
['Physiological-Clinical']

There O
were O
no O
differences O
between O
SDMI O
, O
SDLI O
, O
and O
CTRL O
( O
359.4 O
? O
[]

Early O
versus O
late O
hCG O
administration O
to O
trigger O
ovulation O
in O
mild O
stimulated O
IUI O
cycles O
: O
a O
randomized O
clinical O
trial O
. O
[]

Group O
1 O
( O
25 O
heels O
) O
was O
treated O
immediately O
with O
three O
sessions O
of O
ESWT O
( O
3000 O
shock O
waves/session O
of O
0.2 O
mJ/mm2 O
) O
at O
weekly O
intervals O
. O
[]

Sildenafil O
was O
started O
at O
50 O
mg O
and O
increased O
( O
100 O
mg O
) O
or O
decreased O
( O
25 O
mg O
) O
at O
week O
2 O
if O
necessary O
. O
[]

Esmolol O
compares O
favorably O
with O
verapamil O
with O
respect O
to O
both O
efficacy O
and O
safety O
in O
acutely O
decreasing O
ventricular B-outcome ['Physiological-Clinical']
response B-outcome ['Physiological-Clinical']
during O
atrial O
fibrillation O
or O
flutter O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
total O
of O
681 O
low O
back O
pain O
patients O
presenting O
to O
a O
managed-care O
facility O
were O
randomized O
to O
chiropractic O
with O
or O
without O
physical O
modalities O
, O
or O
medical O
care O
with O
or O
without O
physical O
therapy O
, O
and O
followed O
for O
18 O
months O
. O
[]

The O
second O
group O
was O
treated O
by O
ESWL O
with O
diuresis O
during O
the O
ESWL O
session O
. O
[]

SD O
patients O
also O
became O
refractory O
to O
random O
platelets O
less O
frequently O
( O
p O
less O
than O
0.005 O
) O
, O
after O
a O
longer O
time O
period O
, O
and O
after O
a O
higher O
number O
of O
transfusions B-outcome ['Resource-use']
( O
p O
less O
than O
0.02 O
) O
. O
['Resource-use']

Because O
weight O
loss O
in O
older O
people O
often O
reflects O
a O
disproportionate O
reduction O
of O
skeletal O
muscle O
, O
anabolic O
treatments O
may O
be O
beneficial O
. O
[]

Analysis O
by O
stage O
showed O
no O
significant O
benefit O
of O
ASI O
in O
stage O
III O
disease O
. O
[]

In O
97 O
% O
of O
these O
, O
fever B-outcome ['Physiological-Clinical']
occurred O
in O
the O
postoperative O
period O
. O
['Physiological-Clinical']

The O
effect O
of O
initial O
scores O
on O
the O
MCIC O
was O
also O
assessed O
. O
[]

When O
analyzed O
according O
to O
whether O
or O
not O
visible B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
was O
achieved O
( O
some O
of O
the O
polyps O
in O
the O
fixed O
duration O
cautery O
group O
showed O
necrosis O
with O
2 O
s O
cautery O
) O
, O
19 O
of O
23 O
polyps O
( O
83 O
% O
) O
were O
eradicated B-outcome ['Physiological-Clinical']
when O
necrosis O
was O
evident O
, O
compared O
to O
5 O
of O
12 O
( O
42 O
% O
) O
without O
necrosis O
( O
p O
= O
0.004 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
thus O
no O
explanation O
other O
than O
treatment O
for O
the O
improved O
outcome O
in O
patients O
who O
received O
immunosuppressive O
therapy O
. O
[]

Moreover O
, O
percentage O
change O
of O
monocyte B-outcome ['Physiological-Clinical']
chemoattractant I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

PARTICIPANTS O
Twenty-four O
patients O
who O
had O
suffered O
TBI O
and O
reported O
problems O
with O
focused O
or O
sustained O
attention O
. O
[]

Group O
2 O
additionally O
wore O
an O
HMD O
unit O
that O
was O
switched O
off O
. O
[]

We O
used O
continuous O
intraluminal O
esophageal O
and O
tracheal O
pH O
monitoring O
probes O
to O
investigate O
the O
effect O
of O
ranitidine O
on O
the O
incidence O
of O
GER B-outcome ['Physiological-Clinical']
and O
tracheal B-outcome ['Physiological-Clinical']
aspiration I-outcome ['Physiological-Clinical']
in O
80 O
adult O
patients O
undergoing O
thoracotomy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Randomized O
placebo O
controlled O
human O
volunteer O
trial O
of O
a O
live O
oral O
cholera O
vaccine O
VA1.3 O
for O
safety O
and O
immune O
response O
. O
[]

BACKGROUND O
AND O
AIM O
Considering O
that O
lymph O
node O
status O
is O
a O
key O
factor O
in O
colorectal O
cancer O
staging O
, O
and O
the O
main O
determinant O
for O
adjuvant O
therapy O
of O
colorectal O
cancer O
being O
this O
therapy O
, O
responsible O
for O
a O
significant O
increase O
in O
colorectal O
cancer O
patients O
survival O
, O
the O
staging O
methods O
should O
be O
the O
most O
accurate O
possible O
in O
order O
to O
offer O
this O
individuals O
the O
opportunity O
to O
be O
adequate O
treated O
in O
order O
to O
achieve O
the O
best O
survival O
possible O
. O
[]

2 O
) O
In O
18 O
children O
, O
clinical B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
were O
similar O
to O
those O
of O
the O
first O
group O
at O
the O
early O
stage O
, O
but O
95 O
% O
exhibited O
myoclonic B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
and O
vibratory B-outcome ['Physiological-Clinical']
tonic I-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
, O
with O
persisting O
seizures O
on O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

AIM O
To O
determine O
the O
efficacy O
of O
an O
individualized O
telephone O
patient O
education O
intervention O
, O
delivered O
at O
two O
different O
points O
in O
time O
( O
1-2 O
days O
pre-discharge O
versus O
1-2 O
days O
post-discharge O
) O
in O
enhancing O
the O
CABG O
patient O
's O
knowledge O
of O
self-care O
behaviours O
, O
performance O
of O
self-care O
behaviours O
, O
and O
symptom O
frequency O
. O
[]

A O
phase O
III O
trial O
confirming O
these O
results O
would O
be O
necessary O
and O
prudent O
before O
widespread O
adoption O
of O
the O
150 O
mg/m O
( O
2 O
) O
dose O
in O
clinical O
practice O
. O
[]

PATIENTS O
AND O
METHODS O
In O
this O
prospective O
randomized O
intervention O
study O
, O
19 O
patients O
suffering O
from O
periorbital O
pain O
after O
an O
AACG O
attack O
were O
injected O
with O
BoNT-A O
or O
placebo O
for O
pain O
relief O
. O
[]

Other O
than O
mild B-outcome ['Physiological-Clinical']
sedation I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
in O
a O
few O
patients O
, O
fluvoxamine O
was O
well O
tolerated O
. O
['Physiological-Clinical']

CONCLUSION O
Plasma O
endotoxin O
and O
cytokines O
( O
TNF-alpha O
, O
IL-1 O
beta O
, O
IL-6 O
and O
IL-8 O
) O
can O
be O
removed O
effectively O
with O
CRRT O
in O
severely O
burned O
patients O
with O
sepsis O
. O
[]

's O
finding O
that O
autistic O
adults O
did O
not O
donate O
more O
to O
charity O
when O
observed O
. O
[]

Therefore O
, O
0.15 O
mg/kg O
per O
minute O
can O
be O
considered O
as O
an O
approximate O
ED50 O
value O
. O
[]

Although O
various O
pharmaceutical O
agents O
are O
available O
for O
the O
treatment O
of O
obsessive-compulsive O
disorder O
, O
psychiatrists O
often O
find O
that O
many O
patients O
can O
not O
tolerate O
the O
side O
effects O
of O
these O
medications O
, O
the O
patients O
do O
not O
respond O
properly O
to O
the O
treatment O
, O
or O
the O
medications O
lose O
their O
effectiveness O
after O
a O
period O
of O
treatment O
. O
[]

Before O
hyposensitization O
, O
IgG B-outcome ['Physiological-Clinical']
anti-IgG I-outcome ['Physiological-Clinical']
titres I-outcome ['Physiological-Clinical']
greater O
than O
or O
equal O
to O
9 O
were O
demonstrated O
in O
45 O
% O
of O
the O
patients O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
demonstrate O
the O
long-term O
efficacy O
of O
intranasal O
furosemide O
, O
an O
inhibitor O
of O
the O
sodium O
chloride O
cotransporter O
channel O
at O
the O
basolateral O
surface O
of O
the O
respiratory O
epithelial O
cell O
, O
vs O
no O
therapeutic O
intervention O
vs O
intranasal O
mometasone O
furoate O
, O
a O
corticosteroid O
, O
in O
preventing O
relapses O
of O
chronic O
hyperplastic O
sinusitis O
with O
nasal O
polyposis O
. O
[]

Multivariate O
odds O
ratios O
( O
ORs O
) O
were O
computed O
for O
factors O
associated O
with O
late O
and O
non-attendance O
. O
[]

METHOD O
Factors O
measured O
at O
baseline O
interview O
were O
examined O
in O
multivariate O
analyses O
along O
with O
psychosocial O
factors O
occurring O
during O
follow-up O
, O
such O
as O
'fresh-start O
' O
experiences B-outcome ['Life-Impact']
and O
new B-outcome ['Adverse-effects']
severe I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
and O
difficulties B-outcome ['Life-Impact']
. O
['Life-Impact', 'Adverse-effects', 'Life-Impact']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Systemic B-outcome ['Physiological-Clinical']
hemodynamic I-outcome ['Physiological-Clinical']
, O
neurohormonal B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

In O
this O
study O
, O
47 O
preschool O
and O
K-1 O
students O
in O
ASD O
classrooms O
participated O
from O
Los O
Angeles O
Unified O
School O
District O
. O
[]

The O
decrease O
in O
mean O
daily B-outcome ['Physiological-Clinical']
intraocular I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
from O
0 O
to O
10 O
weeks O
was O
7.48 O
mmHg O
for O
Fotil O
, O
and O
6.31 O
for O
Timpilo O
. O
['Physiological-Clinical']

At O
follow-up O
, O
some O
reported O
minimal O
but O
potentially O
significant O
improvements O
including O
changes O
in O
GI B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
expressive B-outcome ['Life-Impact']
and/or I-outcome ['Life-Impact']
receptive I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
and O
improved O
['Physiological-Clinical', 'Life-Impact']

Of O
all O
participants O
who O
established O
abstinence O
and O
then O
relapsed O
, O
DT+ O
participants O
relapsed O
later O
and O
were O
more O
likely O
to O
reestablish B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
dose O
of O
risperidone O
was O
titrated O
up O
to O
2 O
mg/day O
for O
children O
between O
10 O
and O
40 O
kg O
and O
3 O
mg/day O
for O
children O
weighting O
above O
40 O
kg O
. O
[]

The O
findings O
are O
consistent O
with O
prior O
data O
showing O
decreased O
LESP B-outcome ['Physiological-Clinical']
with O
a O
fat O
meal O
in O
normals O
. O
['Physiological-Clinical']

There O
were O
small O
, O
clinically O
insignificant O
increases O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
following O
zolmitriptan O
which O
were O
unaltered O
by O
fluoxetine O
. O
['Physiological-Clinical']

A O
total O
of O
87.5 O
% O
of O
Avastin-injected O
eyes O
and O
25 O
% O
of O
sham O
group O
showed O
complete O
regression O
at O
week O
6 O
of O
follow-up O
( O
p O
< O
0.005 O
) O
. O
[]

TRIAL O
REGISTRATION O
ClinicalTrials.gov O
NCT01476631 O
. O
[]

RESULTS O
By O
examining O
outcome O
measures O
-- O
including O
satisfaction O
with O
care B-outcome ['Life-Impact']
arrangements I-outcome ['Life-Impact']
, O
consumers O
' O
perceptions B-outcome ['Life-Impact']
of O
paid O
caregivers B-outcome ['Life-Impact']
' O
attitudes B-outcome ['Life-Impact']
, O
unmet O
needs O
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
and O
satisfaction B-outcome ['Life-Impact']
with O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Adverse-effects', 'Life-Impact']

Red B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
major I-outcome ['Physiological-Clinical']
retinal I-outcome ['Physiological-Clinical']
veins I-outcome ['Physiological-Clinical']
tended O
to O
decrease O
by O
-9 O
+/- O
12 O
% O
, O
-9 O
+/- O
20 O
% O
, O
and O
-13 O
+/- O
12 O
% O
, O
but O
this O
effect O
did O
not O
reach O
levels O
of O
significance O
. O
['Physiological-Clinical']

The O
implications O
for O
the O
operation O
of O
reference O
memories O
within O
the O
scalar O
timing O
system O
were O
explored O
via O
models O
that O
made O
different O
assumptions O
about O
how O
the O
individual O
presentations O
of O
the O
standard O
were O
stored O
and O
used O
. O
[]

13 O
( O
76 O
% O
) O
of O
the O
AS O
patients O
were O
rated O
as O
pedantic B-outcome ['Life-Impact']
compared O
to O
4 O
( O
31 O
% O
) O
of O
the O
HFA O
group O
( O
chi O
2 O
= O
6.3 O
; O
p O
= O
.01 O
) O
. O
['Life-Impact']

Assessments O
included O
gait B-outcome ['Life-Impact']
and O
balance B-outcome ['Life-Impact']
measures I-outcome ['Life-Impact']
, O
self-reported B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
the O
number O
of O
medications O
being O
taking O
at O
baseline O
, O
participant O
age O
, O
sex O
, O
and O
history O
of O
falling O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

We O
report O
outcomes O
after O
3 O
months O
of O
follow-up O
( O
immediate O
postdiagnosis O
period O
) O
. O
[]

Survey O
response O
inducements O
for O
registered O
nurses O
. O
[]

However O
, O
its O
combination O
with O
infliximab O
in O
the O
treatment O
of O
ankylosing O
spondylitis O
( O
AS O
) O
is O
not O
recommended O
. O
[]

Continuous O
pralidoxime O
infusion O
versus O
repeated O
bolus O
injection O
to O
treat O
organophosphorus O
pesticide O
poisoning O
: O
a O
randomised O
controlled O
trial O
. O
[]

This O
study O
evaluated O
whether O
333 O
seronegative O
African O
American O
female O
drug O
users O
( O
aged O
18-59 O
years O
) O
participating O
in O
an O
HIV O
intervention O
and O
with O
higher O
levels O
of O
emotional O
distress O
, O
specifically O
symptoms O
of O
depression O
and O
anxiety O
, O
reduced O
HIV O
risk O
behaviors O
to O
a O
lesser O
extent O
than O
those O
with O
lower O
levels O
of O
emotional O
distress O
. O
[]

Furthermore O
, O
the O
quantitative O
sensory O
tests O
provided O
complementing O
information O
to O
the O
clinical O
measures O
. O
[]

Children O
receiving O
vitamin O
C O
had O
fewer O
throat B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
yielding O
beta-hemolytic B-outcome ['Physiological-Clinical']
streptococcus I-outcome ['Physiological-Clinical']
( O
six O
versus O
13 O
, O
P O
less O
than O
0.10 O
) O
, O
but O
no O
difference O
in O
overall O
complicated B-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
rate O
( O
24 O
versus O
25 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Analyses O
reveal O
that O
olanzapine O
shows O
a O
greater O
clinical O
cost B-outcome ['Resource-use']
effectiveness O
, O
as O
well O
as O
a O
greater O
functional O
cost B-outcome ['Resource-use']
effectiveness O
, O
than O
haloperidol O
, O
and O
that O
functional O
outcomes O
, O
in O
particular O
, O
show O
promise O
as O
important O
measures O
of O
effectiveness O
. O
['Resource-use', 'Resource-use']

However O
, O
in O
the O
2-month O
interval O
after O
receipt O
of O
a O
step-up O
letter O
, O
17.1 O
% O
of O
the O
letters O
were O
followed O
by O
scheduled O
visits O
in O
the O
intervention O
group O
compared O
with O
scheduled O
visits O
12.3 O
% O
of O
the O
time O
by O
the O
control O
children O
with O
comparable O
clinical O
symptoms O
. O
[]

The O
pain-free B-outcome ['Physiological-Clinical']
and O
the O
absolute O
walking B-outcome ['Life-Impact']
distance O
( O
ACD O
) O
were O
monitored O
by O
standardized O
treadmill O
test O
at O
baseline O
and O
at O
4 O
, O
12 O
and O
24 O
weeks O
. O
['Physiological-Clinical', 'Life-Impact']

Primary O
outcomes O
were O
NFT O
and O
proportions O
of O
TMV O
, O
which O
were O
subdivided O
into O
eight O
categories O
: O
four O
team O
leader O
verbalisations O
( O
TLV O
) O
with O
different O
accuracy O
levels O
and O
four O
follower O
verbalisation O
categories O
( O
FV O
) O
. O
[]

The O
75 O
patients O
were O
randomly O
assigned O
to O
1 O
of O
3 O
groups O
: O
group O
exercise O
class O
, O
individual O
physiotherapy O
, O
and O
home O
exercises O
alone O
. O
[]

Complications O
such O
as O
cardiac B-outcome ['Physiological-Clinical']
tamponade I-outcome ['Physiological-Clinical']
and O
mitral B-outcome ['Physiological-Clinical']
regurgitation I-outcome ['Physiological-Clinical']
( O
requiring O
or O
not O
requiring O
mitral O
valve O
replacement O
) O
were O
similar O
in O
both O
groups O
, O
with O
3 O
complications O
in O
the O
IBMC O
group O
, O
compared O
with O
4 O
complications O
in O
the O
PMMC O
group O
( O
P O
=.29 O
) O
. O
['Physiological-Clinical']

Vancomycin O
was O
added O
in O
all O
cases O
of O
persistent O
fever O
in O
the O
ceftazidime O
arm O
, O
but O
only O
when O
there O
was O
microbiologically O
documented O
resistance O
in O
the O
piperacillin/tazobactam O
arm O
. O
[]

BACKGROUND O
Targeted O
agents O
presently O
available O
for O
mutant O
KRAS O
metastatic O
colorectal O
cancer O
( O
mCRC O
) O
are O
bevacizumab O
and O
aflibercept O
. O
[]

PURPOSE O
To O
verify O
the O
efficacy O
to O
obtain O
mydriasis O
and O
cardiovascular O
safety O
of O
Mydriasert O
( O
ophthalmic O
insert O
containing O
tropicamide O
and O
phenylephrine O
) O
in O
diabetic O
and O
nondiabetic O
patients O
undergoing O
retinal O
angiography O
by O
comparing O
it O
with O
usually O
administered O
eyedrops O
( O
tropicamide O
1 O
% O
and O
phenylephrine O
10 O
% O
) O
. O
[]

There O
were O
no O
significant O
differences O
between O
routes O
of O
delivery O
with O
misoprostol O
or O
dinoprostone O
. O
[]

Children O
were O
excluded O
if O
they O
had O
undergone O
tracheotomy O
or O
had O
chronic O
respiratory O
diseases O
. O
[]

2 O
, O
heifers O
grazed O
dormant O
pasture O
and O
were O
fed O
0.9 O
kg O
( O
as-fed O
basis O
) O
of O
a O
42 O
% O
CP O
supplement/d O
from O
weaning O
in O
October O
to O
late O
February O
; O
then O
heifers O
were O
assigned O
randomly O
to O
treatments O
for O
60 O
d O
before O
the O
breeding O
season O
. O
[]

Effect O
of O
dietary O
supplementation O
with O
n-3 O
fatty O
acids O
on O
coronary O
artery O
bypass O
graft O
patency O
. O
[]

Prospective O
randomized O
controlled O
trial O
to O
evaluate O
fast-track O
elective O
open O
infrarenal O
aneurysm O
repair O
. O
[]

RESULTS O
Fifty-six O
( O
71 O
% O
) O
out O
of O
79 O
enrolled O
patients O
completed O
the O
OLE O
; O
the O
most O
common O
discontinuations O
were O
for O
insufficient O
response O
( O
7 O
[ O
9 O
% O
] O
) O
or O
adverse O
events O
( O
AE O
) O
( O
5 O
[ O
6 O
% O
] O
) O
. O
[]

Age O
, O
sex O
, O
smoking O
, O
ulcer/non-ulcer O
dyspepsia O
ratio O
and O
antibiotic O
resistance O
were O
not O
significantly O
different O
between O
the O
treatment O
groups O
. O
[]

Grafts O
are O
defined O
as O
failed O
if O
there O
was O
occlusion O
, O
string O
sign O
, O
or O
greater O
than O
80 O
% O
stenosis O
, O
independently O
reported O
by O
3 O
assessors O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
describe O
the O
trajectory O
of O
creatinine B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Cr I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
rise O
and O
its O
determinants O
after O
exposure O
to O
radiocontrast O
media O
. O
['Physiological-Clinical']

Autism O
spectrum O
disorder O
is O
typically O
associated O
with O
social O
deficits O
and O
is O
often O
specifically O
linked O
to O
difficulty O
with O
processing B-outcome ['Physiological-Clinical']
faces I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
other I-outcome ['Physiological-Clinical']
socially I-outcome ['Physiological-Clinical']
relevant I-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
visiting O
doctors O
had O
not O
suspected O
deep O
vein O
thrombosis O
in O
any O
of O
the O
patients O
. O
[]

If O
patients O
had O
an O
episode O
of O
febrile O
neutropenia O
, O
they O
received O
unblinded O
filgrastim O
in O
subsequent O
CAE O
cycles O
. O
[]

Duration O
of O
whoops B-outcome ['Physiological-Clinical']
post-treatment I-outcome ['Physiological-Clinical']
was O
8.7 O
days O
( O
95 O
% O
Cl O
4.8 O
, O
12.6 O
) O
in O
the O
33 O
children O
receiving O
immunoglobulin O
vs O
20.6 O
( O
95 O
% O
Cl O
11.9 O
, O
29.3 O
) O
in O
the O
14 O
receiving O
placebo O
( O
p O
= O
0.0041 O
) O
. O
['Physiological-Clinical']

Analyses O
of O
baseline O
determinants O
of O
exercise O
capacity O
, O
predictors O
of O
change O
in O
exercise O
capacity O
at O
6 O
months O
and O
1 O
year O
, O
and O
the O
short- O
and O
long-term O
effects O
of O
cardioversion O
on O
exercise O
capacity O
were O
made O
. O
[]

Supraventricular B-outcome ['Physiological-Clinical']
arrhythmias I-outcome ['Physiological-Clinical']
were O
the O
most O
common O
type O
of O
arrhythmias O
, O
affecting O
2 O
% O
of O
subjects O
in O
the O
pooled O
degarelix O
group O
and O
4 O
% O
in O
the O
leuprolide O
group O
. O
['Physiological-Clinical']

Patients O
with O
hepatitis O
B O
virus-related O
PAN O
were O
not O
included O
in O
this O
study O
. O
[]

BACKGROUND O
Reducing O
neonatal B-outcome ['Mortality']
death I-outcome ['Mortality']
has O
been O
an O
emerging O
challenge O
in O
low O
and O
middle O
income O
countries O
in O
the O
past O
decade O
. O
['Mortality']

Hyperalgesia B-outcome ['Physiological-Clinical']
was O
induced O
by O
using O
an O
experimental O
pain O
model O
that O
uses O
heat O
and O
capsaicin O
in O
combination O
. O
['Physiological-Clinical']

We O
have O
compared O
the O
efficacy O
of O
granisetron O
with O
perphenazine O
in O
the O
prevention O
of O
vomiting O
after O
tonsillectomy O
with O
or O
without O
adenoidectomy O
in O
children O
. O
[]

[ O
Value O
of O
combining O
64 O
multi-slice O
spiral O
computer O
tomography O
and O
serum O
amyloid O
A O
protein O
in O
surgical O
decision-making O
in O
rectal O
cancer O
] O
. O
[]

All O
patients O
tolerated B-outcome ['Life-Impact']
this O
protocol O
of O
the O
therapy O
and O
the O
main O
toxic B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
fever B-outcome ['Physiological-Clinical']
and O
general B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Subjects O
administered O
or O
omitted O
their O
normal O
dose O
of O
evening O
GH O
and/or O
morning O
hydrocortisone O
. O
[]

Patients O
were O
followed O
up O
for O
at O
least O
1 O
year O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
counter O
these O
effects O
by O
modifying O
the O
LPFST O
using O
a O
computer-based O
adaptive O
procedure O
, O
and O
to O
evaluate O
the O
performance O
of O
normal-hearing O
participants O
of O
varying O
ages O
on O
the O
test O
. O
[]

After O
4 O
min O
the O
full O
anesthetic O
dose O
, O
based O
on O
body O
size O
, O
was O
injected O
with O
the O
patient O
supine O
. O
[]

A O
randomized O
, O
double-blind O
crossover O
study O
on O
platelet O
, O
coagulation O
and O
fibrinolysis O
function O
tests O
. O
[]

During O
the O
study O
, O
56.2 O
percent O
of O
patients O
in O
the O
etanercept O
group O
and O
57.1 O
percent O
of O
those O
in O
the O
control O
group O
had O
at O
least O
one O
severe B-outcome ['Adverse-effects']
or I-outcome ['Adverse-effects']
life-threatening I-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
or O
died B-outcome ['Mortality']
( O
P=0.90 O
) O
. O
['Adverse-effects', 'Mortality']

Safety O
of O
injectable O
opioid O
maintenance O
treatment O
for O
heroin O
dependence O
. O
[]

Wheelchair O
skills O
training O
to O
improve O
confidence B-outcome ['Life-Impact']
with O
using O
a O
manual O
wheelchair O
among O
older O
adults O
: O
a O
pilot O
study O
. O
['Life-Impact']

RESULTS O
At O
24 O
months O
, O
complete O
success B-outcome ['Physiological-Clinical']
rates O
were O
53.3 O
% O
for O
the O
ELT O
group O
and O
40 O
% O
for O
the O
SLT O
group O
( O
P=0.35 O
, O
Fisher O
's O
exact O
test O
) O
; O
['Physiological-Clinical']

Clinical B-outcome ['Physiological-Clinical']
effects O
of O
root O
instrumentation O
using O
conventional O
steel O
or O
non-tooth O
substance O
removing O
plastic O
curettes O
during O
supportive O
periodontal O
therapy O
( O
SPT O
) O
. O
['Physiological-Clinical']

Oral B-outcome ['Physiological-Clinical']
estrogen I-outcome ['Physiological-Clinical']
antagonizes I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
actions I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
hormone-deficient I-outcome ['Physiological-Clinical']
women I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Examination O
of O
pharmacological O
and O
clinical O
predictors O
of O
withdrawal O
phenomena O
and O
later O
relapse B-outcome ['Physiological-Clinical']
showed O
that O
personality O
factors O
were O
the O
most O
important O
, O
patients O
with O
passive-dependent O
traits O
having O
a O
significantly O
greater O
prevalence O
of O
withdrawal O
reactions O
. O
['Physiological-Clinical']

Vancomycin O
added O
to O
empirical O
combination O
antibiotic O
therapy O
for O
fever O
in O
granulocytopenic O
cancer O
patients O
. O
[]

Further O
studies O
are O
needed O
to O
examine O
the O
efficacy O
of O
hygienic O
measures O
such O
as O
using O
skin O
disinfectants O
to O
prevent O
infections O
in O
patients O
who O
are O
immunocompromised O
. O
[]

Obesity O
is O
increasingly O
common O
and O
is O
a O
major O
public O
health O
problem O
. O
[]

Safety O
and O
efficacy O
of O
oral O
DMSA O
therapy O
for O
children O
with O
autism O
spectrum O
disorders O
: O
part O
B O
- O
behavioral O
results O
. O
[]

RESULTS O
Before O
debriefing O
, O
83.9 O
% O
of O
participants O
chose O
public O
data O
release O
. O
[]

A O
web-based O
computer-tailored O
smoking O
prevention O
programme O
for O
primary O
school O
children O
: O
intervention O
design O
and O
study O
protocol O
. O
[]

Abacavir O
once O
or O
twice O
daily O
combined O
with O
once-daily O
lamivudine O
and O
efavirenz O
for O
the O
treatment O
of O
antiretroviral-naive B-outcome ['Physiological-Clinical']
HIV-infected O
adults O
: O
results O
of O
the O
Ziagen O
Once O
Daily O
in O
Antiretroviral O
Combination O
Study O
. O
['Physiological-Clinical']

The O
groups O
were O
compared O
for O
the O
incidence O
of O
pruritus B-outcome ['Physiological-Clinical']
by O
the O
Mann-Whitney O
nonparametric O
test O
. O
['Physiological-Clinical']

This O
randomized O
placebo-controlled O
study O
was O
designed O
to O
determine O
the O
effect O
of O
a O
folic O
acid-based O
supplement O
on O
secondary O
prevention O
of O
clinical O
events O
in O
non-ST-segment O
elevation O
acute O
coronary O
syndromes O
. O
[]

In O
Asian O
patients O
with O
chronic O
hepatitis O
B O
, O
quantitative O
analyses O
of O
subpopulations O
of O
peripheral O
blood O
lymphocytes O
have O
not O
been O
able O
to O
confirm O
these O
findings O
. O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
predominantly O
headache O
, O
nervousness O
, O
and O
somnolence O
) O
were O
minor O
and O
comparable O
for O
all O
treatment O
groups O
. O
['Physiological-Clinical', 'Life-Impact', 'Adverse-effects']

Participants O
will O
be O
recruited O
after O
discharge O
from O
hospital O
and O
up O
to O
12 O
months O
post-stroke O
from O
hospital O
stroke O
services O
and O
community O
therapy-provider O
services O
. O
[]

The O
treatment O
group O
at O
the O
acute O
stage O
( O
1-10 O
days O
) O
were O
treated O
with O
acupuncture O
at O
Dicang O
( O
ST O
4 O
) O
, O
Jiache O
( O
ST O
6 O
) O
, O
Yangbai O
( O
GB O
14 O
) O
, O
etc. O
, O
with O
less O
than O
4 O
points O
selected O
on O
the O
face O
and O
with O
shallow O
puncture O
, O
and O
10 O
days O
later O
electroacupuncture O
were O
added O
at O
acupoints O
selected O
routinely O
; O
the O
control O
group O
were O
treated O
with O
the O
same O
methods O
as O
the O
treatment O
group O
but O
acupuncture O
was O
not O
given O
at O
the O
acute O
stage O
. O
[]

NT O
201 O
and O
BTXCo O
were O
well O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact']

METHODS O
Patients O
were O
recruited O
for O
this O
open-label O
, O
phase O
2 O
randomised O
trial O
between O
March O
17 O
, O
2003 O
, O
and O
May O
19 O
, O
2006 O
, O
at O
a O
single O
centre O
. O
[]

3 O
) O
Protein O
digestibility O
coefficients O
of O
rapeseed O
products O
were O
mostly O
0.10 O
to O
0.15 O
units O
lower O
than O
those O
of O
soybean O
products O
. O
[]

ZH O
, O
P O
? O
[]

PARTICIPANTS O
A O
total O
of O
1,116 O
smokers O
or O
recent O
ex-smokers O
with O
mild-to-moderate O
COPD O
( O
age O
range O
, O
40 O
to O
69 O
years O
; O
mean O
age O
, O
56.3 O
years O
; O
37.2 O
% O
female O
) O
. O
[]

Among O
the O
24 O
initial O
patients O
, O
17 O
heterozygous O
FH O
patients O
( O
age O
: O
54.1 O
years O
; O
5 O
males O
) O
were O
enrolled O
after O
20 O
mg/day O
atorvastatin O
failed O
to O
achieve O
their O
target O
level O
. O
[]

During O
Phase O
3 O
, O
response O
to O
combined O
treatment O
was O
significantly O
better O
than O
overall O
response O
to O
monotherapy O
in O
Phase O
2 O
( O
Fisher O
's O
Exact O
test O
, O
p O
= O
0.043 O
) O
. O
[]

RESULTS O
A O
total O
of O
647 O
patients O
were O
randomly O
assigned O
: O
79 O
SR O
patients O
were O
assigned O
to O
VAIA O
, O
76 O
SR O
patients O
were O
assigned O
to O
VACA O
, O
240 O
HR O
were O
assigned O
to O
VAIA O
, O
and O
252 O
HR O
patients O
were O
assigned O
to O
EVAIA O
. O
[]

Couple-responsible O
process O
consists O
of O
enactments O
, O
accommodation O
, O
and O
inductive O
process O
. O
[]

However O
, O
serum B-outcome ['Physiological-Clinical']
rhG-CSF I-outcome ['Physiological-Clinical']
levels O
can O
not O
be O
maintained O
throughout O
the O
course O
of O
rhG-CSF O
therapy O
. O
['Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
FVIII I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
determined O
using O
a O
validated O
chromogenic O
substrate O
assay O
. O
['Physiological-Clinical']

For O
the O
first O
( O
6-month O
) O
and O
second O
( O
12-month O
) O
surveillance O
cytology O
tests O
separately O
, O
women O
were O
categorized O
as O
'on-time O
attendees O
' O
( O
attended O
?6 O
months O
of O
test O
being O
due O
) O
, O
'late O
attendees O
' O
( O
attended O
greater O
than O
6 O
months O
after O
test O
was O
due O
) O
or O
'non-attendees O
' O
( O
failed O
to O
attend O
) O
. O
[]

RESULTS O
Foreign-born O
adolescents O
were O
more O
likely O
to O
complete B-outcome ['Physiological-Clinical']
care I-outcome ['Physiological-Clinical']
than O
US-born O
adolescents O
, O
with O
82 O
% O
completion O
of O
care O
rate O
. O
['Physiological-Clinical']

Nineteen O
asthmatics O
aged O
6 O
to O
12 O
years O
participated O
in O
this O
study O
. O
[]

Nitroglycerin O
( O
NTG O
) O
has O
long O
been O
used O
beneficially O
to O
reduce O
myocardial B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
demand I-outcome ['Physiological-Clinical']
by O
its O
effects O
on O
the O
systemic O
and O
peripheral O
vascular O
resistances O
. O
['Physiological-Clinical']

CONTEXT O
The O
Certified O
Safe O
Farm O
( O
CSF O
) O
intervention O
program O
aims O
to O
reduce O
occupational O
injuries O
and O
illnesses O
, O
and O
promote O
wellness O
to O
reduce O
health O
care O
and O
related O
costs O
to O
farmers O
, O
insurers O
, O
and O
other O
stakeholders O
. O
[]

Whereas O
no O
difference O
was O
seen O
between O
both O
groups O
regarding O
the O
definitive O
outcome O
of O
the O
treatment O
, O
the O
prophylaxis O
group O
clearly O
showed O
fewer O
infection B-outcome ['Physiological-Clinical']
pointers I-outcome ['Physiological-Clinical']
during O
the O
clinical O
course O
. O
['Physiological-Clinical']

Thirty-one O
women O
received O
single-dose O
treatment O
and O
22 O
conventional-dose O
treatment O
. O
[]

Patients O
, O
who O
were O
on O
stable O
antipsychotic O
treatment O
, O
were O
randomly O
assigned O
to O
the O
active O
or O
sham O
condition O
. O
[]

OBJECTIVES O
To O
determine O
the O
safety O
and O
pharmacokinetics O
of O
single O
doses O
of O
N7-GP O
in O
healthy O
men O
. O
[]

Trained O
therapists O
provided O
parent O
training O
and O
support O
. O
[]

Intra-operative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
significantly O
less O
in O
the O
potassium O
titanyl O
phosphate O
laser O
group O
( O
mean O
21 O
cm3 O
) O
than O
in O
the O
bipolar O
radiofrequency O
group O
( O
mean O
30 O
cm3 O
) O
. O
['Physiological-Clinical']

METHODS O
This O
23-day O
, O
prospective O
, O
double-blind O
, O
randomized O
, O
parallel-group O
study O
was O
conducted O
at O
3 O
Colombian O
centers O
: O
University O
Libre O
, O
Social O
Security O
Institute O
, O
and O
General O
Hospital O
of O
Medell?n O
, O
Cali O
, O
Colombia O
. O
[]

Each O
experimental O
participant O
had O
a O
yoked O
control O
partner O
who O
received O
the O
same O
pattern O
of O
changes O
in O
array O
irrespective O
of O
their O
engagement O
index O
. O
[]

OBJECTIVE O
To O
investigate O
the O
clinical O
efficacy O
and O
safety O
of O
intravenous O
diltiazem O
compared O
with O
nitroglycerin O
in O
the O
patients O
with O
unstable O
angina O
pectoris O
. O
[]

The O
primary O
outcome O
measure O
was O
whether O
the O
decision B-outcome ['Life-Impact']
to O
give O
thrombolysis O
was O
correct O
. O
['Life-Impact']

Studies O
on O
leptin B-outcome ['Physiological-Clinical']
and O
leptin B-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
gene I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
in O
myometrium O
and O
uterine O
myomas O
of O
gnRH O
analogue-treated O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Data O
were O
compared O
with O
an O
unpaired O
t O
test O
. O
[]

PURPOSE O
The O
accuracy O
of O
the O
clinical O
neurosensory O
test O
to O
diagnose O
trigeminal O
nerve O
injuries O
has O
never O
been O
statistically O
evaluated O
. O
[]

While O
[]

In O
the O
olive O
oil O
group O
, O
6 O
subjects O
had O
the O
metabolic O
syndrome O
at O
baseline O
; O
2 O
subjects O
no O
longer O
had O
metabolic O
syndrome O
at O
endpoint O
, O
1 O
person O
developed O
metabolic O
syndrome O
, O
and O
4 O
subjects O
did O
not O
have O
any O
change O
in O
their O
metabolic O
syndrome O
status O
. O
[]

PURPOSE O
To O
analyze O
the O
results O
of O
a O
Phase O
III O
clinical O
trial O
that O
investigated O
whether O
a O
hyperfractionated O
radiotherapy O
( O
RT O
) O
schedule O
could O
reduce O
the O
risk O
of O
locoregional O
recurrence O
in O
patients O
with O
locally O
advanced O
breast O
cancer O
treated O
with O
chemotherapy O
and O
mastectomy O
. O
[]

The O
lag O
time O
was O
significantly O
longer O
at O
01.00 O
hours O
than O
at O
13.00 O
hours O
( O
p O
less O
than O
0.01 O
) O
. O
[]

A O
comparison O
of O
single-dose O
versus O
conventional-dose O
antibiotic O
treatment O
of O
bacteriuria O
in O
elderly O
women O
. O
[]

Failure O
of O
pyridoxine O
to O
suppress O
raised B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

Children O
in O
the O
PRN O
group O
had O
higher O
pain B-outcome ['Physiological-Clinical']
intensity O
scores O
compared O
to O
children O
in O
the O
ATC O
group O
, O
both O
at O
rest O
( O
P=0.017 O
) O
and O
with O
swallowing O
( O
P=0.017 O
) O
. O
['Physiological-Clinical']

Leucine-enriched O
essential O
amino O
acid O
and O
carbohydrate O
ingestion O
following O
resistance O
exercise O
enhances O
mTOR O
signaling O
and O
protein O
synthesis O
in O
human O
muscle O
. O
[]

METHODS O
AND O
RESULTS O
We O
randomized O
symptomatic O
women O
with O
suspected O
CAD O
, O
an O
interpretable O
ECG O
, O
and O
?5 O
metabolic O
equivalents O
on O
the O
Duke O
Activity O
Status O
Index O
to O
1 O
of O
2 O
diagnostic O
strategies O
: O
ETT O
or O
exercise O
MPI O
. O
[]

Controlled O
, O
prospective O
, O
randomized O
, O
clinical O
evaluation O
of O
partial O
ceramic O
crowns O
inserted O
with O
RelyX O
Unicem O
with O
or O
without O
selective O
enamel O
etching O
. O
[]

Abdominal O
surgical O
wound O
infection O
is O
lowered O
with O
improved O
perioperative O
enterococcus O
and O
bacteroides O
therapy O
. O
[]

In O
a O
double-blind O
controlled O
trial O
22 O
patients O
with O
mild O
or O
moderate O
essential O
hypertension O
were O
treated O
with O
nicardipine O
30 O
mg O
t.d.s O
. O
[]

There O
were O
no O
significant O
differences O
in O
any O
of O
these O
study O
measures O
among O
the O
three O
treatment O
conditions O
( O
P O
> O
0.1 O
for O
all O
) O
. O
[]

We O
also O
determined O
fasting B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
total O
cholesterol B-outcome ['Physiological-Clinical']
; O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
, O
including O
the O
subfractions B-outcome ['Physiological-Clinical']
high-density I-outcome ['Physiological-Clinical']
lipoprotein2 I-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
high-density I-outcome ['Physiological-Clinical']
lipoprotein3 B-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
; O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
; O
very O
low-density B-outcome ['Physiological-Clinical']
lipoprotein B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
; O
and O
triglycerides B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Because O
DHA O
is O
a O
highly O
unsaturated O
fatty O
acid O
, O
it O
could O
serve O
as O
a O
target O
for O
free-radical O
induced O
oxidation O
, O
resulting O
in O
increased O
oxidative O
stress O
. O
[]

The O
levels O
of O
exposure O
to O
Der O
p O
1 O
allergen O
were O
constant O
during O
the O
study O
. O
[]

Until O
further O
research O
determines O
a O
benefit O
exists O
, O
we O
can O
not O
recommend O
i.v O
. O
[]

Intention-to-treat O
and O
on-treatment O
analyses O
were O
done O
. O
[]

Similar O
observations O
were O
found O
when O
the O
drug O
was O
injected O
in O
the O
diseased O
coronary O
arteries O
in O
a O
small O
dose O
( O
0.075 O
mg/kg O
) O
so O
that O
peripheral B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
were O
not O
present O
. O
['Physiological-Clinical']

The O
daily B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
response O
was O
assessed O
using O
a O
visual O
analogue O
scale O
card O
in O
19 O
patients O
who O
received O
at O
least O
2 O
weeks O
of O
the O
drug O
, O
16 O
of O
whom O
were O
crossed-over O
to O
receive O
the O
alternate O
agent O
. O
['Physiological-Clinical']

Four O
patients O
( O
three O
of O
combined O
therapy O
and O
one O
of O
prednisone O
therapy O
) O
showed O
proteinuria B-outcome ['Physiological-Clinical']
before O
the O
treatment O
which O
improved O
at O
the O
end O
of O
the O
induction O
therapy O
. O
['Physiological-Clinical']

Stimulation O
of O
the O
thenar O
muscle O
resulted O
in O
a O
significant O
increase O
in O
the O
sympathetic B-outcome ['Physiological-Clinical']
and O
the O
parasympathetic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
during O
the O
stimulation O
period O
( O
P O
< O
0.01 O
) O
and O
during O
the O
post-stimulation O
period O
( O
P O
< O
0.01 O
and O
P O
< O
0.001 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Only O
one O
case O
of O
secondary B-outcome ['Physiological-Clinical']
post-tonsillectomy I-outcome ['Physiological-Clinical']
haemorrhage I-outcome ['Physiological-Clinical']
was O
recorded O
, O
in O
the O
potassium O
titanyl O
phosphate O
laser O
group O
( O
2.5 O
per O
cent O
) O
, O
managed O
conservatively O
. O
['Physiological-Clinical']

Analgesia B-outcome ['Resource-use']
provided O
by O
epidural O
morphine O
was O
comparable O
to O
that O
obtained O
in O
matched O
patients O
given O
an O
intramuscular O
regime O
. O
['Resource-use']

BACKGROUND O
Tobacco O
dependence O
is O
a O
chronic O
, O
relapsing O
condition O
that O
typically O
requires O
multiple O
quit O
attempts O
and O
extended O
treatment O
. O
[]

The O
unconscious O
thought O
effect O
refers O
to O
improved O
judgments O
and O
decisions O
after O
a O
period O
of O
distraction O
. O
[]

Use O
of O
a O
clay O
modeling O
task O
to O
reduce O
chocolate B-outcome ['Life-Impact']
craving I-outcome ['Life-Impact']
. O
['Life-Impact']

Eligible O
patients O
include O
those O
with O
ischemic O
and O
nonischemic O
congestive O
heart O
failure O
and O
with O
> O
or O
= O
10 O
ventricular O
premature O
beats O
per O
hour O
. O
[]

Double-pulse O
transcranial O
magnetic O
stimulation O
( O
dpTMS O
) O
was O
used O
to O
examine O
inhibition O
by O
means O
of O
short-interval O
intracortical O
inhibition O
( O
SICI O
) O
of O
the O
contralateral O
primary O
motor O
cortex O
in O
a O
sample O
of O
64 O
healthy O
right-handed O
human O
subjects O
covering O
a O
wide O
range O
of O
the O
adult O
lifespan O
( O
age O
range O
20-88 O
years O
, O
mean O
47.6 O
? O
[]

A O
case O
of O
intraglomerular O
metastases O
observed O
in O
a O
nephrectomy O
specimen O
removed O
for O
primary O
renal O
cell O
carcinoma O
is O
reported O
. O
[]

Neridronate O
, O
a O
relatively O
new O
bisphosphonate O
, O
is O
able O
to O
prevent O
bone B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
patients O
with O
prostate O
cancer O
during O
androgen O
ablation O
. O
['Physiological-Clinical']

A O
controlled O
study O
. O
[]

Mean O
muscle B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
thigh I-outcome ['Physiological-Clinical']
, O
estimated O
by O
computerised O
tomography O
, O
increased O
significantly O
compared O
with O
that O
of O
the O
initial O
placebo O
period O
( O
p O
= O
0.01 O
) O
, O
and O
a O
slight O
decrease O
was O
recorded O
in O
adipose B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
thigh I-outcome ['Physiological-Clinical']
( O
p O
= O
0.10 O
) O
and O
subscapular B-outcome ['Physiological-Clinical']
skinfold I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
( O
p O
= O
0.10 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
medial B-outcome ['Physiological-Clinical']
subconjunctival I-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
occurred O
in O
one O
patient O
in O
the O
inferior-medial O
group O
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION O
Netherlands O
Trial O
Register O
NTR2327 O
. O
[]

Results O
indicated O
children O
in O
the O
RPMT O
condition O
showed O
greater O
increases O
in O
object B-outcome ['Life-Impact']
interest I-outcome ['Life-Impact']
as O
compared O
to O
children O
in O
the O
PECS O
condition O
. O
['Life-Impact']

This O
study O
was O
conducted O
to O
test O
the O
hypothesis O
that O
weaning O
or O
glutamine O
may O
modulate O
expression O
of O
genes O
that O
are O
crucial O
for O
intestinal O
metabolism O
and O
function O
. O
[]

OBJECTIVE O
To O
compare O
the O
outcomes O
of O
an O
adapted O
pilot O
Changing O
Childbirth O
initiative O
providing O
continuity O
of O
care O
by O
a O
group O
of O
known O
midwives O
with O
traditional O
maternity O
care O
. O
[]

The O
course O
of O
depression B-outcome ['Life-Impact']
in O
recent O
onset O
rheumatoid O
arthritis O
: O
the O
predictive O
role O
of O
disability O
, O
illness O
perceptions O
, O
pain O
and O
coping O
. O
['Life-Impact']

RESULTS O
In O
all O
, O
917 O
( O
15 O
% O
) O
had O
drug-treated O
hypertension O
. O
[]

The O
magnitude O
of O
the O
reduction O
in O
the O
intrinsic B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
of O
caffeine B-outcome ['Life-Impact']
produced O
by O
ciprofloxacin O
was O
greater O
than O
that O
described O
in O
the O
literature O
for O
ciprofloxacin O
and O
theophylline O
. O
['Physiological-Clinical', 'Life-Impact']

The O
primary O
outcome O
was O
changes O
in O
neutrophil O
, O
eosinophil O
, O
macrophage O
, O
lymphocyte O
, O
and O
epithelial O
cell O
levels O
in O
induced O
sputum O
. O
[]

bolus O
. O
[]

Premature O
discontinuation O
for O
toxicity B-outcome ['Adverse-effects']
occurred O
in O
14/59 O
during O
venlafaxine O
and O
5/53 O
during O
clonidine O
( O
P O
= O
.038 O
) O
. O
['Adverse-effects']

0.4 O
to O
2.8 O
? O
[]

Genetic O
interaction O
analysis O
is O
used O
as O
a O
rational O
tool O
to O
study O
the O
contribution O
of O
polygenic O
variation O
in O
relation O
to O
drug O
response O
. O
[]

BACKGROUND O
An O
oral O
formulation O
of O
ganciclovir O
( O
GCV O
) O
was O
recently O
approved O
for O
the O
prevention O
of O
cytomegalovirus O
disease O
in O
solid O
organ O
transplant O
recipients O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
oxaprozin O
in O
comparison O
with O
diclofenac O
in O
patients O
with O
periarthritis O
pain O
of O
the O
shoulder O
previously O
unsuccessfully O
treated O
with O
nonsteroidal O
anti-inflammatory O
drugs O
other O
than O
diclofenac O
and O
oxaprozin O
. O
[]

More O
patients O
were O
relapse O
free O
in O
the O
daclizumab O
HYP O
150 O
mg O
( O
81 O
% O
) O
and O
300 O
mg O
( O
80 O
% O
) O
groups O
than O
in O
the O
placebo O
group O
( O
64 O
% O
; O
p O
< O
0?0001 O
in O
the O
150 O
mg O
group O
and O
p=0?0003 O
in O
the O
300 O
mg O
group O
) O
. O
[]

Evidence O
for O
poorer O
outcome O
in O
patients O
with O
severe O
negative O
trauma-related O
cognitions O
receiving O
prolonged O
exposure O
plus O
cognitive O
restructuring O
: O
implications O
for O
treatment O
matching O
in O
posttraumatic O
stress O
disorder O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
functional B-outcome ['Life-Impact']
score O
or O
bowel B-outcome ['Physiological-Clinical']
frequency O
following O
treatment O
irrespective O
of O
whether O
the O
active O
treatment O
was O
given O
before O
or O
after O
placebo O
. O
['Life-Impact', 'Physiological-Clinical']

Patient O
and O
surgeon O
satisfaction O
were O
determined O
on O
a O
5-point O
scale O
. O
[]

The O
re-enrollment B-outcome ['Life-Impact']
rate O
was O
3.3 O
% O
for O
the O
control O
group O
and O
28.2 O
% O
for O
the O
intervention O
group O
( O
p O
< O
.001 O
) O
. O
['Life-Impact']

There O
were O
no O
significant O
differences O
in O
either O
the O
duration O
of O
response B-outcome ['Physiological-Clinical']
( O
median O
, O
6 O
and O
4.7 O
months O
for O
CDDP/FU O
and O
FU O
groups O
, O
respectively O
) O
or O
['Physiological-Clinical']

While O
the O
dropout O
rate O
was O
significantly O
higher O
in O
the O
Web-based O
intervention O
group O
, O
no O
specific O
user O
characteristics O
explained O
the O
difference O
in O
dropout O
rates O
between O
the O
delivery O
modes O
. O
[]

This O
study O
conducted O
further O
analysis O
of O
the O
Pirarubicin O
Monotherapy O
Study O
Group O
cohort O
, O
focusing O
on O
intravesical O
seeding O
of O
cancer O
cells O
. O
[]

CONCLUSION O
Results O
from O
this O
preliminary O
study O
show O
that O
clonidine O
was O
effective O
in O
reducing O
several O
hyperarousal B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
improved O
social B-outcome ['Life-Impact']
relationships I-outcome ['Life-Impact']
in O
some O
autistic O
subjects O
. O
['Life-Impact', 'Life-Impact']

A O
play O
and O
joint O
attention O
intervention O
for O
teachers O
of O
young O
children O
with O
autism O
: O
a O
randomized O
controlled O
pilot O
study O
. O
[]

BMC B-outcome ['Physiological-Clinical']
fell O
rapidly O
and O
similarly O
in O
both O
groups O
, O
demonstrating O
that O
the O
triple-treatment O
has O
no O
preventive O
effect O
on O
corticosteroid O
induced O
osteopenia O
. O
['Physiological-Clinical']

A O
total O
of O
117 O
patients O
newly O
referred O
to O
a O
medical O
oncology O
clinic O
who O
were O
to O
be O
given O
'bad O
news O
' O
had O
their O
consultations O
audiotaped O
. O
[]

In O
the O
DCT/CDDP O
arm O
14 O
pts O
( O
33 O
% O
; O
95 O
% O
CL O
24-40 O
% O
) O
had O
PR O
, O
and O
10 O
( O
24 O
% O
) O
SD O
for O
a O
57 O
% O
TGCR O
. O
[]

1.4 O
to O
8.2 O
? O
[]

TEE O
was O
performed O
for O
peripheral O
embolism O
in O
two O
patients O
, O
stroke O
or O
transient O
ischemic O
attack O
in O
six O
, O
stroke O
and O
fever O
in O
two O
, O
fever O
in O
one O
patient O
, O
as O
a O
routine O
postoperative O
examination O
in O
two O
patients O
, O
and O
for O
other O
reasons O
in O
seven O
. O
[]

In O
648 O
normal O
karyotype O
( O
NK O
) O
AML O
patients O
, O
we O
found O
a O
significant O
independent O
effect O
of O
the O
quantitative O
FLT3ITD O
mRNA O
level O
-- O
measured O
as O
( O
FLT3ITD/wtFLT3 O
) O
/ O
( O
FLT3ITD/wtFLT3+1 O
) O
-- O
on O
outcome O
. O
[]

Ten O
full-term O
affected O
neonates O
showed O
a O
wide B-outcome ['Physiological-Clinical']
range O
of O
17-OHP B-outcome ['Physiological-Clinical']
levels O
( O
15-1400 O
nmol/L O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Randomized O
, O
double-blind O
, O
multicenter O
study O
with O
210 O
subjects O
?60 O
years O
old O
compared O
immunity O
and O
safety O
profiles O
after O
one O
and O
two O
doses O
of O
ZV O
, O
separated O
by O
6 O
weeks O
, O
vs. O
placebo O
. O
[]

The O
effect O
was O
assessed O
using O
PANSS O
, O
CGI O
, O
MADRS O
and O
neuropsychological O
tests O
. O
[]

The O
reductions O
were O
statistically O
significantly O
lower O
than O
placebo O
up O
to O
1 O
hour O
post-dose O
on O
Day O
1 O
and O
up O
to O
3 O
hours O
post-dose O
on O
Day O
8 O
. O
[]

Most O
frequent O
grade O
3/4 O
adverse O
events O
were O
neutropenia O
( O
37 O
% O
) O
, O
fatigue O
( O
33 O
% O
) O
and O
hypertension O
( O
30 O
% O
) O
. O
[]

METHODS O
Before O
the O
experiment O
, O
72 O
rats O
were O
randomly O
allocated O
to O
receive O
HBO O
or O
air O
treatment O
. O
[]

AIMS O
The O
purpose O
of O
the O
study O
was O
to O
investigate O
the O
effects O
of O
asimadoline O
, O
a O
new O
kappa-opioid O
agonist O
, O
on O
renal O
function O
and O
on O
hormones O
related O
to O
body O
fluid O
balance O
as O
well O
as O
its O
tolerability O
in O
healthy O
subjects O
. O
[]

Three O
infants O
receiving O
the O
high O
copper O
formula O
and O
two O
receiving O
the O
lower O
copper O
formula O
were O
in O
positive O
copper B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
prevalences O
of O
PONV O
were O
not O
significantly O
different O
between O
propofol O
0.5 O
mg/kg O
and O
droperidol O
20 O
microg/kg O
0 O
to O
24 O
hours O
after O
anesthesia O
in O
this O
small O
, O
select O
group O
of O
Japanese O
women O
who O
underwent O
breast O
cancer O
surgery O
. O
[]

Minor B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
occurred O
in O
5/75 O
( O
6.7 O
% O
) O
patients O
of O
either O
group O
. O
['Adverse-effects']

Neither O
LEV O
nor O
AMF O
improved O
( O
P O
> O
0.10 O
) O
carcass O
characteristics O
compared O
with O
control O
or O
non-feed-supplemented O
steers O
. O
[]

[ O
Study O
on O
safety O
and O
immunogenicity O
of O
oral O
poliomyelitis O
attenuated O
live O
vaccine O
( O
human O
diploid O
cell O
) O
] O
. O
[]

Based O
on O
these O
criteria O
, O
nephrotoxicity B-outcome ['Physiological-Clinical']
was O
seen O
in O
2/27 O
( O
7.4 O
% O
) O
patients O
treated O
with O
G-C O
and O
in O
3/19 O
( O
15.8 O
% O
) O
patients O
treated O
with O
N-C. O
Ototoxicity B-outcome ['Physiological-Clinical']
was O
defined O
as O
a O
greater O
than O
20 O
dB O
loss O
at O
any O
frequency O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Study O
2 O
: O
dirithromycin O
500 O
mg O
q.d.s O
. O
[]

Higher O
GMFCS O
level O
, O
bilateral O
CP O
, O
and O
higher O
age O
were O
associated O
with O
lower O
ambulatory O
activity O
on O
school O
days O
( O
R O
( O
2 O
) O
ranged O
from O
43-53 O
% O
) O
, O
whereas O
bilateral O
CP O
, O
higher O
age O
, O
and O
no O
sport O
club O
participation O
were O
associated O
with O
lower O
ambulatory O
activity O
in O
the O
weekend O
( O
R O
( O
2 O
) O
ranged O
from O
21-42 O
% O
) O
. O
[]

Endoscopic B-outcome ['Resource-use']
, O
clinical B-outcome ['Physiological-Clinical']
, O
and O
['Resource-use', 'Physiological-Clinical']

METHODS O
Of O
813 O
patients O
with O
previously O
untreated O
metastatic O
colorectal O
cancer O
, O
we O
randomly O
assigned O
402 O
to O
receive O
irinotecan O
, O
bolus O
fluorouracil O
, O
and O
leucovorin O
( O
IFL O
) O
plus O
bevacizumab O
( O
5 O
mg O
per O
kilogram O
of O
body O
weight O
every O
two O
weeks O
) O
and O
411 O
to O
receive O
IFL O
plus O
placebo O
. O
[]

All O
20 O
stabilized O
patients O
in O
the O
analog-computer O
group O
achieved O
a O
stable O
PT O
ratio O
by O
the O
fourth O
dosage O
prediction O
. O
( O
[]

Measurements O
of O
gingival B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
probing B-outcome ['Physiological-Clinical']
depths I-outcome ['Physiological-Clinical']
, O
bleeding B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
probing I-outcome ['Physiological-Clinical']
and O
suppuration B-outcome ['Physiological-Clinical']
were O
determined O
at O
2 O
periodontal O
sites O
with O
and O
2 O
without O
radiographic O
attachment O
loss O
, O
at O
weeks O
0 O
, O
1 O
, O
3 O
and O
8 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Plasma O
prolactin O
levels O
, O
body O
temperature O
, O
and O
mCPP B-outcome ['Physiological-Clinical']
blood O
level O
were O
also O
measured O
. O
['Physiological-Clinical']

Mold B-outcome ['Physiological-Clinical']
was O
visible O
in O
26.8 O
% O
of O
homes O
, O
water B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
was O
present O
in O
18.6 O
% O
of O
homes O
, O
and O
damp B-outcome ['Life-Impact']
conditions I-outcome ['Life-Impact']
occurred O
in O
64.8 O
% O
of O
households O
, O
while O
39.6 O
% O
of O
caregivers O
were O
aware O
that O
excessive O
moisture O
can O
increase O
exposures O
to O
allergens O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

BACKGROUND O
Melatonin O
is O
often O
used O
for O
autistic O
children O
with O
sleep O
disorders O
, O
despite O
a O
lack O
of O
published O
evidence O
in O
this O
population O
. O
[]

OBJECTIVE O
To O
compare O
efficacy O
among O
1578 O
patients O
with O
osteoarthritis O
randomized O
to O
take O
acetaminophen O
4000 O
mg O
( O
n=269 O
) O
, O
celecoxib O
200 O
mg O
( O
n=523 O
) O
, O
rofecoxib O
12.5 O
mg O
( O
n=259 O
) O
, O
or O
rofecoxib O
25 O
mg O
( O
n=527 O
) O
in O
a O
double O
blind O
trial O
[ O
Vioxx O
, O
Acetaminophen O
, O
Celecoxib O
Trial O
( O
VACT2 O
) O
] O
. O
[]

The O
improvement O
seen O
with O
secretin O
in O
children O
with O
autism/PDD O
and O
chronic O
diarrhea O
suggests O
that O
there O
may O
be O
a O
subtype O
of O
children O
with O
autism/PDD O
who O
respond O
to O
secretin O
. O
[]

Patients O
with O
normal O
levels O
, O
except O
CA72-4 O
, O
also O
had O
more O
clinical O
responses O
( O
PR+SD4 O
) O
than O
patients O
with O
elevated O
values O
. O
[]

In O
addition O
to O
the O
need O
for O
determining O
whether O
deliberate O
mild O
hypothermia O
confers O
cerebral O
protection O
in O
humans O
, O
the O
potential O
risks O
of O
the O
therapy O
need O
to O
be O
further O
characterized O
. O
[]

PMN O
chemotaxis O
is O
in O
part O
sensitive O
to O
microtubule O
antagonists O
( O
MAs O
) O
, O
e.g O
. O
[]

The O
corresponding O
numbers O
in O
patients O
with O
echogenic B-outcome ['Physiological-Clinical']
plaques I-outcome ['Physiological-Clinical']
were O
n O
= O
4/13 O
( O
31 O
% O
) O
and O
n O
= O
4/17 O
( O
24 O
% O
) O
, O
respectively O
( O
NS O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
A O
single O
nasal O
allergen O
challenge O
in O
SAR O
patients O
increased O
markers O
of O
allergic B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
in O
the O
lower O
respiratory O
tract O
, O
possibly O
via O
pronounced O
activation O
of O
inflammatory O
cells O
through O
circulating O
immediate-type O
reaction O
cytokines O
like O
IL-5 O
. O
['Physiological-Clinical']

AIMS O
To O
determine O
the O
pharmacokinetics O
and O
tolerance O
of O
oral O
and O
intravenous O
linezolid O
, O
an O
oxazolidinone O
antibiotic O
, O
in O
healthy O
volunteers O
following O
single- O
and O
multiple-dose O
administration O
. O
[]

RESULTS O
At O
a O
median O
follow-up O
of O
10.5 O
years O
on O
194 O
eligible O
patients O
, O
disease O
evolution O
was O
seen O
in O
54 O
and O
49 O
patients O
in O
the O
surgery O
and O
chemotherapy O
arm O
, O
respectively O
, O
and O
81 O
and O
83 O
patients O
had O
died O
. O
[]

RESULTS O
Of O
85 O
EEGs O
, O
43 O
( O
51 O
% O
) O
were O
abnormal B-outcome ['Physiological-Clinical']
, O
predominantly O
because O
of O
IEDs O
. O
['Physiological-Clinical']

By O
contrast O
, O
clinical O
educators O
were O
split O
in O
their O
use O
of O
the O
timing-based O
( O
n O
= O
10 O
) O
and O
the O
location-based O
( O
n O
= O
6 O
) O
approaches O
. O
[]

SETTING O
Neonatal O
intensive O
care O
unit O
in O
a O
106-bed O
quaternary O
care O
pediatric O
hospital O
. O
[]

The O
current O
study O
was O
undertaken O
to O
determine O
onset O
times O
of O
sensory O
and O
motor O
blockade O
after O
epidural O
anesthesia O
with O
0.5 O
% O
bupivacaine-CO2 O
and O
0.5 O
% O
bupivacaine-HCl O
at O
various O
injection O
temperatures O
. O
[]

VAS O
scores O
of O
group O
C O
were O
higher O
than O
of O
group O
B O
at O
postoperative O
fi O
rst O
2 O
hours O
. O
[]

CONCLUSIONS O
Our O
study O
shows O
that O
a O
short O
cycle O
of O
i.m O
. O
[]

Twenty-one O
patients O
were O
randomized O
to O
receive O
verapamil O
and O
21 O
patients O
to O
receive O
atenolol O
. O
[]

Grade O
3-4 O
haematological B-outcome ['Physiological-Clinical']
toxicities I-outcome ['Physiological-Clinical']
were O
reported O
in O
two O
patients O
in O
the O
FEC O
( O
90 O
) O
arm O
. O
['Physiological-Clinical']

INTERVENTION O
Daily O
dose O
of O
natural O
source O
vitamin O
E O
( O
400 O
IU O
) O
or O
matching O
placebo O
. O
[]

In O
conclusion O
, O
hypnosis O
improves O
IBS O
symptoms O
through O
reductions O
in O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
somatization I-outcome ['Life-Impact']
. O
['Life-Impact']

BACKGROUND O
WHO-defined O
pneumonias O
, O
treated O
with O
antibiotics O
, O
are O
responsible O
for O
a O
significant O
proportion O
of O
childhood O
morbidity O
and O
mortality O
in O
the O
developing O
countries O
. O
[]

Women O
with O
persistent O
HPV O
infection O
remained O
at O
high O
risk O
for O
grade O
2 O
or O
3 O
lesions O
or O
cancer O
after O
referral O
for O
colposcopy O
. O
[]

All O
the O
patients O
were O
given O
1 O
g O
calcium O
by O
mouth O
every O
morning O
. O
[]

Mean O
DBP B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
intervention O
group O
at O
the O
second O
( O
76.0 O
+/- O
11.8 O
vs O
84.9 O
+/- O
6.1 O
) O
and O
fourth O
( O
77.0 O
+/- O
10.2 O
vs O
91.8 O
+/- O
12.0 O
) O
quarters O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

All O
patients O
had O
BOO O
proven O
on O
urodynamic O
studies O
pre-operatively O
( O
prostate O
size O
40-200 O
g O
) O
. O
[]

METHODS O
The O
study O
included O
42 O
patients O
( O
29 O
women O
and O
13 O
men O
; O
mean O
age O
53.2+/-14.2 O
years O
; O
body O
surface O
area O
1.76+/-0.14 O
m2 O
) O
with O
SH O
, O
as O
judged O
by O
elevated O
serum O
TSH O
levels O
( O
> O
3.6 O
mIU/l O
; O
range O
, O
3.8-12.0 O
) O
and O
normal O
free O
thyroid O
hormones O
( O
FT4 O
and O
FT3 O
) O
and O
30 O
euthyroid O
volunteer O
. O
[]

KeraVision O
Intacs O
offer O
an O
alternative O
that O
addresses O
these O
shortcomings O
. O
[]

RESULTS O
The O
FEV1 B-outcome ['Physiological-Clinical']
, O
FVC B-outcome ['Physiological-Clinical']
, O
FEV1/FVC B-outcome ['Physiological-Clinical']
( O
% O
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

AIMS O
To O
investigate O
the O
effects O
of O
proton O
pump O
inhibitors O
on O
roxithromycin O
levels O
in O
plasma O
and O
gastric O
tissue O
under O
steady-state O
conditions O
in O
volunteers O
. O
[]

Evaluation O
of O
a O
new O
wound O
closure O
device O
for O
linear O
surgical O
incisions O
: O
3M O
Steri-Strip O
S O
Surgical O
Skin O
Closure O
versus O
subcuticular O
closure O
. O
[]

Amiodarone O
versus O
digoxin O
and O
metoprolol O
combination O
for O
the O
prevention O
of O
postcoronary B-outcome ['Physiological-Clinical']
bypass I-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Apart O
from O
reinforcing O
the O
belief O
that O
the O
combined O
application O
of O
brushing B-outcome ['Physiological-Clinical']
and O
biopsy B-outcome ['Resource-use']
is O
mandatory O
for O
achieving O
optimal O
results O
, O
this O
study O
indicated O
that O
the O
brushing O
should O
be O
performed O
before O
the O
biopsy O
. O
['Physiological-Clinical', 'Resource-use']

Teriparatide O
improves O
early B-outcome ['Physiological-Clinical']
callus I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
in O
distal O
radial O
fractures O
. O
['Physiological-Clinical']

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

Comparative O
evaluation O
of O
percutaneous O
laser O
and O
radiofrequency O
ablation O
in O
patients O
with O
HCC O
smaller O
than O
4 O
cm O
. O
[]

Energy O
given O
was O
correlated O
( O
p O
< O
0.05 O
) O
with O
the O
reduction O
of O
thyroid B-outcome ['Physiological-Clinical']
nodule I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Post-hoc O
analysis O
of O
data O
from O
a O
randomized O
, O
controlled O
trial O
of O
telcagepant O
( O
150 O
mg O
, O
300 O
mg O
) O
zolmitriptan O
5 O
mg O
, O
or O
placebo O
for O
a O
moderate/severe O
migraine O
. O
[]

These O
data O
suggest O
that O
PFL-therapy O
and O
FL-therapy O
seem O
to O
be O
possible O
and O
promising O
surgical O
adjuvant O
therapies O
for O
advanced B-outcome ['Physiological-Clinical']
colorectal I-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Follow-up O
shows O
a O
relapse B-outcome ['Physiological-Clinical']
rate O
of O
5 O
% O
in O
the O
CP O
treated O
group O
and O
of O
29 O
% O
in O
the O
controls O
( O
P O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
Ten O
weeks O
of O
pravastatin O
therapy O
significantly O
reduced O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
from O
3.8+/-0.6 O
to O
3.1+/-0.6 O
mmol/l O
at O
study O
end O
, O
P=0.04 O
) O
and O
the O
ratio O
of O
total O
to O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
from O
4.9+/-0.8 O
to O
3.7+/-0.7 O
mmol/l O
, O
P=0.002 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
patients O
were O
assigned O
to O
two O
groups O
. O
[]

Comparison O
of O
rectal O
midazolam O
and O
diazepam O
for O
premedication O
in O
pediatric O
dental O
patients O
. O
[]

Patients O
with O
CrCl O
< O
60 O
ml/min O
were O
more O
likely O
to O
be O
older O
, O
women O
, O
hypertensive O
, O
and O
have O
a O
history O
of O
coronary O
artery O
bypass O
surgery O
, O
stroke O
, O
or O
peripheral O
vascular O
disease O
. O
[]

A O
double-blind O
placebo-controlled O
study O
examined O
the O
effect O
of O
a O
single O
dose O
of O
synthetic O
human O
secretin O
on O
aberrant B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
. O
['Life-Impact']

Subjects O
with O
lower O
baseline O
CD4 O
T O
cell O
count O
, O
non-black O
race O
, O
and O
higher O
baseline O
glucose O
demonstrated O
a O
higher O
risk O
for O
> O
5 O
% O
decrease O
in O
[]

At O
month O
24 O
, O
the O
probability O
( O
+/- O
SEM O
) O
of O
survival B-outcome ['Mortality']
on O
treatment O
was O
0.273 O
+/- O
0.09 O
for O
CSA O
and O
0.852 O
+/- O
0.07 O
for O
MTX O
. O
['Mortality']

Skillful O
laser O
ablation O
can O
remove O
any O
volume O
of O
human O
papillomavirus-associated O
vulvar O
disease O
but O
can O
not O
prevent O
reactivation O
of O
the O
surrounding O
latent O
viral O
reservoir O
during O
postoperative O
healing O
. O
[]

This O
study O
was O
undertaken O
to O
investigate O
the O
changes O
of O
activated O
circulating O
endothelial O
cells O
( O
aCECs O
) O
and O
survivin O
after O
anti-angiogenesis O
therapy O
and O
their O
significance O
in O
predicting O
the O
efficacy O
of O
the O
therapy O
. O
[]

They O
are O
presented O
with O
odds O
ratios O
( O
OR O
) O
and O
95 O
% O
confidence O
intervals O
. O
[]

We O
conclude O
that O
postural O
responses O
to O
backward O
and O
forward O
perturbations O
may O
be O
processed O
by O
different O
neural O
circuits O
, O
with O
influence O
of O
startle O
pathways O
on O
postural O
responses O
to O
backward O
perturbations O
. O
[]

METHODS O
The O
authors O
divided O
60 O
participants O
randomly O
into O
three O
groups O
: O
NovaMin O
powder O
with O
NovaMin-containing O
toothpaste O
( O
group O
1 O
) O
, O
a O
placebo O
powder O
with O
NovaMin-containing O
toothpaste O
( O
group O
2 O
) O
and O
a O
placebo O
powder O
with O
the O
control O
toothpaste O
( O
group O
3 O
) O
. O
[]

In O
the O
intent-to-treat O
sample O
, O
10 O
of O
20 O
children O
( O
50 O
% O
) O
in O
the O
CBT O
group O
had O
a O
clinically O
meaningful O
positive O
treatment O
response O
, O
compared O
to O
2 O
of O
23 O
children O
( O
8.7 O
% O
) O
in O
the O
TAU O
group O
. O
[]

Language B-outcome ['Life-Impact']
outcome I-outcome ['Life-Impact']
in O
autism O
: O
randomized O
comparison O
of O
joint O
attention O
and O
play O
interventions O
. O
['Life-Impact']

PATIENTS O
AND O
METHODS O
A O
total O
of O
210 O
patients O
were O
randomly O
assigned O
to O
one O
of O
three O
treatment O
arms O
: O
gemcitabine O
1,250 O
mg/m O
( O
2 O
) O
Days O
1 O
and O
8 O
and O
paclitaxel O
175 O
mg/m O
( O
2 O
) O
as O
a O
3-h O
infusion O
on O
Day O
1 O
( O
GP1 O
) O
; O
gemcitabine O
1,000 O
mg/m O
( O
2 O
) O
Days O
1 O
and O
8 O
and O
paclitaxel O
100 O
mg/m O
( O
2 O
) O
as O
a O
1-h O
infusion O
on O
Days O
1 O
and O
8 O
( O
GP2 O
) O
; O
gemcitabine O
1,000 O
mg/m O
( O
2 O
) O
Days O
1 O
and O
8 O
and O
docetaxel O
40 O
mg/m O
( O
2 O
) O
as O
a O
1-h O
infusion O
on O
Days O
1 O
and O
8 O
( O
GD O
) O
. O
[]

MATERIALS O
AND O
METHODS O
One O
hundred O
forty-two O
patients O
were O
randomized O
into O
three O
groups O
: O
protocol O
A-scan O
delay O
of O
65 O
s O
after O
starting O
contrast O
injection O
over O
30 O
s O
; O
protocol O
B-105 O
and O
70 O
s O
; O
and O
protocol O
C-145 O
and O
110 O
s O
, O
respectively O
. O
[]

RESULTS O
Fatigue B-outcome ['Physiological-Clinical']
did O
not O
significantly O
correlate O
with O
any O
of O
the O
neuropsychological O
outcome O
measures O
at O
baseline O
or O
after O
treatment O
. O
['Physiological-Clinical']

RESULTS O
Baseline O
characteristics O
of O
randomized O
patients O
were O
clinically O
similar O
in O
the O
three O
treatment O
groups O
. O
[]

We O
found O
that O
, O
with O
comparable O
degrees O
of O
neuromuscular B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
, O
the O
onset O
time O
of O
succinylcholine O
at O
the O
adductor O
pollicis O
was O
significantly O
shorter O
( O
P O
< O
0.01 O
) O
than O
for O
rocuronium O
0.6 O
mg O
kg-1 O
and O
0.9 O
mg O
kg-1 O
( O
EMG O
, O
80 O
+/- O
39 O
vs O
145 O
+/- O
48 O
s O
and O
99 O
+/- O
31 O
s O
; O
AMG O
, O
90 O
+/- O
39 O
vs O
124 O
+/- O
53 O
s O
and O
106 O
+/- O
38 O
s O
) O
. O
['Physiological-Clinical']

Corresponding O
inverse O
changes O
in O
BTM B-outcome ['Physiological-Clinical']
were O
seen O
, O
with O
an O
increase O
following O
tamoxifen O
withdrawal O
and O
a O
reduction O
after O
exemestane O
. O
['Physiological-Clinical']

METHODS O
Sixty-two O
( O
62 O
) O
community-recruited O
patients O
with O
fibromyalgia O
( O
FM O
) O
were O
assessed O
at O
baseline O
prior O
to O
a O
clinical O
trial O
of O
individualized O
homeopathy O
. O
[]

11 O
women O
and O
13 O
men O
were O
examined O
, O
the O
average O
age O
was O
67.3 O
years O
, O
the O
Webster O
rating O
17 O
points O
. O
[]

21 O
mm O
. O
[]

An O
imaging O
core O
laboratory O
provided O
central O
validation O
, O
and O
2 O
independent O
reviewers O
, O
masked O
to O
assigned O
treatment O
arm O
and O
clinical O
outcomes O
, O
performed O
consensus O
( O
18 O
) O
F-FDG O
PET/CT O
readings O
. O
[]

The O
majority O
of O
retrospective O
studies O
and O
subjective O
experiences O
favor O
PTFE O
grafts O
over O
BCAHs O
. O
[]

Statistically O
, O
haloperidol O
was O
significantly O
superior O
to O
placebo O
in O
reducing O
behavioral B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

These O
results O
suggest O
a O
need O
to O
increase O
activity O
levels O
in O
women O
at O
moderate O
risk O
for O
breast O
cancer O
, O
provide O
variables O
upon O
which O
interventions O
can O
be O
tailored O
to O
promote O
activity O
, O
and O
point O
to O
psychological O
benefits O
of O
activity O
in O
this O
population O
. O
[]

The O
difference O
in O
the O
change O
from O
baseline O
total O
nasal B-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
scores O
in O
the O
two O
groups O
was O
assessed O
hourly O
for O
12 O
hours O
after O
administration O
. O
['Physiological-Clinical']

In O
the O
combination O
treatment O
group O
, O
9 O
( O
52.9 O
% O
) O
patients O
cured O
, O
improvement O
was O
observed O
in O
5 O
( O
29.4 O
% O
) O
and O
failure O
in O
3 O
( O
17.6 O
% O
) O
. O
[]

There O
was O
a O
suggestion O
that O
ATRA O
reduced O
relapse B-outcome ['Physiological-Clinical']
in O
patients O
with O
lower O
MN1 O
levels O
, O
but O
no O
significant O
effect O
on O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

No O
major O
side-effects O
were O
reported O
. O
[]

Prediction O
of O
the O
infarct-related O
artery O
in O
acute O
myocardial O
infarction O
by O
a O
scoring O
system O
using O
summary O
ST-segment O
and O
T-wave O
changes O
. O
[]

Group O
II O
, O
which O
consisted O
of O
27 O
infants O
, O
received O
simple O
exchanges O
. O
[]

The O
intervention O
led O
to O
significantly O
higher O
levels O
of O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
and O
senior B-outcome ['Life-Impact']
center I-outcome ['Life-Impact']
participation I-outcome ['Life-Impact']
and O
significant O
reductions O
in O
the O
use O
of O
psychoactive B-outcome ['Resource-use']
medications I-outcome ['Resource-use']
. O
['Life-Impact', 'Life-Impact', 'Resource-use']

16 O
mg/dl O
vs. O
51 O
? O
[]

bucket O
) O
as O
well O
as O
a O
visually O
matched O
control O
( O
e.g O
. O
[]

Comparison O
of O
adaptive O
pacing O
therapy O
, O
cognitive O
behaviour O
therapy O
, O
graded O
exercise O
therapy O
, O
and O
specialist O
medical O
care O
for O
chronic O
fatigue O
syndrome O
( O
PACE O
) O
: O
a O
randomised O
trial O
. O
[]

A O
total O
of O
154 O
eyes O
of O
77 O
patients O
were O
randomly O
divided O
into O
2 O
groups O
: O
group O
1 O
consisted O
of O
78 O
eyes O
, O
group O
2 O
consisted O
of O
76 O
eyes O
, O
and O
the O
patients O
were O
monitored O
for O
pupillary O
dilation O
, O
blood O
pressure O
, O
heart O
rate O
, O
and O
possible O
adverse O
effects O
at O
0 O
, O
20 O
, O
40 O
, O
60 O
, O
and O
90 O
minutes O
. O
[]

In O
the O
sibutramine O
group O
, O
it O
decreased O
from O
33.5+/-4.1 O
kg/m O
( O
2 O
) O
to O
30.9+/-4.8 O
kg/m O
( O
2 O
) O
( O
P O
< O
.05 O
) O
. O
[]

Skeletal O
muscle O
STARS O
, O
myocardian-related O
transcription O
factor-A O
( O
MRTF-A O
) O
and O
serum O
response O
factor O
( O
SRF O
) O
mRNA O
and O
protein O
, O
as O
well O
as O
muscle O
cross-sectional O
area O
and O
maximal O
voluntary O
contraction O
, O
were O
measured O
. O
[]

IMPORTANCE O
The O
prevalence O
of O
psychological O
distress O
among O
mothers O
of O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
suggests O
a O
need O
for O
interventions O
that O
address O
parental B-outcome ['Life-Impact']
mental I-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
during O
the O
critical O
period O
after O
the O
child O
's O
autism O
diagnosis O
when O
parents O
are O
learning O
to O
navigate O
the O
complex O
system O
of O
autism O
services O
. O
['Life-Impact']

In O
the O
experimental O
group O
, O
there O
were O
greater O
gains O
in O
language B-outcome ['Life-Impact']
abilities I-outcome ['Life-Impact']
, O
significant O
increases O
in O
caregivers B-outcome ['Life-Impact']
' O
knowledge B-outcome ['Life-Impact']
about O
autism B-outcome ['Life-Impact']
, O
greater O
perception B-outcome ['Life-Impact']
of O
control O
on O
the O
part O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Lymph O
node O
staging O
was O
mandatory O
but O
at O
the O
physician O
's O
discretion O
; O
117 O
( O
26 O
% O
) O
patients O
had O
SL O
, O
while O
332 O
( O
74 O
% O
) O
had O
LAG O
. O
[]

GAS O
is O
a O
promising O
measurement O
approach O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
validate O
the O
measurement O
of O
myocardial O
velocity O
imaging-derived O
RV O
IVRT O
( O
IVRT O
' O
) O
against O
invasively O
measured O
PAP O
. O
[]

METHODS O
From O
January O
2004 O
to O
December O
2006 O
, O
101 O
patients O
with O
high-risk O
breast O
cancer O
after O
surgical O
resection O
were O
enrolled O
into O
this O
study O
. O
[]

AUC O
( O
0-150 O
) O
of O
APAP/pl O
is O
significantly O
different O
from O
pl/pl O
( O
-3452 O
% O
.min O
( O
95 O
% O
CI O
-4705 O
to O
-2199 O
) O
vs. O
-933 O
% O
min O
( O
95 O
% O
CI O
-2273 O
to O
407 O
; O
P O
= O
0.015 O
) O
but O
not O
from O
APAP/Nal O
( O
-1731 O
% O
min O
( O
95 O
% O
CI O
-3676 O
to O
214 O
; O
P O
= O
0.08 O
) O
and O
other O
treatments O
. O
[]

CONCLUSION O
A O
home-based O
exercise O
program O
seems O
capable O
of O
improving O
the O
mobility O
, O
fatigue O
, O
and O
sleep O
quality O
of O
patients O
with O
Stage O
IV O
lung O
and O
colorectal O
cancer O
. O
[]

RESULTS O
There O
were O
no O
differences O
in O
initial O
levels O
of O
illicit B-outcome ['Life-Impact']
drug I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
across O
the O
experimental O
and O
control O
groups O
. O
['Life-Impact']

One O
hundred O
and O
eighty-eight O
patients O
with O
inoperable O
or O
unresectable O
bronchogenic O
carcinoma O
were O
stratified O
by O
cell O
type O
, O
TNM O
staging O
, O
and O
prior O
surgery O
and O
then O
randomized O
into O
two O
treatment O
groups O
: O
continuous O
radiation O
therapy O
and O
split-course O
radiation O
therapy O
. O
[]

Thirty-eight O
women O
with O
benign O
ovarian O
dermoid O
cyst O
were O
allocated O
for O
either O
laparoscopy O
( O
18 O
patients O
) O
or O
laparotomy O
( O
20 O
patients O
) O
. O
[]

A O
simplified O
score O
was O
derived O
from O
the O
final O
predictive O
model O
. O
[]

A O
randomized O
controlled O
trial O
of O
new O
non-urgent O
rheumatology O
out-patient O
referrals O
. O
[]

Four O
participants O
( O
9 O
% O
) O
in O
the O
group O
that O
had O
arthroscopic O
cuff O
repair O
alone O
, O
one O
with O
a O
Type-2 O
and O
three O
with O
a O
Type-3 O
acromion O
, O
required O
additional B-outcome ['Resource-use']
surgery I-outcome ['Resource-use']
by O
the O
twenty-four-month O
time O
point O
. O
['Resource-use']

Although O
long-term O
follow-up O
studies O
are O
needed O
to O
confirm O
the O
results O
, O
this O
study O
suggests O
that O
cyproheptadine O
augmentation O
may O
be O
effective O
in O
treating O
chronic O
schizophrenic B-outcome ['Physiological-Clinical']
patients O
who O
are O
intolerant O
of O
extrapyramidal B-outcome ['Physiological-Clinical']
side I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
conventional O
antipsychotics O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
overall O
response O
rate O
( O
CR+PR O
) O
was O
91.5 O
% O
for O
Chinese O
herb O
group O
and O
46.9 O
% O
for O
control O
group O
( O
P O
less O
than O
0.001 O
) O
. O
[]

The O
primary O
outcome O
of O
the O
study O
is O
change O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
change O
in O
the O
percentage O
of O
patients O
in O
each O
group O
with O
controlled O
blood O
pressure O
. O
['Physiological-Clinical']

In O
this O
8-week O
double-blind O
, O
placebo-controlled O
trial O
, O
we O
assessed O
the O
effects O
of O
cyproheptadine O
plus O
haloperidol O
in O
the O
treatment O
of O
autistic O
disorder O
. O
[]

METHODS O
We O
assessed O
caffeine O
responses O
and O
levels O
of O
saliva O
concentration O
of O
caffeine O
in O
52 O
subjects O
who O
were O
randomly O
assigned O
to O
receive O
one O
of O
two O
drug O
administration O
instructions O
: O
( O
a O
) O
placebo-informed O
instructions O
( O
i.e. O
, O
individuals O
informed O
of O
the O
placebo O
) O
analogous O
to O
those O
used O
in O
double-blind O
studies O
and O
( O
b O
) O
placebo-uninformed O
instructions O
( O
i.e. O
, O
individuals O
informed O
they O
are O
taking O
an O
active O
stimulant O
) O
. O
[]

The O
mean O
risperidone O
dose O
was O
1.96 O
mg/day O
at O
entry O
and O
remained O
stable O
over O
16 O
weeks O
of O
open O
treatment O
. O
[]

Judgment O
during B-outcome ['Life-Impact']
batting B-outcome ['Life-Impact']
, O
batting B-outcome ['Life-Impact']
skill I-outcome ['Life-Impact']
during B-outcome ['Life-Impact']
the O
game O
, O
and O
performance B-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
skill I-outcome ['Life-Impact']
drills I-outcome ['Life-Impact']
prior O
to O
the O
['Life-Impact']

However O
, O
providing O
a O
risk O
anchor O
based O
on O
downward O
social O
comparison O
processes O
resulted O
in O
better O
risk O
acceptance B-outcome ['Life-Impact']
at O
posttest O
that O
persisted O
at O
a O
2-week O
follow-up O
assessment O
. O
['Life-Impact']

QRS B-outcome ['Physiological-Clinical']
score O
indicated O
a O
smaller O
['Physiological-Clinical']

Handwarming O
and O
relaxation O
in O
temperature O
feedback O
: O
positive O
placebo O
effects O
. O
[]

A O
total O
of O
1,615 O
angiographic O
readings O
in O
240 O
patients O
with O
acute O
myocardial O
infarction O
were O
analyzed O
from O
a O
randomized O
trial O
of O
intravenous O
anistreplase O
( O
Eminase O
) O
, O
also O
known O
as O
anisoylated O
plasminogen O
streptokinase O
activator O
complex O
( O
APSAC O
) O
, O
versus O
intracoronary O
streptokinase O
. O
[]

Patients O
were O
comparable O
in O
terms O
of O
age O
, O
performance O
status O
, O
baseline O
laboratory O
values O
, O
dominant O
sites O
of O
measurable O
disease O
, O
and O
percent O
of O
liver O
involvement O
. O
[]

Ozagrel O
Hydrochloride O
( O
400 O
mg/day O
, O
orally O
) O
and O
placebo O
were O
started O
at O
20 O
weeks O
of O
gestation O
and O
continued O
until O
delivery O
. O
[]

Twenty O
nine O
stable O
renal O
transplant O
recipients O
, O
10 O
receiving O
cyclosporin O
, O
10 O
cyclosporin-prednisolone O
and O
nine O
azathioprine-prednisolone O
were O
supplemented O
in O
a O
double O
blind O
randomization O
cross-over O
study O
with O
fish O
oil O
and O
corn O
oil O
for O
a O
period O
of O
4 O
months O
each O
. O
[]

Treatment O
of O
multiple O
myeloma O
according O
to O
the O
extension O
of O
the O
disease O
: O
a O
prospective O
, O
randomised O
study O
comparing O
a O
less O
with O
a O
more O
aggressive O
cystostatic O
policy O
. O
[]

Sixteen O
outpatients O
with O
partially O
reversible O
, O
stable O
COPD O
received O
24 O
microg O
formoterol O
, O
50 O
microg O
salmeterol O
, O
200 O
microg O
oxitropium O
bromide O
, O
or O
placebo O
on O
four O
non-consecutive O
days O
. O
[]

INTRODUCTION O
AND O
OBJECTIVES O
Coronary O
angiography O
is O
the O
gold O
standard O
for O
the O
study O
of O
coronary O
artery O
disease O
. O
[]

No O
significant O
differences O
were O
found O
between O
the O
groups O
. O
[]

Other O
outcome O
measures O
include O
symptom B-outcome ['Physiological-Clinical']
and O
employment B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
, O
quality O
of O
life O
, O
exercise B-outcome ['Life-Impact']
tolerance I-outcome ['Life-Impact']
, O
and O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

We O
can O
not O
recommend O
the O
use O
of O
oral O
premedication O
using O
these O
amounts O
of O
water O
, O
considering O
the O
increased O
risk O
of O
aspiration O
of O
gastric O
contents O
. O
[]

Two O
additional O
patients O
, O
wearing O
half O
of O
the O
TTS-scopolamine O
patch O
, O
suffered O
from O
mild O
central B-outcome ['Physiological-Clinical']
anticholinergic I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Study O
participants O
( O
N=170 O
) O
had O
a O
mean O
age O
of O
28.4 O
years O
( O
SD=9.6 O
; O
range O
18-60 O
) O
and O
formed O
a O
racially O
diverse O
group O
. O
[]

A O
total O
of O
110 O
women O
who O
had O
reported O
urinary O
incontinence O
to O
their O
general O
practitioners O
were O
randomly O
assigned O
to O
a O
treatment O
or O
control O
group O
. O
[]

CONCLUSIONS O
Higher O
dose O
paclitaxel O
prolongs O
the O
median O
time O
to O
progression O
but O
causes O
more O
neurotoxicity O
and O
leucopenia O
. O
[]

Ropivacaine O
had O
a O
mean O
onset B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
of O
4.5 O
minutes O
( O
range O
, O
3.5 O
to O
5.5 O
minutes O
) O
. O
['Physiological-Clinical']

Local O
injection O
of O
bupivacaine O
after O
rubber O
band O
ligation O
of O
hemorrhoids O
: O
prospective O
, O
randomized O
study O
. O
[]

Autism-Spectrum O
Quotient-Japanese O
version O
and O
its O
short O
forms O
for O
screening O
normally O
intelligent O
persons O
with O
pervasive O
developmental O
disorders O
. O
[]

DESIGN O
Randomized O
, O
controlled O
trial O
, O
with O
post O
hoc O
analysis O
. O
[]

CONCLUSION O
There O
was O
considerable O
interest O
in O
participating O
in O
health O
promotion O
. O
[]

OBJECTIVE O
To O
address O
the O
hypothesis O
that O
multiphasic O
oral O
contraceptives O
( O
OCs O
) O
increase O
rather O
than O
decrease O
the O
risk O
of O
functional B-outcome ['Physiological-Clinical']
ovarian I-outcome ['Physiological-Clinical']
cysts I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

More O
than O
one O
third O
of O
the O
cases O
of O
advanced O
tumors O
were O
operable O
by O
local O
chemotherapy O
. O
[]

METHODS O
MEND-CABG O
II O
is O
a O
phase O
III O
study O
evaluating O
the O
efficacy O
and O
safety O
of O
MC-1 O
in O
reducing O
cardiovascular O
morbidity O
and O
mortality O
after O
CABG O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Development O
of O
MS B-outcome ['Physiological-Clinical']
and O
neurologic B-outcome ['Physiological-Clinical']
disability I-outcome ['Physiological-Clinical']
assessment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

With O
infliximab O
treatment O
, O
SDAI O
and O
CDAI O
remission O
rates O
were O
of O
the O
same O
magnitude O
as O
those O
observed O
with O
tocilizumab O
treatment O
, O
and O
DAS28 O
remission O
rates O
were O
lower O
. O
[]

Some O
investigators O
recommend O
low O
volumes O
, O
but O
in O
our O
experience O
this O
produced O
the O
finding O
of O
pseudoloculation B-outcome ['Physiological-Clinical']
, O
which O
could O
change O
treatment O
inappropriately O
. O
['Physiological-Clinical']

Effectiveness O
of O
erythromycin O
in O
the O
treatment O
of O
acute O
bronchitis O
. O
[]

However O
, O
after O
the O
training O
period O
, O
IL-6R B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
was O
increased O
in O
skeletal O
muscle O
, O
suggesting O
a O
sensitization O
of O
skeletal O
muscle O
to O
IL-6 O
at O
rest O
. O
['Physiological-Clinical']

RESULTS O
Both O
groups O
of O
50 O
patients O
were O
comparable O
with O
respect O
to O
demographic O
data O
, O
initial O
parameters O
, O
and O
duration O
of O
colonoscopy O
. O
[]

Trends O
were O
noted O
for O
improvement O
in O
ALSFRS-R B-outcome ['Physiological-Clinical']
, O
Maximum O
['Physiological-Clinical']

Bioequivalence O
evaluation O
of O
a O
fixed O
dose O
combination O
lamivudine O
+ O
stavudine O
tablet O
with O
concurrent O
administration O
of O
lamivudine O
tablet O
and O
stavudine O
capsule O
in O
healthy O
volunteers O
. O
[]

A O
large O
effect O
size O
was O
also O
observed O
( O
partial O
? O
( O
[]

0.32 O
g O
) O
were O
randomly O
distributed O
into O
six O
treatments O
in O
triplicates O
( O
15 O
fish/tank O
) O
. O
[]

The O
effect O
of O
leukocyte O
reduction O
filters O
on O
inflammatory O
mediator O
release O
during O
coronary O
artery O
bypass O
grafting O
. O
[]

To O
evaluate O
the O
effect O
of O
granulocyte/colony-stimulating O
factor O
( O
G-CSF O
) O
on O
the O
onset O
of O
the O
adult O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
, O
we O
investigated O
whether O
the O
incidence O
of O
ARDS O
due O
to O
pulmonary O
infection O
differed O
between O
the O
G-CSF O
group O
which O
received O
chemotherapy O
with O
G-CSF O
and O
historical O
controls O
without O
G-CSF O
. O
[]

OBJECTIVE O
To O
assess O
the O
cost-effectiveness O
of O
clopidogrel O
in O
the O
Canadian O
health O
care O
system O
. O
[]

Early O
steroid O
withdrawal O
after O
liver O
transplantation O
( O
LT O
) O
is O
desirable O
in O
order O
to O
reduce O
steroid O
side O
effects O
. O
[]

Very O
few O
( O
< O
8 O
% O
) O
patients O
missed B-outcome ['Life-Impact']
work/school I-outcome ['Life-Impact']
. O
['Life-Impact']

Still O
, O
some O
argue O
that O
consumer-directed O
care O
may O
not O
be O
appropriate O
for O
consumers O
with O
a O
diagnosis O
of O
mental O
illness O
. O
[]

A O
role O
for O
lymphocytes O
in O
containment O
of O
B. O
fragilis O
has O
not O
been O
suggested O
previously O
, O
although O
unexplained O
occurrence O
of O
bacteroides B-outcome ['Physiological-Clinical']
bacteremia I-outcome ['Physiological-Clinical']
in O
immunocompromised O
patients O
has O
occasionally O
been O
reported O
. O
['Physiological-Clinical']

Significant O
improvement O
in O
6-minute B-outcome ['Life-Impact']
walk I-outcome ['Life-Impact']
test O
( O
45.8 O
m O
; O
95 O
% O
confidence O
interval O
, O
5.2-86.4 O
m O
; O
p=0.031 O
) O
, O
functional B-outcome ['Life-Impact']
class I-outcome ['Life-Impact']
( O
-0.6+/-0.5 O
, O
p=0.014 O
) O
, O
weight O
loss B-outcome ['Physiological-Clinical']
( O
-8.55 O
kg O
; O
95 O
% O
confidence O
interval O
, O
-13.0 O
to O
-4.1 O
kg O
; O
p O
< O
0.001 O
) O
and O
also O
significant O
decreases O
in O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
p=0.017 O
) O
, O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
p=0.03 O
) O
, O
and O
triglycerides B-outcome ['Physiological-Clinical']
( O
p=0.036 O
) O
were O
observed O
in O
the O
orlistat O
group O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
multicenter O
, O
randomized O
, O
open-label O
, O
parallel O
group O
trial O
was O
conducted O
. O
[]

DESIGN O
Randomized O
controlled O
trial O
. O
[]

CONCLUSIONS O
Physicians O
exposed O
to O
a O
narrative O
about O
opioid O
guidelines O
were O
more O
likely O
to O
recall O
guideline O
content O
at O
1 O
hour O
than O
those O
exposed O
to O
a O
summary O
of O
the O
guidelines O
. O
[]

RESULTS O
After O
treatment O
, O
the O
CARS O
in O
both O
groups O
were O
significantly O
reduced O
( O
42.39 O
+/- O
6.86 O
vs O
32.15 O
+/- O
5.12 O
, O
P O
< O
0.001 O
; O
44.58 O
+/- O
6.76 O
vs O
39.72 O
+/- O
7.11 O
, O
P O
< O
0.05 O
) O
, O
which O
was O
more O
significant O
in O
group O
A O
( O
P O
< O
0.01 O
) O
. O
[]

TRIAL O
REGISTRATION O
This O
paper O
uses O
data O
collected O
in O
a O
previous O
clinical O
trial O
registered O
at O
the O
Australian O
Clinical O
Trials O
Registry O
, O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
: O
Anzcrt.org.au O
ACTRN012607000195459 O
. O
[]

Comparison O
of O
the O
acute O
effects O
of O
salbutamol O
and O
terbutaline O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
in O
adult O
asthmatic O
patients O
. O
['Physiological-Clinical']

Effects O
of O
a O
standardized O
pamphlet O
on O
insomnia O
in O
children O
with O
autism O
spectrum O
disorders O
. O
[]

A O
randomised O
trial O
of O
radiotherapy O
compared O
with O
cisplatin O
chemo-radiotherapy O
in O
patients O
with O
unresectable O
squamous O
cell O
cancer O
of O
the O
esophagus O
. O
[]

The O
performance O
of O
an O
adaptive O
automation O
system O
was O
evaluated O
using O
a O
cognitive O
vigilance O
task O
. O
[]

The O
goal O
of O
this O
study O
was O
to O
assess O
the O
tolerability B-outcome ['Life-Impact']
, O
safety O
, O
and O
efficacy O
of O
donepezil O
on O
EF O
in O
a O
sample O
of O
children O
and O
adolescents O
with O
ASD O
. O
['Life-Impact']

After O
a O
submaximal O
exercise O
load O
on O
the O
bicycle O
ergometer O
( O
1 O
watt O
per O
kg O
body O
weight O
) O
following O
an O
evening O
meal O
, O
no O
difference O
could O
be O
observed O
between O
penbutolol O
and O
placebo O
in O
the O
above-mentioned O
parameters O
. O
[]

Cervico-vaginal O
lavage O
was O
collected O
to O
measure O
the O
concentrations O
of O
IL-1? O
, O
TNF? O
and O
IL-6 O
by O
ELISA O
. O
[]

OG O
cost B-outcome ['Resource-use']
$ O
1675 O
and O
PEG O
$ O
979 O
to O
perform O
. O
['Resource-use']

Anti-Hib B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
determined O
by O
the O
Farr-type O
radioimmunoassay O
. O
['Physiological-Clinical']

The O
tolerability O
of O
lactated O
Ringer O
's O
solution O
and O
BSS O
plus O
for O
ocular O
irrigation O
with O
and O
without O
the O
Morgan O
therapeutic O
lens O
. O
[]

The O
acid O
was O
applied O
to O
produce O
a O
frost O
, O
using O
varying O
concentrations O
of O
acid O
, O
ranging O
from O
20 O
to O
50 O
% O
. O
[]

All O
29 O
evaluable O
patients O
with O
ANLL O
were O
treated O
on O
Regimen O
I. O
Eighty-eight O
percent O
of O
evaluable O
patients O
experienced O
severe B-outcome ['Adverse-effects']
or I-outcome ['Adverse-effects']
life-threatening I-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
, O
with O
no O
statistical O
differences O
between O
Regimens O
I O
and O
II O
. O
['Adverse-effects']

Efficacy O
and O
safety O
of O
triamcinolone O
acetonide O
aqueous O
nasal O
spray O
in O
patients O
with O
seasonal O
allergic O
rhinitis O
. O
[]

The O
primary O
endpoint O
was O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
and O
secondary O
endpoints O
were O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
postoperative B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
and O
hospital B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
and O
postoperative B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
change O
of O
respiratory B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Mortality', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

3.2 O
vs O
6.9 O
? O
[]

Those O
who O
failed O
to O
respond O
were O
randomly O
assigned O
to O
double-blind O
treatment O
in O
Phase O
2 O
with O
either O
verapamil O
( O
n O
= O
10 O
) O
or O
continued-lithium O
( O
n O
= O
8 O
) O
. O
[]

with O
respect O
to O
the O
1-year O
retention B-outcome ['Life-Impact']
on O
treatment O
rate O
. O
['Life-Impact']

Chronic O
fatigue O
syndrome O
versus O
neuroendocrineimmune O
dysfunction O
syndrome O
: O
differential O
attributions O
. O
[]

CONCLUSIONS O
This O
is O
the O
first O
experiment O
to O
test O
whether O
psychological O
treatment O
effective O
in O
reducing O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
would O
also O
reduce O
indicators O
of O
inflammation O
. O
['Life-Impact']

Patients O
were O
followed O
for O
at O
least O
four O
years O
( O
mean O
4.7 O
years O
) O
. O
[]

Patients O
were O
examined O
every O
6 O
months O
during O
follow-up O
( O
range O
, O
1-9 O
years O
) O
. O
[]

Obviously O
, O
onions O
contain O
pharmacologically O
active O
substances O
with O
anti-inflammatory O
and/or O
allergic O
properties O
. O
[]

All O
patients O
received O
methylprednisolon O
for O
14 O
days O
, O
thereafter O
a O
double-blinded O
medication O
containing O
either O
placebo O
( O
n O
= O
56 O
) O
or O
methylprednisolon O
( O
n O
= O
54 O
) O
for O
6 O
months O
, O
which O
was O
completely O
stopped O
thereafter O
. O
[]

Comparison O
of O
enflurane O
and O
halothane O
in O
hypotensive O
eye O
surgery O
. O
[]

Efficacy O
and O
safety O
of O
selamectin O
against O
fleas O
and O
heartworms O
in O
dogs O
and O
cats O
presented O
as O
veterinary O
patients O
in O
North O
America O
. O
[]

In O
the O
fistula O
rates O
, O
we O
observed O
that O
technical O
problems O
and O
nutritional O
status O
might O
have O
played O
an O
equally O
important O
role O
, O
and O
therefore O
the O
positive O
effect O
of O
immunonutrition O
in O
this O
parameter O
might O
have O
been O
overestimated O
. O
[]

Heart O
failure O
is O
the O
leading O
cause O
of O
hospitalization O
. O
[]

As O
the O
genesis O
of O
deep O
venous O
thrombosis O
( O
DVT O
) O
is O
due O
to O
haemodynamic O
, O
hemorheologic O
and O
parietal O
factors O
, O
various O
prophylactic O
measures O
have O
been O
considered O
in O
the O
past O
, O
measures O
which O
have O
not O
proved O
able O
to O
provide O
satisfactory O
protection O
in O
orthopaedics O
. O
[]

RESULTS O
intention O
to O
treat O
analysis O
showed O
an O
immunisation B-outcome ['Resource-use']
rate O
in O
the O
control O
group O
of O
44 O
% O
, O
compared O
with O
50 O
% O
in O
the O
intervention O
group O
( O
odds O
ratio O
= O
1.29 O
, O
95 O
% O
confidence O
interval O
= O
1.03 O
to O
1.63 O
) O
. O
['Resource-use']

Both O
children O
's O
eyes O
were O
examined O
according O
to O
the O
World O
Health O
Organization O
( O
WHO O
) O
simplified B-outcome ['Physiological-Clinical']
grading I-outcome ['Physiological-Clinical']
system B-outcome ['Physiological-Clinical']
, O
and O
an O
ocular B-outcome ['Physiological-Clinical']
swab I-outcome ['Physiological-Clinical']
was O
taken O
from O
each O
child O
's O
right O
eye O
and O
processed O
by O
Amplicor O
polymerase O
chain O
reaction O
to O
test O
for O
the O
presence O
of O
C. O
trachomatis O
DNA O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
Interceed B-outcome ['Physiological-Clinical']
( O
TC7 O
) O
-treated O
sidewalls O
also O
had O
significantly O
less O
area O
involved B-outcome ['Physiological-Clinical']
with O
adhesions B-outcome ['Physiological-Clinical']
at O
laparoscopy O
( O
P O
less O
than O
.05 O
, O
P O
less O
than O
.001 O
, O
and O
P O
less O
than O
.001 O
in O
the O
three O
groups O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Compared O
to O
age- O
and O
sex-matched O
normal O
controls O
, O
AAMI O
patients O
showed O
a O
trend O
towards O
P300 O
latency O
prolongation O
and O
a O
significantly O
reduced O
P300 O
global O
field O
power O
( O
GFP O
) O
. O
[]

One O
other O
possible O
factor O
contributing O
to O
pruritus O
is O
the O
pattern O
of O
immune O
dysregulation O
. O
[]

Subjects O
were O
randomly O
assigned O
to O
an O
Aerobic O
Exercise O
group O
, O
a O
Yoga O
and O
Flexibility O
control O
group O
, O
or O
a O
Waiting O
List O
control O
group O
. O
[]

7.89 O
vs O
0.81 O
? O
[]

Patients O
older O
than O
24 O
months O
with O
intracranial O
lesions O
were O
assigned O
randomly O
to O
receive O
either O
lomustine O
, O
vincristine O
, O
and O
prednisone O
( O
control O
regimen O
) O
or O
the O
8-drugs-in-1-day O
regimen O
( O
experimental O
regimen O
) O
; O
younger O
patients O
and O
those O
with O
primary O
spinal O
cord O
tumors O
were O
assigned O
nonrandomly O
to O
the O
experimental O
regimen O
. O
[]

No O
statistically O
significant O
differences O
were O
demonstrated O
in O
terms O
of O
median O
overall O
survival B-outcome ['Mortality']
and O
time O
to O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

Interferon O
treatment O
for O
hairy B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
leukemia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

3 O
) O
Definitive O
diagnosis O
of O
colorectal O
carcinomas O
, O
histologically O
. O
[]

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
preoperative I-outcome ['Physiological-Clinical']
neurological I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
is O
faster O
and O
morphine O
provides O
some O
transitional B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
without O
compromising O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
recovery I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Resource-use', 'Life-Impact']

This O
study O
is O
registered O
, O
number O
ISRCTN78390996 O
. O
[]

Between O
baseline O
and O
6 O
months O
after O
surgery O
, O
there O
were O
no O
differences O
between O
group O
I O
and O
both O
pre-fed O
groups O
. O
[]

OBJECTIVE O
To O
evaluate O
a O
peer O
counseling O
intervention O
for O
pregnant O
smokers O
. O
[]

Fenofibrate O
therapy O
decreased O
total O
cholesterol B-outcome ['Physiological-Clinical']
, O
triglycerides B-outcome ['Physiological-Clinical']
by O
29 O
% O
, O
and O
triglycerides/HDL-cholesterol B-outcome ['Physiological-Clinical']
( O
all O
P O
< O
0.01 O
) O
and O
improved O
flow-mediated B-outcome ['Physiological-Clinical']
dilation I-outcome ['Physiological-Clinical']
when O
compared O
with O
baseline O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Functional O
modification O
of O
agonist-antagonist O
electromyographic O
activity O
for O
rapid O
movement O
inhibition O
. O
[]

Neuroendocrine B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
sumatriptan O
. O
['Physiological-Clinical']

Antihypertensive O
therapy O
resulted O
in O
significant O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
reduction O
( O
p O
less O
than O
.01 O
) O
. O
['Physiological-Clinical']

Whilst O
the O
Triple O
P O
Positive O
Parenting O
Program O
has O
a O
large O
evidence O
base O
( O
Sanders O
, O
Clinical O
Child O
and O
Family O
Psychology O
Review O
2:71-90 O
, O
1999 O
; O
Sanders O
, O
Journal O
of O
Consulting O
and O
Clinical O
Psychology O
68:624-640 O
, O
2000 O
) O
and O
preliminary O
evidence O
indicates O
that O
Stepping O
Stones O
Triple O
P O
is O
also O
efficacious O
( O
Roberts O
, O
Journal O
of O
Clinical O
Child O
and O
Adolescent O
Psychology O
, O
35 O
( O
2 O
) O
:180-193 O
, O
2006 O
) O
, O
to O
date O
Stepping O
Stones O
has O
not O
been O
evaluated O
with O
the O
ASD O
population O
. O
[]

METHODS/DESIGN O
This O
randomised O
, O
controlled O
, O
equivalence O
trial O
conducted O
at O
two O
centres O
will O
recruit O
166 O
individuals O
with O
spirometrically O
confirmed O
COPD O
. O
[]

RELEVANCE O
TO O
CLINICAL O
PRACTICE O
When O
administering O
subcutaneous O
heparin O
injections O
, O
it O
is O
important O
to O
extend O
the O
duration O
of O
the O
injection O
. O
[]

RESULTS O
Baseline O
BCVA O
( O
logMAR O
) O
and O
CMT O
were O
, O
respectively O
, O
0.89 O
+/- O
0.13 O
and O
650 O
+/- O
140 O
microm O
for O
the O
GLP O
group O
, O
0.87 O
+/- O
0.16 O
and O
690 O
+/- O
120 O
microm O
for O
the O
IB O
group O
. O
[]

Blood O
samples O
were O
drawn O
before O
anesthesia O
, O
after O
intubation O
, O
5 O
times O
during O
surgery O
and O
at O
the O
end O
of O
the O
operation O
and O
were O
analysed O
for O
cortisol O
and O
glucose O
. O
[]

These O
findings O
support O
advancing O
the O
present O
sirolimus O
formulation O
into O
phase O
II O
studies O
. O
[]

RESULTS O
Clonidine O
, O
as O
compared O
with O
placebo O
, O
did O
not O
reduce O
the O
number O
of O
primary-outcome B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( O
367 O
and O
339 O
, O
respectively O
; O
hazard O
ratio O
with O
clonidine O
, O
1.08 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.93 O
to O
1.26 O
; O
P=0.29 O
) O
. O
['Physiological-Clinical']

Thrombolysis O
has O
been O
proven O
to O
reduce O
mortality O
in O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
and O
it O
has O
been O
shown O
able O
to O
induce O
recanalisation B-outcome ['Resource-use']
when O
administered O
to O
acute O
stroke O
patients O
. O
['Physiological-Clinical', 'Resource-use']

CONCLUSION O
The O
long-term O
administration O
of O
warfarin O
therapy O
when O
combined O
with O
aspirin O
therapy O
has O
only O
a O
few O
selected O
indications O
for O
improvement O
of O
bypass O
patency O
and O
is O
associated O
with O
an O
increased O
risk O
of O
morbidity B-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

3 O
The O
overall O
incidence O
of O
side-effects B-outcome ['Adverse-effects']
was O
similar O
with O
atenolol O
, O
metoprolol O
and O
pindolol O
but O
was O
slightly O
less O
with O
labetalol O
. O
['Adverse-effects']

Speech O
audiometry O
was O
performed O
under O
four O
different O
conditions O
: O
headset O
only O
, O
and O
three O
different O
ear O
plugs O
worn O
under O
the O
headset O
. O
[]

However O
, O
the O
[]

Students O
were O
assessed O
at O
the O
beginning O
and O
end O
of O
the O
academic O
year O
using O
the O
Differential O
Ability O
Scales O
. O
[]

Myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
occurred O
in O
329 O
patients O
( O
6.6 O
% O
) O
assigned O
to O
clonidine O
and O
in O
295 O
patients O
( O
5.9 O
% O
) O
assigned O
to O
placebo O
( O
hazard O
ratio O
, O
1.11 O
; O
95 O
% O
CI O
, O
0.95 O
to O
1.30 O
; O
P=0.18 O
) O
. O
['Physiological-Clinical']

RESULTS O
The O
number O
of O
matched O
pairs O
varied O
between O
seven O
and O
eight O
, O
and O
the O
required O
number O
of O
children O
per O
treatment O
group O
ranged O
from O
32 O
in O
the O
case O
of O
bone O
heath O
to O
177 O
for O
body O
weight O
. O
[]

Systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
fell O
significantly O
, O
as O
did O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
noradrenaline I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PARTICIPANTS O
Patients O
( O
N=126 O
) O
were O
randomized O
into O
either O
a O
combined O
strength O
training O
and O
stretching O
group O
( O
STG O
, O
n=65 O
) O
or O
a O
control O
group O
( O
CG O
, O
n=61 O
) O
. O
[]

At O
the O
end O
of O
the O
study O
, O
87 O
% O
of O
patients O
said O
that O
they O
would O
take O
the O
medication O
again O
, O
and O
at O
each O
clinic O
visit O
over O
80 O
% O
said O
that O
they O
found O
the O
injector O
easy O
to O
use O
. O
[]

Among O
women O
with O
fewer O
than O
six O
menses O
per O
year O
, O
the O
cumulative O
ovulation O
rates O
over O
three O
cycles O
were O
comparable O
in O
the O
anastrozole O
5 O
mg O
( O
52.4 O
% O
) O
and O
CC O
50 O
mg/d O
( O
42.3 O
% O
) O
groups O
. O
[]

The O
influence O
of O
rTMS O
over O
the O
left O
dorsolateral O
prefrontal O
cortex O
on O
Stroop O
task O
performance O
. O
[]

In O
addition O
we O
investigate O
whether O
there O
is O
an O
increase O
in O
the O
cardiovascular O
metabolism O
in O
persons O
performing O
supervised O
Nordic O
Walking O
compared O
to O
persons O
who O
are O
advised O
to O
stay O
active O
. O
[]

However O
, O
periodic O
endometrial O
biopsies O
are O
required O
to O
monitor O
the O
endometrial O
response O
of O
women O
receiving O
high O
doses O
of O
estrogens O
. O
[]

Spot O
urine O
samples O
were O
collected O
preoperatively O
, O
postoperatively O
, O
after O
3 O
months O
, O
and O
after O
1 O
, O
2 O
, O
and O
5 O
years O
and O
tested O
with O
inductively O
coupled O
plasma-sector O
field O
mass O
spectrometry O
. O
[]

Nucleotides O
added O
to O
milk-based O
formula O
benefit O
infant O
immune O
status O
, O
but O
reports O
of O
the O
immunologic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
adding O
nucleotides O
to O
soy-based O
formula O
are O
not O
available O
. O
['Physiological-Clinical']

The O
effect O
of O
venlafaxine O
on O
unawareness B-outcome ['Life-Impact']
of O
['Life-Impact']

Twenty-six O
responding O
( O
biochemical/clinical O
) O
patients O
were O
randomised O
to O
discontinue O
cytotoxics O
after O
6 O
months O
and O
move O
to O
maintenance O
hormones O
( O
n O
= O
13 O
) O
or O
continue O
chemotherapy O
whilst O
the O
biochemical O
markers O
kept O
falling O
or O
remained O
within O
the O
normal O
range O
. O
[]

Epidural O
block O
was O
performed O
with O
75 O
microg O
clonidine O
( O
n O
= O
20 O
) O
or O
50 O
microg O
fentanyl O
( O
n O
= O
21 O
) O
combined O
with O
0.125 O
% O
bupivacaine O
( O
10 O
mL O
) O
. O
[]

There O
were O
no O
differences O
in O
WORC O
or O
ASES O
scores O
between O
the O
groups O
that O
had O
arthroscopic O
cuff O
repair O
with O
or O
without O
acromioplasty O
at O
any O
time O
point O
. O
[]

The O
erbium O
, O
chromium O
: O
yttrium-scandium-gallium-garnet O
, O
or O
Er O
, O
Cr O
: O
YSGG O
, O
laser O
system O
used O
in O
conjunction O
with O
an O
air-water O
spray O
has O
been O
shown O
to O
be O
efficacious O
in O
vitro O
for O
cavity O
preparation O
. O
[]

Using O
skin O
temperature O
as O
a O
criterion O
of O
sympathetic O
blockade O
, O
all O
three O
mixtures O
demonstrated O
a O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
intermediate O
between O
the O
two O
single O
drugs O
, O
lidocaine O
( O
124 O
+/- O
13 O
min O
) O
and O
bupivacaine O
( O
286 O
+/- O
32 O
min O
) O
. O
['Physiological-Clinical']

Assessments O
were O
made O
at O
baseline O
and O
on O
Day O
10 O
of O
each O
period O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
assess O
the O
role O
of O
tissue O
factor O
and O
serum-induced O
cell O
invasion O
in O
patients O
with O
advanced B-outcome ['Physiological-Clinical']
pancreatic I-outcome ['Physiological-Clinical']
cancer B-outcome ['Physiological-Clinical']
( O
APC O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Logistic O
regression O
analysis O
was O
used O
to O
estimate O
the O
association O
of O
admission O
BNP O
with O
development O
of O
CI-AKI O
. O
[]

RESULTS O
Parent O
education O
and O
behaviour O
management O
resulted O
in O
significant O
improvement O
in O
adaptive B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
and O
autism B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
at O
6 O
months O
follow-up O
for O
children O
with O
greater O
delays O
in O
adaptive B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

In O
comparison O
with O
normal O
controls O
, O
the O
myeloma O
patients O
exhibited O
a O
marked O
heterogeneity O
in O
the O
number O
of O
circulating O
CD19+ B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
as O
detected O
by O
flow O
cytometry O
. O
['Physiological-Clinical']

The O
two O
groups O
were O
similar O
at O
baseline O
( O
D0 O
) O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
in O
a O
prospective O
trial O
AV O
conduction O
during O
the O
long-term O
follow-up O
of O
patients O
with O
sick O
sinus O
syndrome O
. O
[]

Regardless O
of O
outcome O
, O
there O
was O
no O
change O
in O
APC B-outcome ['Physiological-Clinical']
at O
the O
end O
of O
a O
6-month O
course O
of O
interferon O
treatment O
. O
['Physiological-Clinical']

Stentless O
( O
Freestyle O
, O
Toronto O
, O
n O
= O
106 O
) O
or O
conventional O
biological O
aortic O
valves O
( O
Carpentier-Edwards O
, O
n O
= O
74 O
) O
were O
evaluated O
prospectively O
. O
[]

CONCLUSION O
A O
structured O
, O
multicomponent O
skills O
training O
intervention O
that O
targeted O
CG O
self-care O
behaviors O
as O
one O
of O
five O
target O
areas O
, O
improved O
self-reported B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
, O
and O
decreased O
burden B-outcome ['Life-Impact']
and O
bother O
in O
racially O
and O
ethnically O
diverse O
CGs O
of O
people O
with O
dementia O
. O
['Life-Impact', 'Life-Impact']

Untreated O
controls O
at O
the O
2 O
intervals O
showed O
a O
mean O
decrease O
in O
sensitivity B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
cold I-outcome ['Physiological-Clinical']
of O
3.6 O
degrees O
C O
and O
4.1 O
degrees O
C. O
Statistical O
analysis O
showed O
type O
of O
composite O
cement O
to O
be O
a O
significant O
factor O
. O
['Physiological-Clinical']

Outcomes O
evaluated O
over O
a O
12-month O
period O
included O
: O
self-reported O
measures O
of O
back B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
back O
pain O
disability O
level O
, O
physical O
health O
, O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
, O
and O
administrative O
measures O
of O
recurrence O
, O
lost O
work O
time O
, O
and O
medical O
care O
utilization O
. O
['Physiological-Clinical', 'Life-Impact']

OBJECTIVES O
To O
evaluate O
the O
effect O
of O
sperm O
treatment O
with O
exogenous O
platelet-activating O
factor O
( O
PAF O
) O
on O
intrauterine O
insemination O
( O
IUI O
) O
clinical O
pregnancy O
rate O
in O
cases O
of O
mild O
male O
factor O
infertility O
. O
[]

Moreover O
, O
vitamin O
D O
status O
, O
measured O
by O
25 O
( O
OH O
) O
D O
in O
plasma O
, O
interacts O
with O
the O
VDR O
FokI O
polymorphism O
and O
modifies O
prostate O
cancer O
risk O
. O
[]

Baseline O
CRP O
was O
significantly O
inversely O
associated O
with O
the O
baseline O
25 O
[]

RESULTS O
Simvastatin O
lowered O
MSNA B-outcome ['Physiological-Clinical']
burst I-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
( O
from O
32?12 O
to O
25?9 O
bursts/min O
) O
and O
MSNA B-outcome ['Physiological-Clinical']
burst I-outcome ['Physiological-Clinical']
incidence I-outcome ['Physiological-Clinical']
( O
from O
55?23 O
% O
to O
43?17 O
% O
; O
all O
p O
< O
0.01 O
) O
without O
affecting O
BP B-outcome ['Physiological-Clinical']
, O
HR B-outcome ['Physiological-Clinical']
, O
baroreflex B-outcome ['Physiological-Clinical']
modulation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
either I-outcome ['Physiological-Clinical']
MSNA I-outcome ['Physiological-Clinical']
or O
HR B-outcome ['Physiological-Clinical']
, O
or O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

33.6 O
cm/cm? O
in O
CECC O
group O
versus O
217.8 O
? O
[]

RESULTS O
Of O
the O
95 O
randomized O
patients O
, O
88 O
( O
93 O
% O
) O
completed O
the O
study O
. O
[]

Communication B-outcome ['Life-Impact']
and O
language B-outcome ['Life-Impact']
were O
assessed O
at O
study O
entry O
and O
6 O
, O
9 O
, O
and O
12 O
months O
later O
. O
['Life-Impact', 'Life-Impact']

Finite O
element O
( O
FE O
) O
modelling O
has O
been O
proposed O
as O
a O
tool O
for O
estimating O
fracture B-outcome ['Physiological-Clinical']
risk O
and O
patient-specific O
FE O
models O
are O
commonly O
based O
on O
computed O
tomography O
( O
CT O
) O
. O
['Physiological-Clinical']

Interventional O
study O
to O
strengthen O
the O
health O
promoting O
behaviours O
of O
pregnant O
women O
to O
prevent O
anaemia O
in O
southern O
India O
. O
[]

A O
simple O
test O
of O
blood O
coagulability O
was O
used O
to O
assess O
whether O
an O
adequate O
neutralizing O
dose O
of O
antivenom O
had O
been O
given O
. O
[]

Five O
hundred O
and O
sixty-nine O
alcoholics O
were O
included O
in O
a O
double-blind O
placebo-controlled O
randomized O
multicenter O
study O
of O
the O
effects O
of O
Acamprosate O
( O
calcium O
acetylhomotaurinate O
( O
CA O
) O
, O
1.3 O
g/day O
) O
on O
indicators O
of O
alcoholic O
relapse O
after O
withdrawal O
. O
[]

Our O
data O
show O
that O
succinate O
sumatriptan O
can O
be O
used O
with O
safety O
in O
patients O
without O
hypertension O
and O
other O
cardiovascular O
disease O
. O
[]

METHOD O
307 O
schizophrenia O
subjects O
in O
their O
first O
episode O
of O
illness O
were O
recruited O
to O
participate O
in O
a O
clinical O
trial O
comparing O
the O
long-term O
efficacy O
of O
haloperidol O
and O
risperidone O
. O
[]

The O
first O
contribution O
is O
a O
new O
red O
lesion O
candidate O
detection O
system O
based O
on O
pixel O
classification O
. O
[]

Findings O
were O
not O
affected O
by O
endometriosis B-outcome ['Physiological-Clinical']
scores O
noted O
on O
screening O
laparoscopy O
. O
['Physiological-Clinical']

In O
the O
patients O
treated O
with O
the O
active O
drug O
significant O
reductions O
in O
blood B-outcome ['Physiological-Clinical']
triglycerides I-outcome ['Physiological-Clinical']
were O
obtained O
, O
with O
a O
trend O
to O
normal O
. O
['Physiological-Clinical']

Thirty-six O
healthy O
patients O
were O
randomized O
to O
participate O
in O
a O
crossover O
trial O
of O
either O
Lightwand O
or O
GlideScope O
to O
Macintosh O
laryngoscopy O
, O
with O
in-line O
stabilization O
. O
[]

RESULTS O
There O
were O
no O
statistically O
significant O
differences O
between O
the O
pharmacokinetic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
netilmicin I-outcome ['Physiological-Clinical']
( O
volume O
of O
distribution O
, O
elimination O
half-life B-outcome ['Physiological-Clinical']
, O
clearance B-outcome ['Physiological-Clinical']
) O
in O
critically O
ill O
neonates O
> O
32 O
weeks O
during O
the O
first O
week O
of O
life O
that O
received O
either O
fluid O
therapy O
or O
parenteral O
nutrition O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

To O
assess O
adherence B-outcome ['Life-Impact']
to O
medication B-outcome ['Resource-use']
and O
HRQOL B-outcome ['Life-Impact']
, O
the O
Morisky O
test O
and O
the O
EuroQoL O
questionnaire O
were O
administered O
. O
['Life-Impact', 'Resource-use', 'Life-Impact']

AIM O
To O
compare O
patient O
triggered O
, O
with O
conventional O
fast O
rate O
, O
ventilation O
in O
a O
randomised O
controlled O
trial O
using O
the O
incidence O
of O
chronic B-outcome ['Physiological-Clinical']
lung I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
as O
the O
primary O
outcome O
measure O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
the O
results O
of O
the O
two O
visits O
neither O
with O
the O
VAS O
nor O
with O
the O
SGRQ O
on O
the O
QoL B-outcome ['Life-Impact']
['Life-Impact']

Amonafide O
is O
a O
new O
imide O
derivative O
of O
naphthalic O
acid O
. O
[]

Patients O
were O
randomly O
assigned O
to O
begin O
with O
gabapentin O
( O
1200 O
mg O
daily O
) O
or O
vigabatrin O
( O
2000 O
mg O
daily O
) O
. O
[]

BACKGROUND O
AND O
PURPOSE O
Previous O
studies O
have O
shown O
that O
repeated O
sensory O
inputs O
could O
enhance O
brain B-outcome ['Physiological-Clinical']
plasticity I-outcome ['Physiological-Clinical']
and O
cortical B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eliminating O
the O
causes O
of O
pain O
has O
a O
clear O
advantage O
over O
symptomatic O
treatment O
using O
analgetics O
, O
a O
fact O
worth O
a O
good O
consideration O
especially O
with O
the O
post-operative O
sojourn O
at O
the O
hospital O
becoming O
shorter O
and O
shorter O
. O
[]

Cataracts B-outcome ['Physiological-Clinical']
were O
extracted O
in O
93 O
% O
of O
phakic O
implanted O
eyes O
vs O
20 O
% O
of O
phakic O
nonimplanted O
eyes O
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical']

RESULTS O
Of O
the O
469 O
patients O
, O
255 O
( O
54.4 O
% O
) O
were O
female O
and O
214 O
( O
45.6 O
% O
) O
were O
male O
. O
[]

Esomeprazole O
was O
associated O
with O
a O
significantly O
shorter O
mean O
time O
to O
first O
( O
6-7 O
days O
) O
and O
sustained O
( O
12-17 O
days O
) O
resolution B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
compared O
with O
placebo O
( O
first O
, O
10-12 O
days O
; O
sustained O
, O
21-22 O
days O
; O
P O
< O
or O
= O
0.008 O
) O
. O
['Physiological-Clinical']

On O
the O
seventh O
day O
an O
exercise B-outcome ['Physiological-Clinical']
ECG I-outcome ['Physiological-Clinical']
of O
standardized O
level O
and O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
exercise I-outcome ['Life-Impact']
was O
recorded O
. O
['Physiological-Clinical', 'Life-Impact']

Should O
insertion O
of O
intramedullary O
nails O
for O
tibial O
fractures O
be O
with O
or O
without O
reaming O
? O
[]

A O
cooperative O
randomized O
controlled O
study O
of O
bestatin O
immunotherapy O
in O
combination O
with O
remission O
maintenance O
chemotherapy O
for O
adult O
acute O
nonlymphocytic O
leukemia O
( O
ANLL O
) O
was O
performed O
. O
[]

4 O
cm O
in O
diameter O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
15 O
patients O
were O
treated O
with O
PLA O
, O
using O
a O
multifibre O
system O
connected O
to O
a O
neodymium O
yttrium-aluminium-garnet O
laser O
source O
; O
15 O
patients O
were O
treated O
with O
RFA O
, O
using O
an O
expandable O
needle O
electrode O
. O
[]

Repeated-measures O
analysis O
of O
variance O
revealed O
that O
our O
supplementation O
regimen O
significantly O
improved O
Aberrant O
Behavior O
Checklist-Community-measured O
social B-outcome ['Life-Impact']
withdrawal I-outcome ['Life-Impact']
and O
Social O
Responsiveness O
Scale-measured O
communication B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Albendazole O
trial O
at O
15 O
or O
30 O
mg/kg/day O
for O
subarachnoid O
and O
intraventricular O
cysticercosis O
. O
[]

BDDrFVIII O
( O
ReFacto O
) O
has O
been O
developed O
with O
the O
additional O
benefit O
of O
being O
formulated O
without O
human O
albumin O
. O
[]

Baseline O
characteristics O
of O
participants O
in O
the O
Appropriate O
Blood O
Pressure O
Control O
in O
Diabetes O
trial O
. O
[]

The O
potential O
preventive O
value O
of O
a O
short O
programme O
based O
upon O
the O
principles O
of O
AT O
should O
be O
assessed O
in O
future O
, O
randomised O
, O
clinical O
trials O
. O
[]

CONCLUSIONS O
The O
enhanced O
conditions O
failed O
to O
[]

OBJECTIVE O
Ursodeoxycholic O
acid O
( O
UDCA O
) O
improves O
liver B-outcome ['Physiological-Clinical']
biochemistries I-outcome ['Physiological-Clinical']
and O
enriches O
the O
bile O
with O
UDCA O
in O
patients O
with O
primary O
biliary O
cirrhosis O
. O
['Physiological-Clinical']

Finally O
, O
the O
article O
presents O
the O
analysis O
plan O
for O
the O
study O
and O
discusses O
study O
limitations O
. O
[]

In O
this O
study O
, O
an O
Er O
, O
Cr O
: O
YSGG O
laser O
has O
been O
shown O
to O
be O
effective O
for O
cavity O
preparation O
and O
restoration O
replacement O
. O
[]

The O
addition O
of O
inflammatory O
markers O
improves O
the O
discriminatory O
value O
of O
the O
prognostic O
classification O
as O
compared O
with O
established O
factors O
alone O
( O
C-statistic O
0.673 O
vs O
0.654 O
, O
P=0.002 O
for O
the O
difference O
) O
, O
with O
25.8 O
% O
( O
P=0.004 O
) O
of O
patients O
more O
appropriately O
classified O
using O
the O
new O
classification O
. O
[]

CONCLUSION O
The O
results O
of O
LESS O
should O
facilitate O
the O
development O
of O
algorithms O
for O
programming O
ICD O
[]

OBJECTIVES O
Radiotherapy O
may O
cause O
severe O
skin O
changes O
that O
significantly O
interfere O
with O
the O
patient O
's O
quality O
of O
life O
and O
reduce O
radiotherapy O
effectiveness O
. O
[]

CONCLUSIONS O
The O
novel O
syncope O
unit O
designed O
for O
this O
study O
significantly O
improved O
diagnostic B-outcome ['Life-Impact']
yield I-outcome ['Life-Impact']
in O
the O
emergency O
department O
and O
reduced O
hospital B-outcome ['Resource-use']
admission I-outcome ['Resource-use']
and O
total O
length O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
without O
affecting O
recurrent O
syncope O
and O
all-cause O
mortality B-outcome ['Mortality']
among O
intermediate-risk O
patients O
. O
['Life-Impact', 'Resource-use', 'Resource-use', 'Mortality']

Timolol O
reduced O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
cardiovascular B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
at O
both O
administration O
times O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
pre- O
, O
intra- O
and O
postoperative O
relevant O
data O
of O
all O
selected O
patients O
were O
analyzed O
. O
[]

In O
contrast O
, O
when O
the O
same O
amount O
of O
insulin O
was O
delivered O
intermittently O
, O
arginine-induced B-outcome ['Physiological-Clinical']
glucagon I-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
was O
greatly O
reduced O
. O
['Physiological-Clinical']

Patients O
were O
ASA O
I-III O
, O
over O
55 O
years O
of O
age O
and O
randomly O
assigned O
to O
two O
groups O
to O
receive O
5 O
% O
prilocaine O
( O
1 O
mg/kg O
, O
n O
= O
27 O
) O
or O
2 O
% O
mepivacaine O
( O
0.8 O
mg/kg O
, O
n O
= O
30 O
) O
. O
[]

Some O
case O
reports O
mention O
that O
Spironolactone O
, O
a O
mineral O
corticoid O
antagonist O
and O
aldosterone O
antagonist O
, O
reduces O
binging B-outcome ['Life-Impact']
in O
patients O
with O
bulimia O
nervosa O
. O
['Life-Impact']

Autonomic O
function O
was O
assessed O
by O
power O
spectral O
analysis O
and O
RR-variation O
during O
deep O
breathing O
[ O
i.e O
. O
[]

The O
treatment O
of O
gastrointestinal B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
was O
studied O
in O
20 O
phase O
I O
, O
II O
, O
and O
III O
clinical O
trials O
from O
1979 O
to O
1983 O
at O
30 O
member O
institutions O
of O
the O
Southeastern O
Cancer O
Study O
Group O
( O
SECSG O
) O
. O
['Physiological-Clinical']

Rett O
syndrome O
: O
randomized O
controlled O
trial O
of O
L-carnitine O
. O
[]

AIDS O
Clinical O
Trials O
Group O
Protocol O
021 O
. O
[]

RESULTS O
In O
OA O
, O
the O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
for O
overweight O
patients O
was O
significantly O
longer O
than O
that O
for O
patients O
in O
the O
normal O
weight O
range O
( O
40 O
vs O
35 O
min O
, O
p O
< O
0.05 O
) O
. O
['Life-Impact']

Blind O
evaluation O
of O
fluorescein B-outcome ['Resource-use']
angiograms I-outcome ['Resource-use']
performed O
three O
monthly O
showed O
progression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
retinopathy I-outcome ['Physiological-Clinical']
in O
the O
control O
group O
, O
transient O
deterioration O
in O
the O
continuous O
infusion O
group O
, O
and O
no O
change O
in O
the O
multiple O
injection O
group O
. O
['Resource-use', 'Physiological-Clinical']

12 O
% O
. O
[]

Effects O
of O
a O
videotape O
information O
intervention O
at O
discharge O
on O
diet O
and O
exercise O
compliance O
after O
coronary O
bypass O
surgery O
. O
[]

103 O
senile O
hypertensive O
patients O
without O
depression O
in O
the O
same O
period O
served O
as O
controls O
. O
[]

In O
each O
cohort O
, O
eight O
subjects O
were O
randomized O
to O
receive O
N7-GP O
( O
n O
= O
6 O
) O
or O
placebo O
( O
n O
= O
2 O
) O
. O
[]

METHODS O
Three O
randomized O
, O
placebo-controlled O
, O
phase-3 O
trials O
were O
conducted O
in O
patients O
with O
stages O
3 O
and O
4 O
CKD O
with O
SHPT O
. O
[]

RESULTS O
The O
analysis O
included O
1,137 O
patients O
. O
[]

These O
measures O
offer O
potential O
therapeutic O
targets O
for O
improving O
early O
outcome O
after O
acute O
ischemic O
stroke O
. O
[]

This O
successful O
use O
of O
a O
population-based O
cancer O
registry O
illustrates O
an O
efficient O
recruitment O
method O
which O
could O
be O
modified O
for O
other O
cancer O
control/chemoprevention O
trials O
. O
[]

Aspartate O
amino O
transferase O
and O
alanine O
amino O
transferase O
did O
not O
change O
, O
indicating O
that O
the O
intervention O
was O
safe O
. O
[]

Combined O
treatment O
( O
traditional O
therapy O
plus O
electrostimulation O
) O
resulted O
in O
a O
significant O
reduction O
in O
duration O
of O
the O
main B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of O
the O
gastric O
ulcer O
depending O
on O
the O
severity O
of O
ulceration O
process O
, O
patients O
' O
age O
and O
sex O
. O
['Physiological-Clinical']

RESULTS O
There O
was O
no O
significant O
difference O
in O
imaging B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
and O
side O
effects O
between O
the O
contrast O
media O
. O
['Life-Impact']

Effect O
sizes O
suggest O
that O
the O
HIV O
intervention O
also O
reduced O
several O
risk O
behaviors B-outcome ['Life-Impact']
( O
e.g. O
, O
vaginal B-outcome ['Life-Impact']
sex I-outcome ['Life-Impact']
without O
a O
condom B-outcome ['Life-Impact']
, O
giving B-outcome ['Life-Impact']
oral I-outcome ['Life-Impact']
sex I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Solid O
core O
filling O
material O
such O
as O
gutta-percha O
has O
been O
used O
to O
fill O
the O
root O
canal O
in O
conjunction O
with O
a O
sealer O
to O
prevent O
apical O
leakage O
. O
[]

Reaching O
out O
, O
inviting O
back O
: O
using O
Interactive O
voice O
response O
( O
IVR O
) O
technology O
to O
recycle O
relapsed O
smokers O
back O
to O
Quitline O
treatment O
-- O
a O
randomized O
controlled O
trial O
. O
[]

Effects O
of O
four O
dose O
levels O
of O
MPH O
on O
parent O
and O
teacher O
behavioral B-outcome ['Life-Impact']
ratings O
were O
investigated O
using O
a O
within-subject O
, O
crossover O
, O
placebo-controlled O
design O
. O
['Life-Impact']

CONCLUSION O
Among O
patients O
who O
remained O
on O
warfarin O
, O
those O
who O
mostly O
were O
maintained O
in O
sinus O
rhythm O
under O
a O
rhythm-control O
strategy O
did O
not O
have O
a O
superior O
prognosis O
compared O
to O
those O
who O
remained O
in O
AF O
under O
a O
rate-control O
strategy O
. O
[]

Comparative O
bioavailability B-outcome ['Physiological-Clinical']
of O
two O
formulations O
of O
terbinafine O
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
collected O
at O
the O
start O
and O
end O
of O
the O
experimental O
phase O
for O
fatty O
acid O
analysis O
of O
total O
plasma O
phospholipid O
fraction O
. O
['Physiological-Clinical']

OBJECTIVE O
Compare O
the O
increase O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
adults O
after O
0.9 O
vs. O
1.2 O
mg O
of O
atropine O
plus O
neostigmine O
2.5 O
mg O
as O
the O
non-depolarizing O
muscle O
relaxant O
reversal O
agent O
. O
['Physiological-Clinical']

The O
results O
are O
discussed O
with O
respect O
to O
the O
concept O
of O
illness B-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
as O
a O
setting O
event O
for O
problem O
behavior O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
64 O
( O
8 O
% O
) O
patients O
, O
ulcers B-outcome ['Physiological-Clinical']
failed I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
heal I-outcome ['Physiological-Clinical']
or O
there O
was O
no O
benefit O
from O
the O
operation O
. O
['Physiological-Clinical']

In O
our O
study O
, O
vWF O
and O
factor O
VIII B-outcome ['Physiological-Clinical']
: O
C B-outcome ['Physiological-Clinical']
levels O
increased O
while O
the O
bleeding B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
decreased O
significantly O
at O
90 O
min O
and O
24 O
h O
in O
both O
groups O
and O
, O
although O
vWF O
and O
factor O
VIII B-outcome ['Physiological-Clinical']
: O
C B-outcome ['Physiological-Clinical']
levels O
were O
slightly O
higher O
in O
desmopressin-treated O
patients O
at O
90 O
min O
, O
the O
difference O
was O
not O
significant O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Infliximab O
in O
ankylosing O
spondylitis O
: O
alone O
or O
in O
combination O
with O
methotrexate O
? O
[]

Effect O
of O
chronic O
aerobic O
exercise O
and O
progressive O
relaxation O
on O
motor O
performance O
and O
affect O
following O
acute O
stress O
. O
[]

CO O
inhalation O
led O
to O
trends O
in O
reduced O
sputum B-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
( O
median O
reduction O
0.25 O
% O
point O
) O
and O
['Physiological-Clinical']

Four O
clinician O
members O
of O
the O
American O
Academy O
of O
Family O
Physicians O
National O
Research O
Network O
participated O
by O
enrolling O
194 O
patients O
into O
a O
randomized O
patient O
trial O
and O
29 O
physicians O
into O
a O
non-randomized O
clinician O
trial O
of O
respective O
interventions O
. O
[]

In O
part O
II O
the O
subjects O
received O
80 O
mg O
+ O
8 O
mg/h O
during O
3 O
days O
followed O
by O
20 O
mg O
omeprazole O
orally O
, O
once O
or O
twice O
daily O
until O
day O
10 O
. O
[]

STUDY O
DESIGN O
A O
randomized O
controlled O
study O
with O
12 O
months O
intervention O
. O
[]

CONCLUSION O
YDJ O
played O
a O
role O
in O
clearing O
HR-HPV O
infection O
and O
reversing O
the O
cervical B-outcome ['Physiological-Clinical']
precancerous I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
possibly O
through O
down-regulating O
the O
mRNA O
expression O
of O
hTERT O
and O
lowering O
the O
telomerase O
activation O
. O
['Physiological-Clinical']

We O
concluded O
that O
the O
marginal O
clinical O
benefit O
of O
1 O
day O
earlier O
[]

CONCLUSION O
Unopposed O
17beta-estradiol O
reduced O
carotid B-outcome ['Physiological-Clinical']
IMT I-outcome ['Physiological-Clinical']
progression O
in O
postmenopausal O
women O
in O
part O
by O
increasing O
HDL-cholesterol B-outcome ['Physiological-Clinical']
and O
decreasing O
LDL-cholesterol B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

vs. O
5 O
% O
for O
b.i.d O
. O
) O
, O
[]

Plasma B-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
analyzed O
using O
a O
sensitive O
modification O
of O
radioreceptor O
assay O
. O
['Physiological-Clinical']

The O
empirical O
data O
collected O
within O
this O
trial O
will O
be O
useful O
in O
testing O
whether O
this O
theoretical-domain O
approach O
can O
improve O
our O
understanding O
of O
the O
implementation O
of O
TUPAC O
guidelines O
among O
dental O
providers O
. O
[]

Postoperatively O
, O
patients O
of O
group O
B O
showed O
lower O
levels O
of O
damage B-outcome ['Physiological-Clinical']
, O
indicating O
that O
direct O
aortic O
cannulation O
might O
provide O
better O
myocardial O
protection O
. O
['Physiological-Clinical']

In O
a O
prespecified O
analysis O
of O
the O
LIFE-study O
we O
compared O
the O
effects O
of O
losartan O
and O
atenolol O
on O
cardiovascular B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
in O
diabetic O
patients O
. O
['Physiological-Clinical', 'Mortality']

All O
practices O
participated O
in O
4 O
sessions O
of O
training O
, O
including O
didactic O
lectures O
and O
office O
flow O
modification O
workshops O
. O
[]

A O
comparison O
between O
the O
local O
injection O
of O
10 O
mg O
of O
depot O
dexamethasone O
combined O
with O
60 O
mg O
of O
lidocaine O
and O
5 O
mg O
of O
tropisetron O
showed O
that O
the O
two O
regimens O
had O
the O
same O
effect O
. O
[]

ClinicalTrials.gov O
number O
, O
NCT00394537 O
) O
. O
[]

BACKGROUND O
Proponents O
of O
single-incision O
laparoscopic O
surgery O
( O
SILS O
) O
claim O
patients O
have O
less O
pain O
, O
faster O
recovery O
, O
and O
better O
long-term O
cosmetic O
results O
than O
patients O
who O
undergo O
multiport O
laparoscopy O
. O
[]

Treadmill O
exercise O
testing O
with O
measurement O
of O
expired B-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
exchange I-outcome ['Physiological-Clinical']
and O
respiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
was O
performed O
before O
ablation O
and O
4 O
weeks O
after O
pacemaker O
implantation O
, O
with O
the O
pacemaker O
programmed O
to O
both O
the O
fixed-rate O
VVI O
and O
rate-modulating O
minute O
ventilation O
VVIR O
pacing O
modes O
in O
random O
sequence O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Compared O
with O
the O
randomly O
allocated O
placebo O
, O
the O
three O
active O
treatments O
significantly O
reduced O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
without O
changing O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
or O
body B-outcome ['Physiological-Clinical']
weight O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Formoterol O
Turbuhaler O
has O
as O
rapid O
an O
onset O
of O
action O
as O
salbutamol O
pMDI O
when O
given O
at O
the O
recommended O
doses O
. O
[]

However O
, O
other O
behavioral O
rating O
measures O
did O
not O
confirm O
this O
result O
. O
[]

A O
prospective O
, O
randomized O
, O
pilot O
study O
. O
[]

Atorvastatin O
reduced O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
TC B-outcome ['Physiological-Clinical']
) O
, O
LDL-C B-outcome ['Physiological-Clinical']
, O
and O
triglyceride B-outcome ['Physiological-Clinical']
levels O
by O
32 O
% O
( O
P O
< O
0.001 O
) O
, O
40.8 O
% O
( O
P O
< O
0.001 O
) O
, O
and O
19 O
% O
( O
P O
< O
0.001 O
) O
, O
respectively O
, O
and O
increased O
HDL-C B-outcome ['Physiological-Clinical']
by O
6.9 O
% O
, O
( O
P O
= O
0.002 O
) O
in O
the O
first O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
total O
, O
one O
or O
two O
migraine O
attacks O
were O
treated O
in O
268 O
and O
235 O
patients O
, O
respectively O
. O
[]

Anticholinergic O
drugs O
: O
effects O
on O
oxygen B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
and O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Association O
between O
frequency O
of O
ready-to-eat O
cereal O
consumption O
, O
nutrient O
intakes O
, O
and O
body O
mass O
index O
in O
fourth- O
to O
sixth-grade O
low-income O
minority O
children O
. O
[]

Single-use O
plaque O
removal O
efficacy O
of O
three O
power O
toothbrushes O
. O
[]

Including O
results O
obtained O
by O
second-look O
laparotomy O
, O
we O
did O
not O
observe O
a O
statistically O
significant O
difference O
in O
response O
rates O
in O
the O
two O
treatment O
groups O
. O
[]

In O
the O
28 O
that O
had O
been O
positioned O
, O
changes O
were O
found O
in O
only O
3 O
TMJs B-outcome ['Physiological-Clinical']
( O
11 O
% O
) O
postoperatively O
. O
['Physiological-Clinical']

Holter O
monitoring O
data O
were O
variable O
but O
showed O
no O
clinically O
meaningful O
differences O
between O
the O
formoterol O
and O
placebo O
groups O
, O
respectively O
, O
for O
variables O
such O
as O
( O
mean+/-SD O
at O
end O
of O
treatment O
) O
: O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
80+/-8.6 O
vs. O
80+/-10.6 O
bpm O
) O
, O
number O
and O
rate O
of O
ventricular B-outcome ['Physiological-Clinical']
premature I-outcome ['Physiological-Clinical']
beats I-outcome ['Physiological-Clinical']
( O
total O
732+/-2685.4 O
vs. O
650+/-2090.6 O
; O
rate O
35+/-131.0 O
vs. O
30+/-101.3 O
per O
h O
) O
, O
ventricular B-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( O
total O
0.4+/-1.70 O
vs. O
1.0+/-9.23 O
; O
rate O
0.02+/-0.082 O
vs. O
0.05+/-0.479 O
per O
h O
) O
, O
and O
supraventricular B-outcome ['Physiological-Clinical']
premature I-outcome ['Physiological-Clinical']
beats I-outcome ['Physiological-Clinical']
( O
total O
504+/-1844.1 O
vs. O
823+/-2961.8 O
; O
rate O
22+/-80.6 O
vs. O
37+/-129.6 O
per O
h O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
levels O
of O
the O
drugs O
were O
measured O
. O
['Physiological-Clinical']

Reduction O
in O
blood B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
was O
inconsistent O
and O
not O
significant O
. O
['Physiological-Clinical']

CONCLUSION O
The O
results O
of O
this O
study O
suggest O
that O
the O
triage O
process O
in O
this O
setting O
is O
strongly O
dependent O
on O
the O
provider O
's O
availability O
to O
assess O
, O
triage O
, O
and O
discharge O
patients O
. O
[]

Analysis O
using O
paired O
t-tests O
demonstrated O
a O
significant O
decrease O
in O
the O
SAI O
( O
p O
= O
0.10 O
) O
scores O
immediately O
following O
chemotherapy O
treatments O
when O
participants O
used O
VR O
. O
[]

Calving O
interval O
was O
not O
correlated O
( O
P O
> O
0.12 O
) O
with O
weekly O
measures O
of O
serum B-outcome ['Physiological-Clinical']
leptin I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
results O
suggest O
that O
iron O
added O
to O
follow O
on O
milk O
was O
not O
an O
important O
source O
of O
dietary O
iron O
in O
the O
infants O
studied O
. O
[]

SUMMARY O
OF O
BACKGROUND O
DATA O
An O
obvious O
gap O
exists O
in O
knowledge O
concerning O
long-term O
efficacy O
and O
cost-effectiveness O
of O
manipulative O
treatment O
methods O
. O
[]

In O
conclusion O
, O
PLP O
is O
a O
promising O
safe O
and O
effective O
procedure O
for O
treatment O
of O
benign O
thyroid O
nodules O
in O
patients O
at O
high O
surgical O
risk O
. O
[]

At O
baseline O
, O
64 O
% O
of O
the O
patients O
reported O
erectile B-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ED I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
63 O
% O
reported O
ejaculatory B-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EjD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Overall O
, O
a O
response O
rate O
of O
75 O
% O
was O
observed O
. O
[]

Other O
toxicities B-outcome ['Adverse-effects']
were O
minor O
and O
infrequent O
. O
['Adverse-effects']

The O
origin O
of O
sympathetic O
hyperactivity O
and O
its O
potential O
deleterious O
consequences O
require O
further O
study O
. O
[]

3.4 O
) O
( O
t O
= O
10.83 O
, O
P O
< O
0.05 O
) O
. O
[]

Effect O
of O
camel O
milk O
on O
thymus O
and O
activation-regulated O
chemokine O
in O
autistic O
children O
: O
double-blind O
study O
. O
[]

The O
above O
findings O
demonstrated O
that O
root O
planning O
is O
effective O
in O
the O
treatment O
of O
furcation O
involvement O
and O
that O
the O
effects O
are O
enhanced O
by O
the O
local O
administration O
of O
TC O
films O
. O
[]

There O
were O
fewer O
side-effects B-outcome ['Adverse-effects']
with O
tinidazole O
. O
['Adverse-effects']

Side O
effects O
from O
verapamil O
were O
minimal O
, O
consisting O
mainly O
of O
[]

Higher O
scores O
during O
the O
placebo O
period O
in O
the O
group O
given O
lansoprazole O
first O
than O
in O
the O
group O
given O
placebo O
first O
indicated O
a O
rebound O
aggravation O
of O
symptoms O
. O
[]

Follow-up O
data O
suggested O
that O
treatment O
gains O
were O
maintained O
by O
children O
at O
5-months O
post-intervention O
. O
[]

However O
, O
both O
EPL O
and O
LPL O
can O
minimize O
some O
postoperative O
complications O
reducing O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
. O
['Resource-use']

Survivors O
in O
the O
present O
analysis O
( O
n=729 O
) O
underwent O
two O
45- O
to O
60-minute O
telephone O
surveys O
, O
which O
included O
two O
24-hour O
dietary O
recalls O
. O
[]

Treatment O
of O
renal B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
associated O
with O
multiple O
myeloma O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVES O
Breakthrough O
cancer O
pain O
( O
BTcP O
) O
represents O
an O
important O
clinical O
challenge O
in O
the O
care O
of O
patients O
with O
cancer O
. O
[]

The O
control O
group O
( O
n O
= O
40 O
) O
followed O
standard O
CVC O
procedure O
provided O
by O
nurses O
. O
[]

In O
some O
patients O
on O
the O
nucleoside-sparing O
arm O
, O
the O
nucleoside-resistance O
mutation O
L74V O
was O
selected O
for O
in O
combination O
with O
the O
uncommonly O
occurring O
EFV-resistance O
mutations O
K103N+L100I O
; O
L74V O
was O
not O
detected O
as O
a O
minority O
variant O
, O
using O
clonal O
sequence O
analysis O
, O
when O
the O
nucleoside-sparing O
regimen O
was O
initiated O
. O
[]

However O
, O
for O
beneficiaries O
with O
CHF O
who O
resided O
in O
high-cost O
South O
Florida O
counties O
, O
the O
program O
reduced O
Medicare B-outcome ['Resource-use']
expenditures I-outcome ['Resource-use']
by O
9.6 O
percent O
. O
['Resource-use']

Photodynamic O
therapy O
( O
or O
sham O
PDT O
) O
was O
administered O
at O
Day O
0 O
and O
then O
quarterly O
as O
needed O
. O
[]

The O
1-year O
, O
2-year O
and O
3-year O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
71 O
% O
, O
54 O
% O
and O
44 O
% O
for O
the O
one-dose O
group O
and O
74 O
% O
, O
60 O
% O
and O
40 O
% O
for O
the O
four-dose O
group O
( O
P O
= O
0.78 O
) O
. O
['Mortality']

Forty-eight O
matched O
pairs O
of O
osteoarthritic O
knees O
from O
patients O
who O
underwent O
primary O
total O
knee O
arthroplasty O
with O
a O
round-on-round O
, O
Apollo O
Knee O
System O
were O
studied O
to O
evaluate O
the O
outcome O
between O
all-polyethylene O
and O
metal-backed O
tibial O
components O
. O
[]

BACKGROUND O
Groin O
pain O
is O
common O
among O
athletes O
. O
[]

There O
was O
no O
effect O
on O
plasma B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
influence O
of O
serum O
methotrexate O
concentrations O
and O
drug O
dosage O
on O
outcome O
in O
childhood O
acute O
lymphoblastic O
leukaemia O
. O
[]

[ O
Postoperative O
analgesia O
: O
peridural O
morphine O
versus O
sublingual O
buprenorphine O
. O
[]

Twenty-eight O
adult O
Malpura O
ewes O
were O
used O
in O
the O
present O
study O
. O
[]

CONCLUSIONS O
A O
sustained O
, O
multifaceted O
, O
community-level O
intervention O
was O
only O
modestly O
successful O
at O
decreasing O
overall B-outcome ['Life-Impact']
antibiotic I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
beyond O
substantial O
secular O
trends O
. O
['Life-Impact']

As O
compared O
to O
placebo O
, O
8 O
weeks O
of O
oral O
17beta-estradiol O
( O
2 O
mg O
daily O
) O
increased O
the O
mean O
fasting O
and O
postprandial O
plasma O
levels O
of O
total O
factor O
VII O
by O
17 O
and O
21 O
% O
points O
, O
respectively O
( O
both O
P O
< O
0.01 O
) O
, O
but O
did O
not O
affect O
the O
fasting O
and/or O
postprandial O
plasma O
levels O
of O
active O
factor O
VII O
( O
mean O
change O
both O
0.05 O
ng/mL O
; O
P O
> O
0.35 O
) O
. O
[]

TRIAL O
REGISTRATION O
umin.ac.jp/ctr O
Identifier O
: O
UMIN000002241 O
and O
UMIN000004393 O
. O
[]

METHODS O
After O
a O
baseline O
evaluation O
, O
patients O
were O
randomly O
assigned O
to O
4-month O
preoperative O
treatment O
with O
lanreotide O
( O
starting O
with O
30 O
mg/2 O
weeks O
i.m O
. O
[]

SETTING O
Inpatient O
anesthesia O
at O
a O
university O
department O
of O
orthopedic O
surgery O
. O
[]

The O
number O
of O
remissions B-outcome ['Physiological-Clinical']
, O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
and O
survival B-outcome ['Mortality']
were O
similar O
for O
the O
lithium O
treated O
and O
control O
groups O
of O
patients O
. O
['Physiological-Clinical', 'Mortality', 'Mortality']

Anorexics O
were O
randomly O
assigned O
to O
fluoxetine O
( O
n O
= O
16 O
) O
or O
a O
placebo O
( O
n O
= O
19 O
) O
after O
inpatient O
weight O
gain O
and O
then O
were O
observed O
as O
outpatients O
for O
1 O
year O
. O
[]

Effect O
of O
m-chlorophenylpiperazine O
on O
plasma O
homovanillic O
acid O
concentrations O
in O
healthy O
subjects O
. O
[]

Half O
of O
the O
preschoolers O
experienced O
side O
effects O
with O
MPH O
, O
including O
reports O
of O
increased O
stereotypic B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
, O
['Life-Impact']

The O
primary O
endpoint O
for O
the O
first O
treated O
attack O
was O
headache O
relief O
, O
with O
intensity O
decreasing O
from O
moderate O
or O
severe O
to O
mild O
or O
absent O
2 O
h O
after O
drug O
intake O
. O
[]

Therapy O
with O
cardioselective O
beta-blockade O
may O
offer O
significant O
advantages O
in O
respiratory O
function O
for O
elderly O
people O
with O
glaucoma O
over O
non-selective O
drugs O
, O
even O
if O
they O
have O
sympathomimetic O
activity O
. O
[]

MEASUREMENTS O
Distance O
walked B-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
6 I-outcome ['Life-Impact']
minutes I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
sum I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
, O
and O
stiffness B-outcome ['Life-Impact']
subscores O
of O
the O
Western O
Ontario O
and O
McMaster O
Universities O
Osteoarthritis O
Index O
( O
WOMAC O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

These O
data O
were O
recorded O
and O
correlated O
with O
failure O
of O
osseointegration B-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
I I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
at O
stage B-outcome ['Resource-use']
II I-outcome ['Resource-use']
surgery I-outcome ['Resource-use']
( O
uncovering O
) O
. O
['Physiological-Clinical', 'Resource-use']

Clinically O
relevant O
improvement O
of O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
with O
5-aminolevulinic O
acid O
induced O
fluorescence O
diagnosis O
in O
patients O
with O
superficial O
bladder O
tumors O
. O
['Mortality']

Based O
on O
the O
results O
of O
this O
study O
it O
appears O
that O
lasalocid O
fed O
at O
the O
recommended O
rate O
of O
125 O
ppm O
is O
safe O
in O
Chinese O
ring-necked O
pheasants O
. O
[]

AIMS O
To O
estimate O
the O
cost-effectiveness O
of O
intravenous O
treatment O
with O
levosimendan O
compared O
with O
dobutamine O
in O
patients O
with O
severe O
low-output O
heart O
failure O
. O
[]

There O
is O
indirect O
evidence O
that O
agonists O
of O
peroxisome O
proliferator-activated O
receptor O
gamma O
( O
PPAR O
gamma O
) O
could O
reduce O
macrovascular B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
study O
aimed O
to O
ascertain O
whether O
such O
treatment O
might O
halt O
the O
progression O
of O
neovascular O
AMD O
and O
whether O
a O
low O
or O
a O
high O
radiation O
dose O
should O
be O
applied O
. O
[]

Intervention O
was O
unopposed O
micronized O
17beta-estradiol O
versus O
placebo O
. O
[]

However O
, O
retention O
of O
calcium B-outcome ['Physiological-Clinical']
, O
phosphorus B-outcome ['Physiological-Clinical']
( O
both O
formulas O
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
AND O
RESULTS O
Patients O
undergoing O
carotid O
endarterectomy O
were O
randomized O
in O
a O
double-blind O
manner O
between O
L-arginine O
( O
n=14 O
) O
, O
GSNO O
( O
n=14 O
) O
, O
or O
placebo O
( O
n=14 O
) O
administered O
intravenously O
for O
90 O
minutes O
, O
starting O
30 O
minutes O
after O
skin O
closure O
. O
[]

METHOD O
Of O
the O
200 O
women O
who O
agreed O
to O
participate O
in O
the O
project O
, O
100 O
were O
randomly O
allocated O
to O
the O
pilot O
scheme O
and O
100 O
to O
the O
traditional O
care O
package O
. O
[]

CONCLUSION O
Markers O
of O
systemic O
inflammation O
contribute O
significantly O
to O
prognostic O
classification O
in O
addition O
to O
established O
factors O
for O
pre-treated O
patients O
with O
advanced O
RCC O
. O
[]

Radiographic O
assessments O
of O
tumors O
were O
independently O
reviewed O
. O
[]

The O
effect O
of O
recombinant O
human O
erythropoietin O
( O
rHu-EPO O
) O
treatment O
. O
[]

The O
Sur-Catch O
NT O
was O
significantly O
slower O
for O
2 O
mm O
calculi O
than O
the O
N-Circle O
( O
p O
= O
0.01 O
) O
, O
Dimension O
( O
p O
=.03 O
) O
, O
Halo O
( O
p O
=.0005 O
) O
, O
Vantage O
( O
p O
=.001 O
) O
and O
Zerotip O
( O
p O
=.002 O
) O
. O
[]

In O
group O
B O
, O
they O
were O
unchanged O
during O
the O
same O
period O
but O
later O
suppressed O
by O
BF O
. O
[]

Forty-five O
Norwegian O
women O
were O
randomly O
included O
in O
the O
same O
period O
and O
38 O
( O
84 O
% O
) O
of O
these O
women O
participated O
. O
[]

Besides O
, O
20 O
mg/d O
fluoxetine O
was O
additionally O
given O
to O
groups O
A O
and O
one O
tablet O
of O
almitrine O
l/d O
and O
20 O
mg O
oryzanol O
3/d O
were O
given O
to O
group O
B O
. O
[]

The O
RSA O
test O
involved O
straight-line O
sprints O
, O
whereas O
the O
CODS O
test O
required O
a O
change O
of O
direction O
( O
100 O
degrees O
) O
every O
4 O
m O
( O
total O
of O
four O
) O
. O
[]

Therapeutic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
defined O
as O
greater O
than O
or O
equal O
to O
20 O
% O
reduction O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
less O
than O
100 O
bpm B-outcome ['Physiological-Clinical']
, O
or O
conversion B-outcome ['Physiological-Clinical']
to O
normal B-outcome ['Physiological-Clinical']
sinus I-outcome ['Physiological-Clinical']
rhythm B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
medication O
adherence O
measure O
proved O
to O
be O
reliable O
, O
with O
good O
concurrent O
and O
predictive O
validity O
in O
primarily O
low-income O
, O
minority O
patients O
with O
hypertension O
and O
might O
function O
as O
a O
screening O
tool O
in O
outpatient O
settings O
with O
other O
patient O
groups O
. O
[]

Treatment O
of O
hypertension O
with O
ascorbic O
acid O
. O
[]

OBJECTIVES O
To O
measure O
AMP O
recovery O
using O
a O
constant O
predetermined O
AMP O
PC20 O
and O
to O
evaluate O
whether O
fexofenadine O
use O
confers O
add-on O
effects O
to O
treatment O
with O
either O
fluticasone O
propionate O
alone O
or O
combined O
fluticasone O
propionate-salmeterol O
. O
[]

Measurements O
were O
performed O
on O
level O
of O
everyday B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
( O
PA O
, O
novel B-outcome ['Life-Impact']
accelerometry-based I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
monitor O
) O
and O
['Life-Impact', 'Life-Impact']

Considering O
only O
patients O
with O
tumors O
of O
the O
trunk O
( O
22 O
patients O
) O
, O
3-year O
actuarial O
disease-free O
survival O
in O
the O
chemotherapy O
arm O
was O
92 O
% O
, O
compared O
to O
47 O
% O
in O
the O
no-chemotherapy O
arm O
( O
P O
= O
0.006 O
) O
. O
[]

Clinical O
( O
11.9 O
% O
versus O
12.1 O
% O
) O
and O
ongoing O
( O
11.0 O
% O
versus O
8.6 O
% O
) O
pregnancy B-outcome ['Physiological-Clinical']
rates O
per O
randomized O
women O
were O
similar O
in O
the O
two O
groups O
and O
statistical O
non-inferiority O
of O
clinical O
and O
ongoing O
pregnancy O
rates O
was O
demonstrated O
. O
['Physiological-Clinical']

The O
recording O
device O
( O
Snore O
Box O
) O
is O
simple O
for O
the O
patient O
to O
operate O
, O
portable O
with O
a O
built O
in O
microphone O
, O
and O
able O
to O
produce O
objective O
results O
, O
which O
can O
be O
automatically O
analysed O
. O
[]

A O
double-blind O
, O
placebo-controlled O
trial O
of O
intravenous O
immunoglobulin O
therapy O
in O
patients O
with O
chronic O
fatigue O
syndrome O
. O
[]

A O
pooled O
analysis O
of O
eastern O
cooperative O
oncology O
group O
and O
intergroup O
trials O
of O
adjuvant O
high-dose O
interferon O
for O
melanoma O
. O
[]

Effect O
of O
food O
on O
the O
antiviral B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
of O
didanosine O
enteric-coated O
capsules O
: O
a O
pilot O
comparative O
study O
. O
['Physiological-Clinical']

At O
the O
stated O
times O
the O
increases O
in O
the O
maximum O
[]

In O
the O
placebo O
condition O
, O
sleep O
deprivation O
impaired O
PVT O
speed O
more O
in O
caffeine-sensitive O
than O
in O
caffeine-insensitive O
men O
. O
[]

A O
total O
of O
five O
hundred O
forty O
19-wk-old O
HyLine O
Brown O
hens O
were O
used O
to O
study O
the O
long-term O
effects O
of O
increasing O
choline O
with O
0 O
( O
control O
) O
, O
425 O
, O
850 O
, O
1,700 O
, O
3,400 O
, O
and O
6,800 O
mg/kg O
of O
corn-soybean O
meal-based O
diets O
on O
productive B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
egg I-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Can O
sedation O
reduce O
the O
cardiac O
stress O
during O
gastrointestinal O
endoscopy O
? O
[]

RESEARCH O
METHODS O
AND O
PROCEDURES O
This O
randomized O
pilot O
study O
tested O
an O
individualized O
approach O
toward O
weight O
loss B-outcome ['Physiological-Clinical']
in O
obese O
women O
who O
have O
had O
a O
diagnosis O
of O
breast O
cancer O
. O
['Physiological-Clinical']

A O
total O
of O
610 O
patients O
with O
small O
cell O
lung O
cancer O
were O
entered O
into O
a O
randomised O
trial O
designed O
to O
assess O
the O
effect O
of O
duration O
of O
initial O
chemotherapy O
on O
survival O
. O
[]

All O
participants O
received O
either O
placebo O
or O
caffeine O
( O
200 O
mg O
) O
, O
while O
the O
chewing O
condition O
also O
chewed O
on O
a O
tasteless O
and O
odorless O
substance O
for O
15 O
min O
each O
hour O
. O
[]

RESULTS O
In O
the O
first O
protocol O
, O
sites O
administered O
L-NAME O
showed O
significant O
reductions O
in O
CVC B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
following O
acupuncture O
stimulation O
compared O
to O
control O
sites O
( O
administered O
Ringer O
's O
solution O
) O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Effects O
of O
low-dose O
aspirin O
on O
clinic B-outcome ['Physiological-Clinical']
and O
ambulatory B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
treated O
hypertensive O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
- O
RECOMMENDATIONS O
FOR O
FURTHER O
RESEARCH O
: O
Further O
work O
is O
required O
to O
develop O
and O
test O
an O
educational O
package O
that O
educates O
patients O
and O
GPs O
about O
the O
utility O
of O
radiography O
and O
provides O
strategies O
for O
identifying O
and O
meeting O
the O
information O
needs O
of O
patients O
, O
and O
the O
needs O
of O
patients O
and O
GPs O
to O
be O
reassured O
about O
missing O
serious O
disease O
. O
[]

The O
roots O
, O
except O
for O
the O
apical O
2 O
mm O
, O
were O
coated O
with O
two O
layers O
of O
nail O
polish O
. O
[]

CONCLUSION O
The O
presently O
studied O
diphtheria O
, O
tetanus O
, O
acellular O
pertussis-H. O
influenzae O
b O
vaccine O
conjugated O
to O
tetanus O
toxoid O
combination O
was O
at O
least O
as O
immunogenic O
as O
the O
diphtheria O
, O
tetanus O
, O
whole O
cell O
pertussis-H. O
influenzae O
b O
vaccine O
conjugated O
to O
tetanus O
toxoid O
combination O
, O
with O
a O
significantly O
better O
safety O
profile O
. O
[]

In O
the O
present O
study O
, O
the O
influence O
of O
high-frequency O
rTMS O
over O
the O
left O
DLPFC O
on O
Stroop O
task O
performance O
in O
healthy O
female O
volunteers O
was O
investigated O
. O
[]

These O
results O
demonstrate O
the O
effectiveness O
of O
laser O
therapy O
in O
tendonitis O
of O
the O
shoulder O
. O
[]

Standard O
rapid-sequence O
intubation O
requires O
a O
nondepolarizing O
blocking O
agent O
before O
succinylcholine O
administration O
. O
[]

This O
study O
evaluated O
Children O
's O
Friendship O
Training O
( O
CFT O
) O
, O
a O
manualized O
parent-assisted O
intervention O
to O
improve O
social O
skills O
among O
second O
to O
fifth O
grade O
children O
with O
autism O
spectrum O
disorders O
. O
[]

CBT O
outperformed O
the O
waitlist O
condition O
at O
posttreatment/postwaitlist O
on O
total O
parent-reported O
autism B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
( O
Cohen O
's O
d O
effect O
size O
= O
.77 O
) O
. O
['Life-Impact']

OBJECTIVE O
Accurate O
and O
consistent O
outcome O
assessment O
is O
essential O
to O
randomized O
clinical O
trials O
. O
[]

Mask O
ventilation O
, O
full O
neuromuscular O
paralysis O
and O
direct O
laryngoscopy O
were O
performed O
. O
[]

Participants O
will O
be O
measured O
at O
7 O
weeks O
post-randomization O
, O
and O
followed-up O
at O
3 O
and O
6 O
months O
post-randomization O
. O
[]

Subjects O
with O
an O
imputed O
pertactin O
value O
of O
< O
7 O
EU O
ml-1 O
had O
a O
67 O
% O
( O
18/27 O
) O
chance O
of O
infection O
regardless O
of O
the O
PT O
value O
. O
[]

MWC B-outcome ['Physiological-Clinical']
showed O
a O
slight O
, O
insignificant O
decrease O
in O
both O
groups O
. O
['Physiological-Clinical']

CONCLUSIONS O
Posterior O
tibial O
nerve O
stimulation O
can O
be O
a O
viable O
treatment O
option O
in O
some O
patients O
with O
refractory O
monosymptomatic O
nocturnal O
enuresis O
. O
[]

The O
peak O
ELISPOT O
response O
occurred O
?2 O
weeks O
after O
each O
ZV O
dose O
. O
[]

One O
hundred O
hypertensive O
patients O
with O
stable O
angina O
pectoris O
who O
underwent O
elective O
percutaneous O
coronary O
intervention O
were O
randomly O
selected O
to O
receive O
1 O
of O
the O
2 O
angiotensin O
II O
receptor O
blockers O
after O
coronary O
intervention O
. O
[]

The O
unconscious O
thought O
effect O
in O
clinical O
decision O
making O
: O
an O
example O
in O
diagnosis O
. O
[]

Intravenous O
hyperimmune O
globulin O
prophylaxis O
against O
cytomegalovirus O
interstitial O
pneumonitis O
after O
allogenic O
bone O
marrow O
transplantation O
. O
[]

STUDY O
DESIGN O
Thirty O
residents O
in O
general O
surgery O
performed O
2 O
open O
partial O
gastrectomy O
training O
events O
on O
a O
porcine O
model O
. O
[]

INTRODUCTION O
Patients O
with O
diabetes O
complicated O
by O
hypertension O
and O
microalbuminuria O
have O
elevated O
cardiovascular O
risk O
, O
and O
controlling O
blood O
pressure O
in O
these O
patients O
is O
an O
urgent O
clinical O
priority O
. O
[]

However O
, O
most O
studies O
have O
shown O
that O
people O
with O
ASD O
do O
respond O
to O
eye-gaze O
cues O
in O
experimental O
paradigms O
, O
though O
it O
is O
possible O
that O
this O
behaviour O
is O
based O
on O
an O
atypical O
strategy O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Before O
surgery O
, O
women O
were O
assigned O
, O
at O
a O
ratio O
of O
1:1 O
by O
random O
selection O
, O
to O
receive O
injections O
of O
triptorelin O
depot O
11.25 O
mg O
3 O
months O
before O
surgery O
( O
group O
A O
) O
or O
no O
treatment O
( O
group O
B O
) O
. O
[]

All O
patients O
received O
folic O
acid O
and O
vitamin O
B O
( O
12 O
) O
supplementation O
. O
[]

Treatment O
Treatment O
was O
considered O
successful O
only O
if O
spontaneous O
chest B-outcome ['Physiological-Clinical']
pains I-outcome ['Physiological-Clinical']
disappeared O
completely O
. O
['Physiological-Clinical']

INTERVENTION O
( O
S O
) O
The O
study O
group O
underwent O
a O
microdose O
protocol O
with O
a O
GnRH-agonist O
followed O
by O
rFSH O
administration O
. O
[]

To O
see O
whether O
continuous O
intravenous O
infusion O
of O
opiates O
provides O
more O
effective O
postoperative B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
than O
conventional O
intramuscular O
injection O
these O
regimens O
were O
compared O
in O
a O
prospective O
double O
blind O
trial O
. O
['Physiological-Clinical']

To O
assess O
the O
value O
of O
clotting O
factor O
concentrate O
infusions O
in O
fulminant O
hepatic B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
, O
a O
controlled O
trial O
was O
performed O
in O
which O
nine O
patients O
were O
randomly O
allocated O
to O
treatment O
with O
either O
concentrate O
alone O
or O
concentrate O
plus O
heparin O
. O
['Physiological-Clinical']

IS-IL-2 O
therapy O
induced O
a O
high O
incidence O
of O
eosinophilia B-outcome ['Physiological-Clinical']
( O
12/18 O
) O
and O
thrombocythemia B-outcome ['Physiological-Clinical']
( O
12/18 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

21 O
out O
of O
30 O
patients O
( O
70 O
% O
) O
profited O
from O
such O
a O
treatment O
, O
showing O
a O
drop O
from O
5 O
-- O
30 O
attacks O
to O
0 O
-- O
1 O
attack B-outcome ['Physiological-Clinical']
per O
month O
and O
normalization O
of O
high B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
serotonin I-outcome ['Physiological-Clinical']
, O
5-HIAA B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
histamine I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Study O
end O
points O
were O
OS B-outcome ['Mortality']
, O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
DFS I-outcome ['Mortality']
) I-outcome ['Mortality']
, O
and O
toxicity B-outcome ['Adverse-effects']
. O
['Mortality', 'Mortality', 'Adverse-effects']

Patients O
received O
rofecoxib O
( O
50 O
mg O
, O
1 O
h O
prior O
to O
incision O
) O
or O
placebo O
. O
[]

SUBJECTS O
Sixty-three O
community-dwelling O
individuals O
( O
mean O
age O
= O
65 O
years O
, O
age O
range O
= O
50-87 O
years O
) O
with O
a O
chronic O
stroke O
( O
post-stroke O
duration O
: O
mean O
= O
5.5 O
years O
, O
range O
= O
1-28 O
years O
) O
. O
[]

Benzodiazepine O
and O
opioid O
sedation O
attenuate O
the O
sympathetic O
response O
to O
fiberoptic B-outcome ['Resource-use']
bronchoscopy I-outcome ['Resource-use']
. O
['Resource-use']

The O
authors O
herein O
present O
their O
personal O
series O
on O
the O
clinical O
evaluation O
of O
the O
analgesic O
efficacy O
of O
2 O
opiodes O
, O
peridural O
morphine O
hydrochloride O
( O
0.5 O
mg/kg O
) O
administered O
to O
group O
A O
patients O
, O
and O
sublingual O
buprenorphine O
( O
0.4 O
mg O
) O
administered O
to O
group O
B O
patients O
in O
the O
management O
of O
post-operative O
pain O
in O
major O
abdominal O
surgery O
. O
[]

In O
this O
study O
, O
we O
sought O
to O
evaluate O
the O
implicit O
ability O
to O
perceive O
the O
temporal O
outcome O
of O
different O
movements O
in O
a O
group O
of O
patients O
with O
writer O
's O
cramp O
. O
[]

Patients O
were O
randomly O
assigned O
to O
either O
pentoxifylline O
400 O
mg O
or O
placebo O
3 O
times O
daily O
for O
14 O
days O
. O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
MRI O
study O
of O
anti-herpes O
virus O
therapy O
in O
MS O
. O
[]

Dysthymia O
: O
a O
randomized O
study O
of O
cognitive O
marital O
therapy O
and O
antidepressants O
. O
[]

The O
intra-individual O
comparison O
with O
the O
control O
period O
( O
100 O
% O
) O
showed O
a O
significant O
prolongation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
after O
a O
fixed O
dose O
of O
vecuronium O
. O
['Physiological-Clinical']

A O
limited O
access O
dataset O
from O
the O
Evaluation O
Study O
of O
Congestive O
Heart O
Failure O
and O
Pulmonary O
Artery O
Catheterization O
Effectiveness O
( O
ESCAPE O
) O
trial O
provided O
by O
The O
National O
Heart O
, O
Lung O
, O
and O
Blood O
Institute O
was O
analyzed O
. O
[]

RESULTS O
The O
frequency O
of O
the O
G84E B-outcome ['Physiological-Clinical']
mutation I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
among O
patients O
with O
prostate O
cancer O
and O
highest O
among O
patients O
with O
a O
family O
history O
of O
the O
disease O
, O
hereditary O
prostate O
cancer O
[ O
8.4 O
% O
vs. O
1.0 O
% O
in O
controls O
; O
OR O
8.8 O
; O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
4.9-15.7 O
] O
. O
['Physiological-Clinical']

Short-term O
effects O
of O
denopamine O
on O
anaerobic B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
and O
related O
parameters O
in O
patients O
with O
chronic O
heart O
failure O
: O
a O
double-blind O
crossover O
study O
. O
['Physiological-Clinical']

To O
evaluate O
the O
direct O
psychophysiologic O
benefits O
of O
non-verbal O
communication O
of O
compassion O
( O
NVCC O
) O
, O
it O
is O
important O
to O
minimize O
the O
effect O
of O
subjects O
' O
expectation O
. O
[]

The O
Acne-QoL B-outcome ['Physiological-Clinical']
questionnaire O
was O
administered O
at O
baseline O
and O
at O
the O
end O
of O
treatment O
( O
week O
12 O
) O
. O
['Physiological-Clinical']

10 O
patients O
of O
Chinese O
herb O
group O
was O
alive O
beyond O
more O
than O
2 O
years O
. O
[]

RESULTS O
Mean O
fracture B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
was O
505.4 O
N O
+/- O
42.0 O
N O
and O
564.1 O
N O
+/- O
41.7 O
N O
in O
group O
A O
, O
411.3 O
N O
+/- O
23.3 O
N O
and O
315.3 O
N O
+/- O
19.1 O
N O
in O
group O
B O
and O
358.4 O
N O
+/- O
36.1 O
N O
and O
423.4 O
N O
+/- O
47.5 O
N O
in O
group O
C. O
In O
all O
groups O
, O
there O
was O
no O
posts B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
and O
polycarbonate B-outcome ['Physiological-Clinical']
resin I-outcome ['Physiological-Clinical']
crowns I-outcome ['Physiological-Clinical']
fragmentation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
1,524 O
smokers O
( O
649 O
men O
and O
875 O
women O
) O
of O
average O
age O
45.1 O
years O
were O
randomized O
to O
receive O
one O
of O
four O
combinations O
of O
bupropion O
SR O
( O
150 O
or O
300 O
mg O
) O
and O
behavioral O
counseling O
( O
tailored O
mailings O
or O
proactive O
telephone O
counseling O
) O
and O
assessed O
for O
point-prevalent O
smoking O
status O
at O
3 O
and O
12 O
months O
. O
[]

A O
coincident O
entomological O
investigation O
measured O
malaria B-outcome ['Physiological-Clinical']
vector I-outcome ['Physiological-Clinical']
abundance I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
biting I-outcome ['Physiological-Clinical']
behaviour I-outcome ['Physiological-Clinical']
and O
the O
human O
population O
sleeping B-outcome ['Physiological-Clinical']
habits B-outcome ['Life-Impact']
, O
factors O
relevant O
to O
ITN O
effectiveness O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

CONCLUSION O
Oral O
ciprofloxacin O
was O
as O
safe O
and O
effective O
as O
intramuscular O
ceftriaxone O
for O
the O
empiric O
treatment O
of O
acute O
invasive O
diarrhea O
in O
ambulatory O
pediatric O
patients O
requiring O
an O
emergency O
room O
visit O
. O
[]

Effects O
of O
sensory-level O
high-volt O
pulsed O
electrical O
current O
ondelayed-onset B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
soreness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Patients O
receiving O
the O
high-dose O
pralidoxime O
regimen O
required O
less O
atropine B-outcome ['Physiological-Clinical']
during O
the O
first O
24 O
h O
than O
controls O
( O
median O
6 O
mg O
vs O
30 O
mg O
; O
difference O
24 O
mg O
[ O
95 O
% O
CI O
24-26 O
, O
p O
< O
0.0001 O
] O
) O
. O
['Physiological-Clinical']

Also O
it O
was O
evaluated O
the O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
, O
the O
range O
of O
motion B-outcome ['Life-Impact']
and O
weight O
test O
. O
['Life-Impact', 'Life-Impact']

[ O
The O
chemotherapy O
of O
advanced O
breast O
cancer O
. O
[]

There O
were O
no O
between O
group O
differences O
in O
the O
child O
's O
body O
mass O
index O
z-score O
, O
dietary O
intake O
or O
physical O
activity O
post O
intervention O
. O
[]

30 O
patients O
with O
supraspinatus O
or O
bicipital O
tendonitis O
were O
randomly O
allocated O
to O
active O
infrared O
laser O
therapy O
at O
904 O
nm O
three O
times O
weekly O
for O
2 O
weeks O
, O
dummy O
laser O
or O
drug O
treatment O
for O
2 O
weeks O
. O
[]

We O
tested O
the O
hypothesis O
that O
calcium O
supplementation O
may O
improve O
bone B-outcome ['Physiological-Clinical']
accrual I-outcome ['Physiological-Clinical']
in O
premenarcheal O
females O
. O
['Physiological-Clinical']

I O
: O
comparison O
of O
placebo O
and O
single O
dose O
of O
human O
synthetic O
secretin O
. O
[]

RESULTS O
Of O
750 O
randomly O
assigned O
patients O
with O
CKD O
, O
60 O
% O
were O
not O
on O
dialysis O
therapy O
. O
[]

BACKGROUND O
Although O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
are O
better O
tolerated O
than O
tricyclic O
antidepressants O
, O
their O
efficacy O
in O
severe O
depression O
remains O
to O
be O
further O
elucidated O
. O
[]

The O
primary O
efficacy O
end O
point O
is O
2 O
consecutive O
decreases O
in O
iPTH O
levels O
greater O
than O
30 O
% O
from O
baseline O
. O
[]

Patients O
had O
received O
epoetin O
for O
> O
or O
= O
3 O
months O
upon O
study O
entry O
and O
had O
achieved O
a O
target O
Hb O
level O
of O
10.5-12.5 O
g/dL O
with O
a O
stable O
epoetin O
dose O
. O
[]

Panic O
management O
( O
PM O
) O
had O
an O
ICER B-outcome ['Physiological-Clinical']
of O
$ O
124.05 O
, O
per O
the O
Anxiety O
Disorders O
Interview O
Schedule O
for O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
Fourth O
Edition O
, O
severity O
score O
change O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
$ O
54.63- O
$ O
314.57 O
) O
, O
compared O
with O
pharmacotherapy O
( O
paroxetine O
) O
, O
with O
an O
ICER B-outcome ['Physiological-Clinical']
of O
$ O
213.90 O
( O
95 O
% O
CI O
, O
$ O
133.51- O
$ O
394.94 O
) O
, O
and O
brief O
CBT O
, O
with O
an O
ICER B-outcome ['Physiological-Clinical']
of O
$ O
309.31 O
( O
95 O
% O
CI O
, O
$ O
151.27- O
$ O
548.28 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Families O
were O
recruited O
through O
schools O
and O
community O
centers O
and O
were O
included O
if O
there O
was O
1 O
child O
in O
Grades O
1-3 O
at O
moderate O
to O
high O
risk O
for O
skin O
cancer O
. O
[]

In O
33 O
patients O
with O
PAN O
related O
to O
HBV O
, O
a O
new O
therapeutic O
strategy O
was O
applied O
as O
an O
alternative O
to O
long-term O
steroid O
and O
immunosuppressive O
therapy O
: O
short-term O
steroid O
therapy O
and O
PE O
were O
used O
to O
control O
the O
evolution O
of O
PAN O
and O
anti-viral O
therapy O
was O
administered O
to O
suppress O
the O
etiological B-outcome ['Physiological-Clinical']
agent I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
vasculitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
lavender O
and O
control O
conditions O
showed O
higher O
mean O
vigor-activity B-outcome ['Life-Impact']
ratings O
relative O
to O
the O
rosemary O
group O
, O
while O
both O
rosemary O
and O
lavender O
scents O
were O
associated O
with O
lower O
mean O
ratings O
on O
the O
fatigue-inertia B-outcome ['Life-Impact']
subscale O
, O
relative O
to O
the O
control O
group O
. O
['Life-Impact', 'Life-Impact']

The O
findings O
suggest O
that O
unblinded O
assessment O
by O
trial O
nurses O
is O
unacceptable O
on O
its O
own O
. O
[]

Quality O
of O
life O
assessments O
were O
based O
on O
the O
standardized O
rhinoconjunctivitis B-outcome ['Physiological-Clinical']
quality O
of O
life O
questionnaire O
( O
RQLQ O
( O
S O
) O
) O
; O
completed O
weekly O
during O
the O
entire O
grass O
pollen O
season O
. O
['Physiological-Clinical']

This O
analysis O
is O
based O
upon O
publicly O
available O
evidence O
presented O
in O
a O
complaint O
of O
research O
misconduct O
filed O
with O
the O
Office O
of O
Research O
Integrity O
of O
the O
Department O
of O
Health O
and O
Human O
Services O
. O
[]

Plasmapheresis O
and O
chemotherapy O
lowered O
the O
serum B-outcome ['Physiological-Clinical']
myeloma O
protein O
value O
much O
more O
rapidly O
than O
chemotherapy O
alone O
. O
['Physiological-Clinical']

Caffeine O
's O
main O
mechanism O
of O
action O
on O
the O
central O
nervous O
system O
is O
antagonism O
of O
adenosine O
receptors O
. O
[]

United O
States O
children O
two O
months O
of O
age O
were O
randomly O
assigned O
to O
two O
groups O
that O
received O
either O
the O
commercially O
available O
oral O
trivalent O
poliovirus O
vaccine O
( O
OPV O
) O
or O
an O
injectable O
( O
inactivated O
) O
trivalent O
poliovirus O
vaccine O
( O
IPV O
) O
with O
a O
confirmed O
minimum O
D-antigen O
content O
of O
27 O
, O
3.5 O
, O
and O
29 O
units O
for O
poliovirus O
types O
1 O
, O
2 O
, O
and O
3 O
, O
respectively O
. O
[]

59 O
mild O
to O
moderate O
hypertensives O
were O
treated O
for O
four O
weeks O
with O
50 O
mg O
hydrochlorothiazide O
plus O
5 O
mg O
of O
amiloride O
, O
then O
concomitantly O
with O
these O
diuretics O
with O
either O
enalapril O
( O
10-20 O
mg O
) O
or O
timolol O
( O
10-20 O
mg O
) O
in O
two O
parallel O
treatment O
groups O
for O
an O
additional O
12 O
weeks O
in O
an O
open O
study O
. O
[]

Liquid O
fluoxetine O
did O
not O
significantly O
differ O
from O
placebo O
on O
treatment B-outcome ['Adverse-effects']
emergent I-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

Median O
onset O
of O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
was O
12 O
min O
for O
both O
drugs O
and O
median O
duration O
was O
49 O
( O
range O
3-129 O
) O
min O
and O
51 O
( O
7-157 O
) O
min O
for O
S O
( O
- O
) O
-bupivacaine O
and O
RS O
bupivacaine O
, O
respectively O
. O
['Physiological-Clinical']

With O
regard O
to O
age O
, O
sex O
, O
diagnosis O
and O
the O
site O
of O
te O
trepanation O
, O
control O
patients O
( O
n O
= O
355 O
) O
and O
cefotiam O
treated O
patients O
( O
n O
= O
356 O
) O
were O
shown O
to O
be O
comparable O
. O
[]

A O
prospective O
, O
randomized O
controlled O
trial O
of O
single-incision O
laparoscopic O
vs O
conventional O
3-port O
laparoscopic O
appendectomy O
for O
treatment O
of O
acute O
appendicitis O
. O
[]

This O
was O
more O
pronounced O
in O
those O
patients O
who O
were O
treated O
for O
the O
initial O
2 O
weeks O
with O
indomethacin O
plus O
placebo O
( O
and O
subsequently O
with O
cilazapril O
in O
addition O
) O
than O
in O
the O
subjects O
who O
first O
received O
cilazapril O
plus O
placebo O
and O
then O
the O
combination O
. O
[]

BACKGROUND O
The O
pulse O
oximeter O
perfusion O
index O
( O
PI O
) O
has O
been O
used O
to O
indicate O
sympathectomy-induced O
vasodilatation O
. O
[]

This O
state O
may O
in O
part O
be O
caused O
by O
an O
imbalance O
in O
the O
somatostatin/somatomedine O
axis O
resulting O
in O
increased O
catabolism O
. O
[]

In O
cases O
of O
classic O
CNV O
, O
low-dose O
irradiation O
with O
10 O
Gy O
postponed O
severe B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
by O
a O
maximum O
of O
18 O
months O
. O
['Physiological-Clinical']

DESIGN O
Critical O
review O
of O
safety O
data O
from O
three O
randomized O
controlled O
clinical O
trials O
with O
supplemental O
information O
from O
an O
expanded O
drug O
access O
program O
. O
[]

Resurfacing O
after O
laser-assisted O
topical O
anesthesia O
was O
well O
tolerated B-outcome ['Life-Impact']
by O
72 O
% O
of O
subjects O
in O
pass O
1 O
and O
58 O
% O
in O
pass O
2 O
. O
['Life-Impact']

METHODS O
In O
this O
double-blind O
, O
placebo-controlled O
study O
, O
we O
randomly O
assigned O
5362 O
patients O
who O
had O
not O
been O
treated O
with O
clopidogrel O
to O
receive O
either O
cangrelor O
or O
placebo O
at O
the O
time O
of O
PCI O
, O
followed O
by O
600 O
mg O
of O
clopidogrel O
. O
[]

The O
presence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
mean O
of O
physiological O
parameters O
such O
as O
Hba1c B-outcome ['Physiological-Clinical']
, O
P-glucose B-outcome ['Physiological-Clinical']
, O
P-insulin B-outcome ['Physiological-Clinical']
, O
lipids B-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
physical B-outcome ['Physiological-Clinical']
working I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
, O
body O
mass O
index O
, O
Heart B-outcome ['Physiological-Clinical']
Score O
were O
investigated O
and O
participants O
' O
satisfaction B-outcome ['Life-Impact']
assessed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

The O
overall O
results O
show O
that O
of O
the O
four O
possible O
treatment O
randomizations O
, O
four O
courses O
of O
chemotherapy O
alone O
is O
inferior O
in O
terms O
of O
overall O
survival O
( O
30 O
weeks O
median O
survival O
) O
to O
the O
other O
three O
treatment O
options O
( O
39 O
weeks O
median O
survival O
, O
P O
less O
than O
0.01 O
) O
. O
[]

All O
were O
participating O
in O
the O
Canadian-European O
randomized O
placebo-controlled O
cyclosporin O
trial O
in O
newly O
diagnosed O
Type O
1 O
diabetic O
patients O
, O
nine O
being O
randomized O
to O
placebo O
, O
and O
nine O
to O
cyclosporin O
A O
. O
[]

The O
diagnostic B-outcome ['Life-Impact']
superiority I-outcome ['Life-Impact']
of O
brushings O
obtained O
before O
biopsy O
did O
not O
relate O
to O
the O
site O
or O
endoscopic O
appearance O
of O
the O
tumor O
. O
['Life-Impact']

A O
chart O
audit O
is O
performed O
at O
6months O
. O
[]

Children O
with O
prolonged O
diarrhoea O
receiving O
green O
banana O
had O
significantly O
higher O
recovery O
rates O
by O
day O
10 O
: O
79.8 O
% O
vs O
. O
[]

A O
comparison O
of O
single-dose O
cefixime O
with O
ceftriaxone O
as O
treatment O
for O
uncomplicated B-outcome ['Physiological-Clinical']
gonorrhea I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
preliminary O
study O
suggests O
that O
supplementation O
with O
larger O
ARA O
doses O
added O
to O
DHA O
improves O
impaired O
social B-outcome ['Life-Impact']
interaction I-outcome ['Life-Impact']
in O
individuals O
with O
autism O
spectrum O
disorder O
by O
up-regulating O
signal O
transduction O
. O
['Life-Impact']

Tramal O
can O
be O
recommended O
for O
obstetrical B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
since O
it O
does O
not O
excert O
inhibitory B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
upon O
the O
respiratory O
center O
. O
['Resource-use', 'Physiological-Clinical']

While O
long-term O
flosequinan O
administration O
also O
effected O
a O
progressive O
increase O
in O
resting B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate O
, O
it O
did O
not O
consistently O
improve O
indices O
of O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Forty-nine O
healthy O
women O
aged O
20-35 O
years O
who O
had O
not O
been O
pregnant O
or O
using O
an O
oral O
contraceptive O
( O
OC O
) O
for O
the O
previous O
3 O
months O
were O
randomized O
into O
two O
groups O
, O
one O
group O
taking O
an O
OC O
containing O
75 O
micrograms O
gestodene O
( O
GTD O
) O
and O
30 O
micrograms O
ethinyl O
estradiol O
( O
EE O
) O
, O
and O
the O
other O
group O
using O
an O
OC O
with O
150 O
micrograms O
desogestrel O
( O
DSG O
) O
and O
30 O
micrograms O
EE O
. O
[]

Fifteen O
patients O
showed O
abnormalities B-outcome ['Physiological-Clinical']
at O
the O
site B-outcome ['Physiological-Clinical']
of O
the O
original O
tumour B-outcome ['Physiological-Clinical']
consisting O
of O
nodular B-outcome ['Physiological-Clinical']
elevations I-outcome ['Physiological-Clinical']
, O
narrowing B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bronchi I-outcome ['Physiological-Clinical']
and/or I-outcome ['Physiological-Clinical']
fibrous I-outcome ['Physiological-Clinical']
strands I-outcome ['Physiological-Clinical']
or O
membranes B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
a O
randomized O
, O
2-group O
clinical O
study O
, O
acupuncture O
was O
used O
for O
the O
relief O
of O
menopausal B-outcome ['Physiological-Clinical']
hot I-outcome ['Physiological-Clinical']
flushes I-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
, O
and O
mood B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

3.0 O
?10?/L O
, O
both O
P O
< O
0.05 O
) O
, O
but O
there O
was O
no O
significant O
difference O
in O
amylase O
between O
P+EN O
group O
and O
PN O
group O
( O
211 O
? O
[]

The O
constitutive O
enzymes O
( O
COX-1 O
and O
eNOS O
) O
did O
not O
change O
after O
treatment O
. O
[]

There O
were O
no O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Modifications O
of O
both O
amplitude O
and O
single-trial O
potential O
variability O
were O
considered O
according O
to O
the O
clinical O
and O
biochemical O
responsiveness O
to O
this O
drug O
. O
[]

One O
vaccinee O
in O
the O
DTPa O
HBV-HPV- O
Hib O
group O
failed O
to O
respond O
to O
the O
poliovirus O
type O
1 O
antigen O
. O
[]

Several O
mechanisms O
of O
actions O
detected O
in O
vivo/in O
vitro O
including O
N-methyl-D-aspartate B-outcome ['Physiological-Clinical']
( O
NMDA O
) O
-receptor O
antagonism B-outcome ['Life-Impact']
, O
blockage O
of O
potassium O
channels O
, O
dopamine O
receptor O
agonism O
, O
enhancement O
of O
noradrenergic O
release O
, O
and O
anticholinergic O
effects O
have O
been O
described O
. O
['Physiological-Clinical', 'Life-Impact']

Also O
, O
there O
were O
no O
significant O
differences O
in O
LDL B-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
after O
in O
vitro O
enrichment O
of O
LDL O
with O
RRR-AT O
and O
all-rac-AT O
. O
['Physiological-Clinical']

CONCLUSION O
Mean O
adherence B-outcome ['Life-Impact']
rates O
were O
greater O
with O
a O
once-daily O
dosing O
regimen O
of O
MF-DPI O
than O
with O
a O
twice-daily O
dosing O
regimen.This O
trial O
was O
completed O
prior O
to O
the O
ISMJE O
requirements O
for O
trial O
registration O
. O
['Life-Impact']

Improvement O
in O
lifestyle B-outcome ['Life-Impact']
seemed O
to O
reduce O
the O
need O
for O
supplementary O
treatment O
with O
['Life-Impact']

This O
24 O
% O
drop O
in O
emergency B-outcome ['Resource-use']
department I-outcome ['Resource-use']
visits I-outcome ['Resource-use']
resulted O
in O
an O
intervention O
that O
was O
cost O
saving O
in O
its O
first O
year O
. O
['Resource-use']

INTRODUCTION O
Significant O
malnutrition O
exists O
in O
a O
high O
percentage O
of O
patients O
with O
head O
and O
neck O
cancer O
. O
[]

Hemiarthroplasty O
was O
thus O
cost O
effective O
. O
[]

Wound B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
occurred O
in O
5/32 O
( O
16 O
per O
cent O
) O
of O
the O
cefotaxime O
group O
and O
9/31 O
( O
29 O
per O
cent O
) O
of O
the O
cephamandole O
group O
. O
['Physiological-Clinical']

Twenty O
( O
33 O
% O
) O
desmopressin-treated O
patients O
compared O
with O
seven O
( O
11 O
% O
) O
placebo-treated O
patients O
showed O
a O
clinical O
response O
, O
defined O
as O
a O
> O
or O
=50 O
% O
reduction O
in O
the O
number O
of O
nocturnal B-outcome ['Physiological-Clinical']
voids I-outcome ['Physiological-Clinical']
compared O
with O
baseline O
( O
p=0.0014 O
) O
. O
['Physiological-Clinical']

METHODS O
& O
PROCEDURES O
In O
a O
single-blind O
RCT O
design O
, O
88 O
children O
with O
pragmatic O
and O
social O
communication O
needs O
aged O
5 O
; O
11-10 O
; O
8 O
, O
recruited O
from O
UK O
speech O
and O
language O
therapy O
services O
, O
were O
randomly O
assigned O
in O
a O
2:1 O
ratio O
to O
SCIP O
or O
to O
treatment-as-usual O
. O
[]

Most O
of O
the O
patients O
had O
advanced O
disease O
: O
stage O
IIE O
( O
23 O
% O
) O
, O
III O
( O
13 O
% O
) O
, O
or O
IV O
( O
47 O
% O
) O
; O
38 O
% O
disseminated O
nodes O
; O
38 O
% O
two O
or O
more O
extranodal O
sites O
; O
and O
41 O
% O
a O
tumoral O
mass O
greater O
than O
10 O
cm O
. O
[]

During O
each O
treatment O
period O
, O
subjects O
received O
a O
single O
dose O
of O
either O
donepezil O
HCl O
( O
5 O
mg O
) O
, O
digoxin O
( O
0.25 O
mg O
) O
, O
or O
a O
combination O
of O
both O
drugs O
. O
[]

The O
efficacy O
of O
eprinomectin O
versus O
ivermectin O
( O
Study O
1 O
: O
a O
single-centre O
, O
randomised O
, O
treatment-controlled O
, O
blinded O
field O
trial O
) O
, O
and O
the O
field B-outcome ['Physiological-Clinical']
efficacy O
of O
eprinomectin O
( O
Study O
2 O
: O
a O
single-centre O
, O
open O
, O
un-controlled O
field O
trial O
) O
for O
the O
treatment O
of O
chorioptic O
infestation O
in O
naturally O
infested O
alpacas O
were O
assessed O
in O
two O
studies O
. O
['Physiological-Clinical']

Treatment O
consisted O
of O
pelvic O
floor O
exercises O
in O
the O
case O
of O
stress O
incontinence O
and O
bladder O
training O
in O
the O
case O
of O
urge O
incontinence O
. O
[]

Objective B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
were O
observed O
in O
55 O
of O
82 O
( O
67 O
% O
) O
and O
59 O
of O
81 O
( O
73 O
% O
) O
assessable O
patients O
treated O
with O
VP O
and O
VIP O
, O
respectively O
( O
difference O
not O
significant O
) O
. O
['Physiological-Clinical']

A O
Norwegian O
multicenter O
study O
. O
[]

plus O
omeprazole O
20 O
mg O
b.d. O
, O
or O
amoxycillin O
500 O
mg O
q.d.s O
. O
[]

RESULTS O
Statistically O
significantly O
greater O
improvement O
was O
seen O
with O
aripiprazole O
versus O
placebo O
( O
p O
< O
0.05 O
) O
for O
all O
arms O
in O
both O
trials O
on O
the O
ABC-Irritability O
total O
subscale O
score O
and O
on O
the O
following O
individual O
ABC-Irritability O
items O
: O
Mood B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
quickly O
, O
cries/screams B-outcome ['Life-Impact']
inappropriately B-outcome ['Life-Impact']
, O
and O
stamps B-outcome ['Life-Impact']
feet/bangs I-outcome ['Life-Impact']
objects B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
most O
frequently O
reported O
treatment-related O
adverse O
events O
in O
the O
treatment O
and O
placebo O
groups O
were O
local B-outcome ['Physiological-Clinical']
tenderness I-outcome ['Physiological-Clinical']
( O
21 O
% O
) O
, O
subcutaneous B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
( O
10.5 O
% O
) O
, O
and O
conjunctivitis B-outcome ['Physiological-Clinical']
( O
10.5 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
In O
younger O
patients O
a O
boost O
dose O
resulted O
in O
a O
greater O
absolute O
reduction O
of O
local B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Both O
interventions O
were O
delivered O
with O
high O
fidelity O
and O
participants O
in O
both O
groups O
reported O
positive O
experiences O
. O
[]

Safety O
, O
tolerability B-outcome ['Life-Impact']
, O
and O
immunogenicity B-outcome ['Physiological-Clinical']
after O
1 O
and O
2 O
doses O
of O
zoster O
vaccine O
in O
healthy O
adults O
?60 O
years O
of O
age O
. O
['Life-Impact', 'Physiological-Clinical']

Objective B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates O
were O
87.5 O
% O
for O
the O
U-type O
method O
and O
80.1 O
% O
for O
the O
H-type O
method O
( O
p=0.091 O
) O
. O
['Physiological-Clinical']

ALT B-outcome ['Physiological-Clinical']
values O
decreased O
from O
pre-treatment O
levels O
of O
157.0 O
+/- O
62.6 O
IU/l O
to O
82.5 O
+/- O
46.4 O
IU/l O
( O
P O
< O
0.05 O
) O
, O
and O
GGT O
fell O
from O
141.3 O
+/- O
86.2 O
IU/l O
to O
66.0 O
+/- O
49.5 O
IU/l O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

The O
mechanism O
by O
which O
cyclosporin O
can O
prevent O
an O
anti-HLA B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
promote O
an O
anti-idiotypic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
is O
unclear O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mood O
forms O
and O
psychomotor O
tests O
were O
completed O
, O
and O
miosis O
was O
assessed O
, O
during O
and O
after O
the O
infusions O
. O
[]

Despite O
our O
study O
's O
limitations O
, O
we O
have O
effectively O
demonstrated O
the O
potential O
for O
preventing O
medical O
error O
risk O
among O
night-shift O
workers O
. O
[]

HBHS O
was O
organized O
into O
five O
3-8-week O
phases O
: O
Healthy O
Beverages O
, O
Healthy O
Desserts O
, O
Healthy O
Cooking O
, O
Healthy O
Snacking O
and O
Eating O
Out O
and O
Physical O
Activity O
. O
[]

The O
AQ-J O
had O
satisfactory B-outcome ['Life-Impact']
internal I-outcome ['Life-Impact']
consistency O
reliability O
( O
Cronbach O
's O
alpha O
> O
0.70 O
in O
the O
two O
groups O
) O
, O
test-retest O
reliability O
, O
and O
discriminant B-outcome ['Physiological-Clinical']
validity B-outcome ['Physiological-Clinical']
[ O
i.e O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Additionally O
, O
pretreatment O
with O
gabapentin O
reduced O
the O
degree O
of O
postoperative O
nausea B-outcome ['Physiological-Clinical']
and O
incidence O
of O
vomiting/retching B-outcome ['Physiological-Clinical']
possibly O
either O
due O
to O
the O
diminished O
need O
for O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
treatment O
with O
opioids O
or O
because O
of O
an O
anti-emetic O
effect O
of O
gabapentin O
itself O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
ranitidine O
group O
received O
RNT O
300 O
mg O
, O
CAM O
400 O
mg O
, O
MTZ O
500 O
mg O
( O
RCM O
group O
) O
. O
[]

Findings O
demonstrate O
the O
importance O
of O
identifying O
transitional O
periods O
and O
the O
need O
for O
alternative O
intervention O
strategies O
that O
may O
help O
the O
progression O
of O
this O
population O
into O
young O
adulthood O
. O
[]

To O
evaluate O
the O
influence O
of O
body O
temperature O
during O
cardiopulmonary O
bypass O
( O
CPB O
) O
on O
postoperative B-outcome ['Physiological-Clinical']
systemic I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
, O
32 O
patients O
undergoing O
elective O
cardiac O
surgery O
were O
randomly O
assigned O
to O
either O
hypothermia O
( O
n O
= O
16 O
) O
or O
normothermia O
( O
n O
= O
16 O
) O
. O
['Physiological-Clinical']

The O
reduction O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
caused O
by O
diazoxide O
was O
slightly O
greater O
than O
that O
due O
to O
labetalol O
. O
['Physiological-Clinical']

Seven O
patients O
in O
the O
radiotherapy O
group O
and O
25 O
in O
the O
combined-therapy O
group O
were O
alive B-outcome ['Mortality']
at O
the O
time O
of O
the O
analysis O
. O
['Mortality']

Child O
outcomes O
focused O
on O
joint O
engagement B-outcome ['Life-Impact']
, O
joint O
attention O
, O
and O
play O
. O
['Life-Impact']

Data O
show O
that O
the O
intervention O
reduced O
directly O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
reduced O
indirectly O
inflammation B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Those O
assigned O
to O
the O
exercise O
group O
received O
a O
standardized O
, O
self-administered O
, O
home-based O
brisk O
walking O
intervention O
in O
addition O
to O
usual O
care O
. O
[]

Recent O
developments O
in O
medical O
simulation O
seem O
promising O
with O
regard O
to O
the O
possibility O
of O
training O
out O
undesirable O
parts O
of O
the O
learning O
curve O
outside O
the O
operating O
room O
. O
[]

Patients O
were O
assessed O
for O
pain O
and O
functional O
ability O
, O
using O
a O
modified O
version O
of O
the O
WOMAC O
questionnaire O
, O
pre-treatment O
, O
immediately O
post-treatment O
and O
at O
eight O
weeks O
post-treatment O
. O
[]

From O
April O
1972 O
to O
May O
1980 O
, O
72 O
children O
and O
adolescents O
( O
aged O
5 O
to O
19 O
years O
old O
, O
median O
16 O
) O
with O
Hodgkin O
's O
disease O
, O
clinical O
stages O
IA-IIB O
( O
IA O
, O
18 O
; O
II2A O
, O
two O
areas O
involved O
on O
the O
same O
side O
of O
the O
diaphragm O
, O
23 O
; O
II3+A O
, O
three O
areas O
or O
more O
, O
16 O
; O
IIB O
, O
15 O
) O
were O
prospectively O
treated O
in O
two O
successive O
clinical O
trials O
( O
H O
72 O
and O
H O
77 O
) O
. O
[]

The O
cervical O
biopsy O
and O
cervical O
smear O
were O
performed O
using O
vaginoscope O
before O
and O
after O
treatment O
. O
[]

In O
116 O
patients O
with O
chronic O
tinnitus O
different O
parameters O
of O
cortical O
excitability O
were O
assessed O
before O
and O
after O
ten O
rTMS O
treatment O
sessions O
. O
[]

One O
eye O
of O
each O
patient O
with O
symmetric O
, O
threshold O
ROP O
was O
treated O
with O
an O
814/815 O
nm O
diode O
laser O
, O
while O
the O
other O
eye O
was O
treated O
with O
cryotherapy O
. O
[]

Of O
the O
remaining O
75 O
cases O
with O
recurrent O
tuberculosis O
and O
genotyping O
data O
available O
, O
72 O
( O
96 O
% O
; O
95 O
% O
confidence O
interval O
, O
88.8-99.2 O
% O
) O
paired O
isolates O
had O
the O
same O
genotype O
; O
only O
3 O
( O
4 O
% O
; O
95 O
% O
confidence O
interval O
, O
0.8-11.2 O
% O
) O
had O
a O
different O
genotype O
and O
were O
categorized O
as O
reinfection O
. O
[]

Shear B-outcome ['Physiological-Clinical']
bond I-outcome ['Physiological-Clinical']
and O
microtensile B-outcome ['Physiological-Clinical']
bond I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
data I-outcome ['Physiological-Clinical']
were O
analyzed O
using O
two-way O
ANOVA O
and O
Tukey O
's O
post-hoc O
test O
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
is O
concluded O
that O
patients O
with O
acute O
deep O
vein O
thrombosis O
with O
proximal O
extension O
of O
the O
thrombus O
beyond O
the O
calf O
veins O
should O
be O
offered O
a O
therapeutic O
trial O
with O
streptokinase O
. O
[]

Seminomas O
were O
found O
in O
10 O
patients O
, O
while O
non-seminomatous O
tumors O
in O
24 O
. O
[]

We O
previously O
found O
that O
resting O
state O
functional O
connectivity O
( O
rsFC O
) O
between O
the O
dorsal O
anterior O
cingulate O
( O
dACC O
) O
and O
striatum O
is O
independently O
associated O
with O
nicotine O
addiction O
and O
psychiatric O
illness O
. O
[]

A O
variety O
of O
breast O
pumps O
exist O
in O
the O
current O
US O
market O
which O
vary O
considerably O
in O
price O
and O
effectiveness O
. O
[]

Acute O
[]

RESULTS O
Twenty-seven O
patients O
were O
treated O
; O
14 O
received O
placebo O
in O
cycle-1 O
followed O
by O
aflibercept O
in O
later O
cycles O
and O
13 O
received O
aflibercept O
4 O
mg/kg O
upfront O
. O
[]

RESULTS O
Training O
in O
use O
of O
a O
notebook/calendar O
system O
significantly O
improved O
adherence O
over O
those O
who O
received O
the O
calendars O
but O
no O
training O
. O
[]

CONCLUSION O
There O
were O
no O
different O
of O
seroconversion B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
between O
study O
population O
received O
1 O
dose O
and O
3 O
dose O
booster O
( O
P O
> O
0.05 O
) O
, O
but O
high O
titer O
was O
observed O
after O
3 O
dose O
booster O
. O
['Physiological-Clinical']

A O
sensitivity O
analysis O
on O
dosage B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
drug I-outcome ['Life-Impact']
and O
duration B-outcome ['Mortality']
of I-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
performed O
. O
['Life-Impact', 'Mortality']

Such O
improvements O
can O
even O
be O
maintained O
4 O
weeks O
after O
treatment O
ended O
. O
[]

BACKGROUND O
AND O
PURPOSE O
This O
prospective O
study O
was O
conducted O
to O
compare O
the O
outcomes O
of O
surgical O
clipping O
and O
endovascular O
treatment O
in O
acute O
( O
< O
72 O
hours O
) O
aneurysmal O
subarachnoid O
hemorrhage O
( O
SAH O
) O
. O
[]

Patients O
were O
allocated O
to O
two O
groups O
: O
group O
I O
( O
n O
= O
8 O
) O
received O
streptokinase-mediated O
fibrinolysis O
; O
group O
II O
( O
n O
= O
12 O
) O
received O
intravenous O
heparin O
by O
infusion O
. O
[]

Another O
45 O
patients O
( O
control O
group O
) O
were O
treated O
with O
Xueshuantong O
and O
BHI O
intravenous O
dripping O
, O
once O
daily O
for O
14 O
days O
. O
[]

Antidepressant B-outcome ['Life-Impact']
response I-outcome ['Life-Impact']
was O
assessed O
by O
the O
Hamilton O
Depression B-outcome ['Life-Impact']
and O
Anxiety B-outcome ['Life-Impact']
Scales O
, O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Severity I-outcome ['Physiological-Clinical']
and O
Improvement O
Ratings O
, O
and O
the O
Zung O
Self-Rating O
Depression B-outcome ['Life-Impact']
Scale O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

OBJECTIVE O
To O
determine O
whether O
once-daily O
, O
in O
the O
morning O
, O
topical O
application O
of O
the O
new O
ocular O
hypotensive O
prostaglandin O
analogue O
, O
latanoprost O
, O
yields O
nocturnal B-outcome ['Physiological-Clinical']
intraocular I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IOP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
similar O
to O
its O
diurnal O
IOP O
reducing O
efficacy O
. O
['Physiological-Clinical']

Several O
distinct O
substance O
involvement O
trajectories O
were O
evident O
during O
the O
4 O
years O
following O
treatment O
. O
[]

The O
intervention O
provides O
individualized O
feedback O
that O
guides O
participants O
through O
the O
stages O
of O
change O
for O
cessation O
. O
[]

This O
study O
aimed O
to O
evaluate O
the O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
KAb201 O
, O
an O
anti-carcinoembryonic O
antigen O
monoclonal O
antibody O
, O
labelled O
with O
I O
( O
131 O
) O
in O
pancreatic O
cancer O
( O
ISRCTN O
16857581 O
) O
. O
['Life-Impact']

One O
intervention O
involved O
a O
peer-mediated O
approach O
( O
PEER O
) O
and O
the O
other O
involved O
a O
child-assisted O
approach O
( O
CHILD O
) O
. O
[]

AIMS O
Cardiovascular O
( O
CV O
) O
hospitalization O
is O
a O
predictor O
of O
CV B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
has O
a O
negative O
impact O
on O
patients O
' O
quality O
of O
life O
. O
['Mortality']

The O
patients O
' O
ages O
ranged O
from O
19 O
to O
48 O
years O
( O
mean O
age O
28 O
+/- O
1.6 O
) O
. O
[]

CONCLUSION O
Uniform O
and O
identical O
standardised O
wounds O
created O
using O
an O
abrasive O
brush O
technique O
can O
be O
used O
to O
reliably O
detect O
differences O
in O
the O
performance B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
plasters I-outcome ['Life-Impact']
intended O
for O
superficial O
wounds O
. O
['Life-Impact']

Protein B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
, O
as O
estimated O
by O
the O
ammonia B-outcome ['Physiological-Clinical']
end-product I-outcome ['Physiological-Clinical']
method O
, O
tended O
to O
rise O
post-operatively O
, O
but O
there O
was O
no O
significant O
difference O
between O
the O
increases O
observed O
with O
or O
without O
insulin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
pharmacodynamic O
effect O
of O
the O
enzyme O
was O
studied O
through O
changes O
in O
plasma O
porphobilinogen O
concentrations O
. O
[]

METHODS O
Eighty O
patients O
in O
whom O
ultrasonography O
revealed O
unilateral O
, O
mobile O
, O
unilocular O
, O
thin-walled O
ovarian O
cysts O
without O
internal O
echoes O
and O
greater O
than O
30 O
mm O
but O
not O
exceeding O
60 O
mm O
in O
diameter O
were O
enrolled O
into O
the O
study O
. O
[]

Plasma O
level O
of O
ISDN O
and O
the O
mononitrates O
, O
measured O
one O
and O
four O
hours O
after O
drug O
intake O
, O
rose O
almost O
linearly O
in O
relation O
to O
dose O
. O
[]

The O
pain O
was O
determined O
by O
verbal O
pain O
scale O
intraoperatively O
and O
postoperatively O
. O
[]

Forty O
healthy O
subjects O
were O
randomly O
allocated O
to O
receive O
7 O
days O
of O
treatment O
with O
NCX-4016 O
( O
400 O
and O
800 O
mg O
twice O
daily O
) O
, O
equimolar O
doses O
of O
aspirin O
( O
200 O
and O
420 O
mg O
twice O
daily O
) O
, O
or O
placebo O
. O
[]

Imitation O
is O
an O
early O
skill O
thought O
to O
play O
a O
role O
in O
social O
development O
, O
leading O
some O
to O
suggest O
that O
teaching O
imitation O
to O
children O
with O
autism O
should O
lead O
to O
improvements O
in O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact']

SETTING O
University O
Hospital O
. O
[]

Randomized O
study O
of O
chlorambucil O
( O
CB O
) O
compared O
to O
interferon O
( O
alfa-2b O
) O
combined O
with O
CB O
in O
low-grade O
non-Hodgkin O
's O
lymphoma O
: O
an O
interim O
report O
of O
a O
randomized O
study O
. O
[]

This O
study O
will O
assess O
the O
impact O
of O
a O
simplified O
neonatal O
resuscitation O
protocol O
provided O
by O
Helping O
Babies O
Breathe O
( O
HBB O
) O
at O
a O
tertiary O
hospital O
in O
Nepal O
. O
[]

SETTING O
8 O
university O
hospitals O
. O
[]

Serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
in O
15 O
patients O
with O
dipyridamole O
and O
in O
12 O
with O
placebo O
( O
7.6 O
% O
vs O
6.0 O
, O
P=0.52 O
) O
. O
['Adverse-effects']

Post-CABG B-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
was O
treated O
with O
a O
rhythm O
control O
strategy O
in O
81 O
% O
of O
patients O
and O
with O
warfarin O
in O
23 O
% O
of O
patients O
. O
['Physiological-Clinical']

SD O
age O
of O
58.8 O
? O
[]

Regurgitation O
was O
assessed O
by O
the O
patient O
ingesting O
a O
methylene O
blue O
capsule O
10 O
min O
before O
induction O
of O
anaesthesia O
and O
examining O
the O
oropharynx O
by O
direct O
laryngoscopy O
at O
the O
end O
of O
surgery O
. O
[]

This O
study O
compared O
live O
ratings O
with O
ratings O
of O
videotapes O
and O
compared O
response O
to O
clomipramine O
with O
response O
to O
haloperidol O
in O
8 O
subjects O
, O
mean O
age O
5.62 O
years O
, O
who O
met O
criteria O
for O
autism O
. O
[]

24 O
healthy O
subjects O
( O
10 O
men O
; O
mean O
age O
26.2 O
y O
) O
received O
a O
single O
dose O
of O
rabeprazole O
20 O
mg O
or O
esomeprazole O
40 O
mg O
, O
with O
a O
14-day O
'washout O
' O
. O
[]

Patients O
who O
responded O
to O
a O
baseline O
telephone O
survey O
are O
randomized O
to O
a O
GERA O
or O
Control O
group O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effects O
of O
treatment O
with O
interleukin-1 O
receptor O
antagonist O
( O
IL-1Ra O
) O
on O
synovial O
tissue O
in O
rheumatoid O
arthritis O
( O
RA O
) O
. O
[]

Oral B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
was O
considered O
to O
have O
occurred O
if O
a O
patient O
reported O
any O
clinical O
sign O
or O
symptom O
of O
oral B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
with O
or O
without B-outcome ['Physiological-Clinical']
oral I-outcome ['Physiological-Clinical']
candidiasis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
increased O
concentration O
of O
serum B-outcome ['Physiological-Clinical']
Se I-outcome ['Physiological-Clinical']
, O
Zn B-outcome ['Physiological-Clinical']
was O
observed O
in O
patients O
treated O
with O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

ELISA O
results O
from O
individual O
cow O
milk O
samples O
were O
used O
to O
predict O
milk O
production O
response O
following O
a O
randomized O
anthelmintic O
treatment O
in O
a O
large O
field O
trial O
. O
[]

An O
indirect O
response O
model O
was O
developed O
to O
describe O
the O
pharmacodynamic B-outcome ['Physiological-Clinical']
relationships O
between O
flare O
or O
wheal O
areas O
and O
bilastine O
plasma O
concentrations O
. O
['Physiological-Clinical']

In O
one O
group O
, O
intramedullary O
alignment O
jigs O
were O
used O
. O
[]

During O
3 O
years O
, O
we O
implemented O
a O
physician O
behavior-change O
strategy O
that O
included O
guideline O
dissemination O
, O
small-group O
education O
, O
frequent O
updates O
and O
educational O
materials O
, O
and O
prescribing O
feedback O
. O
[]

2 O
) O
Compared O
with O
nitroglycerin O
, O
intravenous O
diltiazem O
lowered B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
myocardial B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
consumption I-outcome ['Physiological-Clinical']
index O
( O
systolic O
pressure O
x O
heart O
rate O
) O
to O
more O
extent O
significantly O
. O
( O
['Physiological-Clinical', 'Physiological-Clinical']

Follow-ups O
were O
at O
weeks O
6 O
, O
12 O
, O
24 O
, O
and O
at O
1-2 O
years O
posttreatment O
. O
[]

Thus O
, O
progression O
of O
atherosclerosis B-outcome ['Physiological-Clinical']
predominantly O
occurred O
in O
mild O
preexisting O
coronary O
stenoses O
and O
developed O
at O
previously O
angiographically O
normal O
sites O
. O
['Physiological-Clinical']

OBJECTIVE O
Although O
a O
diet O
that O
is O
rich O
in O
fiber O
is O
widely O
recommended O
for O
preventing O
and O
treating O
constipation O
, O
the O
efficacy O
of O
fiber O
supplements O
have O
not O
been O
tested O
sufficiently O
in O
children O
. O
[]

A O
subset O
of O
42 O
women O
at O
one O
site O
underwent O
colposcopy O
. O
[]

Future O
studies O
investigating O
the O
long-term O
efficacy O
of O
atomoxetine O
in O
children O
and O
adolescents O
with O
ASD O
should O
be O
randomized O
and O
placebo O
controlled O
. O
[]

During O
recovery O
, O
4E-BP1 B-outcome ['Physiological-Clinical']
phosphorylation I-outcome ['Physiological-Clinical']
increased O
in O
both O
experiments O
( O
P O
< O
0.01 O
) O
, O
and O
tended O
to O
be O
higher O
in O
the O
CHO+PRO O
test O
( O
P O
= O
0.08 O
) O
. O
['Physiological-Clinical']

One O
potential O
candidate O
could O
be O
the O
CD38 O
gene O
, O
which O
codes O
for O
a O
transmembrane O
protein O
engaged O
in O
OT O
secretion O
processes O
. O
[]

The O
average O
dose O
of O
prednisone O
during O
the O
placebo-treatment O
period O
was O
11.97 O
mg/day O
compared O
to O
8.37 O
mg/day O
while O
subjects O
were O
taking O
MTX O
. O
[]

A O
6 O
week O
double-blind O
placebo-controlled O
trial O
of O
cyproheptadine O
augmentation O
of O
ongoing O
haloperidol O
treatment O
was O
conducted O
in O
40 O
chronic O
schizophrenic O
in-patients O
. O
[]

Conversely O
, O
in O
the O
endurance O
group O
the O
V/M B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
was O
not O
altered O
, O
whereas O
the O
['Physiological-Clinical']

The O
long-term O
effect O
of O
oxandrolone O
on O
hepatic O
acute O
phase O
proteins O
in O
severely O
burned O
children O
. O
[]

Program B-outcome ['Life-Impact']
fidelity I-outcome ['Life-Impact']
was O
measured O
through O
video O
coding O
and O
use O
of O
a O
checklist O
. O
['Life-Impact']

CONCLUSION O
The O
placebo-controlled O
study O
suggested O
that O
S. O
boulardii O
significantly O
reduced O
the O
duration O
of O
[]

All O
329 O
patients O
were O
followed O
for O
clinical B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
thromboembolic I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
correlations O
were O
seen O
between O
the O
GHQ O
scores O
and O
fT3 O
( O
b O
: O
0.318 O
, O
P O
= O
0.275 O
) O
, O
rT O
( O
3 O
) O
( O
b O
: O
0.095 O
, O
P O
= O
0.95 O
) O
, O
rT O
( O
3 O
) O
to O
fT4 O
ratio O
( O
b O
: O
71.83 O
, O
P O
= O
0.09 O
) O
or O
fT3 O
to O
rT O
( O
3 O
) O
ratio O
( O
b O
: O
0.05 O
, O
P O
= O
0.32 O
) O
. O
[]

The O
major O
causes O
of O
poor O
nutritional O
status O
are O
related O
to O
the O
underlying O
disease O
, O
socio-economic O
factors O
, O
age O
, O
and O
length O
of O
hospitalization O
. O
[]

No O
group O
or O
medication O
effects O
were O
observed O
for O
the O
inhibition B-outcome ['Life-Impact']
condition I-outcome ['Life-Impact']
( O
AY O
trials O
) O
. O
['Life-Impact']

The O
sample O
consists O
of O
225 O
anaemic O
pregnant O
women O
randomly O
allocated O
in O
experimental O
( O
n=75 O
) O
, O
control O
group O
A O
( O
n=75 O
) O
and O
control O
group O
B O
( O
n=75 O
) O
. O
[]

Exogenous O
glucocorticoids O
are O
thus O
unlikely O
to O
have O
any O
more O
beneficial O
effects O
than O
endogenous O
cortisol O
. O
[]

Belatacept O
was O
associated O
with O
superior O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
similar O
patient/graft B-outcome ['Mortality']
survival I-outcome ['Mortality']
versus O
cyclosporine O
at O
1 O
year O
posttransplant O
, O
despite O
a O
higher O
rate O
of O
early B-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

METHODS O
AND O
MATERIALS O
One O
hundred O
and O
sixty-one O
recurrence-free O
breast O
cancer O
patients O
were O
examined O
for O
radiation-induced O
brachial O
plexopathy O
after O
a O
median O
follow-up O
period O
of O
50 O
months O
( O
13-99 O
months O
) O
. O
[]

METHODS O
In O
a O
randomized O
, O
placebo-controlled O
, O
double-blind O
trial O
of O
exemestane O
designed O
to O
detect O
a O
65 O
% O
relative O
reduction O
in O
invasive O
breast O
cancer O
, O
eligible O
postmenopausal O
women O
35 O
years O
of O
age O
or O
older O
had O
at O
least O
one O
of O
the O
following O
risk O
factors O
: O
60 O
years O
of O
age O
or O
older O
; O
Gail O
5-year O
risk O
score O
greater O
than O
1.66 O
% O
( O
chances O
in O
100 O
of O
invasive O
breast O
cancer O
developing O
within O
5 O
years O
) O
; O
prior O
atypical O
ductal O
or O
lobular O
hyperplasia O
or O
lobular O
carcinoma O
in O
situ O
; O
or O
ductal O
carcinoma O
in O
situ O
with O
mastectomy O
. O
[]

The O
volunteers O
were O
continuously O
monitored O
for O
any O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
resulting O
from O
the O
irrigation O
solutions O
or O
MTL O
. O
['Adverse-effects']

A O
similar O
decrease O
in O
VEGF O
expression O
was O
found O
( O
6.7 O
% O
in O
EGCG O
vs. O
11.0 O
% O
in O
in O
vehicle-treated O
skin O
( O
p O
< O
0.005 O
) O
. O
[]

11 O
were O
systematically O
treated O
by O
BCG O
and O
they O
also O
have O
a O
fairly O
good O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality']

This O
randomised O
trial O
indicates O
that O
GM-CSF O
is O
useful O
for O
chemotherapy O
acceleration O
. O
[]

We O
concluded O
that O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
increases O
significantly O
in O
a O
dose-response O
manner O
in O
response O
to O
acute O
isocapnic O
hypoxemia O
in O
normal O
persons O
. O
['Physiological-Clinical']

PURPOSE O
Pulmonary O
vein O
isolation O
( O
PVI O
) O
using O
phased O
radiofrequency O
( O
RF O
) O
energy O
has O
been O
shown O
to O
be O
effective O
in O
the O
treatment O
of O
paroxysmal O
atrial O
fibrillation O
( O
AF O
) O
. O
[]

Each O
year O
, O
cows O
were O
blocked O
by O
age O
and O
BCS O
and O
assigned O
randomly O
to O
one O
of O
three O
treatments O
: O
PRE O
( O
n O
= O
115 O
) O
cows O
received O
1.14 O
kg/d O
( O
DM O
basis O
) O
of O
whole O
corn O
germ O
for O
approximately O
45 O
d O
before O
calving O
; O
POST O
( O
n O
= O
109 O
) O
cows O
were O
fed O
1.14 O
kg/d O
of O
whole O
corn O
germ O
for O
approximately O
45 O
d O
after O
calving O
; O
and O
control O
cows O
( O
n O
= O
118 O
) O
were O
fed O
similar O
energy O
and O
protein O
from O
dry-rolled O
corn O
( O
1.82 O
kg O
of O
DM/d O
) O
for O
45 O
d O
before O
and O
after O
calving O
. O
[]

The O
difference O
in O
time O
to O
relapse O
between O
aripiprazole O
and O
placebo O
was O
not O
statistically O
significant O
( O
P O
= O
.097 O
) O
. O
[]

Follow-up O
through O
April O
, O
1993 O
shows O
that O
only O
14 O
patients O
have O
expired O
. O
[]

A O
proper B-outcome ['Life-Impact']
fluoroscopic I-outcome ['Life-Impact']
evaluation I-outcome ['Life-Impact']
was O
rapidly O
( O
15 O
+/- O
5 O
seconds O
) O
achieved O
in O
all O
patients O
with O
the O
former O
orientation O
, O
whereas O
it O
was O
impossible O
to O
obtain O
it O
in O
8 O
of O
20 O
( O
40 O
% O
) O
, O
19 O
of O
20 O
( O
95 O
% O
) O
, O
and O
4 O
of O
5 O
( O
80 O
% O
) O
of O
patients O
with O
the O
latter O
orientation O
. O
['Life-Impact']

No O
significant O
difference O
was O
found O
for O
the O
relationship O
between O
orimethen O
and O
tamoxifen O
treatment O
with O
respect O
to O
5-year O
survival B-outcome ['Mortality']
and O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

Failure B-outcome ['Physiological-Clinical']
criteria O
developed O
in O
13 O
of O
25 O
insulin-withdrawal O
patients O
, O
at O
a O
median O
of O
four O
weeks O
after O
withdrawal O
, O
compared O
with O
two O
of O
24 O
control O
subjects O
. O
['Physiological-Clinical']

RESULTS O
A O
1-way O
between-groups O
analysis O
of O
covariance O
revealed O
a O
significant O
difference O
in O
postintervention O
WheelCon-M O
scores O
between O
the O
intervention O
and O
control O
groups O
( O
F1,17=10.9 O
, O
P=.004 O
) O
after O
controlling O
for O
baseline O
WheelCon-M O
scores O
. O
[]

OBJECTIVES O
We O
studied O
the O
consequences O
of O
applying O
the O
recent O
WHO/ISH O
risk O
stratification O
scheme O
to O
a O
MONICA O
sample O
of O
6000 O
subjects O
from O
a O
geographically O
defined O
population O
in O
northern O
Sweden O
, O
regarding O
indications O
for O
treatment O
, O
target O
blood O
pressure O
and O
risk O
distribution O
. O
[]

A O
low-dose O
combination O
of O
flutamide-metformin O
and O
ethinylestradiol-drospirenone O
was O
recently O
found O
to O
reduce O
the O
excess O
of O
total O
and O
abdominal O
fat O
, O
to O
diminish O
the O
deficit O
in O
lean B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
, O
and O
to O
attenuate O
the O
dysadipocytokinemia B-outcome ['Physiological-Clinical']
of O
young O
women O
with O
ovarian O
hyperandrogenism O
, O
a O
variant O
of O
polycystic O
ovary O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Nighttime B-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
was O
relieved O
in O
53.1 O
% O
( O
111/209 O
) O
, O
50.5 O
% O
( O
111/220 O
) O
, O
and O
12.7 O
% O
( O
28/221 O
) O
of O
patients O
who O
received O
esomeprazole O
40 O
mg O
, O
esomeprazole O
20 O
mg O
, O
and O
placebo O
, O
respectively O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
assisted O
vaginal O
delivery O
by O
forceps O
with O
delivery O
by O
vacuum O
extractor O
, O
where O
a O
new O
vacuum O
extractor O
policy O
was O
employed O
which O
dictated O
the O
cup O
to O
be O
used O
in O
specific O
situations O
. O
[]

Safety O
and O
immunogenicity B-outcome ['Physiological-Clinical']
of O
IMVAMUNE O
, O
a O
promising O
candidate O
as O
a O
third O
generation O
smallpox O
vaccine O
. O
['Physiological-Clinical']

RESULTS O
Between O
December O
2001 O
and O
October O
2003 O
, O
92 O
patients O
were O
enrolled O
and O
randomly O
assigned O
to O
treatment O
with O
ixabepilone O
alone O
( O
45 O
patients O
) O
or O
in O
combination O
with O
EMP O
( O
47 O
patients O
) O
. O
[]

The O
newly O
formed O
bone O
seems O
to O
have O
normal O
bone B-outcome ['Physiological-Clinical']
elasticity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Regression O
of O
left O
ventricular O
hypertrophy O
after O
stentless O
versus O
conventional O
aortic O
valve O
replacement O
. O
[]

Dosing O
was O
based O
on O
serum O
iPTH O
, O
calcium O
, O
and O
phosphorus O
levels O
. O
[]

In O
348 O
patients O
with O
moderate O
coronary O
artery O
disease O
, O
standardized O
coronary O
angiograms O
were O
taken O
3 O
years O
apart O
and O
were O
quantitatively O
analysed O
. O
[]

This O
study O
compared O
surgical O
outcomes O
after O
laparoscopic O
and O
open O
approaches O
for O
mid O
and O
low O
rectal O
cancers O
. O
[]

Studies O
were O
interpreted O
by O
an O
experienced O
echocardiographer O
unaware O
of O
the O
sequence O
and O
site O
of O
injections O
. O
[]

There O
were O
no O
clinically O
meaningful O
differences O
between O
the O
treatment O
groups O
in O
the O
incidence O
and O
severity O
of O
adverse B-outcome ['Adverse-effects']
experiences O
, O
except O
that O
weight O
gain O
, O
fluid B-outcome ['Physiological-Clinical']
retention B-outcome ['Physiological-Clinical']
, O
and O
dyspnea B-outcome ['Physiological-Clinical']
were O
observed O
in O
more O
patients O
in O
the O
megestrol O
acetate O
group O
compared O
with O
those O
receiving O
fadrozole O
HCL O
, O
whereas O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
were O
observed O
in O
more O
patients O
in O
the O
fadrozole O
HCL O
group O
compared O
with O
those O
receiving O
megestrol O
acetate O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Intervention O
group O
attended O
monthly O
sessions O
and O
self-selected O
child O
behaviours O
and O
parenting O
practices O
to O
change O
. O
[]

The O
preparation O
of O
patients O
for O
cardiac O
surgery O
. O
[]

RESULTS O
Compared O
with O
before O
priming O
, O
after O
priming O
the O
times B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
nadir I-outcome ['Physiological-Clinical']
( O
12.8 O
+/- O
2.5 O
days O
v O
14.8 O
+/- O
1.5 O
days O
, O
respectively O
; O
P O
=.0001 O
) O
and O
platelet B-outcome ['Physiological-Clinical']
nadir I-outcome ['Physiological-Clinical']
( O
mean O
+/- O
SD O
, O
10.1 O
+/- O
1.9 O
days O
v O
11.1 O
+/- O
2.2 O
days O
, O
P O
< O
.05 O
) O
were O
shorter O
, O
indicating O
a O
shift O
of O
cytotoxicity O
to O
later O
progenitors O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
study O
included O
39 O
patients O
with O
elevated O
triglyceride O
levels O
and O
peripheral O
artery O
sclerosis O
, O
treated O
for O
90 O
days O
with O
either O
simvastatin O
( O
40 O
mg O
daily O
) O
or O
placebo O
. O
[]

Data O
of O
the O
playroom O
observation O
pointed O
to O
an O
activating B-outcome ['Life-Impact']
influence O
of O
Org O
2766 O
, O
as O
revealed O
by O
a O
significant O
decrease O
of O
stereotypic B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
and O
significant O
increases O
in O
change O
toys O
, O
locomote B-outcome ['Life-Impact']
, O
and O
talk B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Reports O
of O
adverse O
reactions O
were O
based O
on O
information O
volunteered O
by O
patients O
and O
that O
were O
elicited O
during O
interviews O
. O
[]

Motion O
style O
acupuncture O
treatment O
( O
MSAT O
) O
for O
acute O
low O
back O
pain O
with O
severe O
disability O
: O
a O
multicenter O
, O
randomized O
, O
controlled O
trial O
protocol O
. O
[]

Patients O
received O
1-3 O
g/kg/day O
of O
fat O
emulsion O
into O
either O
the O
ecmo O
circuit O
or O
separate O
intravenous O
access O
. O
[]

In O
this O
comparative O
controlled O
trial O
, O
the O
ADPT O
vaccines O
were O
more O
immunogenic B-outcome ['Physiological-Clinical']
, O
with O
less O
local B-outcome ['Physiological-Clinical']
and O
systemic B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
, O
than O
the O
WCDPT O
vaccine O
but O
there O
was O
a O
considerable O
drop O
in O
antibody B-outcome ['Physiological-Clinical']
titres I-outcome ['Physiological-Clinical']
in O
all O
the O
vaccine O
groups O
12 O
months O
after O
primary O
vaccination O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In-person O
recall O
data O
were O
combined O
for O
comparison O
with O
the O
telephone O
recalls O
. O
[]

METHODS O
We O
administered O
a O
double-blind O
placebo-controlled O
trial O
of O
fluoxetine O
to O
35 O
patients O
with O
restricting-type O
anorexia O
nervosa O
. O
[]

Objective B-outcome ['Physiological-Clinical']
regression I-outcome ['Physiological-Clinical']
( O
CR O
+ O
PR O
) O
was O
observed O
in O
58 O
% O
of O
group O
A O
and O
75 O
% O
of O
group O
B O
, O
with O
CR O
in O
11 O
% O
and O
23 O
% O
, O
respectively O
. O
['Physiological-Clinical']

This O
may O
explain O
the O
functional O
need O
for O
high-dose O
vitamin O
B O
( O
6 O
) O
supplementation O
in O
many O
children O
and O
adults O
with O
autism O
. O
[]

All O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
recorded O
. O
['Adverse-effects']

Randomly O
assigned O
treatments O
on O
days O
1 O
, O
3 O
, O
and O
5 O
were O
: O
group O
1 O
( O
n=27 O
) O
placebo O
, O
placebo O
, O
rhTPO O
1.5 O
microg/kg O
; O
group O
2 O
( O
n=27 O
) O
rhTPO O
1.5 O
microg/kg O
, O
placebo O
, O
placebo O
; O
groups O
3 O
( O
n=28 O
) O
and O
4 O
( O
n=22 O
) O
rhTPO O
0.5 O
microg/kg O
on O
all O
3 O
treatment O
days O
; O
and O
group O
5 O
( O
n=30 O
) O
placebo O
on O
all O
3 O
treatment O
days O
. O
[]

Pyridostigmine O
was O
administered O
orally O
in O
a O
randomized O
double-blind O
cross-over O
study O
in O
four O
doses O
of O
30 O
mg O
every O
8 O
h. O
An O
average O
of O
33 O
% O
whole O
blood O
cholinesterase O
inhibition O
was O
induced O
in O
the O
pyridostigmine O
treated O
group O
4 O
h O
after O
ingestion O
of O
last O
tablet O
. O
[]

Eight O
group O
interviews O
were O
held O
with O
Cambodian O
American O
men O
( O
48 O
) O
and O
women O
( O
49 O
) O
. O
[]

Results O
from O
this O
study O
suggest O
that O
anti-migraine O
efficacy O
is O
not O
mediated O
solely O
through O
the O
5-HT O
( O
1D O
) O
receptor O
subtype O
, O
although O
this O
receptor O
may O
contribute O
, O
at O
least O
in O
part O
, O
to O
the O
adverse O
cardiovascular O
effects O
observed O
with O
5-HT O
agonist O
medications O
. O
[]

Correlational O
studies O
have O
revealed O
a O
positive O
relationship O
between O
parent O
verbal O
responsiveness O
and O
language O
outcomes O
in O
children O
with O
autism O
. O
[]

Superior O
fixation O
of O
pegged O
trabecular O
metal O
over O
screw-fixed O
pegged O
porous O
titanium O
fiber O
mesh O
: O
a O
randomized O
clinical O
RSA O
study O
on O
cementless O
tibial O
components O
. O
[]

In O
contrast O
, O
SDZ O
ENS-163 O
with O
saline O
had O
no O
effect O
on O
CNTB O
scores O
, O
increased O
salivation B-outcome ['Physiological-Clinical']
, O
and O
increased O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Patients O
with O
SID O
were O
randomly O
assigned O
to O
retapamulin O
ointment O
1 O
% O
( O
twice O
daily O
[ O
bid O
] O
) O
for O
5 O
days O
, O
or O
oral O
cephalexin O
( O
500 O
mg O
bid O
) O
for O
10 O
days O
. O
[]

CONCLUSION O
[]

The O
effect O
of O
prethrombolytic O
cyclosporine-A O
injection O
on O
clinical O
outcome O
of O
acute O
anterior O
ST-elevation O
myocardial O
infarction O
. O
[]

Patients O
recorded O
daily O
the O
number O
and O
severity O
of O
their O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
; O
response O
was O
defined O
as O
a O
> O
or O
=50 O
% O
decrease O
in O
the O
number O
and O
severity O
of O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thrombin-activatable O
fibrinolysis O
inhibitor O
in O
hypothyroidism O
and O
hyperthyroxinaemia O
. O
[]

This O
study O
examined O
whether O
abstinence-contingent O
incentives O
would O
improve O
outcomes O
for O
patients O
entering O
outpatient O
opiate B-outcome ['Physiological-Clinical']
detoxification I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
associated O
with O
PNU-142633 O
treatment O
included O
chest B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
two O
patients O
) O
and O
QTc B-outcome ['Physiological-Clinical']
prolongation I-outcome ['Physiological-Clinical']
( O
three O
patients O
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Significantly O
more O
patients O
in O
the O
clonidine O
group O
than O
in O
the O
placebo O
group O
had O
clinically O
important O
hypotension B-outcome ['Physiological-Clinical']
( O
2385 O
patients O
[ O
47.6 O
% O
] O
vs. O
1854 O
patients O
[ O
37.1 O
% O
] O
; O
hazard O
ratio O
1.32 O
; O
95 O
% O
CI O
, O
1.24 O
to O
1.40 O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

METHODS O
Patients O
who O
had O
symptomatic O
atrial O
fibrillation O
for O
> O
48 O
hours O
but O
< O
6 O
months O
were O
eligible O
for O
this O
multicenter O
, O
randomized O
, O
placebo-controlled O
clinical O
trial O
. O
[]

Twenty O
typical O
and O
19 O
autistic O
adults O
donated O
to O
charity O
and O
to O
a O
person O
, O
both O
when O
alone O
and O
when O
observed O
. O
[]

No O
statistically O
significant O
evidence O
for O
a O
contribution O
in O
CRC O
risk O
was O
detected O
, O
but O
a O
suggestive O
role O
for O
the O
mutation O
was O
observed O
in O
familial O
BRCA1/2-negative O
breast O
cancer O
. O
[]

OBJECTIVE O
To O
screen O
for O
bacterial O
vaginosis O
( O
BV O
) O
and O
to O
investigate O
the O
effect O
of O
treatment O
with O
vaginal O
clindamycin O
in O
order O
to O
observe O
the O
effect O
on O
late B-outcome ['Physiological-Clinical']
miscarriage I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
prior I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
37 I-outcome ['Physiological-Clinical']
completed I-outcome ['Physiological-Clinical']
weeks I-outcome ['Physiological-Clinical']
( O
primary O
outcome O
) O
. O
['Physiological-Clinical']

Clonidine-related O
side O
effects O
are O
still O
evident O
, O
but O
the O
overall O
tolerance O
profile O
for O
this O
reduced O
dosage O
of O
the O
drug O
appears O
to O
be O
favorable O
. O
[]

When O
response O
was O
analyzed O
by O
hematological B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
, O
there O
was O
a O
35.7 O
% O
response O
if O
patients O
had O
leukopenia B-outcome ['Physiological-Clinical']
grade O
3/4 O
( O
versus O
8.3 O
% O
, O
P O
= O
0.08 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Times O
were O
recorded O
to O
awakening O
and O
tracheal O
extubation O
. O
[]

None O
of O
these O
patients O
died O
from O
the O
reaction O
. O
[]

One O
of O
the O
frequent O
long-term O
complications O
after O
stent O
implantation O
is O
restenosis O
due O
to O
the O
building O
up O
of O
a O
neointima O
within O
the O
artery O
, O
as O
well O
as O
endovascular O
hyperplasia O
( O
tissue O
growth O
) O
. O
[]

Thus O
succinylcholine O
may O
be O
used O
as O
the O
sole O
paralytic O
agent O
in O
rapid-sequence O
intubation O
of O
head O
trauma O
patients O
. O
[]

We O
also O
compared O
changes O
in O
other O
ABC-C O
subscale O
scores O
and O
Clinical O
Global O
Impressions-Improvement O
( O
CGI-I O
) O
scale O
scores O
between O
the O
two O
groups O
. O
[]

Alvimopan O
for O
the O
management O
of O
postoperative O
ileus O
after O
bowel O
resection O
: O
characterization O
of O
clinical O
benefit O
by O
pooled O
responder O
analysis O
. O
[]

The O
primary O
efficacy O
endpoint O
was O
response O
rate O
. O
[]

min O
( O
-1 O
) O
) O
was O
infused O
from O
the O
end O
of O
anesthesia O
to O
15 O
min O
after O
extubation O
. O
[]

RESULTS O
In O
placebo O
treated O
men O
without O
prostate O
cancer O
there O
was O
an O
8.3 O
% O
median O
increase O
in O
PSA O
at O
month B-outcome ['Physiological-Clinical']
24 I-outcome ['Physiological-Clinical']
compared O
with O
-59.5 O
% O
in O
those O
who O
received O
dutasteride O
, O
using O
doubled O
values O
to O
correct O
for O
dutasteride O
treatment O
. O
['Physiological-Clinical']

Elevated B-outcome ['Physiological-Clinical']
stimulated I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
predicted O
the O
need O
for O
insulin O
therapy O
. O
['Physiological-Clinical']

Only O
minor B-outcome ['Adverse-effects']
side-effects I-outcome ['Adverse-effects']
were O
reported O
. O
['Adverse-effects']

Exposure O
was O
by O
means O
of O
a O
head O
dome O
, O
a O
head-only O
exposure O
device O
that O
permitted O
continuous O
measurement O
( O
unfettered O
breathing O
) O
of O
Vr O
, O
f O
, O
VE O
, O
and O
the O
onset O
and O
persistence O
of O
oronasal B-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Terbinafine O
, O
250 O
mg O
daily O
for O
3 O
months O
( O
continuous O
) O
or O
terbinafine O
, O
500 O
mg O
daily O
for O
1 O
week O
per O
month O
for O
3 O
months O
( O
pulse O
) O
was O
administered O
. O
[]

Combined O
use O
of O
vasopressin O
and O
synthetic O
hypothalamic O
releasing O
factors O
as O
a O
new O
test O
of O
anterior O
pituitary O
function O
. O
[]

At O
9-12 O
months O
after O
AMI O
, O
ejection B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
remained O
significantly O
higher O
than O
at O
baseline O
in O
both O
groups O
. O
['Physiological-Clinical']

METHODS O
Peanut-allergic O
subjects O
were O
re-challenged O
with O
a O
lower O
fat O
recipe O
after O
reacting O
more O
severely O
than O
was O
anticipated O
to O
an O
initial O
peanut O
challenge O
. O
[]

It O
is O
proposed O
that O
there O
are O
two O
components O
underlying O
the O
auditory O
MAE B-outcome ['Physiological-Clinical']
: O
( O
1 O
) O
a O
generalized O
bias O
to O
respond O
that O
probes O
move O
in O
the O
direction O
opposite O
to O
that O
of O
the O
adaptor O
, O
independent O
of O
their O
spectra O
; O
and O
( O
2 O
) O
a O
loss O
of O
sensitivity O
to O
the O
velocity O
of O
moving O
sounds O
after O
prolonged O
exposure O
to O
moving O
sounds O
having O
the O
same O
spectral O
content O
. O
['Physiological-Clinical']

Knowledge O
of O
risk O
factors O
can O
help O
target O
control O
interventions O
. O
[]

However O
, O
38 O
% O
of O
H. O
influenzae O
patients O
treated O
with O
CB O
had O
positive O
CSF B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
on O
day O
1 O
follow-up O
lumbar O
punctures O
, O
compared O
with O
only O
5.8 O
% O
of O
AMP O
patients O
with O
H. O
influenzae O
. O
['Physiological-Clinical']

The O
great O
dispersion O
of O
the O
results O
of O
plasminogen B-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
the O
plausible O
cause O
of O
the O
lack O
of O
any O
significant O
difference O
in O
this O
variable O
. O
['Physiological-Clinical']

For O
MSCT O
and O
SAA O
combined O
group O
, O
the O
accuracies O
of O
preoperative O
staging O
of O
T O
, O
N O
, O
M B-outcome ['Physiological-Clinical']
and O
TNM B-outcome ['Physiological-Clinical']
was O
87.3 O
% O
, O
85.2 O
% O
, O
100 O
% O
and O
86.4 O
% O
, O
respectively O
; O
and O
for O
MSCT O
group O
, O
the O
corresponding O
rates O
was O
85.2 O
% O
, O
67.0 O
% O
, O
100 O
% O
and O
66.1 O
% O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Baseline O
clinical O
characteristics O
of O
the O
allopurinol O
and O
placebo O
groups O
demonstrated O
no O
differences O
in O
terms O
of O
clinical B-outcome ['Physiological-Clinical']
characteristics O
, O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
inflammatory B-outcome ['Physiological-Clinical']
markers B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
rate O
of O
severe O
( O
inpatient O
treatment O
required O
) O
definite O
infections B-outcome ['Physiological-Clinical']
after O
engraftment B-outcome ['Physiological-Clinical']
was O
2.4-fold O
higher O
in O
marrow O
recipients O
( O
P O
=.002 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
gestational B-outcome ['Physiological-Clinical']
age O
at O
delivery B-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
in O
the O
treatment O
group O
( O
39.9 O
+/- O
1.0 O
weeks O
vs O
40.5 O
+/- O
0.99 O
weeks O
, O
p O
= O
0.003 O
) O
as O
was O
the O
incidence O
of O
postdates O
['Physiological-Clinical', 'Physiological-Clinical']

Increased O
atrial O
electromechanical O
coupling O
time O
interval O
measured O
by O
tissue O
Doppler O
is O
accepted O
as O
an O
important O
factor O
for O
prediction O
of O
AF B-outcome ['Physiological-Clinical']
development I-outcome ['Physiological-Clinical']
in O
hypertensive O
patients O
. O
['Physiological-Clinical']

Comparison O
of O
patient-controlled O
and O
nurse-administered O
analgesia O
using O
intravenous O
fentanyl O
during O
labor O
. O
[]

BACKGROUND O
Nitric O
oxide O
( O
NO O
) O
is O
present O
in O
the O
exhaled O
air O
of O
animals O
and O
humans O
. O
[]

The O
control O
group O
had O
significantly O
more O
positive O
blood B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
( O
P=0.002 O
) O
. O
['Physiological-Clinical']

AIDS-free O
survival O
in O
mothers O
at O
18 O
months O
will O
be O
reported O
in O
a O
different O
publication O
. O
[]

qEEG B-outcome ['Physiological-Clinical']
spectral I-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
in O
the O
treatment O
, O
but O
not O
in O
the O
control O
group O
, O
were O
also O
reduced O
significantly O
. O
['Physiological-Clinical']

The O
effect O
on O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
was O
a O
13 O
% O
lowering O
( O
i.e O
. O
['Physiological-Clinical']

Possible O
over-reading O
of O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
with O
the O
mini-Wright O
meter O
at O
low O
mean O
values O
was O
also O
seen O
. O
['Physiological-Clinical']

Sixteen O
were O
ineligible O
as O
they O
were O
immediately O
transferred O
to O
another O
acute O
ward O
, O
were O
managed O
conservatively O
or O
died O
preoperatively O
. O
[]

Randomization O
was O
unbalanced O
1:2 O
in O
favor O
of O
the O
combination O
therapy O
, O
since O
study O
conditions O
were O
identical O
to O
the O
previous O
CML-study O
I O
and O
it O
had O
been O
planned O
in O
advance O
to O
add O
the O
HU O
patients O
of O
study O
I O
( O
n=194 O
) O
to O
the O
HU O
control O
group O
. O
[]

It O
is O
concluded O
that O
hypnosis O
and O
CB O
coping O
skills O
are O
effective O
in O
preparing O
pediatric O
oncology O
patients O
for O
bone O
marrow O
aspiration O
. O
[]

In O
rats O
, O
50 O
micrograms/kg O
mouse O
EGF O
( O
mEGF O
) O
and O
2 O
% O
hydroxypropyl O
cellulose O
( O
HPC O
) O
or O
1.0 O
g/kg O
sucralfate O
given O
by O
gastric O
intubation O
significantly O
raised O
the O
residual O
mEGF B-outcome ['Physiological-Clinical']
levels O
in O
both O
gastric O
luminal O
content O
( O
HPC O
: O
x O
30 O
; O
sucralfate O
: O
x O
300 O
as O
high O
as O
those O
in O
EGF O
alone O
) O
and O
tissue O
( O
HPC O
: O
x O
60 O
; O
sucralfate O
: O
x O
100 O
) O
. O
['Physiological-Clinical']

The O
relative O
rates O
of O
grade O
2 O
or O
3 O
cervical B-outcome ['Physiological-Clinical']
intraepithelial I-outcome ['Physiological-Clinical']
neoplasia I-outcome ['Physiological-Clinical']
or O
cancer B-outcome ['Physiological-Clinical']
detected O
at O
enrollment O
and O
at O
subsequent O
screening O
examinations O
were O
calculated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Results O
indicated O
the O
treatment O
group O
made O
significantly O
more O
gains O
in O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
initiations I-outcome ['Life-Impact']
at O
post-treatment O
and O
follow-up O
and O
social-emotional B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
at O
follow-up O
than O
the O
control O
group O
. O
['Life-Impact', 'Life-Impact']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Serum B-outcome ['Physiological-Clinical']
and O
urine B-outcome ['Physiological-Clinical']
cotinine I-outcome ['Physiological-Clinical']
, O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
and O
cytokines B-outcome ['Physiological-Clinical']
IL-4 I-outcome ['Physiological-Clinical']
, O
IL-5 B-outcome ['Physiological-Clinical']
, O
IL-6 B-outcome ['Physiological-Clinical']
, O
tumor B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor O
( O
TNF B-outcome ['Physiological-Clinical']
) O
-alpha O
, O
and O
IFN-gamma B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
4 O
weeks O
, O
'responders O
' O
to O
treatment O
( O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
reduced O
to O
less O
than O
or O
equal O
to O
90 O
mmHg O
or O
by O
greater O
than O
or O
equal O
to O
10 O
mmHg O
) O
were O
kept O
on O
monotherapy O
and O
checked O
at O
4-weekly O
intervals O
for O
another O
3 O
months O
. O
['Physiological-Clinical']

Treatment O
with O
metformin O
of O
non-diabetic O
men O
with O
hypertension O
, O
hypertriglyceridaemia O
and O
central O
fat O
distribution O
: O
the O
BIGPRO O
1.2 O
trial O
. O
[]

[ O
A O
prospective O
randomized O
study O
of O
the O
radiotherapy O
volume O
for O
limited-stage O
small O
cell O
lung O
cancer O
: O
a O
preliminary O
report O
] O
. O
[]

CONCLUSIONS O
Pre-treatment O
with O
pronase O
reduced O
the O
artefacts B-outcome ['Physiological-Clinical']
during O
endoscopic O
ultrasonography O
. O
['Physiological-Clinical']

The O
primary O
study O
endpoint O
was O
the O
change O
from O
baseline O
at O
day O
15 O
in O
the O
patient-assessed O
shoulder B-outcome ['Physiological-Clinical']
pain B-outcome ['Physiological-Clinical']
score O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Highly O
distressed B-outcome ['Life-Impact']
women O
did O
not O
derive O
a O
['Life-Impact']

During O
followup O
urethral B-outcome ['Physiological-Clinical']
stricture I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
was O
observed O
in O
3 O
patients O
( O
6.1 O
% O
) O
cases O
in O
the O
former O
group O
and O
in O
1 O
( O
2.1 O
% O
) O
in O
the O
latter O
group O
( O
p O
= O
0.002 O
) O
. O
['Physiological-Clinical']

Acute B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
infusion I-outcome ['Physiological-Clinical']
resulted O
in O
maternal B-outcome ['Physiological-Clinical']
hyperglycemia I-outcome ['Physiological-Clinical']
, O
hyperinsulinemia B-outcome ['Physiological-Clinical']
, O
and O
an O
increase O
in O
the O
blood O
lactate I-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
used O
data O
from O
a O
prospective O
French O
study O
comparing O
four O
doses O
of O
immunoglobulins O
. O
[]

In O
the O
case O
of O
the O
right O
colon O
, O
changes O
in O
transit B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
also O
were O
significant O
between O
groups O
. O
['Life-Impact']

HYPOTHESIS O
Bovine O
pericardium O
( O
BP O
) O
demonstrates O
improved O
intraoperative O
hemostasis O
and O
equivalent O
perioperative O
morbidity O
compared O
with O
Dacron O
when O
used O
as O
patch O
material O
for O
angioplasty O
following O
carotid O
endarterectomy O
. O
[]

AIM O
OF O
THE O
STUDY O
To O
assess O
the O
effectivity O
and O
safeness O
of O
intravenous O
treatment O
of O
pospartal O
anemia O
with O
trivalent O
ferrum O
preparation O
. O
[]

In O
addition O
, O
37 O
placebo O
nonresponders O
received O
open-label O
risperidone O
for O
another O
8 O
weeks O
. O
[]

The O
outcome O
of O
patients O
with O
rectal O
cancer O
treated O
by O
abdominoperineal O
or O
anterior O
resection O
, O
with O
or O
without O
preoperative O
radiotherapy O
, O
was O
assessed O
to O
detect O
any O
differences O
attributable O
to O
the O
operative O
method O
and O
interactions O
between O
radiotherapy O
and O
type O
of O
surgery O
. O
[]

Median O
adrenal B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
was O
2.7 O
cm O
( O
range O
1 O
to O
9 O
) O
in O
the O
TLA O
group O
and O
2.6 O
cm O
( O
range O
0.5 O
to O
6 O
) O
in O
the O
RLA O
group O
( O
p O
= O
0.83 O
) O
. O
['Physiological-Clinical']

We O
investigated O
in O
healthy O
nonobese O
males O
the O
effect O
of O
the O
GH O
receptor O
antagonist O
pegvisomant O
in O
different O
metabolic O
conditions O
. O
[]

Efficacy O
and O
safety O
of O
10 O
% O
HES O
130/0.4 O
versus O
10 O
% O
HES O
200/0.5 O
for O
plasma O
volume O
expansion O
in O
cardiac O
surgery O
patients O
. O
[]

These O
data O
are O
comparable O
to O
the O
OS B-outcome ['Mortality']
for O
the O
137 O
HLA-A*0201-positive O
patients O
randomized O
to O
ipilimumab O
in O
the O
phase O
III O
study O
[ O
10.1 O
months O
, O
95 O
% O
CI O
8.0-13.8 O
] O
. O
['Mortality']

We O
investigated O
whether O
acupressure O
on O
the O
extra O
1 O
point O
could O
alleviate O
the O
pain B-outcome ['Physiological-Clinical']
of O
needle O
insertion O
. O
['Physiological-Clinical']

catheters O
. O
[]

Anderson O
Dysphagia O
Inventory O
( O
MDADI O
) O
, O
with O
secondary O
endpoints O
including O
survival O
, O
toxicity O
, O
other O
QOL O
outcomes O
, O
and O
swallowing O
function O
. O
[]

This O
was O
a O
12-week O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Only O
patients O
with O
extensive O
thromboses O
were O
included O
. O
[]

There O
was O
no O
statistically O
significant O
difference O
of O
plaque O
regression O
between O
the O
2 O
groups O
( O
p O
= O
0.96 O
) O
. O
[]

This O
randomized O
phase O
III O
trial O
compared O
concurrent O
chemoradiotherapy O
( O
CCRT O
) O
versus O
radiotherapy O
( O
RT O
) O
alone O
in O
patients O
with O
advanced O
NPC O
. O
[]

Additional O
irradiation+/-surgery O
was O
performed O
if O
and O
when O
feasible O
. O
[]

DESIGN O
This O
was O
a O
placebo-controlled O
, O
dose-response O
, O
randomized O
, O
double-blind O
study O
of O
the O
effect O
of O
vitamin O
D O
on O
calcium O
absorption O
in O
healthy O
postmenopausal O
women O
. O
[]

on O
day O
1 O
and O
200 O
mg/m2 O
orally O
on O
days O
2 O
and O
3 O
) O
or O
symptomatic O
treatment O
. O
[]

Comparison O
of O
outcomes O
on O
the O
whole O
series O
, O
patients O
with O
uteri O
< O
or O
= O
500 O
g O
( O
Group O
1 O
) O
and O
patients O
with O
uteri O
> O
500 O
g O
( O
Group O
2 O
) O
. O
[]

METHODS O
Children O
between O
the O
ages O
3 O
and O
11 O
years O
( O
inclusive O
) O
with O
a O
DSM O
IV O
clinical O
diagnosis O
of O
autism O
and O
who O
were O
outpatients O
from O
a O
specialty O
clinic O
for O
children O
at O
Roozbeh O
Psychiatric O
Teaching O
Hospital O
were O
recruited O
. O
[]

Of O
the O
40 O
children O
enrolled O
, O
39 O
completed O
the O
trial O
over O
a O
period O
of O
18 O
months O
; O
19 O
received O
risperidone O
, O
and O
20 O
received O
placebo O
. O
[]

Group O
1 O
received O
a O
one-on-one O
educational O
presentation O
by O
a O
clinical O
pharmacist O
, O
written O
educational O
materials O
, O
a O
brief O
follow-up O
visit O
, O
and O
feedback O
with O
recommendations O
. O
[]

SETTING O
Sports O
Medical O
Department O
of O
the O
Hague O
Medical O
Centre O
. O
[]

We O
could O
not O
find O
any O
relationship O
between O
ARDS O
due O
to O
pulmonary B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
and O
any O
anticancer O
agent O
or O
antibiotics O
. O
['Physiological-Clinical']

Running O
in O
parallel O
with O
the O
main O
study O
is O
a O
prospective O
economic O
analysis O
, O
the O
objectives O
of O
which O
are O
( O
1 O
) O
to O
estimate O
the O
effectiveness O
of O
pravastatin O
compared O
with O
placebo O
in O
terms O
of O
survival B-outcome ['Mortality']
, O
quality O
of O
life O
( O
QOL B-outcome ['Life-Impact']
) O
, O
and O
quality-adjusted O
life-years O
( O
QALY O
) O
; O
( O
2 O
) O
to O
estimate O
the O
resource O
usage O
associated O
with O
pravastatin O
compared O
with O
placebo-in O
particular O
, O
to O
study O
whether O
it O
alters O
resource O
usage O
through O
prevention O
of O
disease O
progression O
; O
and O
( O
3 O
) O
to O
use O
this O
information O
for O
a O
cost-utility O
analysis O
with O
cost O
per O
quality-adjusted O
life-year O
as O
the O
unit O
of O
analysis O
. O
['Mortality', 'Life-Impact']

In O
the O
treatment O
of O
carcinoma O
in O
situ O
complete O
responses O
have O
been O
reported O
in O
about O
60 O
% O
of O
cases O
. O
[]

RESULTS O
No O
side O
effects O
were O
observed O
. O
[]

Cardiovascular B-outcome ['Physiological-Clinical']
risk O
markers O
were O
measured O
before O
, O
after O
cycle O
1 O
, O
3 O
and O
6 O
and O
at O
4 O
weeks O
post-treatment O
. O
['Physiological-Clinical']

In O
Study O
1 O
, O
the O
authors O
found O
that O
in O
the O
made-in-the-U.S. O
scenario O
condition O
, O
European O
Americans O
were O
more O
accurate O
than O
were O
Asian O
Americans O
in O
their O
retrospective O
frequency O
judgments B-outcome ['Life-Impact']
of O
emotions B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Patient O
and O
tumor O
characteristics O
were O
well O
balanced O
between O
the O
two O
arms O
. O
[]

RESULTS O
Methylphenidate O
was O
superior O
to O
placebo O
on O
the O
primary O
outcome O
measure O
, O
with O
effect O
sizes O
ranging O
from O
0.20 O
to O
0.54 O
depending O
on O
dose O
and O
rater O
. O
[]

Comparison O
of O
antihypertensives O
after O
coronary O
artery O
surgery O
. O
[]

CONCLUSION O
Adapalene O
was O
the O
favorable O
option O
in O
the O
treatment O
of O
pityriasis O
versicolor O
. O
[]

However O
the O
results O
need O
confirmation O
by O
a O
larger O
randomized O
controlled O
trial O
. O
[]

BACKGROUND/AIMS O
To O
evaluate O
and O
compare O
obtained O
mydriasis O
with O
phenylephrine O
10 O
% O
associated O
with O
tropicamide O
1 O
% O
in O
type O
2 O
diabetics O
and O
non-diabetic O
patients O
. O
[]

Intervention O
was O
based O
on O
receiving O
a O
single O
dose O
of O
oral O
steroid O
, O
with O
or O
without O
vitamin O
D O
( O
3 O
) O
, O
or O
placebo O
only O
on O
the O
day O
of O
the O
build-up O
phase O
of O
SIT O
. O
[]

METHODS O
Background O
infusions O
were O
saline O
, O
or O
GLP-1 O
at O
0.3 O
or O
0.9 O
pmol/ O
kg/min O
on O
separate O
days O
in O
random O
order O
. O
[]

For O
the O
34 O
( O
60 O
% O
) O
patients O
who O
participated O
in O
the O
study O
18 O
months O
after O
treatment O
was O
terminated O
, O
the O
mean O
weight O
loss B-outcome ['Physiological-Clinical']
at O
treatment O
's O
end O
was O
8.5 O
kg O
( O
SD=16.1 O
) O
. O
['Physiological-Clinical']

Quality O
of O
individual O
INR O
control O
and O
the O
risk O
of O
stroke O
and O
bleeding O
events O
in O
atrial O
fibrillation O
patients O
: O
a O
nested O
case O
control O
analysis O
of O
the O
ACTIVE O
W O
study O
. O
[]

PATIENTS O
AND O
METHODS O
Study O
group O
consisted O
of O
56,653 O
screened O
men O
in O
the O
ERSPC O
centres O
of O
Finland O
, O
Italy O
, O
Netherlands O
, O
Sweden O
and O
Switzerland O
, O
who O
underwent O
3-7 O
screening O
rounds O
at O
2-4 O
year O
interval O
. O
[]

One O
case O
of O
cardiotoxicity B-outcome ['Physiological-Clinical']
resulting O
in O
the O
patient O
's O
['Physiological-Clinical']

A O
combination O
of O
tolfenamic O
acid O
( O
200 O
mg O
) O
with O
either O
caffeine O
( O
100 O
mg O
) O
, O
metoclopramide O
( O
10 O
mg O
) O
or O
pyridoxine O
( O
300 O
mg O
) O
was O
given O
twice O
to O
each O
patient O
in O
random O
order O
. O
[]

The O
percentage O
of O
patients O
with O
at B-outcome ['Physiological-Clinical']
least I-outcome ['Physiological-Clinical']
one I-outcome ['Physiological-Clinical']
SRE I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
excluding I-outcome ['Physiological-Clinical']
HCM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
by O
20 O
% O
by O
zoledronic O
acid O
( O
29.8 O
% O
v O
49.6 O
% O
for O
placebo O
; O
P O
= O
.003 O
) O
. O
['Physiological-Clinical']

The O
Gonorrhea O
Treatment O
Study O
Group O
. O
[]

and O
if O
so O
( O
2 O
) O
is O
this O
effect O
different O
for O
forward O
versus O
backward O
perturbations O
? O
; O
( O
[]

METHODS O
A O
total O
of O
433 O
actively O
employed O
hourly O
union O
workers O
who O
had O
a O
recent O
diagnosis O
of O
a O
WR-LBD O
: O
1 O
) O
those O
who O
wore O
a O
specially O
designed O
back O
support O
plus O
received O
education O
on O
back O
health O
; O
and O
2 O
) O
those O
who O
received O
education O
on O
back O
health O
only O
. O
[]

A O
2 O
x O
6 O
( O
treatment O
x O
game O
day O
) O
analysis O
of O
variance O
indicated O
that O
the O
group O
practicing O
with O
lighter O
balls O
had O
significantly O
more O
correct O
sets O
and O
a O
higher O
average O
daily O
success B-outcome ['Physiological-Clinical']
rate O
for O
the O
set O
and O
underhand O
serve O
on O
game O
days O
than O
the O
group O
using O
a O
regulation O
ball O
. O
['Physiological-Clinical']

RESULTS O
Of O
the O
681 O
patients O
, O
610 O
( O
89.6 O
% O
) O
were O
followed O
through O
18 O
months O
. O
[]

Four O
of O
the O
forty-eight O
women O
treated O
with O
intraperitoneal O
phosphorus O
required O
surgical B-outcome ['Physiological-Clinical']
reexploration I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
intestinal I-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
or O
bowel B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
current O
study O
, O
we O
investigated O
the O
safety O
profile O
and O
immunological O
effect O
of O
cluster O
SIT O
in O
children O
with O
allergic O
asthma O
due O
to O
house O
dust O
mite O
allergy O
. O
[]

Acute O
and O
subchronic O
effects O
of O
levocetirizine O
and O
diphenhydramine O
on O
memory O
functioning O
, O
psychomotor O
performance O
, O
and O
mood B-outcome ['Life-Impact']
. O
['Life-Impact']

Late O
after O
surgery O
, O
ejection B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
was O
greater O
at O
similar O
end-diastolic B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
indexes I-outcome ['Physiological-Clinical']
( O
P O
< O
.005 O
by O
rm O
ANCOVA O
) O
, O
and O
preload O
recruitable O
stroke O
work O
indexes O
( O
P O
< O
.001 O
by O
rm O
ANCOVA O
) O
were O
better O
in O
the O
Pres O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Nicotine O
is O
known O
to O
have O
many O
physiologic O
effects O
. O
[]

Use O
of O
abciximab O
prior O
to O
primary O
angioplasty O
in O
STEMI O
results O
in O
early O
recanalization O
of O
the O
infarct-related B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
and O
improved O
myocardial B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
reperfusion I-outcome ['Physiological-Clinical']
- O
results O
of O
the O
Austrian O
multi-centre O
randomized O
ReoPro-BRIDGING O
Study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PFS B-outcome ['Mortality']
was O
significantly O
prolonged O
with O
pazopanib O
compared O
with O
placebo O
in O
the O
overall O
study O
population O
( O
median O
, O
PFS O
9.2 O
v O
4.2 O
months O
; O
hazard O
ratio O
[ O
HR O
] O
, O
0.46 O
; O
95 O
% O
CI O
, O
0.34 O
to O
0.62 O
; O
P O
< O
.0001 O
) O
, O
the O
treatment-naive O
subpopulation O
( O
median O
PFS O
11.1 O
v O
2.8 O
months O
; O
HR O
, O
0.40 O
; O
95 O
% O
CI O
, O
0.27 O
to O
0.60 O
; O
P O
< O
.0001 O
) O
, O
and O
the O
cytokine-pretreated O
subpopulation O
( O
median O
PFS O
, O
7.4 O
v O
4.2 O
months O
; O
HR O
, O
0.54 O
; O
95 O
% O
CI O
, O
0.35 O
to O
0.84 O
; O
P O
< O
.001 O
) O
. O
['Mortality']

Basal O
characteristics O
of O
the O
participants O
, O
stimulation B-outcome ['Physiological-Clinical']
cycle O
responses B-outcome ['Physiological-Clinical']
, O
pregnancy B-outcome ['Physiological-Clinical']
outcomes O
, O
incidence O
of O
OHSS B-outcome ['Physiological-Clinical']
and O
types B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
OHSS I-outcome ['Physiological-Clinical']
were O
considered O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
controlled O
trial O
was O
conducted O
to O
evaluate O
a O
solar O
protection O
intervention O
targeting O
outdoor O
workers O
. O
[]

There O
was O
no O
haemorrhagic B-outcome ['Physiological-Clinical']
episode I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
conducted O
a O
randomized O
trial O
comparing O
bed O
rest O
with O
tocolysis O
to O
determine O
the O
therapeutic B-outcome ['Physiological-Clinical']
efficacy O
, O
safety O
, O
and O
cost-effectiveness O
of O
tocolysis O
for O
the O
treatment O
of O
preterm O
labor O
after O
membrane O
rupture O
. O
['Physiological-Clinical', 'Resource-use']

Both O
are O
cost-effective O
and O
help O
reduce O
CMV-associated B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
by O
some O
40 O
% O
compared O
with O
patients O
without O
prophylaxis O
. O
['Resource-use', 'Resource-use']

Up O
to O
650 O
patients O
from O
80 O
sites O
will O
be O
recruited O
and O
randomized O
in O
a O
3:2 O
ratio O
to O
receive O
active O
treatment O
or O
standard O
optimal O
medical O
therapy O
. O
[]

RESULTS O
No O
differences O
were O
found O
in O
analgesic O
administration O
or O
pain B-outcome ['Physiological-Clinical']
intensity O
scores O
between O
the O
2 O
ATC O
groups O
. O
['Physiological-Clinical']

The O
t80 B-outcome ['Physiological-Clinical']
of O
fentanyl O
was O
longer O
( O
P O
< O
0.05 O
) O
than O
that O
of O
alfentanil O
or O
sufentanil O
, O
and O
there O
was O
a O
linear O
correlation O
between O
the O
t80 B-outcome ['Physiological-Clinical']
of O
the O
opioid O
and O
the O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
tracheal I-outcome ['Life-Impact']
extubation B-outcome ['Resource-use']
( O
r O
= O
0.51 O
; O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

CONCLUSION O
Despite O
seemingly O
favourable O
results O
, O
the O
4-week O
course O
of O
acetazolamide O
( O
250 O
mg O
b.i.d O
. O
) O
[]

Both O
groups O
exercised O
for O
30 O
min O
at O
75-85 O
% O
age O
predicted O
maximum O
heart O
rate O
, O
3-4 O
times O
per O
week O
, O
for O
a O
total O
of O
18 O
sessions O
. O
[]

This O
study O
seeks O
to O
evaluate O
two O
candidate O
regimens O
( O
5-fluorouracil O
and O
interferon O
) O
as O
adjuvants O
to O
optimally O
performed O
laser O
surgery O
in O
the O
treatment O
of O
condylomata B-outcome ['Physiological-Clinical']
acuminata I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

DESIGN O
28 O
normal O
adult O
volunteers O
were O
administered O
sustained O
low-dose O
caffeine O
or O
placebo O
( O
randomized O
double-blind O
) O
during O
the O
last O
66 O
hours O
of O
an O
88-hour O
period O
of O
extended O
wakefulness O
that O
included O
seven O
2-hour O
naps O
during O
which O
polysomnographical O
recordings O
were O
made O
. O
[]

This O
trial O
confirmed O
the O
efficacy O
of O
the O
piperacillin/tazobactam O
combination O
for O
empirical O
treatment O
of O
febrile O
neutropenic O
patients O
. O
[]

Both O
groups O
were O
treated O
in O
the O
same O
way O
as O
far O
as O
anaesthesia O
and O
reduction O
were O
concerned O
. O
[]

SETTING O
Five O
academic O
outpatient O
clinics O
. O
[]

Statin O
treatment O
withdrawal O
in O
ischemic O
stroke O
: O
a O
controlled O
randomized O
study O
. O
[]

[ O
Hepatoprotective B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
of O
remaxol O
in O
patients O
with O
chronic O
hepatic O
disorders O
] O
. O
['Physiological-Clinical']

Primary O
efficacy O
assessments O
were O
the O
percentage O
of O
patients O
rated O
much O
or O
very O
much O
improved O
on O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
( O
CGI O
) O
improvement O
item O
and O
the O
mean O
changes O
from O
baseline O
to O
study O
endpoint O
['Physiological-Clinical']

Fewer O
( O
P O
= O
0.02 O
) O
major O
infectious O
events O
( O
infectious B-outcome ['Mortality']
death I-outcome ['Mortality']
or O
delay O
in O
treatment O
of O
underlying O
disease B-outcome ['Physiological-Clinical']
due O
to O
infection B-outcome ['Physiological-Clinical']
) O
were O
observed O
during O
piperacillin/ O
tazobactam O
treatment O
( O
2.6 O
% O
) O
than O
with O
the O
ceftazidime O
regimen O
( O
11.3 O
% O
) O
, O
despite O
a O
lower O
frequency O
of O
glycopeptide B-outcome ['Physiological-Clinical']
addition I-outcome ['Physiological-Clinical']
when O
piperacillin/tazobactam O
was O
used O
( O
54.4 O
% O
versus O
77.4 O
% O
) O
according O
to O
the O
rules O
adopted O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
A O
total O
of O
40 O
patients O
were O
available O
for O
analysis O
. O
[]

We O
conclude O
that O
the O
rubber O
hand O
illusion O
does O
not O
induce O
analgesia O
. O
[]

Captopril O
has O
potential O
value O
in O
the O
treatment O
of O
moderate O
essential O
hypertension O
. O
[]

METHODS O
AND O
MATERIALS O
A O
total O
of O
449 O
eligible O
males O
were O
entered O
into O
RTOG O
protocol O
7706 O
between O
1978 O
and O
1983 O
. O
[]

DESIGN O
Randomized O
, O
controlled O
intervention O
study O
in O
which O
37 O
healthy O
, O
sedentary O
men O
and O
women O
( O
52+/-2 O
years O
) O
performed O
13 O
weeks O
of O
ST O
( O
n=13 O
) O
, O
ST+aerobic O
exercise O
( O
n=12 O
) O
or O
stretching O
exercises O
as O
a O
control O
group O
( O
n=12 O
) O
. O
[]

Communicative O
abilities O
were O
analyzed O
through O
two O
indexes O
related O
to O
message O
complexity O
and O
self-regulation O
. O
[]

When O
compared O
with O
all O
3 O
groups O
, O
the O
TENS+TRT O
group O
showed O
significantly O
greater O
improvement O
in O
gait B-outcome ['Life-Impact']
velocity I-outcome ['Life-Impact']
( O
P O
< O
0.01 O
) O
. O
['Life-Impact']

No O
significant O
differences O
, O
within O
and O
between O
groups O
, O
were O
observed O
in O
the O
exercise-induced B-outcome ['Life-Impact']
increase O
in O
the O
ratios O
para- B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
ortho-hydroxyantipyrine I-outcome ['Physiological-Clinical']
to O
antipyrine B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Overall O
, O
9 O
( O
69 O
% O
) O
of O
13 O
patients O
noted O
subjective O
improvement O
after O
BTX-A O
treatment O
. O
[]

Use O
of O
topical O
selamectin O
for O
the O
treatment O
of O
Syphacia O
muris O
infection O
in O
laboratory O
rats O
. O
[]

RESULTS O
Groups O
1 O
and O
2 O
showed O
significant O
hypersensitivity B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
over O
baseline O
at O
all O
time O
points O
. O
['Physiological-Clinical']

Seventy-six O
patients O
took O
part O
in O
a O
randomized O
, O
comparative O
study O
of O
the O
efficacy O
of O
buflomedil O
hydrochloride O
and O
dihydrogenated O
ergot O
alkaloids O
in O
the O
treatment O
of O
senile B-outcome ['Physiological-Clinical']
dementia I-outcome ['Physiological-Clinical']
associated O
with O
cerebrovascular O
insufficiency O
. O
['Physiological-Clinical']

Measurements O
by O
spring-weighted O
scales O
were O
taken O
to O
assess O
the O
efficiency O
of O
each O
splint O
design O
in O
the O
reduction O
of O
hypertonus B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
reductions I-outcome ['Physiological-Clinical']
in O
the O
FeAST O
trial O
were O
within O
conventionally O
normal O
reference O
ranges O
and O
were O
quantitatively O
similar O
to O
ferritin O
reductions O
in O
observational O
studies O
in O
regular O
aspirin O
users O
. O
['Physiological-Clinical']

Plasma O
A? O
increased O
with O
dose O
, O
and O
CSF O
A? O
increased O
at O
the O
highest O
dose O
, O
suggesting O
that O
intravenous O
ponezumab O
alters O
central O
A? O
levels O
. O
[]

Saline O
or O
granisetron O
was O
given O
intravenously O
( O
IV O
) O
over O
5 O
min O
approximately O
30 O
min O
before O
the O
end O
of O
anesthesia O
. O
[]

Maintenance O
of O
anesthesia O
with O
enflurane O
did O
not O
prolong O
recovery B-outcome ['Physiological-Clinical']
compared O
with O
maintenance O
with O
propofol O
, O
but O
enflurane O
was O
associated O
with O
increased O
frequency O
of O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
impairment O
was O
absent O
in O
the O
caffeine O
condition O
. O
[]

ISDN O
was O
successful B-outcome ['Physiological-Clinical']
in O
treating O
hypertension B-outcome ['Physiological-Clinical']
in O
63 O
% O
of O
the O
events O
, O
whereas O
NTG O
had O
an O
83 O
% O
success O
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIMS O
To O
examine O
the O
role O
of O
other O
psychosocial O
factors O
relevant O
for O
outcome O
. O
[]

The O
potential O
effects O
of O
antipsychotic O
medication O
on O
brain O
structure O
represent O
a O
key O
factor O
in O
understanding O
brain O
changes O
in O
psychosis O
. O
[]

METHODS O
AND O
RESULTS O
We O
studied O
23 O
patients O
in O
NYHA O
class O
II O
and O
III O
( O
20 O
men O
, O
three O
women O
, O
mean O
age O
59+/-9 O
years O
) O
with O
stable O
CHF O
secondary O
to O
ischaemic O
heart O
disease O
[ O
ejection O
fraction O
37+/-7 O
% O
] O
, O
using O
a O
double-blind O
, O
placebo-controlled O
cross-over O
design O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
contact O
sensitization O
potential O
of O
one O
nicotine O
transdermal O
system O
( O
Nicoderm O
, O
Marion O
Merrell O
Dow O
Inc O
, O
Kansas O
City O
, O
Mo O
, O
and O
ALZA O
Corporation O
, O
Palo O
Alto O
, O
Calif O
) O
in O
a O
population O
who O
were O
allowed O
to O
continue O
smoking O
. O
[]

No O
toxicity B-outcome ['Adverse-effects']
was O
observed O
on O
either O
treatment O
. O
['Adverse-effects']

BACKGROUND O
Chemotherapy-induced O
peripheral O
neuropathy O
( O
CIPN O
) O
continues O
to O
be O
a O
substantial O
problem O
for O
many O
cancer O
patients O
. O
[]

Subjects O
received O
one O
intravenous O
dose O
of O
MEDI-545 O
( O
0.3-30.0 O
mg/kg O
) O
or O
placebo O
. O
[]

Preventing O
disability B-outcome ['Life-Impact']
and O
managing B-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
in O
frail O
older O
adults O
: O
a O
randomized O
trial O
of O
a O
community-based O
partnership O
with O
primary O
care O
. O
['Life-Impact', 'Physiological-Clinical']

Along O
with O
motor O
clumsiness O
, O
pedantic O
speech O
has O
been O
proposed O
as O
a O
clinical O
feature O
of O
AS O
. O
[]

Neutropenia B-outcome ['Physiological-Clinical']
and O
thrombocytopenia B-outcome ['Physiological-Clinical']
grade O
> O
or O
= O
3 O
were O
observed O
in O
40 O
% O
and O
15 O
% O
in O
the O
experimental O
arm O
versus O
30 O
% O
and O
12 O
% O
in O
the O
control O
arm O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
contrast O
, O
plasma O
lysozyme O
level O
in O
coronary O
sinus O
blood O
samples O
at O
the O
end O
of O
reperfusion O
in O
Group O
II O
was O
significantly O
higher O
compared O
to O
that O
in O
pre-clamping O
samples O
( O
p O
< O
0.014 O
) O
. O
[]

RESULTS O
Among O
ABC-C O
subscales O
, O
Hyperactivity B-outcome ['Life-Impact']
and O
Irritability B-outcome ['Life-Impact']
showed O
significantly O
greater O
reduction O
in O
the O
amantadine O
group O
than O
the O
placebo O
group O
. O
['Life-Impact', 'Life-Impact']

Effect O
of O
recombinant O
adenovirus-p53 O
combined O
with O
radiotherapy O
on O
long-term B-outcome ['Physiological-Clinical']
prognosis I-outcome ['Physiological-Clinical']
of O
advanced O
nasopharyngeal O
carcinoma O
. O
['Physiological-Clinical']

Participants O
were O
assigned O
to O
each O
treatment O
for O
four O
weeks O
, O
and O
were O
instructed O
to O
drink O
five O
packets O
per O
day O
while O
on O
the O
treatment O
. O
[]

A O
significant O
loss O
of O
lysozyme O
content O
was O
observed O
in O
the O
PGE1 O
group O
on O
day O
1 O
of O
the O
infusion O
-- O
ratio O
P O
: O
C O
79 O
+/- O
8 O
% O
( O
P O
less O
than O
0.03 O
) O
, O
and O
was O
associated O
with O
a O
reduction O
in O
the O
plasma O
suppressive O
activity O
. O
( O
[]

Final O
results O
showed O
no O
differences O
in O
significant O
reduction O
of O
attack B-outcome ['Physiological-Clinical']
frequency O
or O
symptoms B-outcome ['Physiological-Clinical']
between O
both O
different O
therapeutic O
principals O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Nasal B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
and O
serum B-outcome ['Physiological-Clinical']
soluble I-outcome ['Physiological-Clinical']
intercellular I-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
molecule I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
in O
patients O
with O
allergic O
rhinitis O
treated O
with O
montelukast O
alone O
or O
in O
combination O
with O
desloratadine O
or O
levocetirizine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Moreover O
, O
MIP B-outcome ['Physiological-Clinical']
and O
MEP B-outcome ['Physiological-Clinical']
significantly O
improved O
only O
after O
magnesium O
administration O
( O
change O
in O
MIP O
: O
11 O
% O
predicted O
after O
magnesium O
compared O
with O
0.5 O
% O
predicted O
after O
placebo O
; O
change O
in O
MEP O
: O
11.9 O
% O
predicted O
after O
magnesium O
compared O
with O
0.8 O
% O
predicted O
after O
placebo O
; O
P O
< O
0.001 O
for O
both O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Cure B-outcome ['Physiological-Clinical']
was O
established O
in O
24 O
of O
49 O
( O
49.0 O
% O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
35.0-63.0 O
% O
) O
pretreated O
patients O
( O
Group O
1 O
) O
versus O
9 O
of O
49 O
( O
18.4 O
% O
, O
95 O
% O
CI O
, O
7.6-29.2 O
% O
) O
direct O
surgery O
patients O
( O
Group O
2 O
; O
P=0.001 O
) O
. O
['Physiological-Clinical']

DESIGN O
Randomized O
study O
. O
[]

Overall B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
25 O
% O
and O
22 O
% O
for O
HART O
and O
qdRT O
, O
respectively O
( O
P O
= O
.69 O
) O
. O
['Physiological-Clinical']

In O
addition O
, O
measured O
parameters O
, O
such O
as O
intraoperative B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
emesis I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
opioid I-outcome ['Physiological-Clinical']
requirements I-outcome ['Physiological-Clinical']
, O
were O
not O
different O
between O
the O
groups O
. O
['Physiological-Clinical']

Even O
though O
both O
groups O
showed O
a O
significant O
rise O
in O
post-operative O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate O
and O
inspiratory B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
after O
surgery B-outcome ['Resource-use']
, O
the O
post-operative O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow B-outcome ['Physiological-Clinical']
rate O
and O
inspiratory B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
in O
group O
I O
was O
significantly O
higher O
than O
in O
group O
II O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
randomized O
controlled O
trial O
. O
[]

Net O
change O
in O
diet O
due O
to O
the O
intervention O
was O
modest O
. O
[]

The O
cumulative O
number O
of O
chronic B-outcome ['Physiological-Clinical']
rejections I-outcome ['Physiological-Clinical']
up O
to O
4 O
years O
was O
0.09 O
, O
0.29 O
, O
0.25 O
, O
and O
0.34 O
per O
patient O
per O
group O
( O
P O
= O
ns O
) O
, O
respectively O
. O
['Physiological-Clinical']

METHODS O
AND O
MATERIALS O
The O
prospective O
study O
included O
112 O
patients O
with O
advanced O
larynx O
cancer O
after O
radical O
surgical O
treatment O
. O
[]

After O
bandpass O
filtering O
( O
30 O
to O
300 O
Hz O
) O
and O
amplification O
, O
signals O
were O
sampled O
over O
7.2 O
minutes O
at O
2000 O
Hz O
. O
[]

After O
placebo O
, O
the O
tests O
always O
were O
positive O
, O
and O
the O
ECG B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
occurred O
at O
the O
same O
+/- O
1 O
dose O
of O
ergometrine O
in O
10 O
cases O
, O
showing O
good O
reproducibility B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Comparison O
of O
the O
therapeutic O
effects O
of O
epoetin O
zeta O
to O
epoetin O
alfa O
in O
the O
maintenance O
phase O
of O
renal O
anaemia O
treatment O
. O
[]

RESULTS O
The O
PKVP O
loop O
achieved O
a O
fast O
and O
sharp O
cutting O
action O
similar O
to O
that O
with O
the O
traditional O
TURP O
loop O
. O
[]

Subjects O
completed O
10-point O
visual O
analog O
scales O
( O
VAS O
) O
for O
stress O
, O
relaxation B-outcome ['Life-Impact']
, O
and O
peacefulness B-outcome ['Life-Impact']
before O
and O
after O
LKM O
. O
['Life-Impact', 'Life-Impact']

METHODS O
Seventy-two O
patients O
with O
a O
carpal O
tunnel O
syndrome O
were O
individually O
randomized O
into O
the O
trial O
( O
limited O
incision O
CTR O
) O
( O
n=36 O
) O
and O
control O
group O
( O
traditional O
technique O
CTR O
) O
( O
n=36 O
) O
. O
[]

Whether O
improvements O
in O
current O
clinical O
practice O
( O
stents O
, O
IIb/IIIa O
antagonists O
) O
have O
resulted O
in O
substantial O
improvement O
of O
these O
outcomes O
remains O
an O
issue O
. O
[]

The O
sodium B-outcome ['Life-Impact']
intakes I-outcome ['Life-Impact']
and O
blood B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
of O
the O
intervention O
and O
control O
group O
were O
compared O
1 O
year O
after O
randomization O
. O
['Life-Impact', 'Physiological-Clinical']

The O
reduction O
in O
mean O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
at O
the O
end O
of O
haemodialysis O
was O
21.5 O
+/- O
2.6 O
% O
in O
patients O
treated O
with O
a O
single O
dose O
and O
24.8 O
+/- O
3.5 O
% O
in O
patients O
treated O
with O
the O
repeated O
dose O
of O
diazoxide O
. O
['Physiological-Clinical']

Human O
synthetic O
secretin O
, O
mean O
dose O
3.4 O
clinical O
units O
, O
and O
placebo O
were O
administered O
intravenously O
in O
randomized O
order O
every O
4th O
wk O
, O
on O
three O
occasions O
each O
. O
[]

METHODS O
AND O
RESULTS O
A O
prospective O
, O
randomized O
, O
multicenter O
trial O
was O
conducted O
to O
evaluate O
the O
non-inferiority O
of O
a O
zotarolimus-eluting O
stent O
( O
ZES O
; O
Endeavor O
Sprint? O
, O
n=80 O
) O
to O
a O
sirolimus-eluting O
stent O
( O
SES O
; O
Cypher? O
, O
n=80 O
) O
in O
patients O
with O
CTO O
lesion O
with O
a O
reference O
vessel O
diameter O
? O
[]

OBJECTIVE O
Identify O
factors O
predictive O
of O
severe B-outcome ['Physiological-Clinical']
hypoglycemia I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
assess O
the O
clinical B-outcome ['Life-Impact']
utility I-outcome ['Life-Impact']
of O
continuous B-outcome ['Resource-use']
glucose I-outcome ['Resource-use']
monitoring I-outcome ['Resource-use']
( I-outcome ['Resource-use']
CGM I-outcome ['Resource-use']
) I-outcome ['Resource-use']
to O
warn O
of O
impending O
SH O
. O
['Physiological-Clinical', 'Life-Impact', 'Resource-use']

In O
Phase O
2 O
, O
after O
a O
CMZ O
elimination O
interval O
of O
7 O
days O
, O
38 O
patients O
received O
either O
sustained-release O
morphine O
( O
90 O
mg/d O
) O
or O
placebo O
for O
8 O
days O
. O
[]

RESULTS O
Ninety-seven O
participants O
were O
included O
in O
the O
study O
. O
[]

A O
total O
of O
108 O
volunteers O
undergoing O
an O
elective O
surgical O
procedure O
were O
randomly O
given O
a O
single O
2-g O
intravenous O
prophylactic O
dose O
of O
either O
a O
cephalosporin O
or O
mezlocillin O
. O
[]

It O
was O
considered O
that O
local O
instillation O
of O
anti-cancer O
agents O
with O
pericardial O
drainage O
was O
a O
useful O
therapeutic O
modality O
for O
malignant O
pericarditis O
. O
[]

5 O
patients O
( O
Group O
A O
) O
underwent O
LI O
and O
subcutaneous O
injections O
of O
placebo O
, O
5 O
patients O
( O
Group O
B O
) O
underwent O
PI O
and O
inhalation O
of O
lactose O
for O
6 O
months O
. O
[]

We O
evaluated O
the O
efficacy O
of O
local O
application O
of O
a O
combination O
of O
minoxidil O
and O
lignocaine O
in O
healing O
anal O
fissures O
. O
[]

The O
complete B-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
rate O
of I-outcome ['Physiological-Clinical']
vomiting I-outcome ['Physiological-Clinical']
was O
as O
high O
as O
71.4 O
% O
and O
92.3 O
% O
in O
the O
single O
and O
combination O
groups O
, O
respectively O
, O
showing O
no O
significant O
difference O
. O
['Physiological-Clinical']

In O
this O
study O
metronidazole O
did O
not O
have O
disease B-outcome ['Physiological-Clinical']
modifying I-outcome ['Physiological-Clinical']
properties I-outcome ['Physiological-Clinical']
and O
was O
unacceptably O
toxic B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

However O
, O
the O
effects O
on O
residualized O
gains O
in O
parental B-outcome ['Life-Impact']
responsivity I-outcome ['Life-Impact']
from O
Time O
1 O
to O
both O
Times O
2 O
and O
3 O
yielded O
noteworthy O
effect O
sizes O
( O
Glass O
's O
? O
['Life-Impact']

OPN O
suppresses O
the O
proliferation O
of O
hematopoietic O
stem O
cells O
in O
vitro O
and O
may O
regulate O
the O
hematopoietic O
stem O
cell O
pool O
. O
[]

The O
mechanisms O
of O
this O
effect O
could O
be O
associated O
with O
plaque O
regression O
due O
to O
the O
anti-atherosclerotic O
properties O
of O
CCBs O
. O
[]

Based O
on O
these O
data O
the O
Durie/Salmon O
classification O
could O
be O
improved O
by O
defining O
poor O
prognosis O
patients O
( O
50 O
% O
TRS O
: O
16 O
months O
) O
characterised O
by O
pretreatment O
platelets O
of O
< O
or O
= O
150,000 O
and/or O
poorly O
differentiated O
myeloma O
cell O
morphology O
. O
[]

At O
that O
intake O
, O
whites O
accumulated B-outcome ['Physiological-Clinical']
385 O
+/- O
153 O
mmol O
compared O
with O
909 O
+/- O
153 O
mmol O
for O
blacks O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
children O
were O
randomly O
assigned O
to O
two O
groups O
: O
the O
flumazenil O
group O
( O
group O
F O
, O
n=20 O
) O
and O
the O
etomidate O
group O
( O
group O
E O
, O
n=20 O
) O
. O
[]

RESULTS O
In O
both O
groups O
( O
1 O
) O
the O
mean O
hemoglobin B-outcome ['Physiological-Clinical']
was O
lower O
( O
p O
< O
0.01 O
) O
at O
40 O
weeks O
' O
gestation O
than O
when O
first O
examined O
and O
( O
2 O
) O
the O
mean O
serum O
erythropoietin O
was O
higher O
( O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Urinary B-outcome ['Physiological-Clinical']
levels O
fell I-outcome ['Physiological-Clinical']
from O
145.5+/-24.9 O
to O
114.6+/-27.1 O
( O
week O
2 O
, O
P O
< O
.05 O
) O
and O
112.6+/-24.9 O
( O
week O
3 O
, O
P O
< O
.05 O
) O
on O
cessation O
of O
smoking O
. O
['Physiological-Clinical']

We O
randomly O
grouped O
the O
61 O
patients O
into O
control O
group O
( O
group O
C O
) O
, O
block O
group O
( O
group O
B O
) O
and O
dexketoprofen-block O
group O
( O
group O
DB O
) O
. O
[]

Patients O
receiving O
a O
late O
intensification O
had O
the O
same O
relapse B-outcome ['Physiological-Clinical']
rate O
as O
the O
other O
patients O
. O
['Physiological-Clinical']

A O
single-blind O
trial O
as O
done O
in O
10 O
patients O
with O
MPD O
with O
subthreshold O
TENS O
( O
frequency O
35 O
Hz O
, O
pulse O
width O
100 O
milliseconds O
, O
modulation O
50 O
% O
) O
compared O
with O
sham O
TENS O
at O
8 O
visits O
over O
14 O
weeks O
. O
[]

We O
used O
functional O
magnetic O
resonance O
imaging O
of O
the O
human O
spinal O
cord O
to O
test O
the O
hypothesis O
that O
placebo O
analgesia O
results O
in O
a O
reduction O
of O
nociceptive O
processing O
in O
the O
spinal O
cord O
. O
[]

[ O
Report O
of O
a O
controlled O
clinical O
trial O
of O
a O
new O
synthetic O
drug O
, O
parsalmide O
, O
in O
rheumatic O
arthropathies O
( O
inflammatory O
and O
degenerative O
) O
] O
. O
[]

The O
clinical O
relevance O
of O
these O
findings O
remains O
to O
be O
determined O
. O
[]

It O
is O
concluded O
that O
tumour O
regression O
may O
be O
accompanied O
by O
scar B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
, O
which O
complicate O
the O
interpretation O
of O
post-treatment B-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
, O
and O
that O
further O
regression O
of O
intrabronchial O
lesions O
may O
occur O
beyond O
3-4 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
safety O
, O
pharmacokinetics O
, O
and O
pharmacodynamics O
of O
single O
oral O
doses O
of O
up O
to O
48 O
mg O
and O
daily O
( O
for O
28 O
days O
) O
doses O
of O
up O
24 O
mg O
mofegiline O
were O
investigated O
in O
healthy O
male O
volunteers O
. O
[]

BACKGROUND O
AND O
AIM O
The O
aim O
of O
this O
randomized O
double O
blind O
placebo O
controlled O
study O
was O
to O
investigate O
the O
effectiveness O
and O
the O
safety O
of O
venlafaxine O
XR O
75 O
and O
150 O
mg O
on O
ongoing O
pain O
and O
on O
quantitative O
sensory O
tests O
in O
60 O
patients O
with O
neuropathic O
pain O
for O
8 O
weeks O
. O
[]

In O
the O
H. O
pylori-infected O
group O
, O
increase O
in O
GA B-outcome ['Physiological-Clinical']
was O
seen O
in O
the O
corpus O
( O
P O
= O
0.01 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
We O
conclude O
that O
endogenous O
GHRH O
is O
indispensable O
for O
the O
nocturnal O
augmentation O
of O
GH O
secretion O
, O
but O
that O
it O
is O
unlikely O
to O
participate O
in O
the O
genesis O
of O
SWS O
. O
[]

AP-1 O
activation O
was O
quantified O
by O
phospho-c-Jun O
nuclear O
translocation O
( O
immunohistochemistry O
) O
on O
a O
biobank O
of O
aortic O
wall O
samples O
from O
organ O
donors O
. O
[]

Subjects O
showed O
improvement O
on O
the O
CPRS O
Autism B-outcome ['Life-Impact']
Factor O
( O
F1,9 O
= O
24.4 O
, O
p O
= O
.0008 O
) O
. O
['Life-Impact']

BACKGROUND O
Glucagon-like O
peptide-1 O
( O
7-36 O
) O
amide O
( O
GLP-1 O
) O
retards O
gastric O
emptying O
, O
reduces O
food O
intake O
, O
and O
inhibits O
antroduodenal O
and O
stimulates O
pyloric O
motility O
. O
[]

Information O
about O
pupils B-outcome ['Physiological-Clinical']
' O
smoking B-outcome ['Life-Impact']
status B-outcome ['Life-Impact']
and O
other O
factors O
related O
to O
smoking O
will O
be O
obtained O
using O
a O
web-based O
questionnaire O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

RESULTS O
Although O
differences O
between O
the O
treatment O
groups O
were O
found O
in O
both O
the O
maxillary O
and O
mandibular O
arches O
after O
phase O
1 O
, O
these O
differences O
were O
no O
longer O
evident O
by O
the O
end O
of O
full O
orthodontic O
treatment O
or O
after O
posttreatment O
retention O
. O
[]

OBJECTIVE O
To O
determine O
the O
effects O
of O
daily O
walnut O
consumption O
on O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
cardiovascular B-outcome ['Physiological-Clinical']
biomarkers I-outcome ['Physiological-Clinical']
, O
and O
anthropometric B-outcome ['Physiological-Clinical']
measures O
in O
type O
2 O
diabetic O
individuals O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Consecutively O
listed O
candidates O
for O
elective O
bypass O
were O
randomly O
assigned O
to O
either O
off-pump O
or O
on-pump O
techniques O
( O
n O
= O
107 O
) O
. O
[]

BACKGROUND O
Individualized O
problem-solving O
counseling O
for O
caregivers O
of O
cognitively O
impaired O
relatives O
is O
thought O
to O
help O
caregivers O
cope O
with O
the O
stress O
and O
burden O
of O
caregiving O
. O
[]

Treatment O
consisted O
of O
30 O
subjects O
applying O
a O
warm O
perineal O
pack O
, O
30 O
applying O
a O
cold O
perineal O
pack O
, O
and O
30 O
taking O
a O
warm O
sitz O
bath O
. O
[]

Effectiveness O
and O
safety O
of O
donepezil O
in O
boys O
with O
fragile O
x O
syndrome O
: O
a O
double-blind O
, O
randomized O
, O
controlled O
pilot O
study O
. O
[]

One-month O
urinalysis O
follow-up O
data O
showed O
a O
significant O
reduction O
in O
heroin B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
in O
the O
experimental O
group O
( O
from O
63 O
% O
positive O
at O
intake O
to O
29 O
% O
positive O
) O
with O
no O
change O
in O
the O
control O
group O
( O
62 O
% O
to O
60 O
% O
positive O
) O
. O
['Life-Impact']

The O
number O
, O
duration O
, O
and O
[]

BACKGROUND O
Pyoderma O
( O
bacterial O
superficial O
skin O
infection O
) O
is O
an O
extremely O
common O
disorder O
in O
tropical O
developing O
countries O
. O
[]

A O
1-liter O
resuscitation O
bag O
, O
lung O
performance O
analyzer O
and O
Wright O
spirometer O
were O
used O
to O
measure O
tidal O
volume O
. O
[]

METHODS O
A O
prospective O
randomized O
controlled O
trial O
of O
patients O
with O
a O
presumptive O
diagnosis O
of O
acute O
pyelonephritis O
was O
performed O
. O
[]

Experiment O
2 O
compared O
effects O
on O
craving B-outcome ['Life-Impact']
of O
a O
simpler O
verbal O
task O
( O
counting O
by O
ones O
) O
and O
clay O
modeling O
. O
['Life-Impact']

Chlorhexidine O
swabbing O
applications O
under O
various O
conditions O
of O
use O
in O
preventive O
oral O
care O
for O
persons O
with O
disabilities O
. O
[]

The O
treatment O
effect O
of O
eptifibatide O
is O
realized O
regardless O
of O
renal O
function O
and O
trends O
toward O
being O
greater O
in O
patients O
with O
mild O
[]

A O
positive O
correlation O
was O
found O
between O
the O
decreased O
activated B-outcome ['Physiological-Clinical']
CECs I-outcome ['Physiological-Clinical']
after O
therapy O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TTP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( O
r O
= O
0.322 O
, O
P O
= O
0.012 O
) O
; O
a O
negative O
correlation O
was O
found O
between O
the O
amount O
of O
survivin B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
post-therapy I-outcome ['Physiological-Clinical']
and O
TTP B-outcome ['Physiological-Clinical']
( O
r O
= O
-0.291 O
, O
P O
= O
0.048 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Blood O
pressure O
control O
was O
achieved O
with O
verapamil O
alone O
in O
18 O
patients O
, O
but O
with O
atenolol O
alone O
in O
only O
8 O
patients O
( O
p O
< O
0.01 O
) O
. O
( O
[]

BACKGROUND O
Recent O
studies O
have O
reported O
that O
in O
patients O
under O
antihypertensive O
treatment O
visit-to-visit O
( O
or O
long-term O
) O
variability O
of O
clinic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
within O
a O
given O
patient O
has O
an O
independent O
prognostic O
significance O
. O
['Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
C-peptide I-outcome ['Physiological-Clinical']
was O
measured O
fasting O
and O
6 O
minutes O
after O
glucagon O
( O
1 O
mg O
given O
intravenously O
) O
in O
49 O
patients O
with O
non-insulin-dependent O
diabetes O
mellitus O
, O
after O
4 O
and O
6 O
months O
of O
successive O
periods O
of O
treatment O
with O
insulin O
and O
oral O
hypoglycaemics O
( O
glibenclamide O
and O
metformin O
) O
, O
given O
in O
random O
order O
. O
['Physiological-Clinical']

Vitamin O
E O
supplementation O
was O
well O
tolerated B-outcome ['Life-Impact']
and O
showed O
an O
excellent O
safety O
profile O
. O
['Life-Impact']

Various O
complications O
, O
such O
as O
infections O
and O
delayed O
wound O
healing O
, O
influence O
the O
clinical O
course O
of O
such O
patients O
. O
[]

CONCLUSIONS O
One O
in O
four O
eligible O
primary O
care O
patients O
enrolled O
in O
the O
study O
. O
[]

Naproxen O
enhanced O
the O
anti-aggregatory B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of O
aspirin O
after O
24 O
h O
( O
CT B-outcome ['Physiological-Clinical']
rising O
from O
104+/-16 O
s O
at O
baseline O
to O
212+/-69 O
s O
at O
24 O
h O
, O
P O
< O
0.001 O
) O
, O
which O
was O
not O
seen O
with O
any O
other O
drug O
combination O
. O
['Physiological-Clinical', 'Physiological-Clinical']

TIVA O
was O
induced O
by O
intravenous O
administration O
of O
fentanyl O
( O
2 O
microg/kg O
) O
, O
midazolam O
( O
0.05 O
mg/kg O
) O
and O
propofol O
( O
dosage O
titrated O
) O
. O
[]

Use O
of O
CFCs O
as O
propellants O
in O
metered-dose O
inhalers O
( O
MDIs O
) O
is O
still O
allowed O
, O
but O
the O
U.S. O
Food O
and O
Drug O
Administration O
is O
planning O
the O
transition O
to O
alternative O
propellants O
for O
use O
in O
MDIs O
. O
[]

METHODS O
From O
March O
2000 O
to O
May O
2003 O
, O
112 O
patients O
with O
potentially O
curable O
pancreatic O
head O
cancer O
were O
enrolled O
and O
intraoperatively O
randomized O
to O
a O
standard O
or O
extended O
lymphadenectomy O
group O
. O
[]

Efficacy O
of O
primaquine O
regimens O
for O
primaquine-resistant O
Plasmodium O
vivax O
malaria O
in O
Thailand O
. O
[]

The O
dipeptidyl O
peptidase-4 O
inhibitor O
PHX1149 O
improves O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
. O
['Physiological-Clinical']

A O
majority O
of O
the O
men O
encountered O
a O
variety O
of O
barriers O
including O
economic O
, O
social O
, O
and O
lifestyle O
obstacles O
to O
adequate O
BP O
care O
and O
control O
, O
including O
no O
current B-outcome ['Physiological-Clinical']
HBP I-outcome ['Physiological-Clinical']
care I-outcome ['Physiological-Clinical']
( O
49 O
% O
) O
, O
risk O
of O
alcoholism B-outcome ['Life-Impact']
( O
62 O
% O
) O
, O
use O
of O
illicit B-outcome ['Life-Impact']
drugs I-outcome ['Life-Impact']
( O
45 O
% O
) O
, O
social B-outcome ['Life-Impact']
isolation I-outcome ['Life-Impact']
( O
47 O
% O
) O
, O
unemployment B-outcome ['Life-Impact']
( O
40 O
% O
) O
, O
and O
lack O
of O
health B-outcome ['Life-Impact']
insurance I-outcome ['Life-Impact']
( O
51 O
% O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Whether O
fat O
gain O
impairs O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
is O
unknown O
. O
['Physiological-Clinical']

The O
treatment O
began O
the O
day O
before O
operation O
and O
continued O
on O
average O
up O
to O
the O
eighth O
day O
for O
the O
Defibrotide O
group O
. O
[]

Human O
papillomavirus O
genotypes O
in O
cervical O
intraepithelial O
neoplasia O
grade O
3 O
. O
[]

METHODS O
Three O
hundred O
fourteen O
patients O
with O
grades O
2 O
or O
3 O
esophageal O
varices O
( O
Child O
A O
and O
B/C O
: O
218 O
and O
96 O
) O
were O
enrolled O
. O
[]

Significant O
reductions O
in O
drinking B-outcome ['Life-Impact']
days I-outcome ['Life-Impact']
were O
observed O
in O
both O
treatment O
conditions O
. O
['Life-Impact']

Trial O
Registration O
ClinicalTrials.gov O
Identifier O
: O
NCT00235456 O
. O
[]

The O
median O
survival O
is O
less O
than O
10 O
months O
, O
and O
less O
than O
10 O
percent O
of O
patients O
survive O
for O
5 O
years O
. O
[]

AIM O
Anaesthetics O
may O
have O
protective O
effect O
against O
myocardial O
ischemia O
. O
[]

Immune B-outcome ['Physiological-Clinical']
suppression I-outcome ['Physiological-Clinical']
resulting O
from O
prolonged O
chemoprophylaxis O
and O
potential O
drug-vaccine O
interaction O
were O
investigated O
within O
the O
context O
of O
a O
randomized O
placebo-controlled O
trial O
that O
compared O
daily O
primaquine O
or O
weekly O
chloroquine O
administration O
for O
malaria O
prevention O
. O
['Physiological-Clinical']

We O
blended O
oxygen O
and O
hypoxic O
gas O
to O
achieve O
arterial O
oxygen O
saturations O
( O
SaO2 O
) O
of O
80 O
, O
85 O
, O
and O
90 O
percent O
; O
subjects O
also O
breathed O
100 O
percent O
oxygen O
and O
room O
air O
( O
RA O
) O
. O
[]

Horses O
were O
randomly O
divided O
into O
non-exercised O
and O
exercised O
groups O
. O
[]

After O
3 O
months O
about O
60 O
% O
of O
the O
patients O
were O
either O
dry B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
only I-outcome ['Physiological-Clinical']
mildly I-outcome ['Physiological-Clinical']
incontinent I-outcome ['Physiological-Clinical']
; O
the O
mean O
number O
of O
wet B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
had O
gone O
down O
from O
20 O
to O
7 O
, O
and O
74 O
% O
of O
the O
women O
felt O
improved O
or O
cured B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

It O
was O
shown O
that O
the O
degree O
of O
bronchodilatation O
achieved O
after O
salbutamol O
200 O
microg O
is O
not O
affected O
by O
prior O
bronchoprovocation O
testing O
when O
enough O
time O
is O
allowed O
for O
the O
airways O
to O
recover O
spontaneously O
to O
baseline O
forced O
expiratory O
volume O
in O
one O
second O
. O
[]

The O
slope O
relating O
symptoms O
to O
ventilation B-outcome ['Physiological-Clinical']
( O
ie O
, O
Borg/VE O
) O
was O
significantly O
reduced O
in O
the O
patients O
after O
bronchodilators O
( O
17 O
% O
+/-8 O
% O
, O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
assess O
whether O
efforts O
to O
actively O
involve O
General O
Practitioners O
( O
GPs O
) O
in O
the O
postdischarge O
care O
of O
their O
paediatric O
asthma O
patients O
improved O
their O
satisfaction O
with I-outcome ['Life-Impact']
communication B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
hospital I-outcome ['Life-Impact']
staff O
. O
['Life-Impact']

In O
a O
prospective O
randomized O
study O
of O
50 O
consecutive O
eyes O
, O
we O
compared O
the O
safety O
and O
efficacy O
of O
draining O
subretinal O
fluid O
transchoroidally O
in O
primary O
scleral O
buckling O
for O
rhegmatogenous O
retinal O
detachment O
using O
a O
needle O
, O
with O
the O
safety O
and O
efficacy O
of O
the O
same O
procedure O
using O
an O
angulated O
endolaser O
probe O
set O
at O
1 O
W O
for O
0.2 O
seconds O
, O
using O
an O
average O
of O
2.4 O
laser O
burns O
. O
[]

A O
direct O
linear O
regression O
between O
R-R O
and O
% O
D O
was O
found O
after O
both O
alinidine O
and O
placebo O
treatments O
either O
at O
rest O
or O
during O
exercise O
. O
[]

The O
cure B-outcome ['Physiological-Clinical']
rates O
at O
1 O
and O
6 O
weeks O
for O
the O
single-dose O
treatments O
were O
52 O
% O
and O
38 O
% O
, O
respectively O
, O
and O
the O
cure B-outcome ['Physiological-Clinical']
rates O
for O
the O
conventional-dose O
treatments O
at O
1 O
and O
6 O
weeks O
were O
59 O
% O
and O
52 O
% O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Significant O
improvements O
were O
found O
in O
the O
score O
of O
the O
'Issues O
on O
treatment O
compliance O
' O
factor O
and O
the O
score O
of O
the O
'Autistic O
life O
' O
factor O
, O
which O
are O
subscales O
of O
the O
Discharge B-outcome ['Life-Impact']
Difficulty I-outcome ['Life-Impact']
Scale O
, O
for O
the O
DPP O
group O
, O
on O
two-way O
ANOVA O
( O
'Issues O
on O
treatment O
compliance O
' O
: O
F O
= O
3.818 O
, O
P O
< O
0.10 O
; O
'Autistic O
life O
' O
: O
F O
= O
4.155 O
, O
P O
< O
0.05 O
) O
These O
factors O
affected O
discharge B-outcome ['Life-Impact']
outcome O
. O
['Life-Impact', 'Life-Impact']

Only O
deoxypyridinoline B-outcome ['Physiological-Clinical']
values O
were O
significantly O
lower O
after O
consumption O
of O
the O
BD O
( O
13.0 O
+/- O
1.1 O
compared O
to O
18.3 O
+/- O
2.1 O
nM/Mm O
Cr O
in O
the O
WD O
) O
, O
possibly O
indicative O
of O
less O
efficient O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
during O
this O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subjects O
received O
in O
random O
order O
, O
enalapril O
( O
20 O
mg O
) O
or O
matched O
placebo O
daily O
for O
2 O
weeks O
. O
[]

Cockroach B-outcome ['Life-Impact']
infestation I-outcome ['Life-Impact']
in O
the O
past O
3 O
months O
was O
reported O
by O
23.4 O
% O
of O
caregivers O
, O
while O
57.1 O
% O
were O
unaware O
of O
the O
association O
of O
roaches B-outcome ['Life-Impact']
and O
asthma B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

The O
cephalad O
dermatome O
level O
of O
the O
block O
and O
degree O
of O
motor B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
was O
comparable O
in O
the O
two O
groups O
. O
['Physiological-Clinical']

We O
found O
no O
significant O
differences O
between O
patients O
who O
received O
fibrin O
glue O
and O
those O
who O
did O
not O
. O
[]

Its O
major O
advantages O
are O
the O
ease O
with O
which O
the O
techniques O
can O
be O
learned O
, O
reproducibility O
of O
values O
, O
sensitivity O
of O
measurement O
and O
availability O
of O
normotensive O
data O
. O
[]

FINDINGS O
None O
of O
the O
active O
medications O
produced O
greater O
reductions O
in O
urine B-outcome ['Physiological-Clinical']
BE I-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
over O
the O
treatment O
period O
than O
did O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
operative B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
were O
: O
63+/-7.6 O
, O
54+/-6.7 O
and O
75+/-8.4 O
min O
( O
TPL O
vs O
EPL O
P O
< O
0.001 O
; O
EPL O
vs O
LPL O
P O
< O
0.001 O
; O
TPL O
vs O
LPL O
P O
< O
0.001 O
) O
for O
TPL O
, O
EPL O
and O
LPL O
respectively O
. O
['Life-Impact']

A O
clear O
difference O
in O
morphine B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
became O
evident O
after O
24 O
hours O
( O
P O
= O
0.010 O
) O
. O
['Resource-use']

Although O
the O
fall O
in O
tcPCO2 B-outcome ['Physiological-Clinical']
associated O
with O
panic O
was O
not O
substantial O
and O
did O
not O
indicate O
clinically O
significant O
acute B-outcome ['Physiological-Clinical']
hyperventilation I-outcome ['Physiological-Clinical']
, O
it O
appears O
to O
be O
a O
sensitive O
index O
for O
epinephrine-induced O
panic O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Three O
patients O
died B-outcome ['Mortality']
in O
hospital O
after O
LTA O
but O
none O
after O
TH O
. O
['Mortality']

3 O
. O
[]

In O
patients O
with O
ulcerative O
lesions O
, O
healing B-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
were O
reduced O
in O
the O
ME-609 O
and O
acyclovir O
groups O
compared O
with O
placebo O
( O
P O
< O
.01 O
for O
both O
) O
. O
['Physiological-Clinical']

A O
significant O
correlation O
between O
changes O
in O
ROS B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
monocytes I-outcome ['Physiological-Clinical']
and O
LVMI B-outcome ['Physiological-Clinical']
or O
between O
CRP B-outcome ['Physiological-Clinical']
and O
LVMI B-outcome ['Physiological-Clinical']
was O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
dose O
received O
of O
general O
program O
information O
was O
moderate O
to O
high O
. O
[]

The O
ZAR O
group O
showed O
a O
percentage O
of O
eyes O
( O
94.4 O
% O
) O
within O
the O
0.5-D O
range O
in O
SE O
higher O
than O
that O
shown O
by O
the O
Planoscan O
group O
( O
88.8 O
% O
) O
. O
[]

The O
main O
acupoints O
included O
Sishen O
Xue O
, O
Dingshen O
Sanxue O
( O
3 O
points O
for O
mental O
tranquilization O
) O
, O
Nao O
Sanxue O
( O
3 O
points O
for O
the O
function O
of O
brain O
) O
, O
Shou O
Zhisanxue O
( O
3 O
points O
for O
mental O
activities O
on O
hand O
) O
and O
Zozhi O
Sonxue O
( O
3 O
points O
for O
mental O
activities O
on O
foot O
) O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
develop O
regression O
equations O
to O
estimate O
GAI O
scores O
from O
demographic O
variables O
and O
WAIS-III O
subtest O
performance O
. O
[]

The O
areas O
of O
allodynia B-outcome ['Physiological-Clinical']
and O
pin-prick B-outcome ['Physiological-Clinical']
hyperalgesia I-outcome ['Physiological-Clinical']
decreased O
significantly O
in O
venlafaxine O
groups O
compared O
to O
the O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
PBSCT O
, O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
achieve I-outcome ['Physiological-Clinical']
an I-outcome ['Physiological-Clinical']
absolute I-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ANC O
) O
of O
> O
0.5 O
x O
10 O
( O
9 O
) O
/L O
in O
the O
treatment O
group O
was O
less O
than O
that O
in O
the O
control O
group O
( O
median O
, O
11 O
v O
12 O
days O
; O
the O
log-rank O
test O
, O
P O
=.046 O
) O
, O
although O
the O
last O
day O
of O
red O
blood O
cell O
( O
RBC O
) O
transfusion O
( O
day O
11 O
v O
day O
10 O
) O
and O
the O
duration O
of O
febrile B-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
( O
> O
38 O
degrees O
C O
) O
after O
PBSCT O
( O
4 O
v O
4 O
days O
) O
were O
identical O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thirty-seven O
healthy O
volunteers O
, O
19 O
of O
whom O
had O
consistently O
elevated O
total O
serum B-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TSB I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
took O
part O
in O
an O
open O
, O
randomised O
cross-over O
study O
to O
determine O
the O
effect O
of O
fasting O
on O
TSB O
concentrations O
. O
['Physiological-Clinical']

Comparison O
of O
the O
effects O
of O
terazosin O
and O
enalapril O
on O
laboratory O
stress O
testing O
blood O
pressure O
in O
patients O
with O
essential O
hypertension O
. O
[]

The O
potential O
of O
the O
aldose O
reductase O
inhibitor O
tolrestat O
to O
ameliorate O
definite O
diabetic O
autonomic O
neuropathy O
( O
DAN O
) O
, O
as O
defined O
by O
standard O
cardiovascular O
autonomic O
function O
tests O
, O
was O
evaluated O
in O
35 O
patients O
over O
a O
period O
of O
2 O
years O
, O
with O
repeated O
measurements O
at O
3-month O
intervals O
. O
[]

The O
study O
had O
a O
placebo O
controlled O
, O
double O
blind O
, O
cross O
over O
design O
with O
6 O
weeks O
' O
metformin O
treatment O
( O
850 O
mg O
b.i.d O
) O
vs O
placebo O
. O
[]

Only O
245 O
patients O
( O
100 O
% O
of O
patients O
with O
prior O
variceal O
hemorrhage O
, O
61 O
% O
of O
patients O
without O
prior O
hemorrhage O
) O
were O
receiving O
some O
form O
of O
prophylactic O
therapy O
. O
[]

Pelvic O
lymphocysts O
following O
retroperitoneal O
lymphadenectomy O
: O
retroperitoneal O
partial O
no-closure O
for O
ovarian O
and O
endometrial O
cancers O
. O
[]

Estimated O
5-year O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
RFS B-outcome ['Mortality']
) O
rate O
is O
50 O
% O
in O
arm O
1 O
and O
48 O
% O
in O
arm O
2 O
, O
with O
median O
RFS O
times O
of O
58 O
and O
50 O
months O
, O
respectively O
. O
['Mortality', 'Mortality']

Subjects O
were O
stratified O
by O
PAE O
; O
adverse O
events O
( O
AEs O
) O
, O
and O
changes O
in O
weight O
, O
and O
metabolic O
measures O
were O
evaluated O
. O
[]

Of O
153 O
patients O
evaluable O
for O
response O
, O
there O
were O
47 O
, O
or O
30.7 O
% O
, O
complete B-outcome ['Physiological-Clinical']
responders I-outcome ['Physiological-Clinical']
( O
all O
determined O
surgically O
) O
, O
6 O
partial O
responders O
, O
and O
100 O
nonresponders O
. O
['Physiological-Clinical']

To O
determine O
the O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
junctional I-outcome ['Physiological-Clinical']
ectopic I-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
JET I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
a O
modern O
cohort O
of O
pediatric O
patients O
, O
evaluate O
possible O
risk O
factors B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
JET I-outcome ['Physiological-Clinical']
, O
and O
examine O
the O
effects O
of O
JET O
on O
postoperative B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

On O
the O
other O
hand O
, O
indomethacin O
had O
no O
effect O
on O
the O
duration O
of O
chest B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
mean O
days O
+/- O
SE O
: O
placebo O
1.4 O
+/- O
0.6 O
, O
indomethacin O
5.5 O
+/- O
3.3 O
) O
, O
duration O
of O
pericardial B-outcome ['Physiological-Clinical']
friction I-outcome ['Physiological-Clinical']
rub I-outcome ['Physiological-Clinical']
( O
placebo O
10.3 O
+/- O
1.7 O
, O
indomethacin O
16.0 O
+/- O
3.8 O
) O
, O
or O
on O
the O
amount O
of O
pericardial B-outcome ['Physiological-Clinical']
effusion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
summary O
, O
the O
irritative B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
obstructive I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
caused O
by O
benign B-outcome ['Physiological-Clinical']
prostatic I-outcome ['Physiological-Clinical']
hypertrophy I-outcome ['Physiological-Clinical']
were O
decreased O
and O
urodynamic B-outcome ['Physiological-Clinical']
studies I-outcome ['Physiological-Clinical']
were O
markedly O
improved O
by O
the O
alpha O
1-blocker O
, O
YM617 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Cirrhosis O
and O
bleeding O
: O
the O
need O
for O
very O
early O
management O
. O
[]

Naproxen O
sodium O
significantly O
improved O
only O
movement B-outcome ['Life-Impact']
and O
function B-outcome ['Life-Impact']
compared O
to O
dummy O
laser O
. O
['Life-Impact']

Computer O
generated O
block O
randomization O
is O
used O
to O
assure O
both O
groups O
have O
the O
same O
number O
of O
subjects O
. O
[]

This O
study O
was O
designed O
to O
evaluate O
the O
safety O
and O
efficacy O
of O
the O
mini-extracorporeal O
circulation O
system O
( O
ECC.O O
) O
in O
CABG O
patients O
. O
[]

Under O
hypoglycemic O
conditions O
, O
theophylline O
enhanced O
responses O
of O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
symptoms B-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
pulse B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
all O
P O
< O
.05 O
) O
, O
induced B-outcome ['Physiological-Clinical']
sweating I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
higher I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
( O
P O
=.039 O
) O
, O
and O
reduced O
exogenous B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
requirements I-outcome ['Physiological-Clinical']
( O
P O
=.018 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
significant O
increase O
in O
palatal B-outcome ['Physiological-Clinical']
width I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
premolar I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
molar I-outcome ['Physiological-Clinical']
level O
, O
occurred O
in O
both O
groups O
. O
['Physiological-Clinical']

CONCLUSION O
There O
was O
no O
statistical O
difference O
in O
the O
effectiveness O
of O
the O
medications O
on O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
, O
or O
in O
stinging B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
instillation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

STUDY O
OBJECTIVE O
To O
assess O
the O
safety O
and O
efficacy O
of O
amiprilose O
hydrochloride O
( O
HCl O
) O
, O
a O
novel O
synthetic O
carbohydrate O
with O
anti-inflammatory O
and O
immunomodulatory O
properties O
, O
in O
patients O
with O
rheumatoid O
arthritis O
. O
[]

RESULTS O
There O
was O
no O
difference O
between O
groups O
for O
in-patient O
hospital O
stay O
( O
number O
of O
admissions O
or O
length O
of O
stay O
) O
. O
[]

In O
a O
one-year O
field O
experiment O
involving O
over O
1,200 O
respondents O
, O
people O
assigned O
memory O
aids O
reported O
over O
50 O
per O
cent O
more O
symptom O
episodes O
than O
those O
not O
assigned O
memory O
aids O
. O
[]

Effect O
of O
a O
ferrule O
and O
increased O
clinical O
crown O
length O
on O
the O
in O
vitro O
fracture O
resistance O
of O
premolars O
restored O
using O
two O
dowel-and-core O
systems O
. O
[]

Significant O
clinical O
benefit O
persisted O
not O
only O
within O
the O
6-month O
course O
of O
therapy O
, O
but O
3 O
months O
after O
. O
[]

Both O
esomeprazole O
groups O
had O
greater O
[]

A O
prospective O
double-blind O
placebo-controlled O
trial O
of O
intramuscular O
Naftidrofuryl O
was O
carried O
out O
on O
32 O
randomly O
selected O
hospitalized O
male O
alcoholic O
patients O
with O
clinical O
, O
biochemical O
and O
histological O
evidence O
of O
hepatic O
damage O
. O
[]

1 O
, O
2 O
and O
Table O
2 O
) O
. O
( O
[]

It O
was O
observed O
that O
the O
decrease O
in O
serum B-outcome ['Physiological-Clinical']
TC I-outcome ['Physiological-Clinical']
, O
LDL-C B-outcome ['Physiological-Clinical']
and O
triglyceride B-outcome ['Physiological-Clinical']
levels O
were O
significantly O
higher O
in O
the O
second O
group O
than O
the O
first O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

When O
enoximone O
is O
acutely O
administered O
to O
patients O
with O
stable O
angina O
and O
angiographically O
proven O
relevant O
coronary O
stenosis O
i.v O
. O
[]

PURPOSE O
To O
evaluate O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
dofequidar O
plus O
cyclophosphamide O
, O
doxorubicin O
, O
and O
fluorouracil O
( O
CAF O
) O
therapy O
in O
comparison O
with O
CAF O
alone O
, O
in O
patients O
with O
advanced O
or O
recurrent O
breast O
cancer O
. O
['Life-Impact']

Data O
collection O
consisted O
of O
a O
baseline O
and O
two O
annual O
follow-up O
surveys O
. O
[]

The O
bark O
extract O
was O
easy O
to O
apply O
and O
additional O
wound O
care O
was O
not O
usually O
necessary O
, O
while O
the O
treatment O
with O
saline O
gauze O
was O
laborious O
for O
both O
patients O
and O
staff O
and O
was O
much O
more O
expensive B-outcome ['Life-Impact']
. O
['Life-Impact']

Randomized O
prospective O
study O
to O
evaluate O
child O
abuse O
documentation O
in O
the O
emergency O
department O
. O
[]

The O
outcome O
measures O
are O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
palliation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
performance B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
, O
analgesic B-outcome ['Resource-use']
usage I-outcome ['Resource-use']
, O
toxicity B-outcome ['Adverse-effects']
, O
quality O
of O
life O
, O
tumor B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
and O
recurrence/progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality', 'Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Adverse-effects', 'Physiological-Clinical', 'Mortality']

However O
, O
nicotinic O
acid O
therapy O
resulted O
in O
the O
deterioration O
of O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
as O
evidenced O
by O
a O
16 O
% O
increase O
in O
mean O
plasma B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
, O
a O
21 O
% O
increase O
in O
glycosylated B-outcome ['Physiological-Clinical']
hemoglobin B-outcome ['Physiological-Clinical']
levels O
, O
and O
the O
induction O
of O
marked B-outcome ['Physiological-Clinical']
glycosuria B-outcome ['Physiological-Clinical']
in O
some O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
The O
study O
used O
a O
double O
blind O
randomized O
trial O
. O
[]

Operative O
time O
and O
intra-operative O
blood O
loss O
were O
recorded O
. O
[]

Premedication O
has O
been O
shown O
to O
affect O
both O
oxygen B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
( O
VO2 O
) O
and O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
( O
EE O
) O
. O
['Resource-use', 'Physiological-Clinical']

The O
median O
number O
of O
samples B-outcome ['Physiological-Clinical']
collected O
from O
each O
patient O
was O
5 O
for O
blood O
( O
range O
, O
0-15 O
) O
and O
5 O
for O
urine O
( O
range O
, O
0-15 O
) O
. O
['Physiological-Clinical']

Positive O
HER2 B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
levels O
were O
found O
in O
19.8 O
% O
( O
55/278 O
) O
. O
['Physiological-Clinical']

Many O
interventions O
focus O
on O
improving O
theory O
of O
mind O
skills O
in O
children O
with O
ASD O
. O
[]

The O
results O
revealed O
that O
whole O
body O
vibration O
was O
not O
able O
to O
uniformly O
decrease O
the O
rates O
of O
all O
types O
of O
stereotypy B-outcome ['Life-Impact']
; O
that O
is O
, O
some O
stereotypy B-outcome ['Life-Impact']
decreased O
while O
others O
were O
unchanged O
. O
['Life-Impact', 'Life-Impact']

Effect O
of O
betamethasone O
valerate O
on O
the O
normal O
human B-outcome ['Physiological-Clinical']
facial I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
flora I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

With O
the O
multiphasic O
pill O
, O
the O
[]

Statistic O
analysis O
of O
the O
data O
was O
performed O
using O
chi-square O
analysis O
and O
, O
when O
appropriate O
, O
a O
Fischer O
exact O
probability O
test O
. O
[]

The O
primary O
outcome O
was O
defined O
as O
the O
number O
of O
patients O
with O
a O
modified O
Rankin O
score O
[]

RESULTS O
A O
total O
of O
598 O
patients O
were O
enrolled O
; O
337 O
were O
randomized O
to O
the O
PAC7 O
group O
and O
261 O
to O
the O
PAC14 O
group O
. O
[]

The O
outcome O
of O
both O
treatment O
arms O
, O
as O
well O
as O
a O
comparison O
of O
the O
LAG O
group O
, O
to O
that O
of O
the O
SL O
group O
, O
are O
updated O
. O
[]

A O
prospective O
multicenter O
randomized O
comparative O
study O
between O
the O
U- O
and O
H-type O
methods O
of O
the O
TVT O
SECUR O
procedure O
for O
the O
treatment O
of O
female O
stress O
urinary O
incontinence O
: O
1-year O
follow-up O
. O
[]

Endoscopy O
and O
evaluator-blind O
assessments O
of O
the O
esophageal O
, O
gastric O
, O
and O
duodenal O
mucosa O
were O
performed O
at O
baseline O
and O
on O
Days O
8 O
and O
15 O
. O
[]

We O
aimed O
to O
compare O
the O
cure B-outcome ['Physiological-Clinical']
rates O
achieved O
by O
these O
new O
therapy O
regimens O
. O
['Physiological-Clinical']

RESULTS O
Incidence O
rates O
were O
dose O
and O
schedule O
dependent O
( O
165 O
microg/injection O
, O
4.06 O
events/patient-year O
; O
330 O
microg/injection O
, O
6.58 O
events/patient-year O
[ O
less O
intense O
regimen O
] O
and O
8.35 O
events/patient-year O
[ O
more O
intense O
regimen O
] O
) O
. O
[]

Radiographic O
outcomes O
were O
assessed O
relative O
to O
randomization O
baseline O
for O
both O
PBO-randomized O
and O
RTX-randomized O
groups O
. O
[]

Those O
assigned O
to O
the O
intervention O
arm O
were O
given O
a O
choice O
of O
age-appropriate O
distracters O
during O
laceration O
repair O
. O
[]

However O
, O
none O
of O
the O
indices O
of O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
improved O
. O
['Physiological-Clinical']

RESULTS O
There O
was O
improvement O
in O
both O
the O
treatment O
and O
control O
groups O
in O
all O
assessed O
measures O
but O
more O
so O
in O
the O
treatment O
than O
in O
the O
control O
group O
: O
( O
1 O
) O
eye-hand B-outcome ['Life-Impact']
coordination I-outcome ['Life-Impact']
, O
performance B-outcome ['Life-Impact']
, O
and O
practical B-outcome ['Life-Impact']
reasoning I-outcome ['Life-Impact']
of O
Griffiths O
Mental O
Developmental O
Scale O
; O
( O
2 O
) O
sensory-motor B-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
, O
affectual B-outcome ['Life-Impact']
, O
language B-outcome ['Life-Impact']
, O
and O
total O
score O
of O
Ritvo-Freeman O
Real O
Life O
Scale O
; O
( O
3 O
) O
Comprehension B-outcome ['Life-Impact']
Language I-outcome ['Life-Impact']
age O
in O
the O
Reynell O
Language B-outcome ['Life-Impact']
Developmental I-outcome ['Life-Impact']
Scale O
; O
and O
( O
4 O
) O
Total O
Score O
and O
Mental B-outcome ['Life-Impact']
Age O
in O
Symbolic O
Play B-outcome ['Life-Impact']
Test O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
diabetic O
patients O
also O
were O
infused O
in O
random O
order O
and O
on O
different O
days O
with O
either O
saline O
or O
a O
smaller O
amount O
of O
insulin O
delivered O
continuously O
( O
0.15 O
mU O
kg-1 O
min-1 O
) O
or O
in O
a O
pulsatile O
manner O
( O
0.97 O
mU O
kg-1 O
min-1 O
for O
2 O
min O
, O
followed O
by O
11 O
min O
during O
which O
no O
insulin O
was O
infused O
) O
. O
[]

Impaired O
social O
interaction O
, O
communication O
and O
imaginative O
skills O
characterize O
autistic O
syndromes O
. O
[]

Fulvestrant O
versus O
anastrozole O
for O
the O
treatment O
of O
advanced O
breast O
carcinoma O
: O
a O
prospectively O
planned O
combined O
survival O
analysis O
of O
two O
multicenter O
trials O
. O
[]

There O
were O
no O
significant O
differences O
in O
any O
measured O
toxicities B-outcome ['Adverse-effects']
between O
any O
of O
the O
arms O
. O
['Adverse-effects']

RESULTS O
Children O
with O
autism O
were O
slower O
to O
respond B-outcome ['Life-Impact']
, O
which O
suggests O
a O
slight O
difference O
in O
the O
general O
cognitive B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
of O
the O
groups O
. O
['Life-Impact', 'Life-Impact']

To O
compare O
the O
efficacy O
of O
chemoendocrine O
treatment O
with O
that O
of O
endocrine O
treatment O
( O
ET O
) O
alone O
for O
postmenopausal O
women O
with O
highly O
endocrine O
responsive O
breast O
cancer O
. O
[]

Longitudinal O
quality O
of O
life O
study O
in O
patients O
with O
metastatic O
gastric O
cancer O
. O
[]

Twenty O
highly O
trained O
soccer O
players O
( O
age O
18.3 O
+/- O
0.6 O
years O
, O
height O
177 O
+/- O
4 O
cm O
, O
body O
mass O
71.4 O
+/- O
6.9 O
kg O
, O
sum O
skinfolds O
48.1 O
+/- O
11.4 O
mm O
) O
, O
members O
of O
a O
professional O
soccer O
academy O
, O
were O
randomly O
allocated O
to O
either O
a O
CONTRAST O
( O
n O
= O
10 O
) O
or O
SPRINT O
( O
n O
= O
10 O
) O
group O
. O
[]

This O
kind O
of O
lexically O
induced O
perceptual B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
enables O
people O
to O
adjust O
to O
the O
variations O
in O
utterances O
due O
to O
talker-specific O
characteristics O
, O
such O
as O
individual O
identity O
and O
dialect O
. O
['Life-Impact']

The O
haemoglobin B-outcome ['Physiological-Clinical']
level O
at O
presentation O
was O
strongly O
correlated O
with O
prognosis O
among O
patients O
in O
the O
good O
renal-function O
group O
. O
['Physiological-Clinical']

Randomised O
, O
double O
blind O
, O
placebo O
controlled O
study O
of O
fluticasone O
propionate O
in O
patients O
with O
moderate O
to O
severe O
chronic O
obstructive O
pulmonary O
disease O
: O
the O
ISOLDE O
trial O
. O
[]

We O
then O
analyzed O
the O
CEA O
clearance O
pattern O
as O
a O
prognostic O
indicator O
. O
[]

Sitting B-outcome ['Life-Impact']
balance I-outcome ['Life-Impact']
( O
measured O
by O
dimension O
B O
of O
the O
Gross O
Motor O
Function O
Measure O
) O
improved O
significantly O
in O
the O
treatment O
group O
( O
effect O
size O
= O
0.36 O
; O
95 O
% O
CI O
0.01-0.71 O
) O
and O
the O
effect O
size O
was O
greater O
in O
the O
severely O
disabled O
group O
( O
effect O
size O
= O
0.80 O
; O
95 O
% O
CI O
0.13-1.47 O
) O
. O
['Life-Impact']

The O
completeness O
of O
two O
World O
Wide O
Web-based O
directories O
( O
Canada411 O
and O
InfoSpace O
Canada O
) O
for O
subject O
tracing O
was O
evaluated O
by O
using O
a O
randomized O
crossover O
design O
for O
346 O
adults O
randomly O
selected O
from O
respondents O
in O
an O
ongoing O
cohort O
study O
. O
[]

Regular O
Z O
4 O
mg O
infusions O
appear O
to O
be O
safe O
in O
these O
patients O
, O
with O
routine O
monitoring O
of O
serum O
creatinine O
. O
[]

The O
patients O
reported O
that O
the O
breast O
augmentation O
had O
had O
an O
extremely O
high O
impact O
on O
their O
quality O
of O
life O
. O
[]

Comparing O
the O
mean O
individual O
daily B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scores O
for O
each O
phase O
of O
study O
, O
5 O
patients O
( O
31 O
% O
) O
had O
significantly O
less O
pain B-outcome ['Physiological-Clinical']
while O
receiving O
mexiletine O
compared O
with O
their O
response O
to O
placebo O
, O
5 O
patients O
( O
31 O
% O
) O
had O
significantly O
less O
pain O
while O
receiving O
placebo O
, O
and O
no O
difference O
was O
noted O
in O
6 O
patients O
( O
38 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Is O
individual O
peer O
support O
a O
promising O
intervention O
for O
persons O
with O
heart O
failure O
? O
[]

Double-blind O
, O
placebo-controlled O
trial O
of O
risperidone O
plus O
amantadine O
in O
children O
with O
autism O
: O
a O
10-week O
randomized O
study O
. O
[]

A O
randomized O
trial O
of O
genetic O
and O
environmental O
risk O
assessment O
( O
GERA O
) O
for O
colorectal O
cancer O
risk O
in O
primary O
care O
: O
trial O
design O
and O
baseline O
findings O
. O
[]

All O
these O
patients O
had O
received O
steroids O
and O
none O
of O
the O
patients O
without O
steroids O
had O
these O
abnormalities O
. O
[]

CONCLUSIONS O
The O
combination O
of O
clonidine O
( O
2 O
microg/kg O
) O
and O
ropivacaine O
0.1 O
% O
is O
associated O
with O
an O
improved O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
postoperative I-outcome ['Life-Impact']
analgesia I-outcome ['Life-Impact']
compared O
to O
plain O
0.2 O
% O
ropivacaine O
. O
['Life-Impact']

OBJECTIVE O
To O
examine O
the O
predictive O
validity O
of O
symptom B-outcome ['Life-Impact']
severity I-outcome ['Life-Impact']
, O
cognitive B-outcome ['Life-Impact']
and O
language B-outcome ['Life-Impact']
measures O
taken O
at O
ages O
2 O
and O
3 O
years O
to O
outcome O
at O
age O
7 O
in O
a O
sample O
of O
children O
diagnosed O
with O
autism O
at O
age O
2 O
. O
['Life-Impact', 'Life-Impact']

Dexmedetomidine O
infusion O
for O
maintenance O
of O
anesthesia O
in O
patients O
undergoing O
abdominal O
hysterectomy O
. O
[]

They O
assisted O
in O
the O
management O
of O
a O
simulated O
patient O
with O
septic O
shock O
. O
[]

After O
treatment O
, O
patients O
in O
the O
case O
group O
scored O
better O
than O
patients O
in O
the O
control O
group O
( O
FIM B-outcome ['Physiological-Clinical']
total O
score O
, O
P=.02 O
; O
FIM B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
subscore I-outcome ['Physiological-Clinical']
, O
P=.001 O
; O
Tinetti O
scale O
score O
, O
P=.04 O
) O
; O
patients O
in O
the O
case O
group O
were O
assigned O
more O
['Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
Saccharomyces O
boulardii O
in O
children O
with O
acute O
diarrhoea O
. O
[]

Videoconferencing O
technology O
, O
as O
a O
scalable O
tool O
, O
has O
promise O
for O
facilitating O
access O
to O
autism O
specialists O
and O
bridging O
the O
research-to-practice O
gap O
. O
[]

MAIN O
OUTCOME O
MEASURE O
( O
S O
) O
Quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
visualization I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
uterine I-outcome ['Life-Impact']
cavity I-outcome ['Life-Impact']
, O
procedure B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
complications B-outcome ['Adverse-effects']
, O
patient B-outcome ['Life-Impact']
discomfort I-outcome ['Life-Impact']
, O
and O
satisfaction B-outcome ['Life-Impact']
rate O
. O
['Life-Impact', 'Life-Impact', 'Adverse-effects', 'Life-Impact', 'Life-Impact']

The O
repeated O
measure O
P O
value O
for O
the O
entire O
time O
interval O
was O
not O
significant O
( O
P O
= O
.69 O
) O
. O
[]

METHODS O
A O
descriptive O
report O
using O
data O
entered O
in O
the O
COMET O
study O
data-base O
. O
[]

The O
effect O
of O
guar O
( O
15.6 O
g/day O
) O
, O
a O
dietary O
fibre O
, O
and O
simultaneous O
administration O
of O
bezafibrate O
( O
600 O
mg/day O
) O
during O
dietetic O
treatment O
on O
the O
plasma O
lipoproteins O
and O
apolipoproteins O
was O
investigated O
in O
12 O
patients O
with O
familial O
hypercholesterolemia O
( O
corresponding O
to O
the O
HLP O
type O
IIa O
pattern O
) O
. O
[]

Uterine O
volume O
was O
measured O
at O
bimonthly O
intervals O
by O
sonography O
. O
[]

Lamivudine O
300 O
mg O
QD O
versus O
continued O
lamivudine O
150 O
mg O
BID O
with O
stavudine O
and O
a O
protease O
inhibitor O
in O
suppressed O
patients O
. O
[]

The O
data O
were O
analyzed O
by O
means O
of O
two-way O
analysis O
of O
variance O
to O
test O
for O
significant O
differences O
between O
tablet O
formulation O
and O
differences O
between O
the O
first O
and O
second O
trial O
periods O
. O
[]

Moreover O
, O
enalapril O
is O
more O
effective O
in O
reducing O
central B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
augmentation I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
than O
indapamide O
. O
['Physiological-Clinical']

The O
primary O
outcome O
variable O
for O
the O
trial O
was O
dichotomized O
Glasgow O
Outcome O
Scale O
( O
good O
outcome O
versus O
all O
others O
) O
. O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
those O
expected O
with O
an O
EGFR O
inhibitor O
. O
['Adverse-effects']

METHODS O
Patients O
with O
post-myocardial O
infarction O
left O
ventricular O
dysfunction O
underwent O
beat-to-beat O
blood O
pressure O
( O
BP O
) O
( O
Finapres O
, O
Ohmeda O
Inc. O
, O
Englewood O
, O
Colorado O
) O
and O
R-R O
interval O
( O
electrocardiogram O
) O
recording O
; O
baroreceptor O
reflexes O
were O
assessed O
from O
the O
bradycardic O
and O
depressor O
responses O
to O
graded O
neck O
suction O
( O
NS O
) O
as O
well O
as O
by O
computation O
of O
the O
alpha O
spontaneous O
baroreflex O
sensitivity O
index O
. O
[]

Hormone O
replacement O
therapy O
is O
contraindicated O
in O
patients O
with O
breast O
cancer O
. O
[]

During O
recovery B-outcome ['Physiological-Clinical']
, O
S6K1 B-outcome ['Physiological-Clinical']
phosphorylation I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
( O
389 O
) O
remained O
higher O
in O
CHO+PRO O
than O
in O
CHO O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Changes O
in O
the O
fatty B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
esters I-outcome ['Physiological-Clinical']
during O
lipid-lowering O
treatment O
with O
diet O
, O
clofibrate O
and O
niceritrol O
. O
['Physiological-Clinical']

FINDINGS O
Patients O
who O
received O
the O
intervention O
reported O
a O
significant O
reduction O
in O
the O
number O
of O
symptoms B-outcome ['Physiological-Clinical']
experienced I-outcome ['Physiological-Clinical']
and O
improved O
physical B-outcome ['Physiological-Clinical']
and O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

The O
clinical O
response O
and O
remission O
were O
defined O
with O
various O
clinical O
variables O
including O
Montgomery O
Asberg O
Depression B-outcome ['Life-Impact']
Rating O
Scale O
. O
['Life-Impact']

INTRODUCTION O
The O
teaching O
of O
medical O
anatomy O
is O
changing O
. O
[]

METHOD O
In O
this O
study O
, O
97 O
patients O
aged O
6 O
to O
17 O
years O
with O
ADHD O
and O
ASD O
were O
randomly O
assigned O
to O
double-blind O
treatment O
with O
1.2 O
mg/kg/day O
atomoxetine O
or O
placebo O
for O
8 O
weeks O
. O
[]

One O
subject O
was O
identified O
to O
be O
a O
poor O
metabolizer B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

On O
intergroup O
comparison O
; O
the O
control O
of O
diabetes O
with O
gliclazide O
( O
group O
II O
) O
showed O
improvement O
in O
oxidative B-outcome ['Physiological-Clinical']
stress O
( O
MDA B-outcome ['Physiological-Clinical']
, O
GSH B-outcome ['Physiological-Clinical']
) O
better O
( O
p O
< O
0.001 O
) O
than O
glibenclamide O
( O
group O
I O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Taking O
a O
reduction O
of O
50 O
% O
or O
more O
on O
the O
Social B-outcome ['Life-Impact']
Phobia I-outcome ['Life-Impact']
Scale I-outcome ['Life-Impact']
as O
a O
criterion O
for O
clinically O
relevant O
improvement O
, O
only O
1 O
patient O
on O
buspirone O
and O
1 O
on O
placebo O
were O
classified O
as O
responder O
to O
treatment O
. O
['Life-Impact']

The O
primary O
predictors O
of O
participation O
for O
cases O
( O
OR=1.6 O
; O
CI=1.01-2.51 O
) O
and O
FDRs O
( O
OR=2.15 O
; O
CI=1.11-4.13 O
) O
included O
higher O
educational B-outcome ['Life-Impact']
attainment I-outcome ['Life-Impact']
. O
['Life-Impact']

In O
those O
with O
prostate O
cancer O
these O
changes O
were O
23.8 O
% O
and O
-37.2 O
% O
, O
respectively O
. O
[]

Labetalol O
decreased O
mean O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
to O
the O
same O
extent O
on O
the O
first O
and O
the O
seventh O
days O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
surgical O
technique O
for O
corticotomy O
was O
the O
same O
in O
both O
groups O
. O
[]

The O
competition O
between O
enamel O
and O
dentin O
adhesion O
within O
a O
cavity O
: O
an O
in O
vitro O
evaluation O
of O
class O
V O
restorations O
. O
[]

Injurious B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
reduced O
by O
70 O
% O
( O
202 O
in O
controls O
compared O
to O
61 O
in O
paced O
patients O
) O
. O
['Physiological-Clinical']

Oral O
contraceptive O
use O
is O
associated O
with O
increased O
cardiovascular B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
in O
nonsmokers O
. O
['Physiological-Clinical']

Group O
B O
patients O
were O
pretreated O
with O
lidocaine O
0.5 O
mg/kg O
followed O
by O
propofol O
2.0 O
mg/kg O
at O
3.3 O
mg/sec O
. O
[]

At O
treatment O
week O
10 O
, O
12/19 O
( O
63 O
% O
) O
in O
the O
24 O
week O
group O
and O
14/18 O
( O
78 O
% O
) O
patients O
in O
the O
48 O
week O
group O
had O
lost B-outcome ['Physiological-Clinical']
HCV I-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
( O
p O
= O
0.33 O
) O
. O
['Physiological-Clinical']

CONCLUSION O
Peer B-outcome ['Life-Impact']
counseling I-outcome ['Life-Impact']
reduced O
the O
number O
of O
cigarettes B-outcome ['Life-Impact']
smoked I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
but O
did O
not O
increase O
cigarette B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
rates O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

MATERIAL O
AND O
METHODS O
Between O
January O
1998 O
and O
December O
2003 O
, O
51 O
rectal O
carcinoma O
patients O
without O
distant O
metastasis O
or O
peritoneal O
carcinomatosis O
were O
randomly O
divided O
into O
pre-operative O
( O
PRE O
) O
and O
postoperative O
( O
POST O
) O
radiochemotherapy O
groups O
. O
[]

No O
neutralizing O
antibodies O
against O
N7-GP O
were O
detected O
. O
[]

Allergen O
challenge O
was O
performed O
after O
the O
loading O
dose O
and O
a O
histamine O
challenge O
was O
performed O
before O
and O
24 O
hours O
after O
allergen O
. O
[]

One O
hundred O
thirty-two O
other O
patients O
received O
chemotherapy O
and O
RT O
during O
induction O
( O
up-front O
RT O
) O
. O
[]

All O
patients O
were O
seen O
in O
follow-up O
period O
after O
16 O
weeks O
; O
clinical O
evaluation O
using O
Melasma O
Area O
and O
Severity O
Index O
( O
MASI O
) O
score O
and O
photography O
were O
recorded O
before O
and O
after O
treatment O
and O
after O
16 O
weeks O
. O
[]

All O
baseline O
marker O
levels O
, O
except O
CA72-4 O
, O
correlated O
with O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
and O
survival B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

There O
were O
highly O
significant O
reductions O
in O
the O
number O
of O
Doppler B-outcome ['Physiological-Clinical']
embolic I-outcome ['Physiological-Clinical']
signals I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
L-arginine I-outcome ['Physiological-Clinical']
and O
GSNO B-outcome ['Physiological-Clinical']
groups O
; O
first O
4 O
hours O
, O
median O
( O
range O
) O
number O
of O
embolic B-outcome ['Physiological-Clinical']
signals I-outcome ['Physiological-Clinical']
, O
placebo O
44.7 O
( O
6 O
to O
778 O
) O
, O
L-arginine O
9.5 O
( O
0 O
to O
225 O
) O
, O
and O
GSNO O
0.8 O
( O
0 O
to O
8 O
) O
, O
both O
P O
< O
0.001 O
versus O
control O
values O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PROCEDURE O
Four O
, O
4 O
cm2 O
, O
full-thickness O
wounds O
were O
created O
on O
the O
dorsomedial O
and O
dorsolateral O
aspect O
of O
the O
metacarpus O
or O
metatarsus O
of O
each O
limb O
of O
four O
horses O
, O
giving O
a O
total O
of O
64 O
wounds O
. O
[]

Afterwards O
they O
received O
the O
combination O
of O
both O
drugs O
for O
a O
further O
2 O
weeks O
. O
[]

No O
clear O
associations O
with O
TNF B-outcome ['Physiological-Clinical']
or O
['Physiological-Clinical']

Group O
III O
showed O
a O
negative O
change O
in O
appetite B-outcome ['Physiological-Clinical']
( O
P=0.049 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
This O
randomized O
double-blinded O
control O
trial O
was O
conducted O
to O
compare O
the O
effectiveness O
of O
tramodol O
and O
placebo O
rectal O
suppository O
for O
the O
management O
of O
postpartum B-outcome ['Physiological-Clinical']
perineal I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
perineorrhaphy O
. O
['Physiological-Clinical']

Only O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
was O
significantly O
associated O
with O
outcome O
( O
P=0.025 O
) O
: O
the O
5-year O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
estimates O
( O
+/-se O
) O
were O
52.0+/-9.6 O
% O
for O
those O
with O
late O
relapse O
and O
20.0+/-8.0 O
% O
for O
those O
with O
early O
relapse O
. O
['Physiological-Clinical', 'Mortality']

These O
measurements O
were O
performed O
on O
each O
of O
three O
occasions O
following O
one O
week O
of O
matched O
placebo O
, O
quinapril O
40 O
mg O
or O
losartan O
50 O
mg O
daily O
administered O
in O
a O
double-blind O
randomized O
crossover O
design O
. O
[]

The O
score O
of O
symptoms O
and O
signs O
, O
RI O
, O
ADI O
were O
observed O
and O
compared O
between O
two O
groups O
. O
[]

CRP B-outcome ['Physiological-Clinical']
results O
followed O
a O
similar O
pattern O
but O
were O
delayed O
by O
1 O
day O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
Junior O
Detective O
Training O
Program O
appeared O
to O
be O
effective O
in O
enhancing O
the O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
and O
emotional B-outcome ['Life-Impact']
understanding I-outcome ['Life-Impact']
of O
children O
with O
AS O
. O
['Life-Impact', 'Life-Impact']

Stability B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
glucose O
self-measurement O
values O
, O
expressed O
as O
SD O
of O
the O
nine-point O
blood O
glucose O
profiles O
, O
improved O
in O
the O
insulin O
pump O
group O
by O
29.3 O
+/- O
41.1 O
vs. O
8.2 O
+/- O
36.5 O
% O
in O
the O
injection O
group O
( O
P O
= O
0.039 O
) O
. O
['Physiological-Clinical']

There O
were O
no O
deaths B-outcome ['Mortality']
or O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
either O
treatment O
arm O
. O
['Mortality', 'Adverse-effects']

In O
a O
randomized O
, O
double-blind O
and O
placebo-controlled O
study O
in O
25 O
healthy O
postmenopausal O
women O
( O
52.5 O
+/- O
2.8 O
years O
) O
, O
we O
therefore O
examined O
the O
short-term O
effect O
of O
unopposed O
estrogen O
on O
the O
fasting O
and O
fat-load-stimulated O
plasma O
levels O
of O
total O
factor O
VII O
versus O
active O
factor O
VII O
. O
[]

In O
experimental O
study O
, O
monoaminic B-outcome ['Physiological-Clinical']
transmitters I-outcome ['Physiological-Clinical']
activated O
in O
hypothalamus O
; O
weight O
of O
pituitary B-outcome ['Physiological-Clinical']
, O
adrenal B-outcome ['Physiological-Clinical']
and O
thymus B-outcome ['Physiological-Clinical']
decreased O
; O
number O
of O
CRH B-outcome ['Physiological-Clinical']
positive I-outcome ['Physiological-Clinical']
neurons I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
hypothalamic I-outcome ['Physiological-Clinical']
paraventricular I-outcome ['Physiological-Clinical']
nucleus B-outcome ['Physiological-Clinical']
, O
CRH B-outcome ['Physiological-Clinical']
positive I-outcome ['Physiological-Clinical']
neurofibrilin B-outcome ['Physiological-Clinical']
median O
eminence B-outcome ['Physiological-Clinical']
and O
anterior B-outcome ['Physiological-Clinical']
pituitary I-outcome ['Physiological-Clinical']
ACTH B-outcome ['Physiological-Clinical']
positive I-outcome ['Physiological-Clinical']
secretory I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
decreased O
; O
adrenal B-outcome ['Physiological-Clinical']
fasciculate B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Pioglitazone O
and O
glimepiride O
improve O
glycemic O
control O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
by O
different O
mechanisms O
. O
[]

A O
randomized O
phase O
II O
trial O
of O
5-fluorouracil O
, O
with O
or O
without O
human O
interferon-beta O
, O
for O
advanced O
colorectal O
cancer O
. O
[]

The O
authors O
studied O
39 O
patients O
being O
treated O
with O
high O
flux O
dialysis O
. O
[]

The O
upper B-outcome ['Physiological-Clinical']
lip I-outcome ['Physiological-Clinical']
bite I-outcome ['Physiological-Clinical']
test O
showed O
significantly O
higher O
specificity O
and O
accuracy B-outcome ['Physiological-Clinical']
than O
the O
modified O
Mallampati O
test O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Pethidine O
seems O
to O
be O
a O
better O
alternative O
than O
tramadol O
in O
obstetric O
analgesia O
because O
of O
its O
superiority O
in O
analgesic B-outcome ['Resource-use']
efficacy O
and O
low O
incidence O
of O
maternal B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Resource-use', 'Adverse-effects']

METHODS O
Fifty-five O
cases O
were O
divided O
into O
an O
observation O
group O
( O
25 O
cases O
) O
and O
a O
control O
group O
( O
30 O
cases O
) O
randomly O
. O
[]

Endoscopic O
examination O
was O
the O
main O
parameter O
for O
the O
assessment O
of O
treatment O
efficacy O
and O
ulcer B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
rate O
. O
['Physiological-Clinical']

Both O
the O
practice O
and O
the O
no-practice O
groups O
received O
information O
that O
described O
the O
inoculation O
procedure O
and O
how O
to O
cope O
with O
it O
by O
using O
cognitive-behavioral O
coping O
skills O
. O
[]

The O
NFT O
is O
defined O
as O
the O
time O
during O
resuscitation O
when O
no O
chest O
compressions O
take O
place O
. O
[]

Patients O
with O
good O
clinical O
recovery B-outcome ['Physiological-Clinical']
did O
not O
differ O
in O
their O
neuropsychological B-outcome ['Physiological-Clinical']
test O
scores O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
An O
sVLPD O
was O
effective O
and O
safe O
when O
postponing O
dialysis O
treatment O
in O
elderly O
patients O
without O
diabetes O
. O
[]

Relation O
between O
early O
mitral O
regurgitation O
and O
left O
ventricular O
thrombus O
formation O
after O
acute O
myocardial O
infarction O
: O
results O
of O
the O
GISSI-3 O
echo O
substudy O
. O
[]

The O
10-year O
OS O
rate O
was O
13.8 O
% O
in O
the O
surgery O
arm O
and O
13.1 O
% O
in O
the O
chemotherapy O
arm O
. O
[]

A O
greater O
proportion O
of O
cats O
receiving O
meloxicam O
medication O
showed O
a O
significant O
worsening O
of O
owner O
assessment O
scores O
once O
the O
placed O
was O
introduced O
, O
when O
compared O
to O
the O
Glu-Ch O
group O
. O
[]

RESULTS O
In O
comparison O
with O
placebo O
, O
oxytocin O
administration O
improved O
performance O
on O
the O
Reading O
the O
Mind O
in O
the O
Eyes O
Task O
. O
[]

Recent O
studies O
have O
suggested O
that O
children O
with O
autism O
perform O
better O
than O
matched O
controls O
on O
visual O
search O
tasks O
and O
that O
this O
stems O
from O
a O
superior O
visual B-outcome ['Life-Impact']
discrimination I-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
. O
['Life-Impact']

Groups O
were O
well O
matched O
, O
and O
there O
were O
no O
differences O
between O
the O
two O
methods O
in O
surgical B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
or O
in O
anesthesia B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
. O
['Life-Impact', 'Adverse-effects']

Dietary O
sodium O
intake O
modulates O
myocardial B-outcome ['Physiological-Clinical']
relaxation I-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
to O
angiotensin O
II O
. O
['Physiological-Clinical']

The O
effects O
of O
lithium O
carbonate O
and O
haloperidol O
on O
cognition O
were O
examined O
in O
a O
placebo-controlled O
, O
double-blind O
study O
of O
61 O
treatment-resistant O
, O
hospitalized O
school-aged O
children O
. O
[]

The O
treatment O
outcome O
was O
measured O
through O
a O
detailed O
scoring O
system O
that O
included O
the O
ability B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
eradicate I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
, O
the O
functional B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
limb I-outcome ['Life-Impact']
, O
and O
the O
radiographic B-outcome ['Physiological-Clinical']
appearance I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
and O
joint B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Short-term O
GHQ B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
was O
determined O
by O
a O
return O
to O
a O
normal O
GHQ B-outcome ['Physiological-Clinical']
score O
( O
< O
5 O
) O
or O
a O
reduction O
of O
> O
or O
=50 O
% O
after O
the O
two O
visits O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
We O
randomized O
121 O
patients O
: O
66 O
to O
CLD O
and O
55 O
to O
LFSD O
. O
[]

Are O
back O
supports O
plus O
education O
more O
effective O
than O
education O
alone O
in O
promoting O
recovery O
from O
low O
back O
pain O
? O
: O
[]

It O
is O
now O
recognized O
that O
left O
ventricular O
hypertrophy O
( O
LVH O
) O
, O
often O
associated O
with O
hypertension O
, O
is O
itself O
a O
risk O
factor O
for O
coronary O
disease O
in O
the O
elderly O
. O
[]

No O
data O
from O
a O
randomized O
prospective O
clinical O
study O
of O
the O
prophylactic O
use O
of O
antibiotics O
in O
implant O
surgery O
have O
been O
previously O
published O
. O
[]

1,3,4,14b-Tetrahydro-2,7-dimethyl-2H-dibenzo O
( O
b O
, O
f O
) O
pyrazino- O
( O
1,2-d O
) O
- O
( O
1,4 O
) O
-oxazepine O
hydrogen O
maleate O
( O
Org O
GC O
94 O
) O
is O
an O
oral O
antamine O
preparation O
with O
anti-serotoninergic O
and O
anti-histaminic O
effects O
. O
[]

In O
all O
groups O
, O
the O
teeth O
were O
etched O
with O
37 O
% O
phosphoric O
acid O
for O
20 O
seconds O
, O
and O
RMGIC O
( O
Fuji O
Ortho O
LC O
, O
GC O
Europe O
, O
Leuven O
, O
Belgium O
) O
was O
used O
for O
bracket O
bonding O
. O
[]

CONCLUSIONS O
The O
strongest O
covariation O
was O
observed O
for O
diet B-outcome ['Life-Impact']
variables O
that O
are O
inherently O
related O
( O
calories O
and O
fat O
, O
fiber O
, O
and O
fruit/vegetables O
) O
. O
['Life-Impact']

CONCLUSIONS O
Many O
low-income O
urban O
children O
with O
asthma O
in O
King O
County O
live O
in O
indoor O
environments O
that O
place O
them O
at O
substantial O
risk O
of O
ongoing O
exposure O
to O
asthma O
triggers O
. O
[]

To O
increase O
surface B-outcome ['Physiological-Clinical']
proteins I-outcome ['Physiological-Clinical']
associated O
with O
adherence O
and O
invasion O
, O
Shigella O
sonnei O
were O
grown O
in O
BHI O
broth O
containing O
deoxycholate O
. O
['Physiological-Clinical']

Patients O
were O
identified O
who O
: O
( O
a O
) O
met O
the O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
BP O
) O
criteria O
for O
first-dose O
hypotension O
( O
sitting O
or O
standing O
systolic O
BP O
< O
100 O
mmHg O
, O
or O
a O
fall O
in O
systolic O
BP O
> O
or O
= O
20 O
mmHg O
on O
standing O
) O
; O
( O
b O
) O
had O
symptoms O
suggestive O
of O
hypotension O
; O
and O
( O
c O
) O
met O
the O
BP O
criteria O
and O
had O
symptoms O
. O
['Physiological-Clinical']

Children O
with O
autism O
exhibit O
significant O
deficits O
in O
imitation B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact']

Joint O
attention O
and O
symbolic O
play O
in O
young O
children O
with O
autism O
: O
a O
randomized O
controlled O
intervention O
study O
. O
[]

Before O
and O
after O
4 O
weeks O
of O
treatment O
, O
we O
( O
1 O
) O
performed O
anthropometry O
, O
a O
physical O
examination O
, O
and O
routine O
laboratory O
measurements O
, O
( O
2 O
) O
determined O
total O
and O
segmental O
colonic O
transit O
time O
, O
( O
3 O
) O
evaluated O
bowel O
movement O
habits O
and O
stool O
consistency O
using O
a O
diary O
, O
and O
( O
4 O
) O
received O
a O
subjective O
evaluation O
from O
the O
parents O
regarding O
the O
efficacy O
of O
the O
treatment O
. O
[]

METHODS O
In O
a O
prospective O
, O
double-blind O
, O
randomized O
controlled O
trial O
conducted O
in O
a O
tertiary O
maternity O
hospital O
622 O
women O
received O
either O
400 O
mug O
of O
oral O
misoprostol O
or O
5 O
U O
of O
intravenous O
oxytocin O
after O
delivery O
of O
the O
anterior O
shoulder O
or O
within O
1 O
min O
of O
delivery O
. O
[]

The O
primary O
study O
end O
point O
was O
the O
grading B-outcome ['Adverse-effects']
of I-outcome ['Adverse-effects']
acute I-outcome ['Adverse-effects']
and I-outcome ['Adverse-effects']
late I-outcome ['Adverse-effects']
nonhematologic I-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
( O
mucositis B-outcome ['Physiological-Clinical']
, O
dysphagia B-outcome ['Physiological-Clinical']
, O
xerostomia B-outcome ['Physiological-Clinical']
) O
induced O
by O
radiochemotherapy O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
Palpitations O
can O
generate O
feelings O
of O
anxiety B-outcome ['Life-Impact']
and O
decrease O
quality O
of O
life O
( O
QoL B-outcome ['Life-Impact']
) O
due O
to O
fear O
of O
a O
cardiac O
abnormality O
. O
['Life-Impact', 'Life-Impact']

BACKGROUND O
Colonization O
patterns O
, O
especially O
by O
anaerobic O
flora O
, O
may O
play O
an O
important O
role O
in O
neonatal O
gut O
function O
. O
[]

The O
extension O
group O
had O
the O
knee O
extended O
fully O
. O
[]

This O
is O
possibly O
due O
to O
the O
fact O
that O
either O
subacromial O
tissue O
, O
despite O
of O
chronic O
inflammation O
, O
does O
not O
show O
the O
same O
reagibility O
as O
synovia O
or O
it O
is O
a O
problem O
of O
the O
nearly O
complete O
resection O
of O
the O
subacromial O
bursa O
. O
[]

Individual O
and O
total O
fecal B-outcome ['Physiological-Clinical']
SCFA I-outcome ['Physiological-Clinical']
excretion B-outcome ['Physiological-Clinical']
, O
weight O
, O
and O
moisture B-outcome ['Physiological-Clinical']
were O
higher O
than O
those O
for O
habitual O
diets O
when O
either O
fiber O
diet O
was O
consumed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
experimental O
protocol O
included O
clinical O
evaluation O
, O
assessment O
of O
urinary O
concentration O
of O
magnesium O
, O
and O
manuvacuometric O
measurements O
[ O
maximal B-outcome ['Physiological-Clinical']
inspiratory I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MIP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
maximal B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MEP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Concomitant O
therapy O
with O
aspirin O
may O
prevent O
this O
withdrawal O
phenomenon O
. O
[]

Before O
the O
intervention O
, O
strenuous O
exercise O
up O
to O
exhaustion O
increased O
the O
mobilization O
of O
CD3 O
, O
CD4 O
, O
CD8 O
, O
or O
CD8 O
( O
bright O
) O
lymphocytes O
expressing O
activated O
( O
CD11a O
) O
or O
senescent O
( O
KLRG1 O
) O
molecules O
into O
the O
peripheral O
blood O
compartment O
. O
[]

A O
reduction O
in O
PVC/hour O
of O
more O
than O
70 O
per O
cent O
was O
seen O
in O
7 O
patients O
with O
C O
and O
in O
9 O
patients O
with O
P. O
C B-outcome ['Physiological-Clinical']
was O
better O
tolerated O
than O
P O
on O
the O
basis O
of O
both O
clinical O
and O
electrocardiographic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Few O
controlled O
psychopharmacologic O
trials O
have O
been O
conducted O
in O
autistic O
children O
to O
determine O
which O
agents O
may O
be O
effective O
for O
these O
associated O
features O
. O
[]

IIT O
also O
decreased O
IGFBP-3 B-outcome ['Physiological-Clinical']
( O
P O
= O
0.0005 O
) O
and O
acid-labile B-outcome ['Physiological-Clinical']
subunit O
( O
P O
= O
0.007 O
) O
, O
while O
increasing O
IGFBP-1 B-outcome ['Physiological-Clinical']
( O
P O
= O
0.04 O
) O
and O
the O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

For O
histological O
grade O
, O
there O
was O
no O
obvious O
difference O
in O
treatment O
response O
between O
the O
groups O
. O
[]

The O
median O
duration O
of O
response B-outcome ['Physiological-Clinical']
was O
longer O
than O
1 O
year O
. O
['Physiological-Clinical']

RESULTS O
Hematologic B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
was O
similar O
. O
['Physiological-Clinical']

SCORAD O
decreased O
in O
the O
Bifidobacterium O
lactis O
Bb-12 O
group O
to O
0 O
( O
0-3.8 O
) O
, O
and O
in O
the O
Lactobacillus O
GG O
group O
to O
1 O
( O
0.1-8.7 O
) O
, O
vs O
unsupplemented O
13.4 O
( O
4.5-18.2 O
) O
, O
median O
( O
interquartile O
range O
) O
, O
in O
parallel O
with O
a O
reduction O
in O
the O
concentration O
of O
soluble O
CD4 B-outcome ['Physiological-Clinical']
in O
serum O
and O
eosinophilic O
protein O
X O
in O
urine O
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
and O
compare O
laparoscopic O
treatment O
for O
stage O
I O
endometrial O
cancer O
with O
the O
traditional O
transabdominal O
approach O
. O
[]

Recently O
, O
the O
Prostate O
, O
Lung O
, O
Colorectal O
and O
Ovarian O
( O
PLCO O
) O
Trial O
reported O
no O
mortality O
benefit O
for O
annual O
screening O
with O
CA-125 O
and O
transvaginal O
ultrasound O
( O
TVU O
) O
. O
[]

While O
the O
importance O
of O
seizure O
duration O
to O
the O
antidepressant O
response O
of O
ECT O
grows O
less O
certain O
, O
there O
is O
growing O
evidence O
that O
seizure O
morphology O
predicts O
the O
antidepressant O
effect O
of O
ECT O
. O
[]

By O
study O
endpoint O
, O
risperidone-treated O
subjects O
exhibited O
a O
64 O
% O
improvement O
over O
baseline O
in O
the O
irritability B-outcome ['Life-Impact']
score O
almost O
double O
that O
of O
placebo-treated O
subjects O
( O
31 O
% O
) O
. O
['Life-Impact']

Rizatriptan O
5 O
mg O
for O
the O
acute O
treatment O
of O
migraine B-outcome ['Physiological-Clinical']
in O
adolescents O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
. O
['Physiological-Clinical']

Anesthesia O
was O
maintained O
with O
fentanyl O
and O
halothane O
or O
isoflurane O
in O
nitrous O
oxide O
and O
oxygen O
( O
50/50 O
) O
. O
[]

PATIENTS O
AND O
METHODS O
The O
randomized O
, O
three-arm O
trial O
recruited O
patients O
in O
stages O
IIB O
and O
IIIA O
with O
risk O
factors O
and O
stages O
IIIB O
and O
IV O
. O
[]

Adding O
latanoprost O
to O
timolol O
reduced O
IOP B-outcome ['Physiological-Clinical']
with O
5.9 O
+/- O
0.9 O
mmHg O
( O
p O
< O
0.001 O
) O
and O
switching O
from O
timolol O
to O
latanoprost O
reduced O
IOP B-outcome ['Physiological-Clinical']
with O
5.0 O
+/- O
0.9 O
mmHg O
( O
p O
< O
0.001 O
) O
, O
which O
caused O
in O
each O
group O
a O
significant O
IOP B-outcome ['Physiological-Clinical']
reduction O
of O
about O
25 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
C-statistics O
for O
prediction O
models O
that O
used O
IOP O
adjusted O
for O
CCT O
by O
various O
formulas O
ranged O
from O
0.75 O
to O
0.77 O
, O
no O
better O
than O
the O
original O
prediction O
model O
( O
0.77 O
) O
that O
did O
not O
adjust O
IOP O
for O
CCT O
. O
[]

Cystoid B-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
edema I-outcome ['Physiological-Clinical']
8 O
( O
4.7 O
% O
) O
, O
postoperative B-outcome ['Physiological-Clinical']
vitreous I-outcome ['Physiological-Clinical']
prolaps I-outcome ['Physiological-Clinical']
into I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
anterior I-outcome ['Physiological-Clinical']
chamber I-outcome ['Physiological-Clinical']
4 O
( O
2.3 O
% O
) O
and O
spontaneous B-outcome ['Physiological-Clinical']
complaints I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
16 O
( O
9.4 O
% O
) O
occurred O
in O
a O
low O
percentage O
after O
ICCE O
with O
ACL O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
a O
statistically O
significant O
difference O
between O
SML O
and O
TK O
for O
this O
criterion O
: O
46 O
% O
and O
39 O
% O
success O
with O
SML O
during O
periods O
I O
( O
first O
28-day O
period O
) O
and O
II O
( O
following O
the O
cross-over O
) O
, O
compared O
to O
only O
15 O
% O
and O
26 O
% O
with O
TK O
, O
respectively O
( O
p O
< O
0.01 O
) O
. O
[]

This O
study O
provided O
sleep O
education O
to O
parents O
of O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
to O
determine O
whether O
an O
individual O
or O
group O
format O
was O
more O
effective O
in O
improving O
sleep B-outcome ['Physiological-Clinical']
and O
aspects O
of O
daytime B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
and O
family B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Alpha-adrenergic O
agonists O
produce O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
through O
an O
opioid O
independent O
mechanism O
and O
may O
be O
alternatives O
to O
opioids O
for O
combination O
with O
local O
anaesthetics O
for O
analgesia O
during O
labour O
. O
['Physiological-Clinical']

The O
methods O
and O
sample O
sizes O
for O
these O
substudies O
have O
been O
a O
crucial O
issue O
in O
validity O
and O
feasibility O
. O
[]

The O
loop O
technique O
was O
1.11 O
times O
more O
likely O
to O
cause O
overlapping B-outcome ['Physiological-Clinical']
than O
the O
holder O
technique O
. O
['Physiological-Clinical']

5 O
% O
imiquimod O
cream O
and O
reflectance-mode O
confocal O
microscopy O
as O
adjunct O
modalities O
to O
Mohs O
micrographic O
surgery O
for O
treatment O
of O
basal O
cell O
carcinoma O
. O
[]

METHODS O
The O
study O
included O
98 O
patients O
who O
underwent O
intestinal O
recanalization O
procedures O
between O
December O
2003 O
and O
December O
2008 O
, O
with O
the O
stoma O
as O
the O
surgical O
site O
. O
[]

CONCLUSION O
Leucocyte O
depletion O
is O
not O
associated O
with O
better O
long-term O
survival B-outcome ['Mortality']
and O
lower O
recurrence B-outcome ['Physiological-Clinical']
rates O
in O
patients O
with O
gastrointestinal O
cancer O
. O
['Mortality', 'Physiological-Clinical']

Our O
data O
confirm O
that O
the O
rFeIFN-omega O
can O
exert O
a O
significant O
therapeutic O
effect O
on O
dogs O
with O
parvoviral O
enteritis O
by O
improving O
clinical O
signs O
and O
reducing O
mortality O
. O
[]

acceptance O
and O
attrition O
, O
have O
often O
been O
overlooked O
. O
[]

Unit O
costs O
were O
derived O
from O
the O
DCCT O
, O
manufacturers O
, O
and O
Medicare O
and O
chosen O
to O
reflect O
what O
an O
item O
would O
cost O
to O
a O
single-payer O
national O
health O
system O
. O
[]

Twelve O
percent O
of O
caudal O
block O
patients O
and O
20 O
% O
of O
diclofenac O
patients O
needed O
rescue B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
, O
a O
statistically O
insignificant O
difference O
. O
['Resource-use']

Levosimendan O
increased O
the O
mean O
cost B-outcome ['Resource-use']
per O
patient O
by O
1108 O
, O
which O
was O
entirely O
due O
to O
the O
cost O
of O
the O
study O
drug O
. O
['Resource-use']

Warfarin O
is O
an O
established O
treatment O
for O
prevention O
of O
ischaemic O
stroke O
in O
patients O
with O
atrial O
fibrillation O
, O
but O
the O
value O
of O
this O
agent O
relative O
to O
aspirin O
in O
unclear O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Measures O
of O
fetal B-outcome ['Physiological-Clinical']
and O
maternal B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
, O
health B-outcome ['Resource-use']
service I-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
psychosocial B-outcome ['Life-Impact']
outcomes O
, O
and O
maternal B-outcome ['Life-Impact']
and O
professional B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Life-Impact', 'Life-Impact']

The O
benefits O
of O
lowering O
a O
systolic O
blood O
pressure O
below O
140 O
mmHg O
in O
elderly O
hypertension O
remain O
controversial O
. O
[]

Individuals O
with O
a O
DSM-IV O
diagnosis O
of O
autistic O
disorder O
( O
mean O
age O
, O
16.3 O
years O
; O
range O
, O
10-36 O
years O
) O
were O
randomly O
assigned O
, O
by O
using O
a O
Latin O
square O
design O
, O
to O
the O
following O
7-week O
trials O
: O
placebo O
, O
clomipramine O
( O
mean O
daily O
dose O
, O
128.4 O
mg O
; O
range O
, O
100-150 O
mg O
) O
, O
or O
haloperidol O
( O
mean O
daily O
dose O
, O
1.3 O
mg O
; O
range O
, O
1-1.5 O
mg O
) O
. O
[]

METHODS O
Phase O
1 O
involved O
65 O
children O
with O
ASD O
who O
received O
one O
round O
of O
DMSA O
( O
3 O
days O
) O
. O
[]

Fourteen O
had O
pituitary O
hormone O
deficiency O
( O
PHD O
) O
including O
GH O
deficiency O
( O
GHD O
) O
. O
[]

No O
marked O
differences O
in O
follow-up O
new O
and O
recurrent B-outcome ['Physiological-Clinical']
caries I-outcome ['Physiological-Clinical']
were O
found O
between O
the O
stannous O
fluoride O
gel O
control O
and O
IFRS O
groups O
during O
the O
study O
period O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
sensitivity B-outcome ['Physiological-Clinical']
, O
specificity O
, O
and O
['Physiological-Clinical']

One O
interpretation O
is O
that O
feed-forward O
processes O
lead O
to O
awareness O
of O
the O
movement O
prior O
to O
execution O
. O
[]

During O
the O
experimental O
phase O
, O
subjects O
were O
asked O
to O
use O
soybean O
oil O
or O
perilla O
oil O
as O
the O
sole O
cooking O
oil O
for O
8 O
mo O
. O
[]

CONCLUSION O
MP O
and O
NTI O
alone O
or O
combined O
were O
not O
superior O
to O
placebo O
in O
improving O
CRF O
. O
[]

CONCLUSIONS O
The O
results O
of O
the O
present O
analysis O
suggest O
that O
continued O
treatment O
with O
atomoxetine O
up O
to O
28 O
weeks O
further O
improve O
ADHD B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
children O
and O
adolescents O
with O
ASD O
, O
while O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
tend O
to O
subside O
. O
['Life-Impact', 'Adverse-effects']

METHODS O
Forty-three O
CABG O
patients O
were O
randomised O
into O
an O
ischaemic O
preconditioning O
and O
a O
control O
group O
. O
[]

The O
decrease O
in O
mean O
score O
values O
was O
directly O
proportional O
to O
L-5-HTP O
treatment O
, O
and O
statistical O
significance O
( O
Wilcoxon O
's O
test O
) O
was O
observed O
only O
for O
L-5-HTP O
in O
both O
groups O
, O
from O
0.05 O
to O
0.01 O
. O
[]

The O
correlations O
between O
the O
changes O
in O
bone O
mineral O
at O
the O
sites O
measured O
were O
all O
significant O
( O
r O
approximately O
0.2-0.4 O
) O
. O
[]

CONCLUSION O
Findings O
support O
the O
contention O
that O
participation O
in O
recreation O
activities O
positively O
influenced O
the O
stress O
and O
quality O
of O
life O
of O
adults O
with O
ASD O
. O
[]

Successful B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
was O
defined O
as O
two O
negative O
13C-urea B-outcome ['Physiological-Clinical']
breath O
tests O
or O
one O
negative O
and O
one O
missing O
test O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subjects O
treated O
with O
fixed O
doses O
of O
200 O
mg/day O
desipramine O
( O
N O
= O
17 O
) O
, O
400 O
mg/day O
amantadine-placebo O
( O
N O
= O
16 O
) O
, O
and O
placebo O
( O
N O
= O
21 O
) O
did O
not O
differ O
for O
lifetime O
cocaine O
use O
, O
lifetime O
histories O
of O
psychopathology O
, O
admission O
scores O
on O
psychometric O
assessments O
, O
and O
sociodemographics O
. O
[]

These O
results O
support O
the O
durable B-outcome ['Life-Impact']
efficacy O
and O
long-term O
safety O
of O
EVG/COBI/FTC/TDF O
. O
['Life-Impact']

Clinical B-outcome ['Physiological-Clinical']
, O
biochemical B-outcome ['Physiological-Clinical']
, O
and O
48-hour B-outcome ['Physiological-Clinical']
ambulatory I-outcome ['Physiological-Clinical']
electrocardiographic I-outcome ['Physiological-Clinical']
data O
was O
collected O
after O
each O
treatment O
phase O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Energy B-outcome ['Life-Impact']
expenditure I-outcome ['Life-Impact']
( O
24 O
h O
) O
( O
ENT O
9.6 O
( O
se O
0.4 O
) O
, O
PLA O
9.5 O
( O
se O
0.4 O
) O
MJ O
) O
, O
sleeping B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
resting I-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
diet-induced B-outcome ['Physiological-Clinical']
thermogenesis I-outcome ['Physiological-Clinical']
, O
activity-induced B-outcome ['Physiological-Clinical']
energy I-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
24 I-outcome ['Physiological-Clinical']
h I-outcome ['Physiological-Clinical']
RQ I-outcome ['Physiological-Clinical']
( O
ENT O
0.77 O
( O
se O
0.01 O
) O
, O
PLA O
0.77 O
( O
se O
0.01 O
) O
) O
were O
similar O
for O
both O
treatments O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
addition O
of O
hydrochlorothiazide O
resulted O
in O
similar O
response O
rates O
in O
the O
lisinopril O
and O
nifedipine O
groups O
( O
89 O
% O
and O
75 O
% O
respectively O
) O
. O
[]

Participants O
were O
assigned O
to O
receive O
3 O
weeks O
of O
oral O
dosing O
with O
placebo O
or O
fluoxetine O
, O
40 O
mg O
per O
day O
. O
[]

These O
results O
support O
a O
twice-daily O
schedule O
for O
linezolid O
and O
demonstrate O
the O
feasibility O
of O
converting O
from O
intravenous O
to O
oral O
dosing O
without O
a O
dose O
adjustment O
. O
[]

Multiparous O
women O
showed O
no O
difference O
in O
rates O
of O
UI O
( O
VB O
17.1 O
% O
vs. O
CS O
16.0 O
% O
) O
, O
whether O
there O
was O
a O
prior O
history O
of O
UI O
or O
not O
. O
[]

RESULTS O
Compared O
with O
the O
cisplatin-only O
arm O
, O
there O
was O
a O
9 O
% O
improvement O
( O
95 O
% O
confidence O
interval O
, O
0 O
% O
to O
19 O
% O
) O
in O
overall O
response O
rate O
for O
the O
paclitaxel/cisplatin O
arm O
( O
17 O
% O
v O
26 O
% O
, O
respectively O
; O
P=.028 O
) O
. O
[]

Included O
were O
98 O
subjects O
who O
underwent O
cardiac O
catheterization O
and O
were O
randomized O
to O
forced O
diuresis O
with O
i.v O
. O
[]

The O
only O
difference O
between O
the O
two O
groups O
was O
the O
higher O
number O
of O
headaches B-outcome ['Physiological-Clinical']
in O
the O
ondansetron O
group O
. O
['Physiological-Clinical']

METHODS O
Forty O
below-knee O
amputees O
( O
after O
war O
wounding O
) O
, O
average O
age O
35.6 O
+/- O
10.6 O
years O
, O
that O
were O
included O
in O
primary O
rehabilitation O
program O
with O
prosthetics O
, O
were O
examined O
. O
[]

[ O
Potentiation O
of O
the O
effect O
of O
non-depolarizing O
muscle O
relaxants O
by O
acylaminopenicillins O
. O
[]

Adjuvant O
therapy O
of O
breast O
cancer O
: O
the O
Southwest O
Oncology O
Group O
experience O
. O
[]

Recatheterization O
and O
submaximal O
exercise O
thallium-201 O
single O
photon O
emission O
computed O
tomography O
were O
performed O
before O
hospital O
discharge O
. O
[]

METHODS/DESIGN O
This O
paper O
presents O
the O
rationale O
and O
design O
of O
a O
randomised O
controlled O
trial O
examining O
the O
effects O
of O
advice O
and O
individualized B-outcome ['Physiological-Clinical']
sub-maximal I-outcome ['Physiological-Clinical']
exercise I-outcome ['Physiological-Clinical']
programs I-outcome ['Physiological-Clinical']
in O
the O
treatment O
of O
whiplash O
associated O
disorders O
. O
['Physiological-Clinical']

A O
randomized O
, O
prospective O
trial O
of O
adjuvant O
chemotherapy O
in O
adults O
with O
soft O
tissue O
sarcomas O
of O
the O
head O
and O
neck O
, O
breast O
, O
and O
trunk O
. O
[]

Therefore O
, O
we O
were O
interested O
in O
determining O
whether O
this O
also O
was O
the O
case O
in O
people O
with O
type O
2 O
diabetes O
. O
[]

The O
primary O
outcome O
was O
the O
number O
of O
falls B-outcome ['Life-Impact']
during O
one O
year O
of O
follow-up O
. O
['Life-Impact']

Sphincter-saving O
procedures O
appear O
to O
have O
no O
adverse O
effects O
on O
outcome O
of O
rectal O
cancer O
, O
but O
the O
optimum O
use O
of O
radiotherapy O
is O
still O
to O
be O
defined O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
determine O
if O
tHcy O
lowering O
vitamins O
decrease O
the O
circulating O
levels O
of O
A-beta O
protein O
1-40 O
( O
A O
beta O
40 O
) O
. O
[]

The O
putty O
material O
was O
characterized O
by O
ease O
of O
handling O
, O
simple O
placement O
, O
and O
enhanced O
graft O
particle O
containment O
. O
[]

Further O
investigation O
in O
people O
at O
high O
risk O
for O
CRC O
seems O
warranted O
. O
[]

Shock O
success O
was O
defined O
as O
return O
of O
sinus B-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
for O
> O
/=30 O
seconds O
. O
['Physiological-Clinical']

Similarly O
, O
there O
were O
no O
clinically O
significant O
[]

Eighty-eight O
patients O
determined O
as O
eligible O
for O
treatment O
were O
enrolled O
in O
the O
study O
. O
[]

This O
study O
demonstrated O
the O
safety O
and O
enhanced O
immunogenicity B-outcome ['Physiological-Clinical']
of O
the O
candidate O
meningococcal O
conjugate O
vaccine O
as O
compared O
with O
the O
licensed O
polysaccharide O
vaccine O
in O
adolescents O
. O
['Physiological-Clinical']

Neonates O
with O
mild B-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
or O
with O
seizures B-outcome ['Physiological-Clinical']
that O
were O
decreasing O
in O
severity O
before O
treatment O
were O
more O
likely O
to O
have O
their O
seizures B-outcome ['Physiological-Clinical']
end O
, O
regardless O
of O
the O
treatment O
assignment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PARTICIPANTS O
Hypertensive O
patients O
, O
210 O
females O
and O
160 O
males O
, O
treated O
or O
untreated O
with O
antihypertensive O
drugs O
with O
a O
sitting O
diastolic O
blood O
pressure O
between O
95 O
and O
115 O
mmHg O
and O
a O
serum O
total O
cholesterol O
between O
6.5 O
mmol/l O
( O
7.0 O
for O
those O
age O
60-67 O
years O
) O
and O
9.0 O
mmol/l O
. O
[]

In O
addition O
, O
both O
combination O
treatments O
resulted O
in O
the O
reduction O
of O
proteinuria B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

As O
compared O
with O
vidarabine O
, O
acyclovir O
treatment O
shortened O
the O
median O
periods O
during O
which O
cultures O
were O
positive O
for O
the O
virus B-outcome ['Physiological-Clinical']
( O
four O
vs. O
seven O
days O
, O
P O
= O
0.004 O
) O
and O
new B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
formed O
( O
three O
vs. O
six O
days O
, O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
controlled O
trial O
. O
[]

MEASUREMENTS O
Gait O
was O
tested O
in O
30 O
transitionally O
frail O
older O
adults O
( O
mean O
age O
82.6 O
+/- O
7.1 O
years O
, O
90 O
% O
female O
) O
while O
either O
walking B-outcome ['Life-Impact']
alone I-outcome ['Life-Impact']
, O
performing B-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
simple I-outcome ['Life-Impact']
arithmetic I-outcome ['Life-Impact']
task I-outcome ['Life-Impact']
, O
or O
performing O
a O
task O
of O
verbal O
fluency O
. O
['Life-Impact', 'Life-Impact']

Patients O
were O
stratified O
into O
two O
groups O
: O
favorable-prognosis O
, O
group O
1 O
( O
carcinoma O
, O
lymphoma O
, O
multiple O
myeloma O
) O
, O
or O
unfavorable-prognosis O
, O
group O
2 O
( O
acute O
leukemia O
, O
bone O
marrow O
transplantation O
) O
, O
based O
on O
anticipated O
duration O
of O
granulocytopenia O
. O
[]

Epirubicin O
and O
cyclophosphamide O
versus O
epirubicin O
and O
docetaxel O
as O
first-line O
therapy O
for O
women O
with O
metastatic O
breast O
cancer O
: O
final O
results O
of O
a O
randomised O
phase O
III O
trial O
. O
[]

RESULTS O
Symptomatic O
tendons O
showed O
less O
pixels O
in O
echo-types O
I O
and O
II O
than O
asymptomatic O
tendons O
( O
51.5 O
% O
vs O
76.6 O
% O
, O
p O
< O
0.001 O
) O
, O
thus O
less O
three-dimensional O
stability O
of O
the O
echo B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
allogeneic B-outcome ['Physiological-Clinical']
product I-outcome ['Physiological-Clinical']
transfusion I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
and O
the O
chest-tube B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
drainage I-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
were O
lower O
in O
the O
multiple-pass O
hemoconcentration O
group O
as O
compared O
to O
the O
centrifugation O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Of O
the O
four O
patients O
in O
the O
intravenous-access O
group O
, O
one O
had O
layering O
and O
agglutination O
, O
and O
two O
had O
blood O
clots O
. O
[]

Double-blind O
study O
on O
the O
activity O
of O
plafibride O
in O
the O
treatment O
of O
type O
IV O
hyperlipoproteinemia O
. O
[]

A O
study O
in O
ASA O
I O
and O
II O
patients O
. O
[]

This O
study O
was O
conducted O
to O
assess O
the O
effects O
of O
systemic O
chemotherapy O
on O
ALVAC-CEA/B7.1-induced O
T-cell O
immunity O
in O
patients O
with O
metastatic O
colorectal O
cancer O
. O
[]

We O
enrolled O
postmenopausal O
women O
with O
hormone-receptor-positive O
, O
locally O
advanced O
or O
metastatic O
breast O
cancer O
previously O
treated O
with O
endocrine O
treatment O
. O
[]

The O
beneficial O
effect O
of O
paromomycin O
treatment O
on O
endotoxemia B-outcome ['Physiological-Clinical']
in O
cirrhotics O
reported O
in O
earlier O
studies O
could O
not O
be O
reproduced O
under O
the O
conditions O
of O
this O
trial O
in O
patients O
with O
alcoholic O
liver O
disease O
. O
['Physiological-Clinical']

Group O
1 O
eyes O
not O
undergoing O
retinotomy O
had O
better O
anatomic B-outcome ['Physiological-Clinical']
( O
six O
months O
) O
and O
visual B-outcome ['Physiological-Clinical']
( O
six O
and O
24 O
months O
) O
outcomes O
and O
less O
hypotony B-outcome ['Physiological-Clinical']
( O
six O
months O
) O
than O
eyes O
that O
did O
regardless O
of O
tamponade O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODOLOGY O
For O
the O
treatment O
group O
, O
forty-five O
mg O
of O
Glakay O
was O
given O
orally O
every O
day O
after O
therapy O
for O
HCC O
. O
[]

RESULTS O
The O
SCORAD O
score O
reflecting O
the O
extent B-outcome ['Physiological-Clinical']
and O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
atopic I-outcome ['Physiological-Clinical']
eczema I-outcome ['Physiological-Clinical']
was O
16 O
( O
7-25 O
) O
during O
breast-feeding O
, O
median O
( O
interquartile O
range O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
, O
however O
, O
a O
significant O
( O
p O
less O
than O
0.001 O
) O
decrease O
compared O
to O
baseline O
values O
both O
in O
systolic B-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
during O
the O
xipamide O
period O
and O
a O
decrease O
in O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.05 O
) O
when O
taking O
bumetanide O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
An O
overall O
recurrence B-outcome ['Physiological-Clinical']
rate O
of O
22.7 O
% O
and O
an O
overall O
progression B-outcome ['Physiological-Clinical']
rate O
of O
9.8 O
% O
was O
found O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
different O
pattern O
of O
untoward B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
was O
seen O
in O
the O
final O
14 O
weeks O
of O
treatment O
. O
['Adverse-effects']

pCRs O
were O
associated O
with O
greater O
SUVmax O
reductions O
at O
both O
time O
points O
. O
[]

Adverse O
events O
were O
transient O
and O
not O
considered O
severe O
( O
e.g. O
, O
gastrointestinal O
[ O
GI O
] O
irritability O
, O
blood O
chemistry O
alterations O
) O
. O
[]

During O
the O
second O
and O
third O
periods O
, O
the O
patient O
received O
3 O
X O
2 O
inhalations O
of O
drug O
or O
placebo O
in O
a O
cross-over O
design O
. O
[]

In O
total O
, O
173 O
eligible O
men O
with O
untreated O
ED O
were O
randomized O
to O
double-blind O
treatment O
with O
40 O
mg O
of O
simvastatin O
or O
placebo O
once O
daily O
for O
6 O
months O
. O
[]

Pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
, O
functional B-outcome ['Life-Impact']
back I-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
, O
clinical B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
and O
depressive B-outcome ['Life-Impact']
dysfunction I-outcome ['Life-Impact']
revealed O
significant O
improvement O
in O
both O
treatment O
groups O
at O
end O
of O
3 O
weeks O
therapy O
( O
T1 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Despite O
considerable O
ignorance O
of O
factors O
affecting O
the O
inheritance O
of O
breast O
cancer O
, O
education O
neither O
reduced O
nor O
increased O
interest B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
undergo I-outcome ['Life-Impact']
testing I-outcome ['Life-Impact']
. O
['Life-Impact']

Long-term O
cultures O
showed O
no O
evidence O
of O
stem-cell B-outcome ['Physiological-Clinical']
depletion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
randomized O
, O
phase O
II O
trial O
of O
two O
dose O
schedules O
of O
carboplatin/paclitaxel/cetuximab O
in O
stage O
IIIB/IV O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O
[]

Glucocorticoids O
are O
used O
in O
an O
attempt O
to O
reduce O
brain O
edema O
secondary O
to O
head O
injury O
. O
[]

Mixed O
results O
were O
found O
on O
the O
control O
test O
and O
changes O
in O
context-related B-outcome ['Life-Impact']
behaviours I-outcome ['Life-Impact']
. O
['Life-Impact']

Subsequently O
, O
all O
patients O
received O
aflibercept O
with O
irinotecan-LV5FU2 O
every O
2 O
weeks O
. O
[]

51.9 O
% O
( O
RR O
= O
0.42 O
; O
0.23-0.73 O
) O
, O
( O
P O
< O
0.001 O
) O
and O
day O
14 O
: O
93.6 O
% O
vs O
. O
[]

CONCLUSIONS O
We O
recommend O
the O
use O
of O
subconjunctival O
5-fluorouracil O
after O
trabeculectomy O
in O
eyes O
after O
previous O
cataract O
surgery O
or O
unsuccessful O
filtering O
surgery O
, O
but O
caution O
against O
its O
routine O
use O
in O
patients O
with O
good O
prognoses O
. O
[]

CONCLUSION O
Although O
the O
trial O
closed O
prematurely O
and O
definitive O
statements O
regarding O
the O
efficacy O
of O
adjuvant O
gefitinib O
can O
not O
be O
made O
, O
these O
results O
indicate O
that O
it O
is O
unlikely O
to O
be O
of O
benefit O
. O
[]

This O
double-masked O
study O
included O
60 O
patients O
( O
43 O
women O
and O
17 O
men O
) O
aged O
31 O
to O
80 O
years O
with O
the O
following O
conditions O
: O
12 O
, O
epicondylitis O
; O
30 O
, O
scapulohumeral O
periarthritis O
; O
10 O
, O
gonalgia O
; O
and O
8 O
, O
metatarsalgia O
. O
[]

This O
international O
phase O
III O
trial O
compared O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
capecitabine/docetaxel O
therapy O
with O
single-agent O
docetaxel O
in O
anthracycline-pretreated O
patients O
with O
MBC O
. O
['Life-Impact']

Economic B-outcome ['Resource-use']
evaluation O
of O
aquatic O
exercise O
for O
persons O
with O
osteoarthritis O
. O
['Resource-use']

We O
conclude O
that O
granisetron O
is O
a O
[]

Results O
showed O
that O
patients O
in O
Arm O
II O
had O
a O
significantly O
better O
rate O
of O
complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
fewer B-outcome ['Physiological-Clinical']
nodes I-outcome ['Physiological-Clinical']
, O
and O
better O
overall B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
compared O
to O
those O
in O
Arm O
I O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Analyses O
were O
by O
intention-to-treat O
. O
[]

OBJECTIVE O
To O
compare O
thermal O
welding O
tonsillectomy O
( O
TWT O
) O
with O
bipolar O
electrocautery O
tonsillectomy O
( O
BET O
) O
procedure O
. O
[]

RESULTS O
Significant O
improvements O
were O
found O
in O
social O
network O
salience O
, O
number O
of O
friendship O
nominations O
, O
teacher O
report O
of O
social O
skills O
in O
the O
classroom O
, O
and O
decreased O
isolation O
on O
the O
playground O
for O
children O
who O
received O
PEER O
interventions O
. O
[]

METHODS O
Twenty-one O
patients O
( O
21 O
eyes O
) O
underwent O
PACK-CXL O
treatment O
in O
addition O
to O
antimicrobial O
therapy O
. O
[]

Each O
treatment O
lasted O
4 O
weeks O
with O
2 O
weeks O
of O
washout O
in O
between O
. O
[]

Methotrexate B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
was O
not O
found O
to O
be O
of O
prognostic O
significance O
. O
['Physiological-Clinical']

Incidence O
rates O
have O
ranged O
from O
0.9-14 O
% O
. O
[]

Maintenance O
therapy O
with O
fluconazole O
is O
highly O
effective O
in O
preventing O
recurrent O
cryptococcal O
infection O
. O
[]

INTERVENTIONS O
Cholecystectomy O
. O
[]

We O
also O
report O
an O
analysis O
comparing O
the O
proportion O
of O
eyes O
that O
developed O
one O
or O
more O
key O
events O
to O
the O
cumulative O
number O
of O
injections O
. O
[]

RESULTS O
Initial O
hospitalization B-outcome ['Resource-use']
for O
therapy O
selection O
was O
less O
costly B-outcome ['Resource-use']
by O
the O
noninvasive O
approach O
( O
$ O
6,869 O
+/- O
4,019 O
) O
than O
by O
the O
invasive O
approach O
( O
$ O
13,164 O
+/- O
6,740 O
) O
( O
P O
less O
than O
0.001 O
) O
. O
['Resource-use', 'Resource-use']

The O
latter O
metabolite O
is O
not O
formed O
in O
man O
through O
the O
mono-oxygenase O
pathway O
of O
cytochrome O
P450 O
. O
[]

SETTING O
Academic O
hospital-based O
study O
. O
[]

Marimastat O
as O
maintenance O
therapy O
for O
patients O
with O
advanced O
gastric O
cancer O
: O
a O
randomised O
trial O
. O
[]

METHODS O
A O
prospective O
randomized O
study O
included O
patients O
with O
OAB O
symptoms O
. O
[]

OBJECTIVE O
Autism O
is O
a O
childhood-onset O
disorder O
of O
unknown O
, O
possibly O
of O
multiple O
aetiologies O
. O
[]

Factor O
VIIa O
was O
increased O
in O
the O
DYDR O
group O
only O
. O
[]

In O
the O
combination O
regimen O
vindesine O
given O
at O
3 O
mg O
m-2 O
per O
week O
was O
included O
. O
[]

Aspirin O
was O
significantly O
more O
effective O
than O
placebo O
from O
Hours O
2 O
to O
8 O
for O
[]

There O
were O
3 O
and O
1 O
couplets O
and O
0.2 O
and O
0.2 O
runs O
of O
ventricular B-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
per O
patient O
per O
hour O
, O
respectively O
. O
['Physiological-Clinical']

Phase O
III O
study O
of O
concurrent O
chemoradiotherapy O
versus O
radiotherapy O
alone O
for O
advanced O
nasopharyngeal O
carcinoma O
: O
positive O
effect O
on O
overall B-outcome ['Mortality']
and O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

Metabolic O
and O
ventilatory O
responses O
during O
very O
low O
level O
exercise O
. O
[]

During O
its O
lifetime O
, O
PVSG O
has O
developed O
a O
widely O
accepted O
and O
highly O
effective O
set O
of O
criteria O
for O
the O
specific O
diagnosis O
of O
polycythemia O
vera O
as O
well O
as O
useful O
criteria O
for O
the O
diagnosis O
of O
essential O
thrombocythemia O
. O
[]

Weight O
loss B-outcome ['Physiological-Clinical']
during O
index O
admission B-outcome ['Resource-use']
and O
cardiac O
index/cardiac O
output O
increase O
were O
the O
only O
factors O
associated O
with O
LVEF O
improvement O
from O
baseline O
to O
month O
3 O
. O
['Physiological-Clinical', 'Resource-use']

RESULTS O
CSP O
and O
acyclovir O
were O
highly O
effective O
( O
mean O
SGAT O
= O
7.89 O
and O
8.00 O
, O
respectively O
) O
, O
with O
no O
significant O
difference O
observed O
( O
P O
= O
0.65 O
) O
. O
[]

The O
results O
suggest O
that O
PRP-P O
is O
both O
well B-outcome ['Physiological-Clinical']
tolerated O
clinically B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Forty-eight O
nurses O
with O
critical O
care O
experience O
volunteered O
to O
take O
part O
in O
this O
randomized O
, O
blinded O
, O
controlled O
study O
conducted O
in O
the O
simulation O
centre O
of O
an O
urban O
hospital O
. O
[]

Movement B-outcome ['Physiological-Clinical']
trajectories I-outcome ['Physiological-Clinical']
for O
both O
tasks O
were O
analyzed O
. O
['Physiological-Clinical']

DESIGN O
Allopurinol O
( O
1 O
g O
) O
was O
given O
blind O
prior O
to O
cardiopulmonary O
bypass O
and O
prior O
to O
opening O
the O
aorta O
. O
[]

Three O
weeks O
later O
, O
the O
participants O
returned O
and O
the O
protocol O
was O
repeated O
on O
the O
contralateral O
limb O
, O
using O
the O
opposite O
intervention O
( O
HVPC O
or O
placebo O
) O
. O
[]

For O
women O
, O
the O
mean O
annual O
change O
in O
BMD B-outcome ['Physiological-Clinical']
was O
-0.5 O
% O
in O
the O
treated O
group O
and O
-2.3 O
% O
in O
the O
control O
group O
. O
['Physiological-Clinical']

The O
beneficial O
effect O
of O
general O
anaesthesia O
is O
documented O
by O
normal O
plasma O
levels O
of O
epinephrine O
and O
norepinephrine O
throughout O
the O
operation O
. O
( O
[]

No O
significant O
differences O
were O
observed O
between O
the O
treatment O
arms O
for O
high-sensitivity B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
, O
P-selectin B-outcome ['Physiological-Clinical']
, O
and O
N-terminal B-outcome ['Physiological-Clinical']
pro-brain I-outcome ['Physiological-Clinical']
natriuretic I-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
pilot O
study O
, O
rosiglitazone O
had O
no O
cognitive B-outcome ['Life-Impact']
benefit O
in O
clozapine-treated O
patients O
with O
schizophrenia O
. O
['Life-Impact']

25 O
cases O
in O
control O
group O
with O
39 O
eyes O
were O
treated O
with O
routine O
program O
. O
[]

Multicenter O
randomized O
controlled O
trial O
of O
the O
management O
of O
unresectable O
malignant O
mesothelioma O
proposed O
by O
the O
British O
Thoracic O
Society O
and O
the O
British O
Medical O
Research O
Council O
. O
[]

To O
obtain O
basic O
kinetic O
data O
for O
such O
simulations O
, O
the O
plasma B-outcome ['Physiological-Clinical']
dilution-time I-outcome ['Physiological-Clinical']
curves I-outcome ['Physiological-Clinical']
were O
measured O
during O
and O
after O
i.v O
. O
['Physiological-Clinical']

METHODS O
Patients O
with O
type O
2 O
diabetes O
, O
mild-to-moderate O
hypertension O
( O
diastolic O
blood O
pressure O
85-105 O
mmHg O
, O
systolic O
blood O
pressure O
< O
160 O
mmHg O
, O
and O
24-hour O
mean O
systolic O
blood O
pressure O
> O
130 O
mmHg O
) O
, O
and O
microalbuminuria O
were O
randomized O
to O
1 O
year O
of O
doubleblind O
treatment O
with O
fixed-dose O
manidipine/delapril O
( O
n=54 O
) O
or O
losartan/hydrochlorothiazide O
( O
HCTZ O
) O
( O
n=56 O
) O
. O
[]

In O
the O
first O
study O
, O
180 O
patients O
with O
chronic O
and O
prolonged O
episodes O
of O
reflux O
were O
investigated O
. O
[]

To O
compare O
the O
efficacy O
and O
safety O
of O
nifedipine O
sustained O
release O
with O
Ginkgo O
biloba O
extract O
to O
treat O
patients O
with O
primary O
Raynaud O
's O
phenomenon O
in O
South O
Korea O
; O
Korean O
Raynaud O
study O
( O
KOARA O
study O
) O
. O
[]

We O
evaluated O
the O
effects O
of O
treatment O
with O
peginterferon O
alpha O
( O
pegIFNalpha O
) O
2a O
monotherapy O
and O
the O
combination O
of O
interferon O
alpha O
( O
IFNalpha O
) O
2b O
plus O
ribavirin O
( O
RBV O
) O
on O
health-related B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
, O
work B-outcome ['Life-Impact']
productivity I-outcome ['Life-Impact']
and O
resource B-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
. O
['Life-Impact', 'Life-Impact', 'Resource-use']

Determination O
of O
vital O
status O
at O
the O
end O
of O
the O
DIG O
trial O
. O
[]

After O
a O
2-week O
washout O
period O
, O
the O
E O
( O
+ O
) O
group O
was O
changed O
to O
L O
( O
+ O
) O
and O
vice O
versa O
in O
a O
crossover O
design O
. O
[]

On O
the O
basis O
of O
all O
patients O
treated O
, O
the O
rate O
of O
H. O
pylori O
eradication O
was O
significantly O
higher O
for O
triple O
therapy O
20/23 O
cases O
, O
87.0 O
% O
; O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
0.664-0.972 O
) O
than O
for O
dual O
therapy O
13/25 O
, O
52.0 O
% O
; O
0.313-0.722 O
; O
P O
< O
0.05 O
) O
. O
[]

All O
had O
been O
paced O
for O
complete O
or O
Mobitz O
II O
heart O
block O
. O
[]

min O
( O
-1 O
) O
or O
an O
AT O
of O
11 O
to O
14 O
mL O
? O
[]

During O
months O
1 O
and O
8 O
, O
while O
taking O
their O
prescribed O
treatments O
, O
NPSGs O
and O
MSLTs O
the O
following O
day O
were O
conducted O
. O
[]

Immediately O
after O
the O
first O
dose O
of O
each O
medication O
( O
day O
1 O
) O
, O
nasal B-outcome ['Physiological-Clinical']
congestion I-outcome ['Physiological-Clinical']
and O
related O
symptoms B-outcome ['Physiological-Clinical']
were O
assessed O
during O
a O
7-h O
challenge O
with O
HDM O
feces O
, O
with O
the O
Vienna O
Challenge O
Chamber O
( O
VCC O
) O
, O
to O
investigate O
onset O
of O
action O
of O
the O
preparation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Infants O
in O
the O
restrictive-transfusion O
group O
were O
more O
likely O
to O
have O
intraparenchymal B-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
periventricular I-outcome ['Physiological-Clinical']
leukomalacia I-outcome ['Physiological-Clinical']
, O
and O
they O
had O
more O
frequent B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
apnea I-outcome ['Physiological-Clinical']
, O
including O
both O
mild B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
severe I-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Treatment O
effect O
trended O
toward O
a O
greater O
magnitude O
in O
patients O
with O
lower O
CrCl O
( O
60 O
ml/min O
) O
( O
odds O
ratio O
0.53 O
, O
confidence O
interval O
0.34 O
to O
0.83 O
) O
compared O
with O
those O
with O
higher O
CrCl O
( O
90 O
ml/min O
) O
( O
odds O
ratio O
0.68 O
, O
confidence O
interval O
0.49 O
to O
0.94 O
) O
. O
[]

The O
improvement O
in O
range O
of O
motion O
was O
significantly O
greater O
in O
both O
physiotherapy B-outcome ['Physiological-Clinical']
groups I-outcome ['Physiological-Clinical']
over I-outcome ['Physiological-Clinical']
home I-outcome ['Physiological-Clinical']
exercises I-outcome ['Physiological-Clinical']
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

ELISA O
detected O
far O
lower O
levels O
of O
peanut O
in O
the O
higher O
fat O
recipe O
( O
220 O
000 O
parts O
per O
million O
( O
p.p.m O
. O
) O
) O
[]

AIM O
This O
phase O
II O
trial O
evaluated O
the O
biomodulation O
of O
5-fluorouracil O
( O
5-FU O
) O
plus O
folinic O
acid O
( O
FA O
) O
with O
or O
without O
ifosfamide O
( O
IFO O
) O
in O
chemotherapy-naive O
patients O
with O
colorectal O
cancer O
. O
[]

Following O
a O
7-day O
placebo O
washout O
period O
, O
patients O
could O
be O
treated O
for O
up O
to O
13 O
weeks O
on O
either O
treatment O
. O
[]

Topical O
treatment O
of O
alopecia O
areata O
. O
[]

BACKGROUND O
Considerable O
interest O
has O
focused O
on O
the O
development O
of O
therapies O
that O
target O
the O
functionality O
of O
high-density O
lipoproteins O
( O
HDL O
) O
. O
[]

Before O
and O
after O
reperfusion O
of O
the O
graft B-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
, O
signs B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hyperfibrinolysis I-outcome ['Physiological-Clinical']
, O
measured O
by O
thrombelastography O
, O
were O
significantly O
lower O
in O
the O
infusion O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
256 O
unaffected O
adults O
fulfilled O
the O
study O
criteria O
. O
[]

Cost-effectiveness O
analysis O
of O
serum O
vancomycin O
concentration O
monitoring O
in O
patients O
with O
hematologic O
malignancies O
. O
[]

The O
secondary O
endpoints O
include O
remission B-outcome ['Physiological-Clinical']
rate O
, O
improvement O
of O
social B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
, O
alleviation B-outcome ['Physiological-Clinical']
, O
aggravation B-outcome ['Life-Impact']
or O
recurrence B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
psychiatric I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
and O
safety O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

The O
investigator O
questioned O
the O
patients O
as O
to O
whether O
they O
experienced O
extrapyramidal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

While O
the O
selective O
serotonin-receptive O
inhibitor O
fluvoxamine O
has O
been O
shown O
to O
be O
effective O
in O
adults O
with O
autism O
, O
as O
yet O
no O
published O
placebo O
controlled O
trials O
with O
these O
agents O
document O
safety O
and O
efficacy O
in O
children O
with O
autism O
. O
[]

The O
cuff B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
baseline O
was O
20 O
cmH2O O
and O
CPRV O
was O
set O
to O
25 O
cmH2O O
. O
['Physiological-Clinical']

A O
mean O
+/- O
SD O
peak O
serum B-outcome ['Physiological-Clinical']
itraconazole I-outcome ['Physiological-Clinical']
concentration B-outcome ['Physiological-Clinical']
of O
0.90 O
+/- O
0.30 O
micrograms/ml O
was O
observed O
at O
3.0 O
+/- O
0.7 O
hours O
when O
itraconazole O
was O
administered O
alone O
, O
compared O
with O
undetectable O
levels O
in O
all O
patients O
during O
therapy O
with O
ddI O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
participants O
performed O
a O
two-back O
working O
memory B-outcome ['Life-Impact']
task O
before O
and O
after O
the O
administration O
of O
the O
transcranial O
direct O
current O
stimulation O
. O
['Life-Impact']

After O
the O
6-month O
follow-up O
, O
the O
Kaplan-Meier O
estimates O
of O
the O
percentage O
of O
patients O
remaining O
free O
of O
recurrent B-outcome ['Physiological-Clinical']
symptomatic I-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
on O
aprindine O
, O
digoxin O
and O
placebo O
were O
33.3 O
% O
, O
29.2 O
% O
and O
21.5 O
% O
, O
respectively O
. O
['Physiological-Clinical']

In O
a O
competing-risks O
analysis O
, O
those O
factors O
that O
increased O
the O
risk O
of O
arrhythmic B-outcome ['Mortality']
death I-outcome ['Mortality']
also O
increased O
the O
risk O
of O
nonarrhythmic B-outcome ['Mortality']
deaths I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

California O
Collaborative O
Treatment O
Group O
. O
[]

Results O
among O
participants O
were O
similar O
despite O
children O
's O
differing O
impairments O
. O
[]

METHODS O
Patients O
undergoing O
elective O
major O
colorectal O
or O
urological O
surgery O
who O
had O
an O
AT O
of O
< O
11 O
mL O
? O
[]

All O
patients O
received O
Ciprodex O
or O
no O
treatment O
for O
5 O
days O
post-operatively O
and O
returned O
at O
2 O
weeks O
. O
[]

Physical B-outcome ['Physiological-Clinical']
scores O
declined O
significantly O
over O
time O
, O
independent O
of O
treatment O
, O
and O
patients O
with O
cirrhosis O
reported O
lower O
scores O
. O
['Physiological-Clinical']

The O
volume O
of O
blood O
completely O
cleared O
of O
the O
'hepatic O
pathological O
processes O
' O
which O
led O
to O
the O
hepatomegaly O
( O
CL O
( O
Bhp O
) O
) O
and O
the O
fractional O
reduction O
of O
AUC O
( O
hp O
) O
at O
48 O
and O
96 O
h O
( O
i.e O
. O
[]

The O
measure O
of O
the O
outcome O
was O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist-Community O
( O
ABC-C O
) O
Rating O
Scale O
( O
total O
score O
) O
. O
['Life-Impact']

A O
double-blind O
study O
. O
[]

For O
the O
prevention O
of O
VTE O
, O
fondaparinux O
has O
been O
studied O
as O
extended O
prophylaxis O
following O
hip O
fracture O
surgery O
( O
PENTHIFRA O
Plus O
) O
, O
for O
use O
in O
high-risk O
abdominal O
surgical O
patients O
( O
PEGASUS O
and O
APOLLO O
) O
, O
and O
for O
use O
in O
medical O
patients O
( O
ARTEMIS O
) O
. O
[]

Using O
a O
choice O
assessment O
to O
predict O
reinforcer O
effectiveness O
. O
[]

At O
week O
8 O
, O
olmesartan O
reduced O
mean O
SeDBP B-outcome ['Physiological-Clinical']
more O
than O
losartan O
( O
P O
< O
.001 O
) O
; O
more O
patients O
in O
the O
olmesartan O
medoxomil O
group O
achieved O
a O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
goal O
of O
< O
140/90 O
mm O
Hg O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
BMD B-outcome ['Physiological-Clinical']
is O
subnormal O
in O
adults O
with O
GHD O
. O
['Physiological-Clinical']

Significant O
treatment O
effects O
were O
found O
on O
all O
measures O
at O
posttreatment O
. O
[]

Antihistamines O
do O
not O
inhibit O
the O
wheal O
induced O
by O
the O
intradermal O
injection O
of O
autologous O
serum O
in O
resistant O
chronic O
idiopathic O
urticaria O
. O
[]

Among O
participants O
not O
assigned O
to O
receive O
physical O
therapy O
or O
modalities O
, O
the O
estimated O
improvements O
in O
pain B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
and O
18-month O
risk O
of O
complete B-outcome ['Physiological-Clinical']
remission B-outcome ['Physiological-Clinical']
were O
a O
little O
greater O
in O
the O
chiropractic O
group O
than O
in O
the O
medical O
group O
( O
adjusted O
RR O
of O
remission O
= O
1.29 O
; O
95 O
% O
CI O
= O
0.80-2.07 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

With O
the O
addition O
of O
transoperative B-outcome ['Physiological-Clinical']
lympho-scintigraphy I-outcome ['Physiological-Clinical']
five O
extra B-outcome ['Physiological-Clinical']
sentinel I-outcome ['Physiological-Clinical']
nodes I-outcome ['Physiological-Clinical']
, O
not O
identified O
by O
the O
blue O
dye O
alone O
, O
were O
identified O
and O
considered O
for O
histopathology O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Efficacy O
of O
intramuscular O
oxytetracycline O
as O
a O
dry O
cow O
treatment O
for O
Staphylococcus O
aureus O
mastitis O
. O
[]

RESULTS O
In O
the O
NB O
group O
, O
stable B-outcome ['Physiological-Clinical']
hemodynamic I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
were O
obtained O
with O
a O
lower O
sevoflurane O
concentration O
than O
in O
the O
control O
group O
. O
['Physiological-Clinical']

A O
baseline O
of O
12 O
weeks O
in O
which O
no O
changes O
were O
noted O
in O
core B-outcome ['Life-Impact']
deficits I-outcome ['Life-Impact']
was O
followed O
by O
12 O
weeks O
of O
intervention O
for O
children O
randomized O
to O
the O
JASPER O
treatment O
. O
['Life-Impact']

Diarrhoea B-outcome ['Physiological-Clinical']
occurred O
in O
7 O
patients O
on O
rioprostil O
and O
3 O
patients O
on O
ranitidine O
. O
['Physiological-Clinical']

Indomethacin O
did O
not O
reduce O
the O
frequency O
of O
dose O
reductions O
for O
toxic B-outcome ['Adverse-effects']
side-effects I-outcome ['Adverse-effects']
and O
did O
not O
permit O
the O
administration O
of O
higher O
interferon B-outcome ['Life-Impact']
doses I-outcome ['Life-Impact']
. O
['Adverse-effects', 'Life-Impact']

BACKGROUND O
The O
value O
of O
pancreatoduodenectomy O
( O
PD O
) O
with O
extended O
lymphadenectomy O
for O
pancreatic O
cancer O
has O
been O
evaluated O
by O
many O
retrospective O
studies O
and O
3 O
randomized O
controlled O
trials O
( O
RCT O
) O
. O
[]

performance O
index O
and O
Durie O
& O
Salmon O
stage O
, O
and O
( O
2 O
) O
the O
sensitivity O
to O
changes O
in O
objective O
disease O
status O
( O
response O
and O
relapse O
) O
. O
[]

These O
findings O
support O
the O
prediction O
that O
ambient O
lenses O
, O
worn O
without O
engaging O
in O
visual-motor O
exercises O
, O
have O
positive O
effects O
on O
autistic O
individuals O
. O
[]

METHODS O
The O
women O
were O
randomised O
to O
receive O
either O
sublingual O
or O
vaginal O
misoprostol O
400 O
microg O
every O
3 O
hours O
for O
a O
maximum O
of O
five O
doses O
. O
[]

Ezetimibe O
added O
to O
simvastatin O
improves O
several O
indices O
of O
platelet O
reactivity O
beyond O
statin O
monotherapy O
. O
[]

RESULTS O
The O
objective O
response O
rate O
was O
18 O
% O
and O
27.5 O
% O
in O
group O
A O
and O
B O
, O
respectively O
( O
p O
= O
0.413 O
) O
. O
[]

If O
resistance O
to O
aspiration O
by O
needle O
tap O
was O
noted O
, O
a O
vitreous O
biopsy O
was O
performed O
. O
[]

Combination O
of O
arteriovenous O
extracorporeal O
lung O
assist O
and O
high-frequency O
oscillatory O
ventilation O
in O
a O
porcine O
model O
of O
lavage-induced O
acute O
lung O
injury O
: O
a O
randomized O
controlled O
trial O
. O
[]

These O
are O
the O
branching O
case O
pathways O
( O
present O
or O
absent O
) O
and O
structured O
clinical O
reasoning O
feedback O
( O
present O
or O
absent O
) O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

We O
performed O
a O
2:1:1-randomization O
as O
follows O
: O
CONTROL O
GROUP O
Ablation O
without O
visualization O
of O
the O
esophagus O
using O
25 O
Watt O
( O
W O
) O
power O
limit O
on O
the O
posterior O
wall O
, O
n O
= O
70 O
. O
[]

AIM O
To O
compare O
the O
effectiveness O
of O
treatment B-outcome ['Resource-use']
of O
peri-implantitis O
with O
a O
novel O
ultrasonic O
device O
, O
the O
Vector O
system O
, O
with O
that O
of O
subgingival O
debridement O
with O
carbon O
fiber O
curettes O
. O
['Resource-use']

Veterans O
Affairs O
congestive O
heart O
failure O
antiarrhythmic O
trial O
. O
[]

PATIENTS O
AND O
METHODS O
757 O
patients O
from O
the O
GISSI-3 O
echo O
substudy O
population O
with O
their O
first O
acute O
myocardial O
infarct O
were O
studied O
by O
echocardiography O
at O
24-48 O
hours O
from O
symptom O
onset O
( O
S1 O
) O
, O
at O
discharge O
( O
S2 O
) O
, O
at O
six O
weeks O
( O
S3 O
) O
, O
and O
at O
six O
months O
( O
S4 O
) O
. O
[]

These O
findings O
suggest O
clinically O
significant O
benefits O
of O
actively O
treating O
JA O
and O
SP O
skills O
in O
young O
children O
with O
autism O
. O
[]

Addition O
of O
azathioprine O
and O
prednisone O
to O
ursodeoxycholic O
acid O
resulted O
in O
a O
further O
reduction O
of O
sICAM-1 B-outcome ['Physiological-Clinical']
levels O
by O
a O
median O
of O
25 O
% O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Factors O
such O
as O
age O
of O
the O
patient B-outcome ['Life-Impact']
, O
lens B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
number O
of O
cryo B-outcome ['Physiological-Clinical']
applications I-outcome ['Physiological-Clinical']
, O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
surgery I-outcome ['Life-Impact']
, O
and O
the O
size O
and O
extent O
of O
buckle B-outcome ['Physiological-Clinical']
were O
assessed O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Global B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
status O
of O
the O
EORTC O
QLQ-C30 O
scale O
and O
specific O
symptoms O
control O
( O
LC13 O
module O
) O
improved O
during O
treatment O
without O
any O
statistically O
significant O
difference O
between O
the O
two O
arms O
. O
['Physiological-Clinical']

Overall O
, O
there O
was O
no O
clear O
advantage O
of O
one O
directory O
over O
the O
other O
. O
[]

The O
present O
study O
was O
designed O
to O
compare O
the O
efficacy O
and O
safety O
of O
10 O
% O
HES O
130/0.4 O
and O
10 O
% O
HES O
200/0.5 O
. O
[]

BACKGROUND O
Patients O
with O
type O
2 O
diabetes O
are O
at O
high O
risk O
of O
fatal O
and O
non-fatal O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
and O
stroke B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Individuals O
with O
chronic O
depression O
exhibit O
heterogeneous O
responses O
to O
treatment O
. O
[]

RESULTS O
Acupressure O
at O
the O
extra O
1 O
point O
significantly O
reduced O
the O
VRS O
, O
but O
acupressure O
at O
the O
sham O
increased O
the O
VRS O
. O
[]

Paracetamol O
reduces O
postoperative O
pain B-outcome ['Physiological-Clinical']
and O
rescue O
analgesic O
demand O
after O
robot-assisted O
endoscopic O
thyroidectomy O
by O
the O
transaxillary O
approach O
. O
['Physiological-Clinical']

Drinking O
orange O
juice O
. O
[]

Therefore O
, O
patients O
with O
the O
risk O
factors O
above O
presented O
should O
routinely O
undergo O
nutritional O
screening O
and/or O
assessment O
in O
order O
to O
be O
able O
to O
early O
diagnose O
or O
prevent O
malnutrition O
and O
its O
correlated O
morbidity O
and O
mortality O
. O
[]

After O
12 O
months O
this O
successful O
outcome O
was O
improved O
slightly O
further O
. O
[]

The O
response O
rates O
( O
CR O
+ O
PR O
) O
were O
52 O
% O
( O
15/29 O
) O
with O
S-MEC O
therapy O
, O
76 O
% O
( O
22/29 O
) O
with O
I-MEC O
therapy O
and O
47 O
% O
( O
14/30 O
) O
with O
M-VAC O
therapy O
. O
[]

However O
, O
PAI-1 B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
suppressed O
. O
['Physiological-Clinical']

The O
treatments O
did O
not O
modify O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
and O
exhibited O
a O
similar O
effect O
on O
body O
weight O
, O
urinary O
volume O
, O
and O
fractional B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
, O
sodium B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Because O
child O
characteristics O
such O
as O
interest O
in O
objects O
may O
influence O
response O
to O
interventions O
using O
object O
play O
as O
contexts O
for O
treatment O
, O
it O
is O
important O
to O
improve O
our O
understanding O
of O
whether O
intervention O
can O
affect O
object O
interest O
. O
[]

Insulin O
pump O
therapy O
started O
at O
the O
time O
of O
diagnosis O
: O
effects O
on O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
pancreatic O
?-cell O
function O
in O
type O
1 O
diabetes O
. O
['Physiological-Clinical']

RESULTS O
The O
SRE B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
at O
1 O
year O
( O
excluding O
HCM O
and O
adjusted O
for O
prior O
fracture O
) O
was O
0.61 O
( O
permutation O
test O
; O
P O
= O
.027 O
) O
, O
indicating O
that O
zoledronic O
acid O
reduced O
the O
rate O
of O
SRE B-outcome ['Physiological-Clinical']
by O
39 O
% O
compared O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Suboptimal O
adherence O
to O
antiepileptic O
drug O
( O
AED O
) O
treatment O
is O
commonplace O
, O
and O
increases O
the O
risk O
of O
status O
epilepticus O
and O
sudden O
unexplained O
death O
in O
epilepsy O
. O
[]

STUDY O
DESIGN O
AND O
SETTING O
Patients O
( O
n=244 O
) O
participated O
in O
a O
randomized O
trial O
. O
[]

The O
global O
perceived O
effect O
scale O
( O
GPE O
) O
was O
used O
as O
an O
external O
criterion O
. O
[]

INTERVENTIONS O
Subjects O
received O
either O
intravenous O
fructose-1,6-diphosphate O
125 O
mg/kg O
or O
normal O
saline O
1.3 O
ml/kg O
every O
12 O
hours O
over O
10 O
minutes O
for O
four O
consecutive O
doses O
. O
[]

One O
group O
continued O
on O
timolol O
, O
one O
switched O
from O
timolol O
to O
latanoprost O
, O
50 O
microg/ml O
once O
daily O
, O
and O
a O
third O
group O
received O
latanoprost O
in O
addition O
to O
timolol O
. O
[]

By O
the O
sixth O
quarter O
post-quit O
, O
sustained O
quitters O
were O
less O
costly O
than O
trial O
participants O
who O
continued O
smoking O
. O
[]

The O
model O
calibrated O
well O
. O
[]

With O
Dimerex O
the O
mixing O
of O
the O
contrast O
medium O
with O
the O
synovial B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
was O
slower O
than O
with O
Conray O
Meglumin O
, O
and O
a O
good O
or O
fair O
image B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
, O
as O
evaluated O
subjectively O
, O
lasted O
longer O
. O
['Physiological-Clinical', 'Life-Impact']

SETTING O
Clinical O
assisted O
conception O
program O
. O
[]

PURPOSE O
The O
role O
of O
antiviral O
prophylaxis O
in O
preventing O
hepatitis O
B O
virus O
( O
HBV O
) O
reactivation O
before O
rituximab-based O
chemotherapy O
in O
patients O
with O
lymphoma O
and O
resolved O
hepatitis O
B O
is O
unclear O
. O
[]

Beneficial O
effects O
of O
a O
soy-based O
dietary O
supplement O
on O
lipid B-outcome ['Physiological-Clinical']
levels O
and O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
markers B-outcome ['Physiological-Clinical']
in O
type O
2 O
diabetic O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
was O
measured O
at O
six O
points O
before O
, O
during O
and O
after O
endoscopy O
from O
automated O
cardiac O
flow O
measurement O
by O
color O
Doppler O
echocardiography O
. O
['Physiological-Clinical']

Several O
centres O
replaced O
one O
of O
the O
staplers O
by O
a O
new O
product O
, O
and O
the O
study O
was O
ended O
before O
the O
stipulated O
number O
of O
patients O
was O
reached O
. O
[]

FP/M O
led O
to O
significantly O
greater O
reductions O
in O
sputum B-outcome ['Physiological-Clinical']
cysteinyl I-outcome ['Physiological-Clinical']
leukotrienes I-outcome ['Physiological-Clinical']
than O
SFC O
( O
treatment O
ratio O
1.80 O
; O
95 O
% O
CI O
1.09 O
, O
2.94 O
) O
. O
['Physiological-Clinical']

METHODS O
In O
an O
open O
trial O
children O
with O
suspected O
typhoid O
fever O
were O
randomized O
to O
receive O
either O
ofloxacin O
( O
10 O
mg/kg/day O
in O
two O
divided O
doses O
) O
for O
5 O
days O
or O
cefixime O
( O
20 O
mg/kg/day O
in O
two O
divided O
doses O
) O
for O
7 O
days O
. O
[]

The O
frequency O
of O
infusion B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
was O
three O
times O
lower O
with O
the O
glyceryl O
trinitrate O
than O
with O
placebo O
patches O
. O
['Physiological-Clinical']

BACKGROUND O
The O
value O
of O
routine O
administration O
of O
intravenous O
thrombolytic O
agents O
during O
percutaneous O
transluminal O
coronary O
angioplasty O
( O
PTCA O
) O
therapy O
of O
acute O
myocardial O
infarction O
( O
MI O
) O
has O
not O
been O
determined O
. O
[]

The O
placebo O
group O
had O
subtherapeutic O
ultrasound O
to O
the O
knee O
at O
an O
intensity O
of O
0.1 O
W/cm2 O
with O
a O
10 O
% O
pulsed O
mode O
. O
[]

The O
cysteinyl O
leukotriene O
LTE4 O
has O
been O
shown O
to O
induce O
airway B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
in O
asthmatics O
in O
vivo O
. O
['Physiological-Clinical']

Patient B-outcome ['Life-Impact']
acceptance I-outcome ['Life-Impact']
of O
the O
induced O
contact O
dermatitis O
was O
excellent O
. O
['Life-Impact']

Functional O
ability O
was O
assessed O
with O
the O
Childhood O
Health O
Assessment O
Questionnaire O
( O
CHAQ O
) O
. O
[]

Twenty O
children O
were O
included O
in O
the O
study O
but O
four O
( O
two O
in O
each O
group O
) O
had O
to O
be O
excluded O
; O
three O
because O
the O
entry O
criteria O
turned O
out O
not O
to O
be O
fulfilled O
and O
one O
because O
of O
lack O
of O
data O
. O
[]

Superior O
survival B-outcome ['Mortality']
with O
capecitabine O
plus O
docetaxel O
combination O
therapy O
in O
anthracycline-pretreated O
patients O
with O
advanced O
breast O
cancer O
: O
phase O
III O
trial O
results O
. O
['Mortality']

RESULTS O
CDI B-outcome ['Physiological-Clinical']
was O
significantly O
increased O
in O
the O
G-CSF O
group O
compared O
with O
the O
non-G-CSF O
group O
( O
mean O
+/- O
95 O
% O
confidence O
interval O
, O
105 O
+/- O
5 O
% O
v O
91 O
+/- O
4 O
% O
; O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

The O
mean O
decrease O
in O
mean O
daily B-outcome ['Physiological-Clinical']
intraocular I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
29.3 O
% O
for O
Fotil O
, O
and O
26.0 O
% O
for O
Timpilo O
. O
['Physiological-Clinical']

on O
the O
first O
postoperative O
day O
until O
discharge O
. O
[]

[ O
The O
value O
of O
local O
administration O
of O
antibiotics O
in O
treatment O
of O
bone O
infections O
] O
. O
[]

The O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
was O
rated O
on O
a O
numeric O
analog O
scale O
. O
['Physiological-Clinical']

In O
the O
bowel O
they O
were O
observed O
in O
53.3 O
% O
of O
patients O
after O
neutron O
therapy O
compared O
with O
8 O
% O
after O
photon O
therapy O
( O
p O
less O
than O
0.0001 O
) O
. O
[]

Subjects O
were O
divided O
into O
2 O
equal O
groups-the O
placebo O
and O
sibutramine O
treatment O
groups O
. O
[]

Double-blind O
placebo-controlled O
trial O
of O
secretin O
: O
effects O
on O
aberrant B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
children O
with O
autism O
. O
['Life-Impact']

The O
experiment O
was O
modeled O
after O
the O
free-recall O
test O
, O
an O
established O
technique O
in O
studies O
of O
memory O
. O
[]

These O
favorable O
changes O
in O
hemorheological O
parameters O
improves O
myocardial B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
, O
lowers O
the O
strength B-outcome ['Physiological-Clinical']
and O
frequency O
of O
coronary B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
, O
retards O
postinfarction B-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
, O
and O
increases O
the O
quality O
of O
life O
of O
patients O
with O
various O
CAD O
forms O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
a O
significantly O
lower O
prevalence O
of O
tachysystole B-outcome ['Physiological-Clinical']
( O
six O
or O
more O
uterine O
contractions O
in O
a O
10-minute O
window O
for O
two O
consecutive O
10-minute O
periods O
) O
in O
the O
misoprostol O
group O
( O
7.1 O
% O
) O
than O
in O
the O
dinoprostone O
group O
( O
18.4 O
% O
) O
( O
relative O
risk O
0.52 O
, O
95 O
% O
confidence O
interval O
0.31 O
to O
0.89 O
, O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical']

Diarrhea B-outcome ['Physiological-Clinical']
and O
diaper-area B-outcome ['Physiological-Clinical']
dermatitis I-outcome ['Physiological-Clinical']
were O
more O
common O
among O
children O
who O
received O
amoxicillin-clavulanate O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
demonstrates O
the O
efficacy O
of O
nefazodone O
compared O
with O
placebo O
in O
the O
treatment O
of O
patients O
hospitalized O
for O
major O
depression O
. O
[]

Twenty-two O
head O
and O
neck O
cancer O
patients O
from O
U. O
T. O
M. O
D. O
Anderson O
Cancer O
Center O
, O
with O
radiation-induced O
xerostomia O
, O
were O
entered O
into O
a O
pilot O
study O
to O
contrast O
the O
daily O
home O
use O
of O
a O
0.4 O
% O
stannous O
fluoride-gel-containing O
tray O
( O
control O
group O
) O
to O
IFRS O
( O
study O
group O
) O
with O
respect O
to O
tolerability O
and O
adherence O
, O
and O
to O
obtain O
information O
on O
relative O
caries O
preventive O
efficacy O
. O
[]

Also O
, O
because O
no O
placebo O
control O
group O
was O
utilized O
, O
the O
authors O
of O
that O
study O
could O
not O
rule O
out O
the O
possibility O
that O
the O
apparent O
therapeutic O
effect O
from O
fluoxetine O
was O
the O
result O
of O
the O
placebo O
effect O
. O
[]

Actuarial O
survival B-outcome ['Mortality']
was O
97 O
% O
and O
90 O
% O
( O
P=0.30 O
) O
, O
and O
survival B-outcome ['Mortality']
free I-outcome ['Mortality']
from I-outcome ['Mortality']
recurrent I-outcome ['Mortality']
syncope I-outcome ['Mortality']
was O
88 O
% O
and O
89 O
% O
( O
P=0.72 O
) O
at O
2 O
years O
for O
the O
syncope O
unit O
and O
standard O
care O
groups O
, O
respectively O
. O
['Mortality', 'Mortality']

RESULTS O
S. O
typhi O
was O
isolated O
from O
82 O
patients O
( O
44 O
in O
the O
cefixime O
group O
, O
38 O
in O
the O
ofloxacin O
group O
) O
and O
70 O
( O
85 O
% O
) O
of O
the O
isolates O
were O
multidrug-resistant O
. O
[]

It O
is O
our O
opinion O
that O
, O
in O
the O
future O
, O
laser O
conization O
will O
replace O
cold O
knife O
conization O
. O
[]

The O
Km O
values O
for O
the O
N-demethylation O
pathways O
( O
3MX O
and O
1-MU O
) O
were O
lower O
corresponding O
to O
therapeutic O
serum O
concentrations O
of O
drug O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
groups O
with O
respect O
to O
the O
persistence O
of O
cutaneous B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
after O
starting O
treatment O
; O
the O
mean O
durations O
were O
10.5 O
days O
in O
the O
penicillin O
group O
, O
8.8 O
days O
in O
the O
doxycycline O
group O
and O
8.6 O
days O
in O
the O
azithromycin O
group O
. O
['Physiological-Clinical']

Chorea O
was O
scored O
using O
the O
abnormal O
involuntary O
movement O
scale O
( O
AIMS O
) O
, O
the O
chorea O
score O
of O
the O
unified O
Huntington O
's O
disease O
rating O
scale O
( O
UHDRS O
) O
, O
and O
judgement O
of O
video O
recordings O
. O
[]

Hyperglycemia B-outcome ['Physiological-Clinical']
( O
blood O
glucose O
, O
10.1+/-1.9 O
micromol/L O
) O
occurred O
only O
in O
the O
presence O
of O
glucose O
infusion O
. O
['Physiological-Clinical']

In O
this O
study O
, O
we O
report O
the O
development O
and O
evaluation O
of O
a O
computer-based O
program O
to O
teach O
and O
test O
the O
ability O
to O
identify O
basic B-outcome ['Life-Impact']
facially I-outcome ['Life-Impact']
expressed I-outcome ['Life-Impact']
emotions I-outcome ['Life-Impact']
. O
['Life-Impact']

We O
also O
examined O
the O
effect O
of O
physician O
prompting O
on O
counseling O
of O
female O
patients O
, O
patients O
with O
inactive O
disorders O
, O
and O
nondependent O
but O
harmful O
drinkers O
. O
[]

Similarly O
, O
median O
OS B-outcome ['Mortality']
was O
12.2 O
, O
48.6 O
, O
and O
24.5 O
mo O
, O
respectively O
( O
p O
= O
0.0003 O
) O
. O
['Mortality']

Levels O
of O
serum B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Fe I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
total O
iron B-outcome ['Physiological-Clinical']
binding I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
( O
TIBC O
) O
, O
transferrin B-outcome ['Physiological-Clinical']
saturation O
( I-outcome ['Physiological-Clinical']
TS O
) I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
serum B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
transferrin B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Tf I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
soluble I-outcome ['Physiological-Clinical']
transferrin B-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
sTfR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
blood O
routine O
test O
, I-outcome ['Physiological-Clinical']
as O
well O
as O
scoring O
of O
TCM O
qi-blood O
deficiency B-outcome ['Physiological-Clinical']
Syndrome I-outcome ['Physiological-Clinical']
were O
conducted O
before O
and O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
general O
increase O
in O
the O
number O
of O
microorganisms B-outcome ['Physiological-Clinical']
from O
gastric O
mucosa B-outcome ['Physiological-Clinical']
was O
observed O
in O
both O
treatment O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Implications O
of O
these O
findings O
to O
leisure O
services O
and O
the O
quality O
of O
life O
of O
individuals O
with O
ASD O
are O
discussed O
. O
[]

Seventy O
immunocompromised O
febrile O
patients O
with O
hematologic O
malignancies O
were O
randomly O
assigned O
to O
either O
a O
vancomycin O
therapeutic O
drug O
monitoring O
group O
( O
TDM O
group O
; O
n O
= O
37 O
) O
or O
to O
a O
control O
group O
( O
n O
= O
33 O
) O
. O
[]

Pretreatment O
plasma O
EBV O
positivity O
was O
an O
independent O
predictor O
of O
treatment O
failure O
on O
multivariate O
analyses O
. O
[]

However O
, O
other O
retrospective O
data O
suggested O
a O
beneficial O
effect O
on O
overall O
survival O
for O
patients O
in O
complete O
remission O
. O
[]

METHODS O
In O
this O
24-week O
, O
double-blind O
, O
phase O
IIb O
study O
, O
patients O
with O
active O
RA O
( O
n O
= O
507 O
) O
were O
randomized O
to O
receive O
placebo O
or O
tofacitinib O
( O
20 O
mg/day O
, O
1 O
mg O
twice O
daily O
, O
3 O
mg O
twice O
daily O
, O
5 O
mg O
twice O
daily O
, O
10 O
mg O
twice O
daily O
, O
or O
15 O
mg O
twice O
daily O
) O
. O
[]

METHODS O
AND O
DESIGN O
The O
ADDITION-Cambridge O
study O
aims O
to O
evaluate O
the O
effectiveness O
and O
cost-effectiveness O
of O
( O
i O
) O
a O
stepwise O
screening O
strategy O
for O
type O
2 O
diabetes O
; O
and O
( O
ii O
) O
intensive O
multifactorial O
treatment O
for O
people O
with O
screen-detected O
diabetes O
in O
primary O
care O
. O
['Resource-use']

Clinical O
evaluation O
of O
the O
contact O
sensitization O
potential O
of O
a O
transdermal O
nicotine O
system O
( O
Nicoderm O
) O
BACKGROUND O
Transdermal O
nicotine O
therapy O
has O
shown O
promise O
as O
a O
smoking O
cessation O
aid O
, O
but O
questions O
about O
its O
contact O
sensitization O
potential O
and O
long-term O
topical O
safety O
have O
been O
raised O
. O
[]

RESULTS O
Both O
eye O
drops O
reduced O
subjective O
and O
objective O
ocular B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
effective O
. O
['Physiological-Clinical']

Fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
, O
lipid B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
, O
testosterone B-outcome ['Physiological-Clinical']
, O
adiponectin B-outcome ['Physiological-Clinical']
, O
and O
IL-6 B-outcome ['Physiological-Clinical']
were O
determined O
at O
baseline O
and O
after O
3 O
months O
, O
together O
with O
body O
composition O
( O
by O
dual O
x-ray O
absorptiometry O
) O
and O
with O
Doppler O
assessment O
of O
ovarian O
arterial O
resistance O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Vitamin O
E O
did O
not O
appear O
to O
reduce O
the O
incidence O
of O
sensory O
neuropathy O
in O
the O
studied O
group O
of O
patients O
receiving O
neurotoxic O
chemotherapy O
. O
[]

The O
patients O
received O
20 O
mg/day O
atorvastatin O
and O
3 O
g/day O
colestimide O
or O
40 O
mg/day O
atorvastatin O
. O
[]

Patients O
were O
randomized O
into O
exercise O
and O
control O
groups O
. O
[]

BACKGROUND O
Nonsmokers O
have O
a O
potentially O
supportive O
role O
in O
tobacco O
cessation O
efforts O
. O
[]

In O
the O
single O
administration O
study O
, O
YM17E O
was O
administered O
after O
a O
meal O
to O
two O
groups O
of O
subjects O
( O
each O
containing O
six O
subjects O
taking O
the O
drug O
and O
three O
taking O
placebo O
) O
receiving O
3 O
, O
60 O
and O
300 O
mg O
or O
15 O
, O
60 O
and O
450 O
mg O
YM17E O
, O
respectively O
. O
[]

Maternal B-outcome ['Physiological-Clinical']
erythropoietin I-outcome ['Physiological-Clinical']
in O
singleton O
pregnancies O
: O
a O
randomized O
trial O
on O
the O
effect O
of O
oral O
hematinic O
supplementation O
. O
['Physiological-Clinical']

Effect O
of O
device-guided O
breathing O
exercises O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
patients O
with O
hypertension O
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

1.9 O
mg O
vs O
2.8 O
? O
[]

During O
phase O
1 O
, O
the O
effect O
of O
room O
assignment O
was O
evaluated O
. O
[]

Acute O
prolactin O
and O
oxytocin O
responses O
and O
milk B-outcome ['Physiological-Clinical']
yield I-outcome ['Physiological-Clinical']
to O
infant O
suckling O
and O
artificial B-outcome ['Resource-use']
methods I-outcome ['Resource-use']
of I-outcome ['Resource-use']
expression I-outcome ['Resource-use']
in O
lactating O
women O
. O
['Physiological-Clinical', 'Resource-use']

A O
compensatory O
increase O
in O
the O
pelvic B-outcome ['Physiological-Clinical']
tilt I-outcome ['Physiological-Clinical']
was O
observed O
in O
both O
groups O
. O
['Physiological-Clinical']

Each O
test O
condition O
included O
five O
matched O
pairs O
of O
sheep O
tibiae O
. O
[]

Potential O
participants O
underwent O
three O
stages O
of O
screening O
: O
initial O
interview O
, O
dual-energy O
x-ray O
absorptiometry O
, O
and O
blood O
testing O
for O
biochemical O
screening O
. O
[]

Participants O
were O
recruited O
largely O
during O
the O
era O
prior O
to O
highly O
active O
antiretroviral O
therapy O
( O
HAART O
; O
1992-1997 O
) O
. O
[]

Assuming O
that O
bronchial B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
could O
be O
an O
indirect O
measurement O
of O
airway O
inflammation O
, O
overtreatment O
of O
asthma O
in O
relationship O
with O
the O
classification O
of O
asthma O
severity O
of O
the O
International O
Guidelines O
could O
improve O
both O
airway O
inflammation O
and O
the O
prognosis O
of O
airway O
obstruction O
. O
['Physiological-Clinical']

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
on O
the O
immediate O
clinical B-outcome ['Physiological-Clinical']
and O
microbiological B-outcome ['Physiological-Clinical']
efficacy O
of O
doxycycline O
( O
100 O
mg O
for O
14 O
days O
) O
was O
carried O
out O
to O
determine O
the O
benefit O
of O
adjunctive O
medication O
in O
16 O
patients O
with O
localized O
juvenile O
periodontitis O
. O
['Physiological-Clinical']

The O
quality O
of O
these O
randomized O
controlled O
trials O
was O
scored O
. O
[]

Chemotherapy O
for O
operable O
gastric O
cancer O
: O
results O
of O
the O
Dutch O
randomised O
FAMTX O
trial O
. O
[]

BACKGROUND O
The O
purpose O
of O
the O
study O
was O
to O
prospectively O
compare O
the O
functional O
outcome O
of O
intramedullary O
nailing O
of O
the O
femur O
performed O
with O
use O
of O
a O
trochanteric O
and O
a O
piriformis O
fossa O
entry O
portal O
. O
[]

The O
checklist O
was O
filled O
out O
by O
an O
industrial O
hygienist O
while O
conducting O
a O
walk-through O
inspection O
( O
N O
= O
131 O
manufacturing O
processes/areas O
in O
17 O
large O
work O
sites O
) O
. O
[]

After O
four O
weeks O
of O
treatment O
and O
24 O
hours O
since O
the O
patient O
's O
last O
dose O
, O
both O
cetamolol O
groups O
showed O
a O
significantly O
greater O
( O
P O
less O
than O
or O
equal O
to O
.05 O
) O
reduction O
in O
supine B-outcome ['Physiological-Clinical']
systolic/diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
-18.1 O
+/- O
2.3/-9.2 O
+/- O
1.5 O
mm O
Hg O
[ O
low O
dose O
] O
and O
-17.3 O
+/- O
2.3/-8.3 O
+/- O
1.6 O
mm O
Hg O
[ O
high O
dose O
] O
) O
than O
the O
placebo O
group O
( O
-9.9 O
+/- O
2.5/-3.5 O
+/- O
1.7 O
mm O
Hg O
) O
. O
['Physiological-Clinical']

Tube O
feeding O
was O
initiated O
in O
both O
groups O
within O
a O
mean O
of O
29 O
( O
24 O
to O
72 O
) O
hours O
of O
the O
gastrostomy O
placement O
. O
[]

Median O
FACIT-F O
fatigue O
scores O
improved O
from O
baseline O
to O
day O
15 O
in O
all O
groups O
: O
MP+NTI O
( O
median O
score O
, O
4.5 O
; O
P O
= O
.005 O
) O
, O
PL+NTI O
( O
median O
score O
, O
8.0 O
; O
P O
< O
.001 O
) O
, O
MP+CTI O
( O
median O
score O
, O
7.0 O
; O
P O
= O
.004 O
) O
, O
and O
PL+CTI O
( O
median O
score O
, O
5.0 O
; O
P O
= O
.03 O
) O
. O
[]

Major O
, O
minor O
, O
and O
minimal O
bleedings O
( O
Thrombolysis O
In O
Myocardial O
Infarction O
criteria O
) O
occurred O
in O
2.7 O
% O
, O
4.7 O
% O
, O
and O
15.1 O
% O
of O
enrolled O
patients O
. O
[]

The O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
lanthanum O
carbonate O
were O
assessed O
by O
monitoring O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
throughout O
the O
study O
. O
['Life-Impact', 'Adverse-effects']

patients O
with O
stable O
cardiac O
diseases O
including O
arrhythmia O
can O
be O
included O
. O
[]

RESULTS O
56 O
patients O
were O
randomly O
assigned O
to O
each O
group O
, O
median O
follow-up O
was O
26.5 O
months O
( O
interquartile O
range O
, O
40 O
) O
, O
and O
patients O
in O
the O
diet O
group O
spent O
a O
median O
of O
10.7 O
months O
( O
interquartile O
range O
, O
11 O
) O
following O
an O
sVLPD O
. O
[]

BACKGROUND O
We O
recently O
obtained O
evidence O
of O
long-term B-outcome ['Physiological-Clinical']
adaptation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
to O
changes O
in O
intakes O
of O
carbohydrate O
and O
fiber O
in O
subjects O
with O
type O
2 O
diabetes O
. O
['Physiological-Clinical']

During O
the O
3-month O
treatment O
period O
, O
no O
significant O
differences O
between O
the O
treatment O
groups O
were O
noted O
in O
morning O
or O
evening O
PEF O
values O
, O
in O
spirometric O
parameters O
, O
in O
asthmatic O
symptoms O
or O
in O
the O
use O
of O
rescue O
beta2-agonists O
. O
[]

Loss O
of O
lean B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
was O
not O
spared O
in O
the O
HPLC O
group O
. O
['Physiological-Clinical']

Median O
OS B-outcome ['Mortality']
on O
lapatinib O
plus O
vinorelbine O
was O
24.3 O
months O
( O
95 O
% O
CI O
16.4 O
, O
NE O
) O
and O
19.4 O
months O
( O
95 O
% O
CI O
16.4 O
, O
27.2 O
) O
on O
lapatinib O
plus O
capecitabine O
. O
['Mortality']

Moreover O
, O
98 O
% O
of O
patients O
had O
low O
( O
< O
15 O
J O
) O
thresholds O
with O
the O
dual-coil O
lead O
system O
, O
compared O
with O
88 O
% O
of O
patients O
with O
the O
single-coil O
configuration O
( O
p=0.05 O
) O
. O
[]

All O
patients O
then O
received O
G-CSF O
5 O
micro O
g/kg/day O
from O
day O
+31 O
to O
day O
+90 O
. O
[]

All O
patients O
received O
5 O
mg O
EM O
and O
i.v O
. O
[]

OBJECTIVES O
To O
determine O
the O
effect O
of O
food O
on O
the O
antiviral O
activity O
of O
enteric-coated O
( O
EC O
) O
capsules O
of O
didanosine O
( O
ddI O
) O
. O
[]

Moreover O
, O
adding O
a O
low O
dose O
of O
HCTZ O
appears O
to O
be O
the O
most O
effective O
strategy O
in O
enhancing O
the O
antihypertensive O
activity O
of O
this O
angiotensin O
II O
receptor O
blocker O
in O
contrast O
to O
either O
doubling O
the O
dose O
or O
adding O
an O
angiotensin O
converting O
enzyme O
inhibitor O
. O
[]

Dexamethasone O
versus O
prednisone O
and O
daily O
oral O
versus O
weekly O
intravenous O
mercaptopurine O
for O
patients O
with O
standard-risk O
acute O
lymphoblastic O
leukemia O
: O
a O
report O
from O
the O
Children O
's O
Cancer O
Group O
. O
[]

These O
observations O
support O
the O
hypothesis O
that O
GM-CSF O
priming O
protects O
hematopoietic O
progenitors O
from O
the O
cytotoxic O
effects O
of O
chemotherapy O
. O
[]

Intravenous O
aflibercept O
administered O
in O
combination O
with O
irinotecan O
, O
5-fluorouracil O
and O
leucovorin O
in O
patients O
with O
advanced O
solid O
tumours O
: O
results O
from O
the O
expansion O
cohort O
of O
a O
phase O
I O
study O
. O
[]

Pre- O
and O
posttest O
outcome O
measures O
included O
solar B-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
( O
assessed O
using O
a O
validated O
diary O
) O
, O
knowledge B-outcome ['Life-Impact']
, O
and O
attitudes B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

One-year O
survival B-outcome ['Mortality']
rate O
was O
57.4 O
% O
for O
bevacizumab-erlotinib O
and O
53.8 O
% O
for O
bevacizumab-chemotherapy O
compared O
with O
33.1 O
% O
for O
chemotherapy O
alone O
. O
['Mortality']

Median O
total O
sleep B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
increased O
by O
25.75-66.75min O
, O
vs. O
25.50 O
( O
p O
< O
0.05 O
for O
0.50mg/d O
) O
, O
and O
median O
time O
in O
stages O
2-4/rapid O
eye B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
REM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
increased O
by O
37.00-68.00min O
, O
vs. O
26.75 O
( O
p O
< O
0.05 O
for O
0.50mg/d O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
MPH O
treatment O
was O
associated O
with O
significant O
declines O
in O
hyperactive B-outcome ['Life-Impact']
and O
impulsive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
at O
both O
home O
and O
school B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Significantly O
lower O
PIPP O
scores O
at O
second O
ROP O
examinations O
suggested O
that O
infants O
of O
older O
GA O
may O
have O
a O
greater O
ability O
to O
tolerate O
ROP O
screening O
. O
[]

AIM O
To O
investigate O
the O
role O
of O
exogenous O
bile O
acid O
therapy O
in O
patients O
with O
poor O
pouch O
function O
after O
restorative O
proctocolectomy O
for O
ulcerative O
colitis O
. O
[]

The O
results O
showed O
that O
no O
significant O
weight O
change O
took O
place O
during O
the O
study O
period O
. O
[]

A O
therapeutic O
trial O
with O
verapamil O
, O
a O
calcium-antagonist O
drug O
, O
was O
performed O
in O
12 O
patients O
admitted O
to O
our O
coronary O
care O
unit O
because O
of O
frequent O
daily O
attacks O
of O
angina O
at O
rest O
attributed O
to O
coronary O
vasospasm O
. O
[]

On O
the O
first O
postoperative O
day O
, O
the O
increase O
in O
the O
mean O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
also O
significantly O
lower O
in O
the O
IP O
patients O
. O
['Physiological-Clinical']

UNLABELLED O
In O
paired O
biopsies O
of O
osteoporotic O
women O
treated O
with O
either O
strontium O
ranelate O
or O
a O
placebo O
for O
36 O
months O
, O
characteristics O
of O
bone O
apatite O
crystals O
were O
not O
influenced O
by O
the O
presence O
of O
strontium O
. O
[]

Marker O
changes O
at O
2 O
and O
4 O
months O
showed O
a O
highly O
significant O
correlation O
with O
the O
UICC O
assessed O
response O
at O
3 O
and O
6 O
months O
( O
P O
< O
0.001 O
) O
; O
sensitivity O
100 O
% O
, O
specificity O
87 O
% O
; O
positive O
predictive O
value O
85 O
% O
; O
negative O
predictive O
value O
100 O
% O
. O
[]

The O
booklet O
was O
adapted O
from O
two O
previous O
versions O
evaluated O
in O
randomized O
controlled O
trials O
( O
RCTs O
) O
and O
the O
website O
was O
created O
to O
closely O
match O
the O
content O
of O
the O
revised O
booklet O
. O
[]

On O
each O
occasion O
the O
observer O
gave O
the O
child O
a O
pain B-outcome ['Physiological-Clinical']
score O
from O
1 O
( O
no O
pain O
) O
to O
5 O
( O
severe O
pain O
) O
. O
['Physiological-Clinical']

Their O
ages O
ranged O
from O
3 O
to O
13 O
years O
, O
and O
all O
belonged O
to O
American O
Society O
of O
Anesthesiologists O
( O
ASA O
) O
class O
I O
or O
II O
. O
[]

SETTING O
Teaching O
hospital O
. O
[]

Paricalcitol O
capsule O
for O
the O
treatment O
of O
secondary B-outcome ['Physiological-Clinical']
hyperparathyroidism I-outcome ['Physiological-Clinical']
in O
stages O
3 O
and O
4 O
CKD O
. O
['Physiological-Clinical']

The O
effect O
of O
tolrestat O
( O
200 O
mg O
a O
day O
) O
was O
compared O
with O
that O
of O
placebo O
on O
35 O
controls O
with O
diabetes O
mellitus O
, O
of O
similar O
age O
, O
gender O
, O
and O
glycemic O
control O
. O
[]

Efficacy O
and O
safety O
of O
a O
fixed O
low-dose O
perindopril/indapamide O
combination O
in O
essential O
hypertension O
. O
[]

Therefore O
, O
an O
instructional O
approach O
involving O
comparison O
can O
be O
an O
effective O
tool O
for O
learning O
about O
concepts O
in O
mathematics O
. O
[]

However O
, O
surgical O
ligation O
requires O
availability O
of O
surgical O
resources O
and O
patients O
who O
are O
able O
to O
withstand O
an O
anesthetic O
. O
[]

The O
Study O
group O
performed O
significantly O
better O
than O
the O
Control O
group O
in O
the O
post-test O
, O
in O
which O
the O
group O
to O
which O
the O
students O
had O
been O
allocated O
was O
the O
only O
significant O
predictor O
of O
performance O
. O
[]

There O
was O
a O
50 O
% O
reduction O
( O
p O
less O
than O
0.05 O
) O
in O
the O
overall O
incidence O
of O
shivering B-outcome ['Physiological-Clinical']
in O
patients O
who O
received O
fentanyl O
and O
there O
was O
some O
evidence O
to O
suggest O
that O
low-dose O
epidural O
fentanyl O
might O
reduce O
shivering B-outcome ['Physiological-Clinical']
by O
an O
influence O
on O
thermoregulation B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Treatment O
took O
place O
every O
other O
day O
for O
20 O
minutes O
. O
[]

The O
hemoglobin B-outcome ['Physiological-Clinical']
levels O
increased O
non-significantly O
at O
7 O
hrs O
post O
DE O
[ O
0.3 O
gm/dL O
( O
95 O
% O
CI O
: O
0.2 O
to O
0.5 O
gm/dL O
) O
] O
versus O
FA O
exposure O
[ O
0.2 O
gm/dL O
( O
95 O
% O
CI O
: O
0 O
to O
0.3 O
gm/dL O
) O
] O
; O
p=0.06 O
. O
['Physiological-Clinical']

Twenty O
patients O
( O
mean O
age O
, O
60 O
+/- O
15 O
years O
) O
with O
ET B-outcome ['Physiological-Clinical']
were O
randomized O
to O
receive O
ZNS O
or O
placebo O
. O
['Physiological-Clinical']

In O
patients O
who O
received O
the O
full O
7 O
days O
of O
infusion O
, O
the O
plasma B-outcome ['Physiological-Clinical']
suppressive I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
remained O
significantly O
diminished O
in O
the O
PGE1 O
group O
-- O
ratio O
P O
: O
C O
77 O
+/- O
4 O
% O
versus O
61 O
+/- O
5 O
% O
( O
P O
less O
than O
0.04 O
) O
. O
['Physiological-Clinical']

On O
the O
basis O
of O
these O
examinations O
, O
the O
authors O
identified O
64 O
women O
who O
had O
at O
least O
one O
ruptured O
implant O
at O
the O
first O
magnetic O
resonance O
imaging O
examination O
and O
, O
for O
comparison O
, O
all O
women O
who O
had O
intact O
implants O
at O
both O
examinations O
( O
n O
= O
98 O
) O
. O
[]

Effects O
of O
interaction O
of O
RRR-alpha-tocopheryl O
acetate O
and O
fish O
oil O
on O
low-density-lipoprotein O
oxidation O
in O
postmenopausal O
women O
with O
and O
without O
hormone-replacement O
therapy O
. O
[]

CONCLUSION O
Concomitant O
boost O
postoperative O
radiation O
therapy O
did O
not O
improve O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
loco-regional B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
disease B-outcome ['Mortality']
free I-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality', 'Physiological-Clinical', 'Mortality']

MAIN O
OUTCOME O
MEASURE O
( O
S O
) O
Rate O
of I-outcome ['Physiological-Clinical']
development B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
expanded I-outcome ['Physiological-Clinical']
blastocysts I-outcome ['Physiological-Clinical']
suitable O
for O
transfer B-outcome ['Physiological-Clinical']
or O
vitrification B-outcome ['Physiological-Clinical']
( O
primary O
outcome O
) O
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Suppression O
of O
immediate O
and O
late O
anti-IgE-induced B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
by O
topically O
applied O
alcohol/onion O
extract O
. O
['Physiological-Clinical']

None O
of O
those O
treated O
with O
croton O
oil O
regrew B-outcome ['Physiological-Clinical']
hair I-outcome ['Physiological-Clinical']
when O
treated O
later O
with O
DNCB O
. O
['Physiological-Clinical']

Chronic O
myeloid O
leukemia O
blast O
phase O
( O
CML-BP O
) O
cells O
commonly O
express O
the O
multidrug O
transporter O
, O
P-glycoprotein O
( O
Pgp O
) O
. O
[]

METHODS O
Thirteen O
healthy O
human O
volunteers O
( O
6 O
men O
and O
7 O
women O
, O
aged O
20-28 O
years O
) O
were O
included O
in O
the O
study O
. O
[]

A O
total O
of O
12 O
were O
intubated O
using O
the O
TAMS O
. O
[]

RESULTS O
The O
median O
duration O
of O
survival B-outcome ['Mortality']
was O
20.3 O
months O
in O
the O
group O
given O
IFL O
plus O
bevacizumab O
, O
as O
compared O
with O
15.6 O
months O
in O
the O
group O
given O
IFL O
plus O
placebo O
, O
corresponding O
to O
a O
hazard O
ratio O
for O
death O
of O
0.66 O
( O
P O
< O
0.001 O
) O
. O
['Mortality']

Eleven O
healthy O
tobacco O
smoking O
adult O
male O
volunteers O
of O
mixed O
race O
were O
tobacco O
abstinent O
overnight O
for O
this O
study O
. O
[]

Moreover O
, O
perfect O
control O
was O
achieved O
through O
the O
study O
of O
clinical B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
which O
even O
disappeared O
in O
some O
cases O
. O
['Physiological-Clinical']

Fatal B-outcome ['Mortality']
cardiac I-outcome ['Mortality']
toxicity I-outcome ['Mortality']
occurred O
in O
one O
patient O
. O
['Mortality']

Patients O
receiving O
tamoxifen O
had O
significantly O
more O
vaginal B-outcome ['Physiological-Clinical']
discharge I-outcome ['Physiological-Clinical']
( O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical']

Vitamin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
levels O
were O
measured O
at O
the O
end O
of O
the O
study O
, O
and O
the O
placebo O
group O
had O
levels O
that O
were O
significantly O
below O
average O
for O
typical O
children O
, O
whereas O
the O
supplement O
group O
had O
near-average O
levels O
. O
['Physiological-Clinical']

Consequently O
, O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
start I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
PCI I-outcome ['Physiological-Clinical']
was O
shortened O
in O
argatroban O
groups O
. O
['Physiological-Clinical']

KSS O
measured O
at O
week O
2 O
, O
6 O
and O
12 O
showed O
no O
significant O
difference O
between O
groups O
. O
[]

RESULTS O
The O
difference O
in O
mean O
( O
95 O
% O
CI O
) O
change O
scores O
( O
final O
minus O
baseline O
) O
between O
treatments O
was O
13.3 O
mm O
( O
-8.6 O
to O
35.2 O
) O
for O
pain O
( O
total O
scale O
500 O
mm O
) O
, O
71.0 O
mm O
( O
-2.4 O
to O
144.5 O
) O
for O
physical O
function O
( O
total O
scale O
1700 O
mm O
) O
, O
and O
4.3 O
mm O
( O
-1.2 O
to O
9.8 O
) O
for O
PGA O
( O
total O
scale O
100 O
mm O
) O
. O
[]

024 O
liter O
. O
[]

For O
each O
interview O
, O
they O
were O
randomized O
to O
receive O
1 O
of O
2 O
elicitation O
methods O
: O
ping-ponging O
or O
starting O
at O
the O
known O
efficacy O
. O
[]

All O
but O
six O
of O
the O
women O
continued O
to O
breast-feed O
for O
> O
or O
= O
12 O
mo O
. O
[]

This O
study O
investigated O
the O
effectiveness O
of O
public O
preschool O
teachers O
implementing O
a O
validated O
intervention O
( O
the O
Joint O
Attention O
and O
Symbolic O
Play/Engagement O
and O
Regulation O
intervention O
; O
JASP/ER O
) O
on O
a O
core O
deficit O
of O
autism O
, O
initiating O
joint O
attention O
. O
[]

Serum O
and O
ascitic O
levels O
of O
tumor O
necrosis O
factor-alpha O
, O
interferon-gamma O
, O
interleukin-12 B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical']

Patients O
who O
had O
high O
proportions O
of O
spirochetes O
, O
i.e. O
, O
> O
20 O
% O
, O
in O
plaques O
removed O
from O
diseased O
periodontal O
sites O
, O
were O
given O
metronidazole O
( O
500 O
mg O
bid O
) O
under O
supervision O
. O
[]

All O
treatment O
groups O
demonstrated O
dramatic B-outcome ['Life-Impact']
and O
persistent B-outcome ['Life-Impact']
decreases O
in O
cocaine B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
, O
craving B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
cocaine I-outcome ['Life-Impact']
, O
and O
psychiatric B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
consequent O
to O
treatment O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

At O
0 O
hours O
most O
lung B-outcome ['Physiological-Clinical']
function B-outcome ['Life-Impact']
parameters O
were O
significantly O
reduced O
( O
indicative O
: O
FEV O
( O
1 O
) O
, O
4.3 O
+/- O
0.4 O
vs. O
3.8 O
+/- O
0.3 O
L O
; O
FEV O
( O
1 O
) O
/FVC O
, O
0.9 O
+/- O
0.1 O
vs. O
0.8 O
+/- O
0.1 O
; O
P O
< O
0.05 O
) O
but O
at O
3 O
hours O
they O
were O
at O
baseline O
levels O
. O
['Physiological-Clinical', 'Life-Impact']

Concerning O
the O
growth O
of O
Staph O
. O
[]

CONCLUSIONS O
These O
findings O
indicate O
that O
oxytocin O
increases O
the O
saliency O
of O
social O
stimuli O
and O
in O
ASD O
and O
suggest O
that O
oxytocin O
might O
promote O
face O
processing O
and O
eye O
contact O
in O
individuals O
with O
ASD O
as O
prerequisites O
for O
neurotypical O
social O
interaction O
. O
[]

Antiviral O
prophylaxis O
can O
potentially O
prevent O
rituximab-associated O
HBV O
reactivation O
in O
patients O
with O
lymphoma O
and O
resolved O
hepatitis O
B O
. O
[]

METHODS O
We O
randomly O
assigned O
39 O
adults O
with O
cystic O
fibrosis O
and O
at O
least O
one O
G551D-CFTR O
allele O
to O
receive O
oral O
VX-770 O
every O
12 O
hours O
at O
a O
dose O
of O
25 O
, O
75 O
, O
or O
150 O
mg O
or O
placebo O
for O
14 O
days O
( O
in O
part O
1 O
of O
the O
study O
) O
or O
VX-770 O
every O
12 O
hours O
at O
a O
dose O
of O
150 O
or O
250 O
mg O
or O
placebo O
for O
28 O
days O
( O
in O
part O
2 O
of O
the O
study O
) O
. O
[]

The O
co-primary O
endpoints O
at O
12 O
months O
were O
patient/graft B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
a O
composite O
renal B-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
endpoint O
( O
percent O
with O
a O
measured O
glomerular O
filtration O
rate O
( O
mGFR O
) O
< O
60 O
mL/min/1.73 O
m O
( O
2 O
) O
at O
Month O
12 O
or O
a O
decrease O
in O
mGFR O
> O
or O
=10 O
mL/min/1.73 O
m O
( O
2 O
) O
Month O
3-Month O
12 O
) O
and O
the O
incidence O
of O
acute B-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
significant O
difference O
among O
the O
drugs O
in O
the O
Holter-monitoring O
group O
. O
[]

[ O
Drug O
therapy O
of O
condylomata O
acuminata O
] O
. O
[]

On O
stepwise O
logistic O
regression O
analysis O
, O
hepatitis O
B O
virus O
DNA O
, O
AST O
and O
a O
history O
of O
acute O
hepatitis O
predicted O
response O
independently O
( O
p O
less O
than O
0.05 O
) O
. O
[]

Patients O
were O
followed O
for O
bleeding B-outcome ['Physiological-Clinical']
and O
recurrent B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
AND O
RESULTS O
A O
total O
of O
979 O
ST-segment-elevation O
myocardial O
infarction O
patients O
enrolled O
in O
the O
Harmonizing O
Outcomes O
with O
Revascularization O
and O
Stents O
in O
Acute O
Myocardial O
Infarction O
( O
HORIZONS-AMI O
) O
trial O
had O
BNP B-outcome ['Physiological-Clinical']
levels O
measured O
in O
the O
emergency O
room O
prior O
to O
primary O
percutaneous O
coronary O
intervention O
as O
part O
of O
the O
study O
protocol O
. O
['Physiological-Clinical']

We O
conducted O
a O
randomized O
trial O
to O
evaluate O
the O
impact O
of O
lay O
patient O
navigators O
on O
time O
to O
resolution O
and O
completion O
of O
follow-up O
testing O
among O
patients O
with O
abnormal O
screening O
tests O
in O
a O
medically O
underserved O
patient O
population O
. O
[]

Treatment O
groups O
did O
not O
differ O
on O
any O
of O
the O
six O
cognitive B-outcome ['Life-Impact']
tests O
( O
p O
> O
0.05 O
for O
all O
) O
. O
['Life-Impact']

Postintervention O
, O
the O
MET O
group O
had O
a O
35 O
% O
improvement O
in O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
WBISI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
compared O
with O
the O
placebo O
group O
( O
p O
= O
0.008 O
) O
. O
['Physiological-Clinical']

With O
the O
addition O
of O
cholestyramine O
, O
there O
was O
a O
41 O
per O
cent O
total O
decrease O
in O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
from O
the O
control O
value O
and O
a O
50 O
percent O
decrease O
in O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
outcome O
will O
be O
measured O
at O
30 O
minutes O
after O
treatment O
using O
the O
numerical O
rating O
scale O
( O
NRS O
) O
of O
low O
back O
pain O
while O
the O
patient O
is O
moving O
. O
[]

The O
strong O
effect O
among O
the O
lowest O
socio-economic O
group O
shows O
that O
school O
dental O
screening O
may O
be O
used O
to O
decrease O
dental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
inequalities I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
2 O
groups O
were O
compared O
for O
mean O
survival B-outcome ['Mortality']
, O
hazard O
ratio O
, O
1-year O
survival B-outcome ['Mortality']
, O
quality O
of O
life O
scores O
, O
and O
hematologic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
chemical I-outcome ['Physiological-Clinical']
data I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Mortality', 'Physiological-Clinical']

METHOD O
We O
recorded O
EEG O
in O
15 O
MDD O
patients O
and O
14 O
age-matched O
controls O
. O
[]

The O
maximal O
time O
of O
tolerance O
( O
Tlim O
) O
, O
metabolic O
equivalents O
( O
METs O
) O
and O
Bruce O
stage O
reached O
significantly O
higher O
values O
in O
the O
LED O
group O
and O
the O
exercise O
group O
( O
p O
< O
0.01 O
) O
. O
[]

PURPOSE O
We O
evaluated O
the O
early O
clinical O
and O
urodynamic O
results O
of O
posterior O
tibial O
nerve O
stimulation O
in O
patients O
with O
refractory O
monosymptomatic O
nocturnal O
enuresis O
. O
[]

In O
Exp O
. O
[]

RESULTS O
Results O
of O
an O
intent-to-treat O
analysis O
did O
not O
meet O
the O
prespecified O
criterion O
for O
noninferiority O
but O
did O
demonstrate O
the O
superiority O
of O
continuous-dose O
terbinafine O
for O
: O
mycological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
of O
the O
target O
toenail O
( O
70.9 O
% O
[ O
105/148 O
] O
vs O
58.7 O
% O
[ O
84/143 O
] O
; O
P O
=.03 O
, O
relative O
risk O
[ O
RR O
] O
of O
1.21 O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
1.02-1.43 O
] O
) O
; O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
of O
the O
target O
toenail O
( O
44.6 O
% O
[ O
66/148 O
] O
vs O
29.3 O
% O
[ O
42/143 O
] O
; O
P O
=.007 O
, O
RR O
=1.52 O
[ O
95 O
% O
CI O
, O
1.11-2.07 O
) O
; O
complete B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
of O
the O
target O
toenail O
( O
40.5 O
% O
[ O
60/148 O
] O
vs O
28.0 O
% O
[ O
40/143 O
] O
; O
P O
=.02 O
, O
RR=1.45 O
[ O
95 O
% O
CI O
, O
1.04-2.01 O
) O
; O
and O
complete O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Blepharitis O
therapy O
with O
the O
antiseptic O
bibrocathol O
2 O
% O
in O
this O
trial O
was O
highly O
efficacious O
and O
safe O
. O
[]

On O
the O
basis O
of O
this O
reduced O
nephrotoxicity B-outcome ['Physiological-Clinical']
, O
a O
['Physiological-Clinical']

Primary O
outcome O
measures O
included O
Functional O
Independence O
Measure O
for O
Children O
( O
WeeFIM O
) O
, O
Pediatric O
Evaluation O
of O
Disability B-outcome ['Life-Impact']
Inventory O
( O
PEDI O
) O
, O
Leiter O
International O
Performance B-outcome ['Life-Impact']
Scale-Revised O
( O
Leiter-R O
) O
, O
and O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression-Improvement O
( O
CGI-I O
) O
scale O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

The O
most O
salient O
feature O
in O
the O
verum O
group O
was O
a O
drastic O
increase O
in O
the O
absolute O
number O
of O
immunocompetent B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
with O
an O
especially O
pronounced O
effect O
on O
T O
lymphocytes B-outcome ['Physiological-Clinical']
, O
predominantly O
of O
the O
helper/inducer B-outcome ['Physiological-Clinical']
type I-outcome ['Physiological-Clinical']
, O
but O
also O
on O
cytotoxic B-outcome ['Physiological-Clinical']
and O
natural B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
study O
also O
demonstrated O
the O
potential O
for O
consents O
to O
aid O
the O
student O
provider O
in O
better O
communicating B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
patients I-outcome ['Life-Impact']
. O
['Life-Impact']

1.78 O
vs. O
49.5 O
? O
[]

The O
use O
of O
vascularized O
bone O
grafts O
to O
reconstruct O
extremity O
and O
mandibular O
defects O
is O
now O
commonplace O
in O
reconstructive O
surgery O
. O
[]

RESULTS O
We O
found O
a O
significant O
reduction O
in O
the O
amount O
of O
contrast O
administered O
( O
A O
vs O
B O
, O
93.1 O
[ O
41.7 O
] O
vs O
50.9 O
[ O
14.7 O
] O
mL O
; O
P O
< O
.0001 O
) O
and O
radiation B-outcome ['Resource-use']
exposure I-outcome ['Resource-use']
( O
27.6 O
[ O
11.5 O
] O
vs O
18 O
[ O
6.4 O
] O
mGycm O
( O
2 O
) O
; O
P O
< O
.0001 O
) O
. O
['Resource-use']

Clinical O
Trials O
# O
: O
NCT00065910 O
. O
[]

Complications B-outcome ['Adverse-effects']
occurred O
in O
26 O
% O
of O
OG O
patients O
and O
9 O
% O
died B-outcome ['Mortality']
. O
['Adverse-effects', 'Mortality']

Long-term O
survival B-outcome ['Mortality']
in O
one O
patient O
, O
77 O
months O
, O
can O
occasionally O
be O
achieved O
in O
patients O
with O
hepatic O
metastases O
. O
['Mortality']

In O
conclusion O
, O
ViviScal O
appears O
to O
be O
the O
first O
highly O
active O
treatment O
for O
androgenic O
alopecia O
in O
young O
males O
. O
[]

This O
study O
examined O
the O
effectiveness O
of O
a O
treatment O
program O
comprised O
of O
several O
components O
based O
on O
evidence-based O
treatments O
( O
EBTs O
) O
for O
disruptive O
behavior O
problems O
delivered O
to O
youth O
participating O
in O
a O
school O
mental O
health O
program O
in O
an O
underserved O
community O
in O
the O
Appalachian O
region O
. O
[]

Histologic B-outcome ['Physiological-Clinical']
conversion I-outcome ['Physiological-Clinical']
in O
the O
non-Hodgkin O
's O
lymphomas O
. O
['Physiological-Clinical']

In O
the O
majority O
of O
subjects O
, O
the O
changes O
in O
alphaEGOT B-outcome ['Physiological-Clinical']
and O
alphaEGPT B-outcome ['Physiological-Clinical']
with O
time O
correlated O
poorly O
with O
the O
changes O
in O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
control O
group O
, O
bone O
marrow O
was O
not O
collected O
from O
two O
patients O
because O
of O
disease O
progression O
, O
one O
patient O
withdrew O
consent O
, O
and O
three O
patients O
were O
not O
consented O
at O
the O
time O
of O
surgery O
. O
[]

Eligible O
patients O
acknowledged O
that O
loss O
of O
appetite O
or O
weight O
was O
a O
problem O
and O
reported O
the O
loss O
of O
5 O
pounds O
or O
more O
during O
2 O
months O
and/or O
a O
daily O
intake O
of O
less O
than O
20 O
calories/kg O
of O
body O
weight O
. O
[]

The O
most O
common O
adverse O
events O
were O
dizziness O
( O
13.3 O
% O
Cappra O
( O
? O
) O
, O
[]

BACKGROUND O
Populations O
in O
South O
and O
East O
Asia O
and O
many O
other O
regions O
of O
the O
world O
are O
chronically O
exposed O
to O
arsenic-contaminated O
drinking O
water O
. O
[]

The O
mean O
heart O
rate O
( O
HR O
) O
, O
RPE O
, O
number O
of O
steps O
( O
determined O
by O
step O
counter O
) O
, O
and O
blood O
lactate O
concentrations O
were O
determined O
at O
3 O
, O
6 O
, O
9 O
, O
12 O
, O
and O
15 O
minutes O
during O
the O
recovery O
from O
the O
exercise O
, O
with O
and O
without O
motivational O
music O
( O
2 O
separate O
sessions O
, O
at O
random O
order O
) O
. O
[]

The O
SNRI O
venlafaxine O
improves O
emotional B-outcome ['Life-Impact']
unawareness I-outcome ['Life-Impact']
in O
patients O
with O
post-stroke O
depression O
. O
['Life-Impact']

After O
a O
median O
follow-up O
of O
79.5 O
months O
, O
there O
was O
no O
significant O
difference O
in O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
DFS O
; O
85 O
% O
in O
both O
arms O
) O
or O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
91 O
% O
v O
92 O
% O
) O
at O
5 O
years O
. O
['Mortality', 'Mortality']

The O
total O
dosage O
of O
magnesium B-outcome ['Physiological-Clinical']
sulphate I-outcome ['Physiological-Clinical']
in O
the O
shortened O
group O
was O
reduced O
by O
40 O
% O
in O
66 O
% O
of O
patients O
. O
['Physiological-Clinical']

Under O
BF O
, O
pulse B-outcome ['Physiological-Clinical']
and O
respiratory B-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
were O
significantly O
higher O
, O
and O
elevation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
due O
to O
mental O
stress O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

It O
is O
widely O
held O
that O
first-order O
modulations O
are O
represented O
by O
the O
firing O
rates O
of O
simple O
and O
complex O
cells O
( O
first-order O
neurons O
) O
in O
primary O
visual O
cortex O
( O
V1 O
) O
that O
, O
likewise O
, O
have O
spatially O
localized O
receptive O
fields O
that O
are O
selective O
for O
orientation- O
and O
SF O
. O
[]

Postclinic O
chart O
review O
compared O
immunizations O
due O
with O
those O
administered O
. O
[]

Monitoring O
with O
the O
bispectral O
index O
in O
those O
aged O
from O
1 O
to O
3 O
years O
revealed O
use O
of O
lower O
doses O
of O
midazolam O
, O
at O
2.09 O
mg O
per O
kg O
per O
hr O
, O
with O
standard O
deviation O
of O
0.36 O
, O
and O
similarly O
lowers O
doses O
of O
ketamine O
, O
at O
2.07 O
mg O
per O
kg O
per O
hr O
, O
with O
standard O
deviation O
of O
0.22 O
, O
the O
values O
in O
those O
not O
monitored O
being O
2.93 O
, O
with O
standard O
deviation O
of O
0.45 O
, O
and O
2.96 O
with O
standard O
deviation O
of O
0.51 O
respectively O
, O
these O
difference O
being O
statistically O
significant O
( O
p O
= O
0.001 O
and O
p O
= O
0.04 O
, O
respectively O
) O
. O
[]

In O
the O
montelukast/levocetirizine O
arm O
, O
montelukast O
decreased O
nasal B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
more O
significantly O
than O
levocetirizine O
, O
whereas O
in O
reduction O
of O
sICAM-1 B-outcome ['Physiological-Clinical']
all O
active O
treatment O
options O
were O
equally O
effective O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Just-in-time O
evidence-based O
e-mail O
reminders O
in O
home O
health O
care O
: O
impact O
on O
nurse O
practices O
. O
[]

After O
5 O
min O
of O
baseline O
recording O
, O
acupuncture O
was O
applied O
to O
PC4 O
and O
a O
control O
site O
in O
proximity O
to O
PC4 O
for O
10 O
min O
and O
scanning O
was O
performed O
for O
60 O
min O
after O
acupuncture O
stimulation O
. O
[]

It O
is O
clearly O
feasible O
to O
treat O
most O
psychiatric O
patients O
in O
the O
community O
without O
increasing O
the O
burden B-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
relatives I-outcome ['Life-Impact']
. O
['Life-Impact']

Both O
treatments O
were O
well O
tolerated O
, O
with O
discontinuation O
for O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
for O
one O
( O
1.9 O
% O
) O
patient O
in O
the O
manidipine/delapril O
group O
and O
two O
( O
3.6 O
% O
) O
in O
the O
losartan/HCTZ O
group O
. O
['Adverse-effects']

PURPOSE O
To O
determine O
if O
the O
accuracy O
of O
the O
baseline O
prediction O
model O
for O
the O
development O
of O
primary O
open-angle O
glaucoma O
( O
POAG O
) O
in O
patients O
with O
ocular O
hypertension O
can O
be O
improved O
by O
correcting O
intraocular O
pressure O
( O
IOP O
) O
for O
central O
corneal O
thickness O
( O
CCT O
) O
. O
[]

In O
one O
group O
of O
14 O
patients O
( O
28 O
TMJ O
) O
, O
the O
condyles O
were O
placed O
in O
the O
centre O
of O
the O
articular O
fossa O
before O
and O
during O
the O
operation O
, O
and O
in O
the O
other O
group O
they O
were O
not O
. O
[]

Concentrations O
of O
both O
cortisol B-outcome ['Physiological-Clinical']
and O
vasopressin B-outcome ['Physiological-Clinical']
were O
increased O
for O
an O
hour O
following O
IV O
methadone O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
are O
, O
however O
, O
signs O
of O
minor O
and O
perhaps O
chronic O
renal O
injury O
. O
[]

Group O
I O
initially O
received O
professional O
mechanical O
tooth-cleaning O
, O
tongue-scraping O
, O
chlorhexidine O
treatment O
, O
and O
oral O
hygiene O
instructions O
concentrated O
on O
the O
approximal O
surfaces O
most O
colonized O
by O
S. O
mutans O
. O
[]

Incidence O
of O
hip O
fractures O
is O
high O
in O
chronically O
hospitalized O
, O
disabled O
, O
elderly O
patients O
after O
stroke O
. O
[]

Participants O
were O
women O
in O
a O
breast O
self-examination O
trial O
in O
Shanghai O
, O
China O
who O
were O
diagnosed O
with O
fibroadenomas O
( O
n O
= O
258 O
) O
and O
1035 O
controls O
. O
[]

In O
both O
groups O
the O
test O
drug O
( O
0.005 O
% O
latanoprost O
) O
and O
its O
vehicle O
( O
placebo O
) O
was O
applied O
by O
hospital O
staff O
every O
morning O
for O
9 O
days O
. O
[]

There O
was O
a O
single O
major B-outcome ['Adverse-effects']
complication I-outcome ['Adverse-effects']
of O
venous B-outcome ['Physiological-Clinical']
perforation I-outcome ['Physiological-Clinical']
following O
CBA O
. O
['Adverse-effects', 'Physiological-Clinical']

Two O
of O
42 O
patients O
who O
underwent O
resection O
and O
had O
been O
treated O
with O
n-BCA O
experienced O
[]

Here O
, O
we O
investigated O
the O
effects O
of O
temporal O
low-frequency O
rTMS O
on O
motor O
cortex O
plasticity O
in O
a O
large O
sample O
of O
tinnitus O
patients O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
examine O
the O
effect O
of O
direct O
renin O
inhibition O
on O
cardiovascular O
autonomic O
function O
. O
[]

There O
was O
, O
however O
, O
a O
significantly O
increased O
incidence O
of O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
in O
the O
group O
which O
received O
disopyramide O
phosphate O
. O
['Physiological-Clinical']

CONTEXT O
AND O
OBJECTIVE O
An O
association O
between O
mood O
disorders O
and O
overt O
thyroid O
dysfunction O
is O
well O
established O
, O
but O
there O
are O
few O
data O
on O
the O
potential O
for O
thyroid O
hormone O
levels O
closer O
to O
the O
reference O
range O
to O
correlate O
with O
psychological O
well-being O
. O
[]

Exercise O
training O
has O
been O
reported O
to O
improve O
endothelial O
function O
of O
patients O
at O
risk O
of O
or O
with O
established O
CAD O
. O
[]

Pulse B-outcome ['Physiological-Clinical']
oximetry I-outcome ['Physiological-Clinical']
, O
noninvasive B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Total O
UVA O
doses O
received O
were O
107 O
J O
cm O
( O
-2 O
) O
( O
range O
1?4-489?9 O
) O
in O
the O
PUVA O
arm O
vs. O
101?7 O
J O
cm O
( O
-2 O
) O
( O
0?2-529?9 O
) O
in O
the O
combination O
arm O
. O
[]

Further O
studies O
are O
indicated O
to O
evaluate O
the O
longer-term O
effects O
of O
levocetirizine O
on O
asthma B-outcome ['Physiological-Clinical']
exacerbations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Secondary O
outcomes O
included O
kinematic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
the O
Motor B-outcome ['Physiological-Clinical']
Activity I-outcome ['Physiological-Clinical']
Log I-outcome ['Physiological-Clinical']
and O
ABILHAND O
Questionnaire O
for O
daily B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Prior O
adjuvant O
chemotherapy O
was O
permitted O
. O
[]

Relative O
numbers O
of O
CD16 B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
were O
significantly O
elevated O
, O
but O
NK B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
cytotoxic I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
within O
a O
normal O
range O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PARTICIPANTS O
Infants O
( O
N O
= O
280 O
) O
born O
weighing O
< O
or O
= O
1500 O
gm O
and O
selected O
for O
the O
Infant O
Health O
and O
Development O
Program O
. O
[]

After O
the O
resumption O
of O
menstruation O
, O
13 O
of O
28 O
women O
displayed O
positive O
spine B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
between O
the O
6th O
and O
12th O
months O
; O
in O
this O
group O
, O
bone B-outcome ['Physiological-Clinical']
biochemical I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
measured O
at O
6 O
months O
were O
significantly O
higher O
( O
P O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Poor B-outcome ['Physiological-Clinical']
results I-outcome ['Physiological-Clinical']
( O
no O
improvement O
) O
were O
significantly O
higher O
in O
the O
placebo-treated O
group O
, O
while O
good O
results O
were O
significantly O
higher O
in O
the O
ketorolac-treated O
group O
. O
['Physiological-Clinical']

A O
set O
of O
geometrical O
parameters O
of O
the O
femur O
were O
determined O
from O
seven O
a-p O
hip O
radiographs O
and O
compared O
to O
the O
3D O
femoral O
shape O
obtained O
from O
CT O
as O
training O
material O
; O
the O
error O
in O
reconstructing O
the O
3D O
model O
from O
the O
2D O
radiographs O
was O
assessed O
. O
[]

A O
5-year O
protocol O
, O
including O
an O
initial O
6-months O
( O
randomised O
) O
pilot O
study O
, O
consisting O
of O
dietary O
treatment O
and/or O
increase O
of O
physical O
activity O
or O
training O
with O
annual O
check-ups O
, O
was O
completed O
by O
90 O
% O
of O
subjects O
. O
[]

RESULTS O
Of O
261 O
eligible O
clinicians O
responding O
to O
the O
statewide O
survey O
, O
about O
half O
provide O
sun O
protection O
counseling O
most O
of O
the O
time O
or O
almost O
always O
during O
summer O
well O
care O
visits O
. O
[]

Angiotensin O
II O
, O
whose O
production O
is O
ultimately O
inhibited O
by O
these O
agents O
, O
exerts O
significant O
regulatory O
influence O
on O
a O
variety O
of O
target O
organs O
including O
the O
central O
and O
peripheral O
nervous O
systems O
. O
[]

94 O
evaluable O
patients O
with O
metastatic O
breast O
cancer O
were O
randomly O
assigned O
to O
5-fluorouracil O
, O
adriamycin O
, O
and O
cyclophosphamide O
( O
FAC O
) O
or O
5-fluorouracil O
, O
epirubicin O
, O
and O
cyclophosphamide O
( O
FEC O
) O
, O
with O
cycles O
repeated O
every O
3 O
weeks O
. O
[]

Four O
patients O
( O
50 O
% O
) O
in O
the O
control O
group O
had O
HBsAg B-outcome ['Physiological-Clinical']
reverse I-outcome ['Physiological-Clinical']
seroconversion I-outcome ['Physiological-Clinical']
after O
HBV O
reactivation O
. O
['Physiological-Clinical']

The O
differences O
were O
not O
significantly O
different O
. O
[]

The O
median O
time O
to O
documentation O
of O
conversion B-outcome ['Life-Impact']
was O
51 O
mo O
. O
['Life-Impact']

METHODS O
hsCRP B-outcome ['Physiological-Clinical']
was O
measured O
on O
admission O
in O
3225 O
patients O
with O
ACS O
. O
['Physiological-Clinical']

[ O
Long O
term O
observation O
in O
effects O
of O
potassium O
and O
calcium O
supplementation O
on O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
sodium B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
adolescents O
with O
higher O
blood O
pressure O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
significantly O
higher O
integral O
dose O
( O
absorbed O
energy O
within O
the O
body O
) O
of O
the O
pre- O
compared O
with O
the O
postoperative O
group O
( O
p O
less O
than O
0.025 O
) O
is O
associated O
with O
the O
differences O
in O
morbidity O
between O
the O
two O
irradiated O
groups O
. O
[]

At O
28-35 O
days O
post-therapy O
, O
the O
continued O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rate O
in O
the O
faropenem O
daloxate O
group O
was O
92.6 O
% O
and O
that O
for O
the O
cefuroxime O
axetil O
group O
was O
94.9 O
% O
( O
95 O
% O
CI O
: O
-6.8 O
% O
; O
+1.2 O
% O
) O
. O
['Physiological-Clinical']

The O
predominant O
causative O
organisms O
were O
Streptococcus O
pneumoniae O
( O
47.1 O
% O
) O
, O
Haemophilus O
influenzae O
( O
30.1 O
% O
) O
, O
Staphylococcus O
aureus O
( O
14.7 O
% O
) O
and O
Moraxella O
catarrhalis O
( O
8.8 O
% O
) O
. O
[]

Hyperinsulinemia O
fails O
to O
augment O
ET-1 O
action O
in O
the O
skeletal O
muscle O
vascular O
bed O
in O
vivo O
in O
humans O
. O
[]

We O
investigated O
efficacy O
and O
safety O
of O
autologous O
implantation O
of O
bone O
marrow-mononuclear O
cells O
in O
patients O
with O
ischaemic O
limbs O
because O
of O
peripheral O
arterial O
disease O
. O
[]

PURPOSE O
To O
evaluate O
whether O
the O
position O
of O
the O
anterior O
continuous O
curvilinear O
capsulorhexis O
influences O
the O
rate O
of O
posterior B-outcome ['Physiological-Clinical']
capsule I-outcome ['Physiological-Clinical']
opacification I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PCO I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Parents O
in O
both O
intervention O
and O
control O
groups O
received O
health O
and O
safety O
counseling O
during O
home O
visits O
on O
the O
same O
schedule O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
AGE-peptides I-outcome ['Physiological-Clinical']
and O
C-peptide B-outcome ['Physiological-Clinical']
in O
early-stage O
diabetic O
nephropathy O
patients O
on O
thiamine O
and O
pyridoxine O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Magnesium O
sulphate O
is O
currently O
the O
most O
ideal O
drug O
for O
the O
treatment O
of O
eclampsia O
but O
its O
use O
in O
Nigeria O
is O
still O
limited O
due O
its O
cost O
and O
clinicians O
inexperience O
with O
the O
drug O
. O
[]

Pain B-outcome ['Physiological-Clinical']
VAS O
and O
overall O
assessment O
of O
analgesia O
was O
similar O
between O
groups O
, O
although O
more O
side-effects O
( O
nausea B-outcome ['Physiological-Clinical']
, O
dizziness B-outcome ['Physiological-Clinical']
) O
were O
noted O
in O
the O
pethidine O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

It O
is O
reported O
about O
a O
synthetic O
secretin O
( O
Hoe O
069 O
+ O
depot O
component O
) O
given O
prophylactically O
to O
100 O
patients O
postoperatively O
. O
[]

Patients O
in O
arm O
B O
were O
given O
cisplatin O
and O
5-FU O
in O
the O
same O
dosage O
and O
schedule O
as O
in O
arm O
A O
. O
[]

Tumour B-outcome ['Physiological-Clinical']
marker I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
early O
during O
treatment O
provided O
modest O
predictive O
information O
for O
tumour O
response O
and O
survival O
. O
['Physiological-Clinical']

CONCLUSION O
The O
treatment O
of O
auditory O
integrative O
training O
( O
AIT O
) O
could O
greatly O
improve O
on O
language B-outcome ['Life-Impact']
disorders I-outcome ['Life-Impact']
, O
the O
difficulties O
of O
social B-outcome ['Life-Impact']
interactions I-outcome ['Life-Impact']
, O
typical B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
developmental B-outcome ['Life-Impact']
levels O
, O
therefore O
it O
is O
positive O
to O
the O
autistic O
children O
in O
its O
short-term O
treatment O
effect O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
midbuccal B-outcome ['Physiological-Clinical']
vertical I-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
for O
the O
PUT O
group O
was O
a O
loss O
of O
0.3+/-0.7 O
mm O
versus O
a O
gain O
of O
0.7+/-1.2 O
mm O
for O
the O
BDX O
group O
, O
a O
difference O
of O
1.0 O
mm O
( O
P O
> O
.05 O
) O
. O
['Physiological-Clinical']

Again O
we O
found O
the O
regime O
of O
4 O
g O
of O
cefotaxime O
given O
peri-operatively O
to O
be O
a O
simple O
, O
safe O
and O
effective O
single O
agent O
as O
prophylaxis O
for O
emergency B-outcome ['Resource-use']
abdominal I-outcome ['Resource-use']
surgery I-outcome ['Resource-use']
. O
['Resource-use']

The O
present O
study O
shows O
that O
cortical O
bone O
dimensions O
also O
benefit O
from O
GH O
treatment O
, O
with O
endosteal O
expansion O
and O
increased O
cortical O
thickness O
leading O
to O
improved O
bone B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
of O
losartan O
which O
is O
an O
antihypertensive O
drug O
with O
uricosuric O
properties O
vs. O
amlodipine O
in O
hypertensive O
neoplastic O
elderly O
patients O
. O
[]

Ex O
vivo O
protection O
from O
H O
( O
2 O
) O
O B-outcome ['Physiological-Clinical']
( O
2 O
) O
-induced O
DNA B-outcome ['Physiological-Clinical']
damage B-outcome ['Physiological-Clinical']
and O
endogenous B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
damage B-outcome ['Physiological-Clinical']
were O
evaluated O
in O
lymphocytes O
by O
means O
of O
the O
comet O
assay O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
therefore O
might O
provide O
a O
more O
appropriate O
frame O
of O
reference O
for O
interpretation O
of O
the O
[]

Questionnaires O
inquired O
about O
pain O
( O
visual O
analog O
scale O
( O
VAS O
) O
) O
, O
disability B-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
ODI I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
, O
health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
( O
15D O
Quality O
of O
Life O
Instrument B-outcome ['Physiological-Clinical']
) O
, O
satisfaction B-outcome ['Life-Impact']
with O
care O
, O
and O
costs B-outcome ['Resource-use']
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

OBJECTIVE O
To O
compare O
the O
fracture B-outcome ['Physiological-Clinical']
resistances I-outcome ['Physiological-Clinical']
of O
pulpless O
teeth O
restored O
with O
FRC O
( O
Fiber O
Reinforced O
Composite O
) O
posts O
and O
three O
kinds O
of O
resin O
core O
material O
. O
['Physiological-Clinical']

Comparison O
of O
participants O
who O
remained O
on O
placebo O
continued O
beyond O
the O
run-in O
period O
to O
the O
end O
of O
the O
study O
. O
[]

Transcutaneous O
electrical O
nerve O
stimulation O
after O
thoracotomy O
. O
[]

In O
addition O
, O
rHuEPO-treated O
patients O
experienced O
a O
statistically O
significant O
improvement O
in O
energy B-outcome ['Life-Impact']
level I-outcome ['Life-Impact']
and O
ability B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
perform I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
( O
P O
< O
or O
= O
.05 O
) O
. O
['Life-Impact', 'Life-Impact']

The O
primary O
outcome O
was O
pain-specific O
brain O
activity O
evoked O
by O
one O
time-locked O
heel O
lance O
, O
recorded O
with O
electroencephalography O
and O
identified O
by O
principal O
component O
analysis O
. O
[]

RESULTS O
None O
of O
the O
41 O
patients O
exhibited O
heterozygous B-outcome ['Physiological-Clinical']
or O
homozygous B-outcome ['Physiological-Clinical']
M66I I-outcome ['Physiological-Clinical']
and O
R492W B-outcome ['Physiological-Clinical']
variant I-outcome ['Physiological-Clinical']
alleles I-outcome ['Physiological-Clinical']
, O
or O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
estimates O
, O
however O
, O
are O
influenced O
by O
the O
degree O
to O
which O
the O
dose O
of O
exogenous O
insulin O
is O
greater O
than O
the O
physiologic O
response O
to O
a O
glucose O
load O
. O
[]

Each O
treatment O
was O
directly O
applied O
to O
the O
suture O
line O
after O
confirmation O
of O
anastomotic O
bleeding O
. O
[]

CONCLUSION O
Compared O
with O
usual O
care O
plus O
written O
education O
, O
pharmaceutical O
care O
focused O
on O
patient O
evaluation O
and O
follow-up O
in O
collaboration O
with O
physicians O
improved O
the O
achievement O
of O
BP B-outcome ['Physiological-Clinical']
, O
TC B-outcome ['Physiological-Clinical']
, O
and O
BP/TC B-outcome ['Physiological-Clinical']
treatment O
goals O
in O
patients O
with O
CVD O
and/or O
high O
or O
intermediate O
CV O
risk O
attending O
community O
pharmacies O
in O
Spain O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Granulocyte-macrophage O
colony-stimulating O
factor O
treatment O
before O
doxorubicin O
and O
cyclophosphamide O
chemotherapy O
priming O
in O
women O
with O
early-stage O
breast O
cancer O
. O
[]

0.4 O
) O
years O
who O
had O
been O
anaesthetised O
with O
either O
propofol/alfentanil/N2O O
or O
thiopentone/halothane/N2O O
. O
[]

Having O
utilized O
ROCA O
in O
PLCO O
would O
not O
have O
led O
to O
a O
significant O
mortality B-outcome ['Mortality']
benefit O
of O
screening O
. O
['Mortality']

[ O
Clinical O
study O
of O
the O
efficacy O
of O
and O
tolerance O
to O
nimesulide O
in O
suppository O
formulation O
in O
pain-inflammatory O
pathologies O
of O
the O
ear O
, O
nose O
, O
and O
throat O
] O
. O
[]

Immediately O
before O
and O
after O
the O
five O
treatment O
sessions O
and O
7 O
days O
after O
treatment O
ended O
, O
both O
patient O
and O
physician O
measured O
the O
degree O
of O
pain B-outcome ['Physiological-Clinical']
using O
a O
categoric O
scale O
( O
no O
pain O
, O
slight O
pain O
, O
intermediate O
pain O
, O
strong O
pain O
, O
and O
very O
strong O
pain O
) O
and O
evaluated O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
using O
the O
Scott O
and O
Huskisson O
Visual O
Analogue O
Scale O
( O
VAS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
AND O
RESULTS O
The O
Japanese O
Rhythm O
Management O
Trial O
II O
for O
Atrial O
Fibrillation O
( O
J-RHYTHM O
II O
study O
) O
is O
an O
open-label O
randomized O
comparison O
between O
an O
ARB O
( O
candesartan O
) O
and O
a O
CCB O
( O
amlodipine O
) O
in O
the O
treatment O
of O
paroxysmal O
AF O
associated O
with O
hypertension O
. O
[]

Stoppage B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
occurred O
more O
often O
with O
combination O
treatment O
than O
with O
lignocaine O
alone O
. O
['Physiological-Clinical']

The O
insertion B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
scope I-outcome ['Life-Impact']
was O
easier O
via O
the O
oral O
route O
, O
as O
reflected O
in O
a O
shorter O
examination B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
( O
mean O
165 O
vs. O
210 O
seconds O
, O
p O
= O
0.017 O
) O
and O
patients O
' O
tolerance O
for O
the O
scope O
insertion B-outcome ['Physiological-Clinical']
( O
mean O
score O
: O
8 O
for O
oral O
vs. O
4 O
for O
nasal O
route O
; O
p O
= O
0.03 O
) O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

VZV O
IFN-? O
ELISPOT O
geometric O
mean O
count O
( O
GMC O
) O
of O
spot-forming O
cells O
per O
10 O
( O
6 O
) O
peripheral O
blood O
mononuclear O
cells O
increased O
in O
the O
ZV O
group O
from O
16.9 O
prevaccination O
to O
49.5 O
and O
32.8 O
at O
2 O
and O
6 O
weeks O
postdose O
1 O
, O
respectively O
. O
[]

Costs B-outcome ['Resource-use']
data I-outcome ['Resource-use']
were O
combined O
with O
quality O
adjusted O
life O
years O
( O
QALYs O
) O
to O
obtain O
the O
incremental O
costs O
per O
QALY O
. O
['Resource-use']

5-HTTLPR O
may O
influence O
the O
individual O
responses O
to O
fluvoxamine O
administration O
. O
[]

Respiratory B-outcome ['Physiological-Clinical']
variables I-outcome ['Physiological-Clinical']
remained O
almost O
unchanged O
in O
both O
groups O
. O
['Physiological-Clinical']

RESULTS O
Eighty O
patients O
entered O
the O
study O
. O
[]

METHODOLOGY O
A O
total O
of O
48 O
patients O
with O
acute O
upper O
gastrointestinal O
bleeding O
due O
to O
duodenal O
or O
gastric O
ulcer O
were O
divided O
into O
2 O
groups O
. O
[]

CONCLUSION O
Paliperidone O
extended-release O
tablets O
are O
effective O
to O
improve O
social O
functions O
and O
psychiatric O
symptoms O
of O
schizophrenics O
. O
[]

In O
1,002 O
men O
aged O
45-80 O
y O
, O
81 O
% O
of O
the O
cancers O
detectable O
by O
serum B-outcome ['Physiological-Clinical']
prostate-specific I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
digital B-outcome ['Physiological-Clinical']
rectal I-outcome ['Physiological-Clinical']
examination I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DRE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
transrectal B-outcome ['Resource-use']
ultrasonography I-outcome ['Resource-use']
( I-outcome ['Resource-use']
TRUS I-outcome ['Resource-use']
) I-outcome ['Resource-use']
were O
present O
in O
a O
subpopulation O
( O
19 O
% O
of O
total O
) O
identified O
by O
serum O
PSA O
above O
the O
threshold O
value O
of O
3.0 O
micrograms/L O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

To O
examine O
a O
role O
for O
adenosine O
A O
( O
2A O
) O
receptors O
, O
we O
investigated O
whether O
variation O
of O
the O
A O
( O
2A O
) O
receptor O
gene O
( O
ADORA2A O
) O
modified O
effects O
of O
caffeine O
on O
PVT B-outcome ['Physiological-Clinical']
and O
SWA B-outcome ['Physiological-Clinical']
after O
sleep O
deprivation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Secondary O
end O
points O
included O
treatment O
duration O
, O
hematologic B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
, O
and O
clinical B-outcome ['Physiological-Clinical']
outcome O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Forty-seven O
patients O
( O
49 O
feet O
) O
with O
a O
previously O
unsuccessful O
nonsurgical O
treatment O
of O
at O
least O
6 O
months O
were O
randomized O
to O
two O
groups O
. O
[]

The O
Fogarty O
balloon O
has O
been O
inflated O
in O
case O
of O
bleeding O
. O
[]

The O
authors O
investigated O
the O
effect O
of O
altering O
central O
cholinergic O
transmission O
, O
by O
physostigmine O
and O
scopolamine O
, O
on O
unconsciousness O
produced O
by O
propofol O
. O
[]

Benefit O
of O
FSH O
priming O
of O
women O
with O
PCOS O
to O
the O
in O
vitro O
maturation O
procedure O
and O
the O
outcome O
: O
a O
randomized O
prospective O
study O
. O
[]

The O
study O
design O
included O
also O
an O
endocrine O
work-up O
aimed O
to O
study O
the O
hypothalamic-pituitary-adrenal B-outcome ['Physiological-Clinical']
axis I-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
UFC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
0800 I-outcome ['Physiological-Clinical']
h I-outcome ['Physiological-Clinical']
, O
plasma B-outcome ['Physiological-Clinical']
ACTH I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
0800 I-outcome ['Physiological-Clinical']
h I-outcome ['Physiological-Clinical']
, O
morning B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
overnight I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
mg I-outcome ['Physiological-Clinical']
dexamethasone I-outcome ['Physiological-Clinical']
] O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
home O
TEACCHing O
program O
for O
toddlers O
with O
autism O
. O
[]

All O
three O
groups O
of O
children O
showed O
some O
improvement O
in O
oral B-outcome ['Physiological-Clinical']
hygiene I-outcome ['Physiological-Clinical']
and O
in O
gingival B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
, O
but O
there O
were O
no O
significant O
differences O
between O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Zoledronic O
acid O
( O
4 O
mg O
) O
was O
administered O
via O
a O
15-minute O
infusion O
every O
3 O
or O
4 O
weeks O
for O
12 O
infusions O
. O
[]

The O
primary O
outcome O
measure O
involved O
identifying O
those O
tests O
, O
if O
any O
, O
where O
simulators O
were O
significantly O
different O
from O
normal O
and O
memory-impaired O
participants O
. O
[]

Uric O
acid O
levels O
were O
lowered O
with O
high O
doses O
. O
[]

Leptin B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
did O
not O
differ O
among O
treatments O
and O
were O
2.15 O
+/- O
0.75 O
, O
1.88 O
+/- O
0.76 O
, O
and O
1.91 O
+/- O
0.75 O
ng/mL O
for O
control O
, O
POST O
, O
and O
PRE O
cows O
, O
respectively O
. O
['Physiological-Clinical']

CONCLUSION O
TIOSPIR O
will O
provide O
precise O
estimates O
of O
the O
relative O
safety O
and O
efficacy O
of O
the O
Respimat O
and O
HandiHaler O
formulations O
of O
tiotropium O
, O
assess O
potential O
dose-dependence O
of O
important O
outcomes O
and O
provide O
information O
on O
the O
clinical O
epidemiology O
of O
COPD O
in O
a O
large O
international O
patient O
cohort O
. O
[]

Of O
all O
the O
risperidone O
responders O
( O
n=65 O
) O
, O
63 O
entered O
an O
open O
extension O
of O
another O
16 O
weeks O
( O
6 O
months O
total O
risperidone O
exposure O
) O
, O
and O
32 O
of O
them O
were O
rerandomized O
to O
either O
continued O
risperidone O
therapy O
( O
n=16 O
) O
or O
gradual O
replacement O
with O
placebo O
( O
n=16 O
) O
over O
8 O
weeks O
. O
[]

Patients O
were O
allocated O
at O
random O
to O
receive O
a O
daily O
bedtime O
dose O
of O
either O
1 O
ketoprofen O
tablet O
or O
1 O
indomethacin O
suppository O
plus O
the O
dummy O
of O
the O
other O
formulation O
for O
a O
period O
of O
3 O
weeks O
. O
[]

In O
a O
prospective O
controlled O
study O
, O
involving O
42 O
patients O
subdivided O
into O
four O
groups O
namely O
, O
higher O
or O
lower O
insufflation O
pressures O
, O
chemically O
inert O
insufflation O
gas O
and O
control O
groups O
; O
the O
use O
of O
analgetics B-outcome ['Resource-use']
, O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
operation B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
, O
amount O
of O
insufflated B-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
, O
intraperitoneal B-outcome ['Physiological-Clinical']
pH-values I-outcome ['Physiological-Clinical']
and O
post-operative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
in O
the O
various O
subgroups O
were O
compared O
to O
each O
other O
with O
regard O
to O
post-operative O
pain O
perception O
. O
['Resource-use', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

In O
addition O
, O
four O
cases O
describing O
unusual O
effects O
found O
in O
a O
sample O
of O
170 O
patients O
treated O
with O
fenfluramine O
are O
also O
reported O
. O
[]

Eight O
horses O
received O
3 O
injections O
( O
Weeks O
0 O
, O
3 O
, O
6 O
) O
of O
MIA O
( O
2 O
mL O
; O
60 O
mg/mL O
) O
into O
the O
right O
or O
left O
front O
PIJ O
. O
[]

The O
aim O
of O
the O
study O
was O
to O
determine O
whether O
a O
home-based O
programme O
provided O
over O
12 O
months O
resulted O
in O
sustained O
improvement O
in O
development B-outcome ['Life-Impact']
and O
behaviour B-outcome ['Life-Impact']
12 O
months O
after O
the O
intervention O
ceased O
. O
['Life-Impact', 'Life-Impact']

It O
is O
encouraging O
that O
children O
with O
autism O
show O
a O
strong O
response O
to O
early O
intervention O
, O
yet O
more O
research O
is O
needed O
for O
understanding O
the O
variability O
in O
responsiveness O
to O
specialized O
programs O
. O
[]

The O
incidence O
of O
stroke O
increases O
exponentially O
with O
age O
, O
yet O
, O
traditionally O
, O
many O
medical O
practitioners O
have O
been O
reluctant O
to O
treat O
hypertension O
in O
older O
patients O
. O
[]

Outcome O
measures O
include O
the O
completion B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
theory I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
mind I-outcome ['Life-Impact']
and O
emotion B-outcome ['Life-Impact']
understanding I-outcome ['Life-Impact']
tasks I-outcome ['Life-Impact']
, O
and O
parent O
and O
teacher O
questionnaires O
on O
children O
's O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Preliminary O
data O
from O
a O
randomized O
study O
of O
the O
effectiveness O
of O
combined O
marital O
therapy O
and O
antidepressant O
medication O
in O
the O
treatment O
of O
dysthymic O
married O
women O
is O
presented O
. O
[]

In O
addition O
, O
L74V O
, O
when O
combined O
with O
K103N+L100I O
, O
may O
confer O
a O
selective O
advantage O
to O
the O
virus O
that O
is O
independent O
of O
its O
effects O
on O
nucleoside B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Apart O
from O
the O
dialyzer O
, O
the O
dialysis O
prescription O
remained O
unchanged O
. O
[]

Histologic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
chronicity B-outcome ['Physiological-Clinical']
indexes I-outcome ['Physiological-Clinical']
were O
determined O
in O
renal O
biopsies O
performed O
at O
trial O
entry O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Results O
indicate O
that O
both O
intervention O
groups O
improved O
significantly O
over O
the O
control O
group O
on O
certain O
behaviors O
. O
[]

69 O
patients O
were O
treated O
over O
a O
2 O
weeks O
course O
of O
therapy O
. O
[]

Seizure B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
was O
assessed O
by O
electroencephalographic O
criteria O
. O
['Physiological-Clinical']

BACKGROUND O
Amantadine O
hydrochloride O
and O
pemoline O
, O
both O
frequently O
used O
to O
treat O
the O
fatigue O
of O
multiple O
sclerosis O
( O
MS O
) O
, O
may O
also O
improve O
attention O
and O
other O
cognitive O
functions O
in O
MS. O
To O
our O
knowledge O
, O
these O
agents O
have O
never O
been O
compared O
in O
a O
placebo-controlled O
trial O
of O
patients O
with O
MS O
. O
[]

A O
second O
dose O
of O
ipratropium O
did O
not O
result O
in O
a O
further O
significant O
increase O
in O
FEV1 O
. O
[]

Nurses O
took O
156 O
s O
to O
start O
infusions O
when O
using O
pre-filled O
syringes O
compared O
with O
276 O
s O
when O
preparing O
them O
de O
novo O
, O
a O
mean O
delay O
of O
106 O
s O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
73-140 O
s O
, O
P O
< O
0.0001 O
] O
. O
[]

SETTING O
Colposcopy O
clinic O
at O
Aberdeen O
Royal O
Infirmary O
. O
[]

Models O
were O
run O
including O
and O
excluding O
CCT O
. O
[]

RESULTS O
Twenty-six O
patients O
were O
included O
in O
the O
study O
. O
[]

This O
was O
a O
prospective O
randomized O
clinical O
trial O
conducted O
in O
the O
Department O
of O
Orthodontics O
at O
the O
University O
of O
Florida O
between O
1990 O
and O
2003 O
. O
[]

This O
study O
should O
be O
repeated O
on O
a O
larger O
sample O
. O
[]

Logistic O
regression O
modeling O
for O
death O
was O
used O
to O
categorize O
patients O
into O
low- O
, O
medium- O
, O
and O
high-risk O
groups O
. O
[]

Two O
three-minute O
periods O
of O
spontaneous B-outcome ['Physiological-Clinical']
EEG I-outcome ['Physiological-Clinical']
were O
recorded O
before O
the O
capsule O
and O
before O
and O
after O
gum O
chewing O
from O
bipolar O
electrode O
montages O
at O
the O
following O
positions O
: O
Cz-T5 O
, O
Cz-T6 O
, O
Cz-F7 O
and O
Cz-F8 O
. O
['Physiological-Clinical']

CPRS O
rating O
data O
were O
analyzed O
for O
19 O
schizophrenic O
children O
, O
16 O
males O
and O
3 O
females O
, O
mean O
age O
8.9 O
years O
( O
range O
5.5-11.7 O
) O
, O
evaluated O
in O
a O
double-blind O
, O
placebo-controlled O
crossover O
study O
of O
haloperidol O
. O
[]

RESULTS O
For O
the O
primary O
end O
point O
, O
mean O
+/- O
sd O
maximum O
negative O
intrathoracic B-outcome ['Physiological-Clinical']
pressures B-outcome ['Physiological-Clinical']
( O
mm O
Hg O
) O
during O
the O
decompression O
phase O
of O
cardiopulmonary B-outcome ['Physiological-Clinical']
resuscitation I-outcome ['Physiological-Clinical']
were O
-1.0 O
+/- O
0.73 O
mm O
Hg O
with O
a O
sham O
vs. O
-4.6 O
+/- O
3.7 O
mm O
Hg O
with O
an O
active O
ITD O
on O
the O
facemask O
( O
p O
= O
.003 O
) O
and O
-1.3 O
+/- O
1.3 O
mm O
Hg O
with O
a O
sham O
ITD O
vs. O
-7.3 O
+/- O
4.5 O
mm O
Hg O
with O
an O
active O
ITD O
on O
an O
ETT O
( O
p O
= O
.0009 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
all O
, O
664 O
completed O
questionnaires O
were O
returned O
, O
giving O
a O
response O
rate O
of O
67.8 O
% O
. O
[]

Epidemiological O
studies O
suggest O
that O
children O
living O
in O
homes O
with O
unvented O
heating O
sources O
are O
more O
prone O
to O
respiratory O
infections O
than O
children O
living O
in O
homes O
with O
lower O
levels O
of O
NO2 O
. O
[]

Although O
adjunctive O
intravenous O
streptokinase O
therapy O
did O
not O
improve O
outcome O
, O
it O
did O
complicate O
the O
hospital O
course O
. O
[]

CONCLUSION O
It O
is O
suggested O
that O
these O
two O
tests O
, O
when O
administered O
jointly O
, O
might O
be O
of O
use O
in O
clinical O
settings O
to O
assist O
in O
the O
detection O
of O
malingerers O
. O
[]

Many O
investigations O
support O
the O
view O
that O
a O
number O
of O
key O
processes O
in O
atherosclerosis O
may O
be O
influenced O
by O
CCBs O
. O
[]

However O
for O
distal O
ureteric O
stones O
, O
the O
addition O
of O
diuresis O
during O
ESWL O
was O
associated O
with O
a O
lower O
mean O
number O
of O
ESWL B-outcome ['Resource-use']
sessions I-outcome ['Resource-use']
and O
shocks B-outcome ['Physiological-Clinical']
per O
stone O
compared O
with O
standard O
ESWL O
: O
1.38 O
and O
4950 O
for O
ESWL O
with O
diuresis O
compared O
with O
2.9 O
and O
8544 O
for O
standard O
ESWL O
respectively O
. O
['Resource-use', 'Physiological-Clinical']

Weight O
and O
leptin B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
among O
risperidone-treated O
youths O
with O
autism O
: O
6-month O
prospective O
data O
. O
['Physiological-Clinical']

CONCLUSIONS O
In O
low-risk O
, O
exercising O
women O
, O
a O
diagnostic O
strategy O
that O
uses O
ETT O
versus O
exercise O
MPI O
yields O
similar O
2-year O
posttest O
outcomes O
while O
providing O
significant O
diagnostic O
cost O
savings O
. O
[]

Pacing B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
highly O
correlated O
with O
minute O
ventilation B-outcome ['Life-Impact']
( O
r O
= O
0.89 O
) O
, O
respiratory B-outcome ['Physiological-Clinical']
quotient B-outcome ['Physiological-Clinical']
( O
r O
= O
0.89 O
) O
, O
VCO2 B-outcome ['Physiological-Clinical']
( O
r O
= O
0.87 O
) O
, O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( O
r O
= O
0.87 O
) O
, O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Eligibility O
included O
localized O
prostate O
cancer O
with O
an O
elevated O
prostate-specific O
antigen O
( O
PSA O
) O
< O
or O
= O
100 O
ng/mL O
and O
an O
estimated O
risk O
of O
lymph O
node O
( O
LN O
) O
involvement O
of O
15 O
% O
. O
[]

The O
rats O
of O
treated O
and O
control O
groups O
were O
necropsied O
on O
the O
24th O
day O
after O
the O
treatment O
. O
[]

The O
effect O
of O
splinting O
of O
teeth O
in O
combination O
with O
reconstructive O
periodontal O
surgery O
in O
humans O
. O
[]

Management O
of O
unstable O
angina O
at O
rest O
by O
verapamil O
. O
[]

Compared O
to O
lowlanders O
at O
sea O
level O
and O
high O
altitude O
, O
highlanders O
had O
a O
lower O
carotid B-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
: O
lumen B-outcome ['Physiological-Clinical']
ratio O
( O
?19 O
% O
, O
P O
? O
['Physiological-Clinical', 'Physiological-Clinical']

kg-1 O
) O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

Multimodal O
evaluation O
of O
risperidone O
for O
destructive O
behavior O
: O
functional O
analysis O
, O
direct O
observations O
, O
rating O
scales O
, O
and O
psychiatric O
impressions O
. O
[]

We O
assigned O
patients O
to O
receive O
either O
EVAR O
( O
n=166 O
) O
or O
no O
intervention O
( O
n=172 O
) O
. O
[]

Antiarrhythmic O
efficacy O
of O
azimilide O
in O
patients O
with O
atrial O
fibrillation O
. O
[]

Cosmesis B-outcome ['Life-Impact']
was O
assessed O
by O
review O
of O
postoperative O
photographs O
by O
a O
blinded O
, O
independent O
plastic O
surgeon O
using O
the O
modified O
Hollander O
cosmesis O
score O
. O
['Life-Impact']

The O
naproxen B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
2 O
h O
after O
ingestion O
and O
the O
Cmax O
were O
higher O
on O
the O
second O
occasion O
, O
regardless O
of O
preparation O
, O
suggesting O
that O
the O
subjects O
were O
clinically B-outcome ['Physiological-Clinical']
different O
on O
the O
two O
occasions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

application O
of O
0.75 O
mg/kg O
exhibits O
pronounced O
antiischemic B-outcome ['Physiological-Clinical']
effects O
. O
['Physiological-Clinical']

35.3 O
cm/cm? O
in O
MECC O
group O
; O
P O
= O
.034 O
) O
. O
[]

50 O
tracings O
were O
presented O
twice O
to O
4 O
obstetricians O
in O
a O
double-blind O
manner O
. O
[]

We O
measured O
DR O
curves O
of O
PaO2/FIO2 B-outcome ['Physiological-Clinical']
versus O
the O
inhaled O
NO O
dose O
at O
regular O
intervals O
. O
['Physiological-Clinical']

METHODS O
We O
investigated O
the O
impact O
of O
dose O
and O
duration O
of O
parenteral O
amino O
acids O
, O
with O
cysteine O
, O
on O
acid-base O
parameters O
in O
122 O
low-birth-weight O
infants O
. O
[]

Three O
of O
five O
participants O
acquired O
word B-outcome ['Life-Impact']
production I-outcome ['Life-Impact']
within O
the O
DTT O
framework O
and O
achieved O
milestones O
of O
early B-outcome ['Life-Impact']
functional I-outcome ['Life-Impact']
spoken I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
( O
Tager-Flusberg O
et O
al. O
, O
J O
Speech O
Lang O
Hear O
Res O
52:643-652 O
, O
2009 O
) O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Serum B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
metrics I-outcome ['Physiological-Clinical']
were O
not O
associated O
with O
GCC B-outcome ['Physiological-Clinical']
, O
except O
for O
a O
potential O
n O
-shaped O
relationship O
with O
TIBC O
( O
global O
P O
= O
0.038 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Twelve O
patients O
preferred O
infiltration O
analgesia O
. O
[]

The O
results O
of O
this O
study O
suggest O
that O
indomethacin O
phonophoresis O
provides O
significant O
pain B-outcome ['Physiological-Clinical']
relieving O
effect O
over O
the O
TMJ O
pain O
. O
['Physiological-Clinical']

RESULTS O
All O
subjects O
showed O
improvements O
in O
affective B-outcome ['Life-Impact']
speech I-outcome ['Life-Impact']
comprehension I-outcome ['Life-Impact']
from O
pre- O
to O
post-infusion O
; O
however O
, O
whereas O
those O
who O
received O
placebo O
first O
tended O
to O
revert O
to O
baseline O
after O
a O
delay O
, O
those O
who O
received O
oxytocin O
first O
retained O
the O
ability O
to O
accurately O
assign O
emotional B-outcome ['Life-Impact']
significance O
to O
speech O
intonation B-outcome ['Life-Impact']
on O
the O
speech O
comprehension O
task O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

9 O
patients O
were O
classified O
as O
poor O
( O
7 O
had O
received O
placebo O
, O
1 O
low-dose O
, O
and O
1 O
high-dose O
) O
( O
p O
< O
0.001 O
) O
. O
[]

Induction O
chemotherapy O
in O
head O
and O
neck O
cancer O
: O
results O
of O
a O
phase O
III O
trial O
. O
[]

The O
contingency O
condition O
appeared O
to O
be O
a O
more O
effective O
way O
to O
facilitate O
a O
distal B-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
, O
whereas O
the O
imitative O
condition O
was O
a O
more O
effective O
way O
to O
facilitate O
a O
proximal B-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
( O
touching B-outcome ['Life-Impact']
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Increases O
in O
serum B-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
in O
men O
receiving O
dutasteride O
should O
be O
considered O
suspicious O
and O
serial O
PSA B-outcome ['Physiological-Clinical']
measurements O
should O
be O
used O
to O
evaluate O
changes O
from O
nadir O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
suggests O
that O
their O
dependence O
on O
chemotherapy O
to O
control O
parasite O
infections O
had O
failed O
. O
[]

Patients O
in O
the O
other O
3 O
groups O
showed O
negative O
parasitemias B-outcome ['Physiological-Clinical']
within O
7 O
days O
after O
treatment O
. O
['Physiological-Clinical']

The O
gain O
of O
sweating O
was O
well O
preserved O
indicating O
that O
this O
response O
remains O
effective O
in O
the O
presence O
of O
sedatives O
and O
anesthetics O
. O
[]

IEDs O
clustered O
in O
13 O
subjects O
( O
57 O
% O
) O
, O
whereas O
9 O
subjects O
( O
39 O
% O
) O
had O
EEGs O
consistently O
free O
of O
IEDs O
. O
[]

2 O
) O
Macroscopic O
diagnosis O
as O
being O
noncuratively O
resected O
on O
completion O
of O
the O
surgical O
procedure O
. O
[]

The O
10-year O
PFS O
rates O
were O
8.5 O
% O
and O
10.8 O
% O
, O
respectively O
. O
[]

Middle B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
velocities I-outcome ['Physiological-Clinical']
were O
measured O
by O
transcranial O
Doppler O
, O
and O
hemodynamics B-outcome ['Physiological-Clinical']
were O
measured O
by O
the O
thermodilution O
technique O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
sensitivity O
and O
specificity O
of O
the O
HBP O
method O
to O
classify O
correctly O
clinic O
reactors O
( O
ABP O
method O
used O
as O
the O
standard O
) O
were O
57 O
% O
and O
85 O
% O
, O
respectively O
, O
whereas O
its O
positive O
and O
negative O
predictive O
value O
were O
57 O
% O
and O
85 O
% O
. O
[]

METHODS O
333 O
consecutive O
adult O
patients O
with O
a O
suspected O
first O
acute O
myocardial O
infarction O
were O
randomly O
assigned O
in O
a O
1:1 O
ratio O
by O
computerised O
block O
randomisation O
to O
receive O
primary O
percutaneous O
coronary O
intervention O
with O
( O
n=166 O
patients O
) O
versus O
without O
( O
n=167 O
) O
remote O
conditioning O
( O
intermittent O
arm O
ischaemia O
through O
four O
cycles O
of O
5-min O
inflation O
and O
5-min O
deflation O
of O
a O
blood-pressure O
cuff O
) O
. O
[]

Clinical B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
at I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
adductor I-outcome ['Life-Impact']
pollicis I-outcome ['Life-Impact']
( O
AMG O
) O
was O
significantly O
longer O
( O
P O
< O
0.01 O
) O
for O
both O
rocuronium O
groups O
than O
for O
succinylcholine O
( O
T4 O
: O
T1 O
= O
0.7 O
, O
54 O
+/- O
18 O
and O
77 O
+/- O
21 O
vs O
8 O
+/- O
6 O
min O
) O
. O
['Life-Impact']

Although O
France O
has O
one O
of O
the O
most O
generous O
health O
and O
social O
care O
systems O
for O
infant O
and O
maternal O
well-being O
in O
the O
Western O
world O
, O
professionals O
have O
been O
increasingly O
concerned O
by O
the O
rising O
number O
of O
children O
being O
referred O
for O
mental O
health O
problems O
. O
[]

A O
blood O
patch O
was O
performed O
in O
36 O
( O
73.4 O
% O
) O
of O
patients O
in O
the O
therapeutic O
group O
. O
[]

LS O
retained O
in O
hospital O
for O
full O
nutritional O
rehabilitation O
mean O
40 O
days O
) O
. O
[]

Among O
184 O
patients O
, O
19 O
episodes O
of O
renal B-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
were O
noted O
, O
mostly O
owing O
to O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( O
e.g O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
in O
both O
groups O
, O
about O
two O
thirds O
of O
women O
continued O
to O
overestimate B-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
lifetime I-outcome ['Life-Impact']
risks I-outcome ['Life-Impact']
substantially O
following O
counseling O
. O
['Life-Impact']

Subjects O
completed O
an O
attentional B-outcome ['Life-Impact']
capture I-outcome ['Life-Impact']
task O
alone O
( O
single-task O
) O
or O
while O
engaged O
in O
a O
working O
memory O
task O
( O
dual-task O
) O
. O
['Life-Impact']

BACKGROUND O
Human O
rights O
legislation O
safeguards O
the O
privacy O
and O
dignity O
of O
patients O
. O
[]

Botulinum O
toxin O
A O
( O
BTX-A O
) O
produces O
prolonged O
muscle O
relaxation O
that O
is O
dose-dependent O
and O
can O
be O
easily O
targeted O
to O
affected O
muscles O
. O
[]

Clinician O
and O
patient B-outcome ['Life-Impact']
acceptance I-outcome ['Life-Impact']
, O
feasibility B-outcome ['Life-Impact']
, O
and O
technology B-outcome ['Life-Impact']
issues I-outcome ['Life-Impact']
were O
measured O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Masticatory B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
well I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
chewing I-outcome ['Physiological-Clinical']
experience I-outcome ['Physiological-Clinical']
were O
substantially O
better O
for O
the O
implant-retained O
overdentures O
compared O
with O
the O
complete O
denture O
group O
. O
['Physiological-Clinical']

We O
tested O
the O
hypothesis O
that O
the O
ITD O
could O
lower O
intratracheal O
pressures O
when O
attached O
to O
either O
a O
facemask O
or O
ETT O
. O
[]

Patients O
with O
writer O
's O
cramp O
exhibited O
greater O
absolute O
timing O
error O
compared O
with O
control O
subjects O
in O
the O
human O
body O
motion O
task O
( O
whereas O
no O
difference O
was O
observed O
in O
the O
inanimate O
object O
motion O
task O
) O
. O
[]

ADS O
quartiles O
differed O
significantly O
on O
proportion O
with O
DSM-IV O
physiological B-outcome ['Life-Impact']
dependence I-outcome ['Life-Impact']
, O
but O
AUROC O
curves O
indicated O
that O
the O
ADS O
had O
limited O
accuracy O
as O
a O
continuous O
measure O
to O
detect O
DSMIV O
physiological B-outcome ['Life-Impact']
dependence I-outcome ['Life-Impact']
( O
AUROC O
= O
.75 O
[ O
95 O
% O
confidence O
interval O
{ O
CI O
} O
: O
.70-.79 O
] O
and O
.67 O
[ O
95 O
% O
CI O
: O
.60-.74 O
] O
for O
men O
and O
women O
, O
respectively O
; O
p O
= O
.08 O
) O
or O
withdrawal O
alone O
( O
AUROC O
= O
.77 O
[ O
95 O
% O
CI O
: O
.74-.80 O
] O
and O
.74 O
[ O
95 O
% O
CI O
: O
.69-.79 O
] O
for O
men O
and O
women O
, O
respectively O
; O
p O
= O
.30 O
) O
. O
['Life-Impact', 'Life-Impact']

Fifty-eight O
patients O
were O
randomized O
to O
treatment O
with O
atorvastatin O
( O
n=28 O
) O
or O
simvastatin O
( O
n=30 O
) O
for O
1 O
year O
. O
[]

In O
the O
placebo O
group O
, O
significant O
increases O
in O
QTcb B-outcome ['Physiological-Clinical']
, O
QTcf B-outcome ['Physiological-Clinical']
and O
QTcF O
values O
were O
observed O
after O
intubation O
compared O
to O
either O
control O
measurements O
or O
to O
comparative O
measurements O
in O
the O
lidocaine O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
benefit O
of O
combined O
mechanical O
and O
pharmacologic O
methods O
for O
venous B-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
prevention O
after O
abdominal O
surgery O
has O
not O
been O
clearly O
established O
. O
['Physiological-Clinical']

DESIGN O
Randomized O
, O
single-blinded O
, O
placebo-controlled O
study O
. O
[]

The O
mean O
number/hr O
. O
[]

Enteric-coating O
( O
Entrox O
) O
, O
which O
improves O
stability O
of O
omega-3 O
capsules O
, O
has O
been O
shown O
to O
facilitate O
fish O
oil O
absorption O
after O
chronic O
treatment O
. O
[]

Residual O
platelet O
reactivity O
, O
bleedings O
, O
and O
adherence O
to O
treatment O
in O
patients O
having O
coronary O
stent O
implantation O
treated O
with O
prasugrel O
. O
[]

In O
addition O
, O
medical O
review O
showed O
an O
improvement O
on O
the O
Hand B-outcome ['Life-Impact']
Apraxia I-outcome ['Life-Impact']
Scale O
for O
a O
higher O
proportion O
of O
girls O
on O
L-carnitine O
. O
['Life-Impact']

We O
report O
two O
studies O
focusing O
on O
the O
treatment O
process O
and O
the O
dropout O
rate O
of O
children B-outcome ['Physiological-Clinical']
with O
persistent O
conduct O
problems O
presenting O
to O
a O
community O
mental O
health O
service O
, O
using O
a O
prospective O
design O
. O
['Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
ascorbic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
levels O
were O
higher O
in O
the O
vitamin O
group O
24 O
to O
26 O
hours O
after O
supplementation O
( O
1.28 O
versus O
1.04 O
mg O
per O
100 O
ml O
, O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

Bone B-outcome ['Physiological-Clinical']
levels O
were O
recorded O
on O
radiographs O
taken O
prior O
to O
the O
start O
of O
the O
study O
, O
and O
after O
6 O
months O
. O
['Physiological-Clinical']

CONCLUSIONS O
Disposition B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
rocuronium I-outcome ['Physiological-Clinical']
was O
similar O
under O
stable O
N2O-fentanyl O
and O
N2O-sevoflurane O
anesthesia O
. O
['Physiological-Clinical']

OBJECTIVE O
This O
study O
expanded O
upon O
previous O
work O
on O
naltrexone O
efficacy O
and O
safety O
in O
young O
autistic O
children O
and O
assessed O
performance O
on O
learning O
measures O
. O
[]

The O
effects O
of O
peer O
counseling O
on O
smoking O
cessation B-outcome ['Life-Impact']
and O
reduction O
. O
['Life-Impact']

PURPOSE O
Nearly O
2000 O
patients O
with O
stage O
IIB O
and O
III O
melanoma O
have O
participated O
in O
four O
multicenter O
, O
randomized O
trials O
, O
conducted O
by O
the O
Eastern O
Cooperative O
Oncology O
Group O
and O
the O
Intergroup O
, O
investigating O
adjuvant O
high-dose O
IFN-alpha O
2b O
therapy O
. O
[]

5-HTTLPR O
( O
long O
( O
l O
) O
or O
short O
( O
s O
) O
) O
, O
was O
analyzed O
by O
the O
PCR O
method O
. O
[]

At O
the O
18-month O
follow-up O
, O
two O
patients O
in O
group O
A O
and O
only O
one O
in O
groups O
B O
and O
C O
maintained O
the O
response O
. O
[]

CONCLUSIONS O
Mitral O
surgery O
produces O
an O
atrial O
postoperative O
volume O
that O
decrease O
especially O
when O
reduction O
techniques O
are O
employed O
. O
[]

Both O
fenoterol O
( O
delta O
FEV1 O
34 O
percent O
, O
p O
less O
than O
0.0001 O
) O
and O
the O
combination O
regimen O
( O
delta O
FEV1 O
38 O
percent O
, O
p O
less O
than O
0.0001 O
) O
resulted O
in O
a O
significantly O
larger O
increase O
in O
FEV1 B-outcome ['Physiological-Clinical']
than O
ipratropium O
alone O
( O
delta O
FEV1 O
17 O
percent O
, O
p O
less O
than O
0.0001 O
) O
. O
['Physiological-Clinical']

Bone B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
was O
measured O
weekly O
by O
quantitative O
ultrasound O
measurement O
of O
tibial B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
speed I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sound I-outcome ['Physiological-Clinical']
( O
SOS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTERVENTIONS O
Twelve O
weeks O
of O
treatment O
with O
citalopram O
( O
10 O
mg/5 O
mL O
) O
or O
placebo O
. O
[]

Standard O
versus O
newer O
antibacterial O
agents O
in O
the O
treatment O
of O
severe O
acute O
exacerbation O
of O
chronic O
obstructive O
pulmonary O
disease O
: O
a O
randomized O
trial O
of O
trimethoprim-sulfamethoxazole O
versus O
ciprofloxacin O
. O
[]

Overall O
, O
sublingual O
fentanyl O
ODT O
was O
well-tolerated B-outcome ['Life-Impact']
both O
systemically O
and O
sublingually O
, O
with O
41 O
patients O
experiencing O
> O
or O
=1 O
study O
['Life-Impact']

Efficacy O
and O
safety O
of O
de O
novo O
or O
early O
everolimus O
with O
low O
cyclosporine O
in O
deceased-donor O
kidney O
transplant O
recipients O
at O
specified O
risk O
of O
delayed O
graft O
function O
: O
12-month O
results O
of O
a O
randomized O
, O
multicenter O
trial O
. O
[]

RESULTS O
In O
the O
pooled O
series O
, O
ORR B-outcome ['Physiological-Clinical']
was O
33 O
% O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
27 O
% O
-39 O
% O
) O
. O
['Physiological-Clinical']

A O
significant O
number O
of O
new B-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
were O
heard O
in O
the O
home O
environment O
for O
the O
MBCT O
group O
( O
p O
= O
.04 O
) O
. O
['Life-Impact']

METHODS O
A O
systematic O
search O
of O
the O
literature O
was O
carried O
out O
from O
1985 O
to O
October O
1997 O
for O
randomized O
controlled O
trials O
of O
isoniazid O
prophylaxis O
in O
HIV-infected O
persons O
. O
[]

4.6 O
kg/m O
( O
2 O
) O
) O
with O
normal O
lipid O
and O
inflammatory O
markers O
. O
[]

Stratified O
block O
randomization O
is O
used O
for O
the O
psychiatric O
diagnosis O
of O
ICD-10 O
, O
F1 O
. O
[]

Women O
aged O
50 O
to O
80 O
years O
received O
raloxifene O
for O
96 O
weeks O
and O
were O
then O
randomized O
to O
continue O
raloxifene O
( O
group O
1 O
, O
n=20 O
) O
or O
placebo O
( O
group O
2 O
, O
n=20 O
) O
for O
a O
further O
96 O
weeks O
. O
[]

At O
baseline O
, O
at O
the O
end O
of O
the O
treatment O
, O
and O
after O
a O
2-month O
follow-up O
, O
clinical O
findings O
were O
assessed O
according O
to O
the O
Dover O
classification O
scale O
for O
photoaging O
and O
by O
biophysical B-outcome ['Physiological-Clinical']
and O
ecographic B-outcome ['Physiological-Clinical']
measurements O
. O
['Physiological-Clinical']

Overall O
, O
both O
primiparous O
and O
multiparous O
women O
who O
had O
intact O
perineums O
after O
VB O
had O
less O
dyspareunia B-outcome ['Physiological-Clinical']
than O
those O
undergoing O
CS O
( O
VB O
26.2 O
, O
CS O
40.7 O
% O
) O
. O
['Physiological-Clinical']

The O
authors O
suggest O
that O
the O
true O
result O
lies O
somewhere O
in O
the O
middle O
, O
with O
the O
trial O
dressing O
likely O
to O
be O
as O
effective O
as O
, O
but O
not O
more O
effective O
than O
, O
a O
standard O
dressing O
. O
[]

4.0 O
vs O
9.3 O
? O
[]

Classic O
sternal O
approximation O
with O
stainless O
steel O
wires O
may O
not O
be O
the O
ideal O
approach O
in O
patients O
predisposed O
to O
these O
complications O
. O
[]

BACKGROUND O
AND O
AIMS O
Inflammation O
may O
be O
one O
mediating O
mechanism O
for O
cardiovascular O
diseases O
in O
obstructive O
sleep O
apnea O
( O
OSA O
) O
. O
[]

Of O
the O
62 O
patients O
who O
entered O
the O
study O
, O
51 O
were O
considered O
evaluable O
( O
24 O
with O
adjuvant O
hormone O
therapy O
and O
27 O
with O
no O
further O
treatment O
) O
. O
[]

In O
the O
treatment O
of O
periodontal O
infections O
with O
systemic O
antimicrobial O
agents O
, O
in O
situations O
where O
the O
efficacy O
of O
the O
antimicrobial O
agent O
is O
being O
evaluated O
, O
non-compliance O
could O
underestimate O
the O
true O
efficacy O
of O
the O
agent O
. O
[]

CONCLUSIONS O
Naltrexone O
was O
associated O
with O
modest O
improvement O
of O
behavior B-outcome ['Life-Impact']
in O
11 O
of O
24 O
children O
, O
but O
learning B-outcome ['Life-Impact']
did O
not O
improve O
. O
['Life-Impact', 'Life-Impact']

Significantly O
fewer O
patients O
( O
seven O
per O
cent O
versus O
29 O
per O
cent O
, O
p O
= O
0.04 O
) O
in O
the O
ofloxacin O
group O
had O
active O
disease B-outcome ['Physiological-Clinical']
at O
the O
end O
of O
the O
two-week O
treatment O
. O
['Physiological-Clinical']

The O
median O
was O
3 O
mg/min O
at O
onset O
and O
2.45 O
mg/min O
after O
2 O
months O
treatment O
with O
the O
placebo O
. O
[]

Clozapine O
had O
no O
beneficial O
effect O
on O
chorea B-outcome ['Physiological-Clinical']
in O
patients O
already O
receiving O
neuroleptic O
medication O
. O
['Physiological-Clinical']

Patients O
in O
the O
conventional O
treatment O
group O
( O
n=119 O
) O
were O
not O
given O
insulin O
unless O
glucose B-outcome ['Physiological-Clinical']
levels O
were O
greater O
than O
11.1 O
m O
mol/l O
( O
200mg/dl O
) O
. O
['Physiological-Clinical']

Propranolol O
and O
atenolol O
did O
not O
significantly O
influence O
insulin B-outcome ['Physiological-Clinical']
binding I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
erythrocytes I-outcome ['Physiological-Clinical']
, O
but O
they O
clearly O
reduced O
the O
glucose B-outcome ['Physiological-Clinical']
disappearance I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
KITT I-outcome ['Physiological-Clinical']
was O
compared O
to O
placebo O
( O
p O
= O
0.0036 O
and O
p O
= O
0.0003 O
) O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
all O
other O
pain O
outcomes O
and O
length O
of O
treatment O
, O
there O
was O
a O
trend O
for O
lower O
pain B-outcome ['Physiological-Clinical']
scores O
and O
treatment O
['Physiological-Clinical']

This O
hypothesis O
has O
now O
received O
strong O
support O
and O
is O
currently O
based O
on O
three O
types O
of O
arguments O
: O
( O
1 O
) O
similarity O
between O
autistic O
symptomatology O
and O
abnormal O
behaviors O
induced O
in O
young O
animals O
by O
injections O
of O
exogenous O
opioids O
, O
such O
as O
increasing O
social O
aloofness O
and O
decreasing O
social O
vocalization O
; O
( O
2 O
) O
direct O
biochemical O
evidence O
of O
abnormalities O
of O
peripheral O
endogenous O
opioids O
being O
reported O
in O
autism O
and O
( O
3 O
) O
therapeutic O
effects O
of O
the O
long O
lasting O
opioid O
receptor O
blocking O
agent O
naltrexone O
in O
autism O
. O
[]

In O
a O
double-blind O
, O
placebo-controlled O
crossover O
trial O
23 O
autistic O
children O
were O
treated O
with O
a O
single O
40-mg O
dose O
of O
the O
opiate O
antagonist O
naltrexone O
. O
[]

HOXB13 O
G84E O
mutation O
in O
Finland O
: O
population-based O
analysis O
of O
prostate O
, O
breast O
, O
and O
colorectal O
cancer O
risk O
. O
[]

It O
therefore O
appears O
that O
once-yearly O
treatment O
of O
children O
, O
in O
this O
and O
similar O
endemic O
areas O
, O
is O
sufficient O
to O
reduce O
schistosomiasis O
morbidity O
to O
, O
and O
maintain O
it O
at O
, O
a O
tolerable O
level O
. O
[]

DESIGN O
Participating O
physicians O
were O
randomized O
to O
either O
the O
demonstration O
or O
the O
control O
arm O
, O
and O
patients O
were O
assigned O
to O
a O
study O
arm O
based O
on O
the O
randomization O
of O
their O
physicians O
. O
[]

No O
clinically O
significant O
effect O
improvement O
of O
autism B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
with O
enzyme O
use O
was O
shown O
with O
this O
trial O
, O
however O
, O
possible O
effects O
on O
improvement O
in O
['Life-Impact']

Typically O
developed O
children O
located B-outcome ['Life-Impact']
targets I-outcome ['Life-Impact']
cued O
by O
eye B-outcome ['Life-Impact']
gaze B-outcome ['Life-Impact']
more O
quickly O
, O
while O
the O
arrow O
cue O
did O
not O
trigger O
such O
reflexive B-outcome ['Life-Impact']
orienting B-outcome ['Life-Impact']
in O
these O
children O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

When O
coupled O
to O
the O
reported O
experience O
of O
other O
studies O
in O
adults O
with O
ALL O
, O
the O
results O
of O
this O
randomized O
trial O
raise O
the O
possibility O
that O
ultimate O
outcomes O
in O
adult O
ALL O
may O
be O
independent O
of O
the O
specific O
regimen O
chosen O
. O
[]

Autism B-outcome ['Life-Impact']
Diagnostic I-outcome ['Life-Impact']
Observation I-outcome ['Life-Impact']
Schedule O
( O
ADOS O
) O
and O
the O
Gilliam O
Autism O
Rating O
Scale O
( O
GARS O
) O
were O
used O
to O
assess O
core B-outcome ['Life-Impact']
autism B-outcome ['Life-Impact']
behaviours B-outcome ['Life-Impact']
, O
Vineland O
Adaptive O
Behaviour O
Scales O
( O
VABS O
) O
to O
ascertain O
developmental O
level O
, O
and O
Attention-Deficit O
Hyperactivity O
Disorder O
- O
IV O
scale O
( O
ADHD-IV O
) O
to O
determine O
inattention O
and O
hyperactivity O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Effect O
of O
a O
synthetic O
appeasing O
pheromone O
on O
behavioral O
, O
neuroendocrine O
, O
immune O
, O
and O
acute-phase O
perioperative O
stress O
responses O
in O
dogs O
. O
[]

The O
best O
results O
are O
obtained O
by O
integration O
with O
wall O
motion O
. O
[]

Midlife O
women O
online O
: O
evaluation O
of O
an O
internet-based O
program O
to O
prevent O
unintended O
pregnancy O
& O
STIs O
. O
[]

This O
difference O
was O
counteracted O
by O
caffeine O
. O
[]

Among O
the O
placebo O
group O
, O
the O
new O
brain B-outcome ['Physiological-Clinical']
infarcts I-outcome ['Physiological-Clinical']
of O
3 O
subjects O
were O
symptomatic O
while O
those O
of O
the O
remaining O
5 O
subjects O
were O
subclinical O
. O
['Physiological-Clinical']

METHODS O
A O
prospective O
randomized O
controlled O
trial O
was O
undertaken O
in O
122 O
patients O
with O
squamous O
cell O
cancer O
of O
the O
thoracic O
esophagus O
who O
underwent O
a O
Lewis-Tanner O
esophagectomy O
. O
[]

No O
significant O
differences O
were O
found O
in O
bond B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
modes I-outcome ['Physiological-Clinical']
in O
the O
4 O
groups O
. O
['Physiological-Clinical']

METHODS O
A O
prospective O
randomized O
trial O
of O
65 O
eyes O
was O
designed O
, O
with O
31 O
eyes O
receiving O
750 O
rads O
of O
intraoperative O
beta O
radiation O
( O
group O
1 O
) O
, O
and O
34 O
eyes O
receiving O
no O
supplementation O
( O
group O
2 O
) O
. O
[]

Prevalence O
of O
active O
trachoma O
was O
6.7 O
% O
( O
335/5033 O
) O
in O
The O
Gambia O
and O
32.3 O
% O
( O
1008/3122 O
) O
in O
Tanzania O
. O
[]

Behavioral O
and O
physiological O
effects O
of O
deep O
pressure O
on O
children O
with O
autism O
: O
a O
pilot O
study O
evaluating O
the O
efficacy O
of O
Grandin O
's O
Hug O
Machine O
. O
[]

After O
randomization O
, O
PTF O
( O
1,200 O
mg/d O
) O
was O
administered O
for O
4 O
months O
to O
30 O
patients O
and O
results O
were O
compared O
with O
data O
from O
a O
control O
group O
( O
n O
= O
15 O
) O
. O
[]

Significant O
differences O
by O
group O
were O
noted O
in O
Clinician O
Severity O
Ratings O
, O
diagnostic O
status O
, O
and O
clinician O
ratings O
of O
global O
improvement O
. O
[]

Both O
the O
antacid O
and O
placebo O
groups O
showed O
improvement O
in O
the O
degree O
of O
esophagitis B-outcome ['Physiological-Clinical']
as O
assessed O
endoscopically O
. O
['Physiological-Clinical']

In O
a O
30-day O
study O
, O
we O
compared O
the O
abilities O
of O
four O
different O
treatments O
( O
lithium O
plus O
early O
morning O
sleep O
deprivation O
, O
lithium O
plus O
a O
control O
sleep O
deprivation O
procedure O
, O
and O
desipramine O
with O
either O
of O
the O
two O
sleep O
manipulations O
) O
to O
induce O
a O
rapid O
( O
next-day O
) O
and O
sustained O
antidepressant B-outcome ['Life-Impact']
response I-outcome ['Life-Impact']
in O
16 O
depressed O
patients O
. O
['Life-Impact']

The O
Kaplan-Meier O
survivorship O
with O
revision O
as O
the O
end O
point O
at O
10.8 O
years O
was O
98.8 O
% O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.96 O
to O
1.00 O
) O
in O
the O
computernavigated O
total O
knee O
arthroplasty O
group O
and O
99.2 O
% O
( O
95 O
% O
CI O
, O
0.96 O
to O
1.00 O
) O
in O
the O
conventional O
total O
knee O
arthroplasty O
group O
. O
[]

ANALYSIS O
Descriptive O
and O
summary O
statistics O
, O
repeated O
measures O
analysis O
of O
variance O
, O
and O
regression O
analysis O
. O
[]

Individuals O
with O
ASD O
performed B-outcome ['Life-Impact']
more O
poorly O
than O
non-ASD O
individuals O
in O
the O
working O
memory O
condition O
( O
BX O
trials O
) O
. O
['Life-Impact']

One O
month O
post-transplantation O
, O
357 O
patients O
were O
randomized O
to O
receive O
standard-dose O
cyclosporine O
( O
sCsA O
, O
n O
= O
179 O
) O
or O
reduced-dose O
cyclosporine O
( O
rCsA O
, O
n O
= O
178 O
) O
. O
[]

Plasma O
and O
urine O
concentrations O
of O
tyrosine B-outcome ['Physiological-Clinical']
and O
phenylalanine B-outcome ['Physiological-Clinical']
were O
far O
higher O
in O
the O
infants O
fed O
F1 O
to O
F4 O
, O
especially O
F2 O
and O
F4 O
, O
than O
in O
the O
infants O
fed O
BM O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Spinal O
2-chloroprocaine O
: O
the O
effect O
of O
added O
clonidine O
. O
[]

Scores O
for O
cleansing B-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
entire I-outcome ['Physiological-Clinical']
colon I-outcome ['Physiological-Clinical']
as O
determined O
by O
endoscopists O
who O
were O
blinded O
to O
the O
cathartic O
agent O
were O
highest O
in O
patients O
receiving O
sodium O
phosphate O
( O
p O
< O
0.02 O
) O
. O
['Physiological-Clinical']

The O
objective O
of O
this O
research O
was O
to O
determine O
if O
bioelastic O
matrices O
could O
provide O
controlled B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
of O
thromboxane O
A2 O
synthetase O
inhibitor O
( O
dazmegrel O
) O
at O
tissue O
concentrations O
sufficient O
for O
inhibition O
of O
thromboxane O
synthesis O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
increases O
in O
any O
other O
reactogenicity B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
or O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
the O
vaccine O
recipients O
compared O
with O
the O
placebo O
group O
. O
['Physiological-Clinical', 'Adverse-effects']

Concerning O
the O
selected O
pharmacodynamic O
model O
to O
fit O
the O
data O
( O
type O
I O
indirect O
response O
model O
) O
, O
this O
selection O
is O
attributable O
to O
the O
presence O
of O
inhibitory O
bilastine O
plasma O
concentrations O
that O
decrease O
the O
input O
response O
function B-outcome ['Life-Impact']
, O
i.e O
. O
['Life-Impact']

RESULTS O
Basal B-outcome ['Physiological-Clinical']
lower O
esophageal B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
( O
LESP O
) O
and O
swallow-induced B-outcome ['Physiological-Clinical']
relaxation B-outcome ['Life-Impact']
were O
not O
affected O
by O
loxiglumide O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

It O
is O
administered O
in O
a O
fixed O
dose O
without O
laboratory O
monitoring O
and O
is O
being O
compared O
with O
warfarin O
( O
international O
normalized O
ratio O
2-3 O
) O
in O
the O
RE-LY O
trial O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
lipid B-outcome ['Physiological-Clinical']
measures O
were O
taken O
at O
rest O
, O
during O
a O
videotaped O
speech O
task O
, O
and O
during O
recovery O
from O
the O
task O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Paired O
randomized O
controlled O
trial O
. O
[]

If O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
not O
adequately O
controlled O
( O
less O
than O
85 O
mm O
Hg O
) O
after O
four O
weeks O
of O
monotherapy O
, O
1 O
mg O
of O
polythiazide O
was O
added O
to O
the O
daily O
regimen O
. O
['Physiological-Clinical']

Health O
professionals O
should O
consider O
using O
more O
theory-driven O
approaches O
in O
intervention O
studies O
. O
[]

Impact O
of O
a O
leptin O
single O
nucleotide O
polymorphism O
and O
zilpaterol O
hydrochloride O
on O
growth O
and O
carcass O
characteristics O
in O
finishing O
steers O
. O
[]

The O
National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
. O
[]

The O
results O
show O
that O
an O
improvement O
in O
masticatory O
performance O
does O
not O
imply O
the O
same O
improvement O
in O
chewing O
experience O
and O
vice O
versa O
. O
[]

Participants O
in O
the O
former O
groups O
demonstrated O
significantly O
greater O
procedural B-outcome ['Life-Impact']
and O
declarative B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
DTT I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

1 O
) O
Apparent O
ileal O
and O
total O
tract O
protein O
digestibilities O
of O
rapeseed O
meal O
and O
cake O
and O
soybean O
meal O
and O
cake O
were O
assayed O
in O
growing O
turkeys O
at O
4 O
, O
8 O
and O
12 O
weeks O
of O
age O
. O
( O
[]

Fifty-three O
percent O
of O
the O
patients O
had O
a O
neutropenia B-outcome ['Physiological-Clinical']
less O
than O
0.500 O
x O
10 O
( O
9 O
) O
/L O
, O
58 O
% O
fever O
( O
6 O
% O
grade O
4 O
) O
, O
and O
49 O
% O
a O
documented B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( O
8 O
% O
grade O
4 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
patients O
had O
history O
of O
gross O
hematuria O
and O
evaluated O
by O
ultrasonography O
and O
cystoscopy O
. O
[]

METHODS O
We O
performed O
a O
multicenter O
, O
blinded O
, O
randomized O
trial O
to O
assess O
the O
effectiveness O
and O
safety O
of O
this O
regimen O
as O
compared O
with O
sham O
treatment O
in O
807 O
infants O
in O
need O
of O
respiratory O
support O
24 O
hours O
after O
birth O
. O
[]

Minor O
complication O
was O
defined O
as O
delayed B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
seroma I-outcome ['Physiological-Clinical']
or O
hematoma B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
Fourteen O
non-hyperlipidaemic O
primary O
hypertensive O
subjects O
( O
10 O
men O
; O
overall O
mean?SD O
age O
58?12 O
years O
) O
. O
[]

Besides O
there O
is O
some O
evidence O
for O
a O
more O
favourable O
clinical B-outcome ['Physiological-Clinical']
outcome O
within O
this O
subgroup O
after O
rTMS O
in O
the O
CGI-S O
and O
PANSS O
negative O
scale O
, O
too O
. O
['Physiological-Clinical']

Following O
the O
first O
3 O
years O
of O
recruitment O
, O
due O
to O
unexpected O
late O
morbidity O
, O
brachytherapy O
was O
excluded O
and O
the O
protocol O
modified O
to O
66 O
Gy/33 O
fx/6.5 O
weeks O
. O
[]

Study O
design O
included O
two O
randomized O
8-week O
fluoxetine O
and O
placebo O
phases O
separated O
by O
a O
4-week O
washout O
phase O
. O
[]

Impact O
on O
learning B-outcome ['Life-Impact']
of O
an O
e-learning O
module O
on O
leukaemia O
: O
a O
randomised O
controlled O
trial O
. O
['Life-Impact']

Comparison O
of O
coronary O
bypass O
surgery O
with O
angioplasty O
in O
patients O
with O
multivessel O
disease O
. O
[]

Indications O
to O
prasugrel O
therapy O
were O
( O
1 O
) O
ST-elevation O
acute O
myocardial O
infarction O
( O
41 O
% O
) O
, O
( O
2 O
) O
drug-eluting O
stent O
implantation O
in O
diabetics O
( O
24 O
% O
) O
, O
( O
3 O
) O
stent O
thrombosis O
( O
3 O
% O
) O
, O
( O
4 O
) O
left O
main O
coronary O
artery O
drug-eluting O
stent O
implantation O
( O
6 O
% O
) O
, O
and O
( O
5 O
) O
percutaneous O
coronary O
intervention O
in O
patients O
with O
high O
residual O
platelet O
reactivity O
on O
clopidogrel O
therapy O
( O
26 O
% O
) O
. O
[]

The O
results O
showed O
that O
there O
were O
no O
color B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
over O
time O
, O
only O
a O
high B-outcome ['Physiological-Clinical']
luminosity I-outcome ['Physiological-Clinical']
equal I-outcome ['Physiological-Clinical']
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
oil O
supplementation O
resulted O
in O
an O
increased O
polyunsaturated B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
in O
the O
plasma O
phospholipids O
. O
['Physiological-Clinical']

However O
, O
there O
was O
no O
evidence O
either O
during O
the O
trial O
or O
subsequently O
when O
Senokot O
was O
employed O
to O
supplement O
behavioural O
treatment O
in O
every O
child O
who O
continued O
with O
therapy O
that O
this O
laxative O
contributed O
in O
any O
way O
to O
relieving B-outcome ['Physiological-Clinical']
the O
problem O
in O
this O
group O
of O
cases O
. O
['Physiological-Clinical']

DESIGN O
Subjects O
with O
type O
2 O
diabetes O
( O
n O
= O
62 O
) O
were O
randomly O
assigned O
to O
receive O
approximately O
10 O
% O
of O
energy O
from O
low-fiber O
breakfast O
cereal O
( O
LF O
diet O
) O
, O
high-fiber O
breakfast O
cereal O
( O
HF O
diet O
) O
, O
or O
monounsaturated O
fatty O
acids O
( O
MUFA O
diet O
) O
for O
6 O
mo O
. O
[]

Informal O
data O
suggested O
that O
a O
range O
of O
abnormal B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
sound B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
other I-outcome ['Life-Impact']
sensory I-outcome ['Life-Impact']
abnormalities I-outcome ['Life-Impact']
may O
also O
have O
improved O
. O
['Physiological-Clinical', 'Life-Impact']

Proven O
, O
probable O
, O
or O
[]

The O
following O
were O
the O
administration O
schedules O
: O
Arm O
A O
was O
13 O
mg/m2 O
of O
CDDP O
, O
300 O
mg/m2 O
of O
5-FU O
, O
and O
30 O
mg/body O
of O
dl-LV O
for O
5 O
consecutive O
days O
and O
arm O
B O
was O
300 O
mg/m2 O
of O
5-FU O
and O
30 O
mg/body O
of O
dl-LV O
for O
5 O
consecutive O
days O
. O
[]

Better O
airway B-outcome ['Physiological-Clinical']
seal I-outcome ['Physiological-Clinical']
was O
detected O
in O
the O
PLMA O
group O
. O
['Physiological-Clinical']

The O
number O
of O
infections B-outcome ['Physiological-Clinical']
in O
the O
first O
30 O
d O
was O
significantly O
lower O
in O
the O
TE O
group O
( O
P=0.015 O
) O
, O
with O
a O
median O
number O
of O
2 O
versus O
4 O
infections O
per O
patient O
in O
the O
TE O
and O
V O
groups O
, O
respectively O
, O
as O
a O
result O
of O
a O
reduction O
in O
pulmonary O
infections O
( O
P=0.03 O
) O
. O
['Physiological-Clinical']

Caries B-outcome ['Physiological-Clinical']
preventive I-outcome ['Physiological-Clinical']
effects O
of O
toothpastes O
containing O
monofluorophosphate O
and O
trimetaphosphate O
: O
a O
3-year O
clinical O
trial O
. O
['Physiological-Clinical']

Treatment O
in O
infants O
weighing O
less O
than O
1500 O
g O
resulted O
in O
a O
significant O
increase O
in O
species B-outcome ['Physiological-Clinical']
number O
by O
day O
7 O
, O
with O
further O
increases O
by O
day O
21 O
. O
['Physiological-Clinical']

The O
medical O
charts O
for O
a O
random O
sample O
of O
patients O
with O
ADHD O
for O
each O
of O
the O
participating O
pediatricians O
were O
examined O
at O
baseline O
and O
6 O
months O
. O
[]

However O
, O
more O
research O
is O
needed O
to O
fully O
understand O
the O
implications O
of O
these O
findings O
. O
[]

INTRODUCTION O
While O
definitive O
therapy O
awaits O
level O
I O
evidence O
, O
controversy O
persists O
regarding O
the O
optimal O
operation O
for O
treatment O
of O
advanced O
chronic O
venous O
insufficiency O
( O
CVI O
) O
. O
[]

We O
present O
the O
results O
of O
two O
blind O
randomized O
trials O
comparing O
both O
guanethidine O
3 O
per O
cent O
and O
adrenaline O
0.5 O
per O
cent O
( O
Ganda O
3.0/0.5 O
) O
and O
guanethidine O
1 O
per O
cent O
and O
adrenaline O
0.2 O
per O
cent O
( O
Ganda O
1.0/0.2 O
) O
in O
single O
drop O
form O
with O
Timolol O
( O
Timoptol O
) O
0.25 O
per O
cent O
. O
[]

BACKGROUND O
& O
AIMS O
The O
miss O
rate O
of O
colonoscopy O
for O
neoplasms O
is O
poorly O
understood O
. O
[]

RESULTS O
Patients O
with O
non-eosinophilic O
asthma O
had O
absence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
( O
median O
4.4 O
cells/mm O
( O
2 O
) O
vs O
23 O
cells/mm O
( O
2 O
) O
in O
eosinophilic O
asthma O
and O
0 O
cells/mm O
( O
2 O
) O
in O
normal O
controls O
; O
p O
= O
0.03 O
) O
and O
normal O
subepithelial B-outcome ['Physiological-Clinical']
layer I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
( O
5.8 O
microm O
vs O
10.3 O
microm O
in O
eosinophilic O
asthma O
and O
5.1 O
microm O
in O
controls O
, O
p O
= O
0.002 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

0.11 O
% O
; O
p O
= O
0.002 O
) O
. O
[]

BACKGROUND O
Radiation O
treatment O
of O
head O
and O
neck O
cancer O
can O
cause O
chronic O
xerostomia O
which O
impairs O
patients O
' O
quality O
of O
life O
. O
[]

Overall B-outcome ['Life-Impact']
tolerability I-outcome ['Life-Impact']
of O
both O
treatments O
was O
similar O
to O
placebo O
, O
and O
there O
were O
no O
clinically O
relevant O
effects O
on O
cardiac B-outcome ['Physiological-Clinical']
repolarisation I-outcome ['Physiological-Clinical']
with O
either O
mizolastine O
or O
loratadine O
. O
['Life-Impact', 'Physiological-Clinical']

[ O
A O
controlled O
study O
of O
treating O
haemophilia O
A O
on O
an O
out-patient O
basis O
( O
author O
's O
transl O
) O
] O
. O
[]

CONCLUSION O
When O
applying O
BNP O
cut-off O
values O
without O
adjustment O
for O
the O
presence O
of O
kidney O
disease O
, O
the O
use O
of O
BNP B-outcome ['Physiological-Clinical']
levels O
does O
significantly O
improve O
the O
management O
of O
patients O
without O
kidney O
disease O
, O
but O
not O
of O
those O
with O
kidney O
disease O
. O
['Physiological-Clinical']

RESULTS O
The O
overall O
sensitivity O
of O
endocervical B-outcome ['Resource-use']
sampling I-outcome ['Resource-use']
was O
56 O
% O
, O
with O
a O
false O
negative O
rate O
of O
44 O
% O
and O
a O
negative O
predictive O
value O
of O
26 O
% O
. O
['Resource-use']

After O
a O
general O
clinical O
observation O
period O
of O
over O
4 O
weeks O
, O
20 O
essential O
hypertensive O
subjects O
( O
Japanese O
) O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

Secondary O
outcomes O
were O
the O
incidence O
of O
positive O
blood B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
, O
necrotising B-outcome ['Physiological-Clinical']
enterocolitis I-outcome ['Physiological-Clinical']
( O
NEC B-outcome ['Physiological-Clinical']
) O
stage B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
or O
III B-outcome ['Physiological-Clinical']
, O
or O
death B-outcome ['Mortality']
, O
and O
the O
duration O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Resource-use']

METHODS O
Participants O
( O
n O
= O
283 O
) O
reporting O
at O
least O
two O
sexual O
partners O
and O
unprotected O
anal O
intercourse O
with O
a O
man O
in O
the O
past O
3 O
months O
were O
enrolled O
and O
randomized O
to O
a O
social-cognitive O
theory-based O
intervention O
or O
control O
comparison O
. O
[]

Secondary O
outcomes O
include O
glycemic B-outcome ['Physiological-Clinical']
control O
and O
frequency O
of O
infections B-outcome ['Physiological-Clinical']
, O
changes O
in O
REE B-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Cumulative O
5-FU B-outcome ['Physiological-Clinical']
dose B-outcome ['Life-Impact']
was O
higher O
with O
combined O
therapy O
( O
P O
< O
0.001 O
) O
: O
more O
patients O
receiving O
monotherapy O
discontinued O
treatment O
because O
of O
['Physiological-Clinical', 'Life-Impact']

A O
comparison O
of O
two O
double-injection O
techniques O
for O
peribulbar O
block O
analgesia O
: O
infero-temporal O
plus O
supero-medial O
vs. O
infero-temporal O
plus O
medial-percaruncular O
. O
[]

Social O
skills O
training O
for O
young O
adults O
with O
high-functioning O
autism O
spectrum O
disorders O
: O
a O
randomized O
controlled O
pilot O
study O
. O
[]

BACKGROUND O
Experimental O
data O
in O
humans O
on O
the O
contribution O
of O
angiotensin-converting O
enzyme O
inhibitors O
and O
angiotensin O
II O
type O
1 O
receptor O
blockers O
to O
the O
nitric O
oxide O
system O
of O
the O
renal O
vasculature O
are O
inconsistent O
. O
[]

INTERVENTIONS O
Patients O
were O
randomized O
to O
receive O
one O
of O
5 O
modes O
of O
ventilation O
during O
bypass O
. O
[]

Interleukin-1 B-outcome ['Physiological-Clinical']
beta I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IL-1 I-outcome ['Physiological-Clinical']
beta I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PBC O
by O
contributing O
to O
altered O
immune O
function O
and O
fibrosis O
. O
['Physiological-Clinical']

B-type O
natriuretic O
peptide O
and O
risk O
of O
contrast-induced O
acute O
kidney O
injury O
in O
acute O
ST-segment-elevation O
myocardial O
infarction O
: O
a O
substudy O
from O
the O
HORIZONS-AMI O
trial O
. O
[]

In O
the O
zinc-treated O
group O
of O
16 O
patients O
, O
serum B-outcome ['Physiological-Clinical']
zinc I-outcome ['Physiological-Clinical']
rose O
from O
a O
normal O
mean O
value O
of O
13.3 O
to O
17.4 O
mumol/l O
, O
whereas O
the O
mean O
serum B-outcome ['Physiological-Clinical']
vitamin I-outcome ['Physiological-Clinical']
A O
level O
remained O
practically O
unaltered O
within O
the O
normal O
range O
, O
1.89 O
at O
the O
entry O
and O
1.83 O
mumol/l O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Furthermore O
, O
physical B-outcome ['Life-Impact']
fitness I-outcome ['Life-Impact']
and O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
were O
assessed O
. O
['Life-Impact', 'Physiological-Clinical']

RESULTS O
Baseline O
mean O
+/- O
SEM O
values O
after O
washout O
prior O
to O
each O
randomized O
treatment O
comparing O
levocetirizine O
vs O
placebo O
were O
not O
significantly O
different O
for O
prechallenge O
FEV1 B-outcome ['Physiological-Clinical']
( O
% O
predicted O
) O
83 O
+/- O
4 O
vs O
82 O
+/- O
4 O
, O
or O
AMP B-outcome ['Physiological-Clinical']
PC20 I-outcome ['Physiological-Clinical']
( O
mg O
ml O
( O
-1 O
) O
) O
45 O
+/- O
24 O
vs O
45 O
+/- O
22 O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Phenytoin O
or O
placebo O
was O
added O
to O
their O
current O
therapy O
in O
a O
double-blind O
cross-over O
design O
for O
6 O
months O
in O
each O
phase O
. O
[]

These O
data O
suggest O
that O
lack O
of O
sleep O
in O
hypertensive O
patients O
may O
increase O
sympathetic B-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
during O
the O
night O
and O
the O
following O
morning O
, O
leading O
to O
increased O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Compared O
to O
GFR O
> O
or=60 O
ml/min/1.73 O
m O
( O
2 O
) O
BSA O
, O
HR O
for O
all-cause B-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
for O
GFR B-outcome ['Physiological-Clinical']
45-59 O
and O
< O
45 O
ml/min/1.73 O
m O
( O
2 O
) O
BSA O
were O
respectively O
1.04 O
( O
95 O
% O
CI O
, O
0.94-1.16 O
; O
P O
= O
0.422 O
) O
and O
1.58 O
( O
95 O
% O
CI O
, O
1.34-1.87 O
; O
P O
< O
0.0001 O
) O
. O
['Resource-use', 'Physiological-Clinical']

All-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
( O
103 O
deaths O
in O
the O
amiodarone O
group O
, O
102 O
in O
the O
placebo O
group O
) O
and O
cardiac B-outcome ['Mortality']
mortality I-outcome ['Mortality']
did O
not O
differ O
between O
the O
two O
groups O
. O
['Mortality', 'Mortality']

Other O
studies O
found O
that O
there O
is O
an O
aerobic O
( O
in O
the O
gastrointestinal O
tract O
) O
oxidation O
of O
ferrous O
ion O
to O
ferric O
ion O
caused O
in O
iron-paracetamol O
in O
vivo O
reactions O
. O
[]

These O
statements O
described O
hypothetical O
patients O
with O
different O
likelihoods O
of O
having O
systemic B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
was O
a O
suggestion O
that O
it O
had O
a O
beneficial O
effect O
on O
decreasing O
self-injurious B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
. O
['Life-Impact']

No O
significant O
differences O
in O
plasma B-outcome ['Physiological-Clinical']
secretin I-outcome ['Physiological-Clinical']
levels O
were O
detected O
between O
the O
early O
feeding O
and O
control O
groups O
at O
1 O
or O
2 O
days O
, O
7 O
days O
and O
28 O
days O
after O
birth O
, O
but O
a O
significant O
difference O
in O
['Physiological-Clinical']

Clonidine O
premedication O
improves O
metabolic B-outcome ['Physiological-Clinical']
control O
in O
type O
2 O
diabetic B-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
during O
ophthalmic O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Paclitaxel O
administered O
as O
a O
single O
agent O
or O
in O
combination O
with O
cisplatin O
has O
been O
shown O
to O
be O
a O
potentially O
new O
useful O
agent O
for O
the O
treatment O
of O
NSCLC O
. O
[]

No O
major B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
effect O
was O
observed O
. O
['Adverse-effects']

PRINCIPAL O
FINDINGS O
Both O
the O
basic O
and O
the O
augmented O
interventions O
greatly O
increased O
the O
practice O
of O
evidence-based O
care O
, O
according O
to O
patient O
records O
, O
in O
the O
areas O
of O
patient O
assessment O
and O
instructions O
about O
HF O
disease O
management O
. O
[]

There O
were O
4 O
and O
5 O
patients O
in O
group O
I O
showing O
post-treatment B-outcome ['Physiological-Clinical']
reappearance I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
parasitemia I-outcome ['Physiological-Clinical']
at O
< O
or O
= O
16 O
days O
and O
between O
17 O
and O
28 O
days O
, O
respectively O
. O
['Physiological-Clinical']

POPULATION O
Four O
hundred O
and O
four O
women O
due O
to O
receive O
treatment O
for O
suspected O
CIN O
. O
[]

Previously O
reported O
equations O
typically O
overestimated O
the O
subjects O
' O
peak O
oxygen B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Secondary O
end O
points O
were O
change O
from O
baseline O
in O
sitting O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
SiSBP O
) O
at O
week O
8 O
in O
the O
total O
population O
and O
in O
the O
subgroup O
of O
patients O
who O
had O
previously O
received O
antihypertensive O
treatment O
versus O
those O
who O
had O
not O
. O
['Physiological-Clinical']

The O
incidence O
of O
lymphocysts B-outcome ['Physiological-Clinical']
in O
the O
two O
groups O
as O
determined O
using O
ultrasonography O
was O
compared O
. O
['Physiological-Clinical']

All O
patients O
received O
neoadjuvant O
antiandrogen O
therapy O
. O
[]

The O
median O
time O
to O
control O
refractory B-outcome ['Physiological-Clinical']
status O
epilepticus O
was O
less O
in O
the O
valproate O
group O
( O
5 O
minutes O
) O
than O
the O
diazepam O
group O
( O
17 O
minutes O
; O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

Leeds O
Help O
Study O
Group O
. O
[]

In O
two O
subjects O
given O
40 O
ml O
of O
1 O
% O
, O
complete B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
took O
90 O
minutes O
. O
['Physiological-Clinical']

The O
standard O
surgical O
procedure O
was O
a O
limited O
lymphadenectomy O
( O
D1 O
) O
with O
staging O
biopsy O
of O
the O
para-aortic O
lymph O
nodes O
. O
[]

7.6 O
years O
and O
with O
a O
mean O
BMI O
of O
32.8 O
? O
[]

There O
was O
no O
significant O
difference O
between O
the O
fatigue B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
measurements O
for O
the O
four O
modes O
of O
stimulation O
. O
['Physiological-Clinical']

METHODS O
Patients O
evaluated O
over O
Days O
1 O
to O
6 O
and O
6 O
weeks O
with O
Patient B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
of O
Response O
to O
Therapy B-outcome ['Resource-use']
( O
PGART O
) O
and O
Western O
Ontario O
and O
McMaster O
Universities O
( O
WOMAC O
) O
Osteoarthritis O
Index O
. O
['Physiological-Clinical', 'Resource-use']

IFN-alpha-2b O
SC O
was O
begun O
on O
week O
4 O
and O
continued O
thrice O
weekly O
at O
5 O
MU/m2 O
for O
2 O
years O
. O
[]

CONCLUSIONS O
Instruction O
about O
common O
errors O
, O
when O
combined O
with O
instruction O
about O
the O
correct O
performance O
enhanced O
the O
acquisition O
of O
this O
surgical O
skill O
. O
[]

The O
sequencing O
of O
chemotherapy O
and O
radiation O
therapy O
after O
conservative O
surgery O
for O
early-stage O
breast O
cancer O
. O
[]

CONCLUSION O
UTC O
can O
quantitatively O
evaluate O
tendon O
structure O
and O
thereby O
discriminate O
symptomatic O
and O
asymptomatic O
tendons O
. O
[]

Participants O
consisted O
of O
those O
subjects O
in O
the O
WAIS-III O
standardization O
sample O
that O
has O
complete O
demographic O
data O
( O
N=2,401 O
) O
and O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

Of O
34 O
patients O
registered O
, O
10 O
patients O
were O
with O
minimal O
disease O
in O
stages O
IIA O
, O
IIIO O
and O
IIIA O
and O
24 O
with O
extensive O
disease O
in O
IIB O
, O
IIIB2 O
and O
IIIC O
. O
[]

Results O
show O
an O
overall O
response O
rate O
of O
73 O
% O
with O
26 O
% O
complete O
responses O
in O
the O
combined O
treatment O
arm O
, O
whereas O
in O
the O
alternating O
arm O
, O
an O
overall O
response O
rate O
of O
76 O
% O
with O
20 O
% O
complete O
responses O
was O
observed O
. O
[]

Group O
2 O
received O
5 O
mL O
i.v O
. O
[]

METHODS O
In O
the O
current O
investigation O
, O
changes O
in O
autonomic O
tone O
associated O
with O
long-term O
administration O
of O
an O
angiotensin-converting O
enzyme O
inhibitor O
were O
measured O
using O
spectral O
analysis O
of O
heart O
rate O
variability O
in O
13 O
patients O
with O
congestive O
heart O
failure O
who O
were O
enrolled O
in O
a O
double-blind O
randomized O
placebo-controlled O
trial O
of O
the O
angiotensin-converting O
enzyme O
inhibitor O
zofenopril O
. O
[]

Subjects O
received O
IV O
lidocaine O
( O
bolus O
2 O
mg/kg O
, O
then O
infusion O
3 O
mg. O
kg O
. O
[]

Stapled B-outcome ['Resource-use']
hemorrhoidopexy I-outcome ['Resource-use']
versus O
milligan-morgan B-outcome ['Resource-use']
hemorrhoidectomy I-outcome ['Resource-use']
: O
a O
prospective O
, O
randomized O
, O
multicenter O
trial O
with O
2-year O
postoperative O
follow O
up O
. O
['Resource-use', 'Resource-use']

A O
comparison O
of O
3 O
regimens O
for O
protecting O
contrast-induced O
nephropathy O
in O
patients O
undergoing O
coronary O
procedures O
. O
[]

METHODS O
Twenty O
randomized O
patients O
who O
underwent O
a O
primary O
total O
hip O
replacement O
with O
use O
of O
a O
minimally O
invasive O
modified O
Watson-Jones O
approach O
( O
minimally O
invasive O
group O
) O
were O
compared O
with O
a O
group O
of O
twenty O
patients O
who O
underwent O
a O
total O
hip O
arthroplasty O
with O
use O
of O
a O
standard O
transgluteal O
Hardinge O
approach O
( O
standard O
group O
) O
. O
[]

The O
remaining O
ten O
patients O
served O
as O
controls O
and O
received O
inhalation O
anesthesia O
alone O
( O
Group O
C O
) O
. O
[]

Complete B-outcome ['Physiological-Clinical']
resection I-outcome ['Physiological-Clinical']
was O
achieved O
in O
approximately O
95 O
% O
of O
patients O
. O
['Physiological-Clinical']

A O
prospective O
study O
of O
plasma O
vitamin O
D O
metabolites O
, O
vitamin O
D O
receptor O
polymorphisms O
, O
and O
prostate O
cancer O
. O
[]

Chemotherapy O
treatments O
are O
intensive O
and O
difficult O
to O
endure O
. O
[]

Anastomotic O
leakage O
was O
defined O
as O
a O
clinically O
manifest O
leak O
. O
[]

A O
separate O
Cox O
proportional O
hazards O
model O
was O
run O
using O
IOP O
adjusted O
for O
CCT O
by O
each O
of O
the O
5 O
formulae O
published O
to O
date O
. O
[]

Bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
was O
determined O
by O
ICTP O
( O
type O
I O
collagen O
carboxyterminal O
cross-linked O
telopeptide O
) O
as O
parameter O
of O
bone O
resorption O
and O
PICP O
( O
carboxyterminal O
propeptide O
of O
type O
I O
procollagen O
) O
as O
marker O
of O
bone O
formation O
. O
['Physiological-Clinical']

Effect O
of O
nitazoxanide O
on O
morbidity B-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
in O
Zambian O
children O
with O
cryptosporidiosis O
: O
a O
randomised O
controlled O
trial O
. O
['Physiological-Clinical', 'Mortality']

Safety O
and O
efficacy O
of O
dalcetrapib O
on O
atherosclerotic O
disease O
using O
novel O
non-invasive O
multimodality O
imaging O
( O
dal-PLAQUE O
) O
: O
a O
randomised O
clinical O
trial O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Positive O
response O
was O
defined O
by O
a O
score O
of O
much O
improved O
or O
very O
much O
improved O
on O
the O
Clinical O
Global O
Impressions O
, O
Improvement O
subscale O
. O
[]

The O
incidence O
of O
symptoms O
generally O
associated O
with O
infectious O
disease O
was O
assessed O
by O
a O
questionnaire O
sent O
out O
to O
519 O
disease-free O
breast O
cancer O
patients O
7 O
to O
12 O
years O
after O
primary O
treatment O
. O
[]

There O
was O
a O
significant O
decrease O
in O
clinical B-outcome ['Physiological-Clinical']
scores O
in O
the O
BID O
and O
QID O
groups O
by O
days O
3 O
to O
5 O
( O
2.6-3.0 O
points O
) O
and O
a O
further O
decrease O
by O
day O
11 O
( O
4.3-5.0 O
points O
) O
. O
['Physiological-Clinical']

METHODS O
Volunteers O
from O
the O
Yantai O
County O
in O
China O
underwent O
upper O
endoscopy O
with O
biopsy O
specimens O
obtained O
from O
the O
antrum O
and O
corpus O
. O
[]

SETTING O
Endoscopic O
gynecology O
units O
at O
tertiary O
care O
university O
hospitals O
. O
[]

RESULTS O
The O
noradrenaline O
spillover O
rate O
, O
indicative O
of O
whole O
body O
sympathetic O
activity O
, O
was O
reduced O
35 O
% O
by O
rilmenidine O
at O
rest O
( O
p O
< O
0.01 O
) O
and O
remained O
significantly O
lower O
during O
mental O
stress O
and O
tilting O
, O
although O
the O
increases O
in O
noradrenaline B-outcome ['Physiological-Clinical']
spillover I-outcome ['Physiological-Clinical']
with O
both O
stimuli O
were O
preserved O
. O
['Physiological-Clinical']

The O
frequencies O
of O
the O
three O
genotypes O
GG O
, O
GA O
and O
AA O
were O
15.6 O
% O
, O
47.7 O
% O
and O
36.7 O
% O
among O
these O
patients O
, O
compared O
with O
24.4 O
% O
, O
49.5 O
% O
and O
26.1 O
% O
, O
respectively O
, O
among O
patients O
without O
severe B-outcome ['Physiological-Clinical']
diarrhea I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Participants O
are O
clinically O
stable O
renal O
transplant O
recipients O
who O
are O
6 O
months O
or O
longer O
posttransplant O
with O
elevated O
tHcy O
. O
[]

they O
did O
not O
differ O
significantly O
. O
[]

RESULTS O
When O
expressed O
as O
a O
percentage O
, O
the O
improvement O
in O
time O
to O
progression O
, O
overall B-outcome ['Mortality']
and O
cancer B-outcome ['Mortality']
specific I-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
the O
Anandron O
treated O
patients O
was O
identical O
in O
both O
groups O
. O
['Mortality', 'Mortality']

Induction O
treatment O
was O
that O
of O
the O
LNH84 O
protocol O
with O
an O
open O
randomization O
on O
the O
anthracycline O
. O
[]

Standardized O
questionnaires O
were O
completed O
before O
and O
after O
the O
brochures O
to O
assess O
change O
in O
blood B-outcome ['Life-Impact']
donation I-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
, O
attitude B-outcome ['Life-Impact']
, O
self-efficacy B-outcome ['Life-Impact']
, O
and O
intention B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

A O
randomized O
controlled O
one-year O
follow-up O
study O
of O
haloperidol O
, O
risperidone O
and O
olanzapine O
. O
[]

In O
addition O
, O
mechanical O
prophylaxis O
with O
graduated O
compression O
stockings O
and O
pneumatic O
compression O
boots O
is O
preferable O
to O
anticoagulation O
therapy O
. O
[]

Superior O
visual O
search O
in O
adults O
with O
autism O
. O
[]

In O
a O
double O
blind O
randomized O
study O
, O
branched-chain O
amino O
acids O
and O
placebo O
( O
casein O
) O
were O
compared O
as O
a O
treatment O
for O
chronic O
hepatic O
encephalopathy O
in O
cirrhosis O
. O
[]

CONCLUSION O
Prolonged O
interatrial O
electromechanical O
time O
intervals O
in O
hypertensives O
are O
improved O
with O
antihypertensive O
treatment O
. O
[]

Accelerated O
CEF O
+ O
GM-CSF O
is O
a O
moderately O
dose-intensive O
regimen O
that O
can O
be O
administered O
in O
an O
outpatient O
clinic O
and O
is O
associated O
with O
a O
high O
objective O
response O
. O
[]

However O
, O
there O
was O
no O
significant O
difference O
between O
the O
two O
groups O
in O
24-hour O
hospital O
mortality O
. O
( O
[]

The O
number O
of O
peripheral B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
and O
the O
ability O
to I-outcome ['Physiological-Clinical']
become O
sensitized B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
DNCB I-outcome ['Physiological-Clinical']
were O
increased O
after O
CP O
stimulation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Furthermore O
, O
Web-based O
interventions O
often O
have O
to O
deal O
with O
high O
rates O
of O
attrition O
. O
[]

Measuring O
adherence O
in O
a O
hypertension O
clinical O
trial O
. O
[]

It O
is O
concluded O
that O
the O
tablet O
product O
can O
be O
used O
as O
a O
substitute O
for O
parenteral O
methylprednisolone O
in O
situations O
requiring O
high-dose O
therapy O
. O
[]

METHODS O
Patients O
with O
totally O
occluded O
coronary O
arteries O
randomized O
to O
either O
sirolimus-eluting O
Cypher O
stents O
( O
SESs O
) O
( O
Cordis O
, O
a O
Johnson O
& O
Joshson O
Company O
, O
Miami O
Lakes O
, O
FL O
) O
( O
100 O
patients O
) O
or O
bare-metal O
BxVelocity O
stents O
( O
BMSs O
) O
( O
Cordis O
) O
( O
100 O
patients O
) O
were O
followed O
clinically O
for O
3 O
years O
. O
[]

Autism O
is O
a O
neurodevelopmental O
disorder O
characterized O
by O
dysfunction O
in O
three O
primary O
behavioural O
domains O
: O
repetitive O
behaviours O
, O
social O
deficits O
, O
and O
language O
abnormalities O
. O
[]

RESULTS O
Nasal B-outcome ['Physiological-Clinical']
itching I-outcome ['Physiological-Clinical']
was O
markedly O
reduced O
following O
either O
of O
the O
two O
steroids O
within O
10 O
min O
after O
administration O
of O
study O
drug O
. O
['Physiological-Clinical']

Laryngoscopy O
and O
tracheal O
intubation O
may O
provoke O
changes O
of O
cardiac B-outcome ['Physiological-Clinical']
repolarisation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Eighteen O
months O
from O
its O
initiation O
, O
140 O
women O
were O
entered O
on O
study O
. O
[]

CONCLUSION O
The O
safety O
profile O
of O
MEDI-545 O
supports O
further O
clinical O
development O
. O
[]

There O
are O
scant O
data O
on O
the O
direct O
comparison O
of O
RRR-AT O
and O
all-racemic O
( O
rac O
) O
-AT O
on O
LDL O
oxidizability O
. O
[]

CS O
and O
OS O
were O
performed O
in O
random O
order O
, O
30 O
minutes O
apart O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
The O
number O
of O
painful B-outcome ['Physiological-Clinical']
joints I-outcome ['Physiological-Clinical']
and O
swollen B-outcome ['Physiological-Clinical']
joints I-outcome ['Physiological-Clinical']
, O
joint B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
joint B-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
indices O
, O
left B-outcome ['Physiological-Clinical']
and O
right B-outcome ['Physiological-Clinical']
grip I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
, O
investigator B-outcome ['Physiological-Clinical']
global I-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
, O
and O
patient B-outcome ['Physiological-Clinical']
global I-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
returned O
to O
baseline O
for O
the O
amiprilose O
group O
and O
showed O
statistically O
significant O
( O
P O
less O
than O
0.05 O
) O
differences O
from O
the O
placebo O
group O
within O
4 O
to O
6 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
objective B-outcome ['Physiological-Clinical']
partial I-outcome ['Physiological-Clinical']
response O
rate O
was O
57 O
% O
for O
DC O
and O
8 O
% O
for O
CF O
. O
['Physiological-Clinical']

Dofequidar O
fumarate O
( O
MS-209 O
) O
in O
combination O
with O
cyclophosphamide O
, O
doxorubicin O
, O
and O
fluorouracil O
for O
patients O
with O
advanced O
or O
recurrent O
breast O
cancer O
. O
[]

Three O
hundred O
adult O
patients O
were O
enrolled O
in O
this O
study O
. O
[]

The O
atrial B-outcome ['Physiological-Clinical']
flutter I-outcome ['Physiological-Clinical']
cycle O
length B-outcome ['Physiological-Clinical']
was O
prolonged O
significantly O
less O
( O
p O
< O
0.001 O
) O
, O
and O
the O
atrial O
monophasic B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
was O
increased O
significantly O
more O
( O
p O
< O
0.001 O
) O
by O
ibutilide O
than O
by O
procainamide O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

doses O
resulting O
in O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
up O
to O
100 O
times O
those O
measured O
after O
therapeutic O
doses O
( O
6 O
mg O
b.i.d O
. O
) O
['Physiological-Clinical']

CONCLUSIONS O
The O
rate O
of O
long B-outcome ['Physiological-Clinical']
term I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
interferon O
of O
anti-HBe-positive O
chronic O
hepatitis O
B O
is O
poor O
, O
independent O
of O
IFN O
type O
, O
dose O
, O
or O
schedule O
; O
the O
more O
stringent O
the O
monitoring O
, O
the O
higher O
the O
relapse O
rate O
. O
['Physiological-Clinical']

Randomly O
selected O
, O
half O
of O
the O
students O
( O
3 O
males O
, O
3 O
females O
) O
was O
trained O
in O
the O
traditional O
way O
, O
while O
the O
other O
half O
was O
given O
biofeedback O
with O
real-time O
spectrum O
analysis O
. O
[]

The O
reduction O
of O
ventricular B-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
was O
evaluated O
by O
the O
measurement O
of O
the O
Evans O
Index O
. O
['Physiological-Clinical']

This O
score O
and O
Blatt-Kuperman O
were O
recorded O
and O
performed O
in O
every O
control O
. O
[]

DESIGN O
This O
was O
a O
preplanned O
subanalysis O
of O
a O
randomized O
controlled O
trial O
on O
IIT O
. O
[]

For O
all O
analyses O
, O
differences O
were O
considered O
to O
be O
significant O
at O
P O
< O
0.05 O
. O
[]

A O
vigilance O
decrement O
was O
seen O
only O
for O
the O
positive O
feedback O
, O
experimental O
group O
. O
[]

Four O
treatments O
for O
soft-tissue O
rheumatism O
-- O
sham O
ionisation O
, O
placebo O
ionisation O
, O
and O
pharmacological O
ionisation O
with O
pirprofen O
( O
two-dose O
levels O
) O
-- O
were O
assessed O
in O
a O
randomized O
double-blind O
, O
between-patient O
controlled O
trial O
in O
73 O
outpatients O
affected O
by O
scapulo-humeral O
periarthritis O
or O
elbow O
epicondylitis O
. O
[]

The O
maxilla O
moves O
slightly O
downward O
in O
SARME O
. O
[]

Postdischarge B-outcome ['Resource-use']
community I-outcome ['Resource-use']
care I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
were O
lower O
. O
['Resource-use']

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
performance B-outcome ['Life-Impact']
of O
a O
new O
cuff B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
release O
valve O
( O
CPRV O
) O
, O
in O
which O
the O
release O
pressure O
can O
be O
adjusted O
from O
10 O
to O
25 O
cmH2O O
, O
particularly O
intended O
to O
control O
pressure O
in O
paediatric O
cuffed O
tracheal O
tubes O
and O
to O
avoid O
cuff O
hyperinflation O
caused O
by O
N2O O
diffusion O
. O
['Life-Impact', 'Physiological-Clinical']

P O
< O
0.001 O
) O
, O
non-Staphylococcus O
spp O
. O
( O
[]

Plasma B-outcome ['Physiological-Clinical']
cholinesterase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
not O
significantly O
affected O
by O
physostigmine O
. O
['Physiological-Clinical']

OBJECTIVE O
Our O
objective O
was O
to O
determine O
whether O
risedronate O
, O
35 O
mg O
weekly O
, O
is O
efficacious O
and O
safe O
in O
preventing O
bone O
loss O
associated O
with O
chemotherapy-induced O
menopause O
. O
[]

At O
the O
end O
of O
this O
period O
, O
if O
the O
patient O
experienced O
a O
decrease O
on O
the O
total O
Hamilton O
Anxiety O
Rating O
Scale O
( O
HAM-A O
) O
of O
at O
least O
25 O
% O
of O
basal O
value O
, O
the O
treatment O
was O
kept O
unchanged O
for O
a O
further O
15 O
days O
, O
otherwise O
15 O
mg O
of O
ketazolam O
were O
added O
to O
the O
previous O
treatment O
( O
second O
period O
) O
. O
[]

0.32 O
kg O
, O
P O
< O
0.0001 O
) O
. O
[]

CONCLUSIONS O
Although O
the O
number O
of O
enrolled O
women O
was O
very O
small O
this O
study O
shows O
that O
: O
1 O
. O
[]

In O
6 O
episodes O
a O
second O
dose O
labetalol O
50 O
mg O
was O
given O
41 O
+/- O
9 O
min O
after O
the O
first O
injection O
. O
[]

AIMS O
The O
purpose O
of O
this O
paper O
is O
to O
examine O
the O
measurement O
of O
adherence B-outcome ['Life-Impact']
to O
medication O
taking O
in O
hypertensive O
patients O
. O
['Life-Impact']

The O
primary O
outcome O
is O
freedom O
from O
having O
, O
or O
meeting O
the O
criteria O
for O
, O
a O
major O
amputation O
( O
below O
knee O
amputation O
, O
or O
metatarsal O
level O
) O
up O
to O
12 O
weeks O
after O
randomization O
. O
[]

Therefore O
, O
we O
set O
out O
to O
determine O
1 O
) O
the O
contribution O
of O
prostacyclin O
to O
the O
bradykinin-mediated O
vasodepressor O
effects O
of O
ACE O
inhibitors O
, O
2 O
) O
whether O
ACE O
inhibitors O
alter O
the O
effect O
of O
bradykinin O
on O
prostacyclin O
, O
and O
3 O
) O
whether O
the O
effects O
of O
ACE O
inhibitors O
on O
bradykinin O
and O
prostaglandins O
are O
class O
effects O
or O
dependent O
on O
ACE O
inhibitor O
structure O
. O
[]

Ten O
active O
female O
subjects O
participated O
( O
32 O
+/- O
7 O
yrs O
( O
mean O
+/- O
SD O
) O
; O
65.7 O
+/- O
16.4 O
kg O
; O
VO2peak O
40.0 O
+/- O
7.5 O
ml.kg-1.min-1 O
) O
. O
[]

erythema O
, O
matrix O
changes O
and O
mitochondrial O
DNA O
( O
mtDNA O
) O
damage O
. O
[]

Prevalence O
of O
metabolic B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
in O
rural O
and O
urban O
Chinese O
population O
in O
Qingdao O
. O
['Physiological-Clinical']

Although O
the O
patient O
groups O
exhibited O
higher O
baseline O
NE B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
and O
a O
greater O
NE B-outcome ['Physiological-Clinical']
area O
under B-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentration O
versus O
time O
curve O
( O
AUC0-90 O
) O
during O
the O
yohimbine O
infusion O
, O
the O
differences O
were O
not O
statistically O
significant O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
outcomes O
were O
restoration O
of O
spontaneous B-outcome ['Physiological-Clinical']
menses I-outcome ['Physiological-Clinical']
, O
ovulation B-outcome ['Physiological-Clinical']
induction O
( O
spontaneous B-outcome ['Physiological-Clinical']
or O
clomiphene B-outcome ['Resource-use']
induced B-outcome ['Physiological-Clinical']
) O
and O
pregnancy B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Ten O
highly O
trained O
male O
cyclists O
and O
triathletes O
( O
age O
= O
30.6 O
? O
[]

Here O
we O
report O
the O
clinical O
outcome O
of O
the O
preplanned O
interim O
futility O
analysis O
scheduled O
to O
occur O
after O
documentation O
of O
34 O
events O
in O
the O
early O
PET-negative O
group O
. O
[]

Anesthesia O
was O
maintained O
with O
isoflurane O
and O
nitrous O
oxide O
in O
all O
patients O
. O
[]

The O
effects O
of O
propofol O
, O
a O
new O
non-barbiturate O
intravenous O
anaesthetic O
agent O
, O
on O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
IOP O
) O
were O
assessed O
and O
compared O
with O
those O
of O
thiopentone O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Fifty O
patients O
were O
randomly O
assigned O
to O
receive O
12 O
weeks O
of O
acupuncture O
( O
n O
= O
25 O
) O
or O
venlafaxine O
( O
n O
= O
25 O
) O
treatment O
. O
[]

5.1 O
) O
, O
( O
68.1 O
? O
[]

CONCLUSIONS O
A O
short O
period O
of O
exercise O
training O
in O
CAD O
patients O
improved O
their O
physical O
capacity O
, O
but O
did O
not O
influence O
BMI O
, O
WHR O
and O
waist O
circumference O
. O
[]

The O
2 O
groups O
were O
comparable O
. O
[]

Most O
surgeons O
use O
metal O
clips O
in O
laparoscopic O
cholecystectomy O
. O
[]

Complication O
rates O
did O
not O
differ O
between O
closure O
types O
. O
['Adverse-effects']

No O
significant O
differences O
in O
any O
of O
the O
effect O
variables O
were O
found O
between O
the O
two O
groups O
before O
, O
during O
or O
after O
treatment O
. O
[]

The O
advantages O
were O
evident O
in O
hypo-anergic O
subjects O
both O
with O
regard O
to O
the O
frequency O
of O
early B-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
, O
and O
with O
regard O
to O
immunological B-outcome ['Physiological-Clinical']
parameters O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Laparoscopic O
vs O
open O
appendectomy O
in O
overweight O
patients O
. O
[]

Location O
of O
ICH O
also O
affects O
efficacy O
of O
aggressive O
treatment O
of O
ICH O
. O
[]

RESULTS O
Recruitment O
led O
to O
22 O
patients O
in O
group O
1 O
and O
25 O
patients O
in O
group O
2 O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
safety O
and O
Immunogenicity B-outcome ['Physiological-Clinical']
of O
the O
Poliomyelitis O
vaccine O
( O
Human O
Diploid O
Cell O
) O
in O
> O
or O
=2 O
month-old O
children O
. O
['Physiological-Clinical']

The O
costs B-outcome ['Resource-use']
and O
health B-outcome ['Physiological-Clinical']
benefits O
of O
Telephone B-outcome ['Resource-use']
Counselling I-outcome ['Resource-use']
, O
Usual O
Care O
and O
an O
existing O
practice O
( O
Real O
Control O
) O
group O
were O
compared O
. O
['Resource-use', 'Physiological-Clinical', 'Resource-use']

The O
index O
could O
find O
use O
as O
an O
additional O
measure O
of O
oral O
hygiene O
, O
in O
clinical O
trials O
on O
plaque O
control O
and O
possibly O
epidemiological O
studies O
relating O
to O
caries O
. O
[]

According O
to O
recent O
reports O
, O
a O
new O
diuretic O
, O
muzolimine O
( O
MZ O
) O
, O
which O
acts O
on O
the O
loop O
of O
Henle O
, O
seems O
to O
present O
a O
minor O
effect O
on O
carbohydrate O
metabolic O
balance O
. O
[]

Sixty-one O
( O
88 O
percent O
) O
of O
69 O
patients O
have O
experienced O
a O
positive O
response B-outcome ['Physiological-Clinical']
to O
the O
surgery O
after O
5 O
years O
. O
['Physiological-Clinical']

Primary B-outcome ['Physiological-Clinical']
hemostasis I-outcome ['Physiological-Clinical']
was O
assessed O
with O
a O
platelet O
function O
analyser O
( O
PFA-100 O
) O
, O
which O
measures O
the O
closure O
time O
( O
CT O
) O
of O
a O
collagen- O
and O
epinephrine-coated O
pore O
by O
aggregating O
platelets O
in O
flowing O
blood O
. O
['Physiological-Clinical']

If O
long O
term O
safety O
can O
be O
confirmed O
, O
the O
simvastatin-cholestyramine O
regimen O
may O
prove O
useful O
in O
heterozygous O
familial O
hypercholesterolemia O
. O
[]

METHODS O
In O
a O
prospective O
randomized O
trial O
, O
50 O
patients O
with O
permanent O
atrial O
fibrillation O
and O
dilated O
left O
atrium O
, O
submitted O
to O
surgical O
mitral O
repair O
, O
were O
divided O
into O
two O
groups O
: O
Group O
I O
contained O
25 O
patients O
with O
left O
auricular O
reduction O
and O
mitral O
surgery O
, O
and O
Group O
II O
contained O
25 O
patients O
with O
isolated O
valve O
surgery O
. O
[]

METHODS O
From O
May O
2008 O
to O
July O
2010 O
, O
78 O
patients O
with O
knee O
osteoarthritis O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

Studies O
in O
mink O
have O
mainly O
focused O
on O
short-term O
consequences O
of O
low O
protein O
provision O
in O
utero O
whereas O
the O
long-term O
responses O
to O
low O
protein O
( O
LP O
) O
provision O
in O
metabolically O
programmed O
mink O
are O
unknown O
. O
[]

Statins O
and O
fibrates O
influence O
endothelial O
activity O
and O
consequently O
atherogenesis O
but O
the O
mechanisms O
are O
not O
well O
understood O
. O
[]

The O
authors O
hypothesized O
that O
the O
Dietary O
Approaches O
to O
Stop O
Hypertension O
( O
DASH O
) O
diet O
and O
reduced O
sodium O
intake O
would O
control O
stage O
1 O
hypertension O
and O
reduce O
high-normal O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
to O
optimal O
levels O
. O
['Physiological-Clinical']

Six O
patients O
entered O
and O
completed O
the O
study O
. O
[]

Prophylaxis O
was O
discontinued O
if O
the O
patient O
experienced O
a O
possible O
or O
proven O
fungal O
infection O
or O
a O
serious O
toxicity O
. O
[]

PATIENTS O
35 O
patients O
with O
chronic O
stable O
coronary O
artery O
disease O
. O
[]

Coverage O
efficiency O
increased O
from O
1.29 O
to O
1.56 O
children O
covered O
per O
bednet O
owned O
. O
[]

This O
article O
analyzes O
two O
potential O
pathways O
for O
racial O
disparities O
: O
primary O
amputation O
, O
defined O
as O
a O
major O
amputation O
performed O
without O
any O
prior O
attempt O
at O
revascularization O
, O
and O
repeat O
amputation O
, O
defined O
as O
a O
major O
amputation O
subsequent O
to O
a O
previous O
through-foot O
or O
major O
amputation O
. O
[]

All O
eyes O
had O
uncontrolled O
intra-ocular B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
( O
greater O
than O
or O
equal O
to O
22 O
mm O
Hg O
) O
despite O
medical O
therapy O
. O
['Physiological-Clinical']

Among O
the O
non-pharmacological O
approach O
is O
physiotherapy O
, O
which O
involves O
the O
use O
of O
physical O
modalities O
like O
, O
heat O
therapy O
, O
exercise O
therapy O
, O
electrical O
stimulation O
, O
therapeutic O
ultrasound O
, O
iontophoresis O
, O
and O
phonophoresis O
. O
[]

There O
were O
no O
significant O
differences O
in O
plasma B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
lipid-standardized I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
LDL I-outcome ['Physiological-Clinical']
AT I-outcome ['Physiological-Clinical']
levels O
between O
RRR-AT O
and O
all-rac-AT O
supplementation O
at O
any O
dose O
comparison O
. O
['Physiological-Clinical']

Of O
72 O
patients O
in O
the O
Pirarubicin O
Monotherapy O
Study O
Group O
trial O
, O
31 O
had O
positive O
urine B-outcome ['Physiological-Clinical']
cytology I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Conservative O
surgery O
with O
and O
without O
radiotherapy O
in O
elderly O
patients O
with O
early-stage O
breast O
cancer O
: O
a O
prospective O
randomised O
multicentre O
trial O
. O
[]

Reputation O
management O
: O
evidence O
for O
ability O
but O
reduced O
propensity O
in O
autism O
. O
[]

Effect O
sizes O
for O
observational O
measures O
ranged O
from O
d O
= O
0.10 O
to O
d O
= O
1.32 O
favoring O
the O
parent O
+ O
therapist O
group O
, O
with O
the O
largest O
effect O
sizes O
found O
12 O
months O
after O
intervention O
. O
[]

Follow-up O
after O
3 O
months O
and O
then O
yearly O
included O
measurement O
of O
the O
PQ B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
and O
, O
in O
patients O
with O
atrial O
pacemakers O
, O
determination O
of O
the O
atrial O
stimulus-Q B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
pacing I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
100 I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
120 I-outcome ['Physiological-Clinical']
bpm I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
might O
partly O
account O
for O
the O
lack O
of O
significance O
of O
some O
of O
the O
parameters O
under O
study O
. O
[]

The O
Excyte B-outcome ['Physiological-Clinical']
IV I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
reduced O
and O
, O
ultimately O
, O
eliminated O
from O
the O
subsequent O
and O
final O
prototype O
lots O
of O
SSS O
. O
['Physiological-Clinical']

Pulmonary O
mechanics O
were O
measured O
before O
and O
at O
the O
end O
of O
a O
week O
of O
treatment O
with O
oral O
diuretics O
( O
chlorothiazide O
, O
20 O
mg/kg/dose O
and O
spironolactone O
, O
1.5 O
mg/kg/dose O
) O
given O
twice O
daily O
, O
or O
placebo O
. O
[]

Since O
no O
significant O
differences O
were O
found O
between O
AD O
patients O
and O
age-matched O
controls O
with O
regard O
to O
the O
fraction O
of O
CD45RA+ B-outcome ['Physiological-Clinical']
or O
CD45RO+ B-outcome ['Physiological-Clinical']
CD4+ I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
nor O
the O
ability O
of O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
mononuclear I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
produce I-outcome ['Physiological-Clinical']
IL-2 I-outcome ['Physiological-Clinical']
or O
IL-4 B-outcome ['Physiological-Clinical']
, O
it O
is O
unlikely O
that O
the O
difference O
in O
DEX O
sensitivity O
is O
due O
to O
a O
changed O
lymphokine O
profile O
or O
a O
changed O
composition O
of O
the O
CD4+ O
T O
cell O
population O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
systemic O
therapies O
which O
may O
modulate O
the O
pattern O
of O
immune B-outcome ['Physiological-Clinical']
dysregulation I-outcome ['Physiological-Clinical']
seen O
in O
HIV-1 O
disease O
may O
be O
beneficial O
in O
the O
pruritus O
seen O
in O
late-stage O
patients O
. O
['Physiological-Clinical']

Covariates O
introduced O
. O
[]

6.1 O
years O
) O
were O
recruited O
and O
randomly O
assigned O
to O
either O
the O
PM O
or O
SM O
group O
. O
[]

Health O
Belief O
Model O
constructs O
were O
used O
to O
develop O
tailored O
messages O
and O
examined O
as O
outcomes O
. O
[]

The O
intervention O
will O
be O
conducted O
by O
specially O
trained O
oncology O
nurses O
and O
includes O
components O
of O
patient O
education O
, O
skills O
training O
and O
counseling O
to O
improve O
self O
care O
regarding O
pain O
management O
beginning O
with O
admission O
followed O
by O
booster O
session O
every O
3rd O
day O
and O
one O
follow O
up O
telephone O
counseling O
within O
2 O
to O
3 O
days O
after O
discharge O
. O
[]

Cytokine B-outcome ['Physiological-Clinical']
levels O
and O
systemic O
toxicity B-outcome ['Adverse-effects']
in O
patients O
undergoing O
isolated O
limb O
perfusion O
with O
high-dose O
tumor O
necrosis O
factor O
, O
interferon O
gamma O
, O
and O
melphalan O
. O
['Physiological-Clinical', 'Adverse-effects']

The O
high-frequency O
repetitive O
transcranial O
magnetic O
stimulation O
( O
HF-rTMS O
) O
over O
the O
prefrontal O
cortex O
is O
a O
promising O
method O
for O
the O
treatment O
of O
negative O
symptoms O
of O
schizophrenia O
. O
[]

The O
numbers O
of O
patients O
who O
had O
hepatotoxic O
and O
nephrotoxic O
effects O
did O
not O
differ O
significantly O
between O
the O
standard O
diagnosis O
and O
biomarker O
diagnosis O
groups O
( O
hepatotoxic O
effects O
: O
21 O
[ O
17 O
% O
] O
vs O
12 O
[ O
10 O
% O
] O
, O
p=0?11 O
; O
nephrotoxic O
effects O
: O
52 O
[ O
43 O
% O
] O
vs O
60 O
[ O
51 O
% O
] O
, O
p=0?20 O
) O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
CF-240I O
and O
PCF O
240L O
groups O
with O
regard O
to O
the O
cecal B-outcome ['Resource-use']
intubation I-outcome ['Resource-use']
rate O
( O
96.9 O
% O
vs O
98.5 O
% O
, O
P O
= O
0.18 O
) O
, O
the O
need O
for O
abdominal B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
71.7 O
% O
vs O
73.4 O
% O
, O
P O
= O
0.55 O
) O
and O
change O
of O
position O
( O
13.5 O
% O
vs O
11.5 O
% O
, O
P O
= O
0.37 O
) O
. O
['Resource-use', 'Physiological-Clinical']

Results O
showed O
that O
along O
with O
the O
central O
executive O
, O
visual O
and O
spatial O
working O
memory O
influenced O
selective B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
, O
but O
phonological O
working O
memory O
did O
not O
. O
['Life-Impact']

BACKGROUND O
The O
maximal O
calcium O
absorption O
in O
response O
to O
vitamin O
D O
has O
been O
proposed O
as O
a O
biomarker O
for O
vitamin O
D O
sufficiency O
. O
[]

LDL B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxidative I-outcome ['Physiological-Clinical']
modification I-outcome ['Physiological-Clinical']
was O
assessed O
by O
calculating O
lag O
time O
, O
propagation B-outcome ['Physiological-Clinical']
rate O
, O
and O
maximum O
production O
of O
conjugated O
dienes B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
incidence O
of O
major O
and O
minor O
side O
effects O
between O
therapy O
groups O
was O
not O
significantly O
different O
( O
14.6 O
% O
in O
the O
triple O
therapy O
group O
vs. O
23.5 O
% O
in O
sequential O
group O
, O
p O
= O
0.12 O
) O
. O
[]

Eight O
participants O
( O
mean O
age O
+/- O
standard O
deviation O
, O
22 O
+/- O
0.9 O
years O
) O
received O
either O
50 O
microL O
of O
0.5 O
% O
timolol O
or O
placebo O
in O
the O
lower O
conjunctival O
sacs O
of O
both O
eyes O
in O
the O
morning O
or O
evening O
. O
[]

METHODS O
This O
was O
a O
randomized O
controlled O
trial O
conducted O
between O
December O
2008 O
and O
April O
2011 O
to O
improve O
CRC O
screening O
in O
16 O
rural O
family O
physician O
offices O
. O
[]

SETTING O
& O
PARTICIPANTS O
750 O
patients O
with O
CKD O
stages O
1 O
to O
5 O
and O
5D O
. O
[]

Exposure O
to O
lead O
impairs O
cognitive O
development O
in O
young O
children O
, O
but O
the O
benefits O
of O
lowering O
blood O
lead O
pharmacologically O
are O
not O
clear O
. O
[]

200 O
mg O
caffeine O
or O
2 O
? O
[]

Also O
, O
28 O
% O
of O
the O
patients O
on O
lisinopril O
and O
30 O
% O
of O
those O
on O
nifedipine O
presented O
microalbuminuria O
. O
[]

A O
cross-over O
pilot O
trial O
comparing O
brisk O
walking O
in O
two O
different O
environments O
: O
park O
and O
urban O
. O
[]

This O
work O
serves O
as O
a O
prelude O
to O
further O
studies O
in O
subjects O
with O
low O
HDL O
, O
or O
combinations O
of O
dyslipidemia O
, O
in O
assessing O
the O
role O
of O
CETP O
in O
atherosclerosis O
. O
[]

It O
also O
significantly O
reduced O
( O
P O
< O
0.05 O
) O
the O
endoscopic B-outcome ['Resource-use']
ultrasonography I-outcome ['Resource-use']
score O
on O
the O
gastric O
wall O
surface O
( O
score O
4 O
, O
14 O
% O
) O
in O
comparison O
with O
that O
observed O
for O
treatment O
A O
( O
3 O
% O
) O
. O
['Resource-use']

Efficacy O
did O
not O
occur O
until O
after O
several O
months O
of O
leuprolide O
treatment O
, O
but O
there O
was O
no O
evidence O
that O
PMS B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
worsened O
with O
the O
onset O
of O
treatment O
. O
['Physiological-Clinical']

This O
article O
summarizes O
these O
methods O
and O
their O
efficacies O
for O
critically O
ill O
patients O
, O
especially O
those O
with O
severe O
sepsis O
. O
[]

Glucocorticoid O
receptor O
( O
GR O
) O
binding O
and O
neurotransmitter O
concentrations O
were O
measured O
in O
stress-related O
brain O
regions O
, O
and O
histological O
analyses O
of O
the O
adrenal O
were O
performed O
. O
[]

The O
primary O
finding O
was O
that O
patients O
were O
generally O
able O
to O
use O
ESRA-C O
quickly O
and O
without O
difficulty O
in O
a O
real-world O
clinical O
setting O
and O
that O
they O
were O
overall O
quite O
satisfied B-outcome ['Life-Impact']
with O
the O
ESRA-C O
program O
. O
['Life-Impact']

The O
U.S. O
Multicenter O
trial O
found O
a O
significant O
difference O
favoring O
idarubicin O
in O
the O
original O
analysis O
, O
but O
the O
difference O
was O
not O
significant O
in O
the O
updated O
analysis O
. O
[]

Preliminary O
evidence O
of O
the O
efficacy O
of O
the O
intervention O
was O
obtained O
using O
a O
randomized O
trial O
with O
62 O
sexually-active O
, O
single O
girls O
. O
[]

Additionally O
, O
the O
number O
of O
jaw B-outcome ['Resource-use']
lift I-outcome ['Resource-use']
interventions I-outcome ['Resource-use']
was O
significantly O
higher O
in O
both O
groups O
who O
received O
fentanyl O
. O
['Resource-use']

In O
a O
randomized O
, O
controlled O
study O
, O
610 O
patients O
undergoing O
coronary O
artery O
bypass O
grafting O
were O
assigned O
either O
to O
a O
fish O
oil O
group O
, O
receiving O
4 O
g/day O
of O
fish O
oil O
concentrate O
, O
or O
to O
a O
control O
group O
. O
[]

This O
effect O
was O
still O
apparent O
at O
4 O
month O
follow-up O
( O
13.1 O
versus O
22.9 O
% O
, O
P O
= O
0.036 O
) O
. O
[]

Each O
item O
was O
rated O
as O
to O
the O
seriousness O
of O
the O
pathology O
it O
would O
represent O
if O
manifested O
by O
either O
a O
boy O
child O
, O
girl O
child O
, O
boy O
adolescent O
, O
or O
girl O
adolescent O
, O
with O
one-fourth O
of O
the O
raters O
assigned O
to O
each O
condition O
. O
[]

This O
response O
is O
therefore O
unlikely O
to O
be O
due O
to O
removal O
of O
myocardial B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
angiotensin I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
treatment O
ratios O
of O
Cmax B-outcome ['Physiological-Clinical']
and O
associated O
90 O
% O
CIs O
for O
risperidone O
active O
moiety O
( O
ratio O
= O
114.6 O
% O
; O
90 O
% O
CI O
= O
107.0-122.8 O
) O
and O
for O
donepezil O
( O
ratio O
= O
96.1 O
% O
; O
90 O
% O
CI O
= O
90.0-102.6 O
) O
were O
also O
within O
the O
bioequivalence O
range O
. O
['Physiological-Clinical']

Comparing O
the O
effectiveness O
of O
peer O
mentoring O
and O
student O
mentoring O
in O
a O
35-week O
fitness O
program O
for O
older O
adults O
. O
[]

UNLABELLED O
It O
has O
been O
shown O
that O
the O
stress O
response O
to O
lower O
abdominal O
surgery O
can O
be O
inhibited O
by O
epidural O
analgesia O
( O
EA O
) O
. O
[]

Anxiety B-outcome ['Life-Impact']
levels O
did O
not O
differ O
between O
the O
groups O
and O
exposure O
to O
TC+TSE O
resulted O
in O
greater O
perceived B-outcome ['Life-Impact']
message I-outcome ['Life-Impact']
benefit I-outcome ['Life-Impact']
, O
increased O
intention B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
self-examine I-outcome ['Life-Impact']
and O
lower O
message B-outcome ['Life-Impact']
denigration I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Bronchodilators O
reduced O
peripheral O
airways O
resistance O
in O
patients O
( O
0.53 O
versus O
0.38 O
, O
P O
< O
.02 O
) O
and O
controls O
( O
0.21 O
versus O
0.19 O
, O
P O
< O
.005 O
) O
and O
increased O
measures O
of O
compliance O
in O
both O
groups O
. O
[]

CLINICAL O
TRIAL O
REGISTRATION O
URL O
: O
http O
: O
//www.clinicaltrials.gov O
. O
[]

RESULTS O
By O
36 O
weeks O
' O
postmenstrual O
age O
, O
59 O
of O
the O
405 O
infants O
( O
15 O
percent O
) O
in O
the O
vitamin O
A O
group O
and O
55 O
of O
the O
402 O
infants O
( O
14 O
percent O
) O
in O
the O
control O
group O
had O
died O
. O
[]

Hydrocortisone O
infusion O
induced O
an O
increase O
of O
mean O
arterial O
pressure O
, O
systemic O
vascular O
resistance O
, O
and O
a O
decline O
of O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
cardiac B-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
, O
and O
norepinephrine B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

CONCLUSION O
Disease O
activity O
in O
RA O
is O
reduced O
by O
tocilizumab O
treatment O
, O
irrespective O
of O
the O
type O
of O
composite O
measure O
used O
to O
evaluate O
disease O
activity O
. O
[]

Values O
are O
given O
as O
median O
( O
range O
) O
or O
n O
( O
% O
) O
. O
( O
[]

Utilization O
patterns O
of O
conventional O
and O
complementary/alternative O
treatments O
in O
children O
with O
autism O
spectrum O
disorders O
and O
developmental O
disabilities O
in O
a O
population-based O
study O
. O
[]

DESIGN O
Randomized O
trial O
of O
20-week O
aquatic O
classes O
. O
[]

Anal O
wall O
DVHs O
were O
used O
for O
fecal O
incontinence O
, O
whereas O
anorectal O
wall O
dose O
best O
described O
the O
other O
two O
endpoints O
. O
[]

Fifty O
patients O
with O
active O
rheumatoid O
arthritis O
were O
randomly O
allocated O
to O
receive O
active O
drug O
( O
n O
= O
24 O
) O
or O
placebo O
( O
n O
= O
26 O
) O
and O
reviewed O
at O
weeks O
0 O
, O
1 O
, O
4 O
, O
8 O
, O
12 O
, O
16 O
, O
and O
24 O
. O
[]

PATIENTS O
30 O
ASA O
physical O
status O
I O
and O
II O
patients O
, O
who O
were O
scheduled O
for O
elective O
hip O
or O
knee O
arthroplasty O
and O
were O
free O
from O
systemic O
disease O
. O
[]

ZNS O
was O
initiated O
at O
a O
dosage O
of O
100 O
mg/day O
and O
escalated O
to O
200 O
mg/day O
at O
day O
14 O
. O
[]

Regression O
models O
were O
adjusted O
for O
age O
, O
sex O
, O
medications O
, O
and O
physical O
activity O
. O
[]

Furthermore O
, O
amantadine O
had O
no O
significant O
effects O
on O
motor B-outcome ['Life-Impact']
thresholds I-outcome ['Life-Impact']
, O
MEP B-outcome ['Physiological-Clinical']
recruitment I-outcome ['Physiological-Clinical']
curves I-outcome ['Physiological-Clinical']
, O
CSP B-outcome ['Physiological-Clinical']
, O
or O
peripheral B-outcome ['Physiological-Clinical']
excitability I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Every O
2 O
hours O
of O
wakefulness O
, O
and O
immediately O
after O
abrupt O
awakening O
from O
the O
naps O
, O
psychomotor B-outcome ['Life-Impact']
vigilance I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
was O
tested O
. O
['Life-Impact']

Surface O
preparation O
of O
the O
lesion O
is O
commonly O
performed O
before O
application O
of O
ALA O
but O
the O
extent O
of O
the O
preparation O
varies O
from O
centre O
to O
centre O
and O
there O
has O
been O
no O
study O
of O
its O
effects O
. O
[]

Fifty-nine O
consecutive O
patients O
( O
19 O
men O
, O
40 O
women O
, O
mean O
age O
60.8 O
[ O
27-80 O
] O
years O
) O
with O
primary O
osteoporosis O
were O
studied O
to O
see O
if O
there O
was O
any O
significant O
gain O
in O
bone O
mass O
after O
treatment O
with O
salmon O
calcitonin O
. O
[]

Helicobacter O
pylori O
infected O
10-21 O
year O
olds O
were O
offered O
treatment O
, O
individuals O
with O
abdominal O
pain O
underwent O
upper O
endoscopy O
and O
those O
with O
peptic O
ulcers O
were O
excluded O
. O
[]

The O
Measure O
Yourself O
Medical O
Outcomes O
Profile O
( O
MYMOP B-outcome ['Physiological-Clinical']
) O
a O
patient-centered O
health B-outcome ['Physiological-Clinical']
questionnaire O
was O
completed O
monthly O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
500 O
mg O
of O
sacharose O
ferric O
oxide O
( O
Venofer O
) O
was O
intravenously O
administered O
in O
two O
days O
regimen O
to O
50 O
women O
with O
clinical O
and O
lab O
signs O
of O
postpartal O
anemia O
. O
[]

in O
tibialis O
anterior O
and O
rectus O
femoris O
) O
. O
[]

Analyses O
controlled O
for O
level O
of O
acculturation O
and O
immigration O
status O
. O
[]

An O
important O
secondary O
outcome O
was O
the O
score O
on O
the O
Children O
's O
Yale-Brown O
Obsessive O
Compulsive O
Scales O
modified O
for O
pervasive O
developmental O
disorders O
. O
[]

The O
short-term O
efficacy O
of O
diltiazem O
( O
D O
) O
has O
been O
compared O
to O
that O
of O
propranolol O
( O
P O
) O
, O
in O
a O
group O
of O
70 O
patients O
hospitalized O
in O
the O
Coronary O
Care O
Unit O
for O
unstable O
angina O
, O
defined O
as O
recent O
( O
less O
than O
one O
month O
) O
appearance O
or O
aggravation O
of O
spontaneous O
chest O
pains O
. O
[]

Glucose B-outcome ['Physiological-Clinical']
values O
of O
less O
than O
2.5 O
mmol/L O
developed O
7 O
times O
in O
5 O
patients O
, O
4 O
of O
whom O
were O
in O
the O
intensive O
insulin O
therapy O
group O
; O
however O
, O
no O
adverse O
consequences O
were O
documented O
. O
['Physiological-Clinical']

In O
the O
treated O
group O
, O
25 O
ulcers O
( O
58 O
% O
) O
healed O
in O
8 O
weeks O
, O
whereas O
in O
the O
placebo O
group O
, O
only O
one O
ulcer O
( O
3 O
% O
) O
healed O
and O
most O
ulcers B-outcome ['Physiological-Clinical']
increased O
in O
size O
. O
['Physiological-Clinical']

Overall O
, O
side-effects B-outcome ['Adverse-effects']
were O
fewer O
with O
ketoprofen B-outcome ['Resource-use']
than O
with O
indomethacin B-outcome ['Resource-use']
. O
['Adverse-effects', 'Resource-use', 'Resource-use']

Early O
RAO O
occurred O
in O
5.6 O
% O
( O
n O
= O
14 O
) O
of O
the O
intravenous O
group O
and O
6 O
% O
( O
n O
= O
15 O
) O
of O
the O
intra-arterial O
group O
. O
[]

0.3 O
m O
s O
( O
-1 O
) O
; O
P O
= O
0.001 O
) O
. O
[]

OBJECTIVE O
This O
study O
was O
designed O
to O
evaluate O
the O
analgesic O
efficacy O
of O
caudal O
midazolam-bupivacaine O
combination O
in O
providing O
post-operative O
pain O
relief O
in O
children O
undergoing O
genitourinary O
surgery O
and O
to O
study O
the O
occurrence O
of O
adverse O
effects O
. O
[]

Treatment O
outcome O
of O
appliance O
therapy O
in O
temporomandibular O
disorder O
patients O
with O
myofascial B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
6 O
and O
12 O
months O
. O
['Physiological-Clinical']

The O
digestibility O
coefficients O
of O
all O
nutrients O
and O
MPS O
increased O
( O
P O
< O
0.05 O
) O
quadratically O
with O
increasing O
level O
of O
RDN O
supplementation O
. O
[]

[ O
Effect O
of O
Yufeining O
on O
induced O
sputum B-outcome ['Physiological-Clinical']
interleukin-8 I-outcome ['Physiological-Clinical']
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
at O
the O
stable O
phase O
] O
. O
['Physiological-Clinical']

Dietary O
and O
water O
intakes O
were O
recorded O
daily O
. O
[]

Walking O
time O
in O
seconds O
, O
number O
of O
steps B-outcome ['Life-Impact']
, O
frequency O
of O
lateral O
line O
stepping-over O
, O
and O
['Life-Impact']

We O
predicted O
that O
, O
under O
these O
circumstances O
, O
insulin-stimulated O
endothelin-1 O
( O
ET-1 O
) O
action O
( O
assessed O
with O
the O
type O
A O
endothelin O
receptor O
antagonist O
BQ-123 O
) O
would O
be O
augmented O
in O
proportion O
to O
hyperinsulinemia O
. O
[]

UNLABELLED O
Dramatic O
effects O
on O
autistic B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
after O
repeated O
injections O
of O
the O
gastrointestinal O
hormone O
secretin O
have O
been O
referred O
in O
a O
number O
of O
case O
reports O
. O
['Life-Impact']

This O
study O
elucidates O
how O
various O
exercises O
regimens O
with/without O
hypoxia O
affect O
phenotypic B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
T-lymphocyte I-outcome ['Physiological-Clinical']
subsets I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESEARCH O
DESIGN O
AND O
METHODS O
Twenty O
type O
2 O
diabetic O
subjects O
participated O
in O
a O
crossover O
trial O
. O
[]

Data O
about O
clinical O
outcomes O
for O
the O
two O
groups O
were O
also O
obtained O
. O
[]

Tracheal O
mucosal O
blood O
flow O
in O
40 O
patients O
undergoing O
surgery O
was O
assessed O
using O
an O
endoscopic O
photographic O
technique O
while O
varying O
the O
cuff O
inflation O
pressure O
. O
[]

We O
conducted O
a O
randomised O
, O
double-blind O
, O
3-month O
trial O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Patient O
outcomes O
were O
measured O
as O
changes O
in O
global B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
scores O
, O
functioning B-outcome ['Life-Impact']
and O
well-being B-outcome ['Life-Impact']
, O
and O
patients O
' O
reports O
of O
global O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
aim O
of O
this O
study O
is O
to O
investigate O
the O
process O
of O
postoperative O
auricular O
remodeling O
in O
patients O
with O
permanent O
atrial O
fibrillation O
undergoing O
mitral O
surgery O
. O
[]

The O
authors O
report O
the O
results O
of O
a O
randomized O
clinical O
trial O
of O
antibiotic O
prophylaxis O
of O
postoperative O
infection O
following O
breast O
reconstruction O
by O
transposition O
of O
rectus O
abdominis O
myocutaneous O
flap O
( O
TRAMF O
) O
. O
[]

RESULTS O
Of O
379 O
patients O
, O
a O
total O
of O
44 O
patients O
( O
11.6 O
% O
) O
experienced O
spasm O
. O
[]

From O
April O
1990 O
to O
September O
1992 O
, O
the O
authors O
studied O
8 O
patients O
( O
age O
43-65 O
years O
) O
with O
ovarian O
cancer O
. O
[]

AIM O
To O
compare O
the O
immediate O
restoration O
of O
single O
implants O
in O
the O
esthetic O
zones O
performed O
on O
implants O
placed O
immediately O
after O
tooth O
extraction O
or O
8 O
weeks O
later O
( O
immediate O
replacement O
vs. O
immediate O
restoration O
) O
. O
[]

At O
day O
45 O
, O
median O
decrease O
in O
retinal O
thickness O
was O
-23.7 O
?m O
. O
[]

BACKGROUND O
The O
diagnostic O
accuracy O
of O
technetium-99m O
methoxyisobutylisonitrile O
( O
Tc-MIBI O
) O
single O
photon O
emission O
computed O
tomography O
( O
SPECT O
) O
and O
computed O
tomography O
( O
CT O
) O
of O
the O
head O
and O
neck O
for O
differentiating O
recurrent O
or O
residual O
nasopharyngeal O
carcinomas O
( O
NPC O
) O
from O
benign O
lesions O
after O
radiotherapy O
was O
compared O
with O
positron O
emission O
tomography O
( O
PET O
) O
with O
18-fluoro-2-deoxyglucose O
( O
FDG O
) O
. O
[]

RAB-plate O
versus O
sliding O
hip O
screw O
for O
unstable O
trochanteric O
hip O
fractures O
: O
stability O
of O
the O
fixation O
and O
modes O
of O
failure O
-- O
radiographic O
analysis O
of O
218 O
fractures O
. O
[]

Hexetidine O
reduced O
aerobic B-outcome ['Physiological-Clinical']
bacterial I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
on O
Day O
1 O
and O
Day O
8 O
by O
a O
maximum O
of O
83 O
% O
and O
86 O
% O
, O
respectively O
, O
at O
2 O
minutes O
post-dosing O
. O
['Physiological-Clinical']

In O
both O
males O
and O
females O
, O
tobacco O
users O
consumed B-outcome ['Life-Impact']
more O
fat B-outcome ['Physiological-Clinical']
, O
cholesterol O
, O
and O
alcohol B-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Once-daily O
versus O
twice-daily O
lamivudine O
, O
in O
combination O
with O
zidovudine O
and O
efavirenz O
, O
for O
the O
treatment O
of O
antiretroviral-naive O
adults O
with O
HIV O
infection O
: O
a O
randomized O
equivalence O
trial O
. O
[]

Genetic O
polymorphisms O
of O
human O
flavin O
monooxygenase O
3 O
in O
sulindac-mediated O
primary O
chemoprevention O
of O
familial O
adenomatous O
polyposis O
. O
[]

Patients O
suffering O
from O
some O
psychiatric O
and O
neurological O
disorders O
demonstrate O
abnormally O
high O
levels O
of O
saccadic O
distractibility O
when O
carrying O
out O
the O
antisaccade O
task O
. O
[]

METHODS O
This O
randomized O
, O
double O
blind O
, O
placebo O
controlled O
study O
compares O
outcome O
measures O
in O
26 O
patients O
with O
chronic O
neck O
pain O
( O
WAD-II O
chronic O
) O
subsequent O
to O
a O
motor O
vehicle O
accident O
. O
[]

Nephrotoxicity O
of O
cyclosporin O
A O
in O
patients O
with O
newly O
diagnosed O
type O
1 O
diabetes O
mellitus O
. O
[]

During O
the O
same O
follow-up O
period O
children O
in O
both O
groups O
exhibited O
comparable O
patterns O
of O
weight O
gain O
; O
1 O
y O
after O
the O
intervention O
the O
mean O
weight O
for O
age O
of O
children O
in O
both O
groups O
was O
76 O
% O
of O
the O
NCHS O
standard O
. O
[]

0.7 O
kg O
) O
were O
used O
in O
a O
trial O
with O
a O
3 O
? O
[]

METHODS O
Newborn O
, O
term O
infants O
studied O
in O
a O
masked O
12-month O
feeding O
trial O
were O
assigned O
randomly O
to O
soy O
formula O
groups O
with O
and O
without O
added O
nucleotides O
( O
n O
= O
94 O
, O
n O
= O
92 O
) O
. O
[]

BACKGROUND O
AND O
OBJECTIVE O
Acute O
intermittent O
porphyria O
is O
an O
autosomal O
dominant O
disorder O
caused O
by O
deficient O
activity O
of O
the O
third O
enzyme O
in O
the O
haem O
biosynthetic O
pathway O
, O
porphobilinogen O
deaminase O
. O
[]

They O
affect O
mostly O
younger O
population O
that O
need O
a O
higher O
level O
of O
activities O
as O
compared O
with O
the O
elderly O
. O
[]

However O
, O
changes O
in O
circulating O
cholesterol O
can O
not O
explain O
the O
entire O
effect O
. O
[]

With O
atorvastatin O
, O
the O
distensibility B-outcome ['Physiological-Clinical']
coefficient O
( O
DC O
) O
and O
compliance B-outcome ['Life-Impact']
coefficient O
( O
CC O
) O
increased O
from O
18.7 O
+/- O
3.4 O
to O
21.3 O
+/- O
2.9 O
10 O
( O
-3 O
) O
x O
kPa O
( O
-1 O
) O
( O
P O
< O
0.001 O
) O
and O
from O
0.69 O
+/- O
0.05 O
to O
0.77 O
+/- O
0.03 O
mm2 O
x O
kPa O
( O
-1 O
) O
( O
P O
< O
0.001 O
) O
in O
the O
first O
group O
while O
they O
changed O
from O
18.3 O
+/- O
3.6 O
to O
21.9 O
+/- O
3.0 O
10 O
( O
-3 O
) O
x O
kPa O
( O
-1 O
) O
( O
P O
< O
0.001 O
) O
and O
from O
0.70 O
+/- O
0.04 O
to O
0.81 O
+/- O
0.01 O
mm2 O
x O
kPa O
( O
-1 O
) O
( O
P O
< O
0.001 O
) O
respectively O
, O
in O
the O
second O
group O
. O
['Physiological-Clinical', 'Life-Impact']

CONCLUSION O
PKVP O
achieved O
comparable O
results O
to O
traditional O
TURP O
and O
was O
an O
effective O
and O
safe O
procedure O
. O
[]

The O
trained O
individuals O
improved O
significantly O
on O
the O
affect B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
task I-outcome ['Life-Impact']
, O
but O
not O
on O
any O
other O
measure O
. O
['Life-Impact']

All O
patients O
improved O
both O
symptomatically O
and O
by O
objective O
measures O
of O
lung O
function O
. O
[]

Persistent O
muscle O
inhibition O
of O
the O
fibularis O
longus O
and O
soleus O
muscles O
and O
altered O
joint O
arthrokinematics O
may O
play O
a O
role O
in O
chronic O
ankle O
instability O
( O
CAI O
) O
. O
[]

Low O
body O
mass O
index O
and O
dyslipidemia O
in O
dialysis O
patients O
linked O
to O
elevated O
plasma O
fibroblast O
growth O
factor O
23 O
. O
[]

The O
left O
eye O
served O
as O
a O
control O
without O
administration O
. O
[]

No O
DE O
effect O
was O
observed O
for O
WBC B-outcome ['Physiological-Clinical']
, O
neutrophils B-outcome ['Physiological-Clinical']
, O
lymphocytes B-outcome ['Physiological-Clinical']
or O
erythrocytes B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
differences O
were O
detected O
between O
sham O
ionisation O
and O
placebo O
ionisation O
. O
[]

DESIGN O
AND O
HYPOTHESIS O
We O
hypothesize O
that O
changes O
in O
body O
composition O
affect O
REE O
during O
HSCT O
, O
and O
that O
standard O
nutritional O
support O
may O
lead O
to O
overfeeding O
. O
[]

In O
the O
prosthetic O
bypass O
group O
, O
there O
was O
no O
significant O
difference O
in O
patency B-outcome ['Physiological-Clinical']
rate O
in O
the O
8-mm O
bypass O
subgroup O
, O
but O
there O
was O
a O
significant O
difference O
in O
patency B-outcome ['Physiological-Clinical']
rate O
in O
the O
6-mm O
bypass O
subgroup O
( O
femoral-popliteal O
; O
71.4 O
% O
in O
the O
WASA O
group O
versus O
57.9 O
% O
in O
the O
ASA O
group O
; O
P O
=.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Treatment O
assignment O
did O
not O
have O
a O
significant O
impact O
on O
caregiver B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
during O
infancy O
or O
on O
the O
change O
in O
stress O
during O
the O
child O
's O
first O
2 O
years O
of O
life O
. O
['Life-Impact']

In O
13 O
patients O
in O
whom O
frequency O
of O
crying B-outcome ['Life-Impact']
could O
be O
assessed O
, O
the O
number O
of O
daily B-outcome ['Life-Impact']
crying I-outcome ['Life-Impact']
episodes I-outcome ['Life-Impact']
decreased O
by O
at O
least O
50 O
% O
in O
all O
cases O
during O
citalopram O
treatment O
vs O
2 O
patients O
during O
placebo O
treatment O
( O
p O
< O
0.005 O
, O
McNemar O
's O
test O
) O
, O
the O
effect O
being O
rapid O
( O
1-3 O
days O
) O
and O
pronounced O
in O
11 O
( O
73 O
% O
) O
. O
['Life-Impact', 'Life-Impact']

Schizophrenia O
. O
[]

The O
drug O
is O
extensively O
metabolized O
and O
detected O
in O
plasma O
and O
urine O
. O
[]

Three O
weeks O
of O
intervention O
with O
fluoxetine O
was O
associated O
with O
a O
5.2 O
% O
reduction O
in O
brain B-outcome ['Physiological-Clinical']
5-HT4R I-outcome ['Physiological-Clinical']
binding I-outcome ['Physiological-Clinical']
( O
P=0.017 O
) O
, O
whereas O
placebo O
intervention O
did O
not O
change O
5-HT4R O
binding O
( O
P=0.52 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
Patients O
with O
stroke O
have O
a O
high O
prevalence O
of O
depression O
and O
unawareness O
of O
emotions O
or O
alexithymia B-outcome ['Life-Impact']
. O
['Life-Impact']

CONCLUSIONS O
KC O
11458 O
, O
in O
a O
dose O
of O
8 O
mg O
t.d.s O
. O
[]

514 O
of O
2605 O
patients O
in O
the O
pioglitazone O
group O
and O
572 O
of O
2633 O
patients O
in O
the O
placebo O
group O
had O
at O
least O
one O
event O
in O
the O
primary B-outcome ['Physiological-Clinical']
composite I-outcome ['Physiological-Clinical']
endpoint I-outcome ['Physiological-Clinical']
( O
HR O
0.90 O
, O
95 O
% O
CI O
0.80-1.02 O
, O
p=0.095 O
) O
. O
['Physiological-Clinical']

The O
method O
is O
compared O
with O
several O
different O
automatic O
systems O
and O
is O
shown O
to O
outperform O
them O
all O
. O
[]

We O
recommend O
the O
use O
of O
proparacaine O
eye O
drops O
for O
the O
short O
term O
, O
immediate O
relief O
of O
pain O
during O
ROP O
screening O
in O
preterm O
infants O
of O
lesser O
GA O
. O
[]

We O
doubt O
that O
the O
difference O
is O
clinically O
significant O
. O
[]

INTERVENTION O
Subjects O
were O
randomly O
allocated O
to O
either O
the O
U- O
or O
H-type O
method O
of O
TVT-S. O
MEASUREMENTS O
Pre- O
and O
postoperative O
evaluations O
included O
a O
standing O
stress O
test O
, O
the O
Sandvik O
questionnaire O
, O
the O
Incontinence B-outcome ['Physiological-Clinical']
Quality O
of O
Life O
( O
I-QOL O
) O
questionnaire O
, O
and O
the O
International O
Consultation B-outcome ['Resource-use']
on O
Incontinence B-outcome ['Physiological-Clinical']
Questionnaire-Female O
Lower O
Urinary B-outcome ['Physiological-Clinical']
Tract I-outcome ['Physiological-Clinical']
Symptoms I-outcome ['Physiological-Clinical']
( O
ICIQ-FLUTS O
) O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Leakage B-outcome ['Physiological-Clinical']
rates O
were O
1.6 O
% O
and O
4.9 O
% O
( O
p O
= O
NS O
) O
. O
['Physiological-Clinical']

Normally O
, O
Healthway O
staff O
attends O
these O
events O
to O
help O
promote O
health O
messages O
. O
[]

Verapamil O
, O
480 O
mg/day O
, O
reduced O
anginal B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
from O
5.6 O
+/- O
7.3 O
to O
2.2 O
+/- O
3.9 O
attacks O
per O
week O
( O
p O
less O
than O
0.001 O
) O
and O
nitroglycerin B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
from O
3.4 O
+/- O
4.9 O
to O
1.2 O
+/- O
2.5 O
tablets O
per O
week O
( O
p O
less O
than O
0.05 O
) O
compared O
with O
placebo O
. O
['Physiological-Clinical', 'Resource-use']

RESULTS O
For O
sleeping B-outcome ['Physiological-Clinical']
behavior I-outcome ['Physiological-Clinical']
, O
midazolam O
was O
found O
to O
be O
significantly O
more O
effective O
than O
diazepam O
as O
the O
duration O
of O
stimulation O
increased O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

Seventeen O
patients O
received O
the O
drug O
( O
40 O
mg O
in O
5 O
ml O
i.m O
. O
[]

Two O
of O
three O
control O
subjects O
also O
had O
increased O
erythron B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
turnovers I-outcome ['Physiological-Clinical']
, O
which O
in O
one O
case O
was O
related O
to O
increased O
dialysis-associated B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
losses I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
TOISD O
was O
found O
to O
be O
effective O
in O
reducing O
bacterial O
colonisation O
on O
the O
surgical O
site O
compared O
with O
no O
dressing O
. O
[]

This O
study O
was O
designed O
to O
check O
whether O
the O
skin B-outcome ['Physiological-Clinical']
wheal I-outcome ['Physiological-Clinical']
and O
flare B-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
produced O
by O
the O
intradermal O
injection O
of O
autologous O
serum O
( O
AS O
) O
and O
by O
histamine O
differs O
in O
AH-resistant O
and O
AH O
responder O
CIU O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
There O
are O
few O
published O
placebo-controlled O
clinical O
trials O
demonstrating O
the O
efficacy O
of O
the O
newer O
antidepressants O
in O
markedly O
or O
severely O
depressed O
hospitalized O
patients O
. O
[]

CONCLUSIONS O
A O
total O
of O
2,048 O
side O
branches O
were O
evaluated O
( O
EES O
N=1,345 O
side O
branches O
in O
688 O
stented O
lesions O
, O
PES O
N=703 O
side O
branches O
in O
346 O
stented O
lesions O
) O
. O
[]

No O
significant O
intervention O
effects O
were O
observed O
on O
height B-outcome ['Physiological-Clinical']
, O
BMI O
, O
['Physiological-Clinical']

PURPOSE O
Docosahexaenoic O
acid O
( O
DHA O
) O
continues O
to O
be O
evaluated O
and O
recommended O
as O
treatment O
and O
prophylaxis O
for O
various O
diseases O
. O
[]

15,000 O
per O
?L O
) O
, O
use O
of O
treatment O
for O
immune O
thrombocytopenia O
, O
and O
splenectomy O
status O
. O
[]

Fifty O
percent O
of O
the O
usual-care O
group O
reported O
maintaining B-outcome ['Physiological-Clinical']
or O
increasing O
their O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
to O
a O
moderate-intensity B-outcome ['Physiological-Clinical']
level O
, O
while O
33 O
% O
of O
the O
exercise O
group O
did O
not O
exercise O
at O
the O
prescribed O
levels O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
59 O
% O
in O
the O
control O
and O
69 O
in O
the O
infusion O
group O
( O
p O
= O
0.048 O
) O
. O
['Mortality']

Twenty-one O
pretreatment O
variables O
were O
assessed O
for O
their O
significance O
in O
response O
prediction O
using O
data O
from O
114 O
patients O
given O
alpha-interferon O
for O
chronic O
hepatitis O
B O
virus O
infection O
. O
[]

Clomipramine O
, O
haloperidol O
, O
and O
placebo O
were O
compared O
with O
baseline O
in O
the O
treatment O
of O
autism O
, O
and O
overall O
outcome O
, O
specific B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
and O
side O
effects O
were O
examined O
. O
['Life-Impact']

By O
activating O
patients O
to O
become O
involved O
in O
their O
own O
care O
, O
we O
believe O
the O
addition O
of O
the O
web-based O
intervention O
will O
improve O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
compared O
to O
a O
control O
group O
who O
receive O
web-based O
preventive O
messages O
unrelated O
to O
hypertension O
. O
['Physiological-Clinical']

Adjusting O
intraocular O
pressure O
for O
central O
corneal O
thickness O
does O
not O
improve O
prediction O
models O
for O
primary O
open-angle O
glaucoma O
. O
[]

Where O
an O
aroma O
was O
presented O
, O
an O
instructional O
priming O
procedure O
was O
used O
to O
manipulate O
participants O
' O
expectancies O
about O
the O
aroma O
's O
likely O
impact O
on O
their O
ability O
to O
relax O
. O
[]

A O
meta-analysis O
of O
13 O
randomized O
placebo-controlled O
trials O
published O
between O
1960 O
and O
1992 O
showed O
evidence O
of O
benefit O
for O
dipyridamole O
in O
the O
treatment O
of O
angina O
pectoris O
, O
especially O
with O
longer O
duration O
of O
treatment O
. O
[]

The O
values O
of O
several O
intraoperative O
parameters O
were O
significantly O
better O
in O
the O
trochanteric O
nailing O
group O
. O
[]

In O
both O
tasks O
, O
the O
obtained O
psychometric O
functions O
revealed O
higher O
pitch B-outcome ['Life-Impact']
sensitivity I-outcome ['Life-Impact']
for O
subjects O
with O
autism O
, O
with O
a O
more O
pronounced O
advantage O
over O
control O
participants O
in O
the O
categorization B-outcome ['Life-Impact']
task O
. O
['Life-Impact', 'Life-Impact']

The O
15-year O
actuarial O
rate O
of O
severe B-outcome ['Adverse-effects']
late I-outcome ['Adverse-effects']
RT I-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
did O
not O
differ O
between O
the O
two O
arms O
( O
6 O
% O
for O
q.d O
. O
['Adverse-effects']

Promoting O
question-asking O
in O
school-aged O
children O
with O
autism O
spectrum O
disorders O
: O
effectiveness O
of O
a O
robot O
intervention O
compared O
to O
a O
human-trainer O
intervention O
. O
[]

The O
mean O
age O
of O
randomised O
children O
was O
24 O
months O
and O
mean O
blood O
lead O
level O
26 O
micrograms/dL O
. O
[]

This O
finding O
may O
indicate O
that O
the O
level O
of O
infection B-outcome ['Physiological-Clinical']
or O
the O
frequency O
of O
infection B-outcome ['Physiological-Clinical']
may O
have O
to O
be O
altered O
in O
future O
trials O
to O
induce O
a O
therapeutically O
conducive O
immunologic O
phenotype O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
sought O
to O
investigate O
whether O
allopurinol O
alters O
expression O
of O
inflammatory O
markers O
after O
acute O
ischemic O
stroke O
. O
[]

RESULTS O
Nineteen O
of O
20 O
subjects O
taking O
5 O
mg O
and O
all O
20 O
subjects O
taking O
10 O
mg O
completed O
all O
6 O
months O
of O
the O
study O
. O
[]

In O
view O
of O
the O
correlation O
between O
angiographic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
and O
subsequent O
clinical B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
as O
demonstrated O
in O
several O
large O
trials O
, O
it O
is O
not O
unrealistic O
to O
also O
anticipate O
in O
this O
population O
, O
a O
beneficial O
effect O
on O
clinical O
events O
with O
longer O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
double-blind O
, O
placebo-controlled O
randomized O
trial O
of O
13-cis O
retinoic O
acid O
was O
performed O
to O
determine O
if O
the O
drug O
has O
a O
therapeutic O
effect O
in O
patients O
with O
myelodysplastic O
syndromes O
( O
MDS O
) O
. O
[]

Treatment O
consisted O
of O
4 O
sessions O
of O
anxiety O
management O
training O
followed O
either O
by O
exposure O
to O
a O
virtual O
airplane O
( O
VRE O
) O
or O
an O
actual O
airplane O
at O
the O
airport O
( O
SE O
) O
conducted O
over O
6 O
weeks O
. O
[]

However O
, O
it O
failed O
to O
predict O
the O
outcome O
of O
CIN2 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Naltrexone O
, O
an O
opiate O
antagonist O
, O
fails O
to O
modify O
motor B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
patients O
with O
Parkinson O
's O
disease O
. O
['Life-Impact']

Male O
Sprague-Dawley O
rats O
( O
n O
= O
6 O
per O
group O
) O
were O
housed O
in O
photobiologic O
light-exposure O
chambers O
configured O
to O
create O
1 O
) O
a O
12:12-h O
light O
: O
dark O
cycle O
without O
dark-phase O
light O
contamination O
( O
control O
condition O
; O
123 O
?W/cm O
( O
2 O
) O
, O
lights O
on O
at O
0600 O
) O
, O
2 O
) O
experimental O
exposure O
to O
a O
low O
level O
of O
light O
during O
the O
12-h O
dark O
phase O
( O
with O
0.02 O
, O
0.05 O
, O
0.06 O
, O
or O
0.08 O
?W/cm O
( O
2 O
) O
light O
at O
night O
) O
, O
or O
3 O
) O
constant O
bright O
light O
( O
123 O
?W/cm O
( O
2 O
) O
) O
. O
[]

Effects O
of O
a O
fish-oil O
and O
vegetable-oil O
formula O
on O
aggregation O
and O
ethanolamine-containing O
lysophospholipid B-outcome ['Physiological-Clinical']
generation I-outcome ['Physiological-Clinical']
in O
activated O
human O
platelets O
and O
on O
leukotriene B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
in O
stimulated O
neutrophils O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Nebulized O
bronchodilators O
improve O
airways B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
, O
lung B-outcome ['Physiological-Clinical']
reactance I-outcome ['Physiological-Clinical']
, O
and O
peak O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
during O
exercise O
in O
chronic O
heart O
failure O
but O
do O
not O
increase O
peak O
exercise O
capacity O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Simulating O
a O
memory O
impairment O
: O
can O
amnesics O
implicitly O
outperform O
simulators O
? O
[]

Rehabilitation B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
following O
percutaneous O
coronary O
interventions O
( O
PCI O
) O
. O
['Physiological-Clinical']

SETTING O
The O
study O
was O
performed O
in O
General O
Clinical O
Research O
Centers O
at O
two O
University O
Hospitals O
. O
[]

CONCLUSIONS O
In O
patients O
with O
high-risk O
resected O
melanoma O
, O
HDI O
is O
effective O
adjuvant O
therapy O
with O
strong O
evidence O
for O
improved O
RFS B-outcome ['Mortality']
and O
evidence O
for O
moderate O
improvement O
in O
OS B-outcome ['Mortality']
based O
on O
two O
prospective O
randomized O
studies O
but O
not O
the O
pooled O
analysis O
. O
['Mortality', 'Mortality']

RESULTS O
Between O
January O
2001 O
and O
March O
2003 O
, O
1212 O
individuals O
seeking O
help O
for O
mental O
health O
problems O
were O
screened O
for O
putative O
prodromal O
symptoms O
at O
four O
university O
centres O
. O
[]

It O
is O
essential O
to O
provide O
an O
adequate O
amount O
of O
rumen-degradable O
nitrogen O
( O
RDN O
) O
for O
optimum O
microbial O
protein O
synthesis O
in O
the O
rumen O
on O
straw-based O
diets O
. O
[]

Terbinafine B-outcome ['Resource-use']
levels O
were O
determined O
by O
high B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
liquid I-outcome ['Physiological-Clinical']
chromatography I-outcome ['Physiological-Clinical']
with O
tandem O
mass O
detection O
( O
HPLC-MS/MS O
) O
and O
the O
lower O
limit O
of O
quantification O
was O
set O
at O
9.99 O
ng/mL O
. O
['Resource-use', 'Physiological-Clinical']

METHODS O
Men O
with O
erectile O
dysfunction O
were O
randomized O
into O
two O
groups O
of O
25 O
each O
. O
[]

Sixteen O
males O
and O
females O
were O
randomly O
assigned O
to O
either O
temperature O
feedback O
groups O
warm-relax O
( O
WR O
) O
or O
cool-relax O
( O
CR O
) O
to O
determine O
how O
successful O
hand-warming O
and O
-cooling O
alters O
the O
subjective O
report O
of O
relaxation O
. O
[]

All O
eight O
products O
were O
effective O
in O
bleaching B-outcome ['Physiological-Clinical']
teeth I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PATIENTS O
Two O
groups O
( O
control O
group O
[ O
group O
1 O
] O
and O
hemodiluted O
group O
[ O
group O
2 O
] O
) O
of O
13 O
healthy O
patients O
were O
studied O
during O
a O
long-term O
( O
> O
4 O
hrs O
) O
surgical O
procedure O
. O
[]

METHODS O
This O
study O
had O
a O
statewide O
group-randomized O
prospective O
trial O
design O
. O
[]

No O
significant O
difference O
was O
observed O
between O
resting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
on O
the O
two O
combinations O
at O
either O
dose O
level O
. O
['Physiological-Clinical']

However O
, O
in O
the O
amiodarone O
group O
, O
there O
was O
a O
35 O
% O
risk O
reduction O
( O
95 O
% O
CI O
0-58 O
, O
p O
= O
0.05 O
) O
in O
arrhythmic B-outcome ['Mortality']
deaths I-outcome ['Mortality']
. O
['Mortality']

Time B-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
day I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
in O
the O
range O
of O
71-180 O
mg/dl O
increased O
significantly O
( O
P O
= O
0.02 O
) O
from O
baseline O
to O
12 O
months O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURE O
The O
main O
outcome O
measure O
was O
the O
antiplatelet B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ASA I-outcome ['Physiological-Clinical']
, O
as O
assessed O
by O
ARU B-outcome ['Resource-use']
ratio O
relative O
to O
baseline O
in O
the O
VerifyNow O
ASA O
assay O
; O
suppression O
of O
serum B-outcome ['Physiological-Clinical']
thromboxane I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Physiological O
measures O
included O
measurement O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
lipids B-outcome ['Physiological-Clinical']
, O
bone B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
, O
and O
cardiorespiratory B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
including O
direct O
measurements O
of O
peak O
oxygen B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
( O
VO2 B-outcome ['Physiological-Clinical']
) O
and O
anaerobic B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

The O
study O
was O
observed O
by O
an O
independent O
clinician O
with O
an O
intraexaminer O
reliability O
of O
88 O
% O
. O
[]

The O
effectiveness O
of O
antidepressant O
drugs O
in O
the O
management O
of O
post-stroke O
depression O
( O
PSD O
) O
has O
been O
widely O
investigated O
. O
[]

Visualization O
and O
15 O
W O
maximum O
: O
Ablation O
guided O
by O
barium O
visualization O
of O
the O
esophageal O
course O
using O
a O
limit O
of O
15 O
W O
, O
n O
= O
35 O
. O
[]

INTERVENTIONS O
All O
participants O
underwent O
conventional O
physiotherapy O
. O
[]

After O
ten O
weeks O
of O
combined O
treatment O
, O
the O
dysthymic O
women O
show O
statistically O
significant O
improvement O
on O
all O
the O
depression B-outcome ['Life-Impact']
measures O
as O
well O
as O
on O
the O
intimacy B-outcome ['Life-Impact']
scale O
. O
['Life-Impact', 'Life-Impact']

It O
is O
proposed O
that O
manikin O
training O
alone O
may O
be O
adopted O
as O
a O
future O
training O
modality O
if O
, O
as O
is O
expected O
, O
the O
use O
of O
the O
LMA O
in O
resuscitation O
becomes O
more O
commonplace O
. O
[]

The O
erythropoietic O
stimulus O
of O
phlebotomy O
for O
autologous O
blood O
donations O
is O
often O
not O
efficient O
enough O
to O
guarantee O
a O
constant O
haematocrit B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
administration O
of O
granisetron O
had O
no O
significant O
effect O
on O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
or O
clinical O
laboratory O
test O
profiles O
. O
['Physiological-Clinical']

Unique O
identifiers O
: O
NCT00328692 O
and O
NCT00354458 O
. O
[]

One O
hour O
after O
reading O
the O
text O
, O
participants O
listed O
all O
content O
that O
they O
could O
recall O
. O
[]

However O
, O
the O
effect O
of O
long-term O
metal O
exposure O
remains O
uncertain O
. O
[]

Typical O
symptoms O
of O
the O
depression O
such O
as O
lack B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
, O
tiredness B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
disturbed B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
, O
were O
especially O
responsive O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
visual O
cortex O
, O
including O
the O
right O
and O
left O
cuneus O
and O
left O
lateral O
occipito-temporal O
gyrus O
fusiformis O
, O
also O
showed O
an O
increase O
in O
regional B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
with O
Z O
scores O
> O
3 O
. O
['Physiological-Clinical']

Efficacy O
, O
safety O
, O
and O
[]

Later O
on O
, O
oxygen B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
was O
equal O
in O
both O
groups O
, O
with O
no O
further O
changes O
due O
to O
clamping O
or O
declamping O
of O
the O
aorta O
. O
['Physiological-Clinical']

infusion O
) O
, O
doxorubicin O
( O
25 O
mg/m O
( O
2 O
) O
i.v O
. O
) O
[]

Increased O
arterial O
stiffness O
is O
associated O
with O
enhanced O
risk O
of O
cardiovascular O
disease O
in O
obese O
individuals O
. O
[]

The O
duration O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
shorter O
in O
the O
S. O
boulardii O
group O
than O
in O
the O
placebo O
group O
( O
2.9 O
vs O
3.9 O
d O
, O
p O
< O
0.001 O
) O
. O
['Resource-use']

Ten O
weeks O
later O
, O
all O
pigs O
were O
challenge-exposed O
intranasally O
with O
strain O
NIA-3 O
. O
[]

To O
our O
knowledge O
we O
report O
the O
first O
prospective O
randomized O
trial O
to O
assess O
the O
infectious B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
hemorrhagic I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
associated O
with O
this O
method O
. O
['Physiological-Clinical']

However O
, O
prior O
work O
has O
not O
identified O
the O
optimal O
precessation O
dose O
or O
means O
for O
personalizing O
NRT O
. O
[]

A O
number O
of O
recent O
studies O
have O
assessed O
the O
impact O
of O
dietary O
omega-3 O
polyunsaturated O
fatty O
acids O
( O
n-3 O
PUFAs O
) O
on O
behavioral O
outcomes O
; O
however O
, O
very O
little O
attention O
has O
been O
given O
to O
their O
impact O
upon O
brain O
function O
in O
physiological O
terms O
. O
[]

An O
experimental O
design O
with O
three O
repeated O
measures O
was O
used O
( O
pre-treatment O
, O
post-treatment/post-waiting O
list O
and O
follow-up O
) O
. O
[]

The O
most O
common O
adverse O
effect O
with O
risperidone O
was O
somnolence B-outcome ['Life-Impact']
( O
74 O
% O
vs. O
7 O
% O
with O
placebo O
) O
. O
['Life-Impact']

A O
randomly O
selected O
diet O
and O
control O
group O
with O
10 O
children O
in O
each O
group O
participated O
. O
[]

Reported O
frequency O
of O
GI B-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
, O
including O
abnormal B-outcome ['Physiological-Clinical']
stool I-outcome ['Physiological-Clinical']
consistency I-outcome ['Physiological-Clinical']
( O
e.g. O
, O
bulky B-outcome ['Physiological-Clinical']
or O
loose B-outcome ['Physiological-Clinical']
) O
, O
was O
increased O
( O
54 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
its O
association O
with O
hospitalization O
in O
HF O
patients O
has O
not O
been O
well O
studied O
. O
[]

There O
was O
a O
12.5 O
% O
frequency O
of O
allergic B-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
in O
the O
CX516 O
group O
and O
1 O
subject O
developed O
a O
substantial B-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
clinical B-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
score O
also O
showed O
significant O
improvement O
in O
the O
MgSO4 O
group O
1 O
, O
2 O
, O
3 O
and O
11 O
hours O
after O
stopping O
the O
infusion O
( O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

By O
end O
of O
follow O
up O
142 O
patients O
had O
died B-outcome ['Mortality']
, O
42 O
of O
aneurysm-related O
factors O
; O
overall B-outcome ['Mortality']
mortality I-outcome ['Mortality']
after O
4 O
years O
was O
64 O
% O
. O
['Mortality', 'Mortality']

RESULTS O
The O
total O
number O
of O
exacerbations B-outcome ['Physiological-Clinical']
was O
slightly O
lower O
in O
the O
flunisolide O
group O
compared O
to O
the O
placebo O
group O
( O
19 O
vs. O
34 O
, O
p O
= O
0.054 O
) O
; O
the O
number O
of O
patients O
experiencing O
at O
least O
one O
exacerbation B-outcome ['Physiological-Clinical']
during O
the O
study B-outcome ['Life-Impact']
was O
also O
decreased O
( O
16 O
vs. O
26 O
, O
p O
= O
0.059 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

It O
aimed O
to O
educate O
parents O
and O
train O
them O
in O
adapted O
communication O
tailored O
to O
their O
child O
's O
individual O
competencies O
. O
[]

We O
have O
therefore O
evaluated O
, O
in O
a O
randomized O
clinical O
trial O
, O
the O
effect O
of O
these O
aminoacids O
in O
chronic O
outstanding O
and O
stable O
patients O
with O
HFpEF O
. O
[]

Major O
toxicities B-outcome ['Adverse-effects']
were O
anorexia B-outcome ['Physiological-Clinical']
and O
neutropenia B-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

In O
particular O
, O
the O
parameter-specific O
provocation O
doses O
are O
considered O
to O
be O
the O
main O
target O
values O
. O
[]

The O
pre-study O
sample O
size O
calculation O
was O
22 O
patients O
per O
group O
. O
[]

BACKGROUND O
Levosimendan O
, O
a O
novel O
calcium O
sensitiser O
, O
improves O
cardiac O
performance O
and O
symptoms O
without O
increasing O
oxygen O
consumption O
, O
and O
decreases O
the O
mortality O
of O
patients O
with O
low-output O
heart O
failure O
. O
[]

DESIGN O
, O
SETTING O
, O
AND O
PATIENTS O
A O
double-blind O
, O
randomized O
controlled O
trial O
of O
300 O
patients O
aged O
18 O
to O
80 O
years O
who O
underwent O
elective O
colorectal O
surgery O
in O
14 O
Spanish O
hospitals O
from O
March O
1 O
, O
2003 O
, O
to O
October O
31 O
, O
2004 O
. O
[]

The O
experimental O
group O
preferred O
double-looping O
over O
propulsion O
, O
while O
the O
control O
group O
mainly O
used O
single-looping O
over O
propulsion O
patterns O
during O
the O
post-test O
. O
[]

Effect O
of O
Orlistat O
in O
obese O
patients O
with O
heart O
failure O
: O
a O
pilot O
study O
. O
[]

The O
test O
teeth O
received O
SRP O
and O
a O
25 O
% O
metronidazole O
gel O
applied O
subgingivally O
on O
days O
0 O
and O
7 O
. O
[]

METHODS O
On O
four O
separate O
occasions O
, O
12 O
male O
team-sport O
players O
performed O
a O
standardized O
warm-up O
, O
followed O
by O
a O
test O
of O
either O
RSA B-outcome ['Physiological-Clinical']
or O
CODS O
( O
on O
two O
occasions O
each O
) O
in O
a O
counterbalanced O
design O
. O
['Physiological-Clinical']

There O
is O
concern O
that O
public O
education O
about O
testicular O
cancer O
( O
TC O
) O
may O
cause O
unnecessary O
anxiety O
. O
[]

Cephalometry B-outcome ['Physiological-Clinical']
with O
and O
without O
a O
chinstrap O
was O
randomly O
performed O
on O
six O
patients O
. O
['Physiological-Clinical']

The O
current O
study O
was O
aimed O
to O
compare O
the O
effects O
of O
the O
selective O
alpha O
1-adrenergic O
blocker O
terazosin O
( O
5 O
mg O
once O
daily O
) O
and O
of O
the O
angiotensin-converting O
enzyme O
inhibitor O
enalapril O
( O
20 O
mg O
once O
daily O
) O
on O
cardiovascular O
response O
to O
a O
set O
of O
standardized O
laboratory O
stressors O
, O
such O
as O
mental O
arithmetic O
, O
handgrip O
test O
and O
cycle O
ergometry O
, O
in O
a O
group O
of O
16 O
essential O
hypertensive O
patients O
. O
[]

BNP B-outcome ['Physiological-Clinical']
increased O
diagnostic B-outcome ['Life-Impact']
certainty I-outcome ['Life-Impact']
as O
defined O
by O
the O
need O
for O
further O
diagnostic O
work-up O
( O
33 O
% O
vs. O
45 O
% O
; O
P O
= O
0.02 O
) O
and O
accelerated O
the O
initiation O
of O
the O
appropriate O
treatment O
( O
13 O
days O
vs. O
25 O
days O
; O
P O
= O
0.01 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

The O
aim O
of O
our O
study O
was O
to O
evaluate O
the O
efficacy O
of O
neridronate O
, O
a O
relatively O
new O
bisphosphonate O
, O
to O
prevent O
bone O
loss O
during O
androgen O
ablation O
. O
[]

METHODS O
Forty O
patients O
were O
divided O
into O
four O
groups O
of O
ten O
. O
[]

in O
moderately O
severe O
reflux O
oesophagitis O
( O
grades O
II-III O
) O
. O
[]

POPULATION O
Women O
attending O
their O
general O
practitioner O
in O
the O
first O
trimester O
to O
confirm O
pregnancy O
, O
in O
whom O
a O
first O
trimester O
ultrasound O
scan O
was O
not O
indicated O
. O
[]

In O
the O
SR O
group O
, O
the O
hazard O
ratios O
( O
VACA O
v O
VAIA O
) O
for O
EFS O
and O
OS O
were O
0.91 O
( O
95 O
% O
CI O
, O
0.55 O
to O
1.53 O
) O
and O
1.08 O
( O
95 O
% O
CI O
, O
0.58 O
to O
2.03 O
) O
, O
respectively O
. O
[]

The O
study O
was O
performed O
as O
a O
30-day O
study O
. O
[]

A O
single O
dose O
of O
diazoxide O
150 O
mg O
or O
labetalol O
50 O
mg O
was O
effective O
in O
74 O
% O
and O
70 O
% O
of O
the O
hypertensive B-outcome ['Physiological-Clinical']
episodes O
, O
respectively O
. O
['Physiological-Clinical']

CONCLUSIONS O
These O
findings O
suggest O
that O
VK2 O
does O
not O
appear O
to O
prevent O
recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
HCC I-outcome ['Physiological-Clinical']
after O
curative O
treatment O
. O
['Physiological-Clinical']

It O
ensures O
lesser O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
early B-outcome ['Life-Impact']
discharge I-outcome ['Life-Impact']
, O
less O
time O
off O
work O
, O
complications B-outcome ['Adverse-effects']
similar O
to O
the O
open O
technique O
, O
and O
in O
the O
end O
a O
more O
satisfied B-outcome ['Life-Impact']
patient O
with O
no O
perianal O
wound O
. O
['Physiological-Clinical', 'Life-Impact', 'Adverse-effects', 'Life-Impact']

Anecdotal O
reports O
suggest O
that O
metronidazole O
may O
have O
disease O
modifying O
activity O
in O
the O
treatment O
of O
rheumatoid O
arthritis O
. O
[]

RESULTS O
Five O
hundred O
twenty-nine O
patients O
were O
randomised O
( O
58 O
% O
male O
) O
. O
[]

Eighteen O
patients O
received O
the O
combination O
and O
were O
compared O
with O
six O
concurrent O
control O
and O
65 O
historical O
control O
patients O
treated O
with O
rhGM-CSF O
alone O
. O
[]

Eligible O
patients O
then O
entered O
a O
3-wk O
double-blind O
treatment O
period O
and O
received O
either O
desmopressin O
or O
placebo O
. O
[]

We O
examined O
the O
efficacy O
and O
safety O
of O
naltrexone O
hydrochloride O
, O
an O
opioid O
antagonist O
, O
in O
the O
treatment O
of O
SIB O
and O
autism O
in O
mentally O
retarded O
adults O
. O
[]

Pigs O
were O
inoculated O
intranasally O
with O
the O
virulent O
NIA-3 O
strain O
or O
the O
avirulent O
Bartha O
strain O
, O
or O
they O
were O
inoculated O
IM O
with O
an O
inactivated O
vaccine O
containing O
the O
Phylaxia O
strain O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
clinical O
efficacy O
and O
mechanism O
of O
Feiyangqin O
Rectum O
Condensed O
Liquid O
( O
FRCL O
) O
in O
treating O
children O
syncytial O
viral O
pneumonia O
. O
[]

at O
250 O
mg O
m-2 O
per O
day O
X O
V O
every O
4 O
weeks O
. O
[]

The O
complexity O
of O
ectopic B-outcome ['Physiological-Clinical']
supraventricular I-outcome ['Physiological-Clinical']
beats I-outcome ['Physiological-Clinical']
did O
not O
change O
. O
['Physiological-Clinical']

CONCLUSION O
GnRH O
agonist O
and O
norethindrone O
acetate O
alone O
or O
combined O
with O
low-dose O
conjugated O
equine O
estrogens O
administered O
to O
symptomatic O
endometriosis O
patients O
for O
12 O
months O
provides O
extended O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
and O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
preservation O
after O
completion O
of O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Sun O
protection O
behaviors O
and O
stages O
of O
change O
for O
the O
primary O
prevention O
of O
skin O
cancers O
among O
beachgoers O
in O
southeastern O
New O
England O
. O
[]

Anabolic O
steroids O
are O
effective O
only O
when O
given O
combination O
with O
exercise O
and O
high-protein O
diet O
. O
[]

Direct B-outcome ['Resource-use']
healthcare I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
and O
indirect B-outcome ['Resource-use']
( I-outcome ['Resource-use']
patient-related I-outcome ['Resource-use']
) I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
will O
be O
measured O
to O
compare O
the O
cost-effectiveness O
of O
each O
program O
. O
['Resource-use', 'Resource-use']

The O
efficacy O
and O
safety O
indices O
were O
evaluated O
at O
the O
baseline O
and O
24 O
weeks O
after O
treatment O
, O
including O
clinical B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
, O
condition B-outcome ['Physiological-Clinical']
assessment O
, O
Health B-outcome ['Physiological-Clinical']
Assessment O
Questionnaire O
( O
HAQ O
) O
, O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
index O
28 O
( O
DAS28 O
) O
, O
laboratory B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
erythrocyte I-outcome ['Physiological-Clinical']
sedimentation B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ESR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( B-outcome ['Physiological-Clinical']
CRP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
safety O
indicators O
, O
and O
Chinese O
medical O
syndrome B-outcome ['Physiological-Clinical']
integrals O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Safety O
and O
pharmacology O
of O
a O
single O
intravenous O
dose O
of O
ponezumab O
in O
subjects O
with O
mild-to-moderate O
Alzheimer O
disease O
: O
a O
phase O
I O
, O
randomized O
, O
placebo-controlled O
, O
double-blind O
, O
dose-escalation O
study O
. O
[]

Treatment O
gains O
were O
largely O
maintained O
at O
two-month O
follow-up O
. O
[]

The O
number O
of O
attacks B-outcome ['Physiological-Clinical']
during O
the O
run-in O
and O
2 O
placebo O
periods O
were O
128 O
, O
123 O
, O
and O
130 O
, O
respectively O
, O
and O
31 O
and O
23 O
during O
the O
2 O
treatment O
periods O
( O
P O
less O
than O
0.006 O
and O
P O
less O
than O
0.003 O
) O
. O
['Physiological-Clinical']

METHODS O
In O
a O
randomized O
, O
double-blind O
fashion O
; O
subjects O
with O
metabolic O
syndrome O
were O
treated O
with O
allopurinol O
( O
n O
= O
28 O
) O
or O
placebo O
( O
n O
= O
22 O
) O
for O
one O
month O
. O
[]

METHODS O
Sixty O
ASA O
class O
I O
patients O
scheduled O
for O
herniorrhapy O
under O
spinal O
anesthesia O
were O
assigned O
randomly O
into O
two O
groups O
. O
[]

Videos O
representing O
movements O
were O
shown O
in O
full O
before O
experimental O
trials O
; O
the O
actual O
tasks O
consisted O
of O
watching O
the O
same O
videos O
, O
but O
interrupted O
after O
a O
variable O
interval O
( O
'pre-dark O
' O
) O
from O
its O
onset O
by O
a O
dark O
interval O
of O
variable O
duration O
. O
[]

Baseline O
Hamilton O
depression B-outcome ['Physiological-Clinical']
scale O
scores O
were O
compared O
with O
scores O
obtained O
14 O
days O
after O
the O
first O
dose O
of O
study O
medication O
. O
['Physiological-Clinical']

Both O
of O
these O
components O
were O
administered O
during O
a O
10-week O
period O
. O
[]

Over O
two O
years O
, O
274 O
patients O
required O
a O
hospital O
outpatient O
dermatology O
referral O
-- O
126 O
patients O
( O
46 O
% O
) O
were O
randomized O
to O
a O
telemedicine O
consultation O
and O
148 O
( O
54 O
% O
) O
to O
a O
conventional O
hospital O
outpatient O
consultation O
. O
[]

Increasing O
the O
load O
on O
verbal O
working O
memory O
using O
a O
mental O
arithmetic O
task O
( O
counting O
backwards O
by O
threes O
) O
did O
not O
reduce O
craving B-outcome ['Life-Impact']
further O
. O
['Life-Impact']

Furthermore O
, O
the O
special-effect O
lenses O
were O
associated O
with O
a O
decrease O
in O
lens B-outcome ['Physiological-Clinical']
wearing I-outcome ['Physiological-Clinical']
comfort I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

For O
one O
theme O
, O
recall B-outcome ['Life-Impact']
was O
significantly O
greater O
in O
the O
summary O
arm O
. O
['Life-Impact']

The O
array O
with O
the O
target O
stimulus O
was O
presented O
once O
each O
minute O
. O
[]

However O
, O
the O
grey-green O
CL O
showed O
a O
statistically O
significant O
difference O
from O
baseline O
( O
p O
= O
0.006 O
) O
. O
[]

Breast O
reduction O
alleviates O
depression B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
and O
restores O
self-esteem B-outcome ['Life-Impact']
: O
a O
prospective O
randomised O
clinical O
trial O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Twenty O
patients O
with O
palmoplantar O
pustulosis O
( O
PPP O
) O
were O
treated O
with O
topical O
PUVA O
, O
oral O
etretinate O
( O
Re O
) O
, O
or O
combined O
PUVA O
and O
etretinate O
( O
Re-PUVA O
) O
. O
[]

CONCLUSIONS O
Adjunctive O
exenatide O
therapy O
reduces O
postprandial B-outcome ['Physiological-Clinical']
hyperglycemia I-outcome ['Physiological-Clinical']
in O
adolescents O
with O
type O
1 O
diabetes O
. O
['Physiological-Clinical']

BACKGROUND O
Although O
moderate O
caffeine O
ingestion O
has O
not O
been O
shown O
to O
be O
arrhythmogenic O
, O
caffeine O
toxicity O
can O
cause O
severe O
cardiac O
arrhythmias O
, O
including O
atrial O
fibrillation O
and O
ventricular O
tachycardia O
. O
[]

Among O
patients O
with O
BRAF O
wild-type O
cancer O
, O
IFL O
conferred O
no O
suggestion O
of O
benefit O
beyond O
FU/LV O
alone O
( O
multivariate O
HR O
= O
1.02 O
; O
95 O
% O
CI O
: O
0.72-1.46 O
) O
. O
[]

In O
20 O
operations O
, O
19 O
children O
were O
randomized O
to O
heparin-coated O
( O
group O
HC O
, O
n O
= O
10 O
) O
or O
standard O
( O
group O
C O
, O
n O
= O
10 O
) O
bypass O
circuits O
. O
[]

CONCLUSIONS O
Providing O
physicians O
with O
the O
results O
of O
the O
Diagnostic O
Interview O
Schedule O
and O
counseling O
directives O
resulted O
in O
short-term O
improvement O
in O
their O
rates O
of O
counseling O
patients O
with O
a O
history O
of O
dependent O
or O
nondependent O
but O
harmful O
drinking O
. O
[]

RESULTS O
Complication B-outcome ['Adverse-effects']
rate O
was O
5.26 O
% O
for O
group O
A O
( O
none O
needed O
conversion O
) O
and O
4.68 O
% O
for O
group O
B O
. O
['Adverse-effects']

Twenty O
patients O
were O
treated O
with O
intranasal O
Bdp O
and O
twenty O
patients O
received O
no O
treatment O
after O
polypectomy O
. O
[]

Both O
of O
these O
patients O
were O
in O
the O
control O
group O
. O
[]

The O
patients O
were O
randomized O
into O
two O
groups O
: O
30 O
men O
treated O
using O
visual O
laser O
ablation O
of O
urethral O
strictures O
( O
VLASU O
) O
with O
Nd O
: O
YAGlaser O
and O
20 O
men O
treated O
by O
correction O
of O
urethral O
strictures O
using O
Sachse O
's O
optical O
urethrotomy O
. O
[]

The O
intensity O
of O
chemotherapy B-outcome ['Resource-use']
was O
not O
considered O
to O
significantly O
differ O
between O
the O
two O
groups O
, O
though O
the O
chemotherapy O
regimens O
administered O
differed O
slightly O
. O
['Resource-use']

After O
a O
48-hour O
run-in O
period O
, O
oral O
verapamil O
480 O
mg/day O
and O
placebo O
were O
administered O
alternately O
during O
4 O
randomised O
48-hour O
periods O
. O
[]

RESULTS O
Success O
rate O
for O
nasal B-outcome ['Physiological-Clinical']
passage B-outcome ['Physiological-Clinical']
was O
100 O
% O
in O
the O
G O
( O
+ O
) O
group O
( O
62/62 O
) O
and O
82.6 O
% O
in O
the O
G O
( O
- O
) O
group O
( O
57/69 O
; O
P O
= O
0.0006 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
These O
data O
support O
the O
hypothesis O
that O
some O
insomniacs O
show O
a O
reliable O
disorder O
of O
[]

There O
are O
no O
comparative O
studies O
between O
CLO O
and O
GHB O
in O
a O
medical O
ICU O
setting O
. O
[]

Exclusion O
criteria O
were O
neutropenia O
or O
severely O
impaired O
renal O
function O
. O
[]

Adenosine O
induced O
dyspnea O
, O
hyperpnea O
, O
tachycardia O
, O
and O
significant O
RIII O
inhibition O
( O
24 O
? O
[]

CONCLUSION O
Irradiated O
drug-containing O
porcine-cornea O
might O
well O
be O
an O
ideal O
therapeutic O
material O
for O
the O
management O
of O
patients O
with O
ocular O
burns O
. O
[]

Group O
1 O
( O
15 O
patients O
) O
received O
radiation O
therapy O
totaling O
4000 O
to O
4500 O
rads O
in O
4 O
to O
5 O
weeks O
. O
[]

Smokeless O
tobacco O
might O
be O
effective O
as O
an O
adjunct O
for O
smoking B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
. O
['Life-Impact']

After O
exclusions O
, O
data O
were O
analyzed O
on O
39 O
patients O
in O
group O
T O
( O
bilateral O
TAP O
block O
) O
and O
35 O
patients O
in O
group O
I O
( O
infiltration O
) O
. O
[]

Significant O
improvements O
in O
patients O
' O
global B-outcome ['Physiological-Clinical']
function B-outcome ['Life-Impact']
were O
seen O
versus O
placebo O
at O
week O
24 O
( O
observed O
cases O
) O
, O
on O
the O
Clinician O
's O
Interview-Based O
Impression O
of O
Change-Plus O
version O
only O
for O
patients O
on O
donepezil O
5 O
mg/d O
( O
P=0.014 O
) O
, O
and O
on O
the O
Sum O
of O
the O
Boxes O
of O
the O
Clinical B-outcome ['Physiological-Clinical']
Dementia I-outcome ['Physiological-Clinical']
Rating O
only O
for O
patients O
on O
10 O
mg/d O
( O
P=0.007 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Treatment-na?ve O
or O
previously O
treated O
patients O
with O
unresectable O
stage O
III/IV O
melanoma O
( O
n O
= O
115 O
) O
received O
open-label O
ipilimumab O
( O
10 O
mg/kg O
every O
3 O
weeks O
for O
four O
doses O
) O
and O
were O
randomized O
to O
receive O
concomitant O
blinded O
prophylactic O
oral O
budesonide O
( O
9 O
mg/d O
with O
gradual O
taper O
through O
week O
16 O
) O
or O
placebo O
. O
[]

Data O
on O
repeatability O
and O
comparability O
of O
different O
presyncopal O
symptom-limited O
lower O
body O
negative O
pressure O
( O
PSL-LBNP O
) O
exposure O
protocols O
, O
while O
scarce O
, O
are O
critical O
to O
the O
interpretation O
of O
studies O
using O
PSL-LBNP O
methods O
. O
[]

Electrical O
sources O
of O
P300 O
event-related O
brain O
potentials O
revealed O
by O
low O
resolution O
electromagnetic O
tomography O
. O
[]

Neuro-ophthalmological O
and O
electro-oculographic O
( O
EOG O
) O
evaluations O
were O
performed O
four O
and O
three O
times O
, O
respectively O
. O
[]

[ O
Intra-arterial O
chemotherapy O
in O
advanced O
ovarian O
cancers O
. O
[]

65 O
years O
with O
functional O
impairment O
were O
recruited O
through O
general O
( O
family O
) O
practices O
. O
[]

TTI B-outcome ['Physiological-Clinical']
was O
recorded O
pre-operatively O
at O
end-expiration O
with O
the O
apical O
paddle O
in O
both O
longitudinal O
and O
transverse O
orientations O
. O
['Physiological-Clinical']

RESULTS O
In O
ovulation B-outcome ['Physiological-Clinical']
induction O
, O
fertilization B-outcome ['Physiological-Clinical']
, O
and O
pregnancy B-outcome ['Physiological-Clinical']
rates O
the O
ultrashort O
regimen O
produces O
results O
that O
were O
no O
different O
to O
the O
short O
regimen O
but O
it O
did O
not O
always O
prevent O
an O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Inflating O
the O
cuff O
caused O
an O
instantaneous O
rise O
in O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
13 O
and O
12 O
mm O
Hg O
( O
hypertensive O
and O
normotensive O
subjects O
, O
respectively O
) O
. O
['Physiological-Clinical']

In O
the O
first O
week O
, O
post-operative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scores O
were O
less O
in O
the O
potassium O
titanyl O
phosphate O
laser O
group O
than O
in O
the O
bipolar O
radiofrequency O
group O
( O
means O
7.5 O
and O
8.5 O
, O
respectively O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
This O
study O
confirmed O
that O
a O
220-microgram O
dose O
of O
triamcinolone O
acetonide O
aqueous O
nasal O
spray O
, O
administered O
once O
daily O
for O
2 O
weeks O
, O
is O
well O
tolerated O
and O
reduces O
effectively O
the O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
seasonal I-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
due I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
ragweed I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Cognitive B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
serotonergic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
users O
of O
ecstasy O
. O
['Life-Impact', 'Physiological-Clinical']

Parent-mediated O
communication-focused O
treatment O
in O
children O
with O
autism O
( O
PACT O
) O
: O
a O
randomised O
controlled O
trial O
. O
[]

We O
evaluated O
the O
safety O
and O
diagnostic O
yield O
to O
describe O
the O
feasibility O
of O
cryobiopsy O
. O
[]

No O
significant O
difference O
was O
seen O
between O
the O
two O
drugs O
regarding O
the O
decrease O
in O
the O
total O
number O
of O
PVC/hour O
in O
the O
15 O
patients O
completing O
the O
cross-over O
protocol O
. O
['Physiological-Clinical']

Although O
contraindicated O
, O
coingestion O
of O
alcohol O
and O
opioids O
by O
patients O
or O
drug O
abusers O
is O
a O
major O
health O
concern O
because O
of O
dangerous O
additive O
and O
potentially O
life-threatening O
sedative O
and O
respiratory O
effects O
. O
[]

Effect O
of O
membrane O
permeability O
on O
inflammation O
and O
arterial O
stiffness O
: O
a O
randomized O
trial O
. O
[]

Documented O
histologic B-outcome ['Physiological-Clinical']
conversion B-outcome ['Life-Impact']
was O
often O
associated O
with O
a O
more O
aggressive B-outcome ['Life-Impact']
clinical I-outcome ['Life-Impact']
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

8-oxo-dG O
was O
assayed O
by O
HPLC O
( O
with O
coulometric O
detection O
) O
in O
DNA O
isolated O
from O
lymphocytes O
from O
the O
same O
blood O
samples O
. O
[]

Antibiotic O
prophylaxis O
in O
high-risk O
head O
and O
neck O
surgery O
: O
one-day O
vs. O
five-day O
therapy O
. O
[]

Reducing O
breathing O
frequency O
has O
been O
advocated O
as O
a O
method O
to O
reduce O
BP B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Their O
results O
were O
detected O
by O
the O
revised O
Chinese O
version O
of O
Psycho-Educational B-outcome ['Life-Impact']
Profile O
for O
autistic O
and O
developmentally O
disabled O
children O
( O
C-PEP O
) O
. O
['Life-Impact']

The O
aim O
of O
this O
study O
was O
to O
compare O
a O
long O
pediatric O
colonoscope O
with O
an O
intermediate O
length O
adult O
colonoscope O
with O
regards O
to O
completion B-outcome ['Life-Impact']
rate O
and O
cecal B-outcome ['Life-Impact']
intubation I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Furthermore O
, O
perceptual B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
occurred O
only O
in O
the O
first O
of O
two O
sessions O
for O
each O
participant O
, O
and O
only O
for O
atypical O
/s/ O
sounds O
and O
not O
for O
atypical O
/f/ O
sounds O
. O
['Life-Impact']

METHODS O
EORTC O
21011 O
( O
NCT O
00056056 O
) O
was O
a O
randomized O
phase O
III O
study O
comparing O
combined O
bexarotene O
( O
Targretin O
( O
? O
) O
) O
[]

The O
primary O
analysis O
of O
safety O
was O
based O
on O
the O
incidence O
of O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
during O
10 O
days O
of O
treatment O
. O
['Physiological-Clinical']

Sixty O
obese O
women O
were O
included O
in O
the O
study O
. O
[]

The O
patient O
education O
intervention O
produced O
no O
significant O
change O
in O
guideline-consistent B-outcome ['Physiological-Clinical']
behavior I-outcome ['Physiological-Clinical']
, O
but O
was O
poorly O
adopted O
. O
['Physiological-Clinical']

Subjects O
assigned O
to O
HCT O
exercised O
on O
a O
9 O
station O
circuit O
, O
completing O
3 O
circuits.d-1 O
. O
[]

CONCLUSIONS O
During O
this O
OLE O
, O
safety O
findings O
with O
risperidone O
treatment O
( O
maximum O
weight-based O
dose O
of O
1.25 O
mg/day O
or O
1.75 O
mg/day O
) O
were O
consistent O
with O
those O
observed O
in O
the O
DB O
phase O
, O
and O
with O
the O
current O
safety O
information O
for O
risperidone O
in O
autistic O
, O
psychiatric O
, O
and O
behavioral O
disorders O
. O
[]

All O
247 O
episodes O
were O
evaluable O
by O
intent-to-treat O
analysis O
. O
[]

We O
compared O
'unguided O
' O
SRL O
with O
'directed O
' O
SRL O
( O
DSRL O
) O
, O
wherein O
learners O
followed O
an O
expert-designed O
booklet O
. O
[]

We O
tested O
the O
hypotheses O
that O
systemic O
absorption O
of O
epidural O
lidocaine O
: O
( O
1 O
) O
contributes O
to O
the O
shivering-like B-outcome ['Physiological-Clinical']
tremor I-outcome ['Physiological-Clinical']
seen O
during O
epidural O
anesthesia B-outcome ['Resource-use']
by O
causing O
central O
nervous O
system O
disinhibition O
of O
spinal O
reflexes O
, O
or O
( O
2 O
) O
activates O
or O
alters O
thermoregulatory B-outcome ['Physiological-Clinical']
mechanisms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

METHODS O
Sixteen O
adults O
with O
adenomas O
detected O
and O
removed O
at O
screening O
colonoscopy O
were O
recruited O
to O
a O
12-week O
physical O
activity O
intervention O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
efficacy O
of O
3 O
nonhormonal O
therapies O
for O
the O
improvement O
of O
menopause-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
women O
with O
vasomotor O
symptoms O
. O
['Life-Impact']

PATIENTS O
AND O
METHODS O
Fifteen O
patients O
with O
mouth O
leak O
complaining O
of O
mouth O
dryness O
and O
nasal O
obstruction O
underwent O
two O
consecutive O
overnight O
polysomnographies O
, O
one O
with O
a O
chinstrap O
, O
in O
random O
order O
. O
[]

Lower O
energy O
settings O
may O
increase O
safety O
without O
losing O
efficacy O
. O
[]

The O
aim O
of O
the O
Big O
Lung O
Trial O
was O
therefore O
to O
run O
a O
large O
pragmatic O
trial O
to O
confirm O
the O
survival B-outcome ['Mortality']
benefits O
seen O
in O
the O
meta-analysis O
. O
['Mortality']

The O
INR B-outcome ['Physiological-Clinical']
results O
were O
not O
influenced O
by O
whether O
patients O
were O
maintained O
on O
Coumadin O
only O
( O
control O
group O
) O
or O
interchanged O
between O
Coumadin O
and O
generic O
warfarin O
( O
p O
= O
0.98 O
) O
. O
['Physiological-Clinical']

CONTEXT O
Dipeptidyl O
peptidase O
4 O
( O
DPP-4 O
) O
inhibitors O
are O
proposed O
to O
lower O
blood O
glucose O
in O
type O
2 O
diabetes O
mellitus O
( O
T2DM O
) O
by O
prolonging O
the O
activity O
of O
the O
circulating O
incretins O
, O
glucose-dependent O
insulinotropic O
polypeptide O
( O
GIP O
) O
and O
glucagon-like O
peptide O
1 O
( O
GLP-1 O
) O
. O
[]

The O
children B-outcome ['Physiological-Clinical']
's O
IQ B-outcome ['Life-Impact']
, O
['Physiological-Clinical', 'Life-Impact']

In O
addition O
to O
this O
, O
enhanced O
azithromycin O
penetration O
from O
plasma O
into O
bronchial O
secretion O
and O
lung O
tissue O
was O
evidenced O
by O
the O
increase O
in O
the O
ratio O
of O
AUC O
( O
[]

METHODOLOGY/PRINCIPAL O
FINDINGS O
We O
used O
event-related O
fMRI O
to O
investigate O
brain B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
to O
images O
of O
the O
subjects O
' O
own O
face O
and O
to O
faces O
of O
others O
. O
['Physiological-Clinical']

In O
infantile O
autism O
, O
the O
serotoninergic O
( O
5-HT O
) O
hypothesis O
is O
corroborated O
by O
biological O
dosages O
and O
therapeutic O
effects O
of O
fenfluramine O
which O
decrease O
blood O
serotonin O
. O
[]

Likewise O
a O
significant O
( O
p O
less O
than O
0.001 O
) O
difference O
between O
treatments O
was O
observed O
, O
on O
the O
4-point O
scale O
, O
in O
the O
population O
as O
a O
whole O
( O
end O
of O
first O
period O
) O
as O
well O
as O
in O
responder O
patients O
( O
end O
second O
period O
) O
. O
[]

In O
this O
study O
, O
we O
aimed O
to O
characterize O
early O
thermal O
burns O
injury O
in O
adult O
patients O
with O
< O
40 O
% O
total O
body O
surface O
area O
( O
TBSA O
) O
and O
to O
determine O
the O
effects O
of O
HBOT O
administered O
within O
24 O
h O
to O
48 O
h O
of O
a O
burn O
injury O
. O
[]

Median O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
on O
day O
120 O
were O
comparable O
in O
the O
two O
groups O
: O
Hb O
10.5 O
and O
9.5 O
g/dL O
in O
group O
A O
and O
B O
, O
respectively O
( O
p=0.6 O
) O
, O
Neutrophil B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
were O
2.4 O
vs O
1.9x10 O
( O
9 O
) O
/L O
in O
groups O
A O
and O
B O
( O
p=0.4 O
) O
and O
platelet B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
were O
, O
respectively O
, O
42 O
vs O
36x10 O
( O
9 O
) O
/L O
( O
p=0.3 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Effect O
of O
a O
nutritional O
supplement O
containing O
vitamin O
E O
, O
selenium O
, O
vitamin O
c O
and O
coenzyme O
Q10 O
on O
serum B-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
in O
patients O
with O
hormonally O
untreated O
carcinoma O
of O
the O
prostate O
: O
a O
randomised O
placebo-controlled O
study O
. O
['Physiological-Clinical']

One O
family O
dropped O
out O
after O
the O
first O
infusion O
, O
and O
one O
family O
was O
lost O
to O
follow O
up O
after O
the O
second O
infusion O
. O
[]

Maximal B-outcome ['Physiological-Clinical']
diameters I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
were O
used O
for O
the O
analyses O
. O
['Physiological-Clinical']

The O
cumulative O
HBV B-outcome ['Physiological-Clinical']
reactivation I-outcome ['Physiological-Clinical']
rates O
at O
months O
6 O
, O
12 O
, O
and O
18 O
after O
chemotherapy O
were O
8 O
% O
, O
11.2 O
% O
, O
and O
25.9 O
% O
, O
respectively O
, O
in O
the O
control O
group O
, O
and O
0 O
% O
, O
0 O
% O
, O
and O
4.3 O
% O
in O
the O
ETV O
prophylactic O
group O
( O
P O
= O
.019 O
) O
. O
['Physiological-Clinical']

[ O
Effects O
of O
Kang O
Gang O
Qian O
Granule O
( O
KGQG O
) O
on O
clinical B-outcome ['Physiological-Clinical']
and O
pathological B-outcome ['Physiological-Clinical']
features I-outcome ['Physiological-Clinical']
in O
chronic O
hepatitis O
B O
patients O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Sixty-eight O
percent O
were O
boys O
. O
[]

At O
the O
end O
of O
each O
study O
week O
, O
the O
authors O
assessed O
diastolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
( O
myocardial B-outcome ['Physiological-Clinical']
relaxation I-outcome ['Physiological-Clinical']
velocities I-outcome ['Physiological-Clinical']
[ O
E O
' O
] O
using O
tissue O
Doppler O
imaging O
) O
and O
RBF B-outcome ['Physiological-Clinical']
( O
para-aminohippurate O
clearance O
) O
at O
baseline O
and O
after O
infusion O
of O
Ang O
II O
( O
3 O
ng/kg/min O
x O
45 O
min O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
Scandinavian O
Simvastatin O
Survival O
Study O
( O
4S O
) O
was O
designed O
to O
evaluate O
the O
effects O
of O
cholesterol O
reduction O
with O
simvastatin O
on O
mortality B-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
in O
patients O
with O
coronary O
artery O
disease O
( O
CAD O
) O
. O
['Mortality', 'Physiological-Clinical']

Statistical O
analysis O
was O
performed O
using O
Fisher O
, O
Spearman O
correlation O
coefficient O
, O
kappa O
, O
Kruskal-Wallis O
and O
Miller O
tests O
( O
P O
< O
0.05 O
) O
. O
[]

This O
study O
compared O
the O
efficacy O
of O
these O
two O
techniques O
in O
achieving O
ocular O
and O
lid O
akinesia O
. O
[]

The O
renin-angiotensin O
system O
is O
the O
major O
contributor O
to O
development O
of O
hypertension O
, O
atherosclerosis O
, O
and O
many O
other O
cardiovascular O
diseases O
. O
[]

Recombinant O
human O
granulocyte-macrophage O
colony-stimulating O
factor O
ameliorates O
zidovudine-induced O
neutropenia O
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
/AIDS-related O
complex O
. O
[]

Parent O
and O
neighborhood O
leader O
surveys O
were O
conducted O
over O
the O
phone O
by O
trained O
interviewers O
. O
[]

This O
was O
also O
evident O
if O
these O
patients O
were O
pooled O
with O
15 O
patients O
excluded O
from O
the O
double O
blind O
study O
as O
already O
receiving O
DMARD O
treatment O
( O
n O
= O
63 O
; O
p O
< O
0.01 O
) O
. O
[]

For O
a O
comparison O
of O
propranolol O
and O
nadolol O
pharmacokinetics B-outcome ['Physiological-Clinical']
and O
clinical O
effects O
, O
20 O
newly O
diagnosed O
patients O
with O
thyrotoxicosis O
were O
randomly O
selected O
to O
receive O
as O
sole O
therapy O
, O
either O
propranolol O
, O
40 O
mg O
every O
6 O
hours O
for O
14 O
days O
, O
or O
nadolol O
, O
80 O
mg O
each O
morning O
for O
14 O
days O
. O
['Physiological-Clinical']

Seven O
were O
allocated O
to O
labetalol O
treatment O
( O
Group O
A O
) O
, O
eight O
to O
hydralazine O
treatment O
( O
Group O
B O
) O
and O
seven O
women O
received O
both O
drugs O
due O
to O
poor O
blood O
pressure O
control O
with O
a O
single O
drug O
therapy O
( O
Group O
C O
) O
. O
[]

Groups O
had O
similar O
characteristics O
at O
baseline O
. O
[]

BACKGROUND O
Despite O
it O
is O
accepted O
that O
acne O
is O
mostly O
caused O
by O
an O
hyper-responsiveness O
of O
the O
pilo-sebaceous O
unit O
to O
normal O
circulating O
androgen O
hormones O
, O
in O
a O
few O
patients O
, O
especially O
women O
, O
acneic O
lesions O
can O
be O
associated O
with O
increased O
serum B-outcome ['Physiological-Clinical']
androgen I-outcome ['Physiological-Clinical']
levels O
( O
hyperandrogenism O
) O
, O
of O
which O
polycystic O
ovary O
syndrome O
( O
PCOS O
) O
is O
the O
most O
common O
cause O
. O
['Physiological-Clinical']

The O
blood O
loss O
during O
and O
after O
surgery O
was O
measured O
using O
a O
photometer O
. O
[]

GH O
injections O
caused O
a O
1.6-fold O
increase O
in O
IGF-I B-outcome ['Physiological-Clinical']
, O
despite O
caloric O
restriction O
. O
['Physiological-Clinical']

A O
subset O
of O
92 O
patients O
with O
C4 O
disease O
were O
prospectively O
randomized O
, O
and O
ambulatory O
venous O
pressure O
( O
AVP O
) O
was O
determined O
preoperatively O
and O
postoperatively O
. O
[]

The O
findings O
will O
allow O
midwives O
to O
offer O
women O
requesting O
SWI O
during O
labour O
an O
evidence-based O
alternative O
technique O
more O
easily O
administered O
by O
staff O
and O
accepted O
by O
labouring O
women O
. O
[]

In O
this O
trial O
, O
telmisartan O
( O
an O
ARB O
) O
was O
non-inferior O
to O
ramipril O
( O
an O
ACEI O
) O
in O
reducing O
fatal O
and O
nonfatal B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Effects O
of O
dietary O
coconut O
oil O
on O
the O
biochemical B-outcome ['Physiological-Clinical']
and O
anthropometric B-outcome ['Physiological-Clinical']
profiles O
of O
women O
presenting O
abdominal O
obesity O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
changes O
were O
observed O
in O
histamine B-outcome ['Physiological-Clinical']
and O
DAO B-outcome ['Physiological-Clinical']
levels O
within O
the O
first O
80 O
minutes O
in O
non-reactors O
as O
well O
as O
reactors O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
number O
of O
supracostal B-outcome ['Physiological-Clinical']
accesses I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
group O
2 O
than O
in O
group O
1 O
( O
P O
= O
0.02 O
) O
. O
['Physiological-Clinical']

This O
is O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
aimed O
to O
assess O
the O
efficacy O
and O
safety O
of O
Cappra O
( O
? O
) O
, O
[]

22 O
; O
95 O
% O
CI O
1.02 O
to O
1.45 O
; O
P=0.032 O
) O
independently O
predicted O
worsened O
clinical B-outcome ['Physiological-Clinical']
outcome O
regardless O
of O
the O
treatment O
modality O
. O
['Physiological-Clinical']

A O
double-blind O
placebo O
controlled O
trial O
of O
piracetam O
added O
to O
risperidone O
in O
patients O
with O
autistic O
disorder O
. O
[]

However O
, O
analysis O
of O
total O
relapses B-outcome ['Physiological-Clinical']
revealed O
that O
patients O
treated O
with O
ABVD/OPP O
had O
a O
significantly O
higher O
likelihood O
of O
achieving O
a O
second B-outcome ['Physiological-Clinical']
CR I-outcome ['Physiological-Clinical']
compared O
to O
patients O
who O
entered O
the O
ABVD/MOPP O
arm O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Comparative O
clinical O
and O
microbiological O
effects O
of O
subgingival O
metronidazole O
application O
in O
adult O
periodontitis O
; O
12-months O
results O
. O
[]

RESULTS O
Systemic O
thrombolytic O
therapy O
significantly O
reduced O
the O
number O
of O
closed B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
segments I-outcome ['Physiological-Clinical']
after O
12 O
months O
in O
patients O
with O
acute O
DVT O
compared O
with O
conventional O
treatment O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Self-control B-outcome ['Life-Impact']
problems O
commonly O
manifest O
as O
temper O
outbursts O
and O
repetitive/rigid/impulsive O
behaviors O
, O
in O
children O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
, O
which O
often O
contributes O
to O
learning O
difficulties O
and O
caregiver O
burden O
. O
['Life-Impact']

OBJECTIVE O
Our O
study O
was O
designed O
to O
examine O
the O
efficacy O
of O
stepwise O
hook O
extension O
technique O
for O
radiofrequency O
ablation O
( O
RFA O
) O
therapy O
of O
hepatocellular O
carcinoma O
in O
a O
randomized O
controlled O
study O
. O
[]

Urine B-outcome ['Physiological-Clinical']
bacteriological I-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
was O
found O
in O
63.4 O
% O
in O
group O
A O
and O
60 O
% O
in O
group O
B O
( O
p=0.75 O
, O
95 O
% O
CI O
-0.18 O
to O
0.25 O
) O
. O
['Physiological-Clinical']

OBJECTIVES O
Febuxostat O
or O
allopurinol O
was O
administered O
to O
patients O
with O
hyperuricemia O
including O
gout O
for O
8 O
weeks O
to O
compare O
the O
efficacy O
and O
safety O
of O
these O
drugs O
. O
[]

3 O
adverse O
events O
did O
not O
differ O
between O
MP O
and O
PL O
( O
40 O
of O
93 O
patients O
v O
29 O
of O
97 O
patients O
, O
respectively O
; O
P O
= O
.06 O
) O
. O
[]

Two O
intervention O
strategies O
are O
being O
studied O
by O
two O
large-scale O
multicentre O
projects O
. O
[]

Increased O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response O
to O
sumatriptan O
challenge O
in O
adult O
autistic O
disorders O
. O
['Physiological-Clinical']

Our O
objective O
was O
to O
determine O
if O
calcium O
chloride O
( O
CaCl O
( O
2 O
) O
) O
pre-treatment O
would O
blunt O
a O
SBP B-outcome ['Physiological-Clinical']
drop O
after O
i.v O
. O
['Physiological-Clinical']

SUMMARY O
BACKGROUND O
DATA O
After O
esophageal O
resection O
for O
cancer O
, O
the O
relative O
merits O
of O
the O
hand-sewn O
and O
the O
stapled O
methods O
of O
esophagogastric O
anastomosis O
, O
especially O
regarding O
leakage B-outcome ['Physiological-Clinical']
and O
stricture B-outcome ['Physiological-Clinical']
rates O
, O
have O
not O
adequately O
been O
studied O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND/AIMS O
Vitamin O
K2 O
( O
VK2 O
) O
appears O
to O
have O
a O
potent O
inhibitory O
activity O
for O
cell O
growth O
including O
HCC O
cells O
. O
[]

Nine O
patients O
died B-outcome ['Mortality']
during O
the O
study O
( O
ablation O
group O
, O
five O
; O
control O
group O
, O
four O
) O
. O
['Mortality']

Of O
the O
37 O
patients O
who O
completed O
the O
trial O
16 O
out O
of O
19 O
( O
84 O
% O
) O
of O
the O
patients O
in O
the O
Grenz O
ray O
group O
, O
and O
13 O
out O
of O
18 O
( O
72 O
% O
) O
of O
the O
patients O
in O
the O
combination O
group O
healed B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
addition O
, O
patients O
target O
N1 B-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
were O
attenuated O
compared O
with O
controls O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
The O
study O
group O
consisted O
of O
26 O
healthy O
adolescents O
( O
mean O
age O
14.6 O
years O
) O
exhibiting O
60 O
teeth O
with O
152 O
visible O
WSL O
sites O
on O
incisors O
and O
canines O
immediately O
after O
debonding O
of O
fixed O
orthodontic O
appliances O
. O
[]

The O
control O
group O
( O
group O
1 O
) O
had O
no O
alteration O
to O
the O
bone O
. O
[]

At O
last O
follow-up O
these O
figures O
were O
respectively O
9 O
, O
12 O
, O
and O
17 O
vs O
19 O
, O
2 O
, O
and O
18 O
( O
p=0.004 O
) O
. O
[]

RESULTS O
No O
treatment O
difference O
was O
observed O
statistically O
between O
VPA O
and O
PBO O
groups O
. O
[]

The O
results O
of O
this O
trial O
clearly O
support O
the O
plan O
to O
integrate O
simulator O
training O
into O
endoscopic O
education O
curricula O
. O
[]

Although O
both O
groups O
improved O
in O
their O
knowledge B-outcome ['Life-Impact']
score O
, O
the O
intervention O
group O
showed O
a O
significantly O
greater O
improvement O
at O
posttest O
. O
['Life-Impact']

CONCLUSIONS O
Warfarin O
was O
associated O
with O
significantly O
higher O
rates O
of O
adverse O
events O
and O
provided O
no O
benefit O
over O
aspirin O
in O
this O
trial O
. O
[]

Forty-six O
children O
were O
included O
. O
[]

The O
participants O
will O
be O
60 O
adults O
with O
ASD O
; O
30 O
will O
be O
assigned O
to O
a O
CBT O
group O
and O
30 O
to O
a O
waitlist O
control O
group O
. O
[]

GER O
patients O
had O
greater O
( O
p O
less O
than O
0.05 O
) O
acid B-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
than O
normals O
in O
all O
study O
periods O
, O
but O
no O
differences O
were O
found O
between O
low O
and O
high O
fat O
meals O
in O
either O
study O
position O
. O
['Physiological-Clinical']

The O
absolute O
bioavailability B-outcome ['Physiological-Clinical']
of O
the O
tablet O
product O
was O
82 O
% O
, O
which O
is O
in O
agreement O
with O
published O
data O
for O
other O
oral O
dosage O
forms O
of O
methylprednisolone O
. O
['Physiological-Clinical']

However O
, O
in O
the O
CPAP O
group O
only O
5 O
patients O
had O
failed O
at O
the O
end O
of O
the O
first O
3-hour O
study O
period O
. O
[]

CONCLUSIONS O
In O
this O
largest O
retrospective O
analysis O
to O
date O
we O
observed O
that O
Ca/Mg O
infusions O
significantly O
reduced O
all O
grade O
oxaliplatin-related O
neurotoxicity O
. O
[]

CONCLUSIONS O
Etanercept O
is O
not O
effective O
for O
the O
maintenance B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
in O
patients O
with O
Wegener O
's O
granulomatosis O
. O
['Physiological-Clinical']

Subjects O
were O
155 O
young O
( O
aged O
18-30 O
y O
) O
, O
healthy O
, O
normal-weight O
women O
with O
intake O
of O
dietary O
calcium O
< O
800 O
mg/d O
and O
energy O
intake O
< O
/= O
2200 O
kcal/d O
. O
[]

Twenty-seven O
minutes O
after O
drug O
instillation O
subjects O
were O
challenged O
with O
allergen O
. O
[]

Ciprofloxacin O
and O
rifampicin O
treatment O
for O
brucellosis B-outcome ['Physiological-Clinical']
is O
as O
effective O
as O
the O
standard O
regimen O
of O
doxycycline O
and O
rifampicin O
and O
offers O
the O
advantage O
of O
a O
shorter O
duration O
of O
treatment O
. O
['Physiological-Clinical']

BACKGROUND O
Duration O
of O
untreated O
psychosis O
( O
DUP O
) O
has O
been O
significantly O
associated O
with O
poor O
clinical B-outcome ['Physiological-Clinical']
and O
social B-outcome ['Physiological-Clinical']
outcomes O
in O
First O
Episode O
Psychosis O
( O
FEP O
) O
patients O
, O
but O
an O
association O
with O
cognitive O
outcomes O
has O
not O
been O
clearly O
established O
. O
['Physiological-Clinical']

AIM O
To O
confirm O
the O
important O
risk O
factors O
for O
fracture O
in O
older O
women O
. O
[]

Randomized O
trial O
comparing O
induction O
chemotherapy O
versus O
induction O
chemotherapy O
followed O
by O
maintenance O
chemotherapy O
in O
small-cell O
lung O
cancer O
. O
[]

OBJECTIVE O
To O
compare O
the O
efficacy O
and O
safety O
of O
autologous O
fibroblast O
treatment O
of O
moderate O
to O
severe O
, O
depressed O
, O
distensible O
facial O
acne O
scars O
with O
that O
of O
vehicle O
control O
. O
[]

The O
practical O
implications O
of O
these O
findings O
are O
discussed O
. O
[]

In O
this O
ongoing O
study O
, O
a O
total O
of O
523 O
overweight O
subjects O
with O
IGT O
based O
on O
two O
oral O
glucose O
tolerance O
tests O
were O
randomized O
to O
either O
an O
intervention O
group O
or O
a O
control O
group O
. O
[]

1 O
. O
[]

Non-contrast-enhanced O
4D O
MR O
angiography O
with O
STAR O
spin O
labeling O
and O
variable O
flip O
angle O
sampling O
: O
a O
feasibility O
study O
for O
the O
assessment O
of O
Dural O
Arteriovenous O
Fistula O
. O
[]

No O
effect O
of O
vitamin O
C O
within O
the O
drug O
or O
placebo O
group O
was O
found O
. O
[]

PARTICIPANTS O
Patients O
scheduled O
for O
coronary O
artery O
bypass O
graft O
surgery O
with O
CPB O
. O
[]

Mean O
prolactin B-outcome ['Physiological-Clinical']
of O
adult O
females O
, O
while O
similar O
to O
that O
of O
adult O
males O
at O
baseline O
, O
was O
2.2 O
times O
male O
levels O
acutely O
and O
3.7 O
times O
greater O
in O
maintenance O
. O
['Physiological-Clinical']

The O
significance O
of O
a O
delay O
of O
CSF B-outcome ['Physiological-Clinical']
sterilization I-outcome ['Physiological-Clinical']
among O
CB-treated O
patients O
is O
unknown O
, O
since O
there O
was O
no O
correlation O
between O
persistence O
of O
hemophilus O
organisms O
and O
the O
frequency O
of O
adverse O
outcome O
. O
['Physiological-Clinical']

Effects O
of O
glucagon-like O
peptide-1 O
( O
7-36 O
) O
amide O
on O
motility B-outcome ['Physiological-Clinical']
and O
sensation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
proximal I-outcome ['Physiological-Clinical']
stomach I-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
controlled O
study O
of O
the O
effect O
of O
indomethacin O
in O
uremic B-outcome ['Physiological-Clinical']
pericarditis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
was O
more O
pronounced O
in O
patients O
receiving O
two O
or O
three O
drugs O
. O
['Physiological-Clinical']

[ O
European O
topic O
: O
liver O
surgery O
II O
-- O
regional O
chemotherapy O
] O
. O
[]

Eight O
children O
( O
seven O
on O
CRT O
+ O
ITC O
, O
one O
on O
CSpRT O
) O
developed O
presumed O
therapy B-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
encephalopathy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
ADS O
reflected O
variation O
in O
symptom O
severity O
but O
did O
not O
adequately O
identify O
physiological O
dependence O
or O
withdrawal O
in O
treatment-seeking O
individuals O
with O
DSM-IV O
alcohol O
dependence O
. O
[]

The O
inflammatory O
actions O
of O
synthetic O
C16:0 O
and O
C18:0 O
platelet O
activating O
factor O
( O
PAF O
) O
homologues O
, O
both O
alone O
and O
in O
combination O
, O
have O
been O
compared O
in O
an O
in O
vitro O
human O
neutrophil O
chemokinesis O
assay O
and O
by O
intradermal O
injection O
in O
human O
skin O
. O
[]

CONCLUSION O
Our O
findings O
indicate O
that O
Autism O
Spectrum O
Disorder O
manifests O
as O
a O
distinct O
behavioral B-outcome ['Life-Impact']
phenomenon I-outcome ['Life-Impact']
in O
Down O
syndrome O
. O
['Life-Impact']

In O
the O
linear O
structural O
relation O
analysis O
( O
LISREL O
) O
no O
direct O
relationship O
was O
found O
between O
masticatory B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
and O
functional B-outcome ['Life-Impact']
complaints I-outcome ['Life-Impact']
mandibular O
denture O
. O
['Physiological-Clinical', 'Life-Impact']

Anti-idiotypic B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
detectable O
in O
9 O
of O
9 O
patients O
in O
group O
1 O
and O
7 O
of O
12 O
patients O
in O
group O
2 O
( O
P O
less O
than O
0.006 O
) O
. O
['Physiological-Clinical']

Data O
analysis O
was O
based O
on O
51 O
patients O
. O
[]

One O
of O
the O
postoperative O
complications O
after O
strumectomy O
is O
hypoparathyroidism O
. O
[]

SETTING O
Academic O
. O
[]

While O
the O
initial B-outcome ['Physiological-Clinical']
agonist I-outcome ['Physiological-Clinical']
burst I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AG1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
decreased O
linearly O
after O
the O
modification O
time O
exceeded O
100 O
ms O
, O
the O
antagonist B-outcome ['Physiological-Clinical']
burst I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ANT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
increased O
compared O
with O
the O
go O
trial O
for O
the O
modification O
time O
from O
0 O
to O
200 O
ms O
and O
decreased O
after O
the O
modification O
time O
exceeded O
300 O
ms O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
time O
x O
training O
group O
effect O
was O
found O
for O
Sprint-15m O
performance O
with O
the O
CONTRAST O
group O
showing O
significantly O
better O
scores O
than O
the O
SPRINT O
group O
( O
7.23 O
+/- O
0.18 O
vs. O
7.09 O
+/- O
0.20 O
m.s O
, O
p O
< O
0.01 O
) O
. O
[]

The O
efficacy O
of O
erythromycin B-outcome ['Physiological-Clinical']
base O
( O
E-Mycin B-outcome ['Physiological-Clinical']
tablets B-outcome ['Resource-use']
, O
333 O
mg O
) O
and O
the O
efficacy O
of O
tetracycline B-outcome ['Physiological-Clinical']
hydrochloride I-outcome ['Physiological-Clinical']
( O
Panmycin O
tablets O
) O
were O
compared O
in O
this O
double-blind O
, O
randomized O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Lumbar B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
femoral I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
was O
evaluated O
by O
DXA O
at O
baseline O
and O
after O
1 O
year O
of O
therapy O
; O
moreover O
, O
deoxypyridinoline O
( O
DPD O
) O
and O
bone O
alkaline O
phosphatase O
( O
BALP O
) O
were O
determined O
at O
the O
beginning O
, O
midway O
through O
, O
and O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical']

We O
enrolled O
73 O
children O
aged O
less O
than O
36 O
months O
who O
were O
admitted O
with O
a O
clinical O
diagnosis O
of O
whooping O
cough O
. O
[]

RESULTS O
There O
was O
a O
significant O
improvement O
in O
knowledge B-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
schizophrenia I-outcome ['Life-Impact']
in O
the O
experimental O
group O
and O
a O
significant O
difference O
in O
symptom O
scores O
and O
functioning O
at O
9 O
months O
after O
discharge O
. O
['Life-Impact']

The O
Heart O
Outcomes O
Prevention O
Evaluation O
( O
HOPE O
) O
study O
was O
important O
because O
it O
showed O
the O
benefits O
of O
ramipril O
- O
an O
angiotensin-converting O
enzyme O
( O
ACE O
) O
inhibitor O
- O
in O
patients O
at O
high O
risk O
for O
cardiovascular O
events O
. O
[]

These O
changes O
regressed O
in O
all O
but O
four O
patients O
after O
12 O
months O
. O
[]

C. O
difficile B-outcome ['Physiological-Clinical']
was O
detected O
in O
23.0 O
% O
of O
patients O
who O
received O
a O
cephalosporin O
( O
cefoxitin O
, O
8.3 O
% O
; O
cefazolin O
, O
14.3 O
% O
; O
cefotetan O
, O
20.0 O
% O
; O
ceftriaxone O
, O
25.0 O
% O
; O
cefoperazone O
, O
43.7 O
% O
) O
, O
in O
3.3 O
% O
of O
patients O
given O
mezlocillin O
, O
and O
in O
none O
of O
15 O
control O
volunteers O
given O
no O
antimicrobial O
agent O
. O
['Physiological-Clinical']

Group O
A O
patients O
were O
pretreated O
with O
normal O
saline O
followed O
by O
propofol O
2.0 O
mg/kg O
at O
3.3 O
mg/sec O
. O
[]

DESIGN O
Prospective O
, O
randomized O
, O
parallel O
, O
single-blind O
( O
investigator O
) O
, O
placebo-controlled O
, O
multicenter O
clinical O
trial O
. O
[]

However O
, O
burning B-outcome ['Physiological-Clinical']
was O
more O
common O
in O
patients O
on O
Fotil O
, O
and O
blurring B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
vision I-outcome ['Physiological-Clinical']
and O
light B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
were O
more O
common O
in O
patients O
on O
Timpilo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Clinical B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
were O
equivalent O
on O
either O
antibiotic O
regimen O
. O
['Physiological-Clinical']

BACKGROUND O
Effectiveness O
studies O
have O
tested O
interventions O
to O
improve O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
for O
depression O
in O
primary O
care O
, O
but O
none O
, O
to O
our O
knowledge O
, O
have O
been O
completed O
for O
panic O
disorder O
( O
PD O
) O
in O
this O
setting O
. O
['Life-Impact']

0 O
% O
in O
the O
treatment O
group O
, O
better O
than O
that O
of O
the O
control O
group O
( O
66.7 O
% O
) O
, O
showing O
statistical O
difference O
( O
P O
< O
0.01 O
) O
. O
[]

However O
, O
there O
have O
been O
no O
controlled O
clinical O
trials O
to O
evaluate O
its O
systemic O
safety O
when O
used O
in O
treating O
children O
. O
[]

In O
addition O
, O
high O
CD19 B-outcome ['Physiological-Clinical']
levels O
also O
predicted O
a O
clinical O
response O
and O
longer O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

Cox O
proportional O
hazards O
analysis O
was O
performed O
. O
[]

Skin O
biopsies O
were O
obtained O
from O
randomized O
subjects O
for O
fibroblast O
production O
. O
[]

Effects O
of O
pentoxifylline O
administration O
on O
urinary O
N-acetyl-beta-glucosaminidase O
excretion O
in O
type O
2 O
diabetic O
patients O
: O
a O
short-term O
, O
prospective O
, O
randomized O
study O
. O
[]

Side-effects B-outcome ['Adverse-effects']
were O
five O
times O
less O
frequent O
in O
SML-treated O
patients O
( O
p O
< O
0.004 O
) O
. O
['Adverse-effects']

OBJECTIVE O
To O
evaluate O
and O
compare O
the O
analgesic B-outcome ['Resource-use']
efficacy O
and O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
of O
tramadol O
and O
pethidine O
in O
labor O
. O
['Resource-use', 'Adverse-effects']

METHODS O
The O
intervention O
was O
given O
in O
addition O
to O
existing O
care O
and O
involved O
regular O
monthly O
therapist O
contact O
for O
6 O
months O
with O
a O
further O
6 O
months O
of O
2-monthly O
consolidation O
sessions O
. O
[]

If O
N-acetylcysteine O
is O
needed O
because O
of O
a O
toxic O
serum O
acetaminophen O
level O
, O
bioavailability O
can O
be O
ensured O
by O
increasing O
the O
N-acetylcysteine O
loading O
dose O
from O
140 O
mg/kg O
to O
235 O
mg/kg O
. O
[]

Hemodynamic B-outcome ['Physiological-Clinical']
parameters O
and O
transthoracic B-outcome ['Physiological-Clinical']
echocardiographic I-outcome ['Physiological-Clinical']
measurement I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
were O
the O
variables O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Rather O
, O
NO O
mechanisms O
appear O
to O
contribute O
to O
the O
vasodilator O
response O
. O
[]

Another O
subject O
( O
0.1 O
mg/kg O
) O
demonstrated O
slight O
enlargement O
of O
a O
preexisting O
midbrain B-outcome ['Physiological-Clinical']
lesion O
. O
['Physiological-Clinical']

After O
a O
median O
follow-up O
of O
65 O
months O
, O
26.2 O
% O
( O
37 O
of O
141 O
) O
and O
46.2 O
% O
( O
66 O
of O
143 O
) O
of O
patients O
developed O
tumor B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
in O
the O
CCRT O
and O
RT-alone O
groups O
, O
respectively O
. O
['Physiological-Clinical']

The O
intraglomerular O
metastases O
arose O
by O
dissemination O
of O
malignant O
cells O
into O
the O
systemic O
circulation O
via O
invasion O
of O
the O
renal O
veins O
. O
[]

Synthetic O
carbohydrates O
may O
represent O
an O
important O
new O
class O
of O
drugs O
for O
the O
treatment O
of O
inflammatory O
, O
autoimmune O
diseases O
. O
[]

In O
contrast O
, O
in O
the O
8 O
CPAP-treated O
patients O
, O
OSA B-outcome ['Physiological-Clinical']
was O
attenuated O
, O
and O
there O
were O
significant O
reductions O
in O
daytime B-outcome ['Physiological-Clinical']
MSNA I-outcome ['Physiological-Clinical']
( O
from O
58 O
+/- O
4 O
bursts/min O
to O
48 O
+/- O
5 O
bursts/min O
; O
84 O
+/- O
4 O
bursts/100 O
heart O
beats O
to O
72 O
+/- O
5 O
bursts/100 O
heart O
beats O
; O
p O
< O
0.001 O
and O
p O
= O
0.003 O
, O
respectively O
) O
, O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
( O
from O
135 O
+/- O
5 O
mm O
Hg O
to O
120 O
+/- O
6 O
mm O
Hg O
, O
p O
= O
0.03 O
) O
, O
and O
HR B-outcome ['Physiological-Clinical']
( O
from O
69 O
+/- O
2 O
min O
( O
-1 O
) O
to O
66 O
+/- O
2 O
min O
( O
-1 O
) O
; O
p O
= O
0.013 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

IMPLICATIONS O
Pain B-outcome ['Physiological-Clinical']
associated O
with O
IV O
injection O
of O
propofol O
is O
seen O
in O
28 O
% O
-90 O
% O
patients O
. O
['Physiological-Clinical']

Patient-reported O
outcome O
( O
PROs O
) O
measures O
were O
completed O
at O
baseline O
and O
weeks O
5 O
, O
9 O
, O
13 O
, O
17 O
, O
and O
21 O
. O
[]

Other O
endpoints O
included O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
and O
safety O
. O
['Mortality']

Several O
investigators O
have O
reported O
a O
significantly O
reduced O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
as O
defined O
by O
monoclonal O
antibodies O
, O
in O
the O
peripheral O
blood O
of O
Caucasian O
patients O
with O
chronic O
active O
hepatitis O
B O
( O
CAHB O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
Individuals O
with O
amnestic O
mild O
cognitive O
impairment O
( O
MCI O
) O
have O
few O
empirically O
based O
treatment O
options O
for O
combating O
their O
memory B-outcome ['Life-Impact']
loss I-outcome ['Life-Impact']
. O
['Life-Impact']

morphine O
was O
used O
for O
postoperative O
analgesia O
. O
[]

Leuprolide O
was O
not O
effective O
for O
women O
with O
ongoing O
dysphoric O
symptoms O
, O
suggesting O
that O
premenstrual O
depression O
may O
have O
mechanisms O
different O
from O
those O
of O
other O
dysphoric O
mood O
disorders O
. O
[]

We O
conducted O
a O
randomized O
, O
double-blind O
placebo-controlled O
trial O
of O
oral O
clodronate O
in O
patients O
with O
bone O
metastases O
from O
tumors O
poorly O
responsive O
to O
chemotherapy O
, O
with O
the O
aims O
of O
evaluating O
the O
effects O
of O
this O
drug O
on O
symptoms B-outcome ['Physiological-Clinical']
control O
and O
bone B-outcome ['Physiological-Clinical']
metastases I-outcome ['Physiological-Clinical']
evolution I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Twenty-five O
sedentary O
healthy O
subjects O
were O
randomized O
into O
an O
endurance O
group O
( O
n O
= O
13 O
) O
or O
strength O
group O
( O
n O
= O
12 O
) O
. O
[]

Plasma O
IGF-I O
( O
RIA O
after O
acid-ethanol O
extraction O
) O
was O
measured O
in O
a O
morning O
sample O
. O
[]

RESULTS O
At O
basal O
conditions O
there O
were O
no O
significant O
differences O
between O
groups O
. O
[]

Other O
anticoagulation O
strategies O
, O
including O
no O
bridging O
therapy O
or O
intravenous O
heparin O
, O
need O
comparative O
evaluation O
in O
this O
unique O
patient O
population O
. O
[]

[ O
Sublingually O
administered O
captopril O
versus O
nifedipine O
in O
hypertension O
emergencies O
] O
. O
[]

Thus O
evaluation O
of O
airway O
responsiveness O
by O
both O
bronchial O
provocation O
tests O
and O
bronchodilator O
testing O
can O
be O
assessed O
reliably O
within O
a O
few O
hours O
in O
asthmatic O
patients O
. O
[]

BACKGROUND O
The O
aim O
of O
this O
prospective O
study O
was O
to O
evaluate O
and O
compare O
operative O
performance O
and O
technical O
improvement O
of O
surgical O
trainees O
learning O
open O
gastrectomy O
using O
an O
objective O
structured O
stepwise O
assessment O
tool O
of O
operative O
skills O
( O
SATOS O
) O
previously O
validated O
for O
open O
surgery O
. O
[]

The O
pain B-outcome ['Physiological-Clinical']
score O
was O
lower O
two O
hours O
after O
surgery O
and O
on O
postoperative O
day O
1 O
in O
Group O
IT0.5 O
than O
in O
the O
other O
groups O
. O
['Physiological-Clinical']

These O
results O
led O
to O
the O
termination O
of O
the O
study O
based O
on O
the O
raised O
criteria O
since O
we O
anticipated O
the O
actual O
cause O
of O
the O
shoulder O
pain O
to O
be O
due O
to O
an O
unknown O
factor O
. O
[]

Lidocaine O
and O
bupivacaine O
mixtures O
for O
epidural O
blockade O
. O
[]

Half O
received O
i.v O
. O
[]

Erythema O
and O
adverse O
events O
were O
assessed O
1 O
week O
following O
each O
treatment O
. O
[]

Is O
psychotherapy O
more O
effective O
when O
therapists O
disclose O
information O
about O
themselves O
? O
[]

CONCLUSIONS O
The O
use O
of O
periprocedural O
cangrelor O
during O
PCI O
was O
not O
superior O
to O
placebo O
in O
reducing O
the O
primary O
end O
point O
. O
[]

Training O
with O
haptic O
guidance O
has O
been O
proposed O
as O
a O
technique O
for O
learning O
complex O
movements O
in O
rehabilitation O
and O
sports O
, O
but O
it O
is O
unclear O
how O
to O
best O
deliver O
guidance-based O
training O
. O
[]

PATIENTS O
AND O
METHODS O
From O
December O
1993 O
to O
April O
1999 O
, O
284 O
patients O
with O
1992 O
American O
Joint O
Committee O
on O
Cancer O
stage O
III O
to O
IV O
( O
M0 O
) O
NPC O
were O
randomly O
allocated O
into O
two O
arms O
. O
[]

Substance O
use O
relapse O
rates O
are O
often O
high O
in O
the O
first O
months O
after O
discharge O
from O
inpatient O
substance O
abuse O
treatment O
, O
and O
patient B-outcome ['Life-Impact']
adherence I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
aftercare I-outcome ['Life-Impact']
plans O
is O
often O
low O
. O
['Life-Impact']

BACKGROUND O
Previous O
studies O
in O
patients O
and O
in O
dogs O
with O
experimentally O
induced O
heart O
failure O
( O
HF O
) O
showed O
that O
electrical O
signals O
applied O
to O
the O
failing O
myocardium O
during O
the O
absolute O
refractory O
period O
improved O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSION O
With O
shorter O
operative O
time O
, O
less O
blood O
loss O
and O
similar O
morbidity O
profile O
exteriorization O
of O
uterus O
during O
caesarean O
section O
seems O
to O
be O
preferred O
except O
where O
it O
is O
not O
possible O
because O
of O
adhesions O
and O
surgeons O
inexperience O
. O
[]

METHOD O
Twenty O
patients O
with O
hepatocellular O
carcinoma O
measuring O
< O
25 O
mm O
were O
divided O
randomly O
into O
two O
equal O
groups O
. O
[]

A O
total O
of O
335 O
patients O
were O
randomized O
into O
treatment O
with O
the O
oral O
administration O
of O
XS0601 O
, O
or O
a O
placebo O
for O
6 O
months O
after O
successful O
PCI O
. O
[]

Therapeutic O
regimens O
were O
as O
follows O
: O
after O
complete O
transurethral O
resection O
of O
all O
visible O
tumors O
, O
BCG O
RIVM O
( O
1 O
x O
10 O
( O
9 O
) O
bacilli O
in O
50 O
mL O
saline O
) O
was O
instilled O
once O
a O
week O
for O
six O
consecutive O
weeks O
, O
and O
mitomycin O
C O
( O
30 O
mg O
in O
50 O
mL O
saline O
) O
was O
administered O
once O
a O
week O
for O
one O
month O
( O
weeks O
1 O
to O
4 O
) O
and O
thereafter O
once O
a O
month O
for O
a O
total O
of O
six O
months O
. O
[]

OBJECTIVE O
In O
this O
study O
, O
we O
tested O
in O
patients O
with O
metabolic O
syndrome O
whether O
allopurinol O
through O
decreasing O
oxidative O
stress O
improves O
endothelial O
function O
, O
and O
ameliorates O
inflammatory O
state O
represented O
by O
markers O
of O
myeloperoxidase O
, O
C-reactive O
protein O
( O
CRP O
) O
and O
fibrinogen O
. O
[]

Among O
groups O
A O
and O
B O
, O
there O
was O
no O
statistical O
difference O
in O
clinicopathological O
profiles O
. O
[]

The O
impact O
on O
curriculum O
implementation O
of O
two O
approaches O
to O
teacher O
training O
are O
compared O
. O
[]

CONCLUSION O
LM O
supplemented O
with O
CM O
may O
facilitate O
weight O
loss O
in O
patients O
taking O
antipsychotic O
medications O
; O
financial O
reimbursement O
for O
behavioral O
change O
may O
be O
particularly O
effective O
in O
this O
population O
. O
[]

There O
was O
also O
some O
evidence O
that O
cumulative O
time O
to O
perform O
the O
three O
100-m O
swims O
was O
decreased O
in O
the O
Cr O
group O
. O
[]

Immune B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
evaluated O
by O
studying O
immunoglobulin B-outcome ['Physiological-Clinical']
A I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IgA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Coping O
with O
distress O
and O
self O
harm O
: O
the O
impact O
of O
a O
primary O
prevention O
program O
among O
adolescents O
. O
[]

Those O
results O
coupled O
with O
the O
known O
composition O
characteristics O
of O
Plasmatein O
were O
used O
as O
the O
starting O
basis O
to O
formulate O
test O
lots O
of O
synthetic O
serum O
substitute O
( O
SSS O
) O
. O
[]

A O
10-day O
, O
second-line O
therapy O
with O
omeprazole O
20mg O
, O
levofloxacin O
250 O
mg O
, O
and O
amoxicillin O
1g O
, O
all O
given O
twice O
daily O
, O
was O
offered O
to O
the O
eradication O
failure O
patients O
. O
[]

MAIN O
OUTCOME O
MEASURE O
Genital O
arousal O
was O
assessed O
as O
vaginal B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
amplitude O
( O
VPA O
) O
using O
vaginal B-outcome ['Physiological-Clinical']
photoplethysmography I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
authors O
recorded O
improvement O
of O
the O
prooxidation B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
which O
followed O
after O
the O
dynamics O
of O
improvement O
of O
the O
impaired O
['Physiological-Clinical']

RESULTS O
In O
group O
A O
, O
BPs O
of O
white-coat B-outcome ['Physiological-Clinical']
hypertensives I-outcome ['Physiological-Clinical']
and O
essential B-outcome ['Physiological-Clinical']
hypertensives I-outcome ['Physiological-Clinical']
were O
significantly O
reduced O
by O
22/11 O
and O
14/8 O
mmHg O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
all O
secondary O
efficacy O
parameter O
results O
were O
similar O
. O
- O
[]

Reflexive O
orienting O
in O
response O
to O
eye O
gaze O
and O
an O
arrow O
in O
children O
with O
and O
without O
autism O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

These O
results O
suggest O
that O
the O
C1772T B-outcome ['Physiological-Clinical']
polymorphism I-outcome ['Physiological-Clinical']
in O
HIF-1alpha O
is O
not O
involved O
in O
progression O
or O
metastasis O
of O
colorectal O
carcinoma O
. O
['Physiological-Clinical']

RESULTS O
A O
Global O
Impressions O
parental O
questionnaire O
found O
that O
the O
supplement O
group O
reported O
statistically O
significant O
improvements O
in O
sleep B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
compared O
to O
the O
placebo O
group O
. O
['Physiological-Clinical']

Two-year O
prospective O
clinical O
comparison O
of O
immediate O
replacement O
vs. O
immediate O
restoration O
of O
single O
tooth O
in O
the O
esthetic O
zone O
. O
[]

Echis O
carinatus O
is O
the O
most O
important O
cause O
of O
morbidity O
and O
mortality O
from O
snake O
bite O
in O
Nigeria O
and O
in O
many O
other O
parts O
of O
the O
world O
. O
[]

Disopyramide-pyridostigmine O
interaction O
: O
selective O
reversal O
of O
anticholinergic O
symptoms O
with O
preservation O
of O
antiarrhythmic O
effect O
. O
[]

We O
also O
sought O
to O
identify O
factors O
associated O
with O
BMD O
loss O
, O
including O
markers O
of O
systemic O
inflammation O
[ O
soluble O
tumor O
necrosis O
factor-alpha O
receptors O
( O
sTNFR O
I O
and O
II O
) O
] O
. O
[]

Group O
cognitive O
behavior O
therapy O
for O
children O
with O
high-functioning O
autism O
spectrum O
disorders O
and O
anxiety O
: O
a O
randomized O
trial O
. O
[]

RESULTS O
The O
original O
results O
of O
the O
SEG O
trial O
demonstrated O
no O
significant O
difference O
between O
idarubicin O
and O
daunorubicin B-outcome ['Resource-use']
. O
['Resource-use']

INTERPRETATION O
Our O
findings O
do O
not O
support O
the O
systematic O
prophylactic O
use O
of O
amiodarone O
in O
all O
patients O
with O
depressed O
left-ventricular O
function O
after O
myocardial O
infarction O
. O
[]

PATIENTS O
50 O
pediatric O
patients O
( O
18 O
girls O
, O
32 O
boys O
) O
, O
aged O
4 O
months O
to O
15 O
years O
, O
undergoing O
elective O
repair O
of O
congenital O
heart O
disease O
. O
[]

The O
total O
dose O
required O
by O
the O
epidural O
route O
was O
less O
than O
one-fifth O
that O
required O
intramuscularly O
, O
and O
sedation O
was O
correspondingly O
reduced O
. O
[]

CONCLUSION O
Propranolol O
may O
shorten O
the O
induction O
[]

Patients O
had O
postoperative O
radiation O
therapy O
, O
conventional O
( O
C O
) O
or O
accelerated O
( O
CB O
) O
. O
[]

Association O
between O
platelet O
activation O
and O
fibrinolysis O
in O
acute O
stroke O
patients O
. O
[]

Both O
second O
and O
third O
generation O
OCs O
were O
clinically O
effective O
in O
treating O
hirsutism O
. O
[]

The O
overall O
results O
indicated O
that O
dietary O
PN O
supplementation O
at O
100 O
mg/kg O
diet O
may O
reverse O
the O
negative O
effects O
caused O
by O
ET O
and O
may O
protect O
the O
haemato-immunological O
status O
of O
L. O
rohita O
fingerlings O
reared O
at O
higher O
water O
temperature O
. O
[]

Patients O
randomized O
to O
CDDP/FU O
also O
received O
CDDP O
20 O
mg/m2 O
intravenous O
( O
IV O
) O
bolus O
on O
days O
1 O
to O
5 O
of O
each O
cycle O
. O
[]

RESULTS O
Cognitive B-outcome ['Life-Impact']
development I-outcome ['Life-Impact']
scores O
were O
7.2 O
points O
higher O
( O
p O
= O
0.002 O
) O
in O
the O
INT O
group O
, O
after O
adjustment O
for O
baseline O
differences O
in O
site O
, O
sociodemographic O
characteristics O
, O
and O
neonatal B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
, O
and O
were O
9.4 O
points O
higher O
( O
p O
< O
0.0003 O
) O
when O
the O
29 O
children O
with O
significant O
cerebral O
palsy O
were O
removed O
. O
['Life-Impact', 'Physiological-Clinical']

Future O
innovative O
educational O
studies O
to O
improve O
recognition B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
abuse I-outcome ['Life-Impact']
are O
warranted O
. O
['Life-Impact']

FINDINGS O
50 O
HIV-seropositive O
and O
50 O
HIV-seronegative O
children O
were O
recruited O
for O
the O
study O
, O
four O
of O
whom O
were O
subsequently O
excluded O
. O
[]

BACKGROUND O
Autism O
is O
a O
developmental O
disorder O
characterized O
by O
decreased O
interest O
and O
engagement O
in O
social O
interactions O
and O
by O
enhanced O
self-focus O
. O
[]

Educational O
games O
may O
provide O
an O
efficient O
vehicle O
for O
carrying O
out O
developmentally O
specific O
nursing O
interventions O
in O
school O
settings O
. O
[]

A O
comparison O
of O
once O
and O
twice O
daily O
atenolol O
for O
angina O
pectoris O
. O
[]

Inclusion O
criteria O
were O
myocardial O
infarction O
or O
unstable O
ischemic O
attack O
, O
age O
under O
70 O
years O
, O
use O
of O
betablockers O
and O
presence O
of O
sinus O
rhythm O
. O
[]

The O
authors O
assessed O
the O
safety O
and O
effectiveness O
of O
atomoxetine O
monotherapy O
compared O
with O
combined O
atomoxetine/fluoxetine O
therapy O
in O
a O
population O
of O
children O
and O
adolescents O
with O
ADHD O
and O
concurrent O
symptoms O
of O
depression O
or O
anxiety O
. O
[]

CONCLUSIONS O
Bonding O
resin O
or O
liquid O
polish O
coatings O
significantly O
reduce O
early O
biofilm B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
, O
which O
in O
turn O
might O
affect O
the O
overall O
plaque O
accumulation O
on O
provisional O
restorations O
. O
['Physiological-Clinical']

Both O
techniques O
demonstrated O
minimal B-outcome ['Physiological-Clinical']
cone I-outcome ['Physiological-Clinical']
cutting I-outcome ['Physiological-Clinical']
( O
1 O
in O
the O
loop O
versus O
0 O
in O
the O
holder O
) O
. O
['Physiological-Clinical']

PURPOSE O
To O
characterize O
the O
maximum-tolerated O
dose O
, O
recommended O
dose O
, O
dose-limiting O
toxicities O
( O
DLT O
) O
, O
pharmacokinetic O
profile O
, O
and O
food O
effect O
of O
orally O
administered O
irinotecan O
formulated O
as O
new O
semisolid O
matrix O
capsules O
. O
[]

We O
compared O
the O
prophylactic O
anti-emetic O
efficacy O
of O
midazolam O
and O
ondansetron O
in O
90 O
patients O
scheduled O
for O
minor O
gynaecological O
( O
hysteroscopy O
) O
or O
urological O
( O
ureteroscopy O
) O
procedures O
planned O
to O
last O
1-2 O
h O
under O
sevoflurane O
anaesthesia O
with O
spontaneous O
ventilation O
of O
the O
lungs O
via O
a O
laryngeal O
mask O
airway O
. O
[]

Nordic O
Myeloma O
Study O
Group O
. O
[]

ClinicalTrials.gov O
number O
, O
NCT00385138 O
. O
) O
[]

Prediction O
of O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
in O
patients O
with O
rheumatoid O
arthritis O
: O
comparison O
of O
six O
formulae O
and O
one O
nomogram O
. O
['Physiological-Clinical']

CONCLUSIONS O
In O
this O
multi-institutional O
study O
, O
the O
rates O
of O
recurrent B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
were O
similar O
after O
laparoscopically O
assisted O
colectomy O
and O
open O
colectomy O
, O
suggesting O
that O
the O
laparoscopic O
approach O
is O
an O
acceptable O
alternative O
to O
open O
surgery O
for O
colon O
cancer O
. O
['Physiological-Clinical']

We O
conclude O
that O
simvastatin O
and O
fenofibrate O
interact O
, O
by O
different O
mechanisms O
, O
with O
oxidative O
stress O
, O
a O
key O
factor O
in O
the O
modification O
of O
fibrinolysis O
and O
endothelial O
function O
in O
Type O
2 O
diabetes O
. O
[]

OBJECTIVE O
To O
observe O
the O
therapeutic O
effect O
of O
probucol O
on O
serum O
malondialdehyde O
( O
MDA O
) O
and O
superoxide O
dismutase O
( O
SOD O
) O
in O
patients O
with O
primary O
hypertension O
. O
[]

The O
estimated O
7-year O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
EFS I-outcome ['Mortality']
) I-outcome ['Mortality']
for O
subjects O
randomized O
to O
TG O
was O
84.1 O
% O
( O
+/- O
1.8 O
% O
) O
and O
to O
MP O
was O
79.0 O
% O
( O
+/- O
2.1 O
% O
; O
P O
= O
.004 O
log O
rank O
) O
, O
although O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
91.9 O
% O
( O
+/- O
1.4 O
% O
) O
and O
91.2 O
% O
( O
+/- O
1.5 O
% O
) O
, O
respectively O
( O
P O
= O
.6 O
log O
rank O
) O
. O
['Mortality', 'Mortality']

BACKGROUND O
Cryptosporidiosis O
in O
children O
in O
developing O
countries O
causes O
persistent O
diarrhoea O
and O
malnutrition O
and O
is O
associated O
with O
increased O
mortality O
, O
but O
there O
is O
no O
effective O
treatment O
. O
[]

Interobserver O
variation O
was O
analyzed O
using O
the O
kappa O
statistic O
. O
[]

Secondary O
outcomes O
included O
anxiety O
, O
depression O
, O
and O
sleep O
. O
[]

213 O
cancer O
patients O
with O
different O
diagnoses O
were O
randomised O
into O
an O
intervention O
group O
or O
wait-list O
control O
group O
. O
[]

Treatment O
response O
was O
defined O
as O
improvement O
by O
at O
least O
five O
points O
in O
the O
tinnitus O
questionnaire O
( O
TQ O
) O
. O
[]

CONCLUSIONS O
Results O
suggest O
that O
universal O
, O
school-based O
programs O
can O
benefit O
the O
emotional O
health O
of O
youth O
in O
low-income O
, O
urban O
settings O
. O
[]

RESULTS O
The O
area O
under O
the O
curve O
for O
N-acetylcysteine O
was O
significantly O
higher O
for O
phase O
II O
than O
phase O
I O
( O
P O
< O
.05 O
, O
two-tailed O
paired O
t-test O
) O
. O
[]

METHODS O
A O
multicenter O
, O
double-blind O
, O
randomized O
trial O
was O
performed O
in O
653 O
patients O
with O
dermatophytoses O
, O
randomized O
to O
eberconazole O
1 O
% O
cream O
every O
12 O
h O
or O
miconazole O
2 O
% O
cream O
every O
12 O
h O
for O
4 O
weeks O
. O
[]

Patients O
who O
were O
in O
sinus O
rhythm O
spontaneously O
or O
had O
sinus O
rhythm O
restored O
by O
electric O
cardioversion O
on O
day O
4 O
were O
discharged O
from O
the O
hospital O
. O
[]

A O
thymocyte O
proliferative O
response O
assay O
was O
used O
to O
evaluate O
the O
in O
vitro B-outcome ['Physiological-Clinical']
IL-1 I-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
by O
AMs O
in O
healthy O
subjects O
who O
received O
D53 O
immunostimulant O
. O
['Physiological-Clinical']

Microbial B-outcome ['Physiological-Clinical']
contamination I-outcome ['Physiological-Clinical']
was O
evaluated O
with O
three O
swabs O
( O
in O
subcutaneous O
tissue O
and O
the O
dermis O
) O
, O
in O
the O
operating O
room O
before O
wound O
packing O
and O
on O
the O
2nd O
and O
3rd O
postoperative O
day O
( O
before O
suturing O
the O
skin O
) O
. O
['Physiological-Clinical']

Vitamin O
supplements O
were O
delivered O
weekly O
by O
community O
health O
volunteers O
who O
also O
recorded O
mortality B-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

Needle O
versus O
loop O
diathermy O
excision O
of O
the O
transformation O
zone O
for O
the O
treatment O
of O
cervical O
intraepithelial O
neoplasia O
: O
a O
randomised O
controlled O
trial O
. O
[]

These O
results O
show O
that O
AVP O
is O
able O
to O
dissociate O
the O
natriuretic B-outcome ['Physiological-Clinical']
and O
diuretic B-outcome ['Physiological-Clinical']
effects O
of O
ANF O
. O
['Physiological-Clinical', 'Physiological-Clinical']

C O
demonstrates O
dose-linear O
behavior O
. O
[]

Suspected B-outcome ['Physiological-Clinical']
bile-duct I-outcome ['Physiological-Clinical']
stones I-outcome ['Physiological-Clinical']
were O
investigated O
by O
preoperative O
endoscopic O
retrograde O
cholangiography O
( O
LC O
group O
) O
or O
intraoperative O
cholangiography O
( O
OC O
group O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
clinical O
benefit O
of O
montelukast O
, O
a O
cysteinyl O
leukotriene O
receptor O
antagonist O
, O
administered O
once O
daily O
for O
treating O
seasonal B-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Periodically O
recorded O
were O
body B-outcome ['Physiological-Clinical']
weight O
, O
BP B-outcome ['Physiological-Clinical']
( O
mercury O
sphygmomanometer O
) O
, O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
, O
electrolytes B-outcome ['Physiological-Clinical']
, O
complete B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
, O
urine B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
drainage B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

added O
to O
images O
of O
thin/attractive O
models O
would O
affect O
body B-outcome ['Life-Impact']
dissatisfaction I-outcome ['Life-Impact']
and O
intent O
to O
diet O
in O
female O
undergraduate O
students O
( O
n=342 O
) O
. O
['Life-Impact']

However O
, O
more O
and O
smaller O
fibroadenomas O
were O
detected O
in O
the O
instruction O
group O
than O
in O
the O
control O
group O
( O
P O
< O
0.01 O
) O
. O
[]

Control O
of O
perioperative O
hypertension B-outcome ['Physiological-Clinical']
during O
coronary O
artery O
surgery O
. O
['Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Few O
therapeutic O
options O
are O
aimed O
at O
improving O
walking B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
. O
['Life-Impact']

Forty-six O
patients O
were O
irradiated O
with O
7 O
Gy O
single O
dose O
within O
16-20 O
h O
before O
operation O
. O
[]

Narratives O
, O
or O
stories O
, O
offer O
a O
novel O
dissemination O
strategy O
for O
clinical O
recommendations O
. O
[]

RESULTS O
Of O
the O
186 O
subjects O
completing O
the O
study O
, O
3 O
( O
1.6 O
% O
) O
exhibited O
evidence O
of O
delayed O
contact O
sensitization O
manifested O
as O
erythema O
with O
or O
without B-outcome ['Physiological-Clinical']
infiltration I-outcome ['Physiological-Clinical']
and O
confined O
solely O
to O
sites O
of O
active O
transdermal O
nicotine O
system O
application O
. O
['Physiological-Clinical']

Enrolled O
patients O
were O
randomly O
assigned O
( O
1:1 O
) O
by O
a O
computer-generated O
schedule O
to O
follow O
either O
a O
standard O
diagnostic O
strategy O
( O
based O
on O
culture O
and O
histology O
) O
or O
a O
biomarker-based O
diagnostic O
strategy O
( O
aspergillus O
galactomannan O
and O
PCR O
) O
to O
direct O
treatment O
with O
antifungal O
drugs O
. O
[]

The O
responses O
of O
renal O
haemodynamic O
and O
natriuretic O
indices O
to O
the O
oral O
prostaglandin O
synthetase O
inhibitor O
indomethacin O
( O
200 O
mg O
) O
, O
to O
infused O
angiotensin O
II O
( O
1 O
ng O
min-1 O
kg-1 O
) O
and O
to O
the O
combination O
of O
the O
two O
were O
studies O
in O
placebo-controlled O
fashion O
in O
eight O
normal O
male O
subjects O
both O
prior O
to O
and O
following O
administration O
of O
intravenous O
frusemide O
( O
20 O
mg O
) O
. O
[]

Three O
hundred O
and O
fifty-five O
women O
randomized O
to O
receive O
either O
oral O
misoprostol O
400 O
mug O
or O
intramuscular O
syntometrine O
in O
the O
third O
stage O
of O
labor O
were O
studied O
. O
[]

2.46 O
ml/min O
, O
P O
< O
0.001 O
) O
in O
patients O
receiving O
rCsA O
versus O
sCsA O
at O
1 O
year O
, O
respectively O
. O
[]

Impact O
of O
the O
quantity O
and O
flavonoid B-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
of O
fruits O
and O
vegetables O
on O
markers O
of O
intake O
in O
adults O
with O
an O
increased O
risk O
of O
cardiovascular O
disease O
: O
the O
FLAVURS O
trial O
. O
['Physiological-Clinical']

713 O
patients O
received O
ferumoxytol O
, O
and O
711 O
received O
placebo O
. O
[]

The O
primary O
objective O
of O
this O
trial O
was O
to O
demonstrate O
similar O
risks O
after O
the O
resection O
with O
both O
techniques O
. O
[]

One O
group O
received O
UFT O
600 O
mg/day O
preoperatively O
for O
7 O
consecutive O
days O
and O
a O
control O
group O
received O
no O
chemotherapy O
or O
radiotherapy O
. O
[]

However O
, O
no O
significant O
reduction O
in O
respiratory B-outcome ['Physiological-Clinical']
distress I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
( O
p O
= O
0.286 O
) O
was O
found O
after O
one O
study O
, O
with O
the O
lowest O
quality O
score O
, O
was O
excluded O
. O
['Physiological-Clinical']

In O
the O
placebo O
group O
, O
245 O
patients O
remained O
H. O
pylori O
infected O
. O
[]

After O
a O
3- O
to O
5-day O
placebo O
run-in O
period O
, O
patients O
were O
randomly O
assigned O
to O
treatment O
with O
montelukast O
10 O
mg O
( O
n O
= O
522 O
) O
, O
loratadine O
10 O
mg O
( O
n O
= O
171 O
) O
, O
or O
placebo O
( O
n O
= O
521 O
) O
once O
daily O
at O
bedtime O
for O
2 O
weeks O
. O
[]

THE O
AIM O
OF O
THE O
STUDY O
This O
article O
presents O
the O
incidence O
of O
prostate O
cancer O
, O
isolated O
high O
grade O
prostatic O
intraepithelial O
neoplasia O
( O
PIN O
) O
and O
atypical O
lesions O
suspicious O
for O
prostate O
cancer O
( O
LSPC O
) O
during O
subsequent O
screening O
rounds O
in O
the O
centres O
of O
five O
of O
the O
countries O
participating O
in O
the O
European O
Randomized O
Study O
of O
Screening O
for O
Prostate O
Cancer O
( O
ERSPC O
) O
. O
[]

OUTCOMES O
& O
MEASUREMENTS O
Descriptive O
comparison O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
laboratory O
tests O
, O
and O
vital O
signs O
. O
['Adverse-effects']

Participants O
fixated B-outcome ['Physiological-Clinical']
an O
object O
picture O
( O
e.g O
. O
['Physiological-Clinical']

Obstetric O
care O
practitioners O
who O
viewed O
the O
training O
video O
were O
rated O
as O
showing O
greater O
empathy B-outcome ['Life-Impact']
, O
minimizing O
patient B-outcome ['Life-Impact']
defensiveness I-outcome ['Life-Impact']
, O
and O
supporting B-outcome ['Life-Impact']
women I-outcome ['Life-Impact']
's O
beliefs B-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
change I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

PURPOSE O
To O
compare O
the O
performance O
of O
partial B-outcome ['Physiological-Clinical']
ceramic I-outcome ['Physiological-Clinical']
crowns I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PCCs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
inserted O
with O
RelyX O
Unicem O
( O
RXU O
) O
either O
with O
( O
RXU+E O
) O
or O
without O
( O
RXU O
) O
selective O
enamel O
etching O
. O
['Physiological-Clinical']

This O
double-blind O
, O
placebo-controlled O
study O
compared O
the O
postoperative O
analgesic O
effects O
of O
preoperatively O
administered O
oral O
acetaminophen O
or O
ibuprofen O
. O
[]

Assessments O
pre-treatment O
, O
post-treatment O
, O
and O
after O
6 O
months O
included O
parent O
ratings O
of I-outcome ['Life-Impact']
symptoms B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
ASD I-outcome ['Life-Impact']
, O
executive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
tasks O
, O
and O
19-channel O
EEG O
recordings O
. O
['Life-Impact', 'Life-Impact']

Flow-cytometric O
studies O
with O
eleutherococcus O
senticosus O
extract O
as O
an O
immunomodulatory O
agent O
. O
[]

Venous B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
the O
diameter O
of O
the O
radial B-outcome ['Physiological-Clinical']
and O
temporal B-outcome ['Physiological-Clinical']
arteries I-outcome ['Physiological-Clinical']
, O
calf O
blood O
flow O
and O
subcutaneous B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
were O
measured O
at O
baseline O
and O
repeated O
after O
1 O
and O
23 O
h O
of O
infusion O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
valsartan O
, O
an O
angiotensin O
receptor O
blocker O
, O
and O
nebivolol O
, O
a O
beta-blocker O
, O
on O
atrial O
electromechanical O
coupling O
in O
newly O
diagnosed O
stage O
1 O
hypertensive O
patients O
. O
[]

No O
differences O
in O
post B-outcome ['Physiological-Clinical']
immunisation I-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
were O
noted O
between O
the O
two O
vaccinated O
groups O
. O
['Physiological-Clinical']

Neither O
the O
number O
of O
infants B-outcome ['Physiological-Clinical']
requiring O
intermittent B-outcome ['Physiological-Clinical']
positive O
pressure B-outcome ['Physiological-Clinical']
ventilation B-outcome ['Physiological-Clinical']
or O
duration O
of O
O2- B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
, O
nor O
number O
of O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

BACKGROUND O
AND O
METHODS O
In O
patients O
with O
the O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
, O
the O
rate O
of O
relapse O
after O
primary O
treatment O
for O
cryptococcal O
meningitis O
remains O
high O
. O
[]

Effectiveness O
of O
sensory O
integration O
interventions O
in O
children O
with O
autism O
spectrum O
disorders O
: O
a O
pilot O
study O
. O
[]

Twenty-four O
living O
liver O
donors O
( O
n O
= O
12 O
for O
each O
group O
) O
were O
randomized O
to O
undergo O
hepatic O
transection O
using O
CUSA O
with O
BP O
or O
CUSA O
with O
TL O
. O
[]

Each O
treatment O
was O
delivered O
3 O
times O
per O
week O
, O
in O
20-min O
sessions O
, O
for O
6 O
months O
. O
[]

This O
finding O
may O
be O
applicable O
to O
a O
lineup O
task O
: O
The O
presence O
of O
duds O
( O
i.e. O
, O
highly O
dissimilar O
fillers O
) O
may O
increase O
a O
witness O
's O
confidence B-outcome ['Life-Impact']
that O
an O
identified O
( O
non-dud O
) O
lineup O
member O
is O
the O
criminal O
. O
['Life-Impact']

RESULTS O
There O
was O
no O
significant O
difference O
in O
the O
success B-outcome ['Physiological-Clinical']
rate O
at O
48 O
hours O
( O
sublingual O
: O
91 O
% O
; O
vaginal O
: O
95 O
% O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
prevalence O
and O
correlates O
of O
left O
ventricular O
thrombosis O
in O
patients O
with O
acute O
myocardial O
infarction O
, O
and O
whether O
the O
occurrence O
of O
early O
mitral O
regurgitation O
has O
a O
protective O
effect O
against O
the O
formation O
of O
left O
ventricular O
thrombus O
. O
[]

This O
study O
has O
high O
potential O
to O
have O
a O
major O
impact O
on O
clinical O
management O
and O
outcomes O
after O
a O
breast O
cancer O
diagnosis O
. O
[]

Febuxostat O
is O
potentially O
a O
safe O
and O
efficacious O
alternative O
. O
[]

Left O
ventricular O
( O
LV O
) O
hypertrophy O
is O
known O
to O
be O
an O
independent O
risk O
factor O
for O
cardiac O
death O
, O
but O
its O
significance O
in O
non-Q-wave O
acute O
myocardial O
infarction O
( O
AMI O
) O
has O
not O
been O
assessed O
previously O
. O
[]

Although O
the O
repeated O
measures O
analysis O
showed O
a O
significant O
height B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
there O
was O
no O
difference O
between O
treatment O
arms O
( O
P O
= O
.98 O
) O
. O
['Physiological-Clinical']

Three O
multiple-pass O
24-hour O
dietary O
recalls O
were O
collected O
at O
the O
beginning O
of O
their O
fourth-grade O
year O
and O
at O
the O
end O
of O
their O
fifth- O
and O
sixth-grade O
years O
. O
[]

METHODS O
Asymptomatic O
patients O
admitted O
to O
the O
physical O
check-up O
department O
of O
Buddhist O
Dalin O
Tzu O
Chi O
General O
Hospital O
were O
included O
. O
[]

OBJECTIVE O
To O
explore O
the O
role O
of O
fixed-point O
spin O
reduction O
of O
spinal O
manipulation O
therapy O
in O
the O
treatment O
of O
cervical O
vertigo O
and O
its O
effect O
on O
cervical O
artery O
spasm O
index O
( O
RI O
) O
and O
atlantoaxial O
displacement O
index O
( O
ADI O
) O
. O
[]

The O
total O
propofol B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
( O
infusion O
+ O
bolus O
) O
increased O
from O
0.102 O
+/- O
0.028 O
( O
+/- O
SD O
) O
with O
the O
lowest O
infusion B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
to O
0.202 O
+/- O
0.006 O
mg/kg O
per O
minute O
with O
the O
highest O
infusion B-outcome ['Physiological-Clinical']
rate O
and O
recovery B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
from O
5.2 O
+/- O
1.4 O
to O
9.9 O
+/- O
2.6 O
min O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
follow-up O
was O
37 O
months O
. O
[]

MAIN O
RESULTS O
The O
clinician O
intervention O
was O
associated O
with O
an O
absolute O
increase O
in O
guideline-consistent B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
of O
5.4 O
% O
in O
the O
intervention O
group O
versus O
a O
decline O
of O
2.7 O
% O
in O
the O
control O
group O
( O
P O
=.04 O
) O
. O
['Life-Impact']

In O
123 O
patients O
( O
per O
protocol O
set O
) O
, O
those O
remaining O
free O
from O
PAF/PAFL B-outcome ['Physiological-Clinical']
after O
the O
treatment O
were O
3.1 O
% O
on O
placebo O
, O
7.7 O
% O
on O
25 O
mg/BID O
, O
9.4 O
% O
on O
50 O
mg/BID O
, O
and O
39.4 O
% O
on O
100 O
mg/BID O
of O
flecainide O
. O
['Physiological-Clinical']

Gonadotropin-releasing O
hormone O
agonist O
in O
the O
treatment O
of O
premenstrual O
symptoms O
with O
and O
without O
ongoing O
dysphoria O
: O
a O
controlled O
study O
. O
[]

SETTING O
Twenty-two O
U.S. O
medical O
centers O
( O
including O
Puerto O
Rico O
) O
participated O
. O
[]

Several O
investigations O
which O
have O
taken O
treatment O
time O
into O
account O
have O
shown O
that O
the O
pharmacokinetic O
parameters O
, O
the O
therapeutic B-outcome ['Physiological-Clinical']
efficacy O
and O
even O
the O
toxicity B-outcome ['Adverse-effects']
of O
a O
large O
number O
of O
products O
may O
vary O
according O
to O
the O
administration O
schedule O
. O
['Physiological-Clinical', 'Adverse-effects']

Heat-exercise O
performance O
of O
pyridostigmine-treated O
subjects O
wearing O
chemical O
protective O
clothing O
. O
[]

15.13 O
, O
p O
= O
0.004 O
and O
basal O
citrulline O
= O
49.51 O
? O
[]

This O
was O
a O
single-blind O
, O
single-dose O
, O
randomized O
crossover O
study O
to O
determine O
the O
absolute B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
of O
Medrol O
, O
a O
new O
high O
dose O
( O
100 O
mg O
) O
methylprednisolone O
tablet O
product O
, O
by O
comparing O
it O
with O
100 O
mg O
methylprednisolone O
from O
an O
intravenous O
formulation O
, O
Solu-Medrol O
. O
['Physiological-Clinical']

Both O
preparations O
were O
tolerated B-outcome ['Life-Impact']
and O
accepted B-outcome ['Life-Impact']
well I-outcome ['Life-Impact']
, O
thus O
showing O
both O
skin B-outcome ['Physiological-Clinical']
protection I-outcome ['Physiological-Clinical']
and O
skin B-outcome ['Physiological-Clinical']
care I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Other O
reasons O
for O
termination B-outcome ['Life-Impact']
were O
hematuria B-outcome ['Physiological-Clinical']
, O
latex B-outcome ['Life-Impact']
sensitivity I-outcome ['Life-Impact']
, O
deceased/severe B-outcome ['Mortality']
illness I-outcome ['Mortality']
, O
or O
personal B-outcome ['Physiological-Clinical']
choice I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Mortality', 'Physiological-Clinical']

The O
C B-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
level O
was O
lower O
after O
6 O
days O
of O
both O
nutrition O
formulas O
compare O
to O
75 O
g O
OGTT O
, O
but O
not O
different O
from O
the O
standard O
mixed O
meal O
. O
['Physiological-Clinical']

BTX-A O
therapy O
may O
be O
an O
effective O
form O
of O
therapy O
offering O
an O
alternative O
or O
adjunct O
to O
conventional O
modalities O
. O
[]

The O
teeth O
were O
thermocycled O
and O
artificial O
caries O
were O
created O
using O
an O
acid-gel O
. O
[]

Theory-driven O
intervention O
improves O
calcium B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
osteoporosis B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
, O
and O
self-efficacy B-outcome ['Life-Impact']
in O
community-dwelling O
older O
Black O
adults O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Over O
2 O
years O
, O
patients O
treated O
with O
hemiarthroplasty O
gained O
more O
quality-adjusted O
life O
years O
than O
patients O
treated O
with O
internal O
fixation O
. O
[]

Mean O
initial B-outcome ['Physiological-Clinical']
endotoxin I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
significantly O
elevated O
in O
both O
groups O
( O
mean O
+/- O
SEM O
; O
paromomycin O
, O
16.7 O
+/- O
5.3 O
pg/ml O
; O
placebo O
, O
17.5 O
+/- O
6.9 O
pg/ml O
; O
healthy O
controls O
, O
2.3 O
+/- O
0.4 O
pg/ml O
) O
. O
['Physiological-Clinical']

Although O
the O
three O
groups O
had O
no O
difference O
in O
frequency O
of O
ventricular B-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
, O
length O
of O
longest O
run B-outcome ['Life-Impact']
or O
frequency O
of O
ventricular B-outcome ['Physiological-Clinical']
premature I-outcome ['Physiological-Clinical']
beats B-outcome ['Physiological-Clinical']
on O
baseline O
Holter B-outcome ['Physiological-Clinical']
monitoring O
, O
the O
group O
with O
hypomagnesemia O
had O
more O
frequent O
ventricular O
couplets O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
article O
, O
it O
is O
proposed O
that O
children O
acquire O
generic O
knowledge O
by O
sharing O
in O
pretend O
play O
. O
[]

Two O
other O
patients O
had O
week O
1 O
measurements O
performed O
but O
died B-outcome ['Mortality']
before O
the O
week O
4 O
sample O
was O
collected O
due O
to O
their O
underlying O
cancer O
. O
['Mortality']

On O
assessment O
using O
phytohemagglutinin O
and O
herpesvirus O
antigen-stimulated O
proliferation O
, O
T O
cells B-outcome ['Physiological-Clinical']
in O
the O
2 O
groups O
of O
patients O
appeared O
equally O
functional B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Official O
documentation O
from O
the O
hospital O
were O
accessed O
and O
six O
staff O
interviewed O
to O
identify O
assumptions O
underlying O
practice O
. O
[]

One O
hundred O
and O
fifty-six O
infants O
aged O
between O
7 O
weeks O
and O
24 O
months O
who O
had O
had O
an O
episode O
of O
wheezing O
and O
other O
signs O
and O
symptoms O
of O
bronchiolitis O
were O
randomized O
to O
three O
groups O
as O
follows O
: O
( O
i O
) O
nebulized O
salbutamol O
was O
administered O
to O
52 O
patients O
in O
group O
I O
at O
a O
dose O
of O
0.15 O
mg/kg O
in O
2 O
mL O
saline O
; O
( O
ii O
) O
saline O
was O
nebulized O
to O
52 O
patients O
in O
group O
II O
and O
( O
iii O
) O
in O
group O
III O
52 O
patients O
received O
mist O
in O
a O
tent O
. O
[]

Intravesical O
treatment O
with O
adriamycin O
has O
been O
extensively O
employed O
in O
the O
last O
decade O
. O
[]

METHODS O
57 O
chronic O
hepatitis O
B O
patients O
with O
liver O
fibrosis O
were O
randomly O
divided O
into O
two O
groups O
: O
45 O
cases O
in O
KGQG O
group O
were O
treated O
by O
KGQG O
and O
routine O
medications O
; O
12 O
cases O
in O
control O
group O
were O
treated O
by O
routine O
medications O
only O
. O
[]

COX-1 B-outcome ['Physiological-Clinical']
, O
COX-2 B-outcome ['Physiological-Clinical']
, O
eNOS B-outcome ['Physiological-Clinical']
, O
and O
iNOS B-outcome ['Physiological-Clinical']
were O
detectable O
in O
all O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
patients O
had O
responded O
to O
a O
notice O
asking O
for O
volunteers O
. O
[]

In O
the O
clinically O
relevant O
period O
of O
days O
3-7 O
, O
both O
12 O
and O
18 O
mg O
pegfilgrastim O
doses O
produced O
significantly O
higher O
peak O
CD34+ B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
( O
8.18 O
and O
9.96 O
vs O
4.51 O
x O
10 O
( O
4 O
) O
/ml O
for O
filgrastim O
; O
P=0.034 O
and O
0.006 O
) O
. O
['Physiological-Clinical']

IL-4 B-outcome ['Physiological-Clinical']
and O
TNF-alpha B-outcome ['Physiological-Clinical']
increased O
only O
in O
men O
, O
whereas O
IL-5 B-outcome ['Physiological-Clinical']
, O
IL-6 B-outcome ['Physiological-Clinical']
, O
and O
IFN-gamma B-outcome ['Physiological-Clinical']
were O
different O
between O
sexes O
after O
exposure O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
the O
41 O
children O
receiving O
cyclosporin O
alone O
, O
26 O
exhibited O
gingival B-outcome ['Physiological-Clinical']
overgrowth I-outcome ['Physiological-Clinical']
compared O
to O
zero O
of O
20 O
patients O
receiving O
tacrolimus O
alone O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
goals O
of O
this O
study O
were O
to O
compare O
changes O
in O
measures O
of O
glycemic O
control O
and O
insulin O
sensitivity O
in O
Mexican O
patients O
with O
type O
2 O
diabetes O
who O
received O
pioglitazone O
or O
glimepiride O
for O
1 O
year O
. O
[]

Compared O
with O
patients O
without O
previous O
treatment O
with O
statins O
, O
statin O
withdrawal O
was O
associated O
with O
a O
19.01 O
( O
1.96 O
to O
184.09 O
) O
-fold O
increase O
in O
the O
risk O
of O
END O
and O
an O
increase O
in O
mean O
infarct B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of O
43.51 O
mL O
( O
SE O
21.91 O
; O
p O
= O
0.048 O
) O
. O
['Physiological-Clinical']

Ten O
participants O
from O
nine O
elementary O
schools O
in O
a O
suburban O
Texas O
school O
district O
were O
randomly O
assigned O
to O
an O
intervention O
or O
a O
control O
group O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
with O
extensive O
SCLC O
with O
a O
Karnofsky O
performance O
score O
( O
KPS O
) O
> O
or O
= O
50 O
and O
adequate O
renal O
function O
and O
bone O
marrow O
reserve O
were O
eligible O
. O
[]

Therapeutic O
results O
in O
relation O
to O
prognostic O
factors O
] O
. O
[]

In O
addition O
, O
there O
was O
no O
evidence O
to O
suggest O
that O
either O
atenolol O
, O
or O
propranolol O
reduced O
the O
incidence O
of O
'serious O
' O
ventricular B-outcome ['Physiological-Clinical']
arrhythmias I-outcome ['Physiological-Clinical']
in O
the O
coronary O
care O
unit O
. O
['Physiological-Clinical']

Prolonged O
critical O
illness O
is O
characterized O
by O
feeding-resistant O
wasting O
of O
protein O
, O
whereas O
reesterification O
, O
instead O
of O
oxidation O
of O
fatty O
acids O
, O
allows O
fat O
stores O
to O
accrue O
and O
associate O
with O
a O
low-activity O
status O
of O
the O
somatotropic O
and O
thyrotropic O
axis O
, O
which O
seems O
to O
be O
partly O
of O
hypothalamic O
origin O
. O
[]

Effects O
of O
weight O
reduction O
interventions O
by O
community O
pharmacists O
. O
[]

[ O
Triple O
therapy O
regimens O
involving O
H2 O
blockaders O
for O
therapy O
of O
Helicobacter B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Based O
on O
this O
study O
, O
chemical O
arthrodesis O
can O
not O
be O
advocated O
in O
clinical O
cases O
because O
of O
the O
high O
complication B-outcome ['Adverse-effects']
rate O
and O
lack O
of O
bony B-outcome ['Physiological-Clinical']
fusion I-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical']

Data O
from O
the O
V-HeFT O
II O
show O
that O
at O
2-year O
follow-up O
, O
a O
progressive O
rise O
of O
plasma B-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
was O
observed O
in O
both O
treatment O
arms O
, O
suggesting O
that O
disease O
progresses O
despite O
treatment O
with O
either O
an O
angiotensin-converting O
enzyme O
inhibitor O
, O
enalapril O
, O
or O
vasodilator O
therapy O
with O
hydralazine/isosorbide O
dinitrate O
. O
['Physiological-Clinical']

Fewer O
individuals O
experienced O
side O
effects O
( O
30 O
% O
vs. O
53 O
% O
) O
with O
the O
low-dose O
test O
( O
P O
= O
.0013 O
) O
. O
[]

There O
were O
no O
significant O
differences O
in O
length O
of O
stay O
, O
complications O
, O
oral O
pain O
medication O
usage O
after O
discharge O
, O
or O
return O
to O
work O
. O
[]

This O
effect O
was O
more O
marked O
if O
the O
epidural O
catheter O
was O
sited O
in O
the O
thoracic O
rather O
than O
the O
lumbar O
area O
. O
[]

The O
antiarrhythmic O
efficacy O
of O
tocainide O
, O
a O
new O
antiarrhythmic O
substance O
, O
has O
been O
compared O
with O
that O
of O
prajmalium O
bitartrate O
, O
a O
drug O
in O
clinical O
use O
for O
many O
years O
in O
the O
German O
speaking O
countries O
. O
[]

A O
randomized O
prospective O
study O
] O
. O
[]

Results O
suggest O
that O
pedantic O
speech O
is O
common O
in O
AS O
and O
may O
help O
differentiate O
AS O
from O
high-functioning O
autism O
. O
[]

We O
describe O
the O
development O
of O
a O
behavioral O
intervention O
designed O
to O
decrease O
sexual O
and O
injection B-outcome ['Resource-use']
risk O
behaviors B-outcome ['Life-Impact']
among O
young O
IDUs O
. O
['Life-Impact', 'Resource-use', 'Life-Impact']

Along O
with O
metformin O
, O
group O
A O
received O
CC O
and O
group O
B O
received O
rFSH O
. O
[]

The O
pharmacodynamic B-outcome ['Physiological-Clinical']
effects O
of O
zolmitriptan O
were O
also O
unaffected O
by O
fluoxetine O
pretreatment O
. O
['Physiological-Clinical']

The O
sample O
consisted O
of O
40 O
patients O
, O
16 O
of O
whom O
were O
randomized O
to O
use O
chlorhexidine O
and O
24 O
of O
whom O
were O
randomized O
to O
use O
nonmedicated O
skin O
cleanser O
. O
[]

RESULTS O
There O
were O
133 O
deaths B-outcome ['Mortality']
in O
the O
WASA O
group O
( O
31.8 O
% O
) O
and O
95 O
deaths B-outcome ['Mortality']
in O
the O
ASA O
group O
( O
23.0 O
% O
; O
risk O
ratio O
, O
1.41 O
; O
95 O
% O
confidence O
interval O
, O
1.09 O
to O
1.84 O
; O
P O
=.0001 O
) O
. O
['Mortality', 'Mortality']

Adverse O
experiences O
( O
AEs O
) O
were O
recorded O
on O
a O
standardized O
Vaccination O
Report O
Card O
. O
[]

BACKGROUND O
Contrast-induced O
acute O
kidney O
injury O
( O
CI-AKI O
) O
after O
percutaneous O
coronary O
intervention O
is O
associated O
with O
adverse O
short- O
and O
long-term O
outcomes O
. O
[]

Forty-four O
patients O
, O
surgically O
treated O
for O
advanced O
periodontal O
disease O
, O
were O
distributed O
at O
random O
among O
three O
groups O
. O
[]

After O
ulnar O
artery O
compression O
, O
the O
final O
incidence O
of O
RAO O
was O
4.1 O
% O
in O
the O
2,000-IU O
group O
and O
0.8 O
% O
in O
the O
5,000-IU O
group O
( O
p O
= O
0.03 O
) O
. O
[]

The O
follow-up O
examinations O
were O
performed O
upon O
dismission O
from O
the O
hospital O
, O
after O
6 O
, O
12 O
and O
24 O
months O
. O
[]

The O
specific O
aims O
of O
this O
comparative-effectiveness O
research O
trial O
are O
to O
: O
compare O
the O
effectiveness O
of O
three O
promising O
strategies O
for O
implementation O
of O
tobacco O
use O
treatment O
guidelines-staff O
training O
and O
current O
best O
practices O
( O
CBP O
) O
, O
CBP O
+ O
provider O
performance O
feedback O
( O
PF O
) O
, O
and O
CBP O
+ O
PF O
+ O
provider O
reimbursement O
for O
delivery O
of O
tobacco O
cessation O
treatment O
( O
pay-for-performance O
, O
or O
P4P O
) O
; O
examine O
potential O
theory-driven O
mechanisms O
hypothesized O
to O
explain O
the O
comparative O
effectiveness O
of O
three O
strategies O
for O
implementation O
; O
and O
identify O
baseline O
organizational O
factors O
that O
influence O
the O
implementation O
of O
evidence-based O
tobacco O
use O
treatment O
practices O
in O
dental O
clinics O
. O
[]

EXPERIMENTAL O
DESIGN O
Survival O
and O
disease O
status O
were O
updated O
to O
April O
2001 O
. O
[]

The O
neuropeptide O
oxytocin O
has O
been O
shown O
to O
promote O
face O
processing O
and O
modulate O
brain O
activity O
in O
healthy O
adults O
. O
[]

We O
report O
the O
impact O
of O
a O
multifaceted O
guideline O
implementation O
intervention O
on O
primary O
care O
clinician O
utilization O
of O
radiologic O
and O
specialty O
services O
for O
the O
care O
of O
acute O
low O
back O
pain O
. O
[]

Success O
rate O
, O
duration O
of O
both O
pulpal B-outcome ['Physiological-Clinical']
and O
soft B-outcome ['Resource-use']
tissue I-outcome ['Resource-use']
anesthesia I-outcome ['Resource-use']
, O
and O
its O
width O
were O
significantly O
better O
in O
the O
ISA O
compared O
with O
the O
PLA O
. O
['Physiological-Clinical', 'Resource-use']

TRIAL O
REGISTRATION O
ClinicalTrials.govNCT00677209 O
. O
[]

Immediately O
after O
treatment O
all O
three O
groups O
showed O
a O
similar O
pattern O
of O
improvement O
, O
although O
the O
two O
behavior O
therapy O
groups O
did O
show O
a O
greater O
decrease O
in O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

Patients O
were O
randomized O
between O
satraplatin O
100 O
mg/m O
( O
2 O
) O
for O
5 O
days O
plus O
prednisone O
10 O
mg O
orally O
BID O
or O
prednisone O
alone O
. O
[]

Blood B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
levels O
were O
measured O
. O
['Physiological-Clinical']

A O
total O
of O
168 O
Holstein O
steers O
( O
182.7 O
+/- O
27.5 O
kg O
) O
were O
used O
in O
a O
completely O
randomized O
design O
experiment O
( O
eight O
treatments O
; O
three O
pens O
of O
seven O
steers/treatment O
) O
. O
[]

As O
a O
result O
, O
ischemic O
postconditioning O
reduced O
postoperative O
peak O
[]

The O
mean O
change O
in O
hemoglobin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
overall O
: O
1.2 O
+/- O
2.2 O
g/dL O
) O
during O
the O
study O
represents O
a O
statistically O
significant O
( O
p O
< O
.0001 O
) O
decrease O
of O
9.7 O
% O
. O
['Physiological-Clinical']

To O
avoid O
this O
complication O
, O
it O
is O
necessary O
to O
better O
understand O
the O
depth O
of O
the O
wound O
produced O
by O
different O
strengths O
and O
combinations O
of O
peeling O
agents O
applied O
to O
living O
eyelid O
tissue O
and O
, O
more O
important O
, O
to O
determine O
the O
concentrations O
of O
TCA O
that O
are O
likely O
to O
lead O
to O
cicatricial O
ectropion O
when O
applied O
in O
a O
consistent O
fashion O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
antioxidant I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
was O
measured O
before O
conditioning O
therapy O
and O
serially O
at O
days O
1 O
, O
3 O
, O
7 O
, O
10 O
, O
and O
14 O
after O
BMT O
. O
['Physiological-Clinical']

This O
study O
evaluated O
the O
immunogenicity B-outcome ['Physiological-Clinical']
and O
reactogenicity B-outcome ['Physiological-Clinical']
of O
a O
group O
C O
meningococcal O
conjugate O
vaccine O
( O
MenC O
) O
compared O
with O
a O
group O
A+C O
meningococcal O
polysaccharide O
vaccine O
( O
MenPS O
) O
in O
healthy O
adolescents O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Insular O
and O
anterior O
cingulate O
circuits O
in O
smokers O
with O
schizophrenia O
. O
[]

Does O
3-day O
course O
of O
oral O
amoxycillin O
benefit O
children O
of O
non-severe O
pneumonia O
with O
wheeze O
: O
a O
multicentric O
randomised O
controlled O
trial O
. O
[]

No O
vaccine-related B-outcome ['Adverse-effects']
serious I-outcome ['Adverse-effects']
AEs B-outcome ['Adverse-effects']
were O
reported O
in O
either O
group O
, O
and O
the O
['Adverse-effects', 'Adverse-effects']

A O
prospective O
randomized O
trial O
with O
long-term O
follow-up O
. O
[]

A O
slight O
interactive O
effect O
was O
observed O
in O
arithmetic B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
( O
p O
less O
than O
.05 O
) O
. O
['Life-Impact']

After O
8 O
months O
of O
follow-up O
, O
there O
were O
statistically O
significant O
differences O
in O
favor O
of O
pharmaceutical O
care O
in O
the O
proportions O
of O
patients O
who O
achieved O
therapeutic O
goals O
for O
BP B-outcome ['Physiological-Clinical']
( O
52.5 O
% O
vs. O
43.0 O
% O
, O
P=0.017 O
) O
, O
TC B-outcome ['Physiological-Clinical']
( O
56.5 O
% O
vs. O
44.1 O
% O
, O
P=0.001 O
) O
, O
and O
BP/TC B-outcome ['Physiological-Clinical']
( O
37.1 O
% O
vs. O
21.8 O
% O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

To O
assess O
sensitivity O
of O
the O
5-HT1d O
receptor O
, O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
the O
5-HT1d O
receptor O
agonist O
sumatriptan O
was O
studied O
in O
adult O
autistic O
patients O
and O
matched O
normal O
controls O
. O
['Physiological-Clinical']

In O
a O
series O
of O
studies O
, O
the O
safety O
and O
efficacy O
of O
terazosin O
, O
alone O
and O
in O
combination O
with O
other O
antihypertensive O
agents O
, O
were O
evaluated O
in O
1180 O
black O
patients O
with O
mild O
to O
moderate O
essential O
hypertension O
. O
[]

No O
modification O
was O
found O
in O
nonresponders O
. O
[]

OBJECTIVE O
To O
determine O
whether O
the O
use O
of O
opioids O
could O
reduce O
the O
hypoxemia B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
hemodynamic I-outcome ['Physiological-Clinical']
instability I-outcome ['Physiological-Clinical']
associated O
with O
routine O
intensive O
care O
procedures O
in O
neonates O
with O
respiratory O
distress O
. O
['Physiological-Clinical']

Continued O
remission O
may O
be O
more O
likely O
in O
patients O
who O
achieved O
remission O
earlier O
. O
[]

AE O
profile O
was O
similar O
for O
both O
products O
; O
the O
most O
commonly O
reported O
AEs O
were O
[]

RESULTS O
Of O
the O
105 O
patients O
alive O
in O
Norway O
and O
Sweden O
after O
4 O
to O
12 O
years O
of O
follow-up O
, O
78 O
( O
74 O
% O
) O
responded O
. O
[]

The O
initial O
subject O
pool O
was O
the O
24,178 O
members O
of O
a O
managed O
care O
company O
. O
[]

Of O
all O
PVs O
, O
81 O
% O
showed O
reconnection O
( O
s O
) O
; O
52 O
% O
of O
them O
had O
reconnected O
in O
all O
PVs O
. O
[]

These O
results O
are O
discussed O
in O
relation O
to O
the O
effects O
of O
frustration O
. O
[]

INTERVENTIONS O
Guideline O
implementation O
utilized O
an O
education/audit/feedback O
model O
with O
local O
peer O
opinion O
leaders O
. O
[]

MRIcro O
was O
used O
to O
quantify O
MRI-hyperintensity O
volume O
into O
total O
hyperintensity O
, O
deep O
white O
matter O
hyperintensity O
( O
DWMH O
) O
, O
and O
periventricular O
hyperintensity O
( O
PVH O
) O
volumes O
. O
[]

As O
in O
other O
indications O
, O
the O
growth B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
in O
these O
patients O
is O
more O
marked O
during O
the O
first O
year O
of O
treatment O
and O
then O
decreases O
. O
['Physiological-Clinical']

Anaerobic O
infection O
in O
cancer O
patients O
: O
comparative O
evaluation O
of O
clindamycin O
and O
cefoxitin O
. O
[]

The O
safety O
profile O
was O
acceptable O
with O
few O
grade O
3-4 O
toxicities O
observed O
in O
either O
arm O
. O
[]

This O
small O
study O
confirms O
that O
this O
combination O
of O
bupivacaine O
and O
clonidine O
provides O
satisfactory B-outcome ['Life-Impact']
analgesia I-outcome ['Life-Impact']
for O
first-stage O
labour O
, O
and O
of O
longer O
duration O
than O
bupivacaine-fentanyl O
. O
['Life-Impact']

RESULTS O
No O
significant O
differences O
were O
found O
between O
study O
arms O
at O
3 O
months O
in O
number O
of O
male B-outcome ['Life-Impact']
partners I-outcome ['Life-Impact']
, O
number O
of O
unprotected B-outcome ['Life-Impact']
anal B-outcome ['Life-Impact']
intercourse I-outcome ['Life-Impact']
partners I-outcome ['Life-Impact']
, O
proportion O
reporting O
unprotected B-outcome ['Life-Impact']
sex I-outcome ['Life-Impact']
, O
number O
of O
acts B-outcome ['Life-Impact']
protected O
by O
condoms B-outcome ['Life-Impact']
, O
self-efficacy B-outcome ['Life-Impact']
, O
condom B-outcome ['Life-Impact']
attitudes I-outcome ['Life-Impact']
, O
condom B-outcome ['Life-Impact']
intentions I-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
isolation I-outcome ['Life-Impact']
and O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
baseline O
temperature O
, O
final O
temperature O
, O
total O
time O
in O
the O
operating O
room O
, O
and O
amount O
of O
irrigation O
fluid O
used O
during O
the O
procedure O
were O
recorded O
for O
each O
patient O
. O
[]

RESULTS O
When O
compared O
with O
the O
control O
group O
and O
baseline O
data O
, O
in O
both O
laser O
groups O
, O
laser O
irradiation O
provided O
a O
desensitizing B-outcome ['Physiological-Clinical']
effect O
immediately O
after O
treatment O
and O
this O
effect O
was O
maintained O
throughout O
the O
study O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Patients O
were O
ineligible O
if O
they O
had O
uncontrolled O
hypertension O
, O
recent O
myocardial O
infarction O
, O
haematological O
disorders O
or O
a O
history O
of O
seizures O
. O
[]

Vascular B-outcome ['Physiological-Clinical']
pedicle I-outcome ['Physiological-Clinical']
width I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VPW I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
a O
non-invasive O
measurement O
of O
intravascular O
volume O
status O
. O
['Physiological-Clinical']

METHODS O
The O
study O
was O
conducted O
with O
21 O
children O
with O
Autism O
Spectrum O
Disorder O
diagnoses O
, O
randomly O
allocated O
into O
two O
groups O
, O
who O
received O
the O
same O
short-term O
intervention O
types O
( O
6 O
weeks O
with O
the O
mother O
and O
6 O
weeks O
with O
the O
support O
of O
an O
educational O
software O
program O
) O
. O
[]

METHODS O
This O
study O
is O
a O
randomized O
controlled O
trial O
. O
[]

Physicians O
were O
randomized O
to O
view O
either O
a O
seminar O
about O
type O
2 O
diabetes O
or O
a O
seminar O
about O
systolic O
heart O
failure O
. O
[]

Children O
( O
N=296 O
; O
M O
age=10.21 O
years O
) O
received O
information O
about O
an O
unfamiliar O
child O
with O
autism O
from O
one O
of O
the O
following O
sources O
: O
( O
a O
) O
videotape O
, O
( O
b O
) O
teacher O
, O
( O
c O
) O
hypothetical O
mother O
, O
( O
d O
) O
hypothetical O
father O
, O
or O
( O
e O
) O
hypothetical O
doctor O
. O
[]

Concentrations O
of O
CP O
in O
pasture O
, O
urea B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
and O
progesterone B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
milk I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
( O
P=0.76 O
) O
and O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
( O
P=0.29 O
) O
were O
comparable O
between O
the O
groups O
on O
study O
entry O
. O
['Physiological-Clinical', 'Life-Impact']

Intervention O
consisted O
of O
a O
treatment O
regime O
comprising O
of O
30 O
sessions O
of O
Seven-star O
Needle O
Stimulation O
, O
delivered O
over O
6 O
weeks O
. O
[]

There O
were O
no O
significant O
differences O
in O
vaginal B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
mood B-outcome ['Life-Impact']
alteration I-outcome ['Life-Impact']
, O
or O
low B-outcome ['Physiological-Clinical']
energy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

This O
study O
is O
registered O
with O
ClinicalTrials.gov O
, O
number O
NCT00349193 O
. O
[]

Radial O
artery O
occlusion O
( O
RAO O
) O
is O
an O
infrequent O
, O
asymptomatic O
, O
complication O
of O
transradial O
catheterization O
and O
probably O
1 O
of O
the O
few O
. O
[]

Of O
the O
nine O
TSCS O
scales O
, O
the O
improvement O
on O
the O
Moral-Ethical O
scale O
was O
significantly O
greater O
in O
the O
PALS O
group O
. O
[]

ITC O
consisted O
of O
six O
weekly O
injections O
of O
methotrexate O
, O
hydrocortisone O
, O
and O
arabinosylcytosine O
. O
[]

Parents O
also O
reported O
increases O
in O
their O
own O
confidence B-outcome ['Life-Impact']
and O
their O
child O
's O
ability B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
deal I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
anger I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Bisphosphonates O
are O
used O
in O
oncology O
as O
a O
means O
of O
decreasing O
complications O
due O
to O
bone O
metastases O
, O
in O
association O
with O
anticancer O
treatment O
, O
especially O
in O
patients O
with O
breast O
cancer O
, O
prostate O
cancer O
and O
myeloma O
. O
[]

Maximal O
plasma B-outcome ['Physiological-Clinical']
concentration O
and O
area O
under O
the O
plasma O
concentration-time O
curve O
increased O
and O
oral O
clearance O
decreased O
disproportionately O
with O
dose O
. O
['Physiological-Clinical']

METHODS O
40 O
patients O
received O
either O
topical O
treatment O
with O
Moist O
Exposed O
Burn O
Ointment O
( O
MEBO O
) O
or O
standard O
Flammazine O
treatment O
. O
[]

RESULTS O
A O
total O
of O
528 O
patients O
were O
randomised O
, O
267 O
of O
which O
were O
assigned O
to O
the O
PRE O
group O
and O
261 O
to O
the O
PERI O
group O
. O
[]

The O
quality O
of O
the O
motor O
process O
of O
an O
eye O
movement O
is O
known O
as O
saccade O
metrics O
. O
[]

MgSO4 O
solution O
and O
normal O
saline O
were O
coded O
and O
dispensed O
in O
identical O
containers O
. O
[]

A O
total O
of O
170 O
patients O
were O
included O
in O
the O
study O
. O
[]

Though O
this O
prolongation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
was O
not O
significant O
in O
the O
bestatin O
group O
compared O
to O
the O
control O
group O
in O
the O
15-49 O
yr O
age O
group O
, O
in O
the O
50-65 O
yr O
age O
group O
it O
was O
significantly O
longer O
. O
['Physiological-Clinical']

Didanosine O
( O
125 O
to O
200 O
mg O
given O
as O
buffered O
tablets O
) O
and O
delavirdine O
mesylate O
( O
400 O
mg O
) O
pharmacokinetics O
were O
evaluated O
when O
each O
drug O
was O
given O
alone O
( O
treatments O
A O
and O
B O
, O
respectively O
) O
, O
when O
the O
two O
drugs O
were O
given O
concurrently O
( O
treatment O
C O
) O
, O
and O
when O
didanosine O
was O
given O
1 O
h O
after O
delavirdine O
( O
treatment O
D O
) O
. O
[]

Diagnosis O
was O
confirmed O
by O
ADI-R O
( O
Autism O
Diagnostic O
Interview-Revised O
) O
algorithm O
. O
[]

Induction O
was O
with O
8 O
% O
sevoflurane O
, O
60 O
% O
nitrous O
oxide O
( O
N2O O
) O
, O
40 O
% O
oxygen O
at O
a O
flow O
rate O
of O
8 O
L O
x O
min O
( O
-1 O
) O
through O
a O
Mapleson O
C O
circuit O
. O
[]

DESIGN O
In O
this O
preliminary O
, O
open-labeled O
, O
randomized O
study O
, O
the O
effects O
of O
lime O
juice O
on O
the O
clinical O
and O
some O
laboratory O
characteristics O
of O
children O
with O
SCA O
were O
tested O
. O
[]

Complications B-outcome ['Adverse-effects']
occurred O
in O
25 O
% O
of O
PEG O
patients O
and O
12 O
% O
died B-outcome ['Mortality']
. O
['Adverse-effects', 'Mortality']

Zolmitriptan O
( O
311C90 O
) O
does O
not O
interact O
with O
fluoxetine O
in O
healthy O
volunteers O
. O
[]

PAF O
is O
a O
phospholipid O
mediator O
, O
which O
is O
present O
in O
human O
sperm O
. O
[]

The O
degrees O
of O
UVB-induced O
erythema O
and O
pigmentation O
correlate O
linearly O
and O
are O
reduced O
in O
a O
parallel O
manner O
by O
topical O
anti-inflammatory O
agents O
. O
[]

Univariate O
analysis O
of O
variance O
indicated O
significant O
findings O
for O
each O
of O
the O
three O
dimensions O
of O
the O
inventory O
. O
[]

The O
potential O
advantages O
over O
other O
vaginal O
products O
include O
keeping O
a O
low O
pH O
, O
decrease O
of O
the O
irritating O
effect O
of O
N-9 O
on O
the O
cervix O
or O
vaginal O
mucosa O
associated O
with O
greater O
retention O
of O
the O
product O
after O
application O
, O
and O
decreasing O
messiness O
as O
compared O
to O
other O
vaginal O
products O
. O
[]

[ O
Effectiveness O
of O
morphine O
by O
periarticular O
injections O
after O
shoulder O
arthroscopy O
] O
. O
[]

Troublesome O
spiral O
fractures O
of O
the O
distal O
radius O
are O
the O
most O
common O
fractures O
associated O
with O
the O
use O
of O
the O
distal O
radius O
as O
a O
vascularized O
bone-graft O
donor O
site O
. O
[]

Metronidazole O
in O
periodontitis O
( O
IV O
) O
. O
[]

HDL B-outcome ['Physiological-Clinical']
cholesterols I-outcome ['Physiological-Clinical']
were O
lower O
in O
both O
female O
and O
male O
tobacco O
users O
. O
['Physiological-Clinical']

Baseline O
data O
and O
clinical O
events O
were O
retrieved O
. O
[]

CONCLUSIONS O
Ribavirin O
exposure O
to O
week O
12 O
is O
significantly O
associated O
with O
EVR O
and O
SVR O
in O
genotype O
1 O
patients O
. O
[]

Calcium O
absorption O
in O
this O
range O
is O
not O
a O
useful O
biomarker O
to O
determine O
nutritional O
recommendations O
for O
vitamin O
D O
. O
[]

RESULTS O
The O
urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ferulic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
averaged O
approximately O
4.8 O
mg O
per O
day O
during O
intervention O
with O
rye O
bran O
breads O
and O
approximately O
1.9 O
mg O
per O
day O
on O
the O
control O
breads O
( O
P O
= O
0.002 O
) O
. O
['Physiological-Clinical']

The O
decrease O
in O
serum B-outcome ['Physiological-Clinical']
Na I-outcome ['Physiological-Clinical']
level O
was O
found O
to O
be O
significantly O
higher O
in O
the O
TURP O
group O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Whereas O
standard O
laboratory O
tests O
of O
coagulation O
were O
comparable O
between O
groups O
, O
von B-outcome ['Physiological-Clinical']
Willebrand I-outcome ['Physiological-Clinical']
factor O
activity B-outcome ['Life-Impact']
on O
the O
first O
postoperative O
morning O
tended O
to O
be O
higher O
following O
treatment O
with O
10 O
% O
HES O
130/0.4 O
as O
compared O
to O
10 O
% O
HES O
200/0.5 O
( O
P=0.025 O
) O
with O
this O
difference O
being O
statistically O
significant O
only O
in O
the O
per-protocol O
analysis O
( O
P=0.02 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Microbiologic B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
rates O
at O
follow-up O
were O
87.2 O
% O
for O
retapamulin O
and O
91.8 O
% O
for O
cephalexin O
. O
['Physiological-Clinical']

This O
study O
was O
aimed O
to O
investigate O
the O
effects O
of O
water O
extracts O
of O
Graptopetalum O
paraguayense O
( O
WGP O
, O
4 O
g/d O
) O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
level O
, O
and O
lipid B-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
in O
subjects O
with O
metabolic O
syndrome O
( O
MS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
nefazodone B-outcome ['Resource-use']
dose O
was O
491 O
mg/day O
at O
the O
end O
of O
week O
2 O
and O
503 O
mg/day O
at O
the O
end O
of O
treatment O
. O
['Resource-use']

Expectant O
management O
of O
functional O
ovarian O
cysts O
: O
an O
alternative O
to O
hormonal O
therapy O
. O
[]

Data O
were O
available O
for O
efficacy O
analysis O
on O
80 O
patients O
( O
M O
group O
; O
43 O
, O
E O
group O
; O
37 O
) O
. O
[]

We O
examined O
the O
prophylactic O
effect O
of O
granisetron O
on O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
in O
120 O
female O
patients O
( O
ASA O
physical O
status O
I O
) O
undergoing O
gynecologic O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Based O
on O
current O
literature O
and O
expert O
experience O
, O
guidelines O
were O
formulated O
for O
this O
phase O
III O
study O
of O
stereotactic O
radiotherapy O
versus O
[]

Using O
a O
large O
contemporary O
randomized O
trial O
database O
of O
patients O
with O
ST-segment-elevation O
myocardial O
infarction O
, O
we O
therefore O
sought O
to O
examine O
whether O
admission O
B-type O
natriuretic O
peptide O
( O
BNP O
) O
levels O
predict O
the O
development O
of O
CI-AKI O
. O
[]

No O
differences O
in O
pain B-outcome ['Physiological-Clinical']
scores O
were O
found O
between O
the O
three O
groups O
at O
the O
next O
morning O
phone O
call O
. O
['Physiological-Clinical']

LIMITATIONS O
The O
unblinded O
nature O
of O
the O
study O
, O
exclusion O
of O
patients O
with O
diabetes O
, O
and O
incomplete O
enrollment O
. O
[]

RESULTS O
The O
scopolamine-treated O
patients O
suffered O
more O
from O
moderate B-outcome ['Physiological-Clinical']
peroperative I-outcome ['Physiological-Clinical']
bradycardia I-outcome ['Physiological-Clinical']
( O
8/25 O
; O
P O
< O
.05 O
) O
than O
the O
atropine-treated O
patients O
( O
1/25 O
) O
. O
['Physiological-Clinical']

Supplementation O
with O
both O
doses O
of O
fish O
oil O
, O
in O
comparison O
with O
placebo O
, O
resulted O
in O
significantly O
increased O
concentrations O
of O
oxyhemoglobin O
and O
total O
levels O
of O
hemoglobin O
, O
indicative O
of O
increased O
cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
during O
the O
cognitive O
tasks O
. O
['Physiological-Clinical']

CONCLUSIONS O
Although O
SILS O
is O
feasible O
, O
as O
shown O
in O
clinical O
series O
published O
by O
laparoscopically O
experienced O
experts O
, O
SILS O
techniques O
are O
demanding O
due O
to O
restrictions O
that O
come O
with O
the O
loss O
of O
triangulation O
. O
[]

RESULTS O
Proteinuria B-outcome ['Physiological-Clinical']
was O
positively O
correlated O
with O
circulating B-outcome ['Physiological-Clinical']
AGE O
and O
sRAGE O
levels O
in O
our O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Myelosuppressive O
chemotherapy O
impairs O
erythropoiesis O
, O
which O
may O
not O
fully O
recover O
between O
treatment O
cycles O
. O
[]

A O
double-blind O
clinical O
trial O
with O
zinc O
sulfate O
, O
0.2 O
g O
three O
times O
daily O
, O
and O
a O
placebo O
was O
performed O
in O
30 O
patients O
with O
biopsy-proven O
alcoholic O
liver O
cirrhosis O
. O
[]

METHODS O
Thirty O
premolars O
were O
divided O
into O
three O
groups O
: O
I O
- O
high-speed O
handpiece O
+ O
37 O
% O
phosphoric O
acid O
; O
II O
- O
Er O
: O
YAG O
laser O
( O
350 O
mJ O
, O
4 O
Hz O
and O
112 O
J/cm O
( O
2 O
) O
) O
+ O
37 O
% O
phosphoric O
acid O
; O
and O
III O
- O
Er O
: O
YAG O
laser O
( O
350 O
mJ O
, O
4 O
Hz O
and O
112 O
J/cm O
( O
2 O
) O
) O
+ O
Er O
: O
YAG O
laser O
( O
80 O
mJ O
, O
4 O
Hz O
, O
and O
25 O
mJ/cm O
( O
2 O
) O
) O
. O
[]

As O
part O
of O
an O
RCT O
, O
opinions O
of O
ulcerative O
colitis O
patients O
and O
their O
doctors O
were O
sought O
on O
a O
guidebook O
designed O
to O
support O
self-care O
and O
mediate O
doctor/patient O
interaction O
during O
consultations O
. O
[]

We O
believe O
that O
the O
interactivity O
, O
dialogic O
feedback O
and O
integration O
with O
the O
curriculum O
offered O
by O
the O
e-learning O
module O
contributed O
to O
its O
impact O
. O
[]

These O
properties O
suggest O
possible O
analgesic B-outcome ['Resource-use']
effects O
. O
['Resource-use']

The O
Stroke O
Team O
Remote O
Evaluation O
Using O
a O
Digital O
Observation O
Camera O
( O
STRokE O
DOC O
) O
trial O
reported O
more O
accurate O
decision O
making O
for O
telemedicine O
consultations O
compared O
with O
telephone-only O
and O
that O
the O
California-based O
research O
network O
facilitated O
a O
high O
rate O
of O
thrombolysis O
use O
, O
improved O
data O
collection O
, O
low O
risk O
of O
complications O
, O
low O
technical O
complications O
, O
and O
favorable O
assessment O
times O
. O
[]

The O
primary O
end O
point O
was O
to O
evaluate O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality']

RESULTS O
At O
mean O
follow O
up O
of O
5.5 O
years O
, O
protocol O
angiography O
has O
been O
performed O
in O
groups O
1 O
and O
2 O
in O
237 O
and O
113 O
patients O
, O
respectively O
. O
[]

In O
every O
group O
, O
the O
core O
material O
was O
processed O
by O
hot-press O
and O
non O
hot-press O
respectively O
. O
[]

On O
patient B-outcome ['Life-Impact']
comfort I-outcome ['Life-Impact']
, O
closure O
devices O
performed O
better O
than O
MC O
. O
['Life-Impact']

The O
length O
of O
HBV B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
before O
its O
diagnosis O
, O
delay O
before O
initiation O
of O
treatment O
and O
previous O
immunosuppressive O
therapy O
led O
to O
a O
poor O
seroconversion B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
glucocorticoids O
on O
energy B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
and O
food B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
in O
humans O
. O
['Physiological-Clinical', 'Life-Impact']

Twenty-eight-day O
mortality B-outcome ['Mortality']
and O
1-year O
mortality B-outcome ['Mortality']
rate O
as O
well O
as O
quality-of-life B-outcome ['Life-Impact']
scores O
were O
similar O
in O
both O
groups O
. O
['Mortality', 'Mortality', 'Life-Impact']

Significant O
improvements O
were O
observed O
in O
Qmax B-outcome ['Physiological-Clinical']
for O
both O
tamsulosin O
groups O
but O
not O
for O
the O
placebo O
group O
. O
['Physiological-Clinical']

A O
secondary O
objective O
was O
to O
document O
the O
frequency O
of O
metaphase B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
oocytes I-outcome ['Physiological-Clinical']
after O
IVM O
with O
FF-MAS O
supplements O
. O
['Physiological-Clinical']

During O
eight O
weeks O
of O
treatment O
, O
the O
patients O
of O
the O
two O
groups O
received O
12 O
sessions O
of O
laser O
or O
placebo O
, O
two O
sessions O
per O
week O
( O
weeks O
1-4 O
) O
and O
one O
session O
per O
week O
( O
weeks O
5-8 O
) O
. O
[]

Furthermore O
, O
pathoanatomic O
studies O
and O
coronary O
angiography O
have O
confirmed O
a O
relationship O
between O
coronary B-outcome ['Physiological-Clinical']
thrombus I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
and O
acute B-outcome ['Physiological-Clinical']
Q-wave I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
emerging O
concept O
of O
opioid O
peptides O
as O
a O
new O
class O
of O
chemical O
messengers O
of O
the O
neuroimmune O
axis O
and O
the O
presence O
of O
a O
number O
of O
immunological O
abnormalities O
in O
infantile O
autism O
prompted O
us O
to O
correlate O
biological O
( O
hormonal O
and O
immunological O
) O
determinations O
and O
behavioural O
performances O
during O
treatment O
with O
the O
potent O
opiate O
antagonist O
, O
naltrexone O
( O
NAL O
) O
. O
[]

Important O
correlates O
of O
pump O
activity O
were O
height O
, O
plasma O
glucose O
, O
and O
physical O
fitness O
. O
[]

Furthermore O
, O
the O
plasma O
and O
follicular O
fluid O
concentrations O
of O
arginine O
, O
citrulline O
, O
nitrite/nitrate O
( O
NO2-/NO3- O
) O
, O
and O
insulin-like O
growth O
factor-1 O
( O
IGF-1 O
) O
were O
assayed O
. O
[]

Red-cell O
( O
p O
= O
0.76 O
) O
, O
fresh O
frozen O
plasma O
( O
r O
= O
0.66 O
) O
and O
platelet O
unit O
( O
p O
= O
0.74 O
) O
requirements O
were O
also O
similar O
. O
[]

INTERVENTION O
Participants O
were O
assigned O
randomly O
to O
receive O
a O
9-week O
course O
of O
bupropion O
SR O
or O
placebo O
pill O
and O
to O
receive O
eight O
brief O
individual O
counseling O
sessions O
or O
no O
counseling O
. O
[]

METHODS O
A O
naturalistic O
, O
observational O
, O
multi-center O
, O
prospective O
study O
of O
12 O
months O
' O
follow-up O
was O
performed O
. O
[]

BACKGROUND O
This O
prospective O
, O
randomized O
, O
controlled O
study O
was O
designed O
to O
investigate O
the O
effects O
of O
a O
diabetes O
specific O
formula O
( O
Diason O
low O
energy O
: O
313.8 O
kJ/100 O
ml O
) O
, O
compared O
with O
a O
standard O
formula O
, O
on O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
and O
free B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FFA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
type O
2 O
diabetics O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Caliceal O
models O
of O
stone O
basketing O
may O
be O
useful O
to O
train O
novice O
urology O
residents O
and O
nursing O
assistants O
. O
[]

[ O
The O
effects O
of O
early O
enteral O
nutrition O
with O
addition O
of O
probiotics O
on O
the O
prognosis O
of O
patients O
suffering O
from O
severe O
acute O
pancreatitis O
] O
. O
[]

However O
, O
mortality B-outcome ['Mortality']
rates O
of O
3 O
% O
are O
low O
, O
and O
half O
of O
the O
patients O
will O
die O
from O
intercurrent O
disease O
. O
['Mortality']

The O
objective O
of O
this O
study O
was O
to O
determine O
whether O
significant O
drug B-outcome ['Physiological-Clinical']
interactions I-outcome ['Physiological-Clinical']
occur O
with O
concomitant O
administration O
of O
donepezil O
and O
risperidone O
. O
['Physiological-Clinical']

Since O
retinal O
detachment O
occurs O
in O
2.5 O
% O
after O
YAG-laser O
capsulotomy O
we O
can O
not O
regard O
capsular O
fibrosis O
as O
a O
totally O
harmless O
complication O
. O
[]

In O
the O
BCG-treated O
group O
( O
N O
= O
148 O
) O
, O
44 O
( O
29.8 O
% O
) O
had O
recurrent B-outcome ['Physiological-Clinical']
tumors I-outcome ['Physiological-Clinical']
, O
while O
in O
the O
MMC-treated O
group O
( O
N O
= O
160 O
) O
, O
40 O
( O
25.0 O
% O
) O
had O
a O
recurrence O
. O
['Physiological-Clinical']

Topical O
therapy O
with O
beta-antagonists O
, O
such O
as O
timolol O
, O
may O
cause O
unrecognized O
impairment O
of O
respiratory O
and O
cardiovascular O
function O
in O
elderly O
people O
. O
[]

Patients O
began O
at O
the O
lowest O
dose O
and O
were O
titrated O
to O
higher O
doses O
based O
on O
the O
first O
two O
assessments O
of O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
which O
were O
conducted O
each O
week O
after O
double-blind O
treatment O
was O
dispensed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
the O
prostacyclin O
analogue O
iloprost O
was O
studied O
during O
a O
2 O
week O
treatment O
and O
6 O
month O
follow-up O
period O
in O
103 O
patients O
with O
ischaemic O
ulcers O
who O
were O
randomised O
to O
receive O
active O
treatment O
or O
placebo O
. O
['Physiological-Clinical']

METHODS O
TCM B-outcome ['Physiological-Clinical']
typing I-outcome ['Physiological-Clinical']
and O
sCD44v6 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
were O
determined O
in O
all O
the O
enrolled O
patients O
( O
30 O
in O
the O
control O
and O
32 O
in O
the O
trial O
group O
) O
before O
operation O
, O
and O
3-4 O
courses O
of O
chemotherapy O
was O
applied O
to O
them O
from O
3-4 O
weeks O
after O
operation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
examine O
the O
effects O
of O
wheelchair O
skills O
training O
on O
confidence B-outcome ['Life-Impact']
in O
older O
adults O
who O
are O
inexperienced O
wheelchair O
users O
. O
['Life-Impact']

Propofol O
sedation O
with O
bispectral O
index O
monitoring O
is O
useful O
for O
endoscopic O
submucosal O
dissection O
: O
a O
randomized O
prospective O
phase O
II O
clinical O
trial O
. O
[]

BACKGROUND O
Talc O
has O
been O
generally O
accepted O
to O
be O
the O
most O
effective O
sclerosant O
for O
chemical O
pleurodesis O
, O
although O
the O
optimal O
route O
of O
administration O
remains O
unclear O
. O
[]

There O
also O
was O
no O
difference O
in O
INR O
variation O
based O
on O
warfarin O
formulation O
( O
p O
> O
0.69 O
) O
, O
nor O
was O
a O
patient O
and O
warfarin O
interaction O
found O
( O
p O
> O
0.81 O
) O
. O
[]

Although O
on O
two-dimensional O
echo O
21 O
patients O
( O
42.9 O
% O
) O
were O
found O
to O
have O
valvar B-outcome ['Physiological-Clinical']
thickening I-outcome ['Physiological-Clinical']
, O
19 O
( O
38.8 O
% O
) O
pericardial B-outcome ['Physiological-Clinical']
thickening I-outcome ['Physiological-Clinical']
and O
9 O
( O
18.4 O
% O
) O
a O
reduced O
fibre O
shortening O
fraction O
, O
the O
Doppler B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
were O
statistically O
not O
significantly O
different O
from O
those O
in O
25 O
controls O
with O
normal O
hearts O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

'typewriter O
' O
) O
following O
a O
related O
prime O
that O
shared O
manipulation O
features O
with O
the O
target O
( O
e.g O
. O
[]

Comparing O
microvascular B-outcome ['Physiological-Clinical']
alterations I-outcome ['Physiological-Clinical']
during O
minimal O
extracorporeal O
circulation O
and O
conventional O
cardiopulmonary O
bypass O
in O
coronary O
artery O
bypass O
graft O
surgery O
: O
a O
prospective O
, O
randomized O
study O
. O
['Physiological-Clinical']

Group-based O
HIV O
risk O
reduction O
intervention O
for O
adolescent O
girls O
: O
evidence O
of O
feasibility O
and O
efficacy O
. O
[]

INTERVENTIONS O
IP O
was O
induced O
by O
occluding O
the O
LAD O
twice O
for O
a O
2-min O
period O
followed O
by O
3-min O
LAD O
reperfusion O
before O
bypass O
grafting O
of O
the O
first O
coronary O
vessel O
. O
[]

Because O
of O
its O
high O
spontaneous O
regression O
rate O
, O
follow-up O
could O
be O
considered O
as O
a O
management O
option O
of O
CIN2 O
in O
young O
and O
compliant O
women O
. O
[]

In O
the O
acupuncture O
group O
, O
the O
conventional O
acupuncture O
therapy O
was O
applied O
to O
Baihui O
( O
GV O
20 O
) O
, O
Sishencong O
( O
EX-HN O
1 O
) O
, O
Fengchi O
( O
GB O
20 O
) O
, O
Taiyang O
( O
EX-HN O
5 O
) O
, O
Touwei O
( O
ST O
18 O
) O
, O
Hegu O
( O
LI O
4 O
) O
, O
etc O
. O
[]

[ O
Accelerated O
postoperative O
radiotherapy O
in O
patients O
with O
advanced O
larynx O
cancer O
] O
. O
[]

Estimates O
of O
respiratory O
and O
heart O
rate O
power O
spectra O
and O
linear O
transfer O
functions O
between O
the O
two O
groups O
were O
generated O
by O
Fourier O
analysis O
. O
[]

The O
study O
itself O
demonstrates O
that O
it O
is O
possible O
to O
do O
strictly O
controlled O
trials O
for O
homeopathic O
drugs O
and O
with O
medical O
practitioners O
. O
[]

Preservation O
times O
beyond O
3 O
hours O
, O
however O
, O
have O
been O
associated O
with O
decreased O
survival B-outcome ['Mortality']
. O
['Mortality']

METHODS O
This O
study O
was O
a O
double O
blind O
, O
randomized O
study O
. O
[]

We O
retrospectively O
assessed O
the O
effect O
of O
Ca/Mg O
infusions O
on O
the O
incidence O
of O
neurotoxicity B-outcome ['Physiological-Clinical']
and O
on O
clinical B-outcome ['Physiological-Clinical']
outcome O
in O
advanced O
colorectal O
cancer O
( O
ACC O
) O
patients O
treated O
in O
the O
phase O
III O
CAIRO2 O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
One O
type O
of O
test O
commonly O
used O
to O
examine O
auditory O
processing O
disorders O
( O
APD O
) O
is O
the O
low-pass O
filtered O
speech O
test O
( O
LPFST O
) O
, O
of O
which O
there O
are O
various O
versions O
. O
[]

Accordingly O
, O
development O
of O
new O
treatments O
for O
steroid-dependent O
Crohn O
's O
disease O
is O
a O
research O
priority O
. O
[]

Two O
studies O
were O
conducted O
to O
determine O
the O
effects O
of O
diet O
and O
feed O
additive O
on O
growth O
and O
carcass O
characteristics O
of O
lambs O
and O
cattle O
destined O
for O
all O
natural O
markets O
. O
[]

The O
PRE O
group O
received O
two O
preoperative O
cycles O
followed O
by O
two O
additional O
preoperative O
cycles O
, O
while O
the O
PERI O
group O
underwent O
two O
preoperative O
cycles O
followed O
by O
two O
postoperative O
cycles O
, O
the O
3rd O
and O
4th O
cycles O
being O
given O
only O
to O
responders O
in O
both O
cases O
. O
[]

RESULTS O
Aliskiren O
and O
perindopril O
reduced O
proteinuria B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Statistically O
significant O
differences O
between O
groups O
indicated O
that O
the O
sensory O
integration O
therapy O
program O
positively O
affected O
treated O
children O
. O
[]

Compliments B-outcome ['Life-Impact']
given I-outcome ['Life-Impact']
and O
partnership B-outcome ['Life-Impact']
were O
more O
common O
on O
the O
videophone O
. O
['Life-Impact', 'Life-Impact']

3.6 O
) O
, O
( O
45.0 O
? O
[]

Compared O
with O
placebo O
, O
EPO O
at O
day O
3 O
after O
CPB O
augmented O
the O
TNF-alpha B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
and O
at O
2 O
hours O
after O
CPB O
increased O
NT-proBNP O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
main O
problem O
of O
this O
study O
was O
the O
difficulty O
in O
recruiting O
an O
adequate O
number O
of O
patients O
and O
following O
them O
for O
a O
sufficient O
period O
of O
time O
: O
general O
conditions O
rapidly O
deteriorated O
in O
many O
patients O
, O
and O
approximately O
25 O
% O
of O
the O
66 O
enrolled O
were O
not O
considered O
evaluable O
; O
few O
patients O
survived O
for O
the O
length O
of O
the O
study O
, O
one O
year O
. O
[]

Pediatric O
AIDS O
Clinical O
Trials O
Group O
Protocol O
185 O
Pharmacokinetic O
Study O
Group O
. O
[]

Tryptophan O
depletion O
led O
to O
a O
significant O
increase O
in O
behaviors O
such O
as O
whirling B-outcome ['Physiological-Clinical']
, O
flapping B-outcome ['Life-Impact']
, O
pacing B-outcome ['Life-Impact']
, O
banging B-outcome ['Life-Impact']
and O
hitting B-outcome ['Life-Impact']
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Asymmetric O
dosage O
regimes O
have O
been O
introduced O
to O
circumvent O
development O
of O
nitrate O
tolerance O
. O
[]

RESULTS O
Topical O
capsaicin O
caused O
> O
50 O
% O
reduction O
of O
arterial B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
in O
absence O
of O
attack O
in O
17/23 O
patients O
, O
as O
opposed O
to O
two O
with O
vaseline O
. O
['Physiological-Clinical']

Sixteen O
strength-trained O
men O
were O
tested O
for O
1RM O
leg B-outcome ['Physiological-Clinical']
press I-outcome ['Physiological-Clinical']
after O
4 O
GWU O
conditions O
after O
specific O
warm-up O
: O
short O
duration O
and O
low O
intensity O
( O
SDLI O
; O
i.e. O
, O
5 O
minutes O
at O
40 O
% O
V O
[ O
Combining O
Dot O
Above O
] O
O2max O
) O
, O
long O
duration O
and O
low O
intensity O
( O
LDLI O
; O
i.e. O
, O
15 O
minutes O
at O
40 O
% O
V O
[ O
Combining O
Dot O
Above O
] O
O2max O
) O
, O
short O
duration O
and O
moderate O
intensity O
( O
SDMI O
; O
i.e. O
, O
5 O
minutes O
at O
70 O
% O
V O
[ O
Combining O
Dot O
Above O
] O
O2max O
) O
, O
long O
duration O
and O
moderate O
intensity O
( O
LDMI O
; O
i.e. O
, O
15 O
minutes O
at O
70 O
% O
V O
[ O
Combining O
Dot O
Above O
] O
O2max O
) O
, O
and O
the O
control O
( O
CTRL O
) O
no-GWU O
condition O
. O
['Physiological-Clinical']

5.0 O
) O
, O
( O
50.2 O
? O
[]

Thirty-three O
eligible O
women O
were O
randomized O
to O
double-blind O
treatment O
and O
administered O
3.75 O
mg O
of O
depot O
leuprolide O
or O
a O
placebo O
once O
a O
month O
for O
3 O
months O
. O
[]

However O
, O
the O
clinical O
effects O
of O
such O
plastic O
curettes O
with O
regard O
to O
the O
control O
of O
the O
periodontal O
infection O
has O
not O
yet O
been O
established O
. O
[]

Twenty O
ASA O
physical O
status O
I O
patients O
undergoing O
gynecological O
laparoscopy O
were O
randomized O
to O
receive O
either O
SSA O
with O
lidocaine O
10 O
mg O
+ O
sufentanil O
10 O
microg O
or O
general O
anesthesia O
with O
DES O
and O
N O
( O
2 O
) O
O. O
Intraoperative O
conditions O
, O
recovery O
times O
, O
postanesthesia O
recovery O
scores O
, O
and O
postoperative O
outcomes O
were O
recorded O
. O
[]

0.44 O
kg O
, O
P O
= O
0.003 O
) O
and O
overweight/obese O
( O
61 O
% O
, O
2.22 O
? O
[]

METHODS O
The O
European O
Myocardial O
Infarct O
Amiodarone O
Trial O
( O
EMIAT O
) O
was O
a O
randomised O
double-blind O
placebo-controlled O
trial O
to O
assess O
whether O
amiodarone O
reduced O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
( O
primary O
endpoint O
) O
and O
cardiac B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
arrhythmic B-outcome ['Mortality']
death I-outcome ['Mortality']
( O
secondary O
endpoints O
) O
in O
survivors O
of O
myocardial O
infarction O
with O
a O
left-ventricular O
ejection O
fraction O
( O
LVEF O
) O
of O
40 O
% O
or O
less O
. O
['Mortality', 'Mortality', 'Mortality']

Interferon O
recipients O
had O
significantly O
higher O
frequencies O
of O
blood O
in O
nasal B-outcome ['Physiological-Clinical']
mucus I-outcome ['Physiological-Clinical']
( O
16 O
to O
18 O
% O
) O
than O
did O
placebo O
recipients O
( O
4 O
% O
) O
during O
treatment O
. O
['Physiological-Clinical']

Major B-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
noted O
in O
10 O
% O
of O
the O
SES O
group O
versus O
34 O
% O
in O
the O
BMS O
group O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

RESULTS O
Serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
increased O
in O
all O
three O
groups O
( O
mean O
change O
within O
a O
group O
: O
11 O
micromol/l O
in O
group O
1 O
, O
P= O
0.045 O
; O
9 O
micromol/l O
in O
group O
2 O
, O
P= O
0.030 O
; O
15 O
micromol/l O
in O
group O
3 O
, O
P= O
0.0006 O
) O
. O
['Physiological-Clinical']

The O
subjects O
were O
randomly O
assigned O
to O
one O
of O
three O
groups O
: O
endurance O
training O
group O
( O
n=8 O
) O
, O
resistance O
training O
group O
( O
n=8 O
) O
and O
control O
group O
( O
n=8 O
) O
. O
[]

The O
primary O
outcome O
was O
the O
cumulative O
number O
of O
GdE B-outcome ['Physiological-Clinical']
lesions B-outcome ['Physiological-Clinical']
at O
weeks O
24 O
, O
28 O
, O
32 O
, O
and O
36 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
younger O
patients O
, O
warfarin O
decreased O
the O
absolute O
rate O
of O
primary O
events O
by O
0.7 O
% O
per O
year O
( O
95 O
% O
CI-0.4 O
to O
1.7 O
) O
. O
[]

There O
were O
36 O
patients O
in O
the O
control O
group O
, O
including O
14 O
males O
and O
22 O
females O
, O
ranging O
in O
age O
from O
40 O
to O
62 O
years O
, O
with O
an O
average O
of O
( O
54.34 O
+/- O
7.67 O
) O
years O
; O
the O
disease B-outcome ['Physiological-Clinical']
course I-outcome ['Physiological-Clinical']
ranged O
from O
6 O
to O
25 O
months O
, O
with O
an O
average O
of O
( O
11.94 O
+/- O
5.13 O
) O
months O
. O
['Physiological-Clinical']

This O
is O
another O
factor O
to O
be O
considered O
in O
assessing O
the O
risk O
of O
certain O
foods O
to O
food-allergic O
consumers O
and O
adds O
another O
dimension O
to O
clinical O
, O
research O
and O
regulatory O
practice O
. O
[]

A O
training O
study O
of O
theory O
of O
mind O
and O
executive O
function O
in O
children O
with O
autistic O
spectrum O
disorders O
. O
[]

OBJECTIVES O
Periprostatic O
nerve O
block O
( O
PPNB O
) O
is O
the O
standard O
anesthesia O
for O
ultrasound O
( O
US O
) O
guided O
transrectal O
prostate O
biopsy O
( O
TPB O
) O
, O
but O
periprostatic O
infiltration O
itself O
constitutes O
a O
major O
, O
though O
often O
neglected O
, O
source O
of O
discomfort O
even O
in O
patients O
receiving O
perianal-intrarectal O
lidocaine-prilocaine O
( O
PILP O
) O
cream O
before O
PPNB O
. O
[]

Dark O
adaptation O
was O
assessed O
by O
PT O
score O
. O
[]

After O
8 O
weeks O
of O
risperidone O
, O
prolactin B-outcome ['Physiological-Clinical']
increased O
to O
39.0 O
+/- O
19.2 O
ng/ml O
, O
compared O
with O
10.1 O
+/- O
8.8 O
ng/ml O
for O
placebo O
( O
p O
< O
.0001 O
) O
. O
['Physiological-Clinical']

However O
, O
the O
determination O
of O
endogenous B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Clcr I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
from O
a O
24-h O
urine O
collection O
is O
an O
unreliable O
and O
time-consuming O
procedure O
. O
['Physiological-Clinical']

We O
performed O
a O
randomized O
study O
comparing O
pneumatic O
compression O
versus O
no O
treatment O
in O
patients O
with O
postmastectomy O
lymphedema O
. O
[]

Pre-operative O
and O
post-operative O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate O
, O
inspiratory B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
, O
post-operative B-outcome ['Life-Impact']
ventilation I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
post-operative B-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
complication B-outcome ['Adverse-effects']
and O
hospital B-outcome ['Resource-use']
stay B-outcome ['Resource-use']
were O
determined O
in O
both O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Adverse-effects', 'Resource-use', 'Resource-use']

HMTW O
facilitated O
communication O
in O
children O
with O
lower O
levels O
of O
Time O
1 O
object O
interest O
. O
[]

Elevated O
concentration O
of O
placental O
growth O
factor O
( O
PlGF O
) O
and O
long O
term O
risk O
in O
patients O
with O
acute O
coronary O
syndrome O
in O
the O
PROVE O
IT-TIMI O
22 O
trial O
. O
[]

Dose O
response O
was O
primarily O
linear O
in O
the O
dose O
range O
studied O
. O
[]

Patients O
with O
compared O
to O
those O
without O
transient O
or O
final O
side O
branch O
occlusion O
had O
significantly O
higher O
non-Q-wave B-outcome ['Physiological-Clinical']
MI I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NQMI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
in-hospital O
( O
9.0 O
% O
vs. O
0.5 O
% O
, O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
test O
the O
effect O
of O
a O
nonabsorbable O
, O
broad-spectrum O
antibiotic O
on O
endotoxemia B-outcome ['Physiological-Clinical']
in O
patients O
with O
alcoholic O
liver O
disease O
. O
['Physiological-Clinical']

METHODS O
All O
primary O
care O
referrals O
of O
frozen O
shoulder O
to O
our O
physiotherapy O
department O
were O
included O
during O
a O
12-month O
period O
. O
[]

Our O
study O
aims O
to O
evaluate O
the O
effects O
of O
daily O
consumption O
of O
EVOO O
in O
the O
healthy O
institutionalized O
elderly O
. O
[]

Both O
groups O
were O
treated O
with O
insulin O
infusion O
to O
maintain O
normoglycemia O
after O
leaving O
NICU O
. O
[]

All O
patients O
were O
randomly O
assigned O
to O
receive O
2 O
years O
of O
goserelin O
, O
goserelin O
plus O
tamoxifen O
, O
tamoxifen O
alone O
or O
no O
endocrine O
treatment O
. O
[]

METHODS O
Electroneurographic B-outcome ['Physiological-Clinical']
assessments O
with O
surface O
electrodes O
were O
performed O
after O
single O
injections O
of O
NT O
201 O
( O
2 O
, O
4 O
, O
16 O
, O
or O
32 O
units O
) O
into O
the O
extensor O
digitorum O
brevis O
( O
EDB O
) O
muscle O
and O
the O
same O
dose O
( O
Botox O
; O
Allergan O
Pharmaceuticals O
( O
Ireland O
) O
Ltd. O
Westport O
, O
Ireland O
) O
into O
the O
contralateral O
EDB O
. O
['Physiological-Clinical']

BACKGROUND O
Ankle O
injuries O
account O
for O
30 O
to O
60 O
% O
of O
all O
parachuting O
injuries O
. O
[]

One O
year O
after O
completed O
CMF- O
and O
endocrine O
therapy O
, O
36 O
% O
of O
the O
women O
in O
the O
goserelin O
group O
reported O
menses B-outcome ['Physiological-Clinical']
, O
compared O
to O
7 O
% O
in O
the O
goserelin O
plus O
tamoxifen O
group O
, O
13 O
% O
in O
the O
tamoxifen O
group O
and O
10 O
% O
of O
the O
controls O
. O
['Physiological-Clinical']

2 O
. O
[]

Seventy O
patients O
with O
cancer O
were O
randomly O
assigned O
to O
receive O
losartan O
or O
amlodipine O
. O
[]

However O
, O
after O
30 O
min O
, O
diltiazem O
affords O
better O
myocardial B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
and O
more O
effective O
control O
of O
hypertension B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
this O
article O
, O
we O
describe O
the O
outcome O
of O
an O
intensive O
series O
of O
interrater O
reliability O
training O
sessions O
for O
the O
17-item O
Hamilton O
Depression B-outcome ['Life-Impact']
Rating O
Scale O
conducted O
at O
the O
start O
of O
a O
Phase O
II O
multisite O
clinical O
drug O
trial O
. O
['Life-Impact']

Two O
serious O
adverse O
events O
were O
reported O
; O
one O
drug-related B-outcome ['Physiological-Clinical']
hypotensive I-outcome ['Physiological-Clinical']
infusion I-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
occurred O
in O
one O
subject O
in O
the O
30.0 O
mg/kg O
MEDI-545 O
dose O
group O
, O
causing O
discontinuation O
of O
study O
drug O
in O
that O
subject O
and O
study O
dismissal O
of O
the O
other O
subjects O
in O
the O
same O
cohort O
; O
and O
a O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
occurred O
in O
one O
subject O
in O
the O
10 O
mg/kg O
MEDI-545 O
dose O
group O
, O
which O
was O
considered O
to O
be O
unrelated O
to O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
. O
[]

RESULTS O
Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
reduced O
to O
146/79 O
and O
148/79 O
in O
losartan-treated O
patients O
and O
atenolol-treated O
patients O
, O
respectively O
. O
['Physiological-Clinical']

BACKGROUND O
Patients O
with O
acute O
ischaemic O
stroke O
and O
atrial O
fibrillation O
have O
an O
increased O
risk O
of O
early B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
, O
and O
anticoagulant O
treatment O
with O
heparins O
has O
been O
widely O
advocated O
, O
despite O
missing O
data O
on O
the O
balance O
of O
risk O
and O
benefit O
. O
['Physiological-Clinical']

Moreover O
, O
the O
patients O
were O
back O
to O
work O
in O
less O
than O
10 O
days O
. O
[]

Cycle O
control O
with O
oral O
contraceptives O
containing O
20 O
micrograms O
of O
ethinyl O
estradiol O
. O
[]

Safety O
and O
efficacy O
of O
PNU-142633 O
, O
a O
selective O
5-HT1D O
agonist O
, O
in O
patients O
with O
acute O
migraine O
. O
[]

Thus O
, O
VEGF/VEGFR-2 O
might O
constitute O
promising O
targets O
for O
antiangiogenic O
and O
antileukemic O
treatment O
strategies O
in O
AML O
. O
[]

The O
incidence O
of O
grade O
5 O
hemorrhage B-outcome ['Physiological-Clinical']
in O
patients O
receiving O
bevacizumab O
was O
5.1 O
% O
. O
['Physiological-Clinical']

One O
patient O
in O
each O
arm O
had O
fatal O
pneumonitis O
. O
[]

High-calcium O
milk O
prevents O
overweight O
and O
obesity O
among O
postmenopausal O
women O
. O
[]

The O
second O
method O
evaluated O
whether O
the O
observed O
trend O
was O
so O
impressive O
that O
the O
conclusion O
was O
unlikely O
to O
change O
even O
if O
the O
trial O
should O
continue O
to O
the O
scheduled O
end O
. O
[]

RESULTS O
Among O
the O
227 O
randomized O
subjects O
, O
33 O
( O
14.5 O
% O
) O
had O
SBI O
at O
baseline O
. O
[]

The O
patients O
were O
evaluated O
for O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
, O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
, O
visual O
analogue O
score O
( O
VAS O
) O
, O
verbal O
rating O
scale O
( O
VRS O
) O
, O
rescue B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
requirements O
, O
total O
opioid B-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
, O
side O
effects O
and O
time O
to O
first O
mobilisation O
at O
the O
1st O
, O
2nd O
, O
4th O
, O
6th O
, O
12th O
and O
24th O
hours O
postoperatively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Life-Impact']

All O
were O
given O
as O
nutritional O
supplements O
for O
six O
months O
to O
a O
group O
of O
primiparous O
and O
multiparous O
pregnant O
women O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
in O
change O
in O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
, O
respiratory B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
RDAI B-outcome ['Physiological-Clinical']
score O
at O
any O
assessment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

1988 O
) O
has O
also O
reported O
a O
tranquilizing B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
stimulating I-outcome ['Life-Impact']
effect O
in O
6 O
out O
of O
8 O
children O
with O
autism O
. O
['Life-Impact']

RESULTS O
After O
24 O
months O
, O
women O
who O
took O
medications O
without O
exercising O
had O
significant O
improvements O
in O
BMD B-outcome ['Physiological-Clinical']
at O
the O
total O
hip B-outcome ['Physiological-Clinical']
( O
+1.81 O
% O
) O
and O
spine B-outcome ['Physiological-Clinical']
( O
+2.85 O
% O
) O
and O
significant O
decreases O
in O
Alkphase B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
( O
-8.7 O
% O
) O
and O
serum B-outcome ['Physiological-Clinical']
NTx I-outcome ['Physiological-Clinical']
( O
-16.7 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Types O
of O
parent O
verbal O
responsiveness O
that O
predict O
language O
in O
young O
children O
with O
autism O
spectrum O
disorder O
. O
[]

Despite O
being O
widely O
available O
, O
outpatient O
detoxification O
has O
limited O
efficacy O
as O
a O
stand-alone O
treatment O
. O
[]

We O
conclude O
that O
regular O
consumption O
of O
commercially O
prepared O
Fe-fortified O
beikost O
with O
meat O
prevents O
most O
healthy O
term O
infants O
from O
Fe O
deficiency O
even O
if O
Fe O
intake O
is O
substantially O
below O
the O
recommended O
intake O
. O
[]

OBJECTIVES O
The O
objective O
was O
to O
test O
the O
hypothesis O
that O
hydrocodone/acetaminophen O
( O
Vicodin O
[ O
5/500 O
] O
) O
provides O
more O
efficacious O
analgesia O
than O
codeine/acetaminophen O
( O
Tylenol O
# O
3 O
[ O
30/300 O
] O
) O
in O
patients O
discharged O
from O
the O
emergency O
department O
( O
ED O
) O
. O
[]

In O
neither O
group O
was O
milk B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
suppressed O
. O
['Physiological-Clinical']

The O
treatment O
was O
given O
four O
times O
with O
intervals O
of O
two O
days O
, O
followed O
by O
one O
single O
treatment O
every O
six O
months O
throughout O
the O
experimental O
period O
. O
[]

Before O
and O
after O
Biostimine O
supplementation O
, O
exercise O
significantly O
increased O
the O
values O
of O
SOD B-outcome ['Physiological-Clinical']
, O
IL-6 B-outcome ['Physiological-Clinical']
, O
IL-10 B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Angiographic B-outcome ['Life-Impact']
and O
procedural B-outcome ['Life-Impact']
success I-outcome ['Life-Impact']
rates O
and O
in-hospital B-outcome ['Resource-use']
events I-outcome ['Resource-use']
were O
similar O
between O
the O
two O
groups O
. O
['Life-Impact', 'Resource-use']

Efficacy O
of O
erbium O
: O
yttrium-aluminum-garnet O
laser-assisted O
delivery O
of O
topical O
anesthetic O
. O
[]

However O
, O
few O
studies O
have O
used O
population-level O
samples O
nor O
taken O
into O
account O
contextual O
factors O
on O
Internet O
addiction O
. O
[]

or O
matching O
placebo O
for O
28 O
days O
. O
[]

Patients O
received O
oral O
esomeprazole O
40 O
mg O
( O
n O
= O
220 O
) O
or O
20 O
mg O
( O
n O
= O
226 O
) O
or O
placebo O
( O
n O
= O
229 O
) O
once O
daily O
for O
4 O
wk O
. O
[]

Relative O
to O
normoxic O
PECO O
, O
inhibition O
of O
the O
CC O
during O
hyperoxic O
PECO O
resulted O
in O
lower O
MSNA O
( O
P O
= O
0.038 O
) O
and O
HR O
( O
P O
= O
0.021 O
) O
. O
[]

Outcome O
indicators O
included O
factors O
that O
make O
patient O
discharge O
difficult O
( O
which O
nurses O
evaluated O
) O
, O
psychiatric B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
, O
knowledge B-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
illness I-outcome ['Life-Impact']
or O
medication O
, O
and O
the O
number O
of O
patients O
who O
were O
discharged B-outcome ['Resource-use']
within O
6 O
months O
after O
the O
end O
of O
a O
program B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Resource-use', 'Life-Impact']

Further O
prolongation O
caused O
by O
excessive O
caffeine O
intake O
may O
be O
a O
factor O
in O
the O
genesis O
of O
arrhythmias O
associated O
with O
caffeine O
toxicity O
. O
[]

OBJECTIVES O
To O
investigate O
efficacy O
, O
safety O
, O
and O
impact O
on O
quality B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
of O
desmopressin O
in O
the O
treatment O
of O
nocturia O
. O
['Physiological-Clinical']

Patients O
treated O
with O
a O
low-salt O
diet O
showed O
a O
significant O
decrease O
of O
both O
intralymphocytic B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
compression-to-bag-valve O
ventilation O
ratio O
was O
15:2 O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

For O
the O
modified O
ITT O
sample O
, O
desvenlafaxine O
( O
n O
= O
208 O
) O
and O
placebo O
( O
n O
= O
102 O
) O
, O
baseline O
HAM-D?? O
scores O
were O
23.8 O
and O
23.9 O
; O
the O
SDS O
baseline O
scores O
were O
20.1 O
and O
20.8 O
. O
[]

Median O
PFS B-outcome ['Mortality']
in O
both O
arms O
was O
6.2 O
months O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
4.2 O
, O
8.8 O
( O
lapatinib O
plus O
vinorelbine O
) O
; O
4.4 O
, O
8.3 O
( O
lapatinib O
plus O
capecitabine O
) O
] O
. O
['Mortality']

The O
patients O
suffered O
from O
partial O
or O
total O
intestinal O
obstruction O
, O
necrotizing O
enterocolitis O
or O
pyloric O
stenosis.All O
infants O
were O
fasting O
and O
studied O
during O
periods O
of O
at O
least O
one O
hour O
. O
[]

[ O
Unstable O
angina O
: O
comparison O
of O
the O
effects O
of O
diltiazem O
and O
propranolol O
] O
. O
[]

Neuromuscular O
blockers O
were O
injected O
at O
the O
same O
time O
with O
the O
fentanyl O
; O
haemodynamics O
were O
recorded O
with O
the O
patients O
awake O
( O
baseline O
) O
, O
at O
two O
minutes O
post-induction O
, O
and O
at O
two O
and O
five O
minutes O
after O
intubation O
. O
[]

The O
levels O
of O
serum B-outcome ['Physiological-Clinical']
ACE I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
imidapril O
group O
decreased O
significantly O
( O
p O
< O
0.01 O
) O
8 O
hours O
after O
the O
administration O
of O
imidapril O
, O
and O
the O
levels O
24 O
hours O
after O
administration O
were O
significantly O
lower O
than O
those O
in O
the O
placebo O
group O
( O
3.6 O
+/- O
0.6 O
IU/L O
vs O
7.4 O
+/- O
0.8 O
IU/L O
; O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Mediastinal O
lymphadenectomy O
in O
non-small O
cell O
lung O
cancer O
: O
effectiveness O
in O
patients O
with O
or O
without O
nodal O
micrometastases O
- O
results O
of O
a O
preliminary O
study O
. O
[]

Which O
socio-demographic O
factors O
are O
associated O
with O
participation O
in O
oral O
cancer O
screening O
in O
the O
developing O
world O
? O
[]

Enhanced O
inotropic O
state O
of O
the O
failing O
left O
ventricle O
by O
cardiac O
contractility O
modulation O
electrical O
signals O
is O
not O
associated O
with O
increased O
myocardial B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
consumption I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Employing O
the O
same O
instruments O
, O
these O
videotapes O
were O
rated O
by O
two O
raters O
who O
did O
not O
know O
the O
subjects O
and O
were O
blind O
to O
study O
design O
, O
treatment O
, O
and O
study O
phase O
. O
[]

This O
finding O
suggests O
that O
excitatory B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
inhibitory I-outcome ['Physiological-Clinical']
control O
operate B-outcome ['Resource-use']
comparably O
in O
autism O
and O
['Physiological-Clinical', 'Resource-use']

Between O
5 O
and O
25 O
min O
after O
morphine O
administration O
, O
pain B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
in O
the O
IV O
group O
was O
significantly O
improved O
compared O
with O
the O
IM O
group O
. O
['Physiological-Clinical']

RESULTS O
Endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
significantly O
improved O
after O
consumption O
of O
a O
walnut-enriched O
ad O
libitum O
diet O
compared O
with O
that O
after O
consumption O
of O
an O
ad O
libitum O
diet O
without O
walnuts O
( O
2.2 O
+/- O
1.7 O
vs. O
1.2 O
+/- O
1.6 O
% O
; O
P O
= O
0.04 O
) O
. O
['Physiological-Clinical']

This O
was O
statistically O
significant O
( O
P O
< O
0.05 O
) O
using O
both O
the O
t-test O
and O
the O
Wilcoxon O
Rank O
Sum O
test O
. O
[]

We O
compared O
two O
combined O
spinal O
epidural O
anaesthesia O
techniques O
: O
the O
needle-through-needle O
technique O
and O
the O
double O
segment O
technique O
in O
this O
respect O
. O
[]

OBJECTIVE O
We O
studied O
whether O
the O
administration O
of O
oral O
contraceptives O
facilitates O
the O
disappearance O
of O
spontaneously O
formed O
functional O
ovarian O
cysts O
. O
[]

Healing B-outcome ['Physiological-Clinical']
rates O
were O
shown O
to O
be O
comparable O
for O
all O
treatment O
regimens O
. O
['Physiological-Clinical']

Adjustment O
for O
LDL- B-outcome ['Physiological-Clinical']
and O
HDL-cholesterol B-outcome ['Physiological-Clinical']
did O
not O
affect O
these O
results O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
and O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
-- O
a O
trial O
of O
transcutaneous O
electrical O
nerve O
stimulation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
low O
success B-outcome ['Life-Impact']
rate O
for I-outcome ['Life-Impact']
catheter I-outcome ['Life-Impact']
insertion I-outcome ['Life-Impact']
is O
a O
problem O
because O
of O
cost O
implications O
. O
['Life-Impact']

Thus O
, O
expression O
of O
sialyl O
Lewis O
( O
a O
) O
, O
which O
is O
one O
of O
the O
important O
molecules O
of O
cell O
surface O
carbohydrates O
, O
may O
serve O
as O
a O
prognostic O
marker O
of O
aggressive O
and O
metastasizing O
tumor O
growth O
. O
[]

INTERVENTIONS O
( O
1 O
) O
IFT O
painful O
area O
and O
The O
Back O
Book O
, O
( O
2 O
) O
IFT O
spinal O
nerve O
and O
The O
Back O
Book O
, O
and O
( O
3 O
) O
Control O
, O
The O
Back O
Book O
only O
. O
[]

Hypothesis O
2 O
was O
that O
high-BP O
individuals O
would O
specifically O
show O
greater O
reactivity O
of O
shame- B-outcome ['Life-Impact']
and O
anger-related B-outcome ['Life-Impact']
emotions B-outcome ['Life-Impact']
to O
the O
negative O
evaluation/social O
rejection O
stressor O
compared O
with O
the O
negative O
evaluation/academic O
stressor O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSION O
Nasal O
irrigation O
with O
isotonic O
or O
hypertonic O
saline O
can O
improve O
mucociliary B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
in O
various O
nasal O
pathologies O
. O
['Physiological-Clinical']

They O
were O
then O
randomly O
stepped O
down O
to O
single-agent O
maintenance O
treatment O
for O
another O
18 O
months O
. O
[]

Clindamycin O
and O
cefoxitin O
with O
or O
without O
gentamicin O
were O
administered O
to O
cancer O
patients O
having O
localized O
infections O
presumably O
caused O
by O
anaerobic O
pathogens O
. O
[]

We O
conducted O
a O
small O
randomized O
, O
double O
blind O
, O
split O
face O
trial O
using O
a O
cream O
containing O
2.5 O
% O
w/w O
of O
EGCG O
. O
[]

MAIN O
OUTCOME O
MEASURES O
The O
primary O
hypothesis O
was O
that O
duloxetine O
would O
be O
more O
effective O
than O
placebo O
in O
decreasing O
chemotherapy-induced B-outcome ['Physiological-Clinical']
peripheral I-outcome ['Physiological-Clinical']
neuropathic I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

INTERVENTION O
The O
infants O
were O
assigned O
randomly O
to O
either O
the O
liberal- O
or O
the O
restrictive-transfusion O
group O
. O
[]

METHODS O
The O
ROCAS O
study O
is O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
evaluating O
the O
effects O
of O
simvastatin O
20 O
mg O
daily O
upon O
progression O
of O
asymptomatic O
middle O
cerebral O
artery O
stenosis O
among O
stroke-free O
individuals O
over O
2 O
years O
. O
[]

Follow-up O
angiography O
was O
scheduled O
after O
clipping O
and O
3 O
and O
12 O
months O
after O
endovascular O
treatment O
. O
[]

During O
period O
1 O
: O
ErSn O
there O
were O
reductions O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
noradrenaline I-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
but O
not O
in O
systolic B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Overall O
, O
these O
findings O
indicate O
that O
there O
are O
no O
apparent O
advantages O
in O
toxicity B-outcome ['Adverse-effects']
and O
efficacy O
by O
giving O
CDA O
weekly O
rather O
than O
daily O
. O
['Adverse-effects']

This O
suggests O
a O
reason O
for O
the O
popularity O
of O
caffeine-containing O
beverages O
after O
awakening O
. O
[]

A O
first-in-man O
, O
randomized O
, O
placebo-controlled O
study O
to O
evaluate O
the O
safety O
and O
feasibility B-outcome ['Life-Impact']
of O
autologous O
delipidated O
high-density O
lipoprotein O
plasma O
infusions O
in O
patients O
with O
acute O
coronary O
syndrome O
. O
['Life-Impact']

In O
a O
double-blind O
placebo-controlled O
crossover O
trial O
, O
14 O
autistic O
children O
were O
treated O
with O
the O
neuropeptide O
ORG O
2766 O
, O
a O
synthetic O
analog O
of O
adrenocorticotrophic O
hormone O
( O
ACTH O
) O
( O
4-9 O
) O
. O
[]

METHODS O
In O
a O
population-based O
screening O
program O
in O
Sweden O
, O
12,527 O
women O
32 O
to O
38 O
years O
of O
age O
were O
randomly O
assigned O
at O
a O
1:1 O
ratio O
to O
have O
an O
HPV O
test O
plus O
a O
Papanicolaou O
( O
Pap O
) O
test O
( O
intervention O
group O
) O
or O
a O
Pap O
test O
alone O
( O
control O
group O
) O
. O
[]

Low-dose O
clonidine O
, O
which O
blunts O
central O
sympathetic O
outflow O
, O
may O
prevent O
perioperative B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
and O
death B-outcome ['Mortality']
without O
inducing O
hemodynamic O
instability O
. O
['Physiological-Clinical', 'Mortality']

All O
patients O
completed O
the O
follow-up O
period O
, O
and O
most O
of O
the O
R O
group O
patients O
had O
normal O
eating O
habits O
10 O
to O
14 O
days O
after O
surgery O
. O
[]

RESULTS O
Followup O
information O
was O
obtained O
for O
261 O
of O
the O
280 O
patients O
( O
93 O
% O
) O
in O
the O
white O
light O
group O
and O
255 O
of O
the O
271 O
( O
94 O
% O
) O
in O
the O
fluorescence O
group O
. O
[]

Two O
large O
preoperative O
doses O
of O
erythropoietin O
do O
not O
reduce O
the O
systemic O
inflammatory O
response O
to O
cardiac O
surgery O
. O
[]

Diclofenac O
, O
a O
nonsteroidal O
anti-inflammatory O
drug O
, O
decreases O
proteinuria O
in O
some O
glomerular O
diseases O
: O
a O
controlled O
study O
. O
[]

Eighteen O
patients O
were O
eventually O
treated O
with O
pentostatin O
and O
ten O
with O
2-chlorodeoxyadenosine O
( O
2-CdA O
) O
. O
[]

RESULTS O
Evaluation O
of O
wound B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
on O
days O
2 O
, O
5 O
, O
8 O
and O
14 O
+/- O
1 O
showed O
best O
results O
for O
the O
polyurethane O
and O
hydrocolloid O
plasters O
. O
['Physiological-Clinical']

METHODS O
A O
prospective O
, O
randomized O
controlled O
study O
was O
carried O
out O
. O
[]

5-FU/FA-therapy O
is O
therefore O
the O
method O
of O
choice O
outside O
clinical O
trials O
. O
[]

RESULTS O
At O
3-month O
follow-up O
, O
both O
groups O
showed O
significant O
decreases O
in O
the O
proportion O
who O
were O
positive O
for O
at-risk O
drinking O
, O
the O
primary O
outcome O
variable O
. O
[]

Genotyping O
of O
CYP21 O
, O
linked O
chromosome O
6p O
markers O
, O
and O
a O
sex-specific O
gene O
in O
neonatal O
screening O
for O
congenital O
adrenal O
hyperplasia O
. O
[]

There O
was O
no O
difference O
between O
the O
right O
and O
left O
calcanean O
BMC O
or O
BMD O
( O
p O
> O
0.15 O
) O
. O
[]

Milk O
protein O
quantity O
and O
quality O
in O
low-birth-weight O
infants O
. O
[]

0.3 O
and O
6.8 O
? O
[]

Cancer O
2013 O
. O
? O
[]

The O
absolute O
risk O
difference O
was O
14.8 O
% O
in O
favor O
of O
enoxaparin O
( O
95 O
% O
Cl O
, O
5.3 O
% O
to O
24.1 O
% O
) O
Twenty-two O
warfarin O
recipients O
( O
10.4 O
% O
) O
and O
24 O
enoxaparin O
recipients O
( O
11.7 O
% O
) O
had O
proximal O
venous O
thrombosis O
( O
P O
> O
0.2 O
) O
. O
[]

METHODS O
Patients O
presenting O
for O
cataract O
surgery O
in O
one O
eye O
were O
randomized O
to O
receive O
either O
the O
Tecnis O
Z9000 O
intraocular O
lens O
( O
Pharmacia O
) O
or O
the O
AMO O
AR40e O
Opti-Edge O
intraocular O
lens O
( O
AMO O
) O
. O
[]

SETTINGS O
The O
trial O
was O
conducted O
at O
a O
private O
CHM O
clinic O
in O
Hove O
( O
U.K. O
) O
and O
at O
a O
National O
Health O
Service O
outpatient O
clinic O
in O
London O
( O
U.K. O
) O
. O
[]

In O
the O
case O
of O
RAO O
as O
assessed O
by O
duplex O
ultrasonography O
3 O
to O
4 O
hours O
after O
hemostasis O
, O
immediate O
1-hour O
ulnar O
artery O
compression O
was O
applied O
. O
[]

Future O
studies O
should O
examine O
whether O
the O
incorporation O
of O
narratives O
in O
dissemination O
campaigns O
improves O
guideline O
adoption O
and O
changes O
clinical O
practice O
[]

However O
, O
a O
modest O
benefit O
can O
not O
be O
excluded O
and O
larger O
randomised O
placebo-controlled O
trials O
with O
longer O
durations O
of O
pentoxifylline B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
may O
be O
justified O
. O
['Resource-use']

The O
average O
age O
was O
30 O
; O
subjects O
were O
predominantly O
female O
, O
and O
mostly O
wore O
frequent-replacement O
contact O
lenses O
. O
[]

Prospective O
randomized O
evaluation O
of O
diode-laser O
and O
cryotherapy O
in O
prethreshold B-outcome ['Physiological-Clinical']
retinopathy I-outcome ['Physiological-Clinical']
of O
prematurity O
. O
['Physiological-Clinical']

Serial O
blood B-outcome ['Physiological-Clinical']
and O
urine B-outcome ['Physiological-Clinical']
samples O
were O
obtained O
after O
the O
first- O
and O
multiple-dose O
administrations O
for O
up O
to O
18 O
days O
. O
['Physiological-Clinical']

Complications B-outcome ['Adverse-effects']
of I-outcome ['Adverse-effects']
therapy I-outcome ['Adverse-effects']
occurred O
in O
only O
4 O
patients O
, O
3 O
of O
whom O
had O
transient O
incontinence B-outcome ['Physiological-Clinical']
of O
flatus O
. O
['Adverse-effects', 'Physiological-Clinical']

Neither O
treatment O
significantly O
influenced O
the O
agonist-induced B-outcome ['Physiological-Clinical']
accumulation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
lysoplasmenylethanolamine I-outcome ['Physiological-Clinical']
as O
derived O
via O
phospholipase O
A2 O
hydrolysis O
of O
plasmenylethanolamine O
. O
['Physiological-Clinical']

Assessments O
of O
side-effects O
and O
outcomes O
of O
benefit O
were O
made O
monthly O
by O
independent O
, O
blinded O
observers O
. O
[]

Erythrocyte B-outcome ['Physiological-Clinical']
deformability I-outcome ['Physiological-Clinical']
, O
endothelin B-outcome ['Physiological-Clinical']
levels O
, O
and O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
cyclosporin-treated O
renal O
transplant O
recipients O
: O
effects O
of O
intervention O
with O
fish O
oil O
and O
corn O
oil O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Isoniazid O
prophylaxis O
for O
tuberculosis O
in O
HIV O
infection O
: O
a O
meta-analysis O
of O
randomized O
controlled O
trials O
. O
[]

Intervention O
in O
children O
with O
Developmental O
Coordination O
Disorder O
: O
the O
role O
of O
parents O
and O
teachers O
. O
[]

INTERVENTIONS O
Patients O
were O
randomly O
assigned O
to O
either O
30 O
% O
or O
80 O
% O
fraction O
of O
inspired O
oxygen O
( O
FIO2 O
) O
intraoperatively O
and O
for O
6 O
hours O
after O
surgery O
. O
[]

The O
results O
show O
that O
the O
infusion O
test O
of O
somatostatin O
is O
fitted O
to O
measure O
a O
steady O
state O
of O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Resource-use']
and O
that O
it O
is O
possible O
by O
this O
technique O
to O
quantify O
a O
changed O
utilisation O
of O
blood O
glucose O
induced O
by O
specific O
therapy O
. O
['Physiological-Clinical', 'Resource-use']

The O
patient O
experience O
of O
community O
hospital O
-- O
the O
process O
of O
care O
as O
a O
determinant O
of O
satisfaction O
. O
[]

RESULTS O
Mean O
concentrations O
of O
CP O
in O
pasture O
and O
urea B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
High-N O
than O
the O
Control O
group O
( O
25.2 O
vs O
21.6 O
and O
8.3 O
vs O
5.4 O
mmol/L O
for O
CP O
and O
urea O
, O
respectively O
; O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

The O
median O
TTP B-outcome ['Physiological-Clinical']
was O
2.9 O
months O
on O
TLC O
D-99 O
versus O
3.1 O
months O
on O
doxorubicin O
. O
['Physiological-Clinical']

There O
was O
no O
difference O
in O
survival B-outcome ['Mortality']
between O
the O
treatments O
, O
either O
overall O
or O
in O
any O
subgroup O
of O
patients O
. O
['Mortality']

With O
320 O
events O
assessed O
, O
the O
median O
TTP B-outcome ['Physiological-Clinical']
was O
3.4 O
months O
( O
95 O
% O
Confidence O
interval O
[ O
CI O
] O
, O
2.6 O
to O
3.8 O
) O
on O
UFT/LV O
and O
3.3 O
months O
( O
95 O
% O
CI O
, O
2.5 O
to O
3.7 O
) O
on O
5-FU/LV O
( O
P O
=.591 O
, O
stratified O
log-rank O
test O
) O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
The O
study O
was O
designed O
to O
demostrate O
a O
difference O
in O
the O
proportion O
of O
women O
with O
clear B-outcome ['Physiological-Clinical']
histological I-outcome ['Physiological-Clinical']
margins I-outcome ['Physiological-Clinical']
of O
82 O
% O
for O
LLETZ O
compared O
to O
94 O
% O
for O
NETZ O
with O
90 O
% O
power O
at O
a O
5 O
% O
significance O
level O
, O
allowing O
for O
absence O
of O
CIN O
in O
the O
treatment O
specimen B-outcome ['Physiological-Clinical']
in O
15 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
both O
modes O
of O
NPPV O
, O
a O
full O
face O
mask O
and O
an O
artificial O
leak O
in O
the O
ventilatory O
circuit O
were O
used O
at O
three O
different O
settings O
, O
and O
applied O
during O
daytime O
NPPV O
, O
either O
without O
leakage O
( O
setting O
I O
) O
, O
with O
leakage O
during O
inspiration O
only O
( O
setting O
II O
) O
, O
and O
with O
leakage O
during O
inspiration O
and O
expiration O
( O
setting O
III O
) O
. O
[]

RESULTS O
Plasma B-outcome ['Physiological-Clinical']
linezolid I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
and O
area O
under O
the O
concentration-time O
curves O
increased O
proportionally O
with O
dose O
irrespective O
of O
the O
route O
of O
administration O
. O
['Physiological-Clinical']

Main O
Exposures O
Autism O
and O
other O
special O
health O
care O
needs O
including O
asthma O
. O
[]

The O
vaccine B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
evaluated O
as O
significant O
increases O
in O
levels O
of O
influenza B-outcome ['Physiological-Clinical']
hemagglutination-inhibition I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HAI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
and O
of O
IgG B-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
measured O
by O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Among O
the O
120 O
patient O
, O
complete O
response O
was O
achieved O
in O
11.7 O
% O
( O
7/60 O
patients O
of O
arm O
1 O
) O
and O
5 O
% O
( O
3/60 O
patients O
of O
arm O
2 O
) O
. O
[]

However O
, O
for O
placebo O
and O
control O
sites O
, O
bacterial B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
increased O
and O
reached O
the O
baseline O
value O
on O
week O
17 O
. O
['Physiological-Clinical']

PURPOSE O
To O
evaluate O
the O
risk O
of O
developing O
radiation B-outcome ['Physiological-Clinical']
myelitis I-outcome ['Physiological-Clinical']
after O
a O
cervical O
spinal O
cord O
dose O
of O
50.6 O
Gy O
given O
via O
1.1 O
Gy O
b.i.d O
. O
['Physiological-Clinical']

CONCLUSIONS O
in O
patients O
receiving O
ICDs O
early O
after O
myocardial O
infarction O
, O
those O
factors O
that O
are O
associated O
with O
arrhythmia O
requiring O
ICD O
therapy O
are O
also O
associated O
with O
a O
high O
risk O
of O
[]

CONCLUSIONS O
Phenobarbital O
and O
phenytoin O
are O
equally O
but O
incompletely O
effective O
as O
anticonvulsants B-outcome ['Resource-use']
in O
neonates O
. O
['Resource-use']

MEASUREMENTS O
Pain O
on O
injection O
was O
measured O
using O
a O
4-point O
scale O
. O
[]

Data O
on O
autistic B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
urinary B-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
levels O
were O
collected O
in O
the O
subjects O
' O
homes O
over O
the O
12 O
weeks O
that O
they O
were O
on O
the O
diet O
. O
['Life-Impact', 'Physiological-Clinical']

RESULTS O
A O
total O
of O
226 O
patients O
were O
evaluable O
for O
response O
. O
[]

Prospective O
study O
of O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
, O
homocysteine B-outcome ['Physiological-Clinical']
, O
and O
plasma B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
levels O
as O
predictors O
of O
sudden O
cardiac O
death O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
We O
conclude O
that O
ECD O
registrations O
with O
CD O
or O
NMI O
are O
as O
accurate O
as O
TCT O
registrations O
with O
CD O
and O
that O
TCT O
registrations O
with O
NMI O
should O
be O
avoided O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
protective O
effect O
of O
broccoli O
intake O
in O
smokers O
and O
nonsmokers O
. O
[]

RESULTS O
The O
mean O
nocturnal B-outcome ['Physiological-Clinical']
IOPs I-outcome ['Physiological-Clinical']
( O
Goldmann O
's O
applanation O
tonometer O
) O
collected O
for O
5 O
days O
were O
mean O
+/-SEM O
17.9+/-0.6 O
vs O
20.2+/-0.6 O
mm O
Hg O
and O
16.8+/-0.3 O
vs O
20.6+/-0.5 O
mm O
Hg O
for O
the O
study O
vs O
the O
control O
eyes O
in O
group O
1 O
and O
group O
2 O
, O
respectively O
. O
['Physiological-Clinical']

Patients O
in O
Group O
2 O
( O
n=72 O
) O
received O
totally O
1200 O
mg O
intravenous/24 O
h O
amiodarone O
which O
the O
300 O
mg O
- O
bolus O
dose/1 O
h O
was O
given O
as O
soon O
as O
the O
operation O
had O
been O
finished O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
( O
44.3 O
% O
vs. O
22.2 O
% O
) O
and O
vomiting B-outcome ['Physiological-Clinical']
( O
21.3 O
% O
vs. O
6.3 O
% O
) O
were O
more O
frequent O
in O
the O
placebo O
group O
than O
in O
the O
paracetamol O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
multivariate O
analysis O
revealed O
histological B-outcome ['Physiological-Clinical']
grading I-outcome ['Physiological-Clinical']
, O
TCM B-outcome ['Physiological-Clinical']
and O
platelets B-outcome ['Physiological-Clinical']
as O
the O
most O
reliable O
prognostic O
factors O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mosquitoes O
were O
collected O
in O
these O
communities O
by O
the O
all-night O
landing O
catch O
method O
and O
were O
individually O
dissected O
to O
identify O
rates O
of O
infection O
and O
infectiveness O
. O
[]

The O
estimated O
date O
of O
delivery O
( O
EDD O
) O
was O
changed O
if O
there O
was O
a O
discrepancy O
of O
more O
than O
5 O
days O
from O
the O
gestation O
, O
calculated O
from O
the O
last O
menstrual O
period O
( O
LMP O
) O
. O
[]

METHOD O
The O
present O
study O
examined O
whether O
pretreatment O
levels O
of O
dysfunctional O
attitudes O
( O
DA O
) O
moderated O
treatment O
response O
in O
a O
large O
sample O
of O
chronically O
depressed O
individuals O
. O
[]

Subjects O
began O
with O
a O
steroid O
taper O
and O
then O
were O
randomized O
to O
a O
3-month O
trial O
of O
drug O
or O
placebo O
therapy O
. O
[]

Dose O
regimen O
was O
400 O
mg O
twice O
daily O
from O
weeks O
0 O
to O
eight O
, O
increasing O
to O
400 O
mg O
three O
times O
a O
day O
from O
weeks O
nine O
to O
24 O
provided O
that O
no O
adverse O
effects O
were O
recorded O
. O
[]

RESULTS O
Although O
participants O
randomized O
to O
the O
2 O
arms O
did O
not O
differ O
statistically O
in O
age O
, O
gender O
, O
[]

METHODS O
Subjects O
comprised O
131 O
adult O
patients O
who O
under-went O
NTI O
. O
[]

CONTRAST O
protocol O
consisted O
of O
alternating O
heavy-light O
resistance O
( O
15-50 O
% O
body O
mass O
) O
with O
soccer-specific O
drills O
( O
small-sided O
games O
or O
technical O
skills O
) O
. O
[]

The O
incremental O
cost-effectiveness O
ratio O
of O
the O
treatment O
was O
1044 O
pounds O
sterling O
per O
point O
improvement O
of O
the O
Barthel O
Index O
. O
['Resource-use']

acetaminophen O
, O
and O
lidocaine O
groups O
was O
64 O
% O
, O
22 O
% O
and O
8 O
% O
, O
respectively O
( O
P O
< O
0.05 O
) O
. O
[]

DISCUSSION O
These O
data O
indicate O
that O
the O
most O
weight O
loss B-outcome ['Physiological-Clinical']
was O
achieved O
when O
the O
counseling O
approach O
combined O
both O
Weight O
Watchers O
and O
individualized O
contacts O
. O
['Physiological-Clinical']

Greater O
adherence O
to O
the O
high O
fruits O
and O
vegetables O
pattern O
among O
urban O
survivors O
was O
inversely O
associated O
with O
BMI O
( O
P O
trend O
< O
0.05 O
) O
. O
[]

Both O
drugs O
reduced O
acne B-outcome ['Physiological-Clinical']
severity B-outcome ['Physiological-Clinical']
to O
the O
same O
extent O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Although O
percutaneous O
endoscopic O
gastrostomy O
( O
PEG O
) O
has O
become O
popular O
for O
patients O
with O
swallowing O
disorders O
as O
a O
nutrition O
support O
or O
a O
decompressant O
of O
gastrointestine O
, O
perioperative O
complications O
associated O
with O
PEG O
have O
not O
decreased O
, O
especially O
peristomal O
infections O
. O
[]

In O
a O
previous O
study O
it O
was O
demonstrated O
that O
patients O
with O
multiallergy O
hyposensitized O
with O
combined O
allergen O
extracts O
showed O
a O
statistically O
significant O
increase O
in O
[]

CONCLUSION O
Overall O
, O
both O
one O
and O
seven O
rounds O
of O
DMSA O
therapy O
seems O
to O
be O
reasonably O
safe O
in O
children O
with O
ASD O
who O
have O
high O
urinary O
excretion O
of O
toxic O
metals O
, O
and O
possibly O
helpful O
in O
reducing O
some O
of O
the O
symptoms O
of O
autism O
in O
those O
children O
. O
[]

The O
outcomes O
were O
patients O
' O
disease-related B-outcome ['Physiological-Clinical']
knowledge B-outcome ['Life-Impact']
, O
active B-outcome ['Life-Impact']
coping I-outcome ['Life-Impact']
with O
illness B-outcome ['Physiological-Clinical']
, O
and O
quality O
of O
life O
( O
QoL B-outcome ['Life-Impact']
) O
at O
the O
end O
of O
their O
stay O
and O
6 O
and O
12 O
months O
thereafter O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

4 O
. O
[]

Using O
data O
from O
three O
trials O
of O
CM O
for O
cocaine O
use O
, O
we O
compared O
baseline O
characteristics O
and O
posttreatment O
and O
follow-up O
cocaine B-outcome ['Life-Impact']
outcomes O
between O
methadone-maintained O
, O
cocaine-dependent O
patients O
( O
N O
= O
193 O
) O
with O
and O
without O
concurrent O
AD O
, O
randomized O
to O
standard O
care O
( O
SC O
) O
with O
or O
without O
CM O
. O
['Life-Impact']

Data O
were O
analyzed O
using O
repeated-measures O
general O
linear O
mixed O
models O
. O
[]

Participants O
were O
20 O
children O
with O
ASD O
( O
M O
age O
= O
14.3 O
yr. O
, O
SD O
= O
4.2 O
; O
6 O
girls O
, O
14 O
boys O
) O
in O
the O
role O
of O
speakers O
and O
20 O
control O
children O
, O
who O
acted O
as O
listeners O
. O
[]

INTERPRETATION O
AT O
with O
a O
programme O
aimed O
at O
improving O
strength O
and O
coordination O
of O
the O
muscles O
acting O
on O
the O
pelvis O
, O
in O
particular O
the O
adductor O
muscles O
, O
is O
very O
effective O
in O
the O
treatment O
of O
athletes O
with O
long-standing O
adductor-related O
groin O
pain O
. O
[]

No O
difference O
was O
found O
between O
these O
two O
groups O
with O
regard O
to O
the O
necessary O
interval O
for O
ERCP O
( O
20.6 O
+/- O
14.1 O
min O
versus O
21.4 O
+/- O
14.7 O
min O
; O
NS O
) O
or O
the O
success B-outcome ['Life-Impact']
rate O
for I-outcome ['Life-Impact']
cholangiopancreatography I-outcome ['Life-Impact']
( O
92.1 O
% O
versus O
91.7 O
% O
; O
NS O
) O
. O
['Life-Impact']

Wounds O
were O
treated O
on O
day O
0 O
and O
day O
8 O
. O
[]

OBJECTIVES O
The O
aim O
of O
the O
present O
study O
was O
to O
elucidate O
the O
mechanism O
of O
cutaneous O
vasodilation O
following O
acupuncture O
stimulation O
by O
investigating O
the O
roles O
of O
nitric O
oxide O
( O
NO O
) O
and O
axon O
reflex O
vasodilation O
. O
[]

SETTING O
Needle O
exchange O
program-Providence O
, O
Rhode O
Island O
, O
USA O
. O
[]

Music O
or O
guided O
imagery O
for O
women O
undergoing O
colposcopy O
: O
a O
randomized O
controlled O
study O
of O
effects O
on O
anxiety B-outcome ['Life-Impact']
, O
perceived B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Nurse O
and O
patient B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
profiles I-outcome ['Life-Impact']
in O
a O
home-based O
telehealth O
intervention O
for O
heart O
failure O
management O
. O
['Life-Impact']

This O
paper O
examines O
the O
effect O
of O
the O
addition O
of O
the O
early O
intensification O
block O
to O
treatment O
which O
included O
late O
intensification O
, O
combining O
the O
data O
from O
UKALL O
X O
and O
the O
first O
part O
of O
UKALL O
XI O
. O
[]

A O
vaccine O
was O
developed O
against O
bovine O
mastitis O
based O
on O
inactivated O
, O
highly O
encapsulated O
Staphylococcus O
aureus O
cells O
; O
a O
crude O
extract O
of O
Staph O
. O
[]

A O
total O
of O
174 O
patients O
were O
included O
in O
the O
economic O
evaluation O
. O
[]

Effects O
of O
nutritional O
supplementation O
on O
IQ B-outcome ['Life-Impact']
and O
certain O
other O
variables O
associated O
with O
Down O
syndrome O
. O
['Life-Impact']

Concomitant O
radiochemotherapy O
vs O
radiotherapy O
alone O
in O
patients O
with O
head O
and O
neck O
cancer O
: O
a O
Hellenic O
Cooperative O
Oncology O
Group O
Phase O
III O
Study O
. O
[]

METHODS O
This O
was O
a O
randomized O
double-blind O
study O
. O
[]

This O
treatment O
was O
effective O
and O
cured O
a O
majority O
of O
patients O
within O
2 O
to O
3 O
months O
; O
half O
of O
them O
seroconverted O
. O
[]

The O
modified O
intent-to-treat O
cohort O
( O
DHA O
= O
33 O
; O
placebo O
= O
27 O
) O
adhered O
to O
the O
protocol O
? O
[]

CONCLUSION O
Caudal O
administration O
of O
bupivacaine-midazolam O
mixture O
prolongs O
post-operative O
analgesia O
compared O
to O
bupivacaine O
alone O
without O
causing O
any O
adverse O
effects O
. O
[]

DESIGN O
A O
double-blind O
, O
3 O
( O
aroma O
) O
x O
3 O
( O
instruction O
) O
x O
10 O
( O
time O
in O
minutes O
) O
mixed-factorial O
placebo-controlled O
trial O
. O
[]

After O
completion O
, O
the O
oxygenators O
were O
dissected O
and O
examined O
. O
[]

The O
findings O
were O
consistent O
with O
a O
rapid O
metabolism O
of O
RU B-outcome ['Physiological-Clinical']
486 I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
RU I-outcome ['Physiological-Clinical']
42633 I-outcome ['Physiological-Clinical']
; O
removal O
of O
the O
second O
methyl O
group O
leading O
to O
RU O
42698 O
occurred O
much O
more O
slowly O
and O
to O
a O
much O
less O
extent O
than O
removal O
of O
the O
first O
. O
['Physiological-Clinical']

In O
each O
stage O
, O
5-year O
survival B-outcome ['Mortality']
rates O
in O
groups O
A O
and O
B O
were O
100 O
% O
, O
93 O
% O
in O
stage O
I O
, O
82 O
% O
and O
85 O
% O
in O
stage O
II O
, O
62 O
% O
and O
52 O
% O
in O
stage O
II O
and O
22 O
% O
and O
31 O
% O
in O
stage O
IV O
, O
respectively O
. O
['Mortality']

Behavioral B-outcome ['Life-Impact']
rating O
scales O
( O
Clinical O
Global O
Impression O
Scale O
[ O
CGI-I O
] O
, O
Ritvo-Freeman O
Real O
Life O
Rating O
Scale O
[ O
RF-RLRS O
] O
) O
, O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
[ O
ABC O
] O
, O
Turgay O
DSM-IV O
Pervasive B-outcome ['Life-Impact']
Developmental I-outcome ['Life-Impact']
Disorder I-outcome ['Life-Impact']
Rating O
Scale O
[ O
TPDDRS O
] O
) O
and O
safety O
assessment O
scales O
( O
Extrapyramidal O
Symptoms O
Rating O
Scale O
[ O
ESRS O
] O
, O
UKU-Side O
Effect O
Rating O
Scale O
) O
were O
performed O
at O
12 O
, O
16 O
, O
20 O
and O
24 O
weeks O
, O
following O
the O
12 O
week O
double-blind O
phase O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

There O
still O
existed O
immune B-outcome ['Physiological-Clinical']
memory I-outcome ['Physiological-Clinical']
11 O
years O
after O
immunization O
, O
but O
it O
was O
significantly O
weaker O
than O
that O
within O
the O
first O
10 O
years O
after O
immunization O
. O
['Physiological-Clinical']

Changes O
in O
parent O
measures O
( O
CGI O
, O
Conners O
Impulsivity-Hyperactivity B-outcome ['Life-Impact']
Factor O
, O
and O
SE-Restlessness O
) O
and O
Teacher O
CGI O
achieved O
statistical O
significance O
. O
['Life-Impact', 'Life-Impact']

METHODS O
The O
endpoint O
of O
this O
4-week O
multicenter O
, O
randomized O
, O
double-blind O
, O
parallel-group O
study O
comparing O
a O
2 O
% O
polyvinylpyrrolidone O
( O
PVP O
) O
solution O
with O
a O
0.9 O
% O
NaCl O
solution O
was O
to O
assess O
ocular O
discomfort O
using O
a O
visual O
analog O
scale O
. O
[]

The O
control O
group O
consisted O
of O
40 O
specimens O
from O
normal O
gastric O
mucosa O
. O
[]

Therapy O
for O
progressive O
supranuclear O
palsy O
: O
past O
and O
future O
. O
[]

AIM O
To O
assess O
ambulatory B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
of O
children O
with O
cerebral O
palsy O
( O
CP O
) O
, O
aged O
7 O
to O
13 O
years O
, O
and O
identify O
associated O
characteristics O
. O
['Life-Impact']

The O
control O
group O
received O
only O
conventional B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
, O
including O
debridement B-outcome ['Resource-use']
, O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
control O
agents B-outcome ['Resource-use']
, O
systemic B-outcome ['Resource-use']
antibiotics I-outcome ['Resource-use']
, O
wound B-outcome ['Physiological-Clinical']
cleaning I-outcome ['Physiological-Clinical']
with O
normal B-outcome ['Resource-use']
saline I-outcome ['Resource-use']
, O
offloading O
( O
pressure O
relief O
) O
, O
and O
daily B-outcome ['Resource-use']
wound I-outcome ['Resource-use']
dressings I-outcome ['Resource-use']
. O
['Resource-use', 'Resource-use', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Physiological-Clinical', 'Resource-use', 'Resource-use']

Pyridostigmine O
bromide O
is O
currently O
the O
pretreatment O
of O
choice O
for O
operation O
in O
a O
chemical O
warfare O
( O
CW O
) O
environment O
. O
[]

Subjects O
were O
randomly O
assigned O
to O
one O
of O
three O
groups O
: O
amnioinfusion O
with O
warmed O
saline O
solution O
, O
room-temperature O
saline O
, O
or O
control O
. O
[]

Patients O
younger O
than O
75 O
years O
of O
age O
with O
a O
good O
physical O
and O
mental O
condition O
and O
a O
histologically O
proven O
adenocarcinoma O
of O
the O
stomach O
without O
clinical O
or O
radiographic O
( O
computed O
tomography O
scan O
) O
evidence O
of O
distant O
metastases O
were O
eligible O
for O
this O
trial O
. O
[]

The O
routine O
use O
of O
agents O
potentially O
capable O
of O
reducing O
these O
side-effects O
has O
not O
been O
recommended O
out O
of O
concern O
for O
possible O
reductions O
in O
the O
therapeutic O
activity O
of O
interferon O
. O
[]

Their O
improvemments O
were O
significantly O
greater O
on O
methandienone O
than O
on O
placebo O
; O
their O
body B-outcome ['Physiological-Clinical']
weights I-outcome ['Physiological-Clinical']
rose I-outcome ['Physiological-Clinical']
( O
though O
this O
seemed O
to O
be O
associated O
with O
water O
retention O
) O
; O
and O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
rose I-outcome ['Physiological-Clinical']
significantly O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effect O
of O
spinal O
versus O
general O
anesthesia O
on O
bladder B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
and O
intraabdominal B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
during O
transurethral O
procedures O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
Chinese B-outcome ['Physiological-Clinical']
medicine I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
integral I-outcome ['Physiological-Clinical']
was O
( O
16.07 O
+/- O
6.77 O
) O
score O
and O
( O
7.25 O
+/- O
3.27 O
) O
score O
before O
and O
3 O
months O
after O
drug O
therapy O
in O
the O
test O
group O
, O
while O
it O
was O
( O
15.92 O
+/- O
7.51 O
) O
score O
and O
( O
12.73 O
+/- O
6.12 O
) O
score O
in O
the O
control O
group O
. O
['Physiological-Clinical']

Ofloxacin O
was O
usually O
administered O
as O
a O
200 O
mg O
dose O
bd O
. O
[]

OBJECTIVE O
To O
establish O
a O
new O
wound O
model O
that O
can O
induce O
uniform O
abrasions O
and O
use O
it O
to O
assess O
the O
healing B-outcome ['Physiological-Clinical']
properties I-outcome ['Physiological-Clinical']
of O
a O
range O
of O
products O
commonly O
applied O
to O
these O
wounds O
. O
['Physiological-Clinical']

People O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
often O
exhibit O
superior O
performance O
in O
visual O
search O
compared O
to O
others O
. O
[]

METHODS O
. O
[]

METHODS O
Six O
female O
and O
18 O
male O
volunteers O
( O
median O
age O
26 O
years O
) O
with O
a O
history O
of O
allergic O
rhinitis O
but O
currently O
free O
of O
symptoms O
were O
included O
in O
this O
randomized O
, O
placebo-controlled O
, O
double-blind O
, O
three-period O
crossover O
study O
. O
[]

The O
trial O
was O
stopped O
after O
the O
accumulated O
results O
in O
121 O
patients O
demonstrated O
a O
significant O
advantage O
for O
survival O
in O
the O
patients O
who O
received O
chemotherapy O
and O
radiation O
therapy O
. O
[]

Specifically O
, O
the O
intervention O
reduces O
hopelessness B-outcome ['Life-Impact']
and O
depression B-outcome ['Life-Impact']
levels O
. O
['Life-Impact']

MAIN O
OUTCOMES O
AND O
MEASURES O
Primary O
outcomes O
were O
parental B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
and O
maternal B-outcome ['Life-Impact']
depressive I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Of O
330 O
patients O
intended O
for O
enrollment O
, O
23 O
were O
randomized O
( O
MARVEL-1 O
) O
before O
stopping O
the O
study O
for O
financial O
reasons O
. O
[]

Competitive O
employment O
for O
youth O
with O
autism O
spectrum O
disorders O
: O
early O
results O
from O
a O
randomized O
clinical O
trial O
. O
[]

Also O
, O
the O
duration O
of O
untreated O
illness B-outcome ['Physiological-Clinical']
( O
DUI B-outcome ['Physiological-Clinical']
) O
prior O
to O
assessment O
was O
not O
significantly O
associated O
with O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Fourteen O
patients O
were O
randomised O
to O
receive O
laser O
only O
, O
and O
12 O
to O
receive O
laser O
followed O
by O
brachytherapy O
. O
[]

Synthetic O
serum O
substitute O
( O
SSS O
) O
: O
a O
globulin-enriched O
protein O
supplement O
for O
human O
embryo O
culture O
. O
[]

Better O
event-related O
modulation O
of O
inhibition O
correlated O
with O
better O
performance O
in O
more O
demanding O
tasks O
, O
in O
which O
fast O
alternating O
activation O
of O
cortical O
representations O
are O
necessary O
. O
[]

All O
patients O
underwent O
a O
washout O
period O
of O
6 O
weeks O
from O
any O
prior O
antibiotic O
or O
PPI O
usage O
. O
[]

In O
the O
BAL O
, O
there O
were O
no O
NO2-induced O
changes O
in O
either O
cell B-outcome ['Physiological-Clinical']
numbers I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
soluble I-outcome ['Physiological-Clinical']
mediators I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Subjects O
with O
gastric B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
or O
adverse O
reactions O
had O
lower O
PGE2 O
levels O
. O
['Physiological-Clinical']

The O
PANSS O
( O
11 O
) O
psychotic O
subscale O
showed O
clinically O
significant O
effect O
sizes O
for O
all O
doses O
of O
sertindole O
( O
12 O
, O
20 O
, O
and O
24 O
mg O
) O
and O
haloperidol O
( O
4 O
, O
8 O
, O
and O
16 O
mg O
) O
. O
[]

Enalapril O
did O
not O
alter O
subjective O
ratings O
. O
[]

A O
dose-response O
study O
of O
the O
effect O
of O
levobunolol O
on O
ocular B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Predictors O
of O
recruited O
melanoma O
families O
into O
a O
behavioral O
intervention O
project O
. O
[]

METHODS O
The O
randomised O
controlled O
study O
was O
embedded O
in O
the O
obligatory O
advanced O
life O
support O
( O
ALS O
) O
course O
for O
final-year O
medical O
students O
. O
[]

Healthy O
controls O
showed O
a O
significantly O
larger O
conditioned O
pain B-outcome ['Physiological-Clinical']
modulation I-outcome ['Physiological-Clinical']
response O
compared O
to O
all O
chronic O
pancreatitis O
patients O
taken O
together O
. O
['Physiological-Clinical']

The O
aim O
of O
the O
present O
study O
was O
to O
assess O
the O
effect O
of O
LOLA O
in O
healthy O
patients O
with O
cirrhosis O
and O
no O
evidence O
of O
clinical O
encephalopathy O
after O
challenging O
the O
central O
nervous O
system O
by O
administration O
of O
oral O
glutamine O
. O
[]

ST-segment B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
was O
defined O
as O
an O
average O
value O
below O
-1.00 O
mm O
. O
['Physiological-Clinical']

CONCLUSION O
Reporting O
the O
percentage O
of O
patients O
who O
have O
made O
a O
MCIC O
adds O
to O
the O
interpretability O
of O
study O
results O
. O
[]

STUDY O
DESIGN O
A O
randomized O
controlled O
trial O
of O
2 O
outreach O
interventions O
( O
a O
mail O
reminder O
and O
a O
telephone O
reminder O
plus O
appointment O
scheduling O
) O
compared O
with O
a O
routine O
publicity O
campaign O
to O
encourage O
continued B-outcome ['Life-Impact']
participation I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
mammography I-outcome ['Life-Impact']
screening I-outcome ['Life-Impact']
. O
['Life-Impact']

METHODS O
The O
effects O
of O
captopril O
( O
12.5 O
mg O
and O
25 O
mg O
) O
and O
enalapril O
( O
5 O
mg O
and O
10 O
mg O
) O
administered O
during O
7-day O
periods O
on O
electroencephalogram B-outcome ['Resource-use']
( I-outcome ['Resource-use']
EEG I-outcome ['Resource-use']
) I-outcome ['Resource-use']
, O
cognitive B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
, O
and O
subjective O
assessments O
were O
investigated O
in O
healthy O
males O
. O
['Resource-use', 'Life-Impact']

The O
discriminatory O
potential O
of O
the O
corrected O
PSA B-outcome ['Physiological-Clinical']
value O
is O
better O
at O
predicting O
the O
results O
of O
needle O
biopsy O
of O
the O
prostate O
when O
compared O
with O
PSA O
alone O
. O
['Physiological-Clinical']

Sensitivity O
to O
change O
was O
assessed O
by O
comparing O
change O
from O
baseline O
to O
post-treatment O
with O
change O
on O
the O
Aberrant O
Behavior O
Checklist-Irritability O
and O
Clinical O
Global O
Impressions-Improvement O
subscale O
scores O
in O
a O
subset O
of O
14 O
children O
. O
[]

Pulse O
versus O
continuous O
terbinafine O
for O
onychomycosis O
: O
a O
randomized O
, O
double-blind O
, O
controlled O
trial O
. O
[]

Subjects O
were O
treated O
with O
a O
capsule O
containing O
either O
centrally O
acting O
nicotine O
blocker O
, O
mecamylamine O
( O
10 O
mg O
) O
, O
or O
placebo O
. O
[]

The O
investigator O
and O
volunteers O
assessed O
cosmetic B-outcome ['Life-Impact']
outcomes I-outcome ['Life-Impact']
on O
day O
31 O
+/- O
2 O
. O
['Life-Impact']

Averaged O
convalescence B-outcome ['Life-Impact']
was O
4.7 O
weeks O
in O
the O
TLA O
group O
and O
2.3 O
weeks O
in O
the O
RLA O
group O
( O
p O
= O
0.02 O
) O
. O
['Life-Impact']

A O
sample O
of O
14 O
high-functioning O
adults O
with O
ASD O
and O
a O
demographically-matched O
comparison O
group O
of O
13 O
typically O
developing O
individuals O
participated O
. O
[]

This O
study O
used O
baseline O
data O
collected O
in O
the O
Fall O
of O
2006 O
for O
the O
Sun O
Protection O
for O
Florida O
's O
Children O
( O
SPF O
) O
project O
. O
[]

Kaplan-Meier O
curves O
were O
calculated O
and O
tested O
for O
statistical O
significance O
using O
the O
log-rank O
test O
. O
[]

Patient O
education O
and O
supervised O
exercise O
( O
PE+SE O
) O
. O
[]

They O
may O
thus O
be O
a O
useful O
alternative O
for O
the O
debridement O
of O
root O
surfaces O
. O
[]

No O
signs O
of O
postoperative B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical']

However O
, O
clinical O
symptoms O
are O
less O
likely O
to O
be O
induced O
. O
[]

METHODS O
34 O
patients O
( O
15 O
male O
, O
19 O
female O
) O
participated O
in O
the O
investigation O
, O
with O
a O
total O
of O
68 O
PCC O
restorations O
. O
[]

Change O
in O
exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
( O
peak O
VO B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) O
and O
quality O
of O
life O
( O
secondary O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Recatheterization B-outcome ['Resource-use']
was O
necessary O
in O
3 O
cases O
( O
6.1 O
% O
) O
cases O
in O
the O
PlasmaKinetic O
group O
and O
in O
1 O
( O
2.1 O
% O
) O
in O
the O
TURP O
group O
. O
['Resource-use']

[ O
Rapidity O
of O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
, O
medication B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
with O
reflux O
treatment O
in O
the O
physician O
's O
office O
] O
. O
['Physiological-Clinical', 'Resource-use', 'Life-Impact']

Distinction O
should O
be O
made O
regarding O
chain O
length O
when O
it O
comes O
to O
discussing O
the O
effects O
of O
saturated O
fats O
on O
metabolic O
risk O
factors O
. O
[]

Studies O
performed O
on O
airway O
smooth O
muscle O
in O
vitro O
have O
indicated O
that O
salmeterol O
is O
a O
partial O
agonist O
on O
the O
beta2-receptor O
in O
comparison O
to O
formoterol O
. O
[]

Their O
action O
is O
macrophage-dependent O
and O
the O
dosage O
is O
critical O
. O
[]

CONCLUSIONS O
Epileptiform O
discharges O
are O
common O
in O
SLOS O
, O
despite O
a O
relatively O
low O
prevalence O
of O
epilepsy O
. O
[]

BACKGROUND O
Imiquimod O
is O
an O
immune O
response O
modifier O
that O
up-regulates O
cytokines O
and O
has O
been O
shown O
in O
clinical O
studies O
to O
reduce O
or O
clear O
basal O
cell O
carcinoma O
tumors O
when O
applied O
topically O
. O
[]

However O
, O
this O
idea O
has O
not O
been O
empirically O
evaluated O
. O
[]

The O
TENS O
group O
showed O
a O
significant O
improvement O
that O
persisted O
for O
3 O
weeks O
in O
three O
of O
the O
four O
measures O
. O
[]

No O
statistically O
significant O
difference O
was O
found O
between O
the O
mean O
daily B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scores O
for O
patients O
receiving O
mexiletine O
versus O
placebo O
, O
irrespective O
of O
the O
order O
in O
which O
the O
agents O
were O
received O
. O
['Physiological-Clinical']

In O
pigs O
without O
passively O
acquired O
antibody O
, O
intranasal O
inoculation O
with O
strains O
NIA-3 O
or O
Bartha O
was O
followed O
by O
primary O
IgM B-outcome ['Physiological-Clinical']
and O
IgA B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
in O
serum B-outcome ['Physiological-Clinical']
and O
in O
oropharyngeal B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
as O
well O
as O
primary O
IgG1 O
and O
IgG2 O
responses O
in O
serum O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Amount O
of O
intraoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
( O
surgeons O
' O
subjective O
estimate O
) O
, O
need O
for O
additional B-outcome ['Resource-use']
packings I-outcome ['Resource-use']
, O
need O
for O
electrocautery B-outcome ['Resource-use']
, O
laryngeal B-outcome ['Physiological-Clinical']
spasm B-outcome ['Physiological-Clinical']
, O
postoperative O
bleeding B-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
, O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
procedure I-outcome ['Life-Impact']
and O
duration O
of O
patients O
' O
stay B-outcome ['Resource-use']
in O
the O
operation B-outcome ['Resource-use']
room O
( O
OR O
) O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Resource-use']

During O
phase O
2 O
, O
a O
4-day O
double-blind O
challenge O
period O
, O
subjects O
wore O
active O
and O
placebo O
systems O
concurrently O
. O
[]

The O
medical O
staff O
was O
blind O
to O
the O
nature O
of O
the O
aerosol O
( O
drug O
or O
placebo O
) O
, O
which O
was O
given O
in O
random O
order O
. O
[]

Only O
those O
patients O
who O
have O
finished O
8 O
weeks O
of O
active O
treatment O
in O
both O
groups O
were O
included O
into O
the O
final O
analysis O
. O
[]

It O
is O
estimated O
that O
for O
bladder B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
the O
RBE B-outcome ['Physiological-Clinical']
value I-outcome ['Physiological-Clinical']
, O
for O
photon O
dose O
fractions O
of O
2.75 O
Gy O
, O
is O
less O
than O
3.3 O
for O
early O
reactions O
and O
equal O
to O
3.4 O
for O
late O
effects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Constant O
scores O
were O
significantly O
higher O
after O
6 O
months O
and O
2 O
years O
after O
intramedullary O
stabilization O
. O
[]

One O
HCT O
group O
( O
HCTmax O
) O
completed O
the O
maximal O
repetitions O
possible O
( O
RM O
) O
during O
each O
work O
interval O
. O
[]

[ O
Administration O
of O
tobramycin O
aerosols O
in O
patients O
with O
nosocomial O
pneumonia O
: O
a O
preliminary O
study O
] O
. O
[]

Pain B-outcome ['Physiological-Clinical']
was O
assessed O
by O
visual O
analogue O
scale O
( O
VAS O
) O
and O
the O
lumbar B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
range I-outcome ['Physiological-Clinical']
was O
determined O
before O
and O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
A O
total O
of O
1370 O
people O
participated O
in O
the O
study O
( O
69 O
% O
response O
rate O
) O
. O
[]

Interobserver O
reliability O
was O
calculated O
between O
radiologists O
for O
both O
imaging O
modalities O
, O
and O
intermethod B-outcome ['Physiological-Clinical']
reliability I-outcome ['Physiological-Clinical']
was O
calculated O
between O
the O
2 O
imaging O
modalities O
. O
['Physiological-Clinical']

Complete O
response O
was O
achieved O
by O
four O
( O
20 O
% O
) O
patients O
in O
the O
placebo O
group O
and O
11 O
( O
55 O
% O
) O
patients O
in O
the O
celecoxib O
group O
( O
? O
( O
[]

An O
unfavorable O
outcome O
was O
defined O
as O
posterior B-outcome ['Physiological-Clinical']
retinal I-outcome ['Physiological-Clinical']
detachment I-outcome ['Physiological-Clinical']
, O
retinal B-outcome ['Physiological-Clinical']
fold I-outcome ['Physiological-Clinical']
involving I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
macula I-outcome ['Physiological-Clinical']
, O
or O
retrolental B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Oral O
rizatriptan O
versus O
oral O
sumatriptan O
: O
a O
direct O
comparative O
study O
in O
the O
acute O
treatment O
of O
migraine O
. O
[]

BACKGROUND O
Tiotropium O
bromide O
is O
an O
effective O
therapy O
for O
COPD O
patients O
. O
[]

A O
double-blind O
randomised O
, O
placebo-controlled O
, O
prospective O
trial O
. O
[]

The O
main O
interest O
of O
this O
study O
, O
however O
, O
lies O
in O
its O
methodology O
( O
video O
analysis O
) O
. O
[]

METHODS O
AND O
RESULTS O
The O
11 O
482 O
patients O
enrolled O
in O
the O
Prevention O
of O
REStenosis O
with O
Tranilast O
and O
its O
Outcomes O
( O
PRESTO O
) O
Trial O
were O
stratified O
according O
to O
the O
presence O
( O
n=2694 O
) O
or O
absence O
( O
n=8798 O
) O
of O
diabetes O
. O
[]

If O
the O
ulcer O
was O
still O
present O
at O
this O
time O
, O
the O
second O
endoscopic O
examination O
was O
done O
after O
a O
further O
14 O
days O
. O
[]

Women O
in O
the O
intervention O
group O
received O
a O
6-month O
yoga O
intervention O
in O
addition O
to O
hospital O
routine O
care O
, O
and O
women O
in O
the O
control O
group O
received O
hospital O
routine O
care O
only O
. O
[]

induction O
and O
VEGF O
expression O
and O
may O
serve O
as O
a O
potential O
agent O
in O
the O
prevention O
of O
telangiectasias O
. O
[]

Fibroadenomas O
are O
the O
most O
common O
benign O
breast O
condition O
among O
women O
and O
account O
for O
up O
to O
50 O
% O
of O
all O
breast O
biopsies O
being O
performed O
. O
[]

In O
multiple-dose O
bioequivalence O
studies O
, O
it O
is O
possible O
at O
steady O
state O
to O
take O
repeated O
measurements O
of O
pharmacokinetic B-outcome ['Physiological-Clinical']
variables O
, O
such O
as O
area O
under O
the O
curve O
( O
AUC O
) O
and O
the O
maximum O
concentration O
( O
['Physiological-Clinical']

There O
was O
a O
dose-dependent O
response O
compared O
with O
2 O
g O
daily O
( O
US O
2 O
G O
) O
. O
[]

198 O
( O
52 O
% O
) O
of O
patients O
have O
died O
, O
but O
there O
is O
currently O
no O
evidence O
of O
a O
benefit O
in O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
to O
the O
C O
group O
: O
HR O
1.02 O
( O
95 O
% O
CI O
0.77-1.35 O
) O
, O
P O
= O
0.90 O
) O
. O
['Mortality']

CONCLUSION O
A O
significant O
majority O
preferred O
the O
sedation O
technique O
with O
1-minute O
increment O
intervals O
( O
chi O
2 O
= O
4.6 O
; O
P O
< O
.05 O
) O
. O
[]

No O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
with O
the O
rubber O
hand O
illusion O
. O
['Physiological-Clinical']

A O
prospective O
, O
placebo-controlled O
, O
randomized O
trial O
of O
intravenous O
streptokinase O
and O
angioplasty O
versus O
lone O
angioplasty O
therapy O
of O
acute O
myocardial O
infarction O
. O
[]

It O
is O
concluded O
that O
in O
clinical O
practice O
it O
will O
be O
very O
difficult O
to O
make O
a O
clear O
cut O
recommendation O
about O
treatment O
goal O
at O
initial O
assessment O
except O
in O
a O
few O
cases O
. O
[]

RESULTS O
At O
the O
end O
of O
the O
40-week O
study O
, O
27 O
children O
showed O
significant O
improvement O
in O
their O
motor B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact']

Outcomes O
were O
assessed O
by O
independent O
reviewers O
unaware O
of O
the O
prophylaxis O
allocation O
. O
[]

OBJECTIVES O
Resistance O
to O
standard O
Helicobacter O
pylori O
( O
HP O
) O
treatment O
regimens O
has O
led O
to O
unsatisfactory O
cure O
rates O
in O
HP-infected O
patients O
. O
[]

To O
determine O
whether O
the O
addition O
of O
muramyl O
tripeptide O
( O
MTP O
) O
to O
chemotherapy O
enhances O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
EFS O
) O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
newly O
diagnosed O
patients O
with O
osteosarcoma O
. O
['Mortality', 'Mortality']

The O
behaviors O
were O
observed O
in O
a O
controlled O
environment O
before O
and O
after O
2 O
exercise O
and O
1 O
non-exercise O
conditions O
. O
[]

Results O
indicate O
that O
the O
reduction O
in O
symptoms O
of O
[]

A O
multi-center O
, O
randomized O
, O
controlled O
trial O
of O
parenteral O
nutrition O
titrated O
to O
resting O
energy O
expenditure O
in O
children O
undergoing O
hematopoietic O
stem O
cell O
transplantation O
( O
PNTREE O
) O
: O
rationale O
and O
design O
. O
[]

Patients O
with O
an O
objective O
response O
to O
chemotherapy O
on O
either O
treatment O
arm O
survived B-outcome ['Mortality']
twice O
as O
long O
as O
the O
nonresponders O
. O
['Mortality']

Exenatide O
could O
benefit O
type O
1 O
diabetes O
as O
well O
. O
[]

The O
'antioxidant O
hypothesis O
' O
proposes O
that O
vitamin O
C O
, O
vitamin O
E O
, O
carotenoids O
, O
and O
other O
antioxidants O
occurring O
in O
fruit O
and O
vegetables O
afford O
protection O
against O
heart O
disease O
and O
cancer O
by O
preventing O
oxidative O
damage O
to O
lipids O
and O
to O
DNA O
, O
respectively O
. O
[]

Combined O
insulin O
and O
sulfonylurea O
therapy O
for O
type O
2 O
diabetes B-outcome ['Physiological-Clinical']
may O
improve O
the O
effectiveness O
of O
a O
single O
injection O
of O
insulin O
, O
thereby O
postponing O
the O
need O
for O
multiple O
injections O
. O
['Physiological-Clinical']

Bu O
as O
pretransplant O
conditioning O
therapy O
are O
warranted O
. O
[]

Twenty O
four-hour O
continuous O
electrocardiography O
( O
Holter O
monitoring O
) O
was O
performed O
at O
screening O
and O
after O
2 O
and O
8 O
weeks O
of O
treatment O
. O
[]

The O
primary O
end O
point O
was O
a O
change O
in O
tests O
of O
cardiovascular O
autonomic O
function O
. O
[]

Monoclonal O
antibodies O
in O
Other O
Blood O
Groups O
were O
tested O
with O
random O
blood O
samples O
collected O
from O
the O
various O
ethnic O
groups O
in O
KwaZulu-Natal O
, O
South O
Africa O
, O
and O
with O
samples O
of O
selected O
red O
cell O
phenotypes O
. O
[]

Cronassial O
( O
100 O
mg O
) O
administered O
by O
intramuscular O
( O
IM O
) O
injection O
daily O
provided O
no O
protection O
against O
the O
development O
of O
neuropathic B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

SUBJECTS O
66 O
patients O
with O
the O
chronic O
fatigue O
syndrome O
who O
had O
neither O
a O
psychiatric O
disorder O
nor O
appreciable O
sleep O
disturbance O
. O
[]

In O
the O
group O
with O
only O
one O
invaded O
lymph O
node O
, O
the O
estimated O
relapse B-outcome ['Physiological-Clinical']
rate O
was O
significantly O
lower O
( O
P O
( O
adjusted O
) O
=0.0285 O
) O
and O
the O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
increased O
( O
P O
( O
adjusted O
) O
=0.039 O
) O
in O
the O
TIL+IL-2 O
arm O
compared O
with O
the O
IL-2 O
only O
arm O
. O
['Physiological-Clinical', 'Mortality']

Fourteen O
patients O
affected O
by O
writer O
's O
cramp O
in O
the O
right O
hand O
and O
17 O
age- O
and O
gender-matched O
healthy O
subjects O
were O
recruited O
for O
the O
study O
. O
[]

In O
nonanterior O
wall O
AMI O
, O
treatment O
with O
PTCA O
and O
tPA O
results O
in O
similar O
early O
mortality B-outcome ['Mortality']
, O
although O
PTCA-treated O
patients O
have O
a O
more O
stable O
hospital O
course O
characterized O
by O
reduced O
recurrent B-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
, O
fewer O
subsequent B-outcome ['Resource-use']
invasive I-outcome ['Resource-use']
procedures I-outcome ['Resource-use']
, O
and O
earlier O
discharge B-outcome ['Life-Impact']
. O
['Mortality', 'Physiological-Clinical', 'Resource-use', 'Life-Impact']

In O
addition O
, O
supportive O
work O
was O
undertaken O
with O
families O
. O
[]

Treatment O
with O
palifermin O
showed O
beneficial O
effects O
on O
mucositis B-outcome ['Physiological-Clinical']
, O
but O
no O
significant O
effect O
on O
engraftment B-outcome ['Physiological-Clinical']
, O
acute B-outcome ['Physiological-Clinical']
graft-versus-host I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( O
GVHD B-outcome ['Physiological-Clinical']
) O
, O
or O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Electro-acupuncture O
may O
reduce O
immunologic B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
caused O
by O
chemotherapy O
, O
thus O
it O
can O
be O
used O
as O
the O
auxiliary O
therapy O
for O
patients O
undergoing O
chemotherapy O
. O
['Physiological-Clinical']

lack O
of O
comparison O
groups O
in O
research O
designs O
and O
longitudinal O
follow-up O
data O
) O
. O
[]

Three O
patients O
of O
colorectal O
cancer O
from O
an O
unresectable O
group O
were O
presumed O
to O
have O
micrometastases O
to O
the O
liver O
as O
suggested O
by O
an O
elevated O
serum O
CEA O
level O
. O
[]

There O
was O
a O
9.2-point O
( O
standard O
deviation O
= O
9.6 O
) O
increase O
in O
Differential O
Ability B-outcome ['Life-Impact']
Scales O
score O
over O
the O
8-month O
study O
period O
, O
but O
no O
main O
effect O
of O
program O
. O
['Life-Impact']

After O
two O
weeks O
of O
peroxide O
gel O
use O
prior O
to O
SRP O
, O
mean O
PPD B-outcome ['Physiological-Clinical']
for O
the O
test O
group O
significantly O
decreased O
from O
baseline O
by O
0.21 O
mm O
and O
mean O
BI B-outcome ['Physiological-Clinical']
significantly O
dropped O
by O
0.14 O
; O
clinical O
parameters O
for O
the O
control O
group O
were O
unchanged O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Breast O
Cancer O
Education O
Intervention O
modules O
and O
interventions O
are O
organized O
within O
a O
QOL O
framework O
. O
[]

METHODS O
Healthy O
premenopausal O
women O
were O
randomly O
assigned O
to O
exercise O
0 O
, O
2 O
, O
4 O
, O
or O
7 O
days/week O
for O
6 O
months O
. O
[]

After O
12 O
months O
, O
outcomes O
were O
measured O
to O
determine O
changes O
in O
the O
groups O
in O
social O
interaction O
and O
communication O
. O
[]

Every O
participant O
was O
randomized O
to O
one O
of O
three O
different O
airway O
management O
groups O
( O
LTS-D O
vs O
. O
[]

Recurrence B-outcome ['Physiological-Clinical']
rates O
in O
surgical O
wounds O
were O
less O
than O
1 O
percent O
in O
both O
groups O
( O
P=0.50 O
) O
. O
['Physiological-Clinical']

Enalapril O
and O
eprosartan O
, O
alone O
and O
in O
combination O
, O
were O
used O
to O
determine O
their O
short-term O
effects O
on O
the O
renal O
nitric O
oxide O
system O
and O
renal O
hemodynamics O
of O
human O
subjects O
with O
essential O
hypertension O
. O
[]

CONCLUSIONS O
The O
laparoscopic O
surgery O
in O
combination O
of O
QYJDR O
could O
effectively O
improve O
clinical O
symptoms O
of O
EMs O
patients O
of O
blood B-outcome ['Physiological-Clinical']
stasis I-outcome ['Physiological-Clinical']
and O
toxin B-outcome ['Physiological-Clinical']
accumulation I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, O
promote O
negative O
conversion B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
EMAb I-outcome ['Physiological-Clinical']
, O
lower O
serum B-outcome ['Physiological-Clinical']
CA125 I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
levels O
in O
the O
placebo O
group O
decreased O
gradually O
but O
remained O
high O
during O
the O
study O
period O
. O
[]

PATIENTS O
AND O
METHODS O
Eligible O
patients O
were O
treatment O
naive O
, O
and O
had O
stage O
IIIA O
and O
B O
unresectable O
non-small-cell O
lung O
cancer O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
0/1 O
, O
and O
normal O
organ O
function O
. O
[]

Two O
experiments O
investigated O
sensory/motor-based B-outcome ['Life-Impact']
functional I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
of O
man-made O
objects O
: O
manipulation O
features O
associated O
with O
the O
actual O
usage O
of O
objects O
. O
['Life-Impact']

PURPOSE O
We O
report O
a O
prospective O
, O
randomized O
comparison O
of O
transperitoneal O
laparoscopic O
adrenalectomy O
( O
TLA O
) O
vs O
retroperitoneal O
laparoscopic O
adrenalectomy O
( O
RLA O
) O
for O
adrenal O
lesions O
with O
long-term O
followup O
. O
[]

Fibrin O
application O
for O
preventing O
lymphocysts O
after O
retroperitoneal O
lymphadenectomy O
in O
patients O
with O
gynecologic O
malignancies O
. O
[]

The O
therapy O
became O
effective O
after O
six O
weeks O
of O
training O
. O
[]

Thirty O
minutes O
after O
the O
infusion O
started O
, O
a O
second O
MACISO O
( O
MACISO+drug O
) O
was O
determined O
. O
[]

Cardiac O
failure O
: O
symptoms O
and O
functional O
status O
. O
[]

However O
, O
the O
proportion O
of O
women O
experiencing O
dyspareunia B-outcome ['Physiological-Clinical']
was O
greatest O
among O
those O
who O
had O
an O
episiotomy O
with O
or O
without O
forceps O
. O
['Physiological-Clinical']

BACKGROUND O
Hypertonic O
saline O
improves O
organ B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
and O
patient B-outcome ['Mortality']
survival I-outcome ['Mortality']
during O
hemorrhagic O
shock O
because O
it O
expands O
plasma O
volume O
and O
increases O
tissue O
oxygenation O
. O
['Physiological-Clinical', 'Mortality']

The O
average O
total O
cost B-outcome ['Resource-use']
to O
achieve O
healing B-outcome ['Physiological-Clinical']
was O
$ O
25,954 O
for O
patients O
treated O
with O
NPWT O
( O
n O
= O
43 O
) O
compared O
with O
$ O
38,806 O
for O
the O
MWT O
group O
( O
n O
= O
33 O
) O
. O
['Resource-use', 'Physiological-Clinical']

STATISTICAL O
ANALYSIS O
Sample O
size O
was O
calculated O
to O
achieve O
90 O
% O
power O
at O
an O
alpha O
of O
0.025 O
to O
detect O
a O
non-inferiority O
margin O
of O
?1 O
cm O
on O
the O
VAS O
, O
using O
a O
one-sided O
, O
two-sample O
t-test O
. O
[]

?-Blockers O
in O
patients O
with O
intermittent O
claudication O
and O
arterial O
hypertension O
: O
results O
from O
the O
nebivolol O
or O
metoprolol O
in O
arterial O
occlusive O
disease O
trial O
. O
[]

INTERVENTION O
Participants O
were O
randomly O
assigned O
to O
receive O
risedronate O
35 O
mg/wk O
or O
placebo O
. O
[]

Fifteen O
patients O
completed O
the O
trial O
and O
their O
LDL-C B-outcome ['Physiological-Clinical']
reduced O
from O
5.07 O
+/- O
1.10 O
mmol/L O
to O
3.76 O
+/- O
0.90 O
mmol/L O
with O
the O
combined O
therapy O
and O
to O
3.81 O
+/- O
0.50 O
mmol/L O
with O
the O
intensive O
monotherapy O
. O
['Physiological-Clinical']

The O
data O
further O
indicate O
that O
probiotics O
may O
counteract O
inflammatory B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
beyond O
the O
intestinal O
milieu O
. O
['Physiological-Clinical']

The O
combined O
administration O
of O
MMC O
and O
HCFU O
was O
suggested O
to O
be O
a O
safe O
and O
effective O
adjuvant O
chemotherapy O
for O
noncuratively O
resected O
cases O
of O
colorectal O
carcinoma O
. O
[]

Controlled O
prospective O
trial O
of O
prednisolone O
and O
cytotoxics O
in O
progressive O
IgA O
nephropathy O
. O
[]

Fibrinogen O
and O
plasminogen O
concentrations B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
, O
plasminogen B-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
and O
fibrinolytic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
concentrated I-outcome ['Physiological-Clinical']
euglobulins I-outcome ['Physiological-Clinical']
were O
determined O
before O
surgery O
and O
on O
the O
first O
, O
third O
and O
seventh O
postoperative O
days O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

prolongation B-outcome ['Physiological-Clinical']
of O
the O
claudication B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
, O
while O
in O
a O
comparable O
control O
group O
without O
statins O
the O
efficiency O
deteriorated O
further O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Several O
recent O
studies O
have O
described O
the O
benefits O
of O
fenfluramine O
for O
the O
symptomatic O
treatment O
of O
infantile O
autism O
. O
[]

Contribution O
of O
endogenous O
bradykinin O
to O
fibrinolysis B-outcome ['Physiological-Clinical']
, O
inflammation B-outcome ['Physiological-Clinical']
, O
and O
blood O
product O
transfusion O
following O
cardiac O
surgery O
: O
a O
randomized O
clinical O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Verapamil O
appears O
to O
be O
of O
no O
use O
for O
conversion O
of O
AF B-outcome ['Physiological-Clinical']
or O
AFI B-outcome ['Physiological-Clinical']
to O
sinus O
rhythm O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
management O
of O
dermoid O
cysts O
-- O
a O
comparative O
study O
of O
laparoscopy O
and O
laparotomy O
. O
[]

METHODS O
Randomised O
, O
single-blind O
multicentre O
trial O
in O
four O
university O
hospitals O
in O
Germany O
including O
276 O
primigravidae O
. O
[]

In O
the O
sibutramine O
group O
, O
mean O
thermogenic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
changed O
from O
a O
baseline O
value O
of O
1.27+/-0.29 O
kcal/kg/h O
to O
1.44+/-0.13 O
kcal/kg/h O
after O
12 O
wk O
of O
treatment O
. O
['Physiological-Clinical']

Oxaprozin O
versus O
diclofenac O
in O
NSAID-refractory O
periarthritis O
pain O
of O
the O
shoulder O
. O
[]

The O
survival B-outcome ['Mortality']
until O
definitive O
global O
health O
score O
( O
GHS O
['Mortality']

The O
Chinese B-outcome ['Physiological-Clinical']
medicine I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
integral I-outcome ['Physiological-Clinical']
after O
drug O
therapy O
was O
lower O
than O
that O
before O
drug O
therapy O
in O
the O
same O
group O
. O
['Physiological-Clinical']

CONCLUSION O
CFNB O
represents O
the O
optimal O
analgesia O
with O
fewer O
side O
effects O
and O
greater O
patient O
, O
satisfaction B-outcome ['Life-Impact']
. O
['Life-Impact']

No O
significant O
difference O
of O
pain B-outcome ['Physiological-Clinical']
and O
walking B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
after O
further O
nonsurgical O
treatment O
( O
3 O
months O
) O
was O
seen O
in O
group O
2 O
. O
['Physiological-Clinical', 'Life-Impact']

In O
a O
companion O
study O
, O
chronic O
bumetanide O
treatment O
significantly O
improved O
accuracy O
in O
facial O
emotional O
labelling O
, O
and O
increased O
brain O
activation O
in O
areas O
involved O
in O
social O
and O
emotional O
perception O
( O
Hadjikhani O
et O
al. O
, O
submitted O
) O
. O
[]

CONCLUSIONS O
Applying O
TBNA O
to O
EBUS-guided O
CDPs O
further O
increased O
the O
diagnostic O
yield O
of O
PPLs O
without O
additional O
risk O
. O
[]

Two O
infants O
from O
each O
group O
achieved O
the O
in O
utero B-outcome ['Physiological-Clinical']
accretion I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
copper I-outcome ['Physiological-Clinical']
for O
a O
34-week O
gestation O
fetus O
( O
0.088 O
mg/d O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
Although O
the O
overall O
mood O
profiles O
were O
similar O
for O
the O
users O
of O
any O
of O
the O
standard O
malaria O
chemoprophylaxis O
regimens O
, O
we O
found O
that O
women O
using O
mefloquine O
showed O
more O
fatigue O
and O
confusion O
than O
men O
and O
that O
younger O
persons O
aged O
less O
than O
34 O
years O
, O
regardless O
of O
chemoprophylaxis O
used O
, O
reported O
more O
tension O
and O
fatigue O
than O
their O
older O
counterparts O
. O
[]

RESULTS O
After O
8 O
weeks O
of O
initial O
treatment O
, O
the O
mean O
total O
, O
inattention B-outcome ['Life-Impact']
, O
and O
hyperactivity-impulsivity B-outcome ['Life-Impact']
ADHD-RS O
further O
decreased O
significantly O
from O
34.9 O
to O
27.0 O
for O
the O
total O
ADHD-RS O
, O
from O
18.3 O
to O
14.5 O
for O
the O
ADHD-RS O
inattention I-outcome ['Life-Impact']
subscale O
, O
and O
from O
16.5 O
to O
12.6 O
for O
the O
hyperactivity-impulsivity B-outcome ['Life-Impact']
subscale O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Before O
sessions O
subjects O
received O
oral O
doses O
of O
mecamylamine O
( O
2.5 O
, O
5.0 O
, O
10 O
, O
20 O
mg O
) O
or O
placebo O
. O
[]

Area O
under O
the O
curve O
analysis O
of O
activity O
interference O
from O
the O
Brief B-outcome ['Physiological-Clinical']
Fatigue I-outcome ['Physiological-Clinical']
Inventory I-outcome ['Physiological-Clinical']
was O
460-467 O
in O
the O
placebo O
group O
and O
750 O
mg/day O
group O
versus O
480-551 O
in O
the O
1,000- O
and O
2,000-mg/day O
arms O
, O
respectively O
. O
['Physiological-Clinical']

Prevalence O
and O
treatment O
outcome O
of O
cervicitis B-outcome ['Physiological-Clinical']
of O
unknown O
etiology O
. O
['Physiological-Clinical']

PURPOSE O
To O
determine O
whether O
participation O
in O
aerobic O
exercise O
before O
classroom O
activities O
improves O
academic O
engagement O
and O
reduces O
stereotypic O
behaviors O
in O
young O
children O
with O
autism O
spectrum O
disorder O
. O
[]

The O
effects O
of O
the O
angiotensin-converting O
enzyme O
lisinopril O
were O
compared O
with O
those O
of O
the O
calcium O
antagonist O
nifedipine O
in O
162 O
non-insulin-dependent O
diabetic O
hypertensive O
patients O
for O
a O
24-week O
period O
. O
[]

Transcutaneous O
electrical O
nerve O
stimulation O
combined O
with O
task-related O
training O
improves O
lower B-outcome ['Physiological-Clinical']
limb I-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
in O
subjects O
with O
chronic O
stroke O
. O
['Physiological-Clinical']

[ O
Effect O
of O
liu O
wei O
di O
huang O
or O
jin O
gui O
shen O
qi O
decoction O
as O
on O
adjuvant O
treatment O
in O
small O
cell O
lung O
cancer O
] O
. O
[]

Manual O
grading O
of O
emboli B-outcome ['Physiological-Clinical']
correlated O
highly O
with O
software O
quantification O
. O
['Physiological-Clinical']

METHODS O
Blood O
samples O
from O
41 O
patients O
randomized O
to O
the O
control O
, O
nitric O
oxide O
( O
20 O
ppm O
) O
, O
iloprost O
( O
2 O
ng O
x O
kg O
-1 O
x O
min O
-1 O
) O
, O
or O
nitric O
oxide O
plus O
iloprost O
groups O
were O
collected O
during O
cardiopulmonary O
bypass O
. O
[]

In O
the O
experimental O
groups O
, O
plaque O
samples O
were O
collected O
from O
selected O
sound O
and O
carious O
root O
surfaces O
at O
baseline O
and O
at O
three O
, O
six O
, O
and O
nine O
months O
after O
the O
onset O
of O
the O
study O
. O
[]

The O
two O
groups O
did O
not O
differ O
with O
regard O
to O
AUC O
( O
[]

Assessment O
of O
the O
severity O
of O
symptoms O
and O
associated O
disability O
, O
both O
before O
and O
after O
treatment O
, O
was O
completed O
at O
detailed O
interviews O
by O
a O
physician O
and O
psychiatrist O
, O
who O
were O
unaware O
of O
the O
treatment O
status O
. O
[]

Effect O
of O
systemic O
nitric O
oxide O
synthase O
inhibition O
on O
postexercise O
hypotension O
in O
humans O
. O
[]

Rapid B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
, O
with O
most O
Cmax B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
from O
50-60 O
micrograms/ml O
reached O
within O
1.5-3 O
h O
, O
was O
found O
for O
both O
tablet O
formulations O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
crossover O
study O
in O
patients O
with O
leukaemia O
showed O
that O
insertion B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
reduced O
by O
20 O
seconds O
( O
8 O
to O
32 O
, O
P=0.013 O
) O
with O
active O
warming O
and O
that O
failure B-outcome ['Physiological-Clinical']
rates O
at O
first O
attempt O
were O
6 O
% O
with O
warming O
and O
30 O
% O
with O
passive O
insulation O
( O
P O
< O
0.001 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

The O
patients O
were O
randomly O
divided O
into O
3 O
groups O
as O
A O
, O
B O
and O
C O
for O
study O
. O
[]

To O
compare O
the O
imaging B-outcome ['Life-Impact']
capability I-outcome ['Life-Impact']
of O
the O
multiplane O
probe O
with O
that O
of O
the O
biplane O
probe O
, O
317 O
consecutive O
patients O
were O
randomized O
to O
undergo O
transesophageal O
echocardiography O
with O
either O
probe O
. O
['Life-Impact']

METHODS O
Thirty-one O
adults O
( O
age O
[ O
mean+/-SD O
] O
, O
28.1+/-7.3 O
years O
) O
with O
autistic O
disorder O
( O
n=17 O
) O
or O
pervasive O
developmental O
disorder O
not O
otherwise O
specified O
( O
n=14 O
) O
participated O
in O
a O
12-week O
double-blind O
, O
placebo-controlled O
trial O
of O
risperidone O
. O
[]

An O
accompanying O
increase O
in O
bleeding B-outcome ['Physiological-Clinical']
risk O
also O
was O
not O
apparent O
with O
lower O
CrCl O
. O
['Physiological-Clinical']

Effects O
of O
nifedipine O
and O
nitrendipine O
on O
insulin B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
obese O
patients O
. O
['Physiological-Clinical']

Root O
cause O
analysis O
( O
RCA O
) O
has O
been O
implemented O
to O
prevent O
such O
errors O
. O
[]

Comparisons O
were O
also O
made O
for O
self-reported O
breast O
symptoms O
occurring O
during O
the O
study O
period O
and O
for O
changes O
in O
serum O
values O
of O
antinuclear O
antibodies O
, O
rheumatoid O
factor O
, O
and O
cardiolipin O
antibodies O
immunoglobulin O
G O
and O
immunoglobulin O
M. O
The O
majority O
of O
the O
women O
with O
implant O
rupture O
had O
no O
visible O
magnetic B-outcome ['Physiological-Clinical']
resonance I-outcome ['Physiological-Clinical']
imaging I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
of O
their O
ruptured O
implants O
. O
['Physiological-Clinical']

Furthermore O
, O
measures O
to O
further O
increase O
the O
proportion O
of O
ursodeoxycholic O
acid O
in O
circulating O
bile O
acids O
should O
be O
explored O
. O
[]

The O
aim O
was O
to O
evaluate O
the O
efficacy O
and O
tolerability O
of O
a O
short-term O
parenteral O
prophylaxis O
with O
Teicoplanin O
and O
the O
end-point O
of O
the O
study O
was O
the O
evaluation O
of O
wound O
contamination O
assessed O
by O
means O
of O
microbiologic O
culture O
of O
drainage O
fluid O
. O
[]

BACKGROUND O
The O
objective O
was O
to O
evaluate O
efficacy O
and O
safety O
of O
rapid O
, O
large-dose O
intravenous O
( O
IV O
) O
administration O
of O
ferric O
carboxymaltose O
compared O
to O
oral O
iron O
in O
correcting O
iron O
deficiency O
anemia O
due O
to O
heavy O
uterine O
bleeding O
. O
[]

Pharmacokinetic B-outcome ['Physiological-Clinical']
and O
safety O
assessments O
of O
galantamine O
and O
risperidone O
after O
the O
two O
drugs O
are O
administered O
alone O
and O
together O
. O
['Physiological-Clinical']

The O
CER O
group O
had O
three O
times O
more O
cardiac B-outcome ['Physiological-Clinical']
diagnoses B-outcome ['Physiological-Clinical']
than O
the O
UC O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Adherence O
was O
measured O
by O
prescription O
refill O
, O
pill O
count O
, O
and O
self-report O
. O
[]

Theta O
burst O
stimulation O
in O
the O
rehabilitation O
of O
the O
upper O
limb O
: O
a O
semirandomized O
, O
placebo-controlled O
trial O
in O
chronic O
stroke O
patients O
. O
[]

This O
sample O
of O
38 O
was O
a O
subset O
of O
101 O
subjects O
who O
participated O
in O
the O
clinical O
trial O
; O
63 O
were O
unable O
to O
perform O
the O
cognitive O
tasks O
. O
[]

PURPOSE/OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
test O
the O
utility O
of O
the O
Working O
Well O
with O
a O
Disability O
health-promotion O
program O
with O
vocational O
rehabilitation O
( O
VR O
) O
clients O
. O
[]

RESULTS O
Overall O
, O
gastric B-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
> O
or O
= O
3 O
mm O
were O
observed O
in O
18 O
( O
6.0 O
% O
) O
of O
300 O
evaluable O
subjects O
in O
the O
risedronate O
group O
and O
36 O
( O
12.1 O
% O
) O
of O
297 O
in O
the O
alendronate O
group O
during O
treatment O
( O
p O
= O
0.013 O
) O
. O
['Physiological-Clinical']

CONCLUSION O
Cardioversion O
resulted O
in O
a O
sustained O
improvement O
in O
exercise O
capacity O
over O
the O
course O
of O
1 O
year O
, O
and O
this O
improvement O
was O
similar O
between O
those O
in O
SR O
and O
those O
with O
SR O
and O
recurrent O
AF O
. O
[]

BACKGROUND O
A O
large O
body O
of O
evidence O
suggests O
that O
fine O
particulate O
matter O
( O
PM O
) O
air O
pollution O
is O
a O
cause O
of O
cardiovascular O
disease O
, O
but O
little O
is O
known O
in O
particular O
about O
the O
cardiovascular O
effects O
of O
indoor O
air O
pollution O
from O
household O
use O
of O
solid O
fuels O
in O
developing O
countries O
. O
[]

Patients O
with O
platinum-sensitive O
tumours O
survived O
longer O
when O
they O
were O
treated O
with O
platinum-containing O
chemotherapy O
( O
P O
= O
0.005 O
) O
. O
[]

The O
authors O
present O
a O
computational O
neural-network O
model O
of O
how O
the O
hippocampus O
and O
medial O
temporal O
lobe O
cortex O
( O
MTLC O
) O
contribute O
to O
recognition B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
. O
['Life-Impact']

In O
contrast O
, O
cotinine B-outcome ['Physiological-Clinical']
( O
serum O
, O
8.9 O
+/- O
3.2 O
vs. O
35.5 O
+/- O
10.2 O
ng O
x O
ml O
( O
-1 O
) O
) O
, O
IL-4 O
( O
41.3 O
+/- O
5.8 O
vs. O
44.2 O
+/- O
4.5 O
pg O
x O
ml O
( O
-1 O
) O
) O
, O
IL-5 O
( O
36.1 O
+/- O
3.2 O
vs. O
60.1 O
+/- O
7.0 O
pg O
x O
ml O
( O
-1 O
) O
) O
, O
IL-6 O
( O
2.5 O
+/- O
0.3 O
vs. O
7.6 O
+/- O
1.4 O
pg O
x O
ml O
( O
-1 O
) O
) O
and O
IFN-gamma B-outcome ['Physiological-Clinical']
( O
0.3 O
+/- O
0.2 O
vs. O
0.6 O
+/- O
0.2 O
IU O
x O
ml O
( O
-1 O
) O
) O
at O
3 O
hours O
were O
higher O
than O
at O
baseline O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIM O
In O
our O
randomized O
prospective O
study O
, O
we O
aimed O
to O
evaluate O
the O
efficiency O
of O
plasmakinetic O
resection O
of O
prostate O
( O
PKRP O
) O
by O
comparing O
the O
preoperative O
and O
postoperative O
results O
of O
the O
transurethral O
resection O
of O
prostate O
( O
TURP O
) O
and O
PKRP O
techniques O
which O
we O
administered O
in O
patients O
with O
benign O
prostate O
hyperplasia O
( O
BPH O
) O
in O
our O
clinic O
. O
[]

Individuals O
with O
autism O
appear O
to O
have O
access O
to O
a O
similar O
representation O
of O
voluntary B-outcome ['Life-Impact']
movements I-outcome ['Life-Impact']
, O
however O
this O
representation O
may O
be O
more O
variable O
. O
['Life-Impact']

Combination O
acetaminophen O
and O
propoxyphene O
napsylate O
was O
the O
only O
supplemental O
analgesic O
medication O
allowed O
. O
[]

The O
two O
groups O
showed O
no O
differences O
in O
measurements O
of O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
FEV1 B-outcome ['Physiological-Clinical']
, O
and O
FVC B-outcome ['Physiological-Clinical']
at O
baseline O
and O
at O
the O
end O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Inhaled O
nitric O
oxide O
( O
NO O
) O
improves O
systemic O
oxygenation O
( O
PaO2/FIO2 O
) O
in O
adult O
patients O
with O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
. O
[]

At O
the O
end O
of O
the O
intervention O
, O
41.7 O
% O
and O
75.0 O
% O
of O
the O
patients O
who O
received O
cocoa O
husk O
supplementation O
or O
placebo O
, O
respectively O
, O
[]

Similarly O
no O
differences O
were O
evident O
in O
subtype O
analysis O
. O
[]

CONCLUSIONS O
Risperidone O
showed O
persistent O
efficacy O
and O
good O
tolerability B-outcome ['Life-Impact']
for O
intermediate-length O
treatment O
of O
children O
with O
autism O
characterized O
by O
tantrums O
, O
aggression O
, O
and/or O
self-injurious O
behavior O
. O
['Life-Impact']

Ondansetron O
is O
widely O
believed O
to O
prevent O
postoperative O
vomiting B-outcome ['Physiological-Clinical']
more O
effectively O
than O
nausea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Both O
diazepam O
and O
midazolam O
were O
shown O
to O
be O
effective O
sedative O
agents O
, O
successfully O
and O
safely O
used O
to O
sedate O
autistic O
patients O
for O
dental O
treatment O
. O
[]

Knowledge O
and O
attitudinal O
changes O
were O
maintained O
at O
follow-up O
. O
[]

Effects O
of O
an O
Internet-based O
intervention O
on O
plasma B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
in O
patients O
with O
type O
2 O
diabetes O
. O
['Physiological-Clinical']

Glass O
ionomer O
cement O
with O
10 O
% O
bioactive O
glass O
showed O
better O
adhesion B-outcome ['Physiological-Clinical']
and O
spreading B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
than O
glass O
ionomer O
cement O
with O
0.01 O
% O
collagen O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
sample O
of O
68 O
patients O
is O
required O
. O
[]

Results O
suggest O
that O
children O
in O
the O
treatment O
group O
made O
significantly O
greater O
gains O
in O
social B-outcome ['Life-Impact']
interaction O
skills B-outcome ['Life-Impact']
in O
comparison O
to O
the O
community O
treatment O
group O
, O
but O
no O
between-group O
differences O
were O
found O
for O
standard B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
assessments I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

PURPOSE O
To O
compare O
the O
efficacy O
and O
safety O
between O
low-fluence O
photodynamic O
therapy O
( O
PDT O
) O
and O
the O
intravitreal O
ranibizumab O
in O
the O
treatment O
of O
chronic O
central O
serous O
chorioretinopathy O
( O
CSC O
) O
. O
[]

Nevertheless O
, O
their O
usefulness O
remains O
uncertain O
and O
contradictory O
. O
[]

The O
impact O
of O
patient O
and O
physician O
computer O
mediated O
communication O
skill O
training O
on O
reported O
communication O
and O
patient O
satisfaction O
. O
[]

CONCLUSIONS O
Gas O
extraction O
decreased O
the O
level O
of O
exposure B-outcome ['Physiological-Clinical']
by O
up O
to O
94 O
% O
, O
achieving O
levels O
that O
were O
below O
the O
recommended O
limits O
and O
greatly O
reducing O
occupational B-outcome ['Physiological-Clinical']
risk O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
This O
was O
a O
multicenter O
, O
open-label O
, O
pilot O
study O
enrolling O
consecutive O
non-ulcer O
dyspepsia O
patients O
with O
H. O
pylori O
infection O
never O
previously O
treated O
for O
the O
infection O
. O
[]

Lung B-outcome ['Physiological-Clinical']
volume-to-heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
spectral I-outcome ['Physiological-Clinical']
coherence I-outcome ['Physiological-Clinical']
was O
highest O
at O
frequencies O
associated O
with O
respiration O
and O
greater O
in O
young O
than O
in O
older O
subjects O
( O
P O
< O
0.07 O
) O
. O
['Physiological-Clinical']

[ O
Plasma O
separation O
combined O
with O
CVVHF O
in O
septic O
and O
SIRS O
patients O
] O
. O
[]

5 O
% O
of O
patients O
, O
except O
infection O
, O
fatigue O
, O
and O
pain O
. O
[]

CONCLUSION O
Efforts O
to O
counsel O
women O
about O
their O
breast O
cancer O
risks O
are O
not O
likely O
to O
be O
effective O
unless O
their O
breast O
cancer O
anxieties O
are O
also O
addressed O
. O
[]

There O
was O
no O
correlation O
between O
PSA B-outcome ['Physiological-Clinical']
response B-outcome ['Physiological-Clinical']
and O
survival B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

The O
effects O
of O
consuming O
a O
liquid O
formula O
containing O
either O
fish O
oil O
enriched O
in O
omega-3 O
fatty O
acids O
or O
vegetable O
oil O
enriched O
in O
oleic O
acid O
was O
evaluated O
in O
20 O
male O
subjects O
randomly O
allocated O
into O
two O
groups O
over O
a O
42-d O
period O
. O
[]

Immediately O
after O
the O
CETs O
horses O
were O
allowed O
water O
ad O
libitum O
and O
either O
: O
1 O
) O
8 O
L O
of O
a O
hypertonic O
NaAcetate/acetic O
acid O
solution O
via O
nasogastric O
tube O
followed O
by O
a O
typical O
hay/grain O
meal O
( O
NAA O
trial O
) O
; O
or O
2 O
) O
a O
hay/grain O
meal O
alone O
( O
Control O
trial O
) O
. O
[]

OBJECTIVE O
To O
compare O
levels O
of O
serum O
LH O
during O
continued O
use O
of O
leuprolide O
acetate O
( O
LA O
) O
with O
levels O
during O
the O
first O
week O
after O
discontinuing O
LA O
. O
[]

In O
random O
order O
, O
subjects O
either O
breathed O
room O
air O
, O
hypoxia O
( O
target O
SPo2 O
= O
85 O
% O
) O
, O
or O
hyperoxia O
( O
FiO2 O
= O
1.0 O
) O
during O
the O
PECO O
to O
modulate O
the O
chemoreflex O
. O
[]

Decreased O
erythrocyte B-outcome ['Physiological-Clinical']
deformability I-outcome ['Physiological-Clinical']
could O
play O
a O
role O
in O
the O
cyclosporin-induced O
deterioration O
of O
renal O
haemodynamics O
. O
['Physiological-Clinical']

Patients O
were O
followed O
up O
annually O
through O
August O
1989 O
. O
[]

INTERPRETATION O
Interventions O
should O
focus O
at O
increasing O
physical O
activity O
at O
the O
weekend O
for O
children O
with O
bilateral O
spastic O
CP O
. O
[]

In O
addition O
, O
the O
BOP B-outcome ['Physiological-Clinical']
percentage I-outcome ['Physiological-Clinical']
was O
determined O
10 O
days O
following O
baseline O
. O
['Physiological-Clinical']

A O
coronary O
arteriography O
was O
done O
on O
study O
entry O
. O
[]

Dofequidar O
is O
a O
novel O
, O
orally O
active O
quinoline O
derivative O
that O
reverses O
multidrug O
resistance O
. O
[]

Preliminary O
results O
of O
controlled O
randomized O
trials O
implemented O
from O
the O
EORTC O
Urological O
Group O
show O
that O
adriamycin O
instillations O
significantly O
reduce O
recurrence B-outcome ['Physiological-Clinical']
rate O
after I-outcome ['Physiological-Clinical']
TUR I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
day O
before O
and O
24 O
h O
after O
the O
allergen O
provocation O
, O
patients O
were O
challenged O
with O
methacholine O
( O
Mth O
) O
( O
until O
FEV1 O
fell O
by O
40 O
% O
) O
and O
blood O
and O
sputum O
samples O
were O
obtained O
. O
[]

Increase O
in O
2-long O
terminal O
repeat O
circles O
and O
decrease O
in O
D-dimer O
after O
raltegravir O
intensification O
in O
patients O
with O
treated O
HIV O
infection O
: O
a O
randomized O
, O
placebo-controlled O
trial O
. O
[]

Composite O
incidences O
of O
death B-outcome ['Mortality']
, O
myocardial O
infarction O
, O
and O
urgent O
revascularization O
until O
day O
30 O
were O
not O
significantly O
different O
between O
the O
groups O
( O
ARG250 O
: O
2.8 O
% O
, O
ARG300 O
: O
0.0 O
% O
, O
ARG350 O
: O
3.2 O
% O
vs. O
UFH O
: O
3.0 O
% O
) O
. O
['Mortality']

We O
studied O
94 O
patients O
( O
mean O
age O
, O
35.6 O
+/- O
11.2 O
years O
) O
with O
moderate O
to O
severe O
acute O
asthma O
. O
[]

SETTING O
Hypertensive O
families O
of O
East O
African O
descent O
from O
the O
general O
population O
in O
the O
Seychelles O
. O
[]

At O
baseline O
, O
pain/discomfort B-outcome ['Physiological-Clinical']
was O
the O
dimension O
showing O
the O
highest O
percentage O
of O
women O
reporting O
problems O
: O
86.4 O
% O
vs O
83.2 O
% O
in O
groups O
A O
and O
B O
, O
respectively O
( O
P=0.22 O
) O
. O
['Physiological-Clinical']

Age O
and O
gender O
were O
balanced O
within O
each O
group O
. O
[]

As O
compared O
with O
placebo O
, O
angiotensin O
II O
infusion O
alone O
caused O
significant O
reductions O
in O
absolute B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
, O
fractional B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
, O
urine B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
effective B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( O
all O
P O
< O
0.001 O
vs O
placebo O
) O
but O
had O
no O
effect O
on O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CLINICAL O
TRIAL O
REGISTRATION O
ClinicalTrials.gov O
, O
www.ClinicalTrials.gov O
, O
NCT00918996 O
. O
[]

Individuals O
who O
received O
education O
pre-discharge O
were O
compared O
to O
individuals O
who O
received O
education O
post-discharge O
on O
the O
outcomes O
. O
[]

During O
the O
treatment O
with O
IFN-alpha2b O
, O
a O
second O
increase O
in O
the O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
was O
observed O
, O
which O
was O
caused O
by O
an O
increase O
in O
CD4+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
used O
competing O
risks O
methodology O
to O
analyze O
death O
without O
transplantation O
, O
cardiac O
transplantation O
, O
and O
survival O
without O
transplantation O
. O
[]

Use O
of O
a O
lower O
concentration O
of O
ropivacaine-fentanyl O
may O
further O
improve O
analgesia O
or O
decrease O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

No O
serious B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
were O
reported O
in O
either O
group O
. O
['Adverse-effects']

RESULTS O
Caregivers O
in O
the O
IOL O
group O
reported O
higher O
levels O
of O
stress O
than O
those O
in O
the O
CL O
group O
3 O
months O
after O
surgery O
, O
but O
there O
were O
no O
group O
differences O
in O
stress O
scores O
at O
the O
post-VA O
assessment O
. O
[]

The O
addition O
of O
bioactive O
glass O
improved O
the O
biocompatibility O
of O
glass O
ionomer O
cement O
to O
fibroblasts O
better O
than O
addition O
of O
collagen O
. O
[]

CONCLUSION O
Our O
study O
provides O
additional O
support O
for O
the O
use O
of O
modified O
CIMT O
during O
a O
subacute O
rehabilitation O
period O
of O
poststroke O
patients O
. O
[]

Strip O
use O
( O
peroxide O
or O
placebo O
) O
was O
for O
30 O
minutes O
, O
twice O
daily O
for O
2 O
weeks O
, O
while O
dentifrice O
use O
was O
at O
least O
twice O
daily O
for O
12 O
weeks O
. O
[]

SETTING O
A O
tertiary O
referral O
center O
. O
[]

However O
, O
the O
standard O
error O
of O
the O
estimate O
of O
the O
change O
represented O
59 O
% O
of O
the O
observed O
change O
. O
[]

RESULTS O
Baseline O
blood O
pressures O
, O
electrocardiographic O
and O
echocardiographic O
findings O
, O
and O
atrial O
electromechanical O
coupling O
were O
similar O
in O
both O
groups O
( O
p O
> O
0.05 O
) O
. O
[]

RESULTS O
Repeated-measures O
analysis O
of O
variance O
indicated O
a O
significant O
interaction O
effect O
of O
transcranial O
direct O
current O
stimulation O
type O
and O
time O
on O
the O
recognition B-outcome ['Life-Impact']
accuracy I-outcome ['Life-Impact']
. O
['Life-Impact']

CONCLUSIONS O
Post-myocardial O
infarction O
interventions O
that O
reduce O
psychological O
distress O
have O
the O
potential O
to O
improve O
long-term O
prognosis O
and O
psychological B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
for O
both O
men O
and O
women O
. O
['Life-Impact']

The O
role O
of O
ethnic O
matching O
between O
patient O
and O
provider O
on O
the O
effectiveness O
of O
brief O
alcohol O
interventions O
with O
Hispanics O
. O
[]

Furthermore O
, O
men O
responded O
better O
than O
women O
. O
[]

In O
addition O
, O
opioids O
often O
provide O
insufficient O
pain O
relief O
. O
[]

Clinical O
trials O
in O
chronic O
schizophrenic O
patients O
have O
shown O
trends O
in O
favor O
of O
risperidone O
in O
the O
control O
of O
negative O
symptoms B-outcome ['Life-Impact']
compared O
with O
haloperidol O
, O
perphenazine O
or O
zuclopenthixol O
, O
but O
the O
differences O
were O
not O
consistently O
statistically O
significant O
. O
['Life-Impact']

The O
combination O
of O
these O
two O
modalities O
in O
relieving O
post-thoracotomy B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
improving O
postoperative B-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
has O
not O
been O
investigated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Additionally O
, O
JASP/ER O
children O
spent O
more O
time O
in O
supported O
engagement O
and O
less O
time O
in O
object O
engagement O
than O
control O
preschoolers O
on O
a O
taped O
play O
interaction O
. O
[]

Efficacy O
( O
based O
upon O
the O
decrease O
in O
PVC/hour O
in O
a O
24 O
hour O
Holter O
) O
and O
tolerability O
were O
evaluated O
at O
the O
end O
of O
each O
sequence O
, O
with O
samples O
drawn O
at O
the O
same O
times O
for O
assay O
of O
the O
study O
drugs O
. O
[]

There O
were O
no O
complications B-outcome ['Resource-use']
in O
the O
4-hour O
group O
. O
['Resource-use']

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
below-knee O
amputation O
on O
the O
hip O
isometric O
muscle O
strength O
and O
effect O
of O
rehabilitation O
on O
improvement O
of O
hip O
muscle O
strength O
in O
below-knee O
amputees O
, O
secondary O
to O
war O
wounding O
. O
[]

Confounding O
perinatal O
factors O
such O
as O
maternal B-outcome ['Physiological-Clinical']
position O
, O
maternal B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
, O
and O
prolonged O
time O
of O
surgery O
did O
not O
influence O
the O
fetal O
acid-base O
status O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Their O
persistent O
sleeplessness O
was O
tentatively O
attributed O
to O
an O
undiagnosed O
intolerance O
to O
cow O
's O
milk O
. O
[]

Overall O
response B-outcome ['Physiological-Clinical']
by O
means O
of O
complete O
control O
of O
both O
vomiting B-outcome ['Physiological-Clinical']
and O
nausea B-outcome ['Physiological-Clinical']
during O
the O
whole O
therapy O
period O
was O
29 O
% O
of O
tropisetron O
group O
and O
55 O
% O
of O
granisetron O
group O
( O
p O
= O
0.007 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Parent-based O
sleep O
education O
, O
delivered O
in O
relatively O
few O
sessions O
, O
was O
associated O
with O
improved O
sleep O
onset O
delay O
in O
children O
with O
ASD O
. O
[]

OBJECTIVES O
We O
explored O
whether O
a O
successful O
randomized O
controlled O
trial O
of O
early O
education O
, O
the O
Carolina O
Abecedarian O
Project O
( O
ABC O
) O
, O
which O
enrolled O
infants O
from O
1972 O
to O
1977 O
at O
the O
Frank O
Porter O
Graham O
Child O
Development O
Institute O
in O
Chapel O
Hill O
, O
North O
Carolina O
, O
improved O
health O
outcomes O
and O
behaviors O
by O
21 O
years O
of O
age O
. O
[]

Before O
and O
after O
treatment O
, O
blood O
samples O
were O
collected O
and O
the O
flow-mediated B-outcome ['Physiological-Clinical']
dilation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
isosorbide B-outcome ['Physiological-Clinical']
dinitrate I-outcome ['Physiological-Clinical']
( O
ISDN B-outcome ['Physiological-Clinical']
) O
-mediated O
dilation B-outcome ['Physiological-Clinical']
of O
the O
brachial O
artery O
were O
performed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Risk O
comprehension B-outcome ['Life-Impact']
was O
assessed O
as O
the O
concordance O
between O
perceived O
subjective O
lifetime O
breast O
cancer O
risk O
and O
estimated O
objective O
lifetime O
risk O
. O
['Life-Impact']

0 O
microg/mL O
by O
using O
computer-assisted O
target-controlled O
infusion O
to O
3 O
groups O
of O
healthy O
male O
patients O
: O
Control O
( O
n O
= O
35 O
) O
, O
2.5 O
microg/kg O
Clonidine O
( O
n O
= O
36 O
) O
, O
and O
5.0 O
microg/kg O
Clonidine O
( O
n O
= O
36 O
) O
groups O
. O
[]

Children O
( O
N O
= O
576 O
; O
M O
age O
= O
10.06 O
) O
were O
randomly O
assigned O
to O
view O
two O
videotapes O
of O
a O
boy O
engaging O
in O
typical O
and O
autistic O
behaviors O
receiving O
either O
descriptive O
( O
AUT-D O
) O
or O
descriptive O
and O
explanatory O
information O
( O
AUT-D O
+ O
E O
) O
. O
[]

Treatment O
of O
acute O
ischaemic O
stroke O
with O
the O
low-affinity O
, O
use-dependent O
NMDA O
antagonist O
AR-R15896AR O
. O
[]

Because O
implant O
ruptures O
often O
occur O
asymptomatically O
, O
any O
woman O
with O
silicone O
implants O
, O
regardless O
of O
rupture O
status O
, O
should O
be O
evaluated O
at O
regular O
intervals O
. O
[]

RESULTS O
Hernia B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
occurred O
in O
six O
patients O
after O
Shouldice O
repair O
, O
and O
in O
one O
patient O
each O
after O
Lichtenstein O
and O
TAPP O
repairs O
. O
['Physiological-Clinical']

The O
results O
of O
that O
double-blind O
, O
placebo-controlled O
study O
suggest O
that O
fluoxetine O
was O
effective O
in O
decreasing O
but O
not O
eliminating O
both O
the O
depressive O
symptoms O
( O
including O
suicidal O
ideations O
) O
and O
the O
level O
of O
alcohol O
consumption O
among O
a O
study O
group O
of O
subjects O
with O
comorbid O
major O
depressive O
disorder O
and O
alcohol O
dependence O
, O
many O
of O
whom O
displayed O
suicidal O
ideations O
. O
[]

Seventy-five O
women O
aged O
20-37 O
years O
undergoing O
detoxification O
for O
heroin O
dependence O
at O
AnKang O
Hospital O
were O
allocated O
randomly O
into O
an O
intervention O
or O
a O
control O
group O
. O
[]

Sodium O
bicarbonate O
, O
N-acetylcysteine O
, O
and O
saline O
for O
prevention O
of O
radiocontrast-induced B-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Nine O
patients O
( O
7 O
% O
) O
could O
not O
be O
monitored O
at O
1 O
or O
2 O
years O
, O
but O
4 O
of O
these O
9 O
nevertheless O
filled O
in O
the O
1-year O
questionnaire O
. O
[]

A O
modified O
World O
Health O
Organization O
14-day O
in O
vivo O
drug O
efficacy O
test O
for O
uncomplicated O
Plasmodium O
falciparum O
malaria O
in O
areas O
with O
intense O
malaria O
transmission O
was O
adapted O
to O
reflect O
the O
clinical O
and O
epidemiologic O
features O
of O
a O
low-intensity O
malaria O
transmission O
area O
in O
the O
Pacific O
Coast O
Region O
of O
Colombia O
. O
[]

STUDY O
DESIGN O
Randomized O
clinical O
trial O
. O
[]

When O
compared O
with O
placebo O
and O
omega-3 O
fatty O
acids O
, O
fenofibrate O
therapy O
decreased O
non-HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
and O
triglycerides/HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
P=0.016 O
) O
while O
increasing O
HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
and O
apolipoprotein B-outcome ['Physiological-Clinical']
AI I-outcome ['Physiological-Clinical']
( O
P=0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
both O
groups O
, O
the O
angle O
between O
the I-outcome ['Physiological-Clinical']
radiographic B-outcome ['Physiological-Clinical']
image I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
bar I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
axial B-outcome ['Physiological-Clinical']
inclination I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
upper I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
premolar I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
molar I-outcome ['Physiological-Clinical']
teeth I-outcome ['Physiological-Clinical']
was O
( O
5.34 O
and O
2.73 O
degrees O
for O
the O
right O
premolars O
, O
5.17 O
and O
2.28 O
degrees O
for O
the O
left O
premolars O
, O
11.83 O
and O
3.73 O
degrees O
for O
the O
right O
molars O
, O
and O
9.75 O
and O
5.64 O
degrees O
for O
the O
left O
molars O
in O
the O
banded O
and O
bonded O
groups O
, O
respectively O
. O
['Physiological-Clinical']

[ O
Combined O
preoperative O
xeloda O
and O
radiotherapy O
for O
lower O
rectal O
cancer O
] O
. O
[]

One O
hundred O
and O
sixty O
children O
with O
autism O
spectrum O
disorders O
, O
aged O
4-10 O
years O
, O
suffering O
from O
sleep O
onset O
insomnia O
and O
impaired O
sleep O
maintenance O
, O
were O
assigned O
randomly O
to O
either O
( O
1 O
) O
combination O
of O
controlled-release O
melatonin O
and O
cognitive-behavioural O
therapy O
; O
( O
2 O
) O
controlled-release O
melatonin O
; O
( O
3 O
) O
four O
sessions O
of O
cognitive-behavioural O
therapy O
; O
or O
( O
4 O
) O
placebo O
drug O
treatment O
condition O
for O
12 O
weeks O
in O
a O
1 O
: O
1 O
: O
1 O
: O
1 O
ratio O
. O
[]

Change O
in O
exercise O
capacity O
during O
three O
months O
treatment O
was O
correlated O
with O
changes O
in O
measures O
of O
symptoms B-outcome ['Physiological-Clinical']
, O
limitation O
of O
activity B-outcome ['Life-Impact']
and O
['Physiological-Clinical', 'Life-Impact']

Comparative O
study O
of O
the O
efficacy O
of O
eprinomectin O
versus O
ivermectin O
, O
and O
field B-outcome ['Physiological-Clinical']
efficacy O
of O
eprinomectin O
only O
, O
for O
the O
treatment O
of O
chorioptic O
mange O
in O
alpacas O
. O
['Physiological-Clinical']

METHODS O
Ninety O
patients O
with O
VBIV O
were O
randomly O
divided O
into O
two O
groups O
; O
45 O
patients O
( O
the O
treated O
group O
) O
were O
treated O
with O
YXDM O
and O
BHI O
intravenous O
dripping O
, O
once O
a O
day O
for O
14 O
days O
. O
[]

With O
devices O
as O
described O
here O
, O
there O
is O
no O
reason O
to O
continue O
the O
practice O
of O
wasting O
the O
blood O
of O
critically O
ill O
patients O
in O
order O
to O
prevent O
preanalytic O
error O
. O
[]

Eligible O
patients O
were O
randomly O
assigned O
to O
receive O
1 O
tablet O
of O
codeine/acetaminophen O
( O
C/A O
) O
30/500 O
mg O
or O
hydrocodone/acetaminophen O
( O
H/A O
) O
5/500 O
mg O
PO O
q4h O
( O
total O
daily O
doses O
, O
150/2500 O
and O
25/2500 O
mg O
, O
respectively O
) O
for O
23 O
days O
. O
[]

More O
important O
, O
however O
, O
is O
that O
the O
corresponding O
figures O
for O
the O
range O
of O
bleeding B-outcome ['Physiological-Clinical']
were O
0.4 O
to O
155.4 O
milliliters O
and O
5.6 O
to O
1,570.9 O
milliliters O
, O
respectively O
. O
['Physiological-Clinical']

The O
mean O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
in O
the O
healthy O
controls O
was O
1.9 O
( O
95 O
% O
confidence O
interval O
= O
1.1-2.7 O
) O
. O
['Physiological-Clinical']

RESULTS O
A O
total O
of O
101 O
children O
( O
82 O
boys O
and O
19 O
girls O
; O
mean O
[ O
+/-SD O
] O
age O
, O
8.8+/-2.7 O
years O
) O
were O
randomly O
assigned O
to O
receive O
risperidone O
( O
49 O
children O
) O
or O
placebo O
( O
52 O
) O
. O
[]

RESULTS O
The O
consumption O
of O
L. O
plantarum O
CECT O
7315/7316 O
during O
3 O
months O
after O
influenza O
vaccination O
increased O
the O
levels O
of O
influenza-specific B-outcome ['Physiological-Clinical']
IgA I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
IgG I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

S-potassium B-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
corrected I-outcome ['Physiological-Clinical']
Q-T I-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
( O
Q-Tc O
) O
, O
and O
tremor B-outcome ['Physiological-Clinical']
score O
were O
followed O
as O
measures O
of O
systemic O
effects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
controls O
, O
beta-endorphin O
reduced O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
P O
< O
0.01 O
) O
and O
circulating B-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
( O
P O
< O
0.02 O
) O
and O
increased O
plasma O
atrial O
natriuretic B-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
( O
P O
< O
0.003 O
) O
and O
GH O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
definite O
or O
probable O
stent O
thrombosis O
occurred O
, O
although O
3 O
patients O
develop O
de O
novo O
myocardial O
infarction O
and O
1 O
an O
ischemic O
stroke O
. O
[]

The O
clinically O
important O
difference O
was O
defined O
as O
10 O
% O
of O
the O
maximum O
score O
. O
[]

Rates O
were O
compared O
between O
groups O
. O
[]

Appetite B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
developed O
in O
92.9 O
% O
and O
41.7 O
% O
, O
respectively O
, O
and O
the O
prevention O
effect O
was O
clearly O
higher O
in O
the O
combination O
group O
. O
['Physiological-Clinical']

BACKGROUND O
A O
pooled O
post O
hoc O
responder O
analysis O
was O
performed O
to O
assess O
the O
clinical O
benefit O
of O
alvimopan O
, O
a O
peripherally O
acting O
mu-opioid O
receptor O
( O
PAM-OR O
) O
antagonist O
, O
for O
the O
management O
of O
postoperative O
ileus O
after O
bowel O
resection O
. O
[]

The O
most O
common O
nasal B-outcome ['Physiological-Clinical']
and O
non-nasal B-outcome ['Physiological-Clinical']
adverse B-outcome ['Adverse-effects']
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

A O
reduced O
oxygen O
uptake O
at O
the O
anaerobic O
threshold O
( O
AT O
) O
has O
been O
shown O
to O
confer O
a O
significant O
risk O
of O
mortality O
in O
patients O
undergoing O
major O
abdominal O
surgery O
and O
allows O
objective O
identification O
of O
a O
high-risk O
operative O
group O
. O
[]

Pain B-outcome ['Physiological-Clinical']
was O
graded O
by O
the O
patient O
and O
by O
the O
study O
nurse O
within O
30 O
minutes O
, O
and O
any O
associated O
symptoms B-outcome ['Physiological-Clinical']
were O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Of O
the O
patients O
who O
received O
C/A O
, O
58 O
% O
responded O
to O
the O
initial O
dosage O
of O
150/2500 O
mg/d O
, O
and O
8 O
% O
of O
the O
patients O
responded O
to O
the O
double O
dosage O
; O
34 O
% O
did O
not O
experience O
pain O
relief O
. O
[]

METHODS O
In O
this O
randomized O
, O
double-blind O
, O
sham-controlled O
study O
, O
we O
investigated O
safety O
and O
efficacy O
of O
iTBS O
of O
the O
motor O
and O
dorsolateral O
prefrontal O
cortices O
in O
8 O
sessions O
over O
2 O
weeks O
( O
evidence O
Class O
I O
) O
. O
[]

The O
study O
was O
supposed O
to O
investigate O
a O
possible O
prevention B-outcome ['Physiological-Clinical']
or O
reduction O
of O
the O
toxicity B-outcome ['Adverse-effects']
of O
radiotherapy O
by O
an O
additional O
treatment O
with O
Esberitox O
. O
['Physiological-Clinical', 'Adverse-effects']

A O
randomised O
trial O
comparing O
preoperative O
to O
perioperative O
chemotherapy O
in O
early-stage O
non-small-cell O
lung O
cancer O
( O
IFCT O
0002 O
trial O
) O
. O
[]

She O
developed O
status B-outcome ['Physiological-Clinical']
epilepticus I-outcome ['Physiological-Clinical']
and O
later O
symptoms O
of O
systemic B-outcome ['Physiological-Clinical']
lupus I-outcome ['Physiological-Clinical']
erythematodes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Pretreatment O
leukocytosis O
and O
high O
clinical O
stage O
were O
independent O
adverse O
factors O
in O
a O
Cox O
model O
of O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
but O
the O
effect O
of O
cisplatin O
was O
not O
significant O
. O
['Mortality']

xenon-133 O
in O
20 O
patients O
undergoing O
craniotomy O
for O
supratentorial O
cerebral O
tumours O
. O
[]

Atracurium O
caused O
unexplained O
elevations O
in O
[]

CONCLUSIONS O
Five-day O
quadruple O
therapy O
( O
with O
omeprazole O
, O
metronidazole O
, O
clarithromycin O
and O
amoxicillin O
) O
represents O
an O
effective O
and O
safe O
new O
regimen O
for O
H. O
pylori O
eradication O
. O
[]

This O
study O
was O
conducted O
at O
the O
Trakya O
University O
Training O
and O
Research O
Center O
for O
Mentally O
and O
Physically O
Handicapped O
Children O
in O
Turkey O
. O
[]

For O
5 O
mm O
calculi O
the O
Halo O
was O
superior O
( O
12 O
+/- O
8 O
seconds O
) O
, O
while O
the O
Zerotip O
were O
superior O
for O
8 O
mm O
calculi O
( O
8 O
+/- O
3 O
seconds O
) O
compared O
to O
the O
N-Circle O
( O
23 O
+/- O
28 O
seconds O
, O
p O
= O
0.026 O
) O
, O
Halo O
( O
26 O
+/- O
18 O
seconds O
, O
p O
= O
0.021 O
) O
and O
Vantage O
( O
23 O
+/- O
15 O
seconds O
, O
p O
= O
0.006 O
) O
. O
[]

Although O
the O
incidence O
of O
myelosuppression B-outcome ['Physiological-Clinical']
and O
alopecia B-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
group O
B O
, O
neuropathy B-outcome ['Physiological-Clinical']
was O
significantly O
more O
frequent O
in O
group O
A O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Inhibition O
of O
awake O
sympathetic O
nerve O
activity O
of O
heart O
failure O
patients O
with O
obstructive O
sleep O
apnea O
by O
nocturnal O
continuous O
positive O
airway O
pressure O
. O
[]

RESULTS O
Cuffed O
tubes O
selected O
by O
our O
formula O
were O
appropriate O
for O
99 O
% O
of O
patients O
. O
[]

Vitamin O
C O
and O
acute O
illness O
in O
Navajo O
school O
children O
. O
[]

Although O
statistically O
not O
significant O
the O
preoperatively O
irradiated O
patients O
also O
had O
a O
higher O
morbidity B-outcome ['Physiological-Clinical']
than O
those O
treated O
with O
surgery O
alone O
. O
['Physiological-Clinical']

RESULTS O
Equivalent O
volumes O
of O
investigational O
medication O
were O
infused O
until O
24 O
hours O
after O
the O
first O
administration O
( O
1577 O
vs. O
1540 O
mL O
; O
treatment O
difference O
37 O
[ O
-150 O
; O
223 O
] O
mL O
; O
P O
< O
0.0001 O
for O
equivalence O
) O
. O
[]

Eradication B-outcome ['Physiological-Clinical']
rate O
of O
3 O
day O
, O
6 O
day O
and O
7 O
day O
miconazole O
courses O
for O
complicated O
VVC O
at O
day O
14 O
was O
86.7 O
% O
, O
92.5 O
% O
, O
and O
86.4 O
% O
, O
respectively O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

The O
post-acute O
management O
of O
CHF O
must O
be O
a O
collaborative O
multi-disciplinary O
effort O
by O
the O
health O
care O
team O
as O
it O
is O
the O
additive O
effect O
of O
interventions O
that O
are O
most O
effective O
. O
[]

CONCLUSION O
The O
preliminary O
results O
of O
this O
trial O
suggest O
that O
brachytherapy O
in O
addition O
to O
laser O
therapy O
prolongs O
the O
first O
therapeutic B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Drug B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
levels O
were O
analyzed O
by O
gas O
chromatography/mass O
spectrometry O
, O
and O
weights O
were O
obtained O
weekly O
. O
['Physiological-Clinical']

Caffeine O
eliminates O
psychomotor B-outcome ['Life-Impact']
vigilance I-outcome ['Life-Impact']
deficits I-outcome ['Life-Impact']
from O
sleep O
inertia O
. O
['Life-Impact']

METHODS O
The O
satisfaction B-outcome ['Life-Impact']
questionnaire O
( O
score O
range O
0-100 O
) O
comprised O
28 O
items O
covering O
11 O
domains O
. O
['Life-Impact']

Serial O
computed O
tomography O
( O
CT O
) O
scans O
were O
performed O
during O
follow-up O
. O
[]

Third- O
and O
sixth-grade O
children O
( O
N O
= O
233 O
) O
were O
randomly O
assigned O
to O
view O
a O
video O
of O
the O
same O
boy O
in O
one O
of O
three O
conditions O
: O
No O
Autism O
, O
Autism O
, O
or O
Autism/Information O
. O
[]

Median O
OS B-outcome ['Mortality']
time I-outcome ['Mortality']
exceeds O
84 O
months O
in O
arm O
1 O
and O
is O
83 O
months O
in O
arm O
2 O
( O
P O
= O
.56 O
) O
. O
['Mortality']

Children O
with O
autism O
exhibit O
significant O
deficits O
in O
their O
ability O
to O
spontaneously B-outcome ['Life-Impact']
imitate I-outcome ['Life-Impact']
the O
play B-outcome ['Life-Impact']
actions I-outcome ['Life-Impact']
and O
descriptive B-outcome ['Life-Impact']
gestures I-outcome ['Life-Impact']
of O
others O
. O
['Life-Impact', 'Life-Impact']

Development O
of O
a O
telehealth O
intervention O
for O
head O
and O
neck O
cancer O
patients O
. O
[]

Five O
experiments O
tested O
the O
idea O
that O
instructing O
a O
witness O
to O
close O
their O
eyes O
during O
retrieval O
might O
increase O
retrieval B-outcome ['Life-Impact']
success I-outcome ['Life-Impact']
. O
['Life-Impact']

AIM O
To O
examine O
the O
impact O
of O
exposure O
to O
peginterferon O
alpha-2a O
and O
ribavirin O
on O
early O
virological O
response O
( O
EVR O
) O
and O
sustained O
virological O
response O
( O
SVR O
) O
in O
treatment-naive O
patients O
with O
HCV O
genotype O
1 O
infection O
enrolled O
in O
a O
large O
expanded O
access O
programme O
. O
[]

Asymptomatic O
, O
obese O
, O
insulin-treated O
patients O
were O
given O
diet O
and O
diabetes O
education O
and O
, O
in O
half O
of O
these O
patients O
, O
insulin O
therapy O
was O
withdrawn O
. O
[]

In O
view O
of O
the O
usefulness O
of O
long-term O
adjuvant O
chemotherapy O
, O
the O
Cooperative O
Study O
Group O
of O
Surgical O
Adjuvant O
Chemotherapy O
for O
Gastric O
Cancer O
adopted O
as O
the O
second O
cooperative O
study O
a O
prospective O
randomized O
trial O
on O
three O
groups O
; O
MMC O
alone O
, O
Futraful O
alone O
and O
a O
combination O
of O
MMC O
and O
Futraful O
. O
[]

In O
contrast O
, O
a O
significant O
difference O
for O
better O
EFS O
( O
p=0.0015 O
) O
in O
the O
BCL2 O
positive O
group O
of O
the O
ABC O
subgroups O
subtypes O
treated O
with O
rituximab O
containing O
chemotherapy O
. O
[]

70.5 O
kg O
; O
p O
= O
0.01 O
) O
. O
[]

NNRTI O
versus O
PI O
hazard O
ratios O
( O
HRs O
) O
for O
the O
composite O
endpoint O
, O
for O
AIDS B-outcome ['Physiological-Clinical']
or O
death B-outcome ['Mortality']
, O
for O
death B-outcome ['Mortality']
, O
and O
for O
virological B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
were O
1.02 O
( O
95 O
% O
CI O
0.79-1.31 O
) O
, O
1.07 O
( O
0.80-1.41 O
) O
, O
0.95 O
( O
0.66-1.37 O
) O
, O
and O
0.66 O
( O
0.56-0.78 O
) O
, O
respectively O
. O
['Physiological-Clinical', 'Mortality', 'Mortality', 'Physiological-Clinical']

RESULTS O
A O
significant O
difference O
( O
P=.018 O
) O
was O
observed O
in O
pain B-outcome ['Physiological-Clinical']
levels O
between O
both O
groups O
at O
6 O
hours O
postoperatively O
. O
['Physiological-Clinical']

For O
AVF O
stenoses O
resistant O
to O
conventional O
PTA O
, O
CBA O
may O
be O
a O
better O
second-line O
treatment O
given O
its O
superior O
patency O
rates O
. O
[]

The O
time O
course O
of O
plasma B-outcome ['Physiological-Clinical']
all-E-3-'dehydro-lutein O
concentrations B-outcome ['Physiological-Clinical']
resembled O
that O
of O
all-E-zeaxanthin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
demonstrates O
that O
ketorolac O
relieves O
pain B-outcome ['Physiological-Clinical']
when O
delivered O
by O
EMDA O
and O
offers O
longer-lasting O
pain B-outcome ['Physiological-Clinical']
relief O
than O
does O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
The O
slit-lamp B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
corneal I-outcome ['Physiological-Clinical']
ulceration I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
corrected I-outcome ['Physiological-Clinical']
distance O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
, O
duration B-outcome ['Physiological-Clinical']
until I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
, O
and O
complications B-outcome ['Resource-use']
were O
documented O
in O
each O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

MAIN O
OUTCOME O
MEASUREMENT O
Complications B-outcome ['Adverse-effects']
after O
operative O
and O
nonoperative O
treatments O
, O
Disabilities B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
Arm I-outcome ['Life-Impact']
, O
Shoulder B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
Hand I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DASH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
score O
and O
Constant O
Shoulder B-outcome ['Physiological-Clinical']
Score O
for O
outcome O
measurement O
, O
and O
clavicular B-outcome ['Physiological-Clinical']
shortening I-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Use O
of O
the O
guides O
combined O
with O
the O
absence O
of O
intramedullary O
alignment O
jigs O
may O
lead O
to O
reduced O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
improved O
early B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
FLT3ITD O
mRNA O
level O
contributes O
to O
relapse O
risk O
stratification O
and O
might O
help O
to O
guide O
postremission O
therapy O
in O
NPM1-mutated O
AML O
. O
[]

RESULTS O
In O
children O
and O
adolescents O
( O
n=10 O
) O
, O
mean O
age O
of O
12.5 O
years O
, O
prolactin B-outcome ['Physiological-Clinical']
increased O
from O
mean O
13.2+/-8.6 O
at O
baseline O
to O
31.0+/-11.6 O
acutely O
and O
remained O
elevated O
at O
37.9+/-10.4 O
in O
maintenance O
. O
['Physiological-Clinical']

In O
addition O
, O
70 O
% O
of O
the O
children O
exhibited O
abnormally O
low O
levels O
of O
adrenocorticotropic B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
and O
smaller O
subsets O
exhibited O
elevated O
norepinephrine B-outcome ['Physiological-Clinical']
( O
60 O
% O
) O
, O
arginine-vasopressin B-outcome ['Physiological-Clinical']
( O
50 O
% O
) O
, O
and O
serotonin B-outcome ['Physiological-Clinical']
( O
20 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Moreover O
, O
the O
group O
has O
defined O
more O
precisely O
than O
ever O
before O
the O
nature O
of O
the O
complications B-outcome ['Adverse-effects']
of O
the O
disease O
and O
the O
association O
of O
the O
risks O
of O
specific O
complications B-outcome ['Adverse-effects']
with O
specific O
forms O
of O
therapy O
. O
['Adverse-effects', 'Adverse-effects']

Patients O
who O
were O
obstructed O
according O
to O
a O
modified O
Abrams-Griffiths O
nomogram O
were O
randomized O
to O
5 O
mg O
finasteride O
( O
n O
= O
81 O
) O
or O
placebo O
( O
n O
= O
40 O
) O
for O
12 O
months O
; O
all O
patients O
continuing O
into O
an O
open O
extension O
received O
finasteride O
during O
the O
second O
12 O
months O
of O
therapy O
. O
[]

OBJECTIVE O
Hypoglycaemia O
may O
be O
a O
frequent O
occurrence O
in O
young O
GH O
deficient O
patients O
and O
so O
we O
studied O
the O
response O
to O
fasting O
in O
children O
and O
adolescents O
with O
GH O
and/or O
cortisol O
deficiency O
. O
[]

Placebo O
analgesia O
is O
a O
prime O
example O
of O
the O
impact O
that O
psychological O
factors O
have O
on O
pain O
perception O
. O
[]

The O
role O
of O
adjunctive O
exenatide O
therapy O
in O
pediatric O
type O
1 O
diabetes O
. O
[]

FINDINGS O
Two O
patients O
were O
excluded O
from O
group O
B O
after O
randomisation O
. O
[]

The O
adoption O
of O
PDS O
in O
other O
subsets O
of O
patients O
, O
i.e. O
, O
obese O
individuals O
, O
is O
to O
be O
questioned O
. O
[]

METHODS O
We O
conducted O
a O
multisite O
, O
randomized O
, O
double-blind O
trial O
of O
risperidone O
as O
compared O
with O
placebo O
for O
the O
treatment O
of O
autistic O
disorder O
accompanied O
by O
severe O
tantrums O
, O
aggression O
, O
or O
self-injurious O
behavior O
in O
children O
5 O
to O
17 O
years O
old O
. O
[]

DESIGN O
Forty O
patients O
undergoing O
elective O
coronary O
surgery O
were O
randomized O
into O
two O
groups O
, O
the O
ECC.O O
group O
and O
the O
standard O
CPB O
group O
. O
[]

The O
fee O
for O
the O
As O
test O
was O
US O
$ O
0.28 O
, O
higher O
than O
the O
cost O
of O
the O
test O
( O
US O
$ O
0.16 O
) O
. O
[]

The O
difference O
in O
infectious B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
between O
groups O
1 O
and O
3 O
was O
statistically O
highly O
significant O
( O
p O
< O
0.01 O
) O
and O
between O
groups O
2 O
and O
3 O
it O
was O
significant O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Parameters O
assessed O
were O
the O
tolerance O
of O
scope B-outcome ['Resource-use']
insertion I-outcome ['Resource-use']
and O
the O
assessment O
of O
the O
entire O
procedure O
( O
0-10 O
scale O
) O
, O
the O
method O
of O
insertion O
preferred O
by O
the O
volunteers O
, O
the O
completeness O
of O
the O
examination B-outcome ['Resource-use']
( O
assessed O
by O
an O
independent O
endoscopist O
) O
, O
and O
the O
time B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
procedure I-outcome ['Life-Impact']
. O
['Resource-use', 'Resource-use', 'Life-Impact']

The O
IL-6R B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
evaluated O
in O
both O
trials O
. O
['Physiological-Clinical']

In O
this O
study O
, O
a O
group O
of O
30 O
senior O
medical O
students O
were O
randomly O
assigned O
to O
one O
of O
four O
different O
training O
groups O
: O
none O
, O
error O
only O
, O
correct O
only O
, O
and O
error+correct O
. O
[]

Suppression O
of O
endogenous O
levels O
of O
angiotensin O
II O
by O
angiotensin O
converting O
enzyme O
inhibition O
, O
may O
result O
in O
up-regulation O
of O
vascular O
AT1 O
receptors O
. O
[]

METHODS O
Our O
randomized O
controlled O
trial O
( O
RCT O
) O
compared O
CBT O
with O
SMC O
in O
an O
outpatient O
neuropsychiatric O
setting O
. O
[]

Participants O
were O
randomly O
assigned O
to O
receive O
19.6 O
g O
of O
arginine/d O
( O
n O
= O
6 O
) O
or O
placebo O
( O
n O
= O
5 O
) O
for O
14 O
d. O
Plasma B-outcome ['Physiological-Clinical']
HIV I-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
levels O
, O
neuropsychologic B-outcome ['Physiological-Clinical']
functioning I-outcome ['Physiological-Clinical']
, O
and O
self-reported O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
analyzed O
for O
safety O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

The O
changes O
of O
density O
, O
motility B-outcome ['Physiological-Clinical']
and O
morphology B-outcome ['Physiological-Clinical']
of O
sperm B-outcome ['Physiological-Clinical']
in O
patients O
before O
and O
after O
3-month O
treatment O
were O
examined O
using O
computerized O
WLJY-9000 O
colour O
semen B-outcome ['Physiological-Clinical']
analysis O
system O
with O
refined O
Papanicolaou O
's O
stain O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Helping O
HAND O
is O
feasible O
, O
due O
to O
low O
attrition O
, O
good O
programme O
attendance O
, O
and O
clinically O
relevant O
improvements O
in O
some O
child O
and O
parenting O
behaviours O
. O
[]

Group O
TF O
( O
48 O
infants O
) O
received O
trophic O
feeding O
from O
day O
3 O
( O
0.5-1 O
ml/h O
) O
along O
with O
parenteral O
nutrition O
until O
ventilatory O
support O
finished O
. O
[]

BACKGROUND O
Autistic O
individuals O
often O
exhibit O
hyperarousal O
behaviors O
( O
e.g. O
, O
stereotyped O
body O
movements O
, O
self-stimulation O
, O
hypervigilance O
, O
and O
hyperactivity O
) O
. O
[]

Children O
acquire O
general O
knowledge O
about O
many O
kinds O
of O
things O
, O
but O
there O
are O
few O
known O
means O
by O
which O
this O
knowledge O
is O
acquired O
. O
[]

A O
greater O
number O
of O
patients O
showed O
[]

Netilmicin O
in O
the O
neonate O
: O
pharmacokinetic O
analysis O
and O
influence O
of O
parenteral O
nutrition O
. O
[]

METHOD O
Adult O
outpatients O
with O
generalized O
social O
phobia O
( O
N=204 O
) O
from O
10 O
Canadian O
centers O
were O
randomly O
assigned O
to O
receive O
sertraline O
or O
placebo O
in O
a O
2:1 O
ratio O
for O
a O
20-week O
double-blind O
study O
following O
a O
1-week O
, O
single-blind O
, O
placebo O
run-in O
. O
[]

The O
results O
indicate O
that O
no O
clinically B-outcome ['Physiological-Clinical']
meaningful I-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
interactions I-outcome ['Physiological-Clinical']
occurred O
between O
risperidone O
1 O
mg O
daily O
and O
donepezil O
5 O
mg O
daily O
at O
steady O
state O
, O
and O
therefore O
no O
dosage O
adjustment O
is O
required O
when O
both O
drugs O
are O
combined O
with O
the O
dosage O
regimen O
studied O
. O
['Physiological-Clinical']

The O
effects O
of O
L-carnitine O
on O
cardiac O
performance O
after O
open O
heart O
surgery O
were O
evaluated O
in O
a O
balanced O
, O
placebo-controlled O
, O
double-blind O
study O
in O
38 O
patients O
. O
[]

The O
conclusions O
resulted O
in O
no O
significant O
differences O
in O
morbidity B-outcome ['Physiological-Clinical']
in O
adult O
patients O
with O
common O
variable O
immunodeficiency O
treated O
in O
cross-over O
pattern O
with O
IVIG O
200 O
mg/kg O
, O
400 O
mg/kg O
and O
600 O
mg/kg O
. O
['Physiological-Clinical']

AIM O
To O
see O
whether O
laparoscopy O
improves O
the O
accuracy O
of O
a O
clinical O
diagnosis O
of O
acute O
appendicitis O
in O
women O
of O
reproductive O
age O
, O
and O
to O
determine O
what O
the O
long-term O
sequelae O
are O
of O
not O
removing O
an O
appendix O
deemed O
at O
laparoscopy O
to O
be O
normal O
. O
[]

No O
consistently O
effective O
and O
safe O
drugs O
have O
been O
developed O
for O
treating O
the O
symptoms O
of O
autism O
. O
[]

In O
this O
prospective O
study O
, O
14 O
patients O
with O
colonic O
cancer O
were O
randomly O
assigned O
to O
undergo O
a O
6-hour O
stable O
isotope O
infusion O
study O
( O
3 O
hours O
of O
fasting O
followed O
by O
3-hour O
infusions O
of O
amino O
acids O
, O
Travasol O
[ O
Baxter O
, O
Montreal O
, O
Canada O
] O
10 O
% O
at O
0.02 O
mL.kg O
( O
-1 O
) O
.min O
( O
-1 O
) O
, O
with O
or O
without O
glucose O
at O
4 O
mg.kg O
( O
-1 O
) O
.min O
( O
-1 O
) O
) O
on O
the O
second O
day O
after O
colorectal O
surgery O
. O
[]

Three O
of O
the O
volunteers O
in O
each O
case O
preferred O
the O
oral O
or O
the O
nasal O
route O
, O
and O
three O
were O
not O
decided O
, O
in O
case O
of O
a O
repeated O
endoscopy O
. O
[]

The O
study O
consisted O
of O
five O
treatment O
periods O
. O
[]

The O
study O
lasted O
for O
5 O
weeks O
, O
and O
in O
groups O
2 O
and O
3 O
benazepril O
was O
added O
on O
top O
of O
valsartan O
after O
the O
first O
week O
of O
therapy O
with O
the O
angiotensin O
receptor O
blocker O
. O
[]

Patients O
were O
randomly O
assigned O
to O
one O
of O
three O
protocols O
: O
A O
, O
contrast O
material O
of O
300 O
mg O
I/mL O
; O
B O
, O
370 O
mg O
I/mL O
; O
C O
, O
370 O
mg O
I/mL O
plus O
saline O
flush O
. O
[]

Rating O
scales O
that O
accurately O
capture O
and O
measure O
subtypes O
of O
aggression O
phenomenology O
, O
frequency O
and O
severity O
are O
urgently O
needed O
, O
in O
both O
clinical O
practice O
and O
research O
. O
[]

Children O
< O
or O
=21 O
years O
old O
with O
biopsy-proven O
, O
pathologically O
staged O
I O
, O
IIA O
, O
or O
IIIA1 O
Hodgkin O
disease O
were O
randomly O
assigned O
6 O
courses O
of O
alternating O
nitrogen O
mustard O
, O
oncovin O
, O
prednisone O
, O
and O
procarbazine/doxorubicin O
, O
bleomycin O
, O
vinblastine O
, O
and O
dacarbazine O
( O
treatment O
1 O
) O
or O
4 O
courses O
of O
alternating O
nitrogen O
mustard O
, O
oncovin O
, O
prednisone O
, O
and O
procarbazine/doxorubicin O
, O
bleomycin O
, O
vinblastine O
, O
and O
dacarbazine O
+2550 O
cGy O
involved-field O
radiotherapy O
( O
treatment O
2 O
) O
. O
[]

The O
effects O
of O
chronic O
naltrexone O
treatment O
in O
young O
autistic O
children O
: O
a O
double-blind O
placebo-controlled O
crossover O
study O
. O
[]

The O
time B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
pass I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
endotracheal I-outcome ['Life-Impact']
tube I-outcome ['Life-Impact']
through I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
nasal I-outcome ['Life-Impact']
cavity I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
nasal I-outcome ['Life-Impact']
passage I-outcome ['Life-Impact']
time B-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
, O
success B-outcome ['Life-Impact']
rate I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
nasal I-outcome ['Life-Impact']
passage I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
nasotracheal I-outcome ['Life-Impact']
tube I-outcome ['Life-Impact']
, O
and O
the O
incidence O
and O
severity O
of O
nasal B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
were O
compared O
. O
['Life-Impact', 'Physiological-Clinical']

Use O
of O
these O
guides O
may O
reduce O
operating O
time O
. O
[]

Effects O
of O
statins O
on O
progression O
of O
subclinical B-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
infarct I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Training O
programmes O
were O
administered O
individually O
, O
lasting O
for O
25 O
minutes O
per O
day O
for O
5-10 O
days O
. O
[]

These O
data O
support O
the O
efficacy O
of O
cryotherapy O
in O
reducing O
by O
approximately O
one O
half O
the O
risk O
of O
unfavorable O
retinal O
outcome O
from O
threshold O
ROP O
. O
[]

RESULTS O
There O
were O
67 O
patients O
in O
each O
group O
. O
[]

The O
analgesic B-outcome ['Resource-use']
effect O
of O
1,2,6-IP3 O
was O
evaluated O
in O
a O
double-blind O
, O
randomized O
study O
in O
24 O
patients O
undergoing O
cholecystectomy O
. O
['Resource-use']

The O
space-analysis O
showed O
excessive O
dental-arch B-outcome ['Physiological-Clinical']
space I-outcome ['Physiological-Clinical']
in O
patients O
with O
a O
palatally-displaced O
canine O
. O
['Physiological-Clinical']

They O
completed O
the O
Measure O
of O
Current O
Status O
prior O
to O
receiving O
chemotherapy O
and O
12 O
weeks O
after O
the O
first O
infusion O
. O
[]

BACKGROUND O
Cases O
of O
severe O
gastrointestinal O
toxicity O
were O
monitored O
prospectively O
during O
NSABP O
C-07 O
, O
a O
randomized O
clinical O
trial O
of O
adjuvant O
therapy O
for O
patients O
with O
stage O
II/III O
colon O
cancer O
. O
[]

Treatment O
of O
polyarteritis O
nodosa O
and O
Churg-Strauss O
syndrome O
: O
indications O
of O
plasma O
exchanges O
. O
[]

METHODS O
49 O
Malnourished O
( O
weight O
loss O
> O
10 O
% O
) O
head O
and O
neck O
cancer O
patients O
who O
were O
included O
in O
a O
nutrition O
intervention O
trial O
were O
randomized O
to O
receive O
either O
no O
preoperative O
and O
standard O
postoperative O
tube-feeding O
( O
group O
I O
) O
, O
standard O
preoperative O
and O
postoperative O
tube-feeding O
( O
group O
II O
) O
or O
arginine-supplemented O
preoperative O
and O
postoperative O
tube-feeding O
( O
group O
III O
) O
. O
[]

Serum B-outcome ['Physiological-Clinical']
hormone-binding I-outcome ['Physiological-Clinical']
globulin I-outcome ['Physiological-Clinical']
levels O
increased O
in O
41.4 O
% O
of O
women O
in O
the O
experimental O
group O
compared O
with O
37.5 O
% O
of O
women O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

Relapses B-outcome ['Physiological-Clinical']
were O
observed O
more O
frequently O
and O
were O
more O
severe O
with O
betamethasone O
than O
with O
pimecrolimus O
. O
['Physiological-Clinical']

Recent O
studies O
show O
that O
the O
elderly O
have O
increased O
oxidative O
stress O
and O
impaired O
antioxidant O
defense O
systems O
. O
[]

The O
surgical O
procedures O
and O
the O
surgeons O
were O
defined O
prior O
to O
the O
beginning O
of O
patient O
recruitment O
. O
[]

CONCLUSION O
Our O
findings O
suggest O
that O
naltrexone O
has O
no O
clinical O
value O
for O
a O
broad O
group O
of O
mentally O
retarded O
subjects O
with O
SIB O
and/or O
autism O
. O
[]

In O
a O
randomized O
, O
double-blind O
trial O
, O
we O
included O
170 O
patients O
with O
an O
acute O
exacerbation O
of O
COPD O
requiring O
mechanical O
ventilation O
. O
[]

Comparison O
of O
inguinal O
approach O
, O
scrotal O
sclerotherapy O
and O
subinguinal O
antegrade O
sclerotherapy O
in O
varicocele O
treatment O
: O
a O
randomized O
prospective O
study O
. O
[]

MAIN O
OUTCOME O
MEASUREMENTS O
The O
raw O
ultrasonographic O
images O
were O
analysed O
with O
a O
custom-designed O
algorithm O
that O
quantifies O
the O
three-dimensional B-outcome ['Physiological-Clinical']
stability I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
echo I-outcome ['Physiological-Clinical']
patterns I-outcome ['Physiological-Clinical']
, O
qua O
intensity O
and O
distribution O
over O
contiguous B-outcome ['Physiological-Clinical']
transverse I-outcome ['Physiological-Clinical']
images I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
groups O
A O
and O
B O
, O
35 O
% O
and O
43 O
% O
of O
the O
patients O
achieved O
complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
and O
45 O
% O
and O
50 O
% O
achieved O
partial B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Sixty-four O
patients O
with O
a O
first-time O
sick O
leave O
between O
3 O
and O
12 O
weeks O
due O
to O
low O
back O
pain O
were O
randomly O
assigned O
to O
either O
a O
conventional O
biomedical O
therapy O
( O
MT O
; O
n=33 O
) O
group O
, O
or O
a O
biopsychosocial O
therapy O
( O
BT O
; O
n=31 O
) O
group O
including O
a O
psychotherapeutic O
module O
; O
both O
in O
accordance O
with O
a O
standardized O
3 O
weeks O
inpatient O
treatment O
. O
[]

Perturbation O
trials O
were O
interspersed O
with O
SAS-only O
trials O
. O
[]

The O
children O
with O
autism O
were O
overall O
better O
than O
the O
typically O
developing O
children O
at O
visual B-outcome ['Physiological-Clinical']
search I-outcome ['Physiological-Clinical']
, O
thus O
replicating O
demonstrations O
of O
superior O
discrimination O
in O
autism O
. O
['Physiological-Clinical']

Blood O
was O
obtained O
hourly O
. O
[]

INTRODUCTION O
Compared O
to O
ischemic O
stroke O
, O
intracerebral O
hemorrhage O
( O
ICH O
) O
is O
easily O
and O
rapidly O
identified O
, O
occurs O
in O
younger O
patients O
, O
and O
produces O
relatively O
small O
initial O
injury O
to O
cerebral O
tissues O
-- O
all O
factors O
suggesting O
that O
interventional O
amelioration O
is O
possible O
. O
[]

ASI O
was O
three O
weekly O
vaccinations O
starting O
4 O
weeks O
after O
surgery O
, O
with O
a O
booster O
vaccination O
at O
6 O
months O
with O
10 O
( O
7 O
) O
irradiated O
autologous O
tumour O
cells O
. O
[]

Procalcitonin O
is O
a O
good O
tool O
to O
guide O
duration O
of O
antibiotic O
therapy O
in O
patients O
with O
severe O
acute O
pancreatitis O
. O
[]

This O
difference O
reached O
statistical O
significance O
when O
first O
study O
episodes O
were O
considered O
separately O
( O
six O
flu O
versus O
nil O
itra O
, O
P O
= O
0.03 O
) O
. O
[]

We O
hypothesized O
that O
the O
beneficial O
effects O
of O
heparin-coated O
circuits O
might O
be O
seen O
in O
patients O
who O
had O
cardiac O
reoperations O
. O
[]

This O
paper O
describes O
a O
study O
of O
the O
outcome O
of O
psychotherapy O
with O
patients O
disabled O
by O
chronic O
obstructive O
airways O
disease O
giving O
rise O
to O
dyspnoea O
. O
[]

The O
effects O
of O
haloperidol O
on O
behavioral B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
learning B-outcome ['Life-Impact']
were O
critically O
assessed O
in O
autistic O
children O
in O
an O
ongoing O
double-blind O
placebo-controlled O
clinical O
trial O
. O
['Life-Impact', 'Life-Impact']

These O
findings O
indicated O
that O
Skp2 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
closely O
associated O
with O
tumor O
progression O
and O
represented O
an O
independent O
marker O
for O
prognosis O
of O
LSCC O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
in O
functional B-outcome ['Life-Impact']
outcome O
or O
death B-outcome ['Mortality']
at O
14 O
days O
or O
3 O
months O
. O
['Life-Impact', 'Mortality']

INTERVENTIONS O
Patient O
education O
( O
PE O
) O
. O
[]

Five-year O
OS B-outcome ['Mortality']
rate O
is O
61 O
% O
in O
arm O
1 O
and O
57 O
% O
in O
arm O
2 O
. O
['Mortality']

The O
primary O
efficacy O
end O
point O
was O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
at O
follow-up O
. O
['Physiological-Clinical']

A O
greater O
proportion O
of O
children O
in O
the O
ASD O
group O
used O
special O
educational O
services O
( O
76 O
% O
vs. O
7 O
% O
in O
the O
control O
group O
, O
P O
< O
.05 O
) O
. O
[]

Change O
in O
peak O
urinary B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
a O
secondary O
end O
point O
. O
['Physiological-Clinical']

Using O
data O
from O
the O
Cholesterol O
Lowering O
Atherosclerosis O
Study O
( O
CLAS O
) O
, O
we O
explored O
the O
association O
of O
self-selected O
supplementary O
antioxidant O
vitamin O
intake O
on O
the O
rate O
of O
progression O
of O
early O
preintrusive O
atherosclerosis O
. O
[]

Recent O
studies O
propose O
both O
hyper-and O
hypoglutamatergic O
ideologies O
for O
autism O
. O
[]

RESULTS O
A O
complete O
response O
was O
obtained O
in O
87 O
% O
lesions O
treated O
with O
PLA O
and O
in O
93 O
% O
lesions O
treated O
with O
RFA O
( O
p O
= O
ns O
) O
. O
[]

We O
performed O
multiplex O
cytokine O
assay O
to O
measure O
the O
changes O
in O
the O
systemic O
inflammatory O
cytokines O
, O
and O
endothelial O
adhesion O
molecules O
( O
n=15 O
) O
. O
[]

Dose-dependent O
increases O
in O
FEV1 B-outcome ['Physiological-Clinical']
were O
seen O
( O
mean O
values O
( O
L O
) O
before O
salbutamol O
and O
after O
a O
cumulative O
dose O
of O
100 O
, O
200 O
, O
400 O
, O
and O
800 O
microg O
= O
placebo O
: O
1.06 O
, O
1.28 O
, O
1.35 O
, O
1.39 O
, O
1.41 O
; O
formoterol O
: O
1.33 O
, O
1.37 O
, O
1.41 O
, O
1.44 O
, O
1.44 O
; O
salmeterol O
: O
1.30 O
, O
1.33 O
, O
1.36 O
, O
1.39 O
, O
1.42 O
; O
oxitropium O
bromide O
: O
1.27 O
, O
1.34 O
, O
1.37 O
, O
1.41 O
, O
1.40 O
) O
. O
['Physiological-Clinical']

In O
both O
groups O
, O
IL-6 B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
TNF-alpha I-outcome ['Physiological-Clinical']
levels O
remained O
low O
throughout O
the O
study O
period O
. O
['Physiological-Clinical']

The O
antiemetic B-outcome ['Resource-use']
efficacy O
of O
prophylactic O
granisetron O
in O
gynecologic O
surgery O
. O
['Resource-use']

As O
secondary O
objectives O
we O
examine O
five O
year O
survival B-outcome ['Mortality']
rates O
( O
OS B-outcome ['Mortality']
and O
DFS B-outcome ['Mortality']
) O
, O
['Mortality', 'Mortality', 'Mortality']

In O
total O
, O
42 O
patients O
opted O
to O
cross O
over O
; O
median O
PFS O
was O
3.2 O
months O
( O
95 O
% O
CI O
1.7 O
, O
5.1 O
) O
on O
lapatinib O
plus O
vinorelbine O
and O
4.0 O
months O
( O
95 O
% O
CI O
2.1 O
, O
5.8 O
) O
on O
lapatinib O
plus O
capecitabine O
. O
[]

The O
low O
solubility O
of O
desflurane O
has O
been O
shown O
to O
contribute O
to O
faster O
awakening O
from O
anesthesia O
when O
compared O
with O
other O
anesthetics O
in O
common O
use O
. O
[]

There O
were O
80 O
students O
in O
each O
group O
. O
[]

Parecoxib O
for O
analgesia O
after O
craniotomy O
. O
[]

PURPOSE O
The O
HD9 O
trial O
aims O
to O
evaluate O
whether O
moderate O
dose O
escalation O
and/or O
acceleration O
of O
standard O
polychemotherapy O
is O
beneficial O
for O
advanced-stage O
Hodgkin O
's O
disease O
( O
HD O
) O
. O
[]

Changes O
in O
the O
total O
score O
of O
the O
Gross B-outcome ['Physiological-Clinical']
Motor I-outcome ['Physiological-Clinical']
Function I-outcome ['Physiological-Clinical']
Measure O
and O
the O
Sitting B-outcome ['Life-Impact']
Assessment O
Scale O
were O
not O
significant O
. O
['Physiological-Clinical', 'Life-Impact']

The O
impact O
of O
the O
DASH O
diet O
on O
fibrinolytic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
is O
not O
known O
. O
['Physiological-Clinical']

Side O
effects O
, O
compliance B-outcome ['Life-Impact']
and O
treatment O
response O
were O
evaluated O
by O
questionnaire O
. O
['Life-Impact']

Placebo O
or O
histamine O
was O
administered O
intravenously O
in O
stepwise O
increasing O
doses O
( O
0.08 O
microg/kg/min O
, O
0.16 O
microg/kg/min O
, O
and O
0.32 O
microg/kg/min O
) O
. O
[]

Emphasis O
must O
be O
laid O
on O
regular O
, O
frequent O
, O
and O
correct O
application O
of O
a O
product O
for O
it O
to O
be O
effective O
. O
[]

Similarly O
, O
the O
[]

Sleep B-outcome ['Physiological-Clinical']
variables I-outcome ['Physiological-Clinical']
, O
including O
sleep O
duration O
, O
sleep-onset O
time O
, O
sleep-onset O
latency O
time O
, O
and O
the O
number O
of O
night O
awakenings O
, O
were O
recorded O
using O
an O
Actiwatch O
and O
from O
sleep O
diaries O
completed O
by O
parents O
. O
['Physiological-Clinical']

Patients O
were O
randomly O
assigned O
to O
intervention O
( O
n O
= O
242 O
) O
or O
enhanced O
usual O
care O
( O
EUC O
; O
n O
= O
230 O
) O
. O
[]

The O
authors O
utilized O
an O
ion-selective O
electrode O
to O
measure O
IMg B-outcome ['Physiological-Clinical']
in O
26 O
hemodialysis O
patients O
and O
10 O
peritoneal O
dialysis O
( O
CAPD O
) O
patients O
and O
compared O
the O
results O
with O
those O
from O
66 O
age O
matched O
control O
subjects O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
Transporters O
programme O
showed O
limited O
efficacy O
in O
teaching O
basic O
emotion O
recognition O
skills O
to O
young O
children O
with O
autism O
with O
a O
lower O
range O
of O
cognitive O
ability O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Preoperative B-outcome ['Physiological-Clinical']
cervical I-outcome ['Physiological-Clinical']
dilatation I-outcome ['Physiological-Clinical']
, O
acceptability B-outcome ['Life-Impact']
and O
complications B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Life-Impact', 'Adverse-effects']

Using O
polysomnographic O
criteria O
, O
MAS O
treatment O
was O
completely O
successful B-outcome ['Physiological-Clinical']
in O
four O
( O
21 O
% O
) O
patients O
, O
partially O
['Physiological-Clinical']

Effectiveness O
of O
manual O
physical O
therapy O
and O
exercise O
in O
osteoarthritis O
of O
the O
knee O
. O
[]

Protein B-outcome ['Physiological-Clinical']
synthesis I-outcome ['Physiological-Clinical']
was O
lower O
during O
oral O
estrogen O
both O
before O
and O
during O
GH O
administration O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Impact O
of O
angiotensin O
II O
receptor O
blocker O
therapy O
( O
olmesartan O
or O
valsartan O
) O
on O
coronary O
atherosclerotic O
plaque O
volume O
measured O
by O
intravascular O
ultrasound O
in O
patients O
with O
stable O
angina O
pectoris O
. O
[]

The O
amount B-outcome ['Resource-use']
of I-outcome ['Resource-use']
analgesics I-outcome ['Resource-use']
and O
narcotics B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
after I-outcome ['Life-Impact']
discharge I-outcome ['Life-Impact']
was O
the O
same O
for O
both O
groups O
. O
['Resource-use', 'Life-Impact']

Combination O
treatment O
resulted O
in O
no O
significant O
differences O
in O
appetite B-outcome ['Physiological-Clinical']
or O
weight B-outcome ['Physiological-Clinical']
compared O
with O
megestrol O
acetate O
alone O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Long-term B-outcome ['Physiological-Clinical']
consequences I-outcome ['Physiological-Clinical']
of O
different O
immunosuppressive O
regimens O
for O
renal O
allografts O
. O
['Physiological-Clinical']

CONCLUSIONS O
GS-9620 O
demonstrates O
safety O
and O
pharmacodynamic O
activity O
at O
doses O
up O
to O
12 O
mg. O
Pharmacodynamic O
activity O
is O
seen O
before O
adverse O
events O
, O
suggesting O
the O
potential O
for O
induction O
of O
an O
antiviral O
response O
without O
systemic O
adverse O
events O
in O
subjects O
with O
chronic O
viral O
hepatitis O
. O
[]

CONCLUSION O
At O
12-year O
median O
follow-up O
, O
there O
still O
was O
no O
survival O
difference O
in O
those O
patients O
treated O
prophylactically O
to O
the O
pelvic O
nodes O
and O
prostatic O
bed O
vs. O
the O
prostatic O
bed O
alone O
. O
[]

The O
median O
follow-up O
period O
was O
15 O
years O
. O
[]

METHODS O
To O
address O
this O
issue O
, O
we O
conducted O
a O
randomized O
comparison O
of O
these O
two O
treatment O
strategies O
in O
patients O
who O
had O
been O
resuscitated O
from O
near-fatal O
ventricular O
fibrillation O
or O
who O
had O
undergone O
cardioversion O
from O
sustained O
ventricular O
tachycardia O
. O
[]

No O
significant O
difference O
was O
demonstrated O
in O
symptomatic B-outcome ['Physiological-Clinical']
improvement O
between O
placebo O
, O
domperidone O
, O
and O
metoclopramide O
in O
this O
study O
. O
['Physiological-Clinical']

In O
patients O
with O
neutrophil O
counts O
of O
> O
0.1 O
x O
10 O
( O
9 O
) O
/L O
lasting O
for O
more O
than O
4 O
weeks O
, O
the O
frequency O
of O
infection B-outcome ['Physiological-Clinical']
in O
the O
fluconazole O
group O
( O
5 O
of O
9 O
patients O
) O
was O
significantly O
higher O
than O
in O
the O
itraconazole O
group O
( O
0 O
of O
7 O
patients O
; O
P O
= O
.03 O
) O
. O
['Physiological-Clinical']

Thus O
the O
benefit O
of O
initial O
application O
of O
transdermal O
nitroglycerin O
is O
maintained O
with O
intermittent O
treatment O
and O
a O
daily O
nitrate-free O
interval O
, O
whereas O
tolerance O
to O
antianginal B-outcome ['Physiological-Clinical']
effect O
occurs O
with O
continuous O
treatment O
. O
['Physiological-Clinical']

BACKGROUND O
The O
absence O
of O
a O
pharmacokinetic B-outcome ['Physiological-Clinical']
interaction I-outcome ['Physiological-Clinical']
between O
the O
proton O
pump O
inhibitor O
esomeprazole O
( O
40 O
mg O
) O
and O
acetylsalicylic O
acid O
( O
aspirin O
, O
ASA O
; O
325 O
mg O
) O
has O
previously O
been O
established O
. O
['Physiological-Clinical']

CONCLUSION O
In O
subjects O
with O
hyperinsulinemia O
an O
energy-restrictive O
diet O
containing O
an O
increased O
protein-to-carbohydrate B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
does O
not O
enhance O
weight O
['Physiological-Clinical']

The O
purpose O
of O
this O
randomized O
study O
was O
to O
examine O
if O
goserelin O
concomitant O
to O
CMF-chemotherapy O
as O
adjuvant O
treatment O
for O
premenopausal O
breast O
cancer O
, O
protects O
the O
ovaries B-outcome ['Physiological-Clinical']
from O
premature O
failure O
. O
['Physiological-Clinical']

Reports O
of O
complications O
associated O
with O
local O
anesthesia O
in O
ophthalmic O
surgery O
have O
increased O
conspicuously O
in O
recent O
years O
. O
[]

The O
basal B-outcome ['Physiological-Clinical']
segment I-outcome ['Physiological-Clinical']
IVRT I-outcome ['Physiological-Clinical']
' O
corrected O
for O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
correlates O
well O
with O
the O
invasive O
PAP O
measurement O
and O
, O
therefore O
, O
can O
be O
used O
to O
predict O
systolic B-outcome ['Physiological-Clinical']
PAP I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
determine O
the O
level O
of O
occupational O
exposure O
to O
anesthetic O
gases O
in O
the O
absence O
of O
an O
extractor O
during O
pediatric O
anesthesia O
and O
to O
assess O
the O
efficacy O
of O
a O
purpose-built O
extraction O
system O
. O
[]

DA-supported O
subjects O
had O
significantly O
better O
mean O
daily B-outcome ['Life-Impact']
energy I-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
( O
1,105 O
kcal O
versus O
756 O
kcal/24 O
h O
, O
95 O
% O
CI O
259-440 O
kcal/24 O
h O
, O
P O
< O
0.001 O
) O
, O
significantly O
smaller O
reduction O
in O
mid-arm O
circumference O
during O
their O
inpatient O
stay O
( O
0.39 O
cm O
, O
P O
= O
0.002 O
) O
and O
nonsignificantly O
favourable O
results O
for O
other O
anthropometric B-outcome ['Physiological-Clinical']
and O
laboratory B-outcome ['Physiological-Clinical']
measurements O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
disparity O
in O
the O
degree O
of O
early B-outcome ['Adverse-effects']
and I-outcome ['Adverse-effects']
late I-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
makes O
assessment O
of O
RBE O
values O
difficult O
. O
['Adverse-effects']

In O
the O
study O
group O
93 O
% O
felt O
the O
urge B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
defecate I-outcome ['Physiological-Clinical']
after O
administration O
of O
the O
suppositories O
as O
compared O
to O
37 O
% O
in O
the O
control O
group O
( O
P O
= O
0.001 O
) O
. O
['Physiological-Clinical']

MLSS O
is O
an O
excellent O
tool O
for O
assessing O
fitness O
level O
, O
predicting O
endurance O
performance O
, O
and O
designing O
training O
programs O
. O
[]

The O
two-sided O
90 O
% O
confidence O
interval O
of O
the O
difference O
was O
calculated O
on O
intent O
to O
treat O
( O
ITT O
) O
population O
; O
the O
acceptance O
limit O
for O
non-inferiority O
was O
3 O
% O
. O
[]

Participants O
tended O
to O
be O
50-59years O
( O
64 O
% O
) O
, O
female O
( O
58 O
% O
) O
, O
white O
( O
52 O
% O
) O
, O
married O
( O
51 O
% O
) O
, O
and O
have O
more O
than O
a O
high O
school O
education O
( O
67 O
% O
) O
. O
[]

This O
study O
was O
carried O
out O
to O
evaluate O
the O
effects O
of O
perioperative O
indomethacin O
on O
intracranial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ICP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CBF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
cerebral B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Both O
groups O
achieved O
comparable O
improvement O
in O
International O
Prostate B-outcome ['Physiological-Clinical']
Symptom O
Score O
( O
p O
= O
0.862 O
) O
, O
quality-of-life O
score O
( O
p O
= O
0.169 O
) O
and O
peak O
flow O
rate O
( O
p O
= O
0.96 O
) O
at O
3-month O
follow-up O
. O
['Physiological-Clinical']

[ O
Study O
on O
classification O
and O
treatment O
of O
vulvovaginal O
candidiasis O
] O
. O
[]

The O
response O
rate O
with O
I-MEC B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
was O
significantly O
higher O
than O
that O
with O
M-VAC O
therapy O
( O
P O
= O
0.02 O
) O
. O
['Resource-use']

The O
LPS-induced B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
factor O
['Physiological-Clinical']

An O
average O
of O
106.6 O
+/- O
8.9 O
and O
107.7 O
+/- O
6.2 O
gingival O
sites O
per O
subject O
( O
four O
sites O
per O
tooth O
) O
in O
Groups O
C O
and O
T O
, O
respectively O
, O
were O
examined O
by O
the O
same O
calibrated O
examiner O
on O
two O
occasions O
. O
[]

However O
, O
these O
regimens O
are O
still O
costly O
, O
duration O
is O
about O
one O
week O
or O
less O
, O
and O
side-effects O
are O
not O
negligible O
. O
[]

CONCLUSIONS O
Osteoporosis O
was O
prevalent O
in O
low O
ASM O
groups O
( O
SS O
and O
SO O
) O
and O
related O
to O
gait O
and O
balance O
deficits O
, O
particularly O
in O
the O
SO O
. O
[]

On O
the O
other O
hand O
, O
in O
relatively O
hypo-ergic O
subjects O
, O
benefits O
were O
limited O
to O
the O
improvement O
of O
some O
immunological B-outcome ['Physiological-Clinical']
parameters O
. O
['Physiological-Clinical']

Finding O
alternatives O
to O
these O
agents O
in O
the O
local O
treatment O
of O
the O
disease O
therefore O
seems O
desirable O
. O
[]

The O
other O
25 O
patients O
were O
operated O
on O
immediately O
and O
received O
radiotherapy O
postoperatively O
2 O
to O
4 O
weeks O
after O
surgery O
. O
[]

There O
were O
no O
significant O
differences O
( O
P O
> O
.05 O
) O
between O
the O
lidocaine O
and O
mepivacaine O
solutions O
. O
[]

METHODS O
Double-blind O
, O
randomised O
, O
placebo-controlled O
trial O
, O
including O
children O
( O
age O
3-36 O
m O
) O
with O
acute O
diarrhoea O
who O
were O
allocated O
to O
placebo O
or O
synbiotic O
group O
. O
[]

The O
efficacy O
and O
safety O
of O
tamsulone-FS O
was O
comparable O
to O
those O
of O
omnik O
. O
[]

All O
patients O
were O
asked O
to O
complete O
a O
validated O
questionnaire O
regarding O
presence O
and O
intensity O
of O
drug O
side O
effects O
. O
[]

Do O
catheter O
washouts O
extend O
patency B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
in O
long-term O
indwelling B-outcome ['Physiological-Clinical']
urethral O
catheters O
? O
['Physiological-Clinical', 'Physiological-Clinical']

Rabeprazole-based O
short-term O
triple O
therapy O
may O
be O
applicable O
in O
CYP2C19 O
PMs O
for O
H. O
pylori O
eradication O
. O
[]

CONCLUSION O
ApoA-I O
induction O
represents O
a O
potential O
novel O
strategy O
to O
reduce O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
, O
by O
generating O
nascent O
HDL O
particles O
. O
['Physiological-Clinical']

For O
clinical O
C O
tumours O
, O
the O
prevalence O
of O
[]

Adult O
subjects O
with O
FXS O
were O
able O
to O
complete O
an O
intensive O
clinical O
trial O
, O
and O
some O
valid O
outcome O
measures O
were O
identified O
for O
future O
FXS O
trial O
design O
. O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
the O
effect O
of O
dried O
purple O
carrot O
on O
body O
mass O
, O
lipids O
, O
blood O
pressure O
, O
body O
composition O
, O
and O
inflammatory O
markers O
in O
overweight O
and O
obese O
adults O
: O
the O
QUENCH O
trial O
. O
[]

However O
, O
little O
is O
known O
about O
the O
underlying O
airway O
immunopathology O
and O
there O
are O
no O
data O
from O
placebo-controlled O
studies O
examining O
the O
effect O
of O
inhaled O
corticosteroids O
. O
[]

2-D O
gel O
electrophoresis O
of O
delipidated O
plasmas O
established O
successful O
conversion O
of O
alphaHDL O
to O
prebeta-like O
HDL O
. O
[]

One O
case O
per O
group O
was O
electively O
converted O
to O
open O
surgery O
. O
[]

Anxiolytics O
in O
patients O
suffering O
a O
suspected O
acute O
coronary O
syndrome O
: O
multi-centre O
randomised O
controlled O
trial O
in O
Emergency O
Medical O
Service O
. O
[]

Patients O
were O
followed O
up O
at O
4 O
, O
12 O
, O
and O
24 O
months O
. O
[]

On O
rioprostil O
, O
14.9 O
% O
of O
patients O
showed O
a O
relapse B-outcome ['Physiological-Clinical']
after O
6 O
months O
compared O
to O
10.1 O
% O
on O
ranitidine O
. O
['Physiological-Clinical']

New O
mini-extracorporeal O
circulation O
system O
( O
ECC.O O
) O
is O
a O
safe O
technique O
in O
coronary O
surgery O
. O
[]

Traditionally O
, O
this O
information O
has O
been O
collected O
with O
paper O
and O
pencil O
. O
[]

METHODS O
Three O
hundred O
sixty-six O
patients O
undergoing O
elective O
cardiac O
surgery O
with O
full O
median O
sternotomy O
and O
having O
body O
surface O
area O
( O
BSA O
) O
less O
than O
1.5 O
m O
( O
2 O
) O
were O
randomly O
assigned O
to O
receive O
PDS O
( O
n O
= O
181 O
) O
or O
stainless O
steel O
( O
SS O
, O
n O
= O
185 O
) O
sternal O
approximation O
. O
[]

DESIGN O
We O
used O
a O
randomized O
, O
1-y O
intervention O
for O
dairy O
calcium O
. O
[]

The O
mean O
volumes B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
injected I-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
needed O
for O
a O
positive O
result B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
inferomedial I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
superomedial I-outcome ['Physiological-Clinical']
needle I-outcome ['Physiological-Clinical']
locations B-outcome ['Physiological-Clinical']
were O
64.0 O
and O
95.2 O
mL O
, O
respectively O
; O
this O
difference O
was O
significant O
( O
p O
= O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Wound B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
developed O
in O
14 O
( O
25 O
% O
) O
of O
these O
patients O
( O
P O
greater O
than O
.05 O
) O
. O
['Physiological-Clinical']

Randomized O
, O
comparative O
study O
of O
the O
efficacy O
and O
safety O
of O
artesunate O
plus O
amodiaquine O
, O
administered O
as O
a O
single O
daily O
intake O
versus O
two O
daily O
intakes O
in O
the O
treatment O
of O
uncomplicated O
falciparum O
malaria O
. O
[]

Of O
63 O
patients O
undergoing O
deep O
anterior O
resection O
of O
the O
rectum O
, O
39 O
patients O
received O
a O
straight O
colo-anal O
anastomosis O
( O
CAA O
) O
, O
24 O
additionally O
had O
a O
colon-j-pouch O
( O
CPA O
) O
constructed O
. O
[]

The O
prepartum O
group O
received O
two O
injections O
of O
the O
vaccine O
at O
8 O
and O
4 O
wk O
before O
calving O
, O
and O
the O
postpartum O
group O
received O
two O
injections O
at O
1 O
and O
5 O
wk O
after O
calving O
. O
[]

Poor O
performance O
on O
the O
SAT O
was O
highly O
correlated O
with O
deficits O
in O
early O
processing O
, O
which O
were O
also O
related O
to O
poor O
performance O
on O
the O
Wechsler O
Memory O
Scale O
Attention/Concentration O
index O
. O
[]

However O
, O
in O
the O
second O
week O
pain B-outcome ['Physiological-Clinical']
scores O
increased O
more O
in O
the O
potassium O
titanyl O
phosphate O
laser O
group O
than O
in O
the O
bipolar O
radiofrequency O
group O
( O
means O
8.5 O
and O
6 O
, O
respectively O
) O
. O
['Physiological-Clinical']

These O
muscles O
also O
demonstrated O
the O
most O
common O
SAS-triggered B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
without O
perturbation O
. O
['Physiological-Clinical']

Changes O
in O
symptomatology B-outcome ['Physiological-Clinical']
, O
exercise B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
, O
and O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
were O
assessed O
serially O
during O
the O
two-month O
treatment O
period O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

All O
children O
were O
assessed O
before O
and O
after O
the O
intervention O
, O
and O
families O
completed O
questionnaires O
assessing O
family B-outcome ['Life-Impact']
stress O
, O
support O
, O
and O
['Life-Impact']

The O
use O
of O
glycerol O
as O
an O
osmotic O
agent O
in O
two O
different O
concentrations O
( O
92 O
mmol/l O
and O
272 O
mmol/l O
) O
in O
peritoneal O
dialysis O
fluid O
was O
investigated O
over O
3 O
days O
in O
six O
patients O
on O
continuous O
ambulatory O
peritoneal O
dialysis O
and O
compared O
with O
two O
concentrations O
of O
glucose O
( O
76 O
mmol/l O
and O
215 O
mmol/l O
) O
in O
the O
same O
patients O
. O
[]

No O
mortality B-outcome ['Mortality']
was O
observed O
. O
['Mortality']

Pain B-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
procedure I-outcome ['Physiological-Clinical']
, O
reduction O
in O
bleeding B-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
rectum I-outcome ['Physiological-Clinical']
and O
overall B-outcome ['Life-Impact']
patient I-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
, O
were O
studied O
as O
outcome O
measures O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

RESULTS O
One O
hundred O
twelve O
potential O
participants O
were O
screened O
; O
73 O
were O
enrolled O
, O
randomized O
, O
and O
included O
in O
the O
final O
analysis O
. O
[]

OBJECTIVE O
The O
presence O
of O
cognitive B-outcome ['Life-Impact']
dysfunction I-outcome ['Life-Impact']
in O
schizophrenia O
has O
been O
well O
documented O
, O
but O
questions O
remain O
about O
whether O
there O
are O
relationships O
between O
this O
dysfunction B-outcome ['Physiological-Clinical']
and O
clinical B-outcome ['Physiological-Clinical']
symptomatology I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Quantitative O
muscle O
strength O
testing O
sum O
scores O
declined O
in O
both O
treatment O
groups O
, O
-0.2 O
% O
for O
methotrexate O
and O
-3.4 O
% O
for O
placebo O
( O
95 O
% O
confidence O
interval O
= O
-2.5 O
% O
to O
+9.1 O
% O
for O
difference O
) O
. O
[]

Transfusion B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
and O
surgical B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
were O
recorded O
. O
['Resource-use', 'Life-Impact']

An O
incremental O
cost-effectiveness O
analysis O
was O
performed O
using O
data O
from O
a O
randomized O
controlled O
trial O
among O
cancer O
patients O
receiving O
inpatient O
rehabilitation O
. O
[]

RESULTS O
As O
a O
result O
of O
early O
closure O
, O
503 O
of O
1,242 O
planned O
patients O
were O
randomly O
assigned O
( O
251 O
to O
gefitinib O
and O
252 O
to O
placebo O
) O
. O
[]

Influence O
of O
acute O
myocardial O
infarction O
location O
on O
in-hospital O
and O
late O
outcome O
after O
primary O
percutaneous O
transluminal O
coronary O
angioplasty O
versus O
tissue O
plasminogen O
activator O
therapy O
. O
[]

After O
1 O
month O
of O
vaccination O
with O
3 O
doses O
of O
the O
OPV O
( O
HDC O
) O
vaccine O
, O
the O
immune B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
I I-outcome ['Physiological-Clinical']
, O
II B-outcome ['Physiological-Clinical']
, O
III B-outcome ['Physiological-Clinical']
type I-outcome ['Physiological-Clinical']
were O
98.28 O
% O
, O
99.45 O
% O
, O
and O
95.71 O
% O
respectively O
, O
the O
GMTs B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
I I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
III I-outcome ['Physiological-Clinical']
type I-outcome ['Physiological-Clinical']
in O
susceptible O
children O
were O
1:1243.72 O
, O
1:234.38 O
and O
1:273.10 O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

t.w O
. O
[]

Clobazam O
in O
catamenial O
epilepsy O
. O
[]

Furthermore O
, O
positive O
affect B-outcome ['Life-Impact']
increased O
in O
the O
intervention O
group O
, O
but O
not O
in O
the O
control O
group O
. O
['Life-Impact']

The O
role O
of O
pre-operative O
short-term O
pulmonary O
rehabilitation O
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
who O
undergo O
coronary O
artery O
bypass O
graft O
surgery O
has O
been O
assessed O
for O
the O
first O
time O
prospectively O
. O
[]

We O
hypothesized O
that O
the O
high O
rate O
of O
success O
and O
the O
lower O
energy O
requirement O
associated O
with O
biphasic O
cardioversion O
might O
eliminate O
any O
advantage O
of O
the O
transesophageal O
approach O
. O
[]

aureus O
, O
and O
to O
a O
minor O
degree O
diphtheroids O
( O
Corynebacterium O
species O
) O
. O
[]

PATIENTS O
AND O
METHOD O
115 O
patients O
( O
mean O
age O
: O
14 O
years O
10 O
months O
; O
females O
: O
77 O
males O
: O
38 O
) O
treated O
in O
the O
Department O
of O
Orthodontics O
, O
University O
of O
Munich O
were O
included O
in O
the O
study O
. O
[]

Piroxicam O
20 O
mg O
was O
significantly O
more O
efficacious O
than O
placebo O
for O
all O
analgesic O
variables O
, O
including O
the O
sum O
of O
the O
pain B-outcome ['Physiological-Clinical']
intensity O
differences O
( O
SPID O
) O
, O
total O
pain B-outcome ['Physiological-Clinical']
relief O
( O
TOTAL O
) O
, O
percent O
SPID O
, O
duration O
of O
effect O
, O
and O
time O
to O
remedication B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

One O
group O
( O
FDTV O
) O
received O
2/180 O
mg O
once O
a O
day O
; O
the O
other O
group O
received O
T O
2 O
mg O
once O
a O
day O
. O
[]

In O
task O
one O
, O
participants O
brought O
their O
eyes O
to O
the O
target O
. O
[]

Experience O
and O
perception O
of O
bodily O
symptoms O
therefore O
play O
an O
important O
role O
in O
social O
anxiety O
. O
[]

Protocol-directed O
angiography O
has O
been O
performed O
at O
randomly O
assigned O
intervals O
, O
weighted O
toward O
the O
end O
of O
the O
study O
period O
. O
[]

0.12 O
) O
ng?ml???h?? O
, O
AII O
( O
111.25 O
? O
[]

Among O
the O
patients O
with O
previous O
CABG O
, O
those O
with O
saphenous O
vein O
graft O
intervention O
using O
a O
first-generation O
drug-eluting O
stent O
had O
worse O
clinical O
outcomes O
than O
those O
with O
a O
native O
coronary O
artery O
target O
only O
. O
[]

Each O
session O
lasted O
5 O
to O
10 O
min O
, O
children O
in O
the O
treatment O
group O
were O
stimulated O
at O
the O
front O
and O
back O
sides O
of O
their O
body O
and O
the O
head O
by O
using O
Seven-star O
Needles O
. O
[]

We O
found O
significant O
treatment O
x O
baseline O
drinking B-outcome ['Life-Impact']
day I-outcome ['Life-Impact']
interaction O
['Life-Impact']

Isolates O
that O
showed O
low O
sensitivity B-outcome ['Physiological-Clinical']
to O
mefloquine O
in O
vitro O
were O
sensitive O
to O
chloroquine O
in O
vitro O
, O
and O
the O
4 O
that O
were O
resistant O
to O
chloroquine O
were O
sensitive O
to O
mefloquine O
. O
['Physiological-Clinical']

Loads O
ranged O
in O
magnitude O
from O
imperceptible O
( O
R0/E0 O
) O
through O
just O
perceptible O
( O
R1/E1 O
) O
to O
large O
( O
R2/E2 O
) O
and O
resulted O
in O
respiratory O
pattern O
responses O
that O
were O
due O
to O
reflex O
responses O
alone O
( O
R0/E0 O
) O
or O
to O
a O
combination O
of O
reflex O
responses O
and O
behavioral O
reactions O
to O
the O
perception O
of O
impeded O
breathing O
( O
R1/E1 O
and O
R2/E2 O
) O
. O
[]

Learning O
about O
the O
equal O
sign O
: O
does O
comparing O
with O
inequality O
symbols O
help O
? O
[]

MATERIAL O
AND O
METHODS O
This O
was O
a O
double-blind O
randomized O
controlled O
trial O
conducted O
in O
a O
tertiary O
care O
hospital O
. O
[]

CONCLUSIONS O
Our O
formula O
for O
cuffed O
tube O
selection O
is O
appropriate O
for O
young O
children O
. O
[]

Treatments O
were O
arranged O
as O
a O
2 O
x O
4 O
factorial O
. O
[]

Despite O
the O
high O
prevalence O
of O
symptomatic O
overlap O
, O
the O
underlying O
etiology O
remains O
poorly O
defined O
. O
[]

Steroid-resistant B-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
rejections I-outcome ['Physiological-Clinical']
were O
reported O
for O
8.6 O
% O
( O
induction O
) O
and O
8.9 O
% O
( O
noninduction O
) O
of O
patients O
. O
['Physiological-Clinical']

Patients O
without O
evidence O
of O
mediastinal O
involvement O
did O
not O
have O
mediastinal O
radiotherapy O
. O
[]

Salmeterol O
versus O
slow-release O
theophylline O
combined O
with O
ketotifen O
in O
nocturnal O
asthma O
: O
a O
multicentre O
trial O
. O
[]

From O
originally O
918 O
consecutive O
patients O
operated O
on O
711 O
fulfilled O
the O
entry O
criteria O
. O
[]

The O
control O
group O
received O
rehabilitation O
training O
including O
ABA O
training O
, O
the O
Conductive O
Education O
Approach O
and O
the O
training O
of O
sensory O
integration O
, O
about O
90 O
sessions O
for O
each O
training O
; O
the O
treatment O
group O
received O
acupuncture O
treatment O
for O
60-90 O
sessions O
after O
the O
rehabilitation O
training O
. O
[]

Patients O
( O
N O
= O
96 O
; O
5-17 O
years O
) O
, O
received O
risperidone O
( O
low-dose O
: O
0.125 O
mg/day O
[ O
20 O
to O
< O
45 O
kg O
] O
, O
0.175 O
mg/day O
[ O
> O
45 O
kg O
] O
or O
high-dose O
: O
1.25 O
mg/day O
[ O
20 O
to O
< O
45 O
kg O
] O
, O
1.75 O
mg/day O
[ O
> O
45 O
kg O
] O
) O
or O
placebo O
. O
[]

Third- O
and O
fourth-grade O
students O
in O
a O
comparing O
symbols O
group O
learned O
about O
the O
greater O
than O
, O
less O
than O
, O
and O
equal O
signs O
and O
had O
the O
opportunity O
to O
compare O
the O
inequality O
symbols O
with O
the O
equal O
sign O
. O
[]

Several O
ureteral B-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
at O
operative O
laparoscopy O
have O
been O
reported O
. O
['Physiological-Clinical']

Ambulatory O
phlebectomy O
versus O
compression O
sclerotherapy O
: O
results O
of O
a O
randomized O
controlled O
trial O
. O
[]

[ O
Propofol O
infusion O
for O
the O
maintenance O
of O
short-term O
anesthesia B-outcome ['Resource-use']
] O
. O
['Resource-use']

They O
used O
case O
descriptions O
from O
the O
DSM-IV O
casebook O
. O
[]

BACKGROUND O
Different O
types O
of O
single-incision O
laparoscopic O
surgery O
( O
SILS O
) O
have O
become O
increasingly O
popular O
. O
[]

Long-term O
follow O
up O
is O
needed O
to O
determine O
effects O
and O
side O
effects O
of O
health O
checks O
and O
health O
talks O
. O
[]

The O
prolonged O
t O
( O
1/2 O
) O
of O
N7-GP O
can O
potentially O
reduce O
the O
dosing O
frequency O
and O
thereby O
facilitate O
convenience O
and O
compliance O
, O
which O
are O
two O
significant O
barriers O
to O
effective O
prophylaxis O
. O
[]

In O
the O
control O
group O
, O
patients O
were O
discharged O
from O
hospital O
following O
standard O
procedures O
that O
included O
a O
discharge O
letter O
to O
the O
general O
practitioner O
listing O
current O
medications O
. O
[]

The O
prophylactic O
effect O
of O
itraconazole O
capsules O
and O
fluconazole O
capsules O
for O
systemic B-outcome ['Physiological-Clinical']
fungal I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
patients O
with O
acute O
myeloid O
leukemia O
and O
myelodysplastic O
syndromes O
: O
a O
Japanese O
multicenter O
randomized O
, O
controlled O
study O
. O
['Physiological-Clinical']

RESULTS O
At O
the O
end O
of O
the O
infusions O
of O
Ringer O
's O
acetate O
, O
pulse O
oximetry O
haemoglobin O
concentration O
had O
decreased O
more O
than O
the O
true O
haemoglobin O
concentration O
( O
15 O
vs. O
8 O
% O
; O
P O
< O
0.005 O
; O
n O
= O
10 O
) O
whereas O
starch O
solution O
decreased O
pulse O
oximetry O
haemoglobin O
concentration O
less O
than O
true O
haemoglobin O
concentration O
( O
7 O
vs. O
11 O
% O
; O
P O
< O
0.02 O
; O
n O
= O
20 O
) O
. O
[]

ETAC O
Study O
Group O
. O
[]

IMPLICATIONS O
Attention O
to O
the O
psychological O
aspects O
of O
breast O
cancer O
risk O
will O
be O
critical O
in O
the O
development O
of O
risk-counseling O
programs O
that O
incorporate O
testing O
for O
the O
recently O
cloned O
breast O
cancer O
susceptibility O
gene O
, O
BRCA1 O
( O
and O
BRCA2 O
when O
that O
gene O
has O
also O
been O
cloned O
) O
. O
[]

BACKGROUND O
A O
recent O
randomized O
trial O
to O
compare O
external O
beam O
radiation O
therapy O
( O
EBRT O
) O
to O
cryoablation O
for O
localized O
disease O
showed O
cryoablation O
to O
be O
noninferior O
to O
external O
beam O
EBRT O
in O
disease O
progression O
and O
overall O
and O
disease-specific O
survival O
. O
[]

Although O
esmolol O
may O
be O
used O
as O
a O
primary O
hypotensive O
agent O
, O
the O
potential O
for O
marked B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
must O
be O
recognized O
. O
['Physiological-Clinical']

intravenously O
or O
0.5 O
g O
imipenem O
q.i.d O
. O
[]

We O
further O
show O
that O
these O
regions O
are O
sensitive O
to O
the O
scrambling O
of O
both O
pitch B-outcome ['Physiological-Clinical']
and O
rhythmic B-outcome ['Physiological-Clinical']
structure I-outcome ['Physiological-Clinical']
but O
are O
insensitive O
to O
high-level O
linguistic B-outcome ['Life-Impact']
structure I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

In O
a O
double-blind O
placebo-controlled O
crossover O
trial O
23 O
autistic O
children O
, O
aged O
3-7 O
years O
, O
were O
treated O
with O
a O
mean O
daily O
dosage O
of O
1 O
mg/kg O
naltrexone O
for O
4 O
weeks O
. O
[]

Effects O
of O
mecamylamine O
on O
human O
cigarette O
smoking O
and O
subjective O
ratings O
. O
[]

The O
sample O
included O
15 O
children O
aged O
2-16 O
years O
with O
autism O
spectrum O
disorder O
. O
[]

Predictors O
of O
survival O
and O
eradication O
of O
Mycobacterium O
avium O
complex O
bacteremia O
( O
MAC O
) O
in O
AIDS O
patients O
in O
the O
Canadian O
randomized O
MAC O
treatment O
trial O
. O
[]

The O
future O
of O
SILS O
depends O
on O
further O
improvements O
in O
the O
available O
equipment O
or O
the O
development O
of O
new O
approaches O
such O
as O
needlescopically O
assisted O
or O
robotically O
assisted O
procedures O
. O
[]

The O
Digitalis O
Investigation O
Group O
( O
DIG O
) O
trial O
was O
a O
randomized O
, O
double-blind O
placebo-controlled O
trial O
whose O
primary O
objective O
was O
to O
determine O
whether O
digoxin O
had O
beneficial O
, O
harmful O
, O
or O
no O
effect O
on O
total O
mortality O
in O
patients O
with O
heart O
failure O
who O
were O
in O
sinus O
rhythm O
and O
whose O
ejection O
fraction O
was O
< O
/=0.45 O
. O
[]

RESULTS O
There O
was O
no O
difference O
in O
PT O
, O
PTA O
, O
INR O
between O
the O
2 O
groups O
, O
but O
significant O
differences O
were O
observed O
in O
APTT O
and O
TT O
and O
fibrinogen O
( O
Fbg O
) O
. O
[]

Changes O
in O
spinal O
and/or O
supraspinal O
central O
nervous O
system O
pain O
processing O
due O
to O
visceral O
nociceptive O
input O
play O
an O
important O
role O
in O
this O
pain O
. O
[]

In O
high O
risk O
hypertensive O
subjects O
with O
incidental O
and O
unilateral O
renal O
artery O
stenosis O
percutaneous O
revascularization O
with O
stent O
improves O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
but O
not O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
in O
vitro O
dissolution O
study O
was O
adopted O
to O
compare O
the O
dissolution B-outcome ['Physiological-Clinical']
behavior I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
FDC I-outcome ['Physiological-Clinical']
with O
respect O
to O
separate O
marketed O
tablets O
. O
['Physiological-Clinical']

Intravenous O
flecainide O
versus O
verapamil O
for O
acute O
conversion O
of O
paroxysmal O
atrial O
fibrillation O
or O
flutter O
to O
sinus O
rhythm O
. O
[]

FINDINGS O
100 O
patients O
were O
assigned O
the O
high-dose O
regimen O
, O
and O
100 O
the O
control O
regimen O
. O
[]

Supplementation O
of O
diets O
with O
increasing O
levels O
of O
RPLM B-outcome ['Physiological-Clinical']
did O
not O
affect O
( O
P O
> O
.10 O
) O
ADG O
or O
carcass O
characteristics O
. O
['Physiological-Clinical']

These O
data O
suggest O
the O
effectiveness O
of O
interferon O
given O
as O
induction O
and O
as O
maintenance O
treatment O
in O
the O
therapy O
of O
II O
type O
mixed O
essential O
cryoglobulinemia O
. O
[]

Evaluation O
of O
three O
dosage-prediction O
methods O
for O
initial O
in-hospital O
stabilization O
of O
warfarin O
therapy O
. O
[]

Given O
the O
current O
limitations O
of O
psychosocial O
treatments O
and O
the O
lack O
of O
pharmacological O
treatments O
for O
social O
cognitive O
deficits O
, O
the O
development O
of O
novel O
therapeutic O
agents O
could O
greatly O
enhance O
functional O
recovery O
in O
schizophrenia O
. O
[]

RESULTS O
Patients O
with O
SH O
showed O
higher O
QT B-outcome ['Physiological-Clinical']
dispersion I-outcome ['Physiological-Clinical']
and O
lower B-outcome ['Physiological-Clinical']
HRV I-outcome ['Physiological-Clinical']
measures O
than O
healthy O
controls O
( O
P O
< O
0.01 O
for O
all O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
200 O
patients O
were O
recruited O
to O
our O
single-centre O
, O
open O
randomised O
controlled O
trial O
after O
moderately O
severe O
poisoning O
by O
anticholinesterase O
pesticide O
. O
[]

Clonidine O
treatment O
of O
hyperactive O
and O
impulsive O
children O
with O
autistic O
disorder O
. O
[]

Mortality B-outcome ['Mortality']
associated O
with O
JET O
is O
lower O
than O
historically O
reported O
, O
but O
morbidity B-outcome ['Physiological-Clinical']
remains O
high O
. O
['Mortality', 'Physiological-Clinical']

We O
aimed O
to O
assess O
the O
effectiveness O
of O
a O
constant O
pralidoxime O
infusion O
compared O
with O
repeated O
bolus O
doses O
to O
treat O
patients O
with O
moderately O
severe O
poisoning O
from O
organophosphorus O
pesticides O
. O
[]

Significant O
depression O
of O
the O
soleus O
H-reflex B-outcome ['Physiological-Clinical']
was O
observed O
when O
subjects O
swung O
their O
ipsilateral O
arms O
or O
both O
arms O
reciprocally O
during O
testing O
. O
['Physiological-Clinical']

During O
the O
postoperative O
period O
, O
the O
patients O
were O
assessed O
for O
the O
occurrence O
and O
severity O
of O
pruritus B-outcome ['Physiological-Clinical']
( O
classified O
as O
absent O
, O
mild O
, O
moderate O
, O
or O
severe O
) O
or O
other O
untoward B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Beneficial O
effects O
on O
the O
severity O
and O
duration O
of O
thrombocytopenia B-outcome ['Physiological-Clinical']
were O
also O
noted O
. O
['Physiological-Clinical']

NRT B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
, O
level O
of O
nicotine B-outcome ['Life-Impact']
dependence B-outcome ['Life-Impact']
and O
genotype B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
displayed O
significant O
interactive O
effects O
on O
successful O
quitting O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Plans O
were O
optimised O
according O
to O
parameters O
adopted O
from O
RTOG O
trials O
using O
both O
an O
algorithm O
with O
a O
simple O
homogeneity O
correction O
( O
Type O
A O
) O
and O
a O
more O
advanced O
algorithm O
( O
Type O
B O
) O
. O
[]

This O
randomised O
, O
double-blind O
, O
placebo-controlled O
study O
was O
designed O
to O
evaluate O
the O
ability O
of O
the O
orally O
administered O
matrix O
metalloproteinase O
inhibitor O
, O
marimastat O
, O
to O
prolong O
survival B-outcome ['Mortality']
in O
patients O
with O
non-resectable O
gastric O
and O
gastro-oesophageal O
adenocarcinoma O
. O
['Mortality']

In O
this O
study O
, O
the O
effects O
of O
levosimendan O
and O
dobutamine O
on O
plasma O
levels O
of O
proinflammatory O
and O
proapoptotic O
mediators O
in O
decompensated O
HF O
were O
compared O
and O
correlated O
with O
the O
concomitant O
effects O
on O
cardiac O
function O
and O
prognosis O
. O
[]

Study O
outcomes O
were O
safety O
profile O
, O
pharmacokinetics B-outcome ['Physiological-Clinical']
, O
immunogenicity B-outcome ['Physiological-Clinical']
, O
and O
clinical O
effects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Interaction O
between O
HFLCS O
and O
bracket O
type O
was O
not O
statistically O
significant O
( O
P O
= O
0.15 O
) O
. O
[]

Randomised O
controlled O
trial O
of O
improvisational O
music O
therapy O
's O
effectiveness O
for O
children O
with O
autism O
spectrum O
disorders O
( O
TIME-A O
) O
: O
study O
protocol O
. O
[]

Although O
it O
has O
been O
suggested O
that O
individuals O
with O
an O
Autism O
spectrum O
disorder O
( O
ASD O
) O
process O
faces O
less O
holistically O
than O
typically O
developing O
controls O
, O
there O
are O
few O
direct O
investigations O
of O
this O
hypothesis O
. O
[]

Slit-lamp O
biomicroscopy O
and O
circadian O
intra O
ocular O
pressure O
( O
IOP O
) O
curve O
was O
performed O
at O
Day O
3 O
, O
every O
3 O
hours O
from O
6 O
pm O
. O
[]

BACKGROUND O
The O
study O
evaluated O
the O
efficacy O
of O
recombinant O
human O
antithrombin O
( O
rhAT O
) O
for O
restoring O
heparin B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
in O
heparin O
resistant O
patients O
undergoing O
cardiac O
surgery O
. O
['Physiological-Clinical']

No O
significant O
difference O
( O
all O
P O
values O
> O
0.05 O
) O
was O
found O
in O
baseline O
data O
between O
the O
two O
groups O
. O
[]

A O
randomized O
phase O
III O
study O
. O
[]

The O
children O
presented O
with O
a O
chief O
complaint O
of O
severely O
disruptive O
symptoms O
related O
to O
autistic O
disorder O
. O
[]

We O
report O
preliminary O
results O
from O
an O
ongoing O
randomized O
controlled O
trial O
of O
51 O
children O
aged O
2 O
years O
0 O
months O
to O
4 O
years O
11 O
months O
. O
[]

MATERIAL O
AND O
METHOD O
One O
hundred O
women O
who O
gave O
birth O
vaginally O
with O
episiotomy O
and O
a O
second- O
or O
third-degree O
tear O
, O
were O
randomly O
assign O
to O
receive O
two O
tablets O
oftramadol O
50 O
mg O
or O
two O
tablets O
ofplacebo O
, O
the O
pill O
were O
physically O
similar O
to O
the O
real O
drug O
. O
[]

METHODS O
A O
total O
of O
81 O
schizophrenics O
were O
randomly O
divided O
into O
study O
group O
with O
paliperidone O
extended-release O
tablets O
and O
control O
group O
with O
risperidone O
for O
a O
12-week O
treatment O
. O
[]

There O
was O
a O
significant O
interaction O
between O
fidelity O
and O
group O
. O
[]

Spring-born O
Hereford O
x O
Angus O
heifers O
( O
n O
= O
206 O
) O
were O
used O
to O
determine O
effects O
of O
energy O
supplementation O
programs O
and O
amount O
of O
starch O
in O
the O
diet O
on O
incidence O
of O
puberty B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Prolonged O
coadministration O
of O
N-acetylcysteine O
and O
nitroglycerin O
potentiated O
the O
acute B-outcome ['Physiological-Clinical']
venodilator I-outcome ['Physiological-Clinical']
effect O
of O
nitroglycerin O
as O
estimated O
by O
changes O
in O
venous B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( O
nitroglycerin O
plus O
N-acetylcysteine O
, O
4.45 O
+/- O
0.36 O
ml/100 O
g O
; O
nitroglycerin O
plus O
placebo O
, O
3.65 O
+/- O
0.46 O
ml/100 O
g O
, O
mean O
+/- O
SEM O
, O
p O
< O
0.05 O
) O
and O
prevented O
development B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
tolerance I-outcome ['Life-Impact']
as O
seen O
after O
23 O
h O
of O
treatment O
with O
nitroglycerin O
plus O
placebo O
( O
4.35 O
+/- O
0.25 O
vs. O
3.47 O
+/- O
0.41 O
ml/100 O
g O
, O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Patients O
with O
writer O
's O
cramp O
present O
sensory O
and O
representational O
abnormalities O
relevant O
to O
motor O
control O
, O
such O
as O
impairment O
in O
the O
temporal O
discrimination O
between O
tactile O
stimuli O
and O
in O
pure O
motor O
imagery O
tasks O
, O
like O
the O
mental O
rotation O
of O
corporeal O
and O
inanimate O
objects O
. O
[]

CONCLUSIONS O
The O
authors O
conclude O
that O
both O
methods O
were O
safe O
, O
but O
the O
stapled O
technique O
resulted O
in O
more O
stricture B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION O
ClinicalTrials.gov O
: O
NCT00678405ISRCTN O
: O
ISRCTN04119516 O
. O
[]

Stepwise O
linear O
regression O
analysis O
showed O
that O
loss O
of O
periprosthetic O
BMD B-outcome ['Physiological-Clinical']
in O
the O
proximal O
high-pressure O
region O
after O
2 O
years O
increased O
with O
higher O
postoperative B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
and O
when O
the O
uncemented O
design O
had O
been O
used O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Results O
support O
the O
usefulness O
of O
the O
program O
to O
teach O
the O
detection B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
facial I-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
. O
['Life-Impact']

Potential O
effect O
of O
the O
risk O
of O
ovarian O
cancer O
algorithm O
( O
ROCA O
) O
on O
the O
mortality B-outcome ['Mortality']
outcome O
of O
the O
Prostate O
, O
Lung O
, O
Colorectal O
and O
Ovarian O
( O
PLCO O
) O
trial O
. O
['Mortality']

METHODS O
Packed O
red O
cells O
without O
buffy O
coat O
( O
PC O
group O
) O
were O
compared O
with O
filtered O
, O
leucoreduced O
, O
red O
cells O
( O
LD O
group O
) O
in O
a O
randomized O
trial O
of O
697 O
patients O
with O
colorectal O
carcinoma O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
extended-release O
niacin O
( O
niacin O
ER O
) O
either O
alone O
or O
in O
combination O
with O
atorvastatin O
for O
the O
lipid O
profile O
modification O
in O
the O
patients O
with O
coronary O
heart O
disease O
( O
CHD O
) O
and O
its O
equivalents O
. O
[]

They O
were O
all O
reconstructed O
with O
stomach O
interposition O
through O
the O
retrosternal O
route O
. O
[]

However O
, O
the O
proportion O
of O
patients B-outcome ['Mortality']
dying I-outcome ['Mortality']
beyond O
30 O
days O
was O
similar O
in O
the O
three O
groups O
( O
44 O
% O
, O
43 O
% O
, O
and O
41 O
% O
of O
death O
, O
respectively O
) O
. O
['Mortality']

At O
15 O
and O
30-day O
follow-ups O
, O
control O
group O
and O
nonsteroid O
leads O
show O
a O
higher O
threshold O
value O
growth O
( O
in O
unipolar O
from O
0.16 O
+/- O
0.11 O
to O
1.19 O
+/- O
0.85 O
microJ O
; O
in O
bipolar O
from O
0.18 O
+/- O
0.13 O
to O
1.24 O
+/- O
0.88 O
microJ O
) O
than O
the O
membrane O
steroid O
leads O
( O
in O
unipolar O
from O
0.13 O
+/- O
0.11 O
to O
0.70 O
+/- O
0.39 O
microJ O
; O
in O
bipolar O
from O
0.23 O
+/- O
0.32 O
to O
0.76 O
+/- O
0.36 O
microJ O
) O
; O
the O
threshold O
of O
nonsteroid O
leads O
decreases O
after O
1-3 O
months O
and O
it O
settles O
at O
the O
same O
threshold O
level O
of O
the O
leads O
with O
membrane O
and O
steroid O
( O
in O
unipolar O
0.60 O
+/- O
0.33 O
microJ O
; O
in O
bipolar O
0.55 O
+/- O
0.26 O
microJ O
) O
, O
which O
has O
been O
stable O
since O
the O
first O
month O
. O
[]

Eighteen O
( O
62 O
% O
) O
of O
29 O
patients O
treated O
with O
OK-432 O
had O
a O
fever O
, O
but O
well O
tolerated O
. O
[]

Assessment O
of O
analgesia O
and O
sedation O
during O
vagotonia O
( O
first O
part O
of O
the O
study O
) O
and O
hypokinetic O
type O
of O
haemodynamics O
( O
second O
part O
of O
the O
study O
) O
was O
carried O
out O
with O
visual O
analogue O
scale O
( O
VAS O
) O
and O
Richmond B-outcome ['Physiological-Clinical']
scale I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
To O
investigate O
whether O
a O
sham O
device O
( O
a O
validated O
sham O
acupuncture O
needle O
) O
has O
a O
greater O
placebo O
effect O
than O
an O
inert O
pill O
in O
patients O
with O
persistent O
arm O
pain O
. O
[]

All O
IVUS O
images O
( O
immediately O
after O
the O
procedure O
and O
at O
6-month O
follow-up O
) O
were O
analyzed O
at O
an O
independent O
core O
laboratory O
in O
a O
blind O
manner O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
specify O
the O
most O
accurate O
, O
reliable O
and O
valid O
technique O
for O
a O
general O
sexual O
behavioral O
survey O
in O
Japan O
. O
[]

Ninety-one O
female O
bulimic O
outpatients O
received O
lithium O
carbonate O
or O
placebo O
on O
a O
random O
basis O
, O
after O
being O
separated O
into O
depressed O
and O
nondepressed O
subgroups O
, O
in O
an O
8-week O
double-blind O
trial O
. O
[]

At O
the O
24W O
of O
follow O
up O
, O
in O
the O
patients O
who O
were O
ELISPOT O
positive O
, O
HBV B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
became O
undetectable O
in O
4 O
of O
the O
patients O
treated O
with O
recombinant O
hepatitis O
B O
vaccine O
( O
at O
doses O
of O
90 O
micrograms O
and O
60 O
micrograms O
) O
, O
and O
HBeAg/Anti-HBe B-outcome ['Physiological-Clinical']
seroconversion I-outcome ['Physiological-Clinical']
or O
HBeAg B-outcome ['Physiological-Clinical']
disappearance I-outcome ['Physiological-Clinical']
were O
found O
in O
9 O
of O
the O
cases O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Twelve O
patients O
with O
stable O
chronic O
heart O
failure O
and O
10 O
matched O
controls O
underwent O
repeated O
assessment O
of O
airways O
resistance O
using O
impulse O
oscillometry O
and O
peak O
exercise O
testing O
with O
metabolic O
gas O
exchange O
after O
receiving O
nebulized O
saline O
as O
placebo O
or O
combined O
salbutamol O
and O
ipratropium O
bromide O
in O
a O
double-blind O
crossover O
randomized O
fashion O
. O
[]

Participants O
were O
all O
musically O
untrained O
and O
were O
divided O
into O
a O
group O
of O
12 O
high-functioning O
individuals O
with O
autism O
and O
a O
group O
of O
12 O
normally O
developing O
individuals O
. O
[]

The O
activated B-outcome ['Physiological-Clinical']
clotting I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
was O
211 O
+/- O
16 O
seconds O
in O
the O
intravenous O
group O
and O
213 O
+/- O
17 O
seconds O
in O
the O
intra-arterial O
group O
, O
a O
statistically O
insignificant O
difference O
( O
t O
= O
-1.095 O
, O
p O
> O
0.2 O
) O
. O
['Physiological-Clinical']

The O
results O
support O
treatment O
with O
progesterone O
caproate O
for O
the O
prevention O
of O
premature O
labor O
. O
[]

A O
multicenter O
, O
randomized O
comparison O
of O
levonorgestrel/ethinyl O
estradiol O
( O
100 O
micrograms/20 O
micrograms O
) O
and O
norethindrone/ethinyl O
estradiol O
( O
1000 O
micrograms/20 O
micrograms O
) O
. O
[]

Contrast-induced B-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
was O
defined O
as O
an O
increase O
in O
serum O
creatinine O
level O
> O
25 O
% O
or O
0.5 O
mg/dL O
after O
48 O
hours O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
determine O
whether O
a O
multimodal O
physiotherapy O
programme O
including O
taping O
, O
exercises O
, O
and O
massage O
is O
effective O
for O
knee O
osteoarthritis O
, O
and O
if O
benefits O
can O
be O
maintained O
with O
self O
management O
. O
[]

Comparison O
of O
hypnotherapy O
with O
systematic O
relaxation O
in O
the O
treatment O
of O
cigarette O
habituation O
. O
[]

CONCLUSIONS O
The O
LD O
( O
50 O
) O
for O
acute B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
mallard O
ducks O
was O
60 O
% O
of O
their O
total O
blood O
volume O
. O
['Physiological-Clinical']

RESULTS O
At O
6 O
months O
, O
similar O
numbers O
of O
events O
occurred O
in O
each O
group O
: O
8 O
( O
placebo O
) O
, O
7 O
( O
low O
dose O
) O
, O
and O
8 O
( O
high O
dose O
) O
, O
without O
deaths O
. O
[]

Group O
A O
( O
n O
= O
25 O
) O
was O
treated O
with O
a O
904 O
Ga-As O
laser O
CW O
, O
frequency O
50 O
Hz O
, O
intensity O
40 O
mW O
and O
energy O
density O
2.4 O
J/cm O
( O
2 O
) O
, O
plus O
plyometric O
exercises O
and O
group O
B O
( O
n O
= O
25 O
) O
that O
received O
placebo O
laser O
plus O
the O
same O
plyometric O
exercises O
. O
[]

Ten O
minutes O
after O
reperfusion O
the O
arterial B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
were O
8.6 O
( O
1.5 O
) O
in O
the O
allopurinol O
and O
7.6 O
( O
0.7 O
) O
in O
the O
placebo O
group O
, O
the O
sinus B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
being O
7.6 O
( O
1.3 O
) O
and O
8.3 O
( O
0.8 O
) O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

5 O
) O
The O
needs O
of O
beta O
receptor O
blocker O
or O
calcium O
antagonists O
were O
reduced O
more O
significantly O
in O
the O
diltiazem O
group O
compared O
with O
those O
in O
the O
nitroglycerin O
group O
[ O
2 O
( O
1.9 O
% O
) O
vs O
13 O
( O
11.9 O
% O
) O
, O
P O
< O
0.01 O
] O
. O
[]

In O
elderly O
black O
patients O
, O
terazosin O
, O
1 O
to O
10 O
mg O
daily O
, O
was O
as O
effective O
in O
lowering O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
as O
propranolol O
( O
40 O
to O
120 O
mg O
twice O
daily O
) O
. O
['Physiological-Clinical']

For O
sustained O
resolution O
of O
symptoms O
, O
the O
corresponding O
values O
were O
20 O
% O
, O
41 O
% O
, O
and O
67 O
% O
with O
amoxicillin-clavulanate O
, O
as O
compared O
with O
14 O
% O
, O
36 O
% O
, O
and O
53 O
% O
with O
placebo O
( O
P=0.04 O
for O
the O
overall O
comparison O
) O
. O
[]

Continuous O
application O
of O
transdermal O
nitroglycerin O
appears O
to O
result O
in O
tolerance O
to O
the O
antianginal B-outcome ['Physiological-Clinical']
effect O
. O
['Physiological-Clinical']

The O
influence O
of O
penbutolol O
and O
placebo O
on O
blood O
sugar O
levels O
and O
insulin O
consumption O
in O
the O
glucose-controlled O
insulin O
infusion O
system O
( O
artificial O
endocrine O
pancreas O
) O
. O
[]

Divalproex O
sodium O
vs O
placebo O
for O
the O
treatment O
of O
irritability B-outcome ['Life-Impact']
in O
children O
and O
adolescents O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

Evaluation O
of O
nonpharmacologic O
methods O
of O
pain O
and O
anxiety O
management O
for O
laceration O
repair O
in O
the O
pediatric O
emergency O
department O
. O
[]

They O
also O
indicate O
that O
advice O
to O
increase O
fruit O
and O
vegetable O
consumption O
should O
emphasize O
total O
energy O
intake O
because O
the O
additional O
energy O
contributed O
may O
promote O
weight O
gain O
, O
especially O
among O
overweight O
and O
obese O
individuals O
. O
[]

This O
manipulation O
was O
designed O
to O
encourage O
an O
expectation O
of O
a O
reciprocal O
tit-for-tat O
strategy O
in O
the O
participant O
, O
which O
may O
motivate O
participants O
to O
change O
their O
behavior O
to O
receive O
more O
donations O
. O
[]

In O
patients O
with O
mitral O
valve O
replacement O
, O
L-carnitine O
therapy O
was O
associated O
with O
significantly O
higher O
concentrations O
of O
pyruvate B-outcome ['Physiological-Clinical']
, O
ATP B-outcome ['Physiological-Clinical']
and O
creatine B-outcome ['Physiological-Clinical']
phosphate I-outcome ['Physiological-Clinical']
in O
papillary O
muscle O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
used O
bootstrap O
techniques O
to O
estimate O
incremental B-outcome ['Resource-use']
cost-effectiveness O
ratios O
and O
create O
cost-effectiveness O
acceptability O
curves O
. O
['Resource-use', 'Resource-use']

Patients O
were O
randomly O
assigned O
to O
one O
of O
five O
groups O
. O
[]

The O
four O
intravenous O
( O
10-mg/kg O
dose O
) O
regimens O
included O
( O
1 O
) O
intraoperative O
dose O
( O
IO O
) O
given O
before O
tourniquet O
deflation O
, O
( O
2 O
) O
additional O
preoperative O
dose O
( O
POIO O
) O
, O
( O
3 O
) O
additional O
postoperative O
dose O
( O
IOPO O
) O
, O
and O
( O
4 O
) O
all O
three O
doses O
( O
POIOPO O
) O
. O
[]

Even O
though O
the O
number O
of O
serious O
adverse O
events O
is O
small O
, O
because O
this O
study O
did O
not O
show O
an O
effect O
in O
the O
intent-to-treat O
group O
, O
rheopheresis O
should O
not O
be O
performed O
for O
AMD O
outside O
of O
an O
approved O
randomized O
controlled O
trial O
. O
[]

An O
additional O
approach O
for O
prevention O
of O
the O
progression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
is O
calcium O
channel O
blocker O
( O
CCB O
) O
treatment O
. O
['Physiological-Clinical']

METHODS O
Sixty-six O
adults O
with O
Stage O
IV O
lung O
or O
colorectal O
cancer O
were O
randomized O
, O
in O
an O
eight-week O
trial O
, O
to O
usual O
care O
or O
incremental O
walking O
and O
home-based O
strength O
training O
. O
[]

Fifty-one O
girls O
were O
randomly O
assigned O
to O
practice O
, O
no-practice O
, O
or O
control O
groups O
. O
[]

4 O
months O
after O
the O
end O
of O
treatment O
a O
standardised O
examination O
was O
done O
. O
[]

INTRODUCTION O
Delusions O
may O
arise O
from O
abnormalities O
in O
emotional O
perception O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
hsCRP O
across O
the O
spectrum O
of O
ACS O
. O
[]

One O
minute O
before O
induction O
glycopyrrolate O
0.2 O
mg O
and O
alfentanil O
15 O
micrograms.kg-1 O
i.v O
. O
[]

Incidence O
of O
LSPC B-outcome ['Physiological-Clinical']
was O
2.4 O
% O
, O
2.7 O
% O
, O
2.2 O
% O
and O
2.6 O
% O
in O
the O
first O
, O
second O
, O
third O
and O
fourth O
round O
, O
respectively O
. O
['Physiological-Clinical']

No O
individual O
child O
was O
identified O
as O
benefiting O
clinically O
or O
educationally B-outcome ['Life-Impact']
from O
the O
treatment O
. O
['Physiological-Clinical', 'Life-Impact']

Differences O
in O
primary O
( O
VAS O
pain O
score O
) O
and O
secondary O
outcomes O
between O
groups O
will O
be O
analysed O
by O
intention O
to O
treat O
and O
per O
protocol O
analysis O
using O
Student O
's O
t-test O
and O
ANOVA O
. O
[]

Eight O
participants O
were O
assigned O
to O
an O
aquatic O
exercise O
group O
and O
eight O
to O
a O
control O
group O
. O
[]

There O
were O
no O
differences O
in O
use O
of O
any O
other O
services B-outcome ['Life-Impact']
, O
medication B-outcome ['Resource-use']
use I-outcome ['Resource-use']
or O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
at O
3 O
or O
9 O
months O
. O
['Life-Impact', 'Resource-use', 'Life-Impact']

The O
intervention O
featured O
a O
group-based O
cognitive-behavioral O
weight O
loss O
program O
with O
telephone O
counseling O
and O
tailored O
newsletters O
to O
support O
initial O
weight O
loss O
and O
subsequent O
maintenance O
, O
with O
the O
goal O
of O
7 O
% O
weight O
loss O
at O
two O
years O
. O
[]

OBJECTIVE O
To O
investigate O
the O
effects O
of O
80-kilovoltage O
( O
kV O
) O
tube O
voltage O
coronary O
computed O
tomographic O
angiography O
( O
CCTA O
) O
with O
a O
reduced O
amount O
of O
contrast O
agent O
on O
qualitative O
and O
quantitative O
image O
quality O
parameters O
and O
on O
radiation O
dose O
in O
patients O
with O
a O
body O
mass O
index O
( O
BMI O
) O
< O
23.0 O
kg/m O
( O
2 O
) O
. O
[]

There O
was O
no O
effect O
of O
whey B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
supplementation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

After O
8 O
weeks O
on O
L-carnosine O
, O
children O
showed O
statistically O
significant O
improvements O
on O
the O
Gilliam O
Autism B-outcome ['Life-Impact']
Rating O
Scale O
( O
total O
score O
and O
the O
Behavior B-outcome ['Life-Impact']
, O
Socialization B-outcome ['Life-Impact']
, O
and O
Communication B-outcome ['Life-Impact']
subscales O
) O
and O
the O
Receptive O
One-Word O
Picture O
Vocabulary B-outcome ['Physiological-Clinical']
test O
( O
all O
P O
< O
.05 O
) O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

The O
patients O
were O
investigated O
using O
clinical B-outcome ['Physiological-Clinical']
manifestation I-outcome ['Physiological-Clinical']
and O
Autism B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
( O
ABC O
) O
and O
intelligence B-outcome ['Life-Impact']
quotient I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
IQ I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
before O
and O
after O
six O
months O
of O
treatment O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

However O
, O
aircrew O
often O
complain O
about O
having O
to O
maximize O
intercom O
volume O
for O
speech O
understanding O
, O
causing O
a O
situation O
with O
no O
reserve O
volume O
and O
bad O
sound O
quality O
. O
[]

RESULTS O
After O
the O
intervention O
period O
, O
the O
diabetes O
specific O
formula O
resulted O
in O
a O
significantly O
lower O
postprandial B-outcome ['Physiological-Clinical']
rise I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
at O
0.5 O
hour O
( O
P O
< O
0.05 O
) O
and O
1 O
hour O
( O
P O
< O
0.01 O
) O
; O
significantly O
lower O
peak O
height O
of O
plasma B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
( O
P O
= O
0.05 O
) O
; O
significantly O
lower O
plasma B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
at O
0.5 O
hour O
( O
P O
< O
0.01 O
) O
, O
1 O
hour O
( O
P O
< O
0.01 O
) O
and O
2 O
hours O
( O
P O
< O
0.01 O
) O
; O
and O
a O
significantly O
lower O
plasma B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
peak I-outcome ['Physiological-Clinical']
compared O
to O
controls O
; O
both O
OGTT O
and O
a O
standard O
test O
meal O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
positive O
association O
was O
found O
between O
the O
ECV O
and O
left O
atrial O
volume O
( O
ECV O
vs O
indexed O
left O
atrial O
volume O
, O
r O
= O
0.65 O
, O
p O
< O
0.001 O
) O
, O
and O
negative O
association O
was O
found O
between O
the O
ECV O
and O
diastolic O
function O
( O
E O
' O
lateral O
, O
r O
= O
-0.64 O
, O
p O
< O
0.001 O
) O
. O
[]

These O
subjects O
were O
recruited O
from O
the O
University O
of O
Vermont O
population O
and O
surrounding O
community O
. O
[]

At O
the O
end O
of O
the O
study O
, O
the O
carotid B-outcome ['Physiological-Clinical']
intima-media I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
decreased O
in O
group O
L O
( O
P O
< O
.01 O
) O
, O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
in O
groups O
E O
and O
L O
( O
P O
< O
.05 O
and O
P O
< O
.001 O
, O
respectively O
) O
, O
with O
a O
concomitant O
reduction O
in O
cholesterol B-outcome ['Physiological-Clinical']
in O
group O
L O
( O
P O
< O
.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
This O
study O
confirms O
a O
sympatholytic O
effect O
of O
rilmenidine O
during O
supine O
rest O
but O
demonstrates O
that O
sympathetic B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
during O
mental O
stress O
and O
tilting O
are O
preserved O
, O
the O
latter O
underlying O
a O
perhaps O
surprising O
absence O
of O
postural O
hypotension O
on O
the O
drug O
. O
['Physiological-Clinical']

In O
conclusion O
, O
variceal O
band O
ligation O
in O
children O
is O
a O
safe O
and O
[]

Low O
protein O
provision O
in O
utero O
and O
post-partum O
may O
induce O
metabolic B-outcome ['Physiological-Clinical']
disorders I-outcome ['Physiological-Clinical']
in O
adulthood O
. O
['Physiological-Clinical']

However O
, O
there O
were O
no O
significant O
differences O
between O
the O
treatment O
groups O
in O
health O
status O
or O
COPD O
exacerbations O
. O
[]

A O
previous O
study O
showed O
single O
doses O
of O
tirasemtiv O
to O
be O
well O
tolerated O
and O
associated O
with O
potentially O
important O
improvements O
in O
a O
variety O
of O
functional O
outcomes O
. O
[]

morphine O
was O
more O
effective O
for O
treatment O
of O
pain B-outcome ['Physiological-Clinical']
after O
laparoscopic O
cholecystectomy O
. O
['Physiological-Clinical']

A O
double-blind O
randomized O
clinical O
evaluation O
of O
enamel O
matrix O
derivative O
proteins O
for O
the O
treatment O
of O
proximal O
class-II O
furcation O
involvements O
. O
[]

In O
two O
separate O
studies O
, O
eight O
GHD O
women O
randomly O
received O
either O
oral O
or O
transdermal O
estrogen O
for O
8 O
wk O
before O
crossing O
over O
to O
the O
alternate O
route O
of O
administration O
. O
[]

BACKGROUND O
The O
aim O
of O
this O
study O
was O
the O
examination O
of O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
an O
application-form O
of O
the O
new O
combination O
of O
Xylometazoline O
with O
Dexpanthenol O
( O
Nasic O
) O
versus O
Xylometazoline O
alone O
. O
['Life-Impact']

Overall O
, O
faropenem O
daloxate O
was O
at O
least O
as O
effective O
clinically B-outcome ['Physiological-Clinical']
and O
bacteriologically B-outcome ['Physiological-Clinical']
as O
cefuroxime O
axetil O
and O
was O
well O
tolerated B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

RESULTS O
The O
incidence O
of O
hypotension B-outcome ['Physiological-Clinical']
was O
17/30 O
( O
57 O
% O
) O
in O
the O
isotonic O
lactated O
Ringer O
's O
solution O
group O
as O
against O
7/30 O
( O
23 O
% O
) O
in O
the O
hypertonic O
saline O
group O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Sixteen O
male O
subjects O
were O
randomized O
to O
one O
of O
two O
groups O
( O
control O
or O
EAA+CHO O
) O
. O
[]

Mechanical O
efficiency O
and O
propulsion B-outcome ['Physiological-Clinical']
technique I-outcome ['Physiological-Clinical']
after O
7 O
weeks O
of O
low-intensity O
wheelchair O
training O
. O
['Physiological-Clinical']

The O
drop O
in O
serum B-outcome ['Physiological-Clinical']
rhG-CSF I-outcome ['Physiological-Clinical']
levels O
may O
vary O
with O
the O
duration O
of O
rhG-CSF O
administration O
or O
with O
the O
circulating O
neutrophil O
counts O
. O
['Physiological-Clinical']

In O
order O
to O
effectively O
diagnose O
50 O
% O
of O
the O
arthrotomies O
, O
75 O
mL O
of O
injected O
fluid O
was O
needed O
; O
the O
volumes O
that O
were O
needed O
in O
order O
to O
effectively O
diagnose O
75 O
% O
, O
90 O
% O
, O
95 O
% O
, O
and O
99 O
% O
of O
the O
arthrotomies O
were O
110 O
, O
145 O
, O
155 O
, O
and O
175 O
mL O
, O
respectively O
. O
[]

Citalopram O
use O
was O
significantly O
more O
likely O
to O
be O
associated O
with O
adverse O
events O
, O
particularly O
increased O
energy O
level O
, O
impulsiveness O
, O
decreased O
concentration O
, O
hyperactivity B-outcome ['Life-Impact']
, O
stereotypy B-outcome ['Physiological-Clinical']
, O
diarrhea B-outcome ['Physiological-Clinical']
, O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

An O
open-label O
, O
randomised O
, O
cross-over O
single O
dose O
study O
, O
using O
2 O
periods O
x O
2 O
sequences O
, O
with O
a O
minimum O
washout O
period O
of O
21 O
days O
, O
was O
conducted O
in O
order O
to O
assess O
the O
comparative O
bioavailability B-outcome ['Physiological-Clinical']
of O
two O
formulations O
of O
terbinafine O
( O
CAS O
78628-80-5 O
) O
250 O
mg O
tablets O
. O
['Physiological-Clinical']

Forty O
patients O
were O
randomized O
for O
being O
operated O
on O
with O
either O
MECC O
or O
CECC O
. O
[]

Hence O
, O
a O
prolonged O
supplementation O
regime O
may O
be O
more O
effective O
. O
[]

The O
Halo O
( O
14 O
+/- O
9 O
seconds O
) O
and O
Vantage O
( O
19 O
+/- O
12 O
seconds O
) O
baskets O
were O
significantly O
faster O
for O
2 O
mm O
calculi O
than O
the O
N-Circle O
( O
73 O
+/- O
60 O
seconds O
, O
p O
= O
0.006 O
) O
, O
Sur-Catch O
( O
169 O
+/- O
85 O
seconds O
, O
p O
= O
0.0005 O
) O
and O
Dimension O
( O
73 O
+/- O
70 O
seconds O
, O
p O
= O
0.017 O
) O
. O
[]

Dexamethasone O
therapy O
and O
cortisol O
excretion O
in O
severe O
pediatric O
head O
injury O
. O
[]

Measurements O
were O
made O
12 O
hours O
after O
the O
last O
twice O
daily O
dose O
and O
24 O
hours O
after O
the O
last O
once O
daily O
dose O
. O
[]

Efficacy O
was O
82 O
% O
for O
1500 O
mg O
and O
63 O
% O
for O
750 O
mg O
. O
[]

Prophylactic O
amnioinfusion O
in O
pregnancies O
complicated O
by O
oligohydramnios O
: O
a O
prospective O
study O
. O
[]

This O
randomized O
controlled O
trial O
tested O
whether O
acupuncture O
reduces O
vasomotor B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
produces O
fewer O
adverse O
effects O
than O
venlafaxine O
. O
['Physiological-Clinical']

METHODS O
A O
three-day O
treatment O
period O
and O
14-day O
follow-up O
period O
was O
performed O
in O
any O
subject O
weighting O
more O
than O
10 O
kg O
, O
presenting O
with O
a O
malaria O
paroxysm O
confirmed O
by O
parasitaemia O
> O
or O
= O
1,000/microl O
, O
after O
informed O
consent O
. O
[]

Classes O
in O
each O
grade O
were O
randomized O
to O
receive O
a O
micronutrient-enriched O
beverage O
or O
a O
placebo O
without O
added O
micronutrients O
. O
[]

RESULTS O
Of O
the O
118 O
patients O
27 O
( O
23 O
% O
) O
had O
a O
negative O
repeat O
sextant O
biopsy O
. O
[]

Clinical O
evidence O
of O
intravascular B-outcome ['Physiological-Clinical']
coagulation I-outcome ['Physiological-Clinical']
appeared O
in O
two O
patients O
treated O
with O
concentrate O
alone O
and O
the O
laboratory O
evidence O
of O
this O
progressed O
during O
the O
period O
of O
infusions O
in O
all O
patients O
in O
both O
treatment O
groups O
, O
although O
to O
a O
lesser O
extent O
in O
those O
receiving O
heparin O
. O
['Physiological-Clinical']

Measurements O
were O
repeated O
3 O
times O
for O
each O
specimen O
. O
[]

Fluorescein O
angiography O
was O
performed O
at O
baseline O
and O
at O
weeks O
6 O
and O
16 O
, O
and O
proliferative O
diabetic O
retinopathy O
regression O
was O
evaluated O
in O
a O
masked O
fashion O
. O
[]

Early O
response O
to O
therapy B-outcome ['Resource-use']
was O
associated O
with O
higher O
EFS O
, O
a O
concept O
that O
has O
led O
to O
the O
Children O
's O
Oncology O
Group O
paradigm O
of O
response-based O
risk-adapted O
therapy O
for O
pediatric O
Hodgkin O
disease O
. O
['Resource-use']

OBJECTIVE O
To O
describe O
the O
methodological O
challenges O
and O
decisions O
made O
in O
developing O
a O
multisite O
, O
controlled O
study O
of O
risperidone O
in O
children O
and O
adolescents O
with O
autism O
. O
[]

This O
blood O
volume O
was O
removed O
in O
the O
fluid O
resuscitation O
study O
to O
create O
a O
model O
of O
acute O
blood O
loss O
. O
[]

These O
results O
indicate O
a O
[]

CONCLUSIONS O
ME-609 O
prevented O
progression O
of O
cold B-outcome ['Physiological-Clinical']
sores I-outcome ['Physiological-Clinical']
to O
ulcerative B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
and O
significantly O
reduced O
the O
cumulative O
lesion B-outcome ['Physiological-Clinical']
area O
compared O
with O
acyclovir O
and O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
suggests O
that O
the O
children O
who O
relapsed O
did O
not O
receive O
any O
less O
aggressive O
treatment O
than O
those O
who O
remained O
in O
remission O
. O
[]

SUBJECTS/SETTING O
Data O
from O
13,277 O
postmenopausal O
women O
randomly O
assigned O
to O
the O
low-fat O
intervention O
arm O
of O
the O
Women O
's O
Health O
Initiative O
Dietary O
Modification O
Trial O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Any O
surgical B-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SSI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
; O
secondary O
outcomes O
included O
return O
of O
bowel B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
ability B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
tolerate I-outcome ['Life-Impact']
solid I-outcome ['Life-Impact']
food I-outcome ['Life-Impact']
, O
ambulation B-outcome ['Life-Impact']
, O
suture B-outcome ['Physiological-Clinical']
removal I-outcome ['Physiological-Clinical']
, O
and O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Resource-use']

The O
xanthine O
oxidase O
inhibitor O
allopurinol O
lowers O
uric O
acid O
but O
also O
attenuates O
expression O
of O
inflammatory O
adhesion O
molecules O
in O
murine O
models O
, O
reduces O
oxidative O
stress O
in O
the O
vasculature O
, O
and O
improves O
endothelial O
function O
. O
[]

Patients O
with O
asthma O
stabilized O
on O
CFC O
albuterol O
during O
a O
12-week O
safety O
and O
efficacy O
trial O
were O
randomized O
to O
either O
continue O
receiving O
CFC O
albuterol O
or O
to O
be O
switched O
to O
receive O
HFA O
albuterol O
in O
a O
yearlong O
safety O
and O
efficacy O
trial O
. O
[]

METHODS O
This O
randomized O
controlled O
pilot O
study O
recruited O
African O
Americans O
in O
2 O
North O
Carolina O
neighborhoods O
who O
had O
high O
blood O
pressure O
and O
used O
fewer O
than O
3 O
antihypertension O
medications O
. O
[]

Transcranial O
Doppler O
recordings O
were O
made O
from O
the O
ipsilateral O
middle O
cerebral O
artery O
for O
4 O
hours O
after O
surgery O
, O
beginning O
30 O
minutes O
after O
skin O
closure O
, O
and O
also O
at O
6 O
and O
24 O
hours O
. O
[]

RESULTS O
Mean O
baseline O
values O
for O
the O
three O
co-primary O
endpoints O
ranged O
from O
62.52 O
to O
70.14 O
mm O
. O
[]

Mean O
age O
was O
75.7 O
( O
standard O
deviation O
[ O
SD O
] O
6.8 O
) O
years O
. O
[]

Rioprostil O
, O
a O
new O
prostaglandin O
E1 O
analogue O
, O
in O
the O
once-daily O
treatment O
for O
the O
prevention O
of O
duodenal O
ulcer O
recurrence O
: O
a O
comparison O
with O
ranitidine O
. O
[]

There O
was O
no O
effect O
of O
surgical O
grouping O
on O
these O
significant O
comparisons O
. O
[]

Total O
anthelmintic O
failure O
to O
control O
nematode O
parasites O
of O
small O
ruminants O
on O
government O
breeding O
farms O
in O
Sabah O
, O
East O
Malaysia O
. O
[]

All O
patients O
had O
typical O
grass O
pollen O
hay O
fever O
, O
in O
27 O
% O
associated O
with O
grass O
pollen O
asthma O
and O
in O
13 O
% O
with O
birch O
pollen O
allergy O
. O
[]

However O
, O
the O
effects O
of O
conjugated O
equine O
estrogens O
( O
CEEs O
) O
alone O
on O
mammographic B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
in O
diverse O
racial/ethnic O
populations O
are O
not O
established O
. O
['Physiological-Clinical']

Nevertheless O
not O
even O
a O
small O
difference O
could O
be O
demonstrated O
in O
the O
presence O
of O
the O
anti O
CD O
20 O
monoclonal O
antibody O
. O
[]

Akt B-outcome ['Physiological-Clinical']
phosphorylation I-outcome ['Physiological-Clinical']
was O
elevated O
at O
1 O
h O
and O
returned O
to O
baseline O
by O
2 O
h O
in O
the O
control O
group O
, O
but O
it O
remained O
elevated O
in O
the O
EAA+CHO O
group O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

When O
the O
infusion O
was O
stopped O
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
returned O
to O
within O
15 O
% O
of O
the O
control O
with O
15 O
minutes O
. O
['Physiological-Clinical']

Older O
patients O
and O
women O
reported O
worse O
symptoms B-outcome ['Physiological-Clinical']
and O
poorer O
well-being O
despite O
similar O
ventricular B-outcome ['Physiological-Clinical']
dimensions I-outcome ['Physiological-Clinical']
and O
systolic B-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
This O
study O
did O
not O
meet O
the O
prespecified O
benchmark O
of O
35 O
% O
6-month O
PFS O
rate O
; O
both O
combination O
schedules O
of O
cetuximab O
plus O
paclitaxel/carboplatin O
were O
feasible O
and O
equivalent O
for O
treating O
advanced O
NSCLC O
. O
[]

In O
this O
study O
, O
we O
evaluated O
if O
increased O
sympathetic O
stimulation O
is O
an O
essential O
requirement O
for O
the O
development O
of O
neurally O
mediated O
syncope O
( O
NMS O
) O
by O
manipulating O
overall O
sympathetic O
outflow O
in O
subjects O
susceptible O
to O
tilt-induced O
syncope O
. O
[]

For O
up O
to O
1 O
year O
they O
continued O
on O
Z O
infusions O
every O
3-4 O
weeks O
, O
while O
their O
renal O
safety O
was O
monitored O
. O
[]

This O
follow-up O
study O
investigated O
the O
effect O
of O
hearing-aid O
use O
on O
emotional O
experience O
in O
adults O
with O
hearing O
impairment O
. O
[]

Parenteral O
S-adenosylmethionine O
proved O
to O
be O
effective O
in O
reversing O
intrahepatic B-outcome ['Physiological-Clinical']
cholestasis I-outcome ['Physiological-Clinical']
in O
pregnant O
women O
. O
['Physiological-Clinical']

INTERVENTION O
( O
S O
) O
An O
ice O
bag O
was O
secured O
to O
the O
lateral O
ankle O
joint O
for O
20 O
minutes O
. O
[]

Comparison O
of O
sedative O
drugs O
under O
peribulbar O
or O
topical O
anesthesia O
during O
phacoemulsification O
. O
[]

Each O
group O
of O
volunteers O
suspended O
tooth O
cleaning O
for O
48 O
h O
and O
the O
index O
scored O
after O
disclosing O
plaque O
deposits O
. O
[]

METHODS O
cluster-RCT O
designed O
to O
compare O
stroke O
patient O
referrals O
by O
Emergency O
Medical O
Service O
( O
EMS O
) O
and O
Emergency O
Room O
( O
ER O
) O
health O
professionals O
trained O
in O
the O
ECP O
, O
with O
those O
of O
non-trained O
EMS O
and O
ER O
controls O
. O
[]

Results O
favored O
a O
muscle O
protein-sparing O
effect O
of O
exercise O
, O
as O
a O
significant O
decrease O
in O
creatinine B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
in O
controls O
only O
suggested O
muscle B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
associated O
with O
inactivity O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
double-blind O
study O
included O
18 O
members O
of O
the O
Polish O
Rowing O
Team O
. O
[]

From O
2004 O
to O
2008 O
, O
81 O
patients O
seeking O
elective O
THRs O
were O
randomly O
assigned O
into O
a O
standard O
rehabilitation O
group O
or O
an O
early O
rehabilitation O
group O
. O
[]

A O
double-blind O
study O
. O
[]

RESULTS O
Pregnancy B-outcome ['Physiological-Clinical']
rate O
was O
23.4 O
% O
in O
group O
1 O
, O
27.5 O
% O
in O
group O
2 O
, O
and O
28.1 O
% O
in O
group O
3 O
. O
['Physiological-Clinical']

With O
respect O
to O
film O
positioning O
, O
the O
loop O
technique O
was O
1.12 O
times O
more O
likely O
to O
cause O
improper O
positioning O
than O
the O
holder O
technique O
. O
[]

Autism O
is O
a O
neurodevelopmental O
disorder O
that O
causes O
significant O
impairment O
in O
socialization O
and O
communication O
. O
[]

The O
volume O
of O
irrigation B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
used O
and O
its O
hemoglobin O
concentration O
as O
well O
as O
resected O
prostate O
weight O
were O
recorded O
. O
['Physiological-Clinical']

[ O
Clinical O
observation O
on O
effect O
of O
fuzheng O
yiliu O
granule O
on O
cell O
cycle O
and O
nuclear O
transcription O
factor-kappa O
B O
in O
tissue O
of O
esophageal-gastric O
carcinoma O
] O
. O
[]

Subjective O
responses B-outcome ['Physiological-Clinical']
were O
obtained O
. O
['Physiological-Clinical']

Pattern B-outcome ['Physiological-Clinical']
regulation I-outcome ['Physiological-Clinical']
dynamics I-outcome ['Physiological-Clinical']
were O
estimated O
from O
the O
computed B-outcome ['Physiological-Clinical']
impulse I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
inspiratory B-outcome ['Physiological-Clinical']
and O
expiratory B-outcome ['Physiological-Clinical']
durations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

2.7 O
vs O
16.4 O
? O
[]

TZD O
, O
but O
not O
placebo O
, O
decreased O
mean O
high-sensitivity B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
to O
43 O
+/- O
19 O
% O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

CONCLUSION O
The O
results O
show O
that O
memory B-outcome ['Life-Impact']
, O
attention B-outcome ['Life-Impact']
, O
and O
tracking B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
are O
unaffected O
after O
acute O
and O
subchronic O
administration O
of O
levocetirizine O
( O
5 O
mg O
) O
, O
whereas O
diphenhydramine O
( O
50 O
mg O
) O
significantly O
affected O
divided B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
and O
tracking B-outcome ['Life-Impact']
after O
acute O
administration O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

AIMS O
To O
compare O
, O
in O
post-acute O
hemiparetic O
patients O
, O
gait B-outcome ['Life-Impact']
improvement I-outcome ['Life-Impact']
after O
conventional O
physical O
therapy O
alone O
or O
with O
a O
specialised O
balance O
retraining O
program O
. O
['Life-Impact']

One O
hundred O
and O
fifty O
five O
male O
subjects O
were O
randomized O
( O
2:1 O
) O
to O
sildenafil O
( O
n O
= O
104 O
) O
or O
placebo O
( O
n O
= O
51 O
) O
. O
[]

A O
statistically O
significant O
correlation O
between O
acute B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
late I-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
was O
found O
only O
in O
the O
conventional O
fractionation O
group O
. O
['Physiological-Clinical']

Efficacy O
variables O
were O
pain O
and O
physical O
function O
, O
measured O
by O
the O
Western O
Ontario O
and O
McMaster O
Universities O
( O
WOMAC O
) O
VA O
3.1 O
OA O
Index O
, O
and O
patient O
global O
assessment O
( O
PGA O
) O
. O
[]

To O
share O
or O
not O
to O
share O
: O
a O
randomized O
trial O
of O
consent O
for O
data O
sharing B-outcome ['Life-Impact']
in O
genome O
research O
. O
['Life-Impact']

To O
determine O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
patient O
followup O
was O
performed O
every O
3 O
months O
by O
white O
light O
cystoscopy O
and O
urine O
cytology O
. O
['Mortality']

Patients O
were O
randomized O
to O
receive O
either O
10 O
ml O
0.5 O
% O
bupivacaine O
or O
10 O
ml O
0.25 O
% O
bupivacaine O
. O
[]

In O
this O
study O
are O
presented O
five O
variations O
of O
SWAT O
in O
an O
effort O
to O
overcome O
the O
limitations O
. O
[]

None O
excreted O
the O
vaccine O
strain O
. O
[]

This O
was O
associated O
with O
a O
greater O
decrease O
in O
RPE O
( O
77.7 O
? O
[]

The O
most O
reliable O
combination O
of O
predictive O
factors O
was O
a O
negative O
anti-human B-outcome ['Physiological-Clinical']
immunodeficiency I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
with O
either O
a O
positive O
history O
of O
acute B-outcome ['Physiological-Clinical']
icteric I-outcome ['Physiological-Clinical']
hepatitis I-outcome ['Physiological-Clinical']
and O
AST O
greater O
than O
45 O
IU O
per O
liter O
or O
no O
history O
of O
acute O
icteric O
hepatitis O
and O
AST O
greater O
than O
85 O
IU O
per O
liter O
, O
which O
predicted O
response O
in O
77 O
% O
with O
a O
specificity O
of O
79 O
% O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Two O
hundred O
patients O
with O
moderate O
to O
moderately O
severe O
acne O
vulgaris O
were O
randomly O
assigned O
to O
the O
study O
. O
[]

Malignant O
mesothelioma O
is O
almost O
invariably O
fatal O
. O
[]

In O
the O
indomethacin O
group O
, O
dura O
was O
sufficiently O
relaxed O
in O
eight O
of O
nine O
patients O
and O
dura O
was O
opened O
without O
the O
occurrence O
of O
cerebral B-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Until O
data O
from O
such O
studies O
are O
available O
, O
women O
planning O
a O
pregnancy O
should O
continue O
to O
consume O
a O
daily O
folic O
acid O
supplement O
of O
400 O
microg O
. O
[]

4 O
months O
, O
recurrence O
of O
AF O
was O
detected O
in O
5 O
of O
22 O
patients O
( O
22.7 O
% O
) O
in O
group O
A O
vs. O
3 O
of O
22 O
patients O
( O
13.6 O
% O
) O
in O
group O
B O
( O
p O
= O
0.722 O
) O
. O
[]

Paired O
contrast O
agent O
injections O
( O
10 O
ml O
dextrose O
in O
water/0.25 O
ml O
air O
) O
were O
administered O
from O
an O
upper O
extremity O
vein O
and O
femoral O
vein O
in O
each O
patient O
during O
spontaneous O
respiration O
, O
cough O
and O
Valsalva O
maneuvers O
. O
[]

Effects O
of O
two O
types O
of O
social O
support O
and O
education O
on O
adaptation O
to O
early-stage O
breast O
cancer O
. O
[]

There O
were O
1115 O
patients O
including O
27 O
protocol O
deviants O
. O
[]

A O
total O
of O
32 O
social O
phobics O
and O
32 O
controls O
were O
asked O
twice O
to O
sit O
in O
a O
chair O
and O
appear O
relaxed O
while O
being O
evaluated O
. O
[]

Tipifarnib O
was O
given O
at O
200 O
mg O
bid O
orally O
continuously O
; O
gemcitabine O
was O
given O
at O
1,000 O
mg/m O
( O
2 O
) O
intravenously O
weekly O
x O
7 O
for O
8 O
weeks O
, O
then O
weekly O
x O
3 O
every O
4 O
weeks O
. O
[]

DESIGN O
, O
SETTING O
, O
AND O
PATIENTS O
We O
analyzed O
the O
relationship O
between O
psychological O
well-being O
and O
free O
T O
( O
4 O
) O
( O
fT4 O
) O
, O
free O
T O
( O
3 O
) O
( O
fT3 O
) O
, O
TSH O
, O
and O
total O
rT O
( O
3 O
) O
in O
697 O
patients O
on O
thyroid O
hormone O
replacement O
therapy O
at O
entry O
to O
a O
randomized O
, O
controlled O
trial O
of O
combined O
T O
( O
4 O
) O
and O
T O
( O
3 O
) O
replacement O
therapy O
. O
[]

The O
effect O
of O
cessation O
of O
raloxifene O
treatment O
on O
bone O
turnover O
in O
postmenopausal O
women O
. O
[]

I O
. O
[]

This O
article O
presents O
a O
randomized O
controlled O
study O
evaluating O
the O
effect O
of O
a O
5-month O
intervention O
directed O
toward O
improving O
sensory B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
, O
digestion B-outcome ['Physiological-Clinical']
, O
and O
sleep B-outcome ['Physiological-Clinical']
in O
46 O
children O
with O
autism O
< O
age O
6 O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

This O
prospective O
, O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
compared O
the O
cardiac O
safety O
of O
formoterol O
and O
placebo O
in O
patients O
with O
COPD O
. O
[]

CONCLUSION O
In O
the O
present O
study O
, O
patients O
with O
SLN O
metastatic O
deposits O
< O
or O
=0.2 O
mm O
had O
no O
additional O
positive O
non-SLNs O
, O
and O
no O
recurrences O
or O
deaths O
were O
recorded O
, O
suggesting O
that O
their O
prognosis O
is O
equivalent O
to O
that O
of O
patients O
with O
negative O
SLN O
. O
[]

This O
study O
shows O
that O
combining O
a O
single O
infusion O
of O
low O
dose O
ketamine O
with O
regular O
opioid O
analgesia O
can O
result O
in O
a O
significant O
improvement O
in O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
for O
this O
patient O
group O
. O
['Physiological-Clinical']

We O
also O
observed O
a O
reduction O
in O
the O
percentage O
of O
patients O
who O
reported O
hard O
stools O
( O
hard B-outcome ['Physiological-Clinical']
scybalous I-outcome ['Physiological-Clinical']
or O
pebble-like B-outcome ['Physiological-Clinical']
stools I-outcome ['Physiological-Clinical']
) O
, O
although O
this O
reduction O
was O
significantly O
greater O
in O
the O
cocoa O
husk O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
safety O
of O
whey O
protein O
concentrate O
derived O
from O
the O
milk O
of O
cows O
immunized O
against O
Clostridium O
difficile O
. O
[]

Measurements O
were O
made O
using O
high-resolution O
B-mode O
ultrasonography O
to O
measure O
carotid B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
IMT I-outcome ['Physiological-Clinical']
at O
baseline O
and O
every O
6 O
months O
on-trial O
. O
['Physiological-Clinical']

The O
latter O
complication O
is O
considered O
by O
our O
surgeons O
to O
be O
a O
contraindication O
to O
the O
inferior-medial O
technique O
in O
patients O
undergoing O
trabeculectomy O
. O
[]

METHODS O
The O
study O
was O
performed O
in O
the O
Assisted O
Reproduction O
Unit O
of O
the O
2nd O
Department O
of O
Obstetrics O
and O
Gynecology O
, O
University O
of O
Athens O
, O
Aretaieion O
Hospital O
, O
Athens O
, O
Greece O
, O
and O
included O
92 O
couples O
who O
presented O
with O
mild O
male O
factor O
infertility-all O
candidates O
for O
IUI O
. O
[]

CONCLUSIONS O
Our O
results O
suggest O
that O
periprostatic O
local O
anesthesia O
for O
prostate O
biopsy O
does O
not O
increase O
the O
risk O
of O
urethral B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Smokeless O
tobacco O
was O
provided O
for O
7 O
weeks O
( O
or O
up O
to O
12 O
) O
, O
combined O
with O
eight O
group O
support O
visits O
provided O
by O
nurses O
. O
[]

Conversion O
to O
sinus O
rhythm O
( O
SR O
) O
resulted O
in O
significant O
reductions O
in O
resting B-outcome ['Physiological-Clinical']
( O
approximately O
25 O
beat/min O
) O
and O
peak O
exercise B-outcome ['Life-Impact']
( O
approximately O
40 O
beat/min O
) O
heart B-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
at O
6 O
months O
and O
1 O
year O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Trial O
visits O
were O
conducted O
every O
3 O
months O
, O
assessing O
kidney B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
by O
estimated O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate O
and O
24 O
h O
urine B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
showed O
no O
significant O
difference O
of O
contracture B-outcome ['Physiological-Clinical']
with O
smooth O
versus O
fine O
textured O
implants O
. O
['Physiological-Clinical']

The O
primary O
outcome O
was O
percentage O
change O
in O
body O
weight O
. O
[]

Complete B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
achieved O
in O
57 O
% O
of O
patients O
receiving O
high-dose O
therapy O
as O
compared O
to O
21 O
% O
of O
patients O
receiving O
standard-dose O
therapy O
( O
P O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
During O
9158 O
catheter O
days O
, O
6.5 O
% O
of O
the O
patients O
in O
the O
heparin O
group O
and O
15.6 O
% O
of O
the O
patients O
in O
the O
heparin-vancomycin O
group O
had O
bacteremia O
attributable O
to O
luminal O
colonization O
with O
vancomycin-susceptible O
organisms O
( O
p O
= O
0.43 O
) O
. O
[]

BACKGROUND O
This O
pilot O
study O
investigated O
the O
efficacy O
of O
a O
novel O
virtual O
reality-cognitive O
rehabilitation O
( O
VR-CR O
) O
intervention O
to O
improve O
contextual B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
of O
objects O
in O
children O
with O
autism O
. O
['Life-Impact']

In O
the O
sheep O
model O
, O
it O
was O
clearly O
shown O
that O
the O
release O
of O
bupivacaine O
from O
microspheres O
was O
controlled O
and O
prolonged O
despite O
the O
largest O
dose O
of O
bupivacaine O
used O
( O
500 O
mg O
; O
n O
= O
4 O
) O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
long-term O
effects O
of O
GH O
replacement O
therapy O
on O
bone B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
, O
BMD B-outcome ['Physiological-Clinical']
, O
and O
bone B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
in O
patients O
with O
GHD O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Otherwise O
, O
the O
groups O
performed O
similarly O
on O
tests O
of O
full-scale O
intelligence B-outcome ['Life-Impact']
quotient O
, O
academic B-outcome ['Life-Impact']
achievement B-outcome ['Life-Impact']
, O
attention/concentration B-outcome ['Life-Impact']
, O
memory B-outcome ['Life-Impact']
, O
and O
visual B-outcome ['Life-Impact']
motor I-outcome ['Life-Impact']
integration B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

From O
ECG O
no O
significant O
ST O
deviations O
were O
found O
and O
no O
significant O
changes O
regarding O
B-Hb O
, O
blood O
pressure O
or O
pulse O
were O
observed O
in O
the O
two O
groups O
. O
[]

PE O
was O
less O
than O
5 O
days O
old O
and O
the O
clinical O
diagnosis O
was O
confirmed O
by O
pulmonary O
angiograms O
demonstrating O
a O
vascular O
obstruction O
of O
more O
than O
30 O
% O
( O
Miller O
's O
index O
greater O
than O
11 O
) O
. O
[]

Imminent O
premature O
labor O
occurred O
in O
29.0 O
% O
of O
the O
treated O
group O
and O
in O
59.4 O
% O
of O
the O
control O
group O
( O
p O
less O
than O
0.025 O
) O
. O
[]

In O
Stratum O
II O
, O
16 O
of O
29 O
( O
55 O
% O
) O
patients O
receiving O
CRT O
+ O
ITC O
experienced O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
: O
3 O
deaths O
during O
continuous O
complete O
remission O
( O
CCR O
) O
and O
13 O
relapses B-outcome ['Physiological-Clinical']
( O
2 O
CNS O
, O
1 O
CNS O
+ O
BM O
, O
1 O
BM O
+ O
testes O
, O
and O
2 O
testes O
) O
as O
compared O
with O
only O
5 O
relapses B-outcome ['Physiological-Clinical']
in O
20 O
( O
25 O
% O
) O
patients O
on O
CSpRT O
( O
1 O
CNS O
, O
1 O
CNS O
+ O
BM O
, O
1 O
BM O
, O
and O
2 O
testes O
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Contrast O
enhancement O
is O
demonstrated O
by O
STIR O
, O
FATSAT O
, O
T1-weighted O
and O
dynamic O
screening O
sequence O
. O
[]

Stapled O
mucosectomy O
for O
acute O
thrombosed O
circumferentially O
prolapsed O
piles O
: O
a O
prospective O
randomized O
comparison O
with O
conventional O
haemorrhoidectomy O
. O
[]

During O
ad O
libitum O
food O
intake O
, O
after O
4 O
days O
of O
METH O
( O
40 O
mg/day O
) O
or O
PLAC O
oral O
therapy O
, O
both O
groups O
increased O
their O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
over O
weight O
maintenance O
, O
but O
the O
increase O
was O
significantly O
larger O
in O
the O
METH O
group O
compared O
with O
the O
PLAC O
group O
( O
4,554 O
+/- O
1,857 O
vs. O
2,867 O
+/- O
846 O
kcal/day O
; O
P O
= O
0.04 O
) O
. O
['Life-Impact']

Between-group O
differences O
in O
baseline O
characteristics O
of O
participants O
with O
and O
without O
IEDs O
were O
analyzed O
. O
[]

Mammography O
is O
the O
only O
screening O
method O
. O
[]

Intermediate O
accuracy O
scores O
indicated O
that O
participants O
could O
match O
one O
of O
the O
samples O
but O
not O
both O
of O
them O
. O
[]

METHODS O
A O
cohort O
of O
139 O
nondepressed O
elderly O
patients O
( O
> O
60 O
years O
) O
hospitalized O
for O
hip O
fracture O
surgery O
were O
followed O
up O
for O
six O
months O
. O
[]

Camazepam B-outcome ['Resource-use']
shows O
modification O
, O
with O
the O
same O
trend O
, O
but O
not O
reaching O
statistical O
significance O
. O
['Resource-use']

Ten O
male O
subjects O
with O
untreated O
type O
2 O
diabetes O
were O
given O
, O
in O
random O
sequence O
, O
50 O
g O
protein O
in O
the O
form O
of O
very O
lean O
beef O
or O
only O
water O
at O
0800 O
h O
and O
studied O
over O
the O
subsequent O
8 O
h. O
Protein O
ingestion O
resulted O
in O
an O
increase O
in O
circulating B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
, O
C-peptide B-outcome ['Physiological-Clinical']
, O
glucagon B-outcome ['Physiological-Clinical']
, O
alpha B-outcome ['Physiological-Clinical']
amino I-outcome ['Physiological-Clinical']
and O
urea B-outcome ['Physiological-Clinical']
nitrogen I-outcome ['Physiological-Clinical']
, O
and O
triglycerides B-outcome ['Physiological-Clinical']
; O
a O
decrease O
in O
nonesterified B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
; O
and O
a O
modest O
increase O
in O
respiratory B-outcome ['Physiological-Clinical']
quotient I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Eight-week O
treatment O
phases O
were O
completed O
for O
both O
a O
placebo O
and O
L-carnitine O
. O
[]

Adverse O
events O
not O
requiring O
cessation O
of O
therapy O
were O
more O
commonly O
seen O
among O
CSA O
patients O
. O
[]

Fingerplethysmography O
proved O
a O
sensitive O
measurement O
for O
the O
detection O
of O
the O
vasodilating O
effects O
of O
sodium O
nitroprusside O
, O
but O
was O
not O
specific O
, O
and O
showed O
low O
reproducibility O
. O
[]

Median O
salvage B-outcome ['Physiological-Clinical']
index O
was O
0.75 O
( O
IQR O
0.50-0.93 O
, O
n=73 O
) O
in O
the O
remote O
conditioning O
group O
versus O
0.55 O
( O
0.35-0.88 O
, O
n=69 O
) O
in O
the O
control O
group O
, O
with O
median O
difference O
of O
0.10 O
( O
95 O
% O
CI O
0.01-0.22 O
; O
p=0.0333 O
) O
; O
mean O
salvage O
index O
was O
0.69 O
( O
SD O
0.27 O
) O
versus O
0.57 O
( O
0.26 O
) O
, O
with O
mean O
difference O
of O
0.12 O
( O
95 O
% O
CI O
0.01-0.21 O
; O
p=0.0333 O
) O
. O
['Physiological-Clinical']

Hematoma B-outcome ['Physiological-Clinical']
occurred O
in O
15 O
AS O
patients O
, O
in O
17 O
SC O
patients O
, O
and O
in O
14 O
MC O
patients O
( O
11 O
vs. O
14 O
vs. O
9 O
% O
, O
ns O
) O
. O
['Physiological-Clinical']

The O
efficacy O
was O
evaluated O
by O
comparing O
IOP B-outcome ['Physiological-Clinical']
at O
9 O
AM O
at O
baseline O
and O
after O
6 O
weeks O
of O
treatment O
. O
['Physiological-Clinical']

Antitoxin B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
assessed O
after O
4 O
weeks O
and O
4 O
months O
. O
['Physiological-Clinical']

Secondary O
outcomes O
were O
death O
at O
30 O
days O
, O
interleukin-6 O
levels O
, O
inotropic O
score O
, O
fluid O
balance O
, O
serum O
creatinine O
, O
and O
intensive O
care O
unit O
and O
hospital O
stay O
. O
[]

The O
primary O
outcome O
measure O
was O
the O
number O
of O
new B-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
infarcts I-outcome ['Physiological-Clinical']
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical']

This O
research O
conceptualizes O
and O
investigates O
treatment O
process O
as O
it O
relates O
to O
the O
occurrence O
of O
struggle O
versus O
cooperation O
. O
[]

The O
purposes O
of O
this O
pilot O
study O
were O
( O
a O
) O
to O
assess O
the O
feasibility B-outcome ['Life-Impact']
of O
a O
community-based O
, O
small O
group O
HIV O
risk O
reduction O
intervention O
with O
adolescent O
girls O
, O
and O
( O
b O
) O
to O
obtain O
preliminary O
evidence O
of O
the O
efficacy O
of O
this O
theoretically-guided O
intervention O
using O
a O
controlled O
design O
. O
['Life-Impact']

The O
protocol O
for O
ischaemic O
preconditioning O
was O
two O
cycles O
of O
2-min O
ischaemia O
followed O
by O
3-min O
reperfusion O
. O
[]

Increased O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
neural B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
in O
the O
silent O
ischemia O
of O
hypertension O
: O
disparate O
effects O
of O
immediate O
release O
nifedipine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
difference O
in O
curative B-outcome ['Physiological-Clinical']
resectability I-outcome ['Physiological-Clinical']
rate O
was O
6.5 O
% O
( O
95 O
% O
confidence O
interval O
-32 O
to O
+19 O
% O
) O
in O
favour O
of O
surgery O
only O
. O
['Physiological-Clinical']

The O
significantly O
greater O
GFR O
increase O
observed O
in O
PR-STENT O
than O
in O
NO-STENT O
at O
univariate O
analysis O
at O
the O
end O
of O
follow-up O
( O
62.5 O
? O
[]

Impact O
of O
surgical O
staging O
in O
evaluating O
the O
radiotherapeutic O
outcome O
in O
RTOG O
# O
77-06 O
, O
a O
phase O
III O
study O
for O
T1BN0M0 O
( O
A2 O
) O
and O
T2N0M0 O
( O
B O
) O
prostate O
carcinoma O
. O
[]

Retrograde O
tracing O
and O
electrophysiological O
findings O
of O
collateral O
sprouting O
after O
end-to-side O
neurorrhaphy O
. O
[]

RESULTS O
The O
IVR O
system O
successfully B-outcome ['Physiological-Clinical']
reached I-outcome ['Physiological-Clinical']
715 O
( O
23.9 O
% O
) O
former O
QL O
participants O
. O
['Physiological-Clinical']

The O
characteristics O
of O
the O
contrast O
media O
enhancement O
argue O
for O
an O
active O
concomitant O
process O
of O
destruction O
and O
regeneration O
. O
[]

Systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
reduced O
in O
the O
study O
group O
( O
151 O
mm O
Hg O
baseline O
, O
140 O
mm O
Hg O
at O
6 O
mo O
, O
p O
< O
0.001 O
) O
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
at O
2 O
, O
4 O
, O
and O
5 O
months O
compared O
with O
baseline O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effectiveness O
of O
a O
combination O
preparation O
with O
standardized O
blood O
leech O
extract O
] O
. O
[]

RESULTS O
Pregnant O
women O
allocated O
to O
new O
style O
care O
had O
fewer O
day B-outcome ['Resource-use']
admissions I-outcome ['Resource-use']
( O
0.8 O
v O
1.0 O
; O
P=0.002 O
) O
and O
ultrasound B-outcome ['Resource-use']
scans I-outcome ['Resource-use']
( O
1.6 O
v O
1.7 O
; O
P=0.003 O
) O
and O
were O
less O
often O
suspected O
of O
carrying O
fetuses O
that O
were O
small B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
gestational I-outcome ['Physiological-Clinical']
age O
( O
odds O
ratio O
0.73 O
; O
95 O
% O
confidence O
interval O
0.54 O
to O
0.99 O
) O
. O
['Resource-use', 'Resource-use', 'Physiological-Clinical']

Clinical O
evaluation O
is O
performed O
with O
respect O
to O
catheter B-outcome ['Resource-use']
insertion I-outcome ['Resource-use']
, O
complications B-outcome ['Resource-use']
, O
accuracy O
of O
oxygen B-outcome ['Physiological-Clinical']
sensor I-outcome ['Physiological-Clinical']
data O
and O
fibrin B-outcome ['Physiological-Clinical']
deposition I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
catheter I-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Studies O
of O
the O
effect O
of O
vascular O
volume O
and O
intraperitoneal O
pressure O
on O
renal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
hepatic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Myocardial O
ultrastructure O
on O
septal O
biopsies O
, O
obtained O
within O
5 O
min O
from O
weaning O
from O
extracorporeal O
circulation O
, O
showed O
better O
preservation O
scores O
for O
all O
considered O
parameters O
( O
nucleus B-outcome ['Physiological-Clinical']
, O
sarcoplasmic B-outcome ['Physiological-Clinical']
reticulum I-outcome ['Physiological-Clinical']
, O
mitochondria B-outcome ['Physiological-Clinical']
and O
cellular B-outcome ['Physiological-Clinical']
oedema I-outcome ['Physiological-Clinical']
) O
in O
the O
treated O
subjects O
, O
although O
the O
difference O
reached O
statistical O
significance O
only O
for O
nuclei O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Ninety-eight O
patients O
completed O
the O
study O
. O
[]

Complications O
in O
825 O
patients O
were O
less O
than O
3 O
% O
and O
consisted O
mostly O
of O
transient B-outcome ['Physiological-Clinical']
neurologic I-outcome ['Physiological-Clinical']
disorders I-outcome ['Physiological-Clinical']
( O
eg O
, O
paradysthesia O
) O
, O
but O
deep B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
occurred O
in O
2 O
patients O
, O
with O
pulmonary O
embolus O
in O
1 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Systemic O
lidocaine O
reduced O
the O
area O
of O
secondary B-outcome ['Physiological-Clinical']
hyperalgesia I-outcome ['Physiological-Clinical']
to O
brush O
, O
but O
not O
to O
von O
Frey O
hair O
stimulation O
. O
['Physiological-Clinical']

The O
actual O
total O
dose B-outcome ['Life-Impact']
was O
44.7+/-a O
standard O
deviation O
( O
S.D O
. O
) O
['Life-Impact']

From O
July O
1984 O
to O
September O
1987 O
, O
737 O
patients O
with O
aggressive O
malignant O
lymphoma O
( O
ML O
) O
were O
treated O
by O
an O
intensive O
regimen O
( O
LNH-84 O
) O
comprising O
three O
or O
four O
courses O
of O
doxorubicin O
, O
75 O
mg/m2 O
; O
cyclophosphamide O
, O
1,200 O
mg/m2 O
; O
vindesine O
, O
2 O
mg/m2 O
x O
2 O
; O
bleomycin O
, O
10 O
mg O
x O
2 O
; O
and O
prednisolone O
, O
60 O
mg/m2 O
x O
5 O
( O
ACVB O
) O
, O
consolidation O
with O
high-dose O
methotrexate O
, O
ifosfamide O
, O
etoposide O
, O
asparaginase O
, O
and O
cytarabine O
, O
and O
a O
randomized O
late O
intensification O
with O
two O
courses O
of O
cytarabine O
, O
cyclophosphamide O
, O
teniposide O
, O
bleomycin O
, O
and O
prednisone O
( O
AraCVmB O
) O
. O
[]

CONCLUSIONS O
In O
patients O
with O
chronic O
stroke O
, O
20 O
sessions O
of O
a O
combined O
TENS+TRT O
home-based O
program O
decreased O
plantarflexor O
spasticity O
, O
improved O
dorsiflexor O
and O
plantarflexor O
strength O
, O
and O
increased O
gait O
velocity O
significantly O
more O
than O
TENS O
alone O
, O
placebo+TRT O
, O
or O
no O
treatment O
. O
[]

These O
limited O
the O
extent O
and O
speed O
of O
physical O
activities O
, O
restricted O
social O
, O
leisure O
and O
family O
life O
and O
were O
associated O
with O
emotional O
distress O
. O
[]

CONCLUSIONS O
The O
results O
suggest O
that O
a O
modest O
, O
one-time O
prevention O
program O
appeared O
to O
confer O
[]

The O
participants O
were O
294 O
men O
and O
women O
, O
aged O
60 O
years O
or O
older O
, O
who O
had O
either O
a O
hospital O
admission O
or O
bed O
rest O
for O
2 O
days O
or O
more O
within O
the O
previous O
month O
. O
[]

Data O
from O
2 O
separate O
multicenter O
, O
double-blind O
clinical O
studies O
following O
the O
same O
protocol O
, O
except O
for O
the O
selection O
of O
doses O
, O
were O
pooled O
to O
evaluate O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
fixed O
doses O
of O
a O
new O
sustained-release O
( O
SR O
) O
formulation O
of O
nifedipine O
compared O
with O
placebo O
in O
388 O
patients O
with O
mild O
to O
moderate O
uncomplicated O
essential O
hypertension O
. O
['Life-Impact']

Although O
EMDA O
has O
been O
used O
to O
treat O
patients O
with O
various O
diseases O
, O
controlled O
studies O
are O
lacking O
in O
patients O
with O
rheumatic O
disease O
. O
[]

A O
group O
of O
45 O
healthy O
volunteers O
was O
also O
longitudinally O
evaluated O
. O
[]

During O
the O
last O
two O
months O
the O
second O
drug O
was O
added O
. O
[]

Participants O
were O
randomized O
by O
shelter O
to O
a O
peer-mentored B-outcome ['Life-Impact']
, O
a O
nurse O
case-managed O
, O
or O
a O
standard O
care O
HIV B-outcome ['Physiological-Clinical']
risk-reduction O
program O
. O
['Life-Impact', 'Physiological-Clinical']

The O
primary O
outcome O
measure O
was O
total O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
. O
['Life-Impact']

OBJECTIVES O
To O
study O
the O
effect O
of O
single-needle O
acupuncture O
in O
suppressing O
gag-reflex O
in O
transesophageal O
echocardiography O
( O
TEE O
) O
. O
[]

AIM O
The O
aim O
of O
study O
was O
test O
efficacy O
of O
accelerated O
postoperative O
radiotherapy O
-- O
concomitant O
boost O
in O
patients O
with O
advanced O
larynx O
cancer O
. O
[]

The O
effectiveness O
and O
cost B-outcome ['Resource-use']
of O
passive B-outcome ['Life-Impact']
warming I-outcome ['Life-Impact']
in O
adult O
ambulatory O
surgery O
patients O
. O
['Resource-use', 'Life-Impact']

OBJECTIVE O
The O
aim O
of O
the O
study O
was O
to O
compare O
safety O
, O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
risperidone O
with O
haloperidol O
in O
the O
treatment O
of O
Autistic O
Disorder O
( O
AD O
) O
. O
['Life-Impact']

However O
, O
individual O
response O
varies O
, O
and O
previous O
trials O
demonstrated O
no O
outcome O
benefit O
. O
[]

Due O
to O
the O
sample O
size O
and O
short O
time O
frame O
, O
results O
of O
a O
repeated O
measures O
analysis O
of O
variance O
did O
not O
reach O
significance O
. O
[]

Double-blind O
placebo-controlled O
studies O
. O
[]

Genital O
self-stimulation O
was O
used O
in O
both O
the O
groups O
. O
[]

Once O
the O
ability O
to O
ask O
the O
question O
was O
acquired O
, O
the O
children O
's O
ability O
to O
learn O
novel O
information O
by O
asking O
the O
question O
was O
assessed O
. O
[]

3 O
) O
Eleven O
children O
had O
later O
onset O
, O
atypical B-outcome ['Physiological-Clinical']
absences I-outcome ['Physiological-Clinical']
, O
tonic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
partial I-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
, O
and O
no O
myoclonus O
, O
or O
vibratory O
tonic O
seizures O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
compare O
the O
discriminatory O
potential O
between O
prostate O
cancer O
and O
benign O
conditions O
of O
the O
prostate O
in O
a O
population-based O
screening O
study O
, O
of O
serum O
prostate-specific O
antigen O
levels O
( O
PSA O
) O
and O
PSA O
corrected O
for O
both O
the O
total O
prostate O
volume O
( O
PSA-D O
) O
and O
the O
transition O
zone O
volume O
( O
PSA-T O
) O
. O
[]

This O
study O
investigated O
the O
effects O
of O
beta2-adrenergic O
agonist O
therapy O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability O
( O
HRV B-outcome ['Physiological-Clinical']
) O
in O
adult O
asthmatic O
patients O
by O
using O
frequency O
domain O
measures O
of O
HRV O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Secondary O
outcomes O
were O
rate O
of O
thrombolytic B-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
90-day O
functional B-outcome ['Life-Impact']
outcomes O
, O
incidence O
of O
intracerebral B-outcome ['Physiological-Clinical']
hemorrhages I-outcome ['Physiological-Clinical']
, O
and O
technical B-outcome ['Life-Impact']
observations I-outcome ['Life-Impact']
. O
['Resource-use', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

The O
misattribution O
of O
salience O
in O
delusional O
patients O
with O
schizophrenia O
. O
[]

A O
novel O
technique O
was O
applied O
using O
an O
escape O
envelope O
containing O
a O
reference O
drug O
which O
could O
be O
taken O
under O
controlled O
conditions O
if O
, O
after O
48 O
hours O
, O
the O
patient O
experienced O
no O
relief B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

GMTs B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
FHA I-outcome ['Physiological-Clinical']
in O
all O
the O
vaccine O
groups O
also O
dropped O
during O
the O
same O
period O
from O
49.94 O
, O
41.73 O
and O
20.74 O
ELISA O
U/ml O
to O
7.26 O
, O
7.72 O
and O
5.91 O
ELISA O
U/ml O
, O
respectively O
. O
['Physiological-Clinical']

The O
rate O
of O
cure B-outcome ['Physiological-Clinical']
by O
30 O
d O
after O
calving O
for O
systemic O
oxytetracycline O
( O
in O
combination O
with O
cephapirin O
treatment O
) O
was O
29.4 O
% O
for O
infected O
quarters O
and O
29.4 O
% O
for O
infected O
cows O
, O
compared O
with O
27.5 O
and O
25.0 O
% O
, O
respectively O
, O
for O
the O
cephapirin O
treatment O
only O
. O
['Physiological-Clinical']

RESULTS O
TLT O
failed O
to O
arrest O
progression O
of O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
dilation I-outcome ['Physiological-Clinical']
by O
the O
end O
of O
the O
hospital O
stay O
. O
['Physiological-Clinical']

Load O
theory O
of O
selective O
attention O
and O
cognitive O
control O
. O
[]

OBJECTIVE O
In O
this O
pilot O
study O
, O
we O
determined O
the O
effectiveness O
of O
a O
weighted O
vest O
on O
attention O
to O
task O
for O
second-grade O
general O
education O
students O
with O
difficulty O
attending O
. O
[]

Still O
, O
the O
muscle B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
ratio O
of O
the O
thigh B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
compared O
with O
that O
of O
normal O
subjects O
( O
72.6/27.4 O
vs O
77.9/22.1 O
) O
( O
p O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
freshly O
extracted O
juice O
of O
50 O
g O
of O
garlic O
or O
onion O
, O
as O
well O
as O
an O
equivalent O
amount O
of O
their O
ether-extracted O
essential O
oils O
, O
was O
administered O
randomly O
on O
four O
different O
days O
during O
a O
one-week O
period O
. O
[]

Echo-Doppler O
of O
renal O
arteries O
was O
performed O
to O
verify O
the O
anatomic O
patency O
and O
flow O
velocities O
of O
the O
reperfused O
artery O
. O
[]

Fulvestrant O
continued O
to O
be O
well O
tolerated O
, O
and O
was O
associated O
with O
a O
significantly O
lower O
incidence O
of O
joint B-outcome ['Physiological-Clinical']
disorders I-outcome ['Physiological-Clinical']
compared O
with O
anastrozole O
( O
P O
= O
0.0234 O
) O
. O
['Physiological-Clinical']

Phlebitis B-outcome ['Physiological-Clinical']
occurred O
in O
7/51 O
( O
13.7 O
% O
) O
and O
12/52 O
( O
23.0 O
% O
) O
. O
['Physiological-Clinical']

We O
hypothesized O
that O
bleeding O
in O
patients O
undergoing O
transurethral O
prostate O
resection O
could O
be O
decreased O
by O
giving O
finasteride O
for O
2 O
weeks O
before O
surgery O
. O
[]

Mitral O
surgery O
allows O
an O
immediate O
surgical O
auricular O
remodeling O
and O
besides O
in O
those O
cases O
in O
which O
sinus O
rhythm O
is O
reached O
, O
it O
is O
followed O
by O
a O
late O
remodeling O
. O
[]

Research O
questions O
addressing O
aim O
1 O
were O
as O
follows O
: O
( O
a O
) O
can O
rural O
breast O
cancer O
survivors O
be O
recruited O
into O
a O
longitudinal O
intervention O
trial O
, O
and O
( O
b O
) O
can O
their O
participation O
be O
retained O
. O
[]

The O
implementation O
of O
a O
multisite O
, O
randomized O
, O
clinical O
psychopharmacologic O
trial O
involves O
a O
substantial O
investment O
of O
time O
and O
effort O
on O
the O
part O
of O
all O
participants O
. O
[]

The O
control O
group O
was O
not O
a O
non-intervention O
group O
. O
[]

Parietal B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
in O
duodenal O
ulcer O
patients O
after O
short-term O
treatment O
with O
cimetidine O
and O
antacids O
. O
['Physiological-Clinical']

Evaluation O
of O
the O
topical O
hemostatic O
efficacy O
and O
safety O
of O
TISSEEL O
VH O
S/D O
fibrin O
sealant O
compared O
with O
currently O
licensed O
TISSEEL O
VH O
in O
patients O
undergoing O
cardiac O
surgery O
: O
a O
phase O
3 O
, O
randomized O
, O
double-blind O
clinical O
study O
. O
[]

Improvement O
was O
only O
in O
sperm B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
and O
total O
motility B-outcome ['Physiological-Clinical']
for O
all O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Through O
behavioural O
analysis O
, O
this O
study O
investigated O
the O
social-motivational O
aspects O
of O
musical O
interaction O
between O
the O
child O
and O
the O
therapist O
in O
improvisational O
music O
therapy O
by O
measuring O
emotional O
, O
motivational O
and O
interpersonal O
responsiveness O
in O
children O
with O
autism O
during O
joint O
engagement O
episodes O
. O
[]

STUDY O
DESIGN O
The O
participants O
were O
randomized O
into O
two O
groups O
, O
to O
receive O
pills O
containing O
ethynylestradiol O
( O
EE O
) O
30 O
mcg O
and O
levonorgestrel O
( O
LNG O
) O
150 O
mcg O
or O
EE O
20 O
mcg O
and O
LNG O
100 O
mcg O
, O
for O
six O
cycles O
. O
[]

The O
anti-thermal O
hyperalgesia O
and O
anti-mechanical O
allodynia O
may O
be O
partly O
attributable O
to O
the O
decreased O
expression O
of O
HMGB1 O
and O
inhibition O
of O
HMGB1-RAGE O
pathway O
. O
[]

Cord O
blood O
glucose O
, O
insulin O
, O
and O
lactate O
levels O
were O
also O
increased O
in O
this O
group O
. O
[]

MATERIALS O
AND O
METHODS O
Seven O
hundred O
and O
fifty O
five O
previously O
untreated O
ACC O
patients O
were O
randomised O
between O
treatment O
with O
capecitabine O
, O
oxaliplatin O
and O
bevacizumab O
or O
the O
same O
combination O
with O
the O
addition O
of O
cetuximab O
. O
[]

Thus O
, O
a O
source O
of O
metal O
ion O
exposure O
with O
the O
potential O
to O
sensitize O
patients O
is O
present O
. O
[]

Our O
data O
indicate O
that O
the O
blood O
conservation O
system O
eliminates O
a O
significant O
factor O
in O
the O
decline O
in O
hemoglobin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Thus O
the O
potassium-retaining O
diuretic O
amiloride O
, O
like O
the O
aldosterone O
antagonist O
spironolactone O
, O
markedly O
reduces O
both O
the O
ulcer-healing B-outcome ['Physiological-Clinical']
and O
the O
metabolic B-outcome ['Physiological-Clinical']
side-effects I-outcome ['Physiological-Clinical']
of O
carbenoxolone O
sodium O
, O
and O
should O
not O
be O
used O
together O
with O
it O
in O
the O
treatment O
of O
peptic O
ulcer O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
topical O
boswellic O
acid O
on O
photo O
and O
age-damaged O
skin O
: O
clinical B-outcome ['Physiological-Clinical']
, O
biophysical B-outcome ['Physiological-Clinical']
, O
and O
echographic B-outcome ['Physiological-Clinical']
evaluations I-outcome ['Physiological-Clinical']
in O
a O
double-blind O
, O
randomized O
, O
split-face O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

When O
accumulated O
into O
IIEF O
domains O
, O
all O
five O
domains O
were O
significant O
in O
favor O
of O
sildenafil O
. O
[]

Previous O
studies O
using O
volumetrics O
in O
outpatient O
samples O
have O
relied O
on O
total O
lesion B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

DESIGN O
Double-blind O
, O
placebo-controlled O
, O
crossover O
trial O
followed O
by O
open-label O
continuation O
. O
[]

Group O
C O
, O
the O
control O
group O
, O
received O
no O
supplement O
. O
[]

Motion O
aftereffects O
with O
horizontally O
moving O
sound O
sources O
in O
the O
free O
field O
. O
[]

Low O
doses O
of O
ketazolam O
in O
anxiety B-outcome ['Life-Impact']
: O
a O
double-blind O
, O
placebo-controlled O
study O
. O
['Life-Impact']

The O
control O
group O
received O
similar O
intensive O
regular O
rehabilitation O
. O
[]

RESULTS O
Two O
thirds O
of O
the O
smokers O
reported O
low-moderate O
levels O
of O
motivation B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
quit I-outcome ['Life-Impact']
at O
baseline O
as O
assessed O
by O
the O
contemplation O
ladder O
. O
['Life-Impact']

The O
predominant O
failure O
mode O
was O
adhesive O
. O
[]

Results O
of O
a O
phase O
III O
, O
8-week O
, O
multicenter O
, O
prospective O
, O
randomized O
, O
double-blind O
, O
parallel-group O
clinical O
trial O
to O
assess O
the O
effects O
of O
amlodipine O
camsylate O
versus O
amlodipine O
besylate O
in O
Korean O
adults O
with O
mild O
to O
moderate O
hypertension O
. O
[]

Thus O
, O
experimental O
evidence O
on O
the O
beneficial O
effects O
of O
combining O
pharmacotherapy O
and O
exportable O
behavioral O
interventions O
is O
needed O
to O
guide O
clinical O
practice O
. O
[]

Desmopressin O
has O
no O
beneficial O
effect O
on O
excessive O
postoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
or O
blood O
product O
requirements O
associated O
with O
cardiopulmonary O
bypass O
. O
['Physiological-Clinical']

Cardiac B-outcome ['Physiological-Clinical']
event O
rates O
were O
based O
on O
reductions O
in O
left O
ventricular O
ejection O
fraction O
as O
a O
function O
of O
cumulative O
anthracycline O
dose O
. O
['Physiological-Clinical']

The O
overall O
dropout O
rate O
was O
36 O
% O
. O
[]

A O
randomized O
, O
double-blind O
, O
vehicle-controlled O
study O
to O
assess O
5 O
% O
imiquimod O
cream O
for O
the O
treatment O
of O
multiple B-outcome ['Physiological-Clinical']
actinic I-outcome ['Physiological-Clinical']
keratoses I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

These O
data O
support O
the O
concept O
that O
P-selectin O
on O
the O
microvascular O
endothelium O
is O
critical O
to O
both O
acute B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
occlusion I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
chronically I-outcome ['Physiological-Clinical']
impaired I-outcome ['Physiological-Clinical']
microvascular I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
SCD I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
recorded O
throughout O
the O
study O
. O
[ O
['Adverse-effects']

Pathological O
parameters O
and O
prostate B-outcome ['Mortality']
specific I-outcome ['Mortality']
antigen I-outcome ['Mortality']
relapse-free I-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
compared O
to O
determine O
the O
clinical O
significance O
of O
false-negative O
biopsies O
. O
['Mortality']

This O
was O
particularly O
evident O
over O
the O
first O
2 O
years O
among O
those O
not O
on O
vitamin O
A O
prior O
to O
entry O
( O
test O
for O
trend O
, O
P O
=.003 O
) O
. O
[]

DESIGN O
A O
secondary O
analysis O
of O
data O
obtained O
from O
a O
prospective O
, O
single-blind O
, O
randomized O
controlled O
intervention O
trial O
. O
[]

Perceptual O
wind-up O
in O
the O
human O
oesophagus O
is O
enhanced O
by O
central O
sensitisation O
. O
[]

There O
were O
no O
differences O
in O
the O
incidence O
of O
nausea B-outcome ['Physiological-Clinical']
, O
headache B-outcome ['Physiological-Clinical']
, O
diarrhea B-outcome ['Physiological-Clinical']
and O
pyrexia B-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Efficacy O
outcome O
measures O
included O
the O
Aberrant O
Behavior O
Checklist O
irritability B-outcome ['Life-Impact']
subscale O
and O
the O
Clinical O
Global O
Impression-Improvement O
score O
( O
CGI-I O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Analysis O
of O
covariance O
indicated O
no O
significant O
differences O
between O
groups O
on O
posttest O
means O
for O
any O
skill O
. O
[]

RESULTS O
The O
effects O
of O
5 O
g/day O
of O
MF101 O
did O
not O
differ O
from O
those O
of O
placebo O
. O
[]

Mitigation O
of O
sociocommunicational O
deficits O
of O
autism O
through O
oxytocin-induced O
recovery O
of O
medial O
prefrontal O
activity O
: O
a O
randomized O
trial O
. O
[]

The O
different O
terms O
led O
to O
different O
attributions O
, O
with O
PA O
respondents O
rating O
the O
CNDS O
label O
as O
more O
severe O
. O
[]

Performance O
on O
the O
BBT B-outcome ['Physiological-Clinical']
and O
the O
10 O
MWT B-outcome ['Physiological-Clinical']
( O
velocity O
and O
stride O
length O
in O
self-paced O
task O
and O
velocity O
in O
as-quickly-as-possible O
task O
) O
were O
improved O
after O
MT O
+ O
MG O
compared O
with O
MT O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
& O
AIMS O
The O
COMET O
trial O
was O
a O
prospective O
, O
double-blind O
, O
randomised O
trial O
comparing O
carvedilol O
, O
a O
comprehensive O
adrenergic O
receptor O
antagonist O
, O
with O
metoprolol O
, O
a O
beta-1-selective O
agent O
in O
patients O
with O
heart O
failure O
and O
left O
ventricular O
systolic O
dysfunction O
. O
[]

Physician B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
in O
both O
groups O
was O
similar O
. O
['Life-Impact']

Retinotomy O
may O
be O
required O
more O
often O
in O
patients O
undergoing O
repeat O
vitreous O
surgery O
for O
proliferative O
vitreoretinopathy O
, O
in O
which O
case O
both O
silicone O
oil O
and O
long-acting O
perflouropropane O
gas O
appear O
to O
be O
[]

We O
designed O
and O
carried O
out O
a O
multi-centre O
study O
to O
compare O
and O
evaluate O
the O
efficacy O
of O
ISDN B-outcome ['Physiological-Clinical']
and O
NTG O
in O
the O
management O
of O
perioperative O
hypertension O
in O
85 O
patients O
undergoing O
elective O
coronary O
artery O
surgery O
. O
['Physiological-Clinical']

Statin O
withdrawal O
was O
associated O
with O
a O
4.66 O
( O
1.46 O
to O
14.91 O
) O
-fold O
increase O
in O
the O
risk O
of O
death B-outcome ['Mortality']
or O
dependency O
, O
a O
8.67 O
( O
3.05 O
to O
24.63 O
) O
-fold O
increase O
in O
the O
risk O
of O
END O
, O
and O
an O
increase O
in O
mean O
infarct B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of O
37.63 O
mL O
( O
SE O
10.01 O
; O
p O
< O
0.001 O
) O
after O
adjusting O
for O
age O
and O
baseline O
stroke O
severity O
. O
['Mortality', 'Physiological-Clinical']

CONCLUSIONS O
Retapamulin O
ointment O
1 O
% O
( O
bid O
) O
for O
5 O
days O
was O
as O
effective O
as O
oral O
cephalexin O
( O
bid O
) O
for O
10 O
days O
in O
treatment O
of O
patients O
with O
SID O
, O
and O
was O
well O
tolerated O
. O
[]

In O
the O
eyes O
followed O
up O
, O
5 O
of O
11 O
2 O
eyes O
( O
4.5 O
% O
) O
in O
A O
group O
and O
41 O
of O
96 O
eyes O
( O
42.7 O
% O
) O
in O
B O
group O
were O
recurred B-outcome ['Physiological-Clinical']
, O
the O
difference O
being O
very O
significant O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

In O
patients O
without O
kidney O
disease O
, O
BNP O
testing O
significantly O
reduced O
median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
discharge I-outcome ['Physiological-Clinical']
( O
from O
9.5 O
days O
to O
2.5 O
days O
) O
( O
P= O
0.003 O
) O
and O
total O
cost B-outcome ['Resource-use']
of I-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
( O
from O
7184 O
dollars O
to O
4151 O
dollars O
) O
( O
P= O
0.004 O
) O
. O
['Physiological-Clinical', 'Resource-use']

A O
cohort O
of O
39 O
patients O
with O
APC O
, O
without O
thrombosis O
, O
receiving O
chemotherapy O
, O
were O
entered O
in O
a O
randomized O
controlled O
trial O
( O
ISRCTN O
= O
76464767 O
) O
of O
thromboprevention O
with O
weight-adjusted O
dalteparin O
( O
WAD O
) O
. O
[]

Mean O
temperature O
upon O
intensive B-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit I-outcome ['Resource-use']
admission I-outcome ['Resource-use']
was O
35.8 O
+/- O
1.0 O
degrees O
C O
for O
the O
hypothermic O
group O
and O
37.1 O
+/- O
0.5 O
degrees O
C O
for O
the O
normothermic O
group O
( O
P O
< O
0.0001 O
) O
. O
['Resource-use']

The O
pharmacokinetics B-outcome ['Physiological-Clinical']
and O
the O
pharmacodynamic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
biochemical I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
of O
the O
new O
cathepsin O
K O
inhibitor O
, O
ONO-5334 O
, O
were O
investigated O
in O
a O
multiple O
ascending O
dose O
, O
phase O
1 O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
rofecoxib O
group O
( O
n O
= O
85 O
) O
73 O
patients O
( O
86 O
% O
) O
showed O
no O
[]

At O
1 O
year O
the O
intervention O
group O
showed O
significantly O
greater O
reductions O
in O
2 O
h B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
fasting B-outcome ['Physiological-Clinical']
and O
2 B-outcome ['Physiological-Clinical']
h I-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
serum B-outcome ['Physiological-Clinical']
triglycerides I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Neither O
training O
nor O
intramuscular O
glycogen O
levels O
had O
an O
effect O
on O
the O
IL-6R B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
exercise O
. O
['Physiological-Clinical']

The O
study O
was O
conducted O
at O
three O
Swedish O
hospitals O
. O
[]

The O
intervention O
paid O
particular O
attention O
to O
postnatal O
maternal O
depression O
and O
promoting O
parenting O
skills O
and O
attachment O
security O
, O
particularly O
through O
the O
use O
of O
video O
during O
home-visits O
. O
[]

Long-term O
body O
image O
and O
cosmetic O
appearance O
were O
excellent O
in O
both O
groups O
. O
[]

Spirometry B-outcome ['Resource-use']
, O
pulse B-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
measured O
on O
enrollment O
and O
after O
4 O
weeks O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

BK O
caused O
cough B-outcome ['Physiological-Clinical']
at O
13.4 O
+/- O
1.2 O
( O
-log O
M O
) O
in O
5 O
patients O
with O
cough O
associated O
with O
ACE O
inhibitors O
, O
but O
it O
did O
not O
cause O
cough B-outcome ['Physiological-Clinical']
at O
concentrations O
up O
to O
10 O
( O
-5 O
) O
M O
in O
other O
5 O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Additional O
positive O
non-SLN O
were O
detected O
in O
29 O
% O
of O
patients O
with O
macrometastasis O
, O
in O
25 O
% O
of O
patients O
with O
micrometastasis O
, O
and O
in O
0 O
% O
of O
patients O
with O
submicrometastases O
. O
[]

In O
these O
patients O
DBP B-outcome ['Physiological-Clinical']
decreased O
throughout O
the O
following O
eight O
weeks O
. O
['Physiological-Clinical']

Intrathecal B-outcome ['Physiological-Clinical']
immunoactivation I-outcome ['Physiological-Clinical']
in O
patients O
with O
HIV-1 O
infection O
is O
reduced O
by O
zidovudine O
but O
not O
by O
didanosine O
. O
['Physiological-Clinical']

CONCLUSION O
PR-STENT O
reduces O
systolic O
BP O
without O
improving O
GFR O
. O
[]

METHODS O
Data O
were O
collected O
in O
a O
combined O
crossover O
multiple O
baseline O
design O
across O
participants O
. O
[]

Contingency O
management O
( O
CM O
) O
is O
a O
behavioral O
intervention O
that O
rewards O
positive O
performance O
and O
has O
demonstrated O
effectiveness O
in O
reducing O
drug O
use O
in O
SMI O
populations O
. O
[]

In O
the O
first O
group O
( O
oxytocin O
group O
= O
75 O
) O
, O
oxytocin O
alone O
was O
used O
for O
induction O
of O
labor B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

practising O
aortic O
murmurs O
separately O
from O
mitral O
murmurs O
) O
during O
a O
second O
, O
unguided O
practice O
session O
. O
[]

A O
randomized O
, O
parallel O
group O
study O
evaluated O
the O
safety O
, O
efficacy O
, O
and O
effect O
of O
the O
alpha O
blocking O
agent O
prazosin O
and O
the O
angiotensin O
converting O
enzyme O
inhibitor O
captopril O
on O
serum O
lipid O
levels O
in O
patients O
with O
mild O
to O
moderate O
hypertension O
. O
[]

Clinical O
stages O
IA O
and O
II2A O
received O
three O
courses O
of O
mechlorethamine O
, O
Oncovin O
, O
procarbazine O
, O
and O
prednisone O
( O
MOPP O
) O
and O
supradiaphragmatic O
radiotherapy O
( O
40 O
Gy O
) O
, O
and O
no O
laparotomy O
was O
performed O
. O
[]

According O
to O
the O
primary O
endpoint O
, O
systemic B-outcome ['Resource-use']
glucocorticoid I-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
for O
graft-versus-host O
disease O
was O
given O
to O
60 O
of O
the O
92 O
participants O
( O
65 O
% O
) O
in O
the O
BDP O
arm O
, O
versus O
31 O
of O
46 O
participants O
( O
67 O
% O
) O
in O
the O
placebo O
arm O
. O
['Resource-use']

The O
aim O
is O
to O
determine O
anxiety B-outcome ['Life-Impact']
and O
health-related B-outcome ['Physiological-Clinical']
( O
HR B-outcome ['Physiological-Clinical']
) O
-QoL O
and O
evaluate O
the O
burden O
of O
carrying O
a O
CER O
in O
general O
practice O
populations O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

During O
treatment O
, O
HS O
and O
LS O
heifers O
had O
greater O
weight O
gains O
than O
control O
heifers O
. O
[]

Patients O
treated O
with O
concomitant O
chemoradiotherapy O
experienced O
more O
frequently O
[]

A O
prospective O
randomized O
study O
. O
[]

Additional O
analyses O
revealed O
consistent O
results O
demonstrating O
functional O
connectivity O
among O
the O
OFC O
, O
rACC O
, O
and O
insula O
. O
[]

Methylphenidate O
and/or O
a O
nursing O
telephone O
intervention O
for O
fatigue B-outcome ['Physiological-Clinical']
in O
patients O
with O
advanced O
cancer O
: O
a O
randomized O
, O
placebo-controlled O
, O
phase O
II O
trial O
. O
['Physiological-Clinical']

Serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
in O
? O
['Adverse-effects']

After O
the O
discontinuation O
of O
therapy O
, O
clinical B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
including O
reactivation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
unstable I-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
occurring I-outcome ['Physiological-Clinical']
within I-outcome ['Physiological-Clinical']
96 I-outcome ['Physiological-Clinical']
hours I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
hospitalization I-outcome ['Physiological-Clinical']
, O
were O
closely O
monitored O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
relapse-free B-outcome ['Physiological-Clinical']
survival B-outcome ['Mortality']
was O
significantly O
improved O
by O
60Co O
radiation O
in O
Stage O
II O
patients O
, O
but O
was O
unaffected O
by O
radiation O
in O
the O
other O
subgroups O
. O
['Physiological-Clinical', 'Mortality']

CONCLUSION O
Midazolam-tramadol O
combination O
may O
be O
used O
as O
an O
alternative O
to O
midazolam-pethidine O
combination O
for O
sedation O
during O
surgical O
procedures O
performed O
under O
regional O
anaesthesia O
. O
[]

The O
results O
show O
that O
all O
four O
variants O
are O
more O
sensitive O
than O
the O
conventional O
SWAT O
scale O
and O
that O
the O
pairwise O
comparison O
procedure O
takes O
significantly O
less O
pretask B-outcome ['Life-Impact']
completion I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
compared O
with O
the O
original O
SWAT O
scale O
. O
['Life-Impact']

Large-dose O
intravenous O
ferric O
carboxymaltose O
injection O
for O
iron O
deficiency O
anemia O
in O
heavy O
uterine O
bleeding O
: O
a O
randomized O
, O
controlled O
trial O
. O
[]

Understanding O
these O
relationships O
is O
an O
essential O
part O
of O
the O
ongoing O
search O
for O
quantitative O
spasticity O
measures O
. O
[]

No O
significant O
signs B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
levels O
were O
observed O
during O
the O
single O
and O
repeated O
oral O
dose O
studies O
at O
150 O
mg O
b.d O
. O
['Physiological-Clinical']

Daily O
administration O
of O
2-chlorodeoxyadenosine O
( O
Cladribine O
, O
CDA O
) O
is O
a O
standard O
treatment O
for O
hairy O
cell O
leukemia O
, O
but O
may O
cause O
severe O
neutropenia B-outcome ['Physiological-Clinical']
and O
neutropenic B-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
the O
methods O
in O
resection B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
postoperative B-outcome ['Life-Impact']
catheterization I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
. O
['Life-Impact', 'Life-Impact', 'Resource-use']

However O
, O
a O
higher O
rate O
of O
recurrence O
was O
observed O
in O
the O
PLA O
group O
for O
lesions O
? O
[]

BACKGROUND O
The O
primary O
objective O
of O
this O
study O
was O
to O
investigate O
the O
behavioral O
and O
biochemical O
responses O
to O
acute O
tryptophan O
depletion O
in O
drug-free O
adult O
patients O
with O
autistic O
disorder O
. O
[]

CONCLUSION O
Fibrinogen O
should O
be O
adsorbed O
while O
the O
blood O
touches O
the O
MARS O
circuit O
path O
and O
anticoagulants O
can O
prevent O
it O
. O
[]

The O
groups O
received O
intrathecal O
0.5 O
mg O
morphine O
( O
Group O
IT0.5 O
) O
, O
intrathecal O
0.1 O
mg O
morphine O
( O
Group O
IT0.1 O
) O
or O
10 O
mg O
morphine O
i.v O
. O
( O
[]

After O
3 O
months O
, O
RBC B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
increased O
in O
two O
of O
4 O
androgen-treated O
patients O
. O
['Physiological-Clinical']

Secondary O
outcomes O
included O
actigraphically B-outcome ['Physiological-Clinical']
recorded I-outcome ['Physiological-Clinical']
sleep-onset I-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
efficiency I-outcome ['Physiological-Clinical']
, O
assessments O
of O
child B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
, O
family B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
and O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Adverse-effects']

RESULTS O
Data O
from O
30 O
patients O
( O
13 O
females O
) O
, O
14 O
on O
R1 O
and O
16 O
on O
R2 O
, O
were O
analysed O
. O
[]

We O
used O
the O
prospective O
Alpha-Tocopherol O
, O
Beta-Carotene O
( O
ATBC O
) O
Cancer O
Prevention O
Study O
to O
assess O
whether O
iron O
metrics O
were O
associated O
with O
gastric B-outcome ['Physiological-Clinical']
cardia I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GCC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
gastric B-outcome ['Physiological-Clinical']
noncardia I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GNCC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Methylphenidate O
was O
associated O
with O
significant O
improvement O
that O
was O
most O
evident O
at O
the O
.25- O
and O
.5-mg/kg O
doses O
. O
[]

A O
total O
of O
577 O
episodes O
of O
uncomplicated O
Plasmodium O
falciparum O
malaria O
were O
treated O
with O
study O
drugs O
; O
all O
regimens O
were O
safe O
and O
well O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact']

Independent O
risk O
factors O
for O
catheter B-outcome ['Physiological-Clinical']
colonization I-outcome ['Physiological-Clinical']
were O
catheter O
insertion O
into O
the O
jugular O
vein O
( O
adjusted O
relative O
risk O
, O
2.01 O
; O
95 O
% O
confidence O
interval O
, O
1.24-3.24 O
) O
and O
use O
of O
povidone-iodine O
( O
adjusted O
relative O
risk O
, O
1.87 O
; O
95 O
% O
confidence O
interval O
, O
1.18-2.96 O
) O
. O
['Physiological-Clinical']

Each O
dose O
and O
placebo O
was O
given O
for O
seven O
days O
. O
[]

In O
contrast O
, O
basal B-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
and O
standard O
deviation O
were O
greater O
in O
older O
subjects O
( O
P O
= O
0.05 O
) O
and O
were O
unaffected O
by O
double O
blockade O
in O
young O
and O
older O
subjects O
. O
['Physiological-Clinical']

RESULTS O
FMA B-outcome ['Physiological-Clinical']
total O
scores O
were O
significantly O
higher O
and O
synergistic B-outcome ['Physiological-Clinical']
shoulder B-outcome ['Physiological-Clinical']
abduction B-outcome ['Physiological-Clinical']
during O
reach B-outcome ['Physiological-Clinical']
was O
less O
in O
the O
MT O
+ O
MG O
and O
MT O
groups O
compared O
with O
the O
CT O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Altered O
peripheral B-outcome ['Physiological-Clinical']
vasodilator I-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
of O
nitroglycerin O
during O
long-term O
infusion O
of O
N-acetylcysteine O
. O
['Physiological-Clinical']

All O
of O
the O
ambulatory O
milestones O
were O
significantly O
faster O
in O
Group O
1 O
. O
[]

In O
12 O
subjectively O
caffeine-sensitive O
and O
10 O
-insensitive O
young O
men O
, O
psychomotor O
vigilance O
task O
( O
PVT O
) O
performance O
and O
EEG O
were O
assessed O
at O
3 O
h O
intervals O
before O
, O
during O
, O
and O
after O
one O
night O
without O
sleep O
. O
[]

AIM O
To O
investigate O
efficacy O
and O
safety O
of O
two O
different O
preparations O
of O
testosterone O
undecanoate O
( O
TU O
) O
in O
52 O
hypogonadal O
men O
[ O
mean O
age O
57 O
yr O
and O
mean O
testosterone O
( O
T O
) O
< O
320 O
ng/dl O
] O
with O
metabolic O
syndrome O
( O
MS O
) O
. O
[]

These O
differences O
are O
not O
statistically O
significant O
. O
[]

CONCLUSION O
Toothbrushes O
containing O
the O
antimicrobial O
additive O
showed O
lower O
microbial B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
than O
those O
without O
, O
but O
between-group O
means O
were O
not O
statistically O
significant O
. O
['Physiological-Clinical']

MAIN O
RESULTS O
Of O
the O
60 O
patients O
who O
were O
enrolled O
( O
60 O
% O
men O
, O
mean O
age O
53 O
years O
, O
mean O
Acute O
Physiology O
and O
Chronic O
Health O
Evaluation O
II O
score O
, O
19.5 O
) O
, O
30 O
were O
evaluable O
for O
both O
pharmacokinetics O
and O
pharmacodynamics O
( O
50 O
% O
) O
. O
[]

[ O
Prevention O
of O
thromboembolism B-outcome ['Physiological-Clinical']
in O
patients O
operated O
on O
for O
hip O
prosthesis O
] O
. O
['Physiological-Clinical']

Mean O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
increased O
with O
increasing O
hypoxemia B-outcome ['Physiological-Clinical']
from O
6.84 O
L/min O
at O
FIo2 O
1.0 O
to O
8.44 O
L/min O
at O
SaO2 O
80 O
percent O
( O
p O
less O
than O
0.0005 O
) O
; O
the O
increase O
was O
entirely O
due O
to O
increased O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Settings/locations O
: O
Patients O
with O
ischemic O
stroke O
or O
transient O
ischemic O
attack O
undergoing O
TEE O
because O
of O
presumed O
cardioembolic O
origin O
in O
a O
specialized O
stroke O
unit O
of O
the O
Johann O
Wolfgang O
Goethe-University O
, O
Frankfurt/Main O
, O
Germany O
. O
[]

The O
indexes O
of O
TCD B-outcome ['Physiological-Clinical']
and O
hemorheology B-outcome ['Physiological-Clinical']
in O
the O
treated O
group O
were O
obviously O
improved O
after O
treatment O
, O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
usefulness O
of O
psychological O
training O
programs O
( O
P.T.P O
. O
) O
[]

Patterns O
of O
failure O
were O
analyzed O
according O
to O
total O
event O
rates O
and O
also O
according O
to O
an O
isolated O
first O
site O
of O
relapse O
, O
using O
a O
competing-risk O
approach O
. O
[]

The O
effects O
were O
measured O
at O
baseline O
and O
20 O
, O
40 O
, O
60 O
, O
and O
120 O
min O
after O
the O
first O
inhalation O
. O
[]

Depression B-outcome ['Life-Impact']
, O
functioning B-outcome ['Life-Impact']
, O
perceived B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
, O
utilization B-outcome ['Life-Impact']
, O
and O
costs B-outcome ['Resource-use']
were O
secondary O
outcomes O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Resource-use']

Urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
phenylethylamine I-outcome ['Physiological-Clinical']
increased O
proportionately O
with O
doses O
up O
to O
24 O
mg. O
No O
changes O
in O
urinary B-outcome ['Physiological-Clinical']
elimination O
of O
catecholamines B-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
repeated O
oral O
dose O
study O
, O
the O
subjects O
received O
test O
drug O
at O
150 O
mg O
or O
300 O
mg O
( O
n O
= O
6 O
each O
) O
or O
placebo O
( O
n O
= O
3 O
) O
twice O
a O
day O
( O
after O
breakfast O
and O
after O
dinner O
) O
for O
7 O
days O
. O
[]

2.8 O
) O
were O
significantly O
lower O
than O
those O
in O
control O
group O
( O
8.8 O
? O
[]

The O
present O
double-blind O
, O
double-dummy O
, O
controlled O
trial O
was O
designed O
to O
investigate O
the O
effect O
of O
a O
short-term O
( O
7 O
days O
) O
treatment O
with O
nitrendipine O
, O
20 O
mg O
b.i.d O
. O
; O
[]

This O
difference O
was O
statistically O
different O
between O
these O
two O
groups O
( O
P O
= O
0.000 O
) O
. O
[]

BACKGROUND O
Malaria O
infections O
are O
the O
leading O
cause O
of O
death O
for O
children O
in O
Madagascar O
. O
[]

RESULTS O
No O
significant O
inter- O
or O
intra-group O
differences O
in O
mean O
counts O
were O
found O
; O
however O
, O
when O
four-hour O
and O
24-hour O
data O
for O
Aa O
, O
Pg O
, O
or O
NS O
were O
combined O
, O
experimental O
counts O
were O
lower O
than O
controls O
in O
39/50 O
( O
78 O
% O
) O
of O
the O
matched O
pairs O
( O
Wilcoxon O
signed-rank O
test O
p O
= O
0.01 O
) O
. O
[]

FUNDING O
Medical O
Research O
Council O
. O
[]

The O
CBT O
program O
emphasized O
in O
vivo O
exposure O
supported O
by O
parent O
training O
and O
school O
consultation O
to O
promote O
social O
communication O
and O
emotion O
regulation O
skills O
. O
[]

Twenty O
seven O
patients O
were O
mobilized O
with O
etoposide O
and O
G-CSF O
and O
28 O
with O
etoposide O
, O
G-CSF O
and O
rituximab O
. O
[]

The O
average O
plasma B-outcome ['Physiological-Clinical']
lidocaine I-outcome ['Physiological-Clinical']
level O
10 O
minutes O
after O
administration O
for O
patients O
without O
a O
myocardial O
infarction O
was O
significantly O
higher O
than O
that O
for O
patients O
with O
an O
acute O
infarction O
. O
['Physiological-Clinical']

Body O
size O
indexes O
for O
optimizing O
iodine O
dose O
for O
aortic O
and O
hepatic O
enhancement O
at O
multidetector O
CT O
: O
comparison O
of O
total O
body O
weight O
, O
lean O
body O
weight O
, O
and O
blood O
volume O
. O
[]

CONCLUSION O
The O
results O
show O
that O
zinc O
, O
as O
adjuvant O
agent O
for O
obsessive-compulsive O
disorder O
, O
produces O
improved O
outcomes O
. O
[]

OBJECTIVES O
Cardiac O
surgery O
and O
cardiopulmonary O
bypass O
( O
CPB O
) O
induce O
an O
inflammatory O
reaction O
that O
may O
lead O
to O
tissue O
injury O
. O
[]

RESULTS O
In O
univariate O
analysis O
, O
a O
boost O
reduced O
local B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
by O
a O
factor O
of O
2 O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

METHODS O
Eleven O
thousand O
one O
hundred O
and O
forty O
patients O
aged O
at O
least O
55 O
years O
with O
type O
2 O
diabetes O
( O
mean O
66+/-6 O
years O
) O
were O
randomly O
assigned O
to O
perindopril-indapamide O
or O
placebo O
. O
[]

Twenty-six O
patients O
received O
rofecoxib O
and O
29 O
patients O
received O
placebo O
. O
[]

BACKGROUND O
Non-eosinophilic O
asthma O
is O
a O
potentially O
important O
clinicopathological O
phenotype O
since O
there O
is O
evidence O
that O
it O
responds O
poorly O
to O
inhaled O
corticosteroid O
therapy O
. O
[]

SETTING O
The O
intensive O
care O
units O
of O
105 O
hospitals O
in O
the O
United O
States O
and O
Canada O
. O
[]

Cytotoxic O
agents O
included O
taxanes O
( O
109 O
) O
, O
cisplatin O
( O
8 O
) O
, O
carboplatin O
( O
2 O
) O
, O
oxaliplatin O
( O
50 O
) O
, O
or O
combination O
( O
20 O
) O
. O
[]

The O
active B-outcome ['Life-Impact']
and O
cumulative O
active B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
recorded O
from O
the O
pairs O
of O
catheters O
within O
each O
uterine O
cavity O
were O
compared O
. O
['Life-Impact', 'Physiological-Clinical']

Children O
in O
the O
joint O
attention O
intervention O
initiated O
significantly O
more O
showing B-outcome ['Life-Impact']
and O
responsiveness B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
joint I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
on O
the O
structured O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
assessment O
and O
more O
child-initiated B-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
attention I-outcome ['Physiological-Clinical']
in O
the O
mother-child O
interaction O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

This O
Phase O
III O
study O
( O
Belatacept O
Evaluation O
of O
Nephroprotection O
and O
Efficacy O
as O
First-line O
Immunosuppression O
Trial O
) O
assessed O
a O
more O
intensive O
( O
MI O
) O
or O
less O
intensive O
( O
LI O
) O
regimen O
of O
belatacept O
versus O
cyclosporine O
in O
adults O
receiving O
a O
kidney O
transplant O
from O
living O
or O
standard O
criteria O
deceased O
donors O
. O
[]

Five O
grams O
of O
purified O
talc O
was O
used O
for O
either O
video-assisted O
thoracoscopic O
talc O
insufflation O
or O
talc O
slurry O
. O
[]

Our O
primary O
outcome O
parameters O
were O
as O
follows O
: O
recurrence O
rates O
at O
1 O
and O
2 O
years O
and O
complications O
related O
to O
therapy O
. O
[]

This O
skill O
was O
generalized O
to O
unfamiliar O
contexts O
and O
maintained O
through O
follow-up O
. O
[]

After O
ACE O
inhibition O
, O
fasting B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
levels O
correlated O
with O
the O
decline O
in O
mean O
arterial B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
( O
r O
= O
-0.71 O
; O
P O
< O
0.006 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
To O
evaluate O
the O
antitumor B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
patients O
with O
T3b O
, O
T4 O
or O
metastatic O
urothelial O
carcinoma O
treated O
with O
MEC O
or O
M-VAC O
chemotherapy O
, O
by O
performing O
a O
multi-center O
randomized O
prospective O
study O
. O
['Physiological-Clinical']

The O
test O
design O
takes O
the O
crowding O
phenomenon O
into O
account O
. O
[]

CONCLUSIONS O
Finasteride O
improves O
urodynamic O
measures O
of O
obstruction O
in O
men O
with O
BPE O
and O
LUTS O
, O
with O
continued O
improvement O
during O
the O
second O
12 O
months O
of O
therapy O
. O
[]

METHODS O
A O
total O
of O
379 O
patients O
undergoing O
the O
procedure O
were O
randomly O
enrolled O
in O
1 O
of O
3 O
groups O
. O
[]

2.5mm O
. O
[]

Naltrexone O
plasma O
levels O
, O
clinical O
response O
and O
effect O
on O
weight O
in O
autistic O
children O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
derive O
symptom O
item O
weights O
representing O
clinically O
judged O
seriousness O
of O
each O
symptom O
through O
the O
application O
of O
Steven O
's O
psychophysical O
method O
of O
magnitude O
estimation O
. O
[]

We O
also O
observed O
inverse O
associations O
between O
higher O
percentages O
of O
the O
RBC O
( O
n-3 B-outcome ['Physiological-Clinical']
) O
fatty B-outcome ['Physiological-Clinical']
acids B-outcome ['Physiological-Clinical']
, O
eicosapentaenoic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( O
EPA B-outcome ['Physiological-Clinical']
) O
( O
[ O
0.38 O
( O
0.19-0.77 O
) O
; O
P-trend O
= O
0.007 O
] O
and O
docosapentaenoic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( O
DPA B-outcome ['Physiological-Clinical']
) O
[ O
0.32 O
( O
0.15-0.70 O
) O
; O
P-trend O
= O
0.024 O
] O
, O
and O
fibroadenoma O
risk O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Group O
1 O
patients O
received O
ketamine O
0.15 O
mg/kg O
as O
a O
5-mL O
i.v O
. O
[]

We O
conclude O
from O
this O
study O
that O
antiplatelet O
agents O
have O
no O
effect O
on O
the O
primary B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
end I-outcome ['Physiological-Clinical']
points I-outcome ['Physiological-Clinical']
, O
vascular B-outcome ['Mortality']
deaths I-outcome ['Mortality']
and/or O
amputation O
of O
the O
opposite B-outcome ['Physiological-Clinical']
extremity I-outcome ['Physiological-Clinical']
, O
in O
this O
population O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

The O
difference O
in O
cancer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rate O
between O
transfused O
and O
non-transfused O
patients O
was O
not O
statistically O
significant O
( O
29.8 O
versus O
24.3 O
per O
cent O
; O
P O
= O
0.13 O
) O
. O
['Physiological-Clinical']

Subject-reported O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs O
) O
were O
also O
recorded O
for O
safety O
. O
['Adverse-effects']

Overall O
differences O
in O
strength B-outcome ['Physiological-Clinical']
were O
consistently O
significant O
between O
the O
study O
groups O
( O
P O
= O
.0025 O
) O
. O
['Physiological-Clinical']

This O
stereotype O
threat O
may O
be O
lessened O
by O
a O
values-affirmation O
intervention O
. O
[]

Grade O
3/4 O
haematological B-outcome ['Physiological-Clinical']
toxicities I-outcome ['Physiological-Clinical']
were O
more O
frequent O
in O
the O
two O
GC-containing O
arms O
, O
no O
grade O
3/4 O
['Physiological-Clinical']

This O
relatively O
high O
incidence O
is O
important O
to O
consider O
in O
treatment O
modalities O
in O
which O
prostate O
biopsy O
may O
be O
performed O
to O
determine O
response O
to O
therapy O
. O
[]

The O
synergistic O
toxic B-outcome ['Adverse-effects']
effect O
of O
irradiation O
followed O
by O
methotrexate O
treatment O
seems O
to O
have O
contributed O
to O
three O
of O
the O
five O
deaths O
which O
occurred O
in O
complete O
remission B-outcome ['Physiological-Clinical']
in O
this O
trial O
; O
all O
deaths O
in O
remission O
occurred O
in O
patients O
who O
had O
received O
central O
nervous O
system O
prophylaxis O
. O
['Adverse-effects', 'Physiological-Clinical']

In O
phase O
1 O
, O
the O
control O
group O
had O
no O
weights O
placed O
. O
[]

Subtherapeutic O
doses O
of O
amphotericin O
B O
( O
AMB O
) O
have O
been O
considered O
effective O
as O
prophylaxis O
in O
these O
patients O
. O
[]

RESULTS O
After O
six O
months O
treatment O
, O
the O
general O
effective O
rate O
in O
treatment O
group O
was O
70.00 O
% O
, O
which O
was O
markedly O
higher O
than O
that O
in O
control O
group O
( O
37.50 O
% O
, O
P O
< O
0.01 O
) O
. O
[]

RESULTS O
Only O
the O
sarpogrelate O
group O
showed O
increases O
in O
plasma B-outcome ['Physiological-Clinical']
adiponectin I-outcome ['Physiological-Clinical']
and O
decreases O
in O
both O
plasma B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
monocyte B-outcome ['Physiological-Clinical']
chemoattractant I-outcome ['Physiological-Clinical']
protein-1 I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
albumin-to-creatinine I-outcome ['Physiological-Clinical']
ratio O
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
developing O
countries O
still O
face O
the O
critical O
problem O
of O
anaemia O
in O
pregnancy O
. O
[]

ASD O
families O
received O
more O
hours O
of O
conventional B-outcome ['Resource-use']
services I-outcome ['Resource-use']
compared O
with O
DD O
families O
( O
17.8 O
vs O
11 O
; O
p O
< O
.001 O
) O
. O
['Resource-use']

A O
large O
proportion O
of O
children O
were O
not O
[]

Best-corrected O
visual O
acuity O
was O
determined O
before O
and O
at O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
months O
following O
treatment O
. O
[]

Additionally O
, O
we O
defined O
clinically B-outcome ['Physiological-Clinical']
evident I-outcome ['Physiological-Clinical']
sympathectomy I-outcome ['Physiological-Clinical']
criteria O
( O
a O
100 O
% O
increase O
in O
the O
PI O
, O
a O
15 O
% O
decrease O
in O
MAP O
and O
a O
1 O
degrees O
C O
increase O
in O
toe O
temperature B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Physician-observed B-outcome ['Physiological-Clinical']
otorrhea I-outcome ['Physiological-Clinical']
was O
reported O
in O
5 O
( O
4.95 O
% O
) O
patients O
receiving O
Ciprodex O
and O
39 O
( O
39.39 O
% O
) O
patients O
receiving O
no O
treatment O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

INTERVENTIONS O
Each O
volunteer O
underwent O
three O
infusion O
experiments O
on O
separate O
days O
and O
in O
random O
order O
. O
[]

It O
is O
suggested O
that O
subjects O
who O
are O
discouraged O
from O
blinking O
try O
to O
protect O
themselves O
against O
the O
arousing O
effects O
of O
stimuli O
. O
[]

Mofegiline B-outcome ['Physiological-Clinical']
rapidly I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
markedly I-outcome ['Physiological-Clinical']
inhibited I-outcome ['Physiological-Clinical']
platelet I-outcome ['Physiological-Clinical']
monoamine I-outcome ['Physiological-Clinical']
oxidase I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MAOB I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
which O
returned O
to O
baseline O
within O
14 O
days O
. O
['Physiological-Clinical']

Beneficial O
interventions O
may O
decrease O
the O
disability B-outcome ['Life-Impact']
associated O
with O
osteoarthritis O
and O
the O
need O
for O
more O
invasive O
treatments O
. O
['Life-Impact']

Subsequently O
, O
the O
group O
A O
specimens O
were O
immediately O
brushed O
( O
40 O
strokes O
) O
, O
and O
the O
others O
were O
brushed O
after O
the O
following O
times O
: O
B O
, O
20 O
min O
; O
C O
, O
40 O
min O
; O
and O
D O
, O
60 O
min O
. O
[]

Controlled O
Clinical O
Trials O
Registry O
no O
. O
[]

The O
expression O
of O
phospho-c-Jun O
diminished O
as O
the O
lesion O
stabilized O
( O
P O
< O
0.016 O
) O
and O
does O
not O
significantly O
differ O
from O
the O
normal O
aortic O
wall O
( O
P O
< O
0.33 O
) O
. O
[]

Changes O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
following O
intravenous O
boluses O
of O
isoprenaline O
in O
the O
presence O
of O
practolol O
and O
propranolol O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
In O
the O
treatment O
of O
acute O
clinical O
symptoms O
, O
appetite B-outcome ['Physiological-Clinical']
was O
described O
as O
similar O
to O
that O
during O
good O
health O
by O
61.1 O
% O
of O
patients O
( O
55/93 O
) O
in O
the O
instillation O
group O
and O
by O
47.3 O
% O
( O
44/93 O
) O
in O
the O
slow O
injection O
group O
, O
a O
significant O
advantage O
in O
the O
infusion O
group O
. O
['Physiological-Clinical']

At O
the O
gait O
follow-up O
that O
was O
conducted O
between O
1 O
and O
3 O
months O
after O
walking O
onset O
, O
three O
groups O
significantly O
different O
in O
overall O
gait O
patterns O
( O
p=0.037 O
) O
were O
examined O
by O
six O
basic O
gait O
parameters O
including O
average O
velocity O
, O
stride O
length O
, O
step O
width O
, O
stride O
time O
, O
stance O
time O
, O
and O
dynamic O
base O
. O
[]

These O
observed O
changes O
in O
insulin O
sensitivity O
are O
likely O
to O
be O
clinically O
relevant O
, O
especially O
in O
individuals O
predisposed O
to O
develop O
glucose O
intolerance O
. O
[]

DESIGN O
A O
randomized O
controlled O
trial O
. O
[]

The O
primary O
outcome O
variables O
were O
direct O
and O
indirect B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
of O
treatment O
and O
PD B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

The O
main O
outcome O
measures O
were O
combined B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( O
coronary B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
nonfatal B-outcome ['Physiological-Clinical']
MI I-outcome ['Physiological-Clinical']
, O
percutaneous O
transluminal O
coronary O
angioplasty O
[ O
PTCA O
] O
or O
coronary O
artery O
bypass O
graft O
surgery O
[ O
CABG O
] O
) O
, O
the O
primary O
trial O
end O
point O
( O
coronary B-outcome ['Mortality']
death I-outcome ['Mortality']
or I-outcome ['Mortality']
nonfatal I-outcome ['Mortality']
MI I-outcome ['Mortality']
) O
and O
stroke B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

BACKGROUND O
Intravenous O
cangrelor O
, O
a O
rapid-acting O
, O
reversible O
adenosine O
diphosphate O
( O
ADP O
) O
receptor O
antagonist O
, O
might O
reduce O
ischemic O
events O
during O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
[]

These O
findings O
suggest O
that O
PGE1 O
can O
be O
used O
safely O
to O
control O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
during O
surgery O
. O
['Physiological-Clinical']

A O
small O
statistically O
significant O
improvement O
on O
enzyme O
therapy O
was O
seen O
for O
the O
food O
variety O
scores O
. O
[]

After O
3 O
months O
of O
treatment O
we O
did O
not O
observe O
statistically O
significant O
differences O
in O
heart B-outcome ['Physiological-Clinical']
diameters I-outcome ['Physiological-Clinical']
and O
left B-outcome ['Physiological-Clinical']
ventricle I-outcome ['Physiological-Clinical']
systolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
between O
treated O
group O
and O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Neutrophil B-outcome ['Physiological-Clinical']
and O
platelet B-outcome ['Physiological-Clinical']
engraftment I-outcome ['Physiological-Clinical']
were O
more O
rapid O
in O
the O
Tac/Sir O
arm O
( O
14 O
vs O
16 O
days O
, O
P O
< O
.001 O
; O
16 O
vs O
19 O
days O
, O
P O
= O
.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Two O
patients O
described O
side O
effects O
with O
domperidone O
, O
including O
one O
woman O
with O
galactorrhea B-outcome ['Physiological-Clinical']
after O
36 O
h O
of O
treatment O
. O
['Physiological-Clinical']

At O
a O
median O
follow-up O
of O
35 O
months O
, O
11 O
invasive O
breast O
cancers O
were O
detected O
in O
those O
given O
exemestane O
and O
in O
32 O
of O
those O
given O
placebo O
, O
with O
a O
65 O
% O
relative O
reduction O
in O
the O
annual O
incidence O
of O
invasive B-outcome ['Physiological-Clinical']
breast I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
( O
0.19 O
% O
vs. O
0.55 O
% O
; O
hazard O
ratio O
, O
0.35 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.18 O
to O
0.70 O
; O
P=0.002 O
) O
. O
['Physiological-Clinical']

The O
effect O
of O
RVX-208 O
on O
other O
lipid B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
, O
safety O
and O
tolerability B-outcome ['Life-Impact']
will O
also O
be O
assessed O
in O
both O
studies O
. O
['Physiological-Clinical', 'Life-Impact']

This O
study O
evaluated O
the O
effects O
of O
concurrent O
naloxone O
on O
the O
opioid O
agonist O
effects O
of O
buprenorphine O
, O
a O
mixed O
agonist-antagonist O
marketed O
as O
an O
analgesic O
and O
under O
development O
as O
a O
treatment O
for O
drug O
abuse O
. O
[]

Applying O
to O
the O
criterion O
of O
a O
reduction O
of O
VA B-outcome ['Physiological-Clinical']
of O
more O
than O
75 O
% O
or O
an O
improvement O
according O
to O
the O
Lown B-outcome ['Physiological-Clinical']
grading I-outcome ['Physiological-Clinical']
8 O
pts O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
The O
ENDEAVOR O
IV O
( O
Randomized O
Comparison O
of O
Zotarolimus-Eluting O
and O
Paclitaxel-Eluting O
Stents O
in O
Patients O
with O
Coronary O
Artery O
Disease O
) O
trial O
evaluated O
the O
safety O
and O
efficacy O
of O
the O
zotarolimus-eluting O
stent O
( O
ZES O
) O
compared O
with O
the O
paclitaxel-eluting O
stent O
( O
PES O
) O
. O
[]

The O
results O
of O
the O
propranolol O
limb O
of O
the O
Multicenter O
Investigation O
of O
the O
Limitation O
of O
Infarct O
Size O
are O
reviewed O
. O
[]

PURPOSE O
To O
compare O
the O
results O
of O
a O
limbal O
versus O
a O
pars O
plana O
approach O
for O
primary O
posterior O
capsulectomy O
and O
anterior O
vitrectomy O
in O
the O
management O
of O
childhood B-outcome ['Physiological-Clinical']
cataract I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
Previous O
research O
has O
suggested O
that O
music O
therapy O
may O
facilitate O
skills B-outcome ['Life-Impact']
in O
areas O
typically O
affected O
by O
autism O
spectrum O
disorders O
such O
as O
social B-outcome ['Life-Impact']
interaction O
and O
communication B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSIONS O
Dalteparin O
and O
tinzaparin O
significantly O
accumulate O
in O
HD O
patients O
at O
therapeutic O
doses O
. O
[]

5 O
. O
[]

PATIENTS O
AND O
METHODS O
Twenty O
ulcerative O
colitis O
patients O
with O
poor O
pouch O
function O
( O
score O
> O
4 O
on O
a O
12-point O
score O
) O
were O
recruited O
for O
inclusion O
to O
a O
prospective O
, O
randomized O
, O
double-blind O
crossover O
, O
placebo-controlled O
trial O
of O
ursodeoxycholic O
acid O
( O
10 O
mg/kg O
per O
day O
in O
two O
divided O
doses O
for O
1 O
month O
) O
. O
[]

A O
significant O
decrease O
in O
ICP B-outcome ['Physiological-Clinical']
from O
6.5 O
to O
1.5 O
mm O
Hg O
( O
median O
) O
was O
found O
after O
indomethacin O
administration O
. O
['Physiological-Clinical']

Silicone O
Study O
Report O
5 O
. O
[]

Dose-response O
curves O
to O
Mth O
were O
evaluated O
in O
terms O
of O
Mth-PD20 O
( O
dose O
of O
Mth O
that O
induced O
20 O
% O
drop O
in O
FEV1 O
) O
, O
slope O
( O
Mth-DRS O
) O
and O
level O
of O
plateau O
. O
[]

CONCLUSION O
On O
the O
basis O
of O
our O
experience O
, O
even O
if O
a O
longer O
follow-up O
is O
needed O
, O
the O
validity O
of O
laparoscopic O
approach O
to O
inguinal O
hernia O
is O
confirmed O
. O
[]

One O
possible O
reason O
for O
tumor O
recurrence O
may O
be O
intraoperative O
hematogenous O
tumor O
cell O
dissemination O
due O
to O
mechanical O
manipulation O
of O
the O
tumor O
during O
hepatic O
resection O
. O
[]

CONCLUSIONS O
This O
project O
confirms O
, O
in O
an O
Australian O
setting O
, O
the O
high O
prevalence O
of O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
among O
hospitalized O
cardiac O
patients O
. O
['Life-Impact']

Humoral O
immune O
responses O
were O
measured O
by O
standard O
ELISA O
assay O
, O
and O
carcinoembryonic O
antigen O
( O
CEA O
) O
-specific O
T-cell O
responses O
were O
measured O
by O
IFN-gamma O
enzyme-linked O
immunospot O
assay O
. O
[]

RESULTS O
The O
study O
enrolled O
195 O
patients O
, O
of O
whom O
188 O
were O
eligible O
for O
analysis O
. O
[]

There O
were O
no O
differences O
in O
acquired B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
by O
intervention O
group O
. O
['Life-Impact']

The O
individual O
Michaelis-Menten O
parameters O
Km O
and O
Vmax O
were O
estimated O
for O
six O
subjects O
receiving O
three O
different O
single O
doses O
. O
[]

All O
these O
studies O
involved O
middle-aged O
men O
and O
women O
in O
rural O
or O
semirural O
areas O
and O
comprised O
a O
baseline O
period O
, O
a O
six O
week O
( O
or O
12 O
weeks O
in O
the O
third O
study O
) O
intervention O
period O
and O
a O
four O
to O
six O
week O
return O
to O
baseline O
. O
[]

RESULTS O
The O
technique O
of O
alginate O
compared O
with O
antacids O
provided O
significantly O
more O
complete O
and O
earlier O
effect O
on O
the O
relief B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
, O
regurgitation B-outcome ['Physiological-Clinical']
, O
chronic B-outcome ['Physiological-Clinical']
cough I-outcome ['Physiological-Clinical']
, O
sore B-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Newborn O
single-dose O
half-life O
, O
Vd O
, O
and O
clearance O
were O
30 O
days O
, O
143 O
mL/kg O
, O
and O
4 O
mL/kg/day O
, O
respectively O
. O
[]

Both O
angiotensin O
receptor O
blockers O
( O
ARB O
) O
and O
the O
DASH O
( O
Dietary O
Approaches O
to O
Stop O
Hypertension O
) O
diet O
effectively O
lower O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
hypertensive O
patients O
. O
['Physiological-Clinical']

C-spine B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
was O
reduced O
50 O
% O
at O
the O
C2-5 O
segment O
using O
the O
GlideScope O
( O
P O
< O
0.04 O
) O
but O
unchanged O
at O
the O
other O
segments O
. O
['Physiological-Clinical']

The O
main O
outcome O
measure O
was O
protection O
against O
severe B-outcome ['Physiological-Clinical']
rotavirus I-outcome ['Physiological-Clinical']
gastroenteritis I-outcome ['Physiological-Clinical']
( O
score O
> O
or O
=11 O
on O
a O
20-point O
severity O
scale O
) O
. O
['Physiological-Clinical']

Two-eighth-grade O
classes O
were O
randomly O
allocated O
to O
the O
intervention O
condition O
and O
all O
remaining O
students O
were O
either O
allocated O
to O
the O
no-intervention O
peer O
or O
no-intervention O
non-peer O
condition O
. O
[]

Similarly O
, O
DC O
demonstrated O
a O
significantly O
superior O
subjective O
response O
rate O
( O
partial O
plus O
complete O
) O
of O
82 O
% O
, O
compared O
to O
48 O
% O
for O
CF O
. O
[]

OBJECTIVE O
To O
study O
the O
relation O
between O
moderate O
coronary O
dissections O
, O
coronary O
flow O
velocity O
reserve O
( O
CFVR O
) O
, O
and O
long O
term O
outcome O
. O
[]

Of O
the O
204 O
( O
86.8 O
% O
) O
boys O
with O
negative O
biopsies O
, O
175 O
( O
85.8 O
% O
) O
remained O
in O
CCR O
10 O
to O
12 O
years O
after O
diagnosis O
and O
25 O
( O
12.3 O
% O
) O
relapsed O
, O
11 O
( O
44 O
% O
) O
of O
whom O
died O
. O
[]

Thirteen O
age-matched O
healthy O
volunteers O
served O
as O
controls O
. O
[]

Because O
buspirone O
20 O
mg O
was O
less O
liked O
than O
were O
other O
drugs O
, O
dose O
escalation O
as O
part O
of O
drug B-outcome ['Life-Impact']
abuse I-outcome ['Life-Impact']
is O
not O
likely O
to O
occur O
. O
['Life-Impact']

The O
two O
groups O
were O
comparable O
regarding O
age O
and O
sex O
distribution O
. O
[]

It O
was O
lowered O
after O
drug O
therapy O
in O
the O
two O
groups O
with O
statistical O
difference O
( O
P O
< O
0.05 O
) O
. O
[]

The O
overall B-outcome ['Mortality']
local I-outcome ['Mortality']
recurrence-free I-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
at O
3 O
, O
6 O
and O
12 O
months O
were O
comparable O
. O
['Mortality']

The O
children O
were O
assessed O
regularly O
throughout O
the O
project O
using O
the O
Movement O
ABC O
, O
together O
with O
diaries O
and O
comments O
from O
teachers O
and O
parents O
. O
[]

chemotherapy O
) O
and O
Arm O
2 O
( O
TORS O
? O
[]

RESULTS O
A O
significant O
increase O
in O
the O
hematocrit B-outcome ['Physiological-Clinical']
was O
noted O
7 O
hrs O
after O
DE O
[ O
1.4 O
% O
( O
95 O
% O
CI O
: O
0.9 O
to O
1.9 O
% O
) O
] O
compared O
to O
FA O
exposure O
[ O
0.5 O
% O
( O
95 O
% O
CI O
: O
-0.09 O
to O
1.0 O
% O
) O
; O
p=0.008 O
. O
['Physiological-Clinical']

i.v O
. O
[]

Following O
efficacy O
evaluation O
, O
patients O
entered O
a O
long-term O
safety O
phase O
of O
up O
to O
12 O
months O
. O
[]

The O
primary O
end O
point O
was O
the O
proportion O
of O
vaccine B-outcome ['Resource-use']
high O
responders O
at O
9 O
months O
, O
defined O
as O
a O
2-fold O
increase O
in O
IgG O
levels O
to O
> O
or O
= O
1 O
microg/mL O
for O
at O
least O
5 O
of O
7 O
of O
the O
7vPnC O
serotypes O
. O
['Resource-use']

Patients O
were O
assigned O
to O
receive O
monthly O
5-fluorouracil O
96-hour O
continuous O
infusions O
with O
either O
bolus O
mitomycin-C O
or O
oral O
methyl-CCNU O
. O
[]

For O
both O
groups O
, O
the O
P2 O
and O
N250 O
were O
sensitive O
to O
repetition O
( O
Other O
vs. O
Novels O
) O
and O
personal O
familiarity O
( O
Familiar O
vs. O
Other O
) O
, O
and O
the O
face-N400 O
was O
sensitive O
to O
repetition O
. O
[]

The O
effect O
of O
aging O
on O
circulating O
levels O
of O
proinflammatory O
cytokines O
during O
septic O
shock O
. O
[]

[ O
Preoperative O
chemotherapy O
of O
esophageal O
cancer O
] O
. O
[]

Compliance O
was O
> O
90 O
% O
in O
all O
patients O
. O
[]

METHODS O
Data O
from O
a O
randomized O
controlled O
trial O
with O
442 O
patients O
with O
low O
back O
pain O
were O
used O
. O
[]

No O
change O
in O
fibrinogen B-outcome ['Physiological-Clinical']
or O
factor O
VIIc B-outcome ['Physiological-Clinical']
was O
detected O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Potassium O
titanyl O
phosphate O
laser O
resulted O
in O
reduced O
operative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
and O
immediate B-outcome ['Physiological-Clinical']
post-operative I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
compared O
with O
the O
bipolar O
radiofrequency O
technique O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
study O
design O
was O
randomized O
, O
controlled O
, O
and O
double-blind O
( O
regarding O
ondansetron O
) O
and O
single-blind O
( O
regarding O
the O
anesthetic O
technique O
) O
. O
[]

During O
the O
therapy O
of O
bezafibrate O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
was O
significantly O
decreased O
by O
36 O
% O
130 O
min O
after O
beginning O
the O
infusion O
. O
['Physiological-Clinical']

The O
stiffnesses B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
strengths I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
osteotomies I-outcome ['Physiological-Clinical']
fixed I-outcome ['Physiological-Clinical']
with O
slotted O
nails O
in O
10-30 O
degrees O
torsion O
were O
6-8 O
% O
and O
the O
values O
of O
non-slotted O
nails O
40 O
% O
of O
control O
bone O
. O
['Physiological-Clinical']

[ O
The O
effects O
of O
mexicor O
on O
thrombocyte B-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
viscosity I-outcome ['Physiological-Clinical']
, O
hemodynamics B-outcome ['Physiological-Clinical']
, O
and O
the O
clinical O
course O
of O
coronary O
artery O
disease O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
dose O
of O
midazolam O
was O
titrated O
in O
the O
same O
manner O
in O
both O
groups O
. O
[]

OBJECTIVE O
The O
objective O
was O
to O
evaluate O
parallel B-outcome ['Life-Impact']
patient I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
physician I-outcome ['Life-Impact']
computer-mediated I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
skill I-outcome ['Life-Impact']
training I-outcome ['Life-Impact']
on O
participants O
' O
report O
of O
skill O
use O
and O
patient O
satisfaction O
. O
['Life-Impact']

The O
Self-Care O
Rehabilitation O
in O
Pediatric O
Asthma O
( O
SCRPA O
) O
project O
was O
designed O
to O
ascertain O
the O
level O
to O
which O
children O
with O
asthma O
are O
able O
to O
acquire O
the O
asthma O
knowledge O
and O
skills O
presented O
in O
a O
self-management O
training O
program O
conducted O
by O
the O
American O
Lung O
Association O
of O
Utah O
and O
the O
effect O
of O
such O
training O
on O
the O
asthma O
experience O
. O
[]

Groups O
were O
equally O
matched O
for O
indications O
and O
underlying O
disease O
. O
[]

Several O
reports O
have O
described O
salutary O
effects O
such O
as O
decreased O
physical O
aggression O
and O
improved O
social O
responsiveness O
being O
associated O
with O
the O
administration O
of O
high O
doses O
of O
pyridoxine O
and O
magnesium O
( O
HDPM O
) O
in O
open-labeled O
and O
controlled O
studies O
of O
patients O
with O
autism O
. O
[]

Lower O
fornix O
and O
lid O
margin O
cultures O
were O
taken O
from O
both O
eyes O
before O
and O
after O
treatment O
. O
[]

AIMS O
To O
determine O
whether O
metformin O
pretreatment O
has O
beneficial O
effects O
in O
clomiphene O
resistant O
infertile O
women O
with O
polycystic O
ovary O
syndrome O
( O
PCOS O
) O
in O
an O
infertility O
clinic O
. O
[]

Virtual O
reality O
hypnosis O
for O
pain O
associated O
with O
recovery O
from O
physical O
trauma O
. O
[]

Median O
TTP O
for O
GP1 O
, O
GP2 O
and O
GD O
was O
7.5 O
, O
7.0 O
and O
7.4 O
months O
, O
respectively O
. O
[]

This O
study O
evaluated O
the O
efficacy O
of O
hyperbaric O
oxygen O
therapy O
( O
HBOT O
) O
. O
[]

CONCLUSIONS O
MT O
+ O
MG O
improved O
[]

Phase O
III O
comparative O
study O
of O
high-dose O
cisplatin O
versus O
a O
combination O
of O
paclitaxel O
and O
cisplatin O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
. O
[]

BACKGROUND O
Constraint-induced O
movement O
therapy O
( O
CIMT O
) O
has O
been O
advocated O
as O
a O
means O
of O
facilitating O
motor O
function O
in O
poststroke O
patients O
; O
however O
, O
the O
evidence O
for O
its O
efficacy O
is O
controversial O
. O
[]

The O
study O
comprised O
a O
2-week O
open-label O
titration O
phase O
, O
followed O
by O
a O
double-blind O
efficacy O
phase O
, O
during O
which O
patients O
received O
sublingual O
fentanyl O
citrate O
orally O
disintegrating O
tablet O
( O
sublingual O
fentanyl O
ODT O
) O
or O
placebo O
, O
in O
a O
random O
order O
. O
[]

This O
decreased O
the O
number O
of O
patients O
that O
were O
evaluated O
for O
adverse O
events O
to O
198 O
patients O
. O
[]

ELISA O
showed O
that O
autologous O
SCT O
patients O
with O
breast O
cancer O
who O
received O
GM-CSF O
had O
a O
better O
response O
to O
influenza B-outcome ['Physiological-Clinical']
A O
( O
P O
< O
.05 O
) O
and O
B O
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical']

AIM O
To O
assess O
whether O
the O
use O
of O
a O
night O
splint O
is O
of O
added O
benefit O
on O
functional O
outcome O
in O
treating O
chronic O
midportion O
Achilles O
tendinopathy O
. O
[]

This O
study O
has O
been O
registered O
in O
ClinicalTrials.gov O
( O
www.clinicaltrials.gov O
) O
under O
registration O
number O
NCT00380692 O
. O
[]

Low O
protein O
provision O
during O
the O
first O
year O
of O
life O
, O
but O
not O
during O
foetal O
life O
, O
affects O
metabolic B-outcome ['Physiological-Clinical']
traits I-outcome ['Physiological-Clinical']
, O
organ B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
development I-outcome ['Physiological-Clinical']
and O
growth B-outcome ['Physiological-Clinical']
in O
male O
mink O
( O
Neovison O
vison O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Inter- O
and O
intrapatient O
differences O
between O
generic O
warfarin O
and O
Coumadin O
were O
compared O
, O
and O
overall O
study O
patient O
results O
were O
compared O
with O
those O
of O
a O
Coumadin O
control O
group O
. O
[]

Moreover O
, O
group O
A O
required O
significantly O
more O
analgesics O
after O
the O
procedure O
than O
group O
B O
. O
[]

We O
evaluated O
the O
benefits O
of O
physiological O
pacing O
in O
the O
elderly O
by O
recruiting O
13 O
subjects O
> O
75 O
years O
of O
age O
, O
already O
fitted O
with O
a O
physiological O
pacing O
system O
. O
[]

CONCLUSIONS O
The O
data O
demonstrate O
a O
high O
risk O
for O
patients O
undergoing O
low O
anterior O
resection O
without O
diverting O
ileostomy O
. O
[]

The O
median O
survival B-outcome ['Mortality']
was O
22 O
months O
in O
the O
chemotherapy O
group O
and O
29 O
months O
in O
the O
control O
group O
. O
['Mortality']

Cytotoxic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
NK I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
. O
['Physiological-Clinical']

Alveolar O
macrophages O
( O
AMs O
) O
may O
play O
a O
key O
role O
in O
human O
respiratory O
immune O
defenses O
, O
partially O
by O
synthesizing O
and O
releasing O
interleukin O
1 O
( O
IL O
= O
1 O
) O
. O
[]

There O
were O
no O
significant O
differences O
in O
the O
analgesic O
onset O
time O
of O
the O
caudal O
block O
. O
[]

SETTING O
For O
menu O
validation O
, O
a O
set O
of O
12 O
menus O
for O
each O
diet O
was O
prepared O
in O
duplicate O
and O
chemically O
assayed O
. O
[]

During O
2 O
years O
and O
7 O
months O
from O
June O
, O
1985 O
to O
December O
, O
1987 O
, O
a O
randomized O
multi-center O
trial O
of O
PVB O
, O
VAB-6 O
, O
BVP O
regimen O
( O
group O
A O
) O
without O
etoposide O
versus O
PEB O
chemotherapy O
( O
bleomycin O
, O
etoposide O
and O
cisplatinum O
) O
( O
group O
B O
) O
was O
given O
to O
patients O
with O
disseminated O
testicular O
tumors O
. O
[]

A O
total O
of O
296 O
patients O
fulfilling O
the O
International O
Headache O
Society O
diagnostic O
criteria O
for O
migraine O
were O
enrolled O
. O
[]

In O
the O
present O
study O
, O
10 O
patients O
( O
3 O
men O
and O
7 O
women O
, O
aged O
48-63 O
yr O
) O
with O
an O
adrenal O
mass O
discovered O
serendipitously O
underwent O
, O
on O
separate O
occasions O
, O
a O
GHRH O
injection O
alone O
or O
combined O
with O
an O
infusion O
of O
the O
functional O
somatostatin O
antagonist O
, O
arginine O
. O
[]

BACKGROUND O
There O
are O
no O
guidelines O
on O
second-line O
therapies O
for O
Helicobacter O
pylori O
eradication O
failures O
of O
omeprazole-clarithromycin-amoxicillin O
triple O
therapy O
. O
[]

Only O
standing O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
showed O
a O
dose-dependent O
inhibition O
both O
in O
the O
supine O
and O
upright O
position O
. O
['Physiological-Clinical']

[ O
Effect O
of O
transcranial O
electrostimulation O
on O
clinical B-outcome ['Physiological-Clinical']
and O
laboratory B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
in O
patients O
with O
gastric O
ulcer O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS/DESIGN O
One O
hundred O
and O
eighteen O
( O
59 O
patients O
per O
arm O
) O
patients O
with O
non-healing O
diabetic O
ulcers O
of O
the O
lower O
limb O
, O
referred O
to O
the O
Judy O
Dan O
Research O
and O
Treatment O
Centre O
are O
being O
recruited O
if O
they O
are O
at O
least O
18 O
years O
of O
age O
, O
have O
either O
Type O
1 O
or O
2 O
diabetes O
with O
a O
Wagner O
grading O
of O
foot O
lesions O
2 O
, O
3 O
or O
4 O
on O
lower O
limb O
not O
healing O
for O
at O
least O
4 O
weeks O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Statistically O
significant O
correlations O
between O
smoking O
and O
nutrient B-outcome ['Physiological-Clinical']
intake I-outcome ['Physiological-Clinical']
, O
HbA1c B-outcome ['Physiological-Clinical']
, O
and O
serum B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
All O
patients O
underwent O
NCE O
4D O
MRA O
without O
any O
difficulty O
. O
[]

There O
are O
no O
differences O
in O
terms O
of O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
and O
distant B-outcome ['Physiological-Clinical']
disease-free I-outcome ['Physiological-Clinical']
['Mortality', 'Physiological-Clinical']

Nine O
dogs O
in O
each O
group O
experienced O
at O
least O
one O
serious O
[]

The O
mean O
cadence O
for O
the O
whole O
walk O
was O
higher O
in O
the O
park O
: O
119.3 O
( O
8.3 O
) O
vs. O
110.9 O
( O
8.9 O
) O
steps/min O
. O
[]

Thirty-two O
healthy O
, O
opioid-naive O
adults O
were O
randomized O
to O
MS-sNT O
administered O
with O
240 O
mL O
of O
4 O
% O
, O
20 O
% O
, O
or O
40 O
% O
alcohol O
or O
water O
. O
[]

Subjects O
were O
asked O
to O
perform O
a O
temporal O
expectation O
task O
by O
predicting O
the O
end O
of O
visually O
perceived O
human O
body O
motion O
( O
handwriting O
, O
i.e O
. O
[]

MATERIALS O
AND O
METHODS O
The O
Microvasive O
Zerotip O
( O
2.4Fr O
, O
3.0Fr O
) O
, O
Cook O
N-Circle O
( O
2.2Fr O
, O
3.0Fr O
, O
3.2Fr O
) O
, O
Bard O
Dimension O
( O
3.0Fr O
, O
Sacred O
Heart O
Medical O
Halo O
( O
1.9Fr O
) O
, O
Vantage O
( O
1.9Fr O
) O
and O
Circon-ACMI O
Sur-Catch-NT O
( O
3.0Fr O
) O
were O
tested O
by O
3 O
novice O
and O
3 O
experienced O
basket O
operators O
. O
[]

PATIENTS O
AND O
METHODS O
Serial O
blood O
counts O
were O
performed O
in O
20 O
women O
with O
early-stage O
breast O
cancer O
receiving O
four O
courses O
of O
cyclophosphamide O
and O
doxorubicin O
chemotherapy O
. O
[]

Patients O
treated O
with O
intravenous O
betalactam O
and O
tobramycin O
were O
randomly O
allocated O
to O
receive O
aerosolized O
tobramycin O
( O
6 O
mg/kg/day O
, O
n O
= O
21 O
) O
or O
placebo O
( O
n O
= O
17 O
) O
. O
[]

Knee B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
measured O
on O
days O
7 O
, O
10 O
and O
at O
week O
6 O
, O
12 O
and O
knee B-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
measured O
on O
days O
1 O
, O
3 O
, O
10 O
and O
at O
week O
6 O
, O
12 O
showed O
no O
significant O
difference O
between O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

From O
baseline O
to O
3 O
months O
, O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LVEF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
increased O
in O
43.4 O
% O
of O
patients O
, O
decreased O
in O
23.9 O
% O
, O
and O
remained O
unchanged O
in O
32.7 O
% O
. O
['Physiological-Clinical']

At O
the O
end O
of O
infusion O
, O
the O
mean O
concentrations B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
imipenem I-outcome ['Physiological-Clinical']
and O
meropenem B-outcome ['Physiological-Clinical']
measured O
in O
serum O
were O
61.2 O
+/- O
9.8 O
and O
51.6 O
+/- O
6.5 O
mg/liter O
, O
respectively O
; O
urinary B-outcome ['Physiological-Clinical']
recoveries I-outcome ['Physiological-Clinical']
were O
48.6 O
% O
+/- O
8.2 O
% O
and O
60.0 O
% O
+/- O
6.5 O
% O
of O
the O
dose O
in O
12 O
h O
, O
respectively O
; O
and O
the O
areas O
under O
the O
concentration-time O
curve O
from O
time O
zero O
to O
infinity O
were O
96.1 O
+/- O
14.4 O
and O
70.5 O
+/- O
10.3 O
mg.h/liter O
, O
respectively O
( O
P O
< O
or O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

STUDY O
DESIGN O
A O
prospective O
study O
was O
performed O
. O
[]

CCR O
was O
seen O
in O
25 O
patients O
of O
whom O
10 O
received O
PUVA O
alone O
( O
CCR O
22 O
% O
) O
and O
15 O
received O
combination O
therapy O
( O
CCR O
31 O
% O
) O
( O
P O
= O
0?45 O
) O
. O
[]

The O
vehicle O
alone O
is O
capable O
of O
positively O
influencing O
skin O
status O
. O
[]

CONCLUSIONS O
Two O
cycles O
of O
regional O
2-min O
IP O
in O
the O
LAD O
, O
followed O
by O
3 O
min O
of O
reperfusion O
, O
proved O
to O
be O
applicable O
and O
safe O
in O
patients O
undergoing O
off-pump O
myocardial O
revascularization O
, O
it O
tended O
to O
decrease O
the O
immediate O
myocardial B-outcome ['Physiological-Clinical']
enzyme B-outcome ['Physiological-Clinical']
release O
, O
it O
prohibited O
the O
postoperative O
increase O
in O
['Physiological-Clinical', 'Physiological-Clinical']

An O
evaluation O
of O
an O
adaptive O
automation O
system O
using O
a O
cognitive O
vigilance O
task O
. O
[]

Today O
, O
physicians O
can O
choose O
from O
a O
number O
of O
different O
devices O
to O
achieve O
arterial O
closure O
. O
[]

Intra-arterial O
fibrinolysis O
( O
IAF O
) O
with O
pro-urokinase O
in O
PROACT O
II O
study O
provides O
quite O
the O
same O
benefit O
in O
the O
first O
6 O
hours O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
anesthesia I-outcome ['Resource-use']
, O
invasiveness B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
surgery I-outcome ['Life-Impact']
, O
and O
baseline O
['Resource-use', 'Life-Impact']

A O
dose-response O
curve O
. O
[]

Safety O
was O
monitored O
by O
recording O
adverse O
events O
. O
[]

CONTEXT O
AND O
OBJECTIVE O
Stimulation O
with O
recombinant O
human O
TSH O
( O
rhTSH O
) O
before O
radioiodine O
( O
131I O
) O
therapy O
augments O
goiter B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GVR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Patients O
in O
the O
intervention O
group O
requested O
and O
provided O
more O
information O
about O
their O
medical B-outcome ['Physiological-Clinical']
condition I-outcome ['Physiological-Clinical']
( O
mean O
[ O
SE O
] O
number O
of O
utterances O
, O
66.3 O
[ O
6.8 O
] O
in O
the O
values-affirmation O
group O
vs O
48.1 O
[ O
5.9 O
] O
in O
the O
control O
group O
[ O
P O
= O
.03 O
] O
) O
. O
['Physiological-Clinical']

We O
compared O
adolescents O
with O
ASDs O
to O
controls O
matched O
on O
sex O
, O
age O
and O
IQ O
on O
a O
more O
complete O
version O
of O
the O
composite O
paradigm O
. O
[]

Parents O
noted O
significant O
declines O
in O
inattentive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
oppositional I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
, O
and O
improvements O
in O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Better O
[]

Nevertheless O
considerable O
progress O
has O
been O
made O
. O
[]

Among O
diabetic O
patients O
randomized O
to O
tirofiban O
( O
n=560 O
) O
, O
the O
incidence O
of O
death B-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
( O
MI B-outcome ['Physiological-Clinical']
) O
, O
or O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Venous O
blood O
samples O
( O
0.5 O
, O
1 O
, O
2 O
, O
3 O
hours O
) O
were O
collected O
at O
day-7 O
after O
a O
75 O
g O
oral O
glucose O
tolerance O
test O
( O
OGTT O
) O
, O
day O
1 O
after O
a O
standard O
test O
meal O
( O
1673.6 O
kJ O
) O
and O
after O
6 O
days O
of O
either O
the O
test O
diabetes O
specific O
formula O
or O
a O
standard O
formula O
. O
[]

Compared O
to O
the O
control O
group O
, O
the O
intervention O
group O
showed O
a O
significant O
and O
larger O
reduction O
in O
GI O
score O
by O
8 O
% O
at O
6 O
months O
( O
p=0.0007 O
) O
. O
[]

Likewise O
, O
for O
six-month O
abstinence B-outcome ['Life-Impact']
, O
patients O
were O
significantly O
more O
likely O
to O
have O
quit B-outcome ['Life-Impact']
smoking I-outcome ['Life-Impact']
if O
they O
were O
older O
( O
OR O
= O
1.04 O
, O
95 O
% O
CI O
: O
1.01-1.08 O
, O
p O
< O
0.05 O
) O
and O
were O
significantly O
less O
likely O
to O
have O
quit O
smoking O
if O
they O
were O
female O
( O
OR O
= O
0.47 O
, O
95 O
% O
CI O
: O
0.22-0.97 O
, O
p O
< O
0.05 O
) O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
There O
were O
no O
differences O
in O
functional B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
between O
the O
home O
based O
care O
group O
and O
the O
hospital O
group O
. O
['Life-Impact']

Few O
attempts O
have O
been O
made O
to O
conduct O
randomised O
control O
trials O
( O
RCTs O
) O
of O
interventions O
for O
pre-school O
children O
with O
autism O
. O
[]

A O
prospective O
randomized O
clinical O
trial O
of O
melphalan O
and O
cis-platinum O
versus O
hexamethylmelamine O
, O
adriamycin O
, O
and O
cyclophosphamide O
in O
advanced O
ovarian O
cancer O
. O
[]

Adverse B-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
were O
reported O
by O
70 O
out O
of O
89 O
patients O
by O
the O
end O
of O
2 O
weeks O
, O
but O
were O
severe O
enough O
only O
in O
11 O
for O
the O
treatment O
to O
be O
discontinued O
. O
['Adverse-effects']

For O
most O
youth O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
, O
employment O
upon O
graduation O
from O
high O
school O
or O
college O
is O
elusive O
. O
[]

Baseline O
characteristics O
were O
: O
median O
age O
61 O
years O
, O
69 O
% O
male O
, O
48 O
% O
squamous O
cell O
, O
93 O
% O
WHO O
PS O
0-1 O
, O
27 O
% O
stage O
I O
, O
38 O
% O
stage O
II O
, O
and O
34 O
% O
stage O
III O
. O
[]

Differences O
in O
reach O
and O
attrition O
between O
Web-based O
and O
print-delivered O
tailored O
interventions O
among O
adults O
over O
50 O
years O
of O
age O
: O
clustered O
randomized O
trial O
. O
[]

The O
alpha-tocopherol B-outcome ['Physiological-Clinical']
concentration O
in O
LDL B-outcome ['Physiological-Clinical']
increased O
significantly O
( O
P O
< O
0.01 O
) O
in O
both O
diet O
groups O
relative O
to O
the O
run-in O
diet O
period O
, O
but O
LDL B-outcome ['Physiological-Clinical']
particle I-outcome ['Physiological-Clinical']
score I-outcome ['Physiological-Clinical']
did O
not O
change O
in O
either O
of O
the O
diet O
groups O
during O
the O
dietary O
intervention O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
relationship O
between O
the O
response O
of O
Plasmodium O
falciparum O
malaria O
to O
mefloquine O
in O
African O
children O
and O
its O
sensitivity O
in O
vitro O
. O
[]

Three O
subjects O
with O
a O
personal O
or O
family O
history O
of O
atopy O
developed O
urticarial B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
after O
PCECV O
. O
['Physiological-Clinical']

Their O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
increased O
in O
a O
slightly O
greater O
than O
dose-dependent O
manner O
from O
3 O
to O
300 O
mg O
. O
['Physiological-Clinical']

Venous O
samples O
for O
interleukin O
( O
IL O
) O
-1beta O
, O
IL-2 O
, O
IL-6 O
, O
tumour O
necrosis O
factor-alpha O
( O
TNF-alpha O
) O
and O
interferon-gamma O
( O
IFN-gamma O
) O
were O
taken O
before O
anaesthesia O
, O
before O
incision O
, O
at O
the O
end O
of O
anaesthesia O
and O
24 O
h O
postoperatively O
. O
[]

Group O
C O
( O
52 O
infants O
) O
received O
parenteral O
nutrition O
alone O
. O
[]

A O
significantly O
higher O
level O
of O
anxiety B-outcome ['Life-Impact']
was O
found O
in O
the O
experimental O
group O
on O
admission O
, O
but O
this O
difference O
became O
nonsignificant O
when O
baseline O
level O
and O
length O
of O
waiting O
time O
were O
entered O
as O
covariates O
. O
['Life-Impact']

METHODOLOGY O
49 O
patients O
who O
underwent O
gastrectomy O
with O
Longmire-Interposition O
with O
( O
n O
= O
33 O
) O
or O
without O
( O
n O
= O
16 O
) O
an O
additional O
pouch O
and O
46 O
patients O
with O
a O
Roux-en-Y-reconstruction O
were O
analysed O
retrospectively O
. O
[]

Following O
treatment O
, O
patients O
were O
assessed O
based O
on O
demographics O
, O
decisional B-outcome ['Life-Impact']
conflict I-outcome ['Life-Impact']
, O
satisfaction B-outcome ['Life-Impact']
, O
health B-outcome ['Life-Impact']
literacy I-outcome ['Life-Impact']
, O
and O
knowledge B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
Steroid B-outcome ['Physiological-Clinical']
sparing I-outcome ['Physiological-Clinical']
occurred O
in O
53 O
of O
181 O
( O
29.3 O
% O
) O
CDP571 O
patients O
and O
33 O
of O
90 O
( O
36.7 O
% O
) O
placebo O
patients O
( O
P O
= O
0.24 O
) O
. O
['Physiological-Clinical']

The O
impact O
of O
this O
treatment O
on O
clinical O
outcomes O
of O
acute O
STEMI O
remains O
unknown O
. O
[]

The O
ABC-C O
Rating O
Scale O
scores O
improved O
with O
piracetam O
. O
[]

Results O
of O
a O
prospective O
, O
randomized O
study O
] O
. O
[]

However O
, O
with O
respect O
to O
language B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
, O
a O
significant O
effectiveness O
was O
noted O
in O
the O
s O
allele O
. O
['Life-Impact']

kg O
( O
-1 O
) O
? O
[]

In O
patients O
from O
this O
subgroup O
with O
central-medial O
tumors O
, O
comprising O
62 O
% O
of O
the O
total O
, O
survival B-outcome ['Mortality']
after O
RDL O
at O
10 O
years O
was O
60 O
% O
( O
+/- O
8 O
% O
) O
, O
and O
after O
EXT O
86 O
% O
( O
+/- O
6 O
% O
) O
( O
P O
= O
0.025 O
) O
. O
['Mortality']

Five O
children O
showed O
clinical O
improvement O
in O
standard O
scores O
: O
two O
after O
HSS O
and O
three O
after O
placebo O
. O
[]

CONCLUSION O
CRC B-outcome ['Resource-use']
screening I-outcome ['Resource-use']
rates O
increased O
significantly O
among O
patients O
who O
were O
overdue O
for O
screening O
after O
they O
received O
mailed O
educational O
materials O
and O
a O
FIT O
. O
['Resource-use']

RESULTS O
None O
of O
these O
101 O
patients O
developed O
cervical B-outcome ['Physiological-Clinical']
radiation I-outcome ['Physiological-Clinical']
myelitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Caffeine O
attenuated O
this O
power O
gradient O
in O
caffeine O
sensitive O
subjects O
. O
[]

Patients O
were O
evaluated O
for O
the O
amount O
of O
rectal O
and O
urethral B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
and O
symptoms O
and O
signs O
of O
infection B-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
biopsy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
fixed O
combination O
between O
troxerutin O
150 O
mg O
and O
carbazochrome O
1.5 O
mg O
( O
Fleboside O
ampoules O
) O
was O
previously O
shown O
to O
have O
a O
good O
efficacy O
and O
safety O
profile O
in O
non-surgical O
patients O
with O
acute O
uncomplicated O
hemorrhoids O
. O
[]

Blood O
pressure O
( O
BP O
) O
, O
blood O
urea O
nitrogen O
( O
BUN O
) O
levels O
, O
creatinine O
, O
serum O
and O
urinary O
uric O
acid O
, O
creatinine O
and O
uric O
acid O
clearance O
were O
determined O
before O
and O
after O
chemotherapy O
. O
[]

There O
was O
no O
significant O
differences O
between O
the O
agents O
with O
respect O
to O
[]

Data O
were O
collected O
at O
time O
1 O
( O
T O
( O
1 O
) O
) O
during O
hospital O
admission O
, O
time O
2 O
( O
T O
( O
2 O
) O
) O
approximately O
2 O
months O
post-PCI O
, O
and O
time O
3 O
( O
T O
( O
3 O
) O
) O
approximately O
12 O
months O
post-PCI O
. O
[]

The O
current O
study O
examined O
the O
relationship O
between O
multisensory B-outcome ['Physiological-Clinical']
temporal I-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
( O
assessed O
via O
a O
simultaneity O
judgment O
task O
wherein O
participants O
were O
to O
report O
whether O
a O
visual O
stimulus O
and O
an O
auditory O
stimulus O
occurred O
at O
the O
same O
time O
or O
at O
different O
times O
) O
and O
self-reported O
symptoms B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
autism I-outcome ['Life-Impact']
( O
assessed O
via O
the O
Autism O
Spectrum O
Quotient O
questionnaire O
) O
. O
['Physiological-Clinical', 'Life-Impact']

There O
were O
no O
significant O
differences O
between O
dazmegrel O
in O
the O
skin O
layers O
( O
epidermis O
, O
dermis O
and O
subcutaneous O
layers O
) O
on O
1 O
, O
7 O
and O
14-day O
exposures O
. O
[]

Three-year O
actuarial O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
the O
chemotherapy O
arm O
was O
77 O
% O
, O
compared O
to O
49 O
% O
in O
the O
no-chemotherapy O
arm O
( O
P O
= O
0.075 O
) O
. O
['Mortality']

Serum B-outcome ['Physiological-Clinical']
total O
triglyceride B-outcome ['Physiological-Clinical']
concentration B-outcome ['Physiological-Clinical']
did O
not O
significantly O
change O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
It O
has O
been O
suggested O
that O
the O
use O
of O
pure-cut O
electrosurgical O
current O
for O
endoscopic O
sphincterotomy O
may O
reduce O
the O
risk O
of O
post-ERCP O
pancreatitis O
. O
[]

STUDY O
OBJECTIVE O
To O
estimate O
whether O
the O
suture O
of O
the O
ovary O
is O
superior O
to O
bipolar O
coagulation O
in O
preserving O
ovarian O
reserve O
in O
infertile O
women O
undergoing O
laparoscopic O
stripping O
of O
bilateral O
endometriomas O
. O
[]

This O
study O
was O
designed O
to O
investigate O
the O
validity O
of O
the O
then O
current O
recommendations O
for O
initiation O
of O
therapy O
with O
enalapril O
in O
hypertensive O
patients O
on O
treatment O
with O
a O
diuretic O
. O
[]

Breathlessness O
and O
psychiatric O
morbidity O
in O
chronic O
bronchitis O
and O
emphysema O
: O
a O
study O
of O
psychotherapeutic O
management O
. O
[]

RESULTS O
The O
average O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
was O
16.7 O
weeks O
in O
the O
reamed O
group O
and O
25.7 O
weeks O
in O
the O
unreamed O
group O
. O
['Physiological-Clinical']

METHODS O
A O
parallel O
, O
randomised O
, O
controlled O
, O
dose-response O
dietary O
intervention O
study O
. O
[]

CONCLUSIONS O
Non-obstructive O
PVT O
may O
be O
asymptomatic O
in O
one-third O
of O
patients O
. O
[]

CONCLUSIONS O
Prophylaxis O
with O
isoniazid O
reduces O
the O
risk O
of O
tuberculosis O
in O
persons O
with O
HIV O
infection O
. O
[]

After O
screening O
, O
assessments O
were O
conducted O
at O
baseline O
, O
post-treatment O
, O
and O
3-month O
follow-up O
. O
[]

The O
study O
reported O
here O
examined O
the O
efficacy O
of O
acupuncture O
in O
alleviating O
xerostomia O
symptoms O
especially O
dry O
mouth O
. O
[]

In O
the O
clonidine O
plus O
naltrexone O
protocol O
, O
clonidine O
was O
administered O
and O
naltrexone O
was O
administered O
in O
increasing O
doses O
over O
five O
days O
. O
[]

Randomized O
clinical O
trial O
comparing O
mitoxantrone O
with O
doxorubicin O
in O
previously O
treated O
patients O
with O
metastatic O
breast O
cancer O
. O
[]

Arginine O
vasopressin O
dissociates O
the O
diuresis B-outcome ['Physiological-Clinical']
and O
natriuresis B-outcome ['Physiological-Clinical']
due O
to O
atrial O
natriuretic O
factor O
in O
man O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Randomly O
selected O
medical O
records O
were O
reviewed O
for O
248 O
African O
American O
, O
30 O
Hispanic O
, O
and O
235 O
white O
or O
other-race O
patients O
undergoing O
above- O
or O
below-knee O
amputation O
between O
1995 O
and O
2003 O
at O
three O
Chicago O
teaching O
hospitals O
. O
[]

Abnormal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
accounts O
for O
most O
of O
the O
clinical O
morbidity O
of O
sickle O
cell O
disease O
( O
SCD O
) O
[ O
1,2 O
] O
. O
['Physiological-Clinical']

In O
brief O
, O
the O
SPF O
project O
is O
a O
group O
randomized O
trial O
to O
test O
the O
effectiveness O
of O
a O
school O
based O
intervention O
promoting O
sun O
protection O
in O
general O
, O
and O
hat O
use O
in O
particular O
, O
in O
Hillsborough O
County O
Schools O
, O
Florida O
. O
[]

F1+2 O
increased O
0.15 O
nmol/L O
after O
the O
combined O
vaccination O
; O
an O
increase O
in O
response O
to O
the O
influenza B-outcome ['Physiological-Clinical']
vaccination I-outcome ['Physiological-Clinical']
was O
not O
statistically O
significant O
. O
['Physiological-Clinical']

The O
purpose O
of O
the O
present O
study O
was O
to O
examine O
how O
pentoxifylline O
at O
a O
dose O
of O
800 O
mg O
thrice O
daily O
would O
influence O
the O
cellular B-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
in O
HIV-seropositive O
persons O
with O
elevated O
TNF-alpha O
. O
['Physiological-Clinical']

Results O
of O
a O
prospective O
randomized O
study O
of O
hepatic O
artery O
infusion O
with O
5-fluorouracil O
versus O
intravenous O
5-fluorouracil O
in O
patients O
with O
hepatic O
metastases O
from O
colorectal O
cancer O
: O
A O
Central O
Oncology O
Group O
study O
. O
[]

The O
opioid O
infusion O
continued O
until O
the O
level O
of O
anesthesia O
was O
deemed O
appropriate O
for O
intubation O
. O
[]

This O
three-dimensional O
stability O
was O
related O
to O
tendon O
structure O
in O
previous O
studies O
. O
[]

The O
accuracy O
of O
clinical B-outcome ['Physiological-Clinical']
neurosensory I-outcome ['Physiological-Clinical']
testing O
for O
nerve O
injury O
diagnosis O
. O
['Physiological-Clinical']

Changes O
in O
natural B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
inversely O
related O
to O
plasma O
beta-endorphin O
levels O
. O
['Physiological-Clinical']

The O
new B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
for O
quarters O
that O
received O
intramammary O
tilmicosin O
compared O
with O
the O
intramammary O
placebo O
were O
14.4 O
and O
19.4 O
% O
, O
respectively O
. O
['Physiological-Clinical']

In O
Group O
C O
, O
patients O
were O
pretreated O
with O
lidocaine O
1.0 O
mg/kg O
followed O
by O
propofol O
2.0 O
mg/kg O
at O
3.3 O
mg/sec O
. O
[]

Statistical O
analysis O
was O
by O
2-tailed O
Fisher O
's O
Exact O
Test O
. O
[]

Patients O
, O
investigators O
, O
study O
monitors O
, O
and O
the O
sponsor O
staff O
were O
masked O
to O
treatment O
allocation O
. O
[]

CaCl O
( O
2 O
) O
pre-treatment O
; O
the O
other O
half O
received O
placebo O
. O
[]

The O
GEE-independent O
method O
yields O
consistent O
and O
robust O
variance O
[]

Six O
months O
after O
treatment O
the O
sample O
as O
a O
whole O
showed O
[]

In O
the O
PlasmaKinetic O
and O
TURP O
groups O
mean O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
40.3 O
+/- O
11.4 O
( O
range O
30 O
to O
60 O
) O
and O
57.8 O
+/- O
13.4 O
minutes O
( O
range O
45 O
to O
75 O
) O
, O
respectively O
( O
p O
< O
0.01 O
) O
. O
['Life-Impact']

Dependent O
measures O
included O
tests B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sustained I-outcome ['Physiological-Clinical']
attention I-outcome ['Physiological-Clinical']
, O
verbal B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
, O
hand-eye B-outcome ['Physiological-Clinical']
coordination I-outcome ['Physiological-Clinical']
, O
and O
spatial B-outcome ['Physiological-Clinical']
memory I-outcome ['Physiological-Clinical']
assessed I-outcome ['Physiological-Clinical']
before O
, O
during O
, O
and O
after O
the O
8-week O
treatment O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Immobilisation O
of O
the O
thumb O
is O
widely O
believed O
to O
be O
important O
in O
the O
management O
of O
fractures O
of O
the O
carpal O
scaphoid O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
were O
randomly O
assigned O
to O
receive O
either O
subcutaneous O
denosumab O
120 O
mg O
and O
intravenous O
placebo O
( O
n O
= O
1,026 O
) O
or O
intravenous O
zoledronic O
acid O
4 O
mg O
adjusted O
for O
creatinine O
clearance O
and O
subcutaneous O
placebo O
( O
n O
= O
1,020 O
) O
every O
4 O
weeks O
. O
[]

4 O
Propranolol O
10 O
mg O
and O
propranolol O
40 O
mg O
significantly O
attenuated O
both O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
responses O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
This O
prospective O
, O
randomized O
study O
included O
30 O
consecutive O
eyes O
assigned O
randomly O
to O
either O
ELT O
or O
SLT O
group O
. O
[]

The O
achieved O
rates O
of O
remission O
and O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
showed O
an O
obvious O
dependence O
on O
the O
histological O
type O
of O
tumor O
and O
on O
the O
degree O
of O
differentiation O
. O
['Mortality']

METHOD O
The O
target O
population O
was O
300 O
control O
and O
300 O
test O
subjects O
across O
three O
sites O
in O
the O
UK O
, O
but O
recruitment O
difficulties O
resulted O
in O
only O
125 O
patients O
being O
evaluable O
. O
[]

The O
hypopnea B-outcome ['Physiological-Clinical']
index O
showed O
no O
response O
to O
sleeping O
angle O
. O
['Physiological-Clinical']

Group O
LE O
received O
lidocaine O
1.5 O
mg/kg O
and O
esmolol O
1.0 O
mg/kg O
. O
[]

Twenty-four O
patients O
with O
chronic O
arthritis O
[ O
20 O
with O
rheumatoid O
arthritis O
( O
RA O
) O
and O
4 O
with O
psoriatic O
arthritis O
( O
PsA O
) O
] O
were O
divided O
into O
2 O
groups O
( O
10 O
RA O
, O
2 O
PsA O
) O
and O
randomly O
given O
CysA O
5 O
mg/kg O
daily O
or O
hydroxychloroquine O
( O
OH-Chlor O
) O
6 O
mg/kg O
daily O
in O
divided O
doses O
. O
[]

The O
mean O
cord B-outcome ['Physiological-Clinical']
blood O
hematologic O
values O
were O
similar O
in O
the O
two O
groups O
. O
['Physiological-Clinical']

In O
vitro O
, O
D53 O
enhances O
the O
IL-1 B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
by O
mouse O
spleen O
adherent O
cells O
. O
['Physiological-Clinical']

RESULTS O
: O
The O
percent O
changes O
in O
serum B-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
levels O
after O
8 O
weeks O
were O
-40.75 O
% O
for O
the O
febuxostat O
group O
and O
-34.41 O
% O
for O
the O
allopurinol O
group O
( O
P O
< O
0.001 O
, O
analysis O
of O
variance O
, O
closing O
testing O
procedure O
) O
. O
['Physiological-Clinical']

Taken O
together O
in O
our O
small O
study O
group O
, O
our O
findings O
display O
that O
BChE B-outcome ['Physiological-Clinical']
is O
a O
potential O
marker O
for O
synthetic O
function O
of O
liver O
, O
fat O
metabolism O
, O
an O
obesity O
marker O
, O
a O
function O
long O
overlooked O
. O
['Physiological-Clinical']

Multivariable O
regression O
analysis O
indicated O
coronary B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
, O
heart O
failure O
, O
and O
digitalis B-outcome ['Physiological-Clinical']
as O
independent O
risk O
indicators O
of O
cardiovascular O
morbidity O
and O
mortality O
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTERVENTIONS O
Both O
groups O
completed O
a O
12-week O
heavy-load O
eccentric O
training O
programme O
. O
[]

UNLABELLED O
BACKGROUND O
AND O
AIM O
OF O
INVESTIGATION O
: O
Intramuscular O
( O
IM O
) O
administration O
has O
been O
considered O
to O
be O
safer O
than O
intravenous O
( O
IV O
) O
for O
opioids O
on O
wards O
, O
but O
a O
comparative O
knowledge O
of O
patient O
safety O
and O
analgesic B-outcome ['Resource-use']
potency O
following O
a O
single O
dose O
of O
IV O
and O
IM O
administration O
is O
lacking O
. O
['Resource-use']

Nine O
healthy O
male O
volunteers O
undergoing O
stable O
maximal O
water O
diuresis O
were O
studied O
on O
four O
separate O
occasions O
. O
[]

OBJECTIVES O
The O
purpose O
of O
this O
study O
was O
to O
determine O
atheroma B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
in O
patients O
with O
spotty O
calcification O
. O
['Physiological-Clinical']

Effects O
of O
single O
doses O
of O
rabeprazole O
20 O
mg O
and O
esomeprazole O
40 O
mg O
on O
24-h B-outcome ['Physiological-Clinical']
intragastric I-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
in O
healthy O
subjects O
. O
['Physiological-Clinical']

PURPOSE O
To O
centrally O
assess O
the O
safety O
, O
efficacy O
, O
and O
[]

Recent O
evidence O
suggests O
that O
other O
hemodynamic O
parameters O
may O
also O
be O
associated O
with O
outcomes O
following O
stroke O
. O
[]

In O
randomised O
sequence O
lung O
function O
analysis O
tests O
were O
carried O
out O
with O
the O
bodyplethysmograph O
( O
Raw O
, O
FEV1 O
) O
and O
the O
polyfrequent O
oscillation O
method O
( O
resistance O
, O
reactance O
between O
2 O
and O
52 O
Hz O
) O
, O
whereas O
the O
transcutaneous O
oxygen O
pressure O
( O
tc-PO2 O
) O
was O
measured O
continuously O
. O
[]

The O
surgical O
resection O
group O
had O
better O
results O
than O
the O
radiochemotherapy O
group O
as O
measured O
by O
1-year O
survival B-outcome ['Mortality']
( O
62 O
% O
vs O
32 O
% O
, O
P=.05 O
) O
, O
mean O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
( O
> O
17 O
vs O
11 O
months O
, O
P O
< O
.03 O
) O
, O
and O
hazard O
ratio O
( O
0.46 O
, O
P=.04 O
) O
. O
['Mortality', 'Mortality']

DESIGN O
A O
multi-arm O
, O
modified O
blinded O
, O
placebo-controlled O
design O
was O
used O
. O
[]

EE30/LNG150 O
group O
presented O
54 O
% O
and O
67 O
% O
decreases O
of O
total O
testosterone B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
androgen I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
, O
respectively O
, O
with O
statistical O
significance O
. O
['Physiological-Clinical']

The O
five-year O
survival B-outcome ['Mortality']
rate O
was O
89.3 O
percent O
for O
those O
assigned O
to O
CABG O
and O
86.3 O
percent O
for O
those O
assigned O
to O
PTCA O
( O
P O
= O
0.19 O
; O
95 O
percent O
confidence O
interval O
of O
the O
difference O
in O
survival O
, O
-0.2 O
percent O
to O
6.0 O
percent O
) O
. O
['Mortality']

Material-independent O
blood O
activation O
( O
eg O
, O
blood-air O
interface O
and O
cardiotomy O
suction O
) O
blunted O
the O
total O
effect O
of O
the O
heparin-coated O
surface O
. O
[]

Patients O
were O
assessed O
using O
Aberrant O
Behavior O
Checklist-Community O
( O
ABC-C O
) O
rating O
scale O
and O
the O
side O
effect O
check O
list B-outcome ['Life-Impact']
every O
2 O
weeks O
until O
the O
endpoint O
. O
['Life-Impact', 'Life-Impact']

OBJECTIVE O
This O
exploratory O
study O
focuses O
on O
the O
mental O
health O
( O
MH O
) O
and O
caregiving O
experience O
of O
carers O
of O
adolescents O
with O
Bulimia O
Nervosa O
( O
BN O
) O
/Eating O
Disorder O
not O
otherwise O
specified O
( O
EDNOS O
) O
, O
aiming O
to O
determine O
: O
levels O
of O
MH O
problems O
in O
carers O
and O
if O
a O
negative O
experience O
of O
caregiving O
predicts O
carer O
MH O
status O
and O
which O
factors O
predict O
a O
negative O
experience O
of O
caregiving O
. O
[]

Study O
protocol O
: O
Rehabilitation O
including O
Social O
and O
Physical O
activity O
and O
Education O
in O
Children O
and O
Teenagers O
with O
Cancer O
( O
RESPECT O
) O
. O
[]

Phase O
I O
pharmacokinetic O
, O
food O
effect O
, O
and O
pharmacogenetic O
study O
of O
oral O
irinotecan O
given O
as O
semisolid O
matrix O
capsules O
in O
patients O
with O
solid O
tumors O
. O
[]

PRA O
, O
AII O
, O
ALD O
, O
renal O
blood O
flow O
and O
damage O
to O
renal O
function O
of O
the O
two O
groups O
before O
treatment O
and O
20 O
days O
after O
treatment O
were O
compared O
. O
[]

The O
neuroendocrine O
effects O
of O
sumatriptan O
differ O
from O
those O
of O
previously O
described O
5-HT-receptor O
agonists O
, O
and O
may O
be O
a O
consequence O
of O
selective O
activation O
of O
5-HT1D O
or O
5-HT1B O
receptors O
. O
[]

Impact O
of O
dronedarone O
on O
hospitalization B-outcome ['Resource-use']
burden I-outcome ['Resource-use']
in O
patients O
with O
atrial O
fibrillation O
: O
results O
from O
the O
ATHENA O
study O
. O
['Resource-use']

The O
comfortable B-outcome ['Life-Impact']
walking I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
had O
increased O
significantly O
in O
both O
groups O
. O
['Life-Impact']

The O
effects O
of O
atropine O
and O
metoclopramide O
on O
the O
lower O
oesophageal B-outcome ['Physiological-Clinical']
sphincter I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
LOSP O
) O
were O
studied O
in O
12 O
healthy O
volunteers O
using O
oesophageal O
pressure O
transducers O
. O
['Physiological-Clinical']

METHODS O
The O
relationship O
between O
blood B-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
and O
dietary B-outcome ['Life-Impact']
folate I-outcome ['Life-Impact']
intakes I-outcome ['Life-Impact']
, O
determined O
by O
weighed O
food O
records O
, O
were O
assessed O
in O
a O
sample O
of O
predominantly O
university-educated O
lactating O
women O
( O
32 O
+/- O
4 O
yr O
) O
at O
4- O
( O
n O
= O
53 O
) O
and O
16-wk O
postpartum O
( O
n O
= O
55 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

A O
multi-centre O
, O
double-blind O
, O
parallel O
group O
study O
was O
carried O
out O
in O
38 O
patients O
with O
seasonal O
rhinitis O
to O
compare O
a O
new O
aqueous O
nasal O
spray O
of O
beclomethasone O
dipropionate O
with O
the O
conventional O
pressurized O
nasal O
spray O
. O
[]

14 O
] O
% O
to O
21 O
[ O
17 O
] O
) O
, O
but O
was O
not O
in O
subjects O
receiving O
casein O
( O
from O
37 O
[ O
13 O
] O
% O
to O
36 O
[ O
12 O
] O
) O
. O
[]

[ O
Effects O
of O
betamethasone O
on O
neuromuscular B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
induced O
by O
vecuronium O
in O
continuous O
infusion O
] O
. O
['Physiological-Clinical']

OBJECTIVES O
We O
aimed O
to O
investigate O
the O
effects O
of O
large O
, O
intravenous O
doses O
of O
TE O
supplements O
on O
circulating O
and O
cutaneous O
TE O
tissue O
concentrations O
, O
on O
antioxidant O
status O
, O
and O
on O
clinical B-outcome ['Physiological-Clinical']
outcome O
after O
major O
burns O
. O
['Physiological-Clinical']

The O
increase O
in O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
induced O
by O
fasting O
was O
comparable O
to O
the O
increase O
in O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
induced O
by O
fasting O
combined O
with O
pegvisomant O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Among O
women O
, O
stress O
was O
not O
related O
to O
the O
prevalence O
of O
lesions B-outcome ['Physiological-Clinical']
or O
intima-media B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
efficacy O
of O
patient O
education O
and O
supervised O
exercise O
with O
that O
of O
patient O
education O
alone O
for O
the O
management O
of O
pain B-outcome ['Physiological-Clinical']
in O
patients O
with O
hip O
osteoarthritis O
( O
OA O
) O
. O
['Physiological-Clinical']

All O
patients O
had O
regional O
lymph O
node O
metastases O
at O
the O
time O
of O
surgery O
. O
[]

SETTING O
Private O
practices O
and O
hospital O
clinics O
in O
Ontario O
, O
Quebec O
and O
Manitoba O
. O
[]

Twenty-nine O
patients O
received O
epinephrine O
, O
ten O
patients O
received O
placebo O
. O
[]

Participants O
were O
58 O
children O
( O
46 O
boys O
) O
with O
autism O
between O
3 O
and O
4 O
years O
of O
age O
. O
[]

Subjects O
( O
n O
= O
99 O
) O
underwent O
three O
intradermal O
injection O
sessions O
with O
2 O
mL O
of O
autologous O
fibroblast O
suspension O
( O
10-20 O
million O
cells/mL O
) O
on O
one O
cheek O
and O
vehicle O
control O
( O
cell O
culture O
medium O
) O
on O
the O
other O
at O
14-day O
intervals O
. O
[]

All O
patients O
were O
treated O
in O
the O
context O
of O
a O
randomized O
trial O
where O
pre- O
and O
postoperative O
radiation O
( O
45 O
Gy O
) O
was O
evaluated O
versus O
surgery O
only O
. O
[]

Patients O
with O
large O
, O
potentially O
operable O
, O
locally-advanced O
breast O
cancer O
were O
randomized O
to O
receive O
anastrozole O
( O
1 O
mg/day O
) O
plus O
tamoxifen O
placebo O
or O
tamoxifen O
( O
20 O
mg/day O
) O
plus O
anastrozole O
placebo O
pre-operatively O
. O
[]

[ O
Prevention O
of O
migraine B-outcome ['Physiological-Clinical']
with O
flunarizine O
and O
acetylsalicylic O
acid O
. O
['Physiological-Clinical']

METHODS O
Patients O
were O
randomly O
assigned O
to O
undergo O
sphincterotomy O
over O
a O
non-conductive O
guidewire O
with O
30 O
W/sec O
pure-cut O
current O
or O
30 O
W/sec O
blend-2 O
current O
by O
a O
blinded O
endoscopist O
. O
[]

Bacteriuria O
in O
post-biopsy B-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
was O
significantly O
more O
common O
in O
the O
anesthesia O
group O
. O
['Physiological-Clinical']

The O
nurse O
wrote O
28 O
letters O
to O
the O
general O
practitioners O
suggesting O
changes O
in O
epilepsy O
management O
. O
[]

None O
of O
the O
5 O
subscales O
of O
ABC-C O
rating O
[]

No O
significant O
differences O
between O
the O
two O
treatment O
methods O
were O
found O
in O
primary O
or O
any O
of O
the O
secondary O
endpoints O
. O
[]

Registry O
: O
www.clinicaltrials.gov O
. O
[]

In O
summary O
, O
we O
observed O
in O
suboptimally O
operated O
ovarian O
carcinoma O
patients O
similar O
response O
rates O
, O
progression-free B-outcome ['Physiological-Clinical']
interval O
, O
and O
['Physiological-Clinical']

The O
overall O
main O
reason B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
sunbathing I-outcome ['Life-Impact']
was O
appearance O
, O
both O
for O
own O
sunbathing O
, O
and O
to O
an O
even O
higher O
degree O
, O
as O
a O
supposed O
reason O
for O
other O
adolescents O
' O
behaviour O
, O
and O
was O
reported O
most O
frequently O
by O
girls O
and O
the O
older O
age O
groups O
. O
['Life-Impact']

We O
investigated O
the O
effects O
of O
GH O
treatment O
and O
dietary O
restriction O
on O
lipolytic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
anabolic I-outcome ['Physiological-Clinical']
actions B-outcome ['Physiological-Clinical']
, O
as O
well O
as O
the O
consequent O
changes O
in O
insulin B-outcome ['Resource-use']
and O
GH B-outcome ['Physiological-Clinical']
secretion B-outcome ['Physiological-Clinical']
in O
obesity O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
the O
study O
was O
to O
compare O
the O
number O
of O
patients O
treated O
in O
the O
2 O
arms O
. O
[]

Fourteen O
adults O
participated O
in O
a O
randomized O
, O
counterbalanced O
protocol O
employing O
a O
chewing O
, O
placebo O
and O
caffeine O
condition O
. O
[]

Subjective O
effects O
of O
, O
and O
preference O
for O
, O
ethanol O
and O
diazepam O
vs. O
placebo O
were O
measured O
using O
a O
choice O
procedure O
. O
[]

'piano O
' O
) O
significantly O
more O
often O
than O
an O
unrelated O
object O
picture O
( O
e.g O
. O
[]

Efficacy O
was O
evaluated O
using O
standard B-outcome ['Life-Impact']
psychiatric I-outcome ['Life-Impact']
rating I-outcome ['Life-Impact']
scales O
, O
and O
patients O
were O
monitored O
for O
safety O
. O
['Life-Impact']

1.7 O
mg O
; O
p O
= O
0.01 O
) O
than O
3-port O
laparoscopy O
. O
[]

Patients O
were O
evaluated O
by O
the O
American O
Orthopaedic O
Foot O
and O
Ankle O
Society O
( O
AOFAS O
) O
Ankle-Hindfoot O
Scale O
and O
followed-up O
after O
12 O
months O
. O
[]

Visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
measurements O
['Physiological-Clinical']

METHODS O
This O
was O
an O
open-label O
, O
randomized O
, O
three-period O
crossover O
study O
in O
healthy O
male O
volunteers O
( O
n=12 O
) O
. O
[]

A O
study O
to O
evaluate O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
repeated O
doses O
of O
tirasemtiv O
in O
patients O
with O
amyotrophic O
lateral O
sclerosis O
. O
['Life-Impact']

Continuous O
low-level O
heatwrap O
therapy O
for O
treating O
acute O
nonspecific O
low O
back O
pain O
. O
[]

BACKGROUND O
Post-thrombotic O
syndrome O
( O
PTS O
) O
is O
the O
most O
important O
late O
complication O
of O
acute O
deep O
venous O
thrombosis O
( O
DVT O
) O
, O
with O
as O
many O
as O
two-thirds O
of O
patients O
developing O
symptoms O
of O
pain B-outcome ['Physiological-Clinical']
, O
edema B-outcome ['Physiological-Clinical']
, O
hyperpigmentation B-outcome ['Physiological-Clinical']
, O
or O
ulceration B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Some O
epidemiological O
studies O
have O
suggested O
that O
high O
dietary O
intake O
of O
calcium O
and O
fibre O
reduces O
colorectal O
carcinogenesis O
. O
[]

In O
Exp O
. O
[]

CONCLUSIONS O
In O
low O
concentrations O
( O
0.1 O
% O
) O
, O
bupivacaine O
did O
not O
reduce O
the O
titrated O
dose O
of O
epidural O
fentanyl O
required O
for O
adequate O
pain O
relief O
during O
forced O
inspiration O
after O
major O
abdominal O
surgery O
. O
[]

Of O
200 O
evaluable O
patients O
, O
51 O
were O
treated O
intramuscularly O
( O
IM O
) O
with O
3 O
x O
10 O
( O
6 O
) O
U O
( O
3 O
MU O
) O
/m2 O
daily O
for O
3 O
weeks O
( O
total O
dose O
63 O
MU/m2 O
) O
, O
50 O
received O
subcutaneous O
thrice-weekly O
injections O
of O
3 O
MU/m2 O
for O
4 O
weeks O
( O
total O
dose O
36 O
MU/m2 O
) O
, O
51 O
underwent O
diathermocoagulation O
, O
and O
48 O
were O
not O
treated O
and O
were O
used O
as O
a O
control O
group O
. O
[]

Efficiency O
of O
adjuvant O
immunochemotherapy O
following O
curative O
resection O
in O
patients O
with O
locally O
advanced O
gastric O
cancer O
. O
[]

The O
post-operative O
follow-up O
periods O
ranged O
from O
18 O
approximately O
28 O
( O
22.4 O
+/- O
4.9 O
) O
months O
. O
[]

Only O
antecedent O
aerobic O
exercise O
significantly O
reduced O
maladaptive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
stereotypic I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
the O
controlled O
setting O
. O
['Life-Impact']

Forty-two O
subjects O
completed O
the O
study O
( O
placebo O
, O
n O
= O
19 O
; O
WGP O
, O
n O
= O
23 O
) O
. O
[]

Effectiveness O
and O
safety O
of O
inhaled O
treprostinil O
for O
the O
treatment O
of O
pulmonary O
arterial O
hypertension O
in O
children O
. O
[]

In O
the O
entire O
cohort O
, O
red O
blood O
cell O
phosphatidylethanolamine O
docosahexaenoic O
acid O
level O
was O
inversely O
related O
to O
rate O
of O
decline O
in O
total O
field B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
over O
4 O
years O
( O
test O
for O
trend O
, O
P O
=.05 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
The O
subjective B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
psychomotor I-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
of O
remifentanil O
have O
not O
been O
evaluated O
. O
['Life-Impact']

Twelve O
patients O
( O
group O
1 O
) O
received O
dexamethasone O
and O
12 O
( O
group O
2 O
) O
did O
not O
. O
[]

The O
median O
survival O
time O
( O
FUDR O
, O
pump O
) O
is O
17 O
months O
for O
palliative O
local O
chemotherapy O
of O
unresectable O
colorectal O
liver O
metastases O
. O
[]

The O
results O
of O
our O
manikin O
study O
suggest O
that O
for O
personnel O
not O
experienced O
in O
tracheal O
intubation O
, O
the O
LTS-D O
offers O
a O
good O
alternative O
to O
ET O
and O
BMV O
to O
manage O
the O
airway O
during O
resuscitation O
, O
and O
to O
avoid O
the O
failure O
to O
achieve O
tracheal O
intubation O
with O
the O
ET O
, O
and O
the O
failure O
to O
achieve O
adequate O
ventilation O
with O
the O
BMV O
. O
[]

The O
ability O
to O
formulate O
recommendations O
regarding O
clinical O
use O
of O
hsCRP O
is O
limited O
by O
a O
paucity O
of O
data O
regarding O
several O
key O
issues O
. O
[]

The O
propofol O
group O
( O
II O
) O
received O
2 O
mg/kg O
for O
induction O
and O
a O
mean O
continuous O
infusion O
of O
1.7 O
mg/kg.h O
. O
[]

[ O
Postlaparoscopic O
pain O
syndrome O
. O
[]

CONCLUSION O
sICAM-1 B-outcome ['Physiological-Clinical']
levels O
in O
primary O
biliary O
cirrhosis O
are O
reduced O
by O
ursodeoxycholic O
acid O
. O
['Physiological-Clinical']

The O
next O
trial O
, O
UKALL O
XI O
, O
for O
children O
aged O
1-14 O
years O
, O
randomised O
between O
different O
central O
nervous O
system O
( O
CNS O
) O
directed O
therapies O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
statistical O
efficacy O
of O
the O
clinical B-outcome ['Physiological-Clinical']
neurosensory I-outcome ['Physiological-Clinical']
test O
using O
surgical O
findings O
as O
the O
gold O
standard O
, O
and O
to O
determine O
whether O
a O
correlation O
existed O
between O
the O
sensory O
impairment O
score O
obtained O
by O
preoperative O
testing O
and O
the O
degree O
of O
nerve O
injury O
found O
at O
surgery O
. O
['Physiological-Clinical']

Whereas O
the O
results O
of O
the O
treatment O
were O
nearly O
identical O
in O
both O
groups O
of O
treatment O
with O
badly O
differentiated O
carcinomas O
, O
a O
significant O
improvement O
could O
be O
achieved O
by O
the O
initial O
local O
treatment O
of O
well O
and O
moderately O
differentiated O
malignancies O
. O
[]

Over O
a O
24-month O
observation O
period O
the O
immunized O
group O
always O
had O
higher O
levels O
of O
peripheral B-outcome ['Physiological-Clinical']
leukocytes I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
peripheral B-outcome ['Physiological-Clinical']
lymphocytes I-outcome ['Physiological-Clinical']
; O
this O
difference O
was O
significant O
for O
the O
first O
21 O
months O
. O
['Physiological-Clinical']

A O
greater O
reduction O
in O
the O
duration O
of O
[]

SETTING O
Saint-Fran?ois O
d'Assise O
Hospital O
, O
Qu?bec O
, O
Canada O
. O
[]

RESULTS O
In O
part O
A O
, O
plasma O
AUC O
and O
C O
( O
max O
) O
of O
cediranib O
were O
lower O
in O
the O
presence O
of O
food O
by O
a O
mean O
of O
24 O
and O
33 O
% O
, O
respectively O
( O
94 O
% O
CI O
: O
AUC O
, O
12-34 O
% O
and O
C O
( O
max O
) O
, O
20-43 O
% O
) O
, O
indicating O
food O
reduces O
cediranib O
plasma O
exposure O
. O
[]

70 O
mg/dL O
after O
treatment O
with O
atorvastatin O
10 O
mg/day O
or O
rosuvastatin O
2.5 O
mg/day O
were O
randomly O
assigned O
to O
receive O
ezetimibe O
10 O
mg/day O
+ O
statin O
( O
n O
= O
78 O
) O
or O
double-dose O
statin O
( O
n O
= O
72 O
) O
for O
52 O
weeks O
. O
[]

INTERVENTIONS O
When O
concurrent O
illnesses O
had O
been O
treated O
and O
normal O
feeding O
re-established O
( O
weight O
gain O
5 O
g/kg.day-1 O
) O
, O
subjects O
were O
randomly O
allocated O
to O
short-stay O
( O
SS O
) O
or O
long-stay O
( O
LS O
) O
group O
. O
[]

It O
is O
not O
known O
whether O
parenteral O
nutrition O
( O
PN O
) O
administered O
during O
bone O
marrow O
transplantation O
( O
BMT O
) O
supports O
systemic O
antioxidant O
status O
. O
[]

Nine O
of O
10 O
patients O
completed O
the O
trial O
; O
1 O
withdrew O
due O
to O
pain B-outcome ['Physiological-Clinical']
during O
the O
second O
Er O
: O
YAG O
treatment O
. O
['Physiological-Clinical']

One O
year O
, O
double O
blind O
, O
randomised O
study O
( O
ESS-1 O
) O
: O
echocardiographic O
substudy O
-- O
three O
months O
follow-up O
. O
[]

OBJECTIVE O
To O
investigate O
the O
myocardial O
effects O
of O
long-term O
exogenous O
subclinical O
hyperthyroidism O
using O
two-dimensional O
speckle O
tracking O
echocardiography O
imaging O
( O
2D-STE O
) O
. O
[]

Physicians O
who O
viewed O
the O
seminars O
were O
significantly O
more O
likely O
to O
recommend B-outcome ['Life-Impact']
guideline-consistent I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
to O
patients O
in O
the O
vignettes O
. O
['Life-Impact']

Girls O
sunbathed O
and O
used O
sunbeds O
more O
than O
boys O
at O
all O
ages O
. O
[]

PURPOSE O
Intensive O
chemotherapy O
followed O
by O
autotransplantation O
has O
given O
promising O
results O
in O
partially O
responding O
or O
sensitive O
relapsed O
patients O
with O
aggressive O
non-Hodgkin O
's O
lymphoma O
. O
[]

METHODS O
This O
12-month O
, O
open O
, O
prospective O
study O
was O
conducted O
in O
15 O
centers O
in O
France O
and O
1 O
center O
in O
Belgium O
; O
309 O
patients O
were O
randomized O
to O
receive O
either O
induction O
therapy O
with O
ATG O
( O
n=151 O
) O
followed O
by O
initiation O
of O
tacrolimus O
on O
day O
9 O
or O
immediate O
tacrolimus-based O
triple O
therapy O
( O
n=158 O
) O
. O
[]

Compared O
to O
placebo-treated O
patients O
, O
delta O
power B-outcome ['Physiological-Clinical']
was O
significantly O
increased O
in O
all O
dose O
groups O
. O
['Physiological-Clinical']

Enalapril O
in O
single O
doses O
of O
10 O
and O
20 O
mg O
was O
given O
to O
13 O
hypertensive O
patients O
on O
treatment O
with O
bendrofluazide O
5 O
mg O
daily O
in O
a O
randomised O
, O
crossover O
, O
placebo O
controlled O
study O
. O
[]

The O
toxicities O
and O
possible O
utility O
of O
the O
combination O
of O
recombinant O
human O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
rhGM-CSF O
) O
and O
recombinant O
human O
erythropoietin O
( O
rHuEPO O
) O
given O
after O
autologous O
BMT O
were O
evaluated O
in O
this O
pilot O
trial O
. O
[]

RESULTS O
A O
total O
of O
16 O
patients O
completed O
the O
study O
. O
[]

A O
randomized O
trial O
of O
immunotherapy O
for O
persistent O
genital O
warts O
. O
[]

Overall O
response O
[]

Serum B-outcome ['Physiological-Clinical']
creatine I-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
decreased O
significantly O
in O
the O
methotrexate O
group O
. O
['Physiological-Clinical']

This O
study O
demonstrates O
the O
generalized O
estimating O
equations O
( O
GEE O
) O
method O
, O
focusing O
specifically O
on O
the O
GEE-independent O
method O
, O
to O
control O
for O
within-cluster O
correlation O
in O
regression O
models O
with O
either O
continuous O
or O
binary O
outcomes O
. O
[]

Verapamil O
also O
caused O
less O
marked O
ST-segment B-outcome ['Physiological-Clinical']
depressions I-outcome ['Physiological-Clinical']
at O
peak O
exercise B-outcome ['Life-Impact']
( O
p O
less O
than O
0.05 O
) O
at O
a O
similar O
rate-pressure O
product O
, O
suggesting O
a O
favorable O
redistribution O
of O
coronary B-outcome ['Physiological-Clinical']
blood B-outcome ['Physiological-Clinical']
flow B-outcome ['Physiological-Clinical']
to O
the O
ischemic O
zone O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Average O
aspiration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
clots I-outcome ['Physiological-Clinical']
for O
all O
patients O
randomized O
to O
surgery O
plus O
rtPA O
was O
20 O
% O
of O
mean O
initial O
clot O
size O
. O
['Physiological-Clinical']

A O
dose O
of O
5 O
x O
10 O
( O
9 O
) O
CFU O
( O
n=186 O
) O
or O
a O
placebo O
( O
n=116 O
) O
containing O
the O
diluent O
buffer O
was O
administered O
. O
[]

BACKGROUND O
The O
safety O
and O
immunogenicity B-outcome ['Physiological-Clinical']
of O
Viatim O
, O
a O
combined O
hepatitis O
A O
( O
HA O
) O
and O
typhoid O
fever O
( O
Vi O
) O
vaccine O
, O
were O
compared O
with O
the O
monovalent O
component O
vaccines O
up O
to O
and O
1 O
month O
after O
a O
booster O
dose O
at O
3 O
years O
. O
['Physiological-Clinical']

At O
Week O
8 O
, O
the O
intervention O
group O
reported O
improved O
mobility O
( O
P=0.01 O
) O
, O
fatigue O
( O
P=0.02 O
) O
, O
and O
sleep O
quality O
( O
P=0.05 O
) O
compared O
with O
the O
usual O
care O
group O
, O
but O
did O
not O
differ O
on O
the O
other O
measures O
. O
[]

In O
the O
experimental O
group O
, O
after O
the O
twelve O
week O
, O
the O
mean O
rank O
of O
perceived B-outcome ['Life-Impact']
self-efficacy I-outcome ['Life-Impact']
and O
outcome O
expectancy B-outcome ['Life-Impact']
increased O
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
decreased O
after O
the O
eight O
week O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

CONCLUSION O
Patients O
with O
hip O
fracture O
often O
develop O
asymptomatic O
and O
clinically O
unrecognized O
perioperative O
myocardial O
infarctions O
. O
[]

2 O
) O
=.39 O
) O
. O
[]

The O
Coping O
Cat O
program O
for O
children O
with O
anxiety O
and O
autism O
spectrum O
disorder O
: O
a O
pilot O
randomized O
controlled O
trial O
. O
[]

CONCLUSIONS O
Intravitreous O
fomivirsen O
is O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
with O
an O
acceptable O
safety O
profile O
. O
['Life-Impact']

The O
assessment O
was O
performed O
by O
comparison O
with O
control O
group O
( O
4 O
patients O
) O
who O
was O
instilled O
with O
natural O
tears O
( O
with O
different O
preservative O
) O
. O
[]

A O
scanning O
electron O
microscopic O
study O
of O
different O
caries O
removal B-outcome ['Resource-use']
techniques I-outcome ['Resource-use']
on O
human O
dentin O
. O
['Resource-use']

Seventeen O
children O
were O
randomized O
into O
the O
Intervention O
( O
n O
= O
9 O
) O
and O
Control O
( O
n O
= O
8 O
) O
groups O
. O
[]

No O
serious O
spinal O
pathology O
was O
identified O
in O
either O
group O
. O
[]

However O
, O
recent O
evidence O
suggests O
that O
the O
manic O
switch O
rate O
may O
be O
low O
in O
BP O
II O
MDE O
during O
SSRI O
therapy O
. O
[]

While O
the O
N170 O
was O
predominant O
in O
the O
right O
hemisphere O
in O
TD O
and O
ADHD O
, O
children O
with O
ASD O
( O
ASD/ASD+ADHD O
) O
showed O
a O
bilateral O
distribution O
. O
[]

CONCLUSION O
Both O
the O
potassium O
titanyl O
phosphate O
and O
the O
bipolar O
radiofrequency O
techniques O
were O
safe O
and O
easy B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
for O
tonsillectomy O
, O
with O
reduced O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
complication B-outcome ['Adverse-effects']
rates O
and O
better O
post-operative O
general O
patient O
condition O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Adverse-effects']

Surgery O
of O
aphakic O
retinal O
detachment O
. O
[]

Wearing O
the O
inflated O
cuff O
did O
not O
change O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Safety O
and O
tolerability B-outcome ['Life-Impact']
were O
also O
assessed O
. O
['Life-Impact']

CONCLUSIONS O
IFO O
does O
not O
increase O
the O
activity O
of O
the O
5-FU O
plus O
FA O
combination O
in O
advanced B-outcome ['Physiological-Clinical']
colorectal I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHOD O
84 O
children O
from O
15 O
schools O
participated O
in O
a O
randomized O
controlled O
trial O
( O
RCT O
) O
of O
PECS O
( O
P. O
Howlin O
, O
R. O
K. O
Gordon O
, O
G. O
Pasco O
, O
A O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
miss O
rate O
of O
colonoscopy O
by O
same O
day O
back-to-back O
colonoscopy O
. O
[]

Lipids O
and O
hepatic/renal O
function O
were O
measured O
at O
baseline O
and O
after O
4 O
weeks O
. O
[]

METHOD O
30 O
individuals O
( O
BMI O
? O
[]

METHODS O
Patients O
with O
histological/cytological O
proven O
inoperable O
adenocarcinoma O
of O
the O
head O
of O
pancreas O
were O
randomised O
to O
receive O
KAb O
201 O
via O
either O
the O
intra-arterial O
or O
intravenous O
delivery O
route O
. O
[]

A O
randomized O
study O
comparing O
glucagon O
and O
hyoscine O
N-butyl O
bromide O
before O
endoscopic O
retrograde O
cholangiopancreatography O
. O
[]

Perceptual B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
occurred O
in O
the O
two O
optimal O
conditions O
and O
in O
the O
two O
cognitive O
load O
conditions O
, O
but O
not O
in O
the O
noise O
condition O
. O
['Life-Impact']

There O
were O
also O
no O
differences O
in O
short-term O
prevention B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

All O
nine O
women O
who O
tested O
positive O
for O
high-risk O
HPV O
attended O
for O
a O
cervical O
smear O
and O
colposcopy O
. O
[]

METHODS O
We O
conducted O
a O
secondary O
analysis O
of O
a O
free O
bednet O
distribution O
program O
in O
Madagascar O
from O
2007-2008 O
. O
[]

3 O
) O
The O
case O
number O
of O
patients O
in O
need O
of O
receiving O
the O
treatment O
again O
within O
1-month O
follow-up O
and O
the O
difference O
between O
the O
[]

There O
was O
no O
statistically O
significant O
difference O
between O
any O
of O
the O
treatment O
arms O
with O
respect O
to O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
or O
3-year O
survival B-outcome ['Mortality']
( O
P O
> O
0.54 O
and O
P O
> O
or= O
0.09 O
for O
all O
pairwise O
comparisons O
) O
, O
schedules O
( O
dose O
level O
1/2 O
vs. O
3/4 O
; O
P O
= O
0.46 O
and O
P O
= O
0.5 O
) O
, O
or O
dose O
of O
IL-2 O
administered O
( O
dose O
level O
1/3 O
vs. O
2/4 O
; O
P O
= O
0.99 O
and O
P O
= O
0.1 O
) O
. O
['Mortality', 'Mortality']

This O
suggests O
that O
a O
vitamin/mineral O
supplement O
is O
a O
reasonable O
adjunct O
therapy O
to O
consider O
for O
most O
children O
and O
adults O
with O
autism O
. O
[]

After O
three-month O
drug O
therapy O
, O
the O
serum B-outcome ['Physiological-Clinical']
EMAb I-outcome ['Physiological-Clinical']
negative O
conversion B-outcome ['Physiological-Clinical']
rate O
was O
obviously O
higher O
in O
the O
test O
group O
than O
in O
the O
control O
group O
( O
44.44 O
% O
vs O
15.62 O
% O
) O
, O
showing O
statistical O
difference O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Laparoscopic O
appendectomy O
( O
LA O
) O
has O
been O
associated O
with O
a O
faster O
recovery O
and O
less O
postoperative O
pain O
than O
the O
open O
technique O
. O
[]

In O
both O
groups O
, O
the O
hot B-outcome ['Physiological-Clinical']
flash I-outcome ['Physiological-Clinical']
score O
peaked O
at O
3 O
months O
and O
decreased O
thereafter O
. O
['Physiological-Clinical']

Due O
to O
the O
significantly O
improved O
diagnostic O
methods O
and O
the O
increasing O
use O
of O
PSA O
screening O
, O
there O
has O
been O
a O
stage O
migration O
towards O
early O
tumour O
stages O
that O
are O
prognostically O
heterogeneous O
and O
require O
differentiated O
treatment O
. O
[]

The O
study O
was O
closed O
when O
inferior O
PFS O
and O
greater O
toxicity O
were O
demonstrated O
at O
the O
time O
of O
the O
planned O
interim O
efficacy O
analysis O
. O
[]

Adverse O
events O
were O
obtained O
by O
diary O
cards O
. O
[]

BACKGROUND O
Chemotherapy O
and O
radiation O
therapy O
result O
in O
increased O
free O
radical O
formation O
and O
depletion O
of O
tissue O
antioxidants O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
test O
the O
effectiveness O
of O
a O
regimen O
of O
combination O
chemotherapy O
known O
to O
be O
active O
in O
advanced O
breast O
cancer O
when O
given O
as O
an O
adjuvant O
treatment O
after O
mastectomy O
. O
[]

Blood O
donation O
had O
to O
be O
cancelled O
if O
the O
haematocrit O
was O
below O
30 O
% O
. O
[]

Anti-tetanus B-outcome ['Physiological-Clinical']
GMTs I-outcome ['Physiological-Clinical']
in O
placebo O
and O
chloroquine O
groups O
declined O
over O
14 O
months O
to O
levels O
comparable O
to O
those O
of O
unvaccinated O
controls O
, O
but O
levels O
in O
the O
primaquine O
group O
remained O
significantly O
higher O
than O
in O
controls O
. O
['Physiological-Clinical']

PURPOSE O
The O
necessity O
of O
a O
protective O
stoma O
in O
patients O
undergoing O
low O
anterior O
resection O
with O
total O
mesorectal O
excision O
for O
primary O
rectal O
cancer O
is O
discussed O
controversially O
. O
[]

We O
previously O
reported O
that O
propofol O
at O
a O
subhypnotic O
dose O
of O
0.5 O
mg/kg O
was O
more O
effective O
than O
placebo O
in O
preventing O
PONV O
in O
women O
who O
undergo O
mastectomy O
. O
[]

Subjects O
randomized O
to O
surgery O
underwent O
stereotactic O
catheter O
placement O
and O
clot O
aspiration O
. O
[]

Here O
, O
we O
report O
results O
of O
a O
double-blind O
, O
randomized O
placebo-controlled O
phase O
II O
study O
designed O
to O
test O
the O
hypothesis O
that O
acute O
graft-versus-host O
disease O
could O
be O
prevented O
by O
administration O
of O
oral O
BDP O
, O
beginning O
before O
hematopoietic O
cell O
transplantation O
and O
continuing O
until O
day O
75 O
after O
hematopoietic O
cell O
transplantation O
after O
myeloablative O
conditioning O
. O
[]

Avatar O
assistant O
: O
improving O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
students O
with O
an O
ASD O
through O
a O
computer-based O
intervention O
. O
['Life-Impact']

Patients O
and O
their O
partners O
completed O
a O
questionnaire O
regarding O
functional O
disability O
. O
[]

In O
SD O
patients O
, O
the O
increments B-outcome ['Physiological-Clinical']
after O
the O
first O
and O
the O
last O
transfusion O
were O
in O
the O
same O
range O
, O
whereas O
in O
MD O
patients O
, O
the O
1-hr O
( O
p O
less O
than O
0.001 O
) O
and O
the O
24-hr O
( O
p O
less O
than O
0.025 O
) O
increments B-outcome ['Physiological-Clinical']
decreased O
from O
the O
first O
to O
the O
last O
transfusion O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Recent O
reports O
show O
that O
sumatriptan O
administration O
increases O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
vascular B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
both O
in O
systemic O
and O
pulmonary O
circulation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Lower O
pre-Norwood O
right O
ventricular O
fractional O
area O
change O
, O
pre-Norwood O
surgery O
, O
and O
anatomy O
other O
than O
hypoplastic O
left O
heart O
syndrome O
were O
independently O
associated O
with O
transplantation O
( O
all O
P O
< O
.03 O
) O
, O
but O
shunt O
type O
was O
not O
( O
P O
= O
.43 O
) O
. O
[]

The O
ability O
to O
culture O
virus O
from O
peripheral O
blood O
mononuclear O
cells O
was O
not O
changed O
by O
the O
regimen O
. O
[]

RESULTS O
Detrusor B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
at O
maximum O
flow O
( O
PdetQmax B-outcome ['Physiological-Clinical']
) O
continued O
to O
decrease O
during O
the O
second O
12 O
months O
of O
therapy O
( O
decreases O
of O
5.3 O
and O
11.7 O
cm O
H2O O
at O
months O
12 O
and O
24 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Improvements O
in O
the O
secondary O
endpoints O
of O
PLM B-outcome ['Physiological-Clinical']
while I-outcome ['Physiological-Clinical']
asleep I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
while I-outcome ['Physiological-Clinical']
awake I-outcome ['Physiological-Clinical']
were O
also O
significantly O
superior O
for O
pramipexole O
. O
['Physiological-Clinical']

Similarly O
, O
there O
were O
no O
clinically O
or O
statistically O
important O
differences O
in O
side-effect O
profiles O
or O
patient O
satisfaction O
. O
[]

The O
sections O
were O
submitted O
to O
push-out O
testing O
in O
a O
universal O
testing O
machine O
EMIC O
( O
1 O
mm/min O
) O
. O
[]

Around O
20 O
% O
of O
the O
subjects O
noticed O
a O
higher B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
blurred O
vision O
in O
both O
eyes O
as O
well O
as O
headaches B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Of O
the O
infants O
aged O
6 O
to O
< O
16 O
weeks O
, O
31 O
received O
influenza O
vaccine O
and O
28 O
received O
placebo O
, O
and O
of O
those O
aged O
16 O
to O
< O
24 O
weeks O
, O
30 O
received O
influenza O
vaccine O
and O
31 O
received O
placebo O
. O
[]

Using O
the O
spinal O
technique O
, O
patients O
can O
walk O
from O
the O
operating O
room O
table O
to O
a O
stretcher O
on O
completion O
of O
surgery O
. O
[]

Anastomotic B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
developed O
in O
only O
one O
patient O
in O
each O
group O
. O
['Physiological-Clinical']

Those O
factors O
include O
being O
of O
African-American O
race O
, O
having O
a O
preoperative O
intraocular O
pressure O
of O
20 O
mm O
Hg O
or O
more O
on O
maximum O
tolerated O
medications O
, O
and O
being O
on O
two O
or O
more O
medications O
preoperatively O
. O
[]

Saccade O
accuracy O
is O
1 O
component O
of O
metrics O
, O
which O
to O
function O
optimally O
requires O
several O
cortical O
brain O
structures O
as O
well O
as O
an O
intact O
cerebellum O
and O
brain-stem O
. O
[]

The O
effect O
of O
cyclosporin O
administered O
during O
a O
third-party O
blood O
transfusion O
protocol O
on O
humoral O
immune O
responses O
. O
[]

Epilepsy O
Care O
Evaluation O
Group O
. O
[]

METHOD O
Eleven O
children O
with O
autistic O
disorder O
, O
aged O
3.0 O
to O
8.3 O
years O
, O
were O
studied O
in O
home O
, O
school O
, O
and O
outpatient O
laboratory O
, O
bringing O
to O
24 O
the O
combined O
study O
sample O
. O
[]

METHODS O
A O
randomized O
controlled O
trial O
was O
done O
of O
consecutive O
older O
patients O
( O
> O
50 O
years O
) O
attending O
an O
accident O
and O
emergency O
facility O
because O
of O
a O
non-accidental B-outcome ['Physiological-Clinical']
fall I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
To O
test O
the O
hypotheses O
that O
telephone-delivered O
psychosocial O
interventions O
decrease O
depression B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
in O
women O
with O
breast O
cancer O
and O
their O
partners O
. O
['Life-Impact', 'Life-Impact']

This O
was O
set O
in O
a O
multicenter O
, O
randomized O
, O
placebo-controlled O
, O
double-blind O
, O
confirmatory O
clinical O
study O
undertaken O
in O
four O
outpatient O
orthopedic O
clinics O
. O
[]

ORs O
for O
predicting O
hip O
fracture O
were O
: O
previous B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
, O
2.31 O
( O
95 O
% O
CI O
1.31-4.08 O
) O
; O
low B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
( O
< O
58 O
kg O
) O
, O
2.20 O
( O
95 O
% O
CI O
1.28-3.77 O
) O
; O
maternal O
history O
of O
hip O
fracture O
, O
1.68 O
( O
95 O
% O
CI O
0.85-3.31 O
) O
; O
a O
fall O
in O
the O
last O
12 O
months O
, O
2.92 O
( O
95 O
% O
CI O
1.70-5.01 O
) O
; O
and O
age O
( O
per O
year O
increase O
) O
, O
1.09 O
( O
95 O
% O
CI O
1.04-1.13 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
characteristics O
of O
the O
patients O
of O
the O
two O
groups O
did O
not O
differ O
significantly O
. O
[]

This O
paper O
describes O
a O
randomized O
trial O
( O
n O
= O
31 O
) O
that O
was O
conducted O
at O
a O
regional O
diagnostic O
center O
of O
a O
large O
metropolitan O
children O
's O
hospital O
to O
( O
a O
) O
refine O
a O
nursing O
intervention O
designed O
for O
parents O
of O
children O
with O
ASD O
and O
( O
b O
) O
to O
identify O
methodological O
revisions O
for O
a O
larger O
study O
. O
[]

Serial O
radionuclide O
ventriculography O
demonstrated O
no O
difference O
in O
24-hour O
( O
52 O
+/- O
12 O
% O
versus O
50 O
+/- O
12 O
% O
) O
or O
6-week O
( O
51 O
+/- O
12 O
% O
versus O
51 O
+/- O
13 O
% O
) O
ejection B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
values O
for O
placebo O
and O
streptokinase O
groups O
, O
respectively O
. O
['Physiological-Clinical']

The O
interval O
to O
recurrence B-outcome ['Physiological-Clinical']
was O
shown O
by O
Kaplan-Meier O
survivorship O
curves O
, O
and O
the O
log-rank O
test O
was O
used O
to O
compare O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
did O
not O
find O
a O
significant O
effect O
of O
oral O
contraceptive O
administration O
on O
the O
disappearance B-outcome ['Physiological-Clinical']
rate O
of O
['Physiological-Clinical']

Subjects/caregivers O
reported O
improvements O
in O
dental B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
as O
well O
as O
in O
attitude O
, O
quality O
of O
life O
, O
and O
['Physiological-Clinical']

Mean O
confidence B-outcome ['Life-Impact']
scores O
and O
additional O
imaging O
recommendations O
were O
compared O
between O
CT O
and O
DSA O
groups O
in O
an O
intention-to-diagnose-and-treat O
analysis O
. O
['Life-Impact']

The O
production O
of O
new B-outcome ['Physiological-Clinical']
red I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
was O
176.3+/-90.8 O
ml O
in O
the O
200 O
U/kg O
group O
and O
268.4+/-79.4 O
ml O
in O
the O
400 O
U/kg O
group O
( O
p O
= O
0.036 O
) O
. O
['Physiological-Clinical']

The O
main O
factors O
were O
two O
sources O
of O
dietary O
CP O
and O
four O
levels O
of O
RPLM O
. O
[]

Our O
ongoing O
work O
is O
directed O
at O
further O
defining O
force O
interactions O
. O
[]

Effective O
surgical B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
costing O
$ O
40,000 O
would O
be O
cost-effective O
compared O
with O
unsuccessful O
medical O
treatment O
. O
['Resource-use', 'Resource-use']

Impaired O
kidney O
function O
often O
accompanies O
heart O
failure O
( O
HF O
) O
and O
is O
associated O
with O
a O
worse O
prognosis O
. O
[]

102 O
subjects O
received O
the O
first O
booster O
vaccination O
, O
and O
83 O
were O
vaccinated O
twice O
. O
[]

Misoprostol O
versus O
oxytocin O
for O
the O
reduction O
of O
postpartum B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Five-year O
follow-up O
of O
the O
Fluorouracil O
Filtering O
Surgery O
Study O
. O
[]

Feedback O
on O
the O
content O
and O
presentation O
led O
to O
iterative O
modifications O
of O
the O
tools O
. O
[]

Comparison O
of O
the O
cardiorespiratory O
effects O
of O
a O
combination O
of O
ketamine O
and O
propofol O
, O
propofol O
alone O
, O
or O
a O
combination O
of O
ketamine O
and O
diazepam O
before O
and O
after O
induction O
of O
anesthesia O
in O
dogs O
sedated O
with O
acepromazine O
and O
oxymorphone O
. O
[]

Anti-IgG O
antibodies O
during O
immunotherapy O
with O
purified O
grass O
pollen O
extracts O
. O
[]

Geometric O
mean O
anti-tetanus B-outcome ['Physiological-Clinical']
titers I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GMTs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
the O
primaquine O
group O
were O
significantly O
higher O
than O
those O
of O
the O
placebo O
group O
at O
1 O
, O
3 O
, O
and O
14 O
months O
. O
['Physiological-Clinical']

Unlike O
other O
sedatives O
and O
anesthetics O
, O
the O
concentration-dependence O
of O
clonidine O
demonstrates O
a O
ceiling O
beyond O
which O
the O
administration O
of O
an O
additional O
drug O
fails O
to O
enhance O
the O
effect O
, O
suggesting O
that O
the O
thermoregulatory O
effect O
of O
clonidine O
may O
be O
limited O
, O
even O
at O
high O
plasma O
concentrations O
. O
[]

Compliance O
, O
male O
gender O
, O
no O
antibiotic O
prescription O
in O
the O
subsequent O
2 O
years O
and O
[]

Convenience O
sample O
. O
[]

10 O
% O
net O
reduction O
compared O
with O
control O
group O
) O
, O
and O
about O
a O
50 O
% O
reduction O
in O
cigarette B-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
. O
['Life-Impact']

Efficacy O
and O
safety O
of O
timolol/pilocarpine O
combination O
drops O
in O
glaucoma O
patients O
. O
[]

Moreover O
, O
the O
intervention O
effect O
on O
inflammation B-outcome ['Physiological-Clinical']
was O
mediated O
by O
its O
effect O
on O
depressive O
symptoms O
. O
['Physiological-Clinical']

The O
main O
goal O
of O
this O
study O
is O
to O
examine O
the O
effectiveness O
of O
a O
short O
theory O
of O
mind O
intervention O
for O
children O
with O
ASD O
. O
[]

We O
investigated O
if O
these O
difficulties O
could O
be O
attributable O
to O
a O
deficit O
in O
the O
ability O
to O
linguistically O
converge O
with O
an O
interlocutor O
, O
which O
is O
posited O
to O
be O
important O
for O
successful O
communication O
. O
[]

We O
also O
observed O
an O
increase O
in O
intima-media B-outcome ['Physiological-Clinical']
thickness B-outcome ['Physiological-Clinical']
in O
the O
highest O
quintile O
relative O
to O
the O
lowest O
( O
difference O
= O
0.048 O
+/- O
0.025 O
mm O
) O
among O
men O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Inclusion/exclusion O
criteria O
were O
defined O
according O
to O
the O
clinical O
diagnosis O
of O
ASD O
, O
the O
presence O
or O
absence O
of O
additional O
or O
associated O
disability O
, O
previous O
training O
in O
referential O
communication O
, O
and O
any O
drug O
treatment O
. O
[]

There O
is O
much O
evidence O
suggesting O
that O
the O
decline O
in O
ovarian O
function O
after O
menopause O
is O
associated O
with O
spontaneous O
increases O
in O
proinflammatory O
cytokines O
. O
[]

CONCLUSIONS O
Our O
findings O
are O
consistent O
with O
previous O
research O
reports O
in O
which O
there O
was O
no O
difference O
in O
functional B-outcome ['Life-Impact']
and O
quality-of-life B-outcome ['Life-Impact']
indices O
for O
patients O
who O
had O
rotator O
cuff O
repair O
with O
or O
without O
acromioplasty O
. O
['Life-Impact']

Minimal O
treatment-related B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
seen O
at O
doses O
up O
to O
8 O
mg. O
Serum O
interferon O
( O
IFN O
) O
-? O
was O
only O
detected O
in O
subjects O
who O
received O
8 O
or O
12 O
mg O
doses O
, O
and O
the O
adverse O
event O
profile O
at O
8 O
and O
12 O
mg O
doses O
was O
generally O
consistent O
with O
that O
associated O
with O
IFN-? O
exposure O
( O
flu-like O
symptoms O
) O
, O
consistent O
with O
the O
mechanism O
of O
TLR7 O
agonism O
. O
['Adverse-effects']

This O
mode O
was O
used O
to O
assess O
the O
pain-relieving O
effect O
of O
carbamazepine O
( O
CMZ O
) O
and O
opioids O
in O
a O
double-blinded O
, O
placebo-controlled O
trial O
. O
[]

The O
aim O
of O
the O
intervention O
was O
to O
promote O
infant B-outcome ['Life-Impact']
mental I-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
and O
reduce O
the O
incidence O
of O
infant B-outcome ['Life-Impact']
mental I-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
problems O
at O
the O
age O
of O
two O
years O
. O
['Life-Impact', 'Life-Impact']

We O
aimed O
to O
assess O
the O
effect O
of O
nitazoxanide-a O
new O
broad-spectrum O
antiparasitic O
drug-on O
morbidity B-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
in O
Zambian O
children O
with O
diarrhoea O
due O
to O
Cryptosporidium O
parvum O
. O
['Physiological-Clinical', 'Mortality']

Clinically O
significant O
[]

There O
was O
no O
significant O
difference O
between O
curettage B-outcome ['Resource-use']
and O
abrasion B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

In O
the O
clinical O
control O
group O
, O
pain O
from O
the O
iliac O
crest O
was O
worse O
than O
pain O
from O
the O
primary O
surgical O
site O
. O
[]

Within-program O
data O
showed O
a O
significant O
reduction O
in O
errors O
made O
from O
first O
to O
last O
use O
. O
[]

Argon O
laser O
indirect O
ophthalmoscope O
photocoagulation O
has O
been O
used O
as O
an O
alternative O
to O
cryotherapy O
, O
with O
fewer O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

A O
significant O
difference O
was O
observed O
on O
the O
change O
in O
scores O
in O
the O
ABC-C O
Rating O
Scale O
in O
week O
10 O
compared O
with O
baseline O
in O
the O
two O
groups O
( O
t O
= O
6.017 O
, O
d.f O
. O
[]

D53 O
( O
Ribomunyl O
) O
, O
a O
composite O
bacterial O
ribosomal O
immunostimulant O
, O
has O
been O
recognized O
as O
an O
efficient O
prevention O
of O
respiratory B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
the O
morning O
of O
the O
fourth O
day O
, O
volunteers O
orally O
received O
3.5 O
mg O
glibenclamide O
together O
with O
either O
10 O
mg O
enalapril O
or O
placebo O
. O
[]

The O
first O
treatment O
is O
the O
insertion O
of O
a O
chest O
tube O
( O
ICT O
) O
but O
in O
a O
great O
number O
of O
patients O
there O
is O
recurrence O
of O
the O
disease O
. O
[]

Analysis O
of O
variance O
was O
used O
to O
analyze O
mean O
differences O
on O
demographic O
variables O
and O
mean O
number O
of O
weeks O
in O
study O
. O
[]

METHODS O
Patients O
with O
multivessel O
disease O
were O
randomly O
assigned O
to O
an O
initial O
treatment O
strategy O
of O
CABG O
( O
n O
= O
914 O
) O
or O
PTCA O
( O
n O
= O
915 O
) O
and O
were O
followed O
for O
an O
average O
of O
5.4 O
years O
. O
[]

Outcomes O
were O
evaluated O
at O
baseline O
, O
immediately O
after O
treatment O
, O
at O
10 O
and O
30 O
min O
. O
[]

Atorvastatin O
and O
quinapril O
inhibit O
blood O
coagulation O
in O
patients O
with O
coronary O
artery O
disease O
following O
28 O
days O
of O
therapy O
. O
[]

In O
Japan O
, O
no O
effectiveness O
study O
has O
been O
reported O
: O
thus O
, O
it O
is O
desirable O
to O
collect O
data O
that O
will O
serve O
as O
evidence O
for O
selection O
of O
the O
3 O
SGAs O
approved O
after O
olanzapine O
. O
[]

Regression O
analysis O
showed O
that O
urinary B-outcome ['Physiological-Clinical']
NAG I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
was O
significantly O
associated O
with O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
DM I-outcome ['Physiological-Clinical']
( O
r O
= O
0.61 O
; O
P O
< O
0.001 O
) O
and O
proteinuria B-outcome ['Physiological-Clinical']
( O
r O
= O
0.51 O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Outcome O
measurements O
included O
Composite O
Spasticity O
Scale O
, O
peak O
torques O
generated O
during O
maximum O
isometric O
voluntary O
contraction O
of O
ankle O
dorsiflexors O
and O
plantarflexors O
, O
and O
gait O
velocity O
recorded O
at O
baseline O
, O
after O
2 O
and O
4 O
weeks O
of O
treatment O
, O
and O
4 O
weeks O
after O
treatment O
ended O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
computer-navigated O
total O
knee O
arthroplasty O
improves O
the O
clinical O
function O
, O
alignment O
, O
and O
survivorship O
of O
the O
components O
. O
[]

Seven O
subjects O
( O
four O
healthy O
men O
and O
three O
asymptomatic O
porphobilinogen O
deaminase-deficient O
subjects O
) O
developed O
antibodies O
against O
recombinant B-outcome ['Physiological-Clinical']
human I-outcome ['Physiological-Clinical']
porphobilinogen I-outcome ['Physiological-Clinical']
deaminase B-outcome ['Physiological-Clinical']
but O
did O
not O
experience O
allergic B-outcome ['Physiological-Clinical']
manifestations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Participants O
randomized O
to O
saline O
or O
commercial O
solution O
had O
a O
weekly O
washout O
with O
the O
appropriate O
solution O
. O
[]

5 O
) O
Total O
tract O
digestibility O
of O
protein O
decreased O
from O
4 O
to O
8 O
weeks O
of O
age O
for O
soybean O
meal O
and O
rapeseed O
meal O
but O
increased O
for O
soybean O
cake O
and O
rapeseed O
cake O
. O
[]

Comparison O
of O
short-term O
efficacy O
of O
diltiazem O
and O
propranolol O
in O
unstable O
angina O
at O
rest O
-- O
a O
randomized O
trial O
in O
70 O
patients O
. O
[]

Then O
, O
in O
a O
sheep O
model O
of O
iliac O
crest O
infiltration O
, O
we O
compared O
the O
pharmacokinetics O
of O
single O
administration O
of O
plain O
bupivacaine O
( O
100 O
mg O
) O
and O
bupivacaine O
( O
500 O
mg O
) O
-loaded O
microspheres O
. O
[]

The O
response O
rate O
was O
18 O
% O
, O
including O
one O
complete O
response O
. O
[]

The O
development O
of O
the O
low O
cost O
interventions O
and O
their O
effective O
delivery O
are O
needed O
to O
reduce O
deaths B-outcome ['Mortality']
from O
birth O
asphyxia O
. O
['Mortality']

This O
approach O
is O
based O
on O
a O
fine O
needle O
aspiration O
technique O
, O
which O
allows O
us O
to O
extract O
a O
small O
tissue O
sample O
in O
a O
significantly O
less O
invasive O
manner O
than O
with O
classic O
biopsy O
. O
[]

METHODS O
Elite O
sprint O
and O
middle-distance O
swimmers O
( O
three O
females O
and O
six O
males O
; O
aged O
21-26 O
yr O
) O
performed O
6-13 O
time O
trials O
in O
training O
and O
competition O
in O
the O
9 O
wk O
before O
and O
including O
Olympic-qualifying O
trials O
, O
all O
in O
their O
specialty O
event O
. O
[]

Retinal B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
significantly I-outcome ['Physiological-Clinical']
increased O
by O
3 O
+/- O
4 O
% O
, O
2 O
+/- O
4 O
% O
, O
and O
3 O
+/- O
5 O
% O
( O
P O
= O
0.047 O
, O
ANOVA O
) O
and O
1 O
+/- O
2 O
% O
, O
3 O
+/- O
2 O
% O
, O
and O
3 O
+/- O
2 O
% O
( O
P O
= O
0.015 O
, O
ANOVA O
) O
, O
respectively O
. O
['Physiological-Clinical']

Spearman O
's O
coefficients O
for O
correlation O
of O
quantitative O
spasticity O
measures O
with O
MAS O
scores O
ranged O
from O
0.39 O
to O
0.49 O
with O
associated O
probabilities O
< O
or O
= O
0.002 O
. O
[]

CONCLUSIONS O
Compared O
with O
total O
thyroidectomy O
alone O
, O
CND O
significantly O
increases O
the O
rate O
of O
postoperative B-outcome ['Physiological-Clinical']
hypocalcemia I-outcome ['Physiological-Clinical']
, O
which O
can O
be O
prevented O
by O
routine O
postoperative O
supplementation O
with O
oral O
calcium O
and O
vitamin O
D O
. O
['Physiological-Clinical']

Addition O
of O
these O
drugs O
lowered O
the O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
by O
25 O
+/- O
3/16 O
+/- O
2 O
mm O
Hg O
and O
15 O
+/- O
3/14 O
+/- O
1 O
mm O
Hg O
, O
respectively O
. O
['Physiological-Clinical']

At O
the O
end O
of O
six O
years O
of O
intervention O
, O
those O
who O
did O
not O
receive O
anti-H O
pylori O
treatment O
were O
offered O
it O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Patient-rated B-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
disability B-outcome ['Life-Impact']
, O
and O
functional B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
at O
5 O
and O
11 O
wk O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

During O
and O
following O
cancer O
treatment O
, O
children O
describe O
school O
related O
problems O
, O
reduced O
physical O
fitness O
, O
and O
problems O
related O
to O
interaction O
with O
peers O
. O
[]

Changes O
in O
meq O
of O
dietary B-outcome ['Life-Impact']
[ O
( O
Na+ B-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
K+ I-outcome ['Physiological-Clinical']
) O
- O
( O
Cl- B-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
SO4= O
) O
] O
were O
achieved O
by O
adding O
KCl O
, O
K2SO4 O
and O
( O
NH4 O
) O
2SO4 O
( O
anion O
diet O
) O
or O
K2CO3 O
( O
cation O
diet O
) O
to O
basal O
concentrates O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
rate O
of O
healing B-outcome ['Physiological-Clinical']
of O
['Physiological-Clinical']

Calcium O
supplementation O
was O
effective O
in O
increasing O
aBMD B-outcome ['Physiological-Clinical']
at O
regional O
sites O
over O
the O
first O
12-18 O
months O
, O
but O
these O
gains O
were O
not O
maintained O
to O
24 O
months O
. O
['Physiological-Clinical']

Symptoms O
were O
analyzed O
by O
repeated-measures O
analysis O
of O
variance O
. O
[]

The O
study O
aims O
to O
evaluate O
the O
effect O
of O
MSAT O
on O
acute O
low O
back O
pain O
with O
severe O
disability O
. O
[]

Thirty-two O
adults O
with O
asthma O
, O
randomized O
into O
two O
groups O
, O
underwent O
a O
10-week O
supervised O
rehabilitation O
program O
with O
emphasis O
on O
physical O
training O
. O
[]

Abnormal B-outcome ['Physiological-Clinical']
fetal I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
tracings I-outcome ['Physiological-Clinical']
were O
found O
in O
23 O
( O
23.2 O
% O
) O
of O
misoprostol-treated O
patients O
and O
35 O
( O
35.7 O
% O
) O
of O
dinoprostone-treated O
patients O
( O
relative O
risk O
0.73 O
, O
95 O
% O
confidence O
interval O
0.52 O
to O
1.01 O
, O
p O
= O
0.0546 O
) O
. O
['Physiological-Clinical']

The O
SPACE O
trial O
compared O
risk O
and O
effectiveness O
of O
stent-supported O
angioplasty O
( O
CAS O
) O
vs O
carotid O
endarterectomy O
( O
CEA O
) O
using O
a O
noninferiority O
design O
in O
patients O
with O
symptomatic O
stenoses O
. O
[]

Quality O
of O
life O
was O
assessed O
with O
the O
'Profile O
of O
Mood B-outcome ['Life-Impact']
States B-outcome ['Life-Impact']
' O
scale O
and O
the O
'Everyday O
Life B-outcome ['Life-Impact']
' O
questionnaire O
at O
baseline O
, O
treatment O
week O
( O
TW O
) O
8 O
, O
TW24 O
, O
TW48 O
, O
and O
at O
follow-up O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

These O
results O
suggest O
that O
the O
shear-induced O
pathway O
of O
aspirin-treated O
platelets O
is O
more O
vulnerable O
to O
cardiopulmonary O
bypass O
than O
the O
pathway O
in O
normal O
platelets O
and O
causes O
severe O
impairment O
of O
hemostasis O
afterward O
. O
[]

Voluntary B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
did O
not O
improve O
with O
clozapine O
. O
['Physiological-Clinical']

Both O
treatments O
were O
well O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact']

For O
those O
patients O
attaining O
12 O
weeks O
of O
treatment O
an O
overall B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
articular I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
and O
morning B-outcome ['Physiological-Clinical']
stiffness I-outcome ['Physiological-Clinical']
was O
found O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
of O
treatment O
on O
the O
58 O
ABC O
items O
were O
evaluated O
. O
[]

CONCLUSION O
Pregnancy B-outcome ['Physiological-Clinical']
rate O
and O
endometriosis B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rate O
are O
comparable O
among O
the O
3 O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Sequestered O
naltrexone O
is O
designed O
for O
release O
upon O
product O
tampering O
( O
crushing O
) O
to O
potentially O
mitigate O
morphine-induced O
subjective O
effects O
. O
[]

Group O
A O
( O
32 O
nurses O
) O
were O
trained O
only O
on O
a O
manikin O
and O
group O
B O
( O
20 O
nurses O
) O
were O
trained O
on O
a O
manikin O
and O
with O
live O
anaesthetised O
patient O
practice O
in O
theatre O
( O
five O
successful O
insertions O
) O
. O
[]

They O
were O
randomly O
assigned O
to O
undergo O
either O
radiofrequency O
ablation O
of O
the O
palate O
( O
RFAP O
) O
for O
a O
planned O
3-stage O
treatment O
or O
laser-assisted O
uvulopalatoplasty O
( O
LAUP O
) O
, O
also O
for O
3 O
stages O
of O
treatment O
, O
using O
a O
CO O
( O
2 O
) O
laser O
. O
[]

Variables O
of O
interest O
were O
resting B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
( O
RMT B-outcome ['Physiological-Clinical']
) O
, O
short-interval B-outcome ['Physiological-Clinical']
intra-cortical I-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SICI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
intracortical B-outcome ['Physiological-Clinical']
facilitation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ICF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
cortical B-outcome ['Physiological-Clinical']
silent I-outcome ['Physiological-Clinical']
period O
( O
CSP O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Transient B-outcome ['Physiological-Clinical']
lower O
esophageal B-outcome ['Physiological-Clinical']
sphincter I-outcome ['Physiological-Clinical']
relaxations B-outcome ['Life-Impact']
( O
TLESRs O
) O
are O
the O
main O
mechanism O
underlying O
gastroesophageal O
reflux O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

A O
series O
of O
studies O
were O
conducted O
to O
develop O
cartoon O
illustrations O
to O
accompany O
a O
standard B-outcome ['Life-Impact']
written I-outcome ['Life-Impact']
hostile B-outcome ['Life-Impact']
attributional B-outcome ['Life-Impact']
bias O
vignette O
measure O
( O
Study O
1 O
) O
, O
to O
determine O
initial O
['Life-Impact', 'Life-Impact', 'Life-Impact']

In O
patients O
with O
atrial O
fibrillation O
, O
it O
has O
shown O
excellent O
efficacy O
in O
some O
previous O
trials O
and O
minimal O
efficacy O
in O
others O
. O
[]

Inflammatory O
cells O
( O
> O
or O
= O
250 O
) O
were O
counted O
twice O
on O
coded O
cytospins O
and O
expressed O
as O
percentages O
of O
nonsquamous O
cells O
. O
[]

The O
CT O
follow-up O
in O
the O
DSV O
group O
was O
characterized O
by O
an O
only O
minimal O
( O
14 O
) O
or O
only O
slight O
( O
16 O
) O
reduction O
of O
ventricular O
size O
in O
the O
vast O
majority O
of O
cases O
. O
[]

In O
a O
double-blind O
, O
controlled O
study O
these O
patients O
were O
given O
either O
penicillin O
( O
10 O
( O
6 O
) O
IU O
three O
times O
daily O
for O
6 O
days O
; O
37 O
patients O
) O
or O
placebo O
( O
32 O
patients O
) O
. O
[]

Effect O
of O
intravenous O
dezocine O
on O
fentanyl-induced O
cough B-outcome ['Physiological-Clinical']
during O
general O
anesthesia O
induction O
: O
a O
double-blinded O
, O
prospective O
, O
randomized O
, O
controlled O
trial O
. O
['Physiological-Clinical']

Seventeen O
subjects O
underwent O
mitral O
valve O
replacement O
and O
19 O
patients O
coronary O
artery O
bypass O
grafting O
. O
[]

RESULTS O
Compared O
to O
lenses O
worn O
by O
subjects O
in O
Group O
I O
, O
lenses O
worn O
by O
Group O
II O
subjects O
showed O
significantly O
more O
mucous B-outcome ['Physiological-Clinical']
coating I-outcome ['Physiological-Clinical']
, O
lens B-outcome ['Physiological-Clinical']
binding I-outcome ['Physiological-Clinical']
, O
and O
corneal B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
over O
time O
( O
P O
< O
0.05 O
; O
ANCOVA O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
showed O
no O
intervention O
effect O
in O
both O
studies O
, O
with O
children B-outcome ['Physiological-Clinical']
's O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
decreasing O
over O
time O
regardless O
of O
whether O
they O
were O
in O
the O
story-reading O
( O
attention O
control O
) O
or O
FRIENDS O
condition O
. O
['Physiological-Clinical', 'Life-Impact']

Two O
studies O
utilizing O
1,862 O
yearling O
heifers O
were O
conducted O
to O
determine O
the O
effects O
of O
a O
fenbendazole O
oral O
drench O
in O
addition O
to O
an O
ivermectin O
pour-on O
( O
SG+IVPO O
) O
, O
compared O
with O
an O
ivermectin O
pour-on O
( O
IVPO O
) O
or O
a O
doramectin O
injectable O
( O
DMX O
) O
alone O
, O
on O
parasite B-outcome ['Physiological-Clinical']
burden I-outcome ['Physiological-Clinical']
, O
feedlot B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
, O
and O
carcass O
merit O
of O
feedlot O
cattle O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
there O
is O
no O
statistical O
significance O
, O
adjuvant O
therapy O
appears O
to O
result O
in O
an O
increase O
in O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
the O
group O
of O
patients O
with O
deep O
myometrial O
invasion O
and O
undifferentiated O
carcinoma O
. O
['Mortality']

Ninety-eight O
per O
cent O
of O
the O
intravenous O
digital O
subtraction O
angiograms O
were O
assessed O
as O
adequate O
for O
clinical O
management O
by O
the O
vascular O
surgeon O
. O
[]

The O
mean O
maximal B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
similar O
with O
both O
doses O
( O
35/20 O
mmHg O
supine O
, O
38/20 O
mmHg O
standing O
) O
, O
occurred O
on O
average O
within O
6 O
h O
of O
tablet O
ingestion O
, O
and O
was O
not O
accompanied O
by O
any O
significant O
change O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Children O
were O
studied O
at O
baseline O
and O
after O
12 O
weeks O
of O
treatment O
. O
[]

The O
tools O
were O
also O
reviewed O
by O
a O
plain O
language O
expert O
and O
the O
interdisciplinary O
research O
team O
. O
[]

Simvastatin O
reduces O
sympathetic O
outflow O
and O
augments O
endothelium-independent O
dilation O
in O
non-hyperlipidaemic O
primary O
hypertension O
. O
[]

All O
3 O
doses O
of O
mizolastine O
were O
more O
effective O
than O
placebo O
in O
suppressing O
wheal B-outcome ['Physiological-Clinical']
and O
flare O
reactions B-outcome ['Physiological-Clinical']
, O
and O
the O
antihistamine B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
highest O
at O
both O
the O
10- O
and O
15-mg O
dose O
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

One O
day O
after O
chemotherapy O
in O
losartan O
group O
vs. O
amlodipine O
group O
we O
observed O
a O
significant O
difference O
in O
urinary B-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
of O
18 O
mg/24 O
h O
vs. O
40 O
mg/24 O
h. O
Thirty O
days O
after O
chemotherapy O
we O
observed O
a O
significant O
difference O
in O
azotemia B-outcome ['Physiological-Clinical']
of O
0.0 O
mg/dl O
vs. O
3.8 O
mg/dl O
( O
p O
< O
0.001 O
) O
, O
serum B-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
of O
0.05 O
mg/dl O
vs. O
0.49 O
mg/dl O
( O
p O
< O
0.001 O
) O
, O
urinary B-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
of O
23 O
mg/24 O
h O
vs. O
0.0 O
mg/24 O
h O
, O
GFR O
of O
2 O
ml/min/1.73 O
m O
( O
2 O
) O
vs. O
-8 O
ml/min/1.73 O
m O
( O
2 O
) O
( O
p O
< O
0.05 O
) O
and O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
( O
SBP O
) O
of O
3.6 O
mmHg O
vs. O
0.8 O
mmHg O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mindfulness-based O
therapy O
in O
adults O
with O
an O
autism O
spectrum O
disorder O
: O
a O
randomized O
controlled O
trial O
. O
[]

The O
Low O
Energy O
Safety O
Study O
( O
LESS O
) O
tests O
the O
hypothesis O
that O
programming O
shocks O
to O
lower O
energy O
margins O
is O
safe O
and O
effective O
. O
[]

In O
the O
CES O
study O
, O
HYPO O
subjects O
reached O
HYD O
status O
at O
45 O
minutes O
in O
all O
conditions O
( O
W O
1.013 O
? O
[]

CONCLUSIONS O
In O
WRIST O
, O
not O
only O
was O
( O
192 O
) O
Ir O
therapy O
effective O
in O
reducing O
restenosis O
, O
but O
it O
also O
reduced O
the O
lesion O
length O
of O
treatment O
failures O
by O
50 O
% O
, O
and O
it O
was O
not O
associated O
with O
edge O
proliferation O
. O
[]

Human O
subjects O
performed O
either O
10 O
wk O
of O
training O
with O
an O
acute O
exercise O
bout O
before O
and O
after O
the O
training O
period O
, O
or O
a O
low-glycogen O
vs. O
normal-glycogen O
acute O
exercise O
trial O
. O
[]

The O
baseline O
( O
printed O
or O
Web-based O
) O
results O
were O
analyzed O
using O
ANOVA O
and O
chi-square O
tests O
to O
establish O
the O
differences O
in O
user O
characteristics O
between O
both O
intervention O
groups O
. O
[]

An O
open O
, O
randomized O
study O
evaluated O
the O
immune B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
safety O
of O
two O
different O
regimens O
of O
diphtheria-tetanus-acellular O
pertussis-hepatitis O
B-inactivated O
poliovirus-Haemophilus O
influenzae O
type O
b O
( O
DTPa-HBV-IPV-Hib O
) O
immunization O
in O
infants O
primed O
at O
birth O
with O
hepatitis O
B O
vaccine O
. O
['Physiological-Clinical']

The O
total O
number O
of O
patients O
with O
adverse B-outcome ['Adverse-effects']
experiences I-outcome ['Adverse-effects']
were O
10 O
( O
45.5 O
% O
) O
, O
14 O
( O
33.3 O
% O
) O
and O
11 O
( O
25 O
% O
) O
in O
groups O
1,2 O
and O
3 O
, O
respectively O
. O
['Adverse-effects']

CONCLUSION O
The O
r-HuEPO O
dose O
of O
400 O
U/kg O
appears O
significantly O
more O
effective O
than O
the O
200 O
U/kg O
to O
stimulate O
erythropoiesis O
in O
anemic O
sideropenic O
cancer O
patients O
. O
[]

Citalopram O
exhibited O
greater O
efficacy O
in O
anxious O
depressed O
patients O
, O
while O
reboxetine O
was O
more O
effective O
in O
retarded O
depressed O
patients O
. O
[]

RESULTS O
There O
were O
significant O
improvements O
in O
the O
language B-outcome ['Physiological-Clinical']
comprehension B-outcome ['Life-Impact']
domain O
of O
WeeFIM O
( O
p=0.02 O
) O
, O
self-care B-outcome ['Physiological-Clinical']
caregiver I-outcome ['Physiological-Clinical']
assistant O
domain O
of O
PEDI B-outcome ['Physiological-Clinical']
( O
p=0.028 O
) O
, O
and O
CGI-I B-outcome ['Physiological-Clinical']
( O
p=0.003 O
) O
in O
the O
EA O
group O
compared O
to O
the O
SEA O
group O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
findings O
support O
that O
KC O
is O
a O
safe O
and O
effective O
pain O
intervention O
in O
the O
neonatal O
intensive O
care O
unit O
. O
[]

Baseline O
demographic O
and O
clinical O
characteristics O
will O
be O
analysed O
for O
comparability O
between O
groups O
. O
[]

Blockade O
of O
cytotoxic O
T-lymphocyte O
antigen-4 O
by O
ipilimumab O
results O
in O
dysregulation O
of O
gastrointestinal O
immunity O
in O
patients O
with O
advanced O
melanoma O
. O
[]

We O
hypothesized O
that O
12 O
sessions O
of O
1 O
Hz O
rTMS O
bilaterally O
applied O
over O
the O
DLPFC O
will O
result O
in O
improvements O
reflected O
in O
both O
behavioral B-outcome ['Life-Impact']
and O
ERP O
measures O
. O
['Life-Impact']

An O
estimated O
15 O
% O
of O
patients O
with O
diabetes O
will O
develop O
a O
foot B-outcome ['Physiological-Clinical']
ulcer I-outcome ['Physiological-Clinical']
sometime O
in O
their O
life O
, O
making O
them O
30 O
to O
40 O
times O
more O
likely O
to O
undergo O
amputation O
due O
to O
a O
non-healing O
foot O
ulcer O
than O
the O
non-diabetic O
population O
. O
['Physiological-Clinical']

The O
randomised O
, O
double-blind O
, O
clinical O
trial O
involved O
40 O
women O
aged O
20-40 O
years O
. O
[]

Thirty O
patients O
undergoing O
resection O
of O
arteriovenous O
malformations O
with O
deliberate O
hypotension O
were O
randomized O
to O
receive O
1 O
of O
3 O
hypotensive O
agents O
. O
[]

DESIGN O
Prospective O
, O
randomized O
, O
and O
controlled O
. O
[]

Imagined O
movements O
imparted O
a O
further O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
, O
but O
only O
if O
they O
followed O
hand O
laterality O
recognition O
. O
['Physiological-Clinical', 'Life-Impact']

Sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
was O
longer O
for O
overweight O
patients O
who O
underwent O
OA O
than O
for O
normal-weight O
patients O
treated O
with O
the O
same O
technique O
( O
17 O
vs O
13 O
days O
, O
p O
< O
0.01 O
) O
. O
['Life-Impact']

Duration O
of O
untreated O
negative O
and O
positive O
symptoms O
of O
psychosis O
and O
cognitive O
impairment O
in O
first O
episode O
psychosis O
. O
[]

CONCLUSIONS O
Tumor O
budding O
independently O
predicted O
patient O
outcome O
in O
patients O
with O
AJCC/UICC O
stage O
II O
colorectal O
cancer O
and O
may O
therefore O
be O
used O
for O
accurate O
prognostication O
, O
patient O
counseling O
, O
and O
design O
of O
clinical O
trials O
by O
using O
integrated O
multimodal O
therapy O
. O
[]

A O
trend O
for O
a O
transient O
change O
on O
the O
CPRS O
was O
found O
that O
was O
possibly O
due O
to O
a O
placebo O
response O
. O
[]

It O
is O
known O
that O
the O
parahippocampal O
cortex O
is O
involved O
in O
object-place O
associations O
in O
spatial O
learning O
, O
but O
it O
remains O
unknown O
whether O
activity O
within O
this O
region O
is O
modulated O
by O
affective O
signals O
during O
navigation O
. O
[]

A O
hybrid O
technique O
using O
bipolar O
energy O
in O
transurethral O
prostate O
surgery O
: O
a O
prospective O
, O
randomized O
comparison O
. O
[]

These O
types O
of O
gastric O
myoelectrical O
activity O
and O
dysrhythmia O
can O
be O
measured O
by O
electrogastrography O
using O
cutaneous O
electrodes O
. O
[]

As O
expected O
, O
steady-state B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
levels O
were O
approximately O
threefold O
higher O
in O
obese O
than O
lean O
subjects O
( O
109.2 O
+/- O
10.2 O
pmol/l O
vs. O
518.4 O
+/- O
84.0 O
, O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical']

However O
, O
the O
majority O
did O
not O
have O
concerns O
about O
their O
sex O
life O
. O
[]

Two O
traditional O
dose-based O
models O
( O
Lyman-Kutcher-Burman O
( O
LKB O
) O
and O
Relative O
Seriality O
( O
RS O
) O
and O
a O
logistic O
model O
were O
fitted O
using O
a O
maximum O
likelihood O
approach O
. O
[]

Overall O
, O
patients O
reported O
that O
sodium O
phosphate O
and O
castor O
oil O
were O
easier O
to O
complete O
( O
p O
< O
0.05 O
) O
. O
[]

The O
plasma O
half-life O
of O
LY450139 O
was O
approximately O
2.5 O
hours O
. O
[]

The O
results O
indicate O
that O
the O
combination O
therapy O
in O
mild B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
moderate I-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
should O
not O
be O
initiated O
before O
individual O
response O
to O
single O
drug O
therapy O
is O
evaluated O
. O
['Physiological-Clinical']

In O
Rickard O
, O
Lau O
, O
and O
Pashler O
's O
( O
2008 O
) O
investigation O
of O
the O
lag O
effect O
on O
memory-based B-outcome ['Life-Impact']
automaticity I-outcome ['Life-Impact']
, O
response O
times O
were O
faster O
and O
proportion O
of O
trials O
retrieved O
was O
higher O
at O
the O
end O
of O
practice O
for O
short O
lag O
items O
than O
for O
long O
lag O
items O
. O
['Life-Impact']

Impact O
of O
a O
controlled O
heated O
breathing O
tube O
humidifier O
on O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
during O
CPAP O
therapy O
in O
a O
cool O
sleeping O
environment O
. O
['Physiological-Clinical']

The O
addition O
of O
psychotherapy O
to O
hypotensive O
drugs O
contributed O
to O
a O
higher B-outcome ['Physiological-Clinical']
hypotensive I-outcome ['Physiological-Clinical']
effect O
, O
long-term O
improvement O
of O
psychic B-outcome ['Physiological-Clinical']
condition I-outcome ['Physiological-Clinical']
, O
more O
active B-outcome ['Life-Impact']
attitude I-outcome ['Life-Impact']
to O
the O
treatment O
process B-outcome ['Life-Impact']
and O
psychic B-outcome ['Life-Impact']
adaptation I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSION O
These O
results O
indicate O
that O
low O
atrial O
DFTs O
can O
be O
achieved O
using O
a O
transvenous O
ventricular O
defibrillation O
lead O
. O
[]

In O
the O
intent-to-treat O
sample O
, O
which O
is O
perhaps O
more O
clinically O
relevant O
, O
only O
haloperidol O
proved O
superior O
to O
baseline O
on O
a O
global O
measure O
of O
autistic B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
severity I-outcome ['Life-Impact']
, O
as O
well O
as O
specific O
measures O
for O
irritability B-outcome ['Life-Impact']
and O
hyperactivity B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

BACKGROUND O
Paliperidone O
ER O
monotherapy O
was O
efficacious O
in O
treating O
acute O
mania O
in O
two O
3-week O
studies O
in O
patients O
with O
bipolar O
I O
disorder O
. O
[]

Competitive O
memory O
training O
( O
COMET O
) O
for O
treating O
low O
self-esteem B-outcome ['Life-Impact']
in O
patients O
with O
depressive O
disorders O
: O
a O
randomized O
clinical O
trial O
. O
['Life-Impact']

METHODS O
Recalcitrant O
foot O
and O
hand O
warts O
were O
randomly O
assigned O
to O
six O
repetitive O
ALA-PDT O
or O
placebo-PDT O
interventions O
combined O
with O
standard O
treatment O
encompassing O
paring O
followed O
by O
a O
keratolytic O
( O
Verucid O
) O
. O
[]

Side O
effects O
( O
e.g. O
, O
apnea B-outcome ['Physiological-Clinical']
occurring I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
more I-outcome ['Physiological-Clinical']
than I-outcome ['Physiological-Clinical']
30 I-outcome ['Physiological-Clinical']
seconds I-outcome ['Physiological-Clinical']
, O
involuntary B-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
, O
limb B-outcome ['Physiological-Clinical']
hypertonus I-outcome ['Physiological-Clinical']
) O
occurred O
at O
a O
similar O
incidence O
with O
both O
treatments O
, O
but O
pain O
following O
injection O
was O
greater O
with O
propofol O
( O
59 O
% O
vs. O
9 O
% O
) O
. O
['Physiological-Clinical']

Median O
observation O
time O
of O
nontransplanted O
living O
patients O
was O
7.6 O
years O
( O
7.9 O
years O
for O
IFN/HU O
and O
7.3 O
years O
for O
HU O
) O
. O
[]

CONCLUSIONS O
AND O
IMPLICATIONS O
Common O
genetic O
variation O
of O
ADORA2A O
is O
an O
important O
determinant O
of O
psychomotor O
vigilance O
in O
rested O
and O
sleep-deprived O
state O
. O
[]

Serial O
electrocardiographic O
( O
ECG O
) O
changes O
are O
a O
critical O
component O
of O
the O
diagnostic O
algorithm O
for O
classification O
of O
myocardial O
ischemic O
events O
in O
large-scale O
clinical O
trials O
. O
[]

In O
the O
recovery O
ward O
, O
patients O
who O
requested O
analgesia O
were O
allocated O
randomly O
to O
receive O
ketorolac O
30 O
mg O
or O
pethidine O
75 O
mg O
intramuscularly O
. O
[]

OBJECTIVES O
Hypertension O
is O
an O
important O
cardiovascular O
risk O
factor O
for O
the O
development O
of O
atrial O
fibrillation B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Individual O
concentrations O
in O
serum O
versus O
time O
data O
were O
evaluated O
by O
linear O
regression O
analysis O
. O
[]

The O
study O
evaluates O
a O
social-communication-based O
approach O
to O
autism O
intervention O
aimed O
at O
improving O
the O
social B-outcome ['Life-Impact']
interaction O
skills B-outcome ['Life-Impact']
of O
children O
with O
autism O
spectrum O
disorder O
. O
['Life-Impact', 'Life-Impact']

Only O
24.5 O
% O
of O
the O
patients O
had O
a O
positive O
family O
history O
of O
haemorrhoids O
. O
[]

Gentamicin O
4 O
mg/kg O
every O
day O
( O
OD O
) O
or O
gentamicin O
1.33 O
mg/kg O
three O
times O
daily O
( O
MD O
) O
( O
with O
dose-reduction O
in O
case O
of O
renal O
dysfunction O
) O
were O
given O
intravenously O
. O
[]

Initiated O
4 O
months O
after O
hospitalization O
, O
intervention O
groups O
of O
4 O
to O
8 O
women O
met O
for O
a O
total O
of O
20 O
sessions O
that O
were O
spread O
over O
a O
year O
. O
[]

Operators O
in O
complex O
event-driven O
domains O
must O
coordinate O
competing O
attentional O
demands O
in O
the O
form O
of O
multiple O
tasks O
and O
interactions O
. O
[]

All O
patients O
had O
undergone O
a O
9-month O
course O
of O
total O
androgen O
deprivation O
, O
with O
radiotherapy O
starting O
2 O
months O
after O
initiation O
of O
the O
total O
androgen O
deprivation O
. O
[]

In O
this O
group O
, O
there O
were O
27 O
serious O
adverse O
events O
, O
but O
only O
1.8 O
% O
of O
treatments O
were O
suspended O
because O
of O
adverse O
events O
. O
[]

The O
two O
groups O
did O
not O
differ O
significantly O
on O
the O
timed O
up O
and O
go O
test O
at O
either O
six O
or O
twelve O
months O
. O
[]

Systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
were O
151 O
+/- O
10/95 O
+/- O
5 O
mmHg O
after O
placebo O
and O
146 O
+/- O
5/94 O
+/- O
5 O
mmHg O
after O
metformin O
treatment O
( O
ns O
) O
. O
['Physiological-Clinical']

Psychosocial O
nursing O
therapy O
following O
sudden O
cardiac O
arrest O
: O
impact O
on O
two-year O
survival B-outcome ['Mortality']
. O
['Mortality']

BFST-D O
improved O
family B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
and O
problem B-outcome ['Life-Impact']
solving I-outcome ['Life-Impact']
relative O
to O
SC O
and O
modestly O
relative O
to O
ES O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
A O
significant O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
was O
obtained O
using O
the O
multifactorial O
strategy O
, O
as O
assessed O
by O
self-reported O
VAS O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

AIMS O
The O
aim O
of O
the O
study O
was O
to O
compare O
two O
methods O
in O
respect O
with O
the O
variation O
in O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
MAP O
) O
. O
['Physiological-Clinical']

BACKGROUND O
In O
the O
interest O
of O
preserving O
residual O
insulin O
secretory O
capacity O
present O
at O
the O
time O
of O
diagnosis O
with O
type O
1 O
diabetes O
( O
T1D O
) O
, O
we O
compared O
the O
efficacy O
of O
starting O
insulin O
pump O
therapy O
at O
diagnosis O
with O
standard O
multiple O
daily O
insulin O
injections O
( O
MDIs O
) O
. O
[]

Lipid B-outcome ['Physiological-Clinical']
and O
protein B-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
were O
determined O
as O
malondialdehyde B-outcome ['Physiological-Clinical']
and O
carbonyl B-outcome ['Physiological-Clinical']
group O
levels O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

SETTING O
Medical O
center O
. O
[]

TRIAL O
REGISTRATION O
ClinicalTrials.gov O
identifier O
: O
NCT00562939 O
. O
[]

METHODS O
We O
performed O
a O
cohort O
analysis O
of O
data O
from O
a O
randomized O
controlled O
trial O
of O
episiotomy O
conducted O
in O
3 O
Montreal O
hospitals O
in O
1990-1991 O
. O
[]

Infant B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
increases O
with O
both O
smoking O
cessation O
and O
smoking O
reduction O
, O
suggesting O
that O
peer O
counseling O
intervention O
programs O
may O
improve O
newborn B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
despite O
their O
failure O
to O
affect O
smoking O
cessation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Patients O
with O
stable O
CHF O
( O
NYHA O
II/III O
; O
59 O
( O
11 O
) O
years O
) O
were O
randomly O
assigned O
to O
a O
training O
group O
( O
n=18 O
; O
3-month O
aerobic O
program O
above O
standard O
treatment O
) O
or O
control O
group O
( O
n=16 O
; O
standard O
treatment O
without O
special O
advice O
for O
exercise O
) O
. O
[]

BMI O
explained O
27 O
% O
of O
inter-individual O
butyrate O
variation O
, O
whereas O
protein O
, O
starch O
, O
carbohydrate O
, O
fiber O
, O
and O
fat O
intake O
explained O
up O
to O
16 O
, O
6 O
, O
2 O
, O
4 O
, O
and O
2 O
% O
of O
butyrate O
variation O
, O
respectively O
. O
[]

p O
< O
0.07 O
) O
. O
[]

Tolfenamic O
acid O
and O
caffeine O
: O
a O
useful O
combination O
in O
migraine B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Additionally O
study O
was O
done O
to O
determine O
if O
the O
use O
of O
topical O
anesthetic O
decreased O
the O
pain B-outcome ['Physiological-Clinical']
of O
needle O
insertion O
with O
the O
P-ASA O
injection O
. O
['Physiological-Clinical']

Samples O
of O
vastus O
lateralis O
muscle O
were O
obtained O
from O
21 O
healthy O
subjects O
with O
different O
fitness O
levels O
. O
[]

At O
the O
dose O
schedules O
investigated O
, O
and O
in O
a O
heavily O
pretreated O
patient O
population O
, O
AMSA O
had O
activity O
in O
childhood B-outcome ['Physiological-Clinical']
leukemia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

4.4 O
% O
) O
than O
for O
NHL O
( O
7.4 O
? O
[]

We O
treated O
patients O
with O
coronary O
artery O
disease O
with O
sulfasalazine O
, O
an O
inhibitor O
of O
NF?B O
, O
and O
placebo O
in O
a O
randomized O
, O
double-blind O
, O
crossover O
study O
design O
. O
[]

Glycosaminoglycan O
heparin O
possesses O
multiple O
noncoagulant O
properties O
including O
antiinflammatory O
actions O
. O
[]

These O
changes O
were O
associated O
with O
improved O
clinical O
outcome O
, O
including O
fewer O
pulmonary O
infections O
and O
better O
wound O
healing O
. O
[]

Therapist-couple O
struggle O
vs. O
cooperation O
is O
linked O
to O
clinical O
outcome O
. O
[]

Study O
exclusion O
criteria O
were O
patient O
age O
greater O
than O
80 O
years O
, O
body O
mass O
index O
greater O
than O
40 O
, O
bilateral O
adrenalectomy O
and O
significant O
prior O
abdominal O
surgery O
in O
the O
quadrant O
of O
interest O
. O
[]

CONCLUSION O
Blocking O
Cys O
LT1 O
receptors O
for O
8 O
hours O
attenuated O
the O
early O
and O
late O
responses O
but O
did O
not O
interrupt O
the O
cascade O
of O
events O
leading O
to O
subsequent O
allergen-induced O
airway O
obstruction O
and O
hyperreactivity O
. O
[]

An O
important O
part O
of O
the O
mechanism O
of O
DVT O
prophylaxis O
with O
intermittent O
pneumatic O
compression O
( O
IPC O
) O
is O
reduced O
venous O
stasis O
with O
increased O
velocity O
of O
venous O
return O
. O
[]

Reduction O
in O
SVR B-outcome ['Physiological-Clinical']
as O
a O
function O
of O
increasingly O
severe O
disease O
was O
independent O
of O
age O
, O
percent O
African O
American O
, O
HCV O
genotype O
, O
HCV O
level O
, O
and O
type O
of O
prior O
therapy O
. O
['Physiological-Clinical']

Intensive O
treatment O
was O
most O
effective O
when O
begun O
early O
, O
before O
complications O
were O
detectable O
. O
[]

Phase O
1 O
peak O
voltage O
was O
increased O
in O
a O
stepwise O
progression O
from O
50 O
V O
to O
300V O
. O
[]

Effect O
of O
acebutolol O
on O
left O
ventricular O
performance O
. O
[]

This O
finding O
indicates O
that O
the O
combination O
of O
a O
dihydropyridine O
calcium O
antagonist O
+ O
a O
thiazide O
diuretic O
is O
probably O
devoid O
of O
any O
particular O
clinical O
significance O
in O
the O
treatment O
of O
uncomplicated O
essential O
hypertensives O
. O
[]

Here O
, O
we O
present O
a O
novel O
method O
to O
automatically O
create O
personalised O
3D O
models O
from O
standard O
2D O
hip O
radiographs O
. O
[]

The O
treatment O
was O
continued O
till O
the O
hematocrit B-outcome ['Physiological-Clinical']
level O
reached O
30 O
% O
. O
['Physiological-Clinical']

Preliminary O
evaluation O
of O
psychoeducational O
support O
interventions O
on O
quality O
of O
life O
in O
rural O
breast O
cancer O
survivors O
after O
primary O
treatment O
. O
[]

METHODS O
Thirty-six O
eyes O
of O
18 O
premature O
infants O
less O
than O
34 O
weeks O
gestational O
age O
and/or O
less O
than O
1600 O
g O
birth O
weight O
with O
prethreshold O
ROP O
were O
prospectively O
randomized O
to O
treatment O
with O
either O
indirect O
laser O
photocoagulation O
or O
cryotherapy O
. O
[]

Thirty-three O
patients O
had O
measurable O
disease O
and O
thirteen O
had O
only O
microscopic O
residual O
disease O
in O
the O
resection O
margins O
. O
[]

Personality O
( O
16-PF O
and O
IIQ O
) O
, O
quality O
of O
life O
( O
FLIC O
) O
, O
and O
depression B-outcome ['Life-Impact']
( O
BDI O
) O
scores O
were O
the O
endpoints O
for O
this O
study O
, O
and O
the O
questionnaires O
were O
completed O
by O
the O
patients O
at O
diagnosis O
, O
and O
up O
to O
9 O
months O
after O
diagnosis O
. O
['Life-Impact']

Z-250 O
composite O
resin O
was O
placed O
incrementally O
on O
the O
treated O
ceramic O
surface O
to O
build O
a O
6x6x6 O
mm O
block O
. O
[]

BACKGROUND O
Medication O
errors O
are O
an O
important O
public O
health O
concern O
, O
and O
poor O
understanding O
of O
medication O
labels O
are O
a O
root O
cause O
. O
[]

Memory O
aids O
in O
longitudinal O
health O
surveys O
: O
results O
from O
a O
field O
experiment O
. O
[]

Direct O
evidence O
for O
spinal O
cord O
involvement O
in O
placebo O
analgesia O
. O
[]

The O
other O
six O
secondary O
end-points O
and O
variables O
for O
safety O
analysis O
showed O
no O
difference O
between O
the O
two O
groups O
. O
[]

Pulsatile B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
is O
more O
efficient O
than O
continuous O
infusion O
in O
modulating O
islet O
cell O
function O
in O
normal O
subjects O
and O
patients O
with O
type O
1 O
diabetes O
. O
['Physiological-Clinical']

METHODS O
After O
initial O
colonoscopic O
polypectomy O
patients O
were O
randomized O
to O
surveillance O
with O
either O
2 O
years O
( O
group O
A O
) O
or O
4 O
years O
( O
group O
B O
) O
between O
colorectal O
examinations O
. O
[]

Comparative O
study O
of O
postoperative O
analgesia O
and O
sedation O
with O
trimeperidine O
and O
dexmedetomidine O
and O
their O
effects O
on O
haemodynamics O
and O
vegetative O
nervous O
system O
was O
performed O
. O
[]

RESULTS O
The O
overall O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate O
after O
a O
maximum O
of O
4 O
IUI O
cycles O
was O
comparable O
in O
cases O
with O
and O
without O
sperm O
treatment O
with O
PAF O
( O
12.24 O
% O
vs O
11.11 O
% O
) O
. O
['Physiological-Clinical']

Anastrozole O
single-dose O
protocol O
in O
women O
with O
oligo- O
or O
anovulatory O
infertility O
: O
results O
of O
a O
randomized O
phase O
II O
dose-response O
study O
. O
[]

Home-based O
nursing O
pulmonary O
rehabilitation O
can O
be O
an O
effective O
, O
inexpensive O
and O
accessible B-outcome ['Life-Impact']
programme O
for O
decreasing O
fatigue B-outcome ['Physiological-Clinical']
and O
improving O
ADL B-outcome ['Life-Impact']
and O
QOL B-outcome ['Life-Impact']
for O
patients O
with O
COPD O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Changes O
in O
cardiac B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
and O
function O
in O
hemodialysis O
patients O
during O
growth O
hormone O
treatment O
. O
['Physiological-Clinical']

Randomisation O
was O
done O
centrally O
with O
a O
computer-generated O
randomisation O
schedule O
and O
was O
stratified O
by O
baseline O
platelet O
count O
( O
? O
[]

Three O
diets O
were O
fed O
for O
8 O
weeks O
to O
103 O
healthy O
men O
and O
women O
aged O
22 O
to O
67 O
years O
at O
4 O
field O
centers O
. O
[]

The O
total O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
for O
the O
epidural O
group O
( O
median O
, O
101 O
hours O
) O
was O
significantly O
less O
than O
the O
PCA O
group O
( O
median O
, O
126 O
hours O
; O
P O
= O
.0498 O
) O
. O
['Resource-use']

Using O
repeated O
measures O
of O
symptom O
score O
, O
uroflowmetry O
and O
prostate O
specific O
antigen O
in O
the O
clinical O
management O
of O
prostate O
disease O
. O
[]

And O
changes O
of O
total O
triiodothyronine B-outcome ['Physiological-Clinical']
( O
['Physiological-Clinical']

SETTING O
The O
study O
involved O
two O
intensive O
care O
units O
in O
two O
adult O
acute O
care O
hospitals O
. O
[]

After O
fenfluramine O
treatment O
N1 B-outcome ['Physiological-Clinical']
latencies I-outcome ['Physiological-Clinical']
increased O
. O
['Physiological-Clinical']

Insertion B-outcome ['Life-Impact']
was O
more O
frequently O
successful O
( O
50/50 O
vs O
15/50 O
, O
P=0.0002 O
) O
and O
faster O
( O
35+/-17 O
s O
vs O
54+/-45 O
s O
, O
mean+/-SD O
, O
P=0.006 O
) O
with O
the O
bougie-guided O
technique O
. O
['Life-Impact']

Antibiotics B-outcome ['Resource-use']
for O
presumed O
secondary O
infections O
were O
given O
more O
often O
in O
the O
20-MU O
group O
( O
11 O
% O
) O
than O
in O
the O
placebo O
group O
( O
0 O
% O
) O
( O
P O
less O
than O
0.01 O
) O
. O
['Resource-use']

Patients O
were O
evaluated O
using O
four O
measures O
of O
dystonic B-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Plasma O
levels O
of O
lysozyme O
and O
beta-glucuronidase O
were O
determined O
using O
previously O
described O
methods O
. O
[]

Measurement O
of O
peptidase B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
evaluation O
of O
effectiveness O
of O
administration O
of O
minocycline O
for O
treatment O
of O
dogs O
with O
periodontitis O
. O
['Physiological-Clinical']

Western O
Ontario O
and O
McMaster O
University O
Osteoarthritis B-outcome ['Physiological-Clinical']
Index O
( O
WOMAC O
) O
scores O
, O
20 O
meters O
ambulatory B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
and O
knee O
range O
of O
motion B-outcome ['Life-Impact']
( O
ROM B-outcome ['Physiological-Clinical']
) O
were O
evaluated O
before O
and O
after O
therapy O
as O
the O
outcome O
measures O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Take O
a O
walk O
in O
the O
park O
? O
[]

Cost B-outcome ['Resource-use']
differences O
for O
the O
period O
preceding O
and O
subsequent O
to O
the O
cessation O
attempt O
were O
assessed O
by O
trial O
participants O
' O
12-month O
sustained O
quit O
status O
. O
['Resource-use']

OUTCOMES O
MEASURED O
Primary O
study O
outcomes O
were O
changes O
in O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
evaluate O
factors O
associated O
with O
visual B-outcome ['Physiological-Clinical']
field I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
, O
using O
all O
available O
follow-up O
through O
9 O
years O
after O
treatment O
initiation O
, O
in O
the O
Collaborative O
Initial O
Glaucoma O
Treatment O
Study O
( O
CIGTS O
) O
. O
['Physiological-Clinical']

For O
the O
acquisition O
of O
NCE O
4D O
MRA O
, O
a O
STAR O
spin O
tagging O
method O
was O
used O
, O
and O
a O
VFA O
sampling O
was O
applied O
in O
the O
data O
readout O
module O
instead O
of O
a O
constant O
flip O
angle O
. O
[]

Results O
were O
also O
combined O
with O
other O
second-line O
irinotecan O
trials O
. O
[]

The O
primary O
outcome O
was O
the O
amplitude O
of O
the O
RIII O
component O
of O
the O
nociceptive O
flexor O
reflex O
recorded O
by O
biceps O
femoris O
electromyogram O
in O
response O
to O
painful O
electrical O
sural O
nerve O
stimulation O
( O
RIII O
) O
, O
taken O
as O
a O
substitute O
for O
pain O
perception O
. O
[]

The O
new O
DSM-5 O
diagnostic O
criteria O
for O
autism O
spectrum O
disorders O
( O
ASDs O
) O
include O
sensory O
disturbances O
in O
addition O
to O
the O
well-established O
language O
, O
communication O
, O
and O
social O
deficits O
. O
[]

However O
, O
all O
patients O
had O
a O
unilateral O
uptake O
of O
the O
tracer O
on O
the O
side O
of O
the O
mass O
with O
suppression O
of O
the O
contralateral O
normal O
adrenal O
gland O
. O
[]

0.4 O
and O
5.8 O
? O
[]

Subjects O
with O
white-coat O
hypertension O
in O
Tecumseh O
appear O
to O
be O
at O
an O
increased O
risk O
for O
coronary B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
: O
they O
show O
repeated O
elevated O
clinic O
readings O
throughout O
their O
life O
time O
, O
their O
parents O
have O
higher O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
their O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
is O
decreased O
and O
insulin B-outcome ['Resource-use']
, O
cholesterol B-outcome ['Physiological-Clinical']
and O
triglycerides B-outcome ['Physiological-Clinical']
are O
elevated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

These O
discrepancies O
could O
be O
largely O
resolved O
by O
the O
instructional O
variable O
, O
in O
conjunction O
with O
different O
tone B-outcome ['Physiological-Clinical']
intensities I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
Physicians O
in O
the O
general O
medical O
setting O
commonly O
encounter O
but O
rarely O
counsel O
patients O
with O
dependent O
or O
harmful O
drinking O
behaviors O
. O
[]

Actuarial O
long-term O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
64 O
% O
for O
patients O
treated O
with O
GM-CSF O
and O
58 O
% O
for O
patients O
who O
received O
placebo O
after O
32 O
months O
of O
follow-up O
( O
P O
= O
0.15 O
) O
. O
['Mortality']

The O
telephone O
intervention O
did O
not O
have O
an O
effect O
on O
anxiety B-outcome ['Life-Impact']
and O
knowledge B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

An O
open O
label O
maintenance O
study O
. O
[]

A O
prospective O
randomized O
study O
of O
transurethral O
resection O
of O
the O
prostate O
and O
transurethral O
vaporization O
of O
the O
prostate O
as O
a O
therapeutic O
alternative O
in O
the O
management O
of O
men O
with O
BPH O
. O
[]

RESULTS O
Median O
PFS B-outcome ['Physiological-Clinical']
was O
4.7 O
and O
4.3 O
months O
for O
arms O
A O
and O
B O
, O
respectively O
( O
6-month O
PFS O
, O
27.3 O
% O
versus O
30.9 O
% O
) O
. O
['Physiological-Clinical']

Whereas O
the O
latter O
induces O
above O
all O
a O
systemic O
damage O
to O
the O
hemopoietic O
system O
, O
radiotherapy O
is O
a O
regional O
noxa O
. O
[]

Consecutive O
patients O
were O
randomized O
to O
undergo O
colonoscopy O
with O
either O
intermediate O
length O
adult O
colonoscope O
( O
CF-240I O
) O
or O
long O
pediatric O
colonoscope O
( O
PCF-240L O
) O
. O
[]

compared O
with O
that O
of O
a O
nutrition O
education O
intervention O
alone O
on O
caloric B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
weight O
gain O
in O
children O
with O
cystic O
fibrosis O
and O
pancreatic O
insufficiency O
. O
['Life-Impact']

RESULTS O
Groups O
were O
comparable O
across O
risk O
factors O
. O
[]

The O
experimental O
group O
and O
Control O
Group O
1 O
reported O
less O
mood B-outcome ['Life-Impact']
disturbance I-outcome ['Life-Impact']
at O
the O
end O
of O
all O
three O
phases O
, O
less O
loneliness B-outcome ['Life-Impact']
at O
the O
end O
of O
Phases O
II O
and O
III O
, O
and O
a O
higher-quality O
relationship B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
significant I-outcome ['Life-Impact']
other O
at O
the O
end O
of O
Phase O
II O
than O
did O
Control O
Group O
2 O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

We O
conclude O
that O
, O
although O
a O
lack O
of O
oral O
vaccine O
efficacy O
was O
suspected O
, O
larger O
study O
samples O
are O
needed O
to O
strengthen O
our O
conclusion O
. O
[]

Further O
, O
to O
investigate O
the O
link O
between O
team O
leader O
verbalisation O
accuracy O
and O
NFT O
. O
[]

METHODS O
A O
randomised O
, O
multi-centre O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
was O
carried O
out O
at O
19 O
centres O
in O
France O
, O
Germany O
and O
the O
Netherlands O
in O
patients O
with O
a O
clinical O
diagnosis O
of O
acute O
ischaemic O
stroke O
, O
and O
onset O
of O
symptoms O
within O
12 O
hours O
before O
start O
of O
study O
drug O
administration O
. O
[]

More O
recently O
, O
magnetic O
resonance O
imaging O
( O
MRI O
) O
has O
been O
proposed O
as O
an O
equivalent O
method O
, O
but O
this O
has O
not O
yet O
been O
fully O
validated O
. O
[]

Tympanic O
membrane O
temperature O
was O
monitored O
at O
anesthetic O
induction O
, O
throughout O
the O
isoflurane-fentanyl-N2O-O2 O
anesthetic O
, O
and O
for O
18 O
h O
postoperatively O
. O
[]

The O
airway B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
measured O
by O
FEV1 O
, O
followed O
by O
sputum O
induction O
with O
4.5 O
% O
NaCl O
, O
4 O
h O
postchallenge O
. O
['Physiological-Clinical']

3 O
. O
[]

Use O
of O
World O
Wide O
Web-based O
directories O
for O
tracing O
subjects O
in O
epidemiologic O
studies O
. O
[]

The O
children O
who O
received O
cocoa O
husk O
supplements O
tended O
to O
increase O
the O
number O
of O
bowel B-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
by O
more O
than O
that O
of O
the O
children O
of O
the O
placebo O
group O
. O
['Physiological-Clinical']

Moreover O
, O
the O
number O
of O
episodes B-outcome ['Physiological-Clinical']
of O
['Physiological-Clinical']

The O
results O
suggest O
that O
intravesical O
seeding O
of O
upper O
urinary O
tract O
urothelial O
carcinoma O
occurs O
during O
nephroureterectomy O
. O
[]

We O
conducted O
a O
prospective O
randomized O
trial O
of O
alpha-interferon O
given O
with O
or O
without O
indomethacin O
to O
patients O
with O
malignant O
melanoma O
to O
determine O
what O
effect O
, O
if O
any O
, O
indomethacin O
might O
have O
on O
the O
toxic B-outcome ['Adverse-effects']
, O
immunomodulatory B-outcome ['Physiological-Clinical']
, O
and O
therapeutic O
properties O
of O
interferon O
in O
this O
disease O
. O
['Adverse-effects', 'Physiological-Clinical']

The O
study O
differed O
from O
several O
other O
comparative O
studies O
in O
which O
the O
dose O
and O
choice O
of O
ACEI O
was O
left O
to O
individual O
physicians O
. O
[]

Assessment O
of O
the O
pain O
of O
blood-sugar O
testing O
: O
a O
randomised O
controlled O
trial O
. O
[]

BACKGROUND O
Delays O
and O
deficits O
in O
joint O
attention O
and O
symbolic O
play O
constitute O
two O
important O
developmental O
problems O
in O
young O
children O
with O
autism O
. O
[]

Median O
( O
interquartile O
range O
) O
PD20 O
in O
the O
three O
groups O
before O
and O
after O
treatment O
with O
clarithromycin O
were O
: O
arm O
A O
: O
0.3 O
( O
0.1-1 O
) O
and O
1.3 O
( O
0.6-2 O
) O
mg O
; O
arm O
B O
: O
0.4 O
( O
0.1-0.9 O
) O
and O
2 O
( O
2-2 O
) O
mg O
; O
and O
arm O
C O
: O
0.4 O
( O
0.1-0.9 O
) O
and O
0.3 O
( O
0.1-0.6 O
) O
mg O
, O
respectively O
. O
[]

Overall B-outcome ['Physiological-Clinical']
tooth I-outcome ['Physiological-Clinical']
width I-outcome ['Physiological-Clinical']
( O
including O
all O
tooth O
groups O
) O
in O
patients O
with O
palatally-displaced O
canines O
was O
significantly O
less O
than O
that O
in O
the O
control O
group O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
study O
the O
effects O
of O
a O
synthetic O
, O
dog-appeasing O
pheromone O
( O
sDAP O
) O
on O
the O
behavioral O
, O
neuroendocrine O
, O
immune O
, O
and O
acute-phase O
perioperative O
stress O
responses O
in O
dogs O
undergoing O
elective O
orchiectomy O
or O
ovariohysterectomy O
. O
[]

This O
model O
resulted O
in O
the O
best O
fit O
of O
wheal O
and O
flare O
data O
. O
[]

Of O
the O
total O
series O
, O
112 O
were O
treated O
by O
the O
same O
surgeon O
and O
confirmed O
pathologically O
as O
having O
invasive O
mammary O
carcinoma O
. O
[]

Speilberger B-outcome ['Physiological-Clinical']
's O
State O
Trait O
Inventory O
, O
the O
Side B-outcome ['Adverse-effects']
Effects O
Profile O
, O
and O
the O
Coping B-outcome ['Life-Impact']
Strategies I-outcome ['Life-Impact']
Profile O
were O
used O
along O
with O
a O
telephone O
survey O
to O
collect O
data O
. O
['Physiological-Clinical', 'Adverse-effects', 'Life-Impact']

Melatonin O
, O
but O
not O
placebo O
, O
reduced O
task-related B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
rostro-medial O
aspect O
of O
the O
occipital O
cortex O
during O
a O
visual-search O
task O
and O
in O
the O
auditory O
cortex O
during O
a O
music O
task O
. O
['Physiological-Clinical']

Thereafter O
there O
was O
no O
difference O
between O
the O
groups O
. O
[]

AUC O
( O
hpFr148 O
) O
and O
AUC O
( O
hpFr96 O
) O
) O
were O
significantly O
higher O
in O
the O
CQCP O
group O
than O
in O
the O
other O
treatment O
groups O
. O
[]

The O
effect O
of O
vitamin O
D3 O
( O
cholecalciferol O
) O
supplementation O
on O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
is O
uncertain O
. O
['Physiological-Clinical']

SETTING O
Departments O
of O
physical O
medicine O
and O
rehabilitation O
and O
orthopedics O
at O
a O
Finnish O
hospital O
. O
[]

Estimation O
of O
the O
predictive O
factor O
( O
gastric B-outcome ['Physiological-Clinical']
metaplasia I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
duodenum I-outcome ['Physiological-Clinical']
) O
was O
carried O
out O
in O
patients O
with O
non-complicated O
DU O
( O
Group O
1 O
; O
n O
= O
73 O
) O
, O
and O
with O
such O
complications O
as O
bleeding O
, O
perforation O
, O
penetration O
, O
pyloroduodenal O
stenosis O
( O
Group O
2 O
; O
n O
= O
51 O
) O
which O
were O
revealed O
within O
the O
8 O
to O
10 O
years O
of O
observation O
. O
['Physiological-Clinical']

Illuminance B-outcome ['Life-Impact']
was O
7.500 O
lux O
in O
the O
active O
treatment O
group O
and O
950 O
lux O
in O
the O
placebo O
group O
. O
['Life-Impact']

The O
time O
course O
of O
symptomatic O
relief O
for O
allergic O
rhinitis O
by O
steroids O
has O
not O
been O
examined O
in O
detail O
to O
date O
, O
although O
the O
onset O
of O
steroid O
action O
is O
one O
of O
the O
main O
discriminations O
between O
genomic O
and O
nongenomic O
actions O
of O
steroids O
. O
[]

Measurement O
of O
serum B-outcome ['Physiological-Clinical']
bile I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
in O
32 O
patients O
( O
18 O
ursodeoxycholic O
acid O
, O
14 O
placebo O
) O
indicated O
that O
at O
2 O
yr O
, O
ursodeoxycholic O
acid O
comprised O
65 O
% O
of O
serum O
bile O
acids O
in O
the O
treated O
group O
and O
7 O
% O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

METHODS O
In O
the O
Cholesterol O
and O
Recurrent O
Events O
( O
CARE O
) O
trial O
, O
576 O
postmenopausal O
women O
, O
between O
3 O
and O
20 O
months O
after O
MI O
, O
with O
a O
total O
cholesterol O
level O
< O
240 O
mg/dl O
and O
a O
low O
density O
lipoprotein O
cholesterol O
level O
115 O
to O
174 O
mg/dl O
, O
were O
randomized O
to O
receive O
pravastatin O
40 O
mg/day O
or O
matching O
placebo O
for O
a O
median O
follow-up O
period O
of O
5 O
years O
. O
[]

No O
relevant O
pain B-outcome ['Physiological-Clinical']
reduction O
was O
apparent O
in O
the O
morphine O
group O
. O
['Physiological-Clinical']

LIMITATIONS O
The O
study O
did O
not O
contain O
a O
group O
treated O
with O
a O
topical O
corticosteroid O
alone O
. O
[]

At O
high O
doses O
there O
is O
presumably O
an O
added O
effect O
of O
the O
high O
blood O
level O
of O
the O
basic O
substance.U O
[]

To O
test O
the O
hypothesis O
that O
gabapentin O
reduces O
the O
postoperative B-outcome ['Physiological-Clinical']
need I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
additional I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
treatment I-outcome ['Physiological-Clinical']
( O
postoperative O
opioid O
sparing O
effect O
of O
gabapentin O
in O
humans O
) O
, O
we O
gave O
1200 O
mg O
of O
gabapentin O
or O
15 O
mg O
of O
oxazepam O
( O
active O
placebo O
) O
2.5 O
h O
prior O
to O
induction O
of O
anaesthesia O
to O
patients O
undergoing O
elective O
vaginal O
hysterectomy O
in O
an O
active O
placebo-controlled O
, O
double O
blind O
, O
randomised O
study O
. O
['Physiological-Clinical']

We O
investigated O
whether O
low O
protein O
provision O
in O
utero O
affects O
the O
long-term O
response O
to O
adequate O
( O
AP O
) O
or O
LP O
provision O
after O
weaning O
in O
male O
mink O
. O
[]

Multiple O
regression O
analysis O
did O
not O
identify O
any O
independent O
relations O
between O
change O
in O
OP-1 B-outcome ['Physiological-Clinical']
, O
OP-2 B-outcome ['Physiological-Clinical']
, O
OP-3 B-outcome ['Physiological-Clinical']
, O
OP-sum B-outcome ['Physiological-Clinical']
and O
change O
in O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
or O
background O
variables O
, O
including O
change O
in O
age O
and O
duration O
of O
diabetes O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Interventions O
that O
counteract O
women O
's O
psychosocial O
stress O
have O
not O
previously O
been O
presented O
. O
[]

A O
> O
50 O
% O
decrease O
in O
prostrate B-outcome ['Physiological-Clinical']
specific I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
( O
PSA O
) O
was O
seen O
in O
9/27 O
( O
33.3 O
% O
) O
in O
the O
satraplatin O
plus O
prednisone O
arm O
vs. O
2/23 O
( O
8.7 O
% O
) O
on O
the O
prednisone O
alone O
arm O
. O
['Physiological-Clinical']

Patients O
received O
preoperative O
radiation O
therapy O
had O
significantly O
higher O
rate O
of O
minor B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
than O
patients O
underwent O
surgery O
only O
( O
18.2 O
% O
vs. O
3.9 O
% O
, O
P O
= O
0.039 O
) O
. O
['Adverse-effects']

We O
hypothesized O
that O
higher O
amounts O
of O
wear O
particles O
result O
in O
increased O
release O
of O
metal B-outcome ['Physiological-Clinical']
ions I-outcome ['Physiological-Clinical']
and O
ultimately O
lead O
to O
an O
increased O
incidence O
of O
metal B-outcome ['Physiological-Clinical']
allergy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
most O
common O
adverse O
events O
during O
phase O
1 O
were O
weight O
increase O
( O
25.2 O
% O
) O
, O
somnolence O
( O
14.8 O
% O
) O
, O
and O
vomiting O
( O
14.2 O
% O
) O
; O
and O
, O
during O
phase O
2 O
( O
aripiprazole O
vs O
placebo O
) O
, O
they O
were O
upper O
respiratory O
tract O
infection O
( O
10.3 O
% O
vs O
2.3 O
% O
) O
, O
constipation O
( O
5.1 O
% O
vs O
0 O
% O
) O
, O
and O
movement O
disorder O
( O
5.1 O
% O
vs O
0 O
% O
) O
. O
[]

No O
significant O
differences O
were O
observed O
in O
the O
proportion O
of O
each O
group O
that O
experienced O
a O
major B-outcome ['Physiological-Clinical']
deterioration I-outcome ['Physiological-Clinical']
or O
improvement B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
nutritional I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Environmental O
enrichment O
as O
an O
effective O
treatment O
for O
autism B-outcome ['Life-Impact']
: O
a O
randomized O
controlled O
trial O
. O
['Life-Impact']

Time B-outcome ['Resource-use']
spent I-outcome ['Resource-use']
in I-outcome ['Resource-use']
the I-outcome ['Resource-use']
neonatal I-outcome ['Resource-use']
intensive I-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit I-outcome ['Resource-use']
did O
not O
differ O
between O
groups O
. O
['Resource-use']

STUDY O
OBJECTIVE O
To O
evaluate O
the O
influence O
of O
spinal O
versus O
general O
anesthesia O
on O
bladder B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
and O
intraabdominal B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
elderly O
males O
undergoing O
elective O
transurethral O
resection O
of O
the O
prostate O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Age-related B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
two O
Haemophilus O
influenzae O
type O
b O
vaccines O
. O
['Physiological-Clinical']

The O
role O
of O
IgA O
in O
providing O
protection O
against O
influenza O
in O
children O
vaccinated O
with O
live O
attenuated O
influenza O
vaccine O
( O
LAIV O
) O
has O
not O
been O
well O
described O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
We O
compared O
the O
cost-benefits O
of O
the O
two O
methods O
using O
a O
randomized O
, O
prospective O
, O
6-month O
, O
crossover O
design O
in O
10 O
adult O
type O
I O
diabetic O
patients O
. O
['Resource-use']

The O
trial O
was O
designed O
to O
assess O
the O
impact O
of O
the O
Asha-Life O
intervention O
engaging O
with O
an O
HIV-trained O
village O
woman O
, O
Asha O
( O
Accredited O
Social O
Health O
Activist O
) O
, O
to O
participate O
in O
the O
care O
of O
women O
living O
with O
AIDS O
( O
WLA O
) O
, O
along O
with O
other O
health O
care O
providers O
compared O
to O
a O
Usual O
Care O
group O
. O
[]

Objective O
and O
subjective O
cures O
were O
defined O
as O
no O
leakage O
on O
the O
stress O
test O
and O
responses O
on O
the O
Sandvik O
questionnaire O
, O
respectively O
. O
[]

BACKGROUND O
AND O
OBJECTIVES O
Transversus O
abdominis O
plane O
( O
TAP O
) O
block O
has O
been O
shown O
to O
reduce O
pain O
and O
analgesic O
requirements O
after O
abdominal O
surgery O
. O
[]

In O
patients O
with O
arterial O
occlusion O
of O
the O
lower O
extremities O
with O
baseline O
dyslipidaemia O
statin O
treatment O
proved O
protective B-outcome ['Physiological-Clinical']
, O
i.e O
. O
['Physiological-Clinical']

Randomized O
trial O
of O
intensive O
early O
intervention O
for O
children O
with O
pervasive O
developmental O
disorder O
. O
[]

The O
children O
were O
randomly O
divided O
into O
two O
groups O
( O
intervention O
and O
control O
) O
by O
means O
of O
a O
simple O
drawing O
. O
[]

II O
: O
Continued O
lifestyle O
intervention O
combined O
with O
captopril O
or O
atenolol O
. O
[]

Toxicity B-outcome ['Adverse-effects']
was O
mainly O
restricted O
to O
bladder B-outcome ['Physiological-Clinical']
irritation I-outcome ['Physiological-Clinical']
in O
about O
10 O
% O
of O
patients O
in O
each O
instillation O
arm O
. O
['Adverse-effects', 'Physiological-Clinical']

Each O
specimen O
was O
embedded O
in O
a O
self-cured O
acrylic O
resin O
block O
from O
2.0 O
mm O
apical O
to O
the O
margins O
of O
a O
cast O
Ni-Cr O
alloy O
crown O
, O
then O
loaded O
at O
150 O
degrees O
from O
the O
long O
axis O
in O
a O
universal O
testing O
machine O
at O
a O
crosshead O
speed O
of O
1.0 O
mm/minute O
until O
fracture O
. O
[]

Are O
brand-name O
and O
generic O
warfarin O
interchangeable O
? O
[]

An O
open O
multicenter O
efficacy O
and O
safety O
evaluation O
of O
amlodipine O
in O
the O
treatment O
of O
symptomatic O
myocardial O
ischemia O
. O
[]

The O
incidence O
of O
wound B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
among O
the O
ampicillin/sulbactam O
patients O
was O
2 O
% O
and O
among O
cefoxitin O
patients O
it O
was O
7 O
% O
( O
p O
< O
0.004 O
) O
. O
['Physiological-Clinical']

An O
intervention O
and O
intervention O
+ O
prompt O
condition O
will O
be O
evaluated O
for O
effects O
on O
smoking B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
, O
compared O
with O
a O
no O
information O
control O
condition O
. O
['Life-Impact']

Although O
TOISD O
might O
not O
be O
necessarily O
on O
surgical O
incisional O
site O
not O
infested O
with O
bacteria O
for O
the O
initial O
post-operation O
days O
, O
it O
is O
helpful O
in O
preventing O
further O
transcription O
and O
division O
for O
opportunistic O
bacteria O
, O
thus O
might O
reduce O
the O
risk O
of O
superficial O
incisional O
SSI O
. O
[]

The O
Silicone O
Study O
Group O
. O
[]

2.8 O
) O
, O
( O
12.1 O
? O
[]

0.25 O
mm O
) O
. O
[]

Both O
groups O
maintained O
significant O
BMI-Z O
reduction O
at O
follow-up O
; O
changes O
were O
not O
significantly O
different O
between O
groups O
. O
['Physiological-Clinical']

The O
hypothesis O
was O
that O
, O
although O
the O
concentration O
of O
bupivacaine O
( O
0.1 O
% O
) O
was O
low O
to O
minimize O
its O
adverse O
effects O
, O
if O
the O
infusion O
rate O
of O
a O
fentanyl/bupivacaine O
solution O
was O
closely O
adjusted O
according O
to O
need O
, O
the O
presence O
bupivacaine O
would O
reduce O
the O
requirement O
for O
epidural O
fentanyl O
. O
[]

Of O
these O
, O
14 O
patients O
were O
treated O
with O
emergency O
angioplasty O
and O
14 O
patients O
received O
intracoronary O
streptokinase O
. O
[]

BACKGROUND O
Intramuscular O
pethidine O
is O
routinely O
used O
throughout O
the O
UK O
for O
labour O
analgesia O
. O
[]

Bismuth O
subsalicylate O
in O
the O
treatment O
of O
gastritis O
due O
to O
Campylobacter O
pylori O
. O
[]

CONCLCUSION O
: O
Oral O
sildenafil O
was O
as O
effective O
as O
injection O
papaverine O
in O
evaluating O
erectile O
dysfunction O
. O
[]

Stability B-outcome ['Physiological-Clinical']
was O
achieved O
at O
3 O
months O
, O
with O
96 O
% O
of O
subjects O
( O
86 O
of O
90 O
) O
having O
less O
than O
1.00 O
D O
of O
change O
from O
their O
previous O
examination O
. O
['Physiological-Clinical']

The O
majority O
( O
51 O
% O
) O
of O
these O
participants O
reported O
only O
mild B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

These O
results O
indicate O
that O
priming O
with O
recombinant O
FSH O
before O
harvesting O
of O
immature O
oocytes O
from O
patients O
with O
PCOS O
may O
improve O
the O
maturational B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
oocytes I-outcome ['Physiological-Clinical']
and O
the I-outcome ['Physiological-Clinical']
implantation B-outcome ['Physiological-Clinical']
rate O
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cleaved I-outcome ['Physiological-Clinical']
embryos I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Eighteen O
sedentary O
male O
volunteers O
were O
randomly O
divided O
into O
CLA O
and O
Placebo O
( O
PLC O
) O
supplementation O
groups O
. O
[]

The O
studies O
found O
pharmacokinetics O
and O
pharmacodynamics O
similar O
to O
those O
of O
amlodipine O
besylate O
. O
[]

MATERIALS O
AND O
METHODS O
Patients O
diagnosed O
with O
bone O
metastases O
< O
or O
= O
6 O
weeks O
prior O
to O
first O
visit O
were O
enrolled O
. O
[]

The O
patients O
were O
randomised O
into O
a O
control O
group O
( O
n O
= O
10 O
) O
and O
an O
experimental O
group O
( O
n O
= O
8 O
) O
. O
[]

[ O
Initial O
nuclear O
magnetic O
resonance O
tomography O
results O
of O
the O
treatment O
course O
of O
avascular O
femur O
head O
necrosis O
after O
femoral O
core O
decompression O
] O
. O
[]

BACKGROUND O
Thrombocytopenia O
and O
platelet O
dysfunction O
are O
major O
mechanisms O
of O
cardiopulmonary O
bypass-induced O
postoperative O
hemorrhage O
. O
[]

Median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
was O
9.4 O
months O
in O
the O
white O
light O
group O
and O
16.4 O
months O
in O
the O
fluorescence O
group O
( O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical']

Response O
was O
defined O
as O
a O
> O
or O
= O
25 O
% O
reduction O
in O
delta O
value O
. O
[]

The O
supported O
housing O
facilities O
with O
residents O
and O
staff O
were O
randomly O
assigned O
to O
either O
a O
health O
intervention O
programme O
or O
a O
control O
programme O
with O
an O
aesthetic O
content O
. O
[]

No O
significant O
differences O
were O
observed O
in O
the O
mean O
1-y O
change O
in O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
between O
the O
control O
, O
medium-dairy O
, O
and O
high-dairy O
groups O
( O
0.8 O
+/- O
2.8 O
, O
0.7 O
+/- O
3.0 O
, O
and O
1.5 O
+/- O
4.1 O
kg O
, O
respectively O
; O
P O
= O
0.45 O
) O
. O
['Physiological-Clinical']

In O
this O
article O
, O
we O
report O
results O
from O
one O
intervention O
, O
offering O
non-attendees O
a O
high-risk O
human O
papillomavirus O
( O
HPV O
) O
self-test O
. O
[]

However O
, O
it O
is O
invasive O
and O
may O
be O
associated O
with O
pain O
and O
priapism O
. O
[]

Our O
results O
suggest O
the O
existence O
of O
brain O
regions O
with O
representations O
of O
musical O
structure O
that O
are O
distinct O
from O
high-level O
linguistic O
representations O
and O
lower-level O
acoustic O
representations O
. O
[]

A O
prospective O
multicenter O
trial O
was O
conducted O
in O
155 O
consecutive O
patients O
with O
Stage O
IV O
breast O
cancer O
randomly O
allocated O
to O
receive O
either O
( O
1 O
) O
vincristin O
( O
V O
) O
1.2 O
mg/m2 O
( O
maximum O
dose O
, O
2 O
mg O
) O
, O
Adriamycin O
( O
A O
) O
( O
doxorubicin O
) O
40 O
mg/m2 O
, O
and O
cyclophosphamide O
( O
C O
) O
500 O
mg/m2 O
, O
all O
intravenously O
on O
day O
1 O
, O
every O
4 O
weeks O
, O
in O
combination O
with O
medroxyprogesteron O
acetate O
( O
MPA O
) O
600 O
mg O
orally O
on O
days O
1 O
through O
14 O
, O
500 O
mg O
intramuscularly O
on O
days O
1 O
through O
28 O
, O
and O
twice O
weekly O
afterwards O
( O
combined O
chemoendocrine O
approach O
) O
or O
( O
2 O
) O
the O
same O
combination O
chemotherapy O
( O
VAC O
) O
for O
three O
cycles O
alternating O
with O
MPA O
in O
the O
above-mentioned O
dosage O
during O
8 O
weeks O
( O
alternating O
chemoendocrine O
approach O
) O
. O
[]

Whereas O
older O
HES O
specimen O
tended O
to O
accumulate O
in O
the O
plasma O
and O
to O
cause O
negative O
effects O
on O
hemostasis O
, O
more O
recent O
products O
, O
e.g. O
, O
HES O
130/0.4 O
, O
are O
characterised O
by O
improved O
pharmacological O
properties O
. O
[]

Laparoscopic O
hysterectomy O
: O
is O
dissecting O
the O
ureter O
necessary O
? O
[]

To O
trigger O
immunologic B-outcome ['Physiological-Clinical']
priming I-outcome ['Physiological-Clinical']
, O
patients O
underwent O
between O
one O
and O
five O
priming O
sessions O
with O
exposure O
to O
3,500 O
grains/m O
( O
3 O
) O
( O
+/-500 O
) O
of O
ragweed O
pollen O
in O
an O
environmental O
exposure O
chamber O
. O
['Physiological-Clinical']

This O
result O
provides O
the O
first O
evidence O
for O
the O
activation O
of O
object-based O
representations O
during O
visual O
search O
task O
performance O
and O
further O
supports O
the O
notion O
that O
both O
excitatory B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
inhibitory I-outcome ['Physiological-Clinical']
guidance I-outcome ['Physiological-Clinical']
mechanisms I-outcome ['Physiological-Clinical']
are O
involved O
in O
target O
location O
in O
visual O
search O
. O
['Physiological-Clinical']

Surgical B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
was O
recorded O
in O
12 O
patients O
( O
12.2 O
% O
) O
and O
was O
similar O
in O
Group O
1 O
and O
2 O
patients O
( O
14.3 O
and O
10.2 O
% O
respectively O
; O
P=0.538 O
) O
. O
['Physiological-Clinical']

extract O
on O
selected O
parameters O
of O
pro-oxidant-antioxidant B-outcome ['Physiological-Clinical']
equilibrium I-outcome ['Physiological-Clinical']
and O
cytokine B-outcome ['Physiological-Clinical']
synthesis I-outcome ['Physiological-Clinical']
in O
rowers O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
trial O
is O
registered O
with O
the O
International O
Standard O
Randomised O
Controlled O
Number O
26727615 O
with O
the O
name O
ALL97 O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
the O
use O
of O
the O
AccuTouch O
flexible O
endoscopy O
simulator O
improves O
the O
early B-outcome ['Life-Impact']
part I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
curve O
in O
colonoscopy O
training O
. O
['Life-Impact']

Plasma B-outcome ['Physiological-Clinical']
levels O
were O
measured O
to O
study O
the O
dose-effect O
relationship O
. O
['Physiological-Clinical']

Volunteers O
, O
aged O
25 O
45 O
, O
all O
nonsmokers O
, O
gave O
blood O
samples O
before O
and O
after O
a O
12-wk O
carotenoid O
supplementation O
regime O
. O
[]

This O
measurement O
was O
performed O
twice O
for O
every O
participant O
, O
and O
the O
average O
of O
the O
2 O
measurements O
was O
calculated O
. O
[]

It O
has O
gathered O
an O
enormous O
volume O
of O
data O
on O
the O
natural O
history O
of O
the O
myeloproliferative O
diseases O
and O
in O
particular O
on O
the O
nature O
of O
the O
prevalent O
complications O
, O
such O
as O
thrombotic O
events O
and O
hematologic O
and O
nonhematologic O
malignancies O
. O
[]

A O
total O
of O
106 O
patients O
were O
randomized O
1:1 O
to O
sildenafil O
( O
n=53 O
) O
or O
placebo O
( O
n=53 O
) O
. O
[]

Epileptogenic O
activity O
of O
folic O
acid O
after O
drug O
induces O
SLE O
( O
folic O
acid O
and O
epilepsy O
) O
OBJECTIVE O
To O
study O
the O
effect O
of O
folic O
acid-containing O
multivitamin O
supplementation O
in O
epileptic O
women O
before O
and O
during O
pregnancy O
in O
order O
to O
determine O
the O
rate O
of O
structural O
birth O
defects O
and O
epilepsy-related O
side O
effects O
. O
[]

Eighty-three O
patients O
with O
small O
cell O
lung O
cancer O
were O
randomized O
with O
or O
without O
using O
a O
traditional O
Chinese O
Kidney-tonifying O
decoction O
( O
Liu O
Wei O
Di O
Huang O
or O
Jin O
Gui O
Shen O
Qi O
medicinal O
decoction O
) O
in O
chemotherapy O
or O
radiotherapy O
courses O
. O
[]

RESULTS O
Single O
30- O
and O
200-mg O
doses O
of O
R317573 O
resulted O
in O
dose-related O
changes O
in O
rCMglu B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Uncorrected O
visual O
acuity O
( O
UCVA O
) O
, O
best-corrected O
visual O
acuity O
( O
BCVA O
) O
, O
manifest O
refraction O
, O
CS O
by O
means O
of O
the O
Functional O
Acuity O
Contrast O
Test O
, O
and O
HOAs O
by O
means O
of O
Zywave O
aberrometry O
were O
evaluated O
preoperatively O
and O
6 O
months O
after O
retreatment O
. O
[]

STUDY O
OBJECTIVE O
To O
compare O
the O
clinical O
efficacy O
of O
a O
rapid O
injection O
of O
propofol O
in O
regard O
to O
pain O
and O
ability O
to O
facilitate O
Laryngeal O
Mask O
Airway O
( O
LMA O
) O
insertion O
. O
[]

Vitamin O
K O
antagonists O
( O
VKAs O
) O
are O
effective O
for O
stroke O
prevention O
in O
patients O
with O
atrial O
fibrillation O
( O
AF O
) O
but O
are O
difficult O
to O
use O
. O
[]

The O
effect O
of O
a O
parent-implemented O
imitation O
intervention O
on O
spontaneous B-outcome ['Life-Impact']
imitation I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
young O
children O
with O
autism O
. O
['Life-Impact']

The O
amount O
of O
supplemental O
i.v O
. O
[]

Graft-versus-host O
disease O
( O
GVHD O
) O
prophylaxis O
was O
tacrolimus O
and O
mini-methorexate O
( O
MTX O
) O
, O
and O
those O
who O
had O
an O
unrelated O
or O
1 O
antigen-mismatched O
donor O
received O
low-dose O
rabbit-ATG O
( O
Thymoglobulin? O
) O
. O
[]

In O
addition O
, O
82 O
of O
these O
patients O
received O
cytotoxic O
therapy O
( O
cyclophosphamide O
, O
methotrexate O
, O
and O
5-fluorouracil O
) O
and O
46 O
received O
tamoxifen O
. O
[]

The O
results O
showed O
that O
there O
were O
no O
statistically O
significant O
differences O
between O
the O
2 O
treatment O
modalities O
regarding O
BOP B-outcome ['Physiological-Clinical']
and O
PPD B-outcome ['Physiological-Clinical']
at O
any O
observation O
time O
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTERVENTIONS O
Each O
head O
trauma O
patient O
requiring O
rapid-sequence O
intubation O
who O
met O
the O
inclusion O
criteria O
received O
standard O
rapid-sequence O
intubation O
maneuvers O
and O
lidocaine O
( O
1 O
mg/kg O
) O
IV O
. O
[]

Six O
subjects O
withdrew O
because O
of O
adverse O
effects O
, O
and O
1 O
was O
unavailable O
for O
follow-up O
. O
[]

In O
four O
patients O
in O
groups O
I O
and O
II O
, O
in O
whom O
attempts O
to O
puncture O
the O
IJV O
had O
not O
been O
successful O
, O
this O
could O
subsequently O
be O
achieved O
with O
ultrasonographic O
aid O
. O
[]

METHODS O
AND O
MATERIALS O
Between O
January O
2003 O
and O
December O
2007 O
, O
168 O
patients O
were O
randomized O
to O
receive O
either O
hypofractionated O
( O
62 O
Gy O
in O
20 O
fractions O
within O
5 O
weeks O
, O
4 O
fractions/wk O
) O
or O
conventionally O
fractionated O
( O
80 O
Gy O
in O
40 O
fractions O
within O
8 O
weeks O
) O
three-dimensional O
conformal O
radiotherapy O
to O
the O
prostate O
and O
seminal O
vesicles O
. O
[]

Measurement O
of O
health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
multiple O
myeloma O
. O
['Life-Impact']

Between-group O
comparisons O
revealed O
no O
significant O
differences O
in O
clinical B-outcome ['Physiological-Clinical']
outcome O
variables O
. O
['Physiological-Clinical']

Age O
, O
sex O
, O
and O
body O
mass O
index O
were O
matched O
among O
groups O
. O
[]

According O
to O
Choi O
, O
both O
regimens O
( O
chemotherapy O
or O
immunotherapy O
antibody O
) O
revealed O
similar O
results O
to O
the O
Hans O
algorithm O
on O
5 O
years O
OS O
as O
well O
as O
3 O
year O
EFS O
when O
comparing O
GCB O
versus O
ABC O
or O
non-GCB O
subgroups O
. O
[]

The O
SEPS O
subset O
of O
randomized O
patients O
with O
C4 O
disease O
experienced O
significant O
decrease O
in O
AVP O
, O
objectively O
supporting O
the O
effectiveness O
of O
reflux O
surgery O
in O
advanced O
CVI O
. O
[]

CONCLUSIONS O
This O
study O
to O
evaluate O
the O
safety O
and O
adverse-event B-outcome ['Adverse-effects']
profile I-outcome ['Adverse-effects']
of O
VX-770 O
showed O
that O
VX-770 O
was O
associated O
with O
within-subject O
improvements O
in O
CFTR B-outcome ['Physiological-Clinical']
and O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Results O
held O
across O
formats O
and O
suggest O
that O
parent O
management O
training O
can O
provide O
an O
[]

Treatment O
of O
bulimia B-outcome ['Life-Impact']
nervosa I-outcome ['Life-Impact']
with O
lithium O
carbonate O
. O
['Life-Impact']

At O
5 O
years O
, O
we O
evaluated O
the O
cumulative O
incidence O
of O
allergic B-outcome ['Physiological-Clinical']
diseases I-outcome ['Physiological-Clinical']
( O
eczema B-outcome ['Physiological-Clinical']
, O
food B-outcome ['Physiological-Clinical']
allergy I-outcome ['Physiological-Clinical']
, O
allergic B-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
results O
of O
our O
study O
suggest O
that O
irrigation O
fluid O
temperature O
is O
not O
a O
factor O
responsible O
for O
altering O
the O
core O
body B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
TURP O
. O
['Physiological-Clinical']

The O
primary O
endpoint O
was O
median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
the O
intention-to-treat O
population O
. O
['Mortality']

Randomised O
trial O
of O
effect O
of O
amiodarone O
on O
mortality B-outcome ['Mortality']
in O
patients O
with O
left-ventricular O
dysfunction O
after O
recent O
myocardial O
infarction O
: O
EMIAT O
. O
['Mortality']

We O
studied O
whether O
these O
very O
instructions O
have O
any O
impact O
on O
P3 B-outcome ['Physiological-Clinical']
amplitude O
. O
['Physiological-Clinical']

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
feasibility O
and O
anti-inflammatory B-outcome ['Physiological-Clinical']
effects O
of O
100-125 O
ppm O
CO O
inhalation O
in O
patients O
with O
stable O
COPD O
. O
['Physiological-Clinical']

Vitamin O
C O
does O
not O
seem O
to O
be O
an O
effective O
prophylactic O
or O
therapeutic O
agent O
for O
upper O
respiratory O
illness O
. O
[]

Patients O
( O
55 O
met O
criteria O
for O
efficacy O
analysis O
) O
received O
standard O
of O
care O
, O
which O
included O
products O
that O
provide O
a O
moist O
environment O
, O
offloading O
diabetic O
shoes O
and O
socks O
, O
debridement O
, O
wound O
evaluation O
, O
and O
measurement O
. O
[]

Four O
major O
AWS B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
( O
tremor B-outcome ['Physiological-Clinical']
, O
sweating B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
restlessness B-outcome ['Life-Impact']
) O
were O
scored O
, O
and O
the O
administration O
of O
additional B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
was O
registered O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

In O
iron O
depletion O
, O
less O
iron O
may O
be O
available O
for O
carcinogenesis O
through O
free-radical O
mediated O
mechanisms O
and O
for O
promotion O
of O
tumor O
growth O
. O
[]

OBJECTIVE O
The O
objective O
was O
to O
develop O
effective O
weight-loss O
methods O
for O
women O
who O
have O
had O
breast O
cancer O
, O
because O
obesity O
may O
result O
in O
an O
adverse O
prognosis O
. O
[]

For O
clinical O
efficacy O
and O
safety O
analyses O
, O
PBO-randomized O
patients O
were O
re-baselined O
prior O
to O
first O
RTX O
treatment O
and O
the O
data O
were O
pooled O
with O
RTX-randomized O
patient O
data O
. O
[]

Radiotherapy O
increased O
postoperative B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
complications B-outcome ['Adverse-effects']
and O
reduced O
local B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
distant I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
, O
but O
had O
no O
effect O
on O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality', 'Adverse-effects', 'Physiological-Clinical', 'Mortality']

pCR B-outcome ['Resource-use']
was O
achieved O
in O
3 O
patients O
( O
8 O
% O
) O
. O
['Resource-use']

Results O
of O
these O
studies O
indicated O
that O
selamectin O
was O
highly O
effective O
in O
the O
control O
of O
flea O
infestations O
in O
dogs O
and O
cats O
without O
the O
need O
for O
simultaneous O
treatment O
of O
the O
environment O
or O
of O
in-contact O
animals O
and O
also O
was O
beneficial O
in O
alleviating O
signs O
associated O
with O
FAD O
. O
[]

Simultaneously O
, O
this O
intervention O
increased O
interferon-? O
( O
IFN-? O
) O
level O
and O
unchanged O
interleukin-4 O
level O
, O
as O
well O
as O
, O
decreased O
myeloperoxidase O
( O
MPO O
) O
and O
interleukin-6 O
levels O
in O
plasma O
. O
[]

MATERIALS O
AND O
METHODS O
Thirty-three O
edentulous O
patients O
who O
experienced O
difficulties O
when O
using O
hard O
denture O
bases O
because O
of O
changes O
in O
denture-supporting O
tissues O
were O
accepted O
for O
the O
study O
and O
randomly O
received O
Molloplast O
B O
, O
GC O
Reline O
Soft O
, O
Silagum O
Comfort O
, O
or O
Mollosil O
Plus O
relines O
. O
[]

Health B-outcome ['Physiological-Clinical']
advice I-outcome ['Physiological-Clinical']
was O
given O
to O
76 O
% O
of O
905 O
participants O
following O
health O
checks O
. O
['Physiological-Clinical']

Involvement O
of O
cholecystokininA O
receptors O
in O
transient O
lower O
esophageal O
sphincter O
relaxations O
triggered O
by O
gastric O
distension O
. O
[]

The O
complete O
( O
IOP O
< O
22 O
mm O
Hg O
without O
medication O
) O
and O
qualified O
( O
IOP O
< O
22 O
mm O
Hg O
with O
or O
without O
medication O
) O
success B-outcome ['Physiological-Clinical']
rates O
at O
the O
end O
of O
the O
follow-up O
period O
were O
42.5 O
% O
and O
72.5 O
% O
in O
the O
DS O
group O
and O
50 O
% O
and O
95 O
% O
in O
the O
DSMMC O
group O
. O
['Physiological-Clinical']

[ O
Cardiac O
protection O
is O
a O
clinical O
evidence O
] O
. O
[]

Data O
from O
a O
cross-over O
, O
randomised O
, O
open-label O
bioequivalence O
study O
in O
healthy O
volunteers O
. O
[]

All O
patients O
received O
epidural O
anaesthesia O
with O
0.25 O
% O
bupivacaine O
and O
were O
then O
randomly O
allocated O
to O
one O
of O
three O
groups O
. O
[]

Patients O
on O
pentoxifylline O
had O
the O
fewest O
side O
effects O
of O
all O
oral O
therapies O
. O
[]

Error O
sensitivity O
can O
be O
readily O
examined O
by O
measuring O
event-related O
potentials O
( O
ERP O
) O
associated O
with O
responses O
to O
errors O
, O
the O
fronto-central O
error-related B-outcome ['Life-Impact']
negativity O
( O
ERN O
) O
, O
and O
the O
error-related B-outcome ['Life-Impact']
positivity O
( O
Pe O
) O
. O
['Life-Impact', 'Life-Impact']

While O
in O
the O
regular O
group O
, O
it O
was O
used O
only O
under O
the O
condition O
that O
grade O
II O
neutropenia O
occurred O
. O
[]

The O
FEV1/FVC O
( O
% O
) O
and O
the O
FEV1 O
% O
were O
calculated O
. O
[]

Promoting O
health O
in O
schools O
through O
a O
board O
game O
. O
[]

BACKGROUND O
This O
study O
aimed O
to O
assess O
the O
impact O
of O
leak O
compensation O
capabilities O
during O
pressure- O
and O
volume-limited O
non-invasive O
positive-pressure O
ventilation O
( O
NPPV O
) O
in O
COPD O
patients O
. O
[]

In O
group O
1 O
there O
was O
complete O
suppression O
of O
endogenous B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
primary O
outcome O
was O
the O
total O
number O
of O
themes B-outcome ['Life-Impact']
recalled I-outcome ['Life-Impact']
per I-outcome ['Life-Impact']
participant I-outcome ['Life-Impact']
. O
['Life-Impact']

RESULTS O
[]

MAIN O
OUTCOME O
MEASURE O
( O
S O
) O
Rate O
of O
premature B-outcome ['Physiological-Clinical']
LH I-outcome ['Physiological-Clinical']
surge I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Similar O
patient O
numbers O
had O
BTM O
measured O
post O
EOT O
. O
[]

Two-way O
analysis O
of O
variance O
tests O
indicated O
no O
significant O
differences O
among O
treatment O
groups O
for O
( O
1 O
) O
pain B-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
cough I-outcome ['Physiological-Clinical']
, O
( O
2 O
) O
narcotic B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
intake I-outcome ['Resource-use']
, O
( O
3 O
) O
FVC B-outcome ['Physiological-Clinical']
, O
( O
4 O
) O
FEV1 B-outcome ['Physiological-Clinical']
, O
and O
( O
5 O
) O
PEFR B-outcome ['Physiological-Clinical']
( O
p O
> O
0.05 O
) O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Previous O
research O
from O
the O
Cash O
and O
Counseling O
Demonstration O
and O
Evaluation O
( O
CCDE O
) O
programs O
in O
New O
Jersey O
, O
Arkansas O
, O
and O
Florida O
suggests O
that O
consumers O
' O
control O
over O
personal O
care O
greatly O
improves O
their O
satisfaction O
with O
care B-outcome ['Life-Impact']
arrangements I-outcome ['Life-Impact']
and O
their O
outlook B-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

BACKGROUND O
The O
aim O
of O
the O
study O
was O
to O
investigate O
safety O
, O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
risperidone O
in O
comparison O
with O
haloperidol O
in O
the O
long-term O
treatment O
of O
autistic O
disorder O
. O
['Life-Impact']

The O
aim O
of O
this O
study O
was O
to O
compare O
a O
combination O
of O
Lactobacillus O
GG O
( O
LGG O
) O
and O
galacto-oligosaccharides O
( O
GOS O
) O
with O
LGG O
on O
its O
own O
, O
and O
their O
effects O
on O
the O
intestinal O
microbiota O
in O
school-aged O
children O
. O
[]

RESULTS O
The O
primary O
efficacy O
endpoint O
was O
ovulation B-outcome ['Physiological-Clinical']
induction I-outcome ['Physiological-Clinical']
as O
measured O
by O
follicle B-outcome ['Physiological-Clinical']
?17 O
mm O
, O
pre-ovulatory O
estradiol O
( O
E O
2 O
) O
?400 O
pmol/l O
and O
mid-luteal O
phase O
progesterone O
( O
P O
4 O
) O
?25 O
nmol/l O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eur O
Child O
Adolesc O
Psychiatr O
11:266-272 O
, O
2002 O
) O
. O
[]

Pedantic O
speaking O
style O
differentiates O
Asperger O
syndrome O
from O
high-functioning O
autism O
. O
[]

Using O
individualized O
, O
anatomically O
defined O
anterior O
and O
posterior O
insula O
and O
dACC O
as O
regions O
of O
interest O
( O
ROI O
) O
, O
whole O
brain O
rsFC O
was O
performed O
using O
each O
ROI O
as O
a O
seed O
. O
[]

The O
latter O
observation O
highlights O
the O
need O
to O
examine O
steroid-induced O
changes O
closely O
in O
the O
airway O
structure O
in O
patients O
with O
asthma O
. O
[]

METHODS O
It O
is O
a O
prospective O
, O
randomized O
, O
double O
blind O
, O
placebo O
controlled O
multinational O
multicenter O
trial O
. O
[]

This O
knowledge O
might O
profitably O
be O
incorporated O
into O
the O
evaluation O
of O
existing O
treatments O
. O
[]

The O
aetiology O
of O
failed B-outcome ['Life-Impact']
insertion I-outcome ['Life-Impact']
was O
similar O
for O
the O
digital O
and O
introducer O
tool O
techniques O
in O
94 O
% O
( O
33/35 O
) O
of O
patients O
. O
['Life-Impact']

The O
ADDITION-Cambridge O
trial O
protocol O
: O
a O
cluster O
-- O
randomised O
controlled O
trial O
of O
screening O
for O
type O
2 O
diabetes O
and O
intensive O
treatment O
for O
screen-detected O
patients O
. O
[]

The O
characteristics O
of O
labour B-outcome ['Physiological-Clinical']
were O
similar O
in O
both O
groups O
. O
['Physiological-Clinical']

One O
hundred O
consecutive O
patients O
with O
symptomatic O
gallstones O
without O
complications O
were O
randomized O
into O
groups O
; O
group O
T O
had O
two O
metal O
clips O
( O
titan O
clip O
ETHICONR O
) O
, O
group O
R O
( O
laproclipR O
Davis O
and O
Geck O
) O
had O
one O
absorbable O
clip O
applied O
on O
the O
cystic O
duct O
and O
cystic O
artery O
. O
[]

CONCLUSION O
It O
is O
possible O
to O
validate O
statistically O
the O
distinction O
between O
discrete O
epileptic O
syndromes O
. O
[]

[ O
Gluten-free O
diet O
in O
infantile O
autism O
. O
[]

No O
differences O
were O
found O
in O
thermal B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
( O
esophagus O
( O
p=0.67 O
) O
and O
duodenum O
( O
p=0.17 O
) O
) O
, O
sensory B-outcome ['Physiological-Clinical']
response O
to O
electrical B-outcome ['Physiological-Clinical']
stimulation I-outcome ['Physiological-Clinical']
( O
esophagus O
( O
p=0.57 O
) O
and O
duodenum B-outcome ['Physiological-Clinical']
( O
p=0.52 O
) O
) O
or O
induced O
somatic B-outcome ['Physiological-Clinical']
referred O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
patients O
have O
been O
divided O
into O
two O
groups O
according O
to O
ST-T O
changes O
during O
chest O
pain O
: O
29 O
with O
ST O
elevation O
( O
group O
A O
) O
and O
41 O
with O
other O
repolarization O
abnormalities O
( O
group O
B O
) O
. O
[]

We O
undertook O
a O
randomised O
comparison O
of O
the O
safety O
and O
outcome O
of O
LC O
and O
open O
cholecystectomy O
( O
OC O
) O
in O
patients O
with O
acute O
cholecystitis O
. O
[]

CONCLUSION O
The O
combination O
of O
fluoxetine O
plus O
local O
application O
of O
lidocaine O
ointment O
was O
found O
to O
be O
more O
effective O
than O
fluoxetine O
alone O
in O
the O
treatment O
of O
premature O
ejaculation O
. O
[]

Overall O
, O
99 O
% O
of O
women O
found O
office O
polypectomy O
to O
be O
acceptable B-outcome ['Life-Impact']
, O
with O
only O
one O
woman O
in O
the O
electrosurgical O
resection O
group O
considering O
the O
procedure O
unacceptable B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Gastric O
distension O
was O
induced O
by O
inflation O
of O
400 O
ml O
of O
air O
. O
[]

MATERIAL O
AND O
METHODS O
This O
was O
a O
prospective O
, O
randomized O
, O
9-month O
study O
of O
the O
effects O
of O
low O
doses O
of O
losartan O
( O
25 O
mg O
; O
n O
= O
18 O
) O
versus O
enalapril O
( O
10 O
mg O
; O
n O
= O
18 O
) O
versus O
the O
combination O
of O
losartan O
( O
25 O
mg O
) O
and O
enalapril O
( O
10 O
mg O
) O
( O
n O
= O
16 O
) O
on O
proteinuria B-outcome ['Physiological-Clinical']
, O
kidney B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
metabolic B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
in O
54 O
patients O
with O
biopsy-proven O
chronic O
glomerulonephritis O
, O
hypertension O
and O
normal O
or O
slightly O
impaired O
kidney O
function O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Open O
, O
randomised O
, O
2-way O
crossover O
, O
clinical O
pharmacology O
study O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
social O
class O
or O
demographic O
characteristics O
of O
the O
two O
treatment O
groups O
or O
in O
the O
proportion O
of O
each O
group O
completing O
the O
trial O
. O
[]

We O
conclude O
that O
high-functioning O
adults O
with O
ASC O
demonstrate O
atypical B-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
modulation I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
imitation I-outcome ['Life-Impact']
. O
['Life-Impact']

Results O
showed O
that O
the O
treatment O
group O
demonstrated O
significant O
improvement O
in O
language B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
interaction I-outcome ['Life-Impact']
, O
but O
not O
in O
stereotyped B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
motor I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
compared O
to O
the O
control O
group O
. O
['Life-Impact', 'Life-Impact']

The O
biological O
factors O
in O
the O
etiopathogenesis O
and O
management O
of O
cervical O
spondylosis O
. O
[]

RESULTS O
There O
were O
76 O
bleeding B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
and O
14 O
related B-outcome ['Mortality']
deaths I-outcome ['Mortality']
( O
18 O
% O
) O
; O
nine O
of O
these O
deaths O
occurred O
within O
24 O
h O
of O
bleeding B-outcome ['Physiological-Clinical']
onset O
( O
two O
at O
home O
, O
two O
during O
hospital O
transfer O
, O
and O
five O
in O
hospital O
, O
a O
mean O
of O
2.5 O
h O
after O
onset O
; O
six O
involved O
Child O
C O
patients O
) O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

A O
significantly O
smaller O
volume O
of O
0.2 O
% O
ropivacaine-4 B-outcome ['Resource-use']
microg I-outcome ['Resource-use']
fentanyl I-outcome ['Resource-use']
solution I-outcome ['Resource-use']
was O
used O
, O
whereas O
the O
0.1 O
% O
ropivacaine-2 O
microg O
fentanyl O
group O
used O
a O
significantly O
greater O
amount O
of O
ropivacaine O
and O
fentanyl O
. O
['Resource-use']

Clay O
modeling O
reduced O
overall B-outcome ['Life-Impact']
craving I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
and O
strength O
of O
craving B-outcome ['Life-Impact']
imagery I-outcome ['Life-Impact']
, O
and O
reduced O
the O
frequency O
of O
thoughts B-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
chocolate I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

and O
( O
4 O
) O
is O
this O
effect O
different O
for O
low- O
and O
high-magnitude O
perturbations O
? O
[]

After O
adjusting O
for O
baseline O
eGFR O
, O
each O
5-ml/min/1.73 O
m O
( O
2 O
) O
increase O
in O
eGFR O
at O
1 O
year O
was O
associated O
with O
a O
lower O
risk O
of O
subsequent O
HF O
hospitalization O
( O
hazard O
ratio O
0.85 O
, O
95 O
% O
confidence O
interval O
0.77 O
to O
0.94 O
, O
p O
= O
0.002 O
) O
. O
[]

RESULTS O
There O
was O
a O
significant O
increase O
( O
16 O
% O
) O
in O
the O
percentage O
of O
outdoor O
workers O
who O
were O
using O
a O
high O
level O
of O
solar O
protection O
at O
posttest O
compared O
to O
pretest O
in O
the O
intervention O
group O
, O
but O
there O
was O
no O
change O
in O
the O
control O
group O
. O
[]

Twenty-three O
percent O
had O
complete O
remission O
; O
39 O
% O
had O
partial O
remission O
; O
28 O
% O
had O
no O
change O
; O
and O
3 O
% O
had O
disease O
progression O
. O
[]

SUMMARY O
OF O
BACKGROUND O
DATA O
Evidence O
comparing O
the O
long-term O
relative O
effectiveness O
of O
common O
treatment O
strategies O
offered O
to O
low O
back O
pain O
patients O
in O
managed O
care O
is O
lacking O
. O
[]

vessel O
wall O
without O
any O
signs O
of O
atherosclerotic O
disease O
) O
. O
[]

On O
the O
CGI-C O
, O
60 O
% O
( O
n O
= O
6 O
) O
of O
patients O
in O
the O
ZNS O
group O
felt O
that O
their O
tremor B-outcome ['Physiological-Clinical']
was O
unchanged O
, O
while O
the O
remaining O
patients O
felt O
that O
their O
tremor B-outcome ['Physiological-Clinical']
was O
minimally O
improved O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Participants O
were O
randomized O
into O
one O
of O
two O
intervention O
groups O
: O
a O
tailored O
intervention O
, O
in O
which O
they O
received O
personalized O
skin O
cancer O
education O
through O
the O
mail O
; O
or O
a O
control O
group O
who O
received O
generic O
skin O
cancer O
information O
materials O
. O
[]

Total O
analgesic B-outcome ['Resource-use']
( I-outcome ['Resource-use']
paracetamol I-outcome ['Resource-use']
) I-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
was O
significantly O
more O
in O
Group O
I O
( O
697.6 O
+/- O
240.7 O
mg O
) O
than O
in O
the O
groups O
receiving O
caudal O
neostigmine O
( O
II O
- O
248.0 O
+/- O
178.4 O
; O
III O
- O
270.2 O
+/- O
180.8 O
and O
IV O
-230.6 O
+/- O
166.9 O
mg O
; O
P O
< O
0.05 O
) O
. O
['Resource-use']

BACKGROUND O
There O
is O
a O
growing O
debate O
about O
injectable O
opioid O
treatment O
programs O
in O
many O
Western O
countries O
. O
[]

RESULTS O
The O
mean O
follow-up O
period O
was O
2.21 O
years O
+/- O
0.26 O
( O
1.89-3.07 O
) O
. O
[]

The O
primary O
outcome O
measure O
was O
the O
Clinical O
Global O
Impressions O
Improvement O
and O
Severity O
Scales O
( O
CGI-I O
and O
CGI-S O
) O
; O
secondary O
outcomes O
were O
the O
Preschool B-outcome ['Life-Impact']
Language I-outcome ['Life-Impact']
Scale-4 O
( O
PLS-4 O
) O
, O
Social O
Responsiveness O
Scale O
( O
SRS O
) O
, O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
( O
ABC O
) O
, O
and O
Vineland O
Adaptive O
Behavior O
Scales O
( O
Vineland O
) O
. O
['Life-Impact', 'Life-Impact']

Similarly O
for O
anaerobic B-outcome ['Physiological-Clinical']
bacterial I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
, O
92 O
% O
and O
88 O
% O
maximum O
reductions O
were O
recorded O
on O
Day O
1 O
and O
Day O
8 O
, O
which O
again O
were O
significantly O
lower O
than O
placebo O
for O
up O
to O
3 O
hours O
post-dose O
. O
['Physiological-Clinical']

These O
data O
do O
, O
however O
, O
provide O
valuable O
information O
on O
RU O
associated O
with O
COPD O
and O
insights O
into O
adjustments O
associated O
with O
changes O
in O
disease O
course O
. O
[]

Peri- O
and O
postoperative O
outcome O
data O
at O
3 O
months O
were O
obtained O
. O
[]

OBJECTIVES O
A O
recent O
patient O
series O
reported O
the O
incidental O
findings O
of O
improved O
social O
and O
language O
skills O
in O
3 O
children O
with O
autistic O
spectrum O
disorders O
after O
the O
administration O
of O
secretin O
, O
a O
peptide O
hormone O
. O
[]

METHODS O
This O
study O
examined O
nonelderly O
Medicaid O
beneficiaries O
in O
New O
Jersey O
with O
a O
diagnosis O
of O
mental O
illness O
and O
compared O
and O
contrasted O
the O
experiences O
of O
those O
in O
New O
Jersey O
's O
CCDE O
program O
( O
N=109 O
) O
and O
those O
who O
received O
services O
provided O
by O
an O
agency O
( O
N=119 O
) O
. O
[]

Recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
the O
fluorescence O
diagnosis O
group O
was O
89.6 O
% O
after O
12 O
and O
24 O
months O
compared O
with O
73.8 O
% O
and O
65.9 O
% O
, O
respectively O
, O
in O
the O
white O
light O
group O
( O
p O
= O
0.004 O
) O
. O
['Mortality']

However O
, O
no O
evidence O
of O
systemic B-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
regulation I-outcome ['Physiological-Clinical']
was O
seen O
in O
infected O
participants O
. O
['Physiological-Clinical']

The O
effect O
of O
L-arginine O
and O
citrulline O
on O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
in O
heart O
failure O
with O
preserved O
ejection O
fraction O
. O
['Physiological-Clinical']

RESULTS O
Significantly O
( O
P O
< O
0.05 O
) O
more O
of O
the O
human O
embryos O
cultured O
in O
Plasmatein O
supplemented O
medium O
reached O
the O
four-cell O
or O
greater O
stage B-outcome ['Physiological-Clinical']
by O
40 O
hr O
postinsemination O
than O
a O
comparable O
group O
cultured O
in O
HSA O
alone O
. O
['Physiological-Clinical']

However O
, O
the O
number O
of O
patients O
was O
small O
and O
confirmation O
is O
necessary O
. O
[]

BACKGROUND O
A O
pilot O
study O
was O
conducted O
to O
investigate O
the O
toxicity B-outcome ['Adverse-effects']
and O
tolerance B-outcome ['Life-Impact']
to O
low-dose O
subcutaneous O
interleukin-2 O
( O
IL-2 O
) O
for O
patients O
with O
resected O
renal O
cell O
carcinoma O
( O
RCC O
) O
at O
high O
risk O
for O
recurrent O
disease O
( O
TNM O
stages O
III O
and O
IV O
resected O
distant O
metastases O
) O
. O
['Adverse-effects', 'Life-Impact']

By O
day O
7 O
, O
all O
tested O
doses O
of O
rhuGM-CSF O
resulted O
in O
an O
increase O
in O
the O
absolute B-outcome ['Physiological-Clinical']
monocyte I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AMC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
compared O
with O
placebo-treated O
neonates O
. O
['Physiological-Clinical']

Relationship O
between O
biliary O
and O
serum O
bile O
acids O
and O
response O
to O
ursodeoxycholic O
acid O
in O
patients O
with O
primary O
biliary O
cirrhosis O
. O
[]

Men O
whose O
levels O
for O
both O
25 O
( O
OH O
) O
D O
and O
1,25 O
( O
OH O
) O
2D O
were O
below O
( O
versus O
above O
) O
the O
median O
had O
a O
significantly O
increased O
risk O
of O
aggressive B-outcome ['Physiological-Clinical']
prostate I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
( O
odds O
ratio O
[ O
OR O
] O
= O
2.1 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
1.2-3.4 O
) O
, O
although O
the O
interaction O
between O
the O
two O
vitamin O
D O
metabolites O
was O
not O
statistically O
significant O
( O
pinteraction O
= O
0.23 O
) O
. O
['Physiological-Clinical']

CONCLUSION O
Obstetric O
care O
practitioners O
can O
improve O
their O
alcohol O
intervention O
skills O
through O
the O
use O
of O
a O
20-minute O
videotaped O
instruction O
in O
motivational O
interviewing O
. O
[]

RESULTS O
Between O
February O
2003 O
and O
July O
2005 O
, O
25 O
patients O
were O
enrolled O
. O
[]

This O
trial O
is O
strategically O
designed O
as O
a O
vanguard O
for O
a O
fully-powered O
trial O
of O
women O
who O
will O
be O
evaluated O
for O
breast O
cancer O
recurrence O
and O
disease-free O
survival O
. O
[]

Evidence O
from O
three O
systematic O
reviews O
demonstrates O
that O
sterile O
water O
injections O
( O
SWI O
) O
provide O
statistically O
and O
clinically O
significant O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
women O
experiencing O
continuous O
lower O
back O
pain O
during O
labour O
. O
['Physiological-Clinical']

METHODS O
A O
multi-center O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
was O
conducted O
. O
[]

The O
median O
time B-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
MV I-outcome ['Life-Impact']
was O
5 O
days O
for O
both O
groups O
( O
p O
= O
0.120 O
) O
. O
['Life-Impact']

The O
current O
study O
used O
a O
randomized O
controlled O
design O
to O
test O
the O
effectiveness O
of O
a O
16-week O
ToM O
treatment O
in O
8-13 O
year O
old O
children O
with O
ASD O
and O
normal O
IQs O
( O
n O
= O
40 O
) O
. O
[]

All O
six O
with O
no O
difference O
received O
aspirin O
plus O
omeprazole O
in O
the O
first O
treatment O
period O
. O
[]

2 O
) O
( O
1 O
) O
= O
5.227 O
, O
P O
= O
0.022 O
) O
. O
[]

OBJECTIVE O
To O
compare O
bipolar O
with O
the O
conventional O
monopolar O
transurethral O
resection O
of O
the O
prostate O
( O
TURP O
) O
for O
blood O
loss O
and O
speed O
of O
resection O
. O
[]

Only O
5/16 O
( O
31.2 O
% O
) O
patients O
treated O
with O
H O
( O
2 O
) O
RAs O
had O
a O
complete B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
after O
3 O
months O
; O
1/11 O
was O
treated O
again O
with O
H O
( O
2 O
) O
RAs O
during O
3 O
months O
, O
and O
10/11 O
were O
changed O
to O
PPIs O
. O
['Physiological-Clinical']

METHODS O
Simplified O
Disease O
Activity O
Index O
( O
SDAI O
) O
scores O
, O
Clinical O
Disease O
Activity O
Index O
( O
CDAI O
) O
scores O
, O
and O
the O
Disease O
Activity O
Score O
in O
28 O
joints O
( O
DAS28 O
) O
were O
calculated O
using O
data O
from O
tocilizumab O
trials O
in O
patients O
with O
RA O
in O
whom O
disease O
had O
remained O
active O
despite O
treatment O
with O
disease-modifying O
antirheumatic O
drugs O
. O
[]

The O
two O
treatment O
groups O
were O
closely O
matched O
in O
age O
, O
sex O
, O
per O
cent O
of O
BSA O
burned O
, O
and O
in O
burn O
severity O
and O
locations O
. O
[]

groups O
( O
46.9 O
% O
vs O
47.5 O
% O
vs O
45.3 O
% O
, O
respectively O
) O
. O
[]

Alpha O
power O
was O
increased O
by O
the O
8 O
mg O
gum O
dose O
and O
that O
increase O
was O
prevented O
by O
mecamylamine O
. O
[]

RESULTS O
The O
sample O
comprised O
30 O
patients O
of O
age O
between O
1 O
and O
27 O
months O
, O
of O
whom O
13 O
( O
43 O
% O
) O
were O
male O
. O
[]

The O
efficacy O
of O
0.03 O
% O
flurbiprofen O
in O
preventing O
intraoperative O
miosis O
was O
evaluated O
by O
a O
prospective O
randomized O
, O
double-masked O
controlled O
trial O
of O
60 O
patients O
. O
[]

OBJECTIVE O
To O
ensure O
that O
generic O
warfarin O
products O
can O
be O
safely O
interchanged O
with O
Coumadin O
. O
[]

Statistically O
significant O
benefits O
of O
partner O
treatment O
were O
noted O
in O
the O
initial O
cure O
rate O
by O
Gram-stained O
smear O
criteria O
( O
P O
less O
than O
.01 O
) O
and O
in O
percentage O
of O
women O
with O
symptoms O
eight O
weeks O
after O
initiating O
therapy O
( O
P O
less O
than O
.05 O
) O
. O
[]

Inhibitors O
of O
COX O
indicate O
that O
upregulation O
of O
inflammatory O
eicosanoids O
produced O
by O
COX O
, O
and O
in O
particular O
prostaglandin O
E O
( O
2 O
) O
( O
PGE O
( O
2 O
) O
) O
, O
are O
early O
events O
in O
the O
development O
of O
colorectal O
cancer O
( O
CRC O
) O
. O
[]

Randomized O
trial O
of O
a O
stage-of-change O
oriented O
smoking O
cessation O
intervention O
in O
infertile O
and O
pregnant O
women O
. O
[]

Deliberate O
mild O
intraoperative O
hypothermia O
for O
craniotomy O
. O
[]

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
measured O
for O
5 O
h O
post-first-dose O
of O
medication O
. O
['Physiological-Clinical']

Double-blind O
randomized O
evaluation O
of O
intercostal O
nerve O
blocks O
as O
an O
adjuvant O
to O
subarachnoid O
administered O
morphine O
for O
post-thoracotomy O
analgesia O
. O
[]

Nebulized O
racemic O
epinephrine O
by O
IPPB O
for O
the O
treatment O
of O
croup O
: O
a O
double-blind O
study O
. O
[]

The O
improved O
side-effect O
profile O
of O
the O
wax-matrix O
form O
of O
niacin O
was O
particularly O
notable O
. O
[]

The O
effects O
of O
amantadine O
and O
pemoline O
on O
cognitive O
functioning O
in O
multiple O
sclerosis O
. O
[]

BACKGROUND O
We O
tested O
the O
hypothesis O
that O
asymmetric B-outcome ['Physiological-Clinical']
dimethylarginine I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ADMA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
could O
be O
elevated O
and O
influence O
endothelin-1 B-outcome ['Physiological-Clinical']
and O
nitric B-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
in O
patients O
with O
cardiac O
syndrome O
X O
( O
CSX O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Prophylactic O
Transluminal O
Balloon O
Angioplasty O
( O
pTBA O
) O
appeared O
to O
prevent O
delayed O
ischemic B-outcome ['Physiological-Clinical']
neurological I-outcome ['Physiological-Clinical']
deficit I-outcome ['Physiological-Clinical']
in O
a O
pilot O
study O
. O
['Physiological-Clinical']

We O
assessed O
the O
efficacy O
of O
the O
remedy O
in O
an O
open O
, O
randomised O
controlled O
clinical O
trial O
, O
in O
which O
20 O
patients O
with O
second O
degree O
burns O
were O
treated O
with O
the O
extract O
of O
the O
Choerospondias O
axillaris O
and O
19 O
with O
saline O
gauze O
. O
[]

The O
patients O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

Matched O
samples O
labelled O
with O
Ber O
EP4 O
were O
separated O
magnetically O
by O
adding O
a O
secondary O
bead-antibody O
conjugate O
for O
confirmation O
of O
tumour O
cell O
identity O
. O
[]

METHODS O
We O
recruited O
three O
family O
members O
per O
family O
for O
assessment O
- O
the O
melanoma O
case O
, O
a O
first-degree O
relative O
( O
FDR O
) O
, O
and O
a O
relative O
who O
is O
a O
parent O
of O
a O
child O
age O
18 O
or O
younger O
. O
[]

Veterans O
Administration O
Cooperative O
Study O
on O
Treatment O
of O
Alcoholic O
Cirrhosis O
with O
Ascites O
. O
[]

In O
34 O
patients O
vancomycin O
was O
the O
only O
effective O
antibiotic O
. O
[]

PURPOSE O
To O
support O
multicyclic O
, O
dose-intensive O
chemotherapy O
, O
we O
assessed O
the O
effects O
of O
reinfusing O
hematopoietic O
progenitors O
collected O
at O
each O
cycle O
in O
leukapheresis O
product O
or O
whole O
blood O
. O
[]

CONCLUSIONS O
For O
patients O
with O
respiratory O
allergies O
, O
sublingual O
immunotherapy O
with O
an O
8-day O
induction O
protocol O
is O
safe O
and O
effective O
. O
[]

Twenty O
patients O
died B-outcome ['Mortality']
during O
the O
LTE O
( O
n O
= O
5 O
MI O
; O
n O
= O
9 O
LI O
; O
n O
= O
6 O
CsA O
) O
, O
and O
eight O
experienced O
graft B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
( O
n O
= O
2 O
MI O
; O
n O
= O
1 O
LI O
; O
n O
= O
5 O
CsA O
) O
. O
['Mortality', 'Physiological-Clinical']

All O
had O
elevated O
serum O
cholesterol O
and O
4 O
out O
of O
5 O
smoked O
every O
day O
. O
[]

plus O
tobramycin O
3 O
mg/kg O
per O
day O
( O
1.5 O
mg/kg O
b.i.d. O
) O
. O
[]

Diagnosis O
of O
pertussis O
was O
confirmed O
by O
laboratory O
tests O
and O
the O
follow-up O
was O
completed O
in O
67 O
children O
. O
[]

Twenty O
percent O
and O
28 O
% O
of O
the O
subjects O
had O
incisive B-outcome ['Physiological-Clinical']
papilla I-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
or O
soreness B-outcome ['Physiological-Clinical']
with O
the O
lidocaine O
and O
mepivacaine O
solutions O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
measure O
the O
effects O
of O
case O
management O
on O
an O
older O
population O
's O
costs O
of O
health B-outcome ['Resource-use']
care I-outcome ['Resource-use']
. O
['Resource-use']

AIM O
Gonadotropin-releasing O
hormone O
( O
GnRH O
) O
antagonists O
have O
reduced O
the O
incidence O
of O
severe O
ovarian O
hyper O
stimulation O
syndrome O
( O
OHSS O
) O
and O
rate O
of O
hospitalization O
due O
to O
severe O
OHSS O
, O
especially O
in O
polycystic O
ovarian O
syndrome O
( O
PCOS O
) O
patients O
. O
[]

HBV B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
, O
HBeAg B-outcome ['Physiological-Clinical']
and O
liver B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
were O
detected O
at O
different O
time O
points O
, O
and O
the O
number O
of O
cells O
that O
secrete B-outcome ['Physiological-Clinical']
IFN-gamma I-outcome ['Physiological-Clinical']
were O
detected O
by O
ELISPOT O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Aims O
included O
evaluating O
the O
acceptability O
of O
the O
program O
and O
gathering O
preliminary O
evidence O
on O
efficacy O
. O
[]

Pre-operative O
short-term O
pulmonary O
rehabilitation O
for O
patients O
of O
chronic O
obstructive O
pulmonary O
disease O
undergoing O
coronary O
artery O
bypass O
graft O
surgery O
. O
[]

RESULTS O
One O
hundred O
twenty O
patients O
were O
randomly O
assigned O
and O
treated O
. O
[]

Independent O
evaluators O
blind O
to O
treatment O
condition O
conducted O
structured O
diagnostic O
interviews O
and O
parents O
and O
children O
completed O
anxiety B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
checklists O
at O
baseline O
and O
posttreatment/postwaitlist O
. O
['Life-Impact']

There O
were O
data O
on O
FLT3 O
internal O
tandem O
duplications O
and O
NPM1 O
mutations O
( O
n O
= O
592 O
) O
, O
CEBPA O
mutations O
( O
n O
= O
423 O
) O
, O
and O
MN1 O
expression O
( O
n O
= O
195 O
) O
. O
[]

The O
applicability O
of O
this O
model O
for O
bioequivalence O
testing O
was O
established O
by O
showing O
that O
it O
had O
sufficient O
power O
to O
determine O
that O
three O
test O
tretinoin O
cream O
products O
and O
two O
approved O
generic O
tretinoin O
gel O
products O
were O
equivalent O
to O
their O
corresponding O
reference O
products O
. O
[]

The O
results O
show O
that O
4 O
months O
after O
treatment O
, O
the O
intensive O
multidisciplinary O
program O
is O
superior O
to O
the O
less O
intensive O
programs O
in O
terms O
of O
return-to-work O
rate O
, O
health-care O
contacts O
, O
pain O
and O
disability O
scores O
, O
and O
staying O
physically O
active O
. O
( O
[]

Parents B-outcome ['Life-Impact']
completed I-outcome ['Life-Impact']
a O
medication B-outcome ['Resource-use']
log O
, O
and O
recorded O
the O
presence O
and O
severity O
of O
opioid-related B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
and O
children O
's O
reports O
of O
pain B-outcome ['Physiological-Clinical']
intensity O
using O
a O
0 O
to O
10 O
numeric O
rating O
scale O
. O
['Life-Impact', 'Resource-use', 'Adverse-effects', 'Physiological-Clinical']

Different O
doses O
of O
two O
liquid O
antacids O
, O
alone O
and O
combined O
with O
an O
anticholinergic O
agent O
, O
were O
studied O
with O
respect O
to O
the O
duration O
of O
antacid B-outcome ['Resource-use']
action O
. O
['Resource-use']

From O
May O
, O
2006 O
, O
we O
conducted O
a O
quasi-randomized O
trial O
to O
determine O
if O
an O
in-home O
education O
and O
invitation O
intervention O
would O
increase O
uptake O
of O
cervical O
cancer O
screening O
. O
[]

We O
compared O
two O
procedures O
for O
the O
emergency O
treatment O
of O
bleeding B-outcome ['Physiological-Clinical']
esophageal O
varices O
in O
patients O
who O
did O
not O
respond O
to O
blood O
transfusion O
and O
vasoactive O
drugs O
. O
['Physiological-Clinical']

There O
was O
no O
evidence O
that O
the O
relative O
effect O
of O
a O
boost O
on O
local B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
depends O
on O
age O
( O
P=0.97 O
) O
However O
in O
younger O
patients O
the O
5-year O
local B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
was O
higher O
, O
therefore O
the O
absolute O
reduction O
was O
greater O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
significant O
redistribution O
of O
tidal O
variation O
to O
the O
posterior O
parts O
of O
the O
lung O
was O
observed O
on O
electrical O
impedance O
tomography O
measurements O
when O
increasing O
mean O
airway O
pressure O
. O
[]

CONCLUSION O
Liposome-entrapped O
D. O
Pteronyssinus O
vaccination O
: O
( O
i O
) O
protects O
mild O
asthma O
patients O
from O
the O
worsening O
of O
asthma O
due O
to O
sustained O
mite O
exposure O
; O
and O
( O
ii O
) O
reduces O
the O
functional O
and O
inflammatory O
changes O
induced O
by O
allergen O
bronchial O
provocation O
. O
[]

CONCLUSION O
In O
a O
regimen O
of O
postmenopausal O
hormone O
replacement O
therapy O
with O
a O
fixed O
mid-range O
daily O
dose O
of O
CEE O
combined O
with O
a O
cyclical O
regimen O
of O
a O
C21 O
progestogen O
spanning O
the O
current O
clinical O
dose O
range O
, O
the O
progestogen O
has O
either O
no O
effect O
or O
a O
small O
dose-dependent O
reduction O
in O
[]

69.3 O
kg O
, O
and O
359.4 O
? O
[]

OBJECTIVE O
Most O
children O
with O
autism O
rely O
on O
schools O
as O
their O
primary O
source O
of O
intervention O
, O
yet O
research O
has O
suggested O
that O
teachers O
rarely O
use O
evidence-based O
practices O
. O
[]

The O
rise O
in O
blocking B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
polymer O
group O
was O
from O
a O
mean O
of O
181 O
ng O
AgE O
bound O
per O
ml O
to O
1,574 O
. O
['Physiological-Clinical']

The O
second O
randomized O
assignment O
was O
for O
daily O
oral O
or O
weekly O
IV O
6-mercaptopurine O
during O
consolidation O
. O
[]

Efficacy O
of O
rofecoxib O
, O
celecoxib O
, O
and O
acetaminophen O
in O
patients O
with O
osteoarthritis O
of O
the O
knee O
. O
[]

The O
intestinal B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
was I-outcome ['Physiological-Clinical']
determined I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
H2-exhalation I-outcome ['Physiological-Clinical']
tests I-outcome ['Physiological-Clinical']
and O
the O
clinical B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Children O
who O
show O
disproportionate O
difficulty O
with O
the O
pragmatic O
as O
compared O
with O
the O
structural O
aspects O
of O
language O
are O
described O
as O
having O
pragmatic O
language O
impairment O
( O
PLI O
) O
or O
social O
communication O
disorder O
( O
SCD O
) O
. O
[]

Risperidone O
in O
children O
with O
autism O
: O
randomized O
, O
placebo-controlled O
, O
double-blind O
study O
. O
[]

hexacetonide O
( O
TH O
) O
and O
i/a O
hyaluronic O
acid O
( O
HA O
) O
in O
inflammatory O
knee O
osteoarthritis O
. O
[]

A O
Roy O
adaptation O
model-based O
support O
and O
education O
intervention O
for O
women O
with O
early-stage O
breast O
cancer O
was O
tested O
in O
a O
three-group O
, O
three-phase O
randomized O
clinical O
trial O
of O
a O
sample O
of O
125 O
women O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
and O
microbiological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates O
at O
the O
first O
follow-up O
visit O
were O
also O
equivalent O
between O
the O
2 O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
oat O
cereal O
group O
experienced O
a O
7.5 O
mm O
Hg O
reduction O
in O
SBP B-outcome ['Physiological-Clinical']
( O
P O
& O
lt.01 O
) O
and O
a O
5.5 O
mm O
Hg O
reduction O
in O
DBP B-outcome ['Physiological-Clinical']
( O
P O
& O
lt.02 O
) O
, O
while O
there O
was O
virtually O
no O
change O
in O
either O
SBP O
or O
DBP O
in O
the O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
1918 O
patients O
were O
screened O
for O
participation O
; O
1214 O
were O
recruited O
. O
[]

Uncuffed O
tubes O
selected O
by O
Cole O
's O
formula O
were O
appropriate O
for O
77 O
% O
of O
patients O
( O
P O
< O
0.001 O
) O
. O
[]

In O
conclusion O
, O
endurance O
training O
favorably O
affects O
blood B-outcome ['Physiological-Clinical']
lipoprotein B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
correlation O
between O
CBFV B-outcome ['Physiological-Clinical']
and O
COe B-outcome ['Physiological-Clinical']
at O
any O
time O
point O
during O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Moreover O
, O
the O
parietal O
P300 O
source O
strength O
increased O
after O
acute O
, O
subacute O
and O
superimposed O
infusion O
of O
Actovegin O
as O
compared O
to O
placebo O
. O
[]

This O
anatomical O
alteration O
may O
affect O
the O
absorption O
and O
consequently O
the O
bioavailability O
of O
oral O
drugs O
. O
[]

Main O
outcome O
measures O
were O
incidence O
of O
clomiphene B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
, O
monofollicular B-outcome ['Physiological-Clinical']
response O
, O
fasting B-outcome ['Physiological-Clinical']
insulin/glucose I-outcome ['Physiological-Clinical']
ratio O
, O
serum B-outcome ['Physiological-Clinical']
testosterone I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
single-task O
random-interval O
repetition O
performance O
was O
sampled O
and O
compared O
to O
performance O
in O
the O
dual-task O
conditions O
of O
all O
four O
experiments O
. O
[]

When O
the O
total O
experience O
is O
considered O
( O
clindamycin O
or O
cefoxitin O
with O
and O
without O
gentamicin O
) O
, O
20 O
of O
24 O
patients O
( O
83 O
% O
) O
responded B-outcome ['Physiological-Clinical']
to O
clindamycin O
and O
18 O
of O
22 O
( O
82 O
% O
) O
responded B-outcome ['Physiological-Clinical']
to O
cefoxitin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
relation O
of O
pacing B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
consumption I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VO2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
expired B-outcome ['Physiological-Clinical']
carbon I-outcome ['Physiological-Clinical']
dioxide I-outcome ['Physiological-Clinical']
concentration O
( O
VCO2 B-outcome ['Physiological-Clinical']
) O
, O
respiratory B-outcome ['Physiological-Clinical']
quotient I-outcome ['Physiological-Clinical']
, O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
respiratory B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
minute O
ventilation B-outcome ['Physiological-Clinical']
was O
determined O
during O
exercise O
in O
the O
rate-modulating O
minute O
ventilation O
pacing O
mode O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
ICD O
shocks O
are O
painful O
and O
do O
not O
provide O
complete O
protection O
against O
sudden O
cardiac O
death O
. O
[]

The O
median O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
for O
tamoxifen O
( O
20 O
months O
) O
was O
longer O
than O
that O
for O
surgical O
oophorectomy O
( O
7 O
months O
) O
, O
but O
this O
did O
not O
achieve O
statistical O
significance O
( O
P O
= O
.056 O
) O
. O
['Physiological-Clinical']

Previous O
attempts O
to O
identify O
and O
suppress O
arrhythmias O
with O
various O
antiarrhythmic O
drugs O
failed O
to O
reduce O
or O
actually O
increase O
mortality O
. O
[]

CONCLUSION O
A O
single O
oral O
dose O
of O
Naproxen O
, O
Novafen O
and O
Tramadol O
taken O
immediately O
after O
treatment O
reduced O
postoperative O
pain O
following O
pulpectomy O
and O
root O
canal O
preparation O
of O
teeth O
with O
irreversible O
pulpitis O
. O
[]

Ongoing O
studies O
are O
evaluating O
combinations O
of O
agents O
with O
different O
mechanisms O
of O
action O
, O
such O
as O
epinephrine O
( O
for O
vasoconstriction O
to O
minimize O
secondary O
bleeding O
) O
plus O
alcohol O
, O
and/or O
tetradecyl O
sulfate O
( O
for O
variceal O
thrombosis O
and O
sclerosis O
) O
. O
( O
[]

Cost B-outcome ['Resource-use']
analysis O
was O
performed O
from O
a O
societal O
perspective O
alongside O
a O
prospective O
, O
randomised O
, O
double-blinded O
, O
multicentre O
trial O
. O
['Resource-use']

OBJECTIVES O
To O
compare O
the O
effects O
of O
a O
water-washed O
soy O
protein O
concentrate O
with O
a O
milk-protein O
based O
control O
on O
blood O
lipid O
levels O
in O
hyperlipidemic O
men O
and O
women O
. O
[]

Designing O
studies O
that O
consider O
the O
consumer O
's O
perspective O
will O
help O
to O
forge O
a O
better O
alliance O
between O
participants O
and O
researchers O
. O
[]

Concern O
about O
the O
possible O
adverse B-outcome ['Adverse-effects']
health I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
of O
acid O
fog O
has O
been O
fed O
by O
two O
observations O
: O
air O
pollution O
disasters O
earlier O
in O
this O
century O
were O
typically O
associated O
with O
fog O
, O
and O
current O
samples O
of O
fog O
water O
can O
be O
strongly O
acid O
. O
['Adverse-effects']

Eighteen O
autistic O
individuals O
, O
ranging O
in O
age O
from O
7 O
to O
18 O
years O
, O
participated O
in O
the O
study O
. O
[]

METHODS O
Fifty O
consecutive O
patients O
undergoing O
vitrectomy O
were O
randomly O
assigned O
to O
diclofenac O
( O
n O
= O
24 O
) O
or O
control O
( O
n O
= O
26 O
) O
groups O
. O
[]

Data O
collection O
included O
questionnaires O
and O
interviews O
. O
[]

A O
repeat O
study O
using O
our O
standard O
technique O
rendered O
free B-outcome ['Physiological-Clinical']
intraperitoneal I-outcome ['Physiological-Clinical']
distribution I-outcome ['Physiological-Clinical']
in O
this O
patient O
, O
as O
well O
as O
in O
the O
other O
seven O
cases O
. O
['Physiological-Clinical']

Another O
50 O
samples O
from O
Swiss O
and O
North O
American O
infants O
with O
correlative O
hormonal O
data O
were O
also O
genotyped O
. O
[]

RESULTS O
There O
were O
significant O
overall O
intervention O
effects O
for O
all O
adiposity B-outcome ['Physiological-Clinical']
measures O
( O
weight O
, O
body O
mass O
index O
[ O
BMI O
] O
, O
BMI O
z-scores O
, O
and O
DEXA B-outcome ['Physiological-Clinical']
total O
body B-outcome ['Physiological-Clinical']
fat B-outcome ['Physiological-Clinical']
) O
, O
with O
a O
decrease O
of O
3 O
% O
in O
the O
N O
+ O
CAST O
group O
compared O
with O
a O
3 O
% O
increase O
in O
the O
N O
+ O
ST O
group O
( O
P O
< O
or O
= O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Anaesthesia B-outcome ['Resource-use']
was O
maintained O
with O
isoflurane O
. O
['Resource-use']

Effect O
on O
hypertension B-outcome ['Physiological-Clinical']
and O
lipid B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Randomized O
, O
placebo-controlled O
, O
double-blind O
clinical O
trial O
evaluating O
the O
treatment O
of O
plantar O
fasciitis O
with O
an O
extracoporeal O
shockwave O
therapy O
( O
ESWT O
) O
device O
: O
a O
North O
American O
confirmatory O
study O
. O
[]

Then O
the O
teeth O
were O
prepared O
and O
obturated O
with O
gutta-percha O
by O
a O
lateral O
condensation O
and O
either O
AH O
plus O
and O
EndoRez O
used O
as O
a O
sealer O
. O
[]

In O
conclusion O
, O
the O
bioavailability O
of O
beta-carotene O
derived O
from O
Dunaliella O
bardawil O
was O
preferential O
for O
all-trans O
beta-carotene O
, O
although O
a O
small O
amount O
of O
the O
9-cis O
form O
was O
detected O
in O
the O
plasma O
and O
blood O
cells O
. O
[]

Addition O
of O
rituximab O
( O
R O
) O
to O
fludarabine O
and O
cyclophosphamide O
( O
FC O
) O
has O
significantly O
improved O
patient B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
in O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
. O
['Physiological-Clinical']

The O
primary O
endpoint O
was O
polyp O
number O
in O
the O
rectum O
and O
sigmoid O
colon O
( O
at O
the O
end O
of O
intervention O
) O
, O
and O
the O
major O
secondary O
endpoint O
was O
size O
of O
the O
largest O
polyp O
. O
[]

C-spine B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
was O
examined O
at O
the O
Occiput-C1 O
junction O
, O
C1-2 O
junction O
, O
C2-5 O
motion O
segment O
, O
and O
C5-thoracic O
motion O
segment O
during O
manual O
ventilation O
via O
bag-mask O
, O
laryngoscopy O
, O
and O
intubation O
. O
['Physiological-Clinical']

The O
most O
common O
[]

No O
increased O
risk O
of O
UTI B-outcome ['Physiological-Clinical']
was O
associated O
with O
washout O
regimes O
. O
['Physiological-Clinical']

Dietary O
supplementation O
of O
glutamine O
prevents O
intestinal O
dysfunction O
and O
atrophy O
in O
weanling O
piglets O
, O
but O
the O
underlying O
mechanism O
( O
s O
) O
are O
largely O
unknown O
. O
[]

A O
Bayesian O
decision-theoretic O
clinical O
trial O
design O
was O
used O
to O
determine O
the O
probability O
of O
remaining O
posttraumatic O
seizure O
free O
for O
each O
treatment O
group O
. O
[]

No O
patients O
had O
sustained O
postbaseline B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
postbaseline I-outcome ['Physiological-Clinical']
run I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ectopic I-outcome ['Physiological-Clinical']
beats I-outcome ['Physiological-Clinical']
associated O
with O
relevant O
symptoms O
( O
e.g O
. O
['Physiological-Clinical']

However O
, O
after O
150 O
min O
, O
nasal B-outcome ['Physiological-Clinical']
airflow I-outcome ['Physiological-Clinical']
was O
21 O
% O
rsp O
. O
['Physiological-Clinical']

2.8 O
) O
were O
significantly O
lower O
than O
those O
in O
the O
6 O
( O
th O
) O
weekend O
of O
treatment O
( O
7.6 O
? O
[]

Analgesia B-outcome ['Resource-use']
was O
assessed O
at O
intervals O
up O
to O
six O
hours O
, O
using O
a O
visual O
analogue O
scale O
and O
a O
four-point O
verbal O
scale O
, O
while O
duration O
of O
analgesia O
was O
taken O
as O
the O
time O
until O
the O
patient O
requested O
additional O
analgesia O
. O
['Resource-use']

PURPOSE O
To O
prospectively O
study O
and O
compare O
the O
effectiveness O
and O
the O
safety O
of O
primary O
deep O
sclerectomy O
with O
and O
without O
the O
use O
of O
mitomycin O
C O
in O
eyes O
with O
open-angle O
glaucoma O
. O
[]

Lithium O
levels O
between O
0.5 O
and O
1.0 O
meq/liter O
were O
easily O
maintained O
in O
11 O
of O
12 O
patients O
receiving O
lithium O
, O
300 O
mg O
t.i.d. O
, O
and O
toxicity B-outcome ['Adverse-effects']
directly O
attributable O
to O
lithium O
was O
not O
observed O
. O
['Adverse-effects']

CONCLUSION O
ESUL O
is O
a O
rare O
finding O
when O
using O
a O
reasonable O
energy O
maximum O
of O
25 O
W O
with O
open-irrigated O
tip O
catheters O
at O
the O
posterior O
wall O
. O
[]

OBJECTIVES O
The O
primary O
study O
end O
point O
was O
the O
prevention O
of O
ulcerative B-outcome ['Physiological-Clinical']
HSL I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

DESIGN O
AND O
PATIENTS O
Prospective O
study O
over O
16 O
weeks O
of O
children O
randomized O
to O
receive O
prednisolone O
( O
40 O
mg/m2 O
) O
or O
dexamethasone O
( O
6.5 O
mg/m2 O
) O
as O
part O
of O
the O
MRC-ALL97/99 O
induction O
chemotherapy O
for O
ALL O
. O
[]

Although O
lasalocid O
has O
been O
demonstrated O
to O
be O
effective O
against O
pheasant O
specific O
coccidia O
, O
information O
regarding O
its O
safety O
in O
this O
species O
is O
lacking O
. O
[]

Analysis O
of O
variance O
failed O
to O
demonstrate O
an O
effect O
of O
either O
intervention O
on O
the O
median O
change O
in O
[]

Healthy O
first-time O
mothers O
delivering O
in O
the O
capital O
Beirut O
between O
March O
and O
July O
2009 O
, O
were O
interviewed O
at O
1-3 O
days O
and O
8-12 O
weeks O
post O
delivery O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
od O
and O
bd O
groups O
for O
all O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

After O
a O
1-week O
, O
single-blind O
placebo O
run-in O
, O
patients O
received O
a O
single O
daily O
dose O
of O
amantadine O
( O
2.5 O
mg/kg O
per O
day O
) O
or O
placebo O
for O
the O
next O
week O
, O
and O
then O
bid O
dosing O
( O
5.0 O
mg/kg O
per O
day O
) O
for O
the O
subsequent O
3 O
weeks O
. O
[]

Although O
i.v O
. O
[]

CONCLUSIONS O
RFA O
is O
more O
effective O
in O
the O
treatment O
of O
HCC O
compared O
to O
PLA O
for O
lesions O
? O
[]

Many O
patients O
did O
not O
perceive O
their O
information O
needs O
were O
met O
within O
the O
consultation O
. O
[]

Eighteen O
children O
, O
1 O
to O
10 O
years O
of O
age O
, O
were O
evaluated O
using O
the O
Childhood O
Autism O
Rating O
Scale O
, O
Second O
Edition O
( O
CARS2 O
) O
; O
the O
PlayWisely O
Interactive O
Test O
of O
Attention O
, O
Recognition O
, O
and O
Memory O
Skills O
; O
Autism O
Treatment O
Evaluation O
Checklist O
( O
ATEC O
) O
, O
and O
the O
Modified O
Checklist O
for O
Autism O
in O
Toddlers O
( O
M-CHAT O
) O
. O
[]

Observers O
judged O
the O
direction O
of O
motion O
( O
left O
or O
right O
) O
of O
each O
probe O
. O
[]

INTERVENTIONS O
Patients O
in O
the O
experimental O
group O
had O
a O
blood O
conservation O
device O
incorporated O
into O
the O
arterial O
pressure O
monitoring O
system O
, O
while O
patients O
in O
the O
control O
group O
received O
a O
conventional O
arterial O
pressure O
monitoring O
system O
. O
[]

Eighty O
cats O
were O
randomly O
allocated O
so O
that O
there O
were O
20 O
cats O
in O
four O
different O
treatment O
groups O
. O
[]

Interventions O
were O
conducted O
30 O
minutes O
daily O
for O
5-6 O
weeks O
. O
[]

Four O
children O
( O
18 O
% O
) O
of O
22 O
in O
the O
placebo O
group O
had O
[]

METHODS O
A O
total O
of O
214 O
patients O
( O
mean O
age O
: O
54.1 O
years O
; O
120 O
male O
, O
94 O
female O
) O
from O
four O
university O
hospitals O
were O
included O
in O
the O
analysis O
. O
[]

In O
group O
A O
, O
both O
ovulation O
and O
pregnancy B-outcome ['Physiological-Clinical']
rate O
were O
much O
lower O
than O
the O
other O
two O
groups O
( O
27.27 O
% O
and O
12.73 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical']

Although O
most O
cancer O
survivors O
are O
at O
risk O
for O
being O
lost O
in O
the O
transition O
from O
treatment O
to O
survivorship O
, O
rural O
breast O
cancer O
survivors O
face O
special O
challenges O
that O
might O
place O
them O
at O
particular O
risk O
. O
[]

Methylphenidate O
and O
baseball O
playing O
in O
ADHD O
children O
: O
who O
's O
on O
first O
? O
[]

METHODS O
One O
hundred O
fifteen O
patients O
with O
PD O
from O
3 O
primary O
care O
clinics O
were O
randomized O
to O
CC O
or O
usual O
care O
( O
UC O
) O
. O
[]

Heel O
cups O
had O
to O
be O
worn O
throughout O
the O
study O
. O
[]

RESULTS O
Only O
a O
small O
number O
of O
patients O
met O
the O
predefined O
criteria O
for O
a O
proarrhythmic B-outcome ['Physiological-Clinical']
event I-outcome ['Physiological-Clinical']
( O
4 O
formoterol O
and O
2 O
placebo O
patients O
) O
. O
['Physiological-Clinical']

The O
follow-up O
rate O
was O
91.0 O
% O
. O
[]

CONCLUSION O
Our O
results O
indicate O
that O
intrathecal O
lentiviral-mediated O
transfer O
of O
IL-10 O
attenuates O
CCI-induced O
neuropathic O
pain O
in O
rats O
. O
[]

A O
prospective O
, O
randomized O
open-label O
trial O
of O
sevelamer O
hydrochloride O
with O
or O
without O
calcium O
carbonate O
( O
CC O
) O
involved O
86 O
hemodialysis O
patients O
in O
Japan O
. O
[]

However O
, O
analgesic O
block O
lasted O
significantly O
longer O
in O
patients O
receiving O
bupivacaine O
( O
P=0.03 O
) O
. O
[]

Only O
the O
basic O
treatments O
were O
given O
to O
the O
control O
group O
. O
[]

Each O
half O
of O
the O
lesion O
was O
randomly O
assigned O
to O
( O
a O
) O
no O
surface O
preparation O
or O
( O
b O
) O
surface O
preparation O
( O
randomly O
allocated O
to O
gentle O
curettage O
or O
abrasion O
with O
a O
spatula O
) O
. O
[]

CONCLUSIONS O
Combined O
preoperative O
and O
intraoperative O
use O
of O
glucocorticoids O
in O
neonatal O
cardiac O
surgery O
does O
not O
favorably O
affect O
early O
clinical O
outcomes O
and O
may O
exacerbate O
perioperative O
renal O
dysfunction O
. O
[]

CONCLUSIONS O
Hexaminolevulinate O
fluorescence O
cystoscopy O
significantly O
improves O
long-term O
bladder O
cancer O
time O
to O
recurrence O
with O
a O
trend O
toward O
improved O
bladder O
preservation O
. O
[]

The O
dose O
of O
risperidone O
and O
celecoxib O
were O
titrated O
up O
to O
3 O
and O
300 O
mg/day O
, O
respectively O
. O
[]

All O
patients O
received O
identical O
cumulative O
doses O
of O
cisplatin O
, O
doxorubicin O
, O
and O
methotrexate O
and O
underwent O
definitive O
surgical O
resection O
of O
primary O
tumor O
. O
[]

Lipoprotein O
( O
a O
) O
serum O
levels O
in O
post-menopausal O
women O
treated O
with O
oral O
estrogens O
administered O
at O
different O
times O
. O
[]

Gait B-outcome ['Life-Impact']
velocity I-outcome ['Life-Impact']
increased O
significantly O
between O
JM O
and O
JM O
+ O
30 O
in O
both O
groups O
, O
with O
no O
difference O
between O
groups O
. O
['Life-Impact']

RESULTS O
The O
low-tilt O
waveform O
produced O
successful O
termination O
of O
persistent B-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
at O
a O
mean O
voltage O
of O
223 O
V O
( O
8.2 O
J O
) O
versus O
270 O
V O
( O
6.7 O
J O
) O
with O
the O
conventional O
waveform O
( O
P O
= O
0.002 O
for O
voltage O
, O
P O
= O
ns O
for O
energy O
) O
. O
['Physiological-Clinical']

CONCLUSION O
Application O
of O
5 O
% O
imiquimod O
cream O
for O
12 O
weeks O
is O
an O
effective O
and O
well-tolerated O
treatment O
for O
AK B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Impaired B-outcome ['Physiological-Clinical']
sphincter I-outcome ['Physiological-Clinical']
function B-outcome ['Life-Impact']
was O
observed O
at O
1 O
year O
with O
no O
significant O
difference O
between O
the O
groups O
for O
urgency O
( O
12 O
% O
) O
, O
continence O
problems O
( O
10 O
% O
) O
, O
or O
tenesmus O
( O
3 O
% O
) O
. O
['Physiological-Clinical', 'Life-Impact']

The O
median O
time O
delay O
between O
the O
injections O
was O
55 O
min O
. O
[]

METHODS O
Therefore O
, O
we O
exposed O
patients O
with O
mild O
asthma O
to O
2 O
weeks O
of O
repeated O
low-dose O
allergen O
, O
with O
concomitant O
inhaled O
steroid O
or O
placebo O
treatment O
. O
[]

RESULTS O
Clozapine O
tended O
to O
reduce O
chorea B-outcome ['Physiological-Clinical']
in O
neuroleptic O
naive O
patients O
only O
( O
AIMS O
) O
; O
improvement O
seemed O
more O
pronounced O
in O
patients O
receiving O
higher O
doses O
of O
clozapine O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
PURPOSE O
High O
blood O
pressure O
( O
BP O
) O
in O
acute O
stroke O
is O
associated O
independently O
with O
a O
poor O
outcome O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
detect O
a O
difference O
in O
knowledge B-outcome ['Life-Impact']
gain O
between O
students O
receiving O
structured O
versus O
student-directed O
learning O
for O
the O
two-week O
Child O
Health O
outpatient O
module O
. O
['Life-Impact']

METHODS O
A O
total O
of O
109 O
patients O
with O
HBV O
were O
randomized O
into O
FK506 O
group O
( O
52 O
cases O
) O
and O
CsA O
group O
( O
57 O
cases O
) O
after O
KT O
, O
and O
a O
2-year-long O
follow-up O
of O
the O
patients O
was O
conducted O
to O
record O
the O
patient O
and O
graft B-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
, O
incidence O
of O
acute B-outcome ['Physiological-Clinical']
graft I-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
and O
postoperative B-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

More O
high-quality B-outcome ['Physiological-Clinical']
embryos I-outcome ['Physiological-Clinical']
were O
obtained O
after O
ICSI O
in O
patients O
of O
the O
IVF+ O
group O
. O
['Physiological-Clinical']

Data O
also O
show O
quite O
a O
large O
intra-individual O
variability O
in O
cyclosporin B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
in O
the O
placebo O
group O
, O
suggesting O
that O
poor O
absorption O
of O
the O
drug O
formulation O
and/or O
poor O
compliance O
might O
have O
contributed O
to O
the O
decreased O
cyclosporin B-outcome ['Physiological-Clinical']
blood O
levels O
in O
the O
patient O
withdrawn O
from O
this O
study O
and O
in O
previous O
uncontrolled O
studies O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
report O
from O
the O
Cross-National O
Collaborative O
Panic O
Study O
. O
[]

Infection B-outcome ['Physiological-Clinical']
was O
more O
likely O
if O
the O
common O
bile O
duct O
was O
explored O
( O
6 O
of O
28 O
) O
rather O
than O
cholecystectomy O
alone O
( O
8 O
of O
83 O
) O
. O
['Physiological-Clinical']

Dimensions O
of O
the O
bruising O
on O
the O
heparin O
applied O
areas O
were O
measured O
using O
transparent O
millimetric O
measuring O
paper O
. O
[]

Twenty-five O
patients O
were O
allocated O
randomly O
either O
to O
a O
TAMS O
group O
or O
to O
an O
on-scene O
directed O
( O
OSD O
) O
group O
. O
[]

Thirty-three O
patients O
with O
II O
type O
mixed O
essential O
cryoglobulinemia O
( O
MEC O
) O
were O
randomized O
into O
two O
groups O
: O
one O
to O
receive O
combined O
therapy O
including O
prednisone O
plus O
interferon O
, O
the O
other O
to O
receive O
prednisone O
therapy O
. O
[]

The O
questionnaire O
and O
VAS O
scores O
in O
the O
total O
group O
were O
75 O
( O
SD O
12 O
) O
and O
83 O
( O
SD O
20 O
) O
, O
respectively O
. O
[]

ROMEO O
: O
rethink O
organization O
to O
improve O
education O
and O
outcomes O
. O
[]

The O
significant O
independent O
predictors O
were O
VLDL-apoB B-outcome ['Physiological-Clinical']
( O
relative O
risk O
[ O
RR O
] O
3.2 O
for O
highest O
to O
lowest O
quintiles O
, O
P O
: O
=0.04 O
) O
, O
apoCIII B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
VLDL+LDL I-outcome ['Physiological-Clinical']
( O
RR O
2.3 O
, O
P O
: O
=0.04 O
) O
, O
and O
apoE B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
HDL I-outcome ['Physiological-Clinical']
( O
RR O
1.8 O
, O
P O
: O
=0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

SETTING O
Bologna O
University O
School O
of O
Medicine O
. O
[]

METHODS O
Diagnosed O
hypertensive O
patients O
were O
enrolled O
in O
this O
RCT O
and O
randomized O
to O
one O
of O
two O
study O
groups O
: O
( O
1 O
) O
the O
intervention O
condition O
-- O
Web-based O
hypertension O
feedback O
, O
based O
on O
the O
individual O
patient O
's O
self-report O
of O
health O
variables O
and O
previous O
BP O
measurements O
, O
to O
prompt O
them O
to O
ask O
questions O
during O
their O
next O
physician O
's O
visit O
about O
hypertension O
care O
( O
2 O
) O
the O
control O
condition O
-- O
Web-based O
preventive O
health O
feedback O
, O
based O
on O
the O
individual O
's O
self-report O
of O
receiving O
preventive O
care O
( O
e.g. O
, O
pap O
testing O
) O
, O
to O
prompt O
them O
to O
ask O
questions O
during O
their O
next O
physician O
's O
visit O
about O
preventive O
care O
. O
[]

A O
randomized O
trial O
was O
conducted O
by O
the O
Southwest O
Oncology O
Group O
( O
SWOG O
) O
in O
advanced O
carcinoma O
of O
the O
stomach O
and O
pancreas O
. O
[]

The O
effect O
of O
the O
plasma O
oestradiol O
concentration O
on O
climacteric B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
gonadotrophin B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
, O
and O
bone B-outcome ['Physiological-Clinical']
resorption I-outcome ['Physiological-Clinical']
was O
studied O
in O
three O
groups O
of O
postmenopausal O
women O
given O
0.025 O
mg O
, O
0.05 O
mg O
, O
or O
0.1 O
mg O
transdermal O
oestradiol O
daily O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
a O
double O
blind O
, O
crossover O
study O
of O
the O
response O
of O
autistic O
subjects O
to O
fenfluramine O
, O
event-related O
potentials O
( O
ERPs O
) O
were O
recorded O
from O
7 O
subjects O
on O
an O
attention-demanding O
auditory O
choice O
reaction O
time O
task O
( O
ACRT O
) O
. O
[]

Long O
lines O
offer O
practical O
advantages O
over O
short O
lines O
for O
patients O
requiring O
longer O
term O
i.v O
. O
[]

INTERPRETATION O
The O
addition O
of O
chemotherapy O
to O
ASC O
offers O
no O
significant O
benefits O
in O
terms O
of O
overall O
survival B-outcome ['Mortality']
or O
quality O
of O
life O
. O
['Mortality']

In O
the O
placebo O
group O
, O
a O
significant O
deterioration O
of O
the O
indices O
, O
with O
the O
exception O
of O
Valsalva B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
was O
recorded O
, O
while O
tolrestat O
induced O
a O
significant O
beneficial O
change O
in O
the O
values O
of O
most O
standard O
cardiovascular B-outcome ['Physiological-Clinical']
reflex I-outcome ['Physiological-Clinical']
tests O
, O
in O
comparison O
to O
baseline O
and O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Circulating B-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
were O
measured O
by O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
. O
['Physiological-Clinical']

BACKGROUND O
L-Arginine O
reduces O
platelet B-outcome ['Physiological-Clinical']
aggregation O
and O
adhesion B-outcome ['Physiological-Clinical']
in O
ex O
vivo O
studies O
, O
but O
there O
is O
no O
evidence O
as O
yet O
that O
it O
has O
a O
therapeutic O
effect O
on O
clinical O
end O
points O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
a O
trend O
toward O
a O
higher O
risk O
of O
mortality B-outcome ['Mortality']
or O
stroke B-outcome ['Physiological-Clinical']
at O
30 O
days O
in O
patients O
with O
AF O
( O
2.4 O
% O
vs O
1.9 O
% O
, O
P O
= O
.08 O
) O
. O
['Mortality', 'Physiological-Clinical']

N O
, O
N-dimethylglycine O
, O
a O
dietary O
supplement O
, O
has O
been O
reported O
to O
be O
beneficial O
in O
children O
with O
autism O
and O
pervasive O
developmental O
disorder O
. O
[]

Since O
the O
excretion O
of O
cortisol B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
reflects O
the O
production O
rate O
closely O
and O
is O
not O
influenced O
by O
liver O
function O
and O
barbiturates O
, O
the O
results O
in O
group O
2 O
show O
that O
the O
endogenous O
production O
of O
steroids O
is O
an O
adequate O
reaction O
to O
severe O
head O
injury O
. O
['Physiological-Clinical']

[ O
Radiotherapy O
of O
malignant O
brain O
gliomas O
using O
teniposide O
] O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
determine O
if O
restrictive O
guidelines O
for O
red O
blood O
cell O
( O
RBC O
) O
transfusions O
for O
preterm O
infants O
can O
reduce O
the O
number O
of O
transfusions B-outcome ['Resource-use']
without O
adverse O
consequences O
. O
['Resource-use']

2.9 O
) O
, O
( O
93.5 O
? O
[]

CONCLUSION O
Combination O
of O
CDDP O
and O
5-FU O
reduced O
[]

The O
18 O
: O
2/18 O
: O
1 O
ratio O
decreased O
significantly O
in O
all O
the O
lipid O
esters O
analyzed O
. O
[]

In O
this O
study O
, O
we O
evaluate O
the O
effect O
of O
milrinone O
on O
patients O
with O
ventricular O
dysfunction O
undergoing O
coronary O
artery O
bypass O
graft O
( O
CABG O
) O
. O
[]

No O
significant O
intergroup O
differences O
in O
the O
trend O
of O
the O
two O
plasma O
proteins O
( O
albumin O
, O
transferrin O
) O
, O
lymphocytes O
, O
weight O
, O
IL-6 O
, O
CPR O
and O
TNFalpha O
were O
detected O
. O
[]

The O
incidence O
of O
grade O
III-IV B-outcome ['Physiological-Clinical']
neutropenia B-outcome ['Physiological-Clinical']
was O
16.0 O
% O
in O
the O
dose-dense O
group O
versus O
54.9 O
% O
in O
the O
regular O
group O
( O
P O
= O
0.000 O
) O
; O
postponing O
of O
chemotherapy O
was O
2.4 O
% O
versus O
6.0 O
% O
( O
P O
= O
0.027 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Primary O
outcomes O
were O
pain B-outcome ['Physiological-Clinical']
measured O
by O
visual O
analogue O
scale O
and O
patient B-outcome ['Physiological-Clinical']
global I-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
both O
phases O
, O
a O
physical O
therapist O
assessed O
balance O
for O
the O
BBTW O
group O
and O
then O
placed O
weights O
to O
decrease O
balance B-outcome ['Life-Impact']
loss I-outcome ['Life-Impact']
. O
['Life-Impact']

Plasma O
and O
tissue O
antioxidant O
status O
was O
improved O
by O
supplementation O
. O
[]

The O
most O
frequently O
reported O
adverse O
events O
, O
regardless O
of O
relationship O
to O
study O
drug O
, O
were O
pyrexia B-outcome ['Physiological-Clinical']
( O
22 O
% O
) O
and O
bone B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
10 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
scheduled O
for O
follow O
up O
during O
the O
first O
, O
second O
and O
fourth O
post-operative O
weeks O
. O
[]

P O
< O
0.001 O
) O
and O
attainment O
of O
sterile O
eyes O
( O
P O
< O
0.001 O
) O
at O
operation O
gained O
by O
patient O
self-administration O
of O
1 O
% O
fusidic O
acid O
four O
times O
daily O
for O
seven O
days O
before O
surgery O
. O
[]

A O
clinical O
trial O
of O
glutathione O
supplementation O
in O
autism O
spectrum O
disorders O
. O
[]

In O
addition O
, O
COX-2-treated O
patients O
had O
less O
difficulty O
coughing B-outcome ['Physiological-Clinical']
on O
postoperative O
day O
1 O
. O
['Physiological-Clinical']

The O
behavior O
training O
and O
sensory O
integration O
training O
were O
carried O
out O
in O
group O
B O
and O
the O
ETTAA O
was O
added O
in O
group O
A O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
psychological O
intervention O
had O
a O
beneficial O
effect O
on O
the O
quality O
of O
life O
and O
behaviour B-outcome ['Life-Impact']
of O
women O
diagnosed O
with O
breast O
cancer O
. O
['Life-Impact']

The O
improvement O
in O
TC B-outcome ['Physiological-Clinical']
and O
LDL-C B-outcome ['Physiological-Clinical']
achieved O
by O
combination O
treatment O
was O
superior O
to O
treatment O
of O
atorvastatin O
alone O
and O
treatment O
of O
niacin O
ER O
alone O
( O
all O
P O
< O
0.05 O
) O
. O
( O
['Physiological-Clinical', 'Physiological-Clinical']

Transurethral O
prostate O
resection O
and O
bleeding O
: O
a O
randomized O
, O
placebo O
controlled O
trial O
of O
role O
of O
finasteride O
for O
decreasing O
operative O
blood O
loss O
. O
[]

These O
results O
are O
suggestive O
of O
a O
treatment O
benefit O
but O
do O
not O
support O
a O
change O
in O
clinical O
practice O
. O
[]

No O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
reported O
during O
the O
study O
or O
follow-up O
period O
. O
['Adverse-effects']

A O
total O
of O
412 O
patients O
with O
hepatitis O
C O
infection O
were O
randomized O
to O
open-label O
treatment O
with O
either O
pegIFNalpha O
2a O
( O
n O
= O
206 O
) O
or O
IFNalpha O
2b/RBV O
( O
n O
= O
206 O
) O
. O
[]

This O
difference O
remained O
significant O
whether O
or O
not O
there O
was O
a O
prior O
history O
of O
UI O
. O
[]

METHODS O
The O
study O
was O
an O
8-week O
controlled O
, O
parallel O
intervention O
. O
[]

For O
exposure O
to O
atole O
from O
0 O
to O
2 O
years O
, O
the O
increase O
was O
US O
$ O
0.67 O
per O
hour O
( O
95 O
% O
CI O
0.16-1.17 O
) O
, O
which O
meant O
a O
46 O
% O
increase O
in O
average O
wages O
. O
[]

There O
is O
increasing O
interest O
in O
the O
use O
of O
gluten- O
and O
casein-free O
diets O
for O
children O
with O
autism O
spectrum O
disorders O
( O
ASDs O
) O
. O
[]

Effect O
of O
beta-blocking O
drugs O
on O
beta-cell O
function O
and O
insulin O
sensitivity O
in O
hypertensive O
non-diabetic O
patients O
. O
[]

The O
95 O
% O
confidence O
interval O
( O
CI O
) O
of O
the O
absolute O
risk O
difference O
ranged O
from O
-1.94 O
% O
to O
+2.87 O
% O
, O
therefore O
the O
noninferiority O
was O
not O
proven O
. O
[]

Integration O
of O
IVR O
intervention O
for O
recycling O
smokers O
with O
previous O
QL O
treatment O
has O
the O
potential O
to O
decrease O
tobacco-related O
disparities O
. O
[]

IGOH O
was O
well-tolerated B-outcome ['Life-Impact']
; O
there O
were O
no O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Life-Impact', 'Adverse-effects']

The O
lungs B-outcome ['Physiological-Clinical']
of O
patients O
with O
cuffed O
tubes O
were O
adequately B-outcome ['Life-Impact']
ventilated I-outcome ['Life-Impact']
with O
2 O
1.min-1 O
fresh O
gas O
flow O
, O
whereas O
11 O
% O
of O
those O
with O
uncuffed O
tubes O
needed O
greater O
fresh O
gas O
flow O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

In O
addition O
, O
data O
will O
be O
collected O
on O
physical B-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
( O
e.g. O
, O
flexion B-outcome ['Physiological-Clinical']
) O
at O
baseline O
and O
12 O
weeks O
and O
saliva O
samples O
will O
be O
obtained O
at O
baseline O
, O
6 O
and O
12 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
analyzed O
for O
both O
analytes O
lamivudine O
and O
stavudine O
by O
a O
validated O
analytical O
method O
. O
['Physiological-Clinical']

There O
was O
also O
a O
trend O
toward O
fewer O
isolated O
bone B-outcome ['Physiological-Clinical']
marrow I-outcome ['Physiological-Clinical']
relapses I-outcome ['Physiological-Clinical']
with O
dexamethasone O
. O
['Physiological-Clinical']

Patients O
received O
a O
5 O
mg O
kg O
( O
-1 O
) O
bolus O
of O
magnesium O
sulphate O
followed O
by O
a O
500 O
mg O
h O
( O
-1 O
) O
infusion O
or O
saline O
in O
the O
same O
volumes O
for O
24 O
h. O
Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
analgesic O
request O
, O
return O
of O
motor B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
visual O
analogue O
pain B-outcome ['Physiological-Clinical']
and O
sedation B-outcome ['Physiological-Clinical']
scores O
were O
evaluated O
every O
4 O
h O
during O
the O
24 O
h O
postoperative O
period O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
purpose O
of O
the O
present O
study O
was O
to O
compare O
the O
effects O
of O
a O
carbohydrate O
and O
a O
carbohydrate-protein O
supplement O
on O
aerobic B-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

After O
1 O
and O
6 O
h O
the O
median O
SBAs B-outcome ['Physiological-Clinical']
for O
imipenem O
and O
meropenem O
, O
were O
409 O
and O
34.9 O
and O
97.9 O
and O
5.8 O
, O
respectively O
, O
against O
Staphylococcus O
aureus O
, O
19.9 O
and O
4.4 O
and O
19.4 O
and O
4.8 O
, O
respectively O
, O
against O
Pseudomonas O
aeruginosa O
, O
34.3 O
and O
2.2 O
and O
232 O
and O
15.5 O
, O
respectively O
, O
against O
Enterobacter O
cloacae O
, O
and O
13.4 O
and O
2.25 O
and O
90.7 O
and O
7.9 O
, O
respectively O
, O
against O
Proteus O
mirabilis O
. O
['Physiological-Clinical']

Intravenous O
fibrinolysis O
( O
IVF O
) O
with O
rt-PA O
( O
alteplase O
) O
provides O
significant O
benefits O
in O
acute O
ischaemic O
stroke O
when O
it O
is O
given O
within O
the O
first O
three O
hours O
following O
stroke O
onset O
. O
[]

OBJECTIVES O
To O
assess O
, O
in O
a O
randomised O
controlled O
trial O
( O
RCT O
) O
and O
in O
clinical O
practice O
, O
an O
association O
of O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
and O
baseline O
disease O
activity O
with O
both O
induction O
of O
remission O
and O
sustained O
remission O
in O
etanercept-treated O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
. O
['Physiological-Clinical']

Clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
was O
observed O
in O
39 O
of O
41 O
( O
95.1 O
% O
) O
patients O
in O
group O
A O
and O
41 O
of O
41 O
( O
100 O
% O
) O
patients O
in O
group O
B O
( O
p=0.15 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
-0.12 O
to O
0.02 O
) O
. O
['Physiological-Clinical']

The O
SEM O
examination O
showed O
both O
sealers O
had O
better O
adaptation B-outcome ['Physiological-Clinical']
and O
penetration B-outcome ['Physiological-Clinical']
in O
coronal O
and O
middle O
thirds O
than O
apical O
third O
of O
root O
canal O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Overall O
our O
data O
seem O
to O
suggest O
that O
for O
most O
BCC O
and O
BD O
lesions O
, O
surface O
preparation O
did O
not O
increase O
ALA B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Gastric B-outcome ['Physiological-Clinical']
compliance B-outcome ['Life-Impact']
derived O
from O
isobaric O
distension O
rose O
in O
a O
dose O
related O
manner O
( O
42.6 O
( O
5.5 O
) O
and O
63.6 O
( O
7.7 O
) O
v O
27.0 O
( O
3.5 O
) O
ml/mm O
Hg O
; O
p=0.0004 O
) O
with O
a O
concomitant O
reduction O
of O
the O
pressure B-outcome ['Physiological-Clinical']
at O
half O
maximum O
bag O
volume O
( O
6.4 O
( O
0.4 O
) O
and O
5.5 O
( O
0.4 O
) O
v O
7.2 O
( O
0.1 O
) O
mm O
Hg O
; O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

A O
single O
treatment O
was O
insufficient O
in O
intraventricular O
and O
giant O
cysts O
. O
[]

Breathing B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
and O
thoracoabdominal B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
were O
determined O
before O
and O
after O
surgery O
while O
the O
patients O
awake O
by O
respiratory O
inductance O
plethysmography O
( O
Respisomnography O
, O
Chest O
MI O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
compare O
Angio-Seal O
( O
AS O
) O
and O
StarClose O
( O
SC O
) O
and O
manual O
compression O
( O
MC O
) O
on O
efficacy O
of O
hemostasis B-outcome ['Physiological-Clinical']
, O
complication B-outcome ['Adverse-effects']
rate O
, O
safety O
of O
early B-outcome ['Life-Impact']
mobilization I-outcome ['Life-Impact']
, O
and O
patient B-outcome ['Life-Impact']
comfort I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Adverse-effects', 'Life-Impact', 'Life-Impact']

Also O
, O
the O
Kaplan-Meier O
survival O
curves O
of O
these O
two O
groups O
were O
not O
significantly O
different O
by O
log-rank O
test O
( O
p=0.286 O
) O
. O
[]

Complications O
occurring O
up O
to O
20 O
days O
after O
the O
procedure O
were O
also O
recorded O
. O
[]

This O
technique O
may O
have O
a O
role O
in O
improving O
the O
quality O
of O
management O
of O
procedural O
pain O
in O
a O
pediatric O
ED O
setting O
. O
[]

The O
effect O
of O
the O
intervention O
on O
reducing O
disparities O
was O
significant O
( O
P O
= O
0.04 O
) O
. O
[]

CONCLUSIONS O
In O
this O
study O
, O
printed O
, O
tailored O
, O
iterative O
dietary O
feedback O
was O
more O
effective O
than O
small O
group O
nutrition O
education O
in O
improving O
the O
short-term O
fruit O
intake O
behaviour O
, O
and O
as O
effective O
in O
improving O
saturated O
fat O
intake O
of O
middle-aged O
adults O
with O
cardiovascular O
risk O
factors O
. O
[]

The O
results O
of O
this O
exploratory O
study O
found O
significant O
evidence O
supporting O
the O
value O
of O
music O
therapy O
in O
promoting O
social B-outcome ['Life-Impact']
, O
emotional B-outcome ['Life-Impact']
and O
motivational B-outcome ['Life-Impact']
development I-outcome ['Life-Impact']
in O
children O
with O
autism O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
clinical O
and O
biochemical O
effects O
of O
propofol O
infusion O
with O
and O
without O
EDTA O
for O
maintenance O
anesthesia O
in O
healthy O
children O
undergoing O
ambulatory O
surgery O
. O
[]

RESULTS O
In O
both O
groups O
, O
HV B-outcome ['Physiological-Clinical']
and O
HV B-outcome ['Physiological-Clinical']
standard I-outcome ['Physiological-Clinical']
deviation O
score O
HV-SDSCA B-outcome ['Physiological-Clinical']
increased O
during O
treatment O
and O
decreased O
during O
observation O
periods O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
examine O
long-term O
effects O
and O
costs O
of O
combined O
manipulative O
treatment O
, O
stabilizing O
exercises O
, O
and O
physician O
consultation O
compared O
with O
physician O
consultation O
alone O
for O
chronic O
low O
back O
pain O
( O
cLBP O
) O
. O
[]

No O
[]

Twenty-eight O
children O
( O
27 O
boys O
) O
ages O
3 O
to O
11 O
years O
( O
M O
= O
5.8 O
) O
with O
a O
primary O
diagnosis O
of O
autistic O
disorder O
received O
either O
placebo O
or O
lamotrigine O
twice O
daily O
. O
[]

Ratings O
from O
the O
matrix O
were O
then O
combined O
to O
generate O
a O
single O
overall O
exposure O
prevention O
rating O
for O
each O
area O
. O
[]

We O
measured O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
, O
eGFR B-outcome ['Physiological-Clinical']
, O
urinary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
, O
L-FABP B-outcome ['Physiological-Clinical']
and O
ET-1 B-outcome ['Physiological-Clinical']
before O
the O
start O
of O
treatment O
and O
6 O
and O
12 O
months O
after O
the O
start O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Prospective O
randomised O
multicentre O
trial O
with O
the O
birth O
trainer O
EPI-NO O
for O
the O
prevention O
of O
perineal B-outcome ['Physiological-Clinical']
trauma I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Forty-three O
required O
re-treatment O
( O
41 O
received O
a O
second O
course O
of O
IFN O
and O
2 O
received O
pentostatin O
) O
. O
[]

Three O
out O
of O
eight O
patients O
dropped O
out O
due O
to O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

A O
comparison O
of O
asthma O
episodes O
during O
the O
3 O
months O
before O
and O
after O
training O
showed O
a O
statistically O
significant O
decrease O
in O
the O
number O
of O
episodes O
but O
no O
change O
in O
severity O
in O
the O
preschool O
, O
school O
study O
, O
and O
school O
control O
groups O
. O
[]

The O
overall O
cecal O
mean O
insertion B-outcome ['Life-Impact']
time O
was O
6.00 O
+/- O
3.66 O
min O
. O
['Life-Impact']

Combined O
therapy O
for O
obese B-outcome ['Physiological-Clinical']
type O
2 O
diabetes B-outcome ['Physiological-Clinical']
: O
suppertime O
mixed O
insulin O
with O
daytime O
sulfonylurea O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
with O
observation O
for O
60 O
days O
and O
until O
discharge O
for O
patients O
with O
major O
infection O
on O
day O
60 O
. O
[]

d O
) O
. O
[]

A O
4 O
( O
intervention O
) O
x O
4 O
( O
occasions O
) O
( O
0,6,12 O
, O
and O
18 O
months O
) O
design O
was O
used O
. O
[]

Evaluation O
of O
AMSA O
in O
children O
with O
acute O
leukemia O
. O
[]

We O
evaluated O
the O
effect O
of O
DE O
inhalation O
on O
circulating O
blood O
cell O
populations O
, O
hematological O
indices O
, O
and O
systemic O
inflammatory O
cytokines O
in O
humans O
using O
a O
specialized O
facility O
. O
[]

CONCLUSION O
Riluzole O
add-on O
therapy O
shows O
several O
therapeutic O
outcomes O
, O
particularly O
for O
improving O
irritability O
, O
in O
children O
with O
autism O
. O
[]

Bovine O
collagen O
is O
widely O
used O
as O
a O
dermal O
filler O
for O
facial O
soft-tissue O
augmentation O
, O
but O
it O
provides O
only O
temporary O
cosmetic O
improvement O
. O
[]

The O
diagnosis O
of O
osteoporosis O
is O
based O
on O
bone O
mass O
measurement O
. O
[]

The O
therapy O
was O
either O
active O
40 O
KHz O
ultrasound O
delivered O
by O
a O
saline O
mist O
or O
a O
sham O
device O
which O
delivered O
a O
saline O
mist O
without O
the O
use O
of O
ultrasound O
. O
[]

VLDL B-outcome ['Physiological-Clinical']
, O
apolipoproteins B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
, O
CIII B-outcome ['Physiological-Clinical']
, O
and O
E B-outcome ['Physiological-Clinical']
, O
and O
risk O
of O
recurrent B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
the O
Cholesterol O
and O
Recurrent O
Events O
( O
CARE O
) O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

With O
regard O
to O
the O
range O
of O
motion B-outcome ['Physiological-Clinical']
of O
the O
operatively O
treated O
hip O
, O
the O
minimally O
invasive O
group O
had O
a O
smaller O
decrease O
at O
the O
ten-day O
time O
point O
in O
comparison O
with O
the O
standard O
group O
. O
['Physiological-Clinical']

This O
study O
involved O
12 O
patients O
, O
all O
of O
whom O
demonstrated O
recent O
suicidal B-outcome ['Life-Impact']
ideations I-outcome ['Life-Impact']
and O
had O
made O
a O
lifetime O
suicide O
attempt O
. O
['Life-Impact']

Rapid O
injection O
of O
propofol O
reduces O
vascular O
pain O
and O
facilitates O
Laryngeal O
Mask O
Airway O
insertion O
. O
[]

Studies O
evaluating O
fondaparinux O
for O
the O
treatment O
of O
VTE O
are O
part O
of O
the O
large O
MATISSE O
clinical O
program O
( O
MATISSE O
DVT O
and O
MATISSE O
PE O
) O
. O
[]

In O
conclusion O
, O
our O
study O
demonstrated O
that O
while O
the O
manipulation O
of O
hormone O
receptors O
seems O
possible O
, O
results O
indicating O
better O
overall O
survival O
and O
time O
to O
progression O
were O
not O
obtained O
with O
alternate O
sequential O
TAM-MPA O
therapy O
. O
[]

Physiologic O
parameters O
accounted O
for O
70 O
% O
of O
the O
variability O
, O
of O
which O
34 O
% O
was O
due O
to O
differences O
in O
duration O
of O
oronasal B-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
tON I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
36 O
% O
to O
differences O
in O
ventilation B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
oronasal I-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VE I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ON I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
; O
inhaled B-outcome ['Physiological-Clinical']
hydrogen I-outcome ['Physiological-Clinical']
ion I-outcome ['Physiological-Clinical']
concentration O
[ O
H+ O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Other O
safety O
and O
efficacy O
parameters O
were O
evaluated O
in O
cohorts O
of O
patients O
based O
on O
etoricoxib O
dose O
and O
disease O
. O
[]

M-mode O
echocardiographic O
measurements O
were O
made O
in O
21 O
patients O
with O
coronary O
artery O
disease O
who O
were O
receiving O
placebo O
, O
acebutolol O
, O
and O
propranolol O
in O
a O
double-blind O
, O
randomized O
, O
crossover O
study O
. O
[]

METHODS O
Patients O
with O
refractory O
AF O
underwent O
AV O
node O
ablation O
and O
were O
randomized O
( O
2:2:1 O
) O
to O
BiV O
pacing O
with O
CLS O
, O
BiV O
pacing O
with O
accelerometer O
, O
or O
right O
ventricular O
( O
RV O
) O
pacing O
. O
[]

The O
objectives O
of O
this O
randomized O
, O
comparative O
, O
open-label O
, O
multicentre O
study O
, O
conducted O
in O
Senegal O
and O
in O
Cameroon O
in O
2005 O
, O
was O
to O
demonstrate O
the O
non-inferiority O
and O
to O
compare O
the O
safety O
of O
artesunate B-outcome ['Resource-use']
plus I-outcome ['Resource-use']
amodiaquine I-outcome ['Resource-use']
, O
as O
a O
single O
daily O
intake O
versus O
two O
daily O
intakes O
. O
['Resource-use']

Effects O
of O
perioperative O
indomethacin O
on O
intracranial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
and O
cerebral B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
patients O
subjected O
to O
craniotomy O
for O
cerebral O
tumors O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
absorption O
of O
synthetic O
pteroyltriglutamate O
has O
been O
measured O
in O
nine O
normal O
students O
with O
and O
without O
the O
anticonvulsant O
drug O
phenytoin O
. O
[]

The O
local B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rates O
were O
32.4 O
% O
and O
28.2 O
% O
respectively O
( O
P O
= O
0.80 O
) O
; O
the O
isolated O
nodal B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
INF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
rates O
were O
3.0 O
% O
and O
2.6 O
% O
respectively O
( O
P O
= O
0.91 O
) O
; O
all O
INF O
sites O
were O
in O
the O
ipsilateral O
supraclavicular O
fossa O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Both O
anaesthetic O
agents O
produced O
adequate B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
. O
['Resource-use']

Findings O
highlight O
the O
importance O
of O
considering O
parental O
anxiety O
when O
targeting O
anxiety O
among O
youth O
with O
ASD O
. O
[]

Regression O
analysis O
identified O
that O
younger O
subjects O
with O
higher O
baseline O
weight O
z-score O
were O
at O
highest O
risk O
for O
weight O
gain O
. O
[]

The O
chi-square O
test O
was O
used O
for O
statistical O
analysis O
. O
[]

METHODS O
This O
was O
a O
randomised O
non-inferiority O
trial O
carried O
out O
in O
a O
school-based O
clinic O
in O
New O
Zealand O
. O
[]

Translating O
the O
Dietary O
Approaches O
to O
Stop O
Hypertension O
( O
DASH O
) O
diet O
for O
use O
in O
underresourced O
, O
urban O
African O
American O
communities O
, O
2010 O
. O
[]

CBT O
is O
a O
promising O
treatment O
for O
children O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
and O
focuses O
, O
in O
part O
, O
on O
children O
's O
independence O
and O
self-help B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact']

RESULTS O
Total O
costs B-outcome ['Resource-use']
per O
patient O
were O
the O
following O
: O
mean O
76,237 O
Euros O
; O
standard O
deviation O
32,565 O
Euros O
; O
median O
69,516 O
Euros O
; O
range O
183,758 O
to O
14,761Euros O
. O
['Resource-use']

Research O
linking O
the O
theory O
and O
findings O
from O
job O
strain O
and O
informal O
caregiving O
studies O
may O
elucidate O
both O
fields O
of O
research O
. O
[]

Neridronate O
prevents O
bone B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
patients O
receiving O
androgen O
deprivation O
therapy O
for O
prostate O
cancer O
. O
['Physiological-Clinical']

Five-year O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
menopausal O
females O
with O
breast O
tumors O
, O
stage O
IIb O
, O
was O
71.1 O
% O
among O
those O
treated O
with O
diethylstilbestrol O
and O
as O
low O
as O
57.4 O
% O
in O
the O
tamoxifen O
group O
( O
P O
< O
0.05 O
) O
. O
['Mortality']

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
a O
first O
trimester O
ultrasound O
dating O
scan O
on O
the O
rate O
of O
induction O
of O
labour B-outcome ['Physiological-Clinical']
for O
prolonged B-outcome ['Physiological-Clinical']
pregnancy B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
previously O
reported O
a O
decline O
in O
bone O
mineral O
density O
( O
BMD O
) O
following O
the O
switch O
from O
tamoxifen O
to O
exemestane O
in O
the O
Intergroup O
Exemestane O
Study O
( O
IES O
) O
. O
[]

PATIENTS O
AND O
METHODS O
A O
total O
of O
145 O
patients O
with O
chronic O
radiation-induced O
xerostomia O
> O
18 O
months O
after O
treatments O
were O
recruited O
from O
seven O
UK O
cancer O
centres O
. O
[]

We O
found O
beneficial O
effects O
of O
iTBS O
on O
mood B-outcome ['Life-Impact']
, O
but O
no O
improvement O
of O
gait B-outcome ['Life-Impact']
, O
bradykinesia B-outcome ['Physiological-Clinical']
, O
UPDRS B-outcome ['Physiological-Clinical']
, O
and O
other O
measures O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Fifty-six O
clinical O
centers O
screened O
all O
patients O
who O
presented O
with O
ventricular O
tachycardia O
or O
ventricular O
fibrillation O
during O
a O
period O
of O
nearly O
four O
years O
. O
[]

Fingertip B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
and O
laser B-outcome ['Physiological-Clinical']
Doppler I-outcome ['Physiological-Clinical']
flux I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
a O
radiological O
examination O
, O
no O
leak O
of O
contrast O
medium O
under O
the O
tourniquet O
cuff O
( O
300 O
mmHg O
) O
was O
detected O
. O
[]

METHODS O
AND O
RESULTS O
A O
primary O
4:1 O
bipolar/unipolar O
mode O
in O
group O
A O
patients O
( O
n O
= O
22 O
) O
was O
compared O
with O
a O
primary O
2:1 O
mode O
in O
group O
B O
( O
n O
= O
22 O
) O
acutely O
and O
during O
follow-up O
. O
[]

Cyclosporin O
A O
increases O
somatomedin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
insulin-like I-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor O
I O
levels O
in O
chronic O
rheumatic O
diseases O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Response O
to O
ovarian B-outcome ['Physiological-Clinical']
stimulation I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
occurrence I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
spontaneous I-outcome ['Physiological-Clinical']
luteinizing I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( O
LH B-outcome ['Physiological-Clinical']
) O
surges B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pharmacodynamic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
pregnanolone O
was O
assessed O
before O
treatment O
, O
and O
during O
the O
last O
week O
of O
each O
treatment O
cycle O
, O
by O
comparing O
the O
effects O
of O
intravenous O
pregnanolone O
( O
3alpha-hydroxy-5beta-pregnan-20-one O
) O
on O
saccadic B-outcome ['Physiological-Clinical']
eye I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
( O
SEV B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Lower O
relapse O
rates O
after O
neighbourhood O
injection O
of O
Corynebacterium O
parvum O
in O
operable O
cervix O
carcinoma O
. O
[]

No O
decline O
in O
performance O
occurred O
with O
risperidone O
. O
[]

1196 O
patients O
were O
assessed O
for O
the O
three-class O
versus O
combined O
two-class O
primary O
endpoint O
. O
[]

The O
treatment O
group O
was O
hypnotized O
and O
read O
a O
passage O
while O
in O
hypnosis O
. O
[]

Many O
randomized O
controlled O
trials O
( O
RCTs O
) O
in O
dental O
research O
test O
the O
efficacy O
of O
interventions O
on O
more O
than O
one O
outcome O
variable O
. O
[]

Efficacy O
outcomes O
24 O
weeks O
after O
each O
course O
were O
calculated O
relative O
to O
first O
RTX O
pretreatment O
baseline O
. O
[]

Participants O
will O
be O
recruited O
from O
two O
major O
maternity O
hospitals O
in O
Australia O
. O
[]

Therapist-responsible O
process O
consists O
of O
primary O
therapist-couple O
interaction O
, O
therapist O
interpretation O
, O
and O
direct O
instruction O
. O
[]

We O
observed O
the O
percent O
improvement O
of O
the O
RP B-outcome ['Physiological-Clinical']
attack I-outcome ['Physiological-Clinical']
rate O
between O
before O
and O
after O
the O
8-week O
treatment O
. O
['Physiological-Clinical']

This O
study O
of O
plantar O
flexor O
spasticity O
describes O
relationships O
among O
a O
traditional O
qualitative O
spasticity O
scale O
, O
three O
potential O
quantitative O
spasticity O
measures O
and O
a O
measure O
of O
voluntary O
ankle O
muscle O
function O
. O
[]

RESULTS O
Acupuncture O
compared O
with O
oral O
care O
, O
produced O
significant O
reductions O
in O
patient O
reports O
of O
severe B-outcome ['Physiological-Clinical']
dry I-outcome ['Physiological-Clinical']
mouth B-outcome ['Physiological-Clinical']
( O
OR O
= O
2.01 O
, O
P O
= O
0.031 O
) O
sticky B-outcome ['Physiological-Clinical']
saliva I-outcome ['Physiological-Clinical']
( O
OR O
= O
1.67 O
, O
P O
= O
0.048 O
) O
, O
needing B-outcome ['Physiological-Clinical']
to O
sip B-outcome ['Physiological-Clinical']
fluids I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Five O
of O
10 O
patients O
taking O
omeprazole-amoxycillin O
dual O
therapy O
had O
their O
H. O
pylori O
infection O
cured O
( O
P O
= O
0.0007 O
vs. O
patients O
taking O
dirithromycin O
plus O
omeprazole O
) O
. O
[]

Overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
73 O
percent O
and O
81 O
percent O
( O
P O
= O
0.11 O
) O
, O
respectively O
. O
['Mortality']

Relief O
of O
pain B-outcome ['Physiological-Clinical']
by O
infusion O
of O
morphine O
after O
operation O
: O
does O
tolerance O
develop O
? O
['Physiological-Clinical']

METHODS O
63 O
of O
68 O
consecutive O
patients O
who O
met O
criteria O
for O
acute O
cholecystitis O
were O
randomly O
assigned O
OC O
( O
31 O
patients O
) O
or O
LC O
( O
32 O
patients O
) O
. O
[]

All O
vaccinations O
were O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
with O
mainly O
mild O
or O
moderate B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
at O
the O
injection O
site O
being O
the O
most O
frequent O
symptom O
. O
['Life-Impact', 'Physiological-Clinical']

[ O
Using O
gaviscon O
preparation O
for O
relief O
of O
esophageal O
, O
extraesophageal O
syndromes O
and O
functional O
dyspepsia O
in O
elderly O
patients O
with O
GERD O
] O
. O
[]

The O
right O
ventricular O
coil O
was O
the O
cathode O
for O
the O
first O
phase O
of O
the O
biphasic O
defibrillation O
waveform O
. O
[]

SETTING O
A O
specialized O
outpatient O
dermatology O
clinic O
within O
a O
state-funded O
hospital O
in O
Germany O
. O
[]

RE-LY O
is O
a O
phase O
3 O
, O
prospective O
, O
randomized O
, O
open-label O
multinational O
( O
44 O
countries O
) O
trial O
of O
patients O
with O
nonvalvular O
AF O
and O
at O
least O
1 O
risk O
factor O
for O
stroke O
. O
[]

Contribution O
of O
[]

The O
incidence O
rate O
for O
bleeding O
complications B-outcome ['Resource-use']
requiring I-outcome ['Resource-use']
surgical I-outcome ['Resource-use']
intervention I-outcome ['Resource-use']
was O
1.8 O
per O
cet O
for O
the O
laser O
group O
and O
14.6 O
per O
cent O
for O
the O
cold O
knife O
group O
. O
['Resource-use']

METHODS O
A O
pilot O
multinational O
, O
multicentre O
, O
randomized O
, O
active-controlled O
, O
parallel O
group O
open-label O
study O
has O
been O
conducted O
in O
a O
group O
of O
patients O
with O
progressive O
chronic O
renal O
failure O
( O
creatinine O
clearance O
20-45 O
ml/min O
) O
either O
with O
or O
without O
proteinuria O
and O
hypertension O
. O
[]

The O
effect O
of O
RPMT O
on O
growth B-outcome ['Physiological-Clinical']
rate O
['Physiological-Clinical']

The O
side-effect B-outcome ['Adverse-effects']
profile O
was O
similar O
among O
treatments O
. O
['Adverse-effects']

Peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
220.0 O
+/- O
12.9 O
and O
324.3 O
+/- O
84.3 O
in O
group O
I O
, O
218.0 O
+/- O
16.4 O
and O
260.5 O
+/- O
35.2 O
in O
group O
II O
) O
and O
inspiratory B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
( O
844.0 O
+/- O
147.4 O
and O
1100.0 O
+/- O
158.1 O
in O
group O
I O
, O
830.0 O
+/- O
117.4 O
and O
1090 O
+/- O
137 O
in O
group O
II O
) O
were O
significantly O
lower O
before O
and O
after O
surgery O
respectively O
in O
both O
groups O
compared O
to O
normal O
values O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
importance O
of O
the O
VEGF/VEGFR-2 O
system O
for O
angiogenesis O
in O
hematologic O
malignancies O
such O
as O
AML O
remains O
to O
be O
elucidated O
. O
[]

Similar O
responses O
occurred O
in O
167 O
patients O
who O
completed O
Year O
7 O
. O
[]

The O
risk O
profile O
( O
new O
CML O
score O
) O
was O
available O
for O
532 O
patients O
: O
200 O
patients O
( O
38 O
% O
) O
were O
low O
, O
239 O
patients O
( O
45 O
% O
) O
intermediate O
, O
and O
93 O
patients O
( O
17 O
% O
) O
high O
risk O
. O
[]

In O
this O
paper O
we O
report O
on O
individual O
and O
family-level O
factors O
associated O
with O
enrollment O
in O
a O
cancer O
prevention O
research O
project O
. O
[]

The O
primary O
outcome O
measure O
is O
IUD B-outcome ['Life-Impact']
expulsion I-outcome ['Life-Impact']
rate O
at O
1 O
year O
. O
['Life-Impact']

Eligibility O
was O
limited O
primarily O
by O
geographic O
distance O
from O
the O
day O
care O
center O
. O
[]

An O
exponential O
trend O
line O
was O
drawn O
using O
the O
three O
CEA O
values O
. O
[]

Sodium O
cromoglycate O
formulated O
as O
a O
pressurized O
aerosol O
( O
2 O
mg O
4-times O
daily O
) O
and O
placebo O
were O
compared O
in O
31 O
adult O
asthmatic O
patients O
in O
a O
double-blind O
crossover O
trial O
lasting O
12 O
weeks O
. O
[]

In O
the O
combination O
phase O
, O
RPF B-outcome ['Physiological-Clinical']
increased O
by O
123 O
+/- O
36 O
mL/min O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Ganitumab O
is O
a O
monoclonal O
IgG1 O
antibody O
that O
blocks O
IGF-1R O
. O
[]

The O
CYP1A2 B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
, O
oral B-outcome ['Physiological-Clinical']
caffeine I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( O
6.2 O
+/- O
3.3 O
l/h O
before O
and O
5.7 O
+/- O
4.2 O
l/h O
after O
, O
p O
> O
0.05 O
) O
and O
the O
6-h B-outcome ['Physiological-Clinical']
paraxanthine I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
caffeine I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
concentration O
ratio O
( O
0.49 O
+/- O
0.3 O
before O
and O
0.44 O
+/- O
0.3 O
after O
, O
p O
> O
0.05 O
) O
, O
were O
unchanged O
following O
clarithromycin O
dosing O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Relative O
to O
controls O
, O
patients O
who O
viewed O
either O
of O
the O
videotapes O
before O
hospital O
release O
reported O
higher O
self-efficacy O
for O
adhering B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
recommended I-outcome ['Life-Impact']
low-fat I-outcome ['Life-Impact']
diet I-outcome ['Life-Impact']
both O
at O
discharge O
and O
1 O
month O
after O
surgery O
. O
['Life-Impact']

However O
, O
the O
survey O
indicated O
that O
the O
telephone O
calls O
were O
clinically O
significant O
and O
provided O
a O
mechanism O
for O
demonstrating O
that O
the O
health O
care O
professionals O
cared O
about O
their O
patients O
and O
provided O
an O
opportunity O
for O
patients O
to O
talk O
about O
their O
concerns O
. O
[]

INTRODUCTION O
Reperfusion O
injury O
reduces O
the O
benefits O
of O
early O
reperfusion O
therapies O
after O
acute O
ST-elevation O
myocardial O
infarction O
( O
STEMI O
) O
. O
[]

Examinations O
included O
ETDRS B-outcome ['Physiological-Clinical']
best-corrected I-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BCVA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
fluorescein O
angiography O
( O
FLA O
) O
and O
OCT O
at O
baseline O
, O
3 O
and O
6 O
months O
postoperatively O
. O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
statistical O
differences O
between O
the O
groups O
in O
terms O
of O
age O
, O
sex O
, O
indication O
for O
MV O
, O
PRISM O
score O
, O
Comfort O
scale O
, O
use O
of O
sedatives O
or O
ventilation O
and O
oxygenation O
parameters O
. O
[]

CONCLUSIONS O
Women O
at O
highest O
risk O
of O
default O
from O
follow-up O
cytology O
tend O
to O
be O
young O
, O
smoke O
, O
lack O
post-secondary O
education O
, O
and O
have O
defaulted O
from O
a O
previous O
surveillance O
appointment O
. O
[]

Significant O
( O
3.6 O
mm O
Hg O
) O
and O
nonsignificant O
( O
1.9 O
mm O
Hg O
) O
decreases O
in O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
respectively O
, O
were O
observed O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
in O
vitro O
secondary O
caries O
study O
was O
to O
examine O
the O
glass-ionomer O
liner O
's O
effect O
on O
wall-lesion O
inhibition O
when O
a O
conventional O
and O
a O
light-cured O
glass O
ionomer O
liner O
was O
placed O
under O
amalgam O
and O
composite O
resin O
restorations O
. O
[]

Patients O
also O
completed O
measures O
of O
dietary B-outcome ['Life-Impact']
fat I-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
and O
activity O
level O
1 O
and O
3 O
months O
after O
discharge O
. O
['Life-Impact']

Risedronate O
significantly O
increased O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
at O
the O
spine O
and O
hip O
within O
6 O
months O
. O
['Physiological-Clinical']

In O
groups O
1 O
and O
3 O
, O
the O
brackets O
were O
bonded O
directly O
to O
etched O
enamel O
surfaces O
; O
in O
groups O
2 O
and O
4 O
, O
the O
etched O
enamel O
was O
covered O
with O
HFLCS O
( O
Pro O
Seal O
, O
Reliance O
Orthodontic O
Products O
, O
Itasca O
, O
Ill O
) O
. O
[]

To O
compare O
interventions O
, O
we O
analysed O
students O
' O
diagnostic O
accuracy O
. O
[]

The O
haemodynamic O
response O
to O
antagonistic O
( O
10 O
microgram O
min-1 O
kg-1 O
) O
and O
agonistic O
( O
40 O
microgram O
min-1 O
kg-1 O
) O
doses O
of O
saralasin O
was O
studied O
in O
young O
essential O
hypertensive O
patients O
. O
[]

All O
patients O
underwent O
single-photon O
emission O
computed O
tomography O
( O
SPECT O
) O
after O
the O
injection O
of O
technetium-99m O
( O
Tc-99m O
) O
sestamibi O
at O
rest O
. O
[]

DESIGN O
Single O
blind O
randomized O
clinical O
trial O
. O
[]

This O
study O
investigated O
the O
influence O
of O
pre-treatment O
proliferation O
characteristics O
, O
assessed O
by O
Ki-67 O
staining O
, O
in O
patients O
treated O
in O
the O
CHART O
trial O
of O
accelerated O
radiotherapy O
in O
head O
and O
neck O
cancer O
. O
[]

Multivariate O
logistic O
regression O
analysis O
showed O
a O
1.66-fold O
increased O
risk O
for O
severe B-outcome ['Physiological-Clinical']
diarrhea I-outcome ['Physiological-Clinical']
in O
patients O
with O
AA O
genotype O
( O
95 O
% O
CI O
1.03 O
- O
2.67 O
, O
P O
= O
0.038 O
) O
compared O
with O
the O
cases O
with O
GG O
or O
GA O
genotypes O
. O
['Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

An O
infected O
quarter O
was O
defined O
as O
cured O
if O
S. O
aureus O
was O
not O
isolated O
from O
the O
fresh O
or O
frozen O
culture O
from O
milk O
samples O
obtained O
following O
calving O
. O
[]

CONCLUSION O
For O
such O
a O
subset O
of O
patients O
, O
consolidation O
with O
the O
CBV O
regimen O
followed O
by O
autologous O
bone O
marrow O
transplantation O
is O
not O
superior O
to O
sequential O
chemotherapy O
. O
[]

Patients O
, O
investigators O
, O
and O
those O
assessing O
data O
were O
masked O
to O
allocation O
. O
[]

POPULATION O
Immigrants O
with O
LTBI O
. O
[]

METHODS O
A O
randomised O
, O
controlled O
, O
prospective O
study O
of O
100 O
preterm O
infants O
, O
weighing O
less O
than O
1750 O
g O
at O
birth O
and O
requiring O
ventilatory O
support O
and O
parenteral O
nutrition O
, O
was O
performed O
. O
[]

Any O
progression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
albuminuria I-outcome ['Physiological-Clinical']
( O
defined O
as O
new O
microalbuminuria O
or O
new O
clinical O
proteinuria O
) O
occurred O
in O
1859 O
participants O
; O
1542 O
developed O
new O
microalbuminuria B-outcome ['Physiological-Clinical']
, O
and O
317 O
participants O
developed O
clinical B-outcome ['Physiological-Clinical']
proteinuria I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Participants O
were O
recruited O
via O
direct O
mailing O
within O
the O
participating O
Municipal O
Health O
Council O
regions O
and O
randomized O
to O
the O
printed O
or O
Web-based O
intervention O
by O
their O
region O
. O
[]

SC O
was O
more O
often O
not O
used O
or O
successfully O
deployed O
. O
[]

Indoor O
exposure O
to O
asthma O
triggers O
has O
emerged O
as O
an O
important O
cause O
of O
asthma O
exacerbations O
. O
[]

Analysis O
of O
covariance O
models O
were O
used O
to O
compare O
changes O
between O
CRC B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
and O
health I-outcome ['Life-Impact']
belief I-outcome ['Life-Impact']
scores O
at O
baseline O
and O
1 O
week O
post-intervention O
. O
['Life-Impact']

CONCLUSIONS O
Patient-specific O
feedback O
to O
inner-city O
providers O
increased O
scheduled O
asthma O
visits O
, O
increased O
asthma O
visits O
in O
which O
medications O
were O
stepped O
up O
when O
clinically O
indicated O
, O
and O
reduced O
emergency O
department O
visits O
. O
[]

CONCLUSIONS O
Simple O
knee O
flexion O
and O
extension O
exercises O
( O
WB O
and O
NWB O
) O
performed O
over O
8 O
weeks O
resulted O
in O
significant O
improvement O
in O
the O
WOMAC O
function B-outcome ['Life-Impact']
scale O
and O
knee O
strength O
compared O
with O
the O
control O
group O
. O
['Life-Impact']

CONCLUSIONS O
Although O
the O
7-day O
PPI-containing O
triple O
anti-H. O
pylori O
therapy O
is O
not O
inferior O
to O
the O
14-day O
therapy O
, O
neither O
treatment O
duration O
provides O
acceptable O
eradication B-outcome ['Physiological-Clinical']
rate O
reaching O
90 O
% O
in O
per-protocol O
analysis O
. O
['Physiological-Clinical']

An O
increased O
[ O
Atot O
] O
, O
due O
to O
increased O
[ O
PP O
] O
and O
a O
sustained O
increase O
in O
plasma B-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
acetate I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
, O
contributed O
a O
minor O
acidifying B-outcome ['Physiological-Clinical']
effect O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
may O
be O
useful O
in O
the O
decision O
to O
administer O
thrombolytic O
treatment O
. O
[]

To O
date O
the O
vastus O
medialis O
( O
VM O
) O
and O
soleus O
( O
SOL O
) O
H-reflexes O
have O
been O
examined O
primarily O
in O
control O
subjects O
with O
induced O
knee O
joint O
effusion O
. O
[]

The O
association O
between O
changes O
in O
the O
QLQ-C30 O
change O
and O
the O
corresponding O
SSQ O
ratings O
were O
determined O
by O
calculation O
of O
mean O
change O
scores O
for O
each O
SSQ O
category O
and O
by O
Spearman O
rank O
correlation O
coefficient O
analysis O
. O
[]

RESULTS O
At O
the O
beginning O
of O
the O
study O
BMD B-outcome ['Physiological-Clinical']
at O
both O
measuring O
sites O
was O
lower O
in O
patients O
with O
GHD O
than O
in O
healthy O
controls O
. O
['Physiological-Clinical']

Further O
studies O
with O
larger O
sample O
sizes O
and O
longer O
follow-up O
times O
are O
warranted O
to O
justify O
its O
use O
in O
routine O
clinical O
practice O
. O
[]

Patients O
were O
randomly O
assigned O
to O
receive O
or O
not O
to O
receive O
ifosfamide O
and/or O
MTP O
in O
a O
2 O
x O
2 O
factorial O
design O
. O
[]

A O
standardized O
anaesthetic O
technique O
of O
propranolol O
, O
thiopentone-vecuronium-isoflurane O
was O
used O
in O
all O
patients O
and O
hypotension O
induced O
with O
sodium O
nitroprusside O
, O
trimetaphan O
camsylate O
or O
additional O
isoflurane O
. O
[]

Twenty O
subjects O
with O
chronic O
CRPS1 O
initiated O
by O
wrist O
fracture O
and O
who O
satisfied O
stringent O
inclusion O
criteria O
, O
were O
randomly O
allocated O
to O
one O
of O
three O
groups O
: O
hand O
laterality O
recognition O
, O
imagined O
movements O
, O
mirror O
movements O
( O
RecImMir O
, O
MIP O
) O
; O
imagined O
movements O
, O
recognition O
, O
imagined O
movements O
( O
ImRecIm O
) O
; O
recognition O
, O
mirror O
movements O
, O
recognition O
( O
RecMirRec O
) O
. O
[]

Larger O
livestock O
units O
, O
a O
decline O
in O
the O
farm O
labor O
force O
, O
animal O
welfare O
concerns O
, O
and O
a O
trend O
toward O
more O
selective O
use O
of O
drugs O
have O
increased O
the O
focus O
on O
animal O
handling O
, O
time O
management O
, O
convenience O
, O
and O
compliance O
in O
administering O
veterinary O
therapeutics O
. O
[]

Mean O
symptom B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
over O
the O
first O
7 O
days O
were O
lower O
for O
the O
children O
treated O
with O
amoxicillin-clavulanate O
than O
for O
those O
who O
received O
placebo O
( O
P=0.02 O
) O
. O
['Physiological-Clinical']

Arm O
: O
docetaxel O
cisplatin O
( O
cycles O
repeated O
every O
21 O
days O
) O
, O
4 O
cycles O
followed O
by O
2 O
cycles O
of O
docetaxel O
alone O
in O
case O
of O
objective B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
or O
stabilisation O
. O
['Physiological-Clinical']

Stage O
II/FH O
patients O
also O
had O
either O
zero O
or O
2000 O
cGy O
irradiation O
( O
RT O
) O
postoperatively O
and O
Stage O
III/FH O
patients O
either O
1000 O
or O
2000 O
cGy O
. O
[]

METHODS O
Thirty-four O
consecutive O
patients O
were O
randomly O
assigned O
to O
the O
GCA O
( O
18 O
patients O
) O
or O
EPA O
( O
16 O
patients O
) O
CS O
cannulation O
strategy O
. O
[]

The O
results O
are O
reported O
using O
intraclass O
correlation O
coefficients O
( O
ICCs O
) O
and O
Bland-Altman O
analysis O
. O
[]

Registry O
information O
from O
the O
last O
9 O
years O
was O
used O
to O
identify O
3,585 O
women O
who O
met O
the O
study O
criteria O
with O
respect O
to O
age O
, O
stage O
, O
and O
previous O
therapy O
. O
[]

RESULTS O
Coadministration O
of O
enalapril-compared O
with O
placebo-resulted O
in O
a O
temporarily O
higher O
metabolic B-outcome ['Physiological-Clinical']
effect O
of O
glibenclamide B-outcome ['Physiological-Clinical']
( O
AUC O
GIR O
( O
0-120 O
) O
229 O
+/- O
173 O
vs O
137 O
+/- O
44 O
mg O
kg O
( O
-1 O
) O
, O
p O
< O
0.01 O
; O
mean O
+/- O
SD O
) O
, O
which O
lasted O
from O
120 O
min O
to O
240 O
min O
after O
enalapril O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Prospective O
controlled O
study O
of O
androgen O
therapy O
in O
the O
anemia B-outcome ['Physiological-Clinical']
of O
chronic O
renal O
disease O
: O
effects O
on O
iron O
kinetics O
. O
['Physiological-Clinical']

The O
study O
was O
performed O
with O
two O
groups O
of O
5 O
healthy O
subjects O
, O
each O
group O
receiving O
one O
of O
the O
active O
treatments O
or O
placebo O
randomly O
under O
blind O
conditions O
. O
[]

The O
number O
of O
hospitalized B-outcome ['Resource-use']
participants O
increased O
by O
69 O
% O
among O
the O
controls O
and O
decreased O
by O
38 O
% O
in O
the O
intervention O
group O
( O
P O
= O
.083 O
) O
. O
['Resource-use']

However O
, O
3-port O
patients O
reported O
better O
physical O
attractiveness O
( O
4.0 O
? O
[]

The O
mean O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
intubation I-outcome ['Life-Impact']
( O
TAMS O
62 O
s O
vs. O
OSD O
56 O
s O
) O
and O
the O
success B-outcome ['Physiological-Clinical']
rate O
was O
not O
different O
between O
the O
two O
groups O
( O
P O
> O
0.05 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

These O
results O
provide O
further O
support O
that O
even O
brief O
, O
targeted O
interventions O
on O
joint O
attention O
and O
play O
can O
improve O
core O
deficits O
in O
minimally O
verbal O
children O
with O
ASD O
. O
[]

Assessment O
of O
object B-outcome ['Life-Impact']
interest I-outcome ['Life-Impact']
was O
conducted O
in O
an O
unstructured O
play O
session O
with O
different O
toys O
, O
activities O
, O
adult O
, O
and O
location O
than O
experienced O
in O
treatment O
. O
['Life-Impact']

OBJECTIVE O
To O
describe O
the O
process O
and O
results O
of O
diet O
standardization O
, O
diet O
validation O
, O
and O
monitoring O
of O
diet O
composition O
, O
which O
were O
key O
components O
of O
protocol O
1 O
of O
Dietary O
Effects O
on O
Lipoproteins O
and O
Thrombogenic O
Activity O
( O
DELTA-1 O
) O
, O
the O
initial O
protocol O
in O
a O
program O
of O
multicenter O
human O
feeding O
studies O
designed O
to O
evaluate O
the O
effects O
of O
amount O
and O
type O
of O
fat O
on O
lipoproteins O
and O
hemostasis O
parameters O
in O
various O
demographic O
groups O
. O
[]

Effect O
of O
cigarette O
smoking O
on O
gastric O
emptying O
of O
solids O
in O
Japanese O
smokers O
: O
a O
crossover O
study O
using O
the O
13C-octanoic O
acid O
breath O
test O
. O
[]

Thermal O
welding O
versus O
bipolar O
tonsillectomy O
: O
a O
comparative O
study O
. O
[]

This O
study O
establishes O
the O
short-term B-outcome ['Physiological-Clinical']
antiproteinuric I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of O
diclofenac O
. O
['Physiological-Clinical']

The O
second O
most O
'important O
' O
reason O
for O
sunbathing O
was O
'feeling O
warm O
and O
comfortable O
' O
. O
[]

Cell-mediated O
immunity O
was O
evaluated O
by O
T-cell O
subset O
analysis O
, O
delayed-type O
hypersensitivity O
skin O
testing O
, O
and O
lymphocyte O
transformation O
with O
phytohemagglutinin O
. O
[]

Dacarbazine O
was O
given O
i.v O
. O
[]

We O
examined O
supine O
resting O
HRV O
in O
373 O
post-menopausal O
women O
( O
45-75 O
y O
) O
after O
6-months O
of O
randomly O
assigned O
and O
double-blinded O
administered O
exercise O
training O
exercise O
training O
at O
50 O
% O
, O
100 O
% O
and O
150 O
% O
of O
the O
NIH O
Consensus O
Development O
Panel O
's O
recommended O
minimal O
physical O
activity O
level O
. O
[]

In O
this O
randomized O
, O
blinded O
, O
multicenter O
comparison O
study O
, O
377 O
infants O
and O
children O
with O
acute O
otitis O
media O
( O
AOM O
) O
received O
a O
10-day O
course O
of O
an O
oral O
suspension O
of O
one O
of O
the O
following O
: O
cefuroxime O
axetil O
( O
CAE O
) O
, O
30 O
mg/kg/day O
; O
cefaclor O
( O
CEC O
) O
, O
40 O
mg/kg/day O
; O
or O
amoxicillin-clavulanate O
potassium O
( O
AMX-CL O
) O
, O
40 O
mg/kg/day O
. O
[]

The O
degree O
of O
ventilatory B-outcome ['Physiological-Clinical']
limitation I-outcome ['Physiological-Clinical']
, O
as O
expressed O
by O
the O
Ve/maximum B-outcome ['Physiological-Clinical']
voluntary I-outcome ['Physiological-Clinical']
ventilation I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
was O
similar O
in O
both O
conditions O
in O
patients O
with O
COPD O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
are O
no O
differences O
in O
efficacy O
or O
safety O
between O
the O
insert O
and O
the O
usually O
administered O
eyedrops O
, O
but O
the O
low O
total O
drug O
dose O
administered O
with O
the O
insert O
reduces O
the O
risk O
of O
cardiovascular O
side O
effects O
. O
[]

Using O
functional O
magnetic O
resonance O
imaging O
, O
we O
examined O
whether O
oxytocin O
would O
enhance O
emotion B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
from O
facial O
sections O
of O
the O
eye O
vs O
the O
mouth O
region O
and O
modulate B-outcome ['Physiological-Clinical']
regional B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
areas I-outcome ['Physiological-Clinical']
associated O
with O
face O
perception B-outcome ['Life-Impact']
in O
both O
adults O
with O
AS O
, O
and O
a O
neurotypical O
control O
group O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

However O
, O
it O
did O
not O
demonstrate O
obvious O
advantages O
over O
TURP O
in O
this O
acute O
regional O
hospital O
regular O
TURP O
list O
setting O
. O
[]

CONCLUSION O
Orally O
administered O
misoprostol O
at O
a O
dose O
of O
400 O
mug O
is O
an O
acceptable O
alternative O
in O
preventing O
post-partum O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
as O
measured O
by O
the O
peri-partum O
change O
in O
hemoglobin B-outcome ['Physiological-Clinical']
level O
and O
was O
not O
associated O
with O
an O
increased O
incidence O
of O
side O
effects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Six O
hundred O
fifty-five O
patients O
with O
chronic O
AF O
underwent O
maximal O
exercise O
testing O
at O
baseline O
and O
8 O
weeks O
, O
6 O
months O
, O
and O
1 O
year O
after O
randomization O
to O
sotalol O
, O
amiodarone O
, O
or O
placebo O
therapy O
and O
attempted O
direct O
current O
cardioversion O
. O
[]

Phenylbutazone O
delayed O
the O
postoperative O
rise O
of O
fibrinogen B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
reduced O
the O
plasminogen B-outcome ['Physiological-Clinical']
level O
on O
the O
first O
day O
after O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
differences O
were O
detected O
between O
the O
two O
treatment O
groups O
in O
time O
to O
progression B-outcome ['Physiological-Clinical']
, O
objective O
response O
rates O
, O
duration O
of O
response B-outcome ['Physiological-Clinical']
, O
and O
survival B-outcome ['Mortality']
in O
either O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

CONCLUSIONS O
Despite O
advances O
in O
interventional O
techniques O
, O
diabetes O
remains O
a O
significant O
independent O
predictor O
of O
adverse O
events O
in O
the O
intermediate O
term O
after O
PCI O
. O
[]

All O
patients O
received O
melphalan O
and O
prednisone O
daily O
for O
4 O
days O
every O
4 O
weeks O
as O
the O
primary O
chemotherapy O
for O
their O
disease O
. O
[]

Evoked O
potentials O
to O
auditory O
stimulations O
varying O
in O
intensity O
were O
studied O
in O
13 O
children O
with O
autistic O
behavior O
treated O
with O
fenfluramine O
. O
[]

All O
patients O
were O
evaluated O
with O
echocardiography O
and O
a O
standardized O
CPX O
test O
as O
part O
of O
the O
trial O
. O
[]

Reperfusion O
with O
leukocyte-depleted O
blood O
or O
whole O
blood O
was O
carried O
out O
for O
10 O
minutes O
, O
with O
enriched O
cardioplegic O
solution O
added O
for O
the O
first O
3 O
minutes O
of O
reperfusion O
. O
[]

BACKGROUND O
The O
primary O
care O
setting O
offers O
the O
opportunity O
to O
reach O
children O
and O
parents O
to O
encourage O
healthy O
lifestyle O
behaviours O
, O
and O
improve O
weight O
status O
among O
children O
. O
[]

This O
trial O
is O
registered O
with O
the O
Iranian O
Clinical O
Trials O
Registry O
( O
IRCT1138901151556N10 O
; O
www.irct.ir O
) O
. O
[]

Patients O
were O
randomly O
allocated O
into O
one O
of O
the O
two O
regimens O
, O
with O
dosage O
according O
to O
bodyweight O
range O
. O
[]

PATIENTS O
Twenty-four O
patients O
( O
twelve O
of O
whom O
were O
controls O
) O
treated O
with O
high-dose O
chemotherapy O
and O
autologous O
bone O
marrow O
transplantation O
. O
[]

Children O
viewed O
an O
educational O
film O
, O
and O
memory O
for O
this O
was O
later O
assessed O
. O
[]

However O
, O
in O
experimental O
studies O
hypercapnia O
impairs O
myocardial O
contractility O
and O
hemodynamic O
function O
. O
[]

A O
statistically O
significant O
linear O
trend O
of O
an O
increase O
in O
calcium O
absorption O
adjusted O
for O
age O
and O
body O
mass O
index O
with O
increasing O
vitamin O
D? O
dose O
or O
serum O
25 O
( O
OH O
) O
D O
concentration O
was O
observed O
. O
[]

In O
terms O
of O
cancer O
deaths O
, O
only O
colorectal O
cancer O
in O
men O
shows O
a O
significant O
positive O
correlation O
( O
r O
= O
0.91 O
, O
P O
< O
0.05 O
) O
, O
and O
[]

This O
study O
compared O
oral O
mucositis O
pain O
levels O
in O
4 O
groups O
of O
cancer O
patients O
receiving O
bone O
marrow O
transplants O
( O
BMT O
) O
: O
( O
1 O
) O
treatment O
as O
usual O
control O
, O
( O
2 O
) O
therapist O
support O
, O
( O
3 O
) O
relaxation O
and O
imagery O
training O
, O
and O
( O
4 O
) O
training O
in O
a O
package O
of O
cognitive-behavioral O
coping O
skills O
which O
included O
relaxation O
and O
imagery O
. O
[]

The O
absorption B-outcome ['Physiological-Clinical']
rate O
constant O
after O
treatment O
at O
01.00 O
hours O
was O
less O
than O
at O
the O
other O
times O
of O
administration O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

The O
levels O
of O
the O
systolic B-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
at O
entry O
were O
not O
predictive O
of O
the O
dose O
of O
nifedipine O
required O
for O
effective O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Aerosolized O
pentamidine O
had O
significant O
prophylactic B-outcome ['Physiological-Clinical']
efficacy O
, O
but O
we O
could O
not O
detect O
any O
major O
effect O
on O
mortality B-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

The O
median O
survival O
time O
from O
the O
start O
of O
CAF O
was O
20.2 O
months O
. O
[]

They O
were O
treated O
respectively O
with O
pricking O
thyroid O
gland O
high O
point O
or O
oral O
administration O
of O
tapazole O
. O
[]

The O
surgeon O
and O
the O
nurse O
were O
asked O
about O
symptoms O
related O
to O
occupational O
exposure O
. O
[]

MATERIALS O
AND O
METHODS O
This O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
. O
[]

The O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
rise O
in O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
and O
fall O
in O
serum B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
, O
loss O
of O
appetite B-outcome ['Physiological-Clinical']
and O
shivering B-outcome ['Physiological-Clinical']
, O
rigor O
and O
fever O
during O
infusion O
indicative O
of O
renal O
, O
GIT O
and O
infusion O
related O
toxicities O
respectively O
) O
was O
similar O
in O
the O
three O
groups O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

The O
optimal O
anesthetic O
technique O
should O
allow O
good O
surgical O
anesthesia O
with O
minimal O
side O
effects O
, O
a O
short O
recovery O
time O
, O
and O
, O
if O
possible O
, O
a O
high O
rate O
of O
successful O
pregnancy O
. O
[]

The O
frequency O
of O
adverse O
events O
was O
similar O
in O
both O
the O
placebo O
and O
N7-GP O
groups O
. O
[]

Pre-existing O
carious O
lesions O
were O
restored O
prior O
to O
the O
beginning O
of O
the O
study O
. O
[]

OBJECTIVE O
To O
analyze O
clinical O
, O
radiological O
, O
and O
drug O
( O
disease O
modifying O
antirheumatic O
drug O
, O
DMARD O
) O
dependent O
factors O
influencing O
bone O
turnover O
in O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
. O
[]

Successful O
new O
method O
of O
extracorporeal O
percutaneous O
endoscopic O
gastrostomy O
( O
E-PEG O
) O
. O
[]

Cyclosporine-A O
( O
CsA O
) O
is O
a O
potent O
inhibitor O
of O
opening O
of O
the O
mitochondrial O
permeability O
transition O
pore O
, O
which O
has O
been O
shown O
to O
play O
a O
key O
role O
in O
myocardial O
reperfusion O
injury O
. O
[]

METHODS O
We O
have O
risk-classified O
each O
of O
these O
patients O
using O
a O
computer O
program O
, O
according O
to O
the O
WHO/ISH O
scheme O
. O
[]

BACKGROUND O
Patients O
with O
chronic B-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
but O
with O
no O
endoscopic O
evidence O
of O
erosive O
oesophagitis O
require O
gastric O
acid O
suppression O
to O
relieve B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIMS O
Our O
objective O
was O
to O
compare O
the O
efficacy O
and O
safety O
of O
imidafenacin O
over O
fesoterodine O
in O
patients O
with O
overactive O
bladder O
( O
OAB O
) O
. O
[]

Compared O
with O
their O
respective O
controls O
, O
the O
study O
mean O
[]

The O
root O
slices O
were O
incubated O
in O
tissue O
culture O
plates O
with O
BHK-21 O
fibroblast O
cell O
line O
. O
[]

Although O
many O
agents O
are O
capable O
of O
controlling O
blood O
pressure O
, O
the O
ability O
of O
these O
agents O
to O
induce O
regression O
of O
left O
ventricular O
( O
LV O
) O
mass O
, O
and O
the O
effect O
of O
regression O
on O
diastolic O
relaxation O
and O
contractile O
indices O
in O
the O
elderly O
are O
less O
well O
known O
. O
[]

A O
randomized O
controlled O
trial O
of O
a O
cognitive O
behavioural O
intervention O
for O
anger O
management O
in O
children O
diagnosed O
with O
Asperger O
syndrome O
. O
[]

Interferon O
was O
administered O
as O
induction O
treatment O
( O
3 O
Mu/day O
) O
and O
then O
as O
maintenance O
therapy O
( O
3 O
Mu O
three O
times O
a O
week O
) O
. O
[]

DESIGN O
The O
combined O
vaccines O
were O
given O
at O
2 O
, O
4 O
, O
6 O
and O
12 O
months O
of O
age O
, O
and O
serum O
samples O
were O
obtained O
at O
ages O
2 O
, O
6 O
, O
7 O
, O
12 O
and O
13 O
months O
. O
[]

The O
present O
study O
sought O
to O
establish O
whether O
lavender O
aroma O
and/or O
expectancies O
affect O
post-stress O
relaxation O
. O
[]

PATIENTS O
AND O
METHODS O
In O
this O
multisite O
study O
, O
171 O
children O
with O
standard-risk O
ALL O
, O
age O
1 O
to O
9.99 O
years O
at O
diagnosis O
, O
previously O
randomly O
assigned O
to O
IT O
methotrexate O
( O
n O
= O
82 O
) O
or O
to O
triple O
IT O
therapy O
( O
n O
= O
89 O
) O
on O
CCG O
1952 O
, O
underwent O
neurocognitive O
evaluation O
by O
a O
licensed O
psychologist O
at O
a O
mean O
of O
5.9 O
years O
after O
random O
assignment O
. O
[]

Primary O
care O
physicians O
( O
113 O
) O
participated O
in O
a O
randomized O
controlled O
trial O
to O
evaluate O
an O
online O
CME O
series O
. O
[]

Long-term O
growth O
hormone O
treatment O
in O
growth O
hormone O
deficient O
adults O
. O
[]

Sixty O
patients O
with O
peptic O
ulcer O
( O
gastric O
, O
32 O
patients O
; O
duodenal O
, O
28 O
patients O
) O
who O
had O
a O
history O
of O
ulcer O
recurrence O
were O
randomly O
assigned O
to O
dual O
therapy O
with O
amoxycillin O
( O
500 O
mg O
three O
times O
daily O
for O
2 O
weeks O
) O
and O
omeprazole O
( O
20 O
mg O
once O
daily O
for O
8 O
weeks O
) O
or O
to O
triple O
therapy O
with O
metronidazole O
( O
500 O
mg O
twice O
daily O
for O
2 O
weeks O
) O
plus O
amoxycillin O
and O
omeprazole O
, O
given O
in O
the O
same O
dosages O
as O
dual O
therapy O
. O
[]

Randomized O
clinical O
trial O
of O
radiofrequency O
ablation O
or O
conventional O
high O
ligation O
and O
stripping O
for O
great O
saphenous O
varicose O
veins O
. O
[]

RESULTS O
After O
one O
week O
of O
therapy O
, O
the O
combination O
therapy O
decreased O
casual B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
by O
5 O
+/- O
2/3 O
+/- O
1 O
mm O
Hg O
versus O
placebo O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

To O
better O
understand O
intervention O
trial O
findings O
, O
we O
asked O
participants O
about O
their O
intervention O
experiences O
and O
examined O
potential O
contamination O
across O
arms O
. O
[]

Results O
support O
the O
effectiveness O
of O
using O
this O
caregiver-assisted O
, O
manualized O
intervention O
for O
young O
adults O
with O
ASD O
. O
[]

The O
odds O
of O
responding O
were O
greater O
in O
patients O
in O
the O
eltrombopag O
group O
compared O
with O
those O
in O
the O
placebo O
group O
throughout O
the O
6-month O
treatment O
period O
( O
odds O
ratio O
8?2 O
, O
99 O
% O
CI O
3?59-18?73 O
; O
p O
< O
0?0001 O
) O
. O
[]

DESIGN O
Prospective O
clinical O
trial O
. O
[]

RESULTS O
Rabeprazole B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
was O
lower O
in O
CYP2C19 O
PMs O
than O
in O
EMs O
( O
with O
average O
values O
of O
10.7 O
vs. O
16.8 O
l O
h O
( O
-1 O
) O
in O
PMs O
and O
EMs O
, O
respectively O
) O
, O
resulting O
in O
higher O
plasma O
levels O
in O
the O
former O
group O
. O
['Physiological-Clinical']

Treatment O
group O
is O
obviously O
better O
than O
control O
group O
on O
decreasing O
hematuria B-outcome ['Physiological-Clinical']
, O
proteinuria B-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
IgA I-outcome ['Physiological-Clinical']
and O
improving O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
( O
P B-outcome ['Physiological-Clinical']
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

According O
to O
the O
official O
radiation O
regulation O
, O
hospitalization B-outcome ['Resource-use']
was O
required O
in O
14 O
patients O
in O
the O
placebo O
group O
vs. O
one O
patient O
in O
the O
rhTSH O
group O
( O
P O
< O
0.0001 O
) O
. O
['Resource-use']

In O
both O
groups O
I O
and O
II O
, O
the O
treatment O
was O
stopped O
at O
the O
first O
manifestation O
of O
progression O
of O
the O
disease O
. O
[]

During O
follow-up O
( O
mean O
, O
5.5+/-2.4 O
years O
) O
, O
there O
was O
no O
change O
in O
PQ B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
in O
either O
group O
and O
no O
change O
in O
atrial O
stimulus-Q B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
or O
Wenckebach B-outcome ['Physiological-Clinical']
block O
point B-outcome ['Physiological-Clinical']
in O
the O
atrial O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
[]

The O
effects O
of O
face O
expertise O
training O
on O
the O
behavioral B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
brain B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
of O
adults O
with O
high O
functioning O
autism O
spectrum O
disorders O
. O
['Life-Impact', 'Physiological-Clinical']

Median O
LOS B-outcome ['Resource-use']
on I-outcome ['Resource-use']
ICU I-outcome ['Resource-use']
was O
shorter O
in O
the O
fast-track O
group O
, O
41 O
vs. O
20 O
h. O
The O
rate O
of O
postoperative B-outcome ['Adverse-effects']
medical I-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
was O
significantly O
lower O
in O
the O
fast-track O
group O
, O
16.2 O
% O
vs. O
35.7 O
% O
( O
p O
= O
0.045 O
) O
. O
['Resource-use', 'Adverse-effects']

Sleep B-outcome ['Physiological-Clinical']
Diary O
( O
SD O
) O
, O
recorded O
by O
the O
parents O
, O
assessed O
the O
patient O
's O
sleeping O
patterns O
every O
week O
. O
['Physiological-Clinical']

METHODS O
This O
study O
is O
a O
prospective O
randomized O
trial O
comparing O
individualized O
breast O
cancer O
risk O
counseling O
to O
general O
health O
counseling O
( O
control O
) O
. O
[]

In O
such O
circumstances O
, O
including O
cancer O
in O
situ O
, O
adriamycin O
compares O
favorably O
with O
other O
local O
forms O
of O
treatment O
. O
[]

Evaluation O
of O
rapid O
radiation O
treatment O
schedules O
utilizing O
two O
treatment O
sessions O
per O
day O
. O
[]

RESULTS O
Significant O
advantages O
for O
LS O
group O
on O
NCHS B-outcome ['Physiological-Clinical']
weight O
& O
length O
for O
age O
at O
['Physiological-Clinical']

The O
effects O
of O
melatonin O
on O
brain O
activities O
and O
their O
relation O
to O
induction O
of O
sleepiness O
were O
studied O
in O
a O
randomized O
, O
double-blind O
, O
placebo O
controlled O
functional O
magnetic O
resonance O
imaging O
( O
fMRI O
) O
study O
. O
[]

II O
: O
parents O
are O
unable O
to O
distinguish O
secretin O
from O
placebo O
under O
double-blind O
conditions O
. O
[]

Untoward B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
mild O
and O
transient O
. O
['Adverse-effects']

CONCLUSIONS O
The O
ARB O
valsartan O
has O
BP-independent O
effects O
on O
LVH O
, O
ROS O
formation O
by O
monocytes O
, O
and O
CRP O
in O
hypertensive O
patients O
with O
LVH O
. O
[]

Positive O
correlations O
could O
be O
found O
between O
erythema B-outcome ['Physiological-Clinical']
and O
thickness O
values O
at O
all O
of O
the O
three O
test O
points O
while O
changes O
in O
erythema B-outcome ['Physiological-Clinical']
and O
thickness B-outcome ['Physiological-Clinical']
only O
correlated O
significantly O
after O
the O
first O
month O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
detectable O
or O
undetectable O
viral O
load O
could O
develop O
HBV B-outcome ['Physiological-Clinical']
reactivation I-outcome ['Physiological-Clinical']
and O
HBsAg B-outcome ['Physiological-Clinical']
reverse I-outcome ['Physiological-Clinical']
seroconversion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Efficiency O
of O
anaferon O
in O
complex O
therapy O
of O
genital O
herpes O
. O
[]

OBJECTIVE O
To O
determine O
whether O
balance-based O
torso O
weighting O
( O
BBTW O
) O
has O
immediate O
effects O
on O
upright O
mobility O
in O
people O
with O
multiple O
sclerosis O
. O
[]

Fifty O
endoscopic O
resections O
were O
performed O
with O
a O
suck-and-ligate O
device O
without O
prior O
submucosa O
injection O
and O
50 O
with O
the O
cap O
technique O
with O
prior O
submucosa O
injection O
of O
a O
dilute O
saline O
solution O
of O
epinephrine O
. O
[]

RESULTS O
Using O
a O
serum O
PSA O
cut-off O
of O
4 O
ng/ml O
, O
the O
mean O
lead-time B-outcome ['Physiological-Clinical']
in O
the O
whole O
study O
population O
was O
estimated O
as O
6.8 O
years O
( O
95 O
% O
confidence O
interval O
( O
95 O
% O
CI O
) O
7.9-8.4 O
) O
. O
['Physiological-Clinical']

The O
onset O
of O
action B-outcome ['Physiological-Clinical']
of O
ciclesonide B-outcome ['Resource-use']
occurred O
within O
1 O
hour O
of O
administration O
( O
p O
= O
0.01 O
vs. O
placebo O
) O
, O
and O
the O
significant O
difference O
in O
total O
['Physiological-Clinical', 'Resource-use']

Severe O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
occurred O
in O
9.5 O
% O
of O
mitoxantrone O
patients O
and O
25.3 O
% O
of O
doxorubicin O
patients O
( O
P O
less O
than O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DISCUSSION O
Individual O
counselling O
promotes O
regular O
exercise O
with O
subsequent O
improvements O
in O
[]

Of O
the O
29 O
, O
16 O
men O
and O
13 O
were O
women O
. O
[]

Effect O
of O
pravastatin O
on O
kidney B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
in O
autosomal O
dominant O
polycystic O
kidney O
disease O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Serum O
total O
magnesium O
( O
TMg O
) O
measurements O
in O
dialysis O
patients O
are O
variable O
, O
with O
some O
groups O
reporting O
hypermagnesemia O
and O
some O
hypomagnesemia O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Operative O
parameters O
( O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
fluid B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
, O
complications B-outcome ['Adverse-effects']
, O
need O
for O
second B-outcome ['Physiological-Clinical']
intervention I-outcome ['Physiological-Clinical']
) O
and O
reproductive O
outcome O
parameters O
( O
pregnancy B-outcome ['Physiological-Clinical']
, O
abortion B-outcome ['Mortality']
, O
term B-outcome ['Physiological-Clinical']
and O
preterm B-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
, O
modality O
of O
delivery B-outcome ['Physiological-Clinical']
, O
cervical B-outcome ['Physiological-Clinical']
cerclage I-outcome ['Physiological-Clinical']
) O
were O
measured O
. O
['Life-Impact', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Inconvenience B-outcome ['Physiological-Clinical']
experienced I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
was O
reported O
as O
significantly O
less O
in O
the O
triamcinolone O
group O
compared O
with O
the O
conservative O
and O
surgical O
treatment O
groups O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Sixty O
patients O
were O
initially O
recruited O
but O
49 O
of O
these O
received O
either O
pravastatin O
20 O
mg O
or O
no O
treatment O
for O
2 O
years O
. O
[]

OBJECTIVES O
The O
aim O
of O
this O
in O
vitro O
study O
was O
to O
evaluate O
the O
microleakage O
in O
occlusal B-outcome ['Physiological-Clinical']
surfaces I-outcome ['Physiological-Clinical']
, O
after O
preparation O
with O
Er O
: O
YAG O
laser O
and O
compared O
to O
the O
diamond-bur O
conventional O
technique O
. O
['Physiological-Clinical']

Also O
, O
the O
immunological O
measures O
did O
not O
appear O
relevant O
to O
the O
significantly O
favourable O
effect O
of O
levamisole O
on O
the O
prognosis O
. O
[]

H. O
pylori O
infection O
was O
confirmed O
by O
histology O
. O
[]

Investigator-rated O
ADHD B-outcome ['Life-Impact']
Rating O
Scale-IV O
and O
Clinical O
Global O
Impression O
( O
CGI O
) O
scale O
were O
outcome O
measures O
. O
['Physiological-Clinical', 'Life-Impact']

Symptoms O
did O
not O
predict O
the O
presence O
of O
mucosal O
damage O
. O
[]

The O
Social O
Communication O
Assessment O
for O
Toddlers O
with O
Autism O
( O
SCATA O
) O
was O
designed O
to O
measure O
non-verbal B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
, I-outcome ['Life-Impact']
including I-outcome ['Life-Impact']
early I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
atypical I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
, O
in O
young O
children O
with O
autism O
spectrum O
disorder O
. O
['Life-Impact']

As O
with O
dogs O
, O
the O
increase O
in O
LV B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
after O
30 O
minutes O
of O
CCM O
therapy O
was O
not O
associated O
with O
increased O
MVO B-outcome ['Physiological-Clinical']
( O
['Physiological-Clinical', 'Physiological-Clinical']

The O
[]

Funded O
by O
the O
National O
Heart O
, O
Lung O
, O
and O
Blood O
Institute O
; O
TOPCAT O
ClinicalTrials.gov O
number O
, O
NCT00094302 O
. O
) O
. O
[]

The O
respective O
in O
vivo O
proximal B-outcome ['Physiological-Clinical']
resection I-outcome ['Physiological-Clinical']
margins I-outcome ['Physiological-Clinical']
( O
standard O
error O
of O
the O
mean O
) O
were O
8 O
( O
0.4 O
) O
cm O
and O
7.6 O
( O
0.4 O
) O
cm O
( O
p O
= O
NS O
) O
. O
['Physiological-Clinical']

Bilateral O
venography O
was O
performed O
in O
all O
patients O
on O
day O
seven O
after O
operation O
, O
and O
showed O
an O
overall O
deep O
vein O
thrombosis O
incidence O
of O
16 O
% O
. O
[]

After O
a O
median O
follow-up O
of O
46.9 O
months O
, O
for O
the O
study O
population O
the O
analysis O
did O
not O
show O
a O
significant O
extension O
of O
the O
relapse-free B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
or O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

Repeated-measures O
ANOVA O
indicated O
a O
trend O
toward O
superiority O
of O
omega-3 O
fatty O
acids O
over O
placebo O
for O
hyperactivity B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
This O
is O
a O
post-treatment O
follow-up O
analysis O
of O
a O
randomized O
, O
double-masked O
, O
placebo-controlled O
52-week O
trial O
. O
[]

Cancer O
control O
investigations O
in O
the O
United O
States O
rarely O
use O
population-based O
registries O
as O
a O
resource O
for O
recruitment O
. O
[]

METHODS O
Randomised O
, O
double O
blind O
, O
placebo O
controlled O
trial O
; O
140 O
community O
volunteers O
with O
knee O
osteoarthritis O
participated O
and O
119 O
completed O
the O
trial O
. O
[]

The O
median O
return B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
was O
significantly O
shorter O
for O
the O
stapled O
group O
( O
14 O
days O
vs O
28 O
days O
, O
P O
< O
0.05 O
) O
. O
['Life-Impact']

These O
results O
show O
that O
resistance O
exercise O
provides O
an O
acute B-outcome ['Physiological-Clinical']
stimulation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
STARS I-outcome ['Physiological-Clinical']
pathway I-outcome ['Physiological-Clinical']
that O
is O
contraction O
mode O
dependent O
. O
['Physiological-Clinical']

In O
an O
attempt O
to O
compensate O
for O
the O
lower O
efficacy O
, O
H2-receptor O
antagonists O
are O
now O
increasingly O
being O
used O
at O
a O
higher O
dose O
. O
[]

METHOD O
Patients O
were O
randomized O
to O
treatment O
with O
fluoxetine O
( O
n O
= O
127 O
) O
or O
placebo O
( O
n O
= O
46 O
) O
under O
double-blind O
conditions O
for O
8 O
weeks O
, O
with O
concomitant O
atomoxetine O
use O
the O
last O
5 O
weeks O
. O
[]

RESULTS O
For O
VACT2 O
, O
median O
time O
to O
good O
or O
excellent O
PGART B-outcome ['Physiological-Clinical']
response B-outcome ['Physiological-Clinical']
was O
6 O
, O
5 O
, O
4 O
, O
and O
3 O
days O
for O
acetaminophen O
, O
celecoxib O
, O
rofecoxib O
12.5 O
mg O
, O
and O
rofecoxib O
25 O
mg O
( O
COX-2 O
inhibitors O
vs O
acetaminophen O
, O
p O
< O
or=0.035 O
; O
rofecoxib O
25 O
mg O
vs O
celecoxib O
, O
p=0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
, O
double-blind O
, O
sham-controlled O
, O
clinical O
trial O
. O
[]

This O
study O
investigated O
the O
advantages O
of O
combined O
therapy O
with O
atorvastatin O
and O
colestimide O
vs O
intensive O
monotherapy O
with O
atorvastatin O
. O
[]

RESULTS O
Patients O
with O
kidney O
disease O
were O
older O
, O
more O
often O
had O
CHF O
as O
the O
cause B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
dyspnea I-outcome ['Physiological-Clinical']
, O
and O
more O
often O
died O
in-hospital O
or O
within O
30 O
days O
as O
compared O
to O
patients O
without O
kidney O
disease O
. O
['Physiological-Clinical']

To O
study O
the O
comparability O
of O
different O
PSL-LBNP O
protocols O
, O
nine O
subjects O
were O
exposed O
randomly O
to O
five O
PSL-LBNP O
tests O
using O
protocols O
that O
varied O
in O
stage O
duration O
but O
not O
pressure O
profile O
. O
[]

CONCLUSIONS O
Interferon O
alpha-2a O
administered O
subcutaneously O
offers O
no O
benefit O
as O
a O
chemotherapeutic O
adjuvant O
to O
cryotherapy O
when O
used O
alone O
in O
the O
therapy O
of O
genital O
warts O
in O
this O
population O
of O
patients O
with O
recurrent O
condylomata O
. O
[]

There O
were O
no O
statistically O
significant O
differences O
between O
the O
two O
treatment O
groups O
as O
regards O
the O
anthropometric B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
, O
the I-outcome ['Physiological-Clinical']
basal B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
Lp I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
the I-outcome ['Physiological-Clinical']
sex B-outcome ['Physiological-Clinical']
steroid I-outcome ['Physiological-Clinical']
and O
pituitary B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
purpose O
of O
this O
pilot O
study O
was O
to O
establish O
a O
model O
for O
randomized O
controlled O
trial O
research O
, O
identify O
appropriate O
outcome O
measures O
, O
and O
address O
the O
effectiveness O
of O
sensory O
integration O
( O
SI O
) O
interventions O
in O
children O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
. O
[]

Study O
protocol O
for O
a O
randomized O
controlled O
trial O
. O
[]

Chlorofluorocarbon O
( O
CFC O
) O
propellants O
deplete O
stratospheric O
ozone O
. O
[]

Serum O
from O
baseline O
and O
week O
8 O
was O
analysed O
for O
circulating-tissue O
factor O
antigen O
using O
ELISA O
. O
[]

UNLABELLED O
The O
effect O
of O
subclinical O
hypothyroidism O
( O
SH O
) O
on O
cardiovascular O
autonomic O
function O
and O
ventricular O
repolarization O
has O
not O
been O
yet O
elucidated O
. O
[]

Further O
studies O
are O
warranted O
to O
evaluate O
the O
mechanism O
( O
s O
) O
for O
increased O
cancer-specific B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
to O
assess O
whether O
weight O
loss B-outcome ['Physiological-Clinical']
after O
prostate O
cancer O
diagnosis O
alters O
disease O
course O
. O
['Mortality', 'Physiological-Clinical']

DESIGN O
A O
multisite O
randomized O
controlled O
trial O
. O
[]

Both O
techniques O
provided O
good O
operating B-outcome ['Life-Impact']
conditions I-outcome ['Life-Impact']
, O
stable O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
, O
mild O
to O
moderate O
sedation O
, O
without O
loss O
of O
verbal B-outcome ['Life-Impact']
contact I-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Rosiglitazone O
and O
cognitive O
function O
in O
clozapine-treated O
patients O
with O
schizophrenia O
: O
a O
pilot O
study O
. O
[]

A O
clinical O
randomized O
investigation O
was O
undertaken O
to O
determine O
the O
value O
of O
midazolam O
as O
a O
narcotic O
adjuvant O
for O
anesthetic O
induction O
. O
[]

Primary O
outcome O
measure O
was O
the O
change O
in O
irritability B-outcome ['Life-Impact']
subscale O
of O
ABC-C O
. O
['Life-Impact']

The O
subjects O
came O
to O
the O
study O
centre O
once O
a O
week O
after O
an O
overnight O
fast O
to O
ingest O
test O
meals O
and O
a O
control O
meal O
in O
random O
order O
. O
[]

61 O
inpatients O
with O
the O
diagnosis O
Rhinitis O
following O
nasal O
operation O
were O
included O
in O
this O
study O
and O
30 O
patients O
were O
treated O
with O
verum O
and O
placebo O
each O
. O
[]

As O
part O
of O
a O
trial O
, O
11 O
patients O
received O
either O
standard O
( O
four O
weekly O
) O
chemotherapy O
with O
ifosfamide O
, O
carboplatin O
, O
and O
etoposide O
( O
ICE O
) O
or O
accelerated O
( O
two O
weekly O
) O
ICE O
with O
filgrastim O
( O
granulocyte O
colony-stimulating O
factor O
[ O
G-CSF O
] O
) O
and O
autologous O
stem O
cell O
support O
. O
[]

In O
conclusion O
, O
if O
tolerated O
, O
captopril O
should O
remain O
the O
preferred O
treatment O
for O
patients O
after O
complicated O
acute B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Intravenous O
infusion O
was O
kept O
over O
48 O
hours O
. O
[]

Subsequent O
data O
were O
collected O
by O
means O
of O
an O
Interactive B-outcome ['Physiological-Clinical']
Voice I-outcome ['Physiological-Clinical']
Response O
System O
( O
IVRS O
) O
at O
30-day O
intervals O
( O
14 O
time O
points O
) O
during O
the O
study O
and O
in O
the O
follow-up O
period O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
identify O
the O
best O
drug O
, O
dose O
, O
and O
treatment O
. O
[]

The O
clinical O
behavior O
of O
the O
tumor O
was O
analysed O
according O
to O
the O
histological O
grade O
. O
[]

Evaluation O
of O
the O
effect O
of O
acetazolamide O
on O
cystoid O
macular O
oedema O
in O
patients O
with O
Behcet O
's O
disease O
. O
[]

Attempts O
have O
also O
been O
made O
to O
remove O
proinflammatory O
cytokines O
, O
eicosanoides O
, O
and O
coagulative O
factors O
from O
the O
circulation O
in O
the O
human O
body O
. O
[]

Good O
or O
excellent O
PGART O
was O
numerically O
, O
but O
not O
significantly O
, O
greater O
with O
rofecoxib O
25 O
mg O
( O
55.4 O
% O
) O
than O
celecoxib O
( O
50.6 O
% O
) O
at O
Week O
6 O
; O
a O
significant O
difference O
was O
seen O
at O
Weeks O
2 O
( O
6.9 O
, O
p=0.022 O
) O
and O
4 O
( O
6.7 O
, O
p=0.027 O
) O
and O
over O
6 O
weeks O
with O
analysis O
of O
all O
5 O
PGART O
categories O
of O
response O
( O
p=0.035 O
) O
. O
[]

Gingival B-outcome ['Physiological-Clinical']
overgrowth I-outcome ['Physiological-Clinical']
scores O
of O
the O
patients O
on O
each O
immunosuppressant O
drug O
were O
then O
compared O
. O
['Physiological-Clinical']

Patients O
aged O
75 O
years O
or O
less O
were O
randomized O
in O
a O
double-blind O
, O
placebo-controlled O
study O
to O
test O
whether O
long-term O
treatment O
with O
warfarin O
reduces O
the O
risk O
of O
death B-outcome ['Mortality']
, O
reinfarction B-outcome ['Physiological-Clinical']
, O
and O
thromboembolic B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

A O
series O
of O
early O
inflammatory O
markers O
, O
such O
as O
IL-1 O
, O
TNF-? O
, O
and O
IFN-? O
, O
and O
advanced O
inflammatory O
markers O
, O
such O
as O
high-mobility O
group O
box O
1 O
( O
HMGB1 O
) O
, O
are O
involved O
in O
neuroinflammation O
. O
[]

Blacks O
, O
Hispanics O
and O
( O
non-Hispanic O
) O
whites O
were O
all O
more O
highly O
educated O
, O
less O
likely O
to O
currently B-outcome ['Life-Impact']
smoke I-outcome ['Life-Impact']
and O
more O
likely O
to O
get O
regular B-outcome ['Life-Impact']
exercise I-outcome ['Life-Impact']
than O
their O
counterparts O
in O
the O
general O
population O
. O
['Life-Impact', 'Life-Impact']

The O
main O
outcomes O
were O
mean O
change O
of O
visual O
analog O
rating O
scale O
( O
VARS O
) O
and O
index O
scores O
measured O
through O
a O
quality-of-life O
questionnaire O
( O
EQ-5D O
) O
, O
and O
changes O
in O
the O
visual O
analog O
scale O
( O
VAS O
) O
, O
all O
of O
which O
were O
assessed O
at O
each O
visit O
. O
[]

Participants O
in O
the O
Age-Related O
Eye O
Disease O
Study O
were O
randomly O
assigned O
to O
receive O
daily O
antioxidants O
( O
vitamin O
C O
, O
500 O
mg O
; O
vitamin O
E O
, O
400 O
IU O
; O
beta O
carotene O
, O
15 O
mg O
) O
, O
zinc O
and O
copper O
( O
zinc O
, O
80 O
mg O
; O
cupric O
oxide O
, O
2 O
mg O
) O
, O
antioxidants O
plus O
zinc O
and O
copper O
, O
or O
placebo O
. O
[]

A O
persistent B-outcome ['Physiological-Clinical']
phasic I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
was O
found O
in O
19 O
of O
the O
21 O
patients O
, O
high O
frequency O
phasic B-outcome ['Physiological-Clinical']
activity B-outcome ['Life-Impact']
in O
11 O
of O
the O
21 O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

CONCLUSIONS O
BoNT-A O
is O
effective O
and O
well O
tolerated O
for O
the O
treatment O
of O
periorbital O
pain O
after O
an O
AACG O
attack O
. O
[]

A O
prospective O
, O
randomized O
trial O
of O
nerve O
monitoring O
of O
the O
external O
branch O
of O
the O
superior O
laryngeal O
nerve O
during O
thyroidectomy O
under O
local/regional O
anesthesia O
and O
IV O
sedation O
. O
[]

RESULTS O
9 O
patients O
were O
classified O
as O
rich O
( O
none O
had O
received O
placebo O
, O
3 O
low-dose O
teriparatide O
, O
and O
6 O
high-dose O
teriparatide O
) O
. O
[]

Of O
the O
98 O
patients O
who O
did O
not O
have O
type O
I O
or O
II O
diabetes O
at O
the O
time O
of O
transplantation O
, O
17 O
developed O
posttransplantation B-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
mellitus I-outcome ['Physiological-Clinical']
or O
an O
abnormal B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
tolerance O
test O
within O
2 O
years O
posttransplantation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
> O
or O
=1 O
year O
of O
age O
with O
a O
parasite O
density O
> O
or O
=1,000 O
asexual O
parasites O
per O
microliter O
were O
enrolled O
in O
this O
study O
. O
[]

DESIGN O
Randomized O
, O
double-blind O
, O
placebo-controlled O
phase O
3 O
trial O
conducted O
from O
July O
1997 O
through O
May O
1999 O
. O
[]

Correlates O
of O
cognitive B-outcome ['Life-Impact']
deficits I-outcome ['Life-Impact']
in O
first O
episode O
schizophrenia O
. O
['Life-Impact']

At O
a O
cut-off O
of O
26 O
, O
the O
AQ-J B-outcome ['Physiological-Clinical']
had O
satisfactory B-outcome ['Life-Impact']
sensitivity I-outcome ['Life-Impact']
, O
specificity O
, O
and O
negative O
predictive O
value O
, O
but O
it O
had O
low O
positive O
predictive O
value O
( O
0.24 O
) O
possibly O
due O
to O
the O
facts O
that O
the O
25 O
mild O
HPDD O
patients O
scored O
lower O
and O
the O
controls O
scored O
higher O
on O
the O
AQ-J O
than O
British O
counterparts O
on O
the O
AQ O
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
Preoperative O
patient O
characteristics O
and O
operative O
parameters O
were O
similar O
in O
three O
groups O
. O
[]

A O
mastoid O
oscillator O
was O
not O
used O
, O
nor O
were O
any O
instructions O
given O
for O
patients O
after O
the O
maneuver O
. O
[]

The O
result O
of O
our O
study O
suggested O
that O
only O
depression O
was O
related O
to O
anxiety O
, O
functional O
ability O
, O
and O
well-being O
in O
children O
and O
adolescents O
with O
JIA O
. O
[]

The O
median O
LOH B-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
refeeding I-outcome ['Physiological-Clinical']
was O
identical O
in O
both O
groups O
( O
1-day O
interquartile O
range O
, O
1-2 O
; O
P O
= O
.77 O
) O
. O
['Physiological-Clinical']

RESULTS O
Capecitabine/docetaxel O
resulted O
in O
significantly O
superior O
efficacy O
in O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TTP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( O
hazard O
ratio O
, O
0.652 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.545 O
to O
0.780 O
; O
P O
=.0001 O
; O
median O
, O
6.1 O
v O
4.2 O
months O
) O
, O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
hazard O
ratio O
, O
0.775 O
; O
95 O
% O
CI O
, O
0.634 O
to O
0.947 O
; O
P O
=.0126 O
; O
median O
, O
14.5 O
v O
11.5 O
months O
) O
, O
and O
objective B-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
response O
rate O
( O
42 O
% O
v O
30 O
% O
, O
P O
=.006 O
) O
compared O
with O
docetaxel O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

If O
effective O
across O
the O
Atlantic O
and O
across O
different O
health O
care O
systems O
, O
it O
is O
also O
likely O
to O
be O
an O
effective O
strategy O
to O
implement O
in O
the O
treatment O
of O
major O
depressive O
disorder O
in O
the O
Netherlands O
. O
[]

Hearing O
loss O
may O
lead O
to O
major O
changes O
in O
the O
social O
and O
emotional O
aspects O
of O
daily O
life O
. O
[]

Pretreatment O
with O
thiopental O
0.25 O
mg/kg O
and O
0.5 O
mg/kg O
after O
manual O
venous O
occlusion O
for O
1 O
min O
effectively O
attenuated O
pain B-outcome ['Physiological-Clinical']
associated O
with O
propofol O
injection O
. O
['Physiological-Clinical']

The O
key O
finding O
of O
this O
study O
was O
the O
significant O
lowering O
of O
pH B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
umbilical I-outcome ['Physiological-Clinical']
cord I-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
( O
7.31 O
+/- O
0.04 O
) O
and O
artery B-outcome ['Physiological-Clinical']
( O
7.21 O
+/- O
0.06 O
) O
in O
the O
glucose-infused O
group O
when O
compared O
with O
the O
non-glucose O
infusion O
groups O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Full B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
also O
occurred O
earlier O
in O
the O
D O
group O
( O
D O
: O
22.1 O
+/- O
3.1 O
min O
vs O
I O
: O
37.6 O
+/- O
4.0 O
min O
, O
P O
< O
0.005 O
for O
stating O
name O
) O
. O
['Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
RU I-outcome ['Physiological-Clinical']
42633 I-outcome ['Physiological-Clinical']
were O
similar O
to O
those O
of O
RU O
486 O
but O
concentrations O
of O
RU O
42848 O
and O
RU O
42698 O
were O
much O
lower O
. O
['Physiological-Clinical']

When O
meloxicam O
and O
Glu-Ch O
were O
discontinued O
and O
the O
placebo O
commenced O
, O
a O
significant O
proportion O
of O
the O
meloxicam O
group O
showed O
worsening O
of O
all O
the O
owner-assessed O
scores O
between O
day O
70 O
and O
day O
98 O
, O
when O
compared O
to O
the O
Glu-Ch O
group O
( O
mobility B-outcome ['Life-Impact']
p=0.01 O
; O
activity B-outcome ['Life-Impact']
p=0.02 O
; O
temperament B-outcome ['Life-Impact']
p=0.04 O
; O
lifestyle B-outcome ['Life-Impact']
p=0.01 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Plasma O
samples O
were O
analyzed O
for O
intact B-outcome ['Physiological-Clinical']
BMS-181101 B-outcome ['Physiological-Clinical']
using O
a O
validated O
high-performance O
liquid O
chromatography O
method O
with O
an O
electrochemical O
detector O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Two O
of O
these O
4 O
patients O
had O
right B-outcome ['Physiological-Clinical']
bundle-branch I-outcome ['Physiological-Clinical']
block B-outcome ['Physiological-Clinical']
at O
pacemaker O
implantation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
the O
initial O
dose-finding O
period O
of O
four O
weeks O
, O
supine B-outcome ['Physiological-Clinical']
DBP I-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
in O
eight O
patients O
receiving O
captopril O
and O
in O
four O
of O
the O
patients O
receiving O
propranolol O
. O
['Physiological-Clinical']

Coccidiosis O
remains O
a O
significant O
threat O
to O
the O
welfare O
of O
game O
farm-reared O
pheasants O
in O
the O
United O
States O
. O
[]

Improvisational O
music O
therapy O
produced O
markedly O
more O
and O
longer O
events O
of O
'joy O
' O
, O
'emotional O
synchronicity B-outcome ['Life-Impact']
' O
and O
'initiation O
of O
engagement B-outcome ['Life-Impact']
' O
behaviours B-outcome ['Life-Impact']
in O
the O
children O
than O
toy O
play O
sessions O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Appropriate O
modulation O
of O
imitation O
according O
to O
social O
context O
is O
important O
for O
successful O
social O
interaction O
. O
[]

RESULTS O
After O
4 O
courses O
of O
treatment O
with O
chemotherapy O
and O
electro-acupuncture O
, O
no O
obvious O
changes O
were O
found O
in O
T O
cell B-outcome ['Physiological-Clinical']
subpopulations I-outcome ['Physiological-Clinical']
, O
NK B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
humoral B-outcome ['Physiological-Clinical']
immunity I-outcome ['Physiological-Clinical']
and O
leukocyte B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( O
P O
> O
0.05 O
) O
as O
compared O
with O
those O
before O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

INTRODUCTION O
Posttransplant B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
is O
a O
well-known O
risk O
factor O
for O
long-term O
allograft O
failure O
and O
mortality O
in O
kidney O
recipients O
. O
['Physiological-Clinical']

BACKGROUND O
Consumption O
of O
soluble O
dietary O
fibre O
is O
correlated O
with O
decreased O
postprandial B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
and O
hence O
has O
beneficial O
effects O
on O
the O
metabolic O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Sixty O
qualified O
autism O
children O
were O
divided O
randomly O
into O
simultaneous O
head O
needling O
retention O
and O
behavior O
training O
group O
( O
trial O
group O
) O
and O
behavior O
training O
after O
acupuncture O
treatment O
group O
( O
control O
group O
) O
with O
30 O
case O
in O
each O
group O
. O
[]

bolus O
days O
1-4 O
and O
1000 O
mg/m O
( O
2 O
) O
/24 O
h O
5-FU O
in O
a O
4-h O
infusion O
on O
days O
1-4 O
. O
[]

Patients O
with O
psychotic O
reactions O
or O
abnormal O
psychiatric O
behaviour O
( O
3/38 O
) O
and O
one O
patient O
who O
died B-outcome ['Mortality']
after O
alcohol O
intake O
were O
excluded O
from O
the O
analysis O
. O
['Mortality']

The O
long-term O
effects O
of O
auditory O
training O
on O
children O
with O
autism O
. O
[]

Wart O
area O
reduction O
following O
destructive O
treatment O
correlated O
with O
prior O
duration O
of O
disease O
. O
[]

Between O
group O
differences O
in O
measures O
of O
impact O
of O
[]

The O
goal O
of O
this O
study O
is O
to O
determine O
the O
effects O
of O
CCB O
on O
volumetric O
quantitative O
changes O
of O
coronary O
plaques O
accessed O
by O
intravascular O
ultrasound O
( O
IVUS O
) O
. O
[]

Two O
patients O
in O
the O
placebo O
group O
needed O
antihypertensive O
treatment O
because O
they O
developed O
microalbuminuria B-outcome ['Physiological-Clinical']
and/or O
hypertension B-outcome ['Physiological-Clinical']
, O
but O
no O
patient O
in O
the O
candesartan O
group O
did O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
safety O
profile O
of O
etanercept O
was O
consistent O
over O
time O
, O
with O
rates O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
similar O
to O
those O
reported O
for O
patients O
with O
RA O
in O
general O
. O
['Adverse-effects']

One O
group O
( O
n=127 O
) O
carried O
a O
CER O
during O
4 O
weeks O
. O
[]

The O
findings O
support O
the O
view O
that O
beta-blocking O
drugs O
can O
influence O
glucose B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
by O
mechanisms O
other O
than O
inhibition O
of O
endogenous B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
We O
sought O
to O
determine O
the O
effect O
of O
pravastatin O
on O
recurrent B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
women O
with O
average O
cholesterol O
levels O
after O
myocardial O
infarction O
( O
MI O
) O
. O
['Physiological-Clinical']

and O
increasing O
to O
30 O
mg/week O
i.m O
. O
[]

Overall O
, O
the O
use O
of O
the O
MTL O
appears O
well O
tolerated O
by O
healthy O
, O
adult O
volunteers O
. O
[]

METHODS/DESIGN O
Consenting O
women O
choosing O
to O
use O
an O
IUD O
after O
an O
abortion O
for O
a O
pregnancy O
of O
less O
than O
12 O
weeks O
of O
gestation O
will O
be O
randomized O
to O
device-type O
groups O
to O
receive O
immediate O
post-abortion O
placement O
of O
either O
a O
Flexi-T380 O
( O
+ O
) O
IUD O
, O
a O
device O
for O
which O
no O
current O
evidence O
on O
expulsion O
or O
effectiveness O
rates O
is O
available O
, O
or O
the O
Nova-T200 O
IUD O
, O
the O
only O
other O
brand O
of O
copper O
IUD O
available O
in O
Canada O
at O
the O
time O
of O
study O
initiation O
. O
[]

Unchanged O
YM17E O
was O
not O
detected O
in O
urine O
after O
single O
administration O
, O
suggesting O
that O
it O
was O
excreted O
via O
the O
bile O
or O
urine O
after O
metabolism O
. O
[]

METHODS O
Forty-three O
chronic O
stroke O
patients O
with O
mild O
to O
moderate O
upper O
extremity O
impairment O
were O
randomly O
assigned O
to O
receive O
MT O
+ O
MG O
, O
MT O
, O
or O
CT O
for O
1.5 O
hours/day O
, O
5 O
days/week O
for O
4 O
weeks O
. O
[]

BACKGROUND O
The O
aim O
of O
the O
present O
study O
was O
to O
further O
investigate O
a O
previously O
reported O
attention-related O
impairment O
in O
dependent O
amphetamine O
users O
using O
event-related O
potential O
( O
ERP O
) O
indices O
of O
selective O
attention O
. O
[]

Thiopental O
0.5 O
mg/kg O
was O
the O
most O
effective O
in O
prevention O
of O
propofol B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
can O
be O
used O
routinely O
. O
['Physiological-Clinical']

BACKGROUND O
Smoking O
is O
associated O
with O
endothelial O
dysfunction O
. O
[]

CONCLUSIONS O
A O
significant O
association O
exists O
between O
smoking O
and O
a O
diet O
with O
higher O
risks O
of O
atherosclerosis B-outcome ['Physiological-Clinical']
, O
cancer B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Twenty-five O
cases O
were O
selected O
from O
the O
surgical O
pathology O
files O
of O
the O
Mayo O
Clinic O
from O
patients O
who O
had O
undergone O
radical O
retropubic O
prostatectomy O
and O
bilateral O
lymphadenectomy O
between O
1987-1991 O
. O
[]

RESULTS O
The O
P600 O
( O
47 O
patients O
) O
and O
P900 O
( O
45 O
patients O
) O
arms O
had O
response O
rates O
of O
17.0 O
% O
( O
95 O
% O
confidence O
interval O
, O
7.7-30.8 O
% O
) O
and O
15.6 O
% O
( O
95 O
% O
confidence O
interval O
, O
6.5-29.5 O
% O
) O
with O
approximately O
50 O
% O
stable O
disease O
per O
arm O
, O
median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
of O
4.2 O
and O
4.1 O
months O
, O
and O
median O
times B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
of O
4.2 O
and O
4.6 O
months O
, O
respectively O
. O
['Mortality', 'Physiological-Clinical']

The O
principal O
echocardiographic O
finding O
was O
a O
statistically O
significant O
decrease O
in O
pulmonary B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
the O
L-arginine O
( O
56.3 O
? O
['Physiological-Clinical']

Randomization O
was O
performed O
before O
LT O
. O
[]

Lactoferrin O
supplementation O
to O
Holstein O
calves O
during O
the O
preweaning O
and O
postweaning O
phases O
. O
[]

Study O
protocol O
: O
Phase O
III O
single-blinded O
fast-track O
pragmatic O
randomised O
controlled O
trial O
of O
a O
complex O
intervention O
for O
breathlessness O
in O
advanced B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Fifty-nine O
earthquake O
survivors O
in O
Turkey O
were O
randomized O
into O
either O
single-session O
modified O
behavioral O
treatment O
( O
SSBT O
) O
designed O
to O
enhance O
sense O
of O
control O
over O
earthquake-related B-outcome ['Life-Impact']
fears I-outcome ['Life-Impact']
or O
waiting O
list O
control O
condition O
( O
WL O
) O
. O
['Life-Impact']

MATERIAL O
AND O
METHODS O
One O
hundred O
and O
eighty O
randomly O
selected O
healthy O
volunteers O
( O
ASA O
I O
) O
entered O
the O
single-blinded O
study O
to O
receive O
16 O
mg O
+ O
4 O
?g O
, O
24 O
mg O
+ O
6 O
?g O
, O
and O
32 O
mg O
+ O
8 O
?g O
of O
Ar O
+ O
Ep O
, O
obtained O
with O
different O
volumes O
( O
0.4 O
, O
0.6 O
, O
and O
0.8 O
ml O
, O
respectively O
) O
, O
for O
the O
ISA O
and O
PLA O
. O
[]

METHODS O
A O
clear O
soft O
contact O
lens O
and O
a O
special-effect O
soft O
contact O
lens O
( O
Crazy O
lens O
, O
) O
were O
fit O
in O
changing O
sequence O
in O
nine O
healthy O
subjects O
. O
[]

Post-void B-outcome ['Physiological-Clinical']
residual O
volumes B-outcome ['Physiological-Clinical']
, O
transrectal B-outcome ['Physiological-Clinical']
ultrasound B-outcome ['Physiological-Clinical']
( O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Hyperbaric O
oxygen O
( O
HBO O
) O
attenuates O
lipopolysaccharide O
( O
LPS O
) O
-induced O
acute O
lung O
injury O
. O
[]

Changes O
of O
gastric B-outcome ['Physiological-Clinical']
drainage I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
therapeutic O
times O
and O
cured O
rate O
were O
investigated O
in O
the O
3 O
groups O
. O
['Physiological-Clinical']

CONCLUSION O
With O
the O
effective O
use O
of O
goal-directed O
fluid O
therapy O
in O
elective O
surgical O
patients O
, O
the O
routine O
use O
of O
dopexamine O
does O
not O
confer O
an O
additional O
clinical O
benefit O
. O
[]

Prevention O
of O
spinal B-outcome ['Physiological-Clinical']
anesthesia-induced I-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
in O
the O
elderly O
: O
comparison O
between O
preanesthetic O
administration O
of O
crystalloids O
, O
colloids O
, O
and O
no O
prehydration O
. O
['Physiological-Clinical']

No O
patient O
needed O
a O
second O
procedure O
for O
recurrence O
within O
2 O
years O
, O
although O
partial O
residual O
prolapse B-outcome ['Physiological-Clinical']
was O
detected O
in O
4 O
SH O
patients O
( O
7.5 O
% O
) O
versus O
1 O
MM O
patient O
( O
1.8 O
% O
) O
( O
P O
= O
0.194 O
) O
. O
['Physiological-Clinical']

This O
experiment O
examined O
the O
efficacy O
of O
an O
acustimulation O
wrist O
band O
for O
the O
relief O
of O
chemotherapy-induced B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
using O
a O
randomized O
three-arm O
clinical O
trial O
( O
active O
acustimulation O
, O
sham O
acustimulation O
, O
and O
no O
acustimulation O
) O
in O
96 O
women O
with O
breast O
cancer O
who O
experienced O
nausea O
at O
their O
first O
chemotherapy O
treatment O
. O
['Physiological-Clinical']

Moreover O
, O
the O
technic O
of O
exteriorization O
is O
a O
safe O
adjunct O
to O
management O
and O
is O
recommended O
in O
any O
patient O
with O
a O
colonic O
injury O
above O
18 O
cm O
in O
which O
one O
suture O
line O
is O
required O
and O
in O
which O
the O
additional O
operating O
time O
of O
twenty O
minutes O
will O
not O
compromise O
the O
management O
of O
secondary O
injuries O
. O
[]

For O
those O
randomized O
to O
receive O
prophylactic O
pelvic O
lymph O
nodal O
irradiation O
, O
45 O
Gy O
of O
megavoltage O
RT O
was O
delivered O
via O
multiple O
portals O
in O
4.5-5 O
weeks O
, O
while O
all O
patients O
received O
65 O
Gy O
in O
6.5-8 O
weeks O
to O
the O
prostatic O
bed O
. O
[]

According O
to O
our O
results O
, O
long-duration O
low-intensity O
general O
warm-up O
seems O
be O
appropriately O
to O
improve O
1RM O
performance O
in O
strength-trained O
individuals O
. O
[]

Safety O
was O
assessed O
by O
measuring O
changes O
in O
pulse B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
blood O
pressure O
, O
and O
electrocardiogram O
( O
ECG O
) O
intervals O
after O
dosing O
with O
study O
drug O
, O
['Physiological-Clinical']

Skin B-outcome ['Physiological-Clinical']
manifestations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
inhaled I-outcome ['Physiological-Clinical']
corticosteroids I-outcome ['Physiological-Clinical']
in O
COPD O
patients O
: O
results O
from O
Lung O
Health O
Study O
II O
. O
['Physiological-Clinical']

By O
logistic O
regression O
, O
cirrhosis B-outcome ['Physiological-Clinical']
( O
P O
< O
.0001 O
) O
was O
the O
major O
determinant O
that O
impaired O
['Physiological-Clinical']

Strand B-outcome ['Physiological-Clinical']
breaks I-outcome ['Physiological-Clinical']
decreased O
significantly O
after O
the O
broccoli O
diet O
in O
smokers O
as O
well O
as O
in O
nonsmokers O
( O
-22.2 O
% O
; O
P O
< O
0.0001 O
) O
, O
whereas O
oxidized B-outcome ['Physiological-Clinical']
purines I-outcome ['Physiological-Clinical']
decreased O
significantly O
only O
in O
smokers O
( O
-51.0 O
% O
; O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
findings O
emphasize O
the O
importance O
of O
careful O
evaluation O
of O
novel O
medical O
education O
strategies O
before O
their O
implementation O
in O
medical O
schools O
, O
and O
the O
need O
for O
further O
research O
to O
define O
the O
effective O
methods O
for O
delivering O
medical O
education O
in O
Child O
Health O
. O
[]

Although O
social B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
improved O
significantly O
as O
a O
result O
of O
watching O
The O
Transporters O
, O
a O
significant O
improvement O
in O
social B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
was O
however O
, O
also O
observed O
in O
the O
Thomas O
the O
Tank O
Engine O
condition O
suggesting O
the O
unique O
content O
of O
The O
Transporters O
DVD O
was O
not O
pivotal O
to O
the O
improvement O
of O
social B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
in O
general O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

METHODS O
Between O
July O
, O
1995 O
, O
and O
December O
, O
2003 O
, O
167 O
patients O
were O
enrolled O
from O
27 O
Japanese O
hospitals O
and O
randomly O
assigned O
to O
TH O
( O
n=82 O
) O
or O
LTA O
( O
n=85 O
) O
. O
[]

Efficacy O
, O
tolerability B-outcome ['Life-Impact']
and O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
two O
nelfinavir-based O
regimens O
in O
human O
immunodeficiency O
virus-infected O
children O
and O
adolescents O
: O
pediatric O
AIDS O
clinical O
trials O
group O
protocol O
403 O
. O
['Life-Impact', 'Physiological-Clinical']

RESULTS O
ST O
performed O
alone O
, O
or O
in O
conjunction O
with O
aerobic O
exercise O
, O
improved O
maximal B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
and O
increased O
total O
lean B-outcome ['Physiological-Clinical']
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
( O
both O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Comparable O
efficacy O
between O
the O
compounds O
was O
found O
across O
the O
13-week O
study O
. O
[]

Of O
the O
patients O
treated O
with O
photons O
45.7 O
% O
had O
severe O
reactions B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
bladder I-outcome ['Physiological-Clinical']
compared O
with O
10.6 O
% O
after O
neutron O
therapy O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
Further O
examination O
of O
the O
efficacy O
of O
the O
spiritually O
based O
approach O
to O
health O
communication O
is O
warranted O
. O
[]

The O
full O
induction O
dose O
of O
intravenous O
propranolol O
( O
0.1 O
mg/kg O
) O
was O
tolerated O
by O
90 O
% O
of O
treated O
patients O
, O
and O
oral O
maintenance O
therapy O
was O
being O
continued O
in O
82 O
% O
of O
treated O
patients O
on O
the O
second O
hospital O
day O
. O
[]

Hampshire O
lambs O
( O
initial O
BW O
29.4 O
? O
[]

BACKGROUND O
Intracavernosal O
injection O
of O
vasoactive O
drugs O
is O
an O
established O
method O
of O
evaluating O
erectile O
dysfunction O
. O
[]

The O
antiFXa B-outcome ['Physiological-Clinical']
level O
in O
the O
plasma O
was O
correlated O
strongly O
with O
patient O
weight O
. O
['Physiological-Clinical']

Conversely O
, O
proteinuria B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
NAG I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
did O
not O
change O
in O
the O
control O
group O
. O
['Physiological-Clinical']

The O
adjusted O
hazard O
ratio O
of O
fluorescence O
diagnosis O
versus O
white O
light O
transurethral O
resection O
was O
0.33 O
( O
95 O
% O
confidence O
interval O
0.16 O
to O
0.67 O
) O
. O
[]

The O
weight O
difference O
between O
the O
treatment O
group O
and O
controls O
was O
nearly O
the O
same O
at O
18 O
months O
after O
end O
of O
treatment O
as O
at O
six O
months O
. O
[]

Rizatriptan O
is O
a O
potent O
, O
oral O
, O
5-HT1B/1D O
agonist O
with O
more O
rapid O
absorption O
and O
higher O
bioavailability O
than O
oral O
sumatriptan O
. O
[]

3 O
) O
Adverse O
effect O
, O
such O
as O
flushing B-outcome ['Physiological-Clinical']
( O
15.8 O
% O
) O
and O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
( O
23.7 O
% O
) O
were O
found O
in O
the O
niacin O
ER O
group O
, O
however O
, O
no O
more O
adverse O
effects O
were O
found O
in O
the O
combination O
therapy O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
women O
with O
acne O
and O
proven O
PCOS O
therapy O
with O
estroprogestins O
( O
EPs O
) O
can O
be O
an O
excellent O
option O
. O
[]

Our O
study O
was O
designed O
to O
explore O
this O
issue O
. O
[]

Twelve O
subjects O
received O
150 O
mg O
YM17E O
in O
both O
the O
fasted O
and O
post-prandial O
states O
. O
[]

There O
were O
no O
significant O
differences O
in O
average O
sedation B-outcome ['Physiological-Clinical']
scores O
or O
pain B-outcome ['Physiological-Clinical']
scores O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Only O
infants O
of O
allergic O
, O
atopic O
mothers O
were O
colonized O
with O
B. O
adolescentis O
. O
[]

Improvements O
were O
unrelated O
to O
changes O
in O
the O
physiological O
parameters O
measured O
. O
[]

RESULTS O
The O
average O
participation O
rate O
for O
QC O
testing O
was O
91 O
% O
or O
greater O
. O
[]

The O
fentanyl O
infusion O
( O
2 O
micrograms/kg/hour O
) O
reduced O
the O
induction O
dose B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
thiopentone I-outcome ['Life-Impact']
and O
caused O
marked B-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
with O
a O
reduction O
in O
the O
patients O
' O
response O
to O
surgery O
. O
['Life-Impact', 'Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
the O
two O
agents O
in O
either O
end-point O
, O
with O
over O
95 O
% O
optimal B-outcome ['Life-Impact']
sedation I-outcome ['Life-Impact']
achieved O
by O
the O
use O
of O
each O
drug O
. O
['Life-Impact']

There O
is O
no O
significant O
difference O
between O
the O
two O
groups O
. O
[]

On O
day O
3 O
, O
17 O
beta-estradiol B-outcome ['Resource-use']
, O
follicle-stimulating B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
luteinizing B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
and O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Fifty-four O
untreated O
, O
mildly O
hypertensive O
men O
whose O
daily O
alcohol O
consumption O
was O
> O
or O
= O
28 O
ml O
ethanol O
and O
who O
drank O
at O
least O
4 O
times O
per O
week O
took O
part O
in O
a O
randomized O
, O
controlled O
crossover O
trial O
. O
[]

OBJECTIVE O
To O
compare O
the O
efficacy O
of O
conventional O
Percutaneous O
Nephrolithotomy O
( O
PCNL O
) O
with O
two O
of O
its O
modified O
procedures O
. O
[]

MAIN O
OUTCOME O
MEASURES O
The O
number O
of I-outcome ['Life-Impact']
attempts B-outcome ['Life-Impact']
at I-outcome ['Life-Impact']
successful I-outcome ['Life-Impact']
identification I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
spinal I-outcome ['Life-Impact']
space B-outcome ['Physiological-Clinical']
, O
intraoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
incidence O
of O
postdural O
puncture B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PDPH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
non-postdural B-outcome ['Physiological-Clinical']
puncture B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NPDPH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
backache B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Treatment O
of O
stable O
angina O
of O
effort O
with O
verapamil O
: O
a O
double-blind O
, O
placebo-controlled O
randomized O
crossover O
study O
. O
[]

This O
study O
showed O
that O
amphotericin O
B O
should O
be O
given O
at O
a O
dosage O
of O
1 O
mg/kg O
bw/day O
for O
20 O
days O
for O
Indian O
kala-azar O
patients O
to O
minimise O
relapses B-outcome ['Physiological-Clinical']
and O
prevent O
development O
of O
drug B-outcome ['Physiological-Clinical']
unresponsiveness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Parent-based O
sleep O
education O
for O
children O
with O
autism O
spectrum O
disorders O
. O
[]

DESIGN O
Parallel O
group O
, O
single-blind O
randomized O
controlled O
trial O
. O
[]

Randomized O
trial O
of O
liberal O
versus O
restrictive O
guidelines O
for O
red O
blood O
cell O
transfusion O
in O
preterm O
infants O
. O
[]

Effect O
of O
milrinone O
on O
short-term O
outcome O
of O
patients O
with O
myocardial O
dysfunction O
undergoing O
coronary O
artery O
bypass O
graft O
: O
A O
randomized O
controlled O
trial O
. O
[]

FINDINGS O
Compared O
with O
placebo O
, O
treatment O
with O
laquinimod O
0.6 O
mg O
per O
day O
showed O
a O
40.4 O
% O
reduction O
of O
the O
baseline O
adjusted O
mean O
cumulative O
number O
of O
GdE B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
per O
scan O
on O
the O
last O
four O
scans O
( O
simple O
means O
4.2 O
[ O
SD O
9.2 O
] O
vs O
2.6 O
[ O
5.3 O
] O
, O
p=0.0048 O
) O
; O
treatment O
with O
0.3 O
mg O
per O
day O
showed O
no O
significant O
effects O
( O
3.9 O
[ O
5.5 O
] O
vs O
placebo O
, O
p=0.6740 O
) O
. O
['Physiological-Clinical']

Therefore O
, O
the O
choice O
among O
these O
3 O
treatments O
should O
be O
guided O
by O
the O
patient O
's O
comfort O
and O
convenience O
. O
[]

At O
follow-up O
, O
minorities O
in O
the O
control O
group O
continued O
to O
have O
more O
pain B-outcome ['Physiological-Clinical']
( O
6.4 O
vs O
4.7 O
, O
P O
= O
0.01 O
) O
, O
whereas O
in O
the O
experimental O
group O
, O
disparities O
were O
eliminated O
( O
4.0 O
vs O
4.3 O
, O
P O
= O
0.71 O
) O
. O
['Physiological-Clinical']

The O
CD19+ B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
levels O
in O
myeloma O
patients O
is O
an O
important O
parameter O
in O
the O
overall O
assessment O
of O
these O
patients O
. O
['Physiological-Clinical']

The O
goal O
of O
the O
present O
study O
was O
to O
use O
a O
new O
calorimetry O
method O
in O
which O
resting O
metabolic O
rate O
is O
enhanced O
to O
evaluate O
the O
effects O
of O
sibutramine O
treatment O
on O
thermogenesis O
. O
[]

CONCLUSIONS O
Measurement O
of O
serum O
BNP O
at O
hospital O
admission O
may O
help O
identify O
patients O
who O
are O
at O
risk O
for O
developing O
CI-AKI O
after O
primary O
percutaneous O
coronary O
intervention O
in O
ST-segment-elevation O
myocardial O
infarction O
. O
[]

Lateral O
spinal O
radiographs O
were O
taken O
annually O
for O
assessment O
of O
vertebral B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
, O
and O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
was O
measured O
by O
dual-energy O
X-ray O
absorptiometry O
at O
6-month O
intervals O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Stools O
were O
collected O
before O
treatment O
and O
on O
day O
7 O
to O
8 O
( O
and O
day O
14 O
and O
21 O
, O
in O
the O
infants O
weighing O
less O
than O
1500 O
g O
) O
for O
quantitative B-outcome ['Physiological-Clinical']
aerobic I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
anaerobic I-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Cardiovascular O
effects O
of O
tamoxifen O
in O
women O
with O
and O
without O
heart O
disease O
: O
breast O
cancer O
prevention O
trial O
. O
[]

No O
significant O
difference O
was O
found O
between O
the O
digital-brachial B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
of O
group O
A O
compared O
with O
group O
B O
. O
['Physiological-Clinical']

RESULTS O
Prior O
AIDS O
diagnosis O
, O
low O
Karnofsky O
score O
, O
active O
unstable O
AIDS-related O
conditions O
, O
absence O
of O
antiretroviral O
therapy O
and O
absence O
of O
Pneumocystis O
carinii O
pneumonia O
prophylaxis O
were O
associated O
with O
shorter O
survival B-outcome ['Mortality']
by O
univariate O
regression O
using O
the O
proportional O
hazards O
model O
. O
['Mortality']

Phase O
III O
, O
randomized O
, O
open-label O
study O
of O
daily O
imatinib O
mesylate O
400 O
mg O
versus O
800 O
mg O
in O
patients O
with O
newly O
diagnosed O
, O
previously O
untreated O
chronic O
myeloid O
leukemia O
in O
chronic O
phase O
using O
molecular O
end O
points O
: O
tyrosine O
kinase O
inhibitor O
optimization O
and O
selectivity O
study O
. O
[]

BACKGROUND O
In O
colorectal O
cancer O
, O
the O
morphology O
of O
the O
invasive O
tumor O
margin O
may O
reflect O
aggressiveness O
of O
tumor O
growth O
, O
thus O
providing O
important O
prognostic O
information O
. O
[]

The O
cardiovascular O
and O
behavioral O
adaptations O
associated O
with O
a O
4-month O
program O
of O
aerobic O
exercise O
training O
were O
examined O
in O
101 O
older O
men O
and O
women O
( O
mean O
age O
= O
67 O
years O
) O
. O
[]

Eight O
normal O
male O
volunteers O
were O
studied O
on O
three O
occasions O
. O
[]

OBJECTIVE O
The O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
impact O
of O
indices O
of O
central O
nervous O
system O
( O
CNS O
) O
serotonin O
function O
on O
cardiovascular B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
to O
mental O
stress O
. O
['Physiological-Clinical']

Patients O
in O
the O
operative O
group O
showed O
a O
significant O
improvement O
of O
posttraumatic B-outcome ['Physiological-Clinical']
clavicular I-outcome ['Physiological-Clinical']
shortening I-outcome ['Physiological-Clinical']
; O
they O
were O
also O
more O
satisfied B-outcome ['Life-Impact']
with O
cosmetic O
appearance O
and O
overall O
outcome O
. O
['Physiological-Clinical', 'Life-Impact']

It O
was O
therefore O
concluded O
that O
, O
although O
patients O
with O
LV O
hypertrophy O
and O
non-Q-wave O
AMI O
have O
smaller O
enzymatic O
infarcts O
and O
the O
same O
short-term O
prognosis O
as O
do O
patients O
without O
LV O
hypertrophy O
, O
their O
reinfarction O
and O
mortality O
rates O
are O
significantly O
increased O
during O
the O
first O
year O
of O
follow-up O
. O
( O
[]

The O
maximum O
numbers O
of O
repetitions O
in O
each O
station O
was O
12 O
. O
[]

Fatigue B-outcome ['Physiological-Clinical']
, O
ADL B-outcome ['Life-Impact']
and O
QOL B-outcome ['Life-Impact']
were O
assessed O
before O
and O
after O
the O
intervention O
in O
both O
groups O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

There O
were O
thus O
10 O
pairs O
available O
for O
the O
study O
. O
[]

However O
, O
because O
of O
shortcomings O
of O
the O
design O
, O
it O
was O
not O
possible O
to O
distinguish O
whether O
individuals O
with O
Autism O
processed O
both O
aligned O
and O
misaligned O
composites O
in O
a O
part-based O
fashion O
, O
or O
both O
in O
a O
holistic O
fashion O
. O
[]

Their O
therapeutic O
effects O
were O
ob O
served O
. O
[]

Furthermore O
, O
the O
transfusion O
rate O
was O
significantly O
lower O
in O
Group O
IE O
( O
20.4 O
% O
vs. O
53.7 O
% O
, O
p=0.011 O
) O
and O
the O
mean O
number O
of O
red O
blood O
cell O
units O
transfused O
was O
markedly O
lower O
in O
Group O
IE O
( O
0.2?0.5 O
vs. O
0.8?0.8 O
, O
p=0.005 O
) O
. O
[]

MAIN O
RESULTS O
Given O
a O
baseline O
risk O
of O
having O
a O
stroke O
in O
the O
next O
2 O
years O
, O
if O
not O
taking O
warfarin O
, O
of O
10 O
of O
100 O
, O
the O
mean O
[]

The O
primary O
outcome O
measure O
was O
the O
irritability B-outcome ['Life-Impact']
subscale O
of O
Aberrant O
Behavior O
Checklist-Community O
( O
ABC-C O
) O
. O
['Life-Impact']

Pentoxifylline O
to O
treat O
radiation O
proctitis O
: O
a O
small O
and O
inconclusive O
randomised O
trial O
. O
[]

A O
two-part O
phase O
II O
study O
of O
cediranib O
in O
patients O
with O
advanced O
solid O
tumours O
: O
the O
effect O
of O
food O
on O
single-dose O
pharmacokinetics O
and O
an O
evaluation O
of O
safety O
, O
efficacy O
and O
imaging B-outcome ['Physiological-Clinical']
pharmacodynamics I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
is O
a O
prospective O
study O
that O
compares O
the O
effects O
of O
calcium O
acetate O
and O
sevelamer O
on O
coronary B-outcome ['Physiological-Clinical']
calcification I-outcome ['Physiological-Clinical']
( O
CAC O
) O
and O
bone B-outcome ['Physiological-Clinical']
histology I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Moreover O
, O
[]

Hepatobiliary B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
postoperative O
lipid O
therapy O
in O
gastrointestinal O
surgery O
. O
['Physiological-Clinical']

The O
risk O
of O
any O
hospitalization O
for O
AF O
[ O
hazard O
ratio O
( O
95 O
% O
confidence O
interval O
) O
0.626 O
( O
0.546-0.719 O
) O
] O
and O
duration O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
were O
significantly O
reduced O
by O
dronedarone O
( O
P O
< O
0.0001 O
vs. O
placebo O
) O
. O
['Resource-use']

The O
teeth O
were O
randomly O
allocated O
to O
the O
following O
groups O
according O
to O
treatment O
; O
( O
1 O
) O
4 O
consecutive O
administrations O
of O
tetracycline-immobilized O
cross-linked O
collagen O
film O
( O
TC O
film O
) O
at O
intervals O
of O
1 O
week O
( O
TC O
group O
) O
; O
( O
2 O
) O
1 O
root O
planing O
treatment O
( O
RP O
group O
) O
; O
( O
3 O
) O
combination O
treatment O
( O
TC O
+ O
RP O
group O
) O
; O
( O
4 O
) O
no O
treatment O
( O
control O
group O
) O
. O
[]

Chewing O
has O
been O
shown O
to O
alleviate O
feelings O
of O
sleepiness O
and O
improve O
cognitive O
performance O
during O
the O
day O
. O
[]

Survival B-outcome ['Mortality']
was O
poor O
in O
both O
groups O
and O
not O
significantly O
different O
. O
['Mortality']

The O
insulin O
sensitivity O
index O
, O
Si O
, O
calculated O
as O
the O
quotient O
of O
augmentation O
of O
M/I O
between O
Step O
1 O
and O
2 O
, O
was O
reduced O
by O
35.3 O
% O
( O
p O
< O
0.01 O
) O
and O
23.5 O
% O
( O
p O
< O
0.05 O
) O
for O
25 O
and O
10 O
mg O
prednisone O
, O
respectively O
. O
[]

In O
contrast O
to O
the O
previously O
used O
evaluation O
procedures O
, O
this O
allows O
a O
reliable O
statistical O
confirmation O
of O
the O
results O
of O
clinical O
tests O
in O
the O
therapy O
for O
bronchial O
hyperresponsiveness O
. O
[]

A O
small O
trial O
comparing O
intramuscular O
pethidine O
with O
diamorphine O
, O
showed O
diamorphine O
to O
have O
some O
benefits O
over O
pethidine O
when O
used O
for O
labour O
analgesia O
but O
the O
study O
did O
not O
investigate O
the O
adverse O
effects O
of O
either O
opioid O
. O
[]

CONCLUSIONS O
Intramuscular O
administration O
of O
5000 O
IU O
of O
vitamin O
A O
three O
times O
per O
week O
for O
four O
weeks O
reduced O
biochemical O
evidence O
of O
vitamin O
A O
deficiency O
and O
slightly O
decreased O
the O
risk O
of O
chronic B-outcome ['Physiological-Clinical']
lung I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
in O
extremely-low-birth-weight O
infants O
. O
['Physiological-Clinical']

The O
days B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
in I-outcome ['Resource-use']
NICU I-outcome ['Resource-use']
was O
shorter O
in O
intensive O
insulin O
control O
group O
than O
that O
in O
conventional O
therapy O
group O
[ O
4.2 O
days O
vs. O
5.6 O
days O
( O
medians O
) O
P O
< O
0.05 O
] O
. O
['Resource-use']

Group O
C O
meningococcal B-outcome ['Physiological-Clinical']
IgG I-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
and O
bactericidal B-outcome ['Physiological-Clinical']
titres I-outcome ['Physiological-Clinical']
were O
higher O
in O
the O
MenC O
group O
than O
the O
MenPS O
group O
at O
1 O
month O
( O
22.8 O
U/ml O
vs O
4.0 O
U/ml O
, O
p O
< O
0.001 O
, O
and O
87 O
vs O
20 O
, O
p O
< O
0.001 O
, O
respectively O
) O
and O
12 O
months O
( O
6.1 O
U/ml O
vs O
3.0 O
U/ml O
, O
p O
< O
0.001 O
, O
and O
81.3 O
vs O
20.2 O
, O
p O
< O
0.001 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
improvement O
of O
nasal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
patients O
with O
AR O
treated O
with O
antihistamines O
, O
with O
or O
without O
montelukast O
, O
may O
additionally O
result O
from O
the O
reduction O
of O
sICAM-1 B-outcome ['Physiological-Clinical']
and O
nasal B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Regardless O
of O
ZH-feeding O
duration O
, O
TT O
steers O
produced O
a O
greater O
( O
P O
= O
0.006 O
) O
percentage O
of O
USDA O
yield O
grade O
( O
YG O
) O
4 O
or O
higher O
carcasses O
( O
5.4 O
vs. O
2.7 O
% O
) O
and O
a O
lesser O
( O
P O
= O
0.006 O
) O
percentage O
of O
YG O
1 O
carcasses O
( O
17.7 O
vs. O
26.8 O
% O
) O
than O
CC O
steers O
. O
[]

BACKGROUND O
Gastric O
mucus O
usually O
induces O
artefacts B-outcome ['Physiological-Clinical']
during O
endoscopic O
ultrasonography O
. O
['Physiological-Clinical']

There O
is O
a O
need O
for O
more O
studies O
and O
for O
the O
development O
of O
differentiated O
rehabilitative O
measures O
for O
such O
therapeutic O
consequences O
. O
[]

UNLABELLED O
This O
study O
compared O
the O
acute B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
and O
metabolic B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
during O
interval O
and O
continuous O
training O
after O
coronary O
bypass O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
clinical O
use O
of O
the O
GAI O
is O
currently O
limited O
by O
the O
absence O
of O
a O
method O
to O
estimate O
premorbid O
functioning O
as O
measured O
by O
this O
index O
. O
[]

Blood-impregnated O
filter O
papers O
( O
Guthrie O
cards O
) O
from O
603 O
randomly O
chosen O
New O
Zealand O
neonates O
were O
genotyped O
blind O
to O
17-hydroxyprogesterone O
( O
17-OHP O
) O
levels O
. O
[]

Echocardiography O
was O
performed O
at O
baseline O
and O
6 O
months O
, O
with O
paired O
data O
available O
for O
108 O
patients O
. O
[]

Estrogen O
therapy O
for O
severe O
persistent O
depressions O
in O
women O
. O
[]

We O
did O
not O
observe O
an O
association O
between O
TP53 B-outcome ['Physiological-Clinical']
tumour I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
and O
prognosis O
for O
patients O
who O
received O
paclitaxel/cisplatin O
combination O
treatment O
, O
indicating O
that O
the O
effect O
of O
this O
therapy O
is O
not O
influenced O
by O
this O
parameter O
. O
['Physiological-Clinical']

In O
the O
rat O
surgical O
model O
used O
, O
right O
femora O
were O
fixed O
to O
a O
polyethylene O
plate O
and O
then O
defects O
were O
created O
mid-diaphysis O
and O
subsequently O
filled O
with O
demineralized O
bone O
matrix O
. O
[]

Profound O
effects O
on O
cellular B-outcome ['Physiological-Clinical']
distribution O
and O
viral B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Similarly O
, O
no O
significant O
differences O
in O
urinary B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Comparing O
the O
two O
treatments O
, O
no O
statistically O
significant O
differences O
were O
found O
in O
PD B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
( O
GTR O
: O
1.67 O
mm O
; O
OFD O
: O
2.51 O
mm O
, O
P O
= O
0.26 O
) O
, O
CAL-v B-outcome ['Physiological-Clinical']
gain I-outcome ['Physiological-Clinical']
( O
GTR O
: O
0.62 O
mm O
; O
OFD O
: O
1.16 O
mm O
, O
P= O
0.37 O
) O
, O
and O
GR O
increase O
( O
GTR O
: O
1.04 O
mm O
; O
OFD O
: O
1.24 O
mm O
, O
P O
= O
0.31 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
bias O
of O
measuring O
haemoglobin O
concentration O
by O
pulse O
oximetry O
is O
dependent O
on O
whether O
a O
crystalloid O
or O
a O
colloid O
fluid O
is O
infused O
. O
[]

STUDY O
DESIGN O
Forty O
individuals O
participated O
in O
this O
two-part O
study O
: O
20 O
asymptomatic O
porphobilinogen O
deaminase-deficient O
subjects O
( O
both O
male O
and O
female O
) O
with O
> O
or O
=4 O
times O
the O
upper O
reference O
urinary O
porphobilinogen O
level O
, O
and O
20 O
healthy O
male O
subjects O
. O
[]

This O
study O
tests O
the O
hypothesis O
that O
putative O
activation O
of O
pulmonary O
C O
fibers O
by O
adenosine O
would O
trigger O
DNICs O
in O
humans O
and O
induce O
counterirritation O
. O
[]

The O
SiDBP B-outcome ['Physiological-Clinical']
response O
rates O
in O
the O
subgroups O
that O
had O
and O
had O
not O
been O
previously O
treated O
with O
antihypertensives O
were O
statistically O
similar O
( O
56/69 O
[ O
81.2 O
% O
] O
and O
83/92 O
[ O
90.2 O
% O
] O
, O
respectively O
) O
. O
['Physiological-Clinical']

For O
monitoring O
of O
diet O
composition O
during O
the O
study O
, O
an O
8-day O
diet O
cycle O
( O
6 O
weekday O
and O
2 O
weekend O
menus O
) O
was O
sampled O
by O
every O
field O
center O
twice O
during O
each O
of O
3 O
feeding O
periods O
. O
[]

A O
non-significant O
decrease O
in O
30-day O
mortality B-outcome ['Mortality']
was O
observed O
in O
favour O
of O
the O
pre-hospital O
group O
( O
13 O
% O
: O
P O
= O
0.08 O
) O
, O
whereas O
the O
decrease O
in O
cardiac B-outcome ['Mortality']
death I-outcome ['Mortality']
observed O
, O
also O
in O
favour O
of O
the O
pre-hospital O
group O
, O
was O
on O
the O
borderline O
of O
significance O
( O
16 O
% O
; O
P O
= O
0.049 O
) O
. O
['Mortality', 'Mortality']

On O
serial O
evaluation O
, O
spotty O
calcification O
was O
associated O
with O
greater O
progression O
of O
PAV O
( O
+0.43 O
? O
[]

Patients O
were O
examined O
after O
52 O
months O
to O
assess O
hernia B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
, O
nerve B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
, O
testicular B-outcome ['Physiological-Clinical']
atrophy I-outcome ['Physiological-Clinical']
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

OBJECTIVES O
The O
demand-control O
( O
D-C O
) O
model O
of O
job O
strain O
has O
generated O
a O
considerable O
body O
of O
empirical O
support O
in O
predicting O
psychological O
health O
outcomes O
in O
the O
context O
of O
work O
. O
[]

epidermidis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
total O
of O
38 O
patients O
was O
randomized O
to O
3-month O
treatment O
with O
either O
oral O
ganciclovir O
( O
1 O
g O
t.i.d. O
, O
n=14 O
, O
GAN O
group O
) O
or O
oral O
valacyclovir O
( O
2 O
g O
q.i.d. O
, O
n=12 O
, O
VAL O
group O
) O
. O
[]

4.6 O
kg O
, O
25.2 O
? O
[]

PURPOSE O
Vasomotor B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
are O
common O
adverse O
effects O
of O
antiestrogen O
hormone O
treatment O
in O
conventional O
breast O
cancer O
care O
. O
['Physiological-Clinical']

The O
impact O
of O
the O
two O
plans O
on O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
was O
compared O
over O
24 O
months O
of O
follow-up O
. O
['Physiological-Clinical']

Implementing O
a O
simplified O
neonatal O
resuscitation O
protocol-helping O
babies O
breathe O
at O
birth O
( O
HBB O
) O
- O
at O
a O
tertiary O
level O
hospital O
in O
Nepal O
for O
an O
increased O
perinatal B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality']

Secondary O
end O
points O
included O
percentage O
of O
patients O
with O
at O
least O
one O
SRE O
, O
time-to-first O
SRE O
, O
and O
Andersen-Gill O
multiple-event O
analysis O
. O
[]

Alignment O
and O
the O
survivorship O
of O
the O
components O
were O
not O
significantly O
different O
between O
the O
two O
groups O
. O
[]

Cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CBF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
cerebral B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CMRO2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
measured O
by O
a O
modification O
of O
the O
Kety-Schmidt O
technique O
using O
i.v O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
therapy O
group O
the O
endotracheal O
colonisation O
with O
ps O
. O
[]

OBJECTIVE O
To O
develop O
a O
cycle-based O
risk O
prediction O
model O
for O
neutropenic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
during O
chemotherapy O
with O
doxorubicin O
( O
DOX O
) O
or O
a O
pegylated O
liposomal O
formulation O
( O
PLD O
) O
for O
patients O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
['Physiological-Clinical']

Good O
functional O
outcomes O
at O
90 O
days O
were O
not O
significantly O
different O
. O
[]

This O
study O
assessed O
the O
effects O
of O
orthotic O
heel O
lifts O
on O
Achilles O
tendon O
( O
AT O
) O
force O
and O
strain O
during O
running O
. O
[]

The O
study O
was O
placebo-controlled O
, O
randomized O
, O
and O
double-blinded O
. O
[]

Ibuprofen-arginate O
caused O
a O
lower O
rate O
of O
clinical B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
than O
ibuprofen O
. O
['Adverse-effects']

RESULTS O
Data O
analysis O
showed O
sustained O
, O
statistically O
significant O
improvements O
in O
gingival B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
measured I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
gingival I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
plaque I-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
( O
GBI B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
PI I-outcome ['Physiological-Clinical']
) O
comparing O
users O
and O
non-users O
of O
toothbrushes O
and O
dentifrice O
in O
the O
original O
study O
( O
PI O
: O
p O
= O
0.04 O
; O
GBI O
: O
p O
= O
0.03 O
) O
and O
sustained B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
toothbrushes I-outcome ['Life-Impact']
and O
dentifrice B-outcome ['Resource-use']
by O
60 O
% O
of O
the O
subjects O
at O
follow-up O
one O
year O
later O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

Patient O
characteristics O
including O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
prior O
history O
of O
low O
back O
pain O
, O
and O
number O
of O
visits B-outcome ['Resource-use']
during O
the O
illness O
episode O
were O
strong O
predictors O
of O
service O
utilization O
and O
guideline-consistent O
behavior O
. O
['Physiological-Clinical', 'Resource-use']

RESULTS O
A O
total O
of O
587 O
H. O
pylori-infected O
subjects O
were O
randomized O
to O
OAC O
( O
n O
= O
295 O
) O
and O
placebo O
( O
n O
= O
292 O
) O
. O
[]

The O
data O
provided O
evidence O
that O
all-E-3-'dehydro-lutein O
was O
derived O
from O
all-E-zeaxanthin B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
study O
was O
approved O
by O
the O
local O
ethics O
committee O
. O
[]

The O
benefit O
of O
low-dose O
dopamine O
during O
vigorous O
diuresis O
for O
congestive O
heart O
failure O
associated O
with O
renal O
insufficiency O
: O
does O
it O
protect O
renal O
function O
? O
[]

Malnutrition O
is O
associated O
with O
defects O
in O
immune O
function O
that O
may O
impair O
the O
host O
response O
to O
malignancy O
. O
[]

In O
the O
primary O
efficacy O
analysis O
, O
time O
to O
recurrence O
in O
the O
2 O
treatment O
groups O
was O
compared O
with O
the O
log-rank O
test O
in O
the O
subgroup O
of O
patients O
with O
structural O
heart O
disease O
. O
[]

They O
were O
all O
enrolled O
in O
mainstream O
compulsory O
education O
. O
[]

Our O
setting O
was O
a O
270,000 O
member O
group-model O
PPGP O
in O
Colorado O
, O
from O
1990 O
to O
1991 O
. O
[]

In O
the O
training O
study O
10 O
boys O
from O
the O
hypertensive O
subgroup O
and O
10 O
boys O
from O
the O
normotensive O
subgroup O
were O
also O
evaluated O
after O
eight O
months O
of O
physical O
training O
. O
[]

To O
test O
this O
assumption O
, O
54 O
PTSD O
patients O
were O
randomized O
to O
prolonged O
exposure O
therapy O
or O
prolonged O
exposure O
therapy O
plus O
cognitive O
restructuring O
. O
[]

A O
chinese O
mind-body O
exercise O
improves O
self-control B-outcome ['Life-Impact']
of O
children O
with O
autism O
: O
a O
randomized O
controlled O
trial O
. O
['Life-Impact']

FINDINGS O
We O
screened O
189 O
patients O
and O
enrolled O
156 O
( O
106 O
in O
the O
ganitumab O
group O
and O
50 O
in O
the O
placebo O
group O
) O
. O
[]

Evidence O
suggests O
that O
atherothrombosis O
and O
intravascular O
inflammation O
share O
predictive O
biomarkers O
, O
including O
high-sensitivity O
C-reactive O
protein O
, O
CD40 O
ligand O
, O
P-selectin O
, O
and O
N-terminal O
pro-brain O
natriuretic O
peptide O
. O
[]

The O
occurrence O
of O
spasm B-outcome ['Physiological-Clinical']
was O
similar O
, O
independent O
of O
the O
vasodilator O
cocktail O
used O
( O
Group O
A O
: O
12.2 O
% O
, O
Group O
B O
: O
13.4 O
% O
, O
Group O
C O
: O
9.5 O
% O
; O
p O
= O
0.597 O
) O
. O
['Physiological-Clinical']

Safety O
of O
the O
combination O
of O
valsartan O
and O
benazepril O
in O
patients O
with O
chronic O
renal O
disease O
. O
[]

Bronchial O
biopsies O
, O
which O
were O
taken O
before O
and O
after O
this O
exposure O
, O
were O
stained O
and O
digitally O
analysed O
. O
[]

This O
study O
examines O
the O
psychometric O
properties O
and O
tests O
the O
concurrent O
and O
predictive O
validity O
of O
a O
structured O
, O
self-reported O
medication O
adherence O
measure O
in O
patients O
with O
hypertension O
. O
[]

Overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
was O
the O
primary O
endpoint O
, O
while O
progression-free O
survival O
( O
PFS O
) O
was O
a O
secondary O
endpoint O
. O
['Mortality']

MATERIALS O
AND O
METHODS O
Between O
December O
1997 O
and O
November O
1999 O
, O
57 O
consecutive O
eligible O
patients O
with O
surgical O
adrenal O
disease O
were O
prospectively O
randomized O
to O
undergo O
TLA O
( O
25 O
) O
or O
RLA O
( O
32 O
) O
. O
[]

A O
total O
of O
2,615 O
questionnaires O
were O
returned O
. O
[]

The O
treatment O
lasted O
12 O
weeks O
. O
[]

Determinants O
of O
exclusive O
breastfeeding O
in O
an O
urban O
population O
of O
primiparas O
in O
Lebanon O
: O
a O
cross-sectional O
study O
. O
[]

Total O
sleep O
time O
per O
24 O
hours O
increased O
from O
5.5 O
hours O
( O
range O
3 O
to O
8.5 O
hours O
) O
to O
13.0 O
hours O
( O
range O
10 O
to O
14.5 O
hours O
, O
P O
= O
.001 O
) O
. O
[]

Cardiovascular O
reactivity O
to O
psychological O
stress O
may O
be O
one O
mechanism O
for O
the O
enhanced O
risk O
, O
but O
the O
small O
number O
of O
studies O
examining O
whether O
OC O
users O
who O
smoke O
have O
greater O
reactivity B-outcome ['Physiological-Clinical']
have O
produced O
mixed O
results O
. O
['Physiological-Clinical']

Some O
26 O
cases O
composed O
of O
11 O
cases O
of O
arm O
A O
and O
15 O
cases O
of O
arm O
B O
completed O
the O
administration O
schedules O
. O
[]

To O
detect O
DU B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
, O
the O
gastroscopy B-outcome ['Resource-use']
was O
performed O
at O
6 O
, O
12 O
, O
18 O
, O
and O
24 O
months O
after O
therapy O
. O
['Physiological-Clinical', 'Resource-use']

In O
the O
Sedation O
group O
, O
the O
average O
pain B-outcome ['Physiological-Clinical']
intensity O
score O
was O
0.4 O
( O
0.8 O
) O
. O
['Physiological-Clinical']

RESULTS O
The O
spiritually O
based O
intervention O
appeared O
to O
be O
more O
effective O
in O
areas O
such O
as O
knowledge O
, O
and O
men O
read O
more O
of O
their O
materials O
in O
the O
spiritually O
based O
group O
than O
in O
the O
non-spiritual O
group O
. O
[]

Comparison O
of O
clinical B-outcome ['Physiological-Clinical']
effectiveness O
of O
acupuncture O
and O
a O
Western O
drug O
on O
allergic O
rhinitis O
: O
study O
protocol O
for O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

The O
cutoff O
of O
these O
tests O
was O
0.1 O
IU/mL O
. O
[]

In O
group O
III O
( O
Mi/Fe O
) O
, O
midazolam O
and O
fentanyl O
were O
used O
for O
induction O
and O
maintenance O
. O
[]

Subjects O
with O
treatment O
failure O
despite O
a O
full O
8-week O
fourfold O
fexofenadine O
treatment O
were O
included O
in O
the O
resistant O
CIU O
( O
R-CIU O
group O
) O
. O
[]

However O
, O
between O
3 O
and O
6 O
months O
, O
RBC B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
increased O
in O
all O
4 O
androgen-treated O
patients O
studied O
even O
though O
erythron O
iron O
turnovers O
remained O
unchanged O
and O
dialysis-associated B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
losses I-outcome ['Physiological-Clinical']
did O
not O
decrease O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
such O
alterations O
in O
the O
formation O
of O
lipoxygenase O
products O
were O
found O
with O
the O
vegetable O
oil O
treatment O
. O
[]

The O
relationship O
between O
subjective O
effects O
and O
drug O
preferences O
in O
normal O
volunteers O
was O
explored O
in O
a O
meta-analysis O
of O
several O
previously O
published O
studies O
. O
[]

Peripheral B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
oxygenation I-outcome ['Physiological-Clinical']
decreased O
to O
78.9 O
+/- O
8.7 O
% O
( O
mean O
+/- O
SD O
) O
ranging O
from O
52 O
% O
-90 O
% O
. O
['Physiological-Clinical']

Although O
controlled O
studies O
on O
the O
effect O
of O
mainly O
one O
single O
dose O
have O
not O
documented O
any O
effect O
, O
many O
children O
still O
continue O
to O
receive O
secretin O
. O
[]

Ferulic O
acid O
is O
the O
major O
phenolic O
compound O
in O
rye O
bran O
and O
is O
an O
antioxidant O
in O
vitro O
and O
may O
, O
therefore O
, O
contribute O
to O
cardioprotective O
effects O
of O
whole O
grain O
consumption O
. O
[]

Accelerated O
approval O
was O
based O
on O
demonstration O
of O
a O
beneficial O
effect O
on O
progression-free O
survival O
( O
PFS O
) O
. O
[]

BACKGROUND O
Poor O
pouch O
function O
is O
associated O
with O
impaired O
bile O
acid O
absorption O
and O
increased O
faecal O
loss O
of O
bile O
acids O
. O
[]

We O
found O
that O
physical B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
did O
not O
differ O
between O
10 O
and O
20 O
mg O
MPA O
. O
['Life-Impact']

After O
acute O
salt O
loading O
, O
borderline O
subjects O
with O
high O
intralymphocytic O
sodium O
showed O
a O
significant O
greater O
natriuresis B-outcome ['Physiological-Clinical']
whereas O
intralymphocytic B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
increased O
only O
in O
those O
subjects O
in O
whom O
it O
was O
initially O
normal O
. O
['Physiological-Clinical', 'Physiological-Clinical']

STUDY O
DESIGN O
Two O
hundred O
patients O
with O
indications O
for O
induction O
of O
labor O
and O
unfavorable O
cervical O
examinations O
were O
randomly O
assigned O
to O
receive O
vaginally O
administered O
misoprostol O
( O
prostaglandin O
E1 O
) O
or O
the O
dinoprostone O
( O
prostaglandin O
E2 O
) O
vaginal O
insert O
. O
[]

Standardized O
tests O
of O
speech B-outcome ['Life-Impact']
production I-outcome ['Life-Impact']
, O
receptive B-outcome ['Life-Impact']
and O
expressive B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
were O
administered O
, O
and O
parent O
ratings O
were O
collected O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
median O
number O
of O
aflibercept B-outcome ['Physiological-Clinical']
cycles I-outcome ['Physiological-Clinical']
was O
16 O
( O
range O
1-44 O
) O
, O
12 O
patients O
received O
?20 O
cycles O
. O
['Physiological-Clinical']

This O
study O
aimed O
to O
compare O
the O
impact O
, O
on O
patients O
' O
anxiety O
, O
of O
a O
basic O
communication O
skills O
training O
programme O
( O
BT O
) O
and O
the O
same O
programme O
consolidated O
by O
consolidation O
workshops O
( O
CW O
) O
, O
and O
to O
investigate O
physicians O
' O
communication O
variables O
associated O
with O
patients O
' O
anxiety O
. O
[]

Increasing O
Ki-67 O
positivity O
was O
associated O
with O
decreasing O
differentiation O
( O
P O
< O
0.001 O
) O
and O
increasing O
N-stage O
( O
P O
< O
0.004 O
) O
. O
[]

We O
investigated O
the O
effect O
of O
inhaled O
heparin O
on O
adenosine-induced O
bronchoconstriction O
and O
compared O
the O
inhibitory O
role O
of O
heparin O
on O
the O
adenosine O
challenge O
test O
with O
that O
on O
the O
methacholine O
challenge O
test O
. O
[]

Although O
clinically O
significant O
elevations B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
aminotransferases I-outcome ['Physiological-Clinical']
and O
reductions O
of O
cholinesterase B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

A O
second O
, O
independent O
group O
of O
43 O
patients O
was O
used O
to O
test O
the O
predictive O
value O
of O
APC O
( O
using O
0.25 O
mL/min/kg O
body O
wt O
as O
a O
cut-off O
) O
for O
response O
to O
interferon O
treatment O
. O
[]

On O
subjective O
preference O
measures O
, O
parents O
and O
children O
favored O
the O
weighted O
blanket O
. O
[]

The O
roots O
were O
stained O
with O
india O
ink O
, O
decalcified O
, O
dehydrated O
, O
and O
then O
placed O
in O
methylsalicylate O
to O
make O
them O
transparent O
. O
[]

A O
randomized O
trial O
of O
an O
interim O
methadone O
maintenance O
clinic O
. O
[]

The O
improvement O
[]

PATIENTS O
AND O
METHODS O
Patients O
with O
completely O
resected O
( O
stage O
IB O
, O
II O
, O
or O
IIIA O
) O
NSCLC O
stratified O
by O
stage O
, O
histology O
, O
sex O
, O
postoperative O
radiotherapy O
, O
and O
chemotherapy O
were O
randomly O
assigned O
( O
1:1 O
) O
to O
receive O
gefitinib O
250 O
mg O
per O
day O
or O
placebo O
for O
2 O
years O
. O
[]

The O
results O
did O
not O
show O
significant O
differences O
among O
the O
3 O
groups O
. O
[]

This O
study O
was O
conducted O
to O
clarify O
the O
feasibility O
of O
newly O
developed O
vitrification O
techniques O
for O
porcine O
embryos O
using O
the O
micro O
volume O
air O
cooling O
( O
MVAC O
) O
method O
without O
direct O
contact O
with O
liquid O
nitrogen O
( O
LN? O
) O
. O
[]

CONCLUSIONS O
Although O
there O
was O
an O
increase O
in O
mild B-outcome ['Physiological-Clinical']
reactogenicity I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
children O
6 O
to O
< O
16 O
weeks O
of O
age O
, O
cold-adapted O
influenza O
vaccine O
, O
trivalent O
, O
was O
generally O
well O
tolerated O
in O
infants O
6 O
to O
< O
24 O
weeks O
of O
age O
. O
['Physiological-Clinical']

Outcome O
measures O
included O
the O
Brief B-outcome ['Physiological-Clinical']
Fatigue I-outcome ['Physiological-Clinical']
Inventory I-outcome ['Physiological-Clinical']
, O
vitality O
subscale O
of O
the O
Medical O
Outcome O
Scale O
Short O
Form-36 O
( O
SF-36 O
) O
, O
and O
the O
Global B-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
Benefit I-outcome ['Physiological-Clinical']
Scale O
at O
4 O
and O
8 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Side O
effects O
in O
group O
I O
were O
observed O
in O
6 O
patients O
( O
23 O
% O
) O
and O
in O
5 O
( O
29.4 O
% O
) O
in O
group O
II O
. O
[]

Efficacy O
and O
safety O
of O
sildenafil O
in O
Asian O
males O
with O
erectile O
dysfunction O
and O
cardiovascular O
risk O
. O
[]

The O
effect O
of O
two O
types O
of O
teacher O
training O
on O
implementation O
of O
Smart O
Choices O
: O
a O
tobacco O
prevention O
curriculum O
. O
[]

Variance O
in O
albumin O
loading O
in O
exchange O
transfusions O
. O
[]

Comparisons O
between O
the O
original O
data O
and O
longer-term O
follow-up O
data O
may O
be O
of O
interest O
, O
particularly O
with O
regard O
to O
promising O
new O
therapies O
. O
[]

The O
patients O
were O
followed O
for O
one O
year O
. O
[]

When O
comparing O
the O
efficacy O
of O
the O
three O
randomized O
therapeutic O
regimens O
while O
on O
the O
Na+ O
supplement O
, O
the O
valsartan O
160 O
mg/HCTZ O
12.5 O
mg O
was O
the O
most O
effective O
therapy O
with O
an O
incremental O
reduction O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
-10.5/-6.9 O
mm O
Hg O
( O
P O
< O
.01 O
) O
, O
compared O
to O
valsartan O
160 O
mg/day O
alone O
. O
['Physiological-Clinical']

However O
, O
deterioration O
in O
some O
responders O
with O
time O
suggests O
the O
need O
for O
maintenance O
protocols O
. O
[]

After O
one O
month O
of O
treatment O
, O
the O
patients O
treated O
with O
propionyl-L-carnitine O
, O
compared O
to O
the O
control O
group O
, O
showed O
significant O
increases O
in O
the O
values O
of O
both O
tests O
, O
increases O
which O
became O
even O
more O
evident O
after O
90 O
and O
180 O
days O
. O
[]

Patients O
in O
the O
control O
group O
had O
received O
significantly O
more O
radiation O
than O
those O
in O
the O
test O
group O
( O
68Gy O
vs. O
60Gy O
; O
p=0.047 O
) O
. O
[]

The O
group O
of O
treatment O
responders O
showed O
a O
decrease O
of O
[]

3.2 O
vs. O
82.1 O
? O
[]

OBJECTIVE O
To O
compare O
antisecretory O
effects O
of O
single O
doses O
of O
rabeprazole O
and O
esomeprazole O
. O
[]

The O
two O
drugs O
did O
not O
significantly O
influence O
the O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical']

A O
randomized O
intervention O
to O
improve O
ongoing O
participation O
in O
mammography B-outcome ['Resource-use']
. O
['Life-Impact', 'Resource-use']

CONCLUSIONS O
Octreotide O
therapy O
reduces O
liver B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
in O
patients O
with O
ADPKD O
and O
is O
safe O
. O
['Physiological-Clinical']

If O
the O
hematocrit B-outcome ['Physiological-Clinical']
reached O
this O
target O
level O
before O
12 O
weeks O
, O
the O
rHuEPO O
dose O
could O
be O
reduced O
to O
maintain O
the O
hematocrit O
at O
that O
level O
for O
the O
duration O
of O
the O
study O
. O
['Physiological-Clinical']

Mean O
pain B-outcome ['Physiological-Clinical']
scores O
showed O
an O
increase O
of O
pain B-outcome ['Physiological-Clinical']
in O
patients O
receiving O
placebo O
and O
a O
decrease O
of O
pain O
in O
patients O
receiving O
clodronate O
, O
although O
the O
difference O
failed O
to O
be O
statistically O
significant O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
efficacy O
of O
preemptive O
epidural O
analgesia O
combined O
with O
postoperative O
epidural O
analgesia O
, O
postoperative O
epidural O
analgesia O
alone O
and O
intravenous O
analgesia O
for O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
and O
their O
effects O
on O
plasma B-outcome ['Physiological-Clinical']
interleukin-6 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IL-6 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
following O
radical O
surgery O
for O
gastric O
carcinoma O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Mineralocorticoid-receptor O
antagonists O
improve O
the O
prognosis O
for O
patients O
with O
heart O
failure O
and O
a O
reduced O
left O
ventricular O
ejection O
fraction O
. O
[]

The O
volatile O
agents O
were O
used O
to O
decrease O
the O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
to O
80 O
mmHg O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
AIMS O
This O
study O
evaluated O
the O
use O
of O
perioperative O
nutritional O
support O
on O
Quality O
of O
Life O
( O
QOL B-outcome ['Life-Impact']
) O
in O
malnourished O
head O
and O
neck O
cancer O
patients O
undergoing O
surgery O
. O
['Life-Impact']

A O
prospective O
comparison O
of O
transthoracic O
and O
transhiatal O
resection O
for O
esophageal O
carcinoma O
in O
Asians O
. O
[]

Using O
200 O
mg/kg O
, O
mean O
half-life O
and O
volume O
of O
distribution O
( O
Vd O
) O
in O
women O
were O
15 O
days O
and O
72 O
mL/kg O
, O
respectively O
, O
after O
one O
and O
32 O
days O
and O
154 O
mL/kg O
after O
three O
monthly O
infusions O
, O
with O
stable O
4 O
mL/kg/day O
clearance O
. O
[]

Decrements O
of O
symptom B-outcome ['Physiological-Clinical']
grade I-outcome ['Physiological-Clinical']
were O
lower O
in O
titanoreine O
group O
than O
those O
of O
control O
group O
at O
any O
point O
after O
PPH O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

A O
best-case O
scenario O
assumed O
that O
all O
cancers O
showing O
a O
positive O
screen O
result O
earlier O
with O
ROCA O
than O
under O
the O
PLCO O
protocol O
would O
have O
avoided O
mortality B-outcome ['Mortality']
; O
under O
a O
stage-shift O
scenario O
, O
such O
women O
were O
assigned O
survival O
equivalent O
to O
Stage O
I/II O
screen-detected O
cases O
. O
['Mortality']

In O
systemic O
T1 O
samples O
, O
microparticle-bound O
CRP O
, O
whereas O
in O
pericardial O
blood O
, O
microparticle-bound O
SAP O
and O
IgM O
were O
associated O
with O
complement O
activation O
. O
[]

A O
phase O
I O
study O
of O
recombinant O
human O
ciliary O
neurotrophic O
factor O
( O
rHCNTF O
) O
in O
patients O
with O
amyotrophic O
lateral O
sclerosis O
. O
[]

However O
, O
a O
slight O
decrease O
in O
early B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
response O
['Physiological-Clinical']

An O
ad O
hoc O
analysis O
of O
all O
available O
data O
is O
reported O
here O
. O
[]

Eighty-two O
patients O
were O
randomised O
, O
40 O
to O
have O
the O
operation O
, O
and O
42 O
patients O
to O
conservative O
treatment O
. O
[]

6 O
. O
[]

A O
randomized O
, O
evaluator-blind O
, O
multicenter O
comparison O
of O
the O
efficacy O
and O
tolerability O
of O
Perlane O
versus O
Zyplast O
in O
the O
correction O
of O
nasolabial O
folds O
. O
[]

Engagement O
with O
electronic O
screen O
media O
among O
students O
with O
autism O
spectrum O
disorders O
. O
[]

METHODS O
Healthy O
, O
adult O
volunteers O
were O
randomized O
to O
receive O
Viatim O
( O
group O
A O
, O
n O
= O
179 O
) O
or O
separate O
HA O
and O
Vi O
vaccines O
( O
group O
B O
, O
n O
= O
181 O
) O
; O
subgroups O
were O
boosted O
after O
3 O
years O
with O
Viatim O
( O
groups O
C O
and O
D O
, O
n O
= O
56 O
and O
46 O
, O
respectively O
) O
. O
[]

We O
evaluated O
the O
cost-effectiveness O
of O
rapid O
diagnostic O
tests O
( O
RDTs O
) O
in O
comparison O
to O
microscopy O
in O
guiding O
treatment O
of O
non-severe O
febrile O
illness O
at O
varying O
levels O
of O
malaria O
endemicity O
using O
data O
on O
test O
accuracy O
and O
costs B-outcome ['Resource-use']
collected O
as O
part O
of O
a O
Tanzanian O
trial O
. O
['Resource-use', 'Resource-use']

In O
experiment O
2 O
, O
observers O
aimed O
a O
laser O
gun O
at O
targets O
while O
fixating O
either O
the O
rear O
or O
the O
front O
gunsight O
monocularly O
, O
or O
the O
target O
either O
monocularly O
or O
binocularly O
. O
[]

14 O
years O
) O
we O
assessed O
brachial O
endothelium-dependent O
flow-mediated O
dilatation O
( O
FMD O
) O
, O
endothelium-independent O
dilatation O
( O
via O
glyceryl O
trinitrate O
; O
GTN O
) O
, O
common O
carotid O
intima-media O
thickness O
( O
CIMT O
) O
and O
diameter O
( O
ultrasound O
) O
, O
and O
arterial O
stiffness O
via O
pulse O
wave O
velocity O
( O
PWV O
; O
applanation O
tonometry O
) O
. O
[]

Primary O
endpoints O
are O
modelled B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
risk O
at O
one O
year O
, O
and O
cardiovascular B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
at O
five O
years O
after O
diagnosis O
of O
diabetes O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

Overall O
clinical B-outcome ['Physiological-Clinical']
improvement O
( O
e.g O
. O
['Physiological-Clinical']

Dropout O
of O
treatment O
is O
one O
of O
the O
key O
issues O
in O
outcome O
in O
a O
child O
and O
adolescent O
mental O
health O
service O
. O
[]

All O
patients O
were O
followed O
up O
for O
6 O
months O
. O
[]

Secondary O
outcomes O
include O
: O
pregnancy B-outcome ['Physiological-Clinical']
rate O
, O
method B-outcome ['Life-Impact']
continuation I-outcome ['Life-Impact']
rate O
, O
complication O
rates O
( O
infection O
, O
perforation O
) O
, O
and O
satisfaction B-outcome ['Life-Impact']
with O
contraceptive B-outcome ['Resource-use']
method I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Resource-use']

So O
, O
further O
evaluation O
on O
more O
patients O
seems O
necessary O
. O
[]

Surprisingly O
, O
although O
9 O
out O
of O
52 O
patients O
recur O
six O
weeks O
after O
the O
combination O
treatment O
, O
the O
re-administration O
of O
low-dose O
CY O
alone O
completely O
eliminates O
most O
recurred B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
Clinical O
trials O
have O
not O
shown O
a O
consistent O
benefit O
of O
treating O
bronchitis O
with O
antibiotics O
. O
[]

Similarly O
, O
66 O
vitrified O
embryos O
were O
transferred O
to O
5 O
recipient O
gilts O
, O
and O
9 O
healthy O
piglets O
were O
produced O
from O
2 O
recipients O
in O
the O
CT O
group O
. O
[]

Patients O
in O
the O
intervention O
group O
will O
receive O
treatment O
based O
on O
the O
collaborative O
care O
approach O
, O
and O
patients O
in O
the O
control O
group O
will O
receive O
care O
as O
usual O
. O
[]

Parecoxib O
( O
40 O
mg O
) O
was O
given O
in O
all O
the O
patients O
immediately O
before O
the O
operation O
, O
and O
the O
mixture O
( O
4-5 O
ml O
) O
of O
lidocaine O
and O
ropivacaine O
was O
administered O
into O
the O
3 O
intercostal O
spaces O
upper O
and O
lower O
to O
the O
incision O
before O
chest O
closure O
. O
[]

Thirty-six O
patients O
with O
subarachnoid O
and O
intraventricular O
cysticercosis O
were O
randomly O
assigned O
to O
receive O
albendazole O
at O
15 O
or O
30 O
mg/kg/day O
plus O
dexamethasone O
for O
8 O
days O
. O
[]

RESULTS O
Bulbar B-outcome ['Physiological-Clinical']
conjunctival I-outcome ['Physiological-Clinical']
hyperemia I-outcome ['Physiological-Clinical']
and O
ocular B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
decreased O
and O
temperature O
recovered O
to O
baseline O
faster O
with O
nonpharmaceutical O
treatments O
compared O
with O
no O
treatment O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Although O
both O
transfusion O
programs O
were O
well O
tolerated O
, O
our O
finding O
of O
more O
frequent O
major B-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
neurologic I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
the O
restrictive O
RBC-transfusion O
group O
suggests O
that O
the O
practice O
of O
restrictive O
transfusions O
may O
be O
harmful O
to O
preterm O
infants O
. O
['Physiological-Clinical']

1996 O
) O
and O
Frame O
et O
al O
. O
( O
[]

Funded O
by O
the O
Canadian O
Institutes O
of O
Health O
Research O
and O
others O
; O
POISE-2 O
ClinicalTrials.gov O
number O
, O
NCT01082874 O
. O
) O
. O
[]

The O
clinical O
relevance O
of O
this O
study O
is O
enhanced O
by O
the O
addition O
of O
an O
extended O
maintenance O
phase O
followed O
by O
a O
placebo O
discontinuation O
. O
[]

CONCLUSION O
There O
is O
no O
difference O
in O
safety O
between O
the O
three O
methods O
of O
arterial O
closure O
. O
[]

INTERPRETATION O
Even O
though O
LC O
for O
acute O
and O
gangrenous O
cholecystitis O
is O
technically O
demanding O
, O
in O
experienced O
hands O
it O
is O
safe O
and O
effective O
. O
[]

However O
, O
the O
success B-outcome ['Physiological-Clinical']
rate O
at O
24 O
hours O
was O
significantly O
higher O
in O
the O
vaginal O
group O
( O
85 O
% O
) O
compared O
with O
the O
sublingual O
group O
( O
64 O
% O
) O
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
overnight B-outcome ['Physiological-Clinical']
polysomnography B-outcome ['Physiological-Clinical']
did O
not O
change O
after O
fat O
gain O
or O
loss O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
pair O
of O
defibrillator O
paddles O
were O
instrumented O
to O
measure O
paddle B-outcome ['Physiological-Clinical']
force I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
preparations O
were O
equally O
and O
highly O
bioavailable O
. O
[]

MATERIAL O
AND O
METHOD O
Thirty O
six O
patients O
were O
randomized O
in O
both O
branches O
: O
diet O
I O
with O
lunch O
and O
dinner O
substituted O
by O
two O
Optisource O
( O
1109,3 O
kcal/day O
, O
166,4g O
of O
carbohydrates O
( O
60 O
% O
) O
, O
63g O
of O
proteins O
( O
23 O
% O
) O
, O
21,3g O
of O
lipids O
17 O
% O
) O
and O
diet O
II O
with O
nutritional O
counselling O
with O
a O
decrease O
of O
500 O
cal/day O
from O
the O
previous O
dietary O
intake O
. O
[]

Tumour O
necrosis O
factor-? O
was O
significantly O
higher O
in O
the O
RFA O
group O
( O
p O
< O
0.05 O
) O
. O
[]

Mean O
changes O
tended O
toward O
faster O
transit O
times O
in O
the O
left O
colon O
and O
the O
rectum O
, O
although O
the O
differences O
were O
not O
statistically O
significant O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
were O
randomized O
to O
21-day O
cycles O
of O
oral O
capecitabine O
1,250 O
mg/m O
( O
2 O
) O
twice O
daily O
on O
days O
1 O
to O
14 O
plus O
docetaxel O
75 O
mg/m O
( O
2 O
) O
on O
day O
1 O
( O
n O
= O
255 O
) O
or O
to O
docetaxel O
100 O
mg/m O
( O
2 O
) O
on O
day O
1 O
( O
n O
= O
256 O
) O
. O
[]

RESULTS O
The O
serum O
levels O
of O
25-hydroxyvitamin O
D3 O
were O
significantly O
lower O
in O
the O
Pakistanis O
compared O
with O
the O
Norwegians O
( O
median O
19 O
nmol/l O
vs O
55 O
nmol/l O
, O
P O
< O
0.001 O
) O
and O
83 O
% O
of O
the O
Pakistani O
women O
had O
25-hydroxyvitamin B-outcome ['Physiological-Clinical']
D3 I-outcome ['Physiological-Clinical']
levels O
below O
the O
reference O
value O
( O
< O
30 O
nmol/l O
) O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
the O
degree O
of O
enrichment O
of O
bile O
correlated O
with O
that O
of O
serum O
and O
whether O
either O
of O
these O
measures O
correlated O
with O
improvement O
in O
measures O
of O
liver O
disease O
. O
[]

The O
Family O
End-of-study O
Up-to-date O
Index O
is O
the O
proportion O
of O
procedures O
for O
which O
the O
family O
was O
eligible O
and O
for O
which O
they O
were O
up-to-date O
at O
the O
end O
of O
the O
study O
. O
[]

The O
correlation O
of O
plasma O
drug O
levels O
with O
inhibition O
( O
EC50=43 O
nM O
) O
was O
as O
expected O
based O
on O
in O
vitro O
potency O
( O
IC50 O
approximately O
50 O
nM O
) O
, O
and O
increases O
in O
CETP B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
were O
consistent O
with O
the O
proposed O
mechanism O
of O
inhibition O
. O
['Physiological-Clinical']

These O
results O
suggest O
that O
intrapleural O
instillation O
using O
a O
combination O
of O
anti-cancer O
agent O
and O
immunopotentiator O
is O
an O
effective O
treatment O
for O
malignant O
pleurisy O
. O
[]

No O
significant O
differences O
were O
found O
with O
regard O
to O
pregnancy B-outcome ['Physiological-Clinical']
rates O
between O
those O
two O
groups O
: O
pregnancy O
rates O
were O
54 O
% O
in O
the O
IVF- O
group O
and O
48 O
% O
in O
the O
IVF+ O
group O
. O
['Physiological-Clinical']

The O
study O
design O
is O
feasible O
, O
and O
minor O
improvements O
will O
help O
to O
minimize O
the O
potential O
bias O
. O
[]

Eleven O
patients O
were O
excluded O
from O
analysis O
and O
another O
5 O
patients O
were O
excluded O
from O
response O
analysis O
. O
[]

During O
phase O
I O
( O
control O
) O
, O
subjects O
ingested O
3 O
g O
acetaminophen O
, O
followed O
one O
hour O
later O
by O
the O
normal O
loading O
dose O
of O
N-acetylcysteine O
( O
140 O
mg/kg O
) O
. O
[]

Compared O
with O
ETT O
, O
index O
testing O
costs O
were O
higher O
for O
exercise O
MPI O
( O
P O
< O
0.001 O
) O
, O
whereas O
downstream O
procedural O
costs O
were O
slightly O
lower O
( O
P=0.0008 O
) O
. O
[]

METHODS O
Sixty-one O
parturients O
undergoing O
labor O
selected O
for O
delivery O
with O
epidural O
analgesia O
were O
randomized O
into O
two O
groups O
: O
Group O
tramadol O
( O
0.125 O
% O
ropivacaine O
plus O
tramadol O
5 O
mg/mL O
) O
and O
Group O
fentanyl O
( O
0.125 O
% O
ropivacaine O
plus O
fentanyl O
3 O
ug/mL O
) O
. O
[]

All O
patients O
treated O
with O
verapamil O
( O
17 O
AF O
, O
3 O
AFI O
) O
showed O
lower B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
after O
1 O
hour O
; O
however O
, O
only O
1 O
( O
6 O
% O
) O
with O
AF O
converted O
to O
sinus O
rhythm O
and O
1 O
( O
6 O
% O
) O
converted O
to O
AFI O
. O
['Physiological-Clinical']

Airway B-outcome ['Physiological-Clinical']
calibre I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
prechallenge I-outcome ['Physiological-Clinical']
FEV1 I-outcome ['Physiological-Clinical']
for O
levocetirizine O
vs O
placebo O
was O
not O
significantly O
different O
following O
the O
first O
dose O
86 O
+/- O
4 O
vs O
82 O
+/- O
4 O
, O
or O
the O
last O
dose O
85 O
+/- O
4 O
vs O
83 O
+/- O
4 O
, O
respectively O
. O
['Physiological-Clinical']

Relapse B-outcome ['Physiological-Clinical']
is O
less O
frequent O
when O
a O
combination O
of O
bismuth O
and O
an O
antimicrobial O
agent O
is O
used O
; O
such O
a O
combination O
is O
characterized O
by O
local B-outcome ['Physiological-Clinical']
and O
systemic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
stability O
at O
low B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
, O
and O
good B-outcome ['Physiological-Clinical']
penetration I-outcome ['Physiological-Clinical']
into I-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
mucus I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

One O
case O
was O
not O
informative O
at O
any O
of O
the O
loci O
tested O
and O
was O
excluded O
from O
further O
analysis O
. O
[]

RESULTS O
The O
minimum B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
achieved O
by O
the O
hypothermic O
group O
was O
34.3 O
+/- O
0.4 O
degrees O
C. O
Cooling B-outcome ['Physiological-Clinical']
occurred O
at O
a O
rate O
of O
1.0 O
+/- O
0.4 O
degrees O
C/h O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Participants O
were O
32 O
smokers O
and O
33 O
non-smokers O
without O
any O
evidence O
of O
premalignant O
oral O
lesions O
. O
[]

The O
most O
pronounced O
excess O
concerned O
second B-outcome ['Physiological-Clinical']
lung I-outcome ['Physiological-Clinical']
cancers I-outcome ['Physiological-Clinical']
occurring O
after O
10 O
years O
. O
['Physiological-Clinical']

Results O
suggest O
that O
youth O
who O
completed O
the O
JobTIPS O
employment O
program O
demonstrated O
significantly O
more O
effective O
verbal B-outcome ['Life-Impact']
content I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
than O
those O
who O
did O
not O
. O
['Life-Impact']

Resource O
utilization O
and O
costs B-outcome ['Resource-use']
of I-outcome ['Resource-use']
care I-outcome ['Resource-use']
in O
the O
diabetes O
control O
and O
complications O
trial O
. O
['Resource-use']

In O
an O
age-adjusted O
model O
, O
the O
prevalence O
of O
carotid B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
among O
men O
scoring O
in O
the O
highest O
stress O
quintile O
was O
36 O
% O
compared O
with O
21 O
% O
among O
men O
in O
the O
lowest O
quintile O
. O
['Physiological-Clinical']

Statistical O
differences O
was O
found O
in O
the O
accuracy O
of O
preoperative B-outcome ['Physiological-Clinical']
N I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
TNM I-outcome ['Physiological-Clinical']
staging I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
( O
P O
= O
0.009 O
and O
0.001 O
, O
respectively O
) O
. O
['Physiological-Clinical']

Overall O
, O
1075 O
patients O
less O
than O
60 O
years O
of O
age O
were O
randomized O
to O
receive O
or O
not O
receive O
ATRA O
in O
addition O
to O
daunorubicin/Ara-C/thioguanine O
chemotherapy O
with O
Ara-C O
at O
standard O
or O
double O
standard O
dose O
. O
[]

min O
plus O
paclitaxel O
225 O
mg/m2 O
on O
day O
1 O
. O
[]

We O
examined O
the O
effects O
of O
ACEi O
therapy O
on O
physical B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
older O
people O
undergoing O
exercise O
training O
. O
['Life-Impact']

No O
component O
required O
revision O
, O
and O
no O
revisions O
were O
pending O
. O
[]

Mean O
pain B-outcome ['Physiological-Clinical']
and O
analgesic B-outcome ['Resource-use']
scores O
declined O
from O
baseline O
, O
and O
quality-of-life B-outcome ['Life-Impact']
scores O
remained O
stable O
to O
study O
end O
. O
['Physiological-Clinical', 'Resource-use', 'Life-Impact']

No O
acute B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
occurred O
. O
['Physiological-Clinical']

Renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
during O
the O
hypotensive O
period O
was O
well O
maintained O
. O
['Physiological-Clinical']

Side-effects O
in O
both O
groups O
were O
those O
commonly O
seen O
with O
non-steroidal O
anti-inflammatory O
drugs O
and O
, O
as O
expected O
, O
gastro-intestinal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
CNS I-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
predominated O
. O
['Physiological-Clinical']

Higher O
parity O
cows O
and O
those O
that O
had O
a O
linear B-outcome ['Physiological-Clinical']
score O
somatic B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SCC I-outcome ['Physiological-Clinical']
) O
above O
4 O
on O
the O
last O
DHI O
test O
were O
also O
at O
increased O
risk O
for O
new B-outcome ['Physiological-Clinical']
IMI I-outcome ['Physiological-Clinical']
( O
P O
< O
0.10 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Here O
we O
used O
fMRI O
to O
measure O
the O
neural B-outcome ['Physiological-Clinical']
consequences I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
emotional I-outcome ['Physiological-Clinical']
experiences I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
place I-outcome ['Physiological-Clinical']
memory I-outcome ['Physiological-Clinical']
during O
navigation O
. O
['Physiological-Clinical']

RESULTS O
All O
treatments O
produced O
increasing O
tissue B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
over I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
which O
was O
considerably O
greater O
for O
dentine O
than O
enamel O
. O
['Physiological-Clinical']

CONCLUSION O
Results O
for O
PFS B-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
favor O
combination O
of O
bevacizumab O
with O
either O
chemotherapy O
or O
erlotinib O
over O
chemotherapy O
alone O
in O
the O
second-line O
setting O
. O
['Mortality', 'Mortality']

Morbidity B-outcome ['Physiological-Clinical']
attributable O
to O
treatment O
or O
to O
renal B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
occurred O
in O
both O
groups O
; O
an O
audit O
showed O
that O
benefits O
of O
therapy O
outweighed O
expected O
or O
minor O
side O
effects O
of O
drugs O
in O
this O
population O
at O
risk O
of O
end-stage O
renal O
failure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
severity O
and O
frequency O
of O
late O
complications O
was O
equivalent O
between O
the O
two O
treatment O
groups O
. O
[]

Thus O
, O
further O
study O
of O
American O
ginseng O
is O
warranted O
. O
[]

Children O
were O
investigated O
who O
were O
receiving O
glucocorticoid O
treatment O
for O
acute O
lymphoblastic O
leukaemia O
( O
ALL O
) O
. O
[]

Body B-outcome ['Physiological-Clinical']
weight O
loss B-outcome ['Physiological-Clinical']
was O
also O
significantly O
higher O
( O
2.5 O
+/- O
1.6 O
vs. O
0.2 O
+/- O
1.3 O
kg O
, O
p O
< O
0.01 O
) O
during O
the O
torasemide O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
therapy O
content O
and O
methodology O
was O
derived O
from O
an O
intervention O
manual O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
of O
8 O
hours O
of O
continuous O
low-level O
heatwrap O
therapy O
for O
the O
treatment O
of O
acute O
nonspecific O
low O
back O
pain O
( O
LBP O
) O
. O
[]

The O
combined O
treatment O
with O
diet O
, O
clofibrate O
and O
niceritrol O
caused O
highly O
significant O
serum B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
reductions O
. O
['Physiological-Clinical']

Physicians O
reported O
significantly O
greater O
liking B-outcome ['Life-Impact']
for O
whites O
over O
blacks O
( O
P O
< O
.0001 O
) O
and O
reported O
believing O
whites O
were O
more O
medically B-outcome ['Life-Impact']
cooperative I-outcome ['Life-Impact']
than O
blacks O
( O
P O
< O
.0001 O
) O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
No O
patient O
in O
the O
dezocine O
group O
had O
cough B-outcome ['Physiological-Clinical']
, O
and O
42 O
patients O
in O
the O
control O
group O
had O
cough O
. O
['Physiological-Clinical']

CONCLUSIONS O
Considering O
efficacy O
, O
immunological O
response O
, O
and O
tolerability O
, O
a O
maintenance O
dose O
of O
80 O
?g O
of O
rBet O
v O
1-FV O
appears O
to O
be O
the O
ideal O
dose O
for O
allergen O
immunotherapy O
in O
birch O
pollen O
allergic O
patients O
. O
[]

A O
contract O
search O
agency O
was O
hired O
to O
locate O
the O
remaining O
participants O
. O
[]

Association O
of O
race O
with O
complications O
and O
prognosis O
following O
acute O
coronary O
syndromes O
. O
[]

After O
3 O
months O
, O
the O
same O
treatments O
were O
repeated O
. O
[]

Inhibition O
of O
bone B-outcome ['Physiological-Clinical']
marrow I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
is O
sometimes O
observed O
with O
radiotherapy O
. O
['Physiological-Clinical']

CONCLUSION O
ZJC1 O
can O
enhance O
the O
[]

Relative O
risk O
reduction O
24 O
% O
( O
p O
< O
0.031 O
) O
. O
[]

BACKGROUND O
Inflammatory O
Bowel O
Disease O
( O
IBD O
) O
impacts O
quality O
of O
life O
( O
QoL O
) O
. O
[]

This O
study O
used O
a O
randomized O
clinical O
trial O
with O
133 O
incontinent O
elderly O
in O
seven O
nursing O
homes O
to O
evaluate O
the O
effectiveness O
of O
a O
behavioral O
training O
therapy O
and O
its O
cost O
implications O
. O
[]

The O
time B-outcome ['Physiological-Clinical']
difference I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
scaling I-outcome ['Physiological-Clinical']
between O
the O
product O
and O
placebo O
side O
was O
not O
significant O
. O
['Physiological-Clinical']

Between O
December O
1982 O
and O
October O
1986 O
, O
131 O
patients O
with O
stage O
II-III-IV O
squamous O
cell O
carcinoma O
of O
the O
oropharynx O
or O
oral O
cavity O
were O
randomized O
to O
induction O
chemotherapy O
, O
consisting O
of O
bleomycin O
( O
10 O
mg/m2/day O
in O
continuous O
infusion O
from O
day O
1 O
to O
day O
5 O
) O
, O
methotrexate O
( O
120 O
mg/m2 O
on O
day O
2 O
) O
followed O
by O
folinic O
acid O
, O
5-fluorouracil O
( O
5 O
FU O
) O
( O
600 O
mg/m2 O
on O
day O
2 O
) O
, O
and O
cisplatin O
( O
120 O
mg/m2 O
on O
day O
4 O
) O
every O
4 O
weeks O
for O
a O
total O
of O
three O
cycles O
followed O
by O
definitive O
locoregional O
treatment O
versus O
locoregional O
treatment O
alone O
. O
[]

BACKGROUND O
Pneumocystis O
carinii O
pneumonia O
( O
PCP O
) O
continues O
to O
be O
the O
most O
common O
index O
diagnosis O
in O
the O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
, O
but O
it O
is O
not O
clear O
which O
of O
several O
available O
agents O
is O
the O
most O
effective O
in O
preventing O
a O
recurrence O
of O
PCP O
. O
[]

The O
primary O
endpoint O
is O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality']

Other O
variables O
compared O
included O
indices O
of O
resection O
speed O
and O
transfusion O
rate O
. O
[]

In O
2 O
patients O
, O
caudal O
block O
was O
technically O
difficult O
and O
they O
were O
excluded O
from O
the O
study O
. O
[]

CONCLUSION O
A O
subgroup O
of O
children O
and O
adolescents O
with O
ADHD B-outcome ['Life-Impact']
, O
characterized O
by O
inattention O
and O
associated O
neurodevelopmental O
disorders O
, O
treated O
with O
omega O
3/6 O
fatty O
acids O
for O
6 O
months O
responded O
with O
meaningful O
reduction O
of O
ADHD B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

This O
dose O
was O
then O
maintained O
for O
4 O
weeks O
. O
[]

BACKGROUND O
Myocardial O
dysfunction O
needing O
inotropic O
support O
is O
a O
typical O
complication O
after O
on-pump O
cardiac O
surgery O
. O
[]

Deliberate B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
in O
patients O
with O
intracranial O
arteriovenous O
malformations O
: O
esmolol O
compared O
with O
isoflurane O
and O
sodium O
nitroprusside O
. O
['Physiological-Clinical']

Treatment O
decreased O
otorrhea B-outcome ['Physiological-Clinical']
in O
all O
groups O
, O
while O
the O
greatest O
benefit O
was O
observed O
in O
patients O
with O
bilateral O
effusion O
( O
93 O
% O
reduction O
) O
. O
['Physiological-Clinical']

Key O
features O
of O
diet O
standardization O
included O
central O
procurement O
of O
fat-containing O
foods O
, O
inclusion O
of O
standard O
ingredients O
, O
precision O
weighing O
of O
foods O
-- O
especially O
sources O
of O
fat O
and O
cholesterol O
-- O
and O
use O
of O
standardized O
written O
procedures O
. O
[]

Eighteen O
children O
with O
autistic O
disorder O
completed O
a O
12-week O
double-blind O
, O
placebo-controlled O
, O
randomized O
crossover O
study O
of O
fluvoxamine O
. O
[]

Acute O
pain O
outcomes O
including O
adolescent O
self-report O
, O
nursing O
staff O
behavioral O
observation O
, O
caregiver O
observation O
and O
physiological O
measures O
were O
collected O
. O
[]

Group O
1 O
showed O
significant O
improvement O
compared O
with O
groups O
2 O
and O
3 O
, O
except O
for O
response O
to O
tactile B-outcome ['Physiological-Clinical']
stimulus I-outcome ['Physiological-Clinical']
at O
four O
weeks O
with O
group O
2 O
. O
['Physiological-Clinical']

Women O
were O
followed O
up O
until O
the O
infant O
was O
12 O
mo O
of O
age O
, O
or O
later O
if O
menses O
had O
not O
occurred O
by O
then O
. O
[]

53 O
patients O
were O
stratified O
according O
to O
performance O
status O
and O
randomized O
to O
receive O
alpha O
2b-interferon O
, O
20 O
million O
units O
per O
m2 O
i.v. O
, O
5 O
days O
per O
week O
for O
4 O
weeks O
followed O
by O
10 O
million O
units O
per O
m2 O
s.c. O
three O
times O
per O
week O
, O
either O
with O
or O
without O
indomethacin O
, O
25 O
mg O
orally O
three O
times O
a O
day O
. O
[]

Working O
well O
with O
a O
disability O
: O
health O
promotion O
as O
a O
means O
to O
employment O
. O
[]

MATERIALS O
AND O
METHODS O
Long-term O
followup O
was O
assessed O
in O
551 O
participants O
enrolled O
in O
a O
prospective O
, O
randomized O
study O
of O
fluorescence O
cystoscopy O
for O
Ta O
or O
T1 O
urothelial O
bladder O
cancer O
. O
[]

It O
should O
be O
emphasized O
that O
we O
have O
not O
encountered O
any O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
with O
intravenous O
trivalent O
saccharose O
ferric O
oxide O
treatment O
. O
['Adverse-effects']

They O
also O
use O
the O
model O
to O
address O
the O
stochastic O
relationship O
between O
recall O
and O
familiarity O
and O
the O
effects O
of O
partial O
versus O
complete O
hippocampal O
lesions O
on O
recognition B-outcome ['Life-Impact']
. O
['Life-Impact']

Effects O
of O
body O
orientation O
on O
maximum O
voluntary O
arm O
torques O
. O
[]

Cumulative O
incidence O
of O
HCC O
recurrence B-outcome ['Physiological-Clinical']
did O
not O
differ O
between O
the O
two O
groups O
, O
and O
the O
cumulative O
survival B-outcome ['Mortality']
rate O
tended O
to O
be O
high O
in O
treatment O
group O
( O
p O
=0.054 O
) O
. O
['Physiological-Clinical', 'Mortality']

Participants O
in O
the O
experimental O
arm O
received O
the O
BCEI O
consisting O
of O
3 O
face-to-face O
education O
and O
support O
sessions O
and O
2 O
face-to-face O
and O
3 O
telephone O
follow-up O
sessions O
, O
along O
with O
supplemental O
written O
and O
audiotape O
materials O
over O
a O
6-month O
period O
. O
[]

CONCLUSION O
Venlafaxine O
and O
clonidine O
are O
equally O
, O
but O
moderately O
effective O
in O
HF B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
study O
examined O
the O
effects O
of O
esomeprazole O
on O
nighttime B-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
, O
GERD-related B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
, O
work B-outcome ['Life-Impact']
productivity I-outcome ['Life-Impact']
, O
and O
regular B-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

EEG-biofeedback O
seems O
to O
be O
an O
applicable O
tool O
to O
regulate O
EEG O
activity O
and O
has O
specific O
effects O
on O
cognitive B-outcome ['Life-Impact']
flexibility I-outcome ['Life-Impact']
, O
but O
it O
did O
not O
result O
in O
significant O
reductions O
in O
symptoms B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
ASD I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Clinical O
application O
of O
C-reactive O
protein O
across O
the O
spectrum O
of O
acute O
coronary O
syndromes O
. O
[]

Sucralfate O
overcomes O
adverse O
effect O
of O
cigarette O
smoking O
on O
duodenal O
ulcer B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
and O
prolongs O
subsequent O
remission O
. O
['Physiological-Clinical']

The O
mean O
age O
was O
51.1 O
years O
. O
[]

an O
index O
of O
inhomogeneity O
of O
repolarization O
, O
and O
heart O
rate O
variability O
( O
HRV O
) O
, O
i.e O
. O
[]

The O
present O
study O
determined O
whether O
polymorphisms O
in O
the O
gene O
encoding O
flavin O
monooxygenase O
3 O
( O
FMO3 O
) O
, O
a O
hepatic O
microsomal O
enzyme O
that O
inactivates O
sulindac O
, O
played O
a O
role O
in O
determining O
the O
efficacy O
of O
sulindac O
in O
preventing O
polyposis O
in O
this O
cohort O
of O
FAP O
patients O
. O
[]

PURPOSE O
To O
compare O
the O
efficacy O
and O
safety O
of O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
and O
topotecan O
in O
patients O
with O
epithelial O
ovarian O
carcinoma O
that O
recurred O
after O
or O
did O
n't O
respond O
to O
first-line O
, O
platinum-based O
chemotherapy O
. O
[]

Primary O
surgery O
, O
good O
performance O
status O
( O
PS O
) O
, O
only O
one O
metastatic O
site O
, O
and O
oxaliplatin-based O
second-line O
treatment O
independently O
predicted O
a O
[]

Energy B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
was O
measured O
by O
indirect O
calorimetry O
and O
food B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
by O
an O
automated O
food-selection O
system O
. O
['Physiological-Clinical', 'Life-Impact']

PATIENTS O
AND O
METHOD O
A O
prospective O
, O
randomized O
, O
clinical O
study O
with O
participation O
of O
medical O
statisticians O
was O
performed O
. O
[]

In O
both O
duodenal O
ulcer O
treatment O
groups O
, O
and O
with O
both O
drugs O
, O
healing B-outcome ['Physiological-Clinical']
was O
negatively O
influenced O
by O
ulcer B-outcome ['Physiological-Clinical']
size O
, O
ulcer B-outcome ['Physiological-Clinical']
number I-outcome ['Physiological-Clinical']
, O
smoking B-outcome ['Life-Impact']
habits I-outcome ['Life-Impact']
and O
a O
disease B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
of O
5 O
years O
or O
more O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

The O
mean O
AMP O
recovery O
time O
was O
25.0 O
vs O
23.4 O
minutes O
for O
fexofenadine O
and O
placebo O
, O
respectively O
, O
as O
add-on O
to O
fluticasone-salmeterol O
and O
22.5 O
vs O
23.9 O
minutes O
, O
respectively O
, O
as O
add-on O
to O
fluticasone O
alone O
. O
[]

Oral O
ribavirin O
treatment O
of O
influenza O
A O
and O
B O
. O
[]

p16 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
INK4a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
detected O
in O
68.9 O
% O
of O
the O
patients O
. O
['Physiological-Clinical']

Study O
1 O
examined O
supervisor O
response O
to O
and O
tolerance O
of O
coworker O
substance O
use O
and O
ways O
of O
interfacing O
with O
the O
Employee O
Assistance O
Program O
( O
EAP O
) O
in O
two O
workplaces O
( O
n O
= O
244 O
and O
107 O
) O
. O
[]

OBJECTIVE O
To O
observe O
the O
effects O
of O
electro-acupuncture O
on O
T O
cell B-outcome ['Physiological-Clinical']
subpopulations I-outcome ['Physiological-Clinical']
, O
natural B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NK I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
humoral B-outcome ['Physiological-Clinical']
immunity I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
leukocyte I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Relation O
of O
improvement O
in O
estimated O
glomerular O
filtration O
rate O
with O
atorvastatin O
to O
reductions O
in O
hospitalizations O
for O
heart O
failure O
( O
from O
the O
Treating O
to O
New O
Targets O
[ O
TNT O
] O
study O
) O
. O
[]

Changes O
in O
sleep O
quality O
, O
but O
not O
hormones O
predict O
time O
to O
postpartum O
depression O
recurrence O
. O
[]

Timed O
variables O
, O
such O
as O
time O
[]

Telephone O
assessments O
of O
panic B-outcome ['Life-Impact']
, O
anxiety B-outcome ['Life-Impact']
sensitivity I-outcome ['Life-Impact']
, O
depression B-outcome ['Life-Impact']
, O
and O
disability B-outcome ['Life-Impact']
variables O
were O
performed O
at O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
months O
' O
follow-up O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
children O
presented O
with O
a O
chief O
complaint O
of O
severely O
disruptive O
symptoms O
related O
to O
autistic O
disorder O
. O
[]

SUBJECTS O
AND O
METHODS O
The O
study O
included O
149 O
patients O
, O
among O
whom O
36 O
patients O
with O
hypervascular O
hepatocellular O
carcinoma O
were O
identified O
. O
[]

One O
hundred O
and O
eleven O
previously O
untreated O
patients O
with O
extensive O
small O
cell O
lung O
cancer O
were O
included O
in O
a O
prospective O
randomized O
study O
with O
the O
aim O
to O
assess O
the O
efficacy O
and O
tolerance O
of O
high-dose O
epirubicin O
( O
120 O
mg/m2 O
) O
in O
combination O
with O
either O
cyclophosphamide O
( O
800 O
mg/m2 O
; O
arm O
1 O
) O
or O
cisplatin O
( O
60 O
mg/m2 O
; O
arm O
2 O
) O
. O
[]

Subjects O
performed O
a O
2,000-meter-maximum O
test O
on O
a O
rowing O
ergometer O
at O
the O
beginning O
and O
end O
of O
the O
preparatory O
camp O
. O
[]

There O
were O
individual O
differences O
in O
performance O
, O
such O
that O
poorer O
[]

Bronchospasm B-outcome ['Physiological-Clinical']
does O
not O
appear O
to O
be O
an O
important O
contrast-induced O
effect O
in O
non-atopic O
individuals O
. O
['Physiological-Clinical']

Dosages O
tested O
were O
70 O
and O
80 O
mg/m O
( O
2 O
) O
/day O
. O
[]

The O
immediate O
response O
and O
the O
changes O
in O
Mth-DRS B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
sputum I-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
ECP I-outcome ['Physiological-Clinical']
levels O
following O
the O
allergen O
challenge O
were O
attenuated O
in O
the O
active O
group O
. O
['Physiological-Clinical']

QoL B-outcome ['Life-Impact']
increased O
in O
the O
SST O
Group O
in O
the O
dimension O
of O
school O
environment O
, O
as O
a O
marker O
of O
the O
transfer O
of O
skills O
acquired O
in O
the O
treatment O
setting O
to O
their O
use O
in O
the O
community O
. O
['Life-Impact']

Half O
of O
the O
participants O
were O
randomly O
assigned O
to O
the O
conscious-processing-condition O
( O
i.e. O
, O
consciously O
thinking O
about O
the O
information O
they O
read O
in O
the O
case O
description O
) O
, O
the O
other O
half O
to O
the O
unconscious-processing O
condition O
( O
i.e. O
, O
performing O
an O
unrelated O
distracter O
task O
) O
. O
[]

Low-dose O
MTX O
significantly O
reduced O
the O
steroid B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
in O
this O
group O
of O
subjects O
with O
steroid-dependent O
asthma O
. O
['Resource-use']

METHODS O
Long-stay O
patients O
with O
schizophrenia O
in O
a O
state O
hospital O
were O
randomly O
assigned O
to O
begin O
open-label O
clozapine O
( O
n O
= O
138 O
) O
or O
to O
continue O
receiving O
conventional O
antipsychotic O
medications O
( O
n O
= O
89 O
) O
. O
[]

[ O
Effect O
of O
probucol O
on O
serum O
malondialdehyde O
and O
superoxide O
dismutase O
in O
patients O
with O
primary O
hypertension O
] O
. O
[]

Speech O
following O
sign O
language O
training O
in O
autistic O
children O
with O
minimal O
verbal O
language O
. O
[]

Analgesia B-outcome ['Resource-use']
was O
evaluated O
using O
a O
visual O
analogue O
scale O
( O
VAS O
) O
; O
sedation B-outcome ['Physiological-Clinical']
was O
scored O
using O
a O
five-point O
scale O
. O
['Resource-use', 'Physiological-Clinical']

We O
included O
a O
double-blind O
, O
randomized O
, O
diet-controlled O
crossover O
intervention O
, O
in O
which O
the O
swimmers O
consumed O
caffeine O
( O
5 O
mg O
x O
kg O
( O
-1 O
) O
body O
mass O
) O
or O
placebo O
. O
[]

Patients O
who O
had O
complete O
symptom O
relief O
in O
the O
initial O
therapy O
were O
randomized O
to O
either O
hydrotalcite O
or O
esomeprazole O
in O
the O
on-demand O
therapy O
. O
[]

For O
ventricular O
defibrillation O
, O
use O
of O
an O
active O
pectoral O
electrode O
( O
active O
can O
) O
in O
the O
shocking O
pathway O
markedly O
reduces O
defibrillation O
thresholds O
( O
DFTs O
) O
. O
[]

Effectiveness O
of O
N O
, O
N-dimethylglycine O
in O
autism O
and O
pervasive O
developmental O
disorder O
. O
[]

METHODS O
A O
total O
of O
59 O
support O
persons O
( O
mean O
age O
= O
36 O
years O
, O
92 O
% O
female O
, O
95 O
% O
White O
) O
were O
randomly O
assigned O
to O
a O
control O
condition O
( O
N O
= O
30 O
; O
written O
materials O
only O
) O
or O
to O
a O
social O
cognitive O
theory-based O
intervention O
( O
N O
= O
29 O
; O
written O
materials O
and O
5 O
weekly O
, O
20- O
to O
30-min O
telephone O
counseling O
sessions O
) O
. O
[]

Decreased O
sensitivity B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
dexamethasone I-outcome ['Physiological-Clinical']
in O
lymphocytes O
from O
patients O
with O
Alzheimer O
's O
disease O
. O
['Physiological-Clinical']

As O
a O
secondary O
objective O
, O
changes O
in O
injected B-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
tenderness I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
scores O
, O
each O
measured O
on O
a O
four-point O
scale O
, O
were O
evaluated O
. O
['Physiological-Clinical']

This O
was O
designed O
as O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
pilot O
study O
. O
[]

Effect O
of O
delayed O
cord O
clamping O
on O
iron B-outcome ['Physiological-Clinical']
stores I-outcome ['Physiological-Clinical']
in O
infants O
born O
to O
anemic O
mothers O
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

Because O
testing O
for O
futility O
in O
this O
noninferiority O
trial O
corresponds O
to O
testing O
the O
hypothesis O
of O
no O
difference O
, O
a O
one-sided O
superiority O
test O
was O
conducted O
. O
[]

A O
population-based O
sample O
served O
as O
controls O
and O
received O
a O
single O
NPSG O
followed O
by O
MSLT O
. O
[]

Dronabinol O
versus O
megestrol O
acetate O
versus O
combination O
therapy O
for O
cancer-associated O
anorexia O
: O
a O
North O
Central O
Cancer O
Treatment O
Group O
study O
. O
[]

Lignans O
and O
proanthocyanidins O
are O
plant O
polyphenols O
that O
have O
shown O
protective O
properties O
against O
colorectal B-outcome ['Physiological-Clinical']
neoplasms I-outcome ['Physiological-Clinical']
in O
some O
human O
studies O
. O
['Physiological-Clinical']

RESULTS O
All O
the O
3 O
therapeutic O
methods O
could O
significantly O
decrease O
gastric B-outcome ['Physiological-Clinical']
drainage I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHOD O
Twenty-nine O
medically O
healthy O
women O
with O
sexual O
arousal O
disorder O
( O
15 O
premenopausal O
and O
14 O
postmenopausal O
) O
, O
diagnosed O
using O
the O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
4th O
Edition O
( O
DSM-IV O
) O
criteria O
, O
and O
30 O
age-matched O
women O
without O
sexual O
problems O
( O
16 O
premenopausal O
and O
14 O
postmenopausal O
) O
were O
shown O
sexual O
stimuli O
depicting O
cunnilingus O
and O
intercourse O
. O
[]

CONCLUSION O
Our O
results O
demonstrated O
that O
anodal O
transcranial O
direct O
current O
stimulation O
over O
the O
left O
dorsolateral O
prefrontal O
cortex O
was O
associated O
with O
enhanced O
[]

CONCLUSIONS O
Single O
and O
short-term O
dosing O
with O
levocetirizine O
conferred O
similar O
improvements O
in O
bronchial B-outcome ['Physiological-Clinical']
hyper-responsiveness I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
AMP I-outcome ['Physiological-Clinical']
challenge O
, O
which O
was O
unrelated O
to O
prechallenge O
airway O
calibre O
. O
['Physiological-Clinical']

PARTICIPANTS O
A O
total O
of O
1433 O
of O
1636 O
participants O
randomized O
to O
OHTS O
who O
had O
complete O
baseline O
data O
for O
factors O
in O
the O
prediction O
model O
: O
age O
, O
IOP O
, O
CCT O
, O
vertical O
cup-to-disc O
ratio O
( O
VCDR O
) O
, O
and O
pattern O
standard O
deviation O
( O
PSD O
) O
. O
[]

The O
study O
enrolled O
318 O
patients O
( O
66 O
years O
, O
male/female O
219/99 O
, O
158 O
in O
the O
ARB O
group O
and O
160 O
in O
the O
CCB O
group O
) O
treated O
at O
48 O
sites O
throughout O
Japan O
. O
[]

Early B-outcome ['Physiological-Clinical']
neurologic I-outcome ['Physiological-Clinical']
deterioration I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
END I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
infarct B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
at O
days O
4 O
to O
7 O
were O
secondary O
outcome O
variables O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
is O
the O
first O
randomised O
phase O
II O
trial O
to O
compare O
S-1+paclitaxel O
with O
S-1+cisplatin O
in O
this O
setting O
. O
[]

Impact O
of O
different O
platelet O
glycoprotein O
IIb/IIIa O
receptor O
inhibitors O
among O
diabetic O
patients O
undergoing O
percutaneous O
coronary O
intervention O
: O
: O
Do O
Tirofiban O
and O
ReoPro O
Give O
Similar O
Efficacy O
Outcomes O
Trial O
( O
TARGET O
) O
1-year O
follow-up O
. O
[]

RESULTS O
Patients O
who O
received O
aromatherapy O
massage O
had O
no O
significant O
improvement O
in O
clinical B-outcome ['Physiological-Clinical']
anxiety I-outcome ['Physiological-Clinical']
and/or I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
compared O
with O
those O
receiving O
usual O
care O
at O
10 O
weeks O
postrandomization O
( O
odds O
ratio O
[ O
OR O
] O
, O
1.3 O
; O
95 O
% O
CI O
, O
0.9 O
to O
1.7 O
; O
P O
= O
.1 O
) O
, O
but O
did O
at O
6 O
weeks O
postrandomization O
( O
OR O
, O
1.4 O
; O
95 O
% O
CI O
, O
1.1 O
to O
1.9 O
; O
P O
= O
.01 O
) O
. O
['Physiological-Clinical']

Efficacy O
was O
maintained O
over O
24 O
h O
and O
diltiazem O
also O
significantly O
improved O
exercise B-outcome ['Life-Impact']
test O
parameters O
. O
['Life-Impact']

Inflammations O
of O
the O
external O
auditory O
canal O
number O
among O
the O
most O
frequently O
occurring O
ear-nose-throat O
diseases O
. O
[]

Multivariate O
analysis O
identified O
the O
predictors O
of O
PDT O
complications O
as O
the O
Griggs O
PDT O
kit O
( O
p O
= O
.027 O
) O
and O
the O
Acute B-outcome ['Physiological-Clinical']
Physiology I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
Chronic I-outcome ['Physiological-Clinical']
Health I-outcome ['Physiological-Clinical']
Evaluation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
APACHE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
score O
( O
p O
= O
.041 O
) O
. O
['Physiological-Clinical']

The O
present O
study O
reports O
the O
effects O
of O
referential O
communication O
training O
in O
individuals O
formally O
diagnosed O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

METHODS O
In O
the O
context O
of O
a O
clinical O
trial O
for O
SLOS O
, O
we O
performed O
cross-sectional O
and O
repeated-measure O
observational O
studies O
of O
the O
relationship O
between O
EEG O
findings O
and O
cognitive/behavioral O
factors O
on O
23 O
children O
( O
aged O
4-17 O
years O
) O
. O
[]

Urine O
samples O
from O
4122 O
women O
at O
27-31 O
weeks O
' O
gestation O
were O
examined O
for O
bacteria O
. O
[]

This O
paper O
presents O
the O
rationale O
for O
a O
24-week O
, O
randomized O
trial O
designed O
to O
test O
whether O
risperidone O
plus O
structured O
parent O
training O
would O
be O
superior O
to O
risperidone O
only O
on O
measures O
of O
noncompliance B-outcome ['Life-Impact']
, O
irritability B-outcome ['Life-Impact']
and O
adaptive B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

There O
was O
a O
statistically O
significant O
decrease O
in O
mite B-outcome ['Physiological-Clinical']
counts O
on O
day O
7 O
( O
P O
< O
0.001 O
) O
within O
treatment O
Groups O
A O
and O
B O
of O
Study O
1 O
, O
but O
mite B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
increased O
again O
on O
day O
14 O
and O
remained O
high O
for O
the O
duration O
of O
the O
trial O
in O
both O
treatment O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
use O
of O
effective O
instructional O
strategies O
in O
small O
groups O
was O
investigated O
to O
determine O
learning O
effects O
for O
24 O
elementary O
age O
students O
with O
autism O
and O
developmental O
disabilities O
. O
[]

Left O
thoracoabdominal O
approach O
versus O
abdominal-transhiatal O
approach O
for O
gastric O
cancer O
of O
the O
cardia O
or O
subcardia O
: O
a O
randomised O
controlled O
trial O
. O
[]

A O
random O
sample O
of O
800 O
employees O
of O
a O
steel O
manufacturing O
company O
were O
randomly O
assigned O
to O
one O
of O
four O
self-report O
methods O
of O
assessing O
illicit O
drug O
use O
: O
1 O
) O
Individual O
interview O
in O
the O
workplace O
, O
2 O
) O
group-administered O
questionnaire O
in O
the O
workplace O
, O
3 O
) O
telephone O
interview O
, O
and O
4 O
) O
individual O
interview O
off O
the O
worksite O
. O
[]

Simvastatin O
blunts O
endotoxin-induced O
tissue O
factor O
in O
vivo O
. O
[]

We O
hypothesized O
that O
adding O
CPG O
7909 O
, O
a O
toll-like O
receptor O
9 O
( O
TLR9 O
) O
agonist O
and O
vaccine O
adjuvant O
, O
to O
7-valent O
pneumococcal O
conjugate O
vaccine O
( O
7vPnC O
) O
would O
increase O
its O
immunogenicity O
in O
HIV-infected O
adults O
. O
[]

RESULTS O
The O
time O
taken O
for O
the O
infusion O
to O
be O
started O
and O
the O
final O
concentration O
of O
the O
drugs B-outcome ['Resource-use']
were O
measured O
. O
['Resource-use']

Formation O
of O
ROS O
by O
monocytes O
was O
measured O
by O
gated O
flow O
cytometry O
. O
[]

METHODS/DESIGN O
A O
Quality O
Assurance O
Working O
Party O
was O
formed O
by O
radiation O
oncologists O
and O
clinical O
physicists O
from O
both O
academic O
as O
well O
as O
non-academic O
hospitals O
that O
had O
already O
implemented O
stereotactic O
radiotherapy O
for O
lung O
cancer O
. O
[]

OBJECTIVE O
Captopril O
and O
enalapril O
have O
been O
reported O
to O
influence O
cognitive B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
and O
quality O
of O
life O
in O
hypertensive O
patients O
. O
['Life-Impact']

After O
4 O
days O
, O
the O
DR O
curve O
of O
the O
NO-treated O
patients O
was O
left O
shifted O
with O
a O
peak O
response O
at O
1 O
ppm O
. O
[]

BACKGROUND O
Almost O
one O
third O
of O
women O
suffer O
continuous O
lower O
back O
pain O
during O
labour O
. O
[]

Men O
in O
the O
intervention O
group O
participated O
in O
five O
2-h O
group O
sessions O
focused O
on O
creating O
a O
group O
environment O
with O
sexual O
risk-reduction O
information O
and O
exercises O
woven O
into O
joint O
meal O
preparation O
and O
sharing O
activities O
, O
while O
exploring O
self-efficacy O
perceptions O
and O
outcome O
expectancies O
. O
[]

CONCLUSION O
In O
comparison O
with O
surgical O
castration O
MAB O
using O
Anandron O
, O
in O
patients O
with O
metastatic O
prostate O
cancer O
improves O
the O
time O
to O
objective B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
, O
overall B-outcome ['Mortality']
and O
cancer B-outcome ['Mortality']
specific I-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
irrespective O
of O
certain O
poor O
prognostic O
factors O
. O
['Physiological-Clinical', 'Mortality', 'Mortality']

OBJECTIVE O
The O
present O
study O
compares O
the O
efficacy O
and O
side O
effects O
of O
fluoxetine O
alone O
vs. O
fluoxetine O
plus O
local O
lidocaine O
ointment O
in O
the O
treatment O
of O
premature O
ejaculation O
. O
[]

In O
mastectomy O
group O
70 O
% O
remained O
alive O
and O
free O
of O
local B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
at O
24 O
months O
; O
in O
tamoxifen O
group O
only O
47 O
% O
remained O
alive O
and O
free O
of O
local O
progression O
. O
['Physiological-Clinical']

PARTICIPANTS O
Two O
hundred O
thirty-eight O
elderly O
men O
and O
women O
aged O
60 O
to O
80 O
at O
high O
risk O
for O
cardiovascular O
disease O
were O
randomly O
assigned O
to O
three O
interventional O
groups O
: O
a O
recommended O
low-fat O
diet O
( O
control O
diet O
group O
) O
, O
a O
Mediterranean O
diet O
supplemented O
with O
virgin O
olive O
oil O
, O
or O
a O
Mediterranean O
diet O
supplemented O
with O
mixed O
nuts O
. O
[]

Changes O
in O
quality O
of O
life O
and O
sexual B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
are O
associated O
with O
low-dose O
peginterferon O
therapy O
and O
disease O
progression O
in O
patients O
with O
chronic O
hepatitis O
C. O
BACKGROUND O
Primary O
analysis O
of O
the O
Hepatitis O
C O
Antiviral O
Long-Term O
Treatment O
against O
Cirrhosis O
( O
HALT-C O
) O
Trial O
showed O
long-term O
peginterferon O
therapy O
did O
not O
reduce O
complications O
in O
patients O
with O
chronic O
hepatitis O
C O
and O
advanced O
fibrosis O
or O
cirrhosis O
. O
['Physiological-Clinical']

Although O
the O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
probability O
for O
5 O
years O
did O
not O
differ O
between O
the O
SPG O
and O
control O
groups O
, O
in O
264 O
patients O
with O
curatively O
resected O
cancer O
, O
the O
probability O
to O
5 O
year O
survival O
and O
to O
recurrence B-outcome ['Physiological-Clinical']
in O
the O
sizofiran-administered O
patients O
was O
better O
than O
in O
the O
controls O
. O
['Mortality', 'Physiological-Clinical']

Patients O
in O
the O
CEI O
group O
experienced O
dizziness B-outcome ['Physiological-Clinical']
, O
pruritus B-outcome ['Physiological-Clinical']
, O
and O
PONV B-outcome ['Physiological-Clinical']
more O
than O
the O
CFNB O
group O
significantly O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

INTERVENTIONS O
Patients O
underwent O
stripping O
of O
bilateral O
endometriomas O
and O
were O
randomized O
to O
undergo O
hemostasis O
by O
use O
of O
either O
laparoscopic O
suturing O
( O
LS O
group O
) O
or O
bipolar O
coagulation O
( O
BC O
group O
) O
. O
[]

70 O
m O
( O
p O
= O
0.01 O
) O
and O
peak O
oxygen B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
increasing O
from O
25.5 O
? O
['Resource-use']

No O
beneficial O
effect O
of O
griseofulvin O
treatment O
was O
noted O
on O
clinical B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
or O
laboratory B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
of O
rheumatoid O
arthritis O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Single O
and O
short-term O
dosing O
effects O
of O
levocetirizine O
on O
adenosine O
monophosphate O
bronchoprovocation O
in O
atopic O
asthma O
. O
[]

RESULTS O
61 O
women O
( O
age O
33.6+/-11.1 O
years O
) O
completed O
the O
intervention O
. O
[]

They O
reflect O
processes O
with O
opioid O
effect O
. O
[]

Fifty-two O
patients O
with O
Fredrickson O
Type O
IIb O
or O
Type O
IV O
hyperlipidaemia O
, O
in O
whom O
diet O
had O
not O
achieved O
satisfactory O
lipid O
levels O
, O
completed O
a O
double O
blind O
randomised O
study O
of O
acipimox O
versus O
placebo O
. O
[]

Getting O
a O
high O
response O
rate O
of O
sexual O
behavior O
survey O
among O
the O
general O
population O
in O
Japan O
: O
three O
different O
methods O
of O
survey O
on O
sexual O
behavior O
. O
[]

Randomized O
, O
double-blind O
, O
multicenter O
trial O
comparing O
two O
doses O
of O
arzoxifene O
( O
LY353381 O
) O
in O
hormone-sensitive O
advanced O
or O
metastatic O
breast O
cancer O
patients O
. O
[]

Response O
to O
induction O
therapy O
was O
determined O
at O
weeks O
0 O
and O
8 O
. O
[]

The O
addition O
of O
rhTPO O
to O
G-CSF O
increased O
median O
CD34+ B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
yield/pheresis I-outcome ['Physiological-Clinical']
in O
cohorts O
in O
which O
rhTPO O
was O
started O
before O
day O
5 O
, O
with O
higher O
yields O
in O
groups O
2 O
( O
2.67 O
x O
10 O
( O
6 O
) O
/kg O
) O
and O
groups O
3 O
and O
4 O
( O
3.10 O
x O
10 O
( O
6 O
) O
/kg O
) O
than O
in O
group O
1 O
( O
1.86 O
x O
10 O
( O
6 O
) O
/kg O
) O
or O
group O
5 O
( O
1.65 O
x O
10 O
( O
6 O
) O
/kg O
) O
( O
P=.006 O
across O
groups O
) O
. O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
significant O
effects O
of O
time O
( O
F O
( O
1,47 O
) O
< O
1.66 O
; O
P O
> O
0.204 O
) O
, O
treatment O
group O
( O
F O
( O
2,47 O
) O
< O
1.47 O
; O
P O
> O
0.242 O
) O
or O
group-by-time O
interaction O
( O
F O
( O
2,47 O
) O
< O
1.82 O
; O
P O
> O
0.174 O
) O
for O
any O
of O
the O
cortical B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
variables O
. O
['Physiological-Clinical']

It O
can O
even O
be O
considered O
as O
an O
alternative O
to O
tricuspid O
regurgitation-derived O
PAP O
systolic O
when O
tricuspid O
regurgitation O
is O
nonrecordable O
. O
[]

CONCLUSIONS O
Retroperitoneal O
partial O
no-closure O
appears O
to O
be O
a O
useful O
procedure O
for O
reducing O
the O
incidence O
of O
pelvic B-outcome ['Physiological-Clinical']
lymphocysts I-outcome ['Physiological-Clinical']
associated O
with O
retroperitoneal O
lymphadenectomy O
. O
['Physiological-Clinical']

VCAM-1 B-outcome ['Physiological-Clinical']
, O
ICAM B-outcome ['Physiological-Clinical']
, O
and O
E-selectin B-outcome ['Physiological-Clinical']
were O
measured O
by O
ELISA O
at O
the O
beginning O
and O
end O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Confocal O
microscopy O
readings O
were O
correlated O
to O
the O
histologic O
diagnosis O
. O
[]

The O
study O
revealed O
a O
high O
and O
significant O
( O
p O
< O
0.001 O
) O
predictive O
value O
of O
gastric B-outcome ['Physiological-Clinical']
metaplasia I-outcome ['Physiological-Clinical']
in O
the O
duodenum O
as O
a O
marker O
of O
non-complicated O
clinical O
course O
of O
DU O
in O
HP-positive O
patients O
within O
an O
8 O
to O
10-year O
period O
. O
['Physiological-Clinical']

The O
subjects O
enrolled O
to O
the O
study O
were O
randomly O
assigned O
to O
receive O
either O
latanoprost O
stored O
at O
4 O
degrees O
C O
or O
that O
stored O
at O
30 O
degrees O
C. O
The O
eye O
drop O
was O
applied O
to O
the O
right O
eye O
of O
each O
subject O
for O
3 O
days O
. O
[]

The O
3 O
experimental O
groups O
did O
not O
differ O
significantly O
in O
terms O
of O
their O
interruption O
task O
performance B-outcome ['Life-Impact']
; O
however O
, O
the O
group O
that O
automatically O
received O
task-related O
information O
showed O
better O
ATC O
performance O
, O
thus O
experiencing O
a O
net O
performance O
gain O
. O
['Life-Impact']

2D-STE O
is O
a O
more O
sensitive O
technique O
to O
evaluate O
subtle O
changes O
in O
LV O
performance O
of O
these O
patients O
. O
[]

Several O
aspects O
of O
monkeys O
' O
performance O
suggest O
the O
cognitive O
sophistication O
of O
their O
decisions O
to O
escape O
. O
[]

Retinal O
lesions O
placed O
with O
diode O
lasers O
are O
deeper O
than O
similar O
argon O
laser O
lesions O
, O
and O
it O
is O
not O
known O
whether O
this O
difference O
could O
influence O
the O
response O
to O
ablative O
therapy O
. O
[]

METHOD O
Twenty-two O
lower O
extremities O
from O
healthy O
volunteers O
and O
11 O
lower O
extremities O
from O
patients O
with O
class O
4 O
to O
class O
6 O
post-thrombotic O
chronic O
venous O
insufficiency O
were O
studied O
. O
[]

DNA O
was O
extracted O
from O
all O
swabs O
and O
HSV-1 O
DNA O
copy O
numbers O
were O
determined O
. O
[]

Severe O
[]

Melatonin O
, O
the O
hormone O
produced O
nocturnally O
by O
the O
pineal O
gland O
, O
is O
an O
endogenous O
regulator O
of O
the O
sleep-wake O
cycle O
. O
[]

The O
primary O
aim O
of O
the O
study O
was O
to O
investigate O
the O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
the O
combination O
of O
valsartan O
and O
benazepril O
. O
['Life-Impact']

The O
levels O
of O
serum B-outcome ['Physiological-Clinical']
MMP-9 I-outcome ['Physiological-Clinical']
and O
TIMP-1 B-outcome ['Physiological-Clinical']
were O
detected O
using O
ELISA O
before O
and O
after O
treatment O
, O
and O
compared O
with O
20 O
healthy O
subjects O
as O
the O
control O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Both O
etoricoxib O
and O
ibuprofen O
demonstrated O
superior O
( O
P O
< O
or O
=0.002 O
) O
efficacy O
for O
all O
primary O
endpoints O
. O
[]

The O
effect O
of O
captopril O
monotherapy O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
metabolism B-outcome ['Physiological-Clinical']
was O
investigated O
in O
a O
placebo-controlled O
study O
in O
30 O
non-insulin O
dependent O
( O
Type O
II O
) O
diabetic O
subjects O
during O
a O
3-week O
observation O
period O
( O
run-in/drug O
; O
placebo/wash-out O
) O
on O
a O
metabolic O
ward O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
aimed O
to O
study O
whether O
the O
use O
of O
risperidone O
in O
comparison O
with O
placebo O
improved O
functioning O
in O
children O
with O
autism O
with O
regard O
to O
behavior O
( O
aggressiveness O
, O
hyperactivity O
, O
irritability O
) O
, O
social O
and O
emotional O
responsiveness O
, O
and O
communication O
skills O
. O
[]

CT O
findings O
of O
a O
smooth O
and O
thin-walled O
cavity O
filled O
with O
a O
water-equivalent O
fluid O
, O
sharply O
demarcated O
from O
its O
surroundings O
and O
without O
signs O
of O
infiltration O
were O
interpreted O
as O
lymphocysts B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Methylphenidate O
dose O
was O
5 O
mg O
every O
2 O
hours O
as O
needed O
up O
to O
20 O
mg O
per O
day O
. O
[]

BACKGROUND O
language O
and O
speech-language O
intervention O
. O
[]

The O
effects O
on O
respiratory O
function O
during O
intravenous O
urography O
of O
the O
ionic O
contrast O
medium O
sodium O
iothalamate O
and O
the O
non-ionic O
contrast O
medium O
iopamidol O
were O
compared O
. O
[]

We O
evaluated O
whether O
type O
of O
response O
to O
the O
migraine-induction O
test O
with O
a O
nitroglycerin O
ointment O
applied O
to O
the O
frontotemporal O
head O
region O
could O
predict O
the O
efficacy O
of O
antimigraine O
therapy O
. O
[]

These O
relationships O
have O
not O
been O
examined O
in O
low-income O
minority O
children O
. O
[]

RESULTS O
Biofilm B-outcome ['Physiological-Clinical']
, O
250 O
Mum O
thick O
, O
was O
observed O
with O
CLSM O
on O
the O
polished O
acrylic O
surface O
. O
['Physiological-Clinical']

Participants O
reported O
providing O
similar O
care B-outcome ['Life-Impact']
for O
white O
and O
black O
patients O
( O
P O
= O
.10 O
) O
but O
agreed O
that O
subconscious O
biases O
could O
influence O
their O
treatment O
decisions O
( O
P O
< O
.0001 O
) O
. O
['Life-Impact']

The O
aim O
of O
the O
study O
was O
to O
evaluate O
whether O
and O
to O
what O
extent O
different O
intraoperative O
valve O
orientation O
influence O
feasibility B-outcome ['Life-Impact']
and O
accuracy B-outcome ['Physiological-Clinical']
of O
postoperative O
fluoroscopic O
evaluation O
of O
bileaflet O
prostheses O
. O
['Life-Impact', 'Physiological-Clinical']

OBJECTIVE O
Obsessive-compulsive O
disorder O
is O
a O
common O
neuropsychiatric O
condition O
. O
[]

The O
mean O
change O
from O
baseline O
in O
instantaneous O
and O
reflective B-outcome ['Physiological-Clinical']
ocular I-outcome ['Physiological-Clinical']
itching I-outcome ['Physiological-Clinical']
scores O
at O
the O
end O
of O
2 O
weeks O
of O
treatment O
were O
evaluated O
based O
on O
subject-assessed O
severity O
of O
instantaneous O
and O
reflective O
itching O
. O
['Physiological-Clinical']

PARTICIPANTS O
Forty O
eyes O
from O
40 O
patients O
with O
advanced O
infectious O
keratitis O
and O
coexisting O
corneal O
melting O
. O
[]

Overall O
, O
the O
cumulative O
therapeutic B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
rate O
was O
28 O
% O
in O
the O
CPAP O
group O
and O
60 O
% O
in O
the O
control O
group O
during O
a O
6-hour O
observation O
study O
. O
['Physiological-Clinical']

Atrioventricular B-outcome ['Physiological-Clinical']
conduction O
during O
long-term O
follow-up O
of O
patients O
with O
sick O
sinus O
syndrome O
. O
['Physiological-Clinical']

Still O
, O
the O
neural O
mechanisms O
subserving O
self-representations O
in O
ASD O
are O
relatively O
unexplored O
. O
[]

A O
randomized O
controlled O
trial O
. O
[]

As O
the O
late O
intensification O
therapy O
( O
LIT O
) O
, O
five O
courses O
of O
high-dose O
MTX O
( O
2000 O
mg/m2 O
per O
dose O
per O
week O
intravenously O
for O
three O
doses O
every O
12 O
weeks O
) O
with O
leucovorin O
rescue O
were O
administered O
to O
all O
patients O
who O
were O
in O
continuous O
complete O
remission O
( O
CCR O
) O
for O
more O
than O
2 O
years O
. O
[]

OBJECTIVE O
We O
evaluated O
the O
ability O
of O
topical O
pimecrolimus O
to O
reduce O
the O
severity O
of O
cetuximab-related O
facial O
rash O
. O
[]

Although O
antacids O
have O
been O
the O
mainstay O
of O
pharmacologic O
therapy O
for O
reflux O
esophagitis O
, O
their O
effectiveness O
has O
not O
been O
tested O
in O
a O
placebo-controlled O
double-blind O
trial O
. O
[]

CONCLUSIONS O
Administration O
of O
GM-CSF O
was O
associated O
with O
acceleration O
of O
myeloid B-outcome ['Physiological-Clinical']
and O
platelet B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
and O
was O
cost B-outcome ['Resource-use']
effective O
in O
the O
treatment O
of O
patients O
with O
relapsed O
Hodgkin O
disease O
who O
received O
intensive O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

calcitonin O
subcutaneously O
every O
second O
evening O
and O
group O
3 O
( O
n O
= O
20 O
) O
received O
the O
same O
dose O
every O
evening O
. O
[]

All O
cases O
received O
standard O
laser O
treatment O
according O
to O
Early O
Treatment O
Diabetic O
Retinopathy O
Study O
protocol O
. O
[]

A O
total O
of O
12 O
( O
6.5 O
% O
) O
patients O
receiving O
nicorandil O
and O
30 O
( O
16.4 O
% O
) O
receiving O
placebo O
had O
cardiovascular B-outcome ['Mortality']
death I-outcome ['Mortality']
or O
hospital B-outcome ['Resource-use']
admission I-outcome ['Resource-use']
for O
congestive B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
( O
hazard O
ratio O
, O
0.39 O
; O
95 O
% O
CI O
, O
0.20 O
to O
0.76 O
; O
P=0.0058 O
) O
. O
['Mortality', 'Resource-use', 'Physiological-Clinical']

This O
study O
investigated O
the O
effect O
of O
a O
crown-lengthening O
ferrule O
on O
the O
fracture O
resistance O
of O
endodontically-treated O
teeth O
restored O
with O
two O
dowel-core O
systems O
. O
[]

Comparison O
of O
ranitidine O
and O
lansoprazole O
in O
short-term O
low-dose O
triple O
therapy O
for O
Helicobacter O
pylori O
infection O
. O
[]

Total O
albumin B-outcome ['Physiological-Clinical']
supplementation I-outcome ['Physiological-Clinical']
and O
hepatic B-outcome ['Physiological-Clinical']
transaminases I-outcome ['Physiological-Clinical']
were O
also O
assessed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
results O
show O
the O
potential O
merits O
of O
unconscious O
processing O
in O
diagnostic B-outcome ['Life-Impact']
decision I-outcome ['Life-Impact']
making I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
average O
interval O
from O
start O
of O
induction O
to O
vaginal B-outcome ['Physiological-Clinical']
delivery B-outcome ['Physiological-Clinical']
was O
1 O
hour O
shorter O
in O
the O
misoprostol O
group O
( O
1296.7 O
+/- O
722.1 O
minutes O
) O
than O
in O
the O
dinoprostone O
group O
( O
1360.0 O
+/- O
792.0 O
minutes O
) O
, O
but O
this O
difference O
was O
not O
statistically O
significant O
( O
p O
= O
0.97 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
studied O
the O
effect O
of O
combining O
prophylactic O
ondansetron O
( O
4 O
mg O
intravenously O
[ O
IV O
] O
) O
to O
desflurane-based O
anesthesia O
in O
90 O
ASA O
grade O
I O
or O
11 O
women O
undergoing O
outpatient O
gynecological O
laparoscopy O
. O
[]

All O
failed B-outcome ['Life-Impact']
insertions I-outcome ['Life-Impact']
with O
the O
introducer O
tool O
technique O
were O
successful O
with O
the O
bougie-guided O
technique O
. O
['Life-Impact']

CONCLUSION O
The O
combination O
of O
ALVAC-CEA/B7.1 O
vaccine O
and O
systemic O
chemotherapy O
has O
an O
acceptable O
safety O
profile O
in O
patients O
with O
metastatic O
colorectal O
cancer O
. O
[]

Quality-of-life B-outcome ['Life-Impact']
assessment O
was O
based O
on O
patients O
' O
responses O
to O
questionnaires O
before O
and O
after O
the O
courses O
of O
therapy O
. O
['Life-Impact']

DESIGN O
Double-blind O
randomized O
clinical O
trial O
. O
[]

ELT O
was O
carried O
out O
using O
a O
XeCl O
Excimer O
Laser O
with O
an O
emission O
wavelength O
of O
308 O
nm O
. O
[]

Primary O
drug O
therapy O
for O
CMV O
retinitis O
was O
determined O
by O
the O
treating O
physician O
. O
[]

METHODS O
AND O
RESULTS O
A O
total O
of O
143 O
patients O
at O
30 O
centers O
were O
randomized O
to O
receive O
25 O
, O
50 O
, O
or O
100 O
mg O
of O
flecainide O
or O
placebo O
twice O
daily O
( O
BID O
) O
. O
[]

RESULTS O
Low O
and O
high O
loads O
of O
GLP-1 O
induced O
physiological B-outcome ['Physiological-Clinical']
and O
supraphysiological B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
immunoreactivities I-outcome ['Physiological-Clinical']
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
16 O
weeks O
the O
combined O
therapy O
group O
used O
half O
as O
much O
insulin B-outcome ['Resource-use']
as O
the O
insulin-only O
group O
( O
50 O
+/- O
5 O
versus O
101 O
+/- O
13 O
units/d O
; O
p O
less O
than O
0.01 O
) O
. O
['Resource-use']

In O
group O
2 O
( O
n O
= O
15 O
) O
the O
basal O
period O
preceded O
a O
control O
period O
with O
no O
intervention O
, O
which O
was O
followed O
by O
taking O
a O
diet O
restricted O
in O
energy O
( O
5.1 O
MJ O
; O
1220 O
kcal O
) O
and O
sodium O
( O
2 O
: O
ErSr O
) O
. O
[]

At O
2 O
, O
3 O
, O
and O
4 O
years O
posttransplantation O
, O
the O
graft B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
significantly O
worse O
in O
the O
Aza O
plus O
MP O
group O
compared O
with O
the O
triple O
therapy O
group O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
we O
recruited O
362 O
patients O
, O
of O
whom O
181 O
were O
randomized O
to O
each O
group O
. O
[]

We O
conclude O
that O
[]

INTERVENTIONS O
Hysteroscopic O
resection O
of O
the O
uterine O
septum O
performed O
with O
either O
a O
26F O
resectoscope O
with O
unipolar O
knife O
( O
80 O
women O
, O
group O
A O
) O
or O
a O
5-mm O
diameter O
hysteroscope O
with O
Versapoint O
device O
( O
80 O
women O
, O
group O
B O
) O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Recovery B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
anesthesia I-outcome ['Physiological-Clinical']
was O
assessed O
by O
a O
research O
nurse O
who O
was O
unaware O
of O
the O
anesthetic O
technique O
used O
. O
['Physiological-Clinical']

However O
, O
a O
timolol-induced O
reduction O
in O
respiratory B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
observed O
only O
in O
the O
evening O
: O
percent O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
second I-outcome ['Physiological-Clinical']
, O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
significant O
improvements O
( O
P O
< O
0.05 O
) O
in O
AMP B-outcome ['Physiological-Clinical']
PC20 I-outcome ['Physiological-Clinical']
comparing O
levocetirizine O
vs O
placebo O
following O
the O
first O
dose O
123 O
+/- O
73 O
vs O
48 O
+/- O
24 O
, O
a O
1.4 O
doubling O
dilution O
difference O
( O
95 O
% O
CI O
0.8 O
, O
1.9 O
) O
, O
and O
the O
last O
dose O
127 O
+/- O
74 O
vs O
53 O
+/- O
29 O
, O
a O
1.2 O
doubling O
dilution O
difference O
( O
95 O
% O
CI O
0.5 O
, O
2.0 O
) O
. O
['Physiological-Clinical']

Spirochaetes O
were O
searched O
for O
by O
dark-field O
microscopy O
. O
[]

OBJECTIVE O
To O
quantify O
and O
compare O
the O
effects O
of O
two O
different O
cognitive O
tasks O
on O
gait O
in O
transitionally O
frail O
older O
adults O
. O
[]

This O
study O
examined O
the O
impact O
of O
oxytocin O
on O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
15 O
adults O
with O
autism O
or O
Asperger O
's O
disorder O
via O
randomized O
double-blind O
oxytocin O
and O
placebo O
challenges O
. O
['Life-Impact']

Relapses B-outcome ['Physiological-Clinical']
tended O
to O
occur O
earlier O
in O
patients O
with O
the O
highest O
TSAb B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

21.1 O
mm? O
at O
6 O
months O
: O
4.7 O
% O
decrease O
, O
p O
= O
0.0002 O
; O
and O
47.2 O
? O
[]

RESULTS O
There O
was O
no O
statistically O
significant O
( O
P O
= O
.117 O
) O
difference O
in O
filtration B-outcome ['Physiological-Clinical']
success B-outcome ['Physiological-Clinical']
of O
primary O
glaucoma O
triple O
procedure O
between O
the O
control O
and O
mitomycin O
C O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Six O
HIV-seropositive O
subjects O
with O
elevated O
amounts O
of O
TNF-alpha O
in O
plasma O
at O
least O
at O
two O
occasions O
were O
included O
in O
an O
open O
, O
controlled O
, O
randomized O
, O
cross-over O
study O
consisting O
of O
a O
6 O
week O
treatment O
period O
and O
a O
6 O
week O
control O
period O
. O
[]

It O
may O
be O
that O
a O
combination O
of O
these O
drugs O
, O
providing O
a O
multireceptor O
approach O
to O
analgesia O
, O
will O
prove O
to O
be O
more O
effective O
. O
[]

The O
relationship O
between O
changes O
in O
biochemical B-outcome ['Physiological-Clinical']
parameters O
, O
percent O
atheroma B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
and O
total O
atheroma B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
investigated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

7 O
days O
) O
diarrhoea O
at O
the O
community O
level O
. O
[]

PURPOSE O
Pazopanib O
is O
an O
oral O
angiogenesis O
inhibitor O
targeting O
vascular O
endothelial O
growth O
factor O
receptor O
, O
platelet-derived O
growth O
factor O
receptor O
, O
and O
c-Kit O
. O
[]

The O
toxicity B-outcome ['Adverse-effects']
profile O
of O
the O
bevacizumab-erlotinib O
combination O
is O
favorable O
compared O
with O
either O
chemotherapy-containing O
group O
. O
['Adverse-effects']

Neurophysiological B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
faces I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
gaze I-outcome ['Physiological-Clinical']
direction I-outcome ['Physiological-Clinical']
differentiate O
children O
with O
ASD O
, O
ADHD O
and O
ASD+ADHD O
. O
['Physiological-Clinical']

Children O
were O
tested O
before O
training O
, O
after O
training O
and O
at O
a O
two-month O
follow-up O
. O
[]

Men O
who O
wish O
to O
increase O
their O
odds O
of O
retaining O
sexual B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
might O
be O
counseled O
to O
choose O
EBRT O
over O
cryoablation O
. O
['Life-Impact']

We O
evaluated O
single O
and O
short-term O
dosing O
effects O
of O
a O
modern O
histamine O
H1-receptor O
antagonist O
, O
levocetirizine O
, O
given O
at O
the O
usual O
clinically O
recommended O
dose O
, O
on O
the O
primary O
outcome O
of O
AMP O
bronchoprovocation O
. O
[]

METHODS O
We O
studied O
nine O
healthy O
male O
volunteers O
( O
18-40 O
yr O
) O
on O
two O
randomly O
assigned O
treatment O
days O
: O
( O
1 O
) O
control O
and O
( O
2 O
) O
magnesium O
( O
80 O
mg O
kg O
( O
-1 O
) O
followed O
by O
infusion O
at O
2 O
g O
h O
( O
-1 O
) O
) O
. O
[]

Among O
84 O
randomized O
responders O
, O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
significantly O
improved O
( O
P O
= O
.003 O
) O
by O
maintenance O
therapy O
, O
with O
median O
durations O
( O
maintenance O
v O
follow-up O
) O
of O
25 O
versus O
12 O
weeks O
after O
the O
second O
randomization O
, O
but O
survival B-outcome ['Mortality']
was O
not O
significantly O
increased O
( O
P O
= O
.10 O
) O
, O
with O
median O
durations O
of O
48 O
and O
38 O
weeks O
. O
['Mortality', 'Mortality']

At O
intervals O
6 O
, O
24 O
, O
and O
48 O
hours O
postbanding O
, O
the O
patient O
recorded O
[]

There O
was O
no O
significant O
difference O
between O
the O
two O
groups O
in O
VISA-A O
score O
( O
p O
= O
0.815 O
) O
and O
[]

Memory B-outcome ['Life-Impact']
monitoring O
by O
animals O
and O
humans O
. O
['Life-Impact']

The O
duration O
of O
the O
standard O
changed O
between O
blocks O
. O
[]

We O
conclude O
that O
LTD4 O
induces O
eosinophilia B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
sputum I-outcome ['Physiological-Clinical']
of O
asthmatic O
subjects O
4 O
h O
after O
inhalation O
. O
['Physiological-Clinical']

The O
slight O
increase O
in O
local O
recurrence B-outcome ['Physiological-Clinical']
rate O
in O
transfused O
patients O
appears O
to O
be O
related O
to O
complicated O
, O
in O
particular O
rectal O
, O
surgery O
. O
['Physiological-Clinical']

DESIGN O
Prospective O
randomized O
study O
( O
Canadian O
Task O
Force O
classification O
I O
) O
. O
[]

CONCLUSIONS O
The O
genetic O
polymorphism O
of O
CCND1 O
A870G O
might O
be O
a O
potential O
biomarker O
for O
predicting O
acute B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
in O
postoperative O
stage O
II O
and O
III O
rectal O
cancer O
patients O
treated O
with O
adjuvant O
concurrent O
chemoradiotherapy O
of O
capecitabine O
and O
oxaliplatin O
. O
['Adverse-effects']

The O
primary O
endpoint O
was O
in-segment B-outcome ['Physiological-Clinical']
binary I-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
at O
9-month O
angiographic O
follow-up O
. O
['Physiological-Clinical']

Sick O
or O
preterm O
infants O
or O
infants O
screened O
on O
the O
first O
day O
of O
life O
with O
high O
17-OHP B-outcome ['Physiological-Clinical']
proved O
genetically O
unaffected O
. O
['Physiological-Clinical']

All O
significant O
differences O
( O
P O
less O
than O
0.05 O
) O
or O
trends O
( O
0.10 O
greater O
than O
P O
greater O
than O
0.05 O
) O
were O
in O
favor O
of O
a O
superior O
effect O
of O
CA O
over O
placebo O
. O
[]

About O
half O
( O
45 O
% O
) O
of O
Hispanics O
were O
recruited B-outcome ['Life-Impact']
at O
the O
center O
with O
the O
special O
Hispanic O
recruitment O
effort O
. O
['Life-Impact']

Two O
types O
of O
Hib O
vaccines O
were O
compared O
for O
efficacy O
and O
safety O
in O
71 O
normal O
children O
in O
three O
age O
groups O
: O
36 O
to O
72 O
months O
, O
15 O
to O
18 O
months O
, O
and O
6 O
to O
8 O
months O
. O
[]

The O
median O
survival B-outcome ['Mortality']
of O
patients O
initially O
randomized O
to O
receive O
mitoxantrone O
was O
273 O
days O
; O
for O
doxorubicin O
268 O
days O
( O
P O
= O
.40 O
) O
. O
['Mortality']

Our O
primary O
endpoint O
is O
the O
one O
year O
combined O
incidence O
of O
death B-outcome ['Mortality']
, O
reinfarction B-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
or O
new O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Increased O
intake O
of O
dairy O
products O
does O
not O
alter O
body B-outcome ['Physiological-Clinical']
weight O
or O
fat B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
young I-outcome ['Physiological-Clinical']
, O
healthy B-outcome ['Physiological-Clinical']
women I-outcome ['Physiological-Clinical']
over O
1 O
y O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Once-daily O
amoxicillin O
versus O
twice-daily O
penicillin O
V O
in O
group O
A O
beta-haemolytic O
streptococcal O
pharyngitis O
. O
[]

FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
was O
measured O
prior O
to O
and O
5 O
, O
10 O
, O
15 O
, O
20 O
, O
25 O
and O
30 O
min O
following O
inhalation O
of O
study O
drug O
. O
['Physiological-Clinical']

RESULTS O
A O
total O
of O
249 O
patients O
( O
166 O
balsalazide O
, O
83 O
placebo O
) O
received O
at O
least O
1 O
dose O
of O
study O
medication O
. O
[]

Even O
in O
the O
women O
around O
the O
menopausal O
, O
CETP B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
in O
postmenopause O
was O
significantly O
lower O
than O
that O
in O
premenopause O
( O
1.93+/-1.33 O
vs. O
3.42+/-1.35 O
mg/l O
, O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Recommendations O
are O
provided O
to O
ensure O
methodological O
quality O
. O
[]

3 O
months O
) O
subpopulations O
] O
were O
subgrouped O
by O
age O
; O
gender O
; O
menopausal O
status O
in O
women O
; O
dose O
and O
duration O
of O
prednisone O
during O
the O
trial O
; O
and O
baseline O
serum O
25-OH O
vitamin O
D O
, O
LS O
BMD O
T-score O
, O
creatinine O
clearance O
, O
and O
concomitant O
medication O
use O
. O
[]

Plasma O
pH O
does O
not O
influence O
the O
cerebral O
metabolic O
ratio O
during O
maximal O
whole O
body O
exercise O
. O
[]

RESULTS O
KC O
11458 O
had O
no O
statistically O
significant O
or O
clinically O
relevant O
effect O
on O
gastric B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
of O
either O
the O
solid O
intragastric O
retention O
at O
100 O
min O
( O
T100 O
) O
( O
P O
= O
0.87 O
) O
or O
liquid O
50 O
% O
emptying O
time O
( O
T50 O
) O
( O
P O
= O
0.17 O
) O
components O
of O
the O
meal O
. O
['Physiological-Clinical']

OBJECTIVE O
Consumption O
of O
soy O
protein O
has O
recently O
been O
shown O
to O
improve O
the O
blood B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
levels O
in O
nondiabetic O
subjects O
. O
['Physiological-Clinical']

All O
patients O
received O
a O
combined O
spinal-epidural O
anesthetic O
technique O
. O
[]

Is O
altered O
central O
pain O
processing O
related O
to O
disease O
stage O
in O
chronic O
pancreatitis O
patients O
with O
pain O
? O
[]

The O
aim O
of O
our O
study O
was O
to O
assess O
the O
effect O
of O
zoledronic O
acid O
on O
clearance O
of O
disseminated B-outcome ['Physiological-Clinical']
tumour I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( O
DTCs B-outcome ['Physiological-Clinical']
) O
from O
the O
bone O
marrow O
in O
women O
undergoing O
neoadjuvant O
chemotherapy O
for O
breast O
cancer O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
statistically O
significant O
differences O
in O
the O
other O
respiratory O
parameters O
. O
[]

Endotoxin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
also O
determined O
in O
15 O
healthy O
controls O
. O
['Physiological-Clinical']

No O
patient O
developed O
HCMV B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Neither O
of O
the O
less O
vigorous O
antecedent O
conditions O
did O
. O
[]

These O
results O
suggest O
that O
, O
when O
individual O
perception O
of O
scent O
pleasantness O
is O
controlled O
, O
scent O
has O
the O
potential O
to O
moderate O
different O
aspects O
of O
mood O
following O
an O
anxiety-provoking O
task O
. O
[]

A O
total O
of O
128 O
recipients O
of O
first O
cadaveric O
renal O
allograft O
were O
randomized O
, O
after O
an O
initial O
induction O
period O
, O
to O
receive O
either O
triple O
drug O
therapy O
-- O
i.e. O
, O
( O
low-dose O
) O
cyclosporine O
, O
azathioprine O
, O
and O
methylprednisolone O
, O
or O
any O
possible O
combination O
of O
two O
drugs O
-- O
i.e. O
, O
Aza O
plus O
CsA O
, O
Aza O
plus O
MP O
, O
and O
CsA O
plus O
MP O
. O
[]

PATIENTS O
AND O
METHODS O
This O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
superiority O
trial O
. O
[]

However O
, O
while O
TD O
children O
showed O
activation O
of O
this O
system O
during O
both O
self- O
and O
other-processing O
, O
children O
with O
ASD O
only O
recruited O
this O
system O
while O
viewing O
images O
containing O
mostly O
their O
own O
face O
. O
[]

All O
patients O
received O
conventional O
therapy O
with O
digoxin O
, O
diuretic O
drugs O
and O
a O
converting O
enzyme O
inhibitor O
throughout O
the O
trial O
. O
[]

For O
each O
patient O
, O
the O
teeth O
were O
randomized O
to O
three O
groups O
. O
[]

Spontaneous B-outcome ['Physiological-Clinical']
EEG I-outcome ['Physiological-Clinical']
was O
recorded O
in O
nine O
cigarette O
smokers O
who O
had O
been O
abstinent O
from O
tobacco O
for O
12 O
hr O
. O
['Physiological-Clinical']

Proparacaine O
use O
significantly O
lowered O
mean O
PIPP O
scores O
( O
P=0.027 O
) O
and O
delta O
scores O
( O
P=0.013 O
) O
at O
1 O
min O
after O
examination O
, O
but O
there O
was O
no O
difference O
at O
5 O
min O
after O
examination O
. O
[]

The O
hypothesis O
was O
that O
it O
is O
easier O
to O
control O
energy O
intake O
and O
lose O
weight O
if O
snacks O
in O
between O
meals O
are O
omitted O
. O
[]

Significantly O
more O
patients O
receiving O
flu O
required O
amphotericin O
B O
( O
58 O
v O
39 O
, O
P O
= O
0.043 O
) O
but O
this O
may O
have O
been O
affected O
by O
the O
fact O
that O
the O
study O
was O
not O
blinded O
. O
[]

Spontaneous O
regression O
of O
cervical O
intraepithelial O
neoplasia O
grade O
2 O
( O
CIN2 O
) O
lesions O
has O
been O
recognized O
since O
1955 O
, O
but O
predictors O
of O
this O
are O
poorly O
understood O
. O
[]

The O
main O
study O
group O
consisted O
of O
47 O
children O
with O
less O
than O
or O
equal O
to O
14 O
days O
of O
disease O
before O
therapy O
. O
[]

Three-year-survival O
rate O
of O
histologically O
confirmed O
non-curatively O
resected O
colon O
carcinoma O
patients O
was O
higher O
in O
the O
group O
receiving O
regimen O
C O
than O
in O
regimen O
D. O
But O
no O
significant O
difference O
was O
found O
among O
the O
other O
groups O
. O
['Mortality']

RESULTS O
Of O
the O
200 O
patients O
enrolled O
, O
99 O
were O
randomized O
to O
misoprostol O
and O
101 O
to O
dinoprostone O
. O
[]

Toxicity B-outcome ['Adverse-effects']
and O
rates O
of O
discontinuations O
because O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs O
; O
27 O
% O
v O
7 O
% O
) O
were O
greater O
with O
sunitinib O
than O
placebo O
. O
['Adverse-effects', 'Adverse-effects']

METHODS O
This O
study O
is O
a O
randomised O
, O
double-blind O
, O
parallel-group O
, O
fesoterodine-controlled O
study O
in O
patients O
with O
continuous O
OAB O
symptoms O
for O
? O
[]

Cardiac O
and O
haemodynamic O
measurements O
in O
hypertensive O
pregnancy O
. O
[]

Atorvastatin O
alone O
accelerated O
FVa B-outcome ['Physiological-Clinical']
inactivation I-outcome ['Physiological-Clinical']
( O
P=0.005 O
) O
. O
['Physiological-Clinical']

0.02 O
, O
p O
< O
0.001 O
) O
. O
[]

Treatment O
had O
to O
be O
abandoned O
in O
one O
patient O
receiving O
antacid O
because O
of O
diarrhoea O
and O
in O
one O
patient O
receiving O
cimetidine O
because O
of O
the O
absence O
of O
any O
response O
. O
( O
[]

Riluzole O
as O
an O
adjunctive O
therapy O
to O
risperidone O
for O
the O
treatment O
of O
irritability B-outcome ['Life-Impact']
in O
children O
with O
autistic O
disorder O
: O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
trial O
. O
['Life-Impact']

The O
fluticasone O
group O
had O
one O
and O
the O
placebo O
group O
three O
episodes O
of O
exacerbation B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

General B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
systematically O
dropped O
to O
a O
lower O
level O
in O
both O
groups O
, O
but O
participants O
from O
the O
health-promotion O
group O
reported O
fewer B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
questioned O
the O
need O
to O
give O
flutamide O
, O
an O
androgen O
receptor O
blocker O
, O
together O
with O
an O
oral O
contraceptive O
that O
contains O
drospirenone O
, O
a O
progestin O
claimed O
to O
have O
antiandrogen O
properties O
. O
[]

The O
WAIS-III O
General O
Ability O
Index O
( O
GAI O
; O
Tulsky O
, O
Saklofske O
, O
Wilkins O
, O
& O
Weiss O
, O
2001 O
) O
is O
a O
recently O
developed O
, O
6-subtest O
measure O
of O
global O
intellectual O
functioning O
. O
[]

BACKGROUND O
AND O
OBJECTIVES O
No O
medical O
treatment O
is O
available O
for O
polycystic O
liver O
disease O
, O
a O
frequent O
manifestation O
of O
autosomal-dominant O
polycystic O
kidney O
disease O
( O
ADPKD O
) O
. O
[]

Remifentanil O
was O
used O
intraoperatively O
, O
and O
i.v O
. O
[]

Patients O
with O
autism O
spectrum O
disorders O
showed O
a O
significant O
increase O
in O
repetitive B-outcome ['Life-Impact']
behaviours I-outcome ['Life-Impact']
at O
end-point O
following O
['Life-Impact']

We O
have O
studied O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
and O
pharmacodynamics B-outcome ['Physiological-Clinical']
of O
alfentanil O
, O
fentanyl O
and O
sufentanil O
together O
with O
propofol O
in O
patients O
undergoing O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Age O
and O
gender O
, O
as O
well O
as O
the O
severity O
of O
cardiac O
dysfunction O
, O
appear O
to O
have O
an O
important O
effect O
on O
the O
severity O
of O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Changes O
in O
depression B-outcome ['Life-Impact']
appeared O
to O
mediate O
these O
relationships O
. O
['Life-Impact']

There O
was O
no O
difference O
in O
survival B-outcome ['Mortality']
between O
the O
two O
groups O
. O
['Mortality']

Short-term O
speech-language O
intervention O
for O
children O
with O
disorders O
of O
the O
autism O
spectrum O
. O
[]

They O
were O
assigned O
to O
a O
one O
week O
triple O
standard O
therapy O
, O
consisting O
of O
metronidazole O
400 O
mg O
bid O
+ O
omeprazole O
20 O
mg O
bid O
+ O
clarithromycin O
250 O
mg O
bid O
, O
or O
a O
newly O
created O
quadruple-regimen O
, O
which O
adds O
amoxicillin O
( O
1 O
g O
bid O
) O
to O
the O
above O
triple O
regimen O
. O
[]

Children O
were O
randomized O
to O
a O
JA O
intervention O
, O
an O
SP O
intervention O
, O
or O
control O
group O
. O
[]

Results O
are O
presented O
as O
mean O
scores O
with O
standard O
deviations O
or O
95 O
% O
confidence O
intervals O
( O
CI O
) O
in O
parentheses O
. O
[]

The O
median O
follow-up O
for O
patients O
who O
remain O
at O
risk O
is O
15 O
+ O
months O
. O
[]

In O
conclusion O
, O
in O
different O
metabolic O
conditions O
the O
GH O
receptor O
antagonist O
pegvisomant O
induces O
no O
significant O
acute O
changes O
in O
the O
major O
risk O
markers O
for O
cardiovascular B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
group O
patients O
were O
given O
either O
PVB O
, O
VAB-6 O
or O
BVP O
according O
to O
the O
physician O
's O
discretion O
. O
[]

PATIENT O
( O
S O
) O
Thirty-seven O
women O
with O
polycystic O
ovary O
syndrome O
( O
PCOS O
) O
were O
randomly O
submitted O
to O
drospirenone+ethinylestradiol O
( O
group O
I O
; O
n=19 O
) O
or O
combined O
contraceptive O
vaginal O
ring O
( O
group O
II O
; O
n=18 O
) O
therapy O
. O
[]

Dietary O
factors O
may O
influence O
benign O
fibrocystic O
breast O
conditions O
, O
but O
little O
is O
known O
of O
their O
association O
with O
fibroadenomas O
. O
[]

All O
the O
patients O
received O
tapered O
effect O
( O
TE O
) O
implants O
from O
the O
Straumann O
Dental O
Implant O
System O
. O
[]

BACKGROUND O
Cytomegalovirus O
( O
CMV O
) O
disease O
is O
a O
frequent O
cause O
of O
serious O
morbidity O
after O
solid-organ O
transplantation O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
determine O
the O
RDN O
requirement O
for O
optimum O
microbial O
protein O
synthesis O
( O
MPS O
) O
, O
nitrogen O
capture O
efficiency O
( O
NCE O
) O
and O
nutrient O
utilisation O
in O
Nellore O
rams O
fed O
on O
a O
finger O
millet O
straw O
( O
FMS O
) O
-based O
diet O
. O
[]

In O
the O
study O
reported O
here O
, O
8 O
healthy O
volunteers O
were O
exposed O
to O
2.0 O
ppm O
NO2 O
and O
to O
filtered O
air O
for O
4 O
h O
while O
undergoing O
intermittent O
moderate O
exercise O
. O
[]

These O
results O
suggest O
that O
continuous O
infusion O
of O
morphine O
may O
be O
an O
inferior O
regimen O
to O
intermittent O
bolus O
administration O
in O
the O
relief O
of O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Administration O
of O
sivelestat O
was O
found O
to O
reduce O
[]

Thereafter O
, O
another O
needle O
was O
inserted O
into O
the O
skin O
of O
the O
other O
forearm O
during O
acupressure O
. O
[]

International O
standards O
exist O
which O
define O
precisely O
what O
constitutes O
a O
VP O
. O
[]

Alive B-outcome ['Mortality']
at O
30 O
days O
for O
HSD O
and O
NS O
, O
respectively O
, O
was O
70 O
% O
( O
35/50 O
) O
and O
75 O
% O
( O
42/56 O
) O
and O
at O
discharge O
was O
68 O
% O
( O
34/50 O
) O
and O
73 O
% O
( O
41/56 O
) O
. O
['Mortality']

Although O
active O
symptom O
control O
( O
ASC O
) O
has O
been O
recommended O
for O
the O
management O
of O
this O
disease O
, O
no O
consensus O
exists O
for O
the O
role O
of O
chemotherapy O
. O
[]

In O
the O
hemodiluted O
group O
( O
group O
2 O
) O
, O
15 O
mL/kg O
of O
blood O
was O
withdrawn O
over O
30 O
mins O
( O
T O
= O
20 O
mins O
to O
T O
= O
50 O
mins O
) O
and O
simultaneously O
replaced O
by O
an O
equal O
volume O
of O
4 O
% O
albumin O
solution O
( O
0.6 O
g/kg O
) O
. O
[]

OBJECTIVE O
To O
identify O
possible O
nonspecific O
, O
baseline O
predictors O
of O
response O
to O
intervention O
in O
a O
large O
randomized O
clinical O
trial O
of O
children O
and O
adolescents O
with O
autism O
spectrum O
disorders O
. O
[]

Such O
serious O
toxicity B-outcome ['Adverse-effects']
as O
previously O
reported O
by O
high O
dose O
IL-2 O
therapy O
was O
not O
observed O
. O
['Adverse-effects']

CONCLUSION O
The O
use O
of O
ozone O
gas O
to O
disinfect O
the O
cavity O
before O
placing O
a O
restoration O
had O
no O
influence O
on O
immediate O
enamel O
and O
dentin O
bond O
strength O
. O
[]

The O
blastocysts O
were O
collected O
from O
gilts O
and O
vitrified O
using O
the O
new O
device O
( O
MVAC O
) O
or O
a O
Cryotop O
( O
CT O
) O
. O
[]

PURPOSE O
New O
effective O
chemotherapy O
is O
needed O
to O
improve O
the O
outcome O
of O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O
[]

Additional O
progression O
of O
coronary B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
became O
manifest O
through O
development O
of O
228 O
stenoses B-outcome ['Physiological-Clinical']
and O
19 O
occlusions B-outcome ['Physiological-Clinical']
at O
arterial O
sites O
free O
from O
definitive O
stenoses O
in O
the O
baseline O
angiograms O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
initial O
study O
, O
two O
villages O
were O
randomly O
assigned O
a O
nutritious O
supplement O
( O
atole O
) O
for O
all O
children O
and O
two O
villages O
a O
less O
nutritious O
one O
( O
fresco O
) O
. O
[]

Each O
patient O
received O
subglandularly O
a O
Siltex O
textured O
saline-filled O
prosthesis O
with O
a O
pore O
size O
of O
30 O
to O
70 O
microm O
in O
one O
breast O
, O
and O
a O
smooth O
saline-filled O
prosthesis O
in O
the O
other O
. O
[]

The O
trial O
was O
stratified O
by O
HIV O
serology O
. O
[]

About O
half O
of O
the O
CV B-outcome ['Physiological-Clinical']
hospitalizations B-outcome ['Resource-use']
were O
AF-related B-outcome ['Physiological-Clinical']
, O
with O
a O
median O
duration O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
of O
four O
nights O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Resource-use']

Prospective O
randomized O
trial O
of O
an O
anterior O
surface O
modified O
prolate O
intraocular O
lens O
. O
[]

Assessments O
were O
performed O
at O
baseline O
and O
3 O
weeks O
after O
each O
injection O
using O
several O
outcome O
measures O
. O
[]

RESULTS O
In O
the O
PUFA-diet O
group O
( O
n O
= O
15 O
) O
lag O
time O
tended O
to O
decrease O
during O
the O
experimental O
diet O
( O
97 O
+/- O
28 O
vs O
90 O
+/- O
25 O
min O
, O
mean O
+/- O
s.d. O
, O
P O
= O
0.073 O
) O
, O
whereas O
in O
the O
MUFA-diet O
group O
( O
n O
= O
14 O
) O
there O
was O
no O
significant O
change O
( O
lag O
time O
96 O
+/- O
24 O
vs O
100 O
+/- O
16 O
min O
, O
P O
= O
0.408 O
) O
. O
[]

BACKGROUND O
Although O
the O
number O
of O
smokers O
has O
declined O
in O
the O
last O
decade O
, O
smoking O
is O
still O
a O
major O
health O
problem O
among O
youngsters O
and O
adolescents O
. O
[]

RESULTS O
Of O
46 O
patients O
, O
eight O
of O
19 O
( O
42 O
% O
) O
in O
the O
pancuronium O
group O
and O
six O
of O
27 O
( O
22 O
% O
) O
in O
the O
succinylcholine O
group O
experienced O
fasciculations B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
MRI O
signal O
hyperintensities O
predict O
poor O
remission B-outcome ['Physiological-Clinical']
to O
antidepressant O
treatment O
. O
['Physiological-Clinical']

Sixty-three O
infertility O
patients O
had O
bilateral O
pelvic O
sidewall O
adhesions O
removed O
at O
laparotomy O
. O
[]

The O
mean O
volumes O
of O
contrast O
agent O
used O
and O
prehydration O
given O
for O
each O
of O
the O
three O
groups O
did O
not O
differ O
significantly O
( O
p O
> O
0.83 O
) O
. O
[]

Delivery O
of O
the O
Lunar O
stent O
was O
successful O
in O
most O
lesions O
and O
the O
optimal O
radiopacity O
facilitated O
optimal O
stent B-outcome ['Physiological-Clinical']
positioning O
with O
optimal O
immediate O
clinical O
and O
angiographic O
results O
is O
an O
unselected O
patient O
and O
lesion O
population O
. O
['Physiological-Clinical']

METHODS O
This O
study O
was O
performed O
for O
190 O
patients O
with O
DU O
. O
[]

Across O
all O
measures O
of O
work O
functioning O
and O
productivity O
at O
each O
visit O
, O
patients O
randomized O
to O
pegIFNalpha O
2a O
treatment O
showed O
less O
impairment O
relative O
to O
the O
group O
treated O
with O
IFNalpha O
2b/RBV O
. O
[]

Adjusted O
mean O
change O
of O
initial O
claudication O
distance O
was O
33.9 O
% O
after O
nebivolol O
( O
P=0.003 O
) O
and O
16.6 O
% O
after O
metoprolol O
( O
P=0.12 O
) O
treatment O
. O
[]

Total O
platelet B-outcome ['Physiological-Clinical']
and O
fibrin B-outcome ['Physiological-Clinical']
deposition I-outcome ['Physiological-Clinical']
was O
determined O
by O
immunoenzymatic O
methods O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
contrast O
to O
the O
placebo O
, O
indomethacin O
produced O
an O
immediate O
and O
sustained O
reduction O
of O
fever B-outcome ['Physiological-Clinical']
in O
all O
but O
one O
patient O
. O
['Physiological-Clinical']

Findings O
indicate O
that O
teachers O
can O
implement O
an O
intervention O
to O
significantly O
improve O
joint B-outcome ['Physiological-Clinical']
engagement I-outcome ['Physiological-Clinical']
of O
young O
children O
with O
autism O
in O
their O
classrooms O
. O
['Physiological-Clinical']

Women O
's O
sexual B-outcome ['Life-Impact']
dissatisfaction I-outcome ['Life-Impact']
was O
greater O
among O
primiparous O
women O
who O
had O
a O
vaginal O
birth O
( O
VB O
70.1 O
% O
, O
CS O
54.5 O
% O
) O
, O
but O
in O
multiparous O
women O
, O
the O
rates O
of O
sexual B-outcome ['Life-Impact']
dissatisfaction I-outcome ['Life-Impact']
were O
similar O
( O
VB O
64.2 O
% O
, O
CS O
71.4 O
% O
) O
. O
['Life-Impact', 'Life-Impact']

A O
double-blind O
phase O
II O
study O
of O
propionyl-L-carnitine O
( O
CAS O
17298-37-2 O
) O
versus O
placebo O
was O
carried O
out O
on O
a O
group O
of O
60 O
patients O
with O
mild O
to O
moderate O
( O
II O
and O
III O
NYHA O
class O
) O
congestive O
heart O
failure O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
antihistamine O
activity O
of O
single O
oral O
doses O
of O
75 O
mg O
cinnarizine O
using O
75 O
mg O
diphenhydramine O
as O
control O
, O
both O
being O
compared O
to O
placebo O
. O
[]

Parents O
received O
educational O
materials O
by O
mail O
and O
in O
primary O
care O
practices O
, O
pharmacies O
, O
and O
child O
care O
settings O
. O
[]

OBJECTIVES O
To O
determine O
the O
effectiveness O
of O
individualized O
problem-solving O
counseling O
by O
nurses O
for O
caregivers O
and O
the O
expenditures O
of O
health O
care O
utilization O
. O
[]

The O
primary O
end O
point O
of O
the O
study O
was O
the O
rate O
of O
major B-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MACEs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
at O
1 O
month O
, O
defined O
as O
a O
composite O
of O
cardiac B-outcome ['Life-Impact']
death I-outcome ['Life-Impact']
, O
reinfarction B-outcome ['Physiological-Clinical']
, O
serious B-outcome ['Physiological-Clinical']
arrhythmias I-outcome ['Physiological-Clinical']
( O
ventricular B-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
and/or I-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
) O
, O
and O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Age O
and O
autonomic O
effects O
on O
interrelationships O
between O
lung O
volume O
and O
heart O
rate O
. O
[]

0.05 O
) O
. O
[]

Naltrexone O
treatment O
failed O
to O
have O
therapeutic O
effects O
on O
SIB O
and O
autism O
. O
[]

OBJECTIVE O
To O
examine O
whether O
the O
effects O
of O
physical O
and O
emotional O
status O
on O
adherance O
to O
a O
low-fat O
( O
20 O
% O
energy O
) O
dietary O
pattern O
are O
mediated O
by O
participation O
in O
an O
intervention O
program O
( O
attending O
sessions O
and O
self-monitoring O
) O
. O
[]

A O
positive O
relationship O
was O
found O
between O
the O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
granulocytopenia I-outcome ['Physiological-Clinical']
and O
the O
incidence O
of O
rectal B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
( O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
tested O
the O
hypothesis O
that O
remote O
ischaemic O
conditioning O
during O
evolving O
ST-elevation O
myocardial O
infarction O
, O
and O
done O
before O
primary O
percutaneous O
coronary O
intervention O
, O
increases O
myocardial B-outcome ['Physiological-Clinical']
salvage I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Mixed-effects O
modeling O
tested O
the O
hypothesis O
that O
the O
intervention O
reduced O
self-reported O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
( O
Center O
for O
Epidemiological O
Studies O
Depression O
scale O
, O
Profile O
of O
Mood O
States O
Depression O
and O
Fatigue O
subscales O
, O
and O
Medical O
Outcomes O
Study-Short O
Form O
36 O
Bodily O
Pain O
subscale O
) O
and O
immune B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
numbers I-outcome ['Physiological-Clinical']
that O
are O
elevated O
in O
the O
presence O
of O
inflammation O
( O
white O
blood O
cell O
count O
, O
neutrophil O
count O
, O
and O
helper/suppressor O
ratio O
) O
. O
['Life-Impact', 'Physiological-Clinical']

A O
highly O
significant O
( O
P O
< O
0.001 O
) O
number O
of O
lid B-outcome ['Physiological-Clinical']
margins I-outcome ['Physiological-Clinical']
were O
rendered O
'clinically O
clean O
' O
( O
i.e. O
, O
0-49 O
organisms/swab O
) O
by O
fusidic O
acid O
when O
compared O
with O
untreated O
eyes O
. O
['Physiological-Clinical']

The O
vaccine O
did O
not O
elicit O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
except O
in O
two O
vaccine O
recipients O
with O
mild B-outcome ['Physiological-Clinical']
diarrhoea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Effectiveness O
was O
evaluated O
at O
5 O
years O
. O
[]

Perivascular O
afferent O
fibres O
of O
the O
superficial O
temporal O
artery O
contain O
peptides O
, O
like O
calcitonin O
gene-related O
peptide O
( O
CGRP O
) O
and O
substance O
P O
( O
SP O
) O
. O
[]

Patients O
with O
endoscopically O
documented O
duodenal O
ulcer O
received O
cimetidine O
, O
1200 O
mg O
daily O
, O
or O
Mylanta O
II O
, O
7 O
oz O
daily O
, O
in O
a O
randomized O
, O
double-blind O
trial O
. O
[]

A O
series O
of O
randomized O
, O
controlled O
, O
masked O
field O
studies O
was O
conducted O
to O
assess O
the O
efficacy O
and O
safety O
of O
selamectin O
in O
the O
treatment O
of O
flea O
infestations O
on O
dogs O
and O
cats O
, O
and O
in O
the O
prevention O
of O
heartworm B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
in O
dogs O
. O
['Physiological-Clinical']

mTOR B-outcome ['Physiological-Clinical']
signaling I-outcome ['Physiological-Clinical']
was O
assessed O
by O
immunoblotting O
from O
repeated O
muscle O
biopsy O
samples O
. O
['Physiological-Clinical']

An O
average O
of O
15.2 O
ml O
S.A.I.M.R O
. O
[]

Findings O
suggest O
the O
potential O
of O
earlier O
intervention O
and O
further O
evaluation O
of O
oxytocin O
nasal O
spray O
as O
a O
treatment O
to O
improve O
social O
communication O
and O
interaction O
in O
young O
people O
with O
autism O
spectrum O
disorders O
. O
[]

RESULTS O
Bivariate O
and O
multivariate O
statistical O
analyses O
showed O
that O
participation O
was O
significantly O
higher O
for O
women O
contacted O
by O
telephone O
than O
through O
routine O
publicity O
. O
[]

Further O
reductions O
were O
achieved O
by O
adding O
prednisone O
and O
azathioprine O
. O
[]

DESIGN O
, O
SETTING O
, O
AND O
PARTICIPANTS O
Ten O
healthy O
adult O
volunteers O
participated O
in O
a O
controlled O
cross-over O
experiment O
. O
[]

Accordingly O
, O
it O
is O
suggested O
that O
pindolol O
could O
be O
a O
more O
favorable O
beta-blocker O
drug O
to O
be O
used O
on O
hypertensive O
subjects O
with O
metabolic O
coronary O
risk O
factors O
. O
[]

The O
primary O
end O
point O
was O
time O
to O
first O
on-study O
SRE O
( O
defined O
as O
pathologic O
fracture O
, O
radiation O
or O
surgery O
to O
bone O
, O
or O
spinal O
cord O
compression O
) O
. O
[]

These O
results O
were O
later O
corroborated O
by O
the O
control O
group O
. O
[]

The O
authors O
explain O
the O
objectives O
and O
the O
structure O
of O
a O
programme O
evolved O
for O
the O
methodic O
study O
of O
advanced O
breast O
cancers O
which O
they O
have O
worked O
out O
and O
carried O
out O
in O
cooperation O
with O
the O
departments O
of O
medicine O
in O
eight O
French O
anticancer O
centres O
. O
[]

This O
randomized O
, O
double-blind O
, O
phase O
II O
study O
was O
conducted O
to O
assess O
the O
efficacy O
and O
safety O
of O
two O
doses O
of O
pemetrexed O
in O
a O
homogeneous O
population O
. O
[]

Tamsulosin O
at O
both O
dosages O
was O
well O
tolerated B-outcome ['Life-Impact']
as O
maintenance O
therapy O
. O
['Life-Impact']

Assessing O
the O
bioequivalence O
of O
topical O
retinoid O
products O
by O
pharmacodynamic O
assay O
. O
[]

Our O
primary O
endpoint O
was O
the O
total O
number O
of O
treatments B-outcome ['Resource-use']
for I-outcome ['Resource-use']
malaria I-outcome ['Resource-use']
per O
time O
at O
risk O
. O
['Resource-use']

Study O
2 O
showed O
for O
a O
separate O
sample O
of O
normal O
children O
( O
n O
= O
12 O
) O
that O
the O
TOM O
test O
possesses O
sufficient O
test-retest O
stability O
. O
[]

Recording O
blocks O
consisted O
of O
targets O
preceded O
by O
randomized O
sequences O
of O
standards O
and O
by O
sequences O
of O
standards O
that O
included O
a O
predictive O
sequence O
signaling O
the O
occurrence O
of O
a O
subsequent O
target O
event O
. O
[]

Visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
was O
decreased O
to O
0.9 O
+/- O
0.23 O
in O
the O
Crazy O
lens O
group O
as O
compared O
with O
1.2 O
+/- O
0.13 O
in O
the O
clear O
lens O
group O
. O
['Physiological-Clinical']

Fifty-nine O
percent O
of O
those O
initially O
receiving O
duloxetine O
vs O
38 O
% O
of O
those O
initially O
receiving O
placebo O
reported O
decreased O
[]

Metabolic O
syndrome O
is O
associated O
with O
intravascular O
inflammation O
, O
as O
determined O
by O
increased O
levels O
of O
inflammatory O
biomarkers O
and O
an O
increased O
risk O
of O
ischemic O
atherothrombotic O
events O
. O
[]

Results O
indicate O
that O
DTkid O
offers O
the O
potential O
for O
an O
effective O
means O
of O
teaching O
DTT O
skills O
to O
novice O
tutors O
of O
children O
with O
autism O
. O
[]

OBJECTIVE O
To O
assess O
whether O
action O
observation O
treatment O
( O
AOT O
) O
may O
also O
improve O
motor O
recovery O
in O
postsurgical O
orthopedic O
patients O
, O
in O
addition O
to O
conventional O
physiotherapy O
. O
[]

We O
intended O
to O
evaluate O
the O
compliance O
and O
response O
to O
antiviral O
treatment O
for O
CHC O
in O
IVDUs O
compared O
with O
non-IVDUs O
. O
[]

This O
study O
investigated O
the O
effects O
of O
faking O
bad O
( O
FB O
) O
on O
the O
Test O
of O
Variables O
of O
Attention O
( O
TOVA O
) O
using O
subjects O
randomly O
placed O
into O
two O
groups O
. O
[]

Many O
physicians O
, O
however O
, O
treat O
acute O
bronchitis O
with O
antibiotics O
because O
of O
the O
possibility O
of O
Mycoplasma O
pneumoniae O
or O
other O
pathogens O
. O
[]

These O
children O
, O
who O
were O
aged O
between O
3 O
and O
10 O
years O
, O
had O
a O
diagnosis O
of O
chronic O
idiopathic O
constipation O
. O
[]

Five O
pairs O
were O
used O
in O
a O
pilot O
study O
and O
45 O
pairs O
were O
used O
in O
the O
main O
experiment O
. O
[]

The O
mean O
( O
sd O
) O
end O
tidal O
isoflurane O
concentration O
( O
per O
cent O
) O
needed O
to O
maintain O
a O
light B-outcome ['Resource-use']
surgical I-outcome ['Resource-use']
anaesthesia I-outcome ['Resource-use']
( O
stage O
III O
, O
plane O
2 O
) O
was O
significantly O
lower O
in O
group O
KM O
( O
0.91 O
[ O
0.03 O
] O
) O
than O
in O
groups O
TG O
( O
1.11 O
[ O
0.03 O
] O
) O
and O
KG O
( O
1.14 O
[ O
0.03 O
] O
) O
. O
['Resource-use']

After O
two O
sessions O
of O
treatment O
and O
after O
three O
months O
follow-up O
, O
CTTH B-outcome ['Physiological-Clinical']
score O
( O
including O
the O
score O
of O
headache B-outcome ['Physiological-Clinical']
attack I-outcome ['Physiological-Clinical']
frequency O
and O
the O
score O
of O
headache B-outcome ['Physiological-Clinical']
severity B-outcome ['Physiological-Clinical']
) O
was O
observed O
and O
compared O
before O
and O
after O
treatment O
separately O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Medastinal B-outcome ['Physiological-Clinical']
N3 I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
was O
the O
risk O
factor O
for O
INF O
( O
P O
= O
0.02 O
, O
OR O
= O
14.13 O
, O
95 O
% O
CI O
: O
1.47-136.13 O
) O
. O
['Physiological-Clinical']

Those O
who O
were O
least O
satisfied O
with O
themselves O
reported O
feeling O
most O
susceptible B-outcome ['Life-Impact']
. O
['Life-Impact']

The O
quality O
of O
anaesthesia O
provided O
by O
three O
dosages O
of O
prilocaine O
, O
40 O
ml O
0.5 O
% O
, O
20 O
ml O
1 O
% O
, O
or O
40 O
ml O
1 O
% O
, O
administered O
in O
random O
order O
, O
for O
intravenous O
regional O
anaesthesia O
of O
the O
lower O
extremity O
below O
the O
knee O
was O
compared O
in O
six O
volunteers O
. O
[]

Groups O
received O
daily O
dietary O
supplements O
comprising O
30 O
mL O
of O
either O
soy O
bean O
oil O
( O
group O
S O
; O
n O
= O
20 O
) O
or O
coconut O
oil O
( O
group O
C O
; O
n O
= O
20 O
) O
over O
a O
12-week O
period O
, O
during O
which O
all O
subjects O
were O
instructed O
to O
follow O
a O
balanced O
hypocaloric O
diet O
and O
to O
walk O
for O
50 O
min O
per O
day O
. O
[]

METHODS O
In O
this O
prospective O
, O
multicenter O
, O
two-phase O
controlled O
trial O
, O
2416 O
infants O
were O
stratified O
according O
to O
birth O
weight O
( O
501 O
to O
1000 O
g O
and O
1001 O
to O
1500 O
g O
) O
and O
randomly O
assigned O
to O
an O
intravenous O
immune O
globulin O
group O
( O
n O
= O
1204 O
) O
or O
a O
control O
group O
( O
n O
= O
1212 O
) O
. O
[]

Patients O
were O
examined O
weekly O
during O
the O
treatment O
period O
and O
then O
at O
monthly O
intervals O
for O
a O
further O
6 O
months O
. O
[]

Based O
on O
these O
criteria O
, O
ototoxicity B-outcome ['Physiological-Clinical']
was O
seen O
in O
5/27 O
( O
18.5 O
% O
) O
patients O
treated O
with O
G-C O
and O
2/19 O
( O
10.5 O
% O
) O
patients O
treated O
with O
N-C O
. O
['Physiological-Clinical']

orange O
juice O
was O
significantly O
more O
erosive O
than O
water O
) O
, O
but O
no O
significant O
effect O
for O
abrasion B-outcome ['Physiological-Clinical']
( O
i.e O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
test O
the O
hypothesis O
that O
amantadine O
hydrochloride O
is O
a O
safe O
and O
effective O
treatment O
for O
behavioral B-outcome ['Life-Impact']
disturbances I-outcome ['Life-Impact']
-- O
for O
example O
, O
hyperactivity B-outcome ['Life-Impact']
and O
irritability B-outcome ['Life-Impact']
-- O
in O
children O
with O
autism O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

We O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
cross-over O
study O
in O
10 O
healthy O
females O
( O
age O
range O
22-36 O
years O
, O
mean O
29.1 O
+/- O
5.4 O
) O
who O
were O
hospitalized O
and O
challenged O
on O
two O
consecutive O
days O
with O
placebo O
( O
peppermint O
tea O
) O
or O
75 O
mg O
of O
pure O
histamine O
( O
equaling O
124 O
mg O
histamine O
dihydrochloride O
, O
dissolved O
in O
peppermint O
tea O
) O
. O
[]

METHODS O
We O
assessed O
status O
of O
BRAF O
c.1799T O
> O
A O
( O
p.V600E O
) O
mutation O
and O
MSI O
in O
506 O
stage O
III O
colon O
cancer O
patients O
enrolled O
in O
a O
randomized O
adjuvant O
chemotherapy O
trial O
[ O
5-fluorouracil O
and O
leucovorin O
( O
FU/LV O
) O
vs. O
irinotecan O
( O
CPT11 O
) O
, O
FU O
and O
LV O
( O
IFL O
) O
; O
CALGB O
89803 O
] O
. O
[]

The O
clinical B-outcome ['Physiological-Clinical']
outcomes O
of O
the O
two O
types O
of O
consultation B-outcome ['Resource-use']
were O
similar O
-- O
almost O
half O
the O
patients O
were O
managed O
after O
a O
single O
consultation O
with O
the O
dermatologist O
. O
['Physiological-Clinical', 'Resource-use']

CONCLUSIONS O
Cognitive O
functioning O
in O
MS O
is O
independent O
of O
fatigue O
. O
[]

However O
, O
overall O
home B-outcome ['Physiological-Clinical']
readiness I-outcome ['Physiological-Clinical']
( O
toleration O
of O
oral O
fluids O
, O
walking O
, O
pain O
tolerable O
by O
oral O
analgesics O
, O
no O
or O
only O
mild O
nausea O
) O
was O
achieved O
faster O
in O
the O
desflurane O
group O
receiving O
ondansetron O
( O
109 O
[ O
21-937 O
] O
min O
, O
P O
< O
0.01 O
) O
and O
in O
the O
propofol O
group O
( O
110 O
[ O
33-642 O
] O
min O
, O
P O
< O
0.001 O
) O
when O
compared O
to O
the O
desflurane O
only O
group O
( O
372 O
[ O
45-723 O
] O
min O
) O
( O
median O
[ O
range O
] O
) O
. O
['Physiological-Clinical']

7-hexanoyltaxol-eluting O
stent O
for O
prevention O
of O
neointimal O
growth O
: O
an O
intravascular O
ultrasound O
analysis O
from O
the O
Study O
to O
COmpare O
REstenosis O
rate O
between O
QueST O
and O
QuaDS-QP2 O
( O
SCORE O
) O
. O
[]

If O
present O
, O
such O
relationships O
should O
be O
most O
clearly O
observable O
in O
patients O
with O
first O
episode O
schizophrenia O
; O
that O
is O
, O
before O
the O
effects O
of O
chronic O
illness O
, O
institutionalization O
, O
or O
treatment O
might O
confound O
them O
. O
[]

METHODS O
Forty-nine O
patients O
were O
assigned O
to O
receive O
UDCA O
( O
450 O
mg/day O
) O
over O
a O
period O
of O
6 O
months O
and O
52 O
to O
receive O
no O
treatment O
. O
[]

STUDY O
DESIGN O
In O
this O
open-label O
study O
, O
healthy O
women O
were O
randomized O
to O
EE O
20 O
microg/DRSP O
3 O
mg O
or O
EE O
20 O
microg/DSG O
150 O
microg O
for O
seven O
cycles O
. O
[]

Therapeutic O
trials O
with O
naltrexone O
] O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
triglycerides I-outcome ['Physiological-Clinical']
, O
a O
univariate O
predictor O
of O
coronary B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( O
RR O
1.6 O
, O
P O
: O
=0.03 O
) O
, O
was O
not O
related O
to O
coronary B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( O
RR O
1.3 O
, O
P O
: O
=0.6 O
) O
when O
apoCIII B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
VLDL+LDL I-outcome ['Physiological-Clinical']
was O
included O
in O
the O
model O
, O
whereas O
apoCIII B-outcome ['Physiological-Clinical']
remained O
significant O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Oral O
ganciclovir O
dosing O
in O
transplant O
recipients O
and O
dialysis O
patients O
based O
on O
renal O
function O
. O
[]

Additional B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
was O
more O
often O
in O
the O
fentanyl-bupivacaine O
group O
and O
total O
bupivacaine O
requirement O
was O
less O
in O
the O
clonidine-bupivacaine O
group O
( O
22.5 O
+/- O
12.5 O
mg O
vs. O
30.9 O
+/- O
12.8 O
mg O
) O
( O
P O
= O
0.04 O
) O
. O
['Resource-use']

The O
changes O
caused O
by O
the O
diet O
were O
partly O
reversed O
by O
clofibrate O
while O
niceritrol O
did O
not O
cause O
any O
major O
changes O
of O
the O
fatty B-outcome ['Physiological-Clinical']
acid B-outcome ['Physiological-Clinical']
composition B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Prophylactic O
administration O
of O
amantadine O
in O
doses O
of O
100 O
mg. O
twice O
a O
day O
offered O
statistically O
significant O
protection O
against O
influenza B-outcome ['Physiological-Clinical']
A2 I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
in O
a O
double-blind O
field O
trial O
involving O
391 O
medical O
student O
volunteers O
during O
the O
influenza O
A2 O
Hong O
Kong O
epidemic O
in O
Helsinki O
in O
the O
winter O
of O
1969 O
. O
['Physiological-Clinical']

Sleeping B-outcome ['Physiological-Clinical']
polysomnographic I-outcome ['Physiological-Clinical']
and O
impedance B-outcome ['Physiological-Clinical']
cardiographic I-outcome ['Physiological-Clinical']
data I-outcome ['Physiological-Clinical']
were O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Importantly O
, O
the O
clinical O
and O
immunological O
effects O
of O
SIT O
were O
not O
affected O
by O
intervention O
with O
steroids O
administered O
with O
vitamin O
D O
( O
3 O
) O
. O
[]

Survival B-outcome ['Mortality']
was O
estimated O
with O
the O
Kaplan-Meier O
method O
. O
['Mortality']

BACKGROUND O
Self-esteem O
is O
a O
major O
concern O
in O
mood O
disorders O
. O
[]

BACKGROUND O
Closure O
of O
the O
femoral O
artery O
after O
cardiac O
catheterization O
can O
be O
obtained O
through O
different O
methods O
. O
[]

The O
pulsed-dye O
laser O
as O
an O
adjuvant O
treatment O
modality O
in O
acne O
vulgaris O
: O
a O
randomized O
controlled O
single-blinded O
trial O
. O
[]

Primary O
endpoints O
were O
a O
composite O
of O
an O
AIDS-defining B-outcome ['Physiological-Clinical']
event I-outcome ['Physiological-Clinical']
, O
death B-outcome ['Mortality']
, O
or O
CD4 B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
decline I-outcome ['Physiological-Clinical']
to O
less O
than O
200 O
cells O
per O
mm3 O
for O
the O
PI O
versus O
NNRTI O
comparison O
, O
and O
average O
change O
in O
CD4 B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
at O
or O
after O
32 O
months O
for O
the O
three-class O
versus O
combined O
two-class O
comparison O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
MDM2 O
regulates O
p53 O
, O
which O
controls O
cell O
cycle O
arrest O
and O
apoptosis O
. O
[]

The O
clinical B-outcome ['Physiological-Clinical']
efficacy O
and O
toxic/adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
were O
assessed O
using O
Karnofsky O
performance O
scale O
( O
KPS O
) O
. O
['Physiological-Clinical', 'Adverse-effects']

Changes O
in O
liver B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
were O
significantly O
different O
between O
the O
two O
treatment O
periods O
( O
-71 O
+/- O
57 O
ml O
versus O
+14 O
+/- O
85 O
ml O
) O
. O
['Physiological-Clinical']

This O
effect O
may O
be O
mediated O
by O
additive O
actions O
on O
PKC O
inhibition O
, O
which O
may O
be O
an O
important O
mechanism O
for O
antimanic O
agents O
in O
general O
. O
[]

2 O
) O
= O
5.67 O
, O
P O
= O
.02 O
) O
. O
[]

Psychological B-outcome ['Life-Impact']
measures O
included O
['Life-Impact']

[ O
Supplementary O
treatment O
with O
Esberitox O
of O
female O
patients O
undergoing O
curative O
adjuvant O
irradiation O
following O
breast O
cancer O
] O
. O
[]

Thus O
, O
endurance O
physical O
activity O
improves O
the O
fibrinolytic O
risk O
factor O
profile O
by O
reducing O
PAI-1 O
while O
leaving O
tPA B-outcome ['Physiological-Clinical']
activity O
unaffected O
, O
independently O
of O
food O
composition O
. O
['Physiological-Clinical']

SETTING O
Eighty-four O
outpatient O
centers O
throughout O
the O
United O
States O
. O
[]

Secondary O
outcome O
measures O
Family O
stress O
, O
support O
and O
empowerment B-outcome ['Life-Impact']
. O
['Life-Impact']

This O
prompted O
us O
to O
analyze O
microarray O
data O
from O
261 O
patients O
from O
a O
third O
cohort O
. O
[]

The O
increase O
of O
plasma B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
lower O
in O
the O
epidural O
group O
as O
compared O
to O
the O
NA O
group O
. O
['Physiological-Clinical']

In O
the O
combined O
analysis O
, O
347 O
patients O
crossed O
over O
to O
800 O
mg/day O
imatinib O
at O
the O
time O
of O
progression O
. O
[]

Feasibility B-outcome ['Life-Impact']
and O
effects O
of O
nurse O
run O
clinics O
for O
patients O
with O
epilepsy O
in O
general O
practice O
: O
randomised O
controlled O
trial O
. O
['Life-Impact']

CONCLUSIONS O
This O
Phase O
I O
study O
demonstrated O
that O
CS O
vaginal O
gel O
was O
safe O
, O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
and O
acceptable B-outcome ['Life-Impact']
by O
HIV-infected O
women O
and O
their O
male O
partners O
. O
['Life-Impact']

After O
6 O
months O
from O
therapy O
, O
no O
significant O
differences O
in O
complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
were O
found O
among O
the O
different O
types O
of O
treatment O
: O
20 O
, O
20 O
, O
and O
35 O
% O
for O
the O
two O
interferon O
groups O
and O
the O
diathermocoagulation O
group O
, O
respectively O
. O
['Physiological-Clinical']

Service O
variation O
in O
baseline O
variables O
and O
prediction O
of O
risk O
in O
a O
randomised O
controlled O
trial O
of O
psychological O
treatment O
in O
repeated O
parasuicide O
: O
the O
POPMACT O
Study O
. O
[]

Chlamydia B-outcome ['Physiological-Clinical']
trachomatis I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
persisted O
in O
at O
least O
half O
the O
patients O
infected O
in O
each O
treatment O
group O
. O
['Physiological-Clinical']

Side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
and O
overall O
opinion O
were O
assessed O
. O
['Adverse-effects']

Similarly O
, O
there O
was O
no O
DFS B-outcome ['Mortality']
( O
HR O
, O
1.84 O
; O
95 O
% O
CI O
, O
0.44 O
to O
7.73 O
; O
P O
= O
.395 O
) O
or O
OS B-outcome ['Mortality']
benefit O
( O
HR O
, O
3.16 O
; O
95 O
% O
CI O
, O
0.61 O
to O
16.45 O
; O
P O
= O
.15 O
) O
from O
gefitinib O
for O
the O
15 O
patients O
with O
EGFR O
mutation-positive O
tumors O
. O
['Mortality', 'Mortality']

Future O
studies O
are O
needed O
to O
make O
conclusions O
about O
its O
efficacy O
. O
[]

This O
study O
aimed O
to O
determine O
if O
the O
addition O
of O
deep O
breathing O
exercises O
and O
secretion O
clearing O
techniques O
to O
a O
standardised O
physiotherapist-directed O
program O
of O
early O
mobilisation O
improved O
clinical O
outcomes O
in O
patients O
undergoing O
open O
abdominal O
surgery O
. O
[]

At O
the O
end O
of O
1 O
year O
24 O
group O
1 O
( O
92.3 O
% O
) O
and O
23 O
group O
2 O
( O
90.3 O
% O
) O
patients O
had O
an O
improved O
drainage B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

No O
difference O
was O
observed O
in O
the O
basal B-outcome ['Physiological-Clinical']
and O
peak O
concentrations O
of O
luteinising B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
follicle B-outcome ['Physiological-Clinical']
stimulating I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
thyroid B-outcome ['Physiological-Clinical']
stimulating I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mean O
glucose B-outcome ['Physiological-Clinical']
values O
were O
different O
in O
the O
2 O
groups O
( O
7.1 O
+/- O
2.6 O
vs O
9.4 O
+/- O
2.1 O
mmol/L O
, O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

In O
conclusion O
, O
acebutolol O
is O
safe O
for O
use O
in O
patients O
with O
coronary O
disease O
and O
a O
wide O
range O
of O
ejection O
fractions O
but O
, O
as O
with O
all O
beta O
blockers O
, O
should O
be O
used O
cautiously O
in O
patients O
with O
markedly O
reduced O
resting O
left O
ventricular O
function O
. O
[]

Our O
aim O
was O
to O
evaluate O
blood O
loss O
and O
early B-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
minimally O
invasive O
TKA O
using O
custom-fit O
magnetic O
resonance O
imaging O
( O
MRI O
) O
-based O
pin O
guides O
. O
['Physiological-Clinical']

After O
randomisation O
, O
there O
were O
no O
significant O
differences O
in O
gender O
, O
race O
, O
age O
, O
and O
parent O
and O
teacher O
GBRS O
and O
Ritvo O
Scale O
between O
the O
two O
groups O
. O
[]

The O
in-hospital B-outcome ['Mortality']
mortality I-outcome ['Mortality']
of O
257 O
patients O
with O
nonanterior O
wall O
AMI O
was O
similar O
after O
PTCA O
and O
tPA O
( O
3.2 O
% O
vs O
3.8 O
% O
, O
p O
= O
0.82 O
) O
. O
['Mortality']

This O
study O
was O
designed O
to O
compare O
the O
rates O
of O
duodenal O
ulcer O
healing O
and O
recurrence O
after O
treatment O
with O
cimetidine O
or O
antacid O
. O
[]

Muscle B-outcome ['Physiological-Clinical']
relaxation I-outcome ['Physiological-Clinical']
was O
maintained O
using O
the O
short O
acting O
nondepolarizing O
relaxant O
vecuronium O
, O
which O
shows O
no O
cumulative O
effect O
within O
clinical O
dosages O
. O
['Physiological-Clinical']

However O
, O
placebo O
showed O
little O
effect O
on O
these O
lipid B-outcome ['Physiological-Clinical']
levels O
, O
urinary B-outcome ['Physiological-Clinical']
protein B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
podocyte I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Data O
suggest O
that O
inflammation O
can O
contribute O
to O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
although O
the O
converse O
remains O
untested O
. O
['Life-Impact']

Two O
patients O
were O
colonised O
with O
enterobacteria O
in O
the O
oral O
cavity O
and O
stomach O
during O
the O
omeprazole O
plus O
amoxycillin O
treatment O
. O
[]

Corresponding O
median O
survival B-outcome ['Mortality']
times I-outcome ['Mortality']
were O
9.6 O
, O
9.3 O
, O
and O
7.3 O
months O
( O
P=0.61 O
) O
respectively O
. O
['Mortality']

Consequently O
, O
armodafinil O
produced O
greater O
increases O
in O
predicted O
placebo-subtracted O
MSLT O
times O
of O
0.5-1 O
minute O
( O
up O
to O
10 O
hours O
after O
dosing O
) O
compared O
with O
modafinil O
. O
[]

RESULTS O
The O
serum O
levels O
of O
TARC O
decreased O
significantly O
( O
P O
= O
0.004 O
) O
in O
boiled O
CM O
and O
in O
raw O
CM O
group O
( O
P O
= O
0.01 O
) O
too O
, O
but O
no O
effect O
was O
observed O
( O
P O
= O
0.68 O
) O
in O
placebo O
group O
. O
[]

OBJECTIVES O
The O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
meta-analysis O
suggested O
a O
survival O
benefit O
for O
cisplatin-based O
chemotherapy O
when O
given O
in O
addition O
to O
surgery O
, O
radical O
radiotherapy O
or O
'best O
supportive O
care O
' O
. O
[]

BACKGROUND O
Low O
HDL O
is O
associated O
with O
increased O
risk O
of O
cardiovascular O
disease O
. O
[]

There O
were O
no O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
drug B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects', 'Adverse-effects']

In O
an O
additional O
study O
, O
36 O
healthy O
male O
subjects O
received O
iv O
. O
[]

In O
addition O
, O
the O
combined O
treatments O
significantly O
promoted O
healing O
of O
rat B-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
whereas O
each O
agent O
alone O
had O
no O
significant O
effect O
as O
compared O
with O
control O
( O
saline O
) O
. O
['Physiological-Clinical']

The O
effects O
of O
chewing O
versus O
caffeine O
on O
alertness O
, O
cognitive O
performance O
and O
cardiac O
autonomic O
activity O
during O
sleep O
deprivation O
. O
[]

BACKGROUND O
The O
role O
of O
bronchodilators O
in O
the O
treatment O
of O
bronchiolitis O
remains O
controversial O
. O
[]

morphine O
( O
P O
< O
0.05 O
) O
. O
[]

The O
effect O
of O
Naftidrofuryl O
on O
ethanol-induced O
liver O
damage O
in O
chronic O
alcoholic O
patients O
. O
[]

Patients O
with O
poor O
general O
condition O
( O
Karnofsky O
score O
less O
than O
30 O
% O
) O
, O
poor O
pulmonary O
function O
( O
forced O
expiratory O
volume O
in O
1 O
second O
less O
than O
0.5 O
L O
) O
, O
or O
trapped O
lungs O
were O
excluded O
from O
this O
study O
. O
[]

In O
neither O
the O
test O
nor O
the O
control O
group O
, O
were O
there O
any O
differences O
between O
baseline O
and O
6 O
months O
regarding O
PPD B-outcome ['Physiological-Clinical']
and O
bone B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Monthly O
follow-up O
was O
done O
to O
assess O
tolerance O
, O
side O
effects O
and O
adherence O
. O
[]

The O
secondary O
end O
points O
were O
the O
combined O
incidence O
of O
death B-outcome ['Mortality']
, O
target B-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
nonfatal I-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
repeat B-outcome ['Resource-use']
angioplasty I-outcome ['Resource-use']
, O
and O
['Mortality', 'Physiological-Clinical', 'Resource-use']

There O
was O
a O
positive O
relationship O
between O
GH B-outcome ['Physiological-Clinical']
AUC I-outcome ['Physiological-Clinical']
and O
minimum B-outcome ['Physiological-Clinical']
BG I-outcome ['Physiological-Clinical']
in O
patients O
with O
PHD O
on O
treatment O
( O
r O
( O
2 O
) O
= O
0.45 O
, O
P O
= O
0.012 O
) O
with O
increased O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
off O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

0.8 O
% O
; O
P O
= O
0.006 O
) O
, O
and O
raised O
central O
PWV O
( O
6.0 O
? O
[]

This O
study O
assessed O
invasively O
the O
hemodynamics O
during O
supine O
rest O
and O
exercise O
before O
and O
after O
4 O
weeks O
treatment O
with O
30 O
mg O
isosorbide O
dinitrate O
( O
ISDN O
) O
or O
placebo O
asymmetrically O
b.i.d O
. O
[]

SUBJECTS O
47 O
children O
aged O
between O
1-12 O
years O
with O
acute O
severe O
asthma O
showing O
inadequate O
or O
poor O
response B-outcome ['Physiological-Clinical']
to O
3 O
doses O
of O
nebulized O
salbutamol O
given O
at O
an O
interval O
of O
20 O
min O
each O
. O
['Physiological-Clinical']

However O
, O
overall O
survival O
was O
worse O
in O
the O
the O
ganitumab O
group O
than O
in O
the O
placebo O
group O
( O
HR O
1?78 O
, O
80 O
% O
CI O
1?27-2?50 O
; O
p=0?025 O
) O
. O
[]

Nifedipine O
30 O
mg O
orally O
inhibited O
basal O
acid O
output O
by O
37 O
% O
( O
p O
less O
than O
0.025 O
) O
and O
that O
stimulated O
by O
low O
infusion O
rates O
of O
pentagastrin O
-- O
that O
is O
, O
0.031 O
and O
0.062 O
microgram/kg/h O
by O
44 O
% O
( O
p O
= O
0.05 O
) O
and O
39 O
% O
( O
p O
less O
than O
0.02 O
) O
respectively O
. O
[]

The O
patients O
were O
monitored O
by O
CMV-nested O
PCR O
in O
whole O
blood O
. O
[]

A O
choice O
assessment O
has O
been O
found O
to O
be O
a O
more O
accurate O
method O
of O
identifying O
preferences O
than O
is O
single-item O
presentation O
. O
[]

RESULTS O
At O
the O
end O
of O
treatment O
, O
12 O
, O
8 O
, O
and O
13 O
patients O
from O
groups O
A O
, O
B O
, O
and O
C O
, O
respectively O
, O
were O
responders O
. O
[]

Cost-effectiveness O
would O
be O
worse O
if O
prescribers O
do O
not O
comply O
with O
test O
results O
. O
['Resource-use']

After O
reoperation O
, O
anatomic B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
was O
100 O
% O
in O
both O
groups O
. O
['Physiological-Clinical']

RESULTS O
There O
was O
no O
difference O
between O
the O
study O
groups O
with O
respect O
to O
mental O
or O
physical O
health O
, O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
back O
pain O
disability O
, O
neurogenic B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
lost O
work O
time O
, O
likelihood O
of O
recurrence O
of O
an O
episode O
of O
a O
back O
['Physiological-Clinical', 'Physiological-Clinical']

Montelukast O
was O
significantly O
more O
effective O
than O
placebo O
( O
P O
= O
0.003 O
) O
in O
improving O
the O
daytime B-outcome ['Physiological-Clinical']
nasal I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
score O
( O
difference O
in O
least O
square O
means O
, O
-0.09 O
; O
95 O
% O
confidence O
interval O
, O
-0.16 O
, O
-0.03 O
) O
averaged O
over O
2 O
weeks O
of O
therapy O
. O
['Physiological-Clinical']

The O
SEM O
model O
constructed O
in O
this O
study O
suggested O
that O
one O
of O
the O
potential O
root O
causes O
was O
sleep B-outcome ['Physiological-Clinical']
disturbance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Both O
groups O
improved O
significantly O
in O
all O
measures O
of O
fitness O
and O
there O
were O
no O
significant O
post-test O
differences O
between O
the O
groups O
in O
the O
fitness O
measures O
. O
[]

To O
examine O
the O
continuing O
effects O
over O
time O
, O
an O
analysis O
of O
the O
data O
from O
54 O
patients O
who O
completed O
24 O
months O
of O
treatment O
with O
finasteride O
is O
provided O
. O
[]

Participants O
in O
the O
control O
group O
were O
each O
given O
a O
manual O
toothbrush O
and O
dental O
floss O
. O
[]

A O
third O
series O
of O
randomized O
tests O
was O
undertaken O
to O
evaluate O
the O
efficacy O
of O
postoperative O
adjuvant O
hormone O
therapy O
( O
tamoxifen O
, O
diethylstilbestrol O
, O
orimethen O
amino O
glutethymide O
) O
in O
breast O
cancer O
patients O
. O
[]

A O
prospective O
randomized O
study O
was O
carried O
out O
to O
evaluate O
the O
efficacy O
of O
surgical O
adjuvant O
chemotherapy O
for O
non-curatively O
resected O
colorectal O
carcinoma O
patients O
as O
a O
collaborative O
study O
at O
428 O
institutes O
in O
Japan O
from O
Jan. O
, O
1984 O
to O
Dec. O
, O
1985 O
. O
[]

More O
studies O
are O
needed O
to O
examine O
the O
relationship O
between O
blood B-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
NTD O
risk O
. O
['Physiological-Clinical']

Calcium O
channel O
blocker O
inhibition O
of O
AGE O
and O
RAGE O
axis O
limits O
renal B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
in O
nondiabetic O
patients O
with O
stage O
I O
or O
II O
chronic O
kidney O
disease O
. O
['Physiological-Clinical']

For O
FPV O
1,400 O
mg O
BID O
plus O
RTV O
100 O
mg O
BID O
, O
the O
values O
for O
plasma B-outcome ['Physiological-Clinical']
amprenavir I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
APV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
area O
under O
the O
concentration-time O
profile O
over O
the O
dosing O
interval O
( O
tau O
) O
at O
steady O
state O
[ O
AUC O
( O
0-tau O
) O
] O
, O
maximum O
concentration O
of O
drug B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
plasma O
concentration O
at O
the O
end O
of O
tau O
at O
steady B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
( O
C O
( O
tau O
) O
) O
were O
54 O
, O
81 O
, O
and O
26 O
% O
higher O
, O
respectively O
, O
and O
the O
values O
for O
plasma B-outcome ['Physiological-Clinical']
RTV I-outcome ['Physiological-Clinical']
AUC O
( O
0-tau O
) O
, O
C B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
C B-outcome ['Physiological-Clinical']
( O
tau O
) O
were O
49 O
% O
higher O
, O
71 O
% O
higher O
, O
and O
11 O
% O
lower O
, O
respectively O
, O
than O
those O
for O
FPV O
700 O
mg O
BID O
plus O
RTV O
100 O
mg O
BID O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Circulating B-outcome ['Physiological-Clinical']
tumour I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
were O
detected O
and O
monitored O
throughout O
treatment O
periods O
. O
['Physiological-Clinical']

They O
experienced O
significantly O
less O
stomatitis/mucositis B-outcome ['Physiological-Clinical']
( O
P O
< O
.001 O
) O
and O
myelosuppression B-outcome ['Physiological-Clinical']
, O
resulting O
in O
fewer O
episodes O
of O
febrile B-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
( O
P O
< O
.001 O
) O
and O
less O
documented B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( O
P O
=.04 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
, O
C B-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
and O
lipids B-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Fifty-nine O
mothers O
were O
randomized O
to O
receive O
PSE O
and O
63 O
to O
receive O
usual O
care O
. O
[]

RESULTS O
The O
ESDM O
group O
exhibited O
greater O
improvements O
in O
autism B-outcome ['Life-Impact']
symptoms B-outcome ['Life-Impact']
, O
['Life-Impact', 'Life-Impact']

BACKGROUND O
A O
smooth O
, O
cohesive O
, O
24-mg/mL O
hyaluronic O
acid O
( O
HA O
) O
gel O
with O
uniform O
consistency O
, O
even O
flow O
characteristics O
, O
and O
extended O
duration O
was O
designed O
for O
injection O
into O
the O
mid O
to O
deep O
dermis O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Finally O
, O
69 O
% O
of O
parents O
in O
the O
enriched O
group O
and O
31 O
% O
of O
parents O
in O
the O
control O
group O
reported O
improvement O
in O
their O
child O
over O
the O
6-month O
study O
. O
[]

Participants O
were O
scored O
on O
functional O
scales O
at O
baseline O
and O
after O
treatment O
by O
a O
physician O
blinded O
to O
group O
assignment O
. O
[]

Twelve O
patients O
were O
given O
fluoxetine O
( O
20 O
mg/d O
) O
plus O
zinc O
( O
440 O
mg/d O
) O
and O
11 O
patients O
were O
given O
fluoxetine O
plus O
placebo O
for O
8 O
wk O
. O
[]

Thus O
, O
the O
use O
of O
chemotherapy O
when O
combined O
with O
aggressive O
local O
measures O
appears O
to O
improve O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
but O
additional O
patients O
and O
longer O
follow-up O
are O
necessary O
to O
determine O
if O
improved O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
will O
result O
. O
['Mortality', 'Mortality']

MAIN O
OUTCOME O
MEASURES O
Plasmatic O
levels O
of O
total O
antioxidant O
status O
as O
well O
as O
erythrocyte B-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical']

17 O
years O
, O
who O
presented O
a O
median O
of O
84 O
months O
after O
chemotherapy O
with O
a O
cumulative O
anthracycline O
exposure O
of O
282 O
? O
[]

Induction O
time O
was O
prolonged O
in O
the O
group O
E1 O
compared O
to O
the O
other O
two O
groups O
( O
P O
< O
0.05 O
) O
. O
[]

RESULTS O
Parecoxib O
reduced O
pain B-outcome ['Physiological-Clinical']
scores O
at O
6 O
h O
and O
morphine O
use O
at O
6 O
and O
12 O
h O
after O
operation O
. O
['Physiological-Clinical']

in O
1989 O
, O
which O
confirmed O
the O
possibility O
of O
laparoscopic O
hysterectomy O
being O
employed O
as O
a O
replacement O
of O
the O
vast O
majority O
of O
traditional O
abdominal O
hysterectomies O
. O
[]

Response O
rates O
to O
surveys O
are O
decreasing O
. O
[]

PURPOSE O
To O
evaluate O
survival O
and O
time O
to O
metastatic O
disease O
in O
patients O
treated O
for O
localized O
prostatic O
carcinoma O
in O
a O
Phase O
III O
radiotherapy O
( O
RT O
) O
protocol O
, O
Radiation O
Therapy O
Oncology O
Group O
( O
RTOG O
) O
77-06 O
. O
[]

In O
vitro O
and O
in O
vivo O
studies O
have O
shown O
that O
carbon O
monoxide O
( O
CO O
) O
has O
both O
anti-inflammatory O
and O
anti-oxidant O
capacities O
. O
[]

Accordingly O
, O
the O
authors O
used O
mood O
inventories O
and O
psychomotor O
tests O
to O
characterize O
the O
effects O
of O
remifentanil O
in O
healthy O
, O
non-drug-abusing O
volunteers O
. O
[]

INTERPRETATION O
Treatment O
with O
gefitinib O
was O
not O
associated O
with O
significant O
improvement O
in O
survival B-outcome ['Mortality']
in O
either O
coprimary O
population O
. O
['Mortality']

Five O
trigger O
points O
received O
0.2 O
ml O
each O
of O
injectant O
via O
a O
30 O
gauge O
needle O
. O
[]

Ejection B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
decreased O
insignificantly O
with O
RV O
pacing O
compared O
to O
significant O
increase O
with O
BiV O
pacing O
. O
['Physiological-Clinical']

We O
conclude O
that O
( O
1 O
) O
Clo O
? O
[]

Adults O
with O
haematological O
malignancies O
receiving O
chemotherapy O
or O
bone O
marrow O
transplants O
were O
randomly O
allocated O
5 O
mg/kg/d O
itraconazole O
( O
itra O
) O
solution O
( O
288 O
episodes O
) O
or O
100 O
mg O
fluconazole O
suspension O
( O
flu O
) O
( O
293 O
episodes O
) O
from O
before O
the O
onset O
of O
neutropenia O
until O
neutrophil O
recovery O
or O
suspected O
fungal O
infection O
. O
[]

RESULTS O
Two-hundred O
seven O
patients O
were O
enrolled O
between O
December O
1 O
, O
2006 O
and O
December O
14 O
, O
2007 O
, O
producing O
189 O
evaluable O
cases O
for O
analysis O
. O
[]

All O
patients O
were O
operated O
on O
under O
spinal O
anesthesia O
. O
[]

Genes O
specific O
for O
benefit O
from O
R-FC O
were O
determined O
by O
assessing O
treatment-gene O
interactions O
in O
Cox O
proportional O
hazards O
models O
. O
[]

RESULTS O
Regardless O
of O
treatment O
arm O
, O
participants O
reported O
high O
levels O
of O
QOL B-outcome ['Life-Impact']
with O
few O
exceptions O
. O
['Life-Impact']

The O
effects O
of O
treatment O
with O
interleukin-1 O
receptor O
antagonist O
on O
the O
inflamed O
synovial O
membrane O
in O
rheumatoid O
arthritis O
. O
[]

Intramuscular O
phenobarbitone O
is O
well O
absorbed O
in O
children O
with O
severe O
malaria O
; O
the O
optimum O
prophylactic O
anticonvulsant O
dose O
remains O
to O
be O
determined O
. O
[]

Randomisation O
was O
done O
by O
computer-generated O
randomly O
permuted O
blocks O
and O
stratified O
by O
centre O
and O
LVEF O
( O
< O
or=30 O
% O
or O
> O
30 O
% O
) O
. O
[]

RESULTS O
Among O
202 O
patients O
who O
received O
ketorolac O
and O
417 O
who O
did O
not O
, O
ketorolac O
use O
was O
associated O
with O
decreased O
pneumonia B-outcome ['Physiological-Clinical']
( O
odds O
ratio O
, O
.14 O
; O
95 O
% O
confidence O
interval O
, O
.04 O
to O
.46 O
) O
and O
increased O
ventilator-free B-outcome ['Resource-use']
days I-outcome ['Resource-use']
( O
difference O
, O
1.8 O
days O
; O
95 O
% O
confidence O
interval O
, O
1.1 O
to O
2.5 O
) O
and O
intensive B-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit-free I-outcome ['Resource-use']
days I-outcome ['Resource-use']
( O
difference O
, O
2.1 O
days O
; O
95 O
% O
confidence O
interval O
, O
1.3 O
to O
3.0 O
) O
within O
30 O
days O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use']

Assessments O
were O
conducted O
at O
pretreatment O
, O
posttreatment O
, O
and O
three-week O
follow-up O
. O
[]

For O
all O
models O
rectal O
bleeding O
fits O
had O
the O
highest O
AUC O
( O
0.77 O
) O
where O
it O
was O
0.63 O
and O
0.68 O
for O
high O
stool O
frequency O
and O
fecal O
incontinence O
, O
respectively O
. O
[]

This O
study O
evaluated O
the O
clinical O
effects O
of O
one O
SRP O
procedure O
alone O
or O
combined O
with O
local O
administration O
of O
hydrogen O
peroxide O
gel O
using O
customized O
trays O
for O
the O
treatment O
of O
subjects O
with O
chronic O
periodontitis O
over O
a O
period O
of O
six O
months O
. O
[]

Forty-five O
male O
patients O
( O
mean O
age O
, O
57 O
+/- O
6 O
years O
) O
were O
randomly O
assigned O
to O
( O
1 O
) O
TENS O
, O
( O
2 O
) O
placebo O
TENS O
, O
or O
( O
3 O
) O
control O
treatments O
( O
n O
= O
15 O
each O
) O
, O
following O
extubation O
and O
during O
the O
24- O
to O
72-h O
postoperative O
period O
. O
[]

BACKGROUND O
Incidence O
and O
severity O
of O
herpes O
zoster O
( O
HZ O
) O
and O
postherpetic O
neuralgia O
increase O
with O
age O
, O
associated O
with O
age-related O
decrease O
in O
immunity O
to O
varicella-zoster O
virus O
( O
VZV O
) O
. O
[]

The O
response O
per O
24 O
h O
of O
chemotherapy O
was O
defined O
as O
complete O
( O
no O
nausea O
and O
vomiting O
) O
, O
partial O
( O
1-4 O
events O
of O
vomiting O
and/or O
nausea O
) O
, O
and O
failure O
( O
more O
than O
4 O
events O
of O
vomiting O
and/or O
nausea O
) O
. O
[]

Clarithromycin O
reduces O
the O
severity O
of O
bronchial B-outcome ['Physiological-Clinical']
hyperresponsiveness I-outcome ['Physiological-Clinical']
in O
patients O
with O
asthma O
. O
['Physiological-Clinical']

OBJECTIVE O
One-third O
of O
the O
total O
population O
seems O
to O
develop O
minor O
recurrent O
aphthous O
stomatitis O
( O
RAS O
) O
during O
their O
lifetime O
. O
[]

Their O
therapeutic O
effects O
were O
observed O
, O
and O
the O
picture O
and O
vocabulary O
scale O
( O
PPVT O
) O
and O
behavior B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
were O
detected O
. O
['Life-Impact']

Furthermore O
, O
oxytocin O
and O
the O
closely O
related O
peptide O
vasopressin O
are O
known O
to O
play O
a O
role O
in O
social O
and O
repetitive O
behaviors O
. O
[]

In O
patients O
with O
pT2/T3 O
primary O
tumors O
, O
10-year O
survival B-outcome ['Mortality']
was O
55.3 O
% O
for O
BCG O
+ O
FAM O
vs O
28.2 O
% O
for O
FAM O
( O
P O
< O
0.01 O
) O
and O
14.6 O
% O
for O
the O
control O
group O
( O
P O
< O
0.00018 O
) O
. O
['Mortality']

t.w O
. O
[]

RESULT O
( O
S O
) O
Intervention O
and O
control O
were O
similarly O
effective O
for O
infertile O
women O
: O
the O
rate O
of O
maintained B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
rose O
significantly O
from O
4 O
% O
to O
24 O
% O
over O
twelve O
months O
, O
with O
a O
mean O
delta O
stage-of-change O
0.28 O
. O
['Life-Impact']

Serum B-outcome ['Physiological-Clinical']
Na+ I-outcome ['Physiological-Clinical']
levels O
were O
significantly O
higher O
predialysis O
and O
postdialysis O
for O
those O
patients O
on O
Na+ O
modeling O
. O
['Physiological-Clinical']

The O
aim O
of O
the O
present O
study O
was O
to O
examine O
the O
effect O
of O
8 O
weeks O
of O
assisted O
exercise O
on O
bone O
strength O
and O
metabolism O
in O
VLBW O
premature O
infants O
. O
[]

The O
task O
involved O
the O
recognition O
of O
a O
specific O
illusory O
shape O
, O
in O
this O
case O
a O
square O
or O
triangle O
, O
created O
by O
three O
or O
four O
inducer O
disks O
. O
[]

No O
consultations O
were O
aborted O
; O
however O
, O
technical B-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
( O
74 O
% O
) O
were O
prevalent O
in O
the O
telemedicine O
arm O
. O
['Life-Impact']

OBJECTIVE O
This O
study O
compared O
differences O
in O
nurse O
and O
patient B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
profiles I-outcome ['Life-Impact']
between O
two O
telehealth O
modes O
: O
telephone O
and O
videophone O
, O
and O
evaluated O
longitudinal O
changes O
in O
communication B-outcome ['Life-Impact']
, O
nurse B-outcome ['Life-Impact']
perceptions I-outcome ['Life-Impact']
, O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
median O
[]

The O
highest O
rates O
of O
dropouts B-outcome ['Life-Impact']
occurred O
between O
the O
first O
and O
second O
treatment O
visits O
in O
both O
smokers O
( O
38 O
% O
dropout O
) O
and O
non-smokers O
( O
18 O
% O
dropout O
) O
. O
['Life-Impact']

Baseline O
attention O
was O
then O
used O
to O
separate O
low O
and O
high O
attenders O
. O
[]

Intermittent O
Holter O
monitoring O
, O
radionuclide O
ventriculograms O
, O
pulmonary O
function O
tests O
, O
echocardiograms O
, O
and O
blood O
tests O
, O
including O
arterial O
blood O
gases O
, O
will O
be O
required O
for O
each O
patient O
. O
( O
[]

A O
double-blind O
controlled O
trial O
. O
[]

The O
frequency O
of O
breakfast O
consumption O
was O
examined O
using O
a O
6?4 O
cross-tabulation O
table O
with O
? O
( O
[]

The O
survey O
was O
carried O
out O
from O
October O
1995 O
to O
February O
1996 O
. O
[]

Twenty O
six O
subjects O
were O
randomized O
to O
the O
intervention O
( O
no O
. O
[]

The O
clinical O
data O
of O
percentage O
of O
deep O
probing O
depth O
, O
deep O
clinical O
attachment O
level O
, O
and O
bleeding O
on O
probing O
were O
found O
to O
be O
correlated O
significantly O
with O
oral O
health O
impacts O
. O
[]

INTERVENTIONS O
In O
the O
clonidine O
protocol O
, O
clonidine O
was O
administered O
every O
4 O
hours O
as O
needed O
for O
up O
to O
12 O
days O
. O
[]

METHODS O
We O
have O
developed O
a O
low-tilt O
biphasic O
waveform O
for O
defibrillation O
. O
[]

Subjective O
and O
blinded O
physician O
evaluations O
were O
performed O
at O
baseline O
and O
4 O
, O
8 O
, O
and O
20 O
weeks O
posttreatment O
using O
a O
nominal O
scale O
from O
1 O
to O
4 O
. O
[]

The O
114 O
patients O
with O
healed O
ulcer O
were O
observed O
on O
no O
therapy O
and O
underwent O
additional O
endoscopy O
to O
detect O
recurrences O
when O
symptomatic O
or O
at O
3 O
, O
6 O
, O
and O
12 O
mo O
. O
[]

Impact O
of O
a O
16-community O
trial O
to O
promote O
judicious O
antibiotic O
use O
in O
Massachusetts O
. O
[]

NCE O
decreased O
linearly O
( O
P O
< O
0.05 O
) O
as O
the O
level O
of O
RDN O
increased O
. O
[]

The O
effects O
of O
chloroquine O
, O
amodiaquine O
and O
chloroquine O
plus O
chlorpheniramine O
on O
the O
disposition O
kinetics O
of O
the O
hepatomegaly O
associated O
with O
acute O
, O
uncomplicated O
, O
Plasmodium O
falciparum O
malaria O
in O
children O
. O
[]

The O
patients O
were O
divided O
into O
two O
groups O
( O
20 O
in O
each O
) O
. O
[]

Eighteen O
subjects O
were O
treated O
in O
a O
crossover O
design O
with O
oral O
placebo/intravenous O
saline O
, O
50 O
mg O
of O
oral O
SDZ O
ENS-163/intravenous O
saline O
, O
oral O
placebo/0.4 O
mg O
of O
intravenous O
scopolamine O
, O
and O
50 O
mg O
of O
oral O
SDZ O
ENS-163/0.4 O
mg O
of O
intravenous O
scopolamine O
. O
[]

day O
1 O
. O
[]

The O
mean O
breathing O
patterns O
of O
seven O
normal O
, O
healthy O
male O
subjects O
and O
eight O
male O
patients O
who O
had O
undergone O
upper O
abdominal O
surgery O
2-4 O
days O
previously O
were O
studied O
breathing O
through O
a O
mouthpiece O
fitted O
in O
random O
order O
with O
a O
5 O
, O
6 O
, O
7 O
, O
8 O
, O
or O
15 O
mm O
diameter O
( O
17 O
mm O
long O
) O
resistor O
. O
[]

Patients O
were O
matched O
for O
patient O
factors O
, O
preoperative O
deformities O
, O
cruciate O
salvage O
or O
sacrifice O
, O
and O
surgical O
technique O
. O
[]

Statistics O
are O
mean O
+/- O
standard O
deviation O
. O
[]

BACKGROUND O
WHO O
has O
targeted O
lymphatic O
filariasis O
for O
elimination O
. O
[]

The O
volumetric O
wear O
rate O
has O
been O
greatly O
reduced O
with O
MOM O
arthroplasties O
; O
however O
, O
because O
of O
nano-size O
wear O
particles O
, O
the O
absolute O
number O
has O
been O
greatly O
increased O
. O
[]

They O
reported O
a O
decrease O
in O
hyperactivity B-outcome ['Life-Impact']
and O
irritability B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

line B-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
when O
analyzed O
separately O
for O
both O
short O
and O
long O
lines O
. O
['Life-Impact']

Patients O
with O
newly O
diagnosed O
small-cell O
lung O
cancer O
( O
SCLC O
) O
were O
treated O
with O
CAE O
chemotherapy O
( O
cyclophosphamide O
, O
doxorubicin O
, O
and O
etoposide O
) O
and O
placebo O
or O
filgrastim O
. O
[]

After O
adjusting O
for O
certain O
baseline O
characteristics O
, O
diabetes O
was O
independently O
associated O
with O
death B-outcome ['Mortality']
at O
9 O
months O
( O
relative O
risk O
[ O
RR O
] O
, O
1.87 O
; O
95 O
% O
CI O
, O
1.31 O
to O
2.68 O
, O
P O
< O
0.01 O
) O
and O
with O
an O
increased O
likelihood O
of O
TVR B-outcome ['Physiological-Clinical']
( O
RR O
, O
1.27 O
; O
95 O
% O
CI O
, O
1.14 O
to O
1.42 O
, O
P O
< O
0.01 O
) O
, O
as O
well O
as O
the O
composite O
end O
point O
of O
death/myocardial B-outcome ['Mortality']
infarction/TVR I-outcome ['Mortality']
( O
RR O
, O
1.26 O
; O
95 O
% O
CI O
, O
1.13 O
to O
1.40 O
, O
P O
< O
0.01 O
) O
. O
['Mortality', 'Physiological-Clinical', 'Mortality']

We O
applied O
external O
flow O
resistive O
( O
R O
) O
and O
elastic O
( O
E O
) O
mechanical O
loads O
over O
the O
entire O
respiratory O
cycle O
to O
five O
normal O
subjects O
by O
using O
a O
pseudorandom O
loading O
protocol O
. O
[]

Evaluation O
of O
a O
device O
to O
facilitate O
female O
urethral O
catheterization O
. O
[]

The O
effects O
of O
torasemide O
( O
20 O
mg/day O
) O
and O
furosemide O
( O
50 O
mg/day O
) O
, O
each O
given O
over O
4 O
days O
, O
were O
compared O
in O
a O
randomized O
and O
crossover O
study O
carried O
out O
in O
seven O
patients O
with O
cirrhosis O
and O
tense O
ascites O
. O
[]

Though O
propofol O
seemed O
to O
be O
better O
for O
effectiveness O
and O
safety O
, O
there O
were O
no O
statistically O
significant O
differences O
for O
all O
three O
primary O
end O
points O
and O
the O
safety O
parameters O
( O
hypotension B-outcome ['Physiological-Clinical']
, O
hypoxia B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

Mode O
of O
ventilation O
during O
cardiopulmonary O
bypass O
does O
not O
affect O
immediate O
postbypass O
oxygenation O
in O
pediatric O
cardiac O
patients O
. O
[]

[ O
The O
effect O
of O
losartan O
versus O
atenolol O
on O
cardiovascular O
morbidity O
and O
mortality B-outcome ['Mortality']
in O
patients O
with O
diabetes O
mellitus O
in O
the O
LIFE-study O
] O
. O
['Mortality']

AIM O
To O
assess O
the O
efficacy O
of O
a O
mandibular O
advancement O
splint O
( O
MAS O
) O
in O
the O
treatment O
of O
obstructive B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
apnoea I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OSAS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
introduced O
a O
double-blind O
controlled O
clinical O
study O
to O
compare O
intravenous O
human O
epidermal O
growth O
factor O
( O
hEGF O
) O
to O
cetraxate O
hydrochloride O
( O
CH O
) O
, O
an O
antiulcer O
drug O
, O
for O
their O
healing O
effect O
on O
gastric B-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
will O
be O
the O
first O
double-blind O
randomized O
controlled O
trial O
for O
this O
health O
technology O
which O
evaluates O
the O
efficacy O
of O
hyperbaric O
oxygen O
therapy O
in O
prevention O
of O
amputations B-outcome ['Resource-use']
in O
diabetic O
patients O
. O
['Resource-use']

CHF O
patients O
with O
clinical O
features O
-- O
with O
( O
156 O
( O
28 O
) O
IU/dl O
) O
and O
without O
( O
152 O
( O
31 O
) O
IU/dl O
) O
LV O
dysfunction O
-- O
also O
had O
higher O
mean O
vWf B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
than O
patients O
with O
asymptomatic O
LV O
dysfunction O
( O
146 O
( O
31 O
) O
IU/dl O
, O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Two O
basic O
statistical O
methods O
were O
used O
in O
declaring O
the O
overall B-outcome ['Mortality']
mortality I-outcome ['Mortality']
results O
significant O
. O
['Mortality']

CONCLUSIONS O
Physicians O
possessed O
explicit O
and O
implicit O
racial O
biases O
, O
but O
those O
biases O
did O
not O
predict O
treatment O
recommendations O
. O
[]

CONCLUSION O
Both O
treatments O
led O
to O
similar O
control O
of O
eosinophilic B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
, O
although O
PEF O
and O
symptom O
control O
were O
better O
with O
SFC O
. O
['Physiological-Clinical']

Clonidine O
administration O
increased O
the O
sweating O
threshold O
approximately O
0.4 O
degree O
C O
( O
P O
< O
0.05 O
) O
, O
but O
the O
increase O
was O
comparable O
at O
each O
dose O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

Asymptomatic B-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
were O
relatively O
infrequent O
and O
daily B-outcome ['Life-Impact']
drug I-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
was O
high O
. O
['Physiological-Clinical', 'Life-Impact']

METHODS O
Spring-calved O
dairy O
cows O
were O
grazed O
for O
101 O
days O
in O
paddocks O
that O
were O
either O
not O
fertilised O
( O
Control O
; O
n=20 O
) O
during O
the O
course O
of O
the O
study O
, O
or O
were O
fertilised O
with O
40-50 O
kg O
nitrogen O
( O
N O
) O
/ha O
every O
4-6 O
weeks O
( O
High-N O
; O
n=20 O
) O
. O
[]

Trachoma O
prevalence O
and O
associated O
risk O
factors O
in O
the O
gambia O
and O
Tanzania O
: O
baseline O
results O
of O
a O
cluster O
randomised O
controlled O
trial O
. O
[]

A O
1.5-year O
follow-up O
of O
an O
Internet-based O
intervention O
for O
complicated O
grief O
. O
[]

The O
fracture B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
with O
risedronate O
2.5 O
mg O
was O
similar O
to O
that O
in O
the O
5 O
mg O
group O
over O
2 O
years O
. O
['Physiological-Clinical']

We O
used O
a O
novel O
visuospatial O
task O
to O
test O
the O
hypothesis O
that O
visual O
imagery O
plays O
a O
key O
role O
in O
craving B-outcome ['Life-Impact']
. O
['Life-Impact']

Decrease O
in O
VEGFR2 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
significantly O
associated O
with O
response O
rate O
( O
P O
= O
0.02 O
) O
. O
['Physiological-Clinical']

We O
report O
the O
results O
of O
a O
randomized O
trial O
of O
more O
than O
1000 O
subjects O
that O
examined O
the O
efficacy O
of O
dexamethasone O
and O
IV O
6-mercaptopurine O
. O
[]

METHODS O
Fifty-nine O
HIV-infected O
women O
were O
enrolled O
in O
a O
randomized O
double-blind O
placebo-controlled O
study O
comparing O
6 O
% O
CS O
to O
placebo O
gel O
used O
for O
14 O
days O
. O
[]

CONCLUSIONS O
Locally O
administered O
sirolimus O
was O
well-tolerated O
with O
minimal O
systemic O
exposure O
at O
all O
doses O
tested O
in O
this O
small O
phase O
I O
population O
. O
[]

The O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions I-outcome ['Physiological-Clinical']
scale O
indicated O
that O
clonidine O
produced O
a O
significant O
improvement O
on O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
, O
global B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
, O
and O
efficacy O
index O
for O
therapeutic O
effect O
of O
the O
drug O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Between O
September O
2002 O
and O
September O
2004 O
, O
among O
a O
group O
of O
postoperative O
children O
with O
large O
septal O
defects O
, O
moderate O
to O
severe O
pulmonary O
hypertension O
[ O
pulmonary O
artery O
( O
PA O
) O
to O
aortic O
( O
Ao O
) O
pressure O
ratio O
of O
0.76 O
+/- O
0.17 O
] O
and O
systemic O
desaturation O
( O
Ao O
Sat O
= O
0.89 O
+/- O
0.11 O
) O
, O
oral O
sildenafil O
( O
0.3 O
mg O
x O
kg O
( O
-1 O
) O
, O
every O
3 O
hours O
) O
was O
administered O
for O
a O
period O
of O
24-48 O
hours O
( O
sildenafil O
group O
) O
. O
[]

TRIAL O
REGISTRATION O
CLINICAL O
TRIAL O
REGISTRATION O
NUMBER O
NCT01225198 O
. O
[]

Thus O
, O
in O
cases O
in O
which O
Hispanic O
patients O
were O
provided O
intervention O
by O
a O
Hispanic O
clinician O
improved O
drinking O
outcomes O
were O
expected O
. O
[]

CONCLUSIONS O
Activated O
CECs O
and O
survivin O
may O
be O
ideal O
markers O
forecasting O
efficacy O
and O
prognosis O
of O
NSCLC O
. O
[]

Twenty-nine O
patients O
undergoing O
cholecystectomy O
because O
of O
chronic O
calculous O
cholecystitis O
were O
randomised O
to O
receive O
phenylbutazone O
10 O
mg/kg O
intramuscularly O
or O
a O
control O
injection O
( O
vehicle-containing O
local O
anaesthetic O
) O
immediately O
after O
completion O
of O
surgery O
. O
[]

UNLABELLED O
We O
conducted O
this O
randomized O
, O
double-blinded O
, O
comparative O
, O
parallel-group O
study O
to O
determine O
whether O
adding O
EDTA O
to O
propofol O
would O
affect O
the O
clinical O
profile O
, O
calcium O
and O
magnesium O
homeostasis O
, O
or O
renal O
function O
in O
healthy O
children O
. O
[]

Neither O
platelet B-outcome ['Physiological-Clinical']
adhesiveness I-outcome ['Physiological-Clinical']
nor O
aggregation O
rate O
changed O
. O
['Physiological-Clinical']

The O
larger O
and O
small O
forceps O
were O
used O
in O
a O
random O
sequence O
to O
avoid O
a O
reduction O
in O
diagnostic O
yield O
of O
the O
second O
series O
of O
biopsies O
related O
to O
possible O
bleeding O
by O
first O
series O
of O
biopsies O
. O
[]

Several O
hypotheses O
are O
discussed O
, O
highlighting O
the O
selective O
nature O
of O
the O
effect O
of O
soy O
consumption O
in O
the O
population O
. O
[]

As O
expected O
, O
older O
patients O
had O
more O
co-morbidity O
. O
[]

PURPOSE O
To O
estimate O
the O
safety O
, O
activity B-outcome ['Life-Impact']
, O
and O
['Life-Impact']

METHODS O
A O
total O
of O
60 O
consecutive O
men O
admitted O
from O
a O
waiting O
list O
for O
surgery O
for O
benign O
prostatic O
hyperplasia O
( O
BPH O
) O
were O
prospectively O
randomized O
to O
either O
PKVP O
or O
TURP O
. O
[]

Multivariate O
analysis O
in O
this O
same O
age O
group O
showed O
that O
the O
intervention O
was O
independently O
associated O
with O
a O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
distress I-outcome ['Physiological-Clinical']
as O
perceived O
by O
parents O
based O
on O
the O
mean O
change O
in O
visual O
analog O
scale O
scores O
. O
['Physiological-Clinical']

SETTING O
University O
laboratory O
. O
[]

Intrathecal O
( O
IT O
) O
methotrexate O
was O
the O
sole O
central O
nervous O
system-directed O
therapy O
. O
[]

For O
LMO2 O
similar O
results O
on O
survival O
outcome O
were O
seen O
thus O
showing O
no O
difference O
in O
5 O
years O
OS B-outcome ['Mortality']
or O
EFS B-outcome ['Mortality']
- O
regardless O
of O
subtype O
or O
treatment O
modality O
. O
['Mortality', 'Mortality']

METHODS O
The O
authors O
randomly O
selected O
subjects O
for O
cavity O
preparation O
with O
conventional O
air O
turbine/bur O
dental O
surgery O
or O
an O
Er O
, O
Cr O
: O
YSGG O
laser-powered O
system O
using O
a O
split-mouth O
design O
. O
[]

Lisinopril O
vs. O
placebo O
significantly O
improved O
whole B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
disposal I-outcome ['Physiological-Clinical']
( O
40.4 O
+/- O
0.4 O
vs. O
30.3 O
+/- O
0.4 O
mumol/kg O
LBM O
x O
min O
; O
P O
< O
0.01 O
) O
, O
non-oxidative B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
( O
18.1 O
+/- O
0.7 O
vs. O
10.9 O
+/- O
0.6 O
mumol/kg O
LBM O
x O
min O
; O
P O
< O
0.01 O
) O
and O
fasting B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
levels O
( O
4.8 O
+/- O
3 O
vs. O
4.4 O
+/- O
0.4 O
mmol/l O
; O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
intervention O
group O
showed O
less O
decline O
in O
function B-outcome ['Life-Impact']
, O
as O
measured O
by O
disability O
days O
and O
lower O
scores O
on O
the O
Health B-outcome ['Physiological-Clinical']
Assessment O
Questionnaire O
. O
['Life-Impact', 'Physiological-Clinical']

Major O
complication O
was O
defined O
as O
wound B-outcome ['Physiological-Clinical']
dehiscence I-outcome ['Physiological-Clinical']
or O
wound B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
that O
the O
perineal O
wound O
should O
be O
reopened O
for O
drainage O
. O
['Physiological-Clinical', 'Physiological-Clinical']

When O
patients O
were O
divided O
into O
two O
different O
disease O
cohorts O
, O
ALL O
patients O
showed O
no O
difference O
in O
engraftment B-outcome ['Physiological-Clinical']
kinetics I-outcome ['Physiological-Clinical']
between O
the O
G-CSF O
treatment O
and O
control O
groups O
, O
while O
differences O
were O
seen O
in O
those O
with O
solid O
tumors O
. O
['Physiological-Clinical']

METHODS O
In O
this O
study O
, O
88 O
patients O
6-17 O
years O
of O
age O
, O
with O
ADHD O
and O
ASD O
, O
were O
treated O
with O
1.2 O
mg/kg/day O
atomoxetine O
for O
20 O
weeks O
as O
follow-up O
of O
an O
8 O
week O
double-blind O
placebo-controlled O
period O
. O
[]

The O
reasons O
are O
discussed O
for O
the O
disparity O
between O
this O
result O
and O
those O
reported O
in O
the O
literature O
when O
folate O
polyglutamates O
derived O
from O
yeast O
were O
used O
. O
[]

After O
starting O
the O
electrocardiogram O
record O
, O
a O
27-gauge O
needle O
was O
inserted O
into O
the O
skin O
of O
a O
forearm O
. O
[]

Sputum O
cells O
and O
supernatant O
levels O
of O
ECP O
, O
sICAM B-outcome ['Physiological-Clinical']
, O
IL-5 B-outcome ['Physiological-Clinical']
and O
IL-10 B-outcome ['Physiological-Clinical']
, O
and O
plasma O
levels O
of O
IL-5 O
and O
ECP O
, O
were O
measured O
before O
and O
24 O
h O
after O
nasal O
allergen O
challenge O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
main O
outcome O
measure O
was O
the O
Mental B-outcome ['Life-Impact']
Development I-outcome ['Life-Impact']
Index O
( O
MDI O
) O
of O
the O
Bayley O
Scales O
of O
Infant O
Development O
, O
2nd O
edition O
, O
assessed O
at O
36 O
months O
by O
evaluators O
unaware O
of O
treatment O
group O
and O
resuscitation O
history O
. O
['Life-Impact']

The O
purpose O
of O
this O
study O
was O
to O
test O
whether O
remission O
from O
geriatric O
depression O
depends O
on O
lesion B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
region I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
interest I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ROI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
study O
investigated O
whether O
prolonged O
use O
of O
theophylline O
retains O
efficacy O
for O
counterregulatory B-outcome ['Physiological-Clinical']
defects I-outcome ['Physiological-Clinical']
in O
patients O
with O
type O
1 O
diabetes O
and O
hypoglycemia O
unawareness O
. O
['Physiological-Clinical']

The O
effects O
of O
trimetazidine O
( O
20 O
mg O
three O
times O
daily O
) O
were O
compared O
with O
those O
of O
propranolol O
( O
40 O
mg O
three O
times O
daily O
) O
in O
a O
double-blind O
parallel O
group O
multicentre O
study O
in O
149 O
men O
with O
stable O
angina O
. O
[]

Results O
indicate O
that O
the O
parent-delivered O
component O
of O
the O
program O
provided O
effective O
early O
intervention O
for O
autism O
that O
was O
suitable O
for O
delivery O
at O
home O
. O
[]

It O
also O
resulted O
in O
a O
25-hour O
reduction O
in O
time O
of O
hospitalization O
. O
[]

IMPACT O
This O
study O
confirms O
the O
overall O
importance O
of O
the O
HOXB13 O
G84E O
mutation O
in O
prostate O
cancer O
susceptibility O
. O
[]

A O
randomized O
controlled O
trial O
of O
itraconazole O
versus O
fluconazole O
for O
the O
prevention O
of O
fungal B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
patients O
with O
haematological O
malignancies O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
objective O
of O
this O
study O
was O
to O
determine O
if O
African-American O
renal O
transplant O
patients O
who O
received O
direct O
patient O
care O
from O
a O
clinical O
pharmacist O
had O
better O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
compared O
to O
African-American O
renal O
transplant O
patients O
who O
did O
not O
have O
clinical O
pharmacy O
services O
. O
['Physiological-Clinical']

There O
was O
a O
significant O
relationship O
between O
failure O
of O
the O
fixation O
and O
varus O
reduction O
( O
p O
= O
0.04 O
) O
as O
well O
as O
screw/neck O
angle O
deviation O
more O
than O
20 O
degrees O
in O
the O
lateral O
projection O
( O
p O
= O
0.005 O
) O
or O
if O
the O
implant O
was O
in O
a O
superior O
or O
posterior O
position O
( O
p O
= O
0.02 O
) O
. O
[]

The O
prevalences O
of O
PONV O
were O
significantly O
lower O
with O
propofol O
and O
droperidol O
compared O
with O
metoclopramide O
0.2 O
mg/kg O
and O
placebo O
. O
[]

Ventilator-delivered O
mask O
ventilation O
compared O
with O
three O
standard O
methods O
of O
mask O
ventilation O
in O
a O
manikin O
model O
. O
[]

CONCLUSION O
Although O
it O
is O
necessary O
to O
consider O
all O
factors O
which O
can O
have O
an O
influence O
on O
SSI O
and O
use O
all O
the O
means O
shown O
to O
be O
effective O
to O
reduce O
the O
risk O
of O
SSI O
, O
there O
is O
a O
rationale O
for O
using O
ORC O
to O
prevent O
this O
kind O
of O
infection O
, O
especially O
in O
patients O
who O
undergo O
dirty O
surgery O
. O
[]

METHODS O
Of O
130 O
patients O
with O
locally O
advanced O
, O
unresectable O
, O
nonmetastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
( O
SCC O
H O
& O
N O
) O
who O
entered O
a O
prospective O
, O
randomised O
trial O
, O
101 O
patients O
received O
50.6 O
Gy O
to O
a O
portion O
of O
their O
spinal O
cord O
and O
survived O
> O
1 O
year O
following O
the O
beginning O
of O
therapy O
. O
[]

CONCLUSION O
These O
results O
suggest O
that O
activated O
charcoal O
can O
be O
used O
safely O
for O
victims O
of O
acetaminophen O
overdose O
. O
[]

Amifostine O
( O
300 O
mg/m O
( O
2 O
) O
) O
was O
administered O
in O
the O
study O
group O
only O
15-30 O
min O
before O
RT O
for O
6-7.5 O
weeks O
. O
[]

CONCLUSION O
( O
S O
) O
For O
infertile O
women O
, O
basic O
information O
describing O
the O
impact O
of O
smoking O
on O
fertility O
, O
along O
with O
exhaled O
CO O
monitoring O
and O
a O
more O
intensive O
intervention O
were O
both O
highly O
effective O
. O
[]

for O
5 O
days O
, O
and O
repeated O
at O
21-day O
intervals O
for O
a O
maximum O
of O
four O
cycles O
. O
[]

It O
is O
preferred O
by O
patients O
, O
is O
more O
convenient B-outcome ['Life-Impact']
, O
and O
probably O
aids O
compliance B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
patients O
were O
divided O
into O
two O
groups O
: O
dose-dense O
and O
regular O
groups O
. O
[]

The O
present O
study O
examined O
the O
effect O
of O
repeated O
vaccination O
and O
of O
dehydroepiandrosterone O
( O
DHEA O
) O
treatment O
on O
the O
immune O
response O
to O
influenza O
vaccine O
in O
elderly O
subjects O
. O
[]

DESIGN O
Prospective O
study O
. O
[]

In O
a O
double O
blind O
study O
, O
alcohol/onion O
extract O
( O
5 O
% O
ethanol O
) O
was O
injected O
simultaneously O
with O
20 O
IU O
and O
200 O
IU O
rabbit O
anti-human-IgE O
intradermally O
in O
12 O
adult O
volunteers O
( O
6 O
atopics O
, O
6 O
non-atopics O
) O
. O
[]

BFST-D O
improved O
individual O
communication O
of O
adolescents O
and O
mothers O
, O
but O
not O
fathers O
. O
[]

Three O
long-term O
survivors B-outcome ['Mortality']
were O
seen O
in O
the O
latter O
group O
. O
['Mortality']

SUBJECTS O
Six O
hundred-seven O
women O
requiring O
assisted O
vaginal O
delivery O
, O
of O
whom O
296 O
were O
allocated O
to O
vacuum O
extractor O
delivery O
and O
311 O
to O
forceps O
. O
[]

In O
a O
subgroup O
of O
patients O
undergoing O
interventional O
bronchoscopy O
, O
there O
was O
a O
trend O
towards O
lower O
SBP B-outcome ['Physiological-Clinical']
( O
p=0.06 O
) O
. O
['Physiological-Clinical']

METHODS O
Patients O
with O
acute O
nonspecific O
low O
back O
pain O
and O
a O
paid O
job O
were O
included O
for O
analysis O
. O
[]

The O
acne-specific O
quality O
of O
life O
( O
Acne-QoL O
) O
questionnaire O
was O
developed O
to O
measure O
the O
impact O
of O
facial B-outcome ['Physiological-Clinical']
acne I-outcome ['Physiological-Clinical']
across O
4 O
domains O
( O
acne O
symptoms O
, O
role-emotional O
, O
self-perception O
, O
role-social O
) O
of O
health-related B-outcome ['Physiological-Clinical']
quality O
of O
life O
( O
HRQL B-outcome ['Life-Impact']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

BACKGROUND O
An O
imbalance O
in O
the O
excitatory/inhibitory O
systems O
with O
abnormalities O
in O
the O
glutamatergic O
pathways O
has O
been O
implicated O
in O
the O
pathophysiology O
of O
autism O
. O
[]

The O
predicted O
gastrin-time O
profile O
showed O
a O
higher O
response O
in O
CYP2C19 O
PMs O
than O
in O
EMs O
on O
days O
4 O
and O
7 O
. O
[]

Pharmacokinetic B-outcome ['Physiological-Clinical']
and O
safety O
assessments O
of O
concurrent O
administration O
of O
risperidone O
and O
donepezil O
. O
['Physiological-Clinical']

To O
maintain O
the O
integrity O
of O
the O
study O
results O
, O
none O
of O
the O
patients O
received O
preanesthetic O
medication O
. O
[]

When O
compared O
to O
the O
IM O
and O
C O
Groups O
, O
the O
ID O
Group O
showed O
improved O
survival B-outcome ['Mortality']
. O
['Mortality']

The O
first O
investigation O
in O
a O
period O
was O
made O
without O
medication O
. O
[]

CONCLUSION O
Treatment O
of O
diabetic O
patients O
with O
post O
amputation O
wounds O
using O
NPWT O
resulted O
in O
lower O
[]

Safety O
was O
evaluated O
for O
28 O
days O
postvaccination O
. O
[]

= O
1.19 O
, O
P O
= O
0.004 O
respectively O
) O
. O
[]

An O
intravenous O
infusion O
of O
glyceryl O
trinitrate O
( O
GTN O
) O
was O
used O
to O
assess O
possible O
nitrate O
tolerance O
. O
[]

The O
main O
outcome O
was O
gingival B-outcome ['Physiological-Clinical']
index O
( O
GI O
) O
, O
an O
indicator O
of O
gingival O
inflammation O
. O
['Physiological-Clinical']

Face O
processing O
in O
adolescents O
with O
autistic O
disorder O
: O
The O
inversion O
and O
composite O
effects O
. O
[]

In O
addition O
, O
tumour O
is O
present O
at O
the O
resection O
margin O
in O
approximately O
30 O
% O
of O
clinical O
T2 O
( O
clinical O
stage O
B O
) O
cases O
. O
[]

INTERVENTIONS O
An O
intravenous O
loading O
dose O
was O
followed O
by O
an O
8-hour O
infusion O
of O
MK-571 O
or O
placebo O
, O
with O
a O
7- O
to O
14-day O
washout O
between O
treatments O
. O
[]

RESULTS O
There O
was O
no O
difference O
in O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
between O
MEDI-545 O
and O
placebo O
. O
['Adverse-effects']

When O
compared O
with O
the O
baseline O
values O
, O
all O
measured O
variables O
at O
60 O
months O
improved O
significantly O
( O
p O
< O
0.0001 O
) O
. O
[]

The O
primary O
efficacy O
measure O
was O
the O
Aberrant O
Behavior O
Checklist-Irritability O
( O
ABC-I O
) O
subscale O
. O
['Life-Impact']

Glycogen B-outcome ['Physiological-Clinical']
levels O
were O
also O
higher O
in O
the O
treated O
group O
, O
but O
the O
difference O
was O
not O
statistically O
significant O
. O
['Physiological-Clinical']

Our O
power O
calculations O
indicate O
a O
sample O
size O
of O
112 O
is O
required O
for O
both O
primary O
outcomes O
. O
[]

Central O
nervous O
system O
serotonin O
function O
and O
cardiovascular B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
stress O
. O
['Physiological-Clinical']

Height O
and O
weight O
data O
were O
available O
at O
baseline O
for O
788 O
( O
83 O
% O
) O
subjects O
. O
[]

Pain O
ratings O
decreased O
over O
the O
next O
3 O
days O
. O
['Physiological-Clinical']

We O
chose O
these O
chemotherapy O
regimens O
because O
they O
have O
been O
shown O
in O
nonrandomized O
studies O
to O
provide O
good O
symptom O
control O
as O
recorded O
by O
patients O
. O
[]

A O
cohort O
study O
within O
the O
TOMBOLA O
trial O
. O
[]

RESULTS O
A O
total O
of O
182 O
patients O
( O
94 O
in O
the O
EBUS O
CDPs O
group O
and O
88 O
in O
the O
EBUS-TBNA O
plus O
CDPs O
group O
) O
were O
analyzed O
. O
[]

RESULTS O
The O
total O
effective O
rate O
in O
the O
treated O
group O
reached O
92 O
% O
, O
it O
was O
shown O
that O
SXN O
could O
improve O
the O
iron O
metabolism O
, O
increase O
levels O
of O
Fe O
, O
TS O
, O
SF O
and O
reduce O
levels O
of O
TIBC O
, O
Tf O
, O
sTfR O
, O
it O
has O
obvious O
effect O
in O
promoting O
erythrocyte O
generation O
and O
could O
promote O
formation O
of O
leucocytes O
and O
platelets O
. O
[]

The O
mean O
dmft O
of O
those O
screening O
positive O
was O
4.85 O
. O
[]

We O
investigated O
whether O
parents O
of O
young O
children O
on O
the O
autism O
spectrum O
could O
learn O
and O
implement O
the O
specific O
categories O
of O
verbal O
responsiveness O
that O
have O
been O
suggested O
to O
facilitate O
language O
development O
. O
[]

Decreased O
expression O
of O
Yes-associated B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
is O
associated O
with O
outcome O
in O
the O
luminal O
A O
breast O
cancer O
subgroup O
and O
with O
an O
impaired O
tamoxifen O
response O
. O
['Physiological-Clinical']

RESULTS O
Thirty-two O
subjects O
( O
seven O
with O
autism O
, O
16 O
with O
autism O
and O
SIB O
, O
and O
nine O
with O
SIB O
) O
completed O
the O
trial O
. O
[]

Myoclonic O
astatic O
epilepsy O
is O
therefore O
distinct O
from O
Lennox-Gastaut O
syndrome O
, O
and O
the O
distinction O
appears O
from O
the O
first O
year O
of O
the O
disorder O
. O
[]

Total O
mortality B-outcome ['Mortality']
did O
not O
differ O
significantly O
between O
the O
two O
groups O
; O
the O
relative O
risk O
of O
death B-outcome ['Mortality']
for O
staple O
transection O
as O
compared O
with O
sclerotherapy O
was O
0.88 O
( O
95 O
percent O
confidence O
interval O
, O
0.51 O
to O
1.54 O
) O
. O
['Mortality', 'Mortality']

At O
the O
end O
of O
the O
procedure O
, O
the O
ovarian O
ties O
were O
released O
but O
the O
uterine O
artery O
suture O
remained O
in O
situ O
. O
[]

2012 O
American O
Cancer O
Society O
. O
[]

The O
Finnish O
Diabetes O
Prevention O
Study O
. O
[]

4 O
patients O
experienced O
serious O
adverse O
events O
( O
1 O
major O
bleed O
after O
traumatic O
arteriovenous O
fistula O
puncture O
in O
the O
tinzaparin O
arm O
, O
2 O
non-ST-elevation O
myocardial O
infarctions O
[ O
1 O
in O
each O
group O
] O
, O
and O
1 O
upper-extremity O
deep O
venous O
thrombosis O
[ O
dalteparin O
group O
] O
) O
. O
[]

Similar O
generous O
pasture O
allowances O
were O
offered O
to O
both O
groups O
. O
[]

We O
have O
evaluated O
the O
relationship O
of O
systemic O
TNF O
exposure O
to O
induction O
of O
several O
secondary B-outcome ['Physiological-Clinical']
mediators I-outcome ['Physiological-Clinical']
and O
incidence O
of O
systemic O
toxicity B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

It O
was O
a O
randomized O
controlled O
study O
employing O
a O
single O
subject O
comparison O
design O
in O
two O
different O
conditions O
, O
improvisational O
music O
therapy O
and O
play O
sessions O
with O
toys O
, O
and O
using O
standardized O
tools O
and O
DVD O
analysis O
of O
sessions O
to O
evaluate O
behavioral O
changes O
in O
children O
with O
autism O
. O
[]

Immunohistochemical O
analysis O
was O
performed O
using O
anti O
HMGB1 O
antibodies O
and O
the O
expression O
of O
HMGB1 O
protein O
in O
the O
spinal O
cord O
was O
determined O
by O
western O
blot O
analysis O
after O
intrathecal O
delivery O
( O
n O
= O
8 O
each O
) O
. O
[]

Renal O
biopsy O
studies O
showed O
no O
differences O
between O
the O
two O
groups O
in O
terms O
of O
incidence O
and O
severity O
of O
the O
histologic B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Sixty O
minutes O
after O
L-arginine O
or O
saline O
infusions O
, O
an O
intravenous O
insulin O
bolus O
( O
0.1 O
U/kg O
) O
combined O
with O
a O
euglycemic O
clamp O
was O
performed O
. O
[]

STUDY O
DESIGN O
Randomized O
, O
cross-over O
, O
experimental O
trial O
. O
[]

Changing O
the O
threshold-age O
to O
60 O
years O
, O
67 O
% O
of O
the O
study O
population O
would O
receive O
a O
boost O
and O
the O
5-year O
local B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
would O
be O
reduced O
to O
4.4 O
% O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
effect O
of O
budesonide O
Turbuhaler O
400 O
microg/day O
with O
budesonide O
aqua O
256 O
microg/day O
in O
the O
treatment O
of O
seasonal O
allergic O
rhinitis O
( O
SAR O
) O
. O
[]

All O
induction O
regimens O
produced O
a O
significant O
improvement O
in O
symptom B-outcome ['Physiological-Clinical']
and O
medication B-outcome ['Resource-use']
usage I-outcome ['Resource-use']
( O
p O
< O
0.0001 O
) O
; O
skin O
test O
scores O
decreased O
( O
p O
< O
0.0001 O
) O
and O
FEV1 B-outcome ['Physiological-Clinical']
improved I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

SRP O
was O
performed O
three O
weeks O
after O
baseline O
, O
and O
clinical O
assessments O
, O
i.e. O
, O
pocket B-outcome ['Physiological-Clinical']
probing I-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
( O
PPD B-outcome ['Physiological-Clinical']
) O
and O
bleeding B-outcome ['Physiological-Clinical']
index O
( O
BI B-outcome ['Physiological-Clinical']
) O
, O
were O
conducted O
at O
baseline O
and O
after O
two O
, O
five O
, O
13 O
, O
and O
26 O
weeks O
of O
peroxide O
gel O
applications O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Terazosin O
( O
5 O
mg O
) O
combined O
with O
methyclothiazide O
( O
2.5 O
to O
5 O
mg O
) O
produced O
a O
significantly O
greater O
( O
p O
less O
than O
0.01 O
) O
antihypertensive B-outcome ['Resource-use']
effect O
than O
that O
of O
terazosin O
alone O
. O
['Resource-use']

In O
colorectal O
cancer O
, O
BRAF O
mutation O
is O
associated O
with O
microsatellite O
instability O
( O
MSI O
) O
, O
and O
typically O
predicts O
inferior O
prognosis O
. O
[]

In O
addition O
, O
this O
application O
also O
provides O
evidence O
to O
support O
a O
change O
in O
the O
label O
to O
allow O
for O
an O
escalation O
of O
imatinib O
dosing O
to O
800 O
mg/day O
for O
patients O
with O
progressive O
disease O
on O
a O
lower O
dose O
. O
[]

Does O
tetanus O
immune O
globulin O
interfere O
with O
the O
immune B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
simultaneous O
administration O
of O
tetanus-diphtheria O
vaccine O
? O
['Physiological-Clinical']

Infants O
nursed O
with O
a O
postural O
support O
roll O
either O
with O
or O
without O
a O
postural O
support O
nappy O
demonstrated O
improved O
shoulder B-outcome ['Physiological-Clinical']
posture I-outcome ['Physiological-Clinical']
to O
term O
equivalent O
age O
. O
['Physiological-Clinical']

A O
low O
intention B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
be I-outcome ['Life-Impact']
physically I-outcome ['Life-Impact']
active I-outcome ['Life-Impact']
was O
a O
strong O
predictor O
for O
dropout O
within O
both O
delivery O
modes O
( O
P O
< O
.001 O
) O
. O
['Life-Impact']

RESULTS O
In O
nine O
control O
patients O
, O
there O
were O
no O
significant O
changes O
in O
the O
severity O
of O
OSA B-outcome ['Physiological-Clinical']
, O
MSNA B-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
, O
or O
HR B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
experimental O
group O
received O
auditory O
training O
and O
the O
control O
group O
listened O
to O
the O
same O
unmodified O
music O
under O
the O
same O
conditions O
. O
[]

The O
secondary O
endpoint O
will O
include O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
, O
antioxidant B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
and O
incidence O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
who O
received O
naloxone O
( O
n O
= O
58 O
) O
showed O
significant O
increases O
in O
mean O
scores O
on O
all O
three O
rating O
scales O
, O
but O
this O
was O
due O
primarily O
to O
increases O
observed O
in O
a O
minority O
of O
patients O
. O
[]

This O
phenomenon O
has O
not O
yet O
been O
reported O
for O
LTD4 O
. O
[]

This O
study O
showed O
that O
imidapril O
, O
an O
ACE O
inhibitor O
, O
might O
be O
useful O
for O
the O
improvement O
of O
fibrinolytic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
the O
acute O
phase O
of O
myocardial O
infarction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
optimal O
duration O
of O
exercise O
for O
bone O
development O
in O
preterm O
infants O
is O
yet O
unknown O
. O
[]

Most O
patients O
responding O
to O
pre-operative O
therapy O
remained O
recurrence-free B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Ten O
out O
of O
18 O
patients O
responded O
to O
fluvoxamine O
treatment O
; O
allele O
type O
analysis O
revealed O
that O
clinical O
global O
effectiveness O
was O
noted O
significantly O
more O
in O
the O
l O
allele O
than O
in O
the O
s O
allele O
. O
[]

Patients O
with O
autism O
spectrum O
disorders O
showed O
a O
significant O
reduction O
in O
[]

We O
assessed O
the O
sensitivity O
and O
specificity O
of O
the O
questionnaire O
to O
identify O
VDI B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
25 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
level O
< O
50 O
nmol/l O
) O
. O
['Physiological-Clinical']

Data O
for O
two O
doses O
( O
165-microg/injection O
[ O
35 O
eyes O
, O
30 O
patients O
] O
and O
330-microg/injection O
[ O
153 O
eyes O
, O
120 O
patients O
] O
) O
and O
two O
330-microg/injection O
dose O
schedules O
of O
different O
intensity O
were O
pooled O
to O
calculate O
incidence O
rates O
for O
each O
event O
. O
[]

Diet O
A O
, O
an O
average O
American O
diet O
, O
was O
designed O
to O
provide O
37 O
% O
of O
energy O
from O
fat O
, O
16 O
% O
of O
energy O
from O
saturated O
fatty O
acids O
( O
SFAs O
) O
; O
diet O
B O
( O
step O
1 O
diet O
) O
was O
designed O
to O
provide O
30 O
% O
of O
energy O
from O
fat O
, O
9 O
% O
of O
energy O
from O
SFA O
; O
and O
diet O
C O
( O
low O
SFA O
diet O
) O
was O
designed O
to O
provide O
26 O
% O
of O
energy O
from O
fat O
, O
5 O
% O
of O
energy O
from O
SFA O
. O
[]

Prostanoid B-outcome ['Physiological-Clinical']
biosynthesis I-outcome ['Physiological-Clinical']
was O
not O
inhibited O
. O
['Physiological-Clinical']

Histologic B-outcome ['Physiological-Clinical']
distribution B-outcome ['Physiological-Clinical']
was O
18 O
% O
S O
, O
3.7 O
% O
CC O
, O
8.5 O
% O
mixed O
, O
51.7 O
% O
E O
and O
18.1 O
% O
other O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
all O
serum O
catecholamine O
concentration O
changes O
were O
within O
normal O
limits O
in O
both O
groups O
, O
after O
endoscopy O
only O
epinephrine O
concentration O
was O
significantly O
lower O
in O
the O
sedated O
group O
than O
in O
the O
non-sedated O
group O
( O
P O
= O
0.0027 O
) O
. O
[]

Of O
5 O
patients O
who O
were O
oliguric O
and O
undergoing O
dialysis O
at O
presentation O
, O
only O
3 O
who O
were O
treated O
by O
plasmapheresis O
recovered O
. O
[]

Patients O
were O
evaluated O
weekly O
, O
and O
gastrointestinal B-outcome ['Physiological-Clinical']
toxicities I-outcome ['Physiological-Clinical']
were O
graded O
according O
to O
the O
Late O
Effect O
of O
Normal O
Tissue-Subjective O
Objective O
Management O
Analytic O
( O
LENT-SOMA O
) O
toxicity B-outcome ['Adverse-effects']
['Physiological-Clinical', 'Adverse-effects']

INTRODUCTION O
To O
evaluate O
the O
outcome O
of O
cystoid O
macular O
edema O
treated O
with O
intravitreal O
injections O
of O
bevacizumab O
and O
macular O
grid O
laser O
photocoagulation O
( O
GLP O
) O
, O
in O
patients O
with O
perfused O
branch O
retinal O
vein O
occlusion O
. O
[]

Parents O
were O
taught O
to O
increase O
their O
verbal O
responsiveness O
in O
the O
context O
of O
a O
short-term O
language O
intervention O
that O
included O
group O
parent O
education O
sessions O
, O
as O
well O
as O
individual O
and O
small-group O
coaching O
sessions O
of O
parent-child O
play O
interactions O
. O
[]

METHOD O
The O
sample O
comprised O
24 O
children O
( O
19 O
boys O
; O
5 O
girls O
) O
who O
met O
American O
Psychiatric O
Association O
, O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
4th O
ed O
. O
( O
[]

We O
aimed O
to O
test O
a O
new O
theoretically O
based O
social O
communication O
intervention O
targeting O
parental O
communication O
in O
a O
randomised O
design O
against O
routine O
care O
alone O
. O
[]

This O
behavior O
checklist O
( O
57 O
items O
) O
allows O
the O
detailed O
description O
of O
non-adaptable O
characteristics O
regarding O
the O
following O
areas O
: O
sensory B-outcome ['Life-Impact']
, O
use B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
body I-outcome ['Life-Impact']
and O
object B-outcome ['Life-Impact']
, O
Language B-outcome ['Life-Impact']
, O
Psycho-social B-outcome ['Life-Impact']
and O
Relational B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

On O
the O
other O
hand O
, O
changes O
in O
intragastric O
pH O
might O
alter O
the O
absorption O
of O
other O
drugs O
. O
[]

Rye O
bran O
intervention O
had O
no O
influence O
on O
lag O
time O
or O
propagation B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

0.07 O
G/L O
) O
compared O
to O
samples O
collected O
before O
filter O
passage O
( O
1.73 O
? O
[]

Low-frequency O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rTMS O
) O
affects O
event-related O
potential O
measures O
of O
novelty O
processing O
in O
autism O
. O
[]

METHODS O
Lansoprazole O
or O
ranitidine O
was O
given O
to O
133 O
patients O
for O
4-8 O
weeks O
in O
a O
double-blind O
, O
randomized O
, O
parallel O
group O
, O
multicentre O
trial O
. O
[]

Concerning O
parameters O
of O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
, O
first O
ICTP O
as O
marker O
of O
bone B-outcome ['Physiological-Clinical']
resorption I-outcome ['Physiological-Clinical']
showed O
a O
significant O
increase O
, O
later O
on O
the O
marker O
of O
bone B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
increased O
as O
well O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
results O
challenge O
previous O
claims O
that O
selective B-outcome ['Life-Impact']
induction I-outcome ['Life-Impact']
in O
children O
is O
the O
product O
of O
implicit O
learning O
. O
['Life-Impact']

In O
the O
development O
set O
, O
these O
2 O
variables O
demonstrated O
respective O
sensitivity O
and O
specificity O
of O
98 O
% O
and O
90 O
% O
for O
LAD O
lesions O
, O
82 O
% O
and O
85 O
% O
for O
right O
narrowings O
, O
and O
82 O
% O
and O
84 O
% O
for O
LC O
narrowings O
. O
[]

In O
the O
subgroup O
of O
Avastin-treated O
eyes O
, O
multivariate O
analysis O
identified O
hemoglobin O
A1c O
as O
the O
strongest O
predictor O
of O
proliferative B-outcome ['Physiological-Clinical']
diabetic I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

PURPOSE O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
anecortave O
acetate O
treatment O
of O
retinal O
angiomatous O
proliferation O
( O
RAP O
) O
, O
a O
neovascular O
form O
of O
age-related O
macular O
degeneration O
, O
with O
specific O
regard O
to O
inhibition O
of O
neovascularization B-outcome ['Physiological-Clinical']
and O
maintenance B-outcome ['Physiological-Clinical']
of O
vision B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
sufficiently O
long O
lead-time O
needs O
to O
be O
achieved O
so O
that O
cancer O
can O
be O
detected O
while O
still O
curable O
. O
[]

Gestational B-outcome ['Physiological-Clinical']
age O
, O
weight O
loss B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

In O
apical O
third O
, O
AH O
plus O
was O
adapted B-outcome ['Life-Impact']
better I-outcome ['Life-Impact']
adpated O
to O
dentine O
than O
EndoRez O
. O
['Life-Impact']

The O
prevalences O
of O
clinical B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
['Adverse-effects']

One O
patient O
had O
visual B-outcome ['Physiological-Clinical']
hallucinations I-outcome ['Physiological-Clinical']
after O
a O
2 O
mg. O
dose O
of O
butorphanol O
, O
possibly O
owing O
to O
its O
antagonistic O
activity O
to O
significant O
narcotic O
experience O
given O
previously O
at O
another O
hospital O
. O
['Physiological-Clinical']

PARTICIPANTS O
Participants O
( O
n O
= O
1758 O
) O
were O
visitors O
to O
the O
QUIT O
website O
who O
were O
based O
in O
the O
United O
Kingdom O
, O
aged O
18 O
years O
or O
over O
and O
who O
smoked O
cigarettes O
or O
hand-rolled O
tobacco O
. O
[]

Effects O
of O
two O
combined O
hormonal O
contraceptives O
with O
the O
same O
composition O
and O
different O
doses O
on O
female O
sexual O
function O
and O
plasma O
androgen O
levels O
. O
[]

The O
primary O
objective O
was O
assessed O
by O
evaluating O
outcome O
variables O
at O
6 O
months O
compared O
with O
baseline O
in O
25 O
patients O
randomly O
assigned O
to O
a O
study O
group O
. O
[]

Estrogen O
therapy O
may O
increase O
the O
risk O
of O
arterial O
thromboembolism O
, O
at O
least O
in O
the O
short O
term O
. O
[]

Intakes O
of O
marine O
food O
products O
and O
EPA O
and O
DHA O
were O
estimated O
by O
FFQ O
on O
the O
basis O
of O
consumption O
of O
marine O
food O
products O
in O
the O
last O
month O
. O
[]

A O
standard O
general O
anaesthetic O
technique O
was O
employed O
throughout O
. O
[]

METHODS O
Pediatric O
patients O
( O
age O
3-13 O
years O
) O
undergoing O
EDAMS O
surgery O
for O
moyamoya O
disease O
were O
randomly O
divided O
into O
a O
nerve O
block O
( O
NB O
) O
group O
( O
18 O
cases O
) O
or O
control O
group O
( O
21 O
cases O
) O
. O
[]

Randomized O
crossover O
study O
comparing O
efficacy O
of O
transnasal O
endoscopy O
with O
that O
of O
standard O
endoscopy O
to O
detect O
Barrett O
's O
esophagus O
. O
[]

Median O
changes O
in O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
( O
mg/dL O
) O
at O
week O
96 O
were O
similar O
to O
week O
48 O
. O
['Physiological-Clinical']

Along O
with O
that O
, O
patients O
in O
Group O
A O
received O
nitroglycerin O
; O
patients O
in O
Group O
B O
received O
nitroprusside O
instead O
of O
nitroglycerin O
; O
and O
patients O
in O
Group O
C O
received O
both O
nitroglycerin O
and O
nitroprusside O
. O
[]

The O
acceptability O
curve O
showed O
that O
, O
even O
in O
the O
case O
of O
a O
maximum O
threshold O
value O
of O
?80,000 O
per O
QALY O
gained O
, O
the O
probability O
of O
AS O
being O
more O
cost-effective O
than O
regular O
cardiac O
surgery O
did O
not O
reach O
beyond O
50 O
% O
. O
[]

Hypotensive O
effects O
and O
influence O
on O
serum B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
of O
SQ29,852 O
, O
a O
new O
angiotensin O
converting O
enzyme O
inhibitor O
, O
in O
patients O
with O
essential O
hypertension O
: O
a O
comparison O
with O
atenolol O
. O
['Physiological-Clinical']

Concluding O
, O
the O
present O
study O
is O
the O
first O
controlled O
trial O
to O
demonstrate O
that O
adults O
with O
ASD O
can O
benefit O
from O
MBT-AS O
. O
[]

[ O
Effectiveness O
of O
adjuvant O
hormone O
therapy O
in O
breast O
cancer O
] O
. O
[]

Hospitalization B-outcome ['Resource-use']
was O
longer O
( O
9.3 O
+/- O
5.0 O
versus O
7.7 O
+/- O
4.4 O
days O
, O
p O
= O
0.046 O
) O
and O
more O
costly B-outcome ['Resource-use']
( O
$ O
25,191 O
+/- O
15,368 O
versus O
$ O
19,643 O
+/- O
7,250 O
, O
p O
< O
0.02 O
) O
. O
['Resource-use', 'Resource-use']

MATERIALS O
AND O
METHODS O
Two O
groups O
of O
40 O
consecutive O
asymptomatic O
patients O
aged O
between O
48 O
and O
72 O
years O
underwent O
CT O
colonography O
. O
[]

In O
this O
paper O
, O
we O
report O
on O
parent O
satisfaction O
in O
a O
randomized O
clinical O
trial O
in O
children O
with O
autistic O
disorder O
and O
severely O
disruptive O
behavior O
. O
[]

53.3 O
% O
[ O
( O
RR O
) O
= O
0.47 O
, O
95 O
% O
CI O
: O
0.41-0.55 O
] O
, O
( O
P O
< O
0.001 O
) O
and O
day O
7 O
: O
96.6 O
% O
vs O
. O
[]

WHO/ISH O
Hypertension O
Guidelines O
from O
1999 O
propose O
a O
risk O
stratification O
for O
estimating O
absolute O
risk O
for O
CVD O
based O
on O
blood O
pressure O
and O
additional O
risk O
factors O
, O
target O
organ O
damage O
( O
TOD O
) O
and O
CVD O
. O
[]

BACKGROUND O
The O
saline O
solution O
load O
test O
helps O
to O
determine O
if O
a O
wound O
extends O
into O
the O
knee O
joint O
. O
[]

The O
lungs O
were O
ventilated O
to O
normocapnia O
. O
[]

OBJECTIVE O
To O
observe O
the O
therapeutic O
effects O
of O
limbal O
epithelial O
autograft O
transplantation O
and O
pterygium O
excision O
in O
the O
treatment O
of O
pterygium O
. O
[]

Our O
primary O
outcome O
measure O
was O
the O
benzodiazepine O
on/off O
status O
of O
the O
elderly O
PPGP O
members O
. O
['Resource-use']

FUNDING O
St O
Jude O
Medical O
. O
[]

Primary O
radiotherapy O
( O
RT O
) O
is O
the O
treatment O
of O
choice O
for O
OPSCC O
at O
most O
centers O
, O
and O
over O
the O
last O
decade O
, O
the O
addition O
of O
concurrent O
chemotherapy O
has O
led O
to O
a O
significant O
improvement O
in O
survival O
, O
but O
at O
the O
cost O
of O
increased O
acute O
and O
late O
toxicity O
. O
[]

RESULTS O
Behavioral O
results O
indicated O
a O
significant O
reduction O
in O
tension B-outcome ['Life-Impact']
and O
a O
marginally O
significant O
reduction O
in O
anxiety B-outcome ['Life-Impact']
for O
children O
who O
received O
the O
deep O
pressure O
compared O
with O
the O
children O
who O
did O
not O
. O
['Life-Impact']

No O
significant O
differences O
between O
the O
two O
interventions O
were O
found O
in O
any O
of O
the O
observations O
. O
[]

BACKGROUND O
Upper O
gastrointestinal O
endoscopy O
( O
UGIE O
) O
may O
cause O
some O
cardiac O
stress O
. O
[]

Amonafide O
was O
chosen O
for O
inclusion O
in O
the O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
) O
master O
metastatic O
breast O
cancer O
protocol O
. O
[]

In O
a O
prospective O
controlled O
clinical O
study O
interactions O
between O
nondepolarizing O
muscle O
relaxants O
and O
acylaminopenicillins O
were O
investigated O
electromyographically O
. O
[]

Our O
objective O
was O
to O
investigate O
possible O
mechanisms O
underlying O
the O
lack O
of O
mortality B-outcome ['Mortality']
benefit O
in O
the O
Defibrillation O
in O
Acute O
Myocardial O
Infarction O
Trial O
( O
DINAMIT O
) O
. O
['Mortality']

Side O
effects O
and O
extrapyramidal O
symptoms O
were O
systematically O
recorded O
throughout O
the O
study O
and O
were O
assessed O
using O
a O
checklist O
and O
the O
Extrapyramidal O
Symptoms O
Rating O
Scale O
, O
administered O
by O
a O
resident O
of O
psychiatry O
during O
weeks O
1 O
, O
2 O
, O
4 O
, O
6 O
and O
8 O
. O
[]

There O
have O
been O
no O
adequate O
randomized O
controlled O
trials O
with O
sufficient O
power O
comparing O
this O
modality O
with O
other O
therapies O
. O
[]

Treatment O
effect O
sizes O
were O
more O
favorable O
for O
the O
treatment O
group O
compared O
with O
the O
placebo O
group O
( O
communication O
: O
treatment O
groups O
, O
0.87 O
vs O
, O
placebo O
, O
0.44 O
; O
social O
withdrawal O
: O
treatment O
groups O
, O
0.88 O
, O
vs O
placebo O
, O
0.54 O
) O
. O
[]

One O
patient O
in O
the O
amlodipine O
camsylate O
group O
dropped O
out O
of O
the O
study O
at O
week O
0 O
of O
treatment O
( O
this O
patient O
did O
not O
use O
any O
study O
medication O
) O
and O
was O
excluded O
from O
the O
modified O
intent-to-treat O
( O
ITT O
) O
analysis O
. O
[]

Both O
treatments O
were O
administered O
at O
a O
dose O
of O
0.25 O
mg/kg O
once O
a O
day O
with O
the O
possibility O
of O
doubling O
this O
dose O
to O
0.5 O
mg/kg O
if O
considered O
necessary O
from O
a O
clinical O
point O
of O
view O
. O
[]

Percutaneous O
absorption O
was O
enhanced O
through O
the O
use O
of O
polyethylene O
film O
occlusion O
( O
5 O
h O
) O
. O
[]

The O
five O
outcomes O
were O
examined O
separately O
using O
analysis O
of O
covariance O
controlling O
for O
age O
and O
severity O
of O
past B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Dose O
reduction O
lowered O
SVR B-outcome ['Physiological-Clinical']
frequencies I-outcome ['Physiological-Clinical']
, O
but O
to O
a O
lesser O
extent O
than O
disease O
severity O
. O
['Physiological-Clinical']

It O
became O
evident O
that O
the O
recurrence B-outcome ['Physiological-Clinical']
rate O
in O
the O
doxorubicin O
or O
epirubicin O
instillation O
arm O
was O
lower O
that O
in O
the O
no O
instillation O
arm O
. O
['Physiological-Clinical']

There O
were O
no O
statistically O
significant O
differences O
found O
in O
the O
improvement O
of O
Ferriman-Gallwey O
scores O
between O
the O
two O
treatment O
arms O
, O
although O
the O
power O
to O
detect O
a O
difference O
was O
limited O
by O
the O
small O
sample O
size O
. O
[]

During O
hypertensive O
crises O
( O
systolic O
blood O
pressure O
exceeding O
200 O
mmHg O
and O
diastolic O
blood O
pressure O
exceeding O
115 O
mmHg O
) O
forty O
hypertensive O
patients O
received O
either O
25 O
mg O
of O
SLC O
or O
10 O
mg O
of O
SLN O
in O
a O
randomized O
single O
blind O
fashion O
. O
[]

The O
trial O
includes O
economic B-outcome ['Resource-use']
evaluation O
. O
['Resource-use']

Magnetic O
resonance O
images O
from O
the O
two O
examinations O
were O
compared O
and O
changes O
in O
rupture O
configuration O
were O
evaluated O
. O
[]

0.04 O
) O
, O
attributable O
to O
a O
narrower O
CIMT O
and O
wider O
lumen O
. O
[]

A O
similar O
procedure O
was O
done O
simultaneously O
on O
the O
other O
arm O
with O
KY O
jelly O
only O
( O
placebo O
) O
. O
[]

Low O
grade O
lymphomas O
( O
16 O
patients O
) O
received O
a O
cyclophosphamide O
, O
vincristine O
, O
prednisone O
association O
. O
[]

Similar O
data O
were O
obtained O
when O
comparing O
GH O
area O
under O
the O
curve O
after O
GHRH O
plus O
saline O
or O
GHRH O
plus O
arginine O
between O
the O
2 O
groups O
. O
[]

Treatment O
with O
various O
drugs O
has O
been O
attempted O
, O
but O
none O
has O
resulted O
in O
cure O
or O
complete O
virus O
elimination O
. O
[]

Direct O
renin O
inhibition O
improves O
parasympathetic O
function O
in O
diabetes O
. O
[]

After O
the O
failure O
of O
torcetrapib O
it O
was O
unknown O
if O
HDL O
produced O
by O
interaction O
with O
CETP O
had O
pro-atherogenic O
or O
pro-inflammatory O
properties O
. O
[]

and O
efavirenz O
( O
600 O
mg O
q.d O
. O
) O
, O
[]

Crossovers O
from O
trimethoprim-sulfamethoxazole O
to O
aerosolized O
pentamidine O
were O
more O
common O
than O
the O
reverse O
( O
27 O
vs. O
4 O
percent O
) O
, O
partly O
because O
of O
the O
study O
protocols O
for O
the O
management O
of O
leukopenia O
. O
[]

These O
factors O
, O
in O
combination O
with O
normal O
peripheral O
resistance O
, O
may O
contribute O
to O
the O
improvement O
in O
foetal B-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
described O
in O
maternal O
hypertension O
of O
pregnancy O
treated O
with O
oxprenolol O
. O
['Physiological-Clinical']

The O
primary O
objective O
of O
this O
study O
was O
to O
compare O
the O
12-h O
pharmacokinetic B-outcome ['Physiological-Clinical']
profile O
of O
S O
( O
+ O
) O
-ibuprofen O
following O
administration O
of O
single O
doses O
of O
ibuprofen O
arginate O
( O
600 O
mg O
) O
and O
dexibuprofen O
( O
400 O
mg O
) O
in O
healthy O
volunteers O
. O
['Physiological-Clinical']

Neither O
torasemide O
nor O
furosemide O
induced O
any O
significant O
change O
in O
[]

Obtained O
results O
show O
that O
administered O
therapy O
increased O
physical B-outcome ['Life-Impact']
fitness I-outcome ['Life-Impact']
and O
decreased O
of O
glucosamine B-outcome ['Physiological-Clinical']
concentration O
, O
insulinaemia B-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
systematically O
elicited O
using O
the O
Safety O
Monitoring O
Uniform O
Report O
Form O
. O
['Adverse-effects']

After O
24 O
hours O
without O
medication O
, O
the O
treatments O
were O
crossed O
over O
and O
nycthemeral O
graph O
curves O
were O
registered O
for O
both O
groups O
. O
[]

A O
randomized O
double-blind O
comparative O
trail O
was O
carried O
out O
in O
a O
rheumatology O
outpatient O
department O
. O
[]

Relative O
polychromasia O
evaluated O
post-phlebotomy O
demonstrated O
regeneration O
starting O
at O
24 O
hours O
and O
continuing O
through O
48 O
hours O
. O
[]

CONCLUSION O
Mizolastine O
( O
10 O
mg O
daily O
) O
is O
confirmed O
as O
an O
[]

MATERIAL O
AND O
METHOD O
A O
randomized O
, O
double O
blind O
, O
controlled O
trial O
on O
46 O
adults O
ASA O
I-II O
, O
undergoing O
elective O
gynecological O
or O
general O
surgery O
with O
balanced O
general O
anesthesia O
was O
performed O
. O
[]

CONCLUSIONS O
Sequential O
therapy O
was O
significantly O
better O
than O
standard O
therapy O
for O
eradicating O
H. O
pylori O
infection O
. O
[]

Fifty-one O
patients O
were O
included O
in O
a O
prospective O
, O
randomized O
comparison O
of O
oral O
ciprofloxacin O
and O
intraperitoneal O
vancomycin/gentamicin O
in O
the O
treatment O
of O
CAPD O
peritonitis O
. O
[]

Efficacy O
was O
measured O
by O
natural O
killer O
cell O
cytotoxicity O
. O
[]

At O
the O
registration O
center O
, O
the O
patients O
were O
stratified O
into O
previously O
untreated O
patients O
and O
patients O
with O
recurrence O
after O
radical O
operation O
and O
then O
randomly O
allocated O
to O
the O
treatment O
groups O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
triacylglycerol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TAG I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
were O
unaffected O
by O
either O
of O
the O
treatments O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Seventy-one O
patients O
were O
randomized O
to O
receive O
either O
esmolol O
( O
n O
= O
36 O
) O
or O
placebo O
( O
n O
= O
35 O
) O
as O
initial O
treatment O
. O
[]

No O
real-world O
trials O
have O
evaluated O
whether O
improved O
medication O
labels O
can O
affect O
appropriate O
medication O
use O
, O
adherence O
or O
health O
outcomes O
. O
[]

Subjects O
were O
included O
in O
the O
study O
if O
they O
had O
inattention O
, O
impulsivity O
, O
and O
hyperactivity O
that O
was O
excessive O
for O
their O
developmental O
level O
. O
[]

For O
examination O
of O
whether O
this O
is O
based O
on O
the O
same O
mechanisms O
as O
angiotensin O
II O
receptor O
blockers O
or O
thiazolidinedione O
, O
effects O
of O
sarpogrelate O
on O
atherosclerotic O
inflammatory O
molecules O
and O
their O
relations O
to O
albuminuria O
in O
patients O
who O
had O
diabetes O
and O
had O
already O
been O
treated O
with O
angiotensin O
II O
receptor O
blockers O
and O
with O
or O
without O
thiazolidinedione O
were O
examined O
. O
[]

Recent O
psychophysical O
analyses O
of O
autism O
spectrum O
disorders O
point O
to O
superior O
local O
processing O
, O
and O
impaired O
or O
ignored O
global O
and O
contextual O
processing O
. O
[]

This O
was O
a O
randomized O
, O
doubleblind O
, O
placebo-controlled O
, O
multicenter O
trial O
, O
performed O
in O
24 O
Italian O
centers O
. O
[]

OBJECTIVES O
To O
compare O
2 O
short-term O
, O
community O
caregiver O
training O
interventions O
for O
preschool-aged O
children O
with O
Autism O
Spectrum O
Disorder O
who O
had O
low O
resources O
. O
[]

The O
pattern O
and O
magnitude O
of O
skin B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
in O
the O
three O
schedules O
are O
nearly O
identical O
but O
tumor B-outcome ['Physiological-Clinical']
regression I-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
were O
achieved O
faster O
in O
the O
rapid O
fractionation O
schedules O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
effects O
correlated O
with O
subjective O
measurements O
of O
fatigue B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

GNCC B-outcome ['Physiological-Clinical']
was O
inversely O
associated O
with O
serum B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
( O
global O
P O
= O
0.024 O
) O
, O
serum B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
( O
global O
P O
= O
0.060 O
) O
and O
, O
possibly O
, O
transferrin B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
continuing O
on O
8 O
mg/h O
showed O
the O
best O
results O
. O
[]

HP O
eradication O
was O
confirmed O
by O
stool B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
testing O
at O
least O
4 O
weeks O
after O
cessation O
of O
therapy O
. O
['Physiological-Clinical']

Levobunolol O
and O
timolol O
were O
equally O
effective O
in O
reducing O
overall O
mean O
IOP B-outcome ['Physiological-Clinical']
; O
reductions O
were O
greater O
than O
8.8 O
mmHg O
in O
all O
three O
treatment O
groups O
. O
['Physiological-Clinical']

If O
those O
who O
failed O
to O
attend O
visits O
( O
who O
did O
not O
withdraw O
as O
a O
result O
of O
drug-related O
events O
) O
are O
removed O
from O
the O
analysis O
, O
the O
clinical O
success O
rates O
are O
89.9 O
% O
for O
retapamulin O
and O
89.7 O
% O
for O
cephalexin O
. O
[]

In O
recent O
years O
, O
further O
developments O
have O
included O
so-called O
hi-fi O
plugs O
and O
custom O
made O
ear O
plugs O
which O
are O
claimed O
to O
improve O
speech O
communication O
. O
[]

In O
comparison O
between O
group O
A O
and O
B O
, O
Bifidobacterium O
was O
detected O
significantly O
earlier O
in O
group O
A O
, O
and O
the O
number O
of O
Enterobacteriaceae O
present O
in O
the O
infants O
at O
2 O
weeks O
after O
birth O
was O
significantly O
lower O
in O
group O
A O
. O
[]

METHODS O
Patients O
of O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
treated O
with O
chemotherapy O
with O
or O
without O
Endostar O
were O
observed O
. O
[]

from O
the O
ratio O
of O
detection O
rate O
( O
prevalence O
of O
screen-detected O
cases O
) O
and O
expected O
incidence O
( O
cumulative O
risk O
) O
. O
[]

The O
main O
purpose O
of O
this O
study O
was O
to O
analyze O
the O
effects O
of O
computer-assisted O
practice O
on O
reading O
and O
spelling O
in O
children O
with O
learning O
disabilities O
( O
LD O
) O
. O
[]

8 O
% O
at O
the O
4th O
min O
, O
P O
< O
0.0001 O
) O
. O
[]

Polysomnography O
demonstrated O
that O
the O
percentage O
of O
SWS B-outcome ['Physiological-Clinical']
was O
not O
different O
when O
saline O
and O
GHRH O
antagonist O
nights O
were O
compared O
( O
P=0.607 O
) O
; O
other O
quantifiable O
sleep B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
were O
also O
unchanged O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
premedication O
with O
0.1 O
mg/kg O
acepromazine O
intramuscularly O
and O
0.6 O
mg/kg O
xylazine O
intravenously O
, O
anaesthesia O
was O
induced O
either O
with O
2 O
g O
thiopentone O
in O
500 O
ml O
of O
a O
10 O
per O
cent O
guaifenesin O
solution O
, O
given O
intravenously O
at O
a O
dose O
of O
1 O
ml/kg O
( O
group O
TG O
) O
, O
or O
with O
100 O
mg/kg O
guaifenesin O
and O
2.2 O
mg/kg O
ketamine O
given O
intravenously O
( O
group O
KG O
) O
, O
or O
with O
0.06 O
mg/kg O
midazolam O
, O
and O
2.2 O
mg/kg O
ketamine O
given O
intravenously O
( O
group O
KM O
) O
. O
[]

LEVEL O
OF O
EVIDENCE O
Epidemiologic O
study O
, O
level O
III O
. O
[]

No O
improvement O
on O
the O
executive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
tasks O
was O
seen O
in O
any O
of O
the O
groups O
. O
['Life-Impact']

A O
significant O
ambulatory B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
reduction O
was O
, O
however O
, O
observed O
in O
the O
subjects O
who O
received O
aspirin O
at O
bedtime O
( O
decrease O
of O
6/3 O
mm O
Hg O
in O
the O
24-h O
mean O
of O
systolic B-outcome ['Physiological-Clinical']
( O
SBP O
) O
/diastolic O
BP I-outcome ['Physiological-Clinical']
( O
DBP O
) O
, O
respectively O
; O
P O
< O
0.001 O
) O
, O
without O
changes O
in O
heart B-outcome ['Physiological-Clinical']
rate O
( O
HR O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Endoscopies O
were O
performed O
1 O
week O
before O
and O
after O
treatment O
. O
[]

The O
use O
of O
a O
water O
extract O
from O
the O
bark O
of O
Choerospondias O
axillaris O
in O
the O
treatment O
of O
second O
degree O
burns O
. O
[]

Abstinence B-outcome ['Life-Impact']
incentive O
effects O
in O
a O
short-term O
outpatient O
detoxification O
program O
. O
['Life-Impact']

In O
the O
present O
study O
, O
a O
minimally O
invasive O
approach O
was O
compared O
with O
a O
traditional O
standard O
approach O
in O
terms O
of O
the O
effect O
on O
gait B-outcome ['Life-Impact']
kinematics I-outcome ['Life-Impact']
as O
demonstrated O
with O
gait O
analysis O
and O
electromyography O
. O
['Life-Impact']

During O
a O
60-d O
breeding O
period O
, O
the O
incidence O
of O
puberty B-outcome ['Physiological-Clinical']
was O
greater O
( O
P O
< O
0.05 O
) O
for O
HS O
and O
LS O
heifers O
than O
for O
control O
heifers O
and O
was O
greater O
( O
P O
< O
0.05 O
) O
in O
HS O
than O
in O
LS O
heifers O
in O
Year O
1 O
. O
['Physiological-Clinical']

We O
present O
secondary O
analyses O
to O
better O
define O
the O
scope O
of O
effects O
of O
methylphenidate O
on O
symptoms O
that O
define O
attention-deficit/hyperactivity O
disorder O
( O
ADHD O
) O
and O
oppositional O
defiant O
disorder O
( O
ODD O
) O
, O
as O
well O
as O
the O
core O
autistic O
symptom O
domain O
of O
repetitive O
behavior O
. O
[]

At O
18 O
months O
of O
follow-up O
, O
the O
percentages O
were O
63 O
% O
and O
75 O
% O
respectively O
. O
[]

Secondary O
measures O
indicated O
significant O
improvements O
for O
BH4 O
relative O
to O
placebo O
with O
regard O
to O
social B-outcome ['Life-Impact']
awareness I-outcome ['Life-Impact']
, O
autism B-outcome ['Life-Impact']
mannerisms I-outcome ['Life-Impact']
, O
hyperactivity B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact']

This O
is O
consistent O
with O
the O
high O
density O
of O
nicotinic O
cholinoceptors O
in O
that O
brain O
region O
. O
[]

One O
hundred O
nine O
women O
participated O
over O
a O
26-month O
interval O
. O
[]

SO O
scored O
lowest O
on O
the O
chair O
stand O
( O
p O
= O
0.03 O
) O
and O
step O
test O
( O
p O
= O
0.03 O
) O
. O
[]

METHODS O
This O
study O
was O
a O
prospective O
randomized O
clinical O
trial O
. O
[]

To O
reduce O
Healthway O
staff O
time O
spent O
helping O
event O
organizers O
promote O
health O
messages O
, O
Healthway O
developed O
a O
sponsor O
kit O
of O
promotional O
materials O
which O
communicate O
health O
messages O
without O
requiring O
Healthway O
staff O
to O
attend O
events O
. O
[]

A O
similar O
pattern O
of O
changes O
was O
observed O
at O
the O
hip O
. O
[]

After O
nifedipine O
, O
the O
tests O
were O
negative O
in O
five O
patients O
and O
positive O
for O
a O
higher O
or O
the O
same O
dose O
of O
ergometrine O
in O
four O
and O
four O
patients O
, O
respectively O
( O
p O
= O
0.0039 O
vs. O
placebo O
) O
. O
[]

However O
, O
few O
data O
are O
available O
on O
the O
clinical O
outcome O
of O
LA O
in O
overweight O
patients O
. O
[]

Total O
[]

These O
results O
demonstrate O
that O
good O
cycle O
control O
was O
achieved O
with O
an O
OC O
containing O
20 O
micrograms O
EE O
and O
that O
100 O
micrograms O
LNG/20 O
micrograms O
EE O
produces O
better O
cycle O
control O
than O
1000 O
micrograms O
NETA/20 O
micrograms O
EE O
. O
[]

PATIENTS O
Sixty-two O
women O
with O
symptomatic O
uterine O
myomas O
( O
size O
16-20 O
wks O
) O
. O
[]

PRACTICE O
IMPLICATIONS O
Nurses O
may O
consider O
assessing O
anxiety B-outcome ['Life-Impact']
levels O
prior O
to O
delivery O
of O
educational O
interventions O
, O
implement O
interventions O
aimed O
at O
reducing O
anxiety O
levels O
, O
and O
provide O
individualized O
teaching O
. O
['Life-Impact']

Here O
, O
we O
report O
the O
experience O
of O
enrolling O
ethnic O
minorities O
in O
a O
large O
cancer O
screening O
trial O
. O
[]

Diverting B-outcome ['Physiological-Clinical']
stoma I-outcome ['Physiological-Clinical']
after O
low O
anterior O
resection O
: O
more O
arguments O
in O
favor O
. O
['Physiological-Clinical']

There O
was O
no O
difference O
in O
the O
number O
of O
detrusor O
contractions O
or O
the O
bladder O
volume O
at O
which O
the O
first O
detrusor O
contraction O
had O
occurred O
with O
and O
without O
rectal O
distension O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
significantly O
less O
after O
RFA O
( O
median O
score O
on O
visual O
analogue O
scale O
1.70 O
( O
0.50-4.30 O
) O
versus O
4.0 O
( O
2.35-6.05 O
) O
; O
P O
= O
0.001 O
) O
. O
['Physiological-Clinical']

Primary O
outcome O
measures O
were O
the O
Aberrant O
Behavior O
Checklist O
irritability B-outcome ['Life-Impact']
subscale O
and O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
improvement O
scale O
. O
['Life-Impact', 'Physiological-Clinical']

Median O
OS B-outcome ['Mortality']
was O
15.1 O
months O
( O
95 O
% O
CI O
, O
13.5-16.6 O
months O
) O
. O
['Mortality']

INTERVENTIONS O
Patients O
were O
randomly O
assigned O
to O
receive O
either O
rhNGF O
, O
0.1 O
microg/kg O
( O
n O
= O
504 O
) O
, O
or O
placebo O
( O
n O
= O
515 O
) O
by O
subcutaneous O
injection O
3 O
times O
per O
week O
for O
48 O
weeks O
. O
[]

METHODS O
We O
conducted O
a O
randomized O
, O
placebo-controlled O
study O
of O
60 O
group O
I-II O
( O
American O
Society O
of O
Anesthesiology O
criteria O
) O
mastectomy O
patients O
, O
20 O
in O
each O
group O
. O
[]

AIMS O
This O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel-group O
study O
evaluated O
the O
safety O
and O
efficacy O
of O
ezetimibe O
10 O
mg/day O
in O
patients O
with O
primary O
hypercholesterolemia O
. O
[]

Twenty O
adult O
patients O
with O
asthma O
were O
studied O
. O
[]

Ethanol O
decreased O
Arousal B-outcome ['Life-Impact']
, O
Elation B-outcome ['Life-Impact']
, O
Positive O
Mood O
and O
Vigor B-outcome ['Life-Impact']
, O
and O
increased O
Anxiety B-outcome ['Life-Impact']
, O
Depression B-outcome ['Life-Impact']
and O
Fatigue B-outcome ['Physiological-Clinical']
in O
the O
non-choosers O
, O
whereas O
it O
increased O
Arousal B-outcome ['Life-Impact']
and O
Vigor B-outcome ['Life-Impact']
in O
the O
choosers O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

The O
impact O
of O
a O
FLT3-internal O
tandem O
duplication O
( O
FLT3ITD O
) O
on O
prognosis O
of O
patients O
with O
acute O
myeloid O
leukemia O
( O
AML O
) O
is O
dependent O
on O
the O
ratio O
of O
mutated O
to O
wild-type O
allele O
. O
[]

The O
36 O
pregnant O
women O
were O
randomized O
into O
four O
groups O
which O
were O
given O
a O
single O
dose O
of O
25 O
, O
100 O
, O
400 O
or O
600 O
mg O
RU O
486 O
. O
[]

OBJECTIVES O
To O
compare O
the O
efficacy O
and O
safety O
of O
R-salbutamol O
cream O
0.5 O
% O
vs. O
placebo O
on O
DLE O
lesions O
in O
a O
multicentre O
, O
double-blinded O
, O
randomized O
, O
placebo-controlled O
phase O
II O
trial O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Quality O
indicators O
pertaining O
to O
processes O
of O
care O
and O
outcomes O
of O
patients O
admitted O
between O
4 O
and O
10 O
months O
after O
randomization O
. O
[]

In O
each O
case O
in O
the O
second O
group O
two O
catheters O
were O
inserted O
independently O
into O
the O
same O
uterine O
cavity O
. O
[]

Adjusted O
MHE B-outcome ['Physiological-Clinical']
remained O
constant O
at O
77.9 O
HU O
+/- O
10.2 O
( O
standard O
deviation O
) O
in O
the O
LBW B-outcome ['Physiological-Clinical']
group O
with O
respect O
to O
TBW B-outcome ['Physiological-Clinical']
, O
but O
it O
increased O
in O
the O
TBW B-outcome ['Physiological-Clinical']
( O
r O
= O
0.80 O
, O
P O
< O
.001 O
) O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Although O
, O
at O
the O
end O
of O
the O
study O
, O
leptin O
levels O
did O
not O
change O
in O
Ex O
patients O
( O
6.7 O
? O
[]

An O
excess O
of O
renal O
AEs O
and O
acute-phase O
reactions O
occurred O
with O
zoledronic O
acid O
; O
hypocalcemia O
occurred O
more O
frequently O
with O
denosumab O
. O
[]

Other O
points O
were O
combined O
according O
to O
conditions O
of O
patients O
. O
[]

A O
total O
of O
110 O
duodenal O
ulcer O
patients O
were O
studied O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
multicentre O
clinical O
trial O
. O
[]

Forty-eight O
bronchial O
carcinoma O
patients O
in O
clinicoanatomical O
stage O
4 O
of O
the O
disease O
( O
advanced O
disease O
) O
were O
randomly O
assigned O
to O
groups O
for O
radiotherapy O
, O
chemotherapy O
( O
cyclophosphamide O
) O
and O
placebo O
treatment O
, O
respectively O
. O
[]

CONCLUSION O
Patients O
affected O
by O
palatal O
canine O
displacement O
showed O
significantly O
smaller O
maxillary O
tooth O
size O
. O
[]

RESULTS O
Mean O
follow-up O
in O
trials O
varied O
between O
0.4 O
and O
3.2 O
years O
. O
[]

A O
double-blind O
, O
placebo-controlled O
trial O
is O
needed O
to O
confirm O
these O
results O
. O
[]

Several O
generic O
formulations O
have O
been O
approved O
, O
raising O
concern O
over O
the O
safety O
and O
efficacy O
of O
these O
products O
compared O
with O
brand-name O
Coumadin O
. O
[]

A O
total O
of O
1,138 O
patients O
were O
entered O
in O
this O
study O
. O
[]

line O
survival O
in O
peripheral O
i.v O
. O
[]

RESULTS O
In O
stratum O
1 O
( O
n O
= O
206 O
) O
, O
the O
PFS B-outcome ['Mortality']
HR O
( O
gefitinib O
: O
placebo O
) O
was O
0.84 O
( O
95 O
% O
CI O
, O
0.59-1.18 O
; O
median O
PFS B-outcome ['Mortality']
10.9 O
versus O
8.8 O
months O
) O
. O
['Mortality', 'Mortality']

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
mild O
and O
tended O
to O
diminish O
over O
time O
during O
continued O
treatment O
, O
especially O
regarding O
nausea B-outcome ['Physiological-Clinical']
and O
fatigue B-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

The O
two O
groups O
had O
similar O
treatment-related O
acute B-outcome ['Adverse-effects']
and I-outcome ['Adverse-effects']
late I-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
, O
i.e O
. O
['Adverse-effects']

Lumbar B-outcome ['Physiological-Clinical']
spine I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
was O
measured O
by O
dual-energy O
X-ray O
absorptiometry O
, O
and O
trabecular B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
at O
the O
distal O
radius O
, O
cortical B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
, O
and O
relative B-outcome ['Physiological-Clinical']
cortical I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
at O
the O
radial O
diaphysis O
by O
peripheral O
computed O
tomography O
before O
the O
beginning O
of O
the O
study O
and O
at O
the O
4th O
, O
8th O
, O
and O
12th O
month O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVES O
In O
a O
previous O
study O
we O
showed O
that O
patients O
with O
severe O
aplastic O
anemia O
( O
SAA O
) O
treated O
with O
anti-lymphocyte O
globulin O
( O
ALG O
) O
, O
cyclosporin O
( O
CyA O
) O
and O
granulocyte O
colony-stimulating O
factor O
( O
G-CSF O
) O
5 O
micro O
g/kg/day O
had O
an O
encouraging O
outcome O
. O
[]

Grade O
3 O
neutropenia O
associated O
with O
fever O
or O
infection O
occurred O
more O
often O
with O
AT O
( O
26 O
% O
v O
10 O
% O
; O
P O
< O
.05 O
) O
. O
[]

Centers O
with O
higher O
enrollment O
rates O
showed O
better O
performance O
. O
[]

METHODS O
A O
group O
of O
14 O
individuals O
with O
AS O
and O
a O
group O
of O
14 O
neurotypical O
control O
participants O
performed O
a O
face-matching O
and O
a O
house-matching O
task O
during O
functional O
magnetic O
resonance O
imaging O
. O
[]

The O
rate O
of I-outcome ['Physiological-Clinical']
symptom B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptom B-outcome ['Physiological-Clinical']
score O
for O
initial O
therapy O
and O
the O
weekly O
average O
symptom O
score O
and O
weekly O
average O
number O
of O
days O
on O
treatment O
for O
on-demand O
therapy O
were O
evaluated O
as O
secondary O
end O
points O
. O
['Physiological-Clinical']

This O
study O
, O
the O
first O
performed O
in O
an O
unselected O
, O
unscreened O
population O
, O
shows O
that O
serum B-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
is O
the O
most O
sensitive B-outcome ['Physiological-Clinical']
technique I-outcome ['Physiological-Clinical']
to O
identify O
men O
at O
high O
risk O
of O
having O
prostate B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
and O
that O
12 O
% O
more O
cancers O
can O
be O
found O
at O
first O
visit O
by O
doing O
DRE O
in O
addition O
to O
PSA O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Spectral O
analysis O
was O
performed O
on O
the O
all-night O
records O
( O
1-min O
epochs O
) O
, O
and O
the O
relative O
power O
of O
six O
frequency O
bands O
calculated O
. O
[]

The O
low O
dose O
may O
not O
be O
enough O
to O
suppress O
asthmatic O
inflammation O
despite O
good O
clinical O
primary O
response O
. O
[]

INTRODUCTION O
Interest O
in O
searching O
for O
mutations O
in O
BRCA1 O
and O
BRCA2 O
is O
high O
. O
[]

Introducing O
baseline O
measures O
of O
clinical O
prognostic O
factors O
, O
including O
use B-outcome ['Resource-use']
of I-outcome ['Resource-use']
aspirin I-outcome ['Resource-use']
, O
beta-blockers O
, O
angiotensin-converting B-outcome ['Physiological-Clinical']
enzyme I-outcome ['Physiological-Clinical']
inhibitors I-outcome ['Physiological-Clinical']
, O
calcium-channel B-outcome ['Physiological-Clinical']
blockers I-outcome ['Physiological-Clinical']
, O
and O
statins O
into O
multivariate O
models O
confirmed O
the O
unadjusted O
results O
( O
P=0.009 O
) O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Blood O
samples O
were O
collected O
at O
0.5-4 O
hours O
( O
peak O
samples O
group O
, O
n O
= O
47 O
) O
and O
at O
22-24 O
hours O
( O
trough O
samples O
group O
, O
n O
= O
84 O
) O
after O
dose O
. O
[]

in O
50 O
ml O
phleboclysis O
in O
5 O
minutes O
( O
n O
= O
108 O
) O
; O
2 O
) O
calcium O
heparin O
at O
a O
dose O
of O
5000 O
IU O
t.i.d O
. O
[]

For O
many O
years O
, O
loco-regional O
radiotherapy O
was O
the O
standard O
postoperative O
treatment O
for O
node O
positive O
breast O
cancer O
patients O
in O
Sweden O
. O
[]

The O
blunted O
GH O
release O
to O
GHRH O
may O
be O
an O
early O
and O
long O
lasting O
sign O
of O
autonomous O
cortisol O
secretion O
by O
the O
adrenal O
adenoma O
. O
[]

METHODS O
Fundamental O
or O
harmonic O
MCE O
was O
performed O
with O
continuous O
or O
triggered O
imaging O
in O
203 O
patients O
with O
a O
previous O
MI O
using O
bolus O
doses O
of O
a O
perfluorocarbon-filled O
contrast O
agent O
( O
NC100100 O
) O
. O
[]

An O
open O
, O
controlled O
, O
randomized O
clinical O
investigation O
was O
carried O
out O
in O
33 O
patients O
suffering O
from O
osteomyelitis O
. O
[]

The O
effect O
of O
oral O
sodium O
acetate O
administration O
on O
plasma B-outcome ['Physiological-Clinical']
acetate I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
acid-base B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
in O
horses O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
randomised O
open O
multicentre O
comparative O
trial O
of O
lamotrigine O
and O
carbamazepine O
as O
monotherapy O
in O
patients O
with O
newly O
diagnosed O
or O
recurrent O
epilepsy O
. O
[]

However O
, O
significantly O
fewer O
individuals O
receiving O
clomipramine O
versus O
haloperidol O
were O
able O
to O
complete O
the O
trial O
( O
37.5 O
% O
vs. O
69.7 O
% O
, O
respectively O
) O
for O
reasons O
related O
to O
both O
side O
effects O
and O
efficacy O
or O
behavior B-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
study O
is O
a O
randomized O
, O
open-label O
, O
clinical O
trial O
. O
[]

2-Chloroprocaine O
antagonism O
of O
epidural O
morphine O
analgesia O
. O
[]

Effects O
of O
intravenous O
sodium O
salicylate O
( O
600 O
mg O
) O
were O
studied O
identically O
in O
eight O
subjects O
. O
[]

The O
present O
study O
compared O
the O
efficacy O
of O
topical O
azithromycin O
ophthalmic O
solution O
1 O
% O
( O
AzaSite O
; O
Inspire O
Pharmaceuticals O
, O
Inc O
, O
NC O
, O
USA O
) O
combined O
with O
warm O
compresses O
( O
azithromycin O
group O
) O
to O
warm O
compresses O
alone O
( O
compress O
group O
) O
in O
patients O
with O
posterior O
blepharitis O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
, O
demographic O
, O
and O
['Physiological-Clinical']

Randomized O
comparison O
of O
interferon O
alpha O
and O
hydroxyurea O
with O
hydroxyurea O
monotherapy O
in O
chronic O
myeloid O
leukemia O
( O
CML-study O
II O
) O
: O
prolongation O
of O
survival O
by O
the O
combination O
of O
interferon O
alpha O
and O
hydroxyurea O
. O
[]

The O
repeat B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate O
in O
the O
experimental O
group O
was O
12 O
% O
after O
18 O
months O
, O
and O
28 O
% O
in O
the O
control O
group O
. O
['Physiological-Clinical']

In O
eight O
out O
of O
15 O
healthy O
patients O
undergoing O
body O
surface O
surgery O
, O
the O
effect O
of O
a O
fentanyl O
infusion O
on O
a O
conventional O
thiopentone O
, O
nitrous O
oxide O
, O
oxygen O
and O
halothane O
anaesthetic O
was O
studied O
. O
[]

METHODS O
The O
main O
goal O
of O
this O
study O
was O
to O
determine O
whether O
PCI O
and O
thrombolytic O
therapy O
achieve O
comparable O
reperfusion O
rates O
, O
as O
evidenced O
by O
ST-segment O
resolution O
. O
[]

OBJECTIVE O
Wound O
healing O
in O
burn O
wounds O
presents O
a O
challenge O
in O
healthcare O
, O
and O
there O
is O
still O
a O
lack O
of O
alternatives O
in O
topical O
burn O
wound O
treatments O
. O
- O
[]

Descriptive O
statistics O
of O
DRE-outcome B-outcome ['Physiological-Clinical']
per O
PSA-range O
were O
used O
to O
determine O
the O
observer O
variability O
of O
six O
examiners O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
addressed O
the O
technique O
of O
intraperitoneal O
distribution O
imaging O
( O
IDI O
) O
. O
[]

SUMMARY O
This O
study O
examined O
whether O
24 O
months O
of O
weight O
training O
exercises O
enhanced O
the O
effectiveness O
of O
risedronate O
, O
calcium O
, O
and O
vitamin O
D O
in O
maintaining O
or O
improving O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
223 O
postmenopausal O
breast O
cancer O
survivors O
. O
['Physiological-Clinical']

Dose-finding O
study O
] O
. O
[]

PRIMARY O
ENDPOINT O
Pain O
score O
after O
15 O
min O
. O
[]

A O
total O
of O
146 O
patients O
( O
mean O
age O
69 O
+/- O
10 O
years O
; O
127 O
men O
) O
were O
screened O
for O
the O
presence O
of O
AAAs O
( O
diameter O
> O
3 O
cm O
) O
using O
CT. O
All O
patients O
were O
examined O
with O
the O
handheld O
ultrasound O
device O
and O
the O
volume O
scanner O
. O
[]

Recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
analyzed O
via O
Kaplan-Meier O
methods O
and O
multivariable O
Cox O
regression O
analysis O
. O
['Mortality']

and O
3TC O
b.i.d O
. O
[]

Also O
, O
there O
was O
no O
significant O
difference O
in O
the O
proportion O
of O
individuals O
who O
improved O
by O
> O
or O
[]

Duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
analgesia I-outcome ['Life-Impact']
was O
longer O
in O
group O
BM O
( O
11 O
+/- O
0.5 O
h O
) O
as O
compared O
to O
group O
B O
( O
7.4 O
+/- O
2.1 O
hours O
) O
( O
p O
< O
0.05 O
) O
. O
['Life-Impact']

Nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
were O
more O
prevalent O
among O
the O
patients O
given O
the O
infusion O
of O
morphine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
recommendation O
is O
the O
result O
of O
concern O
over O
antidepressant-induced O
manic O
switch O
episodes O
. O
[]

There O
was O
a O
significant O
( O
p O
less O
than O
0.05 O
) O
increase O
in O
urinary B-outcome ['Physiological-Clinical']
aldosterone I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
after O
CL O
( O
20.7 O
+/- O
11 O
micrograms/24 O
hours O
vs. O
13.3 O
+/- O
8.5 O
after O
PL O
, O
and O
14.5 O
+/- O
7.2 O
after O
MZ O
) O
( O
mean O
values O
+/- O
standard O
deviations O
) O
. O
( O
['Physiological-Clinical']

Morning B-outcome ['Physiological-Clinical']
predosing I-outcome ['Physiological-Clinical']
supine I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
DBP B-outcome ['Physiological-Clinical']
) O
was O
the O
primary O
efficacy O
measurement O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Quantitative O
sensory O
measurements O
taken O
from O
the O
affected O
area O
before O
and O
after O
the O
drug O
treatment O
included O
pin-prick O
hyperalgesia O
, O
allodynia O
, O
detection O
and O
pain O
thresholds O
to O
electrical O
and O
heat O
stimuli O
, O
temporal O
summation O
of O
repetitive O
electrical O
and O
heat O
stimuli O
. O
[]

Although O
some O
clinical O
trials O
have O
indicated O
that O
chemotherapy O
and O
immunochemotherapy O
may O
be O
effective O
modalities O
, O
more O
recent O
studies O
have O
not O
been O
able O
to O
define O
the O
standard O
treatment O
for O
advanced O
gastric O
cancer O
. O
[]

The O
human O
achaete-scute O
homologue O
( O
hASH1 O
) O
gene O
is O
critical O
in O
olfactory O
neuronal O
differentiation O
and O
is O
expressed O
in O
immature O
olfactory O
cells O
; O
therefore O
, O
it O
could O
have O
potential O
use O
as O
a O
diagnostic O
marker O
The O
aim O
of O
the O
present O
study O
was O
to O
determine O
the O
value O
of O
hASH1 O
messenger O
RNA O
( O
mRNA O
) O
levels O
in O
differentiating O
esthesioneuroblastoma O
from O
other O
poorly O
differentiated O
tumors O
. O
[]

CONCLUSION O
Although O
a O
rhythm O
control O
strategy O
was O
used O
in O
most O
of O
the O
patients O
in O
this O
trial O
and O
the O
overall O
rate O
of O
use O
of O
warfarin O
was O
low O
, O
the O
significance O
of O
these O
findings O
is O
uncertain O
because O
of O
the O
lack O
of O
data O
from O
randomized O
clinical O
trials O
. O
[]

Ten O
adults O
with O
hypertonic O
wrist O
flexors O
volunteered O
as O
subjects O
in O
an O
experiment O
comparing O
the O
effectiveness O
of O
dorsal O
and O
volar O
resting O
hand O
splints O
in O
the O
reduction O
of O
abnormal B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
conducted O
a O
part-blinded O
randomised O
controlled O
trial O
to O
compare O
the O
effect O
of O
routine O
antibiotic O
treatment O
on O
the O
incidence O
of O
clinical O
sepsis O
in O
preterm O
neonates O
. O
[]

A O
vocabulary B-outcome ['Life-Impact']
difference O
score O
, O
calculated O
using O
the O
MacArthur O
Communicative O
Development O
Inventories O
( O
L. O
Fenson O
et O
al. O
, O
1993 O
) O
, O
was O
used O
as O
the O
outcome O
measure O
of O
spoken O
vocabulary O
6 O
months O
later O
. O
['Life-Impact']

The O
study O
took O
place O
on O
a O
midsize O
labor O
and O
delivery O
unit O
, O
in O
an O
academic O
medical O
center O
averaging O
3600 O
births O
per O
year O
. O
[]

RESULTS O
After O
start O
of O
extracorporeal O
circulation O
( O
ECC O
) O
and O
aortic O
crossclamping O
( O
T2 O
) O
, O
both O
groups O
showed O
a O
significant O
drop O
of O
FCD B-outcome ['Physiological-Clinical']
, O
with O
a O
significantly O
higher O
FCD B-outcome ['Physiological-Clinical']
in O
the O
MECC O
group O
( O
206.8 O
? O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
IT O
group O
, O
diabetes O
treatment O
is O
optimised O
through O
guidelines O
, O
target-led O
multifactorial O
treatment O
, O
audit O
, O
feedback O
, O
and O
academic O
detailing O
for O
practice O
teams O
, O
alongside O
provision O
of O
educational O
materials O
for O
newly O
diagnosed O
participants O
. O
[]

The O
results O
showed O
that O
a O
trend O
in O
favour O
of O
the O
buflomedil O
group O
in O
three O
of O
the O
tests O
became O
statistically O
significant O
in O
the O
fourth O
. O
[]

In O
order O
to O
assess O
the O
reliability O
of O
intrauterine B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
measurements O
in O
the O
third O
stage O
of O
labour O
, O
catheter-tip O
transducers O
were O
used O
in O
20 O
women O
randomly O
allocated O
into O
two O
groups O
of O
10 O
. O
['Physiological-Clinical']

To O
determine O
whether O
antioxidants O
can O
influence O
human O
susceptibility O
to O
ozone O
( O
O O
( O
3 O
) O
) O
-induced O
changes O
in O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
airway B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
, O
we O
placed O
31 O
healthy O
nonsmoking O
adults O
( O
18 O
to O
35 O
yr O
old O
) O
on O
a O
diet O
low O
in O
ascorbate O
for O
3 O
wk O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Spatial O
orientation O
adjustments O
in O
children O
with O
autism O
in O
Hong O
Kong O
. O
[]

Both O
FIT O
and O
colonoscopy B-outcome ['Resource-use']
rates O
increased O
significantly O
in O
both O
mailed O
education O
groups O
. O
['Resource-use']

ZH O
, O
P O
= O
0.011 O
) O
. O
[]

Comparison O
of O
a O
nonrandomized O
series O
of O
266 O
RDL O
and O
124 O
EXT O
patients O
treated O
between O
1960 O
and O
1978 O
found O
differences O
consistent O
with O
those O
of O
the O
randomized O
study O
, O
although O
not O
statistically O
significant O
. O
[]

CONCLUSIONS O
The O
five-item O
CYBOCS-PDD O
is O
reliable O
, O
distinct O
from O
other O
measures O
of O
repetitive O
behavior O
, O
and O
sensitive O
to O
change O
. O
[]

BACKGROUND O
This O
trial O
investigated O
the O
efficacy O
and O
safety O
of O
weekly O
cetuximab O
combined O
with O
two O
different O
schedules O
of O
paclitaxel/carboplatin O
for O
stage O
IIIB/IV O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O
[]

RESULTS O
Use O
of O
the O
MAS O
improved O
total O
respiratory B-outcome ['Physiological-Clinical']
disturbance I-outcome ['Physiological-Clinical']
index O
( O
RDI O
) O
from O
22.2 O
+/- O
19.8 O
( O
SD O
) O
events B-outcome ['Physiological-Clinical']
per O
hour O
to O
16.5 O
+/- O
21.4/hr O
( O
p O
= O
0.03 O
) O
, O
supine B-outcome ['Physiological-Clinical']
RDI I-outcome ['Physiological-Clinical']
( O
30.8 O
+/- O
23.8/hr O
to O
18.8 O
+/- O
22.1/hr O
, O
p O
= O
0.01 O
) O
, O
arousal B-outcome ['Physiological-Clinical']
index O
( O
25.2 O
+/- O
18.9/hr O
to O
19.3 O
+/- O
14.2/hr O
, O
p O
= O
0.01 O
) O
and O
snoring B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
( O
52.7 O
+/- O
4.1 O
to O
50.7 O
+/- O
2.7 O
dB O
, O
p O
= O
0.02 O
) O
but O
not O
total O
snore B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
( O
p O
> O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Previous O
research O
has O
demonstrated O
the O
efficacy O
of O
an O
interactive O
expert O
system O
intervention O
for O
smoking O
cessation O
for O
a O
general O
population O
. O
[]

The O
patients O
were O
randomized O
to O
implantation O
with O
either O
a O
silicone O
intraocular O
lens O
( O
IOL O
) O
( O
SI40NB O
, O
Allergan O
) O
or O
an O
AcrySof O
IOL O
( O
MA60BM O
, O
Alcon O
) O
. O
[]

CONCLUSIONS O
Telephone O
contact O
by O
regular O
health O
plan O
staff O
was O
more O
successful O
than O
publicity O
in O
encouraging O
continued O
participation O
in O
mammography B-outcome ['Resource-use']
screening I-outcome ['Resource-use']
in O
women O
enrolled O
in O
a O
group-model O
managed O
health O
care O
plan O
. O
['Resource-use']

of O
isotonic O
saline O
, O
then O
0.15 O
mg/kg O
i.v O
. O
[]

All O
beams O
that O
fractured O
were O
analyzed O
under O
stereomicroscopy O
( O
40? O
) O
. O
[]

After O
one O
week O
of O
baseline O
assessment O
, O
patients O
were O
randomised O
into O
one O
of O
the O
two O
arms O
of O
the O
study O
. O
[]

In O
the O
induction O
group O
, O
[]

HRQOL B-outcome ['Life-Impact']
improved O
in O
both O
groups O
throughout O
the O
study O
, O
with O
an O
overall O
mean O
increment O
in O
the O
EuroQoL O
visual O
analog O
scale O
( O
EQ B-outcome ['Physiological-Clinical']
VAS O
) O
of O
9.2 O
at O
12 O
months O
( O
P O
< O
0.01 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

The O
assertion O
that O
these O
drug O
administration O
instructions O
bias O
estimates O
of O
effectiveness O
has O
undergone O
surprisingly O
little O
empirical O
investigation O
. O
[]

RESULTS O
Compared O
with O
431 O
BRAF O
wild-type O
patients O
, O
75 O
BRAF-mutated O
patients O
experienced O
significantly O
worse O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
[ I-outcome ['Mortality']
OS I-outcome ['Mortality']
; O
log-rank O
P O
= O
0.015 O
; O
multivariate O
HR O
= O
1.66 O
; O
95 O
% O
CI O
: O
1.05-2.63 O
] O
. O
['Mortality']

Enamel O
and O
dentin O
bond O
strength O
following O
gaseous O
ozone O
application O
. O
[]

PURPOSE O
Since O
most O
patients O
do O
not O
undergo O
repeat O
sextant O
prostate O
biopsies O
after O
a O
biopsy O
is O
positive O
for O
prostate O
cancer O
, O
the O
true O
incidence O
of O
false-negative O
biopsies O
is O
not O
well O
defined O
. O
[]

METHODS O
42 O
patients O
with O
chronic O
hepatitis O
B O
were O
divided O
randomly O
into O
two O
groups O
. O
[]

Information O
about O
arousal O
made O
public O
has O
a O
strong O
potential O
to O
increase O
anxiety B-outcome ['Life-Impact']
levels O
in O
social O
phobics O
. O
['Life-Impact']

The O
hepatic O
metabolism O
of O
lidocaine O
( O
1 O
mg/kg O
intravenously O
) O
to O
its O
metabolite O
monoethylglycinexylidide O
( O
MEG-X O
) O
is O
the O
basis O
of O
the O
standard O
MEG-X O
test O
. O
[]

Valsartan B-outcome ['Physiological-Clinical']
significantly I-outcome ['Physiological-Clinical']
reduced I-outcome ['Physiological-Clinical']
LVMI I-outcome ['Physiological-Clinical']
after O
eight O
months O
, O
but O
amlodipine O
had O
less O
effect O
( O
16 O
% O
vs. O
1.2 O
% O
, O
n O
= O
50 O
, O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Validation O
studies O
are O
needed O
as O
a O
next O
step O
. O
[]

The O
protocols O
had O
1- O
, O
3- O
, O
5- O
, O
7- O
, O
or O
9-min O
stage O
durations O
. O
[]

The O
proportion O
of O
responders O
and O
numbers O
needed O
to O
treat O
( O
NNT O
) O
were O
examined O
on O
postoperative O
days O
( O
POD O
) O
3-8 O
for O
GI-2 O
recovery O
( O
first O
bowel O
movement O
, O
toleration O
of O
solid O
food O
) O
and O
hospital O
discharge O
order O
( O
DCO O
) O
written O
. O
[]

Subjects O
received O
either O
6 O
% O
hydrogen O
peroxide O
whitening O
strips O
( O
Crest O
Whitestrips O
) O
and O
an O
anticavity O
toothpaste O
( O
Crest O
Cavity O
Protection O
) O
, O
placebo O
strips O
and O
a O
sodium O
fluoride O
( O
NaF O
) O
whitening O
dentifrice O
( O
Mentadent O
Whitening O
Toothpaste O
) O
or O
placebo O
strips O
and O
a O
sodium O
monofluorophosphate O
( O
MFP O
) O
whitening O
dentifrice O
( O
Rembrandt O
Low O
Abrasion O
Whitening O
Toothpaste O
) O
. O
[]

A O
controlled O
study O
of O
psychiatric O
hospital O
versus O
community O
treatment O
- O
the O
effect O
on O
relatives B-outcome ['Life-Impact']
. O
['Life-Impact']

Despite O
growing O
prospects O
for O
oxytocin O
as O
a O
therapeutic O
agent O
for O
ASD O
, O
no O
direct O
neurobiological O
evidence O
exists O
for O
oxytocin O
's O
beneficial O
effects O
on O
this O
core O
symptom O
of O
ASD O
. O
[]

METHODS O
Ten O
healthy O
volunteers O
, O
and O
seven O
with O
UC O
in O
symptomatic O
remission O
took O
part O
; O
all O
were O
non-smokers O
. O
[]

The O
results O
indicate O
a O
significantly O
higher B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
among O
patients O
treated O
with O
preoperative O
irradiation O
compared O
with O
those O
irradiated O
postoperative O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

Corticosteroid-induced O
osteopenia B-outcome ['Physiological-Clinical']
and O
vitamin B-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CSA B-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
were O
predictable O
and O
manageable O
but O
required O
close O
monitoring O
. O
['Adverse-effects']

CONCLUSION O
Improvements O
following O
the O
provision O
of O
a O
home-based O
programme O
to O
preschool O
children O
with O
developmental O
disabilities O
were O
sustained O
1 O
year O
later O
. O
[]

[ O
Bupivacaine-CO2 O
and O
bupivacaine-HCl O
at O
various O
injection O
temperatures O
in O
peridural O
anesthesia O
for O
extracorporeal O
shock O
wave O
lithotripsy O
] O
. O
[]

Predictors O
of O
response O
to O
ziprasidone O
: O
results O
from O
a O
6-week O
randomized O
double-blind O
, O
placebo-controlled O
trial O
for O
acute O
depressive O
mixed O
state O
. O
[]

The O
study O
, O
therefore O
, O
does O
not O
provide O
support O
for O
the O
contention O
that O
a O
lengthy O
therapy O
for O
obesity O
is O
necessary O
if O
treatment O
results O
are O
lasting O
. O
[]

Fibrinolytic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
euglobulins I-outcome ['Physiological-Clinical']
was O
decreased O
after O
the O
operation O
in O
both O
groups O
. O
['Physiological-Clinical']

Osteopontin O
is O
a O
prognostic O
factor O
for O
survival B-outcome ['Mortality']
of O
acute O
myeloid O
leukemia O
patients O
. O
['Mortality']

DESIGN O
Two O
hundred O
adults O
in O
a O
rural O
region O
of O
Bangladesh O
, O
previously O
found O
to O
have O
low O
plasma O
concentrations O
of O
folate O
( O
< O
/=9 O
nmol/L O
) O
were O
enrolled O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
folic O
acid-supplementation O
trial O
. O
[]

OBJECTIVES O
We O
hypothesized O
that O
outdoor O
temperature O
in O
the O
Boston O
, O
Massachusetts O
, O
area O
( O
1- O
to O
4-day O
moving O
averages O
) O
would O
be O
associated O
with O
higher O
levels O
of O
biomarkers O
of O
inflammation O
and O
myocyte B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
in O
a O
repeated-measures O
study O
of O
individuals O
with O
stable O
heart O
failure O
. O
['Physiological-Clinical']

Primary O
efficacy O
was O
based O
on O
data O
kept O
by O
primary O
caregivers O
, O
including O
a O
daily O
diary O
; O
daily O
visual O
analogue O
scales O
of O
affection O
, O
reciting O
, O
or O
aspects O
of O
social O
interaction O
; O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklists O
( O
ABC B-outcome ['Physiological-Clinical']
, O
Aman B-outcome ['Physiological-Clinical']
) O
; O
and O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Except O
for O
one O
case O
, O
the O
type O
of O
DAVF O
of O
NCE O
4D O
MRA O
was O
agreed O
with O
that O
of O
reference O
standard O
study O
. O
[]

OBJECTIVES O
To O
evaluate O
the O
long-term O
efficacy O
and O
safety O
of O
once-daily O
tamsulosin O
( O
0.4 O
and O
0.8 O
mg O
) O
, O
a O
unique O
selective O
alpha1A-adrenoceptor O
antagonist O
in O
patients O
with O
benign O
prostatic O
hyperplasia O
( O
BPH O
) O
. O
[]

BACKGROUND O
AND O
OBJECTIVES O
Because O
the O
mechanism O
of O
inhibition O
of O
epidural O
morphine-induced O
pruritus O
by O
droperidol O
is O
not O
clear O
, O
this O
study O
was O
undertaken O
to O
determine O
the O
effects O
of O
larger O
doses O
of O
droperidol O
or O
morphine O
, O
or O
both O
. O
[]

More O
active O
regimens O
than O
FAMTX O
are O
required O
for O
future O
randomised O
trials O
. O
[]

After O
the O
intervention O
, O
the O
indicators O
of O
choking O
( O
16.83 O
vs. O
26.17 O
, O
P O
= O
0.007 O
) O
and O
adventitious O
breath O
sounds O
( O
16.4 O
vs. O
26.6 O
, O
P O
= O
0.005 O
) O
were O
higher O
, O
on O
average O
, O
in O
the O
intervention O
group O
. O
[]

Mean O
changes O
in O
log O
serum O
level O
of O
PSA O
, O
testosterone O
, O
dihydrotestosterone O
, O
luteinizing O
hormone O
and O
sex O
hormone O
binding O
globulin O
over O
21 O
weeks O
between O
the O
verum O
and O
the O
placebo O
group O
were O
compared O
by O
analysis O
of O
covariance O
. O
[]

Our O
aim O
was O
to O
compare O
the O
effects O
of O
the O
combination O
of O
trimethoprim O
and O
sulfamethoxazole O
and O
ciprofloxacin O
in O
patients O
treated O
for O
severe O
COPD O
exacerbation O
requiring O
mechanical O
ventilation O
. O
[]

The O
trained O
group O
was O
trained O
in O
referential O
communication O
tasks O
( O
task O
analysis O
, O
role O
taking O
, O
and O
task O
evaluation O
) O
, O
while O
the O
untrained O
group O
took O
part O
in O
a O
communicative O
game O
but O
without O
any O
specific O
communicative O
training O
. O
[]

METHODS O
A O
total O
of O
241 O
consecutive O
patients O
undergoing O
elective O
coronary O
artery O
bypass O
grafting O
were O
randomly O
allocated O
into O
three O
groups O
. O
[]

Toxicities B-outcome ['Adverse-effects']
were O
graded O
according O
to O
the O
National O
Cancer O
Institute O
Common O
Toxicity O
Criteria O
( O
NCI-CTC O
) O
system O
. O
['Adverse-effects']

Further O
investigation O
is O
limited O
by O
the O
relative O
rarity O
of O
, O
and O
the O
lack O
of O
identifying O
features O
in O
boys O
with O
occult O
TL O
. O
[]

CONCLUSIONS O
Fluticasone O
propionate O
powder O
( O
50 O
, O
100 O
, O
and O
250 O
micrograms O
) O
was O
[]

As O
such O
, O
UTC O
might O
be O
useful O
to O
monitor O
treatment O
protocols O
. O
[]

RESULTS O
The O
differences O
in O
DMVF O
at O
12 O
weeks O
were O
-3.38 O
? O
[]

BACKGROUND O
The O
aim O
of O
the O
trial O
was O
to O
evaluate O
the O
effectiveness O
of O
a O
program O
of O
cooperation O
between O
physician O
and O
pharmacist O
to O
reduce O
cardiovascular O
risk O
factors O
in O
patients O
with O
mild O
to O
moderate O
hypertension O
by O
promoting O
better O
blood O
pressure O
( O
BP O
) O
control O
, O
appropriate O
changes O
in O
antihypertensive O
medications O
, O
and O
beneficial O
changes O
in O
lifestyle O
. O
[]

For O
example O
, O
physicians O
who O
viewed O
the O
diabetes O
seminar O
were O
significantly O
more O
likely O
to O
order O
an O
eye B-outcome ['Resource-use']
exam I-outcome ['Resource-use']
for O
diabetes O
patients O
( O
63 O
% O
) O
compared O
with O
physicians O
in O
the O
control O
group O
( O
27 O
% O
) O
. O
['Resource-use']

OBJECTIVE O
To O
compare O
profiles O
and O
related O
factors O
of O
irregular B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
induced O
by O
different O
types O
of O
low-dose O
hormone O
therapy O
( O
HT O
) O
and O
a O
Chinese O
formulated O
herbs O
products O
. O
['Physiological-Clinical']

In O
66 O
chemotherapy O
cycles O
, O
the O
children O
received O
tropisetron O
as O
an O
antiemetic O
agent O
in O
a O
dose O
of O
0.2 O
mg/kg/24 O
h O
intravenously O
and O
, O
in O
67 O
cycles O
, O
they O
received O
granisetron O
40 O
micrograms/kg/24 O
h O
intravenously O
before O
cytotoxic O
drug O
administration O
during O
the O
days O
they O
received O
chemotherapy O
. O
[]

RESULTS O
Compared O
to O
those O
assigned O
to O
ferrous O
sulfate O
, O
more O
patients O
assigned O
to O
ferric O
carboxymaltose O
responded O
with O
a O
hemoglobin B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Hb I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
increase O
of O
2.0 O
g/dL O
or O
more O
( O
82 O
% O
vs. O
62 O
% O
, O
95 O
% O
confidence O
interval O
for O
treatment O
difference O
12.2-28.3 O
, O
p O
< O
0.001 O
) O
, O
more O
achieved O
a O
3.0 O
g/dL O
or O
more O
increase O
( O
53 O
% O
vs. O
36 O
% O
, O
p O
< O
0.001 O
) O
, O
and O
more O
achieved O
correction B-outcome ['Physiological-Clinical']
( O
Hb O
> O
or= O
12 O
g/dL O
) O
of O
anemia O
( O
73 O
% O
vs. O
50 O
% O
, O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
accuracy O
of O
TCT O
registration O
with O
NMI O
was O
lower O
, O
with O
discrepancies O
occurring O
in O
the O
frontal O
inferior O
region O
and O
the O
cerebellum O
. O
[]

MATERIALS O
AND O
METHODS O
Patients O
were O
randomized O
to O
music O
, O
guided O
imagery O
, O
or O
usual O
care O
after O
completing O
a O
baseline O
questionnaire O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
1 O
second O
was O
measured O
serially O
. O
['Physiological-Clinical']

Systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
168 O
+/- O
18 O
mm O
Hg O
after O
the O
placebo O
phase O
and O
146 O
+/- O
15 O
mm O
Hg O
after O
hydrochlorothiazide O
; O
diastolic O
BP O
was O
103 O
+/- O
6 O
mm O
Hg O
and O
89 O
+/- O
9 O
mm O
Hg O
, O
respectively O
. O
['Physiological-Clinical']

The O
objective O
of O
this O
study O
was O
to O
determine O
the O
effects O
of O
source O
of O
dietary O
CP O
and O
level O
of O
ruminally O
protected O
lysine O
and O
methionine O
( O
RPLM O
) O
on O
feedlot B-outcome ['Physiological-Clinical']
performance O
and O
carcass O
characteristics O
of O
Holstein O
steers O
during O
a O
growing-finishing O
trial O
( O
266 O
d O
) O
. O
['Physiological-Clinical']

It O
is O
estimated O
that O
[]

The O
Funen O
Adenoma O
Follow-up O
Study O
. O
[]

h O
( O
-1 O
) O
for O
24 O
hours O
. O
[]

RESULTS O
There O
were O
no O
significant O
differences O
between O
treatment O
groups O
for O
mean O
change O
in O
Fridericia O
's O
correction O
of O
QT O
during O
the O
trial O
. O
[]

Dentine B-outcome ['Physiological-Clinical']
wear I-outcome ['Physiological-Clinical']
was O
measured O
with O
a O
profilometer O
. O
['Physiological-Clinical']

Lack O
of O
antihistamine O
properties O
of O
single O
dose O
cinnarizine O
in O
man O
. O
[]

Rates O
of O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
overall O
rate=14.8 O
events/100 O
patient-yrs O
) O
, O
serious B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
( O
overall O
rate=4.2 O
events/100 O
patient-yrs O
) O
, O
cancer B-outcome ['Physiological-Clinical']
( O
overall O
rate=1.0 O
events/100 O
patient-yrs O
) O
, O
and O
deaths B-outcome ['Mortality']
( O
overall O
rate=0.7 O
events/100 O
patient-yrs O
) O
were O
stable O
each O
year O
, O
through O
8 O
years O
of O
etanercept O
exposure O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Effects O
of O
weight-bearing O
versus O
nonweight-bearing O
exercise O
on O
function B-outcome ['Life-Impact']
, O
walking B-outcome ['Life-Impact']
speed I-outcome ['Life-Impact']
, O
and O
position O
sense B-outcome ['Physiological-Clinical']
in O
participants O
with O
knee O
osteoarthritis O
: O
a O
randomized O
controlled O
trial O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Hypertensive O
patients O
were O
randomly O
assigned O
to O
receive O
5 O
mg O
of O
enalapril O
( O
n O
= O
50 O
) O
or O
10 O
mg O
of O
lisinopril O
( O
n O
= O
47 O
) O
daily O
. O
[]

4 O
. O
[]

Net O
+/- O
SEM O
sponge O
weight O
( O
total O
intraoperative B-outcome ['Physiological-Clinical']
suture I-outcome ['Physiological-Clinical']
line B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
) O
was O
6.25 O
+/- O
0.55 O
g O
in O
the O
BP O
group O
and O
16.34 O
+/- O
1.85 O
g O
in O
the O
Dacron O
group O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

TRIAL O
REGISTRATION O
ISRCTN O
ISRCTN56716589 O
. O
[]

Marginal O
adaptation O
was O
evaluated O
by O
using O
a O
computer-assisted O
quantitative O
marginal O
analysis O
in O
a O
scanning O
electron O
microscope O
( O
SEM O
) O
on O
epoxy O
replicas O
before O
, O
after O
thermal O
and O
mechanical O
stressing O
and O
after O
1 O
year O
of O
water O
storage O
. O
[]

METHOD O
Participants O
were O
two O
groups O
of O
children O
with O
autism O
, O
aged O
between O
3 O
and O
7 O
years O
. O
[]

Eleven O
chronic O
renal O
failure O
patients O
and O
11 O
matched O
controls O
, O
received O
growth O
hormone O
GHRH O
( O
1 O
microgram/kg O
iv O
) O
or O
TRH O
( O
400 O
microgram O
iv O
) O
on O
separate O
occasions O
, O
immediately O
before O
undergoing O
hemodialysis O
. O
[]

The O
MI B-outcome ['Physiological-Clinical']
of O
Group O
FC B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
than O
in O
the O
other O
groups O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
study O
comprised O
240 O
patients O
with O
either O
unstable O
angina O
or O
non-ST-elevation O
myocardial O
infarction O
in O
the O
previous O
2 O
weeks O
who O
were O
randomized O
to O
a O
folate O
group O
( O
n O
=116 O
) O
or O
a O
placebo O
group O
( O
n O
=124 O
) O
. O
[]

Univariate O
and O
multivariate O
logistic O
regression O
analyses O
were O
performed O
to O
identify O
factors O
associated O
with O
completion O
of O
care O
. O
[]

Randomized O
controlled O
trials O
using O
falls O
as O
primary O
outcome O
are O
needed O
. O
[]

Medical O
chart O
data O
were O
abstracted O
regarding O
clinic O
appointment O
keeping O
and O
completion O
of O
treatment O
. O
[]

CONCLUSION O
Dose B-outcome ['Adverse-effects']
limiting I-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
for O
KAb201 O
with O
I O
( O
131 O
) O
by O
the O
intra-arterial O
route O
was O
50 O
mCi O
, O
while O
dose B-outcome ['Adverse-effects']
limiting I-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
was O
not O
reached O
in O
the O
intravenous O
arm O
. O
['Adverse-effects', 'Adverse-effects']

Sixty O
and O
59 O
healthy O
young O
adults O
previously O
immunized O
against O
tetanus O
( O
T O
) O
and O
diphtheria O
( O
D O
) O
were O
randomized O
to O
receive O
intramuscularly O
either O
Td O
vaccine O
alone O
( O
group O
1 O
) O
or O
Td O
vaccine O
plus O
500 O
IU O
of O
TIG O
( O
group O
2 O
) O
simultaneously O
. O
[]

METHODS O
Lumbar O
puncture O
was O
performed O
on O
54 O
healthy O
volunteers O
to O
obtain O
cerebrospinal O
fluid O
( O
CSF O
) O
for O
determination O
of O
5-hydroxyindoleacetic O
acid O
( O
5HIAA O
) O
levels O
. O
[]

REACH O
patients O
with O
higher O
pretreatment O
protein O
tyrosine O
kinase O
2 O
( O
PTK2 O
) O
messenger O
RNA O
levels O
derived O
greater O
benefit O
from O
R-FC O
, O
with O
significant O
improvements O
in O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
independent O
of O
known O
prognostic O
factors O
in O
a O
multivariate O
model O
. O
['Mortality']

MATERIAL/METHODS O
Thirty O
subjects O
diagnosed O
with O
an O
ASD O
were O
randomly O
assigned O
to O
receive O
a O
standardized O
regimen O
( O
50 O
mg O
L-carnitine/kg O
bodyweight/day O
) O
of O
liquid O
L-carnitine O
( O
n=19 O
) O
or O
placebo O
( O
n=11 O
) O
for O
3-months O
. O
[]

Group O
2 O
received O
diclofenac O
suppository O
3 O
mg/kg O
postinduction O
and O
local O
anesthetic O
infiltration O
at O
the O
port O
sites O
at O
the O
end O
of O
the O
procedure O
. O
[]

We O
have O
examined O
the O
changes O
in O
breathing O
pattern O
and O
thoracoabdominal O
movement O
associated O
with O
upper O
abdominal O
surgery O
in O
order O
to O
evaluate O
the O
possible O
influences O
of O
nociceptive O
input O
on O
respiration O
. O
[]

There O
was O
a O
significantly O
higher O
death O
rate O
among O
patients O
receiving O
pyrimethamine O
( O
relative O
risk O
[ O
RR O
] O
, O
2.5 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
1.3-4.8 O
; O
P O
= O
.006 O
) O
, O
even O
after O
adjusting O
for O
factors O
predictive O
of O
survival O
. O
[]

The O
intention-to-treat O
eradication B-outcome ['Physiological-Clinical']
rate O
was O
67 O
% O
( O
44 O
of O
66 O
) O
and O
58 O
% O
( O
38 O
of O
65 O
) O
for O
the O
ATL- O
and O
the O
ATP-group O
, O
respectively O
. O
['Physiological-Clinical']

An O
SRE O
was O
defined O
as O
pathologic O
fracture O
, O
spinal O
cord O
compression O
, O
and O
radiation O
or O
surgery O
to O
bone O
. O
[]

CONCLUSIONS O
Trophic O
feeding O
improves O
clinical O
outcome O
in O
ill O
preterm O
infants O
requiring O
parenteral O
nutrition O
. O
[]

In O
the O
nested O
case-control O
study O
, O
the O
somatotropic O
axis O
, O
cortisol B-outcome ['Physiological-Clinical']
, O
and O
glucagon B-outcome ['Physiological-Clinical']
were O
analyzed O
before O
and O
after O
hypoglycemia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
statistically O
significant O
difference O
in O
the O
improvement O
of O
oral B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
impacts I-outcome ['Physiological-Clinical']
among O
groups O
subjected O
to O
different O
treatments O
. O
['Physiological-Clinical']

There O
is O
a O
high O
proportion O
of O
ineffectiveness O
of O
Fansidar O
for O
treatment O
of O
P. O
vivax O
malaria O
and O
it O
should O
be O
no O
longer O
used O
for O
treatment O
of O
P. O
vivax O
malaria O
acquired O
at O
the O
Thailand-Myanmar O
border O
. O
[]

Simvastatin O
produced O
a O
hypolipidemic B-outcome ['Physiological-Clinical']
effect O
and O
modulates O
the O
phospholipid B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
high-density I-outcome ['Physiological-Clinical']
lipoproteins I-outcome ['Physiological-Clinical']
( O
similarly O
to O
lipostabil O
forte O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
change O
in O
initial O
claudication O
distance O
during O
treatment O
, O
expressed O
as O
integrated O
change O
over O
time O
, O
was O
significantly O
greater O
with O
heparan O
sulfate O
than O
with O
placebo O
( O
306 O
+/- O
494 O
vs. O
250 O
+/- O
510 O
meters O
x O
months O
, O
p O
= O
0.019 O
) O
. O
[]

Specifically O
, O
HPV16-positive B-outcome ['Physiological-Clinical']
CIN3 B-outcome ['Physiological-Clinical']
occurred O
at O
a O
younger O
age O
than O
CIN3 O
positive O
for O
other O
carcinogenic O
HPV O
genotypes O
( O
median O
of O
23.5 O
years O
versus O
25 O
years O
, O
respectively O
; O
P O
= O
0.0003 O
, O
Kruskal-Wallis O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
majority O
( O
63 O
% O
) O
of O
the O
project O
group O
had O
no O
admission O
during O
the O
10 O
month O
study O
period O
. O
[]

An O
initial O
rise O
in O
circulating B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
after O
the O
first O
cycle O
was O
followed O
by O
a O
fall O
in O
both O
treatment O
arms O
to O
baseline O
levels O
set O
by O
normal O
controls O
. O
['Physiological-Clinical']

There O
are O
currently O
no O
effective O
pharmocologic O
treatments O
. O
[]

In O
the O
management B-outcome ['Life-Impact']
of O
outpatient O
burns O
, O
MVPF O
was O
found O
to O
be O
superior O
to O
silver O
sulphadiazine O
. O
['Life-Impact']

METHODS O
During O
a O
6-year O
period O
, O
296 O
patients O
with O
visible O
endoluminal O
tumor O
lesions O
were O
included O
in O
the O
study O
at O
the O
bronchoscopy O
unit O
of O
a O
university O
hospital O
. O
[]

Subjects O
in O
group O
A O
underwent O
BF O
once O
a O
week O
for O
a O
total O
of O
four O
sessions O
. O
[]

Cytology O
provided O
useful O
additional O
information O
with O
the O
Menghini O
technique O
. O
[]

Cyproheptadine O
augmentation O
, O
compared O
to O
administration O
of O
haloperidol O
with O
placebo O
, O
did O
not O
produce O
a O
statistically O
significant O
improvement O
in O
psychotic B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Time O
points O
of O
0 O
, O
0.5 O
, O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
5 O
and O
6 O
h O
were O
selected O
to O
observe O
the O
coagulation O
changes O
of O
prothrombin O
time O
( O
PT O
) O
, O
PTA O
, O
thrombin O
time O
( O
TT O
) O
, O
activated O
partial O
thromboplastin O
time O
( O
APTT O
) O
and O
international O
normalized O
ratio O
( O
INR O
) O
dynamically O
. O
[]

Reflux B-outcome ['Physiological-Clinical']
, O
total O
, O
and O
antacid B-outcome ['Resource-use']
scores O
were O
calculated O
for O
each O
of O
the O
treatment O
periods O
. O
['Physiological-Clinical', 'Resource-use']

However O
, O
none O
of O
the O
RAS O
polymorphisms O
predicted O
the O
antioxidant B-outcome ['Physiological-Clinical']
and O
anti-inflammatory B-outcome ['Physiological-Clinical']
response O
rates O
to O
the O
drugs O
( O
P O
> O
.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Randomized O
controlled O
trial O
of O
acupuncture O
versus O
sham O
acupuncture O
in O
autism O
spectrum O
disorder O
. O
[]

Results O
presented O
here O
suggest O
that O
individuals O
with O
ASD O
achieve O
better O
vocational B-outcome ['Life-Impact']
outcomes O
if O
they O
do O
not O
participate O
in O
sheltered O
workshops O
prior O
to O
enrolling O
in O
supported O
employment O
. O
['Life-Impact']

Linear O
correlation O
showed O
moderate O
to O
large O
magnitude O
associations O
with O
alcohol-related O
self-report O
measures O
and O
most O
indices O
of O
consumption O
. O
[]

OBJECTIVE O
To O
describe O
the O
clinical O
characteristics O
and O
survival O
experience O
of O
a O
prospectively O
followed O
up O
group O
of O
patients O
with O
small O
choroidal O
melanoma O
. O
[]

Using O
a O
conservative O
YMR O
score O
of O
> O
or O
[]

A O
controlled O
study O
of O
early O
discharge O
after O
uncomplicated O
myocardial O
infarction O
. O
[]

Among O
patients O
who O
received O
etanercept O
with O
methotrexate O
, O
remission O
rates O
were O
54 O
% O
and O
36 O
% O
, O
respectively O
. O
[]

CONTEXT O
Supplemental O
perioperative O
oxygen O
has O
been O
variously O
reported O
to O
halve O
or O
double O
the O
risk O
of O
surgical B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
was O
also O
no O
significant O
difference O
between O
the O
2 O
groups O
in O
infarct B-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
estimated O
by O
measurement O
of O
serum B-outcome ['Physiological-Clinical']
CK-MB I-outcome ['Physiological-Clinical']
, O
planimetry B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
infarct I-outcome ['Physiological-Clinical']
area O
on O
technetium B-outcome ['Physiological-Clinical']
pyrophosphate I-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
scintigrams B-outcome ['Physiological-Clinical']
or O
R-wave B-outcome ['Physiological-Clinical']
measurements O
in O
patients O
with O
transmural O
anterior O
and O
inferior O
infarcts O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
decreased O
significantly O
in O
all O
groups O
. O
['Physiological-Clinical']

Sleep B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
are O
regarded O
as O
a O
common O
clinical O
feature O
in O
autistic O
children O
. O
['Physiological-Clinical']

The O
SBAs B-outcome ['Physiological-Clinical']
were O
measured O
by O
the O
microdilution B-outcome ['Physiological-Clinical']
method O
of O
Reller O
and O
Stratton O
( O
L. O
B. O
Reller O
and O
C. O
W. O
Stratton O
, O
J. O
Infect O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Data O
from O
this O
study O
suggest O
that O
clopidogrel O
can O
decrease O
the O
expression O
of O
the O
CD40-ligand B-outcome ['Physiological-Clinical']
biomarker I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Mild B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
was O
observed O
in O
both O
treatment O
groups O
. O
['Physiological-Clinical']

CONCLUSIONS O
Our O
data O
suggest O
that O
a O
large O
proportion O
of O
the O
US O
men O
had O
suboptimal O
vitamin O
D O
status O
( O
especially O
during O
the O
winter/spring O
season O
) O
, O
and O
both O
25 O
( O
OH O
) O
D O
and O
1,25 O
( O
OH O
) O
2D O
may O
play O
an O
important O
role O
in O
preventing O
prostate O
cancer O
progression O
. O
[]

Functional O
performance O
was O
assessed O
using O
timed O
up O
and O
go O
, O
chair O
stand O
, O
single O
leg O
stand O
, O
and O
step O
test O
. O
[]

However O
, O
the O
patients O
frequently O
reported O
gastrointestinal B-outcome ['Physiological-Clinical']
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

After O
12 O
weeks O
, O
the O
mean O
percent O
decrease O
in O
frequency O
of O
hot B-outcome ['Physiological-Clinical']
flushes I-outcome ['Physiological-Clinical']
in O
the O
10 O
g/day O
group O
was O
12.9 O
% O
greater O
than O
that O
in O
the O
placebo O
group O
( O
P O
= O
0.15 O
) O
, O
the O
median O
percent O
decrease O
was O
11.7 O
% O
greater O
than O
that O
in O
the O
placebo O
group O
( O
P O
= O
0.05 O
) O
, O
and O
the O
proportion O
of O
women O
with O
at O
least O
a O
50 O
% O
reduction O
in O
hot B-outcome ['Physiological-Clinical']
flushes I-outcome ['Physiological-Clinical']
was O
16.2 O
% O
greater O
than O
that O
in O
the O
placebo O
group O
( O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
timing O
of O
these O
events O
in O
relation O
to O
index O
event O
is O
less O
clear O
. O
[]

METHODS O
AND O
MATERIALS O
Toxicity O
data O
of O
512 O
patients O
( O
conformally O
treated O
to O
68 O
Gy O
[ O
n O
= O
284 O
] O
and O
78 O
Gy O
[ O
n O
= O
228 O
] O
) O
with O
complete O
follow-up O
at O
3 O
years O
after O
radiotherapy O
were O
studied O
. O
[]

Direct O
aortic O
cannulation O
in O
minimally O
invasive O
mitral-valve O
operations O
. O
[]

The O
clinical O
manifestations O
were O
paraesthesia B-outcome ['Physiological-Clinical']
( O
100 O
% O
) O
, O
hypaesthesia B-outcome ['Physiological-Clinical']
( O
74 O
% O
) O
, O
weakness B-outcome ['Physiological-Clinical']
( O
58 O
% O
) O
, O
decreased O
muscle B-outcome ['Physiological-Clinical']
stretch I-outcome ['Physiological-Clinical']
reflexes I-outcome ['Physiological-Clinical']
( O
47 O
% O
) O
, O
and O
pain B-outcome ['Physiological-Clinical']
( O
47 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
results O
suggest O
that O
anesthesia O
with O
halothane O
is O
associated O
with O
transient B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
vasoconstriction I-outcome ['Physiological-Clinical']
during O
abdominal O
surgery O
. O
['Physiological-Clinical']

AIM O
TISSEEL O
VH O
is O
the O
only O
commercially O
available O
fibrin O
sealant O
indicated O
as O
an O
adjunct O
to O
conventional O
methods O
of O
hemostasis O
during O
cardiac O
surgery O
. O
[]

CONCLUSIONS/SIGNIFICANCE O
This O
functional O
dissociation O
between O
the O
representation O
of O
self O
versus O
others O
points O
to O
a O
potential O
neural O
substrate O
for O
the O
characteristic O
self-focus O
and O
decreased O
social O
understanding O
exhibited O
by O
these O
individuals O
, O
and O
suggests O
that O
individuals O
with O
ASD O
lack O
the O
shared O
neural O
representations O
for O
self O
and O
others O
that O
TD O
children O
and O
adults O
possess O
and O
may O
use O
to O
understand O
others O
. O
[]

In O
addition O
, O
there O
was O
a O
significant O
linear O
relationship O
between O
the O
log O
of O
the O
dose B-outcome ['Life-Impact']
and O
the O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
reduction O
( O
p O
less O
than O
0.05 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Phase O
I O
compared O
the O
new O
spirometer O
with O
the O
mini-Wright O
peak O
flow O
meter O
and O
Phase O
2 O
compared O
the O
new O
spirometer O
and O
the O
turbine O
spirometer O
. O
[]

Prostate O
cancer O
is O
the O
most O
common O
carcinoma O
of O
the O
elderly O
man O
and O
holds O
the O
third O
place O
in O
the O
ranking O
of O
cancer-specific B-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality']

MAIN O
OUTCOME O
MEASURES O
To O
establish O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
complications B-outcome ['Adverse-effects']
, O
febrile B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
, O
analgesics B-outcome ['Resource-use']
administration I-outcome ['Resource-use']
and O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
for O
both O
treatment O
approaches O
. O
['Life-Impact', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Resource-use', 'Resource-use']

FINDINGS O
Between O
1995 O
and O
2000 O
a O
total O
of O
4,824 O
female O
anopheline O
mosquitoes O
were O
caught O
with O
various O
catching O
methods O
. O
[]

Eradication B-outcome ['Physiological-Clinical']
was O
determined O
by O
a O
13C-urea O
breath O
test O
6 O
months O
and O
2 O
years O
after O
the O
first O
visit O
. O
['Physiological-Clinical']

There O
were O
only O
2 O
( O
1.2 O
% O
) O
of O
retinal B-outcome ['Physiological-Clinical']
detachment I-outcome ['Physiological-Clinical']
and O
no O
case O
of O
corneal B-outcome ['Physiological-Clinical']
decompensation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Sham O
injections O
were O
performed O
by O
pressing O
the O
syringe O
hub O
against O
the O
conjunctiva O
to O
mimic O
a O
real O
injection O
. O
[]

To O
accomplish O
our O
goal O
we O
used O
a O
randomized O
, O
blinded O
, O
field O
trial O
in O
2 O
cohorts O
of O
finisher O
pigs O
in O
a O
multi-site O
swine O
production O
system O
located O
in O
southern O
Ontario O
. O
[]

Four O
of O
22 O
isolates O
were O
resistant B-outcome ['Physiological-Clinical']
to O
chloroquine O
( O
MIC O
> O
108 O
nM/litre O
) O
. O
['Physiological-Clinical']

Effect O
of O
cerivastatin O
on O
proteinuria O
and O
urinary O
podocytes O
in O
patients O
with O
chronic O
glomerulonephritis O
. O
[]

After O
a O
1-week O
preparatory O
screening O
period O
, O
240 O
eligible O
participants O
with O
PER O
will O
be O
randomized O
to O
receive O
acupuncture O
or O
pharmacotherapy O
( O
1:1 O
) O
for O
4 O
weeks O
with O
a O
4-week O
follow-up O
. O
[]

The O
total O
response O
rate O
in O
the O
self-testing O
arm O
was O
24.5 O
% O
, O
significantly O
higher O
than O
in O
the O
telephone O
arm O
( O
18 O
% O
, O
RR O
1.36 O
, O
95 O
% O
CI O
1.19-1.57 O
) O
and O
the O
control O
group O
( O
10.6 O
% O
, O
RR O
2.33 O
, O
95 O
% O
CI O
2.00-2.71 O
) O
. O
[]

The O
primary O
end O
points O
were O
the O
Investigator O
's O
Static B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
( O
ISGA O
) O
score O
and O
lesion B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
; O
the O
secondary O
end O
point O
was O
the O
Dermatology B-outcome ['Life-Impact']
Life I-outcome ['Life-Impact']
Quality I-outcome ['Life-Impact']
Index O
( O
DLQI O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

The O
nightly O
use O
of O
sodium O
oxybate O
is O
associated O
with O
a O
reduction O
in O
nocturnal B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
disruption I-outcome ['Physiological-Clinical']
: O
a O
double-blind O
, O
placebo-controlled O
study O
in O
patients O
with O
narcolepsy O
. O
['Physiological-Clinical']

We O
tested O
whether O
combined O
treatment O
( O
COMB O
) O
with O
risperidone O
and O
parent O
training O
( O
PT O
) O
in O
behavior O
management O
is O
superior O
to O
medication O
alone O
( O
MED O
) O
in O
improving O
severe B-outcome ['Life-Impact']
behavioral I-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
in O
children O
with O
PDDs O
. O
['Life-Impact']

OBJECTIVE O
To O
observe O
the O
effects O
of O
Dujieqing O
Oral O
Liquid O
( O
DJQ O
) O
on O
the O
promoter O
methylation O
of O
the O
O6-methylguanine-DNA O
methyltransferase O
( O
MGMT O
) O
gene O
in O
the O
plasma O
DNA O
samples O
from O
middle-and-late O
stage O
tumor O
patients O
receiving O
chemotherapy O
. O
[]

Six O
boys O
were O
matched O
across O
various O
features O
( O
i.e. O
, O
age O
, O
language O
, O
autism O
severity O
) O
and O
randomly O
placed O
in O
a O
treatment O
condition O
. O
[]

A O
selection O
of O
resistant B-outcome ['Physiological-Clinical']
enterobacteria I-outcome ['Physiological-Clinical']
and O
an O
increase O
in O
beta-lactamase B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
was O
observed O
in O
the O
faecal O
samples O
during O
the O
omeprazole O
plus O
amoxycillin O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
budesonide O
Turbuhaler O
with O
budesonide O
aqua O
in O
the O
treatment O
of O
seasonal O
allergic O
rhinitis O
. O
[]

Safety O
and O
immunogenicity O
of O
a O
combined O
pentavalent O
diphtheria O
, O
tetanus O
, O
acellular O
pertussis O
, O
inactivated O
poliovirus O
and O
Haemophilus O
influenzae O
type O
b-tetanus O
conjugate O
vaccine O
in O
infants O
, O
compared O
with O
a O
whole O
cell O
pertussis O
pentavalent O
vaccine O
. O
[]

Results O
suggest O
that O
a O
more O
medical O
sounding O
term O
( O
CNDS O
) O
may O
lead O
to O
attributions O
that O
this O
syndrome O
is O
a O
more O
serious O
, O
disabling O
illness O
. O
[]

Can O
simvastatin O
improve O
erectile O
function O
and O
health-related O
quality O
of O
life O
in O
men O
aged O
?40 O
years O
with O
erectile O
dysfunction O
? O
[]

clinicaltrials.gov O
database O
( O
identifier O
: O
NCT01130922 O
) O
. O
] O
[]

However O
, O
health O
deciders O
need O
reliable O
data O
on O
which O
to O
base O
future O
policies O
concerning O
this O
. O
[]

8.7 O
) O
] O
were O
all O
significantly O
lower O
than O
those O
in O
control O
group O
[ O
( O
16.9 O
? O
[]

CONCLUSIONS O
Brief O
, O
daily O
hopping O
exercises O
increased O
femoral B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
in O
premenopausal O
women O
but O
less O
frequent O
exercise O
was O
not O
effective O
. O
['Physiological-Clinical']

AIM O
To O
test O
if O
treatment O
with O
GnRH O
analogue O
, O
which O
leads O
to O
a O
significant O
reduction O
in O
myoma B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
changes O
expression O
of O
leptin O
genes O
and O
gene O
coding O
leptin B-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
isoforms I-outcome ['Physiological-Clinical']
in O
uterine O
myomas O
and O
in O
the O
surrounding O
unaltered O
myometrium O
. O
['Physiological-Clinical', 'Physiological-Clinical']

FINDINGS O
1397 O
patients O
were O
assessed O
for O
the O
composite O
endpoint O
. O
[]

AIM O
To O
investigate O
the O
sustained O
effect O
on O
quality O
of O
life O
during O
the O
grass O
pollen O
season O
1 O
year O
after O
3 O
years O
of O
treatment O
with O
the O
SQ-standardized O
grass O
allergy O
immunotherapy O
tablet O
( O
AIT O
) O
, O
Graza O
( O
Phleum O
pratense O
75,000 O
SQ-T/2800 O
BAU O
; O
ALK O
, O
Denmark O
) O
. O
[]

BACKGROUND O
There O
is O
substantial O
variability O
in O
the O
perioperative O
administration O
of O
aspirin O
in O
patients O
undergoing O
noncardiac O
surgery O
, O
both O
among O
patients O
who O
are O
already O
on O
an O
aspirin O
regimen O
and O
among O
those O
who O
are O
not O
. O
[]

All O
patients O
were O
strongly O
recommended O
to O
take O
daily O
calcium O
and O
vitamin O
D O
supplements O
. O
[]

An O
efficient O
triage O
system O
is O
essential O
to O
a O
busy O
labor O
and O
delivery O
unit O
for O
the O
evaluation O
of O
unscheduled O
patient O
visits O
. O
[]

INTRODUCTION O
Estimating O
the O
cost O
utility O
of O
hemiarthroplasty O
compared O
to O
internal O
fixation O
in O
the O
treatment O
of O
displaced O
femoral O
neck O
fractures O
in O
the O
elderly O
. O
[]

Wavefront-guided O
versus O
standard O
LASIK O
enhancement O
for O
residual O
refractive O
errors O
. O
[]

DESIGN O
The O
study O
was O
a O
randomized O
, O
controlled O
, O
clinical O
trial O
. O
[]

Based O
upon O
discriminant O
analysis O
, O
a O
total O
of O
26 O
deaths B-outcome ['Mortality']
were O
expected O
from O
the O
entire O
group O
, O
but O
only O
7 O
patients O
died B-outcome ['Mortality']
, O
therefore O
, O
the O
['Mortality', 'Mortality']

Cox O
regression O
analysis O
showed O
that O
the O
use O
of O
chemotherapy O
after O
first O
progression O
( O
HR O
0.54 O
; O
95 O
% O
CI O
0.35-0.86 O
; O
p O
= O
0.008 O
) O
, O
PS O
= O
0 O
( O
HR O
0.53 O
; O
95 O
% O
CI O
0.35-0.81 O
; O
p O
= O
0.001 O
) O
and O
female O
gender O
( O
HR O
0.63 O
; O
95 O
% O
CI O
0.41-0.98 O
; O
p O
= O
0.038 O
) O
were O
significantly O
associated O
with O
a O
longer O
TFPTD O
; O
treatment O
arm O
was O
not O
significant O
( O
HR O
0.88 O
; O
95 O
% O
CI O
0.60-1.31 O
; O
p O
= O
0.54 O
) O
. O
[]

The O
main O
outcome O
measure O
was O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
IOP B-outcome ['Physiological-Clinical']
) O
lowering B-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
ELT I-outcome ['Physiological-Clinical']
and O
SLT B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Kaplan-Meier O
survival O
curve O
analysis O
showed O
no O
statistical O
difference O
between O
the O
groups O
in O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
catheter I-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Primary O
vitrectomy O
for O
combined O
rhegmatogenous O
retinal O
detachment O
and O
choroidal O
detachment O
with O
or O
without O
oral O
corticosteroids O
: O
a O
pilot O
study O
. O
[]

OBJECTIVE O
To O
determine O
clinical O
, O
enzymatic O
, O
and O
microbiologic B-outcome ['Physiological-Clinical']
effects O
of O
controlled-release O
localized O
administration O
of O
minocycline O
on O
dogs O
with O
periodontitis O
. O
['Physiological-Clinical']

Non-verbal O
communication O
of O
compassion O
: O
measuring O
psychophysiologic O
effects O
. O
[]

Response O
, O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
, O
and O
overall O
survival B-outcome ['Mortality']
were O
evaluated O
in O
patients O
treated O
with O
a O
TKI-everolimus-TKI O
sequence O
. O
['Mortality', 'Mortality']

The O
outcomes O
were O
assessed O
with O
the O
following O
scores O
: O
Menopausal O
Quality O
of O
Life O
Questionnaire O
( O
MENQOL O
) O
total O
and O
domain O
( O
vasomotor O
symptoms O
, O
psychosocial O
, O
physical O
and O
sexual O
) O
. O
[]

INTRODUCTION O
There O
is O
an O
ongoing O
debate O
about O
the O
preferred O
technique O
for O
inguinal O
hernia O
repair O
. O
[]

BACKGROUND O
& O
AIMS O
Patients O
recovering O
from O
mild O
acute O
pancreatitis O
typically O
receive O
a O
clear O
liquid O
diet O
( O
CLD O
) O
when O
ready O
to O
initiate O
oral O
nutrition O
. O
[]

The O
patients O
were O
part O
of O
a O
multicentre O
study O
in O
the O
Stockholm O
area O
and O
had O
been O
randomized O
to O
treatment O
with O
either O
estramustine O
phosphate O
( O
Estracyt O
) O
or O
polyestradiol O
phosphate O
and O
ethinyl O
estradiol O
. O
[]

The O
aim O
of O
this O
feasibility O
study O
was O
to O
prospectively O
evaluate O
the O
diagnostic O
yield O
and O
safety O
of O
cryobiopsy O
and O
forceps O
biopsy O
. O
[]

To O
the O
patients O
of O
trial O
group O
, O
oral O
administration O
of O
WTC O
was O
given O
additionally O
with O
4 O
capsules O
, O
3 O
times O
a O
day O
for O
consecutive O
3 O
months O
. O
[]

Preliminary O
treatment O
effects O
were O
also O
noted O
in O
children B-outcome ['Physiological-Clinical']
's O
prompted B-outcome ['Life-Impact']
and O
spontaneous B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

We O
formulated O
four O
specific O
questions O
: O
( O
1 O
) O
can O
a O
concurrent O
SAS O
shorten O
the O
onset O
of O
automatic O
postural O
responses O
? O
; O
[]

A O
randomized O
trial O
of O
exercise O
therapy O
in O
patients O
with O
acute O
low O
back O
pain O
. O
[]

Analyses O
indicated O
that O
aerobic O
exercisers O
, O
in O
comparisons O
with O
the O
other O
groups O
, O
responded O
to O
acute O
stress O
with O
more O
positive O
affect O
, O
lower O
stressor B-outcome ['Physiological-Clinical']
task I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
reduced O
systolic B-outcome ['Physiological-Clinical']
( O
but O
not O
diastolic B-outcome ['Physiological-Clinical']
) O
blood O
pressure O
, O
and O
superior O
motor B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

This O
study O
was O
undertaken O
to O
compare O
the O
recovery O
and O
discharge B-outcome ['Resource-use']
times O
of O
outpatients O
undergoing O
procedures O
greater O
than O
2 O
hours O
in O
length O
. O
['Physiological-Clinical', 'Resource-use']

Side O
effects O
, O
mainly O
diarrhea B-outcome ['Physiological-Clinical']
, O
occurred O
in O
15 O
percent O
of O
the O
patients O
given O
antibiotics O
. O
['Physiological-Clinical']

The O
3 O
year O
disease B-outcome ['Mortality']
free I-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
63.4 O
% O
for O
the O
cisplatin O
group O
and O
60.9 O
% O
for O
the O
carboplatin O
group O
( O
p=0.9613 O
) O
( O
HR O
0.70 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
: O
0.50-0.98 O
) O
. O
['Mortality']

STUDY O
DESIGN O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
was O
performed O
with O
100 O
low-risk O
patients O
having O
well-dated O
pregnancies O
. O
[]

RESULTS O
A O
significant O
increase O
of O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor O
I O
( O
IGF-I O
) O
( O
somatomedin O
C O
) O
levels O
and O
of O
['Physiological-Clinical']

Complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
after O
controlling O
for O
hepatitis O
C O
virus O
was O
similar O
( O
relative O
risk=1.19 O
; O
95 O
% O
confidence O
interval=0.89-1.60 O
) O
. O
['Physiological-Clinical']

We O
provided O
education O
about O
risk O
factors O
, O
relaxation O
training O
techniques O
, O
methods O
for O
self-monitoring O
and O
cognitive O
restructuring O
, O
with O
an O
emphasis O
on O
coping O
with O
stress O
exposure O
from O
family O
and O
work O
, O
and O
self-care O
and O
compliance O
with O
clinical O
advice O
. O
[]

They O
represent O
an O
interesting O
model O
for O
studying O
GH O
secretion O
, O
as O
a O
slight O
degree O
of O
cortisol O
excess O
may O
frequently O
be O
observed O
in O
such O
patients O
who O
do O
not O
present O
with O
any O
clear O
Cushingoid O
sign O
. O
[]

CONCLUSIONS O
Compared O
with O
placebo O
, O
olanzapine O
treatment O
was O
associated O
with O
longer O
maintenance B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
patients O
presenting O
with O
a O
mixed O
index O
episode O
of O
bipolar O
I O
disorder O
. O
['Physiological-Clinical']

BACKGROUND O
Risperidone O
may O
be O
effective O
in O
improving O
tantrums B-outcome ['Life-Impact']
, O
aggression B-outcome ['Physiological-Clinical']
, O
or O
self-injurious B-outcome ['Physiological-Clinical']
behaviour I-outcome ['Physiological-Clinical']
in O
children O
with O
autism O
, O
but O
often O
leads O
to O
weight O
gain O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Postmenopausal O
BCS O
( O
223 O
) O
were O
randomly O
assigned O
to O
exercise O
plus O
medication O
or O
medication O
only O
groups O
. O
[]

The O
hydration O
status O
was O
assessed O
with O
USG O
and O
body O
mass O
measures O
and O
urine O
volume O
collections O
. O
[]

Randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
oral O
sirolimus O
for O
restenosis B-outcome ['Physiological-Clinical']
prevention O
in O
patients O
with O
in-stent O
restenosis O
: O
the O
Oral O
Sirolimus O
to O
Inhibit O
Recurrent O
In-stent O
Stenosis O
( O
OSIRIS O
) O
trial O
. O
['Physiological-Clinical']

Caregivers O
in O
control O
and O
counseling O
groups O
whose O
relatives O
entered O
a O
nursing O
home O
improved O
their O
psychosocial B-outcome ['Life-Impact']
adjustment I-outcome ['Life-Impact']
23 O
% O
on O
average O
whereas O
those O
continuing O
to O
live O
in O
the O
community O
decreased O
by O
8 O
% O
. O
['Life-Impact']

Split-course O
radiation O
therapy O
is O
superior O
to O
continuous O
radiation O
therapy O
because O
it O
is O
better O
tolerated B-outcome ['Life-Impact']
by O
the O
patient O
and O
because O
re-examination O
of O
the O
patient O
prior O
to O
the O
second O
half O
of O
split-course O
therapy O
permits O
the O
detection O
of O
new O
metastatic O
disease O
that O
has O
become O
manifest O
during O
the O
rest O
period O
and O
spares O
the O
patient O
the O
futile O
second O
half O
of O
radiation O
therapy O
. O
['Life-Impact']

OBJECTIVE O
Symptoms O
of O
depression O
and O
anxiety O
are O
commonly O
comorbid O
with O
attention-deficit/hyperactivity O
disorder O
( O
ADHD O
) O
. O
[]

All O
subjects O
participated O
in O
a O
crossover O
study O
of O
2 O
randomly O
scheduled O
15-day O
study O
periods O
during O
which O
250 O
mg O
theophylline O
twice O
daily O
or O
matching O
placebo O
was O
used O
. O
[]

There O
was O
a O
significant O
( O
ANOVA O
) O
drop O
of O
the O
haematocrit B-outcome ['Physiological-Clinical']
value O
only O
in O
the O
control O
group O
, O
and O
end-point O
values O
for O
haematocrit O
and O
haemoglobin O
were O
significantly O
elevated O
in O
the O
400 O
and O
500 O
U/kg O
groups O
compared O
with O
the O
control O
group O
( O
Table O
9 O
) O
. O
['Physiological-Clinical']

4 O
. O
[]

RESULTS O
Eleven O
raters O
showed O
excellent O
reliability O
( O
ICC O
= O
0.97 O
) O
. O
[]

Benefits O
of O
adding O
fluticasone O
propionate/salmeterol O
to O
tiotropium O
in O
moderate O
to O
severe O
COPD O
. O
[]

METHODS O
A O
total O
of O
819 O
women O
with O
a O
Nugent O
score O
of O
6 O
and O
above O
were O
considered O
to O
have O
BV O
and O
treated O
according O
to O
Zelen O
allocation O
. O
[]

The O
children O
in O
each O
group O
were O
assessed O
initially O
on O
a O
checklist O
, O
Sensory O
Evaluation O
Form O
for O
Children O
with O
Autism O
, O
developed O
to O
evaluate O
sensory B-outcome ['Life-Impact']
characteristics I-outcome ['Life-Impact']
of O
children O
with O
autism O
, O
and O
at O
the O
end O
of O
the O
study O
, O
participants O
were O
assessed O
again O
on O
the O
checklist O
. O
['Life-Impact']

Considerable O
differences O
in O
dose B-outcome ['Life-Impact']
( O
atenolol O
138 O
+/- O
13 O
mg O
daily O
; O
labetalol O
308 O
+/- O
34 O
mg O
daily O
; O
metoprolol O
234 O
+/- O
22 O
mg O
daily O
; O
and O
pindolol O
24 O
+/-2 O
mg O
daily O
were O
required O
to O
produce O
similar O
antihypertensive B-outcome ['Physiological-Clinical']
effects O
. O
['Life-Impact', 'Physiological-Clinical']

CONCLUSION O
Among O
the O
parameters O
measured O
, O
plasma B-outcome ['Physiological-Clinical']
AGE-peptides I-outcome ['Physiological-Clinical']
was O
the O
only O
parameter O
found O
to O
be O
higher O
in O
type O
2 O
diabetes O
mellitus O
patients O
with O
nephropathy O
than O
without O
nephropathy O
. O
['Physiological-Clinical']

Primary O
posterior O
capsulectomy O
and O
anterior O
vitrectomy O
were O
performed O
through O
the O
limbus O
in O
half O
of O
the O
eyes O
and O
the O
pars O
plana O
in O
the O
other O
half O
. O
[]

RESULTS O
Evaluation O
of O
all O
patients O
included O
global B-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
nephrotoxicity B-outcome ['Physiological-Clinical']
, O
as O
well O
as O
the O
economic B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
and O
effectiveness O
derived O
from O
the O
vancomycin O
monitoring O
program O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

METHODS O
This O
study O
was O
a O
post-hoc O
analysis O
of O
pooled O
data O
from O
two O
8-week O
, O
double-blind O
, O
randomized O
, O
placebo-controlled O
studies O
evaluating O
aripiprazole O
for O
the O
treatment O
of O
irritability O
in O
pediatric O
subjects O
with O
autistic O
disorder O
, O
aged O
6-17 O
years O
. O
[]

RESULTS O
Subjects O
' O
mean O
age O
was O
43.6 O
years O
; O
all O
were O
women O
. O
[]

METHODS O
A O
prospective O
study O
in O
80 O
patients O
was O
carried O
out O
. O
[]

RESULTS O
In O
the O
usual O
care O
group O
17 O
of O
32 O
( O
53 O
% O
) O
patients O
with O
echolucent B-outcome ['Physiological-Clinical']
plaques I-outcome ['Physiological-Clinical']
at O
baseline O
suffered O
from O
a O
combined O
end-point O
( O
any O
death B-outcome ['Mortality']
or O
nonfatal B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
nonfatal I-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
) O
during O
follow-up O
compared O
with O
seven O
of O
28 O
( O
25 O
% O
) O
patients O
in O
the O
intervention O
group O
( O
P O
= O
0.036 O
) O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
, O
or O
stinging B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
instillation I-outcome ['Physiological-Clinical']
( O
P O
= O
.29 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Immune O
globulin O
was O
administered O
intravenously O
6 O
times O
with O
20 O
days O
interval O
, O
starting O
on O
day O
7 O
before O
transplantation O
. O
[]

The O
primary O
outcome O
was O
between-group O
change O
in O
6-minute O
walk O
distance O
from O
baseline O
to O
20 O
weeks O
. O
[]

Synovial B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
TNFR I-outcome ['Physiological-Clinical']
: O
Fc B-outcome ['Physiological-Clinical']
protein B-outcome ['Physiological-Clinical']
was O
not O
detected O
( O
nor O
expected O
) O
at O
the O
doses O
used O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
latency B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
analgesia I-outcome ['Physiological-Clinical']
for O
the O
first O
blocked O
segment O
( O
T O
12 O
for O
bupivacaine O
and O
ropivacaine O
and O
L-1 O
for O
etidocaine O
) O
was O
6.0 O
min O
for O
bupivacaine O
0.75 O
, O
5.5 O
min O
for O
ropivacaine O
1 O
% O
, O
and O
5.2 O
min O
for O
etidocaine O
1 O
% O
, O
and O
the O
highest O
thoracic O
dermatome O
( O
T O
5 O
for O
bupivacaine O
, O
T O
4 O
for O
ropivacaine O
and O
T O
7 O
for O
etidocaine O
) O
was O
reached O
after O
24 O
+/- O
10 O
, O
26 O
+/- O
9 O
, O
and O
30 O
+/- O
18 O
min O
for O
bupivacaine O
, O
ropivacaine O
, O
and O
etidocaine O
, O
respectively O
. O
['Physiological-Clinical']

In O
adjusted O
analyses O
, O
parents O
who O
reported O
that O
their O
child O
had O
ASD O
did O
not O
have O
significantly O
higher O
out-of-pocket B-outcome ['Resource-use']
['Resource-use']

Domperidone O
, O
metoclopramide O
, O
and O
placebo O
. O
[]

The O
total O
study O
period O
will O
be O
9 O
weeks O
. O
[]

A O
total O
of O
266 O
patients O
will O
receive O
full-dose O
thrombolysis O
, O
preferably O
pre-hospital O
, O
and O
then O
be O
randomized O
to O
either O
strategy O
. O
[]

This O
study O
investigated O
the O
relationship O
between O
parents O
' O
state B-outcome ['Life-Impact']
and O
trait B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
and O
parent-reported O
internalizing O
and O
externalizing O
symptoms O
among O
adolescents O
( O
n O
= O
30 O
) O
with O
ASD O
, O
as O
well O
as O
the O
relationship O
of O
parents O
' O
anxiety O
symptoms O
and O
adolescent O
treatment O
response O
in O
the O
context O
of O
a O
randomized O
controlled O
trial O
. O
['Life-Impact', 'Life-Impact']

All O
the O
patients O
underwent O
tissue O
Doppler O
echocardiographic O
examination O
before O
and O
three O
months O
after O
treatment O
to O
compare O
the O
effects O
of O
the O
two O
drugs O
on O
atrial O
electromechanical O
coupling O
. O
[]

84 O
% O
) O
, O
grade O
3+4 B-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
( O
90 O
% O
vs O
. O
['Physiological-Clinical']

The O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs O
) O
was O
higher O
in O
the O
vilazodone O
group O
( O
57.6 O
% O
) O
than O
in O
the O
moxifloxacin O
( O
37.0 O
% O
) O
and O
placebo O
( O
35.6 O
% O
) O
groups O
, O
though O
AEs B-outcome ['Adverse-effects']
were O
generally O
mild O
to O
moderate O
in O
severity O
and O
resulted O
in O
few O
discontinuations O
. O
['Adverse-effects', 'Adverse-effects']

H. O
pylori O
infection O
did O
not O
increase O
the O
incidence O
of O
bisphosphonate O
related O
gastric O
ulcers O
. O
[]

Improving O
the O
immunogenicity B-outcome ['Physiological-Clinical']
of O
pneumococcal O
conjugate O
vaccine O
in O
HIV-infected O
adults O
with O
a O
toll-like O
receptor O
9 O
agonist O
adjuvant O
: O
a O
randomized O
, O
controlled O
trial O
. O
['Physiological-Clinical']

N-butyl O
cyanoacrylate O
embolization O
of O
cerebral O
arteriovenous O
malformations O
: O
results O
of O
a O
prospective O
, O
randomized O
, O
multi-center O
trial O
. O
[]

The O
findings O
suggest O
that O
the O
Social O
Withdrawal O
subscale O
may O
be O
a O
useful O
measure O
of O
social B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
in O
acute O
treatment O
trials O
. O
['Life-Impact']

Gender O
differences O
in O
response O
to O
nicotine O
replacement O
therapy O
: O
objective O
and O
subjective O
indexes O
of O
tobacco O
withdrawal O
. O
[]

Serum B-outcome ['Physiological-Clinical']
G-CSF I-outcome ['Physiological-Clinical']
levels O
were O
measured O
by O
an O
enzyme O
immunoassay O
method O
. O
['Physiological-Clinical']

However O
, O
snoring B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
showed O
a O
concomitant O
increase O
from O
6.7+/-14.3 O
to O
24.0+/-13.2 O
% O
of O
TST O
. O
['Physiological-Clinical']

Mean O
postoperative B-outcome ['Physiological-Clinical']
intraocular I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
12.2 O
mmHg O
in O
group O
1 O
, O
and O
13.7 O
mmHg O
in O
group O
2 O
( O
P O
= O
0.16 O
) O
. O
['Physiological-Clinical']

Satisfaction O
with O
care O
was O
greater O
in O
the O
group O
receiving O
radiography O
at O
9 O
months O
. O
[]

The O
efficacy O
and O
safety O
of O
an O
aromatase O
inhibitor O
, O
fadrozole O
HCL O
, O
were O
compared O
with O
megestrol O
acetate O
in O
post O
menopausal O
patients O
who O
had O
disease O
progression O
after O
receiving O
antiestrogen O
therapy O
either O
for O
metastatic O
disease O
or O
as O
adjuvant O
therapy O
. O
[]

Treatment O
was O
continued O
for O
6 O
months O
. O
[]

No O
bleeding B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
, O
deaths B-outcome ['Mortality']
or O
pulmonary B-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
were O
recorded O
in O
either O
group O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

In O
14 O
of O
18 O
patients O
who O
received O
both O
treatments O
clobazam O
was O
superior O
to O
placebo O
, O
and O
in O
4 O
patients O
no O
preference O
was O
established O
. O
[]

Specific O
components O
of O
a O
medical O
home O
less O
prevalent O
among O
children O
with O
autism O
than O
among O
children O
with O
other O
special O
health O
care O
needs O
included O
family-centered O
, O
comprehensive O
, O
and O
coordinated O
care O
. O
[]

The O
safety O
and O
efficacy O
of O
granisetron O
( O
10 O
micrograms/kg O
and O
40 O
micrograms/kg O
) O
were O
evaluated O
during O
a O
second O
( O
n O
= O
393 O
) O
and O
third O
( O
n O
= O
200 O
) O
cycle O
of O
chemotherapy O
in O
this O
multicenter O
, O
double-blind O
, O
randomized O
, O
parallel-group O
study O
. O
[]

The O
cost-effectiveness O
of O
parasitologic O
diagnosis O
for O
malaria-suspected O
patients O
in O
an O
era O
of O
combination O
therapy O
. O
['Resource-use']

At-home O
exposure O
completion O
was O
greater O
in O
FCBT O
and O
there O
was O
an O
interaction O
in O
child O
involvement O
for O
treatment O
and O
ASD O
status O
. O
[]

Endogenous O
endothelin O
action O
is O
augmented O
in O
human O
obesity O
and O
type O
2 O
diabetes O
and O
contributes O
to O
endothelial O
dysfunction O
and O
impairs O
insulin-mediated O
vasodilation O
in O
humans O
. O
[]

6-mercaptopurine O
should O
remain O
the O
thiopurine O
of O
choice O
for O
continuing O
therapy O
of O
childhood O
lymphoblastic O
leukaemia O
. O
[]

The O
median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TTP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
3.8 O
months O
in O
arm O
A O
and O
5.8 O
months O
in O
arm O
B O
. O
['Physiological-Clinical']

How O
altered O
pain O
processing O
is O
related O
to O
disease O
stage O
still O
needs O
study O
. O
[]

RESULTS O
No O
new O
or O
worsening B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
existing I-outcome ['Physiological-Clinical']
genital I-outcome ['Physiological-Clinical']
findings I-outcome ['Physiological-Clinical']
were O
observed O
during O
the O
follow-up O
examination O
. O
['Physiological-Clinical']

Eleven O
adult O
patients O
with O
autism O
or O
Asperger O
's O
disorder O
were O
randomized O
to O
single O
dose O
sumatriptan O
( O
6 O
mg O
SQ O
) O
and O
placebo O
challenges O
, O
separated O
by O
a O
one-week O
interval O
. O
[]

We O
analyzed O
thresholds O
for O
contact O
detection O
, O
two-point O
discrimination O
, O
and O
two-point O
perception O
, O
obtained O
during O
the O
clinical O
trial O
before O
and O
at O
1 O
, O
3 O
, O
and O
6 O
months O
after O
surgery O
, O
to O
assess O
tactile O
detection O
and O
discriminative O
sensitivities O
, O
and O
subjective O
interpretation O
of O
tactile O
stimulation O
, O
respectively O
. O
[]

BACKGROUND O
During O
cancer O
treatment O
children O
have O
reduced O
contact O
with O
their O
social O
network O
of O
friends O
, O
and O
have O
limited O
participation O
in O
education O
, O
sports O
, O
and O
leisure O
activities O
. O
[]

All O
patients O
were O
interviewed O
in O
the O
evening O
and O
time O
of O
ambulation O
and O
rating O
of O
OR O
experience O
was O
noted O
. O
[]

RESULTS O
Significant O
differences O
and/or O
trends O
in O
favor O
of O
the O
EG O
were O
observed O
regarding O
the O
primary O
endpoint O
endurance B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
( O
P=0.002 O
) O
, O
muscular B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
( O
P=0.022 O
) O
, O
fatigue B-outcome ['Physiological-Clinical']
( O
P=0.046 O
) O
, O
and O
emotional B-outcome ['Life-Impact']
state I-outcome ['Life-Impact']
( O
P=0.028 O
) O
without O
posing O
an O
additional O
risk O
for O
the O
individual O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Respiratory B-outcome ['Physiological-Clinical']
and O
cardiovascular B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
were O
preserved O
, O
and O
the O
incidence O
of O
nausea B-outcome ['Physiological-Clinical']
, O
pruritus B-outcome ['Physiological-Clinical']
, O
and O
periods O
of O
drowsiness B-outcome ['Physiological-Clinical']
or O
sleep B-outcome ['Physiological-Clinical']
were O
similar O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Correlation O
between O
neuropsychological O
testing O
and O
patients O
' O
self-evaluation O
of O
cognitive O
functioning O
in O
daily O
life O
was O
generally O
low O
. O
[]

Weight O
loss B-outcome ['Physiological-Clinical']
of O
10 O
% O
or O
more O
of O
initial O
body O
weight O
was O
observed O
in O
6 O
of O
10 O
women O
in O
the O
comprehensive O
group O
at O
12 O
months O
. O
['Physiological-Clinical']

Forty-two O
hypertensives O
60 O
years O
of O
age O
or O
above O
, O
without O
evidence O
of O
ischemic O
disease O
underwent O
2-D O
echocardiographic O
evaluation O
of O
LV O
mass O
and O
gated O
blood O
pool O
scan O
determination O
of O
early O
diastolic O
filling O
, O
cardiac O
output O
and O
ejection O
fraction O
. O
[]

RESULTS O
The O
following O
median O
rates O
were O
greater O
for O
the O
FOS-90 O
group O
( O
N O
= O
8 O
) O
than O
for O
the O
FOS-120 O
group O
( O
N O
= O
10 O
) O
: O
greatest O
maximum B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
which I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
enlarged O
in O
a O
posterior O
direction O
( O
43.5 O
vs O
12.5 O
microns/day O
; O
P O
= O
.002 O
) O
; O
posterior B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
closest O
to O
the O
fovea O
( O
42.8 O
vs O
5.5 O
microns/day O
; O
P O
= O
.010 O
) O
; O
and O
maximum B-outcome ['Physiological-Clinical']
foveal I-outcome ['Physiological-Clinical']
proximity I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
either I-outcome ['Physiological-Clinical']
eye I-outcome ['Physiological-Clinical']
( O
32.3 O
vs O
3.4 O
microns/day O
; O
P O
= O
.031 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
in-hospital B-outcome ['Mortality']
mortality I-outcome ['Mortality']
during O
the O
study O
was O
similar O
in O
conventional O
and O
intensive O
therapy O
groups O
( O
34 O
of O
119 O
, O
28.6 O
% O
vs. O
35 O
of O
121 O
, O
28.9 O
% O
in O
the O
conventional O
and O
intensive O
insulin O
therapy O
groups O
; O
P=0.85 O
) O
. O
['Mortality']

Previous O
clinical O
studies O
on O
low-risk O
patients O
who O
had O
coronary O
artery O
bypass O
grafting O
( O
CABG O
) O
and O
received O
full-dose O
systemic O
heparin O
did O
not O
have O
clearly O
improved O
clinical O
outcomes O
. O
[]

The O
primary O
end O
point O
was O
noninferiority O
of O
9-month B-outcome ['Physiological-Clinical']
target I-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
defined O
as O
cardiac B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
or O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

BACKGROUND O
Nightblindness O
affects O
16-52 O
% O
of O
pregnant O
women O
in O
areas O
of O
Nepal O
and O
in O
some O
cases O
persists O
after O
vitamin O
A O
treatment O
. O
[]

Recurrent B-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
was O
seen O
significantly O
more O
often O
in O
patients O
receiving O
continuous O
heparin O
therapy O
. O
['Physiological-Clinical']

Immunisation B-outcome ['Resource-use']
rates O
in O
this O
low-risk O
group O
fell O
well O
short O
of O
the O
60 O
% O
government O
target O
. O
['Resource-use']

RESULTS O
One O
hundred O
twenty-five O
deaths O
occurred O
, O
of O
which O
117 O
were O
not O
accidental O
. O
[]

Use O
of O
activated O
charcoal O
in O
a O
simulated O
poisoning O
with O
acetaminophen O
: O
a O
new O
loading O
dose O
for O
N-acetylcysteine O
? O
[]

A O
recent O
randomized O
controlled O
trial O
( O
RCT O
) O
of O
a O
dual O
parent O
and O
trainer-delivered O
qigong O
massage O
intervention O
for O
young O
children O
with O
autism O
resulted O
in O
improvement O
of O
measures O
of O
autism B-outcome ['Life-Impact']
as O
well O
as O
improvement O
of O
abnormal B-outcome ['Physiological-Clinical']
sensory I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
and O
self-regulation B-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Four O
studies O
( O
N O
= O
665 O
) O
demonstrate O
that O
the O
mere O
presence O
of O
highly O
dissimilar O
fillers O
inflates O
witnesses O
' O
confidence B-outcome ['Life-Impact']
in O
a O
mistaken O
identification O
( O
Studies O
1-4 O
) O
, O
provides O
evidence O
that O
this O
['Life-Impact']

Effects O
of O
glucose-insulin-potassium O
infusion O
on O
ST-elevation B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
in O
patients O
treated O
with O
thrombolytic O
therapy O
. O
['Physiological-Clinical']

Randomized O
study O
of O
six O
umbilical O
cord O
care O
regimens O
. O
[]

Whether O
BMI O
is O
associated O
with O
prostate O
cancer-specific O
mortality O
( O
PCSM O
) O
was O
investigated O
in O
a O
large O
randomized O
trial O
of O
men O
treated O
with O
RT O
and O
androgen O
deprivation O
therapy O
( O
ADT O
) O
for O
locally O
advanced O
prostate O
cancer O
. O
[]

This O
report O
represents O
the O
first O
such O
study O
of O
diflunisal O
used O
for O
an O
extended O
course O
in O
oral O
surgery O
with O
pain B-outcome ['Physiological-Clinical']
assessment O
over O
the O
same O
period O
. O
['Physiological-Clinical']

A O
complete O
ophthalmologic O
examination O
was O
performed O
at O
baseline O
and O
at O
the O
completion O
of O
the O
study O
. O
[]

The O
outcome O
measures O
included O
change O
in O
intelligence O
quotient O
scores O
on O
Stanford-Binet O
Intelligence O
Scale O
( O
Hindi O
adaptation O
by O
Kulshrestha O
) O
, O
change O
in O
behavioral O
scores O
by O
Conners O
3 O
Parent O
Rating O
Scale O
( O
Short O
) O
and O
Childhood B-outcome ['Life-Impact']
Autism I-outcome ['Life-Impact']
Rating O
Scale O
, O
safety O
, O
and O
tolerability B-outcome ['Life-Impact']
of O
donepezil O
. O
['Life-Impact', 'Life-Impact']

Eighty-six O
nurses O
served O
as O
controls O
. O
[]

Usability B-outcome ['Life-Impact']
testing O
was O
conducted O
to O
obtain O
feedback O
regarding O
draft O
versions O
of O
the O
materials O
. O
['Life-Impact']

RATIONALE O
Continuous O
positive O
airway O
pressure O
( O
CPAP O
) O
use O
is O
associated O
with O
reduced O
motor O
vehicle O
accidents O
in O
patients O
with O
obstructive O
sleep O
apnea O
( O
OSA O
) O
. O
[]

One O
hundred O
women O
in O
the O
intervention O
group O
completed O
the O
intervention O
interviews O
and O
after O
four O
months O
, O
100 O
women O
in O
the O
intervention O
group O
and O
100 O
in O
the O
control O
group O
also O
completed O
the O
post-intervention O
interviews O
. O
[]

A O
correlation O
of O
the O
angiographic O
evolution O
of O
coronary O
stenoses O
( O
stenosis O
diameter O
> O
or O
= O
20 O
% O
) O
with O
morphological O
stenosis O
parameters O
at O
baseline O
could O
help O
to O
identify O
the O
risk O
of O
progressive B-outcome ['Physiological-Clinical']
stenoses I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Primary O
end O
points O
of O
effectiveness O
( O
three O
parameters O
) O
and O
secondary O
end O
points O
of O
safety O
during O
ESD O
and O
after O
return O
to O
the O
ward O
were O
compared O
between O
the O
groups O
. O
[]

Median O
time O
to O
progression B-outcome ['Physiological-Clinical']
was O
2.7 O
and O
4.1 O
months O
in O
the O
control O
and O
paclitaxel/cisplatin O
arm O
, O
respectively O
( O
P=.026 O
) O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
This O
was O
a O
single-center O
, O
open-label O
, O
two-period O
, O
randomized O
crossover O
study O
. O
[]

Four O
patients O
achieved O
partial O
responses O
and O
17 O
had O
stable O
disease O
, O
lasting O
> O
3 O
months O
in O
14 O
patients O
. O
[]

Those O
individuals O
randomly O
assigned O
to O
the O
intervention O
group O
( O
n O
= O
33 O
) O
received O
PACT O
case O
management O
in O
addition O
to O
their O
usual O
medical O
and O
nursing O
home O
care O
. O
[]

Thirty O
patients O
were O
included O
, O
divided O
into O
two O
groups O
of O
15 O
, O
to O
whom O
one O
of O
the O
study O
therapies O
was O
administered O
based O
on O
a O
randomization O
code O
. O
[]

The O
effects O
of O
epinephrine-free O
and O
epinephrine-containing O
local O
anesthetic O
solutions O
on O
plasma B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
investigated O
in O
20 O
patients O
undergoing O
oral O
surgery O
with O
intravenous O
midazolam O
sedation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Efforts O
to O
promote O
smoking O
cessation O
should O
highlight O
that O
individuals O
are O
likely O
to O
feel O
more O
rather O
than O
less O
psychologically O
healthy O
when O
they O
successfully O
quit O
smoking O
. O
[]

The O
week O
1 O
to O
0 O
ratio O
was O
8.8-fold O
higher O
( O
P O
= O
.0025 O
) O
and O
the O
week O
2 O
to O
0 O
ratio O
was O
5.7-fold O
higher O
( O
P O
= O
.023 O
) O
in O
the O
raltegravir O
vs. O
placebo O
group O
. O
[]

The O
difference O
in O
genotype O
distribution O
between O
patients O
and O
control O
subjects O
was O
significant O
( O
p O
< O
0.0005 O
) O
. O
[]

RESULTS O
A O
total O
of O
83 O
patients O
were O
eligible O
for O
safety O
and O
efficacy O
analyses O
. O
[]

RESULTS O
This O
study O
enrolled O
743 O
patients O
. O
[]

PARTICIPANTS O
Convenience O
sample O
of O
couples O
. O
[]

Untoward B-outcome ['Adverse-effects']
side-effect I-outcome ['Adverse-effects']
incidence O
was O
much O
higher O
in O
the O
diethylstilbestrol O
group O
( O
30.4 O
% O
) O
as O
compared O
with O
tamoxifen O
( O
3.5 O
% O
) O
. O
['Adverse-effects']

The O
pathogenesis O
of O
stress O
ulcers O
is O
still O
far O
from O
being O
understood O
. O
[]

Fitting O
of O
the O
ear O
plugs O
was O
performed O
by O
an O
ear O
, O
nose O
and O
throat O
specialist O
to O
ensure O
similar O
conditions O
. O
[]

Evaluation O
of O
hypertensive O
patients O
after O
care O
provided O
by O
community O
pharmacists O
in O
a O
rural O
setting O
. O
[]

Twenty-four O
NC O
smokers O
and O
20 O
smokers O
with O
SZ O
matched O
on O
nicotine O
addiction O
severity O
participated O
in O
a O
resting O
state O
fMRI O
study O
and O
were O
scanned O
during O
two O
separate O
sessions O
while O
receiving O
a O
placebo O
or O
nicotine O
patch O
, O
in O
a O
randomized O
, O
cross-over O
design O
. O
[]

The O
geometric O
mean O
titer O
( O
GMT O
) O
values O
ranged O
from O
group O
0.027-0.117 O
IU O
ml O
( O
-1 O
) O
in O
the O
Erig O
group O
and O
from O
0.029 O
to O
0.072 O
IU O
ml O
( O
-1 O
) O
in O
the O
PHT-Erig O
. O
[]

INTERVENTION O
Controlled O
exposure O
to O
grass O
pollen O
using O
an O
environmental O
chamber O
to O
stimulate O
an O
ocular O
allergic O
reaction O
followed O
by O
application O
of O
artificial O
tears O
( O
ATs O
) O
, O
5 O
minutes O
of O
cold O
compress O
( O
CC O
) O
, O
ATs O
combined O
with O
CC O
, O
or O
no O
treatment O
applied O
at O
each O
separate O
visit O
in O
random O
order O
. O
[]

Ebeltoft O
project O
: O
baseline O
data O
from O
a O
five-year O
randomized O
, O
controlled O
, O
prospective O
health O
promotion O
study O
in O
a O
Danish O
population O
. O
[]

A O
comparison O
of O
lisinopril O
and O
nifedipine O
in O
the O
treatment O
of O
mild O
to O
moderate O
hypertension O
. O
[]

Only O
one O
patient O
( O
FEC O
( O
90 O
) O
) O
experienced O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
vomiting B-outcome ['Physiological-Clinical']
and O
throat B-outcome ['Physiological-Clinical']
oedema I-outcome ['Physiological-Clinical']
) O
. O
['Adverse-effects', 'Physiological-Clinical']

Participants O
had O
autistic O
disorder O
, O
Asperger O
syndrome O
, O
or O
pervasive O
developmental O
disorder O
, O
not O
otherwise O
specified O
; O
had O
illness O
severity O
ratings O
that O
were O
moderate O
or O
more O
than O
moderate O
on O
the O
Clinical O
Global O
Impression-Severity O
scale O
; O
and O
scored O
moderate O
or O
more O
than O
moderate O
on O
compulsive O
behaviors O
measured O
with O
the O
modified O
Children O
's O
Yale-Brown O
Obsessive-Compulsive O
Scale O
. O
[]

CONCLUSIONS O
Administration O
of O
aspirin O
before O
surgery O
and O
throughout O
the O
early O
postsurgical O
period O
had O
no O
significant O
effect O
on O
the O
rate O
of O
a O
composite O
of O
death B-outcome ['Mortality']
or O
nonfatal B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
['Mortality', 'Physiological-Clinical']

RESULTS O
At O
the O
end O
of O
two O
weeks O
, O
significant O
improvement O
in O
total O
WOMAC O
scores O
was O
observed O
in O
15 O
( O
60 O
% O
) O
and O
16 O
( O
64 O
% O
) O
patients O
in O
the O
PH O
and O
ION O
groups O
respectively O
, O
indicating O
no O
significant O
difference O
in O
the O
improvement O
rate O
. O
[]

Four O
patients O
preferred O
the O
breast O
with O
the O
smooth O
prosthesis O
, O
three O
preferred O
the O
breast O
with O
the O
textured O
prosthesis O
, O
and O
the O
others O
found O
both O
breasts O
equal O
. O
[]

Its O
effects O
may O
be O
maintained O
for O
3 O
months O
. O
[]

[ O
Clinical O
observation O
on O
acupuncture O
combined O
with O
Yizhi O
Jiannao O
granules O
for O
treatment O
of O
Alzheimer O
's O
disease O
] O
. O
[]

Students O
spent O
an O
average O
of O
59.1 O
minutes O
per O
week O
outdoors O
while O
attending O
school O
and O
35.5 O
minutes O
during O
peak O
sun B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
primary O
endpoint O
occurred O
in O
103 O
patients O
assigned O
losartan O
( O
n O
= O
586 O
) O
and O
139 O
assigned O
atenolol O
( O
n O
= O
609 O
) O
. O
[]

However O
, O
VCAM-1 B-outcome ['Physiological-Clinical']
presented O
a O
significantly O
greater O
reduction O
( O
p O
= O
0.022 O
) O
in O
the O
trandolapril-verapamil O
group O
. O
['Physiological-Clinical']

Analgesic O
effect O
of O
expressed O
breast O
milk O
in O
procedural O
pain O
in O
term O
neonates O
: O
a O
randomized O
, O
placebo-controlled O
, O
double-blind O
trial O
. O
[]

The O
small O
red O
berry O
, O
wolfberry O
( O
Fructus O
barbarum O
L. O
; O
Gou O
Qi O
Zi O
and O
Kei O
Tze O
) O
, O
is O
one O
of O
the O
richest O
natural O
sources O
of O
zeaxanthin O
. O
[]

It O
was O
observed O
an O
improvement O
in O
obstructive O
symptoms O
in O
children O
who O
received O
the O
intervention O
proposed O
. O
[]

Neo-ALTTO O
( O
Neoadjuvant O
Lapatinib O
and/or O
Trastuzumab O
Treatment O
Optimisation O
) O
enrolled O
455 O
women O
with O
invasive O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
-positive O
breast O
cancer O
and O
compared O
rates O
of O
pathologic O
complete O
response O
( O
pCR O
) O
to O
neoadjuvant O
lapatinib O
, O
trastuzumab O
, O
and O
their O
combination O
. O
[]

Group O
3 O
( O
13 O
patients O
) O
received O
radiation O
therapy O
plus O
CCNU O
as O
for O
Groups O
1 O
and O
2 O
. O
[]

In O
contrast O
to O
methacholine O
, O
a O
stimulus O
that O
induces O
airway O
constriction O
mainly O
by O
direct O
stimulation O
of O
airway O
smooth O
muscle O
cells O
, O
adenosine O
airway O
responsiveness O
reflects O
indirectly O
induced O
airway O
narrowing O
via O
inflammatory O
mediators O
or O
neural O
reflex O
mechanisms O
. O
[]

In O
the O
low-risk O
population O
studied O
, O
it O
would O
appear O
that O
the O
incidence O
of O
first-dose O
hypotension O
with O
quinapril O
is O
similar O
to O
placebo O
and O
is O
not O
dose-related O
. O
[]

PURPOSE O
The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
efficacies O
of O
0.3 O
% O
ofloxacin O
eyedrops O
, O
when O
given O
twice-a-day O
( O
BID O
) O
versus O
four-times-a-day O
( O
QID O
) O
, O
for O
the O
treatment O
of O
external O
ocular O
disease O
. O
[]

3.6 O
) O
, O
( O
50.2 O
? O
[]

injection O
of O
propofol O
. O
[]

Throughout O
the O
4 O
months O
study O
period O
, O
no O
adverse B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
reported O
. O
['Adverse-effects']

Esophageal O
variceal O
hemorrhage O
( O
EVH O
) O
is O
a O
serious O
and O
expensive O
sequela O
of O
chronic O
liver O
disease O
, O
leading O
to O
increased O
utilization O
of O
resources O
. O
[]

Trimethoprim-sulfamethoxazole O
was O
administered O
as O
an O
antibacterial O
prophylaxis O
. O
[]

In O
the O
chemokinesis O
assay O
, O
the O
maximum O
distance O
moved B-outcome ['Physiological-Clinical']
by O
neutrophils B-outcome ['Physiological-Clinical']
in O
the O
presence O
of O
C18:0 O
PAF O
was O
significantly O
greater O
than O
that O
seen O
with O
the O
C16:0 O
compound O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Fifty-one O
pairs O
of O
premenarcheal O
female O
twins O
( O
27 O
monozygotic O
and O
24 O
dizygotic O
; O
mean O
+/- O
sd O
age O
, O
10.3 O
+/- O
1.5 O
yr O
) O
participated O
in O
a O
randomized O
, O
single-blind O
, O
placebo-controlled O
trial O
with O
one O
twin O
of O
each O
pair O
receiving O
a O
1200-mg O
calcium O
carbonate O
( O
Caltrate O
) O
supplement O
. O
[]

Significantly O
more O
letrozole-treated O
patients O
underwent O
breast-conserving B-outcome ['Resource-use']
surgery I-outcome ['Resource-use']
( O
45 O
vs. O
35 O
% O
, O
respectively O
; O
P=0.022 O
) O
. O
['Resource-use']

The O
effect O
of O
inhaled O
leukotriene O
D4 O
and O
methacholine O
on O
sputum B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
differentials I-outcome ['Physiological-Clinical']
in O
asthma O
. O
['Physiological-Clinical']

AIMS O
The O
aim O
of O
the O
ReoPro-BRIDGING O
Austrian O
multi-centre O
study O
was O
to O
investigate O
the O
effects O
of O
abciximab O
( O
ReoPro O
) O
on O
early B-outcome ['Physiological-Clinical']
reperfusion I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
ST-elevation I-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
prior O
to O
or O
during O
primary O
percutaneous O
coronary O
angioplasty O
( O
pPCI O
) O
. O
['Physiological-Clinical']

Total O
dose B-outcome ['Life-Impact']
and O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
propofol O
were O
similar O
in O
all O
groups O
. O
['Life-Impact', 'Physiological-Clinical']

Simulations O
of O
plasma O
DPP-4 O
inhibition O
suggest O
that O
5 O
mg O
linagliptin O
once O
daily O
is O
an O
appropriate O
therapeutic O
dose O
for O
Japanese O
patients O
with O
T2DM O
. O
[]

Greater O
abstinence-specific B-outcome ['Life-Impact']
structural I-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
( O
operationalized O
as O
fewer O
drug O
users O
in O
the O
social O
network O
) O
and O
decreases O
in O
three O
types O
of O
negative O
abstinence-specific B-outcome ['Life-Impact']
functional I-outcome ['Life-Impact']
support O
( O
Complaints B-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
Drug I-outcome ['Life-Impact']
Use O
, O
Drug B-outcome ['Life-Impact']
Exposure I-outcome ['Life-Impact']
, O
and O
Demoralization B-outcome ['Life-Impact']
) O
predicted O
cocaine B-outcome ['Life-Impact']
, O
but O
not O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Its O
use O
seems O
not O
to O
be O
indicated O
in O
systematic O
gynecologic O
pelvic O
or O
pelvic O
and O
paraaortic O
lymphadenectomy O
. O
[]

Systemic B-outcome ['Physiological-Clinical']
hemodynamics I-outcome ['Physiological-Clinical']
were O
similar O
in O
both O
groups O
throughout O
surgery O
. O
['Physiological-Clinical']

METHOD O
The O
initial O
part O
of O
the O
study O
was O
undertaken O
during O
1991-1992 O
. O
[]

The O
pressure O
profile O
and O
VO2 O
were O
not O
modified O
by O
ACE O
inhibitor O
. O
[]

Echocardiographic O
evaluation O
of O
children O
with O
systemic O
ventricular O
dysfunction O
treated O
with O
carvedilol O
. O
[]

While O
a O
chinstrap O
prevents O
the O
mouth O
from O
opening O
during O
sleep O
, O
its O
efficacy O
in O
diminishing O
mouth O
leak O
has O
not O
been O
studied O
. O
[]

METHODS O
Denver O
Health O
, O
the O
safety-net O
health O
care O
system O
serving O
Denver O
, O
is O
one O
of O
10 O
performance O
sites O
participating O
in O
the O
Patient O
Navigation O
Research O
Program O
. O
[]

Parent O
rating O
scales O
showed O
marked O
improvements O
, O
presumably O
due O
to O
expectations O
of O
benefits O
. O
[]

3 O
. O
[]

From O
this O
study O
it O
was O
concluded O
that O
the O
given O
dose O
of O
Logiparin O
was O
safe O
with O
regard O
to O
bleeding O
complications O
. O
[]

Effects O
on O
performance B-outcome ['Physiological-Clinical']
of O
1 O
, O
2 O
and O
4 O
g O
ascorbic O
acid O
were O
studied O
from O
0.5-5.5 O
h O
after O
ingestion O
in O
six O
healthy O
females O
. O
['Physiological-Clinical']

Analysis O
of O
multiple-dose O
bioequivalence O
studies O
. O
[]

Measures O
included O
changes O
in O
professionally O
completed O
CARS O
score O
and O
blood B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
for O
TARC B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
level O
were O
taken O
before O
and O
after O
milk O
consumption O
of O
500 O
ml O
per O
day O
in O
children O
's O
regular O
daily O
diet O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Rituximab O
plus O
concurrent O
infusional O
EPOCH O
chemotherapy O
is O
highly O
effective O
in O
HIV-associated O
B-cell O
non-Hodgkin O
lymphoma O
. O
[]

Indomethacin O
abolished O
the O
prostacyclin B-outcome ['Resource-use']
['Resource-use']

OBJECTIVE O
The O
efficacy O
of O
topical O
anesthesia O
during O
retinopathy O
of O
prematurity O
( O
ROP O
) O
screening O
has O
been O
a O
controversial O
issue O
. O
[]

Electrocardiography O
and O
laboratory O
values O
( O
including O
CSF O
) O
were O
unremarkable O
. O
[]

The O
AF O
frequency O
decreased O
similarly O
in O
both O
groups O
, O
and O
there O
was O
no O
significant O
difference O
in O
the O
primary O
endpoint O
between O
the O
two O
groups O
. O
[]

Both O
groups O
completed O
an O
identical O
35-week O
fitness O
program O
. O
[]

Several O
anticoagulation O
quality O
measures O
were O
compared O
, O
overall O
and O
in O
a O
time-dependent O
manner O
. O
[]

CONCLUSIONS O
Oral O
magnesium O
supplementation O
improves O
the O
metabolic O
profile O
and O
blood O
pressure O
of O
MONW O
individuals O
. O
[]

Phase-dependent B-outcome ['Physiological-Clinical']
modulation I-outcome ['Physiological-Clinical']
of O
the O
soleus B-outcome ['Physiological-Clinical']
H-reflex I-outcome ['Physiological-Clinical']
during O
rhythmical O
arm O
swing O
in O
humans O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
adjusted O
mortality B-outcome ['Mortality']
was O
similar O
in O
both O
groups O
, O
as O
were O
length O
of O
in-hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
physician B-outcome ['Resource-use']
visits I-outcome ['Resource-use']
after I-outcome ['Resource-use']
discharge I-outcome ['Resource-use']
, O
waiting O
times O
for O
invasive O
cardiac O
procedures O
, O
and O
readmissions O
for O
cardiac B-outcome ['Physiological-Clinical']
complications O
. O
['Mortality', 'Resource-use', 'Resource-use', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Clinical O
and O
instrumental O
evaluation O
of O
postoperative O
outcomes O
. O
[]

A O
subset O
of O
11 O
subjects O
also O
had O
epinastine O
hydrochloride O
( O
EH O
) O
applied O
alone O
and O
combined O
with O
CC O
in O
random O
order O
or O
instillation O
of O
a O
volume-matched O
saline O
control O
. O
[]

The O
primary O
event O
rate O
per O
[]

isolated O
. O
[]

OBJECTIVE O
To O
compare O
a O
collaborative O
approach O
, O
the O
Three O
Component O
Model O
( O
3CM O
) O
, O
with O
usual O
care O
for O
treating O
PTSD O
in O
primary O
care O
. O
[]

BACKGROUND O
Previous O
epidemiological O
, O
animal O
and O
human O
data O
report O
that O
lycopene O
has O
a O
protective O
effect O
against O
ultraviolet B-outcome ['Physiological-Clinical']
radiation I-outcome ['Physiological-Clinical']
( O
UVR B-outcome ['Physiological-Clinical']
) O
-induced O
erythema B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
We O
found O
only O
limited O
evidence O
to O
support O
parecoxib O
as O
an O
analgesic O
after O
craniotomy O
. O
[]

Many O
athletes O
arrive O
at O
training O
sessions O
and O
competitions O
in O
a O
mildly O
hypohydrated O
( O
HYPO O
) O
state O
and O
are O
instructed O
to O
drink O
fluids O
before O
exercise O
to O
reach O
a O
euhydrated O
( O
HYD O
) O
state O
. O
[]

RESULTS O
It O
was O
observed O
greater O
speed B-outcome ['Physiological-Clinical']
and O
extension O
in O
the O
['Physiological-Clinical']

Angiotensin O
II O
infusion O
increased O
filtration B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
, O
but O
decreased O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
and O
urine B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
sharply O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Visit-to-visit O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
in O
the O
European O
Lacidipine O
Study O
on O
Atherosclerosis O
: O
methodological O
aspects O
and O
effects O
of O
antihypertensive O
treatment O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
Prospective O
, O
randomised O
, O
clinical O
study O
. O
[]

RESULTS O
Patients O
with O
statin O
withdrawal O
showed O
a O
higher O
frequency O
of O
mRS B-outcome ['Physiological-Clinical']
score O
> O
2 O
at O
the O
end O
of O
follow-up O
( O
60.0 O
% O
vs O
39.0 O
% O
; O
p O
= O
0.043 O
) O
, O
END O
( O
65.2 O
% O
vs O
20.9 O
% O
; O
p O
< O
0.0001 O
) O
, O
and O
greater O
infarct B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( O
74 O
[ O
45 O
, O
126 O
] O
vs O
26 O
[ O
12 O
, O
70 O
] O
mL O
; O
p O
= O
0.002 O
) O
compared O
with O
the O
non-statin-withdrawal O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
having O
identified O
implementation O
difficulties O
, O
we O
will O
design O
and O
test O
two O
interventions O
to O
enhance O
TUPAC O
guideline O
adherence O
. O
[]

Twenty-eight O
sepsis-related O
AKI O
patients O
were O
included O
and O
randomized O
into O
online O
HDF O
and O
high-flux O
HD O
. O
[]

The O
treatment O
period O
was O
15 O
+/- O
1 O
days O
. O
[]

RESULTS O
The O
study O
was O
prematurely O
closed O
due O
to O
low O
accrual O
after O
93 O
of O
145 O
required O
patients O
( O
65 O
% O
) O
were O
randomized O
. O
[]

In O
a O
single-blind O
randomized O
study O
, O
the O
efficacy O
of O
intravenous O
flecainide O
( O
2 O
mg/kg/10 O
minutes O
) O
versus O
verapamil O
( O
10 O
mg/1 O
minute O
) O
was O
assessed O
in O
40 O
patients O
with O
paroxysmal O
atrial O
fibrillation O
( O
AF O
) O
or O
atrial O
flutter O
( O
AFI O
) O
. O
[]

At O
the O
end O
of O
the O
treatment O
period O
overall O
assessment O
of O
safety O
and O
efficacy O
were O
recorded O
by O
physician O
and O
patient O
. O
[]

It O
is O
recommended O
to O
vigorously O
promote O
the O
consumption O
of O
vitamin O
A-fortified O
cooking O
oil O
together O
with O
other O
vitamin O
A-rich O
sources O
to O
sustain O
the O
prevention B-outcome ['Physiological-Clinical']
and O
control O
of O
vitamin O
A O
deficiency O
. O
['Physiological-Clinical']

Twenty O
young O
, O
active O
men O
( O
mean O
age O
26.2 O
? O
[]

In O
multivariable O
analysis O
, O
having O
a O
child O
under O
5 O
years O
of O
age O
was O
the O
only O
variable O
associated O
with O
bednet O
use O
( O
OR O
9.10 O
; O
p=0.001 O
) O
, O
yielding O
a O
99 O
% O
likelihood O
of O
using O
a O
bednet O
( O
95 O
% O
CI O
96.4 O
to O
99.9 O
% O
) O
versus O
82 O
% O
( O
95 O
% O
CI O
72.2 O
to O
88.4 O
% O
) O
in O
households O
without O
young O
children O
. O
[]

Use O
of O
an O
inspiratory O
impedance O
threshold O
device O
on O
a O
facemask O
and O
endotracheal O
tube O
to O
reduce O
intrathoracic B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
during O
the O
decompression O
phase O
of O
active O
compression-decompression B-outcome ['Physiological-Clinical']
cardiopulmonary I-outcome ['Physiological-Clinical']
resuscitation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
delivering O
IVR O
messages O
targeting O
these O
reported O
barriers O
, O
32 O
% O
of O
the O
smokers O
reporting O
low O
self-efficacy B-outcome ['Life-Impact']
and O
4.8 O
% O
of O
those O
reporting O
lack O
of O
interest O
in O
quitting O
re-engaged O
in O
a O
new O
QL O
treatment O
cycle O
. O
['Life-Impact']

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
increased O
13 O
% O
with O
sodium O
nitroprusside O
, O
remained O
unchanged O
with O
isoflurane O
, O
and O
decreased O
23 O
% O
with O
esmolol O
. O
['Physiological-Clinical']

Combined O
therapy O
with O
antibiotics O
and O
superlimf O
promotes O
a O
more O
rapid O
reduction O
in O
the O
duration O
of O
clinical B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

In O
the O
dry O
lab O
, O
the O
participants O
performed O
four O
typical O
laparoscopic O
tasks O
of O
increasing O
difficulty O
. O
[]

A O
comparison O
of O
the O
recovery B-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
of O
desflurane O
and O
isoflurane O
in O
outpatient O
anesthesia O
. O
['Physiological-Clinical']

The O
incidence O
rate O
of O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
viral B-outcome ['Physiological-Clinical']
infections O
and O
fungal B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
was O
similar O
across O
groups O
during O
the O
LTE O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Preventing O
paclitaxel-induced B-outcome ['Physiological-Clinical']
peripheral I-outcome ['Physiological-Clinical']
neuropathy I-outcome ['Physiological-Clinical']
: O
a O
phase O
II O
trial O
of O
vitamin O
E O
supplementation O
. O
['Physiological-Clinical']

All O
children O
were O
treated O
with O
40 O
mg O
praziquantel/kg O
at O
the O
start O
of O
the O
study O
. O
[]

Recovery B-outcome ['Physiological-Clinical']
was O
rapid O
( O
mean O
12-13 O
minutes O
) O
in O
these O
two O
groups O
. O
['Physiological-Clinical']

Contour B-outcome ['Physiological-Clinical']
detectability I-outcome ['Physiological-Clinical']
was O
found O
to O
be O
a O
function O
not O
only O
of O
the O
relative O
spacing O
of O
contour O
elements O
with O
respect O
to O
the O
noise O
elements O
but O
also O
of O
the O
average O
density O
of O
the O
overall O
pattern O
. O
['Physiological-Clinical']

Lidocaine O
did O
not O
alter O
heat O
pain B-outcome ['Physiological-Clinical']
detection O
thresholds O
or O
painfulness O
of O
long B-outcome ['Resource-use']
thermal I-outcome ['Resource-use']
stimulation I-outcome ['Resource-use']
in O
normal O
skin O
. O
['Physiological-Clinical', 'Resource-use']

Patients O
were O
evaluated O
by O
accelerometry O
and O
the O
Fahn-Tolosa-Marin O
( O
FTM O
) O
rating O
scale O
at O
baseline O
and O
days O
14 O
and O
28 O
, O
as O
well O
as O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CGI-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
scale O
at O
day O
28 O
. O
['Physiological-Clinical']

In O
self-assessments O
, O
95 O
% O
of O
patients O
( O
55/58 O
) O
reported O
improved O
angina B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
91 O
% O
( O
53/58 O
) O
felt O
their O
ability B-outcome ['Life-Impact']
to O
perform B-outcome ['Physiological-Clinical']
usual B-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
had O
improved O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

The O
tertiary O
prevention O
needs O
of O
rural-dwelling O
survivors O
can O
be O
even O
greater O
, O
yet O
little O
is O
known O
about O
rural O
and O
urban O
differences O
in O
lifestyle O
factors O
among O
this O
high-risk O
population O
. O
[]

STUDY O
DESIGN O
A O
randomized O
, O
double O
blind O
, O
controlled O
animal O
trial O
. O
[]

Taste B-outcome ['Life-Impact']
acceptability I-outcome ['Life-Impact']
was O
highest O
for O
CEC O
and O
lowest O
for O
this O
formulation O
of O
CAE O
. O
['Life-Impact']

Thirty O
observation O
periods O
of O
6 O
months O
each O
were O
studied O
for O
23 O
patients O
. O
[]

RESULT O
Forty O
preterm O
infants O
were O
included O
in O
the O
study O
. O
[]

Non-pharmacological O
care O
for O
patients O
with O
generalized O
osteoarthritis O
: O
design O
of O
a O
randomized O
clinical O
trial O
. O
[]

Atrial O
natriuretic O
factor O
caused O
a O
significant O
increase O
in O
sodium B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
UNaV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
[ O
+56 O
% O
] O
, O
urinary B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
V I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
[ O
+17 O
% O
] O
and O
free B-outcome ['Physiological-Clinical']
water I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CH2O I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
[ O
+23 O
% O
] O
; O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Ccr I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
did O
not O
change O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mean O
airway B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
decreased O
35.3 O
cm O
H2O/L/s O
, O
mean O
specific B-outcome ['Life-Impact']
airway I-outcome ['Life-Impact']
conductance I-outcome ['Life-Impact']
increased O
0.095 O
1/L/s/cm O
H2O O
, O
and O
mean O
dynamic B-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
increased O
1.74 O
mL/cm O
H2O O
during O
treatment O
with O
diuretics O
( O
all O
P O
less O
than O
.001 O
) O
, O
but O
not O
during O
treatment O
with O
placebo O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

BACKGROUND O
Immunoglobulin O
A O
( O
IgA O
) O
is O
the O
predominant O
antibody O
produced O
in O
response O
to O
mucosal O
infections O
. O
[]

AP O
patients O
were O
randomly O
assigned O
to O
either O
receive O
systemic O
metronidazole O
plus O
amoxicillin O
( O
AP+AB O
) O
or O
were O
treated O
mechanically O
alone O
( O
AP O
) O
. O
[]

Cats O
over O
eight O
years O
of O
age O
with O
clinical O
signs O
of O
chronic O
OA O
were O
assigned O
to O
one O
of O
two O
groups O
and O
Glu-Ch O
or O
meloxicam O
was O
administered O
orally O
for O
70 O
days O
, O
followed O
by O
a O
placebo O
until O
day O
98 O
. O
[]

67.2 O
% O
( O
RR O
= O
0.22 O
; O
0.08-0.54 O
) O
, O
( O
P O
< O
0.001 O
) O
. O
[]

Use B-outcome ['Life-Impact']
and O
limitations B-outcome ['Life-Impact']
of O
Holter O
electrocardiography O
in O
assessing O
drug O
therapy O
of O
myocardial O
ischemia O
during O
the O
peri-PTCA O
period O
. O
['Life-Impact', 'Life-Impact']

Work-related O
stress O
and O
early O
atherosclerosis O
. O
[]

After O
warming O
, O
cryoprotective O
agents O
were O
removed O
using O
a O
single O
step O
. O
[]

After O
the O
initial O
three O
cycles O
of O
CHOP O
19 O
% O
of O
the O
whole O
group O
were O
in O
complete B-outcome ['Physiological-Clinical']
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
and O
53 O
% O
in O
partial B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
( O
PR O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
determine O
whether O
local O
warming O
of O
the O
lower O
arm O
and O
hand O
facilitates O
peripheral B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
cannulation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
trial O
involved O
a O
comparison O
between O
two O
groups O
receiving O
implant O
treatment O
and O
one O
group O
receiving O
conventional O
complete O
dentures O
( O
CD O
) O
. O
[]

We O
suggest O
that O
exenatide O
has O
therapeutic O
potential O
as O
adjunctive O
therapy O
in O
type O
1 O
diabetes O
. O
[]

Alloimmunization O
of O
recipients O
of O
random O
multiple-donor O
platelet O
concentrates O
( O
MD O
group O
) O
was O
compared O
to O
that O
of O
patients O
receiving O
random O
single-donor O
platelets O
( O
SD O
group O
) O
. O
[]

The O
time O
from O
end O
of O
the O
procedure O
to O
spontaneous O
breathing O
, O
extubation O
, O
eye-opening O
, O
hand-squeezing O
to O
command O
, O
and O
ability O
to O
state O
name O
, O
birthdate O
and O
phone O
number O
were O
recorded O
. O
[]

A O
single O
dose O
of O
either O
betamethasone O
( O
60 O
mg O
) O
, O
methylprednisolone O
( O
400 O
mg O
) O
or O
placebo O
was O
given O
intravenously O
, O
5 O
min O
after O
intranasal O
allergen O
provocation O
. O
[]

If O
a O
negative O
pressure O
drainage O
system O
is O
to O
be O
used O
, O
a O
low O
pressure O
suction O
drain O
should O
be O
used O
in O
preference O
to O
a O
high O
pressure O
system O
. O
[]

The O
daily O
rations O
consisted O
of O
4 O
kg O
grass O
hay O
and O
7 O
kg O
concentrates O
. O
[]

SD O
1.4 O
? O
[]

No O
difference O
was O
found O
between O
the O
two O
anesthetic O
techniques O
in O
the O
incidence O
of O
nausea O
, O
vomiting O
, O
or O
both O
during O
the O
first O
24 O
hr O
after O
operation O
. O
[]

The O
three-dose O
regimen O
of O
POIOPO O
produced O
maximum O
effective O
reduction O
of O
drain B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
total O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Side O
effects O
were O
slight B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
weight O
gain O
or O
['Physiological-Clinical']

Iron O
and O
riboflavin O
supplements O
significantly O
reduced O
the O
prevalences O
of O
riboflavin B-outcome ['Physiological-Clinical']
deficiency I-outcome ['Physiological-Clinical']
( O
from O
60 O
% O
to O
6 O
% O
; O
P O
< O
0.0001 O
) O
, O
iron B-outcome ['Physiological-Clinical']
deficiency I-outcome ['Physiological-Clinical']
anemia I-outcome ['Physiological-Clinical']
( O
from O
35 O
% O
to O
15 O
% O
; O
P O
< O
0.007 O
) O
, O
and O
abnormal B-outcome ['Physiological-Clinical']
PT I-outcome ['Physiological-Clinical']
( O
from O
87 O
% O
to O
30 O
% O
; O
P O
< O
0.05 O
) O
from O
baseline O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
complications B-outcome ['Adverse-effects']
associated O
with O
the O
solutions O
. O
['Adverse-effects']

Within O
the O
simvastatin O
group O
, O
a O
reduction O
in O
prothrombin B-outcome ['Physiological-Clinical']
F1+2 I-outcome ['Physiological-Clinical']
was O
observed O
( O
P=.038 O
) O
. O
['Physiological-Clinical']

Oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
decreased O
in O
group O
I O
without O
reaching O
statistical O
significance O
. O
['Physiological-Clinical']

The O
primary O
efficacy O
outcome O
was O
venous B-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
up O
to O
day O
10 O
. O
['Physiological-Clinical']

Maternal B-outcome ['Physiological-Clinical']
salivary I-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
increased O
throughout O
gestation O
( O
P O
< O
0.001 O
) O
and O
the O
LP O
gilts O
had O
greater O
salivary B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
compared O
with O
the O
AP O
and O
HP O
gilts O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
dose B-outcome ['Adverse-effects']
limiting I-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
within O
each O
group O
were O
determined O
. O
['Adverse-effects']

[ O
Specific B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
chronic O
hepatitis O
B O
patients O
treated O
with O
different O
doses O
of O
recombinant O
hepatitis O
B O
vaccine O
] O
. O
['Physiological-Clinical']

Sleep O
latency O
, O
insomnia B-outcome ['Physiological-Clinical']
subscales O
on O
the O
Children O
's O
Sleep B-outcome ['Physiological-Clinical']
Habits I-outcome ['Physiological-Clinical']
Questionnaire O
, O
and O
other O
outcomes O
related O
to O
child O
and O
family B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
improved O
with O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Induction O
versus O
noninduction O
in O
renal O
transplant O
recipients O
with O
tacrolimus-based O
immunosuppression O
. O
[]

An O
albendazole O
course O
at O
30 O
mg/kg/day O
combined O
with O
corticosteroids O
is O
safe O
and O
more O
effective O
than O
the O
usual O
dose O
. O
[]

RESULTS O
The O
two O
groups O
were O
well O
matched O
for O
age O
, O
weight O
, O
and O
other O
factors O
, O
which O
could O
predispose O
to O
the O
development O
of O
deep B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DVT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
haemorrhage B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

SETTING O
Six O
academic O
centers O
, O
including O
Mount O
Sinai O
School O
of O
Medicine O
, O
North O
Shore-Long O
Island O
Jewish O
Health O
System O
, O
University O
of O
North O
Carolina O
at O
Chapel O
Hill O
, O
University O
of O
California O
at O
Los O
Angeles O
, O
Yale O
University O
, O
and O
Dartmouth O
Medical O
School O
. O
[]

DESIGN O
. O
[]

Changes O
in O
World O
Health O
Organization O
( O
WHO O
) O
functional O
class O
and O
time O
to O
clinical O
worsening O
( O
TTCW O
) O
were O
secondary O
endpoints O
. O
[]

Systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
increased O
despite O
a O
32 O
% O
decrease O
in O
plasma B-outcome ['Physiological-Clinical']
renin I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
AND O
PURPOSE O
Prolonged O
wakefulness O
impairs O
sustained O
vigilant B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
, O
measured O
with O
the O
psychomotor B-outcome ['Life-Impact']
vigilance I-outcome ['Life-Impact']
task O
( O
PVT O
) O
, O
and O
induces O
a O
compensatory O
increase O
in O
sleep O
intensity O
in O
recovery O
sleep O
, O
quantified O
by O
slow-wave B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SWA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
the O
sleep B-outcome ['Physiological-Clinical']
electroencephalogram I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EEG I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

BCG O
( O
RIVM O
) O
versus O
mitomycin O
intravesical O
therapy O
in O
superficial O
bladder O
cancer O
. O
[]

Two O
experimental O
formulations O
of O
theophylline O
with O
a O
hydrophilic O
starch O
matrix O
were O
evaluated O
for O
their O
sustained-release O
characteristics O
after O
single O
administration O
in O
healthy O
human O
volunteers O
. O
[]

Pharmacokinetics O
of O
azithromycin O
in O
lung O
tissue O
, O
bronchial O
washing O
, O
and O
plasma O
in O
patients O
given O
multiple O
oral O
doses O
of O
500 O
and O
1000 O
mg O
daily O
. O
[]

Nitrous O
oxide O
diffusion O
into O
tracheal O
tube O
cuffs B-outcome ['Physiological-Clinical']
-- O
efficacy O
of O
a O
new O
prototype O
cuff O
pressure O
release O
valve O
. O
['Physiological-Clinical']

METHODS O
In O
this O
single-center O
, O
randomized O
controlled O
study O
, O
women O
were O
assigned O
to O
a O
multiphasic O
pill O
, O
a O
lower-dose O
monophasic O
pill O
, O
a O
higher-dose O
monophasic O
pill O
, O
or O
nonsteroidal O
contraception O
. O
[]

Enalapril O
( O
10 O
mg/day O
) O
in O
systemic O
sclerosis O
. O
[]

Scores O
on O
standardized O
measures O
improved O
after O
training O
for O
both O
groups O
, O
but O
only O
the O
face O
training O
group O
showed O
an O
increased O
face B-outcome ['Life-Impact']
inversion O
effect O
behaviorally B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
electrophysiological I-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
to O
faces O
in O
the O
P100 O
component O
. O
['Life-Impact', 'Life-Impact']

The O
acute B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
and O
mucous B-outcome ['Physiological-Clinical']
membrane I-outcome ['Physiological-Clinical']
was O
milder O
in O
the O
latter O
two O
groups O
, O
but O
the O
differences O
were O
not O
significant O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Previously O
, O
we O
showed O
that O
acute O
respiratory O
distress O
syndrome O
patients O
fed O
an O
enteral O
diet O
containing O
eicosapentaenoic O
acid O
and O
gamma-linolenic O
acid O
and O
elevated O
antioxidants O
( O
EPA+GLA O
; O
Oxepa O
) O
had O
significantly O
reduced O
pulmonary O
inflammation O
, O
increased O
oxygenation O
, O
and O
improved O
clinical O
outcomes O
. O
[]

48 O
% O
of O
the O
patients O
in O
the O
OC O
group O
and O
59 O
% O
in O
the O
LC O
group O
were O
older O
than O
60 O
years O
. O
[]

Total O
bone O
width O
did O
not O
change O
significantly O
( O
0.68 O
% O
, O
CI O
-1.17 O
to O
2.57 O
% O
; O
not O
significant O
( O
NS O
) O
) O
. O
[]

However O
, O
the O
difference O
was O
not O
significant O
( O
p O
> O
0.99 O
) O
. O
[]

This O
suggests O
that O
the O
use O
of O
maintenance O
therapy O
in O
maximally O
tolerated O
doses O
may O
be O
associated O
with O
an O
increased O
survival B-outcome ['Mortality']
in O
childhood O
ALL O
. O
['Mortality']

Prospective O
comparison O
of O
the O
value O
of O
brushings O
before O
and O
after O
biopsy O
in O
the O
endoscopic O
diagnosis O
of O
gastroesophageal O
malignancy O
. O
[]

CONCLUSION O
School O
dental O
screening O
was O
capable O
of O
stimulating O
dental B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
. O
['Life-Impact']

METHODS O
In O
eight O
healthy O
volunteers O
( O
seven O
males O
; O
mean O
age O
32 O
years O
) O
, O
perception O
at O
pain O
threshold O
to O
a O
train O
of O
20 O
electrical O
stimuli O
applied O
to O
the O
hand O
and O
upper O
oesophagus O
( O
UO O
) O
at O
either O
0.1 O
Hz O
( O
control O
) O
or O
2 O
Hz O
was O
determined O
before O
and O
one O
hour O
after O
a O
30 O
minute O
lower O
oesophageal O
acid O
infusion O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
association O
between O
single O
nucleotide O
polymorphism O
( O
SNP O
) O
of O
CCND1 O
A870G O
and O
acute B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs O
) O
in O
postoperative O
rectal O
cancer O
patients O
who O
received O
capecitabine-based O
postoperative O
chemoradiotherapy O
( O
CRT O
) O
. O
['Adverse-effects']

No O
indirect B-outcome ['Physiological-Clinical']
hernias I-outcome ['Physiological-Clinical']
recurred I-outcome ['Physiological-Clinical']
after O
a O
tension-free O
repair O
; O
2 O
recurred O
after O
abdominal O
ring O
repair O
( O
4 O
% O
; O
NS O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Treatment O
with O
bisphosphonates O
decreases O
bone O
loss O
and O
can O
increase O
disease-free O
survival O
in O
patients O
with O
breast O
cancer O
. O
[]

AIM O
The O
aim O
of O
this O
study O
was O
to O
examine O
the O
pharmacokinetics O
of O
donepezil O
HCl O
and O
digoxin O
separately O
, O
and O
in O
combination O
, O
following O
administration O
of O
single O
oral O
doses O
. O
[]

This O
study O
tested O
the O
hypothesis O
that O
2 O
large O
doses O
of O
EPO O
administered O
shortly O
before O
CPB O
ameliorate O
the O
systemic O
inflammatory O
response O
to O
CPB O
. O
[]

In O
pregnant O
women O
neither O
approach O
was O
beneficial O
, O
with O
some O
evidence O
of O
post-partum O
relapse O
. O
[]

All O
patients O
were O
assessed O
at O
day O
0 O
, O
and O
after O
1 O
, O
2 O
, O
4 O
, O
6 O
, O
and O
8 O
weeks O
, O
using O
the O
Mini-Mental O
State O
Examination O
, O
the O
Hamilton O
Depression O
Rating O
Scale O
, O
and O
the O
Toronto O
Alexithymia I-outcome ['Life-Impact']
Scale O
( O
TAS-20 O
) O
. O
['Life-Impact']

CONCLUSION O
We O
find O
the O
analgesic B-outcome ['Resource-use']
efficacy O
of O
diclofenac O
suppository O
combined O
with O
local O
anesthetic O
infiltration O
at O
port O
sites O
comparable O
to O
caudal O
block O
. O
['Resource-use']

The O
purpose O
of O
this O
trial O
was O
to O
evaluate O
the O
efficacy O
of O
eberconazole O
1 O
% O
cream O
compared O
with O
miconazole O
2 O
% O
cream O
in O
the O
treatment O
of O
dermatophytoses O
. O
[]

Diazepam O
choice O
was O
also O
associated O
with O
more O
frequent B-outcome ['Life-Impact']
recreational I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
marijuana I-outcome ['Life-Impact']
and O
stimulants B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

The O
intervention O
group O
received O
an O
educational O
program O
focused O
on O
mammography O
delivered O
by O
a O
lay O
health O
advisor O
, O
and O
the O
control O
group O
received O
a O
physician O
letter/brochure O
focusing O
on O
Pap O
tests O
. O
[]

Sodium O
bicarbonate O
( O
Bicarb O
, O
1 O
M O
; O
350-500 O
ml O
) O
or O
an O
equal O
volume O
of O
normal O
saline O
( O
Sal O
) O
was O
infused O
intravenously O
at O
a O
constant O
rate O
during O
a O
'2000 O
m O
' O
maximal O
ergometer O
row O
in O
six O
male O
oarsmen O
( O
23?2 O
years O
; O
mean?S.D. O
) O
. O
[]

Data O
on O
oxygenation B-outcome ['Physiological-Clinical']
and O
ventilation B-outcome ['Physiological-Clinical']
were O
recorded O
at O
admission O
and O
at O
the O
start O
of O
weaning O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Trends O
favored O
drug O
over O
placebo O
for O
stool B-outcome ['Physiological-Clinical']
weight O
, O
stool B-outcome ['Physiological-Clinical']
character I-outcome ['Physiological-Clinical']
, O
and O
Karnofsky O
score O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Povidone-iodine O
was O
associated O
with O
the O
shortest O
attachment B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
was O
most O
liked O
. O
['Life-Impact']

Operative B-outcome ['Life-Impact']
data O
, O
postoperative B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
pain B-outcome ['Physiological-Clinical']
assessment O
and O
persistent B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
compared O
at O
discharge O
and O
at O
2 O
week O
and O
6 O
week O
review O
. O
['Life-Impact', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
of O
RT-PCR O
were O
confirmed O
by O
Western O
blotting O
, O
which O
documented O
the O
identical O
distribution O
of O
leptin B-outcome ['Physiological-Clinical']
proteins I-outcome ['Physiological-Clinical']
and O
leptin B-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
proteins I-outcome ['Physiological-Clinical']
in O
studied O
tissues O
. O
['Physiological-Clinical', 'Physiological-Clinical']

MSQ B-outcome ['Physiological-Clinical']
scores O
( O
0 O
to O
100 O
, O
higher O
score O
indicates O
better O
functioning O
) O
were O
assessed O
for O
the O
following O
three O
domains O
: O
role O
restriction O
( O
examines O
the O
degree O
to O
which O
performance O
of O
daily O
activities O
is O
limited O
by O
migraine O
) O
, O
role O
prevention O
( O
examines O
the O
degree O
to O
which O
performance O
of O
daily O
activities O
is O
interrupted O
by O
migraine O
) O
, O
and O
emotional B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
( O
examines O
feelings O
of O
frustration O
and O
helplessness O
due O
to O
migraine O
) O
. O
['Physiological-Clinical', 'Life-Impact']

At O
the O
end O
of O
haemodialysis O
the O
decrease O
in O
mean O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
17.2 O
% O
in O
patients O
treated O
with O
a O
single O
dose O
and O
18 O
+/- O
5 O
% O
in O
patients O
given O
the O
repeated O
dose O
of O
labetalol O
. O
['Physiological-Clinical']

We O
monitored O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
systolic/diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP/DBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
throughout O
the O
bronchoscopy O
and O
calculated O
the O
rate-pressure O
product O
( O
RPP= O
( O
HRxSBP O
) O
/100 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
prospectively O
compare O
BP O
and O
Dacron O
patch O
angioplasty O
after O
carotid O
endarterectomy O
in O
a O
randomized O
fashion O
. O
[]

Naltrexone O
in O
young O
autistic O
children O
: O
a O
double-blind O
, O
placebo-controlled O
crossover O
study O
. O
[]

To O
assess O
possible O
beneficial O
effects O
a O
double O
blind O
, O
comparative O
trial O
of O
metronidazole O
and O
placebo O
was O
performed O
. O
[]

In O
adults O
, O
females O
showed O
significantly O
greater O
elevations O
than O
males O
. O
[]

Smokeless O
tobacco O
was O
relatively O
well O
tolerated B-outcome ['Life-Impact']
, O
although O
15 O
subjects O
( O
11.2 O
% O
) O
stopped O
use O
due O
to O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Life-Impact', 'Adverse-effects']

No O
difference O
was O
noted O
between O
the O
2 O
groups O
with O
cemented O
components O
after O
2 O
years O
. O
[]

With O
respect O
to O
mood B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
the O
aim O
to O
lower O
MPA O
doses O
in O
HRT O
is O
unwarranted O
. O
['Life-Impact']

PEERS O
focuses O
on O
improving O
friendship B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
among O
adolescents O
with O
higher-functioning O
ASD O
. O
['Life-Impact', 'Life-Impact']

A O
treatment O
effect O
for O
haloperidol O
was O
detected O
only O
on O
live B-outcome ['Physiological-Clinical']
ratings I-outcome ['Physiological-Clinical']
and O
not O
on O
ratings O
of O
videotapes B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
interval O
between O
the O
beginning B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
induction I-outcome ['Life-Impact']
until I-outcome ['Life-Impact']
delivery I-outcome ['Life-Impact']
at O
the O
first O
day O
of I-outcome ['Life-Impact']
induction B-outcome ['Resource-use']
was O
shorter O
in O
the O
propranolol O
group O
. O
['Life-Impact', 'Resource-use']

After O
ovarian O
stimulation O
with O
GnRH O
agonist/HMG O
, O
the O
luteal O
phase O
seems O
to O
be O
inadequate O
, O
but O
in O
a O
previous O
study O
we O
did O
not O
find O
evidence O
to O
support O
the O
need O
for O
oral O
progesterone O
supplementation O
. O
[]

Of O
the O
1321 O
patients O
with O
atrial O
fibrillation O
( O
AF O
) O
, O
331 O
( O
25 O
% O
) O
had O
a O
documented O
history O
of O
clinical O
heart O
failure O
, O
of O
which O
168 O
cases O
were O
related O
to O
a O
new O
or O
recurrent O
episode O
of O
acute O
decompensated O
heart O
failure O
occurring O
within O
the O
preceding O
three O
months O
. O
[]

PRINCIPAL O
FINDINGS O
Four O
discharge O
screens O
indicated O
an O
increased O
risk O
of O
an O
adverse B-outcome ['Adverse-effects']
outcome-absence O
of O
documentation O
of O
discharge O
planning O
, O
elevated B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
, O
abnormal B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
, O
and O
unaddressed O
abnormal O
test O
results O
at O
discharge O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Electrophysiologic O
Study O
versus O
Electrocardiographic O
Monitoring O
Investigators O
. O
[]

Cervical B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
spasm I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

MGMT O
gene O
was O
indicated O
as O
DJQ O
's O
target O
point O
for O
efficiency O
synergism O
and O
toxicity O
reducing O
. O
[]

During O
treatment O
, O
for O
all O
SF-36 O
summary O
and O
Hepatitis B-outcome ['Physiological-Clinical']
Quality O
of O
Life O
Questionnaire O
( O
HQLQ O
) O
-specific O
scales O
, O
the O
pegIFNalpha O
2a O
group O
experienced O
less O
impairment O
than O
did O
the O
IFNalpha O
2b/RBV O
patients O
. O
['Physiological-Clinical']

Corresponding O
figures O
were O
20 O
and O
3.0 O
% O
, O
respectively O
, O
in O
the O
control O
group O
. O
[]

After O
a O
1-year O
double-blind O
, O
placebo-controlled O
study O
the O
patients O
were O
followed O
for O
another O
72 O
months O
in O
an O
open O
study O
. O
[]

CONTEXT O
Hospital O
report O
cards O
are O
increasingly O
being O
implemented O
for O
quality O
improvement O
despite O
lack O
of O
strong O
evidence O
to O
support O
their O
use O
. O
[]

METHODS O
ABC O
randomized O
111 O
infants O
to O
receive O
an O
intensive O
early O
education O
program O
or O
nutritional O
supplements O
and O
parental O
counseling O
alone O
; O
participants O
have O
been O
followed O
to O
the O
present O
day O
. O
[]

For O
the O
comparison O
of O
clonidine O
with O
placebo O
, O
patients O
were O
randomly O
assigned O
to O
receive O
clonidine O
( O
0.2 O
mg O
per O
day O
) O
or O
placebo O
just O
before O
surgery O
, O
with O
the O
study O
drug O
continued O
until O
72 O
hours O
after O
surgery O
. O
[]

METHODS O
We O
used O
national O
data O
from O
the O
Medical O
Expenditure O
Panel O
Survey O
linked O
to O
the O
National O
Health O
Interview O
Survey O
and O
a O
study-specific O
survey O
to O
estimate O
the O
annual O
utilization B-outcome ['Resource-use']
and O
costs B-outcome ['Resource-use']
for O
health O
care O
, O
school O
, O
ASD-related O
therapy O
, O
family-coordinated O
services O
, O
as O
well O
as O
caregiver O
time O
in O
children O
aged O
3 O
to O
17 O
years O
, O
with O
and O
without O
parent-reported O
ASD O
. O
['Resource-use']

Our O
results O
showed O
: O
1 O
) O
a O
satisfactory O
control O
of O
the O
hypertensive B-outcome ['Physiological-Clinical']
crises I-outcome ['Physiological-Clinical']
in O
80 O
% O
of O
patients O
treated O
with O
SLC O
with O
a O
significant O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
reduction O
after O
10 O
min O
. O
( O
['Physiological-Clinical', 'Physiological-Clinical']

Our O
purpose O
was O
to O
assess O
the O
effect O
on O
research O
enrollment O
and O
data O
sharing O
decisions O
of O
three O
different O
consent O
types O
( O
traditional O
, O
binary O
, O
or O
tiered O
) O
with O
varying O
levels O
of O
control O
and O
choices O
regarding O
data O
sharing O
. O
[]

RG-CMH O
intervention O
was O
also O
associated O
with O
a O
decrease O
in O
levels O
of O
T O
cells O
, O
helper O
T O
cells O
, O
cytotoxic O
T O
cells O
and O
natural O
killer O
cells O
compared O
with O
the O
placebo O
group O
. O
[]

The O
drugs O
were O
given O
with O
a O
Turbuhaler O
dry O
powder O
inhaler O
. O
[]

Average O
visual O
analogue O
scale O
( O
VAS O
) O
report O
of O
pain B-outcome ['Physiological-Clinical']
within O
the O
therapist O
support O
group O
was O
not O
significantly O
lower O
than O
the O
control O
group O
( O
P O
= O
0.103 O
) O
nor O
significantly O
higher O
than O
the O
training O
groups O
. O
['Physiological-Clinical']

CONCLUSION O
Adding O
WBRT O
to O
teniposide O
results O
in O
a O
much O
higher O
response O
rate O
of O
brain O
metastases O
and O
in O
a O
longer O
time O
to O
progression O
of O
brain O
metastases O
than O
teniposide O
alone O
. O
[]

RESULTS O
. O
[]

RESULTS O
Among O
423 O
participants O
with O
1 O
study O
eye O
, O
the O
correct B-outcome ['Life-Impact']
assignment I-outcome ['Life-Impact']
was O
stated O
by O
9.9 O
% O
of O
the O
sham O
plus O
prompt O
laser O
group O
, O
88.0 O
% O
of O
the O
ranibizumab O
plus O
prompt O
laser O
group O
, O
89.6 O
% O
of O
the O
unmasked O
ranibizumab O
plus O
deferred O
laser O
group O
, O
and O
44.0 O
% O
of O
the O
triamcinolone O
plus O
prompt O
laser O
group O
. O
['Life-Impact']

The O
effect O
of O
a O
single O
dose O
of O
1,000 O
mg O
of O
levetiracetam O
on O
essential O
tremor O
was O
investigated O
in O
24 O
patients O
in O
a O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

METHOD O
In O
this O
randomized O
, O
prospective O
study O
we O
analyzed O
85 O
biopsy O
samples O
from O
patients O
with O
gastric O
adenocarcinoma O
. O
[]

The O
current O
study O
examined O
affect O
, O
gaze O
, O
joint O
attention O
behaviors O
, O
and O
verbalizations B-outcome ['Life-Impact']
at O
three O
different O
time O
points O
of O
intervention O
. O
['Life-Impact']

The O
treatment O
effect O
of O
EH O
was O
enhanced O
by O
combining O
it O
with O
a O
CC O
( O
P O
< O
0.001 O
) O
. O
[]

In O
particular O
, O
the O
l O
allele O
could O
contribute O
, O
through O
its O
association O
with O
increased O
cardiovascular B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
to O
stress O
, O
to O
increased O
risk O
of O
cardiovascular O
disease O
. O
['Physiological-Clinical']

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
whether O
untreated O
ruptures O
are O
associated O
with O
changes O
over O
time O
in O
magnetic O
resonance O
imaging O
findings O
, O
serologic O
markers O
, O
or O
self-reported O
breast O
symptoms O
. O
[]

Forty-six O
percent O
of O
the O
surfaces O
with O
high O
values O
developed O
new B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
progressive I-outcome ['Physiological-Clinical']
caries I-outcome ['Physiological-Clinical']
, O
compared O
with O
2 O
% O
of O
the O
surfaces O
with O
low O
values O
. O
['Physiological-Clinical']

Metoclopramide O
increased O
plasma B-outcome ['Physiological-Clinical']
aldosterone I-outcome ['Physiological-Clinical']
to O
approximately O
170 O
% O
of O
baseline O
levels O
( O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

The O
sample O
was O
randomly O
divided O
in O
an O
experimental O
group O
of O
13 O
older O
subjects O
( O
3 O
men O
and O
10 O
women O
, O
mean O
age O
63.5 O
+/- O
3 O
years O
) O
while O
the O
remaining O
9 O
subjects O
( O
3 O
men O
and O
6 O
women O
, O
mean O
age O
64.2 O
+/- O
4 O
years O
) O
served O
as O
inactive O
control O
group O
. O
[]

Patients O
, O
were O
followed O
up O
for O
26 O
weeks O
or O
until O
death O
. O
[]

Four O
residential O
addiction O
treatment O
centers O
participated O
in O
a O
feasibility O
study O
designed O
to O
estimate O
the O
efficacy O
of O
a O
post-discharge O
telephone O
intervention O
intended O
to O
encourage O
compliance O
with O
aftercare O
. O
[]

Final B-outcome ['Physiological-Clinical']
height I-outcome ['Physiological-Clinical']
in O
girls O
with O
turner O
syndrome O
after O
long-term O
growth O
hormone O
treatment O
in O
three O
dosages O
and O
low O
dose O
estrogens O
. O
['Physiological-Clinical']

Eight O
incidents O
of O
PCP O
and O
19 O
deaths B-outcome ['Mortality']
were O
observed O
in O
the O
treatment O
group O
during O
a O
median O
follow-up O
of O
16.4 O
months O
( O
range O
, O
2.3-32.4 O
months O
) O
. O
['Mortality']

Efficacy O
of O
physiotherapy O
management O
of O
knee O
joint O
osteoarthritis O
: O
a O
randomised O
, O
double O
blind O
, O
placebo O
controlled O
trial O
. O
[]

The O
tumor O
tissue O
in O
both O
groups O
was O
resected O
and O
cell B-outcome ['Physiological-Clinical']
cycle I-outcome ['Physiological-Clinical']
and O
apoptosis B-outcome ['Physiological-Clinical']
rate O
as O
well O
as O
NF-kappa O
B O
were O
determined O
by O
flowcytometry O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
2 O
multiinstitutional O
prospective O
trials O
, O
683 O
postmenopausal O
patients O
were O
randomized O
to O
receive O
either O
fadrozole O
HCL O
, O
1 O
mg O
twice O
daily O
, O
or O
megestrol O
acetate O
, O
40 O
mg O
4 O
times O
daily O
, O
in O
a O
double O
blind O
fashion O
after O
progression O
on O
first-line O
hormonal O
therapy O
. O
[]

METHODS O
In O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
, O
crossover O
design O
, O
we O
administered O
oxytocin O
nasal O
spray O
( O
18 O
or O
24 O
IU O
) O
or O
a O
placebo O
to O
16 O
male O
youth O
aged O
12 O
to O
19 O
who O
were O
diagnosed O
with O
Autistic O
or O
Asperger O
's O
Disorder O
. O
[]

A O
total O
of O
fifty-eight O
breast O
cancer O
patients O
who O
received O
chemotherapy O
or O
radiotherapy O
were O
enrolled O
. O
[]

Identifying O
prospective O
predictors O
of O
smoking O
cessation O
among O
patients O
currently O
receiving O
smoking O
cessation O
treatment O
can O
help O
guide O
the O
development O
and O
implementation O
of O
smoking O
cessation O
programs O
with O
this O
population O
. O
[]

Control O
infants O
were O
given O
placebo O
infusions O
during O
phase O
1 O
of O
the O
study O
( O
n O
= O
623 O
) O
but O
were O
not O
given O
any O
infusions O
during O
phase O
2 O
( O
n O
= O
589 O
) O
. O
[]

Demographic O
, O
health O
, O
medical O
, O
and O
occupational O
factors O
were O
obtained O
through O
interview O
or O
abstraction O
of O
computer O
files O
; O
individual O
ergonomic O
exposures O
were O
measured O
with O
a O
lumbar O
motion O
monitor O
. O
[]

Here O
, O
we O
further O
report O
that O
low-dose O
cyclophosphamide O
( O
CY O
) O
, O
a O
conventional O
chemotherapy O
drug O
, O
can O
effectively O
prevent O
the O
recurrence O
of O
large B-outcome ['Physiological-Clinical']
CA I-outcome ['Physiological-Clinical']
in O
clinical O
patients O
after O
laser O
therapy O
. O
['Physiological-Clinical']

After O
approval O
of O
institutional O
ethics O
review O
board O
in O
our O
university O
, O
thirty O
patients O
with O
prior O
consent O
participated O
in O
this O
study O
. O
[]

Both O
MPH-P O
and O
and O
the O
association O
of O
PTC O
, O
VCR O
and O
P O
are O
effective O
in O
inducing O
[]

Mean O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
1.24 O
days O
( O
0.62 O
) O
and O
2.76 O
days O
( O
1.01 O
) O
( O
P O
< O
.001 O
) O
in O
the O
stapled O
and O
open O
group O
, O
respectively O
. O
['Resource-use']

A O
total O
of O
1566 O
attacks O
were O
treated O
by O
the O
80 O
patients O
and O
69 O
patients O
completed O
6 O
months O
of O
treatment O
. O
[]

In O
the O
unfavorable O
subgroup O
, O
74.8 O
% O
had O
a O
negative O
early O
PET O
scan O
( O
standard O
arm O
, O
seven O
events O
v O
experimental O
arm O
, O
16 O
events O
) O
. O
[]

The O
median O
[]

For O
10 O
patients O
( O
8.2 O
% O
) O
in O
the O
febuxostat O
group O
and O
14 O
patients O
( O
11.6 O
% O
) O
in O
the O
allopurinol O
group O
, O
association O
with O
the O
study O
drugs O
could O
not O
be O
ruled O
out O
. O
[]

MAIN O
RESULTS O
Rapid O
injection O
was O
less O
painful B-outcome ['Physiological-Clinical']
than O
after O
pretreatment O
with O
lidocaine O
0.5 O
mg/kg O
, O
but O
was O
similar O
to O
slow O
injection O
after O
pretreatment O
with O
lidocaine O
1.0 O
mg/kg O
. O
['Physiological-Clinical']

Phase O
II O
trial O
of O
nab-paclitaxel O
compared O
with O
docetaxel O
as O
first-line O
chemotherapy O
in O
patients O
with O
metastatic O
breast O
cancer O
: O
final O
analysis O
of O
overall O
survival O
. O
[]

OBJECTIVE O
In O
a O
previously O
published O
randomized O
6-year O
study O
we O
observed O
that O
multiple O
risk O
factor O
intervention O
reduced O
cardiovascular O
risk O
in O
high-risk O
hypertensive O
men O
, O
and O
that O
this O
effect O
was O
confined O
to O
patients O
with O
carotid O
artery O
plaques O
. O
[]

We O
applied O
hyperinsulinemic-euglycemic O
clamps O
with O
higher O
insulin O
dosing O
in O
obese O
subjects O
than O
lean O
subjects O
( O
30 O
vs. O
10 O
mU.m O
( O
-2 O
) O
.min O
( O
-1 O
) O
, O
respectively O
) O
, O
with O
the O
goal O
of O
matching O
insulin O
's O
nitric O
oxide O
( O
NO O
) O
-mediated O
vascular O
effects O
. O
[]

RESULTS O
Pain B-outcome ['Physiological-Clinical']
decreased O
during O
the O
two O
week O
placebo O
run-in O
period O
in O
both O
the O
sham O
device O
and O
placebo O
pill O
groups O
, O
but O
changes O
were O
not O
different O
between O
the O
groups O
( O
-0.14 O
, O
95 O
% O
confidence O
interval O
-0.52 O
to O
0.25 O
, O
P O
= O
0.49 O
) O
. O
['Physiological-Clinical']

The O
questionnaires O
revealed O
a O
greater O
acceptability O
of O
the O
reduced O
bowel B-outcome ['Physiological-Clinical']
preparation I-outcome ['Physiological-Clinical']
compared O
with O
the O
standard O
procedure O
( O
p=0.01 O
) O
. O
['Physiological-Clinical']

The O
difference O
of O
the O
reduction O
of O
the O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
between O
enalapril O
and O
timolol O
group O
at O
the O
end O
of O
the O
combined O
treatment O
was O
statistically O
significant O
( O
p O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

Compared O
with O
the O
control O
group O
, O
improvement O
in O
aspects O
of O
cognitive B-outcome ['Life-Impact']
development I-outcome ['Life-Impact']
in O
the O
children O
who O
received O
the O
extra O
intervention O
was O
sustained O
1 O
year O
later O
( O
P= O
0.007 O
) O
while O
significant O
behavioural B-outcome ['Life-Impact']
differences I-outcome ['Life-Impact']
post O
intervention O
were O
not O
. O
['Life-Impact', 'Life-Impact']

Cases O
without O
cirrhosis O
and O
with O
APC O
of O
> O
0.25 O
mL/min/kg O
body O
weight O
had O
an O
85 O
% O
chance O
of O
responding B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
interferon I-outcome ['Physiological-Clinical']
; O
this O
was O
unlikely O
a O
simple O
reflection O
of O
histological O
activity O
, O
because O
the O
correlation O
with O
Scheuer O
score O
was O
poor O
in O
this O
subgroup O
( O
r O
= O
-.31 O
, O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

Anaesthesia O
was O
induced O
and O
maintained O
with O
midazolam O
, O
fentanyl O
and O
nitrous O
oxide O
. O
[]

In O
this O
double-blind O
, O
randomized O
, O
cross-over O
study O
, O
20 O
adult O
patients O
with O
reversible O
chronic O
airway O
obstruction O
( O
intrinsic O
asthma O
or O
COPD O
) O
inhaled O
single O
doses O
of O
formoterol O
9 O
microg O
or O
salbutamol O
100 O
microg O
( O
group O
A O
) O
or O
formoterol O
18 O
microg O
or O
salbutamol O
200 O
microg O
( O
group O
B O
) O
. O
[]

Intensive O
insulin O
therapy O
decreases O
infection B-outcome ['Physiological-Clinical']
rate O
and O
days O
in O
NICU B-outcome ['Resource-use']
and O
improves O
the O
['Physiological-Clinical', 'Resource-use']

Five O
patients O
who O
were O
re-checked O
after O
24 O
months O
also O
had O
a O
significant O
increase O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
There O
was O
no O
difference O
in O
mean O
change O
in O
Facial B-outcome ['Physiological-Clinical']
Pain I-outcome ['Physiological-Clinical']
Scale O
scores O
between O
the O
control O
and O
the O
intervention O
groups O
in O
children O
< O
10 O
years O
of O
age O
. O
['Physiological-Clinical']

The O
estimates O
were O
further O
compared O
between O
the O
two O
groups O
irrespective O
of O
drug O
used O
to O
evaluate O
the O
difference O
, O
if O
any O
. O
[]

and O
oral O
administration O
, O
and O
the O
metabolic O
disposition O
after O
oral O
administration O
of O
14C-labeled O
drug O
. O
[]

We O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
to O
assess O
whether O
raltegravir O
intensification O
reduces O
low-level O
viral I-outcome ['Physiological-Clinical']
replication I-outcome ['Physiological-Clinical']
, O
as O
defined O
by O
an O
increase O
in O
the O
level O
of O
2-long O
terminal O
repeat O
( O
2-LTR O
) O
circles O
. O
['Physiological-Clinical']

The O
present O
study O
suggests O
that O
memantine O
may O
be O
a O
potential O
adjunctive O
treatment O
strategy O
for O
autism O
and O
it O
was O
generally O
well O
tolerated O
. O
[]

Dietary O
restriction O
as O
a O
basic O
treatment O
for O
obesity O
is O
complicated O
by O
poor O
compliance O
, O
protein O
catabolism O
, O
and O
slow O
rates O
or O
weight O
loss O
. O
[]

METHODS O
DESIGN O
Prospective O
, O
Controlled O
and O
Randomised O
Multicentre O
Trial O
. O
[]

A O
community-based O
randomized O
trial O
of O
praziquantel O
to O
control O
schistosomiasis O
morbidity O
in O
schoolchildren O
in O
Zambia O
. O
[]

Japan O
useful O
medication O
program O
for O
schizophrenia O
( O
JUMPs O
) O
-long-term O
study O
on O
discontinuation O
rate O
, O
resolution O
and O
remission O
, O
and O
improvement O
in O
social O
functioning O
rate O
associated O
with O
atypical O
antipsychotic O
medications O
in O
patients O
with O
schizophrenia O
. O
[]

Dose O
Dependency O
for O
pharmacokinetics O
of O
theophylline O
and O
the O
formation O
of O
its O
major O
metabolites O
, O
3-methylxanthine O
( O
3-MX O
) O
; O
1-methyluric O
acid O
( O
1-MU O
) O
; O
1,3-dimethyluric O
acid O
( O
DMU O
) O
, O
were O
examined O
by O
administering O
three O
single O
oral O
doses O
( O
250 O
, O
375 O
, O
500 O
mg O
) O
of O
theophylline O
to O
six O
healthy O
adult O
volunteers O
. O
[]

STUDY O
DESIGN O
The O
study O
included O
60 O
newly O
diagnosed O
stage O
1 O
hypertensive O
patients O
with O
no O
other O
systemic O
disease O
. O
[]

CONCLUSIONS O
Treatment O
with O
meloxicam O
resulted O
in O
a O
significant O
improvement O
in O
mobility B-outcome ['Life-Impact']
and O
activity B-outcome ['Life-Impact']
levels O
of O
cats O
with O
OA O
until O
the O
placebo O
was O
introduced O
. O
['Life-Impact', 'Life-Impact']

MATERIALS O
AND O
METHODS O
A O
total O
70 O
patients O
scheduled O
to O
undergo O
elective O
transurethral O
prostate O
resection O
were O
randomized O
to O
receive O
5 O
mg. O
finasteride O
daily O
or O
placebo O
for O
2 O
weeks O
before O
surgery O
. O
[]

RESULTS O
The O
complete B-outcome ['Physiological-Clinical']
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
rates O
to O
PELF O
and O
FAMTX O
were O
, O
respectively O
, O
13 O
% O
[ O
95 O
% O
confidence O
intervals O
( O
CI O
) O
6 O
% O
to O
20 O
% O
] O
and O
2 O
% O
( O
95 O
% O
CI O
0 O
% O
to O
5 O
% O
; O
P O
= O
0.003 O
) O
, O
and O
the O
objective O
response O
rates O
[ O
CR O
plus O
partial B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Continuance O
of O
exercise O
during O
the O
follow-up O
year O
, O
regardless O
of O
type O
, O
was O
associated O
with O
a O
better O
outcome O
. O
[]

Fifty-five O
hypertensive O
participants O
( O
35 O
African-American O
, O
20 O
white O
) O
were O
randomly O
assigned O
to O
receive O
8 O
weeks O
of O
either O
a O
control O
diet O
or O
the O
DASH O
diet O
. O
[]

Cigarette O
smoking O
is O
associated O
with O
increased O
circulating O
proinflammatory O
and O
procoagulant O
markers O
in O
patients O
with O
chronic O
coronary O
artery O
disease O
: O
effects O
of O
aspirin O
treatment O
. O
[]

In O
addition O
, O
CRP O
, O
plasma O
renin O
activity O
, O
plasma O
aldosterone O
, O
and O
traditional O
risk O
factors O
were O
assessed O
. O
[]

FUNDING O
Biogen O
Idec O
and O
AbbVie O
Biotherapeutics O
Inc O
. O
[]

Apnoea B-outcome ['Physiological-Clinical']
occurred O
with O
similar O
frequency O
in O
the O
two O
groups O
. O
['Physiological-Clinical']

BACKGROUND O
Little O
evidence O
exists O
to O
indicate O
whether O
community O
psychiatric O
nurses O
can O
achieve O
the O
results O
reported O
by O
expert O
cognitive-behavioural O
therapists O
in O
patients O
with O
schizophrenia O
. O
[]

Accruing O
evidence O
indicates O
a O
primary O
role O
of O
altered O
expectancies O
in O
the O
placebo O
effect O
. O
[]

0.18 O
mg/dL O
vs O
0.53 O
? O
[]

All O
the O
patients O
were O
evaluated O
for O
toxicity B-outcome ['Adverse-effects']
and O
survival B-outcome ['Mortality']
according O
to O
the O
as-treated O
principle O
. O
['Adverse-effects', 'Mortality']

In O
2 O
separate O
phases O
, O
women O
who O
met O
triage O
criteria O
were O
randomly O
assigned O
to O
either O
the O
triage O
room O
or O
the O
standard O
care O
labor O
room O
. O
[]

EGFr O
was O
visualized O
using O
immunohistochemistry O
and O
separated O
into O
high O
and O
low O
expression O
before O
correlation O
with O
clinical O
data O
. O
[]

Could O
changing O
reappraisals O
following O
a O
stressful O
event O
reduce O
the O
emergence O
of O
PTSD O
symptoms O
? O
[]

The O
subjects O
were O
divided O
randomly O
into O
2 O
groups O
. O
[]

In O
conclusion O
, O
the O
upper O
lip O
bite O
test O
is O
an O
acceptable O
option O
for O
predicting O
difficult O
intubation O
as O
a O
simple O
, O
single O
test O
. O
[]

Social O
phobics O
reported O
substantially O
more O
anxiety B-outcome ['Life-Impact']
than O
controls O
. O
['Life-Impact']

1 O
. O
[]

At O
month O
6 O
, O
22 O
patients O
were O
randomized O
to O
CSA O
and O
27 O
to O
MTX O
. O
[]

Pretreatment O
with O
HFLCS O
did O
not O
cause O
a O
statistically O
significant O
change O
in O
the O
shear O
bond O
values O
of O
either O
metal O
or O
ceramic O
brackets O
( O
P O
= O
0.38 O
) O
. O
[]

Patients O
received O
either O
nicotinic O
acid O
( O
1.5 O
g O
three O
times O
daily O
) O
or O
no O
therapy O
( O
control O
period O
) O
for O
8 O
weeks O
each O
. O
[]

The O
Minneapolis O
Children O
's O
Blood O
Pressure O
Study O
. O
[]

This O
trial O
includes O
clients O
with O
psychiatric O
disabilities O
living O
in O
supported O
housing O
and O
their O
staff O
. O
[]

Prognostic O
significance O
and O
beneficial O
effect O
of O
diltiazem O
on O
the O
incidence O
of O
early B-outcome ['Physiological-Clinical']
recurrent I-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
after O
non-Q-wave O
myocardial O
infarction O
: O
results O
from O
the O
Multicenter O
Diltiazem O
Reinfarction O
Study O
. O
['Physiological-Clinical']

By O
multivariate O
analysis O
using O
the O
Cox O
proportional O
hazards O
model O
, O
tumor B-outcome ['Physiological-Clinical']
grade O
, O
tumor B-outcome ['Physiological-Clinical']
size O
, O
clinical B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
and O
Skp2 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
were O
independent O
prognostic O
factors O
both O
in O
disease-free B-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Mortality']

Adverse O
effects O
reported O
by O
patients O
treated O
with O
imiquimod O
included O
erythema B-outcome ['Physiological-Clinical']
, O
edema B-outcome ['Physiological-Clinical']
, O
induration B-outcome ['Physiological-Clinical']
, O
vesicles B-outcome ['Physiological-Clinical']
, O
erosion B-outcome ['Physiological-Clinical']
, O
ulceration B-outcome ['Physiological-Clinical']
, O
excoriation B-outcome ['Physiological-Clinical']
, O
and O
scabbing B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Combined O
pindolol-clopamide O
therapy O
decreased O
total O
triglycerides B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
increased O
HDL B-outcome ['Physiological-Clinical']
significantly O
( O
p O
less O
than O
0.05 O
) O
and O
did O
not O
influence O
total O
cholesterol B-outcome ['Physiological-Clinical']
and O
LDL B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
a O
classical O
test O
of O
executive O
function O
( O
random O
response O
generation O
) O
, O
BOLD B-outcome ['Physiological-Clinical']
signal I-outcome ['Physiological-Clinical']
differed O
between O
the O
groups O
in O
the O
cerebellum O
but O
not O
in O
the O
frontal O
lobes O
. O
['Physiological-Clinical']

Postoperative O
injection O
of O
phenylbutazone O
does O
not O
influence O
fibrinolytic B-outcome ['Physiological-Clinical']
shutdown I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
were O
fewer O
patients O
in O
group O
I O
( O
5/15 O
) O
needing B-outcome ['Physiological-Clinical']
inotropic I-outcome ['Physiological-Clinical']
support I-outcome ['Physiological-Clinical']
compared O
to O
group O
II O
( O
9/14 O
) O
. O
['Physiological-Clinical']

Recurrence B-outcome ['Physiological-Clinical']
was O
confirmed O
by O
abdominal O
angiography O
. O
['Physiological-Clinical']

Five O
patients O
( O
two O
in O
the O
treatment O
group O
and O
three O
in O
the O
control O
group O
) O
were O
subsequently O
removed O
due O
to O
protocol O
violations O
. O
[]

Long-term O
results O
of O
a O
randomized O
clinical O
trial O
of O
Shouldice O
, O
Lichtenstein O
and O
transabdominal O
preperitoneal O
hernia O
repairs O
. O
[]

BP B-outcome ['Physiological-Clinical']
was O
measured O
for O
48 O
consecutive O
hours O
before O
and O
after O
3 O
months O
of O
intervention O
. O
['Physiological-Clinical']

These O
diameters O
were O
selected O
because O
they O
simulate O
the O
pressure-flow O
relationships O
of O
adult O
endotracheal O
tubes O
. O
[]

Local B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
was O
similar O
in O
both O
groups O
, O
but O
local B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
occurred O
in O
three O
patients O
treated O
with O
Behringwerke O
antivenom O
and O
in O
none O
given O
S.A.I.M.R O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Perispinal O
analgesia O
for O
labour O
followed O
by O
patient-controlled O
infusion O
with O
bupivacaine O
and O
sufentanil O
: O
combined O
spinal-epidural O
vs. O
epidural O
analgesia O
alone O
. O
[]

A O
3-week O
, O
double-blind O
, O
placebo-controlled O
crossover O
study O
was O
performed O
in O
a O
private O
physician O
, O
office-based O
practice O
. O
[]

The O
study O
hypothesis O
was O
that O
catheter O
life O
would O
be O
extended O
by O
25 O
% O
in O
the O
commercial O
solution O
group O
. O
[]

MAIN O
OUTCOME O
MEASURES O
The O
Family O
Received O
Index O
is O
the O
proportion O
of O
all O
procedures O
for O
which O
a O
family O
was O
overdue O
that O
they O
received O
. O
[]

Maintenance O
was O
with O
2 O
% O
sevoflurane O
at O
the O
same O
flow O
rate O
and O
gas O
mixture O
under O
spontaneous O
ventilation O
with O
an O
endotracheal O
tube O
and O
a O
Mapleson O
D O
circuit O
. O
[]

Compared O
to O
patients O
without O
LV O
hypertrophy O
, O
patients O
with O
LV O
hypertrophy O
were O
significantly O
older O
( O
65 O
vs O
60 O
years O
, O
p O
less O
than O
0.0001 O
) O
and O
had O
smaller O
peak O
adjusted O
CK O
levels O
( O
490 O
+/- O
376 O
vs O
666 O
+/- O
726 O
IU/liter O
, O
p O
less O
than O
0.001 O
) O
than O
patients O
without O
LV O
hypertrophy O
. O
[]

Term O
infants O
with O
aortic O
atresia O
benefited O
from O
a O
right O
ventricle-to-pulmonary O
artery O
shunt O
, O
and O
preterm O
infants O
with O
a O
patent O
aortic O
valve O
benefited O
from O
a O
modified O
Blalock-Taussig O
shunt O
. O
[]

Laparoscopic O
hysterectomy O
has O
been O
first O
reported O
by O
Reich O
et O
al O
. O
[]

These O
increases O
indicated O
buccal B-outcome ['Physiological-Clinical']
tipping I-outcome ['Physiological-Clinical']
of O
the O
teeth O
. O
['Physiological-Clinical']

Participants O
were O
drawn O
from O
a O
randomized-controlled-treatment O
trial O
that O
examined O
the O
effects O
of O
targeted O
interventions O
on O
the O
social B-outcome ['Life-Impact']
networks I-outcome ['Life-Impact']
of O
60 O
elementary-aged O
children O
with O
ASD O
. O
['Life-Impact']

Laboratory O
studies O
included O
measurements O
of O
lactoferrin B-outcome ['Physiological-Clinical']
( O
LF O
) O
and O
tumour B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor-alpha I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TNF-alpha I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
besides O
standard O
analyses O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
studied O
27 O
patients O
with O
stable O
chronic O
obstuctive O
pulmonary O
disease O
( O
COPD O
) O
in O
a O
randomised O
, O
single-blind O
, O
within-patient O
, O
placebo-controlled O
clinical O
study O
. O
[]

Each O
was O
given O
five O
HA O
injections O
at O
weekly O
intervals O
; O
or O
20 O
mg O
TH O
followed O
by O
four O
placebo O
( O
saline O
) O
injections O
. O
[]

Twelve O
children O
, O
all O
boys O
, O
aged O
4 O
to O
7 O
years O
, O
with O
a O
diagnosis O
of O
autistic O
disorder O
and O
low O
concentrations O
of O
spinal O
6R-l-erythro-5,6,7,8-tetrahydrobiopterin O
( O
tetrahydrobiopterin O
) O
were O
selected O
to O
participate O
in O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
, O
crossover O
study O
. O
[]

We O
prepared O
the O
nitric-oxide-generating O
system O
by O
mixing O
a O
solution O
of O
KY O
jelly O
and O
sodium O
nitrite O
( O
5 O
% O
weight/volume O
) O
, O
with O
a O
solution O
of O
KY O
jelly O
and O
ascorbic O
acid O
( O
5 O
% O
weight/volume O
) O
. O
[]

63 O
practices O
in O
the O
East O
Anglia O
region O
participated O
. O
[]

At O
the O
point O
of O
protocol-defined O
study O
completion O
( O
85 O
% O
mortality O
in O
the O
placebo O
arm O
) O
there O
was O
a O
modest O
difference O
in O
survival O
in O
the O
intention-to-treat O
population O
in O
favour O
of O
marimastat O
( O
P=0.07 O
log-rank O
test O
, O
hazard O
ratio=1.23 O
( O
95 O
% O
confidence O
interval O
0.98-1.55 O
) O
) O
. O
[]

At O
follow-up O
, O
qDES O
showed O
reduced O
neointimal B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
by O
70 O
% O
at O
the O
tightest O
cross O
section O
and O
by O
68 O
% O
over O
the O
stented O
segment O
( O
P O
< O
0.0001 O
for O
both O
) O
, O
resulting O
in O
a O
significantly O
larger O
lumen O
in O
qDES O
than O
in O
BMS O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
AND O
METHODS O
Participants O
were O
randomly O
assigned O
to O
read O
one O
of O
three O
brochures O
: O
1 O
) O
a O
new O
brochure O
addressing O
common O
donor O
concerns O
and O
suggesting O
specific O
coping O
strategies O
, O
2 O
) O
a O
standard O
blood O
center O
brochure O
, O
or O
3 O
) O
a O
control O
brochure O
on O
healthy O
eating O
and O
exercise O
. O
[]

Offering O
a O
self-test O
for O
HPV O
as O
an O
alternative O
to O
Pap O
smears O
increases O
participation B-outcome ['Life-Impact']
among O
long-term O
non-attendees O
. O
['Life-Impact']

No O
significant O
differences O
were O
demonstrated O
between O
the O
two O
groups O
in O
performance O
on O
common B-outcome ['Life-Impact']
facts I-outcome ['Life-Impact']
or O
in O
fame O
attributed O
to O
the O
names O
. O
['Life-Impact']

Of O
the O
14 O
patients O
, O
seven O
were O
ACTH O
sufficient O
( O
PHDC+ O
) O
and O
seven O
ACTH O
deficient O
( O
PHDC- O
) O
. O
[]

BACKGROUND O
Second-line O
treatment O
with O
irinotecan O
for O
advanced O
or O
metastatic O
colorectal O
cancer O
prolongs O
survival B-outcome ['Mortality']
. O
['Mortality']

It O
is O
, O
however O
, O
unclear O
whether O
these O
observations O
apply O
to O
human O
atherosclerosis O
. O
[]

Serum B-outcome ['Physiological-Clinical']
total O
cholesterol B-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Urinary B-outcome ['Physiological-Clinical']
NAG I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
is O
elevated O
in O
patients O
with O
type O
2 O
DM O
compared O
with O
healthy O
individuals O
and O
increases O
as O
nephropathy O
progresses O
. O
['Physiological-Clinical']

A O
search O
for O
serologic O
correlates O
of O
immunity O
to O
Bordetella O
pertussis O
cough O
illnesses O
. O
[]

The O
aim O
of O
the O
current O
study O
was O
to O
address O
the O
influence O
of O
EGFr O
and O
histopathological B-outcome ['Physiological-Clinical']
differentiation I-outcome ['Physiological-Clinical']
when O
the O
overall O
treatment O
time O
of O
radiotherapy O
was O
moderately O
reduced O
. O
['Physiological-Clinical']

Adverse O
events O
were O
similar O
to O
those O
reported O
previously O
with O
sumatriptan O
and O
were O
mostly O
mild O
to O
moderate O
in O
intensity O
, O
short-lived O
, O
and O
resolved O
spontaneously O
. O
[]

Comparative O
drug O
effects O
and O
abuse O
liability O
of O
lorazepam O
, O
buspirone O
, O
and O
secobarbital O
in O
nondependent O
subjects O
. O
[]

Tunnelling O
of O
the O
catheter O
subcutaneously O
for O
a O
distance O
of O
5 O
cm O
reduced O
the O
incidence O
of O
inward O
migration O
of O
1 O
cm O
or O
more O
( O
p O
< O
0.01 O
) O
compared O
to O
a O
standard O
method B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
fixation I-outcome ['Physiological-Clinical']
with O
a O
transparent B-outcome ['Physiological-Clinical']
adhesive I-outcome ['Physiological-Clinical']
dressing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIM O
To O
evaluate O
neoton O
therapy O
effects O
in O
acute O
myocardial O
infarction O
( O
MI O
) O
on O
systolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricle I-outcome ['Physiological-Clinical']
, O
arrhythmia B-outcome ['Physiological-Clinical']
and O
clinical B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
patients O
on O
thrombolytic O
therapy O
( O
TLT O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
of O
the O
thiopurine O
comparison O
are O
as O
follows O
. O
[]

We O
randomized O
122 O
premenopausal O
women O
to O
receive O
tamoxifen O
or O
to O
undergo O
a O
surgical O
oophorectomy O
. O
[]

BACKGROUND O
Interferon-alfa O
( O
IFN-alpha O
) O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
psoriasis O
. O
[]

Furthermore O
, O
PTK2 O
inhibition O
blunted O
R-dependent B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
death I-outcome ['Physiological-Clinical']
in O
vitro O
. O
['Physiological-Clinical']

Decreased O
insula-dACC O
rsFC O
may O
index O
overlapping O
circuitry O
associated O
with O
smoking O
and O
SZ O
. O
[]

METHOD O
In O
a O
prospective O
, O
multicenter O
, O
open-label O
, O
parallel-group O
study O
we O
determined O
the O
concentration O
of O
moxifloxacin O
in O
plasma O
and O
uterine O
tissue O
after O
a O
single O
, O
400-mg O
intravenous O
dose O
of O
moxifloxacin O
. O
[]

DESIGN O
Randomized O
, O
controlled O
clinical O
trial O
. O
[]

Tacrolimus O
ointment O
0.03 O
% O
is O
approved O
for O
moderate O
to O
severe O
atopic O
dermatitis O
in O
the O
patient O
population O
between O
two O
to O
seventeen O
years O
of O
age O
and O
Tacrolimus O
0.1 O
% O
ointment O
for O
moderate O
to O
severe O
atopic O
dermatitis O
in O
patients O
18 O
years O
of O
age O
and O
older O
. O
[]

STEPP O
analyses O
showed O
little O
effect O
of O
chemotherapy O
for O
tumors O
with O
high O
levels O
of O
ER B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
( O
P O
= O
0.07 O
) O
, O
or O
for O
the O
cohort O
with O
one O
positive O
node O
( O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical']

Epidural O
blood O
patch O
is O
a O
standard O
treatment O
for O
obstetric O
patients O
experiencing O
a O
severe O
post-dural O
puncture O
headache O
. O
[]

Secondary O
measures O
were O
baseline O
behavioural O
and O
physiological O
measures O
, O
observational O
pain O
scores O
( O
PIPP O
) O
, O
and O
spinal B-outcome ['Physiological-Clinical']
nociceptive I-outcome ['Physiological-Clinical']
reflex I-outcome ['Physiological-Clinical']
withdrawal I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
other O
two O
capsules O
, O
with O
in O
vitro O
burst O
times O
of O
62 O
and O
229 O
min O
, O
produced O
significant O
delays O
in O
digoxin O
absorption O
. O
[]

Therapist B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
and O
its O
determinants O
. O
['Physiological-Clinical']

A O
rationale O
for O
evaluating O
higher O
doses O
of O
nimodipine O
for O
the O
treatment O
of O
cocaine O
addiction O
is O
presented O
. O
[]

They O
were O
assessed O
at O
baseline O
and O
one O
year O
after O
randomisation O
with O
validated O
measures O
of O
physical B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
psychological I-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
quality O
of O
life O
( O
SF-36 O
health B-outcome ['Physiological-Clinical']
survey O
) O
. O
['Life-Impact', 'Physiological-Clinical']

These O
Positive O
and O
Negative O
Syndrome B-outcome ['Physiological-Clinical']
Scales I-outcome ['Physiological-Clinical']
consist O
of O
items O
selected O
from O
the O
Children O
's O
Psychiatric O
Rating O
Scale O
( O
CPRS O
) O
, O
which O
contains O
items O
covering O
a O
wide O
range O
of O
childhood O
psychopathology O
. O
['Physiological-Clinical']

Central O
venous O
catheters O
cause O
psychosocial B-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
including O
altered B-outcome ['Life-Impact']
body I-outcome ['Life-Impact']
perception I-outcome ['Life-Impact']
, O
['Life-Impact', 'Life-Impact']

obstructive O
uropathy O
) O
, O
with O
none O
linked O
to O
Z O
therapy O
. O
[]

The O
patients O
were O
given O
acipimox O
, O
250 O
mg O
three O
times O
daily O
or O
placebo O
for O
a O
three O
month O
period O
, O
and O
plasma B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
and O
glucose B-outcome ['Physiological-Clinical']
were O
monitored O
. O
['Physiological-Clinical', 'Physiological-Clinical']

5-items O
questionnaire O
is O
more O
associated O
with O
the O
physician O
diagnosed O
group O
and O
more O
consistent O
than O
6-items O
clinical B-outcome ['Physiological-Clinical']
score O
. O
['Physiological-Clinical']

CONCLUSIONS O
This O
study O
showed O
that O
MEBO O
ointment O
for O
topical O
treatment O
of O
burn B-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
presents O
an O
attractive O
alternative O
for O
the O
topical O
treatment O
of O
limited O
partial O
thickness O
thermal O
burns O
. O
['Physiological-Clinical']

Intra-group O
comparisons O
also O
failed O
to O
show O
any O
differences O
between O
baseline O
and O
14-day O
P2Y B-outcome ['Physiological-Clinical']
( O
12 O
) O
reactivity B-outcome ['Physiological-Clinical']
index O
['Physiological-Clinical', 'Physiological-Clinical']

Changes O
in O
motor O
cortex O
excitability O
associated O
with O
temporal O
repetitive O
transcranial O
magnetic O
stimulation O
in O
tinnitus O
: O
hints O
for O
cross-modal O
plasticity O
? O
[]

Peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
natural I-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
significantly O
enhanced O
in O
patients O
during O
maintenance O
therapy O
whether O
or O
not O
they O
received O
indomethacin O
. O
['Physiological-Clinical']

CRC O
screening O
was O
completed B-outcome ['Physiological-Clinical']
by O
17.8 O
% O
in O
the O
usual O
care O
group O
, O
20.5 O
% O
in O
the O
chart O
reminder O
group O
, O
56.5 O
% O
in O
the O
mailed O
education/FIT O
group O
, O
and O
57.2 O
% O
in O
the O
mailed O
education/FIT O
plus O
phone O
call O
group O
. O
['Physiological-Clinical']

Accordingly O
, O
arzoxifene O
20 O
mg/day O
was O
selected O
for O
further O
study O
in O
patients O
with O
breast O
cancer O
. O
[]

In O
the O
present O
study O
we O
evaluated O
whether O
these O
pharmacological O
differences O
between O
salmeterol O
and O
formoterol O
also O
are O
applicable O
to O
asthmatic O
patients O
. O
[]

This O
was O
defined O
as O
the O
ability O
to O
utilize O
predictive O
contextual O
information O
to O
facilitate O
detection O
of O
predictable O
versus O
random O
targets O
. O
[]

Naltrexone O
has O
been O
tested O
in O
several O
open O
studies O
. O
[]

[ O
Laparoscopic O
lymphadenectomy O
as O
treatment O
of O
endometrial O
cancer O
] O
. O
[]

Patients O
and O
investigators O
were O
not O
masked O
to O
treatment O
. O
[]

Improvement O
in O
patient O
safety O
is O
a O
high-priority O
issue O
of O
great O
social O
import O
. O
[]

We O
argue O
that O
the O
middle O
temporal O
( O
MT O
) O
cortical O
region O
does O
not O
confer O
us O
the O
[]

A O
recent O
meta O
analysis O
of O
small-sized O
studies O
suggests O
that O
thrombolysis O
could O
offer O
some O
benefit O
to O
stroke O
patients O
, O
by O
reducing O
the O
mortality B-outcome ['Mortality']
and O
severe B-outcome ['Physiological-Clinical']
invalidity I-outcome ['Physiological-Clinical']
by O
56 O
% O
; O
these O
results O
need O
to O
be O
confirmed O
in O
adequately O
designed O
and O
sized O
studies O
. O
['Mortality', 'Physiological-Clinical']

Similarly O
, O
no O
statistically O
significant O
differences O
in O
digoxin O
pharmacokinetics O
were O
observed O
when O
digoxin O
was O
administered O
alone O
or O
in O
combination O
with O
donepezil O
. O
[]

Intravenous O
sodium O
valproate O
versus O
diazepam O
infusion O
for O
the O
control O
of O
refractory O
status O
epilepticus O
in O
children O
: O
a O
randomized O
controlled O
trial O
. O
[]

The O
findings O
support O
the O
hypothesis O
that O
modification O
of O
dietary O
fat O
intake O
is O
a O
significant O
predictor O
of O
change O
in O
BP B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

One O
pelvic O
sidewall O
was O
covered O
by O
Interceed O
( O
TC7 O
) O
and O
the O
other O
was O
left O
uncovered O
. O
[]

Although O
midazolam O
failed O
to O
produce O
anaesthesia B-outcome ['Resource-use']
in O
the O
dose O
range O
used O
, O
the O
dose O
of O
propofol O
['Resource-use']

The O
hazard O
ratio O
for O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
with O
the O
addition O
of O
MTP O
was O
0.71 O
( O
95 O
% O
CI O
, O
0.52 O
to O
0.96 O
) O
. O
['Mortality']

RESULTS O
Difference O
between O
the O
two O
protocols O
was O
significant O
as O
the O
group O
that O
received O
topiramate O
had O
a O
greater O
reduction O
in O
ABC-C O
subscale O
scores O
for O
irritability O
, O
stereotypic B-outcome ['Physiological-Clinical']
behavior I-outcome ['Physiological-Clinical']
and O
hyperactivity/noncompliance B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Blood O
losses O
were O
replaced O
with O
5 O
per O
cent O
human O
albumin O
, O
red O
cell O
concentrates O
, O
and O
fresh O
frozen O
plasma O
. O
[]

They O
used O
Kruskal-Wallis O
and O
Mann-Whitney O
U O
tests O
for O
between-group O
comparison O
. O
[]

N-acetylcysteine O
had O
no O
effect O
on O
nitroglycerin-induced B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
diameters I-outcome ['Physiological-Clinical']
( O
p O
> O
0.05 O
) O
but O
significantly O
increased O
microcirculatory B-outcome ['Physiological-Clinical']
subcutaneous I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
after O
1 O
h O
( O
nitroglycerin O
plus O
N-acetylcysteine O
: O
6.3 O
+/- O
1.3 O
ml/100 O
g O
per O
min O
vs. O
nitroglycerin O
plus O
placebo O
: O
3.5 O
+/- O
0.3 O
ml/100 O
g O
per O
min O
, O
p O
< O
0.05 O
) O
and O
after O
23 O
h O
( O
4.4 O
+/- O
0.6 O
vs. O
3.1 O
+/- O
0.5 O
ml/100 O
g O
per O
min O
, O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
endpoint O
was O
first B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
after O
transurethral O
resection O
. O
['Physiological-Clinical']

Do O
cervical O
cancer O
screening O
rates O
increase O
in O
association O
with O
an O
intervention O
designed O
to O
increase O
mammography O
usage O
? O
[]

METHODS O
This O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
included O
adults O
with O
GERD-associated B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
and O
moderate-to-severe B-outcome ['Physiological-Clinical']
nighttime I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
( O
recorded O
by O
patient O
diary O
during O
screening O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

During O
the O
48-hour O
observation O
period O
, O
3 O
( O
7 O
% O
) O
of O
46 O
patients O
given O
phenytoin O
and O
3 O
( O
5 O
% O
) O
of O
56 O
patients O
given O
placebo O
experienced O
a O
posttraumatic B-outcome ['Physiological-Clinical']
seizure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
There O
is O
evidence O
that O
ARBs O
have O
blood O
pressure O
( O
BP O
) O
-independent O
effects O
on O
LV O
mass O
. O
[]

The O
improved O
analgesic B-outcome ['Resource-use']
quality O
of O
the O
clonidine-ropivacaine O
mixture O
is O
achieved O
without O
causing O
any O
significant O
degree O
of O
postoperative O
sedation O
. O
['Resource-use']

The O
efficacy O
was O
evaluated O
in O
two O
groups O
. O
[]

CDP571 O
was O
well O
tolerated O
. O
[]

Left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
was O
increased O
in O
normal O
pregnancy O
, O
but O
displayed O
an O
exaggerated O
increase O
in O
hypertensive O
patients O
. O
['Physiological-Clinical']

Mortality B-outcome ['Mortality']
in O
patients O
with O
small O
choroidal O
melanoma O
. O
['Mortality']

Effects O
occurred O
in O
regions O
that O
may O
be O
behaviorally O
relevant O
to O
mood O
and O
anxiety O
disorders O
. O
[]

CONCLUSION O
It O
is O
concluded O
that O
oral O
NaAcetate O
could O
be O
used O
as O
both O
an O
alkalinizing O
agent O
and O
an O
alternative O
energy O
source O
in O
the O
horse O
. O
[]

There O
was O
also O
an O
intervention O
effect O
for O
fasting B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
with O
the O
N O
group O
increasing O
by O
3 O
% O
and O
the O
N O
+ O
CAST O
group O
decreasing O
by O
4 O
% O
( O
P O
< O
or O
= O
0.05 O
) O
. O
['Physiological-Clinical']

In O
line O
with O
earlier O
investigations O
, O
our O
results B-outcome ['Physiological-Clinical']
suggest I-outcome ['Physiological-Clinical']
a O
moderate O
- O
potentially O
clinically B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Neither O
the O
fasting O
plasma O
glucose O
level O
nor O
the O
body O
weight O
were O
affected O
. O
[]

For O
the O
remainder O
of O
treatment O
, O
however O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
these O
behaviors O
between O
the O
trials O
( O
P O
> O
.05 O
) O
. O
[]

RESULTS O
GS-9620 O
was O
well-absorbed B-outcome ['Life-Impact']
and O
well-tolerated B-outcome ['Life-Impact']
in O
oral O
doses O
up O
to O
12 O
mg O
. O
['Life-Impact', 'Life-Impact']

Treadmill B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
increased O
from O
6.4 O
+/- O
2.1 O
minutes O
during O
the O
placebo O
phase O
to O
7.5 O
+/- O
1.8 O
minutes O
during O
the O
verapamil O
phase O
( O
p O
less O
than O
0.001 O
) O
. O
['Life-Impact']

CONCLUSIONS O
Repeated O
high-dose O
bronchial O
allergen O
challenges O
resulted O
in O
severe O
asthma O
symptoms O
and O
marked O
Th-2-mediated O
allergic O
airway O
inflammation O
. O
[]

METHODS O
Sixty-four O
participating O
schools O
were O
assigned O
to O
study O
and O
control O
groups O
using O
a O
stratified O
, O
blocked O
randomisation O
technique O
. O
[]

IOP B-outcome ['Physiological-Clinical']
was O
measured O
using O
an O
applanation O
tonometer O
for O
5 O
min O
following O
administration O
of O
induction O
doses O
of O
propofol O
or O
thiopentone O
and O
inhalation O
of O
66 O
% O
nitrous O
oxide O
in O
oxygen O
. O
['Physiological-Clinical']

Reducing O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
at O
open O
myomectomy O
using O
triple O
tourniquets O
: O
a O
randomised O
controlled O
trial O
. O
['Physiological-Clinical']

RESULTS O
The O
duration O
of O
enteral B-outcome ['Physiological-Clinical']
nutrition I-outcome ['Physiological-Clinical']
in O
the O
three O
groups O
was O
similar O
with O
an O
average O
duration O
of O
14,5 O
+/- O
8 O
days O
. O
['Physiological-Clinical']

Wounds O
were O
evaluated O
for O
60 O
up O
to O
days O
regarding O
wound B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
, O
water B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
inflammation B-outcome ['Physiological-Clinical']
, O
and O
pain B-outcome ['Physiological-Clinical']
alleviation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
controlled O
clinical O
trial O
tested O
virtual O
reality O
exposure O
( O
VRE O
) O
therapy O
for O
the O
fear O
of O
flying O
( O
FOF O
) O
, O
a O
relatively O
new O
and O
innovative O
way O
to O
do O
exposure O
therapy O
, O
and O
compared O
it O
to O
standard O
( O
in O
vivo O
) O
exposure O
therapy O
( O
SE O
) O
and O
a O
wait O
list O
( O
WL O
) O
control O
with O
a O
6- O
and O
12-month O
follow-up O
. O
[]

or O
placebo O
. O
[]

All O
patients O
completed O
a O
postprocedure O
questionnaire O
. O
[]

The O
duration O
of O
hospital B-outcome ['Resource-use']
stay B-outcome ['Resource-use']
, O
the O
number O
of O
['Resource-use', 'Resource-use']

METHODS O
We O
studied O
433 O
patients O
( O
36.0 O
% O
women O
) O
from O
the O
M-HART O
treatment O
group O
who O
received O
two O
home O
visits O
after O
achieving O
a O
high O
psychological O
distress O
score O
( O
ie O
, O
> O
or O
=5 O
) O
on O
the O
General O
Health O
Questionnaire O
( O
GHQ O
) O
. O
[]

INTERVENTION O
Stabilization O
of O
tibial O
fractures O
either O
with O
a O
slotted O
, O
stainless O
steel O
reamed O
nail O
or O
a O
solid O
, O
titanium O
unreamed O
nail O
. O
[]

Exercise O
training O
prevented O
an O
increase O
in O
leptin O
levels O
during O
the O
study O
period O
. O
[]

Efficacy O
was O
assessed O
as O
success/failure B-outcome ['Physiological-Clinical']
, O
success B-outcome ['Physiological-Clinical']
being O
defined O
as O
the O
complete O
disappearance O
of O
nocturnal O
symptoms/awakening O
during O
the O
last O
week O
of O
each O
treatment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
primary O
outcome O
occurred O
in O
351 O
of O
4998 O
patients O
( O
7.0 O
% O
) O
in O
the O
aspirin O
group O
and O
in O
355 O
of O
5012 O
patients O
( O
7.1 O
% O
) O
in O
the O
placebo O
group O
( O
hazard O
ratio O
in O
the O
aspirin O
group O
, O
0.99 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.86 O
to O
1.15 O
; O
P=0.92 O
) O
. O
[]

METHODS O
Accordingly O
, O
we O
evaluated O
26,466 O
NSTE O
ACS O
patients O
from O
the O
Global O
Use O
of O
Strategies O
to O
Open O
Occluded O
Arteries O
in O
Acute O
Coronary O
Syndromes O
( O
GUSTO-IIb O
) O
, O
Platelet O
Glycoprotein O
IIb/IIIa O
in O
Unstable O
Angina O
: O
Receptor O
Suppression O
Using O
Integrilin O
Therapy O
( O
PURSUIT O
) O
, O
and O
Platelet O
IIb/IIIa O
Antagonism O
for O
the O
Reduction O
of O
Acute O
Coronary O
Syndrome O
Events O
in O
a O
Global O
Organization O
Network O
( O
PARAGON O
) O
A O
and O
B O
trials O
to O
ascertain O
the O
timing O
of O
adverse O
events O
. O
[]

During O
conventional O
mechanical O
ventilation O
, O
nine O
patients O
presented O
a O
right O
ventricular O
dysfunction O
( O
right O
ventricular O
end-diastolic O
area/left O
ventricular O
end-diastolic O
area O
ratio O
> O
0.6 O
) O
of O
whom O
four O
patients O
had O
a O
right O
ventricular O
failure O
( O
right O
ventricular O
end-diastolic O
area/left O
ventricular O
end-diastolic O
area O
ratio O
> O
0.9 O
) O
. O
[]

The O
study O
was O
conducted O
in O
the O
framework O
of O
the O
Primary O
Prevention O
Project O
( O
PPP O
) O
, O
a O
randomized O
, O
controlled O
factorial O
trial O
on O
the O
preventive O
effect O
of O
aspirin O
or O
vitamin O
E O
in O
people O
with O
one O
or O
more O
cardiovascular O
risk O
factors O
. O
[]

Vital O
force O
also O
showed O
correlations O
( O
p O
< O
0.05 O
) O
with O
lower O
[]

BACKGROUND O
The O
authors O
examined O
the O
impact O
of O
parenteral O
iron O
and O
recombinant O
human O
erythropoietin-? O
( O
rHuEPO-? O
) O
administered O
in O
the O
bilateral O
total O
knee O
replacement O
arthroplasty O
( O
TKRA O
) O
, O
on O
postoperative O
anemia O
and O
transfusion O
requirements O
in O
iron-deficient O
patients O
. O
[]

CONCLUSIONS O
Moderate O
dissections O
left O
untreated O
result O
in O
no O
increased O
risk O
of O
major B-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION O
NCT00623090 O
. O
[]

Comparison O
of O
antihypertensive B-outcome ['Physiological-Clinical']
effects O
of O
captopril O
and O
propranolol O
in O
essential O
hypertension O
. O
['Physiological-Clinical']

CONCLUSION O
The O
results O
of O
the O
present O
study O
suggest O
that O
very O
early O
administration O
of O
B. O
breve O
to O
low O
birth O
weight O
infants O
is O
useful O
in O
promoting O
the O
colonization O
of O
the O
Bifidobacterium O
and O
the O
formation O
of O
a O
normal O
intestinal O
flora O
. O
[]

Predictive O
and O
prognostic O
roles O
of O
BRAF O
mutation O
in O
stage O
III O
colon O
cancer O
: O
results O
from O
intergroup O
trial O
CALGB O
89803 O
. O
[]

Outcomes O
were O
assessed O
using O
linear O
regression O
with O
random O
effects O
for O
classroom O
and O
student O
. O
[]

Subjects O
are O
randomly O
assigned O
to O
either O
the O
control O
group O
or O
to O
the O
treatment O
group O
. O
[]

CONCLUSIONS O
The O
addition O
of O
intravenous O
nicorandil O
to O
PCI O
leads O
to O
beneficial O
clinical B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
short-term O
efficacy O
and O
safety O
of O
aripiprazole O
in O
the O
treatment O
of O
irritability O
in O
children O
and O
adolescents O
with O
autistic O
disorder O
. O
[]

Arm O
B O
: O
docetaxel O
alone O
( O
cycles O
repeated O
every O
21 O
days O
) O
, O
4 O
cycles O
followed O
by O
2 O
cycles O
of O
docetaxel O
alone O
in O
case O
of O
objective O
response O
or O
stabilisation O
. O
[]

A O
double-blind O
randomized O
controlled O
trial O
of O
oral O
misoprostol O
and O
intramuscular O
syntometrine O
in O
the O
management O
of O
the O
third O
stage O
of O
labor O
. O
[]

The O
sirolimus B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
on O
the O
day O
of O
the O
procedure O
correlated O
significantly O
with O
the O
late O
lumen O
loss O
at O
follow-up O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

2 O
) O
( O
1 O
) O
= O
3.750 O
, O
P O
= O
0.05 O
] O
. O
[]

MAIN O
OUTCOMES O
AND O
MEASURES O
A O
positive O
response O
was O
defined O
as O
having O
a O
score O
of O
at O
least O
much O
improved O
on O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression-Improvement O
scale O
at O
week O
12 O
. O
['Physiological-Clinical']

Two O
regimens O
were O
randomly O
allocated O
to O
all O
patients O
within O
half O
an O
hour O
after O
the O
endoscopic O
procedure O
: O
1 O
) O
somatostatin-UCB O
250 O
mcg O
i.v O
. O
[]

In O
12 O
patients O
, O
teeth O
were O
treated O
with O
surgical O
debridement O
( O
DEBR O
) O
alone O
and O
not O
splinted O
. O
[]

The O
mean O
serum B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
was O
elevated O
by O
0.3 O
mmol/l O
after O
addition O
of O
enalapril O
to O
the O
diuretic O
treatment O
, O
but O
none O
of O
the O
patients O
developed O
hyperkalaemia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Research O
questions O
for O
aim O
2 O
were O
as O
follows O
: O
( O
a O
) O
do O
participants O
who O
received O
the O
BCEI O
show O
improvement O
in O
overall B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
, O
and O
( O
b O
) O
is O
the O
QOL O
improvement O
sustained O
over O
time O
. O
['Life-Impact', 'Life-Impact']

Three O
patients O
in O
each O
treatment O
group O
experienced O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
two O
in O
each O
group O
requiring O
blood O
transfusions O
. O
['Physiological-Clinical']

However O
, O
not O
all O
brain O
regions O
affected O
by O
nicotine O
are O
known O
to O
have O
many O
nicotinic O
cholinoceptors O
. O
[]

The O
authors O
suggest O
that O
future O
home-based O
asthma O
education O
programs O
contain O
a O
more O
limited O
number O
of O
home B-outcome ['Life-Impact']
visits I-outcome ['Life-Impact']
but O
add O
telephone O
follow-ups O
and O
address O
the O
broader O
needs O
of O
low-income O
families O
that O
most O
likely O
function O
as O
barriers O
to O
program O
success O
. O
['Life-Impact']

SETTING O
Kanta-Hame O
Central O
Hospital O
, O
a O
district O
referral O
center O
in O
Finland O
. O
[]

Mean O
daily O
in-school O
steps O
for O
the O
intervention O
at O
baseline O
and O
follow-up O
were O
5351 O
and O
5054 O
. O
[]

The O
treatment O
used O
in O
Vietnam O
is O
single O
dose O
oral O
mebendazole O
( O
Phardazone O
) O
500 O
mg. O
We O
tested O
the O
efficacy O
of O
single O
dose O
mebendazole O
500 O
mg O
in O
the O
therapy O
of O
hookworm O
infection O
in O
a O
randomized O
double-blind O
placebo-controlled O
trial O
among O
271 O
Vietnamese O
schoolchildren O
. O
[]

antibiotics O
, O
glucocorticoids O
or O
analgesics O
[ O
1 O
] O
. O
[]

The O
surface O
laryngeal O
electrode O
proved O
non-invasive O
, O
easy O
to O
use O
and O
reliable O
in O
measuring O
onset O
of O
the O
neuromuscular B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
at O
the O
larynx O
. O
['Physiological-Clinical']

Daily O
pollen O
counts O
were O
measured O
throughout O
the O
trial O
. O
[]

Nevertheless O
, O
the O
incidence O
of O
final O
RAO O
remained O
significantly O
lower O
after O
a O
higher O
anticoagulation O
level O
. O
[]

Randomization O
was O
successful O
in O
that O
three O
was O
no O
significant O
difference O
in O
male O
to O
female O
ratio O
, O
age O
, O
preoperative O
hemoglobin O
, O
or O
number O
of O
units O
predonated O
between O
the O
early O
and O
delayed O
reinfusion O
groups O
. O
[]

Albumin B-outcome ['Physiological-Clinical']
supplementation I-outcome ['Physiological-Clinical']
during O
the O
acute B-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
was O
reduced O
in O
the O
oxandrolone O
group O
. O
['Physiological-Clinical', 'Resource-use']

The O
impact O
of O
these O
regimens O
on O
patients O
' O
QoL O
as O
well O
as O
symptoms B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
type O
and O
grading O
chemo-related O
side-effects B-outcome ['Adverse-effects']
has O
been O
compared O
prospectically O
. O
['Physiological-Clinical', 'Adverse-effects']

This O
could O
be O
observed O
in O
patients O
during O
exercise O
and O
in O
those O
in O
whom O
the O
ischemia B-outcome ['Physiological-Clinical']
was O
provoked O
by O
rapid O
cardiac O
stimulation O
. O
['Physiological-Clinical']

In O
addition O
to O
quantifying O
falls B-outcome ['Life-Impact']
, O
we O
shall O
measure O
mobility B-outcome ['Life-Impact']
, O
activity B-outcome ['Life-Impact']
limitations I-outcome ['Life-Impact']
and O
quality O
of O
life O
as O
secondary O
outcomes O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

PATIENTS O
AND O
METHODS O
Between O
May O
1996 O
and O
July O
1997 O
, O
380 O
patients O
were O
randomized O
to O
receive O
either O
UFT O
( O
300 O
mg/m O
( O
2 O
) O
/d O
) O
and O
LV O
( O
90 O
mg/d O
) O
, O
administered O
for O
28 O
days O
every O
35 O
days O
, O
or O
5-FU O
( O
425 O
mg/m O
( O
2 O
) O
/d O
) O
and O
LV O
( O
20 O
mg/m O
( O
2 O
) O
/d O
) O
, O
given O
IV O
for O
5 O
days O
every O
35 O
days O
. O
[]

Despite O
the O
increasing O
use O
of O
these O
approaches O
, O
there O
is O
still O
relatively O
little O
known O
about O
how O
the O
content O
of O
these O
interventions O
may O
influence O
outcomes O
and O
who O
may O
benefit O
most O
from O
these O
approaches O
. O
[]

OBJECTIVE O
The O
present O
study O
assessed O
the O
validity B-outcome ['Physiological-Clinical']
and O
reliability O
of O
the O
Siriraj O
Asthma O
Control O
Questionnaire O
in O
Asthma O
Clinic O
, O
Siriraj O
Hospital O
. O
['Physiological-Clinical']

FG B-outcome ['Physiological-Clinical']
, O
SBP B-outcome ['Physiological-Clinical']
, O
and O
LDL-C B-outcome ['Physiological-Clinical']
levels O
were O
significantly O
lower O
and O
HDL-C B-outcome ['Physiological-Clinical']
level O
and O
antioxidant B-outcome ['Physiological-Clinical']
enzymes I-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
( O
CAT B-outcome ['Physiological-Clinical']
and O
SOD B-outcome ['Physiological-Clinical']
) O
were O
significantly O
higher O
after O
WGP O
supplementation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
positive O
predictors O
for O
fixation B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
were O
identical O
for O
both O
devices O
. O
['Physiological-Clinical']

The O
intervention O
was O
endorsed O
by O
parents O
as O
a O
useful O
programme O
for O
children O
diagnosed O
with O
Asperger O
syndrome O
and O
exhibiting O
anxiety O
symptoms O
, O
and O
active O
parent O
involvement O
enhanced O
the O
usefulness O
of O
the O
programme O
. O
[]

Improvement O
in O
anxiety B-outcome ['Life-Impact']
and O
sedation B-outcome ['Physiological-Clinical']
were O
significantly O
better O
in O
the O
two O
drug O
groups O
than O
in O
those O
patients O
who O
had O
received O
placebo O
. O
['Life-Impact', 'Physiological-Clinical']

FINDINGS O
the O
results O
show O
the O
mean O
gain O
of O
knowledge B-outcome ['Life-Impact']
scores O
of O
experimental O
group O
was O
comparatively O
higher O
and O
control O
groups O
A O
and O
B O
showed O
that O
F O
ratio O
was O
( O
F O
( O
2,190 O
) O
=11.910 O
, O
p O
< O
0.01 O
) O
indicating O
that O
the O
pregnant O
women O
learned O
more O
about O
anaemia O
prevention O
than O
others O
. O
['Life-Impact']

This O
study O
compared O
operative O
gastrostomy O
( O
OG O
) O
( O
by O
surgeons O
) O
with O
endoscopic O
gastrostomy O
( O
PEG O
) O
( O
by O
physicians O
) O
in O
a O
prospective O
randomized O
fashion O
to O
determine O
whether O
one O
technique O
was O
superior O
. O
[]

INTERPRETATION O
AND O
CONCLUSIONS O
Increasing O
the O
dose O
of O
G-CSF O
does O
not O
appear O
to O
reduce O
early B-outcome ['Mortality']
deaths I-outcome ['Mortality']
, O
does O
not O
improve O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
nor O
survival B-outcome ['Mortality']
, O
and O
may O
reduce O
the O
response O
rate O
in O
patients O
with O
SAA O
receiving O
ALG O
and O
CyA O
. O
['Mortality', 'Physiological-Clinical', 'Mortality']

CONCLUSIONS O
Incidence O
of O
AF B-outcome ['Physiological-Clinical']
after O
coronary O
operation O
was O
significantly O
reduced O
by O
the O
administration O
of O
sotalol O
alone O
and O
magnesium O
alone O
; O
more O
importantly O
, O
the O
incidence O
was O
further O
reduced O
by O
combining O
these O
agents O
. O
['Physiological-Clinical']

RESULTS O
The O
Family O
Received O
Index O
for O
families O
mailed O
customized O
letters O
was O
more O
than O
double O
the O
index O
for O
patients O
not O
mailed O
letters O
( O
Kruskal-Wallis O
P O
= O
.0139 O
) O
. O
[]

Resisting O
good O
news O
: O
reactions O
to O
breast O
cancer O
risk O
communication O
. O
[]

Therefore O
, O
we O
evaluated O
the O
influence O
of O
internal O
limiting O
membrane O
( O
ILM O
) O
removal O
on O
longterm O
morphological O
and O
functional O
outcome O
in O
patients O
with O
diabetes O
mellitus O
( O
DM O
) O
type O
2 O
and O
chronic O
CME O
without O
evident O
vitreomacular O
traction O
. O
[]

TRIAL O
REGISTRATION O
clinicaltrials.gov O
Identifier O
: O
NCT01021384 O
. O
[]

Mirror O
movements O
also O
imparted O
a O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
, O
but O
only O
when O
they O
followed O
imagined O
movements O
. O
['Physiological-Clinical', 'Life-Impact']

At O
the O
12 O
months O
recall O
, O
66 O
of O
68 O
controlled O
restorations O
were O
functional B-outcome ['Life-Impact']
without O
need O
of O
replacement O
. O
['Life-Impact']

Text O
samples O
read O
at O
different O
loudness O
levels O
were O
recorded O
before O
and O
after O
training O
. O
[]

Prevention O
of O
acute O
postoperative O
pressure O
rises O
in O
glaucoma O
patients O
undergoing O
cataract O
extraction O
with O
posterior O
chamber O
lens O
implant O
. O
[]

The O
effect O
of O
cessation O
of O
raloxifene O
therapy O
on O
bone O
turnover O
is O
unknown O
. O
[]

In O
response O
to O
improved O
blood O
folate O
concentrations O
, O
many O
health O
care O
professionals O
are O
asking O
whether O
a O
folic O
acid O
supplement O
is O
necessary O
for O
NTD O
prevention O
among O
women O
with O
high O
blood O
folate O
values O
, O
and O
how O
reliably O
high O
RBC O
folate O
concentrations O
predict O
folate O
intakes O
shown O
in O
randomized O
controlled O
trials O
to O
be O
protective O
against O
NTDs O
. O
[]

18F-FDG O
PET/CT O
for O
early O
prediction O
of O
response O
to O
neoadjuvant O
lapatinib O
, O
trastuzumab O
, O
and O
their O
combination O
in O
HER2-positive O
breast O
cancer O
: O
results O
from O
Neo-ALTTO O
. O
[]

Letrozole O
in O
the O
neoadjuvant O
setting O
: O
the O
P024 O
trial O
. O
[]

SETTING O
The O
practices O
of O
2 O
university-affiliated O
family O
medicine O
centers O
( O
8 O
physicians O
each O
) O
, O
14 O
community-based O
family O
physicians O
, O
and O
2 O
cardiologists O
. O
[]

Of O
the O
409 O
patients O
enrolled O
, O
323 O
were O
evaluable O
for O
their O
clinical O
and O
bacteriological O
responses O
; O
of O
these O
323 O
children O
, O
172 O
received O
cefprozil O
and O
151 O
received O
penicillin O
V. O
The O
clinical B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
in O
patients O
treated O
with O
cefprozil O
were O
significantly O
better O
than O
those O
in O
patients O
who O
received O
penicillin O
( O
95.3 O
versus O
88.1 O
% O
; O
P O
= O
0.023 O
) O
. O
['Physiological-Clinical']

Patients O
with O
persistent O
AF O
or O
AF O
induced O
during O
a O
routine O
electrophysiology O
study O
( O
EPS O
) O
were O
randomized O
to O
receive O
either O
the O
low-tilt O
waveform O
or O
a O
conventional O
waveform O
. O
[]

Urinary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
, O
L-FABP B-outcome ['Physiological-Clinical']
and O
ET-1 B-outcome ['Physiological-Clinical']
levels O
were O
significantly O
reduced O
in O
both O
groups O
6 O
and O
12 O
months O
( O
P O
< O
0.001 O
) O
after O
treatment O
, O
but O
the O
reduction O
rates O
were O
more O
pronounced O
in O
patients O
receiving O
telmisartan O
than O
in O
those O
receiving O
enalapril O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Neuropsychological B-outcome ['Physiological-Clinical']
deficits I-outcome ['Physiological-Clinical']
were O
still O
evident O
in O
a O
subgroup O
of O
patients O
6 O
months O
later O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
LD O
( O
50 O
) O
for O
acute O
blood O
loss O
in O
mallard O
ducks O
( O
Anas O
platyrhynchos O
) O
, O
compare O
the O
mortality O
rate O
among O
3 O
fluid O
resuscitation O
groups O
, O
and O
determine O
the O
time O
required O
for O
a O
regenerative O
RBC O
response O
. O
[]

The O
significant O
fall O
of O
MDA B-outcome ['Physiological-Clinical']
and O
SOD B-outcome ['Physiological-Clinical']
and O
increased O
levels O
of O
GSH B-outcome ['Physiological-Clinical']
in O
blood O
in O
both O
groups O
after O
control O
revealed O
beneficial O
effects O
of O
glycemic O
control O
on O
oxidative B-outcome ['Physiological-Clinical']
stress O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
none O
of O
the O
differences O
between O
the O
study O
groups O
were O
statistically O
significant O
( O
P O
> O
0.05 O
) O
. O
[]

The O
negative O
reactions O
may O
be O
exacerbated O
in O
individuals O
with O
autism O
spectrum O
disorders O
. O
[]

Is O
Na+ O
modeling O
necessary O
in O
high O
flux O
dialysis O
? O
[]

This O
prospective O
, O
randomized O
clinical O
trial O
evaluated O
the O
affect O
of O
ACLR O
, O
utilizing O
hamsting B-outcome ['Physiological-Clinical']
( O
HS B-outcome ['Physiological-Clinical']
) O
or O
bone-patellar B-outcome ['Physiological-Clinical']
tendon-bone I-outcome ['Physiological-Clinical']
( O
BTB B-outcome ['Physiological-Clinical']
) O
autograft B-outcome ['Physiological-Clinical']
, O
on O
VM B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
SOL I-outcome ['Physiological-Clinical']
H-reflex I-outcome ['Physiological-Clinical']
latency B-outcome ['Physiological-Clinical']
and O
amplitude B-outcome ['Physiological-Clinical']
in O
twenty O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Sotalol O
alone O
and O
magnesium O
alone O
have O
been O
shown O
to O
partially O
decrease O
the O
incidence O
of O
AF O
. O
[]

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
total O
peripheral B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
responses B-outcome ['Physiological-Clinical']
were O
dependent O
on O
pre- O
( O
antagonist/agonist O
) O
setting O
, O
but O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
deteriorated I-outcome ['Physiological-Clinical']
pre O
vs O
post O
run-in O
, O
which O
was O
significant O
( O
P O
< O
0.05 O
) O
for O
FEF25-75 O
% O
predicted O
. O
['Physiological-Clinical']

An O
oral B-outcome ['Resource-use']
glucose I-outcome ['Resource-use']
tolerance O
test O
including O
measurement O
of O
insulin O
response O
was O
performed O
before O
treatment O
and O
after O
3 O
, O
6 O
, O
and O
12 O
months O
of O
treatment O
. O
['Resource-use']

CONCLUSIONS O
Application O
of O
RFA O
using O
stepwise O
hook O
extension O
technique O
is O
superior O
to O
the O
full O
extension O
method O
since O
it O
produces O
the O
same O
therapeutic B-outcome ['Physiological-Clinical']
effects O
within O
a O
short O
period O
using O
a O
lower O
energy O
. O
['Physiological-Clinical']

The O
most O
common O
adverse O
events O
were O
increases O
in O
liver B-outcome ['Physiological-Clinical']
enzymes I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
; O
no O
event O
resulted O
in O
discontinuation O
. O
['Physiological-Clinical']

for O
6 O
months O
. O
[]

Preoperative O
radiation O
therapy O
tends O
to O
increase O
the O
incidence O
of O
minor O
complications O
. O
[]

No O
increasing O
of O
growth O
of O
fungi B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
upper I-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
was O
observed O
, O
but O
these O
was O
a O
non-significantly O
higher O
incidence O
mainly O
of O
staph B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
neodymium-doped O
yttrium O
aluminum O
garnet O
laser O
treatment O
with O
cold O
knife O
endoscopic O
incision O
of O
urethral O
strictures O
in O
male O
patients O
. O
[]

A O
tendency O
towards O
increased O
plasma B-outcome ['Physiological-Clinical']
6-keto-prostaglandin I-outcome ['Physiological-Clinical']
F1 I-outcome ['Physiological-Clinical']
alpha B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
decreased O
serum B-outcome ['Physiological-Clinical']
thromboxane B-outcome ['Physiological-Clinical']
B2 I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
found O
during O
the O
period O
of O
regular O
exercise O
, O
but O
prostaglandin B-outcome ['Physiological-Clinical']
E2 I-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
remained O
unchanged O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Immunochemotherapy O
was O
well O
tolerated O
. O
[]

Limits O
of O
agreement O
between O
ultrasound O
and O
CT O
( O
-6.6 O
to O
9.4 O
mm O
) O
exceeded O
the O
limits O
of O
clinical O
acceptability O
( O
+/-5 O
mm O
) O
. O
[]

METHODS O
This O
was O
a O
multicenter O
, O
8-week O
, O
parallel-group O
, O
randomized O
, O
double-blind O
, O
double-dummy O
, O
Phase O
III O
clinical O
trial O
. O
[]

PRACTICE O
IMPLICATIONS O
Computer-mediated O
interventions O
are O
cost O
and O
time O
effective O
thereby O
increasing O
patient O
and O
clinician O
willingness O
to O
undertake O
training O
. O
[]

The O
[]

A O
growing O
body O
of O
scientific O
literature O
indicates O
that O
astaxanthin O
is O
a O
more O
powerful O
antioxidant O
than O
other O
carotenoids O
and O
vitamin O
E O
and O
may O
confer O
numerous O
health O
benefits O
. O
[]

The O
metabolic O
syndrome O
definitions O
of O
National O
Cholesterol O
Education O
Program O
Adult O
Treatment O
Expert O
Panel O
III O
( O
NCEPATPIII O
) O
2004 O
, O
NCEP O
2005 O
and O
International O
Diabetes O
Federation O
( O
IDF O
) O
were O
used O
. O
[]

In O
continual O
dosage O
phase O
( O
Part O
B O
) O
, O
patients O
were O
randomised O
to O
a O
fixed-dose O
or O
dose-escalation O
arm O
. O
[]

There O
was O
a O
significant O
improvement O
in O
group O
A O
( O
decrease O
in O
WOMAC O
score O
) O
immediately O
post-treatment O
( O
p=0.002 O
) O
and O
this O
was O
maintained O
at O
the O
eight-week O
follow-up O
( O
p=0.03 O
) O
. O
[]

No O
significant O
change O
was O
observed O
in O
cocaine B-outcome ['Physiological-Clinical']
urinalyses I-outcome ['Physiological-Clinical']
( O
approximately O
70 O
% O
positive O
for O
both O
groups O
at O
intake O
and O
follow-up O
) O
. O
['Physiological-Clinical']

One-year O
results O
from O
the O
phase O
III O
investigation O
of O
the O
KeraVision O
Intacs O
. O
[]

Of O
the O
patients O
, O
27 O
had O
grade O
2 O
and O
15 O
had O
grade O
3 O
cancer O
. O
[]

The O
early O
rehabilitation O
protocol O
increases O
the O
pace O
of O
recovery O
compared O
to O
a O
pathway O
with O
hip O
precautions O
without O
increasing O
complications B-outcome ['Adverse-effects']
. O
['Adverse-effects']

A O
total O
of O
189 O
patients O
completed O
the O
study O
( O
79 O
on O
stable O
antihypertensive O
treatment O
) O
. O
[]

Thirty O
of O
these O
patients O
were O
chosen O
randomly O
and O
for O
180 O
days O
, O
500 O
mg O
of O
propionyl-L-carnitine O
was O
orally O
administered O
, O
3 O
times O
a O
day O
in O
addition O
to O
their O
usual O
treatment O
. O
[]

OBJECTIVE O
The O
aim O
of O
the O
study O
was O
to O
investigate O
whether O
hydrotalcite O
was O
comparable O
to O
esomeprazole O
, O
a O
proton O
pump O
inhibitor O
, O
in O
on-demand O
therapy O
for O
non-erosive O
reflux O
disease O
( O
NERD O
) O
. O
[]

In O
38 O
patients O
who O
completed O
Phase O
1 O
, O
significant O
delay O
in O
pain B-outcome ['Physiological-Clinical']
increase O
was O
observed O
in O
the O
CMZ O
group O
as O
compared O
with O
placebo O
( O
P O
= O
0.038 O
) O
. O
['Physiological-Clinical']

Furthermore O
, O
the O
fatigue B-outcome ['Physiological-Clinical']
inducing O
effect O
of O
melatonin O
on O
brain O
activity O
is O
essentially O
different O
from O
that O
of O
sleep O
deprivation O
thus O
revealing O
differences O
between O
fatigues O
related O
to O
the O
circadian O
sleep O
regulation O
as O
opposed O
to O
increased O
homeostatic O
sleep O
need O
. O
['Physiological-Clinical']

von B-outcome ['Physiological-Clinical']
Willebrand I-outcome ['Physiological-Clinical']
factor O
antigen B-outcome ['Physiological-Clinical']
levels O
declined O
significantly O
under O
the O
influence O
of O
pegvisomant O
alone O
( O
1.1 O
+/- O
0.07 O
vs. O
0.8 O
+/- O
0.06 O
U/ml O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
We O
describe O
the O
rationale O
and O
protocol O
for O
a O
randomized O
noninferiority O
controlled O
trial O
( O
RCT O
) O
to O
determine O
if O
the O
Flexi-T380 O
( O
+ O
) O
copper O
intrauterine O
contraceptive O
device O
( O
IUD O
) O
is O
comparable O
in O
terms O
of O
effectiveness O
and O
expulsion O
rates O
to O
the O
most O
common O
Canadian O
IUD O
currently O
in O
use O
, O
NovaT-200 O
, O
when O
placed O
immediately O
after O
a O
first-trimester O
abortion O
. O
[]

We O
tested O
this O
possibility O
in O
adults O
with O
ASD O
using O
a O
cueing O
task O
combined O
with O
eye-movement O
recording O
. O
[]

The O
median O
follow-up O
period O
was O
11 O
months O
with O
a O
maximum O
follow-up O
of O
19 O
months O
( O
range O
2-19 O
months O
) O
. O
[]

Bivariate O
, O
lagged O
autoregressive O
analyses O
of O
the O
successive O
relationships O
from O
one O
assessment O
to O
the O
next O
showed O
consistent O
, O
significant O
associations O
from O
peer O
use I-outcome ['Life-Impact']
to O
adolescent B-outcome ['Life-Impact']
substance I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
. O
['Life-Impact']

BACKGROUND O
Trial O
findings O
show O
cognitive O
behaviour O
therapy O
( O
CBT O
) O
and O
graded O
exercise O
therapy O
( O
GET O
) O
can O
be O
effective O
treatments O
for O
chronic O
fatigue O
syndrome O
, O
but O
patients O
' O
organisations O
have O
reported O
that O
these O
treatments O
can O
be O
harmful O
and O
favour O
pacing O
and O
specialist O
health O
care O
. O
[]

Overall O
rectally O
administered O
midazolam O
appeared O
to O
be O
somewhat O
more O
efficacious O
than O
diazepam O
. O
[]

BACKGROUND O
In O
a O
recent O
open O
pilot O
trial O
, O
R-salbutamol O
sulphate O
, O
a O
well-known O
molecule O
with O
anti-inflammatory O
effects O
, O
was O
tested O
successfully O
on O
patients O
with O
therapy-resistant O
discoid O
lupus O
erythematosus O
( O
DLE O
) O
. O
[]

When O
BMD B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
upper I-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
, O
lower O
neck B-outcome ['Physiological-Clinical']
and O
trochanter B-outcome ['Physiological-Clinical']
were O
compared O
using O
RM-MANOVA O
, O
a O
significant O
exercise O
effect O
was O
observed O
( O
p=0.048 O
) O
, O
but O
this O
did O
not O
differ O
significantly O
between O
sites O
( O
p=0.439 O
) O
despite O
greatest O
mean O
increases O
at O
the O
upper O
femoral O
neck O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
supplementation O
of O
oral O
branched-chain O
amino O
acids O
to O
the O
diet O
is O
superior O
to O
casein O
as O
a O
treatment O
for O
providing O
adequate O
nitrogen O
supply O
and O
improving O
the O
mental O
state O
of O
cirrhotic O
patients O
with O
chronic O
encephalopathy O
. O
[]

Over O
24 O
months O
in O
both O
groups O
, O
serum B-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
histologic I-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
remained O
stable O
and O
alkaline B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
decreased O
significantly O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Delivered O
energy B-outcome ['Physiological-Clinical']
at O
the O
defibrillation B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
was O
10.1+/-5.0 O
J O
for O
the O
single-coil O
configuration O
and O
8.7+/-4.0 O
J O
for O
the O
dual-coil O
configuration O
( O
p O
< O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mean O
baseline O
( O
range O
27-29 O
) O
to O
endpoint O
change O
in O
Aberrant O
Behavior O
Checklist-Irritability O
( O
primary O
endpoint O
) O
was O
significantly O
greater O
in O
the O
high-dose- O
( O
-12.4 O
[ O
6.5 O
] O
; O
p O
< O
0.001 O
) O
, O
but O
not O
low-dose O
( O
-7.4 O
[ O
8.1 O
] O
; O
p O
= O
0.164 O
) O
group O
, O
versus O
placebo O
( O
-3.5 O
[ O
10.7 O
] O
) O
. O
[]

Previous O
research O
strongly O
suggests O
that O
positioning O
with O
the O
healthy O
( O
unaffected O
) O
lung O
in O
the O
dependent O
lateral O
( O
down O
) O
position O
is O
related O
to O
improved O
oxygenation O
, O
but O
knowledge O
about O
whether O
this O
effect O
is O
maintained O
over O
time O
is O
lacking O
. O
[]

Ninety O
nine O
patients O
( O
group O
A O
) O
were O
randomized O
to O
receive O
paclitaxel O
175 O
mg/m2 O
in O
three-hour O
infusion O
plus O
carboplatin O
dosed O
to O
an O
area O
under O
the O
concentration-time O
curve O
of O
6 O
every O
3 O
weeks O
and O
99 O
( O
group O
B O
) O
to O
receive O
the O
same O
regimen O
with O
paclitaxel O
increased O
to O
225 O
mg/m2 O
. O
[]

AMP B-outcome ['Physiological-Clinical']
PC20 I-outcome ['Physiological-Clinical']
was O
also O
improved O
( O
P O
< O
0.05 O
) O
by O
the O
first O
and O
last O
doses O
of O
levocetirizine O
but O
not O
placebo O
, O
vs O
respective O
baseline O
values O
, O
with O
there O
being O
no O
difference O
in O
the O
degree O
of O
protection O
between O
first O
and O
last O
doses O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
in O
mean O
percent O
change O
between O
baseline O
and O
day O
28 O
for O
any O
of O
the O
eicosanoids B-outcome ['Physiological-Clinical']
, O
when O
normalized O
to O
protein O
. O
['Physiological-Clinical']

The O
study O
is O
registered O
at O
http O
: O
//www.clinicaltrials.gov O
with O
the O
identifier O
NCT00333944 O
. O
[]

Eight O
further O
maintenance O
infusions O
were O
administered O
at O
intervals O
of O
8 O
hours O
over O
a O
total O
treatment O
period O
of O
3 O
days O
. O
[]

Orlistat O
and O
diet O
counseling O
were O
compared O
with O
diet O
counseling O
alone O
. O
[]

Cone O
biopsy O
: O
has O
endocervical O
sampling O
a O
role O
? O
[]

Physician B-outcome ['Life-Impact']
confidence I-outcome ['Life-Impact']
in O
the O
treatment O
decision B-outcome ['Life-Impact']
was O
measured O
as O
a O
continuous O
outcome O
on O
a O
scale O
of O
0-10 O
( O
uncertain O
to O
certain O
) O
and O
as O
a O
dichotomous O
outcome O
( O
further O
imaging O
recommended O
, O
yes O
or O
no O
) O
. O
['Life-Impact', 'Life-Impact']

Furthermore O
, O
Study O
4 O
showed O
that O
intelligence B-outcome ['Life-Impact']
as O
indexed O
by O
the O
Wechsler O
Intelligence O
Scale O
for O
Children O
was O
positively O
associated O
with O
TOM O
test O
scores O
. O
['Life-Impact']

Social O
skills O
improvement O
in O
children O
with O
high-functioning O
autism O
: O
a O
pilot O
randomized O
controlled O
trial O
. O
[]

In O
the O
placebo O
, O
vitamin O
A O
, O
and O
beta O
carotene O
groups O
the O
rates O
of O
stillbirth O
and O
infant O
mortality O
were O
47.9 O
( O
95 O
% O
CI O
, O
44.3-51.5 O
) O
, O
45.6 O
( O
95 O
% O
CI O
, O
42.1-49.2 O
) O
, O
and O
51.8 O
( O
95 O
% O
CI O
, O
48.0-55.6 O
) O
per O
1000 O
births O
and O
68.1 O
( O
95 O
% O
CI O
, O
63.7-72.5 O
) O
, O
65.0 O
( O
95 O
% O
CI O
, O
60.7-69.4 O
) O
, O
and O
69.8 O
( O
95 O
% O
CI O
, O
65.4-72.3 O
) O
per O
1000 O
live O
births O
, O
respectively O
. O
[]

These O
results O
will O
have O
a O
major O
impact O
on O
the O
choice O
of O
anti-hypertensive O
treatment O
for O
patients O
with O
hypertension O
and O
diabetes O
. O
[]

Duration O
of O
granulocytopenia B-outcome ['Physiological-Clinical']
was O
reduced O
in O
the O
G-CSF O
group O
, O
but O
thrombocytopenia B-outcome ['Physiological-Clinical']
was O
prolonged O
, O
and O
the O
number O
of O
['Physiological-Clinical', 'Physiological-Clinical']

Participants O
were O
recruited O
from O
two O
academic O
centers O
and O
nine O
oncology O
practices O
, O
which O
were O
members O
of O
NCI O
's O
Community O
Clinical O
Oncology O
Program O
( O
CCOP O
) O
and O
were O
followed O
over O
2 O
years O
. O
[]

We O
used O
standardized O
behavioral O
measures O
of O
the O
primary O
and O
secondary O
features O
of O
autism O
, O
including O
the O
Autism O
Behavior O
Checklist O
, O
to O
assess O
the O
degree O
of O
impairment O
at O
base O
line O
and O
over O
the O
course O
of O
a O
four-week O
period O
after O
treatment O
. O
[]

Stool O
samples O
were O
cultured O
for O
Clostridium O
difficile O
the O
day O
before O
the O
operation O
and O
later O
on O
postoperative O
days O
4 O
, O
7 O
, O
and O
14 O
. O
[]

Because O
the O
combination O
therapy O
may O
bring O
inconclusive O
benefits O
in O
this O
area O
there O
is O
a O
strong O
need O
of O
further O
studies O
to O
find O
mechanisms O
that O
favor O
combination O
therapy O
. O
[]

The O
mean O
successful B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
rate O
for O
ISDN O
was O
6.5 O
micrograms O
kg-1 O
min-1 O
, O
whereas O
for O
NTG O
this O
was O
3.8 O
micrograms O
kg-1 O
min-1 O
. O
['Life-Impact']

The O
hospital O
philosophy O
and O
staff B-outcome ['Life-Impact']
views I-outcome ['Life-Impact']
about O
service O
delivery O
were O
closely O
in O
harmony O
, O
they O
delivered O
rehabilitation O
in O
a O
home-based O
atmosphere O
. O
['Life-Impact']

Physician O
and O
patient O
global O
evaluations O
of O
overall O
treatment O
effectiveness O
were O
assessed O
at O
the O
end O
of O
the O
treatment O
period O
. O
[]

JET-related O
mortality O
has O
been O
a O
rare O
event O
at O
our O
center O
, O
which O
is O
different O
from O
previous O
reports O
. O
[]

Subjects O
were O
divided O
into O
a O
control O
group O
( O
CG O
) O
who O
maintained O
their O
dietary O
habits O
( O
n=39 O
) O
and O
an O
olive O
group O
( O
OG O
) O
who O
consumed O
EVOO O
as O
the O
only O
added O
fat O
, O
plus O
a O
daily O
dose O
of O
50ml O
( O
n=23 O
) O
. O
[]

The O
intervention O
had O
no O
additional O
effect O
among O
children O
aged O
3 O
to O
< O
24 O
months O
but O
was O
responsible O
for O
a O
4.2 O
% O
decrease O
among O
those O
aged O
24 O
to O
< O
48 O
months O
and O
a O
6.7 O
% O
decrease O
among O
those O
aged O
48 O
to O
< O
72 O
months O
. O
[]

Eleven O
patients O
with O
a O
diagnosis O
of O
either O
autism O
, O
Asperger O
's O
syndrome O
, O
or O
PDD O
not O
otherwise O
specified O
( O
PDD-NOS O
) O
and O
aged O
6-14 O
years O
were O
randomized O
into O
an O
8-week O
double-blind O
, O
placebo-controlled O
, O
parallel O
treatment O
study O
with O
olanzapine O
. O
[]

There O
were O
significant O
differences O
in O
the O
root B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
patterns I-outcome ['Physiological-Clinical']
between O
the O
two O
dowel O
systems O
, O
with O
the O
carbon O
fiber-reinforced O
dowel-resin O
core O
system O
, O
being O
the O
less O
severe O
p O
< O
0.05 O
. O
['Physiological-Clinical']

Main O
outcomes O
were O
hospital B-outcome ['Mortality']
death I-outcome ['Mortality']
and O
need O
for O
an O
additional B-outcome ['Resource-use']
course I-outcome ['Resource-use']
of I-outcome ['Resource-use']
antibiotics I-outcome ['Resource-use']
. O
['Mortality', 'Resource-use']

Stereo O
radiographs O
for O
evaluation O
of O
absolute O
component O
migration O
( O
primary O
effect O
size O
) O
and O
single-direction O
absolute O
component O
migration O
( O
secondary O
effect O
size O
) O
were O
obtained O
within O
the O
first O
postoperative O
week O
and O
at O
6 O
weeks O
, O
6 O
months O
, O
1 O
year O
, O
and O
2 O
years O
. O
[]

Two O
variants O
of O
a O
novel O
bleomycin O
, O
etoposide O
, O
doxorubicin O
, O
cyclophosphamide O
, O
vincristine O
, O
procarbazine O
, O
and O
prednisone O
( O
BEACOPP O
) O
scheme O
( O
standard O
and O
escalated O
dose O
) O
are O
compared O
with O
cyclophosphamide O
, O
vincristine O
, O
procarbazine O
, O
and O
prednisone O
( O
COPP O
) O
/doxorubicin O
, O
bleomycin O
, O
vinblastine O
, O
and O
dacarbazine O
( O
ABVD O
) O
. O
[]

Despite O
a O
very O
poor O
prognosis O
, O
no O
treatment O
has O
demonstrated O
an O
efficacy O
in O
lowering O
the O
mortality B-outcome ['Mortality']
and O
disability B-outcome ['Life-Impact']
resulting O
from O
stroke O
events O
. O
['Mortality', 'Life-Impact']

METHODS O
Fifty O
women O
between O
16 O
and O
24 O
weeks O
of O
pregnancy O
were O
recruited O
at O
Tygerberg O
and O
Paarl O
Hospitals O
, O
Western O
Cape O
, O
South O
Africa O
. O
[]

These O
studies O
demonstrate O
that O
VA1.3 O
at O
a O
dose O
of O
5 O
x O
10 O
( O
9 O
) O
is O
safe O
and O
immunogenic B-outcome ['Physiological-Clinical']
in O
adults O
from O
a O
cholera O
endemic O
region O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
In O
a O
nested O
case O
control O
analysis O
among O
ACTIVE O
W O
study O
patients O
, O
cases O
with O
stroke O
and O
cases O
with O
bleeding O
were O
separately O
matched O
with O
controls O
. O
[]

Clinical O
outcomes O
through O
three O
years O
were O
compared O
by O
stent O
type O
and O
presence O
of O
side O
branch O
occlusion O
. O
[]

A O
multicentre O
, O
double-blind O
, O
placebo-controlled O
phase O
II O
study O
. O
[]

Fifty-five O
subjects O
undergoing O
radiation O
therapy O
for O
cure O
and O
who O
were O
able O
to O
communicate O
by O
telephone O
comprised O
the O
sample O
. O
[]

The O
effects O
of O
orthotic O
heel O
lifts O
on O
Achilles B-outcome ['Physiological-Clinical']
tendon I-outcome ['Physiological-Clinical']
force I-outcome ['Physiological-Clinical']
and O
strain B-outcome ['Physiological-Clinical']
during O
running O
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
was O
found O
that O
no O
in O
vitro O
reaction B-outcome ['Physiological-Clinical']
between O
ferrous O
ion O
and O
paracetamol O
. O
['Physiological-Clinical']

Vitamin O
D O
supplementation O
increases O
calcium B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
without O
a O
threshold O
effect O
. O
['Physiological-Clinical']

Primary O
care O
physician O
and O
gynecologist O
visits O
increased O
the O
likelihood O
of O
a O
subsequent B-outcome ['Resource-use']
mammogram I-outcome ['Resource-use']
for O
women O
in O
all O
intervention O
groups O
. O
['Resource-use']

BACKGROUND O
Exposure O
to O
traffic-related O
air O
pollution O
( O
TRAP O
) O
is O
considered O
a O
trigger O
for O
acute O
cardiovascular O
events O
. O
[]

The O
effects O
of O
temafloxacin O
and O
ciprofloxacin O
on O
the O
pharmacokinetics O
of O
caffeine O
were O
therefore O
compared O
in O
a O
3-way O
crossover O
study O
in O
12 O
healthy O
young O
volunteers O
. O
[]

Using O
a O
randomized O
controlled O
trial O
( O
RCT O
) O
design O
, O
the O
current O
study O
tested O
the O
effectiveness O
of O
an O
evidence-based O
, O
caregiver-assisted O
social O
skills O
intervention O
known O
as O
PEERS O
for O
Young O
Adults O
with O
high-functioning O
young O
adults O
with O
ASD O
( O
ages O
18-23 O
) O
using O
self- O
and O
caregiver-report B-outcome ['Life-Impact']
measures O
. O
['Life-Impact']

BACKGROUND O
The O
applications O
of O
minimally O
invasive O
surgery O
( O
MIS O
) O
and O
laparoscopy O
are O
rapidly O
expanding O
. O
[]

Topical O
and O
peribulbar O
anesthesia O
were O
performed O
by O
an O
ophthalmologist O
. O
[]

Grade O
? O
[]

The O
total O
effective O
rate O
of O
85.7 O
% O
in O
the O
combined O
acupuncture O
and O
medication O
group O
was O
better O
than O
71.4 O
% O
in O
the O
Chinese O
herb O
group O
and O
67.9 O
% O
in O
the O
western O
medicine O
group O
. O
[]

CONCLUSIONS O
Designing O
an O
intervention O
, O
choosing O
outcome O
variables O
, O
and O
implementing O
the O
protocol O
in O
a O
typical O
Indian O
school O
setting O
were O
achieved O
. O
[]

We O
conducted O
an O
open O
randomized O
trial O
to O
compare O
the O
efficacy O
of O
parenteral O
and O
oral O
ofloxacin O
with O
that O
of O
amoxycillin/clavulanate O
. O
[]

[ O
Clinilal O
study O
of O
medical O
ozone O
therapy O
in O
chronic O
hepatitis O
B O
of O
20 O
patients O
] O
. O
[]

Calves O
raised O
in O
the O
barn O
consumed O
more O
calf O
starter O
and O
therefore O
grew O
better O
than O
calves O
raised O
in O
hutches O
. O
[]

The O
primary O
endpoint O
was O
death B-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
['Mortality', 'Physiological-Clinical']

of O
ectopic B-outcome ['Physiological-Clinical']
supraventricular I-outcome ['Physiological-Clinical']
beats I-outcome ['Physiological-Clinical']
was O
26.1 O
+/- O
61.9 O
after O
ibopamine O
and O
21.7 O
+/- O
35.8 O
after O
placebo O
( O
p O
= O
ns O
) O
. O
['Physiological-Clinical']

Effects O
of O
fenoterol O
on O
inspiratory O
effort O
sensation O
and O
fatigue O
during O
inspiratory O
threshold O
loading O
. O
[]

Clinical O
outcome O
of O
postoperative O
adjuvant O
immunochemotherapy O
with O
sizofiran O
for O
patients O
with O
resectable O
gastric O
cancer O
: O
a O
randomised O
controlled O
study O
. O
[]

Overall O
, O
complementary B-outcome ['Life-Impact']
and O
alternative B-outcome ['Resource-use']
medicine I-outcome ['Resource-use']
( I-outcome ['Resource-use']
CAM I-outcome ['Resource-use']
) I-outcome ['Resource-use']
use O
was O
not O
significantly O
different O
in O
ASD O
( O
39 O
% O
) O
versus O
DD O
( O
30 O
% O
) O
. O
['Life-Impact', 'Resource-use']

Cardiovascular B-outcome ['Physiological-Clinical']
risk O
markers B-outcome ['Physiological-Clinical']
during O
treatment O
with O
estradiol O
and O
trimegestone O
or O
dydrogesterone O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Efficacy O
was O
evaluated O
using O
the O
caregiver-rated O
Aberrant O
Behavior O
Checklist O
Irritability O
subscale O
( O
primary O
efficacy O
measure O
) O
and O
the O
clinician-rated O
Clinical B-outcome ['Physiological-Clinical']
Global B-outcome ['Physiological-Clinical']
Impressions-Improvement O
score O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Concomitant O
administration O
of O
ferrous O
sulphate O
and O
paracetamol O
, O
decreased O
AUC8 O
from O
42.88 O
+/- O
3.8-34.25 O
+/- O
2.8 O
microg O
h O
mL O
( O
-1 O
) O
( O
p O
= O
0.04 O
) O
and O
Cmax B-outcome ['Physiological-Clinical']
from O
18.75 O
+/- O
1.9 O
to O
15.9 O
+/- O
1.7 O
microg O
mL O
( O
-1 O
) O
( O
p O
= O
0.11 O
) O
, O
while O
no O
change O
in O
tmax O
( O
p O
= O
0.5 O
) O
was O
originated O
. O
['Physiological-Clinical']

We O
therefore O
tested O
the O
accuracy O
of O
six O
equations O
and O
one O
nomogram O
for O
the O
prediction O
of O
Clcr O
from O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Scr I-outcome ['Physiological-Clinical']
) O
in O
38 O
patients O
with O
RA O
and O
20 O
controls O
. O
['Physiological-Clinical']

RESULTS O
The O
current O
prototype O
seems O
beneficial O
in O
female O
laryngectomees O
with O
a O
hypotonic O
PE O
segment O
only O
. O
[]

Bronchodilator B-outcome ['Physiological-Clinical']
efficacy O
was O
evaluated O
by O
serial B-outcome ['Physiological-Clinical']
spirometry I-outcome ['Physiological-Clinical']
for O
6 O
hr O
after O
the O
patients O
self-administered O
the O
study O
drug O
in O
the O
clinic O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Principal O
findings O
from O
a O
multicenter O
trial O
investigating O
the O
safety O
of O
follicular-fluid O
meiosis-activating O
sterol O
for O
in O
vitro O
maturation O
of O
human O
cumulus-enclosed O
oocytes O
. O
[]

AIM O
Anal O
fissures O
are O
associated O
with O
hypertonia O
of O
the O
internal O
anal O
sphincter O
and O
pain O
. O
[]

Class O
V O
preparations O
in O
extracted O
upper O
premolars O
were O
used O
and O
ten O
restorations O
were O
used O
for O
each O
of O
the O
following O
groups O
: O
( O
i O
) O
two O
layers O
of O
copal O
varnish O
and O
amalgam O
; O
( O
ii O
) O
conventional O
glass-ionomer O
and O
amalgam O
; O
( O
iii O
) O
light-cured O
glass-ionomer O
and O
amalgam O
; O
( O
iv O
) O
bonding O
agent O
and O
light-cured O
composite O
resin O
; O
( O
v O
) O
conventional O
glass-ionomer O
, O
bonding O
agent O
and O
light-cured O
composite O
resin O
; O
( O
vi O
) O
light-cured O
glass-ionomer O
, O
extended O
0.3 O
mm O
short O
of O
the O
enamel O
margin O
bonding O
agent O
and O
light-cured O
composite O
resin O
; O
and O
( O
vii O
) O
light-cured O
glass-ionomer O
, O
extended O
1 O
mm O
short O
of O
the O
enamel O
margin O
, O
bonding O
agent O
and O
light-cured O
composite O
resin O
. O
[]

Patients O
were O
admitted O
to O
a O
hospital O
and O
randomly O
assigned O
to O
receive O
either O
azimilide O
125 O
mg O
or O
a O
matched O
placebo O
twice O
daily O
for O
3 O
days O
and O
then O
once O
daily O
. O
[]

No O
relevant O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
recorded O
during O
our O
study O
. O
['Adverse-effects']

Chronic B-outcome ['Life-Impact']
allograft I-outcome ['Life-Impact']
damage I-outcome ['Life-Impact']
index O
was O
lowest O
in O
the O
triple O
therapy O
group O
, O
1.5 O
, O
compared O
with O
the O
other O
groups O
, O
3.2-4.3 O
( O
P O
= O
.01 O
) O
, O
indicating O
the O
least O
histopathological B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
in O
the O
triple O
therapy O
group O
. O
['Life-Impact', 'Physiological-Clinical']

15.32 O
) O
pg/ml O
, O
ALD O
( O
401.20 O
? O
[]

Ambulatory O
activity O
was O
corrected O
for O
body O
height O
. O
[]

The O
aim O
of O
this O
trial O
was O
, O
to O
compare O
the O
efficacy O
of O
two O
doses O
of O
UK O
administered O
via O
a O
catheter O
in O
the O
pulmonary O
artery O
: O
2000 O
IU O
kg-1 O
h-1 O
for O
24 O
hours O
( O
UK O
2000 O
) O
in O
conjunction O
with O
heparin O
versus O
4400 O
IU O
kg-1 O
h-1 O
UK O
alone O
for O
12 O
hours O
( O
UK O
4400 O
) O
followed O
by O
heparin O
. O
[]

[ O
Intravenous O
treatment O
of O
postpartum O
anemia O
with O
trivalent O
ferrum O
preparation O
] O
. O
[]

Oral O
estrogen O
antagonizes O
several O
of O
the O
metabolic B-outcome ['Physiological-Clinical']
actions I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
GH I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Patients O
where O
randomized O
to O
undergo O
either O
percutaneous O
transluminal O
coronary O
angioplasty/stent O
procedure O
( O
n O
= O
23 O
) O
or O
bypass O
surgery O
( O
n O
= O
21 O
) O
. O
[]

BACKGROUND O
A O
low-molecular-weight O
heparin O
, O
enoxaparin O
sodium O
, O
has O
been O
shown O
to O
be O
effective O
and O
safe O
in O
preventing O
deep O
vein O
thrombosis O
both O
in O
general O
surgery O
and O
in O
high-risk O
orthopedic O
surgery O
. O
[]

METHOD O
A O
randomized O
, O
group-comparison O
design O
involving O
a O
parent O
education O
and O
counseling O
intervention O
to O
control O
for O
nonspecific O
therapist O
effects O
and O
a O
control O
sample O
was O
used O
. O
[]

Results O
did O
not O
vary O
by O
gender O
, O
race O
, O
ethnicity O
, O
or O
level O
of O
education O
, O
however O
recycled O
smokers B-outcome ['Life-Impact']
were O
older O
( O
Mean O
= O
45.2 O
; O
SD O
= O
11.7 O
) O
than O
smokers O
who O
declined O
a O
new O
treatment O
cycle O
( O
Mean O
= O
41.8 O
; O
SD O
= O
13.2 O
) O
; O
( O
p O
= O
0.013 O
) O
. O
['Life-Impact']

There O
was O
no O
change O
in O
TEE O
after O
16 O
weeks O
. O
[]

Information O
about O
autism O
did O
not O
affect O
ratings O
of O
either O
[]

During O
phase O
1 O
the O
rate O
of O
nosocomial B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
was O
13.4 O
percent O
in O
the O
immune O
globulin O
group O
and O
17.8 O
percent O
in O
the O
control O
group O
; O
the O
respective O
rates O
during O
phase O
2 O
were O
21.0 O
percent O
and O
20.4 O
percent O
. O
['Physiological-Clinical']

Three O
hundred O
and O
seventy-two O
patients O
were O
randomized O
between O
3 O
regimens O
of O
chemotherapy O
: O
cyclophosphamide O
, O
intermittent O
melphalan O
, O
and O
melphalan O
with O
prednisone O
, O
and O
were O
followed O
up O
to O
death O
or O
for O
at O
least O
5 O
years O
. O
[]

Dependent O
measures O
were O
parent O
and O
teacher O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions I-outcome ['Physiological-Clinical']
( O
CGI O
) O
and O
Naltrexone O
Side O
Effects O
Rating O
Scale O
( O
SE O
) O
, O
Conners O
Parent O
Impulsivity/Hyperactivity B-outcome ['Life-Impact']
Factor O
, O
Teacher O
Hyperactivity B-outcome ['Life-Impact']
Factor O
, O
laboratory O
CGI O
, O
and O
analysis O
of O
videotaped O
behavior O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Leukocyte-depleted O
reperfusion O
of O
transplanted O
human O
hearts O
: O
a O
randomized O
, O
double-blind O
clinical O
trial O
. O
[]

The O
treatment O
is O
well O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact']

Anti-PRP B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
levels O
were O
greater O
after O
vaccination O
with O
PRP-P O
than O
after O
PRP O
in O
all O
three O
age O
groups O
. O
['Physiological-Clinical']

However O
, O
there O
were O
significantly O
more O
symptomatic B-outcome ['Physiological-Clinical']
patients O
among O
the O
bacteriological O
failures O
in O
the O
penicillin O
group O
( O
68.4 O
% O
) O
than O
in O
the O
cefprozil O
group O
( O
26.7 O
% O
) O
. O
['Physiological-Clinical']

The O
results O
revealed O
an O
initial O
clearance B-outcome ['Physiological-Clinical']
rate O
of O
64 O
% O
at O
week O
19 O
for O
R1 O
and O
81 O
% O
for O
R2 O
( O
95 O
% O
CI O
for O
difference O
: O
-14 O
% O
to O
45 O
% O
, O
p O
= O
0.21 O
) O
. O
['Physiological-Clinical']

Here O
, O
we O
report O
results O
from O
the O
FIRST O
trial O
, O
which O
compared O
initial O
treatment O
strategies O
for O
clinical O
, O
immunological O
, O
and O
virological O
outcomes O
. O
[]

With O
advancing O
HIV-1 O
disease O
there O
is O
Th1 O
to O
Th2 O
cytokine O
switching O
. O
[]

METHODS O
The O
randomized O
trial O
involved O
777 O
volunteers O
from O
the O
U.S. O
Army O
Airborne O
School O
, O
Fort O
Benning O
, O
Ga. O
Of O
this O
group O
, O
745 O
completed O
all O
study O
requirements O
( O
369 O
brace-wearers O
and O
376 O
non-brace-wearers O
) O
. O
[]

INTERPRETATION O
AND O
CONCLUSIONS O
Both O
schemes O
of O
chemotherapy O
followed O
by O
radiotherapy O
produce O
high O
percentages O
of O
CR B-outcome ['Physiological-Clinical']
, O
low O
risk O
of O
relapse B-outcome ['Physiological-Clinical']
and O
an O
['Physiological-Clinical', 'Physiological-Clinical']

Phenytoin O
did O
not O
substantially O
reduce O
that O
rate O
. O
[]

PDE5 O
inhibition O
, O
by O
blocking O
degradation O
of O
nitric O
oxide O
second-messenger O
cyclic O
guanosine O
monophosphate O
, O
might O
be O
beneficial O
. O
[]

There O
was O
a O
fall O
in O
urinary B-outcome ['Physiological-Clinical']
dopamine I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
noradrenaline B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
and O
increased O
excretion B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
homovanillic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HVA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
of O
these O
analyses O
provide O
additional O
characterization O
and O
support O
for O
the O
overall O
clinical O
benefit O
of O
alvimopan O
in O
patients O
undergoing O
bowel O
resection O
. O
[]

A O
randomized O
effectiveness O
trial O
of O
collaborative O
care O
for O
patients O
with O
panic O
disorder O
in O
primary O
care O
. O
[]

Participants O
with O
MS O
( O
n O
= O
54 O
) O
were O
randomly O
assigned O
to O
the O
placebo O
( O
n O
= O
28 O
) O
and O
WGP O
groups O
( O
n O
= O
26 O
) O
, O
and O
the O
intervention O
was O
administered O
for O
12 O
weeks O
. O
[]

1 O
to O
2 O
micrograms/kg O
and O
propofol O
i.v O
. O
[]

Patients O
who O
had O
had O
nausea B-outcome ['Physiological-Clinical']
or O
vomiting B-outcome ['Physiological-Clinical']
after O
previous O
anesthetics O
had O
nausea B-outcome ['Physiological-Clinical']
or O
vomiting B-outcome ['Physiological-Clinical']
significantly O
more O
frequently O
than O
patients O
who O
did O
not O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

INTERPRETATION O
Sulfadoxine/pyrimethamine O
plus O
amodiaquine O
could O
be O
used O
as O
an O
inexpensive O
regimen O
to O
decrease O
[]

METHOD O
Randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
design O
. O
[]

Much O
data O
have O
accrued O
in O
support O
of O
the O
concept O
that O
oxidation O
of O
LDL O
is O
a O
key O
early O
step O
in O
atherogenesis O
. O
[]

Nearly O
one O
fifth O
( O
19.4 O
% O
) O
of O
participants O
had O
Center O
for O
Epidemiological O
Studies O
Depression O
Scale O
scores O
> O
27 O
, O
which O
is O
indicative O
of O
major O
depression O
. O
[]

RESULTS O
In O
the O
study O
group O
( O
35 O
patients O
) O
, O
the O
duration O
of O
antibiotic B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
and O
hospitalization B-outcome ['Resource-use']
was O
significantly O
shorter O
than O
the O
control O
group O
( O
36 O
patients O
) O
( O
10.89+/-2.85 O
versus O
16.06+/-2.48 O
days O
, O
p O
< O
0.001 O
, O
and O
16.66+/-4.02 O
days O
versus O
23.81+/-7.56 O
days O
, O
p O
< O
0.001 O
) O
without O
negative O
clinical O
effects O
and O
the O
cost B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
was O
significantly O
lower O
. O
['Resource-use', 'Resource-use', 'Resource-use']

Prenatal O
depression O
predicts O
postpartum O
maternal O
attachment O
in O
low-income O
Latina O
mothers O
with O
infants O
. O
[]

Treatment O
lasted O
two O
weeks O
( O
5 O
sessions O
a O
week O
) O
. O
[]

INTERVENTIONS O
Coronary O
angiography O
was O
conducted O
within O
6 O
weeks O
of O
an O
adenosine O
thallium-201 O
myocardial O
perfusion O
imaging O
study O
. O
[]

Budesonide O
and O
beclomethasone O
dipropionate O
in O
hay O
fever O
- O
a O
single O
blind O
comparison O
. O
[]

In O
phase O
1 O
, O
single-blind O
aripiprazole O
was O
flexibly O
dosed O
( O
2-15 O
mg/d O
) O
for O
13-26 O
weeks O
. O
[]

The O
influence O
of O
nicotine O
delivered O
in O
chewing O
gum O
upon O
cardiac O
hemodynamics O
and O
conduction O
has O
not O
been O
well-characterized O
. O
[]

METHODS O
Fifteen O
atopic O
asthmatics O
were O
randomized O
in O
double-blind O
, O
cross-over O
fashion O
to O
receive O
for O
1 O
week O
either O
levocetirizine O
5 O
mg O
or O
placebo O
. O
[]

Predictors O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
change O
in O
a O
series O
of O
controlled O
dietary O
intervention O
studies O
. O
['Physiological-Clinical']

Blood O
chemistry O
monitoring O
indicated O
that O
reduction O
in O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
level O
strongly O
correlated O
with O
an O
increase O
in O
baseline O
levels O
of O
some O
enzymes O
for O
niacin-treated O
subjects O
. O
['Physiological-Clinical']

Between O
December O
1983 O
and O
December O
1988 O
, O
we O
conducted O
two O
trials O
simultaneously O
: O
one O
aimed O
at O
patients O
without O
HBV O
markers O
and O
the O
second O
at O
patients O
with O
HBV O
markers O
. O
[]

Eradication O
of O
the O
original B-outcome ['Physiological-Clinical']
serotype I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
group O
A O
streptococci B-outcome ['Physiological-Clinical']
was O
achieved O
in O
91.3 O
% O
of O
patients O
treated O
with O
cefprozil O
and O
87.4 O
% O
of O
patients O
treated O
with O
penicillin O
, O
the O
difference O
not O
being O
statistically O
significant O
( O
P O
= O
0.125 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
inhaled O
treprostinil O
on O
exercise O
capacity O
, O
functional O
class O
, O
and O
echocardiographic O
and O
hemodynamic O
data O
were O
evaluated O
. O
[]

However O
, O
vasoconstrictor O
effects O
of O
PGEs O
have O
also O
been O
noted O
at O
selected O
sites O
. O
[]

Utilization O
of O
health O
care O
services O
by O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
. O
[]

The O
strongest O
predictor O
of O
lower O
maternal B-outcome ['Life-Impact']
attachment I-outcome ['Life-Impact']
was O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
late O
in O
pregnancy O
; O
pregnancy O
intention O
was O
marginally O
predictive O
of O
attachment B-outcome ['Life-Impact']
, O
with O
lower O
scores O
being O
associated O
with O
unwanted O
pregnancies O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

All O
subjects O
were O
evaluated O
by O
their O
parents O
at O
baseline O
and O
follow-up O
visits O
( O
3-6 O
weeks O
later O
, O
M O
= O
3.7 O
, O
SD O
= O
1.4 O
weeks O
) O
with O
Childhood O
Autism O
Rating O
Scales O
( O
CARS O
) O
. O
[]

The O
cumulative O
rate O
of O
HIV O
transmission O
or O
death O
at O
12 O
months O
was O
10?2 O
% O
( O
95 O
% O
CI O
7?6-13?6 O
% O
) O
in O
the O
triple O
antiretroviral O
group O
compared O
with O
16?0 O
% O
( O
12?7-20?0 O
% O
) O
in O
the O
zidovudine O
and O
single-dose O
nevirapine O
group O
( O
p=0?017 O
) O
. O
[]

A O
multidisciplinary O
team O
that O
includes O
a O
clinical O
pharmacist O
is O
beneficial O
to O
patient O
care O
. O
[]

Safety O
outcomes O
are O
bleeding B-outcome ['Physiological-Clinical']
, O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
, O
and O
other O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

A O
liquid O
chromatography O
mass O
spectrometry O
method O
was O
used O
to O
determine O
eicosanoid B-outcome ['Physiological-Clinical']
levels O
in O
the O
biopsies O
, O
and O
levels O
were O
expressed O
per O
protein O
or O
per O
free O
arachidonic O
acid O
. O
['Physiological-Clinical']

A O
sample O
of O
301 O
volunteer O
subjects O
recruited O
from O
the O
waiting O
list O
for O
treatment O
in O
the O
Beth O
Israel O
methadone O
program O
were O
randomly O
assigned O
to O
immediate O
entry O
into O
the O
interim O
clinic O
or O
a O
control O
group O
. O
[]

No O
significant O
difference O
in O
median O
time O
to O
disease B-outcome ['Physiological-Clinical']
progression B-outcome ['Physiological-Clinical']
( O
26 O
vs. O
24 O
months O
, O
p O
= O
0.4 O
) O
, O
median O
survival B-outcome ['Mortality']
( O
12 O
vs. O
16 O
months O
, O
p O
= O
0.8 O
) O
, O
and O
1-year O
survival B-outcome ['Mortality']
( O
49.9 O
vs. O
54.7 O
% O
, O
p O
= O
0.8 O
) O
was O
detected O
between O
arms O
1 O
and O
2 O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Mortality']

The O
aim O
of O
the O
study O
was O
to O
assess O
the O
impact O
of O
the O
treatment O
on O
Schistosoma O
mansoni O
morbidity O
. O
[]

Analysis O
of O
the O
global O
evaluations O
for O
each O
group O
revealed O
no O
difference O
in O
the O
distributions O
of O
physician O
and O
volunteer O
scores O
. O
[]

Dependent O
measures O
included O
parent O
and O
teacher O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions I-outcome ['Physiological-Clinical']
( O
CGI O
) O
, O
Conners O
Rating O
Scales O
, O
and O
Naltrexone B-outcome ['Adverse-effects']
Side-Effects I-outcome ['Adverse-effects']
( O
SE O
) O
Rating O
Scale O
; O
laboratory O
CGI O
, O
movement B-outcome ['Life-Impact']
actometer I-outcome ['Life-Impact']
readings O
, O
and O
a O
10-second O
interval O
recording O
system O
analysis O
of O
on-task O
, O
communication B-outcome ['Life-Impact']
initiations I-outcome ['Life-Impact']
, O
disruptive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
, O
and O
self-stimulation B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Adverse-effects', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Women O
who O
also O
exercised O
had O
additional O
increases O
in O
BMD O
at O
the O
femoral B-outcome ['Physiological-Clinical']
neck B-outcome ['Physiological-Clinical']
( O
+0.29 O
% O
) O
, O
total O
hip B-outcome ['Physiological-Clinical']
( O
+0.34 O
% O
) O
, O
spine B-outcome ['Physiological-Clinical']
( O
+0.23 O
% O
) O
, O
total O
radius B-outcome ['Physiological-Clinical']
( O
+0.30 O
% O
) O
, O
and O
additional O
decreases O
in O
Alkphase B-outcome ['Physiological-Clinical']
B O
( O
-2.4 O
% O
) O
and O
Serum B-outcome ['Physiological-Clinical']
NTx B-outcome ['Physiological-Clinical']
( O
-6.5 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Measures O
collected O
1 O
week O
before O
and O
4 O
weeks O
after O
infusion O
included O
autism B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
language B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
and O
problem B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
gathered O
from O
parents O
, O
teachers O
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Onset O
time O
of O
anesthetic O
action O
, O
duration O
of O
anesthesia O
, O
time O
until O
first O
postoperative O
requirement O
for O
pain O
medication O
, O
and O
digital-brachial O
artery O
systolic O
blood O
pressure O
index O
were O
recorded O
and O
evaluated O
. O
[]

Acceptability O
of O
an O
Electronic O
Self-Report O
Assessment O
Program O
for O
patients O
with O
cancer O
. O
[]

OBJECTIVE O
To O
evaluate O
parenting O
stress O
following O
infants O
' O
cataract O
extraction O
surgery O
, O
and O
to O
determine O
if O
levels O
of O
stress O
differ O
between O
2 O
treatments O
for O
unilateral B-outcome ['Physiological-Clinical']
congenital I-outcome ['Physiological-Clinical']
cataract O
in O
a O
randomized O
clinical O
trial O
. O
['Physiological-Clinical']

SETTING O
Chronic O
fatigue O
clinic O
in O
a O
general O
hospital O
department O
of O
psychiatry O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
, O
with O
exclusion O
of O
patients O
subsequently O
found O
to O
be O
negative O
for O
C O
parvum O
or O
co-infected O
at O
baseline O
. O
[]

The O
results O
show O
that O
level O
of O
intervention O
interacts O
with O
the O
child B-outcome ['Physiological-Clinical']
's O
spontaneous B-outcome ['Life-Impact']
tendency I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
focus I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
on O
objects O
. O
['Physiological-Clinical', 'Life-Impact']

Parents O
of O
all O
seven O
subjects O
elected O
to O
have O
their O
children O
continue O
to O
take O
clomipramine O
after O
the O
study O
. O
[]

METHODS O
A O
total O
of O
34 O
children O
( O
6-18 O
years O
) O
with O
allergic O
asthma O
were O
assigned O
to O
cluster O
( O
n O
= O
22 O
) O
or O
classic O
SIT O
( O
n O
= O
12 O
) O
. O
[]

Bupivacaine O
produced O
a O
significant O
incidence O
of O
residual O
motor B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
compared O
with O
levobupivacaine O
or O
ropivacaine O
at O
wake-up O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

A O
serological O
effect O
of O
a O
second O
booster O
vaccination O
four O
weeks O
after O
the O
first O
one O
could O
not O
be O
demonstrated O
neither O
after O
one O
nor O
after O
two O
years O
. O
[]

And O
the O
score O
of O
trail O
group O
was O
lower O
than O
the O
control O
group O
( O
all O
P O
< O
0.05 O
) O
. O
[]

An O
analysis O
of O
the O
radiation O
related O
morbidity B-outcome ['Physiological-Clinical']
observed O
in O
a O
randomized O
trial O
of O
neutron O
therapy O
for O
bladder O
cancer O
. O
['Physiological-Clinical']

METHODS O
On O
six O
occasions O
, O
1 O
to O
3 O
days O
apart O
within O
15 O
days O
, O
199 O
patients O
with O
elbow O
epicondylitis O
received O
40 O
mA-minutes O
of O
either O
active O
or O
placebo O
treatment O
. O
[]

We O
conclude O
that O
the O
routine O
use O
of O
cophenylcaine O
for O
nasal O
preparation O
is O
not O
justified O
before O
flexible O
nasendoscopy O
. O
[]

Methods O
Patients O
randomized O
to O
a O
single O
IV O
infusion O
of O
zoledronic O
acid O
5 O
mg O
or O
risedronate O
( O
5 O
mg/day O
) O
and O
stratified O
based O
on O
glucocorticoids O
duration O
[ O
treatment O
( O
> O
3 O
months O
) O
and O
prevention O
( O
? O
[]

CONCLUSION O
No O
subject O
taking O
dirithromycin O
alone O
or O
in O
combination O
with O
omeprazole O
had O
their O
H. O
pylori O
infection O
cured B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

As O
the O
strength B-outcome ['Life-Impact']
increased O
, O
so O
did O
the O
depth O
of O
peel O
. O
['Life-Impact']

At O
1 O
and O
2 O
h O
post-dose O
, O
8.8 O
% O
and O
29.4 O
% O
of O
the O
PNU-142633 O
group O
, O
respectively O
, O
and O
8.6 O
% O
and O
40.0 O
% O
of O
the O
placebo O
group O
, O
respectively O
, O
experienced O
headache B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
; O
2.9 O
% O
and O
8.8 O
% O
of O
the O
PNU-142633 O
group O
and O
0 O
% O
and O
5.7 O
% O
of O
the O
placebo O
group O
were O
free O
of O
headache O
pain B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Moreover O
, O
the O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
shorter O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
was O
superior O
in O
group O
1 O
( O
P O
= O
0.001 O
and O
P O
= O
0.001 O
, O
respectively O
) O
. O
['Resource-use', 'Life-Impact']

Vigorous O
, O
aerobic O
exercise O
versus O
general O
motor O
training O
activities O
: O
effects O
on O
maladaptive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
stereotypic I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
of O
adults O
with O
both O
autism O
and O
mental O
retardation O
. O
['Life-Impact']

We O
sought O
to O
investigate O
the O
role O
of O
heme O
oxygenase-1 O
( O
HO-1 O
) O
on O
this O
HBO O
inhibition O
of O
iNOS O
induction O
and O
acute O
lung O
injury O
in O
septic O
rat O
lungs O
. O
[]

Exercise O
for O
methamphetamine O
dependence O
: O
rationale O
, O
design O
, O
and O
methodology O
. O
[]

Twenty O
healthy O
women O
with O
a O
mean O
age O
of O
30 O
years O
were O
operated O
on O
for O
breast O
augmentation O
. O
[]

All O
participants O
were O
weighed O
at O
the O
outset O
of O
the O
study O
, O
directly O
after O
treatment O
and O
at O
a O
6- O
, O
12- O
and O
18-month O
post-treatment O
follow-up O
without O
any O
booster O
treatment O
after O
the O
10-week O
program O
. O
[]

Seventy-eight O
patients O
were O
randomized O
( O
Evr O
n O
= O
52 O
; O
CsA O
n O
= O
26 O
) O
. O
[]

At O
week O
12 O
, O
all O
agents O
lowered O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
equivalently O
. O
['Physiological-Clinical']

RESULTS O
The O
duration O
of O
hypoxemia B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
transcutaneous I-outcome ['Physiological-Clinical']
partial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
O2 B-outcome ['Physiological-Clinical']
< O
6.6 O
kPa O
( O
< O
50 O
mm O
Hg O
) O
and/or O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation B-outcome ['Physiological-Clinical']
< O
80 O
% O
) O
during O
treatment O
procedures O
was O
significantly O
longer O
in O
the O
saline O
group O
( O
mean O
82 O
vs O
36 O
seconds O
, O
P O
= O
.001 O
) O
and O
distress O
quantified O
by O
a O
novel O
behavioral O
scoring O
method O
was O
much O
higher O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
article O
briefly O
outlines O
a O
collaboration O
among O
communities O
on O
Hawai'i O
Island O
and O
a O
university-based O
research O
team O
to O
develop B-outcome ['Life-Impact']
, O
implement B-outcome ['Physiological-Clinical']
, O
and O
evaluate O
a O
school-based O
substance B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
prevention O
curriculum O
called O
Ho'ouna O
Pono O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

There O
was O
a O
significant O
( O
p O
< O
0.05 O
) O
decrease O
in O
sputum B-outcome ['Physiological-Clinical']
leukocyte I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
and O
IL-1beta B-outcome ['Physiological-Clinical']
, O
IL-8 B-outcome ['Physiological-Clinical']
, O
and O
LTB4 B-outcome ['Physiological-Clinical']
after O
fluticasone O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Respective O
rates O
of O
culture O
and O
gram B-outcome ['Physiological-Clinical']
stain I-outcome ['Physiological-Clinical']
positivity O
were O
69 O
% O
and O
42 O
% O
in O
tap O
eyes O
and O
66 O
% O
and O
41 O
% O
in O
biopsy O
eyes O
( O
not O
significant O
) O
. O
['Physiological-Clinical']

These O
included O
the O
magnitude O
of O
the O
overall O
results O
; O
consistency O
of O
results O
across O
subgroups O
, O
clinical O
centers O
, O
and O
cause O
of O
death O
; O
and O
completeness O
of O
follow-up O
. O
[]

Plasma O
3,4-dihydroxyphenylethyleneglycol O
and O
3-methoxy-4-hydroxyphenylethyleneglycol O
as O
indicators O
of O
central O
noradrenergic O
activity O
. O
[]

BACKGROUND O
Chronic O
rhinosinusitis O
( O
CRS O
) O
is O
a O
common O
disease O
that O
has O
a O
significant O
impact O
on O
quality O
of O
life O
( O
QOL O
) O
. O
[]

Efficacy O
of O
bepotastine O
besilate O
ophthalmic O
solution O
1.5 O
% O
for O
seasonal B-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
conjunctivitis I-outcome ['Physiological-Clinical']
: O
a O
randomized O
, O
placebo-controlled O
, O
natural O
exposure O
, O
clinical O
trial O
. O
['Physiological-Clinical']

A O
randomized O
single- O
and O
multiple-dose O
crossover O
study O
was O
conducted O
in O
healthy O
subjects O
ingesting O
cephalexin O
before O
and O
after O
steady-state O
administration O
of O
ranitidine O
or O
omeprazole O
. O
[]

ClinicalTrials.govID O
: O
NCT00549809 O
. O
[]

The O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
was O
11.5 O
months O
in O
arm O
A O
and O
12 O
months O
in O
arm O
B O
. O
['Mortality']

PARTICIPANTS O
Sequential O
adult O
head O
trauma O
patients O
requiring O
rapid-sequence O
intubation O
who O
had O
no O
contraindications O
to O
succinylcholine O
or O
pancuronium O
. O
[]

Effect O
of O
weight O
loss O
on O
inflammation O
in O
patients O
with O
mild O
obstructive O
sleep O
apnea O
. O
[]

Bacterial O
ribosomal O
immunostimulants O
prime O
alveolar O
macrophages O
in O
vivo O
to O
produce O
interleukin O
1 O
in O
vitro O
. O
[]

Patients O
who O
had O
metabolic O
syndrome O
were O
randomized O
to O
receive O
clopidogrel O
75 O
mg/day O
plus O
aspirin O
81 O
mg/day O
( O
n O
= O
89 O
) O
or O
placebo O
plus O
aspirin O
81 O
mg/day O
( O
n O
= O
92 O
) O
for O
9 O
weeks O
to O
assess O
the O
efficacy O
of O
each O
treatment O
in O
suppression O
of O
inflammatory O
markers O
. O
[]

There O
were O
no O
adverse O
consequences O
of O
rituximab O
on O
CD34+ B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
yield I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
hematopoietic I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
immunoglobulin I-outcome ['Physiological-Clinical']
levels O
after O
transplantation O
. O
['Physiological-Clinical']

Treatment O
group O
children O
received O
the O
parent-delivered O
program O
for O
4 O
mo O
. O
[]

Atrial O
natriuretic O
factor O
( O
ANF O
) O
has O
an O
inhibitory O
effect O
on O
angiotensin B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
and O
ACTH B-outcome ['Physiological-Clinical']
stimulated I-outcome ['Physiological-Clinical']
aldosterone I-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
man O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Selenium O
sulfide O
( O
2.5 O
% O
) O
lotion O
applied O
daily O
for O
10 O
minutes O
for O
7 O
consecutive O
days O
was O
found O
to O
be O
an O
effective O
therapeutic O
agent O
, O
significantly O
superior O
to O
the O
vehicle O
, O
in O
a O
double-blind O
study O
in O
the O
treatment O
of O
tinea O
versicolor O
. O
[]

Comparison O
of O
two O
sedation O
techniques O
in O
patients O
undergoing O
surgical O
procedures O
under O
regional O
anaesthesia O
. O
[]

A O
randomised O
clinical O
trial O
. O
[]

Active O
specific O
immunotherapy O
was O
injected O
subcutaneously O
( O
SC O
) O
weekly O
for O
4 O
weeks O
, O
at O
week O
8 O
, O
and O
bimonthly O
thereafter O
. O
[]

We O
investigated O
BTX-A O
as O
therapy O
in O
patients O
with O
WAD O
. O
[]

These O
findings O
suggest O
children O
with O
ASD O
have O
specific O
abnormalities B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
gaze I-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
and O
altered B-outcome ['Physiological-Clinical']
neural I-outcome ['Physiological-Clinical']
specialisation I-outcome ['Physiological-Clinical']
, O
whereas O
children O
with O
ADHD O
show O
abnormalities B-outcome ['Physiological-Clinical']
at O
early O
visual O
attention O
stages O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
clinical O
research O
, O
variation O
of O
cortisol O
, O
adrenocorticotrophin O
( O
ACTH O
) O
, O
lymphocyte O
proliferative O
reaction O
were O
observed O
before O
and O
after O
medication O
in O
65 O
patients O
took O
prednisone O
, O
and O
were O
randomly O
divided O
into O
Fufang O
prednisone O
group O
( O
mixture O
of O
prednisone O
and O
EB O
) O
and O
prednisone O
group O
. O
[]

Interleukin-2 O
was O
administered O
in O
2 O
daily O
doses O
on O
days O
1-5 O
of O
each O
week O
indicated O
. O
[]

Cooperative O
Group O
of O
Study O
and O
Treatment O
of O
Multiple O
Myeloma O
. O
[]

Mean O
esophageal B-outcome ['Resource-use']
and I-outcome ['Resource-use']
duodenal I-outcome ['Resource-use']
endoscopy I-outcome ['Resource-use']
scores O
were O
similar O
in O
the O
2 O
groups O
at O
Days O
8 O
and O
15 O
. O
['Resource-use']

Demographic O
and O
histopathological O
characteristics O
of O
the O
two O
groups O
were O
similar O
. O
[]

METHODS O
Sixteen O
healthy O
subjects O
were O
randomised O
to O
inhale O
different O
gas O
mixtures O
of O
oxygen O
and O
nitrogen O
in O
a O
double O
blind O
crossover O
study O
. O
[]

Codeine/acetaminophen O
and O
hydrocodone/acetaminophen O
combination O
tablets O
for O
the O
management O
of O
chronic O
cancer O
pain O
in O
adults O
: O
a O
23-day O
, O
prospective O
, O
double-blind O
, O
randomized O
, O
parallel-group O
study O
. O
[]

However O
, O
the O
risk O
of O
major B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
similar O
in O
the O
subgroups O
receiving O
balloon O
angioplasty O
( O
group O
A O
, O
6 O
( O
19 O
% O
) O
v O
group O
B O
, O
16 O
( O
16 O
% O
) O
, O
NS O
) O
. O
['Adverse-effects']

Three O
out O
of O
four O
of O
those O
having O
a O
health O
check O
were O
given O
health O
advice O
. O
[]

The O
plasma O
triglyceride O
level O
and O
the O
triglyceride O
distribution O
within O
the O
individual O
lipoprotein O
fractions O
were O
not O
altered O
in O
any O
consistent O
manner O
by O
the O
addition O
of O
guar O
. O
[]

Arzoxifene O
was O
well O
tolerated O
. O
[]

STUDY O
OBJECTIVE O
To O
investigate O
the O
impact O
of O
different O
modes O
of O
ventilation O
during O
cardiopulmonary O
bypass O
( O
CPB O
) O
on O
immediate O
postbypass O
oxygenation O
in O
pediatric O
cardiac O
surgery O
. O
[]

Drinking O
water O
and O
brushing O
with O
toothpaste O
A O
. O
[]

RESULTS O
Odds O
ratios O
( O
ORs O
) O
for O
predicting O
any O
non-vertebral O
fracture O
were O
: O
previous B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
, O
2.67 O
( O
95 O
% O
CI O
2.10-3.40 O
) O
; O
a O
fall O
in O
the O
last O
12 O
months O
, O
2.06 O
( O
95 O
% O
CI O
1.63-2.59 O
) O
; O
and O
age O
( O
per O
year O
increase O
) O
, O
1.03 O
( O
95 O
% O
CI O
1.01-1.05 O
) O
. O
['Physiological-Clinical']

The O
mean O
exercise O
time O
until O
marked O
dyspnea O
decreased O
from O
218.5 O
seconds O
in O
the O
carbon O
monoxide O
control O
period O
to O
146.6 O
seconds O
after O
breathing O
carbon O
monoxide O
( O
P O
less O
than O
0.001 O
) O
. O
[]

Comparison O
of O
different O
approaches O
for O
assessment O
of O
HER2 O
expression O
on O
protein O
and O
mRNA O
level O
: O
prediction O
of O
chemotherapy O
response O
in O
the O
neoadjuvant O
GeparTrio O
trial O
( O
NCT00544765 O
) O
. O
[]

For O
enamel O
, O
the O
data O
at O
days O
5 O
and O
10 O
showed O
a O
significant O
effect O
for O
erosion B-outcome ['Physiological-Clinical']
( O
i.e O
. O
['Physiological-Clinical']

METHODS O
Eighty O
patients O
undergoing O
laparoscopic O
cholecystectomy O
were O
randomized O
to O
receive O
either O
bilateral O
TAP O
blocks O
or O
local O
anesthetic O
infiltration O
of O
trocar O
insertion O
sites O
with O
ropivacaine O
0.5 O
% O
. O
[]

Naftopidil O
significantly O
improved O
the O
overall B-outcome ['Physiological-Clinical']
international I-outcome ['Physiological-Clinical']
prostatic I-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
score O
; O
from O
19.2?7.9 O
to O
11.7?5.8 O
in O
the O
M O
group O
and O
from O
19.4?6.4 O
to O
12.3?6.8 O
in O
the O
E O
group O
( O
p O
< O
0.0001 O
) O
, O
QOL O
score O
from O
4.9?0.8 O
to O
3.2?1.4 O
in O
the O
M O
group O
and O
from O
5.0?0.8 O
to O
3.6?1.3 O
in O
the O
E O
group O
( O
p O
< O
0.0001 O
) O
, O
and O
OAB O
symptom O
score O
from O
7.8?2.6 O
to O
5.0?2.5 O
in O
the O
M O
group O
( O
p O
< O
0.0001 O
) O
and O
from O
8.6?2.9 O
to O
5.8? O
3.3 O
in O
the O
E O
group O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Prolonged O
effects O
of O
a O
home-based O
intervention O
in O
patients O
with O
chronic O
illness O
. O
[]

CONCLUSIONS O
ESIN O
of O
displaced O
midshaft O
clavicular O
fractures O
resulted O
in O
a O
lower O
rate O
of O
nonunion B-outcome ['Physiological-Clinical']
and O
delayed B-outcome ['Physiological-Clinical']
union I-outcome ['Physiological-Clinical']
, O
a O
faster O
return B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
, O
and O
a O
better O
functional B-outcome ['Life-Impact']
outcome O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Community O
preschool O
practices O
often O
are O
not O
evidence O
based O
, O
and O
almost O
none O
target O
the O
prelinguistic O
core O
deficits O
of O
ASD O
. O
[]

Effect O
of O
laquinimod O
on O
MRI-monitored O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
patients O
with O
relapsing-remitting O
multiple O
sclerosis O
: O
a O
multicentre O
, O
randomised O
, O
double-blind O
, O
placebo-controlled O
phase O
IIb O
study O
. O
['Physiological-Clinical']

The O
results O
had O
revealed O
that O
adolescents O
with O
ASDs O
were O
less O
sensitive O
than O
controls O
to O
the O
misalignment O
of O
face O
parts O
and O
it O
was O
concluded O
their O
face O
processing O
was O
less O
holistic O
. O
[]

Blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
and O
glucagon B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
rose O
post-operatively O
whether O
or O
not O
insulin O
was O
given O
, O
but O
the O
increment O
in O
insulin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
when O
insulin O
was O
given O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
then O
randomly O
assigned O
to O
control O
and O
study O
groups O
. O
[]

Immediate B-outcome ['Physiological-Clinical']
local I-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
were O
infrequent O
( O
1 O
in O
group O
A O
and O
2 O
in O
group O
B O
) O
. O
['Physiological-Clinical']

[ O
Cannulation O
of O
the O
internal O
jugular O
vein O
using O
2 O
ultrasonic O
technics O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
also O
significantly O
greater O
in O
overweight O
patients O
subjected O
to O
OA O
than O
in O
patients O
of O
normal O
weight O
after O
4 O
weeks O
; O
the O
clinical O
significance O
may O
, O
however O
, O
be O
of O
less O
importance O
since O
the O
values O
are O
low O
( O
0.26 O
vs O
0.09 O
, O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
relation O
of O
pacing O
rate O
to O
physiologic O
variables O
of O
metabolic O
demand O
was O
examined O
in O
10 O
consecutive O
patients O
with O
a O
minute O
ventilation-sensing O
, O
rate-modulating O
ventricular O
pacemaker O
implanted O
for O
complete O
heart O
block O
. O
[]

A O
comparison O
of O
an O
aqueous O
and O
a O
pressurized O
nasal O
spray O
of O
beclomethasone O
dipropionate O
in O
the O
management O
of O
seasonal B-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Subjects O
were O
healthy O
volunteers O
who O
were O
told O
the O
study O
was O
evaluating O
the O
effect O
of O
time O
and O
touch O
on O
the O
autonomic O
nervous O
system O
. O
[]

CONCLUSION O
A O
short O
, O
nurse-based O
educational O
intervention O
seems O
to O
be O
as O
efficacious O
as O
a O
longer O
multidisciplinary O
version O
. O
[]

Neurodevelopmental O
and O
behavioral O
assessments O
were O
performed O
for O
all O
subjects O
before O
injection O
and O
at O
3 O
and O
6 O
weeks O
after O
injection O
. O
[]

Subsequent O
clinical O
course O
, O
serial O
radionuclide O
ventriculography O
, O
and O
6-month O
repeat O
angiography O
were O
analyzed O
. O
[]

Overall B-outcome ['Physiological-Clinical']
bacteriologic I-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
on O
Day O
4 O
to O
5 O
was O
99 O
% O
for O
Shigella O
, O
77 O
% O
for O
Salmonella O
and O
77 O
% O
for O
Campylobacter O
, O
with O
no O
difference O
between O
the O
2 O
groups O
. O
['Physiological-Clinical']

Effect O
of O
topical O
anesthesia O
and O
age O
on O
pain B-outcome ['Physiological-Clinical']
scores O
during O
retinopathy O
of O
prematurity O
screening O
. O
['Physiological-Clinical']

A O
Phase O
I O
clinical O
study O
demonstrated O
that O
a O
single O
oral O
dose O
of O
PPS O
increased O
microvascular B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
in O
patients O
with O
SCD O
. O
['Physiological-Clinical']

Follow-up O
telephone O
surveys O
are O
conducted O
at O
1 O
and O
6months O
. O
[]

Belatacept O
, O
a O
costimulation O
blocker O
, O
may O
preserve O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
improve O
long-term O
outcomes O
versus O
calcineurin O
inhibitors O
in O
kidney O
transplantation O
. O
['Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
median O
survival B-outcome ['Mortality']
durations I-outcome ['Mortality']
( O
10 O
months O
) O
from O
time O
of O
initial O
radiotherapy O
between O
control O
and O
interferon O
patients O
. O
['Mortality']

29 O
GN O
patients O
with O
normal O
renal O
function O
( O
17 O
membranoproliferative O
GN O
, O
12 O
IgA O
GN O
) O
were O
randomly O
assigned O
to O
receive O
100 O
mg/day O
of O
diclofenac O
or O
placebo O
for O
at O
least O
2 O
months O
. O
[]

The O
patients O
underwent O
a O
dynamic B-outcome ['Resource-use']
EMG I-outcome ['Resource-use']
evaluation I-outcome ['Resource-use']
for O
which O
they O
were O
asked O
to O
stand O
and O
then O
bend O
forward O
as O
far O
as O
possible O
, O
stay O
fully O
flexed O
, O
and O
return O
to O
standing O
. O
['Resource-use']

Following O
injection O
patients O
were O
immediately O
positioned O
supine O
. O
[]

0.12 O
mg/dL O
, O
P O
= O
.03 O
) O
and O
poorer O
postoperative O
diuresis O
( O
-96 O
? O
[]

A O
randomized O
trial O
of O
intranasal O
beclomethasone O
dipropionate O
after O
polypectomy O
. O
[]

Persistent B-outcome ['Physiological-Clinical']
bronchial I-outcome ['Physiological-Clinical']
narrowing I-outcome ['Physiological-Clinical']
was O
observed O
in O
patients O
who O
became O
disease-free O
2-yr O
survivors O
. O
['Physiological-Clinical']

A O
significant O
and O
persistent O
increase O
in O
oxygen B-outcome ['Resource-use']
consumption O
identified O
the O
threshold O
. O
['Resource-use']

In O
parallel O
with O
the O
decrease O
in O
LDL-cholesterol B-outcome ['Physiological-Clinical']
, O
the O
apoprotein B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
also O
was O
diminished O
by O
20 O
% O
( O
P O
less O
than O
or O
equal O
to O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
changes O
were O
observed O
in O
plasma B-outcome ['Physiological-Clinical']
vasoconstrictor I-outcome ['Physiological-Clinical']
hormones I-outcome ['Physiological-Clinical']
or O
['Physiological-Clinical']

There O
were O
significant O
effects O
for O
erosion B-outcome ['Physiological-Clinical']
( O
orange O
juice O
produced O
significantly O
more O
erosion O
than O
water O
) O
and O
for O
abrasion B-outcome ['Physiological-Clinical']
( O
paste O
A O
was O
significantly O
more O
abrasive O
to O
dentine O
than O
paste O
B O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Risedronate O
was O
associated O
with O
a O
significantly O
lower O
incidence O
of O
gastric O
ulcers O
than O
alendronate O
. O
[]

Awareness O
of O
the O
role O
of O
context O
was O
assessed O
using O
a O
behavioral O
task O
and O
explicit O
questions O
. O
[]

The O
gain O
of O
sweating B-outcome ['Physiological-Clinical']
was O
approximately O
0.2 O
degree O
C O
and O
was O
not O
influenced O
by O
clonidine O
administration O
. O
['Physiological-Clinical']

OBJECTIVE O
This O
randomised O
controlled O
clinical O
trial O
compared O
a O
capillary O
dressing O
( O
Drawtex O
, O
now O
rebranded O
as O
Vibriant O
RCD O
[ O
Vibriant O
Technology O
Services O
] O
) O
with O
routine O
practice O
for O
exuding O
wounds O
greater O
than O
2.5 O
x O
2.5 O
cm O
. O
[]

The O
latter O
was O
done O
to O
dissociate O
the O
effects O
of O
montelukast O
from O
ICS O
. O
[]

Headache B-outcome ['Physiological-Clinical']
relief O
rates O
after O
rizatriptan O
10 O
mg O
were O
consistently O
higher O
than O
sumatriptan O
at O
all O
time O
points O
up O
to O
2 O
hours O
, O
with O
significance O
at O
1 O
hour O
( O
37 O
% O
versus O
28 O
% O
, O
P O
= O
0.010 O
) O
. O
['Physiological-Clinical']

This O
study O
aimed O
to O
extend O
previous O
work O
using O
the O
D-C O
model O
of O
job O
strain O
to O
predict O
caregiver O
burden O
and O
satisfaction O
in O
the O
informal O
caregivers O
of O
patients O
with O
heart O
failure O
. O
[]

RESULTS O
In O
the O
TWT O
group O
there O
was O
no O
measurable O
intraoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
while O
mean O
bleeding B-outcome ['Physiological-Clinical']
for O
BET O
group O
was O
16 O
mL O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Spread O
of O
sensory B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
was O
significantly O
faster O
with O
bupivacaine-CO2 O
and O
-HCl O
at O
a O
temperature O
of O
36 O
degrees O
C O
as O
compared O
to O
4 O
degrees O
or O
20 O
degrees O
C O
( O
P O
less O
than O
0.05 O
) O
( O
Figs O
. O
['Physiological-Clinical']

Fifty-nine O
families O
with O
a O
child O
with O
ASD O
aged O
between O
2 O
and O
9 O
participated O
in O
this O
randomized O
controlled O
trial O
. O
[]

Median O
PFS B-outcome ['Mortality']
[ O
10.1 O
versus O
10.3 O
months O
; O
hazard O
ratio O
( O
HR O
) O
0.98 O
; O
log-rank O
P O
= O
0.38 O
] O
and O
OS B-outcome ['Mortality']
( O
19.9 O
versus O
30.0 O
months O
; O
HR O
0.663 O
; O
log-rank O
P O
= O
0.21 O
) O
were O
comparable O
in O
both O
arms O
. O
['Mortality', 'Mortality']

arm O
compared O
with O
28 O
% O
of O
the O
patients O
in O
the O
q.d O
. O
[]

One O
patient O
showed O
a O
proarrhythmic O
effect O
with O
P. O
Plasma O
levels O
of O
C O
were O
significantly O
higher O
in O
responders O
( O
328 O
+/- O
149 O
ng/ml O
) O
than O
in O
non-responders O
( O
137 O
+/- O
41 O
ng/ml O
, O
p O
less O
than O
0.05 O
) O
. O
[]

Nebivolol O
( O
5 O
mg/day O
) O
or O
metoprolol O
( O
50 O
mg/day O
) O
was O
administrated O
for O
12 O
weeks O
. O
[]

CONCLUSIONS O
Independent O
risk O
factors O
for O
intermediate-term O
mortality O
include O
lower O
socioeconomic O
status O
, O
anatomy O
, O
genetic O
syndrome O
, O
and O
lower O
gestational O
age O
. O
[]

Onset/offset B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
intubating I-outcome ['Physiological-Clinical']
conditions I-outcome ['Physiological-Clinical']
of O
rapacuronium O
: O
a O
comparison O
with O
rocuronium O
. O
['Physiological-Clinical']

FINDINGS O
82 O
patients O
were O
excluded O
on O
arrival O
at O
hospital O
because O
they O
did O
not O
meet O
inclusion O
criteria O
, O
32 O
were O
lost O
to O
follow-up O
, O
and O
77 O
did O
not O
complete O
the O
follow-up O
with O
data O
for O
salvage O
index O
. O
[]

Compared O
with O
those O
with O
plasma B-outcome ['Physiological-Clinical']
25 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
levels O
above O
the O
median O
and O
with O
the O
FokI O
FF O
or O
Ff O
genotype O
, O
men O
who O
had O
low O
25 O
( O
OH O
) O
D O
levels O
and O
the O
less O
functional O
FokI O
ff O
genotype O
had O
increased O
risks O
of O
total O
( O
OR O
= O
1.9 O
, O
95 O
% O
CI O
1.1-3.3 O
) O
and O
aggressive B-outcome ['Physiological-Clinical']
prostate I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
( O
OR O
= O
2.5 O
, O
95 O
% O
CI O
1.1-5.8 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
receiving O
their O
third O
warfarin O
dose O
, O
patients O
were O
randomly O
assigned O
to O
have O
their O
warfarin O
dosages O
adjusted O
using O
one O
of O
three O
dosage-prediction O
methods O
: O
by O
analog O
computer O
( O
n O
= O
31 O
) O
, O
linear O
regression O
( O
n O
= O
22 O
) O
, O
or O
empiric O
dosing O
by O
the O
physician O
( O
n O
= O
34 O
) O
. O
[]

Standardised O
photographs O
of O
each O
wart O
were O
taken O
before O
, O
during O
( O
week O
7 O
) O
and O
after O
treatment O
( O
weeks O
14 O
and O
18 O
) O
. O
[]

Exhaled O
NO O
during O
graded O
changes O
in O
inhaled O
oxygen O
in O
man O
. O
[]

Contrast O
sensitivity B-outcome ['Physiological-Clinical']
was O
reduced O
in O
the O
Planoscan O
group O
only O
at O
the O
highest O
spatial O
frequency O
( O
18 O
cycles O
per O
degree O
; O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

[ O
Late O
cardiac B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
in O
Hodgkin O
's O
disease O
. O
['Physiological-Clinical']

The O
secondary O
efficacy O
end-points O
were O
differences O
in O
daily O
mean O
: O
( O
i O
) O
voiding O
frequency O
at O
4 O
and O
8 O
weeks O
; O
( O
ii O
) O
urgency O
frequency O
; O
( O
iii O
) O
urgency O
incontinence O
frequency O
; O
( O
iv O
) O
incontinence O
frequency O
; O
( O
v O
) O
nocturia O
frequency O
; O
and O
( O
vi O
) O
quality O
of O
life O
score O
. O
[]

The O
mean O
plasma B-outcome ['Physiological-Clinical']
lidocaine I-outcome ['Physiological-Clinical']
level O
of O
patients O
on O
beta-blocking O
agents O
was O
no O
different O
from O
that O
in O
patients O
not O
on O
beta O
blocking O
agents O
. O
['Physiological-Clinical']

BACKGROUND O
Mitral O
valve O
pathology O
is O
frequently O
associated O
with O
auricular O
dilatation O
and O
atrial O
fibrillation O
. O
[]

Clinical O
periodontal O
measurements O
and O
data O
regarding O
patients O
' O
oral B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
impacts I-outcome ['Physiological-Clinical']
( O
perceived B-outcome ['Physiological-Clinical']
impacts I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
gums I-outcome ['Physiological-Clinical']
, O
gingival B-outcome ['Physiological-Clinical']
recession I-outcome ['Physiological-Clinical']
, O
sensitivity B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
cold I-outcome ['Physiological-Clinical']
, O
packing B-outcome ['Life-Impact']
foods I-outcome ['Life-Impact']
, O
aesthetics B-outcome ['Life-Impact']
, O
bad B-outcome ['Physiological-Clinical']
breath I-outcome ['Physiological-Clinical']
, O
and O
tooth B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
) O
were O
collected O
at O
baseline O
and O
3 O
months O
after O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

We O
recommend O
the O
use O
of O
ofloxacin O
eardrops O
in O
managing O
active O
chronic O
suppurative O
otitis O
media O
since O
it O
has O
high O
clinical B-outcome ['Physiological-Clinical']
efficacy O
, O
contains O
no O
steroid O
component O
and O
has O
no O
demonstrated O
risk O
of O
ototoxicity B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Placebo-controlled O
study O
of O
oral O
enoximone O
in O
congestive O
heart O
failure O
with O
initial O
and O
final O
intravenous O
hemodynamic B-outcome ['Physiological-Clinical']
evaluation O
. O
['Physiological-Clinical']

RESULTS O
Significant O
improvement O
occurred O
in O
both O
groups O
on O
every O
self-rated O
[]

three O
times O
daily O
for O
6 O
days O
) O
and O
15 O
patients O
received O
a O
placebo O
( O
5 O
ml O
in O
normal O
saline O
i.m O
. O
[]

Left O
ventricular B-outcome ['Physiological-Clinical']
time O
intervals O
were O
obtained B-outcome ['Physiological-Clinical']
by O
means O
of O
carotid O
thermistor O
plethysmography O
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTERVENTIONS O
The O
initial O
treatment O
consisted O
of O
taking O
1 O
capsule O
daily O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
for O
the O
first O
week O
and O
2 O
capsules O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
daily O
for O
4 O
additional O
weeks O
. O
[]

Of O
26 O
patients O
treated O
with O
LSA2-L2 O
, O
four O
relapsed B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

INTERVENTIONS O
We O
used O
250 O
mL O
of O
HSD O
vs O
NS O
given O
within O
4 O
hours O
of O
the O
accident O
. O
[]

A O
randomised O
prospective O
study O
comparing O
the O
new O
vacuum O
extractor O
policy O
with O
forceps O
delivery O
. O
[]

Compared O
with O
placebo O
, O
women O
randomized O
to O
estradiol O
showed O
a O
higher O
mean O
on-trial O
HDL-cholesterol B-outcome ['Physiological-Clinical']
level O
and O
a O
lower O
mean O
on-trial O
LDL-cholesterol B-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical', 'Physiological-Clinical']

of O
ectopic B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
beats I-outcome ['Physiological-Clinical']
was O
31.1 O
+/- O
52.5 O
after O
ibopamine O
and O
30.4 O
+/- O
57.8 O
after O
placebo O
( O
p O
= O
ns O
) O
. O
['Physiological-Clinical']

AIM O
Certain O
probiotic O
agents O
, O
e.g O
. O
[]

Administration O
of O
high-dose O
gentamicin O
resulted O
in O
a O
longer O
time O
to O
actual O
T O
( O
max O
) O
( O
P= O
.021 O
) O
but O
did O
not O
change O
model O
T O
( O
max O
) O
( O
P= O
.62 O
) O
. O
[]

METHODS O
Propofol O
was O
administered O
to O
American O
Society O
of O
Anesthesiologists O
physical O
status O
1 O
( O
n O
= O
17 O
) O
volunteers O
with O
use O
of O
a O
computer-controlled O
infusion O
pump O
at O
increasing O
concentrations O
until O
unconsciousness O
resulted O
( O
inability O
to O
respond O
to O
verbal O
commands O
, O
abolition O
of O
spontaneous O
movement O
) O
. O
[]

Three O
children O
were O
provoked O
with O
gluten/placebo O
in O
a O
double-blind O
study O
. O
[]

Sun O
exposure O
is O
the O
most O
important O
avoidable O
cause O
of O
skin O
cancers O
. O
[]

In O
both O
groups O
, O
the O
mean O
hemoglobin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
declined O
most O
rapidly O
in O
the O
first O
24 O
hrs O
of O
ICU O
care O
and O
, O
thereafter O
, O
declined O
more O
slowly O
. O
['Physiological-Clinical']

Only O
one O
subject O
had O
documented O
clinical B-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

STUDY O
Sixty-two O
patients O
( O
19 O
men O
and O
43 O
women O
; O
mean O
age O
, O
54 O
years O
; O
range O
, O
32-77 O
years O
) O
with O
heartburn O
and O
regurgitation O
and O
normal O
upper O
endoscopy O
findings O
were O
studied O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
with O
a O
crossover O
design O
. O
[]

RESULTS O
Only O
one O
case O
in O
group O
A O
had O
urinary B-outcome ['Physiological-Clinical']
leakage I-outcome ['Physiological-Clinical']
after O
removal O
of O
nephrostomy O
tube O
. O
['Physiological-Clinical']

Homeopaths O
rated O
each O
patient O
's O
vital O
force O
( O
five-point O
Likert O
scale O
, O
with O
1 O
= O
very O
weak O
to O
5 O
= O
very O
strong O
) O
. O
[]

SETTING O
Fifty-four O
general O
practice O
surgeries O
in O
Norway O
. O
[]

RESULTS O
Results O
revealed O
that O
the O
number O
of O
self-initiated B-outcome ['Life-Impact']
questions I-outcome ['Life-Impact']
for O
both O
experimental O
groups O
increased O
between O
baseline O
and O
the O
first O
intervention O
and O
was O
maintained O
during O
follow-up O
. O
['Life-Impact']

Effects O
of O
oral O
Lactobacillus O
GG O
on O
enteric B-outcome ['Physiological-Clinical']
microflora I-outcome ['Physiological-Clinical']
in O
low-birth-weight O
neonates O
. O
['Physiological-Clinical']

5.3 O
) O
, O
( O
23.8 O
? O
[]

Treatments O
were O
applied O
once O
a O
day O
to O
both O
groups O
. O
[]

The O
current O
study O
examined O
youth O
substance O
involvement O
over O
4 O
years O
( O
using O
five O
waves O
of O
data O
collection O
) O
following O
treatment O
for O
alcohol O
and O
drug O
abuse O
. O
[]

STUDY O
DESIGN O
Randomized O
clinical O
trial O
. O
[]

In O
conclusion O
, O
low-dose O
flutamide O
is O
herewith O
identified O
as O
a O
pivotal O
component O
within O
a O
first O
contraceptive O
combination O
therapy O
that O
has O
been O
shown O
to O
attenuate O
the O
hypoadiponectinemia B-outcome ['Physiological-Clinical']
, O
ovarian B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
hyperresistance I-outcome ['Physiological-Clinical']
, O
lean B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
deficit I-outcome ['Physiological-Clinical']
, O
and O
central B-outcome ['Physiological-Clinical']
adiposity I-outcome ['Physiological-Clinical']
of O
young O
women O
with O
polycystic O
ovary O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
tested O
the O
effect O
of O
a O
method O
of O
facilitating O
prelinguistic O
communication O
on O
parents O
' O
responsivity B-outcome ['Life-Impact']
and O
children O
's O
communication B-outcome ['Life-Impact']
and O
productive B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
development B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
injection O
flow O
rate O
of O
contrast O
agent O
( O
350 O
mg O
I/mL O
) O
was O
adjusted O
to O
body O
weight O
of O
each O
patient O
( O
4.5-5.5 O
mL/s O
in O
the O
120-kV O
group O
and O
2.8-3.8 O
mL/s O
in O
the O
80-kV O
group O
) O
. O
[]

RESULTS O
A O
total O
of O
71 O
patients O
were O
treated O
by O
quadruple O
therapy O
, O
and O
42 O
patients O
were O
treated O
by O
triple O
therapy O
. O
[]

This O
may O
partly O
be O
explained O
by O
intertrial O
differences O
in O
dosage O
and O
study O
design O
. O
[]

RESULTS O
ICCE O
with O
ACL O
shows O
much O
less O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
as O
usually O
emphasized O
. O
['Adverse-effects']

Treatment O
of O
sperm O
with O
platelet-activating O
factor O
does O
not O
improve O
intrauterine O
insemination O
outcome O
in O
unselected O
cases O
of O
mild O
male O
factor O
infertility O
: O
a O
prospective O
double-blind O
randomized O
crossover O
study O
. O
[]

Standard-dose O
lansoprazole O
is O
more O
effective O
than O
high-dose O
ranitidine O
in O
achieving O
endoscopic O
healing O
and O
symptom O
relief O
in O
patients O
with O
moderately O
severe O
reflux O
oesophagitis O
. O
[]

Sixty O
and O
55 O
patients O
, O
respectively O
, O
were O
registered O
in O
Regimen O
A O
and O
B O
. O
[]

RESULTS O
The O
groups O
receiving O
one O
round O
and O
seven O
rounds O
of O
DMSA O
had O
significant O
improvements O
on O
all O
the O
assessment O
measures O
. O
[]

Neutrophils B-outcome ['Physiological-Clinical']
and O
eosinophils B-outcome ['Physiological-Clinical']
were O
responsible O
for O
the O
majority O
of O
this O
increase O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
additional O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
in O
the O
EBUS-TBNA O
plus O
CDPs O
group O
. O
['Adverse-effects']

PURPOSE O
We O
assessed O
the O
impact O
of O
hexaminolevulinate O
fluorescence O
cystoscopic O
detection O
of O
papillary O
, O
nonmuscle O
invasive O
bladder O
cancer O
on O
the O
long-term B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rate O
. O
['Physiological-Clinical']

The O
mean O
infant B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
and O
Hb B-outcome ['Physiological-Clinical']
at O
3 O
months O
were O
significantly O
higher O
in O
the O
delayed O
clamping O
group O
( O
118.4 O
microg/L O
and O
99 O
g/L O
) O
than O
in O
the O
early O
clamping O
group O
( O
73 O
microg/L O
and O
88 O
g/L O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
estimated O
individual O
cumulative O
area O
under O
the O
concentration O
versus O
time O
curves O
( O
AUC O
) O
for O
infliximab B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
between O
baseline O
and O
week O
18 O
( O
AUC O
( O
0-18 O
) O
) O
. O
['Physiological-Clinical']

Measurement O
of O
transfer B-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
during O
constant O
exhalation O
. O
['Physiological-Clinical']

It O
is O
unclear O
from O
preliminary O
laboratory O
studies O
whether O
a O
high- O
or O
a O
low-dose O
interferon O
treatment O
strategy O
is O
optimal O
. O
[]

In O
the O
first O
phase O
, O
the O
child O
walked O
into O
a O
room O
that O
was O
furnished O
with O
a O
sofa O
, O
a O
table O
, O
chairs O
, O
and O
two O
sets O
of O
identical O
toys O
. O
[]

We O
assessed O
the O
efficacy O
of O
rhesus-human O
reassortant O
rotavirus O
tetravalent O
vaccine O
( O
RRV-TV O
) O
against O
severe O
rotavirus O
gastroenteritis O
in O
Finnish O
children O
in O
a O
randomised O
placebo-controlled O
double-blind O
trial O
. O
[]

RESULTS O
Controlling O
for O
demographic O
, O
functional O
, O
chronic O
disease O
, O
and O
clinical O
characteristics O
, O
African O
American O
patients O
were O
1.7 O
times O
more O
likely O
to O
have O
undergone O
both O
primary O
( O
P O
= O
.01 O
) O
and O
repeat O
( O
P O
= O
.03 O
) O
amputation O
than O
white O
or O
other-race O
amputees O
. O
[]

RESULTS O
Whatever O
the O
method O
of O
rehabilitation O
, O
the O
clinical B-outcome ['Physiological-Clinical']
scores O
improved O
significantly O
between O
J0 O
and O
JM O
+ O
30 O
, O
except O
for O
spasticity O
. O
['Physiological-Clinical']

Dentists O
United O
to O
Extinguish O
Tobacco O
( O
DUET O
) O
: O
a O
study O
protocol O
for O
a O
cluster O
randomized O
, O
controlled O
trial O
for O
enhancing O
implementation O
of O
clinical O
practice O
guidelines O
for O
treating O
tobacco O
dependence O
in O
dental O
care O
settings O
. O
[]

No O
differences O
in O
transcription B-outcome ['Physiological-Clinical']
factor O
expression B-outcome ['Physiological-Clinical']
were O
found O
in O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
the O
two O
immunoglobulin O
preparations O
. O
[]

Such O
enhanced O
suppression O
might O
be O
of O
benefit O
for O
patients O
exhibiting O
a O
progressive O
decline O
in O
renal O
function O
because O
of O
chronic O
renal O
disease O
. O
[]

In O
Arm O
1 O
, O
patients O
with O
N0 O
disease O
will O
receive O
RT O
alone O
, O
whereas O
N1-2 O
patients O
will O
receive O
concurrent O
chemoradiation O
. O
[]

These O
findings O
suggest O
that O
L-carnitine O
is O
of O
benefit O
in O
some O
patients O
with O
Rett O
syndrome O
. O
[]

The O
control O
group O
receives O
general O
information O
about O
the O
benefits O
of O
weight O
reduction O
, O
physical O
activity O
and O
healthy O
diet O
in O
the O
prevention O
of O
diabetes O
. O
[]

BACKGROUND O
Barriers O
to O
timely O
resolution O
of O
abnormal O
cancer O
screening O
tests O
add O
to O
cancer O
health O
disparities O
among O
low-income O
, O
uninsured O
, O
and O
minority O
populations O
. O
[]

The O
shortest O
time B-outcome ['Physiological-Clinical']
of O
the O
control O
periods O
was O
8.6 O
min O
and O
the O
maximum O
time O
was O
32.6 O
min O
. O
['Physiological-Clinical']

At O
the O
end O
of O
haemodialysis O
the O
percentage O
reduction O
in O
mean O
arterial O
blood O
pressure O
was O
23 O
+/- O
2 O
% O
in O
the O
diazoxide-treated O
group O
and O
17 O
+/- O
2 O
% O
after O
labetalol O
. O
( O
[]

Impact O
of O
an O
Asha O
intervention O
on O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
among O
rural O
women O
living O
with O
AIDS O
in O
India O
: O
comparison O
of O
the O
Asha-Life O
and O
Usual O
Care O
program O
. O
['Life-Impact']

Xuezhikang O
, O
an O
extract O
of O
cholestin O
, O
decreases O
plasma O
inflammatory O
markers O
and O
endothelin-1 O
, O
improve O
exercise-induced O
ischemia O
and O
subjective O
feelings O
in O
patients O
with O
cardiac O
syndrome O
X O
. O
[]

The O
advantage O
regarding O
efficacy O
of O
this O
combination O
compared O
with O
glycerol O
eardrops O
must O
be O
demonstrated O
in O
an O
adequately O
powered O
clinical O
trial O
. O
[]

At O
baseline O
, O
higher O
scores O
on O
alexithymia O
were O
associated O
poorer O
emotion B-outcome ['Life-Impact']
regulation I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
fewer O
percent O
days B-outcome ['Life-Impact']
abstinent I-outcome ['Life-Impact']
, O
greater O
alcohol B-outcome ['Life-Impact']
dependence O
severity O
, O
and O
several O
['Life-Impact', 'Life-Impact', 'Life-Impact']

There O
were O
no O
significant O
differences O
in O
the O
GMTs O
of O
tetanus B-outcome ['Physiological-Clinical']
and O
diphtheria B-outcome ['Physiological-Clinical']
antitoxins I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
after O
each O
vaccination O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Consumption O
of O
iTFA O
caused O
4 O
% O
lower O
TNF-RI O
concentrations O
and O
6 O
% O
higher O
E-selectin O
concentrations O
compared O
with O
oleic O
acid O
( O
control O
) O
and O
had O
no O
significant O
effect O
on O
other O
inflammatory O
markers O
. O
[]

RESULTS O
Subjects O
displayed O
a O
strong O
implicit O
preference O
for O
whites O
over O
blacks O
( O
P O
< O
.0001 O
) O
and O
associated O
medically B-outcome ['Life-Impact']
cooperative I-outcome ['Life-Impact']
with O
whites O
over O
blacks O
( O
P O
< O
.0001 O
) O
. O
['Life-Impact']

BACKGROUND O
AND O
OBJECTIVES O
Sarpogrelate O
has O
been O
shown O
to O
reduce O
albuminuria O
in O
diabetic O
nephropathy O
. O
[]

Homocysteinemia O
is O
a O
risk O
factor O
for O
cardiovascular O
diseases O
. O
[]

Average O
follow-up O
was O
11.8 O
months O
for O
patients O
who O
completed O
the O
course O
of O
therapy O
, O
and O
the O
average O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
therapy I-outcome ['Life-Impact']
was O
60.6 O
days O
. O
['Life-Impact']

RESULTS O
There O
was O
no O
statistically O
significant O
difference O
between O
the O
two O
groups O
of O
patients O
with O
respect O
to O
age O
, O
sex B-outcome ['Physiological-Clinical']
ratio O
, O
chest B-outcome ['Life-Impact']
drainage I-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
, O
postprocedural B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
parenteral B-outcome ['Life-Impact']
narcotics I-outcome ['Life-Impact']
requirement I-outcome ['Life-Impact']
, O
complications B-outcome ['Adverse-effects']
, O
or O
procedure B-outcome ['Life-Impact']
failure I-outcome ['Life-Impact']
( O
ie O
, O
recurrence B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Life-Impact', 'Adverse-effects', 'Life-Impact', 'Physiological-Clinical']

Among O
contingent-voucher O
participants O
, O
31 O
% O
were O
drug-free B-outcome ['Life-Impact']
on O
Friday O
compared O
with O
18 O
% O
of O
noncontingent O
controls O
( O
Z O
= O
2.4 O
, O
p O
< O
.05 O
) O
. O
['Life-Impact']

untoward O
reactions O
such O
as O
nausea B-outcome ['Physiological-Clinical']
, O
perspiration B-outcome ['Physiological-Clinical']
and O
skin B-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
were O
noted O
in O
a O
few O
patients O
, O
but O
none O
withdrew O
from O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Changes O
in O
the O
BARS O
score O
did O
not O
differ O
significantly O
between O
the O
DCM O
and O
the O
control O
group O
or O
between O
the O
VPM O
and O
the O
control O
group O
after O
10 O
months O
. O
[]

No O
significant O
differences O
were O
observed O
between O
trimetazidine O
and O
propranolol O
as O
regards O
anginal B-outcome ['Physiological-Clinical']
attack O
rate O
per O
week O
( O
mean O
difference O
P-TMZ O
: O
2 O
; O
95 O
% O
CI O
: O
-4.4 O
, O
0.5 O
) O
and O
exercise B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
( O
mean O
difference O
P-TMZ O
: O
0 O
s O
; O
95 O
% O
CI O
: O
-33 O
, O
34 O
) O
or O
time O
to O
1 O
mm O
ST B-outcome ['Physiological-Clinical']
segment I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
( O
mean O
difference O
P-TMZ O
: O
13 O
s O
; O
95 O
% O
CI O
: O
-24 O
, O
51 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Three O
controlled O
dietary O
intervention O
studies O
were O
carried O
out O
in O
1981-1983 O
in O
North O
Karelia O
, O
Finland O
, O
to O
asses O
the O
impact O
of O
dietary O
fat O
intake O
modification O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

DESIGN O
Randomised O
, O
placebo-controlled O
, O
double-blind O
study O
. O
[]

RESULTS O
There O
were O
no O
significant O
differences O
in O
local B-outcome ['Adverse-effects']
and I-outcome ['Adverse-effects']
systemic I-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
between O
the O
two O
groups O
. O
['Adverse-effects']

Twenty-three O
male O
veterans O
with O
schizophrenia O
completed O
baseline O
assessments O
of O
social O
cognition O
that O
were O
divided O
into O
lower-level O
( O
facial B-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
perception I-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
perception I-outcome ['Life-Impact']
, O
detection B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
lies I-outcome ['Life-Impact']
) O
and O
higher-level O
( O
detection O
of O
sarcasm B-outcome ['Life-Impact']
and O
deception B-outcome ['Life-Impact']
, O
empathy B-outcome ['Life-Impact']
) O
processes O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
effect O
of O
intravenous O
lidocaine O
on O
QT B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
during O
tracheal O
intubation O
. O
['Physiological-Clinical']

SETTING O
Norwegian O
university O
teaching O
hospital O
. O
[]

The O
patients O
were O
randomly O
assigned O
to O
receive O
either O
prophylactic O
cranial O
irradiation O
delivering O
24 O
Gy O
in O
eight O
fractions O
during O
12 O
days O
( O
treatment O
group O
) O
or O
no O
prophylactic O
cranial O
irradiation O
( O
control O
group O
) O
. O
[]

There O
was O
no O
remarkable O
difference O
in O
the O
number O
of O
patients O
, O
gender O
, O
age O
, O
or O
distribution O
of O
primary O
diseases O
between O
the O
two O
groups O
. O
[]

The O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
first I-outcome ['Life-Impact']
ambulation I-outcome ['Life-Impact']
, O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
sounds I-outcome ['Physiological-Clinical']
, O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
tolerating I-outcome ['Life-Impact']
oral I-outcome ['Life-Impact']
nutrition I-outcome ['Life-Impact']
, O
incidence O
of O
nausea/vomiting B-outcome ['Physiological-Clinical']
or O
pruritus B-outcome ['Physiological-Clinical']
, O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
flatus I-outcome ['Physiological-Clinical']
were O
not O
statistically O
different O
between O
the O
groups O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHOD O
Forty O
eyes O
with O
attached O
posterior O
hyaloid O
were O
included O
in O
this O
prospective O
trial O
and O
randomized O
intraoperatively O
. O
[]

Of O
these O
, O
36 O
and O
37 O
patients O
, O
respectively O
, O
completed O
the O
study O
and O
were O
evaluable O
. O
[]

After O
completing O
a O
baseline O
survey O
, O
participants O
were O
randomized O
to O
2 O
groups O
. O
[]

RESULTS O
In O
subjects O
receiving O
combined O
testosterone O
and O
nutritional O
supplements O
( O
n O
= O
11 O
) O
, O
there O
were O
no O
hospital B-outcome ['Resource-use']
admissions I-outcome ['Resource-use']
, O
whereas O
there O
were O
9 O
admissions O
( O
2 O
elective O
) O
in O
13 O
subjects O
in O
the O
no-treatment O
group O
, O
4 O
in O
the O
testosterone-treated O
group O
( O
n O
= O
12 O
) O
, O
and O
5 O
in O
the O
supplement-treated O
group O
( O
n O
= O
13 O
) O
; O
P O
= O
0.06 O
with O
no-treatment O
compared O
with O
combined O
treatment O
. O
['Resource-use']

The O
same O
differences O
were O
seen O
when O
the O
fluids O
were O
infused O
separately O
and O
when O
they O
were O
combined O
. O
[]

METHODS O
130 O
EMs-related O
infertility O
patients O
of O
blood O
stasis O
and O
toxin O
accumulation O
syndrome O
diagnosed O
and O
treated O
by O
laparoscopic O
surgery O
were O
randomly O
assigned O
to O
two O
groups O
, O
i.e. O
, O
the O
test O
group O
( O
75 O
cases O
) O
and O
the O
control O
group O
( O
55 O
cases O
) O
. O
[]

The O
actuarial O
survival B-outcome ['Mortality']
at O
4 O
years O
is O
72 O
% O
in O
group O
A O
and O
67 O
% O
in O
group O
B O
( O
p=0.3 O
) O
. O
['Mortality']

In O
particular O
, O
the O
relative O
contributions O
of O
selection O
and O
socialization O
to O
substance O
use O
progression O
have O
not O
been O
established O
. O
[]

There O
is O
no O
known O
definite O
cure O
for O
mucositis O
. O
[]

CONCLUSIONS O
The O
main O
barrier O
encountered O
was O
in O
the O
recruitment B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
children I-outcome ['Life-Impact']
: O
it O
was O
not O
possible O
to O
recruit O
the O
target O
of O
60 O
patients O
. O
['Life-Impact']

Following O
training O
VO2max B-outcome ['Physiological-Clinical']
( O
ml.kg-1 O
min-1 B-outcome ['Physiological-Clinical']
) O
was O
significantly O
increased O
in O
all O
training O
groups O
( O
18.0 O
, O
12.5 O
, O
and O
11.3 O
% O
for O
cycle O
, O
HCTsub O
, O
and O
HCTmax B-outcome ['Physiological-Clinical']
groups I-outcome ['Physiological-Clinical']
, O
respectively O
; O
P O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
in O
the O
combined O
spinal-epidural O
group O
, O
there O
was O
a O
higher O
incidence O
of O
posterior B-outcome ['Physiological-Clinical']
presentation I-outcome ['Physiological-Clinical']
( O
25.9 O
% O
vs. O
10 O
% O
, O
P O
= O
0.03 O
) O
, O
pruritus B-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
, O
hypotension B-outcome ['Physiological-Clinical']
( O
P O
= O
0.002 O
) O
, O
somnolence B-outcome ['Physiological-Clinical']
( O
P O
= O
0.01 O
) O
, O
nausea B-outcome ['Physiological-Clinical']
( O
P O
= O
0.02 O
) O
and O
one O
case O
of O
meningitis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
day O
29 O
, O
the O
medication O
dose O
was O
increased O
to O
10 O
mg O
QD O
if O
sitting O
diastolic O
blood O
pressure O
( O
SiDBP O
) O
was O
> O
or O
= O
90 O
mm O
Hg O
. O
[]

Men O
aged O
?40 O
years O
who O
were O
not O
receiving O
lipid O
lowering O
or O
anti-hypertensive O
medication O
and O
not O
at O
high O
cardiovascular O
risk O
were O
recruited O
from O
10 O
general O
practices O
in O
the O
East O
of O
England O
. O
[]

Effect O
of O
gemfibrozil O
on O
change O
in O
renal O
function O
in O
men O
with O
moderate O
chronic O
renal O
insufficiency O
and O
coronary O
disease O
. O
[]

The O
primary O
endpoint O
was O
survival B-outcome ['Mortality']
in O
the O
overall O
population O
of O
patients O
and O
those O
with O
adenocarcinoma O
. O
['Mortality']

Fifty-one O
children O
( O
age O
range O
2-18 O
years O
) O
who O
did O
not O
respond O
to O
sleep O
hygiene O
intervention O
were O
enrolled O
. O
[]

The O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
a O
new O
pharmaceutical O
form O
of O
the O
non-steroid O
anti-inflammatory O
drug O
. O
['Life-Impact']

FMD B-outcome ['Physiological-Clinical']
remained O
unchanged O
in O
weight O
maintainers O
. O
['Physiological-Clinical']

Minor O
and O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
were O
observed O
with O
equal O
frequency O
in O
the O
two O
groups O
( O
24 O
% O
and O
29 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical']

METHODS O
Thirty-one O
patients O
with O
cirrhosis O
receiving O
norfloxacin O
( O
400 O
mg/day O
) O
were O
included O
. O
[]

This O
phenomenon O
has O
not O
been O
well O
articulated O
in O
the O
medical O
education O
literature O
, O
and O
may O
have O
important O
implications O
in O
many O
( O
especially O
technology-mediated O
) O
educational O
contexts O
. O
[]

OBJECTIVE O
To O
investigate O
the O
effectiveness O
of O
a O
program O
that O
utilizes O
community O
involvement O
to O
improve O
the O
self-management O
strategies O
among O
people O
living O
with O
hypertension O
. O
[]

Differences O
between O
groups O
were O
significant O
( O
p O
=.021 O
, O
two-way O
ANOVA O
) O
. O
[]

OBJECTIVE O
11-Beta-hydroxysteroid O
dehydrogenase O
type O
1 O
( O
11betaHSD1 O
) O
converts O
inactive O
cortisone O
into O
active O
cortisol O
, O
thereby O
amplifying O
intracellular O
glucocorticoid O
action O
. O
[]

Higher B-outcome ['Physiological-Clinical']
ASM I-outcome ['Physiological-Clinical']
predicted O
faster O
timed O
up O
and O
go O
performance O
( O
p O
= O
0.001 O
) O
. O
['Physiological-Clinical']

RESULTS O
ADHD O
, O
AS/HFA O
, O
and O
RD/WD O
all O
had O
severe O
impact O
on O
family B-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
. O
['Life-Impact']

CONCLUSIONS O
The O
use O
of O
intraoperative O
mitomycin O
C O
during O
deep O
sclerectomy O
significantly O
reduced O
the O
postoperative O
IOP O
and O
increased O
the O
success O
rate O
of O
the O
procedure O
. O
[]

Time O
to O
fi O
rst O
PCA O
demand O
was O
longer O
, O
morphine B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
values O
were O
lower O
and O
satisfaction O
scores O
were O
higher O
in O
group O
DB O
than O
in O
the O
other O
two O
groups O
( O
p O
< O
0.05 O
) O
. O
['Resource-use']

The O
achievement O
of O
learning B-outcome ['Life-Impact']
objectives O
was O
predicted O
by O
caregiver B-outcome ['Life-Impact']
factors I-outcome ['Life-Impact']
, O
such O
as O
education B-outcome ['Life-Impact']
, O
presence B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
father I-outcome ['Life-Impact']
or O
surrogate B-outcome ['Life-Impact']
father I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
household I-outcome ['Life-Impact']
, O
and O
safety B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
neighborhood I-outcome ['Life-Impact']
, O
but O
not O
by O
child O
factors O
, O
such O
as O
age O
or O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
as O
implied O
by O
the O
prescribed O
asthma O
medication O
regimen O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

CONCLUSIONS O
Although O
postoperative O
INB O
provided O
modest O
improvements O
in O
pain O
and O
pulmonary O
function O
when O
used O
as O
an O
adjuvant O
to O
0.5 O
mg O
SM O
for O
post-thoracotomy O
analgesia O
, O
the O
benefits O
were O
transient O
. O
[]

PURPOSE O
This O
randomized O
study O
compared O
denosumab O
, O
a O
fully O
human O
monoclonal O
antibody O
against O
receptor O
activator O
of O
nuclear O
factor O
? O
[]

In O
terms O
of O
percentage O
the O
greatest O
change O
was O
found O
in O
reactance O
, O
in O
relation O
to O
the O
initial O
value O
, O
followed O
by O
Raw O
and O
FEV1 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
pH O
tablet O
containing O
pH O
lowering O
compounds O
induced O
resolution O
of O
BV O
and O
restoration O
of O
normal O
vaginal O
flora O
in O
74 O
% O
and O
26 O
% O
, O
respectively O
. O
[]

Survival O
analysis O
using O
the O
Kaplan-Meier O
method O
showed O
that O
Skp2 O
overexpression O
was O
significantly O
associated O
with O
shorter O
disease-free B-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
p=0.0051 O
and O
p=0.0002 O
, O
respectively O
) O
. O
['Mortality', 'Mortality']

In O
the O
entire O
control O
+ O
A O
group O
, O
dietary O
omega-3 O
fatty O
acid O
intake O
was O
inversely O
related O
to O
loss O
of O
total O
field B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
over O
4 O
years O
( O
intake O
, O
< O
0.20 O
vs O
> O
or O
=0.20 O
g/d O
; O
P O
=.02 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
determine O
whether O
patients O
with O
borderline O
semen O
should O
be O
treated O
with O
conventional O
IVF O
or O
intracytoplasmic O
sperm O
injection O
( O
ICSI O
) O
. O
[]

In O
all O
subjects O
( O
n O
= O
6 O
) O
scopolamine O
blocked O
the O
physostigmine-induced B-outcome ['Physiological-Clinical']
reversal B-outcome ['Physiological-Clinical']
of O
unconsciousness B-outcome ['Physiological-Clinical']
and O
the O
increase O
of O
the O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

High-dose O
weekly O
fractionation O
radiotherapy O
in O
advanced O
cancer O
of O
the O
uterine O
cervix O
. O
[]

Eight O
out O
of O
12 O
had O
melatonin O
first O
. O
[]

To O
enhance O
the O
conditioning O
regimen O
's O
antileukemic O
effect O
, O
we O
decided O
to O
supplant O
Flu O
with O
clofarabine O
( O
Clo O
) O
, O
and O
assayed O
the O
interactions O
of O
these O
nucleoside O
analogs O
alone O
and O
in O
combination O
with O
Bu O
in O
Bu-resistant O
human O
cell O
lines O
in O
vitro O
. O
[]

A O
total O
of O
824 O
women O
were O
randomized O
to O
ETT O
or O
exercise O
MPI O
. O
[]

BACKGROUND O
This O
randomized O
trial O
was O
conducted O
to O
compare O
the O
efficacy O
and O
side O
effects O
of O
intravesical O
mitoxantrone O
instillation O
with O
those O
of O
doxorubicin O
in O
superficial O
bladder O
cancer O
following O
transurethral O
resection O
. O
[]

METHODS O
A O
randomized O
controlled O
trial O
, O
was O
performed O
on O
60 O
patients O
undergoing O
PCNL O
. O
[]

The O
X3 O
condition O
yielded O
the O
greatest O
accrual O
( O
43.2 O
% O
) O
compared O
to O
X1 O
( O
30.9 O
% O
) O
and O
X2 O
( O
29.9 O
% O
; O
p O
< O
0.05 O
) O
. O
[]

But O
only O
17 O
eyes B-outcome ['Physiological-Clinical']
were O
saved O
in O
control O
group O
with O
the O
cure O
rate O
of O
43.59 O
% O
, O
indicating O
significant O
difference O
of O
the O
cure B-outcome ['Physiological-Clinical']
rate O
between O
the O
two O
groups O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PARTICIPANTS O
Twenty O
patients O
with O
hemiplegia O
after O
a O
single-hemisphere O
stroke O
that O
occurred O
at O
least O
12 O
months O
before O
the O
study O
. O
[]

Participants O
with O
a O
CVD O
relative O
risk O
of O
1.5 O
assessed O
by O
risk O
scores O
were O
randomly O
assigned O
to O
one O
of O
the O
3 O
groups O
: O
habitual O
( O
control O
, O
CT O
) O
, O
high-flavonoid O
( O
HF O
) O
or O
low-flavonoid O
( O
LF O
) O
diets O
. O
[]

RESULTS O
Eight O
of O
13 O
subjects O
improved O
in O
two O
or O
more O
settings O
. O
[]

Treatment O
was O
provided O
once O
a O
week O
( O
15 O
minutes O
) O
for O
10 O
weeks O
. O
[]

Six O
or O
more O
cycles O
of O
cisplatin O
could O
be O
delivered O
in O
63 O
% O
( O
41/65 O
) O
, O
which O
resulted O
in O
RTOG O
grade O
3 O
neutropenia B-outcome ['Physiological-Clinical']
of O
3 O
% O
. O
['Physiological-Clinical']

BACKGROUND O
Recombinant O
allergens O
offer O
a O
tool O
for O
improving O
specific O
immunotherapy O
( O
SIT O
) O
. O
[]

The O
overall O
mean O
number O
of O
daily B-outcome ['Life-Impact']
doses I-outcome ['Life-Impact']
of O
supplemental O
analgesics B-outcome ['Resource-use']
was O
significantly O
less O
in O
the O
HI2 O
group O
( O
0.24+/-0.49 O
) O
than O
in O
the O
HI1 O
group O
( O
0.34+/-0.58 O
) O
( O
P O
= O
0.021 O
) O
or O
CA O
group O
( O
0.49+/-0.85 O
) O
( O
P O
= O
0.010 O
) O
. O
['Life-Impact', 'Resource-use']

Two-way O
analysis O
of O
variance O
and O
Fisher O
's O
least O
significant O
difference O
test O
( O
P O
< O
.05 O
) O
were O
used O
to O
determine O
whether O
significant O
differences O
existed O
as O
a O
function O
of O
treatment O
type O
or O
time O
. O
[]

We O
determined O
counseling O
by O
post-visit O
patient O
interviews O
. O
[]

Effect O
of O
simvastatin O
and O
fenofibrate O
on O
endothelium O
in O
Type O
2 O
diabetes O
. O
[]

The O
number O
of O
omission B-outcome ['Life-Impact']
['Life-Impact']

Simple B-outcome ['Physiological-Clinical']
endometrial I-outcome ['Physiological-Clinical']
hyperplasia I-outcome ['Physiological-Clinical']
occurred O
in O
28 O
% O
of O
all O
subjects O
, O
with O
no O
difference O
between O
groups O
. O
['Physiological-Clinical']

CONCLUSIONS O
This O
study O
indicated O
that O
flecainide O
exerted O
a O
significant O
dose-dependent O
effect O
on O
the O
prevention O
of O
symptomatic O
PAF/PAFL O
recurrence O
and O
showed O
that O
there O
was O
no O
inter-ethnic O
difference O
in O
the O
clinical O
effect O
of O
flecainide O
in O
patients O
with O
PAF/PAFL O
. O
[]

The O
median O
survival O
time O
was O
4.7 O
months O
for O
radiotherapy O
, O
4.7 O
months O
for O
cyclophosphamide O
and O
1.7 O
months O
for O
placebo O
. O
[]

The O
low-SF O
grating O
was O
a O
more O
effective O
adapter O
than O
the O
high-SF O
grating O
, O
incompatible O
with O
the O
FRF O
model O
. O
[]

Baseline O
and O
post-TMS/or O
WTL O
EEG B-outcome ['Resource-use']
was O
collected O
using O
128 O
channel O
EEG O
system O
. O
['Resource-use']

MEASUREMENTS O
AND O
RESULTS O
Seventeen O
patients O
had O
Cheyne-Stokes O
apneas O
( O
index O
> O
5/h O
) O
and O
23 O
patients O
had O
hypopneas B-outcome ['Physiological-Clinical']
( O
index O
> O
5/h O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Study O
4 O
found O
that O
children O
with O
PDDs O
( O
n O
= O
20 O
) O
had O
significantly O
lower O
TOM O
test O
scores O
than O
children O
with O
other O
psychiatric O
disorders O
( O
e.g. O
, O
children O
with O
Attention-deficit O
Hyperactivity O
Disorder O
; O
n O
= O
32 O
) O
, O
a O
finding O
that O
underlines O
the O
discriminant O
validity O
of O
the O
TOM O
test O
. O
[]

In O
a O
double-blind O
, O
placebo-controlled O
study O
, O
patients O
with O
naturally O
occurring O
common O
colds O
of O
less O
than O
or O
equal O
to O
48 O
h O
duration O
were O
randomly O
assigned O
to O
receive O
nasal O
sprays O
of O
recombinant O
alfa-2b O
interferon O
at O
10 O
or O
20 O
MU/day O
or O
placebo O
four O
times O
per O
day O
for O
5 O
days O
. O
[]

Eighteen O
variables O
contributed O
independent O
prognostic O
information O
, O
but O
a O
reduced O
model O
using O
only O
8 O
items O
( O
age O
, O
previous O
heart O
failure O
hospitalization O
, O
peripheral O
edema O
, O
systolic O
blood O
pressure O
, O
serum O
sodium O
, O
urea O
, O
creatinine O
, O
and O
albumin O
) O
performed O
similarly O
. O
[]

Patients O
completed O
self-rating O
scales O
on O
pain O
, O
global B-outcome ['Physiological-Clinical']
health B-outcome ['Physiological-Clinical']
, O
mood B-outcome ['Life-Impact']
, O
quality O
of O
life O
, O
coping B-outcome ['Life-Impact']
style I-outcome ['Life-Impact']
, O
health B-outcome ['Physiological-Clinical']
locus B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
control I-outcome ['Life-Impact']
, O
multidimensional B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
, O
spirituality O
, O
sense B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
coherence I-outcome ['Life-Impact']
, O
positive O
states B-outcome ['Life-Impact']
of O
mind B-outcome ['Life-Impact']
, O
and O
social B-outcome ['Life-Impact']
desirability B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

All O
patients O
showed O
a O
mild-to-moderate O
decrease O
in O
baseline O
forced B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Cyanoacrylate B-outcome ['Resource-use']
, O
tetradecyl B-outcome ['Resource-use']
sulfate I-outcome ['Resource-use']
, O
and O
polidocanol B-outcome ['Resource-use']
were O
the O
most O
effective O
agents O
for O
reducing O
gastric O
variceal O
size O
. O
['Resource-use', 'Resource-use', 'Resource-use']

We O
performed O
a O
pilot O
, O
prospective O
, O
open O
label O
, O
randomized O
design O
clinical O
trial O
to O
evaluate O
the O
effects O
of O
the O
angiotensin O
II O
receptor O
blocker O
valsartan O
( O
160 O
mg O
once O
a O
day O
) O
on O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
hypertensive O
African O
Americans O
( O
n O
= O
88 O
) O
on O
a O
low O
salt O
( O
100 O
mEq O
Na+/day O
) O
for O
2 O
weeks O
and O
the O
same O
diet O
supplemented O
by O
100 O
mEq O
Na+ O
for O
4 O
weeks O
. O
['Physiological-Clinical']

Although O
the O
number O
of O
patients O
was O
too O
small O
for O
meaningful O
statistical O
analysis O
of O
outcome O
, O
diode O
laser O
peripheral O
retinal O
ablation O
appeared O
to O
be O
as O
effective O
as O
cryotherapy O
for O
the O
treatment O
of O
threshold O
ROP O
. O
[]

gamma-Glutamyl O
hydrolase O
expression O
correlated O
with O
grade O
3/4 O
[]

We O
observed O
a O
substantial O
downward O
trend O
in O
antibiotic B-outcome ['Resource-use']
prescribing I-outcome ['Resource-use']
, O
even O
in O
the O
absence O
of O
intervention O
. O
['Resource-use']

Each O
of O
the O
patients O
had O
corrected O
anemia B-outcome ['Physiological-Clinical']
and O
well-being O
. O
['Physiological-Clinical']

RESULTS O
The O
intervention O
group O
had O
significantly O
less O
missed O
opportunities/vaccine B-outcome ['Life-Impact']
administration B-outcome ['Life-Impact']
errors I-outcome ['Life-Impact']
( O
11.4 O
% O
vs O
21.6 O
% O
) O
. O
['Life-Impact', 'Life-Impact']

Patients O
completed O
a O
symptom O
monitoring O
diary O
. O
[]

One O
hundred O
ten O
patients O
were O
randomized O
to O
3 O
different O
deep B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
prophylaxis I-outcome ['Physiological-Clinical']
groups O
. O
['Physiological-Clinical']

These O
effects O
of O
insulin O
were O
significantly O
more O
marked O
when O
insulin O
was O
delivered O
in O
a O
pulsatile O
rather O
than O
a O
continuous O
manner O
. O
[]

Sleep O
on O
no-exercise O
and O
exercise O
nights O
were O
assessed O
by O
polysomnography O
. O
[]

METHODS O
This O
is O
a O
cooperative O
, O
multicenter O
, O
retrospective O
review O
of O
832 O
patients O
stratified O
by O
CEAP O
classification O
. O
[]

An O
optimal O
starting O
dose O
of O
enalapril O
in O
such O
patients O
remains O
to O
be O
confirmed O
. O
[]

Lean B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
( O
MAMC O
or O
AMA B-outcome ['Physiological-Clinical']
) O
increased O
significantly O
in O
the O
highest O
hormonal O
dose O
groups O
( O
p O
= O
0.04 O
, O
NETE-6/12 O
; O
p O
= O
0.004 O
, O
NETE-8 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

treatment O
interaction O
was O
observed O
for O
Irritability O
( O
F O
( O
1.658 O
, O
63.021 O
) O
= O
13.580 O
, O
P O
< O
0.001 O
) O
, O
Lethargy/Social O
Withdrawal O
( O
F O
( O
1.948 O
, O
74.032 O
) O
= O
16.811 O
, O
P O
< O
0.001 O
) O
, O
and O
Stereotypic O
Behavior O
( O
F O
( O
1.742 O
, O
66.198 O
) O
= O
12.104 O
, O
P O
< O
0.001 O
) O
, O
but O
not O
for O
Hyperactivity/Noncompliance O
( O
F O
( O
2.564 O
, O
97.424 O
) O
= O
1.469 O
, O
P O
= O
0.232 O
) O
, O
and O
Inappropriate O
Speech O
subscales O
( O
F O
( O
1.607 O
, O
61.075 O
) O
= O
0.173 O
, O
P O
= O
0.794 O
) O
. O
[]

Time O
to O
regression O
to O
two O
segments O
of O
partial O
and O
complete O
sensory O
blockade O
was O
positively O
correlated O
( O
P O
less O
than O
0.05 O
) O
with O
increasing O
dose O
of O
bupivacaine O
in O
the O
solutions O
and O
ranged O
from O
84 O
min O
( O
partial O
) O
and O
70 O
min O
( O
complete O
) O
for O
lidocaine O
, O
to O
128 O
min O
( O
partial O
) O
and O
101 O
min O
( O
complete O
) O
for O
bupivacaine O
. O
[]

Clinical O
trial O
of O
tooth B-outcome ['Physiological-Clinical']
whitening I-outcome ['Physiological-Clinical']
with O
6 O
% O
hydrogen O
peroxide O
whitening O
strips O
and O
two O
whitening O
dentifrices O
. O
['Physiological-Clinical']

CONCLUSION O
Although O
the O
psychoeducational O
intervention O
did O
not O
result O
in O
changes O
in O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
, O
improvements O
in O
adaptive B-outcome ['Life-Impact']
coping I-outcome ['Life-Impact']
and O
indicators O
of O
psychological B-outcome ['Life-Impact']
growth I-outcome ['Life-Impact']
were O
found O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Improvement O
was O
evaluated O
in O
two O
settings O
-- O
preschool O
and O
home O
-- O
by O
teachers O
( O
blind O
to O
group O
) O
and O
parents O
. O
[]

The O
aim O
of O
this O
analysis O
was O
to O
determine O
the O
safety O
of O
a O
more O
rapid O
titration O
of O
rotigotine O
by O
assessing O
the O
tolerability O
of O
escalating O
transdermal O
doses O
of O
rotigotine O
given O
in O
2 O
different O
titration O
schemes O
. O
[]

Systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
in O
the O
intervention O
group O
were O
found O
by O
analysis O
of O
variance O
to O
be O
significantly O
lower O
( O
2.6-4.8 O
and O
2.2-3.0 O
mm O
Hg O
, O
respectively O
) O
than O
those O
in O
the O
control O
group O
during O
experimental O
period O
2 O
for O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
experimental O
period O
1 O
for O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
patient O
in O
group O
A O
, O
dye B-outcome ['Physiological-Clinical']
was I-outcome ['Physiological-Clinical']
present I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
trachea I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
bronchi I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Post-operative O
complications O
were O
also O
recorded O
and O
managed O
. O
[]

METHODS O
Eight-seven O
angina O
pectoris O
patients O
, O
mean O
age O
of O
57 O
+/- O
9 O
, O
82 O
white O
and O
79 O
male O
were O
evaluated O
in O
a O
randomized O
, O
double-blind O
trial O
of O
two O
groups O
of O
patients O
diltiazem O
and O
placebo O
, O
3 O
to O
4 O
tablets O
a O
day O
( O
diltiazem O
180 O
to O
240 O
mg O
daily O
) O
. O
[]

Diltiazem O
also O
improved O
exercise O
test O
end O
points O
but O
to O
a O
lesser O
extent O
. O
[]

All O
groups O
were O
similar O
in O
each O
parameter O
at O
the O
start O
. O
[]

Fusidic O
acid O
prophylaxis O
before O
cataract O
surgery O
: O
patient O
self-administration O
. O
[]

Concurrently O
, O
they O
were O
given O
a O
post-hypnotic O
suggestion O
, O
which O
attempted O
to O
aid O
recognition O
and O
performance O
on O
a O
test O
immediately O
following O
the O
hypnosis O
session O
. O
[]

Patients O
with O
two O
or O
more O
adenomas O
at O
the O
first O
examination O
were O
more O
likely O
than O
patients O
with O
no O
or O
one O
adenoma O
detected O
at O
the O
first O
examination O
to O
have O
one O
or O
more O
adenomas B-outcome ['Physiological-Clinical']
at O
the O
second O
examination O
( O
odds O
ratio O
, O
3.3 O
; O
95 O
% O
confidence O
interval O
, O
1.69-6.46 O
) O
. O
['Physiological-Clinical']

Metabolic O
and O
hormonal O
responses O
to O
induced O
hypotension O
for O
middle O
ear O
surgery O
. O
[]

28.3 O
% O
; O
P O
< O
0.001 O
) O
following O
strength O
training O
, O
but O
the O
maximal O
H B-outcome ['Physiological-Clinical']
wave-to-maximal I-outcome ['Physiological-Clinical']
M I-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
( O
H B-outcome ['Physiological-Clinical']
( O
max O
) O
/M O
( O
max O
) O
) O
ratio O
remained O
unchanged O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Medication O
was O
administered O
in O
a O
double-blind O
, O
placebo-controlled O
cross-over O
study O
. O
[]

Adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
occurred O
in O
a O
comparable O
proportion O
of O
patients O
taking O
sildenafil O
and O
placebo O
, O
and O
none O
of O
the O
patients O
needed O
to O
discontinue O
therapy O
. O
['Adverse-effects']

In O
the O
NR O
group O
, O
patients O
were O
postoperatively O
educated O
in O
the O
possibility O
of O
mandibular B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
and O
were O
given O
an O
emphasis O
on O
the O
necessity O
of O
limiting B-outcome ['Physiological-Clinical']
mastication I-outcome ['Physiological-Clinical']
to O
a O
soft O
diet O
for O
4 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
examination O
and O
treatment O
of O
64 O
patients O
have O
shown O
that O
inclusion O
of O
complex O
antioxidant O
cytoflavin O
in O
intensive O
therapy O
at O
the O
postoperative O
period O
of O
diffuse O
peritonitis O
allows O
the O
hypoxia O
degree O
to O
be O
decreased O
that O
in O
its O
turn O
results O
in O
quicker O
recovery B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
antioxidant I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
decreased O
activity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
peroxidation I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
endotoxicosis I-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical', 'Physiological-Clinical']

While O
behavior O
training O
was O
applied O
to O
the O
control O
group O
when O
acupuncture O
treatment O
was O
completely O
accomplished O
. O
[]

DNA O
was O
extracted O
, O
and O
gene-specific O
PCR O
was O
performed O
. O
[]

A O
randomized O
study O
. O
[]

Randomised O
trial O
of O
laparoscopic O
versus O
open O
cholecystectomy O
for O
acute O
and O
gangrenous O
cholecystitis O
. O
[]

This O
risk O
was O
also O
significantly O
reduced O
in O
subgroups O
consisting O
of O
women O
and O
patients O
of O
both O
sexes O
aged O
> O
or O
= O
60 O
years O
. O
[]

CONCLUSIONS O
Steri-Strip O
S O
permits O
faster O
wound B-outcome ['Physiological-Clinical']
closure B-outcome ['Physiological-Clinical']
than O
suture O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
assess O
a O
stage-of-change O
oriented O
smoking O
cessation O
intervention O
for O
infertile O
and O
pregnant O
women O
, O
compared O
with O
standard O
of O
care O
. O
[]

It O
was O
anticipated O
that O
the O
relationship O
between O
milk B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
and O
ODR O
was O
unlikely O
to O
be O
linear O
, O
so O
fractional O
polynomials O
were O
applied O
to O
the O
continuous O
ODR B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

An O
independent O
test O
set O
was O
derived O
from O
282 O
pretreatment O
specimens O
from O
CLL8 O
, O
a O
study O
of O
FC O
or O
R-FC O
in O
treatment-na?ve O
patients O
. O
[]

The O
GMRs B-outcome ['Physiological-Clinical']
were O
2.6- O
and O
2.9-fold O
, O
respectively O
. O
['Physiological-Clinical']

At O
surgery O
, O
patients O
were O
randomly O
allocated O
to O
three O
groups O
: O
( O
group O
I O
) O
; O
patients O
receiving O
an O
arginine-enhanced O
formula O
( O
group O
II O
) O
; O
patients O
receiving O
a O
standard O
polymeric O
formula O
, O
and O
( O
group O
III O
) O
patients O
receiving O
an O
arginine O
, O
RNA O
and O
omega-3 O
fatty O
acids O
enhanced O
formula O
, O
in O
an O
isonitrogenous O
way O
. O
[]

In O
total O
, O
374 O
patients O
using O
opioid O
PCA O
, O
but O
otherwise O
considered O
to O
be O
low O
risk O
for O
PONV O
, O
were O
randomly O
allocated O
to O
ondansetron O
( O
4 O
mg O
given O
intravenously O
and O
16 O
mg O
added O
into O
the O
PCA O
pump O
) O
or O
saline O
( O
control O
group O
) O
. O
[]

Importantly O
, O
administration O
of O
propranolol O
attenuated B-outcome ['Life-Impact']
this I-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
, O
with O
the O
ASD O
group O
performing B-outcome ['Life-Impact']
significantly O
better O
in O
the O
propranolol O
condition O
than O
the O
placebo O
condition O
. O
['Life-Impact', 'Life-Impact']

A O
predefined O
, O
modified O
ITT O
population O
( O
ie O
, O
those O
in O
the O
ITT O
population O
with O
baseline O
HAM-D?? O
?20 O
) O
was O
also O
analyzed O
. O
[]

BACKGROUND O
Dopexamine O
has O
been O
shown O
to O
reduce O
both O
mortality B-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
in O
major O
surgery O
when O
it O
is O
used O
as O
part O
of O
a O
protocol O
to O
increase O
oxygen O
delivery O
in O
the O
perioperative O
period O
. O
['Mortality', 'Physiological-Clinical']

Cophenylcaine O
spray O
vs. O
placebo O
in O
flexible O
nasendoscopy O
: O
a O
prospective O
double-blind O
randomised O
controlled O
trial O
. O
[]

RESULTS O
From O
December O
2007 O
to O
October O
2008 O
, O
54 O
patients O
were O
assessed O
, O
27 O
of O
whom O
were O
randomized O
to O
each O
arm O
. O
[]

At O
the O
last O
follow-up O
( O
average O
, O
38.4 O
months O
) O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
terms O
of O
knee B-outcome ['Physiological-Clinical']
scores O
, O
patient B-outcome ['Physiological-Clinical']
self-assessment I-outcome ['Physiological-Clinical']
, O
and O
radiographic B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Single O
blinded O
prospective O
randomised O
controlled O
trial O
and O
single O
blinded O
randomised O
crossover O
trial O
. O
[]

Of O
the O
26 O
boys O
who O
did O
not O
undergo O
biopsy O
, O
21 O
( O
80.8 O
% O
) O
remained O
in O
CCR O
; O
two O
( O
7.7 O
% O
) O
developed O
isolated B-outcome ['Physiological-Clinical']
overt I-outcome ['Physiological-Clinical']
TL I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Pharmacokinetic O
parameters O
were O
based O
on O
an O
open O
two-compartment O
model O
and O
a O
noncompartmental O
technique O
. O
[]

Treatment O
was O
started O
within O
14 O
days O
of O
surgery O
in O
94 O
% O
of O
patients O
. O
[]

Group O
Sham O
( O
Sham O
) O
, O
Group O
CCI?Normal O
Saline O
( O
NS O
) O
, O
Group O
CCI?LV/hIL-10 O
( O
LV/hIL-10 O
) O
, O
and O
Group O
CCI?LV/control O
( O
vector O
) O
. O
[]

This O
result O
led O
to O
the O
early O
termination O
of O
the O
trial O
. O
[]

Children O
in O
the O
riluzole O
group O
experienced O
significantly O
more O
increases O
in O
their O
appetite O
and O
bodyweight O
than O
children O
in O
the O
placebo O
group O
by O
the O
end O
of O
the O
study O
. O
[]

OBJECTIVE O
To O
compare O
the O
insertion O
characteristics O
and O
rate O
of O
complications O
between O
25-gauge O
Quincke O
and O
24-gauge O
Gertie O
Marx O
needles O
. O
[]

If O
increasing O
GABA O
concentrations O
in O
the O
CNS O
are O
critical O
for O
the O
treatment O
of O
nystagmus O
, O
then O
a O
selective O
GABAergic O
drug O
should O
be O
highly O
successful O
. O
[]

Of O
39 O
patients O
evaluable O
for O
efficacy O
, O
31 O
have O
experienced O
relapse B-outcome ['Physiological-Clinical']
( O
79 O
% O
) O
, O
and O
15 O
have O
died B-outcome ['Mortality']
( O
38 O
% O
) O
. O
['Physiological-Clinical', 'Mortality']

A O
cluster O
randomized O
controlled O
trial O
was O
conducted O
to O
evaluate O
the O
effectiveness O
of O
household B-outcome ['Life-Impact']
education I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
local I-outcome ['Life-Impact']
media I-outcome ['Life-Impact']
in O
the O
increasing O
demand O
for O
fee-based O
As O
testing O
. O
['Life-Impact']

METHODS O
Among O
104 O
cervical O
cancer O
patients O
selected O
for O
the O
present O
study O
, O
54 O
and O
50 O
patients O
were O
treated O
with O
chemo- O
and O
radiotherapy O
respectively O
. O
[]

There O
was O
no O
difference O
in O
any O
other O
response O
biomarker B-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
up O
to O
36 O
months O
, O
nor O
was O
any O
biomarker O
able O
to O
predict O
recurrence O
risk O
. O
['Physiological-Clinical']

Subjectively O
, O
the O
children O
enjoyed O
whole O
body O
vibration O
which O
was O
easy B-outcome ['Life-Impact']
to O
integrate O
into O
the O
behavioural O
programme O
. O
['Life-Impact']

INTRODUCTION O
Increased O
reliance O
on O
bulbospinal O
motor O
systems O
has O
been O
implicated O
in O
individuals O
with O
chronic O
stroke O
during O
maximum O
voluntary O
arm O
joint O
torque O
generation O
. O
[]

In O
74 O
out O
of O
95 O
patients O
( O
78 O
% O
) O
the O
diagnosis O
was O
placed O
with O
Jumbo O
forcep O
while O
the O
smaller O
forcep O
was O
diagnostic O
in O
62 O
out O
of O
95 O
patients O
( O
65 O
% O
) O
. O
[]

RESULTS O
Follow-up O
indicated O
minimal O
change O
from O
baseline O
in O
each O
initial O
treatment O
group O
's O
average O
MD B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Sedation B-outcome ['Physiological-Clinical']
was O
evaluated O
using O
a O
verbal B-outcome ['Life-Impact']
rating O
score O
( O
VRS O
) O
from O
0 O
to O
10 O
and O
bispectral B-outcome ['Physiological-Clinical']
index O
( O
BIS B-outcome ['Physiological-Clinical']
) O
of O
the O
EEG B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

We O
investigated O
whether O
a O
selective O
angiotensin O
II O
receptor O
blocker O
( O
ARB O
) O
would O
have O
a O
regressive O
effect O
on O
left O
ventricular O
hypertrophy O
( O
LVH O
) O
in O
patients O
on O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
CAPD O
) O
. O
[]

The O
evaluation O
of O
clinical O
efficacy O
was O
based O
on O
the O
change O
in O
the O
number O
of O
facial B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
from O
baseline O
to O
the O
end O
of O
treatment O
, O
and O
noninferiority O
was O
defined O
by O
the O
upper O
95 O
% O
confidence O
limit O
of O
the O
difference O
between O
two O
treatments O
being O
less O
than O
9 O
. O
['Physiological-Clinical']

A O
double-blind O
controlled O
trial O
of O
12 O
months O
' O
treatment O
with O
( O
+ O
) O
-cyanidanol-3 O
was O
carried O
out O
in O
26 O
patients O
with O
chronic O
hepatitis O
B O
liver O
disease O
. O
[]

as O
monotherapy O
for O
24 O
weeks O
. O
[]

Immunological B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
did O
not O
correlate O
with O
response O
status O
. O
['Physiological-Clinical']

A O
comparative O
clinical O
trial O
in O
adults O
. O
[]

Ninety O
two O
normal O
birthweight O
infants O
aged O
6 O
months O
entered O
a O
double O
blind O
controlled O
trial O
which O
compared O
a O
follow O
on O
formula O
milk O
with O
no O
added O
iron O
against O
the O
same O
formula O
milk O
containing O
1.2 O
mg O
of O
iron O
per O
100 O
ml O
. O
[]

Prophylactic O
use O
of O
amifostine O
to O
prevent O
radiochemotherapy-induced O
mucositis O
and O
xerostomia O
in O
head-and-neck O
cancer O
. O
[]

Difference O
between O
the O
two O
treatment O
arms O
was O
significant O
as O
the O
group O
that O
received O
memantine O
had O
greater O
reduction O
in O
ABC-C O
subscale O
scores O
for O
irritability O
, O
stereotypic O
behaviour O
and O
hyperactivity O
. O
[]

Participants O
' O
verbal O
production O
including O
semantics O
, O
phonology O
, O
pragmatics O
, O
and O
prosody O
was O
measured O
by O
an O
experimenter O
designed O
verbal O
production O
evaluation O
scale O
. O
[]

Treatments O
of O
preterm O
premature O
rupture O
of O
the O
membranes O
: O
a O
meta-analysis O
. O
[]

Aripiprazole O
in O
the O
treatment O
of O
irritability B-outcome ['Life-Impact']
in O
children O
and O
adolescents O
with O
autistic O
disorder O
. O
['Life-Impact']

BACKGROUND O
Minority O
populations O
in O
the O
United O
States O
, O
especially O
blacks O
and O
Hispanics O
, O
are O
generally O
underrepresented O
among O
participants O
in O
clinical O
trials O
. O
[]

The O
'number O
needed O
to O
telephone O
' O
was O
17 O
. O
[]

RESULTS O
The O
mean O
follow-up O
for O
the O
overall O
cohort O
was O
27 O
months O
. O
[]

Regarding O
the O
accuracy O
, O
the O
paired O
t O
test O
indicated O
significant O
improvement O
only O
after O
anodal O
transcranial O
direct O
current O
stimulation O
without O
a O
significant O
interaction O
effect O
between O
the O
two O
transcranial O
direct O
current O
stimulation O
types O
. O
[]

A O
set O
of O
five O
factors O
were O
found O
to O
consistently O
predict O
depression B-outcome ['Life-Impact']
at O
the O
following O
assessment O
. O
['Life-Impact']

33 O
% O
of O
these O
patients O
required O
YAG-laser O
capsulotomy O
. O
[]

OBJECTIVES O
To O
study O
the O
sympatholytic O
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
lowering I-outcome ['Physiological-Clinical']
activity O
of O
the O
imidazoline O
binding O
agent O
rilmenidine O
at O
rest O
and O
during O
reflex O
sympathetic O
activation O
. O
['Physiological-Clinical']

DESIGN/SETTING O
Randomized O
clinical O
trial/tertiary-care O
hospital O
. O
[]

10.3 O
U/L O
vs. O
78.1 O
? O
[]

The O
present O
report O
prospectively O
evaluated O
whether O
AS O
was O
predictive O
of O
later O
changes O
in O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
after O
controlling O
for O
potential O
confounding O
factors O
. O
['Life-Impact']

Twelve O
dams O
received O
dexamethasone O
( O
2 O
mg/dose O
) O
72 O
, O
48 O
, O
and O
24 O
h O
before O
abdominal O
delivery O
at O
135 O
+/- O
1 O
days O
of O
gestation O
. O
[]

There O
was O
no O
difference O
in O
the O
frequency O
of O
TNM B-outcome ['Physiological-Clinical']
stages I-outcome ['Physiological-Clinical']
I I-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
in O
both O
treatment O
arms O
: O
15/27 O
versus O
15/29 O
. O
['Physiological-Clinical']

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
compare O
the O
longitudinal B-outcome ['Physiological-Clinical']
quality O
of O
life O
( O
QoL O
) O
between O
LV5FU2-irinotecan O
and O
LV5FU2 O
alone O
or O
LV5FU2-cisplatin O
in O
a O
randomized O
Phase O
II O
trial O
in O
patients O
with O
metastatic O
gastric O
adenocarcinoma O
. O
['Physiological-Clinical']

Intensive O
treatment O
should O
be O
started O
as O
soon O
as O
is O
safely O
possible O
after O
the O
onset O
of O
type O
1 O
diabetes O
mellitus O
and O
maintained O
thereafter O
, O
aiming O
for O
a O
practicable O
[]

BACKGROUND O
Non-adherence O
in O
hypertension O
is O
a O
global O
problem O
and O
promoting O
adherence O
is O
necessary O
to O
decrease O
cardiovascular O
mortality O
. O
[]

METHOD O
Ten O
healthy O
volunteers O
were O
enrolled O
into O
an O
open-label O
, O
randomised O
, O
intra-individual O
comparison O
pilot O
study O
. O
[]

Among O
the O
cases O
treated O
with O
oxibendazole O
, O
the O
egg B-outcome ['Physiological-Clinical']
negative O
conversion B-outcome ['Physiological-Clinical']
rates O
of I-outcome ['Physiological-Clinical']
hookworm I-outcome ['Physiological-Clinical']
, O
Ascaris I-outcome ['Physiological-Clinical']
and O
Trichuris B-outcome ['Physiological-Clinical']
were O
70.3-80.6 O
% O
, O
92.5-97.8 O
and O
67.0-71.0 O
% O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Caffeine O
led O
to O
improved O
speed B-outcome ['Life-Impact']
and O
accuracy O
on O
cognitive B-outcome ['Life-Impact']
tasks O
and O
increased O
alertness B-outcome ['Physiological-Clinical']
when O
compared O
with O
chewing O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Feline O
leukaemia O
virus O
( O
FeLV O
) O
infection O
is O
still O
one O
of O
the O
leading O
causes O
of O
infection-related O
deaths O
in O
domestic O
cats O
. O
[]

Teaching O
young O
nonverbal O
children O
with O
autism O
useful O
speech O
: O
a O
pilot O
study O
of O
the O
Denver O
Model O
and O
PROMPT O
interventions O
. O
[]

Eligible O
patients O
had O
clinical O
stage O
II-III O
( O
> O
or O
= O
T2 O
and/or O
> O
or O
= O
N1 O
) O
newly O
diagnosed O
breast O
cancer O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
of O
0 O
or O
1 O
, O
and O
normal O
cardiac O
, O
renal O
, O
and O
liver O
function O
. O
[]

METHOD O
The O
study O
included O
a O
randomized O
, O
3-month O
, O
omega O
3/6 O
placebo-controlled O
, O
one-way O
crossover O
trial O
with O
75 O
children O
and O
adolescents O
( O
8-18 O
years O
) O
, O
followed O
by O
3 O
months O
with O
omega O
3/6 O
for O
all O
. O
[]

AEs O
were O
self-reported O
on O
a O
4-point O
VRS O
( O
0 O
= O
absent O
; O
1 O
= O
mild O
; O
2 O
= O
moderate O
; O
and O
3 O
= O
severe O
) O
. O
[]

Following O
a O
total O
of O
70 O
cycles O
, O
70 O
% O
of O
r-hFSH/r-hLH O
treated O
patients O
met O
the O
primary O
endpoint O
vs O
88 O
% O
in O
hMG-HP O
group O
( O
p=0.11 O
) O
. O
[]

It O
has O
been O
shown O
, O
however O
that O
pulsatile O
GHRH O
administration O
increases O
both O
slow-wave B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SWS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
GH B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Factors O
with O
a O
P O
value O
of O
< O
or O
=0.25 O
within O
a O
cycle O
were O
included O
in O
a O
generalized O
estimating O
equations O
regression O
model O
. O
[]

normal O
girls O
) O
, O
chronological B-outcome ['Physiological-Clinical']
age O
at O
start O
of O
treatment B-outcome ['Resource-use']
, O
and O
HV B-outcome ['Physiological-Clinical']
in O
the O
first O
year O
of O
GH O
treatment O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Other O
postoperative O
side O
effects O
, O
including O
sedation B-outcome ['Physiological-Clinical']
, O
confusion B-outcome ['Physiological-Clinical']
, O
and O
pruritus B-outcome ['Physiological-Clinical']
, O
were O
similar O
in O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
The O
objective O
of O
this O
secondary O
analysis O
was O
to O
examine O
the O
relationships O
between O
a O
reduction O
in O
psychological O
distress O
and O
long-term O
cardiac O
and O
psychological O
outcomes O
in O
post-myocardial O
infarction O
patients O
who O
participated O
in O
a O
randomized O
trial O
of O
home-based O
psychosocial O
nursing O
interventions O
( O
the O
Montreal O
Heart O
Attack O
Readjustment O
Trial O
[ O
M-HART O
] O
) O
. O
[]

Analysis O
of O
paired O
samples O
obtained O
from O
the O
same O
patients O
showed O
that O
acute B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
gastritis I-outcome ['Physiological-Clinical']
decreased O
in O
both O
the O
antrum O
and O
corpus O
after O
H. O
pylori O
eradication O
( O
P O
< O
0.001 O
) O
and O
activity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
IM I-outcome ['Physiological-Clinical']
decreased O
in O
antrum O
( O
P O
= O
0.014 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
differences O
in O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
were O
analyzed O
with O
the O
paired O
t O
test O
. O
['Physiological-Clinical']

At O
this O
writing O
, O
172 O
infants O
had O
been O
examined O
3 O
months O
after O
randomization O
. O
[]

In O
patients O
without O
risk O
factors O
for O
bleeding O
, O
the O
intermittent O
administration O
of O
heparin O
in O
the O
higher O
dose O
is O
preferable O
because O
of O
fewer O
recurrences O
and O
no O
increase O
in O
hemorrhagic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Anthocyanins O
and O
phenolic O
acids O
from O
purple O
carrots O
are O
effective O
at O
reversing O
inflammation O
and O
metabolic O
alterations O
in O
animal O
models O
, O
potentially O
through O
inhibition O
of O
inflammatory O
pathways O
. O
[]

METHODOLOGY/PRINCIPAL O
FINDINGS O
A O
cost-effectiveness O
modelling O
study O
using O
data O
collected O
between O
February O
2005 O
and O
November O
2007 O
from O
a O
cluster-randomised O
trial O
that O
compared O
Telephone O
Counselling O
with O
a O
Usual O
Care O
( O
brief O
intervention O
) O
alternative O
. O
[]

Reducing O
polycystic B-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
ADPKD O
: O
effects O
of O
somatostatin O
analogue O
octreotide O
. O
['Physiological-Clinical']

This O
study O
was O
performed O
to O
compare O
efficacy O
and O
safety O
of O
the O
two O
products O
. O
[]

Effect O
of O
ranitidine O
and O
amoxicillin O
plus O
metronidazole O
on O
the O
eradication O
of O
Helicobacter O
pylori O
and O
the O
recurrence O
of O
duodenal O
ulcer O
. O
[]

CONCLUSION O
The O
use O
of O
a O
modified O
prolate O
intraocular O
lens O
during O
cataract O
surgery O
has O
the O
potential O
to O
improve O
contrast O
[]

CONCLUSION O
There O
is O
tentative O
indication O
that O
minimally-invasive O
surgery O
plus O
rtPA O
shows O
greater B-outcome ['Physiological-Clinical']
clot I-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
than O
traditional O
medical O
management O
. O
['Physiological-Clinical']

COMP O
is O
an O
excellent O
treatment O
for O
patients O
with O
localized O
disease O
of O
nonlymphoblastic O
type O
, O
but O
the O
relative O
value O
of O
the O
two O
regimens O
for O
patients O
with O
localized O
lymphoblastic O
disease O
is O
uncertain O
. O
[]

METHOD O
Selected O
Positive O
and O
Negative O
Syndrome O
Scale O
( O
PANSS O
) O
subscales O
and O
the O
Simpson-Angus O
scale O
were O
tested O
for O
validity O
. O
[]

The O
incidence O
of O
degeneration B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
squamous I-outcome ['Physiological-Clinical']
epithelium I-outcome ['Physiological-Clinical']
adjacent I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
chemotherapy O
group O
( O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

Hepatorenal O
syndrome O
. O
[]

Implant O
threshold O
( O
chronaxie O
= O
0.413 O
+/- O
0.280 O
ms O
, O
rheobase O
= O
0.264 O
+/- O
0.099 O
V O
) O
, O
signal O
amplitude O
( O
13.45 O
+/- O
5.87 O
mV O
) O
, O
and O
slew O
rate O
( O
2.05 O
+/- O
1.38 O
V/s O
) O
reveal O
no O
significant O
differences O
. O
[]

Recommendations O
for O
implementing O
stereotactic O
radiotherapy O
in O
peripheral O
stage O
IA O
non-small O
cell O
lung O
cancer O
: O
report O
from O
the O
Quality O
Assurance O
Working O
Party O
of O
the O
randomised O
phase O
III O
ROSEL O
study O
. O
[]

We O
investigated O
the O
relationship O
of O
PlGF O
with O
cardiovascular O
outcomes O
in O
a O
large O
cohort O
of O
patients O
presenting O
across O
the O
spectrum O
of O
ACS O
. O
[]

Copper-catalyzed O
oxidation O
of O
LDL O
was O
monitored O
by O
measuring O
the O
formation O
of O
conjugated O
dienes O
and O
lipid O
peroxides O
over O
an O
8-hour O
time O
course O
at O
baseline O
and O
again O
after O
8 O
weeks O
. O
[]

RESULTS O
Baseline O
systolic O
BP O
and O
GFR O
values O
were O
not O
different O
between O
groups O
. O
[]

All O
5 O
horses O
showed O
radiographic B-outcome ['Physiological-Clinical']
evidence I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bony I-outcome ['Physiological-Clinical']
fusion I-outcome ['Physiological-Clinical']
, O
however O
, O
no O
fusion O
was O
present O
when O
injected O
joints O
were O
examined O
on O
postmortem O
examination O
. O
['Physiological-Clinical']

There O
were O
no O
differences O
between O
the O
eradication B-outcome ['Physiological-Clinical']
of O
both O
therapies O
in O
both O
the O
antrum O
and O
gastric O
body O
samples O
( O
over O
80 O
% O
eradication O
) O
, O
allowing O
the O
results O
to O
be O
classified O
as O
satisfactory O
. O
['Physiological-Clinical']

In O
years O
1 O
and O
2 O
, O
the O
mean O
postvaccination O
strain-specific O
to O
total O
IgA O
ratio O
was O
3.1-fold O
( O
P O
< O
0.01 O
) O
and O
2.0-fold O
( O
P O
< O
0.03 O
) O
higher O
among O
LAIV O
recipients O
with O
no O
evidence O
of O
culture-confirmed O
influenza O
illness O
compared O
with O
LAIV O
recipients O
who O
developed O
culture-confirmed O
influenza O
illness O
; O
a O
similar O
and O
consistent O
trend O
was O
observed O
for O
each O
individual O
study O
and O
type/subtype O
. O
[]

Gastric O
dysrhythmia O
in O
infants O
with O
gastrointestinal O
diseases O
measured O
by O
epigastric O
impedance O
. O
[]

Serial O
hemodynamic O
parameters O
and O
blood O
samples O
were O
obtained O
after O
surgery O
. O
[]

Reactivations B-outcome ['Physiological-Clinical']
in O
this O
group O
occurred O
in O
a O
cluster O
a O
mean O
( O
+/- O
SD O
) O
of O
9.5 O
+/- O
5 O
hours O
after O
the O
discontinuation O
of O
the O
study O
drug O
but O
were O
randomly O
distributed O
over O
the O
initial O
96 O
hours O
in O
the O
other O
three O
groups O
. O
['Physiological-Clinical']

antivenom O
. O
[]

Adverse O
events O
led O
to O
study O
drug O
discontinuation O
in O
17 O
IE O
patients O
( O
26.2 O
% O
) O
and O
28 O
DE O
patients O
( O
37.8 O
% O
) O
( O
NS O
) O
. O
[]

Moderate-intensity O
exercise O
training O
with O
elements O
of O
step O
aerobics O
in O
patients O
with O
severe O
chronic O
heart O
failure O
. O
[]

A O
two-filter O
model O
for O
frequency O
discrimination B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

EFS O
was O
similar O
with O
oral O
or O
IV O
6-mercaptopurine O
; O
however O
, O
patients O
assigned O
to O
IV O
6-mercaptopurine O
had O
decreased O
survival B-outcome ['Mortality']
after I-outcome ['Mortality']
relapse I-outcome ['Mortality']
. O
['Mortality']

Before O
surgery O
, O
a O
radial O
arterial O
cannula O
was O
placed O
and O
attached O
to O
an O
Edwards O
Lifesciences O
FloTrac/Vigileo O
system O
for O
measuring O
cardiac O
output O
. O
[]

Recent O
preclinical O
studies O
suggest O
utility O
for O
voltage-sensitive O
calcium O
channel O
blockers O
( O
VSCCBs O
) O
in O
the O
treatment O
of O
cocaine O
addiction O
. O
[]

Modified B-outcome ['Physiological-Clinical']
versions I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
Investigator I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
Patient I-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Improvement I-outcome ['Physiological-Clinical']
Scores O
were O
used O
. O
['Physiological-Clinical']

This O
concept O
was O
tested O
in O
21 O
obese O
subjects O
imperfectly O
controlled O
by O
20 O
mg O
of O
glyburide O
daily O
in O
a O
double O
masked O
, O
placebo-controlled O
, O
parallel O
design O
, O
16-week O
protocol O
. O
[]

A O
new O
social O
communication O
intervention O
for O
children O
with O
autism O
: O
pilot O
randomised O
controlled O
treatment O
study O
suggesting O
effectiveness O
. O
[]

After O
6 O
months O
, O
the O
original O
control O
group O
initiated O
CGM O
while O
the O
treatment O
group O
continued O
use O
of O
CGM O
for O
6 O
months O
. O
[]

The O
disease O
was O
in O
a O
stable O
phase O
, O
and O
none O
of O
the O
patients O
showed O
evidence O
of O
a O
decompensated O
liver O
function O
. O
[]

Anecortave O
acetate O
treatment O
for O
retinal O
angiomatous O
proliferation O
: O
a O
pilot O
study O
. O
[]

METHODS O
A O
cluster O
randomized O
field O
trial O
was O
conducted O
among O
2968 O
Bangladeshi O
rural O
children O
6-36 O
months O
old O
. O
[]

In O
addition O
, O
after O
s-NAC O
operation O
there O
was O
a O
significant O
inhibition O
of O
proliferative B-outcome ['Physiological-Clinical']
potency I-outcome ['Physiological-Clinical']
and O
an O
induction O
of O
apoptosis B-outcome ['Physiological-Clinical']
in O
Group O
FC O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Longitudinal O
models O
support O
baseline O
Cr B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
predictions O
for O
the O
change O
in O
Cr O
at O
24 O
hours O
, O
time O
as O
the O
determinant O
of O
Cr O
trajectory O
, O
and O
requisite O
monitoring O
. O
['Physiological-Clinical']

Larger O
sample O
follow-up O
studies O
are O
warranted O
. O
[]

Both O
women O
with O
a O
history O
of O
PMS O
and O
women O
without O
responded O
with O
more O
negative O
mood B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
with O
the O
lower O
dose O
of O
MPA O
. O
['Life-Impact']

MATERIALS O
AND O
METHODS O
A O
total O
of O
301 O
patients O
underwent O
transurethral O
resection O
of O
bladder O
tumors O
with O
white O
light O
or O
fluorescence O
diagnosis O
. O
[]

These O
can O
be O
compensated O
only O
partially O
by O
currently O
available O
SILS-designed O
instruments O
. O
[]

CONCLUSION O
Acupuncture O
combined O
with O
Yizhi O
Jiannao O
Granules O
has O
a O
significant O
therapeutic O
effect O
on O
Alzheimer O
's O
disease O
, O
which O
is O
better O
than O
that O
of O
Yizhi O
Jiannao O
Granules O
or O
Aricept O
. O
[]

There O
was O
also O
no O
significant O
difference O
in O
patient O
's O
and O
surgeon O
's O
assessment O
of O
their O
experience O
. O
[]

MEASUREMENTS O
Substrate B-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
was O
measured O
during O
a O
standardized O
36 O
h O
stay O
in O
the O
respiration O
chamber O
at O
the O
start O
of O
the O
study O
( O
0 O
months O
) O
, O
and O
at O
4 O
, O
10 O
and O
16 O
months O
. O
['Physiological-Clinical']

CONCLUSIONS/INTERPRETATION O
IIT O
appears O
to O
be O
associated O
with O
improvements O
in O
vascular B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
, O
independently O
of O
changes O
in O
HbA1c O
, O
suggesting O
that O
IIT O
may O
confer O
vascular O
protection O
in O
addition O
to O
improving O
glycaemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
trial O
was O
a O
randomized O
, O
parallel-group O
, O
double-blind O
, O
placebo-controlled O
trial O
in O
adult O
subjects O
with O
a O
history O
of O
moderate-severe O
grass O
pollen O
induced O
rhinoconjunctivitis O
inadequately O
controlled O
by O
symptomatic O
medications O
. O
[]

PURPOSE O
To O
compare O
the O
effectiveness O
of O
a O
computer-assisted O
instruction O
( O
CAI O
) O
-based O
intervention O
to O
a O
more O
traditional O
lecture-based O
intervention O
for O
influencing O
psychosocial O
correlates O
of O
human O
immunodeficiency O
virus O
( O
HIV O
) O
preventive O
behaviors O
. O
[]

New O
studies O
as O
well O
as O
further O
investigation O
of O
the O
subject O
are O
warranted O
. O
[]

The O
increasing O
level O
of O
scores O
of O
cognitive B-outcome ['Life-Impact']
understanding I-outcome ['Life-Impact']
and O
cognitive B-outcome ['Life-Impact']
expression I-outcome ['Life-Impact']
were O
all O
better O
than O
the O
control O
group O
( O
all O
P O
< O
0.05 O
) O
. O
['Life-Impact']

METHOD O
Eighty-five O
children O
with O
autism O
without O
other O
medical O
conditions O
and O
not O
taking O
other O
psychotropic O
medications O
participated O
( O
ages O
between O
3 O
and O
12 O
years O
, O
mean O
IQ O
= O
55 O
) O
. O
[]

RESULTS O
Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
at O
1 O
year O
in O
both O
groups O
( O
-22.2/-14.6 O
mmHg O
and O
-19.5/-14.3 O
mmHg O
, O
for O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
respectively O
, O
P O
< O
0.001 O
for O
each O
) O
, O
with O
no O
significant O
between-group O
difference O
. O
['Physiological-Clinical', 'Physiological-Clinical']

72.4 O
% O
( O
ASS O
73.3 O
% O
; O
Flunarizine O
71.4 O
% O
) O
of O
patients O
were O
attack-free O
or O
had O
at O
least O
a O
50 O
% O
reduction O
. O
[]

Baseline O
concentrations O
of O
VLDL-apolipoprotein B-outcome ['Physiological-Clinical']
( O
apo O
) O
B O
( O
the O
VLDL B-outcome ['Physiological-Clinical']
particle I-outcome ['Physiological-Clinical']
concentration O
) O
, O
VLDL B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
, O
and O
apoCIII B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
apoE I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
VLDL+LDL I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
HDL I-outcome ['Physiological-Clinical']
were O
compared O
in O
patients O
who O
had O
either O
a O
myocardial O
infarction O
or O
coronary O
death O
( O
cases O
, O
n=418 O
) O
with O
those O
in O
patients O
who O
did O
not O
have O
a O
cardiovascular O
event O
( O
control O
subjects O
, O
n=370 O
) O
in O
5 O
years O
of O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Randomised O
community-based O
trial O
of O
annual O
single-dose O
diethylcarbamazine O
with O
or O
without O
ivermectin O
against O
Wuchereria O
bancrofti O
infection O
in O
human O
beings O
and O
mosquitoes O
. O
[]

The O
same O
retention O
rates O
were O
observed O
in O
the O
two O
groups O
, O
but O
SM O
group O
had O
higher O
participation O
. O
[]

BACKGROUND O
New O
antibacterial O
agents O
with O
activity O
against O
pathogenic O
strains O
resistant O
to O
established O
antibiotics O
are O
needed O
to O
treat O
patients O
with O
secondarily O
infected O
dermatitis O
( O
SID O
) O
. O
[]

However O
, O
no O
clear O
relation O
between O
skin B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
circulating O
concentrations O
of O
oestrogens O
or O
progestogens O
has O
yet O
been O
found O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
study O
the O
effects O
of O
cord O
clamping O
on O
iron O
stores O
of O
infants O
born O
to O
anemic O
mothers O
at O
3 O
months O
of O
age O
. O
[]

This O
study O
enrolled O
patients O
with O
symptomatic O
, O
smoking-related O
COPD O
, O
randomized O
to O
receive O
sibenadet O
or O
placebo O
for O
a O
52-week O
treatment O
period O
. O
[]

The O
remission B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
did O
not O
differ O
significantly O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

The O
open O
laparoscopic O
technique O
is O
safer O
and O
faster O
than O
the O
blind O
approach O
; O
therefore O
, O
it O
is O
proposed O
that O
this O
approach O
be O
routinely O
used O
in O
all O
laparoscopic O
procedures O
. O
[]

Participants O
were O
given O
an O
escape O
option O
that O
let O
them O
avoid O
any O
trials O
they O
wished O
and O
receive O
a O
hint O
to O
the O
trial O
's O
answer O
. O
[]

The O
efficacy O
and O
safety O
of O
nizatidine O
was O
evaluated O
in O
comparison O
with O
ranitidine O
in O
230 O
patients O
with O
endoscopically O
documented O
gastric O
( O
71 O
) O
or O
duodenal O
( O
159 O
) O
ulcers O
. O
[]

In O
this O
more O
homogeneous O
subgroup O
, O
the O
10-year O
survival B-outcome ['Mortality']
rates O
( O
and O
standard O
errors O
) O
were O
for O
RDL O
, O
60 O
% O
( O
+/- O
7 O
% O
) O
and O
for O
EXT O
, O
74 O
% O
( O
+/- O
6 O
% O
) O
( O
P O
value O
for O
comparison O
of O
survival O
curves O
= O
0.13 O
) O
. O
['Mortality']

Repeated O
measures O
ANOVA O
showed O
significant O
improvements O
over O
time O
in O
body O
mass O
index O
( O
BMI O
) O
( O
P O
< O
0.01 O
) O
, O
psychological B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
( O
P O
< O
0.001 O
) O
, O
and O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
( O
P O
< O
0.001 O
) O
for O
both O
groups O
. O
['Life-Impact', 'Life-Impact']

OBJECTIVE O
Although O
most O
cases O
of O
epistaxis O
are O
managed O
conservatively O
, O
occasionally O
they O
can O
progress O
to O
significant O
hemorrhage O
requiring O
more O
involved O
management O
or O
surgery O
. O
[]

METHODS O
Fifty O
children O
with O
high-functioning O
ASD O
and O
anxiety O
were O
randomizedto O
group O
CBT O
or O
treatment-as-usual O
( O
TAU O
) O
for O
12 O
weeks O
. O
[]

Multiple O
Cox-regression O
analyses O
yielded O
the O
presence O
of O
subthreshold O
symptoms O
of O
depression B-outcome ['Life-Impact']
, O
anxiety B-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
, O
and O
cognitive B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
at O
baseline O
, O
the O
premorbid O
level O
of O
mobility O
, O
and O
a O
history O
of O
( O
treated O
) O
depression B-outcome ['Life-Impact']
as O
risk O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

In O
all O
patients O
, O
clofibrate O
therapy O
was O
associated O
with O
a O
significant O
19-23 O
% O
reduction O
in O
plasma B-outcome ['Physiological-Clinical']
fibrinogen I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
clinical O
consequences O
of O
the O
insignificant O
differences O
in O
AER O
remain O
unclear O
. O
[]

The O
goal O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
of O
these O
two O
pharmacological O
agents O
, O
used O
alone O
or O
in O
combination O
, O
to O
reduce O
postoperative B-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
Medical O
Research O
Council O
( O
MRC O
) O
United O
Kingdom O
trial O
for O
childhood O
acute O
lymphoblastic O
leukaemia O
( O
UKALL O
X O
) O
randomised O
patients O
aged O
0-14 O
years O
inclusive O
with O
an O
initial O
white O
blood O
count O
of O
less O
than O
100 O
x O
10 O
( O
9 O
) O
/l O
to O
receive O
an O
early O
intensification O
block O
, O
a O
late O
intensification O
block O
, O
both O
, O
or O
neither O
. O
[]

We O
tested O
the O
FRF O
model O
by O
using O
an O
functional O
( O
f O
) O
MRI-adaptation O
protocol O
to O
characterize O
the O
selectivity O
of O
activity O
in O
visual O
cortex O
to O
second-order O
, O
orientation-defined O
gratings O
of O
two O
different O
SFs O
. O
[]

It O
is O
, O
however O
, O
important O
to O
determine O
absolute O
risk O
, O
and O
thereby O
estimate O
indication O
for O
drug O
treatment O
, O
in O
order O
to O
maintain O
a O
cost-effective O
drug O
treatment O
. O
[]

We O
consider O
how O
far O
these O
were O
in O
accord O
with O
the O
hospital O
staffs O
' O
views O
. O
[]

METHOD O
The O
sample O
for O
the O
study O
consisted O
of O
50 O
patients O
to O
whom O
subcutaneous O
heparin O
was O
administered O
. O
[]

CONCLUSION O
Prophylactic O
preoperative O
IABP O
insertion O
in O
EuroSCORE-stratified O
high-risk O
patients O
is O
not O
associated O
with O
decreased O
30-day O
mortality O
. O
[]

Neutralizing B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
titres I-outcome ['Physiological-Clinical']
were O
lower O
after O
intradermal O
( O
i.d O
. O
) O
['Physiological-Clinical']

Overall O
, O
there O
were O
no O
significant O
differences O
in O
main O
effects O
between O
SmartConsent O
and O
standard O
informed O
consents O
for O
decisional B-outcome ['Life-Impact']
conflict I-outcome ['Life-Impact']
and O
satisfaction B-outcome ['Life-Impact']
, O
although O
significant O
differences O
were O
identified O
during O
secondary O
analysis O
of O
satisfaction B-outcome ['Life-Impact']
, O
gender O
, O
and O
ethnicity O
. O
['Life-Impact', 'Life-Impact']

OBJECTIVE O
To O
observe O
the O
effect O
of O
parecoxib O
on O
morphine O
dosage O
in O
patient-controlled O
analgesia O
( O
PCA O
) O
following O
thoracoscope-assisted O
thoracotomy O
. O
[]

We O
aimed O
to O
investigate O
the O
effect O
of O
i.v O
. O
[]

The O
mean O
copy O
numbers O
+/- O
SE O
of O
mean O
( O
SEM O
) O
of O
HSV-1 B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
in O
tears O
were O
340 O
+/- O
35 O
, O
1074 O
+/- O
320 O
, O
and O
630 O
+/- O
51 O
for O
groups O
1 O
, O
2 O
, O
and O
3 O
, O
and O
in O
saliva O
were O
238 O
+/- O
35 O
, O
963 O
+/- O
462 O
, O
and O
493 O
+/- O
25 O
, O
respectively O
, O
for O
groups O
1 O
, O
2 O
, O
and O
3 O
. O
['Physiological-Clinical']

After O
these O
trials O
, O
a O
resting O
hypoxia O
trial O
was O
conducted O
without O
handgrip O
or O
PECO O
. O
[]

BACKGROUND O
This O
study O
was O
designed O
to O
demonstrate O
that O
efficacy O
[ O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
] O
of O
CAELYX O
[ O
pegylated O
liposomal O
doxorubicin O
HCl O
( O
PLD O
) O
] O
is O
non-inferior O
to O
doxorubicin O
with O
significantly O
less O
cardiotoxicity O
in O
first-line O
treatment O
of O
women O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
['Mortality']

Patients O
and O
study O
personnel O
were O
masked O
to O
treatment O
assignment O
, O
except O
for O
the O
site O
pharmacist O
who O
prepared O
the O
study O
drug O
for O
injection O
, O
but O
had O
no O
interaction O
with O
the O
patient O
. O
[]

Consecutive O
procedural O
angiograms O
of O
patients O
randomly O
assigned O
to O
EES O
( O
n=669 O
) O
or O
PES O
( O
n=333 O
) O
were O
analysed O
by O
an O
independent O
angiographic O
core O
laboratory O
. O
[]

There O
is O
significantly O
less O
depression B-outcome ['Life-Impact']
and O
['Life-Impact']

We O
made O
a O
randomised O
prospective O
comparison O
of O
the O
Dynamic O
Hip O
Screw O
and O
the O
Gamma O
locking O
nail O
for O
the O
internal O
fixation O
of O
200 O
petrochanteric O
femoral O
fractures O
in O
elderly O
patients O
. O
[]

OBJECTIVE O
The O
aim O
was O
to O
investigate O
whether O
the O
severity O
of O
observed O
challenge O
reactions O
would O
be O
repeated O
on O
re-challenge O
with O
a O
lower O
fat O
challenge O
vehicle O
. O
[]

While O
L-carnitine O
did O
not O
lead O
to O
major O
functional O
changes O
in O
ability O
, O
the O
type O
of O
changes O
reported O
could O
still O
have O
a O
substantial O
impact O
on O
the O
girls O
and O
their O
families O
. O
[]

SETTING O
Sexual O
Dysfunction O
Clinic O
at O
VA O
Medical O
Center O
, O
Sepulveda O
, O
CA O
. O
[]

The O
mean O
reductions O
in O
serum B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
2 O
hours O
after O
PKVP O
and O
on O
postoperative O
day O
1 O
were O
0.52 O
mmol/L O
and O
3.35 O
mmol/L O
, O
respectively O
, O
while O
mean O
reductions O
in O
haemoglobin O
were O
0.36 O
g/dL O
and O
0.24 O
g/dL O
, O
respectively O
. O
['Physiological-Clinical']

The O
need O
for O
research O
to O
develop O
algorithms O
that O
allow O
one O
to O
select O
the O
best O
combination O
of O
medical O
and O
behavioral O
interventions O
for O
specific O
illnesses O
and O
contexts O
is O
noted O
. O
[]

However O
, O
a O
larger O
study O
will O
be O
required O
to O
determine O
non-superiority O
or O
equivalence O
. O
[]

No O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
. O
['Adverse-effects']

The O
results O
are O
discussed O
. O
[]

Evaluation O
of O
prostaglandin O
E1 O
for O
prevention O
of O
respiratory O
failure O
in O
high O
risk O
trauma O
patients O
: O
a O
prospective O
clinical O
trial O
and O
correlation O
with O
plasma O
suppressive O
factors O
for O
neutrophil O
activation O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
response O
outside O
the O
brain O
were O
not O
different O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Changes O
in O
the O
urogenital B-outcome ['Physiological-Clinical']
and O
sexuality B-outcome ['Life-Impact']
score O
along O
with O
vaginal B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
index O
and O
VMI B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Studies O
have O
shown O
that O
live O
, O
cold-adapted O
influenza O
vaccine O
, O
trivalent O
, O
is O
efficacious O
in O
children O
. O
[]

The O
antidepressant O
venlafaxine O
( O
150 O
mg O
daily O
) O
and O
the O
dopamine O
agonist O
pramipexole O
( O
1.5 O
mg O
daily O
) O
were O
evaluated O
in O
the O
second O
study O
. O
[]

Also O
, O
men O
who O
received O
the O
decision O
aid O
had O
significantly O
higher O
knowledge B-outcome ['Life-Impact']
levels O
regarding O
genetic O
testing O
compared O
with O
men O
who O
received O
the O
control O
pamphlet O
, O
whereas O
no O
such O
differences O
were O
found O
for O
women O
( O
chi-square O
( O
2 O
) O
= O
6.76 O
; O
P O
= O
.034 O
) O
. O
['Life-Impact']

Preliminary O
evidence O
suggests O
oxytocin O
may O
have O
potential O
as O
an O
intervention O
for O
autism O
. O
[]

However O
, O
further O
research O
investigating O
and O
identifying O
intervention O
approaches O
that O
improve O
both O
[]

At O
W24 O
, O
12 O
cases O
, O
12 O
cases O
, O
and O
7 O
cases O
showed O
ELISPOT O
positive O
in O
the O
group O
of O
90 O
micrograms O
, O
60 O
micrograms O
, O
and O
placebo O
. O
[]

PARTICIPANTS O
AND O
METHODS O
Participants O
were O
1908 O
women O
aged O
50 O
to O
75 O
years O
continuously O
enrolled O
in O
a O
large O
group-model O
HMO O
during O
the O
study O
who O
underwent O
a O
bilateral O
mammogram O
during O
the O
first O
quarter O
of O
1994 O
and O
no O
subsequent O
mammogram O
during O
the O
next O
18 O
to O
21 O
months O
. O
[]

RESULTS O
Thirty-seven O
and O
40 O
patients O
were O
randomly O
assigned O
to O
study O
arm O
and O
control O
arm O
. O
[]

There O
were O
also O
no O
differences O
in O
manual O
muscle O
testing O
sum O
scores O
, O
activity O
scale O
scores O
and O
patients O
' O
own O
assessments O
after O
48 O
weeks O
of O
treatment O
. O
[]

5 O
Practolol O
200 O
mg O
had O
the O
same O
effect O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
as O
propranolol O
10 O
mg O
but O
a O
significantly O
smaller O
effect O
on O
the O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
responses O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Twenty O
patients O
with O
herpes O
simplex O
virus O
1-related O
recurrent O
keratitis/keratouveitis O
were O
prospectively O
enrolled O
and O
randomly O
assigned O
to O
receive O
either O
a O
specific O
vaccination O
with O
heat O
shock-inactivated O
herpes O
simplex O
virus O
type O
1 O
( O
10 O
patients O
) O
or O
to O
be O
observed O
as O
controls O
( O
10 O
patients O
) O
. O
[]

BACKGROUND O
Deletion O
of O
the O
B-domain O
of O
recombinant O
blood O
coagulation O
factor O
VIII O
( O
BDDrFVIII O
) O
increases O
the O
manufacturing O
yield O
of O
the O
product O
but O
does O
not O
impair O
in O
vitro O
or O
in O
vivo O
functionality O
. O
[]

Treatment O
was O
successful B-outcome ['Physiological-Clinical']
in O
57 O
of O
64 O
patients O
treated O
with O
amoxicillin O
vs. O
58 O
of O
65 O
patients O
treated O
with O
erythromycin O
( O
P O
= O
0.00 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
In O
patients O
, O
fully O
dentate O
or O
with O
1 O
or O
2 O
teeth O
missing O
and O
older O
than O
25 O
years O
who O
have O
no O
jawbone O
atrophy O
and O
no O
systemic O
problems O
that O
may O
impair B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
, O
mastication O
seems O
not O
to O
affect O
late B-outcome ['Physiological-Clinical']
mandibular I-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
after O
surgical O
removal O
of O
impacted O
M3s O
associated O
with O
no O
gross O
pathology O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mean O
postvaccination B-outcome ['Physiological-Clinical']
IgA I-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
were O
compared O
for O
subjects O
with O
and O
without O
confirmed O
influenza O
illness O
by O
study O
and O
in O
pooled O
analyses O
. O
['Physiological-Clinical']

RESULTS O
Mean O
plasma B-outcome ['Physiological-Clinical']
vWf I-outcome ['Physiological-Clinical']
was O
higher O
among O
patients O
with O
AF O
and O
CHF O
( O
154 O
( O
29 O
) O
v O
144 O
( O
31 O
) O
IU/dl O
, O
p O
< O
0.001 O
) O
, O
particularly O
those O
with O
acute O
or O
recent O
decompensated O
symptoms O
. O
['Physiological-Clinical']

A O
single O
infusion O
of O
intravenous O
ketamine O
improves O
pain O
relief O
in O
patients O
with O
critical O
limb O
ischaemia O
: O
results O
of O
a O
double O
blind O
randomised O
controlled O
trial O
. O
[]

Transient O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
noted O
in O
10 O
patients O
( O
26 O
% O
) O
after O
flecainide O
. O
['Adverse-effects']

The O
incidence O
of O
CIN B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
sodium O
bicarbonate O
group O
( O
4.5 O
% O
) O
compared O
with O
sodium O
chloride O
alone O
( O
13.6 O
% O
, O
P O
= O
.036 O
) O
and O
tended O
to O
be O
lower O
than O
in O
the O
combination O
group O
( O
12.5 O
% O
, O
P O
= O
.059 O
) O
. O
['Physiological-Clinical']

Beta-carotene O
in O
HIV O
infection O
. O
[]

A O
total O
of O
1854 O
children O
were O
evaluated O
and O
780 O
children O
were O
randomised O
between O
August O
1994 O
and O
January O
1997 O
. O
[]

Wound B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
developed O
in O
ten O
patients O
( O
18.9 O
% O
) O
. O
['Physiological-Clinical']

RESULTS O
One O
minute O
after O
reperfusion O
the O
level O
of O
spin-trapped B-outcome ['Physiological-Clinical']
radicals I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
was O
elevated O
significantly O
( O
p O
= O
0.016 O
) O
in O
the O
allopurinol O
group O
, O
from O
7.7 O
( O
SE O
: O
0.8 O
) O
to O
8.6 O
( O
1.4 O
) O
and O
non-significantly O
( O
p O
= O
0.074 O
) O
in O
the O
placebo O
group O
, O
from O
7.3 O
( O
0.7 O
) O
to O
8.3 O
( O
0.8 O
) O
. O
['Physiological-Clinical']

From O
15 O
% O
to O
40 O
% O
of O
these O
events O
occurred O
beyond O
30 O
days O
. O
[]

OBJECTIVE O
To O
observe O
the O
curative B-outcome ['Physiological-Clinical']
effect O
of O
Shenyanning O
( O
SYN O
) O
on O
non-nephrotic O
syndrome O
IgA O
nephropathy O
( O
IgAN O
) O
. O
['Physiological-Clinical']

Sixty O
one O
patients O
completed O
the O
study O
. O
[]

The O
remaining O
219 O
patients O
formed O
a O
nonrandomized O
group O
and O
received O
either O
thrombosis O
embolic O
deterrent O
stockings O
alone O
or O
thrombosis O
embolic O
deterrent O
stockings O
and O
pneumatic O
compression O
boots O
for O
deep O
vein O
thrombosis O
prophylaxis O
. O
[]

Atrial B-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
after O
mitral O
valve O
surgery O
in O
patients O
with O
permanent O
atrial O
fibrillation O
. O
['Physiological-Clinical']

Ramipril O
prevents O
or O
delays O
the O
[]

Neither O
the O
tolbutamide B-outcome ['Physiological-Clinical']
oral I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( O
0.77 O
+/- O
0.28 O
l/h O
before O
and O
0.72 O
+/-0.24 O
l/h O
after O
, O
p O
> O
0.05 O
) O
nor O
the O
tolbutamide B-outcome ['Resource-use']
urinary B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
( O
779 O
+/- O
294 O
before O
and O
681 O
+/- O
416 O
after O
, O
p O
> O
0.05 O
) O
indices O
of O
CYP2C9 O
were O
altered O
by O
clarithromycin O
administration O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Students O
in O
an O
equal O
sign O
group O
learned O
about O
the O
equal O
sign O
only O
. O
[]

OBJECTIVE O
To O
test O
the O
hypothesis O
that O
omission O
of O
the O
bladder O
flap O
in O
primary O
and O
repeat O
cesarean O
deliveries O
shortens O
operating O
time O
without O
increasing O
intraoperative O
and O
postoperative O
complications O
. O
[]

OBJECTIVES O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
relationship O
of O
baseline O
pulse O
pressure O
and O
mean O
arterial O
pressure O
to O
mortality O
in O
patients O
with O
left O
ventricular O
dysfunction O
. O
[]

The O
incidence O
of O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
['Adverse-effects']

METHODS O
A O
total O
of O
25 O
patients O
were O
randomized O
to O
be O
pretreated O
with O
thrombus O
aspiration O
before O
PCI O
of O
the O
culprit O
lesion O
and O
25 O
received O
standard O
PCI O
. O
[]

PATIENTS O
AND O
METHODS O
Forty-eight O
patients O
were O
randomized O
to O
receive O
: O
FA O
( O
25 O
mg/m2 O
iv O
bolus O
days O
1 O
to O
3 O
) O
, O
followed O
by O
5-FU O
( O
750 O
mg/m2 O
iv O
bolus O
days O
1 O
to O
3 O
) O
, O
arm O
A O
; O
or O
FA O
( O
25 O
mg/m2 O
iv O
bolus O
days O
1 O
to O
3 O
) O
, O
followed O
by O
5-FU O
( O
750 O
mg/m2 O
iv O
bolus O
days O
1 O
to O
3 O
) O
plus O
IFO O
( O
2,000 O
mg/m2 O
in O
1000 O
mL O
5 O
% O
dextrose O
in O
a O
2-hr O
infusion O
, O
days O
1 O
to O
3 O
) O
, O
arm O
B. O
Mesna O
was O
added O
during O
and O
after O
IFO O
to O
prevent O
hemorrhagic O
cystitis O
. O
[]

Moreover O
, O
the O
extent O
of O
the O
observed O
effects O
raises O
questions O
about O
the O
appropriateness O
of O
IV O
opioid O
treatment O
in O
the O
present O
form O
. O
[]

Complete O
control O
of O
acute O
vomiting B-outcome ['Physiological-Clinical']
was O
achieved O
in O
74 O
% O
of O
tropisetron O
and O
88 O
% O
of O
granisetron O
patients O
( O
P O
= O
0.04 O
) O
, O
and O
complete O
control O
of O
acute B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
in O
56 O
% O
and O
82 O
% O
respectively O
( O
p O
= O
0.002 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

There O
were O
no O
treatment-related O
deaths B-outcome ['Mortality']
and O
, O
in O
the O
experimental O
arm O
of O
the O
trial O
, O
no O
increased O
morbidity B-outcome ['Physiological-Clinical']
from O
locoregional O
treatment O
. O
['Mortality', 'Physiological-Clinical']

In O
part O
B O
, O
cediranib O
30 O
mg/day O
appeared O
to O
be O
the O
most O
sustainable O
for O
chronic O
dosing O
. O
[]

OBJECTIVE O
Transthoracic B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TTI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
a O
factor O
determining O
the O
magnitude O
of O
the O
transmyocardial O
current O
during O
external O
defibrillation O
. O
['Physiological-Clinical']

Effects O
of O
piracetam O
on O
regional O
cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
mental B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
in O
patients O
with O
organic O
dementia O
. O
['Physiological-Clinical', 'Life-Impact']

Previous O
research O
has O
reported O
that O
autistic O
adults O
do O
not O
manage O
their O
reputation O
, O
purportedly O
due O
to O
problems O
with O
theory O
of O
mind O
[ O
Izuma O
, O
Matsumoto B-outcome ['Physiological-Clinical']
, O
Camerer O
, O
& O
Adolphs O
] O
. O
['Physiological-Clinical']

Twenty O
of O
the O
42 O
AML O
patients O
and O
5 O
of O
9 O
CML O
patients O
are O
alive O
with O
a O
projected O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
of O
23 O
months O
. O
['Mortality']

A O
plethysmographic B-outcome ['Physiological-Clinical']
evaluation I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
RAO I-outcome ['Physiological-Clinical']
was O
performed O
at O
24 O
hours O
and O
30 O
days O
after O
the O
procedure O
. O
['Physiological-Clinical']

After O
repeated O
administration O
of O
300 O
mg O
b.d. O
, O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
prior O
to O
each O
daily O
morning O
dose O
increased O
up O
to O
the O
5th O
day O
( O
mean O
Cmin O
166.6 O
ng.ml-1 O
) O
and O
then O
tended O
to O
decrease O
until O
the O
7th O
day O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
HMTW O
intervention O
showed O
differential O
effects O
on O
child O
communication O
depending O
on O
a O
baseline O
child O
factor O
. O
[]

Women O
were O
randomized O
to O
use O
the O
FemCap O
or O
Ortho O
All-Flex O
contraceptive O
diaphragm O
, O
both O
with O
2 O
% O
nonoxynol-9 O
spermicide O
, O
for O
28 O
weeks O
. O
[]

Atypical O
social O
modulation O
of O
imitation O
in O
autism O
spectrum O
conditions O
. O
[]

Children O
were O
randomized O
to O
receive O
one O
of O
the O
Hib O
vaccines O
( O
Hib O
groups O
) O
or O
into O
a O
control O
group O
. O
[]

RESULTS O
No O
significant O
differences O
were O
observed O
between O
the O
treatment O
groups O
according O
to O
the O
Ottawa B-outcome ['Physiological-Clinical']
cleansing I-outcome ['Physiological-Clinical']
scale I-outcome ['Physiological-Clinical']
findings O
( O
PEG O
4L O
: O
2.97 O
vs O
TM-PEG O
4L O
: O
2.46 O
, O
P O
= O
0.063 O
) O
. O
['Physiological-Clinical']

We O
describe O
the O
item O
composition O
and O
coherence O
of O
each O
scale O
, O
the O
interrater O
reliabilities O
of O
clinicians O
using O
the O
scales O
, O
and O
the O
sensitivity O
of O
the O
scales O
for O
resolving O
treatment O
response O
. O
[]

Steers O
were O
given O
ad O
libitum O
access O
to O
high-concentrate O
diets O
( O
13 O
% O
CP O
) O
containing O
71 O
% O
whole O
shelled O
corn O
, O
10 O
% O
corn O
silage O
, O
4 O
% O
condensed O
distillers O
solubles O
, O
and O
15 O
% O
protein O
supplements O
( O
DM O
basis O
) O
. O
[]

GERD-related B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
resolved O
in O
significantly O
more O
( O
p O
< O
0.0001 O
) O
patients O
who O
received O
esomeprazole O
40 O
( O
73.7 O
% O
) O
or O
20 O
mg O
( O
73.2 O
% O
) O
than O
in O
those O
who O
received O
placebo O
( O
41.2 O
% O
) O
. O
['Physiological-Clinical']

METHODS O
We O
performed O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
to O
investigate O
the O
safety O
, O
tolerability O
, O
and O
effect O
of O
6 O
weeks O
' O
treatment O
with O
high- O
( O
300 O
mg O
once O
a O
day O
) O
or O
low- O
( O
100 O
mg O
once O
a O
day O
) O
dose O
allopurinol O
on O
levels O
of O
uric O
acid O
and O
circulating O
inflammatory O
markers O
after O
ischemic O
stroke O
. O
[]

We O
have O
detailed O
our O
efforts O
at O
developing O
print- O
and O
web-based O
DAs O
to O
assist O
men O
in O
determining O
how O
to O
best O
meet O
their O
PCa O
screening O
preferences O
. O
[]

Home-based O
programs O
will O
involve O
one O
home O
visit O
followed O
by O
seven O
weekly O
telephone O
calls O
, O
using O
a O
motivational O
interviewing O
approach O
to O
enhance O
exercise O
participation O
and O
facilitate O
self O
management O
. O
[]

In O
the O
six O
months O
following O
interferon O
therapy O
, O
only O
31 O
% O
of O
interferon O
and O
27 O
% O
of O
placebo O
recipients O
remained O
free B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
recurrences I-outcome ['Physiological-Clinical']
( O
p O
= O
0.99 O
) O
. O
['Physiological-Clinical']

The O
current O
analyses O
were O
undertaken O
to O
promote O
an O
understanding O
of O
the O
underlying O
mechanism O
of O
action O
and O
to O
identify O
potential O
biomarkers O
that O
could O
help O
in O
the O
prediction O
and O
management O
of O
ipilimumab-induced O
gastrointestinal O
irAEs O
. O
[]

Twenty O
young O
healthy O
males O
( O
10 O
smokers O
and O
10 O
nonsmokers O
) O
were O
randomized O
in O
a O
cross-over O
design O
and O
received O
a O
portion O
of O
broccoli O
( O
200 O
g O
) O
or O
maintained O
a O
controlled O
diet O
for O
10 O
days O
each O
. O
[]

The O
decrease O
was O
of O
similar O
magnitude O
whether O
failure O
was O
due O
to O
extravasation O
or O
phlebitis O
. O
[]

BACKGROUND O
The O
Chronic O
Respiratory O
Questionnaire O
( O
CRQ O
) O
and O
the O
St O
George O
's O
Respiratory O
Questionnaire O
( O
SGRQ O
) O
are O
the O
two O
most O
widely O
used O
quality O
of O
life O
questionnaires O
in O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
. O
[]

The O
trial O
's O
final O
sample O
was O
composed O
of O
521 O
current O
smokers O
. O
[]

Patients O
underwent O
intravascular B-outcome ['Physiological-Clinical']
ultrasound I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IVUS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
evaluation I-outcome ['Physiological-Clinical']
of O
the O
target O
vessel O
during O
the O
catheterization O
for O
ACS O
and O
up O
to O
14 O
days O
following O
the O
final O
apheresis/reinfusion O
session O
. O
['Physiological-Clinical']

CONCLUSION O
The O
study O
showed O
significant O
effect O
of O
venlafaxine O
in O
the O
manifestations O
of O
hyperalgesia O
and O
temporal O
summation O
, O
but O
not O
on O
the O
ongoing O
pain O
intensity O
. O
[]

Polysomnography O
was O
performed O
within O
30 O
days O
of O
the O
first O
study O
. O
[]

Determination O
of O
the O
severity O
of O
autism O
was O
made O
with O
video O
films O
at O
day O
0 O
( O
D0 O
) O
and O
D90 O
by O
blind O
, O
independent O
evaluators O
. O
[]

RESULTS O
No O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
in O
either O
group O
. O
['Adverse-effects']

Of O
23 O
patients O
randomised O
to O
receive O
interferon O
and O
completing O
double O
hemi-body O
irradiation O
, O
15 O
( O
65 O
% O
) O
achieved O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
adequate O
to O
allow O
interferon O
administration O
as O
per O
study O
criteria O
commencing O
at O
a O
mean O
116 O
days O
( O
61-241 O
) O
from O
time O
of O
study O
entry O
. O
['Physiological-Clinical']

CONCLUSIONS O
In O
normal-weight O
healthy O
young O
subjects O
, O
modest O
fat O
gain O
results O
in O
impaired O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
even O
in O
the O
absence O
of O
changes O
in O
['Physiological-Clinical']

We O
examined O
these O
factors O
as O
predictors O
of O
treatment O
toxicity B-outcome ['Adverse-effects']
and O
outcome O
in O
cetuximab-treated O
patients O
with O
ACRC O
. O
['Adverse-effects']

Central B-outcome ['Physiological-Clinical']
temperatures B-outcome ['Physiological-Clinical']
, O
peripheral B-outcome ['Physiological-Clinical']
vasoconstriction B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
followed O
for O
12 O
months O
with O
angiographic O
follow-up O
at O
6 O
months O
. O
[]

A O
randomized O
clinical O
trial O
. O
[]

bolus O
of O
GHRH O
was O
given O
at O
0700 O
h O
and O
GH O
samples O
were O
drawn O
from O
0700 O
to O
0900 O
h O
to O
document O
the O
efficacy O
of O
GH B-outcome ['Physiological-Clinical']
suppression O
by O
the O
GHRH O
antagonist O
. O
['Physiological-Clinical']

The O
GPs O
of O
the O
intervention O
patients O
were O
telephoned O
during O
the O
admission O
. O
[]

In O
all O
three O
classifications O
there O
were O
no O
statistically O
significant O
differences O
between O
the O
incidences O
in O
placebo O
and O
combined O
active O
treatment O
groups O
, O
or O
between O
those O
in O
the O
two O
quinapril O
groups O
. O
[]

[ O
Final O
evaluation O
of O
the O
randomized O
multicenter O
study O
SAKK O
40/81 O
: O
adjuvant O
portal O
chemotherapy O
of O
curatively O
resected O
colorectal O
cancer O
] O
. O
[]

SUBJECTS O
AND O
METHODS O
25 O
healthy O
controls O
received O
25 O
g O
of O
each O
sugar O
within O
3 O
consecutive O
days O
. O
[]

Each O
subject O
received O
a O
15 O
mg O
oral O
dose O
of O
BMS-181101 O
twice O
a O
day O
( O
q O
12 O
h O
) O
for O
11 O
days O
and O
a O
morning O
dose O
of O
BMS-181101 O
on O
day O
12 O
. O
[]

Effects O
of O
aspirin O
and O
dipyridamole O
on O
atherosclerotic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
rates O
. O
['Physiological-Clinical']

Dentin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
was O
ascertained O
with O
an O
accurate O
cold O
testing O
device O
that O
slowly O
decreased O
in O
temperature O
. O
['Physiological-Clinical']

No O
significant O
difference O
in O
eradication B-outcome ['Physiological-Clinical']
rates O
was O
observed O
among O
the O
three O
groups O
both O
in O
intention O
to O
treat O
analysis O
and O
in O
per O
protocol O
analysis O
. O
['Physiological-Clinical']

For O
the O
biomechanical O
study O
of O
donor-site O
defects O
, O
four O
study O
groups O
were O
examined O
with O
random O
assignment O
and O
matched O
pairs O
. O
[]

During O
the O
intervention O
period O
the O
total O
fat B-outcome ['Physiological-Clinical']
intake I-outcome ['Physiological-Clinical']
was O
reduced O
from O
39 O
% O
to O
24 O
% O
of O
energy O
and O
the O
polyunsaturated/saturated O
( O
P/S O
) O
ratio O
increased O
from O
0.2 O
to O
0.4-1.2 O
. O
['Physiological-Clinical']

Efficacy O
on O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
treatment O
was O
acceptable O
to O
families O
, O
subject B-outcome ['Life-Impact']
adherence I-outcome ['Life-Impact']
was O
high O
, O
and O
therapist B-outcome ['Life-Impact']
fidelity I-outcome ['Life-Impact']
was O
high O
. O
['Life-Impact', 'Life-Impact']

CONCLUSION O
We O
concluded O
that O
the O
tolerability O
of O
carboplatin B-outcome ['Resource-use']
based I-outcome ['Resource-use']
regimen I-outcome ['Resource-use']
is O
better O
than O
that O
of O
the O
cisplatin O
regimen O
. O
['Resource-use']

Reduced O
neurosensory B-outcome ['Physiological-Clinical']
retinal I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
( O
OPs B-outcome ['Physiological-Clinical']
) O
seemed O
to O
appear O
after O
7-years O
, O
independently O
of O
vascular B-outcome ['Physiological-Clinical']
defects I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
retinopathy I-outcome ['Physiological-Clinical']
and O
long-term B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
control O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Agreement O
between O
bile O
and O
serum O
was O
fair O
( O
r O
= O
0.75 O
, O
p O
< O
or O
= O
0.00002 O
) O
because O
in O
some O
patients O
, O
plasma O
but O
not O
biliary O
bile O
acids O
were O
enriched O
with O
UDCA O
. O
[]

VO2 B-outcome ['Physiological-Clinical']
and O
EE B-outcome ['Physiological-Clinical']
were O
measured O
using O
an O
indirect O
calorimetry O
( O
Deltatrac O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Treatment O
of O
gastroesophageal B-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GERD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
with O
proton O
pump O
inhibitors O
was O
investigated O
in O
three O
controlled O
prospective O
, O
randomized O
open O
studies O
. O
['Physiological-Clinical']

CONCLUSIONS O
Relative O
to O
usual O
care O
, O
CBT O
adapted O
for O
anxious O
youth O
with O
high-functioning O
ASD O
demonstrates O
large O
effects O
in O
reducing O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

RESULTS O
Pediatricians O
in O
the O
intervention O
group O
, O
compared O
with O
those O
in O
the O
control O
group O
, O
demonstrated O
significantly O
higher O
rates O
of O
many O
American O
Academy O
of O
Pediatrics-recommended O
ADHD O
care O
practices O
, O
including O
collection O
of O
parent O
( O
Cohen O
's O
d O
= O
0.69 O
) O
and O
teacher O
( O
d O
= O
0.68 O
) O
rating O
scales O
for O
assessment O
of O
children O
with O
ADHD O
, O
use O
of O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental B-outcome ['Life-Impact']
Disorders I-outcome ['Life-Impact']
, O
Fourth O
Edition O
, O
criteria O
( O
d O
= O
0.85 O
) O
, O
and O
use O
of O
teacher O
rating O
scales O
to O
monitor O
treatment O
responses O
( O
d O
= O
1.01 O
) O
. O
['Life-Impact']

The O
factor O
Xa O
inhibitor O
fondaparinux O
has O
been O
studied O
extensively O
in O
the O
orthopedic O
surgical O
setting O
for O
the O
prophylaxis O
of O
VTE O
. O
[]

There O
was O
no O
difference O
in O
score O
reduction O
on O
the O
Children O
's O
Yale-Brown O
Obsessive O
Compulsive O
Scales O
modified O
for O
pervasive O
developmental O
disorders O
from O
baseline O
( O
mean O
[ O
SD O
] O
, O
-2.0 O
[ O
3.4 O
] O
points O
for O
the O
citalopram-treated O
group O
and O
-1.9 O
[ O
2.5 O
] O
points O
for O
the O
placebo O
group O
; O
P O
= O
.81 O
) O
. O
[]

METHOD O
A O
total O
of O
45 O
children O
( O
7-11 O
years O
of O
age O
) O
with O
high-functioning O
ASD O
and O
clinically O
significant O
anxiety B-outcome ['Life-Impact']
were O
randomized O
to O
receive O
16 O
sessions O
of O
weekly O
CBT O
or O
TAU O
for O
an O
equivalent O
duration O
. O
['Life-Impact']

In O
addition O
to O
the O
constellation O
of O
traditional O
CVD O
risk O
factors O
in O
chronic O
kidney O
disease O
, O
elevated O
total O
homocysteine B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
tHcy I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
notably O
more O
prevalent O
among O
the O
general O
population O
. O
['Physiological-Clinical']

There O
was O
no O
statistical O
difference O
between O
the O
two O
groups O
after O
drug O
therapy O
( O
P O
> O
0.05 O
) O
. O
[]

A O
battery O
of O
11 O
standardized O
neuropsychological O
tests O
was O
administered O
before O
surgery O
, O
and O
again O
at O
2 O
and O
6 O
months O
after O
surgery O
. O
[]

The O
mean O
follow-up O
period O
was O
10.8 O
years O
( O
range O
, O
ten O
to O
twelve O
years O
) O
. O
[]

Our O
clinical O
experience O
with O
ICCE O
and O
ACL O
implantation O
can O
not O
confirm O
the O
widespread O
rejection O
of O
this O
method O
. O
[]

Blood O
was O
drawn O
before O
treatment O
of O
patients O
with O
newly O
diagnosed O
hypothyroidism O
and O
when O
euthyroidism O
was O
achieved O
. O
[]

The O
potential O
interaction O
between O
racemic O
warfarin O
given O
as O
a O
25 O
mg O
single O
oral O
dose O
and O
chronically O
administered O
ketorolac O
was O
studied O
in O
12 O
young O
healthy O
male O
volunteers O
. O
[]

Exercise B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
was O
assessed O
2 O
to O
4 O
hours O
after O
initial O
application O
and O
after O
1 O
week O
of O
each O
treatment O
given O
in O
random O
order O
with O
a O
3 O
day O
interval O
between O
treatments O
. O
['Life-Impact']

The O
reasons O
for O
low O
overall O
enrollment O
and O
high O
readmission B-outcome ['Resource-use']
rates O
in O
the O
intervention O
group O
require O
further O
study O
. O
['Resource-use']

No O
nonocular O
adverse O
events O
were O
considered O
related O
to O
study O
drug O
. O
[]

At O
least O
2 O
consecutive O
decreases O
in O
iPTH B-outcome ['Physiological-Clinical']
levels O
of O
30 O
% O
or O
greater O
from O
baseline O
occurred O
in O
91 O
% O
of O
paricalcitol O
versus O
13 O
% O
of O
placebo O
patients O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

1 O
% O
v O
12 O
of O
34 O
or O
35.3 O
% O
, O
respectively O
; O
P O
=.04 O
) O
. O
[]

CONCLUSION O
Removal O
of O
hypertrophied O
anal O
papillae O
and O
fibrous O
anal O
polyps O
should O
be O
an O
essential O
part O
of O
treatment O
of O
chronic O
fissure O
in O
ano O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Change O
in O
the O
clinical O
symptom B-outcome ['Physiological-Clinical']
score O
( O
consisting O
of O
the O
subscores O
redness B-outcome ['Physiological-Clinical']
, O
swelling B-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
, O
and O
secretion B-outcome ['Physiological-Clinical']
) O
and O
of O
the O
visual O
analogue O
scale O
( O
VAS O
) O
rating O
for O
pain B-outcome ['Physiological-Clinical']
from O
Visit O
1 O
( O
Day O
1 O
) O
to O
Visit O
2 O
( O
Day O
4 O
+/- O
1 O
) O
, O
patient O
's O
assessment O
of O
efficacy O
at O
Visit O
3 O
( O
Day O
10 O
+/- O
2 O
) O
, O
and O
the O
frequency O
and O
type O
of O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
found O
no O
effect O
from O
the O
chart O
reminder O
compared O
with O
usual O
care O
( O
odds O
ratio O
[ O
OR O
] O
, O
1.2 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.7-2.0 O
) O
; O
and O
a O
beneficial O
effect O
from O
the O
mailed O
education/FIT O
( O
OR O
, O
6.0 O
; O
95 O
% O
CI O
, O
3.7-9.6 O
) O
and O
the O
mailed O
education/FIT O
plus O
phone O
call O
( O
OR O
, O
6.2 O
; O
95 O
% O
CI O
, O
3.8-9.9 O
) O
. O
[]

The O
loco-regional O
anesthesia O
was O
associated O
to O
psychological O
detachment O
in O
84 O
% O
of O
the O
cases O
and O
the O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
of O
36 O
% O
. O
['Physiological-Clinical']

In O
the O
concurrent O
arm O
, O
35 O
of O
48 O
evaluable O
patients O
( O
73 O
% O
; O
95 O
% O
confidence O
interval O
, O
58 O
% O
-85 O
% O
) O
had O
a O
complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
propranolol O
group O
, O
at O
the O
time O
of O
the O
decision O
, O
had O
a O
26 O
% O
lower O
mortality B-outcome ['Mortality']
( O
z O
= O
2.82 O
) O
. O
['Mortality']

There O
was O
no O
statistically O
significant O
difference O
in O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
between O
the O
two O
treatment O
groups O
. O
['Adverse-effects']

Clinic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
measured O
in O
the O
beginning O
and O
end O
of O
the O
study O
. O
['Physiological-Clinical']

This O
assessment O
method O
complements O
quantitative O
exposure O
assessment O
with O
an O
upstream O
prevention O
focus O
. O
[]

RESULTS O
In O
the O
metoprolol O
CR/XL O
group O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
increased O
from O
0.26 O
to O
0.31 O
( O
P O
= O
0.009 O
) O
after O
a O
mean O
observation O
period O
of O
10.6 O
months O
, O
and O
deceleration O
time B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
early I-outcome ['Physiological-Clinical']
mitral I-outcome ['Physiological-Clinical']
filling I-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
( O
E O
) O
increased O
from O
189 O
to O
246 O
ms O
( O
P O
= O
0.0012 O
) O
, O
time B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
integral I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
E-wave I-outcome ['Physiological-Clinical']
increased O
from O
8.7 O
to O
11.2 O
cm O
( O
P O
= O
0.018 O
) O
, O
and O
the O
duration O
of O
the O
late B-outcome ['Physiological-Clinical']
mitral I-outcome ['Physiological-Clinical']
filling I-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
( O
A O
) O
increased O
from O
122 O
to O
145 O
ms O
( O
P O
= O
0.014 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Transfusion O
greatly O
reduces O
the O
risk O
of O
a O
first B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
in O
children O
with O
sickle O
cell O
anemia O
who O
have O
abnormal O
results O
on O
transcranial O
Doppler O
ultrasonography O
. O
['Physiological-Clinical']

The O
effect O
of O
random O
modulation O
of O
functional O
electrical O
stimulation O
parameters O
on O
muscle O
fatigue O
. O
[]

METHODS O
Evaluation O
parameters O
consisted O
of O
ongoing O
pain O
intensity O
( O
VAS O
) O
, O
patient O
satisfaction O
, O
side O
effects O
, O
global O
efficacy O
and O
tolerance O
. O
[]

CONCLUSIONS O
Tidal B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
delivered O
by O
healthcare O
providers O
using O
one- O
vs O
two-handed O
compressions O
were O
found O
to O
be O
significantly O
different O
, O
with O
those O
delivered O
by O
two O
hands O
significantly O
greater O
than O
those O
delivered O
by O
one O
hand O
. O
['Physiological-Clinical']

INTRODUCTION O
Health O
communication O
interventions O
have O
been O
modestly O
effective O
for O
increasing O
informed O
decision O
making O
for O
prostate O
cancer O
screening O
among O
African-American O
men O
; O
however O
, O
knowledge O
and O
informed O
decision O
making O
is O
still O
questionable O
even O
with O
screening O
. O
[]

BP O
control O
was O
defined O
as O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
< O
140 O
mm O
Hg O
and O
diastolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
< O
90 O
mm O
Hg O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
combination O
of O
infusion O
5 O
FU O
and O
methyl-CCNU O
achieved O
responses B-outcome ['Physiological-Clinical']
in O
9 O
% O
and O
5 O
% O
of O
stomach O
and O
pancreatic O
tumors O
, O
respectively O
. O
['Physiological-Clinical']

RESULTS O
Thirty-six O
Nellore O
sheep O
were O
randomly O
divided O
into O
four O
groups O
of O
nine O
animals O
each O
using O
a O
balanced O
, O
completely O
randomised O
design O
. O
[]

The O
findings O
provide O
novel O
detail O
to O
the O
abnormal O
way O
in O
which O
people O
with O
autism O
look O
at O
faces O
, O
an O
impairment O
that O
likely O
influences O
all O
subsequent O
face O
processing O
. O
[]

The O
effects O
of O
a O
single O
dose O
of O
24 O
IU O
intranasally O
administered O
oxytocin O
were O
tested O
in O
a O
randomized O
, O
placebo-controlled O
, O
within-subject O
, O
cross-over O
design O
. O
[]

CONCLUSION O
One-year O
treatment O
with O
clodronate O
induces O
a O
gain O
in O
bone O
mass O
, O
especially O
in O
the O
spine O
. O
[]

Galactomannan O
and O
PCR O
versus O
culture O
and O
histology O
for O
directing O
use O
of O
antifungal O
treatment O
for O
invasive O
aspergillosis O
in O
high-risk O
haematology O
patients O
: O
a O
randomised O
controlled O
trial O
. O
[]

A O
randomized O
, O
double-blind O
trial O
comparing O
enoxaparin O
with O
warfarin O
. O
[]

The O
median O
patient O
age O
was O
41 O
years O
( O
24-59 O
years O
) O
. O
[]

Included O
were O
869 O
children O
who O
were O
6 O
to O
16 O
y O
of O
age O
in O
grades O
1 O
to O
10 O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
rehabilitation O
outcome O
from O
three O
different O
active O
programs O
in O
terms O
of O
: O
( O
1 O
) O
return-to-work B-outcome ['Life-Impact']
rate O
, O
( O
2 O
) O
days O
of O
sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
, O
( O
3 O
) O
health-care B-outcome ['Life-Impact']
contacts I-outcome ['Life-Impact']
, O
( O
4 O
) O
pain B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
scores I-outcome ['Life-Impact']
, O
and O
( O
5 O
) O
staying B-outcome ['Life-Impact']
physically I-outcome ['Life-Impact']
active I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

One O
hundred O
three O
subjects O
were O
randomly O
assigned O
to O
one O
of O
three O
treatment O
categories O
: O
anti-inflammatory O
, O
accommodative O
, O
or O
mechanical O
. O
[]

OPTIMAAL O
( O
Optimal O
Trial O
in O
Myocardial O
Infarction O
with O
the O
Angiotensin O
II O
Antagonist O
Losartan O
) O
is O
the O
first O
major O
study O
to O
compare O
an O
angiotensin O
II O
Type O
1 O
antagonist O
losartan O
( O
Cozaar O
trade O
mark O
, O
Merck O
) O
with O
an O
ACE O
inhibitor O
captonpril O
( O
Capoten O
trade O
mark O
, O
Elan O
) O
after O
myocardial O
infarction O
in O
patients O
with O
left O
ventricular O
dysfunction O
. O
[]

Montelukast O
treatment O
of O
moderate O
to O
severe O
atopic O
dermatitis O
in O
adults O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

OBJECTIVES O
The O
objective O
of O
this O
study O
was O
to O
access O
whether O
there O
were O
any O
therapeutic O
effects O
of O
Thai O
Traditional O
Massage O
( O
TTM O
) O
on O
major O
behavioral O
and O
emotional O
disturbances O
in O
Thai O
autistic O
children O
. O
[]

OBJECTIVE O
To O
describe O
the O
pharmacokinetic O
profiles O
of O
six O
different O
dosing O
regimens O
for O
epoetin O
alfa O
, O
and O
whether O
more O
rapid O
and O
robust O
reticulocytosis O
can O
be O
elicited O
with O
more O
frequent O
administration O
of O
epoetin O
alfa O
in O
anemic O
critically O
ill O
patients O
. O
[]

The O
appearance O
of O
the O
scar B-outcome ['Physiological-Clinical']
, O
including O
scar B-outcome ['Physiological-Clinical']
type O
and O
scar B-outcome ['Physiological-Clinical']
size O
as O
well O
as O
scar B-outcome ['Physiological-Clinical']
colour I-outcome ['Physiological-Clinical']
, O
was O
assessed O
by O
the O
physician O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Correlation O
of O
adenosinergic O
activity O
with O
superior O
efficacy O
of O
clozapine O
for O
treatment O
of O
chronic O
schizophrenia O
: O
a O
double O
blind O
randomised O
trial O
. O
[]

The O
morbidity O
scores O
( O
infection/infusion O
) O
were O
1.59 O
, O
1.21 O
and O
1.77 O
respectively O
( O
p O
- O
N/S O
) O
. O
[]

In O
the O
present O
study O
, O
we O
sought O
to O
determine O
the O
safety O
and O
biologic O
response O
of O
recombinant O
human O
( O
rhu O
) O
GM-CSF O
in O
VLBW O
neonates O
. O
[]

Maintenance O
of O
these O
results O
over O
time O
would O
project O
into O
better O
long-term O
success O
for O
all-polyethylene O
tibial O
components O
because O
of O
the O
amount O
of O
wear O
and O
osteolysis O
with O
current O
modular O
metal-backed O
tibial O
components O
. O
[]

The O
complete O
resistance B-outcome ['Physiological-Clinical']
of O
the O
nose O
was O
measured O
in O
a O
randomized O
order O
by O
means O
of O
aR O
and O
IOS O
. O
['Physiological-Clinical']

ECG O
ST O
shift B-outcome ['Physiological-Clinical']
at O
2 O
min O
of O
coronary O
artery O
balloon O
occlusion O
. O
['Physiological-Clinical']

Results O
of O
SEM O
showed O
that O
the O
observed O
greater O
reduction O
in O
PPD B-outcome ['Physiological-Clinical']
and O
BOP B-outcome ['Physiological-Clinical']
in O
persons O
using O
interdental O
brushing O
than O
in O
those O
flossing O
is O
due O
mainly O
to O
the O
greater O
efficiency O
in O
plaque B-outcome ['Resource-use']
removal I-outcome ['Resource-use']
with O
the O
interdental O
brushes O
( O
indirect O
effect O
) O
rather O
than O
to O
the O
compression O
of O
the O
interdental O
papillae O
( O
direct O
effect O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Seventeen O
patients O
on O
chronic O
digitalis O
and O
diuretic O
therapy O
were O
randomized O
to O
receive O
either O
flosequinan O
( O
n O
= O
9 O
) O
or O
placebo O
( O
n O
= O
8 O
) O
in O
a O
double-blind O
fashion O
. O
[]

PURPOSE O
To O
determine O
whether O
dronabinol O
administered O
alone O
or O
with O
megestrol O
acetate O
was O
more O
, O
less O
, O
or O
equal O
in O
efficacy O
to O
single-agent O
megestrol O
acetate O
for O
palliating O
cancer-associated O
anorexia O
. O
[]

Five O
of O
the O
11 O
neonates O
with O
gestational O
age O
( O
GA O
) O
< O
or O
= O
28 O
weeks O
and O
three O
of O
the O
seven O
neonates O
in O
GA O
29-30 O
weeks O
died B-outcome ['Mortality']
. O
['Mortality']

RESULTS O
The O
questionnaire O
was O
returned O
by O
174 O
patients O
( O
83 O
% O
) O
. O
[]

Treatment O
of O
duodenal O
ulcer O
with O
low-dose O
antacids O
. O
[]

The O
results O
indicated O
that O
the O
PostureJac O
group O
was O
superior O
to O
the O
no-treatment O
control O
( O
p=.001 O
) O
and O
the O
treatment-control O
( O
p=.004 O
) O
groups O
in O
terms O
of O
increasing O
endurance B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
deep I-outcome ['Physiological-Clinical']
cervical I-outcome ['Physiological-Clinical']
flexors I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Another O
secondary O
data O
analysis O
from O
that O
study O
suggested O
that O
marijuana B-outcome ['Life-Impact']
smoking I-outcome ['Life-Impact']
was O
also O
significantly O
decreased O
in O
a O
subgroup O
of O
subjects O
who O
demonstrated O
cannabis O
abuse O
and O
that O
the O
magnitude O
of O
this O
improvement O
was O
robust O
. O
['Life-Impact']

Nine O
trained O
cyclists O
exercised O
on O
3 O
separate O
occasions O
at O
intensities O
that O
varied O
between O
45 O
% O
and O
75 O
% O
VO2max O
for O
3 O
h O
and O
then O
at O
85 O
% O
VO2max O
until O
fatigued O
. O
[]

OBJECTIVES O
In O
aromatherapy O
, O
lavender O
aroma O
is O
reputed O
to O
assist O
with O
relaxation O
. O
[]

There O
were O
no O
study O
drug-related B-outcome ['Mortality']
deaths I-outcome ['Mortality']
. O
['Mortality']

Group O
A O
received O
Jessner O
's O
solution O
peel O
, O
group O
B O
received O
trichloroacetic O
acid O
peel O
20 O
% O
, O
and O
group O
C O
received O
topical O
hydroquinone O
2 O
% O
and O
kojic O
acid O
. O
[]

Other O
side O
effects O
were O
more O
common O
in O
the O
group O
treated O
with O
AR-R15896AR O
: O
vomiting B-outcome ['Physiological-Clinical']
( O
29 O
% O
vs. O
9 O
% O
) O
, O
nausea B-outcome ['Physiological-Clinical']
( O
23 O
% O
vs. O
12 O
% O
) O
, O
fever B-outcome ['Physiological-Clinical']
( O
17 O
% O
vs. O
12 O
% O
) O
, O
agitation B-outcome ['Life-Impact']
( O
7 O
% O
vs. O
3 O
% O
) O
, O
dizziness B-outcome ['Physiological-Clinical']
( O
7 O
% O
vs. O
0 O
% O
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Effect O
of O
allopurinol O
on O
myocardial O
oxygen B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
radical I-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
in O
coronary O
bypass O
surgery O
. O
['Physiological-Clinical']

Mean O
reported B-outcome ['Life-Impact']
energy I-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
was O
significantly O
lower O
than O
estimated O
total O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
for O
the O
telephone O
recalls O
and O
combined O
( O
lean O
and O
obese O
modes O
) O
in-person O
recalls O
. O
['Life-Impact', 'Physiological-Clinical']

These O
technologies O
have O
been O
applied O
not O
only O
to O
the O
removal O
of O
toxic O
substances O
, O
but O
also O
to O
the O
treatment O
of O
objective O
diseases O
and O
the O
removal O
of O
the O
factors O
relating O
to O
the O
associated O
inflammation O
. O
[]

Forty-one O
persons O
with O
a O
DSM- O
? O
[]

Between-group O
differences O
in O
glycosylated O
hemoglobin O
( O
HbA1c O
) O
, O
continuous O
glucose O
sensor O
data O
, O
insulin O
utilization O
, O
anthropometric O
measures O
, O
and O
patient O
satisfaction O
with O
therapy O
were O
also O
compared O
at O
multiple O
time O
points O
. O
[]

BACKGROUND O
The O
rationale O
for O
replacing O
racemic O
bupivacaine O
with O
the O
s-enantiomers O
levobupivacaine O
and O
ropivacaine O
is O
to O
provide O
a O
wider O
margin O
of O
safety O
with O
the O
same O
analgesic B-outcome ['Resource-use']
efficacy O
and O
less O
postoperative B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
block O
. O
['Resource-use', 'Physiological-Clinical']

The O
numbers O
of O
deaths O
and O
all-cause O
, O
pregnancy-related O
mortality O
rates O
( O
per O
100,000 O
pregnancies O
) O
were O
41 O
and O
206 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
140-273 O
) O
in O
the O
placebo O
group O
, O
47 O
and O
237 O
( O
95 O
% O
CI O
, O
166-309 O
) O
in O
the O
vitamin O
A O
group O
, O
and O
50 O
and O
250 O
( O
95 O
% O
CI O
, O
177-323 O
) O
in O
the O
beta O
carotene O
group O
. O
[]

In O
the O
FAMTX O
+ O
surgery O
treatment O
group O
, O
15/27 O
( O
56 O
% O
) O
had O
curative B-outcome ['Physiological-Clinical']
resections I-outcome ['Physiological-Clinical']
versus O
18/29 O
( O
62 O
% O
) O
in O
the O
surgery O
only O
arm O
. O
['Physiological-Clinical']

BACKGROUND O
Results O
of O
small O
trials O
suggest O
that O
early O
interventions O
for O
social O
communication O
are O
effective O
for O
the O
treatment O
of O
autism O
in O
children O
. O
[]

Mean O
ratings O
at O
endpoint O
were O
2.8 O
+/- O
1.2 O
on O
risperidone O
and O
4.5 O
+/- O
1.3 O
on O
placebo O
( O
p O
< O
.001 O
) O
. O
[]

Acupuncture O
using O
menopausal-specific O
sites O
holds O
promise O
for O
nonhormonal O
relief O
of O
hot B-outcome ['Physiological-Clinical']
flushes I-outcome ['Physiological-Clinical']
and O
sleep B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Of O
those O
patients O
in O
whom O
receptors O
were O
known O
, O
response O
rates O
were O
65 O
% O
for O
estrogen O
( O
ER O
) O
-receptor O
positive O
and O
70 O
% O
for O
ER-negative O
patients O
. O
[]

1.1 O
yr O
) O
performed O
three O
trials O
of O
40 O
% O
maximal O
voluntary O
contraction O
handgrip O
for O
2 O
min O
, O
followed O
by O
3 O
min O
of O
postexercise O
circulatory O
occlusion O
( O
PECO O
) O
to O
stimulate O
the O
metaboreflex O
. O
[]

No O
significant O
change O
in O
P-wave B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
or O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
found O
after O
caffeine O
ingestion O
at O
any O
test O
interval O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Surgical O
time O
is O
reduced O
. O
[]

Within O
six O
years O
of O
randomisation O
, O
genetic B-outcome ['Resource-use']
testing I-outcome ['Resource-use']
was O
actually O
undertaken O
on O
12 O
women O
, O
only O
10 O
of O
whom O
would O
now O
be O
eligible O
, O
on O
the O
NICE O
guidelines O
. O
['Resource-use']

Methylphenidate O
doses O
used O
approximated O
.125 O
, O
.25 O
, O
and O
.5 O
mg/kg O
per O
dose O
, O
twice O
daily O
, O
with O
an O
additional O
half-dose O
in O
the O
late O
afternoon O
. O
[]

In O
addition O
, O
we O
investigated O
the O
effect O
of O
pegvisomant O
under O
normal O
, O
i.e O
. O
[]

EXPERIMENTAL O
DESIGN O
Irinotecan O
was O
given O
orally O
in O
fasted O
patients O
once O
daily O
for O
5 O
consecutive O
days O
and O
repeated O
every O
3 O
weeks O
. O
[]

However O
, O
increased O
3-HIA O
excretion O
could O
result O
from O
pregnancy O
per O
se O
( O
eg O
, O
from O
an O
effect O
of O
pregnancy O
on O
renal O
handling O
of O
organic O
acids O
) O
. O
[]

RESULTS O
The O
administration O
of O
penicillin O
did O
not O
significantly O
( O
P O
> O
.05 O
) O
reduce O
pain B-outcome ['Physiological-Clinical']
, O
percussion B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
or O
the O
number O
of O
['Physiological-Clinical', 'Physiological-Clinical']

This O
was O
not O
statistically O
significant O
( O
P O
= O
.977 O
) O
. O
[]

Results O
suggested O
that O
the O
education O
program O
had O
significant O
effects O
on O
knowledge B-outcome ['Life-Impact']
, O
attitudes B-outcome ['Life-Impact']
, O
planned O
and O
['Life-Impact', 'Life-Impact']

However O
, O
during O
testing O
after O
a O
delay O
, O
response O
times O
were O
slower O
and O
proportion O
of O
trials O
retrieved O
was O
lower O
for O
short O
lag O
items O
than O
for O
long O
lag O
items O
. O
[]

Less O
tachycardia B-outcome ['Physiological-Clinical']
in O
adults O
when O
using O
atropine O
0.9 O
mg O
compared O
with O
1.2 O
mg O
plus O
neostigmine O
2.5 O
mg O
. O
['Physiological-Clinical']

It O
is O
an O
effective O
, O
modern O
, O
low-invasive O
, O
and O
repeatable O
technique O
and O
is O
technically O
simple O
and O
easy O
to O
master O
. O
[]

0.45 O
) O
, O
1.07 O
( O
0.21 O
) O
, O
1.13 O
( O
0.30 O
) O
and O
1.02 O
( O
0.27 O
) O
. O
[]

Effects O
of O
halothane O
and O
isoflurane O
on O
transient B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
associated O
with O
infrarenal O
aortic O
cross-clamping O
. O
['Physiological-Clinical']

BACKGROUND O
Eberconazole O
is O
a O
topical O
, O
broad-spectrum O
imidazole O
derivative O
, O
effective O
in O
dermatophytoses O
, O
candidiasis O
, O
and O
pityriasis O
treatment O
. O
[]

Sodium-glucose O
cotransporters O
1 O
( O
SGLT1 O
) O
and O
2 O
( O
SGLT2 O
) O
are O
the O
major O
cellular O
transporters O
responsible O
for O
gastrointestinal O
( O
GI O
) O
glucose O
absorption O
and O
renal O
glucose O
reabsorption O
, O
respectively O
. O
[]

Unfortunately O
, O
enrollment O
was O
terminated O
because O
of O
low O
accrual O
of O
women O
with O
cervicitis O
of O
unknown O
etiology O
, O
but O
important O
prevalence O
and O
outcome O
data O
were O
obtained O
. O
[]

Dietary O
iron O
exposures O
were O
estimated O
from O
a O
food O
frequency O
questionnaire O
. O
[]

However O
, O
patients O
demonstrated O
a O
specific O
prolongation B-outcome ['Physiological-Clinical']
of O
these O
measures O
during O
processing O
of O
predicted O
targets O
, O
as O
well O
as O
an O
attenuation O
of O
P3b B-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
for O
the O
predictive O
sequence O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
ciprofloxacin O
0.3 O
% O
/dexamethasone O
0.1 O
% O
( O
CIPRODEX O
, O
Alcon O
, O
Ft. O
Worth O
, O
TX O
) O
for O
the O
prevention O
of O
early O
post-operative O
otorrhea O
following O
TT O
placement O
. O
[]

METHODS O
Prospective O
, O
blinded O
, O
randomized O
clinical O
trial O
. O
[]

The O
results O
showed O
that O
the O
percentages O
of O
OKT3+ B-outcome ['Physiological-Clinical']
, O
OKT4+ B-outcome ['Physiological-Clinical']
, O
OKT8+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
peripheral I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
of O
the O
51 O
patients O
were O
lower O
than O
those O
of O
the O
normal O
adults O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Secondary O
outcomes O
were O
duration O
of O
mechanical B-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
, O
length B-outcome ['Resource-use']
of O
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
exacerbation-free B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

The O
incidence O
of O
ARDS B-outcome ['Physiological-Clinical']
due I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
chemotherapy I-outcome ['Physiological-Clinical']
session I-outcome ['Physiological-Clinical']
was O
4.21 O
% O
, O
and O
showed O
a O
higher O
tendency O
in O
the O
G-CSF O
group O
( O
p O
< O
0.100 O
, O
chi2 O
test O
) O
. O
['Physiological-Clinical']

Pain O
scores O
( O
rest O
, O
cough O
, O
and O
ambulation O
) O
, O
side O
effects O
( O
nausea O
, O
pruritus O
, O
sedation O
, O
motor O
block O
, O
hypotension O
, O
and O
orthostasis O
) O
, O
and O
patient-controlled O
epidural O
analgesia O
consumption O
were O
measured O
for O
48 O
h. O
RESULTS O
All O
three O
solutions O
produced O
equivalent O
analgesia O
. O
[]

Various O
attempts O
have O
been O
made O
to O
overcome O
restrictions O
due O
to O
loss O
of O
triangulation O
in O
SILS O
by O
specially O
designed O
SILS-specific O
instruments O
. O
[]

Patients O
' O
QoL O
, O
asthma O
knowledge O
was O
assessed O
twice O
, O
once O
before O
and O
after O
the O
education O
seminar O
, O
education O
was O
only O
provided O
for O
the O
intervention O
group O
. O
[]

PURPOSE O
The O
antiemetic O
effect O
of O
granisetron O
injection O
at O
a O
dose O
of O
40 O
microg/kg O
used O
in O
the O
treatment O
of O
nausea/vomiting O
induced O
by O
multidrug O
combined O
cancer O
chemotherapy O
excluding O
cisplatin O
in O
patients O
with O
tumors O
of O
hematopoietic O
organs O
was O
evaluated O
by O
comparing O
a O
30-min O
infusion O
and O
a O
slow O
intravenous O
injection O
given O
over O
30 O
s. O
METHODS O
A O
two-group O
random-allocation O
comparative O
study O
was O
performed O
with O
the O
cooperation O
of O
multiple O
institutions O
using O
a O
central O
registration O
system O
. O
[]

Here O
, O
we O
investigated O
whether O
a O
3-week O
administration O
of O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
expected O
to O
increase O
brain O
5-HT O
levels O
, O
is O
associated O
with O
a O
decline O
in O
brain O
5-HT4R O
binding O
. O
[]

We O
assess O
the O
incidence O
and O
clinical O
significance O
of O
false-negative O
sextant O
prostate O
biopsies O
in O
patients O
undergoing O
radical O
prostatectomy O
. O
[]

DESIGN O
Open O
, O
prospective O
, O
randomized O
, O
multicentre O
, O
controlled O
study O
for O
parallel O
groups O
, O
stratified O
for O
adults O
and O
children O
. O
[]

Muscle O
TCr O
increased O
( O
P O
< O
0.05 O
) O
throughout O
the O
Cr O
trial O
in O
both O
groups O
but O
was O
greater O
( O
P O
< O
0.05 O
) O
in O
VEG O
compared O
with O
NVEG O
, O
at O
days O
1 O
and O
5 O
. O
[]

A O
pilot O
study O
on O
the O
effect O
of O
progressive O
muscle O
relaxation O
training O
of O
patients O
after O
stoma O
surgery O
. O
[]

Medication O
was O
given O
as O
one O
dosage O
in O
the O
evening O
: O
2-5 O
mg/kg O
KG O
ASS O
or O
5-10 O
mg O
Flunarizine O
. O
[]

In O
the O
treated O
group O
, O
the O
percentage O
of O
G0/G1 B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
were O
significantly O
increased O
and O
that O
of O
S O
stage B-outcome ['Physiological-Clinical']
significantly O
decreased O
( O
both O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Prospective O
, O
randomized O
, O
open-label O
study O
. O
[]

Rapid O
tightening O
of O
blood O
glucose O
control O
leads O
to O
transient O
deterioration O
of O
retinopathy B-outcome ['Physiological-Clinical']
in O
insulin O
dependent O
diabetes O
mellitus O
: O
the O
Oslo O
study O
. O
['Physiological-Clinical']

Effect O
of O
augmented O
sensorimotor O
input O
on O
learning B-outcome ['Life-Impact']
verbal I-outcome ['Life-Impact']
and O
nonverbal B-outcome ['Life-Impact']
tasks I-outcome ['Life-Impact']
among O
children O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact', 'Life-Impact']

MATERIAL O
AND O
METHODS O
This O
randomized O
controlled O
trial O
was O
done O
in O
the O
Dhaka O
Medical O
College O
and O
Hospital O
and O
the O
Infertility O
Care O
and O
Research O
Centre O
, O
Dhaka O
, O
Bangladesh O
. O
[]

These O
findings O
seem O
to O
confirm O
reduced O
PMN O
activation O
and/or O
reduced O
myocardial O
infiltration O
by O
activated O
PMN O
. O
[]

In O
this O
study O
, O
we O
examined O
the O
role O
of O
statins O
in O
experimental O
endotoxemia O
on O
inflammatory O
and O
procoagulant O
responses O
in O
vivo O
. O
[]

In O
the O
EC O
, O
using O
the O
EC O
machine O
( O
Wieda O
, O
China O
) O
, O
direct O
current O
of O
10-20 O
mA O
was O
applied O
in O
the O
submucosal O
plane O
of O
each O
pile O
core O
for O
5-7 O
minutes O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Visual O
field O
progression O
, O
measured O
by O
Humphrey O
24-2 O
full-threshold O
testing O
and O
assessed O
by O
the O
change O
in O
the O
mean O
deviation O
( O
MD O
) O
, O
and O
an O
indicator O
of O
substantial B-outcome ['Physiological-Clinical']
worsening I-outcome ['Physiological-Clinical']
of O
the O
VF B-outcome ['Physiological-Clinical']
( O
MD O
decrease O
of O
> O
or O
=3 O
dB O
from O
baseline O
) O
, O
assessed O
at O
each O
follow-up O
visit O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Retinal O
vessels O
showed O
a O
small B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
increase O
, O
whereas O
red B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
speed I-outcome ['Physiological-Clinical']
decreased O
, O
resulting O
in O
an O
unchanged O
total O
retinal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Education/income O
levels O
were O
low O
. O
[]

Complication B-outcome ['Resource-use']
rate O
and O
mortality B-outcome ['Mortality']
were O
studied O
. O
['Resource-use', 'Mortality']

One O
group O
had O
open O
appendicectomy O
, O
as O
planned O
. O
[]

A O
total O
of O
101 O
patients O
were O
stratified O
according O
to O
sex O
, O
age O
, O
BMI O
, O
duration O
of O
diabetes O
, O
and O
HbA1c O
, O
and O
then O
randomized O
to O
receive O
instructions O
to O
eat O
either O
vegetables O
before O
carbohydrate O
( O
VBC O
, O
n=69 O
) O
or O
an O
exchange-based O
meal O
plan O
( O
EXB O
, O
n=32 O
) O
. O
[]

INTRODUCTION O
Double O
hearing O
protection O
is O
used O
in O
many O
air O
forces O
around O
the O
world O
for O
protection O
in O
noisy O
aircraft O
environments O
, O
particularly O
in O
helicopters O
. O
[]

We O
performed O
a O
double-blind O
placebo-controlled O
randomized O
trial O
to O
evaluate O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
zonisamide O
( O
ZNS O
) O
, O
an O
antiepileptic O
agent O
, O
in O
treating O
ET B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

OBJECTIVE O
Although O
patient O
education O
may O
enhance O
knowledge O
, O
coping O
with O
illness O
, O
and O
quality O
of O
life O
among O
cancer O
patients O
, O
it O
is O
uncertain O
which O
didactic O
method O
is O
most O
effective O
. O
[]

Corresponding O
5-year O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
60.0 O
and O
56.6 O
per O
cent O
( O
P O
= O
0.482 O
) O
, O
and O
recurrence B-outcome ['Physiological-Clinical']
rates O
32.9 O
and O
34.3 O
per O
cent O
( O
P O
= O
0.864 O
) O
. O
['Mortality', 'Physiological-Clinical']

BACKGROUND O
The O
thiol O
donor O
N-acetylcysteine O
may O
potentiate O
the O
hemodynamic O
response O
to O
nitrates O
in O
nitrate-tolerant O
and O
nontolerant O
patients O
. O
[]

Efficacy O
of O
treatment O
was O
measured O
using O
the O
Social O
Phobia O
Scale O
( O
subscores O
anxiety O
and O
avoidance O
) O
and O
the O
Hamilton O
Rating O
Scale O
for O
Anxiety O
. O
[]

CONCLUSION O
( O
S O
) O
Performing O
ICSI O
on O
at O
least O
some O
of O
the O
oocytes O
will O
avoid O
unnecessary O
fertilization B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
in O
patients O
with O
borderline O
semen O
: O
in O
this O
study O
, O
26 O
of O
104 O
cycles O
( O
25 O
% O
) O
were O
rescued O
by O
ICSI O
. O
['Physiological-Clinical']

METHODS O
One O
hundred O
patients O
were O
randomized O
into O
2 O
groups O
to O
undergo O
percutaneous O
transmitral O
commissurotomy O
( O
PTMC O
) O
by O
means O
of O
the O
Inoue O
balloon O
technique O
( O
IBMC O
, O
n O
= O
49 O
) O
or O
metallic O
commissurotomy O
( O
PMMC O
, O
n O
= O
51 O
) O
. O
[]

Correlation O
between O
in O
vivo O
humoral O
and O
in O
vitro O
cellular O
immune O
responses O
following O
immunization O
with O
hepatitis O
B O
surface O
antigen O
( O
HBsAg O
) O
vaccines O
. O
[]

CONCLUSIONS O
COMPASS O
is O
effective O
and O
results O
in O
improved O
educational O
outcomes O
for O
young O
children O
with O
autism O
. O
[]

MATERIALS/METHODS O
Clinically O
established O
pathological O
parameters O
were O
assessed O
and O
related O
to O
the O
tamoxifen O
response O
in O
500 O
available O
tumour O
specimens O
from O
564 O
premenopausal O
patients O
with O
breast O
cancer O
randomised O
to O
either O
two O
years O
of O
tamoxifen O
or O
no O
treatment O
with O
14 O
years O
of O
follow O
up O
. O
[]

CONCLUSIONS O
Parents O
did O
not O
report O
statistically O
significant O
behavioral B-outcome ['Life-Impact']
change I-outcome ['Life-Impact']
with O
amantadine O
. O
['Life-Impact']

Dissections O
were O
graded O
at O
the O
core O
laboratory O
by O
two O
observers O
and O
divided O
into O
four O
categories O
: O
none O
, O
mild O
( O
type O
A-B O
) O
, O
moderate O
( O
type O
C O
) O
, O
severe O
( O
types O
D O
to O
F O
) O
. O
[]

Twenty-six O
patients O
, O
aged O
21 O
to O
36 O
years O
( O
mean O
age O
27 O
) O
, O
received O
only O
fluoxetine O
20 O
mg/day O
( O
1 O
capsule O
) O
for O
a O
week O
which O
was O
later O
increased O
to O
40 O
mg/day O
( O
2 O
capsules O
) O
. O
[]

Excluding O
hospital B-outcome ['Mortality']
deaths I-outcome ['Mortality']
, O
patients O
with O
leakage B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
anastomotic I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
, O
and O
those O
who O
received O
radiation O
therapy O
to O
histologically O
infiltrated O
resection O
margin O
, O
anastomotic B-outcome ['Physiological-Clinical']
stricture I-outcome ['Physiological-Clinical']
was O
found O
in O
5 O
( O
9.1 O
% O
) O
of O
55 O
patients O
in O
the O
hand-sewn O
group O
and O
20 O
( O
40 O
% O
) O
of O
50 O
in O
the O
stapler O
group O
( O
p O
= O
0.0003 O
) O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Mean O
sex B-outcome ['Physiological-Clinical']
hormone-binding I-outcome ['Physiological-Clinical']
globulin I-outcome ['Physiological-Clinical']
increased O
significantly O
in O
subjects O
using O
the O
desogestrel-containing O
contraceptive O
compared O
with O
the O
levonorgestrel-containing O
contraceptive O
. O
['Physiological-Clinical']

The O
activated B-outcome ['Physiological-Clinical']
clotting I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
was O
measured O
at O
the O
end O
of O
the O
procedure O
. O
['Physiological-Clinical']

The O
reliability O
of O
catheter-tip O
transducers O
for O
the O
measurement O
of O
intrauterine B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
the O
third O
stage O
of O
labour O
. O
['Physiological-Clinical']

RESULTS O
Each O
of O
101 O
intervention O
participants O
met O
with O
the O
GNP O
from O
1 O
to O
8 O
times O
( O
median O
= O
3 O
) O
during O
the O
study O
year O
. O
[]

Both O
therapies O
last O
six O
weeks O
. O
[]

Each O
patient O
had O
, O
in O
randomized O
order O
, O
a O
treatment O
of O
2 O
weeks O
with O
250 O
ml O
20 O
% O
Actovegin O
and O
250 O
ml O
placebo O
daily O
. O
[]

There O
were O
no O
differences O
between O
the O
two O
treatment O
groups O
in O
the O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

In O
this O
study O
, O
150 O
patients O
with O
gallbladder O
lithiasis O
who O
underwent O
laparoscopy O
were O
randomly O
assigned O
to O
two O
groups O
, O
a O
blind O
( O
V O
group O
) O
or O
an O
open O
( O
H O
group O
) O
, O
in O
order O
to O
compare O
the O
results O
and O
the O
rate O
of O
complications B-outcome ['Adverse-effects']
. O
['Adverse-effects']

This O
study O
examined O
the O
effect O
of O
an O
8-month O
exercise O
intervention O
on O
WMI O
in O
children O
. O
[]

At O
24 O
months O
from O
EOT O
, O
spine B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
increased O
by O
1.53 O
% O
( O
95 O
% O
CI O
0.63-2.43 O
; O
p O
= O
0.001 O
) O
after O
stopping O
exemestane O
and O
fell O
by O
1.93 O
% O
( O
95 O
% O
CI O
-2.91 O
to O
0.95 O
; O
p O
= O
0.0002 O
) O
following O
tamoxifen O
withdrawal O
. O
['Physiological-Clinical']

Accordingly O
, O
the O
cerebral B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
decreased O
equally O
during O
the O
Sal O
and O
Bicarb O
trials O
: O
from O
5.8?0.6 O
at O
rest O
to O
1.7?0.1 O
and O
1.8?0.2 O
, O
respectively O
. O
['Physiological-Clinical']

Based O
on O
those O
data O
, O
a O
randomised O
multicentre O
study O
was O
started O
to O
explore O
the O
risk O
of O
an O
anastomotic B-outcome ['Physiological-Clinical']
leakage I-outcome ['Physiological-Clinical']
based O
upon O
the O
surgical O
device O
. O
['Physiological-Clinical']

The O
tyrosine O
kinase O
receptor O
EGFR O
pathway O
is O
one O
of O
the O
oncogenic O
signaling O
cascades O
involved O
in O
lung O
cancer O
, O
mediating O
the O
epidermal O
growth O
factor O
receptor O
gene O
EGFR O
. O
[]

Compliance O
with O
continuous O
passive O
movement O
is O
low O
after O
surgical O
treatment O
of O
idiopathic O
club O
foot O
in O
infants O
: O
a O
prospective O
, O
double-blinded O
clinical O
study O
. O
[]

Lack O
of O
benefit O
of O
a O
single O
dose O
of O
synthetic O
human O
secretin O
in O
the O
treatment O
of O
autism O
and O
pervasive O
developmental O
disorder O
. O
[]

The O
European O
Myocardial O
Infarction O
Project O
: O
an O
assessment O
of O
pre-hospital O
thrombolysis O
. O
[]

We O
examined O
the O
prognostic O
value O
of O
inflammatory O
markers O
( O
albumin O
, O
white-cell O
count O
and O
its O
components O
, O
and O
platelets O
) O
in O
pre-treated O
patients O
with O
advanced O
renal O
cell O
carcinoma O
( O
RCC O
) O
. O
[]

The O
D-C O
model O
did O
not O
predict O
caregiver B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Life-Impact']

Effect O
of O
erythromycin O
and O
gentamicin O
on O
abomasal B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
rate O
in O
suckling O
calves O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
current O
report O
calls O
attention O
to O
the O
importance O
of O
central O
pathologic O
review O
in O
large O
multiinstitutional O
trials O
of O
children O
with O
gliomas O
and O
suggests O
that O
aggressive O
front-line O
combined O
chemoradiotherapy O
does O
not O
confer O
a O
survival B-outcome ['Mortality']
advantage O
in O
this O
highly O
selected O
population O
of O
patients O
. O
['Mortality']

INTERVENTION O
Supervised O
exercise O
, O
comprising O
high-intensity O
cardiovascular O
and O
heavy O
resistance O
training O
, O
relaxation- O
and O
body O
awareness O
training O
and O
massage O
, O
9 O
h O
weekly O
for O
6 O
weeks O
. O
[]

BACKGROUND O
Home O
based O
medical O
care O
is O
a O
popular O
alternative O
to O
standard O
hospital O
care O
but O
there O
is O
uncertainty O
about O
its O
cost-effectiveness O
. O
['Resource-use']

However O
, O
enrollment O
in O
the O
phase O
III O
trial O
was O
restricted O
to O
class-I O
HLA-A*0201-positive O
patients O
because O
two O
of O
the O
three O
arms O
contained O
an O
HLA-A*0201-restricted O
gp100 O
vaccine O
. O
[]

However O
, O
in O
the O
D53-treated O
group O
, O
but O
not O
in O
the O
placebo O
group O
, O
IL-1 B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
induced O
by O
low O
LPS B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
5 O
mg/L O
) O
was O
significantly O
higher O
( O
mean O
+/- O
SEM O
: O
1,238 O
+/- O
287 O
U/10 O
( O
6 O
) O
AM O
) O
on O
day O
15 O
in O
comparison O
with O
day O
1 O
( O
577 O
+/- O
113 O
U/10 O
( O
6 O
) O
AM O
; O
p O
less O
than O
0.05 O
, O
Wilcoxon O
W O
test O
) O
and O
in O
comparison O
with O
the O
control O
group O
( O
day O
15 O
IL-1 B-outcome ['Physiological-Clinical']
production O
induced O
by O
5 O
mg/L O
LPS O
, O
758 O
+/- O
175 O
U/10 O
( O
6 O
) O
AM O
; O
p O
less O
than O
0.05 O
, O
Mann-Whitney O
U O
test O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

More O
research O
is O
needed O
to O
determine O
what O
caused O
the O
high O
rate O
of O
dropout B-outcome ['Life-Impact']
in O
the O
Web-based O
intervention O
. O
['Life-Impact']

Eight O
of O
the O
ten O
children O
used O
five O
or O
more O
novel O
, O
functional B-outcome ['Life-Impact']
words O
spontaneously O
and O
spoke O
multiple O
times O
per O
hour O
by O
the O
conclusion O
of O
treatment O
. O
['Life-Impact']

Randomized O
controlled O
trials O
are O
needed O
. O
[]

CONCLUSION O
The O
results O
show O
that O
the O
training O
program O
is O
feasible O
and O
seems O
to O
have O
positive O
influences O
on O
physical B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
patients O
undergoing O
an O
allogeneic O
HSCT O
. O
['Physiological-Clinical', 'Life-Impact']

78 O
patients O
with O
bacterial O
meningitis O
were O
evaluated O
in O
a O
prospective O
, O
randomised O
study O
comparing O
twice-daily O
ceftriaxone O
as O
single-drug O
therapy O
with O
ampicillin O
and O
chloramphenicol O
given O
every O
6 O
h. O
The O
groups O
were O
comparable O
in O
age O
, O
sex O
, O
days O
of O
illness O
before O
admission O
, O
and O
bacterial O
colony O
counts O
in O
cerebrospinal O
fluid O
( O
CSF O
) O
. O
[]

Regression O
analysis O
demonstrated O
that O
performance B-outcome ['Physiological-Clinical']
status B-outcome ['Physiological-Clinical']
was O
the O
most O
important O
pretreatment O
characteristic O
for O
predicting O
['Physiological-Clinical', 'Physiological-Clinical']

Based O
on O
the O
magnitude O
of O
the O
immune O
response O
( O
anti-HBs O
titre O
) O
on O
day O
395 O
, O
the O
vaccinees O
could O
be O
divided O
into O
high O
( O
> O
or O
= O
2000 O
U O
l-1 O
) O
and O
low O
( O
< O
or O
= O
2000 O
U O
l-1 O
) O
responders O
. O
[]

METHODS O
Patients O
were O
randomly O
assigned O
to O
undergo O
serial O
testing O
of O
the O
efficacy O
of O
the O
seven O
antiarrhythmic O
drugs O
by O
one O
of O
two O
strategies O
: O
electrophysiologic O
study O
or O
Holter O
monitoring O
together O
with O
exercise O
testing O
. O
[]

BACKGROUND O
Interventions O
for O
pervasive O
developmental O
disorders O
( O
PDD O
) O
aim O
to O
alleviate O
symptoms O
and O
improve O
functioning O
. O
[]

The O
root O
canals O
were O
obturated O
with O
gutta-percha O
and O
one O
of O
the O
sealers O
by O
the O
lateral-vertical O
condensation O
technique O
. O
[]

Because O
the O
latter O
is O
inhibited O
in O
aspirin-treated O
patients O
, O
the O
hemostatic O
function O
depends O
mainly O
on O
the O
former O
pathway O
. O
[]

Standard O
interferon O
is O
more O
effective O
for O
hepatitis O
B O
e O
antigen O
( O
HBeAg O
) O
-negative O
CHB O
when O
given O
for O
longer O
than O
1 O
yr O
. O
[]

The O
low-dose O
monoethylglycinexylidide O
test O
: O
assessment O
of O
liver O
function O
with O
fewer O
side O
effects O
. O
[]

To O
demonstrate O
comparable O
efficacy O
of O
etoricoxib O
vs O
ibuprofen O
, O
the O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
for O
the O
difference O
in O
the O
least O
squares O
( O
LS B-outcome ['Physiological-Clinical']
) O
mean O
change O
over O
12 O
weeks O
for O
all O
three O
co-primary O
endpoints O
had O
to O
fall O
within O
+/-10 O
mm O
. O
['Physiological-Clinical']

Haemodynamic O
profile O
of O
angiotensin O
II O
antagonism O
in O
essential O
hypertensive O
patients O
. O
[]

Patients O
with O
PHD O
have O
altered O
sympathetic B-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Rates O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AE O
) O
, O
serious B-outcome ['Adverse-effects']
AE I-outcome ['Adverse-effects']
, O
and O
infections B-outcome ['Physiological-Clinical']
generally O
remained O
stable O
. O
['Adverse-effects', 'Adverse-effects', 'Physiological-Clinical']

Immunologic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
after O
laparoscopic O
colon O
cancer O
operation O
within O
an O
enhanced O
recovery O
program O
. O
['Physiological-Clinical']

The O
behaviour O
of O
the O
two O
treatments O
was O
not O
homogeneous O
across O
time O
( O
groups-by-time O
interaction O
, O
Greenhouse-Geisser O
correction O
; O
F O
= O
7.30 O
, O
d.f O
. O
[]

An O
adult O
was O
in O
the O
room O
sitting O
very O
still O
like O
a O
statue O
( O
first O
still-face O
condition O
) O
. O
[]

In O
subjects O
with O
impaired O
glucose O
tolerance O
a O
PUFA-rich O
diet O
with O
a O
moderate O
amount O
of O
fat O
tended O
to O
increase O
the O
susceptibility O
of O
[]

Dietary O
sodium O
alters O
renovascular O
responsiveness O
to O
angiotensin O
II O
( O
Ang O
II O
) O
in O
normal O
subjects O
. O
[]

BACKGROUND O
Recently O
, O
there O
has O
been O
an O
increase O
in O
popularity O
and O
participation O
in O
the O
sport O
of O
snowshoeing O
. O
[]

The O
results O
of O
a O
1-year O
naturalistic O
follow-up O
study O
involving O
the O
patients O
from O
that O
study O
suggest O
that O
the O
benefits O
of O
fluoxetine O
in O
decreasing O
depressive O
symptoms O
and O
level O
of O
drinking O
persist O
1 O
year O
after O
entering O
the O
treatment O
program O
. O
[]

Is O
hands-on O
experience O
more O
effective O
than O
didactic O
workshops O
in O
postgraduate O
cancer O
pain O
education O
? O
[]

Emotional B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
remained O
stable O
in O
both O
groups O
during O
treatment O
, O
whereas O
physical B-outcome ['Life-Impact']
and O
role B-outcome ['Life-Impact']
improved O
slightly O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

There O
were O
78 O
patients O
who O
either O
failed O
to O
achieve O
a O
CR B-outcome ['Physiological-Clinical']
or O
achieved O
a O
CR B-outcome ['Physiological-Clinical']
and O
later O
relapsed B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Dietary O
records O
showed O
that O
the O
subjects O
were O
consuming O
similar O
amounts O
and O
types O
of O
fat O
. O
[]

Long-term O
evaluation O
of O
tamsulosin O
in O
benign O
prostatic O
hyperplasia O
: O
placebo-controlled O
, O
double-blind O
extension O
of O
phase O
III O
trial O
. O
[]

METHODS O
This O
was O
a O
2-day O
, O
double-blind O
, O
double-dummy O
, O
randomized O
, O
parallel-group O
, O
placebo-controlled O
study O
of O
diclofenac-K O
( O
12.5 O
mg O
) O
tablets O
vs O
paracetamol O
( O
500 O
mg O
) O
tablets O
and O
placebo O
in O
patients O
with O
moderate O
or O
severe O
pain O
within O
8 O
hours O
of O
extraction O
of O
impacted O
third O
molars O
. O
[]

For O
yoga O
compared O
to O
usual O
activity O
, O
baseline O
to O
12-week O
improvements O
were O
seen O
for O
MENQOL O
total O
-0.3 O
( O
95 O
% O
confidence O
interval O
, O
-0.6 O
to O
0 O
; O
P O
= O
.02 O
) O
, O
vasomotor O
symptom O
domain O
( O
P O
= O
.02 O
) O
, O
and O
sexuality O
domain O
( O
P O
= O
.03 O
) O
scores O
. O
[]

The O
baseline O
characteristics O
of O
60 O
evaluable O
subjects O
, O
40 O
in O
the O
SH O
group O
and O
20 O
in O
the O
placebo O
group O
, O
were O
not O
significantly O
different O
. O
[]

Wilcoxon O
rank O
sum O
test O
was O
used O
for O
continuous O
variables O
. O
[]

To O
assess O
the O
effect O
of O
DUP O
on O
the O
neuropsychological O
status O
of O
the O
patients O
, O
a O
linear O
mixed-effect O
model O
was O
fitted O
to O
each O
neuropsychological O
dimension O
. O
[]

The O
availability O
of O
hematopoietic O
growth O
factors O
has O
greatly O
facilitated O
the O
mobilization O
and O
collection O
of O
peripheral O
blood O
stem O
cells O
( O
PBSC O
) O
. O
[]

SETTING O
Research O
laboratory O
in O
a O
rehabilitation O
hospital O
. O
[]

RESULTS O
Heatwrap O
therapy O
was O
shown O
to O
provide O
significant O
therapeutic B-outcome ['Physiological-Clinical']
benefits O
when O
compared O
with O
placebo O
during O
both O
the O
treatment O
and O
follow-up O
period O
. O
['Physiological-Clinical']

This O
clinical O
trial O
was O
conducted O
to O
determine O
if O
repeated O
intravenous O
paracetamol O
could O
decrease O
postoperative O
pain O
and O
rescue O
analgesic O
requirements O
after O
robot-assisted O
endoscopic O
thyroidectomy O
via O
the O
transaxillary O
approach O
. O
[]

RESULTS O
In O
this O
heterogeneous O
sample O
, O
the O
median O
number O
of O
words O
the O
child O
produced O
on O
placebo O
was O
9.5 O
( O
range O
0-124 O
) O
. O
[]

Results O
indicate O
that O
9 O
days O
of O
Cr O
supplementation O
during O
swim O
training O
may O
provide O
some O
ergogenic O
value O
to O
competitive O
junior O
swimmers O
during O
repetitive O
sprint O
performance O
. O
[]

There O
were O
no O
changes O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
with O
either O
fructose-1,6-diphosphate O
or O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Post-laparoscopic O
cholecystectomy O
pain O
: O
effects O
of O
intraperitoneal O
local O
anesthetics O
on O
pain O
control O
-- O
a O
randomized O
prospective O
double-blinded O
placebo-controlled O
trial O
. O
[]

METHODS O
We O
did O
a O
prospective O
, O
randomised O
controlled O
trial O
in O
5238 O
patients O
with O
type O
2 O
diabetes O
who O
had O
evidence O
of O
macrovascular B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
respective O
modulating O
effects O
of O
continuous O
and O
intermittent O
insulin O
delivery O
on O
pancreatic O
islet O
cell O
function O
were O
studied O
in O
seven O
normal O
men O
and O
nine O
insulin-dependent O
( O
type O
1 O
) O
diabetic O
patients O
. O
[]

Tolerability B-outcome ['Life-Impact']
and O
adverse B-outcome ['Adverse-effects']
event O
['Life-Impact', 'Adverse-effects']

Histologic O
examinations O
were O
performed O
to O
evaluate O
articular O
cartilage O
. O
[]

Knowledge O
regarding O
these O
genes O
and O
the O
advantages O
and O
limitations O
of O
genetic O
testing O
is O
limited O
. O
[]

Many O
subjects O
dropped O
out O
of O
the O
study O
, O
but O
those O
in O
active O
treatment O
who O
completed O
the O
eight O
week O
trial O
had O
a O
decrease O
in O
methamphetamine B-outcome ['Physiological-Clinical']
craving I-outcome ['Physiological-Clinical']
compared O
to O
the O
placebo O
treatment O
as O
measured O
by O
the O
OCDS O
modified O
for O
use O
in O
this O
population O
. O
['Physiological-Clinical']

Screening O
, O
brief O
intervention O
, O
and O
referral O
to O
treatment O
( O
SBIRT O
) O
in O
a O
Polish O
emergency O
department O
: O
three-month O
outcomes O
of O
a O
randomized O
, O
controlled O
clinical O
trial O
. O
[]

MATERIALS O
AND O
METHODS O
This O
investigation O
was O
designed O
as O
a O
randomized O
, O
prospective O
, O
single-blinded O
controlled O
study O
. O
[]

5.2 O
days O
, O
both O
P O
< O
0.01 O
) O
. O
[]

Similarly O
the O
drug O
induced O
a O
reduction O
of O
the O
rate-pressure O
product O
and O
of O
the O
extent O
of O
ischemic O
ST O
segment O
depression O
during O
exercise O
. O
% O
[]

on O
sexual B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
men O
with O
lower O
urinary O
tract O
symptoms O
associated O
with O
benign O
prostatic O
hyperplasia O
( O
BPH O
) O
. O
['Life-Impact']

OBJECTIVE O
The O
response O
rate O
to O
alpha O
interferon O
( O
IFN B-outcome ['Physiological-Clinical']
) O
of O
chronic O
anti-HBe-positive O
hepatitis O
B O
is O
variable O
. O
['Physiological-Clinical']

4 O
. O
[]

In O
addition O
, O
observations O
were O
made O
on O
the O
beneficial O
effect O
of O
selamectin O
treatment O
on O
dogs O
and O
cats O
showing O
signs O
of O
flea O
allergy O
dermatitis O
( O
FAD O
) O
. O
[]

Therapy O
occurred O
for O
1 O
h/week O
over O
18 O
weeks O
. O
[]

Gastrointestinal B-outcome ['Physiological-Clinical']
AEs I-outcome ['Physiological-Clinical']
were O
higher O
in O
the O
treatment O
arm O
. O
['Physiological-Clinical']

4 O
) O
The O
patients O
whose O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
reduced O
significantly O
( O
< O
or= O
50 O
beats O
per O
minute O
) O
in O
the O
diltiazem O
group O
were O
more O
than O
in O
the O
nitroglycerin O
group O
[ O
8 O
( O
7.7 O
% O
) O
vs O
0 O
( O
0 O
% O
) O
, O
P O
< O
0.01 O
] O
. O
['Physiological-Clinical']

Within-practice O
imprecision O
for O
QC O
testing O
was O
calculated O
and O
compared O
with O
the O
analytical O
goals O
for O
imprecision O
set O
prior O
to O
the O
trial O
. O
[]

crystalloid O
, O
furosemide O
, O
mannitol O
( O
if O
pulmonary O
capillary O
wedge O
pressure O
was O
< O
20 O
mmHg O
) O
, O
and O
low O
dose O
dopamine O
versus O
intravenous O
crystalloid O
and O
matching O
placebos O
. O
[]

Four O
months O
after O
the O
completion O
of O
treatment O
, O
Ss O
were O
administered O
a O
questionnaire O
and O
a O
hypnotic B-outcome ['Physiological-Clinical']
susceptibility I-outcome ['Physiological-Clinical']
scale O
. O
['Physiological-Clinical']

Experience O
of O
36 O
patients O
treated O
in O
France O
in O
the O
RECORD-1 O
Trial O
. O
[]

INTERVENTION O
Subjects O
were O
treated O
with O
vildagliptin O
( O
50 O
mg O
twice O
daily O
) O
or O
placebo O
for O
3 O
months O
, O
followed O
by O
a O
2-wk O
washout O
. O
[]

Two O
regimens O
of O
moderate O
dose O
chemoradiation O
therapy O
for O
such O
patients O
were O
compared O
in O
a O
randomized O
phase O
II O
trial O
. O
[]

This O
study O
evaluated O
and O
compared O
the O
effectiveness O
of O
two O
different O
off-season O
, O
short-term O
basketball O
training O
programs O
on O
physical O
and O
technical O
abilities O
of O
young O
basketball O
players O
. O
[]

BMD O
and O
BTM O
were O
assessed O
pre-randomization O
, O
during O
and O
after O
the O
end O
of O
treatment O
( O
EOT O
) O
. O
[]

AIM O
To O
evaluate O
two O
simplified O
Helicobacter B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
treatment O
alternatives O
for O
children O
and O
adolescents O
. O
['Physiological-Clinical']

CONCLUSIONS O
In O
ACS O
patients O
, O
serial O
autologous O
infusions O
of O
selective O
HDL O
delipidated O
plasma O
are O
clinically B-outcome ['Life-Impact']
feasible I-outcome ['Life-Impact']
and O
well O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
ratio O
between O
[]

The O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
similar O
between O
treatments O
, O
being O
27.4 O
months O
and O
27.7 O
months O
in O
fulvestrant O
and O
anastrozole-treated O
patients O
, O
respectively O
( O
hazards O
ratio O
, O
0.98 O
; O
95 O
% O
confidence O
interval O
, O
0.84-1.15 O
; O
P O
= O
0.809 O
) O
. O
['Mortality']

There O
was O
no O
difference O
in O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
Sequential B-outcome ['Physiological-Clinical']
Organ I-outcome ['Physiological-Clinical']
Failure I-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
maximum I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
Multiple I-outcome ['Physiological-Clinical']
Organ I-outcome ['Physiological-Clinical']
Dysfunction I-outcome ['Physiological-Clinical']
Score O
maximum O
, O
delta O
Multiple B-outcome ['Physiological-Clinical']
Organ I-outcome ['Physiological-Clinical']
Dysfunction I-outcome ['Physiological-Clinical']
Score O
, O
or O
Apache B-outcome ['Physiological-Clinical']
scores O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Based O
on O
these O
findings O
, O
it O
may O
be O
concluded O
that O
both O
Er O
, O
Cr O
: O
YSGG O
and O
GaAlAs O
lasers O
were O
effective O
in O
the O
treatment O
of O
DH O
following O
a O
single O
application O
. O
[]

Randomized O
trial O
of O
the O
effects O
of O
risedronate O
on O
vertebral B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
in O
women O
with O
established O
postmenopausal O
osteoporosis O
. O
['Physiological-Clinical']

The O
apoptotic B-outcome ['Physiological-Clinical']
index O
( O
AI O
) O
was O
determined O
by O
the O
terminal O
deoxynucleotidyl O
transferase-mediated B-outcome ['Physiological-Clinical']
deoxyuridine B-outcome ['Resource-use']
triphosphate I-outcome ['Resource-use']
biotin I-outcome ['Resource-use']
nick O
end-labeling O
( O
TUNEL B-outcome ['Resource-use']
) O
method O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use']

OBJECTIVE O
Cefixime O
, O
an O
orally O
administered O
third O
generation O
cephalosporin O
, O
was O
compared O
with O
ofloxacin O
for O
the O
treatment O
of O
uncomplicated O
typhoid O
fever O
in O
children O
. O
[]

Yet O
, O
sleep O
withdrawal O
even O
if O
only O
partial O
, O
has O
a O
negative O
influence O
on O
performance O
, O
particularly O
when O
the O
type O
of O
exercise O
requires O
good O
psychomotor O
performance O
The O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
whether O
the O
intake O
of O
a O
hypnotic O
drug O
would O
have O
negative O
effects O
on O
physical O
performance O
capacity O
. O
[]

Outcome O
measures O
included O
Communication O
and O
Symbolic O
Behavior O
Scale O
( O
CSBS O
) O
, O
Ritvo O
Real-life O
Rating O
Scale O
, O
weekly O
Global O
Rating O
Scale O
( O
GBRS O
) O
by O
parents O
and O
teachers O
, O
and O
daily O
log O
of O
gastrointestinal O
symptoms O
. O
[]

RESULTS O
Serum O
levels O
of O
creatine O
phosphokinase O
( O
CPK O
) O
, O
the O
MB B-outcome ['Physiological-Clinical']
isoenzyme I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
creatine I-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CK-MB I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
occurrence O
of O
myocardial B-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
or O
infarction B-outcome ['Physiological-Clinical']
, O
and O
mean O
duration O
of O
using B-outcome ['Physiological-Clinical']
inotropic I-outcome ['Physiological-Clinical']
agents I-outcome ['Physiological-Clinical']
were O
significantly O
lower O
in O
the O
milrinone O
group O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

proposes O
that O
control O
of O
attention B-outcome ['Life-Impact']
depends O
on O
the O
amount O
and O
type O
of O
load B-outcome ['Life-Impact']
that O
is O
imposed O
by O
current O
processing O
. O
['Life-Impact', 'Life-Impact']

Recently O
a O
newer O
more O
tolerated O
schedule O
of O
the O
VNR/CDDP O
regimen O
has O
been O
published O
and O
is O
widely O
employed O
in O
medical O
practice O
. O
[]

Brachial O
artery O
flow-mediated O
dilation O
( O
FMD O
) O
and O
digital O
vascular O
function O
were O
measured O
at O
baseline O
and O
after O
each O
6-week O
treatment O
period O
. O
[]

Results O
revealed O
a O
reduction O
in O
reaction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
error O
rate O
across O
blocks O
, O
thus O
demonstrating O
a O
practice O
effect O
. O
['Life-Impact']

Diazepam O
produced O
sedative-like B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
in O
both O
choosers O
and O
non-choosers O
, O
but O
markedly O
decreased O
Anxiety B-outcome ['Life-Impact']
and O
increased O
Friendliness B-outcome ['Life-Impact']
in O
choosers O
only O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

These O
improvements O
in O
behaviors O
were O
not O
mediated O
by O
IQ B-outcome ['Life-Impact']
, O
math B-outcome ['Life-Impact']
and O
reading B-outcome ['Life-Impact']
scores O
at O
15 O
years O
of O
age O
, O
educational B-outcome ['Life-Impact']
attainment I-outcome ['Life-Impact']
, O
or O
['Life-Impact', 'Life-Impact']

The O
sources O
of O
dietary B-outcome ['Life-Impact']
CP I-outcome ['Life-Impact']
were O
soybean O
meal O
( O
SBM O
) O
or O
SBM O
and O
urea O
( O
SBM-U O
) O
. O
['Life-Impact']

Levobunolol O
compared O
with O
timolol O
: O
a O
four-year O
study O
. O
[]

The O
incidence O
of O
thrombocytopenia B-outcome ['Physiological-Clinical']
was O
the O
same O
in O
all O
disease O
groups O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
inhaled O
fluticasone O
propionate O
powder O
in O
patients O
with O
moderate O
asthma O
previously O
treated O
with O
an O
inhaled O
corticosteroid O
. O
[]

On O
the O
other O
hand O
, O
patients O
in O
the O
control O
group O
showed O
decrease O
in O
the O
WHOQOL-BREF B-outcome ['Physiological-Clinical']
and O
shoulder B-outcome ['Physiological-Clinical']
ROM B-outcome ['Physiological-Clinical']
and O
increase O
in O
BFI O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
scores O
were O
lower O
in O
the O
conservative O
treatment O
group O
compared O
with O
each O
of O
the O
other O
two O
groups O
which O
in O
turn O
, O
were O
no O
different O
from O
each O
other O
regarding O
this O
outcome O
( O
P O
< O
0.001 O
) O
. O
['Life-Impact']

METHODS O
Students O
enrolled O
in O
a O
Human O
Sexuality O
course O
( O
N O
= O
152 O
) O
were O
randomly O
assigned O
to O
one O
of O
three O
groups O
: O
CAI O
, O
Lecture O
, O
or O
No O
Intervention O
group O
. O
[]

Fifty O
two O
patients O
entered O
the O
trial O
, O
and O
12 O
were O
withdrawn O
. O
[]

High-starch-60 O
and O
LS-30 O
heifers O
were O
heavier B-outcome ['Physiological-Clinical']
( O
P O
< O
0.05 O
) O
than O
control O
and O
HS-30 O
heifers O
at O
the O
beginning O
of O
the O
breeding O
season O
. O
['Physiological-Clinical']

A O
double-blind O
comparative O
study O
of O
ofloxacin O
otic O
drops O
versus O
neomycin-polymyxin O
B-hydrocortisone O
otic O
drops O
in O
the O
medical O
treatment O
of O
chronic O
suppurative O
otitis O
media O
. O
[]

Fondaparinux O
significantly O
reduced O
the O
proximal B-outcome ['Physiological-Clinical']
deep O
vein O
thrombosis I-outcome ['Physiological-Clinical']
rate O
from O
1.7 O
% O
( O
7/417 O
) O
to O
0.2 O
% O
( O
1/424 O
; O
P O
= O
0.037 O
) O
. O
['Physiological-Clinical']

After O
termination O
of O
ECC O
( O
T4 O
) O
, O
FCD O
recovered O
in O
both O
groups O
to O
baseline O
. O
[]

The O
experimental O
condition O
consisted O
of O
20 O
min O
of O
HVPC O
immediately O
after O
the O
induction O
of O
DOMS B-outcome ['Physiological-Clinical']
, O
and O
20 O
min O
every O
24 O
h O
for O
three O
consecutive O
days O
thereafter O
. O
['Physiological-Clinical']

To O
date O
there O
are O
4 O
recurrences B-outcome ['Physiological-Clinical']
in O
the O
coumarin-treated O
group O
of O
13 O
patients O
, O
and O
10 O
recurrences B-outcome ['Physiological-Clinical']
in O
the O
placebo-treated O
group O
of O
14 O
patients O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Significantly O
less O
bacterial B-outcome ['Physiological-Clinical']
accumulation I-outcome ['Physiological-Clinical']
was O
observed O
on O
the O
crowns O
coated O
with O
bonding O
agent O
, O
whereas O
no O
biofilm B-outcome ['Physiological-Clinical']
was O
observed O
on O
the O
crowns O
coated O
with O
liquid O
polish O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Canine O
parvoviral O
enteritis O
continues O
to O
cause O
significant O
morbidity O
and O
mortality O
in O
dogs O
worldwide O
, O
and O
efficacious O
antiviral O
therapies O
are O
lacking O
. O
[]

BACKGROUND O
There O
are O
few O
large O
case O
series O
describing O
the O
human B-outcome ['Physiological-Clinical']
papillomavirus I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HPV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
genotypes O
found O
in O
women O
diagnosed O
with O
rigorously O
reviewed O
cervical O
intraepithelial O
neoplasia O
grade O
3 O
( O
CIN3 O
) O
, O
cervical O
precancer O
. O
['Physiological-Clinical']

In O
addition O
, O
Group O
2 O
received O
2 O
mg O
intravenous O
( O
i.v O
. O
) O
[]

We O
investigated O
whether O
a O
postulated O
biomechanical O
advantage O
conferred O
to O
the O
extensor O
mechanism O
by O
a O
change O
in O
knee O
implant O
design O
was O
detectable O
in O
patients O
by O
direct O
physical O
testing O
. O
[]

RESULTS O
A O
total O
of O
216 O
patients O
were O
randomized O
. O
[]

Ten O
treatment O
periods O
on O
zidovudine O
and O
7 O
on O
didanosine O
were O
analysed O
. O
[]

Two O
subjects O
( O
10 O
mg/kg O
) O
had O
measurable O
CSF O
ponezumab O
concentrations O
( O
~0.5 O
% O
of O
plasma O
values O
) O
at O
day O
29 O
. O
[]

NO O
bioactivity B-outcome ['Physiological-Clinical']
was O
assessed O
using O
the O
nitric O
oxide O
synthase O
inhibitor O
N O
( O
G O
) O
-monomethyl-l-arginine O
. O
['Physiological-Clinical']

METHODS O
Some O
280 O
men O
with O
a O
primary O
hernia O
were O
randomized O
prospectively O
to O
undergo O
Shouldice O
, O
tension-free O
Lichtenstein O
or O
laparoscopic O
TAPP O
repair O
. O
[]

Disease B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
and O
side O
effects O
were O
compared O
using O
Fisher O
's O
exact O
test O
. O
['Physiological-Clinical']

METHODS O
Fifty-two O
cases O
were O
randomly O
divided O
into O
a O
treatment O
group O
( O
n=28 O
) O
and O
a O
control O
group O
( O
n=24 O
) O
. O
[]

Mixed O
class O
V O
cavities O
were O
prepared O
on O
extracted O
human O
molars O
and O
restored O
using O
five O
etch O
and O
rinse O
and O
seven O
self-etch O
adhesive O
systems O
with O
their O
corresponding O
composites O
. O
[]

Lot O
1 O
of O
SSS O
, O
formulated O
with O
HSA O
( O
84 O
% O
of O
total O
protein O
) O
and O
human O
globulins O
( O
16 O
% O
of O
total O
protein O
) O
and O
an O
aqueous O
lipoprotein O
fraction O
derived O
from O
human O
plasma O
( O
Excyte O
IV O
; O
Miles O
Diagnostics O
, O
Kankakee O
, O
Illinois O
) O
, O
produced O
accelerated O
early B-outcome ['Physiological-Clinical']
embryonic I-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
relative O
to O
control O
murine O
embryos O
grown O
in O
the O
presence O
of O
Plasmatein O
, O
however O
, O
the O
percentage O
of O
the O
embryos O
reaching O
the O
hatched O
blastocyst O
stage O
was O
decreased O
( O
45 O
vs O
100 O
% O
) O
. O
['Physiological-Clinical']

[ O
Randomized O
controlled O
study O
of O
OK-432 O
in O
the O
treatment O
of O
cancerous B-outcome ['Physiological-Clinical']
pleurisy I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
development O
of O
a O
self-report O
measure O
to O
assess O
the O
effects O
of O
relaxation O
training O
was O
examined O
. O
[]

Group O
S O
presented O
an O
increase O
( O
P O
< O
0.05 O
) O
in O
total O
cholesterol B-outcome ['Physiological-Clinical']
, O
LDL B-outcome ['Physiological-Clinical']
and O
LDL B-outcome ['Physiological-Clinical']
: O
HDL B-outcome ['Physiological-Clinical']
ratio O
, O
whilst O
HDL B-outcome ['Physiological-Clinical']
diminished O
( O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Technological O
advances O
in O
the O
administration O
of O
volatile O
agents O
as O
long-term O
sedatives O
in O
the O
Intensive O
Care O
Unit O
may O
facilitate O
their O
more O
widespread O
use O
. O
[]

There O
were O
no O
differences O
in O
health B-outcome ['Physiological-Clinical']
or O
functional B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
at O
9 O
months O
. O
['Physiological-Clinical', 'Life-Impact']

High O
fever O
and O
hospitalization B-outcome ['Resource-use']
due O
to O
infectious O
complications O
were O
also O
more O
common O
in O
the O
local O
anesthesia O
group O
, O
although O
not O
statistically O
significant O
. O
['Physiological-Clinical', 'Resource-use']

Gamma-Hydroxybutyric O
acid O
( O
GHB O
) O
has O
also O
been O
introduced O
in O
the O
treatment O
of O
alcoholic O
patients O
and O
is O
effective O
in O
surgical O
intensive O
care O
unit O
( O
ICU O
) O
patients O
in O
preventing O
and O
treating O
AWS B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PGE1 O
decreased O
systolic B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
approximately O
34 O
% O
from O
pre-administration O
values O
. O
['Physiological-Clinical']

Prior O
to O
and O
following O
supplementation O
, O
subjects O
performed O
three O
100-m O
freestyle O
sprint O
swims O
( O
long O
course O
) O
with O
60 O
s O
rest/recovery O
between O
heats O
. O
[]

This O
study O
investigated O
the O
relative O
engagement O
potential O
of O
four O
types O
of O
electronic O
screen O
media O
( O
ESM O
) O
: O
animated O
video O
, O
video O
of O
self O
, O
video O
of O
a O
familiar O
person O
engaged O
with O
an O
immersive O
virtual O
reality O
( O
VR O
) O
game O
, O
and O
immersion O
of O
self O
in O
the O
VR O
game O
. O
[]

49.2 O
mg/L O
, O
63.0 O
? O
[]

Retroinfusion-supported O
stenting O
in O
high-risk O
patients O
for O
percutaneous O
intervention O
and O
bypass O
surgery O
: O
results O
of O
the O
prospective O
randomized O
myoprotect O
I O
study O
. O
[]

2.1HU O
for O
120-kV O
images O
and O
33.2 O
? O
[]

A O
randomized O
controlled O
trial O
. O
[]

Nutritional O
status O
was O
assessed O
by O
using O
Subjective O
Global O
Assessment O
. O
[]

However O
, O
more O
such O
randomized O
trials O
are O
essential O
to O
deny O
any O
long-term O
complication O
. O
[]

A O
blinded O
, O
randomized O
and O
controlled O
clinical O
trial O
was O
developed O
in O
a O
paediatric O
hospital O
located O
on O
northeast O
of O
Brazil O
with O
42 O
asthmatic O
children O
aged O
? O
[]

[ O
Observation O
on O
therapeutic O
effect O
of O
picking O
therapy O
on O
Graves O
' O
disease O
] O
. O
[]

was O
80 O
mg/day O
for O
patients O
under O
30 O
kg O
and O
120 O
mg/day O
for O
patients O
above O
30 O
kg O
. O
[]

Dexamethasone O
phosphate O
in O
antibiotic O
ear O
drops O
for O
the O
treatment O
of O
acute O
bacterial O
otitis O
externa O
. O
[]

We O
have O
reported O
that O
expression O
of O
hypoxia-inducible O
factor O
( O
HIF O
) O
-1alpha O
correlates O
with O
expression O
of O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
, O
tumor O
stage O
, O
lymphatic O
invasion O
, O
venous O
invasion O
, O
and O
liver O
metastasis O
. O
[]

Main O
differences O
consisted O
in O
preoperative O
bowel O
washout O
( O
none O
vs. O
3 O
l O
cleaning O
solution O
) O
and O
analgesia O
( O
patient O
controlled O
analgesia O
vs. O
patient O
controlled O
epidural O
analgesia O
) O
. O
[]

Pain B-outcome ['Physiological-Clinical']
, O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
, O
supplemental B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
and O
side-effects B-outcome ['Adverse-effects']
were O
recorded O
for O
all O
patients O
for O
24 O
h. O
RESULTS O
There O
were O
no O
differences O
between O
the O
three O
groups O
regarding O
pain B-outcome ['Physiological-Clinical']
scores O
( O
at O
rest O
and O
coughing O
) O
during O
the O
study O
except O
in O
the O
first O
2 O
h O
, O
when O
scores O
were O
lower O
for O
patients O
receiving O
intraperitoneal O
bupivacaine O
plus O
i.v O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Adverse-effects', 'Physiological-Clinical']

Mild O
to O
moderate O
adverse O
events O
were O
reported O
for O
both O
products O
. O
[]

CONCLUSIONS O
The O
use O
of O
skull O
block O
during O
EDAMS O
surgery O
provided O
easy O
hemodynamic B-outcome ['Physiological-Clinical']
control O
, O
calm B-outcome ['Life-Impact']
['Physiological-Clinical', 'Life-Impact']

A O
decrease O
in O
leg B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
a O
corresponding O
increase O
in O
leg B-outcome ['Physiological-Clinical']
peripheral I-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
were O
noted O
in O
the O
misoprostol O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
anticipated O
that O
emergence O
of O
behavioral O
contributions O
would O
be O
marked O
by O
increased O
variability O
in O
response O
strategies B-outcome ['Physiological-Clinical']
and O
by O
increased O
nonlinearity B-outcome ['Physiological-Clinical']
in O
the O
observed O
responses O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
also O
no O
significant O
difference O
in O
the O
FTI B-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
is O
the O
first O
study O
to O
document O
the O
importance O
of O
illness O
perceptions O
in O
recent O
onset O
RA O
. O
[]

Secondary O
end O
points O
were O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
and O
quality O
of O
life O
. O
['Mortality', 'Mortality']

The O
probability O
of O
clopidogrel O
resulting O
in O
cost O
per O
life-year O
gained O
of O
less O
than O
$ O
20,000 O
was O
0.975 O
for O
CURE O
patients O
and O
0.904 O
for O
PCI-CURE O
patients O
. O
[]

Changes O
in O
functional B-outcome ['Physiological-Clinical']
capillary I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FCD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
, O
and O
vessel B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
were O
analyzed O
by O
a O
blinded O
investigator O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
An O
Ad O
Hoc O
Melanoma O
Working O
Group O
of O
25 O
investigators O
treated O
604 O
patients O
from O
April O
1997 O
to O
January O
2003 O
. O
[]

No O
patient O
received O
antibiotics O
at O
the O
time O
of O
surgery O
or O
prior O
to O
the O
first O
positive O
blood O
culture O
, O
yet O
B. O
fragilis O
was O
the O
single O
organism O
isolated O
from O
blood O
and O
abscesses O
in O
these O
patients O
. O
[]

We O
conclude O
that O
pre-operative O
radiotherapy O
is O
at O
least O
as O
effective O
[]

DESIGN O
Randomized O
, O
controlled O
, O
single-blind O
trial O
. O
[]

The O
effects O
of O
presentation O
of O
an O
aversive O
stimulus O
and O
simultaneous O
failure O
on O
a O
bogus O
intelligence O
test O
upon O
a O
subject O
's O
aggressive B-outcome ['Life-Impact']
reactions I-outcome ['Life-Impact']
were O
studied O
. O
['Life-Impact']

CONCLUSION O
Parent O
verbal O
utterances O
that O
follow O
into O
the O
child O
's O
current O
focus O
of O
attention O
or O
respond O
to O
child O
verbal O
communication O
acts O
may O
facilitate O
the O
process O
of O
early O
vocabulary O
acquisition O
by O
mitigating O
the O
need O
for O
children O
with O
ASD O
to O
use O
attention-following O
as O
a O
word-learning O
strategy O
. O
[]

METHODS O
Sixty O
wives O
completed O
measures O
prior O
to O
random O
assignment O
to O
either O
the O
psychoeducational O
group O
intervention O
or O
a O
no-treatment O
control O
group O
, O
and O
1 O
month O
after O
completion O
of O
the O
group O
. O
[]

Total O
peripheral B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
was O
inappropriately O
elevated O
in O
hypertensive O
pregnancy O
, O
except O
in O
the O
oxprenolol-treated O
group O
. O
['Physiological-Clinical']

In O
this O
study O
, O
11 O
adult O
patients O
with O
autism O
or O
Asperger O
's O
disorder O
were O
compared O
with O
nine O
matched O
controls O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Primary O
outcomes O
included O
cancer B-outcome ['Physiological-Clinical']
incidence I-outcome ['Physiological-Clinical']
, O
cancer B-outcome ['Mortality']
deaths I-outcome ['Mortality']
, O
and O
major B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
24-month O
FFTF B-outcome ['Physiological-Clinical']
rate O
was O
75 O
% O
for O
COPP/ABVD O
and O
84 O
% O
for O
BEACOPP O
pooled O
( O
P O
= O
.034 O
) O
. O
['Physiological-Clinical']

Prolonged O
surgery O
increased O
the O
risk O
of O
thrombosis B-outcome ['Physiological-Clinical']
in O
the O
placebo O
group O
but O
not O
in O
the O
treatment O
group O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

80 O
% O
) O
, O
acute B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( O
44 O
% O
vs O
. O
['Physiological-Clinical']

For O
all O
patients O
, O
synthesis O
of O
IL-1 B-outcome ['Physiological-Clinical']
beta I-outcome ['Physiological-Clinical']
increased O
constitutively O
and O
in O
response O
to O
immune-mediated O
stimulants O
( O
PHA O
, O
IL-2 O
, O
and O
mitochondrial O
antigen O
) O
but O
not O
the O
bacterial O
stimulants O
LPS O
or O
S O
epidermidis O
. O
['Physiological-Clinical']

CONCLUSION O
This O
study O
has O
shown O
that O
Pakistani O
women O
living O
in O
Oslo O
are O
at O
great O
risk O
of O
developing O
vitamin O
D O
deficiency O
during O
pregnancy O
. O
[]

BACKGROUND O
The O
Affordable O
Care O
Act O
mandates O
that O
new O
insurance O
plans O
cover O
smoking-cessation O
therapy O
without O
cost-sharing O
. O
[]

All O
procedures O
started O
between O
8 O
and O
10 O
AM O
, O
and O
operating O
room O
( O
OR O
) O
temperature O
was O
maintained O
between O
21 O
degrees O
and O
23 O
degrees O
C O
, O
with O
relative O
humidity O
ranging O
between O
40 O
% O
and O
45 O
% O
. O
[]

Long-term O
oral O
branched-chain O
amino O
acid O
treatment O
in O
chronic O
hepatic O
encephalopathy O
. O
[]

Supervisors O
receiving O
this O
training O
( O
n O
= O
29 O
) O
were O
more O
likely O
to O
improve O
on O
several O
dimensions O
of O
responsiveness B-outcome ['Life-Impact']
( O
e.g O
. O
['Life-Impact']

CONCLUSION O
Compared O
with O
the O
inferior-superior O
technique O
, O
the O
inferior-medial O
combination O
achieved O
more O
rapid B-outcome ['Physiological-Clinical']
ocular I-outcome ['Physiological-Clinical']
akinesia I-outcome ['Physiological-Clinical']
with O
less O
need O
for O
supplementation O
, O
but O
induced O
less O
efficient O
lid O
akinesia O
and O
had O
a O
propensity O
to O
cause O
iatrogenic B-outcome ['Physiological-Clinical']
subconjunctival I-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Based O
on O
the O
results O
of O
this O
study O
, O
it O
is O
suggested O
that O
routine O
administration O
of O
antidepressants O
and O
antianxiety O
drugs O
should O
be O
carried O
out O
in O
senile O
hypertensive O
patients O
complicating O
with O
depression O
or O
anxiety O
. O
[]

However O
, O
the O
mean O
acuity B-outcome ['Physiological-Clinical']
difference O
between O
these O
two O
tests O
in O
the O
subgroup O
with O
severe/moderate O
amblyopia O
( O
0.074+/-0.036 O
) O
was O
statistically O
significant O
( O
P=0.0382 O
) O
. O
['Physiological-Clinical']

Hypotheses B-outcome ['Physiological-Clinical']
, O
strengths B-outcome ['Life-Impact']
, O
and O
limitations B-outcome ['Life-Impact']
of O
the O
study O
are O
discussed O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

CONCLUSION O
Tacrolimus O
, O
unlike O
cyclosporin O
, O
is O
not O
associated O
with O
gingival B-outcome ['Physiological-Clinical']
overgrowth I-outcome ['Physiological-Clinical']
when O
used O
for O
immunosuppression O
following O
liver O
transplantation O
in O
children O
, O
and O
may O
be O
the O
drug O
of O
choice O
for O
children O
. O
['Physiological-Clinical']

METHODS O
In O
this O
open O
, O
multicentre O
, O
randomised O
, O
controlled O
study O
, O
eligible O
patients O
with O
periarthritis O
of O
the O
shoulder O
were O
randomised O
to O
receive O
either O
oxaprozin O
1200 O
mg O
once O
daily O
( O
n O
= O
49 O
) O
or O
diclofenac O
50 O
mg O
three O
times O
daily O
( O
n O
= O
47 O
) O
. O
[]

136:196-204 O
, O
1977 O
) O
against O
40 O
clinically O
isolated O
strains O
. O
[]

Baseline O
and O
followup O
surveys O
were O
completed O
by O
815 O
women O
; O
775 O
women O
provided O
data O
to O
be O
included O
in O
these O
analyses O
. O
[]

15/28 O
TMJs O
( O
54 O
% O
) O
that O
had O
not O
been O
positioned O
changed O
the O
position O
of O
the O
disc O
from O
physiological O
to O
anterior O
disc O
derangement O
with O
and O
without O
reduction O
postoperatively O
. O
[]

PURPOSE O
The O
study O
evaluated O
whether O
targeted O
changes O
in O
factors O
influencing O
enjoyment O
of O
physical O
education O
( O
PE O
) O
, O
physical O
activity O
enjoyment O
, O
and O
self-efficacy O
beliefs O
about O
participating O
in O
physical O
activity O
mediated O
the O
effect O
of O
the O
Lifestyle O
Education O
for O
Activity O
Program O
( O
LEAP O
) O
intervention O
on O
participation O
in O
physical O
activity O
. O
[]

Further O
study O
that O
includes O
follow-up O
imaging O
and O
patient-reported O
outcomes O
over O
a O
greater O
follow-up O
period O
is O
needed O
. O
[]

Subjects O
comprised O
24 O
men O
and O
16 O
women O
, O
with O
a O
mean O
age O
of O
40.8+/-14.4 O
years O
; O
27 O
had O
IgA O
nephropathy O
and O
13 O
had O
non-IgA O
proliferative O
glomerulonephritis O
. O
[]

Ages O
ranged O
from O
39 O
to O
80 O
years O
( O
mean O
of O
66.4 O
+/- O
11.3 O
years O
) O
. O
[]

A O
randomized O
comparison O
of O
tamoxifen O
with O
surgical O
oophorectomy O
in O
premenopausal O
patients O
with O
advanced O
breast O
cancer O
. O
[]

Because O
this O
analysis O
did O
not O
correct O
properly O
for O
other O
predictors O
of O
a O
suspicious B-outcome ['Physiological-Clinical']
DRE B-outcome ['Physiological-Clinical']
( O
PSA-level O
, O
biopsy B-outcome ['Physiological-Clinical']
indication I-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Postoperatively O
, O
patients O
developing O
severe B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
, O
retching B-outcome ['Physiological-Clinical']
, O
or O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Five O
percent O
and O
9 O
% O
of O
the O
patients O
receiving O
radiotherapy O
had O
disabling B-outcome ['Life-Impact']
and O
mild B-outcome ['Physiological-Clinical']
radiation-induced I-outcome ['Physiological-Clinical']
brachial I-outcome ['Physiological-Clinical']
plexopathy I-outcome ['Physiological-Clinical']
, O
respectively O
. O
['Life-Impact', 'Physiological-Clinical']

Delayed O
perceptual O
awareness O
in O
rapid O
perceptual O
decisions O
. O
[]

The O
methyl O
adducts O
are O
removed O
by O
the O
DNA O
repair O
enzyme O
AGAT O
. O
[]

In O
EMDA O
, O
or O
iontophoresis O
, O
a O
low-intensity O
electric O
current O
is O
applied O
over O
the O
skin O
to O
deliver O
medication O
into O
body O
tissues O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

RESULTS O
After O
heroin O
injection O
, O
marked O
respiratory B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
progressing O
to O
a O
Cheyne-Stokes O
pattern O
occurred O
. O
['Physiological-Clinical']

Coverage O
efficiency O
was O
calculated O
as O
coverage O
of O
children O
per O
bednet O
owned O
. O
[]

Thirty-five O
university O
students O
were O
assessed O
with O
the O
four O
tonometers O
in O
a O
randomised O
order O
, O
with O
non-contact O
tonometry O
performed O
first O
. O
[]

A O
low O
remission B-outcome ['Physiological-Clinical']
rate O
was O
also O
observed O
in O
subjects O
who O
had O
previously O
failed O
to O
respond O
to O
a O
combination O
of O
an O
antipsychotic O
and O
an O
antidepressant O
. O
['Physiological-Clinical']

Armodafinil O
and O
modafinil O
in O
patients O
with O
excessive O
sleepiness O
associated O
with O
shift O
work O
disorder O
: O
a O
pharmacokinetic/pharmacodynamic B-outcome ['Physiological-Clinical']
model O
for O
predicting O
and O
comparing O
their O
concentration-effect O
relationships O
. O
['Physiological-Clinical']

The O
effects O
of O
heated O
humidification O
on O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
and O
treatment O
side-effects B-outcome ['Adverse-effects']
for O
patients O
who O
prefer O
a O
cold O
bedroom O
environment O
have O
not O
been O
studied O
. O
['Physiological-Clinical', 'Adverse-effects']

One O
hundred O
and O
eighty-three O
patients O
were O
enrolled O
between O
January O
1998 O
and O
November O
2003 O
. O
[]

PARTICIPANTS O
Two-hundred O
nineteen O
subjects O
, O
aged O
18 O
to O
55 O
years O
, O
with O
acute O
nonspecific O
LBP O
. O
[]

The O
patients O
were O
divided O
into O
two O
groups O
: O
those O
in O
early O
stages O
( O
stage O
I O
or O
II O
) O
and O
those O
in O
advanced O
stages O
( O
stage O
III O
or O
IV O
) O
; O
these O
groups O
were O
further O
subdivided O
into O
an O
immunotherapy O
group O
( O
receiving O
OK-432 O
) O
and O
a O
control O
group O
( O
who O
did O
not O
receive O
OK-432 O
) O
. O
[]

OBJECTIVE O
This O
study O
set O
out O
to O
investigate O
the O
potential O
for O
pharmacodynamic B-outcome ['Physiological-Clinical']
interaction I-outcome ['Physiological-Clinical']
between O
low-dose O
ASA O
and O
esomeprazole O
in O
healthy O
volunteers O
, O
by O
measuring O
ASA O
antiplatelet B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
conclusion O
that O
marginal O
biotin O
deficiency O
occurs O
frequently O
in O
the O
first O
trimester O
further O
raises O
concern O
about O
potential O
human O
teratogenicity O
. O
[]

Two O
( O
6 O
% O
) O
patients O
with O
measurable O
disease O
reached O
complete O
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
, O
1 O
( O
3 O
% O
) O
partial O
response O
( O
PR O
) O
, O
12 O
( O
36 O
% O
) O
had O
stable B-outcome ['Physiological-Clinical']
disease B-outcome ['Physiological-Clinical']
( O
SD O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Medical O
therapy O
for O
essential B-outcome ['Physiological-Clinical']
tremor I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ET I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
a O
common O
movement O
disorder O
, O
is O
often O
inadequate O
. O
['Physiological-Clinical']

One O
hundred O
and O
five O
( O
96 O
% O
) O
of O
the O
patients O
were O
given O
verapamil O
and O
other O
antianginal O
drugs O
were O
prescribed O
as O
needed O
. O
[]

Those O
patients O
using O
the O
IB O
recorded O
a O
mean O
55 O
% O
decline O
in O
severity O
and O
a O
mean O
51 O
% O
decline O
in O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
rhinorrhea I-outcome ['Physiological-Clinical']
as O
compared O
to O
placebo O
. O
['Physiological-Clinical']

AIMS O
To O
compare O
the O
efficacy O
and O
safety O
of O
diclofenac-K O
( O
12.5 O
mg O
) O
vs O
paracetamol O
( O
500 O
mg O
) O
and O
placebo O
given O
in O
a O
flexible O
dosage O
regimen O
to O
treat O
pain O
resulting O
from O
extraction O
of O
impacted O
third O
molar O
teeth O
. O
[]

By O
the O
end O
of O
anaesthesia O
and O
surgery O
, O
IL-1beta B-outcome ['Physiological-Clinical']
had O
increased O
significantly O
( O
p O
< O
0.05 O
) O
and O
IFN-gamma B-outcome ['Physiological-Clinical']
had O
decreased O
significantly O
( O
p O
< O
0.05 O
) O
in O
both O
groups O
compared O
with O
pre-incisional O
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thereafter O
no O
further O
significant O
improvement O
between O
the O
two O
different O
treatments O
over O
time O
could O
be O
obtained O
. O
[]

For O
the O
85 O
patients O
who O
completed O
the O
study O
, O
a O
statistically O
significant O
difference O
was O
noted O
between O
groups O
, O
with O
mechanical O
treatment O
with O
taping O
and O
orthoses O
proving O
to O
be O
more O
effective O
than O
either O
anti-inflammatory O
or O
accommodative O
modalities O
. O
[]

To O
ensure O
that O
the O
results O
of O
the O
trial O
would O
be O
reported O
accurately O
without O
possible O
bias O
due O
to O
missing O
data O
, O
the O
study O
leadership O
decided O
that O
no O
outcome O
results O
would O
be O
reported O
until O
the O
vital O
status O
at O
the O
end O
of O
the O
study O
was O
known O
for O
at O
least O
97 O
% O
of O
the O
study O
participants O
. O
[]

OBJECTIVE O
To O
assess O
the O
efficacy O
of O
interferon O
gamma O
in O
reducing O
infection B-outcome ['Physiological-Clinical']
and O
death O
in O
patients O
sustaining O
severe O
injury O
. O
['Physiological-Clinical']

METHODS O
AND O
RESULTS O
Patients O
who O
have O
hypertension O
and O
are O
scheduled O
for O
PCI O
will O
be O
enrolled O
. O
[]

Blood B-outcome ['Physiological-Clinical']
pool I-outcome ['Physiological-Clinical']
IVRT I-outcome ['Physiological-Clinical']
and O
myocardial B-outcome ['Physiological-Clinical']
IVRTs I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
tricuspid I-outcome ['Physiological-Clinical']
valve I-outcome ['Physiological-Clinical']
annulus I-outcome ['Physiological-Clinical']
ring I-outcome ['Physiological-Clinical']
, O
basal B-outcome ['Physiological-Clinical']
and O
apical B-outcome ['Physiological-Clinical']
RV I-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
segments I-outcome ['Physiological-Clinical']
were O
measured O
and O
compared O
with O
data O
from O
33 O
age- O
and O
sex-matched O
control O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

[ O
The O
prognostic O
value O
of O
gastric O
metaplasia O
in O
the O
duodenal O
mucosa O
in O
patients O
with O
Helicobacter O
pylori O
positive O
duodenal O
bulb O
ulcer O
] O
. O
[]

RESULTS O
Median O
age O
was O
54 O
years O
in O
both O
treatment O
groups O
. O
[]

BACKGROUND O
Iron O
deficiency O
anemia O
is O
a O
common O
complication O
in O
patients O
with O
chronic O
kidney O
disease O
( O
CKD O
) O
. O
[]

Grade O
0-I O
and O
II-III O
[]

METHOD O
Nefazodone O
and O
placebo O
treatment O
were O
compared O
in O
a O
6-week O
trial O
of O
120 O
patients O
hospitalized O
for O
DSM-III-R O
diagnosed O
major O
depression O
( O
without O
psychosis O
) O
at O
2 O
study O
centers O
. O
[]

Initial O
analysis O
suggested O
that O
HBI O
had O
only O
a O
marginal O
impact O
in O
reducing O
unplanned B-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
, O
with O
677 O
readmissions O
vs O
824 O
for O
the O
usual O
care O
group O
( O
mean O
+/- O
SD O
rate O
, O
0.72 O
+/- O
0.96 O
vs O
0.84 O
+/- O
1.20 O
readmissions/patient O
per O
year O
; O
P O
= O
.08 O
) O
. O
['Resource-use']

Contrast O
enhancement B-outcome ['Physiological-Clinical']
and O
diagnostic B-outcome ['Life-Impact']
acceptability I-outcome ['Life-Impact']
were O
assessed O
. O
['Physiological-Clinical', 'Life-Impact']

Data O
were O
analyzed O
and O
compared O
using O
Student O
's O
t-test O
( O
p O
< O
0.05 O
was O
considered O
statistically O
significant O
) O
. O
[]

Stratified O
by O
chemotherapeutic O
drug O
and O
comorbid O
pain O
risk O
, O
patients O
were O
randomized O
to O
receive O
either O
duloxetine O
followed O
by O
placebo O
or O
placebo O
followed O
by O
duloxetine O
. O
[]

Current O
investigations O
that O
are O
under O
way O
or O
completed O
evaluate O
the O
efficacy O
and O
safety O
of O
fondaparinux O
for O
the O
management O
of O
various O
thrombotic O
diseases O
. O
[]

The O
efficacy O
of O
intramammary O
tilmicosin O
at O
drying-off O
, O
and O
other O
risk O
factors O
for O
the O
prevention O
of O
new O
intramammary O
infections O
during O
the O
dry O
period O
. O
[]

In O
a O
group O
of O
45 O
patients O
, O
antithrombin B-outcome ['Physiological-Clinical']
III I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
( O
% O
) O
, O
antithrombin B-outcome ['Physiological-Clinical']
III I-outcome ['Physiological-Clinical']
R O
: O
Ag O
( O
% O
) O
, O
plasminogen B-outcome ['Physiological-Clinical']
( O
mg/dl O
) O
, O
alpha-2 B-outcome ['Physiological-Clinical']
macroglobulin I-outcome ['Physiological-Clinical']
( O
% O
) O
, O
factor O
VIII B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
( O
% O
) O
, O
factor O
VIII B-outcome ['Physiological-Clinical']
R O
: O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Prolactin B-outcome ['Physiological-Clinical']
remained O
significantly O
elevated O
above O
normal O
in O
all O
subjects O
for O
at O
least O
26 O
weeks O
. O
['Physiological-Clinical']

These O
outcomes O
were O
sustained O
at O
follow-up O
and O
participants O
rated O
the O
program O
as O
highly O
acceptable O
. O
[]

The O
other O
six O
subjects O
received O
the O
reverse O
conditions O
, O
fed O
for O
days O
1-6 O
and O
fasted O
for O
days O
7-12 O
. O
[]

A O
barbed O
suture O
was O
developed O
that O
is O
self-anchoring O
, O
requiring O
no O
knots O
or O
slack O
management O
for O
wound O
closure O
. O
[]

The O
impact O
of O
a O
psychological O
intervention O
on O
quality O
of O
life O
in O
non-metastatic O
breast O
cancer O
. O
[]

Outcome O
measures O
were O
Knee O
Society O
Scores O
( O
KSS O
) O
, O
knee O
flexion O
, O
knee O
swelling O
and O
pain O
. O
[]

We O
aimed O
to O
investigate O
if O
sevoflurane O
administration O
could O
exert O
myocardial B-outcome ['Physiological-Clinical']
protection I-outcome ['Physiological-Clinical']
during O
following O
coronary O
occlusion O
in O
patients O
with O
coronary O
artery O
disease O
. O
['Physiological-Clinical']

Effects O
of O
a O
long-term O
vitamin O
D O
and O
calcium O
supplementation O
on O
falls B-outcome ['Life-Impact']
and O
parameters O
of O
muscle B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
community-dwelling O
older O
individuals O
. O
['Life-Impact', 'Physiological-Clinical']

In O
a O
placebo-controlled O
double-blind O
cross-over O
study O
lasting O
6 O
weeks O
, O
twenty O
patients O
with O
essential O
hypertension O
were O
treated O
with O
placebo O
for O
2 O
weeks O
followed O
by O
oral O
cilazapril O
2.5 O
mg O
once O
a O
day O
or O
oral O
indomethacin O
50 O
mg O
twice O
daily O
for O
2 O
weeks O
. O
[]

METHODS O
This O
was O
a O
pilot O
study O
of O
eyes O
with O
new-onset O
CNV O
. O
[]

RESULTS O
One O
hundred O
and O
eighty-eight O
out O
of O
the O
193 O
H. O
pylori-positive O
patients O
( O
96 O
% O
) O
completed O
therapy O
. O
[]

At O
the O
larynx O
, O
the O
mean O
( O
+/- O
SD O
) O
time O
to O
90 O
% O
block O
and O
the O
onset O
time O
of O
succinylcholine B-outcome ['Resource-use']
( O
38 O
+/- O
15 O
and O
47 O
+/- O
19 O
s O
, O
respectively O
) O
were O
significantly O
shorter O
( O
P O
< O
0.01 O
) O
than O
for O
rocuronium O
0.6 O
mg O
kg-1 O
( O
92 O
+/- O
42 O
and O
106 O
+/- O
38 O
s O
) O
and O
rocuronium O
0.9 O
mg O
kg-1 O
( O
52 O
+/- O
31 O
and O
64 O
+/- O
30 O
s O
) O
. O
['Resource-use']

In O
response O
to O
acute O
exercise O
, O
an O
increase O
in O
IL-6R B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
levels O
was O
observed O
. O
['Physiological-Clinical']

Between O
April O
1 O
, O
1995 O
, O
and O
June O
1 O
, O
1999 O
, O
1,323 O
patients O
were O
accrued O
. O
[]

Even O
though O
a O
few O
patients O
may O
do O
well O
, O
much O
remains O
to O
be O
done O
in O
and O
out O
of O
the O
hospital O
. O
[]

However O
, O
no O
significant O
differences O
in O
the O
number O
of O
episodes O
of O
vomiting B-outcome ['Physiological-Clinical']
, O
the O
severity O
of O
nausea B-outcome ['Physiological-Clinical']
or O
clinical B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Here O
, O
we O
probed O
the O
mechanism O
by O
which O
expectation O
attenuates O
sensory O
taste O
transmission O
by O
examining O
how O
brain O
areas O
activated O
by O
misleading O
information O
during O
an O
expectancy O
period O
modulate O
insula O
and O
amygdala O
activation O
to O
a O
highly O
aversive O
bitter O
taste O
. O
[]

METHODS/DESIGN O
This O
is O
a O
multi-centre O
prospective O
randomized O
controlled O
, O
superiority O
trial O
to O
compare O
two O
liver O
resection O
techniques O
of O
liver O
metastases O
from O
colorectal O
cancer O
. O
[]

DATA O
SOURCES/STUDY O
SETTING O
Primary O
surveys O
of O
youth O
, O
parents O
, O
and O
key O
neighborhood O
leaders O
were O
carried O
out O
at O
baseline O
( O
1994 O
) O
and O
at O
the O
end O
of O
the O
intervention O
period O
( O
1997 O
) O
. O
[]

The O
TUNEL O
method O
and O
immunohistochemistry O
with O
an O
anti-MIB-1 O
antibody O
were O
used O
to O
evaluate O
cellular B-outcome ['Physiological-Clinical']
apoptosis I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
proliferative I-outcome ['Physiological-Clinical']
ability I-outcome ['Physiological-Clinical']
, O
respectively O
. O
['Physiological-Clinical']

Additional O
controlled O
studies O
are O
needed O
to O
confirm O
these O
findings O
. O
[]

Univariable O
and O
multivariable O
regressions O
were O
used O
to O
determine O
predictors O
of O
bednet O
use O
. O
[]

Fecal O
samples O
were O
collected O
at O
the O
beginning O
and O
end O
of O
both O
study O
periods O
. O
[]

The O
efficacy O
of O
nicorandil O
was O
compared O
with O
that O
of O
nifedipine O
in O
13 O
patients O
with O
vasospastic O
angina O
enrolled O
in O
a O
randomized O
, O
placebo-controlled O
, O
crossover O
study O
. O
[]

RESULTS O
After O
3 O
months O
, O
significant O
decreases O
in O
proteinuria B-outcome ['Physiological-Clinical']
were O
observed O
in O
all O
groups O
: O
losartan O
, O
22.6 O
% O
( O
p O
= O
0.02 O
) O
; O
enalapril O
, O
43 O
% O
( O
p O
= O
0.012 O
) O
; O
and O
combined O
therapy O
, O
63 O
% O
( O
p O
= O
0.001 O
) O
. O
['Physiological-Clinical']

Our O
data O
demonstrate O
for O
the O
first O
time O
in O
humans O
that O
the O
imaging O
of O
central O
5-HT4R O
binding O
may O
be O
used O
as O
an O
in O
vivo O
biomarker O
of O
the O
central O
5-HT O
tonus O
. O
[]

morphine O
was O
titrated O
to O
the O
requirement O
in O
the O
post-anaesthetic O
unit O
. O
[]

The O
tests O
were O
carried O
out O
after O
gastric O
distension O
with O
gas O
had O
occurred O
. O
[]

Adhesion-prevention B-outcome ['Physiological-Clinical']
effects O
of O
fibrin O
sealants O
after O
laparoscopic O
myomectomy O
as O
determined O
by O
second-look O
laparoscopy O
: O
a O
prospective O
, O
randomized O
, O
controlled O
study O
. O
['Physiological-Clinical']

Cisplatin O
plus O
etoposide O
with O
and O
without O
ifosfamide O
in O
extensive O
small-cell O
lung O
cancer O
: O
a O
Hoosier O
Oncology O
Group O
study O
. O
[]

RESULTS O
No O
difference O
was O
found O
between O
baseline O
and O
the O
on- O
and O
off O
periods O
in O
overall B-outcome ['Physiological-Clinical']
gut I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
thresholds O
across O
all O
stimulus O
modalities O
in O
the O
esophagus O
( O
p=0.63 O
) O
, O
duodenum O
( O
p=0.19 O
) O
or O
esophagus O
and O
duodenum O
combined O
( O
p=0.76 O
) O
. O
['Physiological-Clinical']

Wound B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
rate O
was O
25 O
% O
in O
the O
erythromycin O
group O
, O
and O
organisms O
recovered O
from O
the O
wound O
in O
all O
cases O
were O
fecal O
in O
nature O
. O
['Physiological-Clinical']

Peak O
VO2 B-outcome ['Physiological-Clinical']
was O
20.4 O
+/- O
3.2 O
and O
21.2 O
+/- O
3.1 O
ml/min/kg O
, O
respectively O
, O
for O
those O
administered O
the O
placebo O
and O
the O
drug O
, O
and O
anaerobic B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
was O
13.1 O
+/- O
2.1 O
and O
14.0 O
+/- O
2.0 O
ml/min/kg O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
end O
point O
was O
time O
from O
randomization O
to O
relapse O
. O
[]

CONCLUSION O
during O
a O
4-days O
administration O
hepatic O
effect O
of O
the O
intravenous O
lipid O
emulsions O
did O
not O
differ O
significantly O
. O
[]

Omeprazole O
protected O
85 O
% O
of O
subjects O
from O
extensive B-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
erosions I-outcome ['Physiological-Clinical']
( O
often O
associated O
with O
evidence O
of O
intraluminal O
bleeding O
) O
or O
ulceration B-outcome ['Physiological-Clinical']
, O
whereas O
70 O
% O
of O
the O
subjects O
developed O
aspirin-induced B-outcome ['Physiological-Clinical']
grades I-outcome ['Physiological-Clinical']
3 I-outcome ['Physiological-Clinical']
and O
4 O
gastric B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
on O
placebo O
( O
P O
< O
0.01 O
by O
chi O
2 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
measured O
prediagnostic O
serum O
iron O
, O
ferritin O
, O
unsaturated O
iron O
binding O
capacity O
, O
and O
C-reactive O
protein O
. O
[]

METHODS O
Seventy-six O
patients O
with O
esophageal O
gastric O
carcinoma O
were O
randomly O
divided O
into O
two O
groups O
, O
the O
FZYLG O
group O
and O
the O
control O
group O
. O
[]

Moisture-vapour-permeable O
film O
as O
an O
outpatient O
burn O
dressing O
. O
[]

In O
four O
cases O
( O
12.9 O
% O
) O
the O
sentinel O
lymph O
node O
was O
the O
only O
site O
of O
metastasis O
, O
all O
of O
them O
being O
detected O
by O
association O
of O
hematoxylin B-outcome ['Physiological-Clinical']
and O
eosin B-outcome ['Physiological-Clinical']
and O
immunohistochemical B-outcome ['Physiological-Clinical']
examination O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
started O
taking O
aspirin O
( O
at O
a O
dose O
of O
200 O
mg O
) O
or O
placebo O
just O
before O
surgery O
and O
continued O
it O
daily O
( O
at O
a O
dose O
of O
100 O
mg O
) O
for O
30 O
days O
in O
the O
initiation O
stratum O
and O
for O
7 O
days O
in O
the O
continuation O
stratum O
, O
after O
which O
patients O
resumed O
their O
regular O
aspirin O
regimen O
. O
[]

BACKGROUND O
Diabetes O
portends O
an O
adverse O
prognosis O
in O
patients O
undergoing O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
[]

15.17 O
, O
final O
27.13 O
? O
[]

For O
both O
systolic B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
change O
in O
polyunsaturated O
fatty O
acid O
intake O
was O
the O
strongest O
dietary O
predictor O
of O
BP B-outcome ['Physiological-Clinical']
change O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Conventional O
therapy O
for O
childhood O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
includes O
prednisone O
and O
oral O
6-mercaptopurine O
. O
[]

RESULTS O
( O
192 O
) O
Ir O
reduced O
recurrent B-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
( O
23.7 O
% O
vs. O
60.7 O
% O
, O
p O
< O
0.001 O
) O
and O
the O
length O
of O
recurrent B-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
( O
8.99 O
+/- O
4.34 O
mm O
vs. O
17.54 O
+/- O
10.48 O
mm O
, O
p O
< O
0.001 O
) O
at O
follow-up O
compared O
to O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
aim O
of O
this O
prospective O
cohort O
study O
was O
to O
assess O
the O
incidence O
and O
characteristics O
of O
acute O
myocardial O
infarction O
in O
patients O
undergoing O
surgery O
for O
acute O
hip O
fracture O
. O
[]

Four O
young O
boys O
( O
ages O
4-5 O
years O
) O
diagnosed O
with O
autism O
participated O
. O
[]

STUDY O
OBJECTIVE O
To O
examine O
the O
effects O
of O
fructose-1,6-diphosphate O
on O
myocardial B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
using O
nuclear O
scintigraphy O
. O
['Physiological-Clinical']

Adjusting O
for O
baseline O
and O
age O
, O
the O
peroxide O
strip O
group O
had O
-2.45 O
Deltab* O
, O
2.39 O
DeltaL* O
, O
and O
-0.96 O
Deltaa* O
at O
Week O
2 O
. O
[]

Primary O
outcomes O
were O
safety O
and O
feasibility B-outcome ['Life-Impact']
of O
treatment O
, O
based O
on O
ankle-brachial B-outcome ['Physiological-Clinical']
index O
( O
ABI O
) O
and O
rest B-outcome ['Life-Impact']
pain B-outcome ['Physiological-Clinical']
, O
and O
analysis O
was O
per O
protocol O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Clomipramine O
and O
desipramine O
were O
equally O
superior O
to O
placebo O
for O
ratings O
of O
hyperactivity B-outcome ['Life-Impact']
. O
['Life-Impact']

The O
most O
frequently O
cultured O
organisms O
were O
Escherichia O
coli O
( O
15 O
) O
, O
Klebsiella O
sp O
( O
9 O
) O
, O
Proteus O
sp O
( O
6 O
) O
, O
and O
Bacteroides O
sp O
( O
4 O
) O
. O
[]

To O
test O
elements O
of O
this O
hypothesis O
, O
we O
have O
measured O
blood O
levels O
of O
dietary O
antioxidants O
, O
and O
8-oxodeoxyguanosine O
( O
8-oxo-dG O
) O
concentrations O
in O
lymphocyte O
DNA O
, O
in O
healthy O
men O
and O
women O
from O
five O
European O
countries O
: O
France O
, O
Ireland O
, O
The O
Netherlands O
, O
Spain O
, O
and O
the O
U.K O
. O
[]

RESULTS O
No O
significant O
differences O
were O
observed O
between O
the O
two O
groups O
with O
regard O
to O
the O
maximum O
diameters B-outcome ['Physiological-Clinical']
and O
calculated O
area O
of O
the O
resected O
specimens B-outcome ['Physiological-Clinical']
( O
ligation O
group O
: O
16.4 O
[ O
4.0 O
] O
x O
11 O
[ O
3.1 O
] O
mm/185 O
[ O
84 O
] O
mm O
( O
2 O
) O
vs. O
cap O
group O
: O
15.5 O
[ O
4.1 O
] O
x O
10.7 O
[ O
2.7 O
] O
mm/168 O
[ O
83 O
] O
mm O
( O
2 O
) O
) O
, O
or O
the O
maximum O
diameters B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Nociceptive O
brain O
activity O
after O
the O
noxious O
heel O
lance O
did O
not O
differ O
significantly O
between O
infants O
who O
received O
sucrose O
and O
those O
who O
received O
sterile O
water O
( O
sucrose O
: O
mean O
0?10 O
, O
95 O
% O
CI O
0?04-0?16 O
; O
sterile O
water O
: O
mean O
0?08 O
, O
0?04-0?12 O
; O
p=0?46 O
) O
. O
[]

SETTING O
& O
PARTICIPANTS O
HD O
patients O
undergoing O
periprocedure O
bridging O
anticoagulation O
. O
[]

Among O
seven O
patients O
with O
patent O
DAVFs O
, O
all O
cases O
showed O
an O
early B-outcome ['Physiological-Clinical']
visualization I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
transverse I-outcome ['Physiological-Clinical']
sinus I-outcome ['Physiological-Clinical']
on O
NCE O
4D O
MRA O
. O
['Physiological-Clinical']

CONCLUSION O
The O
combination O
of O
gemcitabine O
and O
tipifarnib O
has O
an O
acceptable O
toxicity O
profile O
but O
does O
not O
prolong O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
advanced O
pancreatic O
cancer O
compared O
with O
single-agent O
gemcitabine O
. O
['Mortality']

Lornoxicam O
was O
very O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
at O
all O
three O
doses O
studied O
, O
with O
no O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
definitely O
attributable O
to O
its O
administration O
. O
['Life-Impact', 'Adverse-effects']

On O
the O
last O
treatment O
day O
of O
each O
arm O
a O
20 O
min O
intravenous O
infusion O
of O
GTN O
( O
0.25 O
microg/kg/min O
) O
was O
given O
. O
[]

After O
11 O
months O
of O
prophylaxis O
, O
adult O
male O
subjects O
received O
a O
tetanus-diphtheria O
( O
Td O
) O
vaccination O
. O
[]

Cardiovascular B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
were O
assessed O
using O
standard O
noninvasive O
monitoring O
. O
['Physiological-Clinical']

After O
oxytocin O
treatment O
, O
right B-outcome ['Physiological-Clinical']
amygdala I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
facial I-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
increased O
in O
the O
AS O
group O
. O
['Physiological-Clinical']

Between O
group O
comparisons O
showed O
that O
children O
in O
treatment O
were O
rated O
as O
improved O
on O
the O
primary O
outcome O
measure O
, O
( O
unblinded O
parent O
report O
) O
, O
but O
not O
on O
the O
secondary O
outcome O
measure O
, O
a O
parent O
questionnaire O
. O
[]

METHODS O
Patients O
received O
conventional O
destructive O
therapy O
of O
all O
evident O
warts O
together O
with O
intramuscular O
administration O
of O
1 O
?g O
, O
5 O
?g O
or O
25 O
?g O
of O
VLP O
immunotherapy O
, O
or O
of O
placebo O
immunotherapy O
( O
0.9 O
% O
NaCl O
) O
, O
as O
immunotherapy O
at O
week O
0 O
and O
week O
4 O
. O
[]

RESULTS O
Intra-articular O
injections O
of O
rAAV2-TNFR O
: O
Fc O
were O
well O
tolerated O
with O
no O
major O
safety O
issues O
. O
[]

We O
conclude O
that O
recurrent O
tuberculosis O
in O
the O
United O
States O
and O
Canada O
, O
countries O
with O
low O
rates O
of O
tuberculosis O
, O
is O
rarely O
due O
to O
reinfection O
with O
a O
new O
strain O
of O
M. O
tuberculosis O
. O
[]

METHODS O
As O
part O
of O
a O
10-year O
prospective O
, O
randomized O
, O
single-center O
trial O
, O
patients O
undergoing O
primary O
coronary O
surgery O
were O
allocated O
to O
the O
radial O
artery O
( O
n O
= O
198 O
) O
or O
free O
right O
internal O
thoracic O
artery O
( O
n O
= O
196 O
) O
if O
aged O
less O
than O
70 O
years O
( O
group O
1 O
) O
, O
or O
radial O
artery O
( O
n O
= O
113 O
) O
or O
saphenous O
vein O
( O
n O
= O
112 O
) O
if O
aged O
at O
least O
70 O
years O
( O
group O
2 O
) O
. O
[]

METHODS O
As O
part O
of O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
relapse-prevention O
study O
of O
fluoxetine O
monotherapy O
in O
BP O
II O
MDE O
, O
37 O
patients O
received O
open-label O
fluoxetine O
20 O
mg O
every O
day O
for O
up O
to O
8 O
weeks O
. O
[]

CONCLUSION O
The O
results O
of O
this O
study O
show O
that O
remifentanil O
1 O
mg/kg O
is O
more O
effective O
than O
the O
combination O
of O
lidocaine O
1.5 O
mg/kg O
and O
esmolol O
1 O
mg/kg O
for O
attenuating O
the O
hemodynamic B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
rapid O
sequence O
intubation O
. O
['Physiological-Clinical']

One O
hundred O
four O
children O
with O
advanced O
leukemia O
in O
relapse O
( O
74 O
with O
acute O
lymphocytic O
leukemia O
[ O
ALL O
] O
and O
30 O
with O
acute O
nonlymphocytic O
leukemia O
[ O
ANLL O
] O
) O
received O
AMSA O
( O
4'- O
( O
9-Acridinylamino O
) O
methanesulfon O
-m-anisidide O
) O
at O
a O
dose O
of O
120 O
mg/m2/day O
for O
5 O
days O
( O
Regimen O
I O
) O
or O
60 O
mg/m2/day O
for O
10 O
days O
( O
Regimen O
II O
) O
. O
[]

Other O
kinetic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
did O
not O
differ O
significantly O
between O
groups O
. O
['Physiological-Clinical']

In O
a O
placebo-controlled O
, O
randomised O
, O
double-blind O
clinical O
trial O
, O
the O
authors O
evaluated O
the O
efficacy O
of O
patient-administered O
1 O
% O
fusidic O
acid O
viscous O
eye O
drops O
in O
clearing O
the O
commonest O
organisms O
causing O
pseudophakic O
endophthalmitis O
( O
Staphylococcus O
epidermidis O
and O
aureus O
) O
from O
the O
lids O
and O
conjunctivae O
of O
79 O
patients O
before O
cataract O
surgery O
. O
[]

Twenty O
memory-impaired O
patients O
, O
all O
of O
whom O
had O
been O
diagnosed O
as O
suffering O
from O
a O
memory O
impairment O
following O
acquired O
brain O
damage O
, O
participated O
as O
the O
memory-impaired O
control O
group O
. O
[]

Since O
preliminary O
data O
have O
shown O
that O
6-thioguanine O
is O
more O
effective O
than O
6-mercaptopurine O
, O
we O
compared O
the O
efficacy O
and O
toxicity B-outcome ['Adverse-effects']
of O
the O
two O
drugs O
for O
childhood O
lymphoblastic O
leukaemia O
. O
['Adverse-effects']

The O
yield O
in O
the O
EBUS-TBNA O
plus O
CDPs O
group O
( O
78.4 O
% O
) O
was O
significantly O
higher O
than O
the O
EBUS O
CDPs O
group O
( O
60.6 O
% O
, O
p O
= O
0.015 O
) O
. O
[]

The O
active O
and O
sham O
testing O
sessions O
were O
separated O
by O
7 O
days O
. O
[]

Randomized O
controlled O
study O
of O
chemoprophylaxis O
in O
transurethral O
prostatectomy O
. O
[]

OBJECTIVES O
Physicians O
adopt O
evidence-based O
guidelines O
with O
variable O
consistency O
. O
[]

The O
occurrence O
of O
bleeding B-outcome ['Physiological-Clinical']
and/or O
spotting B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
cycles O
2 O
and O
3 O
in O
the O
LNG/EE O
group O
( O
41.7 O
% O
and O
34.8 O
% O
, O
respectively O
) O
compared O
with O
the O
NETA/EE O
group O
( O
62.3 O
% O
and O
56.3 O
% O
; O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
have O
compared O
the O
effects O
of O
high O
and O
low O
dose O
inhaled O
steroid O
, O
budesonide O
, O
in O
patients O
with O
newly O
detected O
asthma O
. O
[]

The O
primary O
outcome O
is O
change O
in O
6-minute B-outcome ['Life-Impact']
walk I-outcome ['Life-Impact']
distance I-outcome ['Life-Impact']
immediately O
following O
intervention O
. O
['Life-Impact']

Immediately O
restored O
, O
single-tapered O
implants O
in O
the O
anterior O
maxilla O
: O
prosthodontic O
and O
aesthetic O
outcomes O
after O
1 O
year O
. O
[]

Use O
of O
propofol O
was O
associated O
with O
a O
significant O
fall O
in O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
in O
5 O
out O
of O
20 O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Hearing B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
developed O
in O
1/31 O
( O
3.2 O
% O
) O
and O
5/32 O
( O
15.6 O
% O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Acute O
heart O
failure O
is O
a O
common O
reason O
for O
admission O
, O
and O
outcome O
is O
often O
poor O
. O
[]

Tumor O
samples O
from O
49 O
patients O
were O
assessed O
for O
the O
expression O
levels O
of O
12 O
pemetrexed-related O
genes O
. O
[]

The O
specific O
role O
of O
isoflavones O
on O
estrogen O
metabolism O
in O
premenopausal O
women O
. O
[]

Effects O
of O
Thai O
traditional O
massage O
on O
autistic O
children O
's O
behavior O
. O
[]

There O
is O
no O
great O
discrepancy O
between O
objective O
amelioration O
( O
PAD O
test O
) O
and O
subjective O
amelioration O
( O
PRAFAB O
score/quantity O
of O
urinary O
leakage O
) O
, O
if O
the O
objective O
improvement O
is O
adequately O
defined O
. O
[]

Forty-seven O
outpatients O
with O
a O
DSM-IV-TR O
diagnosis O
of O
autism O
ages O
between O
4 O
and O
12 O
years O
were O
assigned O
to O
this O
double O
blinded O
clinical O
trial O
and O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

Nordic O
Walking O
is O
a O
popular O
and O
fast O
growing O
type O
of O
exercise O
in O
Northern O
Europe O
. O
[]

DESIGN O
A O
randomised O
controlled O
trial O
of O
nurse O
run O
clinics O
versus O
usual O
care O
. O
[]

Low O
CD19+ B-outcome ['Physiological-Clinical']
B-cell I-outcome ['Physiological-Clinical']
level O
( O
< O
125 O
microL O
) O
was O
associated O
with O
clinical B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
III I-outcome ['Physiological-Clinical']
( O
P O
= O
.033 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Four O
patients O
showed O
loss O
of O
the O
same O
allele O
at O
one O
or O
more O
marker O
loci O
in O
both O
primary O
and O
metastatic O
tumors O
, O
but O
discordant O
allelic B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
observed O
at O
other O
marker O
loci O
. O
['Physiological-Clinical']

It O
had O
not O
been O
possible O
to O
measure O
the O
biologically O
active O
fraction O
, O
ionized O
magnesium O
( O
IMg2+ O
) O
. O
[]

CONCLUSIONS O
The O
off-pump O
group O
appears O
to O
be O
generally O
comparable O
to O
the O
on-pump O
group O
in O
terms O
of O
short-term O
and O
long-term O
postsurgical O
neurocognitive O
outcomes O
. O
[]

BACKGROUND O
AND O
AIM O
Endothelial O
dysfunction O
in O
hypertensive O
type-2 O
diabetic O
patients O
is O
associated O
with O
increased O
levels O
of O
circulating O
soluble B-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
molecules I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SAM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
antacid O
or O
placebo O
on O
the O
( O
short-term O
) O
natural O
history O
of O
the O
disease O
. O
[]

[ O
Effects O
of O
auditory O
integrative O
training O
on O
autistic O
children O
] O
. O
[]

Children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
and O
attention O
deficit O
hyperactivity O
disorder O
( O
ADHD O
) O
demonstrate O
face B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
abnormalities I-outcome ['Life-Impact']
that O
may O
underlie O
social O
impairment O
. O
['Life-Impact']

We O
studied O
the O
nocturnal B-outcome ['Physiological-Clinical']
melatonin I-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
8 O
healthy O
volunteers O
, O
and O
6 O
women O
with O
untreated O
primary O
hypothyroidism O
, O
a O
disease O
state O
that O
is O
associated O
with O
increased O
nocturnal O
secretion O
of O
melatonin O
. O
['Physiological-Clinical']

BACKGROUND O
The O
Inoue O
balloon O
technique O
for O
mitral O
commissurotomy O
is O
well O
established O
and O
carried O
out O
worldwide O
. O
[]

Group O
A O
( O
n O
= O
35 O
) O
received O
2.5 O
ml O
0.75 O
% O
ropivacaine O
and O
group O
B O
( O
n O
= O
35 O
) O
received O
2.5 O
ml O
of O
2 O
% O
lidocaine O
for O
digital O
anesthesia O
. O
[]

The O
impact O
of O
angiotensin O
II O
receptor O
blockade O
and O
the O
DASH O
diet O
on O
markers B-outcome ['Physiological-Clinical']
of O
endogenous O
fibrinolysis O
. O
['Physiological-Clinical']

During O
the O
24-week O
follow-up O
period O
both O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
decreased O
significantly O
within O
both O
groups O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
nightly O
administration O
of O
SXB O
to O
narcolepsy O
patients O
significantly O
impacts O
measures O
of O
slow B-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
sleep B-outcome ['Physiological-Clinical']
, O
wake O
after O
sleep O
['Physiological-Clinical', 'Physiological-Clinical']

A O
three-drug O
regimen O
comprising O
metronidazole O
, O
amoxycillin O
and O
omeprazole O
has O
been O
proposed O
as O
an O
alternative O
therapy O
. O
[]

The O
spontaneous O
calcanean O
bone O
loss O
occurring O
in O
healthy O
early O
post-menopausal O
women O
and O
the O
effect O
of O
two O
hormone O
replacement O
therapies O
( O
HRT O
's O
) O
were O
investigated O
in O
a O
longitudinal O
study O
. O
[]

Arterial O
thrombus O
formation O
was O
induced O
ex O
vivo O
by O
exposing O
a O
collagen-coated O
surface O
in O
a O
parallel-plate O
perfusion O
chamber O
to O
native O
blood O
for O
3 O
min O
( O
arterial O
wall O
shear O
rate O
2600 O
s O
( O
-1 O
) O
) O
. O
[]

Sex O
steroids O
may O
stimulate O
angiogenesis O
via O
the O
estrogen O
receptor O
( O
ER O
) O
pathway O
. O
[]

Of O
the O
4044 O
girls O
enrolled O
and O
eligible O
, O
2087 O
( O
51.6 O
% O
) O
participated O
in O
the O
measurement O
component O
of O
the O
study O
. O
[]

There O
were O
no O
significant O
differences O
in O
the O
psychosocial B-outcome ['Life-Impact']
data O
between O
centres O
pre-counselling O
. O
['Life-Impact']

METHODS O
At O
surgery O
, O
an O
intraocular O
lens O
( O
IOL O
) O
was O
implanted O
or O
children O
were O
left O
aphakic O
, O
treated O
with O
contact O
lens O
( O
CL O
) O
. O
[]

RESULTS O
The O
5-year O
PCSM B-outcome ['Mortality']
rate O
for O
men O
with O
BMI O
< O
25 O
kg/m O
( O
2 O
) O
was O
6.5 O
% O
, O
compared O
with O
13.1 O
% O
and O
12.2 O
% O
in O
men O
with O
BMI O
> O
or O
=25 O
to O
< O
30 O
and O
BMI O
> O
or O
=30 O
, O
respectively O
( O
Gray O
's O
P O
= O
.005 O
) O
. O
['Mortality']

Eleven O
patients O
with O
detached O
posterior O
hyaloid O
( O
group O
III O
) O
were O
not O
randomized O
, O
and O
ILM O
removal O
was O
performed O
. O
[]

No O
significant O
change O
over O
time O
occurred O
for O
any O
of O
the O
centres O
for O
risk O
perception B-outcome ['Life-Impact']
or O
general B-outcome ['Life-Impact']
psychological I-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

RESULTS O
When O
assessed O
on O
the O
basis O
of O
parent-rated O
ABC-CV O
ratings O
of O
irritability B-outcome ['Life-Impact']
and O
hyperactivity B-outcome ['Life-Impact']
, O
the O
mean O
placebo O
response O
rate O
was O
37 O
% O
versus O
amantadine O
at O
47 O
% O
( O
not O
significant O
) O
. O
['Life-Impact', 'Life-Impact']

After O
the O
48-week O
treatment O
period O
, O
ankle-brachial O
index O
and O
absolute O
claudication O
distance O
improved O
significantly O
in O
both O
patient O
groups O
( O
P O
< O
0.05 O
for O
both O
) O
, O
with O
no O
difference O
across O
treatments O
. O
[]

Gabapentin O
for O
the O
prevention O
of O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
vaginal O
hysterectomy O
. O
['Physiological-Clinical']

However O
, O
there O
were O
no O
significant O
differences O
, O
between O
the O
two O
groups O
, O
in O
the O
prevalences O
of O
these O
symptoms O
of O
morbidity B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
present O
study O
was O
carried O
out O
in O
order O
to O
evaluate O
any O
circadian O
changes O
in O
pharmacokinetic O
parameters O
of O
ketoprofen O
, O
a O
new O
non-steroidal O
anti-inflammatory O
drug O
( O
NSAID O
) O
. O
[]

Six O
children O
( O
responders O
) O
were O
clinically O
improved O
by O
the O
treatment O
. O
[]

Norfloxacin O
modulates O
the O
inflammatory O
response O
and O
directly O
affects O
neutrophils O
in O
patients O
with O
decompensated O
cirrhosis O
. O
[]

HPV16 B-outcome ['Physiological-Clinical']
( O
59.9 O
% O
) O
, O
HPV31 B-outcome ['Physiological-Clinical']
( O
18.1 O
% O
) O
, O
HPV52 B-outcome ['Physiological-Clinical']
( O
14.8 O
% O
) O
, O
HPV51 B-outcome ['Physiological-Clinical']
( O
14.0 O
% O
) O
, O
and O
HPV18 B-outcome ['Physiological-Clinical']
( O
13.2 O
% O
) O
were O
the O
five O
most O
common O
HPV O
genotypes O
detected O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Anaesthesia O
was O
induced O
with O
thiopentone O
and O
suxamethonium O
and O
maintained O
with O
atracurium O
, O
nitrous O
oxide O
and O
isoflurane O
. O
[]

Albumin-glutaraldehyde O
bioadhesive O
( O
Bioglue O
) O
for O
prevention O
of O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
after O
stapled O
hemorrhoidopexy O
: O
A O
randomized O
controlled O
trial O
. O
['Adverse-effects']

Cutaneous B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
conductance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CVC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
calculated O
from O
the O
ratio O
of O
SkBF O
to O
mean O
arterial O
blood O
pressure O
. O
['Physiological-Clinical']

S6K1 B-outcome ['Physiological-Clinical']
phosphorylation I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
421 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
/S I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
424 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
substantially O
increased O
following O
exercise O
and O
remained O
elevated O
during O
recovery O
with O
no O
differences O
between O
treatments O
. O
['Physiological-Clinical']

Urban O
men O
have O
more O
risk O
factors O
and O
higher O
prevalence O
of O
the O
metabolic B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
than O
rural O
men O
, O
but O
the O
differences O
in O
women O
were O
not O
that O
striking O
. O
['Physiological-Clinical']

Uric B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
levels O
were O
significantly O
reduced O
at O
both O
7 O
days O
and O
6 O
weeks O
in O
the O
high-dose O
group O
( O
by O
0.14 O
mmol/L O
at O
6 O
weeks O
, O
P=0.002 O
) O
. O
['Physiological-Clinical']

Baseline O
PIPP B-outcome ['Physiological-Clinical']
scores O
and O
post-examination B-outcome ['Physiological-Clinical']
PIPP I-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
at O
1 O
and O
5 O
min O
were O
compared O
for O
: O
( O
1 O
) O
those O
receiving O
saline O
vs O
proparacaine O
eye O
drops O
( O
2 O
) O
first O
ROP O
screening O
vs O
second O
ROP O
screening O
, O
regardless O
of O
the O
type O
of O
eye O
drops O
used O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Twelve O
subjects O
in O
the O
fenretinide O
arm O
complained O
of O
diminished O
dark B-outcome ['Physiological-Clinical']
adaptability I-outcome ['Physiological-Clinical']
, O
and O
nine O
subjects O
in O
the O
fenretinide O
arm O
versus O
one O
control O
subject O
had O
mild B-outcome ['Physiological-Clinical']
dermatological I-outcome ['Physiological-Clinical']
alterations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Straylight O
values O
were O
0.97 O
+/- O
0.10 O
and O
1.0 O
+/- O
0.10 O
log O
units O
with O
the O
amber O
and O
grey-green O
tinted O
CL O
, O
respectively O
. O
[]

Comparison O
of O
the O
therapeutic O
efficacy O
of O
phonophoresis O
and O
iontophoresis O
using O
dexamethasone O
sodium O
phosphate O
in O
the O
management O
of O
patients O
with O
knee O
osteoarthritis O
. O
[]

Finally O
the O
dependency O
of O
lethality B-outcome ['Life-Impact']
and O
age O
was O
similar O
in O
both O
groups O
. O
['Life-Impact']

Pacing O
converted O
2 O
of O
11 O
patients O
( O
18 O
% O
) O
who O
received O
placebo O
, O
13 O
of O
15 O
patients O
( O
87 O
% O
) O
who O
received O
ibutilide O
, O
and O
29 O
of O
33 O
patients O
( O
88 O
% O
) O
who O
received O
procainamide O
to O
sinus B-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PONV B-outcome ['Physiological-Clinical']
was O
evaluated O
in O
terms O
of O
nausea B-outcome ['Physiological-Clinical']
graded O
on O
a O
visual O
analogue O
scale O
, O
and O
the O
number O
of O
patients O
who O
experienced O
emetic B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
or O
needed B-outcome ['Resource-use']
rescue I-outcome ['Resource-use']
anti-emetics I-outcome ['Resource-use']
in O
the O
48-h O
post-operative O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

RESULTS O
Patients O
who O
received O
CBT O
( O
n=257 O
) O
improved O
in O
overall B-outcome ['Life-Impact']
symptomatology I-outcome ['Life-Impact']
( O
P=0.015 O
; O
number O
needed O
to O
treat O
[ O
NNT O
] O
=13 O
) O
, O
insight B-outcome ['Life-Impact']
( O
P O
< O
0.001 O
; O
NNT=10 O
) O
and O
depression B-outcome ['Life-Impact']
( O
P=0.003 O
; O
NNT=9 O
) O
compared O
with O
the O
control O
group O
( O
n=165 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

In O
MM O
, O
the O
significance O
of O
staging O
for O
survival B-outcome ['Mortality']
is O
independent O
of O
both O
the O
aggressiveness O
of O
induction O
and O
of O
continuing O
or O
discontinuing O
maintenance O
chemotherapy O
after O
the O
maximal O
tumor O
reduction O
has O
been O
achieved O
. O
['Mortality']

Linezolid O
was O
well O
tolerated B-outcome ['Life-Impact']
and O
the O
frequency O
of O
drug-related B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
similar O
between O
the O
linezolid O
and O
placebo O
groups O
. O
['Life-Impact', 'Adverse-effects']

RESULTS O
( O
1 O
) O
The O
therapeutic B-outcome ['Physiological-Clinical']
efficacy O
in O
the O
treatment O
group O
was O
superior O
to O
that O
in O
the O
control O
group O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

All O
93 O
patients O
underwent O
pelvic O
lymphadenectomy O
; O
15 O
patients O
( O
32 O
% O
) O
of O
the O
fibrin O
group O
and O
12 O
( O
26 O
% O
) O
of O
the O
controls O
also O
underwent O
paraaortic O
lymphadenectomy O
. O
[]

RESULTS O
One O
hundred O
two O
patients O
were O
enrolled O
, O
with O
a O
median O
age O
of O
6.1 O
years O
. O
[]

Measurements O
of O
plasma B-outcome ['Physiological-Clinical']
ALA I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
from O
0 O
to O
24h O
showed O
no O
difference O
in O
ALA O
pharmacokinetics O
between O
the O
two O
formulations O
. O
['Physiological-Clinical']

R2 O
= O
0.61 O
, O
p O
< O
0.0005 O
) O
with O
the O
initial O
levels O
of O
biotin O
and O
vitamin O
K O
being O
the O
most O
significant O
( O
p O
< O
0.05 O
) O
; O
both O
biotin O
and O
vitamin O
K O
are O
made O
by O
beneficial O
intestinal O
flora O
. O
[]

We O
then O
recruited O
22 O
patients O
( O
group O
B O
) O
with O
bilateral O
leg O
ischaemia O
, O
who O
were O
randomly O
injected O
with O
bone O
marrow-mononuclear O
cells O
in O
one O
leg O
and O
peripheral O
blood-mononuclear O
cells O
in O
the O
other O
as O
a O
control O
. O
[]

Although O
anxiety O
sensitivity O
( O
AS O
) O
has O
been O
shown O
to O
predict O
anxiety O
symptoms O
and O
panic O
, O
this O
literature O
is O
limited O
in O
regard O
to O
evaluating O
AS O
as O
an O
incremental O
predictor O
of O
anxiety O
psychopathology O
relative O
to O
other O
established O
risk O
factors O
including O
sex O
and O
negative O
affect O
. O
[]

An O
increase O
in O
the O
DFT B-outcome ['Resource-use']
was O
observed O
in O
14 O
patients O
as O
VF O
duration O
increased O
. O
['Resource-use']

RESULTS O
Eighteen O
participants O
( O
10 O
mecamylamine O
, O
8 O
placebo O
) O
completed O
the O
study O
. O
[]

OBJECTIVE O
To O
find O
out O
an O
effective O
therapy O
for O
autism O
. O
[]

The O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
similar O
in O
all O
three O
groups O
. O
['Adverse-effects']

Springer O
, O
New O
York O
, O
2012a O
) O
were O
analyzed O
. O
[]

METHODS O
FAVORIT O
is O
a O
multicenter O
double-blind O
randomized O
controlled O
clinical O
trial O
. O
[]

One O
hundred O
thirty-five O
women O
completed O
the O
trial O
. O
[]

In O
addition O
, O
we O
sought O
to O
compare O
the O
intervention O
's O
impact O
on O
commercially O
and O
Medicaid-insured O
children O
. O
[]

CONCLUSIONS O
Erythromycin O
is O
effective O
in O
significantly O
reducing O
lost O
time O
from O
work O
, O
but O
it O
is O
not O
effective O
in O
reducing O
cough O
or O
other O
symptoms O
in O
patients O
with O
acute O
bronchitis O
, O
regardless O
of O
the O
outcome O
of O
the O
M O
pneumoniae O
antibody O
test O
. O
[]

Drug O
treatment O
consisted O
of O
15 O
ml O
( O
80 O
mEq O
) O
doses O
of O
antacid O
( O
Maalox O
Therapeutic O
Concentration O
, O
William O
H. O
Rorer O
) O
or O
placebo O
taken O
7 O
times O
daily O
, O
ie O
, O
1 O
and O
3 O
hr O
after O
meals O
and O
at O
bedtime O
. O
[]

Randomized O
controlled O
caregiver O
mediated O
joint O
engagement O
intervention O
for O
toddlers O
with O
autism O
. O
[]

RESULTS O
Erythromycin O
increased O
abomasal B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
rate O
, O
as O
indicated O
by O
a O
shorter O
time O
to O
actual O
T O
( O
max O
) O
and O
model O
T O
( O
max O
) O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

Using O
a O
logistic O
regression O
model O
, O
baseline O
quantitative B-outcome ['Physiological-Clinical']
mycobacterial I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

METHODS O
This O
was O
a O
post O
hoc O
analysis O
of O
data O
from O
two O
8-week O
, O
randomized O
, O
double-blind O
, O
multicenter O
trials O
to O
evaluate O
the O
efficacy O
of O
aripiprazole O
dosed O
flexibly O
( O
2-15 O
mg/day O
, O
n=47 O
) O
or O
fixed O
( O
5 O
, O
10 O
, O
or O
15 O
mg/day O
, O
n O
= O
166 O
) O
versus O
placebo O
( O
flexibly O
dosed O
, O
n O
= O
51 O
; O
fixed O
dose O
, O
n O
= O
52 O
) O
. O
[]

The O
objectives O
of O
this O
study O
were O
to O
demonstrate O
the O
means B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
this I-outcome ['Life-Impact']
cooperation I-outcome ['Life-Impact']
and O
the O
results O
of O
therapy O
. O
['Life-Impact']

Studies O
have O
shown O
that O
insulin O
resistance O
is O
associated O
with O
cognitive O
impairment O
. O
[]

Using O
logistic O
regression O
, O
we O
estimated O
odds O
ratios O
( O
ORs O
) O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
to O
prospectively O
evaluate O
the O
association O
between O
lignan O
and O
proanthocyanidin O
intake O
, O
estimated O
from O
databases O
linked O
to O
a O
food O
frequency O
questionnaire O
, O
and O
adenoma B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
in O
1,859 O
participants O
of O
the O
Polyp O
Prevention O
Trial O
. O
['Physiological-Clinical']

This O
study O
examined O
the O
social B-outcome ['Life-Impact']
impact I-outcome ['Life-Impact']
of O
being O
a O
typical O
peer O
model O
as O
part O
of O
a O
social O
skills O
intervention O
for O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
['Life-Impact']

All O
patients O
were O
followed O
up O
for O
24 O
months O
. O
[]

4 O
The O
peak O
effect O
of O
a O
40 O
mg O
dose O
of O
propranolol O
was O
greater O
than O
that O
of O
a O
200 O
mg O
dose O
of O
prizidilol O
but O
both O
drugs O
caused O
persistent O
beta-adrenoceptor B-outcome ['Resource-use']
blockade I-outcome ['Resource-use']
for O
at O
least O
7 O
h O
after O
ingestion O
. O
['Resource-use']

Expenditure O
of O
resources O
on O
waiting O
times O
without O
regard O
to O
clinical O
outcomes O
is O
likely O
to O
be O
wasteful O
and O
additional O
resources O
should O
be O
directed O
at O
achieving O
the O
greatest O
clinical O
benefit O
. O
[]

At O
6 O
months O
, O
four O
of O
the O
Vector-treated O
sites O
, O
and O
only O
one O
site O
treated O
with O
curettes O
, O
had O
stopped O
to O
bleed B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
We O
performed O
a O
randomized O
double-blind O
placebo-controlled O
trial O
of O
labetalol O
10mg O
iv O
given O
with O
midazolam-alfentanil O
sedation O
. O
[]

In O
45 O
patients O
with O
type O
2 O
diabetes O
mellitus O
( O
DM O
) O
, O
we O
prospectively O
analyzed O
urinary O
excretion O
of O
N-acetyl-beta-glucosaminidase O
( O
NAG O
) O
, O
a O
marker O
of O
tubular O
renal O
damage O
; O
the O
potential O
relationship O
with O
urinary O
protein O
excretion O
; O
and O
effects O
of O
pentoxifylline O
( O
PTF O
) O
administration O
. O
[]

A O
low O
mean O
8-oxo-dG B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
is O
seen O
in O
DNA O
of O
women O
from O
all O
five O
countries O
, O
and O
of O
men O
from O
France O
and O
Spain O
. O
['Physiological-Clinical']

The O
greater O
absolute O
benefits O
in O
older O
patients O
in O
this O
age O
group O
were O
not O
offset O
by O
an O
increased O
risk O
of O
side O
effects O
. O
[]

The O
cost O
difference O
ranged O
from O
$ O
270 O
( O
p=0.01 O
) O
during O
the O
quarter O
of O
quit O
, O
to O
$ O
490 O
( O
p O
< O
0.01 O
) O
in O
the O
6th O
quarter O
after O
quitting O
. O
[]

DATA O
SOURCES/STUDY O
SETTING O
Medicaid O
claims O
data O
were O
collected O
for O
all O
enrollees O
in O
the O
Cash O
and O
Counseling O
demonstration O
. O
[]

Principal O
components O
analysis O
and O
multivariable O
general O
linear O
models O
were O
used O
to O
derive O
dietary O
patterns O
and O
to O
evaluate O
associations O
between O
dietary O
patterns O
and O
BMI O
, O
respectively O
. O
[]

Although O
the O
overall O
prevalence O
rates O
produced O
by O
self-reports O
and O
urinalysis O
were O
similar O
, O
there O
was O
little O
concordance O
between O
urinalysis B-outcome ['Physiological-Clinical']
positives O
and O
self-report O
positives O
. O
['Physiological-Clinical']

Children O
were O
assessed O
before O
, O
immediately O
after O
, O
6 O
months O
after O
, O
and O
12 O
months O
after O
intervention O
. O
[]

After O
28 O
and O
42 O
days O
, O
patients O
in O
the O
sulfadoxine/pyrimethamine O
plus O
amodiaquine O
group O
were O
significantly O
less O
likely O
to O
develop O
malaria B-outcome ['Physiological-Clinical']
than O
were O
those O
in O
the O
other O
groups O
. O
['Physiological-Clinical']

'blanket O
' O
) O
. O
[]

This O
was O
a O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
of O
lamotrigine O
, O
an O
agent O
that O
modulates O
glutamate O
release O
. O
[]

Compared O
with O
placebo O
, O
treatment O
with O
enzyme O
was O
not O
associated O
with O
clinically O
significant O
improvement O
in O
behaviour B-outcome ['Physiological-Clinical']
, O
food B-outcome ['Life-Impact']
variety I-outcome ['Life-Impact']
, O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
, O
engagement B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
therapist I-outcome ['Life-Impact']
, O
or O
the O
Language B-outcome ['Life-Impact']
Development I-outcome ['Life-Impact']
Survey O
Vocabulary B-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
Sentence I-outcome ['Life-Impact']
Complexity B-outcome ['Life-Impact']
Scores O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Treadmill B-outcome ['Life-Impact']
exercise I-outcome ['Life-Impact']
tests O
and O
72-hour O
electrocardiographic B-outcome ['Physiological-Clinical']
recordings O
were O
obtained O
at O
the O
end O
of O
two O
2-week O
treatment O
periods O
with O
sustained-release O
diltiazem O
180 O
mg O
b.i.d O
. O
['Life-Impact', 'Physiological-Clinical']

Further O
outcome O
measures O
included O
predictors O
of O
remission B-outcome ['Physiological-Clinical']
and O
other O
clinical O
variables O
over O
time O
. O
['Physiological-Clinical']

Two O
homeopaths O
jointly O
performed O
case-taking O
interviews O
. O
[]

Increases O
in O
PSA O
from O
baseline O
and O
the O
maximum O
increase O
from O
nadir O
to O
month O
24 O
were O
compared O
between O
the O
groups O
and O
analyzed O
by O
prostate O
cancer O
status O
, O
as O
determined O
by O
PSA O
driven O
biopsy O
and O
an O
advised O
cutoff O
of O
more O
than O
4 O
ng/ml O
after O
doubling O
to O
correct O
for O
dutasteride O
treatment O
with O
sensitivity O
and O
specificity O
calculated O
for O
each O
. O
[]

A O
randomized O
comparative O
study O
of O
surgical O
adjuvant O
chemotherapy O
using O
dl-leucovorin O
( O
dl-LV O
) O
and O
5-fluorouracil O
( O
5-FU O
) O
( O
FL-therapy O
) O
with O
CDDP O
, O
5-FU O
, O
and O
dl-LV O
( O
PFL-therapy O
) O
was O
conducted O
. O
[]

OUTCOME O
MEASURES O
Parents O
and O
teachers O
assessed O
major B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
disturbances I-outcome ['Life-Impact']
using O
the O
Conners O
' O
Rating O
Scales O
at O
0 O
and O
8 O
weeks O
. O
['Life-Impact']

RESULTS O
One O
hundred O
and O
seven O
subjects O
between O
the O
ages O
of O
26 O
and O
80 O
participated O
in O
the O
clinical O
trial O
. O
[]

For O
respective O
comparisons O
of O
ALLO O
and O
AUTO O
transplants O
in O
the O
GLN O
and O
GLY O
hematologic O
groups O
and O
AUTO O
in O
the O
solid O
tumor O
groups O
, O
there O
were O
no O
significant O
differences O
in O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
after I-outcome ['Resource-use']
BMT I-outcome ['Resource-use']
, O
TPN B-outcome ['Life-Impact']
days I-outcome ['Life-Impact']
, O
neutrophil B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
> O
500/mm3 O
, O
incidence O
of O
positive O
blood B-outcome ['Physiological-Clinical']
cultures B-outcome ['Physiological-Clinical']
, O
sepsis B-outcome ['Physiological-Clinical']
, O
mucositis B-outcome ['Physiological-Clinical']
, O
and O
diarrhea B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Resource-use', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
procedure O
was O
repeated O
with O
NMI O
as O
cost O
function O
. O
[]

Standard O
echocardiographic O
measurements O
were O
made O
from O
two-dimensional O
images O
. O
[]

The O
capsules O
of O
the O
test O
formulation O
were O
opened O
and O
administered O
on O
a O
tablespoonful O
of O
apple O
sauce O
. O
[]

Additional O
trials O
are O
needed O
to O
test O
if O
it O
has O
value O
for O
wound O
treatment O
in O
horses O
. O
[]

Results O
showed O
a O
significant O
reduction O
in O
depression B-outcome ['Life-Impact']
, O
anxiety B-outcome ['Life-Impact']
and O
rumination B-outcome ['Life-Impact']
in O
the O
intervention O
group O
, O
as O
opposed O
to O
the O
control O
group O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Aim O
To O
assess O
the O
efficacy O
and O
safety O
of O
dipyridamole O
in O
the O
treatment O
of O
patients O
with O
chronic O
stable O
angina O
in O
a O
large O
scale O
, O
international O
, O
randomized O
, O
placebo-controlled O
, O
parallel O
group O
study O
. O
[]

From O
both O
the O
Conners O
' O
Teacher O
Questionnaire O
and O
SD O
, O
statistical O
improvement O
was O
detected O
for O
conduct O
problem O
, O
hyperactivity O
, O
inattention-passivity O
, O
hyperactivity O
index O
, O
and O
sleeping O
behavior O
. O
[]

The O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
reproduce I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
with O
the O
timed O
Bernstein O
test O
was O
increased O
with O
both O
active O
drug O
and O
placebo O
therapy O
. O
['Physiological-Clinical']

The O
effect O
of O
transcutaneous O
electrical O
nerve O
stimulation O
( O
TENS O
) O
plus O
conservative O
therapy O
( O
ibuprofen O
, O
bite O
plate O
, O
self-physiotherapy O
) O
on O
myofascial O
pain O
dysfunction O
( O
MPD O
) O
was O
determined O
. O
[]

PATIENTS O
2121/2292 O
patients O
( O
92.5 O
% O
) O
had O
an O
analysable O
dataset O
for O
either O
biomarker O
. O
[]

Comparison O
of O
autologous O
bone O
marrow O
transplantation O
with O
sequential O
chemotherapy O
for O
intermediate-grade O
and O
high-grade O
non-Hodgkin O
's O
lymphoma O
in O
first O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
: O
a O
study O
of O
464 O
patients O
. O
['Physiological-Clinical']

A O
randomized O
phase O
II O
trial O
of O
two O
regimens O
of O
moderate O
dose O
chemoradiation O
therapy O
for O
patients O
with O
non-small O
cell O
lung O
cancer O
not O
suitable O
for O
curative O
therapy O
: O
Trans O
Tasman O
Radiation O
Oncology O
Study O
TROG O
03.07 O
. O
[]

METHODS O
Forty-eight O
patients O
with O
SSc O
were O
assigned O
randomly O
to O
the O
multifaceted O
oral O
health O
intervention O
or O
usual O
dental O
care O
control O
group O
. O
[]

In O
a O
randomized O
multicenter O
study O
, O
the O
efficacy O
and O
safety O
of O
cefprozil O
were O
compared O
with O
those O
of O
penicillin O
in O
the O
treatment O
of O
group O
A O
streptococcal O
tonsillopharyngitis O
in O
children O
. O
[]

Casein-treated O
patients O
given O
branched-chain O
amino O
acids O
rapidly O
improved O
. O
[]

In O
21 O
( O
35 O
% O
) O
of O
the O
cases O
, O
a O
three-field O
technique O
with O
two O
lateral O
opposed O
wedge O
fields O
and O
a O
posterior O
field O
was O
used O
, O
while O
in O
39 O
( O
65 O
% O
) O
of O
the O
cases O
a O
four-field O
pelvic O
box O
technique O
was O
used O
. O
[]

The O
risk O
of O
SSI B-outcome ['Physiological-Clinical']
was O
39 O
% O
lower O
in O
the O
80 O
% O
FIO2 O
group O
( O
relative O
risk O
[ O
RR O
] O
, O
0.61 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.38-0.98 O
) O
vs O
the O
30 O
% O
FIO2 O
group O
. O
['Physiological-Clinical']

The O
serums B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
assessed O
in O
all O
the O
patients O
before O
treatment O
, O
and O
4 O
and O
8 O
weeks O
after O
treatment O
. O
['Physiological-Clinical', 'Adverse-effects']

Significantly O
more O
adhesions B-outcome ['Physiological-Clinical']
were O
observed O
at O
laparoscopy O
on O
the O
control O
pelvic O
sidewalls O
( O
48 O
of O
63 O
, O
76 O
% O
) O
than O
on O
the O
treated O
sides O
( O
26 O
of O
63 O
, O
41 O
% O
) O
( O
P O
less O
than O
.0001 O
) O
. O
['Physiological-Clinical']

Compared O
with O
DT O
participants O
, O
more O
DT+ O
participants O
established O
abstinence I-outcome ['Life-Impact']
, O
maintained B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
longer I-outcome ['Life-Impact']
durations I-outcome ['Life-Impact']
, O
were O
marginally O
significantly O
more O
likely O
to O
lapse B-outcome ['Life-Impact']
, O
and O
significantly O
less O
likely O
to O
relapse B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
primary O
endpoint O
was O
non-inferiority O
of O
etoricoxib O
vs O
diclofenac O
for O
thrombotic O
CV O
events O
( O
95 O
% O
CI O
upper O
bound O
of O
hazard O
ratio O
< O
1.30 O
) O
. O
[]

Basal B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
measured O
using O
a O
Deltrac O
monitor O
, O
and O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
EEPA I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
was O
estimated O
using O
a O
Caltrac O
accelerometer O
. O
['Physiological-Clinical', 'Life-Impact']

Non-Hodgkin O
's O
malignant O
lymphomas O
: O
treatment O
of O
localized O
relapses O
with O
chemo O
+ O
radio O
+ O
BCG-therapy O
. O
[]

Epidural O
anesthesia O
was O
performed O
at O
the O
L2-3 O
interspace O
with O
an O
18-gauge O
Tuohy O
needle O
using O
loss O
of O
resistance O
. O
[]

Blastocysts O
were O
stored O
in O
LN? O
for O
at O
least O
1 O
month O
. O
[]

Patients O
with O
stroke O
were O
randomly O
assigned O
to O
daily O
treatment O
with O
400 O
mg O
of O
etidronate O
( O
n O
= O
40 O
) O
or O
a O
placebo O
( O
n O
= O
40 O
) O
, O
and O
followed O
up O
for O
2 O
years O
. O
[]

CONCLUSIONS O
Closed O
suctioning O
minimized O
lung O
volume O
loss O
during O
suctioning O
but O
, O
counterintuitively O
, O
resulted O
in O
slower O
recovery O
of O
EELV O
postsuction O
compared O
with O
OS O
. O
[]

Each O
person O
shall O
receive O
therapy O
in O
an O
out-patient O
setting O
in O
groups O
of O
3-4 O
. O
[]

DISCUSSION O
CBSM O
appears O
to O
be O
a O
potentially O
efficacious O
treatment O
that O
reduces O
and O
maintains O
lower O
levels O
of O
depressive O
symptoms O
and O
enhances O
social O
support O
in O
HIV-positive O
homosexual O
and O
bisexual O
men O
. O
[]

In O
the O
R-CIU O
group O
, O
fexofenadine O
at O
180 O
mg O
did O
not O
suppress O
AS-induced B-outcome ['Physiological-Clinical']
wheal I-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
( O
5.96 O
? O
['Physiological-Clinical']

Continuation O
of O
raloxifene O
( O
group O
1 O
) O
maintained O
these O
changes O
. O
[]

CONCLUSIONS O
The O
rapid O
administration O
of O
propofol O
reduces O
pain O
and O
facilitates O
LMA O
insertion O
versus O
slow O
administration O
of O
propofol O
. O
[]

The O
high-dose O
challenge O
model O
is O
suitable O
only O
in O
an O
attenuated O
form O
in O
diseased O
volunteers O
for O
proof-of-concept O
studies O
and O
in O
clinical O
settings O
to O
reduce O
the O
risk O
of O
severe O
asthma O
exacerbations O
. O
[]

6.3 O
in O
the O
CCB O
group O
( O
not O
significant O
) O
. O
[]

CONCLUSIONS O
These O
results O
demonstrate O
that O
risperidone O
is O
more O
efficacious O
and O
well O
tolerated O
than O
haloperidol O
in O
the O
long-term O
maintenance O
treatment O
of O
autistic O
disorder O
. O
[]

We O
conclude O
that O
the O
availability O
of O
dietary O
protein O
further O
enhances O
phosphorylation O
of O
S6K1 O
during O
recovery O
from O
resistance O
type O
exercise O
. O
[]

Comparison O
has O
been O
made O
between O
the O
absorption B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
digoxin I-outcome ['Physiological-Clinical']
from O
Lanoxin O
tablets O
and O
the O
absorption O
of O
international O
chemical O
reference O
substance O
digoxin B-outcome ['Resource-use']
from O
an O
oral O
solution O
. O
['Physiological-Clinical', 'Resource-use']

RESULTS O
There O
were O
no O
cases O
of O
wound B-outcome ['Physiological-Clinical']
dehiscence I-outcome ['Physiological-Clinical']
and O
no O
clinically B-outcome ['Physiological-Clinical']
evident I-outcome ['Physiological-Clinical']
superficial I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
deep I-outcome ['Physiological-Clinical']
surgical I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
either O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
cardiac B-outcome ['Physiological-Clinical']
index O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Compared O
with O
levels O
of O
IL-1 O
beta O
at O
entry O
, O
PHA O
induced O
increases O
for O
patients O
treated O
with O
methotrexate O
( O
12 O
, O
18 O
, O
and O
24 O
months O
) O
or O
colchicine O
( O
18 O
and O
24 O
months O
) O
. O
[]

[ O
Localised O
prostate O
cancer O
: O
the O
PREFERE O
trial O
] O
. O
[]

The O
change O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
EBM O
group O
and O
returned O
to O
baseline O
values O
sooner O
than O
in O
the O
DW O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
NORwegian O
study O
on O
DIstrict O
treatment O
of O
ST-elevation O
myocardial O
infarction O
( O
NORDISTEMI O
) O
. O
[]

DESIGN O
A O
prospective O
randomised O
study O
. O
[]

We O
compared O
a O
standard O
diagnostic O
strategy O
( O
culture O
and O
histology O
) O
with O
a O
rapid O
biomarker-based O
diagnostic O
strategy O
( O
aspergillus O
galactomannan O
and O
PCR O
) O
for O
directing O
the O
use O
of O
antifungal O
treatment O
in O
this O
group O
of O
patients O
. O
[]

RESULTS O
ORR B-outcome ['Physiological-Clinical']
for O
patients O
randomly O
assigned O
to O
receive O
EC O
and O
ED O
were O
42 O
% O
and O
47 O
% O
, O
respectively O
( O
P O
= O
0.63 O
) O
. O
['Physiological-Clinical']

Systematic O
approach O
to O
benign O
paroxysmal O
positional O
vertigo O
in O
the O
elderly O
. O
[]

RESULTS O
Preoperative O
plasma O
levels O
of O
the O
inflammatory O
cytokine O
interleukin-6 O
were O
reduced O
by O
2-fold O
( O
P O
< O
.001 O
) O
in O
the O
2-dose O
methylprednisolone O
group O
, O
consistent O
with O
the O
anti-inflammatory O
effects O
of O
methylprednisolone O
. O
[]

OBJECTIVE O
The O
objective O
was O
to O
assess O
the O
effect O
of O
supplemental O
iron O
and O
riboflavin O
on O
pupillary O
threshold O
( O
PT O
) O
and O
plasma O
retinol O
in O
nightblind O
, O
pregnant O
Nepali O
women O
given O
vitamin O
A-fortified O
rice O
. O
[]

Adverse O
events O
and O
Arizona O
Sexual O
Experience O
Scale O
scores O
were O
comparable O
between O
groups O
. O
[]

Results O
were O
expressed O
in O
incremental O
cost-effectiveness O
ratios O
. O
[]

METHOD O
In O
a O
laboratory O
, O
96 O
healthy O
undergraduate O
women O
were O
exposed O
to O
lavender O
, O
placebo O
, O
or O
no O
aroma O
during O
physiologically O
assessed O
relaxation O
after O
an O
arousing O
cognitive O
task O
. O
[]

The O
rates O
of O
primary B-outcome ['Physiological-Clinical']
rupture I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
membranes I-outcome ['Physiological-Clinical']
( O
11 O
% O
v O
53 O
% O
; O
p O
less O
than O
0.001 O
) O
and O
preterm B-outcome ['Physiological-Clinical']
labour I-outcome ['Physiological-Clinical']
( O
5.4 O
% O
v O
38 O
% O
; O
p O
less O
than O
0.002 O
) O
were O
significantly O
lower O
in O
the O
penicillin O
group O
than O
in O
the O
placebo O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
probability O
for O
quarters O
to O
develop O
new B-outcome ['Physiological-Clinical']
IMI I-outcome ['Physiological-Clinical']
in O
the O
dry O
period O
was O
significantly O
increased O
when O
cows O
had O
higher O
milk O
production O
before O
drying-off O
( O
P O
= O
0.04 O
) O
, O
when O
cows O
had O
longer O
dry O
periods O
( O
P O
= O
0.02 O
) O
, O
and O
when O
dry O
cows O
were O
housed O
in O
tie-stall O
barns O
( O
P O
= O
0.002 O
) O
. O
['Physiological-Clinical']

The O
adequate O
responses O
to O
treatment B-outcome ['Resource-use']
were O
similar O
for O
the O
two O
treatment O
regimens O
on O
D14 O
, O
PCR-corrected O
( O
99,4 O
% O
in O
the O
one-daily O
intake O
group O
versus O
99,3 O
% O
in O
the O
comparative O
group O
) O
. O
['Resource-use']

Urine B-outcome ['Physiological-Clinical']
was O
collected O
from O
T O
= O
10 O
mins O
to O
T O
= O
240 O
mins O
. O
['Physiological-Clinical']

Scales O
for O
the O
assessment O
of O
neuroleptic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
schizophrenic O
children O
: O
specific O
measures O
derived O
from O
the O
CPRS O
. O
['Physiological-Clinical']

The O
inclusion O
criteria O
were O
: O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
ranging O
from O
140-179 O
mm O
Hg O
and/or O
diastolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
ranging O
from O
90-99 O
mm O
Hg O
and O
treatment-naive O
( O
untreated O
for O
hypertension O
) O
; O
or O
on O
a O
regimen O
of O
medication O
for O
hypertension O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
controlled O
trial O
. O
[]

METHODS O
From O
1990 O
to O
1995 O
, O
we O
studied O
59 O
neonates O
with O
seizures O
that O
were O
confirmed O
by O
electroencephalography O
. O
[]

CONCLUSIONS O
R317573 O
appears O
to O
produce O
acute O
dose-dependent O
changes O
in O
rCMglu O
. O
[]

METHODS O
High O
resolution O
B-mode O
ultrasound O
was O
used O
to O
characterize O
plaque B-outcome ['Physiological-Clinical']
echogenicity I-outcome ['Physiological-Clinical']
in O
four O
subgroups O
- O
dominantly O
echolucent O
, O
substantially O
echolucent O
, O
dominantly O
echogenic O
, O
and O
uniformly O
echogenic O
. O
['Physiological-Clinical']

MATERIAL O
AND O
METHOD O
Forty-four O
subjects O
, O
aged O
35 O
to O
59-year-old O
, O
with O
hypertension O
in O
Nakhon O
Pathom O
Province O
, O
Thailand O
, O
were O
randomly O
allocated O
to O
either O
an O
experimental O
group O
( O
n O
= O
22 O
) O
or O
a O
control O
group O
( O
n O
= O
20 O
) O
. O
[]

RESULTS O
The O
analyses O
disclosed O
that O
, O
compared O
to O
participants O
in O
the O
Lecture O
group O
, O
participants O
in O
the O
CAI O
group O
scored O
significantly O
higher O
on O
the O
scales O
measuring O
autoimmune B-outcome ['Life-Impact']
deficiency I-outcome ['Life-Impact']
syndrome I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
AIDS I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
, O
self-evaluative O
outcome O
motivation B-outcome ['Life-Impact']
, I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
intention I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
practice I-outcome ['Life-Impact']
HIV I-outcome ['Life-Impact']
preventive I-outcome ['Life-Impact']
behaviors B-outcome ['Life-Impact']
with O
current O
partner O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

13 O
patients O
in O
each O
group O
had O
gangrene B-outcome ['Physiological-Clinical']
or O
empyema B-outcome ['Physiological-Clinical']
, O
and O
one O
in O
each O
group O
had O
perforation O
of O
the O
gallbladder O
causing O
diffuse O
peritonitis O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Trained O
supervisors O
also O
showed O
increases O
in O
their O
own O
help-seeking B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
. O
['Life-Impact']

We O
applied O
TCA O
to O
the O
preseptal O
skin O
of O
10 O
patients O
48 O
h O
before O
standard O
upper-eyelid O
blepharoplasty O
. O
[]

The O
arc O
of O
the O
necrotic O
portion O
in O
the O
mid-coronal O
image O
( O
A O
) O
and O
that O
in O
the O
mid-sagittal O
image O
( O
B O
) O
were O
used O
to O
quantify O
the O
extent O
of O
necrosis O
by O
the O
formula O
: O
( O
A/180 O
) O
x O
( O
B/180 O
) O
x O
100 O
. O
[]

RESULTS O
TTI O
decreased O
in O
both O
transverse O
and O
longitudinal O
orientations O
as O
paddle O
force O
increased O
. O
[]

RESULTS O
Between O
April O
2005 O
and O
February O
2006 O
, O
a O
total O
of O
918 O
patients O
were O
enrolled O
. O
[]

In O
a O
randomised O
prospective O
study O
of O
68 O
women O
in O
spontaneous O
labour O
half O
were O
allocated O
to O
an O
ambulant O
group O
and O
half O
to O
a O
recumbent O
group O
. O
[]

All O
23 O
patients O
have O
survived B-outcome ['Mortality']
, O
and O
only O
one O
woman O
of O
each O
group O
required O
retransplantation B-outcome ['Physiological-Clinical']
due O
to O
severe O
host-versus-graft B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
three O
nonunions B-outcome ['Physiological-Clinical']
, O
all O
in O
the O
unreamed O
nail O
group O
. O
['Physiological-Clinical']

Discharged O
patients O
were O
followed-up O
in O
the O
outpatient O
clinic O
. O
[]

After O
12 O
months O
, O
the O
infants O
in O
the O
experimental O
group O
were O
more O
likely O
to O
be O
fully B-outcome ['Physiological-Clinical']
immunized I-outcome ['Physiological-Clinical']
( O
33 O
% O
) O
than O
the O
infants O
in O
the O
control O
group O
( O
18 O
% O
) O
. O
['Physiological-Clinical']

Incidences O
of O
nonhematologic B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
similar O
in O
two O
groups O
. O
['Adverse-effects']

Following O
individual O
dosing O
of O
100-300 O
mg O
theophylline O
twice O
a O
day O
, O
a O
pharmacokinetic O
profile O
for O
24 O
h O
was O
derived O
after O
seven O
days O
of O
multiple O
dosing O
. O
[]

In O
Experiment O
2 O
, O
thirty-two O
4- O
to O
5-year-olds O
learned O
from O
scenarios O
lacking O
pretend O
speech B-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
sound I-outcome ['Life-Impact']
['Life-Impact']

The O
mean O
( O
SD O
) O
maximum O
dosage O
of O
citalopram O
hydrobromide O
was O
16.5 O
( O
6.5 O
) O
mg/d O
by O
mouth O
( O
maximum O
, O
20 O
mg/d O
) O
. O
[]

Thus O
, O
patients O
with O
a O
curatively O
resected O
gastric O
cancer O
had O
a O
better O
prognosis O
when O
sizofiran O
was O
prescribed O
in O
combination O
with O
antitumour O
drugs O
. O
[]

Raloxifene O
treatment O
for O
96 O
weeks O
resulted O
in O
a O
decrease O
in O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
( O
PINP O
by O
31 O
% O
) O
and O
an O
increase O
in O
spine B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
( O
by O
2 O
% O
) O
but O
no O
change O
in O
hip B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
for O
groups O
1 O
and O
2 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
of O
chloroquine O
( O
CQ O
) O
, O
amodiaquine O
( O
AQ O
) O
and O
CQ O
plus O
chlorpheniramine O
( O
a O
histamine O
H O
( O
1 O
) O
antagonist O
that O
reverses O
CQ O
resistance O
in O
vitro O
and O
in O
vivo O
) O
on O
the O
disposition O
of O
the O
enlarged O
liver O
associated O
with O
acute O
, O
symptomatic O
, O
uncomplicated O
, O
Plasmodium O
falciparum O
malaria O
were O
evaluated O
. O
[]

No O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
in O
any O
treatment O
group O
. O
['Adverse-effects']

The O
effects O
of O
sex O
, O
the O
menstrual O
cycle O
, O
oral O
contraceptives O
, O
pregnancy O
, O
and O
the O
menopause O
on O
skin O
perfusion O
in O
healthy O
women O
and O
in O
patients O
with O
Raynaud O
's O
phenomenon O
suggest O
a O
role O
of O
female O
sex O
hormones O
. O
[]

It O
considered O
patients O
of O
0-36 O
months O
, O
not O
premature O
, O
treated O
with O
inotropic O
infusion O
with O
monitoring O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Higher O
rates O
of O
primary B-outcome ['Resource-use']
and I-outcome ['Resource-use']
repeat I-outcome ['Resource-use']
amputation I-outcome ['Resource-use']
for O
African O
American O
patients O
at O
study O
hospitals O
, O
which O
all O
have O
significant O
vascular O
surgery O
capacity O
and O
an O
aggressive O
policy O
of O
limb O
salvage O
, O
suggest O
that O
these O
rates O
may O
be O
even O
higher O
at O
less O
well O
equipped O
institutions O
. O
['Resource-use']

OBJECTIVES O
The O
objective O
of O
the O
present O
randomized O
controlled O
trial O
was O
to O
evaluate O
the O
efficacy O
of O
a O
mouthrinse O
containing O
a O
combination O
of O
AmF/SnF2 O
in O
controlling O
supragingival O
plaque O
accumulation O
and O
gingival O
inflammation O
during O
a O
12-week O
period O
in O
patients O
affected O
by O
generalized O
aggressive O
periodontitis O
( O
GAP O
) O
. O
[]

Patients O
in O
the O
control O
group O
received O
no O
additional O
treatment O
. O
[]

METHODS O
Thirty-four O
patients O
with O
RAP O
with O
any O
stage O
of O
neovascularization O
were O
randomized O
1:1:1 O
for O
treatment O
with O
three O
different O
quantities O
( O
30 O
mg O
, O
15 O
mg O
, O
3 O
mg O
) O
of O
anecortave O
acetate O
sterile O
suspension O
for O
juxtascleral O
administration O
. O
[]

We O
examined O
primary O
and O
memory O
isotype-specific O
antibody O
responses O
directed O
against O
pseudorabies O
virus O
in O
serum O
and O
mucosal O
fluids O
of O
pigs O
with O
and O
without O
passively O
acquired O
maternal O
antibody O
, O
and O
we O
studied O
the O
relationship O
between O
these O
responses O
and O
protection O
against O
virus O
challenge O
. O
[]

RESULTS O
No O
patients O
showed O
signs O
of O
respiratory B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

INTRODUCTION O
We O
examined O
the O
need O
for O
counselling O
and O
the O
effect O
on O
willingness O
and O
ability O
to O
change O
life-style B-outcome ['Life-Impact']
, O
and O
subsequent O
changes O
in O
risk O
factors O
for O
CHD B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

CONCLUSION O
Fexofenadine O
did O
not O
affect O
recovery O
to O
a O
fixed O
dose O
of O
AMP O
challenge O
or O
any O
other O
surrogate O
inflammatory O
markers O
when O
given O
as O
add-on O
therapy O
to O
corticosteroid-treatedatopic O
asthmatic O
patients O
. O
[]

No O
asthmatic B-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
occurred O
in O
connection O
with O
the O
training O
sessions O
. O
['Physiological-Clinical']

BACKGROUND O
To O
investigate O
if O
coadministration O
of O
enalapril O
alters O
the O
metabolic O
effect O
of O
glibenclamide O
by O
employing O
an O
euglycemic O
glucose-clamp O
technique O
in O
healthy O
volunteers O
. O
[]

The O
frequency O
of O
severe B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
such O
as O
heart B-outcome ['Physiological-Clinical']
block O
and O
hypotension B-outcome ['Physiological-Clinical']
was O
not O
different O
between O
men O
and O
women O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

The O
authors O
aimed O
to O
identify O
the O
effect O
of O
home-based O
nursing O
pulmonary O
rehabilitation O
on O
fatigue O
, O
activities O
of O
daily O
living O
( O
ADL O
) O
and O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
COPD O
. O
[]

Secondary O
outcomes O
were O
disability B-outcome ['Life-Impact']
and O
quality O
of O
life O
measures O
. O
['Life-Impact']

RESULTS O
Seventy-one O
women O
with O
a O
mean O
? O
[]

Only O
modest O
associations O
existed O
between O
total O
folate B-outcome ['Life-Impact']
intakes I-outcome ['Life-Impact']
and O
plasma B-outcome ['Physiological-Clinical']
( O
r O
= O
0.46 O
, O
P O
< O
0.001 O
) O
and O
RBC O
( O
r O
= O
0.36 O
, O
P O
< O
0.01 O
) O
folate B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
at O
16-wk O
postpartum O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

BK O
caused O
cough B-outcome ['Physiological-Clinical']
at O
14.3 O
+/- O
0.7 O
( O
-log O
M O
) O
although O
BK1-7 O
, O
a O
major O
metabolite O
of O
BK O
by O
ACE O
, O
caused O
cough B-outcome ['Physiological-Clinical']
at O
5.7 O
+/- O
0.7 O
( O
-log O
M O
) O
in O
another O
3 O
patients O
with O
cough O
associated O
with O
ACE O
inhibitor O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
crying I-outcome ['Physiological-Clinical']
in O
EBM O
group O
was O
shorter O
by O
70.7 O
( O
95 O
% O
confidence O
interval O
36.6-104.9 O
) O
s. O
The O
modified O
NFCS O
at O
0 O
, O
1 O
and O
3 O
min O
was O
significantly O
lower O
( O
p O
< O
0.01 O
) O
in O
the O
EBM O
than O
in O
the O
DW O
group O
. O
['Physiological-Clinical']

The O
new O
CBS O
coated O
tablet O
form O
has O
an O
excellent O
patient O
compliance B-outcome ['Life-Impact']
as O
compared O
to O
the O
chewing O
tablets O
. O
['Life-Impact']

The O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
induction I-outcome ['Resource-use']
was O
significantly O
longer O
( O
P O
less O
than O
0.001 O
) O
with O
the O
slower O
infusion O
rates O
( O
104 O
, O
68 O
and O
51 O
s O
) O
, O
but O
the O
total O
dose B-outcome ['Life-Impact']
used I-outcome ['Life-Impact']
was O
significantly O
less O
( O
P O
less O
than O
0.001 O
) O
in O
these O
patients O
( O
1.2 O
, O
1.6 O
and O
2.5 O
mg O
kg-1 O
, O
respectively O
) O
. O
['Resource-use', 'Life-Impact']

Equivalence O
in O
the O
per-protocol O
group O
was O
based O
on O
previously O
defined O
ranges O
of O
clinically O
significant O
difference O
. O
[]

Relaxation O
and O
imagery O
and O
cognitive-behavioral O
training O
reduce O
pain B-outcome ['Physiological-Clinical']
during O
cancer O
treatment O
: O
a O
controlled O
clinical O
trial O
. O
['Physiological-Clinical']

Patients O
were O
divided O
into O
three O
groups O
: O
groups O
A O
and O
B O
were O
given O
metformin O
and O
group O
C O
was O
the O
control O
. O
[]

In O
an O
effort O
to O
minimize O
these O
side O
effects O
of O
therapy O
, O
non-root O
substance O
removing O
curettes O
have O
been O
developed O
. O
[]

Controlling O
the O
dose O
of O
heparin O
with O
coagulation O
tests O
resulted O
in O
the O
administration O
of O
significantly O
larger O
daily O
doses O
of O
heparin O
with O
intermittent O
injections O
than O
with O
continuous O
infusion O
. O
[]

The O
Hi-Lo-Evac O
tube O
with O
and O
without O
pack O
was O
significantly O
more O
effective O
than O
the O
Portex O
tube O
with O
pharyngeal O
pack O
( O
P O
less O
than O
0.002 O
) O
and O
( O
P O
less O
than O
0.01 O
respectively O
) O
. O
[]

We O
used O
logistic O
regression O
analyses O
to O
study O
the O
interaction O
between O
the O
user O
characteristics O
and O
the O
delivery O
mode O
in O
the O
prediction O
of O
dropout O
rate O
within O
the O
intervention O
period O
. O
[]

CONCLUSIONS O
Fixing O
the O
condylar O
process O
in O
the O
centre O
of O
the O
articular O
fossa O
intraoperatively O
before O
bilateral O
sagittal O
split O
osteotomy O
is O
a O
factor O
in O
preventing O
postoperative O
structural O
changes O
in O
the O
temporomandibular O
joint O
. O
[]

Lack O
of O
interaction O
in O
the O
sense O
of O
equivalence O
was O
concluded O
for O
both O
digoxin O
( O
with O
and O
without O
pantoprazole O
) O
and O
pantoprazole O
( O
with O
and O
without O
digoxin O
) O
as O
the O
90 O
% O
-confidence O
intervals O
of O
the O
respective O
AUC- O
and O
Cmax-ratios B-outcome ['Physiological-Clinical']
were O
within O
the O
equivalence O
range O
of O
0.8-1.25 O
. O
['Physiological-Clinical']

IMPLICATIONS O
Oral O
clonidine O
2.5 O
and O
5.0 O
microg/kg O
premedication O
decreases O
the O
propofol O
concentration O
required O
for O
loss O
of O
consciousness O
. O
[]

The O
results O
of O
the O
exploratory O
subgroup O
analysis O
provide O
support O
for O
further O
studies O
of O
antiherpes O
therapy O
for O
patients O
with O
MS O
and O
high O
levels O
of O
MRI-evident O
disease O
activity O
. O
[]

TRIAL O
REGISTRATION O
NCT01615237 O
. O
[]

Escalated O
BEACOPP O
uses O
higher O
doses O
of O
cyclophosphamide O
, O
doxorubicin O
, O
and O
etoposide O
with O
granulocyte O
colony-stimulating O
factor O
( O
G-CSF O
) O
support O
. O
[]

Improvement O
in O
I-QOL O
and O
domain O
scores O
of O
the O
ICIQ-FLUTS O
( O
filling O
and O
incontinence O
sum O
, O
QOL O
score O
) O
, O
and O
patients O
' O
[]

BACKGROUND O
This O
study O
investigated O
the O
effect O
of O
oral O
dimercapto O
succinic O
acid O
( O
DMSA O
) O
therapy O
for O
children O
with O
autism O
spectrum O
disorders O
ages O
3-8 O
years O
. O
[]

The O
elimination O
of O
knot O
tying O
may O
have O
advantages O
over O
conventional O
wound O
closure O
methods O
. O
[]

The O
side O
effects O
of O
both O
drugs O
were O
few O
and O
transient O
. O
[]

Patients O
most O
likely O
to O
benefit O
from O
cardioversion O
were O
those O
most O
limited O
initially O
, O
younger O
, O
not O
obese O
or O
hypertensive O
, O
and O
with O
an O
uncontrolled O
ventricular O
rate O
at O
baseline O
. O
[]

Despite O
the O
duration O
of O
rhG-CSF O
administration O
, O
serum B-outcome ['Physiological-Clinical']
G-CSF I-outcome ['Physiological-Clinical']
levels O
during O
rhG-CSF O
therapy O
were O
inversely O
correlated O
with O
circulating O
neutrophil O
counts O
( O
r2 O
= O
0.73 O
, O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

8-oxo-dG B-outcome ['Physiological-Clinical']
is O
significantly O
higher O
( O
up O
to O
about O
threefold O
) O
in O
lymphocyte O
DNA O
from O
men O
in O
Ireland O
and O
the O
U.K. O
Oxidative B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
is O
not O
significantly O
affected O
by O
carotenoid O
supplementation O
; O
nor O
is O
there O
any O
association O
with O
mean O
baseline O
levels O
of O
antioxidants B-outcome ['Physiological-Clinical']
, O
which O
are O
generally O
similar O
in O
the O
five O
countries O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
outcome O
was O
a O
composite O
of O
death O
from O
cardiovascular O
causes O
, O
aborted B-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
arrest I-outcome ['Physiological-Clinical']
, O
or O
hospitalization B-outcome ['Resource-use']
for I-outcome ['Resource-use']
the I-outcome ['Resource-use']
management I-outcome ['Resource-use']
of I-outcome ['Resource-use']
heart I-outcome ['Resource-use']
failure I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

These O
results O
support O
the O
use O
of O
parent-mediated O
interventions O
targeting O
verbal B-outcome ['Life-Impact']
responsiveness I-outcome ['Life-Impact']
to O
facilitate O
language B-outcome ['Life-Impact']
development I-outcome ['Life-Impact']
and O
communication B-outcome ['Life-Impact']
in O
young O
children O
with O
autism O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Low O
self-esteem B-outcome ['Life-Impact']
is O
a O
symptom O
of O
depressive O
disorders O
and O
is O
considered O
by O
some O
to O
be O
a O
predictor O
for O
relapse O
, O
whereas O
high O
self-esteem O
seems O
to O
buffer O
against O
depression O
. O
['Life-Impact']

The O
patients O
and O
partners O
were O
re-evaluated O
8 O
weeks O
after O
the O
treatment O
. O
[]

Reliance O
on O
visual B-outcome ['Life-Impact']
information I-outcome ['Life-Impact']
after O
stroke O
. O
['Life-Impact']

In O
this O
study O
the O
potential O
benefits O
and O
drawbacks O
of O
this O
new O
AR O
technology O
were O
evaluated O
. O
[]

Tactile O
feedback O
is O
present O
during O
minimally O
invasive O
surgery O
. O
[]

However O
the O
analgesic O
equivalent O
of O
both O
techniques O
have O
not O
been O
confirmed O
. O
[]

The O
groups O
were O
comparable O
for O
maternal O
age O
, O
parity O
, O
weight O
and O
supplemental O
iron O
intake O
, O
infant O
s O
birth O
weight O
, O
gestation O
and O
sex O
. O
[]

Use O
of O
a O
DNAemia O
cut-off O
for O
monitoring O
human O
cytomegalovirus O
infection O
reduces O
the O
number O
of O
preemptively O
treated O
children O
and O
young O
adults O
receiving O
hematopoietic O
stem-cell O
transplantation O
compared O
with O
qualitative O
pp65 O
antigenemia O
. O
[]

The O
patients O
were O
assigned O
at O
random O
to O
one O
of O
the O
following O
treatments O
: O
1 O
) O
Defibrotide O
at O
a O
dose O
of O
400 O
mg O
b.i.d O
. O
[]

fed O
, O
conditions O
. O
[]

The O
primary O
endpoint O
was O
determination O
of O
the O
duration O
of O
the O
relapse-free B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
single O
independent O
physiotherapist O
, O
who O
was O
blinded O
to O
the O
treatment O
groups O
, O
made O
all O
assessments O
. O
[]

To O
assess O
the O
rationale O
of O
albumin O
priming O
prior O
to O
exchange O
transfusions O
, O
42 O
hyperbilirubinemic O
infants O
who O
required O
exchange O
transfusions O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O
[]

The O
goal O
was O
to O
assess O
if O
a O
16-wk O
nutrition O
plus O
CAST O
pilot O
study O
had O
stronger O
effects O
on O
reducing O
adiposity B-outcome ['Physiological-Clinical']
and O
on O
improving O
glucose/insulin B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
compared O
with O
control O
( O
C O
) O
, O
nutrition O
only O
( O
N O
) O
, O
and O
a O
nutrition O
plus O
strength O
training O
( O
N O
+ O
ST O
) O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
former O
declined O
after O
operation O
, O
possibly O
as O
a O
result O
of O
the O
concomitant O
use O
of O
propranolol O
. O
[]

METHODS O
Eight O
hundred O
and O
ninety-one O
patients O
treated O
for O
48 O
weeks O
with O
an O
initial O
ribavirin O
dose O
of O
800 O
or O
1000/1200 O
mg/day O
were O
evaluated O
. O
[]

Sixty O
patients O
( O
age O
40-73 O
yr O
, O
56 O
male O
) O
were O
assigned O
randomly O
to O
receive O
alfentanil O
, O
fentanyl O
or O
sufentanil O
and O
propofol O
. O
[]

METHODS O
Sixty-seven O
English-speaking O
adult O
cancer O
outpatients O
, O
including O
15 O
minorities O
, O
with O
moderate O
pain O
over O
the O
prior O
2 O
weeks O
were O
randomly O
assigned O
to O
the O
experimental O
( O
N O
= O
34 O
) O
or O
control O
group O
( O
N O
= O
33 O
) O
. O
[]

The O
psychopathology O
, O
cognitive O
functioning O
, O
early O
treatment O
history O
, O
and O
duration O
of O
untreated O
psychosis O
of O
these O
subjects O
were O
assessed O
prior O
to O
their O
assignment O
to O
randomized O
, O
double-blind O
treatment O
. O
[]

Participants O
( O
N O
= O
56 O
) O
were O
randomly O
assigned O
to O
a O
control O
group O
or O
a O
treatment O
group O
. O
[]

CONCLUSION O
Student O
performance O
in O
simulator-based O
OSCE O
may O
be O
affected O
by O
the O
clinical O
context O
provided O
. O
[]

Visual O
and O
densitometric O
comparison O
was O
made O
of O
intravenous O
digital O
subtraction O
angiograms O
performed O
for O
peripheral O
vascular O
disease O
. O
[]

Immune O
cell O
levels O
in O
patient O
serum O
were O
determined O
before O
, O
and O
following O
, O
6 O
weeks O
of O
cancer O
treatment O
for O
patients O
receiving O
either O
an O
RG-CMH O
or O
a O
placebo O
. O
[]

RESULTS O
Twenty O
patients O
were O
randomized O
to O
the O
imiquimod O
( O
n O
= O
10 O
) O
or O
vehicle O
( O
n O
= O
10 O
) O
treatment O
group O
. O
[]

Patients O
selected O
for O
moderately O
progressive B-outcome ['Physiological-Clinical']
IgA I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

METHODS O
This O
was O
a O
prospective O
, O
double-blind O
, O
randomized O
study O
of O
healthy O
volunteers O
who O
were O
at O
least O
18 O
years O
of O
age O
. O
[]

CONCLUSIONS O
In O
this O
randomized O
trial O
, O
no O
long-term O
QOL B-outcome ['Life-Impact']
advantage O
for O
either O
treatment O
was O
apparent O
with O
the O
exception O
of O
poorer O
sexual B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
reported O
by O
those O
treated O
with O
cryoablation O
. O
['Life-Impact', 'Life-Impact']

Fifty-one O
procedures O
were O
performed O
using O
BP O
and O
44 O
using O
Dacron O
. O
[]

In O
conclusion O
, O
we O
investigated O
SNP-diet B-outcome ['Physiological-Clinical']
interactions I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

They O
were O
then O
randomized O
to O
use O
either O
IB O
or O
saline O
for O
the O
double-blinded O
portion O
of O
the O
study O
. O
[]

Implications O
of O
the O
findings O
, O
study O
limitations O
, O
and O
recommendations O
for O
future O
research O
are O
discussed O
. O
[]

Cosmesis B-outcome ['Life-Impact']
scores I-outcome ['Life-Impact']
did O
not O
significantly O
differ O
between O
the O
barbed O
suture O
group O
and O
the O
control O
group O
. O
['Life-Impact']

Because O
of O
small O
sample O
, O
data O
analysis O
was O
descriptive O
. O
[]

than O
all O
pre-treatment O
eyes O
( O
for O
lids O
, O
P O
< O
0.001 O
; O
conjunctivae O
, O
P O
= O
0.02 O
) O
. O
[]

Results O
demonstrate O
that O
melatonin O
modulates B-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
a O
manner O
resembling O
actual O
sleep O
although O
subjects O
are O
fully O
awake O
. O
['Physiological-Clinical']

The O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
this O
system O
were O
evaluated O
in O
a O
double-blind O
, O
randomized O
, O
multicenter O
study O
comparing O
patches O
containing O
30 O
mg O
and O
60 O
mg O
physostigmine O
with O
a O
placebo O
patch O
. O
['Life-Impact']

The O
antimycotic O
antibiotic O
griseofulvin O
inhibits O
the O
MA-sensitive O
PMN O
chemotaxis O
in O
vitro O
in O
concentrations O
far O
below O
those O
obtained O
in O
serum O
during O
antimycotic O
therapy O
. O
[]

Histamine O
in O
food O
at O
non-toxic O
doses O
has O
been O
proposed O
to O
be O
a O
major O
cause O
of O
food O
intolerance O
causing O
symptoms O
like O
diarrhea O
, O
hypotension O
, O
headache O
, O
pruritus O
and O
flush O
( O
histamine O
intolerance O
) O
. O
[]

Polyp O
Prevention O
Trial O
Study O
Group O
. O
[]

The O
treatment O
of O
asthma O
in O
adults O
using O
sodium O
cromoglycate O
pressurized O
aerosol O
: O
a O
double-blind O
controlled O
trial O
. O
[]

The O
average O
hospitalizations B-outcome ['Resource-use']
were O
: O
5.6+/-0.9 O
, O
3.2+/-0.4 O
and O
3.1+/-0.3 O
days O
( O
TPL O
vs O
EPL O
P O
< O
0.001 O
; O
TPL O
vs O
LPL O
P O
< O
0.001 O
) O
for O
TPL O
, O
EPL O
and O
LPL O
respectively O
. O
['Resource-use']

INTRODUCTION O
There O
is O
an O
increasing O
amount O
of O
evidence O
showing O
that O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
and O
sun B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
are O
effective O
coadjuvant O
treatments O
for O
patients O
with O
mild O
to O
moderate O
depression O
. O
['Life-Impact', 'Life-Impact']

At O
28 O
days O
after O
treatment O
, O
selamectin O
, O
fipronil- O
( O
S O
) O
-methoprene O
, O
and O
imidacloprid O
had O
killed O
99.0 O
% O
, O
86.4 O
% O
, O
and O
72.6 O
% O
of O
the O
fleas O
within O
48 O
hours O
of O
infestation O
, O
respectively O
. O
[]

Overall O
, O
42 O
patients O
( O
40.4 O
% O
) O
showed O
objective O
clinical O
responses O
. O
[]

Data O
were O
taken O
from O
the O
Research O
Evaluating O
the O
Value O
of O
Augmenting O
Medication O
with O
Psychotherapy O
( O
REVAMP O
) O
treatment O
study O
-- O
a O
multi-site O
treatment O
and O
augmentation O
study O
of O
808 O
chronically O
depressed O
individuals O
. O
[]

INTERPRETATION O
A O
high-dose O
regimen O
of O
pralidoxime O
, O
consisting O
of O
a O
constant O
infusion O
of O
1 O
g/h O
for O
48 O
h O
after O
a O
2 O
g O
loading O
dose O
, O
reduces O
morbidity B-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
in O
moderately O
severe O
cases O
of O
acute O
organophosphorus-pesticide O
poisoning O
. O
['Physiological-Clinical', 'Mortality']

To O
test O
this O
hypothesis O
, O
we O
carried O
out O
a O
randomized O
, O
controlled O
trial O
in O
patients O
with O
type O
2 O
diabetes O
that O
compared O
changes O
in O
HbA1c B-outcome ['Physiological-Clinical']
as O
the O
primary O
outcome O
. O
['Physiological-Clinical']

Mean O
area O
under O
the O
curve O
( O
n O
12 O
) O
results O
were O
9.73 O
( O
sem O
2.45 O
) O
, O
3.24 O
( O
sem O
0.72 O
) O
and O
3.14 O
( O
sem O
1.09 O
) O
nmol O
x O
h/l O
for O
the O
hot O
milk O
, O
warm O
milk O
and O
hot O
water O
formulations O
, O
respectively O
. O
[]

OBJECTIVES O
To O
evaluate O
the O
safety O
and O
efficacy O
of O
a O
new O
twice-daily O
balsalazide O
disodium O
1.1 O
g O
tablet O
dosing O
regimen O
( O
6.6 O
g/day O
, O
three O
tablets O
twice O
daily O
) O
for O
the O
treatment O
of O
mild-to-moderately-active O
ulcerative O
colitis O
( O
UC O
) O
. O
[]

If O
the O
activated O
clotting O
time O
remained O
less O
than O
480 O
s O
, O
this O
was O
considered O
treatment O
failure O
, O
and O
2 O
units O
fresh O
frozen O
plasma O
was O
transfused O
. O
[]

OBJECTIVE O
We O
present O
a O
novel O
Bayesian O
adaptive O
comparative O
effectiveness O
trial O
comparing O
three O
treatments O
for O
status O
epilepticus O
that O
uses O
adaptive O
randomization O
with O
potential O
early O
stopping O
. O
[]

RESULTS O
The O
mean O
ages O
and O
the O
mean O
cyst B-outcome ['Physiological-Clinical']
diameters B-outcome ['Physiological-Clinical']
of O
the O
patients O
for O
each O
group O
were O
not O
significantly O
different O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
comparison O
of O
seven O
antiarrhythmic O
drugs O
in O
patients O
with O
ventricular O
tachyarrhythmias O
. O
[]

The O
index O
was O
rescored O
60-90 O
min O
later O
. O
[]

Moclobemide O
was O
compared O
with O
imipramine O
and O
placebo O
in O
the O
treatment O
of O
major O
depressive O
episodes O
in O
75 O
outpatients O
. O
[]

Primary O
biliary O
cirrhosis O
patients O
received O
ursodeoxycholic O
acid O
for O
12 O
months O
and O
were O
then O
randomized O
in O
a O
double-blind O
fashion O
to O
receive O
prednisone O
and O
azathioprine O
, O
or O
placebo O
in O
addition O
to O
ursodeoxycholic O
acid O
. O
[]

In O
clinical O
research O
, O
sensory O
impairment O
is O
considered O
one O
of O
the O
core O
deficits O
in O
autism O
and O
is O
associated O
with O
impaired O
socialization O
, O
behavioral O
disturbances O
and O
bowel O
and O
sleep O
problems O
. O
[]

In O
the O
TIVA O
group O
, O
changes O
in O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate O
and O
signs B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
depression B-outcome ['Life-Impact']
were O
significant O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

A O
total O
of O
121 O
women O
were O
randomly O
allocated O
to O
polyp O
removal O
by O
one O
of O
the O
two O
methods O
in O
an O
office O
setting O
. O
[]

OBJECTIVES O
We O
investigated O
whether O
anodal O
transcranial O
direct O
current O
stimulation O
over O
the O
left O
dorsolateral O
prefrontal O
cortex O
affected O
the O
working B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
of O
patients O
after O
a O
stroke O
. O
['Life-Impact']

This O
combination O
also O
seemed O
to O
be O
associated O
with O
the O
longest O
response O
duration O
. O
[]

Pharmacokinetics B-outcome ['Physiological-Clinical']
and O
tolerance O
of O
single- O
and O
multiple-dose O
oral O
or O
intravenous O
linezolid O
, O
an O
oxazolidinone O
antibiotic O
, O
in O
healthy O
volunteers O
. O
['Physiological-Clinical']

This O
study O
explored O
the O
effect O
of O
intravenous O
oxytocin O
administration O
on O
the O
retention O
of O
social O
information O
in O
autism O
. O
[]

The O
stages O
of O
change O
construct O
has O
been O
applied O
to O
healthful O
dietary O
behavior O
in O
cross-sectional O
studies O
. O
[]

PURPOSE O
The O
combination O
of O
vaccines O
and O
chemotherapy O
holds O
promise O
for O
cancer O
therapy O
, O
but O
the O
effect O
of O
cytotoxic O
chemotherapy O
on O
vaccine-induced O
antitumor O
immunity O
is O
unknown O
. O
[]

Results O
were O
compared O
to O
the O
more O
traditional O
method O
of O
using O
an O
oral O
analgesic O
with O
shorter O
duration O
of O
action O
( O
paracetamol O
with O
codeine O
) O
with O
lignocaine O
as O
the O
local O
anaesthetic O
. O
[]

Average O
visual O
analog O
scale O
reading O
for O
GLX O
was O
4.6 O
, O
whereas O
that O
for O
PASCAL O
was O
0.33 O
. O
[]

Significant O
differences O
in O
the O
change O
in O
SBP B-outcome ['Physiological-Clinical']
and O
DBP B-outcome ['Physiological-Clinical']
from O
baseline O
between O
the O
intervention O
and O
control O
groups O
were O
observed O
at O
the O
second O
, O
third O
, O
and O
fourth O
quarters O
of O
the O
study O
, O
favoring O
the O
intervention O
group O
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Evaluation O
of O
serum O
androgen O
levels O
, O
grading O
of O
acne O
and O
hirsutism O
( O
respectively O
with O
Pillsbury O
and O
Ferriman-Gallwey O
score O
) O
and O
non-invasive B-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
hydration I-outcome ['Physiological-Clinical']
, O
transepidermal B-outcome ['Physiological-Clinical']
water I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
( O
TEWL B-outcome ['Physiological-Clinical']
) O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
, O
placebo-controlled O
phase O
2 O
study O
of O
ganitumab O
or O
conatumumab O
in O
combination O
with O
FOLFIRI O
for O
second-line O
treatment O
of O
mutant O
KRAS O
metastatic O
colorectal O
cancer O
. O
[]

The O
average O
age O
in O
group O
A O
was O
66 O
years O
and O
in O
group O
B O
it O
was O
68 O
years O
. O
[]

Correlations O
with O
ratings O
of O
repetitive O
behavior O
and O
disruptive O
behavior O
were O
examined O
for O
validity O
. O
[]

Phase O
III O
trial O
of O
gemcitabine O
plus O
tipifarnib O
compared O
with O
gemcitabine O
plus O
placebo O
in O
advanced O
pancreatic O
cancer O
. O
[]

A O
third O
group O
( O
control O
group O
) O
received O
no O
letters O
. O
[]

Preoperative O
lanreotide O
treatment O
in O
acromegalic O
patients O
with O
macroadenomas O
increases O
short-term B-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
: O
a O
prospective O
, O
randomised O
trial O
. O
['Physiological-Clinical']

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
single-dose O
intravenous O
secretin O
as O
treatment O
for O
children O
with O
autism O
. O
[]

Patients O
aged O
at O
least O
40 O
years O
undergoing O
abdominal O
surgery O
were O
randomized O
to O
receive O
either O
fondaparinux O
2.5 O
mg O
or O
placebo O
s.c. O
for O
5-9 O
days O
, O
starting O
6-8 O
h O
postoperatively O
. O
[]

RESULTS O
After O
2 O
and O
4 O
months O
of O
treatment O
with O
the O
drug O
regimen O
, O
hs-CRP B-outcome ['Physiological-Clinical']
and O
TA B-outcome ['Physiological-Clinical']
levels O
were O
significantly O
decreased O
and O
consequently O
increased O
among O
the O
E O
( O
+ O
) O
L O
( O
+ O
) O
, O
L O
( O
+ O
) O
and O
E O
( O
+ O
) O
groups O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
study O
population O
consists O
of O
volunteers O
from O
1100 O
eligible O
employees O
of O
a O
Finnish O
insurance O
company O
. O
[]

The O
relation O
between O
proliferation O
and O
tamoxifen O
response O
seemed O
to O
be O
more O
complex B-outcome ['Physiological-Clinical']
, O
with O
['Physiological-Clinical']

Interference O
on O
metabolism O
induced O
by O
muzolimine O
and O
chlorthalidone O
in O
type O
II O
hypertensive O
diabetics O
. O
[]

Long-term O
outcome O
of O
migraine O
therapy O
: O
predictive O
value O
of O
the O
frontotemporal O
nitroglycerin O
test O
. O
[]

The O
cyclical O
exacerbations O
of O
epilepsy O
( O
catamenial O
epilepsy O
) O
were O
used O
to O
assess O
the O
antiepileptic O
effect O
of O
a O
benzodiazepine O
, O
clobazam O
. O
[]

Thirty-six O
extracted O
human O
carious O
mandibular O
molars O
were O
randomly O
assigned O
to O
six O
groups O
according O
to O
caries O
removal O
technique O
. O
[]

CONCLUSION O
Prefabricated O
wrist O
working O
splints O
are O
highly O
effective O
in O
reducing O
wrist O
pain O
after O
4 O
weeks O
of O
splint O
wearing O
in O
RA O
patients O
with O
wrist O
arthritis O
. O
[]

They O
were O
randomized O
either O
to O
diltiazem O
or O
nitroglycerin O
treatment O
. O
[]

Acute B-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
( O
mucositis B-outcome ['Physiological-Clinical']
and O
dysphagia B-outcome ['Physiological-Clinical']
) O
were O
less O
severe O
in O
the O
amifostine-treated O
group O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

In O
contrast O
to O
group O
C O
and O
B O
, O
group O
DB O
was O
given O
dexketoprofen O
. O
[]

The O
events O
varied O
in O
valence O
( O
positive O
, O
negative O
, O
or O
neutral O
) O
and O
in O
their O
rate O
of O
occurrence O
( O
intermittent O
vs. O
constant O
) O
. O
[]

Therefore O
, O
we O
examined O
whether O
patient O
coaching O
could O
reduce O
disparities O
in O
pain B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
in O
a O
secondary O
analysis O
of O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

A O
recent O
randomized O
multicenter O
trial O
of O
nonoperated O
distal O
radial O
fractures O
showed O
a O
moderate O
shortening O
of O
the O
time O
to O
restoration O
of O
cortical O
continuity O
by O
treatment O
with O
20 O
microg O
( O
low-dose O
) O
teriparatide O
per O
day O
, O
but O
not O
with O
40 O
microg O
( O
high-dose O
) O
. O
[]

After O
12 O
weeks O
a O
greater O
proportion O
of O
patients O
taking O
lisinopril O
was O
controlled O
( O
sitting O
diastolic O
blood O
pressure O
below O
95 O
mm O
Hg O
) O
than O
in O
those O
taking O
nifedipine O
. O
[]

RESULTS O
Diagnostic B-outcome ['Life-Impact']
yield I-outcome ['Life-Impact']
of O
TBLB O
using O
Jumbo O
forceps O
was O
significantly O
higher O
than O
using O
normal O
flexible O
forceps O
via O
rigid O
bronchoscopy O
in O
patients O
with O
DPLD O
( O
p O
= O
0.001 O
) O
. O
['Life-Impact']

The O
global O
efficacy O
evaluation O
, O
rated O
by O
the O
investigators O
, O
was O
significantly O
more O
favorable O
to O
CM O
for O
both O
attacks O
( O
p O
= O
0.001 O
for O
the O
first O
attack O
and O
p O
= O
0.02 O
for O
the O
second O
) O
. O
[]

METHODS O
This O
14-day O
, O
multicenter O
, O
randomized O
, O
double-blind O
study O
was O
conducted O
during O
the O
Texas O
mountain O
cedar O
season O
. O
[]

BACKGROUND/AIMS O
Retrospective O
studies O
suggest O
that O
the O
prognosis O
of O
patients O
with O
cirrhosis O
and O
variceal O
hemorrhage O
has O
improved O
in O
more O
recent O
decades O
. O
[]

Print O
materials O
were O
implemented O
with O
moderate O
to O
high O
fidelity O
and O
high O
dose O
. O
[]

However O
, O
12 O
patients O
receiving O
thrombolysis O
( O
9 O
systemic O
, O
3 O
local O
) O
suffered O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
; O
9 O
patients O
on O
systemic O
treatment O
developed O
pulmonary B-outcome ['Physiological-Clinical']
emboli I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Inflammatory B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
, O
based O
on O
interleukin-6 B-outcome ['Physiological-Clinical']
and O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
levels O
, O
were O
less O
intense O
following O
FT O
laparoscopic O
operation O
compared O
to O
FT O
open O
operation O
; O
however O
, O
there O
were O
no O
differences O
in O
specific O
immunity B-outcome ['Physiological-Clinical']
( O
CD3+ B-outcome ['Physiological-Clinical']
and O
CD4+ B-outcome ['Physiological-Clinical']
counts O
, O
and O
the O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Using O
a O
2-by-2 O
factorial O
trial O
design O
, O
we O
randomly O
assigned O
10,010 O
patients O
who O
were O
preparing O
to O
undergo O
noncardiac O
surgery O
and O
were O
at O
risk O
for O
vascular O
complications O
to O
receive O
aspirin O
or O
placebo O
and O
clonidine O
or O
placebo O
. O
[]

METHODS O
We O
conducted O
a O
controlled O
, O
community-level O
, O
cluster-randomized O
trial O
in O
16 O
nonoverlapping O
Massachusetts O
communities O
, O
studied O
from O
1998 O
to O
2003 O
. O
[]

Tracheal O
soiling O
with O
blood O
during O
intranasal O
surgery O
-- O
comparison O
of O
two O
endotracheal O
tubes O
. O
[]

Triple O
antiretroviral O
compared O
with O
zidovudine O
and O
single-dose O
nevirapine O
prophylaxis O
during O
pregnancy O
and O
breastfeeding O
for O
prevention O
of O
mother-to-child O
transmission O
of O
HIV-1 O
( O
Kesho O
Bora O
study O
) O
: O
a O
randomised O
controlled O
trial O
. O
[]

RESULTS O
All O
groups O
presented O
significant O
improvement O
in O
oral B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
perceived I-outcome ['Physiological-Clinical']
impacts I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

These O
results O
have O
thoroughly O
substantiated O
the O
contention O
that O
concurrent O
chemoradiation O
with O
capecitabine O
and O
cisplatin O
may O
be O
regarded O
as O
an O
effective O
and O
well-tolerated O
regimen O
in O
the O
treatment O
of O
the O
patients O
with O
locally O
advanced O
head O
and O
neck O
cancer O
. O
[]

[ O
The O
efficacy O
of O
psychotherapy O
with O
biofeedback O
in O
the O
rehabilitation O
of O
hypertension O
patients O
] O
. O
[]

MAIN O
OUTCOME O
MEASURE O
( O
S O
) O
Fertilization B-outcome ['Physiological-Clinical']
and O
pregnancy B-outcome ['Physiological-Clinical']
rates O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Patients O
with O
early-stage O
breast O
cancer O
who O
are O
at O
substantial O
risk O
for O
systemic O
metastases O
are O
increasingly O
treated O
with O
breast-conserving O
therapy O
and O
adjuvant O
chemotherapy O
. O
[]

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
compare O
pharmacokinetics O
and O
pharmacokinetic-pharmacodynamic O
( O
PK-PD O
) O
relationship O
of O
rocuronium O
in O
children O
anesthetized O
with O
nitrous O
oxide O
( O
N2O O
) O
and O
fentanyl O
or O
with O
N2O O
and O
sevoflurane O
. O
[]

Preterm O
infants O
are O
at O
risk O
for O
copper O
and O
zinc O
depletion O
if O
sufficient O
quantities O
of O
these O
nutrients O
are O
not O
provided O
in O
a O
bioavailable O
form O
in O
postnatal O
life O
. O
[]

Cyclosporine O
inhibition O
of O
P-glycoprotein O
in O
chronic O
myeloid O
leukemia O
blast O
phase O
. O
[]

Pantoprazole O
did O
not O
influence O
the O
characteristic O
ECG O
modifications O
( O
T-wave O
) O
caused O
by O
digoxin O
. O
[]

Effects O
of O
conjugated O
linoleic O
acid O
supplementation O
and O
exercise O
on O
post-heparin O
lipoprotein O
lipase O
, O
butyrylcholinesterase O
, O
blood B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
profile O
and O
glucose B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
young O
men O
. O
['Physiological-Clinical', 'Physiological-Clinical']

They O
were O
then O
randomized O
to O
receive O
verapamil O
or O
atenolol O
during O
a O
four-week O
titration O
period O
so O
as O
to O
achieve O
a O
BP B-outcome ['Physiological-Clinical']
of O
less O
than O
160/90 O
mm O
Hg O
. O
['Physiological-Clinical']

TENS O
for O
the O
treatment O
of O
writer O
's O
cramp O
dystonia O
: O
a O
randomized O
, O
placebo-controlled O
study O
. O
[]

Moreover O
, O
the O
increased O
level O
of O
HMGB1 O
exhibited O
in O
a O
late O
stage O
of O
CCI O
was O
inhibited O
by O
exogenous O
overexpression O
of O
hIL-10 O
in O
the O
CCI O
model O
. O
[]

OBJECTIVE O
The O
objective O
of O
the O
study O
was O
to O
determine O
the O
effect O
on O
blood B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
of O
a O
daily O
intake O
of O
0.7 O
g O
DHA O
as O
triacylglycerol O
in O
middle-aged O
men O
and O
women O
. O
['Physiological-Clinical']

The O
addition O
of O
ADR O
or O
bilateral O
pulmonary O
RT O
to O
VAC O
was O
highly O
advantageous O
to O
patients O
with O
nonpelvic O
primaries O
. O
[]

BACKGROUND O
Motor O
cortex O
excitability O
was O
found O
to O
be O
changed O
after O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rTMS O
) O
of O
the O
temporal O
cortex O
highlighting O
the O
occurrence O
of O
cross-modal O
plasticity O
in O
non-invasive O
brain O
stimulation O
. O
[]

METHODS O
Subjects O
were O
enrolled O
in O
a O
randomized O
controlled O
clinical O
trial O
evaluating O
a O
90-day O
home-based O
intervention O
for O
heart O
failure O
. O
[]

Effect O
of O
surgical O
technique O
in O
subtotal O
and O
bilateral O
thyroidectomy O
on O
risk O
of O
postoperative O
parathyroid O
insufficiency O
development O
-- O
our O
experience O
. O
[]

The O
median O
response O
duration O
was O
151 O
days O
for O
the O
mitoxantrone O
group O
and O
126 O
days O
for O
the O
doxorubicin O
group O
( O
P O
= O
.16 O
) O
. O
[]

CONCLUSIONS O
This O
study O
indicates O
the O
effectiveness O
of O
risperidone O
during O
a O
period O
of O
several O
months O
, O
reducing O
disruptive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
about O
half O
of O
the O
children O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

Regression O
analyses O
suggested O
that O
targeting O
different O
beliefs O
for O
those O
donors O
who O
had O
and O
had O
not O
reacted O
would O
yield O
most O
benefit O
in O
bolstering O
donors O
' O
intentions O
to O
remain O
donating O
. O
[]

Antihypertensive O
drug O
treatment O
may O
cause O
some O
biochemical O
changes O
and O
those O
changes O
seem O
to O
be O
smallest O
patients O
treated O
with O
combination O
of O
beta-blocker O
and O
hydralazine O
. O
[]

In O
the O
second O
group O
, O
custom-fit O
MRI-based O
pin O
guides O
were O
used O
. O
[]

CONCLUSIONS O
Ropivacaine O
can O
be O
used O
effectively O
as O
a O
local O
anesthetic O
for O
digital O
nerve O
blocks O
. O
[]

The O
gain O
of O
shivering B-outcome ['Physiological-Clinical']
was O
determined O
by O
the O
slope O
of O
oxygen O
consumption O
vs O
core B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
regression O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
the O
subjective O
workload B-outcome ['Life-Impact']
assessment O
technique O
( O
SWAT O
) O
has O
been O
widely O
used O
, O
it O
has O
two O
main O
problems O
: O
it O
is O
not O
very O
sensitive O
for O
low O
mental O
workloads O
and O
it O
requires O
a O
time-consuming O
card O
sorting O
pretask O
procedure O
. O
['Life-Impact']

The O
proportion O
of O
responders O
who O
received O
Cycles O
3 O
and O
4 O
was O
significantly O
higher O
in O
the O
PRE O
group O
( O
90.4 O
% O
versus O
75.2 O
% O
, O
p=0.001 O
) O
. O
[]

Randomisation O
implies O
an O
intention O
to O
treat O
the O
patient O
by O
the O
assigned O
procedure O
and O
the O
analysis O
of O
long O
term O
results O
will O
include O
all O
randomised O
cases O
. O
[]

For O
this O
reason O
, O
there O
is O
a O
need O
for O
effective O
smoking O
prevention O
programmes O
targeting O
primary O
school O
children O
. O
[]

Significantly O
more O
ALA-PDT O
warts O
were O
graded O
at O
a O
higher O
pain B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

RESULTS O
None O
of O
the O
implants O
were O
found O
loose O
during O
the O
follow-up O
period O
( O
100 O
% O
) O
. O
[]

[ O
The O
anti-ischemic B-outcome ['Physiological-Clinical']
effect O
of O
phosphodiesterase O
III O
inhibitors O
] O
. O
['Physiological-Clinical']

MSLT O
in O
primary O
insomnia B-outcome ['Physiological-Clinical']
: O
stability O
and O
relation O
to O
nocturnal B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
of O
a O
commercial O
inactivated O
bivalent O
( O
H1N1/H3N2 O
) O
vaccine O
under O
conditions O
of O
natural O
exposure O
to O
a O
field O
SI O
variant O
. O
[]

Ethanol O
choosers O
were O
also O
more O
likely O
to O
be O
males O
and/or O
full-time O
students O
than O
non-choosers O
. O
[]

During O
1 O
y O
of O
follow-up O
the O
rate O
of O
diarrhea B-outcome ['Physiological-Clinical']
( O
per O
100 O
wk O
) O
in O
children O
less O
than O
6 O
y O
in O
the O
intervention O
group O
was O
5.89 O
episodes O
whereas O
that O
in O
the O
nonintervention O
group O
was O
7.55 O
episodes O
( O
protective O
efficacy O
22 O
% O
; O
p O
less O
than O
0.0001 O
) O
. O
['Physiological-Clinical']

The O
vertical O
clinical O
attachment O
level O
( O
CAL-v O
) O
gain O
was O
statistically O
significant O
only O
for O
the O
OFD-group O
. O
[]

They O
exposed O
seven O
healthy O
young O
men O
on O
alternate O
days O
to O
acid O
or O
control O
equiosmolar O
NaCl O
aerosol O
during O
40 O
min O
of O
resting O
ventilation O
and O
20 O
min O
of O
exercise O
; O
the O
latter O
was O
sufficiently O
intense O
to O
induce O
oronasal B-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Clinical O
description O
of O
encephalopathic O
syndromes O
and O
risk O
factors O
for O
their O
occurrence O
and O
outcome O
during O
melarsoprol O
treatment O
of O
human O
African O
trypanosomiasis O
. O
[]

Fifteen-year O
results O
of O
a O
randomized O
prospective O
trial O
of O
hyperfractionated O
chest O
wall O
irradiation O
versus O
once-daily O
chest O
wall O
irradiation O
after O
chemotherapy O
and O
mastectomy O
for O
patients O
with O
locally O
advanced O
noninflammatory O
breast O
cancer O
. O
[]

A O
significant O
fall O
in O
86rubidium B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
was O
observed O
. O
['Physiological-Clinical']

A O
prospective O
randomized O
treatment O
study O
comparing O
three O
treatment O
options O
for O
chalazia O
: O
triamcinolone O
acetonide O
injections O
, O
incision O
and O
curettage O
and O
treatment O
with O
hot O
compresses O
. O
[]

METHODS O
Seventy O
patients O
with O
impaired O
left O
ventricular O
function O
[ O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
< O
35 O
% O
] O
undergoing O
on-pump O
CABG O
were O
enrolled O
. O
[]

It O
has O
been O
postulated O
that O
there O
may O
be O
a O
connection O
between O
wheat-gluten/milk-casein O
and O
mental O
disorders O
such O
as O
schizophrenia O
, O
hyperactivity O
and O
autism O
. O
[]

Infants O
absorbed O
and O
retained O
( O
milligrams O
per O
kilogram O
per O
day O
) O
more O
calcium B-outcome ['Physiological-Clinical']
, O
phosphorus B-outcome ['Physiological-Clinical']
, O
and O
zinc B-outcome ['Physiological-Clinical']
when O
fed O
Similac O
With O
Iron O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Men O
with O
progressive O
mCRPC O
after O
docetaxel-based O
chemotherapy O
were O
randomly O
assigned O
2:1 O
to O
receive O
sunitinib O
37.5 O
mg/d O
continuously O
or O
placebo O
. O
[]

During O
the O
first O
week O
of O
treatment O
, O
the O
goal O
of O
diastolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
of O
less O
than O
90 O
mmHg O
was O
reached O
by O
40 O
% O
of O
the O
enalapril O
group O
and O
62 O
% O
of O
the O
lisinopril O
group O
; O
by O
the O
end O
of O
the O
titration O
period O
, O
98 O
% O
and O
96 O
% O
, O
respectively O
, O
had O
achieved O
the O
BP B-outcome ['Physiological-Clinical']
goal O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RCT O
of O
a O
manualized O
social O
treatment O
for O
high-functioning O
autism O
spectrum O
disorders O
. O
[]

Effects O
of O
low O
and O
high O
doses O
of O
atorvastatin O
on O
arterial O
compliance O
. O
[]

Survival O
analysis O
was O
estimated O
by O
the O
Kaplan-Meier O
method O
and O
compared O
by O
the O
log-rank O
test O
. O
[]

IMPLICATIONS O
A O
new O
antiinflammatory O
drug O
under O
investigation O
, O
inositol-1,2,6-trisphosphate O
, O
was O
evaluated O
as O
a O
possible O
analgesic O
in O
a O
pilot O
study O
during O
the O
postoperative O
period O
in O
cholecystectomized O
patients O
. O
[]

Therefore O
, O
the O
purpose O
of O
the O
present O
study O
was O
to O
evaluate O
, O
using O
a O
group O
design O
, O
the O
effectiveness O
of O
medical O
intervention O
alone O
( O
N O
= O
11 O
) O
versus O
behavioral O
plus O
medical O
intervention O
( O
N O
= O
10 O
) O
for O
illness-related O
problem O
behavior O
in O
a O
school O
setting O
. O
[]

RESULTS O
Infants O
nursed O
with O
a O
postural O
support O
roll O
and O
a O
postural O
support O
nappy O
demonstrated O
improved O
hip B-outcome ['Physiological-Clinical']
posture I-outcome ['Physiological-Clinical']
to O
term O
equivalent O
age O
compared O
with O
infants O
nursed O
with O
either O
a O
postural O
support O
roll O
only O
, O
or O
a O
postural O
support O
nappy O
only O
. O
['Physiological-Clinical']

The O
mean O
donor O
and O
recipient O
age O
and O
the O
ischemic B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
( O
142 O
versus O
153 O
minutes O
) O
were O
not O
significantly O
different O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

METHODS O
This O
study O
comprised O
two O
phases O
separated O
by O
a O
2-week O
rest O
interval O
. O
[]

RESULTS O
The O
baseline O
venous O
velocities O
were O
higher O
in O
the O
femoral O
veins O
than O
in O
the O
popliteal O
veins O
in O
both O
the O
volunteers O
and O
the O
post-thrombotic O
subjects O
. O
[]

Maintained O
cessation O
did O
not O
significantly O
change O
from O
0 O
to O
12 O
months O
( O
19 O
% O
to O
18 O
% O
) O
. O
[]

REE O
fell O
similarly O
with O
each O
diet O
; O
the O
overall O
decrease O
was O
719+/-106 O
kJ/day O
( O
P O
< O
0.001 O
) O
. O
[]

SETTING O
The O
San O
Paolo O
Hospital O
, O
Milan O
. O
[]

Atypical O
recruitment O
of O
medial O
prefrontal O
cortex O
in O
autism O
spectrum O
disorders O
: O
an O
fMRI O
study O
of O
two O
executive O
function O
tasks O
. O
[]

The O
local O
anaesthetic O
infiltration O
produced O
a O
[]

Significant O
differences O
in O
complications O
occurring O
more O
in O
phlebectomy O
than O
in O
compression O
sclerotherapy O
therapy O
were O
blisters B-outcome ['Physiological-Clinical']
, O
teleangiectatic B-outcome ['Physiological-Clinical']
matting I-outcome ['Physiological-Clinical']
, O
scar B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
prospective O
, O
randomized O
, O
double-blind O
trial O
. O
[]

Morphine O
use O
and O
visual O
analogue O
pain B-outcome ['Physiological-Clinical']
scores O
were O
recorded O
at O
1 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
after O
surgery O
. O
['Physiological-Clinical']

The O
opening O
of O
the O
female O
urethra O
is O
located O
within O
the O
vulvar O
vestibule O
, O
making O
insertion O
of O
urinary O
catheters O
into O
females O
a O
greater O
technical O
challenge O
than O
in O
males O
. O
[]

Aerobic O
and O
strength O
training O
reduces O
adiposity B-outcome ['Physiological-Clinical']
in O
overweight O
Latina O
adolescents O
. O
['Physiological-Clinical']

RESULTS O
Between O
July O
4 O
, O
2006 O
and O
March O
12 O
, O
2007 O
, O
a O
total O
of O
41 O
patients O
were O
screened O
and O
34 O
patients O
were O
randomized O
. O
[]

Within O
MAE O
groups O
combined O
, O
clinical O
and O
EEG O
risk O
factors O
for O
mental O
retardation O
could O
be O
identified O
. O
[]

Asperger O
syndrome O
( O
AS O
) O
is O
a O
pervasive O
developmental O
disorder O
recently O
introduced O
as O
a O
new O
diagnostic O
category O
in O
the O
ICD-10 O
and O
the O
DSM-IV O
. O
[]

Erythrocyte O
( O
RBC O
) O
count O
, O
leucocyte O
( O
WBC O
) O
count O
, O
haemoglobin O
content O
and O
respiratory O
burst O
activity O
were O
significantly O
( O
p O
< O
0.05 O
) O
higher O
in O
100 O
mg O
PN/kg O
diet-fed O
group O
than O
their O
non-PN-fed O
counterpart O
. O
[]

Pre- O
and O
post-testing O
included O
standardized O
and O
experimental O
measures O
of O
behavior B-outcome ['Life-Impact']
and O
event-related O
brain O
potentials O
( O
ERPs O
) O
, O
as O
well O
as O
interviews O
after O
training O
. O
['Life-Impact']

However O
, O
further O
studies O
are O
necessary O
to O
confirm O
these O
results O
. O
[]

Patient O
discharge O
then O
depends O
on O
their O
successful O
advancement O
to O
solid O
food O
. O
[]

In O
successfully O
treated O
patients O
with O
Hodgkin O
's O
disease O
the O
described O
changes O
are O
of O
minor O
significance O
. O
[]

A O
good O
clinical O
response O
was O
observed O
in O
32/35 O
( O
91 O
% O
) O
of O
the O
OD O
and O
in O
25/32 O
( O
78 O
% O
) O
in O
the O
MD O
group O
( O
difference O
13 O
% O
, O
95 O
% O
confidence O
interval O
-6.4 O
% O
to O
+26.9 O
% O
) O
. O
[]

Angina B-outcome ['Physiological-Clinical']
associated O
with O
transient B-outcome ['Physiological-Clinical']
ST-T I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
occurred O
in O
70 O
of O
the O
289 O
patients O
in O
the O
placebo O
group O
but O
in O
only O
45 O
of O
the O
287 O
patients O
in O
the O
diltiazem O
group O
-- O
a O
28 O
% O
reduction O
in O
cumulative O
life-table O
incidence O
( O
p O
= O
0.0103 O
[ O
2-tail O
, O
log O
rank O
] O
; O
95 O
% O
confidence O
interval O
, O
9.3 O
to O
53.8 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
parallel O
, O
the O
maximal B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
effect O
of O
glibenclamide B-outcome ['Physiological-Clinical']
tended O
to O
be O
higher O
with O
enalapril O
( O
GIR O
( O
max O
) O
5.2 O
+/- O
1.9 O
vs O
4.1 O
+/- O
1.3 O
mg O
kg O
( O
-1 O
) O
min O
( O
-1 O
) O
; O
p O
= O
0.19 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
trial O
also O
tested O
the O
hypothesis O
that O
neoadjuvant O
and O
concurrent O
hormonal O
therapy O
( O
NCHT O
) O
improves O
PFS O
compared O
with O
adjuvant O
hormonal O
therapy O
( O
AHT O
) O
by O
10 O
% O
. O
[]

In O
the O
late-pregnancy O
group O
, O
3-HIA B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
decreased O
( O
P O
< O
0.002 O
) O
by O
7.1 O
+/- O
1.2 O
mmol/mol O
creatinine O
in O
the O
8 O
women O
who O
received O
biotin O
supplements O
, O
whereas O
3-HIA B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
increased O
by O
0.9 O
+/- O
1.8 O
mmol/mol O
creatinine O
in O
the O
8 O
women O
who O
received O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
ViviScal O
group O
, O
19 O
( O
95 O
% O
) O
subjects O
showed O
both O
clinical B-outcome ['Physiological-Clinical']
and O
histological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
, O
whereas O
none O
treated O
with O
fish O
extract O
showed O
any O
clinical O
or O
histological O
difference O
after O
6 O
months O
' O
treatment O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
PLD O
and O
doxorubicin O
were O
comparable O
with O
respect O
to O
PFS B-outcome ['Mortality']
[ O
6.9 O
versus O
7.8 O
months O
, O
respectively O
; O
hazard O
ratio O
( O
HR O
) O
=1.00 O
; O
95 O
% O
confidence O
interval O
( O
CI O
) O
0.82-1.22 O
] O
. O
['Mortality']

RESULTS O
Four O
randomised O
women O
were O
excluded O
from O
the O
analysis O
, O
as O
they O
were O
ineligible O
for O
the O
study O
. O
[]

Similar O
correlations O
were O
seen O
with O
the O
Thyroid B-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Questionnaire O
, O
although O
not O
with O
the O
Hospital O
Anxiety B-outcome ['Life-Impact']
and O
Depression B-outcome ['Life-Impact']
Scale O
scores O
. O
['Physiological-Clinical', 'Life-Impact']

One-hundred O
twenty O
patients O
were O
enrolled O
. O
[]

PURPOSE O
Our O
purpose O
was O
1 O
) O
to O
evaluate O
the O
impact O
of O
a O
standardized O
protocol O
for O
individualized O
breast O
cancer O
risk O
counseling O
on O
comprehension O
of O
personal B-outcome ['Life-Impact']
risk I-outcome ['Life-Impact']
among O
first-degree O
relatives O
of O
index O
breast O
cancer O
patients O
and O
2 O
) O
to O
identify O
women O
most O
and O
least O
likely O
to O
benefit O
from O
such O
counseling O
. O
['Life-Impact']

AIMS O
The O
two O
studies O
presented O
here O
were O
conducted O
to O
assess O
the O
efficacy O
of O
paroxetine O
, O
pentoxifylline O
, O
riluzole O
, O
venlafaxine O
and O
pramipexole O
as O
medications O
for O
the O
treatment O
of O
cocaine O
dependence O
. O
[]

It O
has O
not O
been O
studied O
in O
combination O
with O
2-CP O
. O
[]

In O
addition O
six O
of O
eight O
conventional O
catheters O
were O
accidentally O
removed O
whereas O
all O
catheters O
in O
the O
tunnelled O
group O
had O
to O
be O
removed O
via O
a O
small O
incision O
. O
[]

DISCUSSION O
We O
expect O
the O
patients O
in O
the O
active O
recommendations O
group O
to O
experience O
a O
greater O
improvement O
in O
their O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

Validity B-outcome ['Physiological-Clinical']
and O
reliability O
assessment O
of O
the O
Siriraj O
Asthma O
Control O
Questionnaire O
. O
['Physiological-Clinical']

METHODS O
A O
prospective O
, O
randomized O
double-blind O
study O
was O
performed O
to O
compare O
combination O
cyclopentolate O
0.2 O
% O
and O
phenylephrine O
1 O
% O
eye-drops O
with O
triple O
instillation O
of O
tropicamide O
0.5 O
% O
and O
phenylephrine O
2.5 O
% O
. O
[]

METHOD O
Fifty O
patients O
with O
blepharitis O
, O
conjuctivitis O
, O
or O
blepharoconjunctivitis O
were O
randomly O
assigned O
to O
treatment O
with O
0.3 O
% O
ofloxacin O
eyedrops O
, O
BID O
or O
QID O
, O
for O
10 O
days O
. O
[]

Effects O
of O
pyridostigmine O
and O
naloxone O
on O
the O
abnormal B-outcome ['Physiological-Clinical']
TSH I-outcome ['Physiological-Clinical']
response O
to O
TRH B-outcome ['Physiological-Clinical']
during O
starvation B-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Ninety-six O
women O
and O
their O
96 O
partners O
were O
assigned O
randomly O
to O
participate O
in O
one O
of O
three O
different O
6-week O
programs O
: O
( O
a O
) O
telephone O
interpersonal O
counseling O
( O
TIP-C O
) O
; O
( O
b O
) O
self-managed O
exercise O
; O
or O
( O
c O
) O
attention O
control O
( O
AC O
) O
. O
[]

Penetration B-outcome ['Life-Impact']
and O
accumulation B-outcome ['Physiological-Clinical']
of O
moxifloxacin O
in O
uterine O
tissue O
. O
['Life-Impact', 'Physiological-Clinical']

This O
increased O
slightly O
but O
not O
significantly O
to O
6.8 O
+/-1.8 O
in O
the O
prepared O
section O
( O
P O
< O
0.1 O
) O
. O
[]

CONTEXT O
Experimental O
and O
epidemiological O
data O
suggest O
that O
vitamin O
E O
supplementation O
may O
prevent O
cancer O
and O
cardiovascular O
events O
. O
[]

Serum B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
estradiol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
E I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
follicle-stimulating B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FSH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
CETP B-outcome ['Physiological-Clinical']
and O
lipid B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
were O
determined O
in O
196 O
Chinese O
women O
( O
52 O
premenopausal O
with O
ages O
ranging O
from O
18 O
to O
40 O
years O
, O
57 O
perimenopausal O
from O
41 O
to O
60 O
years O
, O
and O
87 O
postmenopausal O
from O
61 O
to O
81 O
years O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Thus O
, O
no O
dose O
adjustment O
for O
either O
risperidone O
orgalantamine O
is O
necessary O
when O
these O
two O
drugs O
are O
administered O
together O
in O
the O
dose O
range O
evaluated O
. O
[]

For O
the O
present O
report O
data O
from O
the O
three O
studies O
were O
pooled O
for O
a O
series O
of O
stepwise O
regression O
analyses O
to O
predict O
changes O
in O
BP B-outcome ['Physiological-Clinical']
with O
different O
dietary O
changes O
. O
['Physiological-Clinical']

The O
levels O
of O
P-selectin B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
tPA I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
, O
and O
PAI-1 B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
all O
significantly O
higher O
in O
stroke O
patients O
compared O
with O
controls O
( O
all O
p O
< O
0.0001 O
) O
; O
the O
level O
of O
tPA B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
patients O
than O
that O
in O
controls O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Subjects O
between O
the O
ages O
of O
40-49 O
years O
were O
randomly O
selected O
from O
the O
lists O
of O
36 O
primary O
care O
centres O
. O
[]

Adverse O
event O
profiles O
were O
comparable O
among O
treatment O
regimens O
, O
and O
no O
new O
safety O
concerns O
were O
raised O
. O
[]

3 O
ml O
ampoules O
twice O
a O
day O
for O
five O
consecutive O
days O
after O
the O
surgical O
procedure O
, O
starting O
from O
the O
day O
of O
surgery O
. O
[]

The O
two O
groups O
were O
compared O
using O
a O
range O
of O
statistical O
procedures O
, O
including O
growth B-outcome ['Physiological-Clinical']
modeling I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

4 O
. O
[]

Effect O
of O
systemic O
penicillin O
on O
pain O
in O
untreated O
irreversible O
pulpitis O
. O
[]

No O
significant O
differences O
were O
observed O
in O
overall B-outcome ['Life-Impact']
feed I-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
, O
weight O
gain O
, O
feed B-outcome ['Physiological-Clinical']
conversion I-outcome ['Physiological-Clinical']
rates O
, O
clinical B-outcome ['Physiological-Clinical']
pathology I-outcome ['Physiological-Clinical']
measurements O
, O
or O
tissue B-outcome ['Physiological-Clinical']
gross I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
histopathologic I-outcome ['Physiological-Clinical']
evaluations I-outcome ['Physiological-Clinical']
between O
controls O
and O
treatment O
groups O
associated O
with O
lasalocid O
administration O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Currently O
a O
number O
of O
studies O
in O
these O
fields O
are O
being O
designed O
or O
are O
already O
underway O
. O
[]

SUBJECTS O
Fifteen O
subjects O
with O
post-stroke O
hemiparesis O
. O
[]

The O
effects O
of O
single O
oral O
doses O
of O
17 O
beta-oestradiol O
and O
progesterone O
on O
finger B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
circulation I-outcome ['Physiological-Clinical']
in O
healthy O
women O
and O
in O
women O
with O
primary O
Raynaud O
's O
phenomenon O
. O
['Physiological-Clinical']

Perioperative O
data O
were O
recorded O
. O
[]

However O
, O
the O
form O
and O
complexity B-outcome ['Life-Impact']
, O
the O
function B-outcome ['Life-Impact']
and O
the O
role B-outcome ['Life-Impact']
the O
child O
took O
in O
the O
interaction O
did O
change O
with O
time O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

3 O
) O
Participants O
choosing O
their O
treatment O
group O
( O
i.e O
. O
[]

The O
difference O
in O
healing O
times O
between O
products O
was O
not O
significant O
( O
median O
, O
7.57 O
days O
with O
CSP O
vs. O
7.03 O
days O
with O
acyclovir O
, O
P O
= O
0.37 O
) O
. O
[]

The O
asthma B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
declined B-outcome ['Life-Impact']
during O
the O
rehabilitation O
period O
, O
and O
the O
subjects O
needed O
less O
acute O
asthma O
care O
after O
the O
rehabilitation O
. O
['Physiological-Clinical', 'Life-Impact']

Alinidine O
in O
chronic O
stable O
angina O
: O
the O
effect O
on O
diastolic B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
Experiment O
1 O
, O
the O
embryos O
vitrified O
by O
the O
MVAC O
or O
CT O
and O
fresh O
embryos O
without O
vitrification O
( O
Control O
) O
were O
used O
. O
[]

In O
the O
present O
study O
, O
we O
investigated O
the O
effects O
of O
diets O
with O
low O
and O
high O
protein O
: O
carbohydrate O
ratios O
on O
cortisol B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
pregnant O
gilts O
as O
well O
as O
the O
long-term O
effects O
on O
the O
function O
of O
the O
HPA B-outcome ['Physiological-Clinical']
and O
SAM B-outcome ['Physiological-Clinical']
axes I-outcome ['Physiological-Clinical']
in O
their O
offspring O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
of O
hormone O
replacement O
therapy O
on O
hemostatic O
variables O
in O
women O
with O
angiographically O
verified O
coronary O
artery O
disease O
: O
results O
from O
the O
estrogen O
in O
women O
with O
atherosclerosis O
study O
. O
[]

The O
cost B-outcome ['Resource-use']
difference O
was O
artifactual O
. O
['Resource-use']

Consecutive O
post-menopausal O
women O
aged O
50 O
years O
to O
86 O
years O
starting O
treatment O
with O
raloxifene O
according O
to O
daily O
practice O
were O
enrolled O
from O
126 O
primary O
care O
offices O
in O
Spain O
. O
[]

BACKGROUND O
There O
is O
increasing O
political O
pressure O
on O
the O
medical O
profession O
to O
approach O
welfare O
diseases O
, O
such O
as O
coronary O
heart O
disease O
and O
diabetes O
, O
through O
prevention O
. O
[]

METHODS O
Radiographic O
views O
of O
the O
TF O
and O
PF O
compartments O
, O
knee O
extension O
strength O
, O
and O
knee O
range O
of O
motion O
were O
obtained O
for O
167 O
patients O
with O
knee O
OA O
. O
[]

BACKGROUND O
Autism O
is O
a O
complex O
neurodevelopmental O
disorder O
that O
forms O
part O
of O
a O
spectrum O
of O
related O
disorders O
referred O
to O
as O
Autism O
Spectrum O
Disorders O
. O
[]

There O
was O
no O
significant O
difference O
in O
[]

Local O
anaesthetic O
use O
for O
the O
iliac O
crest-donor O
site O
: O
pharmacokinetic O
and O
pharmacodynamic O
evaluations O
. O
[]

DESIGN O
Prospective O
randomized O
study O
. O
[]

Treatment O
effects O
of O
eptifibatide O
in O
planned O
coronary O
stent O
implantation O
in O
patients O
with O
chronic O
kidney O
disease O
( O
ESPRIT O
Trial O
) O
. O
[]

The O
results O
from O
the O
spectral-shape-discrimination O
task O
were O
used O
to O
predict O
frequency-difference O
limens O
. O
[]

Only O
19.8 O
% O
of O
the O
children O
had O
allergy-control B-outcome ['Life-Impact']
mattress I-outcome ['Life-Impact']
covers I-outcome ['Life-Impact']
. O
['Life-Impact']

Before O
therapy O
, O
patients O
underwent O
endoscopy O
with O
biopsies O
for O
histology O
, O
culture O
and O
antibiotic O
susceptibility O
tests O
. O
[]

Subjects O
were O
eligible O
for O
inclusion O
if O
they O
had O
aspirin B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
units O
( O
ARU B-outcome ['Resource-use']
, O
as O
measured O
by O
the O
VerifyNow O
ASA O
assay O
) O
of O
< O
550 O
on O
Day O
6 O
. O
['Physiological-Clinical', 'Resource-use']

RESULTS O
The O
3-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
CB O
was O
59 O
% O
, O
in O
C O
-- O
58 O
% O
( O
p O
= O
0.2 O
) O
, O
3-year O
locoregional B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
in O
CB O
-- O
83 O
% O
, O
in O
C O
-- O
75 O
% O
( O
p O
= O
0.01 O
) O
, O
the O
3-year O
disease B-outcome ['Mortality']
free I-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
in O
CB O
-- O
72 O
% O
, O
C O
-- O
66 O
% O
( O
p O
= O
0.1 O
) O
. O
['Mortality', 'Physiological-Clinical', 'Mortality']

Mexiletine O
for O
HIV-infected O
patients O
with O
painful O
peripheral O
neuropathy O
: O
a O
double-blind O
, O
placebo-controlled O
, O
crossover O
treatment O
trial O
. O
[]

Treatment O
efficacy O
was O
also O
assessed O
at O
the O
end O
of O
each O
trial O
period O
by O
means O
of O
an O
articular O
index O
and O
by O
physician O
's O
and O
patient O
's O
overall O
evaluation O
of O
response O
. O
[]

There O
were O
no O
differences O
in O
[]

SUBJECTS O
100 O
women O
with O
abnormal O
cervical O
smears O
selected O
for O
cone O
biopsy O
according O
to O
current O
colposcopy O
criteria O
. O
[]

In O
the O
expectant O
management O
group O
one O
twin B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
occurred O
and O
in O
the O
intervention O
group O
one O
woman O
conceived O
twins B-outcome ['Physiological-Clinical']
and O
one O
a O
triplet B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
who O
received O
CDDP/FU O
experienced O
significantly O
greater O
toxicity B-outcome ['Adverse-effects']
compared O
with O
FU O
alone O
: O
grades O
3 O
and O
4 O
hematologic B-outcome ['Physiological-Clinical']
toxicity B-outcome ['Adverse-effects']
occurred O
in O
22 O
% O
and O
0 O
% O
of O
patients O
, O
respectively O
( O
P O
= O
.0001 O
) O
; O
grades O
2 O
to O
4 O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
occurred O
in O
80 O
% O
and O
15 O
% O
of O
patients O
, O
respectively O
( O
P O
= O
.0001 O
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
FA O
implant O
significantly O
reduced O
uveitis B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
and O
improved O
or O
stabilized B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
in O
subjects O
with O
noninfectious O
posterior O
uveitis O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
known O
ER O
negative O
status O
were O
not O
studied O
. O
[]

CONCLUSION O
The O
financial O
and O
quality-of-life O
effects O
of O
DUB O
represent O
a O
substantial O
burden O
. O
[]

The O
absence O
of O
suppression O
of O
reflexive O
sympathetic O
responses O
contrasts O
with O
the O
effects O
of O
rilmenidine O
in O
experimental O
animals O
, O
and O
emphasises O
the O
previously O
demonstrated O
unique O
importance O
in O
humans O
of O
suprabulbar O
noradrenergic O
neuronal O
projections O
from O
the O
brainstem O
, O
which O
are O
inhibited O
by O
imidazoline O
binding O
agents O
, O
in O
regulating O
tonic B-outcome ['Physiological-Clinical']
sympathetic I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
essential O
hypertension O
. O
['Physiological-Clinical']

The O
requirements O
of O
opioid B-outcome ['Resource-use']
analgesics I-outcome ['Resource-use']
were O
significantly O
reduced O
during O
the O
first O
three O
postoperative O
days O
( O
P O
< O
0.05 O
) O
. O
['Resource-use']

RESULTS O
Although O
given O
at O
half O
the O
recommended O
daily O
dosage O
, O
ticlopidine O
significantly O
reduced O
platelet B-outcome ['Physiological-Clinical']
aggregation O
. O
['Physiological-Clinical']

Compared O
with O
the O
control O
condition O
, O
the O
intervention O
was O
associated O
with O
a O
significant O
increase O
in O
support O
person B-outcome ['Life-Impact']
self-efficacy I-outcome ['Life-Impact']
to O
help O
their O
smoker B-outcome ['Life-Impact']
( O
p O
= O
.034 O
) O
and O
outcome O
expectancies B-outcome ['Life-Impact']
( O
p O
= O
.025 O
) O
from O
baseline O
to O
week O
6 O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Infants O
fed O
F3 O
had O
significantly O
higher O
plasma B-outcome ['Physiological-Clinical']
tyrosine I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
than O
infants O
fed O
F1 O
, O
and O
those O
fed O
F4 O
had O
higher O
concentrations O
than O
those O
fed O
F2 O
. O
['Physiological-Clinical']

Understanding O
long O
term O
effects O
resulting O
from O
the O
cure O
of O
this O
infection O
is O
needed O
to O
design O
cancer O
prevention O
strategies O
. O
[]

Of O
these O
12 O
, O
one O
was O
lost O
to O
follow-up O
and O
four O
did O
not O
receive O
brachytherapy O
because O
they O
were O
unfit O
, O
had O
extension O
into O
the O
cardia O
or O
had O
mainly O
extrinsic O
compression O
. O
[]

Intrapleural O
instillation O
of O
50 O
mg O
of O
adriamycin O
and O
a O
combination O
chemotherapy O
of O
MFC O
( O
mitomycin O
C O
0.08 O
mg/kg O
, O
5-FU O
10 O
mg/kg O
, O
ara-C O
0.8 O
mg/kg O
iv O
, O
weekly O
) O
were O
administered O
in O
both O
groups O
. O
[]

The O
simulation O
group O
was O
directed O
to O
imitate O
a O
person O
with O
a O
memory O
impairment O
. O
[]

CONCLUSION O
These O
data O
demonstrate O
that O
stenting O
of O
chronic O
total O
occlusions O
is O
superior O
to O
balloon O
angioplasty O
alone O
with O
a O
statistically O
significant O
reduction O
in O
the O
need O
for O
target B-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
and O
a O
lower O
, O
but O
not O
significant O
, O
restenosis B-outcome ['Physiological-Clinical']
rate O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
rate O
of O
progression O
of O
early O
preintrusive O
atherosclerosis B-outcome ['Physiological-Clinical']
was O
determined O
in O
146 O
subjects O
using O
high-resolution O
B-mode O
ultrasound O
quantification O
of O
the O
distal O
common O
carotid O
artery O
far O
wall O
intima-media O
thickness O
( O
IMT O
) O
. O
['Physiological-Clinical']

Values O
are O
given O
as O
completely O
acceptable O
, O
n O
( O
% O
) O
; O
fairly O
acceptable O
, O
n O
( O
% O
) O
; O
fairly O
unacceptable O
, O
n O
( O
% O
) O
and O
completely O
unacceptable O
, O
n O
( O
% O
) O
. O
( O
[]

The O
extent O
of O
N-dealkylation B-outcome ['Physiological-Clinical']
, O
as O
indicated O
by O
the O
ratio O
of O
the O
N-dealkylated O
delavirdine B-outcome ['Resource-use']
AUC0 O
-- O
> O
infinity O
to O
the O
delavirdine B-outcome ['Resource-use']
AUC0 O
-- O
> O
['Physiological-Clinical', 'Resource-use', 'Resource-use']

A O
live O
oral O
cholera O
vaccine O
developed O
from O
a O
non-toxigenic O
Vibrio O
cholerae O
O1 O
El O
Tor O
strain O
VA1.3 O
was O
tested O
in O
a O
double-blind O
randomized O
placebo O
controlled O
study O
for O
safety O
and O
immunogenicity O
in O
304 O
men O
aged O
between O
16 O
and O
50 O
years O
from O
Kolkata O
, O
India O
. O
[]

Two O
hundred O
patients O
with O
similar O
demographics O
undergoing O
elective O
LC O
were O
randomized O
to O
one O
of O
four O
groups O
of O
50 O
patients O
each O
, O
including O
Group O
A O
placebo O
control O
, O
Group O
B O
with O
isotonic O
saline O
irrigation O
, O
Group O
C O
with O
bupivacaine O
irrigation O
, O
and O
Group O
D O
with O
lignocaine O
irrigation O
. O
[]

Catheter-related B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
via O
temporary O
vascular O
access O
catheters O
: O
a O
randomized O
prospective O
study O
. O
['Physiological-Clinical']

Fifty-six O
patients O
( O
49 O
boys O
, O
7 O
girls O
, O
mean O
age O
= O
6.4 O
years O
, O
SD O
= O
2.7 O
) O
enrolled O
in O
an O
open-label O
trial O
of O
secretin O
, O
during O
which O
they O
received O
one O
injection O
of O
the O
hormone O
( O
2 O
IU/kg O
) O
. O
[]

However O
, O
the O
noninvasive O
approach O
generated O
higher O
follow-up O
hospital B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
( O
$ O
9,204 O
+/- O
9,217 O
) O
than O
the O
invasive O
approach O
( O
$ O
3,784 O
+/- O
4,944 O
) O
( O
P O
= O
0.01 O
) O
. O
['Resource-use']

Those O
in O
groups O
2 O
, O
3 O
and O
4 O
( O
RDN1 O
, O
RDN2 O
and O
RDN3 O
) O
were O
supplemented O
with O
groundnut O
cake O
to O
provide O
RDN B-outcome ['Physiological-Clinical']
levels O
of O
14 O
, O
18 O
and O
23 O
g O
RDN O
kg?? O
digestible O
organic O
matter O
intake O
( O
DOMI O
) O
or O
21 O
, O
27 O
and O
35 O
g O
RDN O
kg?? O
digestible O
organic O
matter O
apparently O
digested O
in O
the O
rumen O
( O
DOMR O
) O
respectively O
along O
with O
FMS O
. O
['Physiological-Clinical']

For O
subjects O
who O
completed O
the O
three-month O
extension O
( O
i.e. O
, O
23 O
weeks O
post-SRP O
) O
, O
mean O
PPD B-outcome ['Physiological-Clinical']
decreases O
were O
0.72 O
mm O
for O
the O
test O
group O
and O
0.13 O
mm O
for O
the O
control O
, O
and O
mean O
BI B-outcome ['Physiological-Clinical']
reductions O
were O
0.05 O
for O
the O
test O
group O
and O
0.01 O
for O
the O
control O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Forty-five O
children O
and O
their O
parents O
were O
randomly O
assigned O
to O
either O
intervention O
or O
wait-list O
control O
conditions O
. O
[]

METHOD O
A O
randomized O
clinical O
trial O
that O
included O
a O
convenience O
sample O
of O
first O
time O
CABG O
patients O
. O
[]

Subgroup O
analysis O
by O
sex O
, O
age O
, O
and O
body O
mass O
index O
showed O
comparable O
outcomes O
between O
the O
two O
groups O
except O
that O
the O
[]

The O
most O
common O
[]

Microbiologic O
studies O
showed O
a O
reduction O
in O
colony-forming B-outcome ['Physiological-Clinical']
units O
in O
87 O
% O
of O
the O
BID O
group O
and O
in O
80 O
% O
of O
the O
QID O
group O
. O
['Physiological-Clinical']

The O
response O
rate O
among O
cases O
with O
values O
> O
0.25 O
mL/min/kg O
body O
weight O
was O
79 O
% O
, O
the O
same O
as O
in O
cases O
without O
cirrhosis O
. O
[]

At O
baseline O
, O
daily B-outcome ['Life-Impact']
dietary I-outcome ['Life-Impact']
fiber I-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
correlated O
negatively O
with O
PAI-1 O
activity O
. O
['Life-Impact']

10.9 O
ng/L O
vs. O
132.1 O
? O
[]

The O
primary O
endpoint O
is O
QOL O
score O
using O
the O
M.D O
. O
[]

The O
polyps B-outcome ['Physiological-Clinical']
were O
completely O
removed O
in O
61 O
out O
of O
62 O
( O
98 O
% O
) O
women O
assigned O
to O
morcellation O
compared O
with O
49 O
out O
of O
59 O
( O
83 O
% O
) O
women O
treated O
with O
electrosurgical O
resection O
( O
odds O
ratio O
12.5 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
1.5-100.6 O
; O
P=.02 O
) O
. O
['Physiological-Clinical']

Wound O
infections O
were O
diagnosed O
by O
blinded O
investigators O
using O
Centers O
for O
Disease O
Control O
and O
Prevention O
criteria O
. O
[]

After O
a O
baseline O
measure O
of O
spontaneous O
attention O
was O
obtained O
, O
infants O
were O
randomly O
assigned O
to O
1 O
of O
4 O
conditions O
( O
low O
, O
medium O
, O
high O
intervention O
, O
or O
no-intervention O
control O
) O
. O
[]

Peripheral O
opioid O
receptors O
have O
been O
found O
in O
inflamed O
synovia O
and O
the O
analgesic O
effect O
of O
intra-articularly O
administered O
morphine O
after O
arthroscopic O
knee O
surgery O
has O
been O
proven O
. O
[]

A O
literature O
survey O
was O
conducted O
and O
consensus O
meetings O
were O
held O
in O
which O
both O
the O
knowledge O
from O
the O
literature O
and O
clinical O
experience O
were O
pooled O
. O
[]

Group O
VI O
was O
filled O
with O
gutta-percha O
and O
without O
sealer O
to O
serve O
as O
a O
control O
. O
[]

Randomized O
clinical O
trial O
comparing O
systemic O
interferon O
with O
diathermocoagulation O
in O
primary O
multiple O
and O
widespread O
anogenital O
condyloma O
. O
[]

Treatment O
of O
brain O
metastases O
of O
small-cell O
lung O
cancer O
: O
comparing O
teniposide O
and O
teniposide O
with O
whole-brain O
radiotherapy O
-- O
a O
phase O
III O
study O
of O
the O
European O
Organization O
for O
the O
Research O
and O
Treatment O
of O
Cancer O
Lung O
Cancer O
Cooperative O
Group O
. O
[]

was O
not O
superior O
to O
placebo O
in O
reducing O
background O
or O
cue-induced O
cocaine O
craving O
over O
the O
3 O
weeks O
of O
the O
study O
. O
[]

Divalproex O
sodium O
vs. O
placebo O
in O
the O
treatment O
of O
repetitive B-outcome ['Life-Impact']
behaviours I-outcome ['Life-Impact']
in O
autism O
spectrum O
disorder O
. O
['Life-Impact']

For O
plasma O
glucose O
, O
insulin O
and O
leptin O
levels O
and O
BChE O
activity O
fasting O
blood O
was O
used O
. O
[]

In O
people O
with O
diabetes O
, O
renal O
disease O
tends O
to O
progress O
from O
microalbuminuria O
to O
clinical O
proteinuria O
to O
renal O
insufficiency O
. O
[]

FINDINGS O
At O
the O
time O
of O
analysis O
, O
393 O
( O
96 O
% O
) O
patients O
had O
died B-outcome ['Mortality']
( O
ASC O
132 O
[ O
97 O
% O
] O
, O
ASC O
plus O
MVP O
132 O
[ O
96 O
% O
] O
, O
ASC O
plus O
vinorelbine O
129 O
[ O
95 O
% O
] O
) O
. O
['Mortality']

Digestive O
enzyme O
supplementation O
for O
autism O
spectrum O
disorders O
: O
a O
double-blind O
randomized O
controlled O
trial O
. O
[]

The O
trial O
is O
monitored O
and O
analyzed O
by O
means O
of O
a O
sequential O
strategy O
. O
[]

Making O
interpretation O
more O
objective O
removed O
that O
bias O
and O
did O
not O
demonstrate O
a O
significant O
advantage O
for O
the O
test O
dressing O
. O
[]

Of O
children O
who O
were O
using O
spoken O
language O
at O
age O
8 O
years O
, O
several O
baseline O
behaviors O
predicted O
their O
later O
ability O
, O
including O
earlier O
age O
of O
entry O
into O
the O
study O
, O
initiating O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
skill I-outcome ['Life-Impact']
, O
['Life-Impact']

SUBJECTS O
29 O
subjects O
with O
impaired O
glucose O
tolerance O
. O
[]

OBJECTIVE O
To O
assess O
changes O
in O
health-related B-outcome ['Physiological-Clinical']
quality O
of O
life O
( O
HRQoL B-outcome ['Life-Impact']
) O
measures O
among O
patients O
receiving O
topiramate O
( O
TPM O
) O
100 O
mg/d O
in O
two O
divided O
doses O
for O
migraine O
prevention O
in O
three O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
26-week O
trials O
with O
similar O
protocols O
and O
study O
populations O
. O
['Physiological-Clinical', 'Life-Impact']

Mean O
scores O
favored O
the O
RET O
and O
REI O
groups O
, O
but O
no O
significant O
differences O
between O
these O
groups O
and O
the O
ROC O
group O
were O
obtained O
. O
[]

Two O
hour O
control O
urine O
collections O
were O
followed O
by O
2 O
h O
postdose O
urine O
collections O
and O
subsequently O
2.5 O
% O
saline O
was O
given O
i.v O
. O
[]

METHODS O
Between O
October O
15 O
, O
1996 O
, O
and O
March O
24 O
, O
1999 O
, O
104 O
patients O
at O
13 O
centers O
were O
prospectively O
randomized O
to O
undergo O
embolization O
using O
an O
n-BCA/Tantalum O
Powder/Ethiodol O
mixture O
or O
Trufill O
PVA O
. O
[]

Rizatriptan O
030 O
Study O
Group O
. O
[]

[ O
Effects O
of O
computer-assisted O
practice O
on O
reading B-outcome ['Life-Impact']
and O
spelling B-outcome ['Life-Impact']
in O
children O
with O
learning O
disabilities O
] O
. O
['Life-Impact', 'Life-Impact']

These O
findings O
suggest O
that O
over-selectivity B-outcome ['Life-Impact']
is O
not O
simply O
due O
to O
a O
failure O
to O
attend O
to O
all O
of O
the O
stimuli O
presented O
. O
['Life-Impact']

RESULTS O
There O
were O
no O
significant O
differences O
among O
the O
demographics O
, O
myocardial B-outcome ['Physiological-Clinical']
enzyme I-outcome ['Physiological-Clinical']
release B-outcome ['Physiological-Clinical']
, O
occurrence O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Twenty-five O
opioid-dependent O
patients O
on O
intravenous O
( O
IV O
) O
heroin O
or O
IV O
methadone O
maintenance O
treatment O
were O
randomly O
assigned O
to O
either O
their O
individual O
prescribed O
IV O
maintenance O
dose O
or O
placebo O
. O
[]

CONCLUSIONS O
The O
nonlinear O
PK O
of O
linagliptin O
and O
its O
plasma O
DPP-4 O
inhibition O
in O
patients O
were O
well O
characterized O
by O
a O
target-mediated O
drug O
disposition O
model O
relating O
DPP-4 O
occupancy O
with O
linagliptin O
to O
DPP-4 O
inhibition O
. O
[]

Specimens O
from O
the O
Cancer O
Cooperative O
Intergroup O
Trial O
E2496 O
were O
used O
to O
compare O
pretreatment O
plasma O
EBV-DNA O
quantification O
with O
EBV O
tumor B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
by O
EBER-ISH B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
five O
centres O
varied O
widely O
with O
respect O
to O
service O
organisation O
and O
activity O
, O
but O
all O
had O
a O
greater O
proportion O
of O
unaffected O
attendees O
with O
a O
breast O
cancer O
risk O
( O
61-91 O
% O
) O
than O
either O
a O
bowel O
cancer O
risk O
( O
0-33 O
% O
) O
or O
ovarian O
cancer O
risk O
( O
3-25 O
% O
) O
. O
[]

CONCLUSION O
Selaginella O
may O
induce O
radiosensitization O
for O
terminal O
NPC O
and O
does O
not O
increase O
the O
acute O
toxicity O
of O
radiotherapy O
. O
[]

METHODS O
This O
multicenter O
, O
randomized O
, O
controlled O
clinical O
trial O
on O
PER O
will O
be O
conducted O
at O
three O
institutions O
in O
China O
. O
[]

In O
this O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
, O
we O
compared O
the O
effects O
of O
salmeterol O
plus O
fluticasone O
propionate O
( O
FP O
) O
( O
Seretide O
; O
SFC O
) O
and O
FP O
plus O
montelukast O
( O
FP/M O
) O
on O
sputum B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
, O
airway B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
, O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
and O
symptoms B-outcome ['Physiological-Clinical']
in O
adult O
asthmatics O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
A O
sample O
of O
13 O
patients O
randomized O
to O
the O
community O
hospital O
arm O
of O
the O
RCT O
joined O
the O
qualitative O
study O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
high-density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HDL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
non-HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
were O
increased O
by O
5 O
% O
and O
7 O
% O
, O
respectively O
, O
in O
the O
FO O
group O
, O
and O
by O
2 O
% O
and O
0 O
% O
in O
the O
control O
group O
( O
P O
< O
.01-.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
conducted O
a O
prospective O
, O
randomized O
, O
pilot O
trial O
comparing O
MDI O
therapy O
with O
continuous O
subcutaneous O
insulin O
therapy O
( O
pump O
therapy O
) O
in O
24 O
patients O
, O
8-18 O
years O
old O
, O
with O
newly O
diagnosed O
T1D O
. O
[]

Levels O
of O
opioid O
physical O
dependence O
in O
heroin O
addicts O
. O
[]

A O
Bifidobacterium-predominant O
flora O
was O
formed O
at O
an O
average O
of O
2 O
weeks O
after O
birth O
in O
group O
A O
and O
at O
an O
average O
of O
4 O
weeks O
after O
birth O
in O
group O
B O
, O
while O
no O
Bifidobacterium O
was O
isolated O
in O
eight O
out O
of O
10 O
infants O
in O
group O
C O
during O
the O
observation O
period O
of O
7 O
weeks O
. O
[]

The O
questionnaire O
was O
administered O
at O
four O
time O
points O
: O
recruitment O
( O
T1 O
) O
, O
13 O
to O
11 O
days O
before O
departure O
( O
T2 O
) O
, O
6 O
to O
4 O
days O
before O
departure O
( O
T3 O
) O
, O
and O
7 O
to O
14 O
days O
after O
return O
from O
Africa O
( O
T4 O
) O
. O
[]

The O
differences O
in O
SiSBP/SiDBP B-outcome ['Physiological-Clinical']
between O
the O
2 O
groups O
at O
week O
8 O
were O
not O
significant O
. O
['Physiological-Clinical']

This O
randomized O
phase O
II O
trial O
assessed O
tamoxifen O
plus O
placebo O
or O
the O
epidermal O
growth O
factor O
receptor O
inhibitor O
gefitinib O
in O
estrogen O
receptor O
( O
ER O
) O
-positive O
metastatic O
breast O
cancer O
. O
[]

The O
0-to-10 O
points O
visual O
analogue O
scale O
( O
VAS O
) O
was O
used O
for O
assessing O
pain O
at O
probe O
insertion O
and O
movements O
( O
VAS-1 O
) O
, O
at O
prostate O
sampling O
( O
VAS-2 O
) O
, O
and O
maximal O
procedural O
pain O
( O
MPP O
) O
. O
[]

This O
increase O
in O
hilliness O
, O
measured O
by O
the O
GFP O
, O
was O
significant O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
assess O
the O
level O
of O
accuracy O
for O
measurements O
of O
intra-ocular O
pressure O
( O
IOP O
) O
obtained O
with O
a O
new O
non-contact O
tonometer O
( O
NCT O
) O
the O
Reichert O
AT550 O
. O
[]

Significant O
decreases O
in O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
19 O
mg/dL O
) O
, O
and O
LDL-cholesterol B-outcome ['Physiological-Clinical']
( O
11 O
mg/dL O
) O
, O
were O
observed O
during O
the O
run-in O
period O
, O
with O
no O
further O
decreases O
in O
lipids O
during O
the O
intervention O
period O
in O
either O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
for O
this O
prospective O
study O
was O
to O
find O
an O
agent O
that O
is O
cost O
effective O
and O
side O
effect O
free O
( O
or O
at O
least O
with O
a O
low O
incidence O
of O
side O
effects O
) O
for O
the O
prevention O
of O
PONV O
. O
[]

ORG O
2766 O
treatment O
( O
20 O
mg O
per O
day O
during O
4 O
weeks O
) O
was O
associated O
with O
an O
increased O
amount O
and O
an O
improved O
quality O
of O
the O
social O
interaction O
of O
the O
autistic O
children O
with O
a O
familiar O
experimenter O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effectiveness O
of O
early O
administration O
of O
intravenous O
Magnesium O
sulfate O
( O
i.v O
. O
[]

Autism O
spectrum O
disorders O
( O
ASDs O
) O
are O
neurodevelopmental O
disorders O
characterized O
by O
social O
and O
language O
deficits O
and O
by O
repetitive O
behaviors O
and O
interests O
. O
[]

However O
, O
the O
inherent O
heterogeneity O
in O
nasal O
antibody O
levels O
and O
variability O
in O
nasal O
specimen O
collection O
hinders O
the O
precise O
evaluation O
of O
mucosal O
antibody O
responses O
. O
[]

Cooperative O
Study O
Group O
of O
Kyushu O
and O
Chugoku O
for O
HCFU O
Adjuvant O
Chemotherapy O
] O
. O
[]

RESULTS O
KGQG O
group O
showed O
better O
efficacy O
over O
control O
group O
in O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
, O
decrease O
of O
serum B-outcome ['Physiological-Clinical']
PCIII I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
CIV I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
HA I-outcome ['Physiological-Clinical']
levels O
and O
liver B-outcome ['Physiological-Clinical']
pathologic I-outcome ['Physiological-Clinical']
grades I-outcome ['Physiological-Clinical']
( O
P O
0.05 O
or O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

NCX-4016 O
inhibited O
AA-induced B-outcome ['Physiological-Clinical']
platelet I-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
as O
well O
as O
serum B-outcome ['Physiological-Clinical']
TXB I-outcome ['Physiological-Clinical']
( O
2 O
) O
and O
platelet B-outcome ['Physiological-Clinical']
TXB I-outcome ['Physiological-Clinical']
( O
2 O
) O
generation B-outcome ['Physiological-Clinical']
induced O
by O
AA O
to O
the O
same O
extent O
as O
aspirin O
( O
not O
significant O
vs. O
aspirin O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
a O
large O
collaborative O
study O
involving O
15 O
centres O
, O
254 O
patients O
were O
enrolled O
. O
[]

No O
differences O
in O
the O
amount O
of O
knowledge B-outcome ['Life-Impact']
increase O
were O
found O
between O
three O
interventions O
tested O
. O
['Life-Impact']

Before O
incision O
, O
in O
both O
groups O
IL-1beta B-outcome ['Physiological-Clinical']
and O
IFN-gamma B-outcome ['Physiological-Clinical']
showed O
a O
decrease O
( O
p O
< O
0.01 O
for O
IL-1beta B-outcome ['Physiological-Clinical']
in O
isoflurane O
group O
and O
p O
< O
0.05 O
for O
the O
others O
) O
compared O
with O
pre-induction O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

For O
each O
group O
, O
transfusions O
were O
given O
only O
when O
the O
hematocrit O
level O
fell O
below O
the O
assigned O
value O
. O
[]

Overall O
, O
results O
indicate O
that O
while O
supervisor O
tolerance O
of O
coworker O
substance O
use O
inhibits O
EAP O
utilization O
, O
it O
may O
be O
possible O
to O
address O
this O
tolerance O
using O
team-oriented O
prevention O
training O
in O
the O
work-site O
. O
[]

Local B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
were O
observed O
visually O
. O
['Physiological-Clinical']

Cox O
proportional O
hazard O
ratio O
estimates O
for O
selected O
baseline O
covariates O
showed O
a O
significantly O
increased O
risk O
of O
cardiovascular O
events O
by O
age O
( O
p=0.0459 O
) O
and O
systolic O
blood O
pressure O
( O
p=0.0061 O
) O
. O
[]

Sertraline O
treatment O
of O
generalized B-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
phobia I-outcome ['Life-Impact']
: O
a O
20-week O
, O
double-blind O
, O
placebo-controlled O
study O
. O
['Life-Impact']

The O
interactions O
of O
testing O
conditions O
, O
adhesive-composite O
combination O
and O
tooth O
substrate O
with O
marginal O
adaptation O
were O
evaluated O
by O
two-way O
ANOVA O
. O
[]

Maximum O
inspiratory O
airway O
pressure O
also O
increased O
( O
mean O
29 O
% O
; O
P O
less O
than O
0.01 O
) O
, O
suggesting O
improvement O
in O
respiratory B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Subjective O
global B-outcome ['Physiological-Clinical']
facial I-outcome ['Physiological-Clinical']
appearance I-outcome ['Physiological-Clinical']
scores O
worsened O
by O
5 O
% O
while O
blinded O
physician O
scores O
improved O
by O
16 O
% O
3 O
months O
after O
3 O
Er O
: O
YAG O
treatments O
, O
but O
by O
28 O
and O
20 O
% O
for O
IPL O
, O
respectively O
. O
['Physiological-Clinical']

7 O
for O
two O
consecutive O
weeks O
. O
[]

These O
two O
groups O
were O
given O
either O
intravenous O
dezocine O
0.1 O
mg/kg O
or O
a O
matching O
placebo O
( O
equal O
volume O
of O
0.9 O
% O
saline O
) O
10 O
min O
before O
the O
induction O
of O
general O
anesthesia O
. O
[]

Effect O
of O
whole O
body O
vibration O
on O
stereotypy B-outcome ['Life-Impact']
of O
young O
children O
with O
autism O
. O
['Life-Impact']

Only O
a O
minority O
of O
tocilizumab-treated O
patients O
with O
DAS28 O
remission O
also O
had O
disease O
remission O
according O
to O
the O
SDAI O
( O
26 O
% O
) O
or O
CDAI O
( O
?21 O
% O
) O
. O
[]

In O
7 O
hypertensive B-outcome ['Physiological-Clinical']
episodes O
a O
second O
dose O
of O
diazoxide O
150 O
mg O
was O
given O
60 O
+/- O
11 O
min O
after O
the O
first O
injection O
. O
['Physiological-Clinical']

RESULTS O
There O
was O
no O
mortality B-outcome ['Mortality']
in O
either O
group O
. O
['Mortality']

Results O
are O
preliminary O
and O
, O
owing O
to O
the O
small O
sample O
size O
, O
can O
be O
considered O
only O
suggestive O
until O
this O
study O
is O
completed O
or O
replication O
is O
obtained O
from O
independent O
research O
. O
[]

They O
were O
assessed O
for O
functional O
autonomy O
before O
ICU O
stay O
, O
just O
after O
ICU O
discharge O
, O
just O
after O
hospital O
discharge O
, O
and O
6 O
months O
later O
. O
[]

MAIN O
OUTCOME O
MEASURES O
The O
primary O
outcomes O
were O
the O
12-month O
changes O
in O
spine B-outcome ['Physiological-Clinical']
and O
hip B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Furthermore O
, O
young O
children O
only O
succeeded O
on O
TOM O
items O
that O
tap O
the O
basic O
domains O
of O
theory O
of O
mind O
( O
e.g. O
, O
emotion O
recognition O
) O
, O
whereas O
older O
children O
also O
passed O
items O
that O
measure O
the O
more O
mature O
areas O
of O
theory O
of O
mind O
( O
e.g. O
, O
understanding O
of O
humor O
, O
understanding O
of O
second-order O
beliefs O
) O
. O
[]

The O
trial O
ended O
with O
a O
4-week O
drug-free O
period O
. O
[]

All O
patients O
had O
improved O
function B-outcome ['Life-Impact']
and O
regained B-outcome ['Physiological-Clinical']
full I-outcome ['Physiological-Clinical']
extension I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

The O
cytochrome O
P450 O
probes O
caffeine O
( O
CYP1A2 O
) O
, O
tolbutamide O
( O
CYP2C9 O
) O
, O
and O
dextromethorphan O
( O
CYP2D6 O
) O
were O
administered O
as O
an O
oral O
cocktail O
prior O
to O
and O
7 O
days O
after O
oral O
clarithromycin O
( O
500 O
mg O
twice O
daily O
) O
administration O
to O
12 O
healthy O
male O
subjects O
. O
[]

It O
is O
concluded O
that O
an O
antacid O
dose O
should O
be O
so O
great O
that O
it O
binds O
secreted O
acid O
before O
the O
dose O
leaves O
the O
stomach O
. O
[]

Following O
this O
LMT O
, O
two O
constant O
velocity O
28-minute O
runs O
were O
performed O
, O
one O
at O
the O
predicted O
MLSS O
velocity O
( O
trial O
1 O
) O
and O
the O
other O
0.13 O
m O
sec-1 O
( O
4-8 O
% O
) O
above O
the O
predicted O
MLSS O
velocity O
( O
trial O
2 O
) O
. O
[]

Epirubicin-based O
chemotherapy O
in O
metastatic O
breast O
cancer O
patients O
: O
role O
of O
dose-intensity O
and O
duration O
of O
treatment O
. O
[]

The O
average O
direct B-outcome ['Resource-use']
cost I-outcome ['Resource-use']
per O
patient O
treated O
for O
8 O
weeks O
or O
longer O
( O
independent O
of O
clinical O
outcome O
) O
was O
$ O
27,270 O
and O
$ O
36,096 O
in O
the O
NPWT O
and O
MWT O
groups O
, O
respectively O
. O
['Resource-use']

NFV O
pharmacokinetic O
measurements O
were O
not O
statistically O
different O
between O
the O
treatment O
groups O
, O
yet O
exposure O
to O
the O
NFV O
metabolite O
, O
M8 O
, O
was O
significantly O
higher O
in O
subjects O
receiving O
RTV O
. O
[]

Results O
indicated O
significant O
group-by-time O
interactions O
for O
the O
following O
: O
relaxation B-outcome ['Life-Impact']
( O
UCO O
versus O
SM O
, O
p O
= O
0.008 O
) O
, O
awareness B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
tension I-outcome ['Life-Impact']
( O
UCO O
versus O
SMEX O
, O
p O
= O
0.029 O
and O
UCO O
versus O
EX O
, O
p O
< O
0.001 O
) O
, O
getting B-outcome ['Life-Impact']
needs I-outcome ['Life-Impact']
met I-outcome ['Life-Impact']
( O
UCO O
versus O
SMEX O
, O
p O
= O
0.020 O
) O
and O
Measure O
of O
Current O
Status O
total O
score O
( O
UCO O
versus O
SMEX O
, O
p O
= O
0.007 O
and O
UCO O
versus O
EX O
, O
p O
= O
0.016 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Prostaglandin O
E1 O
as O
a O
hypotensive O
drug O
during O
general O
anaesthesia O
. O
[]

The O
purpose O
of O
this O
investigation O
was O
to O
conduct O
a O
human O
safety O
study O
with O
a O
Haematococcus O
pluvialis O
algal O
extract O
with O
high O
levels O
of O
astaxanthin O
. O
[]

No O
significant O
differences O
were O
found O
in O
either O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
or O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
responses O
to O
the O
PSL-LBNP O
or O
the O
tolerance O
indices O
( O
cumulative O
stress O
index O
; O
maximum O
negative O
pressure O
tolerated O
; O
and O
duration O
of O
negative O
pressure O
exposure O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIDS O
Clinical O
Trials O
Group O
. O
[]

Effects O
of O
Positive O
Action O
on O
the O
emotional O
health O
of O
urban O
youth O
: O
a O
cluster-randomized O
trial O
. O
[]

The O
safety O
of O
these O
regimens O
was O
similar O
, O
and O
triple O
therapy O
was O
found O
to O
be O
clinically O
acceptable O
. O
[]

Relationship O
of O
the O
dose O
of O
intravenous O
gammaglobulin O
to O
the O
prevention O
of O
infections O
in O
adults O
with O
common O
variable O
immunodeficiency O
. O
[]

Effects O
of O
ursodeoxycholic O
acid O
on O
serum B-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
enzymes I-outcome ['Physiological-Clinical']
in O
patients O
with O
hepatitis O
C O
virus-related O
chronic O
liver O
disease O
. O
['Physiological-Clinical']

Afterwards O
CC O
or O
rFSH O
were O
added O
for O
induction O
of O
ovulation O
along O
with O
metformin O
. O
[]

Peripheral B-outcome ['Physiological-Clinical']
natural I-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NK I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
LAK B-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
were O
augmented O
in O
all O
patients O
and O
total O
white B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
were O
increased O
during O
IS-IL-2 O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Biochemical B-outcome ['Physiological-Clinical']
[ O
peak-stimulated B-outcome ['Physiological-Clinical']
LH I-outcome ['Physiological-Clinical']
, O
estradiol B-outcome ['Physiological-Clinical']
( O
girls O
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

89.1 O
% O
( O
RR O
= O
0.32 O
; O
0.22-0.46 O
) O
, O
( O
P O
< O
0.001 O
) O
. O
[]

Consolidation O
consisted O
of O
six O
courses O
of O
chemotherapy O
; O
the O
first O
, O
third O
, O
and O
fifth O
courses O
were O
a O
combination O
of O
high-dose O
cytarabine O
, O
etoposide O
, O
and O
dexamethasone O
( O
R3 O
) O
, O
whereas O
the O
second O
, O
fourth O
, O
and O
sixth O
courses O
included O
vincristine O
, O
prednisone O
, O
cyclophosphamide O
, O
doxorubicin O
, O
and O
methotrexate O
( O
COPADM O
) O
. O
[]

There O
is O
considerable O
interest O
in O
the O
development O
of O
simulators O
for O
MIS O
even O
though O
the O
importance O
of O
force O
feedback B-outcome ['Life-Impact']
remains O
poorly O
understood O
. O
['Life-Impact']

Lactobacillus O
GG O
, O
have O
shown O
efficacy O
in O
clinical O
trials O
for O
the O
treatment O
of O
acute O
childhood O
diarrhoea O
, O
but O
few O
studies O
have O
examined O
the O
effect O
of O
Saccharomyces O
boulardii O
. O
[]

Only O
one O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
occurred O
in O
the O
study O
group O
. O
['Physiological-Clinical']

AIM O
To O
assess O
the O
efficacy O
and O
safety O
of O
esomeprazole O
in O
patients O
with O
frequent B-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
for O
> O
or O
= O
6 O
months O
and O
no O
evidence O
of O
erosive O
oesophagitis O
on O
endoscopy O
. O
['Physiological-Clinical']

The O
independent O
beneficial O
effect O
of O
treatment O
with O
primary O
PTCA O
rather O
than O
tPA O
in O
anterior O
wall O
AMI O
was O
confirmed O
by O
multivariate O
analysis O
and O
interaction O
testing O
. O
[]

Dietary B-outcome ['Life-Impact']
iron I-outcome ['Life-Impact']
exposures I-outcome ['Life-Impact']
were O
not O
associated O
with O
either O
subsite O
. O
['Life-Impact']

From O
January O
1985 O
to O
September O
1988 O
, O
60 O
women O
with O
advanced O
breast O
cancer O
were O
randomized O
in O
two O
arms O
to O
receive O
: O
A O
) O
tamoxifen O
( O
TAM O
) O
( O
20 O
mg/die O
) O
until O
progression O
or O
B O
) O
TAM O
( O
20 O
mg/die O
for O
14 O
days O
) O
then O
medroxyprogesterone O
acetate O
( O
MPA O
) O
( O
1500 O
mg/die O
p.o O
. O
[]

The O
link O
between O
emotion O
regulation O
and O
academic B-outcome ['Life-Impact']
achievement I-outcome ['Life-Impact']
is O
well O
documented O
. O
['Life-Impact']

All O
patients O
received O
epidural O
anesthesia O
with O
0.5 O
% O
bupivacaine O
containing O
1:200,000 O
epinephrine O
, O
to O
which O
2 O
mg O
( O
groups O
1 O
, O
2 O
, O
and O
3 O
) O
or O
4 O
mg O
( O
groups O
4 O
, O
5 O
, O
and O
6 O
) O
morphine O
sulfate O
was O
added O
. O
[]

We O
studied O
the O
effect O
of O
topical O
anesthesia O
on O
infant O
stress O
and O
corneal O
haze O
during O
the O
routine O
eye O
examination O
for O
retinopathy O
of O
prematurity O
. O
[]

The O
World O
Health O
Organization O
Quality O
of O
Life-BREF O
( O
WHOQOL-BREF O
) O
, O
brief O
fatigue O
inventory O
( O
BFI O
) O
, O
range O
of O
motion B-outcome ['Physiological-Clinical']
( O
ROM B-outcome ['Physiological-Clinical']
) O
of O
the O
shoulder B-outcome ['Physiological-Clinical']
, O
and O
pain B-outcome ['Physiological-Clinical']
score O
were O
assessed O
before O
and O
after O
radiotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
six O
possible O
combinations O
of O
these O
three O
dosage O
schedules O
were O
used O
in O
the O
patients O
in O
a O
strictly O
randomised O
manner O
, O
and O
all O
patients O
were O
treated O
during O
the O
same O
period O
. O
[]

In O
some O
regions O
, O
these O
effects O
may O
be O
related O
to O
the O
receptor O
( O
target O
) O
density O
. O
[]

Solutions O
containing O
glycerol O
were O
initially O
less O
acid O
( O
pH O
6.5 O
) O
than O
those O
containing O
glucose O
( O
pH O
5.1 O
) O
. O
[]

METHODS O
Recruited O
60 O
patients O
were O
randomly O
assigned O
to O
the O
treatment O
group O
( O
treated O
by O
conventional O
chemotherapy O
combined O
DJQ O
, O
20 O
mL O
each O
time O
, O
three O
times O
daily O
) O
and O
the O
control O
group O
( O
treated O
by O
chemotherapy O
alone O
) O
, O
30 O
in O
each O
group O
. O
[]

We O
collected O
data O
at O
baseline O
( O
March O
2010 O
) O
and O
12 O
weeks O
( O
June O
2010 O
) O
. O
[]

Our O
purpose O
was O
to O
examine O
whether O
catheter O
washouts O
prevent O
or O
reduce O
catheter B-outcome ['Physiological-Clinical']
blockage I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
main O
secondary O
endpoint O
was O
the O
composite O
of O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
non-fatal B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
and O
['Mortality', 'Physiological-Clinical']

CONCLUSIONS O
This O
study O
showed O
no O
significant O
differences O
between O
mechanized O
vitreous O
biopsy O
and O
needle O
tap O
with O
respect O
to O
microbiologic O
yield O
, O
operative O
complications O
, O
short-term O
( O
9-12 O
months O
) O
retinal O
detachment O
risk O
, O
or O
visual O
outcome O
. O
[]

The O
objectives O
of O
this O
study O
were O
to O
compare O
the O
effect O
of O
administered O
recombinant O
human O
TSH O
with O
thyroid O
hormone O
withdrawal O
on O
the O
results O
of O
radioiodine O
whole O
body O
scanning O
( O
WBS O
) O
and O
serum O
thyroglobulin O
( O
Tg O
) O
levels O
. O
[]

Patients O
in O
arm O
A O
had O
longer O
median O
survival B-outcome ['Mortality']
but O
this O
did O
not O
reach O
statistical O
significance O
( O
13.1 O
versus O
8.3 O
months O
, O
p O
= O
0.25 O
) O
. O
['Mortality']

Effects O
of O
sibutramine O
on O
thermogenesis O
in O
obese O
patients O
assessed O
via O
immersion O
calorimetry O
. O
[]

A O
study O
was O
undertaken O
to O
compare O
directly O
the O
self-administered O
version O
of O
the O
CRQ O
and O
the O
SGRQ O
with O
respect O
to O
feasibility O
, O
internal O
consistency O
, O
validity O
, O
and O
sensitivity O
to O
changes O
resulting O
from O
bronchodilator O
therapy O
. O
[]

Tumor B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor O
generation B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
lipopolysaccharide I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LPS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
-stimulated I-outcome ['Physiological-Clinical']
blood B-outcome ['Physiological-Clinical']
was O
30 O
% O
reduced O
after O
whale O
oil O
( O
P O
< O
0.05 O
) O
, O
but O
was O
unaffected O
by O
intake O
of O
seal O
or O
CLO O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Outcome O
results O
applied O
to O
life O
expectancy O
tables O
were O
used O
to O
estimate O
QALYs O
. O
[]

Treatment O
of O
two O
months O
were O
carried O
out O
in O
both O
groups O
. O
[]

Subgroup O
results O
were O
consistent O
. O
[]

Higher O
serum O
concentration O
and O
area O
under O
the O
plasma O
concentration O
curve O
( O
AUC O
) O
were O
not O
associated O
with O
an O
improved O
EFS O
. O
[]

However O
, O
while O
such O
interference O
is O
released O
for O
controls O
if O
parts O
of O
face O
composites O
are O
misaligned O
, O
individuals O
with O
ASDs O
show O
comparable B-outcome ['Life-Impact']
interference I-outcome ['Life-Impact']
from O
irrelevant O
parts O
regardless O
of O
alignment O
. O
['Life-Impact']

The O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
one I-outcome ['Physiological-Clinical']
second I-outcome ['Physiological-Clinical']
( O
FEV1 B-outcome ['Physiological-Clinical']
) O
and O
forced B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
( O
FVC B-outcome ['Physiological-Clinical']
) O
were O
detected O
by O
Spirometer O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Clinical O
inertia O
, O
the O
tendency O
of O
physicians O
not O
to O
intensify O
treatment O
, O
is O
a O
common O
barrier O
in O
controlling O
chronic O
diseases O
. O
[]

Ultrasonographic O
tissue O
characterisation O
of O
human O
Achilles O
tendons O
: O
quantification O
of O
tendon O
structure O
through O
a O
novel O
non-invasive O
approach O
. O
[]

We O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
with O
40 O
consecutive O
children O
with O
autism O
, O
whose O
ages O
ranged O
from O
2 O
to O
9 O
years O
, O
who O
were O
receiving O
either O
risperidone O
or O
placebo O
given O
orally O
at O
a O
dose O
of O
1 O
mg/day O
for O
6 O
months O
. O
[]

RESULTS O
Baseline O
BP B-outcome ['Physiological-Clinical']
and O
R-R B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
were O
unaffected O
by O
PUFA O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
a O
significant O
increase O
in O
peak O
VO2 O
( O
p O
< O
0.05 O
) O
and O
anaerobic O
threshold O
( O
p O
< O
0.01 O
) O
with O
denopamine O
, O
whereas O
no O
significant O
change O
was O
observed O
in O
peak O
work O
rate O
or O
exercise O
time O
. O
[]

The O
endurance B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
with O
fenoterol O
( O
34.4 O
+/- O
8.6 O
min O
) O
was O
longer O
than O
that O
with O
the O
placebo O
( O
22.2 O
+/- O
7.1 O
min O
; O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

METHODS O
A O
double O
blind O
randomized O
controlled O
trial O
was O
performed O
on O
150 O
nulliparas O
with O
a O
gestational O
age O
of O
39-41 O
weeks O
of O
pregnancy O
and O
a O
Bishop O
score O
of O
< O
or O
=5 O
. O
[]

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
prognostic O
significance O
of O
alterations O
in O
serum O
magnesium O
in O
patients O
with O
moderate O
to O
severe O
congestive O
heart O
failure O
. O
[]

The O
walnut-enriched O
diet O
increased O
fasting B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
lowered O
serum B-outcome ['Physiological-Clinical']
total O
cholesterol B-outcome ['Physiological-Clinical']
and O
LDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
from O
baseline O
( O
10.0 O
+/- O
20.5 O
mg/dl O
, O
P O
= O
0.04 O
; O
-9.7 O
+/- O
14.5 O
mg/dl O
, O
P O
< O
0.01 O
; O
and O
-7.7 O
+/- O
10 O
mg/dl O
, O
P O
< O
0.01 O
, O
respectively O
) O
, O
although O
these O
changes O
were O
not O
significant O
compared O
with O
those O
for O
an O
ad O
libitum O
diet O
without O
walnuts O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
Tipless O
stone O
baskets O
facilitate O
caliceal O
calculi O
extraction O
during O
flexible O
ureteroscopy O
. O
[]

Hemoglobin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
during O
the O
study O
decreased O
by O
1.4 O
+/- O
2.2 O
g/dL O
in O
the O
control O
group O
and O
1.0 O
+/- O
2.3 O
g/dL O
in O
the O
blood O
conservation O
group O
( O
p O
= O
nonsignificant O
) O
. O
['Physiological-Clinical']

Both O
drug O
combinations O
can O
be O
considered O
efficient O
, O
well O
tolerated B-outcome ['Life-Impact']
and O
safe O
in O
the O
treatment O
of O
mild O
to O
moderate O
hypertension O
. O
['Life-Impact']

Overall O
evaluation O
showed O
that O
bodyplethysmography O
and O
the O
polyfrequent O
oscillation O
method O
( O
reactance O
or O
resonance O
frequency O
) O
are O
comparably O
sensitive O
. O
[]

There O
was O
a O
significant O
quantitative O
diminished B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
( O
P O
less O
than O
0.05 O
) O
of O
bacteria O
in O
the O
group O
of O
patients O
treated O
with O
PVP-I O
compared O
to O
the O
control O
group O
. O
['Physiological-Clinical']

CONCLUSIONS O
Training O
with O
EPI-NO O
increases O
significantly O
the O
likelihood O
of O
having O
an O
[]

Patients O
were O
randomly O
allocated O
to O
the O
splinting O
group O
( O
n O
= O
17 O
) O
or O
the O
control O
group O
( O
n O
= O
16 O
) O
. O
[]

At O
short O
contour O
spacing O
, O
the O
detectability O
reached O
a O
plateau O
with O
alignment O
of O
a O
few O
line O
segments O
that O
together O
formed O
a O
contour O
subtending O
several O
visual O
degrees O
. O
[]

CONCLUSION O
Nefazodone O
was O
superior O
to O
placebo O
in O
the O
treatment O
of O
marked O
to O
severe O
major O
depression O
in O
patients O
requiring O
hospitalization O
. O
[]

Recurrent O
epithelial O
ovarian O
carcinoma O
: O
a O
randomized O
phase O
III O
study O
of O
pegylated O
liposomal O
doxorubicin O
versus O
topotecan O
. O
[]

Vaginal O
electrical O
stimulation O
of O
the O
pelvic O
floor O
: O
a O
randomized O
feasibility O
study O
in O
urinary O
incontinent O
elderly O
women O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
relative O
efficacy O
and O
technical B-outcome ['Life-Impact']
ease I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
of O
eight O
different O
agents O
for O
endoscopic O
hemostasis O
and O
obliteration O
of O
bleeding O
gastric O
varices O
in O
a O
canine O
model O
, O
as O
no O
comparative O
data O
are O
available O
on O
gastric O
variceal O
sclerotherapy O
. O
['Life-Impact']

OBJECTIVE O
To O
determine O
if O
overweight O
and O
obese O
women O
provide O
more O
accurate O
reports O
of O
their O
energy O
intake O
by O
1 O
) O
in-person O
recall O
with O
an O
obese O
interviewer O
, O
2 O
) O
in-person O
recall O
with O
a O
lean O
interviewer O
, O
or O
3 O
) O
telephone O
recall O
with O
an O
unknown O
interviewer O
. O
[]

Only O
minor O
side O
effects O
of O
CP O
were O
encountered O
. O
[]

A O
placebo-controlled O
trial O
of O
D-cycloserine O
added O
to O
conventional O
neuroleptics O
in O
patients O
with O
schizophrenia O
. O
[]

These O
dogs O
were O
randomised O
into O
two O
groups O
that O
were O
treated O
for O
84 O
days O
with O
either O
the O
test O
product O
, O
imidapril O
, O
or O
the O
positive O
control O
, O
benazepril O
, O
and O
followed O
up O
in O
parallel O
over O
this O
period O
. O
[]

During O
a O
mean O
18-month O
follow-up O
period O
, O
one O
patient O
( O
2.4 O
% O
) O
in O
the O
ETV O
prophylactic O
group O
and O
seven O
patients O
( O
17.9 O
% O
) O
in O
the O
control O
group O
developed O
HBV O
reactivation O
( O
P O
= O
.027 O
) O
. O
[]

All O
patients O
were O
undergoing O
conventional O
treatment O
of O
CF O
. O
[]

Random O
effects O
models O
were O
used O
to O
examine O
differences O
between O
groups O
over O
time O
. O
[]

Effect O
of O
postmenopausal O
hormonal O
replacement O
therapy O
on O
mammographic B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
and O
parenchymal B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
AND O
PURPOSE O
Lasting O
stability B-outcome ['Physiological-Clinical']
of O
cementless O
implants O
depends O
on O
osseointegration O
into O
the O
implant O
surface O
, O
and O
long-term O
implant O
fixation O
can O
be O
predicted O
using O
radiostereometric O
analysis O
( O
RSA O
) O
with O
short-term O
follow-up O
. O
['Physiological-Clinical']

A O
prospective O
randomized O
trial O
of O
topical O
pimecrolimus O
for O
cetuximab-associated O
acnelike O
eruption O
. O
[]

Fifteen O
subjects O
participated O
in O
the O
experiment O
. O
[]

The O
in O
vitro O
assay O
showed O
similar O
solubility B-outcome ['Physiological-Clinical']
after O
the O
in O
vitro O
digestion O
and O
similar O
transport O
across O
Caco-2 O
cells O
. O
['Physiological-Clinical']

This O
study O
evaluated O
a O
tailored O
intervention O
to O
promote O
sun O
protection O
in O
parents O
and O
their O
children O
, O
hypothesizing O
that O
the O
tailored O
intervention O
would O
lead O
to O
improved O
skin B-outcome ['Life-Impact']
cancer I-outcome ['Life-Impact']
prevention I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
compared O
to O
generic O
materials O
. O
['Life-Impact']

Such O
cancers O
are O
potentially O
curable B-outcome ['Physiological-Clinical']
in O
at O
least O
80 O
% O
of O
cases O
detected O
at O
first O
visit O
and O
in O
97 O
% O
of O
cases O
at O
follow-up O
. O
['Physiological-Clinical']

The O
separate O
and O
combined O
effects O
of O
dietary O
energy O
and O
sodium O
restriction O
on O
regulation O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
investigated O
in O
30 O
middle O
aged O
obese O
men O
with O
essential O
hypertension O
attending O
the O
outpatient O
department O
. O
['Physiological-Clinical']

No O
patients O
were O
lost O
to O
follow-up O
. O
[]

Nine O
therapists O
were O
studied O
: O
three O
performed O
supportive-expressive O
psychotherapy O
; O
three O
, O
cognitive-behavioral O
psychotherapy O
; O
and O
three O
, O
drug O
counseling O
. O
[]

The O
survival O
was O
similar O
to O
that O
of O
transthoracic O
approach O
. O
[]

Results O
indicate O
that O
risperidone O
does O
decrease O
destructive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
and O
that O
, O
for O
the O
most O
part O
, O
all O
of O
the O
various O
measures O
yielded O
similar O
results O
. O
['Life-Impact']

Reoperation O
was O
required O
in O
2 O
( O
4.1 O
% O
) O
and O
1 O
( O
2.1 O
% O
) O
cases O
in O
the O
PlasmaKinetic O
and O
TURP O
groups O
, O
respectively O
. O
[]

OBJECTIVE O
To O
determine O
the O
effect O
of O
a O
postural O
support O
nappy O
and/or O
a O
postural O
support O
roll O
on O
neuromotor B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
very O
preterm O
infants O
when O
nursed O
prone O
to O
term O
equivalent O
age O
. O
['Physiological-Clinical']

Exercise O
consisted O
of O
20 O
minutes O
of O
trotting O
on O
a O
treadmill O
( O
4 O
m/s O
) O
, O
3 O
days O
per O
week O
for O
13 O
weeks O
. O
[]

INTERVENTION O
Thirty O
patients O
were O
treated O
with O
a O
simple O
shoulder O
sling O
and O
30 O
patients O
with O
ESIN O
within O
3 O
days O
after O
trauma O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
monocyte I-outcome ['Physiological-Clinical']
chemoattractant I-outcome ['Physiological-Clinical']
protein-1 I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
albumin-to-creatinine I-outcome ['Physiological-Clinical']
ratio O
and O
monocyte B-outcome ['Physiological-Clinical']
chemoattractant B-outcome ['Physiological-Clinical']
protein-1 I-outcome ['Physiological-Clinical']
were O
measured O
at O
baseline O
and O
16 O
wk O
after O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

depot O
MPA O
injections O
provides O
significant O
and O
long-lasting O
relief B-outcome ['Physiological-Clinical']
from O
postmenopausal B-outcome ['Physiological-Clinical']
hot I-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
in O
patients O
with O
a O
history O
of O
breast O
cancer O
, O
offering O
an O
alternative O
to O
estrogen O
replacement O
therapy O
or O
prolonged O
administration O
of O
oral O
megestrol O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Among O
the O
608 O
women O
diagnosed O
with O
CIN3 O
, O
601 O
( O
98.8 O
% O
) O
cases O
were O
positive O
for O
any O
HPV O
genotype O
and O
95.4 O
% O
for O
any O
carcinogenic B-outcome ['Physiological-Clinical']
HPV I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
After O
rTMS O
treatment O
RMT B-outcome ['Physiological-Clinical']
was O
decreased O
by O
about O
1 O
% O
of O
stimulator O
output O
near-significantly O
in O
the O
whole O
group O
of O
patients O
. O
['Physiological-Clinical']

Bupropion O
SR O
effects O
on O
point-prevalence O
abstinence B-outcome ['Life-Impact']
at O
1 O
month O
post-quit O
were O
also O
mediated O
partially O
by O
enhanced O
motivation O
to O
quit O
and O
self-efficacy O
. O
['Life-Impact']

All O
had O
mental B-outcome ['Life-Impact']
retardation I-outcome ['Life-Impact']
and O
persisting B-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

In O
a O
randomized O
, O
double-masked O
study O
of O
glaucoma O
patients O
, O
over O
60 O
years O
of O
age O
, O
without O
history O
of O
bronchospasm O
and O
who O
were O
using O
timolol O
( O
0.5 O
% O
) O
, O
60 O
patients O
were O
allocated O
to O
betaxolol O
( O
0.5 O
% O
) O
or O
carteolol O
( O
2 O
% O
) O
or O
continued O
timolol O
( O
0.5 O
% O
) O
treatment O
. O
[]

PATIENTS O
AND O
METHODS O
Ninety-two O
patients O
with O
advanced O
breast O
cancer O
received O
arzoxifene O
20 O
or O
50 O
mg/day O
. O
[]

Seven O
patients O
lost O
to O
follow O
up O
were O
not O
considered O
in O
the O
analysis O
. O
[]

The O
primary O
end O
point O
was O
the O
proportion O
of O
patients O
achieving O
clinical O
improvement O
( O
> O
or O
=3 O
point O
improvement O
in O
MMDAI O
) O
and O
improvement O
in O
rectal O
bleeding O
( O
> O
or O
=1 O
point O
improvement O
) O
at O
8 O
weeks O
. O
[]

When O
compared O
with O
control O
subjects O
, O
both O
hemodialysis O
and O
CAPD O
patients O
had O
significantly O
lower O
IMg2+ B-outcome ['Physiological-Clinical']
( O
0.55 O
+/- O
0.02 O
and O
0.50 O
+/- O
0.02 O
vs. O
0.60 O
+/- O
0.004 O
mM/L O
; O
p O
< O
0.05 O
) O
and O
greater O
or O
normal O
TMg O
values O
( O
0.99 O
+/- O
0.04 O
, O
different O
at O
the O
p O
< O
0.001 O
level O
, O
and O
0.85 O
+/- O
0.04 O
vs. O
0.84 O
+/- O
0.008 O
) O
. O
['Physiological-Clinical']

Subsequent O
attendance O
at O
the O
GP O
, O
but O
not O
at O
a O
hospital O
, O
was O
associated O
with O
risk O
level O
, O
but O
differences O
between O
centres O
could O
not O
be O
analysed O
. O
[]

Septicemia B-outcome ['Physiological-Clinical']
occurred O
in O
15.5 O
percent O
of O
the O
immune O
globulin O
recipients O
and O
17.2 O
percent O
of O
the O
controls O
. O
['Physiological-Clinical']

Fifteen O
patients O
underwent O
a O
third O
course O
of O
interferon O
therapy O
at O
a O
median O
time O
after O
completion O
of O
a O
second O
course O
of O
IFN O
of O
1.0 O
year O
. O
[]

hsCRP O
measurement O
should O
be O
performed O
early O
after O
presentation O
and O
index O
diagnosis-specific O
cutpoints O
should O
be O
used O
. O
[]

Mean O
pain B-outcome ['Physiological-Clinical']
assessment O
by O
subjects O
was O
3.6 O
for O
HA+lidocaine O
and O
5.8 O
for O
HA O
alone O
( O
p O
< O
.001 O
) O
. O
['Physiological-Clinical']

RESULTS O
Of O
the O
1603 O
patients O
with O
PRO O
data O
, O
105 O
had O
a O
recurrence O
and O
342 O
had O
a O
complication O
at O
2 O
years O
. O
[]

Major O
bleeding O
was O
observed O
only O
in O
UFH O
( O
3.0 O
% O
) O
, O
while O
minor B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
occurred O
in O
ARG350 O
( O
3.2 O
% O
) O
and O
UFH O
( O
6.1 O
% O
, O
n.s. O
) O
. O
['Physiological-Clinical']

RESULTS O
Both O
parameters O
were O
reduced O
in O
all O
five O
regimens O
as O
against O
the O
control O
. O
[]

In O
the O
intervention O
group O
, O
median O
nodule B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
at O
baseline O
was O
8.2 O
ml O
( O
range O
2.8-26.9 O
) O
and O
was O
not O
significantly O
different O
from O
that O
of O
the O
control O
group O
. O
['Physiological-Clinical']

In O
the O
five O
patients O
who O
received O
fat O
emulsion O
into O
the O
ECMO O
circuit O
, O
three O
had O
layering O
out O
of O
the O
emulsion O
and O
agglutination B-outcome ['Physiological-Clinical']
, O
and O
all O
developed O
clots B-outcome ['Physiological-Clinical']
in O
the O
circuit O
despite O
adequate O
anticoagulation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
results O
show O
that O
a O
significant O
gain O
in O
bone B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
can O
be O
achieved O
by O
administration O
of O
calcitonin O
, O
either O
daily O
or O
on O
alternate O
days O
. O
['Physiological-Clinical']

Pre-treatment O
proliferation O
and O
the O
outcome O
of O
conventional O
and O
accelerated O
radiotherapy O
. O
[]

Patients O
and O
investigators O
were O
masked O
to O
treatment O
. O
[]

It O
is O
concluded O
that O
nitrous O
oxide O
does O
not O
contribute O
to O
the O
occurrence O
of O
nausea B-outcome ['Physiological-Clinical']
or O
vomiting B-outcome ['Physiological-Clinical']
after O
isoflurane O
anesthesia O
for O
gynecologic O
laparotomies O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Following O
completion O
of O
our O
ongoing O
RCT O
designed O
to O
test O
these O
materials O
, O
our O
goal O
will O
be O
to O
develop O
a O
dissemination O
project O
for O
the O
more O
effective O
tool O
. O
[]

Pharmacokinetics O
and O
pharmacodynamics O
of O
intravenous O
diltiazem O
in O
patients O
with O
atrial O
fibrillation O
or O
atrial O
flutter O
. O
[]

OBJECTIVES O
To O
compare O
the O
efficacy O
and O
safety O
of O
polymyxin O
sulfate O
7500 O
IU/neomycin O
sulfate O
3500 O
IU/dexamethasone O
phosphate O
0.1 O
% O
( O
PN+Dx O
) O
otic O
solution O
with O
polymyxin O
sulfate O
7500 O
IU/neomycin O
sulfate O
3500 O
IU O
( O
PN-Dx O
) O
in O
patients O
with O
acute O
bacterial O
otitis O
externa O
( O
AOE O
) O
, O
in O
order O
to O
determine O
the O
possible O
benefit O
of O
the O
addition O
of O
dexamethasone O
. O
[]

Patients O
were O
randomized O
to O
receive O
G-CSF O
5 O
micro O
g/kg/day O
( O
n=38 O
, O
group O
A O
) O
or O
10 O
micro O
g/kg/day O
( O
n=39 O
, O
group O
B O
) O
from O
day O
+1 O
to O
day O
+30 O
. O
[]

They O
do O
, O
however O
, O
reduce O
the O
symptom B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
breathlessness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

B-type O
natriuretic O
peptide O
for O
acute O
dyspnea O
in O
patients O
with O
kidney O
disease O
: O
insights O
from O
a O
randomized O
comparison O
. O
[]

There O
was O
a O
dose-dependent O
increase O
in O
dietary O
and O
urinary O
flavonoids O
in O
the O
HF O
group O
, O
with O
no O
change O
in O
other O
groups O
( O
P O
= O
0.0001 O
) O
. O
[]

Especially O
for O
patients O
with O
pulmonary O
tuberculosis O
or O
aged O
patients O
with O
primary O
bladder O
tumors O
, O
mitoxantrone O
and O
doxorubicin O
may O
be O
the O
tolerable O
and O
effective O
intravesical O
agents O
. O
[]

Thirty-two O
extracted O
mandibular O
first O
premolars O
were O
sectioned O
perpendicular O
to O
the O
long O
axis O
at O
a O
point O
1.0 O
mm O
occlusal O
to O
the O
buccal O
cementoenamel O
junction O
. O
[]

The O
authors O
asked O
whether O
animals O
and O
humans O
would O
use O
similarly O
an O
uncertain O
response O
to O
escape O
indeterminate O
memories O
. O
[]

Only O
one O
drop O
per O
eye O
of O
each O
drug O
was O
administered O
. O
[]

BACKGROUND O
Peripheral O
sensory O
neurotoxicity O
is O
a O
frequent O
and O
potentially O
debilitating O
side O
effect O
of O
oxaliplatin O
treatment O
. O
[]

The O
primary O
outcome O
was O
the O
incidence O
of O
low O
cardiac O
output O
syndrome O
( O
standardized O
score O
) O
or O
death O
36 O
hours O
postoperatively O
. O
[]

BACKGROUND O
AND O
STUDY O
AIMS O
Endoscopic O
submucosal O
dissection O
( O
ESD O
) O
has O
become O
a O
standard O
treatment O
. O
[]

We O
sought O
to O
determine O
whether O
preoperative O
methylprednisolone O
would O
improve O
postoperative O
recovery O
in O
neonates O
requiring O
cardiac O
surgery O
. O
[]

Patients O
should O
show O
sufficient O
response O
during O
the O
dose-titration O
period O
( O
> O
or O
=20 O
% O
reduction O
in O
nocturnal O
diuresis O
) O
and O
a O
return O
of O
nocturnal O
diuresis O
to O
> O
or O
=80 O
% O
of O
baseline O
levels O
during O
washout O
. O
[]

All O
patients O
received O
protocol-based O
systemic O
and O
intrathecal O
chemotherapy O
. O
[]

BACKGROUND/AIMS O
Transthoracic O
and O
transhiatal O
esophagectomy O
are O
two O
common O
procedures O
for O
esophageal O
cancer O
resection O
. O
[]

Possible B-outcome ['Adverse-effects']
drug-related I-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
in O
13 O
patients O
[ O
ciprofloxacin O
, O
8 O
( O
8 O
% O
) O
; O
ceftriaxone O
, O
5 O
( O
4.7 O
% O
) O
] O
and O
were O
mild O
and O
transient O
. O
['Adverse-effects']

OBJECTIVES O
To O
compare O
the O
clinical O
efficacy O
and O
safety O
of O
mizolastine O
with O
loratadine O
and O
placebo O
in O
patients O
with O
chronic O
idiopathic O
urticaria O
( O
CIU O
) O
. O
[]

Point O
estimates O
( O
90 O
% O
CI O
) O
were O
0.97 O
( O
0.84 O
, O
1.13 O
) O
for O
the O
AUC O
of O
i.v O
. O
[]

The O
study O
took O
place O
in O
four O
intervention O
and O
six O
control O
neighborhoods O
in O
Seattle O
. O
[]

In O
the O
remaining O
patients O
with O
lateral O
tumors O
, O
survival B-outcome ['Mortality']
rates O
were O
unaffected O
by O
treatment O
: O
58 O
% O
( O
+/- O
13 O
% O
) O
and O
56 O
% O
( O
+/- O
11 O
% O
) O
, O
respectively O
( O
P O
= O
0.62 O
) O
. O
['Mortality']

In O
a O
randomized O
, O
placebo O
controlled O
trial O
, O
eleven O
healthy O
volunteers O
were O
studied O
during O
4 O
separate O
study O
periods O
of O
4 O
days O
each O
. O
[]

Viral B-outcome ['Physiological-Clinical']
replication I-outcome ['Physiological-Clinical']
as O
measured O
by O
human B-outcome ['Physiological-Clinical']
immunodeficiency I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HIV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
p24 I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Ag I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
decreased O
in O
four O
patients O
in O
each O
group O
, O
increased O
in O
one O
patient O
in O
each O
group O
, O
and O
remained O
unchanged O
in O
the O
remainder O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
was O
raised O
in O
the O
last O
trimester O
of O
pregnancy O
in O
both O
normotensive O
and O
hypertensive O
patients O
. O
['Physiological-Clinical']

A O
comparison O
of O
home O
measurement O
and O
ambulatory O
monitoring O
of O
blood O
pressure O
in O
the O
adjustment O
of O
antihypertensive O
treatment O
. O
[]

Although O
all O
patients O
claimed O
to O
be O
continent O
, O
two O
patients O
from O
each O
group O
had O
ultrasonic O
evidence O
of O
internal B-outcome ['Physiological-Clinical']
sphincter I-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

After O
the O
waitlist O
period O
, O
those O
participants O
joined O
a O
LM O
group O
and O
received O
payment O
for O
behavioral O
change O
( O
CM O
( O
behavior O
) O
) O
. O
[]

CONCLUSION O
Intraoperative O
application O
of O
fibrin O
glue O
did O
not O
reduce O
the O
rate O
of O
postoperative B-outcome ['Physiological-Clinical']
lymphocysts I-outcome ['Physiological-Clinical']
after O
lymphadenectomy O
and O
had O
no O
impact B-outcome ['Life-Impact']
on O
any O
follow-up O
parameter O
. O
['Physiological-Clinical', 'Life-Impact']

Fluvoxamine O
was O
superior O
to O
placebo O
in O
reducing O
repetitive B-outcome ['Life-Impact']
thoughts I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
( O
P O
< O
.001 O
) O
, O
maladaptive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
( O
P O
< O
.001 O
) O
, O
and O
aggression B-outcome ['Life-Impact']
( O
P O
< O
.03 O
) O
, O
and O
in O
improving O
some O
aspects O
of O
social B-outcome ['Life-Impact']
relatedness I-outcome ['Life-Impact']
( O
P O
< O
.04 O
) O
, O
especially O
language B-outcome ['Life-Impact']
usage I-outcome ['Life-Impact']
( O
P O
< O
.008 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Murine O
embryos O
grown O
in O
the O
presence O
of O
lipoprotein O
free O
SSS O
showed O
significantly O
accelerated O
( O
P O
< O
0.01 O
) O
growth O
at O
17 O
hr O
postthaw O
compared O
to O
Plasmatein O
and O
all O
embryos O
progressed O
to O
[]

In O
the O
placebo O
group O
concentrations B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
eosinophil I-outcome ['Physiological-Clinical']
cationic I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
and O
exhaled B-outcome ['Physiological-Clinical']
nitric I-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
increased O
( O
p O
= O
0.007 O
and O
p O
= O
0.025 O
, O
respectively O
) O
, O
compared O
with O
no O
change O
in O
the O
ONO-1078 O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Under O
normoglycemic O
conditions O
, O
there O
were O
no O
differences O
between O
theophylline O
and O
placebo O
. O
[]

METHODS O
A O
total O
of O
50 O
patients O
( O
100 O
eyes O
) O
scheduled O
for O
fundoscopy O
were O
dilated O
with O
phenylephrine O
10 O
% O
and O
yropicamide O
1 O
% O
( O
group O
0 O
: O
n O
= O
20 O
type O
2 O
diabetic O
patients O
, O
40 O
eyes O
, O
and O
group O
1 O
: O
n O
= O
30 O
non-diabetic O
patients O
, O
60 O
eyes O
) O
. O
[]

Gains O
correlated O
significantly O
with O
the O
number O
of O
times O
the O
computer O
program O
was O
used O
and O
results O
suggest O
positive O
effects O
. O
[]

Considering O
growth O
over O
all O
3 O
measurement O
periods O
, O
an O
exploratory O
analysis O
showed O
that O
growth O
rate O
of O
the O
number O
of O
different B-outcome ['Life-Impact']
nonimitative I-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
was O
faster B-outcome ['Physiological-Clinical']
in O
the O
PECS O
group O
than O
in O
the O
RPMT O
group O
for O
children O
who O
began O
treatment O
with O
relatively O
high O
object O
exploration O
. O
['Life-Impact', 'Physiological-Clinical']

Sixty-one O
patients O
were O
randomised O
to O
treatment O
: O
30 O
to O
quinapril O
and O
31 O
to O
captopril O
. O
[]

Comparison O
of O
the O
effect O
of O
intra-arterial O
versus O
intravenous O
heparin O
on O
radial O
artery O
occlusion O
after O
transradial O
catheterization O
. O
[]

OBJECTIVE O
The O
safety O
and O
efficacy O
of O
gemcitabine O
plus O
carboplatin O
( O
GC O
) O
or O
paclitaxel O
plus O
carboplatin O
( O
TC O
) O
induction O
regimens O
with O
or O
without O
paclitaxel O
consolidation O
therapy O
were O
assessed O
in O
ovarian O
cancer O
( O
OC O
) O
. O
[]

METHODS O
We O
conducted O
a O
double-blind O
, O
placebo-controlled O
trial O
of O
a O
single O
intravenous O
dose O
of O
synthetic O
human O
secretin O
in O
60 O
children O
( O
age O
, O
3 O
to O
14 O
years O
) O
with O
autism O
or O
pervasive O
developmental O
disorder O
. O
[]

DESIGN O
A O
prospective O
, O
randomized O
, O
clinical O
study O
. O
[]

BACKGROUND O
Standardised O
measures O
of O
behaviour B-outcome ['Life-Impact']
have O
failed O
to O
detect O
short O
term O
improvement O
in O
children O
with O
autism O
following O
treatment O
with O
secretin O
. O
['Life-Impact']

In O
addition O
, O
by O
Poisson O
analysis O
, O
comparison O
of O
cell O
counts O
analyzed O
as O
a O
ratio O
of O
active O
to O
placebo O
demonstrated O
reductions O
of O
CD8+ B-outcome ['Physiological-Clinical']
( O
48 O
% O
p O
< O
0.01 O
) O
and O
CD68+ B-outcome ['Physiological-Clinical']
( O
47 O
% O
p O
= O
0.001 O
) O
cells O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
the O
R3 O
courses O
, O
the O
number O
of O
days O
with O
fever O
and O
intravenous B-outcome ['Resource-use']
antibiotics I-outcome ['Resource-use']
and O
duration B-outcome ['Resource-use']
of O
hospitalization I-outcome ['Resource-use']
were O
significantly O
decreased O
by O
G-CSF O
, O
whereas O
reductions O
observed O
after O
COPADM O
were O
not O
statistically O
significant O
. O
['Physiological-Clinical', 'Resource-use']

Each O
patient O
underwent O
panretinal O
photocoagulation O
: O
one O
eye O
with O
GLX O
and O
the O
other O
with O
PASCAL O
, O
two O
sittings O
per O
eye O
. O
[]

There O
was O
additional O
improvement O
in O
the O
open-label B-outcome ['Physiological-Clinical']
somnolog I-outcome ['Physiological-Clinical']
measures I-outcome ['Physiological-Clinical']
of O
sleep B-outcome ['Physiological-Clinical']
efficiency I-outcome ['Physiological-Clinical']
and O
the O
longest B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
episode I-outcome ['Physiological-Clinical']
in O
the O
open-label O
phase O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Successful O
treatment O
of O
depressed O
, O
distensible O
acne O
scars O
using O
autologous O
fibroblasts O
: O
a O
multi-site O
, O
prospective O
, O
double O
blind O
, O
placebo-controlled O
clinical O
trial O
. O
[]

CONCLUSIONS O
In O
patients O
with O
heart O
failure O
and O
a O
preserved O
ejection O
fraction O
, O
treatment O
with O
spironolactone O
did O
not O
significantly O
reduce O
the O
incidence O
of O
the O
primary O
composite O
outcome O
of O
death O
from O
cardiovascular O
causes O
, O
aborted O
cardiac O
arrest O
, O
or O
hospitalization O
for O
the O
management O
of O
heart O
failure O
. O
( O
[]

Randomized O
trial O
of O
fenretinide O
in O
superficial O
bladder O
cancer O
using O
DNA O
flow O
cytometry O
as O
an O
intermediate O
end O
point O
. O
[]

METHODS O
A O
retrospective O
radiographic O
review O
of O
218 O
unstable O
fractures O
was O
performed O
. O
[]

CONCLUSIONS O
A O
significant O
decline O
in O
GSH-glutathione B-outcome ['Physiological-Clinical']
disulfide I-outcome ['Physiological-Clinical']
, O
cysteine-cystine B-outcome ['Physiological-Clinical']
, O
and O
vitamin B-outcome ['Physiological-Clinical']
E I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
occurs O
after O
chemotherapy O
and O
BMT O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
statistically O
significant O
changes O
in O
lipid B-outcome ['Physiological-Clinical']
variables O
between O
the O
different O
regimens O
. O
['Physiological-Clinical']

The O
changes O
in O
lipid B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
induced O
by O
fasting O
alone O
or O
pegvisomant O
were O
not O
different O
from O
those O
induced O
by O
pegvisomant O
alone O
. O
['Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Eighty-seven O
were O
enrolled O
and O
randomized O
. O
[]

The O
criteria O
for O
recovery O
were O
corneal O
transparency O
with O
stable O
epithelial B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
and O
no O
abnormal B-outcome ['Physiological-Clinical']
proliferation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pterygium-like I-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Studies O
have O
shown O
that O
a O
majority O
of O
women O
with O
a O
family O
history O
of O
breast O
cancer O
have O
exaggerated O
perceptions O
of O
their O
own O
risk O
of O
this O
disease O
and O
experience O
excessive O
anxiety O
. O
[]

The O
higher O
reoperation B-outcome ['Resource-use']
rate O
was O
found O
in O
the O
group O
without O
acromioplasty O
. O
['Resource-use']

RESULTS O
Demographic O
data O
, O
ASA O
classification O
and O
duration O
of O
surgery O
were O
similar O
in O
both O
groups O
. O
[]

Appropriate O
technical O
support O
and O
training O
must O
be O
ensured O
to O
address O
equipment O
maintenance O
. O
[]

Women O
were O
randomly O
assigned O
to O
receive O
( O
1 O
) O
a O
mail O
reminder O
, O
( O
2 O
) O
a O
telephone O
reminder O
, O
or O
( O
3 O
) O
routine O
publicity O
on O
mammography O
for O
all O
women O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
prospectively O
the O
depiction O
of O
hypervascular B-outcome ['Physiological-Clinical']
hepatocellular I-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
on O
64-MDCT O
scans O
obtained O
with O
contrast O
agents O
of O
varying O
iodine O
concentrations O
administered O
with O
and O
without O
saline O
flush O
. O
['Physiological-Clinical']

In O
this O
double-blind O
study O
, O
we O
randomised O
98 O
patients O
to O
receive O
cophenylcaine O
or O
placebo O
nasal O
spray O
before O
flexible O
nasendoscopy O
. O
[]

The O
correlations O
with O
symptom O
scores O
were O
comparable O
for O
both O
questionnaires O
. O
[]

However O
, O
these O
programs O
are O
expensive O
. O
[]

Kaplan-Meier O
survival O
estimates O
showed O
a O
better O
outcome O
for O
patients O
with O
a O
large B-outcome ['Physiological-Clinical']
inotropic I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
( O
DeltaWMSI O
> O
or O
=0.44 O
, O
a O
cutoff O
identified O
by O
receiver-operating O
characteristic O
curves O
analysis O
) O
than O
for O
those O
with O
a O
small O
or O
no O
myocardial O
inotropic O
response O
to O
dobutamine O
( O
93.6 O
% O
vs O
69.4 O
% O
, O
p O
= O
0.00033 O
) O
. O
['Physiological-Clinical']

Mean O
followup O
was O
5.96 O
years O
in O
the O
2 O
groups O
. O
[]

OBJECTIVE O
To O
study O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
markers B-outcome ['Physiological-Clinical']
in O
women O
taking O
estradiol/trimegestone O
or O
estradiol/dydrogesterone O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Treatment O
group O
patients O
attended O
three O
relaxation-training O
sessions O
and O
received O
an O
audio O
disc O
for O
home O
practice O
. O
[]

We O
also O
sought O
to O
determine O
the O
incidence O
of O
scars O
resulting O
from O
skin O
scoring O
. O
[]

For O
example O
, O
after O
two O
weeks O
of O
peroxide O
gel O
use O
prior O
to O
SRP O
, O
mean O
PPD B-outcome ['Physiological-Clinical']
decreased O
by O
0.48 O
mm O
for O
the O
test O
group O
compared O
to O
0.04 O
mm O
for O
the O
control O
. O
['Physiological-Clinical']

There O
were O
no O
statistically O
significant O
differences O
at O
endpoint O
among O
the O
three O
fluticasone O
propionate O
groups O
. O
[]

In O
vivo O
: O
with O
Institutional O
Review O
Board O
approval O
, O
CPRV O
was O
studied O
in O
50 O
children O
undergoing O
general O
anaesthesia O
with O
tracheal O
intubation O
and O
standardized O
anaesthesia O
technique O
( O
including O
66 O
% O
N2O O
in O
O2 O
) O
and O
ventilator O
settings O
. O
[]

All O
values O
returned O
to O
baseline O
conditions O
1 O
h O
after O
permissive O
hypercapnia O
was O
terminated O
. O
[]

The O
11-beta-hydroxysteroid O
dehydrogenase O
type O
1 O
inhibitor O
INCB13739 O
improves O
hyperglycemia B-outcome ['Physiological-Clinical']
in O
patients O
with O
type O
2 O
diabetes O
inadequately O
controlled O
by O
metformin O
monotherapy O
. O
['Physiological-Clinical']

The O
control O
group O
complete O
effective O
and O
partial O
effective O
were O
4.6 O
% O
and O
13.6 O
% O
( O
P O
< O
0.05 O
) O
. O
[]

METHODS O
We O
prospectively O
evaluated O
the O
association O
between O
baseline O
BMI O
and O
the O
risk O
of O
incident B-outcome ['Physiological-Clinical']
distal I-outcome ['Physiological-Clinical']
adenoma I-outcome ['Physiological-Clinical']
( O
1,213 O
cases O
) O
, O
recurrent B-outcome ['Physiological-Clinical']
adenoma I-outcome ['Physiological-Clinical']
( O
752 O
cases O
) O
, O
and O
incident B-outcome ['Physiological-Clinical']
colorectal I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
( O
966 O
cases O
) O
among O
men O
and O
women O
, O
ages O
55 O
to O
74 O
years O
, O
randomly O
assigned O
to O
receive O
flexible O
sigmoidoscopy O
screening O
as O
part O
of O
the O
Prostate O
, O
Lung O
, O
Colorectal O
, O
and O
Ovarian O
Cancer O
Screening O
Trial O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
vitro O
biocompatibility O
tests O
of O
glass O
ionomer O
cements O
impregnated O
with O
collagen O
or O
bioactive O
glass O
to O
fibroblasts O
. O
[]

On O
the O
other O
hand O
, O
those O
with O
a O
negative O
angiogram O
received O
only O
EVL O
. O
[]

The O
statistical O
evaluation O
of O
the O
Cmin O
values O
indicated O
that O
steady B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
of O
BMS-181101 O
was O
achieved O
by O
the O
fourth O
day O
of O
dosing O
regardless O
of O
whether O
the O
subject O
was O
fasted O
or O
fed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eighty O
injections O
were O
randomly O
administered O
in O
the O
study O
, O
40 O
using O
topical O
anesthetic O
gel O
and O
40 O
using O
a O
placebo O
gel O
. O
[]

The O
patient B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
both O
studies O
( O
at O
24 O
months O
in O
the O
first O
; O
at O
19 O
in O
the O
second O
) O
was O
better O
in O
the O
control O
than O
that O
in O
the O
experimental O
groups O
( O
43 O
% O
to O
31 O
% O
; O
69 O
% O
to O
46 O
% O
) O
. O
['Mortality']

Forty O
women O
, O
aged O
26-40 O
years O
, O
were O
investigated O
with O
regard O
to O
gastric O
contents O
and O
pH O
before O
general O
anaesthesia O
. O
[]

We O
conclude O
that O
there O
is O
no O
utility O
for O
TENS O
in O
the O
postoperative O
management O
of O
pain O
after O
knee O
arthroplasty O
. O
[]

There O
was O
no O
significant O
difference O
in O
urine B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
mean O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
between O
two O
groups O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical', 'Resource-use']

All O
patients O
were O
recommended O
to O
maintain O
a O
low O
fat O
diet O
. O
[]

In O
Experiment O
1 O
, O
a O
series O
of O
prime-target O
pairs O
was O
presented O
auditorily O
, O
and O
participants O
were O
asked O
to O
make O
a O
lexical O
decision O
on O
the O
target O
word O
. O
[]

Treatment O
sites O
( O
n O
= O
10 O
) O
received O
a O
periodontal O
formulation O
of O
minocycline O
hydrochloride O
, O
placebo O
sites O
( O
5 O
) O
received O
ointment O
without O
minocycline O
, O
and O
control O
sites O
( O
5 O
) O
did O
not O
receive O
ointment O
. O
[]

This O
effect O
was O
seen O
only O
during O
supine O
sleep O
and O
non-rapid O
eye O
movement O
sleep O
and O
was O
absent O
in O
non-supine O
sleep O
, O
rapid O
eye O
movement O
sleep O
, O
and O
during O
periods O
of O
wakefulness O
. O
[]

These O
results O
support O
recent O
approaches O
to O
apply O
OT O
as O
a O
pharmacological O
treatment O
of O
ASD O
symptoms O
. O
[]

The O
levels O
of O
PGE-M B-outcome ['Physiological-Clinical']
excreted I-outcome ['Physiological-Clinical']
in O
urine O
were O
higher O
( O
p O
less O
than O
0.001 O
) O
in O
males O
than O
in O
females O
( O
15.2 O
+/- O
1.9 O
mug/24 O
hours O
( O
n=24 O
) O
and O
3.3 O
+/- O
0.3 O
mug/24 O
hours O
( O
n=17 O
) O
, O
respectively O
. O
['Physiological-Clinical']

Patients O
with O
complete B-outcome ['Physiological-Clinical']
response O
( O
CR B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Different O
loss O
of O
BMD B-outcome ['Physiological-Clinical']
using O
uncemented O
press-fit O
and O
whole O
polyethylene O
cups O
fixed O
with O
cement O
: O
repeated O
DXA O
studies O
in O
96 O
hips O
randomized O
to O
3 O
types O
of O
fixation O
. O
['Physiological-Clinical']

Tolerance O
of O
the O
drug O
was O
generally O
excellent O
. O
[]

RESULTS O
Two O
hundred O
forty-four O
patients O
( O
125 O
women O
, O
119 O
men O
; O
all O
but O
1 O
Hispanic O
) O
were O
randomized O
to O
receive O
pioglitazone O
( O
n O
= O
121 O
) O
or O
glimepiride O
( O
n O
= O
123 O
) O
. O
[]

Forty-two O
percent O
of O
cisplatin O
patients O
completed O
the O
3 O
cycles O
of O
adjuvant B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
compared O
to O
70 O
% O
in O
the O
carboplatin O
group O
. O
['Resource-use']

The O
difference O
in O
proportions O
, O
TISSEEL O
VH O
S/D O
minus O
TISSEEL O
VH O
, O
was O
1.4 O
% O
with O
a O
standard O
error O
of O
3.70 O
% O
. O
[]

The O
primary O
end O
point O
of O
death B-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
or O
target B-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TVR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
analyzed O
as O
time-to-first O
event O
within O
9 O
months O
of O
the O
index O
PCI O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

From O
1985 O
to O
1987 O
80 O
patients O
with O
acute O
cardiogenic O
pulmonary O
edema O
were O
randomly O
chosen O
to O
receive O
either O
serial O
CPAP O
therapy O
or O
high-flow O
face O
mask O
oxygen O
therapy O
without O
CPAP O
( O
control O
) O
for O
the O
purpose O
of O
evaluating O
the O
efficacy O
of O
CPAP O
therapy O
. O
[]

PURPOSE O
Obesity O
has O
consistently O
been O
linked O
to O
an O
increased O
risk O
of O
colorectal B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
, O
particularly O
among O
men O
. O
['Physiological-Clinical']

METHOD O
The O
cost-effectiveness O
analysis O
was O
part O
of O
a O
randomized-controlled O
trial O
with O
a O
sample O
size O
of O
175 O
, O
of O
which O
89 O
were O
in O
the O
nursing-led O
inpatient O
unit O
arm O
and O
86 O
in O
the O
control O
arm O
. O
['Resource-use']

This O
has O
implications O
for O
e-learning O
design O
in O
medicine O
and O
other O
disciplines O
. O
[]

Second O
, O
delusional O
patients O
took O
significantly O
longer O
than O
both O
other O
groups O
to O
correctly B-outcome ['Life-Impact']
classify I-outcome ['Life-Impact']
neutral I-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
in O
both O
affective O
classification O
tasks O
. O
['Life-Impact']

Therefore O
, O
home O
visit O
education O
and O
invitation O
intervention O
produced O
only O
a O
nominal O
effect O
on O
increasing O
Pap O
smear O
coverage O
within O
a O
4-month O
study O
period O
. O
[]

METHODS O
Forty-one O
adolescents O
( O
11-17 O
years O
) O
participated O
in O
this O
prospective O
randomized O
controlled O
trial O
. O
[]

The O
relative O
risk O
( O
RR B-outcome ['Physiological-Clinical']
) O
of O
developing O
PIPN O
was O
significantly O
higher O
in O
controls O
than O
in O
vitamin O
E O
group O
patients O
( O
RR=0.3 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
=0.1-0.9 O
) O
. O
['Physiological-Clinical']

RESULTS O
At O
6 O
months O
postoperatively O
, O
UCVA B-outcome ['Physiological-Clinical']
was O
20/25 O
or O
better O
in O
100 O
% O
of O
the O
eyes O
. O
['Physiological-Clinical']

BDP O
group O
showed O
a O
significant O
improvement O
in O
FEV1 B-outcome ['Physiological-Clinical']
and O
bronchial B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
to O
methacholine O
after O
6 O
and O
12 O
months O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eradication B-outcome ['Physiological-Clinical']
rate O
of O
3 O
day O
, O
6 O
day O
and O
7 O
day O
miconazole O
courses O
for O
complicated O
VVC O
at O
day O
35 O
was O
89.7 O
% O
, O
97.3 O
% O
and O
86.8 O
% O
, O
respectively O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

After O
adding O
postoperative O
delayed O
ischemic B-outcome ['Physiological-Clinical']
neurological I-outcome ['Physiological-Clinical']
deficits I-outcome ['Physiological-Clinical']
to O
the O
model O
, O
only O
worsened O
National O
Institutes O
of O
Health O
Stroke B-outcome ['Physiological-Clinical']
Scale O
score O
, O
Barthel O
Activities B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
Daily I-outcome ['Life-Impact']
Living I-outcome ['Life-Impact']
index O
, O
and O
discharge B-outcome ['Life-Impact']
destination I-outcome ['Life-Impact']
( O
home O
versus O
other O
) O
remained O
independently O
associated O
with O
fever O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

The O
purpose O
of O
the O
present O
study O
was O
to O
determine O
the O
appropriate B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
needle O
location O
for O
the O
diagnosis O
of O
a O
traumatic O
knee O
arthrotomy O
and O
to O
assess O
the O
effect O
of O
associated O
variables O
, O
including O
knee O
circumference O
, O
body O
mass O
index O
, O
and O
sex O
. O
['Physiological-Clinical']

BCAR B-outcome ['Physiological-Clinical']
rates O
at O
12 O
months O
were O
not O
significantly O
different O
: O
11.2 O
% O
for O
rCsA O
patients O
and O
16.2 O
% O
for O
sCsA O
patients O
. O
['Physiological-Clinical']

Phase O
II O
study O
of O
the O
effects O
of O
ginger O
root O
extract O
on O
eicosanoids O
in O
colon O
mucosa O
in O
people O
at O
normal O
risk O
for O
colorectal O
cancer O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
two O
operating O
techniques O
in O
terms O
of O
complications O
. O
[]

MATERIAL O
AND O
METHOD O
A O
six-week O
, O
double-blind O
, O
randomized O
, O
placebo-controlled O
, O
multicenter O
study O
was O
carried O
out O
in O
Thailand O
, O
Malaysia O
and O
Singapore O
. O
[]

Pre- O
and O
postinjection O
IOP B-outcome ['Physiological-Clinical']
for O
retrobulbar O
and O
1-QST O
patients O
were O
similar O
. O
['Physiological-Clinical']

Parents O
also O
completed O
4-day O
sun O
exposure O
and O
protection O
diaries O
for O
their O
child O
and O
themselves O
. O
[]

30 O
% O
) O
within O
10 O
weeks O
. O
[]

and O
simultaneously O
an O
infusion O
of O
0.05 O
, O
0.10 O
, O
0.15 O
, O
or O
0.20 O
mg O
propofol/kg O
per O
minute O
was O
started O
. O
[]

The O
urogenital B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
sexuality I-outcome ['Physiological-Clinical']
score O
, O
along O
with O
the O
vaginal B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
index O
and O
the O
vaginal B-outcome ['Physiological-Clinical']
maturation I-outcome ['Physiological-Clinical']
index O
( O
VMI B-outcome ['Physiological-Clinical']
) O
, O
was O
calculated O
at O
the O
beginning O
of O
therapy O
and O
12 O
weeks O
later O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Arginine-vasopressin B-outcome ['Physiological-Clinical']
( O
AVP B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

One O
group O
received O
an O
Fe-fortified O
formula O
( O
1.6 O
mg O
Fe/100 O
kcal O
) O
and O
the O
other O
a O
nonfortified O
formula O
. O
[]

Patients O
evaluated O
the O
severity O
of O
seasonal B-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
daily O
for O
2 O
weeks O
according O
to O
a O
4-point O
scale O
( O
0 O
= O
absent O
, O
1 O
= O
mild O
, O
2 O
= O
moderate O
, O
3 O
= O
severe O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
It O
is O
recommended O
that O
cediranib O
be O
administered O
at O
least O
1 O
h O
before O
or O
2 O
h O
after O
food O
. O
[]

A O
detailed O
neurological B-outcome ['Physiological-Clinical']
examination O
and O
electrophysiological B-outcome ['Physiological-Clinical']
study O
was O
performed O
during O
and O
3 O
months O
after O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mortality B-outcome ['Mortality']
at O
six O
weeks O
was O
44 O
percent O
among O
those O
assigned O
to O
sclerotherapy O
and O
35 O
percent O
among O
those O
assigned O
to O
staple O
transection O
. O
['Mortality']

We O
report O
findings O
on O
the O
conditions O
of O
the O
homes O
prior O
to O
this O
intervention O
among O
the O
first O
112 O
enrolled O
households O
. O
[]

Sixty-three O
adults O
with O
chronic O
pain O
were O
randomised O
to O
either O
a O
Treatment O
Group O
or O
waitlist O
Control O
Group O
. O
[]

In O
patients O
with O
measurable O
disease O
, O
partial B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
were O
observed O
in O
eight O
of O
25 O
patients O
( O
32 O
% O
; O
95 O
% O
CI O
, O
14 O
% O
to O
50 O
% O
) O
on O
the O
ixabepilone O
arm O
, O
and O
11 O
of O
23 O
( O
48 O
% O
; O
95 O
% O
CI O
, O
27 O
% O
to O
68 O
% O
) O
on O
the O
ixabepilone O
+ O
EMP O
arm O
. O
['Physiological-Clinical']

Simplified O
subjective O
workload O
assessment O
technique O
. O
[]

This O
study O
tested O
the O
efficacy O
of O
a O
gluten-free O
and O
casein-free O
( O
GFCF O
) O
diet O
in O
treating O
autism O
using O
a O
randomized O
, O
double O
blind O
repeated O
measures O
crossover O
design O
. O
[]

One O
group O
was O
treated O
with O
estramustine O
phosphate O
, O
another O
with O
Epirubicin O
plus O
Medroxyprogesterone O
acetate O
( O
MPA O
) O
, O
while O
the O
third O
arm O
consisted O
of O
Epirubicin O
plus O
placebo O
. O
[]

Clonidine O
increases O
the O
sweating B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
, O
but O
does O
not O
reduce O
the O
gain O
of O
sweating B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
was O
found O
that O
these O
cuffs O
when O
overpressurised O
impaired B-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Argon O
laser O
trabeculoplasty O
is O
an O
effective O
adjunct O
in O
managing O
to O
control O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
black O
Jamaican O
glaucoma O
patients O
. O
['Physiological-Clinical']

PURPOSE O
This O
study O
was O
designed O
to O
determine O
the O
outcome O
and O
safety O
of O
tubeless O
percutaneous O
nephrolithotomy O
( O
PCNL O
) O
in O
the O
treatment O
of O
renal O
calculi O
. O
[]

RESULTS O
Subjects O
who O
were O
taking O
risperidone O
( O
mean O
dosage O
: O
0.04 O
mg/kg/day O
; O
1.17 O
mg/day O
) O
experienced O
a O
significantly O
greater O
mean O
decrease O
on O
the O
irritability B-outcome ['Life-Impact']
subscale O
of O
the O
ABC O
( O
primary O
endpoint O
) O
compared O
with O
those O
who O
were O
taking O
placebo O
. O
['Life-Impact']

The O
mean O
[]

Ozagrel O
Hydrochloride O
significantly O
( O
p O
< O
0.01 O
) O
reduced O
the O
occurrence O
of O
preeclampsia B-outcome ['Physiological-Clinical']
, O
and O
the O
incidence O
of O
both O
hypertension B-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
and O
proteinuria B-outcome ['Physiological-Clinical']
( O
p O
< O
0.01 O
) O
was O
significantly O
less O
in O
the O
treatment O
group O
compared O
with O
the O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
study O
the O
magnitude O
of O
differences O
in O
tumour B-outcome ['Physiological-Clinical']
unidimensional I-outcome ['Physiological-Clinical']
( O
1D O
) O
, O
bidimensional O
( O
2D O
) O
and O
volumetric O
( O
VOL O
) O
measurements O
determined O
from O
computed O
tomography O
( O
CT O
) O
images O
reconstructed O
at O
5 O
, O
2.5 O
and O
1.25 O
mm O
slice O
intervals O
. O
['Physiological-Clinical']

Number O
of O
spontaneous B-outcome ['Life-Impact']
play I-outcome ['Life-Impact']
acts I-outcome ['Life-Impact']
at O
pre-treatment O
was O
related O
to O
improvements O
in O
imitation B-outcome ['Physiological-Clinical']
during O
the O
intervention O
, O
suggesting O
that O
children O
with O
a O
greater O
play O
repertoire O
make O
greater O
gains O
during O
RIT O
. O
['Life-Impact', 'Physiological-Clinical']

PRIMARY O
OUTCOME O
MEASURE O
The O
pain B-outcome ['Physiological-Clinical']
subscale O
of O
the O
Western O
Ontario O
and O
McMaster O
Universities O
Osteoarthritis B-outcome ['Physiological-Clinical']
Index O
( O
WOMAC O
pain B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
20 O
adult O
patients O
with O
GHD O
( O
eleven O
male O
, O
nine O
female O
, O
mean O
age O
42.5 O
years O
) O
were O
included O
in O
the O
study O
and O
randomized O
to O
either O
GH O
or O
placebo O
in O
a O
dose O
of O
0.25 O
U/kg O
body O
weight/week O
. O
[]

OBJECTIVE O
To O
conduct O
a O
randomized O
, O
controlled O
trial O
to O
evaluate O
the O
efficacy O
of O
the O
Early O
Start O
Denver O
Model O
( O
ESDM O
) O
, O
a O
comprehensive O
developmental O
behavioral O
intervention O
, O
for O
improving O
outcomes O
of O
toddlers O
diagnosed O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

Subjects O
were O
examined O
at O
weeks O
4 O
, O
8 O
, O
and O
12 O
of O
treatment O
to O
identify O
adverse O
effects O
. O
[]

At O
baseline O
and O
at O
the O
end O
of O
the O
12-wk O
treatment O
period O
, O
thermogenic O
measurements O
were O
taken O
with O
the O
use O
of O
water B-outcome ['Physiological-Clinical']
immersion I-outcome ['Physiological-Clinical']
calorimetry I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Eighty O
patients O
suffering O
from O
pityriasis O
versicolor O
were O
randomly O
divided O
into O
two O
groups O
; O
one O
group O
were O
treated O
with O
2 O
% O
ketoconazole O
cream O
topically O
twice O
daily O
for O
2 O
weeks O
, O
adapalene O
gel O
was O
used O
for O
the O
other O
group O
in O
a O
similar O
fashion O
. O
[]

This O
randomised O
crossover O
study O
consisted O
of O
a O
single O
oral O
dose O
of O
ketoprofen O
100mg O
administered O
to O
8 O
healthy O
male O
volunteers O
, O
mean O
age O
27.2 O
years O
, O
at O
07.00 O
hours O
, O
13.00 O
hours O
, O
19.00 O
hours O
or O
01.00 O
hours O
in O
4 O
study O
periods O
during O
the O
first O
3 O
months O
of O
the O
year O
. O
[]

Compared O
with O
PN O
and O
EN O
groups O
, O
the O
incidence O
of O
upper O
gastrointestinal O
bleeding O
( O
1 O
vs. O
9 O
, O
2 O
) O
, O
infection O
and O
abscess O
( O
2 O
vs. O
12 O
, O
5 O
) O
was O
lower O
( O
all O
P O
< O
0.01 O
) O
, O
and O
hospital O
day O
was O
significantly O
shortened O
in O
P+EN O
group O
( O
10.4 O
? O
[]

Perceptual B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
speech I-outcome ['Life-Impact']
under O
optimal O
and O
adverse O
conditions O
. O
['Life-Impact']

UNLABELLED O
Today O
, O
androgen O
deprivation O
therapy O
is O
a O
cornerstone O
of O
treatment O
for O
advanced O
prostate O
cancer O
, O
although O
it O
presents O
important O
complications O
such O
as O
osteoporosis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
article O
describes O
a O
first O
attempt O
to O
investigate O
the O
reliability O
and O
validity O
of O
the O
TOM O
test O
, O
a O
new O
instrument O
for O
assessing O
theory O
of O
mind O
ability O
in O
normal O
children O
and O
children O
with O
pervasive O
developmental O
disorders O
( O
PDDs O
) O
. O
[]

A O
Phase O
III O
study O
was O
started O
in O
Japan O
to O
evaluate O
the O
non-inferiority O
of O
overall O
survival O
of O
laparoscopy-assisted O
distal O
gastrectomy O
with O
open O
distal O
gastrectomy O
in O
patients O
with O
clinical O
IA O
( O
T1N0 O
) O
or O
IB O
[ O
T1N1 O
or O
T2 O
( O
MP O
) O
N0 O
] O
gastric O
cancer O
. O
[]

Human O
embryos O
from O
seven O
patients O
, O
randomized O
to O
HTF O
medium O
supplemented O
with O
Plasmatein O
or O
lot O
1 O
of O
SSS O
, O
showed O
equivalent O
growth B-outcome ['Physiological-Clinical']
at O
36-40 O
hr O
postinsemination O
. O
['Physiological-Clinical']

Patients O
were O
randomly O
assigned O
to O
placebo O
or O
eptifibatide O
as O
an O
adjunct O
to O
stent O
implantation O
( O
1,755 O
with O
CrCl O
> O
or O
=60 O
ml/min O
and O
289 O
with O
CrCl O
< O
60 O
ml/min O
) O
. O
[]

One O
patient O
showed O
an O
improvement O
of O
peripheral B-outcome ['Physiological-Clinical']
neuropathy I-outcome ['Physiological-Clinical']
after O
induction O
with O
the O
combined O
therapy O
. O
['Physiological-Clinical']

Of O
women O
who O
seek O
reduction O
mammaplasty O
, O
up O
to O
a O
third O
have O
pathological O
degrees O
of O
anxiety B-outcome ['Life-Impact']
or O
depression B-outcome ['Life-Impact']
, O
or O
both O
. O
['Life-Impact', 'Life-Impact']

Its O
lack O
of O
unpleasant O
side-effects O
permits O
protracted O
use O
for O
the O
preventive O
treatment O
of O
serotonin-migraine O
. O
[]

All O
4 O
positive O
cases O
were O
esthesioneuroblastomas B-outcome ['Physiological-Clinical']
, O
and O
all O
19 O
poorly O
differentiated O
tumors O
were O
negative O
. O
['Physiological-Clinical']

Monitoring O
included O
ECG B-outcome ['Resource-use']
, O
blood O
pressure O
, O
respiratory O
rate O
, O
oxygen O
saturation O
and O
sedation B-outcome ['Life-Impact']
score O
. O
['Resource-use', 'Life-Impact']

Cyproheptadine O
augmentation O
of O
haloperidol O
in O
chronic O
schizophrenic O
patients O
: O
a O
double-blind O
placebo-controlled O
study O
. O
[]

Improving O
patient O
involvement O
in O
chronic O
disease O
management O
: O
the O
views O
of O
patients O
, O
GPs O
and O
specialists O
on O
a O
guidebook O
for O
ulcerative O
colitis O
. O
[]

METHOD O
AND O
MATERIALS O
Four O
bitewing O
films O
were O
taken O
from O
the O
right O
and O
left O
premolar O
and O
molar O
regions O
of O
45 O
dental O
students O
using O
both O
the O
bitewing O
holder O
and O
paper O
loop O
techniques O
. O
[]

Low-preference O
stimuli O
did O
not O
function O
as O
reinforcers O
when O
compared O
to O
high- O
and O
middle-preference O
stimuli O
. O
[]

All O
institutions O
complied O
with O
the O
protocol O
in O
specifying O
the O
reference O
dose O
at O
the O
ICRU O
point O
. O
[]

Mean O
differences O
in O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HDL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
- O
and O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LDL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
-cholesterol I-outcome ['Physiological-Clinical']
levels O
at O
cycle O
7 O
compared O
to O
baseline O
were O
assessed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
621 O
subjects O
participating O
in O
the O
research O
were O
also O
tested O
by O
urinalysis O
. O
[]

Further O
, O
in O
the O
Defibrotide O
group O
, O
scarring B-outcome ['Physiological-Clinical']
was O
considered O
excellent O
in O
96 O
% O
of O
cases O
while O
in O
the O
heparin O
group O
scarring B-outcome ['Physiological-Clinical']
was O
excellent O
in O
85 O
% O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

IOP B-outcome ['Physiological-Clinical']
rises I-outcome ['Physiological-Clinical']
of O
> O
10 O
mm O
Hg O
were O
seen O
in O
7 O
% O
of O
the O
combined O
treatment O
group O
, O
in O
18 O
% O
of O
the O
acetylcholine O
only O
group O
, O
and O
in O
50 O
% O
of O
the O
acetazolamide O
only O
group O
. O
['Physiological-Clinical']

Most O
of O
the O
patients O
in O
group O
I O
( O
92.86 O
% O
) O
maintained O
sinus B-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
without I-outcome ['Physiological-Clinical']
cardioversion I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
defibrillation I-outcome ['Physiological-Clinical']
after O
release O
of O
aortic O
cross O
clamp O
( O
P=0.002 O
) O
. O
['Physiological-Clinical']

Twenty O
patients O
( O
aged O
4 O
months O
to O
5 O
years O
) O
hospitalized O
with O
acute O
croup O
and O
persistent O
inspiratory O
stridor O
at O
rest O
were O
randomly O
assigned O
to O
one O
of O
two O
treatment O
groups O
: O
saline O
or O
racemic O
epinephrine O
, O
both O
nebulized O
and O
delivered O
by O
intermittent O
positive O
pressure O
breathing O
. O
[]

Crossover O
was O
also O
comparable O
, O
with O
1 O
occurring O
in O
the O
IBMC O
group O
, O
compared O
with O
3 O
in O
the O
PMMC O
group O
. O
[]

Twenty O
Type O
2 O
diabetic O
patients O
with O
dyslipidemia O
were O
treated O
3 O
months O
with O
simvastatin O
( O
20 O
mg O
daily O
) O
and O
then O
3 O
months O
with O
fenofibrate O
( O
200 O
mg O
daily O
) O
with O
2 O
months O
of O
wash-out O
between O
the O
two O
treatments O
. O
[]

HYPOTHESIS O
Dermal O
iontophoretic O
administration O
of O
dexamethasone O
sodium O
phosphate O
will O
be O
significantly O
more O
effective O
in O
controlling O
pain B-outcome ['Physiological-Clinical']
than O
a O
placebo O
in O
patients O
with O
medial O
or O
lateral O
elbow O
epicondylitis O
. O
['Physiological-Clinical']

The O
subjects O
were O
asked O
to O
perform O
the O
following O
tasks O
, O
with O
the O
affected O
hand O
for O
30 O
seconds O
: O
( O
1 O
) O
transfer O
pegs O
from O
a O
saucer O
to O
a O
pegboard O
; O
( O
2 O
) O
grasp O
, O
carry O
, O
and O
release O
a O
hard O
rubber O
ball O
; O
and O
( O
3 O
) O
eating O
, O
using O
a O
spoon O
to O
remove O
the O
jelly O
from O
the O
plate O
, O
bring O
it O
towards O
the O
mouth O
, O
and O
then O
place O
it O
on O
another O
plate O
. O
[]

Catheterization O
and O
echocardiographic B-outcome ['Physiological-Clinical']
assessment O
of O
patent B-outcome ['Physiological-Clinical']
foramen I-outcome ['Physiological-Clinical']
ovale I-outcome ['Physiological-Clinical']
were O
compared O
in O
21 O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
looks O
for O
a O
rebound O
aggravation O
of O
symptoms O
after O
short-term O
treatment O
with O
lansoprazole O
. O
[]

A O
risk O
score O
incorporating O
routine O
practice O
data O
was O
used O
to O
identify O
people O
aged O
40-69 O
years O
at O
high-risk O
of O
undiagnosed O
diabetes O
. O
[]

Outcomes O
considered O
in O
these O
analyses O
included O
the O
QT B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
central I-outcome ['Physiological-Clinical']
reading I-outcome ['Physiological-Clinical']
and O
analysis O
, O
and O
cardiovascular B-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
At O
three O
years O
, O
the O
rates O
of O
recurrence B-outcome ['Physiological-Clinical']
were O
similar O
in O
the O
two O
groups O
-- O
16 O
percent O
among O
patients O
in O
the O
group O
that O
underwent O
laparoscopically O
assisted O
surgery O
and O
18 O
percent O
among O
patients O
in O
the O
open-colectomy O
group O
( O
two-sided O
P=0.32 O
; O
hazard O
ratio O
for O
recurrence O
, O
0.86 O
; O
95 O
percent O
confidence O
interval O
, O
0.63 O
to O
1.17 O
) O
. O
['Physiological-Clinical']

Clinical O
usefulness O
of O
serum O
prostate O
specific O
antigen O
for O
the O
detection O
of O
prostate O
cancer O
is O
preserved O
in O
men O
receiving O
the O
dual O
5alpha-reductase O
inhibitor O
dutasteride O
. O
[]

220.1 O
vs. O
413.2 O
? O
[]

The O
peroxisome O
proliferator-activated O
receptor-gamma O
agonist O
pioglitazone O
increases O
number O
and O
function B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
endothelial I-outcome ['Physiological-Clinical']
progenitor I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
in O
patients O
with O
coronary O
artery O
disease O
and O
normal O
glucose O
tolerance O
. O
['Physiological-Clinical']

The O
resulting O
magnitude O
estimation O
ratings O
of O
symptom B-outcome ['Life-Impact']
['Life-Impact']

RESULTS O
Devices O
were O
used O
in O
138/150 O
allocated O
to O
AS O
and O
124/150 O
allocated O
to O
SC O
patients O
( O
92 O
% O
vs. O
83 O
% O
, O
P O
= O
0.015 O
) O
Patients O
with O
MC O
experienced O
more O
pain O
during O
sheath B-outcome ['Resource-use']
removal I-outcome ['Resource-use']
than O
patients O
receiving O
a O
device O
, O
and O
rated O
their O
period O
of O
bed B-outcome ['Life-Impact']
rest I-outcome ['Life-Impact']
as O
less O
comfortable O
. O
['Resource-use', 'Life-Impact']

The O
expectation O
is O
that O
674 O
patients O
will O
be O
entered O
into O
the O
study O
from O
25 O
participating O
centers O
. O
[]

Better O
methods O
of O
risk O
stratification O
are O
required O
. O
[]

Primiparous O
cows O
had O
similar O
leptin B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
to O
3-yr-old O
and O
mature O
cows O
for O
wk O
-7 O
and O
-6 O
relative O
to O
calving O
, O
but O
lower O
( O
P O
< O
0.10 O
) O
concentrations O
than O
mature O
cows O
for O
wk O
-5 O
, O
and O
lower O
( O
P O
< O
0.05 O
) O
concentrations O
than O
either O
3-yr-old O
or O
mature O
cows O
for O
wk O
-4 O
to O
+7 O
relative O
to O
calving O
. O
['Physiological-Clinical']

The O
study O
showed O
levobunolol O
to O
be O
as O
safe O
and O
effective O
as O
timolol O
in O
the O
long-term O
control O
of O
raised O
[]

Sensorimotor O
enrichment O
also O
produced O
a O
clear O
improvement O
in O
cognition B-outcome ['Life-Impact']
, O
as O
determined O
by O
their O
Leiter-R O
Visualization O
and O
Reasoning O
scores O
. O
['Life-Impact']

A O
total O
of O
30 O
subjects O
, O
between O
the O
ages O
of O
8 O
and O
18 O
with O
AD O
based O
on O
DSM O
IV O
criteria O
, O
were O
included O
in O
the O
study O
. O
[]

Group O
1 O
received O
100 O
mg O
pethidine O
; O
group O
2 O
, O
100 O
mg O
tramadol O
, O
intramuscularly O
. O
[]

Monitoring O
of O
the O
central B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
is O
useful O
for O
detecting O
cardiac O
overload O
during O
antiadrenergic O
treatment O
: O
the O
Japan O
Morning O
Surge O
1 O
study O
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION O
ISRCTN59506583 O
. O
[]

A O
reduction O
in O
the O
causes O
of O
myocardial B-outcome ['Physiological-Clinical']
ischaemia I-outcome ['Physiological-Clinical']
remains O
of O
prime O
importance O
during O
coronary O
artery O
surgery O
. O
['Physiological-Clinical']

PURPOSE O
To O
present O
an O
initial O
evaluation O
of O
the O
final O
data O
from O
the O
Multicenter O
Investigation O
of O
Rheopheresis O
for O
age-related O
macular O
degeneration O
( O
AMD O
) O
( O
MIRA-1 O
) O
trial O
. O
[]

Given O
the O
widespread O
use O
of O
MDMA O
, O
our O
lack O
of O
knowledge O
raises O
concerns O
. O
[]

However O
a O
statistically O
significant O
difference O
between O
groups O
of O
p O
< O
0.02 O
, O
p O
< O
0.01 O
and O
p O
< O
0.05 O
was O
found O
in O
favour O
of O
the O
30 O
mg O
dose O
respectively O
at O
30 O
' O
, O
6 O
and O
8 O
hours O
after O
administration O
. O
[]

[ O
Case-controll O
study O
on O
the O
synergistic B-outcome ['Adverse-effects']
effects O
of O
electroacupuncture O
on O
knee O
osteoarthritis O
after O
arthroscopic O
debridement O
] O
. O
['Adverse-effects']

The O
two O
groups O
were O
compared O
on O
their O
subjective O
responses O
to O
drug O
and O
on O
demographic O
variables O
. O
[]

The O
purpose O
of O
this O
substudy O
was O
to O
evaluate O
the O
acute B-outcome ['Physiological-Clinical']
expansion I-outcome ['Physiological-Clinical']
property I-outcome ['Physiological-Clinical']
and O
long-term B-outcome ['Physiological-Clinical']
neointimal I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
of O
qDES O
compared O
with O
BMS O
as O
assessed O
by O
intravascular O
ultrasound O
( O
IVUS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eight O
spots O
were O
equally O
distributed O
at O
a O
distance O
of O
500 O
microm O
from O
one O
another O
over O
the O
anterior O
trabeculum O
. O
[]

A O
high O
remission B-outcome ['Physiological-Clinical']
rate O
was O
observed O
in O
subjects O
with O
a O
history O
of O
no O
prior O
treatment O
or O
inadequate O
treatment O
who O
were O
treated O
with O
a O
combination O
of O
olanzapine O
and O
sertraline O
. O
['Physiological-Clinical']

However O
, O
interruption O
of O
CPAP O
therapy O
is O
common O
and O
is O
associated O
with O
a O
decline O
in O
daytime O
function O
. O
[]

The O
number O
of O
days O
that O
intramuscular B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
injections I-outcome ['Resource-use']
were O
required O
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
were O
also O
assessed O
. O
['Resource-use', 'Resource-use', 'Life-Impact']

After O
7 O
days O
of O
single-agent O
etoposide O
treatment O
, O
peripheral B-outcome ['Physiological-Clinical']
blast I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
( O
P=0.013 O
) O
and O
percentages O
of O
bone B-outcome ['Physiological-Clinical']
marrow I-outcome ['Physiological-Clinical']
blasts I-outcome ['Physiological-Clinical']
( O
P=0.016 O
) O
were O
significantly O
reduced O
. O
['Physiological-Clinical', 'Physiological-Clinical']

During O
n-3 O
PUFA O
supplementation O
, O
accumulations O
of O
eicosapentaenoic B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EPA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
docosapentaenoic B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DPA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
docosahexaenoic B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DHA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
were O
marked O
after O
2 O
mo O
with O
differences O
among O
different O
fractions O
of O
plasma O
and O
RBCs O
in O
further O
accumulation O
up O
to O
4 O
mo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Total O
suture B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

A O
significant O
reduction O
in O
IL-1? O
and O
IL-6 O
vaginal O
cytokines O
was O
observed O
after O
treatment O
with O
lactobacilli O
, O
while O
the O
active O
comparator O
did O
not O
have O
any O
effect O
on O
local O
proinflammatory O
cytokines O
. O
[]

The O
amblyopia O
was O
defined O
as O
severe/moderate O
( O
< O
0.250 O
logMAR O
) O
, O
n=41 O
or O
mild O
( O
> O
or O
= O
0.250 O
logMAR O
) O
, O
n=10 O
. O
[]

The O
Italian O
Multicenter O
Study O
Group O
. O
[]

Cholesteryl B-outcome ['Physiological-Clinical']
ester I-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
decreased O
and O
triglyceride B-outcome ['Physiological-Clinical']
increased O
in O
the O
nonHDL O
plasma O
fraction O
, O
with O
contrasting O
changes O
occurring O
in O
HDL O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Of O
923 O
patients O
( O
mean O
age O
65 O
years O
) O
466 O
received O
silodosin O
and O
457 O
placebo O
. O
[]

Side O
effects O
were O
mild O
. O
[]

The O
only O
change O
observed O
in O
these O
parameters O
with O
indomethacin O
alone O
was O
a O
small O
but O
significant O
reduction O
in O
urine B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
P O
< O
0.005 O
vs O
placebo O
) O
. O
['Physiological-Clinical']

Determinants O
of O
breastfeeding O
practices O
have O
been O
largely O
documented O
in O
high-income O
countries O
. O
[]

There O
was O
pronounced O
heterogeneity O
in O
survival B-outcome ['Mortality']
outcomes O
between O
groups O
of O
patients O
, O
with O
some O
evidence O
of O
benefit O
among O
never-smokers O
and O
patients O
of O
Asian O
origin O
. O
['Mortality']

We O
approached O
families O
affected O
by O
melanoma O
for O
possible O
participation O
in O
a O
randomized O
controlled O
trial O
of O
a O
web-based O
communication O
and O
support O
intervention O
. O
[]

It O
eliminated B-outcome ['Physiological-Clinical']
or O
ameliorated O
stress O
['Physiological-Clinical']

Resistance O
vessel O
remodeling O
is O
determined O
using O
the O
gluteal O
fat O
biopsy O
technique O
in O
the O
hypertensive O
patients O
and O
a O
group O
of O
normotensive O
healthy O
volunteers O
. O
[]

The O
follow-up O
time O
is O
11-20 O
years O
. O
[]

A O
cluster O
randomised O
trial O
to O
evaluate O
a O
physical O
activity O
intervention O
among O
3-5 O
year O
old O
children O
attending O
long O
day O
care O
services O
: O
study O
protocol O
. O
[]

METHODS O
Seventeen O
subjects O
were O
randomized O
into O
control O
( O
n O
= O
9 O
) O
and O
HBOT O
treatment O
( O
n O
= O
8 O
) O
arms O
. O
[]

Angiographic B-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
6-month I-outcome ['Physiological-Clinical']
angiography I-outcome ['Physiological-Clinical']
was O
the O
primary O
end O
point O
of O
the O
study O
. O
['Physiological-Clinical']

The O
numbers O
of O
high-echo B-outcome ['Physiological-Clinical']
spots I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
cavity I-outcome ['Physiological-Clinical']
and O
on O
the O
gastric B-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
were O
significantly O
less O
( O
both O
at O
P O
< O
0.001 O
) O
for O
pre-medication O
with O
pronase O
( O
treatment O
C O
) O
than O
for O
pre-medication O
with O
treatments O
A O
and O
B O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
study O
comprised O
three O
3-week O
periods O
. O
[]

CONCLUSIONS O
Dietary O
PUFA O
supplementation O
markedly O
potentiates O
baroreflex O
function O
and O
enhances O
[]

No O
significant O
difference O
among O
the O
groups O
was O
observed O
during O
the O
treatment O
period O
for O
any O
of O
the O
parameters O
. O
[]

Safety O
analyses O
of O
patients O
applying O
topical O
diclofenac O
solution O
revealed O
some O
minor B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
irritation I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
application I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
-- O
mostly O
skin O
dryness O
in O
83/311 O
( O
27 O
% O
) O
patients O
-- O
but O
a O
significantly O
reduced O
incidence O
, O
relative O
to O
oral O
diclofenac O
, O
of O
total O
and O
severe B-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
including O
dyspepsia B-outcome ['Physiological-Clinical']
, O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
diarrhea B-outcome ['Physiological-Clinical']
, O
and O
nausea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
Study O
2 O
, O
two O
individual O
difference O
measures O
, O
pessimism O
and O
differences O
in O
understanding O
percentages O
, O
were O
unrelated O
to O
risk O
perception B-outcome ['Life-Impact']
persistence I-outcome ['Life-Impact']
. O
['Life-Impact']

No O
benefit O
has O
been O
demonstrated O
from O
the O
addition O
of O
CMF O
chemotherapy O
in O
tamoxifen O
responders O
. O
[]

Seroconversion B-outcome ['Physiological-Clinical']
and O
seroprotection B-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
and O
geometric B-outcome ['Physiological-Clinical']
mean O
antibody B-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
were O
measured O
at O
14 O
and O
28 O
days O
, O
1 O
, O
2 O
, O
and O
3 O
years O
postvaccination O
, O
and O
28 O
days O
after O
the O
booster O
dose O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Group O
II O
also O
showed O
lower B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
intensity O
scores O
than O
group O
I O
immediately O
post-treatment O
( O
p O
= O
0.045 O
) O
and O
a O
strong O
clinical B-outcome ['Physiological-Clinical']
effect O
over O
group O
I O
in O
['Physiological-Clinical', 'Physiological-Clinical']

The O
trial O
is O
expected O
to O
accrue O
a O
minimum O
of O
450 O
events O
with O
a O
minimum O
1-year O
of O
follow-up O
. O
[]

Pain B-outcome ['Physiological-Clinical']
was O
scored O
by O
their O
parents O
and O
a O
pediatric O
nurse O
. O
['Physiological-Clinical']

Before O
that O
test O
and O
3 O
minutes O
after O
its O
termination O
capillary O
and O
venous O
blood O
samples O
were O
drawn O
. O
[]

Five O
active O
metabolites O
( O
M1 O
, O
M2-a O
, O
M2-b O
, O
M3 O
and O
M4 O
) O
were O
observed O
in O
plasma O
at O
concentrations O
comparable O
to O
those O
of O
unchanged O
YM17E O
. O
[]

By O
Week O
3 O
, O
all O
in O
the O
control O
group O
experienced O
Grade O
2 O
mucositis B-outcome ['Physiological-Clinical']
compared O
with O
only O
9 O
% O
in O
the O
amifostine-treated O
group O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

SETTING O
University O
teaching O
hospital O
. O
[]

In O
a O
controlled O
, O
prospectively O
randomized O
trial O
, O
74 O
patients O
with O
hepatic O
metastases O
from O
colorectal O
cancer O
were O
randomized O
to O
either O
intra-arterial O
hepatic O
artery O
infusion O
with O
5-fluorouracil O
( O
5-FU O
) O
or O
systemic O
chemotherapy O
with O
5-FU O
. O
[]

METHODS O
This O
was O
a O
post O
hoc O
subgroup O
analysis O
in O
the O
Veterans O
Affairs O
High-Density O
Lipoprotein O
Intervention O
Trial O
, O
a O
randomized O
double-blind O
trial O
of O
gemfibrozil O
versus O
placebo O
in O
2,531 O
men O
with O
coronary O
disease O
, O
HDL-C O
levels O
of O
40 O
mg/dL O
or O
less O
( O
< O
or O
=1.0 O
mmol/L O
) O
, O
low-density O
lipoprotein O
cholesterol O
levels O
of O
140 O
mg/dL O
or O
less O
( O
< O
or O
=3.6 O
mmol/L O
) O
, O
and O
a O
range O
of O
triglyceride O
values O
. O
[]

All O
initial O
responders O
remained O
HCV B-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
negative O
throughout O
the O
treatment O
period O
. O
['Physiological-Clinical']

The O
data O
presented O
in O
this O
study O
do O
not O
support O
that O
a O
high O
pre-treatment O
Ki-67 O
is O
associated O
with O
a O
therapeutic B-outcome ['Physiological-Clinical']
benefit O
from O
accelerated O
radiotherapy O
. O
['Physiological-Clinical']

It O
is O
important O
that O
new O
types O
of O
spirometer O
for O
widespread O
clinical O
use O
are O
pragmatically O
evaluated O
in O
primary O
care O
. O
[]

Since O
1991 O
, O
the O
results O
of O
3 O
major O
trials O
-- O
the O
British O
Medical O
Research O
Council O
( O
MRC O
) O
trial O
of O
treatment O
in O
older O
adults O
, O
the O
Swedish O
Trial O
in O
Old O
Patients O
with O
Hypertension B-outcome ['Physiological-Clinical']
( O
STOP-Hypertension O
) O
and O
the O
Systolic O
Hypertension O
in O
the O
Elderly O
Program O
( O
SHEP O
) O
-- O
have O
conclusively O
established O
the O
benefits O
of O
treating O
older O
patients O
( O
> O
60 O
years O
) O
with O
both O
diastolic B-outcome ['Physiological-Clinical']
and O
isolated B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
different O
orientation O
given O
to O
the O
prosthesis O
may O
represent O
a O
limitation O
of O
the O
technique O
accounting O
for O
unsatisfactory O
results O
in O
10 O
% O
to O
40 O
% O
of O
the O
cases O
. O
[]

These O
effects O
were O
most O
pronounced O
in O
patients O
with O
extensive O
disease O
; O
a O
[]

Many O
issues O
were O
considered O
in O
this O
decision O
. O
[]

METHODS O
We O
prospectively O
enrolled O
160 O
patients O
aged O
more O
than O
70 O
years O
scheduled O
to O
undergo O
isolated O
myocardial O
revascularization O
. O
[]

Supplementation O
lasted O
for O
14 O
days O
during O
months O
4 O
and O
8 O
. O
[]

Although O
these O
short-term O
studies O
have O
shown O
no O
conclusive O
advantage O
of O
glycerol O
over O
glucose O
, O
long-term O
effects O
of O
glycerol O
, O
particularly O
on O
circulating B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
levels O
, O
will O
determine O
its O
future O
role O
as O
an O
osmotic O
agent O
in O
continuous O
ambulatory O
peritoneal O
dialysis O
. O
['Physiological-Clinical']

The O
correlations O
remained O
when O
the O
data O
set O
was O
limited O
to O
patients O
with O
TSH O
in O
the O
range O
0.3-4.0 O
mIU/liter O
. O
[]

Single-dose O
and O
multi-dose O
clindamycin O
therapy O
fails O
to O
demonstrate O
efficacy O
in O
preventing O
infectious O
and O
inflammatory O
complications O
in O
third O
molar O
surgery O
. O
[]

In O
the O
group O
working O
with O
the O
extractor O
, O
exposure B-outcome ['Physiological-Clinical']
was O
94 O
% O
and O
91 O
% O
lower O
: O
24.7 O
( O
26 O
) O
and O
1.1 O
( O
1 O
) O
ppm O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

This O
procedure O
prompted O
participants O
to O
make O
simultaneous O
identity-matching O
responses O
that O
required O
observation O
and O
discrimination O
of O
both O
sample O
stimuli O
. O
[]

Increased O
concentrations O
of O
hsCRP B-outcome ['Physiological-Clinical']
were O
strongly O
associated O
with O
the O
development O
of O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
at O
30 O
days O
( O
adjHR O
8.2 O
, O
P O
= O
0.001 O
) O
and O
10 O
months O
( O
adjHR O
2.6 O
, O
P O
= O
0.014 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Each O
of O
the O
breast-milk O
samples O
contained O
bifidobacteria O
[ O
median O
1.4 O
x O
10 O
( O
3 O
) O
bacterial O
cells/mL O
; O
interquartile O
range O
( O
IQR O
) O
48.7-3.8 O
x O
10 O
( O
3 O
) O
] O
. O
[]

RU O
486 O
and O
three O
of O
its O
metabolites O
( O
RU O
42633-monodemethyl O
, O
RU O
42848-didemethyl O
, O
and O
RU O
42698-hydroxymetabolite O
) O
were O
determined O
by O
HPLC O
in O
plasma O
from O
nine O
non-pregnant O
and O
36 O
pregnant O
women O
. O
[]

Active O
laser O
therapy O
produced O
significant O
improvement O
over O
drug O
therapy O
for O
all O
three O
objective O
measures O
and O
pain B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Three O
children O
had O
clinically O
nonsignificant O
electrocardiographic O
QT O
prolongation O
. O
[]

Lp B-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
not O
associate O
with O
changes O
in O
tissue-plasminogen B-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
t-PA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
factor O
VII B-outcome ['Physiological-Clinical']
coagualant I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
or O
plasma B-outcome ['Physiological-Clinical']
LDL I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

None O
of O
the O
patients O
in O
the O
valproate O
group O
required O
ventilation B-outcome ['Physiological-Clinical']
or O
developed O
hypotension B-outcome ['Physiological-Clinical']
, O
whereas O
in O
the O
diazepam O
group O
60 O
% O
required O
ventilation B-outcome ['Physiological-Clinical']
and O
50 O
% O
developed O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

chemotherapy O
) O
vs. O
TORS O
( O
? O
[]

The O
duration O
of O
sensory B-outcome ['Physiological-Clinical']
and O
motor B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
is O
shorter O
with O
prilocaine O
than O
with O
mepivacaine O
, O
making O
prilocaine O
more O
appropriate O
for O
short O
interventions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
study O
groups O
( O
TEN O
= O
29 O
vs O
TPN O
= O
30 O
) O
were O
comparable O
in O
age O
, O
injury O
severity O
and O
initial O
metabolic O
stress O
. O
[]

An O
interim O
report O
. O
[]

CONCLUSIONS O
In O
summary O
, O
adequate O
coverage O
can O
be O
obtained O
in O
population-based O
oral O
screening O
in O
developing O
countries O
. O
[]

Usual O
Care O
( O
brief O
intervention O
) O
compared O
to O
existing O
practice O
( O
Real O
Control O
) O
was O
also O
cost-effective O
( O
$ O
12,153 O
per O
quality O
adjusted O
life O
year O
gained O
) O
. O
['Resource-use']

At O
the O
3-week O
follow O
up O
, O
the O
resolution B-outcome ['Physiological-Clinical']
rates O
in O
the O
triamcinolone O
acetonide O
injection O
and O
surgical O
treatment O
groups O
were O
not O
significantly O
different O
from O
each O
other O
at O
84 O
% O
( O
47/56 O
) O
and O
87 O
% O
( O
39/45 O
) O
, O
respectively O
( O
P O
< O
0.001 O
) O
, O
but O
was O
significantly O
lower O
in O
the O
conservative O
treatment O
group O
at O
46 O
% O
( O
16/35 O
) O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Randomized O
controlled O
trial O
: O
Multimodal O
Anxiety O
and O
Social O
Skill O
Intervention O
for O
adolescents O
with O
autism O
spectrum O
disorder O
. O
[]

The O
effect O
of O
neighborhood-based O
community O
organizing O
: O
results O
from O
the O
Seattle O
Minority O
Youth O
Health O
Project O
. O
[]

SETTING O
University O
hospital O
. O
[]

As O
transesophageal O
ECV O
shows O
no O
clear O
advantage O
, O
transthoracic O
cardioversion O
should O
remain O
the O
approach O
of O
first O
choice O
. O
[]

Practical O
experiences O
from O
the O
Oslo O
Study O
. O
[]

A O
total O
of O
19 O
patients O
received O
WAD O
, O
the O
remaining O
20 O
acting O
as O
a O
control O
group O
. O
[]

556 O
cases O
( O
colon O
carcinoma O
regimen O
C O
: O
148 O
, O
D O
: O
185 O
cases O
, O
rectal O
carcinoma O
regimen O
C O
: O
94 O
, O
D O
: O
129 O
cases O
) O
were O
evaluable O
at O
this O
presentation O
. O
[]

This O
prospective O
, O
randomized O
study O
in O
40 O
ARDS O
patients O
analyzed O
dose-response B-outcome ['Physiological-Clinical']
( O
DR O
) O
characteristics O
during O
long-term O
inhaled O
NO O
. O
['Physiological-Clinical']

The O
efficacy O
of O
low O
pressure O
, O
high O
pressure O
and O
passive O
drainage O
systems O
have O
been O
compared O
after O
cholecystectomy O
. O
[]

Treatment O
of O
peri-implantitis O
by O
the O
Vector O
system O
. O
[]

CONCLUSIONS O
Fecal O
incontinence O
and O
erectile O
dysfunction O
are O
frequent O
after O
combined O
treatment O
for O
locally O
advanced O
rectal O
cancer O
. O
[]

Reduction O
in O
bone O
turnover O
markers O
was O
greater O
with O
denosumab O
. O
[]

In O
the O
placebo O
group O
, O
scores O
were O
higher O
than O
in O
the O
flunisolide O
group O
but O
nonsignificant O
for O
[]

In O
addition O
, O
sera O
were O
collected O
from O
a O
randomized O
sample O
of O
subjects O
in O
each O
vaccine O
group O
at O
approximately O
3-month O
intervals O
from O
which O
antibody O
kinetic O
curves O
were O
constructed O
, O
which O
allowed O
us O
to O
estimate O
specific O
antibody O
values O
to O
pertussis O
toxin O
( O
PT O
) O
, O
filamentous O
hemagglutinin O
( O
FHA O
) O
, O
pertactin O
and O
fimbriae-2 O
at O
the O
time O
of O
exposure O
in O
the O
household O
setting O
. O
[]

There O
was O
, O
however O
, O
no O
indication O
of O
an O
effect O
of O
maprotiline O
on O
cognitive B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Life-Impact']

CONCLUSIONS O
These O
results O
suggest O
that O
ropinirole O
is O
more O
effective O
than O
levodopa O
SR O
in O
the O
treatment O
of O
RLS O
in O
patients O
on O
chronic O
hemodialysis O
. O
[]

SEM O
examination O
confirmed O
these O
findings O
. O
[]

Lidocaine O
had O
the O
quickest O
onset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
anesthesia I-outcome ['Physiological-Clinical']
, O
with O
a O
mean O
time O
of O
1.3 O
minutes O
( O
range O
, O
1 O
to O
2.7 O
minutes O
) O
. O
['Physiological-Clinical']

BACKGROUND O
We O
have O
continued O
to O
monitor O
the O
survival O
of O
patients O
randomised O
in O
a O
previously O
reported O
multicentre O
phase O
III O
study O
of O
topotecan O
versus O
paclitaxel O
in O
patients O
with O
advanced O
epithelial O
ovarian O
cancer O
who O
had O
failed O
one O
prior O
platinum-based O
regimen O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
effectiveness O
of O
chlorhexidine O
swabbing O
compared O
with O
placebo O
was O
previously O
reported O
. O
['Physiological-Clinical']

The O
major O
cost O
driver O
was O
hospital O
days O
. O
[]

Pretreatment O
with O
HFLCS O
did O
not O
cause O
a O
statistically O
significant O
change O
in O
the O
shear O
bond O
values O
of O
either O
metal O
or O
ceramic O
brackets O
( O
P O
= O
0.38 O
) O
. O
[]

Hypothesis O
1 O
was O
that O
high-BP O
individuals O
, O
but O
not O
low-BP O
controls O
, O
would O
show O
greater O
emotional B-outcome ['Life-Impact']
reactivity B-outcome ['Life-Impact']
to O
the O
negative O
evaluation/social O
rejection O
stressor O
, O
compared O
with O
the O
negative O
evaluation/academic O
( O
writing O
) O
stressor O
. O
['Life-Impact', 'Life-Impact']

We O
determined O
the O
effect O
of O
an O
educational O
package O
at O
rural O
schools O
in O
Linxiang O
City O
District O
, O
Hunan O
province O
, O
China O
, O
where O
these O
worms O
are O
prevalent O
. O
[]

It O
has O
been O
validated O
in O
patients O
with O
osteoarthritis O
( O
OA O
) O
of O
the O
hip O
or O
knee O
in O
a O
paper-based O
format O
. O
[]

In O
this O
prospective O
multicentre O
trial O
, O
90 O
patients O
undergoing O
autologous O
stem O
cell O
transplantation O
( O
ASCT O
) O
were O
randomised O
to O
receive O
( O
n=43 O
) O
or O
not O
receive O
( O
n=47 O
) O
amifostine O
910 O
mg/m O
( O
2 O
) O
prior O
to O
melphalan O
200 O
mg/m O
( O
2 O
) O
. O
[]

One O
area O
or O
process O
per O
manufacturing O
department O
was O
assessed O
and O
rated O
. O
[]

STUDY O
DESIGN O
Demonstration O
volunteers O
were O
randomly O
assigned O
to O
have O
the O
option O
to O
participate O
in O
Cash O
and O
Counseling O
( O
the O
treatment O
group O
) O
, O
or O
to O
receive O
Medicaid O
services O
as O
usual O
from O
an O
agency O
( O
the O
control O
group O
) O
. O
[]

CONCLUSIONS O
We O
conclude O
that O
the O
prophylactic O
intravenous O
administration O
of O
10 O
mg O
dexamethasone O
immediately O
before O
the O
induction O
of O
anesthesia O
is O
effective O
in O
preventing O
PONV O
in O
the O
general O
surgical O
adult O
patient O
population O
. O
[]

The O
implant B-outcome ['Physiological-Clinical']
stability O
quotient O
values O
between O
the O
test O
and O
control O
groups O
were O
significant O
( O
P O
< O
0.05 O
) O
at O
the O
moment O
of O
implant O
placement O
but O
were O
no O
more O
significant O
at O
the O
loading O
of O
the O
definitive O
restoration O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Individual O
data O
of O
254 O
patients O
were O
merged O
, O
and O
baseline O
features O
potentially O
affecting O
overall O
response O
rate O
( O
ORR O
) O
, O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
PFS B-outcome ['Mortality']
) O
, O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
OS B-outcome ['Mortality']
) O
, O
and O
occurrence O
of O
severe O
toxicity B-outcome ['Adverse-effects']
were O
analyzed O
by O
univariate O
and O
multivariate O
analyses O
. O
['Mortality', 'Mortality', 'Mortality', 'Mortality', 'Adverse-effects']

The O
first O
long-term O
results O
, O
recorded O
after O
2 O
years O
, O
indicate O
statistically O
significant O
differences O
in O
the O
complication B-outcome ['Adverse-effects']
rate O
( O
after O
stenting O
2/62 O
and O
after O
angioplasty O
5/69 O
) O
and O
patency B-outcome ['Physiological-Clinical']
( O
greater O
than O
or O
equal O
to O
70 O
% O
of O
original O
lumen O
size O
upon O
stent O
implantation O
or O
balloon O
inflation O
: O
95 O
% O
after O
stenting O
and O
72 O
% O
after O
angioplasty O
) O
. O
['Adverse-effects', 'Physiological-Clinical']

None O
of O
the O
neonates O
developed O
respiratory B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Overall- O
, O
T- O
and O
N-downstaging O
rates O
were O
73 O
% O
, O
57 O
% O
and O
81 O
% O
respectively O
. O
[]

Throughout O
the O
study O
, O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
vascular B-outcome ['Physiological-Clinical']
resistances I-outcome ['Physiological-Clinical']
remained O
lower O
postexercise O
vs. O
postsham O
despite O
nitric B-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
synthase I-outcome ['Physiological-Clinical']
inhibition O
( O
e.g. O
, O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
after O
L-NMMA O
was O
108.0+/-2.4 O
mmHg O
postsham O
vs. O
102.1+/-3.3 O
mmHg O
postexercise O
; O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
all O
3 O
conditions O
, O
LF/HF B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
decreased O
from O
Baseline O
to O
Heel O
Stick O
and O
increased O
to O
Recovery O
; O
no O
differences O
were O
found O
between O
IC O
and O
two O
KC O
conditions O
. O
['Physiological-Clinical']

The O
effect O
of O
iron O
in O
formula O
milk O
after O
6 O
months O
of O
age O
. O
[]

This O
prospective O
study O
was O
performed O
in O
order O
to O
investigate O
if O
routine O
bedside O
questioning O
and O
examination O
by O
the O
visiting O
doctor O
could O
reveal O
deep O
vein O
thrombosis O
in O
the O
legs O
of O
patients O
who O
had O
received O
a O
hip O
replacement O
. O
[]

We O
conducted O
this O
study O
to O
evaluate O
the O
safety O
and O
acceptability B-outcome ['Life-Impact']
of O
6 O
% O
cellulose O
sulfate O
( O
CS O
) O
gel O
as O
a O
vaginal O
microbicide O
in O
sexually O
abstinent O
and O
active O
HIV-infected O
women O
. O
['Life-Impact']

Heparin O
therapy O
in O
venous O
thromboembolism O
. O
[]

In O
phase O
2 O
, O
the O
alternate O
treatment O
group O
received O
standard O
weight O
placement O
of O
1.5 O
% O
body O
weight O
. O
[]

After O
that O
the O
total O
daily O
doses O
was O
adjusted O
to O
240 O
mg O
and O
160 O
mg O
, O
respectively O
, O
until O
the O
7th O
day O
. O
[]

The O
aim O
of O
this O
study O
was O
threefold O
: O
( O
1 O
) O
Assess O
the O
pressure O
loss O
of O
two O
types O
of O
pressure O
garments O
that O
are O
used O
in O
the O
treatment O
of O
hypertrophic O
scars O
after O
burn O
injury O
, O
( O
2 O
) O
investigate O
the O
influence O
of O
two O
different O
levels O
of O
compression O
on O
erythema B-outcome ['Physiological-Clinical']
and O
thickness B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
burn I-outcome ['Physiological-Clinical']
scars I-outcome ['Physiological-Clinical']
and O
( O
3 O
) O
examine O
the O
association O
between O
erythema B-outcome ['Physiological-Clinical']
and O
thickness B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

INTERPRETATION O
Addition O
of O
ganitumab O
to O
endocrine O
treatment O
in O
women O
with O
previously O
treated O
hormone-receptor-positive O
locally O
advanced O
or O
metastatic O
breast O
cancer O
did O
not O
improve O
outcomes O
. O
[]

To O
determine O
effects O
of O
aging O
and O
autonomic O
input O
on O
interrelationships O
between O
respiratory O
and O
heart O
rate O
variability O
, O
we O
collected O
5 O
min O
of O
lung O
volume O
of O
R-R O
interval O
data O
from O
7 O
young O
[ O
27 O
+/- O
3 O
( O
SD O
) O
yr O
] O
and O
10 O
older O
( O
69 O
+/- O
6 O
yr O
) O
healthy O
supine O
humans O
before O
and O
after O
double O
pharmacological O
autonomic O
blockade O
with O
propranolol O
( O
0.2 O
mg/kg O
iv O
) O
and O
atropine O
( O
0.04 O
mg/kg O
iv O
) O
. O
[]

Twenty-three O
patients O
in O
the O
control O
group O
were O
asked O
to O
perform O
self-shoulder O
stretching O
exercise O
. O
[]

In O
addition O
, O
PSD O
patients O
should O
be O
classified O
according O
to O
their O
clinical O
profile O
( O
similarly O
to O
patients O
affected O
by O
primary O
depression O
) O
for O
the O
selection O
of O
SSRIs O
or O
reboxetine O
as O
drugs O
of O
choice O
in O
particular O
subgroups O
of O
patients O
. O
[]

The O
patients O
were O
evaluated O
openly O
at O
the O
seventh O
day O
of O
treatment O
for O
cure O
or O
marked O
improvement O
of O
the O
clinical B-outcome ['Physiological-Clinical']
features I-outcome ['Physiological-Clinical']
, O
indicating O
successful O
treatment O
. O
['Physiological-Clinical']

RESULTS O
The O
intra-class O
correlation O
coefficients O
for O
pain B-outcome ['Physiological-Clinical']
, O
stiffness O
and O
function O
values O
were O
0.915 O
, O
0.745 O
and O
0.940 O
, O
respectively O
. O
['Physiological-Clinical']

CONCLUSIONS O
Aliskiren O
significantly O
reduced O
proteinuria B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
study O
demonstrates O
that O
adding O
behavioural O
intervention O
to O
melatonin O
treatment O
seems O
to O
result O
in O
a O
better O
treatment O
response O
, O
at O
least O
in O
the O
short O
term O
. O
[]

On O
stepwise O
multiple O
logistic O
regression O
analysis O
the O
only O
independent O
variables O
related O
to O
the O
presence O
of O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
were O
the O
extent O
of O
wall O
motion O
asynergy O
and O
anterior O
site O
of O
infarction O
. O
['Physiological-Clinical']

The O
pharmacokinetics O
of O
two O
naproxen O
tablet O
formulations O
were O
compared O
after O
oral O
administration O
. O
[]

Analyses O
were O
done O
for O
all O
patients O
with O
available O
data O
at O
3 O
months O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
groups O
in O
height B-outcome ['Physiological-Clinical']
, O
weight O
, O
or O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

8.59 O
mm O
Hg O
, O
p O
< O
0.05 O
) O
groups O
. O
[]

One O
of O
these O
techniques O
is O
glycoPEGylation O
, O
which O
has O
also O
been O
applied O
to O
recombinant O
activated O
factor O
VII O
( O
rFVIIa O
) O
, O
resulting O
in O
a O
rFVIIa O
derivative O
( O
N7-GP O
) O
with O
a O
prolonged O
terminal O
half-life O
( O
t O
( O
1/2 O
) O
) O
. O
[]

RESULTS O
Compared O
to O
children O
using O
conventional O
processing O
, O
receptive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
expressive I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
was O
higher O
but O
receptive B-outcome ['Life-Impact']
vocabulary I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
consonant I-outcome ['Life-Impact']
articulation I-outcome ['Life-Impact']
scores O
were O
lower O
for O
children O
who O
use O
NLFC O
. O
['Life-Impact', 'Life-Impact']

We O
undertook O
a O
two-part O
clinical O
trial O
to O
investigate O
these O
claims O
. O
[]

Interventions O
to O
reduce O
HIV B-outcome ['Life-Impact']
stigma I-outcome ['Life-Impact']
should O
be O
implemented O
as O
part O
of O
the O
formal O
training O
of O
future O
health O
care O
professionals O
. O
['Life-Impact']

Secondary O
outcomes O
included O
changes O
in O
Short O
Physical O
Performance O
Battery O
, O
handgrip O
and O
quadriceps O
strength O
, O
self-reported O
quality O
of O
life O
using O
the O
EQ-5D O
, O
and O
functional O
impairment O
measured O
using O
the O
Functional O
Limitations O
Profile O
. O
[]

The O
effect O
on O
the O
flare B-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
appeared O
within O
1 O
hour O
, O
reached O
a O
maximum O
effect O
4 O
hours O
after O
administration O
, O
and O
persisted O
for O
as O
long O
as O
24 O
hours O
. O
['Physiological-Clinical']

CONCLUSION O
ADAPt-C O
collaborative O
care O
is O
feasible O
and O
results O
in O
significant O
reduction O
in O
depressive O
symptoms O
, O
improvement O
in O
quality O
of O
life O
, O
and O
lower O
pain O
levels O
compared O
with O
EUC O
for O
patients O
with O
depressive O
disorders O
in O
a O
low-income O
, O
predominantly O
Hispanic O
population O
in O
public O
sector O
oncology O
clinics O
. O
[]

With O
the O
present O
procedure O
, O
an O
evaluation O
with O
inclusion O
of O
all O
test O
participants O
is O
possible O
. O
[]

Significant O
effects O
of O
age O
group O
( O
below O
median O
age O
34 O
y O
vs O
median O
age O
and O
above O
) O
were O
noted O
on O
the O
tension B-outcome ['Life-Impact']
and O
fatigue B-outcome ['Physiological-Clinical']
scales O
in O
that O
less O
tension B-outcome ['Life-Impact']
( O
p= O
.045 O
) O
and O
less O
fatigue B-outcome ['Physiological-Clinical']
( O
p= O
.000 O
) O
were O
noted O
in O
those O
aged O
34 O
years O
and O
older O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

METHODS O
Healthy O
infants O
aged O
6 O
to O
< O
16 O
weeks O
and O
16 O
to O
< O
24 O
weeks O
, O
respectively O
, O
were O
randomly O
assigned O
to O
receive O
2 O
doses O
of O
influenza O
vaccine O
, O
or O
placebo O
intranasally O
35 O
+/- O
7 O
days O
apart O
. O
[]

INTRODUCTION O
Early O
treatment O
of O
rheumatoid O
arthritis O
( O
RA O
) O
has O
been O
shown O
to O
retard O
the O
development O
of O
joint B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
for O
a O
period O
of O
up O
to O
5 O
years O
. O
['Physiological-Clinical']

The O
results O
did O
not O
show O
any O
differences O
between O
the O
three O
groups O
, O
neither O
in O
physical B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
characteristic O
nor O
in O
['Life-Impact']

Patients O
in O
each O
group O
showed O
an O
increase O
in O
total O
white B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
WBC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
Medium O
chain O
triglyceride O
( O
MCT O
) O
consumption O
may O
have O
a O
beneficial O
impact O
on O
weight O
management O
, O
however O
, O
some O
studies O
point O
to O
a O
negative O
impact O
of O
MCT O
oil O
consumption O
on O
cardiovascular O
disease O
risk O
. O
[]

The O
distribution O
of O
French-American-British O
( O
FAB O
) O
types O
also O
varied O
with O
age O
; O
FAB B-outcome ['Physiological-Clinical']
types I-outcome ['Physiological-Clinical']
M5 I-outcome ['Physiological-Clinical']
( O
P O
< O
.001 O
) O
and O
M7 B-outcome ['Physiological-Clinical']
( O
P O
< O
.001 O
) O
were O
more O
common O
in O
early O
childhood O
, O
whereas O
older O
children O
were O
more O
likely O
to O
have O
FAB O
types O
M0 O
( O
P O
=.03 O
) O
, O
M1 O
( O
P O
=.04 O
) O
, O
M2 B-outcome ['Physiological-Clinical']
( O
P O
=.005 O
) O
, O
and O
M3 B-outcome ['Physiological-Clinical']
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
difference O
in O
challenge O
with O
histamine O
versus O
challenge O
with O
placebo O
. O
[]

Performances O
on O
four O
verbal B-outcome ['Life-Impact']
and O
two O
nonverbal B-outcome ['Life-Impact']
measures O
right O
after O
instruction O
and O
at O
24-48 O
h O
post-instruction O
, O
revealed O
higher O
scores O
for O
the O
??hands-on?? O
, O
participation O
than O
observation O
group O
on O
both O
verbal O
and O
nonverbal O
tasks O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Patent O
foramen O
ovale O
was O
detected O
significantly O
more O
often O
during O
femoral O
vein O
versus O
upper O
extremity O
contrast O
delivery O
( O
23 O
of O
70 O
patients O
[ O
prevalence O
33 O
% O
] O
vs. O
9 O
of O
70 O
patients O
[ O
prevalence O
13 O
% O
] O
, O
p O
< O
0.001 O
) O
. O
[]

Treatment O
was O
continued O
for O
2 O
years O
or O
until O
death O
. O
[]

BACKGROUND O
AND O
AIMS O
Fast-track O
programs O
have O
been O
introduced O
in O
many O
surgical O
fields O
to O
minimize O
postoperative B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

Anacetrapib O
is O
a O
cholesteryl O
ester O
transfer O
protein O
( O
CETP O
) O
inhibitor O
that O
raises O
HDL-C O
and O
reduces O
LDL-C B-outcome ['Physiological-Clinical']
when O
administered O
alone O
or O
with O
a O
statin O
. O
['Physiological-Clinical']

Symptoms O
of O
depression B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
among O
the O
partners O
decreased O
substantially O
over O
the O
course O
of O
the O
investigation O
. O
['Life-Impact', 'Life-Impact']

Only O
those O
patients O
who O
received O
prenatal O
care O
at O
the O
Central O
Maternity O
Hospital O
for O
Luanda O
were O
included O
in O
the O
study O
. O
[]

Secondary O
analysis O
of O
a O
randomized O
controlled O
trial O
. O
[]

These O
results O
suggest O
that O
for O
patients O
with O
active O
cancer O
receiving O
extended O
duration O
therapy O
with O
low O
molecular O
weight O
heparin O
( O
dalteparin O
) O
there O
is O
no O
accumulation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
anti-Xa I-outcome ['Physiological-Clinical']
effect O
over O
the O
first O
month O
of O
therapy O
. O
['Physiological-Clinical']

A O
double-blind O
comparison O
of O
clomipramine O
, O
desipramine O
, O
and O
placebo O
in O
the O
treatment O
of O
autistic O
disorder O
. O
[]

There O
was O
a O
significant O
linear O
trend O
x O
group O
interaction O
on O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions- O
Improvement O
( O
CGI-I O
) O
and O
50 O
% O
on O
olanzapine O
versus O
20 O
% O
on O
placebo O
were O
responders O
. O
['Physiological-Clinical']

Twenty-three O
of O
the O
81 O
patients O
were O
women O
; O
the O
mean O
age O
for O
all O
patients O
was O
74 O
+/- O
10 O
years O
. O
[]

As O
a O
consequence O
, O
homologous O
transfusions O
could O
be O
avoided O
. O
[]

A O
1-compartment O
open O
linear O
PK O
model O
was O
chosen O
to O
describe O
plasma B-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
of O
clonidine B-outcome ['Resource-use']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Dietary O
sodium O
significantly O
modulated O
E B-outcome ['Physiological-Clinical']
' O
and O
RBF B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
to O
Ang O
II O
infusion O
in O
like O
manner O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
6.7 O
% O
absolute O
increase O
in O
calcium O
absorption O
was O
found O
in O
the O
highest O
vitamin O
D? O
group O
( O
100 O
?g O
) O
. O
[]

In O
this O
randomised O
, O
double-blind O
comparison O
trial O
with O
naltrexone O
( O
NAL O
) O
, O
we O
aimed O
to O
investigate O
the O
efficacy O
of O
PRE O
on O
alcohol B-outcome ['Life-Impact']
drinking I-outcome ['Life-Impact']
indices O
. O
['Life-Impact']

Whether O
these O
agents O
work O
by O
inducing O
immunologic O
stimulation O
or O
simply O
a O
nonspecific O
inflammatory O
reaction O
has O
not O
been O
definitively O
demonstrated O
. O
[]

CONCLUSION O
Inflammatory O
responses O
occur O
during O
and O
after O
oesophagectomy O
, O
which O
can O
be O
inhibited O
with O
UTI O
. O
[]

To O
compare O
the O
efficacy O
and O
safety O
of O
IVF O
and O
IAF O
with O
urokinase O
given O
within O
the O
first O
6 O
hours O
of O
acute O
ischaemic O
stroke O
. O
[]

The O
incidence O
of O
side O
effects O
was O
low O
in O
our O
study O
. O
[]

The O
inconvenience O
of O
this O
parenteral O
regimen O
created O
an O
increased O
need O
for O
oral O
pediatric O
formulations O
for O
the O
treatment O
of O
invasive O
diarrhea O
. O
[]

Effect O
of O
postural O
supports O
on O
neuromotor B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
very O
preterm O
infants O
to O
term O
equivalent O
age O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
authors O
designed O
a O
small O
semi-randomized O
clinical O
trial O
to O
explore O
whether O
long-lasting O
clinically O
important O
gains O
can O
be O
achieved O
by O
adding O
theta O
burst O
stimulation O
( O
TBS O
) O
, O
a O
form O
of O
repetitive O
transcranial O
magnetic O
stimulation O
( O
TMS O
) O
, O
to O
a O
rehabilitation O
program O
for O
the O
hand O
. O
[]

In O
addition O
to O
mechanical O
resistance O
and O
long-term O
stability O
, O
differences O
within O
materials O
also O
exist O
in O
their O
ability O
to O
simultaneously O
bond B-outcome ['Physiological-Clinical']
to O
enamel O
and O
dentin O
. O
['Physiological-Clinical']

Liquid O
fluoxetine O
in O
low O
doses O
is O
more O
effective O
than O
placebo O
in O
the O
treatment O
of O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
childhood O
autism O
. O
['Life-Impact']

A O
placebo O
control O
cycle O
followed O
each O
hormonal O
treatment O
. O
[]

A O
comparison O
of O
three O
procedures O
for O
general O
anesthesia O
( O
propofol O
, O
halothane O
and O
midazolam/fentanyl O
) O
in O
combination O
with O
catheter O
epidural O
anesthesia O
] O
. O
[]

Improvement O
was O
evaluated O
in O
two O
settings O
-- O
preschool O
and O
home O
-- O
by O
teachers O
( O
blind O
to O
group O
) O
and O
parents O
. O
[]

Our O
aim O
was O
to O
perform O
a O
randomised O
controlled O
trial O
( O
RCT O
) O
to O
compare O
anatomical O
knowledge O
of O
two O
groups O
of O
second-year O
medical O
students O
, O
the O
first O
group O
taught O
on O
a O
traditional O
course O
, O
the O
second O
on O
an O
integrated O
course O
. O
[]

Patients O
were O
all O
placed O
in O
a O
sitting O
position O
, O
after O
which O
the O
epidural O
space O
was O
identified O
by O
the O
loss O
of O
resistance O
technique O
and O
a O
midline O
approach O
, O
at O
the O
L-3/4 O
interspace O
. O
[]

Network O
coordination O
following O
discharge O
from O
psychiatric O
inpatient O
treatment O
: O
a O
study O
protocol O
. O
[]

OUTCOMES O
& O
RESULTS O
No O
significant O
treatment O
effect O
was O
found O
for O
the O
primary O
outcome O
measure O
of O
structural B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
or O
for O
a O
measure O
of O
narrative B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

They O
were O
randomly O
assigned O
to O
receive O
spinal O
anaesthesia O
with O
either O
25-gauge O
Quincke O
needle O
or O
24-gauge O
Gertie O
Marx O
needle O
. O
[]

Both O
treatments O
were O
found O
to O
be O
equally O
effective O
and O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
. O
['Life-Impact']

In O
Korea O
, O
MSAT O
is O
used O
to O
reduce O
musculoskeletal O
pain O
and O
improve O
functional O
status O
. O
[]

PATIENTS O
AND O
METHODS O
In O
this O
randomized O
, O
prospective O
, O
placebo-controlled O
, O
multicenter O
trial O
, O
previously O
untreated O
patients O
with O
chronic O
hepatitis O
C O
were O
treated O
with O
IFN-alpha O
plus O
ribavirin O
[ O
17 O
] O
and O
randomized O
for O
treatment O
with O
amantadine O
( O
200 O
mg/day O
, O
orally O
, O
n=136 O
) O
or O
placebo O
( O
n=131 O
) O
. O
[]

The O
study O
can O
detect O
a O
three-point O
difference O
in O
full-scale O
IQ B-outcome ['Life-Impact']
at O
3-year O
follow-up O
. O
['Life-Impact']

The O
corresponding O
figures O
for O
moderate O
nephrotoxicity B-outcome ['Physiological-Clinical']
were O
9.1 O
% O
and O
0 O
% O
. O
['Physiological-Clinical']

No O
significant O
variations O
in O
any O
of O
the O
lipid O
parameters O
monitored O
were O
observed O
in O
the O
placebo O
group O
. O
[]

The O
antidepressant O
effect O
of O
maprotiline O
was O
reflected O
in O
the O
GDS O
. O
[]

Parasuicide B-outcome ['Life-Impact']
risk O
was O
also O
significantly O
greater O
in O
those O
with O
their O
first O
parasuicide O
episode O
at O
an O
earlier O
age O
and O
in O
those O
with O
a O
more O
recent O
latest O
episode O
. O
['Life-Impact']

We O
evaluated O
the O
effect O
of O
S. O
boulardii O
in O
children O
with O
acute O
diarrhoea O
. O
[]

Both O
EBRT O
and O
cryoablation O
participants O
reported O
decreases O
in O
sexual B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
at O
3 O
months O
with O
the O
cryoablation O
patients O
reporting O
poorer O
functioning O
( O
mean O
cryoablation=7.2 O
: O
mean O
EBRT=32.9 O
; O
P O
< O
.001 O
) O
. O
['Life-Impact']

INTERVENTIONS O
INDEPENDENT O
VARIABLE O
type O
of O
intervention O
. O
[]

There O
were O
no O
significant O
differences O
in O
cough B-outcome ['Physiological-Clinical']
, O
use O
of O
cough B-outcome ['Resource-use']
medicine I-outcome ['Resource-use']
, O
general B-outcome ['Life-Impact']
feeling I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
, O
or O
chest B-outcome ['Physiological-Clinical']
congestion I-outcome ['Physiological-Clinical']
between O
the O
erythromycin O
and O
placebo O
groups O
. O
['Physiological-Clinical', 'Resource-use', 'Life-Impact', 'Physiological-Clinical']

The O
primary O
end O
point O
was O
bypass B-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
, O
and O
mortality B-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
were O
the O
secondary O
endpoints O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

RESULTS O
Twenty O
seven O
families O
guessed O
their O
child O
's O
group O
assignment O
correctly O
and O
27 O
guessed O
incorrectly O
. O
[]

Secondarily O
to O
ascertain O
patients O
' O
preferences B-outcome ['Life-Impact']
for O
the O
two O
nasal O
devices O
and O
to O
assess O
quality O
of O
life O
. O
['Life-Impact']

METHODS O
We O
studied O
153 O
anemic O
cancer O
patients O
receiving O
cyclic O
combination O
chemotherapy O
in O
a O
prospective O
multicenter O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

SUBJECTS O
150 O
of O
the O
original O
study O
population O
. O
[]

[ O
Efficacy O
and O
safety O
of O
extended-release O
niacin O
alone O
or O
with O
atorvastatin O
for O
lipid O
profile O
modification O
] O
. O
[]

BACKGROUND O
Helicobacter O
pylori O
infection O
induces O
progressive O
inflammatory B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in O
the O
gastric O
mucosa O
that O
may O
lead O
to O
gastric O
cancer O
. O
['Physiological-Clinical']

OBJECTIVES O
We O
tested O
the O
hypotheses O
that O
the O
stove O
intervention O
, O
compared O
with O
open O
fire O
use O
, O
would O
reduce O
ST-segment B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
and O
increase O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability O
( O
HRV B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

2 O
. O
[]

Effectiveness O
of O
a O
calculus O
scaling O
gel O
. O
[]

Of O
24 O
children O
randomized O
to O
the O
CBT O
arm O
, O
18 O
( O
75 O
% O
) O
were O
treatment O
responders O
, O
versus O
only O
3 O
of O
21 O
children O
( O
14 O
% O
) O
in O
the O
TAU O
arm O
. O
[]

METHODS O
We O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
clinical O
trial O
at O
three O
primary O
care O
centers O
in O
North O
Carolina O
. O
[]

CONCLUSIONS O
Our O
findings O
suggest O
that O
cognitive-behavioral O
therapy O
is O
more O
effective O
than O
standard O
medical O
care O
alone O
in O
reducing O
seizure O
frequency O
in O
PNES O
patients O
. O
[]

The O
mutation B-outcome ['Physiological-Clinical']
contributed O
significantly O
to O
younger O
age O
( O
?55 O
years O
) O
at O
onset O
and O
high O
prostate-specific O
antigen O
( O
PSA O
; O
?20 O
ng/mL O
) O
at O
diagnosis O
. O
['Physiological-Clinical']

Before O
and O
after O
intervention O
, O
parents O
completed O
questionnaires O
about O
their O
and O
their O
children O
's O
skin O
cancer O
risk O
and O
prevention O
knowledge O
and O
behaviors O
. O
[]

The O
objectives O
of O
this O
study O
were O
to O
determine O
the O
effectiveness O
of O
erythromycin O
treatment O
in O
patients O
with O
acute O
bronchitis O
and O
to O
determine O
whether O
a O
newly O
developed O
rapid O
M O
pneumoniae O
antibody O
test O
is O
useful O
in O
predicting O
which O
patients O
will O
respond O
to O
therapy O
. O
[]

Chi-square O
and O
t-tests O
were O
used O
to O
analyze O
the O
incidence O
of O
skin B-outcome ['Physiological-Clinical']
breakdown I-outcome ['Physiological-Clinical']
and O
rectal B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
; O
the O
correlation O
between O
the O
two O
factors O
; O
a O
positive O
history O
of O
rectal O
infections O
, O
fissures O
, O
or O
hemorrhoids O
; O
presence O
of O
hemorrhoids O
; O
severity O
of O
diarrhea O
; O
and O
duration O
and O
severity O
of O
granulocytopenia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Consistent O
with O
the O
anemia O
of O
chronic O
disease O
, O
studies O
have O
documented O
serum O
erythropoietin O
levels O
that O
are O
inappropriately O
low O
for O
the O
degree O
of O
anemia O
in O
cancer O
patients O
. O
[]

RESULTS O
At O
12 O
months O
, O
63 O
% O
of O
intervention O
patients O
had O
a O
50 O
% O
or O
greater O
reduction O
in O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
from O
baseline O
as O
assessed O
by O
the O
Patient O
Health O
Questionnaire-9 O
( O
PHQ-9 O
) O
depression B-outcome ['Life-Impact']
scale O
compared O
with O
50 O
% O
of O
EUC O
patients O
( O
odds O
ratio O
[ O
OR O
] O
= O
1.98 O
; O
95 O
% O
CI O
, O
1.16 O
to O
3.38 O
; O
P O
= O
.01 O
) O
. O
['Life-Impact', 'Life-Impact']

Important O
individual O
differences O
may O
therefore O
exist O
within O
this O
particularly O
difficult O
to O
treat O
population O
that O
act O
as O
moderators O
of O
treatment O
response O
. O
[]

This O
study O
was O
carried O
out O
to O
investigate O
whether O
long-term O
treatment O
with O
Bdp O
after O
polypectomy O
could O
prevent O
formation O
of O
new O
polyps O
and O
reduce O
the O
number O
of O
surgical O
removals O
. O
[]

The O
mean O
increase O
was O
+26 O
% O
following O
apalcillin O
, O
+46 O
% O
after O
piperacillin O
, O
+38 O
% O
following O
mezlocillin O
and O
+55 O
% O
following O
azlocillin O
. O
[]

22 O
patients O
treated O
with O
basic O
therapy O
were O
as O
a O
control O
group O
. O
[]

In O
humans O
, O
only O
noxious O
stimuli O
induce O
counterirritation O
. O
[]

Parents O
in O
the O
COMB O
group O
( O
n O
= O
75 O
; O
60.5 O
% O
) O
received O
a O
mean O
of O
10.9 O
PT O
sessions O
. O
[]

The O
primary O
efficacy O
analysis O
was O
powered O
for O
sitaxsentan O
100 O
mg O
versus O
placebo O
. O
[]

Forty-six O
subjects O
were O
included O
in O
the O
CIU O
group O
, O
21 O
were O
in O
the O
R-CIU O
group O
, O
and O
44 O
were O
in O
the O
control O
group O
. O
[]

Patients O
were O
ventilated O
with O
nitrous O
oxide O
, O
oxygen O
and O
either O
halothane O
or O
enflurane O
. O
[]

fractions O
) O
with O
a O
once-daily O
( O
q.d O
. O
) O
[]

OBJECTIVES O
To O
compare O
the O
tolerance O
, O
adherence O
and O
effectiveness O
of O
two O
approaches O
for O
the O
treatment O
of O
latent O
tuberculosis O
infection O
( O
LTBI O
) O
: O
6 O
months O
of O
isoniazid O
( O
6H O
) O
vs. O
3 O
months O
of O
isoniazid O
plus O
rifampicin O
( O
3RH O
) O
. O
[]

A O
randomized O
controlled O
trial O
of O
group O
Stepping O
Stones O
Triple O
P O
: O
a O
mixed-disability O
trial O
. O
[]

The O
projected O
sample O
size O
was O
302 O
. O
[]

Median O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
longer O
for O
LAVH O
( O
135 O
min O
compared O
with O
120 O
min O
for O
TAH O
; O
P O
= O
0.001 O
) O
, O
but O
patients O
undergoing O
LAVH O
had O
less O
analgesics B-outcome ['Resource-use']
administration I-outcome ['Resource-use']
( O
23 O
% O
compared O
with O
77 O
% O
, O
P O
< O
0.001 O
) O
and O
a O
shorter O
median O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
3.8 O
compared O
with O
5.8 O
days O
; O
P O
< O
0.001 O
) O
. O
['Life-Impact', 'Resource-use', 'Resource-use']

Participants O
were O
randomly O
allocated O
to O
the O
intervention O
( O
n=9 O
) O
or O
control O
( O
n=8 O
) O
group O
using O
a O
concealed O
method O
. O
[]

The O
numbers O
of O
supplemental O
injections O
required O
at O
each O
observation O
period O
and O
the O
total O
volume O
of O
injectate O
required O
to O
produce O
ocular O
and O
lid O
akinesia O
were O
compared O
. O
[]

Naftidrofuryl O
significantly O
improved O
the O
physiological B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
reflected I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
indocyanine I-outcome ['Physiological-Clinical']
green I-outcome ['Physiological-Clinical']
( O
ICG B-outcome ['Physiological-Clinical']
) O
clearance B-outcome ['Physiological-Clinical']
by O
the O
liver O
( O
t O
= O
2.61 O
; O
p O
less O
than O
or O
equal O
to O
0.02 O
) O
and O
also O
caused O
a O
larger O
fall O
in O
raised O
serum O
levels O
of O
gamma O
glutamyl O
transpeptidase O
( O
GGT O
) O
than O
did O
the O
placebo O
injections O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Addition O
of O
a O
thiazide O
diuretic O
will O
reduce O
pressure O
further O
. O
[]

Two O
blind O
randomized O
cross-over O
trials O
in O
the O
treatment O
of O
primary B-outcome ['Physiological-Clinical']
open I-outcome ['Physiological-Clinical']
angle I-outcome ['Physiological-Clinical']
glaucoma I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Nine O
years O
after O
initial O
assessments O
the O
stability O
of O
the O
psychosocial O
and O
economic O
resource O
consequences O
over O
time O
was O
studied O
. O
[]

BACKGROUND O
Penetration O
through O
the O
stratum O
corneum O
limits O
effectiveness O
of O
topical O
anesthetics O
. O
[]

Subjects O
in O
both O
groups O
were O
medically O
managed O
according O
to O
standard O
ICU O
protocols O
. O
[]

At O
puberty O
, O
HS-60 O
heifers O
were O
24 O
and O
22 O
d O
younger O
( O
P O
< O
0.05 O
) O
than O
LS-30 O
and O
control O
heifers O
, O
and O
31 O
kg O
lighter O
( O
P O
< O
0.01 O
) O
than O
LS-30 O
heifers O
. O
[]

METHODS O
Plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
vWf B-outcome ['Physiological-Clinical']
and O
sP-sel B-outcome ['Physiological-Clinical']
were O
measured O
by O
enzyme O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
in O
1321 O
participants O
in O
the O
SPAF O
III O
study O
and O
related O
to O
the O
presence O
and O
onset O
of O
clinical O
CHF O
, O
as O
well O
as O
echocardiographic O
findings O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Furthermore O
, O
bi-directional O
interactions O
between O
trigeminal O
and O
upper O
cervical O
afferents O
may O
also O
explain O
neck O
symptoms O
of O
trigeminal O
origin O
( O
e.g. O
, O
migraine O
) O
. O
[]

hypotension B-outcome ['Physiological-Clinical']
, O
syncope B-outcome ['Physiological-Clinical']
) O
, O
or O
an O
episode O
of O
ventricular B-outcome ['Physiological-Clinical']
flutter I-outcome ['Physiological-Clinical']
or O
fibrillation B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
are O
few O
large O
studies O
comparing O
the O
relative O
side O
effects O
and O
efficacy O
of O
different O
opioids O
in O
labour O
. O
[]

A O
horizontally O
moving O
sound O
was O
presented O
to O
an O
observer O
seated O
in O
the O
center O
of O
an O
anechoic O
chamber O
. O
[]

CONCLUSION O
Laparoscopic O
stripping O
of O
ovarian O
endometriotic O
cyst O
significantly O
decreases O
serum B-outcome ['Physiological-Clinical']
AMH I-outcome ['Physiological-Clinical']
levels O
and O
increases O
basal B-outcome ['Physiological-Clinical']
FSH I-outcome ['Physiological-Clinical']
levels O
independent O
from O
the O
method O
used O
to O
obtain O
hemostasis O
on O
the O
ovarian O
tissue O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
three O
regimens O
were O
well O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact']

A O
randomized O
, O
double-blinded O
, O
placebo-controlled O
study O
. O
[]

After O
multivariate O
logistic O
regression O
analysis O
, O
low B-outcome ['Physiological-Clinical']
operative I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
cardiopulmonary B-outcome ['Physiological-Clinical']
bypass I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CPB I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
> O
100 O
min O
, O
and O
immediate B-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
lactic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
level O
> O
20 O
mg/dl O
were O
associated O
with O
increased O
odds O
of O
developing O
JET O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Among O
399 O
study O
subjects O
, O
the O
rate O
of O
change O
in O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
the O
gemfibrozil O
group O
during O
a O
median O
of O
61 O
months O
was O
not O
significantly O
different O
from O
that O
in O
the O
placebo O
group O
( O
0.49 O
mL/min/1.73 O
m2/y O
faster O
; O
95 O
% O
confidence O
interval O
, O
0.09 O
slower O
to O
1.09 O
faster O
; O
P O
= O
0.10 O
) O
. O
['Physiological-Clinical']

SUBJECTS O
n O
= O
81 O
; O
mean O
age O
11 O
months O
; O
79 O
contribute O
longitudinal O
data O
; O
44 O
every O
measurement O
. O
[]

However O
, O
blood O
cardioplegia O
is O
also O
associated O
with O
myocardial O
damage O
induced O
by O
undesirable O
morphotic O
blood O
elements O
. O
[]

Seventy-four O
post-stroke O
depressed O
patients O
were O
diagnosed O
as O
affected O
by O
anxious O
or O
retarded O
depression O
by O
using O
a O
synoptic O
table O
. O
[]

American O
Knee O
Society O
score O
was O
used O
for O
clinical O
assessment O
preoperatively O
, O
and O
at O
1 O
and O
2 O
years O
. O
[]

The O
drug O
seems O
to O
be O
useful O
in O
the O
treatment O
of O
patients O
with O
benign O
prostatic O
hypertrophy O
. O
[]

When O
dazmegrel O
was O
orally O
administered O
to O
greyhound O
dogs O
wearing O
leg O
casts O
, O
it O
resulted O
in O
a O
sparring O
effect O
on O
the O
skin O
areas O
of O
potential O
pressure O
ulcer O
development O
. O
[]

Pharmacokinetics O
and O
disposition O
of O
carvedilol O
in O
humans O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
A O
total O
of O
79 O
patients O
in O
11 O
Dutch O
centers O
were O
randomized O
to O
16 O
weeks O
of O
continuous O
subcutaneous O
insulin O
infusion O
followed O
by O
16 O
weeks O
intensive O
injection O
therapy O
or O
the O
reverse O
order O
. O
[]

Parents O
completed O
a O
standardized O
autism B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
checklist O
at O
baseline O
and O
posttreatment/postwaitlist O
and O
3-month O
follow-up O
assessments O
. O
['Life-Impact']

OBJECTIVE O
This O
article O
focuses O
on O
patients O
' O
clinical O
and O
psychosocial O
experiences O
with O
CVC O
self-care O
compared O
with O
professionally O
controlled O
CVC O
care O
. O
[]

IMPLICATIONS O
The O
efficacy O
of O
systemic O
lidocaine O
in O
nonneuropathic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
remains O
uncertain O
. O
['Physiological-Clinical']

Responders O
to O
chemotherapy O
did O
not O
fare O
better O
than O
nonresponders O
. O
[]

The O
commonest O
X-ray O
reports O
were O
of O
discovertebral B-outcome ['Physiological-Clinical']
degeneration I-outcome ['Physiological-Clinical']
and O
normal O
findings O
. O
['Physiological-Clinical']

Dexamethasone O
effectively O
reduces O
postoperative O
nausea O
and O
vomiting O
in O
a O
general O
surgical O
adult O
patient O
population O
. O
[]

Active O
treatment O
programs O
for O
patients O
with O
chronic O
low O
back O
pain O
: O
a O
prospective O
, O
randomized O
, O
observer-blinded O
study O
. O
[]

At O
the O
end O
of O
both O
study O
periods O
, O
the O
amount B-outcome ['Resource-use']
of I-outcome ['Resource-use']
bifidobacteria I-outcome ['Resource-use']
was O
significantly O
greater O
after O
the O
ingestion O
of O
LGG O
+ O
GOS O
compared O
with O
LGG O
alone O
( O
geometric O
mean O
9.33 O
x O
10 O
( O
9 O
) O
vs. O
4.28 O
x O
10 O
( O
9 O
) O
CFU/g O
, O
p O
< O
0.001 O
) O
. O
['Resource-use']

7.96 O
vs O
47.67 O
? O
[]

Generally O
, O
more O
patients O
with O
lower O
baseline O
CDAI O
scores O
achieved O
remission O
than O
those O
with O
higher O
scores O
. O
[]

Loxiglumide O
significantly O
reduced O
the O
number O
of O
[]

We O
conclude O
that O
intravenous O
aminophylline O
adds O
to O
the O
toxicity B-outcome ['Adverse-effects']
but O
not O
the O
efficacy O
of O
inhaled O
salbutamol O
in O
the O
treatment O
of O
acute O
exacerbations O
of O
asthma O
. O
['Adverse-effects']

[ O
Dose-effect O
relationship O
of O
isosorbide O
dinitrate O
in O
the O
treatment O
of O
angina O
pectoris O
( O
author O
's O
transl O
) O
] O
. O
[]

Indications O
included O
chronic O
tonsillitis O
and O
obstructive O
sleep O
apnea O
syndrome O
. O
[]

Limitations O
and O
suggestions O
for O
future O
research O
are O
discussed O
. O
[]

Randomized O
comparative O
study O
of O
group O
versus O
individual O
cognitive O
behavioural O
therapy O
for O
obsessive O
compulsive O
disorder O
. O
[]

Patients O
were O
assessed O
at O
baseline O
and O
after O
2 O
, O
4 O
, O
6 O
and O
8 O
weeks O
after O
starting O
medication O
. O
[]

Some O
open-label O
studies O
suggest O
that O
risperidone O
can O
be O
useful O
in O
the O
treatment O
of O
certain O
target O
symptoms O
in O
children O
with O
autism O
. O
[]

Decompression B-outcome ['Physiological-Clinical']
phase O
['Physiological-Clinical']

Positive O
effects O
of O
methylphenidate O
on O
inattention B-outcome ['Life-Impact']
and O
hyperactivity B-outcome ['Life-Impact']
in O
pervasive O
developmental O
disorders O
: O
an O
analysis O
of O
secondary O
measures O
. O
['Life-Impact', 'Life-Impact']

In O
the O
same O
group O
, O
increased O
plasma B-outcome ['Physiological-Clinical']
and O
follicular B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
arginine B-outcome ['Physiological-Clinical']
, O
citrulline B-outcome ['Physiological-Clinical']
, O
NO2-/NO3- B-outcome ['Physiological-Clinical']
, O
and O
IGF-1 B-outcome ['Physiological-Clinical']
was O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
optimal O
waveform O
tilt O
for O
defibrillation O
is O
not O
known O
. O
[]

BALF O
levels O
of O
total O
protein B-outcome ['Physiological-Clinical']
, O
neutrophils B-outcome ['Physiological-Clinical']
, O
and O
leukotriene B-outcome ['Physiological-Clinical']
B4 I-outcome ['Physiological-Clinical']
tended O
to O
decrease O
in O
EPA+GLA O
patients O
over O
the O
course O
of O
the O
study O
as O
compared O
with O
control O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

0.003 O
, O
CES O
1.017 O
? O
[]

No O
significant O
changes O
were O
observed O
in O
either O
the O
sympathetic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
model O
provided O
reasonably O
good O
estimates O
for O
both O
AUC O
and O
Cmax B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
logMAR O
Kay O
picture O
test O
and O
the O
logMAR O
acuity O
test O
: O
a O
comparative O
study O
. O
[]

SETTING O
University O
hospital O
; O
most O
patients O
from O
primary O
catchment O
area O
. O
[]

CONCLUSIONS O
The O
nursing-led O
inpatient O
unit O
was O
associated O
with O
higher O
costs O
however O
, O
the O
question O
of O
whether O
the O
nursing-led O
inpatient O
unit O
is O
cost-effective O
has O
not O
been O
clearly O
answered O
because O
of O
the O
limited O
follow-up O
period O
of O
the O
study O
. O
[]

This O
study O
is O
registered O
with O
ClinicalTrials.gov O
, O
number O
NCT00242203 O
. O
[]

FINDINGS O
1129 O
patients O
were O
assigned O
gefitinib O
and O
563 O
placebo O
. O
[]

RESULTS O
Compared O
with O
open O
operation O
, O
laparoscopic O
colon O
operation O
effectively O
inhibited O
the O
release O
of O
post-operative B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
factors O
and O
yielded O
good O
protection O
via O
post-operative O
cell O
immunity O
. O
['Physiological-Clinical']

A O
third O
of O
patients O
had O
associated O
local B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
while O
another O
third O
had O
associated O
mucous B-outcome ['Physiological-Clinical']
discharge I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ileal B-outcome ['Physiological-Clinical']
digestibility I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
increased O
slightly O
or O
remained O
unchanged O
from O
4 O
to O
8 O
weeks O
and O
decreased O
thereafter O
. O
['Physiological-Clinical']

After O
four O
weeks O
of O
treatment O
82.4 O
% O
, O
81.3 O
% O
, O
and O
93.3 O
% O
of O
the O
low-dose O
group O
, O
high-dose O
group O
, O
and O
placebo O
group O
, O
respectively O
, O
were O
titrated O
to O
the O
maximum O
dose O
level O
. O
[]

The O
14 O
preschool O
special O
education O
teachers O
were O
randomly O
assigned O
to O
one O
of O
three O
groups O
: O
( O
1 O
) O
symbolic O
play O
then O
joint O
attention O
intervention O
, O
( O
2 O
) O
joint O
attention O
then O
symbolic O
intervention O
, O
and O
( O
3 O
) O
wait-list O
control O
period O
then O
further O
randomized O
to O
either O
group O
1 O
or O
group O
2 O
. O
[]

Among O
group O
A O
patients O
, O
the O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
risk O
was O
greater O
in O
those O
randomised O
to O
stenting O
( O
odds O
ratios O
6.603 O
v O
1.197 O
, O
p O
= O
0.046 O
) O
, O
whereas O
there O
was O
no O
difference O
in O
risk O
if O
the O
group O
was O
analysed O
according O
to O
whether O
the O
CFVR O
was O
< O
2.5 O
or O
> O
/= O
2.5 O
after O
balloon O
angioplasty O
. O
['Adverse-effects']

RESULTS O
The O
2 O
groups O
were O
comparable O
in O
baseline O
clinical O
and O
urodynamic O
data O
. O
[]

Signs O
, O
symptoms O
, O
and O
cultures O
were O
evaluated O
at O
the O
beginning O
and O
at O
the O
end O
of O
the O
study O
. O
[]

It O
is O
concluded O
that O
caudal O
diamorphine O
gives O
good O
postoperative O
analgesia O
for O
perianal O
operations O
, O
particularly O
when O
motor O
blockade O
is O
not O
wanted O
by O
the O
surgeon O
. O
[]

Improvement O
, O
as O
evaluated O
by O
CGI O
on O
percentage O
distribution O
of O
the O
patients O
, O
was O
homogeneous O
in O
both O
groups O
. O
[]

Ultrasonic O
and O
power-driven O
instrumentation O
is O
gaining O
in O
significance O
as O
an O
acceptable O
alternative O
to O
manual O
periodontal O
root O
treatment O
. O
[]

The O
results O
confirm O
findings O
that O
nimodipine O
stabilizes O
electroencephalographic B-outcome ['Physiological-Clinical']
vigilance I-outcome ['Physiological-Clinical']
at O
a O
medium O
level O
. O
['Physiological-Clinical']

BACKGROUND O
This O
study O
tried O
to O
resolve O
whether O
glucagon O
is O
a O
better O
premedication O
for O
endoscopic O
retrograde O
cholangiopancreatography O
( O
ERCP O
) O
. O
[]

UNLABELLED O
We O
conducted O
a O
randomized O
controlled O
trial O
to O
compare O
the O
recovery O
characteristics O
of O
selective O
spinal O
anesthesia O
( O
SSA O
) O
and O
desflurane O
anesthesia O
( O
DES O
) O
in O
outpatient O
gynecological O
laparoscopy O
. O
[]

Effect O
of O
TENS O
on O
pain B-outcome ['Physiological-Clinical']
, O
medications B-outcome ['Resource-use']
, O
and O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
following O
coronary O
artery O
bypass O
graft O
surgery O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Blind O
to O
the O
clinician O
, O
patients O
were O
randomly O
allocated O
to O
receive O
a O
copy O
of O
the O
tape O
to O
play O
at O
home O
or O
not O
( O
control O
group O
) O
. O
[]

Other O
parameters O
showed O
a O
similar O
trend O
in O
favor O
of O
HA O
. O
[]

Dentine B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
appears O
to O
correlate O
with O
toothpaste O
abrasivity O
( O
RDA O
value O
) O
. O
['Physiological-Clinical']

Itching B-outcome ['Physiological-Clinical']
was O
depressed O
by O
38 O
% O
following O
betamethasone O
( O
P O
< O
0.05 O
) O
and O
by O
18 O
% O
following O
methylprednisolone O
( O
P=0.07 O
) O
compared O
with O
placebo O
. O
['Physiological-Clinical']

During O
the O
trial O
, O
this O
herd O
experienced O
an O
outbreak O
of O
porcine O
circovirus O
associated O
disease O
( O
PCVAD O
) O
. O
[]

The O
participants O
in O
the O
placebo O
condition O
received O
an O
intervention O
similar O
in O
design O
; O
however O
, O
no O
electrical O
current O
was O
administered O
. O
[]

Preferences O
for O
seeing O
themselves O
on O
the O
screen O
, O
as O
well O
as O
for O
viewing O
the O
VR O
scenarios O
, O
emerged O
from O
the O
data O
. O
[]

The O
oligonucleotide O
primer O
pairs O
for O
the O
microsatellite O
DNA O
markers O
were O
D8S133 O
, O
D8S136 O
, O
D8S137 O
, O
ANK1 O
on O
chromosome O
8p12-21 O
, O
LPLTET O
on O
chromosome O
8p22 O
, O
and O
D17S855 O
( O
intragenic O
to O
the O
BRCA1 O
gene O
) O
on O
chromosome O
17q21 O
. O
[]

Treatment O
with O
buspirone O
in O
a O
patient O
with O
autism O
. O
[]

The O
largest O
effect O
was O
in O
the O
detection O
of O
calcification B-outcome ['Physiological-Clinical']
( O
52 O
% O
vs. O
63 O
% O
at O
16:1 O
compression O
vs. O
original O
images O
, O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

After O
aortic O
unclamping O
, O
ERPF B-outcome ['Physiological-Clinical']
increased O
markedly O
in O
both O
groups O
( O
467.8 O
+/- O
122 O
and O
362.5 O
+/- O
57.7 O
mL/min O
in O
the O
halothane O
and O
isoflurane O
groups O
, O
respectively O
) O
, O
as O
did O
GFR B-outcome ['Physiological-Clinical']
( O
74.8 O
+/- O
22 O
and O
71.8 O
+/- O
13.1 O
mL/min O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTERVENTION O
Following O
random O
assignment O
to O
one O
of O
the O
treatment O
groups O
, O
subjects O
received O
active O
medication O
or O
placebo O
for O
8 O
weeks O
in O
combination O
with O
cognitive O
behavioral O
counseling O
. O
[]

METHODS O
AND O
MATERIALS O
Between O
1985 O
and O
1989 O
, O
200 O
patients O
with O
clinical O
Stage O
III O
noninflammatory O
breast O
cancer O
were O
enrolled O
in O
a O
prospective O
study O
investigating O
neoadjuvant O
and O
adjuvant O
chemotherapy O
. O
[]

A O
randomized O
trial O
of O
tailored O
skin O
cancer O
prevention O
messages O
for O
adults O
: O
Project O
SCAPE O
. O
[]

Physiological O
responses O
, O
such O
as O
water B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
, O
surface B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Results O
indicated O
that O
leptin O
R25C O
genotype O
impacted O
most O
traits O
associated O
with O
fatness O
whereas O
feeding O
ZH O
for O
21 O
d O
affected O
HCW O
and O
ADG O
positively O
but O
impacted O
feed O
intake O
, O
marbling O
, O
and O
USDA O
quality O
grades O
negatively O
. O
[]

In O
a O
double-blind O
, O
randomized O
, O
single-dose O
trial O
the O
analgesic O
contribution O
of O
acetaminophen O
, O
1000 O
mg O
, O
and O
codeine O
, O
60 O
mg O
, O
was O
determined O
. O
[]

Also O
, O
morphometric O
and O
mechanical O
factors O
play O
a O
significant O
role O
in O
predicting O
the O
occurrence O
of O
radial B-outcome ['Physiological-Clinical']
spasm I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
explored O
the O
possibility O
that O
a O
simple O
and O
single O
test O
could O
replace O
the O
modified O
Mallampati O
score O
for O
either O
a O
difficult O
or O
an O
unaccomplished O
tracheal B-outcome ['Physiological-Clinical']
intubation I-outcome ['Physiological-Clinical']
in O
an O
impending B-outcome ['Physiological-Clinical']
hypoxic I-outcome ['Physiological-Clinical']
patient O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
clinical O
efficacy O
and O
safety O
of O
bushen O
quhan O
zhiwang O
decoction O
( O
BQZD O
) O
combined O
methotrexate O
( O
MTX O
) O
in O
treating O
rheumatoid O
arthritis O
( O
RA O
) O
. O
[]

Patients O
who O
did O
not O
improve O
were O
given O
an O
alternative O
treatment O
for O
3 O
more O
months O
. O
[]

No O
differences O
were O
found O
between O
the O
control O
and O
the O
treatment O
group O
with O
respect O
to O
all O
clinical O
parameters O
of O
cardiac O
performance O
after O
cardiopulmonary O
bypass O
. O
[]

CONCLUSION O
AF O
may O
be O
cardioverted O
safely O
and O
effectively O
by O
either O
a O
transthoracic O
or O
a O
transesophageal O
approach O
. O
[]

PURPOSE O
To O
determine O
the O
effect O
of O
intravenously O
administered O
histamine O
on O
both O
retinal O
and O
choroidal O
blood O
flow O
in O
humans O
. O
[]

To O
address O
the O
possible O
effects O
of O
attention O
, O
wait-control O
participants O
received O
3 O
face-to-face O
sessions O
and O
3 O
telephone O
sessions O
during O
the O
first O
6 O
months O
of O
participation O
in O
the O
study O
, O
but O
not O
the O
BCEI O
intervention O
. O
[]

METHODS O
From O
a O
random O
sample O
of O
health O
maintenance O
organization O
( O
HMO O
) O
enrollees O
65 O
years O
and O
older O
, O
1559 O
ambulatory O
seniors O
were O
randomized O
to O
one O
of O
three O
groups O
: O
a O
nurse O
assessment O
visit O
and O
follow-up O
interventions O
targeting O
risk O
factors O
for O
disability O
and O
falls O
( O
group O
1 O
, O
n O
= O
635 O
) O
; O
a O
general O
health O
promotion O
nurse O
visit O
( O
group O
2 O
, O
n O
= O
317 O
) O
; O
and O
usual O
care O
( O
group O
3 O
, O
n O
= O
607 O
) O
. O
[]

The O
mean O
change O
from O
baseline O
( O
day O
1 O
) O
in O
sexual O
function O
on O
day O
29 O
was O
assessed O
using O
the O
Danish O
Prostate O
Symptom O
Score O
Sex O
( O
DAN-PSSsex O
) O
questionnaire O
. O
[]

Clinicians O
who O
improve O
their O
skills O
in O
motivational O
interviewing O
can O
intervene O
more O
effectively O
with O
their O
drinking O
pregnant O
patients O
. O
[]

t.w O
. O
[]

Rate-modulated O
cardiac O
pacing O
based O
on O
transthoracic O
impedance O
measurements O
of O
minute O
ventilation O
: O
correlation O
with O
exercise O
gas O
exchange O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
methylprednisolone I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
determined O
by O
high O
performance O
liquid O
chromatography O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
a O
catheterization O
duration O
of O
2 O
weeks O
increased O
the O
risk O
of O
nosocomial B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
when O
compared O
with O
a O
1-week O
duration O
. O
['Physiological-Clinical']

Patients O
who O
satisfy O
the O
trial O
entry O
criteria O
are O
randomised O
to O
treatment O
by O
coronary O
angioplasty O
or O
coronary O
artery O
bypass O
surgery O
, O
with O
prospective O
stratification O
into O
groups O
with O
one O
, O
two O
, O
or O
three O
treatment O
vessels O
. O
[]

RESULTS O
MLMs O
indicated O
a O
slight O
increase O
in O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
over O
time O
in O
the O
sample O
as O
a O
whole O
. O
['Life-Impact']

We O
therefore O
investigated O
the O
efficacy O
of O
such O
an O
intervention O
in O
a O
larger O
trial O
. O
[]

Also O
, O
no O
difference O
was O
found O
in O
the O
incidence O
and O
severity O
of O
late B-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
genitourinary I-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
between O
the O
two O
treatment O
schedules O
, O
with O
a O
3-year O
rate O
of O
Grade O
2 O
or O
greater O
toxicity O
of O
17 O
% O
and O
16 O
% O
for O
the O
hypofractionation O
arm O
and O
14 O
% O
and O
11 O
% O
for O
the O
conventional O
fractionation O
arm O
, O
respectively O
. O
['Physiological-Clinical']

METHODS O
A O
total O
of O
119 O
patients O
, O
aged O
61-86 O
years O
, O
underwent O
cataract O
surgery O
with O
phacoemulsification O
performed O
by O
a O
single O
surgeon O
. O
[]

Comparative O
effects O
of O
valsartan O
versus O
amlodipine O
on O
left O
ventricular O
mass O
and O
reactive O
oxygen O
species O
formation O
by O
monocytes O
in O
hypertensive O
patients O
with O
left O
ventricular O
hypertrophy O
. O
[]

Low O
resource O
was O
defined O
by O
the O
US O
Department O
of O
Housing O
and O
Urban O
Development O
low-income O
index O
or O
1 O
indicator O
, O
( O
e.g. O
, O
Medicaid O
eligibility O
) O
. O
[]

VEGFR2 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
increased O
at O
residual O
tumor O
histology O
in O
both O
treatment O
arms O
, O
with O
a O
lesser O
extent O
in O
patients O
receiving O
tamoxifen O
plus O
epirubicin O
. O
['Physiological-Clinical']

Mu-power O
increased O
at O
frontal O
and O
central O
sensors O
during O
movement O
observation O
. O
[]

This O
survival B-outcome ['Mortality']
benefit O
was O
maintained O
over O
a O
further O
2 O
years O
of O
follow-up O
( O
P=0.024 O
, O
hazard O
ratio=1.27 O
( O
1.03-1.57 O
) O
) O
. O
['Mortality']

METHODS O
At O
the O
end O
of O
laparoscopic O
cholecystectomy O
, O
in O
a O
double-blind O
, O
randomized O
manner O
, O
one O
of O
the O
following O
injections O
was O
given O
intraperitoneally O
. O
[]

Right O
ventricular O
function O
and O
anatomy O
, O
but O
not O
shunt O
type O
, O
were O
associated O
with O
transplantation O
. O
[]

Combination O
therapy O
did O
not O
appear O
to O
confer O
additional O
benefit O
. O
[]

By O
that O
quarter O
, O
continuous O
sustained O
quitters O
cost B-outcome ['Resource-use']
$ O
541 O
( O
p O
< O
0.001 O
) O
less O
than O
continuing O
smokers O
. O
['Resource-use']

Eighteen O
patients O
were O
randomized O
to O
the O
stoma O
group O
and O
16 O
patients O
to O
the O
nonstoma O
group O
The O
symptomatic B-outcome ['Physiological-Clinical']
anastomotic I-outcome ['Physiological-Clinical']
leakage I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
the O
nonstoma O
group O
( O
37.5 O
percent O
) O
than O
in O
the O
stoma O
group O
( O
5.5 O
percent O
, O
P O
= O
0.02 O
) O
. O
['Physiological-Clinical']

The O
therapeutic O
results O
were O
evaluated O
by O
phlebography O
. O
[]

After O
multivariate O
analysis O
, O
the O
following O
variables O
were O
found O
to O
be O
independent O
predictors O
of O
spasm O
: O
radial O
artery O
diameter O
( O
RD O
) O
/height O
index O
( O
p O
= O
0.005 O
) O
, O
RD/BSA O
index O
( O
p O
= O
0.012 O
) O
, O
and O
sheath O
outer O
diameter O
( O
OD O
) O
/RD O
index O
( O
p O
= O
0.024 O
) O
. O
[]

There O
were O
no O
statistically O
significant O
differences O
in O
postoperative B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
in O
patients O
during O
the O
first O
and O
second O
days O
postsurgery O
. O
['Physiological-Clinical']

Reduction O
of O
oral B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
by O
filgrastim O
( O
r-metHuG-CSF O
) O
in O
patients O
receiving O
chemotherapy O
. O
['Physiological-Clinical']

The O
second O
study O
was O
designed O
to O
assess O
the O
impact O
of O
error O
training O
on O
skill O
evaluation O
and O
was O
done O
using O
both O
novice O
and O
expert O
raters O
. O
[]

Long O
pediatric O
colonoscope O
versus O
intermediate O
length O
adult O
colonoscope O
for O
colonoscopy O
. O
[]

The O
overall O
median O
survival B-outcome ['Mortality']
of O
the O
entire O
group O
was O
13.2 O
months O
. O
['Mortality']

These O
results O
show O
that O
the O
pre-hospital O
thrombolytic O
strategy O
in O
patients O
with O
suspected O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
is O
both O
effective O
and O
safe O
when O
performed O
by O
well-equipped B-outcome ['Life-Impact']
well-staffed B-outcome ['Life-Impact']
mobile O
emergency O
units O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Perioperative B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
was O
faster O
in O
the O
laparoscopic-surgery O
group O
than O
in O
the O
open-colectomy O
group O
, O
as O
reflected O
by O
a O
shorter O
median O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
five O
days O
vs. O
six O
days O
, O
P O
< O
0.001 O
) O
and O
briefer O
use O
of O
parenteral O
narcotics O
( O
three O
days O
vs. O
four O
days O
, O
P O
< O
0.001 O
) O
and O
oral O
analgesics O
( O
one O
day O
vs. O
two O
days O
, O
P=0.02 O
) O
. O
['Physiological-Clinical', 'Resource-use']

There O
were O
no O
significant O
differences O
between O
groups O
in O
change O
of O
[]

We O
found O
by O
means O
of O
clinic O
and O
measurement O
methods O
in O
the O
aR O
of O
7 O
patients O
a O
positive O
reaction O
, O
within O
7 O
patient O
a O
negative O
reaction O
, O
3 O
patients O
had O
a O
unspecific B-outcome ['Physiological-Clinical']
nasal I-outcome ['Physiological-Clinical']
hyperreactivity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
YAP1 B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
was O
scored O
as O
absent O
, O
weak O
, O
intermediate O
or O
strong O
in O
two O
primary O
breast O
cancer O
cohorts O
( O
n O
= O
144 O
and O
n O
= O
564 O
) O
and O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
YAP1 I-outcome ['Physiological-Clinical']
was O
evaluated O
in O
a O
gene O
expression O
dataset O
( O
n O
= O
1107 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Glucose O
utilization O
studies O
show O
that O
sibutramine-induced O
thermogenesis O
is O
mediated O
via O
selective O
sympathetic O
activation O
of O
brown O
adipose O
tissue O
. O
[]

Pain B-outcome ['Physiological-Clinical']
was O
assessed O
using O
the O
Hannallah O
objective O
pain B-outcome ['Physiological-Clinical']
scale O
at O
15 O
, O
30 O
, O
60 O
, O
120 O
, O
and O
360 O
minutes O
postextubation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
findings O
are O
compatible O
with O
the O
lack O
of O
efficacy O
of O
enoxaparin O
in O
reducing O
ischemic O
deficit O
after O
SAH O
. O
[]

METHODS O
Eleven O
patients O
( O
7 O
men O
, O
4 O
women O
) O
were O
enrolled O
in O
the O
study O
. O
[]

OBJECTIVE O
This O
study O
was O
conducted O
to O
compare O
the O
efficacy O
and O
safety O
of O
olopatadine O
ophthalmic O
solution O
( O
0.1 O
% O
) O
with O
ketorolac O
ophthalmic O
solution O
( O
0.5 O
% O
) O
in O
a O
clinical O
model O
of O
acute O
allergic O
conjunctivitis O
. O
[]

The O
study O
involved O
51 O
subjects O
, O
of O
whom O
20 O
( O
39 O
% O
) O
had O
made O
a O
suicide O
attempt O
in O
the O
current O
depressive O
episode O
, O
31 O
( O
61 O
% O
) O
had O
made O
a O
suicide O
attempt O
in O
their O
lifetime O
, O
and O
46 O
( O
90 O
% O
) O
had O
reported O
suicidal O
ideations O
in O
the O
week O
before O
hospitalization O
. O
[]

Bilateral O
transversus O
abdominis O
plane O
block O
does O
not O
decrease O
postoperative O
pain O
after O
laparoscopic O
cholecystectomy O
when O
compared O
with O
local O
anesthetic O
infiltration O
of O
trocar O
insertion O
sites O
. O
[]

The O
reduction O
in O
the O
range O
of O
motion B-outcome ['Physiological-Clinical']
was O
mainly O
caused O
by O
reduced O
hip O
extension O
. O
['Physiological-Clinical']

Generalised O
effects O
of O
music O
therapy O
will O
be O
measured O
using O
standardised O
scales O
completed O
by O
blinded O
assessors O
( O
[]

RESULTS O
Initially O
, O
AP B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
were O
69.9- O
( O
Porphyromonas O
gingivalis O
) O
, O
10.2- O
( O
Aggregatibacter O
actinomycetemcomitans O
) O
, O
5.7- O
( O
Tannerella O
forsythia O
) O
, O
and O
3.3-fold O
( O
Prevotella O
intermedia O
) O
enhanced O
compared O
to O
CP O
cell O
counts O
. O
['Physiological-Clinical']

Fourteen O
patients O
are O
alive O
and O
have O
not O
required O
further O
treatment O
after O
completing O
their O
initial O
12 O
or O
more O
months O
of O
interferon O
. O
[]

BACKGROUND O
A O
biweekly O
regimen O
of O
irinotecan O
200 O
mg/m2 O
on O
day O
1 O
and O
levo-leucovorin O
( O
LV O
) O
250 O
mg/m2 O
plus O
5-fluorouracil O
( O
5-FU O
) O
850 O
mg/m2 O
via O
intravenous O
bolus O
on O
day O
2 O
was O
assessed O
in O
2 O
consecutive O
randomized O
trials O
in O
metastatic O
colorectal O
cancer O
( O
CRC O
) O
. O
[]

With O
the O
advent O
of O
atypical O
agents O
in O
the O
treatment O
of O
schizophrenia O
, O
physicians O
and O
policy O
makers O
must O
consider O
the O
costs O
that O
may O
accompany O
greater O
clinical O
efficacy O
. O
[]

Secondary O
outcome O
measures O
included O
quantitative O
sensory O
tests O
using O
the O
CASE O
IV O
System O
, O
the O
Neuropathy O
Symptom O
and O
Change O
questionnaire O
, O
the O
Patient O
Benefit O
Questionnaire O
( O
PBQ O
) O
, O
and O
a O
global O
symptom O
assessment O
, O
as O
well O
as O
nerve O
conduction O
studies O
and O
occurrence O
of O
new O
plantar O
foot O
ulcers O
. O
[]

The O
pattern O
of O
change O
of O
both O
parameters O
correlated O
at O
a O
high O
level O
of O
significance O
after O
3 O
months O
of O
treatment O
. O
[]

BACKGROUND O
Total O
parenteral O
nutrition O
( O
TPN O
) O
supplemented O
with O
glutamine O
( O
GLN O
) O
has O
been O
reported O
to O
be O
effective O
for O
patients O
with O
bone O
marrow O
transplantation O
( O
BMT O
) O
. O
[]

Objective O
sleep O
parameters O
supported O
Perkins O
's O
hypothesis O
and O
indicated O
that O
among O
women O
, O
NRT O
may O
be O
less O
effective O
at O
suppressing O
certain O
withdrawal B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
compared O
with O
men O
and O
may O
produce O
some O
iatrogenic B-outcome ['Physiological-Clinical']
effects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

GM-CSF O
appears O
to O
improve O
the O
response O
to O
influenza B-outcome ['Resource-use']
vaccination I-outcome ['Resource-use']
in O
some O
groups O
of O
SCT O
patients O
, O
but O
only O
to O
a O
limited O
extent O
. O
['Resource-use']

There O
were O
no O
significant O
changes O
in O
group O
B O
. O
[]

Future O
trials O
in O
HCL O
must O
be O
aware O
of O
the O
risk O
of O
second B-outcome ['Physiological-Clinical']
malignancies I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
results O
show O
that O
stimulus B-outcome ['Life-Impact']
overselectivity I-outcome ['Life-Impact']
can O
be O
greatly O
reduced O
by O
a O
behavioral O
intervention O
that O
controls O
observing O
behavior O
and O
verifies O
discrimination O
, O
but O
that O
exposure O
to O
such O
procedures O
alone O
may O
be O
insufficient O
for O
lasting O
benefits O
. O
['Life-Impact']

Verbal B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
IQ I-outcome ['Life-Impact']
increased O
significantly O
3 O
to O
12 O
months O
after O
interventions O
. O
['Life-Impact']

Effect O
of O
aldose O
reductase O
inhibition O
on O
cardiovascular B-outcome ['Physiological-Clinical']
reflex I-outcome ['Physiological-Clinical']
tests O
in O
patients O
with O
definite O
diabetic O
autonomic O
neuropathy O
over O
a O
period O
of O
2 O
years O
. O
['Physiological-Clinical']

The O
end O
point O
of O
the O
study O
was O
control O
of O
the O
disease O
( O
recovery O
or O
remission O
) O
or O
death O
. O
[]

BACKGROUND O
In O
order O
to O
accommodate O
increasing O
patient O
preferences O
a O
new O
aqueous O
formulation O
of O
triamcinolone O
acetonide O
nasal O
spray O
was O
developed O
for O
the O
relief O
of O
symptoms O
associated O
with O
seasonal O
and O
perennial O
allergic O
rhinitis O
. O
[]

Thus O
, O
median O
TTP B-outcome ['Physiological-Clinical']
was O
6.3 O
, O
45.2 O
, O
and O
17.7 O
mo O
in O
groups O
A O
, O
B O
, O
and O
C O
respectively O
( O
p O
= O
0.0002 O
) O
. O
['Physiological-Clinical']

Using O
personalized O
feedback O
to O
reduce O
alcohol O
use O
among O
hazardous O
drinking O
college O
students O
: O
the O
moderating O
effect O
of O
alcohol-related O
negative O
consequences O
. O
[]

OBJECTIVE O
To O
identify O
factors O
associated O
with O
default O
from O
follow-up O
cervical B-outcome ['Resource-use']
cytology I-outcome ['Resource-use']
tests I-outcome ['Resource-use']
. O
['Resource-use']

Radiation B-outcome ['Resource-use']
and O
contrast O
agent B-outcome ['Life-Impact']
doses I-outcome ['Life-Impact']
were O
evaluated O
. O
['Resource-use', 'Life-Impact']

The O
principle O
symptoms O
were O
fatigue O
, O
breathlessness O
and O
chest O
pain O
. O
[]

Further O
analysis O
( O
Manetl-Naenszel O
test O
) O
showed O
the O
over-all O
difference O
in O
outcome O
to O
be O
significant O
( O
P O
= O
0.049 O
) O
, O
but O
the O
general O
applicability O
of O
this O
result O
may O
be O
limited O
by O
the O
rather O
low O
incidence O
of O
gram-negative O
bacterial O
infections O
in O
this O
study O
. O
[]

The O
results O
of O
a O
pretest-posttest O
control O
group O
design O
study O
that O
evaluated O
the O
effectiveness O
of O
a O
board O
game O
as O
a O
primary O
prevention O
teaching O
strategy O
with O
23 O
sixth O
grade O
children O
in O
Winnipeg O
, O
Manitoba O
are O
presented O
. O
[]

However O
, O
the O
results O
from O
a O
postrecall B-outcome ['Physiological-Clinical']
recognition I-outcome ['Physiological-Clinical']
test O
provide O
evidence O
in O
favor O
of O
the O
distinctiveness O
heuristic O
. O
['Physiological-Clinical']

Mood B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
in O
both O
the O
experimental O
acupuncture O
treatment O
group O
and O
the O
comparison O
acupuncture O
treatment O
group O
showed O
a O
significant O
difference O
between O
the O
baseline O
and O
the O
third O
month O
of O
the O
study O
. O
['Life-Impact']

RESULTS O
Initiation O
of O
pump O
therapy O
within O
1 O
month O
of O
diagnosis O
resulted O
in O
consistently O
higher O
mixed-meal O
tolerance O
test-stimulated O
C-peptide O
values O
at O
all O
time O
points O
, O
although O
these O
differences O
were O
not O
statistically O
significant O
. O
[]

The O
mean/median O
Breslow O
tumor B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
in O
the O
overall O
group O
was O
3.4/2.0 O
mm O
and O
in O
the O
SLN O
positive O
patients O
was O
5.72/4.0 O
mm O
. O
['Physiological-Clinical']

The O
objective O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
of O
an O
intramammary O
infusion O
, O
containing O
tilmicosin O
phosphate O
, O
to O
an O
infusion O
of O
a O
negative O
control O
intramammary O
placebo O
for O
preventing O
new O
intramammary B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
( O
IMI O
) O
during O
the O
dry O
period O
. O
['Physiological-Clinical']

Outcome O
measures O
included O
total O
subjective O
neck B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
shoulder I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
head I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
based O
on O
visual O
analog O
scales O
; O
objective O
total O
range O
of O
neck B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ROM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
the O
['Physiological-Clinical', 'Physiological-Clinical']

Illness B-outcome ['Life-Impact']
cognitions I-outcome ['Life-Impact']
, O
global B-outcome ['Physiological-Clinical']
perceived B-outcome ['Life-Impact']
effect O
and O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

These O
parameters O
are O
the O
net O
result O
of O
combinations O
of O
genetic O
alterations O
effecting O
tumour O
behaviour O
and O
could O
potentially O
reflect O
subtypes O
that O
respond O
differently O
to O
endocrine O
treatment O
. O
[]

Assessments O
were O
completed O
at O
baseline O
and O
12 O
weeks O
later O
, O
immediately O
after O
the O
end O
of O
parent O
coaching O
sessions O
. O
[]

0 O
% O
placebo O
) O
. O
[]

Conventional O
therapy O
as O
used O
in O
this O
study O
was O
suboptimal O
in O
preventing O
subsequent O
bone B-outcome ['Physiological-Clinical']
marrow I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
and O
death B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

on O
day O
1 O
or O
the O
same O
chemotherapy O
, O
plus O
GM-CSF O
10 O
micrograms O
kg-1 O
s.c. O
starting O
from O
day O
4 O
, O
repeated O
as O
soon O
as O
haematopoietic O
recovery O
from O
nadir O
occurred O
. O
[]

The O
operation B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
were O
not O
significantly O
different O
between O
the O
groups O
. O
['Life-Impact']

RESULTS O
Patients O
treated O
with O
erythromycin O
missed O
an O
average O
of O
only O
0.81 O
+/- O
1.1 O
days B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
compared O
with O
2.16 O
+/- O
3.2 O
days O
for O
placebo-treated O
patients O
( O
P O
< O
.02 O
) O
. O
['Life-Impact']

Patients O
were O
examined O
for O
caries O
4 O
, O
8 O
, O
12 O
, O
24 O
, O
36 O
, O
and O
48 O
weeks O
after O
initiation O
of O
treatment O
. O
[]

Controls O
received O
no O
intervention O
. O
[]

Single-agent O
irinotecan O
or O
FOLFIRI O
as O
second-line O
chemotherapy O
for O
advanced B-outcome ['Physiological-Clinical']
colorectal I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
; O
results O
of O
a O
randomised O
phase O
II O
study O
( O
DaVINCI O
) O
and O
meta-analysis O
[ O
corrected O
] O
. O
['Physiological-Clinical']

A O
large-scale O
outcome O
trial O
of O
myoblast O
administration O
in O
HF O
patients O
with O
postinfarction O
cardiomyopathy O
is O
feasible O
and O
warranted O
. O
[]

Furthermore O
, O
a O
significant O
positive O
correlation O
between O
mtDNA O
content O
and O
the O
percentage O
of O
MHCI O
present O
in O
the O
aspired O
samples O
were O
found O
( O
p=0.028 O
) O
. O
[]

Although O
polycythemia O
vera O
and O
the O
other O
myeloproliferative O
diseases O
are O
relatively O
uncommon O
, O
the O
PVSG O
was O
able O
to O
accumulate O
well O
over O
1,000 O
patients O
with O
these O
various O
disorders O
and O
to O
study O
them O
according O
to O
a O
total O
of O
15 O
different O
protocols O
. O
[]

Using O
a O
random O
cross-over O
design O
the O
patients O
were O
submitted O
to O
48 O
hr O
. O
[]

OBJECTIVE O
Coffee O
consumption O
has O
been O
associated O
with O
lower O
risk O
of O
type O
2 O
diabetes O
. O
[]

A O
total O
of O
100 O
patients O
with O
benign O
prostatic O
hyperplasia O
( O
BPH O
) O
and O
overactive O
bladder O
( O
OAB O
) O
symptoms O
( O
BPH/OAB O
) O
, O
enrolled O
between O
June O
2006 O
to O
March O
2008 O
, O
were O
randomly O
divided O
into O
2 O
groups O
of O
morning O
medication O
( O
M O
) O
and O
evening O
medication O
( O
E O
) O
groups O
, O
then O
50 O
mg O
of O
naftopidil O
was O
given O
once O
a O
day O
after O
breakfast O
or O
supper O
for O
8 O
weeks O
. O
[]

No O
subject O
taking O
omeprazole O
developed O
duodenal B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
any I-outcome ['Physiological-Clinical']
grade I-outcome ['Physiological-Clinical']
, O
while O
50 O
% O
taking O
placebo O
developed O
erosions B-outcome ['Physiological-Clinical']
and O
15 O
% O
had O
ulcer B-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Patients O
who O
survive O
life-threatening O
ventricular O
arrhythmias O
are O
at O
risk O
for O
recurrent O
arrhythmias O
. O
[]

couch O
) O
. O
[]

Efficacy O
screening O
trials O
of O
paroxetine O
, O
pentoxifylline O
, O
riluzole O
, O
pramipexole O
and O
venlafaxine O
in O
cocaine O
dependence O
. O
[]

OBJECTIVE O
To O
determine O
the O
clinical O
utility O
of O
a O
limited O
sleep-recording O
device O
used O
unsupervised O
in O
the O
patient O
's O
home O
, O
compared O
with O
in-laboratory O
, O
fully O
supervised O
polysomnography O
for O
the O
diagnosis O
of O
sleep B-outcome ['Physiological-Clinical']
apnea/hypopnea I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SAHS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
to O
assess O
its O
impact O
on O
costs B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

Statistically O
significant O
differences O
in O
the O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
found O
for O
cytomegalovirus B-outcome ['Physiological-Clinical']
( O
CMV B-outcome ['Physiological-Clinical']
) O
infection B-outcome ['Physiological-Clinical']
( O
induction O
, O
32.5 O
% O
vs. O
noninduction O
, O
19.0 O
% O
, O
P=0.009 O
) O
, O
leukopenia B-outcome ['Physiological-Clinical']
( O
37.3 O
% O
vs. O
9.5 O
% O
, O
P O
< O
0.001 O
) O
, O
fever B-outcome ['Physiological-Clinical']
( O
25.2 O
% O
vs. O
10.1 O
% O
, O
P=0.001 O
) O
, O
herpes B-outcome ['Physiological-Clinical']
simplex I-outcome ['Physiological-Clinical']
( O
17.9 O
% O
vs. O
5.7 O
% O
, O
P=0.001 O
) O
, O
and O
thrombocytopenia B-outcome ['Physiological-Clinical']
( O
11.3 O
% O
vs. O
3.2 O
% O
, O
P=0.007 O
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

During O
one O
treatment O
period O
volunteers O
ate O
a O
standard O
supper O
but O
fasted O
for O
24 O
h O
thereafter O
. O
[]

When O
the O
correlation O
among O
individuals O
within O
clusters O
is O
not O
accounted O
for O
in O
statistical O
analysis O
, O
the O
standard O
errors O
are O
biased O
, O
potentially O
resulting O
in O
misleading O
conclusions O
about O
the O
significance O
of O
treatment O
effects O
. O
[]

Racemic O
epinephrine O
has O
been O
advocated O
for O
the O
treatment O
of O
croup O
, O
but O
controlled O
studies O
have O
not O
proved O
it O
more O
effective O
than O
saline O
. O
[]

Thus O
, O
the O
overall O
response O
rate O
of O
patients O
in O
arm O
1 O
and O
arm O
2 O
was O
41.7 O
% O
( O
25/60 O
patients O
) O
and O
33.3 O
% O
( O
20/60 O
patients O
) O
, O
respectively O
( O
p O
= O
0.37 O
) O
. O
[]

Inflammatory B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
were O
measured O
postoperatively O
using O
slit-lamp O
examination O
. O
['Physiological-Clinical']

Endotracheal O
cuff O
pressure O
and O
tracheal O
mucosal O
blood O
flow O
: O
endoscopic O
study O
of O
effects O
of O
four O
large O
volume O
cuffs O
. O
[]

Comparisons O
between O
synchronisation O
and O
continuation O
showed O
a O
pattern O
in O
keeping O
with O
prior O
neuroimaging O
studies O
of O
paced O
finger O
tapping O
. O
[]

CONCLUSIONS O
Behavioral O
interventions O
targeted O
to O
patients O
with O
pain B-outcome ['Physiological-Clinical']
and O
fatigue B-outcome ['Physiological-Clinical']
can O
reduce O
symptom B-outcome ['Physiological-Clinical']
burden I-outcome ['Physiological-Clinical']
, O
improve O
the O
quality O
of O
the O
daily O
life O
of O
patients O
, O
and O
demonstrate O
the O
value-added O
role O
of O
nursing O
care O
for O
patients O
undergoing O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
was O
conducted O
to O
determine O
if O
2.0 O
g/d O
of O
ginger O
could O
decrease O
the O
levels O
of O
PGE B-outcome ['Physiological-Clinical']
( O
2 O
) O
, O
13-hydroxy-octadecadienoic B-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
, O
and O
5- O
, O
12- O
, O
and O
15-hydroxyeicosatetraenoic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( O
5- O
, O
12- O
, O
and O
15-HETE B-outcome ['Physiological-Clinical']
) O
, O
in O
the O
colon O
mucosa O
of O
healthy O
volunteers O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
2 O
weeks O
of O
placebo O
run-in O
period O
, O
105 O
patients O
with O
mild O
or O
moderate O
essential O
hypertension O
were O
randomized O
to O
receive O
either O
enalapril O
( O
10 O
mg O
per O
day O
) O
or O
indapamide O
( O
2.5 O
mg O
per O
day O
) O
for O
8 O
weeks O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
determine O
if O
iron O
interacts O
with O
paracetamol O
and O
reduces O
paracetamol B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
The O
results O
are O
expressed O
as O
means O
+/- O
SD O
. O
[]

It O
causes O
membrane O
depolarisation O
of O
sensory O
neurons O
, O
which O
release O
CGRP O
, O
SP O
and O
other O
pain O
peptides O
; O
excitation O
is O
followed O
by O
a O
refractory O
state O
, O
causing O
inactivation O
. O
[]

Weighted O
blankets O
and O
sleep O
in O
autistic O
children O
-- O
a O
randomized O
controlled O
trial O
. O
[]

Evolution O
of O
coronary O
stenoses O
is O
related O
to O
baseline O
severity O
-- O
a O
prospective O
quantitative O
angiographic O
analysis O
in O
patients O
with O
moderate O
coronary O
disease O
. O
[]

Apart O
from O
epidemics O
of O
poststreptococcal O
glomerulonephritis O
where O
mass O
treatment O
with O
intramuscular O
benzathine-penicillin O
is O
recommended O
, O
no O
recommendation O
exists O
for O
the O
treatment O
of O
pyoderma O
in O
this O
setting O
. O
[]

In O
these O
, O
CP O
stimulation O
had O
no O
effect O
on O
relapse B-outcome ['Physiological-Clinical']
rates O
, O
but O
the O
relapse-free B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
were O
longer O
after O
immune O
stimulation O
: O
control O
3.5 O
months O
( O
mean O
) O
+/- O
1.5 O
( O
s.d O
. O
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
difference O
in O
the O
frequency O
of O
recurrences B-outcome ['Physiological-Clinical']
between O
treatments O
. O
['Physiological-Clinical']

On-trial O
HDL-cholesterol B-outcome ['Physiological-Clinical']
and O
LDL-cholesterol B-outcome ['Physiological-Clinical']
were O
significant O
independent O
determinants O
of O
carotid B-outcome ['Physiological-Clinical']
IMT I-outcome ['Physiological-Clinical']
progression O
, O
jointly O
explaining O
30 O
% O
of O
the O
treatment O
effect O
of O
unopposed O
estrogen O
on O
the O
progression O
of O
carotid B-outcome ['Physiological-Clinical']
IMT I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PDE5 O
inhibition O
with O
sildenafil O
improves O
left O
ventricular O
diastolic O
function O
, O
cardiac O
geometry O
, O
and O
clinical O
status O
in O
patients O
with O
stable O
systolic O
heart O
failure O
: O
results O
of O
a O
1-year O
, O
prospective O
, O
randomized O
, O
placebo-controlled O
study O
. O
[]

A O
precycle B-outcome ['Physiological-Clinical']
risk O
score O
from O
> O
or O
=25 O
to O
< O
40 O
for O
a O
given O
patient O
was O
identified O
as O
being O
the O
optimal O
threshold O
for O
sensitivity O
( O
58.0 O
% O
) O
and O
specificity O
( O
78.7 O
% O
) O
. O
['Physiological-Clinical']

100 O
mg O
modafinil O
on O
psychomotor O
vigilance O
, O
sleepiness O
, O
and O
the O
waking O
and O
sleep O
EEG O
. O
[]

The O
heparin O
increased O
the O
geometric O
mean O
log O
methacholine O
PD20 O
value O
from O
0.47 O
+/- O
0.16 O
( O
2.95 O
mg/ml O
) O
to O
0.96 O
+/- O
0.10 O
( O
8.91 O
mg/ml O
) O
, O
( O
P O
< O
0.0009 O
) O
in O
15 O
patients O
and O
the O
geometric O
mean O
log O
adenosine O
PD20 O
values O
from O
1.59 O
+/- O
0.23 O
( O
38.9 O
mg/ml O
) O
to O
1.98 O
+/- O
0.14 O
( O
97.7 O
mg/ml O
) O
( O
NS O
) O
in O
7 O
patients O
whose O
baseline O
adenosine O
PD20 O
levels O
were O
less O
than O
200 O
mg/ml O
. O
[]

The O
VARS O
of O
EQ-5D O
also O
disclosed O
significant O
changes O
from O
day O
2 O
( O
17 O
, O
P O
< O
0.01 O
) O
. O
[]

Recurrence O
of O
active B-outcome ['Physiological-Clinical']
tuberculosis I-outcome ['Physiological-Clinical']
after O
treatment O
can O
be O
due O
to O
relapse O
of O
infection O
with O
the O
same O
strain O
or O
reinfection O
with O
a O
new O
strain O
of O
Mycobacterium O
tuberculosis O
. O
['Physiological-Clinical']

Intra- O
and O
postoperative O
IABP O
support O
was O
required O
by O
13 O
patients O
( O
21 O
% O
) O
in O
group O
A O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
EVAR O
group O
and O
the O
no O
intervention O
group O
for O
[]

Data O
from O
one O
eye O
without O
media O
opacity O
of O
each O
subject O
were O
analyzed O
. O
[]

The O
IV O
group O
had O
a O
significantly O
faster O
onset B-outcome ['Physiological-Clinical']
of O
analgesic B-outcome ['Resource-use']
effect O
than O
the O
IM O
group O
( O
5 O
vs. O
20 O
min O
) O
. O
['Physiological-Clinical', 'Resource-use']

We O
conclude O
that O
, O
at O
this O
moment O
, O
this O
device O
has O
no O
added O
value O
in O
the O
treatment O
of O
hypertension O
. O
[]

There O
was O
a O
paucity O
of O
bacterial O
species O
at O
baseline O
, O
although O
larger O
infants O
had O
more O
bacterial B-outcome ['Physiological-Clinical']
species I-outcome ['Physiological-Clinical']
( O
1.59 O
+/- O
0.13 O
( O
SEM O
) O
vs O
1.11 O
+/- O
0.12 O
; O
P O
< O
0.03 O
) O
and O
higher O
mean O
log B-outcome ['Physiological-Clinical']
colony I-outcome ['Physiological-Clinical']
forming I-outcome ['Physiological-Clinical']
units I-outcome ['Physiological-Clinical']
( O
CFU B-outcome ['Physiological-Clinical']
) O
( O
8.79 O
+/- O
0.43 O
vs O
7.22 O
+/- O
0.63 O
; O
P O
< O
0.05 O
) O
compared O
with O
infants O
weighing O
less O
than O
1500 O
g O
LGG O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
findings O
offer O
further O
evidence O
for O
the O
limited O
capacity O
of O
the O
low-birth-weight O
infant O
to O
catabolize B-outcome ['Physiological-Clinical']
tyrosine I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Program O
participants O
were O
more O
likely O
to O
report O
sexual O
partner O
notification O
at O
1 O
month O
( O
86 O
% O
control O
, O
92 O
% O
intervention O
; O
adjusted O
odds O
ratio O
[ O
AOR O
] O
= O
1.8 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
1.02 O
, O
3.0 O
) O
and O
were O
more O
likely O
to O
report O
no O
unprotected B-outcome ['Life-Impact']
sexual I-outcome ['Life-Impact']
intercourse I-outcome ['Life-Impact']
at O
6 O
months O
( O
38 O
% O
control O
, O
48 O
% O
intervention O
; O
AOR O
= O
1.5 O
; O
95 O
% O
CI O
= O
1.1 O
, O
2.1 O
) O
. O
['Life-Impact']

The O
success O
of O
public O
health O
efforts O
to O
improve O
the O
health O
status O
of O
all O
Canadians O
depends O
substantially O
on O
the O
success O
of O
educational O
programs O
directed O
toward O
children O
. O
[]

The O
Oxford O
data O
base O
on O
perinatal O
trials O
, O
MEDLINE O
, O
Excerpta O
Medica O
, O
and O
Index O
Medicus O
were O
searched O
. O
[]

Primary O
prophylaxis O
with O
pyrimethamine O
for O
toxoplasmic O
encephalitis O
in O
patients O
with O
advanced O
human O
immunodeficiency O
virus O
disease O
: O
results O
of O
a O
randomized O
trial O
. O
[]

In O
our O
opinion O
, O
the O
use O
of O
thymostimulin O
is O
of O
particular O
use O
only O
in O
those O
subjects O
with O
marked O
immunodepression O
since O
the O
incidence O
of O
post-operative B-outcome ['Physiological-Clinical']
sepsis I-outcome ['Physiological-Clinical']
is O
highest O
in O
this O
group O
. O
['Physiological-Clinical']

Sunbathing B-outcome ['Life-Impact']
and O
sunbed B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
increased O
with O
age O
. O
['Life-Impact', 'Life-Impact']

Four O
subjects O
experienced O
delayed O
symptoms O
like O
diarrhea B-outcome ['Physiological-Clinical']
( O
4x O
) O
, O
flatulence B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
3x I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
headache B-outcome ['Physiological-Clinical']
( O
3x O
) O
, O
pruritus B-outcome ['Physiological-Clinical']
( O
2x O
) O
and O
ocular B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
( O
1x O
) O
starting O
3 O
to O
24 O
hours O
after O
provocation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Urea O
Breath O
Test O
was O
performed O
at O
inclusion O
and O
after O
a O
minimum O
of O
6 O
weeks O
after O
end O
of O
therapy O
. O
[]

Further O
studies O
will O
incorporate O
individualized O
dosing O
based O
on O
pretreatment O
acetylator O
phenotyping O
. O
[]

Quantitative O
measurements O
of O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
. O
['Life-Impact']

All O
patients O
received O
routine O
progesterone O
treatment O
after O
laparoscopic O
surgery O
. O
[]

CONCLUSIONS/IMPLICATIONS O
Overall O
, O
health O
data O
indicated O
that O
the O
Working O
Well O
program O
may O
be O
particularly O
helpful O
to O
VR O
clients O
with O
higher O
rates O
of O
secondary O
health O
conditions O
and O
may O
represent O
one O
strategy O
for O
overcoming B-outcome ['Life-Impact']
barriers I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
employment I-outcome ['Life-Impact']
. O
['Life-Impact']

CONCLUSION O
YXDM O
combined O
with O
BHT O
injection O
had O
better O
effect O
in O
[]

Comparative O
evaluation O
of O
olopatadine O
ophthalmic O
solution O
( O
0.1 O
% O
) O
versus O
ketorolac O
ophthalmic O
solution O
( O
0.5 O
% O
) O
using O
the O
provocative O
antigen O
challenge O
model O
. O
[]

One O
hundred O
anaesthetized O
patients O
( O
ASA O
1-2 O
, O
aged O
18 O
to O
80 O
years O
) O
were O
randomized O
for O
the O
second O
insertion O
attempt O
using O
either O
the O
gum O
elastic O
bougie-guided O
or O
introducer O
tool O
techniques O
. O
[]

CONCLUSIONS O
In O
patients O
undergoing O
abdominal O
surgery O
and O
receiving O
intermittent O
pneumatic O
compression O
, O
fondaparinux O
2.5 O
mg O
reduced O
the O
venous B-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
rate O
by O
69.8 O
% O
as O
compared O
to O
pneumatic O
compression O
alone O
, O
with O
a O
low O
bleeding B-outcome ['Physiological-Clinical']
risk O
as O
compared O
to O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
evaluates O
the O
effects O
of O
an O
intensive O
therapy O
program O
designed O
for O
mentally O
handicapped O
persons O
with O
severely O
disturbed O
or O
autistic O
behavior O
on O
their O
staff O
personal O
which O
had O
an O
active O
role O
in O
the O
program O
. O
[]

Fecal B-outcome ['Physiological-Clinical']
SCFA I-outcome ['Physiological-Clinical']
levels O
varied O
widely O
among O
participants O
at O
entry O
( O
butyrate O
concentrations O
: O
3.5-32.6 O
mmol/kg O
; O
butyrate O
excretions O
: O
0.3-18.2 O
mmol/48 O
h O
) O
. O
['Physiological-Clinical']

In O
autism O
, O
glutamate O
may O
be O
increased O
or O
its O
receptors O
up-regulated O
as O
part O
of O
an O
excitotoxic O
process O
that O
damages O
neural O
networks O
and O
subsequently O
contributes O
to O
behavioral O
and O
cognitive O
deficits O
seen O
in O
the O
disorder O
. O
[]

No O
statistically O
significant O
difference O
in O
fasciculations B-outcome ['Physiological-Clinical']
was O
detected O
between O
the O
two O
groups O
using O
chi O
2 O
analysis O
. O
['Physiological-Clinical']

Trunk O
exercise O
combined O
with O
spinal O
manipulative O
or O
NSAID O
therapy O
for O
chronic O
low O
back O
pain O
: O
a O
randomized O
, O
observer-blinded O
clinical O
trial O
. O
[]

Superoxide B-outcome ['Physiological-Clinical']
dismutase I-outcome ['Physiological-Clinical']
and O
glutathione B-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
as O
well O
as O
the O
concentration O
of O
thiobarbituric B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
reactive I-outcome ['Physiological-Clinical']
substances I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TBARS B-outcome ['Physiological-Clinical']
) O
were O
assessed O
in O
erythrocytes O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
these O
patients O
, O
31 O
completed O
a O
full O
QOL B-outcome ['Life-Impact']
assessment O
on O
the O
first O
day O
of O
preoperative O
nutritional O
support O
, O
one O
day O
before O
surgery O
, O
and O
6 O
months O
after O
surgery O
. O
['Life-Impact']

METHODS O
To O
enter O
the O
study O
, O
children O
with O
sickle O
cell O
anemia O
and O
no O
history O
of O
stroke O
had O
to O
have O
undergone O
two O
transcranial O
Doppler O
studies O
that O
showed O
that O
the O
time-averaged O
mean O
blood-flow O
velocity O
in O
the O
internal O
carotid O
or O
middle O
cerebral O
artery O
was O
200 O
cm O
per O
second O
or O
higher O
. O
[]

In O
contrast O
, O
there O
were O
no O
improvements O
in O
the O
control O
group O
. O
[]

BACKGROUND O
Suture O
knots O
present O
several O
disadvantages O
in O
wound O
closure O
, O
because O
they O
are O
tedious O
to O
tie O
and O
place O
ischemic O
demands O
on O
tissue O
. O
[]

Ecological O
referential O
communication O
is O
shown O
to O
be O
an O
appropriate O
paradigm O
for O
studying O
the O
communicative O
process O
and O
its O
products O
and O
could O
be O
used O
to O
develop O
and O
implement O
a O
training O
program O
focused O
on O
those O
skills O
in O
which O
individuals O
with O
ASD O
are O
most O
deficient O
. O
[]

The O
treatment O
groups O
( O
clonidine O
vs O
clonidine/naltrexone O
) O
were O
similar O
at O
baseline O
with O
respect O
to O
: O
age O
at O
first O
heroin O
use O
( O
21 O
years O
vs O
23 O
years O
) O
, O
mean O
admission B-outcome ['Life-Impact']
opioid I-outcome ['Life-Impact']
craving I-outcome ['Life-Impact']
score O
( O
45/100 O
vs O
49/100 O
) O
, O
and O
withdrawal B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
score O
( O
19/72 O
vs O
18/72 O
) O
. O
['Life-Impact', 'Life-Impact']

The O
ability O
of O
sucrose O
to O
reduce O
clinical O
observational O
scores O
after O
noxious O
events O
in O
newborn O
infants O
should O
not O
be O
interpreted O
as O
pain O
relief O
. O
[]

Our O
aim O
was O
to O
compare O
the O
dose O
effect O
in O
the O
prevention O
of O
tumor O
recurrence O
. O
[]

Routine O
therapies O
for O
COPD O
were O
given O
to O
patients O
in O
the O
control O
group O
, O
while O
15 O
mL O
SI O
was O
given O
to O
those O
in O
the O
treatment O
group O
by O
intravenous O
dripping O
, O
twice O
daily O
for O
total O
14 O
days O
. O
[]

Logistic O
regression O
models O
indicated O
that O
positive O
affect O
was O
associated O
with O
increased O
and O
negative O
affect O
was O
associated O
with O
decreased O
overall O
and O
leisure B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
. O
['Life-Impact']

However O
, O
formoterol O
has O
as O
fast O
an O
onset O
of O
action O
as O
salbutamol O
with O
the O
additional O
benefit O
of O
longer-lasting O
bronchodilation O
( O
approximately O
12 O
h O
) O
. O
[]

In O
linear O
regression O
, O
factors O
that O
predicted O
the O
overall B-outcome ['Life-Impact']
unpleasantness I-outcome ['Life-Impact']
of O
the O
experience O
were O
primarily O
pain B-outcome ['Physiological-Clinical']
experienced O
and O
secondarily O
unpleasantness B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
taste I-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

This O
study O
examined O
the O
effects O
of O
a O
virtual O
reality O
distraction O
intervention O
on O
chemotherapy-related O
symptom B-outcome ['Physiological-Clinical']
distress I-outcome ['Physiological-Clinical']
levels O
in O
16 O
women O
aged O
50 O
and O
older O
. O
['Physiological-Clinical']

During O
on-demand O
treatment O
, O
rates O
of O
discontinuation B-outcome ['Life-Impact']
because O
of O
inadequate O
['Life-Impact']

RESULTS O
BG O
was O
related O
to O
age O
and O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
on O
treatment O
but O
no O
subject O
became O
hypoglycaemic O
on O
or O
off O
therapy O
prior O
to O
07.00 O
h. O
Five O
children O
( O
aged O
3 O
, O
4 O
, O
7 O
, O
8 O
and O
11 O
years O
) O
were O
hypoglycaemic B-outcome ['Physiological-Clinical']
between O
07.00 O
and O
12.00 O
h O
off O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Antigen O
pre-treatment O
in O
animals O
undoubtedly O
prolongs O
graft B-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
. O
['Life-Impact']

Longer O
follow-up O
will O
, O
however O
, O
be O
necessary O
to O
substantiate O
this O
hypothesis O
. O
[]

The O
effect O
of O
acupressure O
at O
the O
extra O
1 O
point O
on O
subjective O
and O
autonomic B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
needle O
insertion O
. O
['Physiological-Clinical']

We O
performed O
a O
matched O
case-control O
study O
to O
identify O
risk O
factors O
for O
JET O
and O
a O
matched-cohort O
study O
to O
compare O
outcomes O
between O
patients O
and O
controls O
. O
[]

It O
was O
used O
the O
Autism B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
( O
ABC O
) O
to O
interview O
the O
mothers O
, O
and O
the O
Sample O
of O
Vocal B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
( O
SVB O
) O
, O
in O
three O
occasions O
: O
at O
the O
beginning O
of O
the O
intervention O
process O
( O
time O
0 O
) O
, O
six O
months O
later O
( O
time O
1 O
) O
and O
12 O
months O
later O
( O
time O
2 O
) O
. O
['Life-Impact', 'Life-Impact']

Visual O
field O
progression O
in O
the O
Collaborative O
Initial O
Glaucoma O
Treatment O
Study O
the O
impact O
of O
treatment O
and O
other O
baseline O
factors O
. O
[]

In O
none O
of O
the O
patients O
under O
study O
proarrhythmic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical']

IVF O
and O
IAF O
have O
never O
been O
compared O
. O
[]

CONCLUSIONS O
The O
Sacred O
Heart O
Halo O
and O
Vantage O
baskets O
resulted O
in O
the O
most O
expeditious B-outcome ['Physiological-Clinical']
stone I-outcome ['Physiological-Clinical']
extraction I-outcome ['Physiological-Clinical']
, O
especially O
for O
2 O
to O
5 O
mm O
calculi O
while O
the O
Microvasive O
Zerotip O
was O
optimal O
for O
8 O
mm O
calculi O
. O
['Physiological-Clinical']

INCLUSION O
CRITERIA O
severe O
coronary O
stenosis O
of O
anterior O
descending O
coronary O
artery O
; O
no O
collateral O
flow O
on O
angiography O
; O
at O
least O
two O
normokinetic O
segments O
in O
the O
myocardial O
region O
supplied O
by O
the O
vessel O
being O
bypassed O
. O
[]

CONCLUSIONS O
In O
the O
treatment O
of O
uncomplicated B-outcome ['Physiological-Clinical']
gonorrhea I-outcome ['Physiological-Clinical']
, O
a O
single O
dose O
of O
cefixime O
( O
400 O
or O
800 O
mg O
) O
given O
orally O
appears O
to O
be O
as O
effective O
as O
the O
currently O
recommended O
regimen O
of O
ceftriaxone O
( O
250 O
mg O
given O
intramuscularly O
) O
. O
['Physiological-Clinical']

EE20/LNG100 O
presented O
reductions O
of O
20 O
% O
and O
42 O
% O
, O
respectively O
, O
but O
without O
statistical O
significance O
. O
[]

METHODS O
A O
total O
of O
20 O
patients O
( O
2-18 O
years O
) O
fasted O
for O
14 O
h O
( O
22.00-12.00 O
h O
) O
on O
two O
occasions O
as O
part O
of O
a O
randomized O
cross-over O
study O
. O
[]

Therapy O
was O
started O
at O
an O
average O
time O
of O
8.5 O
hours O
after O
onset O
of O
symptoms O
. O
[]

METHODS O
Children O
6 O
to O
15 O
years O
of O
age O
were O
randomized O
to O
receive O
acetaminophen O
and O
hydrocodone O
( O
167 O
mg/2.5 O
mg/5 O
mL O
) O
for O
3 O
days O
after O
surgery O
: O
Group O
A O
( O
N=39 O
) O
-every O
4 O
hours O
PRN O
, O
with O
standard O
postoperative O
instructions O
; O
Group O
B O
( O
N=34 O
) O
-every O
4 O
hours O
ATC O
, O
with O
standard O
postoperative O
instructions O
, O
without O
nurse O
coaching O
; O
and O
Group O
C O
( O
N=40 O
) O
-every O
4 O
hours O
ATC O
, O
with O
standard O
postoperative O
instructions O
, O
with O
coaching O
. O
[]

PURPOSE O
The O
aim O
of O
the O
study O
was O
to O
find O
out O
whether O
pre-operative O
radiochemotherapy O
had O
any O
survival B-outcome ['Mortality']
advantage O
over O
postoperative O
radiochemotherapy O
for O
rectal O
carcinoma O
patients O
without O
distant O
metastasis O
or O
peritoneal O
carcinomatosis O
. O
['Mortality']

Comparison O
of O
tidal O
volumes O
obtained O
by O
one-handed O
and O
two-handed O
ventilation O
techniques O
. O
[]

After O
11 O
and O
23 O
h O
waking O
, O
subjects O
received O
200 O
mg O
caffeine O
and O
placebo O
in O
double-blind O
, O
cross-over O
manner O
. O
[]

Clinically O
, O
46 O
femoral O
shaft O
fractures O
were O
randomized O
to O
treatment O
with O
Gross-Kempf O
nails O
, O
24 O
with O
slotted O
nails O
and O
22 O
with O
non-slotted O
nails O
. O
[]

MAIN O
OUTCOME O
MEASURE O
( O
S O
) O
Delta O
stage-of-change O
and O
rate O
of O
maintained B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
at O
12 O
months O
post O
follow-up O
. O
['Life-Impact']

Reductions O
in O
sICAM-1 B-outcome ['Physiological-Clinical']
were O
accompanied O
by O
improvement O
in O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
tests O
but O
not O
in O
the O
lymphocyte O
activation O
marker O
, O
soluble O
interleukin-2 O
receptor O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
totally O
effective O
rate O
in O
group O
A O
[ O
90.5 O
% O
( O
38/42 O
) O
] O
was O
superior O
to O
that O
in O
group O
B O
[ O
66.7 O
% O
( O
28/42 O
) O
, O
P O
< O
0.01 O
] O
. O
[]

Data O
were O
collected O
at O
25 O
sites O
across O
the O
state O
of O
North O
Carolina O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
memantine O
plus O
risperidone O
in O
the O
treatment O
of O
children O
with O
autism O
. O
[]

CONCLUSION O
In O
this O
study O
, O
overweight O
patients O
who O
were O
submitted O
to O
LA O
had O
less O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
a O
faster O
postoperative B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
than O
overweight O
patients O
who O
had O
OA O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Unopposed O
estrogen O
increases O
total O
plasma O
factor O
VII O
, O
but O
not O
active O
factor O
VII O
-- O
a O
short-term O
placebo-controlled O
study O
in O
healthy O
postmenopausal O
women O
. O
[]

ME-609 O
( O
Xerese O
, O
Xerclear O
) O
is O
a O
combination O
of O
5 O
% O
acyclovir O
and O
1 O
% O
hydrocortisone O
developed O
for O
the O
topical O
treatment O
of O
HSL O
. O
[]

A O
simplified O
score O
for O
transfer O
of O
patients O
requiring O
mechanical O
ventilation O
to O
a O
long-term O
care O
hospital O
. O
[]

Resolution O
( O
i.e. O
, O
the O
proportion O
of O
patients O
with O
signs B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Side O
effects O
are O
the O
main O
reason O
for O
drug O
discontinuation O
, O
occurring O
more O
often O
with O
venlafaxine O
. O
[]

Postoperative O
physiotherapy O
has O
been O
shown O
to O
reduce O
the O
incidence O
of O
postoperative O
pulmonary O
complications O
after O
open O
abdominal O
surgery O
. O
[]

Liver B-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
did O
a O
randomised O
controlled O
trial O
of O
338 O
patients O
aged O
60 O
years O
or O
older O
who O
had O
aneurysms O
of O
at O
least O
5.5 O
cm O
in O
diameter O
and O
who O
had O
been O
referred O
to O
one O
of O
31 O
hospitals O
in O
the O
UK O
. O
[]

In O
78 O
children O
known O
to O
be O
infected O
with O
Ascaris O
at O
baseline O
, O
the O
rate O
of O
weight O
[]

The O
faux O
pas O
is O
a O
particular O
case O
of O
a O
non-intentional O
action O
reflecting O
an O
involuntary O
socially O
inappropriate O
behavior O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
Eight O
subjects O
completed O
a O
three-part O
double-blinded O
randomized O
controlled O
study O
of O
premeal O
exenatide O
. O
[]

Supplemented O
sheep O
were O
offered O
a O
concentrate O
mix O
daily O
on O
an O
individual O
basis O
. O
[]

CONCLUSION O
Risperidone O
given O
to O
children O
with O
autism O
at O
doses O
up O
to O
3.5 O
mg O
for O
up O
to O
8 O
weeks O
appears O
to O
have O
no O
detrimental O
effect O
on O
cognitive B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Life-Impact']

Plasma B-outcome ['Physiological-Clinical']
clonidine I-outcome ['Physiological-Clinical']
concentration O
data O
were O
obtained O
from O
a O
clinical O
trial O
in O
which O
36 O
newborns O
, O
aged O
1 O
to O
25 O
days O
( O
postnatal O
age O
, O
PNA O
) O
and O
weighing O
2.1 O
to O
3.9 O
kg O
, O
were O
enrolled O
to O
take O
multiple O
oral O
doses O
of O
clonidine O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
open O
, O
prospective O
, O
randomised O
study O
was O
to O
estimate O
the O
eventual O
benefits O
from O
the O
inclusion O
of O
high-dose O
cytarabine O
in O
the O
cisplatin-5-fluorouracil O
( O
5-FU O
) O
regimen O
as O
first-line O
treatment O
of O
patients O
with O
advanced O
head O
and O
neck O
cancer O
. O
[]

CONCLUSIONS O
Nizatidine O
CR O
( O
150 O
and O
300 O
mg O
) O
significantly O
enhanced O
gastric B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
of O
a O
standard O
meal O
in O
patients O
with O
GERD O
with O
DGE O
. O
['Physiological-Clinical']

Twenty O
healthy O
volunteers O
were O
randomized O
to O
a O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
to O
determine O
if O
omeprazole O
, O
40 O
mg/day O
prevents O
gastroduodenal O
injury O
due O
to O
two O
weeks O
of O
aspirin O
administration O
( O
650 O
mg O
four O
times O
a O
day O
) O
. O
[]

Positive O
differences O
were O
found O
for O
changes O
in O
the O
secondary O
outcomes O
: O
the O
NPI-Q O
sum O
score O
as O
well O
as O
the O
subscales O
NPI-Q O
agitation B-outcome ['Life-Impact']
and O
['Life-Impact']

Outcomes O
of O
early B-outcome ['Physiological-Clinical']
endovascular I-outcome ['Physiological-Clinical']
versus I-outcome ['Physiological-Clinical']
surgical I-outcome ['Physiological-Clinical']
treatment I-outcome ['Physiological-Clinical']
of O
ruptured O
cerebral B-outcome ['Physiological-Clinical']
aneurysms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

To O
address O
these O
questions O
, O
we O
compared O
the O
effects O
of O
captopril O
, O
quinapril O
and O
placebo O
on O
blood O
pressure O
, O
urinary O
excretion O
of O
2,3-dinor-6-keto-PGF1 O
alpha O
, O
and O
the O
vasodepressor O
response O
to O
i.v O
. O
[]

DATA O
SOURCES/STUDY O
SETTING O
Information O
on O
nurse O
practices O
was O
abstracted O
from O
the O
clinical O
records O
of O
patients O
admitted O
between O
June O
2000 O
and O
November O
2001 O
to O
the O
care O
of O
354 O
study O
nurses O
at O
a O
large O
, O
urban O
, O
nonprofit O
home O
care O
agency O
. O
[]

The O
Promotion O
of O
Breastfeeding O
Intervention O
Trial O
( O
PROBIT O
) O
is O
a O
cluster-randomized O
trial O
of O
a O
breast-feeding O
promotion O
intervention O
based O
on O
the O
WHO/UNICEF O
Baby-Friendly O
Hospital O
Initiative O
. O
[]

Comparison O
of O
succinylcholine O
with O
two O
doses O
of O
rocuronium O
using O
a O
new O
method O
of O
monitoring O
neuromuscular B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
at O
the O
laryngeal O
muscles O
by O
surface O
laryngeal O
electromyography O
. O
['Physiological-Clinical']

BACKGROUND O
Postoperative O
pain O
following O
endoscopic O
thyroidectomy O
, O
although O
less O
severe O
than O
after O
open O
methods O
, O
is O
still O
a O
source O
of O
marked O
discomfort O
and O
surgical O
stress O
. O
[]

The O
mean O
isometric B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
of O
the O
quadriceps B-outcome ['Physiological-Clinical']
muscles O
increased O
significantly O
during O
long-term O
GH O
therapy O
( O
p O
less O
than O
0.01 O
) O
, O
but O
remained O
lower O
compared O
with O
that O
of O
normal O
subjects O
( O
1.66 O
( O
0.10 O
) O
vs O
2.13 O
( O
0.11 O
) O
Nm/kg O
body O
weight O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
This O
study O
explores O
4th O
grade O
student O
assessment O
of O
their O
sun O
protection O
behaviors O
. O
[]

and O
AUCtablet O
were O
4,049 O
and O
3,334 O
ng.h/ml O
, O
respectively O
. O
[]

Conducting O
the O
clinical O
drug O
trial O
was O
greatly O
facilitated O
by O
the O
appropriate O
setting O
and O
experienced O
clinical O
pharmacology O
staff O
. O
[]

ACE O
inhibitors O
or O
AT-1 O
antagonists O
- O
which O
is O
OPTIMAAL O
after O
acute O
myocardial O
infarction O
? O
[]

Complete B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Breast O
cancer O
is O
the O
most O
common O
invasive O
cancer O
among O
women O
in O
developed O
countries O
. O
[]

OBJECTIVE O
This O
study O
was O
undertaken O
to O
compare O
the O
effectiveness O
of O
a O
protocol O
of O
combination O
of O
laser O
with O
plyometric O
exercises O
and O
a O
protocol O
of O
placebo O
laser O
with O
the O
same O
program O
, O
in O
the O
treatment O
of O
tennis O
elbow O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

2 O
. O
[]

There O
was O
no O
significant O
difference O
in O
bleeding B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
between O
the O
two O
regimens O
. O
['Physiological-Clinical']

Improved O
local O
control O
of O
invasive O
bladder O
cancer O
by O
concurrent O
cisplatin O
and O
preoperative O
or O
definitive O
radiation O
. O
[]

Pain B-outcome ['Physiological-Clinical']
was O
assessed O
on O
a O
visual O
analogue O
scale O
before O
and O
after O
TENS O
at O
each O
visit O
and O
the O
data O
were O
analysed O
with O
the O
analysis O
of O
variance O
( O
ANOVA O
) O
for O
repeated O
measures O
. O
['Physiological-Clinical']

In O
study O
group O
, O
the O
positive O
factor O
, O
negative O
factor O
and O
total O
scores O
of O
PANSS O
in O
the O
12 O
( O
th O
) O
weekend O
of O
treatment O
[ O
( O
12.0 O
? O
[]

Rapeseed O
and O
soybean O
products O
as O
protein O
sources O
for O
growing O
turkeys O
of O
different O
ages O
. O
( O
[]

Patients O
were O
randomly O
assigned O
to O
either O
levosulpiride O
( O
25 O
mg O
tid O
) O
, O
domperidone O
( O
10 O
mg O
tid O
) O
, O
metoclopramide O
( O
10 O
mg O
tid O
) O
or O
placebo O
( O
1 O
tablet O
tid O
) O
for O
4 O
weeks O
. O
[]

Patients O
with O
acute O
myelogenous O
leukemia O
in O
relapse O
who O
were O
ineligible O
for O
further O
anthracycline O
therapy O
either O
because O
they O
were O
judged O
to O
be O
anthracycline O
resistant O
or O
had O
received O
the O
maximum O
doses O
were O
randomized O
to O
receive O
high-dose O
cytarabine O
( O
3 O
g/m2 O
every O
12 O
hours O
for O
6 O
days O
) O
or O
amsacrine O
( O
75 O
mg/m2 O
daily O
for O
7 O
days O
) O
. O
[]

DESIGN O
This O
was O
a O
16-week O
prospective O
, O
double O
blinded O
, O
randomized O
controlled O
trial O
of O
40 O
women O
with O
laparoscopically O
confirmed O
endometriosis O
. O
[]

Intravenous O
adenosine O
activates O
diffuse O
nociceptive O
inhibitory O
controls O
in O
humans O
. O
[]

It O
is O
concluded O
that O
such O
isotonic O
or O
isometric O
training O
of O
thrice O
a O
week O
for O
ten O
weeks O
, O
requiring O
no O
equipment O
, O
less O
time O
and O
space O
can O
be O
promoted O
to O
improve O
physical B-outcome ['Life-Impact']
fitness I-outcome ['Life-Impact']
. O
['Life-Impact']

OBJECTIVES O
To O
determine O
the O
efficacy O
of O
2 O
distinct O
6-week O
robot-assisted O
reaching O
programs O
compared O
with O
an O
intensive O
conventional O
arm O
exercise O
program O
( O
ICAE O
) O
for O
chronic B-outcome ['Physiological-Clinical']
, O
stroke-related B-outcome ['Physiological-Clinical']
upper-extremity I-outcome ['Physiological-Clinical']
( O
UE B-outcome ['Physiological-Clinical']
) O
impairment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
TCT O
and O
ECD O
data O
were O
acquired O
in O
25 O
randomly O
selected O
patients O
. O
[]

This O
study O
compared O
two O
formats O
of O
a O
social O
story O
targeting O
the O
improvement O
of O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
during O
game O
play O
using O
a O
pretest O
posttest O
repeated O
measures O
randomized O
control O
group O
design O
. O
['Life-Impact']

There O
were O
no O
statistically O
significant O
differences O
between O
buspirone O
and O
placebo O
on O
any O
of O
the O
outcome O
measures O
. O
[]

Both O
ibutilide O
and O
procainamide O
significantly O
enhanced O
( O
p O
< O
0.001 O
) O
pacing-induced B-outcome ['Physiological-Clinical']
termination I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
flutter I-outcome ['Physiological-Clinical']
compared O
with O
placebo O
. O
['Physiological-Clinical']

Randomized O
controlled O
trial O
was O
performed O
in O
two O
groups O
. O
[]

The O
mean O
+/- O
SD O
followup O
period O
was O
31.1 O
+/- O
20 O
months O
for O
group O
A O
and O
35.9 O
+/- O
16.8 O
months O
for O
group O
B O
. O
[]

Treatment O
failures B-outcome ['Physiological-Clinical']
( O
including O
relapses O
) O
occurred O
at O
each O
visit O
in O
5.8 O
% O
, O
12.7 O
% O
and O
10.7 O
% O
of O
amoxicillin O
recipients O
and O
6.2 O
% O
, O
11.9 O
% O
and O
11.3 O
% O
of O
penicillin O
V O
recipients O
, O
respectively O
. O
['Physiological-Clinical']

PARTICIPANTS O
Men O
and O
women O
( O
n O
= O
110 O
) O
50 O
years O
old O
and O
older O
from O
3 O
south O
Florida O
counties O
. O
[]

All O
patients O
were O
followed O
for O
16 O
weeks O
. O
[]

However O
, O
platelet B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
to O
> O
20 O
x O
10 O
( O
9 O
) O
/L O
was O
significantly O
longer O
in O
treatment O
group O
than O
control O
group O
( O
26 O
v O
16 O
days O
; O
P O
=.009 O
) O
and O
> O
50 O
x O
10 O
( O
9 O
) O
/L O
tended O
to O
take O
longer O
in O
the O
treatment O
group O
( O
29 O
v O
26 O
days O
; O
P O
=.126 O
) O
, O
with O
significantly O
more O
platelet B-outcome ['Physiological-Clinical']
transfusion-dependent I-outcome ['Physiological-Clinical']
days O
( O
27 O
v O
13 O
days O
; O
t-test O
, O
P O
=.037 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Concomitant O
infusion O
of O
ANF O
3 O
pmol O
kg-1 O
min-1 O
and O
15 O
pmol O
kg-1 O
min-1 O
significantly O
attenuated O
this O
rise O
in O
plasma O
aldosterone O
to O
approximately O
130 O
% O
( O
P O
less O
than O
0.05 O
) O
and O
110 O
% O
( O
P O
less O
than O
0.01 O
) O
of O
baseline O
values O
respectively O
. O
[]

The O
formation O
of O
perindoprilat B-outcome ['Physiological-Clinical']
was O
slightly O
reduced O
in O
the O
group O
also O
receiving O
hydrochlorothiazide O
and O
there O
was O
a O
very O
small O
reduction O
in O
ACE B-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
in O
this O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Studies O
in O
animals O
show O
good O
healing O
after O
1 O
to O
2 O
weeks O
of O
ureterotomy O
. O
[]

OBJECTIVE O
To O
compare O
18-month O
outcomes O
of O
N-terminal O
BNP-guided O
vs O
symptom-guided O
heart O
failure O
therapy O
. O
[]

When O
the O
four O
significant O
variables O
were O
compared O
against O
each O
other O
in O
a O
single O
regression O
analysis O
, O
IEP O
quality O
accounted O
for O
one O
quarter O
of O
the O
variance O
in O
child O
outcomes O
. O
[]

Bacteriologic O
studies O
of O
feces O
and O
colon O
content O
revealed O
no O
significant O
difference O
in O
the O
reduction O
of O
aerobic B-outcome ['Physiological-Clinical']
bacteria I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
investigation O
was O
to O
determine O
: O
( O
1 O
) O
Is O
positioning O
with O
the O
unaffected O
lung O
in O
the O
dependent O
lateral O
position O
related O
to O
increased O
arterial O
blood O
saturation O
levels O
and O
decreased O
blood O
pressure O
, O
pulse O
and O
respiration O
? O
( O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
root O
mean O
square O
of O
the O
successive O
differences O
in O
R-R B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
on O
the O
ECG B-outcome ['Physiological-Clinical']
( O
RMSSD B-outcome ['Physiological-Clinical']
) O
, O
and O
preejection B-outcome ['Physiological-Clinical']
period O
( O
PEP O
) O
were O
simultaneously O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Approximately O
one-third O
of O
all O
patients O
with O
acute O
nontraumatic O
subarachnoid O
hemorrhage O
( O
SAH O
) O
experience O
complications O
owing O
to O
delayed O
ischemic O
deficit O
. O
[]

They O
were O
diagnosed O
and O
operated O
due O
to O
the O
cancer O
( O
near-total O
thyroidectomy O
and O
removal O
of O
lymph O
node O
metastases O
) O
in O
Slovak O
hospitals O
. O
[]

This O
vaccine O
was O
tested O
on O
30 O
heifers O
during O
a O
7-mo O
period O
. O
[]

Cerebrospinal O
fluid O
( O
CSF O
) O
samples O
were O
obtained O
from O
the O
1- O
and O
10-mg/kg O
groups O
at O
baseline O
and O
at O
day O
29 O
. O
[]

During O
the O
initial O
hospitalization O
, O
the O
incidence O
of O
infections B-outcome ['Physiological-Clinical']
, O
gastrointestinal B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
focus O
of O
this O
subanalysis O
was O
the O
separate O
tolerability B-outcome ['Life-Impact']
of O
rotigotine O
in O
each O
randomized O
treatment O
arm O
, O
during O
the O
dose-escalation O
period O
. O
['Life-Impact']

All O
complications O
were O
considered O
minor O
. O
[]

The O
effects O
and O
changes O
of O
the O
indexes O
including O
renal O
function O
, O
hematuria O
, O
proteinuria O
, O
blood O
IgA O
before O
and O
after O
treatment O
were O
observed O
. O
[]

AIMS O
To O
conduct O
a O
longitudinal O
experimental O
study O
examining O
the O
effect O
of O
patient O
and O
family O
education O
in O
a O
sample O
of O
Chinese O
people O
with O
schizophrenia O
. O
[]

INTRODUCTION O
Androgen-deprivation O
therapy O
( O
ADT O
) O
is O
a O
cornerstone O
of O
treatment O
for O
advanced O
prostate O
cancer O
. O
[]

RESULTS O
We O
found O
significant O
differences O
in O
answers O
to O
the O
asthma O
questions O
, O
by O
40 O
% O
improvement O
, O
but O
no O
changes O
in O
the O
control O
group O
. O
[]

Improvements O
were O
found O
in O
all O
seven O
RQLQ O
( O
S O
) O
domains B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

10.2 O
years O
) O
with O
the O
metabolic O
syndrome O
, O
statin O
monotherapy O
( O
simvastatin O
40 O
mg O
daily O
) O
was O
compared O
to O
combination O
therapy O
( O
simvastatin O
40 O
mg O
and O
ezetimibe O
10 O
mg O
daily O
) O
on O
biomarkers O
of O
inflammation O
and O
platelet O
activity O
. O
[]

70 O
) O
with O
ASD O
and O
clinically O
significant O
anxiety O
were O
randomly O
assigned O
to O
16 O
sessions O
of O
the O
Coping O
Cat O
program O
( O
cognitive-behavioral O
therapy O
; O
CBT O
) O
or O
a O
16-week O
waitlist O
. O
[]

Short-course O
nitrofurantoin O
for O
the O
treatment O
of O
acute O
uncomplicated O
cystitis O
in O
women O
. O
[]

BACKGROUND O
Rebound O
acid O
hypersecretion O
might O
occur O
after O
treatment O
with O
proton O
pump O
inhibitors O
. O
[]

BACKGROUND O
Children O
with O
autism O
spectrum O
disorders O
often O
present O
with O
comorbid O
anxiety O
disorders O
that O
cause O
significant O
functional B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
. O
['Life-Impact']

OBJECTIVE O
This O
study O
was O
designed O
to O
compare O
with O
placebo O
the O
dose-response O
effect O
of O
cyclical O
doses O
of O
the O
C21 O
progestogen O
, O
medroxyprogesterone O
acetate O
( O
MPA O
) O
on O
blood O
pressure O
( O
BP O
) O
when O
administered O
to O
normotensive O
postmenopausal O
women O
receiving O
a O
fixed O
mid-range O
daily O
dose O
of O
conjugated O
equine O
oestrogen O
( O
CEE O
) O
. O
[]

[ O
Effect O
of O
Selaginella O
combined O
with O
radiotherapy O
on O
nasopharyngeal O
carcinoma O
] O
. O
[]

The O
accuracy O
of O
the O
preoperative O
T O
, O
N O
, O
M O
, O
and O
TNM O
staging O
and O
the O
concordance O
rate O
of O
predictive O
operative O
strategy O
were O
compared O
between O
the O
two O
groups O
. O
[]

All O
doses O
were O
well O
tolerated O
; O
the O
only O
side O
effect O
of O
note O
was O
constipation B-outcome ['Physiological-Clinical']
( O
50 O
% O
compared O
with O
25 O
% O
of O
placebo O
group O
) O
. O
['Physiological-Clinical']

After O
a O
3-week O
run-in O
period O
during O
which O
all O
subjects O
consumed O
a O
milk O
protein-based O
supplement O
, O
participants O
were O
randomized O
into O
one O
of O
two O
groups O
: O
a O
control O
group O
( O
continued O
milk O
protein O
) O
and O
an O
intervention O
group O
( O
soy O
protein O
) O
for O
a O
five-week O
period O
. O
[]

METHODS O
Sprague-Dawley O
rats O
weighting O
260 O
- O
320 O
g O
were O
randomly O
divided O
into O
4 O
groups O
. O
[]

Images O
were O
analysed O
in O
stereotactic O
coordinates O
using O
pixel-wise O
t O
statistics O
and O
a O
smoothed O
Gaussian O
model O
. O
[]

RESULTS O
MPH O
improved O
parent-rated B-outcome ['Life-Impact']
ADHD I-outcome ['Life-Impact']
symptoms B-outcome ['Life-Impact']
of O
the O
preschoolers O
; O
50 O
% O
were O
rated O
as O
responders O
. O
['Life-Impact', 'Life-Impact']

In O
addition O
, O
any O
change O
in O
physical O
symptoms O
and O
functional O
capacity O
was O
recorded O
using O
visual O
analogue O
scales O
, O
while O
changes O
in O
psychologic O
morbidity O
were O
assessed O
using O
patient-rated O
indices O
of O
depression O
. O
[]

Clinical O
and O
microbial O
evaluation O
of O
a O
histatin-containing O
mouthrinse O
in O
humans O
with O
experimental O
gingivitis O
. O
[]

BACKGROUND O
Contrast O
agents O
used O
in O
angiography O
procedures O
for O
patients O
with O
cardiovascular O
disease O
are O
known O
to O
cause O
contrast-induced O
nephropathy O
( O
CIN O
) O
, O
which O
may O
be O
partially O
due O
to O
the O
production O
of O
nephrotoxic O
oxygen-free O
radicals O
. O
[]

A O
cognitive-behavioral O
intervention O
for O
emotion O
regulation O
in O
adults O
with O
high-functioning O
autism O
spectrum O
disorders O
: O
study O
protocol O
for O
a O
randomized O
controlled O
trial O
. O
[]

A O
randomized O
trial O
of O
a O
health O
care O
program O
for O
first-time O
adolescent O
mothers O
and O
their O
infants O
. O
[]

in O
J O
Autism O
Dev O
Disord O
39 O
( O
4 O
) O
:596-606 O
, O
2009 O
) O
. O
[]

On O
days O
30 O
, O
60 O
, O
and O
90 O
, O
mean O
flea B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
in O
selamectin-treated O
dogs O
were O
reduced O
by O
92.1 O
, O
99.0 O
, O
and O
99.8 O
% O
, O
and O
mean O
flea B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
in O
fenthion-treated O
dogs O
were O
reduced O
by O
81.5 O
, O
86.8 O
, O
and O
86.1 O
% O
, O
respectively O
, O
compared O
with O
day O
0 O
counts O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Multicenter O
trial O
of O
cryotherapy O
for O
retinopathy O
of O
prematurity O
: O
preliminary O
results O
. O
[]

No O
significant O
difference O
was O
found O
between O
progressive O
and O
vulnerable O
lesions O
. O
[]

PURPOSE O
The O
combination O
of O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
is O
a O
standard O
adjuvant O
regimen O
. O
[]

Median O
survival B-outcome ['Mortality']
in O
gastric O
carcinoma O
on O
the O
5 O
FU-mitomycin O
regimen O
was O
25 O
weeks O
vs. O
18 O
weeks O
on O
the O
5 O
FU-METHYL-CCNU O
arm O
. O
['Mortality']

A O
simple O
meal O
plan O
of O
'eating O
vegetables O
before O
carbohydrate O
' O
achieved O
better O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
than O
an O
exchange-based O
meal O
plan O
in O
Japanese O
patients O
with O
type O
2 O
diabetes O
over O
a O
24-month O
period O
. O
['Physiological-Clinical']

However O
, O
the O
nature O
of O
instructional O
prime O
was O
associated O
with O
relaxation B-outcome ['Life-Impact']
patterns I-outcome ['Life-Impact']
: O
when O
expecting O
the O
aroma O
to O
inhibit O
them O
, O
participants O
relaxed B-outcome ['Life-Impact']
more O
; O
when O
expecting O
facilitation O
, O
participants O
relaxed B-outcome ['Life-Impact']
less O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

On O
the O
contrary O
, O
there O
was O
even O
a O
slight O
, O
but O
not O
statistically O
significant O
, O
trend O
toward O
a O
better O
outcome O
in O
the O
placebo O
group O
. O
[]

infusion O
of O
500 O
ml O
normal O
saline O
containing O
40 O
mg O
furosemide O
as O
a O
diuretic O
. O
[]

BACKGROUND O
Vitamin O
A O
supplementation O
may O
reduce O
the O
risk O
of O
chronic O
lung O
disease O
and O
sepsis O
in O
extremely-low-birth-weight O
infants O
. O
[]

RESULTS O
Carbohydrate B-outcome ['Life-Impact']
intakes I-outcome ['Life-Impact']
were O
higher O
in O
the O
LF O
and O
HF O
groups O
than O
in O
the O
MUFA O
group O
( O
54 O
% O
compared O
with O
43 O
% O
) O
, O
and O
more O
fiber O
was O
consumed O
by O
the O
HF O
group O
( O
approximately O
50 O
g/d O
) O
than O
by O
the O
LF O
or O
MUFA O
group O
( O
approximately O
23 O
g/d O
) O
. O
['Life-Impact']

6 O
. O
[]

Comparison O
of O
weakness B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
in O
inclusion O
body O
myositis O
during O
treatment O
with O
methotrexate O
or O
placebo O
. O
['Physiological-Clinical']

Patients O
were O
studied O
through O
35 O
days O
posttransplant O
. O
[]

The O
imputed O
geometric O
mean O
antibody O
values O
to O
PT O
, O
pertactin O
and O
fimbriae-2 O
at O
the O
time O
of O
household O
exposure O
to O
Bordetella O
pertussis O
infection O
were O
higher O
( O
p O
< O
0.07 O
or O
lower O
) O
in O
non-cases O
compared O
with O
cases O
. O
[]

Lumbar O
epidural O
anesthesia O
with O
20 O
ml O
of O
either O
3 O
% O
2-chloroprocaine O
( O
C O
) O
, O
1.5 O
% O
lidocaine O
( O
L O
) O
, O
or O
1.5 O
% O
mepivacaine O
( O
M O
) O
with O
epinephrine O
was O
studied O
in O
84 O
outpatients O
undergoing O
surgery O
( O
extracorporeal O
shock O
wave O
lithotripsy O
( O
ESWL O
] O
. O
[]

Nonparametric O
bootstrap O
sampling O
of O
[]

CONCLUSIONS O
Limited O
services O
interim O
methadone O
maintenance O
can O
reduce O
heroin B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
among O
persons O
awaiting O
entry O
into O
comprehensive O
treatment O
and O
increase O
the O
percentage O
entering O
treatment O
. O
['Life-Impact']

However O
, O
the O
sensitivity O
of O
STARS O
signalling O
to O
different O
mechanical O
stresses O
has O
not O
been O
investigated O
. O
[]

This O
paper O
targets O
the O
cost-effectiveness O
analysis O
of O
a O
cognitive-behavioral O
group O
therapy O
( O
CBT O
) O
in O
comparison O
to O
a O
client-centered O
, O
supportive-experiential O
group O
therapy O
( O
SET O
) O
in O
cancer O
patients O
with O
dysfunctional O
fear O
of O
progression O
. O
[]

Eight O
patients O
( O
13 O
% O
) O
have O
demonstrated O
an O
increase O
in O
their O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
> O
or O
= O
0.044 O
mmol/l O
30 O
days O
after O
administration O
of O
contrast O
agent O
: O
2/19 O
( O
11 O
% O
) O
in O
the O
control O
group O
, O
2/21 O
( O
10 O
% O
) O
in O
the O
600 O
mg O
NAC O
group O
and O
4/20 O
( O
20 O
% O
) O
the O
300 O
mg O
NAC O
group O
( O
p O
= O
0.66 O
) O
. O
['Physiological-Clinical']

TLR7 O
is O
a O
highly O
conserved O
innate O
immune O
receptor O
expressed O
primarily O
on O
plasmacytoid O
dendritic O
cells O
and O
B O
lymphocytes O
. O
[]

METHODS O
We O
conducted O
a O
study O
including O
15 O
depressive O
patients O
who O
had O
been O
under O
antidepressant O
treatment O
for O
at O
least O
one O
month O
. O
[]

Major O
surgery O
impairs O
the O
cellular O
immune O
response O
. O
[]

Risperidone O
versus O
haloperidol O
in O
children O
and O
adolescents O
with O
AD O
: O
a O
randomized O
, O
controlled O
, O
double-blind O
trial O
. O
[]

METHODS O
Unpleasant O
, O
pleasant O
, O
and O
neutral O
words O
were O
randomly O
presented O
to O
three O
subject O
groups O
-- O
patients O
with O
schizophrenia O
with O
prominent O
delusions O
, O
patients O
with O
schizophrenia O
without O
delusions O
, O
and O
healthy O
participants O
. O
[]

Immunoenhanced O
enteral O
nutrition O
formulas O
in O
head O
and O
neck O
cancer O
surgery O
: O
a O
prospective O
, O
randomized O
clinical O
trial O
. O
[]

Doses B-outcome ['Life-Impact']
of O
concomitant O
methotrexate O
or O
corticosteroids O
were O
reduced O
in O
many O
patients O
who O
maintained O
clinical O
responses O
. O
['Life-Impact']

Patients O
were O
randomly O
assigned O
( O
1:1 O
) O
to O
flexibly O
dosed O
aripiprazole O
( O
target O
dosage O
: O
5 O
, O
10 O
, O
or O
15 O
mg/day O
) O
or O
placebo O
. O
[]

Tamoxifen O
was O
studied O
in O
176 O
patients O
with O
T1-2N0M0 O
tumors O
. O
[]

Melatonin O
versus O
placebo O
in O
children O
with O
autism O
spectrum O
conditions O
and O
severe O
sleep O
problems O
not O
amenable O
to O
behaviour O
management O
strategies O
: O
a O
randomised O
controlled O
crossover O
trial O
. O
[]

BACKGROUND O
Despite O
concerns O
about O
safety O
in O
children O
, O
fluoroquinolone O
antibiotics O
have O
become O
the O
treatment O
of O
choice O
in O
patients O
with O
multidrug-resistant O
typhoid O
fever O
in O
Vietnam O
. O
[]

2 O
factorial O
design O
, O
patients O
were O
randomly O
assigned O
to O
the O
following O
four O
study O
arms O
: O
aspirin O
plus O
RS O
placebo O
; O
RS O
plus O
aspirin O
placebo O
; O
aspirin O
plus O
RS O
; O
RS O
placebo O
plus O
aspirin O
placebo O
; O
they O
were O
followed O
with O
standard O
annual O
clinical O
examinations O
including O
endoscopy O
. O
[]

Preliminary O
analysis O
indicates O
that O
clot B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
rates O
are O
greatly O
dependent O
on O
catheter O
placement O
. O
['Physiological-Clinical']

This O
study O
was O
designed O
to O
evaluate O
objectively O
the O
clinical O
effectiveness O
of O
surgery O
for O
snoring O
and O
to O
compare O
the O
results O
of O
conventional O
uvulopalatopharyngoplasty O
( O
UPPP O
) O
and O
laser O
assisted O
uvulopalatoplasty O
( O
LAUP O
) O
in O
the O
treatment O
of O
snoring O
. O
[]

Prostate O
cancer O
incidence O
among O
92,142 O
men O
randomly O
allocated O
to O
the O
control O
arm O
of O
the O
trial O
was O
also O
assessed O
. O
[]

fMRI O
responses O
throughout O
early O
visual O
cortex O
exhibited O
selective O
adaptation O
to O
these O
stimuli O
. O
[]

A O
double-blind O
randomised O
trial O
compared O
20 O
patients O
with O
leukaemia O
receiving O
human O
recombinant O
granulocyte O
macrophage O
colony O
stimulating O
factor O
( O
GM O
CSF O
) O
, O
with O
20 O
patients O
receiving O
placebo O
for O
14 O
days O
after O
allogeneic O
matched O
sibling O
bone O
marrow O
transplantation O
. O
[]

These O
complications O
did O
not O
occur O
after O
ECCE O
with O
PCL O
. O
[]

When O
comparing O
within O
each O
IOL O
type O
, O
patients O
with O
AcrySof O
IOLs O
were O
found O
to O
have O
significantly O
less O
PCO B-outcome ['Physiological-Clinical']
when O
the O
capsulorhexis O
was O
totally O
on O
the O
optic O
( O
p O
= O
0.0048 O
) O
. O
['Physiological-Clinical']

Thirty-four O
were O
willing O
to O
make O
behavioural O
changes O
. O
[]

This O
study O
demonstrated O
a O
statistically O
significant O
difference O
between O
treatment O
groups O
in O
the O
change O
from O
baseline O
to O
3 O
months O
in O
the O
primary O
efficacy O
outcome O
of O
pain B-outcome ['Physiological-Clinical']
during O
the O
first O
few O
minutes O
of O
walking O
measured O
by O
a O
visual O
analog O
scale O
. O
['Physiological-Clinical']

Seventy O
percent O
of O
the O
patients O
in O
each O
group O
were O
taking O
vitamin O
A O
, O
15 O
000 O
IU/d O
, O
prior O
to O
entry O
. O
[]

Candidate O
predictors O
and O
moderators O
included O
21 O
demographics O
and O
baseline O
measures O
of O
behavior O
. O
[]

Those O
with O
dependence O
indicators O
for O
abstinence B-outcome ['Life-Impact']
tended O
to O
prefer O
abstinence O
as O
a O
goal O
, O
but O
there O
were O
many O
departures O
from O
this O
pattern O
particularly O
for O
women O
. O
['Life-Impact']

The O
flourishing O
of O
studies O
on O
the O
neural O
correlates O
of O
decision-making O
calls O
for O
an O
appraisal O
of O
the O
relation O
between O
perceptual O
decisions O
and O
conscious O
perception O
. O
[]

Ambulatory O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control O
with O
bedtime O
aspirin O
administration O
in O
subjects O
with O
prehypertension O
. O
['Physiological-Clinical']

The O
mean O
predicted O
AUC O
of O
flunarizine O
was O
1230 O
+/- O
717 O
ng O
h O
mL-1 O
, O
whereas O
the O
observed O
AUC O
was O
1203 O
+/- O
900 O
ng O
h O
mL-1 O
. O
[]

Brain B-outcome ['Physiological-Clinical']
MRI I-outcome ['Physiological-Clinical']
scans I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
assessments O
were O
done O
at O
week O
-4 O
, O
baseline O
, O
and O
monthly O
from O
week O
12 O
to O
week O
36 O
. O
['Physiological-Clinical']

METHODS O
A O
prospective O
, O
randomized O
, O
blinded O
, O
placebo-controlled O
trial O
was O
conducted O
in O
adults O
undergoing O
elective O
, O
outpatient O
, O
unilateral O
inguinal O
herniorrhaphy O
. O
[]

Among O
patients O
with O
performance O
status O
0 O
or O
1 O
, O
pemetrexed-cisplatin O
( O
n O
= O
347 O
) O
led O
to O
[]

A O
5 O
% O
or O
more O
improvement O
in O
response O
variables O
with O
gefitinib O
was O
considered O
to O
warrant O
further O
investigation O
. O
[]

Results O
indicated O
that O
, O
among O
OC O
nonusers O
, O
there O
was O
no O
effect O
of O
smoking O
status O
or O
nicotine O
administration O
on O
cardiovascular B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Only O
clean O
or O
clean O
contaminated O
cases O
were O
included O
. O
[]

Eleven O
patients O
were O
treated O
in O
each O
group O
. O
[]

Reliable O
connection O
between O
considerable O
increase O
of O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
and O
the O
level O
of O
NT-pro B-outcome ['Physiological-Clinical']
BNP I-outcome ['Physiological-Clinical']
was O
noted O
in O
CHF O
patients O
, O
which O
demands O
necessity O
of O
correction O
of O
observed O
disorders O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Chronic O
RAO O
occurred O
in O
3.2 O
% O
, O
( O
n O
= O
8 O
) O
of O
the O
intravenous O
group O
compared O
to O
4 O
% O
( O
n O
= O
10 O
) O
of O
the O
intra-arterial O
group O
. O
[]

Ilioinguinal-iliohypogastric O
nerve O
block O
within O
travenous O
dexketoprofen O
improves O
postoperative O
analgesia O
in O
abdominal O
hysterectomies O
. O
[]

RESULTS O
There O
were O
no O
significant O
sequence B-outcome ['Physiological-Clinical']
effects O
for O
responses O
as O
to O
whether O
placebo O
or O
montelukast O
were O
given O
first O
or O
second O
. O
['Physiological-Clinical']

Taken O
together O
, O
the O
antioxidative O
capacity O
of O
WGP O
might O
exert O
a O
beneficial O
effect O
on O
MS O
. O
[]

Therefore O
, O
it O
is O
important O
to O
promote O
healthy O
feeding O
practices O
as O
early O
as O
possible O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
aripiprazole O
versus O
placebo O
in O
preventing O
relapse O
of O
irritability B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
associated O
with O
autistic O
disorder O
in O
pediatric O
patients O
. O
['Life-Impact']

All O
17 O
subjects O
were O
given O
nicotine O
or O
placebo O
solution O
on O
two O
separate O
occasions O
in O
a O
randomized O
sequence O
. O
[]

Thrombolysis O
is O
superior O
to O
heparin O
for O
non-obstructive O
mitral O
mechanical O
valve O
thrombosis O
. O
[]

Weakness B-outcome ['Physiological-Clinical']
was O
a O
prominent O
adverse O
reaction O
in O
this O
study O
, O
and O
all O
patients O
had O
moderate O
to O
severe O
signs O
and O
symptoms O
of O
neuropathy B-outcome ['Physiological-Clinical']
and O
myopathy B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
a O
15-day O
run-in O
period O
with O
controlled O
diet O
( O
45-65 O
g O
protein O
) O
, O
the O
patients O
were O
administered O
, O
in O
addition O
to O
their O
diet O
, O
branched-chain O
amino O
acids O
( O
0.24 O
g/kg O
, O
30 O
patients O
) O
or O
an O
equinitrogenous O
amount O
of O
casein O
( O
34 O
patients O
) O
. O
[]

Heavy O
users O
were O
affected O
stronger O
than O
moderate O
users O
. O
[]

RESULTS O
Patients O
with O
a O
short O
duration O
of O
untreated O
negative O
symptoms O
( O
DUNS O
) O
or O
a O
short O
duration O
of O
untreated O
positive O
symptoms O
( O
DUPS O
) O
outperformed O
patients O
with O
a O
long O
duration O
of O
untreated O
symptoms O
on O
memory B-outcome ['Life-Impact']
tasks I-outcome ['Life-Impact']
and O
a O
pre-attentional O
visual B-outcome ['Physiological-Clinical']
task O
but O
not O
on O
measures O
of O
verbal O
fluency O
, O
attention O
, O
reaction O
time O
, O
visual O
processing O
and O
executive O
functions O
. O
['Life-Impact', 'Physiological-Clinical']

was O
significantly O
higher O
than O
placebo O
( O
4.87 O
vs O
3.44 O
, O
p O
= O
0.032 O
) O
. O
[]

Double-blind O
, O
placebo-controlled O
study O
of O
amantadine O
hydrochloride O
in O
the O
treatment O
of O
children O
with O
autistic O
disorder O
. O
[]

METHODS O
Subjects O
were O
randomized O
to O
receive O
risedronate O
5 O
mg O
( O
n O
= O
318 O
) O
or O
alendronate O
10 O
mg O
( O
n O
= O
317 O
) O
daily O
for O
14 O
days O
. O
[]

than O
in O
the O
lower O
fat O
recipe O
( O
990 O
000 O
p.p.m. O
) O
. O
[]

Mandibular O
advancement O
splint O
improves O
indices O
of O
obstructive O
sleep O
apnoea O
and O
snoring O
but O
side O
effects O
are O
common O
. O
[]

To O
determine O
the O
efficacy O
of O
proparacaine O
eye O
drops O
( O
0.5 O
% O
) O
, O
we O
compared O
the O
Premature B-outcome ['Physiological-Clinical']
Infant I-outcome ['Physiological-Clinical']
Pain I-outcome ['Physiological-Clinical']
Profile O
( O
PIPP O
) O
scores O
in O
40 O
preterm O
infants O
undergoing O
ROP O
screening O
. O
['Physiological-Clinical']

Group O
1 O
( O
n O
= O
20 O
) O
received O
no O
other O
specific O
medication O
while O
group O
2 O
( O
n O
= O
19 O
) O
were O
given O
100 O
I.U O
. O
[]

IFN-alpha-2b O
in O
arm O
2 O
was O
administered O
according O
to O
the O
Eastern O
Cooperative O
Oncology O
Group O
1684 O
study O
regimen O
. O
[]

These O
infants O
received O
Fe O
mainly O
from O
fortification O
Fe O
with O
beikost O
( O
75-86 O
% O
) O
and O
less O
than O
10 O
% O
met O
the O
recommended O
intake O
of O
1 O
mg.kg-1.d-1 O
; O
whereas O
80-85 O
% O
of O
the O
infants O
fed O
the O
Fe-fortified O
formula O
did O
. O
[]

BACKGROUND O
This O
study O
was O
designed O
to O
assess O
the O
long-term O
efficacy O
of O
surgical O
deactivation O
of O
migraine B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
trigger O
sites O
. O
['Physiological-Clinical']

RESULTS O
Of O
141 O
patients O
enrolled O
, O
83 O
% O
were O
randomly O
assigned O
after O
chemotherapy O
to O
qdRT O
( O
n O
= O
59 O
) O
or O
HART O
( O
n O
= O
60 O
) O
. O
[]

The O
overall O
response O
rate O
( O
CR+PR O
) O
in O
arm O
1 O
and O
2 O
were O
61.4 O
( O
27/44 O
) O
and O
67.3 O
% O
( O
35/52 O
) O
, O
respectively O
. O
[]

IMPACT O
Our O
findings O
indicate O
that O
inverse O
associations O
between O
iron O
metrics O
and O
gastric O
cancer O
are O
driven O
by O
associations O
with O
GNCC O
. O
[]

24.1 O
mm? O
at O
baseline O
vs O
41.6 O
? O
[]

BACKGROUND O
The O
effectiveness O
of O
heart O
failure O
disease O
management O
programs O
in O
patients O
under O
cardiologists O
' O
care O
over O
long-term O
follow-up O
is O
not O
established O
. O
[]

Epinephrine-induced O
panic O
attacks O
and O
hyperventilation O
. O
[]

The O
secondary O
outcomes O
were O
a O
hemoglobin B-outcome ['Physiological-Clinical']
drop I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
30 I-outcome ['Physiological-Clinical']
mg/L I-outcome ['Physiological-Clinical']
or O
greater O
, O
the O
use O
of O
['Physiological-Clinical']

BACKGROUND O
Hypertension O
and O
tachycardia O
are O
common O
during O
fiber-optic O
bronchoscopy O
( O
FOB O
) O
, O
and O
this O
may O
lead O
to O
cardiac O
ischemia O
. O
[]

With O
a O
median O
follow-up O
duration O
of O
28 O
months O
, O
the O
3-year O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
rate O
was O
52 O
% O
( O
95 O
% O
confidence O
interval O
, O
45 O
% O
to O
59 O
% O
) O
in O
the O
sequential O
chemotherapy O
arm O
and O
59 O
% O
( O
95 O
% O
confidence O
interval O
, O
52 O
% O
to O
66 O
% O
) O
in O
the O
autologous O
transplant O
arm O
( O
P O
= O
.46 O
, O
relative O
risk O
= O
0.90 O
) O
. O
['Mortality']

There O
were O
significantly O
fewer O
reports O
of O
tiredness B-outcome ['Physiological-Clinical']
and O
dizziness B-outcome ['Physiological-Clinical']
among O
the O
health-promotion O
participants O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Hellenic O
Cooperative O
Oncology O
Group O
( O
HeCOG O
) O
. O
[]

Pre-medication O
with O
pronase O
reduces O
artefacts B-outcome ['Physiological-Clinical']
during O
endoscopic O
ultrasonography O
. O
['Physiological-Clinical']

RESULTS O
The O
proportion O
of O
patients O
who O
achieved O
hemostasis B-outcome ['Physiological-Clinical']
at O
the O
primary O
treatment O
site O
within O
5 O
min O
, O
and O
maintained B-outcome ['Physiological-Clinical']
hemostasis I-outcome ['Physiological-Clinical']
until O
surgical O
closure O
was O
88.2 O
% O
for O
TISSEEL O
VH O
S/D O
and O
89.6 O
% O
for O
TISSEEL O
VH O
in O
the O
intent-to-treat O
population O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
Type O
1 O
diabetics O
. O
[]

Thirty O
patients O
( O
mean O
age O
: O
10.38 O
years O
) O
affected O
by O
primary B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
were O
selected O
for O
a O
double-blind O
cross-over O
clinical O
trial O
. O
['Physiological-Clinical']

Of O
the O
patients O
making O
a O
telephone O
appointment O
, O
88 O
% O
recieved O
immunisation B-outcome ['Resource-use']
, O
while O
22 O
% O
of O
those O
not O
wanting O
an O
appointment O
went O
on O
to O
be O
immunised O
. O
['Resource-use']

Maximal O
venous O
velocities O
were O
obtained O
at O
the O
common O
femoral O
vein O
and O
the O
popliteal O
vein O
for O
all O
the O
devices O
and O
were O
recorded O
as O
the O
mean O
peak O
velocity O
of O
three O
compression O
cycles O
and O
compared O
with O
baseline O
velocities O
. O
[]

BACKGROUND O
A O
new O
approach O
in O
the O
treatment O
of O
cystic O
fibrosis O
involves O
improving O
the O
function O
of O
mutant O
cystic O
fibrosis O
transmembrane O
conductance O
regulator O
( O
CFTR O
) O
. O
[]

SPAF-II O
aims O
to O
address O
this O
issue O
and O
also O
to O
assess O
the O
differential O
effects O
of O
the O
two O
treatments O
according O
to O
age O
. O
[]

Serum O
amylase O
and O
lipase O
levels O
were O
determined O
1 O
day O
before O
and O
within O
24 O
hours O
after O
ERCP O
. O
[]

Most O
of O
the O
beneficial O
changes O
in O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
factors O
were O
sustained O
for O
2 O
years O
. O
['Physiological-Clinical']

Evidence O
indicating O
that O
CCBs O
inhibit O
atherosclerosis O
is O
less O
unequivocal O
than O
the O
clear O
evidence O
for O
lipid-lowering O
therapy O
. O
[]

METHOD O
Twenty-four O
children O
( O
aged O
5-17 O
years O
) O
with O
pervasive O
developmental O
disorders O
and O
co-morbid O
disruptive O
behavior O
who O
responded O
favorably O
to O
open-label O
treatment O
with O
risperidone O
as O
part O
of O
a O
previously O
described O
controlled O
discontinuation O
study O
completed O
two O
different O
computerized O
attention O
tasks O
at O
baseline O
, O
weeks O
4 O
, O
8 O
, O
and O
24 O
of O
open-label O
treatment O
, O
and O
, O
at O
8 O
weeks O
after O
random O
assignment O
to O
either O
placebo O
or O
risperidone O
. O
[]

The O
results O
of O
this O
study O
confirm O
that O
ESWT O
administered O
with O
the O
Dornier O
Epos O
Ultra O
is O
a O
safe O
and O
effective O
treatment O
for O
recalcitrant O
plantar O
fasciitis O
. O
[]

The O
rates O
of O
intraoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
30-day O
postoperative B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
complications O
at O
discharge B-outcome ['Physiological-Clinical']
and O
60 O
days O
, O
hospital B-outcome ['Resource-use']
readmission I-outcome ['Resource-use']
, O
and O
reoperation B-outcome ['Resource-use']
were O
very O
similar O
between O
groups O
. O
['Adverse-effects', 'Mortality', 'Physiological-Clinical', 'Resource-use', 'Resource-use']

Families O
of O
104 O
adolescents O
with O
diabetes O
were O
randomized O
to O
standard O
care O
( O
SC O
) O
or O
to O
6 O
months O
of O
an O
educational O
support O
group O
( O
ES O
) O
or O
BFST-D. O
Family B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
and O
problem-solving B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
were O
assessed O
at O
0 O
, O
6 O
, O
12 O
, O
and O
18 O
months O
by O
independent O
rating O
of O
videotaped O
family O
problem-solving O
discussions O
. O
['Life-Impact', 'Life-Impact']

OBJECTIVES O
This O
study O
intended O
to O
determine O
the O
effect O
of O
varying O
degrees O
of O
lossy O
Joint O
Photographic B-outcome ['Physiological-Clinical']
Experts O
Group O
( O
JPEG O
) O
compression O
on O
detection O
of O
coronary B-outcome ['Physiological-Clinical']
angiographic I-outcome ['Physiological-Clinical']
features O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
range O
of O
possibilities O
has O
not O
been O
exploited O
yet O
, O
even O
for O
the O
evaluation O
of O
the O
fetal O
state O
. O
[]

We O
randomized O
299 O
older O
men O
to O
treatment O
with O
2mg O
of O
folate O
, O
plus O
25mg O
of O
B6 O
and O
400 O
microg O
of O
B12 O
, O
or O
placebo O
. O
[]

The O
overall O
response O
rates O
for O
PLD O
and O
topotecan O
were O
19.7 O
% O
and O
17.0 O
% O
, O
respectively O
( O
P O
=.390 O
) O
. O
[]

At O
the O
1-year O
visit O
, O
participants O
were O
asked O
if O
they O
believed O
that O
the O
injections O
received O
during O
the O
study O
were O
real O
, O
sham O
, O
or O
sometimes O
real O
and O
sometimes O
sham O
. O
[]

Protocol O
2 O
: O
40 O
noncarious O
human O
molars O
were O
selected O
. O
[]

BACKGROUND O
Adults O
with O
high-functioning O
autism O
spectrum O
disorders O
( O
ASD O
) O
have O
difficulties O
in O
social O
communication O
; O
thus O
, O
these O
individuals O
have O
trouble O
understanding O
the O
mental O
states O
of O
others O
. O
[]

For O
this O
prospective O
study O
, O
each O
of O
50 O
patients O
with O
type O
A O
2.2 O
, O
A O
3.3 O
, O
C O
1.2 O
or O
C O
2.2 O
( O
AO O
classification O
) O
fractures O
of O
the O
radius O
was O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O
[]

Chronic O
maintenance O
immunotherapy O
after O
disease O
progression O
is O
feasible O
, O
but O
does O
not O
significantly O
increase O
OS B-outcome ['Mortality']
or O
the O
TFPTD O
. O
['Mortality']

509 O
mg/d O
and O
serum O
25 O
( O
OH O
) O
D O
was O
63 O
? O
[]

On O
the O
primary O
outcome O
measure O
, O
the O
Ohio O
Autism B-outcome ['Life-Impact']
['Life-Impact']

RESULTS O
Baseline O
characteristics O
were O
similar O
between O
the O
two O
groups O
. O
[]

Recombinant O
HBV O
vaccine O
induced O
better O
long O
term O
[]

Each O
child O
was O
administered O
placebo O
for O
2 O
weeks O
and O
optimal O
dose O
for O
2 O
weeks O
. O
[]

Clinical O
parameters O
, O
such O
as O
bleeding B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
probing I-outcome ['Physiological-Clinical']
( O
BOP B-outcome ['Physiological-Clinical']
) O
and O
probing B-outcome ['Physiological-Clinical']
pocket I-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
( O
PPD B-outcome ['Physiological-Clinical']
) O
, O
were O
assessed O
at O
baseline O
and O
3-6 O
months O
later O
at O
the O
next O
regular O
SPT O
visit O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Prior O
to O
spinal O
anesthesia O
, O
hydration O
with O
small O
amount O
of O
hypertonic O
saline O
is O
effective O
to O
minimize O
hypotension O
associated O
with O
spinal O
anesthesia O
. O
[]

One O
hundred O
and O
fifty O
fit O
, O
young O
adults O
participated O
in O
this O
randomised O
, O
single O
dose O
, O
double-blind O
, O
parallel O
group O
clinical O
study O
. O
[]

METHODS/DESIGN O
This O
study O
is O
a O
two-armed O
randomised O
clinical O
trial O
, O
with O
randomization O
on O
patient-level O
. O
[]

We O
suggest O
that O
the O
preSMA O
and O
rostral O
dorsal O
PMC O
activities O
during O
initiate O
may O
be O
associated O
with O
selection O
of O
timing O
parameters O
, O
while O
activation O
in O
centromedial O
prefrontal O
cortex O
during O
both O
initiate O
and O
synchronise O
may O
be O
associated O
with O
[]

IMPORTANCE O
Sociocommunicational O
deficits O
make O
it O
difficult O
for O
individuals O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
to O
understand O
communication O
content O
with O
conflicting O
verbal O
and O
nonverbal O
information O
. O
[]

Acid B-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
each I-outcome ['Physiological-Clinical']
hour I-outcome ['Physiological-Clinical']
over O
a O
3-h O
postprandial O
( O
PP O
) O
period O
was O
assessed O
as O
the O
percent O
time O
pH O
less O
than O
4.0 O
. O
['Physiological-Clinical']

One O
group O
received O
4 O
Gy O
of O
Grenz O
rays O
administered O
on O
six O
occasions O
at O
intervals O
of O
1 O
week O
and O
the O
other O
group O
was O
given O
the O
same O
Grenz O
ray O
treatment O
plus O
topical O
corticosteroid O
. O
[]

The O
median O
volume B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
specimens I-outcome ['Physiological-Clinical']
in O
the O
NETZ O
arm O
was O
739 O
mm O
( O
3 O
) O
larger O
( O
P= O
0.33 O
) O
and O
they O
were O
less O
likely O
to O
be O
removed O
in O
multiple O
pieces O
( O
2.5 O
% O
vs O
29.5 O
% O
, O
RR O
0.09 O
, O
95 O
% O
CI O
0.04 O
to O
0.20 O
) O
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
functional O
and O
radiological O
result O
of O
two O
different O
positions O
of O
the O
wrist O
in O
a O
plaster O
cast O
following O
Colles O
' O
fracture O
. O
[]

A O
randomized O
study O
comparing O
levofloxacin O
, O
omeprazole O
, O
nitazoxanide O
, O
and O
doxycycline O
versus O
triple O
therapy O
for O
the O
eradication O
of O
Helicobacter B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Age O
, O
sex O
, O
body O
mass O
index O
( O
BMI O
) O
, O
previous O
surgery O
and O
associated O
diseases O
were O
similar O
between O
the O
two O
groups O
. O
[]

Diazepam O
( O
5 O
mg O
) O
was O
included O
as O
an O
active O
control O
, O
and O
it O
impaired O
digit B-outcome ['Physiological-Clinical']
symbol I-outcome ['Physiological-Clinical']
substitution O
, O
visuomotor B-outcome ['Physiological-Clinical']
coordination I-outcome ['Physiological-Clinical']
and O
complex B-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
time O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Efficacy O
of O
TeachTown O
: O
Basics O
computer-assisted O
intervention O
for O
the O
Intensive O
Comprehensive O
Autism O
Program O
in O
Los O
Angeles O
Unified O
School O
District O
. O
[]

The O
results O
were O
compared O
with O
a O
group O
of O
normal O
deliveries O
in O
which O
analgesia B-outcome ['Resource-use']
was O
achieved O
with O
pethidine O
. O
['Resource-use']

No O
adverse B-outcome ['Adverse-effects']
drug I-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
were O
recorded O
. O
['Adverse-effects']

Bilastine O
was O
characterized O
by O
two-compartmental O
kinetics O
with O
a O
rapid-absorption O
phase O
( O
first-order O
absorption O
rate O
constant O
= O
1.50 O
h O
( O
-1 O
) O
) O
, O
plasma B-outcome ['Physiological-Clinical']
peak O
concentrations B-outcome ['Physiological-Clinical']
were O
observed O
at O
1 O
hour O
following O
administration O
and O
the O
maximal O
response O
was O
observed O
at O
approximately O
4 O
hours O
or O
later O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
We O
examined O
the O
sustained O
efficacy O
of O
a O
group-based O
cognitive-behavioural O
stress O
management O
( O
CBSM O
) O
intervention O
in O
comparison O
to O
a O
modified O
wait-list O
control O
condition O
on O
measures O
of O
mood B-outcome ['Life-Impact']
, O
coping B-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
in O
mildly O
symptomatic O
HIV-positive O
homosexual O
and O
bisexual O
men O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Patients O
were O
randomized O
to O
three O
treatment O
groups O
: O
SCHEDULE O
A O
( O
control O
) O
: O
conventional O
one O
treatment O
per O
day O
regimen O
totalling O
3,760 O
rads O
in O
22-23 O
days O
; O
SCHEDULE O
B O
: O
2 O
sessions O
per O
day O
totalling O
3,440 O
rads O
in O
10-11 O
days O
; O
and O
SCHEDULE O
C O
: O
2 O
sessions O
per O
day O
totalling O
3,568 O
rads O
in O
10-11 O
days O
. O
[]

The O
WOMAC O
score O
at O
three O
, O
six O
, O
and O
twelve O
months O
did O
not O
differ O
significantly O
between O
the O
piriformis O
fossa O
and O
trochanteric O
nailing O
groups O
. O
[]

At O
bone O
flap O
replacement O
, O
either O
morphine O
0.08 O
mg O
x O
kg O
( O
-1 O
) O
( O
remifentanil O
group O
) O
or O
saline O
( O
fentanyl O
group O
) O
was O
given O
. O
[]

MATERIAL O
AND O
METHODS O
Two O
hundred O
and O
two O
patients O
were O
randomized O
to O
either O
the O
surgical O
approach O
( O
total O
laryngectomy O
with O
partial O
pharyngectomy O
and O
neck O
dissection O
, O
followed O
by O
irradiation O
) O
or O
to O
the O
chemotherapy O
arm O
up O
to O
three O
cycles O
of O
induction O
chemotherapy O
( O
cisplatin O
100 O
mg/m O
( O
2 O
) O
day O
1 O
+ O
5-FU O
1000 O
mg/m O
( O
2 O
) O
day O
1-5 O
) O
followed O
for O
complete O
responders O
by O
irradiation O
and O
otherwise O
by O
conventional O
treatment O
. O
[]

SUBJECTS O
One O
hundred O
and O
five O
obese O
[ O
Body O
Mass O
Index O
( O
BMI O
) O
> O
or O
= O
30 O
] O
patients O
participated O
in O
the O
study O
. O
[]

Therefore O
, O
a O
combined O
parameter O
was O
constructed O
showing O
a O
more O
prominent B-outcome ['Physiological-Clinical']
separation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
: O
tumors O
with O
high O
EGFr O
and O
well/moderate O
differentiation O
did O
benefit O
from O
moderate O
acceleration O
of O
treatment O
regarding O
locoregional O
control O
, O
HR O
0.54 O
( O
0.37-0.78 O
) O
, O
whereas O
such O
an O
effect O
was O
not O
seen O
in O
tumors O
with O
low O
EGFr O
and/or O
poor O
differentiation O
, O
HR O
0.8 O
( O
0.51-1.25 O
) O
. O
['Physiological-Clinical']

Among O
serum B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
only O
serum B-outcome ['Physiological-Clinical']
triglycerides I-outcome ['Physiological-Clinical']
increased O
significantly O
as O
a O
result O
of O
pegvisomant O
alone O
( O
1.0 O
+/- O
0.2 O
vs. O
1.6 O
+/- O
0.4 O
mmol/liter O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
VLASU O
can O
be O
used O
as O
a O
method O
of O
treatment O
of O
this O
disorder O
. O
[]

A O
randomized O
, O
controlled O
trial O
of O
wax-matrix O
sustained-release O
niacin O
in O
hypercholesterolemia O
. O
[]

Little O
is O
known O
about O
the O
volume O
of O
injected O
intra-articular O
saline O
solution O
that O
is O
needed O
to O
effectively O
rule O
in O
or O
rule O
out O
a O
traumatic O
arthrotomy O
of O
the O
knee O
. O
[]

Gastrointestinal B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
was O
severe O
in O
both O
groups O
. O
['Physiological-Clinical']

At O
d O
28 O
, O
we O
collected O
small O
intestine O
for O
biochemical O
and O
morphological O
measurements O
and O
microarray O
analysis O
of O
gene B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
using O
the O
Operon O
Porcine O
Genome O
Oligo O
set O
. O
['Physiological-Clinical']

A O
2 O
mg. O
dose O
of O
butorphanol O
was O
found O
to O
be O
analgesically O
equivalent O
to O
80 O
mg. O
meperidine O
, O
while O
a O
4 O
mg. O
dose O
of O
butorphanol O
was O
found O
to O
be O
more O
effective O
than O
80 O
mg. O
meperidine O
and O
2 O
mg. O
butorphanol O
. O
[]

Supplemental O
vitamin O
A O
has O
been O
reported O
to O
reduce O
mortality O
among O
these O
children O
, O
but O
the O
results O
have O
been O
questioned O
. O
[]

OBJECTIVE O
To O
assess O
the O
effectiveness O
of O
the O
Dader O
Method O
for O
pharmaceutical O
care O
on O
achieving O
therapeutic O
goals O
for O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
total O
cholesterol B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
both O
BP B-outcome ['Physiological-Clinical']
and O
TC B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP/TC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
patients O
with O
CVD O
and/or O
high O
or O
intermediate O
cardiovascular O
( O
CV O
) O
risk O
attending O
community O
pharmacies O
in O
Spain O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

and O
600 O
mg/day O
in O
three O
doses O
P.O O
. O
[]

Group O
1 O
received O
caudal O
block O
with O
bupivacaine O
1 O
mL/kg O
after O
anesthetic O
induction O
. O
[]

05 O
) O
GHRH O
( O
1-29 O
) O
NH O
( O
2 O
) O
. O
[]

Seven O
CSA O
recipients O
( O
three O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
two O
neurological B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
two O
other O
) O
and O
12 O
AZA O
recipients O
( O
six O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
four O
inefficacy O
, O
two O
other O
) O
withdrew O
from O
treatment O
prematurely O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
main O
outcome O
measures O
will O
be O
[]

To O
explore O
how O
to O
improve O
classifications O
, O
univariate O
and O
multivariate O
Cox O
model O
analyses O
were O
carried O
out O
. O
[]

Frequently O
, O
gastro-oesophageal O
symptoms O
are O
associated O
with O
these O
drugs O
. O
[]

Recent O
studies O
suggest O
acupuncture O
may O
be O
effective O
in O
reducing O
vasomotor B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
menopausal O
women O
. O
['Physiological-Clinical']

In O
spite O
of O
the O
similarity O
in O
the O
kinematics O
of O
the O
movement O
, O
the O
EMG B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
was O
different O
from O
that O
of O
step-tracking B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Sixteen O
subjects O
were O
deemed O
ineligible O
, O
and O
7 O
failed O
to O
attend O
or O
withdrew O
. O
[]

Mothers O
in O
the O
special O
care O
program O
who O
continued O
to O
attend O
clinic O
used O
the O
emergency O
room O
less O
than O
the O
mothers O
who O
continued O
to O
attend O
in O
the O
control O
group O
. O
[]

However O
, O
residual O
tumor O
is O
present O
immediately O
after O
the O
procedure O
in O
approximately O
20 O
to O
40 O
% O
of O
cases O
. O
[]

They O
ranged O
in O
age O
from O
4 O
months O
to O
15 O
years O
. O
[]

OBJECTIVE O
We O
examined O
the O
ambulatory B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ABP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
a O
diuretic O
and O
an O
ACE O
inhibitor O
in O
hypertensive O
patients O
of O
East O
African O
descent O
and O
evaluated O
the O
individual O
characteristics O
that O
determined O
treatment O
efficacy O
. O
['Physiological-Clinical']

7 O
years O
) O
and O
12 O
highlanders O
( O
Sherpa O
; O
33 O
? O
[]

The O
antibody O
was O
tested O
by O
neutralization O
test O
. O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
porcine O
versus O
synthetic O
secretin O
for O
reducing O
symptoms B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
autism I-outcome ['Life-Impact']
. O
['Life-Impact']

MAIN O
OUTCOME O
MEASURES O
The O
timed O
up-and-go O
test O
and O
electromyographic B-outcome ['Physiological-Clinical']
and O
kinematic O
analyses O
of O
the O
affected O
lower O
limb B-outcome ['Life-Impact']
during O
one O
gait B-outcome ['Life-Impact']
cycle I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

METHODS O
AND O
RESULTS O
The O
prognostic O
model O
included O
37 O
clinical O
characteristics O
collected O
at O
baseline O
in O
PROTECT O
, O
a O
study O
comparing O
rolofylline O
and O
placebo O
in O
2033 O
patients O
admitted O
with O
acute O
heart O
failure O
. O
[]

A O
short-term O
cognitive O
group O
treatment O
program O
gives O
substantial O
weight O
reduction O
up O
to O
18 O
months O
from O
the O
end O
of O
treatment O
. O
[]

Cholesterol-lowering O
effect O
of O
stanol O
ester O
in O
a O
US O
population O
of O
mildly O
hypercholesterolemic O
men O
and O
women O
: O
a O
randomized O
controlled O
trial O
. O
[]

METHODS O
Patients O
were O
randomly O
given O
one O
of O
two O
foscarnet O
maintenance O
therapy O
doses O
( O
90 O
mg/kg O
of O
body O
weight/day O
[ O
FOS-90 O
group O
] O
or O
120 O
mg/kg O
of O
body O
weight/day O
[ O
FOS-120 O
group O
] O
after O
induction O
therapy O
. O
[]

Total O
sleep B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
was O
8.05 O
h O
( O
95 O
% O
CI O
7.65-8.44 O
) O
baseline O
, O
8.75 O
h O
( O
95 O
% O
CI O
8.56-8.98 O
) O
with O
placebo O
and O
9.84 O
h O
( O
95 O
% O
CI O
9.68-9.99 O
) O
with O
melatonin O
. O
['Physiological-Clinical']

METHODS O
A O
total O
of O
145 O
managers O
from O
8 O
organizations O
participated O
in O
a O
6-month O
Internet-based O
program O
or O
a O
control O
condition O
. O
[]

Treatment O
with O
spironolactone O
was O
associated O
with O
increased O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
levels O
and O
a O
doubling O
of O
the O
rate O
of O
hyperkalemia B-outcome ['Physiological-Clinical']
( O
18.7 O
% O
, O
vs. O
9.1 O
% O
in O
the O
placebo O
group O
) O
but O
reduced O
hypokalemia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subjects O
were O
more O
likely O
to O
identify O
buspirone O
as O
unfamiliar O
. O
[]

A O
total O
of O
377 O
infected O
children O
, O
aged O
seven O
to O
19 O
years O
, O
was O
randomized O
into O
two O
groups O
: O
one O
of O
190 O
( O
group O
A O
) O
and O
one O
of O
187 O
( O
group O
B O
) O
. O
[]

Our O
findings O
demonstrate O
that O
peripheral O
muscle O
fatigue O
is O
an O
additional O
important O
factor O
, O
besides O
intense O
dyspnea O
, O
that O
limits O
exercise O
tolerance O
in O
COPD O
. O
[]

beta-Carotene O
resulted O
in O
a O
statistically O
significant O
increase O
in O
total O
WBC B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( O
p O
= O
0.01 O
) O
, O
% O
change O
in O
CD4 B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( O
p O
= O
0.02 O
) O
, O
and O
% O
change O
in O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
( O
p O
= O
0.02 O
) O
compared O
to O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
augmented O
soft O
tissue O
mobilization O
( O
ASTM O
) O
on O
the O
treatment O
of O
lateral O
epicondylitis O
. O
[]

The O
addition O
of O
MTP O
to O
chemotherapy O
resulted O
in O
a O
statistically O
significant O
improvement O
in O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
and O
a O
trend O
toward O
better O
EFS B-outcome ['Mortality']
. O
['Mortality', 'Mortality']

The O
primary O
efficacy O
variable O
was O
the O
change O
from O
baseline O
in O
the O
total O
nasal B-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
score O
( O
TNSS B-outcome ['Physiological-Clinical']
) O
, O
consisting O
of O
nasal B-outcome ['Physiological-Clinical']
congestion B-outcome ['Physiological-Clinical']
, O
runny B-outcome ['Physiological-Clinical']
nose B-outcome ['Physiological-Clinical']
, O
itchy B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
eltanolone O
and O
thiopental O
in O
anaesthesia B-outcome ['Resource-use']
for O
termination O
of O
pregnancy O
. O
['Resource-use']

The O
relationship O
between O
spotty O
calcification O
and O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
has O
not O
been O
investigated O
. O
['Physiological-Clinical']

Hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
significantly O
shorter O
in O
the O
SH O
group O
( O
SH O
2.2 O
+/- O
1.2 O
[ O
0 O
; O
5.0 O
] O
versus O
MM O
3.1 O
+/- O
1.7 O
[ O
1 O
; O
8.0 O
] O
P O
< O
0.001 O
) O
. O
['Resource-use']

The O
Mann-Whitney O
U O
test O
was O
used O
for O
statistical O
analysis O
. O
[]

B-domain O
deleted O
recombinant O
factor O
VIII O
preparations O
are O
bioequivalent O
to O
a O
monoclonal O
antibody O
purified O
plasma-derived O
factor O
VIII O
concentrate O
: O
a O
randomized O
, O
three-way O
crossover O
study O
. O
[]

Corticosteroids O
and O
antifungals O
are O
the O
mainstay O
of O
therapy O
. O
[]

Visual O
analogue O
pain B-outcome ['Physiological-Clinical']
scores O
after O
operation O
were O
similar O
to O
those O
with O
bupivacaine O
alone O
at O
all O
but O
one O
of O
the O
recording O
times O
but O
were O
greater O
than O
those O
in O
patients O
who O
received O
bupivacaine O
and O
morphine O
at O
4 O
, O
6 O
and O
10 O
h O
after O
operation O
( O
P O
< O
0.001 O
, O
P O
< O
0.04 O
, O
P O
< O
0.02 O
) O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
The O
success B-outcome ['Physiological-Clinical']
rate O
at O
48 O
hours O
, O
induction-to-abortion B-outcome ['Mortality']
interval I-outcome ['Mortality']
and O
the O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Mortality', 'Adverse-effects']

Toxicity B-outcome ['Adverse-effects']
was O
primarily O
hematological O
and O
bimodal O
: O
32 O
% O
had O
grade O
3 O
or O
4 O
leukopenia B-outcome ['Physiological-Clinical']
and O
24 O
% O
had O
grade O
3 O
or O
4 O
thrombocytopenia B-outcome ['Physiological-Clinical']
; O
22 O
% O
had O
no O
leukopenia B-outcome ['Physiological-Clinical']
and O
44 O
% O
had O
no O
thrombocytopenia B-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

It O
would O
be O
needed O
to O
investigate O
whether O
the O
differences O
may O
be O
distinct O
or O
not O
the O
same O
when O
other O
dosages O
are O
used O
. O
[]

The O
effect O
of O
case O
management O
on O
the O
costs O
of O
health B-outcome ['Resource-use']
care I-outcome ['Resource-use']
for O
enrollees O
in O
Medicare O
Plus O
Choice O
plans O
: O
a O
randomized O
trial O
. O
['Resource-use']

Extinction O
of O
over-selected B-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
causes O
emergence B-outcome ['Physiological-Clinical']
of O
under-selected O
cues O
in O
higher-functioning O
children O
with O
autistic O
spectrum O
disorders O
. O
['Physiological-Clinical', 'Physiological-Clinical']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
The O
albumin O
diffusion O
space O
, O
the O
colloid O
oncotic O
pressure O
, O
the O
plasma B-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
the O
electrical B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
were O
measured O
before O
( O
T O
= O
10 O
mins O
) O
and O
after O
( O
T O
= O
60 O
, O
120 O
, O
and O
240 O
mins O
) O
hemodilution O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
As O
chemotherapy O
gains O
wider O
acceptance O
for O
the O
treatment O
of O
earlier O
stages O
of O
NSCLC O
, O
particularly O
in O
the O
adjuvant O
and O
neoadjuvant O
setting O
, O
physicians O
face O
a O
growing O
population O
of O
high O
performance O
status O
patients O
who O
have O
relapsed O
after O
their O
first-line O
chemotherapy O
. O
[]

The O
primary O
goal O
of O
the O
telephone O
intervention O
was O
to O
provide O
support O
by O
giving O
additional O
information O
about O
individual O
concerns O
. O
[]

Na+ O
modeling O
should O
always O
be O
used O
in O
patients O
being O
maintained O
on O
high O
flux O
dialysis O
. O
[]

The O
mean O
doses O
of O
CSA O
and O
AZA O
at O
six O
months O
were O
3.4 O
mg/kg O
and O
1.9 O
mg/kg O
. O
[]

Two O
hundred O
three O
patients O
( O
median O
age O
26 O
years O
; O
range O
18-45 O
) O
with O
untreated O
multiple O
and O
widespread O
anogenital O
condyloma O
were O
randomly O
assigned O
to O
one O
of O
four O
study O
arms O
in O
order O
to O
compare O
the O
efficacy O
, O
toxicity B-outcome ['Adverse-effects']
, O
and O
tolerability B-outcome ['Life-Impact']
of O
recombinant O
interferon O
alpha-2b O
with O
those O
of O
diathermocoagulation O
. O
['Adverse-effects', 'Life-Impact']

RESULTS O
Eighty-three O
percent O
( O
432 O
of O
523 O
) O
of O
patients O
reported O
complete O
symptom B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
at O
the O
end O
of O
the O
acute O
phase O
. O
['Physiological-Clinical']

Cicloxilic O
acid O
can O
have O
a O
place O
in O
gallstone O
disease O
therapy O
in O
association O
with O
the O
litholytic O
bile O
acids O
or O
in O
the O
prevention O
of O
gallstone B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
in O
high-risk O
populations O
. O
['Physiological-Clinical']

The O
HER2 B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
was O
analyzed O
by O
three O
different O
approaches O
: O
local O
and O
central O
evaluation O
using O
immunohistochemistry O
combined O
with O
in O
situ-hybridization O
as O
well O
as O
evaluation O
of O
HER2 B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
using O
kinetic O
RT-PCR O
from O
formalin-fixed O
, O
paraffin-embedded O
( O
FFPE O
) O
tissue O
samples O
using O
a O
predefined O
cutoff O
. O
['Physiological-Clinical', 'Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

BACKGROUND O
We O
investigated O
the O
extent O
and O
frequency O
of O
dose O
errors O
and O
treatment O
delays O
made O
as O
a O
consequence O
of O
preparing O
drug O
infusions O
at O
the O
bedside O
, O
rather O
than O
using O
pre-filled O
syringes O
. O
[]

The O
Chinese B-outcome ['Physiological-Clinical']
medicine I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
integrals I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
endometrium I-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EMAb I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
cancer B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
125 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CA125 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
were O
compared O
between O
before O
drug O
therapy O
and O
three O
months O
after O
drug O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

By O
five O
years O
after O
study O
entry O
, O
8 O
percent O
of O
the O
patients O
assigned O
to O
CABG O
had O
undergone O
additional O
revascularization B-outcome ['Resource-use']
procedures I-outcome ['Resource-use']
, O
as O
compared O
with O
54 O
percent O
of O
those O
assigned O
to O
PTCA O
; O
69 O
percent O
of O
those O
assigned O
to O
PTCA O
did O
not O
subsequently O
undergo O
CABG O
. O
['Resource-use']

BACKGROUND O
To O
objectively O
compare O
the O
mood O
profiles O
of O
users O
of O
malaria O
chemoprophylaxis O
regimens O
( O
atovaquone-proguanil O
, O
chloroquine-proguanil O
, O
doxycycline O
, O
or O
mefloquine O
) O
in O
a O
group O
of O
nonimmune O
tourists O
to O
sub-Saharan O
Africa O
. O
[]

Blood O
samples O
were O
drawn O
for O
time-course O
evaluation O
of O
cyclosporin O
blood O
levels O
over O
a O
period O
of O
12 O
h O
, O
following O
the O
morning O
intake O
of O
cyclosporin O
and O
, O
for O
platelet O
aggregation O
studies O
, O
before O
and O
after O
14 O
days O
of O
ticlopidine O
administration O
. O
[]

Two O
hundred O
and O
twenty-eight O
patients O
were O
treated O
with O
concurrent O
capecitabine O
and O
radiotherapy O
( O
Cap-CRT O
) O
, O
and O
172 O
patients O
were O
treated O
with O
capecitabine O
and O
oxaliplatin O
plus O
radiotherapy O
( O
Cap-Oxa-CRT O
) O
. O
[]

OBJECTIVE O
To O
examine O
the O
effect O
of O
waiting O
times O
on O
the O
health O
status O
of O
patients O
referred O
for O
a O
non-urgent O
rheumatology O
opinion O
. O
[]

Wakings B-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
night I-outcome ['Physiological-Clinical']
were O
0.35 O
( O
95 O
% O
CI O
0.18-0.53 O
) O
baseline O
, O
0.26 O
( O
95 O
% O
CI O
0.20-0.34 O
) O
with O
placebo O
and O
0.08 O
( O
95 O
% O
CI O
0.04-0.12 O
) O
with O
melatonin O
. O
['Physiological-Clinical']

RESULTS O
The O
plasma B-outcome ['Physiological-Clinical']
levels O
of O
IL-8 O
, O
TNF-? O
, O
CRP O
, O
LDH O
, O
WBC O
count O
, O
amylase O
and O
lipase O
were O
significantly O
reduced O
after O
nutritional O
intervention O
compared O
with O
their O
levels O
on O
day O
1 O
before O
intervention O
in O
all O
three O
groups O
. O
['Physiological-Clinical']

In O
patients O
with O
chronic O
hepatitis O
C O
, O
advanced O
fibrosis O
and O
cirrhosis O
are O
associated O
with O
lower O
rates O
of O
sustained B-outcome ['Physiological-Clinical']
virologic I-outcome ['Physiological-Clinical']
response O
( O
SVR O
) O
to O
interferon O
( O
IFN O
) O
-based O
therapy O
. O
['Physiological-Clinical']

This O
pilot O
study O
revealed O
that O
the O
IFRS O
was O
well-tolerated B-outcome ['Life-Impact']
and O
safe O
in O
this O
study O
population O
associated O
with O
minimal O
complications B-outcome ['Adverse-effects']
during O
the O
duration O
of O
this O
study O
and O
was O
comparable O
in O
efficacy O
to O
['Life-Impact', 'Adverse-effects']

Faux O
pas O
detection O
and O
intentional O
action O
in O
Asperger O
Syndrome O
. O
[]

Full-face O
laser O
resurfacing O
was O
performed O
, O
and O
visual O
analog O
pain O
scores O
( O
0 O
to O
10 O
) O
were O
recorded O
during O
each O
of O
2 O
passes O
. O
[]

Patients O
, O
aged O
18-50 O
years O
, O
were O
randomly O
assigned O
to O
placebo O
( O
n=102 O
) O
, O
laquinimod O
0.3 O
mg O
a O
day O
( O
n=98 O
) O
, O
or O
0.6 O
mg O
a O
day O
( O
n=106 O
) O
. O
[]

To O
test O
this O
hypothesis O
lymph O
nodes O
of O
patients O
which O
were O
treated O
either O
by O
lymph O
node O
sampling O
or O
systematic O
lymphadenectomy O
were O
screened O
for O
micrometastatic O
spread O
of O
tumor O
cells O
and O
the O
influence O
of O
nodal O
micrometastases O
on O
the O
efficacy O
of O
lymphadenectomy O
was O
analyzed O
. O
[]

DESIGN O
Double-blind O
, O
randomized O
, O
controlled O
study O
. O
[]

Intake O
of O
lime O
juice O
was O
recently O
demonstrated O
to O
facilitate O
clearance O
of O
the O
malaria O
parasite O
. O
[]

A O
review O
. O
[]

The O
subjects O
were O
randomized O
to O
one O
of O
the O
following O
groups O
: O
4 O
meals/week O
fatty O
fish O
( O
n O
= O
11 O
) O
, O
4 O
meals/week O
lean O
fish O
( O
n O
= O
12 O
) O
and O
control O
diet O
including O
lean O
meat O
( O
n O
= O
10 O
) O
. O
[]

PURPOSE O
To O
verify O
the O
influence O
of O
cavity O
access O
diameter O
on O
demineralized B-outcome ['Physiological-Clinical']
dentin I-outcome ['Physiological-Clinical']
removal I-outcome ['Physiological-Clinical']
in O
the O
ART O
approach O
. O
['Physiological-Clinical']

The O
Esmolol O
vs O
Placebo O
Multicenter O
Study O
Group O
. O
[]

Apparent B-outcome ['Physiological-Clinical']
phalangeal I-outcome ['Physiological-Clinical']
ultrasound I-outcome ['Physiological-Clinical']
transmission I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
APU I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
assessed O
as O
parameter O
of O
bone O
quality O
independent O
of O
BMD O
. O
['Physiological-Clinical']

Blockade O
of O
the O
RAAS O
may O
slow O
the O
progression O
of O
end-organ O
damage O
. O
[]

METHODS O
We O
randomly O
assigned O
60 O
patients O
attending O
for O
ECV O
of O
persistent O
AF O
to O
a O
transesophageal O
or O
a O
transthoracic O
approach O
. O
[]

Rehabilitation O
of O
therapy-related O
cognitive O
deficits O
in O
patients O
after O
hematopoietic O
stem O
cell O
transplantation O
. O
[]

SJW O
did O
not O
attenuate O
withdrawal B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
among O
abstinent O
subjects O
. O
['Life-Impact']

Demonstration O
of O
etoricoxib O
's O
efficacy O
vs O
placebo O
and O
comparison O
of O
its O
efficacy O
to O
ibuprofen O
were O
assessed O
using O
three O
co-primary O
endpoints O
: O
Western O
Ontario O
and O
McMaster O
's O
University O
Osteoarthritis O
Index O
( O
WOMAC O
) O
Pain O
Subscale O
( O
WOMAC-PS O
) O
; O
WOMAC O
Physical B-outcome ['Life-Impact']
Function I-outcome ['Life-Impact']
Subscale O
( O
WOMAC-PFS O
) O
; O
and O
Patient B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
Disease I-outcome ['Physiological-Clinical']
Status I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PGADS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Comparison O
of O
the O
efficacy O
and O
safety O
of O
ebrotidine O
in O
the O
treatment O
of O
duodenal O
ulcer O
. O
[]

OBJECTIVE O
We O
aim O
to O
study O
the O
efficacy O
of O
acupuncture B-outcome ['Resource-use']
versus O
sham O
acupuncture O
in O
children O
with O
autism O
spectrum O
disorder O
. O
['Resource-use']

Therefore O
the O
benefits O
of O
using O
Antazolin/Tetryzolin O
eye O
drops O
was O
clearly O
outweigh O
. O
[]

HR B-outcome ['Physiological-Clinical']
changes O
from O
Baseline O
to O
Heel O
Stick O
were O
significantly O
less O
in O
KC30 O
and O
KC15 O
than O
in O
IC O
, O
and O
more O
infants O
had O
HR B-outcome ['Physiological-Clinical']
decrease O
in O
IC O
than O
in O
2 O
KC O
conditions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ratings O
of O
clinical O
case O
vignettes O
were O
used O
to O
assess O
inter-rater O
reliability O
and O
temporal O
stability O
. O
[]

Both O
drugs O
appeared O
to O
be O
safe O
, O
causing O
no O
marked O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
. O
['Adverse-effects']

A O
total O
of O
745 O
post-menopausal O
women O
( O
group O
A O
, O
n=366 O
; O
group O
B O
n=379 O
) O
, O
with O
a O
mean O
age O
of O
62 O
years O
, O
were O
included O
. O
[]

Experiments O
2-5 O
sought O
to O
test O
the O
generality O
of O
this O
effect O
over O
variations O
in O
study O
material O
( O
video O
or O
live O
interaction O
) O
, O
test O
format O
( O
cued- O
or O
free-recall O
) O
and O
information O
modality O
( O
visual O
or O
auditory O
details O
recalled O
) O
. O
[]

Interventricular B-outcome ['Physiological-Clinical']
dyssynchrony I-outcome ['Physiological-Clinical']
significantly O
decreased O
with O
BiV O
compared O
with O
RV O
pacing O
. O
['Physiological-Clinical']

Few O
controlled O
clinical O
trials O
of O
psychological O
interventions O
for O
cancer B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief O
exist O
in O
spite O
of O
frequent O
support O
for O
their O
importance O
as O
adjuncts O
to O
medical O
treatment O
. O
['Physiological-Clinical']

85 O
females O
with O
borderline O
mental O
disorders O
in O
essential O
hypertension O
were O
followed O
up O
for O
a O
month O
and O
6 O
months O
after O
the O
treatment O
( O
hypotensive O
drugs O
+ O
psychotherapy O
with O
biofeedback O
or O
hypotensive O
drugs O
only O
-- O
45 O
patients O
and O
40 O
controls O
, O
respectively O
) O
. O
[]

Measurements O
of O
alphaEGOT B-outcome ['Physiological-Clinical']
and O
alphaEGPT B-outcome ['Physiological-Clinical']
were O
not O
as O
reproducible O
as O
plasma B-outcome ['Physiological-Clinical']
PLP B-outcome ['Physiological-Clinical']
assays I-outcome ['Physiological-Clinical']
and O
were O
less O
sensitive O
and O
quantitative O
indicators O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
residual O
tumor B-outcome ['Physiological-Clinical']
rate O
was O
25.2 O
% O
in O
the O
white O
light O
arm O
versus O
4.5 O
% O
in O
the O
fluorescence O
diagnosis O
arm O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Nineteen O
patients O
with O
limited O
disease O
( O
ID O
and O
IID O
) O
were O
randomly O
assigned O
to O
either O
a O
3-week O
chemotherapy O
regimen O
associated O
with O
whole O
abdominal O
radiotherapy O
or O
chemotherapy O
for O
3 O
years O
. O
[]

Of O
the O
remaining O
patients O
, O
69.0 O
% O
became O
responders O
to O
clonidine O
plus O
chlorthalidone O
, O
whereas O
only O
34.7 O
% O
were O
responders O
to O
placebo O
plus O
chlorthalidone O
( O
P O
less O
than O
0.01 O
for O
both O
groups O
) O
. O
[]

Ceftriaxone O
versus O
ampicillin O
and O
chloramphenicol O
for O
treatment O
of O
bacterial B-outcome ['Physiological-Clinical']
meningitis I-outcome ['Physiological-Clinical']
in O
children O
. O
['Physiological-Clinical']

Patients O
in O
group O
1 O
( O
n=9 O
) O
were O
maintained O
on O
twice-daily O
applications O
of O
0.5 O
% O
timolol O
maleate O
. O
[]

Symptoms O
were O
reassessed O
at O
the O
end O
of O
each O
month O
. O
[]

OBJECTIVES O
To O
test O
the O
hypotheses O
that O
: O
( O
1 O
) O
Lumbar O
spine O
radiography O
in O
primary O
care O
patients O
with O
low O
back O
pain O
is O
not O
associated O
with O
improved O
patient O
outcomes O
, O
including O
pain B-outcome ['Physiological-Clinical']
, O
disability B-outcome ['Life-Impact']
, O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
, O
reassurance B-outcome ['Physiological-Clinical']
, O
and O
patient O
satisfaction B-outcome ['Life-Impact']
or O
belief B-outcome ['Life-Impact']
in O
the O
value O
of O
radiography O
. O
( O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Twenty-five O
patients O
were O
attributed O
to O
the O
coma O
type O
, O
which O
is O
a O
progredient O
coma O
lasting O
several O
days O
. O
[]

DISCUSSION O
The O
RCT O
design O
, O
combined O
with O
access O
to O
clinical O
records O
at O
all O
provincial O
abortion O
clinics O
, O
and O
to O
information O
in O
provincial O
single-payer O
linked O
administrative O
health O
databases O
, O
birth O
registry O
, O
and O
hospital O
records O
, O
offers O
a O
unique O
opportunity O
to O
determine O
if O
a O
novel O
IUD O
has O
a O
comparable O
expulsion B-outcome ['Life-Impact']
rate O
to O
that O
of O
the O
current O
standard O
IUD O
in O
Canada O
, O
in O
addition O
to O
the O
first O
opportunity O
to O
determine O
pregnancy O
rate O
and O
method B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
at O
1 O
year O
post-abortion O
for O
women O
choosing O
a O
range O
of O
post-abortion O
contraceptive O
options O
. O
['Life-Impact', 'Life-Impact']

We O
conducted O
a O
randomized O
, O
double-blind O
, O
parallel-group O
, O
placebo-controlled O
study O
to O
evaluate O
the O
time O
to O
onset O
of O
action O
of O
ciclesonide O
200 O
microg O
once O
daily O
in O
502 O
adults O
with O
seasonal O
allergic O
rhinitis O
of O
at O
least O
2 O
years O
' O
duration O
. O
[]

Clofarabine O
? O
[]

Effectiveness O
of O
two O
quadruple O
, O
tetracycline- O
or O
clarithromycin-containing O
, O
second-line O
, O
Helicobacter B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
therapies I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Neuropathy O
and O
myopathy O
are O
common O
sequelae O
of O
intensive O
chemotherapy O
protocols O
that O
contain O
vincristine O
and O
corticosteroids O
. O
[]

Efficacy O
and O
safety O
of O
zoledronic O
acid O
in O
patients O
with O
breast O
cancer O
metastatic O
to O
bone O
: O
a O
multicenter O
clinical O
trial O
. O
[]

The O
most O
common O
adverse O
events O
were O
upper O
respiratory O
tract O
infection O
, O
headache O
, O
and O
back O
pain O
, O
all O
mild O
to O
moderate O
. O
[]

Factors O
predictive O
of O
severe B-outcome ['Physiological-Clinical']
hypoglycemia I-outcome ['Physiological-Clinical']
in O
type O
1 O
diabetes O
: O
analysis O
from O
the O
Juvenile O
Diabetes O
Research O
Foundation O
continuous O
glucose O
monitoring O
randomized O
control O
trial O
dataset O
. O
['Physiological-Clinical']

Analog O
pain O
scale O
values O
were O
similar O
in O
Group O
A O
( O
2.49 O
) O
and O
Group O
B O
( O
2.15 O
) O
at O
twelve O
months O
postoperatively O
. O
[]

The O
characteristics O
of O
the O
children O
and O
families O
who O
benefited O
most O
from O
the O
intervention O
were O
also O
studied O
. O
[]

Food O
preferences O
are O
established O
in O
early O
childhood O
and O
track O
later O
in O
life O
. O
[]

Active O
specific O
immunotherapy O
for O
stage O
II O
and O
stage O
III O
human O
colon O
cancer O
: O
a O
randomised O
trial O
. O
[]

Even O
so O
, O
the O
cisapride O
group O
did O
not O
gain O
more O
weight O
. O
[]

The O
adjusted O
odds O
ratio O
for O
recurrence B-outcome ['Physiological-Clinical']
was O
0.66 O
( O
95 O
% O
CI O
0.38-1.17 O
; O
p=0.16 O
) O
for O
calcium O
treatment O
and O
1.67 O
( O
1.01-2.76 O
, O
p=0.042 O
) O
for O
the O
fibre O
treatment O
. O
['Physiological-Clinical']

Eighteen O
children O
were O
also O
receiving O
nifedipine O
( O
also O
known O
to O
cause O
gingival B-outcome ['Physiological-Clinical']
overgrowth I-outcome ['Physiological-Clinical']
) O
and O
were O
considered O
separately O
. O
['Physiological-Clinical']

CONCLUSIONS O
In O
patients O
with O
AIDS O
, O
silent O
persistent O
infection O
is O
common O
after O
clinically O
successful O
treatment O
for O
cryptococcal O
meningitis O
. O
[]

AIMS O
Atrial O
fibrillation O
( O
AF O
) O
is O
a O
common O
arrhythmia O
frequently O
associated O
with O
hypertension O
. O
[]

Controlling O
for O
depression B-outcome ['Life-Impact']
, O
previous B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
low B-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
, O
decreased O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
, O
and O
ventricular B-outcome ['Physiological-Clinical']
ectopic I-outcome ['Physiological-Clinical']
beats I-outcome ['Physiological-Clinical']
had O
little O
impact O
on O
estimated O
treatment O
effect O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
blind O
, O
randomised O
study O
evaluates O
three O
widely O
used O
tests O
of O
intubation O
. O
[]

IV O
. O
[]

This O
study O
examined O
the O
effect O
of O
divalproex O
sodium O
for O
irritability/aggression O
in O
children O
and O
adolescents O
with O
ASD O
. O
[]

OBJECTIVE O
The O
study O
investigated O
local B-outcome ['Life-Impact']
contextual I-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
in O
patients O
with O
major O
depressive O
disorder O
( O
MDD O
) O
. O
['Life-Impact']

The O
addition O
of O
labetalol O
did O
not O
confer O
additional O
benefit O
or O
risk O
to O
the O
patients O
. O
( O
[]

Comparison O
of O
provocative O
tests O
for O
unexplained O
syncope O
: O
isoprenaline O
and O
glyceryl O
trinitrate O
for O
diagnosing O
vasovagal B-outcome ['Physiological-Clinical']
syncope I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
arterial B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
evaluated O
at O
baseline O
and O
at O
2 O
and O
4 O
weeks O
after O
initial O
treatment O
. O
[]

Student O
patterns O
of O
use O
of O
the O
VPs O
will O
be O
recorded.In O
one O
centre O
, O
formative O
clinical O
and O
examination O
performance O
will O
be O
recorded O
, O
along O
with O
a O
self O
reported O
pre O
and O
post-intervention O
reasoning O
score O
, O
the O
DTI O
. O
[]

Experimental O
studies O
of O
prevention O
programs O
often O
randomize O
clusters O
of O
individuals O
rather O
than O
individuals O
to O
treatment O
conditions O
. O
[]

This O
indicated O
that O
inspite O
of O
iron O
supplementation O
received O
by O
the O
three O
groups O
health O
education O
contributed O
significantly O
in O
modifying O
their O
health O
seeking O
behaviour O
and O
their O
perception O
about O
significance O
of O
anaemia O
has O
a O
problem O
. O
[]

In O
those O
receiving O
rhuGM-CSF O
5.0 O
micrograms/kg O
twice O
per O
day O
, O
there O
was O
additionally O
a O
significant O
increase O
in O
the O
day O
7 O
and O
8 O
platelet B-outcome ['Physiological-Clinical']
count O
. O
['Physiological-Clinical']

Median O
FFS B-outcome ['Mortality']
for O
FM O
patients O
was O
36 O
months O
, O
compared O
with O
19 O
months O
for O
CHVP O
patients O
, O
and O
has O
not O
yet O
been O
reached O
for O
early O
CR O
patients O
at O
53 O
months O
. O
['Mortality']

RESULTS O
All O
cases O
studied O
met O
full O
Autism O
Diagnostic O
Interview O
( O
ADI O
) O
criteria O
for O
classical O
autism O
. O
[]

Nine O
patients O
showed O
negative O
MRA O
results O
. O
[]

PARTICIPANTS O
Four O
hundred O
ninety-five O
dementia O
CG O
and O
CR O
dyads O
( O
169 O
Hispanic O
, O
160 O
white O
, O
and O
166 O
African O
American O
) O
receiving O
intervention O
and O
their O
controls O
. O
[]

The O
LKSS B-outcome ['Physiological-Clinical']
was O
assessed O
before O
treatment O
, O
10 O
days O
of O
treatment O
, O
by O
the O
end O
of O
the O
treatment O
, O
and O
1 O
month O
after O
treatment O
. O
['Physiological-Clinical']

Outcome O
measures O
were O
: O
mean O
cadence O
; O
moderate-to-vigorous O
physical O
activity O
time O
accumulated O
in O
bouts O
lasting O
? O
[]

Patients O
with O
other O
complications O
after O
laparoscopic O
repair O
reported O
more O
pain B-outcome ['Physiological-Clinical']
and O
less O
activity B-outcome ['Life-Impact']
than O
those O
with O
other O
complications O
after O
open O
repair O
( O
P O
= O
.003 O
and O
P O
= O
.009 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Life-Impact']

15 O
device-related O
complications O
requiring O
surgical O
intervention O
occurred O
in O
13 O
patients O
( O
ablation O
group O
, O
four O
; O
control O
group O
, O
nine O
) O
. O
[]

BACKGROUND O
The O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
of O
ICCE O
with O
ACL O
implantation O
are O
compared O
with O
those O
of O
ECCE O
and O
PCL O
. O
['Adverse-effects']

There O
was O
a O
marginally O
significant O
difference O
in O
the O
sustained B-outcome ['Physiological-Clinical']
virological I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
between O
IVDUs O
( O
46.6 O
% O
) O
and O
non-IVDUs O
( O
34.6 O
% O
) O
( O
relative O
risk=1.35 O
; O
95 O
% O
confidence O
interval=1.00-1.81 O
) O
, O
also O
disappearing O
after O
adjusting O
for O
genotype O
. O
['Physiological-Clinical']

In O
an O
adjusted O
time-dependent O
analysis O
, O
patients O
receiving O
an O
ICD O
and O
having O
appropriate O
ICD O
therapy O
had O
a O
15.1 O
% O
yearly O
hazard O
of O
mortality B-outcome ['Mortality']
compared O
with O
5.2 O
% O
in O
ICD O
patients O
with O
no O
appropriate O
therapy O
( O
P O
< O
0.001 O
) O
. O
['Mortality']

Each O
slice O
was O
immersed O
into O
photo O
developing O
solution O
and O
was O
photographed O
, O
and O
microleakage B-outcome ['Physiological-Clinical']
was O
scored O
from O
0 O
to O
7 O
, O
by O
three O
calibrated O
examiners O
. O
['Physiological-Clinical']

This O
pattern O
of O
learning O
and O
nonlearning O
reflects O
a O
balance O
between O
flexibility O
and O
stability O
that O
the O
speech O
system O
must O
have O
to O
deal O
with O
speech O
variability O
in O
the O
diverse O
conditions O
that O
speech O
is O
encountered O
. O
[]

Distal B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
, O
conduction B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
, O
scar B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
, O
scar B-outcome ['Physiological-Clinical']
width I-outcome ['Physiological-Clinical']
, O
and O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

The O
University O
of O
Canterbury O
Adaptive O
Speech O
Test O
( O
UCAST O
) O
platform O
was O
used O
to O
administer O
a O
four-alternative O
forced-choice O
adaptive O
test O
that O
altered O
a O
low-pass O
filter O
( O
LPF O
) O
to O
track O
the O
corner O
frequency O
at O
which O
participants O
correctly O
identified O
a O
certain O
percentage O
of O
the O
word O
stimuli O
. O
[]

The O
meals O
had O
nearly O
identical O
protein O
content O
, O
volumes O
, O
and O
calories O
. O
[]

The O
needle O
sensation O
was O
evoked O
and O
the O
subject O
was O
trained O
to O
identify O
the O
characteristic O
needle O
sensation O
. O
[]

Endoscopic O
sclerotherapy O
is O
an O
effective O
treatment O
for O
bleeding O
esophageal O
varices O
, O
but O
it O
is O
associated O
with O
significant B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
. O
['Adverse-effects']

There O
was O
no O
significant O
difference O
between O
the O
5-year O
cumulative O
survival B-outcome ['Mortality']
rates O
of O
the O
2 O
groups O
( O
75 O
% O
and O
88 O
% O
, O
respectively O
) O
. O
['Mortality']

These O
studies O
are O
an O
extension O
of O
those O
previously O
reported O
for O
polymerized O
AgE O
using O
a O
readily O
available O
ragweed O
preparation O
containing O
all O
ragweed O
antigens O
. O
[]

RESULTS O
Completion O
of O
the O
program O
increased O
blood B-outcome ['Life-Impact']
draw I-outcome ['Life-Impact']
compliance I-outcome ['Life-Impact']
rates O
from O
85.4 O
% O
to O
96.6 O
% O
( O
odds O
ratio O
= O
4.80 O
; O
95 O
% O
confidence O
interval O
= O
1.12 O
, O
20.59 O
; O
p O
= O
.03 O
) O
. O
['Life-Impact']

However O
, O
this O
redistribution O
was O
not O
observed O
in O
patients O
who O
presented O
a O
worsening O
of O
right O
ventricular O
function O
( O
right O
ventricular O
end-diastolic O
area/left O
ventricular O
end-diastolic O
area O
increase O
> O
40 O
% O
) O
at O
high-frequency O
oscillatory O
ventilation+15 O
. O
[]

Patients O
most O
likely O
to O
improve O
with O
treatment O
tended O
to O
be O
younger O
and O
nonobese O
and O
have O
the O
greatest O
limitations O
initially O
. O
[]

The O
primary O
outcome O
was O
seizure B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
at O
end O
of O
treatment O
and O
at O
6-month O
follow-up O
. O
['Physiological-Clinical']

RESULTS O
Proteinuria B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
NAG I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
were O
significantly O
greater O
in O
patients O
with O
DM O
with O
respect O
to O
healthy O
controls O
. O
['Physiological-Clinical']

CONCLUSIONS O
AV O
conduction O
, O
estimated O
as O
[]

Additionally O
, O
a O
significant O
difference O
between O
E O
and O
P O
was O
observed O
at O
months O
2 O
and O
3 O
, O
although O
no O
differences O
were O
detected O
at O
the O
end O
of O
the O
study O
. O
[]

After O
rTMS O
the O
parieto-occipital B-outcome ['Physiological-Clinical']
P50 I-outcome ['Physiological-Clinical']
amplitude O
decreased O
to O
novel O
distracters O
but O
not O
to O
targets O
; O
also O
the O
amplitude O
and O
latency B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
targets I-outcome ['Physiological-Clinical']
increased O
for O
the O
frontal O
P50 O
while O
decreasing O
to O
non-target B-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
we O
did O
observe O
that O
Caucasian O
women O
and O
those O
taking O
antidepressant O
medications O
had O
lower O
levels O
of O
baseline O
HRV B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Safety O
and O
tolerability B-outcome ['Life-Impact']
of O
cold-adapted O
influenza O
vaccine O
, O
trivalent O
, O
in O
infants O
younger O
than O
6 O
months O
of O
age O
. O
['Life-Impact']

International O
Czech O
and O
Slovak O
cooperation O
in O
the O
treatment O
of O
patients O
with O
differentiated O
thyroid O
cancer O
. O
[]

Thirty-two O
immune B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
populations I-outcome ['Physiological-Clinical']
were O
characterized O
using O
three-color O
flow O
cytometry O
. O
['Physiological-Clinical']

CONCLUSIONS O
These O
data O
suggest O
that O
cutaneous O
vasodilation O
in O
response O
to O
acupuncture O
stimulation O
may O
not O
occur O
through O
an O
axon O
reflex O
as O
previously O
reported O
. O
[]

A O
P-value O
of O
< O
0.5 O
was O
considered O
as O
significant O
. O
[]

Aripiprazole-treated O
AN O
subjects O
were O
more O
likely O
than O
PAE O
subjects O
to O
report O
somnolence O
( O
11.9 O
% O
vs. O
2.8 O
% O
) O
, O
sedation O
( O
22.7 O
% O
vs. O
11.1 O
% O
) O
, O
or O
fatigue O
( O
17.0 O
% O
vs. O
13.9 O
% O
) O
. O
[]

The O
estimated O
recurrence B-outcome ['Physiological-Clinical']
rates O
at O
18 O
months O
were O
11.4 O
percent O
with O
trimethoprim-sulfamethoxazole O
and O
27.6 O
percent O
with O
pentamidine O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Effect O
of O
gravity O
on O
robot-assisted O
motor O
training O
after O
chronic B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
: O
a O
randomized O
trial O
. O
['Physiological-Clinical']

iNOS O
tended O
to O
increase O
mildly O
in O
the O
corpus O
in O
subjects O
with O
adverse O
reactions O
or O
endoscopic O
lesions O
. O
[]

The O
mean O
decreases O
in O
scores O
over O
the O
four-week O
period O
were O
8.9 O
in O
the O
secretin O
group O
and O
17.8 O
in O
the O
placebo O
group O
( O
mean O
difference O
, O
-8.9 O
; O
95 O
percent O
confidence O
interval O
, O
-19.4 O
to O
1.6 O
; O
P=0.11 O
) O
. O
[]

Capsular O
contracture O
around O
saline-filled O
fine O
textured O
and O
smooth O
mammary O
implants O
: O
a O
prospective O
7.5-year O
follow-up O
. O
[]

All O
participants O
used O
linear O
accelerators O
with O
a O
minimum O
of O
6 O
MeV O
photon-beam O
energy O
. O
[]

The O
introducer O
tool O
technique O
involved O
attaching O
the O
introducer O
tool O
, O
single-handed O
rotation O
along O
the O
palatopharyngeal O
curve O
, O
and O
introducer O
tool O
removal O
. O
[]

[ O
Effects O
of O
simvastatin O
on O
plasma B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
, O
lipoproteins B-outcome ['Physiological-Clinical']
and O
apoproteins B-outcome ['Physiological-Clinical']
( O
A1 O
and O
B O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Group O
A O
received O
a O
single O
topical O
administration O
of O
a O
0.5 O
% O
formulation O
of O
eprinomectin O
at O
the O
dose O
rate O
of O
500mug/kg O
. O
[]

There O
were O
31 O
gastric O
lymphoma O
, O
18 O
small O
intestinal O
lymphomas O
, O
and O
19 O
with O
multiple O
involvement O
: O
63 O
patients O
had O
had O
a O
surgical O
staging O
with O
total O
tumor O
resection O
in O
15 O
cases O
. O
[]

Whereas O
subjects O
with O
white-coat O
hypertension O
should O
not O
be O
treated O
with O
antihypertensive O
agents O
, O
they O
must O
be O
followed O
and O
managed O
through O
non-pharmacologic O
means O
. O
[]

Of O
52 O
patients O
screened O
, O
36 O
men O
and O
women O
with O
AK O
confirmed O
by O
histological O
diagnosis O
were O
enrolled O
. O
[]

A O
total O
of O
206 O
randomized O
FAP O
patients O
commenced O
intervention O
, O
of O
whom O
133 O
had O
at O
least O
one O
follow-up O
endoscopy O
and O
were O
therefore O
included O
in O
the O
primary O
analysis O
. O
[]

INTERPRETATION O
Subcutaneous O
daclizumab O
HYP O
administered O
every O
4 O
weeks O
led O
to O
clinically O
important O
effects O
on O
multiple O
sclerosis O
disease O
activity O
during O
1 O
year O
of O
treatment O
. O
[]

A O
questionnaire O
was O
completed O
assessing O
interest B-outcome ['Life-Impact']
in O
BRCA1 B-outcome ['Physiological-Clinical']
testing O
and O
knowledge O
on O
breast O
cancer O
genetics O
and O
screening O
. O
['Life-Impact', 'Physiological-Clinical']

Here O
, O
we O
report O
a O
randomized O
double-blind O
, O
placebo-controlled O
trial O
that O
examined O
the O
neural O
and O
behavioral O
effects O
of O
a O
single O
dose O
of O
intranasal O
oxytocin O
on O
emotion O
recognition O
in O
individuals O
with O
Asperger O
syndrome O
( O
AS O
) O
, O
a O
clinical O
condition O
characterized O
by O
impaired O
eye O
gaze O
and O
facial O
emotion O
recognition O
. O
[]

The O
subjects O
, O
131 O
children O
aged O
0.6-12 O
years O
who O
lived O
in O
an O
endemic O
area O
of O
Nigeria O
, O
were O
randomly O
allotted O
to O
the O
three O
treatment O
groups O
. O
[]

In O
this O
study O
the O
human O
glyceryltrinitrate O
( O
GTN O
) O
model O
of O
migraine O
was O
for O
the O
first O
time O
used O
to O
test O
the O
effect O
of O
a O
prophylactic O
drug O
. O
[]

The O
mean O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
scores O
2 O
hours O
after O
pain B-outcome ['Physiological-Clinical']
medications O
were O
taken O
were O
3.9 O
NRS O
units O
in O
the O
hydrocodone/acetaminophen O
group O
versus O
3.5 O
NRS O
units O
in O
the O
codeine/acetaminophen O
group O
, O
for O
a O
difference O
of O
0.4 O
NRS O
units O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
-0.3 O
to O
1.2 O
NRS O
units O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
DD-CGAS O
scores O
correlated O
with O
measures O
of O
functioning B-outcome ['Life-Impact']
and O
symptoms B-outcome ['Physiological-Clinical']
with O
moderate O
to O
large O
effect O
sizes O
. O
['Life-Impact', 'Physiological-Clinical']

Simvastatin O
and O
preparation O
of O
polyunsaturated O
phospholipids O
produce O
similar O
changes O
in O
the O
phospholipid O
composition O
of O
high-density O
lipoproteins O
during O
hypercholesterolemia O
. O
[]

Both O
groups O
significantly O
improved O
the O
forearm B-outcome ['Physiological-Clinical']
pass I-outcome ['Physiological-Clinical']
from O
pretest O
to O
posttest O
. O
['Physiological-Clinical']

Response O
to O
therapy B-outcome ['Resource-use']
was O
evaluated O
between O
the O
4th O
and O
8th O
week O
and O
classified O
as O
complete O
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
, O
defined O
as O
no O
gross O
and O
microscopic B-outcome ['Physiological-Clinical']
evidence I-outcome ['Physiological-Clinical']
of O
residual O
tumor B-outcome ['Physiological-Clinical']
, O
or O
no O
response O
( O
NR O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

[ O
Observation O
of O
curative O
effect O
on O
fixed-point O
spin O
reduction O
of O
spinal O
manipulation O
therapy O
for O
cervical O
vertigo O
] O
. O
[]

0.4 O
vs O
3.8 O
? O
[]

After O
to O
basal O
evaluation O
, O
the O
patients O
were O
revised O
in O
a O
monthly O
way O
evaluating O
the O
following O
symptoms O
and O
signs O
: O
mastalgia B-outcome ['Physiological-Clinical']
, O
mammary B-outcome ['Physiological-Clinical']
tension I-outcome ['Physiological-Clinical']
, O
presence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
nodules I-outcome ['Physiological-Clinical']
, O
nipple B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
, O
and O
the O
presence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

24 O
obese O
subjects O
( O
22 O
women O
and O
2 O
men O
; O
22-46 O
years O
old O
) O
were O
fed O
a O
diet O
of O
25 O
kcal/kg O
ideal O
body O
weight O
( O
IBW O
) O
with O
1.2 O
g O
protein/kg O
IBW O
daily O
and O
were O
treated O
with O
recombinant O
human O
GH O
( O
n O
= O
12 O
, O
0.18 O
U/kg O
IBW/week O
) O
or O
placebo O
( O
n O
= O
12 O
, O
vehicle O
injection O
) O
in O
a O
12-week O
randomized O
, O
double-blind O
and O
placebo-controlled O
trial O
. O
[]

Penetration O
of O
ofloxacin O
and O
ciprofloxacin O
into O
the O
aqueous O
humor O
of O
eyes O
with O
functioning O
filtering O
blebs O
: O
a O
randomized O
trial O
. O
[]

Here O
we O
investigate O
the O
efficacy O
and O
safety O
of O
a O
selective O
serotonin O
reuptake O
inhibitor O
( O
SSRI O
) O
, O
citalopram O
, O
and O
a O
noradrenaline O
reuptake O
inhibitor O
( O
NARI O
) O
, O
reboxetine O
, O
in O
post-stroke O
patients O
affected O
by O
anxious O
depression O
or O
retarded O
depression O
. O
[]

No O
significant O
group O
differences O
in O
heart B-outcome ['Resource-use']
failure I-outcome ['Resource-use']
readmissions I-outcome ['Resource-use']
, O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
or O
cost B-outcome ['Resource-use']
were O
evident O
at O
90-days O
, O
although O
the O
heart B-outcome ['Resource-use']
failure I-outcome ['Resource-use']
readmission I-outcome ['Resource-use']
rate I-outcome ['Resource-use']
was O
96 O
% O
higher O
in O
the O
intervention O
group O
when O
compared O
to O
that O
in O
the O
control O
group O
. O
['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']

Anti-inflammatory O
effects O
of O
inhaled O
carbon O
monoxide O
in O
patients O
with O
COPD O
: O
a O
pilot O
study O
. O
['Physiological-Clinical']

Endoscopic O
ligation O
surgery O
is O
the O
current O
institutional O
standard O
of O
care O
for O
patients O
who O
fail O
conservative O
management O
. O
[]

Both O
tracheal O
tube O
and O
CTSC O
were O
advanced O
together O
through O
the O
nasopharynx O
; O
b O
) O
NTI O
without O
CTSC O
guidance O
( O
G O
[ O
- O
] O
group O
) O
. O
[]

Nicotine O
was O
the O
most O
commonly O
used O
substance O
throughout O
the O
4 O
years O
after O
treatment O
. O
[]

Primary O
endpoints O
are O
the O
level O
of I-outcome ['Physiological-Clinical']
educational B-outcome ['Physiological-Clinical']
achievement I-outcome ['Physiological-Clinical']
one I-outcome ['Physiological-Clinical']
year I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cessation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
first-line I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
value I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
VO2max I-outcome ['Physiological-Clinical']
one I-outcome ['Physiological-Clinical']
year I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cessation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
first-line I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

One O
month O
after O
administration O
, O
the O
mean O
plasma B-outcome ['Physiological-Clinical']
concentration O
of O
TXB2 B-outcome ['Physiological-Clinical']
, O
a O
metabolite B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
TXA2 I-outcome ['Physiological-Clinical']
, O
was O
significantly O
decreased O
( O
p O
< O
0.01 O
) O
to O
62.4 O
+/- O
13.6 O
% O
, O
whereas O
that O
of O
6-keto B-outcome ['Physiological-Clinical']
prostaglandin I-outcome ['Physiological-Clinical']
F1 I-outcome ['Physiological-Clinical']
alpha B-outcome ['Physiological-Clinical']
, O
a O
metabolite B-outcome ['Physiological-Clinical']
of O
PGI2 B-outcome ['Physiological-Clinical']
, O
was O
significantly O
increased O
( O
p O
< O
0.01 O
) O
to O
206.7 O
+/- O
52.8 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
regions O
provide O
targets O
for O
future O
research O
investigating O
possible O
neural O
specialization O
for O
music O
or O
its O
associated O
mental O
processes O
. O
[]

These O
reductions O
probably O
reflect O
an O
improvement O
in O
hepatobiliary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
and O
a O
reduction O
in O
cellular B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sICAM-1 I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
There O
was O
no O
significant O
difference O
in O
the O
annual O
rate O
of O
decline O
in O
FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
( O
P=0.16 O
) O
. O
['Physiological-Clinical']

The O
remainder O
made O
an O
uncomplicated B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
We O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
6-week O
pilot O
trial O
investigating O
the O
effects O
of O
1.5 O
g/d O
of O
omega-3 O
fatty O
acids O
( O
.84 O
g/d O
eicosapentaenoic O
acid O
, O
.7 O
g/d O
docosahexaenoic O
acid O
) O
supplementation O
in O
13 O
children O
( O
aged O
5 O
to O
17 O
years O
) O
with O
autistic O
disorders O
accompanied O
by O
severe O
tantrums O
, O
aggression O
, O
or O
self-injurious O
behavior O
. O
[]

Cox O
regression O
analysis O
revealed O
that O
serum B-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
alone O
was O
an O
independent O
factor O
affecting O
the O
recurrence O
. O
['Physiological-Clinical']

The O
bias O
of O
the O
prediction O
was O
2 O
% O
and O
precision O
was O
28 O
% O
. O
[]

Our O
results O
suggest O
that O
both O
drugs O
were O
well O
tolerated O
in O
patients O
with O
AML O
or O
MDS O
who O
received O
chemotherapy O
and O
that O
the O
efficacy O
of O
itraconazole O
for O
prophylaxis O
against O
systemic B-outcome ['Physiological-Clinical']
fungal I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
is O
not O
inferior O
to O
that O
of O
fluconazole O
. O
['Physiological-Clinical']

Following O
fluid O
administration O
, O
6 O
birds O
in O
the O
crystalloid O
group O
( O
66 O
% O
) O
, O
4 O
birds O
in O
the O
HES O
group O
( O
40 O
% O
) O
, O
and O
2 O
birds O
in O
the O
HBOCS O
group O
( O
20 O
% O
) O
died O
. O
[]

A O
curve O
was O
observed O
after O
2.5 O
h O
treatment O
between O
the O
2 O
groups O
( O
P=0.001 O
) O
. O
[]

In O
a O
multivariate O
analysis O
, O
the O
Child-Pugh O
score O
was O
inversely O
related O
to O
the O
occurrence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

As O
an O
overall O
7-year O
change O
, O
amplitudes B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
OP-2 I-outcome ['Physiological-Clinical']
, O
OP-3 B-outcome ['Physiological-Clinical']
and O
OP-sum B-outcome ['Physiological-Clinical']
were O
reduced O
( O
p O
< O
0.0001-0.01 O
) O
, O
retinopathy B-outcome ['Physiological-Clinical']
worsened O
( O
p O
= O
0.005 O
) O
, O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
decreased O
( O
p O
< O
0.001 O
) O
, O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
increased O
( O
p O
< O
0.0002 O
) O
, O
and O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
improved O
from O
HbA1 O
of O
11.2 O
+/- O
2.2 O
% O
at O
study O
start O
to O
a O
7-year O
cumulative O
mean O
of O
9.5 O
+/- O
1.5 O
% O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

once O
daily O
was O
compared O
with O
that O
of O
dextran O
70 O
in O
patients O
undergoing O
THR O
. O
[]

AIM O
To O
study O
the O
effects O
of O
local O
estrogen O
with O
or O
without O
local O
testosterone O
on O
urogenital B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
sexual I-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
. O
['Physiological-Clinical']

The O
study O
was O
conducted O
in O
two O
parts O
, O
the O
first O
of O
which O
was O
an O
open O
dose-response O
study O
that O
comprised O
14 O
women O
undergoing O
abdominal O
hysterectomy O
. O
[]

In O
addition O
, O
the O
experimental O
group O
showed O
enhanced O
EEG B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
anterior O
cingulate O
cortex O
, O
a O
region O
that O
mediates O
self-control O
, O
whereas O
the O
PMR O
group O
did O
not O
. O
['Physiological-Clinical']

OBJECTIVE O
Rotigotine O
( O
Neupro O
) O
is O
formulated O
as O
a O
transdermal O
delivery O
system O
designed O
to O
provide O
a O
selective O
, O
non-ergot O
D3/D2/D1 O
agonist O
to O
the O
systemic O
blood O
flow O
over O
a O
24-hour O
period O
. O
[]

American O
Scientific O
, O
92 O
, O
358-365. O
] O
. O
[]

DISCUSSION O
This O
study O
evaluates O
the O
efficacy O
of O
a O
theory O
of O
mind O
intervention O
for O
children O
with O
ASD O
. O
[]

The O
types O
of O
appraisals O
that O
follow O
traumatic O
experiences O
have O
been O
linked O
to O
the O
emergence O
of O
posttraumatic O
stress O
disorder O
( O
PTSD O
) O
. O
[]

Evaluation O
of O
the O
safety O
, O
immunogenicity B-outcome ['Physiological-Clinical']
, O
and O
pharmacokinetic B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
of O
a O
new O
, O
highly O
purified O
, O
heat-treated O
equine O
rabies O
immunoglobulin O
, O
administered O
either O
alone O
or O
in O
association O
with O
a O
purified O
, O
Vero-cell O
rabies O
vaccine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
These O
results O
show O
that O
intensive B-outcome ['Physiological-Clinical']
therapeutic I-outcome ['Physiological-Clinical']
instillation I-outcome ['Physiological-Clinical']
may O
have O
an O
advantage O
over O
less O
intensive O
, O
prophylactic O
regimens O
. O
['Physiological-Clinical']

The O
aim O
of O
the O
present O
trial O
was O
to O
study O
the O
individual O
responsiveness O
to O
GH O
treatment O
in O
terms O
of O
body O
composition O
and O
to O
search O
for O
possible O
predictors O
of O
the O
response O
in O
GH-deficient O
adults O
. O
[]

There O
were O
922 O
( O
59 O
% O
) O
injury O
visits O
and O
653 O
( O
41 O
% O
) O
noninjury O
visits O
. O
[]

Pain B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
rest I-outcome ['Physiological-Clinical']
, O
at I-outcome ['Physiological-Clinical']
palpation I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
lateral I-outcome ['Physiological-Clinical']
epicondyle I-outcome ['Physiological-Clinical']
, O
during I-outcome ['Physiological-Clinical']
resisted I-outcome ['Physiological-Clinical']
wrist I-outcome ['Physiological-Clinical']
extension I-outcome ['Physiological-Clinical']
, O
middle I-outcome ['Physiological-Clinical']
finger I-outcome ['Physiological-Clinical']
test I-outcome ['Physiological-Clinical']
, O
and O
strength B-outcome ['Physiological-Clinical']
testing I-outcome ['Physiological-Clinical']
was O
evaluated O
using O
Visual O
Analogue O
Scales O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pharmacokinetics B-outcome ['Physiological-Clinical']
and O
toxicities B-outcome ['Adverse-effects']
were O
also O
assessed O
. O
['Physiological-Clinical', 'Adverse-effects']

Overall O
, O
eye-closure O
increased O
recall O
of O
both O
visual B-outcome ['Life-Impact']
detail I-outcome ['Life-Impact']
and O
auditory B-outcome ['Life-Impact']
details O
, O
with O
no O
accompanying O
increase O
in O
recall O
of O
false O
details O
. O
['Life-Impact', 'Life-Impact']

Effects O
of O
enalapril O
and O
eprosartan O
on O
the O
renal O
vascular O
nitric O
oxide O
system O
in O
human O
essential O
hypertension O
. O
[]

Compared O
with O
placebo O
, O
NAC O
resulted O
in O
significant O
improvements O
on O
ABC O
irritability B-outcome ['Life-Impact']
subscale O
( O
F O
= O
6.80 O
; O
p O
< O
.001 O
; O
d O
= O
.96 O
) O
. O
['Life-Impact']

CONCLUSION O
The O
results O
support O
the O
conclusion O
that O
the O
positive O
treatment O
outcome O
obtained O
by O
use O
of O
a O
stabilization O
appliance O
to O
alleviate O
the O
signs O
and O
symptoms O
in O
patients O
with O
myofascial O
pain O
persisted O
after O
6 O
and O
12 O
months O
. O
[]

Using O
objective O
measures O
, O
the O
weighted O
blanket O
, O
compared O
with O
the O
control O
blanket O
, O
did O
not O
increase O
TST O
as O
measured O
by O
actigraphy O
and O
adjusted O
for O
baseline O
TST O
. O
[]

MEASUREMENTS O
Blood B-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
analysis O
and O
spirometry B-outcome ['Physiological-Clinical']
data O
were O
recorded O
5 O
minutes O
before O
chest O
opening O
, O
5 O
minutes O
before O
inducing O
bypass O
, O
5 O
minutes O
after O
weaning O
from O
bypass O
, O
and O
5 O
minutes O
after O
chest O
closure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

IVP O
showed O
dilatation B-outcome ['Physiological-Clinical']
without I-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
in O
3 O
subjects O
of O
group O
A O
and O
none O
in O
group O
B O
or O
C O
( O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical']

In O
a O
prepost O
design O
, O
one O
half O
of O
the O
sample O
was O
randomly O
assigned O
to O
receive O
computer O
treatment O
while O
the O
other O
half O
of O
the O
sample O
served O
as O
control O
group O
. O
[]

13/8 O
mmHg O
, O
p O
less O
than O
0.02 O
) O
, O
while O
the O
maximum O
hypotensive B-outcome ['Physiological-Clinical']
effect O
was O
achieved O
after O
30 O
min O
. O
( O
['Physiological-Clinical']

This O
study O
used O
a O
randomized O
controlled O
trial O
to O
evaluate O
the O
effect O
of O
a O
focused O
imitation O
intervention O
on O
initiation O
of O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
and O
social-emotional B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
in O
27 O
young O
children O
with O
autism O
. O
['Life-Impact', 'Life-Impact']

Thirty O
of O
32 O
patients O
maintained O
response O
throughout O
the O
24-hour O
infusion O
of O
diltiazem O
. O
[]

RESULTS O
The O
effect O
of O
donepezil O
treatment O
on O
EF O
was O
examined O
. O
[]

Effect O
of O
antipsychotic O
drugs O
on O
cortical B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Comparative O
efficacy O
and O
safety O
of O
calcium O
carbasalate O
plus O
metoclopramide O
versus O
ergotamine O
tartrate O
plus O
caffeine O
in O
the O
treatment O
of O
acute O
migraine O
attacks O
. O
[]

An O
internet-based O
cognitive-behavioural O
training O
for O
acute O
tinnitus O
: O
secondary O
analysis O
of O
acceptance O
in O
terms O
of O
satisfaction O
, O
trial O
attrition O
and O
non-usage O
attrition O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
, O
chest B-outcome ['Physiological-Clinical']
radiograph I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
, O
evidence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Yoga O
may O
improve O
mood O
status O
and O
quality O
of O
life O
for O
women O
undergoing O
detoxification O
for O
heroin O
dependence O
. O
[]

Comprehensive O
interventions O
are O
needed O
to O
address O
socioeconomic O
and O
lifestyle O
issues O
as O
well O
as O
other O
barriers O
to O
care O
and O
treatment O
, O
if O
HBP O
care O
is O
to O
be O
salient O
and O
effective O
in O
this O
high O
risk O
group O
. O
[]

In O
conclusion O
, O
inhaled O
treprostinil O
was O
associated O
with O
improvement O
in O
exercise O
capacity O
and O
World O
Health O
Organization O
functional O
class O
when O
added O
to O
background O
targeted O
PAH O
therapy O
in O
children O
and O
had O
an O
acceptable O
safety O
profile O
. O
[]

Treatment O
effects O
were O
determined O
by O
analysing O
cumulative O
probability O
of O
cure O
by O
testing O
Cox O
proportional O
hazards O
models O
and O
relative O
risk O
( O
RR O
) O
. O
[]

Before O
PTF O
administration O
, O
baseline O
parameters O
were O
similar O
in O
both O
groups O
of O
patients O
with O
DM O
. O
[]

METHODS O
We O
conducted O
a O
prospective O
randomized O
clinical O
trial O
in O
126 O
patients O
scheduled O
for O
cardiac O
catheterization O
in O
a O
teaching O
hospital O
. O
[]

This O
might O
result O
from O
potentiation O
of O
arterial O
baroreflexes O
, O
but O
whether O
or O
not O
PUFA O
enhance O
baroreflex O
function O
has O
never O
been O
studied O
in O
humans O
. O
[]

The O
Discharge O
Preparation O
Program O
( O
DPP O
) O
was O
the O
intervention O
condition O
( O
n O
= O
26 O
) O
, O
and O
the O
usual O
rehabilitation O
program O
was O
the O
control O
condition O
( O
n O
= O
23 O
) O
. O
[]

OBJECTIVE O
To O
investigate O
whether O
a O
brief O
cognitive O
behavioral O
intervention O
, O
problem-solving O
education O
( O
PSE O
) O
, O
decreases O
parenting B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
and O
maternal B-outcome ['Life-Impact']
depressive I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
during O
the O
period O
immediately O
following O
a O
child O
's O
diagnosis O
of O
ASD O
. O
['Life-Impact', 'Life-Impact']

The O
measures O
for O
each O
child O
were O
accuracy B-outcome ['Physiological-Clinical']
of O
correspondences O
between O
taught O
picture O
and O
object O
pairs O
and O
accuracy B-outcome ['Physiological-Clinical']
of O
delayed O
correspondences O
in O
learning B-outcome ['Life-Impact']
outcome O
['Physiological-Clinical', 'Life-Impact']

6 O
The O
measurement O
of O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
following O
intravenous O
bolus O
injections O
of O
isoprenaline O
provides O
useful O
information O
about O
the O
beta O
2-adrenoceptor O
antagonism O
of O
propranolol O
and O
practolol O
. O
['Physiological-Clinical']

CONCLUSIONS O
This O
open-label O
, O
prospective O
trial O
demonstrates O
that O
LOAD B-outcome ['Physiological-Clinical']
is O
a O
highly O
active O
regimen O
for O
the O
treatment O
of O
HP O
in O
treatment-naive O
patients O
. O
['Physiological-Clinical']

In O
this O
prospective O
observational O
study O
, O
we O
examined O
the O
extent O
to O
which O
general O
and O
abstinence-specific O
support O
, O
both O
structural O
and O
functional O
, O
predicted O
opiate O
and O
cocaine O
abstinence O
in O
128 O
opioid O
maintenance O
patients O
receiving O
either O
methadone O
or O
LAAM O
. O
[]

PBMC O
obtained O
at O
entry O
, O
6 O
, O
12 O
, O
18 O
, O
and O
24 O
months O
were O
stimulated O
to O
produce O
IL-1 O
beta O
with O
phytohemagglutinin O
( O
PHA O
) O
, O
lipopolysaccharide O
( O
LPS O
) O
, O
Staphylococcus O
epidermidis O
, O
recombinant O
IL-2 O
, O
or O
mitochondrial O
antigen O
. O
[]

Remission O
occurred O
more O
rapidly O
in O
TEMPO O
than O
RADIUS O
II O
perhaps O
from O
differences O
in O
compliance O
, O
patient O
populations O
, O
or O
sequence O
of O
combination O
therapy O
initiation O
. O
[]

By O
day O
28 O
, O
6 O
patients O
had O
died B-outcome ['Mortality']
( O
2 O
in O
the O
tobramycin O
group O
and O
4 O
in O
the O
placebo O
group O
, O
p O
= O
0.23 O
) O
. O
['Mortality']

All O
three O
treatment O
groups O
improved O
on O
tests O
of O
attention B-outcome ['Life-Impact']
( O
P O
< O
.003 O
) O
, O
verbal B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
( O
P O
< O
.001 O
) O
, O
and O
motor B-outcome ['Life-Impact']
speed I-outcome ['Life-Impact']
( O
P O
< O
.002 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
study O
was O
conducted O
in O
the O
neonatal O
intensive O
units O
for O
infants O
undergoing O
routine O
ROP O
screening O
exams O
. O
[]

TRIAL O
REGISTRATION O
UMIN O
Clinical O
Trials O
Registry O
000007942 O
. O
[]

Movement-related O
potentials O
associated O
with O
sequential O
movements O
were O
investigated O
under O
various O
cueing O
conditions O
in O
Parkinson O
's O
disease O
subjects O
and O
age-matched O
controls O
. O
[]

Serum B-outcome ['Physiological-Clinical']
ciprofloxacin I-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
determined O
on O
Day O
3 O
of O
the O
treatment O
were O
higher O
in O
the O
majority O
of O
patients O
than O
were O
the O
MIC50 B-outcome ['Physiological-Clinical']
and O
MIC90 B-outcome ['Physiological-Clinical']
values O
for O
the O
Shigella B-outcome ['Physiological-Clinical']
and O
Salmonella B-outcome ['Physiological-Clinical']
spp I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Topical O
capsaicin O
has O
been O
found O
to O
be O
efficacious O
in O
several O
types O
of O
neuropathic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
contrast O
, O
the O
positive O
effects O
of O
L-carnitine O
on O
[]

This O
suggests O
that O
autistic O
patients O
had O
significantly O
greater O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
sumatriptan O
than O
normal O
controls O
, O
independent O
of O
placebo O
effects O
. O
['Physiological-Clinical']

No O
neutralizing O
antibodies O
were O
observed O
. O
[]

Ss O
in O
the O
treatment O
groups O
had O
four O
weekly O
50-minute O
, O
individual O
sessions O
. O
[]

CONCLUSION O
The O
treatment O
of O
external B-outcome ['Physiological-Clinical']
ocular I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
with O
0.3 O
% O
ofloxacin B-outcome ['Resource-use']
eyedrops I-outcome ['Resource-use']
was O
equally O
effective O
when O
given O
BID O
or O
QID O
. O
['Physiological-Clinical', 'Resource-use']

The O
primary O
endpoint O
of O
our O
study O
was O
ongoing B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
within O
6 O
months O
. O
['Physiological-Clinical']

Moreover O
, O
no O
patient O
with O
gram-positive O
bacteremia O
died B-outcome ['Mortality']
during O
the O
first O
3 O
days O
of O
true O
empirical O
therapy O
. O
['Mortality']

15/11 O
mmHg O
, O
p O
less O
than O
0.02 O
) O
and O
hypotensive B-outcome ['Physiological-Clinical']
peak I-outcome ['Physiological-Clinical']
after O
20 O
min O
( O
57/38 O
mmHg O
, O
p O
greater O
than O
0.001 O
) O
; O
2 O
) O
no O
significant O
differences O
for O
hypotensive B-outcome ['Physiological-Clinical']
effectiveness I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
, O
but O
with O
SLC O
having O
a O
mildly O
delayed O
onset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
when O
compared O
to O
SLN O
; O
3 O
) O
antihypertensive B-outcome ['Resource-use']
effect O
lasting O
for O
about O
6 O
hours O
in O
patients O
treated O
with O
SLC O
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
progressively O
raising O
after O
4 O
hours O
in O
patients O
who O
received O
SLN O
; O
4 O
) O
a O
significant O
correlation O
between O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
reduction O
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
before O
drug O
administration O
in O
both O
groups O
; O
a O
significant O
correlation O
between O
pretreatment O
PRA O
and O
antihypertensive O
effect O
in O
the O
SLC O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Bronchoalveolar B-outcome ['Resource-use']
lavage I-outcome ['Resource-use']
( I-outcome ['Resource-use']
BAL I-outcome ['Resource-use']
) I-outcome ['Resource-use']
was O
performed O
at O
baseline O
and O
study O
days O
4 O
and O
7 O
to O
obtain O
BAL O
fluid O
( O
BALF O
) O
for O
measurement O
of O
total O
protein B-outcome ['Physiological-Clinical']
, O
ceruloplasmin B-outcome ['Physiological-Clinical']
, O
and O
transferrin B-outcome ['Physiological-Clinical']
, O
total O
neutrophil B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
IL-8 B-outcome ['Physiological-Clinical']
, O
IL-6 B-outcome ['Physiological-Clinical']
, O
tumor B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor-alpha I-outcome ['Physiological-Clinical']
, O
and O
leukotriene B-outcome ['Physiological-Clinical']
B4 I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Authors O
considered O
several O
risk O
factors O
for O
SSI O
. O
[]

All O
reactions O
resolved O
without O
incident O
. O
[]

Modeling O
was O
performed O
using O
FOCE O
INTERACTION O
estimation O
method O
implemented O
in O
NONMEM O
V. O
The O
linagliptin O
plasma O
concentration- O
and O
DPP-4 O
inhibition- O
time O
profiles O
were O
simulated O
for O
Japanese O
patients O
receiving O
5 O
mg O
linagliptin O
once O
daily O
by O
the O
model O
established O
. O
[]

All O
patients O
were O
pretreated O
with O
aspirin O
and O
given O
heparin O
during O
surgery O
. O
[]

To O
assess O
the O
efficacy O
of O
postoperative O
pain O
management O
and O
the O
concentration O
change O
of O
PGE-2 O
and O
IL-6 O
of O
joint O
fluid O
with O
parecoxib O
after O
postoperative O
total O
knee O
arthroplasty O
. O
[]

A O
double-blind O
study O
of O
terfenadine O
and O
placebo O
in O
110 O
patients O
suffering O
from O
hay O
fever O
( O
confirmed O
by O
skin O
tests O
) O
was O
conducted O
. O
[]

3CM O
participants O
also O
had O
more O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
visits I-outcome ['Life-Impact']
and O
higher O
outpatient B-outcome ['Resource-use']
pharmacy I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
['Life-Impact', 'Resource-use']

BACKGROUND O
Chemical O
peels O
and O
topical O
depigmenting O
agents O
have O
become O
a O
popular O
modality O
in O
the O
treatment O
of O
melasma O
. O
[]

The O
desensitizing O
capabilities O
of O
a O
composite O
cement O
that O
contains O
a O
self-etching O
, O
dual-polymerizing O
resin O
adhesive O
system O
were O
compared O
with O
those O
of O
a O
composite O
cement O
that O
use O
phosphoric O
acid O
etching O
followed O
by O
a O
single-bottle O
, O
light-activated O
primer/resin-based O
adhesive O
. O
[]

All O
materials O
tested O
showed O
a O
distinct O
behavior O
on O
enamel B-outcome ['Physiological-Clinical']
and O
dentin B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
outcome O
measure O
is O
severity O
of O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
according O
to O
the O
PHQ9 B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

A O
secondary O
purpose O
was O
to O
test O
the O
effects O
of O
a O
post-diagnosis O
nursing O
intervention O
on O
parents O
' O
reports O
of O
stress B-outcome ['Life-Impact']
, O
impact O
of O
event O
( O
diagnosis O
) O
, O
and O
use B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
services I-outcome ['Life-Impact']
after O
a O
child O
is O
newly O
diagnosed O
with O
ASD O
. O
['Life-Impact', 'Life-Impact']

[ O
Clinical O
efficiency O
of O
cytokines O
in O
prophylactics O
and O
treatment O
of O
infectious O
and O
inflammatory O
complications O
after O
oral O
surgery O
procedures O
] O
. O
[]

In O
these O
patients O
, O
response O
did O
not O
influence O
FFS B-outcome ['Mortality']
except O
for O
those O
with O
alveolar O
histology O
. O
['Mortality']

RESULTS O
Comparing O
baseline O
to O
6-month O
results O
, O
both O
groups O
showed O
statistically O
significant O
probing B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
( O
PD B-outcome ['Physiological-Clinical']
) O
, O
horizontal O
clinical O
attachment O
level O
( O
CAL-h O
) O
gain O
, O
and O
increase O
in O
gingival B-outcome ['Physiological-Clinical']
recession I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
an O
early B-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
panic I-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
suffered O
more O
often O
from O
agoraphobia B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
intent-to-treat O
analyses O
were O
rerun O
with O
putative O
predictors O
and O
moderators O
. O
[]

Several O
techniques O
have O
been O
described O
for O
maintaining O
this O
orientation O
, O
although O
no O
prior O
investigations O
directly O
compare O
these O
techniques O
. O
[]

Participants O
were O
randomized O
to O
either O
azithromycin O
500 O
mg O
daily O
and O
tinidazole O
500 O
mg O
two O
tablets O
daily O
in O
combination O
with O
lansoprasole O
30 O
mg O
daily O
for O
6 O
days O
( O
ATL-group O
) O
or O
with O
placebo O
( O
ATP-group O
) O
. O
[]

10 O
vs O
44 O
? O
[]

at O
the O
time O
of O
skin O
closure O
. O
[]

In O
each O
case O
in O
the O
first O
group O
two O
catheters O
were O
tied O
together O
and O
introduced O
transcervically O
into O
the O
uterine O
cavity O
after O
delivery O
of O
the O
placenta O
. O
[]

In O
Australia O
, O
a O
tobacco O
tax O
provides O
funding O
for O
Healthway O
, O
the O
Western O
Australian O
Health O
Promotion O
Foundation O
. O
[]

Patients O
were O
off O
drugs O
for O
at O
least O
2 O
weeks O
and O
subdiagnosed O
according O
to O
the O
modified O
Marshall-Hachinski O
ischemic O
score O
and O
CT O
in O
45 O
senile O
dementia O
of O
the O
Alzheimer O
type O
( O
SDAT O
) O
and O
51 O
multiinfarct O
dementia O
( O
MID O
) O
patients O
. O
[]

Are O
postural B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
backward O
and O
forward O
perturbations O
processed O
by O
different O
neural O
circuits O
? O
['Physiological-Clinical']

CONCLUSIONS O
Prolonged O
use O
of O
theophylline O
has O
a O
sustained O
effect O
on O
cardiovascular B-outcome ['Physiological-Clinical']
, O
metabolic B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
and O
without O
concurrent O
AD O
had O
similar O
baseline O
characteristics O
, O
with O
the O
exception O
that O
AD O
patients O
reported O
more O
alcohol O
use O
. O
[]

All O
aripiprazole O
doses O
demonstrated O
significantly O
greater O
improvements O
in O
mean O
Clinical B-outcome ['Physiological-Clinical']
Global B-outcome ['Physiological-Clinical']
Impressions-Improvement O
score O
than O
placebo O
at O
week O
8 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Ferumoxytol O
is O
a O
novel O
, O
semisynthetic O
, O
carbohydrate-coated O
, O
superparamagnetic O
iron O
oxide O
nanoparticle O
that O
is O
administered O
IV O
as O
an O
injection O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
groups O
in O
survival B-outcome ['Mortality']
or O
in O
hematologic B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
hepatic I-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

The O
effect O
of O
zidovudine O
and O
didanosine O
on O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
concentrations O
of O
neopterin O
was O
studied O
in O
12 O
patients O
with O
human O
immunodeficiency O
virus O
type-1 O
( O
HIV-1 O
) O
infection O
3-12 O
months O
after O
initiation O
of O
antiretroviral O
therapy O
. O
[]

We O
set O
out O
to O
clarify O
the O
role O
of O
YAP1 B-outcome ['Physiological-Clinical']
in O
breast O
cancer O
by O
examining O
gene O
and O
protein O
expression O
in O
subgroups O
of O
patient O
material O
and O
by O
downregulating O
YAP1 O
in O
vitro O
and O
studying O
its O
role O
in O
response O
to O
the O
widely O
used O
anti-estrogen O
tamoxifen O
. O
['Physiological-Clinical']

Investigation O
of O
the O
abnormalities O
in O
supplementary O
motor O
area O
activity O
associated O
with O
movement O
deficits O
in O
Parkinson O
's O
disease O
may O
therefore O
reveal O
functions O
of O
the O
basal O
ganglia O
and O
the O
supplementary O
motor O
area O
. O
[]

In O
this O
study O
, O
participants O
were O
required O
to O
locomote O
in O
the O
dark O
to O
a O
lit O
target O
in O
three O
different O
conditions O
: O
monocular O
vision/target O
with O
image O
size O
, O
binocular O
vision/target O
with O
image O
size O
, O
and O
binocular O
vision/point-light O
target O
( O
without O
image O
size O
) O
. O
[]

[ O
Postural O
biofeedback O
and O
locomotion O
reeducation O
in O
stroke O
patients O
] O
. O
[]

The O
mean O
exercise B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
219.9 O
seconds O
in O
the O
air O
control O
period O
and O
221.3 O
seconds O
after O
purified O
air O
( O
P O
not O
significant O
) O
. O
['Life-Impact']

RESULTS O
Single O
agent O
or O
combination O
chemotherapy O
regimens O
including O
doxorubicin O
( O
A O
) O
( O
12 O
% O
) O
, O
doxorubicin/cisplatin O
( O
AP O
) O
( O
63 O
% O
) O
, O
doxorubicin/paclitaxel O
( O
AT O
) O
( O
13 O
% O
) O
, O
and O
paclitaxel/doxorubicin/cisplatin O
( O
TAP O
) O
( O
11 O
% O
) O
were O
used O
among O
1203 O
patients O
treated O
on O
4 O
randomized O
clinical O
trials O
. O
[]

Furthermore O
, O
2.8 O
mg?kg O
BM O
of O
PSE O
taken O
90 O
min O
before O
exercise O
, O
with O
or O
without O
food O
, O
resulted O
in O
urinary O
PSE O
concentrations O
exceeding O
the O
present O
WADA O
threshold O
. O
[]

Paromomycin O
for O
cryptosporidiosis O
in O
AIDS O
: O
a O
prospective O
, O
double-blind O
trial O
. O
[]

RESULTS O
After O
IV O
administration O
, O
the O
plasma B-outcome ['Physiological-Clinical']
concentration O
of O
methadone B-outcome ['Physiological-Clinical']
at O
10 O
minutes O
was O
82.1 O
+/- O
9.2 O
ng O
mL O
( O
-1 O
) O
( O
mean O
+/- O
SD O
) O
, O
the O
terminal O
half-life O
was O
3.9 O
+/- O
1.0 O
hours O
, O
the O
volume O
of O
distribution O
9.2 O
+/- O
3.3 O
L O
kg O
( O
-1 O
) O
and O
plasma O
clearance O
27.9 O
+/- O
7.6 O
mL O
minute O
( O
-1 O
) O
kg O
( O
-1 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Prospective O
, O
randomized O
, O
open-label O
trial O
. O
[]

Control O
and O
intervention O
participants O
provided O
baseline O
and O
four O
waves O
of O
quarterly O
follow-up O
data O
. O
[]

Our O
findings O
suggest O
an O
alteration O
of O
the O
writing O
movement O
representation O
at O
a O
central O
level O
and O
are O
consistent O
with O
the O
view O
that O
dystonia O
is O
not O
a O
purely O
motor O
disorder O
, O
but O
it O
also O
involves O
non-motor O
( O
sensory O
, O
cognitive O
) O
aspects O
related O
to O
movement O
processing O
and O
planning O
. O
[]

Risperidone O
was O
associated O
with O
increased O
appetite B-outcome ['Physiological-Clinical']
and O
a O
mild O
weight O
gain O
, O
mild B-outcome ['Physiological-Clinical']
sedation I-outcome ['Physiological-Clinical']
in O
20 O
% O
, O
and O
transient B-outcome ['Physiological-Clinical']
dyskinesias I-outcome ['Physiological-Clinical']
in O
three O
children O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Combined O
chemotherapy O
and O
radiotherapy O
compared O
with O
radiotherapy O
alone O
in O
patients O
with O
cancer O
of O
the O
esophagus O
. O
[]

CONCLUSION O
The O
rate O
of O
early O
posttraumatic O
seizures O
in O
children O
may O
be O
much O
lower O
than O
previously O
reported O
. O
[]

The O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
in O
the O
DSMMC O
group O
was O
statistically O
significant O
when O
compared O
with O
that O
in O
the O
DS O
group O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

There O
is O
growing O
evidence O
of O
an O
association O
between O
physical O
illness O
and O
problem O
behavior O
in O
children O
with O
developmental O
disabilities O
. O
[]

INTRODUCTION O
Time B-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
therapeutic I-outcome ['Life-Impact']
range O
( O
TTR O
) O
for O
international O
normalized O
ratio O
( O
INR O
) O
is O
an O
accepted O
quality O
measure O
of O
anticoagulation O
control O
in O
patient O
populations O
, O
but O
its O
usefulness O
for O
predicting O
stroke O
and O
bleeding O
in O
individuals O
is O
not O
well O
understood O
. O
['Life-Impact']

Efficacy O
and O
safety O
of O
azithromycin O
and O
doxycycline O
for O
the O
treatment O
of O
moderate O
acne O
vulgaris O
were O
evaluated O
( O
240 O
patients O
) O
in O
both O
intention-to-treat O
and O
per-protocol O
populations O
. O
[]

The O
purpose O
of O
our O
study O
was O
to O
find O
out O
whether O
EA O
is O
able O
to O
diminish O
the O
cortisol B-outcome ['Physiological-Clinical']
and O
glucose B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
major O
transabdominal O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

5-fluorouracil/leucovorin O
) O
. O
[]

The O
Tiotropium O
Safety O
and O
Performance B-outcome ['Life-Impact']
in O
Respimat O
Trial O
( O
TIOSPIR O
) O
, O
a O
large O
scale O
, O
randomized O
, O
controlled O
, O
parallel-group O
trial-design O
and O
rationale O
. O
['Life-Impact']

Patients O
in O
Group1 O
( O
n=77 O
) O
received O
metoprolol O
100 O
mg/24 O
h O
per O
oral O
( O
P.O O
. O
) O
, O
[]

Sociodemographic O
data O
and O
clinical O
features O
were O
assessed O
. O
[]

Masking O
seems O
less O
successful B-outcome ['Physiological-Clinical']
when O
one O
eye O
is O
receiving O
a O
real O
injection O
and O
the O
other O
eye O
is O
receiving O
a O
sham O
injection O
or O
when O
an O
individual O
eye O
receives O
both O
real O
and O
sham O
injections O
. O
['Physiological-Clinical']

In O
addition O
, O
spermiogram B-outcome ['Physiological-Clinical']
, O
testicular B-outcome ['Physiological-Clinical']
enzyme B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
, O
intratesticular B-outcome ['Physiological-Clinical']
steroid B-outcome ['Physiological-Clinical']
hormonal I-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
and O
testicular B-outcome ['Physiological-Clinical']
antioxidant I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
were O
estimated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Among O
participants O
who O
completed O
the O
study O
the O
rate O
of O
compliance O
was O
72 O
% O
. O
[]

In O
fully O
and O
partially O
evaluable O
patients O
with O
a O
68-month O
median O
follow-up O
, O
treatment O
failures B-outcome ['Physiological-Clinical']
have O
occurred O
in O
27 O
% O
of O
172 O
receiving O
CMFVP O
and O
47 O
% O
of O
186 O
women O
given O
L-PAM O
( O
p O
= O
0.002 O
) O
. O
['Physiological-Clinical']

When O
the O
changes O
in O
WOMAC O
scores O
were O
compared O
between O
groups O
, O
a O
significantly O
greater O
improvement O
was O
found O
between O
pre-treatment O
and O
immediately O
post-treatment O
in O
group O
A O
, O
compared O
with O
group O
B O
( O
p=0.02 O
) O
. O
[]

In O
a O
prospective O
, O
randomized O
, O
double-blind O
study O
, O
90 O
paediatric O
patients O
, O
ASA O
I O
, O
aged O
4-10 O
years O
, O
received O
granisetron O
40 O
mg O
kg-1 O
or O
perphenazine O
70 O
mg O
kg-1 O
( O
n O
= O
45 O
each O
) O
intravenously O
immediately O
after O
an O
inhalation O
induction O
of O
anaesthesia O
. O
[]

Of O
618 O
patients O
, O
418 O
( O
68 O
% O
) O
continued O
into O
the O
extension O
phase O
on O
the O
same O
double-blind O
medication O
and O
dose O
. O
[]

STUDY O
OBJECTIVE O
To O
determine O
if O
the O
diagnostic O
accuracy O
and O
safety O
of O
intravenous O
adenosine O
myocardial O
perfusion O
imaging O
is O
significantly O
different O
in O
men O
compared O
with O
women O
. O
[]

Comparisons O
between O
the O
two O
conditions O
indicated O
significant O
reductions O
in O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
as O
measured O
by O
self-report O
, O
parent O
report O
and O
['Life-Impact']

The O
daily O
administration O
of O
60 O
mg O
of O
the O
beta-carotene O
preparation O
( O
30 O
mg O
of O
all-trans O
beta-carotene O
and O
30 O
mg O
of O
9-cis O
beta-carotene O
) O
was O
performed O
and O
beta-carotene O
concentrations O
were O
determined O
in O
the O
plasma B-outcome ['Physiological-Clinical']
, O
red B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RBC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
platelets O
( O
PLT O
) O
, O
and O
mononuclear B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MN I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Needle O
manipulations O
during O
knot-tying O
predispose O
the O
surgeon O
to O
glove O
perforation O
. O
[]

Patients O
were O
randomized O
to O
one O
of O
three O
groups O
: O
hypnosis O
, O
a O
package O
of O
CB O
coping O
skills O
, O
and O
no O
intervention O
. O
[]

Study O
2 O
included O
49 O
subjects O
assigned O
to O
risperidone O
only O
and O
75 O
subjects O
assigned O
to O
risperidone O
plus O
parent O
training O
. O
[]

With O
respect O
to O
angiographic B-outcome ['Physiological-Clinical']
new I-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
, O
in O
the O
pravastatin O
group O
there O
were O
50 O
% O
less O
patients O
with O
new O
angiographic B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
if O
cotreated O
with O
CCBs O
as O
compared O
with O
no O
CCB O
cotreatment O
, O
whereas O
in O
the O
placebo O
( O
no O
pravastatin O
) O
group O
, O
again O
, O
no O
significant O
effect O
of O
CCB O
treatment O
was O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
all O
groups O
energy O
intake O
was O
kept O
constant O
. O
[]

RESULTS O
Six O
hundred O
eighty-eight O
patients O
were O
enrolled O
. O
[]

SETTING O
Department O
of O
Ophthalmology O
, O
Labbafinejad O
Medical O
Center O
, O
Tehran O
, O
Iran O
. O
[]

Zoledronic O
acid O
was O
well O
tolerated B-outcome ['Life-Impact']
with O
a O
safety O
profile O
similar O
to O
placebo O
. O
['Life-Impact']

Both O
groups O
of O
animals O
received O
individual O
supportive O
treatment O
consisting O
of O
adjusted O
diet O
and O
electrolyte O
solution O
. O
[]

Hence O
, O
children O
as O
young O
as O
4 O
can O
learn O
to O
make O
selective O
inferences O
about O
novel O
stimuli O
, O
but O
only O
when O
they O
are O
aware O
of O
the O
relevant O
context O
cues O
. O
[]

Mobility B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
, O
frequency O
and O
intensity O
of O
breathing B-outcome ['Physiological-Clinical']
interventions I-outcome ['Physiological-Clinical']
were O
quantified O
for O
both O
groups O
. O
['Life-Impact', 'Physiological-Clinical']

Lanthanum O
carbonate O
was O
well O
tolerated B-outcome ['Life-Impact']
; O
only O
one O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
was O
reported O
, O
which O
was O
unrelated O
to O
treatment O
. O
['Life-Impact', 'Adverse-effects']

RESULT O
( O
S O
) O
Significantly O
lower O
abdominal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
shoulder I-outcome ['Physiological-Clinical']
tip I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
a O
lower O
incidence O
of O
vasovagal B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
were O
observed O
in O
group O
B O
in O
comparison O
with O
group O
A O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Follow-up O
assessments O
at O
6 O
and O
12 O
months O
indicated O
that O
treatment O
gains O
were O
maintained O
, O
with O
more O
than O
70 O
% O
of O
respondents O
from O
both O
groups O
reporting O
continued O
flying O
at O
follow-up O
. O
[]

Central O
5-HT4 O
receptor O
binding O
as O
biomarker O
of O
serotonergic O
tonus O
in O
humans O
: O
a O
[ O
11C O
] O
SB207145 O
PET O
study O
. O
[]

Results O
were O
based O
on O
intention O
to O
treat O
analysis O
and O
cost-effectiveness O
was O
calculated O
as O
marginal O
cost O
per O
cancer O
case O
prevented O
. O
[]

VX-770 O
, O
a O
CFTR O
potentiator O
, O
has O
been O
shown O
to O
increase O
the O
activity O
of O
wild-type O
and O
defective O
cell-surface O
CFTR O
in O
vitro O
. O
[]

The O
overall O
clinical O
incidence O
of O
deep B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
was O
0.3 O
% O
( O
1 O
in O
329 O
patients O
) O
. O
['Physiological-Clinical']

A O
randomized O
study O
of O
264 O
children O
and O
adults O
with O
previously O
untreated O
localized O
Ewing O
's O
sarcoma O
of O
bone O
was O
undertaken O
between O
1973 O
and O
1978 O
by O
83 O
institutions O
of O
three O
national O
study O
groups O
: O
Children O
's O
Cancer O
Study O
Group O
, O
Southwest O
Oncology O
Group O
, O
and O
Cancer O
and O
Leukemia O
Group O
B O
. O
[]

We O
performed O
this O
study O
to O
test O
the O
hypothesis O
that O
this O
could O
be O
attributed O
to O
sympathetic O
overactivity O
. O
[]

Group O
P O
received O
the O
placebo O
( O
0.9 O
% O
normal O
saline O
2 O
ml O
) O
and O
Group O
D O
received O
10 O
mg O
dexamethasone O
intravenously O
right O
before O
the O
induction O
of O
anesthesia O
. O
[]

Each O
case O
can O
be O
designed O
in O
four O
different O
ways O
, O
equating O
to O
16 O
VPs O
required O
for O
the O
research O
. O
[]

Mean O
hemoglobin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
on O
admission O
was O
similar O
in O
the O
two O
groups O
( O
blood O
conservation O
device O
group O
: O
11.8 O
+/- O
2.5 O
g/dL O
; O
control O
group O
: O
12.6 O
+/- O
2.3 O
g/dL O
) O
. O
['Physiological-Clinical']

Mania B-outcome ['Life-Impact']
ratings O
improved O
during O
combined O
treatment O
in O
Phase O
3 O
by O
88.2 O
% O
( O
linear O
mixed O
model O
analysis O
, O
F O
= O
4.34 O
, O
p O
= O
0.013 O
) O
, O
compared O
with O
10.5 O
% O
improvement O
during O
Phase O
2 O
. O
['Life-Impact']

Youth O
reported O
on O
their O
emotional O
health O
( O
positive O
affect O
, O
life O
satisfaction O
, O
depression O
, O
anxiety O
) O
and O
social-emotional O
and O
character O
development O
. O
[]

RESULTS O
Nosocomial B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
, O
meninges B-outcome ['Physiological-Clinical']
, O
or O
urinary B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
occurred O
in O
439 O
of O
the O
2416 O
infants O
( O
18.2 O
percent O
) O
: O
208 O
( O
17.3 O
percent O
) O
in O
the O
immune O
globulin O
group O
and O
231 O
( O
19.1 O
percent O
) O
in O
the O
control O
group O
( O
relative O
risk O
, O
0.91 O
; O
95 O
percent O
confidence O
interval O
, O
0.77 O
to O
1.08 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Metal-on-metal O
( O
MOM O
) O
total O
hip O
arthroplasties O
were O
reintroduced O
because O
of O
the O
problems O
with O
osteolysis O
and O
aseptic O
loosening O
related O
to O
polyethylene O
wear O
of O
early O
metal-on-polyethylene O
( O
MOP O
) O
arthroplasties O
. O
[]

In O
patients O
with O
AS O
, O
pancuronium O
increased O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
more O
than O
vecuronium O
or O
atracurium O
; O
heart B-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
were O
also O
higher O
with O
the O
pancuronium-metocurine O
mixture O
than O
with O
vecuronium O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
open-label O
clinical O
trial O
. O
[]

FINDINGS O
Between O
Nov O
22 O
, O
2006 O
, O
and O
July O
31 O
, O
2007 O
, O
197 O
patients O
were O
randomly O
allocated O
to O
treatment O
groups O
and O
were O
included O
in O
the O
intention-to-treat O
analysis O
( O
135 O
eltrombopag O
, O
62 O
placebo O
) O
. O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
at O
similar O
frequencies O
in O
both O
treatment O
groups O
. O
['Adverse-effects']

The O
function O
was O
assessed O
using O
the O
pain-free B-outcome ['Physiological-Clinical']
grip I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
at O
baseline O
and O
after O
6 O
weeks O
. O
['Physiological-Clinical']

More O
drop-outs O
due O
to O
toxicity O
were O
observed O
in O
the O
combination O
arm O
compared O
with O
the O
PUVA-alone O
arm O
. O
[]

The O
study O
also O
seeks O
to O
determine O
the O
acceptability B-outcome ['Life-Impact']
and O
extent O
of O
implementation B-outcome ['Life-Impact']
of O
the O
intervention O
by O
services O
and O
their O
staff O
participating O
in O
the O
study O
. O
['Life-Impact', 'Life-Impact']

Children O
's O
age O
, O
sex O
, O
ethnicity O
, O
and O
height O
and O
weight O
( O
used O
to O
calculate O
BMI O
) O
were O
collected O
between O
August O
2001 O
and O
May O
2004 O
. O
[]

III O
: O
Continued O
lifestyle O
intervention O
combined O
with O
the O
same O
drugs O
as O
in O
phase O
II O
and O
in O
addition O
pravastatin O
or O
placebo O
. O
[]

CONCLUSIONS O
Ilioinguinal-iliohypogastric O
nerve O
block O
with O
IV O
dexketoprofen O
increases O
patient O
satisfaction O
by O
decreasing O
opioid O
consumption O
, O
increasing O
patient O
satisfaction O
, O
which O
suggests O
that O
dexketoprofen O
trometamol O
is O
an O
effective O
non-steroidal O
anti-inflammatory O
analgesic O
in O
postoperative O
analgesia O
. O
[]

CONCLUSIONS O
In O
patients O
with O
mainly O
pulmonary O
acute O
respiratory O
distress O
syndrome O
, O
using O
high O
mean O
airway O
pressure O
under O
high-frequency O
oscillatory O
ventilation O
can O
worsen O
right O
ventricular O
function O
when O
compared O
with O
protective O
conventional O
mechanical O
ventilation O
, O
notably O
in O
patients O
in O
whom O
high-frequency O
oscillatory O
ventilation O
produced O
less O
alveolar O
recruitment O
of O
the O
posterior O
parts O
of O
the O
lungs O
. O
[]

Two O
hundred O
and O
twelve O
patients O
treated O
for O
prostatic O
cancer O
grade O
I O
or O
II O
were O
investigated O
for O
cardiovascular O
complications O
. O
[]

Acipimox O
was O
well O
tolerated B-outcome ['Life-Impact']
, O
and O
could O
be O
a O
useful O
addition O
to O
the O
drugs O
available O
for O
the O
treatment O
of O
patients O
with O
hypertriglyceridaemia O
. O
['Life-Impact']

[ O
Antazoline/tetryzoline O
eyedrops O
in O
comparison O
with O
levocabastine O
eyedrops O
in O
acute O
allergic O
conjunctivitis O
] O
. O
[]

Confocal O
microscopy O
was O
used O
for O
the O
6-week O
treatment O
group O
to O
examine O
the O
target O
tumor O
area O
at O
each O
interval O
visit O
and O
immediately O
before O
Mohs O
micrographic O
surgery O
. O
[]

Buspirone O
was O
found O
to O
be O
safe O
and O
efficacious O
, O
without O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
for O
decreasing O
hyperactivity B-outcome ['Life-Impact']
and O
increasing O
completed B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
tasks I-outcome ['Life-Impact']
. O
['Adverse-effects', 'Life-Impact', 'Life-Impact']

Most O
often O
the O
AEs B-outcome ['Adverse-effects']
were O
of O
mild-to-moderate O
severity O
. O
['Adverse-effects']

The O
authors O
previously O
evaluated O
cytarabine O
3 O
g/m O
( O
2 O
) O
daily O
for O
5 O
days O
with O
mitoxantrone O
80 O
mg/m O
( O
2 O
) O
( O
the O
ALL-2 O
regimen O
) O
as O
a O
novel O
induction O
regimen O
. O
[]

This O
is O
the O
first O
placebo-controlled O
study O
of O
the O
safety O
of O
injectable O
opioids O
in O
a O
controlled O
treatment O
setting O
. O
[]

All O
patients O
had O
neutropenia B-outcome ['Physiological-Clinical']
( O
absolute O
neutrophil O
count O
[ O
ANC O
] O
less O
than O
1,000/microL O
) O
while O
taking O
full-dose O
zidovudine O
. O
['Physiological-Clinical']

Subjects O
with O
cardiac O
, O
metabolic O
, O
neurological O
disease O
or O
any O
other O
systemic O
disease O
that O
could O
affect O
autonomic O
activity O
were O
excluded O
from O
the O
study O
. O
[]

A O
double-blind O
study O
evaluated O
the O
effects O
of O
systemic O
and O
topical O
folate O
on O
gingival B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
fourth I-outcome ['Physiological-Clinical']
and O
eighth B-outcome ['Physiological-Clinical']
months I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
view O
of O
the O
abundant O
anatomical O
and O
functional O
interactions O
between O
serotonin O
and O
dopamine O
systems O
, O
this O
study O
examined O
the O
effect O
of O
the O
serotonin O
agonist O
, O
m-chlorophenylpiperazine O
( O
mCPP O
) O
on O
plasma O
concentrations O
of O
the O
dopamine O
metabolite O
, O
homovanillic O
acid O
. O
[]

RESULTS O
There O
were O
no O
significant O
differences O
in O
birth B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
treatment O
with O
antibiotics B-outcome ['Resource-use']
, O
and O
the O
starting O
time O
of O
breast-feeding O
among O
the O
three O
groups O
. O
['Physiological-Clinical', 'Resource-use']

There O
were O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
diarrhea B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
vomiting B-outcome ['Physiological-Clinical']
, O
dyspepsia B-outcome ['Physiological-Clinical']
and O
other O
adverse B-outcome ['Adverse-effects']
reaction I-outcome ['Adverse-effects']
in O
control O
group O
, O
while O
the O
degree O
and O
occurrence O
rate O
of O
those O
in O
observation O
group O
alleviated O
and O
decreased O
obviously O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

CONCLUSIONS O
These O
results O
show O
that O
epidural O
analgesia O
compared O
with O
PCA O
offered O
improved O
pain O
control O
after O
breast O
reconstruction O
with O
immediate O
transverse O
rectus O
abdominis O
musculocutaneous O
flap O
reconstruction O
. O
[]

Because O
bacterial O
populations O
develop O
during O
the O
first O
day O
of O
life O
, O
the O
authors O
examined O
whether O
the O
early O
administration O
of O
bifidobacteria O
has O
a O
positive O
effect O
on O
the O
health B-outcome ['Physiological-Clinical']
of O
low O
birth O
weight O
infants O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
Thirty O
patients O
with O
gynecologic O
malignancy O
, O
who O
had O
laparoscopic O
pelvic O
lymphadenectomy O
were O
randomly O
assigned O
for O
lymphadenectomy O
in O
1 O
side O
of O
the O
pelvis O
using O
the O
Ligaclip O
, O
whereas O
, O
in O
the O
other O
side O
, O
the O
bipolar O
coagulation O
to O
seal O
lymphatic O
vessels O
was O
used O
. O
[]

Improvements O
were O
limited O
to O
the O
recognition O
of O
expressions O
of O
anger O
, O
with O
poor O
maintenance O
of O
these O
skills O
at O
follow-up O
. O
[]

The O
prophylactic B-outcome ['Resource-use']
effect O
of O
valproate O
on O
glyceryltrinitrate B-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
migraine I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

The O
economics O
of O
behavioural O
approaches O
to O
improving O
health O
must O
be O
made O
explicit O
if O
decision O
makers O
are O
to O
be O
convinced O
that O
allocating O
resources O
toward O
such O
programs O
is O
worthwhile O
. O
[]

Analgesic O
efficacy O
of O
low-dose O
diclofenac O
versus O
paracetamol O
and O
placebo O
in O
postoperative O
dental O
pain O
. O
[]

The O
MCIC O
of O
the O
QBPDS O
was O
estimated O
between O
17.5 O
to O
32.9 O
points O
and O
8.5 O
to O
24.6 O
points O
for O
( O
sub O
) O
acute O
and O
chronic O
patients O
with O
low O
back O
pain O
. O
[]

Effects O
of O
bifidobacterium O
breve O
supplementation O
on O
intestinal O
flora O
of O
low O
birth O
weight O
infants O
. O
[]

There O
were O
three O
measurement O
periods O
: O
prior O
to O
randomization O
( O
Time O
1 O
) O
and O
at O
5 O
and O
9 O
months O
post O
enrollment O
( O
Times O
2 O
and O
3 O
) O
. O
[]

Rituximab O
plus O
intravenous O
bolus O
chemotherapy O
is O
a O
standard O
treatment O
for O
immunocompetent O
patients O
with O
B-cell O
non-Hodgkin O
lymphoma O
( O
NHL O
) O
. O
[]

Randomized O
controlled O
trial O
to O
compare O
the O
early O
and O
mid-term O
results O
of O
stapled O
versus O
open O
hemorrhoidectomy O
. O
[]

METHODS O
From O
215 O
patients O
admitted O
within O
24 O
hours O
of O
a O
hemispheric O
ischemic O
stroke O
, O
89 O
patients O
on O
chronic O
statin O
treatment O
were O
randomly O
assigned O
either O
to O
statin O
withdrawal O
for O
the O
first O
3 O
days O
after O
admission O
( O
n O
= O
46 O
) O
or O
to O
immediately O
receive O
atorvastatin O
20 O
mg/day O
( O
n O
= O
43 O
) O
. O
[]

INTERVENTIONS O
AND O
MAIN O
OUTCOME O
MEASURES O
Psychological B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
was O
assessed O
with O
General B-outcome ['Life-Impact']
Health I-outcome ['Life-Impact']
Questionnaire-12 O
( O
GHQ-12 O
) O
, O
Thyroid B-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Questionnaire O
, O
and O
Hospital O
Anxiety B-outcome ['Life-Impact']
and O
Depression B-outcome ['Life-Impact']
Scale O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Of O
5602 O
postcards O
distributed O
, O
5070 O
( O
90.5 O
% O
) O
were O
completed O
and O
returned O
. O
[]

INTERVENTION O
( O
S O
) O
Controlled O
ovarian O
stimulation O
with O
letrozole O
and O
gonadotropins O
, O
cetrorelix O
and O
intrauterine O
insemination O
. O
[]

METHODS O
AND O
RESULTS O
Adult O
and O
pediatric O
patients O
with O
allergic O
rhinoconjunctivitis O
and/or O
asthma O
were O
included O
in O
the O
study O
. O
[]

The O
likelihood O
of O
finding O
organ-confined O
untreated O
prostate O
cancer O
( O
PCa O
) O
by O
pathological O
examination O
at O
the O
time O
of O
radical O
prostatectomy O
( O
RP O
) O
is O
only O
50 O
% O
in O
patients O
with O
clinically O
organ-confined O
disease O
. O
[]

In O
those O
participants O
undergoing O
serial O
measurements O
of O
adrenal O
function O
and O
BMD O
, O
no O
association O
was O
noted O
between O
skin B-outcome ['Physiological-Clinical']
bruising I-outcome ['Physiological-Clinical']
and O
either O
the O
suppression O
of O
adrenal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
or O
the O
loss B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
as O
systemic O
complications O
of O
ICS O
use O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
adverse B-outcome ['Physiological-Clinical']
hematologic I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
chemistry I-outcome ['Physiological-Clinical']
, O
or O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
Internet O
has O
the O
potential O
to O
provide O
large O
populations O
with O
individual O
health O
promotion O
advice O
at O
a O
relatively O
low O
cost O
. O
[]

Results O
of O
the O
initial O
12-month O
study O
demonstrated O
the O
benefit O
of O
finasteride O
treatment O
on O
PFS B-outcome ['Mortality']
parameters O
. O
['Mortality']

At O
1 O
year O
, O
patients O
in O
the O
treatment O
group O
had O
clinically O
and O
statistically O
significant O
gains O
over O
baseline O
WOMAC O
scores O
and O
walking B-outcome ['Life-Impact']
distance I-outcome ['Life-Impact']
; O
20 O
% O
of O
patients O
in O
the O
placebo O
group O
and O
5 O
% O
of O
patients O
in O
the O
treatment O
group O
had O
undergone O
['Life-Impact']

Cost-effectiveness O
of O
ablation O
surgery O
in O
patients O
with O
atrial O
fibrillation O
undergoing O
cardiac O
surgery O
. O
['Resource-use']

Significantly O
more O
patients O
on O
placebo O
opened B-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
envelope I-outcome ['Life-Impact']
than O
patients O
taking O
the O
active O
drug O
. O
['Life-Impact']

This O
study O
was O
designed O
to O
determine O
whether O
a O
selective O
serotonin O
reuptake O
inhibitor O
would O
improve O
outcome O
and O
reduce O
relapse O
after O
weight B-outcome ['Physiological-Clinical']
restoration I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
contributing I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
maintenance I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
healthy I-outcome ['Physiological-Clinical']
normal I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Their O
matched O
controls O
heard O
the O
novel B-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
and O
watched O
the O
juice-making B-outcome ['Life-Impact']
task O
being O
performed O
. O
['Life-Impact', 'Life-Impact']

The O
importance O
of O
early O
initiation O
of O
inhaled O
steroids O
even O
in O
mild O
asthma O
has O
been O
documented O
in O
several O
studies O
. O
[]

resected O
prostate O
was O
calculated O
( O
2.65 O
versus O
4.65 O
gm O
. O
[]

After O
a O
4-week O
placebo O
run-in O
, O
446 O
hypertensive O
patients O
( O
mean O
age O
: O
55.8 O
+/- O
11.0 O
years O
) O
were O
randomised O
to O
receive O
Per/Ind O
or O
Ate O
for O
12 O
weeks O
. O
[]

Mean O
length O
of O
sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
was O
shorter O
in O
the O
LC O
group O
( O
13.9 O
vs O
30.1 O
days O
; O
95 O
% O
CI O
for O
difference O
10.9-21.7 O
) O
. O
['Life-Impact']

Secondary O
caries O
formation O
in O
vitro O
around O
glass O
ionomer-lined O
amalgam O
and O
composite O
restorations O
. O
[]

Daily O
questions O
and O
related O
messages O
were O
then O
programmed O
into O
an O
easy-to-use O
telehealth O
messaging O
device O
, O
the O
Health O
Buddy O
( O
R O
) O
. O
[]

In O
Experiment O
1 O
, O
although O
the O
participants O
were O
instructed O
to O
disregard O
the O
cue O
and O
the O
target O
was O
correctly O
cued O
in O
only O
50 O
% O
of O
the O
trials O
, O
both O
groups O
of O
children O
responded B-outcome ['Physiological-Clinical']
significantly O
faster O
to O
cued O
targets O
than O
to O
uncued O
targets O
, O
regardless O
of O
the O
cue O
. O
['Physiological-Clinical']

Further O
investigation O
of O
this O
intervention O
modality O
with O
larger O
samples O
and O
broader O
outcome O
measures O
appears O
to O
be O
indicated O
. O
[]

CONCLUSION O
In O
women O
with O
a O
large O
uterus O
, O
a O
3-month O
preoperative O
course O
of O
GnRH O
may O
facilitate O
laparoscopic O
hysterectomy O
, O
decreasing O
uterine O
size O
, O
operating O
time O
, O
and O
blood O
loss O
. O
[]

This O
difference O
was O
not O
significant O
. O
[]

Randomized O
trial O
of O
adoptive O
transfer O
of O
melanoma O
tumor-infiltrating O
lymphocytes O
as O
adjuvant O
therapy O
for O
stage O
III O
melanoma O
. O
[]

These O
findings O
may O
provide O
additional O
explanatory O
data O
for O
the O
high O
susceptibility O
of O
SAR O
patients O
to O
incident O
asthma O
. O
[]

Substance B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
and O
the O
number O
of O
substance B-outcome ['Life-Impact']
using O
friends O
increased O
in O
linear O
fashion O
from O
T1 O
to O
T5 O
. O
['Life-Impact', 'Life-Impact']

Comparative O
evaluation O
of O
cefotaxime O
and O
cephamandole O
in O
the O
prevention O
of O
post-operative B-outcome ['Physiological-Clinical']
infective I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
following O
emergency O
abdominal O
surgery O
. O
['Physiological-Clinical']

In O
66 O
patients O
, O
sedation O
was O
performed O
without O
use O
of O
the O
bispectral O
index O
, O
while O
the O
index O
was O
used O
in O
the O
other O
60 O
patients O
. O
[]

Age O
was O
relevant O
for O
OAS O
only O
. O
[]

aureus B-outcome ['Physiological-Clinical']
was O
0.31 O
and O
0.28 O
for O
heifers O
in O
the O
prepartum O
and O
postpartum O
groups O
, O
respectively O
, O
compared O
with O
that O
for O
heifers O
in O
the O
control O
group O
. O
['Physiological-Clinical']

No O
significant O
differences O
were O
found O
in O
the O
lipid B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
LDL I-outcome ['Physiological-Clinical']
from O
the O
two O
groups O
. O
['Physiological-Clinical']

METHODS O
AND O
RESULTS O
Signal-averaged O
electrocardiograms O
were O
obtained O
from O
12 O
normal O
subjects O
( O
6 O
men O
, O
6 O
women O
; O
ages O
21 O
to O
26 O
years O
) O
before O
and O
after O
ingestion O
of O
caffeine O
( O
5 O
mg/kg O
body O
weight O
) O
or O
placebo O
in O
a O
randomized O
, O
double-blind O
, O
crossover O
fashion O
. O
[]

Granulocyte-macrophage O
colony-stimulating O
factor O
as O
immunomodulating O
factor O
together O
with O
influenza O
vaccination O
in O
stem O
cell O
transplant O
patients O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Bulbar B-outcome ['Physiological-Clinical']
conjunctival I-outcome ['Physiological-Clinical']
hyperemia I-outcome ['Physiological-Clinical']
, O
ocular B-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
, O
and O
ocular B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
repeated O
before O
and O
every O
10 O
minutes O
after O
treatment O
for O
1 O
hour O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

AIMS O
AND O
METHODS O
The O
rates O
of O
side O
branch O
occlusion O
and O
subsequent O
periprocedural O
MI O
during O
everolimus-eluting O
stent O
( O
EES O
) O
and O
paclitaxel-eluting O
stent O
( O
PES O
) O
placement O
were O
examined O
in O
the O
randomised O
SPIRIT O
III O
trial O
. O
[]

2 O
factorial O
design O
yielding O
control O
, O
PEER O
, O
CHILD O
, O
and O
both O
PEER O
and O
CHILD O
conditions O
. O
[]

CONCLUSIONS O
Although O
this O
multicenter O
RCT O
was O
conducted O
in O
a O
strict O
setting O
, O
extended O
lymphadenectomy O
in O
radical O
PD O
did O
not O
benefit O
long-term O
survival O
in O
patients O
with O
resectable O
pancreatic O
head O
cancer O
and O
led O
to O
levels O
of O
morbidity O
, O
mortality O
and O
quality O
of O
life O
comparable O
to O
those O
found O
after O
standard O
lymphadenectomy O
. O
[]

All O
patients O
received O
central O
nervous O
system O
prophylaxis O
with O
intrathecal O
methotrexate O
and O
most O
received O
local O
or O
regional O
radiation O
treatment O
. O
[]

The O
correlations O
between O
actual O
and O
estimated O
GAI O
ranged O
from O
r=.76 O
to O
r=.90 O
. O
[]

CONCLUSION O
High-pressure O
, O
rapid-inflation O
pneumatic O
compression O
increases O
popliteal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
femoral I-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
as O
compared O
with O
standard O
, O
low-pressure O
, O
slow-inflation O
pneumatic O
compression O
. O
['Physiological-Clinical']

BACKGROUND O
Conventional O
implant O
protocols O
advocate O
a O
two-stage O
technique O
with O
a O
load-free O
, O
submerged O
healing O
period O
. O
[]

Guar O
led O
to O
an O
additional O
lowering O
of O
the O
total O
cholesterol B-outcome ['Physiological-Clinical']
in O
the O
plasma O
by O
7 O
% O
( O
P O
less O
than O
or O
equal O
to O
0.05 O
) O
associated O
with O
a O
fall O
of O
the O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LDL-cholesterol I-outcome ['Physiological-Clinical']
( O
LDL-cholesterol O
) O
by O
13 O
% O
( O
P O
less O
than O
or O
equal O
to O
0.01 O
) O
without O
any O
changes O
in O
the O
very O
low O
density O
lipoprotein O
( O
VLDL O
) O
and O
high O
density O
lipoprotein O
( O
HDL O
) O
cholesterols O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effect O
of O
ibuprofen O
on O
cyclooxygenase B-outcome ['Physiological-Clinical']
and O
nitric B-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
synthase I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
: O
correlation O
with O
endoscopic B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Baseline O
BNP O
was O
a O
significant O
univariable O
correlate O
of O
CI-AKI O
( O
odds O
ratio O
1.31 O
, O
95 O
% O
confidence O
interval O
, O
1.14-1.51 O
; O
P=0.0001 O
) O
. O
[]

The O
effectiveness O
of O
a O
calcium O
sodium O
phosphosilicate O
desensitizer O
in O
reducing O
cervical O
dentin O
hypersensitivity O
: O
a O
pilot O
study O
. O
[]

Preliminary O
observations O
have O
shown O
that O
fentanyl O
citrate O
, O
a O
potent O
narcotic O
, O
is O
helpful O
during O
labor O
without O
undue O
side O
effects O
. O
[]

We O
evaluated O
in O
a O
randomized O
, O
double-blind O
and O
cross-over O
study O
, O
the O
effects O
of O
a O
DA O
agonist O
( O
bromocriptine O
) O
and O
a O
DA O
antagonist O
( O
amisulpride O
) O
on O
platelet O
5-HT O
in O
infantile O
autism O
. O
[]

PURPOSE O
Bevacizumab O
, O
a O
humanized O
anti-vascular O
endothelial O
growth O
factor O
monoclonal O
antibody O
, O
and O
erlotinib O
, O
a O
reversible O
, O
orally O
available O
epidermal O
growth O
factor O
receptor O
tyrosine O
kinase O
inhibitor O
, O
have O
demonstrated O
evidence O
of O
a O
survival O
benefit O
in O
the O
treatment O
of O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O
[]

Specifically O
, O
we O
assessed O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
the O
5-HT O
1d O
agonist O
, O
sumatriptan O
, O
and O
linked O
this O
measure O
of O
serotonergic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
to O
the O
severity O
of O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
adult O
autistic O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
impact O
of O
fat O
gain O
and O
its O
distribution O
on O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
lean O
healthy O
humans O
. O
['Physiological-Clinical']

The O
diagnostic O
yield O
of O
TBNA O
remained O
unchanged O
even O
when O
the O
EBUS O
probe O
was O
adjacent O
to O
the O
lesions O
( O
p O
= O
0.89 O
) O
. O
[]

Although O
AmB O
in O
lipid B-outcome ['Physiological-Clinical']
emulsion I-outcome ['Physiological-Clinical']
is O
apparently O
cleared O
faster O
and O
distributes O
more O
widely O
than O
AmB B-outcome ['Physiological-Clinical']
in O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Airway O
immunopathology O
was O
investigated O
using O
induced O
sputum O
, O
bronchial O
biopsies O
, O
bronchial O
wash O
and O
bronchoalveolar O
lavage O
in O
12 O
patients O
with O
symptomatic O
eosinophilic O
asthma O
, O
11 O
patients O
with O
non-eosinophilic O
asthma O
and O
10 O
healthy O
controls O
. O
[]

CONCLUSIONS O
AND O
RELEVANCE O
The O
positive O
effects O
of O
PSE O
in O
reducing O
parenting B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
and O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
during O
the O
critical O
postdiagnosis O
period O
, O
when O
parents O
are O
asked O
to O
navigate O
a O
complex O
service O
delivery O
system O
, O
suggest O
that O
it O
may O
have O
a O
place O
in O
clinical O
practice O
. O
['Life-Impact', 'Life-Impact']

Forty O
were O
recommended O
one O
or O
more O
behavioural O
changes O
and O
eight O
had O
no O
need O
. O
[]

There O
were O
no O
significant O
differences O
between O
initial O
and O
final O
results O
in O
either O
group O
in O
terms O
of O
BMI O
, O
WHR O
or O
waist O
circumference O
. O
[]

Best B-outcome ['Life-Impact']
palliation I-outcome ['Life-Impact']
was O
obtained O
by O
the O
combination O
of O
Epirubicin O
and O
MPA O
. O
['Life-Impact']

Patients O
were O
assessed O
for O
complications B-outcome ['Adverse-effects']
, O
mortality B-outcome ['Mortality']
, O
tube B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
and O
cost B-outcome ['Resource-use']
. O
['Adverse-effects', 'Mortality', 'Life-Impact', 'Resource-use']

We O
monitored O
self-reported O
abstinence B-outcome ['Life-Impact']
and O
end-expired B-outcome ['Physiological-Clinical']
air I-outcome ['Physiological-Clinical']
carbon I-outcome ['Physiological-Clinical']
monoxide I-outcome ['Physiological-Clinical']
( O
CO O
) O
. O
['Life-Impact', 'Physiological-Clinical']

We O
assessed O
potential O
risk O
factors O
for O
fracture O
, O
and O
followed-up O
participants O
for O
24 O
months O
for O
incidence O
of O
non-vertebral O
fractures O
. O
[]

METHODS O
We O
conducted O
an O
18-week O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
dose-escalating O
study O
in O
36 O
subjects O
with O
chronic O
plaque O
psoriasis O
. O
[]

The O
main O
outcome O
measures O
were O
1-y O
changes O
in O
body O
weight O
( O
in O
kg O
) O
and O
fat O
mass O
( O
in O
kg O
) O
. O
[]

The O
implant O
treatment O
involved O
either O
a O
mainly O
implant-supported O
mandibular O
overdenture O
on O
a O
transmandibular O
implant O
( O
TMI O
) O
or O
an O
implant-tissue-supported O
mandibular O
overdenture O
on O
two O
IMZ O
implants O
( O
IMZ O
) O
. O
[]

Compared O
with O
other O
drugs O
, O
lorazepam O
drug O
effects O
were O
greater O
and O
resulted O
in O
more O
prolonged B-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
of O
a O
motor B-outcome ['Life-Impact']
tracking I-outcome ['Life-Impact']
task O
, O
standing B-outcome ['Physiological-Clinical']
steadiness I-outcome ['Physiological-Clinical']
, O
and O
memory B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

The O
value O
of O
beta-blockade O
and O
of O
disopyramide O
phosphate O
in O
the O
immediate O
treatment O
of O
patients O
with O
suspected O
acute O
myocardial O
infarction O
was O
assessed O
in O
two O
placebo O
controlled O
trials O
. O
[]

This O
has O
been O
particularly O
thoroughly O
demonstrated O
in O
patients O
with O
schizophrenia O
. O
[]

The O
primary O
measure O
of O
the O
outcome O
was O
the O
Aberrant B-outcome ['Life-Impact']
Behaviour O
Checklist-Community O
( O
ABC-C O
) O
and O
the O
secondary O
measure O
of O
the O
outcome O
was O
the O
Childhood O
Autism O
Rating O
Scale O
( O
relating O
to O
people O
and O
verbal O
communication O
) O
. O
['Life-Impact']

This O
evaluation O
used O
descriptive O
and O
univariate O
statistics O
to O
examine O
data O
from O
342 O
participants O
from O
the O
ongoing O
ESRA-C O
randomized O
clinical O
trial O
. O
[]

Treatment O
failure B-outcome ['Physiological-Clinical']
( O
death B-outcome ['Mortality']
, O
graft B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
CMV B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
, O
or O
withdrawal B-outcome ['Life-Impact']
from O
study O
) O
occurred O
in O
14.3 O
% O
, O
0 O
% O
and O
66.7 O
% O
in O
the O
GAN O
, O
VAL O
, O
and O
C O
groups O
, O
respectively O
( O
P=0.014 O
, O
GAN O
vs O
C O
; O
P=0.001 O
, O
VAL O
vs O
C O
; O
P=NS O
, O
GAN O
vs O
VAL O
) O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Many O
autistic O
children O
have O
associated O
problems O
of O
inattention B-outcome ['Life-Impact']
, O
impulsivity B-outcome ['Life-Impact']
, O
and O
hyperactivity B-outcome ['Life-Impact']
that O
limit O
the O
effectiveness O
of O
educational O
and O
behavioral O
interventions O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

METHODS O
AND O
RESULTS O
Three O
hundred O
symptomatic O
patients O
with O
ISR O
were O
randomly O
assigned O
to O
1 O
of O
3 O
treatment O
arms O
: O
placebo O
or O
usual-dose O
or O
high-dose O
sirolimus O
. O
[]

PARTICIPANTS O
Participants O
met O
criteria O
for O
cocaine O
dependence O
during O
a O
2-week O
screening O
period O
. O
[]

Nurses O
trained O
by O
US O
study O
personnel O
( O
first-generation O
) O
and O
nurses O
trained O
by O
Ghanaian O
nurses O
after O
the O
study O
( O
second-generation O
) O
were O
evaluated O
on O
CPAP O
knowledge O
and O
skills O
. O
[]

Between O
September O
1985 O
and O
April O
1987 O
, O
110 O
consecutive O
patients O
who O
had O
successful O
coronary O
angioplasty O
were O
included O
in O
a O
randomised O
prospective O
controlled O
evaluation O
of O
the O
effects O
of O
warfarin O
on O
restenosis O
. O
[]

Translucency B-outcome ['Physiological-Clinical']
of O
zirconia O
copings O
was O
significantly O
lower O
( O
P=.001 O
) O
than O
that O
of O
the O
lithium O
disilicate O
glass-ceramic O
control O
. O
['Physiological-Clinical']

A O
pharmacokinetic O
comparative O
study O
. O
[]

3 O
There O
was O
no O
difference O
in O
overall B-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
geometry I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
dynamics I-outcome ['Physiological-Clinical']
after O
either O
drug O
. O
['Physiological-Clinical']

C O
was O
three O
3-weekly O
cycles O
of O
cisplatin/vindesine O
, O
mitomycin/ifosfamide/cisplatin O
, O
mitomycin/vinblastine/cisplatin O
or O
vinorelbine/cisplatin O
. O
[]

The O
primary O
efficacy O
parameter O
will O
be O
the O
nominal O
change O
in O
percent O
atheroma B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PAV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
determined O
by O
analysis O
of O
intravascular O
ultrasound O
( O
IVUS O
) O
images O
of O
matched O
coronary O
artery O
segments O
acquired O
at O
baseline O
and O
at O
26-week O
follow-up O
. O
['Physiological-Clinical']

In O
the O
EBUS-TBNA O
plus O
CDPs O
group O
( O
99 O
patients O
) O
, O
TBNA O
, O
TBB O
, O
and O
BW O
were O
performed O
. O
[]

Children O
's O
attitudes B-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
intentions I-outcome ['Life-Impact']
toward O
a O
peer O
with O
autistic O
behaviors O
: O
does O
a O
brief O
educational O
intervention O
have O
an O
effect O
? O
['Life-Impact']

The O
well-trained O
group O
was O
measured O
once O
in O
the O
respiration O
chamber O
for O
36 O
h O
according O
to O
the O
same O
protocol O
. O
[]

At O
the O
end O
of O
the O
follow-up O
, O
an O
investigation O
of O
the O
immune B-outcome ['Physiological-Clinical']
status O
was O
done O
, O
and O
compared O
with O
that O
of O
a O
healthy O
control-group O
. O
['Physiological-Clinical']

CONCLUSION O
The O
CAST O
was O
more O
effective O
than O
nutrition O
alone O
or O
nutrition O
plus O
strength O
training O
for O
reducing O
multiple B-outcome ['Physiological-Clinical']
adiposity I-outcome ['Physiological-Clinical']
outcomes O
and O
fasting B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
in O
overweight O
Latina O
girls O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
clinical O
trial O
followed O
the O
basic O
principles O
of O
the O
various O
guidelines O
on O
the O
evaluation O
of O
anti-dementia O
drugs O
, O
and O
included O
patients O
with O
mild O
to O
moderate O
probable O
Alzheimer O
's O
disease O
. O
[]

Statistical O
analysis O
revealed O
no O
significant O
differences O
in O
[]

Mefloquine O
kinetics O
in O
cured O
and O
recrudescent O
patients O
with O
acute O
falciparum O
malaria O
and O
in O
healthy O
volunteers O
. O
[]

There O
were O
no O
significant O
changes O
in O
the O
FLS B-outcome ['Physiological-Clinical']
or O
CTR B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Also O
, O
CD19 O
is O
an O
independent O
prognostic O
factor O
in O
addition O
to O
plasma O
cell O
labeling O
indices O
, O
beta2-microglobulin O
, O
hemoglobin O
, O
and O
plasmablastic O
morphology O
. O
[]

Treatment O
also O
effectively O
( O
P O
< O
0.05 O
) O
reduced O
the O
numbers O
of O
bacteria B-outcome ['Physiological-Clinical']
isolated I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
conjunctivae I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Antibody O
response O
against O
the O
three O
strains O
of O
vaccine O
was O
measured O
before O
and O
28 O
days O
after O
vaccination O
, O
and O
compared O
between O
previously O
vaccinated O
and O
non-vaccinated O
subjects O
. O
[]

OBJECTIVE O
To O
investigate O
the O
efficacy O
and O
safety O
of O
risperidone O
for O
the O
treatment O
of O
disruptive O
behavioral O
symptoms O
in O
children O
with O
autism O
and O
other O
pervasive O
developmental O
disorders O
( O
PDD O
) O
. O
[]

Granisetron O
revealed O
an O
excellent O
inhibitory B-outcome ['Physiological-Clinical']
effect O
on O
vomiting B-outcome ['Physiological-Clinical']
induced O
by O
remission O
induction O
chemotherapy O
for O
acute O
myeloid O
leukemia O
, O
but O
combination O
with O
granisetron O
and O
methylprednisolone O
was O
considered O
useful O
for O
nausea B-outcome ['Physiological-Clinical']
in O
the O
latter O
half O
of O
the O
treatment O
period O
and O
for O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
operation O
, O
children O
in O
group O
F O
were O
given O
flumazenil O
( O
0.01 O
mg/kg O
) O
and O
children O
in O
group O
E O
received O
placebo O
. O
[]

The O
overall O
response O
rate O
was O
34.6 O
% O
. O
[]

The O
improvements O
in O
gait B-outcome ['Life-Impact']
velocity B-outcome ['Physiological-Clinical']
( O
P= O
.03 O
) O
and O
['Life-Impact', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Eight O
hundred O
and O
three O
patients O
with O
representative O
pretreatment O
tissue O
samples O
from O
the O
randomized O
DAHANCA O
6 O
and O
7 O
study O
of O
5 O
vs. O
6 O
fx/wk O
of O
radiotherapy O
. O
[]

The O
results O
show O
that O
the O
number O
of O
binges B-outcome ['Life-Impact']
and O
the O
scores O
on O
the O
bulimia B-outcome ['Life-Impact']
scale O
decreased O
somewhat O
, O
but O
this O
occurred O
in O
both O
groups O
. O
['Life-Impact']

There O
was O
a O
significant O
correlation O
between O
propofol B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
and O
recovery B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

CPB B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
operation I-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
were O
significantly O
shorter O
and O
the O
platelet B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
during O
CPB O
[ O
= O
( O
platelets O
before O
CPB-platelets O
after O
CPB O
) O
/platelets O
before O
CPB O
] O
was O
significantly O
lower O
in O
normothermic O
patients O
than O
in O
hypothermic O
patients O
. O
['Life-Impact', 'Physiological-Clinical']

Efficiency O
of O
slush O
nitrogen O
vitrification O
of O
human O
oocytes O
vitrified O
with O
or O
without O
cumulus O
cells O
in O
relation O
to O
survival B-outcome ['Mortality']
rate O
and O
meiotic B-outcome ['Physiological-Clinical']
spindle I-outcome ['Physiological-Clinical']
competence I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

Near O
the O
end O
of O
surgery O
and O
every O
6 O
h O
postoperatively O
, O
20 O
ml O
of O
the O
study O
solution O
containing O
normal O
saline O
with O
or O
without O
30 O
mg O
of O
ketorolac O
were O
administered O
simultaneously O
either O
via O
a O
Jackson-Pratt O
drain O
or O
intravenously O
in O
a O
double-blind O
fashion O
. O
[]

Study O
drug O
was O
administered O
as O
soon O
as O
the O
patient O
was O
able O
to O
take O
medication O
by O
mouth O
( O
no O
later O
than O
day O
10 O
) O
until O
the O
98th O
day O
after O
transplantation O
. O
[]

Bipolar O
transurethral O
resection O
of O
the O
prostate O
causes O
less O
bleeding O
than O
the O
monopolar O
technique O
: O
a O
single-centre O
randomized O
trial O
of O
202 O
patients O
. O
[]

With O
the O
exception O
of O
an O
increase O
in O
t O
( O
max O
) O
, O
there O
were O
no O
significant O
pharmacokinetic O
interactions O
between O
cephalexin O
and O
ranitidine O
or O
omeprazole O
. O
[]

No O
difference O
was O
demonstrated O
in O
pain B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
between O
active O
and O
sham O
TENS O
groups O
but O
the O
active O
TENS O
group O
required O
slightly O
less O
analgesia O
. O
['Physiological-Clinical']

Seventeen O
patients O
who O
were O
assigned O
to O
the O
exercise O
group O
performed O
supervised O
moderate-intensity O
exercise O
therapy O
for O
50 O
min O
3 O
times O
per O
week O
for O
5 O
weeks O
. O
[]

Treatment O
with O
risperidone O
for O
eight O
weeks O
( O
dose O
range O
, O
0.5 O
to O
3.5 O
mg O
per O
day O
) O
resulted O
in O
a O
56.9 O
percent O
reduction O
in O
the O
Irritability B-outcome ['Life-Impact']
score O
, O
as O
compared O
with O
a O
14.1 O
percent O
decrease O
in O
the O
placebo O
group O
( O
P O
< O
0.001 O
) O
. O
['Life-Impact']

All O
patients O
received O
peritoneal O
or O
hemodialysis O
treatment O
concurrently O
with O
the O
study O
drug O
. O
[]

Color B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
enamel I-outcome ['Physiological-Clinical']
blocks I-outcome ['Physiological-Clinical']
were O
measured O
using O
a O
Minolta O
colorimeter O
CR300 O
. O
['Physiological-Clinical']

A O
follow-up O
study O
of O
the O
results O
of O
five O
forms O
of O
treatment O
. O
[]

Influence O
of O
SNPs O
in O
nutrient-sensitive O
candidate O
genes O
and O
gene-diet O
interactions O
on O
blood B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
: O
the O
DiOGenes O
study O
. O
['Physiological-Clinical']

We O
compared O
the O
incidence O
of O
ARDS O
due O
to O
pulmonary O
infection O
between O
those O
who O
received O
G-CSF O
and O
those O
who O
did O
not O
. O
[]

METHODS O
In O
this O
6 O
month O
( O
26 O
week O
) O
open-label O
extension O
( O
OLE O
) O
study O
, O
patients O
( O
5-17 O
years O
of O
age O
, O
who O
completed O
the O
previous O
fixed-dose O
, O
6 O
week O
, O
double-blind O
[ O
DB O
] O
phase O
) O
were O
flexibly O
dosed O
with O
risperidone O
based O
on O
body O
weight O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
vitamin I-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
and O
zinc B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
and O
GSH B-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
increased O
over O
time O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

When O
biochemical O
and O
ultrastructural O
data O
are O
considered O
, O
these O
findings O
suggest O
that O
L-carnitine O
improves O
myocardial B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
was O
a O
significant O
difference O
in O
the O
rates O
for O
successful B-outcome ['Life-Impact']
first-time I-outcome ['Life-Impact']
intubation I-outcome ['Life-Impact']
in O
those O
patients O
with O
tube O
orientation O
of O
-90 O
degrees O
( O
with O
the O
bevel O
facing O
posteriorly O
) O
as O
compared O
with O
a O
tube O
orientation O
of O
0 O
degrees O
( O
the O
normal O
orientation O
with O
the O
bevel O
facing O
left O
) O
. O
['Life-Impact']

Subjects O
were O
treated O
openly O
with O
lithium O
in O
Phase O
1 O
( O
n O
= O
45 O
) O
. O
[]

Stress O
incontinence B-outcome ['Physiological-Clinical']
was O
greater O
among O
primiparous O
women O
in O
the O
VB O
group O
( O
VB O
34.5 O
% O
vs. O
CS O
12.8 O
% O
) O
regardless O
of O
prior O
UI O
history O
, O
but O
the O
proportion O
of O
women O
whose O
UI B-outcome ['Physiological-Clinical']
was O
severe O
enough O
to O
wear O
a O
pad O
was O
similar O
in O
primiparous O
women O
( O
VB O
16.0 O
% O
, O
CS O
15.4 O
% O
) O
and O
multiparous O
women O
( O
VB O
23.8 O
% O
, O
CS O
25.0 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Intracapillary B-outcome ['Physiological-Clinical']
glomerular I-outcome ['Physiological-Clinical']
metastases I-outcome ['Physiological-Clinical']
in O
a O
nephrectomy O
specimen O
removed O
for O
ipsilateral O
renal O
cell O
carcinoma O
. O
['Physiological-Clinical']

Oral O
magnesium O
supplementation O
improves O
the O
metabolic B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
of O
metabolically O
obese O
, O
normal-weight O
individuals O
: O
a O
randomized O
double-blind O
placebo-controlled O
trial O
. O
['Physiological-Clinical']

Mean O
postoperative B-outcome ['Resource-use']
days I-outcome ['Resource-use']
of I-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
use O
were O
9.0 O
and O
6.7 O
, O
respectively O
, O
and O
differed O
significantly O
( O
p O
= O
.005 O
) O
. O
['Resource-use']

Amiprilose O
hydrochloride O
for O
rheumatoid O
arthritis O
. O
[]

The O
TP53 B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
has O
been O
analysed O
at O
the O
DNA O
level O
in O
tumours O
from O
45 O
ovarian O
cancer O
patients O
randomized O
to O
treatment O
with O
paclitaxel O
and O
cisplatin O
or O
cyclophosphamide O
and O
cisplatin O
. O
['Physiological-Clinical']

Hormone O
therapy O
consisted O
of O
gestonorone O
caproate O
( O
17 O
alpha-hydroxy-19-norpregn-4-en O
3 O
, O
20 O
dione O
caproate O
) O
administered O
i.m O
. O
[]

Change O
from O
0 O
to O
3 O
months O
of O
plasma O
levels O
of O
25 O
( O
OH O
) O
D O
, O
high-sensitivity B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( O
CRP B-outcome ['Physiological-Clinical']
) O
, O
interleukin B-outcome ['Physiological-Clinical']
( O
IL B-outcome ['Physiological-Clinical']
) O
-6 O
, O
IL-10 B-outcome ['Physiological-Clinical']
, O
and O
soluble O
TNF-? O
receptor O
type O
2 O
( O
sTNF-R2 O
) O
in O
292 O
( O
89 O
% O
) O
participants O
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Differential O
inhibition B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bronchoconstriction I-outcome ['Physiological-Clinical']
by O
the O
calcium O
channel O
blockers O
, O
verapamil O
and O
nifedipine O
. O
['Physiological-Clinical']

Social O
competence O
and O
social O
skills O
training O
and O
intervention O
for O
children O
with O
Autism O
Spectrum O
Disorders O
. O
[]

Diagnosis O
and O
the O
location O
of O
the O
displacement O
were O
determined O
on O
the O
basis O
of O
standardized O
radiographs O
and O
confirmed O
by O
surgical O
documentation O
. O
[]

Healing B-outcome ['Physiological-Clinical']
rate O
in O
the O
group O
treated O
with O
200 O
mg O
of O
ebrotidine O
daily O
was O
not O
significantly O
different O
from O
that O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

The O
dropout O
group O
was O
associated O
with O
mothers O
who O
were O
younger O
and O
less O
educated O
, O
a O
poorer O
rating O
by O
the O
clinicians O
at O
the O
last O
meeting O
, O
parental B-outcome ['Life-Impact']
dissatisfaction I-outcome ['Life-Impact']
with O
the O
treatment O
service B-outcome ['Life-Impact']
and O
perception O
that O
the O
treatment O
was O
less O
organised O
and O
having O
less O
behavioural O
tasks O
. O
['Life-Impact', 'Life-Impact']

Comparison O
of O
cefuroxime O
axetil O
, O
cefaclor O
, O
and O
amoxicillin-clavulanate O
potassium O
suspensions O
in O
acute O
otitis O
media O
in O
infants O
and O
children O
. O
[]

METHODS O
In O
this O
Phase O
1 O
, O
randomized O
, O
doubleblind O
, O
placebo- O
and O
active-controlled O
, O
3-arm O
, O
parallel O
, O
single-center O
study O
, O
healthy O
subjects O
received O
placebo O
; O
moxifloxacin O
400 O
mg O
; O
or O
vilazodone O
( O
sequentially O
escalated O
every O
3 O
days O
) O
10 O
, O
20 O
, O
40 O
, O
60 O
, O
and O
80 O
mg/day O
. O
[]

Recent O
work O
suggests O
, O
however O
, O
that O
the O
use O
of O
lithium O
with O
early O
morning O
sleep O
deprivation O
sustains O
this O
rapid O
antidepressant B-outcome ['Resource-use']
effect O
and O
makes O
it O
clinically O
useful O
. O
['Resource-use']

OBJECTIVES O
Prophylactic O
antibiotics O
are O
helpful O
in O
decreasing O
the O
incidence O
of O
septic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
in O
acute O
pancreatitis O
. O
['Physiological-Clinical']

The O
four-hour B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
acetaminophen I-outcome ['Physiological-Clinical']
level O
was O
significantly O
lower O
for O
phase O
II O
than O
phase O
I O
( O
P O
< O
.05 O
, O
two-tailed O
paired O
t-test O
) O
. O
['Physiological-Clinical']

Safety O
, O
pharmacokinetics B-outcome ['Physiological-Clinical']
and O
pharmocodynamics B-outcome ['Physiological-Clinical']
of O
recombinant O
human O
porphobilinogen O
deaminase O
in O
healthy O
subjects O
and O
asymptomatic O
carriers O
of O
the O
acute O
intermittent O
porphyria O
gene O
who O
have O
increased O
porphyrin O
precursor O
excretion O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Coils O
were O
used O
more O
commonly O
with O
PVA O
embolization O
( O
P O
< O
.0001 O
) O
. O
[]

154 O
+/- O
16 O
and O
151 O
+/- O
24 O
bpm O
, O
rectal O
temperature O
( O
Tre O
) O
was O
39.0 O
+/- O
0.4 O
and O
38.9 O
+/- O
0.2 O
degrees O
C O
, O
heat O
storage O
over O
the O
2 O
h O
of O
exercise O
was O
62 O
+/- O
15 O
and O
70 O
+/- O
15 O
W.m-2 O
, O
and O
sweat O
rate O
was O
832 O
+/- O
185 O
and O
748 O
+/- O
52 O
g.h-1 O
, O
in O
the O
pyridostigmine O
and O
placebo O
treatments O
, O
respectively O
. O
( O
[]

Local O
control O
within O
the O
irradiated O
volume O
was O
better O
in O
the O
group O
treated O
by O
the O
daily O
fractionation O
method O
. O
[]

Incorporation O
of O
14C-palmitate B-outcome ['Physiological-Clinical']
into I-outcome ['Physiological-Clinical']
lung I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
was O
not O
influenced O
by O
dexamethasone O
, O
but O
a O
significantly O
greater O
portion O
of O
the O
label O
appeared O
in O
the O
DPC O
fraction O
with O
treatment O
. O
['Physiological-Clinical']

BACKGROUND/AIMS O
To O
determine O
whether O
a O
Longmire-Interposition O
with O
or O
without O
a O
pouch O
used O
for O
reconstruction O
after O
gastrectomy O
influences O
the O
postoperative O
complication O
rate O
. O
[]

They O
were O
all O
exposed O
to O
environmental O
factors O
such O
as O
routine O
use O
of O
video O
monitors O
or O
air O
conditioning O
. O
[]

Measurements O
were O
made O
of O
oxygen B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
( O
VO2 B-outcome ['Physiological-Clinical']
) O
, O
['Resource-use', 'Physiological-Clinical']

RESULTS O
One-hundred O
and O
sixty-six O
patients O
were O
recruited O
. O
[]

Participants O
in O
the O
patient O
preference O
group O
achieved O
marginally O
better O
outcomes O
than O
those O
randomised O
to O
a O
treatment O
group O
, O
but O
the O
clinical O
significance O
of O
these O
differences O
is O
unclear O
. O
[]

The O
most O
important O
predictor O
of O
non-attendance O
for O
the O
second O
surveillance O
test O
was O
late O
attendance O
for O
the O
first O
test O
( O
OR O
= O
9.65 O
; O
95 O
% O
CI O
, O
6.60-16.62 O
) O
. O
[]

51 O
% O
of O
all O
carcinomas O
detected O
at O
the O
first O
screening O
were O
either O
in O
situ O
or O
invasive O
with O
a O
diameter O
of O
10 O
mm O
or O
less O
. O
[]

Neurophysiological O
double-blind O
trial O
of O
a O
botulinum O
neurotoxin O
type O
a O
free O
of O
complexing O
proteins O
. O
[]

Drinking O
orange O
juice O
and O
brushing O
with O
toothpaste O
A O
. O
[]

Individuals O
received O
in O
a O
double O
blinded O
fashion O
either O
1000 O
mg O
of O
calcium O
or O
1000 O
mg O
of O
calcium O
plus O
800 O
IU O
of O
vitamin O
D O
per O
day O
over O
a O
treatment O
period O
of O
12 O
months O
, O
which O
was O
followed O
by O
a O
treatment-free O
but O
still O
blinded O
observation O
period O
of O
8 O
months O
. O
[]

The O
authors O
experimentally O
activated O
self-face O
representations O
to O
assess O
its O
effects O
on O
the O
recognition O
of O
dynamically B-outcome ['Life-Impact']
emerging I-outcome ['Life-Impact']
facial I-outcome ['Life-Impact']
expressions I-outcome ['Life-Impact']
of O
others O
. O
['Life-Impact']

DESIGN O
We O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Between O
2001 O
and O
2005 O
, O
749 O
women O
aged O
55-75 O
years O
with O
infiltrating O
breast O
carcinoma O
were O
randomly O
assigned O
to O
breast O
conservative O
surgery O
, O
with O
or O
without O
radiotherapy O
( O
RT O
) O
, O
to O
evaluate O
the O
incidence O
of O
in-breast B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IBR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
group O
1 O
the O
wrist O
was O
immobilized O
in O
neutral O
flexion-extension O
. O
[]

We O
report O
the O
preliminary O
3-month O
outcome O
of O
a O
multicenter O
randomized O
trial O
of O
cryotherapy O
for O
treatment O
of O
retinopathy O
of O
prematurity O
( O
ROP O
) O
. O
[]

There O
was O
no O
generalisation O
of O
skills O
to O
TOM O
or O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact']

Women O
in O
both O
enhanced O
intervention O
conditions O
reduced O
their O
sexual B-outcome ['Life-Impact']
and O
drug-taking B-outcome ['Life-Impact']
risks O
more O
than O
women O
in O
the O
standard O
intervention O
. O
['Life-Impact', 'Life-Impact']

Comparison O
of O
menopausal O
symptoms O
during O
the O
first O
year O
of O
adjuvant O
therapy O
with O
either O
exemestane O
or O
tamoxifen O
in O
early O
breast O
cancer O
: O
report O
of O
a O
Tamoxifen O
Exemestane O
Adjuvant O
Multicenter O
trial O
substudy O
. O
[]

No O
ulcer B-outcome ['Physiological-Clinical']
, O
exulceration B-outcome ['Physiological-Clinical']
, O
or O
de-epithelialization B-outcome ['Physiological-Clinical']
was O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
was O
achieved O
in O
79 O
% O
of O
the O
trimethoprim-sulfamethoxazole O
group O
and O
in O
84 O
% O
of O
the O
nitrofurantoin O
group O
, O
for O
a O
difference O
of O
-5 O
% O
( O
95 O
% O
confidence O
interval O
, O
-13 O
% O
to O
4 O
% O
) O
. O
['Physiological-Clinical']

OBJECTIVES O
To O
evaluate O
the O
safety O
and O
efficacy O
of O
0.59-mg O
and O
2.1-mg O
fluocinolone O
acetonide O
( O
FA O
) O
intravitreous O
implants O
in O
noninfectious O
posterior O
uveitis O
. O
[]

Evidence O
supporting O
aspirin O
and O
resistant O
starch O
( O
RS O
) O
for O
colorectal O
cancer O
prevention O
comes O
from O
epidemiologic O
and O
laboratory O
studies O
( O
aspirin O
and O
RS O
) O
and O
randomized O
controlled O
clinical O
trials O
( O
aspirin O
) O
. O
[]

Subjects O
were O
randomised O
to O
receive O
one O
dose O
of O
either O
MenC O
( O
n=92 O
) O
or O
MenPS O
( O
n=90 O
) O
. O
[]

Promoting O
imitation O
in O
young O
children O
with O
autism O
: O
a O
comparison O
of O
reciprocal O
imitation O
training O
and O
video O
modeling O
. O
[]

AIM O
To O
evaluate O
the O
effect O
of O
the O
use O
of O
leukocyte O
reduction O
filters O
on O
the O
activity O
of O
polymorphonuclear O
neutrophils O
( O
PMN O
) O
in O
patients O
undergoing O
surgical O
myocardial O
revascularisation O
. O
[]

RESULTS O
Patients O
with O
cirrhosis O
( O
n O
= O
427 O
) O
reported O
lower O
general B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
and O
more O
fatigue B-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
than O
patients O
with O
fibrosis O
( O
n O
= O
622 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Substituted O
benzimidazole O
inhibitors O
of O
the O
gastric O
H+/K+ATPase O
may O
interact O
with O
the O
cytochrome O
P450 O
enzyme O
system O
and O
alter O
the O
pharmacokinetics O
of O
coadministered O
drugs O
. O
[]

RESULTS O
Oral O
NAA O
resulted O
in O
a O
profound B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
alkalosis I-outcome ['Physiological-Clinical']
marked O
by O
decreased O
plasma B-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
H+ I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
and O
increased O
plasma B-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
TCO2 I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
HCO3- I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
compared O
to O
Control O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Thirty-five O
patients O
completed O
the O
study O
, O
18 O
received O
regular O
opioids O
plus O
ketamine O
, O
while O
17 O
received O
regular O
opioids O
plus O
placebo O
. O
[]

Systemic O
exposure O
of O
these O
drugs O
was O
similar O
to O
that O
reported O
in O
other O
HIV-infected O
children O
and O
adults O
. O
[]

However O
, O
in O
a O
multi-variate O
analysis O
that O
took O
into O
account B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
extent I-outcome ['Physiological-Clinical']
, O
maintenance B-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
, O
Karnofsky O
performance B-outcome ['Physiological-Clinical']
status O
( O
PS B-outcome ['Physiological-Clinical']
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
proportion O
of O
catheter B-outcome ['Physiological-Clinical']
failures I-outcome ['Physiological-Clinical']
( O
blocked B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
non-reading I-outcome ['Physiological-Clinical']
) O
is O
14 O
% O
in O
laser-cut O
compared O
with O
30 O
% O
in O
standard O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Regardless O
of O
training O
condition O
, O
pretreatment O
verbal O
imitation O
ability O
positively O
predicted O
the O
size O
of O
child-initiated B-outcome ['Life-Impact']
spoken I-outcome ['Life-Impact']
vocabulary I-outcome ['Life-Impact']
observed O
during O
training O
. O
['Life-Impact']

The O
severity O
of O
mucosal B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
was O
quantitated O
by O
endoscopy O
and O
stratified O
by O
a O
scale O
from O
0 O
( O
normal O
) O
to O
4 O
( O
ulcer O
) O
. O
['Physiological-Clinical']

RESULTS O
Overall O
, O
270 O
patients O
were O
enrolled O
, O
but O
13 O
patients O
early O
interrupted O
treatment O
due O
to O
side O
effects O
. O
[]

Aspirin B-outcome ['Physiological-Clinical']
inhibited I-outcome ['Physiological-Clinical']
bradykinin I-outcome ['Physiological-Clinical']
stimulated I-outcome ['Physiological-Clinical']
PG I-outcome ['Physiological-Clinical']
and O
platelet O
TX O
biosynthesis O
0.5 O
h O
after O
the O
dose O
. O
['Physiological-Clinical']

The O
Kaplan-Meier O
estimate O
of O
5-year O
all-cause O
mortality B-outcome ['Mortality']
was O
6.0 O
% O
( O
95 O
% O
confidence O
interval O
, O
2.7 O
% O
-9.3 O
% O
) O
and O
8-year O
all-cause O
mortality B-outcome ['Mortality']
was O
14.9 O
% O
( O
95 O
% O
confidence O
interval O
, O
9.6 O
% O
-20.2 O
% O
) O
. O
['Mortality', 'Mortality']

Most O
patients O
had O
significant O
anxiety B-outcome ['Life-Impact']
and O
depressive B-outcome ['Life-Impact']
disturbance I-outcome ['Life-Impact']
with O
42 O
% O
having O
a O
personality O
disorder O
. O
['Life-Impact', 'Life-Impact']

This O
study O
was O
designed O
to O
determine O
the O
bioavailability O
of O
GCV O
and O
to O
test O
a O
dosing O
algorithm O
in O
transplant O
and O
dialysis O
patients O
with O
different O
levels O
of O
renal O
function O
. O
[]

We O
evaluated O
the O
potential O
advantages O
of O
the O
use O
of O
left O
internal O
thoracic O
artery-radial O
artery O
composite O
grafts O
compared O
with O
conventional O
coronary O
artery O
bypass O
grafts O
in O
elderly O
patients O
. O
[]

Aortic O
cross-clamping O
for O
reconstructive O
aortic O
surgery O
is O
associated O
with O
impairment O
of O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
effectiveness O
of O
yoga O
will O
be O
assessed O
using O
analysis O
of O
covariance O
( O
using O
general O
estimating O
equations O
- O
GEE O
) O
within O
an O
intention-to-treat O
context O
. O
[]

During O
the O
first O
and O
second O
months O
of O
the O
washout O
, O
slight O
differences O
were O
observed O
in O
changes O
of O
various B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
among I-outcome ['Physiological-Clinical']
different I-outcome ['Physiological-Clinical']
phospholipid I-outcome ['Physiological-Clinical']
fractions I-outcome ['Physiological-Clinical']
, O
but O
after O
3 O
mo O
of O
washout O
, O
only O
minor O
alterations O
were O
still O
detectable O
with O
respect O
to O
pretreatment O
values O
. O
['Physiological-Clinical']

We O
will O
evaluate O
the O
effect O
of O
providing O
this O
label O
to O
randomly O
sampled O
patients O
who O
receive O
their O
care O
from O
free O
clinics O
, O
mobile O
vans O
and O
federally O
qualified O
health O
centers O
( O
FQHCs O
) O
in O
Northern O
Virginia O
. O
[]

In O
the O
DNAemia O
arm O
, O
antiviral O
therapy O
was O
initiated O
on O
reaching O
a O
DNAemia O
cut-off O
of O
10 O
000 O
DNA O
copies/mL O
of O
whole O
blood O
, O
whereas O
in O
the O
antigenemia O
arm O
, O
therapy O
was O
started O
in O
the O
presence O
of O
a O
positive O
antigenemia O
. O
[]

Three-year O
overall B-outcome ['Mortality']
actuarial I-outcome ['Mortality']
survivals I-outcome ['Mortality']
in O
the O
two O
treatment O
arms O
, O
however O
, O
were O
68 O
% O
and O
58 O
% O
, O
respectively O
( O
P O
= O
0.38 O
) O
. O
['Mortality']

The O
volumes O
of O
distribution O
at O
steady O
state O
of O
imipenem O
and O
meropenem O
were O
15.3 O
+/- O
3.3 O
and O
18.6 O
+/- O
3.0 O
liters/70 O
kg O
, O
respectively O
, O
and O
the O
mean O
renal O
clearances O
per O
1.73 O
m2 O
were O
85.6 O
+/- O
17.6 O
and O
144.6 O
+/- O
26.0 O
ml/min O
, O
respectively O
. O
[]

The O
measurements O
were O
comparative O
study O
of O
the O
number O
and O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
using O
3 O
various O
dosages O
of O
intravenous O
gammaglobulins O
, O
each O
given O
monthly O
for O
M O
least O
6 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
levels O
of O
RPLM O
were O
0 O
, O
5 O
, O
10 O
, O
and O
15 O
g O
per O
steer O
daily O
. O
[]

The O
objectives O
of O
this O
study O
were O
to O
update O
the O
analyses O
of O
each O
individual O
trial O
and O
to O
analyze O
prognostic O
factors O
and O
treatment O
effects O
based O
on O
pooled O
data O
. O
[]

The O
median O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
completion I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
was O
6 O
min O
and O
55 O
s O
( O
range O
3 O
min O
to O
14 O
min O
and O
3 O
s O
) O
and O
15 O
min O
( O
6-15 O
min O
) O
, O
respectively O
. O
['Life-Impact']

A O
multivariate O
( O
classification O
tree O
) O
analysis O
found O
that O
only O
pertactin O
and O
PT O
were O
significant O
in O
protection O
. O
[]

A O
positive O
correlation O
was O
found O
for O
all O
methods O
in O
the O
controls O
( O
r O
= O
0.83-0.94 O
) O
and O
RA O
patients O
( O
r O
= O
0.51-0.69 O
) O
. O
[]

The O
difference O
between O
the O
two O
groups O
was O
not O
statistically O
significant O
, O
confirming O
the O
hypothesis O
of O
the O
study O
that O
oxaprozin O
is O
as O
effective O
as O
diclofenac O
. O
[]

RESULTS O
From O
pre- O
to O
post-treatment O
, O
all O
children O
had O
less O
parent O
reported O
negativity/lability B-outcome ['Life-Impact']
, O
better O
parent O
reported O
emotion B-outcome ['Life-Impact']
regulation I-outcome ['Life-Impact']
, O
and O
shorter O
outbursts B-outcome ['Life-Impact']
, O
and O
also O
generated B-outcome ['Life-Impact']
more I-outcome ['Life-Impact']
coping I-outcome ['Life-Impact']
strategies I-outcome ['Life-Impact']
in O
response O
to O
vignettes O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

OBJECTIVE O
A O
consumer-oriented O
efficacy O
assessment O
in O
clinical O
trials O
should O
measure O
changes O
in O
chief O
complaint O
and O
consumer O
request O
( O
symptoms O
of O
most O
concern O
to O
patient/caregiver O
) O
, O
which O
may O
be O
diluted O
in O
change O
scores O
of O
multisymptom O
scales O
. O
[]

Patients O
' O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
evaluated O
using O
a O
visual O
analogue O
scale O
and O
a O
verbal B-outcome ['Life-Impact']
rating I-outcome ['Life-Impact']
score I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

No O
improvement O
in O
laboratory B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
seen O
, O
however O
. O
['Physiological-Clinical']

The O
bougie-guided O
technique O
involved O
priming O
the O
drain O
tube O
with O
the O
bougie O
, O
placing O
the O
bougie O
in O
the O
oesophagus O
using O
laryngoscope O
guidance O
, O
digital O
insertion O
along O
the O
palato-pharyngeal O
curve O
, O
and O
bougie O
removal O
. O
[]

SPRINT O
training O
protocol O
used O
line O
30-m O
sprints O
( O
2-4 O
sets O
of O
4 O
x O
30 O
m O
with O
180 O
and O
90 O
seconds O
of O
recovery O
, O
respectively O
) O
. O
[]

Positive O
changes O
in O
spatial B-outcome ['Life-Impact']
orientation I-outcome ['Life-Impact']
were O
evident O
when O
the O
children O
wore O
ambient O
prism O
lenses O
and O
included O
changes O
in O
posture B-outcome ['Life-Impact']
from O
slanted O
to O
erect O
. O
['Life-Impact', 'Life-Impact']

DESIGN O
Prospective O
, O
randomized O
clinical O
trial O
. O
[]

OBJECTIVE O
To O
examine O
the O
adhesion B-outcome ['Physiological-Clinical']
prevention I-outcome ['Physiological-Clinical']
effects O
of O
2 O
types O
of O
fibrin O
sealant O
after O
laparoscopic O
myomectomy O
( O
LM O
) O
. O
['Physiological-Clinical']

Fourty-eight O
S. O
muris-positive O
rats O
were O
divided O
into O
six O
treated O
and O
two O
control O
groups O
. O
[]

The O
number O
of O
intubations B-outcome ['Resource-use']
required O
to O
achieve O
an O
appropriately O
sized O
tube O
, O
the O
need O
to O
use O
more O
than O
21.min-1 O
fresh B-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
the O
concentration O
of O
nitrous B-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
operating I-outcome ['Physiological-Clinical']
room I-outcome ['Physiological-Clinical']
, O
and O
the O
incidence O
of O
croup B-outcome ['Physiological-Clinical']
were O
compared O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Osteoporosis O
was O
prevalent O
in O
low O
muscle O
mass O
participants O
and O
related O
to O
gait O
and O
balance O
deficits O
. O
[]

DESIGN O
Randomized O
repeated O
measures O
experimental O
design O
. O
[]

Vascular O
function O
was O
assessed O
by O
brachial O
dilation O
as O
well O
as O
by O
plasma O
samples O
analysed O
for O
hs-CRP O
( O
high-sensitivity O
C-reactive O
protein O
) O
, O
IL-6 O
( O
interleukin-6 O
) O
, O
IL-8 O
, O
ICAM-1 O
( O
intercellular O
adhesion O
molecule-1 O
) O
, O
vWF O
( O
von O
Willebrand O
factor O
) O
, O
MCP-1 O
( O
monocyte O
chemoattractant O
protein-1 O
) O
, O
PAI-1 O
( O
plasminogen O
activator O
inhibitor-1 O
) O
and O
fibrinogen O
. O
[]

After O
caffeine O
ingestion O
QRS B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
prolonged O
in O
9 O
of O
11 O
subjects O
at O
90 O
minutes O
( O
mean O
+/- O
SEM O
= O
0.8+/-0.3 O
ms O
, O
P O
< O
.02 O
) O
and O
in O
8 O
of O
9 O
after O
3 O
hours O
( O
1.1+/-0.2 O
ms O
, O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

Multivariate O
logistic O
analysis O
showed O
that O
insulin O
treatment O
was O
the O
only O
independent O
predictor O
of O
MACE B-outcome ['Physiological-Clinical']
[ O
odds O
ratio O
( O
OR O
) O
8.60 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
3.25-22.76 O
, O
P O
< O
0.001 O
] O
and O
target B-outcome ['Physiological-Clinical']
vessel B-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
( O
TVR B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
program O
applied O
social O
cognitive O
theory O
( O
SCT O
) O
to O
promote O
self-management O
techniques O
, O
increased O
the O
health B-outcome ['Life-Impact']
promoting I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
among O
hypertensive O
people O
. O
['Life-Impact']

The O
diode O
laser O
treatment O
was O
better O
tolerated B-outcome ['Life-Impact']
than O
cryotherapy O
, O
and O
the O
treatment O
apparatus O
was O
more O
easily O
transported O
. O
['Life-Impact']

FUNDING O
Agence O
nationale O
de O
recherches O
sur O
le O
sida O
et O
les O
h?patites O
virales O
, O
Department O
for O
International O
Development O
, O
European O
and O
Developing O
Countries O
Clinical O
Trials O
Partnership O
, O
Thrasher O
Research O
Fund O
, O
Belgian O
Directorate O
General O
for O
International O
Cooperation O
, O
Centers O
for O
Disease O
Control O
and O
Prevention O
, O
Eunice O
Kennedy O
Shriver O
National O
Institute O
of O
Child O
Health O
and O
Human O
Development O
, O
and O
UNDP/UNFPA/World O
Bank/WHO O
Special O
Programme O
of O
Research O
, O
Development O
and O
Research O
Training O
in O
Human O
Reproduction O
. O
[]

Plasma O
levels O
were O
measured O
by O
radioimmunoassay O
before O
and O
after O
jejunoileal O
bypass O
randomized O
to O
different O
jejunoileal O
ratios O
. O
[]

The O
percentage O
of O
patients O
with O
adverse B-outcome ['Adverse-effects']
drug I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
was O
lowest O
among O
those O
receiving O
sotalol O
. O
['Adverse-effects']

The O
overall O
response O
rate O
( O
RR B-outcome ['Physiological-Clinical']
) O
based O
on O
the O
evaluable O
patients O
was O
48/74 O
( O
65 O
% O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
54-75 O
% O
) O
; O
The O
RR O
based O
on O
an O
intent-to-treat O
analysis O
was O
57 O
% O
, O
95 O
% O
CI O
47-67 O
% O
; O
Median O
survival B-outcome ['Mortality']
was O
13 O
months O
; O
There O
were O
50 O
episodes O
of O
granulocytopenia B-outcome ['Physiological-Clinical']
grade O
IV B-outcome ['Physiological-Clinical']
and O
15 O
of O
febrile B-outcome ['Physiological-Clinical']
neutropenia B-outcome ['Physiological-Clinical']
per O
316 O
cycles O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

GOAL O
The O
aim O
of O
this O
analysis O
was O
to O
determine O
whether O
patients O
' O
demographic O
variables O
affect O
the O
efficacy O
of O
imiquimod O
5 O
% O
cream O
versus O
vehicle O
cream O
for O
the O
treatment O
of O
external O
genital O
and O
perianal O
warts O
. O
[]

There O
was O
, O
however O
, O
no O
difference O
in O
the O
total O
time B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
catheter I-outcome ['Life-Impact']
placement I-outcome ['Life-Impact']
, O
because O
puncture O
was O
performed O
faster O
when O
aided O
by O
sonography O
. O
['Life-Impact']

Children O
in O
the O
CBT O
condition O
evidenced O
significantly O
larger O
reductions O
in O
anxiety B-outcome ['Life-Impact']
than O
those O
in O
the O
waitlist O
. O
['Life-Impact']

Corticosteroids O
plus O
pulse O
cyclophosphamide O
and O
plasma O
exchanges O
versus O
corticosteroids O
plus O
pulse O
cyclophosphamide O
alone O
in O
the O
treatment O
of O
polyarteritis O
nodosa O
and O
Churg-Strauss O
syndrome O
patients O
with O
factors O
predicting O
poor O
prognosis O
. O
[]

By O
intention-to-treat O
analysis O
, O
no O
significant O
differences O
were O
observed O
in O
abstinence B-outcome ['Life-Impact']
rates O
at O
12 O
and O
24 O
weeks O
between O
SJW O
dose O
groups O
and O
placebo O
. O
['Life-Impact']

Both O
groups O
were O
allowed O
supplementary O
morphine O
boluses O
as O
requested O
. O
[]

Effect O
of O
intensive O
therapy O
on O
the O
microvascular B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
of O
type O
1 O
diabetes O
mellitus O
. O
['Physiological-Clinical']

This O
prospective O
, O
6-week O
, O
multicenter O
, O
double-blind O
study O
examined O
the O
benefits O
of O
initiating O
treatment O
with O
combination O
valsartan/hydrochlorothiazide O
( O
HCTZ O
) O
compared O
with O
initial O
valsartan O
monotherapy O
for O
648 O
patients O
with O
stage-1 O
or O
stage-2 O
hypertension O
( O
age=52.6+/-10 O
years O
; O
54 O
% O
male O
; O
baseline O
blood O
pressure O
( O
BP O
) O
=161/98 O
mm O
Hg O
, O
32 O
% O
stage O
1 O
) O
. O
[]

Age O
, O
FIGO O
stage O
, O
histologic O
grade O
, O
and O
residual O
disease O
all O
exerted O
a O
significant O
effect O
on O
survival O
time O
. O
[]

In O
contrast O
, O
on O
both O
days O
1 O
and O
4 O
, O
levocetirizine O
did O
not O
significantly O
impair O
laboratory B-outcome ['Physiological-Clinical']
test O
performance O
. O
['Physiological-Clinical']

Reduction O
in O
GI O
scores O
of O
the O
intervention O
group O
at O
6 O
months O
was O
20.8 O
% O
which O
is O
considered O
to O
be O
clinically O
significant O
. O
[]

No O
relevant O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
with O
any O
of O
the O
induction O
regimens O
. O
['Adverse-effects']

Sera O
were O
collected O
at O
six O
weeks O
of O
age O
for O
the O
Hib O
groups O
and O
one O
month O
after O
the O
third O
dose O
for O
all O
subjects O
. O
[]

The O
SAS O
accelerated O
and O
strengthened O
postural B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
with O
clear O
functional O
benefits O
( O
better O
balance O
control O
) O
, O
but O
this O
was O
only O
true O
for O
responses O
that O
protected O
against O
falling O
backwards O
( O
i.e O
. O
['Physiological-Clinical']

At O
6 O
and O
18 O
weeks O
, O
reduced O
pain B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
were O
greater O
for O
the O
RecImMir O
group O
than O
for O
the O
other O
groups O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Both O
drugs O
were O
given O
orally O
in O
a O
single O
daily O
dose O
of O
2g O
for O
a O
minimum O
of O
3 O
days O
, O
with O
treatment O
extended O
if O
considered O
clinically O
advisable O
. O
[]

One O
year O
after O
withdrawal O
of O
the O
drug O
, O
all O
variables O
were O
similar O
in O
the O
two O
groups O
, O
except O
for O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
which O
was O
worse O
in O
the O
cyclosporin O
A O
treated O
group O
. O
['Physiological-Clinical']

Using O
the O
virtual O
reality-cognitive O
rehabilitation O
approach O
to O
improve O
contextual B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
in O
children O
with O
autism O
. O
['Life-Impact']

RESULTS O
Patients O
in O
the O
highest O
quartile O
of O
hsCRP O
compared O
to O
those O
in O
the O
lowest O
quartile O
were O
at O
increased O
risk O
of O
death B-outcome ['Mortality']
at O
30 O
days O
[ O
adjusted O
hazard O
ratio O
( O
adjHR O
) O
4.6 O
, O
P O
< O
0.001 O
] O
and O
10 O
months O
( O
adjHR O
3.9 O
, O
P O
< O
0.001 O
) O
. O
['Mortality']

The O
6-year O
Malm? O
feasibility O
study O
. O
[]

However O
, O
there O
was O
an O
inverse O
relation O
between O
time-varying O
abstinence O
( O
vs. O
smoking O
) O
and O
concurrent O
level O
of O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
indicating O
that O
transitions O
from O
smoking O
to O
abstinence O
within O
individuals O
were O
associated O
with O
reductions O
in O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
effect O
of O
pioglitazone O
therapy O
on O
EPCs O
was O
examined O
. O
[]

Effect O
compartment O
concentrations O
corresponding O
to O
50 O
% O
inhibition O
of O
T1 O
( O
EC50 O
) O
were O
1.41 O
+/- O
0.45 O
and O
2.32 O
+/- O
1.00 O
microg O
x O
ml O
( O
-1 O
) O
( O
P O
< O
0.02 O
) O
, O
and O
rate O
constants O
for O
equilibration O
between O
plasma O
and O
effect O
compartment O
( O
k O
( O
e0 O
) O
) O
values O
were O
0.10 O
+/- O
0.04 O
and O
0.24 O
+/- O
0.14 O
min O
( O
-1 O
) O
( O
P O
< O
0.009 O
) O
in O
sevoflurane O
and O
fentanyl O
groups O
, O
respectively O
. O
[]

CONCLUSIONS O
Lesser O
concentrations O
of O
ropivacaine O
and O
fentanyl O
provide O
comparable O
analgesia O
with O
less O
motor B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
despite O
the O
use O
of O
similar O
amounts O
of O
ropivacaine O
and O
fentanyl O
. O
['Physiological-Clinical']

Besides O
the O
established O
cytokines O
, O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
is O
demonstrated O
as O
an O
important O
factor O
in O
enhancing O
vascular O
leakage O
in O
sepsis O
. O
[]

Calcitriol O
for O
bone O
disease O
in O
patients O
with O
cirrhosis O
of O
the O
liver O
. O
[]

Continuous O
epidural O
block O
was O
instituted O
prior O
to O
the O
induction O
of O
anesthesia O
and O
maintained O
throughout O
the O
surgery O
in O
8 O
of O
16 O
patients O
( O
Group O
1 O
) O
while O
it O
was O
instituted O
upon O
the O
peritoneal O
closure O
and O
maintained O
thereafter O
in O
the O
remaining O
8 O
patients O
( O
Group O
2 O
) O
. O
[]

The O
frequencies O
of O
ST B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
and O
chest B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
were O
significantly O
greater O
in O
women O
than O
men O
, O
although O
their O
etiologies O
are O
unknown O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
Groups O
IT0.1 O
, O
C O
and O
IV O
, O
the O
NK B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
showed O
no O
significant O
changes O
. O
['Physiological-Clinical']

Coprimary O
endpoints O
were O
MRI-assessed O
indices O
( O
total O
vessel B-outcome ['Physiological-Clinical']
area O
, O
wall B-outcome ['Physiological-Clinical']
area O
, O
wall B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
, O
and O
normalised O
wall O
index O
[ O
average O
carotid O
] O
) O
after O
24 O
months O
and O
( O
18 O
) O
F-fluorodeoxyglucose O
( O
( O
18 O
) O
F-FDG O
) O
PET/CT O
assessment O
of O
arterial O
inflammation O
within O
an O
index O
vessel O
( O
right O
carotid O
, O
left O
carotid O
, O
or O
ascending O
thoracic O
aorta O
) O
after O
6 O
months O
, O
with O
no-harm O
boundaries O
established O
before O
unblinding O
of O
the O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Clonidine O
improves O
the O
quality O
of O
spinal B-outcome ['Physiological-Clinical']
bupivacaine I-outcome ['Physiological-Clinical']
and O
ropivacaine B-outcome ['Resource-use']
, O
but O
in O
traditional O
doses O
( O
1-2 O
microg/kg O
) O
it O
produces O
systemic O
side O
effects O
. O
['Physiological-Clinical', 'Resource-use']

CONCLUSION O
In O
this O
first O
study O
using O
Bioglue O
in O
patients O
undergoing O
circumferential O
stapled O
hemorrhoidopexy O
we O
have O
shown O
that O
application O
of O
the O
glue O
is O
effective O
in O
reducing O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
. O
['Adverse-effects']

There O
was O
a O
higher O
incidence O
of O
hematologic B-outcome ['Physiological-Clinical']
toxicities I-outcome ['Physiological-Clinical']
in O
the O
VACA O
arm O
. O
['Physiological-Clinical']

The O
participants O
were O
followed O
for O
a O
median O
of O
17.4 O
months O
. O
[]

The O
third O
intervention O
consisted O
of O
the O
brochure O
together O
with O
the O
conversation O
with O
a O
trained O
technologist O
. O
[]

Desogestrel O
and O
gestodene O
in O
oral O
contraceptives O
: O
12 O
months O
' O
assessment O
of O
carbohydrate B-outcome ['Life-Impact']
and O
lipoprotein B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
a O
community O
mobilization O
and O
youth O
development O
strategy O
to O
prevent O
drug B-outcome ['Life-Impact']
abuse I-outcome ['Life-Impact']
, O
violence B-outcome ['Life-Impact']
, O
and O
risky B-outcome ['Life-Impact']
sexual I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
Visual O
Analogue O
Scale O
assessed O
pain B-outcome ['Physiological-Clinical']
, O
depression B-outcome ['Life-Impact']
, O
stress O
and O
mood B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Randomised O
clinical O
trial O
: O
efficacy O
of O
a O
new O
synbiotic O
formulation O
containing O
Lactobacillus O
paracasei O
B21060 O
plus O
arabinogalactan O
and O
xilooligosaccharides O
in O
children O
with O
acute O
diarrhoea O
. O
[]

Hitting O
the O
target O
: O
relatively O
easy O
, O
yet O
absolutely O
difficult O
. O
[]

Angioedema B-outcome ['Physiological-Clinical']
was O
improved O
to O
a O
clinically O
significant O
extent O
with O
mizolastine O
, O
and O
loratadine O
compared O
with O
placebo O
in O
those O
patients O
who O
had O
this O
symptom O
before O
treatment O
. O
['Physiological-Clinical']

A O
battery O
of O
cognitive B-outcome ['Life-Impact']
tests O
were O
performed O
during O
the O
placebo O
phase O
and O
after O
16 O
weeks O
of O
active O
therapy O
. O
['Life-Impact']

MATERIALS O
AND O
METHODS O
Patients O
undergoing O
MMS O
were O
prospectively O
randomized O
to O
have O
their O
tissue O
margins O
oriented O
using O
light O
scoring O
using O
a O
scalpel O
versus O
marking O
them O
using O
a O
gentian O
violet O
marker O
. O
[]

We O
conducted O
an O
international O
, O
multicenter O
, O
randomized O
, O
placebo-controlled O
trial O
of O
aspirin O
( O
600 O
mg/d O
) O
and/or O
RS O
( O
30 O
g/d O
) O
for O
from O
1 O
to O
12 O
years O
to O
prevent O
disease O
progression O
in O
FAP O
patients O
from O
10 O
to O
21 O
years O
of O
age O
. O
[]

Efficacy O
of O
a O
barrier O
cream O
and O
its O
vehicle O
as O
protective O
measures O
against O
occupational B-outcome ['Physiological-Clinical']
irritant I-outcome ['Physiological-Clinical']
contact I-outcome ['Physiological-Clinical']
dermatitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
Previous O
studies O
have O
suggested O
that O
post-irradiation O
GH O
insufficiency O
results O
from O
a O
loss O
of O
GHRH O
secretion O
, O
since O
many O
patients O
were O
able O
to O
release O
GH O
following O
exogenous O
GHRH O
stimulation O
. O
[]

Newly O
formed O
lymph O
node O
metastases O
were O
surgically O
treated O
in O
Slovakia O
, O
too O
. O
[]

DESIGN O
, O
SETTING O
, O
PARTICIPANTS O
, O
& O
MEASUREMENTS O
Stable O
patients O
who O
had O
anuria O
and O
were O
on O
low-flux O
polysulfone O
membrane O
were O
randomly O
allocated O
either O
to O
HD O
with O
high-flux O
polyamide O
membrane O
( O
group O
A O
; O
22 O
patients O
) O
or O
to O
HD O
with O
low-flux O
polyamide O
membrane O
( O
group O
B O
; O
24 O
patients O
) O
for O
24 O
weeks O
, O
then O
they O
were O
started O
on O
24 O
weeks O
of O
the O
alternative O
HD O
treatment O
. O
[]

Neither O
10 O
weeks O
of O
pravastatin O
nor O
mild O
endurance O
exercise O
training O
improved O
[]

The O
outcome O
measures O
were O
the O
changes O
in O
intensity O
of O
LBP B-outcome ['Physiological-Clinical']
, O
disability B-outcome ['Life-Impact']
, O
self-evaluated B-outcome ['Physiological-Clinical']
future I-outcome ['Physiological-Clinical']
work I-outcome ['Physiological-Clinical']
ability I-outcome ['Physiological-Clinical']
, O
and O
neuromuscular B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
investigate O
whether O
weight-bearing O
( O
WB O
) O
exercise O
enhances O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
to O
a O
greater O
extent O
than O
nonweight-bearing O
( O
NWB O
) O
exercise O
in O
participants O
with O
knee O
osteoarthritis O
. O
['Life-Impact']

In O
40 O
patients O
( O
56 O
% O
) O
, O
the O
perioperative O
myocardial O
infarction O
was O
the O
first O
manifestation O
of O
coronary O
artery O
disease O
. O
[]

morphine O
in O
2 O
mL O
saline O
, O
and O
Groups O
1 O
and O
3 O
, O
2 O
mL O
saline O
intravenously O
. O
[]

Why O
distinctive O
information O
reduces O
false B-outcome ['Life-Impact']
memories I-outcome ['Life-Impact']
: O
evidence O
for O
both O
impoverished O
relational-encoding O
and O
distinctiveness O
heuristic O
accounts O
. O
['Life-Impact']

However O
, O
there O
was O
no O
difference O
in O
the O
improvements O
made O
by O
children O
in O
the O
intervention O
and O
control O
conditions O
on O
facial B-outcome ['Life-Impact']
expression I-outcome ['Life-Impact']
and O
body-posture B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
measures I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

It O
is O
unknown O
whether O
increasing O
knowledge O
about O
breast O
cancer O
genetic O
testing O
alters O
interest O
in O
testing O
. O
[]

RM-MANOVA O
was O
conducted O
to O
determine O
whether O
bone B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
from O
exercise O
differed O
between O
hip O
sites O
. O
['Physiological-Clinical']

In O
addition O
, O
the O
texture O
, O
depth O
, O
and O
color O
of O
the O
root-surface O
lesions O
were O
monitored O
. O
[]

Vascular B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
acetylcholine O
improved O
in O
patients O
on O
IIT O
( O
p=0.017 O
) O
, O
but O
not O
in O
patients O
receiving O
CIT O
. O
['Physiological-Clinical']

Oral O
6-mercaptopurine O
versus O
oral O
6-thioguanine O
and O
veno-occlusive O
disease O
in O
children O
with O
standard-risk O
acute O
lymphoblastic O
leukemia O
: O
report O
of O
the O
Children O
's O
Oncology O
Group O
CCG-1952 O
clinical O
trial O
. O
[]

No O
changes O
in O
[]

As O
second O
significant O
( O
p O
= O
0.012-0.016 O
) O
factor O
, O
cardiac O
history O
was O
included O
in O
all O
three O
rectal O
bleeding O
fits O
, O
whereas O
including O
diabetes O
was O
significant O
( O
p O
= O
0.039-0.048 O
) O
in O
fecal O
incontinence O
modeling O
but O
only O
in O
the O
LKB O
and O
logistic O
models O
. O
[]

The O
authors O
conclude O
that O
peritonsillar O
infiltration O
with O
bupivacaine O
is O
only O
moderately O
useful O
as O
analgesia O
for O
children O
having O
tonsillectomy O
. O
[]

A O
pilot O
study O
of O
extended O
duration O
peginterferon O
alfa-2a O
for O
patients O
with O
hepatitis O
B O
e O
antigen-negative O
chronic O
hepatitis O
B O
. O
[]

METHODS O
AND O
RESULTS O
We O
investigated O
the O
effects O
of O
a O
disease O
management O
program O
with O
repetitive O
education O
and O
telephone O
monitoring O
on O
primary O
( O
combined O
death B-outcome ['Mortality']
or O
unplanned B-outcome ['Resource-use']
first I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
and O
quality-of-life B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
) O
and O
secondary O
end O
points O
( O
hospitalization B-outcome ['Resource-use']
, O
death B-outcome ['Mortality']
, O
and O
adherence B-outcome ['Life-Impact']
) O
. O
['Mortality', 'Resource-use', 'Life-Impact', 'Resource-use', 'Mortality', 'Life-Impact']

Plasma O
concentrations O
of O
6-oxo-PGF1 O
alpha O
and O
13,14-dihydro-15-oxo-PGF2 O
alpha O
were O
measured O
in O
samples O
obtained O
during O
repeated O
10 O
min O
intravenous O
infusions O
of O
bradykinin O
before O
and O
up O
to O
6 O
h O
after O
the O
dose O
of O
aspirin O
. O
[]

METHODS O
Twenty-two O
patients O
with O
a O
history O
of O
recently O
diagnosed O
RA O
of O
less O
than O
2 O
years O
were O
assessed O
on O
a O
variety O
of O
clinical B-outcome ['Physiological-Clinical']
outcome O
and O
process O
measures O
on O
six O
assessment O
occasions O
over O
a O
21-month O
period O
. O
['Physiological-Clinical']

METHODS O
For O
evaluation O
of O
GLN O
in O
BMT O
, O
66 O
patients O
with O
43 O
hematologic O
and O
23 O
solid O
malignancies O
( O
21 O
breast O
carcinomas O
) O
, O
were O
randomized O
, O
double-blinded O
, O
to O
either O
oral O
GLN O
( O
n O
= O
35 O
) O
or O
glycine-control O
( O
GLY O
) O
( O
n O
= O
31 O
) O
, O
10 O
g O
three O
times O
daily O
. O
[]

CONCLUSION O
Stepping O
down O
to O
single O
agent O
maintenance O
therapy O
following O
6 O
months O
of O
combination O
treatment O
with O
CSA O
and O
MTX O
in O
early O
RA O
was O
only O
successful O
with O
MTX O
. O
[]

2 O
) O
Does O
virtual O
reality O
have O
a O
lasting O
effect O
? O
[]

Enrollment O
was O
stopped O
when O
an O
interim O
analysis O
concluded O
that O
the O
trial O
would O
be O
unlikely O
to O
show O
superiority O
for O
the O
primary O
end O
point O
. O
[]

No O
impact O
of O
the O
training O
programme O
was O
observed O
. O
[]

An O
assessment O
of O
beta-adrenoceptor O
blockade O
in O
man O
by O
prizidilol O
hydrochloride O
. O
[]

The O
last O
two O
decades O
have O
witnessed O
a O
surge O
in O
research O
investigating O
the O
application O
of O
oxytocin O
as O
a O
method O
of O
enhancing O
social O
behaviour O
in O
humans O
. O
[]

Using O
single-subject O
research O
analysis O
and O
medication O
given O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
cross-over O
design O
, O
4 O
of O
9 O
children O
randomized O
( O
44 O
% O
) O
had O
evidence O
of O
behavioral B-outcome ['Life-Impact']
improvement I-outcome ['Life-Impact']
. O
['Life-Impact']

OBJECTIVE O
To O
investigate O
the O
effects O
on O
wound O
healing O
of O
transforming O
growth O
factor-beta O
1 O
as O
a O
topical O
treatment O
to O
full-thickness O
, O
excisional O
wounds O
of O
the O
distal O
limb O
of O
horses O
. O
[]

Subgroup O
analysis O
of O
children O
( O
5-12 O
years O
) O
with O
autism O
enrolled O
in O
an O
8-week O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
risperidone O
for O
pervasive O
developmental O
disorders O
. O
[]

Contour B-outcome ['Physiological-Clinical']
detectability I-outcome ['Physiological-Clinical']
deteriorated O
with O
increasing O
spacing B-outcome ['Physiological-Clinical']
between O
contour O
elements O
and O
improved O
as O
the O
number O
of O
colinear O
line O
elements O
was O
increased O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Non-specific O
spinal O
pain O
( O
NSP O
) O
, O
comprising O
back O
and/or O
neck O
pain O
, O
is O
one O
of O
the O
leading O
disorders O
in O
long-term O
sick-listing O
. O
[]

Twelve O
healthy O
volunteers O
were O
included O
( O
with O
valid O
results O
available O
in O
9 O
) O
and O
studied O
according O
to O
a O
double-blind O
, O
randomized O
, O
cross-over O
design O
( O
intravenous O
adenosine O
, O
140 O
?g?kg O
( O
-1 O
) O
?min O
( O
-1 O
) O
, O
during O
5 O
min O
vs. O
placebo O
) O
. O
[]

4 O
. O
[]

In O
order O
to O
evaluate O
changes O
in O
the O
functional O
autonomy O
of O
elderly O
patients O
after O
a O
stay O
in O
a O
medical O
intensive O
care O
unit O
( O
ICU O
) O
, O
and O
the O
impact O
of O
post-ICU O
management O
in O
geriatric O
ward O
, O
we O
included O
in O
a O
randomized O
controlled O
trial O
45 O
patients O
aged O
> O
or=75 O
years O
. O
[]

The O
patients O
were O
followed O
for O
change O
in O
outcome O
measures O
during O
the O
five-month O
study O
period O
. O
[]

All O
groups O
showed O
additional O
improvement O
in O
efficacy O
scale O
scores O
during O
the O
OLE O
. O
[]

PATIENTS O
AND O
METHODS O
Between O
January O
2002 O
and O
November O
2004 O
, O
200 O
patients O
undergoing O
stapled O
hemorrhoidopexy O
were O
enrolled O
in O
a O
prospective O
, O
randomized O
clinical O
trial O
. O
[]

54 O
patients O
were O
included O
, O
with O
6 O
losses O
. O
[]

INTERVENTIONS O
Inhaled O
fluticasone O
propionate O
500 O
microgram O
twice O
daily O
from O
a O
metered O
dose O
inhaler O
or O
identical O
placebo O
. O
[]

In O
the O
intra-arterial O
arm O
, O
dose O
limiting O
toxicity B-outcome ['Adverse-effects']
was O
seen O
in O
2/6 O
( O
33 O
% O
) O
patients O
at O
50 O
mCi O
whereas O
in O
the O
intravenous O
arm O
, O
dose O
limiting O
toxicity B-outcome ['Adverse-effects']
was O
noted O
in O
1/6 O
patients O
at O
50 O
mCi O
, O
but O
did O
not O
occur O
at O
75 O
mCi O
( O
0/3 O
) O
.The O
overall O
response O
rate O
was O
6 O
% O
( O
1/18 O
) O
. O
['Adverse-effects', 'Adverse-effects']

Functionally O
, O
the O
glutamine O
treatment O
enhanced O
intestinal O
oxidative-defense O
capacity O
( O
indicated O
by O
a O
29 O
% O
increase O
in O
glutathione O
concentration O
) O
, O
prevented O
[]

Resource B-outcome ['Resource-use']
use I-outcome ['Resource-use']
data O
included O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
investigations B-outcome ['Resource-use']
performed O
, O
multiprofessional B-outcome ['Resource-use']
input I-outcome ['Resource-use']
and O
nursing B-outcome ['Life-Impact']
input I-outcome ['Life-Impact']
. O
['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use', 'Life-Impact']

Given O
the O
efficacy O
of O
systemic O
sirolimus O
administration O
to O
prevent O
neointimal B-outcome ['Physiological-Clinical']
hyperplasia I-outcome ['Physiological-Clinical']
in O
animal O
models O
and O
to O
halt O
and O
even O
reverse O
the O
progression O
of O
allograft O
vasculopathy O
, O
the O
aim O
of O
the O
present O
double-blind O
, O
placebo-controlled O
study O
was O
to O
evaluate O
the O
efficacy O
of O
a O
10-day O
oral O
sirolimus O
treatment O
with O
2 O
different O
loading O
regimens O
for O
the O
prevention O
of O
recurrent O
restenosis O
in O
patients O
with O
ISR O
. O
['Physiological-Clinical']

Effectiveness O
of O
vaginal O
tablets O
containing O
lactobacilli O
versus O
pH O
tablets O
on O
vaginal B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
: O
a O
randomized O
, O
double-blind O
study O
. O
['Physiological-Clinical']

Accuracy O
( O
correction O
rate O
) O
, O
recognition O
accuracy O
( O
correction O
rate-commission O
error O
rate O
) O
, O
and O
response O
time O
were O
measured O
during O
each O
experiment O
. O
[]

Blood O
and O
sputum O
eosinophils O
and O
serum O
levels O
of O
eosinophil O
cationic O
protein O
( O
ECP O
) O
and O
intercellular O
adhesion O
molecule-1 O
( O
ICAM-1 O
) O
were O
measured O
. O
[]

A O
quasi-experimental O
, O
repeated-measures O
cross-over O
design O
study O
on O
the O
effect O
of O
body O
position O
on O
oxygenation O
( O
SaO2 O
) O
blood O
pressure O
, O
respiration O
and O
pulse O
in O
patients O
with O
unilateral O
lung O
pathology O
was O
conducted O
. O
[]

AIMS O
AND O
OBJECTIVES O
We O
report O
findings O
from O
a O
qualitative O
study O
to O
identify O
patient O
views O
of O
community O
hospital O
care O
. O
[]

Serial O
blood O
samples O
were O
collected O
up O
to O
12 O
h O
on O
days O
6 O
and O
12 O
following O
the O
administration O
of O
the O
morning O
dose O
. O
[]

OBJECTIVE O
We O
assessed O
the O
effectiveness O
of O
distraction O
techniques O
in O
reducing O
the O
sensory O
and O
affective O
components O
of O
pain O
among O
pediatric O
patients O
undergoing O
laceration O
repair O
in O
the O
ED O
. O
[]

OBJECTIVE O
To O
examine O
the O
effect O
of O
ulinastatin O
( O
UTI O
) O
on O
the O
inflammatory B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
induced O
by O
oesophagectomy O
. O
['Physiological-Clinical']

Subjective O
cure B-outcome ['Physiological-Clinical']
rates O
were O
77.1 O
% O
for O
the O
U-type O
method O
and O
75.7 O
% O
for O
the O
H-type O
method O
( O
p=0.786 O
) O
. O
['Physiological-Clinical']

Sixty O
patients O
rated O
their O
pain B-outcome ['Physiological-Clinical']
intensity O
and O
relief B-outcome ['Physiological-Clinical']
hourly O
for O
12 O
hours O
and O
at O
24 O
hours O
after O
administration O
of O
study O
medication O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
same O
questionnaire O
was O
administered O
by O
telephone O
4 O
to O
6 O
weeks O
after O
the O
screening O
experience O
to O
all O
study O
subjects O
. O
[]

Fifty O
of O
the O
60 O
girls O
( O
83 O
% O
) O
had O
reached O
a O
normal B-outcome ['Physiological-Clinical']
FH I-outcome ['Physiological-Clinical']
( O
FH O
SD O
score O
, O
more O
than O
-2 O
) O
. O
['Physiological-Clinical']

Immunogenicity B-outcome ['Physiological-Clinical']
and O
reactogenicity B-outcome ['Physiological-Clinical']
of O
a O
group O
C O
meningococcal O
conjugate O
vaccine O
compared O
with O
a O
group O
A+C O
meningococcal O
polysaccharide O
vaccine O
in O
adolescents O
in O
a O
randomised O
observer-blind O
controlled O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Cold O
compress O
combined O
with O
ATs O
or O
EH O
lowered O
the O
antigen-raised O
ocular B-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
to O
less O
than O
the O
pre-exposure O
baseline O
. O
['Physiological-Clinical']

CONCLUSIONS O
Orthogonal O
polarization O
spectral O
imaging O
data O
reveal O
an O
impairment O
of O
microvascular O
perfusion O
during O
on-pump O
CABG O
. O
[]

A O
multicenter O
, O
randomized O
, O
controlled O
trial O
was O
conducted O
comparing O
active O
treatment O
with O
placebo O
in O
227 O
patients O
with O
breast O
, O
colorectal O
, O
lung O
and O
other O
solid O
forms O
of O
cancer O
. O
[]

METHODS O
Women O
randomised O
to O
the O
study O
group O
( O
scan O
group O
) O
underwent O
an O
ultrasound O
dating O
scan O
between O
8 O
and O
12 O
weeks O
, O
measuring O
crown-rump O
length O
. O
[]

From O
the O
negative O
and O
positive O
studies O
with O
CCBs O
performed O
in O
animals O
and O
humans O
we O
must O
conclude O
that O
apparently O
some O
, O
but O
not O
all O
, O
types O
or O
stages O
of O
the O
atherosclerotic O
process O
are O
inhibited O
by O
CCBs O
. O
[]

METHODS O
Forty O
adult O
American O
Society O
of O
Anaesthesiologists O
( O
ASA O
) O
grade O
1-111 O
patients O
, O
aged O
between O
40-65 O
years O
undergoing O
surgery O
under O
regional O
anaesthesia O
( O
sub-arachnoid O
block O
) O
were O
included O
. O
[]

CONCLUSION O
( O
S O
) O
Complete O
denudation O
of O
oocytes O
before O
slush O
nitrogen O
vitrification O
does O
not O
influence O
survival B-outcome ['Mortality']
rates O
but O
positively O
affects O
oocyte O
meiotic B-outcome ['Physiological-Clinical']
spindle I-outcome ['Physiological-Clinical']
competence I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

The O
diagnostic O
impact O
of O
TBNA O
when O
the O
EBUS O
probe O
is O
adjacent O
to O
lesions O
remains O
to O
be O
determined O
. O
[]

In O
the O
12 O
( O
th O
) O
weekend O
of O
treatment O
, O
the O
total O
scores O
of O
SDSS O
in O
study O
group O
( O
5.9 O
? O
[]

Manipulation O
of O
afferent O
inputs O
may O
temporarily O
modulate O
dystonic O
spasms O
. O
[]

CONCLUSIONS O
Despite O
the O
advent O
of O
effective O
drugs O
and O
endoscopic O
therapy O
for O
variceal O
bleeding O
, O
about O
a O
quarter O
of O
deaths B-outcome ['Mortality']
occur O
very O
early O
after O
bleeding O
onset O
, O
confirming O
the O
need O
for O
rapid O
specific O
management O
. O
['Mortality']

DESIGN O
Participants O
were O
allocated O
randomly O
to O
one O
of O
two O
groups O
, O
to O
receive O
either O
a O
cessation O
advice O
report O
and O
progress O
report O
that O
were O
tailored O
to O
individual-level O
characteristics O
or O
a O
cessation O
advice O
report O
that O
presented O
standardized O
( O
non-tailored O
) O
content O
. O
[]

RESULTS O
Two O
hundred O
twenty O
patients O
participated O
( O
n O
= O
107 O
, O
paricalcitol O
; O
n O
= O
113 O
, O
placebo O
) O
. O
[]

Single O
negative O
colposcopy O
: O
is O
it O
enough O
to O
rule O
out O
high-grade O
disease O
? O
[]

Fever B-outcome ['Physiological-Clinical']
( O
> O
or O
= O
37.5 O
degrees O
C O
) O
occurred O
in O
7.27 O
% O
( O
29/399 O
) O
to O
9.8 O
% O
( O
38/385 O
) O
in O
the O
acellular O
vaccine O
groups O
compared O
with O
36.6 O
% O
( O
145/394 O
) O
in O
the O
whole-cell O
vaccine O
group O
. O
['Physiological-Clinical']

Remifentanil O
with O
morphine O
transitional O
analgesia O
shortens O
neurological B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
compared O
to O
fentanyl O
for O
supratentorial O
craniotomy O
. O
['Physiological-Clinical']

We O
compared O
the O
efficacy O
of O
pretreatment O
with O
thiopental O
0.25 O
mg/kg O
and O
0.5 O
mg/kg O
and O
lidocaine O
40 O
mg O
after O
venous O
occlusion O
for O
prevention O
of O
propofol-induced B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
incidence O
of O
late B-outcome ['Physiological-Clinical']
miscarriage I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
spontaneous I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
noniatrogenic I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
preterm I-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
was O
assessed O
. O
['Physiological-Clinical']

Two O
doses O
of O
exenatide O
( O
1.25 O
and O
2.5 O
microg O
) O
were O
compared O
with O
insulin O
monotherapy O
. O
[]

Evidence O
supports O
a O
connection O
among O
dietary O
sodium O
, O
the O
rennin-angiotensin O
system O
, O
and O
myocardial O
function O
. O
[]

Ipilimumab O
resulted O
in O
dysregulation O
of O
gastrointestinal O
mucosal O
immunity O
as O
evidenced O
by O
altered O
antibody O
levels O
to O
enteric O
flora O
, O
inflammatory B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
infiltration I-outcome ['Physiological-Clinical']
into O
gastrointestinal O
mucosa O
, O
and O
increased O
fecal B-outcome ['Physiological-Clinical']
calprotectin I-outcome ['Physiological-Clinical']
associated O
with O
diarrhea B-outcome ['Physiological-Clinical']
and O
clinical O
evidence O
of O
colitis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

One O
of O
the O
objectives O
of O
Childrens O
Cancer O
Study O
Group O
( O
CCSG O
) O
study O
141 O
( O
CCG-141 O
) O
was O
to O
determine O
the O
frequency O
of O
occult B-outcome ['Physiological-Clinical']
testicular I-outcome ['Physiological-Clinical']
leukemia I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
after O
3 O
years O
of O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
DFS I-outcome ['Mortality']
) I-outcome ['Mortality']
and O
to O
retreat O
boys O
with O
occult O
TL O
to O
prolong O
their O
subsequent O
DFS O
. O
['Physiological-Clinical', 'Mortality']

Association O
of O
chronic O
kidney O
disease O
with O
outcomes O
in O
chronic B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
: O
a O
propensity-matched O
study O
. O
['Physiological-Clinical']

Circulating-tissue B-outcome ['Physiological-Clinical']
factor O
antigen B-outcome ['Physiological-Clinical']
rose O
from O
324 O
pg/ml O
, O
[ O
interquartile O
range O
( O
IQR O
) O
282-347 O
pg/ml O
] O
to O
356 O
pg/ml O
, O
( O
IQR O
319-431 O
pg/ml O
) O
in O
controls O
( O
C O
) O
, O
and O
decreased O
in O
the O
dalteparin-treated O
group O
( O
D O
) O
from O
336 O
pg/ml O
( O
IQR O
281-346 O
pg/ml O
) O
to O
303 O
pg/ml O
( O
IQR O
274-339 O
pg/ml O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

When O
the O
treatment O
groups O
were O
combined O
, O
gastric B-outcome ['Physiological-Clinical']
endoscopy I-outcome ['Physiological-Clinical']
scores O
were O
significantly O
higher O
among O
H. O
pylori O
negative O
than O
H. O
pylori O
positive O
subjects O
at O
Days O
8 O
and O
15 O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

METHODS O
Eighty O
postmenopausal O
women O
with O
osteoporosis O
were O
randomly O
assigned O
to O
a O
control O
group O
( O
n O
= O
38 O
) O
or O
an O
exercise O
group O
( O
n O
= O
42 O
) O
. O
[]

The O
sample O
consisted O
of O
182 O
prenatal O
Vietnamese O
women O
. O
[]

The O
status O
of O
H. O
pylori B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
evaluated O
. O
['Physiological-Clinical']

METHODS O
A O
cohort O
of O
199 O
patients O
with O
early O
active O
RA O
were O
initially O
randomized O
to O
receive O
treatment O
with O
a O
combination O
of O
methotrexate O
, O
sulfasalazine O
, O
and O
hydroxychloroquine O
with O
prednisolone O
( O
FIN-RACo O
) O
, O
or O
treatment O
with O
a O
single O
DMARD O
( O
initially O
, O
sulfasalazine O
) O
with O
or O
without O
prednisolone O
( O
SINGLE O
) O
. O
[]

Measures O
of O
the O
relative O
areas O
under O
the O
power O
spectral O
curve O
were O
made O
for O
each O
of O
the O
following O
frequency O
bands O
: O
slow O
alpha O
( O
7.5 O
to O
10 O
Hz O
) O
; O
fast O
alpha O
( O
10.5 O
to O
13.0 O
Hz O
) O
; O
slow O
beta O
( O
13.5 O
to O
19.5 O
Hz O
) O
; O
and O
fast O
beta O
( O
20 O
to O
26 O
Hz O
) O
at O
electrodes O
F3 O
, O
F4 O
, O
C3 O
, O
C4 O
, O
P3 O
, O
P4 O
, O
O1 O
, O
and O
O2 O
. O
[]

Terazosin O
, O
a O
new O
selective O
alpha O
1-adrenergic O
receptor O
antagonist O
, O
has O
been O
found O
to O
be O
an O
effective O
antihypertensive O
agent O
. O
[]

Nevertheless O
, O
the O
use O
of O
stentless O
bioprostheses O
leads O
to O
a O
significant O
enhancement O
, O
which O
may O
result O
in O
a O
reduction O
of O
the O
cardiac O
risk O
profile O
for O
the O
patient O
. O
[]

Ketorolac O
is O
a O
non-steroidal O
anti-inflammatory O
drug O
approved O
in O
the O
United O
States O
for O
the O
relief O
of O
ocular O
itching O
associated O
with O
seasonal O
allergic O
conjunctivitis O
. O
[]

Captopril O
12.5 O
mg O
decreased O
subjective O
activity B-outcome ['Life-Impact']
compared O
with O
placebo O
. O
['Life-Impact']

In O
thirteen O
patients O
, O
under O
reasonably O
good O
control O
, O
clofibrate O
did O
not O
reduce O
fasting B-outcome ['Physiological-Clinical']
or O
post-prandial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
nor O
24 O
h B-outcome ['Physiological-Clinical']
glycosuria I-outcome ['Physiological-Clinical']
; O
no O
improvement O
was O
noted O
in O
the O
M-value B-outcome ['Physiological-Clinical']
, O
an O
index O
of O
diabetes B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Switching O
patients O
with O
asthma O
from O
chlorofluorocarbon O
( O
CFC O
) O
albuterol O
to O
hydrofluoroalkane-134a O
( O
HFA O
) O
albuterol O
. O
[]

We O
previously O
demonstrated O
that O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
GM-CSF O
) O
production O
and O
mRNA O
expression O
from O
stimulated O
neonatal O
mononuclear O
cells O
are O
significantly O
less O
than O
that O
from O
adult O
cells O
. O
[]

CONTEXT O
The O
Diabetic O
Control O
and O
Complications O
Trial O
( O
DCCT O
) O
researchers O
kept O
careful O
records O
of O
the O
food O
consumption O
and O
tobacco O
using O
habits O
of O
type O
1 O
diabetic O
subjects O
. O
[]

The O
dose O
of O
fluconazole O
was O
100 O
mg O
daily O
in O
the O
first O
phase O
of O
study O
and O
200 O
mg O
daily O
in O
the O
second O
phase O
. O
[]

DESIGN O
Patients O
with O
septic O
shock O
who O
were O
enrolled O
in O
the O
placebo O
limb O
of O
the O
North O
American O
Sepsis O
Trial O
( O
NORASEPT O
II O
) O
study O
were O
analyzed O
. O
[]

The O
serum B-outcome ['Physiological-Clinical']
CA125 I-outcome ['Physiological-Clinical']
level O
was O
( O
31.88 O
+/- O
15.78 O
) O
U/mL O
before O
drug O
therapy O
and O
( O
18.82 O
+/- O
10.08 O
) O
U/mL O
three O
months O
after O
drug O
therapy O
in O
the O
test O
group O
, O
while O
it O
was O
( O
30.63 O
+/- O
19.28 O
) O
U/mL O
and O
( O
18.05 O
+/- O
11.20 O
) O
U/mL O
respectively O
in O
the O
control O
group O
. O
['Physiological-Clinical']

A O
crossover O
study O
of O
risperidone O
in O
children O
, O
adolescents O
and O
adults O
with O
mental O
retardation O
. O
[]

DESIGN O
Randomized O
controlled O
trial O
. O
[]

CONCLUSIONS O
The O
addition O
of O
concurrent O
cisplatin O
to O
radiotherapy O
resulted O
in O
a O
[]

AIM O
To O
compare O
the O
efficacy O
of O
human O
recombinant O
FSH O
( O
r-hFSH O
) O
plus O
human O
recombinant O
LH O
( O
r-hLH O
) O
in O
a O
2:1 O
ratio O
with O
highly O
purified O
human O
menopausal O
gonadotropin O
( O
hMG-HP O
) O
urinary O
extract O
, O
containing O
LH-like O
activity O
, O
in O
women O
with O
HH O
. O
[]

Endotoxin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
, O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
tests O
, O
and O
other O
laboratory O
parameters O
were O
determined O
in O
weekly O
intervals O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Such O
a O
treatment O
appears O
to O
be O
of O
value O
in O
treating O
these O
patients O
and O
even O
probably O
of O
curing O
some O
of O
them O
. O
[]

BACKGROUND O
the O
interplay O
between O
comorbidity O
, O
age O
and O
performance B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
as O
predictors O
of O
outcome O
in O
advanced O
colorectal O
cancer O
( O
ACRC O
) O
is O
poorly O
understood O
. O
['Physiological-Clinical']

Exclusion O
criteria O
were O
: O
insertional O
disorders O
, O
partial O
or O
complete O
ruptures O
, O
or O
systemic O
illness O
. O
[]

However O
, O
the O
new O
type O
of O
120 O
degrees O
fixed O
angle O
blade-plate O
with O
a O
buttress O
rod O
( O
RAB-plate O
) O
showed O
encouraging O
clinical O
results O
. O
[]

In O
conclusion O
, O
the O
occlusal B-outcome ['Physiological-Clinical']
fissure I-outcome ['Physiological-Clinical']
plaque I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
was O
easy O
to O
apply O
, O
repeatable O
and O
sufficiently O
sensitive O
to O
detect O
plaque O
removed O
by O
brushing O
. O
['Physiological-Clinical']

No O
side O
effects O
were O
observed O
. O
[]

Systemic O
lidocaine O
showed O
a O
selective O
effect O
on O
secondary O
hyperalgesia O
. O
[]

To O
determine O
the O
effectiveness O
of O
nicotinic O
acid O
in O
dyslipidemic O
patients O
with O
non-insulin-dependent O
diabetes O
mellitus O
, O
13 O
patients O
were O
treated O
in O
a O
randomized O
crossover O
trial O
. O
[]

Patients O
received O
three O
treatments O
each O
spaced O
1 O
month O
apart O
. O
[]

There O
were O
no O
differences O
in O
response O
to O
erythromycin O
based O
on O
whether O
the O
patient O
had O
a O
positive O
test O
for O
M O
pneumoniae O
. O
[]

This O
intent-to-treat O
analysis O
includes O
16 O
patients O
who O
were O
not O
eligible O
and O
17 O
patients O
who O
had O
protocol O
violations O
. O
[]

All O
patients O
in O
the O
TIVA O
group O
found O
the O
colonoscopy B-outcome ['Physiological-Clinical']
painless I-outcome ['Physiological-Clinical']
( O
NRS O
score O
0 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
AIM O
Adjuvant O
locoregional O
chemotherapy O
has O
been O
shown O
to O
be O
useful O
to O
prevent O
recurrence O
after O
curative O
resection O
of O
hepatocellular O
carcinoma O
( O
HCC O
) O
in O
some O
retrospective O
studies O
. O
[]

to O
dogs O
, O
and O
tissue O
samples O
were O
harvested O
24 O
to O
300 O
hours O
later O
. O
[]

This O
study O
investigated O
whether O
instruction O
that O
involves O
comparing O
the O
equal O
sign O
with O
other O
relational O
symbols O
is O
more O
effective O
at O
imparting O
a O
relational B-outcome ['Life-Impact']
interpretation I-outcome ['Life-Impact']
of O
the O
equal O
sign O
than O
instruction O
about O
the O
equal O
sign O
alone O
. O
['Life-Impact']

Discontinuation O
after O
6 O
months O
was O
associated O
with O
a O
rapid O
return O
of O
disruptive O
and O
aggressive O
behavior O
in O
most O
subjects O
. O
[]

The O
effects O
of O
three O
different O
regimens O
of O
inhaled O
bronchodilators O
on O
spirometry O
and O
respiratory O
impedance O
as O
measured O
with O
the O
technique O
of O
forced O
oscillations O
were O
compared O
in O
a O
double-blind O
crossover O
study O
in O
22 O
patients O
with O
stable O
chronic O
obstructive O
pulmonary O
disease O
( O
FEV1 O
less O
than O
70 O
percent O
predicted O
) O
. O
[]

Early O
intensification O
was O
associated O
with O
fewer O
bone B-outcome ['Physiological-Clinical']
marrow I-outcome ['Physiological-Clinical']
relapses I-outcome ['Physiological-Clinical']
and O
a O
reduction O
in O
the O
odds O
of O
death B-outcome ['Mortality']
of O
0.63 O
( O
95 O
% O
confidence O
interval O
: O
0.46-0.87 O
) O
. O
['Physiological-Clinical', 'Mortality']

The O
effect O
of O
quality O
and O
amount O
of O
dietary O
fat O
on O
the O
susceptibility O
of O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
in O
subjects O
with O
impaired O
glucose O
tolerance O
. O
['Physiological-Clinical']

CONCLUSION O
( O
S O
) O
In O
terms O
of O
ovulation O
rates O
in O
cycle O
1 O
, O
single-dose O
anastrozole O
at O
5 O
, O
10 O
, O
20 O
, O
and O
30 O
mg O
was O
not O
as O
effective O
as O
CC O
at O
50 O
mg/d O
for O
5 O
days O
( O
noninferiority O
was O
not O
shown O
) O
. O
[]

A O
similar O
comparison O
during O
trial O
2 O
revealed O
a O
1.8 O
+/- O
0.3 O
mmol.l-1 O
increase O
in O
lactate B-outcome ['Physiological-Clinical']
, O
signifying O
a O
workload O
above O
LSS O
and O
therefore O
confirming O
trial O
1 O
as O
the O
maximum O
LSS O
( O
MLSS O
) O
. O
['Physiological-Clinical']

Rates O
of O
infection B-outcome ['Physiological-Clinical']
, O
dehiscence B-outcome ['Physiological-Clinical']
, O
and O
other O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
did O
not O
significantly O
differ O
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

The O
results O
show O
that O
the O
experimental O
group O
demonstrated O
significantly O
greater O
improvement O
in O
self-control B-outcome ['Life-Impact']
than O
the O
control O
group O
, O
which O
concurs O
with O
the O
parental O
reports O
of O
reduced O
autistic B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
increased O
control O
of O
temper B-outcome ['Life-Impact']
and O
behaviors B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Comparison O
of O
the O
two O
groups O
made O
use O
of O
the O
Wilcoxon O
test O
for O
the O
continuous O
variables O
and O
the O
Fisher O
's O
exact O
test O
for O
the O
comparison O
of O
frequencies O
, O
at O
significance O
value O
of O
5 O
% O
. O
[]

The O
striated O
muscle O
activator O
of O
Rho O
signalling O
( O
STARS O
) O
pathway O
is O
suggested O
to O
provide O
a O
link O
between O
external O
stress O
responses O
and O
transcriptional O
regulation O
in O
muscle O
. O
[]

Recruitment B-outcome ['Life-Impact']
, O
adherence B-outcome ['Life-Impact']
, O
withdrawals B-outcome ['Life-Impact']
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs O
) O
, O
and O
completeness O
of O
data O
will O
be O
recorded O
and O
reported O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Adverse-effects']

PATIENTS O
AND O
METHODS O
90 O
patients O
( O
96 O
hips O
) O
scheduled O
for O
THA O
were O
stratified O
in O
three O
groups O
according O
to O
the O
method O
of O
fixation O
of O
the O
acetabular O
component O
: O
acrylic O
bone O
cement O
with O
fluoride O
( O
Cemex-F O
) O
, O
porous-coated O
press-fit O
cup O
with O
ceramic O
coating O
( O
Trilogy O
, O
uncemented O
) O
and O
acrylic O
cement O
with O
gentamicin O
( O
Palacos O
) O
. O
[]

Bupropion O
SR O
and O
counseling O
for O
smoking O
cessation O
in O
actual O
practice O
: O
predictors O
of O
outcome O
. O
[]

CONCLUSION O
The O
low-tilt O
biphasic O
waveform O
was O
more O
successful O
for O
the O
internal O
cardioversion O
of O
both O
persistent O
and O
induced O
AF O
in O
patients O
( O
in O
terms O
of O
leading O
edge O
voltage O
) O
. O
[]

RESULTS O
The O
modified O
CIMT O
group O
showed O
significantly O
higher O
changes O
in O
all O
3 O
tests O
compared O
to O
the O
standard O
rehabilitation O
group O
. O
[]

Deficits O
in O
social O
cognition O
are O
common O
in O
schizophrenia O
and O
predict O
poor O
community O
functioning O
. O
[]

Clonidine O
, O
a O
centrally O
acting O
alpha O
( O
2 O
) O
-adrenoceptor O
agonist O
, O
has O
neuroendocrine O
effects O
, O
including O
inhibition O
of O
sympathoadrenal O
activity O
. O
[]

Alinidine O
was O
administered O
at O
a O
dosage O
of O
30 O
mg O
3 O
times O
a O
day O
. O
[]

This O
trial O
is O
registered O
with O
ClinicalTrials.gov O
NCT01463748 O
. O
[]

However O
, O
its O
clinical O
value O
, O
including O
anticipated O
size O
and O
duration O
of O
the O
treatment O
effects O
, O
remains O
largely O
unknown O
. O
[]

Stability B-outcome ['Physiological-Clinical']
, O
segmental B-outcome ['Physiological-Clinical']
maxillary I-outcome ['Physiological-Clinical']
tipping I-outcome ['Physiological-Clinical']
and O
relapse B-outcome ['Physiological-Clinical']
were O
studied O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
total O
of O
66 O
eyes O
of O
54 O
patients O
with O
primary O
pterygium O
were O
treated O
with O
excision O
, O
with O
or O
without O
a O
single O
intraoperative O
application O
of O
mitomycin O
C O
( O
0.1 O
mg/ml O
for O
5 O
minutes O
) O
to O
evaluate O
the O
efficacy O
and O
toxicity B-outcome ['Adverse-effects']
of O
this O
adjunctive O
treatment O
. O
['Adverse-effects']

These O
children O
were O
randomly O
divided O
into O
two O
groups O
: O
Therapy O
Group O
( O
TG O
) O
- O
composed O
by O
six O
subjects O
receiving O
both O
direct O
and O
indirect O
intervention O
; O
and O
Orientation O
Group O
( O
OG O
) O
- O
constituted O
by O
five O
subjects O
receiving O
exclusively O
indirect O
intervention O
. O
[]

There O
were O
significant O
differences O
between O
centres O
in O
reduction O
of O
cancer B-outcome ['Physiological-Clinical']
worry O
from O
baseline O
to O
12 O
months O
and O
with O
the O
number O
of O
women O
who O
were O
recommended O
to O
have O
mammographic O
surveillance O
who O
had O
not O
received O
this O
. O
['Physiological-Clinical']

At O
Month O
12 O
, O
both O
belatacept O
regimens O
had O
similar O
patient/graft B-outcome ['Mortality']
survival I-outcome ['Mortality']
versus O
cyclosporine O
( O
MI O
: O
95 O
% O
, O
LI O
: O
97 O
% O
and O
cyclosporine O
: O
93 O
% O
) O
, O
and O
were O
associated O
with O
superior B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
as O
measured O
by O
the O
composite O
renal B-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
endpoint O
( O
MI O
: O
55 O
% O
; O
LI O
: O
54 O
% O
and O
cyclosporine O
: O
78 O
% O
; O
p O
< O
or O
= O
0.001 O
MI O
or O
LI O
versus O
cyclosporine O
) O
and O
by O
the O
mGFR B-outcome ['Physiological-Clinical']
( O
65 O
, O
63 O
and O
50 O
mL/min O
for O
MI O
, O
LI O
and O
cyclosporine O
; O
p O
< O
or O
= O
0.001 O
MI O
or O
LI O
versus O
cyclosporine O
) O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
past O
20 O
years O
have O
seen O
an O
overall O
decline O
in O
survey O
response O
rates O
and O
an O
even O
more O
pronounced O
decline O
in O
samples O
of O
health O
care O
professionals O
. O
[]

[ O
Clinical O
effect O
of O
transcatheter O
arterial O
chemoembolization O
combined O
with O
high O
intensity O
focused O
ultrasound O
ablation O
in O
treatment O
of O
large O
hepatocellular O
carcinoma O
] O
. O
[]

Thus O
, O
adolescents O
with O
impairments O
in O
these O
skills O
are O
at O
risk O
for O
a O
variety O
of O
negative O
outcomes O
. O
[]

CONCLUSIONS O
The O
results O
of O
this O
study O
show O
that O
the O
evaluation O
of O
ICCE O
with O
ACL O
is O
too O
negative O
. O
[]

Two O
fixed O
ratio O
combination O
tablets O
, O
10 O
mg O
pindolol O
combined O
with O
5 O
mg O
clopamide O
and O
100 O
mg O
metoprolol O
combined O
with O
12.5 O
mg O
hydrochlorothiazide O
, O
were O
compared O
at O
two O
dose O
levels O
in O
a O
double-blind O
crossover O
trial O
in O
10 O
previously O
untreated O
hypertensive O
patients O
. O
[]

After O
six O
weeks O
, O
the O
ulcers B-outcome ['Physiological-Clinical']
were O
healed B-outcome ['Physiological-Clinical']
in O
48 O
patients O
given O
antibiotics O
and O
39 O
given O
placebo O
( O
92 O
percent O
vs. O
75 O
percent O
, O
P O
= O
0.011 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
Ninety-five O
patients O
from O
southwestern O
iowa O
and O
southeastern O
Nebraska O
were O
enrolled O
, O
of O
whom O
88 O
were O
considered O
eligible O
for O
comparison O
( O
by O
continuing O
through O
week O
2 O
of O
the O
study O
) O
. O
[]

The O
tumor B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
and O
minification B-outcome ['Physiological-Clinical']
rates O
of O
the O
TACE+HIFU O
and O
TACE O
groups O
were O
73.7 O
% O
and O
68.4 O
% O
respectively O
, O
both O
significantly O
higher O
than O
those O
of O
TACE O
group O
( O
26.7 O
% O
and O
33.3 O
% O
respectively O
, O
both O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

As O
for O
cardiovascular O
function O
, O
only O
the O
CPAP O
therapy O
achieved O
a O
significant O
reduction O
in O
rate O
pressure O
product O
in O
contrast O
to O
the O
control O
( O
face O
mask O
) O
therapy O
alone O
. O
[]

RESULTS O
There O
were O
no O
differences O
in O
patient O
characteristics O
for O
both O
groups O
. O
[]

MATERIALS O
AND O
METHODS O
This O
prospective O
, O
randomized O
, O
double-blinded O
, O
and O
placebo-controlled O
study O
enrolled O
124 O
women O
21-60 O
years O
of O
age O
who O
were O
scheduled O
for O
elective O
gasless O
robot-assisted O
endoscopic O
thyroidectomy O
via O
the O
transaxillary O
approach O
. O
[]

DESIGN O
AND O
METHOD O
Churches O
were O
randomized O
to O
receive O
either O
the O
spiritually O
based O
or O
the O
non-spiritual O
intervention O
. O
[]

Calculated O
retinal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
was O
not O
changed O
by O
administration O
of O
histamine O
( O
-7 O
+/- O
14 O
% O
, O
-4 O
+/- O
20 O
% O
, O
and O
-8 O
+/- O
12 O
% O
, O
P O
= O
0.28 O
, O
ANOVA O
) O
. O
['Physiological-Clinical']

RESULTS O
Both O
groups O
incurred O
similar O
costs O
during O
the O
2-year O
study O
period O
, O
with O
a O
trend O
for O
clozapine O
to O
be O
less O
costly O
than O
usual O
care O
in O
the O
second O
study O
year O
. O
[]

5 O
vs. O
23 O
? O
[]

[ O
Comparison O
of O
three O
analgesic O
methods O
for O
postoperative O
pain O
relief O
and O
their O
effects O
on O
plasma B-outcome ['Physiological-Clinical']
interleukin-6 I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
following O
radical O
surgery O
for O
gastric O
carcinoma O
] O
. O
['Physiological-Clinical']

CONCLUSION O
Both O
ischaemic O
preconditioning O
and O
cardiopulmonary O
bypass O
induced O
free B-outcome ['Physiological-Clinical']
radicals I-outcome ['Physiological-Clinical']
generation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
chemotherapy O
regimens O
resulted O
in O
similar O
EFS B-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

The O
drug O
alone O
and O
ECT O
groups O
tended O
to O
have O
the O
best O
outcome O
and O
the O
psychotherapy O
alone O
group O
the O
worst O
. O
[]

Two O
hundred O
and O
seventy O
fingerlings O
( O
6.71 O
? O
[]

METHODS O
Sixty O
Thai O
children O
with O
autism O
, O
aged O
three O
to O
nine O
years O
, O
were O
randomly O
assigned O
to O
receive O
20 O
one-hour O
sessions O
of O
either O
HBOT O
at O
153 O
kPa O
( O
1.5 O
ATA O
) O
or O
sham O
air O
at O
116 O
kPa O
( O
1.15 O
ATA O
) O
. O
[]

At O
1 O
week O
, O
patients O
who O
received O
the O
computer-delivered O
tailored O
intervention O
had O
greater O
changes O
in O
CRC O
knowledge O
scores O
( O
P O
< O
0.001 O
) O
, O
perceived O
CRC O
risk O
scores O
( O
P O
= O
0.005 O
) O
, O
FOBT O
barriers O
scores O
( O
P O
= O
0.034 O
) O
and O
colonoscopy O
benefit O
scores O
( O
P O
< O
0.001 O
) O
. O
[]

Though O
the O
response O
rate O
for O
the O
intra-arterial O
infusion O
arm O
was O
slightly O
higher O
than O
for O
the O
systemic O
arm O
, O
the O
difference O
was O
not O
significant O
, O
and O
the O
intra-arterial O
infusion O
arm O
was O
associated O
with O
a O
greater O
incidence O
of O
nausea B-outcome ['Physiological-Clinical']
, O
vomiting B-outcome ['Physiological-Clinical']
, O
diarrhea B-outcome ['Physiological-Clinical']
, O
in O
addition O
to O
complications O
of O
femoral-arterial B-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
, O
bleeding B-outcome ['Physiological-Clinical']
, O
and O
infection B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
catheter I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
not O
seen O
in O
patients O
treated O
by O
systemic O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
In O
both O
methods O
there O
were O
no O
significant O
differences O
in O
systolic O
and O
diastolic B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
, O
rate-pressure O
product O
, O
in O
glucose B-outcome ['Physiological-Clinical']
or O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
compared O
venlafaxine O
and O
clonidine O
for O
the O
treatment O
of O
HF O
with O
regard O
to O
side O
effects O
, O
efficacy O
, O
quality O
of O
life O
and O
sexual B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact']

A O
controlled O
comparison O
between O
single O
doses O
of O
intravenous O
and O
intramuscular O
morphine O
with O
respect O
to O
analgesic B-outcome ['Resource-use']
effects O
and O
patient O
safety O
. O
['Resource-use']

RESULTS O
Patients O
had O
lower O
peak O
oxygen B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
and O
a O
steeper O
slope O
relating O
ventilation O
to O
carbon O
dioxide O
production O
than O
controls O
. O
['Resource-use']

Predictive O
validity O
of O
assessments O
at O
age O
3 O
years O
was O
greater O
. O
[]

Thus O
, O
in O
hypertensive O
African-American O
men O
with O
moderate O
to O
severe O
LV O
hypertrophy O
, O
hydrochlorothiazide O
does O
not O
worsen O
ventricular B-outcome ['Physiological-Clinical']
arrhythmias I-outcome ['Physiological-Clinical']
or O
signal-averaged B-outcome ['Physiological-Clinical']
electrocardiographic I-outcome ['Physiological-Clinical']
variables I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Neural O
basis O
of O
self O
and O
other O
representation O
in O
autism O
: O
an O
FMRI O
study O
of O
self-face B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
women O
received O
2 O
mg O
estradiol O
continuously O
during O
five O
28-day O
cycles O
and O
10 O
mg O
or O
20 O
mg O
MPA O
sequentially O
for O
12 O
days O
during O
each O
cycle O
. O
[]

Periotest/Osstell O
measurements O
were O
completed O
before O
and O
during O
staged O
bone O
removal O
( O
to O
enlarge O
defect O
size O
) O
. O
[]

These O
effects O
were O
dose-dependent O
. O
[]

RESULTS O
All O
subjects O
completed O
the O
12-week O
evaluation O
. O
[]

PURPOSE O
Several O
pilot O
studies O
have O
indicated O
that O
low-dose O
radiation O
therapy O
might O
have O
a O
beneficial O
effect O
on O
the O
course O
of O
choroidal O
neovascularization O
( O
CNV O
) O
in O
age-related O
macular O
degeneration O
( O
AMD O
) O
. O
[]

A O
retrospective O
analysis O
of O
29 O
children O
treated O
with O
inhaled O
treprostinil O
for O
?6 O
weeks O
was O
performed O
. O
[]

CONCLUSION O
Results O
indicate O
the O
efficacy O
of O
the O
program O
in O
a O
research O
setting O
and O
suggest O
a O
potential O
clinical O
application O
. O
[]

Alfentanil O
was O
used O
as O
a O
comparator O
drug O
. O
[]

This O
was O
confirmed O
by O
another O
self-report O
scale O
( O
the O
facial B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scale O
revised O
: O
P O
= O
0.005 O
) O
, O
as O
well O
as O
with O
hetero-evaluations O
by O
GPs O
and O
parents O
[ O
Children O
's O
Hospital O
of O
Eastern O
Ontario O
Pain B-outcome ['Physiological-Clinical']
Scale O
: O
P O
= O
0.0007 O
; O
GPs O
VAS O
( O
P O
< O
0.0001 O
) O
, O
parents O
VAS O
( O
P O
< O
0.0001 O
) O
] O
, O
which O
were O
secondary O
outcome O
criteria O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
multivariate O
analyses O
, O
greater O
BMI O
was O
significantly O
associated O
with O
higher O
PCSM B-outcome ['Mortality']
( O
for O
BMI O
> O
or O
=25 O
to O
< O
30 O
, O
hazard O
ratio O
[ O
HR O
] O
1.52 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
1.02-2.27 O
, O
P O
= O
.04 O
; O
for O
BMI O
> O
or O
=30 O
, O
HR O
1.64 O
, O
95 O
% O
CI O
, O
1.01-2.66 O
, O
P O
= O
.04 O
) O
. O
['Mortality']

RESULTS O
Of O
1857 O
patients O
, O
79 O
( O
4.3 O
% O
) O
developed O
a O
syndrome O
of O
bowel B-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
( O
BWI O
, O
small O
or O
large O
) O
characterized O
by O
hospitalization O
for O
the O
management O
of O
['Physiological-Clinical']

Complications O
related O
to O
the O
ablation O
procedure O
occurred O
in O
two O
patients O
; O
no O
deaths B-outcome ['Mortality']
occurred O
within O
30 O
days O
after O
ablation O
. O
['Mortality']

However O
, O
PR O
in O
r-hFSH/r-hLH O
group O
was O
55.6 O
% O
compared O
to O
23.3 O
% O
in O
hMG-HP O
group O
( O
p=0.01 O
) O
. O
[]

METHODS O
A O
retrospective O
cohort O
study O
-- O
secondary O
analysis O
of O
the O
results O
of O
a O
treatment O
trial O
-- O
was O
performed O
in O
Belgium O
and O
The O
Netherlands O
. O
[]

RESULTS O
Although O
the O
decision O
aid O
had O
no O
significant O
effect O
on O
postdecisional O
regret O
or O
actual O
genetic O
testing O
decision O
, O
the O
trial O
results O
demonstrated O
that O
participants O
who O
received O
the O
decision O
aid O
had O
significantly O
lower O
levels O
of O
decisional B-outcome ['Life-Impact']
conflict I-outcome ['Life-Impact']
( O
ie O
, O
uncertainty B-outcome ['Life-Impact']
) O
regarding O
genetic B-outcome ['Physiological-Clinical']
testing I-outcome ['Physiological-Clinical']
( O
chi-square O
( O
1 O
) O
= O
8.97 O
; O
P O
= O
.003 O
) O
and O
were O
more O
likely O
to O
be O
classified O
as O
having O
made O
an O
informed B-outcome ['Life-Impact']
choice I-outcome ['Life-Impact']
concerning O
genetic O
testing O
( O
chi-square O
( O
1 O
) O
= O
4.37 O
; O
P O
= O
.037 O
) O
than O
participants O
who O
received O
a O
control O
pamphlet O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Efficacy O
was O
assessed O
by O
total O
amount O
of O
morphine O
consumed O
, O
pain O
intensity O
, O
range O
of O
motion O
( O
ROM O
) O
, O
the O
concentration O
change O
of O
PGE-2 O
and O
IL-6 O
of O
joint O
fluid O
, O
and O
postoperative O
nausea O
and O
vomiting O
( O
PONV O
) O
postoperatively O
. O
[]

RESULTS O
Wearing O
foam O
ear O
plugs O
under O
the O
headset O
decreased O
speech B-outcome ['Life-Impact']
intelligibility I-outcome ['Life-Impact']
dramatically O
. O
['Life-Impact']

A O
good O
response O
to O
oil O
with O
medium- O
and O
long-chain O
fatty O
acids O
in O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
profiles O
of O
male O
hypertriglyceridemic O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

They O
were O
treated O
with O
SXN O
( O
0.1 O
g O
, O
three O
times O
per O
day O
) O
and O
ferrous O
gluconate O
( O
0.1 O
g O
, O
three O
times O
per O
day O
) O
respectively O
, O
for O
30 O
days O
. O
[]

The O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
was O
significantly O
longer O
with O
unreamed O
nails O
. O
['Physiological-Clinical']

Patients O
were O
randomly O
enrolled O
into O
patient-controlled O
anesthesia O
( O
PCA O
) O
alone O
, O
PCA O
plus O
TENS O
, O
or O
PCA O
plus O
sham O
TENS O
. O
[]

Children O
with O
chronic O
, O
active O
diarrhea O
showed O
a O
reduction O
in O
aberrant B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
when O
treated O
with O
the O
secretin O
but O
not O
when O
treated O
with O
the O
placebo O
. O
['Life-Impact']

The O
infusion O
regimens O
of O
dexmedetomidine O
tested O
in O
the O
dose-response O
study O
ranged O
from O
120 O
ng.kg-1 O
x O
min-1 O
, O
followed O
by O
6 O
ng.kg-1 O
x O
min-1 O
, O
to O
270 O
+ O
13.5 O
ng.kg-1 O
x O
min-1 O
. O
[]

This O
study O
indicates O
that O
treatment O
with O
heparin B-outcome ['Physiological-Clinical']
and O
dipyridamole B-outcome ['Physiological-Clinical']
has O
no O
benefit O
over O
symptomatic B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
alone O
in O
the O
typical O
form O
of O
childhood O
hemolytic-uremic O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

However O
, O
there O
are O
no O
between-subject O
studies O
to O
date O
assessing O
the O
efficacy O
of O
CAI O
with O
this O
population O
. O
[]

RESULTS O
Recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
HCC I-outcome ['Physiological-Clinical']
occurred O
in O
7 O
cases O
( O
33.3 O
% O
) O
for O
the O
treatment O
group O
and O
12 O
cases O
( O
50.0 O
% O
) O
for O
the O
control O
group O
during O
mean O
observation O
periods O
of O
19.5 O
and O
16.5 O
months O
, O
respectively O
. O
['Physiological-Clinical']

The O
importance O
of O
control O
groups O
, O
RBC B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
determinations O
and O
the O
monitoring O
of O
dialysis-associated B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
losses I-outcome ['Physiological-Clinical']
in O
studying O
the O
effects O
of O
androgens O
on O
erythropoiesis O
in O
chronic O
hemodialysis O
patients O
is O
also O
demonstrated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Of O
316 O
randomized O
subjects O
, O
259 O
( O
82.0 O
% O
) O
were O
antipsychotic O
na?ve O
( O
AN O
) O
and O
57 O
( O
18.0 O
% O
) O
had O
a O
PAE O
. O
[]

OBJECTIVES O
Conventional O
neuroleptics O
ameliorate O
symptoms O
in O
children O
with O
autistic O
disorder O
; O
however O
, O
they O
are O
known O
to O
cause O
dyskinesias O
. O
[]

No O
incidents O
of O
dislocation B-outcome ['Physiological-Clinical']
occurred O
. O
['Physiological-Clinical']

Minimally O
invasive O
treatment O
combined O
with O
cytokine-induced O
killer O
cells O
therapy O
lower O
the O
short-term O
recurrence O
rates O
of O
hepatocellular O
carcinomas O
. O
[]

acetaminophen O
, O
and O
5 O
ml O
of O
saline O
, O
respectively O
. O
[]

Group O
1 O
: O
500 O
mg O
of O
Diamox O
Sustets O
( O
acetazolamide O
) O
1 O
hour O
preoperatively O
( O
10 O
patients O
) O
; O
Group O
2 O
: O
peroperative O
intracameral O
Miochol O
( O
acetylcholine O
) O
( O
11 O
patients O
) O
; O
Group O
3 O
: O
the O
above O
treatments O
combined O
( O
15 O
patients O
) O
. O
[]

Our O
data O
suggest O
that O
enhanced O
activation O
of O
the O
mTOR O
signaling O
pathway O
is O
playing O
a O
role O
in O
the O
greater O
synthesis O
of O
muscle O
proteins O
when O
resistance O
exercise O
is O
followed O
by O
EAA+CHO O
ingestion O
. O
[]

BACKGROUND O
Volunteer O
befriending O
promoted O
remission O
of O
chronic O
depression O
when O
clinical O
and O
other O
treatment O
variables O
were O
controlled O
. O
[]

RESULTS O
Greater O
LDL-C O
reduction O
was O
observed O
and O
maintained O
until O
52 O
weeks O
in O
ezetimibe-plus-statin O
, O
while O
LDL-C O
levels O
re-increased O
after O
12 O
weeks O
in O
double-dose O
statin O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
LAUP O
and O
UPPP O
regarding O
the O
fall O
in O
[]

The O
children O
were O
assessed O
on O
awakening B-outcome ['Life-Impact']
, O
and O
then O
10 O
minutes O
, O
1 O
hour O
, O
4 O
hours O
and O
24 O
hours O
later O
. O
['Life-Impact']

The O
CBT O
model O
emphasized O
behavioral O
experimentation O
, O
parent-training O
, O
and O
school O
consultation O
. O
[]

Both O
agents O
produced O
a O
significant O
fall O
in O
IOP B-outcome ['Physiological-Clinical']
for O
the O
period O
of O
study O
, O
by O
a O
maximum O
of O
53 O
% O
with O
propofol O
and O
40 O
% O
with O
thiopentone O
. O
['Physiological-Clinical']

Sixty O
percent O
of O
the O
dose O
is O
recovered O
in O
the O
feces O
. O
[]

Effect O
of O
broccoli O
intake O
on O
markers B-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxidative I-outcome ['Physiological-Clinical']
stress O
and O
cancer B-outcome ['Physiological-Clinical']
risk O
in O
healthy O
smokers O
and O
nonsmokers O
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
may O
also O
shorten O
the O
operative O
time O
since O
tissue O
is O
resected O
instead O
of O
just O
vaporized O
. O
[]

STUDY O
DESIGN O
Prospective O
multicenter O
randomized O
controlled O
study O
designed O
to O
assess O
the O
noninferiority O
of O
diet O
versus O
dialysis O
in O
1-year O
mortality O
assessed O
by O
using O
intention-to-treat O
and O
per-protocol O
analysis O
. O
[]

Comparison O
of O
the O
relative O
efficacy O
of O
formoterol O
and O
salmeterol O
in O
asthmatic O
patients O
. O
[]

Doses O
of O
20 O
mg O
, O
and O
in O
some O
cases O
30 O
mg O
, O
per O
day O
were O
compared O
with O
placebo O
over O
predetermined O
ten-day O
periods O
in O
a O
double-blind O
cross-over O
study O
. O
[]

BACKGROUND O
Non-pharmacological O
treatment O
( O
NPT O
) O
is O
a O
useful O
treatment O
option O
in O
the O
management O
of O
hip B-outcome ['Physiological-Clinical']
or O
knee B-outcome ['Physiological-Clinical']
osteoarthritis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
intraobserver O
variability O
was O
25 O
% O
. O
[]

Ascorbic O
acid O
and O
performance B-outcome ['Physiological-Clinical']
in O
man O
. O
['Physiological-Clinical']

CONTEXT O
Hyperactivity O
and O
inattention O
are O
common O
symptoms O
in O
children O
with O
autistic O
disorder O
and O
related O
pervasive O
developmental O
disorders O
, O
but O
studies O
of O
stimulants O
in O
these O
conditions O
have O
been O
inconclusive O
. O
[]

RESULTS O
After O
treatment O
, O
the O
pain B-outcome ['Physiological-Clinical']
and O
the O
lumbar B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
range I-outcome ['Physiological-Clinical']
were O
significantly O
improved O
in O
the O
two O
groups O
; O
and O
after O
treatment O
, O
the O
VAS O
score O
and O
the O
lumbar B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
range I-outcome ['Physiological-Clinical']
were O
( O
1.60 O
+/- O
0.38 O
) O
points O
and O
( O
65.76 O
+/- O
15.11 O
) O
cm O
in O
the O
needle-knife O
group O
and O
( O
4.59 O
+/- O
1.09 O
) O
points O
and O
( O
53.74 O
+/- O
15.13 O
) O
cm O
in O
the O
physiotherapy O
group O
, O
respectively O
, O
the O
needle-knife O
group O
being O
significantly O
better O
than O
the O
physiotherapy O
group O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

INTERVENTION O
The O
subjects O
were O
placed O
in O
one O
of O
two O
groups O
, O
initially O
by O
flipping O
a O
coin O
then O
into O
alternate O
groups O
. O
[]

The O
results O
showed O
that O
, O
compared O
to O
controls O
, O
the O
treated O
children O
with O
ASD O
improved O
in O
their O
conceptual O
ToM O
skills O
, O
but O
their O
elementary O
understanding O
, O
self O
reported O
empathic O
skills O
or O
parent O
reported O
social O
behaviour O
did O
not O
improve O
. O
[]

Oxytocin B-outcome ['Resource-use']
augmentation I-outcome ['Resource-use']
of O
labor B-outcome ['Physiological-Clinical']
was O
used O
in O
50 O
( O
50.5 O
% O
) O
misoprostol-treated O
patients O
and O
43 O
( O
43.5 O
% O
) O
dinoprostone-treated O
patients O
( O
relative O
risk O
1.14 O
, O
95 O
% O
confidence O
interval O
0.86 O
to O
1.51 O
, O
p O
= O
0.35 O
) O
. O
['Resource-use', 'Physiological-Clinical']

The O
gpELISA O
geometric O
mean O
titers O
( O
GMTs O
) O
in O
the O
ZV O
group O
were O
higher O
than O
in O
the O
placebo O
group O
at O
6 O
weeks O
after O
each O
dose O
. O
[]

OBJECTIVE O
We O
determined O
the O
effect O
of O
increased O
carbohydrate O
and O
fiber O
intakes O
on O
serum B-outcome ['Physiological-Clinical']
short-chain I-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SCFAs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
the O
relation O
between O
changes O
in O
serum B-outcome ['Physiological-Clinical']
acetate I-outcome ['Physiological-Clinical']
and O
changes O
in O
blood B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
The O
two O
groups O
were O
demographically O
comparable O
. O
[]

Median O
survival B-outcome ['Mortality']
was O
22.8 O
and O
8.5 O
months O
after O
initiation O
of O
second-line O
treatment O
for O
the O
platinum-containing O
and O
platinum-free O
regimens O
, O
respectively O
. O
['Mortality']

Continuous O
clodronate O
treatment O
resulted O
in O
a O
clear O
fall O
in O
biochemical O
indices O
of O
bone B-outcome ['Physiological-Clinical']
resorption I-outcome ['Physiological-Clinical']
, O
together O
with O
a O
consequent O
decrease O
in O
osteocalcin O
at O
6 O
( O
P O
< O
.02 O
) O
and O
12 O
months O
( O
P O
< O
.003 O
) O
and O
a O
significant O
increase O
in O
parathyroid B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
after O
12 O
months O
( O
P O
< O
.001 O
) O
of O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
quality-of-life B-outcome ['Life-Impact']
questionnaire O
score O
improved O
only O
in O
the O
intervention O
group O
( O
P O
< O
0.003 O
) O
. O
['Life-Impact']

QYJDR O
was O
given O
to O
patients O
in O
the O
test O
group O
after O
laparoscopic O
surgery O
, O
lasting O
for O
twelve O
months O
. O
[]

In O
contrast O
, O
the O
number O
of O
wet B-outcome ['Physiological-Clinical']
nights I-outcome ['Physiological-Clinical']
and O
urodynamic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
in O
group O
2 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
nine O
of O
the O
transplant O
recipients O
, O
absolute B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
was O
determined O
by O
comparing O
GCV B-outcome ['Physiological-Clinical']
levels O
after O
single O
oral O
and O
intravenous O
doses O
of O
GCV O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Specific O
allergen B-outcome ['Physiological-Clinical']
sensitization I-outcome ['Physiological-Clinical']
as O
represented O
by O
detectable O
['Physiological-Clinical']

In O
the O
multivariate O
analysis O
, O
four O
of O
six O
prognostic O
factors O
correlated O
with O
the O
prognosis O
of O
the O
264 O
patients O
who O
underwent O
curative O
surgery O
, O
that O
is O
, O
nodal B-outcome ['Physiological-Clinical']
involvement I-outcome ['Physiological-Clinical']
( O
chi O
2 O
= O
21.426 O
, O
P O
= O
less O
than O
0.0001 O
) O
, O
age O
distribution O
( O
chi O
2 O
= O
9.262 O
, O
P O
= O
0.010 O
) O
, O
sizofiran B-outcome ['Resource-use']
administration I-outcome ['Resource-use']
( O
chi O
2 O
= O
6.507 O
, O
P O
= O
0.011 O
) O
, O
and O
primary B-outcome ['Physiological-Clinical']
tumour I-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
( O
chi O
2 O
= O
9.345 O
, O
P O
= O
0.025 O
) O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

We O
tested O
the O
hypothesis O
that O
clonidine O
produces O
a O
dose-dependent O
increase O
in O
the O
sweating B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
but O
does O
not O
reduce O
the O
gain O
of O
sweating O
. O
['Physiological-Clinical']

RESULTS O
Femoral B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
osteoporosis I-outcome ['Physiological-Clinical']
was O
present O
in O
22 O
% O
SS O
, O
17 O
% O
SO O
, O
12 O
% O
NL O
, O
and O
7 O
% O
OO O
. O
['Physiological-Clinical']

In O
all O
patients O
values O
of O
C O
reactive O
protein O
( O
CRP O
) O
in O
the O
blood O
were O
examined O
, O
and O
later O
on O
every O
third O
day O
after O
the O
operation O
. O
[]

Postoperative O
response O
to O
treatment O
, O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
( O
ALT B-outcome ['Physiological-Clinical']
) O
, O
AFP B-outcome ['Physiological-Clinical']
, O
imaging B-outcome ['Resource-use']
examination I-outcome ['Resource-use']
of I-outcome ['Resource-use']
the I-outcome ['Resource-use']
tumor I-outcome ['Resource-use']
, O
patient O
's O
survival B-outcome ['Mortality']
were O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Mortality']

DESIGN O
A O
simulation O
design O
was O
implemented O
, O
based O
on O
an O
analogue O
design O
in O
which O
normal O
participants O
were O
given O
experimental O
instructions O
to O
feign O
a O
mental O
impairment O
and O
are O
compared O
to O
( O
a O
) O
other O
normal O
participants O
with O
instructions O
to O
perform O
honestly O
, O
and O
( O
b O
) O
a O
comparison O
group O
, O
for O
example O
, O
acquired O
brain-injured O
persons O
, O
with O
similar O
instructions O
. O
[]

There O
was O
some O
improvement O
in O
the O
prothrombin B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
in O
both O
groups O
of O
patients O
but O
not O
complete O
correction O
, O
and O
serial O
assays O
of O
clotting O
factors O
showed O
that O
although O
factor O
II B-outcome ['Physiological-Clinical']
rose O
to O
high O
levels O
during O
treatment O
, O
factors B-outcome ['Physiological-Clinical']
IX I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
X I-outcome ['Physiological-Clinical']
showed O
little O
response O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
greater O
in O
those O
receiving O
fentanyl O
during O
induction O
( O
145.6 O
+/-17.5 O
mmHg O
vs O
128.8 O
+/-18.3 O
mmHg O
; O
P O
= O
0.006 O
) O
and O
intubation O
( O
126.9 O
+/-17.1 O
vs O
110.9 O
+/-16.5 O
mmHg O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Procedural O
success O
was O
similar O
in O
both O
groups O
: O
45 O
of O
49 O
procedures O
( O
91.8 O
% O
) O
in O
the O
IBMC O
group O
, O
compared O
with O
46 O
of O
51 O
procedures O
( O
90.18 O
% O
) O
in O
the O
PMMC O
group O
( O
P O
= O
1.0 O
) O
. O
[]

This O
higher B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
was O
a O
result O
of O
shorter O
post-R3 B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
in O
the O
G-CSF O
group O
, O
whereas O
the O
post-COPADM O
intervals O
were O
not O
statistically O
reduced O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Our O
study O
investigated O
the O
effect O
of O
exposure O
to O
whole-body O
mild-cold O
on O
measures O
of O
arterial B-outcome ['Physiological-Clinical']
stiffness I-outcome ['Physiological-Clinical']
( O
aortic B-outcome ['Physiological-Clinical']
and O
brachial B-outcome ['Physiological-Clinical']
PWV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
on O
central B-outcome ['Physiological-Clinical']
haemodynamics I-outcome ['Physiological-Clinical']
[ O
including O
augmented O
pressure B-outcome ['Physiological-Clinical']
( O
AP B-outcome ['Physiological-Clinical']
) O
, O
AIx O
] O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Parents O
' O
checklist O
ratings O
( O
ABC O
) O
as O
well O
as O
clinicians O
' O
ratings O
( O
CGI O
) O
pointed O
to O
significant O
improvements O
after O
the O
course O
of O
treatment O
; O
improvements O
were O
clearest O
on O
the O
ABC O
social B-outcome ['Life-Impact']
withdrawal I-outcome ['Life-Impact']
subscale O
. O
['Life-Impact']

The O
school O
has O
been O
identified O
as O
a O
key O
setting O
to O
promote O
physical O
activity O
. O
[]

The O
diclofenac O
group O
also O
received O
diclofenac O
( O
1 O
% O
) O
preoperatively O
. O
[]

Beta-sitosterol O
Study O
Group O
. O
[]

To O
measure O
global O
functioning O
in O
treatment O
studies O
, O
the O
Children O
's O
Global O
Assessment O
Scale O
was O
modified O
and O
psychometric O
properties O
of O
the O
revised O
version O
( O
DD-CGAS O
) O
were O
assessed O
in O
children O
with O
PDD O
. O
[]

RESULTS O
There O
were O
no O
significant O
differences O
among O
groups O
regarding O
baseline O
demographic O
properties O
and O
nephropathy O
risk O
factors O
. O
[]

Teeth O
were O
submitted O
to O
thermal O
cycling O
and O
immersed O
in O
50 O
% O
silver O
nitrate O
solutions O
for O
8 O
h O
in O
total O
darkness O
. O
[]

OBJECTIVE O
Gastric O
carcinoma O
can O
be O
divided O
into O
two O
main O
histological O
and O
clinical O
types O
: O
diffuse O
and O
intestinal O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
demonstrate O
the O
interest O
of O
using O
tumor-infiltrating O
lymphocytes O
( O
TIL O
) O
as O
adjuvant O
therapy O
for O
stage O
III O
( O
regional O
lymph O
nodes O
) O
melanoma O
. O
[]

DESIGN O
A O
60-day O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
with O
a O
60-day O
no O
treatment O
follow-up O
. O
[]

RESULTS O
At O
week O
54 O
, O
patients O
who O
did O
not O
show O
20 O
% O
improvement O
by O
American O
College O
of O
Rheumatology B-outcome ['Physiological-Clinical']
criteria O
( O
ACR20 O
nonresponders O
) O
while O
receiving O
infliximab O
plus O
MTX O
exhibited O
mild O
but O
statistically O
significant O
improvement O
in O
clinical O
variables O
, O
including O
the O
28-joint B-outcome ['Physiological-Clinical']
Disease I-outcome ['Physiological-Clinical']
Activity I-outcome ['Physiological-Clinical']
Score O
( O
DAS28 O
) O
( O
P O
< O
0.001 O
) O
, O
tender B-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( O
P O
= O
0.014 O
) O
, O
swollen B-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
, O
and O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( B-outcome ['Physiological-Clinical']
CRP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
level O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Peritoneovenous O
shunting O
as O
compared O
with O
medical O
treatment O
in O
patients O
with O
alcoholic O
cirrhosis O
and O
massive O
ascites O
. O
[]

UNLABELLED O
D-myo-inositol-1,2,6-trisphosphate O
( O
1,2,6-IP3 O
) O
possesses O
antiinflammatory O
properties O
, O
such O
as O
reduced O
eicosanoid O
synthesis O
and O
inhibition O
of O
inflammation-induced O
edema O
. O
[]

The O
patients O
were O
allocated O
to O
one O
of O
the O
two O
groups O
randomly O
and O
followed O
for O
24-36 O
months O
( O
average O
: O
30 O
months O
) O
. O
[]

Dogs O
( O
n O
= O
24 O
and O
22 O
in O
the O
sDAP O
and O
sham O
treatment O
exposure O
groups O
, O
respectively O
) O
were O
placed O
in O
treated O
cages O
for O
30 O
minutes O
before O
and O
after O
surgery O
. O
[]

The O
additive O
analgesic O
efficacy O
of O
acetaminophen O
, O
1000 O
mg O
, O
and O
codeine O
, O
60 O
mg O
, O
in O
dental O
pain O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Primary O
efficacy O
endpoints O
were O
intra-individual O
differences O
( O
test-reference O
) O
in O
mean O
Hb O
levels O
and O
mean O
weekly O
dose/kg O
of O
body O
weight O
. O
[]

The O
primary O
outcome O
of O
the O
study O
was O
the O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
the O
caudal B-outcome ['Physiological-Clinical']
block O
during O
the O
operation B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

After O
successful O
balloon O
angioplasty O
, O
patients O
were O
randomised O
to O
stenting O
or O
no O
further O
treatment O
. O
[]

The O
standard O
error O
of O
estimate O
ranged O
from O
6.44 O
to O
9.57 O
. O
[]

The O
specificity O
of O
bupropion O
SR O
effects O
was O
also O
tested O
in O
exploratory O
analyses O
. O
[]

However O
, O
it O
is O
not O
known O
whether O
oral O
CoQ O
( O
10 O
) O
supplementation O
may O
improve O
cardiocirculatory B-outcome ['Physiological-Clinical']
efficiency O
and O
endothelial O
function B-outcome ['Life-Impact']
in O
patients O
with O
CHF O
. O
['Physiological-Clinical', 'Life-Impact']

In O
addition O
, O
this O
analysis O
strongly O
suggests O
that O
low O
peripheral O
blood O
levels O
of O
CD19+ O
cells O
are O
an O
adverse O
prognostic O
sign O
in O
myeloma O
. O
[]

Two O
patients O
in O
group O
R O
and O
15 O
patients O
in O
group O
LE O
developed O
hypertension B-outcome ['Physiological-Clinical']
( O
odds O
ratio O
[ O
OR O
] O
: O
0.064 O
) O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
We O
demonstrated O
that O
intermittent O
pneumatic O
compression O
has O
a O
limited O
clinical O
role O
in O
the O
treatment O
of O
postmastectomy O
lymphedema O
. O
[]

METHODS O
Eye-tracking O
methodology O
was O
used O
to O
explore O
fixation B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
and O
time B-outcome ['Life-Impact']
taken I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
fixate I-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
Eye I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
Mouth I-outcome ['Life-Impact']
regions I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
familiar I-outcome ['Life-Impact']
, O
unfamiliar O
and O
Self O
Faces O
. O
['Life-Impact', 'Life-Impact']

Study O
measures O
were O
similar O
to O
previous O
Research O
Units O
on O
Pediatric O
Psychopharmacology O
trials O
. O
[]

METHODS O
A O
randomized O
study O
was O
performed O
on O
40 O
patients O
with O
hypertension O
. O
[]

More O
patients O
who O
received O
alvimopan O
achieved O
GI-2 B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
before I-outcome ['Physiological-Clinical']
POD I-outcome ['Physiological-Clinical']
5 I-outcome ['Physiological-Clinical']
( O
alvimopan O
, O
80 O
% O
; O
placebo O
, O
66 O
% O
) O
and O
DCO O
written O
before O
POD O
7 O
( O
alvimopan O
, O
87 O
% O
; O
placebo O
, O
72 O
% O
) O
, O
with O
corresponding O
NNTs O
equal O
to O
7 O
. O
['Physiological-Clinical']

Aspiration O
of O
2 O
ml O
of O
the O
patient O
's O
blood O
into O
a O
syringe O
of O
propofol O
immediately O
before O
injection O
was O
compared O
with O
the O
addition O
of O
lignocaine O
20 O
mg O
or O
normal O
saline O
2 O
ml O
to O
the O
propofol O
before O
injection O
. O
[]

No O
significant O
differences O
in O
serum O
levels O
of O
PSA O
, O
testosterone O
, O
dihydrotestosterone O
, O
luteinizing O
hormone O
or O
sex O
hormone O
binding O
globulin O
( O
p O
> O
0.2 O
) O
were O
observed O
between O
the O
intervention O
and O
control O
group O
. O
[]

The O
statistical O
analysis O
( O
depending O
on O
the O
emetogenicity O
of O
the O
chemotherapy O
cycles O
) O
showed O
increased O
efficacy O
of O
granisetron O
in O
highly O
( O
grade O
3 O
) O
emetogenic O
chemotherapy O
cycles O
( O
p O
= O
0.002 O
) O
, O
whereas O
there O
was O
no O
difference O
in O
the O
very O
highly O
emetogenic O
cycles O
( O
p O
= O
0.7 O
) O
. O
[]

Quantifications O
of O
the O
major O
urinary B-outcome ['Physiological-Clinical']
metabolite I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
E I-outcome ['Physiological-Clinical']
prostaglandins I-outcome ['Physiological-Clinical']
by O
mass O
spectrometry O
: O
evaluation O
of O
the O
method O
's O
application O
to O
clinical O
studies O
. O
['Physiological-Clinical']

Neutral O
sphingomyelinase O
activity O
was O
also O
quantified O
in O
both O
arms O
before O
and O
after O
treatment O
. O
[]

The O
study O
was O
designed O
to O
compare O
the O
rate O
and O
extent O
of O
absorption B-outcome ['Physiological-Clinical']
of O
a O
fixed O
dose O
combination O
tablet O
of O
lamivudine O
( O
CAS O
134678-17-4 O
) O
and O
stavudine O
( O
CAS O
3056-17-5 O
) O
with O
the O
concurrent O
administration O
of O
lamivudine O
tablet O
and O
stavudine O
capsule O
in O
24 O
healthy O
volunteers O
under O
fasting O
conditions O
. O
['Physiological-Clinical']

RESULTS O
Of O
201 O
patients O
undergoing O
tap O
or O
biopsy O
, O
70 O
( O
35 O
% O
) O
had O
needle O
tap O
, O
127 O
( O
63 O
% O
) O
had O
mechanized O
biopsy O
, O
and O
4 O
( O
2 O
% O
) O
had O
initial O
needle O
tap O
that O
was O
aborted O
to O
mechanized O
biopsy O
( O
abort O
eyes O
) O
. O
[]

A O
consensus O
view O
has O
emerged O
favoring O
an O
anticancer O
effect O
of O
long-term O
aspirin O
use O
. O
[]

The O
results O
reveal O
variability O
in O
the O
prolactin B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
the O
artificial O
pumping O
methods O
, O
with O
the O
greatest O
responses O
found O
with O
an O
electric O
pulsatile O
pump O
; O
these O
responses O
compare O
favorably O
with O
those O
of O
natural O
infant O
suckling O
. O
['Physiological-Clinical']

Pretreatment O
with O
thiopental O
for O
prevention O
of O
pain B-outcome ['Physiological-Clinical']
associated I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
propofol I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
describe O
immunologic O
findings O
from O
a O
clinical O
study O
designed O
to O
investigate O
the O
safety O
of O
iatrogenic O
hookworm O
infection O
in O
participants O
with O
allergic O
rhinitis O
. O
[]

This O
reduction O
in O
glucose B-outcome ['Physiological-Clinical']
excursion I-outcome ['Physiological-Clinical']
occurs O
despite O
reduction O
in O
insulin O
dose O
. O
['Physiological-Clinical']

Experimental O
patients O
received O
a O
20-minute O
individualized O
education O
and O
coaching O
session O
to O
increase O
knowledge O
of O
pain O
self-management O
, O
to O
redress O
personal O
misconceptions O
about O
pain O
treatment O
, O
and O
to O
rehearse O
an O
individually O
scripted O
patient-physician O
dialog O
about O
pain B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Twenty-four O
hour O
urinary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
increased O
in O
both O
groups O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

METHODS/DESIGN O
The O
study O
is O
conducted O
as O
a O
randomized O
controlled O
trial O
. O
[]

We O
aimed O
to O
investigate O
the O
effects O
of O
low O
doses O
of O
haloperidol O
, O
risperidone O
and O
olanzapine O
on O
cortical B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Use O
of O
metformin O
increases O
the O
response O
of O
ovulation-inducing O
agents O
and O
can O
be O
used O
safely O
in O
PCOS O
. O
[]

METHODS O
Patients O
were O
randomized O
to O
receive O
either O
weekly O
docetaxel O
40 O
mg/m O
( O
2 O
) O
( O
group O
A O
, O
n O
= O
34 O
) O
or O
the O
combination O
of O
weekly O
docetaxel O
35 O
mg/m O
( O
2 O
) O
with O
gemcitabine O
600 O
mg/m O
( O
2 O
) O
( O
group O
B O
, O
n O
= O
41 O
) O
. O
[]

METHODS O
This O
was O
a O
randomized O
multicenter O
, O
double-blind O
, O
placebo-controlled O
trial O
in O
subjects O
with O
bilateral O
moderate O
to O
severe O
acne O
scarring O
; O
subjects O
served O
as O
their O
own O
controls O
. O
[]

Wound B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
developed O
in O
two O
( O
4.5 O
% O
) O
of O
44 O
patients O
receiving O
aztreonam O
and O
in O
seven O
( O
19.4 O
% O
) O
of O
36 O
patients O
treated O
with O
gentamicin O
. O
['Physiological-Clinical']

Central O
venous O
catheter O
was O
viewed O
as O
important O
because O
it O
was O
the O
main O
port O
of O
treatment O
toward O
a O
cure O
, O
although O
patients O
constantly O
fear O
complications O
. O
[]

Olanzapine O
may O
be O
a O
promising O
treatment O
for O
improving O
global B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Response O
rate O
was O
81 O
% O
( O
95 O
% O
CI O
, O
76 O
% O
to O
86 O
% O
; O
CR B-outcome ['Physiological-Clinical']
, O
22 O
% O
; O
PR O
, O
59 O
% O
) O
. O
['Physiological-Clinical']

AIM O
To O
follow-up O
, O
one O
year O
later O
, O
a O
double-blind O
, O
randomised O
study O
, O
which O
investigated O
the O
effect O
of O
regular O
brushing O
with O
dentifrices O
on O
the O
oral O
health O
of O
an O
economically O
disadvantaged O
rural O
population O
in O
Andhra O
Pradesh O
, O
India O
who O
were O
primarily O
users O
of O
traditional O
materials O
. O
[]

The O
addition O
of O
ezetimibe O
to O
simvastatin O
over O
a O
4-week O
period O
was O
associated O
with O
reduced O
expression O
of O
CD141 O
( O
thrombomodulin O
; O
p O
= O
0.02 O
) O
, O
platelet O
endothelial O
cell O
adhesion O
molecule O
( O
p O
< O
0.0001 O
) O
and O
CD51/61 O
( O
vitronectin O
receptor O
; O
p O
= O
0.048 O
) O
compared O
to O
statin O
monotherapy O
. O
[]

In O
HIV-seronegative O
children O
, O
diarrhoea B-outcome ['Physiological-Clinical']
resolved O
in O
14 O
( O
56 O
% O
) O
of O
25 O
receiving O
nitazoxanide O
and O
5 O
( O
23 O
% O
) O
of O
22 O
receiving O
placebo O
( O
difference O
33 O
% O
, O
95 O
% O
CI O
7-59 O
; O
p=0.037 O
) O
. O
['Physiological-Clinical']

This O
question O
was O
addressed O
before O
using O
the O
composite O
paradigm O
( O
Teunisse O
, O
J. O
P. O
, O
& O
de O
Gelder O
, O
B O
. O
( O
[]

In O
group O
I O
, O
all O
thrombi O
were O
mobile O
and O
5-13 O
mm O
in O
diameter O
; O
in O
group O
II O
, O
all O
thrombi O
but O
three O
were O
mobile O
and O
3-18 O
mm O
in O
diameter O
. O
[]

There O
was O
a O
significant O
group O
difference O
on O
improvement O
in O
repetitive B-outcome ['Life-Impact']
behaviours I-outcome ['Life-Impact']
as O
measured O
by O
the O
Children O
's O
Yale-Brown O
Obsessive O
Compulsive O
Scale O
( O
C-YBOCS O
) O
( O
p=0.037 O
) O
and O
a O
large O
effect O
size O
( O
d=1.616 O
) O
. O
['Life-Impact']

Incidences O
of O
hypercalcemia B-outcome ['Physiological-Clinical']
, O
hyperphosphatemia B-outcome ['Physiological-Clinical']
, O
and O
elevated B-outcome ['Physiological-Clinical']
calcium-phosphorus I-outcome ['Physiological-Clinical']
product I-outcome ['Physiological-Clinical']
levels O
were O
not O
significantly O
different O
between O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Substantial O
safety O
benefits O
were O
observed O
in O
patients O
treated O
with O
UFT/LV O
. O
[]

BACKGROUND O
Limited O
data O
suggest O
that O
low O
levels O
of O
serum O
high-density O
lipoprotein O
cholesterol O
( O
HDL-C O
) O
and O
high O
levels O
of O
triglyceride-rich O
lipoproteins O
may O
be O
associated O
with O
more O
rapid O
rates O
of O
kidney O
function O
loss O
in O
individuals O
with O
chronic O
renal O
insufficiency O
( O
CRI O
) O
. O
[]

The O
pelvic B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
rate O
in O
the O
two O
groups O
was O
significantly O
reduced O
by O
concurrent O
cisplatin O
( O
P O
= O
.038 O
, O
log-rank O
test O
) O
and O
this O
effect O
was O
preserved O
in O
a O
stepwise O
Cox O
regression O
model O
of O
prognostic O
factors O
( O
hazards O
ratio O
, O
0.50 O
; O
90 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.29 O
to O
0.86 O
; O
P O
= O
.036 O
) O
. O
['Physiological-Clinical']

Data O
were O
collected O
at O
baseline O
and O
12 O
months O
post-intervention O
. O
[]

Face O
composite O
effects O
reveal O
abnormal O
face O
processing O
in O
Autism O
spectrum O
disorders O
. O
[]

The O
glucose B-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Resource-use']
area O
under O
the O
curve O
after O
the O
diabetes O
specific O
formula O
compared O
to O
the O
standard O
formula O
were O
significantly O
lower O
. O
['Physiological-Clinical', 'Resource-use']

The O
effect O
of O
antisecretory O
treatment O
on O
extraesophageal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
gastroesophageal I-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
was O
evaluated O
. O
['Physiological-Clinical']

The O
PME O
leuprolide O
group O
, O
who O
had O
dysphoric B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
throughout O
the O
cycle O
, O
did O
not O
improve O
. O
['Life-Impact']

The O
long-term O
effects O
of O
FZ O
are O
still O
not O
clear O
. O
[]

Secondary O
measures O
included O
assessments O
of O
cocaine B-outcome ['Life-Impact']
craving I-outcome ['Life-Impact']
and O
psychiatric B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

We O
hypothesized O
that O
participants O
randomized O
to O
an O
intervention O
condition O
would O
report O
improvements O
in O
relaxation B-outcome ['Life-Impact']
, O
awareness B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
tension I-outcome ['Life-Impact']
, O
getting B-outcome ['Life-Impact']
needs I-outcome ['Life-Impact']
met I-outcome ['Life-Impact']
and O
coping B-outcome ['Life-Impact']
confidence I-outcome ['Life-Impact']
compared O
with O
those O
receiving O
UCO O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Patients O
in O
the O
high O
haloperidol O
plasma O
range O
tended O
to O
have O
more O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

Blood O
samples O
were O
collected O
up O
to O
24 O
h O
after O
administration O
of O
the O
first O
dose O
, O
and O
the O
concentration O
of O
AmB B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
was O
analyzed O
by O
a O
high-performance O
liquid O
chromatography O
assay O
. O
['Physiological-Clinical']

The O
study O
was O
carried O
out O
to O
evaluate O
the O
effect O
of O
prophylactic O
single-dose O
intravenous O
amiodarone O
in O
patients O
undergoing O
valve O
replacement O
surgery O
. O
[]

By O
the O
end O
of O
April O
1999 O
there O
were O
65 O
new O
cases O
of O
diabetes O
, O
34 O
drop-outs O
and O
one O
death B-outcome ['Mortality']
. O
['Mortality']

The O
percentage O
of O
cancers B-outcome ['Physiological-Clinical']
with O
negative O
margins B-outcome ['Physiological-Clinical']
was O
statistically O
significantly O
greater O
in O
patients O
treated O
with O
neoadjuvant O
therapy O
than O
those O
treated O
with O
immediate O
surgery O
alone O
( O
69 O
% O
vs. O
42 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
two O
deaths O
that O
occurred O
were O
in O
the O
comparator O
group O
. O
[]

Peripheral O
nerves O
in O
younger O
patients O
seems O
more O
vulnerable O
. O
[]

CONCLUSION O
BBTW O
can O
have O
immediate O
advantages O
over O
a O
nonweighted O
condition O
for O
gait B-outcome ['Life-Impact']
velocity I-outcome ['Life-Impact']
and O
over O
a O
standardized O
weighted O
condition O
for O
a O
functional B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
in O
people O
with O
multiple O
sclerosis O
( O
MS O
) O
who O
are O
ambulatory O
but O
have O
balance O
and O
mobility O
abnormalities O
. O
['Life-Impact', 'Life-Impact']

CONCLUSIONS O
In O
pericardial O
blood O
of O
patients O
undergoing O
cardiac O
surgery O
with O
CPB O
, O
microparticles O
contribute O
to O
activation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
complement I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
via O
bound O
SAP O
and O
IgM O
. O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
differences O
between O
groups O
in O
age O
; O
sex O
distribution O
; O
refraction B-outcome ['Physiological-Clinical']
; O
blood B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
; O
baseline O
IOP B-outcome ['Physiological-Clinical']
; O
MD O
, O
CPSD B-outcome ['Physiological-Clinical']
, O
or O
TD O
at O
each O
point O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
role O
of O
oximes O
for O
the O
treatment O
of O
organophosphorus O
pesticide O
poisoning O
has O
not O
been O
conclusively O
established O
. O
[]

Enteral O
nutrition O
with O
eicosapentaenoic O
acid O
, O
gamma-linolenic O
acid O
, O
and O
antioxidants O
reduces O
alveolar O
inflammatory O
mediators O
and O
protein O
influx O
in O
patients O
with O
acute O
respiratory O
distress O
syndrome O
. O
[]

We O
compared O
the O
incidence O
and O
frequency O
of O
hypotension B-outcome ['Physiological-Clinical']
and O
vasopressor B-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
after O
spinal O
anesthesia O
and O
no O
prehydration O
with O
crystalloid O
and O
colloid O
prehydration O
in O
elderly O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PARTICIPANTS O
Participants O
( O
N=20 O
) O
who O
were O
community-living O
older O
adults O
at O
least O
65 O
years O
old O
( O
mean O
age O
, O
70y O
) O
, O
50 O
% O
women O
, O
and O
who O
had O
no O
experience O
of O
using O
a O
wheelchair O
were O
randomly O
allocated O
to O
an O
intervention O
( O
n=10 O
) O
or O
control O
( O
n=10 O
) O
group O
. O
[]

Most O
patients O
preferred O
Polym O
to O
Plc O
when O
they O
were O
asked O
. O
[]

The O
additive O
or O
synergistic O
effects O
of O
perindopril O
and O
hydrochlorothiazide O
on O
blood O
pressure O
must O
be O
due O
to O
their O
complementary O
physiological O
actions O
and O
not O
to O
a O
pharmacokinetic O
interaction O
. O
[]

Evaluation O
of O
umbilical O
cord O
serum O
therapy O
for O
persistent O
corneal O
epithelial O
defects O
. O
[]

Colorectal O
carcinoma O
is O
one O
of O
the O
most O
common O
malignancies O
in O
the O
world O
, O
and O
its O
incidence O
has O
increased O
in O
recent O
years O
. O
[]

The O
study O
will O
run O
for O
a O
total O
of O
about O
3 O
years O
. O
[]

We O
randomly O
recruited O
304 O
women O
from O
the O
Samliem O
inner-city O
community O
, O
Khon O
Kaen O
, O
Northeast O
Thailand O
, O
and O
assigned O
participants O
to O
either O
the O
intervention O
or O
control O
zone O
. O
[]

RESULTS O
TB1 O
( O
containing O
ginseng O
leaf O
, O
cistanche O
, O
fleeceflower O
root O
, O
immature O
bitter O
orange O
, O
rhubarb O
, O
etc O
) O
could O
improve O
various O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
aging I-outcome ['Physiological-Clinical']
, O
and O
had O
the O
effect O
in O
regulating B-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
and O
endocrinal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
scavenging B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
radicals I-outcome ['Physiological-Clinical']
and O
adjusting B-outcome ['Physiological-Clinical']
coli I-outcome ['Physiological-Clinical']
flora I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

4 O
. O
[]

Injections O
of O
rtPA O
were O
then O
given O
through O
hematoma O
catheter O
every O
8 O
h O
, O
up O
to O
9 O
doses O
, O
or O
until O
a O
clot-reduction O
endpoint O
. O
[]

A O
randomised O
controlled O
trial O
of O
bumetanide O
in O
the O
treatment O
of O
autism O
in O
children O
. O
[]

METHODS O
Participants O
were O
236 O
heavy O
drinking O
smokers O
in O
a O
randomized O
clinical O
trial O
testing O
the O
efficacy O
of O
incorporating O
brief O
alcohol O
intervention O
into O
smoking O
cessation O
treatment O
. O
[]

The O
TG O
starting O
dose O
was O
reduced O
from O
60 O
to O
50 O
mg/m O
( O
2 O
) O
per O
day O
after O
recognition O
of O
hepatic B-outcome ['Physiological-Clinical']
veno-occlusive I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VOD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
allergen O
and O
concentration O
that O
consistently O
elicited O
a O
positive O
allergic O
reaction O
was O
used O
for O
challenge O
. O
[]

In O
the O
symptomatic O
treatment O
of O
thyrotoxicosis B-outcome ['Physiological-Clinical']
, O
nadolol O
, O
a O
once-daily O
nonmetabolized O
beta O
blocker O
, O
has O
certain O
advantages O
compared O
with O
propranolol O
. O
['Physiological-Clinical']

Small O
choroidal O
melanomas O
were O
defined O
as O
1.0 O
to O
3.0 O
mm O
in O
apical O
height O
and O
at O
least O
5.0 O
mm O
in O
basal O
diameter O
. O
[]

STUDY O
OBJECTIVE O
To O
evaluate O
the O
effect O
of O
a O
potent O
experimental O
leukotriene O
receptor O
antagonist O
, O
MK-571 O
, O
on O
airway O
responses O
to O
inhaled O
allergen O
. O
[]

We O
showed O
that O
prospective O
design O
path O
analysis O
using O
structural O
equation O
modeling O
( O
SEM O
) O
model O
for O
both O
direct O
and O
indirect O
effects O
enabled O
statistical O
exploration O
of O
root O
causes O
and O
estimation O
of O
their O
impact O
on O
the O
outcome O
. O
[]

The O
peak O
dispersion O
created O
a O
false O
impression O
of O
flattened O
curves O
or O
sustained O
hypersecretion O
in O
uremia O
. O
( O
[]

On O
the O
final O
day O
of O
each O
period O
, O
hyperinsulinemic O
( O
360 O
pmol O
x O
m O
( O
-2 O
) O
x O
min O
( O
-1 O
) O
) O
hypoglycemic O
( O
5.0 O
, O
3.5 O
, O
2.5 O
mmol O
x O
L O
( O
-1 O
) O
) O
glucose O
clamps O
were O
used O
to O
assess O
counterregulatory B-outcome ['Physiological-Clinical']
and O
cardiovascular B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

If O
we O
shifted O
the O
target O
blood O
pressure O
from O
below O
140/90 O
to O
below O
130/85 O
for O
drug-treated O
subjects O
under O
60 O
( O
n O
= O
278 O
) O
the O
number O
of O
inadequately B-outcome ['Life-Impact']
treated I-outcome ['Life-Impact']
subjects O
increased O
by O
34 O
( O
12.2 O
% O
of O
278 O
) O
; O
14 O
in O
the O
low-risk O
group O
, O
15 O
in O
the O
medium-risk O
group O
, O
and O
only O
five O
in O
the O
high- O
or O
very-high-risk O
groups O
. O
['Life-Impact']

With O
the O
current O
budgetary O
limitations O
in O
South O
African O
public O
hospitals O
chemotherapy O
protocols O
for O
lymphoproliferative O
disorders O
exclude O
agents O
such O
as O
rituximab O
. O
[]

What O
is O
the O
place O
of O
plasma O
exchanges O
( O
PE O
) O
in O
the O
treatment O
of O
systemic O
vasculitis O
? O
[]

The O
mean O
anti-Xa B-outcome ['Physiological-Clinical']
levels O
at O
weeks O
1 O
and O
4 O
were O
1.11 O
and O
1.03 O
anti-Xa O
units/ml O
respectively O
( O
P=0.13 O
) O
. O
['Physiological-Clinical']

METHODS O
This O
was O
a O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
in O
heparin-resistant O
patients O
undergoing O
cardiac O
surgery O
with O
cardiopulmonary O
bypass O
. O
[]

The O
majority O
of O
enrolled O
patients O
with O
persistent O
nasal O
hemorrhage O
were O
adequately O
managed O
with O
the O
hemostatic O
matrix O
alone O
and O
were O
discharged B-outcome ['Resource-use']
from I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
in O
a O
timeframe O
comparable O
to O
that O
of O
surgical O
managment O
. O
['Resource-use']

Blood O
samples O
were O
drawn O
before O
and O
every O
30 O
min O
up O
to O
180 O
min O
after O
the O
meals O
. O
[]

Children O
in O
the O
SCIP O
condition O
received O
up O
to O
20 O
sessions O
of O
direct O
intervention O
from O
a O
specialist O
research O
speech O
and O
language O
therapist O
working O
with O
supervised O
assistants O
. O
[]

Over O
twice O
as O
many O
patients O
on O
ginseng O
perceived O
a O
benefit O
and O
were O
satisfied B-outcome ['Life-Impact']
with O
treatment O
over O
those O
on O
placebo O
. O
['Life-Impact']

At O
baseline O
and O
after O
6 O
months O
' O
treatment O
, O
a O
biopsy O
was O
taken O
for O
histological O
examination O
. O
[]

Higher O
levels O
of O
emotional O
distress O
were O
positively O
associated O
with O
post-intervention O
sexual B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
drug-taking I-outcome ['Life-Impact']
risk O
. O
['Life-Impact']

To O
determine O
the O
effect O
of O
two O
levels O
of O
educational O
intervention O
on O
benzodiazepine-prescribing O
behavior O
in O
an O
elderly O
population O
in O
a O
controlled O
prepaid O
group O
practice O
( O
PPGP O
) O
setting O
, O
we O
designed O
a O
prospective O
controlled O
trial O
, O
with O
six-month O
follow-up O
. O
[]

No O
stoma O
and O
good O
anal O
function O
were O
seen O
in O
5 O
patients O
( O
11 O
% O
) O
in O
the O
CRT O
group O
and O
in O
11 O
( O
30 O
% O
) O
in O
the O
RT O
group O
( O
p O
= O
0.046 O
) O
. O
[]

In O
addition O
, O
all O
of O
the O
children O
with O
bowel O
and O
sleep O
abnormalities O
demonstrated O
improvement O
after O
treatment O
. O
[]

Treatment O
with O
ramipril O
significantly O
reduced O
the O
rates O
of O
death O
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
, O
coronary B-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
, O
cardiac B-outcome ['Physiological-Clinical']
arrest I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
, O
as O
well O
as O
the O
risk O
of O
diabetes-related B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
and O
of O
diabetes B-outcome ['Physiological-Clinical']
itself O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
little O
is O
known O
about O
the O
effect O
of O
azelnidipine O
on O
the O
AGE-RAGE B-outcome ['Physiological-Clinical']
axis I-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical']

European O
League O
Against O
Rheumatism O
good/moderate O
responses O
were O
77.2 O
% O
and O
84.4 O
% O
at O
courses O
1 O
( O
n O
= O
390 O
) O
and O
5 O
( O
n O
= O
90 O
) O
. O
[]

RESULTS O
To O
date O
, O
over O
17,000 O
participants O
have O
been O
randomized O
from O
over O
1200 O
sites O
in O
50 O
countries O
with O
an O
anticipated O
treatment O
duration O
of O
2-3 O
years O
. O
[]

Antihypertensive O
treatment O
was O
adjusted O
at O
6-week O
intervals O
according O
to O
the O
mean O
daytime B-outcome ['Physiological-Clinical']
ambulatory I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
or O
the O
mean O
home B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
, O
depending O
on O
the O
patient O
's O
randomization O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
a O
multicenter O
trial O
, O
we O
compared O
fixed-dose O
subcutaneous O
enoxaparin O
, O
given O
twice O
daily O
, O
with O
adjusted-dose O
intravenous O
unfractionated O
heparin O
( O
UFH O
) O
given O
by O
continuous O
intravenous O
infusion O
for O
the O
initial O
10 O
days O
of O
treatment O
of O
patients O
with O
proximal O
vein O
thrombosis O
. O
[]

Blood O
flow O
velocity O
tended O
to O
be O
higher O
in O
the O
MECC O
group O
, O
with O
a O
significant O
intergroup O
difference O
after O
aortic O
crossclamping O
( O
T2 O
) O
. O
[]

Pimecrolimus O
cream O
1 O
% O
vs. O
betamethasone O
17-valerate O
0.1 O
% O
cream O
in O
the O
treatment O
of O
seborrhoeic O
dermatitis O
. O
[]

Compared O
with O
ASC O
alone O
, O
we O
noted O
a O
small O
, O
non-significant O
survival B-outcome ['Mortality']
benefit O
for O
ASC O
plus O
chemotherapy O
( O
hazard O
ratio O
[ O
HR O
] O
0.89 O
[ O
95 O
% O
CI O
0.72-1.10 O
] O
; O
p=0.29 O
) O
. O
['Mortality']

OBJECTIVES O
The O
primary O
objective O
of O
this O
study O
was O
to O
determine O
whether O
drug O
administration O
instructions O
informing O
subjects O
of O
a O
placebo O
condition O
affect O
the O
drug O
response O
and O
affect O
the O
saliva B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
of O
the O
stimulant O
. O
['Physiological-Clinical']

This O
article O
describes O
a O
new O
method O
for O
( O
1 O
) O
systematically O
prioritizing O
needs O
for O
intervention O
on O
hazardous O
substance O
exposures O
in O
manufacturing O
work O
sites O
, O
and O
( O
2 O
) O
evaluating O
intervention O
effectiveness O
. O
[]

Of O
147 O
FEC O
( O
75 O
) O
infusions O
, O
4.1 O
% O
were O
delayed O
, O
while O
9.8 O
% O
of O
143 O
FEC O
( O
90 O
) O
infusions O
were O
delayed O
. O
[]

We O
used O
the O
Bubbles O
method O
to O
vary O
the O
facial O
information O
available O
on O
any O
given O
trial O
by O
revealing O
only O
small O
parts O
of O
the O
face O
, O
and O
measured O
the O
eye B-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
made O
as O
participants O
viewed O
these O
stimuli O
. O
['Physiological-Clinical']

BACKGROUND O
Neurobiological O
research O
has O
implicated O
the O
dopamine O
and O
serotonin O
systems O
in O
the O
pathogenesis O
of O
autism O
. O
[]

Primary O
efficacy O
end O
points O
were O
the O
proportion O
of O
patients O
with O
at O
least O
one O
SRE O
and O
the O
time O
to O
first O
SRE O
. O
[]

This O
randomized O
comparison O
of O
a O
combination O
of O
satraplatin O
and O
prednisone O
versus O
prednisone O
alone O
supports O
the O
antitumor O
activity O
of O
the O
combination O
. O
[]

The O
organisms O
isolated O
were O
typical O
of O
odontogenic B-outcome ['Physiological-Clinical']
bacteremias I-outcome ['Physiological-Clinical']
in O
that O
50 O
% O
of O
the O
isolates O
were O
identified O
as O
varieties O
of O
viridans O
streptococci O
. O
['Physiological-Clinical']

In O
addition O
, O
the O
AFT O
group O
showed O
fewer O
positive O
mood O
effects O
after O
amphetamine O
than O
the O
CTL O
group O
. O
( O
[]

The O
present O
findings O
seem O
to O
indicate O
that O
the O
topical O
application O
of O
BAs O
may O
represent O
a O
suitable O
treatment O
option O
for O
selected O
features O
of O
skin O
photoaging O
. O
[]

The O
occurrence O
of O
cough O
was O
recorded O
2 O
min O
after O
fentanyl O
bolus O
. O
[]

Pharmacokinetics O
of O
individual O
drugs O
were O
unaltered O
in O
any O
of O
the O
mixtures O
. O
[]

A O
comparison O
of O
a O
short O
nurse-based O
and O
a O
long O
multidisciplinary O
version O
of O
structured O
patient O
education O
in O
irritable O
bowel O
syndrome O
. O
[]

In O
logistic O
regression O
analyses O
after O
controlling O
for O
age O
, O
medication B-outcome ['Life-Impact']
taking I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
( O
OR O
1.26 O
, O
95 O
% O
CI O
1.15-1.39 O
) O
, O
living O
with O
both O
parents O
( O
OR O
1.74 O
, O
95 O
% O
CI O
1.02-2.97 O
) O
, O
sexual B-outcome ['Life-Impact']
intercourse I-outcome ['Life-Impact']
( O
OR O
0.66 O
, O
95 O
% O
CI O
0.36-1.19 O
) O
and O
speaking B-outcome ['Life-Impact']
mostly I-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
only I-outcome ['Life-Impact']
English I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
parents I-outcome ['Life-Impact']
( O
OR O
0.39 O
, O
95 O
% O
CI O
0.15-1.03 O
) O
were O
independently O
associated O
with O
completion O
of O
care O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

busulfan O
as O
pretransplant O
conditioning O
therapy O
for O
advanced O
myeloid O
leukemia O
and O
MDS O
. O
[]

RESULTS O
The O
PD O
model O
exhibited O
the O
sensitivity O
and O
specificity O
required O
to O
function O
as O
a O
bioequivalence O
surrogate O
. O
[]

A O
proof O
of O
concept O
study O
to O
evaluate O
putative O
benefits O
of O
montelukast O
in O
moderate O
persistent O
asthmatics O
. O
[]

Some O
data O
, O
such O
a O
mortality B-outcome ['Mortality']
, O
days B-outcome ['Resource-use']
spent I-outcome ['Resource-use']
in I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
, O
major B-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
and O
drug B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
, O
are O
being O
collected O
within O
the O
main O
LIPID O
trial O
. O
['Mortality', 'Resource-use', 'Physiological-Clinical', 'Life-Impact']

MEASUREMENTS O
The O
primary O
outcome O
was O
change O
in O
CG B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
from O
baseline O
to O
after O
the O
intervention O
. O
['Physiological-Clinical']

The O
CSF B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
neopterin I-outcome ['Physiological-Clinical']
decreased O
by O
63 O
% O
( O
from O
29.6 O
to O
12.9 O
nmol/l O
, O
p O
< O
0.01 O
) O
during O
zidovudine O
but O
increased O
by O
15 O
% O
( O
from O
22.6 O
to O
25.9 O
nmol/l O
, O
not O
significant O
during O
didanosine O
treatment O
. O
['Physiological-Clinical']

All O
treatments O
were O
administered O
for O
3 O
consecutive O
days O
with O
2 O
days O
of O
follow-up O
. O
[]

DESIGN/INTERVENTION O
A O
statewide O
survey O
of O
all O
primary O
care O
clinicians O
serving O
children O
addressed O
their O
self-reported O
sun B-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
advocacy I-outcome ['Life-Impact']
practices I-outcome ['Life-Impact']
. O
['Life-Impact']

We O
used O
the O
ambulatory O
24-h O
pH O
monitor O
to O
assess O
esophageal O
acid O
exposure O
in O
10 O
normal O
subjects O
and O
10 O
GER O
patients O
following O
low O
and O
high O
fat O
meals O
eaten O
in O
two O
body O
positions O
. O
[]

Of O
seven O
initial O
non-responders O
, O
five O
patients O
achieved O
a O
complete O
response O
by O
subsequent O
instillation O
, O
resulting O
in O
a O
total O
response O
rate O
of O
95 O
% O
. O
[]

RESULTS O
All O
the O
242 O
patients O
completed O
the O
treatment O
. O
[]

The O
typical O
side-effects O
of O
anti-serotonin O
drugs O
, O
especially O
sedation B-outcome ['Physiological-Clinical']
or O
dizziness B-outcome ['Physiological-Clinical']
and O
hyperorexia B-outcome ['Physiological-Clinical']
were O
hardly O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
group O
2 O
free O
cortisol O
was O
up O
to O
20-fold O
higher O
than O
under O
basal O
conditions O
and O
reached O
maximum O
values O
on O
days O
1-3 O
. O
[]

Effects O
on O
tyrosine B-outcome ['Physiological-Clinical']
and O
phenylalanine B-outcome ['Physiological-Clinical']
in O
plasma O
and O
urine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Acute O
effects O
of O
caffeine O
ingestion O
on O
signal-averaged B-outcome ['Physiological-Clinical']
electrocardiograms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Comparison O
of O
mastectomy O
with O
tamoxifen O
for O
treating O
elderly O
patients O
with O
operable O
breast O
cancer O
. O
[]

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
investigate O
etomidate O
administration O
with O
or O
without O
flumazenil O
in O
autistic O
children O
who O
underwent O
intrathecal O
transplantation O
of O
stem O
cells O
by O
lumbar O
puncture O
. O
[]

The O
therapeutic B-outcome ['Physiological-Clinical']
efficacy O
and O
cost-effectiveness O
of O
aggressive O
tocolysis O
for O
premature O
labor O
associated O
with O
premature O
rupture O
of O
the O
membranes O
. O
['Physiological-Clinical', 'Resource-use']

Body O
mass O
index O
( O
BMI O
) O
was O
calculated O
and O
the O
percentage O
of O
body O
fat O
( O
fat O
% O
) O
estimated O
using O
skinfold O
measurements O
. O
[]

Evaluation O
of O
the O
doxycycline O
intervention O
only O
revealed O
a O
borderline-significant O
reduction O
of O
circulating O
hs-CRP O
levels O
( O
-0.51 O
?g/ml O
, O
P=0.05 O
) O
and O
did O
not O
affect O
any O
of O
the O
other O
markers O
of O
systemic O
inflammation O
and O
vascular O
function O
. O
[]

Clinical O
endpoints O
were O
tumor B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
, O
survival B-outcome ['Mortality']
and O
toxicity B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Adverse-effects']

After O
the O
treatment O
with O
allopurinol O
, O
FMD B-outcome ['Physiological-Clinical']
was O
increased O
from O
8.0 O
+/- O
0.5 O
% O
to O
11.8 O
+/- O
0.6 O
% O
( O
P O
< O
0.01 O
) O
, O
but O
there O
were O
no O
change O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

Moreover O
, O
ONTARGET O
is O
an O
example O
of O
a O
high-quality O
noninferiority O
trial O
. O
[]

RESULTS O
Although O
on O
average O
, O
all O
caregivers O
receiving O
nurse O
counseling O
indicated O
no O
improvement O
in O
psychosocial O
adjustment O
to O
their O
relative B-outcome ['Life-Impact']
's O
illness B-outcome ['Physiological-Clinical']
, O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
, O
or O
caregiver B-outcome ['Life-Impact']
burden I-outcome ['Life-Impact']
, O
they O
found O
counseling O
very O
helpful O
and O
it O
was O
effective O
for O
a O
subgroup O
of O
caregivers O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

BCL2 O
and O
LMO2 O
marker O
expression O
of O
the O
respective O
immunohistochemical O
( O
IHC O
) O
subtype O
, O
despite O
small O
sample O
size O
, O
revealed O
the O
following O
. O
[]

In O
a O
Cox O
model O
, O
the O
presence O
of O
tense O
ascites O
( O
relative O
risk O
3.4 O
, O
95 O
% O
confidence O
interval O
, O
CI O
2.5-5.9 O
) O
and O
a O
prior O
history O
of O
hemorrhage O
( O
relative O
risk O
4.4 O
, O
95 O
% O
CI O
2.6-7.5 O
) O
were O
independent O
predictors O
of O
variceal B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Between O
January O
1975 O
and O
December O
1977 O
, O
264 O
adult O
patients O
with O
acute O
non-lymphocytic O
leukaemia O
entered O
the O
Australian O
National O
Leukaemia O
Trial O
. O
[]

A O
longer O
observation O
period O
is O
needed O
to O
make O
a O
definitive O
conclusion O
about O
the O
usefulness O
of O
interferon O
maintenance O
therapy O
and O
to O
evaluate O
further O
the O
effects O
of O
the O
combined O
schedule O
of O
chlorambucil O
and O
interferon O
induction O
on O
the O
duration O
of O
remission O
. O
[]

OBJECTIVES O
The O
clinical O
efficacy O
and O
safety O
of O
imidapril O
were O
evaluated O
in O
dogs O
that O
presented O
with O
mild O
to O
severe O
congestive O
heart O
failure O
( O
New O
York O
Heart O
Association O
stage O
II O
to O
IV O
) O
by O
comparing O
the O
success O
rate O
of O
imidapril O
with O
a O
positive O
control O
by O
a O
non-inferiority O
approach O
. O
[]

The O
main O
objective O
of O
the O
study O
was O
to O
assess O
effects O
of O
long-term O
lowering O
of O
glucosylated B-outcome ['Physiological-Clinical']
hemoglobin I-outcome ['Physiological-Clinical']
( O
HbA1 O
% O
) O
on O
neurosensory O
function O
in O
insulin-dependent O
diabetes O
. O
['Physiological-Clinical']

METHODS O
Subjects O
who O
were O
undergoing O
a O
planned O
course O
of O
radiation O
therapy O
after O
breast-conserving O
surgery O
were O
randomised O
to O
treatment O
( O
using O
one O
of O
two O
topical O
agents O
) O
or O
non-treatment O
( O
control O
) O
groups O
and O
monitored O
over O
8 O
weeks O
. O
[]

central O
sensitization O
, O
may O
be O
influenced O
by O
disease O
stage O
. O
[]

Adjusted O
mean O
differences O
between O
desvenlafaxine O
and O
placebo O
were O
2.1 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.78-3.46 O
; O
P O
= O
0.002 O
) O
on O
the O
HAM-D?? O
and O
1.3 O
( O
95 O
% O
CI O
, O
-0.09 O
to O
2.76 O
; O
P O
= O
0.067 O
) O
on O
the O
SDS O
. O
[]

BACKGROUND O
We O
report O
the O
10-year O
results O
of O
the O
EORTC O
trial O
24891 O
comparing O
a O
larynx-preservation O
approach O
to O
immediate O
surgery O
in O
hypopharynx O
and O
lateral O
epilarynx O
squamous O
cell O
carcinoma O
. O
[]

100 O
patients O
were O
randomized O
. O
[]

The O
power O
of O
the O
outcome O
variables O
ranged O
from O
74 O
% O
to O
100 O
% O
and O
was O
adequate O
for O
successful O
pairing O
. O
[]

Two O
subjects O
had O
severe O
adverse O
events O
requiring O
prednisolone O
to O
cope O
with O
nocturnal O
asthma O
symptoms O
. O
[]

At O
higher O
doses O
( O
10 O
and O
100 O
ppm O
) O
, O
oxygenation B-outcome ['Physiological-Clinical']
deteriorated I-outcome ['Physiological-Clinical']
, O
and O
the O
response O
to O
inhaled O
NO O
disappeared O
in O
several O
patients O
. O
['Physiological-Clinical']

Voluntary O
motor O
performance O
was O
assessed O
using O
the O
UHDRS O
motor O
scale O
. O
[]

At O
week O
4 O
, O
the O
highest O
dose O
was O
statistically O
significantly O
more O
effective O
than O
the O
lowest O
dose O
( O
NT O
201 O
, O
P O
= O
0.019 O
; O
95 O
% O
confidence O
interval O
, O
0.195-1.370 O
; O
and O
BTXCo O
, O
P O
= O
0.002 O
; O
95 O
% O
confidence O
interval O
, O
0.309-1.167 O
) O
. O
[]

PARTICIPANTS O
Forty-nine O
volunteers O
who O
passed O
the O
initial O
assessment O
for O
recurrent O
aphthous O
stomatitis O
entered O
a O
pretrial O
phase O
in O
which O
their O
eligibility O
for O
the O
trial O
phase O
of O
the O
study O
was O
assessed O
. O
[]

OBJECTIVE O
To O
compare O
the O
efficacy O
of O
meloxicam O
and O
a O
glucosamine-chondroitin O
( O
Glu-Ch O
) O
supplement O
in O
the O
management O
of O
feline B-outcome ['Physiological-Clinical']
osteoarthritis I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
6 O
minute O
walk O
in O
idiopathic O
pulmonary O
fibrosis O
: O
longitudinal O
changes O
and O
minimum O
important O
difference O
. O
[]

In O
particular O
, O
the O
healing B-outcome ['Physiological-Clinical']
rate O
of O
smokers O
treated O
with O
sucralfate O
( O
82 O
% O
) O
was O
significantly O
greater O
than O
that O
of O
smokers O
treated O
with O
cimetidine O
( O
63 O
% O
) O
. O
['Physiological-Clinical']

Endurance O
training O
resulted O
in O
significant O
changes O
in O
arterial B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
HDL-C B-outcome ['Physiological-Clinical']
( O
49 O
+/- O
5 O
vs. O
52 O
+/- O
5 O
mg/dl O
, O
pre O
vs. O
post O
) O
and O
LDL-C B-outcome ['Physiological-Clinical']
( O
82 O
+/- O
9 O
vs. O
76 O
+/- O
9 O
mg/dl O
, O
pre O
vs. O
post O
) O
, O
but O
there O
was O
no O
net O
TG B-outcome ['Physiological-Clinical']
or O
LDL-C B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
or O
HDL-C B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
across O
the O
resting O
or O
active O
leg O
before O
or O
after O
endurance O
training O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
outcome O
of O
labetalol O
or O
hydralazine O
therapy O
during O
hypertension O
in O
pregnancy O
in O
very O
low O
birth O
weight O
infants O
. O
[]

In O
83 O
and O
79 O
patients O
, O
respectively O
, O
lisinopril O
and O
slow-release O
nifedipine O
produced O
similar O
reductions O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
systolic/diastolic O
: O
-16/-13 O
mmHg O
supine O
and O
-14/-11 O
mmHg O
standing O
after O
lisinopril O
; O
-15/-12 O
mmHg O
supine O
and O
-14/-11 O
mmHg O
standing O
nifedipine O
) O
. O
['Physiological-Clinical']

The O
patients O
were O
evaluated O
with O
use O
of O
three-dimensional O
gait B-outcome ['Life-Impact']
analysis O
and O
dynamic O
electromyograms O
at O
three O
time O
points O
: O
preoperatively O
, O
ten O
days O
postoperatively O
, O
and O
twelve O
weeks O
postoperatively O
. O
['Life-Impact']

METHODS O
Jugular B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
was O
sampled O
from O
9 O
exercise-conditioned O
horses O
on O
2 O
separate O
occasions O
, O
at O
rest O
and O
for O
24 O
h O
following O
a O
competition O
exercise O
test O
( O
CET O
) O
designed O
to O
simulate O
the O
speed O
and O
endurance O
test O
of O
3-day O
event O
. O
['Physiological-Clinical']

Absolute O
timing B-outcome ['Physiological-Clinical']
error O
on O
the O
human O
body O
motion O
task O
did O
not O
significantly O
correlate O
with O
symptom O
severity O
, O
disease O
duration O
or O
writing O
speed O
. O
['Physiological-Clinical']

Hexetidine O
( O
'Oraldene O
' O
) O
: O
a O
report O
on O
its O
antibacterial B-outcome ['Physiological-Clinical']
and O
antifungal B-outcome ['Physiological-Clinical']
properties O
on O
the O
oral O
flora O
in O
healthy O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

They O
were O
randomly O
divided O
into O
3 O
groups O
of O
20 O
cases O
each O
with O
nephrostomy O
tube O
( O
NT O
) O
and O
temporary O
ureteral O
catheter O
( O
TU O
) O
in O
group O
A O
, O
only O
TU O
in O
group O
B O
and O
only O
indwelling O
ureteral O
catheter O
( O
IU O
) O
in O
group O
C. O
Mean O
age O
of O
cases O
were O
43.2 O
( O
25-70 O
) O
, O
40.1 O
( O
25-73 O
) O
, O
and O
44 O
( O
25-70 O
) O
years O
in O
groups O
A O
, O
B O
and O
C O
, O
respectively O
( O
P O
= O
0.6 O
) O
. O
[]

CONCLUSION O
( O
S O
) O
Uterine O
distension O
with O
normal O
saline O
seems O
to O
have O
less O
adverse O
effects O
and O
is O
better O
tolerated O
by O
patients O
. O
[]

BACKGROUND O
AND O
OBJECTIVE O
Combined O
spinal-epidural O
is O
an O
alternative O
technique O
to O
epidural O
analgesia O
for O
labour O
, O
but O
its O
benefits O
are O
not O
clearly O
identified O
. O
[]

The O
serum O
and O
urine O
concentrations O
of O
theophylline O
and O
the O
metabolites O
in O
serum O
and O
urine O
were O
determined O
by O
high-performance O
liquid O
chromatography O
. O
[]

No O
influence O
on O
heart B-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
was O
noted O
. O
['Physiological-Clinical']

METHODS O
Forty O
patients O
who O
underwent O
digestive O
surgery O
were O
randomly O
received O
parenteral O
nutrition O
with O
either O
BCAA O
enriched O
( O
study O
group O
, O
n=20 O
) O
or O
routine O
amino O
acid O
( O
control O
group O
, O
n=20 O
) O
for O
seven O
consecutive O
days O
. O
[]

The O
effectiveness O
of O
epidurally O
administered O
morphine O
in O
the O
relief B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
upper O
abdominal O
surgery O
was O
assessed O
in O
a O
controlled O
study O
involving O
20 O
patients O
aged O
61 O
to O
78 O
years O
. O
['Physiological-Clinical']

Assigned O
group O
was O
the O
major O
predictor O
of O
change O
in O
calcium B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
. O
['Life-Impact']

Eighteen O
depressed O
patients O
( O
6 O
men O
, O
12 O
women O
; O
69 O
+/- O
12.8 O
years O
old O
) O
received O
ECT O
with O
and O
without O
esmolol O
pretreatment O
in O
a O
randomized O
, O
blinded O
crossover O
design O
. O
[]

The O
studies O
were O
conducted O
to O
help O
examine O
, O
understand O
and O
improve O
supervisor O
responsiveness O
to O
employee O
substance O
abuse O
. O
[]

There O
were O
no O
differences O
in O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
between O
the O
groups O
. O
['Adverse-effects']

The O
first O
group O
was O
treated O
by O
standard O
ESWL O
and O
included O
54 O
patients O
. O
[]

Additionally O
at O
6 O
week O
review O
the O
time O
to O
return O
to O
work O
was O
recorded O
and O
an O
endoanal B-outcome ['Resource-use']
ultrasound I-outcome ['Resource-use']
was O
carried O
out O
. O
['Resource-use']

SC O
patients O
more O
often O
had O
continuing O
oozing B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Arterial O
lactate O
increased O
to O
21.4?0.8 O
and O
32.7?2.3 O
mM O
during O
the O
Sal O
and O
Bicarb O
trials O
, O
respectively O
( O
P O
< O
0.05 O
) O
. O
[]

OBJECTIVE O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
parenteral O
nutrition O
on O
netilmicin O
pharmacokinetics B-outcome ['Physiological-Clinical']
in O
critically O
ill O
neonates O
during O
the O
first O
week O
of O
life O
. O
['Physiological-Clinical']

Parent O
satisfaction O
in O
a O
multi-site O
acute O
trial O
of O
risperidone O
in O
children O
with O
autism O
: O
a O
social O
validity O
study O
. O
[]

The O
irrigation O
fluid O
used O
for O
both O
groups O
was O
glycine O
. O
[]

Regional B-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
score O
index O
( O
WMSI O
) O
, O
contrast O
score O
index O
( O
['Physiological-Clinical']

Somatostatin O
has O
no O
additional O
benefit O
in O
those O
with O
Forrest O
II O
bleeding O
activity O
. O
[]

METHODS O
High O
schools O
( O
N=24 O
) O
paired O
on O
enrollment O
size O
, O
racial O
composition O
, O
urban O
or O
rural O
location O
, O
and O
class O
structure O
were O
randomized O
into O
control O
( O
N=12 O
) O
or O
experimental O
( O
N=12 O
) O
groups O
. O
[]

MAIN O
OUTCOME O
MEASURE O
A O
reduction O
in O
the O
median O
pain B-outcome ['Physiological-Clinical']
score O
, O
ulcer B-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
, O
number O
of O
ulcers B-outcome ['Physiological-Clinical']
, O
or O
total O
number O
of O
ulcer B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
assess O
the O
efficacy O
and O
safety O
of O
imiquimod O
for O
the O
treatment O
of O
AK B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
change O
in O
hsCRP B-outcome ['Physiological-Clinical']
was O
associated O
with O
apnea-hypopnea B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

GnRH O
agonist O
treatment O
before O
total O
laparoscopic O
hysterectomy O
for O
large O
uteri O
. O
[]

Of O
281 O
evaluable O
patients O
with O
favorable O
histologic O
types O
of O
ML O
, O
171 O
( O
61 O
% O
) O
achieved O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
there O
was O
no O
difference O
in O
CR B-outcome ['Physiological-Clinical']
rate O
, O
CR B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
, O
or O
survival B-outcome ['Mortality']
according O
to O
the O
type O
of O
initial O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

After O
both O
sham O
and O
exercise O
, O
subjects O
received O
, O
in O
sequence O
, O
systemic O
alpha-adrenergic O
blockade O
( O
phentolamine O
) O
and O
L-NMMA O
. O
[]

A O
clinically O
relevant O
rise O
in O
TSB B-outcome ['Physiological-Clinical']
took O
place O
after O
12 O
h O
into O
the O
fasting O
period O
( O
TSB O
of O
17.3 O
mumol O
l-1 O
in O
the O
fasted O
group O
vs O
14.0 O
mumol O
l-1 O
in O
the O
non-fasted O
group O
) O
. O
['Physiological-Clinical']

RATIONALE O
Critics O
have O
called O
into O
question O
findings O
from O
double-blind O
placebo-controlled O
studies O
because O
subjects O
are O
given O
drug O
administration O
instructions O
informing O
them O
of O
a O
placebo O
condition O
. O
[]

The O
data O
showed O
that O
T1/2 B-outcome ['Physiological-Clinical']
increases O
with O
increasing O
Na O
intake O
and O
is O
, O
therefore O
, O
dose-dependent O
or O
zero O
order O
. O
['Physiological-Clinical']

The O
Social O
Communication O
Assessment O
for O
Toddlers O
with O
Autism O
( O
SCATA O
) O
: O
an O
instrument O
to O
measure O
the O
frequency O
, O
form O
and O
function B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
in O
toddlers O
with O
autism O
spectrum O
disorder O
. O
['Life-Impact']

RESULTS O
In O
all O
, O
890 O
patients O
were O
randomised O
to O
Mi+Mo O
and O
873 O
to O
Mo O
alone O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Knee O
range O
of O
motion B-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
ROM I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
, O
stretch B-outcome ['Physiological-Clinical']
perception I-outcome ['Physiological-Clinical']
, O
pressure B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PPT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
subjective O
pain B-outcome ['Physiological-Clinical']
intensity O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
comparison O
of O
a O
spiritually O
based O
and O
non-spiritually O
based O
educational O
intervention O
for O
informed O
decision O
making O
for O
prostate O
cancer O
screening O
among O
church-attending O
African-American O
men O
. O
[]

Arm O
discomfort O
, O
elbow O
extension O
range O
of O
motion O
and O
isometric O
elbow O
flexion O
strength O
were O
obtained O
as O
baseline O
measurements O
. O
[]

Ipilimumab O
efficacy O
and O
safety O
in O
patients O
with O
advanced O
melanoma O
: O
a O
retrospective O
analysis O
of O
HLA O
subtype O
from O
four O
trials O
. O
[]

The O
objective O
of O
this O
case O
was O
report O
on O
the O
effects O
of O
acute O
whole O
body O
vibration O
exposure O
on O
stereotyped B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
of O
young O
children O
with O
autism O
. O
['Life-Impact']

Finally O
, O
there O
was O
no O
difference O
between O
the O
three O
groups O
in O
the O
average O
intake O
of O
PCA O
morphine O
. O
[]

Relapse O
was O
defined O
as O
a O
significant O
deterioration O
of O
symptoms O
based O
on O
clinical O
judgment O
and O
a O
parent O
questionnaire O
. O
[]

At O
10-sec O
intervals O
this O
adaptor O
was O
interrupted O
, O
and O
a O
750-msec O
moving O
probe O
( O
a O
500-Hz O
low-pass O
noise O
) O
was O
presented O
from O
a O
horizontal O
arc O
1.6 O
m O
in O
front O
of O
the O
observer O
. O
[]

Aminoglycosides O
are O
usually O
given O
in O
two O
or O
three O
divided O
doses O
. O
[]

CONTEXT O
Selective O
serotonin O
reuptake O
inhibitors O
are O
widely O
prescribed O
for O
children O
with O
autism O
spectrum O
disorders O
. O
[]

In O
comparison O
to O
WL O
, O
IT O
parents O
reported O
increases O
in O
children O
's O
total O
and O
personal B-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
and O
reduced O
involvement O
in O
their O
children O
's O
private B-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
routines I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Thirty-one O
and O
29 O
patients O
were O
included O
respectively O
in O
arms O
A O
and O
B O
. O
[]

CONCLUSIONS O
These O
findings O
suggest O
the O
5HTTLPR O
polymorphism O
affects O
CNS O
serotonin O
function O
, O
and O
they O
are O
consistent O
with O
the O
general O
hypothesis O
that O
CNS O
serotonin O
function O
is O
involved O
in O
the O
regulation O
of O
potentially O
health-damaging O
biobehavioral O
characteristics O
. O
[]

The O
state O
and O
federal O
VR O
system O
represents O
a O
potential O
access O
point O
for O
delivery O
of O
health-promotion O
activities O
. O
[]

Compared O
with O
noninfected O
volunteers O
, O
clinically O
ill O
patients O
displayed O
a O
delayed O
time O
to O
[]

Before O
treatment O
, O
TSAb B-outcome ['Physiological-Clinical']
ranging O
from O
170 O
to O
1529 O
% O
was O
present O
in O
28/29 O
patients O
and O
reached O
significantly O
low O
levels O
at O
the O
end O
of O
treatment O
whatever O
its O
duration O
. O
['Physiological-Clinical']

RESULTS O
Samples O
of O
15-minute O
interaction O
sessions O
between O
the O
child O
and O
speech-language O
pathologist O
were O
used O
to O
assess O
the O
changes O
in O
the O
FCP O
and O
the O
SCP O
. O
[]

A O
neuropsychological O
examination O
and O
a O
computed O
tomography O
scan O
of O
the O
brain O
were O
performed O
at O
the O
time O
of O
random O
assignment O
and O
repeatedly O
assessed O
at O
6 O
, O
18 O
, O
30 O
, O
and O
48 O
months O
. O
[]

In O
the O
control O
group O
, O
no O
instillation O
was O
performed O
before O
TUR O
. O
[]

All O
patients O
were O
scheduled O
for O
varicose O
vein O
stripping O
. O
[]

CONCLUSION O
The O
efficacy O
, O
safety O
, O
and O
durability O
of O
this O
operative O
protocol O
proved O
beneficial O
in O
our O
clinical O
experience O
with O
832 O
patients O
during O
9 O
years O
of O
follow-up O
. O
[]

All O
40 O
were O
then O
assigned O
to O
1 O
of O
2 O
treatment O
groups O
( O
2 O
groups O
of O
20 O
patients O
each O
) O
according O
to O
a O
table O
of O
random O
numbers O
. O
[]

METHODS O
Patients O
were O
recruited O
from O
an O
urban O
Level O
I O
Trauma O
following O
screening O
for O
an O
alcohol-related O
injury O
or O
alcohol O
problems O
. O
[]

The O
Redness B-outcome ['Physiological-Clinical']
Edema I-outcome ['Physiological-Clinical']
Ecchymosis I-outcome ['Physiological-Clinical']
Discharge I-outcome ['Physiological-Clinical']
Approximation I-outcome ['Physiological-Clinical']
( O
REEDA B-outcome ['Physiological-Clinical']
) O
tool O
, O
devised O
to O
evaluate O
postpartum O
healing O
of O
the O
perineum O
following O
an O
episiotomy/laceration O
, O
was O
used O
to O
evaluate O
the O
effects O
of O
heat O
and O
cold O
on O
the O
perineum O
during O
the O
first O
24 O
hours O
after O
delivery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
all-trans B-outcome ['Physiological-Clinical']
beta-carotene I-outcome ['Physiological-Clinical']
level O
increased O
four- O
, O
two- O
, O
and O
threefold O
the O
baseline O
in O
plasma B-outcome ['Physiological-Clinical']
, O
PLT B-outcome ['Physiological-Clinical']
, O
and O
MN O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
best O
overall O
response O
( O
CCR O
+ O
PR O
) O
rate O
was O
71 O
% O
for O
PUVA O
alone O
and O
77 O
% O
for O
the O
combination O
arm O
( O
P O
= O
0?57 O
) O
. O
[]

Ketorolac O
versus O
fentanyl O
for O
gynaecological O
day-case O
surgery O
. O
[]

Repeatability O
and O
protocol O
comparability O
of O
presyncopal O
symptom O
limited O
lower O
body O
negative O
pressure O
exposures O
. O
[]

A O
single-arm O
phase O
I O
and O
II O
study O
of O
bevacizumab O
plus O
erlotinib O
demonstrated O
encouraging O
efficacy O
, O
with O
a O
favorable O
safety O
profile O
. O
[]

At O
week O
24 O
, O
the O
medication O
was O
gradually O
withdrawn O
to O
determine O
whether O
subjects O
in O
the O
combined O
treatment O
group O
could O
be O
managed O
on O
a O
lower O
dose O
or O
off O
medication O
without O
relapse O
. O
[]

Effects O
of O
exposure O
to O
thin-ideal O
media O
images O
on O
body B-outcome ['Life-Impact']
dissatisfaction I-outcome ['Life-Impact']
: O
testing O
the O
inclusion O
of O
a O
disclaimer O
versus O
warning O
label O
. O
['Life-Impact']

Survival B-outcome ['Mortality']
was O
not O
statistically O
different O
between O
the O
two O
treatment O
arms O
. O
['Mortality']

Patients O
randomized O
to O
pegIFNalpha O
2a O
had O
improved O
work B-outcome ['Life-Impact']
productivity I-outcome ['Life-Impact']
, O
less O
activity B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
, O
decreased O
need O
for O
['Life-Impact', 'Life-Impact']

Forty O
patients O
scheduled O
to O
undergo O
thoracotomy O
were O
randomly O
allocated O
to O
receive O
either O
transcutaneous O
electrical O
nerve O
stimulation O
with O
intramuscular O
papaveretum O
( O
20 O
patients O
) O
or O
intramuscular O
papaveretum O
alone O
( O
20 O
patients O
) O
for O
postoperative O
pain O
relief O
. O
[]

The O
study O
had O
an O
18-month O
follow-up O
and O
it O
was O
conducted O
at O
15 O
outpatient O
centers O
in O
Switzerland O
and O
Germany O
between O
January O
2003 O
and O
June O
2008 O
. O
[]

SUBJECTS O
AND O
INTERVENTIONS O
Seventy-three O
patients O
with O
steroid-sensitive O
idiopathic O
NS O
admitted O
to O
the O
study O
were O
randomly O
assigned O
to O
cyclophosphamide O
( O
2.5 O
mg/kg/day O
) O
for O
8 O
weeks O
or O
CsA O
( O
5 O
mg/kg/day O
in O
adults O
, O
6 O
mg/kg/day O
in O
children O
) O
for O
9 O
months O
, O
tapered O
off O
by O
25 O
% O
every O
month O
until O
complete O
discontinuation O
at O
month O
12 O
. O
[]

The O
double-blind O
sham-controlled O
study O
of O
high-frequency O
rTMS O
( O
20 O
Hz O
) O
for O
negative O
symptoms O
in O
schizophrenia O
: O
negative O
results O
. O
[]

Effect O
of O
ischaemic O
preconditioning O
, O
cardiopulmonary O
bypass O
and O
myocardial O
ischaemic/reperfusion O
on O
free B-outcome ['Physiological-Clinical']
radical I-outcome ['Physiological-Clinical']
generation I-outcome ['Physiological-Clinical']
in O
CABG O
patients O
. O
['Physiological-Clinical']

SpO2 B-outcome ['Physiological-Clinical']
hardly O
changed O
during O
endoscopy O
in O
the O
non-sedated O
group O
, O
but O
decreased O
slightly O
in O
the O
sedated O
group O
( O
P O
= O
0.075 O
) O
. O
['Physiological-Clinical']

Of O
the O
group O
2 O
patients O
64 O
% O
preferred O
2 O
weeks O
of O
stenting O
. O
[]

Twenty-nine O
out-patients O
with O
uni- O
or O
bilateral O
osteoarthritis O
of O
the O
knee O
were O
included O
and O
randomly O
assigned O
to O
treatment O
with O
either O
laser O
or O
placebo O
laser O
. O
[]

5.2 O
HU O
for O
80-kV O
images O
( O
p O
< O
0.0001 O
) O
. O
[]

The O
new O
brain B-outcome ['Physiological-Clinical']
infarcts I-outcome ['Physiological-Clinical']
of O
subjects O
in O
the O
active O
group O
were O
subclinical O
. O
['Physiological-Clinical']

Thirty O
percent O
( O
n O
= O
3 O
) O
of O
patients O
taking O
ZNS O
discontinued O
the O
study O
due O
to O
side O
effects O
( O
fatigue B-outcome ['Physiological-Clinical']
, O
headache B-outcome ['Physiological-Clinical']
, O
paresthesias B-outcome ['Physiological-Clinical']
) O
while O
taking O
100 O
mg O
per O
day O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
It O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
conducted O
in O
54 O
asthmatic O
children O
allergic O
to O
house O
dust O
mites O
. O
[]

PURPOSE O
Cancer-related-fatigue B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CRF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
common O
in O
advanced O
cancer O
. O
['Physiological-Clinical']

FINDINGS O
183 O
( O
61 O
% O
) O
of O
316 O
participants O
were O
diagnosed O
with O
at O
least O
one O
episode O
of O
uncomplicated O
malaria O
. O
[]

No O
significant O
difference O
was O
found O
in O
the O
rate O
and O
extent O
of O
absorption B-outcome ['Physiological-Clinical']
between O
the O
two O
formulations O
: O
the O
relative O
bioavailability B-outcome ['Physiological-Clinical']
of O
tablet O
I O
compared O
to O
tablet O
II O
was O
1.05 O
+/- O
0.21 O
( O
mean O
+/- O
SD O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTERPRETATION O
ASI O
gave O
significant O
clinical O
benefit O
in O
surgically O
resected O
patients O
with O
stage O
II O
colon O
cancer O
. O
[]

In O
13 O
patients O
aged O
24 O
years O
at O
baseline O
, O
we O
evaluated O
blood O
pressure O
, O
kidney O
biopsies O
and O
kidney O
function O
tests O
at O
baseline O
and O
after O
5 O
years O
of O
treatment O
. O
[]

AT O
force B-outcome ['Physiological-Clinical']
was O
calculated O
from O
inverse O
dynamics O
. O
['Physiological-Clinical']

The O
apparent O
arrest O
of O
progressive B-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
seen O
in O
four O
patients O
after O
treatment O
with O
IL-1Ra O
was O
associated O
with O
reduced O
intimal O
layer O
macrophage O
accumulation O
in O
all O
patients O
. O
['Physiological-Clinical']

RATIONALE O
( O
+/- O
) O
3,4-Methylenedioxymethamphetamine O
( O
MDMA O
or O
ecstasy O
) O
has O
been O
shown O
to O
cause O
long O
term O
damage O
to O
serotonergic O
cerebral O
neurons O
in O
animals O
. O
[]

Increases O
in O
fitness O
were O
reported O
as O
having O
a O
positive O
impact O
on O
the O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
of O
individuals O
in O
the O
exercise O
group O
as O
well O
as O
enhancing O
the O
individual O
's O
ability B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
complete I-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
successfully O
. O
['Life-Impact', 'Life-Impact']

Measures O
included O
changes O
in O
professionally O
completed O
Childhood O
Autism O
Rating O
Scale O
( O
CARS O
) O
, O
hand B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
testing O
, O
and O
modified O
clinical B-outcome ['Physiological-Clinical']
global I-outcome ['Physiological-Clinical']
impression I-outcome ['Physiological-Clinical']
( O
CGI O
) O
forms O
; O
parent O
completed O
Autism B-outcome ['Life-Impact']
Treatment O
Evaluation O
Checklist O
( O
ATEC O
) O
, O
treatment O
adherence B-outcome ['Life-Impact']
measurement O
( O
TAM O
) O
, O
frequency O
and O
intensity O
of O
side O
effect O
rating O
( O
FISER O
) O
/global O
rating O
of O
side O
effect O
burden B-outcome ['Physiological-Clinical']
( O
GRSEB B-outcome ['Physiological-Clinical']
) O
/patient O
report O
of O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
( O
PRISE B-outcome ['Physiological-Clinical']
) O
forms B-outcome ['Physiological-Clinical']
; O
and O
lab O
testing O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
30 O
patients O
receiving O
3 O
x O
0.5 O
mg O
or O
placebo O
daily O
reacted O
only O
rarely O
. O
[]

Postoperative O
visual O
analog O
pain B-outcome ['Physiological-Clinical']
scale O
( O
VAS O
) O
scores O
at O
8 O
and O
24 O
hours O
and O
14 O
days O
after O
surgery O
, O
in-hospital B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
use O
, O
length O
of O
hospital B-outcome ['Resource-use']
stay B-outcome ['Resource-use']
, O
success B-outcome ['Physiological-Clinical']
rate O
, O
blood B-outcome ['Resource-use']
transfusion I-outcome ['Resource-use']
rate O
, O
and O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
were O
compared O
for O
the O
two O
groups O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use', 'Resource-use', 'Physiological-Clinical', 'Resource-use', 'Adverse-effects']

Docetaxel O
( O
DCT O
) O
and O
cisplatin O
( O
CDDP O
) O
doublet O
has O
been O
reported O
to O
be O
associated O
to O
a O
better O
QoL O
than O
the O
weekly O
vinorelbine O
( O
VNR O
) O
and O
CDDP O
regimen O
. O
[]

After O
40 O
minutes O
, O
subjects O
were O
again O
given O
nicotine O
gum O
or O
placebo O
in O
cross-over O
fashion O
. O
[]

RESULTS O
Eighty-five O
patients O
were O
randomized O
in O
phase O
2 O
. O
[]

One O
dose O
of O
zoster O
vaccine O
( O
ZV O
) O
has O
demonstrated O
substantial O
protection O
against O
HZ O
; O
this O
study O
examined O
impact O
of O
a O
second O
dose O
of O
ZV O
. O
[]

However O
, O
the O
use O
of O
packed B-outcome ['Physiological-Clinical']
red I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
postoperative O
period O
, O
whereas O
there O
was O
no O
significant O
difference O
in O
fresh O
frozen O
plasma B-outcome ['Physiological-Clinical']
requirements I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Blockade O
of O
cytotoxic O
T-lymphocyte O
antigen-4 O
( O
CTLA-4 O
) O
by O
ipilimumab O
leads O
to O
immune-mediated O
tumor O
regression O
and O
immune-related O
adverse O
events O
( O
irAEs O
) O
, O
including O
diarrhea O
and O
colitis O
. O
[]

Observations O
from O
the O
present O
study O
provide O
benchmark O
data O
for O
improving O
patient O
care O
and O
effectively O
utilizing O
healthcare O
resources O
. O
[]

In O
the O
whole O
group O
and O
in O
groups O
A O
and O
B O
considered O
individually O
, O
responses O
to O
D O
and O
P O
did O
not O
differ O
. O
[]

A O
double O
blind O
clinical O
trial O
was O
carried O
out O
to O
clarify O
the O
effects O
of O
oil O
with O
medium- O
and O
long-chain O
triglyceride O
( O
MLCT O
) O
on O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
profiles O
in O
hypertriglyceridemic O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Learning O
measures O
were O
the O
Early O
Intervention O
Developmental O
Profile-Language O
and O
paired-associate B-outcome ['Physiological-Clinical']
learning I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

They O
also O
had O
less O
deterioration O
of O
angiographic B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
over O
that O
of O
placebo O
( O
three O
vs O
seven O
eyes O
) O
. O
['Physiological-Clinical']

Forty O
children O
with O
refractory O
status O
epilepticus O
were O
randomized O
to O
receive O
either O
intravenous O
sodium O
valproate O
or O
diazepam O
infusion O
. O
[]

RESULT O
( O
S O
) O
In O
cycle O
1 O
the O
ovulation O
rates O
for O
a O
single O
dose O
of O
anastrozole O
at O
5 O
, O
10 O
, O
20 O
, O
and O
30 O
mg O
were O
46.2 O
% O
, O
41.0 O
% O
, O
23.1 O
% O
, O
and O
28.9 O
% O
, O
respectively O
, O
whereas O
that O
for O
CC O
at O
50 O
mg/d O
was O
61.5 O
% O
. O
[]

Restlessness B-outcome ['Life-Impact']
consistent O
with O
akathisia O
was O
noted O
by O
35 O
% O
of O
the O
PC O
group O
and O
8 O
% O
of O
the O
OC O
group O
( O
P O
< O
.01 O
) O
. O
['Life-Impact']

Treating O
heparin-resistant O
patients O
with O
rhAT O
may O
decrease O
the O
requirement B-outcome ['Resource-use']
for I-outcome ['Resource-use']
heparin I-outcome ['Resource-use']
and O
fresh O
frozen O
plasma O
. O
['Resource-use']

The O
evolving O
clinical O
status O
of O
patients O
after O
a O
myocardial O
infarction O
: O
the O
importance O
of O
post-hospital O
data O
for O
mortality O
prediction O
. O
[]

Rett O
syndrome O
is O
a O
severe O
neurodevelopmental O
disorder O
of O
unknown O
etiology O
, O
occurring O
almost O
exclusively O
in O
female O
patients O
. O
[]

In O
addition O
to O
providing O
a O
rationale O
for O
the O
project O
, O
the O
goal O
of O
this O
paper O
is O
fourfold O
. O
[]

As O
dental O
procedures O
other O
than O
extractions O
may O
also O
cause O
bacteremias O
, O
we O
studied O
a O
variety O
of O
dental O
procedures O
routinely O
used O
in O
pediatric O
dentistry O
. O
[]

The O
better O
response O
rate O
, O
the O
longer O
overall O
and O
better O
one-year O
survival O
seen O
with O
the O
higher O
dose O
of O
paclitaxel O
are O
not O
statistically O
significant O
. O
[]

Patients O
treated O
with O
EES O
rather O
than O
PES O
were O
less O
likely O
to O
develop O
side B-outcome ['Physiological-Clinical']
branch I-outcome ['Physiological-Clinical']
occlusion I-outcome ['Physiological-Clinical']
during O
stent O
placement O
, O
contributing O
to O
lower O
rates O
of O
periprocedural O
MI O
with O
EES O
compared O
to O
PES O
. O
['Physiological-Clinical']

A O
placebo-controlled O
study O
of O
the O
effect O
of O
an O
Eleutherococcus O
senticosus O
extract O
( O
Eleukokk O
) O
on O
the O
immune O
system O
was O
performed O
with O
36 O
healthy O
volunteers O
utilising O
quantitative O
multi-parameter O
flow O
cytometry O
with O
monoclonal O
antibodies O
directed O
against O
specific O
surface O
markers O
of O
human O
lymphocyte O
subsets O
. O
[]

A O
secondary O
objective O
was O
to O
assess O
the O
cardiovascular O
and O
respiratory O
effects O
of O
the O
two O
opioid O
drugs O
. O
[]

Total O
intramuscular O
analgesic O
requirements O
in O
the O
first O
24 O
hours O
, O
time O
to O
satisfactory O
transfer O
to O
oral O
analgesia O
, O
antiemetic O
requirements O
and O
length O
of O
stay B-outcome ['Resource-use']
in I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
postoperatively I-outcome ['Resource-use']
were O
noted O
. O
['Resource-use']

OBJECTIVE O
To O
compare O
the O
clinical O
and O
psychological O
effectiveness O
of O
the O
traditional O
British O
antenatal O
visit O
schedule O
( O
traditional O
care O
) O
with O
a O
reduced O
schedule O
of O
visits O
( O
new O
style O
care O
) O
for O
low O
risk O
women O
, O
together O
with O
maternal O
and O
professional O
satisfaction O
with O
care O
. O
[]

The O
differences O
in O
pharmacologic O
properties O
for O
the O
different O
hypotensive O
agents O
suggest O
that O
combinations O
of O
these O
agents O
may O
provide O
a O
pharmacologic O
profile O
superior O
to O
either O
agent O
alone O
. O
[]

RESULTS O
IOP B-outcome ['Physiological-Clinical']
at O
baseline O
and O
after O
6 O
weeks O
of O
treatment O
( O
mean O
+/- O
SEM O
) O
were O
24.2 O
+/- O
0.9 O
and O
23.8 O
+/- O
1.0 O
mmHg O
( O
n O
= O
16 O
) O
for O
patients O
continuing O
on O
timolol O
, O
26.3 O
+/- O
1.2 O
and O
19.6 O
+/- O
1.1 O
mmHg O
( O
n O
= O
17 O
) O
for O
patients O
switching O
to O
latanoprost O
, O
and O
23.2 O
+/- O
1.0 O
and O
17.5 O
+/- O
0.8 O
mmHg O
( O
n O
= O
17 O
) O
for O
patients O
with O
combined O
treatment O
. O
['Physiological-Clinical']

CPX O
variables O
, O
including O
oxygen B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
at O
peak O
exercise B-outcome ['Life-Impact']
( O
peak O
VO B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
slope I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
ventilation/carbon I-outcome ['Physiological-Clinical']
dioxide I-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
ratio O
( O
VE/VCO O
( O
2 O
) O
) O
, O
were O
determined O
and O
analyzed O
by O
core O
laboratory O
personnel O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Pain O
on O
the O
visual O
analog O
scale O
( O
VAS O
) O
, O
the O
Oswestry B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
Million I-outcome ['Physiological-Clinical']
disability I-outcome ['Physiological-Clinical']
indexes I-outcome ['Physiological-Clinical']
, O
isometric B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
dynamic I-outcome ['Physiological-Clinical']
trunk I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
, O
mobility O
in O
the O
lumbar B-outcome ['Physiological-Clinical']
spine I-outcome ['Physiological-Clinical']
, O
and O
straight-leg O
raising O
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Recent O
reports O
suggest O
that O
primary O
vitrectomy O
yields O
better O
anatomic O
success O
than O
scleral O
buckling O
. O
[]

In O
1984 O
a O
multicentre O
, O
prospective O
, O
randomised O
, O
double-blind O
trial O
of O
coumarin O
, O
given O
as O
a O
daily O
50-mg O
dose O
for O
2 O
years O
after O
surgery O
in O
patients O
with O
high-risk O
melanoma O
, O
was O
started O
. O
[]

Lymphocele B-outcome ['Physiological-Clinical']
developed O
in O
9 O
( O
30 O
% O
) O
patients O
on O
the O
side O
where O
laparoscopic O
pelvic O
lymphadenectomy O
was O
perfomed O
using O
bipolar O
coagulation O
, O
and O
in O
1 O
( O
3.3 O
% O
) O
patient O
on O
the O
side O
where O
laparoscopic O
pelvic O
lymphadenectomy O
was O
performed O
using O
the O
Ligaclip O
. O
['Physiological-Clinical']

Basal B-outcome ['Physiological-Clinical']
femoral I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
vascular B-outcome ['Physiological-Clinical']
conductance I-outcome ['Physiological-Clinical']
increased O
by O
55-60 O
% O
after O
strength O
training O
( O
both O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Boys O
who O
were O
most O
satisfied O
and O
girls O
least O
satisfied O
with O
themselves O
sunbathed B-outcome ['Life-Impact']
most O
. O
['Life-Impact']

On O
day O
1 O
, O
the O
heatwrap O
group O
had O
greater O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
( O
1.76+/-.10 O
vs O
1.05+/-.11 O
, O
P O
< O
.001 O
) O
, O
less O
muscle B-outcome ['Physiological-Clinical']
stiffness B-outcome ['Life-Impact']
( O
43.1+/-1.21 O
vs O
47.6+/-1.21 O
, O
P=.008 O
) O
, O
and O
increased O
flexibility B-outcome ['Life-Impact']
( O
18.6+/-.44 O
cm O
vs O
16.5+/-.45 O
cm O
, O
P=.001 O
) O
compared O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Relative O
to O
normoxic O
PECO O
, O
stimulation O
of O
the O
CC O
during O
hypoxic O
PECO O
resulted O
in O
higher O
HR O
( O
P O
< O
0.001 O
) O
and O
Ve O
( O
P O
< O
0.001 O
) O
. O
[]

Fibula O
, O
scapula O
, O
iliac O
crest O
, O
rib O
, O
and O
metatarsal O
as O
well O
as O
the O
radial O
forearm O
osseocutaneous O
flaps O
have O
all O
been O
utilized O
for O
this O
purpose O
. O
[]

Serum B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
levels O
decreased O
in O
most O
patients O
after O
surgery O
, O
but O
recovered O
earliest O
in O
Group O
A. O
Hypercalcemia O
and O
PTH O
inhibition O
did O
not O
occur O
in O
gs O
A O
and O
B O
. O
['Physiological-Clinical']

The O
maximum O
allowed O
dose O
was O
1.25 O
mg/day O
for O
those O
weighing O
20 O
to O
< O
45 O
kg O
, O
and O
1.75 O
mg/day O
for O
those O
weighing O
? O
[]

Whole O
milk O
( O
3.8 O
L/d O
) O
containing O
lactoferrin O
supplements O
was O
fed O
from O
bottles O
until O
weaning O
at O
35 O
d. O
From O
d O
36 O
to O
56 O
, O
lactoferrin O
supplements O
were O
added O
to O
water O
( O
15 O
to O
25 O
mL O
) O
and O
fed O
from O
bottles O
. O
[]

On O
multivariate O
analyses O
relationships O
between O
selected O
baseline O
factors O
and O
cardiovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
evaluated O
. O
['Physiological-Clinical']

The O
extravasation B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
was O
0.052 O
+/- O
0.007 O
mL/kg/min O
in O
group O
2 O
vs. O
0.038 O
+/- O
0.020 O
mL/kg/min O
in O
group O
1 O
( O
p O
< O
.05 O
) O
. O
['Physiological-Clinical']

All O
patients O
were O
followed O
for O
at O
least O
2.5 O
years O
. O
[]

Long-term O
administration O
of O
a O
beta-carotene O
preparation O
derived O
from O
Dunaliella O
bardawil O
, O
a O
beta-carotene-rich O
algae O
, O
was O
studied O
in O
healthy O
young O
male O
volunteers O
. O
[]

Peak O
AT O
strain B-outcome ['Physiological-Clinical']
was O
less O
for O
18HL O
( O
5.5 O
? O
['Physiological-Clinical']

Compliance O
with O
inhaler O
use O
was O
assessed O
by O
canister O
weighing O
. O
[]

RESULTS O
A O
total O
of O
21 O
136 O
inflations O
were O
recorded O
and O
analysed O
. O
[]

Although O
various O
neurohormones O
at O
initial O
measurement O
confer O
prognostic O
value O
in O
heart O
failure O
and O
correlate O
with O
the O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
cardiac B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
, O
the O
significance O
of O
their O
temporal O
changes O
( O
Delta O
) O
remains O
undetermined O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
There O
were O
no O
group O
differences O
on O
formal B-outcome ['Life-Impact']
measures I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
, O
cognition B-outcome ['Life-Impact']
, O
or O
['Life-Impact', 'Life-Impact']

However O
, O
current O
standard O
consent O
forms O
may O
not O
accomplish O
their O
intended O
purpose O
due O
to O
the O
variety O
of O
patient O
literacy O
and O
experiences O
and O
, O
in O
the O
dental O
school O
setting O
, O
the O
developing O
competence O
of O
students O
. O
[]

Peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
consecutively O
collected O
for O
analysis O
of O
lymphocyte O
subpopulations O
using O
an O
indirect O
immunofluorescence O
( O
IF O
) O
method O
, O
and O
hepatitis O
B O
virus O
( O
HBV O
) O
DNA O
was O
quantified O
by O
a O
chemiluminescent O
, O
molecular-hybridization O
assay O
. O
['Physiological-Clinical']

METHODS O
This O
was O
a O
phase O
II O
, O
randomized O
, O
multicenter O
study O
. O
[]

Because O
mailings O
did O
not O
influence O
participation O
in O
[]

Treatment O
groups O
were O
well O
balanced O
with O
respect O
to O
known O
prognostic O
factors O
. O
[]

at O
operation O
day O
and O
6 O
mg/m2 O
in O
every O
2 O
months O
+UFT O
600 O
mg/day O
p.o. O
, O
D O
: O
the O
same O
dose O
of O
MMC O
+ O
UFT O
400 O
mg/day O
p.o O
. O
) O
[]

Prevention O
of O
subsequent O
exercise-induced B-outcome ['Physiological-Clinical']
periinfarct I-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
by O
emergency O
coronary O
angioplasty O
in O
acute O
myocardial O
infarction O
: O
comparison O
with O
intracoronary O
streptokinase O
. O
['Physiological-Clinical']

METHODS O
A O
double-blind O
study O
was O
performed O
in O
210 O
ASA O
I O
or O
II O
patients O
undergoing O
cesarean O
delivery O
, O
who O
were O
randomly O
assigned O
to O
six O
groups O
. O
[]

Recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
analysed O
using O
the O
log-rank O
test O
and O
Cox O
multivariate O
analysis O
was O
used O
to O
test O
for O
independence O
. O
['Mortality']

Parametric O
analysis O
revealed O
activity B-outcome ['Life-Impact']
correlating O
with O
temporal O
complexity O
during O
initiate O
in O
bilateral O
supplementary O
and O
pre-supplementary O
motor O
cortex O
( O
SMA O
and O
preSMA O
) O
, O
rostral B-outcome ['Physiological-Clinical']
dorsal I-outcome ['Physiological-Clinical']
premotor I-outcome ['Physiological-Clinical']
cortex I-outcome ['Physiological-Clinical']
( O
PMC O
) O
, O
basal B-outcome ['Physiological-Clinical']
ganglia I-outcome ['Physiological-Clinical']
, O
and O
dorsolateral B-outcome ['Physiological-Clinical']
prefrontal I-outcome ['Physiological-Clinical']
cortex I-outcome ['Physiological-Clinical']
( O
DLPFC O
) O
, O
among O
other O
areas O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
32 O
patients O
with O
nonlymphoblastic O
disease O
treated O
with O
COMP O
only O
one O
relapsed B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

It O
was O
hypothesized O
that O
clomipramine O
would O
be O
better O
tolerated O
than O
haloperidol O
and O
prove O
superior O
on O
a O
measure O
of O
stereotypy O
. O
[]

The O
frequency O
of O
dyspareunia B-outcome ['Physiological-Clinical']
for O
each O
mode O
of O
delivery O
was O
similar O
in O
primiparous O
women O
( O
VB O
30.7 O
% O
, O
CS O
31.6 O
% O
) O
. O
['Physiological-Clinical']

Within O
each O
risk O
group O
, O
mortality B-outcome ['Mortality']
during O
the O
initial O
hospitalization O
and O
median O
long-term O
survival B-outcome ['Mortality']
were O
similar O
among O
patients O
receiving O
either O
treatment O
. O
['Mortality', 'Mortality']

CONCLUSION O
For O
HBV-carrying O
renal O
transplant O
recipients O
, O
FK506 O
as O
the O
primary O
choice O
of O
immunosuppressant O
can O
be O
more O
effective O
and O
safer O
than O
CsA O
. O
[]

Acute O
drug O
effects O
were O
recorded O
, O
focusing O
on O
electrocardiography B-outcome ['Resource-use']
, O
respiratory B-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
, O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
, O
and O
electroencephalography B-outcome ['Resource-use']
( I-outcome ['Resource-use']
EEG I-outcome ['Resource-use']
) I-outcome ['Resource-use']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Folic O
acid-based O
intervention O
in O
non-ST O
elevation O
acute O
coronary O
syndromes O
. O
[]

HRV B-outcome ['Physiological-Clinical']
and O
ST-segment B-outcome ['Physiological-Clinical']
values O
were O
assessed O
for O
each O
30-min O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
was O
very O
evident O
for O
the O
ADP O
and O
adrenaline O
inductors O
and O
rather O
less O
significant O
for O
collagen O
. O
[]

We O
conclude O
that O
indoor O
training O
, O
either O
on O
land O
or O
in O
water O
, O
is O
beneficial O
. O
[]

The O
incidence O
of O
gastric B-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
was O
not O
affected O
by O
H. O
pylori O
status O
. O
['Physiological-Clinical']

High-grade O
budding O
, O
but O
not O
the O
infiltrating O
growth O
pattern O
, O
was O
significantly O
associated O
with O
outcome O
in O
univariable O
analysis O
. O
[]

Intervention O
. O
[]

Duration O
remained O
constant O
in O
both O
groups O
( O
1-3 O
h O
) O
. O
[]

Smaller O
improvements O
were O
seen O
in O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
and O
triglyceride B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
The O
objective O
was O
to O
determine O
whether O
an O
educational O
intervention O
for O
health O
care O
providers O
would O
result O
in O
improved O
documentation B-outcome ['Physiological-Clinical']
of O
cases O
of O
possible O
physical O
child O
abuse O
in O
children O
< O
36 O
months O
old O
treated O
in O
the O
emergency O
department O
( O
ED O
) O
setting O
. O
['Physiological-Clinical']

Using O
Centers O
for O
Disease O
Control O
( O
CDC O
) O
standardized O
scores O
, O
both O
weight O
and O
body O
mass O
index O
( O
BMI O
) O
increased O
with O
risperidone O
during O
the O
acute O
trial O
( O
0.5 O
and O
0.6 O
SDs O
, O
respectively O
, O
for O
risperidone O
; O
0.0 O
and O
0.1 O
SDs O
, O
respectively O
, O
for O
placebo O
) O
and O
into O
open-label O
extension O
( O
0.19 O
and O
0.16 O
SDs O
, O
respectively O
) O
, O
although O
the O
amount O
of O
gain O
decelerated O
with O
time O
. O
[]

They O
are O
often O
coexpressed O
in O
breast O
cancer O
. O
[]

Participants O
( O
14-18 O
years O
old O
) O
were O
consecutive O
admissions O
to O
inpatient O
adolescent O
alcohol O
and O
drug O
treatment O
centers O
in O
San O
Diego O
that O
were O
abstinence O
focused O
and O
based O
on O
the O
12-step O
approach O
. O
[]

Increasing O
the O
reach O
of O
health B-outcome ['Physiological-Clinical']
sponsorship O
: O
using O
a O
sponsorship O
kit O
to O
promote O
health O
. O
['Physiological-Clinical']

RESULTS O
There O
were O
14 O
in-hospital O
deaths O
without O
relationship O
to O
GLN O
administration O
. O
[]

Based O
on O
the O
multivariate O
analysis O
in O
the O
control O
group O
, O
voided O
urine O
cytology O
was O
an O
independent O
predictive O
factor O
of O
bladder O
recurrence O
( O
hazard O
ratio O
, O
5.54 O
; O
95 O
% O
confidence O
interval O
1.12-27.5 O
; O
P O
= O
0.036 O
) O
. O
[]

[ O
The O
effects O
of O
antidepressant O
treatment O
on O
efficacy O
of O
antihypertensive O
therapy O
in O
elderly O
hypertension O
] O
. O
[]

Correlations O
between O
changes O
in O
serum B-outcome ['Physiological-Clinical']
bile I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
and O
biochemical B-outcome ['Physiological-Clinical']
measures I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
even O
weaker O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
warfarin O
group O
symptoms B-outcome ['Physiological-Clinical']
improved O
in O
46 O
( O
85 O
% O
) O
patients O
by O
at O
least O
1 O
angina O
class O
and O
31 O
( O
57 O
% O
) O
were O
symptom B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
; O
the O
exercise O
test O
remained O
positive O
in O
20 O
( O
36 O
% O
) O
patients O
and O
the O
angiographic B-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
rate O
was O
25 O
% O
per O
lesion O
and O
29 O
% O
per O
patient O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Prognostic O
value O
of O
clinical O
, O
laboratory O
, O
and O
histological O
characteristics O
in O
multiple O
myeloma O
: O
improved O
definition O
of O
risk O
groups O
. O
[]

RESULTS O
In O
the O
PRE O
group O
the O
rates O
of O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
were O
92 O
% O
, O
70 O
% O
, O
56 O
% O
and O
56 O
% O
at O
the O
end O
of O
the O
1st O
, O
2nd O
, O
3rd O
and O
4th O
years O
, O
respectively O
. O
['Mortality']

RESULTS O
All O
three O
groups O
had O
a O
spike O
in O
cost O
associated O
with O
the O
index O
clinic O
visit O
. O
[]

Anesthetic O
treatment O
and O
antibiotic O
administration O
were O
standardized O
. O
[]

Twenty-eight O
nurses O
participated O
in O
the O
study O
, O
9 O
first-generation O
and O
19 O
second-generation O
. O
[]

There O
were O
no O
significant O
( O
P O
> O
0.18 O
) O
differences O
between O
the O
whitening O
dentifrice O
groups O
at O
any O
timepoints O
. O
[]

The O
Beta-Blocker O
Heart O
Attack O
Trial O
was O
a O
randomized O
double O
blind O
controlled O
trial O
comparing O
propranolol O
with O
placebo O
in O
3837 O
patients O
with O
a O
recent O
myocardial O
infarction O
. O
[]

CONCLUSION O
Using O
MFF O
after O
hemorrhoidectomy O
reduced O
the O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
intramuscular B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

METHODS O
A O
consecutive O
cohort O
of O
patients O
( O
n O
= O
200 O
, O
68 O
men O
) O
referred O
to O
acute O
surgical O
correction O
of O
hip O
fracture O
was O
studied O
. O
[]

Primary O
outcome O
measures O
were O
median O
atropine B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
needed O
within O
24 O
h O
, O
proportion O
of O
patients O
who O
needed O
intubation B-outcome ['Resource-use']
, O
and O
number O
of O
days B-outcome ['Resource-use']
on I-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
. O
['Life-Impact', 'Resource-use', 'Resource-use']

All O
serum O
25-hydroxyvitamin O
D O
( O
25 O
[ O
OH O
] O
D O
) O
levels O
were O
below O
78 O
nmol/l O
. O
[]

OBJECTIVE O
The O
objectives O
were O
to O
evaluate O
the O
efficacy O
of O
5 O
% O
imiquimod O
cream O
in O
treating O
basal O
cell O
carcinoma O
preceding O
excision O
by O
Mohs O
micrographic O
surgery O
and O
to O
determine O
if O
reflectance-mode O
confocal O
microscopy O
is O
useful O
to O
establish O
the O
need O
for O
surgical O
intervention O
after O
imiquimod O
treatment O
. O
[]

min O
( O
-1 O
) O
) O
or O
saline O
0.9 O
% O
for O
24 O
hours O
. O
[]

CONCLUSIONS O
Small-diameter O
hysteroscopy O
with O
bipolar O
electrode O
for O
the O
incision O
of O
uterine O
septum O
is O
as O
effective O
as O
resectoscopy O
with O
unipolar O
electrode O
regarding O
reproductive O
outcome O
and O
is O
associated O
with O
shorter O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
lower O
complication B-outcome ['Adverse-effects']
rate O
. O
['Life-Impact', 'Adverse-effects']

The O
St. O
Louis O
University O
program O
detects O
and O
codes O
serial B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
Q I-outcome ['Physiological-Clinical']
, O
ST B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

A O
pressure B-outcome ['Physiological-Clinical']
rise I-outcome ['Physiological-Clinical']
> O
20 O
mm O
Hg B-outcome ['Physiological-Clinical']
was O
seen O
in O
one O
patient O
receiving O
acetazolamide O
only O
and O
one O
patient O
receiving O
acetylcholine O
only O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Low O
dose O
risperidone O
was O
effective O
for O
aggressive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
persons O
with O
MR. O
More O
long-term O
studies O
are O
needed O
, O
incorporating O
weight O
control O
interventions O
. O
['Life-Impact']

36 O
consecutive O
patients O
with O
non-metastatic O
breast O
cancer O
assigned O
to O
surgery O
and O
systemic O
chemotherapy O
were O
randomised O
to O
receive O
either O
psychological O
intervention O
( O
weekly O
cognitive O
individual O
psychotherapy O
and O
bimonthly O
family O
counselling O
) O
or O
standard O
follow-up O
. O
[]

Feasibility O
of O
a O
telephone-based O
intervention O
for O
support O
persons O
to O
help O
smokers B-outcome ['Life-Impact']
quit O
: O
a O
pilot O
study O
. O
['Life-Impact']

All O
the O
volunteers O
were O
vaccinated O
with O
a O
trivalent O
influenza O
vaccine O
( O
A/Wisconsin/67/2005 O
NYMC O
X-161B O
( O
H3N2 O
) O
, O
A/Solomon O
Islands/3/2006 O
( O
H1N1 O
) O
and O
B/Malaysia/2506/2004 O
) O
for O
the O
Spanish O
vaccine O
campaign O
2006/2007 O
. O
[]

The O
inferior-superior O
technique O
achieved O
greater O
lid B-outcome ['Physiological-Clinical']
akinesia I-outcome ['Physiological-Clinical']
at O
5 O
min O
than O
the O
inferior-medial O
technique O
( O
mean O
score O
+/- O
standard O
deviation O
of O
0.7 O
+/- O
0.9 O
vs. O
0.3 O
+/- O
0.58 O
; O
P O
< O
0.005 O
) O
. O
['Physiological-Clinical']

National O
Institute O
of O
Child O
Health O
and O
Human O
Development O
Neonatal O
Research O
Network O
. O
[]

STUDY O
DESIGN O
A O
prospective O
randomized O
trial O
with O
2 O
years O
of O
follow-up O
was O
carried O
out O
in O
the O
Department O
of O
Gynecology O
of O
the O
University O
of O
Naples O
. O
[]

Diode O
laser O
photocoagulation O
for O
threshold O
retinopathy O
of O
prematurity O
. O
[]

Evidence O
of O
covariation O
among O
behaviors O
would O
suggest O
multi-behavior O
interventions O
could O
have O
synergistic O
effects O
. O
[]

Group O
B O
subjects O
were O
first O
placed O
in O
the O
45-degree O
upright O
position O
, O
and O
after O
5 O
minutes O
had O
cardiac O
output O
measurements O
performed O
. O
[]

There O
were O
no O
differences O
in O
the O
healing B-outcome ['Physiological-Clinical']
rate O
of O
the O
duodenal O
ulcer O
after O
four O
weeks O
, O
86.7 O
% O
being O
achieved O
for O
both O
groups O
. O
['Physiological-Clinical']

BACKGROUND O
Postoperative O
nausea O
and O
vomiting O
( O
PONV O
) O
is O
still O
common O
, O
especially O
among O
female O
patients O
. O
[]

DISCUSSION O
The O
results O
of O
this O
study O
will O
provide O
detailed O
information O
on O
the O
efficacy O
of O
hyperbaric O
oxygen O
therapy O
for O
the O
treatment O
of O
non-healing O
ulcers O
of O
the O
lower O
limb O
. O
[]

RESULTS O
The O
cumulated O
risk O
of O
a O
patient O
having O
new B-outcome ['Physiological-Clinical']
adenomas I-outcome ['Physiological-Clinical']
was O
35.0 O
% O
( O
28.7-41.4 O
% O
) O
in O
group O
A O
and O
35.5 O
% O
( O
28.4-42.7 O
% O
) O
in O
group O
B O
after O
48 O
months O
. O
['Physiological-Clinical']

Neu B-outcome ['Physiological-Clinical']
oncoprotein B-outcome ['Physiological-Clinical']
and O
PR B-outcome ['Physiological-Clinical']
were O
determined O
by O
ELISA B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

The O
four O
kinds O
of O
HepB O
, O
including O
5 O
microg O
HepB-Y,10 O
microg O
HepB-Y O
, O
10 O
microg O
HepB-CHO O
, O
10 O
microg O
HepB-HY O
had O
the O
same O
immunization O
effect O
after O
3 O
doses O
revaccination O
at O
0 O
, O
1 O
, O
6 O
months O
to O
non-and-low O
response O
children O
. O
[]

In O
conclusion O
, O
early O
steroid O
withdrawal O
after O
LT O
is O
feasible B-outcome ['Life-Impact']
under O
tacrolimus O
monotherapy O
without O
increased O
rejection O
rates O
and O
with O
a O
lower O
rate O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Life-Impact', 'Adverse-effects']

Sensitization O
was O
produced O
by O
heating O
the O
skin O
to O
45 O
degrees O
C O
for O
5 O
min O
, O
followed O
by O
a O
30-min O
application O
of O
0.075 O
% O
capsaicin O
cream O
, O
and O
maintained O
by O
periodically O
reheating O
the O
sensitized O
skin O
. O
[]

Subjects O
with O
a O
difference O
of O
> O
or O
= O
20 O
mm O
Hg O
systolic O
or O
> O
or O
= O
10 O
mm O
Hg O
diastolic O
BP O
between O
CBP O
and O
awake O
ABP O
or O
CBP O
and O
HBP O
, O
were O
classified O
as O
clinic O
reactors O
. O
[]

salicinius O
, O
L. O
plantarum O
) O
or O
the O
vaginal O
pH O
tablet O
( O
active O
comparator O
) O
. O
[]

RESULTS O
Among O
almost O
155,000 O
subjects O
enrolled O
in O
PLCO O
, O
minority O
enrollment O
was O
as O
follows O
: O
black O
( O
5.0 O
% O
) O
, O
Hispanic O
( O
1.8 O
% O
) O
and O
Asian O
( O
3.6 O
% O
) O
. O
[]

METHODS O
We O
analyzed O
data O
from O
a O
completed O
clinical O
trial O
that O
randomized O
100 O
patients O
to O
12 O
weeks O
of O
tai O
chi O
classes O
or O
to O
time-matched O
education O
control O
. O
[]

GM-CSF O
had O
to O
be O
reduced O
or O
suspended O
in O
50 O
% O
of O
patients O
because O
of O
toxicity B-outcome ['Adverse-effects']
. O
['Adverse-effects']

Coagulation O
factor O
concentrate O
in O
the O
treatment O
of O
the O
haemorrhagic B-outcome ['Physiological-Clinical']
diathesis I-outcome ['Physiological-Clinical']
of O
fulminant O
hepatic O
failure O
. O
['Physiological-Clinical']

Documented O
attack B-outcome ['Physiological-Clinical']
frequency O
and O
duration O
were O
controlled O
at O
monthly O
physical O
examinations O
. O
['Physiological-Clinical']

The O
pain B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
and O
the O
summation B-outcome ['Life-Impact']
threshold I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
electrical I-outcome ['Life-Impact']
stimuli I-outcome ['Life-Impact']
and O
the O
summation B-outcome ['Life-Impact']
threshold I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
heat I-outcome ['Life-Impact']
stimuli I-outcome ['Life-Impact']
increased O
significantly O
following O
treatment O
in O
both O
venlafaxine O
groups O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

RESULTS O
The O
toxicity B-outcome ['Adverse-effects']
could O
be O
evaluated O
in O
101 O
patients O
. O
['Adverse-effects']

In O
a O
recent O
randomized O
clinical O
trial O
, O
people O
who O
performed O
sensory O
re-training O
exercises O
reported O
less O
difficulty O
related O
to O
residual O
numbness O
and O
decreased O
lip O
sensitivity O
than O
those O
who O
performed O
standard O
opening O
exercises O
only O
. O
[]

Reversal O
of O
skeletal O
effects O
of O
endocrine O
treatments O
in O
the O
Intergroup O
Exemestane O
Study O
. O
[]

.01 O
) O
. O
[]

We O
analyzed O
incidence O
of O
cardiovascular B-outcome ['Mortality']
death I-outcome ['Mortality']
or O
rehospitalization B-outcome ['Resource-use']
for O
congestive B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
after O
PCI O
as O
well O
as O
various O
aspects O
of O
epicardial O
flow O
and O
microvascular O
function O
. O
['Mortality', 'Resource-use', 'Physiological-Clinical']

Control O
group O
participants O
wore O
a O
nonweighted O
vest O
. O
[]

The O
relative O
changes O
in O
wheal O
and O
flare O
areas O
were O
correlated O
with O
mizolastine O
trough O
plasma O
levels O
on O
day O
5 O
. O
[]

CONCLUSION O
No O
difference O
was O
observed O
between O
patients O
treated O
with O
meropenem O
and O
those O
treated O
with O
imipenem O
in O
terms O
of O
incidence O
of O
pancreatic B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( O
11.4 O
% O
versus O
13.6 O
% O
) O
and O
['Physiological-Clinical']

Medium O
chain O
triglyceride O
oil O
consumption O
as O
part O
of O
a O
weight O
loss O
diet O
does O
not O
lead O
to O
an O
adverse O
metabolic O
profile O
when O
compared O
to O
olive O
oil O
. O
[]

Thirty-five O
preschool O
children O
with O
a O
DSM O
III-R O
diagnosis O
of O
autism O
or O
pervasive O
developmental O
disorder O
were O
randomized O
to O
an O
experimental O
or O
control O
group O
. O
[]

Comparison O
of O
indicators O
for O
a O
primary O
care O
medical O
home O
between O
children O
with O
autism O
or O
asthma O
and O
other O
special O
health O
care O
needs O
: O
National O
Survey O
of O
Children O
's O
Health O
. O
[]

Women O
with O
a O
positive O
HPV O
test O
and O
a O
normal O
Pap O
test O
result O
were O
offered O
a O
second O
HPV O
test O
at O
least O
1 O
year O
later O
, O
and O
those O
who O
were O
found O
to O
be O
persistently O
infected O
with O
the O
same O
high-risk O
type O
of O
HPV O
were O
then O
offered O
colposcopy O
with O
cervical O
biopsy O
. O
[]

METHODS O
Multicenter O
, O
randomized O
, O
controlled O
, O
two O
arm-parallel O
, O
clinical O
trial O
. O
[]

Of O
the O
174 O
patients O
who O
could O
be O
evaluated O
, O
126 O
( O
72.4 O
percent O
) O
had O
a O
sustained B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
, O
but O
only O
86 O
( O
49.4 O
percent O
) O
remained O
in O
remission B-outcome ['Physiological-Clinical']
for O
the O
remainder O
of O
the O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
some O
evidence O
of O
therapeutic O
carry-over O
effects O
in O
both O
clinical O
and O
biochemical O
measures O
in O
those O
children O
who O
received O
NTX O
before O
PLC O
. O
[]

70 O
mg/dL O
on O
the O
prior O
day O
( O
4.5 O
vs. O
0.5 O
% O
; O
P O
< O
0.001 O
) O
, O
but O
the O
positive O
predictive O
value O
( O
PPV O
) O
was O
low O
( O
< O
5 O
% O
) O
. O
[]

Cases O
in O
which O
the O
EBUS O
probe O
was O
located O
within O
the O
lesions O
had O
a O
significantly O
higher B-outcome ['Physiological-Clinical']
diagnostic I-outcome ['Physiological-Clinical']
yield I-outcome ['Physiological-Clinical']
( O
78.3 O
% O
) O
than O
when O
the O
EBUS O
probe O
was O
adjacent O
to O
them O
( O
47.2 O
% O
, O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

The O
patients O
in O
the O
ozone O
therapy O
group O
were O
treated O
with O
basic O
treatments O
plus O
ozone O
therapy O
system O
. O
[]

A O
preliminary O
trial O
of O
ascorbic O
acid O
as O
supplemental O
therapy O
for O
autism O
. O
[]

However O
, O
the O
combination O
of O
the O
2 O
agents O
was O
associated O
with O
more O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
without O
an O
increase O
in O
benefit O
. O
['Adverse-effects']

We O
conclude O
that O
CAE O
suspension O
has O
greater O
clinical B-outcome ['Physiological-Clinical']
efficacy O
than O
CEC O
and O
fewer O
side O
effects O
than O
AMX-CL O
. O
['Physiological-Clinical']

The O
3-year O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
+/- O
SE O
for O
all O
patients O
with O
CNS+ O
disease O
was O
45 O
% O
+/- O
7 O
% O
. O
['Mortality']

An O
interval O
of O
five O
days B-outcome ['Physiological-Clinical']
without I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
achieved O
in O
88 O
percent O
of O
those O
assigned O
to O
staple O
transection O
and O
in O
62 O
percent O
of O
those O
assigned O
to O
sclerotherapy O
after O
a O
single O
injection O
( O
P O
less O
than O
0.01 O
) O
and O
82 O
percent O
after O
three O
injections O
. O
['Physiological-Clinical']

In O
the O
2nd O
group O
35 O
patients O
were O
given O
a O
daily O
dose O
of O
TAM O
of O
20 O
mg/m2 O
for O
15 O
days O
and O
then O
an O
oral O
daily O
dose O
of O
medroxyprogesterone O
acetate O
of O
350 O
mg/m2 O
for O
the O
next O
15 O
days O
. O
[]

MATERIAL O
AND O
METHODS O
399 O
out O
of O
457 O
patients O
recruited O
in O
this O
study O
were O
divided O
in O
a O
good O
or O
poor O
prognostic O
group O
depending O
on O
the O
presence O
of O
two O
or O
more O
poor O
prognostic O
factors O
, O
these O
were O
pain O
requiring O
treatment O
, O
> O
5 O
bone O
metastases O
, O
hydronephrosis O
, O
and O
alkaline O
phosphatase O
> O
2 O
ULN O
. O
[]

In O
the O
EPA O
group O
plasma B-outcome ['Physiological-Clinical']
free-EPA I-outcome ['Physiological-Clinical']
increased O
significantly O
from O
1000 O
mg O
onwards O
and O
plasma B-outcome ['Physiological-Clinical']
free-arachidonic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
decreased O
after O
1000 O
mg O
EPA O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Surprisingly O
, O
neither O
[]

Fasting O
in O
combination O
with O
pegvisomant O
also O
decreased O
serum B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
IGF-I I-outcome ['Physiological-Clinical']
levels O
( O
1.0 O
+/- O
0.15 O
vs. O
0.31 O
+/- O
0.07 O
ng/ml O
) O
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
potential O
for O
online O
continuing O
medical O
education O
( O
CME O
) O
seminars O
to O
improve O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
. O
['Life-Impact']

Direct O
microscopy O
of O
the O
bile O
was O
performed O
during O
cholecystectomy O
in O
111 O
patients O
in O
an O
attempt O
to O
identify O
those O
with O
a O
high O
risk O
of O
wound O
infection O
. O
[]

The O
incidence O
rate O
of O
severe B-outcome ['Physiological-Clinical']
hypoglycemia I-outcome ['Physiological-Clinical']
was O
21.8 O
and O
7.1 O
events O
per O
100 O
person-years O
in O
the O
first O
and O
last O
6 O
months O
, O
respectively O
. O
['Physiological-Clinical']

Ketorolac O
produced O
no O
major B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
pharmacokinetics I-outcome ['Physiological-Clinical']
of O
( O
R O
) O
- O
or O
( O
S B-outcome ['Physiological-Clinical']
) O
-warfarin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
a O
significant O
difference O
at O
Week O
6 O
in O
model-adjusted B-outcome ['Physiological-Clinical']
CD40-ligand I-outcome ['Physiological-Clinical']
levels O
in O
favor O
of O
clopidogrel O
plus O
aspirin O
compared O
with O
placebo O
plus O
aspirin O
in O
both O
the O
intent-to-treat O
population O
( O
difference O
between O
least-squares O
means O
= O
-186.5 O
; O
95 O
% O
confidence O
interval O
, O
-342.3 O
to O
-30.8 O
; O
P O
= O
0.02 O
) O
and O
the O
per-protocol O
population O
( O
P O
= O
0.05 O
) O
. O
['Physiological-Clinical']

In O
101 O
patients O
, O
embryo B-outcome ['Physiological-Clinical']
transfer I-outcome ['Physiological-Clinical']
was O
performed O
: O
26 O
in O
the O
IVF- O
group O
and O
75 O
in O
the O
IVF+ O
group O
. O
['Physiological-Clinical']

The O
cannulation O
site O
was O
examined O
for O
complications B-outcome ['Adverse-effects']
such O
as O
hematoma O
, O
nerve B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
, O
and O
['Adverse-effects', 'Physiological-Clinical']

XS0601 O
reduces O
the O
incidence O
of O
restenosis O
: O
a O
prospective O
study O
of O
335 O
patients O
undergoing O
percutaneous O
coronary O
intervention O
in O
China O
. O
[]

There O
were O
no O
significant O
between-group O
differences O
in O
outcome O
at O
any O
data O
point O
( O
ds= O
-0.13 O
to O
0.15 O
) O
. O
[]

The O
tapes O
differed O
in O
the O
extent O
to O
which O
they O
portrayed O
the O
recovery O
period O
as O
a O
steady O
, O
forward O
progression O
versus O
a O
series O
of O
ups O
and O
downs O
. O
[]

Data O
on O
the O
effect O
of O
hormone O
replacement O
therapy O
on O
hemostasis O
are O
inconsistent O
, O
and O
there O
are O
few O
data O
in O
women O
with O
coronary O
artery O
disease O
. O
[]

RESULTS O
Analysis O
of O
the O
primary O
outcome O
measures O
found O
no O
statistically O
significant O
difference O
between O
paroxetine O
or O
imipramine O
versus O
placebo O
. O
[]

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
tumors I-outcome ['Physiological-Clinical']
larger I-outcome ['Physiological-Clinical']
than I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
cm I-outcome ['Physiological-Clinical']
was O
significantly O
longer O
in O
the O
THP O
group O
( O
P O
= O
0.0137 O
) O
. O
['Physiological-Clinical']

In O
particular O
, O
the O
clinical O
results O
of O
endotoxin O
removal O
with O
polymyxin O
B O
immobilized O
fiber O
are O
summarized O
in O
this O
article O
. O
[]

Changes O
in O
mean O
deviation O
( O
MD O
) O
, O
corrected O
pattern O
standard O
deviation O
( O
CPSD B-outcome ['Physiological-Clinical']
) O
, O
and O
total O
deviation O
( O
TD O
) O
at O
74 O
test O
points O
were O
analyzed O
using O
regression O
analysis O
with O
linear O
mixed O
model O
. O
['Physiological-Clinical']

rHu O
EPO O
treatment O
affects O
the O
T O
lymphocyte O
subsets O
inducing O
a O
deep O
decrease O
of O
CD8 B-outcome ['Physiological-Clinical']
and O
CD16 B-outcome ['Physiological-Clinical']
cell O
percentage O
leading O
to O
normalisation O
of O
the O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
a O
single-center O
, O
multiple-referral O
source O
study O
, O
38 O
patients O
with O
progressive O
IgA O
nephropathy O
and O
controlled O
hypertension O
were O
randomized O
to O
treatment O
with O
prednisolone O
and O
cytotoxic O
agents O
, O
to O
therapy O
with O
low-dose O
cyclophosphamide O
then O
azathioprine O
, O
and O
to O
control O
groups O
. O
[]

BACKGROUND O
AND O
AIM O
In O
this O
study O
we O
developed O
a O
new O
methodology O
for O
obtaining O
human O
skeletal O
muscle O
samples O
to O
evaluate O
gene O
expression O
. O
[]

The O
reduction O
in O
the O
signals B-outcome ['Physiological-Clinical']
persisted O
at O
the O
24-hour O
recording O
. O
['Physiological-Clinical']

However O
, O
the O
number O
of O
deaths B-outcome ['Mortality']
prevented O
analysis O
with O
statistical O
controls O
. O
['Mortality']

Planimetric O
and O
prolate O
ellipsoid O
volumes O
of O
the O
total O
prostate O
as O
well O
as O
of O
the O
transition O
zone O
were O
measured O
. O
[]

To O
evaluate O
the O
untoward O
effects O
of O
fenfluramine O
in O
children O
with O
autism O
, O
12 O
subjects O
were O
systematically O
studied O
. O
[]

In O
general O
, O
the O
effects O
of O
creation O
of O
a O
fistula O
on O
LV O
structure O
were O
limited O
. O
[]

The O
MSLTs O
of O
insomniacs O
during O
treatment O
in O
study O
month O
1 O
were O
correlated O
( O
r O
= O
0.44 O
, O
P O
< O
0.001 O
) O
with O
their O
month O
8 O
MSLT O
. O
[]

The O
PANSS O
( O
6 O
) O
depression O
subscale O
, O
a O
proxy O
measure O
of O
quality O
of O
life O
, O
showed O
a O
clinically O
significant O
effect O
for O
sertindole O
20 O
mg O
and O
no O
effect O
for O
haloperidol O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
is O
to O
examine O
some O
of O
the O
variables O
involved O
in O
obstetric O
triage O
in O
an O
effort O
to O
develop O
a O
more O
efficient O
patient O
care O
delivery O
system O
in O
a O
high-volume O
obstetric O
unit O
. O
[]

A O
study O
of O
a O
Self-Care O
Rehabilitation O
Program O
in O
pediatric O
asthma O
. O
[]

Although O
quality O
of O
life O
did O
not O
differ O
significantly O
, O
chemotherapy O
compliance O
was O
significantly O
higher O
in O
the O
PRE O
group O
. O
[]

In O
Group O
GA O
, O
mean O
intraabdominal B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
significantly O
( O
p O
= O
0.006 O
) O
decreased O
when O
compared O
to O
baseline O
preanesthetic O
recordings O
. O
['Physiological-Clinical']

At O
the O
end O
of O
the O
study O
, O
urinary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
NAG-creatinine I-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
decreased O
in O
the O
active O
group O
from O
920 O
+/- O
522 O
mg/d O
and O
14.3 O
+/- O
16.9 O
U/g O
to O
803 O
+/- O
523 O
mg/d O
( O
P O
< O
0.001 O
) O
and O
10.5 O
+/- O
9.3 O
U/g O
( O
P O
< O
0.05 O
) O
, O
respectively O
. O
['Physiological-Clinical']

Screening O
was O
completed O
for O
19,236 O
members O
( O
79.6 O
% O
) O
, O
of O
whom O
4,653 O
were O
smokers O
; O
85.3 O
% O
of O
the O
smokers O
were O
enrolled O
. O
[]

The O
number O
of O
complete B-outcome ['Life-Impact']
arousals I-outcome ['Life-Impact']
decreased O
from O
5 O
( O
range O
1 O
to O
12 O
) O
to O
less O
than O
1 O
per O
night O
( O
range O
0 O
to O
2 O
) O
( O
P O
= O
.001 O
) O
. O
['Life-Impact']

The O
integrity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
lenses I-outcome ['Physiological-Clinical']
and O
the O
ocular B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
lens O
wear O
were O
monitored O
in O
both O
groups O
every O
three O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
aimed O
to O
analyse O
the O
effectiveness O
of O
an O
intervention O
for O
the O
nursing O
diagnosis O
of O
ineffective O
airway B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
in O
asthmatic O
children O
. O
['Physiological-Clinical']

The O
increased O
number O
of O
steps O
during O
the O
recovery O
was O
accompanied O
by O
a O
significantly O
greater O
decrease O
in O
blood O
lactate O
concentration O
percentage O
( O
28.1 O
? O
[]

The O
present O
findings O
suggest O
that O
norepinephrine O
may O
play O
a O
role O
in O
some O
, O
but O
not O
necessarily O
all O
, O
cognitive B-outcome ['Life-Impact']
impairments I-outcome ['Life-Impact']
associated O
with O
ASD O
. O
['Life-Impact']

RESULTS O
Of O
43 O
participants O
, O
40 O
were O
randomized O
to O
tissue O
sampling O
. O
[]

Goodstart O
: O
a O
cluster O
randomised O
effectiveness O
trial O
of O
an O
integrated O
, O
community-based O
package O
for O
maternal O
and O
newborn O
care O
, O
with O
prevention O
of O
mother-to-child O
transmission O
of O
HIV O
in O
a O
South O
African O
township O
. O
[]

The O
purposes O
of O
this O
study O
were O
to O
examine O
the O
influence O
of O
ultrasound O
on O
the O
transdermal O
delivery O
of O
ketoprofen O
in O
humans O
and O
to O
compare O
the O
concentrations O
found O
after O
continuous O
and O
pulsed O
application O
. O
[]

Patients O
demonstrated O
a O
modest O
improvement O
in O
PFS B-outcome ['Mortality']
but O
no O
improvement O
in O
OS B-outcome ['Mortality']
compared O
with O
children O
with O
low-grade O
gliomas O
who O
were O
treated O
with O
contemporary O
chemotherapy-alone O
approaches O
. O
['Mortality', 'Mortality']

These O
findings O
provide O
support O
for O
further O
studies O
of O
pharmacologic O
potentiation O
of O
CFTR O
as O
a O
means O
to O
treat O
cystic O
fibrosis O
. O
( O
[]

On O
the O
next O
day O
patients O
were O
administered O
450 O
mg/24 O
h O
amiodarone O
i.v O
. O
[]

A O
controlled O
prospective O
evaluation O
of O
pregnancy O
complicated O
by O
chronic O
hypertension O
is O
proposed O
and O
preliminary O
data O
on O
population O
selection B-outcome ['Life-Impact']
and O
pregnancy B-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
are O
presented O
. O
['Life-Impact', 'Physiological-Clinical']

The O
IJV B-outcome ['Physiological-Clinical']
could O
be O
located O
in O
all O
patients O
with O
both O
ultrasound O
methods O
, O
but O
the O
course O
of O
the O
IJV B-outcome ['Physiological-Clinical']
could O
only O
be O
identified O
by O
ultrasonography O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Our O
goals O
were O
to O
evaluate O
the O
efficacy O
of O
intravenous O
octreotide O
( O
OC O
) O
for O
the O
treatment O
of O
migraines O
, O
when O
compared O
to O
standard O
therapy O
with O
prochlorperazine O
. O
[]

Since O
the O
central O
figure O
in O
implementing O
this O
training O
protocol O
is O
the O
nursing O
aide O
, O
it O
is O
important O
to O
find O
an O
organizational O
management O
scheme O
that O
will O
stimulate O
nursing O
aides O
to O
reduce O
incontinence O
among O
nursing O
home O
residents O
. O
[]

Patients O
who O
previously O
received O
radiotherapy O
did O
not O
benefit O
from O
adjuvant O
therapy O
. O
[]

Three O
splinterings O
of O
the O
distal B-outcome ['Physiological-Clinical']
fragment I-outcome ['Physiological-Clinical']
, O
one O
resulting O
in O
a O
change O
of O
the O
osteosynthesis O
implant O
to O
a O
condylar O
plate O
, O
were O
considered O
to O
result O
from O
the O
high O
stiffness O
of O
the O
non-slotted O
nail O
. O
['Physiological-Clinical']

Compliance O
with O
depot O
medroxyprogesterone O
acetate O
: O
a O
randomized O
, O
controlled O
trial O
of O
intensive O
reminders O
. O
[]

The O
present O
study O
investigated O
zeaxanthin B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
from O
three O
wolfberry O
formulations O
. O
['Physiological-Clinical']

The O
data O
were O
analysed O
by O
the O
non-parametric O
Wilcoxon O
rank O
sum O
test O
using O
STATA O
7.0 O
. O
[]

A O
randomized O
, O
double-blind O
crossover O
trial O
, O
in O
10 O
adult O
healthy O
subjects O
, O
was O
carried O
out O
to O
compare O
the O
antibacterial B-outcome ['Physiological-Clinical']
and O
antifungal B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
of O
a O
0.1 O
% O
solution O
of O
hexetidine O
with O
that O
of O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Transfusion B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
were O
similar O
in O
both O
groups O
. O
['Resource-use']

At O
baseline O
, O
there O
were O
no O
significant O
differences O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
, O
basal B-outcome ['Physiological-Clinical']
femoral I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( O
via O
Doppler O
ultrasound O
) O
, O
vascular B-outcome ['Physiological-Clinical']
conductance I-outcome ['Physiological-Clinical']
, O
and O
vascular B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

On O
each O
study O
day O
, O
spirometric B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
were O
measured O
at O
5 O
, O
10 O
, O
15 O
and O
60 O
minutes O
, O
and O
hourly O
thereafter O
up O
to O
and O
including O
12 O
hours O
after O
study O
drug O
administration O
. O
['Physiological-Clinical']

BACKGROUND O
Communication O
between O
African O
American O
patients O
and O
white O
health O
care O
providers O
has O
been O
shown O
to O
be O
of O
poorer O
quality O
when O
compared O
with O
race-concordant O
patient-provider O
communication O
. O
[]

Breathing O
100 O
ppm O
of O
carbon O
monoxide O
for O
1 O
hour O
caused O
a O
significant O
reduction O
in O
exercise O
performance O
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
. O
[]

IP O
resulted O
in O
a O
complete O
recovery O
of O
the O
mean O
stroke B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
index O
( O
SVI O
) O
after O
the O
operation O
. O
['Physiological-Clinical']

The O
subjects O
in O
this O
double-blind O
randomized O
controlled O
study O
were O
24 O
adult O
patients O
who O
underwent O
chemotherapy O
during O
2009-2010 O
. O
[]

The O
bacteriological B-outcome ['Physiological-Clinical']
success O
rate O
at O
the O
7-16 O
days O
post-therapy O
evaluation O
was O
similar O
in O
both O
treatment O
groups O
: O
91.5 O
% O
and O
90.8 O
% O
in O
the O
faropenem O
daloxate O
and O
cefuroxime O
axetil O
groups O
, O
respectively O
( O
95 O
% O
CI=-9.2 O
% O
; O
+9.5 O
% O
) O
. O
['Physiological-Clinical']

Constant O
phase O
factors O
associated O
with O
death O
included O
genetic O
syndrome O
( O
P O
< O
.001 O
) O
and O
lower O
gestational O
age O
( O
P O
< O
.001 O
) O
. O
[]

Increasing O
the O
perturbation O
magnitude O
accelerated O
postural B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
, O
but O
again O
with O
a O
larger O
acceleration O
for O
backward O
perturbations O
. O
['Physiological-Clinical']

The O
patients O
were O
randomly O
allocated O
to O
each O
of O
three O
2-week O
treatment O
periods O
with O
propranolol O
80 O
mg O
b.i.d. O
, O
atenolol O
50 O
mg O
b.i.d O
. O
[]

After O
treatment O
, O
eyes O
receiving O
fusidic O
acid O
were O
more O
likely O
to O
be O
free O
of O
clinically O
relevant O
Staphylococcus O
spp O
. O
[]

Although O
aging O
is O
associated O
with O
multiple O
abnormalities O
in O
immune O
function O
, O
the O
effect O
of O
aging O
on O
the O
production O
of O
proinflammatory B-outcome ['Physiological-Clinical']
cytokines O
has O
not O
been O
well O
studied O
under O
conditions O
of O
clinical O
stress O
. O
['Physiological-Clinical']

24 O
min O
and O
17 O
? O
[]

Patient O
education O
materials O
did O
not O
enhance O
guideline O
effectiveness O
. O
[]

BACKGROUND O
Allogeneic O
hematopoietic O
stem-cell O
transplantation O
is O
a O
widely O
used O
, O
cost-intensive O
procedure O
. O
[]

For O
each O
limb O
, O
wounds O
were O
randomly O
assigned O
to O
four O
treatment O
groups O
: O
no O
treatment O
( O
control O
) O
, O
carrier O
( O
Methyl O
Cellulose O
gel O
) O
, O
50 O
ng/wound O
rhTGF-beta O
1 O
in O
carrier O
, O
and O
500 O
ng/wound O
rhTGF-beta O
1 O
in O
carrier O
. O
[]

The O
effects O
of O
clonidine O
and O
hydrochlorothiazide O
on O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
were O
studied O
in O
hypertensive O
adolescents O
requiring O
pharmacologic O
therapy O
for O
blood O
pressure O
control O
. O
['Life-Impact']

The O
overall O
diagnostic B-outcome ['Life-Impact']
yield I-outcome ['Life-Impact']
of O
cryobiopsy O
was O
89.5 O
% O
. O
['Life-Impact']

Greater O
proportions O
of O
high O
responders B-outcome ['Physiological-Clinical']
were O
also O
observed O
at O
3 O
( O
51.1 O
% O
vs O
39.6 O
% O
; O
P O
= O
.26 O
) O
, O
4 O
( O
77.3 O
% O
vs O
56.3 O
% O
; O
P O
= O
.03 O
) O
, O
and O
10 O
months O
( O
87.8 O
% O
vs O
51.1 O
% O
; O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

Median O
response O
duration O
, O
time O
to O
treatment O
failure B-outcome ['Physiological-Clinical']
, O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( O
TTP B-outcome ['Physiological-Clinical']
) O
were O
similar O
in O
each O
arm O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
drop-outs O
. O
[]

SML O
was O
also O
significantly O
better O
for O
the O
other O
criteria O
( O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
rescue B-outcome ['Resource-use']
salbutamol I-outcome ['Resource-use']
intake I-outcome ['Resource-use']
during I-outcome ['Resource-use']
day I-outcome ['Resource-use']
and O
night B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

More O
perceived B-outcome ['Life-Impact']
impact I-outcome ['Life-Impact']
was O
reported O
for O
injection B-outcome ['Resource-use']
risk O
behaviors B-outcome ['Life-Impact']
than O
for O
['Life-Impact', 'Resource-use', 'Life-Impact']

It O
adds O
to O
methodological O
developments O
in O
palliative O
care O
research O
where O
complex O
interventions O
are O
common O
but O
evidence O
sparse O
. O
[]

The O
first O
group O
( O
n O
= O
49 O
) O
received O
ketoconazole O
( O
400 O
mg O
daily O
) O
till O
correction O
of O
metabolic O
syndrome O
followed O
by O
clomiphene O
( O
100 O
mg/day O
) O
; O
the O
second O
group O
( O
n O
= O
48 O
) O
receiving O
clomiphene O
without O
ketoconazole O
pretreatment O
. O
[]

The O
incidence O
of O
necrotizing B-outcome ['Physiological-Clinical']
enterocolitis I-outcome ['Physiological-Clinical']
was O
12.0 O
percent O
in O
the O
immune O
globulin O
group O
and O
9.5 O
percent O
in O
the O
control O
group O
. O
['Physiological-Clinical']

Azathioprine O
was O
administered O
at O
1-2 O
mg/kg O
per O
day O
. O
[]

Patients O
with O
post-thrombotic O
venous O
disease O
have O
a O
compromised O
hemodynamic O
response O
to O
all O
IPC O
devices O
. O
[]

On O
follow-up O
, O
the O
sevelamer O
group O
had O
higher O
levels O
of O
intact B-outcome ['Physiological-Clinical']
parathyroid I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( O
498 O
+/- O
352 O
vs. O
326 O
+/- O
236 O
pg/ml O
, O
p O
= O
0.017 O
) O
, O
bone B-outcome ['Physiological-Clinical']
alkaline I-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
( O
38 O
+/- O
24 O
vs. O
28 O
+/- O
15 O
U/l O
, O
p O
= O
0.03 O
) O
and O
deoxypyridinoline B-outcome ['Physiological-Clinical']
( O
135 O
+/- O
107 O
vs. O
89 O
+/- O
71 O
nmol/l O
, O
p O
= O
0.03 O
) O
and O
lower B-outcome ['Physiological-Clinical']
LDL I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
74 O
+/- O
21 O
vs. O
91 O
+/- O
28 O
mg/dl O
, O
p O
= O
0.015 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
randomly O
allocated O
( O
17 O
patients O
in O
each O
group O
) O
to O
risperidone O
( O
6 O
mg/day O
) O
or O
haloperidol O
15 O
mg/day O
or O
clozapine O
( O
300 O
mg/day O
) O
. O
[]

The O
appreciably O
greater O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
with O
lansoprazole O
was O
due O
tothe O
faster O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
achieved O
with O
this O
drug O
. O
['Life-Impact', 'Physiological-Clinical']

This O
study O
supports O
our O
previous O
work O
by O
confirming O
that O
lorazepam O
reliably O
worsens O
saccadic B-outcome ['Life-Impact']
distractibility I-outcome ['Life-Impact']
, O
in O
contrast O
to O
other O
psychotropic O
drugs O
such O
as O
sertraline O
and O
chlorpromazine O
. O
['Life-Impact']

Toothbrush O
heads O
were O
vortexed O
and O
cultured O
for O
Prevotella O
species O
( O
Ps O
) O
, O
Porphyromonas O
gingivalis O
( O
Pg O
) O
, O
Actinobacillus O
actinomycetemcomitans O
( O
Aa O
) O
, O
and O
non-specific O
colony-forming O
units O
( O
NS O
) O
. O
[]

Thirty-nine O
prelinguistic O
toddlers O
with O
intellectual O
disabilities O
and O
their O
primary O
caregivers O
participated O
in O
this O
study O
. O
[]

RESULTS O
Four O
( O
1.3 O
% O
) O
patients O
were O
excluded O
because O
of O
unbearable B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
during O
the O
procedure O
, O
leaving O
Group O
1 O
with O
98 O
patients O
, O
Group O
2 O
with O
99 O
, O
and O
Group O
3 O
with O
99 O
; O
the O
3 O
groups O
were O
comparable O
for O
patients O
' O
age O
, O
serum B-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
, O
prostate B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
and O
cancer B-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Standardized O
effect O
sizes O
[ O
last O
observation O
carried O
forward O
( O
LOCF O
) O
] O
at O
endpoint O
were O
calculated O
. O
[]

Anesthesia O
was O
induced O
with O
2.0 O
mg/kg O
propofol O
i.v O
. O
[]

The O
extent O
of O
vertebral O
deformity O
was O
measured O
by O
a O
vertebral O
index O
as O
well O
as O
height O
. O
[]

Follow-up O
of O
a O
randomised O
controlled O
trial O
. O
[]

The O
results O
before O
and O
after O
irrigation O
were O
compared O
using O
the O
Wilcoxon O
t-test O
. O
[]

METHODS O
In O
this O
randomized O
, O
right-left O
comparison O
study O
, O
35 O
women O
with O
axillary O
hair O
received O
single-session O
diode O
laser O
therapy O
. O
[]

The O
doses O
100 O
mg O
twice O
daily O
and O
50 O
mg O
, O
100 O
mg O
and O
200 O
mg O
once O
daily O
were O
given O
double-blind O
and O
randomised O
within O
patients O
following O
run-in O
on O
placebo O
. O
[]

Short- O
and O
long-term O
results O
after O
thrombolytic O
treatment O
of O
deep O
venous O
thrombosis O
. O
[]

The O
objective O
of O
the O
study O
was O
to O
carry O
out O
a O
12-wk O
randomized O
, O
single-blind O
trial O
to O
test O
the O
effect O
of O
a O
25 O
% O
energy O
deficit O
weight O
loss O
diet O
alone O
( O
WL O
) O
( O
n O
= O
12 O
) O
or O
WL O
plus O
4 O
g/d O
Omacor O
( O
46 O
% O
EPA O
and O
38 O
% O
DHA O
) O
supplementation O
( O
WL+FAEE O
) O
( O
n O
= O
13 O
) O
on O
arterial O
elasticity O
in O
obese O
adults O
. O
[]

RESULTS O
Task B-outcome ['Life-Impact']
performances I-outcome ['Life-Impact']
were O
significantly O
better O
in O
the O
CLS O
group O
than O
in O
either O
SPLS O
group O
. O
['Life-Impact']

Topical O
treatment O
of O
tinea O
pedis O
using O
6 O
% O
coriander O
oil O
in O
unguentum O
leniens O
: O
a O
randomized O
, O
controlled O
, O
comparative O
pilot O
study O
. O
[]

Qualitative O
information O
gathered O
from O
parents O
and O
teachers O
indicated O
some O
generalization O
of O
strategies O
learned O
in O
the O
clinic O
setting O
to O
both O
home O
and O
school O
settings O
. O
[]

Twenty-nine O
were O
assigned O
to O
a O
control O
group O
and O
56 O
to O
an O
intervention O
group O
( O
I O
group O
) O
( O
dropouts O
= O
8 O
) O
. O
[]

The O
impact O
of O
allergy O
on O
patient O
's O
quality O
of O
life O
is O
substantial O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
satisfaction B-outcome ['Life-Impact']
rate O
and O
the O
effectiveness O
of O
transcervical O
hysteroscopic O
endometrial O
resection O
and O
thermal O
destruction O
of O
the O
endometrium O
in O
the O
treatment O
of O
menorrhagia O
. O
['Life-Impact']

Time B-outcome ['Physiological-Clinical']
since I-outcome ['Physiological-Clinical']
MI I-outcome ['Physiological-Clinical']
and O
SPECT B-outcome ['Physiological-Clinical']
defect I-outcome ['Physiological-Clinical']
location O
and O
intensity B-outcome ['Physiological-Clinical']
were O
all O
determinants O
of O
the O
MCE O
response O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Treatment O
was O
not O
found O
to O
induce O
gastritic B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in O
the O
mucosa O
. O
['Physiological-Clinical']

RESULTS O
Between O
1 O
and O
3 O
years O
, O
there O
were O
infrequent O
additional O
clinical O
events O
that O
were O
equally O
distributed O
between O
the O
SES O
and O
the O
BMS O
group O
. O
[]

The O
proximal O
tibiofibular O
joint O
manipulation O
and O
control O
groups O
did O
not O
demonstrate O
a O
change O
in O
soleus B-outcome ['Physiological-Clinical']
H/M I-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
midazolam O
plus O
fentanyl O
group O
had O
a O
mean O
TICS O
score O
of O
34.76 O
at O
24 O
hours O
compared O
with O
36.26 O
at O
48 O
hours O
( O
P O
= O
.004 O
) O
. O
[]

Risk O
factors O
for O
smoking O
at O
both O
endpoints O
in O
the O
combined O
sample O
included O
treatment O
with O
tailored O
mailings O
, O
female O
gender O
, O
younger O
age O
, O
higher O
levels O
of O
tobacco O
dependence O
, O
shorter O
previous O
quit O
attempts O
, O
previous O
use O
of O
nicotine O
replacement O
therapy O
, O
and O
report O
of O
current O
depressive O
symptoms O
or O
lifetime O
depression O
. O
[]

Thirty-six O
out O
of O
38 O
( O
94.7 O
% O
) O
recipients O
were O
CMV-seropositive B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Participants O
( O
n O
= O
80 O
) O
were O
recruited O
from O
a O
hospital O
clinic O
in O
Chandigarh O
, O
India O
, O
and O
randomized O
to O
a O
3-month O
group O
intervention O
or O
individual O
enhanced O
standard O
of O
care O
followed O
by O
crossover O
of O
condition O
and O
assessed O
over O
6 O
months O
. O
[]

Linagliptin O
exhibits O
non-linear O
pharmacokinetics O
( O
PK O
) O
due O
to O
saturable O
binding O
to O
plasma O
and O
tissue O
DPP-4 O
. O
[]

Our O
results O
showed O
that O
IL-10 O
inhibits O
activation O
of O
the O
inflammatory O
HMGB1-RAGE O
pathway O
in O
the O
CCI O
rat O
model O
. O
[]

Group O
2 O
subjects O
took O
the O
TOVA O
under O
the O
same O
fake O
bad O
instructions O
first O
, O
then O
took O
the O
test O
under O
normal O
conditions O
the O
second O
time O
. O
[]

Growth O
hormone O
( O
GH O
) O
has O
been O
reported O
to O
have O
beneficial O
effects O
on O
bone B-outcome ['Physiological-Clinical']
in O
GHD O
. O
['Physiological-Clinical']

Effects O
of O
mild O
physical O
exercise O
on O
serum B-outcome ['Physiological-Clinical']
lipoproteins I-outcome ['Physiological-Clinical']
and O
metabolites O
of O
arachidonic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
: O
a O
controlled O
randomised O
trial O
in O
middle O
aged O
men O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
they O
did O
not O
report O
the O
relationship O
of O
tobacco B-outcome ['Life-Impact']
using I-outcome ['Life-Impact']
habits I-outcome ['Life-Impact']
with O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
low-dose O
dopexamine O
on O
morbidity O
after O
major O
abdominal O
surgery O
in O
patients O
who O
were O
at O
increased O
risk O
by O
virtue O
of O
a O
reduced O
AT O
. O
[]

One O
individual O
experienced O
tachycardia B-outcome ['Physiological-Clinical']
, O
mild B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
20 I-outcome ['Physiological-Clinical']
minutes I-outcome ['Physiological-Clinical']
, O
sneezing B-outcome ['Physiological-Clinical']
, O
itching O
of O
the O
nose O
, O
and O
rhinorrhea O
after O
60 O
minutes O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Microalbuminuria B-outcome ['Physiological-Clinical']
itself O
predicts O
clinical O
proteinuria O
in O
nondiabetic O
and O
in O
diabetic O
people O
. O
['Physiological-Clinical']

In O
the O
WP-CRT O
arm O
, O
13 O
patients O
had O
stage O
IIB O
disease O
and O
9 O
had O
stage O
IIIB O
disease O
; O
in O
the O
IMRT O
arm O
, O
12 O
patients O
had O
stage O
IIB O
disease O
and O
10 O
had O
stage O
IIIB O
disease O
. O
[]

Pace B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
was O
the O
only O
significant O
difference O
between O
the O
2 O
groups O
. O
['Physiological-Clinical']

Part O
II O
included O
32 O
patients O
. O
[]

Ten O
recreational O
athletes O
( O
6 O
women O
, O
4 O
men O
; O
71.9 O
? O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
validity O
of O
cardiotocography O
for O
the O
detection O
of O
cord B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
battery O
of O
five O
randomly O
sequenced O
tests O
was O
performed O
for O
each O
subject O
on O
one O
ankle O
. O
[]

The O
principal O
outcome O
measure O
was O
pain O
on O
a O
self-selected O
activity B-outcome ['Life-Impact']
assessed O
by O
Vas O
. O
['Life-Impact']

Extrapyramidal O
symptoms O
were O
not O
reported O
in O
any O
of O
the O
groups O
. O
[]

Lipid B-outcome ['Physiological-Clinical']
results O
, O
clinical B-outcome ['Physiological-Clinical']
CV I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
and O
safety O
outcomes O
from O
this O
trial O
are O
anticipated O
in O
2010 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Parent O
reports O
indicated O
a O
significant O
decrease O
in O
episodes B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
anger I-outcome ['Life-Impact']
following O
intervention O
and O
a O
significant O
increase O
in O
their O
own O
confidence B-outcome ['Life-Impact']
in O
managing B-outcome ['Life-Impact']
anger I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
child I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSION O
With O
the O
intervention O
sessions O
structured O
over O
12 O
weeks O
, O
it O
was O
possible O
to O
observe O
a O
few O
changes O
in O
the O
children O
's O
FCP O
and O
in O
the O
SCP O
. O
[]

After O
the O
final O
tightening O
of O
the O
crowns O
, O
no O
significant O
differences O
were O
observed O
between O
the O
test O
and O
control O
groups O
( O
p O
> O
.05 O
) O
. O
[]

Although O
less O
frequent O
with O
diltiazem O
administration O
( O
45 O
versus O
54 O
patients O
, O
p O
less O
than O
0.03 O
) O
, O
[]

These O
data O
show O
that O
salmeterol O
is O
a O
partial O
agonist O
on O
the O
beta2-receptor O
in O
relation O
to O
formoterol O
in O
human O
airways O
in O
vivo O
. O
[]

Risperidone O
also O
improved O
social B-outcome ['Life-Impact']
responsiveness I-outcome ['Life-Impact']
and O
nonverbal B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
and O
reduced O
the O
symptoms B-outcome ['Physiological-Clinical']
of O
hyperactivity B-outcome ['Life-Impact']
and O
aggression B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Apparent B-outcome ['Physiological-Clinical']
nitrogen I-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
was O
positive O
pre-operatively O
and O
became O
less O
so O
post-operatively O
whether O
insulin O
was O
given O
or O
not O
. O
['Physiological-Clinical']

GI O
and O
GII O
ewes O
were O
provided O
with O
ad O
libitum O
feeding O
while O
GIII O
and O
GIV O
ewes O
were O
provided O
with O
restricted O
feed O
( O
30 O
% O
intake O
of O
GI O
and O
GII O
ewes O
) O
to O
induce O
nutritional O
insufficiency O
. O
[]

There O
seems O
no O
benefit O
in O
delaying O
initiation O
of O
everolimus O
. O
[]

The O
mean O
treatment O
duration O
was O
10 O
and O
14 O
weeks O
, O
median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
was O
27.2 O
and O
30.8 O
weeks O
, O
median O
survival O
time O
was O
44 O
and O
50.9 O
weeks O
, O
and O
PSA B-outcome ['Physiological-Clinical']
response O
rate O
was O
only O
24.6 O
and O
28.9 O
% O
in O
the O
EMP/VBL O
and O
EMP O
arms O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
the O
changes O
in O
inflammatory B-outcome ['Physiological-Clinical']
biomarkers I-outcome ['Physiological-Clinical']
favored I-outcome ['Physiological-Clinical']
the O
supervised O
lifestyle O
intervention O
, O
the O
only O
significant O
reduction O
observed O
between O
the O
groups O
was O
for O
the O
anti-inflammatory O
IL-1 O
receptor O
antagonist O
( O
IL-1RA O
) O
. O
['Physiological-Clinical']

Results O
of O
a O
randomized O
double-blind O
placebo-controlled O
study O
. O
[]

RESULTS O
Progression O
of O
carotid B-outcome ['Physiological-Clinical']
IMT I-outcome ['Physiological-Clinical']
was O
inversely O
related O
to O
on-trial O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HDL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
P O
= O
0.04 O
) O
and O
was O
directly O
related O
to O
on-trial O
LDL-cholesterol O
( O
P O
= O
0.005 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

plus O
omeprazole O
20 O
mg O
b.d. O
, O
dirithromycin O
1000 O
mg O
q.d.s O
. O
[]

Each O
of O
the O
six O
sets O
of O
indicator O
variables O
was O
reduced O
to O
a O
high/moderate/low O
rating O
. O
[]

BACKGROUND O
Loss O
of O
muscle B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
and O
strength B-outcome ['Physiological-Clinical']
with O
ageing O
is O
a O
major O
cause O
for O
falls O
, O
disability O
, O
and O
morbidity O
in O
older O
people O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
suggests O
the O
efficacy O
of O
divalproex O
for O
the O
treatment O
of O
irritability B-outcome ['Life-Impact']
in O
children O
and O
adolescents O
with O
ASD O
. O
['Life-Impact']

METHODS O
Four O
interventions O
were O
compared O
: O
( O
a O
) O
the O
interactive O
expert O
system O
intervention O
; O
( O
b O
) O
the O
expert O
system O
intervention O
plus O
counselor O
calls O
; O
( O
c O
) O
the O
expert O
system O
intervention O
plus O
the O
stimulus O
control O
computer O
; O
and O
( O
d O
) O
an O
assessment O
only O
condition O
. O
[]

BACKGROUND O
Soil-transmitted O
helminths O
are O
among O
the O
most O
prevalent O
sources O
of O
human O
infections O
globally O
. O
[]

Improvements O
were O
significantly O
associated O
with O
higher O
stress O
in O
the O
families O
. O
[]

The O
cost-effectiveness O
of O
a O
Telephone O
Counselling O
intervention O
to O
improve O
physical O
activity O
and O
diet O
, O
targeting O
adults O
with O
established O
chronic O
diseases O
in O
a O
low O
socio-economic O
area O
of O
a O
major O
Australian O
city O
was O
examined O
. O
['Resource-use']

Other O
studies O
have O
demonstrated O
that O
LAIV-induced O
immunity O
is O
also O
partially O
explained O
by O
T-cell O
immunity O
, O
serum O
antibody O
responses O
, O
and O
innate O
immunity O
, O
consistent O
with O
the O
multi-faceted O
nature O
of O
immunity O
induced O
by O
wild-type O
influenza O
infection O
and O
other O
live O
virus O
vaccines O
. O
[]

This O
study O
is O
registered O
with O
ClinicalTrial.gov O
, O
number O
NCT00163722 O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
two O
groups O
at O
any O
time O
interval O
. O
[]

Ten O
patients O
underwent O
deactivation O
of O
additional O
( O
different O
) O
trigger O
sites O
during O
the O
follow-up O
period O
and O
were O
not O
included O
in O
the O
data O
analysis O
. O
[]

Amonafide O
: O
An O
active O
agent O
in O
the O
treatment O
of O
previously O
untreated O
advanced O
breast O
cancer O
-- O
a O
cancer O
and O
leukemia O
group O
B O
study O
( O
CALGB O
8642 O
) O
. O
[]

Breast-feeding O
is O
today O
the O
major O
form O
of O
infant O
nutrition O
in O
the O
immediate O
postpartum O
period O
. O
[]

The O
effects O
of O
sleep B-outcome ['Physiological-Clinical']
deprivation I-outcome ['Physiological-Clinical']
and O
caffeine O
on O
sustained O
attention O
and O
regional O
EEG O
power O
in O
['Physiological-Clinical']

BMI O
was O
not O
associated O
with O
nonprostate O
cancer O
or O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality']

Impact O
of O
a O
single O
intravenous O
administration O
of O
nicorandil O
before O
reperfusion O
in O
patients O
with O
ST-segment-elevation O
myocardial O
infarction O
. O
[]

Mean O
decrease O
in O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
10.3 O
mmHg O
in O
group O
1 O
, O
and O
9.3 O
mmHg O
in O
group O
2 O
( O
P O
= O
0.49 O
) O
. O
['Physiological-Clinical']

Measure O
of O
outcome O
was O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist-Community O
( O
ABC-C O
) O
Rating O
Scale O
. O
['Life-Impact']

OBJECTIVES O
to O
investigate O
the O
effectiveness O
of O
a O
pharmacy O
discharge O
plan O
in O
elderly O
hospitalized O
patients O
. O
[]

Thus O
, O
a O
combination O
product O
of O
buprenorphine O
and O
naloxone O
may O
have O
lower O
abuse B-outcome ['Physiological-Clinical']
liability I-outcome ['Physiological-Clinical']
than O
buprenorphine O
alone O
. O
['Physiological-Clinical']

The O
effect O
of O
patient O
position O
on O
the O
reproducibility O
of O
cardiac O
output O
measurements O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
split-face O
randomized O
prospective O
open-label O
trial O
was O
to O
determine O
the O
effectiveness O
of O
sequential O
erbium O
: O
yttrium-aluminum-garnet O
( O
Er O
: O
YAG O
) O
laser O
versus O
intense O
pulsed O
light O
( O
IPL O
) O
for O
the O
treatment O
of O
mild O
to O
moderate O
facial O
photodamage O
. O
[]

The O
primary O
end O
point O
was O
2-year O
incidence O
of O
major O
adverse O
cardiac O
events O
, O
defined O
as O
CAD O
death O
or O
hospitalization O
for O
an O
acute O
coronary O
syndrome O
or O
heart O
failure O
. O
[]

Safety O
assessments O
included O
vital O
signs O
, O
electrocardiogram O
, O
extrapyramidal O
symptoms O
, O
adverse O
events O
, O
and O
laboratory O
tests O
. O
[]

PATIENTS O
We O
studied O
369 O
patients O
who O
stayed O
in O
PICU O
for O
at O
least O
3 O
d O
( O
study O
1 O
) O
and O
126 O
patients O
in O
a O
nested O
case-control O
study O
( O
study O
2 O
) O
. O
[]

DESIGN O
A O
prospective O
randomized O
trial O
comparing O
short O
and O
ultrashort O
regimens O
of O
GnRH-a O
. O
[]

METHODS O
Participants O
were O
pregnant O
women O
( O
N=56 O
) O
, O
with O
past O
histories O
of O
MDD/PPMD O
but O
not O
depressed O
in O
their O
current O
pregnancy O
. O
[]

IL-6 O
is O
tightly O
regulated O
in O
response O
to O
exercise O
, O
being O
affected O
by O
factors O
such O
as O
exercise O
intensity O
and O
duration O
, O
as O
well O
as O
energy O
availability O
. O
[]

This O
study O
was O
designed O
to O
address O
the O
possibility O
that O
treatment O
with O
etidronate O
may O
reduce O
the O
bone O
resorption O
and O
lower O
the O
incidence O
of O
fractures O
in O
elderly O
patients O
who O
are O
chronically O
hospitalized O
and O
disabled O
as O
a O
result O
of O
hemiparesis O
after O
stroke O
. O
[]

However O
, O
at O
6 O
months O
( O
T2 O
) O
, O
analysis O
revealed O
significant O
better O
results O
for O
nearly O
all O
parameters O
in O
the O
BT O
group O
that O
showed O
further O
improvement O
from O
T1 O
to O
T2 O
, O
whereas O
the O
values O
in O
the O
MT O
group O
deteriorated O
from O
T1 O
back O
to O
the O
baseline O
values O
. O
[]

All O
patients O
suffered O
from O
partial-thickness O
burn O
injuries O
( O
< O
20 O
% O
TBSA O
) O
. O
[]

After O
8 O
weeks O
of O
treatment O
, O
all O
active O
treatments O
were O
superior O
to O
placebo O
( O
effect O
sizes O
ranging O
from O
0.42 O
to O
0.65 O
) O
. O
[]

Cardiopulmonary O
bypass O
during O
open-heart O
surgery O
is O
sometimes O
associated O
with O
excessive O
perioperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Lengthening O
the O
moment O
arm O
of O
the O
patella O
confers O
enhanced O
extensor B-outcome ['Physiological-Clinical']
mechanism I-outcome ['Physiological-Clinical']
power I-outcome ['Physiological-Clinical']
following O
total O
knee O
arthroplasty O
. O
['Physiological-Clinical']

METHODS O
We O
investigated O
in O
a O
one-year O
double O
blind O
randomized O
study O
comparing O
intramuscular O
( O
im O
) O
gold O
with O
im O
methotrexate O
( O
MTX O
) O
, O
whether O
the O
variation O
of O
inflammatory B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
or O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
, O
the O
ascending O
anatomic O
stage O
, O
or O
DMARD O
treatments O
have O
an O
influence O
on O
bone O
formation O
( O
osteocalcin O
) O
in O
patients O
with O
RA O
. O
['Physiological-Clinical', 'Life-Impact']

It O
greatly O
reduced O
volume B-outcome ['Physiological-Clinical']
waves I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
total O
volume B-outcome ['Physiological-Clinical']
displaced B-outcome ['Physiological-Clinical']
by O
these O
events O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
difference O
was O
observed O
between O
the O
two O
treatment O
groups O
in O
the O
mean O
change O
from O
baseline O
in O
ejaculatory B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
on O
day O
29 O
. O
['Physiological-Clinical']

The O
efficacy O
of O
single-dose O
antibiotic O
therapy O
for O
the O
treatment O
of O
bacteriuria O
in O
a O
group O
of O
non-catheterized O
elderly O
women O
was O
compared O
with O
that O
of O
conventional O
7-10 O
day O
courses O
of O
antibiotic O
therapy O
. O
[]

RESULTS O
Twenty-nine O
boys O
and O
9 O
girls O
with O
autism O
and O
severe O
behavioral O
disturbance O
and O
a O
mental O
age O
> O
or=18 O
months O
completed O
the O
cognitive O
part O
of O
the O
study O
. O
[]

Eighty-eight O
per O
cent O
of O
patients O
received O
at O
least O
seven O
cycles O
of O
chemotherapy O
with O
no O
dose O
reduction O
. O
[]

Although O
the O
differences O
were O
not O
statistically O
significant O
, O
the O
tendency O
favours O
Defibrotide O
. O
[]

In O
this O
multicentre O
, O
multinational O
, O
comparative O
, O
double-blind O
clinical O
trial O
, O
outpatients O
with O
both O
clinical O
signs O
and O
symptoms O
and O
radiographic O
evidence O
of O
acute O
sinusitis O
were O
randomly O
assigned O
to O
receive O
for O
7 O
days O
either O
a O
twice-daily O
oral O
regimen O
of O
faropenem O
daloxate O
( O
300 O
mg O
) O
or O
a O
twice O
daily O
oral O
regimen O
of O
cefuroxime O
axetil O
( O
250 O
mg O
) O
. O
[]

We O
report O
our O
methodology O
in O
detail O
as O
a O
possible O
model O
for O
future O
burns O
studies O
. O
[]

Experiments O
were O
performed O
four O
times O
using O
two O
different O
CPRVs O
. O
[]

The O
changes O
in O
NAR B-outcome ['Physiological-Clinical']
and O
eosinophil O
cationic O
protein B-outcome ['Physiological-Clinical']
( O
ECP O
) O
, O
mast O
cell O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Mirror O
therapy O
( O
MT O
) O
and O
mesh O
glove O
( O
MG O
) O
afferent O
stimulation O
may O
be O
effective O
in O
reducing O
motor O
impairment O
after O
stroke O
. O
[]

When O
the O
drugs O
were O
given O
individually O
, O
mecamylamine O
decreased O
beta B-outcome ['Physiological-Clinical']
power I-outcome ['Physiological-Clinical']
and O
nicotine O
gum O
( O
4 O
and O
8 O
mg O
) O
increased O
alpha B-outcome ['Physiological-Clinical']
frequency O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
spotty O
calcification O
demonstrated O
a O
greater O
percent O
atheroma O
volume O
( O
PAV O
) O
( O
36.0 O
? O
[]

CONCLUSIONS O
This O
easily O
implemented O
, O
low-intensity O
exercise O
program O
appears O
to O
reduce O
the O
risk O
for O
falls B-outcome ['Life-Impact']
among O
elderly O
men O
and O
women O
recovering O
from O
recent O
hospitalizations O
, O
bed O
rest O
, O
or O
both O
who O
have O
low O
levels O
of O
physical O
functioning O
. O
['Life-Impact']

Three-quarters O
( O
n O
= O
737 O
) O
were O
inadequately O
treated O
, O
with O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
levels O
at O
or O
above O
140 O
or O
90 O
mmHg O
. O
['Physiological-Clinical']

METHODS O
A O
prospective O
randomized O
trial O
of O
60 O
patients O
with O
symptomatic O
BPH O
was O
performed O
. O
[]

[ O
Methodologic O
comparison O
of O
the O
polyfrequency O
oscillation O
method O
, O
transcutaneous O
oxygen O
pressure O
measurement O
and O
body O
plethysmography O
in O
bronchial O
provocation O
with O
methacholine O
] O
. O
[]

A O
further O
purpose O
was O
to O
compare O
responses O
from O
a O
snowshoe O
training O
program O
to O
a O
similarly O
designed O
run O
training O
program O
. O
[]

Data O
from O
248 O
cows O
and O
938 O
bacteriologically O
negative O
quarters O
at O
drying-off O
are O
summarized O
. O
[]

The O
introduction O
of O
prostanoid O
therapy O
has O
revolutionized O
the O
treatment O
of O
pulmonary O
arterial O
hypertension O
( O
PAH O
) O
. O
[]

OBJECTIVE O
To O
determine O
the O
effect O
of O
replacing O
some O
dietary O
carbohydrate O
with O
protein O
, O
during O
energy O
restriction O
, O
on O
weight O
loss B-outcome ['Physiological-Clinical']
, O
total O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
( O
TEE B-outcome ['Physiological-Clinical']
) O
, O
resting B-outcome ['Physiological-Clinical']
energy I-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
( O
REE B-outcome ['Physiological-Clinical']
) O
, O
respiratory B-outcome ['Physiological-Clinical']
quotient I-outcome ['Physiological-Clinical']
( O
RQ B-outcome ['Physiological-Clinical']
) O
, O
and O
the O
thermic B-outcome ['Physiological-Clinical']
effect O
of O
feeding B-outcome ['Life-Impact']
( O
TEF B-outcome ['Physiological-Clinical']
) O
in O
subjects O
with O
hyperinsulinemia O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Children O
in O
the O
ATC O
group O
received O
more O
analgesic B-outcome ['Resource-use']
than O
those O
in O
the O
PRN O
group O
( O
P O
< O
0.0001 O
) O
. O
['Resource-use']

PPIX B-outcome ['Physiological-Clinical']
fluorescence I-outcome ['Physiological-Clinical']
was O
measured O
using O
an O
excitation O
wavelength O
of O
405+/-5 O
nm O
and O
emission O
spectrum O
recorded O
using O
a O
photodiode O
array O
. O
['Physiological-Clinical']

In O
all O
, O
38 O
( O
84.4 O
% O
) O
attained O
second B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

An O
unfavorable O
outcome O
was O
significantly O
less O
frequent O
in O
the O
eyes O
undergoing O
cryotherapy O
( O
21.8 O
% O
) O
compared O
with O
the O
untreated O
eyes O
( O
43 O
% O
) O
. O
[]

After O
brushing O
with O
the O
assigned O
toothbrush O
and O
a O
commercially O
available O
dentifrice O
for O
2 O
minutes O
, O
oral O
tissues O
were O
then O
re-examined O
and O
post-brushing O
plaque O
scores O
recorded O
. O
[]

PARTICIPANTS O
Adults O
( O
N=62 O
) O
with O
chronic O
, O
stroke-related O
arm O
weakness O
stratified O
by O
impairment O
severity O
using O
baseline O
UE O
motor O
assessments O
. O
[]

In O
the O
current O
article O
, O
we O
address O
the O
existing O
assumption O
in O
the O
literature O
on O
cognitive O
behavioral O
treatment O
of O
PTSD O
that O
patients O
with O
severe O
negative O
trauma-related O
cognitions O
would O
benefit O
more O
from O
a O
treatment O
package O
that O
includes O
exposure O
and O
cognitive O
techniques O
compared O
with O
a O
treatment O
that O
includes O
exposure O
only O
. O
[]

There O
was O
no O
difference O
between O
the O
groups O
in O
VAS O
scores O
on O
postoperative O
day O
14 O
. O
[]

Median O
estimated O
glomerular O
filtration O
rate O
was O
48 O
ml/min/1.73 O
m O
( O
2 O
) O
and O
49 O
ml/min/1.73 O
m O
( O
2 O
) O
in O
the O
IE O
and O
DE O
groups O
, O
respectively O
, O
at O
month O
12 O
. O
[]

Our O
primary O
endpoint O
was O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
with O
secondary O
endpoints O
of O
aneurysm-related B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
health-related B-outcome ['Physiological-Clinical']
quality O
of O
life O
( O
HRQL O
) O
, O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
and O
hospital B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
['Mortality', 'Mortality', 'Physiological-Clinical', 'Adverse-effects', 'Resource-use']

Secondary O
end O
points O
were O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
complication B-outcome ['Adverse-effects']
rate O
( O
including O
conversions B-outcome ['Resource-use']
) O
, O
and O
recovery O
time O
( O
days O
of O
oral O
opiate O
usage O
and O
return O
to O
work O
) O
. O
['Life-Impact', 'Adverse-effects', 'Resource-use']

Biomarkers O
of O
dietary O
exposure O
are O
associated O
with O
lower O
risk O
of O
breast O
fibroadenomas O
in O
Chinese O
women O
. O
[]

We O
compared O
the O
incidence O
of O
RAO O
with O
2 O
heparin O
dosage O
regimens O
after O
transradial O
coronary O
angiography O
, O
and O
we O
evaluated O
the O
efficacy O
and O
safety O
of O
transient O
homolateral O
ulnar O
artery O
compression O
to O
achieve O
acute O
radial O
artery O
recanalization O
. O
[]

RESULTS O
The O
overall O
frequency O
of O
allelic B-outcome ['Physiological-Clinical']
imbalance B-outcome ['Physiological-Clinical']
was O
79 O
% O
in O
primary O
tumors O
and O
88 O
% O
in O
paired O
metastases O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
prospective O
cohort O
study O
is O
a O
re-assessment O
of O
the O
data O
from O
the O
randomized O
trial O
with O
the O
2 O
treatment O
groups O
considered O
as O
a O
single O
cohort O
. O
[]

In O
a O
randomized O
double O
blind O
study O
the O
rate O
of O
malabsorption O
of O
these O
sugars O
was O
compared O
and O
the O
concomitant O
symptoms O
were O
recorded O
. O
[]

Five O
grams O
L-carnitine O
were O
given O
intravenously O
over O
2 O
h O
, O
twice O
daily O
for O
5 O
consecutive O
days O
; O
moreover O
, O
10 O
g O
L-carnitine O
in O
1500 O
ml O
cardioplegia O
were O
administered O
through O
the O
aortic O
root O
after O
aortic O
cross-clamping O
. O
[]

OBJECTIVE O
Our O
aim O
was O
to O
compare O
the O
efficacy O
and O
safety O
of O
the O
two O
types O
of O
TVT-S O
for O
female O
stress O
urinary O
incontinence O
( O
SUI O
) O
. O
[]

This O
study O
was O
designed O
to O
evaluate O
a O
novel O
four-drug O
regimen O
( O
three O
antibiotics O
and O
a O
proton O
pump O
inhibitor O
( O
PPI O
) O
) O
for O
eradication O
of O
HP O
infection O
in O
treatment-naive O
patients O
. O
[]

Ionized B-outcome ['Resource-use']
calcium I-outcome ['Resource-use']
( O
ICa2+ O
) O
values O
were O
similar O
for O
all O
three O
groups O
( O
1.15 O
+/- O
0.02 O
and O
1.21 O
+/- O
0.04 O
vs. O
1.17 O
+/- O
0.01 O
) O
, O
resulting O
in O
increased O
mean O
ICa2+/IMg2+ B-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
( O
2.14 O
+/- O
0.07 O
and O
2.42 O
+/- O
0.06 O
vs. O
1.95 O
+/- O
0.02 O
for O
the O
control O
subjects O
; O
p O
< O
0.05 O
) O
. O
['Resource-use', 'Physiological-Clinical']

Assessments O
were O
repeated O
after O
prolonged O
treatment O
with O
PUFA O
( O
2 O
g/die O
, O
n O
= O
15 O
) O
or O
placebo O
( O
n O
= O
10 O
) O
. O
[]

These O
findings O
replicate O
the O
results O
from O
previous O
studies O
, O
indicating O
that O
RIT O
is O
effective O
for O
teaching O
imitation B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
to O
young O
children O
with O
autism O
in O
a O
naturalistic O
setting O
and O
extend O
the O
findings O
to O
parents O
. O
['Life-Impact']

BACKGROUND O
It O
is O
unclear O
whether O
locoregional O
or O
systemic O
thrombolysis O
is O
superior O
in O
treating O
acute O
leg O
DVT O
or O
even O
whether O
lysis O
is O
more O
effective O
than O
anticoagulation O
therapy O
in O
preventing O
postthrombotic O
syndrome O
. O
[]

Two O
hundred O
seventeen O
patients O
with O
intermittent O
claudication O
( O
stages O
IIa O
and O
IIb O
of O
Fontaine O
's O
PAD O
classification O
) O
were O
randomly O
assigned O
to O
heparan O
sulfate O
( O
40 O
mg O
orally O
twice O
a O
day O
) O
or O
placebo O
for O
6 O
months O
. O
[]

The O
primary O
objective O
was O
to O
determine O
the O
effect O
of O
an O
aquatic O
exercise O
programme O
on O
the O
physical B-outcome ['Life-Impact']
fitness I-outcome ['Life-Impact']
of O
people O
with O
a O
brain O
injury O
. O
['Life-Impact']

Peri-operatively O
, O
the O
horses O
received O
phenylbutazone O
, O
butorphanol O
, O
and O
abaxial O
sesamoidean O
nerve O
blocks O
to O
relieve O
pain O
. O
[]

Carbenicillin-trimethoprim/sulfamethoxazole O
versus O
carbenicillin-gentamicin O
as O
empiric O
therapy O
of O
infection O
in O
granulocytopenic O
patients O
. O
[]

Similar O
gains O
were O
observed O
for O
initiation O
of O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
and O
shared O
positive O
affect O
, O
but O
between-group O
differences O
did O
not O
reach O
statistical O
significance O
. O
['Life-Impact']

Regression O
results O
revealed O
little O
difference O
in O
healthcare B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
by O
quit O
status O
for O
trial O
participants O
until O
the O
sixth O
quarter O
post-quit O
. O
['Resource-use']

To O
establish O
whether O
or O
not O
glaucomatous B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
is O
reversible O
, O
we O
obtained O
pattern-reversal B-outcome ['Resource-use']
electroretinograms I-outcome ['Resource-use']
( I-outcome ['Resource-use']
PERGs I-outcome ['Resource-use']
) I-outcome ['Resource-use']
and O
visual O
evoked O
potentials O
( O
VEPs O
) O
in O
25 O
eyes O
of O
25 O
patients O
suffering O
from O
bilateral O
primary O
open-angle O
glaucoma O
( O
POAG O
) O
before O
and O
after O
argon-laser O
trabeculoplasty O
. O
['Physiological-Clinical', 'Resource-use']

However O
, O
the O
arterial B-outcome ['Physiological-Clinical']
CO I-outcome ['Physiological-Clinical']
( O
2 O
) O
tension B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
postanesthesia I-outcome ['Physiological-Clinical']
care I-outcome ['Physiological-Clinical']
unit O
did O
not O
differ O
between O
the O
2 O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Children O
with O
neurodevelopmental O
disabilities O
, O
who O
had O
treatment O
resistant B-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
delayed I-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
phase O
syndrome B-outcome ['Physiological-Clinical']
and O
impaired B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

2 O
) O
Lumbar O
spine O
radiography O
in O
primary O
care O
patients O
with O
low O
back O
pain O
is O
not O
associated O
with O
changes O
in O
patient O
management O
, O
including O
medication O
use O
, O
and O
the O
use O
of O
primary O
and O
secondary O
care O
services O
, O
physical O
therapies O
and O
complementary O
therapies O
. O
( O
[]

Twenty-four O
patients O
( O
12 O
female O
; O
mean O
age O
51 O
yr O
) O
were O
randomized O
into O
receiving O
either O
inhaled O
fluticasone O
( O
500 O
microgram O
twice O
daily O
) O
via O
the O
Accuhaler O
device O
( O
n O
= O
12 O
) O
or O
placebo O
. O
[]

Another O
clinical O
assessment O
was O
done O
3 O
months O
after O
the O
first O
followup O
. O
[]

They O
were O
proved O
by O
X-ray O
, O
cytology O
and O
histopathology O
prior O
to O
treatment O
. O
[]

Although O
some O
complications B-outcome ['Adverse-effects']
occurred O
more O
frequently O
in O
the O
pre-hospital O
group O
in O
the O
pre-hospital O
period O
, O
the O
overall O
incidence O
for O
serious B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
was O
similar O
for O
both O
groups O
. O
['Adverse-effects', 'Adverse-effects']

Prognostic O
significance O
of O
the O
dobutamine O
echocardiography O
test O
in O
idiopathic B-outcome ['Physiological-Clinical']
dilated I-outcome ['Physiological-Clinical']
cardiomyopathy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Therefore O
, O
a O
long-term O
combined O
adjuvant O
chemotherapy O
with O
MMC O
and O
Futraful O
seems O
to O
be O
one O
of O
the O
most O
effective O
chemotherapy O
regimens O
for O
resectable O
advanced O
gastric O
cancer O
. O
[]

FM O
comprised O
fludarabine O
( O
20 O
mg/m O
( O
2 O
) O
i.v O
. O
) O
, O
[]

The O
same O
was O
true O
for O
the O
analysis O
of O
protocols O
. O
[]

CONCLUSIONS O
Intravesical O
instillation O
of O
pirarubicin O
immediately O
after O
nephroureterectomy O
significantly O
reduced O
the O
bladder B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
rate O
in O
patients O
with O
positive O
voided O
urine O
cytology O
. O
['Physiological-Clinical']

All O
complications B-outcome ['Adverse-effects']
resolved O
with O
dose O
reduction O
or O
when O
MTX O
was O
stopped O
at O
the O
end O
of O
the O
study O
. O
['Adverse-effects']

DISCUSSION O
. O
[]

Significantly O
higher O
geometric O
mean O
titers O
against O
types O
[]

Patients O
' O
knowledge B-outcome ['Life-Impact']
of O
their O
stroke B-outcome ['Life-Impact']
risk O
, O
acceptability B-outcome ['Life-Impact']
of O
the O
interview O
process O
, O
and O
factors O
determining O
their O
preferences B-outcome ['Life-Impact']
were O
also O
assessed O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Weekly O
contact O
was O
made O
with O
at O
least O
88 O
percent O
of O
the O
children O
in O
both O
study O
groups O
. O
[]

METHODS O
This O
study O
included O
60 O
patients O
undergoing O
elective O
laparoscopic O
cholecystectomy O
who O
were O
prospectively O
randomized O
into O
2 O
groups O
. O
[]

Of O
these O
, O
82 O
were O
randomly O
assigned O
6-thioguanine O
, O
representing O
11 O
% O
of O
all O
6-thioguanine O
recipients O
. O
[]

METHODS O
In O
this O
double-blind O
, O
placebo-controlled O
trial O
, O
60 O
individuals O
with O
diabetes O
were O
randomly O
assigned O
to O
300 O
mg O
of O
aliskiren O
or O
placebo O
once O
daily O
for O
6 O
weeks O
. O
[]

Intensive O
insulin O
therapy O
improves O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
microvascular O
reactivity O
in O
young O
people O
with O
type O
1 O
diabetes O
. O
['Physiological-Clinical']

Oat O
powder O
, O
containing O
a O
low O
amount O
of O
total O
fibre O
and O
a O
high O
amount O
of O
carbohydrates O
in O
liquid O
matrix O
, O
gave O
a O
higher O
incremental B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
peak O
concentration B-outcome ['Physiological-Clinical']
compared O
to O
rye O
bran O
and O
sugar O
beet O
fibre O
and O
higher O
insulin B-outcome ['Physiological-Clinical']
incremental I-outcome ['Physiological-Clinical']
area O
under O
curve O
compared O
to O
control O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
trial O
of O
external O
beam O
radiotherapy O
versus O
cryoablation O
in O
patients O
with O
localized O
prostate O
cancer O
: O
quality O
of O
life O
outcomes O
. O
[]

The O
dose-dense O
group O
had O
repeated O
treatment O
every O
two O
weeks O
, O
while O
the O
regular O
group O
repeated O
it O
every O
three O
weeks O
. O
[]

This O
study O
was O
designed O
to O
determine O
if O
outside-the-boot O
ankle O
braces O
could O
reduce O
ankle O
sprains O
during O
Army O
paratrooper O
training O
. O
[]

Twenty-nine O
of O
them O
were O
blindly O
randomised O
to O
tactile O
massage O
( O
TM O
) O
and O
16 O
of O
them O
to O
the O
control O
group O
, O
rest O
to O
music O
( O
RTM O
) O
. O
[]

A O
PaCO2 O
level O
averaging O
4.8 O
kPa O
( O
median O
) O
was O
achieved O
. O
[]

OBJECTIVE O
To O
determine O
the O
accuracy O
and O
clinical O
value O
of O
combining O
64 O
multi-slice O
spiral O
computer O
tomography O
( O
MSCT O
) O
and O
serum O
amyloid O
A O
protein O
( O
SAA O
) O
in O
the O
preoperative O
staging O
of O
rectal O
cancer O
. O
[]

Mean O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
score O
and O
mean O
time B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
return I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
normal I-outcome ['Life-Impact']
diet I-outcome ['Life-Impact']
were O
significantly O
lower O
in O
the O
TWT O
group O
. O
['Physiological-Clinical', 'Life-Impact']

A O
randomized O
comparative O
trial O
of O
combined O
versus O
alternating O
therapy O
with O
cytostatic O
drugs O
and O
high-dose O
medroxyprogesteron O
acetate O
in O
advanced O
breast O
cancer O
. O
[]

Patients O
were O
randomised O
in O
two O
groups O
: O
the O
training O
group O
( O
n O
= O
21 O
) O
, O
staying O
in O
Cardiac O
Rehabilitation O
Department O
and O
the O
control O
group O
( O
n O
= O
11 O
) O
, O
discharged O
home O
for O
3 O
weeks O
. O
[]

The O
basic O
intervention O
was O
a O
one-time O
e-mail O
reminder O
highlighting O
six O
HF-specific O
clinical O
recommendations O
. O
[]

Following O
the O
relaxation-training O
intervention O
, O
the O
treatment O
group O
's O
( O
n O
= O
18 O
) O
measured O
results O
showed O
a O
statistically O
significant O
improvement O
as O
compared O
to O
the O
control O
group O
( O
n O
= O
21 O
) O
( O
time O
by O
treatment O
interaction O
) O
: O
anxiety O
levels O
decreased O
( O
p O
< O
0.01 O
) O
, O
QoL O
and O
mood O
improved O
( O
p O
< O
0.05 O
) O
, O
while O
levels O
of O
pain O
and O
stress O
decreased O
( O
p O
< O
0.01 O
) O
. O
[]

Comprehensive O
preplanned O
interim O
safety O
analyses O
will O
be O
performed O
at O
the O
6- O
and O
12-month O
time O
points O
to O
examine O
treatment O
effects O
on O
key O
safety O
end O
points O
, O
including O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
electrolytes B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
experimental O
group O
received O
13 O
months O
of O
combined O
individual O
telephone O
and O
in-person O
group O
support O
and O
education O
, O
Control O
Group O
1 O
received O
13 O
months O
of O
telephone-only O
individual O
support O
and O
education O
, O
and O
Control O
Group O
2 O
received O
one-time O
mailed O
educational O
information O
. O
[]

In O
the O
intent-to-treat O
sample O
, O
pioglitazone O
and O
glimepirede O
produced O
comparable O
reductions O
in O
HbA B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
from O
baseline O
to O
the O
end O
of O
the O
study O
( O
-0.78 O
% O
and O
-0.68 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical']

6 O
) O
Feed O
containing O
rapeseed O
led O
to O
enlargement O
of O
thyroid O
glands O
and O
hearts O
, O
but O
did O
not O
affect O
liver B-outcome ['Physiological-Clinical']
size O
or O
mortality B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

The O
ITT B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
the O
imiquimod-treated O
group O
was O
higher O
in O
females O
( O
72 O
% O
) O
than O
in O
males O
( O
33 O
% O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
Intrauterine B-outcome ['Resource-use']
insemination I-outcome ['Resource-use']
( I-outcome ['Resource-use']
IUI I-outcome ['Resource-use']
) I-outcome ['Resource-use']
with O
controlled B-outcome ['Physiological-Clinical']
ovarian I-outcome ['Physiological-Clinical']
hyperstimulation I-outcome ['Physiological-Clinical']
( O
COH B-outcome ['Physiological-Clinical']
) O
is O
commonly O
used O
as O
treatment O
of O
first O
choice O
in O
couples O
with O
unexplained B-outcome ['Physiological-Clinical']
subfertility I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

It O
is O
recommended O
that O
investigators O
having O
an O
outcome O
measure O
with O
a O
common O
end O
date O
include O
plans O
in O
their O
protocols O
for O
obtaining O
their O
measures O
and O
activate O
those O
plans O
as O
early O
as O
possible O
during O
the O
course O
of O
the O
study O
. O
[]

The O
effect O
size O
was O
in O
the O
moderate O
to O
large O
range O
, O
and O
the O
doses O
used O
were O
low O
. O
[]

RESULTS O
There O
were O
no O
statistically O
significant O
differences O
in O
operative O
duration O
, O
resection B-outcome ['Resource-use']
weight O
, O
resection B-outcome ['Life-Impact']
speed I-outcome ['Life-Impact']
or O
radicality O
of O
resection B-outcome ['Resource-use']
. O
['Resource-use', 'Life-Impact', 'Resource-use']

A O
single O
drop O
of O
placebo O
or O
levobunolol O
( O
at O
concentrations O
of O
0.03 O
% O
, O
0.3 O
% O
, O
0.6 O
% O
, O
1 O
% O
, O
and O
2 O
% O
) O
was O
administered O
to O
one O
eye O
of O
each O
of O
48 O
patients O
with O
ocular O
hypertension O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
of O
three O
different O
intra-arterial O
vasodilating O
cocktails O
in O
reducing O
the O
incidence O
of O
radial B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
spasm I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
transradial O
coronary O
angiography O
. O
['Physiological-Clinical']

LTD4 O
induced O
a O
significant O
increase O
in O
the O
percentage O
of O
sputum B-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
as O
compared O
with O
its O
diluent O
( O
mean O
+/- O
SD O
, O
26.6 O
+/- O
21.3 O
% O
and O
10.2 O
+/- O
8.8 O
% O
, O
respectively O
; O
p O
= O
0.025 O
) O
, O
whereas O
a O
similar O
trend O
for O
methacholine O
failed O
to O
reach O
significance O
( O
mean O
+/- O
SD O
, O
19.1 O
+/- O
22.9 O
% O
and O
7.8 O
+/- O
5.8 O
% O
, O
respectively O
; O
p O
= O
0.11 O
) O
. O
['Physiological-Clinical']

The O
postoperative B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
similar O
between O
groups O
: O
being O
4.5+/-1.6 O
days O
in O
Group O
1 O
vs O
4.8+/-1.9 O
days O
in O
Group O
2 O
( O
P=0.328 O
) O
. O
['Resource-use']

Risk O
of O
aspiration O
with O
the O
laryngeal O
mask O
. O
[]

Target O
SaO2 O
and O
end-tidal O
carbon O
dioxide O
were O
continuously O
monitored O
using O
an O
ear O
oximeter O
and O
CO2 O
gas O
analyzer O
. O
[]

Effect O
of O
perioperative O
parecoxib O
on O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
local B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
factors O
PGE2 O
and O
IL-6 O
for O
total O
knee O
arthroplasty O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CYP21 O
genotyping O
indicated O
a O
heterozygote B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
of O
2.8 O
% O
for O
classic O
mutations O
( O
excluding O
CYP21 O
deletions O
) O
, O
and O
2.0 O
% O
for O
nonclassic O
mutations O
in O
New O
Zealanders O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
explore O
a O
more O
effective O
therapy O
for O
acute O
gouty O
arthritis O
. O
[]

RESULTS O
Significant O
changes O
over O
time O
occurred O
for O
group O
II O
in O
all O
outcomes O
( O
p O
< O
or O
= O
0.001 O
) O
. O
[]

BACKGROUND O
Children O
with O
high-functioning O
autism O
spectrum O
disorders O
( O
ASD O
) O
are O
at O
high O
risk O
for O
developing O
significant O
anxiety B-outcome ['Life-Impact']
. O
['Life-Impact']

Ipilimumab-induced B-outcome ['Physiological-Clinical']
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
and O
['Physiological-Clinical', 'Adverse-effects']

All O
three O
intervention O
groups O
showed O
a O
reduction O
in O
total O
saturated B-outcome ['Life-Impact']
fat I-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
. O
['Life-Impact']

We O
investigated O
the O
above O
objective O
in O
patients O
enrolled O
in O
WRIST O
. O
[]

Efficacy O
and O
safety O
of O
transient O
ulnar O
artery O
compression O
to O
recanalize O
acute O
radial O
artery O
occlusion O
after O
transradial O
catheterization O
. O
[]

The O
netilmicin O
group O
developed O
significantly O
less O
nephrotoxicity B-outcome ['Physiological-Clinical']
than O
the O
tobramycin O
group O
( O
0 O
% O
versus O
15 O
% O
, O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical']

We O
discontinued O
the O
antibiotic O
therapy O
if O
clinical O
signs O
and O
symptoms O
of O
infection O
improved O
and O
PCT O
was O
< O
0.5ng/ml O
over O
3 O
days O
. O
[]

Necessary O
but O
not O
sufficient O
: O
the O
effect O
of O
screening O
and O
feedback O
on O
outcomes O
of O
primary O
care O
patients O
with O
untreated O
anxiety O
. O
[]

In O
addition O
, O
the O
patients O
answered O
a O
questionnaire O
about O
hypersensitivity B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
were O
three O
deaths O
after O
complete O
remission O
of O
the O
disease O
( O
infection O
, O
two O
; O
acute O
nonlymphocytic B-outcome ['Physiological-Clinical']
leukemia I-outcome ['Physiological-Clinical']
[ O
ANLL O
] O
, O
one O
) O
. O
['Physiological-Clinical']

A O
31 O
% O
increase O
in O
STARS B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
was O
observed O
exclusively O
after O
CONC O
exercise O
( O
P O
< O
0.001 O
) O
, O
while O
pSRF B-outcome ['Physiological-Clinical']
protein O
levels O
increased O
similarly O
by O
48 O
% O
with O
both O
CONC O
and O
ECC O
exercise O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
may O
be O
concluded O
that O
the O
majority O
of O
women O
with O
incontinence O
can O
be O
successfully O
treated B-outcome ['Physiological-Clinical']
by O
the O
general O
practitioner O
. O
['Physiological-Clinical']

MAIN O
RESULTS O
Plasma O
level O
of O
endotoxin O
and O
all O
the O
cytokines B-outcome ['Physiological-Clinical']
after O
CRRT O
initiation O
were O
significantly O
lower O
than O
those O
before O
the O
treatment O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

The O
control O
patients O
( O
n=31.72 O
% O
) O
that O
participated O
in O
the O
study O
during O
the O
same O
period O
increased O
in O
weight O
by O
2.3 O
kg O
( O
SD=7.0 O
) O
. O
[]

The O
dosage O
can O
be O
safely O
increased O
up O
to O
150 O
mg O
daily O
but O
this O
offers O
few O
therapeutic O
advantages O
. O
[]

Tooth O
sensitivity O
was O
measured O
both O
immediately O
and O
at O
7 O
days O
after O
placement O
. O
[]

No O
difference O
in O
any O
of O
the O
reproductive B-outcome ['Physiological-Clinical']
parameters O
was O
observed O
between O
the O
2 O
groups O
: O
pregnancy B-outcome ['Physiological-Clinical']
and O
delivery B-outcome ['Physiological-Clinical']
rates O
were O
70 O
% O
and O
81.6 O
% O
in O
group O
A O
vs O
76.9 O
% O
and O
84 O
% O
in O
group O
B O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Fifty-two O
patients O
were O
selected O
randomly O
and O
the O
results O
show O
that O
ofloxacin O
eardrops O
have O
marginal O
benefits O
in O
symptomatic B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
( O
89 O
per O
cent O
versus O
79 O
per O
cent O
, O
p O
= O
0.27 O
) O
and O
bacterial B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
( O
81 O
per O
cent O
versus O
75 O
per O
cent O
, O
p O
= O
0.81 O
) O
in O
active B-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
suppurative I-outcome ['Physiological-Clinical']
otitis I-outcome ['Physiological-Clinical']
media I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
in O
the O
control O
group O
did O
not O
receive O
NB O
. O
[]

This O
was O
well O
below O
the O
[]

OBJECTIVE O
To O
evaluate O
the O
efficiency O
of O
slush O
nitrogen O
vitrification O
of O
human O
oocytes O
with O
or O
without O
cumulus O
cells O
in O
terms O
of O
survival B-outcome ['Mortality']
rate O
and O
maintenance O
of O
meiotic B-outcome ['Physiological-Clinical']
spindle I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

RESULTS O
Thirty-two O
eyes B-outcome ['Physiological-Clinical']
were O
rescued O
in O
treatment O
group O
with O
the O
cure O
rate O
of O
65.3 O
% O
. O
['Physiological-Clinical']

Ss O
in O
the O
hypnosis O
group O
who O
were O
in O
the O
upper O
two-thirds O
of O
the O
group O
in O
terms O
of O
hypnotic O
susceptibility O
reduced O
their O
cigarette B-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
substantially O
more O
than O
Ss O
in O
the O
relaxation O
group O
who O
were O
in O
the O
upper O
two-thirds O
of O
the O
group O
in O
terms O
of O
hypnotic B-outcome ['Life-Impact']
susceptibility I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

A O
one-year O
followup O
study O
. O
[]

SETTING O
The O
sleep-disorders O
unit O
of O
a O
tertiary O
referral O
university O
hospital O
. O
[]

The O
effects O
of O
moderate O
to O
vigorous B-outcome ['Physiological-Clinical']
aerobic O
exercise O
on O
the O
sleep O
need O
of O
sedentary O
young O
adults O
. O
['Physiological-Clinical']

METHODS O
Forty O
patients O
received O
lumbar O
epidural O
catheters O
. O
[]

We O
assessed O
its O
efficacy O
in O
a O
study O
investigating O
maintenance O
treatment O
of O
clinically O
stable O
patients O
with O
this O
disorder O
. O
[]

Granulocyte-macrophage O
colony-stimulating O
factor O
( O
GM-CSF O
) O
allows O
acceleration O
and O
dose O
intensity O
increase O
of O
CEF O
chemotherapy O
: O
a O
randomised O
study O
in O
patients O
with O
advanced O
breast O
cancer O
. O
[]

Effects O
of O
home O
strength O
training O
and O
stretching O
versus O
stretching O
alone O
after O
lumbar O
disk O
surgery O
: O
a O
randomized O
study O
with O
a O
1-year O
follow-up O
. O
[]

The O
effect O
of O
rectal O
distension O
on O
bladder O
function O
in O
patients O
with O
overactive O
bladder O
. O
[]

A O
pilot O
study O
of O
the O
safety O
and O
efficacy O
of O
supplemental O
arginine O
to O
enhance O
immune O
function O
in O
persons O
with O
HIV/AIDS O
. O
[]

DESIGN O
National O
Institutes O
of O
Health-sponsored O
randomized O
controlled O
trial O
. O
[]

Cyproheptadine O
augmentation O
caused O
significant O
reduction O
in O
the O
extrapyramidal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
which O
supports O
the O
atypical O
profile O
of O
antipsychotics O
. O
['Physiological-Clinical']

A O
total O
of O
266 O
064 O
women O
( O
age O
of O
30 O
to O
64 O
years O
) O
associated O
with O
519 O
textile O
factories O
in O
Shanghai O
had O
been O
randomly O
assigned O
to O
a O
BSE O
group O
( O
132 O
979 O
women O
) O
or O
a O
control O
group O
( O
133 O
085 O
women O
) O
since O
1989 O
. O
[]

Rectally O
administered O
midazolam O
( O
0.35 O
mg/kg O
) O
and O
diazepam O
( O
0.70 O
mg/kg O
) O
were O
compared O
with O
each O
other O
and O
with O
placebo O
for O
preanesthetic O
medication O
in O
children O
undergoing O
dental O
extractions O
. O
[]

There O
were O
no O
remarkable O
differences O
concerning O
the O
side-effect B-outcome ['Adverse-effects']
profile O
between O
the O
2 O
different O
titration O
schemes O
. O
['Adverse-effects']

The O
results O
obtained O
indicate O
that O
[]

Urinary B-outcome ['Physiological-Clinical']
porphobilinogen I-outcome ['Physiological-Clinical']
, O
5-aminolevulinic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
and O
porphyrin B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
as O
well O
as O
plasma B-outcome ['Physiological-Clinical']
porphyrin I-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
, O
were O
analysed O
using O
standard O
methods O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Participants O
who O
had O
high O
urinary O
excretion O
of O
toxic O
metals O
were O
selected O
to O
continue O
on O
to O
phase O
2 O
. O
[]

After O
that O
the O
home O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
monitoring O
can O
be O
used O
to O
exclude O
individuals O
who O
are O
at O
risk O
for O
side O
effects O
due O
to O
low O
out-of-office O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
readings O
and O
to O
precisely O
monitor O
the O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
response O
to O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
correlation O
with O
a O
concomitant O
decrease O
of O
triglyceride B-outcome ['Physiological-Clinical']
and O
cholesterol B-outcome ['Physiological-Clinical']
also O
induced O
by O
bezafibrate O
could O
not O
be O
proven O
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIMS O
A O
prospective O
, O
randomised O
, O
double O
blind O
, O
placebo O
controlled O
study O
of O
intraoperative O
mitomycin O
C O
as O
adjunctive O
treatment O
of O
primary O
pterygium O
was O
conducted O
. O
[]

Baseline O
characteristics O
were O
similar O
in O
both O
groups O
. O
[]

At O
the O
beginning O
of O
atherosclerosis O
before O
evidence O
of O
morphological B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
plaques I-outcome ['Physiological-Clinical']
, O
vascular B-outcome ['Physiological-Clinical']
distensibility I-outcome ['Physiological-Clinical']
or O
arterial B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
decreased O
gradually O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
LKSS B-outcome ['Physiological-Clinical']
at O
10 O
days O
( O
times O
) O
of O
treatment O
was O
lower O
in O
the O
treatment O
group O
than O
in O
the O
control O
group O
, O
but O
with O
no O
statistical O
difference O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

Further O
studies O
are O
needed O
in O
a O
larger O
autistic O
population O
to O
determine O
the O
dose-response O
relationship O
of O
clonidine O
. O
[]

Patients O
who O
remained O
on O
assigned O
therapy O
through O
year O
3 O
were O
eligible O
to O
enter O
a O
long-term O
extension O
( O
LTE O
) O
study O
. O
[]

RESULTS O
Trainees O
in O
the O
simulator-trained O
group O
performed O
significantly O
better O
( O
P=0.0011 O
) O
and O
managed B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
reach I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
cecum I-outcome ['Life-Impact']
in O
52 O
% O
of O
their O
cases O
( O
vs. O
19 O
% O
in O
the O
control O
group O
) O
, O
and O
were O
4.53 O
times O
more O
likely O
to O
succeed O
compared O
with O
the O
controls O
. O
['Life-Impact']

It O
is O
therefore O
concluded O
that O
EPA O
and O
DHA O
supplementation O
had O
no O
beneficial O
effects O
in O
mild O
to O
moderate O
essential O
hypertensive O
black O
patients O
except O
for O
a O
[]

Based O
on O
a O
presentation O
by O
Sandra O
L. O
Tunis O
, O
PhD O
. O
[]

The O
training O
intervention O
consisted O
of O
6 O
supervised O
training O
sessions O
over O
7 O
weeks O
, O
targeting O
the O
improvement O
of O
the O
players O
' O
speed B-outcome ['Life-Impact']
and O
power B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Failed O
insertion O
was O
classified O
as O
( O
i O
) O
failed O
passage O
into O
the O
pharynx O
, O
( O
ii O
) O
malposition O
, O
or O
( O
iii O
) O
ineffective O
ventilation O
. O
[]

The O
five O
patients O
receiving O
concentrate O
alone O
all O
died B-outcome ['Mortality']
, O
with O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
as O
the O
direct O
cause O
of O
death O
in O
three O
, O
whereas O
in O
the O
four O
receiving O
heparin O
as O
well O
there O
was O
only O
one O
instance O
of O
bleeding B-outcome ['Physiological-Clinical']
and O
one O
patient O
survived B-outcome ['Mortality']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

We O
evaluated O
the O
response O
to O
the O
recombinant O
Hepatitis O
B O
vaccine O
using O
an O
accelerated O
schedule O
versus O
the O
traditional O
schedule O
by O
studying O
the O
immunologic O
memory O
induced O
in O
200 O
children O
with O
HBs-Ag O
negative O
mothers O
. O
[]

Concurrent O
alcohol O
dependence O
( O
AD O
) O
among O
polysubstance O
abusers O
has O
been O
associated O
with O
negative O
consequences O
, O
although O
it O
may O
not O
necessarily O
lead O
to O
poor O
treatment O
outcomes O
. O
[]

Randomized O
clinical O
trial O
of O
hydrocodone/acetaminophen O
versus O
codeine/acetaminophen O
in O
the O
treatment O
of O
acute O
extremity O
pain O
after O
emergency O
department O
discharge O
. O
[]

A O
placebo-controlled O
, O
randomized O
clinical O
trial O
using O
testosterone O
undecanoate O
with O
injectable O
norethisterone O
enanthate O
: O
effect O
on O
anthropometric O
, O
metabolic O
and O
biochemical O
parameters O
. O
[]

Among O
452 O
patients O
considered O
valid O
for O
clinical O
efficacy O
, O
faropenem O
daloxate O
treatment O
was O
found O
to O
be O
statistically O
equivalent O
to O
cefuroxime O
axetil O
( O
89.0 O
% O
vs. O
88.4 O
% O
-95 O
% O
CI=-5.2 O
% O
; O
+6.4 O
% O
) O
at O
the O
7-16 O
days O
post-therapy O
assessment O
. O
[]

Nasal O
sprays O
of O
recombinant O
alfa-2b O
interferon O
were O
not O
an O
effective O
treatment O
for O
natural O
colds B-outcome ['Physiological-Clinical']
and O
were O
associated O
with O
['Physiological-Clinical']

Alexithymia O
is O
characterized O
by O
difficulties O
identifying O
, O
differentiating O
and O
expressing O
feelings O
, O
a O
limited O
imagination O
and O
fantasy O
life O
, O
and O
an O
externally-oriented O
thinking O
style O
( O
e.g. O
, O
prefer O
talking O
about O
daily O
activities O
rather O
than O
feelings O
) O
. O
[]

The O
hormonal O
receptor O
status O
was O
determined O
in O
30 O
patients O
of O
the O
group O
I O
and O
23 O
patients O
of O
the O
group O
II O
. O
[]

C. O
pylori O
was O
cleared O
from O
14 O
( O
77.8 O
% O
) O
of O
18 O
patients O
given O
locally O
active O
bismuth O
, O
from O
one O
( O
6.7 O
% O
) O
of O
15 O
patients O
given O
erythromycin O
, O
and O
from O
none O
of O
17 O
patients O
given O
placebo O
. O
[]

CONCLUSIONS O
The O
study O
was O
conducted O
on O
a O
limited O
sample O
; O
no O
statistically O
significant O
differences O
were O
detected O
; O
QC O
is O
the O
quickest O
and O
more O
cost-effective O
method O
. O
['Resource-use']

Afterwards O
the O
patients O
had O
to O
report O
on O
their O
reaction O
to O
the O
content O
of O
the O
preoperative O
visit O
and O
information O
quality O
. O
[]

At O
the O
highest O
thermal O
burden O
, O
the O
effect O
of O
nifedipine B-outcome ['Physiological-Clinical']
was O
inconsistent O
and O
not O
significantly O
different O
from O
that O
of O
placebo O
. O
['Physiological-Clinical']

The O
patients O
were O
randomized O
into O
one O
of O
three O
programs O
: O
group O
1 O
-- O
a O
full-time O
, O
intensive O
3-week O
multidisciplinary O
program O
, O
including O
active O
physical O
and O
ergonomic O
training O
and O
psychological O
pain O
management O
, O
followed O
by O
1 O
day O
weekly O
for O
the O
subsequent O
3 O
weeks O
; O
group O
2 O
-- O
active O
physical O
training O
, O
twice O
a O
week O
for O
6 O
weeks O
, O
for O
a O
total O
of O
24h O
; O
group O
3 O
-- O
psychological O
pain O
management O
combined O
with O
active O
physical O
training O
, O
twice O
a O
week O
for O
6 O
weeks O
, O
also O
for O
a O
total O
of O
24h O
. O
[]

METHODS O
Fifty-six O
patients O
with O
unstable O
angina O
, O
mean O
age O
of O
55.4 O
+/- O
8.5 O
, O
41 O
men O
and O
15 O
women O
, O
were O
evaluated O
in O
a O
randomized O
, O
double-blind O
study O
of O
two O
groups O
of O
patients O
treated O
with O
diltiazem O
or O
propranolol O
at O
total O
daily O
doses O
of O
180 O
mg O
and O
120 O
mg O
respectively O
during O
the O
first O
48 O
hours O
. O
[]

OBJECTIVE O
Young O
children O
are O
at O
high O
risk O
for O
influenza-related O
complications O
. O
[]

For O
assessing O
the O
implementation O
of O
TUPAC O
guidelines O
, O
the O
electronic O
dental O
record O
audit O
and O
self-reported O
questionnaires O
will O
be O
used O
. O
[]

Through O
a O
village-based O
surveillance O
system O
, O
diarrhoeal O
morbidity O
data O
( O
severity O
, O
duration O
, O
compliance O
) O
were O
collected O
for O
14 O
days O
. O
[]

DESIGN O
Prospective O
, O
randomized O
, O
comparative O
clinical O
study O
. O
[]

The O
platinum-refractory O
subgroup O
demonstrated O
a O
nonstatistically O
significant O
survival O
trend O
in O
favor O
of O
topotecan O
( O
P O
=.455 O
) O
. O
[]

Patients O
randomly O
assigned O
to O
receive O
dexamethasone O
had O
a O
6-year O
isolated B-outcome ['Physiological-Clinical']
central I-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
system-relapse I-outcome ['Physiological-Clinical']
rate O
of O
3.7 O
% O
+/- O
0.8 O
% O
, O
compared O
with O
7.1 O
% O
+/- O
1.1 O
% O
for O
prednisone O
( O
P O
=.01 O
) O
. O
['Physiological-Clinical']

Eligibility O
required O
that O
patients O
have O
grade O
1 O
or O
higher O
sensory O
neuropathy O
according O
to O
the O
NCI O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
and O
at O
least O
4 O
on O
a O
scale O
of O
0 O
to O
10 O
, O
representing O
average O
chemotherapy-induced O
pain O
, O
after O
paclitaxel O
, O
other O
taxane O
, O
or O
oxaliplatin O
treatment O
. O
[]

Sixty O
children O
with O
autism O
or O
Asperger O
syndrome O
( O
3-11 O
years O
old O
) O
received O
for O
3 O
months O
placebo O
or O
bumetanide O
( O
1 O
mg O
daily O
) O
, O
followed O
by O
1-month O
wash O
out O
. O
[]

Overall O
, O
sulfadoxine/pyrimethamine O
plus O
amodiaquine O
reduced O
the O
rate O
of O
subsequent B-outcome ['Resource-use']
treatments I-outcome ['Resource-use']
for I-outcome ['Resource-use']
malaria I-outcome ['Resource-use']
by O
54 O
% O
( O
95 O
% O
CI O
36-66 O
, O
p O
< O
0.0001 O
) O
compared O
with O
sulfadoxine/ O
pyrimethamine O
alone O
and O
by O
37 O
% O
( O
12-54 O
, O
p=0.007 O
) O
compared O
with O
sulfadoxine/pyrimethamine O
plus O
artesunate O
. O
['Resource-use']

RESULTS O
All O
subjects O
completed O
the O
trial O
. O
[]

At O
two O
years O
the O
mean O
cholesterol B-outcome ['Physiological-Clinical']
level O
was O
highest O
in O
the O
Aza O
plus O
MP O
group O
, O
6.8 O
mmol/L O
and O
lowest O
in O
the O
group O
receiving O
triple O
therapy O
, O
5.8 O
mmol/L O
( O
P O
= O
ns O
) O
. O
['Physiological-Clinical']

Compared O
with O
placebo O
, O
sildenafil O
increased O
the O
6-minute B-outcome ['Life-Impact']
walk I-outcome ['Life-Impact']
test O
by O
a O
nonsignificant O
treatment O
effect O
of O
14 O
m O
( O
P=.67 O
) O
. O
['Life-Impact']

Actual O
uptake O
of O
BRCA1 B-outcome ['Physiological-Clinical']
testing O
is O
reported O
with O
a O
six O
year O
follow-up O
. O
['Physiological-Clinical']

We O
studied O
the O
numbers O
of O
CD19+ B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
by O
flow O
cytometry O
in O
previously O
untreated O
newly O
diagnosed O
myeloma O
patients O
in O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
phase O
III O
trial O
E9486 O
. O
['Physiological-Clinical']

CONCLUSION O
Efforts O
to O
address O
common O
donor O
fears O
and O
to O
provide O
useful O
coping O
suggestions O
may O
improve O
the O
effectiveness O
of O
blood O
donation O
recruitment O
materials O
. O
[]

Based O
on O
the O
resulting O
Exposure B-outcome ['Physiological-Clinical']
Prevention I-outcome ['Physiological-Clinical']
ratings O
, O
we O
concluded O
that O
exposures O
were O
well O
controlled O
in O
the O
majority O
of O
areas O
assessed O
( O
64 O
% O
with O
rating O
of O
1 O
or O
2 O
on O
a O
6-point O
scale O
) O
, O
that O
there O
is O
some O
room O
for O
improvement O
in O
26 O
percent O
of O
areas O
( O
rating O
of O
3 O
or O
4 O
) O
, O
and O
that O
roughly O
10 O
percent O
of O
the O
areas O
assessed O
are O
urgently O
in O
need O
of O
intervention O
( O
rated O
as O
5 O
or O
6 O
) O
. O
['Physiological-Clinical']

PATIENTS O
One O
hundred O
critically O
ill O
patients O
with O
an O
indication O
for O
PDT O
. O
[]

PATIENTS O
A O
referral O
sample O
of O
30 O
male O
and O
female O
autistic O
patients O
were O
enrolled O
, O
and O
24 O
completed O
the O
study O
. O
[]

The O
second O
booster O
did O
not O
show O
a O
significant O
effect O
, O
however O
, O
in O
1 O
of O
the O
5 O
subjects O
who O
were O
still O
unprotected O
after O
the O
first O
booster O
the O
second O
elicited O
an O
antitoxin B-outcome ['Physiological-Clinical']
level O
of O
more O
than O
0.01 O
I.U./ml O
. O
['Physiological-Clinical']

Birth O
weight O
for O
infants B-outcome ['Physiological-Clinical']
born I-outcome ['Physiological-Clinical']
to O
women O
who O
quit O
smoking O
averaged O
7.2 O
lb O
versus O
6.8 O
and O
6.3 O
lb O
for O
mothers O
smoking O
one O
to O
six O
and O
more O
than O
six O
cigarettes O
per O
day O
at O
delivery O
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical']

Strategies O
for O
dietary O
and O
anti-smoking O
advice O
. O
[]

METHODS O
Patients O
with O
steroid-dependent O
Crohn O
's O
disease O
( O
n O
= O
271 O
) O
were O
enrolled O
in O
a O
36-week O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

The O
primary O
outcome O
measure O
was O
mobility B-outcome ['Life-Impact']
assessed O
with O
the O
Ambulatory O
Post O
Acute O
Care O
Basic O
Mobility O
Short O
Form O
. O
['Life-Impact']

METHOD O
One O
hundred O
and O
ten O
out-patients O
with O
OCD O
were O
randomly O
assigned O
to O
15 O
sessions O
of O
either O
group O
CBT O
or O
individual O
CBT O
. O
[]

Irritability B-outcome ['Life-Impact']
, O
agitation B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact']

However O
, O
the O
effects O
of O
a O
general O
warm-up O
( O
GWU O
) O
are O
unclear O
but O
seem O
to O
depend O
on O
its O
ability O
to O
increase O
muscle O
temperature O
while O
avoiding O
fatigue O
. O
[]

The O
blood B-outcome ['Physiological-Clinical']
sugar I-outcome ['Physiological-Clinical']
profile O
and O
insulin B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
over O
a O
24 O
hour O
period O
was O
not O
affected O
by O
either O
penbutolol O
or O
placebo O
, O
nor O
could O
any O
changes O
be O
measured O
in O
these O
parameters O
when O
measured O
after O
food O
intake O
. O
['Physiological-Clinical', 'Resource-use']

To O
investigate O
the O
effect O
of O
Grenz O
ray O
therapy O
alone O
compared O
with O
Grenz O
rays O
combined O
with O
a O
topical O
corticosteroid O
( O
betamethasone O
dipropionate O
) O
in O
psoriasis O
of O
the O
scalp O
, O
40 O
patients O
were O
randomized O
into O
two O
groups O
. O
[]

Absence O
of O
weight O
loss O
( O
hazard O
ratio O
, O
1.40 O
; O
95 O
% O
CI O
, O
1.02-1.93 O
; O
P=0.0377 O
) O
was O
significantly O
associated O
with O
a O
longer O
PFS O
( O
7.5 O
months O
vs. O
6 O
months O
) O
. O
[]

We O
describe O
the O
development O
of O
two O
DAs O
, O
a O
booklet O
and O
an O
interactive O
website O
, O
each O
with O
a O
values O
clarification O
component O
and O
designed O
for O
use O
in O
diverse O
settings O
. O
[]

Furthermore O
, O
even O
with O
visible O
necrosis O
, O
there O
is O
a O
17 O
% O
failure O
rate O
of O
polyp O
eradication O
. O
[]

Intervals O
between O
calving O
and O
first O
oestrus O
, O
first B-outcome ['Physiological-Clinical']
insemination I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
conception I-outcome ['Physiological-Clinical']
, O
the O
time B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
emergence I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
dominant I-outcome ['Physiological-Clinical']
follicle I-outcome ['Physiological-Clinical']
, O
milk B-outcome ['Physiological-Clinical']
progesterone I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
, O
and O
the O
diameter O
of O
the O
corpus B-outcome ['Physiological-Clinical']
luteum I-outcome ['Physiological-Clinical']
( O
CL O
) O
in O
the O
first O
luteal O
phase O
did O
not O
differ O
significantly O
between O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
improvements O
in O
sitting B-outcome ['Life-Impact']
balance I-outcome ['Life-Impact']
were O
not O
maintained O
over O
the O
follow-up O
period O
. O
['Life-Impact']

Ropivacaine-clonidine O
combination O
for O
caudal O
blockade O
in O
children O
. O
[]

18 O
years O
, O
56 O
% O
female O
, O
active O
drug O
: O
vehicle O
= O
97:100 O
) O
over O
2 O
weeks O
treatment O
with O
bibrocathol O
2 O
% O
eye O
ointment O
was O
evaluated O
. O
[]

and O
control O
subjects O
( O
C.S. O
) O
. O
[]

Flosequinan O
evoked O
a O
significant O
increase O
in O
maximal B-outcome ['Physiological-Clinical']
exercise I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

While O
both O
techniques O
were O
associated O
with O
an O
increase O
in O
bladder O
compliance O
, O
statistical O
significance O
was O
demonstrated O
only O
in O
the O
spinal O
anesthesia O
treatment O
group O
. O
[]

Arm O
A O
( O
16 O
males/six O
females O
, O
aged O
48 O
+/- O
16 O
yrs O
) O
received O
clarithromycin O
250 O
mg O
b.i.d O
. O
[]

Mood O
status O
and O
quality O
of O
life O
were O
assessed O
using O
the O
Profile O
of O
Mood B-outcome ['Life-Impact']
States O
and O
Medical O
Outcomes O
Study O
36-item O
Short-Form O
Health O
Survey O
at O
baseline O
and O
following O
3 O
and O
6 O
months O
of O
treatment O
. O
['Life-Impact']

When O
pleasantness O
ratings O
of O
scent O
were O
covaried O
, O
physiological B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
did O
not O
differ O
based O
on O
scent O
exposure O
, O
but O
mood B-outcome ['Life-Impact']
ratings O
differed O
by O
scent O
condition O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Uncontrolled O
vasculitis O
was O
responsible O
for O
4 O
deaths B-outcome ['Mortality']
( O
2 O
in O
each O
group O
) O
, O
and O
treatment B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
caused O
the O
death B-outcome ['Mortality']
of O
1 O
patient O
in O
group O
A O
. O
['Mortality', 'Adverse-effects', 'Mortality']

The O
mean O
duration O
for O
obtaining O
good O
contractions B-outcome ['Physiological-Clinical']
was O
shorter O
in O
the O
propranolol O
group O
in O
both O
the O
first O
and O
second O
day O
of O
induction O
The O
mean O
interval O
between O
the O
beginning O
of O
induction O
until O
the O
beginning O
of O
active O
phase O
at O
the O
first O
day O
of O
induction O
was O
shorter O
in O
the O
propranolol O
group O
. O
['Physiological-Clinical']

Therefore O
, O
this O
study O
evaluated O
the O
effect O
of O
a O
prior O
bronchial O
provocation O
test O
on O
the O
bronchodilator O
response O
to O
salbutamol O
after O
spontaneous O
recovery O
of O
the O
forced O
expiratory O
volume O
in O
one O
second O
( O
FEV1 B-outcome ['Physiological-Clinical']
) O
in O
a O
group O
of O
asthmatic O
subjects O
. O
['Physiological-Clinical']

The O
diagnostic B-outcome ['Life-Impact']
advantage O
of O
TBNA O
became O
more O
obvious O
if O
the O
EBUS O
probe O
was O
adjacent O
to O
the O
lesions O
. O
['Life-Impact']

A O
randomised O
control O
trial O
of O
short-term O
exercises O
on O
specific O
cardiovascular O
and O
respiratory O
parameters O
was O
undertaken O
in O
normal O
male O
college O
students O
. O
[]

Analgesia B-outcome ['Resource-use']
after O
caesarean O
section O
with O
intramuscular O
ketorolac O
or O
pethidine O
. O
['Resource-use']

OBJECTIVE O
To O
compare O
second O
versus O
third O
generation O
combination O
oral O
contraceptives O
( O
OCs O
) O
in O
the O
treatment O
of O
hirsutism O
. O
[]

INTRODUCTION O
Methotrexate O
( O
MTX O
) O
has O
been O
shown O
to O
modify O
infliximab O
pharmacokinetics O
in O
rheumatoid O
arthritis O
. O
[]

Participants O
were O
randomly O
divided O
into O
three O
groups O
-- O
one O
control O
group O
and O
two O
intervention O
groups O
. O
[]

There O
was O
also O
no O
significant O
difference O
in O
outcome O
after O
PDT O
. O
[]

Successful B-outcome ['Physiological-Clinical']
reperfusion I-outcome ['Physiological-Clinical']
was O
achieved O
in O
86 O
% O
of O
patients O
treated O
with O
emergency O
angioplasty O
and O
86 O
% O
of O
patients O
treated O
with O
intracoronary O
streptokinase O
( O
p O
= O
NS O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
Family O
education O
on O
schizophrenia O
by O
nurses O
in O
China O
was O
effective O
in O
improving O
knowledge O
and O
promoting O
improvement O
in O
patients O
' O
symptoms O
. O
[]

In O
contrast O
, O
standard O
assessments O
at O
age O
3 O
did O
predict O
outcome O
. O
[]

The O
Pain O
Course O
: O
a O
randomised O
controlled O
trial O
of O
a O
clinician-guided O
Internet-delivered O
cognitive O
behaviour O
therapy O
program O
for O
managing O
chronic O
pain O
and O
emotional O
well-being O
. O
[]

BACKGROUND O
No O
standard O
treatment O
for O
locally O
advanced O
pancreatic O
cancer O
( O
LAPC O
) O
is O
defined O
. O
[]

A O
hemorrhagic B-outcome ['Physiological-Clinical']
detachment I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
Descemet I-outcome ['Physiological-Clinical']
membrane I-outcome ['Physiological-Clinical']
was O
observed O
in O
one O
eye O
in O
the O
DSMMC O
group O
. O
['Physiological-Clinical']

C-telopeptide B-outcome ['Physiological-Clinical']
( O
A O
: O
40.7 O
% O
; O
B O
: O
34.1 O
% O
and O
C O
: O
38.5 O
% O
) O
; O
hydroxyproline B-outcome ['Resource-use']
( O
A O
: O
31.1 O
% O
; O
B O
: O
25.3 O
% O
and O
C O
: O
31.5 O
% O
) O
and O
osteocalcin B-outcome ['Physiological-Clinical']
( O
A O
: O
27.0 O
% O
; O
B O
: O
25.4 O
% O
and O
C O
: O
25.1 O
% O
) O
decreased O
similarly O
in O
the O
three O
groups O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

All O
TCT O
images O
were O
registered O
to O
the O
TCT O
template O
and O
the O
same O
registration O
parameters O
were O
applied O
to O
the O
ECD O
images O
. O
[]

Seven O
and O
one-half O
years O
after O
surgery O
, O
six O
patents O
with O
smooth O
and O
four O
with O
textured O
implants O
had O
contracture B-outcome ['Physiological-Clinical']
( O
p O
= O
0.66 O
) O
. O
['Physiological-Clinical']

One O
patient O
on O
propranolol O
was O
withdrawn O
from O
the O
trial O
because O
of O
poor O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
suspected B-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
pectoris I-outcome ['Physiological-Clinical']
after O
5 O
weeks O
on O
active O
medication O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Emergency O
cesarean O
deliveries O
, O
planned O
vertical O
uterine O
incisions O
, O
and O
previous O
abdominal O
surgeries O
besides O
cesarean O
deliveries O
were O
excluded O
. O
[]

Predialysis B-outcome ['Physiological-Clinical']
beta I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
-microglobulin I-outcome ['Physiological-Clinical']
levels O
decreased O
significantly O
when O
using O
the O
high-flux O
polyamide O
membrane O
. O
['Physiological-Clinical']

CONCLUSIONS O
Cannulation O
of O
CS O
with O
the O
adjunct O
of O
an O
electrophysiology O
catheter O
to O
dedicated O
delivery O
systems O
significantly O
reduces O
procedural B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
fluoroscopy B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
contrast O
dye B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
compared O
to O
a O
conventional O
strategy O
. O
['Life-Impact', 'Physiological-Clinical']

We O
conclude O
that O
neurons O
in O
human O
visual O
cortex O
are O
selective O
for O
second-order O
SF O
, O
that O
normalization O
( O
surround O
suppression O
) O
contributes O
to O
this O
selectivity O
, O
and O
that O
the O
selectivity O
in O
higher O
visual O
areas O
is O
simply O
fed O
forward O
from O
V1 O
. O
[]

RESULTS O
Forty-nine O
patients O
were O
enrolled O
in O
the O
study O
, O
and O
forty O
children O
completed O
the O
trial O
( O
dropouts O
: O
placebo O
= O
4 O
, O
riluzole O
= O
5 O
) O
. O
[]

Total O
clearance B-outcome ['Physiological-Clinical']
of O
theophylline O
decreased O
and O
its O
half O
life O
increased O
over O
the O
range O
of O
doses O
administered O
( O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

No O
difference O
in O
the O
sensory B-outcome ['Physiological-Clinical']
response O
to O
mechanical B-outcome ['Physiological-Clinical']
stimulation B-outcome ['Physiological-Clinical']
was O
found O
in O
the O
esophagus O
before O
( O
all O
p O
> O
0.31 O
) O
and O
after O
( O
all O
p O
> O
0.43 O
) O
smooth O
muscle O
relaxation O
with O
butylscopolamine O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
HS-60 O
and O
HS-30 O
heifers O
were O
limited-fed O
to O
gain O
0.9 O
kg/d O
, O
and O
the O
LS-30 O
heifers O
had O
ad O
libitum O
access O
to O
the O
diet O
. O
[]

In O
contrast O
, O
incomplete O
dietary O
compensation O
and O
weight O
gain O
occurred O
in O
both O
the O
lean O
( O
43 O
% O
, O
1.61 O
? O
[]

We O
compared O
outcome O
and O
complications O
of O
three O
simple O
varicocelectomy O
techniques O
. O
[]

Preliminary O
clinical O
and O
angiographic O
follow-up O
show O
a O
low O
rate O
of O
cardiac B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
at O
6 O
months O
( O
16.1 O
% O
MACE O
) O
and O
a O
moderate O
hyperplastic B-outcome ['Physiological-Clinical']
response O
. O
['Physiological-Clinical', 'Physiological-Clinical']

While O
not O
all O
results O
were O
statistically O
significant O
at O
conventional O
levels O
, O
intervention O
effects O
were O
positive O
in O
virtually O
all O
cases O
and O
effect O
magnitudes O
frequently O
were O
large O
. O
[]

METHODS O
31 O
patients O
undergoing O
elective O
surgery O
of O
the O
abdominal O
aorta O
were O
subdivided O
at O
random O
into O
3 O
different O
anaesthesia O
groups O
: O
1. O
halothane O
anesthesia O
, O
2. O
neuroleptanalgesia O
( O
NLA O
) O
and O
3. O
thoracic O
EA O
with O
bupivacaine O
( O
0.5 O
% O
) O
in O
combination O
with O
a O
light O
general O
anesthesia O
. O
[]

Primary O
stenting O
of O
occluded O
native O
coronary O
arteries O
: O
final O
results O
of O
the O
Primary O
Stenting O
of O
Occluded O
Native O
Coronary O
Arteries O
( O
PRISON O
) O
study O
. O
[]

Efficacy O
was O
assessed O
by O
facial B-outcome ['Physiological-Clinical']
acne I-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
counts O
, O
an O
investigator O
's O
global B-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
, O
a O
subject O
's O
self-assessment O
, O
and O
an O
analysis O
of O
within-cycle O
variation O
( O
cycle O
6 O
) O
in O
lesion B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
compare O
the O
efficacy O
and O
safety O
of O
fondaparinux O
in O
conjunction O
with O
intermittent O
pneumatic O
compression O
vs. O
intermittent O
pneumatic O
compression O
alone O
in O
this O
context O
. O
[]

Cardiorespiratory B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
and O
bispectral B-outcome ['Physiological-Clinical']
index O
were O
monitored O
and O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
second O
swab O
was O
taken O
from O
the O
superficial O
incisional O
skin O
surface O
for O
culture O
and O
sensitivity O
investigation O
between O
the O
fifth O
to O
seventh O
postoperative O
day O
for O
comparison O
of O
the O
bacterial O
colonisation O
in O
the O
two O
groups O
. O
[]

In O
both O
groups O
, O
there O
was O
no O
difference O
in O
median O
total O
RSI B-outcome ['Physiological-Clinical']
score O
before O
surgery O
or O
at O
3 O
weeks O
and O
3 O
months O
after O
surgery O
. O
['Physiological-Clinical']

Arm-cranking O
exercise O
reduced O
oxidative B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
in O
adults O
with O
chronic O
spinal O
cord O
injury O
. O
['Physiological-Clinical']

Patients O
in O
both O
treatment O
groups O
with O
controlled O
intraocular O
pressures O
were O
more O
likely O
to O
maintain O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Although O
the O
results O
presented O
within O
do O
not O
include O
factors O
of O
study O
and O
study-by-treatment O
interaction O
, O
analyses O
were O
performed O
to O
confirm O
that O
the O
results O
were O
consistent O
across O
the O
2 O
identical O
, O
double-blind O
, O
randomized O
studies O
and O
within O
each O
treatment O
group O
across O
studies O
to O
justify O
pooling O
the O
data O
from O
both O
studies O
. O
[]

METHODS O
In O
a O
randomised O
controlled O
trial O
with O
337 O
participants O
, O
87 O
persons O
took O
part O
in O
the O
Internet O
training O
. O
[]

We O
aimed O
at O
evaluating O
a O
multifactorial O
strategy O
of O
pain O
management O
combining O
pharmacological O
and O
non-pharmacological O
approaches O
during O
vaccination O
, O
as O
compared O
to O
usual O
care O
, O
in O
4- O
to O
12-year-old O
children O
. O
[]

Video O
recordings O
were O
made O
to O
determine O
the O
stroke B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

It O
is O
suggested O
that O
combination O
products O
should O
be O
used O
only O
after O
patients O
have O
failed O
to O
respond O
adequately O
to O
a O
single O
agent O
. O
[]

RESULTS O
Low-dose O
allergen O
exposure O
alone O
resulted O
in O
a O
significant O
increase O
of O
bronchial B-outcome ['Physiological-Clinical']
epithelial I-outcome ['Physiological-Clinical']
macrophages I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

On O
increasing O
the O
pentagastrin O
infusion O
rate O
the O
inhibition O
was O
surmounted O
suggesting O
it O
was O
competitive O
in O
type O
. O
[]

In O
the O
favorable O
subgroup O
, O
85.8 O
% O
had O
a O
negative O
early O
PET O
scan O
( O
standard O
arm O
, O
one O
event O
v O
experimental O
arm O
, O
nine O
events O
) O
. O
[]

18 O
) O
F-FDG B-outcome ['Physiological-Clinical']
PET/CT I-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
response O
['Physiological-Clinical']

Their O
impact O
on O
acid-base O
homeostasis O
has O
not O
been O
examined O
. O
[]

Patients O
in O
the O
control O
group O
were O
asked O
to O
observe O
video O
clips O
with O
no O
motor O
content O
and O
to O
execute O
the O
same O
actions O
as O
patients O
in O
the O
case O
group O
afterward O
. O
[]

BACKGROUND O
The O
majority O
of O
patients O
with O
Wegener O
's O
granulomatosis O
have O
disease O
flares O
after O
conventional O
medications O
are O
tapered O
. O
[]

In O
patients O
with O
an O
enhanced O
risk O
of O
bleeding B-outcome ['Physiological-Clinical']
, O
major O
bleeding O
was O
significantly O
more O
common O
during O
the O
intermittent O
use O
of O
heparin O
; O
in O
patients O
without O
these O
risk O
factors O
, O
hemorrhage B-outcome ['Physiological-Clinical']
occurred O
with O
equal O
frequency O
during O
intermittent O
and O
continuous O
heparin O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
between-group O
differences O
were O
found O
for O
postprocedure B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
or O
pain B-outcome ['Physiological-Clinical']
rating O
. O
['Life-Impact', 'Physiological-Clinical']

CONCLUSION O
The O
dose-intensity O
of O
ICE O
chemotherapy O
can O
be O
doubled O
by O
reinfusing O
hematopoietic O
progenitors O
collected O
by O
leukapheresis O
or O
venesection O
and O
stored O
at O
4 O
degrees O
C O
. O
[]

Phonophoresis O
versus O
topical O
application O
of O
ketoprofen O
: O
comparison O
between O
tissue O
and O
plasma O
levels O
. O
[]

Calorimetry O
enhances O
resting B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
through O
more O
efficient O
heat O
transfer O
from O
the O
body O
. O
['Physiological-Clinical']

Subjects O
accumulated O
1703 O
person O
years O
free B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

These O
data O
suggest O
that O
the O
antishivering O
effect O
of O
clonidine O
results O
from O
central O
thermoregulatory O
inhibition O
rather O
than O
a O
specific O
peripheral O
action O
on O
thermogenic O
muscular O
activity O
. O
[]

There O
were O
three O
experimental O
conditions O
: O
1 O
) O
tailored O
, O
iterative O
, O
printed O
dietary O
feedback O
( O
TF O
) O
with O
three O
instalments O
mail-delivered O
over O
a O
3-month O
period O
that O
were O
re-tailored O
to O
most O
recent O
assessment O
of O
dietary O
intake O
, O
intention O
to O
change O
and O
assessment O
of O
self-adequacy O
of O
dietary O
intake O
. O
[]

After O
at O
least O
14 O
days O
, O
subjects O
were O
randomized O
to O
receive O
either O
olopatadine O
in O
one O
eye O
and O
placebo O
in O
the O
contralateral O
eye O
, O
or O
ketorolac O
in O
one O
eye O
and O
placebo O
in O
the O
contralateral O
eye O
. O
[]

The O
secondary O
endpoints O
included O
cardiovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
development O
of O
persistent B-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
, O
left B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
dimension I-outcome ['Physiological-Clinical']
, O
and O
quality-of-life B-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

We O
conclude O
that O
frequent O
alterations O
in O
coronary B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
occur O
early O
during O
reperfusion O
therapy O
and O
that O
these O
findings O
may O
explain O
reports O
with O
varying O
results O
of O
thrombolytic O
therapy O
. O
['Physiological-Clinical']

Postoperative O
radiotherapy O
in O
breast O
cancer O
-- O
long-term O
results O
from O
the O
Oslo O
study O
. O
[]

Oxygenation B-outcome ['Physiological-Clinical']
, O
measured O
as O
Pao2/Fio2 O
, O
was O
assessed O
before O
BAL O
. O
['Physiological-Clinical']

DESIGN O
Randomized O
controlled O
trial O
. O
[]

Pre- O
and O
postsupplementation O
, O
UVR O
[]

After O
surgery O
at O
3 O
months O
, O
patients O
continued O
on O
the O
same O
study O
medication O
as O
adjuvant O
therapy O
for O
up O
to O
5 O
years O
or O
until O
recurrence O
, O
intolerable O
toxicity O
or O
withdrawal O
of O
patient O
consent O
. O
[]

Adherence B-outcome ['Life-Impact']
for O
both O
placebo O
and O
amoxycillin O
was O
> O
96 O
% O
and O
98.9 O
% O
subjects O
were O
followed O
up O
on O
day- O
4 O
. O
['Life-Impact']

Interpretation O
of O
the O
texture O
, O
shape O
, O
and O
consistency O
of O
objects O
can O
be O
performed O
. O
[]

DESIGN O
Between-groups O
trial O
to O
compare O
levels O
of O
satisfaction O
and O
clinical O
outcomes O
for O
two O
groups O
of O
women O
, O
cared O
for O
either O
under O
this O
Changing O
Childbirth O
scheme O
or O
the O
traditional O
model O
of O
care O
. O
[]

Comparison O
of O
intermittent O
or O
continuous O
methotrexate O
plus O
6-mercaptopurine O
in O
regimens O
for O
standard-risk O
acute O
lymphoblastic O
leukemia O
in O
childhood O
( O
JCCLSG-S811 O
) O
. O
[]

Contrary O
to O
group O
1 O
, O
in O
group O
2 O
, O
the O
median O
total O
VHI-10 O
score O
was O
significantly O
higher O
3 O
months O
after O
surgery O
( O
P O
= O
.034 O
) O
compared O
with O
preoperatively O
, O
indicating O
a O
subjective O
voice O
handicap O
. O
[]

In O
a O
randomized O
, O
double-blind O
, O
phase O
III O
, O
controlled O
trial O
we O
compared O
the O
caudal O
administration O
of O
levobupivacaine O
0.25 O
% O
and O
ropivacaine O
0.25 O
% O
with O
bupivacaine O
0.25 O
% O
in O
children O
. O
[]

Short-term O
metabolic O
effects O
of O
prednisone O
administration O
in O
healthy O
subjects O
. O
[]

These O
results O
confirm O
that O
plasma O
EBV-DNA O
is O
highly O
concordant O
with O
EBER-ISH O
in O
HL O
and O
suggest O
that O
it O
may O
have O
prognostic O
utility O
both O
at O
baseline O
and O
after O
therapy O
. O
[]

SETTING O
Private O
infertility O
clinic O
. O
[]

Randomized O
comparative O
study O
of O
tegafur/uracil O
and O
oral O
leucovorin O
versus O
parenteral O
fluorouracil O
and O
leucovorin O
in O
patients O
with O
previously O
untreated O
metastatic O
colorectal O
cancer O
. O
[]

Delayed-onset O
reactions O
were O
rare O
and O
did O
not O
reoccur O
after O
Perlane O
retreatment O
. O
[]

In O
vitro O
, O
3 O
of O
21 O
isolates O
showed O
reduced O
susceptibility B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
mefloquine I-outcome ['Life-Impact']
, O
with O
minimum O
inhibitory B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
( O
MIC O
) O
> O
67 O
nM/litre O
. O
['Life-Impact', 'Physiological-Clinical']

In O
both O
arms O
of O
the O
study O
, O
the O
supraclavicular O
fossa O
and O
axillary O
apex O
were O
treated O
once O
daily O
to O
50 O
Gy O
. O
[]

Secondary O
outcome O
measures O
are O
remission B-outcome ['Physiological-Clinical']
as O
measured O
with O
the O
PHQ9 O
and O
the O
IDS-SR O
, O
and O
cost-effectiveness O
measured O
with O
the O
TiC-P O
, O
the O
EQ-5D O
and O
the O
SF-36 O
. O
['Physiological-Clinical', 'Resource-use']

A O
secondary O
aim O
is O
to O
determine O
if O
pain O
severity O
, O
level O
of O
disability O
and O
fear O
of O
movement/ O
( O
re O
) O
injury O
predict O
response O
to O
a O
physical O
activity O
program O
. O
[]

METHOD O
The O
study O
was O
designed O
to O
determine O
whether O
a O
triage O
room O
and/or O
standing O
orders O
decreased O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
as O
compared O
to O
the O
existing O
system O
of O
evaluating O
women O
in O
labor O
rooms O
. O
['Resource-use']

Predicting O
completion O
of O
treatment O
among O
foreign-born O
adolescents O
treated O
for O
latent O
tuberculosis O
infection O
in O
Los O
Angeles O
. O
[]

The O
Beck O
Depression O
Inventory O
( O
BDI O
) O
, O
the O
Hamilton O
Depression O
Rating O
Scale O
( O
HDRS O
) O
and O
a O
synoptic O
table O
were O
used O
to O
score O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

This O
study O
examined O
the O
implementation O
phase O
of O
a O
four-year O
research O
project O
to O
test O
the O
effectiveness O
of O
strategies O
to O
increase O
diffusion O
of O
Smart O
Choices O
, O
a O
school-based O
tobacco O
prevention O
program O
. O
[]

Significant O
treatment O
effects O
were O
found O
for O
blind-rated O
perceptions O
of O
conversational B-outcome ['Life-Impact']
competence I-outcome ['Life-Impact']
, O
for O
parent-reported O
measures O
of O
pragmatic B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
, O
and O
for O
teacher-reported O
ratings O
of O
classroom B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

MAIN O
OUTCOME O
MEASURES O
Efficacy O
measures O
: O
rate O
of O
decline O
in O
FEV B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
after O
the O
bronchodilator B-outcome ['Physiological-Clinical']
and O
in O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
frequency O
of O
exacerbations B-outcome ['Physiological-Clinical']
, O
respiratory B-outcome ['Physiological-Clinical']
withdrawals I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Changes O
in O
RBC B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
were O
not O
consistently O
paralleled O
by O
changes O
in O
Hb O
. O
['Physiological-Clinical']

There O
was O
a O
significant O
decrease O
in O
mean O
percent O
change O
in O
PGE B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( O
P O
= O
0.05 O
) O
and O
5-HETE O
( O
P O
= O
0.04 O
) O
, O
and O
a O
trend O
toward O
significant O
decreases O
in O
12-HETE B-outcome ['Physiological-Clinical']
( O
P O
= O
0.09 O
) O
and O
15-HETE O
( O
P O
= O
0.06 O
) O
normalized O
to O
free B-outcome ['Physiological-Clinical']
arachidonic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHOD O
Participants O
were O
1,820 O
low-risk O
patients O
aged O
65 O
to O
74 O
years O
who O
had O
not O
previously O
been O
in O
a O
recall O
system O
for O
influenza O
immunisation O
at O
their O
general O
practice O
. O
[]

Efficacy O
and O
safety O
of O
recombinant O
human O
nerve O
growth O
factor O
in O
patients O
with O
diabetic O
polyneuropathy O
: O
A O
randomized O
controlled O
trial O
. O
[]

But O
, O
there O
was O
no O
significant O
difference O
in O
HBV B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
rates O
between O
vaccine O
group O
and O
placebo-controlled O
group O
( O
7.89 O
% O
vs. O
13.25 O
% O
, O
P O
> O
0.1 O
) O
nine O
to O
11 O
years O
following O
immunization O
. O
['Physiological-Clinical']

Effects O
of O
two O
combined O
oral O
contraceptives O
containing O
ethinyl O
estradiol O
20 O
microg O
combined O
with O
either O
drospirenone O
or O
desogestrel O
on O
lipids O
, O
hemostatic O
parameters O
and O
carbohydrate O
metabolism O
. O
[]

METHODS O
The O
first O
postoperative O
tacrolimus O
dose O
was O
given O
either O
according O
to O
standard O
care O
( O
control O
group O
) O
or O
0.15 O
mg/kg O
b.d O
. O
[]

CONCLUSION O
Leucocyte O
depletion O
of O
perioperative O
transfused O
blood O
has O
no O
effect O
on O
long-term O
survival B-outcome ['Mortality']
and/or O
cancer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

RESULTS O
Pioglitazone-treated O
patients O
demonstrated O
greater O
increases O
in O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HDL-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
reductions O
in O
glycated O
hemoglobin B-outcome ['Physiological-Clinical']
, O
triglycerides B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Moreover O
, O
the O
treatment O
efficacy O
of O
carboplatin O
arm O
is O
not O
different O
from O
the O
standard O
regimen O
in O
the O
treatment O
of O
locoregional O
advanced O
stage O
NPC O
. O
[]

METHODS O
Tumors O
of O
120 O
randomly O
selected O
patients O
with O
AJCC/UICC O
stage O
II O
disease O
were O
retrospectively O
reviewed O
for O
tumor O
growth O
pattern O
( O
expanding O
vs. O
infiltrating O
) O
and O
the O
extent O
of O
tumor O
budding O
, O
with O
high-grade O
budding O
reflecting O
presence O
of O
10 O
or O
more O
budding O
foci O
scattered O
at O
the O
invasive O
tumor O
margin O
. O
[]

Parameters O
assessed O
included O
severity O
of O
SDB B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
polysomnography I-outcome ['Physiological-Clinical']
) O
, O
subjective O
and O
objective B-outcome ['Physiological-Clinical']
loudness I-outcome ['Physiological-Clinical']
of O
snoring B-outcome ['Physiological-Clinical']
( O
visual O
analog O
scale O
and O
SNAP O
recording O
) O
, O
sleepiness O
( O
Epworth O
Sleepiness O
Scale O
) O
, O
and O
anatomic B-outcome ['Physiological-Clinical']
changes O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
success B-outcome ['Physiological-Clinical']
of O
masking O
study O
participants O
to O
treatment O
allocation O
using O
sham O
intravitreal O
injections O
. O
['Physiological-Clinical']

Results O
suggest O
that O
EBTs O
can O
retain O
their O
effectiveness O
when O
transported O
to O
a O
community O
context O
. O
[]

At O
3-month O
followup O
the O
number O
of O
patients O
with O
a O
partial B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
full I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
group O
1 O
had O
decreased O
from O
11 O
( O
78.6 O
% O
) O
to O
6 O
( O
42.9 O
% O
) O
. O
['Physiological-Clinical']

The O
study O
was O
double O
blinded O
and O
the O
duration O
was O
14 O
mo O
, O
with O
supervised O
feeding O
of O
the O
micronutrient-enriched O
beverage O
. O
[]

It O
has O
been O
shown O
that O
phenytoin O
has O
no O
effect O
on O
the O
absorption O
of O
this O
folate B-outcome ['Physiological-Clinical']
polyglutamate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
If O
the O
capsulorhexis B-outcome ['Physiological-Clinical']
was O
located O
partially O
or O
completely O
off O
the O
optics B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
IOL I-outcome ['Physiological-Clinical']
, O
compared O
to O
totally O
on O
the O
IOL B-outcome ['Physiological-Clinical']
, O
significantly O
more O
PCO B-outcome ['Physiological-Clinical']
was O
found O
( O
p O
= O
0.0014 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Duration O
of O
labour O
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
analgesia I-outcome ['Life-Impact']
and O
side-effects B-outcome ['Adverse-effects']
were O
compared O
between O
groups O
. O
['Life-Impact', 'Adverse-effects']

In O
Experiment O
2 O
, O
children O
were O
instructed O
to O
attend O
to O
the O
direction O
opposite O
that O
of O
the O
cues O
and O
the O
target O
was O
correctly O
cued O
in O
only O
20 O
% O
of O
the O
trials O
. O
[]

However O
, O
substantial O
residual O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
drinking B-outcome ['Life-Impact']
persisted O
at O
the O
end O
of O
the O
trial O
. O
['Life-Impact']

Concentric O
( O
maximal O
EMG O
activity O
during O
extension O
) O
and O
eccentric O
( O
maximal O
EMG O
activity O
during O
flexion O
) O
ratios O
were O
also O
used O
in O
the O
analyses O
. O
[]

The O
authors O
studied O
the O
unconscious O
thought O
effect O
in O
a O
complex O
and O
error-prone O
part O
of O
clinical O
decision O
making O
: O
diagnosis O
. O
[]

The O
mean O
healing B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
was O
significantly O
shorter O
for O
patients O
treated O
with O
Choerospondias O
axillaris O
( O
11 O
days O
) O
compared O
with O
patients O
treated O
with O
saline O
gauze O
( O
17 O
days O
) O
( O
p O
< O
0.01 O
) O
, O
and O
the O
number O
of O
wound B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
Choerospondias O
axillaris O
group O
( O
7/20 O
compared O
with O
16/19 O
, O
p O
= O
0.003 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Intravenous O
heparin O
and O
patent O
hemostasis O
lower O
its O
incidence O
. O
[]

Correlation O
showed O
a O
statistically O
significant O
, O
but O
rather O
weak O
, O
association O
between O
direction B-outcome ['Life-Impact']
errors I-outcome ['Life-Impact']
and O
smooth B-outcome ['Life-Impact']
pursuit I-outcome ['Life-Impact']
measures O
. O
['Life-Impact', 'Life-Impact']

Bar O
specimens O
with O
an O
adhesive O
area O
of O
approximately O
1 O
+/- O
0.1 O
mm O
( O
2 O
) O
were O
obtained O
from O
the O
composite-ceramic O
blocks O
( O
6 O
per O
block O
and O
30 O
per O
group O
) O
for O
microtensile B-outcome ['Physiological-Clinical']
testing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Low-dose O
mifepristone O
for O
uterine O
leiomyomata O
. O
[]

GMC O
in O
the O
placebo O
group O
did O
not O
change O
during O
the O
study O
. O
[]

Increased O
serum O
OPN O
concentrations O
occur O
in O
chronic O
myeloid O
leukemia O
, O
multiple O
myeloma O
, O
and O
acute O
myeloid O
leukemia O
( O
AML O
) O
. O
[]

RESULTS O
Patient O
characteristics O
were O
similar O
among O
the O
groups O
. O
[]

BACKGROUND O
DATA O
The O
use O
of O
low-level O
laser O
has O
been O
recommended O
for O
the O
management O
of O
tennis O
elbow O
with O
contradictory O
results O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

In O
year O
2 O
, O
these O
cost B-outcome ['Resource-use']
differences O
were O
generally O
greater O
than O
in O
year O
1 O
. O
['Resource-use']

Moreover O
, O
oxytocin O
enhanced O
functional O
coordination O
in O
the O
area O
( O
P O
< O
.001 O
) O
, O
and O
the O
magnitude O
of O
these O
neural O
effects O
was O
predictive O
of O
the O
behavioral O
effects O
( O
P O
? O
[]

This O
study O
was O
designed O
to O
investigate O
the O
safety O
and O
effectiveness O
of O
open-label O
olanzapine O
as O
a O
treatment O
for O
children O
with O
autistic O
disorder O
by O
using O
haloperidol O
as O
a O
standard O
comparator O
treatment O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Control O
of O
the O
lumbar O
neutral O
zone O
decreases O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
improves O
self-evaluated B-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
: O
a O
12-month O
randomized O
controlled O
study O
. O
['Physiological-Clinical', 'Life-Impact']

They O
can O
be O
treated O
with O
either O
an O
implantable O
cardioverter-defibrillator O
or O
antiarrhythmic O
drugs O
, O
but O
the O
relative O
efficacy O
of O
these O
two O
treatment O
strategies O
is O
unknown O
. O
[]

The O
primary O
outcome O
measure O
was O
average O
wrist B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
during O
the O
past O
week O
, O
measured O
using O
a O
visual O
analog O
scale O
( O
VAS O
) O
. O
['Physiological-Clinical']

Provisional O
screw-retained O
crowns O
, O
out O
of O
occlusion O
, O
were O
placed O
at O
second-stage O
surgery O
after O
26 O
weeks O
for O
the O
conventional O
restoration O
group O
, O
and O
within O
4 O
hours O
of O
implant O
placement O
for O
the O
immediate O
restoration O
group O
. O
[]

Vertebral O
Efficacy O
with O
Risedronate O
Therapy O
( O
VERT O
) O
Study O
Group O
. O
[]

To O
gain O
more O
insight O
into O
the O
consequences O
of O
curing O
contraction O
within O
the O
tooth O
cavity O
, O
we O
assessed O
the O
margin O
behavior O
of O
12 O
contemporary O
restorative O
systems O
in O
class O
V O
restorations O
with O
margins O
located O
on O
enamel O
and O
dentin O
after O
mechanical O
loading O
and O
water O
storage O
. O
[]

CONCLUSION O
Five O
hundred O
participants O
were O
enrolled O
and O
baseline O
characteristics O
include O
a O
mean O
age O
of O
60.0 O
years O
; O
57.6 O
% O
female O
; O
and O
77.6 O
% O
white O
. O
[]

A O
comparative O
efficacy O
and O
safety O
study O
of O
clarithromycin O
, O
roxithromycin O
and O
erythromycin O
stearate O
in O
mild O
pneumonia O
. O
[]

Biosynthesis O
of O
prostacyclin B-outcome ['Physiological-Clinical']
and O
TXA2 B-outcome ['Physiological-Clinical']
under O
basal O
conditions O
was O
studied O
in O
eight O
subjects O
by O
measuring O
2,3-dinor-6-oxo-PGF1 B-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
and O
2,3-dinor-TXB2 B-outcome ['Physiological-Clinical']
in O
hourly O
urine O
samples O
obtained O
during O
and O
after O
intravenous O
infusion O
of O
aspirin O
and O
, O
on O
a O
separate O
occasion O
, O
of O
vehicle O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Influence O
of O
two O
different O
resection O
techniques O
( O
conventional O
liver O
resection O
versus O
anterior O
approach O
) O
of O
liver O
metastases O
from O
colorectal O
cancer O
on O
hematogenous O
tumor O
cell O
dissemination O
- O
prospective O
randomized O
multicenter O
trial O
. O
[]

Grades O
3 O
and O
4 O
toxicities B-outcome ['Adverse-effects']
experienced O
by O
more O
than O
5 O
% O
of O
patients O
included O
neutropenia B-outcome ['Physiological-Clinical']
( O
22 O
% O
) O
, O
fatigue B-outcome ['Physiological-Clinical']
( O
9 O
% O
) O
, O
and O
neuropathy B-outcome ['Physiological-Clinical']
( O
13 O
% O
) O
on O
the O
ixabepilone O
arm O
, O
and O
neutropenia B-outcome ['Physiological-Clinical']
( O
29 O
% O
) O
, O
febrile B-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
( O
9 O
% O
) O
, O
fatigue B-outcome ['Physiological-Clinical']
( O
9 O
% O
) O
, O
neuropathy B-outcome ['Physiological-Clinical']
( O
7 O
% O
) O
, O
and O
thrombosis B-outcome ['Physiological-Clinical']
( O
6 O
% O
) O
on O
the O
ixabepilone O
+ O
EMP O
arm O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Little O
is O
known O
regarding O
the O
variations O
in O
effective B-outcome ['Life-Impact']
ventilation I-outcome ['Life-Impact']
during O
bag O
and O
mask O
resuscitation O
with O
standard O
methods O
compared O
with O
that O
delivered O
by O
ventilator-delivered O
mask O
ventilation O
( O
VDMV O
) O
. O
['Life-Impact']

An O
in O
vitro O
study O
showed O
that O
Pentosan O
Polysulfate O
Sodium O
( O
PPS O
) O
had O
greater O
P-selectin O
blocking O
activity O
than O
heparin O
. O
[]

CONCLUSION O
Evaluation O
of O
wound B-outcome ['Physiological-Clinical']
progress I-outcome ['Physiological-Clinical']
is O
clearly O
difficult O
. O
['Physiological-Clinical']

Its O
chemical O
structure O
-- O
tetracyclic O
ring O
, O
C-beta O
, O
C-alpha O
, O
amine O
in O
a O
secondary O
position O
-- O
allows O
block O
of O
the O
receptors O
for O
serotonin O
and O
histamine O
. O
[]

CONCLUSIONS O
Prophylactic O
use O
of O
intravenous O
immune O
globulin O
failed O
to O
reduce O
the O
incidence O
of O
hospital-acquired B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
very-low-birth-weight O
infants O
. O
['Physiological-Clinical']

Risk O
factors O
for O
fracture O
in O
a O
UK O
population O
: O
a O
prospective O
cohort O
study O
. O
[]

We O
performed O
a O
randomized O
phase O
2 O
trial O
of O
rituximab O
( O
375 O
mg/m O
( O
2 O
) O
) O
given O
either O
concurrently O
before O
each O
infusional O
etoposide O
, O
vincristine O
, O
doxorubicin O
, O
cyclophosphamide O
, O
and O
prednisone O
( O
EPOCH O
) O
chemotherapy O
cycle O
or O
sequentially O
( O
weekly O
for O
6 O
weeks O
) O
after O
completion O
of O
all O
chemotherapy O
in O
HIV-associated O
NHL O
. O
[]

Of O
the O
832 O
patients O
undergoing O
SEPS O
, O
460 O
( O
55 O
% O
) O
underwent O
saphenous O
vein O
ligation O
and O
stripping O
at O
the O
same O
operation O
. O
[]

Half O
the O
subjects O
were O
instructed O
not O
to O
blink O
, O
whereas O
this O
instruction O
was O
omitted O
for O
the O
other O
subjects O
. O
[]

This O
suggests O
that O
IL-2 B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
IL-4 I-outcome ['Physiological-Clinical']
synthesis I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
AD I-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
is O
less O
sensitive O
to O
regulation O
by O
glucocorticoids O
. O
['Physiological-Clinical']

SETTING O
A O
university O
medical O
center O
in O
The O
Netherlands O
. O
[]

[ O
Application O
of O
tacrolimus O
and O
cyclosporine O
A O
in O
HBV-carrying O
renal O
transplant O
recipients O
] O
. O
[]

CONCLUSIONS O
This O
study O
shows O
a O
beneficial O
effect O
on O
oral B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Moderate O
sodium O
restriction O
, O
angiotensin O
converting O
enzyme O
inhibition O
, O
and O
thiazide O
diuretic O
in O
the O
management O
of O
essential O
hypertension O
. O
[]

Analysis O
by O
Choi O
criteria O
on O
survival O
for O
BCL2 O
, O
no O
matter O
for O
which O
subsets O
( O
GCB O
or O
ABC O
) O
or O
treatment O
modality O
( O
chemotherapy O
with O
or O
without O
the O
addition O
of O
rituximab O
) O
showed O
no O
difference O
in O
5 O
years O
OS O
or O
EFS O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
assessed O
for O
24 O
hr O
using O
an O
objective O
pain B-outcome ['Physiological-Clinical']
score O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
CARS O
scores O
of O
both O
groups O
declined O
after O
the O
treatment O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
long-term O
safety O
and O
efficacy O
of O
risperidone O
in O
treating O
irritability B-outcome ['Life-Impact']
and O
related O
behaviors O
in O
children O
and O
adolescents O
with O
autistic O
disorders O
. O
['Life-Impact']

Although O
lathosterol/TC O
increased O
, O
campesterol/TC O
decreased O
more O
in O
ezetimibe-plus-statin O
. O
[]

Lean B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
( O
LBM B-outcome ['Physiological-Clinical']
) O
and O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
determined O
by O
dual O
energy O
x-ray O
absorptiometry O
, O
and O
total O
body O
water O
( O
TBW O
) O
was O
determined O
by O
bioelectrical O
impedance O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pre-saralasin O
setting O
of O
the O
renin-angiotensin O
axis O
was O
varied O
with O
salt O
intake O
( O
15 O
and O
290 O
mmol O
of O
Na+/day O
) O
each O
for O
10 O
days O
. O
[]

We O
studied O
9 O
Caucasian O
boys O
, O
3.8-8.1 O
years O
old O
, O
with O
a O
DSM-IV O
diagnosis O
of O
a O
pervasive O
developmental O
disorder O
, O
living O
with O
their O
families O
, O
receiving O
no O
chronic O
medications O
, O
and O
without O
significant O
gastrointestinal O
symptoms O
. O
[]

Use O
of O
an O
alpha O
1-blocker O
, O
YM617 O
, O
in O
the O
treatment O
of O
benign O
prostatic O
hypertrophy O
. O
[]

Zinc O
supplementation O
in O
alcoholic O
cirrhosis O
. O
[]

This O
investigation O
evaluated O
24 O
hours O
of O
cefoxitin O
or O
ampicillin/sulbactam O
used O
for O
early O
therapy O
in O
such O
patients O
. O
[]

OBJECTIVE O
We O
evaluate O
whether O
patient O
outcomes O
may O
be O
affected O
by O
possible O
errors O
in O
care O
at O
discharge O
as O
assessed O
by O
Peer O
Review O
Organizations O
( O
PROs O
) O
. O
[]

OBJECTIVE O
To O
determine O
the O
clinical B-outcome ['Physiological-Clinical']
benefit O
of O
oral O
dexamethasone O
in O
children O
admitted O
to O
the O
hospital O
with O
bronchiolitis O
treated O
with O
nebulized O
salbutamol O
. O
['Physiological-Clinical']

CLASSIFICATION O
OF O
EVIDENCE O
This O
study O
provides O
Class O
III O
evidence O
that O
CBT O
in O
addition O
to O
SMC O
, O
as O
compared O
to O
SMC O
alone O
, O
significantly O
reduces O
seizure O
frequency O
in O
patients O
with O
PNES O
( O
change O
in O
median O
monthly O
seizure O
frequency O
: O
baseline O
to O
6 O
months O
follow-up O
, O
CBT O
group O
, O
12 O
to O
1.5 O
; O
SMC O
alone O
group O
, O
8 O
to O
5 O
) O
. O
[]

The O
primary O
aim O
of O
this O
randomised O
controlled O
trial O
is O
to O
determine O
the O
effects O
of O
a O
physical O
activity O
program O
for O
people O
with O
chronic O
( O
symptoms O
of O
> O
3 O
months O
duration O
) O
whiplash O
. O
[]

West O
Midlands O
Oncology O
Association O
trials O
of O
adjuvant O
chemotherapy O
in O
operable O
breast O
cancer O
: O
results O
after O
a O
median O
follow-up O
of O
7 O
years O
. O
[]

Verapamil O
has O
shown O
antimanic O
activity O
in O
some O
but O
not O
all O
studies O
. O
[]

Ocular O
and O
oral O
swabs O
were O
collected O
twice O
daily O
for O
30 O
days O
. O
[]

The O
overall O
clinical B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
rate O
was O
30 O
% O
( O
10/33 O
) O
, O
and O
the O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rate O
was O
only O
24 O
% O
( O
8/33 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
one O
patient O
, O
seven O
days O
' O
of O
unsuccessful O
heparin O
was O
followed O
by O
two O
months O
' O
successful O
coumarin O
therapy O
. O
[]

With O
respect O
to O
the O
final O
question O
, O
the O
optimal O
treatment O
for O
polycythemia O
vera O
, O
it O
is O
apparent O
that O
the O
expectation O
of O
a O
single O
optimal O
therapy O
that O
would O
apply O
to O
all O
patients O
at O
all O
ages O
and O
stages O
of O
the O
disease O
was O
naive O
. O
[]

The O
difference O
between O
the O
two O
groups O
in O
the O
frequency O
of O
side-effects O
was O
not O
significant O
. O
[]

Mean O
gastric B-outcome ['Physiological-Clinical']
endoscopy I-outcome ['Physiological-Clinical']
scores O
at O
Days O
8 O
and O
15 O
were O
significantly O
lower O
in O
the O
risedronate O
group O
than O
in O
the O
alendronate O
group O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

A O
number O
of O
techniques O
have O
been O
tried O
to O
minimize O
propofol-induced O
pain O
, O
with O
variable O
results O
. O
[]

The O
groups O
also O
differed O
in O
their O
N1 B-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
total O
amount O
of O
protein B-outcome ['Physiological-Clinical']
deaminated B-outcome ['Physiological-Clinical']
and O
the O
amino B-outcome ['Physiological-Clinical']
groups I-outcome ['Physiological-Clinical']
incorporated O
into O
urea B-outcome ['Physiological-Clinical']
was O
calculated O
to O
be O
approximately O
20-23 O
g. O
The O
net O
amount O
of O
glucose B-outcome ['Physiological-Clinical']
estimated O
to O
be O
produced O
, O
based O
on O
the O
quantity O
of O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
learning O
curve O
was O
steep O
for O
the O
hub O
and O
spoke O
personnel O
of O
the O
new O
telestroke O
network O
, O
as O
reflected O
by O
frequent O
technical O
problems O
. O
[]

or O
warning O
( O
i.e. O
, O
Warning O
: O
Trying O
to O
look O
as O
thin O
as O
this O
model O
may O
be O
dangerous O
to O
your O
health O
. O
) O
[]

We O
also O
designed O
a O
control O
intervention O
, O
trained O
facilitators O
to O
deliver O
the O
interventions O
, O
and O
conducted O
quality O
assurance O
of O
intervention O
delivery O
. O
[]

Patients O
of O
both O
the O
groups O
were O
evenly O
matched O
with O
respect O
to O
age O
, O
sex O
, O
body O
surface O
area O
, O
duration O
and O
severity O
of O
chronic O
obstructive O
pulmonary O
disease O
and O
coronary O
artery O
disease O
. O
[]

The O
role O
of O
PE O
in O
the O
treatment O
of O
systemic O
necrotizing O
vasculitis O
: O
PE O
are O
obviously O
useful O
in O
PAN O
related O
to O
HBV O
where O
immune O
complex O
deposition O
has O
been O
demonstrated O
. O
[]

Logistic-regression O
analysis O
showed O
that O
a O
higher O
risk O
of O
infection O
( O
P O
less O
than O
0.05 O
) O
was O
associated O
with O
increased O
age O
, O
injury O
to O
the O
left O
colon O
necessitating O
colostomy O
, O
a O
larger O
number O
of O
units O
of O
blood O
or O
blood O
products O
administered O
at O
surgery O
, O
and O
a O
larger O
number O
of O
injured O
organs O
. O
[]

Additionally O
, O
the O
joint O
attention O
group O
improved O
in O
the O
proportion O
of O
time O
spent O
sharing O
coordinated O
joint O
looks O
between O
intervener O
and O
probe O
. O
[]

In O
addition O
, O
supplementation O
did O
not O
affect O
the O
exercise-induced B-outcome ['Life-Impact']
increase O
in O
thiobarbituric B-outcome ['Resource-use']
acid I-outcome ['Resource-use']
reactive I-outcome ['Resource-use']
substances I-outcome ['Resource-use']
in O
plasma B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Resource-use', 'Physiological-Clinical']

Abdominoperineal O
resection O
and O
anterior O
resection O
in O
the O
treatment O
of O
rectal O
cancer O
: O
results O
in O
relation O
to O
adjuvant O
preoperative O
radiotherapy O
. O
[]

When O
the O
subgroup O
of O
patients O
who O
had O
CABG O
reoperations O
was O
analyzed O
separately O
, O
there O
was O
a O
trend O
toward O
less O
reoperation B-outcome ['Resource-use']
for I-outcome ['Resource-use']
bleeding I-outcome ['Resource-use']
in O
the O
study O
group O
( O
0 O
% O
versus O
4.0 O
% O
, O
p O
= O
0.058 O
) O
. O
['Resource-use']

We O
did O
confirm O
these O
preliminary O
results O
in O
a O
double-blind O
study O
performed O
on O
4 O
children O
with O
autism O
. O
[]

BACKGROUND O
Insulin-like O
growth O
factors O
( O
IGF-1 O
and O
IGF-2 O
) O
bind O
to O
the O
IGF-1 O
receptor O
( O
IGF-1R O
) O
, O
increasing O
cell B-outcome ['Physiological-Clinical']
proliferation I-outcome ['Physiological-Clinical']
and O
survival B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

Fewer O
patients O
( O
13 O
% O
) O
in O
the O
bevacizumab-erlotinib O
arm O
discontinued O
treatment O
as O
a O
result O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
than O
in O
the O
chemotherapy O
alone O
( O
24 O
% O
) O
or O
bevacizumab-chemotherapy O
( O
28 O
% O
) O
arms O
. O
['Adverse-effects']

RESULTS O
Hair B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
and O
thicknesses I-outcome ['Physiological-Clinical']
statistically O
significantly O
decreased O
after O
the O
first O
post-treatment O
evaluation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Relative O
to O
children O
in O
the O
wait-list O
group O
, O
program O
participants O
showed O
greater O
improvements O
in O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
over O
the O
course O
of O
the O
intervention O
, O
as O
indicated O
by O
parent-report O
measures O
. O
['Life-Impact']

At O
16 O
weeks O
, O
mean O
HbA B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
0.84 O
% O
( O
95 O
% O
CI O
-1.31 O
to O
-0.36 O
) O
lower O
in O
the O
continuous O
subcutaneous O
insulin O
infusion O
group O
compared O
with O
the O
insulin O
injection O
group O
( O
P O
= O
0.002 O
) O
. O
['Physiological-Clinical']

Among O
the O
children O
with O
only O
partial B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of O
their O
enlarged O
['Physiological-Clinical']

METHODS O
From O
October O
2004 O
to O
August O
2009 O
, O
patients O
with O
rectal O
cancer O
, O
ulcerative O
colitis O
or O
rectal O
gastrointestinal O
stromal O
tumor O
, O
who O
underwent O
APR O
or O
proctocolectomy O
, O
were O
randomized O
into O
two O
arms O
: O
simple O
drainage O
group O
( O
n O
= O
37 O
) O
and O
continuous O
irrigation O
( O
n O
= O
37 O
) O
. O
[]

We O
assessed O
the O
relative O
importance O
of O
lipid B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
apo I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
Lp I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
total O
homocysteine B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
tHcy I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
in O
children O
in O
relation O
to O
premature O
cardiovascular O
disease O
in O
family O
members O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Among O
63 O
evaluable O
patients O
, O
similar O
response O
rates O
( O
62.1 O
% O
and O
64.7 O
% O
respectively O
) O
were O
recorded O
for O
the O
treatment O
arms O
. O
[]

The O
fractional B-outcome ['Physiological-Clinical']
proximal I-outcome ['Physiological-Clinical']
reabsorption I-outcome ['Physiological-Clinical']
was O
increased O
( O
0.82 O
+/- O
0.03 O
vs O
0.78 O
+/- O
0.03 O
, O
p O
less O
than O
0.05 O
) O
, O
and O
the O
fractional B-outcome ['Physiological-Clinical']
distal I-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
reabsorption I-outcome ['Physiological-Clinical']
reduced O
( O
0.88 O
+/- O
0.03 O
vs O
0.94 O
+/- O
0.02 O
, O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
a O
prospective O
randomized O
clinical O
trial O
, O
after O
treatment O
of O
144 O
infertile O
women O
in O
their O
reproductive O
age O
by O
laparoscopy O
( O
whose O
endometriosis O
was O
confirmed O
by O
prior O
laparoscopy O
) O
, O
they O
were O
divided O
into O
3 O
groups O
: O
group O
1 O
( O
47 O
cases O
) O
who O
received O
letrozole O
for O
2 O
months O
, O
group O
2 O
( O
40 O
patients O
) O
who O
were O
prescribed O
triptorelin O
for O
2 O
months O
and O
group O
3 O
who O
were O
57 O
patients O
in O
the O
control O
group O
and O
did O
not O
receive O
any O
medication O
. O
[]

Peroxisome O
proliferator-activated O
receptor-? O
( O
PPAR-? O
) O
agonists O
improve O
insulin O
sensitivity O
. O
[]

BACKGROUND O
AND O
OBJECTIVE O
The O
Laryngeal O
Tube O
Sonda O
( O
LTS O
) O
and O
the O
ProSeal O
Laryngeal O
Mask O
Airway O
( O
PLMA O
) O
are O
two O
new O
devices O
introduced O
for O
maintaining O
the O
airway O
during O
controlled O
ventilation O
under O
general O
anaesthesia O
. O
[]

Coronary B-outcome ['Physiological-Clinical']
atheroma I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
was O
evaluated O
by O
serial O
intravascular O
ultrasound O
. O
['Physiological-Clinical']

3.73 O
in O
the O
imidafenacin O
and O
fesoterodine O
groups O
, O
respectively O
, O
and O
the O
difference O
was O
not O
significant O
between O
the O
two O
groups O
. O
[]

The O
available O
analytical O
and O
clinical O
evidence O
demonstrate O
that O
anti-CD O
WPC O
is O
safe O
for O
use O
by O
individuals O
with O
CDAD O
, O
under O
the O
described O
conditions O
of O
use O
. O
[]

On O
successive O
days O
, O
patients O
ingested O
one O
of O
the O
meals O
twice O
, O
followed O
by O
random O
assignment O
to O
3 O
h O
upright O
and O
3 O
h O
recumbent O
position O
. O
[]

A O
total O
of O
120 O
healthy O
postmenopausal O
women O
were O
enrolled O
, O
and O
doses O
of O
10 O
to O
600 O
mg O
once O
daily O
and O
50 O
and O
300 O
mg O
twice O
daily O
were O
evaluated O
in O
15- O
and O
28-day O
multiple-dosing O
cohorts O
. O
[]

METHODS O
In O
this O
post-hoc O
analysis O
of O
a O
prospective O
, O
randomised O
, O
double-blind O
, O
multi-center O
therapeutic O
equivalence O
trial O
, O
76 O
patients O
undergoing O
elective O
on-pump O
cardiac O
surgery O
received O
perioperative O
volume O
replacement O
using O
either O
10 O
% O
HES O
130/0.4 O
( O
N.=37 O
) O
or O
10 O
% O
HES O
200/0.5 O
( O
N.=39 O
) O
up O
to O
a O
maximum O
dose O
of O
20 O
mL O
kg-1 O
. O
[]

METHODS O
Interviews O
were O
conducted O
at O
baseline O
and O
10 O
and O
20 O
weeks O
. O
[]

Iodixanol O
at O
both O
doses O
was O
diagnostic B-outcome ['Life-Impact']
in O
over O
90 O
% O
of O
cases O
. O
['Life-Impact']

Cronassial O
, O
a O
mixture O
of O
four O
naturally O
occurring O
gangliosides O
, O
was O
administered O
in O
a O
randomized O
double-blind O
test O
to O
evaluate O
whether O
this O
agent O
could O
prevent O
vincristine-induced O
neuropathy O
. O
[]

EEG- O
and O
SC-biofeedback O
sessions O
were O
similar O
and O
participants O
were O
blinded O
to O
the O
type O
of O
feedback O
they O
received O
. O
[]

Antipyretic B-outcome ['Physiological-Clinical']
efficacy O
of O
ibuprofen O
vs O
acetaminophen O
. O
['Physiological-Clinical']

In O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
multicentre O
study O
, O
200 O
patients O
( O
recruited O
between O
April O
and O
October O
1993 O
) O
with O
symptomatic O
benign O
prostatic O
hyperplasia O
were O
treated O
with O
either O
20 O
mg O
beta-sitosterol O
( O
which O
contains O
a O
mixture O
of O
phytosterols O
) O
three O
times O
per O
day O
or O
placebo O
. O
[]

Improvement O
was O
also O
found O
for O
5-point O
decrease O
in O
PHQ-9 O
score O
among O
72.2 O
% O
of O
intervention O
patients O
compared O
with O
59.7 O
% O
of O
EUC O
patients O
( O
OR O
= O
1.99 O
; O
95 O
% O
CI O
, O
1.14 O
to O
3.50 O
; O
P O
= O
.02 O
) O
. O
[]

Primary O
outcome O
was O
clinical B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
on O
or O
before O
day- O
4 O
. O
['Physiological-Clinical']

Cortisol B-outcome ['Physiological-Clinical']
levels O
in O
patients O
with O
Alzheimer O
's O
disease O
( O
AD O
) O
are O
relatively O
unaffected O
by O
a O
challenge O
with O
dexamethasone O
( O
DEX O
) O
in O
vivo O
. O
['Physiological-Clinical']

The O
proportion O
of O
participants O
who O
took O
at O
least O
90 O
% O
of O
the O
prescribed O
study O
drug O
during O
the O
first O
4 O
weeks O
after O
hematopoietic O
cell O
transplantation O
was O
54 O
% O
overall O
. O
[]

Comfort O
scores O
did O
not O
differ O
between O
closures O
[ O
5.8 O
( O
SD O
= O
2.7 O
) O
versus O
6.9 O
( O
SD O
= O
2.0 O
) O
, O
respectively O
, O
on O
breast O
( O
p O
= O
0.142 O
) O
and O
7.7 O
( O
SD O
= O
1.8 O
) O
versus O
7.7 O
( O
SD O
= O
2.3 O
) O
on O
abdomen O
( O
p O
= O
0.903 O
) O
] O
. O
[]

All O
parties O
, O
except O
for O
the O
randomisation O
centre O
, O
were O
blinded O
for O
TS O
status O
. O
[]

Patients O
with O
ER-positive O
disease O
had O
a O
significantly O
[]

16 O
patients O
with O
relapsing O
non-Hodgkin O
's O
malignant O
lymphomas O
considered O
as O
clinical O
stage O
I O
or O
II O
were O
treated O
by O
an O
association O
of O
chemo O
+ O
radiotherapy O
and O
thereafter O
by O
maintenance O
BCG O
therapy O
. O
[]

2.9 O
) O
( O
t O
= O
5.21 O
, O
P O
< O
0.05 O
) O
. O
[]

BACKGROUND O
The O
platelet O
glycoprotein O
IIb/IIIa O
receptor O
inhibitor O
abciximab O
, O
a O
monoclonal O
antibody O
, O
has O
been O
shown O
to O
improve O
early O
and O
late O
outcomes O
among O
diabetic O
patients O
undergoing O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
[]

The O
efficacy O
, O
safety O
and O
cost-effectiveness O
of O
hydrotalcite O
versus O
esomeprazole O
in O
on-demand O
therapy O
of O
NERD O
: O
A O
multicenter O
, O
randomized O
, O
open-label O
study O
in O
China O
. O
['Resource-use']

PTCA O
produced O
an O
abrupt O
decrease O
in O
number O
( O
p O
= O
0.015 O
) O
and O
duration O
( O
p O
= O
0.03 O
) O
of O
spontaneous B-outcome ['Physiological-Clinical']
ischemic I-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Previous O
investigators O
have O
demonstrated O
enhanced O
detection O
of O
atrial O
defects B-outcome ['Physiological-Clinical']
by O
the O
dye-dilution O
technique O
after O
delivery O
of O
contrast O
medium O
into O
the O
inferior O
rather O
than O
the O
superior O
vena O
cava O
. O
['Physiological-Clinical']

Follow-up O
appointments O
were O
made O
for O
intervention O
patients O
to O
attend O
their O
GPs O
. O
[]

A O
high O
number O
of O
cells B-outcome ['Physiological-Clinical']
was O
required O
for O
significant O
improvements O
in O
the O
primary O
end O
points O
. O
['Physiological-Clinical']

The O
neuroendocrine O
effects O
of O
the O
5-HT O
receptor O
agonist O
, O
sumatriptan O
( O
6 O
mg O
subcutaneously O
) O
, O
were O
studied O
in O
11 O
healthy O
male O
subjects O
using O
a O
placebo-controlled O
, O
cross-over O
design O
. O
[]

The O
outcome O
measure O
of O
deep B-outcome ['Physiological-Clinical']
cervical I-outcome ['Physiological-Clinical']
flexor I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
was O
based O
on O
the O
Flexor B-outcome ['Physiological-Clinical']
Endurance I-outcome ['Physiological-Clinical']
Test O
and O
was O
recorded O
in O
seconds O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
, O
double-blind O
, O
placebo O
controlled O
, O
clinical O
trial O
. O
[]

In O
almost O
all O
patients O
intravenous O
amoxycillin O
1 O
g O
every O
6 O
h O
was O
also O
started O
. O
[]

Maintenance O
of O
an O
optimal O
ribavirin O
dose O
is O
the O
most O
important O
modifiable O
factor O
during O
combination O
therapy O
for O
chronic O
hepatitis O
C O
. O
[]

Patients O
treated O
with O
ferric O
carboxymaltose O
compared O
to O
those O
prescribed O
ferrous O
sulfate O
reported O
greater O
gains O
in O
vitality B-outcome ['Physiological-Clinical']
and O
physical B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
and O
experienced O
greater O
improvement B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of O
fatigue B-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
authors O
also O
assessed O
various O
psychosocial O
determinants O
of O
adherence B-outcome ['Life-Impact']
, O
such O
as O
knowledge B-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
, O
satisfaction B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
, O
and O
complexity O
of O
the O
medical B-outcome ['Resource-use']
regimen I-outcome ['Resource-use']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Resource-use']

We O
found O
that O
8-oxo-dG O
levels O
in O
lymphocyte O
DNA O
vary O
significantly O
according O
to O
sex O
and O
country O
. O
[]

BACKGROUND O
Perioperative O
red O
blood O
cell O
( O
RBC O
) O
transfusion O
may O
be O
associated O
with O
a O
poor O
prognosis O
in O
cancer O
surgery O
. O
[]

Complications B-outcome ['Adverse-effects']
and O
recovery B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
also O
did O
not O
show O
any O
significant O
difference O
. O
['Adverse-effects', 'Physiological-Clinical']

RESULTS O
Metformin O
had O
no O
significant O
effect O
either O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or O
plasma B-outcome ['Physiological-Clinical']
triglyceride I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

23 O
bone-borne O
and O
19 O
tooth-borne O
patients O
were O
analyzed O
. O
[]

In O
this O
study O
, O
both O
iobitridol O
and O
iopromide O
provided O
excellent O
image B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
and O
a O
low O
rate O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Life-Impact', 'Adverse-effects']

Moclobemide O
, O
imipramine O
and O
placebo O
in O
the O
treatment O
of O
major O
depression B-outcome ['Life-Impact']
. O
['Life-Impact']

PURPOSE O
To O
evaluate O
the O
cost B-outcome ['Resource-use']
effectiveness O
of O
CSF B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Treatment O
efficacy O
was O
based O
on O
improving O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
and O
EOG B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
( O
amplitude O
or O
frequency O
of O
nystagmus B-outcome ['Physiological-Clinical']
, O
or O
both O
) O
by O
at O
least O
50 O
% O
of O
pretreatment O
values O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Stress O
mediated O
hypokalaemia B-outcome ['Physiological-Clinical']
was O
of O
the O
same O
degree O
in O
both O
groups O
, O
the O
median O
values O
of O
the O
plasma B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
being O
in O
the O
lower O
reference O
range O
( O
3.5-3.7 O
mmol O
X O
1 O
( O
-1 O
] O
, O
although O
large O
amounts O
of O
red O
cell O
concentrates O
were O
given O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
detailed O
history O
was O
taken O
and O
proctoscopic O
examination O
was O
performed O
. O
[]

Their O
recovery B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
was O
similar O
to O
that O
of O
the O
desflurane O
group O
. O
['Physiological-Clinical']

Autism O
spectrum O
disorders O
are O
a O
neurodevelopmental O
disorders O
with O
reduced O
cortical O
functional O
connectivity O
relating O
to O
social O
cognition O
. O
[]

Both O
multiplane O
and O
biplane O
probes O
provided O
excellent O
visualization B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
cardiac I-outcome ['Life-Impact']
structures I-outcome ['Life-Impact']
and O
Doppler B-outcome ['Physiological-Clinical']
signals I-outcome ['Physiological-Clinical']
, O
but O
the O
multiplane O
probe O
was O
significantly O
superior O
to O
the O
biplane O
probe O
. O
['Life-Impact', 'Physiological-Clinical']

We O
evaluated O
alternatives O
to O
routine O
primary O
PCP O
prophylaxis O
with O
aerosolized O
pentamidine O
. O
[]

In O
children O
on O
lamotrigine O
, O
the O
drug O
was O
titrated O
upward O
over O
8 O
weeks O
to O
reach O
a O
mean O
maintenance O
dose O
of O
5.0 O
mg/kg O
per O
day O
. O
[]

PURPOSE O
The O
topical O
medication O
represents O
the O
first O
line O
therapy O
for O
the O
primary O
open O
angle O
glaucoma O
. O
[]

nitrendipine O
, O
20 O
mg O
once O
daily O
; O
or O
placebo O
on O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
and O
C-peptide B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
an O
intravenous O
glucose O
load O
in O
mildly O
or O
transiently O
hypertensive O
nondiabetic O
obese O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
We O
sought O
to O
assess O
the O
effectiveness O
of O
approaches O
targeting O
improved O
sexually O
transmitted O
infection O
( O
STI O
) O
sexual O
partner O
notification O
through O
patient O
referral O
. O
[]

Studies O
on O
the O
platelet O
functioning O
showed O
an O
obvious O
decrease O
in O
platelet B-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
in O
those O
patients O
treated O
with O
the O
active O
drug O
. O
['Physiological-Clinical']

CONCLUSIONS O
EPL O
and O
LPL O
are O
as O
feasible B-outcome ['Life-Impact']
and O
effective O
as O
TPL O
and O
can O
be O
adequately O
performed O
with O
a O
reasonable O
complication O
rate O
. O
['Life-Impact']

5 O
FU O
infusion O
with O
mitomycin-C O
vs. O
5 O
FU O
infusion O
with O
methyl-CCNU O
in O
the O
treatment O
of O
advanced O
upper O
gastrointestinal O
cancer O
: O
a O
Southwest O
Oncology O
Group O
Study O
. O
[]

The O
effect O
of O
intraperitoneal O
pressure O
was O
then O
studied O
by O
measuring O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
pressure B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
vena I-outcome ['Physiological-Clinical']
cava I-outcome ['Physiological-Clinical']
, O
hepatic B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
and O
hepatic B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
wedged I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
before O
, O
during O
, O
and O
after O
paracentesis O
to O
reduce O
the O
intraperitoneal O
pressure O
from O
30 O
to O
40 O
cm O
H2O O
to O
12 O
to O
17 O
cm O
H2O O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Hydrocele B-outcome ['Physiological-Clinical']
occurred O
only O
in O
the O
group O
which O
received O
the O
Ivanissevich O
technique O
( O
5.5 O
% O
) O
. O
['Physiological-Clinical']

Evaluation O
of O
a O
novel O
technique O
for O
wound O
closure O
using O
a O
barbed O
suture O
. O
[]

Five O
of O
15 O
prazosin-treated O
patients O
and O
six O
of O
16 O
captopril-treated O
patients O
required O
the O
addition O
of O
thiazide O
to O
achieve O
[]

Microalbuminuria O
is O
an O
important O
risk O
factor O
for O
cardiovascular O
mortality O
in O
non-insulin-dependent O
diabetic O
patients O
as O
well O
as O
in O
the O
general O
population O
. O
[]

RESULTS O
Expression O
of O
leptin B-outcome ['Physiological-Clinical']
genes I-outcome ['Physiological-Clinical']
was O
demonstrated O
both O
in O
myomas O
and O
in O
the O
surrounding O
myometrium O
, O
and O
a O
similar O
pattern O
of O
expression O
was O
found O
for O
leptin O
receptor O
isoforms O
. O
['Physiological-Clinical']

2.8 O
) O
, O
( O
12.1 O
? O
[]

PARTICIPANTS O
All O
but O
11 O
of O
344 O
consecutive O
admissions O
with O
acute O
nonpathological O
hip O
fracture O
were O
approached O
. O
[]

In O
patients O
with O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
, O
permissive O
hypercapnia O
is O
a O
strategy O
to O
decrease O
airway O
pressures O
to O
prevent O
ventilator-induced O
lung O
damage O
by O
lowering O
tidal O
volumes O
and O
tolerating O
higher O
arterial O
carbon O
dioxide O
tension O
. O
[]

Sleep B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
in O
the O
experimental O
acupuncture O
treatment O
group O
declined O
over O
the O
study O
. O
['Physiological-Clinical']

No O
effect O
of O
feed O
processing O
method O
( O
meal O
vs O
cake O
) O
on O
ileal B-outcome ['Physiological-Clinical']
digestibility I-outcome ['Physiological-Clinical']
was O
observed O
. O
( O
['Physiological-Clinical']

Patients O
could O
not O
have O
had O
prior O
chemotherapy O
for O
metastatic O
disease O
. O
[]

PURPOSE O
In O
a O
register O
study O
, O
the O
risk O
of O
anastomotic B-outcome ['Physiological-Clinical']
leakage I-outcome ['Physiological-Clinical']
correlated O
to O
the O
choice O
of O
circular O
stapling O
device O
with O
a O
4 O
% O
difference O
between O
the O
two O
brands O
used O
. O
['Physiological-Clinical']

Use O
of O
transdermal O
glyceryl O
trinitrate O
to O
reduce O
failure O
of O
intravenous B-outcome ['Resource-use']
infusion I-outcome ['Resource-use']
due O
to O
phlebitis O
and O
extravasation O
. O
['Resource-use']

Tympanic B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
was O
measured O
at O
OR O
arrival O
( O
baseline O
) O
; O
immediately O
following O
general O
anesthesia O
induction O
; O
30 O
, O
60 O
, O
90 O
, O
and O
120 O
minutes O
from O
general O
anesthesia O
induction O
; O
and O
at O
the O
end O
of O
surgery O
. O
['Physiological-Clinical']

One O
third O
were O
nonsmokers O
. O
[]

Two O
independent O
parameters O
of O
drain B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
total O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
calculated O
by O
the O
hemoglobin O
balance O
method O
, O
were O
evaluated O
statistically O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Re O
and O
Re-PUVA O
treated O
sites B-outcome ['Physiological-Clinical']
improved I-outcome ['Physiological-Clinical']
and/or I-outcome ['Physiological-Clinical']
cleared I-outcome ['Physiological-Clinical']
more O
rapidly O
than O
PUVA O
treated O
sites O
. O
['Physiological-Clinical']

Outcome O
measures O
included O
the O
Hamilton O
Depression O
Rating O
( O
HAM-D O
17 O
) O
rating O
and O
the O
Young O
Mania O
Rating O
( O
YMR O
) O
scale O
. O
[]

Sixty-nine O
patients O
were O
randomized O
to O
received O
24-hour O
intravenous O
infusions O
of O
levosimendan O
( O
n O
= O
23 O
) O
, O
dobutamine O
( O
n O
= O
23 O
) O
, O
or O
placebo O
( O
n O
= O
23 O
) O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

A O
different O
need O
of O
antihypertensive O
drugs O
was O
simulated O
by O
the O
exacter O
intake O
of O
medicaments O
in O
the O
index-patients O
. O
[]

6.6 O
yr O
, O
body O
mass O
[ O
BM O
] O
= O
72.9 O
? O
[]

At O
least O
one O
adenoma B-outcome ['Physiological-Clinical']
developed O
in O
28 O
( O
15.9 O
% O
) O
of O
176 O
patients O
in O
the O
calcium O
group O
, O
58 O
( O
29.3 O
% O
) O
of O
198 O
in O
the O
fibre O
group O
, O
and O
36 O
( O
20.2 O
% O
) O
of O
178 O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

CONCLUSIONS O
Citalopram O
or O
other O
SSRIs O
and O
reboxetine O
may O
be O
of O
first O
choice O
treatment O
in O
PSD O
because O
of O
their O
good O
efficacy O
and O
lack O
of O
severe O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

A O
prospective O
, O
randomized O
study O
with O
3.8 O
years O
' O
follow-up O
. O
[]

This O
prospective O
randomized O
trial O
was O
conducted O
to O
compare O
the O
efficacy O
of O
cytokine O
removal O
between O
online O
hemodiafiltration O
( O
HDF O
) O
, O
which O
combines O
convective O
and O
diffusive O
solute O
removal O
, O
and O
high-flux O
hemodialysis O
( O
HD O
) O
. O
[]

A O
total O
of O
17 O
patients O
were O
entered O
, O
eight O
in O
group O
A O
and O
nine O
in O
group O
B O
. O
[]

Tolerance O
was O
very O
good O
, O
particularly O
at O
gastroenteric O
level O
( O
no O
side O
and/or O
undesired O
effects O
were O
observed O
) O
and O
at O
the O
level O
of O
haemopoietic O
, O
renal O
and O
hepatic O
function O
. O
[]

No O
statistically O
significant O
changes O
were O
observed O
in O
any O
of O
the O
measured O
coagulation O
variables O
. O
[]

One O
of O
the O
219 O
patients O
from O
the O
nonrandomized O
group O
developed O
a O
clinically B-outcome ['Physiological-Clinical']
detectable I-outcome ['Physiological-Clinical']
proximal I-outcome ['Physiological-Clinical']
deep I-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
which O
was O
confirmed O
by O
duplex B-outcome ['Resource-use']
ultra-sonography I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

Object-based O
positive O
and O
negative O
priming B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
were O
found O
in O
both O
groups O
of O
children O
. O
['Life-Impact']

Mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
decreased O
and O
mean O
pulmonary B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
increased O
significantly O
only O
in O
the O
pH-uncorrected O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Reduced O
aerobic O
fitness O
is O
associated O
with O
an O
increased O
risk O
of O
cardiovascular O
diseases O
among O
the O
older O
population O
. O
[]

There O
was O
a O
significant O
antiproteinuric B-outcome ['Physiological-Clinical']
effect O
of O
diclofenac O
versus O
placebo O
with O
a O
fall O
of O
70 O
% O
in O
the O
diclofenac O
group O
versus O
6 O
% O
in O
the O
placebo O
group O
( O
p O
less O
than O
0.001 O
with O
the O
Mann-Whitney O
test O
) O
. O
['Physiological-Clinical']

The O
effect O
of O
posture O
on O
Cheyne-Stokes O
respirations O
and O
hemodynamics O
in O
patients O
with O
heart O
failure O
. O
[]

Performance O
on O
the O
multisensory O
temporal O
tasks O
varied O
with O
stimulus O
complexity O
for O
both O
groups O
; O
less O
precise O
temporal B-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
was O
observed O
with O
increasing O
stimulus O
complexity O
. O
['Physiological-Clinical']

Surgical B-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
occurred O
in O
35 O
patients O
( O
24.4 O
% O
) O
administered O
30 O
% O
FIO2 O
and O
in O
22 O
patients O
( O
14.9 O
% O
) O
administered O
80 O
% O
FIO2 O
( O
P=.04 O
) O
. O
['Physiological-Clinical']

This O
randomized O
, O
placebo-controlled O
study O
examined O
the O
efficacy O
of O
the O
GnRH O
agonist O
, O
leuprolide O
acetate O
depot O
, O
in O
a O
clearly O
defined O
PMS O
sample O
versus O
women O
with O
premenstrual O
symptoms O
in O
combination O
with O
dysphoric O
symptoms O
throughout O
the O
cycle O
, O
termed O
the O
premenstrual O
exacerbation O
( O
PME O
) O
group O
. O
[]

These O
results O
suggest O
that O
the O
ionisation O
procedure O
displays O
per O
se O
a O
moderate O
therapeutic O
effect O
which O
seems O
to O
be O
due O
more O
to O
a O
simple O
placebo O
effect O
than O
to O
the O
biological O
effect O
of O
electricity O
. O
[]

Fluoroscopy B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
4.6 O
+/- O
2.3 O
min O
in O
the O
EPA O
group O
versus O
9.2 O
+/- O
4.9 O
min O
in O
the O
GCA O
group O
p O
= O
0.004 O
. O
['Life-Impact']

Plasma O
antioxidant O
status O
after O
high-dose O
chemotherapy O
: O
a O
randomized O
trial O
of O
parenteral O
nutrition O
in O
bone O
marrow O
transplantation O
patients O
. O
[]

The O
effects O
of O
verapamil O
were O
assessed O
in O
26 O
patients O
with O
stable O
exertional O
angina O
pectoris O
in O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
crossover O
protocol O
using O
serial O
treadmill O
tests O
. O
[]

Part O
A O
included O
12 O
asymptomatic O
porphobilinogen O
deaminase-deficient O
subjects O
, O
and O
the O
enzyme O
was O
administered O
in O
an O
open-label O
, O
single-dose O
design O
. O
[]

BACKGROUND O
Diabetes O
mellitus O
, O
as O
well O
as O
subsequent O
ocular O
complications O
such O
as O
cystoid O
macular O
edema O
( O
CME O
) O
, O
are O
of O
fundametal O
socio-economic O
relevance O
. O
[]

We O
also O
determined O
whether O
decline O
in O
ocular O
function O
was O
related O
to O
red O
blood O
cell O
phosphatidylethanolamine O
docosahexaenoic O
acid O
level O
, O
dietary O
omega-3 O
fatty O
acid O
intake O
, O
or O
duration O
of O
vitamin O
A O
use O
. O
[]

Airway B-outcome ['Physiological-Clinical']
management I-outcome ['Physiological-Clinical']
training O
using O
the O
laryngeal O
mask O
airway O
: O
a O
comparison O
of O
two O
different O
training O
programmes O
. O
['Physiological-Clinical']

SUBJECTS O
All O
( O
58 O
) O
healthy O
women O
of O
Pakistani O
origin O
referred O
from O
October O
of O
1991 O
to O
January O
of O
1992 O
were O
included O
, O
of O
whom O
38 O
( O
66 O
% O
) O
participated O
. O
[]

BACKGROUND O
Several O
protective O
therapies O
have O
been O
developed O
to O
prevent O
contrast-induced B-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CIN I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
mean O
follow-up O
was O
2.47+/-1.75 O
years O
, O
with O
54 O
% O
adherence O
to O
the O
program O
. O
[]

SUBJECTS O
AND O
METHODS O
After O
a O
run-in O
phase O
, O
318 O
subjects O
were O
randomized O
to O
receive O
one O
of O
the O
following O
margarine-like O
spreads O
containing O
stanol O
ester O
or O
placebo O
for O
8 O
weeks O
: O
EU O
3 O
G O
: O
1 O
g O
of O
stanol O
( O
ester O
form O
) O
per O
8-g O
serving O
of O
a O
European O
formula O
3 O
times O
a O
day O
; O
US O
3 O
G O
: O
1 O
g O
of O
stanol O
( O
ester O
form O
) O
per O
8-g O
serving O
of O
a O
US O
reformulation O
3 O
times O
a O
day O
; O
US O
2 O
G O
: O
0.67 O
g O
of O
stanol O
( O
ester O
form O
) O
per O
8-g O
serving O
of O
a O
US O
reformulation O
3 O
times O
a O
day O
; O
or O
placebo O
spread O
. O
[]

Effects O
of O
heat O
and O
cold O
on O
the O
perineum O
after O
episiotomy/laceration O
. O
[]

Prophylactic O
vs O
therapeutic O
blood O
patch O
for O
obstetric O
patients O
with O
accidental O
dural O
puncture O
-- O
a O
randomised O
controlled O
trial O
. O
[]

RESULTS O
At O
12 O
weeks O
of O
infant O
age O
, O
the O
intervention O
was O
effective O
in O
almost O
doubling O
the O
rate O
of O
exclusive B-outcome ['Physiological-Clinical']
breastfeeding B-outcome ['Physiological-Clinical']
( O
risk O
ratio O
1.92 O
; O
95 O
% O
CI O
: O
1.59-2.33 O
) O
and O
increasing O
infant O
weight O
and O
length-for-age B-outcome ['Physiological-Clinical']
z-scores I-outcome ['Physiological-Clinical']
( O
weight O
difference O
0.09 O
; O
95 O
% O
CI O
: O
0.00-0.18 O
, O
length O
difference O
0.11 O
; O
95 O
% O
CI O
: O
0.03-0.19 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
a O
double-blind O
study O
the O
effects O
of O
continuous O
( O
24 O
h/day O
) O
and O
intermittent O
( O
16 O
h/day O
) O
application O
of O
transdermal O
nitroglycerin O
in O
a O
dosage O
of O
10 O
mg/day O
were O
compared O
with O
the O
effects O
of O
placebo O
in O
12 O
patients O
with O
chronic O
stable O
angina O
receiving O
treatment O
with O
beta-adrenergic O
blocking O
or O
calcium O
channel O
blocking O
agents O
. O
[]

A O
block O
randomisation O
method O
was O
used O
to O
randomise O
participants O
into O
case O
and O
control O
groups O
. O
[]

Positive O
impact O
of O
crisis O
resource O
management O
training O
on O
no-flow O
time O
and O
team O
member O
verbalisations O
during O
simulated O
cardiopulmonary O
resuscitation O
: O
a O
randomised O
controlled O
trial O
. O
[]

The O
immunoglobulins O
had O
a O
high O
antitoxin O
content O
and O
had O
been O
raised O
with O
acellular O
pertussis O
vaccines O
. O
[]

Post-operative B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
post-operative B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
, O
readmission B-outcome ['Resource-use']
rate O
, O
and O
in-hospital O
mortality B-outcome ['Mortality']
were O
recorded O
. O
['Resource-use', 'Physiological-Clinical', 'Resource-use', 'Mortality']

Results O
were O
similar O
for O
hypoglycemic O
area O
under O
the O
curve O
and O
the O
low O
blood O
glucose O
index O
calculated O
by O
CGM O
. O
[]

Following O
completion O
of O
a O
2-week O
baseline O
period O
, O
435 O
adults O
with O
stable O
, O
symptomatic O
, O
smoking-related O
COPD O
were O
randomized O
to O
receive O
either O
500 O
microg O
sibenadet O
or O
placebo O
delivered O
via O
pressurized O
metered O
dose O
inhaler O
( O
pMDI O
) O
, O
three O
times O
daily O
for O
52 O
weeks O
. O
[]

Subjects O
completed O
one O
telephone-administered O
multiple-pass O
24-hour O
recall O
( O
MP24R O
) O
with O
an O
unknown O
interviewer O
and O
were O
then O
randomly O
assigned O
to O
an O
in-person O
MP24R O
with O
either O
a O
lean O
or O
obese O
interviewer O
to O
gather O
reported B-outcome ['Life-Impact']
energy I-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
( O
rEI B-outcome ['Physiological-Clinical']
) O
. O
['Life-Impact', 'Physiological-Clinical']

OBJECTIVE O
We O
evaluated O
the O
effectiveness O
of O
a O
management O
approach O
that O
combines O
the O
canalith O
repositioning O
maneuver O
( O
CRM O
) O
and O
vestibular O
rehabilitation O
( O
VR O
) O
in O
the O
treatment O
of O
benign O
positional O
paroxysmal O
vertigo O
( O
BPPV O
) O
in O
elderly O
persons O
. O
[]

Preoperative O
small-dose O
ketamine O
has O
no O
preemptive O
analgesic O
effect O
in O
patients O
undergoing O
total O
mastectomy O
. O
[]

METHODS O
Controlled O
, O
prospective O
pilot O
study O
including O
H. O
pylori-positive O
patients O
with O
gastric O
or O
duodenal O
ulcers O
or O
erosive O
gastritis O
, O
treated O
after O
failure O
of O
dual O
therapy O
( O
proton-pump-inhibitors O
or O
ranitidine O
plus O
amoxicillin O
) O
or O
for O
the O
first O
time O
. O
[]

Women O
with O
MPC O
were O
randomized O
to O
the O
treatment O
or O
placebo O
arm O
of O
the O
study O
, O
and O
the O
2 O
arms O
were O
evaluated O
based O
on O
the O
etiology O
, O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates O
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( I-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
) I-outcome ['Adverse-effects']
, O
and O
rates O
of O
pelvic B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical']

in O
comparison O
with O
placebo O
+ O
salbutamol/ipratropium O
bromide O
. O
[]

Weekly O
docetaxel O
with O
or O
without O
gemcitabine O
as O
second-line O
chemotherapy O
in O
paclitaxel-pretreated O
patients O
with O
metastatic O
breast O
cancer O
: O
a O
randomized O
phase O
II O
study O
conducted O
by O
the O
Hellenic O
Co-Operative O
Oncology O
Group O
. O
[]

CONCLUSION O
Intraoperative O
mitomycin O
C O
appears O
to O
be O
an O
effective O
and O
safe O
adjunctive O
treatment O
of O
primary O
pterygium O
. O
[]

METHODS O
In O
all O
, O
2437 O
patients O
with O
a O
history O
of O
HSL O
were O
randomized O
to O
self-initiate O
treatment O
with O
ME-609 O
, O
5 O
% O
acyclovir O
in O
ME-609 O
vehicle O
, O
or O
ME-609 O
vehicle O
( O
placebo O
) O
at O
the O
earliest O
sign O
of O
a O
cold O
sore O
recurrence O
. O
[]

Behavioral B-outcome ['Life-Impact']
Rating O
Scales O
were O
performed O
by O
the O
investigators O
and O
the O
parents O
. O
['Life-Impact']

Scores O
on O
the O
Short-Form O
36-Item O
subscales O
'general O
health B-outcome ['Physiological-Clinical']
' O
and O
'mental O
health B-outcome ['Physiological-Clinical']
' O
improved O
in O
the O
continuous O
subcutaneous O
insulin O
infusion O
group O
, O
compared O
with O
stable O
values O
in O
the O
injection O
group O
( O
P O
= O
0.048 O
and O
0.050 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Middle B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
velocities I-outcome ['Physiological-Clinical']
decreased O
significantly O
after O
administration O
of O
isoflurane O
and O
propofol O
, O
but O
there O
was O
no O
significant O
difference O
between O
the O
groups O
. O
['Physiological-Clinical']

CONCLUSION O
Interpersonal O
communication O
can O
have O
a O
powerful O
effect O
on O
recruitment O
. O
[]

The O
side-effects O
due O
to O
guar O
treatment O
consisted O
of O
slight B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
, O
meteorism B-outcome ['Physiological-Clinical']
and O
constipation B-outcome ['Physiological-Clinical']
, O
but O
this O
did O
not O
in O
any O
of O
the O
cases O
lead O
to O
early O
termination O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
These O
data O
indicate O
that O
folic O
acid O
supplementation O
to O
participants O
with O
low O
plasma O
folate O
enhances O
arsenic O
methylation O
. O
[]

At O
12 O
weeks O
after O
ESWT O
, O
the O
pain O
estimation O
on O
the O
visual O
analogue O
scale O
( O
VAS O
) O
for O
activities B-outcome ['Life-Impact']
of O
daily O
living B-outcome ['Mortality']
diminished O
significantly O
by O
62.9 O
% O
in O
group O
1 O
and O
by O
63.0 O
% O
in O
group O
2 O
. O
['Life-Impact', 'Mortality']

Transoral O
robotic O
surgery O
( O
TORS O
) O
has O
emerged O
as O
a O
promising O
alternative O
treatment O
, O
with O
preliminary O
case O
series O
demonstrating O
encouraging O
oncologic O
, O
functional O
, O
and O
quality O
of O
life O
( O
QOL O
) O
outcomes O
. O
[]

Identification O
of O
predictors O
of O
clinical O
improvement O
has O
been O
limited O
by O
the O
power O
of O
the O
study O
. O
[]

Of O
these O
132 O
subjects O
, O
124 O
( O
94 O
% O
) O
were O
already O
receiving O
treatment O
with O
antihypertensive O
medications O
. O
[]

Role O
of O
posterior O
tibial O
nerve O
stimulation O
in O
the O
treatment O
of O
refractory O
monosymptomatic O
nocturnal O
enuresis O
: O
a O
pilot O
study O
. O
[]

The O
primary O
behavioral O
measure O
( O
Aberrant O
Behavior O
Checklist O
[ O
ABC O
] O
irritability B-outcome ['Life-Impact']
subscale O
) O
and O
safety O
measures O
were O
performed O
at O
baseline O
and O
4 O
, O
8 O
, O
and O
12 O
weeks O
. O
['Life-Impact']

Both O
the O
development O
of O
nitrate B-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
and O
the O
administration O
of O
N-acetylcysteine O
significantly O
change O
the O
normal O
['Physiological-Clinical']

Failure O
to O
employ O
adequate O
placebos O
, O
proper O
blinding O
, O
objective O
measures O
, O
or O
screening O
of O
prior O
beliefs O
about O
aromatherapy O
means O
that O
many O
previous O
findings O
could O
have O
been O
influenced O
by O
expectancy O
biases O
. O
[]

Grade O
3 O
or O
4 O
fatigue B-outcome ['Physiological-Clinical']
, O
neutropenia B-outcome ['Physiological-Clinical']
, O
and O
febrile B-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
were O
less O
frequent O
in O
all O
nab-paclitaxel O
arms O
compared O
with O
docetaxel O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
At O
week O
8 O
, O
all O
aripiprazole O
doses O
produced O
significantly O
greater O
improvement O
than O
placebo O
in O
mean O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
Irritability B-outcome ['Life-Impact']
subscale O
scores O
( O
5 O
mg/day O
, O
-12.4 O
; O
10 O
mg/day O
, O
-13.2 O
; O
15 O
mg/day O
, O
-14.4 O
; O
versus O
placebo O
, O
-8.4 O
; O
all O
p O
< O
.05 O
) O
. O
['Life-Impact', 'Life-Impact']

An O
auricular B-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
with O
size O
regression B-outcome ['Physiological-Clinical']
occurred O
in O
those O
patients O
who O
recovered O
from O
sinus O
rhythm O
, O
worthy O
of O
remark O
in O
Group O
II O
( O
-10.8 O
% O
of O
left O
auricular O
volume O
reduction O
in O
Group O
I O
compared O
to O
-21.5 O
% O
in O
Group O
II O
; O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SD O
) O
undertook O
four O
cycling O
time O
trials O
( O
TT O
) O
, O
each O
requiring O
the O
completion O
of O
a O
set O
amount O
of O
work O
( O
7 O
kJ?kg O
BM O
) O
in O
the O
shortest O
possible O
time O
. O
[]

Superior O
efficacy O
of O
clopidogrel O
plus O
acetylsalicylic O
acid O
compared O
with O
extended-release O
dipyridamole O
plus O
acetylsalicylic O
acid O
in O
preventing O
arterial O
thrombogenesis O
in O
healthy O
volunteers O
. O
[]

Guidelines O
recommend O
everolimus O
for O
patients O
previously O
treated O
with O
tyrosine O
kinase O
inhibitors O
( O
TKI O
) O
sunitinib O
or O
sorafenib O
. O
[]

Angiotensin O
II O
receptor O
blockers O
are O
a O
new O
therapeutic O
entity O
that O
have O
not O
been O
widely O
studied O
in O
African O
American O
hypertensives O
, O
either O
alone O
, O
or O
in O
combination O
with O
other O
therapies O
such O
as O
diuretics O
or O
angiotensin O
converting O
enzyme O
inhibitors O
. O
[]

These O
trials O
have O
reported O
significant O
reductions O
in O
complicated O
grief O
and O
related O
symptoms O
in O
response O
to O
treatment O
relative O
to O
control O
groups O
. O
[]

Co-administration O
of O
pethidine O
and O
clonidine O
: O
a O
spinal O
anaesthetic O
technique O
for O
total O
hip O
replacement O
. O
[]

A O
meta-analysis O
of O
the O
pooled O
results O
from O
six O
double-blind O
trials O
showed O
that O
risperidone O
at O
doses O
ranging O
from O
4 O
to O
8 O
mg/day O
had O
a O
significantly O
( O
p O
< O
0.004 O
) O
higher O
negative O
symptom B-outcome ['Life-Impact']
response O
rate O
, O
defined O
as O
the O
percentage O
of O
patients O
with O
a O
20 O
% O
or O
more O
reduction O
in O
scores O
on O
the O
negative O
subscale O
of O
the O
Positive O
and O
Negative O
Syndrome B-outcome ['Physiological-Clinical']
Scale O
, O
than O
patients O
receiving O
active O
controls O
. O
['Life-Impact', 'Physiological-Clinical']

These O
findings O
were O
confirmed O
by O
parent O
data O
, O
indicating O
that O
the O
gains O
had O
generalized O
across O
contexts O
. O
[]

The O
latter O
two O
groups O
were O
rendered O
diabetic O
by O
i.p O
. O
[]

Ejection O
fraction O
improved O
from O
30.1 O
+/- O
6.8 O
% O
to O
33.9 O
+/- O
9.9 O
% O
in O
the O
enoximone O
group O
while O
it O
remained O
unchanged O
with O
placebo O
( O
23.4 O
+/- O
6.5 O
% O
to O
23.4 O
+/- O
1.5 O
% O
) O
. O
( O
[]

For O
the O
IVT O
group O
( O
n O
= O
25 O
) O
, O
the O
median O
increase O
in O
BCVA O
was O
2.0 O
letters O
at O
day O
7 O
; O
at O
days O
14 O
, O
45 O
, O
and O
90 O
, O
the O
median O
increase O
was O
maintained O
( O
4.0 O
letters O
) O
; O
the O
median O
decrease O
in O
retinal O
thickness O
was O
-52.0 O
?m O
at O
day O
45 O
. O
[]

Effect O
of O
desonide O
ointment O
, O
0.05 O
% O
, O
on O
the O
hypothalamic-pituitary-adrenal O
axis O
of O
children O
with O
atopic O
dermatitis O
. O
[]

Investigator-based O
and O
patient-based O
ratings O
indicated O
that O
Perlane O
was O
more O
effective O
than O
Zyplast O
in O
maintaining O
cosmetic O
correction O
. O
[]

CONCLUSION O
Treatment O
of O
medical O
ozone O
on O
patients O
with O
chronic O
hepatitis O
B O
is O
effective O
. O
[]

The O
present O
study O
aims O
to O
compare O
the O
effect O
of O
a O
traditional O
Chinese O
Chan-based O
mind-body O
exercise O
, O
Nei O
Yang O
Gong O
, O
with O
that O
of O
the O
conventional O
Progressive O
Muscle O
Relaxation O
( O
PMR O
) O
technique O
in O
enhancing O
the O
self-control O
of O
children O
with O
ASD O
. O
[]

A O
flexion-relaxation B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
was O
calculated O
by O
comparing O
maximal B-outcome ['Physiological-Clinical']
EMG I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
while O
flexing O
with O
the O
average O
EMG O
activity O
in O
full O
flexion O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
this O
period O
, O
the O
teeth O
were O
sectioned O
longitudinally O
and O
apical O
leakage O
measurements O
made O
. O
[]

A O
serum B-outcome ['Physiological-Clinical']
acetaminophen I-outcome ['Physiological-Clinical']
level O
was O
measured O
at O
four O
hours O
. O
['Physiological-Clinical']

At O
1 O
year O
, O
endoscopies O
with O
biopsies O
were O
repeated O
. O
[]

Oximetry B-outcome ['Resource-use']
, O
partial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
alveoli/fraction I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
inspired I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
and O
compliance B-outcome ['Life-Impact']
were O
collected O
. O
['Resource-use', 'Physiological-Clinical', 'Life-Impact']

OBJECTIVE O
To O
test O
the O
non-inferiority O
of O
once-daily O
( O
QD O
) O
oral O
amoxicillin O
to O
the O
recommended O
twice-daily O
( O
BID O
) O
oral O
penicillin O
V O
in O
GABHS O
pharyngitis O
. O
[]

There O
was O
a O
34.48 O
% O
dropout O
from O
the O
Internet-based O
training O
( O
dropout O
attrition O
) O
. O
[]

0.11 O
, O
respectively O
, O
with O
statistically O
significant O
differences O
( O
all O
P O
< O
0.01 O
) O
. O
[]

At O
baseline O
one O
randomly O
chosen O
implant O
in O
each O
patient O
was O
treated O
by O
the O
Vector O
system O
( O
test O
) O
while O
the O
other O
implant O
( O
control O
) O
was O
treated O
by O
submucosal O
debridement O
with O
a O
carbon O
fiber O
curette O
. O
[]

As O
part O
of O
a O
prospective O
, O
randomized O
trial O
comparing O
ES O
and O
EL O
for O
the O
treatment O
of O
EVH O
, O
we O
estimated O
the O
direct B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
of I-outcome ['Resource-use']
health I-outcome ['Resource-use']
care I-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
and O
cost-effectiveness O
for O
the O
prevention O
of O
variceal O
rebleeding O
and O
patient O
survival O
at O
1-year O
follow-up O
. O
['Resource-use', 'Resource-use']

Children O
with O
ASD O
( O
n=19 O
) O
, O
ADHD O
( O
n=18 O
) O
, O
comorbid O
ASD+ADHD O
( O
n=29 O
) O
and O
typically O
developing O
( O
TD O
) O
controls O
( O
n=26 O
) O
were O
presented O
with O
upright/inverted O
faces O
with O
direct/averted O
gaze O
, O
with O
concurrent O
recording O
of O
the O
P1 O
and O
N170 O
components O
. O
[]

DESIGN O
A O
randomized O
, O
double-blind O
, O
phase O
III O
clinical O
trial O
. O
[]

SETTING O
Academic O
medical O
centre O
. O
[]

Only O
8 O
patients O
( O
2.7 O
% O
) O
permanently O
discontinued O
prasugrel O
therapy O
because O
of O
bleeding O
events O
( O
n O
= O
4 O
) O
, O
possible O
side O
effects O
( O
n O
= O
2 O
) O
, O
or O
medical O
decisions O
not O
associated O
with O
bleeding O
or O
side O
effects O
( O
n O
= O
2 O
) O
. O
[]

Treatment O
of O
patients O
with O
primary O
mediastinal O
B-cell O
lymphoma O
( O
PMBCL O
) O
remains O
controversial O
. O
[]

Therefore O
, O
we O
point O
out O
the O
need O
for O
new O
research O
studies O
of O
longer O
duration O
. O
[]

PATIENTS O
Twenty-six O
patients O
within O
3 O
months O
of O
onset O
of O
stroke O
were O
randomised O
to O
receive O
physical O
therapy O
( O
control O
group O
) O
or O
therapy O
and O
retraining O
( O
experimental O
group O
) O
, O
most O
of O
the O
patients O
in O
both O
groups O
with O
left O
hemiplegia O
. O
[]

The O
results O
were O
classified O
as O
unsuccessful B-outcome ['Physiological-Clinical']
, O
improvement O
and O
cure B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
AND O
RESULTS O
All O
patients O
underwent O
an O
echocardiogram O
and O
radioisotopic O
ventriculography O
rest/exercise O
, O
and O
were O
randomized O
in O
a O
consecutive O
manner O
to O
the O
L-arginine O
group O
( O
n O
= O
15 O
; O
8 O
g/day O
) O
; O
and O
the O
citrulline O
malate O
group O
( O
n O
= O
15 O
; O
3 O
g/day O
) O
. O
[]

RESULTS O
The O
frequency O
of O
appropriate B-outcome ['Physiological-Clinical']
shocks I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
ATP I-outcome ['Physiological-Clinical']
were O
significantly O
decreased O
among O
AZ-treated O
patients O
compared O
with O
placebo O
patients O
. O
['Physiological-Clinical']

Selamectin O
( O
6 O
mg/kg O
) O
was O
applied O
topically O
to O
the O
skin O
in O
a O
single O
spot O
at O
the O
base O
of O
the O
neck O
in O
the O
treatment O
group O
. O
[]

Sixty-eight O
patients O
with O
prominent O
nasolabial O
folds O
were O
randomized O
to O
intradermal O
treatment O
with O
nonanimal O
stabilized O
hyaluronic O
acid O
gel O
( O
Perlane O
) O
and O
bovine O
collagen O
( O
Zyplast O
) O
on O
contralateral O
sides O
of O
the O
face O
. O
[]

Band O
ligation O
eradicated O
varices B-outcome ['Physiological-Clinical']
in O
fewer O
endoscopic B-outcome ['Resource-use']
sessions I-outcome ['Resource-use']
than O
did O
sclerotherapy O
( O
3.9 O
+/- O
1.1 O
vs. O
6.1 O
+/- O
1.7 O
, O
respectively O
, O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical', 'Resource-use']

METHODS O
A O
4-week O
, O
randomized O
, O
double O
blind O
, O
placebo-controlled O
, O
crossover O
design O
was O
conducted O
following O
a O
1-week O
baseline O
period O
. O
[]

Correlational O
analyses O
showed O
that O
attention O
to O
the O
Eye O
area O
of O
unfamiliar O
and O
Self O
Faces O
was O
related O
to O
socio-communicative O
ability O
in O
children O
with O
ASD O
. O
[]

The O
majority O
of O
the O
patients O
preferred O
the O
smooth O
implants O
. O
[]

Chemoradiation O
comparing O
cisplatin O
versus O
carboplatin O
in O
locally O
advanced O
nasopharyngeal O
cancer O
: O
randomised O
, O
non-inferiority O
, O
open O
trial O
. O
[]

Incorporation O
of O
this O
vaccine O
into O
routine O
immunisation O
schedules O
of O
infants O
could O
reduce O
severe B-outcome ['Physiological-Clinical']
rotavirus I-outcome ['Physiological-Clinical']
gastroenteritis I-outcome ['Physiological-Clinical']
by O
90 O
% O
and O
severe B-outcome ['Physiological-Clinical']
gastroenteritis I-outcome ['Physiological-Clinical']
of O
all O
causes O
in O
young O
children O
by O
60 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
In O
heart O
failure O
( O
HF O
) O
, O
a O
defective O
nitric O
oxide O
signaling O
is O
involved O
in O
left O
ventricular O
( O
LV O
) O
diastolic O
abnormalities O
and O
remodeling O
. O
[]

CONCLUSION O
A O
10 O
mg O
bolus O
dose O
of O
IV O
morphine O
given O
to O
patients O
with O
moderate O
pain O
after O
surgery O
does O
not O
cause O
severe O
[]

Each O
of O
these O
primary O
subdivisions O
was O
further O
evaluated B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
BCL2 I-outcome ['Physiological-Clinical']
and O
LMO2 B-outcome ['Physiological-Clinical']
both O
of O
which O
are O
recognised O
to O
predicate O
response O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Prophylactic O
cranial O
irradiation O
given O
to O
patients O
with O
small-cell O
lung O
cancer O
in O
complete O
remission O
decreases O
the O
risk O
of O
brain O
metastasis O
threefold O
without O
a O
significant O
increase O
in O
complications O
. O
[]

4 O
) O
No O
synchronous O
or O
metachronous O
double O
cancer O
. O
[]

Significant O
and O
clinically O
meaningful O
differences O
occurred O
with O
the O
PEG-IFN-alpha-2b O
treatment O
arm O
compared O
with O
the O
observation O
group O
, O
showing O
decreased O
global O
HRQOL B-outcome ['Life-Impact']
at O
month O
3 O
( O
-11.6 O
points O
; O
99 O
% O
CI O
, O
-8.2 O
to O
-15.0 O
) O
and O
year O
2 O
( O
-10.5 O
points O
; O
99 O
% O
CI O
, O
-6.6 O
to O
-14.4 O
) O
. O
['Life-Impact']

After O
dose O
escalation O
, O
group O
A O
( O
400 O
mg O
t.i.d O
. O
) O
[]

PATIENT O
( O
S O
) O
Premenstrual O
women O
with O
laparoscopically O
diagnosed O
endometriosis O
who O
required O
GnRH O
agonist O
therapy O
for O
treatment O
and O
did O
not O
have O
significant O
depressive O
or O
premenstrual O
mood O
symptoms O
at O
baseline O
. O
[]

Single-session O
behavioral O
treatment O
of O
earthquake-related O
posttraumatic O
stress O
disorder O
: O
a O
randomized O
waiting O
list O
controlled O
trial O
. O
[]

METHODS O
We O
studied O
the O
effects O
of O
nicotine O
in O
nonsmoking O
adults O
( O
6 O
male O
, O
5 O
female O
; O
ages O
23-36 O
years O
) O
using O
a O
double-blind O
, O
randomized O
, O
cross-over O
study O
. O
[]

Growth O
hormone O
( O
GH O
) O
can O
induce O
an O
accelerated B-outcome ['Physiological-Clinical']
lipolysis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
patients O
were O
followed O
up O
for O
between O
4 O
to O
51 O
months O
. O
[]

Actinobacillus O
actinomycetemcomitans O
, O
pigmented O
and O
non-pigmented O
Bacteroides O
spp. O
, O
Capnocytophaga O
, O
Fusobacterium O
and O
Actinomyces O
spp O
. O
[]

4E-BP1 B-outcome ['Physiological-Clinical']
phosphorylation I-outcome ['Physiological-Clinical']
returned O
to O
baseline O
during O
recovery O
in O
control O
but O
became O
elevated O
when O
EAA+CHO O
was O
ingested O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
overall O
clinical O
result O
of O
our O
35 O
patients O
with O
a O
DSV O
was O
excellent O
and O
good O
in O
31 O
patients O
, O
but O
the O
outcome O
seems O
to O
be O
more O
dependent O
on O
the O
preshunt B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
than O
on O
hydrocephalic B-outcome ['Physiological-Clinical']
aspects I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Seventy-seven O
of O
the O
86 O
enrolled O
patients O
presented O
an O
evaluable O
baseline O
( O
18 O
) O
F-FDG O
PET/CT O
scan O
; O
of O
these O
, O
68 O
and O
66 O
were O
evaluable O
at O
weeks O
2 O
and O
6 O
, O
respectively O
. O
[]

The O
increasing O
degree O
of O
BMD O
of O
lumbar B-outcome ['Physiological-Clinical']
vertebrae I-outcome ['Physiological-Clinical']
in O
observation O
group O
after O
treatment O
was O
more O
obvious O
than O
that O
in O
control O
group O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Variables O
such O
as O
level O
of I-outcome ['Physiological-Clinical']
function O
, O
immunization B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
and O
the O
presence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
an I-outcome ['Physiological-Clinical']
identified I-outcome ['Physiological-Clinical']
neurogenetic I-outcome ['Physiological-Clinical']
disorder I-outcome ['Physiological-Clinical']
were O
not O
predictive O
of O
CAM O
use O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
results O
suggest O
that O
the O
combination O
of O
topiramate O
with O
risperidone O
may O
be O
superior O
to O
risperidone O
monotherapy O
for O
children O
with O
autistic O
disorder O
. O
[]

Effectiveness O
of O
hygienic-dietary O
recommendations O
as O
enhancers O
of O
antidepressant O
treatment O
in O
patients O
with O
depression O
: O
study O
protocol O
of O
a O
randomized O
controlled O
trial O
. O
[]

Participants O
reported O
an O
average O
of O
12.0 O
drinking B-outcome ['Life-Impact']
days I-outcome ['Life-Impact']
at O
baseline O
and O
8.3 O
at O
6 O
months O
. O
['Life-Impact']

Osteoporotic O
patients O
in O
the O
prevention O
( O
P=0.0189 O
) O
and O
osteopenic O
patients O
in O
the O
treatment O
subpopulation O
( O
P=0.0305 O
) O
showed O
significant O
LS O
BMD O
increases O
with O
zoledronic O
acid O
versus O
risedronate O
at O
month O
12 O
. O
[]

CONCLUSION O
Iobitridol O
is O
a O
safe O
and O
effective O
nonionic O
contrast O
[]

A O
controlled O
trial O
of O
'Senokot O
' O
in O
faecal O
soiling O
treated O
by O
behavioural O
methods O
. O
[]

Only O
21 O
% O
( O
5 O
) O
of O
the O
children O
used O
the O
continuous O
passive O
movement O
machine O
as O
recommended O
. O
[]

After O
insertion O
of O
the O
endoscope O
, O
endoscopists O
recorded O
visibility O
scores O
before O
the O
procedure O
, O
imaging O
scores O
at O
endoscopic O
ultrasonography O
and O
the O
numbers O
of O
high-echo O
spots O
in O
the O
gastric O
cavity O
and O
on O
the O
gastric O
wall O
surface O
after O
the O
procedure O
. O
[]

The O
odds O
for O
anemia B-outcome ['Physiological-Clinical']
( O
< O
100 O
g/L O
) O
at O
3 O
months O
was O
7.7 O
( O
95 O
% O
CI O
1.84-34.9 O
) O
times O
higher O
in O
the O
early O
compared O
to O
the O
delayed O
clamping O
group O
. O
['Physiological-Clinical']

This O
study O
also O
showed O
no O
statistical O
difference O
( O
p O
less O
than O
or O
equal O
to O
0.05 O
) O
in O
the O
incidence O
of O
dysplasia B-outcome ['Physiological-Clinical']
in O
DES-exposed O
offspring O
as O
compared O
to O
a O
control O
population O
. O
['Physiological-Clinical']

Effects O
of O
a O
Chinese O
medical O
herbs O
complex O
on O
cellular O
immunity O
and O
toxicity-related O
conditions O
of O
breast O
cancer O
patients O
. O
[]

The O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
the O
effect O
of O
practice O
on O
the O
lateralization O
of O
mental O
rotation O
skills O
. O
[]

CONCLUSIONS O
This O
trial O
has O
failed O
to O
observe O
a O
survival B-outcome ['Mortality']
benefit O
with O
adjuvant O
chemotherapy O
following O
complete O
resection O
of O
stage O
I-III O
NSCLC O
. O
['Mortality']

Eighty-one O
patients O
received O
either O
lamivudine O
300 O
mg O
QD O
( O
n O
= O
39 O
) O
or O
150 O
mg O
BID O
( O
n O
= O
42 O
) O
with O
their O
pretrial O
stavudine/PI O
regimens O
for O
24 O
weeks O
. O
[]

We O
compared O
toxicity O
( O
particularly O
diarrhoea O
) O
, O
quality O
of O
life O
, O
and O
efficacy O
of O
combination O
chemotherapy O
and O
irinotecan O
in O
these O
patients O
. O
[]

Randomly O
selected O
households O
( O
N O
= O
452 O
) O
were O
divided O
into O
three O
interventions O
implemented O
by O
community O
workers O
: O
1 O
) O
fee-based O
As O
testing O
with O
household O
education O
( O
HE O
) O
; O
2 O
) O
fee-based O
As O
testing O
with O
household O
education O
and O
a O
local O
media O
campaign O
( O
HELM O
) O
; O
and O
3 O
) O
fee-based O
As O
testing O
alone O
( O
Control O
) O
. O
[]

In O
the O
BL O
, O
NO2 B-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
caused O
increases O
in O
polymorphonuclear B-outcome ['Physiological-Clinical']
neutrophils I-outcome ['Physiological-Clinical']
( O
PMNs B-outcome ['Physiological-Clinical']
) O
, O
interleukin B-outcome ['Physiological-Clinical']
6 I-outcome ['Physiological-Clinical']
( O
IL-6 B-outcome ['Physiological-Clinical']
) O
, O
IL-8 B-outcome ['Physiological-Clinical']
, O
alpha1-antitrypsin B-outcome ['Physiological-Clinical']
, O
and O
tissue B-outcome ['Physiological-Clinical']
plasminogen I-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
, O
and O
decreases O
in O
epithelial B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Patients O
with O
H. O
pylori O
infection O
were O
tested O
for O
CYP2C19 O
genotype O
as O
poor O
metabolizers O
( O
PMs O
) O
or O
extensive O
metabolizers O
( O
EMs O
, O
homozygous O
EM O
or O
heterozygous O
EM O
) O
and O
given O
rabeprazole O
for O
7 O
days O
. O
[]

In O
the O
JIA O
group O
, O
significant O
relationships O
were O
found O
between O
the O
number O
of O
active O
joint O
and O
disease O
duration O
( O
r O
= O
0.44 O
, O
p O
= O
0.000 O
) O
and O
VAS O
pain O
( O
r O
= O
0.30 O
, O
p O
= O
0.02 O
) O
, O
between O
SCARED O
and O
CDI O
( O
r O
= O
0.54 O
, O
p O
= O
0.000 O
) O
. O
[]

Obese O
children O
were O
randomly O
assigned O
to O
a O
family-based O
behavioral O
treatment O
that O
included O
either O
stimulus O
control O
or O
reinforcement O
to O
reduce O
sedentary O
behaviors O
. O
[]

50 O
patients O
were O
investigated O
during O
induction O
of O
anaesthesia O
and O
infrarenal O
aortic O
bypass O
surgery O
. O
[]

One O
scan O
was O
indeterminate O
and O
a O
follow-up O
venogram B-outcome ['Physiological-Clinical']
was O
negative O
. O
['Physiological-Clinical']

Twenty-eight O
consecutive O
babies O
with O
dark O
irides O
and O
birthweight O
< O
1600 O
g O
referred O
for O
screening O
for O
retinopathy O
of O
prematurity O
comprised O
the O
study O
population O
. O
[]

Some O
researchers O
have O
shown O
that O
acupressure O
on O
the O
acupuncture O
extra O
1 O
point O
is O
effective O
for O
sedation O
. O
[]

All O
summary O
scores O
and O
therapist B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
frequency O
['Life-Impact']

Multivariate O
logistic O
regression O
revealed O
that O
old O
age O
( O
odds O
ratio O
[ O
OR O
] O
, O
1.06 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
1.02-1.10 O
; O
p O
= O
0.002 O
) O
, O
earlier O
revascularization O
( O
OR O
, O
3.29 O
; O
95 O
% O
CI O
1.12-9.73 O
; O
p O
= O
0.03 O
) O
, O
and O
heart O
failure O
( O
OR O
, O
2.42 O
; O
95 O
% O
CI O
1.04-5.61 O
; O
p O
= O
0.04 O
) O
were O
independent O
predictors O
of O
TnT O
elevation O
. O
[]

Psychological O
treatment O
may O
treat O
effectively O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
, O
and O
fatigue B-outcome ['Physiological-Clinical']
among O
cancer O
patients O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Prospective O
, O
single-blinded O
, O
placebo-controlled O
randomized O
trial O
of O
6 O
months O
duration O
with O
two O
parallel O
groups O
. O
[]

To O
conclude O
, O
the O
sure O
clinical B-outcome ['Physiological-Clinical']
effectiveness O
, O
tolerance O
, O
['Physiological-Clinical']

The O
primary O
end O
points O
for O
analysis O
were O
EFS B-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

These O
results O
suggest O
that O
latanoprost O
stored O
at O
30 O
degrees O
C O
for O
4 O
[]

Clinical B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
of O
the O
Reichert O
AT550 O
: O
a O
new O
non-contact O
tonometer O
. O
['Physiological-Clinical']

Long O
term O
response O
to O
therapy O
of O
chronic O
anti-HBe-positive O
hepatitis O
B O
is O
poor O
independent O
of O
type O
and O
schedule O
of O
interferon O
. O
[]

1 O
, O
we O
obtained O
small O
intestine O
from O
28-d-old O
pigs O
weaned O
at O
21 O
d O
of O
age O
and O
from O
age-matched O
suckling O
piglets O
. O
[]

Levels O
of O
urinary B-outcome ['Physiological-Clinical']
estrogen I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

0.001 O
in O
the O
HYPO O
trial O
and O
decreased O
< O
1.020 O
by O
45 O
minutes O
( O
1.013 O
? O
[]

Fourteen O
patients O
received O
active O
laser O
treatment O
and O
all O
patients O
included O
completed O
the O
study O
. O
[]

The O
CSF B-outcome ['Physiological-Clinical']
monocytic I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
count O
decreased O
during O
zidovudine O
but O
increased O
during O
didanosine O
treatment O
. O
['Physiological-Clinical']

METHODS O
The O
trial O
includes O
asymptomatic O
patients O
who O
are O
50-79years O
and O
are O
not O
up-to-date O
with O
CRC O
screening O
guidelines O
. O
[]

One O
hundred O
nineteen O
patients O
with O
essential O
hypertension O
( O
96 O
completing O
six O
months O
and O
92 O
a O
one O
year O
study O
period O
) O
were O
randomized O
into O
four O
parallel O
groups O
and O
treated O
with O
one O
of O
four O
programs O
: O
200 O
mg O
of O
metoprolol O
plus O
placebo O
; O
200 O
mg O
of O
metoprolol O
plus O
25 O
mg O
of O
hydrochlorothiazide O
; O
200 O
mg O
of O
metoprolol O
plus O
50 O
mg O
hydrochlorothiazide O
, O
or O
; O
200 O
mg O
metoprolol O
plus O
50 O
mg O
of O
hydralazine O
. O
[]

Integrated O
CE O
in O
women O
discernibly O
reduced O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
( O
-13.2 O
% O
and O
-12.6 O
% O
, O
respectively O
) O
, O
increased O
estimated O
[ O
latin O
capital O
V O
with O
dot O
above O
] O
o2max B-outcome ['Physiological-Clinical']
( O
22.9 O
% O
) O
, O
and O
produced O
a O
trend O
toward O
reduced O
resting B-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
( O
-2.4 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Minimal O
clinically O
important O
change O
for O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
, O
functional B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
, O
and O
general O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
in O
patients O
with O
nonspecific O
low O
back O
pain O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

5 O
. O
[]

A O
pharmacy O
discharge O
plan O
for O
hospitalized O
elderly O
patients O
-- O
a O
randomized O
controlled O
trial O
. O
[]

Serum B-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
and O
vitamin B-outcome ['Physiological-Clinical']
B12 I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

ANIMALS O
10 O
healthy O
adult O
Beagles O
. O
[]

Immunologic O
profiles O
of O
persons O
recruited O
for O
a O
randomized O
, O
placebo-controlled O
clinical O
trial O
of O
hookworm O
infection O
. O
[]

During O
weight O
maintenance O
, O
METH O
intravenous O
infusion O
( O
125 O
mg/30 O
min O
) O
increased O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
compared O
with O
PLAC O
, O
and O
after O
4 O
days O
of O
oral O
therapy O
, O
METH O
( O
40 O
mg/day O
) O
decreased O
24-h B-outcome ['Physiological-Clinical']
NE I-outcome ['Physiological-Clinical']
and O
increased O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
compared O
with O
PLAC O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
MCIC B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
EQ I-outcome ['Physiological-Clinical']
ranged O
from O
0.07 O
to O
0.58 O
in O
( O
sub O
) O
acute O
patients O
and O
0.09 O
to O
0.28 O
in O
patients O
with O
chronic O
low O
back O
pain O
. O
['Physiological-Clinical']

There O
were O
470 O
randomized O
participants O
in O
the O
hypertensive O
population O
and O
480 O
randomized O
participants O
in O
the O
normotensive O
population O
. O
[]

PURPOSE O
This O
study O
evaluated O
the O
efficacy O
and O
safety O
of O
zoledronic O
acid O
in O
breast O
cancer O
patients O
with O
newly O
diagnosed O
bone O
metastases O
. O
[]

CONCLUSIONS O
Patients O
receiving O
supplemental O
inspired O
oxygen O
had O
a O
significant O
reduction O
in O
the O
risk O
of O
wound B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
differences O
between O
the O
two O
groups O
were O
greatly O
significant O
in O
statistics O
( O
P O
< O
0.01 O
) O
. O
[]

To O
determine O
the O
impact O
of O
indomethacin O
on O
the O
course O
of O
uremic O
pericarditis O
we O
performed O
a O
prospective O
, O
double O
blind O
study O
in O
which O
24 O
patients O
with O
endstage O
chronic O
renal O
failure O
and O
pericarditis O
randomly O
received O
indomethacin O
, O
25 O
mg O
four O
times O
daily O
, O
( O
11 O
patients O
) O
or O
a O
placebo O
( O
13 O
patients O
) O
for O
a O
3-week O
period O
. O
[]

OBJECTIVE O
Plasmakinetic O
vaporesection O
of O
the O
prostate O
( O
PKVP O
) O
using O
normal O
saline O
irrigation O
has O
the O
theoretical O
advantage O
of O
avoiding O
transurethral O
resection O
syndrome O
and O
minimizing O
blood O
loss O
. O
[]

Results O
from O
September O
15 O
, O
1983 O
, O
through O
December O
31 O
, O
1993 O
, O
showed O
no O
association O
between O
treatment O
and O
the O
incidence O
of O
basal B-outcome ['Physiological-Clinical']
and O
squamous B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
carcinomas I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Forty O
patients O
were O
followed O
in O
the O
high-risk O
pregnancy O
clinics O
at O
Duke O
University O
. O
[]

Eligible O
patients O
at O
National O
Cholesterol O
Education O
Program-Adult O
Treatment O
Panel O
III O
LDL-C B-outcome ['Physiological-Clinical']
treatment O
goal O
on O
a O
statin O
, O
with O
or O
without O
other O
lipid-modifying O
medications O
, O
are O
treated O
with O
anacetrapib O
, O
100 O
mg O
, O
or O
placebo O
for O
18 O
months O
, O
followed O
by O
a O
3-month O
, O
poststudy O
follow-up O
. O
['Physiological-Clinical']

A O
total O
of O
53 O
patients O
were O
accessed O
to O
the O
study O
: O
29 O
patients O
for O
the O
OK-432 O
group O
and O
24 O
patients O
for O
the O
control O
group O
. O
[]

Functional B-outcome ['Life-Impact']
and O
neuropsychologic B-outcome ['Physiological-Clinical']
outcomes O
were O
assessed O
3 O
months O
postoperatively O
. O
['Life-Impact', 'Physiological-Clinical']

The O
risk O
was O
most O
reduced O
among O
children O
under O
3 O
years O
of O
age O
( O
6 O
to O
11 O
months O
-- O
relative O
risk O
, O
0.28 O
; O
95 O
percent O
confidence O
interval O
, O
0.09 O
to O
0.85 O
; O
12 O
to O
35 O
months O
-- O
relative O
risk O
, O
0.46 O
; O
95 O
percent O
confidence O
interval O
, O
0.26 O
to O
0.81 O
) O
and O
among O
those O
who O
were O
chronically O
undernourished O
, O
as O
manifested O
by O
stunting O
( O
relative O
risk O
, O
0.11 O
; O
95 O
percent O
confidence O
interval O
, O
0.03 O
to O
0.36 O
) O
. O
[]

Individual O
records O
were O
kept O
of O
all O
consumed O
food O
. O
[]

METHODS O
After O
refraining O
from O
all O
oral O
hygiene O
procedures O
for O
23-25 O
hours O
, O
subjects O
received O
an O
oral O
tissue O
examination O
and O
those O
with O
pre-brushing O
whole O
mouth O
mean O
plaque O
scores O
> O
or O
= O
0.6 O
based O
on O
the O
Rustogi O
et O
al O
. O
[]

Due O
to O
the O
strong O
association O
between O
high O
BP O
and O
renal O
damage O
, O
this O
study O
raises O
the O
question O
on O
whether O
PR-STENT O
should O
be O
performed O
in O
all O
HTs O
with O
unilateral O
and O
incidental O
RAS O
. O
[]

Both O
groups O
performed O
treadmill O
test O
to O
assess O
pain-free O
walking O
time O
( O
PFWT O
) O
and O
maximal O
walking O
time O
( O
MWT O
) O
and O
had O
blood B-outcome ['Physiological-Clinical']
analyses O
[ O
for O
haematocrit B-outcome ['Physiological-Clinical']
, O
fibrinogen B-outcome ['Physiological-Clinical']
, O
triglycerides B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
Sixty-four O
patients O
with O
nonvalvular O
atrial O
fibrillation O
who O
were O
initiated O
with O
warfarin O
therapy O
at O
least O
3 O
months O
before O
the O
study O
. O
[]

The O
design O
and O
course O
of O
a O
placebo-controlled O
alpha-2 O
interferon O
trial O
in O
MS O
patients O
are O
described O
. O
[]

A O
non-vellus B-outcome ['Physiological-Clinical']
hair I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
was O
performed O
at O
baseline O
and O
after O
2 O
, O
4 O
and O
6 O
months O
. O
['Physiological-Clinical']

Functional O
studies O
between O
the O
cross-over O
periods O
showed O
flow-rate B-outcome ['Physiological-Clinical']
values O
close O
to O
normal O
, O
with O
an O
increase O
in O
residual I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
functional B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
capacity B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
has O
not O
been O
reached O
; O
however O
, O
the O
3-year O
survival B-outcome ['Mortality']
rate O
was O
70 O
% O
. O
['Mortality', 'Mortality']

The O
intensity O
of O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
opacification I-outcome ['Physiological-Clinical']
was O
also O
greater O
during O
femoral O
vein O
contrast O
injection O
. O
['Physiological-Clinical']

RESULTS O
Forty O
parent-child O
dyads O
enrolled O
: O
82.5 O
% O
were O
Hispanic O
, O
80 O
% O
had O
a O
girl O
and O
65 O
% O
reported O
income O
? O
[]

Treatment O
with O
the O
dipeptidyl O
peptidase-4 O
inhibitor O
vildagliptin O
improves O
fasting O
islet-cell O
function O
in O
subjects O
with O
type O
2 O
diabetes O
. O
[]

In O
both O
groups O
, O
pupil B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
was O
measured O
after O
40 O
minutes O
of O
eye O
drops O
instillation O
. O
['Physiological-Clinical']

The O
proportion O
of O
patients O
with O
ST-segment B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
> O
or O
=50 O
% O
at O
120 O
minutes O
was O
80 O
% O
in O
the O
PCI O
group O
and O
50 O
% O
in O
the O
SK O
group O
( O
P O
=.001 O
) O
. O
['Physiological-Clinical']

In O
LA O
, O
there O
was O
no O
difference O
in O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
between O
the O
normal O
and O
overweight O
patients O
. O
['Life-Impact']

Patients O
were O
randomized O
to O
receive O
either O
an O
intraoperative O
bolus O
of O
milrinone O
( O
50 O
microg/kg O
) O
or O
saline O
as O
placebo O
followed O
by O
a O
24-hour O
infusion O
of O
each O
agent O
( O
0.5 O
microg/kg/min O
) O
. O
[]

The O
effect O
of O
body O
weight O
changes O
and O
endurance O
training O
on O
24h B-outcome ['Physiological-Clinical']
substrate I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Assess O
the O
frequency O
and O
severity O
of O
esophageal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
extraesophageal I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
functional I-outcome ['Physiological-Clinical']
dyspepsia I-outcome ['Physiological-Clinical']
at O
3 O
and O
7 O
days O
of O
study O
on O
5-point O
scale O
Likert O
. O
['Physiological-Clinical']

For O
the O
purpose O
of O
this O
study O
a O
20 O
% O
difference O
in O
the O
relative O
risks O
for O
the O
two O
outcomes O
was O
considered O
clinically O
relevant O
. O
[]

Severe O
alopecia B-outcome ['Physiological-Clinical']
occurred O
in O
5.1 O
% O
of O
mitoxantrone O
patients O
and O
61.0 O
% O
of O
doxorubicin O
patients O
( O
P O
less O
than O
.001 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
inclusion O
of O
CRM O
training O
in O
undergraduate O
medical O
education O
reduces O
NFT O
in O
simulated O
CPR O
and O
improves O
TLV O
proportions O
during O
simulated O
CPR O
. O
[]

Except O
for O
one O
condition O
of O
repeatability O
for O
one O
group O
, O
the O
4 O
conditions O
of O
repeatability O
in O
scoring O
the O
index O
were O
met O
for O
all O
4 O
groups O
of O
subjects O
. O
[]

Two O
fellowship-trained O
musculoskeletal O
radiologists O
measured O
the O
TT-TG B-outcome ['Physiological-Clinical']
distances I-outcome ['Physiological-Clinical']
for O
each O
patient O
by O
CT O
and O
MRI O
in O
a O
randomized O
, O
blinded O
fashion O
. O
['Physiological-Clinical']

All O
patients O
were O
screened O
by O
computed O
tomography O
every O
2 O
months O
to O
observe O
the O
tumor O
recurrent O
conditions O
. O
[]

Distinct B-outcome ['Physiological-Clinical']
lower O
extremity B-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
moment B-outcome ['Physiological-Clinical']
and O
power O
patterns B-outcome ['Physiological-Clinical']
were O
observed O
in O
response O
to O
the O
FP O
but O
an O
overall O
positive O
moment O
of O
support B-outcome ['Physiological-Clinical']
( O
M O
( O
s O
) O
) O
was O
maintained O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Beliefs O
underlying O
the O
intention O
to O
donate O
again O
among O
first-time O
blood O
donors O
who O
experience O
a O
mild O
adverse O
event O
. O
[]

Ninety-seven O
patients O
received O
rioprostil O
, O
600 O
micrograms O
once-daily O
orally O
, O
and O
110 O
patients O
received O
ranitidine O
, O
150 O
mg O
once-daily O
orally O
. O
[]

The O
actual O
four-year O
graft B-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
rates O
for O
the O
triple O
therapy O
, O
Aza O
plus O
CsA O
, O
Aza O
plus O
MP O
, O
and O
CsA O
plus O
MP O
groups O
were O
72 O
% O
, O
69 O
% O
, O
75 O
% O
, O
and O
59 O
% O
, O
and O
patient O
survival O
rates O
were O
78 O
% O
, O
81 O
% O
, O
81 O
% O
, O
and O
84 O
% O
, O
respectively O
, O
with O
no O
significant O
differences O
. O
['Life-Impact']

Children O
with O
a O
positive O
MII/pH O
were O
randomly O
treated O
with O
proton O
pump O
inhibitors O
( O
PPIs O
) O
or O
histamine O
H O
( O
2 O
) O
-receptor O
antagonists O
( O
H O
( O
2 O
) O
RAs O
) O
during O
3 O
months O
. O
[]

Plasma O
pharmacokinetics O
indicated O
rapid O
absorption O
and O
elimination O
: O
time O
to O
reach O
maximum O
concentration O
occurred O
at O
about O
1 O
hour O
; O
half-life O
ranged O
from O
1 O
to O
3 O
hours O
. O
[]

INTERVENTIONS O
Acupuncture O
with O
sham O
device O
twice O
a O
week O
for O
six O
weeks O
or O
placebo O
pill O
once O
a O
day O
for O
eight O
weeks O
. O
[]

Late B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
were O
significantly O
worse O
after O
neutrons O
. O
['Physiological-Clinical']

Absence O
of O
tumour O
cells O
may O
indicate O
a O
more O
favourable O
patient O
group O
who O
would O
benefit O
from O
a O
more O
intense O
course O
of O
treatment O
. O
[]

Pharmacokinetics B-outcome ['Physiological-Clinical']
and O
relative B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
of O
the O
marketed O
prajmalium O
bitartrate O
tablet O
( O
Neo-Gilurytmal O
, O
CAS O
2589-47-1 O
) O
compared O
to O
an O
oral O
solution O
were O
investigated O
in O
an O
open O
, O
randomized O
, O
single-dose O
two-fold O
crossover O
study O
in O
20 O
healthy O
male O
volunteers O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Granisetron O
was O
administered O
as O
a O
single O
intravenous O
dose O
before O
the O
start O
of O
cisplatin O
chemotherapy O
( O
> O
or O
= O
60 O
mg/m2 O
) O
. O
[]

We O
have O
measured O
the O
capacity O
of O
the O
sodium-potassium O
pump O
, O
as O
assessed O
by O
86rubidium O
uptake O
and O
the O
number O
of O
[ O
3H O
] O
-ouabain O
binding O
sites O
on O
white O
blood O
cells O
, O
in O
children O
aged O
9-11 O
years O
, O
partly O
cross-sectionally O
and O
partly O
longitudinally O
after O
a O
physical O
training O
programme O
. O
[]

No O
dose O
adjustment O
of O
either O
protease O
inhibitor O
in O
any O
of O
the O
combinations O
studied O
is O
needed O
. O
[]

PCA O
morphine O
for O
postoperative O
pain O
. O
[]

PURPOSE O
To O
compare O
the O
effectiveness O
and O
safety O
of O
excimer O
laser O
trabeculotomy O
( O
ELT O
) O
ab O
interno O
vs O
selective O
laser O
trabeculoplasty O
( O
SLT O
) O
over O
24 O
months O
of O
follow-up O
in O
patients O
with O
primary O
open-angle O
glaucoma O
( O
POAG O
) O
refractory O
to O
medical O
therapy O
. O
[]

However O
, O
pain O
remains O
often O
undertreated O
due O
to O
institutional O
, O
health O
care O
professional O
and O
patient O
related O
barriers O
. O
[]

This O
involved O
two O
anthelmintic-treatment O
levels O
( O
treated O
vs. O
non-treated O
) O
, O
two O
supplementary O
nutrition O
levels O
( O
protein-energy O
supplementation O
yes/no O
) O
and O
three O
genotypes O
: O
indigenous O
Menz O
( O
n=40 O
) O
, O
50 O
% O
Awassi O
x O
50 O
% O
Menz O
crosses O
( O
n=38 O
) O
and O
75 O
% O
Awassi O
x O
25 O
% O
Menz O
crosses O
( O
n=31 O
) O
. O
[]

However O
, O
acute B-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
were O
more O
frequent O
in O
the O
40-Gy O
arm O
. O
['Adverse-effects']

RESULTS O
Compared O
with O
40 O
patients O
of O
the O
control O
group O
after O
the O
six O
months O
of O
the O
auditory O
integrative O
training O
, O
41 O
of O
the O
experimental O
group O
had O
greatly O
improved O
in O
many O
aspects O
, O
such O
as O
the O
disorders B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
, I-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
interactions I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
typical I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
while O
they O
had O
not O
changed O
in O
their O
abnormal B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

When O
ozone O
is O
used O
during O
caries O
treatment O
, O
bond O
strength O
can O
be O
compromised O
by O
the O
release O
of O
oxygen O
. O
[]

Both O
treatment O
groups O
exhibited O
statistically O
significant O
improvement O
in O
standard O
outcome O
parameters O
when O
compared O
with O
baseline O
values O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
of O
melodic O
based O
communication O
therapy O
( O
MBCT O
) O
to O
traditional O
speech O
and O
language O
therapy O
for O
eliciting B-outcome ['Life-Impact']
speech I-outcome ['Life-Impact']
in O
nonverbal O
children O
with O
autism O
. O
['Life-Impact']

BACKGROUND O
Amlodipine O
besylate O
has O
been O
used O
in O
Korea O
for O
the O
treatment O
of O
hypertension O
for O
> O
17 O
years O
, O
with O
well-established O
efficacy O
and O
tolerability O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
IL-6 I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
determined O
before O
surgery O
and O
at O
24 O
, O
48 O
, O
72 O
h O
after O
surgery O
. O
['Physiological-Clinical']

Secondary O
measures O
are O
the O
Motor B-outcome ['Physiological-Clinical']
Activity I-outcome ['Physiological-Clinical']
Log I-outcome ['Physiological-Clinical']
, O
Stroke B-outcome ['Life-Impact']
Impact I-outcome ['Life-Impact']
Scale O
, O
Carer B-outcome ['Life-Impact']
Strain I-outcome ['Life-Impact']
Index O
, O
and O
health B-outcome ['Resource-use']
and I-outcome ['Resource-use']
social I-outcome ['Resource-use']
care I-outcome ['Resource-use']
resource I-outcome ['Resource-use']
use I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Resource-use']

PATIENTS O
AND O
METHODS O
Patients O
were O
younger O
than O
55 O
years O
and O
had O
at O
least O
one O
adverse O
prognostic O
factor O
. O
[]

CONCLUSIONS O
Although O
referring O
to O
a O
small O
number O
of O
patients O
, O
our O
data O
show O
that O
topical O
capsaicin O
may O
relieve O
arterial B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
in O
absence O
of O
and O
during O
a O
migraine O
attack O
in O
a O
substantial O
number O
of O
patients O
experiencing O
scalp O
arterial O
tenderness O
. O
['Physiological-Clinical']

A O
prospective O
study O
of O
streptokinase O
and O
heparin O
in O
the O
treatment O
of O
deep B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Journal O
of O
Experimental O
Psychology O
: O
General O
, O
133 O
, O
339-354 O
. O
) O
[]

Patients O
were O
instructed O
to O
use O
a O
thin O
layer O
of O
the O
study O
products O
twice O
daily O
at O
the O
lesional O
area O
and O
to O
discontinue O
treatment O
as O
soon O
as O
symptoms O
were O
absent O
. O
[]

Home O
blood O
pressure O
monitoring O
is O
frequently O
used O
to O
find O
subjects O
with O
'white-coat O
' O
hypertension B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
All O
active O
treatments O
in O
both O
arms O
of O
the O
study O
resulted O
in O
the O
decrease O
of O
sICAM-1 B-outcome ['Physiological-Clinical']
and O
nasal B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
, O
which O
correlated O
with O
the O
severity O
of O
nasal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Three O
valid O
straylight O
measurements O
were O
taken O
on O
each O
eye O
before O
and O
a O
few O
minutes O
after O
lens O
insertion O
, O
when O
lens O
stabilization O
had O
occurred O
. O
[]

RESULTS O
Therapy O
with O
vaginal O
clindamycin O
had O
no O
significant O
impact O
on O
the O
incidence O
of O
spontaneous B-outcome ['Physiological-Clinical']
preterm I-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
prior O
to O
37 O
completed O
weeks O
; O
OR O
0.90 O
, O
95 O
% O
CI O
0.40-2.02 O
( O
primary O
outcome O
variable O
) O
. O
['Physiological-Clinical']

Vaginal O
tablets O
containing O
lactobacilli O
can O
cure O
BV O
and O
reduce O
vaginal O
inflammatory O
response O
. O
[]

The O
patients O
were O
assessed O
using O
the O
Aberrant B-outcome ['Life-Impact']
Behavioral O
Checklist-Community O
( O
ABC-C O
) O
and O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
checklist O
as O
well O
as O
clinical O
global O
impression-improvement O
( O
CGI-I O
) O
at2 O
checkpoints O
of O
5-week O
intervals O
after O
the O
baseline O
. O
['Life-Impact', 'Adverse-effects', 'Physiological-Clinical']

RESULTS O
Of O
98 O
randomized O
patients O
, O
61 O
% O
were O
WHO O
functional O
class O
II O
at O
baseline O
. O
[]

The O
standard O
donation O
brochure O
had O
an O
intermediate O
effect O
. O
[]

Thirty-two O
children O
with O
ASD O
were O
assigned O
randomly O
into O
the O
treatment O
and O
control O
groups O
. O
[]

The O
occurrence O
of O
ischemic B-outcome ['Physiological-Clinical']
type O
ST B-outcome ['Physiological-Clinical']
segment I-outcome ['Physiological-Clinical']
depression B-outcome ['Life-Impact']
was O
modulated O
by O
changes O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
rather O
than O
by O
absolute O
heart O
rate O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Effect O
of O
antipyretic O
drugs O
in O
children O
with O
malaria O
. O
[]

In O
a O
prospective O
randomized O
study O
the O
durability B-outcome ['Life-Impact']
of O
tunnelled O
and O
non-tunnelled O
central O
venous O
catheters O
was O
investigated O
in O
children O
with O
malignant O
diseases O
. O
['Life-Impact']

It O
was O
not O
possible O
to O
demonstrate O
efficacy O
of O
huIFN-?2a O
or O
AZT O
alone O
or O
together O
in O
cats O
infected O
naturally O
with O
FeLV O
when O
given O
according O
to O
this O
regimen O
for O
6 O
weeks O
; O
however O
, O
no O
notable O
side O
effects O
were O
detected O
. O
[]

Other O
outcomes O
include O
wound B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
, O
effectiveness O
, O
safety O
, O
healthcare B-outcome ['Resource-use']
resource I-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
, O
quality O
of O
life O
, O
and O
cost-effectiveness O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use']

Epanolol O
, O
a O
selective O
beta O
1-receptor O
blocker O
with O
intrinsic O
sympathomimetic O
activity O
, O
induced O
a O
fall O
in O
intraarterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
8 O
% O
at O
rest O
sitting O
and O
11 O
% O
during O
100 O
W O
bicycle O
exercise O
after O
the O
first O
dose O
of O
200 O
mg O
in O
12 O
patients O
with O
essential O
hypertension O
. O
['Physiological-Clinical']

Although O
continuous O
positive O
airway O
pressure O
( O
CPAP O
) O
therapy O
using O
a O
face O
mask O
is O
known O
to O
improve O
oxygenation O
, O
the O
intrapulmonary O
shunt O
reduction O
remains O
unsettled O
. O
[]

Also O
, O
EPO O
tended O
to O
enhance O
the O
CPB-induced O
increase O
in O
[]

There O
were O
no O
serious O
adverse O
events O
in O
all O
groups O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
dilution I-outcome ['Physiological-Clinical']
and O
the O
rate O
of O
infusion O
of O
Ringer O
's O
solution O
. O
['Physiological-Clinical']

We O
terminated O
this O
study O
because O
of O
the O
negative O
outcome O
with O
ES O
. O
[]

The O
CTSC O
( O
14 O
Fr O
) O
was O
first O
inserted O
through O
the O
tracheal O
tube O
, O
with O
the O
tip O
of O
the O
CTSC O
emerging O
from O
the O
distal O
end O
of O
the O
tube O
. O
[]

Nontarget B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
mild I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
moderate I-outcome ['Physiological-Clinical']
stenosis I-outcome ['Physiological-Clinical']
were O
measured O
by O
volumetric O
intravascular O
ultrasound O
at O
baseline O
and O
after O
6 O
months O
. O
['Physiological-Clinical']

A O
prospective O
cohort-study O
will O
include O
a O
six-month O
baseline O
a O
six O
month O
intervention O
period O
and O
a O
three-month O
post O
intervention O
period O
. O
[]

With O
CrCl O
of O
< O
10 O
ml/min O
, O
the O
mean O
Cmin O
and O
Cmax O
were O
0.75+/-0.42 O
and O
1.59+/-0.55 O
microg/ml O
, O
respectively O
, O
with O
a O
mean O
AUC0-24 O
of O
64.6+/-18.8 O
microg O
x O
hr/ml O
. O
[]

A O
catheter O
was O
advanced O
4 O
cm O
in O
the O
epidural O
space O
and O
4 O
ml O
0.5 O
% O
bupivacaine O
with O
adrenaline O
1:200,000 O
was O
given O
as O
a O
test O
dose O
. O
[]

Effects O
of O
telephone O
call O
interventions O
on O
patients O
' O
well-being O
in O
a O
radiation O
therapy O
department O
. O
[]

DESIGN O
The O
Baron O
and O
Kenny O
mediator O
model O
, O
a O
series O
of O
4 O
regression O
analyses O
, O
was O
used O
to O
evaluate O
whether O
: O
a O
) O
physical O
and O
emotional O
status O
predicted O
program O
participation O
, O
b O
) O
program O
participation O
predicted O
dietary O
adherence O
, O
c O
) O
physical O
and O
emotional O
status O
factors O
predicted O
dietary O
adherence O
, O
and O
, O
ultimately O
d O
) O
the O
effects O
of O
physical O
and O
emotional O
status O
on O
dietary O
adherence O
were O
mediated O
by O
program O
participation O
. O
[]

It O
can O
also O
correlate O
with O
gamma-aminobutyric O
acid O
( O
GABA O
) O
-homocarnosine O
interaction O
, O
with O
possible O
anticonvulsive O
effects O
. O
[]

The O
impact O
of O
the O
intervention O
was O
assessed O
against O
patient B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
: O
routinely O
available O
asthma O
outcome O
measures O
( O
beta2-agonist B-outcome ['Resource-use']
prescription B-outcome ['Resource-use']
rate O
and O
number O
of O
oral B-outcome ['Resource-use']
steroid I-outcome ['Resource-use']
courses I-outcome ['Resource-use']
) O
for O
asthma O
patients O
identified O
as O
being O
poorly-controlled O
from O
practice O
records O
; O
and O
questionnaire O
data O
- O
Mini O
['Physiological-Clinical', 'Resource-use', 'Resource-use', 'Resource-use']

Differential O
effect O
of O
aspirin O
on O
thromboxane B-outcome ['Physiological-Clinical']
and O
prostaglandin B-outcome ['Physiological-Clinical']
biosynthesis I-outcome ['Physiological-Clinical']
in O
man O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
dimension O
was O
one O
diameter O
of O
bone O
, O
and O
a O
one-diameter O
length O
of O
bone O
was O
removed O
. O
[]

Ninety O
patients O
were O
randomly O
assigned O
to O
one O
of O
three O
treatment O
groups O
. O
[]

BACKGROUND O
Microbial O
protein O
synthesised O
in O
the O
rumen O
is O
a O
very O
important O
protein O
source O
for O
ruminants O
. O
[]

There O
were O
no O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
drug I-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
in O
the O
febuxostat O
group O
other O
than O
a O
high O
frequency O
of O
gout B-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
induced O
by O
the O
sudden O
reduction O
in O
blood B-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
levels O
during O
the O
early O
treatment O
period O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

2 O
) O
test O
to O
establish O
categorical O
differences O
. O
[]

There O
was O
a O
significant O
difference O
in O
the O
change O
in O
daily O
steps O
from O
baseline O
to O
follow-up O
between O
groups O
( O
p O
< O
.05 O
) O
. O
[]

PATIENTS O
In O
total O
, O
174 O
patients O
aged O
20-60 O
yr O
were O
admitted O
to O
the O
study O
. O
[]

CONCLUSION O
Short-term O
use O
of O
MET O
is O
well O
tolerated B-outcome ['Life-Impact']
by O
obese O
children O
with O
NGT O
and O
has O
a O
beneficial O
effect O
on O
BMI O
and O
autonomic O
control O
of O
the O
heart O
as O
well O
as O
a O
trend O
toward O
improved O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Analyses O
of O
self-reported B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
treatment B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
did O
not O
reveal O
clinically O
meaningful O
differences O
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Adverse-effects']

INTRODUCTION O
The O
efficacy O
of O
vitamin O
D O
and O
calcium O
supplementation O
on O
risk O
of O
falling B-outcome ['Life-Impact']
in O
the O
elderly O
is O
discussed O
controversially O
. O
['Life-Impact']

The O
geometric O
mean O
x O
: O
tolerance O
factor O
of O
the O
reduction O
in O
AER B-outcome ['Physiological-Clinical']
among O
the O
23 O
microalbuminuric O
patients O
on O
lisinopril O
( O
-10.0 O
x:1.3 O
micrograms/min O
) O
was O
greater O
, O
though O
not O
significantly O
so O
, O
than O
that O
observed O
in O
the O
26 O
on O
nifedipine O
( O
-0.9 O
x O
1.2 O
micrograms/min O
) O
. O
['Physiological-Clinical']

Substandard O
housing O
and O
lack O
of O
resources O
often O
underlie O
these O
exposures O
. O
[]

Hemodynamic B-outcome ['Physiological-Clinical']
data O
were O
recorded O
for O
all O
the O
patients O
during O
the O
operation O
, O
and O
visual O
analogue O
scale O
( O
VAS O
) O
was O
used O
to O
assess O
the O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
at O
4 O
, O
8 O
, O
16 O
, O
24 O
, O
48 O
and O
72 O
h O
after O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
the O
cholinomimetic O
SDZ O
ENS-163 O
on O
scopolamine-induced O
cognitive B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
in O
humans O
. O
['Life-Impact']

INTERVENTIONS O
Either O
the O
centrifugation O
or O
multiple-pass O
hemoconcentration O
method O
was O
used O
to O
process O
the O
residual O
blood O
from O
the O
cardiopulmonary O
bypass O
circuit O
. O
[]

METHODS O
Sixty O
patients O
who O
underwent O
upper O
lobectomy O
were O
prospectively O
randomized O
into O
two O
groups O
: O
30 O
patients O
had O
creation O
of O
pleural O
tent O
( O
group O
1 O
) O
and O
30 O
did O
not O
( O
group O
2 O
) O
. O
[]

The O
clinical B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
rate O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
were O
similar O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Seventeen O
( O
17.5 O
% O
) O
of O
97 O
patients O
in O
group O
1 O
, O
12 O
( O
30.0 O
% O
) O
of O
40 O
patients O
in O
group O
2 O
, O
and O
8 O
( O
24.2 O
% O
) O
of O
33 O
patients O
in O
group O
3 O
experienced O
nasal B-outcome ['Physiological-Clinical']
polyposis I-outcome ['Physiological-Clinical']
relapses I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

They O
were O
randomized O
according O
to O
a O
single-masked O
design O
and O
stratified O
by O
center O
( O
with O
balancing O
every O
4 O
patients O
) O
. O
[]

Exercise O
lowers O
the O
cerebral O
metabolic O
ratio O
of O
O2 O
to O
carbohydrate O
( O
glucose+1/2 O
lactate O
) O
and O
metabolic O
acidosis O
appears O
to O
promote O
cerebral B-outcome ['Physiological-Clinical']
lactate I-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Furthermore O
, O
there O
was O
a O
strong O
correlation O
between O
achievement O
of O
EVR O
and O
SVR B-outcome ['Physiological-Clinical']
and O
ribavirin O
dose O
over O
the O
first O
12 O
weeks O
expressed O
either O
as O
absolute O
dose O
or O
proportion O
of O
optimal O
dose O
received O
( O
P O
< O
0.001 O
for O
both O
) O
. O
['Physiological-Clinical']

GFR B-outcome ['Physiological-Clinical']
was O
unaffected O
by O
any O
treatment O
. O
['Physiological-Clinical']

RESULTS O
Seventy-three O
children O
were O
randomized O
and O
analysis O
conducted O
on O
67 O
children O
who O
completed O
the O
study O
. O
[]

RESULTS O
Nursing O
staff O
reported O
a O
statistically O
significant O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
scores O
during O
dressing O
removal O
, O
and O
significantly O
less O
rescue B-outcome ['Resource-use']
doses I-outcome ['Resource-use']
of I-outcome ['Resource-use']
Entonox I-outcome ['Resource-use']
given O
to O
those O
receiving O
VR O
, O
compared O
to O
those O
receiving O
standard O
distraction O
. O
['Physiological-Clinical', 'Resource-use']

The O
corresponding O
number O
of O
infections B-outcome ['Physiological-Clinical']
per O
catheter O
days O
were O
1 O
in O
1189 O
days O
and O
1 O
in O
522 O
days O
, O
respectively O
. O
['Physiological-Clinical']

PTSD O
patients O
were O
recruited O
from O
five O
primary O
care O
clinics O
at O
four O
Veterans O
Affairs O
healthcare O
facilities O
and O
randomized O
to O
receive O
usual O
care O
or O
usual O
care O
plus O
3CM O
. O
[]

Median O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
transection I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
TL O
group O
than O
in O
the O
BP O
group O
( O
195.2 O
+/- O
84.5 O
versus O
343.3 O
+/- O
198.4 O
mL O
; O
P O
= O
0.023 O
) O
, O
and O
liver B-outcome ['Resource-use']
transection I-outcome ['Resource-use']
was O
significantly O
faster O
in O
the O
TL O
group O
than O
in O
the O
BP O
group O
( O
0.7 O
+/- O
0.2 O
versus O
0.5 O
+/- O
0.2 O
cm O
( O
2 O
) O
/minute O
; O
P O
= O
0.048 O
) O
. O
['Physiological-Clinical', 'Resource-use']

min O
( O
-1 O
) O
with O
a O
history O
of O
ischemic O
heart O
disease O
were O
recruited O
. O
[]

Diclofensine O
inhibits O
the O
uptake O
of O
serotonin O
, O
noradrenaline O
and O
dopamine O
. O
[]

Although O
the O
electrophysiologic O
changes O
induced O
by O
these O
antiarrhythmic O
agents O
contributed O
to O
facilitating O
pacing-induced O
termination O
, O
neither O
tachycardia B-outcome ['Physiological-Clinical']
cycle O
length B-outcome ['Physiological-Clinical']
nor O
action B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Visual O
analog O
scale O
( O
VAS O
) O
pain B-outcome ['Physiological-Clinical']
scores O
were O
lower O
in O
the O
operating O
room O
( O
OR O
) O
( O
P O
< O
0.05 O
) O
and O
postanesthesia O
care O
unit O
( O
PACU O
) O
( O
P O
< O
0.0005 O
) O
for O
the O
group O
that O
received O
fentanyl O
. O
['Physiological-Clinical']

Zinc B-outcome ['Physiological-Clinical']
and O
copper B-outcome ['Physiological-Clinical']
balances I-outcome ['Physiological-Clinical']
in O
preterm O
infants O
. O
['Physiological-Clinical', 'Physiological-Clinical']

UNLABELLED O
Many O
cancer O
patients O
continue O
to O
smoke O
postdiagnosis O
, O
which O
is O
associated O
with O
poorer O
clinical O
outcomes O
. O
[]

CONCLUSIONS O
Pretreatment O
with O
i.v O
. O
[]

RESULTS O
For O
transepidermal B-outcome ['Physiological-Clinical']
water I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
there O
was O
a O
difference O
of O
2.3 O
gr/m2/h O
between O
MEBO O
, O
and O
Flammazine O
, O
favoring O
MEBO O
. O
['Physiological-Clinical']

In O
an O
attempt O
to O
delineate O
the O
effect O
of O
membrane O
permeability O
, O
we O
performed O
a O
randomized O
, O
crossover O
study O
to O
compare O
the O
inflammatory O
biomarkers O
, O
lipid O
profile O
, O
and O
aortic O
pulse O
wave O
velocity O
( O
PWV O
) O
of O
two O
dialyzers O
that O
are O
composed O
of O
identical O
membranes O
but O
with O
different O
flux O
characteristics O
. O
[]

The O
principal O
analysis O
of O
the O
primary O
endpoint O
was O
done O
on O
the O
intention-to-treat O
cohort O
. O
[]

CONCLUSIONS O
Our O
results O
suggest O
that O
MCT O
oil O
can O
be O
incorporated O
into O
a O
weight O
loss O
program O
without O
fear O
of O
adversely O
affecting O
metabolic O
risk O
factors O
. O
[]

After O
ethical O
approval O
, O
12 O
healthy O
male O
volunteers O
were O
included O
in O
this O
randomized O
, O
controlled O
, O
double-blind O
, O
crossover O
, O
four-arm O
study O
. O
[]

After O
this O
period O
, O
all O
participants O
received O
diethylpropion O
in O
an O
open-label O
extension O
for O
an O
additional O
6 O
months O
. O
[]

Enalapril O
and O
lisinopril O
in O
the O
treatment O
of O
mild O
to O
moderate O
essential O
hypertension O
. O
[]

The O
population-based O
program O
provides O
primarily O
telephonic O
patient O
education O
and O
monitoring O
services O
. O
[]

Developing O
the O
Ho'ouna O
Pono O
substance O
use O
prevention O
curriculum O
: O
collaborating O
with O
Hawaiian O
youth O
and O
communities O
. O
[]

Periprocedural O
myocardial O
infarction O
( O
MI O
) O
following O
drug-eluting O
stent O
placement O
is O
associated O
with O
long-term O
adverse O
outcomes O
. O
[]

Clinical O
findings O
were O
compared O
with O
those O
in O
9 O
further O
children O
with O
severe O
malaria O
of O
similar O
age O
range O
( O
four O
of O
whom O
were O
unconscious O
) O
, O
who O
received O
an O
identical O
placebo O
. O
[]

The O
reduction O
of O
incidences O
of O
air O
leak O
in O
the O
two O
groups O
was O
subsequently O
compared O
during O
successive O
postoperative O
periods O
. O
[]

The O
placebo O
group O
received O
atropine O
10 O
microg O
x O
kg O
( O
-1 O
) O
intravenously O
during O
induction O
. O
[]

A O
stratified O
random O
sample O
of O
450 O
parents O
were O
randomized O
into O
three O
incentive O
groups O
: O
( O
a O
) O
no O
incentive O
; O
( O
b O
) O
a O
promised O
incentive O
of O
one O
lottery O
ticket O
to O
be O
received O
upon O
reply O
; O
( O
c O
) O
a O
promised O
incentive O
of O
one O
lottery O
ticket O
to O
be O
received O
upon O
reply O
and O
an O
additional O
lottery O
ticket O
upon O
reply O
within O
1 O
week O
. O
[]

Nineteen O
patients O
completed O
the O
study O
. O
[]

RESULTS O
After O
completing O
the O
program O
, O
balance B-outcome ['Life-Impact']
, O
gait B-outcome ['Life-Impact']
velocity I-outcome ['Life-Impact']
, O
and O
self-assessment O
of O
gait B-outcome ['Life-Impact']
improved O
significantly O
in O
all O
patients O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
Relative O
to O
the O
control O
group O
, O
the O
ABC O
treatment O
group O
was O
previously O
found O
to O
have O
improved O
cognition B-outcome ['Life-Impact']
and O
educational B-outcome ['Life-Impact']
attainment I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

We O
sought O
to O
determine O
whether O
plasma O
EBV-DNA O
could O
serve O
as O
a O
surrogate O
for O
EBER-ISH B-outcome ['Physiological-Clinical']
and O
to O
explore O
its O
prognostic O
utility O
in O
HL O
. O
['Physiological-Clinical']

Exenatide O
administration O
failed B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
suppress I-outcome ['Physiological-Clinical']
glucagon I-outcome ['Physiological-Clinical']
but I-outcome ['Physiological-Clinical']
delayed I-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
( O
P O
< O
0.004 O
) O
. O
['Physiological-Clinical']

The O
endpoint O
'ipsilateral O
ischemic B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
or O
vascular B-outcome ['Mortality']
death I-outcome ['Mortality']
between O
randomisation O
and O
6 O
months O
' O
occurred O
in O
7.4 O
% O
of O
the O
CAS O
and O
6.5 O
% O
of O
the O
CEA O
patients O
( O
odds O
ratio O
1.16 O
, O
95 O
% O
confidence O
interval O
0.74-1.82 O
) O
. O
['Physiological-Clinical', 'Mortality']

The O
visual O
analog O
scale O
( O
VAS O
) O
was O
used O
to O
measure O
pain O
intensity O
and O
a O
stop-watch O
was O
used O
to O
time O
the O
pain O
period O
. O
[]

The O
data O
suggest O
that O
the O
relationship O
observed O
in O
some O
reports O
between O
late-onset O
depression O
and O
MRI O
hyperintensities O
is O
most O
likely O
a O
function O
of O
cerebrovascular O
disease O
risk O
and O
age O
. O
[]

Adverse O
events O
( O
AEs O
) O
occurring O
more O
frequently O
with O
sitaxsentan O
( O
50 O
or O
100 O
mg O
) O
included O
headache B-outcome ['Physiological-Clinical']
, O
peripheral B-outcome ['Physiological-Clinical']
edema I-outcome ['Physiological-Clinical']
, O
dizziness B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
extremity B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
sequential O
treatment O
schedule O
has O
been O
reported O
to O
be O
effective O
, O
but O
studies O
published O
to O
date O
were O
performed O
in O
Italy O
. O
[]

CONTEXT O
Barriers O
impede O
translating O
recommendations O
for O
asthma O
treatment O
into O
practice O
, O
particularly O
in O
inner O
cities O
where O
asthma O
morbidity O
is O
highest O
. O
[]

Significant O
diastolic B-outcome ['Physiological-Clinical']
blood B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
( O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Driving B-outcome ['Life-Impact']
simulator O
performance B-outcome ['Life-Impact']
, O
neurocognitive B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
, O
and O
subjective B-outcome ['Life-Impact']
alertness I-outcome ['Life-Impact']
were O
measured O
by O
the O
AusEd O
driving O
simulator O
, O
psychomotor O
vigilance O
task O
, O
and O
Karolinska O
Sleepiness O
Scale O
, O
respectively O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
aim O
of O
this O
study O
is O
to O
investigate O
if O
the O
Post-Discharge O
Network O
Coordination O
Program O
at O
ipw O
has O
a O
demonstrably O
significant O
impact O
on O
the O
frequency O
and O
duration O
of O
patient B-outcome ['Resource-use']
re-hospitalization I-outcome ['Resource-use']
. O
['Resource-use']

A O
1-year O
randomized O
intervention O
trial O
was O
conducted O
with O
two O
treatment O
arms O
with O
different O
eating O
frequencies O
; O
3 O
meals/day O
( O
3M O
) O
or O
3 O
meals O
and O
3 O
snacks/day O
( O
3+3M O
) O
. O
[]

Sensory O
side O
effects O
from O
this O
low O
dose O
and O
from O
the O
standard O
MEG-X O
test O
were O
compared O
in O
a O
double-blind O
, O
randomized O
, O
cross-over O
study O
( O
study O
II O
) O
comprising O
15 O
individuals O
with O
normal O
liver O
function O
and O
45 O
patients O
with O
cirrhosis O
( O
15 O
Child O
A O
, O
15 O
Child O
B O
, O
and O
15 O
Child O
C O
) O
. O
[]

Reduced O
cardiotoxicity O
and O
comparable O
efficacy O
in O
a O
phase O
III O
trial O
of O
pegylated O
liposomal O
doxorubicin O
HCl O
( O
CAELYX/Doxil O
) O
versus O
conventional O
doxorubicin O
for O
first-line O
treatment O
of O
metastatic O
breast O
cancer O
. O
[]

These O
effects O
might O
interfere O
with O
memory O
functioning O
and O
psychomotor O
performance O
. O
[]

These O
findings O
support O
further O
evaluation O
of O
cold-adapted O
influenza O
vaccine O
, O
trivalent O
, O
in O
infants O
< O
6 O
months O
of O
age O
. O
[]

Efficacy O
was O
assessed O
by O
the O
patients O
' O
performance O
in O
four O
psychometric B-outcome ['Life-Impact']
tests O
. O
['Life-Impact']

The O
[]

Warfarin O
is O
commonly O
used O
in O
preference O
to O
aspirin O
for O
this O
disorder O
, O
but O
these O
therapies O
have O
not O
been O
compared O
in O
a O
randomized O
trial O
. O
[]

Women O
with O
untreated O
implant O
ruptures O
reported O
a O
significant O
increase O
in O
nonspecific B-outcome ['Physiological-Clinical']
breast I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
( O
odds O
ratio O
, O
2.1 O
; O
95 O
percent O
confidence O
interval O
, O
1.2 O
to O
3.8 O
) O
compared O
with O
women O
without O
ruptures O
. O
['Physiological-Clinical']

The O
ICC O
for O
tendon B-outcome ['Life-Impact']
thickness I-outcome ['Life-Impact']
was O
0.84 O
. O
['Life-Impact']

Patients O
receiving O
aripiprazole O
should O
be O
periodically O
reassessed O
to O
determine O
the O
continued O
need O
for O
treatment O
. O
[]

All O
women O
filled O
in O
a O
demographic O
data O
form O
and O
answered O
a O
questionnaire O
containing O
nine O
questions O
about O
breast O
cancer O
, O
risk O
, O
and O
screening O
to O
assess O
their O
knowledge O
and O
perception O
. O
[]

The O
MWT O
group O
had O
11 O
( O
range O
0-106 O
) O
outpatient B-outcome ['Resource-use']
treatment O
visits B-outcome ['Resource-use']
during O
the O
study O
versus O
4 O
( O
range O
0-47 O
) O
in O
the O
NPWT O
group O
( O
P O
< O
.05 O
) O
. O
['Resource-use', 'Resource-use']

METHODS O
We O
have O
pooled O
two O
randomized O
clinical O
trials O
in O
palliative O
condition O
from O
the O
F?d?ration O
Francophone O
de O
Cancerologie O
Digestive O
. O
[]

Recent O
research O
in O
decision-making O
has O
demonstrated O
the O
dud-alternative O
effect O
-- O
the O
tendency O
to O
become O
more O
confident O
that O
a O
chosen O
response O
option O
is O
correct O
if O
it O
is O
surrounded O
by O
implausible O
response O
options O
( O
Windschitl O
& O
Chambers O
, O
J O
Exp O
Psychol O
30:198-215 O
, O
2004 O
) O
. O
[]

A O
similar O
number O
of O
double-blinded B-outcome ['Resource-use']
Pap I-outcome ['Resource-use']
smears I-outcome ['Resource-use']
and O
colposcopies B-outcome ['Resource-use']
with I-outcome ['Resource-use']
biopsy I-outcome ['Resource-use']
were O
performed O
in O
randomly O
selected O
women O
in O
the O
control O
group O
. O
['Resource-use', 'Resource-use']

The O
effect O
of O
compression O
on O
subjective O
measures O
of O
image B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
graded O
by O
the O
angiographers O
was O
also O
examined O
. O
['Life-Impact']

There O
was O
no O
evidence O
of O
haemolysis B-outcome ['Physiological-Clinical']
or O
other O
toxic B-outcome ['Adverse-effects']
effect O
despite O
these O
levels O
. O
['Physiological-Clinical', 'Adverse-effects']

The O
volunteers O
were O
randomly O
assigned O
to O
the O
test O
or O
reference O
treatment O
, O
with O
the O
two O
treatment O
periods O
separated O
by O
a O
washout O
period O
of O
at O
least O
7 O
days O
. O
[]

Scale O
and O
success O
rate O
of O
smooth O
LMA O
insertion O
also O
were O
recorded O
. O
[]

In O
healthy O
volunteers O
, O
tegaserod O
at O
i.v O
. O
[]

Interindividual O
BP O
variability O
was O
markedly O
greater O
than O
the O
intra-individiual O
one O
of O
which O
it O
did O
not O
precisely O
reflect O
the O
treatment-induced O
changes O
. O
[]

Split-sample O
validation O
was O
used O
. O
[]

This O
prospective O
, O
randomized O
trial O
evaluated O
the O
effect O
of O
monotherapy O
and O
different O
combination O
therapies O
on O
cardiovascular O
target O
organ O
damage O
and O
metabolic O
profile O
in O
520 O
hypertensive O
patients O
. O
[]

The O
primary O
aim O
of O
this O
study O
is O
to O
investigate O
whether O
supervised O
Nordic O
Walking O
can O
reduce O
pain B-outcome ['Physiological-Clinical']
and O
improve O
function B-outcome ['Life-Impact']
in O
a O
population O
of O
chronic O
low O
back O
pain O
patients O
when O
compared O
to O
unsupervised O
Nordic O
Walking O
and O
advice O
to O
stay O
active O
. O
['Physiological-Clinical', 'Life-Impact']

Again O
no O
significant O
differences O
were O
seen O
with O
respect O
to O
the O
mortality B-outcome ['Mortality']
at O
six O
weeks O
. O
['Mortality']

In O
vivo O
skin O
penetration O
studies O
showed O
that O
epidermal O
exposure O
to O
bioelastic O
thromboxane O
synthetase O
inhibitor O
( O
TSI O
) O
matrix O
resulted O
in O
local B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
TSI I-outcome ['Physiological-Clinical']
sufficient O
for O
thromboxane O
synthetase O
inhibition O
. O
['Physiological-Clinical']

RESULTS O
No O
statistically O
significant O
change O
over O
time O
and O
between O
groups O
was O
observed O
. O
[]

Clinical O
outcomes O
measured O
included O
total O
energy O
intake O
and O
growth B-outcome ['Physiological-Clinical']
over O
the O
first O
six O
postnatal O
weeks O
, O
sepsis B-outcome ['Physiological-Clinical']
incidence I-outcome ['Physiological-Clinical']
, O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
milk B-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
, O
duration O
of O
respiratory B-outcome ['Resource-use']
support I-outcome ['Resource-use']
, O
duration O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
and O
complication B-outcome ['Adverse-effects']
incidence O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Adverse-effects']

Moreover O
, O
myeloperoxidase B-outcome ['Physiological-Clinical']
levels O
were O
reduced O
by O
the O
treatment O
with O
allopurinol O
( O
56.1 O
+/- O
3.4 O
ng/ml O
vs. O
44.4 O
+/- O
2.4 O
ng/ml O
, O
P O
< O
0.05 O
) O
but O
there O
were O
no O
change O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

Urine O
samples O
for O
analysis O
of O
nocturnal O
urinary O
excretion B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
were O
collected O
. O
['Physiological-Clinical']

We O
conclude O
that O
the O
nephrotoxic O
side-effects O
of O
cyclosporin O
A O
treatment O
for O
1 O
year O
are O
reversible O
. O
[]

OBJECTIVE O
To O
assess O
the O
effectiveness O
in O
terms O
of O
patient O
assessed O
privacy O
of O
confidential O
registration O
. O
[]

Maximal O
LORETA O
source O
strength O
did O
not O
differ O
from O
controls O
. O
[]

3 O
. O
[]

The O
patients O
were O
observed O
for O
a O
period O
of O
24 O
hours O
. O
[]

Double-blind O
placebo-controlled O
administration O
of O
fluoxetine O
in O
restricting- O
and O
restricting-purging-type O
anorexia O
nervosa O
. O
[]

RESULTS O
The O
SH B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
17.9 O
per O
100 O
person-years O
, O
and O
a O
higher O
rate O
was O
associated O
with O
the O
occurrence O
of O
SH B-outcome ['Physiological-Clinical']
in O
the O
prior O
6 O
months O
and O
female O
sex O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patient-provider O
communication O
in O
the O
intervention O
group O
was O
characterized O
as O
being O
more O
interested B-outcome ['Life-Impact']
, O
friendly B-outcome ['Life-Impact']
, O
responsive B-outcome ['Life-Impact']
, O
interactive B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Thus O
, O
both O
demographic O
variables O
and O
subjective O
drug O
effects O
were O
related O
to O
drug O
preference O
. O
[]

In O
order O
to O
bypass O
the O
degenerated O
cortico-striato-pallidal O
loop O
, O
we O
administered O
the O
adrenergic O
agonist O
idazoxan O
( O
IDA O
) O
to O
treat O
PSP O
in O
two O
randomized O
double-blind O
, O
placebo O
controlled O
, O
crossover O
studies O
. O
[]

Prospective O
, O
blinded O
exploratory O
evaluation O
of O
the O
PlayWisely O
program O
in O
children O
with O
autism O
spectrum O
disorder O
. O
[]

Home-based O
reach-to-grasp O
training O
for O
people O
after O
stroke O
: O
study O
protocol O
for O
a O
feasibility O
randomized O
controlled O
trial O
. O
[]

Four O
0.4-mg O
formulations O
with O
different O
in O
vitro O
burst O
times O
and O
dissolution O
rates O
were O
administered O
, O
with O
2-week O
intervals O
between O
treatments O
. O
[]

The O
total O
daily O
dose O
was O
400 O
micrograms O
for O
both O
drugs O
. O
[]

After O
the O
Bonferroni O
adjustment O
for O
multiple O
comparisons O
, O
there O
were O
no O
significant O
associations O
between O
changes O
in O
cortical B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
and O
clinical O
and O
cognitive O
outcome O
. O
['Physiological-Clinical']

Supplementation O
with O
fish O
oil O
and O
placebo O
shortened O
lag O
time O
and O
slowed B-outcome ['Physiological-Clinical']
propagation I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
women O
both O
using O
and O
not O
using O
HRT O
. O
['Physiological-Clinical']

SETTING O
This O
study O
was O
nested O
in O
the O
IMPALA O
study O
, O
a O
clustered O
randomised O
controlled O
trial O
involving O
24 O
general O
practices O
in O
The O
Netherlands O
. O
[]

It O
has O
been O
assessed O
in O
terms O
of O
physical O
stability O
and O
pharmacokinetic O
and O
pharmacodynamic O
properties O
and O
been O
found O
to O
be O
effective O
in O
lowering O
blood O
pressure O
in O
preclinical O
and O
Phase O
I O
and O
II O
trials O
. O
[]

The O
primary O
end O
points O
were O
the O
rate O
of O
biopsy-confirmed B-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BCAR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
as O
measured O
by O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Outcome O
measures O
were O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
EFS I-outcome ['Mortality']
; O
defined O
as O
the O
time O
to O
first O
recurrence O
, O
progression O
, O
second O
malignancy O
, O
or O
death O
) O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

Whole-body O
CT O
screening O
: O
scan O
delay O
and O
contrast O
injection O
duration O
for O
optimal B-outcome ['Physiological-Clinical']
enhancement I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
abdominal I-outcome ['Physiological-Clinical']
organs I-outcome ['Physiological-Clinical']
and O
deep B-outcome ['Physiological-Clinical']
vessels I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Study O
outcomes O
were O
assessed O
at O
baseline O
and O
at O
16 O
and O
32 O
weeks O
after O
randomization O
. O
[]

The O
anastomoses O
created O
by O
PROXIMATE? O
ILS? O
leaked O
in O
25/265 O
( O
9.4 O
% O
) O
anastomoses O
, O
and O
the O
Premium O
Plus O
CEEA? O
leaked O
in O
19/260 O
( O
7.3 O
% O
) O
, O
p O
= O
.419 O
. O
[]

Study O
patients O
were O
insulin O
deficient O
as O
shown O
by O
low O
baseline O
C B-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
values O
( O
0.43 O
+/- O
0.05 O
nmol/L O
) O
. O
['Physiological-Clinical']

METHODS O
Fourteen O
patients O
with O
stable O
hypercapnic O
COPD O
who O
were O
receiving O
long-term O
NPPV O
were O
included O
in O
the O
study O
. O
[]

RESULTS O
Patients O
in O
group O
C O
had O
a O
significantly O
reduced O
need B-outcome ['Resource-use']
for I-outcome ['Resource-use']
propofol I-outcome ['Resource-use']
( O
P O
< O
0.04 O
) O
and O
sevoflurane O
( O
P O
< O
0.01 O
) O
and O
a O
reduced O
early B-outcome ['Resource-use']
need I-outcome ['Resource-use']
for I-outcome ['Resource-use']
ketobemidone I-outcome ['Resource-use']
( O
P O
< O
0.04 O
) O
. O
['Resource-use', 'Resource-use']

Body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
decreased O
by O
4.9-11.7 O
kg O
and O
urinary B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
did O
not O
change O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ringer O
lactate O
solution O
was O
used O
to O
replace O
the O
functional O
extracellular O
fluid O
volume O
. O
[]

INTERVENTION O
All O
patients O
were O
surgically O
treated O
in O
the O
ENT O
Department O
, O
University O
of O
Siena O
Medical O
School O
. O
[]

Twelve O
patients O
presenting O
to O
an O
accident O
and O
emergency O
department O
in O
asystolic O
cardiac O
arrest O
were O
randomly O
allocated O
to O
treatment O
with O
endotracheal O
adrenaline O
( O
five O
patients O
) O
or O
peripheral O
intravenous O
adrenaline O
( O
seven O
patients O
) O
. O
[]

RESULTS O
Significant O
improvement O
in O
posttest B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
was O
seen O
only O
in O
the O
error+correct O
training O
group O
. O
['Physiological-Clinical']

The O
hemi-sections O
were O
reassembled O
and O
occlusal O
access O
preparations O
were O
carried O
out O
using O
ball-shaped O
diamonds O
. O
[]

Effects O
of O
creatine O
supplementation O
on O
repetitive O
sprint O
performance O
and O
body O
composition O
in O
competitive O
swimmers O
. O
[]

No O
correlation O
with O
intellectual B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
was O
found O
at O
any O
of O
these O
sites O
. O
['Life-Impact']

CONCLUSIONS O
In O
this O
pilot O
trial O
of O
ICU O
patients O
with O
high O
illness O
severity O
, O
glucose B-outcome ['Physiological-Clinical']
values O
were O
in O
the O
2 O
target O
ranges O
only O
40 O
% O
of O
the O
time O
, O
using O
well-accepted O
initiation O
and O
maintenance O
insulin O
infusion O
algorithms O
. O
['Physiological-Clinical']

RESULTS O
At O
the O
6 O
, O
12 O
and O
24 O
h O
postoperative O
intervals O
after O
drug O
administration O
, O
the O
intensity O
of O
pain B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
experimental O
groups O
than O
in O
the O
placebo O
group O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Depressive O
mood O
symptoms O
associated O
with O
ovarian O
suppression O
. O
[]

One O
hundred O
twenty-two O
chemotherapy-naive O
patients O
with O
histologically O
confirmed O
colorectal O
adenocarcinoma O
were O
entered O
into O
a O
randomized O
trial O
comparing O
infusional O
fluorouracil O
( O
FU O
) O
versus O
cisplatin O
( O
CDDP O
) O
and O
FU O
. O
[]

Fifty-one O
patients O
were O
randomized O
to O
the O
syncope O
unit O
. O
[]

Although O
the O
number O
of O
patients O
studied O
at O
our O
institution O
was O
small O
, O
administration O
of O
1 O
liter O
intraperitoneally O
provided O
consistent O
IDI B-outcome ['Physiological-Clinical']
results O
. O
['Physiological-Clinical']

CONCLUSION O
These O
preliminary O
findings O
support O
the O
hypothesis O
that O
deep O
pressure O
may O
have O
a O
calming O
effect O
for O
persons O
with O
autism O
, O
especially O
those O
with O
high O
levels O
of O
arousal O
or O
anxiety O
. O
[]

In O
conclusion O
, O
our O
results O
provide O
evidence O
for O
increased O
expression O
of O
VEGF/VEGFR-2 O
of O
leukemic B-outcome ['Physiological-Clinical']
blasts I-outcome ['Physiological-Clinical']
and O
correlation O
with O
angiogenesis O
in O
the O
bone O
marrow O
of O
AML O
patients O
. O
['Physiological-Clinical']

CONCLUSIONS O
Contrary O
to O
our O
predictions O
, O
directing O
students O
' O
SRL O
produced O
no O
additional O
benefit O
and O
increased O
their O
practice B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
. O
['Life-Impact']

Intervention O
Half O
of O
the O
subjects O
received O
an O
additional O
home-based O
programme O
consisting O
of O
40 O
weekly O
visits O
. O
[]

In O
addition O
, O
the O
interactive O
group O
proved O
superior O
to O
the O
lecture O
group O
regarding O
[]

Heart O
rate O
variability O
characteristics O
in O
sedentary O
postmenopausal O
women O
following O
six O
months O
of O
exercise O
training O
: O
the O
DREW O
study O
. O
[]

The O
changes O
in O
enzyme B-outcome ['Physiological-Clinical']
levels O
confirm O
the O
cholestatic O
type O
of O
hepatobiliary O
deviations O
without O
clinical O
impact O
on O
short-term O
TPN O
therapy O
. O
['Physiological-Clinical']

RESULTS O
From O
May O
1989 O
through O
March O
1993 O
, O
171 O
patients O
were O
randomized O
( O
84 O
to O
VP O
and O
87 O
to O
VIP O
) O
. O
[]

Marked O
interpatient O
differences O
within O
each O
dose O
arm O
were O
greater O
than O
differences O
between O
arms O
. O
[]

End O
points O
were O
patient O
and O
graft B-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
, O
acute B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
, O
and O
incidence O
of O
steroid B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
during O
the O
first O
year O
after O
LT O
. O
['Life-Impact', 'Physiological-Clinical', 'Adverse-effects']

Each O
treatment O
was O
given O
for O
3 O
months O
. O
[]

Emotion O
regulation O
strategies O
that O
promote O
learning O
: O
reappraisal O
enhances O
children B-outcome ['Physiological-Clinical']
's O
memory B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
educational I-outcome ['Life-Impact']
information I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Repeated-measures O
analysis O
of O
variance O
revealed O
a O
significant O
increase O
in O
overall O
arm O
discomfort B-outcome ['Physiological-Clinical']
, O
decrease O
in O
elbow B-outcome ['Physiological-Clinical']
extension I-outcome ['Physiological-Clinical']
and O
decrease O
in O
isometric B-outcome ['Physiological-Clinical']
strength B-outcome ['Physiological-Clinical']
for O
both O
conditions B-outcome ['Physiological-Clinical']
over O
time O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
patient O
CGI B-outcome ['Physiological-Clinical']
scale O
showed O
a O
significant O
difference O
favoring O
ropinirole O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Subjects O
were O
first- O
and O
second-year O
pediatric O
residents O
in O
a O
hospital-based O
continuity O
clinic O
. O
[]

The O
most O
frequently O
reported O
events O
were O
anterior B-outcome ['Physiological-Clinical']
chamber I-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
and O
increased O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Stent-supported O
angioplasty O
can O
be O
an O
alternative O
only O
in O
the O
hands O
of O
an O
experienced O
interventionalist O
with O
proven O
low O
periprocedural B-outcome ['Physiological-Clinical']
complication I-outcome ['Physiological-Clinical']
rate O
. O
['Physiological-Clinical']

Two O
features O
have O
limited O
its O
clinical O
utility O
: O
tendency O
to O
elicit O
kidney O
failure O
and O
inability O
to O
produce O
complete O
analgesia O
. O
[]

RESULTS O
Preoperative O
variables O
were O
the O
same O
in O
both O
groups O
. O
[]

Also O
, O
granisetron O
was O
found O
to O
be O
more O
effective O
than O
tropisetron O
, O
especially O
in O
patients O
heavier O
than O
25 O
kg O
( O
p O
= O
0.02 O
) O
. O
[]

The O
methods O
did O
not O
overestimate O
Clcr O
in O
RA O
. O
[]

The O
total O
length O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
ambulation I-outcome ['Life-Impact']
, O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oral I-outcome ['Physiological-Clinical']
nutrition I-outcome ['Physiological-Clinical']
were O
recorded O
. O
['Resource-use', 'Life-Impact', 'Physiological-Clinical']

Our O
objective O
was O
to O
assess O
the O
efficiency O
of O
a O
home-visit O
invitation O
aimed O
to O
increase O
uptake O
of O
cervical O
cancer O
screening O
in O
women O
between O
35 O
and O
60 O
years O
of O
age O
. O
[]

0.09 O
, O
0.71 O
? O
[]

The O
mean O
( O
SD O
) O
maximum O
dose O
of O
citalopram O
was O
16.5 O
( O
6.5 O
) O
mg O
by O
mouth O
daily O
( O
maximum O
dose O
, O
20 O
mg/d O
) O
. O
[]

RESULTS O
Both O
groups O
showed O
improvements O
in O
pain-free B-outcome ['Physiological-Clinical']
grip I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
, O
visual O
analog O
scale O
, O
and O
Patient-Rated B-outcome ['Physiological-Clinical']
Tennis I-outcome ['Physiological-Clinical']
Elbow I-outcome ['Physiological-Clinical']
Evaluation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Plasma O
norepinephrine O
and O
mortality O
. O
[]

Effective O
strategies O
included O
( O
a O
) O
the O
use O
of O
choral O
responding O
; O
( O
b O
) O
the O
use O
of O
student-to-student O
responding O
; O
( O
c O
) O
the O
rotation O
of O
materials O
every O
5 O
minutes O
during O
the O
30-minute O
group O
while O
teaching O
2 O
to O
3 O
concepts O
; O
and O
( O
d O
) O
the O
use O
of O
random O
, O
unpredictable O
trials O
for O
student O
responding O
. O
[]

More O
implanted O
eyes O
than O
nonimplanted O
eyes O
had O
improved O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical']

Median O
post-hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
1.7 O
days O
for O
group O
A O
while O
it O
was O
longer O
( O
2.9 O
days O
) O
for O
group O
B O
. O
['Resource-use']

Source O
localization O
revealed O
stronger O
sources O
in O
premotor O
cortex O
, O
the O
intraparietal O
lobule O
( O
IPL O
) O
and O
the O
mid-occipito-temporal O
gyrus O
( O
MOTG O
) O
and O
weaker O
sources O
in O
prefrontal O
cortex O
in O
typical O
participants O
compared O
to O
Asperger O
. O
[]

The O
effect O
of O
beta-carotene O
on O
the O
susceptibility O
of O
low O
density O
lipoprotein O
( O
LDL O
) O
to O
oxidative O
modification O
was O
investigated O
in O
a O
double-blind O
, O
randomized O
placebo-controlled O
study O
. O
[]

The O
patients O
were O
randomly O
allocated O
to O
Groups O
L O
( O
n O
= O
51 O
) O
and O
LM O
( O
n O
= O
56 O
) O
using O
the O
closed-envelope O
method O
. O
[]

CDP571 O
, O
a O
humanized O
monoclonal O
antibody O
to O
tumour O
necrosis O
factor-alpha O
, O
for O
steroid-dependent O
Crohn O
's O
disease O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

One O
hundred O
and O
twenty O
patients O
presenting O
at O
Macquarie O
Hospital O
for O
admission O
were O
randomly O
allocated O
into O
two O
groups O
. O
[]

This O
was O
interpreted O
as O
indicating O
subject O
's O
tendencies B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
aggression I-outcome ['Life-Impact']
. O
['Life-Impact']

Eighty O
children O
, O
ages O
2-10 O
years O
, O
with O
ASD O
and O
sleep O
onset O
delay O
completed O
the O
study O
. O
[]

When O
PN O
supplementation O
increased O
from O
10 O
to O
200 O
mg/kg O
diet O
, O
a O
significant O
improvement O
in O
weight O
gain O
percentage O
was O
observed O
. O
[]

We O
conclude O
that O
rapacuronium O
1.5 O
mg O
kg-1 O
had O
a O
more O
rapid O
onset O
, O
similar O
intubating B-outcome ['Life-Impact']
conditions I-outcome ['Life-Impact']
, O
and O
shorter O
recovery O
times O
than O
rocuronium O
0.6 O
mg O
kg-1 O
. O
['Life-Impact']

Liquid O
fluoxetine O
was O
only O
slightly O
, O
and O
not O
significantly O
, O
superior O
to O
placebo O
on O
CGI O
autism B-outcome ['Life-Impact']
score O
partially O
due O
to O
a O
phase O
order O
effect O
. O
['Life-Impact']

BACKGROUND O
Cluster O
specific O
immunotherapy O
( O
SIT O
) O
is O
a O
modern O
form O
of O
allergen O
immunotherapy O
allowing O
safe O
administration O
of O
high O
allergen O
doses O
in O
a O
short O
time O
interval O
compared O
to O
classic O
SIT O
. O
[]

A O
web-based O
computer-tailored O
feedback O
programme O
may O
be O
an O
effective O
intervention O
to O
stimulate O
youngsters O
not O
to O
start O
smoking O
, O
and O
increase O
their O
knowledge O
about O
the O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
of O
smoking O
and O
their O
attitudes O
and O
self-efficacy O
regarding O
non-smoking O
. O
['Adverse-effects']

The O
group O
treated O
with O
GM-CSF O
had O
lower O
total O
charges O
after O
infusion B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
autologous I-outcome ['Physiological-Clinical']
marrow I-outcome ['Physiological-Clinical']
than O
the O
placebo O
group O
( O
median O
in-hospital O
charges O
, O
$ O
39,800 O
compared O
with O
$ O
62,500 O
; O
P O
= O
0.005 O
) O
because O
of O
lower B-outcome ['Physiological-Clinical']
post-infusion I-outcome ['Physiological-Clinical']
charges I-outcome ['Physiological-Clinical']
for O
room O
and O
board O
, O
antibiotic O
therapy O
, O
transfusions O
, O
laboratory O
tests O
, O
and O
physical O
therapy O
visits O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
combination O
of O
infiltrating O
growth O
pattern O
and O
high-grade O
budding O
did O
not O
have O
a O
stronger O
prognostic O
significance O
than O
tumor O
budding O
alone O
. O
[]

Patients O
underwent O
minor O
nominal O
dose O
adjustments O
during O
treatment O
crossover O
. O
[]

Language O
, O
speech O
sound O
production O
, O
and O
cognition O
in O
three-year-old O
children O
in O
relation O
to O
otitis O
media O
in O
their O
first O
three O
years O
of O
life O
. O
[]

Visual B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
characteristic O
of O
pilocarpine O
eye-drops O
were O
reduced O
from O
3 O
times O
a O
day O
on O
pilocarpine O
salt O
solution O
to O
once O
a O
day O
on O
pilocarpine O
polymer O
complex O
. O
['Physiological-Clinical']

Sodium B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
was O
significantly O
lower O
in O
the O
intervention O
group O
only O
in O
the O
active O
participants O
as O
compared O
to O
dropouts O
and O
controls O
( O
87 O
vs O
130 O
and O
133 O
mmoles/24 O
hr O
) O
. O
['Life-Impact']

Medical O
Research O
Council O
's O
Working O
Party O
on O
Leukaemia O
in O
Adults O
. O
[]

On O
each O
of O
the O
mornings O
after O
the O
two O
CPAP O
withdrawal O
nights O
, O
patients O
received O
200 O
mg O
modafinil O
or O
placebo O
( O
n O
= O
21 O
) O
in O
a O
randomized O
, O
double-blind O
, O
crossover O
design O
. O
[]

RESULTS O
WORC O
and O
ASES O
scores O
improved O
significantly O
in O
each O
group O
over O
time O
( O
p O
< O
0.001 O
) O
. O
[]

Therefore O
, O
we O
studied O
in O
a O
randomized O
clinical O
trial O
the O
relationship O
between O
the O
comminution O
of O
an O
artificial O
test O
food O
, O
i.e O
. O
[]

Among O
the O
many O
factors O
that O
may O
contribute O
to O
problematic O
clinical O
trial O
results O
, O
error O
in O
measuring O
the O
phenomena O
being O
studied O
is O
of O
particular O
concern O
. O
[]

During O
an O
attempt O
to O
correct O
this O
catabolic O
state O
by O
administration O
of O
exogenous O
growth O
hormone O
, O
cardiac O
muscle O
mass O
and O
performance O
were O
studied O
. O
[]

PARTICIPANTS O
There O
were O
18 O
obese O
, O
mildly O
diabetic O
humans O
included O
in O
the O
study O
. O
[]

To O
identify O
the O
risk O
factors O
for O
the O
development O
of O
postoperative O
septic O
complications O
in O
patients O
with O
intestinal O
perforation O
after O
abdominal O
trauma O
, O
and O
to O
compare O
the O
efficacies O
of O
single-drug O
and O
dual-drug O
prophylactic O
antibiotic O
therapy O
, O
we O
studied O
145 O
patients O
who O
presented O
with O
abdominal O
trauma O
and O
intestinal O
perforation O
at O
two O
hospitals O
between O
July O
1979 O
and O
June O
1982 O
. O
[]

The O
differences O
between O
diurnal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
nocturnal I-outcome ['Physiological-Clinical']
IOP I-outcome ['Physiological-Clinical']
reductions I-outcome ['Physiological-Clinical']
( O
handheld O
electronic O
or O
Goldmann O
's O
applanation O
tonometer O
) O
were O
minimal O
( O
> O
0.3 O
mm O
Hg O
) O
and O
statistically O
not O
significant O
( O
P O
> O
.31 O
, O
two-tailed O
paired O
Student O
's O
t O
test O
) O
. O
['Physiological-Clinical']

The O
prevention O
of O
nausea O
, O
vomiting O
and O
appetite O
loss O
induced O
by O
remission O
induction O
chemotherapy O
for O
acute O
myeloid O
leukemia O
was O
compared O
by O
randomization O
between O
granisetron O
alone O
and O
combination O
with O
granisetron O
plus O
methylprednisolone O
. O
[]

The O
cure B-outcome ['Physiological-Clinical']
rate O
on O
day O
28 O
was O
100 O
% O
in O
both O
groups O
. O
['Physiological-Clinical']

CONCLUSION O
Statin O
withdrawal O
is O
associated O
with O
increased O
risk O
of O
death O
or O
dependency O
at O
90 O
days O
. O
[]

We O
provide O
evidence O
that O
low-dose O
CY O
not O
only O
depletes O
patients O
' O
Treg O
cells O
and O
enhances O
function O
of O
HPV-specific B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
and O
NK B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
in O
the O
periphery O
, O
but O
also O
ameliorates O
the O
immune B-outcome ['Physiological-Clinical']
milieu I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
, O
leading O
to O
the O
elimination O
of O
remnant O
viruses O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
The O
aim O
of O
the O
study O
was O
to O
assess O
omega O
3/6 O
fatty O
acids O
( O
eye O
q O
) O
in O
attention B-outcome ['Life-Impact']
deficit I-outcome ['Life-Impact']
hyperactivity I-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
ADHD I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
changes O
in O
the O
context O
of O
service O
provision O
within O
which O
the O
nursing-led O
inpatient O
unit O
operated O
as O
a O
result O
of O
substantial O
investment O
in O
intermediate O
care O
did O
have O
a O
major O
impact O
. O
[]

In O
this O
randomized O
, O
double-blind O
trial O
, O
smokers O
with O
mild-to-moderate O
COPD O
were O
treated O
with O
varenicline O
1 O
mg O
b.i.d O
. O
[]

Perioperative O
laboratory O
and O
clinical O
outcomes O
( O
Hb O
, O
iron O
variables O
, O
postoperative O
bleeding O
amount O
, O
and O
number O
of O
units O
of O
RBCs O
transfused O
and O
incidences O
) O
were O
documented O
. O
[]

Loss O
of O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
after O
antiretroviral O
therapy O
initiation O
, O
independent O
of O
antiretroviral O
regimen O
. O
['Physiological-Clinical']

14.0 O
% O
, O
p O
< O
0.01 O
) O
and O
plasminogen O
activator O
inhibitor-1 O
( O
from O
76.9 O
? O
[]

RESULTS O
After O
tension-free O
repairs O
five O
hernias B-outcome ['Physiological-Clinical']
recurred I-outcome ['Physiological-Clinical']
( O
5 O
% O
) O
, O
and O
after O
either O
Cooper O
ligament O
or O
abdominal O
ring O
repair O
, O
16 O
recurrences B-outcome ['Physiological-Clinical']
were O
found O
( O
15 O
% O
) O
( O
P O
= O
0.025 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Physical B-outcome ['Physiological-Clinical']
findings I-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
were O
quantified O
, O
and O
lumbar B-outcome ['Physiological-Clinical']
spine I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
was O
determined O
at O
intervals O
for O
up O
to O
12 O
and O
24 O
months O
post-therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Maternal B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
erythropoietin I-outcome ['Physiological-Clinical']
increased O
during O
pregnancy O
, O
but O
this O
response O
was O
reduced O
in O
the O
third O
trimester O
in O
the O
hematinic-supplemented O
group O
. O
['Physiological-Clinical']

CONCLUSIONS O
Lanthanum O
carbonate O
was O
shown O
to O
be O
an O
effective O
and O
well-tolerated B-outcome ['Life-Impact']
phosphate O
binder O
for O
the O
treatment O
of O
hyperphosphatemia O
in O
Chinese O
patients O
with O
ESRD O
. O
['Life-Impact']

Receiver O
operator O
curves O
( O
ROC O
) O
were O
used O
to O
assess O
the O
value O
of O
the O
follow-up O
percent O
diameter O
stenosis O
( O
DS O
) O
for O
each O
of O
the O
three O
analyzed O
segments O
in O
predicting O
target O
vessel O
revascularization O
( O
TVR O
) O
. O
[]

The O
above O
metoclopramide O
regimen O
significantly O
suppressed O
the O
frequency O
of O
vomiting O
on O
the O
day O
of O
CDDP O
administration O
. O
[]

OBJECTIVE O
To O
evaluate O
whether O
the O
same O
or O
different O
patients O
respond B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
triptans I-outcome ['Physiological-Clinical']
and O
telcagepant O
. O
['Physiological-Clinical']

METHODS O
Three O
hundred O
and O
seventy O
nine O
women O
( O
260 O
with O
a O
family O
history O
of O
breast O
cancer O
; O
119 O
with O
breast O
cancer O
) O
from O
The O
Royal O
Marsden O
NHS O
Foundation O
Trust O
were O
randomised O
to O
receive O
or O
not O
receive O
written O
educational O
information O
on O
cancer O
genetics O
. O
[]

METHOD O
Twelve O
children O
with O
autism O
were O
randomly O
assigned O
to O
either O
an O
experimental O
group O
( O
receiving O
deep O
pressure O
) O
or O
a O
placebo O
group O
( O
not O
receiving O
deep O
pressure O
but O
in O
the O
disengaged O
Hug O
Machine O
) O
. O
[]

DHEA O
treatment O
did O
not O
enhance O
established B-outcome ['Physiological-Clinical']
immunity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

One O
hundred O
eighty-four O
patients O
were O
followed O
up O
( O
mean O
15 O
+/- O
13 O
months O
) O
and O
only O
cardiac B-outcome ['Mortality']
death I-outcome ['Mortality']
was O
considered O
as O
an O
end O
point O
. O
['Mortality']

Patients O
randomized O
to O
V.A.C O
. O
( O
[]

Tauber O
's O
technique O
is O
simple O
; O
however O
, O
it O
has O
the O
disadvantage O
of O
multiple B-outcome ['Physiological-Clinical']
branching I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
small I-outcome ['Physiological-Clinical']
veins I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Administration O
of O
IVGG O
presents O
some O
unique O
challenges O
for O
nurses O
. O
[]

All O
patients O
received O
a O
loading O
of O
prasugrel O
60 O
mg O
. O
[]

Inclusion O
of O
lay O
knowledge O
and O
clarification O
of O
treatment O
decision O
processes O
increased O
patients O
' O
perception O
of O
involvement O
in O
disease O
management O
through O
increased O
identification O
and O
awareness O
of O
others O
' O
self-management O
experiences O
. O
[]

There O
was O
no O
significant O
difference O
between O
two O
groups O
in O
relation O
to O
the O
level O
of O
anesthesia B-outcome ['Resource-use']
or O
maximal B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
electrolyte B-outcome ['Physiological-Clinical']
imbalance I-outcome ['Physiological-Clinical']
did O
not O
occur O
in O
either O
group O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

CLINICAL O
TRIAL O
REGISTRATION O
ClinicalTrials.gov O
, O
www.clinicaltrials.gov O
, O
NCT01509313 O
. O
[]

= O
1 O
, O
P O
= O
0.02 O
) O
. O
[]

Clinical O
measures O
assessed O
were O
erythema O
, O
scaling O
and O
pruritus O
which O
were O
evaluated O
using O
a O
four-point O
scale O
( O
0-3 O
) O
. O
[]

Folylpolyglutamate O
synthetase O
and O
thymidine O
phosphorylase O
correlated O
with O
efficacy O
. O
[]

RESULTS O
All O
the O
patients O
were O
followed O
up O
, O
and O
the O
duration O
ranged O
from O
12 O
to O
30 O
months O
, O
with O
an O
average O
of O
15.6 O
months O
. O
[]

Likewise O
, O
morning O
and O
evening B-outcome ['Physiological-Clinical']
PEF I-outcome ['Physiological-Clinical']
decreased O
by O
46 O
+/- O
7 O
L/min O
and O
18 O
+/- O
6 O
L/min O
, O
respectively O
. O
['Physiological-Clinical']

We O
hypothesized O
that O
an O
early O
positron O
emission O
tomography O
( O
PET O
) O
scan O
could O
be O
used O
to O
adapt O
treatment O
. O
[]

Working B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
of O
the O
non-ASD O
group O
was O
unaffected O
by O
propranolol/placebo O
administration O
. O
['Life-Impact']

17 O
minutes O
vs O
38 O
? O
[]

Reintervention O
rates O
were O
higher O
in O
the O
transcervical O
hysteroscopic O
endometrial O
resection O
group O
, O
although O
postoperative O
pain O
was O
not O
significantly O
different O
between O
the O
two O
groups O
. O
['Resource-use']

Using O
single O
subject O
research O
design O
, O
we O
performed O
pilot O
research O
to O
evaluate O
the O
safety O
and O
efficacy O
of O
famotidine O
for O
the O
treatment O
of O
children O
with O
autistic O
spectrum O
disorders O
. O
[]

OBJECTIVES O
Cardiopulmonary O
bypass O
( O
CPB O
) O
is O
known O
to O
cause O
the O
systemic O
inflammatory O
reaction O
after O
cardiac O
surgery O
. O
[]

Randomized O
, O
controlled O
study O
of O
various O
agents O
for O
endoscopic O
injection O
sclerotherapy O
of O
bleeding O
canine O
gastric O
varices O
. O
[]

Sixty-one O
patients O
( O
mean O
age O
, O
41 O
years O
) O
with O
nonspecific O
low O
back O
pain O
were O
randomized O
into O
two O
subgroups O
by O
treatment O
. O
[]

The O
patients O
were O
randomly O
assigned O
to O
receive O
oral O
EHDP O
5 O
mg/kg/d O
or O
placebo O
until O
death O
or O
discontinuation O
due O
to O
intolerance O
or O
refusal O
. O
[]

2 O
) O
=0.98 O
, O
p=.32 O
) O
. O
[]

Evidence-based O
use O
of O
this O
drug O
is O
increasingly O
important O
as O
trimethoprim-sulfamethoxazole O
resistance O
among O
uropathogens O
increases O
. O
[]

CONCLUSIONS O
The O
diagnostic O
accuracy O
and O
safety O
of O
adenosine O
thallium-201 O
myocardial O
perfusion O
imaging O
are O
generally O
similar O
in O
women O
and O
men O
. O
[]

Lipid-lowering O
therapy O
now O
has O
undoubtedly O
proven O
to O
be O
an O
effective O
therapeutic O
modality O
to O
retard O
the O
progression O
of O
coronary O
atherosclerosis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Metabolic B-outcome ['Physiological-Clinical']
and O
cardiovascular B-outcome ['Physiological-Clinical']
effects O
of O
4 O
mg O
oral O
salbutamol O
were O
studied O
in O
ten O
non-diabetic O
, O
ten O
chemical O
diabetic O
and O
five O
juvenile O
diabetic O
women O
in O
late O
pregnancy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Single O
and O
combined O
effects O
of O
atropine O
and O
metoclopramide O
on O
the O
lower O
oesophageal O
sphincter O
pressure O
. O
[]

STUDY O
DESIGN O
AND O
PATIENTS O
Placebo- O
controlled O
, O
randomized O
, O
and O
double-masked O
study O
on O
hospitalized O
patients O
with O
ocular O
hypertension O
or O
glaucoma O
. O
[]

The O
primary O
outcome O
measures O
were O
the O
proportions O
of O
patients O
achieving O
BP B-outcome ['Physiological-Clinical']
, O
TC B-outcome ['Physiological-Clinical']
, O
and O
BP/TC B-outcome ['Physiological-Clinical']
therapeutic I-outcome ['Physiological-Clinical']
goals I-outcome ['Physiological-Clinical']
( O
BP O
lower O
than O
140/90 O
mm O
Hg O
for O
patients O
with O
uncomplicated O
hypertension O
and O
lower O
than O
130/80 O
mm O
Hg O
for O
patients O
with O
diabetes O
, O
chronic O
kidney O
disease O
, O
or O
history O
of O
myocardial O
infarction O
or O
stroke O
; O
TC O
lower O
than O
200 O
mg O
per O
dL O
for O
patients O
without O
CVD O
and O
lower O
than O
175 O
mg O
per O
dL O
for O
patients O
with O
CVD O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Secondary O
outcomes O
included O
ratings O
of O
pain O
and O
sleep O
quality O
as O
well O
as O
the O
ability O
to O
perform O
daily O
activities O
( O
Ambulatory O
Post O
Acute O
Care O
Daily O
Activities O
Short O
Form O
) O
, O
quality O
of O
life O
( O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
) O
, O
and O
fatigue O
( O
Functional O
Assessment O
of O
Cancer O
Therapy-Fatigue O
) O
. O
[]

CONCLUSION O
( O
1 O
) O
Serum O
level O
of O
sCD44v6 O
could O
be O
taken O
as O
the O
criterion O
for O
evaluating O
the O
development O
and O
prognosis O
of O
gastric B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
, O
as O
well O
as O
the O
therapeutic O
target O
for O
anti-metastasis O
treatment O
; O
( O
2 O
) O
Serum O
level O
of O
sCD44v6 O
is O
related O
to O
some O
extent O
with O
TCM O
type O
of O
blood B-outcome ['Physiological-Clinical']
stasis I-outcome ['Physiological-Clinical']
and O
Pi-deficiency B-outcome ['Physiological-Clinical']
; O
( O
3 O
) O
WTC O
combined O
with O
chemotherapy O
could O
further O
inhibit O
the O
expression O
of O
serum B-outcome ['Physiological-Clinical']
sCD44v6 I-outcome ['Physiological-Clinical']
in O
gastric O
carcinoma O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Therefore O
, O
[]

Comparison O
of O
antiresorptive O
activities O
of O
ipriflavone O
, O
an O
isoflavone O
derivative O
, O
and O
elcatonin O
, O
an O
eel O
carbocalcitonin O
. O
[]

The O
effect O
of O
this O
treatment O
continues O
after O
one O
year O
. O
[]

Costs O
were O
based O
on O
study O
drug O
usage O
and O
hospitalisation O
in O
the O
6-month O
follow-up O
. O
[]

Adjusted O
total O
body B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
calcium O
group O
at O
6 O
months O
( O
2.0 O
% O
) O
, O
12 O
months O
( O
2.5 O
% O
) O
, O
18 O
months O
( O
4.6 O
% O
) O
, O
and O
24 O
months O
( O
3.7 O
% O
) O
, O
respectively O
( O
all O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
Mode O
of O
ventilation O
during O
CPB O
did O
not O
affect O
immediate O
postbypass O
oxygenation O
. O
[]

Orlistat O
can O
promote O
significant O
weight O
loss B-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
obese O
patients O
with O
heart O
failure O
, O
as O
measured O
by O
6-minute O
walk O
test O
and O
functional O
capacity O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
pilot O
study O
began O
in O
1993 O
, O
and O
recruitment O
ended O
in O
1998 O
. O
[]

Effect O
of O
treatment O
with O
paromomycin O
on O
endotoxemia B-outcome ['Physiological-Clinical']
in O
patients O
with O
alcoholic O
liver O
disease O
-- O
a O
double-blind O
, O
placebo-controlled O
trial O
. O
['Physiological-Clinical']

A O
secondary O
data O
analysis O
from O
that O
study O
suggested O
that O
cigarette B-outcome ['Life-Impact']
smoking I-outcome ['Life-Impact']
is O
also O
significantly O
decreased O
by O
fluoxetine O
, O
but O
the O
magnitude O
of O
the O
decrease O
is O
limited O
and O
few O
of O
these O
patients O
totally O
quit O
smoking O
with O
fluoxetine O
treatment O
alone O
. O
['Life-Impact']

A O
primary O
outcome O
measure O
of O
structural B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
and O
secondary O
outcome O
measures O
of O
narrative B-outcome ['Life-Impact']
, O
parent-reported O
pragmatic B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
, O
blind-rated O
perceptions O
of O
conversational B-outcome ['Life-Impact']
competence I-outcome ['Life-Impact']
and O
teacher-reported O
ratings O
of O
classroom B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
were O
taken O
pre-intervention O
, O
immediately O
post-intervention O
and O
at O
6-month O
follow-up O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Three O
patients O
complained O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
not O
related O
to O
treatment O
: O
two O
on O
placebo O
and O
one O
on O
ketorolac O
10 O
mg O
. O
['Adverse-effects']

All O
patients O
were O
sensitive O
to O
either O
birch O
or O
grass O
pollen O
, O
their O
sensitivity O
being O
confirmed O
by O
a O
skin O
prick O
test O
. O
[]

Significant O
thrombolysis B-outcome ['Physiological-Clinical']
occurred O
in O
71.4 O
% O
of O
21 O
patients O
treated O
with O
streptokinase O
and O
in O
23.8 O
% O
of O
the O
21 O
heparin-treated O
patients O
. O
['Physiological-Clinical']

Primary O
outcomes O
are O
performance O
for O
each O
case O
design O
in O
a O
standardized O
fifteen O
item O
clinical B-outcome ['Life-Impact']
reasoning I-outcome ['Life-Impact']
assessment O
, O
integrated O
into O
each O
VP O
, O
which O
is O
identical O
for O
each O
topic O
. O
['Life-Impact']

The O
treatment O
was O
given O
once O
a O
day O
, O
and O
30 O
days O
made O
one O
session O
. O
[]

DESIGN O
Twenty-four O
BMT O
patients O
were O
randomly O
assigned O
to O
receive O
either O
standard O
PN O
containing O
conventional O
amounts O
of O
dextrose O
, O
amino O
acids O
, O
micronutrients O
, O
and O
lipid O
( O
120 O
kJ/d O
) O
or O
a O
solution O
containing O
only O
micronutrients O
( O
identical O
to O
those O
in O
standard O
PN O
) O
and O
a O
small O
amount O
of O
lipid O
( O
12 O
kJ/d O
) O
. O
[]

The O
effect O
of O
RRR-AT O
and O
all-rac-AT O
at O
doses O
of O
100 O
, O
200 O
, O
400 O
, O
and O
800 O
IU/d O
on O
plasma O
and O
LDL O
AT O
levels O
and O
LDL O
oxidation O
was O
tested O
in O
a O
randomized O
, O
placebo-controlled O
study O
of O
79 O
healthy O
subjects O
. O
[]

We O
aimed O
to O
determine O
whether O
the O
myocardial B-outcome ['Physiological-Clinical']
extracellular I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ECV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
measured O
using O
T1 B-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
obtained O
during O
cardiac O
magnetic O
resonance O
imaging O
were O
increased O
in O
patients O
treated O
with O
anthracyclines O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Outcome O
measures O
were O
completed O
preoperatively O
and O
at O
three O
, O
six O
, O
twelve O
, O
eighteen O
, O
and O
twenty-four O
months O
after O
surgery O
. O
[]

Use O
of O
granulocyte-macrophage O
colony-stimulating O
factor O
and O
erythropoietin O
in O
combination O
after O
autologous O
marrow O
transplantation O
. O
[]

Antibodies B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
rHCNTF I-outcome ['Physiological-Clinical']
were O
observed O
in O
sera O
of O
most O
patients O
tested O
after O
2 O
weeks O
of O
continuous O
treatment O
and O
4 O
weeks O
' O
withdrawal O
period O
. O
['Physiological-Clinical']

These O
findings O
support O
further O
evaluation O
of O
allopurinol O
as O
a O
preventive O
measure O
after O
stroke O
. O
[]

A O
double-blind O
, O
placebo-controlled O
study O
. O
[]

To O
investigate O
whether O
L-carnitine O
might O
be O
of O
benefit O
in O
Rett O
syndrome O
, O
a O
randomized O
, O
placebo-controlled O
, O
double-blind O
crossover O
trial O
of O
L-carnitine O
has O
been O
completed O
in O
35 O
subjects O
. O
[]

The O
stage O
IIc O
and O
III O
shows O
an O
evident O
enhancement O
in O
contrast O
media O
in O
MRI O
. O
[]

After O
simvastatin O
treatment O
( O
40 O
mg/day O
) O
alone O
for O
12 O
weeks O
, O
serum O
total O
and O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
decreased O
by O
31 O
and O
36 O
percent O
respectively O
. O
['Physiological-Clinical']

OBJECTIVES O
The O
technique O
of O
choice O
for O
myocardial O
revascularization O
in O
elderly O
patients O
remains O
a O
debated O
issue O
. O
[]

A O
value O
of O
P O
< O
or O
= O
.05 O
was O
considered O
significant O
. O
[]

We O
tested O
these O
hypotheses O
in O
a O
'clinician-blind O
' O
, O
prospective O
, O
randomised O
controlled O
trial O
. O
[]

We O
interviewed O
study O
participants O
every O
4 O
months O
for O
2 O
years O
to O
assess O
psychiatric B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
functional B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
, O
and O
we O
collected O
continuous O
measures O
of O
prescribed O
medications O
, O
service O
utilization O
, O
and O
other O
costs O
. O
['Physiological-Clinical', 'Life-Impact']

We O
conclude O
that O
B O
vitamins O
may O
decrease O
the O
plasma O
level O
of O
A O
beta O
40 O
and O
have O
a O
role O
in O
the O
prevention O
of O
AD O
. O
[]

METHODS O
The O
response O
to O
honey-bee O
stings O
was O
assayed O
with O
a O
measurement O
of O
the O
size O
of O
the O
resulting O
weal O
. O
[]

Secondary O
outcome O
measures O
included O
changes O
in O
plasma B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
, O
A1C B-outcome ['Physiological-Clinical']
, O
fasting B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
, O
and O
anthropometric B-outcome ['Physiological-Clinical']
measures O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Most O
external O
defibrillation O
paddles O
are O
rectangular O
in O
shape O
and O
can O
, O
therefore O
, O
be O
placed O
in O
a O
transverse O
or O
longitudinal O
orientation O
. O
[]

The O
study O
was O
performed O
by O
collaboration O
with O
The O
National O
Institute O
of O
Research O
and O
Development O
in O
Pathology O
and O
Biomedical O
Sciences- O
V. O
Babes O
-Bucharest O
. O
[]

CONCLUSIONS O
The O
study O
suggests O
a O
beneficial O
effect O
of O
risperidone O
after O
several O
months O
of O
treatment O
, O
enhancing O
divided O
attention O
in O
children O
with O
pervasive O
developmental O
disorders O
. O
[]

METHODS O
Seventeen O
sedentary O
adults O
aged O
> O
or=55 O
years O
with O
insomnia O
( O
mean O
age O
61.6 O
[ O
SD?4.3 O
] O
years O
; O
16 O
female O
) O
participated O
in O
a O
randomized O
controlled O
trial O
comparing O
16 O
weeks O
of O
aerobic O
physical O
activity O
plus O
sleep O
hygiene O
to O
non-physical O
activity O
plus O
sleep O
hygiene O
. O
[]

All O
six O
criterion O
measures O
were O
characterized O
by O
significant O
changes O
over O
time O
for O
the O
entire O
group O
( O
n O
= O
45 O
; O
time O
main O
effect O
; O
p O
< O
0.01 O
) O
, O
as O
follows O
: O
pain B-outcome ['Physiological-Clinical']
and O
medication B-outcome ['Resource-use']
intake I-outcome ['Resource-use']
were O
similar O
on O
days O
1 O
and O
2 O
, O
but O
were O
significantly O
less O
on O
day O
3 O
, O
and O
pulmonary B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
were O
significantly O
lower O
than O
preoperatively O
on O
day O
1 O
, O
decreased O
further O
on O
day O
2 O
, O
and O
despite O
an O
improvement O
on O
day O
3 O
, O
remained O
significantly O
lower O
than O
preoperative O
values O
( O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

Markers O
of O
bone B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
were O
studied O
before O
therapy O
and O
after O
6 O
months O
. O
['Physiological-Clinical']

The O
objective O
of O
this O
study O
was O
to O
determine O
how O
predictive O
blood B-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
and O
folate B-outcome ['Life-Impact']
intakes I-outcome ['Life-Impact']
are O
of O
each O
other O
in O
a O
sample O
of O
well-educated O
lactating O
Canadian O
women O
exposed O
to O
high O
levels O
of O
synthetic O
folate O
. O
['Physiological-Clinical', 'Life-Impact']

Our O
results O
indicate O
that O
when O
community O
pharmacists O
in O
a O
clinic O
setting O
are O
trained O
and O
included O
as O
members O
of O
the O
primary O
care O
team O
, O
significant O
improvements O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
quality O
of O
life O
, O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
can O
be O
achieved O
. O
['Physiological-Clinical', 'Life-Impact']

The O
effect O
of O
fasting O
on O
total O
serum B-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
To O
assess O
whether O
or O
not O
standard-dose O
lansoprazole O
( O
30 O
mg O
o.d O
. O
) O
[]

890/2121 O
patients O
( O
42 O
% O
) O
presented O
with O
an O
acute O
coronary O
syndrome O
( O
ACS O
) O
. O
[]

Equilibration O
of O
creatinine B-outcome ['Physiological-Clinical']
and O
urea B-outcome ['Physiological-Clinical']
was O
slower O
and O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
lower O
with O
glycerol O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
conclude O
that O
effective O
normalisation O
of O
hypercholesterolaemia B-outcome ['Physiological-Clinical']
may O
retard O
the O
progression O
of O
diabetic B-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Objective O
pain O
scale O
score O
and O
need O
for O
supplemental O
analgesia O
were O
used O
to O
evaluate O
analgesia O
during O
the O
first O
24 O
h O
postoperatively O
. O
[]

RESULTS O
One O
hundred O
one O
patients O
( O
51 O
in O
enalapril O
group O
and O
50 O
in O
indapamide O
group O
) O
completed O
the O
study O
. O
[]

No O
significant O
variation O
was O
found O
in O
bronchial B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
methacholine I-outcome ['Physiological-Clinical']
and O
ultrasonically O
nebulized B-outcome ['Physiological-Clinical']
distilled I-outcome ['Physiological-Clinical']
water B-outcome ['Physiological-Clinical']
( O
UNDW O
) O
and O
in O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Lack O
of O
effect O
of O
warfarin O
on O
the O
restenosis B-outcome ['Physiological-Clinical']
rate O
or O
on O
clinical O
outcome O
after O
balloon O
coronary O
angioplasty O
. O
['Physiological-Clinical']

The O
parameters O
investigated O
were O
the O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( O
leucocytes B-outcome ['Physiological-Clinical']
, O
granulocytes B-outcome ['Physiological-Clinical']
, O
lymphocytes B-outcome ['Physiological-Clinical']
, O
monocytes B-outcome ['Physiological-Clinical']
, O
thrombocytes B-outcome ['Physiological-Clinical']
, O
hemoglobin B-outcome ['Physiological-Clinical']
, O
hematocrit B-outcome ['Physiological-Clinical']
) O
and O
the O
incidence O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Subjects O
were O
randomized O
into O
a O
leg O
exercise O
group O
( O
n O
= O
32 O
) O
or O
an O
arm O
exercise O
group O
( O
n O
= O
31 O
) O
. O
[]

Gingival B-outcome ['Physiological-Clinical']
overgrowth I-outcome ['Physiological-Clinical']
was O
assessed O
in O
a O
blinded O
fashion O
and O
scored O
in O
a O
previously O
validated O
manner O
. O
['Physiological-Clinical']

Outcome O
measures O
are O
pain B-outcome ['Physiological-Clinical']
, O
function B-outcome ['Life-Impact']
, O
overall B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
, O
cardiovascular B-outcome ['Physiological-Clinical']
ability I-outcome ['Physiological-Clinical']
and O
activity B-outcome ['Life-Impact']
level O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Both O
groups O
exhibited O
similar O
improvements O
in O
dietary B-outcome ['Life-Impact']
practices I-outcome ['Life-Impact']
with O
respect O
to O
intake O
of O
carbohydrate O
, O
fats O
and O
sweets O
, O
while O
the O
VBC O
group O
had O
a O
significant O
increase O
in O
consumption O
of O
green B-outcome ['Life-Impact']
vegetables I-outcome ['Life-Impact']
and O
a O
significant O
decrease O
in O
fruit B-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

A O
therapeutic O
trial O
] O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
30 I-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
was O
the O
main O
outcome O
measure O
. O
['Physiological-Clinical']

IMPACT O
By O
shortening O
the O
time O
to O
and O
increasing O
the O
proportion O
of O
patients O
with O
diagnostic O
resolution O
patient O
navigation O
could O
reduce O
disparities O
in O
stage O
at O
diagnosis O
and O
improve O
cancer O
outcomes O
. O
[]

The O
participants O
received O
risperidone O
monotherapy O
from O
0.5 O
to O
3.5 O
mg/day O
( O
with O
switch O
to O
aripiprazole O
if O
risperidone O
was O
ineffective O
) O
. O
[]

METHODS O
Patients O
were O
treated O
with O
weekly O
bolus O
5-fluorouracil O
( O
5-FU O
) O
and O
leucovorin O
( O
FL O
; O
Roswell O
Park O
Regimen O
) O
or O
the O
same O
regimen O
plus O
oxaliplatin O
( O
FLOX O
) O
. O
[]

Radiotherapy O
in O
the O
head O
and O
neck O
region O
and O
chemotherapy O
might O
give O
rise O
to O
oral O
mucositis O
which O
is O
a O
severe O
and O
painful O
inflammation O
. O
[]

Patients O
in O
the O
treatment O
group O
were O
treated O
with O
massage O
combined O
CMM O
footbath O
fumigation O
and O
washing O
, O
while O
those O
in O
the O
control O
group O
were O
treated O
with O
oral O
administration O
of O
meloxicam O
. O
[]

Mechanisms O
underlying O
the O
lack O
of O
effect O
of O
implantable O
cardioverter-defibrillator O
therapy O
on O
mortality B-outcome ['Mortality']
in O
high-risk O
patients O
with O
recent O
myocardial O
infarction O
: O
insights O
from O
the O
Defibrillation O
in O
Acute O
Myocardial O
Infarction O
Trial O
( O
DINAMIT O
) O
. O
['Mortality']

METHODS O
Sixty-eight O
women O
premedicated O
with O
midazolam O
were O
randomly O
allocated O
to O
coinduction O
with O
intravenous O
clonidine O
( O
group O
C O
) O
or O
placebo O
( O
group O
P O
) O
in O
this O
prospective O
, O
double-blind O
study O
. O
[]

Most O
migration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
TM I-outcome ['Physiological-Clinical']
components I-outcome ['Physiological-Clinical']
( O
n O
= O
24 O
) O
occurred O
within O
the O
first O
3 O
months O
after O
surgery O
whereas O
migration O
of O
the O
Ti O
components O
( O
n O
= O
22 O
) O
appeared O
to O
stabilize O
first O
after O
1 O
year O
. O
['Physiological-Clinical']

70.4 O
kg O
, O
respectively O
; O
p O
= O
0.99 O
) O
. O
[]

The O
swimmers O
also O
knowingly O
consumed O
varying O
doses O
of O
caffeine O
in O
some O
time O
trials O
. O
[]

Five O
patients O
displayed O
loss O
of O
one O
allele O
[]

We O
report O
characteristics O
of O
a O
representative O
sample O
( O
N O
= O
2,324 O
) O
of O
beachgoers O
in O
Southeastern O
New O
England O
during O
the O
summer O
of O
1995 O
. O
[]

Sequential O
methotrexate O
( O
Mtx O
) O
absorption O
studies O
were O
undertaken O
in O
127 O
children O
undergoing O
treatment O
for O
childhood O
non-T O
acute O
lymphoblastic O
leukaemia O
( O
ALL O
) O
to O
determine O
whether O
serum O
drug O
concentration O
, O
clearance O
and O
dosage O
affect O
event O
free O
survival B-outcome ['Mortality']
( O
EFS O
) O
. O
['Mortality']

Moderate O
CRI O
is O
defined O
as O
estimated O
glomerular O
filtration O
rate O
( O
GFR O
) O
of O
30 O
to O
59.9 O
mL/min/1.73 O
m2 O
at O
baseline O
. O
[]

METHODS O
Children O
with O
autism O
and O
typically O
developed O
children O
participated O
in O
one O
of O
two O
experiments O
. O
[]

Safety O
and O
tolerability B-outcome ['Life-Impact']
were O
assessed O
, O
as O
well O
as O
measures O
of O
function O
, O
muscle B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
and O
endurance B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
pharmacokinetics O
for O
NVP O
, O
RTV O
and O
d4T O
were O
similar O
to O
those O
of O
previously O
reported O
data O
. O
[]

The O
current O
study O
assesses O
whether O
COMET O
is O
also O
an O
effective O
intervention O
for O
patients O
with O
depressive O
disorders O
. O
[]

Subjects O
were O
videotaped O
performing O
the O
skill O
before O
and O
after O
the O
training O
and O
three O
experts O
evaluated O
these O
performances B-outcome ['Life-Impact']
independently O
using O
a O
7-point O
rating O
scale O
. O
['Life-Impact']

Patients O
were O
randomized O
to O
receive O
intravenous O
CDP571 O
10 O
mg/kg O
or O
placebo O
8-weekly O
through O
to O
week O
32 O
. O
[]

Fluid B-outcome ['Physiological-Clinical']
intake I-outcome ['Physiological-Clinical']
was O
similar O
in O
infants O
receiving O
diuretics O
and O
placebo O
. O
['Physiological-Clinical']

Increased O
pulmonary O
iNOS B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

PURPOSE O
The O
aim O
of O
this O
randomized O
, O
controlled O
, O
blinded O
clinical O
study O
was O
to O
compare O
ridge B-outcome ['Physiological-Clinical']
dimensions I-outcome ['Physiological-Clinical']
and O
histologic B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ridges I-outcome ['Physiological-Clinical']
preserved O
with O
2 O
different O
graft O
materials O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Secondary O
outcomes O
were O
CG B-outcome ['Physiological-Clinical']
burden I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
bother I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
intervention I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
median O
( O
25th O
and O
75th O
percentiles O
) O
annual O
change O
in O
BMD B-outcome ['Physiological-Clinical']
was O
0.6 O
( O
-0.1 O
, O
2.1 O
% O
) O
in O
the O
treated O
group O
and O
-1.4 O
( O
-1.9 O
, O
1.6 O
% O
) O
in O
the O
control O
group O
. O
['Physiological-Clinical']

Secondary O
endpoints O
include O
the O
proportion O
of O
subjects O
achieving O
a O
glycated O
hemoglobin O
A1c O
value O
of O
< O
7 O
% O
, O
change O
from O
baseline O
in O
fasting O
plasma O
glucose O
and O
postprandial O
glucose O
( O
as O
part O
of O
an O
oral O
glucose O
tolerance O
test O
) O
, O
body O
weight O
, O
and O
blood O
pressure O
. O
[]

Cold O
compress O
combined O
with O
ATs O
or O
EH O
had O
a O
similar O
cooling O
effect O
( O
P O
> O
0.05 O
) O
. O
[]

Patients O
in O
intensive O
glucose O
control O
group O
( O
n=121 O
) O
received O
continuous O
insulin O
infusion O
to O
maintain O
glucose O
levels O
between O
4.4 O
m O
mol/l O
( O
80 O
mg/dl O
) O
and O
6.1 O
m O
mol/l O
( O
110 O
mg/dl O
) O
. O
[]

Using O
a O
set O
of O
objective O
diagnostic O
criteria O
, O
we O
saw O
a O
significant O
difference O
in O
the O
incidence O
of O
the O
syndrome B-outcome ['Physiological-Clinical']
between O
corticosteroid- O
( O
0 O
of O
21 O
) O
and O
placebo-treated O
patients O
( O
9 O
of O
41 O
) O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

MATERIAL O
AND O
METHODS O
A O
low-risk O
population O
of O
4196 O
cases O
was O
selected O
in O
which O
cord O
complications O
have O
been O
recognized O
in O
34.3 O
% O
. O
[]

Hypomagnesemia O
was O
defined O
by O
serum O
magnesium O
concentration O
?1.8 O
mg/dL O
. O
[]

RESULTS O
The O
GPs O
of O
intervention O
patients O
were O
more O
satisfied B-outcome ['Life-Impact']
when O
compared O
to O
the O
GPs O
receiving O
a O
standard O
level O
of O
communication O
( O
96.4 O
% O
vs O
48.3 O
% O
of O
the O
intervention O
and O
control O
GPs O
, O
respectively O
, O
described O
the O
communication O
as O
good O
or O
extremely O
good O
, O
P O
= O
0.0001 O
) O
. O
['Life-Impact']

With O
the O
passage O
of O
time O
the O
effect O
of O
the O
intervention O
decreased O
in O
both O
groups O
. O
[]

PURPOSE O
Internal O
stenting O
is O
an O
integral O
part O
of O
endopyelotomy O
. O
[]

Morbidity O
was O
estimated O
from O
the O
number O
of O
days O
patients O
were O
unable O
to O
work O
due O
to O
illness O
, O
number O
of O
days O
hospitalized O
and O
AIDS O
events O
. O
[]

Twenty-four O
hours O
after O
the O
last O
dose O
in O
the O
15-day O
multiple-dose O
cohort O
, O
100 O
, O
300 O
, O
and O
600 O
mg O
once O
daily O
reduced O
urinary B-outcome ['Physiological-Clinical']
C-terminal I-outcome ['Physiological-Clinical']
telopeptide I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
type O
I O
['Physiological-Clinical']

In O
these O
patients O
with O
normal O
or O
near-normal O
resting O
left O
ventricular O
function O
, O
neither O
drug O
induced O
depression O
of O
left O
ventricular O
function O
. O
[]

The O
program O
lasted O
12 O
weeks O
, O
consisted O
of O
1 O
1/2 O
hours O
meeting O
once O
a O
week O
, O
including O
group O
meetings O
and O
home O
visit O
monitoring O
. O
[]

The O
primary O
end O
point O
was O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
; O
secondary O
end O
points O
included O
6-month O
and O
1-year O
survival B-outcome ['Mortality']
rates O
, O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
response O
rate O
, O
safety O
, O
and O
quality O
of O
life O
. O
['Mortality', 'Mortality', 'Mortality']

Group O
2 O
received O
propofol O
2 O
mg/kg O
i.v. O
, O
followed O
by O
0.5 O
% O
to O
1.5 O
% O
enflurane O
and O
67 O
% O
N2O O
in O
O2 O
. O
[]

LDL O
, O
isolated O
before O
and O
after O
treatment O
was O
subjected O
to O
copper-catalysed O
lipid O
peroxidation O
. O
[]

Plasma O
PCSK9 O
levels O
were O
higher O
in O
double-dose O
statin O
than O
in O
ezetimibe-plus-statin O
at O
12 O
weeks O
, O
but O
similar O
at O
52 O
weeks O
. O
[]

Investigations O
into O
the O
potential O
effects O
of O
multiple O
dose O
ketorolac O
on O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
and O
pharmacodynamics B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
racemic I-outcome ['Physiological-Clinical']
warfarin I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
its O
add-on O
to O
risperidone O
also O
results O
in O
significantly O
increased O
appetite O
and O
weight O
gain O
. O
[]

One O
group O
received O
risperidone O
plus O
amantadine O
, O
and O
the O
other O
group O
received O
risperidone O
plus O
placebo O
. O
[]

OBJECTIVES O
The O
purpose O
of O
this O
study O
was O
to O
prospectively O
investigate O
the O
influence O
of O
ventricular O
fibrillation O
( O
VF O
) O
durations O
of O
5 O
, O
10 O
and O
20 O
s O
on O
the O
defibrillation B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DFT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
during O
implantable O
cardioverter-defibrillator O
( O
ICD O
) O
implantation O
. O
['Physiological-Clinical']

We O
tested O
the O
efficacy O
and O
safety O
of O
adding O
ganitumab O
to O
endocrine O
treatment O
for O
patients O
with O
hormone-receptor-positive O
breast O
cancer O
. O
[]

Secondary O
outcomes O
were O
as O
follows O
: O
severity O
of O
immediate B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
as O
graded O
by O
a O
3-point O
scale O
from O
1 O
( O
no O
bleeding O
) O
to O
3 O
( O
injection O
or O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
the O
groups O
in O
the O
proportion O
of O
[]

Enrollment O
criteria O
included O
an O
estimated O
glomerular O
filtration O
rate O
between O
15 O
and O
60 O
mL/min/1.73 O
m2 O
( O
0.25 O
and O
1.00 O
mL/s/1.73 O
m2 O
) O
, O
an O
average O
of O
2 O
consecutive O
intact O
parathyroid O
hormone O
( O
iPTH O
) O
levels O
greater O
than O
150 O
pg/mL O
( O
ng/L O
) O
, O
2 O
consecutive O
serum B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
levels O
between O
8.0 O
and O
10.0 O
mg/dL O
( O
2.00 O
and O
2.50 O
mmol/L O
) O
, O
and O
2 O
consecutive O
serum B-outcome ['Physiological-Clinical']
phosphorus I-outcome ['Physiological-Clinical']
levels O
of O
5.2 O
mg/dL O
or O
less O
( O
< O
or O
= O
1.68 O
mmol/L O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Patients O
receiving O
either O
eltanolone O
or O
propofol O
showed O
similar O
cardiovascular O
changes O
to O
induction O
of O
anesthesia O
, O
although O
there O
were O
greater O
increases O
in O
arterial O
pressure O
and O
HR O
in O
those O
patients O
receiving O
eltanolone O
. O
[]

Fibre-optic O
bronchoscopy O
was O
performed O
in O
21 O
patients O
with O
small B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
bronchogenic I-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
who O
demonstrated O
a O
complete O
radiographic O
regression O
of O
their O
chest O
lesions O
after O
3-4 O
months O
of O
combination O
chemotherapy O
. O
['Physiological-Clinical']

Postoperative O
hemodynamic B-outcome ['Physiological-Clinical']
evaluation I-outcome ['Physiological-Clinical']
revealed O
no O
significant O
differences O
between O
the O
groups O
. O
['Physiological-Clinical']

BACKGROUND O
High-sensitivity O
C-reactive O
protein O
( O
hsCRP O
) O
is O
associated O
with O
adverse O
cardiovascular O
outcomes O
in O
acute O
coronary O
syndromes O
( O
ACS O
) O
. O
[]

Measures O
included O
the O
number O
and O
character B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
each I-outcome ['Physiological-Clinical']
stool I-outcome ['Physiological-Clinical']
and O
weekly O
24-h O
stool B-outcome ['Physiological-Clinical']
specimens I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
and O
oocyst B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Overall O
, O
the O
program O
had O
a O
positive O
effect O
on O
attitudes B-outcome ['Life-Impact']
, O
emotions B-outcome ['Life-Impact']
, O
knowledge B-outcome ['Life-Impact']
and O
awareness O
of O
distress B-outcome ['Life-Impact']
coping I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Skeletal B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
occurs O
during O
marrow O
transplantation O
despite O
total O
parenteral O
nutrition O
. O
['Physiological-Clinical']

Secondary O
outcomes O
included O
thromboembolic B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
and O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Investigator O
Study O
Group O
. O
[]

In O
MRI O
, O
superficial B-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
retraction I-outcome ['Physiological-Clinical']
deficits I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
and O
ischemic B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
in O
the O
territory O
of O
the O
ruptured B-outcome ['Physiological-Clinical']
aneurysm I-outcome ['Physiological-Clinical']
( O
P=0.025 O
) O
were O
more O
frequent O
in O
the O
surgical O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
may O
decrease O
the O
time O
staff O
spend O
inserting O
cannulas B-outcome ['Resource-use']
, O
reduce O
supply B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
, O
and O
improve O
patient O
satisfaction O
. O
['Resource-use', 'Resource-use']

Observations B-outcome ['Physiological-Clinical']
and O
tests O
were O
done O
before O
and O
after O
a O
period O
of O
1 O
year O
. O
['Physiological-Clinical']

2 O
) O
What O
is O
the O
relationship O
between O
the O
dependent O
variables O
-- O
oxygenation O
saturation O
levels O
, O
blood O
pressure O
, O
pulse O
and O
respiration O
-- O
and O
the O
independent O
variables O
-- O
body O
position O
and O
time O
in O
the O
position O
? O
[]

Dark-phase O
light O
contamination O
disrupts O
circadian O
rhythms O
in O
plasma B-outcome ['Physiological-Clinical']
measures O
of O
endocrine O
physiology B-outcome ['Physiological-Clinical']
and O
metabolism B-outcome ['Physiological-Clinical']
in O
rats O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
4,178 O
steers O
( O
mean O
initial O
BW O
= O
403.9 O
? O
[]

When O
baseline O
scores O
were O
controlled O
, O
there O
were O
no O
significant O
differences O
in O
change O
scores O
of O
cognitive B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
over O
eight O
weeks O
between O
the O
two O
groups O
. O
['Life-Impact']

DESIGN O
Randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
trial O
. O
[]

The O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
response O
['Physiological-Clinical']

Bone O
and O
lung O
were O
the O
major O
sites O
of O
distant O
relapse O
, O
but O
the O
addition O
of O
bilateral O
pulmonary O
RT O
showed O
no O
[]

Poylmerized O
whole O
ragweed O
: O
an O
improved O
method O
of O
immunotherapy O
. O
[]

More O
patients O
in O
the O
intervention O
group O
had O
returned B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
at O
T O
( O
2 O
) O
( O
P O
< O
0.001 O
) O
and O
did O
so O
more O
quickly O
( O
P O
< O
0.01 O
) O
. O
['Life-Impact']

In O
the O
chemotherapy O
arm O
, O
the O
10-year O
SFL O
rate O
was O
8.7 O
% O
. O
[]

Thus O
acute O
maternal B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
infusion I-outcome ['Physiological-Clinical']
in O
normal O
patients O
can O
cause O
fetal B-outcome ['Physiological-Clinical']
hyperglycemia I-outcome ['Physiological-Clinical']
, O
metabolic B-outcome ['Physiological-Clinical']
acidosis I-outcome ['Physiological-Clinical']
, O
and O
neonatal B-outcome ['Physiological-Clinical']
hypoglycemia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Specifically O
, O
we O
aim O
to O
investigate O
the O
effects O
of O
a O
12-month O
exercise O
program O
designed O
to O
load O
the O
musculoskeletal O
system O
and O
reduce O
cardiovascular O
and O
diabetes O
disease O
progression O
on O
the O
following O
primary O
endpoints O
: O
1 O
) O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density O
; O
2 O
) O
cardiorespiratory B-outcome ['Physiological-Clinical']
function B-outcome ['Life-Impact']
and O
maximal B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
capacity B-outcome ['Life-Impact']
; O
3 O
) O
body B-outcome ['Physiological-Clinical']
composition B-outcome ['Physiological-Clinical']
( O
lean B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

1 O
This O
study O
was O
designed O
to O
compare O
in O
a O
randomized O
cross-over O
trial O
pindolol O
, O
a O
beta-adrenoceptor O
blocking O
agent O
with O
intrinsic O
sympathomimetic O
activity O
and O
metoprolol O
, O
a O
cardioselective O
beta-adrenoceptor O
blocker O
lacking O
sympathomimetic O
activity O
in O
hypertensives O
with O
incipient O
heart O
failure O
. O
[]

The O
results O
of O
this O
study O
will O
contribute O
new O
knowledge O
regarding O
alternative O
models O
of O
pulmonary O
rehabilitation O
and O
will O
inform O
pulmonary O
rehabilitation O
guidelines O
for O
COPD O
. O
[]

This O
impairment O
of O
tracheal B-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
is O
an O
important O
factor O
in O
tracheal B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
associated O
with O
intubation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Later O
, O
60 O
older O
adults O
( O
mean O
? O
[]

MRI-derived O
change O
in O
total O
[]

The O
rate O
of O
fatal B-outcome ['Mortality']
pulmonary I-outcome ['Mortality']
hemorrhage I-outcome ['Mortality']
was O
consistent O
with O
previous O
bevacizumab O
trials O
. O
['Mortality']

Eight O
patients O
in O
the O
irinotecan O
arm O
and O
4 O
in O
the O
combination O
arm O
had O
grade O
3/4 O
diarrhoea B-outcome ['Physiological-Clinical']
( O
P=0.24 O
) O
. O
['Physiological-Clinical']

RESULTS O
Compared O
to O
calcium O
mono O
, O
supplementation O
with O
calcium O
plus O
vitamin O
D O
resulted O
in O
a O
significant O
decrease O
in O
the O
number O
of O
subjects O
with O
first B-outcome ['Life-Impact']
falls I-outcome ['Life-Impact']
of O
27 O
% O
at O
month O
12 O
( O
RR O
= O
0.73 O
; O
CI O
= O
0.54-0.96 O
) O
and O
39 O
% O
at O
month O
20 O
( O
RR O
= O
0.61 O
; O
CI O
= O
0.34-0.76 O
) O
. O
['Life-Impact']

RESULTS O
The O
authors O
found O
a O
cumulative O
incidence O
rate O
of O
20.5 O
% O
adjusted O
for O
dropouts O
. O
[]

OBJECTIVE O
We O
evaluated O
in O
a O
manikin O
model O
whether O
using O
the O
single-use O
laryngeal O
tube O
with O
suction O
option O
( O
LTS-D O
) O
instead O
of O
endotracheal O
intubation O
( O
ET O
) O
and O
bag-mask-valve O
ventilation O
( O
BMV O
) O
for O
emergency O
airway O
management O
could O
reduce O
the O
no-flow O
time O
( O
NFT O
) O
. O
[]

However O
, O
the O
differences O
among O
the O
groups O
were O
statistically O
insignificant O
. O
[]

Changes O
in O
the O
hormonal O
milieu O
were O
not O
associated O
with O
recurrence O
. O
[]

Patients O
with O
complete O
symptom B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
then O
entered O
the O
on-demand O
phase O
. O
['Physiological-Clinical']

METHOD O
A O
pragmatic O
randomised O
trial O
was O
performed O
involving O
422 O
patients O
and O
carers O
to O
compare O
a O
brief O
CBT O
intervention O
against O
treatment O
as O
usual O
. O
[]

The O
two O
groups O
were O
well O
balanced O
in O
terms O
of O
age O
( O
median O
= O
55 O
years O
) O
, O
performance O
status O
( O
78 O
% O
P.S O
. O
[]

No O
beneficial O
effects O
of O
CCB O
treatment O
on O
clinical B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
observed O
during O
the O
2-year O
study O
follow-up O
. O
['Physiological-Clinical']

Epidural O
morphine O
in O
the O
elderly O
. O
[]

If O
adjuvant O
treatment O
seems O
to O
delay B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
it O
did O
not O
significantly O
decrease O
the O
recurrence B-outcome ['Physiological-Clinical']
rate O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Overall O
, O
the O
follow-up O
outcome O
is O
far O
from O
reassuring O
, O
whatever O
the O
type O
of O
treatment O
. O
[]

The O
children O
were O
taught O
how O
to O
see O
objects O
in O
context O
by O
reinforcing O
attention O
to O
pivotal O
contextual O
information O
. O
[]

The O
number O
of O
patients O
with O
both O
gastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
less O
than O
2.5 O
and O
gastric B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
greater O
than O
25 O
ml O
was O
significantly O
higher O
in O
Group O
100 O
compared O
to O
Group O
50 O
( O
P O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
four O
blinded O
treatments O
were O
MPA O
2.5 O
mg O
, O
MPA O
5 O
mg O
, O
MPA O
10 O
mg O
and O
matching O
placebo O
, O
taken O
for O
the O
last O
14 O
days O
of O
each O
28 O
day O
treatment O
cycle O
. O
[]

Use O
of O
high-dose O
cytarabine O
to O
enhance O
cisplatin O
cytotoxicity-effects B-outcome ['Physiological-Clinical']
on O
the O
response O
and O
overall O
survival B-outcome ['Mortality']
rates O
of O
advanced O
head O
and O
neck O
cancer O
patients O
. O
['Physiological-Clinical', 'Mortality']

The O
VPW O
was O
studied O
in O
ALI O
patients O
to O
determine O
the O
correlation O
between O
VPW O
and O
intravascular O
pressure O
measurements O
and O
whether O
VPW O
could O
predict O
fluid O
status O
. O
[]

AIM O
Sodium O
acetate O
( O
NaAcetate O
) O
has O
received O
some O
attention O
as O
an O
alkalinizing O
agent O
and O
possible O
alternative O
energy O
source O
for O
the O
horse O
, O
however O
the O
effects O
of O
oral O
administration O
remain O
largely O
unknown O
. O
[]

The O
aim O
was O
to O
compare O
late B-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
, O
urinary B-outcome ['Physiological-Clinical']
, O
and O
sexual B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
after O
CRT O
or O
RT O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Twelve O
patients O
with O
known O
or O
suspected O
pituitary O
lesions O
underwent O
MR O
imaging O
with O
gadodiamide O
injection O
at O
a O
dose O
of O
0.1 O
( O
n O
= O
5 O
) O
or O
0.3 O
( O
n O
= O
7 O
) O
mM/kg O
. O
[]

Buspirone O
20 O
mg O
significantly O
impaired B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
at O
1 O
hour O
compared O
with O
placebo O
. O
['Life-Impact']

The O
Study O
group O
's O
evaluation O
of O
the O
module O
was O
overwhelmingly O
positive O
. O
[]

Treatment O
was O
compatible O
with O
normal O
daily O
activity O
. O
[]

PURPOSE/OBJECTIVES O
Through O
a O
randomized O
clinical O
trial O
, O
to O
compare O
patients O
undergoing O
an O
initial O
course O
of O
chemotherapy O
who O
report O
pain B-outcome ['Physiological-Clinical']
and O
fatigue B-outcome ['Physiological-Clinical']
at O
baseline O
and O
who O
are O
receiving O
conventional O
care O
alone O
with O
those O
receiving O
conventional O
care O
plus O
a O
nursing O
intervention O
on O
outcomes O
reported O
at O
20 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
Cancer B-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CRF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
a O
common O
problem O
for O
cancer O
patients O
across O
diagnoses O
during O
chemotherapy O
and O
is O
associated O
with O
physical O
inactivity O
, O
lower O
functional O
level O
and O
lack O
of O
energy O
. O
['Physiological-Clinical']

We O
have O
measured O
serum B-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
levels O
during O
pyridoxine O
administration O
in O
two O
groups O
of O
hyperprolactinaemic O
subjects O
. O
['Physiological-Clinical']

The O
main O
objective O
of O
this O
study O
was O
to O
assess O
the O
safety O
of O
ferumoxytol O
for O
the O
treatment O
of O
patients O
with O
CKD O
stages O
1 O
to O
5 O
and O
5D O
. O
[]

Netilmicin O
peak O
and O
trough O
serum O
concentrations O
were O
monitored O
and O
netilmicin O
pharmacokinetic O
parameters O
were O
compared O
with O
and O
without O
parenteral O
nutrition O
. O
[]

Peripheral O
arterial O
disease O
( O
PAD O
) O
is O
by O
far O
the O
most O
common O
cause O
of O
intermittent O
claudication O
. O
[]

VRH O
patients O
reported O
less O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
and O
less O
pain B-outcome ['Physiological-Clinical']
unpleasantness I-outcome ['Physiological-Clinical']
compared O
to O
control O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
instruction O
to O
refrain O
from O
blinking O
affects O
auditory B-outcome ['Physiological-Clinical']
P3 I-outcome ['Physiological-Clinical']
and O
N1 B-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Pimecrolimus O
cream O
1 O
% O
is O
approved O
for O
mild O
to O
moderate O
atopic O
dermatitis O
in O
children O
older O
than O
two O
years O
of O
age O
and O
adults O
. O
[]

Seven O
days O
after O
treatment O
ended O
, O
both O
physician O
and O
patient O
judged O
the O
result O
of O
treatment O
using O
a O
second O
categoric O
scale O
( O
no O
improvement O
or O
intermediate O
, O
good O
, O
or O
very O
good O
result O
) O
. O
[]

The O
incidence O
of O
clinical O
sepsis O
was O
comparable O
in O
both O
groups O
( O
intervention O
31.9 O
% O
, O
control O
25.4 O
% O
; O
P=0.392 O
) O
. O
[]

MATERIALS O
AND O
METHODS O
Three O
radiologists O
in O
training O
with O
different O
levels O
of O
experience O
in O
MDCT-CA O
scored O
50 O
cases O
at O
various O
time O
points O
of O
the O
learning O
curve O
: O
baseline O
, O
4 O
weeks O
, O
8 O
weeks O
and O
6 O
months O
. O
[]

We O
developed O
suppositories O
and O
ointment O
with O
30 O
% O
free O
fatty O
acid O
( O
FFA O
) O
extract O
from O
omega-3 O
fish O
oil O
. O
[]

CONCLUSION O
A O
fast O
and O
effective O
onset O
of O
action O
is O
of O
high O
clinical O
relevance O
. O
[]

The O
MVPF O
group O
demonstrated O
a O
39.0 O
per O
cent O
greater O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
after O
application O
of O
the O
dressing O
over O
the O
silver O
sulphadiazine O
group O
. O
['Physiological-Clinical']

To O
define O
the O
current O
efficacy O
of O
Fansidar O
( O
F. O
Hoffmann-La O
Roche O
Ltd. O
, O
Basel O
Switzerland O
) O
( O
pyrimethamine O
and O
sulfadoxine O
) O
, O
primaquine O
in O
a O
high O
dose O
, O
and O
artesunate O
for O
treating O
acute O
Plasmodium O
vivax O
malaria O
, O
we O
conducted O
a O
comparative O
clinical O
trial O
of O
these O
3 O
drugs O
in O
an O
open-label O
study O
. O
[]

Over O
the O
28-day O
follow-up O
period O
, O
GMT B-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
of O
the O
two O
groups O
were O
statistically O
equivalent O
. O
['Physiological-Clinical']

Investigation O
of O
erosion B-outcome ['Physiological-Clinical']
and O
abrasion B-outcome ['Physiological-Clinical']
on O
enamel B-outcome ['Physiological-Clinical']
and O
dentine B-outcome ['Physiological-Clinical']
: O
a O
model O
in O
situ O
using O
toothpastes O
of O
different O
abrasivity O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
916 O
person O
nights O
yielded O
3,009 O
female O
anopheline O
mosquitoes O
between O
6 O
pm O
and O
6 O
am O
. O
[]

Supplementation O
with O
n3 O
FAEEs O
improves O
C1 B-outcome ['Physiological-Clinical']
and O
C2 B-outcome ['Physiological-Clinical']
independently O
of O
weight O
loss B-outcome ['Physiological-Clinical']
in O
obese O
adults O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
investigated O
the O
C1772T O
polymorphism O
in O
colorectal O
cancer O
patients O
and O
healthy O
control O
subjects O
to O
clarify O
the O
mechanism O
of O
HIF-1alpha O
activation O
in O
colorectal O
carcinoma O
. O
[]

Effect O
of O
negative O
air O
ionization O
on O
hyperactive O
and O
autistic O
children O
. O
[]

The O
IVRS O
system O
facilitated O
data O
collection O
and O
minimized O
inconvenience O
to O
the O
patient O
. O
[]

Based O
on O
these O
experiments O
, O
nomograms O
were O
constructed O
from O
which O
the O
rate O
of O
infusion O
of O
Ringer O
's O
solution O
and O
the O
infusion O
time O
required O
to O
obtain O
a O
defined O
plasma O
dilution O
in O
both O
males O
and O
females O
can O
be O
estimated O
together O
with O
the O
infusion O
rate O
needed O
to O
maintain O
the O
dilution O
at O
the O
level O
reached O
. O
[]

RESULTS O
A O
non-compartmental O
analysis O
resulted O
in O
linear O
kinetics O
of O
bilastine O
in O
the O
dose O
range O
studied O
. O
[]

7 O
% O
) O
but O
not O
for O
those O
receiving O
1 O
?g O
VLP O
immunotherapy/dose O
( O
42 O
% O
? O
[]

There O
was O
a O
group O
by O
time O
by O
attendance O
interaction O
, O
however O
, O
such O
that O
higher O
attendance O
at O
the O
exercise O
intervention O
, O
but O
not O
the O
control O
intervention O
, O
was O
associated O
with O
increased O
WMI O
. O
[]

When O
the O
movement O
and O
tone O
occurred O
together O
this O
anticipatory O
bias O
was O
also O
present O
, O
regardless O
of O
which O
event O
participants O
focused O
on O
. O
[]

METHODS O
Fifty-nine O
children O
, O
aged O
3-5 O
years O
, O
with O
no O
cerebral O
palsy O
, O
participated O
in O
the O
study O
. O
[]

Of O
the O
66 O
patients O
enrolled O
, O
9 O
were O
observed O
for O
one O
month O
or O
less O
; O
7 O
were O
followed O
for O
two O
months O
; O
only O
50 O
patients O
were O
followed O
for O
more O
than O
2 O
months O
and O
could O
be O
adequately O
evaluated O
. O
[]

RESULTS O
The O
trial O
design O
is O
compared O
to O
a O
trial O
without O
adaptive O
randomization O
and O
produces O
an O
efficient O
trial O
in O
which O
a O
higher O
proportion O
of O
patients O
are O
likely O
to O
be O
randomized O
to O
the O
most O
effective O
treatment O
arm O
while O
generally O
using O
fewer O
total O
patients O
and O
offers O
higher O
power O
than O
an O
analogous O
trial O
with O
fixed O
randomization O
when O
identifying O
a O
superior O
treatment O
. O
[]

In O
69 O
artificially O
ventilated O
patients O
the O
clinical B-outcome ['Physiological-Clinical']
, O
bacteriological B-outcome ['Physiological-Clinical']
and O
pharmacological B-outcome ['Physiological-Clinical']
effects O
of O
endotracheally O
administered O
tobramycin O
were O
studied O
in O
comparison O
to O
a O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Children O
with O
autism O
have O
difficulties O
in O
emotion O
recognition O
and O
a O
number O
of O
interventions O
have O
been O
designed O
to O
target O
these O
problems O
. O
[]

It O
could O
be O
a O
new O
modality O
in O
the O
drug O
therapy O
of O
alcoholism O
, O
not O
involving O
an O
antabuse O
effect O
, O
an O
antidepressant O
action O
, O
or O
conditioning O
. O
[]

This O
hypotension B-outcome ['Physiological-Clinical']
may O
complicate O
therapy O
. O
['Physiological-Clinical']

Lowering O
of O
glucose O
in O
critical O
care O
: O
a O
randomized O
pilot O
trial O
. O
[]

Hand O
size O
, O
grip O
strength O
, O
height O
and O
weight O
were O
correlated O
with O
tidal B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
generated O
by O
one-handed O
and O
two-handed O
procedures O
. O
['Physiological-Clinical']

BACKGROUND O
although O
implantable O
cardioverter-defibrillators O
( O
ICDs O
) O
lower O
mortality O
in O
stable O
patients O
with O
low O
ejection O
fraction O
late O
after O
myocardial O
infarction O
, O
randomized O
trials O
of O
ICD O
versus O
control O
subjects O
implanted O
early O
after O
myocardial O
infarction O
do O
not O
show O
mortality O
benefit O
. O
[]

BACKGROUND O
AND O
OBJECTIVES O
Anecdotal O
reports O
on O
the O
efficacy O
of O
secretin O
in O
autism O
raised O
great O
hopes O
for O
the O
treatment O
of O
children O
with O
this O
disorder O
. O
[]

Both O
interventions O
are O
evaluated O
in O
randomised O
controlled O
trials O
using O
clinical O
management O
as O
the O
control O
condition O
. O
[]

This O
7-week O
program O
included O
a O
computer O
game O
, O
small O
group O
sessions O
, O
parent O
training O
sessions O
and O
teacher O
handouts O
. O
[]

METHODS O
Patients O
in O
REFLEX O
were O
originally O
randomized O
to O
placebo O
( O
PBO O
) O
+ O
methotrexate O
( O
MTX O
; O
PBO-randomized O
) O
or O
RTX O
+ O
MTX O
( O
RTX-randomized O
) O
. O
[]

Evaluation O
was O
performed O
in O
each O
group O
at O
baseline O
and O
after O
posterior O
tibial O
nerve O
stimulation O
to O
compare O
clinical O
and O
urodynamic O
findings O
. O
[]

PATIENTS O
AND O
METHODS O
In O
this O
randomized O
crossover O
study O
, O
each O
subject O
received O
two O
single O
standard O
doses O
of O
400 O
mg O
of O
moxifloxacin O
orally O
or O
intravenously O
administered O
on O
two O
occasions O
separated O
by O
a O
washout O
period O
of O
1 O
week O
. O
[]

In O
order O
to O
examine O
the O
effect O
of O
the O
antifibrinolytic O
drug O
tranexemic O
acid O
on O
perioperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
saline O
or O
tranexemic O
acid O
were O
given O
randomized O
double O
blind O
to O
76 O
consecutive O
patients O
who O
came O
for O
scheduled O
thyroid O
surgery O
. O
['Physiological-Clinical']

The O
amplitude O
of O
cerebral B-outcome ['Physiological-Clinical']
potentials I-outcome ['Physiological-Clinical']
evoked I-outcome ['Physiological-Clinical']
by O
thermal/painful O
stimuli O
applied O
on O
the O
arm O
was O
recorded O
nine O
times O
over O
150 O
min O
, O
witnessing O
of O
pain O
integration O
at O
central O
level O
. O
['Physiological-Clinical']

Sensory O
and O
motor O
block O
were O
of O
shorter O
duration O
than O
that O
after O
0.5 O
% O
isobaric O
bupivacaine O
and O
0.5 O
% O
isobaric O
bupivacaine O
with O
morphine O
0.5 O
mg O
( O
P O
< O
0.001 O
sensory O
block O
, O
P O
< O
0.001 O
motor O
block O
) O
. O
[]

Bites O
by O
the O
saw-scaled O
or O
carpet O
viper O
( O
Echis O
carinatus O
) O
: O
trial O
of O
two O
specific O
antivenoms O
. O
[]

Pleural O
effusion O
is O
a O
common O
complication O
in O
patients O
with O
malignant O
neoplasm O
. O
[]

The O
primary O
outcome O
event O
was O
death B-outcome ['Mortality']
or O
dependency O
( O
modified O
Rankin O
Scale O
[ O
mRS O
] O
score O
> O
2 O
) O
at O
3 O
months O
. O
['Mortality']

Follow-up O
data O
including O
adherence O
to O
prasugrel O
therapy O
were O
collected O
by O
telephone O
interviews O
or O
outpatient O
visits O
. O
[]

Data O
were O
collected O
1 O
week O
before O
( O
T1 O
) O
and O
1 O
week O
after O
( O
T2 O
) O
dietary O
intervention O
. O
[]

A O
comparison O
between O
oral O
ciprofloxacin O
and O
intra-peritoneal O
vancomycin O
and O
gentamicin O
in O
the O
treatment O
of O
CAPD B-outcome ['Physiological-Clinical']
peritonitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Acupressure O
at O
the O
extra O
1 O
point O
significantly O
reduced O
[]

In O
the O
present O
study O
we O
intended O
to O
verify O
the O
possibility O
of O
using O
electrofunctional O
techniques O
to O
determine O
the O
two O
distinct O
and O
, O
probably O
, O
consecutive O
glaucomatous B-outcome ['Physiological-Clinical']
alterations I-outcome ['Physiological-Clinical']
occurring I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
ganglion I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
: O
functional B-outcome ['Life-Impact']
( O
reversible B-outcome ['Physiological-Clinical']
) O
and O
anatomical B-outcome ['Physiological-Clinical']
( O
irreversible B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

route O
; O
half O
of O
the O
dose O
was O
injected O
into O
the O
deltoid O
area O
and O
the O
other O
half O
into O
the O
buttocks O
. O
[]

The O
incidence O
of O
ARDS O
due O
to O
pulmonary O
infection O
per O
case O
was O
25.4 O
% O
and O
was O
significantly O
higher O
in O
the O
G-CSF O
group O
( O
p O
< O
0.025 O
, O
chi2 O
test O
) O
. O
[]

All O
were O
receiving O
background O
PAH O
therapy O
; O
12 O
had O
previously O
received O
parenteral O
prostanoid O
. O
[]

[ O
The O
somatostatin O
infusion O
test O
for O
the O
evaluation O
of O
glucose B-outcome ['Physiological-Clinical']
utilization I-outcome ['Physiological-Clinical']
in O
bezafibrate O
medication O
] O
. O
['Physiological-Clinical']

Meanwhile O
, O
the O
peripheral O
hemogram O
was O
detected O
. O
[]

METHODS O
In O
a O
randomized O
crossover O
study O
, O
10 O
healthy O
subjects O
received O
, O
on O
each O
of O
5 O
dosing O
occasions O
, O
MTX O
alone O
as O
tablets O
or O
intravenous O
solution O
, O
HCQ O
alone O
as O
a O
tablet O
or O
oral O
solution O
, O
or O
a O
coadministered O
dose O
of O
MTX O
tablets O
with O
an O
HCQ O
tablet O
. O
[]

METHODS O
To O
study O
the O
ability O
of O
Lactobacillus O
GG O
( O
LGG O
) O
to O
colonize O
the O
neonatal B-outcome ['Physiological-Clinical']
gut I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
modify I-outcome ['Physiological-Clinical']
its I-outcome ['Physiological-Clinical']
microbial I-outcome ['Physiological-Clinical']
ecology I-outcome ['Physiological-Clinical']
, O
a O
prospective O
, O
randomized O
study O
was O
performed O
in O
71 O
preterm O
infants O
of O
less O
than O
2000 O
g O
birth O
weight O
. O
['Physiological-Clinical']

Participants O
( O
N O
= O
211 O
) O
received O
a O
100 O
US O
dollars O
voucher O
on O
the O
last O
day O
of O
detoxification O
either O
contingent O
on O
opiate O
and O
cocaine O
abstinence O
or O
noncontingently O
. O
[]

Subjects O
reported O
reduced O
acceptance O
of O
the O
HMD O
based O
on O
non-ophthalmological O
reasons O
, O
for O
example O
, O
the O
weight O
of O
the O
unit O
or O
the O
length O
of O
the O
cable O
. O
[]

Systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
levels O
decreased O
in O
the O
lean O
fish O
group O
( O
0 O
vs. O
8 O
week O
: O
3.5 O
+/- O
3.2 O
and O
4.6 O
+/- O
3.6 O
% O
, O
respectively O
, O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Treatment O
with O
GnRH O
analogue O
had O
no O
effect O
on O
the O
expression B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
of O
studied O
genes O
. O
['Physiological-Clinical']

If O
the O
pertactin O
value O
was O
> O
or O
= O
7 O
and O
the O
PT O
value O
was O
< O
66 O
EU O
ml-1 O
the O
predicted O
probability O
of O
being O
a O
case O
was O
31 O
% O
( O
15/49 O
) O
. O
[]

A O
total O
of O
138 O
phase O
3 O
( O
year O
4 O
) O
medical O
students O
in O
10 O
two-week O
paediatric O
outpatient O
blocks O
at O
the O
Department O
of O
Child O
Health O
, O
University O
of O
Dundee O
, O
Scotland O
, O
were O
randomized O
to O
student-directed O
or O
structured O
learning O
between O
January O
and O
December O
2002 O
. O
[]

These O
differences O
are O
not O
statistically O
significant O
at O
the O
5 O
% O
level O
. O
[]

Safety O
is O
evaluated O
with O
particular O
focus O
on O
hypoglycemia B-outcome ['Physiological-Clinical']
, O
GI B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
and O
incidence O
['Physiological-Clinical', 'Physiological-Clinical']

In O
a O
double O
blind O
randomized O
study O
, O
epidural O
anesthesia O
was O
carried O
out O
with O
20 O
ml O
bupivacaine O
0.75 O
% O
( O
n O
= O
24 O
) O
and O
ropivacaine O
1 O
% O
( O
n O
= O
21 O
) O
. O
[]

PATIENTS O
AND O
METHODS O
End O
points O
were O
remission B-outcome ['Physiological-Clinical']
rates O
[ O
overall O
response O
( O
OR O
) O
and O
complete O
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
] O
, O
failure-free B-outcome ['Physiological-Clinical']
survival B-outcome ['Mortality']
( O
FFS B-outcome ['Mortality']
) O
, O
survival B-outcome ['Mortality']
and O
toxicity B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Mortality', 'Mortality', 'Adverse-effects']

Between O
November O
1973 O
and O
July O
1982 O
, O
123 O
women O
younger O
than O
70 O
years O
of O
age O
and O
at O
clinical O
Stages O
I O
and O
II O
were O
enrolled O
. O
[]

Clofibrate O
treatment O
coincided O
with O
increasing O
amounts O
of O
monounsaturated B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
, O
especially O
oleate B-outcome ['Physiological-Clinical']
( O
18 O
: O
1 O
) O
, O
in O
the O
cholesterol O
esters O
, O
triglycerides B-outcome ['Physiological-Clinical']
and O
phospholipids B-outcome ['Physiological-Clinical']
while O
there O
were O
significant O
reductions O
of O
the O
content O
of O
linoleic B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
18 I-outcome ['Physiological-Clinical']
: O
2 O
) O
acid B-outcome ['Physiological-Clinical']
in O
both O
the O
cholesterol O
esters O
and O
triglycerides O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
baseline O
and O
follow-up O
at O
12 O
weeks O
, O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
, O
Victorian B-outcome ['Physiological-Clinical']
Institute I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
Sport I-outcome ['Physiological-Clinical']
Assessment-Achilles I-outcome ['Physiological-Clinical']
questionnaire O
( O
VISA-A O
) O
score O
and O
reported O
compliance B-outcome ['Life-Impact']
were O
recorded O
by O
a O
single-blind O
trained O
researcher O
who O
was O
blinded O
to O
the O
treatment O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

37.4 O
U/L O
, O
37.9 O
? O
[]

Twelve O
radiotherapy O
departments O
with O
more O
than O
10 O
% O
of O
the O
evaluable O
patients O
recruited O
in O
the O
trial O
, O
were O
invited O
to O
participate O
in O
this O
individual O
case O
review O
. O
[]

The O
primary O
measure O
of O
compliance O
was O
the O
Home B-outcome ['Physiological-Clinical']
Situations I-outcome ['Physiological-Clinical']
Questionnaire O
( O
HSQ O
) O
score O
. O
['Physiological-Clinical']

RESULTS O
The O
reduction O
from O
baseline O
in O
Ritvo-Freeman O
Real O
Life O
Rating O
Scale O
( O
RF-RLRS O
) O
, O
sensory O
motor O
( O
subscale O
I O
) O
and O
language O
( O
subscale O
V O
) O
scores O
were O
significant O
in O
risperidone O
group O
( O
P O
< O
0.05 O
) O
. O
[]

During O
labetalol O
treatment O
urinary B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
fell I-outcome ['Physiological-Clinical']
for O
2-3 O
days O
and O
then O
returned O
to O
basal O
values O
. O
['Physiological-Clinical']

RESULTS O
The O
plasma O
levels O
of O
ADA O
in O
patients O
with O
chronic O
schizophrenia O
who O
received O
clozapine O
were O
significantly O
higher O
than O
patients O
who O
received O
haloperidol O
. O
[]

In O
total O
, O
221 O
patients O
were O
assessable O
. O
[]

In O
total O
, O
338 O
patients O
aged O
18-76 O
who O
had O
a O
previous O
episode O
of O
otitis O
externa O
within O
the O
last O
year O
were O
randomized O
to O
receive O
10 O
+/- O
2 O
days O
of O
treatment O
with O
two O
drops O
, O
three O
times O
daily O
, O
of O
either O
PN+Dx O
or O
PN-Dx O
. O
[]

CONCLUSIONS O
Thus O
, O
it O
appears O
that O
a O
low O
intensity O
general O
training O
similar O
to O
that O
followed O
in O
the O
present O
study O
may O
represent O
a O
good O
means O
to O
improve O
physical B-outcome ['Life-Impact']
fitness I-outcome ['Life-Impact']
in O
healthy O
elderly O
people O
. O
['Life-Impact']

3 O
Practolol O
50 O
mg O
attenuated O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
isoprenaline O
but O
did O
not O
significantly O
affect O
the O
changes O
in O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Nonsignificant O
trends O
for O
all O
outcomes O
were O
seen O
in O
favor O
of O
the O
1,000- O
and O
2,000-mg/day O
doses O
of O
American O
ginseng O
. O
[]

With O
the O
aim O
of O
further O
improving O
these O
results O
, O
we O
have O
designed O
a O
randomized O
study O
comparing O
oral O
megestrol O
acetate O
with O
depot O
intramuscular O
( O
i.m O
. O
) O
[]

plus O
omepirazole O
20 O
mg O
b.d O
. O
[]

We O
assessed O
the O
hypothesis O
that O
the O
change O
in O
the O
central O
PP O
is O
more O
useful O
than O
that O
in O
the O
brachial O
PP O
in O
the O
assessment O
of O
the O
change O
in O
cardiac O
load O
. O
[]

Pharmacokinetic O
study O
of O
RU O
486 O
and O
its O
metabolites O
after O
oral O
administration O
of O
single O
doses O
to O
pregnant O
and O
non-pregnant O
women O
. O
[]

In O
the O
cicloxilic O
group O
there O
was O
little O
or O
no O
change O
in O
bile B-outcome ['Physiological-Clinical']
salts I-outcome ['Physiological-Clinical']
and O
phospholipids B-outcome ['Physiological-Clinical']
, O
whereas O
biliary B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
( O
p O
less O
than O
0.05 O
) O
and O
consequently O
the O
lithogenic B-outcome ['Physiological-Clinical']
index O
lowered O
( O
from O
1.5 O
to O
1.2 O
, O
p O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
short- O
and O
long-term O
risperidone O
treatment O
on O
prolactin B-outcome ['Physiological-Clinical']
levels O
in O
children O
with O
autism O
. O
['Physiological-Clinical']

The O
cumulative O
rate O
of O
HIV O
transmission O
at O
6 O
weeks O
was O
3?3 O
% O
( O
95 O
% O
CI O
1?9-5?6 O
% O
) O
in O
the O
triple O
antiretroviral O
group O
compared O
with O
5?0 O
% O
( O
3?3-7?7 O
% O
) O
in O
the O
zidovudine O
and O
single-dose O
nevirapine O
group O
, O
and O
at O
12 O
months O
was O
5?4 O
% O
( O
3?6-8?1 O
% O
) O
in O
the O
triple O
antiretroviral O
group O
compared O
with O
9?5 O
% O
( O
7?0-12?9 O
% O
) O
in O
the O
zidovudine O
and O
single-dose O
nevirapine O
group O
( O
p=0?029 O
) O
. O
[]

Disease B-outcome ['Physiological-Clinical']
flares I-outcome ['Physiological-Clinical']
were O
common O
in O
both O
groups O
, O
with O
118 O
flares O
in O
the O
etanercept O
group O
( O
23 O
severe O
and O
95 O
limited O
) O
and O
134 O
in O
the O
control O
group O
( O
25 O
severe O
and O
109 O
limited O
) O
. O
['Physiological-Clinical']

Eligible O
patients O
were O
Korean O
, O
aged O
18 O
to O
75 O
years O
, O
had O
hypertension O
, O
and O
were O
either O
taking O
antihypertensive O
medications O
or O
had O
a O
documented O
sitting O
diastolic O
blood O
pressure O
of O
90 O
to O
109 O
mm O
Hg O
. O
[]

The O
ABC O
once-daily O
and O
twice-daily O
regimens O
were O
similar O
with O
respect O
to O
infrequency O
of O
virologic B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
( O
10 O
% O
vs. O
8 O
% O
) O
, O
emergence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
mutations I-outcome ['Physiological-Clinical']
, O
CD4 B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
increases O
from O
baseline O
( O
median O
, O
188 O
vs. O
200 O
cells/mm O
) O
, O
safety O
profile O
, O
and O
incidence O
of O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Evidence O
that O
both O
younger O
age O
and O
more O
intervention O
hours O
positively O
affect O
developmental O
rates O
has O
implications O
for O
clinical O
practice O
, O
service O
delivery O
, O
and O
public O
policy O
. O
[]

The O
administration O
of O
amino O
acids O
increased O
protein B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
from O
-16+/-4 O
micromol.kg O
( O
-1 O
) O
.h O
( O
-1 O
) O
in O
the O
fasted O
state O
to O
16+/-3 O
micromol.kg O
( O
-1 O
) O
.h O
( O
-1 O
) O
. O
['Physiological-Clinical']

Acipimox O
in O
the O
treatment O
of O
patients O
with O
hyperlipidaemia O
: O
a O
double O
blind O
trial O
. O
[]

However O
, O
a O
diagnosis O
for O
major B-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
or O
chronic B-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
did O
not O
predict O
quitting O
. O
['Life-Impact', 'Life-Impact']

Titers O
of O
0.1 O
IU/mL O
or O
greater O
were O
considered O
protective O
. O
[]

The O
recovery O
of O
authentic O
, O
underivatized O
PGE-M O
added O
to O
urine O
was O
93 O
+/- O
3 O
% O
( O
mean O
+/- O
SEM O
, O
n=17 O
) O
. O
[]

1.12 O
; O
p O
= O
0.006 O
) O
and O
control O
groups O
( O
2.52 O
? O
[]

These O
small O
changes O
were O
not O
considered O
to O
be O
of O
clinical O
importance O
. O
[]

Primary O
characteristics O
for O
confirmative O
assessment O
of O
no O
interaction O
were O
AUC O
and O
Cmax O
of O
digoxin O
. O
[]

Children O
presenting O
with O
GABHS O
pharyngitis O
were O
randomised O
to O
oral O
amoxicillin O
1500 O
mg O
QD O
( O
or O
750 O
mg O
if O
bodyweight O
was O
< O
or=30 O
kg O
) O
or O
to O
oral O
penicillin O
V O
500 O
mg O
BID O
( O
or O
250 O
mg O
if O
bodyweight O
was O
< O
or=20 O
kg O
) O
for O
10 O
days O
. O
[]

Forty O
children O
with O
ASD O
( O
7-11 O
years O
) O
and O
their O
primary O
caregiver O
were O
randomly O
assigned O
to O
an O
immediate O
treatment O
( O
IT O
; O
n O
= O
17 O
) O
or O
3-month O
waitlist O
( O
WL O
; O
n O
= O
23 O
) O
condition O
. O
[]

Thirteen O
patients O
developed O
a O
second B-outcome ['Physiological-Clinical']
malignancy I-outcome ['Physiological-Clinical']
; O
six O
of O
these O
patients O
developed O
a O
hematologic B-outcome ['Physiological-Clinical']
malignancy I-outcome ['Physiological-Clinical']
between O
44.6 O
months O
and O
99.1 O
months O
after O
initiation O
of O
interferon O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

While O
the O
PSA B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Comparisons O
with O
the O
cyclophosphamide-doxorubicin-5-fluorouracil O
arm O
will O
not O
be O
addressed O
. O
[]

Methodology O
of O
serial O
ECG O
classification O
using O
an O
adaptation O
of O
the O
NOVACODE O
for O
Q O
wave O
myocardial O
infarction O
in O
the O
Bypass O
Angioplasty O
Revascularization O
Investigation O
( O
BARI O
) O
. O
[]

In O
1996 O
a O
randomized O
sample O
of O
4,020 O
Swedish O
adolescents O
from O
three O
birth O
cohorts O
were O
sent O
a O
questionnaire O
consisting O
of O
50 O
items O
concerning O
habitual O
sun-related O
behaviours O
and O
attitudes O
, O
knowledge O
about O
melanoma O
, O
risk O
perception O
and O
self-image O
. O
[]

In O
the O
low-dose O
heparin O
group O
it O
was O
stabilized O
and O
increased O
slightly O
at O
the O
end O
of O
the O
treatment O
. O
[]

Patients O
who O
received O
placebo O
( O
n O
= O
18 O
) O
showed O
a O
significant O
increase O
in O
the O
mean O
score O
on O
one O
of O
three O
rating O
scales O
used O
to O
assess O
opioid O
withdrawal O
. O
[]

To O
measure O
hemodynamic O
parameters O
and O
ShvO2 O
, O
mixed O
venous O
, O
and O
arterial O
lactate O
concentrations O
during O
enflurane O
and O
isoflurane O
anesthesia O
. O
[]

BACKGROUND O
Hydrocolloid O
technology O
has O
been O
proven O
effective O
in O
treating O
dermal O
wounds O
. O
[]

The O
recurrence O
rate O
for O
BCG-treated O
patients O
was O
0.33 O
; O
the O
recurrence O
rate O
for O
MMC-treated O
patients O
was O
0.29 O
( O
P O
= O
0.560 O
, O
not O
significant O
) O
. O
[]

In O
both O
groups O
, O
goiter-related B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
effectively O
relieved O
in O
the O
majority O
of O
patients O
. O
['Physiological-Clinical']

Concentrations O
of O
cephamandole O
in O
drain B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
were O
directly O
proportional O
to O
the O
serum O
concentration O
at O
the O
time O
of O
tourniquet O
release O
. O
['Physiological-Clinical']

The O
postoperative B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
significantly O
shorter O
in O
the O
LC O
than O
the O
OC O
group O
( O
median O
4 O
[ O
IQR O
2-5 O
] O
vs O
6 O
[ O
5-8 O
] O
days O
; O
p=0.0063 O
) O
. O
['Resource-use']

Intervention O
( O
n O
= O
142 O
) O
and O
control O
( O
n O
= O
141 O
) O
groups O
received O
standard O
HIV O
counseling O
and O
testing O
at O
baseline O
. O
[]

Effects O
of O
the O
810-nm O
diode O
laser O
on O
hair O
and O
on O
the O
biophysical O
properties O
of O
skin O
. O
[]

Seventeen O
patients O
from O
group O
C O
requested O
another O
appliance O
and O
were O
given O
a O
stabilization O
appliance O
, O
thus O
creating O
a O
mixed O
group O
( O
group O
M O
) O
. O
[]

A O
study O
was O
performed O
to O
explore O
the O
effects O
of O
supplemental O
intake O
of O
various O
marine O
oils O
known O
to O
be O
part O
of O
the O
Eskimo O
diet O
. O
[]

A O
randomised O
double-blind O
study O
comparing O
isosorbide O
dinitrate O
and O
nitroglycerin O
. O
[]

It O
is O
planned O
to O
run O
for O
at O
least O
five O
years O
with O
9014 O
patients O
from O
85 O
centers O
in O
Australia O
and O
New O
Zealand O
. O
[]

The O
clinical O
benefit O
of O
nefazodone O
was O
evident O
as O
early O
as O
the O
first O
week O
of O
treatment O
as O
judged O
by O
several O
measures O
of O
efficacy O
, O
with O
significant O
differences O
from O
placebo O
sustained O
throughout O
the O
trial O
. O
[]

Parent O
and O
child O
behaviours O
were O
assessed O
using O
parent O
reports O
, O
clinician O
ratings O
, O
and O
[]

CONCLUSION O
Cyclosporin O
bioavailability O
was O
not O
clearly O
modified O
by O
a O
half O
dosage O
of O
ticlopidine O
in O
this O
study O
. O
[]

There O
was O
a O
trend O
towards O
fewer O
PUVA O
sessions O
needed O
to O
achieve O
CCR O
in O
the O
combination O
arm O
( O
median O
22 O
) O
compared O
with O
the O
PUVA O
arm O
( O
median O
27?5 O
) O
( O
P O
= O
0?11 O
) O
. O
[]

After O
this O
, O
subjects O
randomly O
received O
either O
CLO O
or O
YHO O
, O
and O
3 O
h O
later O
another O
tilt O
was O
performed O
. O
[]

STUDY O
DESIGN O
A O
prospective O
, O
randomized O
study O
( O
Canadian O
Task O
Force O
I O
) O
was O
conducted O
at O
a O
University-affiliated O
hospital O
. O
[]

PURPOSE O
We O
evaluated O
the O
difference O
in O
computed B-outcome ['Resource-use']
tomography I-outcome ['Resource-use']
( I-outcome ['Resource-use']
CT I-outcome ['Resource-use']
) I-outcome ['Resource-use']
attenuation O
values O
of O
the O
intracranial B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
systems O
among O
the O
various O
contrast O
injection O
protocols O
( O
higher O
iodine O
delivery O
rate O
or O
higher O
concentration O
of O
the O
agent O
) O
on O
the O
source O
images O
of O
intracranial O
three-dimensional O
CT O
angiography O
( O
3D-CTA O
) O
using O
a O
multidetector-row O
CT O
( O
MDCT O
) O
scanner O
. O
['Resource-use', 'Physiological-Clinical']

Drug O
therapy O
of O
ventricular O
tachycardia O
: O
a O
cost O
comparison O
of O
randomized O
noninvasive O
and O
invasive O
approaches O
. O
[]

The O
study O
underscores O
the O
important O
role O
of O
patient-provider O
communication O
in O
assuring O
high O
compliance O
with O
referral O
. O
[]

Dose-related O
difference O
in O
progression O
rates O
of O
cytomegalovirus O
retinopathy O
during O
foscarnet O
maintenance O
therapy O
. O
[]

Nonetheless O
, O
improved O
glycemic O
control O
was O
observed O
in O
insulin O
pump-treated O
subjects O
( O
more O
time O
spent O
with O
normoglycemia O
, O
better O
mean O
HbA1c O
) O
, O
and O
pump-treated O
subjects O
reported O
comparatively O
greater O
satisfaction O
with O
route O
of O
treatment O
administration O
. O
[]

OBJECTIVE O
To O
explore O
the O
effect O
of O
Dan O
Shao O
Tang O
( O
DST O
) O
in O
treating O
IgA O
nephropathy O
( O
IgAN O
) O
of O
deficiency O
of O
Yin O
with O
damp-heat O
symptom O
. O
[]

Adenocarcinoma O
of O
the O
gastrointestinal O
tract O
remains O
a O
major O
challenge O
to O
tumor O
biologists O
and O
clinical O
oncologists O
because O
it O
is O
generally O
resistant O
to O
chemotherapy O
and O
radiation O
therapy O
, O
yet O
common O
enough O
to O
represent O
a O
vital O
public O
health O
concern O
in O
America O
. O
[]

BACKGROUND O
Bibrocathol O
is O
a O
well-established O
antiseptic O
drug O
for O
the O
treatment O
of O
acute O
eyelid O
diseases O
like O
blepharitis O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O
[]

METHODS O
Forty O
outpatients O
aged O
4 O
to12 O
years O
, O
who O
were O
diagnosed O
with O
autism O
spectrum O
disorders O
based O
on O
the O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
Fourth O
Edition O
, O
Text O
Revision O
criteria O
, O
were O
assigned O
to O
this O
double-blind O
clinical O
trial O
. O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
mainly O
mild O
. O
['Adverse-effects']

Each O
of O
the O
four O
measurement O
devices O
had O
its O
own O
trained O
clinical O
observer O
. O
[]

Quadriceps O
fatigue O
was O
produced O
by O
electrostimulation-induced O
contractions O
and O
quantified O
by O
maximal B-outcome ['Physiological-Clinical']
voluntary I-outcome ['Physiological-Clinical']
contraction I-outcome ['Physiological-Clinical']
and O
potentiated O
twitch B-outcome ['Physiological-Clinical']
force I-outcome ['Physiological-Clinical']
( O
TwQ O
( O
pot O
) O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Randomisation O
was O
stratified O
according O
to O
menopausal O
status O
and O
tumour O
size O
. O
[]

There O
is O
profound O
suppression O
of O
HBV B-outcome ['Physiological-Clinical']
replication I-outcome ['Physiological-Clinical']
and O
improvement O
in O
indicators O
of O
liver B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
in O
most O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subjects O
randomized O
to O
NAC O
were O
initiated O
at O
900 O
mg O
daily O
for O
4 O
weeks O
, O
then O
900 O
mg O
twice O
daily O
for O
4 O
weeks O
and O
900 O
mg O
three O
times O
daily O
for O
4 O
weeks O
. O
[]

We O
assessed O
the O
potential O
benefit O
of O
catheter O
ablation O
before O
implantation O
of O
a O
cardioverter O
defibrillator O
. O
[]

In O
rating O
their O
own O
behavioral B-outcome ['Life-Impact']
intentions I-outcome ['Life-Impact']
, O
children O
showed O
no O
differences O
between O
conditions O
. O
['Life-Impact']

Objective B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CR I-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
PR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
observed O
in O
23/46 O
( O
50 O
% O
) O
of O
breast O
cancer O
patients O
treated O
with O
CT O
+ O
MPA O
, O
and O
in O
13/47 O
( O
28 O
% O
) O
of O
those O
given O
CT O
+ O
placebo O
. O
['Physiological-Clinical']

RESULTS O
The O
age O
of O
the O
patients O
and O
the O
severity O
of O
their O
burns O
did O
not O
differ O
significantly O
between O
the O
groups O
. O
[]

Among O
uteri O
weighing O
> O
500 O
g O
LAVH O
showed O
a O
shorter O
recovery O
, O
but O
longer O
operating O
time O
than O
TAH O
and O
a O
27 O
% O
rate O
of O
conversion B-outcome ['Resource-use']
to I-outcome ['Resource-use']
laparotomy I-outcome ['Resource-use']
. O
['Resource-use']

CONCLUSIONS O
In O
summary O
the O
diabetes O
specific O
formula O
with O
a O
relatively O
high O
monounsaturated O
fatty O
acid O
and O
high O
multi O
fiber O
proportion O
significantly O
improved O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
successful I-outcome ['Life-Impact']
catheterization I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
CS I-outcome ['Life-Impact']
was O
5.0 O
+/- O
2.4 O
min O
in O
the O
EPA O
group O
versus O
10.1 O
+/- O
5.4 O
min O
in O
the O
GCA O
group O
p O
= O
0.004 O
. O
['Life-Impact']

The O
introduction O
of O
quinolones O
has O
revived O
interest O
in O
these O
topical O
agents O
. O
[]

In O
conclusion O
, O
treatment O
with O
high- O
compared O
to O
low-dose O
atorvastatin O
was O
associated O
with O
improvement O
in O
eGFR O
at O
1 O
year O
, O
which O
was O
related O
to O
a O
decrease O
in O
subsequent O
HF O
hospitalization O
. O
[]

The O
effect O
of O
captopril O
, O
atenolol O
and O
pravastatin O
combined O
with O
life O
style O
intervention O
. O
[]

Eighty-three O
participants O
with O
FOF O
were O
randomly O
assigned O
to O
VRE O
, O
SE O
, O
or O
WL O
. O
[]

METHODS O
A O
multicenter O
, O
single-blind O
, O
randomized O
, O
controlled O
trial O
of O
office O
hysteroscopic O
morcellation O
compared O
with O
electrosurgical O
resection O
was O
conducted O
. O
[]

The O
study O
was O
conducted O
as O
a O
double-masked O
, O
randomised O
trial O
in O
which O
medications O
were O
administered O
twice O
daily O
to O
both O
eyes O
. O
[]

The O
radial O
forearm O
flap O
: O
a O
biomechanical O
study O
of O
donor-site O
morbidity O
utilizing O
sheep O
tibia O
. O
[]

RESULTS O
The O
Pa O
group O
( O
n O
= O
101 O
) O
had O
a O
clearly O
lower O
incidence O
of O
both O
local O
and O
systemic O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
than O
the O
Pw O
group O
( O
n O
= O
100 O
) O
. O
['Adverse-effects']

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
onset I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
analgesic I-outcome ['Physiological-Clinical']
effect O
( O
11-point O
numeric O
rating O
scale O
) O
, O
respiratory B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
( O
p O
( O
a O
) O
CO2 O
, O
p O
( O
a O
) O
O2 O
, O
and O
respiratory B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
) O
, O
level O
of O
sedation B-outcome ['Physiological-Clinical']
( O
5-point O
verbal O
rating O
scale O
) O
, O
and O
hemodynamic B-outcome ['Physiological-Clinical']
function B-outcome ['Life-Impact']
were O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Smokers O
( O
n O
= O
20 O
) O
matched O
for O
age O
, O
myocardial O
ischemia O
, O
and O
other O
risk O
factors O
with O
20 O
nonsmokers O
entered O
a O
double-blind O
crossover O
trial O
of O
aspirin O
( O
300 O
mg/d O
for O
3 O
weeks O
) O
versus O
placebo O
. O
[]

Both O
medications O
induced O
rapid B-outcome ['Physiological-Clinical']
bronchodilation I-outcome ['Physiological-Clinical']
that O
had O
a O
longer O
duration O
after O
bitolterol O
. O
['Physiological-Clinical']

During O
the O
first O
period O
the O
percentage O
of O
responders O
was O
almost O
identical O
in O
both O
treatment O
groups O
, O
but O
during O
the O
second O
period O
a O
further O
slight O
improvement O
was O
observed O
in O
the O
early O
placebo O
responders O
, O
while O
the O
HAM-A O
score O
of O
patients O
on O
ketazolam O
continued O
to O
improve O
significantly O
( O
p O
less O
than O
0.01 O
) O
throughout O
the O
study O
. O
[]

In O
Study O
2 O
, O
one O
group O
of O
19 O
alpacas O
received O
four O
administrations O
at O
weekly O
interval O
of O
topical O
eprinomectin O
at O
the O
dose O
rate O
of O
500mug/kg O
, O
and O
response O
to O
treatment O
was O
monitored O
by O
mite B-outcome ['Physiological-Clinical']
counts O
. O
['Physiological-Clinical']

A O
number O
of O
quinolone O
antibacterial O
agents O
, O
particularly O
enoxacin O
, O
pefloxacin O
, O
pipemidic O
acid O
and O
ciprofloxacin O
, O
are O
known O
to O
decrease O
the O
clearance O
of O
methylxanthines O
. O
[]

CONCLUSIONS O
Methylphenidate O
was O
often O
efficacious O
in O
treating O
hyperactivity O
associated O
with O
pervasive O
developmental O
disorders O
, O
but O
the O
magnitude O
of O
response O
was O
less O
than O
that O
seen O
in O
typically O
developing O
children O
with O
attention-deficit/hyperactivity O
disorder O
. O
[]

Total O
cholesterol B-outcome ['Physiological-Clinical']
was O
unchanged O
in O
the O
oil O
groups O
, O
whereas O
high B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
increased O
7 O
% O
in O
the O
seal/cod O
liver O
oil O
( O
CLO O
) O
group O
( O
P O
< O
0.05 O
) O
and O
11 O
% O
in O
the O
whale O
oil O
group O
( O
P O
< O
0.005 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
this O
did O
not O
lead O
to O
a O
change O
in O
the O
overall O
function O
of O
these O
children O
( O
Gross O
Motor O
Function O
Classification O
System O
level O
V O
) O
. O
[]

With O
the O
addition O
of O
simvastatin O
( O
20 O
mg O
per O
day O
) O
, O
there O
was O
a O
32 O
percent O
total O
decrease O
in O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
from O
the O
control O
value O
and O
a O
43 O
percent O
decrease O
in O
low O
density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Sialyl O
Lewisa O
expression O
as O
a O
predictor O
of O
the O
prognosis O
of O
colon O
carcinoma O
patients O
in O
a O
prospective O
randomized O
clinical O
trial O
. O
[]

Risperidone O
and O
donepezil O
are O
both O
metabolized O
through O
cytochrome O
P450 O
2D6 O
and O
3A4 O
, O
raising O
the O
possibility O
of O
drug O
interactions O
with O
combination O
therapy O
. O
[]

PURPOSE O
Studies O
show O
that O
the O
Levitan O
FPS O
( O
first O
pass O
success O
) O
Scope? O
( O
LFS O
) O
is O
analogous O
to O
a O
bougie O
in O
simulated O
difficult O
airways O
with O
comparable O
tracheal O
intubation O
success O
rates O
. O
[]

Evaluating O
online O
continuing O
medical O
education O
seminars O
: O
evidence O
for O
improving O
clinical O
practices O
. O
[]

METHOD O
A O
parallel O
group O
design O
was O
employed O
. O
[]

CONCLUSIONS O
The O
findings O
suggest O
that O
olanzapine O
is O
a O
promising O
treatment O
for O
children O
with O
autistic O
disorder O
. O
[]

All O
patients O
received O
hemostasis O
with O
a O
radial O
compression O
device O
( O
TR O
Band O
) O
, O
applied O
after O
sheath O
removal O
, O
for O
2 O
hours O
. O
[]

BACKGROUND O
The O
use O
of O
warfarin O
reduces O
the O
rate O
of O
ischemic B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
in O
patients O
with O
atrial O
fibrillation O
but O
requires O
frequent O
monitoring O
and O
dose O
adjustment O
. O
['Physiological-Clinical']

These O
determinations O
were O
carried O
out O
using O
a O
sensitive O
and O
reproducible O
microassay O
based O
on O
cAMP O
accumulation O
in O
human O
thyroid O
cell O
cultures O
. O
[]

Hemodynamic O
effects O
during O
induction O
, O
laryngoscopy O
, O
and O
intubation O
with O
eltanolone O
( O
5 O
beta-pregnanolone O
) O
or O
propofol O
. O
[]

VAS O
and O
IL-6 B-outcome ['Physiological-Clinical']
were O
lower O
in O
group O
P O
than O
in O
group O
E O
and O
V O
, O
and O
group O
E O
had O
lower O
measurement O
than O
group O
V O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Effect O
of O
soy O
protein O
containing O
isoflavones O
on O
blood B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
in O
moderately O
hypercholesterolemic O
adults O
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

Limitations O
of O
the O
study O
and O
suggestions O
for O
future O
research O
are O
also O
discussed O
. O
[]

The O
authors O
studied O
normal O
human O
skin O
reactions O
to O
two O
different O
rapid O
radiotherapy O
schedules O
of O
2 O
sessions O
per O
day O
and O
evaluated O
their O
effectiveness O
in O
relief O
of O
pain O
and O
local O
tumor O
control O
. O
[]

METHODS O
This O
was O
a O
randomized O
, O
parallel-group O
, O
double-blind O
study O
on O
114 O
patients O
with O
COPD O
of O
moderate-to-severe O
degree O
. O
[]

Anatomical O
benefit O
from O
ranibizumab O
treatment O
of O
predominantly O
classic O
neovascular O
age-related O
macular O
degeneration O
in O
the O
2-year O
anchor O
study O
. O
[]

The O
fentanyl O
made O
no O
difference O
to O
the O
patients O
' O
postoperative O
analgesic O
requirements O
or O
to O
their O
recovery O
in O
the O
first O
24 O
hours O
. O
[]

RESULTS O
In O
the O
electrophysiologic-study O
group O
, O
the O
percentage O
of O
patients O
who O
had O
predictions O
of O
drug O
efficacy O
was O
higher O
with O
sotalol O
( O
35 O
percent O
) O
than O
with O
the O
other O
drugs O
( O
16 O
percent O
, O
P O
< O
0.001 O
) O
. O
[]

Fabrication O
of O
the O
sampling O
lumen O
of O
an O
intra-arterial O
PO2 O
sensor O
is O
performed O
in O
standard O
catheters O
mechanically O
or O
by O
laser O
. O
[]

At O
entry O
into O
the O
study O
, O
all O
participants O
had O
sterile O
cultures O
of O
cerebrospinal O
fluid O
, O
blood O
, O
and O
urine O
after O
following O
a O
standardized O
course O
of O
therapy O
for O
culture-proved O
cryptococcal O
meningitis O
. O
[]

Combination O
of O
these O
phospholipids O
in O
a O
ratio O
of O
3:1 O
or O
1:9 O
of O
C16:0 O
: O
C18:0 O
did O
not O
significantly O
alter O
the O
dose O
response O
curves O
. O
[]

0.33 O
kg O
) O
( O
77 O
% O
fat O
mass O
) O
and O
solid O
( O
1.36 O
? O
[]

Caregiver-mediated O
intervention O
for O
low-resourced O
preschoolers O
with O
autism O
: O
an O
RCT O
. O
[]

With O
extensive O
pathological O
workup O
, O
increased O
numbers O
of O
small O
metastatic O
deposits O
are O
detected O
in O
SLN O
. O
[]

A O
prospective O
study O
in O
high-risk O
patients O
. O
[]

2 O
: O
Role O
of O
fresh-start O
experiences O
and O
baseline O
psychosocial O
factors O
in O
remission O
from O
depression O
. O
[]

The O
cost O
of O
this O
additional O
benefit O
may O
be O
higher O
than O
many O
countries O
can O
afford O
without O
external O
assistance O
or O
lower O
RDT O
prices O
. O
[]

CONCLUSIONS O
Clomipramine O
and O
desipramine O
are O
differentially O
effective O
in O
treating O
the O
obsessive-compulsive B-outcome ['Life-Impact']
and O
core B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
autistic O
disorder O
. O
['Life-Impact', 'Physiological-Clinical']

At O
the O
end O
of O
the O
study O
period O
there O
were O
no O
differences O
between O
those O
patients O
receiving O
tetracycline O
and O
those O
receiving O
placebo O
. O
[]

BACKGROUND O
Chronic O
kidney O
disease O
( O
CKD O
) O
is O
associated O
with O
increased O
mortality B-outcome ['Mortality']
in O
patients O
with O
heart O
failure O
( O
HF O
) O
. O
['Mortality']

Relapsing B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
( O
fatal O
and O
nonfatal O
) O
was O
reduced O
by O
43 O
% O
( O
P O
= O
0.0001 O
) O
. O
['Physiological-Clinical']

They O
were O
told O
that O
the O
patient O
had O
either O
chronic O
fatigue O
syndrome O
, O
chronic O
neuroendocrineimmune O
dysfunction O
syndrome O
, O
or O
chronic O
neuroendocrineimmune O
dysfunction O
syndrome O
, O
which O
had O
formerly O
been O
called O
chronic O
fatigue O
syndrome O
. O
[]

They O
provide O
supportive O
evidence O
that O
tailored O
intervention O
programs O
should O
be O
developed O
to O
support O
the O
screening O
and O
completion O
of O
treatment O
of O
foreign-born O
adolescents O
. O
[]

Besides O
this O
transformation O
the O
effects O
of O
prompts O
will O
be O
examined O
. O
[]

METHODS O
Experimental O
studies O
for O
E-PEG O
were O
performed O
repeatedly O
using O
pigs O
under O
general O
anesthesia O
to O
confirm O
the O
safety O
of O
its O
procedure O
for O
human O
use O
. O
[]

INTRODUCTION O
Fasciculations B-outcome ['Physiological-Clinical']
during O
rapid-sequence O
intubation O
may O
lead O
to O
increased O
intracranial O
pressure O
and O
emesis B-outcome ['Physiological-Clinical']
with O
aspiration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Tocolysis O
, O
prophylactic O
antibiotics O
, O
and O
other O
interventions O
studied O
were O
not O
found O
to O
be O
of O
proved O
benefit O
and O
therefore O
should O
not O
be O
used O
outside O
of O
a O
randomized O
controlled O
trial O
. O
[]

INTRODUCTION O
Our O
objective O
was O
to O
evaluate O
the O
effects O
of O
a O
highly O
filled O
light-cured O
sealant O
( O
HFLCS O
) O
on O
the O
shear O
bond O
strength O
and O
bond O
failure O
site O
of O
metal O
and O
ceramic O
brackets O
bonded O
with O
resin-modified O
glass O
ionomer O
cement O
( O
RMGIC O
) O
. O
[]

In O
a O
prospective O
, O
randomized O
, O
comparative O
study O
, O
we O
evaluated O
these O
two O
regimens O
with O
respect O
to O
safety O
and O
efficacy O
in O
patients O
with O
H. O
pylori O
infection O
. O
[]

A O
prospective O
randomized O
study O
was O
conducted O
in O
51 O
patients O
with O
stage O
D O
hormone-resistant O
prostatic O
carcinoma O
, O
comparing O
a O
combination O
of O
doxorubicin O
and O
lomustine O
( O
DC O
) O
with O
cyclophosphamide O
and O
5-FU O
( O
CF O
) O
. O
[]

The O
children O
with O
LFA O
demonstrated O
improvements O
in O
two O
areas O
of O
the O
intervention O
: O
emotion O
recognition O
and O
social O
interactions O
. O
[]

Many O
of O
the O
other O
scales O
showed O
statistically O
significant O
differences O
between O
scores O
when O
comparing O
the O
two O
arms O
. O
[]

Overall O
and O
drug-related O
AEs B-outcome ['Adverse-effects']
were O
mild O
to O
moderate O
and O
were O
similar O
between O
V/HCTZ O
( O
53.1 O
and O
14.1 O
% O
, O
respectively O
) O
and O
the O
two O
monotherapy O
groups O
, O
V-low O
( O
50.5 O
and O
13.8 O
% O
) O
and O
V-high O
( O
50.7 O
and O
11.8 O
% O
) O
. O
['Adverse-effects']

The O
basic O
therapy O
for O
all O
cases O
was O
radiotherapy O
and O
, O
when O
required O
, O
surgery O
. O
[]

Then O
either O
placebo O
or O
piracetam O
4.8 O
g/day O
or O
9.6 O
g/day O
was O
given O
during O
four O
weeks O
with O
measurements O
after O
2 O
weekks O
and O
4 O
weeks O
. O
[]

Though O
cardiorespiratory O
exercise O
training O
increases O
HRV O
, O
little O
is O
known O
regarding O
the O
exercise O
dose O
necessary O
to O
promote O
this O
improvement O
. O
[]

The O
continuous O
regimen O
does O
not O
result O
in O
any O
further O
benefit O
in O
lumbar O
bone O
density O
over O
the O
cyclical O
one O
, O
probably O
because O
of O
a O
greater O
suppression O
of O
bone O
turnover O
. O
[]

CONCLUSION O
Concurrent O
cisplatin O
may O
improve O
pelvic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
of O
locally O
advanced O
bladder O
cancer O
with O
preoperative O
or O
definitive O
radiation O
, O
but O
has O
not O
been O
shown O
to O
improve O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

To O
determine O
the O
efficacy O
of O
secretin O
, O
we O
completed O
a O
double-blind O
, O
placebo-controlled O
, O
crossover O
( O
3 O
weeks O
) O
study O
in O
children O
with O
autism/PDD O
and O
various O
GI O
conditions O
using O
a O
single O
dose O
of O
intravenous O
porcine O
secretin O
. O
[]

A O
total O
of O
51 O
children O
( O
mean O
age O
: O
7.7 O
+/- O
4.8 O
year O
) O
were O
studied O
in O
133 O
chemotherapy O
cycles O
. O
[]

Compliance O
amongst O
exercisers O
was O
86.7+/-10.6 O
% O
. O
[]

BACKGROUND O
Minimally O
invasive O
, O
laparoscopically O
assisted O
surgery O
was O
first O
considered O
in O
1990 O
for O
patients O
undergoing O
colectomy O
for O
cancer O
. O
[]

The O
prospective O
randomized O
controlled O
study O
consisted O
of O
two O
groups O
. O
[]

Irrigation O
with O
hypertonic O
saline O
restored O
impaired B-outcome ['Physiological-Clinical']
mucociliary I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
sinusitis I-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
, O
while O
isotonic O
saline O
improved O
mucociliary O
clearance O
times O
significantly O
in O
allergic O
rhinitis O
and O
acute O
sinusitis O
patients O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Previous O
research O
supports O
that O
children O
with O
autism O
show O
deficits O
in O
contextual B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
, O
as O
well O
as O
deficits O
in O
its O
elementary O
components O
: O
abstraction B-outcome ['Life-Impact']
and O
cognitive B-outcome ['Life-Impact']
flexibility I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
adverse O
reactions O
to O
FZ O
are O
not O
severe O
, O
and O
are O
well O
tolerated B-outcome ['Life-Impact']
in O
most O
patients O
. O
['Life-Impact']

As O
calcium O
acquired O
during O
adolescence O
is O
essential O
to O
maximize O
peak O
bone O
mass O
and O
to O
prevent O
osteoporosis O
, O
possible O
long-term O
effects O
of O
excessive O
MRP O
intake O
during O
this O
period O
warrant O
attention O
. O
[]

The O
results O
demonstrate O
that O
the O
QLQ-C30 O
is O
a O
reliable O
and O
valid O
instrument O
for O
the O
measurement O
of O
quality O
of O
life O
in O
these O
patients O
. O
[]

DCF O
significantly O
prolonged O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
definitive I-outcome ['Physiological-Clinical']
worsening I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
KPS I-outcome ['Physiological-Clinical']
compared O
with O
CF O
( O
median O
, O
6.1 O
v O
4.8 O
months O
; O
hazard O
ratio O
, O
1.38 O
; O
95 O
% O
CI O
, O
1.08 O
to O
1.76 O
; O
log-rank O
P O
= O
.009 O
) O
. O
['Physiological-Clinical']

A O
significant O
time O
effect O
was O
found O
for O
all O
outcomes O
( O
p O
< O
.001 O
) O
; O
greatest O
change O
occurred O
during O
the O
intervention O
period O
, O
particularly O
in O
the O
Interpersonal O
Synchrony O
group O
. O
[]

DESIGN O
Physician O
groups O
were O
randomized O
to O
receive O
guideline O
education O
and O
individual O
feedback O
, O
supporting O
patient O
education O
materials O
, O
both O
, O
or O
neither O
. O
[]

Pressure O
garments O
with O
normal O
compression O
did O
lose O
significantly O
more O
compression B-outcome ['Resource-use']
over O
1 O
month O
( O
4.82 O
mmHg O
) O
than O
did O
the O
garments O
from O
the O
low O
compression O
class O
( O
2.57 O
mmHg O
) O
. O
['Resource-use']

This O
study O
examined O
the O
effectiveness O
of O
the O
CCDE O
program O
for O
those O
with O
a O
diagnosis O
of O
mental O
illness O
. O
[]

Outcome O
measures O
were O
production O
of O
[]

The O
specimen O
treatment O
regimens O
were O
: O
1 O
. O
[]

Inotropic O
requirement O
, O
duration O
of O
mechanical O
ventilation O
, O
intensive O
care O
unit O
, O
and O
hospital O
stay O
did O
not O
differ O
between O
the O
2 O
groups O
. O
[]

In O
3/10 O
, O
a O
partial B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
was O
achieved O
, O
while O
in O
7/10 O
, O
a O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
was O
obtained O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
reported O
recently O
that O
enoxaparin O
40 O
mg O
once O
daily O
for O
10 O
days O
seems O
safe O
and O
demonstrates O
thromboprophylactic B-outcome ['Physiological-Clinical']
efficacy O
, O
but O
it O
failed O
to O
improve O
outcome O
in O
a O
randomized O
SAH O
trial O
. O
['Physiological-Clinical']

The O
patients O
were O
randomly O
assigned O
to O
receive O
aliskiren O
( O
150 O
mg O
) O
, O
aliskiren O
( O
300 O
mg O
) O
, O
perindopril O
( O
5 O
mg O
) O
, O
perindopril O
( O
10 O
mg O
) O
or O
placebo O
. O
[]

Median O
PFS B-outcome ['Mortality']
in O
Arms O
A O
, O
B O
, O
and O
C O
was O
6.5 O
months O
( O
HR O
, O
0.69 O
; O
P O
= O
0.147 O
) O
, O
4.5 O
months O
( O
HR O
, O
1.01 O
; O
P O
= O
0.998 O
) O
, O
and O
4.6 O
months O
, O
respectively O
; O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
12.3 O
months O
( O
HR O
, O
0.89 O
; O
P O
= O
0.650 O
) O
, O
12.4 O
months O
( O
HR O
, O
1.27 O
; O
P O
= O
0.357 O
) O
, O
and O
12.0 O
months O
; O
and O
objective O
response O
['Mortality', 'Mortality']

Blood O
samples O
were O
obtained O
from O
participants O
in O
32 O
sectors O
( O
5 O
% O
) O
for O
biochemical O
studies O
. O
[]

Patients O
were O
questioned O
on O
a O
variety O
of O
postoperative B-outcome ['Physiological-Clinical']
pharyngeal I-outcome ['Physiological-Clinical']
morbidities I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Overall O
, O
recurrent B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
were O
significantly O
lower O
( O
14 O
% O
) O
in O
the O
HBI O
group O
( O
mean O
+/- O
SD O
, O
823 O
dollars O
+/- O
1642 O
dollars O
vs O
960 O
dollars O
+/- O
1376 O
dollars O
per O
patient O
per O
year O
; O
P O
= O
.045 O
) O
. O
['Resource-use']

METHODS O
We O
randomly O
assigned O
patients O
with O
transient O
ischemic O
attack O
or O
stroke O
caused O
by O
angiographically O
verified O
50 O
to O
99 O
percent O
stenosis O
of O
a O
major O
intracranial O
artery O
to O
receive O
warfarin O
( O
target O
international O
normalized O
ratio O
, O
2.0 O
to O
3.0 O
) O
or O
aspirin O
( O
1300 O
mg O
per O
day O
) O
in O
a O
double-blind O
, O
multicenter O
clinical O
trial O
. O
[]

Two O
subgroups O
of O
pancreatitis O
patients O
were O
defined O
based O
on O
the O
M-ANNHEIM O
severity O
index O
of O
chronic O
pancreatitis O
; O
i.e O
. O
[]

The O
pretreatment O
histological O
diagnosis O
was O
alopecia O
with O
a O
mild O
to O
moderate O
perifollicular O
inflammation O
zone O
. O
[]

A O
5?C O
change O
in O
3- O
and O
4-day O
moving O
averages O
of O
apparent O
temperature O
was O
associated O
with O
11.3 O
% O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
: O
1.1 O
, O
22.5 O
; O
p O
= O
0.03 O
) O
and O
11.4 O
% O
( O
95 O
% O
CI O
: O
1.2 O
, O
22.5 O
; O
p O
= O
0.03 O
) O
higher O
BNP O
. O
[]

The O
2 O
groups O
were O
comparable O
in O
terms O
of O
age O
, O
sex O
, O
symptoms B-outcome ['Physiological-Clinical']
and O
ipsilateral B-outcome ['Physiological-Clinical']
glomerular I-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
clinical B-outcome ['Physiological-Clinical']
target I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( O
CTV B-outcome ['Physiological-Clinical']
) O
drawn O
on O
the O
CT O
scan O
was O
narrow O
in O
7 O
( O
12 O
% O
) O
cases O
, O
but O
eventually O
the O
actually O
treated O
volumes O
in O
terms O
of O
planned B-outcome ['Physiological-Clinical']
treatment O
volume B-outcome ['Physiological-Clinical']
( O
PTV B-outcome ['Physiological-Clinical']
) O
were O
correct O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
internal O
jugular O
vein O
( O
IJV O
) O
is O
a O
common O
access O
route O
to O
the O
central O
venous O
system O
. O
[]

Virtual O
patients O
design O
and O
its O
effect O
on O
clinical B-outcome ['Life-Impact']
reasoning I-outcome ['Life-Impact']
and O
student B-outcome ['Life-Impact']
experience I-outcome ['Life-Impact']
: O
a O
protocol O
for O
a O
randomised O
factorial O
multi-centre O
study O
. O
['Life-Impact', 'Life-Impact']

SETTING O
Third-level O
referral O
academic O
centers O
, O
including O
reproductive O
biology O
and O
genetics O
laboratories O
. O
[]

Respondents O
assigned O
memory O
aids O
were O
also O
more O
likely O
to O
report O
a O
doctor O
contact O
-- O
especially O
during O
the O
fall/winter O
months O
. O
[]

This O
suggests O
that O
improvement O
in O
kidney O
function O
may O
be O
related O
to O
the O
beneficial O
effect O
of O
high-dose O
atorvastatin O
on O
HF O
hospitalization O
. O
[]

Each O
month O
for O
6 O
months O
, O
subjects O
received O
either O
3 O
consecutive O
weeks O
of O
the O
OC O
( O
i.e. O
, O
tablets O
containing O
a O
fixed O
dose O
of O
ethinyl O
estradiol O
[ O
0.035 O
mg O
] O
and O
increasing O
doses O
of O
norgestimate O
[ O
0.180 O
mg O
, O
0.215 O
mg O
, O
0.250 O
mg O
] O
) O
followed O
by O
7 O
days O
of O
inactive O
drug O
or O
placebo O
( O
color-matched O
tablets O
) O
. O
[]

Normal B-outcome ['Physiological-Clinical']
TSH I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
TRH B-outcome ['Physiological-Clinical']
( O
peak O
less O
than O
or O
equal O
to O
14 O
mU/L O
) O
were O
observed O
in O
all O
normal O
controls O
( O
mean O
peak O
+/- O
SE O
9.8 O
+/- O
0.6 O
mU/L O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
After O
determination O
by O
PCR O
of O
RAS O
genotypes O
, O
consisting O
of O
the O
angiotensin-converting O
enzymes O
( O
ACE O
I/D O
) O
, O
angiotensinogens O
( O
AGT O
M235T O
) O
and O
angiotensin O
II O
type O
1 O
receptors O
( O
ATR1 O
A1166C O
) O
, O
76 O
recipients O
were O
recruited O
randomly O
and O
assigned O
4 O
groups O
. O
[]

Hypotension B-outcome ['Physiological-Clinical']
was O
defined O
as O
a O
30 O
% O
decrease O
from O
baseline O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
BP O
) O
or O
systolic O
< O
90 O
mm O
Hg O
, O
and O
was O
treated O
with O
ephedrine O
3-mg O
boluses O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
is O
considered O
from O
the O
perspective O
of O
clinical O
assessment O
and O
intervention O
in O
school O
contexts O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Peak O
oxygen B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
, O
peak O
workload B-outcome ['Life-Impact']
, O
percent O
of O
predicted O
power O
ability B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

No O
difference O
in O
susceptibility B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
found O
between O
the O
NO2- O
and O
air-exposed O
macrophages O
. O
['Physiological-Clinical']

In O
the O
sildenafil O
group O
only O
, O
at O
6 O
months O
and O
1 O
year O
, O
LV B-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
, O
early B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
Doppler I-outcome ['Physiological-Clinical']
velocities I-outcome ['Physiological-Clinical']
( O
E O
' O
) O
at O
the O
mitral O
lateral B-outcome ['Physiological-Clinical']
( O
from O
4.62 O
to O
5.20 O
and O
5.19 O
m/s O
) O
and O
septal B-outcome ['Physiological-Clinical']
( O
from O
4.71 O
to O
5.23 O
and O
5.24 O
m/s O
) O
annuli O
significantly O
increased O
, O
whereas O
the O
ratio O
of O
early O
transmitral O
( O
E O
) O
to O
E O
' O
lateral O
decreased O
( O
from O
13.1 O
to O
9.8 O
to O
9.4 O
) O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
negatively O
ionized O
condition O
did O
not O
significantly O
affect O
measurements O
of O
activity B-outcome ['Life-Impact']
level O
, O
impulsivity B-outcome ['Life-Impact']
, O
reality B-outcome ['Life-Impact']
orientation I-outcome ['Life-Impact']
, O
destructive/constructiveness B-outcome ['Life-Impact']
, O
attention B-outcome ['Life-Impact']
, O
or O
task B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Preoperative O
endocrine O
therapy O
has O
therefore O
become O
a O
logical O
alternative O
and O
has O
gained O
considerable O
momentum O
from O
the O
finding O
that O
aromatase O
inhibitors O
( O
AIs O
) O
are O
more O
effective O
than O
tamoxifen O
for O
HR+ O
breast O
cancer O
in O
both O
the O
neoadjuvant O
and O
adjuvant O
settings O
. O
[]

Participants O
were O
50 O
children O
with O
ASD O
, O
age O
range O
3 O
to O
5 O
years O
, O
who O
had O
previously O
been O
evaluated O
on O
standard O
tests O
of O
language O
and O
level O
of O
functioning O
. O
[]

CONCLUSION O
This O
study O
showed O
that O
the O
central B-outcome ['Physiological-Clinical']
PP I-outcome ['Physiological-Clinical']
measurement I-outcome ['Physiological-Clinical']
may O
be O
more O
important O
to O
assess O
cardiac O
load O
than O
the O
brachial O
PP O
during O
antiadrenergic O
treatment O
. O
['Physiological-Clinical']

However O
, O
the O
protocols O
used O
and O
the O
results O
found O
in O
the O
3 O
RCTs O
were O
diverse O
. O
[]

Enjoyment O
mediates O
effects O
of O
a O
school-based O
physical-activity O
intervention O
. O
[]

Patients O
were O
then O
randomly O
assigned O
to O
receive O
either O
a O
single O
dose O
of O
ciclesonide O
200 O
microg O
( O
n O
= O
251 O
) O
or O
placebo O
( O
n O
= O
251 O
) O
administered O
intranasally O
. O
[]

Bright O
light O
therapy O
in O
Parkinson O
's O
disease O
: O
a O
pilot O
study O
. O
[]

However O
, O
anterior B-outcome ['Physiological-Clinical']
chamber I-outcome ['Physiological-Clinical']
flare I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
the O
control O
group O
( O
P O
= O
0.035 O
) O
, O
and O
patients O
felt O
significantly O
more O
pain B-outcome ['Physiological-Clinical']
in O
this O
group O
( O
P O
= O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Persons O
infected O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
are O
often O
hyporesponsive O
to O
immunization O
, O
including O
pneumococcal O
vaccines O
. O
[]

PURPOSE O
To O
evaluate O
the O
effects O
of O
Naphcon O
eye O
drops O
for O
preventing O
conjunctival O
bleeding O
during O
Lasik O
surgery O
. O
[]

RESULTS O
On O
d O
3 O
, O
C-peptide B-outcome ['Physiological-Clinical']
was O
more O
than O
10-fold O
lower O
( O
P O
< O
0.0001 O
) O
in O
the O
IIT O
group O
than O
in O
the O
CIT O
group O
. O
['Physiological-Clinical']

Dental O
bacteremia O
in O
children O
. O
[]

Mean O
arterial B-outcome ['Physiological-Clinical']
pressures B-outcome ['Physiological-Clinical']
did O
not O
differ O
significantly O
between O
treatment O
and O
control O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Procalcitonin O
was O
measured O
daily O
by O
a O
semi-quantitative O
immunoassay O
in O
the O
study O
group O
. O
[]

Correlations O
between O
the O
various O
parameters O
, O
the O
change O
of O
the O
values O
at O
PD60 O
sGaw O
in O
relation O
to O
the O
initial O
values O
, O
the O
interindividual O
variability O
and O
the O
reactivity O
were O
determined O
. O
[]

The O
[]

Increased O
dietary O
intake O
of O
fish O
oil O
omega-3 O
fatty O
acids O
, O
eicosapentanoic O
acid O
and O
docosohexanoic O
acid O
, O
and O
their O
precursor O
, O
alpha-linolenic O
acid O
( O
ALA O
) O
, O
is O
associated O
with O
various O
health O
benefits O
. O
[]

PATIENT O
( O
S O
) O
One O
hundred O
eighty-nine O
infertile O
women O
undergoing O
outpatient O
hysteroscopy O
. O
[]

The O
primary O
aim O
of O
this O
study O
is O
to O
compare O
the O
effectiveness O
of O
two O
currently O
existing O
health O
care O
programs O
with O
different O
intensity O
and O
mode O
of O
delivery O
on O
daily O
functioning O
in O
patients O
with O
GOA O
. O
[]

The O
control O
group O
received O
routine O
well-baby O
care O
. O
[]

STATEMENT O
OF O
PROBLEM O
Zirconia O
cores O
are O
reported O
to O
be O
less O
translucent O
than O
glass O
, O
lithium O
disilicate O
, O
or O
alumina O
cores O
. O
[]

BACKGROUND O
Effective O
treatments O
for O
onychomycosis O
are O
expensive O
. O
[]

Planned O
radiotherapy O
was O
the O
same O
in O
both O
groups O
. O
[]

Type-4a O
MI O
was O
not O
associated O
with O
the O
subsequent O
hazard O
for O
cardiac B-outcome ['Mortality']
mortality I-outcome ['Mortality']
( O
p=0.6 O
) O
. O
['Mortality']

To O
explain O
the O
results O
, O
we O
extended O
the O
FRF O
model O
by O
incorporating O
normalization O
, O
yielding O
a O
filter-rectify-normalize-filter O
model O
, O
in O
which O
normalization O
enhances O
selectivity O
for O
second-order O
SF O
but O
only O
for O
low O
spatial O
frequencies O
. O
[]

Recent O
pharmacological O
studies O
confirmed O
the O
role O
of O
hypercholesterolemia O
in O
the O
pathogenesis O
of O
coronary O
atherosclerosis O
. O
[]

CONCLUSION O
It O
appears O
likely O
that O
mitomycin O
C O
plus O
doxorubicin O
instillation O
has O
an O
equivalent O
efficacy O
to O
BCG O
as O
the O
initial O
therapy O
of O
carcinoma O
in O
situ O
and O
the O
combination O
of O
them O
would O
be O
the O
most O
efficient O
treatment O
for O
the O
disease O
. O
[]

On O
the O
day O
of O
the O
O O
( O
3 O
) O
exposure O
, O
supplemented O
subjects O
were O
found O
to O
have O
significantly O
increased O
levels O
of O
plasma B-outcome ['Physiological-Clinical']
ascorbate I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
tocopherols I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
carotenoids I-outcome ['Physiological-Clinical']
as O
compared O
with O
those O
of O
the O
placebo O
group O
. O
['Physiological-Clinical']

This O
is O
an O
important O
finding O
that O
, O
from O
a O
cost-effective O
perspective O
, O
could O
contribute O
toward O
an O
optimized O
management O
of O
patients O
with O
IBS O
. O
[]

MEASUREMENTS O
AND O
RESULTS O
Registration O
included O
hemodynamic O
data O
from O
the O
peripheral O
artery O
and O
the O
pulmonary O
artery O
, O
and O
the O
measurement O
of O
cardiac B-outcome ['Physiological-Clinical']
troponin I-outcome ['Physiological-Clinical']
I I-outcome ['Physiological-Clinical']
( O
CTnI B-outcome ['Physiological-Clinical']
) O
and O
creatine B-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
isoenzyme I-outcome ['Physiological-Clinical']
MB I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CK-MB O
) O
values O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Among O
all O
patients O
, O
mortality B-outcome ['Mortality']
was O
equivalent O
across O
sedation O
groups O
. O
['Mortality']

Lithium O
sustains O
the O
acute O
antidepressant B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
of O
sleep O
deprivation O
: O
preliminary O
findings O
from O
a O
controlled O
study O
. O
['Life-Impact']

Baseline O
screening O
coverage O
interviews O
were O
then O
performed O
: O
58 O
of O
158 O
women O
in O
the O
intervention O
zone O
and O
46 O
of O
146 O
in O
the O
control O
zone O
were O
excluded O
from O
the O
study O
because O
of O
having O
had O
a O
Pap O
smear O
within O
5 O
years O
, O
but O
these O
were O
included O
in O
the O
final O
analysis O
. O
[]

However O
, O
because O
of O
complex O
parameter O
derivation O
, O
the O
method O
is O
rarely O
used O
. O
[]

This O
study O
was O
carried O
out O
to O
test O
the O
main O
and O
interaction O
effects O
of O
training O
condition O
and O
pretreatment-elicited O
verbal O
imitation O
ability O
when O
predicting O
spoken O
language O
use O
during O
language O
training O
of O
60 O
minimally O
verbal O
autistic O
children O
. O
[]

High-frequency O
intravesical O
electroneurostimulation O
was O
made O
simultaneously O
with O
magnetophoresis O
of O
the O
mixture O
based O
on O
oxibutinin O
. O
[]

Thus O
metformin O
treatment O
did O
not O
have O
any O
significant O
effect O
on O
insulin O
sensitivity O
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or O
sympathetic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
this O
small O
group O
of O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Bu O
as O
pretransplant O
conditioning O
is O
safe O
in O
high-risk O
myeloid O
leukemia O
patients O
; O
( O
2 O
) O
clofarabine O
is O
sufficiently O
immunosuppressive O
to O
support O
allo-SCT O
in O
myeloid O
leukemia O
; O
and O
( O
3 O
) O
the O
median O
OS O
of O
23 O
months O
in O
this O
high-risk O
patient O
population O
is O
encouraging O
. O
[]

The O
pseudo-withdrawal B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
consisted O
of O
an O
increase O
in O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
only O
, O
whereas O
true O
withdrawal B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
also O
included O
perceptual B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
and O
psychotic B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

The O
main O
barriers O
reported O
for O
not O
engaging O
in O
a O
new O
treatment O
cycle O
were O
low O
self-efficacy B-outcome ['Life-Impact']
and O
lack B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
interest I-outcome ['Life-Impact']
in O
quitting O
. O
['Life-Impact', 'Life-Impact']

CONCLUSION O
The O
present O
study O
suggests O
that O
the O
grip O
strength O
of O
national O
level O
judo O
athletes O
receiving O
chiropractic O
SMT O
improved O
compared O
to O
those O
receiving O
sham O
. O
[]

Serum O
levels O
of O
PSA O
were O
assessed O
at O
baseline O
( O
-2 O
, O
-1 O
, O
0 O
weeks O
) O
and O
after O
6 O
, O
13 O
, O
19 O
, O
20 O
and O
21 O
weeks O
. O
[]

DESIGN O
AND O
METHOD O
Data O
were O
gathered O
from O
60 O
caregiver/patient O
dyads O
in O
a O
cross-sectional O
design O
. O
[]

The O
method O
involved O
Responsivity O
education O
for O
the O
parents O
and O
Prelinguistic O
Milieu O
Teaching O
for O
the O
children O
( O
RPMT O
) O
. O
[]

After O
adjustment O
for O
important O
covariates O
, O
the O
RR O
of O
infection O
in O
patients O
administered O
supplemental O
oxygen O
was O
0.46 O
( O
95 O
% O
CI O
, O
0.22-0.95 O
; O
P O
= O
.04 O
) O
. O
[]

CONCLUSION O
Use O
of O
intranasal O
furosemide O
represents O
a O
valid O
therapeutic O
treatment O
in O
the O
prevention O
of O
chronic O
hyperplastic O
sinusitis O
with O
nasal O
polyposis O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
dispersion O
of O
QT O
interval O
, O
i.e O
. O
[]

During O
the O
ovarian O
stimulation O
regimen O
, O
the O
patients O
were O
submitted O
to O
hormonal O
( O
oestradiol O
and O
growth O
hormone O
) O
, O
ultrasonographic O
( O
follicular O
number O
and O
diameter O
, O
endometrial O
thickness O
) O
and O
Doppler O
( O
uterine O
and O
perifollicular O
arteries O
) O
evaluations O
. O
[]

The O
subjective O
effects O
produced O
by O
mecamylamine O
were O
not O
characteristic O
of O
those O
of O
psychoactive O
drugs O
. O
[]

Both O
the O
absolute O
and O
percentage O
decreases O
in O
mean O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
induced O
by O
nifedipine O
and O
the O
combination O
compared O
with O
placebo O
were O
similar O
and O
significantly O
greater O
than O
those O
induced O
by O
chlorthalidone O
. O
['Physiological-Clinical']

The O
offspring O
were O
cross-fostered O
, O
and O
the O
plasma B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
and O
catecholamine B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
the O
offspring O
were O
determined O
on O
postnatal O
d O
( O
PND O
) O
1 O
and O
27 O
and O
under O
specific O
challenging O
conditions O
: O
after O
weaning O
( O
PND O
29 O
) O
and O
after O
ACTH O
and O
insulin O
challenges O
( O
PND O
68 O
and O
70 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
PH-LPL B-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
, O
blood O
was O
collected O
15 O
min O
after O
50 O
IU/kg O
iv O
heparin O
injection O
. O
['Physiological-Clinical']

RESULTS O
The O
postreduction O
neck-shaft O
angle O
was O
maintained O
in O
the O
majority O
of O
the O
fractures O
in O
both O
groups O
. O
[]

It O
was O
shown O
that O
a O
6-month O
course O
of O
treatment O
with O
afala O
at O
a O
dose O
of O
2 O
tablets O
4 O
times O
a O
day O
resulted O
in O
a O
significant O
reduction O
in O
the O
severity O
of O
urinary O
disorders O
, O
estimated O
by O
total O
IPSS O
score O
, O
relative O
to O
baseline O
values O
and O
compared O
to O
placebo O
therapy O
. O
[]

Bronchial B-outcome ['Physiological-Clinical']
matrix I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
respond O
to O
inhaled O
steroids O
despite O
ongoing O
allergen O
exposure O
in O
asthma O
. O
['Physiological-Clinical']

RESULTS O
Data O
analysis O
showed O
no O
significant O
difference O
between O
pethidine O
and O
tramadol O
for O
all O
the O
haemodynamic B-outcome ['Physiological-Clinical']
variables O
( O
p O
= O
> O
0.05 O
) O
. O
['Physiological-Clinical']

A O
randomized O
field O
trial O
was O
conducted O
with O
500 O
mother-child O
pairs O
from O
a O
low-income O
area O
of O
S?o O
Leopoldo O
, O
State O
of O
Rio O
Grande O
do O
Sul O
, O
Brazil O
, O
to O
evaluate O
the O
impact O
of O
a O
nutritional O
intervention O
in O
the O
first O
year O
of O
life O
on O
the O
dietary O
quality O
of O
3- O
to O
4-y-old O
children O
. O
[]

Our O
results O
also O
suggest O
that O
other O
studies O
in O
this O
field O
, O
particularly O
those O
using O
parallel O
groups O
design O
, O
should O
take O
account O
of O
practice O
effects O
. O
[]

SETTING O
Outpatient O
. O
[]

CONTEXT O
Exercise O
benefits O
patients O
with O
cancer O
, O
but O
studies O
of O
home-based O
approaches O
, O
particularly O
among O
those O
with O
Stage O
IV O
disease O
, O
remain O
small O
and O
exploratory O
. O
[]

METHODS O
. O
[]

This O
recent O
focus O
on O
TP53 B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
as O
a O
possible O
determinant O
of O
cancer O
therapy O
response O
has O
raised O
the O
question O
of O
whether O
or O
not O
mutations O
in O
the O
TP53 O
gene O
have O
an O
influence O
on O
paclitaxel O
therapy O
. O
['Physiological-Clinical']

Behavioral O
problems O
are O
among O
the O
most O
challenging O
aspects O
of O
caring O
for O
a O
person O
with O
Alzheimer O
's O
disease O
. O
[]

Fatigue O
is O
a O
common O
symptom O
of O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
, O
and O
results O
in O
a O
reduction O
of O
daily O
activity O
and O
quality O
of O
life O
in O
patients O
with O
the O
disease O
. O
[]

Using O
the O
interactive O
multimedia O
learning O
system O
for O
studying O
open-angle O
glaucoma O
[ O
3 O
] O
a O
prospective O
, O
randomized O
, O
case-controlled O
study O
was O
carried O
out O
to O
determine O
the O
value O
of O
this O
new O
form O
of O
learning O
in O
terms O
of O
acceptance B-outcome ['Life-Impact']
and O
the O
imparting B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
. O
['Life-Impact']

OBJECTIVE O
To O
establish O
whether O
SkBF B-outcome ['Physiological-Clinical']
can O
be O
modified O
by O
exposure O
to O
the O
radiofrequency O
waves O
emitted O
by O
a O
mobile O
phone O
when O
the O
latter O
is O
held O
against O
the O
jaw O
and O
ear O
. O
['Physiological-Clinical']

Beverage O
vs. O
solid O
fruits O
and O
vegetables O
: O
effects O
on O
energy O
intake O
and O
body B-outcome ['Physiological-Clinical']
weight O
. O
['Physiological-Clinical']

CBFV B-outcome ['Physiological-Clinical']
, O
COe B-outcome ['Physiological-Clinical']
, O
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
significantly O
lower O
in O
the O
esmolol O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
exhaled B-outcome ['Physiological-Clinical']
NO O
were O
measured O
at O
every O
visit O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
compare O
the O
clinical O
and O
bacteriological B-outcome ['Physiological-Clinical']
effectiveness O
of O
intravenous O
( O
IV O
) O
ceftriaxone O
followed O
by O
oral O
cefditoren O
pivoxil O
or O
IV O
ceftriaxone O
for O
acute O
pyelonephritis O
. O
['Physiological-Clinical']

Further O
exploration O
of O
the O
degree O
to O
which O
poor O
sleep O
contributes O
to O
hormonal O
and O
cytokine O
dysregulation O
and O
how O
they O
are O
involved O
in O
the O
pathophysiology O
of O
PPMD O
is O
warranted O
. O
[]

The O
only O
statistically O
significant O
improvement O
in O
the O
treatment O
as O
compared O
to O
the O
control O
group O
was O
seen O
in O
self-care B-outcome ['Life-Impact']
and O
cognition B-outcome ['Life-Impact']
domains O
of O
the O
Functional O
Independence O
Measure O
for O
children O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Pentoxifylline O
therapy O
regularly O
increased O
the O
PBPI O
in O
impotent O
men O
in O
comparison O
with O
the O
placebo O
, O
frequently O
into O
the O
normal O
range O
. O
[]

Participants O
had O
autistic O
spectrum O
disorders O
, O
Asperger O
disorder O
, O
or O
pervasive O
developmental O
disorder O
, O
not O
otherwise O
specified O
; O
had O
illness O
severity O
ratings O
of O
at O
least O
moderate O
on O
the O
Clinical O
Global O
Impressions O
, O
Severity O
of O
Illness O
Scale O
; O
and O
scored O
at O
least O
moderate O
on O
compulsive O
behaviors O
measured O
with O
the O
Children O
's O
Yale-Brown O
Obsessive O
Compulsive O
Scales O
modified O
for O
pervasive O
developmental O
disorders O
. O
[]

Intervention O
pilot O
for O
parents O
of O
children O
with O
autistic O
spectrum O
disorder O
. O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
monitored O
during O
the O
treatment O
period O
. O
['Adverse-effects']

10 O
, O
22 O
% O
female O
) O
completed O
all O
the O
visits O
, O
with O
a O
high O
rate O
of O
study O
withdrawal O
due O
to O
gastrointestinal O
side O
effects O
. O
[]

Because O
of O
encouraging O
results O
from O
trials O
of O
adjuvant O
chemotherapy O
in O
the O
mid O
1970s O
, O
the O
Stockholm O
Breast O
Cancer O
Study O
Group O
decided O
to O
directly O
compare O
postoperative O
radiation O
( O
RT O
) O
with O
adjuvant O
CMF-type O
chemotherapy O
( O
CT O
) O
. O
[]

Supplements O
( O
200 O
ml O
) O
were O
provided O
every O
20 O
min O
and O
consisted O
of O
placebo O
, O
a O
7.75 O
% O
carbohydrate O
solution O
, O
and O
a O
7.75 O
% O
carbohydrate/1.94 O
% O
protein O
solution O
. O
[]

The O
magnitude O
of O
the O
threshold O
was O
60 O
% O
of O
maximal O
static O
inspiratory O
mouth O
pressure O
( O
PI O
, O
mmax O
) O
at O
functional O
residual O
capacity O
, O
and O
the O
duty O
cycle O
was O
0.5 O
. O
[]

0.3 O
g/l O
, O
p O
< O
0.01 O
) O
, O
factor O
VII O
( O
from O
144.2 O
? O
[]

The O
mean O
maximum B-outcome ['Physiological-Clinical']
Cr I-outcome ['Physiological-Clinical']
was O
3.3 O
+/- O
1.4 O
, O
range O
1.7-8.7 O
mg/dL O
) O
. O
['Physiological-Clinical']

SETTING O
Ten O
centers O
in O
the O
United O
States O
. O
[]

A O
prospective O
randomized O
clinical O
trial O
assessing O
the O
relative O
effectiveness O
of O
erythromycin-neomycin O
and O
metronidazole-neomycin O
as O
a O
preoperative O
bowel O
preparation O
was O
carried O
out O
. O
[]

Secondary O
efficacy O
endpoints O
included O
pain B-outcome ['Physiological-Clinical']
intensity O
difference O
( O
PID O
) O
and O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
( O
PR O
) O
throughout O
the O
60-min O
post-dose O
assessment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Impact O
of O
work O
site O
health O
promotion O
on O
stages O
of O
dietary O
change O
: O
the O
Working O
Well O
Trial O
. O
[]

As O
compared O
with O
controls O
, O
subjects O
at O
the O
experimental O
sites O
improved O
significantly O
in O
cardiovascular B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
aerobic I-outcome ['Physiological-Clinical']
power O
) O
, O
general B-outcome ['Physiological-Clinical']
muscular B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
( O
number O
of O
sit B-outcome ['Life-Impact']
ups B-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
minute I-outcome ['Physiological-Clinical']
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

BACKGROUND O
Controversy O
exists O
on O
how O
the O
length O
and O
diameter O
of O
colonoscopes O
affect O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
colonoscopy I-outcome ['Life-Impact']
. O
['Life-Impact']

Recovery O
following O
outpatient O
anesthesia O
: O
use O
of O
enflurane O
versus O
propofol O
. O
[]

The O
main O
child O
outcome O
variables O
of O
interest O
were O
collected O
through O
direct O
classroom O
observations O
. O
[]

HPV O
testing O
using O
self-collected O
vaginal O
specimens O
may O
be O
useful O
in O
primary O
screening O
but O
performs O
poorly O
for O
detecting O
post-treatment B-outcome ['Physiological-Clinical']
failures I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Between O
1988 O
and O
1997 O
, O
153 O
patients O
in O
pCR O
following O
platinum-based O
intravenous O
CT O
were O
randomized O
between O
four O
courses O
of O
intraperitoneal O
cisplatin O
( O
P O
) O
( O
90 O
mg/m2 O
every O
3 O
weeks O
) O
or O
observation O
. O
[]

Four-year O
( O
postnephrectomy O
) O
survival O
percentages O
and O
randomized O
treatment O
regimens O
for O
low-risk O
patients O
were O
96.5 O
% O
for O
607 O
Stage O
I/FH O
patients O
who O
received O
dactinomycin O
( O
Actinomycin O
D O
[ O
AMD O
] O
, O
Merck O
Sharp O
& O
Dohme O
, O
West O
Point O
, O
PA O
) O
and O
vincristine O
( O
VCR O
) O
for O
10 O
weeks O
versus O
6 O
months O
; O
92.2 O
% O
for O
278 O
Stage O
II/FH O
patients O
; O
and O
86.9 O
% O
for O
275 O
Stage O
III/FH O
patients O
who O
received O
AMD O
+ O
VCR O
+/- O
Adriamycin O
( O
ADR O
, O
Adria O
Laboratories O
, O
Columbus O
, O
OH O
) O
for O
15 O
months O
. O
[]

Cost-effectiveness O
of O
a O
telephone-delivered O
intervention O
for O
physical O
activity O
and O
diet O
. O
['Resource-use']

CONCLUSION O
Our O
data O
highlight O
the O
discrepancy O
between O
the O
Diagnosis O
Related O
Group O
prospective O
payment O
system O
and O
actual B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
['Resource-use']

There O
were O
no O
significant O
differences O
between O
the O
groups O
in O
the O
duration O
of O
intubation B-outcome ['Resource-use']
following O
surgery O
, O
the O
length O
of O
intensive B-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit-stay I-outcome ['Resource-use']
or O
the O
total O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
. O
['Resource-use', 'Resource-use', 'Resource-use']

Retention O
needles O
on O
the O
head O
with O
simultaneous O
behavior O
training O
was O
applied O
for O
the O
trial O
group O
. O
[]

DESIGN O
Randomized O
, O
masked O
clinical O
trial O
. O
[]

145 O
U/L O
, O
310 O
? O
[]

Patients O
in O
both O
groups O
were O
fitted O
with O
two O
IFRS O
retainers O
and O
also O
were O
instructed O
to O
use O
a O
1100-ppm O
fluoride O
conventional O
sodium O
fluoride O
dentifrice O
twice O
daily O
. O
[]

A O
clinical O
trial O
( O
ROMEO O
) O
was O
planned O
to O
evaluate O
applicability O
and O
reproducibility O
of O
group O
care O
in O
other O
outpatients O
facilities O
and O
assess O
its O
impact O
on O
a O
larger O
patient O
population O
. O
[]

In O
the O
premenopausal O
group O
this O
period O
was O
17 O
months O
( O
chi2 O
1 O
= O
8.8 O
; O
P O
= O
0.003 O
) O
compared O
with O
8 O
months O
in O
the O
post-menopausal O
group O
( O
chi2 O
1 O
= O
3.3 O
; O
P O
= O
0.07 O
) O
. O
[]

The O
ulcer B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
rate O
is O
related O
to O
the O
dosage O
and O
course O
of O
treatment O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
in O
interleukin-2 B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
or O
circulating B-outcome ['Physiological-Clinical']
B-cell I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
between O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Norfloxacin O
, O
trimethoprim/sulfamethoxazole O
, O
cytokines O
, O
nitric O
oxide O
, O
expression O
levels O
of O
nuclear O
factor O
( O
NF O
) O
-kappaB O
and O
inhibitor O
of O
NF-kappaB O
( O
IkB-alpha O
) O
, O
neutrophil O
oxidative O
burst O
, O
and O
rate O
of O
apoptotic O
events O
were O
determined O
. O
[]

Prospective O
randomised O
trial O
of O
amifostine O
cytoprotection O
in O
myeloma O
patients O
undergoing O
high-dose O
melphalan O
conditioned O
autologous O
stem O
cell O
transplantation O
. O
[]

The O
effect O
of O
sedation O
on O
hemodynamics O
during O
UGIE O
has O
not O
been O
fully O
studied O
, O
and O
therefore O
the O
aim O
of O
this O
study O
was O
to O
clarify O
whether O
or O
not O
sedation O
can O
reduce O
cardiac O
stress O
dufing O
UGIE O
. O
[]

In O
this O
double O
blind O
placebo O
controlled O
study O
, O
an O
oral O
vaccine O
prepared O
from O
insect O
saliva O
was O
compared O
with O
placebo O
( O
stable O
vaccine O
solvent O
) O
. O
[]

The O
latter O
were O
randomized O
to O
oral O
calcium O
( O
3 O
g/day O
) O
plus O
vitamin O
D O
( O
1 O
mg/day O
) O
( O
Group O
A O
, O
n=49 O
) O
, O
calcium O
alone O
( O
Group O
B O
, O
n=49 O
) O
, O
or O
no O
supplements O
( O
Group O
C O
, O
n=50 O
) O
. O
[]

A O
study O
was O
undertaken O
to O
determine O
whether O
changes O
in O
arterial O
oxygen O
tension O
affect O
levels O
of O
exhaled O
NO O
in O
humans O
. O
[]

The O
benefit-to-risk O
ratio O
for O
longterm O
etanercept O
treatment O
remains O
highly O
favorable O
. O
[]

The O
characteristics O
of O
the O
groups O
were O
similar O
, O
except O
for O
a O
higher O
mean O
weight O
in O
the O
ECMO O
circuit O
group O
( O
3.6 O
+/- O
0.3 O
kg O
vs O
2.8 O
+/- O
0.4 O
kg O
, O
p=0.03 O
) O
. O
[]

In O
addition O
, O
blood O
cardioplegic O
solution O
samples O
were O
collected O
in O
Group O
I O
from O
the O
lines O
proximal O
and O
distal O
to O
the O
filter O
during O
first O
and O
last O
administration O
. O
[]

The O
dose-normalized B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
all-E-zeaxanthin I-outcome ['Physiological-Clinical']
after O
the10-mg O
dose O
was O
40 O
% O
lower O
( O
P O
< O
0.001 O
) O
than O
after O
the O
1-mg O
dose O
. O
['Physiological-Clinical']

A O
randomised O
controlled O
trial O
of O
ranibizumab O
with O
and O
without O
ketorolac O
eyedrops O
for O
exudative B-outcome ['Physiological-Clinical']
age-related I-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
degeneration I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Diclofenac O
reduced O
the O
anti-aggregatory B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of O
aspirin O
in O
the O
first O
two O
days O
, O
since O
the O
CT B-outcome ['Physiological-Clinical']
did O
not O
rise O
significantly O
( O
109+/-19 O
s O
, O
148+/-56 O
s O
, O
and O
168+/-66 O
s O
at O
0 O
h O
, O
24 O
h O
, O
48 O
h O
, O
respectively O
, O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
double-blind O
randomized O
clinical O
trial O
did O
not O
identify O
a O
simplified O
, O
successful O
once O
daily O
H. O
pylori O
treatment O
for O
children O
and O
adolescents O
. O
[]

At O
baseline O
, O
the O
mean O
density O
of O
the O
proteoglycans B-outcome ['Physiological-Clinical']
( O
PGS B-outcome ['Physiological-Clinical']
) O
biglycan B-outcome ['Physiological-Clinical']
and O
decorin B-outcome ['Physiological-Clinical']
were O
, O
respectively O
, O
higher O
and O
lower O
in O
the O
bronchial O
mucosa O
of O
asthmatics O
as O
compared O
with O
normal O
controls O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Consent O
and O
recruitment O
to O
the O
trial O
will O
be O
obtained O
when O
the O
mother O
requests O
opioid O
analgesia O
. O
[]

One O
hundred O
patients O
receiving O
no O
prophylactic O
therapy O
after O
total O
hip O
arthroplasty O
between O
1988 O
and O
1992 O
were O
analyzed O
and O
defined O
as O
the O
historical O
control O
group O
. O
[]

Does O
short-term O
treatment O
with O
proton O
pump O
inhibitors O
cause O
rebound O
aggravation O
of O
symptoms O
? O
[]

A O
phase O
III O
, O
double-blind O
, O
placebo-controlled O
, O
multicenter O
study O
on O
the O
efficacy O
of O
recombinant O
human O
antithrombin O
in O
heparin-resistant O
patients O
scheduled O
to O
undergo O
cardiac O
surgery O
necessitating O
cardiopulmonary O
bypass O
. O
[]

An O
experiment O
was O
conducted O
with O
36 O
primiparous O
and O
40 O
multiparous O
Holstein O
cows O
to O
examine O
the O
effects O
of O
feeding O
wet O
corn O
gluten O
feed O
( O
WCGF O
) O
on O
305-d O
milk B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
, O
dry B-outcome ['Physiological-Clinical']
matter I-outcome ['Physiological-Clinical']
( O
DM B-outcome ['Physiological-Clinical']
) O
intake O
, O
body B-outcome ['Physiological-Clinical']
condition I-outcome ['Physiological-Clinical']
score O
( O
BCS B-outcome ['Physiological-Clinical']
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
study O
, O
33 O
patients O
were O
randomly O
assigned O
to O
receive O
desflurane O
( O
D O
) O
or O
isoflurane O
( O
I O
) O
for O
acoustic O
neuroma O
surgery O
. O
[]

In O
haplotype O
HT4 O
, O
caffeine O
failed O
to O
counteract O
the O
waking-induced O
impairment O
of O
PVT O
performance O
and O
the O
rebound O
of O
SWA O
in O
recovery O
sleep O
. O
[]

Patients O
with O
diastolic O
HF O
had O
decreased O
E/A B-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
( O
0.9 O
+/- O
0.4 O
vs O
1.4 O
+/- O
1.1 O
, O
p O
< O
0.02 O
, O
diastolic O
HF O
vs O
systolic O
HF O
) O
and O
increased O
filling B-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
( O
30.4 O
+/- O
3.2 O
vs O
26.5 O
+/- O
4.7 O
ms O
, O
p O
< O
0.01 O
, O
diastolic O
HF O
vs O
systolic O
HF O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
double-blind O
study O
] O
. O
[]

This O
applied O
to O
186 O
uncomplicated O
pregnancies O
in O
which O
there O
was O
no O
clinical O
suspicion O
of O
poor B-outcome ['Physiological-Clinical']
intrauterine B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
efficacy O
of O
pegfilgrastim+/-chemotherapy O
for O
mobilizing O
stem O
cells O
in O
patients O
with O
solid O
tumours O
was O
assessed O
. O
[]

A O
total O
of O
99 O
subjects O
with O
resected O
superficial O
bladder O
cancer O
( O
pTa O
, O
pT1 O
) O
were O
randomized O
to O
either O
fenretinide O
( O
200 O
mg O
day O
p.o O
. O
[]

The O
plasma O
IL-8 O
, O
TNF-? O
, O
CRP O
, O
lipase O
, O
LDH O
at O
14 O
days O
after O
intervention O
of O
nutrition O
in O
P+EN O
group O
were O
significantly O
lower O
than O
those O
in O
PN O
group O
and O
EN O
group O
( O
IL-8 O
: O
21.00 O
? O
[]

ClinicalTrials.gov O
identifier O
number O
: O
NCT01174823 O
. O
) O
[]

The O
children O
in O
the O
play O
group O
showed O
more O
diverse O
types O
of O
symbolic B-outcome ['Physiological-Clinical']
play I-outcome ['Physiological-Clinical']
in O
interaction O
with O
their O
mothers O
and O
higher O
play B-outcome ['Life-Impact']
levels I-outcome ['Life-Impact']
on O
both O
the O
play B-outcome ['Life-Impact']
assessment I-outcome ['Life-Impact']
and O
in O
interaction O
with O
their O
mothers O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

80 O
% O
of O
predicted O
normal O
and O
FEV O
( O
1 O
) O
/FVC O
of O
?0.70 O
were O
enrolled O
. O
[]

Closure O
time O
and O
pain B-outcome ['Physiological-Clinical']
scores O
were O
comparable O
between O
the O
groups O
. O
['Physiological-Clinical']

RESULTS O
The O
increase O
in O
hematocrit B-outcome ['Physiological-Clinical']
in O
the O
rHuEPO-treated O
group O
compared O
with O
hematocrit B-outcome ['Physiological-Clinical']
in O
the O
placebo-treated O
group O
was O
statistically O
significant O
( O
P O
= O
.0001 O
) O
as O
measured O
by O
percentage O
point O
of O
change O
from O
baseline O
to O
final O
evaluation O
, O
by O
an O
increase O
in O
hematocrit B-outcome ['Physiological-Clinical']
level O
of O
six O
percentage O
points O
or O
more O
unrelated O
to O
transfusion O
, O
and O
by O
a O
rise O
in O
hematocrit B-outcome ['Physiological-Clinical']
level O
to O
38 O
% O
or O
more O
unrelated O
to O
transfusion O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Both O
groups O
underwent O
daily O
supplementation O
of O
either O
3g O
CLA O
or O
3g O
placebo O
for O
30 O
days O
, O
respectively O
, O
and O
performed O
exercise O
on O
a O
bicycle O
ergometer O
3 O
times O
per O
week O
for O
30-40 O
min O
at O
50 O
% O
VO2 O
peak O
workload O
. O
[]

Moreover O
, O
extensive O
acoustical B-outcome ['Physiological-Clinical']
and O
aerodynamic B-outcome ['Physiological-Clinical']
in B-outcome ['Physiological-Clinical']
vivo I-outcome ['Physiological-Clinical']
registrations I-outcome ['Physiological-Clinical']
are O
performed O
using O
a O
newly O
developed O
data O
acquisition O
system O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Olmesartan O
did O
not O
reduce O
mean O
SeDBP B-outcome ['Physiological-Clinical']
significantly O
compared O
with O
valsartan O
, O
although O
more O
patients O
attained O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
goal O
with O
olmesartan O
( O
P=.031 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Microtensile O
bond O
strength O
of O
a O
repair O
composite O
to O
leucite-reinforced O
feldspathic O
ceramic O
. O
[]

A O
simple O
validated O
high-performance O
liquid O
chromatography O
( O
HPLC O
) O
assay O
was O
developed O
for O
determination O
of O
diflunisal O
and O
naproxen O
in O
human O
plasma O
samples O
. O
[]

BACKGROUND O
Long-term O
care O
hospitals O
are O
Medicare O
providers O
of O
postacute O
care O
that O
have O
a O
mean O
length O
of O
stay O
of O
25 O
days O
or O
more O
. O
[]

A O
plaque O
index O
for O
occlusal O
surfaces O
and O
fissures O
. O
[]

0.13 O
) O
ng?ml???h?? O
, O
AII O
( O
155.18 O
? O
[]

The O
GH-induced B-outcome ['Physiological-Clinical']
increment I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
IGF-I I-outcome ['Physiological-Clinical']
and O
TBW B-outcome ['Physiological-Clinical']
was O
greater O
in O
men O
than O
in O
women O
( O
P O
< O
0.01 O
) O
, O
whereas O
the O
decreases O
in O
BF B-outcome ['Physiological-Clinical']
were O
similar O
in O
men O
and O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Combined O
action O
of O
enalapril O
or O
timolol O
with O
hydrochlorothiazide O
plus O
amiloride O
in O
hypertension O
. O
[]

The O
remaining O
dentin O
surfaces O
were O
replicated O
and O
gold-coated O
. O
[]

METHODS O
A O
randomized O
, O
single-blind O
, O
controlled O
trial O
was O
conducted O
in O
30 O
non-diabetic O
patients O
with O
hypertension O
over O
a O
period O
of O
9 O
weeks O
to O
evaluate O
the O
effect O
of O
a O
device O
that O
helps O
to O
slow B-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
( O
Resperate O
) O
on O
BP B-outcome ['Physiological-Clinical']
and O
quality O
of O
life O
( O
QoL O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Sixteen O
young O
adult O
sufferers O
from O
extrinsic O
paroxysmal O
asthma O
with O
pollen O
hypersensitivity O
took O
part O
in O
a O
therapeutic O
trial O
of O
the O
synthetic O
anticholinergic O
agent O
oxitropium O
bromide O
administered O
by O
a O
metered O
dose O
inhaler O
. O
[]

PURPOSE O
This O
study O
prospectively O
assessed O
the O
effects O
of O
knee O
position O
on O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
range O
of O
motion B-outcome ['Life-Impact']
after O
primary O
total O
knee O
arthroplasty O
( O
TKA O
) O
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
Of O
44 O
patients O
, O
22 O
patients O
received O
WP-CRT O
and O
22 O
received O
WP-IMRT O
. O
[]

Therefore O
, O
the O
bleeding O
complications O
of O
intermittent O
heparin O
therapy O
could O
have O
been O
due O
to O
the O
higher O
dose O
, O
and O
the O
recurrences O
associated O
with O
continuous O
heparin O
therapy O
may O
have O
resulted O
from O
lower O
doses O
rather O
than O
from O
differences O
in O
the O
method O
of O
administration O
. O
[]

The O
children O
were O
participants O
in O
an O
early O
intensive O
behavioural O
intervention O
clinic O
and O
during O
downtimes O
stood O
on O
a O
whole O
body O
vibration O
platform O
with O
the O
machine O
turned O
off O
( O
control O
condition O
) O
and O
on O
( O
treatment O
condition O
) O
for O
three O
to O
four O
, O
30 O
s O
periods O
( O
frequency=28 O
Hz O
; O
amplitude O
0.97 O
mm O
) O
. O
[]

INTERPRETATION O
Prophylactic O
VT O
ablation O
before O
defibrillator O
implantation O
seemed O
to O
prolong O
time O
to O
recurrence O
of O
VT O
in O
patients O
with O
stable O
VT O
, O
previous O
myocardial O
infarction O
, O
and O
reduced O
LVEF O
. O
[]

Results O
demonstrated O
that O
the O
standard O
and O
directive O
story O
formats O
were O
equally O
as O
effective O
in O
eliciting B-outcome ['Physiological-Clinical']
, O
generalizing O
and O
maintaining B-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
targeted I-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
participants O
who O
had O
prior O
game O
play O
experience O
and O
Verbal B-outcome ['Life-Impact']
Comprehension I-outcome ['Life-Impact']
Index O
( O
VCI O
) O
scores O
from O
the O
WISC-IV O
intelligence O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

The O
efficacy O
and O
safety O
profile O
of O
od O
administration O
of O
vancomycin O
is O
similar O
to O
that O
of O
the O
customary O
, O
but O
less O
convenient O
, O
bd O
administration O
. O
[]

Because O
of O
their O
complexity O
, O
such O
clinical O
trials O
present O
unique O
methodological O
and O
design O
challenges O
. O
[]

Exploratory O
DCE-MRI O
showed O
no O
significant O
perfusion O
changes O
with O
aflibercept O
. O
[]

OBJECTIVE O
To O
investigate O
the O
clinical O
effect O
of O
transcatheter O
arterial O
chemoembolization O
( O
TACE O
) O
combined O
with O
high O
intensity O
focused O
ultrasound O
( O
HIFU O
) O
ablation O
in O
treatment O
of O
large O
hepatocellular O
carcinoma O
( O
HCC O
) O
. O
[]

A O
possible O
local O
effect O
of O
intra-arterially O
administered O
heparin O
during O
transradial O
procedures O
has O
not O
been O
evaluated O
. O
[]

Outcome O
measures O
included O
the O
Swanson O
, O
Nolan O
, O
and O
Pelham O
Questionnaire O
revised O
for O
DSM-IV O
( O
ADHD O
and O
ODD O
scales O
) O
and O
the O
Children O
's O
Yale-Brown O
Obsessive O
Compulsive O
Scales O
for O
PDD O
. O
[]

The O
main O
inclusion O
criteria O
for O
participants O
were O
a O
positive O
dermatophyte O
culture O
and O
at O
least O
25 O
% O
distal O
subungual O
clinical O
involvement O
. O
[]

Subjects O
were O
given O
the O
Autism B-outcome ['Life-Impact']
Diagnostic I-outcome ['Life-Impact']
Observation I-outcome ['Life-Impact']
Schedule O
( O
ADOS O
) O
and O
other O
pertinent B-outcome ['Life-Impact']
developmental I-outcome ['Life-Impact']
measures I-outcome ['Life-Impact']
at O
baseline O
and O
at O
weeks O
4 O
and O
8 O
to O
assess O
drug O
effects O
. O
['Life-Impact', 'Life-Impact']

The O
findings O
thus O
support O
previous O
conclusions O
that O
early O
discharge O
from O
hospital O
after O
uncomplicated O
MI O
is O
not O
associated O
with O
greater O
risk O
for O
the O
patient O
than O
later O
discharge O
. O
[]

Temporospatial O
and O
joint-kinematic O
parameters O
were O
evaluated O
. O
[]

METHODS O
Fifty-one O
patients O
participated O
in O
this O
study O
for O
a O
total O
of O
174 O
teeth O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
examine O
the O
effects O
of O
extremely O
early O
enteral O
feedings O
on O
the O
development O
in O
very O
low-birthweight O
( O
VLBW O
) O
infants O
. O
[]

A O
second O
group O
received O
a O
form O
letter O
listing O
recommendations O
for O
all O
preventive O
procedures O
for O
all O
age O
and O
sex O
groups O
. O
[]

The O
relationship O
between O
the O
improvement O
in O
VT O
and O
reduction O
in O
gradient O
of O
the O
Borg/VE B-outcome ['Physiological-Clinical']
slope I-outcome ['Physiological-Clinical']
was O
significant O
( O
r=.40 O
, O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

One-year O
observed O
survival B-outcome ['Mortality']
rates O
at O
intention O
to O
treat O
were O
83.7 O
% O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
74.5 O
to O
94.0 O
) O
in O
the O
dialysis O
group O
versus O
87.3 O
% O
( O
95 O
% O
CI O
, O
78.9 O
to O
96.5 O
) O
in O
the O
diet O
group O
( O
log-rank O
test O
for O
noninferiority O
, O
P O
< O
0.001 O
; O
for O
superiority O
, O
P O
= O
0.6 O
) O
: O
the O
difference O
in O
survival B-outcome ['Mortality']
was O
-3.6 O
% O
( O
95 O
% O
CI O
, O
-17 O
to O
+10 O
; O
P O
= O
0.002 O
) O
. O
['Mortality', 'Mortality']

The O
primary O
endpoint O
was O
annualised O
relapse O
rate O
. O
[]

RESULTS O
There O
were O
no O
differences O
between O
warfarin O
products O
in O
terms O
of O
mean O
INR O
results O
or O
number O
of O
dosage O
adjustments O
required O
. O
[]

One O
child O
, O
who O
had O
received O
placebo O
, O
had O
repeated B-outcome ['Physiological-Clinical']
convulsions I-outcome ['Physiological-Clinical']
and O
died O
1 O
h O
after O
admission O
to O
hospital O
. O
['Physiological-Clinical']

CONCLUSION O
In O
this O
small O
subset O
, O
mean O
prolactin B-outcome ['Physiological-Clinical']
elevation I-outcome ['Physiological-Clinical']
persisted O
for O
at O
least O
26 O
weeks O
. O
['Physiological-Clinical']

METHODS O
This O
was O
a O
12-week O
, O
double-blind O
, O
randomized O
, O
placebo-controlled O
study O
of O
NAC O
in O
children O
with O
autistic O
disorder O
. O
[]

Twenty-two O
children O
with O
severe O
CF O
and O
signs O
of O
acute O
lower O
respiratory O
infection O
were O
randomly O
assigned O
to O
receive O
either O
cloxacillin O
or O
carbenicillin O
plus O
gentamicin O
administered O
intravenously O
for O
ten O
days O
. O
[]

Improvements O
in O
emotion B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
appear O
related O
to O
the O
content O
of O
the O
DVD O
as O
participants O
in O
a O
control O
group O
who O
observed O
an O
alternate O
DVD O
showed O
no O
such O
improvement O
. O
['Life-Impact']

This O
change O
of O
activation O
is O
analogous O
to O
functional O
modification O
of O
middle-latency O
reflex O
EMG B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
load O
, O
or O
cutaneous O
perturbation O
. O
['Physiological-Clinical']

Evidence O
from O
brain-damaged O
patients O
suggests O
that O
regions O
in O
the O
temporal O
lobes O
, O
distinct O
from O
those O
engaged O
in O
lower-level O
auditory O
analysis O
, O
process O
the O
pitch O
and O
rhythmic O
structure O
in O
music O
. O
[]

A O
preoperative O
skull O
block O
may O
reduce O
hemodynamic B-outcome ['Physiological-Clinical']
fluctuations I-outcome ['Physiological-Clinical']
and O
hypo- B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
hyperventilation I-outcome ['Physiological-Clinical']
due O
to O
emergence O
delirium O
or O
oversedation O
and O
provide O
adequate O
pain O
relief O
, O
thereby O
reducing O
postoperative B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
findings O
might O
be O
relevant O
to O
P3 O
studies O
working O
with O
patients O
and O
controls O
: O
the O
harder O
some O
frequently O
blinking O
subjects O
try O
to O
refrain O
from O
blinking O
, O
the O
smaller O
might O
become O
their O
P3 B-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Thyroid B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
excess O
resulted O
in O
a O
hypofibrinolytic B-outcome ['Physiological-Clinical']
condition B-outcome ['Physiological-Clinical']
and O
in O
an O
enhanced O
TAFIa-dependent B-outcome ['Physiological-Clinical']
prolongation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
clot I-outcome ['Physiological-Clinical']
lysis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Plasmapheresis O
, O
hemodialysis O
, O
and O
chemotherapy O
. O
[]

Overall O
survival O
in O
both O
groups O
was O
not O
different O
( O
P=.087 O
) O
. O
[]

A O
prospective O
, O
double-blind O
, O
randomized O
, O
controlled O
clinical O
trial O
comparing O
standard O
wound O
care O
with O
adjunctive O
hyperbaric O
oxygen O
therapy O
( O
HBOT O
) O
to O
standard O
wound O
care O
only O
for O
the O
treatment O
of O
chronic O
, O
non-healing O
ulcers O
of O
the O
lower O
limb O
in O
patients O
with O
diabetes O
mellitus O
: O
a O
study O
protocol O
. O
[]

In O
addition O
, O
children O
randomised O
to O
the O
two O
intervention O
groups O
will O
be O
offered O
individual O
, O
improvisational O
music O
therapy O
over O
a O
period O
of O
five O
months O
, O
either O
one O
session O
( O
low-intensity O
) O
or O
three O
sessions O
( O
high-intensity O
) O
per O
week O
. O
[]

In O
week O
14 O
, O
the O
median O
relative B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
wart I-outcome ['Physiological-Clinical']
area O
was O
98 O
% O
in O
the O
ALA-PDT O
group O
( O
interquartile O
range O
100 O
% O
, O
55 O
% O
) O
versus O
52 O
% O
( O
100 O
% O
, O
0 O
) O
in O
the O
placebo O
group O
( O
p=0.0006 O
) O
. O
['Physiological-Clinical']

MPA O
was O
given O
orally O
as O
tablets O
, O
as O
a O
dose O
of O
500 O
mg O
b.i.d O
. O
[]

Treatment O
groups O
did O
not O
differ O
significantly O
in O
overall B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
, O
response O
rate O
or O
progression B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
or O
overall-survival B-outcome ['Mortality']
. O
['Life-Impact', 'Physiological-Clinical', 'Mortality']

Average O
fidelity B-outcome ['Physiological-Clinical']
was O
57 O
% O
in O
Strategies O
for O
Teaching O
based O
on O
Autism O
Research O
classrooms O
and O
48 O
% O
in O
Structured O
Teaching O
classrooms O
. O
['Physiological-Clinical']

On O
Day O
8 O
, O
patients O
started O
to O
receive O
dexamethasone O
, O
vincristine O
, O
and O
L-asparaginase O
. O
[]

The O
V B-outcome ['Physiological-Clinical']
wave-to-maximal I-outcome ['Physiological-Clinical']
M I-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
V/M I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
increased O
significantly O
( O
55.1 O
? O
['Physiological-Clinical']

From O
these O
results O
, O
it O
was O
concluded O
that O
in O
the O
patients O
tested O
, O
intradermal O
injection O
of O
OK-432 O
appears O
to O
be O
clinically O
superior O
to O
intramuscular O
injection O
. O
[]

INTRODUCTION O
Azithromycin O
, O
a O
broad-spectrum O
antibiotic O
with O
potent O
anti-inflammatory O
activities O
, O
has O
the O
potential O
to O
effectively O
treat O
blepharitis B-outcome ['Physiological-Clinical']
, O
an O
inflammatory O
disease O
of O
the O
eyelid O
with O
abnormal O
eyelid O
flora O
as O
an O
etiologic O
determinant O
. O
['Physiological-Clinical']

The O
actual B-outcome ['Resource-use']
cost I-outcome ['Resource-use']
of O
geno-identical O
stem-cell O
transplantation O
results O
from O
posttransplant O
complications O
that O
can O
not O
be O
predicted O
prospectively O
and O
require O
ex O
post O
cost O
adjustment O
. O
['Resource-use']

A O
protocol O
graft O
biopsy O
was O
performed O
at O
two O
years O
on O
all O
functioning O
kidneys O
, O
and O
the O
histological B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
were O
scored O
blindly O
. O
['Physiological-Clinical']

Responders O
were O
defined O
as O
those O
patients O
who O
achieved O
healing O
of O
at O
least O
one O
third O
of O
the O
ulcer O
area O
during O
the O
study O
period O
. O
[]

Patients O
in O
the O
experimental O
group O
received O
a O
brief O
note O
in O
which O
they O
were O
explicitly O
asked O
to O
increase O
both O
their O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
level O
and O
time B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
sun I-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
, O
while O
control O
group O
patients O
did O
not O
receive O
these O
explicit O
recommendations O
. O
['Life-Impact', 'Life-Impact']

Findings O
show O
that O
computer-delivered O
tailored O
interventions O
are O
an O
effective O
adjunct O
to O
the O
clinical O
encounter O
that O
can O
improve O
knowledge O
and O
health O
beliefs O
about O
CRC O
screening O
, O
necessary O
precursors O
to O
behavior O
change O
. O
[]

We O
here O
report O
on O
the O
1-year O
results O
of O
a O
prospective O
randomized O
single-center O
study O
in O
patients O
with O
symptomatic O
main-stem O
and O
main-stem-equivalent O
lesions O
with O
substantially O
increased O
risk O
for O
bypass O
surgery O
. O
[]

However O
, O
15 O
mg O
oxazepam O
was O
more O
effective O
in O
relieving O
preoperative B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
than O
1200 O
mg O
gabapentin O
. O
['Life-Impact']

[ O
Treatment O
of O
autism O
children O
: O
observation O
on O
efficacy O
of O
behavior O
training O
with O
retention O
of O
needles O
on O
head O
] O
. O
[]

There O
were O
two O
5-day O
treatment O
periods O
with O
lansoprazole O
60 O
mg O
once O
daily O
or O
placebo O
in O
random O
order O
, O
separated O
by O
a O
9-day O
washout O
period O
. O
[]

Greater O
than O
90 O
% O
of O
the O
patients O
receiving O
13-CRA O
developed O
[]

METHODS O
This O
phase O
III O
trial O
was O
a O
randomized O
, O
placebo-controlled O
crossover O
design O
. O
[]

Four O
different O
modes O
of O
FES O
were O
applied O
in O
random O
order O
: O
constant O
stimulation O
, O
randomized O
frequency O
( O
mean O
40 O
Hz O
) O
, O
randomized O
current O
amplitude O
, O
and O
randomized O
pulsewidth O
( O
mean O
250 O
micros O
) O
. O
[]

Behavioral B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
in O
autistic O
individuals O
as O
a O
result O
of O
wearing O
ambient O
transitional O
prism O
lenses O
. O
['Life-Impact']

A O
stable O
prostacyclin O
analogue O
( O
iloprost O
) O
in O
the O
treatment O
of O
ischaemic O
ulcers O
of O
the O
lower O
limb O
. O
[]

Nitroglycerin O
, O
nitroprusside O
, O
or O
both O
, O
in O
preventing O
radial B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
spasm I-outcome ['Physiological-Clinical']
during O
transradial O
artery O
catheterization O
. O
['Physiological-Clinical']

METHODS O
A O
number O
1 O
polyglactin O
suture O
was O
tied O
around O
the O
cervix O
to O
occlude O
the O
uterine O
arteries O
, O
and O
polythene O
tourniquets O
were O
tied O
around O
the O
infundibulopelvic O
ligament O
to O
obstruct O
the O
ovarian O
vessels O
. O
[]

Before O
and O
after O
treatment O
plaque B-outcome ['Physiological-Clinical']
index O
( O
PlI O
) O
, O
gingival B-outcome ['Physiological-Clinical']
index O
( O
GI O
) O
, O
angulated B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
index O
( O
AngBI B-outcome ['Physiological-Clinical']
) O
, O
tooth B-outcome ['Physiological-Clinical']
stain B-outcome ['Physiological-Clinical']
( O
GMSI B-outcome ['Physiological-Clinical']
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
order O
to O
establish O
a O
set O
of O
predictive O
equations O
for O
the O
gas B-outcome ['Physiological-Clinical']
exchange I-outcome ['Physiological-Clinical']
, O
ventilatory B-outcome ['Physiological-Clinical']
and O
cardiovascular B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
maximum O
ramp-incremental O
cycle O
ergometry O
, O
this O
study O
prospectively O
evaluated O
120 O
sedentary O
individuals O
( O
60 O
males O
, O
60 O
females O
, O
aged O
20-80 O
) O
, O
randomly-selected O
from O
> O
8,000 O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
present O
study O
evaluated O
the O
use O
of O
divalproex O
in O
the O
treatment O
of O
repetitive B-outcome ['Life-Impact']
, I-outcome ['Life-Impact']
compulsive-like I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
autism I-outcome ['Life-Impact']
spectrum O
disorder B-outcome ['Physiological-Clinical']
( O
ASD O
) O
. O
['Life-Impact', 'Physiological-Clinical']

In O
addition O
, O
986 O
breast O
cancer O
and O
442 O
colorectal O
cancer O
( O
CRC O
) O
cases O
were O
studied O
. O
[]

STUDY O
DESIGN O
Forty O
emergency O
patients O
participated O
, O
and O
each O
had O
a O
clinical O
diagnosis O
of O
an O
irreversible O
pulpitis O
. O
[]

Matched O
Cox O
regression O
analyses O
were O
used O
to O
estimate O
association O
of O
CKD O
with O
outcomes O
. O
[]

Bifidobacterium B-outcome ['Physiological-Clinical']
longum I-outcome ['Physiological-Clinical']
was O
the O
most O
frequently O
detected O
species O
in O
breast-milk O
. O
['Physiological-Clinical']

No O
connection O
was O
observed O
between O
gluten O
and O
behaviour B-outcome ['Life-Impact']
typical O
for O
these O
patients O
. O
['Life-Impact']

RESULTS O
Alcohol B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
other I-outcome ['Life-Impact']
drug I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
were O
reduced O
during O
the O
4 O
years O
posttreatment O
, O
with O
the O
exception O
of O
nicotine O
. O
['Life-Impact']

CONCLUSION O
It O
appears O
that O
knees O
with O
more O
severe O
coexisting O
PF O
disease O
demonstrate O
features O
distinct O
from O
those O
observed O
in O
TFOA O
in O
isolation O
or O
in O
combination O
with O
mild O
PF O
disease O
. O
[]

Progestins O
may O
offer O
a O
good O
alternative O
for O
the O
control O
of O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
in O
this O
setting O
; O
in O
particular O
, O
oral O
megestrol O
acetate O
has O
been O
proven O
effective O
in O
a O
randomized O
, O
placebo-controlled O
clinical O
trial O
. O
['Physiological-Clinical']

The O
placebo-corrected O
effect O
on O
mean O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
1.16 O
mm O
Hg O
( O
95 O
% O
confidence O
interval O
, O
-1.6 O
to O
5.1 O
, O
P O
> O
.05 O
) O
, O
demonstrating O
that O
sildenafil O
did O
not O
decrease O
mean O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Simple O
interventions O
of O
minimal O
contact O
time O
focusing O
on O
walking O
can O
significantly O
increase O
physical O
activity O
in O
individuals O
at O
increased O
risk O
of O
developing O
colon O
cancer O
. O
[]

Mean O
follow-up O
was O
2.4 O
years O
( O
SD O
, O
1.4 O
) O
. O
[]

INTERVENTIONS O
Patients O
were O
withdrawn O
from O
nonsteroidal O
anti-inflammatory O
drug O
therapy O
. O
[]

No O
reduction O
in O
the O
size O
or O
number O
of O
AK B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
was O
observed O
in O
vehicle-treated O
patients O
. O
['Physiological-Clinical']

Patients O
treated O
with O
the O
combination O
tended O
to O
have O
more O
rapid O
recovery B-outcome ['Physiological-Clinical']
to O
an O
absolute B-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
of O
500 O
x O
10 O
( O
6 O
) O
/l O
( O
median O
= O
12.5 O
vs O
18 O
days O
for O
concurrent O
and O
19 O
days O
for O
historical O
control O
patients O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
many O
relationships O
have O
been O
found O
between O
parameters O
of O
objective O
and O
subjective O
oral O
function O
, O
the O
structure O
of O
these O
relationships O
remain O
unclear O
. O
[]

The O
prophylactic O
addition O
of O
a O
beta-adrenergic O
anatagonist O
might O
mask O
this O
response O
and O
prevent O
the O
deleterious O
cardiovascular B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
FOB I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Analysis O
will O
be O
by O
intention-to-treat O
. O
[]

METHODS O
In O
a O
double-blind O
trial O
, O
we O
randomly O
assigned O
14,264 O
patients O
with O
nonvalvular O
atrial O
fibrillation O
who O
were O
at O
increased O
risk O
for O
stroke O
to O
receive O
either O
rivaroxaban O
( O
at O
a O
daily O
dose O
of O
20 O
mg O
) O
or O
dose-adjusted O
warfarin O
. O
[]

Visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
was O
assessed O
uniocularly O
using O
the O
crowded O
and O
uncrowded O
logMAR O
acuity O
tests O
and O
the O
logMAR O
crowded O
and O
uncrowded O
Kay O
picture O
tests O
in O
random O
orders O
. O
['Physiological-Clinical']

BACKGROUND O
The O
problem O
of O
ghostwriting O
in O
corporate-sponsored O
clinical O
trials O
is O
of O
concern O
to O
medicine O
, O
bioethics O
, O
and O
government O
agencies O
. O
[]

A O
safety O
and O
tolerability B-outcome ['Life-Impact']
study O
. O
['Life-Impact']

While O
the O
use O
of O
simulators O
can O
enhance O
test O
validity O
and O
reliability O
, O
the O
given O
clinical O
context O
may O
also O
affect O
student O
performance O
. O
[]

The O
effects O
of O
TB1 O
and O
TB2 O
( O
containing O
ginseng O
leaf O
, O
cistanche O
and O
fleeceflower O
root O
) O
were O
different O
significantly O
( O
P O
< O
0.05 O
, O
P O
< O
0.01 O
) O
. O
[]

In O
conclusion O
, O
the O
investigated O
LMW-heparin O
( O
Logiparin O
) O
is O
safe O
and O
effective O
in O
preventing O
postoperative O
thromboembolism O
in O
patients O
undergoing O
total O
hip O
replacement O
, O
but O
the O
dosage O
can O
probably O
be O
optimized O
. O
[]

DESIGN O
Cross-sectional O
study O
. O
[]

Modulation O
of O
the O
central O
nervous O
system O
excitability O
may O
be O
involved O
. O
[]

The O
median O
time O
to O
interferon O
failure O
was O
31.3 O
months O
. O
[]

Paclitaxel O
( O
175 O
mg/m2 O
) O
plus O
carboplatin O
( O
6 O
AUC O
) O
versus O
paclitaxel O
( O
225 O
mg/m2 O
) O
plus O
carboplatin O
( O
6 O
AUC O
) O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
: O
a O
multicenter O
randomized O
trial O
. O
[]

DESIGN O
The O
study O
was O
a O
two-arm O
, O
parallel O
randomized O
clinical O
trial O
. O
[]

Nine O
patients O
had O
chronic O
myeloid O
leukemia O
( O
CML O
) O
( O
BC O
: O
2 O
, O
second O
AP O
: O
3 O
, O
and O
tyrosine-kinase O
inhibitor O
refractory O
first O
chronic O
phase O
[ O
CP O
] O
: O
4 O
) O
. O
[]

Improvement O
in O
sexuality O
score O
was O
greatest O
with O
combined O
estrogen-androgen O
therapy O
. O
[]

Intake O
of O
vitamin O
A-fortified O
cooking O
oil O
combined O
with O
vitamin O
A-rich O
foods O
was O
necessary O
to O
increase O
serum B-outcome ['Physiological-Clinical']
retinol I-outcome ['Physiological-Clinical']
concentration O
. O
['Physiological-Clinical']

HIVIG B-outcome ['Physiological-Clinical']
rapidly I-outcome ['Physiological-Clinical']
cleared I-outcome ['Physiological-Clinical']
maternal I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
complex-dissociated I-outcome ['Physiological-Clinical']
p24 I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
, O
and O
plasma B-outcome ['Physiological-Clinical']
HIV-1 I-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
levels O
were O
stable O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Bacteremia O
due O
to O
Bacteroides O
fragilis O
after O
elective O
appendectomy O
in O
renal O
transplant O
recipients O
. O
[]

No O
significant O
difference O
was O
found O
between O
the O
two O
groups O
for O
favourable O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
: O
47/51 O
( O
92.1 O
% O
) O
and O
49/52 O
( O
94.2 O
% O
) O
in O
the O
od O
and O
bd O
groups O
, O
respectively O
. O
['Physiological-Clinical']

Lack O
of O
a O
pharmacokinetic B-outcome ['Physiological-Clinical']
interaction I-outcome ['Physiological-Clinical']
between O
steady-state O
roflumilast O
and O
single-dose O
midazolam O
in O
healthy O
subjects O
. O
['Physiological-Clinical']

A O
randomised O
study O
was O
carried O
out O
to O
assess O
the O
effect O
of O
tracheal O
tube O
rotation O
on O
the O
passage O
of O
a O
tube O
over O
a O
gum-elastic O
bougie O
into O
the O
trachea O
in O
100 O
patients O
. O
[]

A O
new O
multidimensional O
self-report O
instrument O
assessing O
abstinence-specific O
functional O
support O
was O
developed O
for O
the O
study O
. O
[]

Effect O
of O
the O
motilin O
agonist O
KC O
11458 O
on O
gastric O
emptying O
in O
diabetic O
gastroparesis O
. O
[]

After O
12 O
hours O
in O
the O
oral O
cavity O
, O
the O
crown O
was O
removed O
and O
examined O
by O
confocal O
laser O
scanning O
microscope O
( O
CLSM O
) O
and O
scanning O
electron O
microscope O
( O
SEM O
) O
. O
[]

The O
combination O
therapy O
was O
better O
[]

Participants O
engaged O
in O
a O
pretest O
roleplay O
with O
an O
actress O
playing O
a O
drinking O
pregnant O
woman O
. O
[]

The O
Treatment O
of O
Lead-exposed O
Children O
( O
TLC O
) O
trial O
: O
design O
and O
recruitment O
for O
a O
study O
of O
the O
effect O
of O
oral O
chelation O
on O
growth O
and O
development O
in O
toddlers O
. O
[]

ACE O
inhibitors O
might O
therefore O
become O
first-line O
drugs O
in O
early O
antihypertensive O
intervention O
in O
Type O
II O
diabetic O
patients O
. O
[]

Sound B-outcome ['Physiological-Clinical']
energy B-outcome ['Life-Impact']
at O
3-5 O
['Physiological-Clinical', 'Life-Impact']

Two O
parameter O
estimates O
, O
the O
maximum B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentration O
( O
Cmax O
) O
and O
the O
area O
under O
plasma B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
vs. O
time O
curves O
( O
AUCs O
) O
, O
were O
used O
to O
evaluate O
bioequivalence O
. O
['Physiological-Clinical', 'Physiological-Clinical']

= O
1.68 O
, O
P O
= O
0.002 O
; O
F O
= O
8.21 O
, O
d.f O
. O
[]

National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
Breast O
Cancer O
Prevention O
Trial O
Investigators O
. O
[]

BACKGROUND O
Adding O
clonidine O
to O
weak O
ropivacaine O
solutions O
( O
< O
0.2 O
% O
) O
could O
potentially O
enhance B-outcome ['Life-Impact']
analgesia I-outcome ['Life-Impact']
as O
well O
as O
further O
reduce O
the O
risk O
for O
unwanted O
motor O
blockade O
. O
['Life-Impact']

We O
found O
that O
the O
intervention O
also O
improved O
heath B-outcome ['Physiological-Clinical']
( O
P O
= O
.05 O
) O
and O
health B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
( O
P O
= O
.03 O
) O
when O
participants O
were O
aged O
21 O
years O
. O
['Physiological-Clinical', 'Life-Impact']

OBJECTIVE O
To O
determine O
the O
efficacy O
of O
interferential O
therapy O
( O
IFT O
) O
electrode O
placement O
technique O
compared O
with O
a O
control O
treatment O
in O
subjects O
with O
acute O
low O
back O
pain O
( O
LBP O
) O
. O
[]

Differences O
remained O
significant O
( O
p O
< O
0.001 O
) O
through O
week O
12 O
. O
[]

OBJECTIVE O
To O
compare O
elastic O
stable O
intramedullary O
nailing O
( O
ESIN O
) O
with O
nonoperative O
treatment O
of O
fully O
displaced O
midshaft O
clavicular O
fractures O
in O
adults O
. O
[]

BACKGROUND O
We O
wanted O
to O
assess O
the O
influence O
of O
various O
surveillance O
intervals O
on O
the O
risk O
of O
new B-outcome ['Physiological-Clinical']
neoplasia I-outcome ['Physiological-Clinical']
after O
removal O
of O
pedunculated O
and O
small O
sessile O
tubular O
and O
tubulovillous O
adenomas O
. O
['Physiological-Clinical']

This O
double-blind O
study O
compares O
two O
antibiotics O
, O
namely O
ofloxacin O
and O
neomycin-polymyxin O
B O
, O
with O
similar O
in O
vitro O
sensitivities O
to O
Gram O
positive O
and O
Gram O
negative O
organisms O
. O
[]

Incidence O
of O
scoring O
scars O
and O
tissue O
orientation O
loss O
were O
the O
primary O
outcome O
measures O
. O
[]

UNLABELLED O
Patients O
with O
headaches O
account O
for O
approximately O
2 O
% O
of O
all O
ED O
visits O
, O
with O
migraines O
being O
the O
most O
common O
defined O
primary O
headache O
syndrome O
. O
[]

This O
condition O
is O
associated O
with O
activation O
of O
the O
renin O
angiotensin O
system O
( O
RAS O
) O
with O
elevated O
levels O
of O
angiotensin O
II O
( O
ANG O
II O
) O
, O
a O
potent O
pulmonary O
pressor O
agent O
. O
[]

INTERVENTION O
( O
S O
) O
Single-dose O
anastrozole O
at O
5 O
mg O
( O
n O
= O
39 O
) O
, O
10 O
mg O
( O
n O
= O
39 O
) O
, O
20 O
mg O
( O
n O
= O
39 O
) O
, O
or O
30 O
mg O
( O
n O
= O
38 O
) O
or O
a O
5-day O
course O
of O
CC O
at O
50 O
mg/d O
( O
n O
= O
39 O
) O
as O
starting O
doses O
. O
[]

The O
addition O
of O
blood O
was O
significantly O
more O
effective O
in O
reducing O
pain B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
than O
the O
addition O
of O
saline O
( O
p O
< O
0.001 O
) O
, O
but O
was O
not O
significantly O
more O
effective O
than O
the O
addition O
of O
lignocaine O
. O
['Physiological-Clinical']

METHODS O
We O
investigated O
the O
effect O
of O
acupressure O
at O
the O
extra O
1 O
point O
or O
a O
sham O
point O
on O
needle O
insertion O
using O
verbal O
rating O
scale O
( O
VRS O
) O
pain B-outcome ['Physiological-Clinical']
scores O
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability O
( O
HRV B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
In O
men O
with O
prostate O
cancer O
degarelix O
and O
leuprolide O
have O
similar O
cardiovascular O
safety O
profiles O
. O
[]

The O
immune O
globulin O
infusions O
were O
repeated O
every O
14 O
days O
until O
the O
infants O
weighed O
1800 O
g O
, O
were O
transferred O
to O
another O
center O
, O
died O
, O
or O
were O
sent O
home O
from O
the O
hospital O
. O
[]

Following O
training O
in O
one O
of O
the O
four O
training O
groups O
, O
each O
subject O
rated O
the O
24 O
performances O
on O
the O
testing O
videotape O
and O
interrater O
reliability O
was O
assessed O
for O
each O
group O
. O
[]

METHODS O
We O
compared O
total O
BMD B-outcome ['Physiological-Clinical']
changes O
over O
96 O
weeks O
in O
106 O
ART-naive O
HIV-infected O
subjects O
who O
were O
randomized O
to O
receive O
efavirenz O
( O
EFV O
) O
+ O
zidovudine/lamivudine O
( O
n O
= O
32 O
) O
or O
lopinavir/ritonavir O
( O
LPV/r O
) O
+ O
zidovudine/lamivudine O
induction O
( O
n O
= O
74 O
) O
for O
24-48 O
weeks O
followed O
by O
LPV/r O
monotherapy O
. O
['Physiological-Clinical']

The O
mean O
duration O
of O
remission B-outcome ['Physiological-Clinical']
was O
4.4 O
months O
( O
arm O
1 O
) O
and O
4.9 O
months O
( O
arm O
2 O
) O
. O
['Physiological-Clinical']

Incompatibility O
between O
the O
scheduling O
needs O
of O
the O
families O
and O
the O
nurse O
home O
visitors O
was O
a O
major O
obstacle O
in O
delivering O
the O
program O
on O
time O
, O
despite O
the O
flexibility O
of O
the O
nurse O
home O
visitors O
. O
[]

Low-dose O
aspirin O
has O
also O
been O
shown O
to O
reduce O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
when O
administered O
at O
bedtime O
, O
as O
opposed O
to O
upon O
awakening O
, O
in O
untreated O
hypertensive O
patients O
and O
high-risk O
pregnant O
women O
. O
['Physiological-Clinical']

A O
randomized O
placebo-controlled O
trial O
comparing O
the O
efficacy O
of O
etoricoxib O
30 O
mg O
and O
ibuprofen O
2400 O
mg O
for O
the O
treatment O
of O
patients O
with O
osteoarthritis O
. O
[]

Nevertheless O
, O
HBP B-outcome ['Physiological-Clinical']
appears O
useful O
as O
a O
screening O
test O
for O
the O
detection O
of O
this O
phenomenon O
. O
['Physiological-Clinical']

At O
each O
visit O
, O
spirometry O
, O
24-h O
sputum O
volume O
, O
sputum O
leukocyte O
density O
, O
bacterial O
densities O
, O
and O
concentrations O
of O
interleukin B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
-1beta I-outcome ['Physiological-Clinical']
, O
IL-8 O
, O
tumor O
necrosis O
factor-alpha O
( O
TNF-alpha O
) O
, O
and O
leukotriene B-outcome ['Physiological-Clinical']
B4 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LTB4 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
determined O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
who O
developed O
cotton O
wool O
spots O
are O
characterised O
by O
a O
larger O
decrement O
in O
glycosylated B-outcome ['Physiological-Clinical']
haemoglobin I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
glucose O
values O
, O
more O
frequent O
episodes B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hypoglycaemia I-outcome ['Physiological-Clinical']
, O
a O
longer B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
, O
and O
more O
severe B-outcome ['Physiological-Clinical']
retinopathy I-outcome ['Physiological-Clinical']
at O
onset O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
differences O
could O
be O
detected O
between O
the O
four O
antibiotics O
. O
[]

Following O
this O
demonstration O
that O
early O
intensification O
improves O
survival O
, O
the O
effect O
of O
a O
third O
intensification O
block O
is O
under O
investigation O
. O
[]

CONCLUSIONS O
To O
our O
knowledge O
, O
this O
is O
the O
first O
prospective O
randomized O
study O
comparing O
the O
three O
methods O
of O
chalazia O
treatment O
. O
[]

RESULTS O
Most O
effects O
were O
clear O
, O
owing O
to O
the O
high O
reliability O
of O
performance O
times O
in O
training O
and O
competition O
( O
typical O
errors O
of O
0.9 O
% O
and O
0.8 O
% O
, O
respectively O
) O
. O
[]

5 O
. O
[]

After O
SRP B-outcome ['Resource-use']
plus I-outcome ['Resource-use']
antibiotic I-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
( O
AP+AB O
) O
, O
the O
prevalence O
scores O
dropped O
beyond O
the O
levels O
of O
AP B-outcome ['Physiological-Clinical']
and O
CP B-outcome ['Physiological-Clinical']
, O
beginning O
at O
day O
7 O
, O
and O
remained O
low O
until O
day O
21 O
( O
P O
=or O
< O
.05 O
) O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
of O
a O
24-h O
psychological O
training O
program O
on O
attitudes B-outcome ['Life-Impact']
, O
communication B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
and O
occupational B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
in O
oncology O
: O
a O
randomised O
study O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Regular O
replacement O
of O
extended O
wear O
rigid O
gas O
permeable O
contact O
lenses O
. O
[]

An O
acute O
bout O
of O
aerobic O
exercise O
results O
in O
a O
reduced O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
that O
lasts O
several O
hours O
. O
['Physiological-Clinical']

The O
relief O
in O
both O
severity B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
rhinorrhea I-outcome ['Physiological-Clinical']
obtained O
by O
patients O
was O
analyzed O
using O
the O
Wilcoxon O
signed-rank O
test O
and O
found O
to O
be O
highly O
significant O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURE O
( O
S O
) O
The O
primary O
endpoint O
was O
the O
incidence O
of O
metaphase B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
oocytes I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
numeric I-outcome ['Physiological-Clinical']
chromosomal I-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
, O
using O
full O
( O
spectral O
karyotyping O
) O
or O
partial O
( O
fluorescent O
in O
situ O
hybridization O
with O
seven O
probes O
) O
karyotyping O
or O
Giemsa O
count O
. O
['Physiological-Clinical']

All O
patients O
were O
evaluated O
for O
both O
subjective O
relief B-outcome ['Physiological-Clinical']
as O
well O
as O
side O
effects O
. O
['Physiological-Clinical']

In O
group O
A O
, O
the O
CT O
scan O
was O
performed O
with O
conventional O
bowel O
preparation O
( O
a O
full O
cathartic O
dose O
and O
oral O
contrast O
medium O
to O
tag O
any O
residue O
in O
the O
3 O
days O
preceding O
the O
study O
) O
. O
[]

We O
randomly O
administered O
target O
effect-site O
concentrations O
of O
propofol O
ranging O
from O
0.5 O
to O
5 O
. O
[]

Our O
results O
showed O
that O
parahippocampal B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
significantly O
enhanced O
bilaterally O
when O
participants O
viewed O
images O
of O
a O
room O
in O
which O
they O
had O
previously O
encountered O
negatively O
arousing O
events O
. O
['Physiological-Clinical']

At O
the O
end O
of O
the O
first O
month O
, O
54.2 O
% O
of O
the O
subjects O
were O
responders O
to O
clonidine O
and O
41.5 O
% O
were O
responders O
to O
the O
placebo O
( O
P O
less O
than O
0.05 O
for O
both O
groups O
) O
. O
[]

In O
conclusion O
, O
social O
phobics O
worried O
about O
the O
broadcast O
of O
a O
bodily B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
, O
whereas O
controls O
did O
not O
. O
['Life-Impact']

A O
community-based O
, O
double-blind O
, O
randomized O
trial O
of O
praziquantel O
was O
carried O
out O
in O
an O
area O
of O
Zambia O
endemic O
for O
schistosomiasis O
. O
[]

Quantitative O
measures O
of O
pain B-outcome ['Physiological-Clinical']
intensity O
, O
situational B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
, O
and O
pain B-outcome ['Physiological-Clinical']
distress I-outcome ['Physiological-Clinical']
( O
as O
perceived O
by O
the O
parent O
) O
were O
assessed O
by O
using O
the O
7-point O
Facial O
Pain O
Scale O
, O
State B-outcome ['Life-Impact']
Trait I-outcome ['Life-Impact']
Anxiety I-outcome ['Life-Impact']
Inventory O
for O
Children O
, O
and O
a O
visual O
analog O
scale O
, O
respectively O
, O
before O
and O
after O
laceration O
repair O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

BACKGROUND O
Cigarette O
smoking O
is O
associated O
with O
an O
increased O
risk O
of O
peptic O
ulcer O
and O
gastroesophageal O
reflux O
disease O
. O
[]

The O
median O
duration B-outcome ['Mortality']
of I-outcome ['Mortality']
survival I-outcome ['Mortality']
for O
ANLL O
patients O
was O
significantly O
longer O
( O
P O
= O
0.004 O
) O
than O
that O
of O
ALL O
patients O
treated O
on O
Regimens O
I O
and O
II O
combined O
. O
['Mortality']

CLINICAL O
TRIAL O
REGISTRATION O
Study O
of O
aripiprazole O
in O
the O
treatment O
of O
children O
and O
adolescents O
with O
autistic O
disorder O
. O
[]

However O
, O
the O
guidebook O
was O
seldom O
used O
as O
it O
had O
been O
intended O
during O
consultations O
. O
[]

Children O
in O
both O
programs O
showed O
significantly O
lower O
levels O
of O
generalized B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
and O
total O
anxiety B-outcome ['Life-Impact']
symptoms B-outcome ['Life-Impact']
at O
6-month O
follow-up O
on O
SCAS-C. O
Clinician O
ratings O
on O
the O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Randomized O
clinical O
study O
comparing O
Compeed O
cold O
sore O
patch O
to O
acyclovir O
cream O
5 O
% O
in O
the O
treatment O
of O
herpes O
simplex O
labialis O
. O
[]

INTERVENTION O
The O
patients O
underwent O
a O
single O
session O
of O
low-fluence O
PDT O
or O
3 O
consecutive O
monthly O
injections O
of O
ranibizumab O
. O
[]

METHODS O
Using O
the O
data O
from O
the O
Pirarubicin O
Monotherapy O
Study O
Group O
trial O
, O
bladder B-outcome ['Mortality']
recurrence-free I-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
and O
factors B-outcome ['Physiological-Clinical']
associated I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
bladder I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
in O
the O
control O
group O
were O
analyzed O
. O
['Mortality', 'Physiological-Clinical']

There O
was O
no O
relationship O
between O
plasma O
levels O
and O
age O
, O
level O
of O
intellectual O
functioning O
, O
scores O
on O
the O
14 O
selected O
Children O
's O
Psychiatric O
Rating O
Scale O
( O
CPRS O
) O
items O
, O
Clinical O
Global O
Impressions O
, O
Global O
Clinical O
Consensus O
, O
and O
the O
CPRS O
hyperactivity O
factor O
. O
[]

7 O
min O
, O
respectively O
) O
. O
[]

PARTICIPANTS O
From O
8770 O
patients O
who O
met O
study O
criteria O
, O
719 O
families O
were O
randomly O
selected O
. O
[]

C B-outcome ['Physiological-Clinical']
parvum I-outcome ['Physiological-Clinical']
was O
eradicated O
from O
stool O
in O
13 O
( O
52 O
% O
) O
of O
25 O
receiving O
nitazoxanide O
and O
three O
( O
14 O
% O
) O
of O
22 O
receiving O
placebo O
( O
38 O
% O
, O
95 O
% O
CI O
14-63 O
; O
p=0.007 O
) O
. O
['Physiological-Clinical']

About O
0.5 O
mL O
of O
each O
solution O
was O
separately O
applied O
to O
the O
skin O
of O
the O
forearm O
( O
3 O
cm2 O
) O
, O
and O
then O
mixed O
with O
a O
sterile O
cotton O
bud O
. O
[]

Thus O
, O
activation O
of O
bilateral B-outcome ['Physiological-Clinical']
SMA I-outcome ['Physiological-Clinical']
and O
basal B-outcome ['Physiological-Clinical']
ganglia I-outcome ['Physiological-Clinical']
was O
greater O
in O
continuation O
tapping O
than O
in O
synchronisation O
tapping O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
probiotic O
vaginal O
tablet O
was O
well O
tolerated O
and O
no O
side O
effects O
were O
reported O
. O
[]

Quantitative O
angiographic O
methods O
for O
appropriate O
end-point O
analysis O
, O
edge-effect B-outcome ['Physiological-Clinical']
evaluation O
, O
and O
prediction O
of O
recurrent B-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
after O
coronary O
brachytherapy O
with O
gamma O
irradiation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
the O
drawback O
is O
the O
accompanying O
systemic O
toxicity O
, O
which O
targeted O
treatments O
may O
overcome O
. O
[]

[ O
Afala O
in O
the O
treatment O
of O
patients O
with O
BPH O
: O
efficacy O
and O
safety O
] O
. O
[]

Adjuvant O
subcutaneous O
interleukin-2 O
in O
patients O
with O
resected O
renal O
cell O
carcinoma O
: O
a O
pilot O
study O
. O
[]

This O
indicates O
that O
the O
error O
associated O
with O
this O
estimate O
is O
too O
great O
to O
allow O
clinically O
meaningful O
conclusions O
to O
be O
drawn O
from O
calculated O
total O
hip B-outcome ['Physiological-Clinical']
BMD B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Our O
results O
do O
not O
support O
further O
study O
of O
ganitumab O
in O
this O
subgroup O
of O
patients O
. O
[]

The O
relative O
risk O
of O
mastitis B-outcome ['Physiological-Clinical']
caused I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
Staph I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Cortical O
stimulation O
did O
not O
augment O
the O
gains O
from O
a O
late O
rehabilitation O
program O
. O
[]

CONCLUSIONS O
Both O
IBMC O
and O
PMMC O
are O
successful O
means O
of O
providing O
relief O
from O
severe O
mitral O
stenosis O
with O
a O
gain O
in O
valve O
area O
and O
reduction O
in O
transmitral O
gradient O
. O
[]

No O
co-relation O
could O
be O
established O
between O
the O
clinical O
features O
and O
the O
radiological O
findings O
in O
these O
cases O
. O
[]

Primary O
outcomes O
will O
be O
back-related O
dysfunction O
and O
symptom B-outcome ['Physiological-Clinical']
bothersomeness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PARTICIPANTS O
Fifty-two O
( O
29 O
men O
and O
23 O
women O
) O
out O
of O
62 O
eligible O
hypertensive O
patients O
were O
included.Main O
outcome O
measures O
ABP B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
20 O
mg O
lisinopril O
( O
LIS O
) O
daily O
and O
25 O
mg O
hydrochlorothiazide O
( O
HCT O
) O
daily O
given O
for O
a O
4-week O
period O
. O
['Physiological-Clinical']

In O
RA O
the O
Cockroft O
formula O
can O
reliably O
be O
used O
to O
predict O
Clcr O
from O
Scr O
. O
[]

Thus O
, O
these O
data O
support O
the O
concept O
that O
insulin O
per O
se O
is O
a O
potent O
physiological B-outcome ['Physiological-Clinical']
modulator I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
islet I-outcome ['Physiological-Clinical']
A- I-outcome ['Physiological-Clinical']
and O
B-cell B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Echocardiographic O
measurements O
included O
the O
LV B-outcome ['Physiological-Clinical']
EF I-outcome ['Physiological-Clinical']
, O
the O
E/A B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
filling B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
cavity B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
, O
right B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function B-outcome ['Life-Impact']
, O
and O
mitral B-outcome ['Physiological-Clinical']
regurgitation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

METHODS O
Consecutive O
children O
with O
lymphoblastic O
leukaemia O
diagnosed O
in O
the O
UK O
and O
Ireland O
between O
April O
, O
1997 O
, O
and O
June O
, O
2002 O
, O
were O
randomly O
assigned O
either O
6-thioguanine O
( O
750 O
patients O
) O
or O
6-mercaptopurine O
( O
748 O
patients O
) O
during O
interim O
maintenance O
and O
continuing O
therapy O
. O
[]

There O
is O
, O
however O
, O
a O
need O
for O
effective O
antibiotics O
that O
can O
be O
administered O
orally O
as O
an O
alternative O
to O
ceftriaxone O
, O
which O
requires O
intramuscular O
administration O
. O
[]

Intensification O
also O
led O
to O
a O
statistically O
significant O
decrease O
in O
the O
D-dimer O
level O
, O
compared O
to O
placebo O
( O
P O
= O
.045 O
) O
. O
[]

A O
pilot O
randomised O
control O
trial O
of O
a O
parent O
training O
intervention O
for O
pre-school O
children O
with O
autism O
. O
[]

2 O
. O
[]

Patients O
were O
randomly O
assigned O
to O
transperitoneal O
( O
TPL O
) O
, O
extraperitoneal O
( O
EPL O
) O
or O
laparoscopic O
pelvic O
lymphadenectomy O
( O
LPL O
) O
. O
[]

How O
can O
we O
help O
witnesses O
to O
remember O
more O
? O
[]

After O
1 O
month O
of O
treatment O
, O
alfuzosin O
10 O
mg O
q.d O
. O
[]

Outcome O
measures O
included O
measures O
of O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
global B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

bolus O
of O
750 O
mg O
m O
( O
-2 O
) O
. O
[]

No O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
or O
toxicities B-outcome ['Adverse-effects']
were O
documented O
in O
any O
of O
the O
subjects O
during O
the O
administration O
period O
. O
['Adverse-effects', 'Adverse-effects']

Thirty-eight O
mechanically O
ventilated O
patients O
with O
documented O
nosocomial O
pneumonia O
were O
included O
. O
[]

The O
noncommunicable O
chronic O
diseases O
, O
such O
as O
heart O
disease O
and O
cancer O
, O
have O
been O
linked O
to O
specific O
lifestyle B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
or O
habits O
, O
which O
often O
develop O
early O
in O
life O
. O
['Life-Impact']

We O
enrolled O
women O
in O
a O
prospective O
, O
randomized O
study O
to O
determine O
whether O
an O
intensive O
reminder O
system O
would O
improve O
compliance O
in O
women O
receiving O
depot O
medroxyprogesterone O
injections O
. O
[]

After O
allowing O
for O
the O
effect O
of O
multiple O
demographic O
variables O
, O
the O
difference O
in O
global B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
scores O
between O
groups O
was O
not O
significant O
( O
effect O
: O
0.8 O
[ O
95 O
% O
confidence O
interval O
: O
- O
6.7 O
, O
8.3 O
] O
) O
. O
['Life-Impact']

Combined O
treatment O
with O
an O
anticholinergic O
and O
antacids O
enhanced O
the O
antacid B-outcome ['Resource-use']
effects O
in O
both O
groups O
. O
['Resource-use']

METHODS O
Eligible O
adults O
with O
cancer O
were O
randomized O
in O
a O
double-blind O
manner O
, O
to O
receive O
American O
ginseng O
in O
doses O
of O
750 O
, O
1,000 O
, O
or O
2,000 O
mg/day O
or O
placebo O
given O
in O
twice O
daily O
dosing O
over O
8 O
weeks O
. O
[]

RESULTS O
Physician O
assessment O
of O
injection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
none O
or O
mild O
in O
81 O
% O
of O
HA O
gel O
injections O
with O
preincorporated O
lidocaine O
and O
36 O
% O
of O
HA-alone O
injections O
( O
p O
< O
.001 O
) O
. O
['Physiological-Clinical']

Endoscopy O
was O
performed O
before O
treatment O
and O
periodically O
during O
follow-up O
for O
up O
to O
12 O
months O
after O
healing O
. O
[]

CONCLUSIONS O
CDP571 O
was O
ineffective O
for O
sparing B-outcome ['Physiological-Clinical']
steroids I-outcome ['Physiological-Clinical']
in O
patients O
with O
steroid-dependent O
Crohn O
's O
disease O
. O
['Physiological-Clinical']

In O
patients O
with O
induced O
AF O
the O
mean O
voltage B-outcome ['Physiological-Clinical']
for O
the O
low-tilt O
waveform O
was O
91V O
( O
1.6 O
J O
) O
and O
for O
the O
conventional O
waveform O
was O
158 O
V O
( O
2.0 O
J O
) O
( O
P O
= O
0.005 O
for O
voltage O
, O
P O
= O
ns O
for O
energy O
) O
. O
['Physiological-Clinical']

In O
contrast O
, O
the O
PECS O
facilitated O
generalized B-outcome ['Life-Impact']
requests I-outcome ['Life-Impact']
more O
than O
the O
RPMT O
in O
children O
with O
very O
little O
initiating B-outcome ['Life-Impact']
joint I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
prior O
to O
treatment O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Patients O
with O
spotty O
calcification O
were O
older O
( O
age O
56 O
years O
vs. O
54 O
years O
; O
p O
= O
0.001 O
) O
, O
more O
likely O
to O
be O
male O
( O
68 O
% O
vs. O
54 O
% O
; O
p O
= O
0.01 O
) O
, O
and O
have O
a O
history O
of O
diabetes O
mellitus O
( O
30 O
% O
vs. O
24 O
% O
; O
p O
= O
0.01 O
) O
and O
myocardial O
infarction O
( O
28 O
% O
vs. O
20 O
% O
; O
p O
= O
0.004 O
) O
, O
and O
have O
lower O
on-treatment O
high-density O
lipoprotein O
cholesterol O
levels O
( O
48 O
? O
[]

In O
addition O
, O
analgesia O
was O
tested O
at O
each O
dose O
level O
using O
a O
cold-pressor O
test O
. O
[]

Subjects O
were O
encouraged O
to O
wear O
a O
restrictive O
mitten O
up O
to O
4 O
hours O
a O
day O
. O
[]

The O
aR O
is O
a O
procedure O
dependent O
on O
the O
cooperation O
of O
the O
patient O
, O
whereas O
IOS O
is O
measured O
regardless O
from O
the O
breathing O
activities O
of O
the O
patient O
. O
[]

Amonafide O
was O
given O
at O
300 O
mg/m2/day O
i.v O
. O
[]

SUMMARY O
OF O
BACKGROUND O
DATA O
Exercise O
therapy O
during O
the O
nonchronic O
phase O
of O
back O
pain O
is O
considered O
to O
reduce O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
, O
but O
this O
opinion O
is O
controversial O
. O
['Life-Impact']

We O
examined O
the O
effectiveness O
of O
dimethylglycine O
in O
children O
with O
autism O
and O
pervasive O
developmental O
disorder O
in O
a O
double-blind O
, O
placebo-controlled O
study O
. O
[]

OBJECTIVE O
The O
current O
study O
aimed O
to O
investigate O
the O
impact O
of O
brief O
mindfulness O
training O
on O
the O
performance O
of O
a O
sample O
of O
patients O
with O
TBI O
in O
an O
over-selectivity B-outcome ['Life-Impact']
task O
. O
['Life-Impact']

Moderate/severe O
PFOA O
and O
mild O
PFOA O
were O
also O
associated O
with O
less O
pain O
while O
standing O
( O
odds O
ratio O
[ O
OR O
] O
0.2 O
, O
95 O
% O
confidence O
interval O
[ O
95 O
% O
CI O
] O
0.1-0.7 O
and O
OR O
0.2 O
, O
95 O
% O
CI O
0.1-0.6 O
, O
respectively O
) O
on O
the O
WOMAC O
, O
and O
moderate/severe O
PFOA O
was O
associated O
with O
greater O
difficulty O
with O
going O
downstairs O
( O
OR O
2.9 O
, O
95 O
% O
CI O
1.0-8.1 O
) O
on O
the O
ADLS O
. O
[]

Secondary O
aims O
were O
the O
influence O
of O
digoxin O
on O
the O
pharmacokinetics O
of O
pantoprazole O
as O
well O
as O
safety O
and O
tolerability O
. O
[]

International O
guidelines O
for O
the O
management O
of O
hypertension O
-- O
including O
the O
Fifth O
Report O
of O
the O
Joint O
National O
Committee O
, O
the O
1993 O
report O
of O
the O
World O
Health O
Organization O
and O
the O
International O
Society O
of O
Hypertension O
and O
the O
second O
report O
of O
the O
British O
Hypertension O
Society O
Working O
Party O
-- O
have O
all O
been O
modified O
to O
reflect O
the O
emerging O
evidence O
concerning O
the O
benefits O
of O
treating O
older O
patients O
. O
[]

The O
pregnancy B-outcome ['Physiological-Clinical']
rate O
within O
one O
year O
after O
laparoscopic O
surgery O
were O
compared O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

Observer O
variation O
in O
the O
assessment O
of O
outcome O
in O
traumatic O
brain O
injury O
: O
experience O
from O
a O
multicenter O
, O
international O
randomized O
clinical O
trial O
. O
[]

A O
randomized O
controlled O
trial O
to O
evaluate O
the O
efficacy O
of O
ultrasound-guided O
laser O
photocoagulation O
for O
treatment O
of O
benign O
thyroid O
nodules O
. O
[]

RESULTS O
The O
treatment O
with O
MET O
was O
well O
tolerated O
. O
[]

Masking O
of O
the O
use O
of O
different O
diagnostic O
tests O
was O
not O
possible O
for O
patients O
, O
treating O
physicians O
, O
or O
investigators O
. O
[]

[ O
Management O
of O
the O
perineal O
wounds O
after O
abdominoperineal O
resection O
: O
simple O
drainage O
only O
or O
with O
continuous O
irrigation O
? O
] O
. O
[]

Late O
toxicity B-outcome ['Adverse-effects']
is O
, O
therefore O
, O
important O
. O
['Adverse-effects']

OBJECTIVE O
Ibuprofen O
arginate O
is O
a O
salt O
formulation O
of O
ibuprofen O
designed O
to O
reach O
target O
concentrations O
rapidly O
. O
[]

Late O
miscarriage O
and O
preterm O
birth O
after O
treatment O
with O
clindamycin O
: O
a O
randomised O
consent O
design O
study O
according O
to O
Zelen O
. O
[]

Prazosin O
versus O
captopril O
as O
initial O
therapy O
. O
[]

A O
third O
group O
( O
C O
, O
n=12 O
) O
received O
no O
prophylaxis O
. O
[]

RESULTS O
At O
ultrasound O
examination O
, O
we O
detected O
lymphocele B-outcome ['Physiological-Clinical']
in O
10 O
patients O
( O
33 O
% O
) O
. O
['Physiological-Clinical']

BACKGROUND O
A O
recent O
report O
showed O
that O
oral O
adjuvant O
immunochemotherapy O
with O
protein-bound O
polysaccharide O
K O
( O
PSK O
) O
and O
tegafur/uracil O
( O
UFT O
) O
for O
stage O
II O
and O
III O
colorectal O
cancer O
improves O
overall O
survival O
compared O
with O
UFT O
alone O
. O
[]

Regression O
of O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
hypertrophy I-outcome ['Physiological-Clinical']
occurs O
in O
all O
patients O
after O
aortic O
valve O
replacement O
. O
['Physiological-Clinical']

DESIGN O
, O
SETTING O
, O
PARTICIPANTS O
, O
& O
MEASUREMENTS O
Forty O
patients O
who O
had O
diabetes O
with O
nephropathy O
and O
arteriosclerosis O
obliterans O
and O
had O
already O
been O
treated O
with O
angiotensin O
II O
receptor O
blocker O
( O
n O
= O
40 O
) O
were O
randomly O
assigned O
to O
sarpogrelate O
( O
300 O
mg/d O
; O
n O
= O
20 O
) O
or O
aspirin O
group O
( O
100 O
mg/d O
; O
n O
= O
20 O
) O
. O
[]

BACKGROUND O
AND O
OBJECTIVES O
Gabapentin O
is O
used O
for O
treatment O
of O
neuropathic O
pain O
, O
but O
its O
effect O
on O
different O
somatic O
pain O
modalities O
and O
integrative O
mechanisms O
are O
not O
completely O
understood O
. O
[]

Estrogen O
replacement O
therapy O
is O
the O
most O
effective O
treatment O
for O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
, O
but O
its O
use O
is O
controversial O
in O
breast O
cancer O
survivors O
. O
['Physiological-Clinical']

METHODS O
Participants O
were O
55 O
children O
with O
autistic O
disorder O
, O
aged O
4-7 O
years O
( O
FSIQ O
42-107 O
) O
. O
[]

The O
preparation O
of O
the O
bis O
( O
D3-methyloxime O
) O
, O
bis-methyl O
ester O
of O
PGE-M O
containing O
a O
tritium O
tracer O
in O
position O
2 O
which O
was O
used O
as O
internal O
standard O
for O
the O
SIM O
method O
is O
described O
. O
[]

METHOD O
Survivors O
of O
out-of-hospital O
ventricular O
fibrillation O
or O
asystole O
( O
N O
= O
129 O
) O
, O
documented O
by O
electrocardiograms O
from O
registries O
of O
a O
citywide O
Medic O
One O
unit O
and O
two O
countywide O
emergency O
units O
, O
were O
randomized O
into O
a O
two O
group O
, O
experimental O
, O
longitudinal O
design O
. O
[]

CONCLUSION O
The O
results O
indicate O
an O
increased O
activity O
of O
the O
enzyme O
ADA O
in O
the O
serum O
of O
schizophrenic O
patients O
being O
treated O
with O
clozapine O
and O
this O
increase O
may O
be O
correlated O
with O
clozapine O
's O
superior O
antipsychotic O
efficacy O
. O
[]

The O
study O
took O
place O
in O
Bad O
Pyrmont O
, O
Germany O
( O
latitude O
52 O
degrees O
) O
and O
Graz O
, O
Austria O
( O
latitude O
46 O
degrees O
) O
. O
[]

BACKGROUND O
Studies O
in O
vitro O
suggest O
that O
abrasion B-outcome ['Physiological-Clinical']
and O
erosion B-outcome ['Physiological-Clinical']
may O
act O
synergistically O
to O
produce O
wear O
of O
enamel B-outcome ['Physiological-Clinical']
and O
dentine B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Five O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
documented O
during O
the O
clinical O
investigation O
, O
none O
of O
which O
was O
considered O
by O
the O
investigators O
to O
be O
related O
to O
the O
study O
medication O
. O
['Adverse-effects']

Mean O
change O
from O
baseline O
at O
Week O
12 O
in O
CCQ B-outcome ['Physiological-Clinical']
Total O
Score O
was O
significantly O
better O
in O
continuous O
abstainers O
( O
-1.04 O
) O
vs. O
continuous O
smokers O
( O
-0.53 O
; O
P O
< O
0.0001 O
) O
: O
this O
improvement O
was O
sustained O
at O
Weeks O
24 O
and O
52 O
. O
['Physiological-Clinical']

The O
women O
were O
randomly O
assigned O
to O
two O
groups O
, O
one O
of O
which O
received O
400 O
ml O
of O
the O
high-calcium O
milk O
daily O
for O
16 O
weeks O
while O
the O
other O
received O
the O
placebo O
drink O
. O
[]

Neither O
the O
chronology O
between O
panic B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
and O
avoidance B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
nor O
the O
age O
of O
onset O
of O
panic B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
predicted O
outcome O
in O
short-term O
treatment O
with O
alprazolam O
or O
imipramine O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

OBJECTIVE O
The O
authors O
' O
goal O
was O
to O
assess O
dexamethasone O
for O
the O
treatment O
of O
depression O
. O
[]

It O
is O
still O
unresolved O
whether O
survival B-outcome ['Mortality']
is O
prolonged O
by O
adjuvant O
treatment O
of O
the O
liver O
following O
curative O
resection O
of O
colorectal O
liver O
metastases O
. O
['Mortality']

After O
methadone O
injection O
, O
respiratory B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
was O
less O
pronounced O
than O
after O
heroin O
injection O
. O
['Physiological-Clinical']

All O
relevant O
parameters O
for O
rate O
( O
Cmax O
ss O
, O
Cmin O
ss O
, O
Cav O
ss O
, O
plateau O
time O
, O
peak-trough O
fluctuation O
, O
nocturnal O
excess O
, O
tmax O
ss O
) O
and O
extent B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
( O
AUCss O
) O
were O
calculated O
for O
both O
formulations O
. O
['Physiological-Clinical']

RESULTS O
The O
most O
appreciated O
details O
were O
those O
on O
the O
intervention O
, O
pharmacologic O
treatment O
, O
postoperative O
complicances O
, O
postoperative O
pain O
and O
operative O
competence O
; O
less O
appreciated O
were O
those O
on O
loco-regional O
anesthesia O
, O
duration O
of O
the O
intervention O
, O
anxiolytic O
techniques O
, O
hospital O
reception O
and O
permanence O
in O
the O
hospital O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
; O
number O
of O
N.S O
. O
['Mortality']

CONCLUSIONS O
Chlorogenic O
acid O
and O
trigonelline O
reduced O
early O
glucose B-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
during O
an O
OGTT O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
effectiveness O
and O
complications B-outcome ['Resource-use']
of O
our O
adaptation O
of O
the O
canalith B-outcome ['Resource-use']
repositioning I-outcome ['Resource-use']
procedure I-outcome ['Resource-use']
( O
CRP B-outcome ['Physiological-Clinical']
) O
with O
the O
expectation O
treatment O
for O
benign O
paroxysmal O
positional O
vertigo O
. O
['Resource-use', 'Resource-use', 'Physiological-Clinical']

PATIENTS O
Patients O
from O
the O
Autologous O
Stem O
cell O
Transplantation O
in O
Acute O
Myocardial O
Infarction O
( O
ASTAMI O
) O
study O
were O
re-assessed O
3 O
years O
after O
inclusion O
. O
[]

Comparison O
of O
cuffed O
and O
uncuffed O
endotracheal O
tubes O
in O
young O
children O
during O
general O
anesthesia O
. O
[]

OBJECTIVE O
To O
investigate O
the O
impact O
of O
nasal O
irrigation O
with O
isotonic O
or O
hypertonic O
sodium O
chloride O
solution O
on O
mucociliary O
clearance O
time O
in O
patients O
with O
allergic O
rhinitis O
, O
acute O
sinusitis O
and O
chronic O
sinusitis O
. O
[]

Results O
from O
the O
Nutritional O
Prevention O
of O
Cancer O
Trial O
conducted O
among O
individuals O
at O
high O
risk O
of O
nonmelanoma O
skin O
cancer O
continue O
to O
demonstrate O
that O
selenium O
supplementation O
is O
ineffective O
at O
preventing O
basal B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
and O
that O
it O
increases O
the O
risk O
of O
['Physiological-Clinical']

METHODS O
One O
hundred O
cases O
( O
200 O
eyes O
) O
were O
divided O
into O
treating O
group O
and O
control O
group O
randomly O
according O
to O
using O
and O
not O
using O
Naphcon O
eye O
drops O
before O
Lasik O
surgery O
. O
[]

The O
response O
rate O
with O
TKI O
re-treatment O
was O
8 O
% O
, O
and O
the O
disease-control B-outcome ['Physiological-Clinical']
rate O
( O
response O
plus O
stable O
['Physiological-Clinical']

CLINICAL O
TRIAL O
REGISTRATION O
NCT00262678 O
] O
RESULTS O
A O
total O
of O
131 O
patients O
entered O
the O
titration O
phase O
, O
of O
whom O
61 O
were O
included O
in O
the O
primary O
efficacy O
analysis O
. O
[]

Cystectomy O
was O
done O
in O
22 O
of O
280 O
cases O
( O
7.9 O
% O
) O
in O
the O
white O
light O
group O
and O
in O
13 O
of O
the O
271 O
( O
4.8 O
% O
) O
in O
the O
fluorescence O
group O
( O
p O
= O
0.16 O
) O
. O
[]

Patients O
were O
evaluated O
with O
the O
O'Leary-Sant O
validated B-outcome ['Physiological-Clinical']
IC I-outcome ['Physiological-Clinical']
questionnaire O
or O
with O
voiding B-outcome ['Physiological-Clinical']
charts O
and O
a O
visual O
analog O
pain O
scale O
1 O
month O
postoperatively O
and O
at O
subsequent O
3-month O
intervals O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Baseline O
characteristics O
were O
similar O
in O
the O
treatment O
and O
control O
groups O
and O
mean O
CD4+ B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
were O
116 O
and O
107 O
x O
10 O
( O
6 O
) O
/l O
, O
respectively O
. O
['Physiological-Clinical']

RESULTS O
A O
total O
of O
4560 O
women O
for O
whom O
the O
median O
age O
was O
62.5 O
years O
and O
the O
median O
Gail O
risk O
score O
was O
2.3 O
% O
were O
randomly O
assigned O
to O
either O
exemestane O
or O
placebo O
. O
[]

After O
restoration O
of O
euthyroidism O
, O
a O
significant O
improvement O
in O
LV B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
as O
assessed O
with O
2D-STE O
strain O
was O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Among O
those O
with O
positive O
angiograms O
, O
the O
rate O
of O
eradication B-outcome ['Physiological-Clinical']
of O
the O
left O
gastric O
vein B-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
EIS-treated O
group O
than O
in O
the O
EVL O
treated O
group O
( O
50 O
% O
vs. O
8.6 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
evidence O
of O
a O
survival B-outcome ['Mortality']
benefit O
with O
ASC O
plus O
MVP O
( O
HR O
0.99 O
[ O
0.78-1.27 O
] O
; O
p=0.95 O
) O
. O
['Mortality']

Study O
design O
and O
rationale O
of O
a O
dose-ranging O
trial O
of O
LX4211 O
, O
a O
dual O
inhibitor O
of O
SGLT1 O
and O
SGLT2 O
, O
in O
type O
2 O
diabetes O
inadequately O
controlled O
on O
metformin O
monotherapy O
. O
[]

Outpatients O
with O
recent O
( O
6 O
to O
40 O
days O
) O
acute O
myocardial O
infarction O
, O
left O
ventricular O
dysfunction O
( O
ejection O
fraction O
< O
35 O
% O
) O
, O
and O
low O
heart O
rate O
variability O
were O
randomized O
to O
ICD O
( O
n=311 O
) O
or O
to O
standard O
medical O
therapy O
( O
n=342 O
) O
. O
[]

Therefore O
, O
it O
is O
no O
longer O
justifiable O
to O
withhold O
treatment O
to O
chronic B-outcome ['Physiological-Clinical']
hepatitis I-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
patients O
who O
use O
intravenous O
drugs O
. O
['Physiological-Clinical']

In O
45 O
% O
of O
trials O
a O
stop O
signal O
was O
presented O
after O
the O
go O
signal O
, O
to O
which O
subjects O
were O
asked O
to O
stop O
the O
movement O
as O
rapidly O
as O
possible O
. O
[]

When O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
was O
defined O
by O
other O
thresholds O
( O
20/40 O
and O
20/100 O
) O
, O
the O
difference O
was O
not O
significant O
. O
['Physiological-Clinical']

SETTING O
A O
university O
medical O
center O
. O
[]

After O
a O
mean O
follow-up O
of O
2.3+/-0.6 O
years O
, O
the O
primary O
endpoint O
( O
a O
composite O
of O
cardiovascular B-outcome ['Life-Impact']
mortality I-outcome ['Life-Impact']
, O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
, O
thrombo-embolic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TECs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
bleeding B-outcome ['Physiological-Clinical']
, O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
of I-outcome ['Adverse-effects']
antiarrhythmic I-outcome ['Adverse-effects']
drugs I-outcome ['Adverse-effects']
and O
pacemaker B-outcome ['Resource-use']
implants I-outcome ['Resource-use']
) O
was O
22.4 O
% O
in O
the O
rhythm-control O
group O
vs. O
15.2 O
% O
in O
the O
rate-control O
group O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Resource-use']

In O
group O
B O
, O
80 O
% O
were O
successful B-outcome ['Life-Impact']
at O
first O
attempt O
and O
20 O
% O
at O
the O
second O
attempt O
. O
['Life-Impact']

Whereas O
imitation B-outcome ['Life-Impact']
levels O
were O
higher O
for O
pro-socially O
primed O
relative O
to O
non-socially O
primed O
control O
participants O
, O
there O
was O
no O
difference O
between O
pro- O
and O
non- O
socially O
primed O
individuals O
with O
ASC O
. O
['Life-Impact']

OBJECTIVE O
To O
find O
out O
the O
optimum O
maximal O
dosage O
of O
recombinant O
follicle O
stimulating O
hormone O
( O
rFSH O
) O
in O
microdose O
gonadotropin-releasing O
hormone O
analog O
( O
GnRH-a O
) O
flare O
cycles O
in O
poor O
responders O
. O
[]

In O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
and O
crossover O
design O
, O
nine O
female O
and O
three O
male O
healthy O
subjects O
( O
age O
34 O
( O
sd O
11 O
) O
years O
, O
BMI O
24.5 O
( O
sd O
2.5 O
) O
kg/m O
( O
2 O
) O
) O
with O
a O
preference O
for O
a O
high-fat O
diet O
ingested O
ENT O
( O
3 O
x O
15 O
mg/d O
) O
or O
placebo O
( O
PLA O
) O
while O
consuming O
a O
high-fat O
diet O
ad O
libitum O
for O
4 O
d. O
Eight O
subjects O
ended O
each O
intervention O
with O
a O
36 O
h O
stay O
in O
the O
respiration O
chamber O
, O
continuing O
the O
diet O
and O
treatment O
. O
[]

Both O
baseline O
PCR B-outcome ['Physiological-Clinical']
viremia I-outcome ['Physiological-Clinical']
and O
PCR B-outcome ['Physiological-Clinical']
viruria I-outcome ['Physiological-Clinical']
were O
significantly O
associated O
with O
future O
cytomegalovirus O
( O
CMV O
) O
disease O
( O
P O
= O
.002 O
and O
P O
= O
.02 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thus O
, O
they O
learned O
about O
three O
symbols O
in O
the O
same O
amount O
of O
time O
as O
other O
students O
learned O
about O
the O
equal O
sign O
alone O
or O
not O
at O
all O
. O
[]

With O
either O
drug O
given O
alone O
, O
the O
seizures B-outcome ['Physiological-Clinical']
were O
controlled B-outcome ['Physiological-Clinical']
in O
fewer O
than O
half O
of O
the O
neonates O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
a O
) O
. O
[]

OBJECTIVE O
To O
assess O
post-treatment O
effects O
in O
endometriosis O
patients O
of O
a O
12-month O
course O
of O
GnRH O
agonist O
alone O
or O
with O
one O
of O
three O
add-back O
regimens O
. O
[]

The O
results O
were O
similar O
in O
both O
groups O
, O
showing O
the O
added O
benefit O
of O
a O
shorter O
hospital O
stay O
for O
children O
with O
blood-borne O
musculoskeletal O
infection O
. O
[]

With O
duplex O
ultrasound O
scanning O
( O
ATL-Ultramark O
9 O
, O
Advanced O
Tech O
Laboratory O
, O
Bothell O
, O
Wash O
) O
, O
acute O
DVT O
was O
excluded O
before O
subject O
evaluation O
. O
[]

PARTICIPANTS O
The O
study O
enrolled O
male O
and O
female O
outpatients O
aged O
5-12 O
years O
with O
a O
diagnosis O
of O
autistic O
disorder O
based O
on O
the O
DSM-IV-TR O
criteria O
and O
a O
score O
of O
?12 O
on O
the O
Aberrant O
Behavior O
Checklist-Community O
( O
ABC-C O
) O
irritability O
subscale O
who O
had O
discontinued O
other O
medications O
because O
of O
a O
lack O
of O
efficacy O
. O
[]

Significant O
improvement O
in O
all O
six O
categories O
was O
maintained O
at O
the O
end O
of O
the O
study O
period O
( O
p O
< O
0.05 O
) O
with O
QOL B-outcome ['Life-Impact']
scores O
within O
limits O
of O
published O
norms O
for O
the O
general O
population O
. O
['Life-Impact']

The O
score O
of O
childhood O
autism O
rating O
scale O
( O
CARS O
) O
and O
clinical B-outcome ['Physiological-Clinical']
efficacy O
in O
both O
groups O
were O
observed O
before O
and O
after O
treatment O
. O
['Physiological-Clinical']

PATIENTS O
A O
consecutive O
sample O
of O
93 O
children O
undergoing O
outpatient O
adenoidectomy O
. O
[]

Effects O
of O
skin-to-skin O
contact O
on O
autonomic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
in O
preterm O
infants O
. O
['Physiological-Clinical']

During O
the O
paromomycin O
treatment O
phase O
, O
oocyst B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
decreased O
from O
314 O
x O
10 O
( O
6 O
) O
to O
109 O
x O
10 O
( O
6 O
) O
24 O
h O
( O
P O
< O
.02 O
) O
. O
['Physiological-Clinical']

Postoperative B-outcome ['Physiological-Clinical']
retinal I-outcome ['Physiological-Clinical']
detachment I-outcome ['Physiological-Clinical']
developed O
in O
8 O
( O
11 O
% O
) O
tap O
eyes O
, O
10 O
( O
8 O
% O
) O
biopsy O
eyes O
, O
and O
0 O
( O
0 O
% O
) O
abort O
eyes O
( O
not O
significant O
) O
. O
['Physiological-Clinical']

There O
is O
no O
clinically O
significant O
difference O
in O
sensor B-outcome ['Physiological-Clinical']
accuracy I-outcome ['Physiological-Clinical']
, O
with O
37.5 O
% O
of O
results O
within O
+/- O
0.05 O
kPa O
and O
80 O
% O
within O
+/- O
2.0 O
kPa O
of O
simultaneous O
blood O
gas O
values O
. O
['Physiological-Clinical']

The O
subjects O
included O
132 O
patients O
randomized O
to O
the O
study O
, O
of O
whom O
123 O
started O
one O
of O
the O
treatment O
programs O
. O
[]

Treatment O
consisted O
of O
approximately O
3,800 O
total O
shock O
waves O
( O
+/-10 O
) O
reaching O
an O
approximated O
total O
energy O
delivery O
of O
1,300 O
mJ/mm O
( O
2 O
) O
( O
ED+ O
) O
in O
a O
single O
session O
versus O
placebo O
treatment O
. O
[]

Active O
chronic O
suppurative O
otitis O
media O
poses O
a O
management O
problem O
when O
patients O
are O
being O
considered O
for O
surgical O
treatment O
. O
[]

BACKGROUND O
The O
literature O
lacks O
studies O
that O
confirm O
whether O
the O
improved O
radiographic O
alignment O
that O
can O
be O
achieved O
with O
computer-navigated O
total O
knee O
arthroplasty O
improves O
patients? O
activities O
of O
daily O
living O
or O
the O
durability O
of O
total O
knee O
prostheses O
. O
[]

Similarly O
, O
struggle B-outcome ['Life-Impact']
was O
even O
lower O
during O
couple-responsible O
episodes O
and O
even O
higher O
during O
therapist-responsible O
episodes O
when O
contrast O
was O
present O
. O
['Life-Impact']

There O
were O
no O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

METHODS O
Twenty O
patients O
with O
mild O
SDB O
for O
whom O
conservative O
treatment O
failed O
were O
identified O
and O
consecutively O
enrolled O
into O
an O
institutional O
review O
board-approved O
surgical O
protocol O
. O
[]

We O
analysed O
event-free B-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
on O
an O
intention-to-treat O
basis O
. O
['Mortality', 'Mortality']

The O
primary O
endpoint O
was O
an O
adequate O
response O
to O
treatment O
on O
D14 B-outcome ['Physiological-Clinical']
( O
WHO O
definition O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Autistic O
disorder O
is O
characterized O
by O
a O
fundamental O
disturbance O
in O
social O
interaction O
, O
impairments O
in O
communication O
, O
and O
a O
markedly O
restricted O
repertoire O
of O
activities O
and O
interests O
. O
[]

Study O
drugs O
were O
administered O
for O
three O
months O
in O
both O
groups O
. O
[]

MATERIAL O
AND O
METHODS O
All O
152 O
male O
employees O
in O
a O
computer O
company O
, O
25-45 O
years O
of O
age O
, O
were O
invited O
to O
participate O
in O
a O
controlled O
intervention O
study O
over O
one O
year O
. O
[]

Lung B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
was O
measured O
during O
suction O
, O
and O
end-expiratory O
lung O
impedance O
was O
measured O
at O
baseline O
and O
postsuctioning O
using O
electrical O
impedance O
tomography O
. O
['Physiological-Clinical']

BACKGROUND O
Completion O
lymph O
node O
dissection O
( O
CLND O
) O
is O
the O
standard O
procedure O
for O
patients O
with O
positive O
sentinel O
lymph O
nodes O
( O
SLN O
) O
. O
[]

Lithium O
plus O
early O
morning O
sleep O
deprivation O
produced O
a O
quicker O
response O
than O
lithium O
with O
the O
control O
sleep O
deprivation O
, O
and O
the O
response O
was O
sustained O
for O
at O
least O
30 O
days O
. O
[]

The O
most O
common O
grade O
3 O
or O
higher O
adverse O
event O
was O
neutropenia-reported O
by O
six O
of O
106 O
( O
6 O
% O
) O
patients O
in O
the O
ganitumab O
group O
and O
one O
of O
49 O
( O
2 O
% O
) O
in O
the O
placebo O
group O
. O
[]

Compared O
with O
those O
trained O
negatively O
, O
those O
trained O
positively O
reported O
in O
a O
diary O
fewer O
intrusive B-outcome ['Life-Impact']
memories I-outcome ['Life-Impact']
of O
the O
film O
during O
the O
subsequent O
week O
, O
and O
lower O
scores O
on O
the O
Impact O
of O
Event O
['Life-Impact']

We O
studied O
, O
if O
menses B-outcome ['Physiological-Clinical']
were O
affected O
in O
the O
treatment O
groups O
, O
up O
to O
36 O
months O
after O
randomization O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
conservation O
of O
blood O
in O
critically O
ill O
patients O
must O
be O
a O
high-priority O
concern O
of O
all O
healthcare O
workers O
. O
[]

Both O
drugs O
were O
associated O
with O
the O
topical O
application O
of O
povidone O
iodine O
. O
[]

CONCLUSION O
These O
findings O
contribute O
to O
our O
understanding O
of O
the O
factors O
that O
may O
explain O
why O
some O
adolescents O
complete O
care O
whereas O
others O
do O
not O
. O
[]

Paracetamol O
has O
been O
reported O
to O
chelate O
with O
iron O
. O
[]

OBJECTIVES O
Linagliptin O
is O
a O
novel O
, O
highly O
selective O
and O
long O
acting O
DPP-4 O
inhibitor O
for O
the O
treatment O
of O
type O
2 O
diabetes O
mellitus O
( O
T2DM O
) O
. O
[]

We O
randomly O
allocated O
116 O
parturients O
undergoing O
elective O
Caesarean O
section O
to O
receive O
anaesthesia O
using O
one O
of O
these O
techniques O
. O
[]

INTRODUCTION O
Conservative O
fluid O
management O
in O
patients O
with O
acute O
lung O
injury O
( O
ALI O
) O
increases O
time O
alive O
and O
free O
from O
mechanical O
ventilation O
. O
[]

Median O
total O
direct O
cost O
outcomes O
were O
similar O
between O
groups O
( O
EL O
= O
$ O
9,696 O
and O
ES O
= O
$ O
13,197 O
; O
P O
=.46 O
) O
. O
[]

STUDY O
DESIGN O
Experimental O
, O
randomized O
, O
crossover O
trial O
. O
[]

In O
this O
randomised O
controlled O
pilot O
trial O
we O
compared O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
a O
24 O
week O
with O
that O
of O
a O
48 O
week O
course O
of O
combination O
therapy O
with O
interferon O
alpha O
and O
ribavirin O
in O
interferon O
monotherapy O
relapsers O
with O
chronic O
hepatitis O
C. O
METHODS O
Interferon O
alpha O
monotherapy O
relapsers O
with O
chronic O
hepatitis O
C O
were O
randomised O
to O
receive O
interferon O
alpha O
2b O
( O
3 O
x O
3 O
MIU O
sc O
weekly O
) O
and O
oral O
ribavirin O
( O
1000/1200 O
mg O
po O
daily O
) O
for O
either O
24 O
weeks O
or O
48 O
weeks O
. O
['Life-Impact']

METHODS O
We O
determined O
the O
urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ferulic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
in O
18 O
postmenopausal O
women O
after O
a O
dietary O
intake O
of O
rye O
bran O
or O
an O
inert O
wheat O
bran O
( O
control O
) O
in O
a O
crossover O
study O
( O
2 O
x O
6 O
weeks O
with O
4 O
weeks O
washout O
) O
. O
['Physiological-Clinical']

Within O
a O
multicentric O
study O
of O
several O
Social O
Pediatric O
Centers O
( O
SPCs O
) O
and O
further O
clinics/institutions O
in O
Germany O
, O
it O
has O
been O
established O
as O
a O
group O
parenting O
training O
( O
3-7 O
families O
per O
training O
) O
. O
[]

Moreover O
, O
a O
trend O
towards O
an O
increase O
in O
influenza-specific B-outcome ['Physiological-Clinical']
IgM I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
was O
also O
observed O
. O
['Physiological-Clinical']

In O
a O
systematic O
review O
of O
29 O
trials O
of O
second-line O
irinotecan-based O
treatment O
, O
single-agent O
irinotecan O
was O
associated O
with O
more O
diarrhoea B-outcome ['Physiological-Clinical']
and O
alopecia B-outcome ['Physiological-Clinical']
than O
the O
combination O
but O
efficacy O
was O
similar O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
patients O
gave O
their O
informed O
consent O
. O
[]

Two O
patients O
wearing O
a O
half O
of O
the O
TTS-scopolamine O
patch O
needed O
intravenous B-outcome ['Resource-use']
atropine I-outcome ['Resource-use']
. O
['Resource-use']

Doses O
were O
twenty O
intramuscular O
injections O
of O
pentamidine O
4 O
mg/kg O
on O
alternate O
days O
or O
fourteen O
definitive O
doses O
of O
amphotericin O
0.5 O
mg/kg O
infused O
in O
5 O
% O
dextrose O
on O
alternate O
days O
. O
[]

The O
caretaker O
of O
each O
child O
received O
a O
bimonthly O
telephone O
call O
to O
collect O
clinical O
information O
about O
the O
child O
's O
asthma O
. O
[]

The O
results O
appear O
better O
than O
those O
reported O
in O
iCBT O
studies O
to O
date O
and O
provide O
support O
for O
the O
potential O
of O
clinician-guided O
iCBT O
in O
the O
treatment O
of O
disability B-outcome ['Life-Impact']
, O
anxiety B-outcome ['Life-Impact']
, O
and O
depression B-outcome ['Life-Impact']
for O
people O
with O
chronic O
pain O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Exercise O
intolerance O
in O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
results O
from O
a O
complex O
interaction O
between O
central O
( O
ventilatory O
) O
and O
peripheral O
( O
limb O
muscles O
) O
components O
of O
exercise O
limitation O
. O
[]

Fatty O
foods O
have O
been O
identified O
as O
precipitating O
factors O
in O
symptomatic O
gastroesophageal O
reflux O
( O
GER O
) O
. O
[]

kg-1 O
) O
. O
[]

LIMITATIONS O
A O
small O
and O
predominantly O
White O
sample O
. O
[]

INTRODUCTION O
Atrial O
defibrillation O
can O
be O
achieved O
with O
standard O
implantable O
cardioverter O
defibrillator O
leads O
, O
which O
has O
led O
to O
the O
development O
of O
combined O
atrial O
and O
ventricular O
devices O
. O
[]

Bronchial O
biopsies O
obtained O
at O
baseline O
and O
at O
Week O
10 O
were O
immunostained O
and O
counted O
for O
neutrophils B-outcome ['Physiological-Clinical']
, O
CD8+ B-outcome ['Physiological-Clinical']
and O
CD4+ B-outcome ['Physiological-Clinical']
T-lymphocyte I-outcome ['Physiological-Clinical']
subsets I-outcome ['Physiological-Clinical']
, O
and O
CD68+ B-outcome ['Physiological-Clinical']
macrophages I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Thrombolysis O
has O
been O
accepted O
for O
obstructive O
PVT O
, O
but O
treatment O
strategies O
of O
non-obstructive O
PVT O
are O
controversial O
. O
[]

The O
best O
response O
to O
GH O
was O
obtained O
in O
younger O
patients O
with O
low O
GHBP O
levels O
. O
[]

CONCLUSIONS O
Taken O
together O
, O
these O
findings O
suggest O
that O
delusions O
are O
associated O
with O
the O
explicit B-outcome ['Life-Impact']
misattribution I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
salience I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
neutral I-outcome ['Life-Impact']
stimuli I-outcome ['Life-Impact']
. O
['Life-Impact']

A O
third O
group O
of O
students O
served O
as O
a O
control O
group O
. O
[]

PURPOSE O
Previous O
studies O
showed O
the O
effectiveness O
of O
early O
preoperative O
( O
4 O
h O
before O
operation O
) O
irradiation O
for O
prevention O
of O
heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HO I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
after O
total O
hip O
replacement O
. O
['Physiological-Clinical']

In O
vitro O
, O
however O
, O
pentoxifylline O
at O
suprapharmacological O
concentrations O
inhibited O
the O
[]

The O
decision O
to O
amputate O
is O
made O
by O
a O
vascular O
surgeon O
. O
[]

While O
the O
medication O
was O
well O
tolerated O
, O
the O
dose O
of O
nimodipine O
used O
in O
this O
study O
( O
90 O
mg O
q.d O
. O
) O
[]

The O
effect O
of O
AP-1 B-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
on O
vascular O
parameters O
was O
tested O
through O
a O
double O
blind O
placebo-controlled O
cross-over O
study O
of O
28 O
days O
doxycycline O
or O
placebo O
in O
patients O
with O
symptomatic O
peripheral O
artery O
disease O
. O
['Physiological-Clinical']

AIMS O
To O
compare O
the O
sensitivity O
, O
specificity O
and O
adverse O
event O
profile O
of O
glyceryl O
trinitrate O
head-up O
tilt O
with O
isoprenaline O
head-up O
tilt O
in O
the O
diagnosis O
of O
vasovagal O
syncope O
in O
patients O
with O
unexplained O
syncope O
and O
healthy O
controls O
. O
[]

RESULTS O
Local O
and O
systemic O
safety O
profiles O
were O
equivalent O
between O
the O
two O
groups O
. O
[]

By O
day O
32 O
, O
eight O
patients O
( O
1.3 O
% O
) O
receiving O
fondaparinux O
and O
five O
( O
0.8 O
% O
) O
receiving O
placebo O
had O
died B-outcome ['Mortality']
. O
['Mortality']

Anti-vascular O
effects O
were O
assessed O
using O
dynamic O
contrast-enhanced O
magnetic O
resonance O
imaging O
( O
DCE-MRI O
) O
. O
[]

8.7 O
) O
] O
were O
all O
significantly O
lower O
than O
those O
at O
baseline O
[ O
( O
24.7 O
? O
[]

Nutrient O
retention O
in O
preterm O
infants O
fed O
standard O
infant O
formulas O
. O
[]

With O
every O
one O
point O
increase O
in O
PSQI O
scores O
across O
time O
, O
a O
woman O
's O
risk O
for O
recurrence O
increased O
by O
approximately O
25 O
% O
There O
was O
no O
significant O
association O
between O
PSQI O
scores O
and O
IL-6 O
concentrations O
in O
early O
postpartum O
( O
? O
( O
[]

INTERVENTION O
Leuprolide O
acetate O
depot O
( O
11.25 O
or O
30 O
mg O
) O
was O
administered O
im O
every O
3 O
months O
. O
[]

There O
was O
a O
significant O
prophylactic B-outcome ['Physiological-Clinical']
effect O
of O
phenytoin O
in O
BP O
disorder O
[ O
Cox O
's O
F-test B-outcome ['Physiological-Clinical']
for O
comparing O
survival B-outcome ['Mortality']
in O
two O
groups O
: O
F O
( O
6 O
, O
18 O
) O
= O
3.44 O
, O
p O
= O
0.02 O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

RESEARCH O
DESIGN O
AND O
METHODS O
This O
study O
was O
a O
randomized O
, O
controlled O
, O
single-blind O
, O
crossover O
trial O
. O
[]

RESULTS O
Omega-3 O
fatty O
acids O
therapy O
decreased O
triglycerides B-outcome ['Physiological-Clinical']
by O
21 O
% O
and O
triglycerides/HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
and O
improved O
flow-mediated B-outcome ['Physiological-Clinical']
dilation I-outcome ['Physiological-Clinical']
( O
P O
< O
0.01 O
) O
, O
however O
, O
did O
not O
significantly O
change O
insulin B-outcome ['Resource-use']
, O
plasma B-outcome ['Physiological-Clinical']
adiponectin I-outcome ['Physiological-Clinical']
levels O
, O
and O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
( O
determined O
by O
QUICKI O
) O
relative O
to O
baseline O
measurements O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
The O
aim O
of O
this O
study O
was O
to O
compare O
recovery O
for O
oral O
surgery O
patients O
given O
a O
deep O
sedation O
regimen O
of O
midazolam O
, O
propofol O
, O
and O
remifentanil O
with O
a O
standard O
control O
of O
fentanyl O
in O
place O
of O
remifentanil O
. O
[]

The O
study O
did O
not O
identify O
any O
subgroup O
of O
patients O
likely O
to O
derive O
a O
significant O
survival O
benefit O
from O
the O
addition O
of O
ATRA O
to O
chemotherapy O
. O
[]

Comparison O
of O
ketoconazole O
and O
griseofulvin O
in O
the O
treatment O
of O
tinea O
pedis O
. O
[]

APTT O
and O
TT O
levels O
in O
the O
low-dose O
heparin O
group O
was O
increased O
rapidly O
after O
the O
first O
given O
dose O
of O
anticoagulant O
heparin O
and O
reached O
the O
peak O
within O
30 O
min.The O
levels O
at O
each O
time O
point O
was O
statistically O
different O
between O
the O
2 O
groups O
( O
P O
< O
0.05 O
) O
. O
[]

Compared O
with O
tPA O
, O
however O
, O
primary O
PTCA O
resulted O
in O
a O
markedly O
lower O
rate O
of O
recurrent B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
( O
9.7 O
% O
vs O
27.8 O
% O
, O
p O
= O
0.0002 O
) O
, O
fewer O
unscheduled B-outcome ['Resource-use']
catheterization I-outcome ['Resource-use']
and O
revascularization B-outcome ['Physiological-Clinical']
procedures I-outcome ['Physiological-Clinical']
, O
and O
a O
shorter O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
7.0 O
vs O
8.6 O
days O
, O
p O
= O
0.01 O
) O
in O
nonanterior O
wall O
AMI O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Resource-use']

1 O
. O
[]

Group O
A O
patients O
received O
midazolam O
0.03 O
mg/kg O
followed O
by O
pethidine O
20 O
mg O
intravenously O
, O
and O
group O
B O
patients O
received O
midazolam O
0.03 O
mg/kg O
followed O
by O
tramadol O
20 O
mg O
intravenously O
after O
the O
institution O
of O
regional O
anaesthesia O
. O
[]

BACKGROUND O
Although O
extensively O
calcified O
atherosclerotic O
lesions O
have O
been O
proposed O
to O
be O
clinically O
quiescent O
, O
the O
presence O
of O
spotty O
calcification O
within O
plaque O
has O
been O
reported O
to O
be O
associated O
with O
an O
increased O
incidence O
of O
ischemic O
cardiovascular O
events O
. O
[]

The O
6-month O
Kaplan-Meier O
cumulative O
unadjusted O
typical O
use O
pregnancy O
probabilities O
were O
13.5 O
% O
among O
FemCap O
users O
and O
7.9 O
% O
among O
diaphragm O
users O
. O
[]

GAS O
has O
been O
criticized O
for O
untested O
assumptions O
of O
scaling O
level O
( O
i.e. O
, O
interval O
or O
ordinal O
) O
, O
inter-individual O
equivalence O
and O
comparability O
, O
and O
reliability O
of O
coding O
across O
different O
behavioral O
observation O
methods O
. O
[]

METHOD O
Forty O
children O
between O
the O
ages O
of O
4 O
and O
12 O
years O
with O
a O
DSM O
IV O
clinical O
diagnosis O
of O
autism O
who O
were O
outpatients O
from O
a O
specialty O
clinic O
for O
children O
were O
recruited O
. O
[]

Both O
groups O
showed O
habituation O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
from O
the O
first O
to O
the O
second O
presentation O
, O
and O
both O
groups O
reported O
perception O
of O
a O
higher B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
but O
only O
social O
phobics O
reported O
significantly O
more O
anxiety B-outcome ['Life-Impact']
and O
were O
more O
worried B-outcome ['Life-Impact']
about O
their O
heart B-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
in O
the O
public O
than O
in O
the O
private O
condition O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Previous O
cost O
difference O
estimates O
, O
which O
show O
a O
spike O
around O
the O
time O
of O
cessation O
, O
suggest O
premiums O
might O
rise O
as O
a O
result O
of O
covering O
these O
services O
. O
[]

Independent O
t-tests O
and O
paired O
t-tests O
were O
used O
to O
analyze O
the O
data O
. O
[]

Thromboprophylaxis O
by O
low-molecular-weight O
heparin O
in O
elective O
hip O
surgery O
. O
[]

RESULTS O
Level O
of O
NF-kappa B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
in O
the O
treated O
group O
was O
significantly O
higher O
than O
that O
in O
the O
control O
group O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
role O
of O
axon O
reflex O
vasodilation O
by O
local O
sensory O
neurones O
was O
investigated O
by O
comparing O
vasodilation O
at O
sites O
treated O
with O
'eutectic O
mixture O
of O
local O
anaesthetics O
' O
( O
EMLA O
) O
cream O
( O
2.5 O
% O
lidocaine O
and O
2.5 O
% O
prilocaine O
) O
with O
untreated O
sites O
( O
control O
site O
) O
( O
protocol O
2 O
; O
n=10 O
) O
. O
[]

Treatment O
reduced O
BP B-outcome ['Physiological-Clinical']
to O
a O
similar B-outcome ['Physiological-Clinical']
extent I-outcome ['Physiological-Clinical']
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
frequency O
of O
rectal B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
is O
increased O
in O
patients O
with O
acute O
leukemia O
. O
['Physiological-Clinical']

Outcomes O
in O
patients O
with O
diabetes O
mellitus O
undergoing O
percutaneous O
coronary O
intervention O
in O
the O
current O
era O
: O
a O
report O
from O
the O
Prevention O
of O
REStenosis O
with O
Tranilast O
and O
its O
Outcomes O
( O
PRESTO O
) O
trial O
. O
[]

Standardized O
Psychological O
tests O
were O
administered O
to O
tap O
the O
behavioral O
differences O
. O
[]

All O
patients O
in O
the O
TZD O
group O
showed O
an O
increase O
of O
adiponectin B-outcome ['Physiological-Clinical']
levels O
as O
an O
indicator O
of O
compliance O
( O
11.4 O
+/- O
1.1 O
to O
36.8 O
+/- O
2.1 O
microg/ml O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Entomological O
determinants O
of O
insecticide-treated O
bed O
net O
effectiveness O
in O
Western O
Myanmar O
. O
[]

Prospective O
evaluation O
was O
performed O
on O
90 O
patients O
receiving O
CT O
planned O
pelvic O
radiotherapy O
using O
weekly O
anterior-posterior O
and O
lateral O
portal O
films O
. O
[]

To O
identify O
associated O
factors O
with O
addictive B-outcome ['Life-Impact']
Internet I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
, O
two-level O
multilevel O
regression O
models O
were O
fitted O
with O
individual-level O
responses O
( O
1st O
level O
) O
nested O
within O
schools O
( O
2nd O
level O
) O
to O
estimate O
associations O
of O
individual O
and O
school O
characteristics O
simultaneously O
. O
['Life-Impact']

The O
head O
of O
the O
implants O
was O
placed O
on O
an O
average O
6.3 O
mm O
( O
SD O
2.24 O
) O
below O
the O
cement/enamel O
junction O
of O
the O
adjacent O
teeth O
( O
range O
2.5-10.0 O
mm O
) O
. O
[]

No O
statistically O
significant O
differences O
were O
found O
in O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
comparison O
within O
the O
sham O
group O
. O
['Life-Impact']

School O
districts O
were O
randomly O
assigned O
to O
a O
live O
workshop O
training O
or O
video O
training O
condition O
. O
[]

CONCLUSIONS O
This O
study O
failed O
to O
demonstrate O
any O
difference O
in O
survival O
between O
patients O
receiving O
preoperative O
and O
perioperative O
chemotherapy O
in O
early-stage O
NSCLC O
. O
[]

Resident B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
was O
measured O
by O
a O
70-item O
examination O
. O
['Life-Impact']

RESULTS O
Patients O
taking O
pentoxifylline O
had O
less O
pain B-outcome ['Physiological-Clinical']
and O
reported O
smaller O
and O
fewer O
['Physiological-Clinical']

Early O
recovery O
( O
eye O
opening O
, O
orientation O
, O
following O
commands O
, O
sitting O
) O
was O
similar O
in O
the O
three O
groups O
. O
[]

Peripheral O
intravenous B-outcome ['Life-Impact']
line I-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
and O
phlebitis B-outcome ['Physiological-Clinical']
prevention O
in O
patients O
receiving O
intravenous O
antibiotics O
: O
heparin/hydrocortisone O
versus O
in-line O
filters O
. O
['Life-Impact', 'Physiological-Clinical']

A O
randomized O
trial O
of O
etoposide O
and O
G-CSF O
with O
or O
without O
rituximab O
for O
PBSC O
mobilization O
in O
B-cell O
non-Hodgkin O
's O
lymphoma O
. O
[]

The O
social O
, O
language O
, O
and O
cognitive O
gains O
in O
our O
participants O
provide O
evidence O
for O
plasticity O
of O
these O
developmental O
systems O
in O
toddlers O
with O
ASD O
. O
[]

The O
duration O
of O
treatment O
was O
measured O
in O
24 O
of O
27 O
consecutive O
children O
with O
a O
mean O
age O
of O
24 O
months O
( O
5 O
to O
75 O
) O
following O
posteromedial O
release O
for O
idiopathic O
club O
foot O
. O
[]

Four O
( O
6 O
% O
) O
of O
67 O
SP-treated O
patients O
were O
therapeutic B-outcome ['Physiological-Clinical']
failures I-outcome ['Physiological-Clinical']
( O
2 O
ETFs O
and O
2 O
LTFs O
) O
. O
['Physiological-Clinical']

The O
primary O
end O
point O
was O
the O
proportion O
of O
patients O
who O
achieved O
pain O
relief O
( O
defined O
as O
a O
score O
of O
> O
1 O
on O
a O
5-point O
verbal O
rating O
scale O
[ O
VRS O
] O
( O
0 O
= O
none O
; O
1 O
= O
a O
little O
; O
2 O
= O
some O
; O
3 O
= O
a O
lot O
; O
and O
4 O
= O
complete O
) O
on O
study O
days O
1 O
and O
2 O
and O
weeks O
1 O
, O
2 O
, O
and O
3 O
. O
[]

METHODS O
Determining O
the O
EFficacy O
and O
Tolerability O
of O
CETP O
INhibition O
with O
AnacEtrapib O
( O
DEFINE O
) O
is O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
to O
assess O
the O
efficacy O
and O
safety O
profile O
of O
anacetrapib O
in O
patients O
with O
coronary O
heart O
disease O
( O
CHD O
) O
or O
CHD O
risk O
equivalents O
( O
clinical O
trials.gov O
NCT00685776 O
) O
. O
[]

METHODS O
Fifty O
inpatients O
with O
first-ever O
stroke O
and O
PSD O
were O
consecutively O
enrolled O
in O
this O
randomized O
open-label O
study O
. O
[]

RESULTS O
Of O
the O
total O
participants O
, O
84.6 O
% O
completed O
the O
study O
( O
mean O
age O
= O
70.2 O
years O
) O
. O
[]

Among O
respondent O
who O
used O
their O
memory O
aids O
at O
least O
once O
( O
N O
= O
252 O
) O
, O
nearly O
35 O
per O
cent O
said O
they O
were O
influenced O
by O
the O
information O
recorded B-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
aids B-outcome ['Life-Impact']
, O
and O
most O
of O
those O
who O
were O
influenced O
said O
that O
they O
became O
more O
aware B-outcome ['Life-Impact']
of O
['Life-Impact', 'Life-Impact', 'Life-Impact']

High-scoring O
individuals O
also O
demonstrated O
difficulty O
in O
[]

Myoclonic B-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
and O
sedation B-outcome ['Physiological-Clinical']
were O
recorded O
on O
a O
scale O
between O
0 O
and O
3 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Recent O
work O
has O
shown O
that O
the O
carotid O
chemoreceptor O
( O
CC O
) O
contributes O
to O
sympathetic O
control O
of O
cardiovascular O
function O
during O
exercise O
, O
despite O
no O
evidence O
of O
increased O
circulating O
CC O
stimuli O
, O
suggesting O
enhanced O
CC O
activity/sensitivity O
. O
[]

METHODS O
We O
applied O
MCA O
to O
a O
series O
of O
72 O
children O
with O
no O
evidence O
of O
brain O
damage O
, O
starting O
epilepsy O
between O
1 O
and O
10 O
years O
, O
with O
two O
or O
more O
types O
of O
generalised O
seizures O
. O
[]

BP O
( O
mercury O
sphygmomanometer O
) O
and O
GFR O
( O
99mTc-DTPA O
clearances O
during O
renal O
scintigraphy O
) O
were O
evaluated O
yearly O
for O
three O
years O
. O
[]

Subjective O
pain B-outcome ['Physiological-Clinical']
ratings O
were O
obtained O
immediately O
and O
8 O
hours O
after O
VRH O
( O
used O
as O
an O
adjunct O
to O
standard O
analgesic O
care O
) O
and O
compared O
to O
both O
adjunctive O
VR O
without O
hypnosis O
and O
standard O
care O
alone O
. O
['Physiological-Clinical']

Both O
coumarin O
( O
1,2-benzopyrone O
) O
and O
warfarin O
( O
4-hydroxycoumarin O
) O
have O
been O
shown O
to O
prevent O
the O
recurrence O
of O
malignant O
melanoma O
. O
[]

Results O
of O
a O
phase O
I/II O
trial O
of O
recombinant O
human O
granulocyte-macrophage O
colony-stimulating O
factor O
in O
very O
low O
birthweight O
neonates O
: O
significant O
induction O
of O
circulatory O
neutrophils O
, O
monocytes O
, O
platelets O
, O
and O
bone O
marrow O
neutrophils O
. O
[]

These O
effects O
of O
sleep O
deprivation O
are O
counteracted O
by O
the O
adenosine O
receptor O
antagonist O
caffeine O
, O
implying O
involvement O
of O
the O
adenosine O
neuromodulator/receptor O
system O
. O
[]

BACKGROUND O
Rotavirus O
is O
the O
most O
common O
cause O
of O
acute O
childhood O
gastroenteritis O
. O
[]

In O
patients O
with O
unstable O
angina/non-ST-elevation O
myocardial O
infarction O
( O
STEMI O
) O
, O
hsCRP O
> O
3 O
mg/L O
was O
associated O
with O
increased O
10-month O
mortality B-outcome ['Mortality']
( O
adjHR O
2.3 O
, O
P O
= O
0.002 O
) O
, O
whereas O
in O
STEMI O
a O
relationship O
with O
mortality O
was O
seen O
at O
hsCRP O
> O
10 O
mg/L O
( O
adjHR O
3.0 O
, O
P O
= O
0.008 O
) O
. O
['Mortality']

No O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
reported O
during O
the O
study O
. O
['Adverse-effects']

Vascular B-outcome ['Physiological-Clinical']
assessments I-outcome ['Physiological-Clinical']
( O
including O
measures B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
endothelial I-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
, O
activation B-outcome ['Physiological-Clinical']
, O
dysfunction B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
oxidative I-outcome ['Physiological-Clinical']
stress O
) O
and O
HbA1c B-outcome ['Physiological-Clinical']
were O
performed O
at O
baseline O
and O
repeated O
after O
12 O
months O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
received O
local O
applications O
of O
ointments O
containing O
5 O
% O
lignocaine O
( O
n=28 O
) O
, O
0.5 O
% O
minoxidil O
( O
n=36 O
) O
, O
or O
both O
( O
n=26 O
) O
. O
[]

TRIAL O
REGISTRATION O
NCT01590355 O
. O
[]

4 O
of O
the O
7 O
results O
with O
negative O
reaction O
in O
the O
aR O
would O
have O
been O
positive O
then O
underlying O
the O
same O
criteria O
in O
the O
IOS O
without O
announcing O
the O
symptomscore O
a O
relevant O
clinical O
symptomatic O
while O
testing O
. O
['Physiological-Clinical']

Applying O
a O
treatment O
policy O
with O
a O
threshold-age O
of O
60 O
would O
result O
in O
0.6 O
% O
increase O
in O
local B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
in O
the O
total O
study O
population O
, O
while O
sparing O
the O
boost O
to O
1/3 O
of O
the O
patients O
. O
['Physiological-Clinical']

A O
low O
dietary O
fiber O
intake O
appears O
to O
be O
associated O
with O
higher O
[]

METHODS O
Ten O
healthy O
volunteers O
underwent O
two O
upper O
gastrointestinal O
endoscopies O
in O
a O
random O
order O
on O
two O
different O
days O
, O
with O
the O
procedure O
being O
carried O
out O
by O
a O
single O
experienced O
endoscopist O
. O
[]

We O
aimed O
to O
find O
an O
optimal O
method O
for O
sedation O
during O
ESD O
. O
[]

An O
increasing O
number O
of O
people O
undergo O
different O
treatment O
options O
. O
[]

Efficacy O
of O
prophylactic O
ondansetron O
in O
a O
patient-controlled O
analgesia O
environment O
. O
[]

Five O
volunteers O
were O
studied O
in O
a O
warm O
room O
( O
to O
test O
for O
nonthermoregulatory B-outcome ['Physiological-Clinical']
tremor I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
four O
volunteers O
were O
studied O
in O
a O
cold O
room O
( O
to O
test O
the O
effects O
of O
lidocaine O
on O
normal B-outcome ['Physiological-Clinical']
thermoregulation I-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

When O
the O
malignancy O
had O
spread O
to O
the O
parametrial O
region O
, O
additional O
postoperative O
radiotherapy O
was O
given O
. O
[]

Sixteen O
infants O
( O
mean O
+/- O
standard O
error O
of O
the O
mean O
birth O
weight O
1,009 O
+/- O
55 O
g O
and O
gestational O
age O
27.3 O
+/- O
0.3 O
weeks O
) O
were O
randomly O
assigned O
into O
exercise O
( O
n O
= O
8 O
) O
and O
control O
( O
n O
= O
8 O
) O
groups O
. O
[]

The O
left B-outcome ['Resource-use']
adrenalectomy I-outcome ['Resource-use']
mean O
OpT O
was O
72.2 O
mins O
( O
range O
55-100 O
mins O
) O
and O
94 O
mins O
( O
range O
65-140 O
mins O
) O
for O
group O
A O
and O
B O
, O
respectively O
( O
P O
< O
0.05 O
) O
. O
['Resource-use']

CONCLUSION O
Iron B-outcome ['Physiological-Clinical']
stores I-outcome ['Physiological-Clinical']
and O
Hb B-outcome ['Physiological-Clinical']
in O
infancy O
can O
be O
improved O
in O
neonates O
born O
to O
anemic O
mothers O
by O
delaying O
cord O
clamping O
at O
birth O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
related O
to O
treatment O
was O
0.91 O
% O
for O
eberconazole O
and O
0.92 O
% O
for O
miconazole O
, O
none O
being O
serious O
, O
and O
all O
being O
local O
and O
transient O
. O
['Adverse-effects']

Effects O
of O
long-term O
vitamin O
E O
supplementation O
on O
cardiovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
and O
cancer B-outcome ['Physiological-Clinical']
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
endpoint O
was O
the O
time-matched O
change O
from O
baseline O
in O
the O
QT B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
corrected I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
QTc B-outcome ['Physiological-Clinical']
) O
using O
an O
individual O
correction O
method O
( O
QTcI O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
is O
a O
significant O
postnatal B-outcome ['Physiological-Clinical']
decrease O
in O
['Physiological-Clinical']

Fifteen O
female O
volunteers O
were O
enrolled O
; O
they O
applied O
creams O
once O
daily O
for O
30 O
days O
. O
[]

It O
is O
noteworthy O
that O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
is O
almost O
identical O
1 O
year O
after O
surgery O
in O
both O
methods O
. O
['Physiological-Clinical']

The O
hypothermic O
patients O
had O
more O
postoperative B-outcome ['Physiological-Clinical']
shivering I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Sixty-six O
subjects O
were O
randomised O
to O
SFC O
or O
FP/M O
for O
12 O
weeks O
. O
[]

Side O
branch O
occlusion O
was O
defined O
as O
Thrombolysis O
In O
Myocardial O
Infarction O
( O
TIMI O
) O
flow O
grade O
0 O
or O
1 O
. O
[]

Comparing O
Telephone O
Counselling O
outcomes O
to O
existing O
practice O
( O
Real O
Control O
) O
, O
the O
intervention O
was O
found O
to O
be O
cost-effective O
( O
$ O
29,375 O
per O
quality O
adjusted O
life O
year O
gained O
) O
. O
['Resource-use']

This O
study O
does O
not O
support O
the O
clinical O
use O
of O
insulin B-outcome ['Resource-use']
as O
a O
means O
of O
modifying O
protein O
metabolic O
losses O
after O
major O
surgery O
. O
['Resource-use']

[ O
Assessment O
of O
natriuretic O
peptide O
indices O
and O
oxidative O
stress O
in O
patients O
with O
chronic O
heart O
failure O
] O
. O
[]

Bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
fell O
by O
4.2 O
+/- O
2.5 O
% O
. O
['Physiological-Clinical']

CONCLUSIONS O
As O
compared O
with O
CABG O
, O
an O
initial O
strategy O
of O
PTCA O
did O
not O
significantly O
compromise O
five-year O
survival B-outcome ['Mortality']
in O
patients O
with O
multivessel O
disease O
, O
although O
subsequent B-outcome ['Resource-use']
revascularization I-outcome ['Resource-use']
was O
required O
more O
often O
with O
this O
strategy O
. O
['Mortality', 'Resource-use']

Twenty-two O
healthy O
female O
volunteers O
were O
randomly O
allocated O
to O
two O
groups O
: O
the O
extra O
1 O
group O
received O
acupressure O
at O
the O
extra O
1 O
point O
, O
and O
the O
sham O
group O
received O
acupressure O
at O
a O
sham O
point O
. O
[]

Subjects O
consumed O
their O
normal O
diet O
for O
two O
menstrual O
cycles O
and O
added O
a O
soy O
beverage O
containing O
20 O
g O
of O
protein O
and O
38 O
mg O
of O
total O
isoflavones O
to O
their O
usual O
diet O
for O
another O
two O
menstrual O
cycles O
. O
[]

SUBJECTS O
Eight O
male O
volunteers O
with O
allergic O
asthma O
. O
[]

METHODS O
This O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo- O
and O
active-controlled O
study O
enrolled O
1,214 O
healthy O
, O
nonsmoking O
outpatients O
aged O
15 O
to O
85 O
years O
with O
spring O
allergic O
rhinitis O
, O
positive O
skin O
test O
to O
a O
spring O
allergen O
, O
and O
predefined O
daytime O
nasal O
symptoms O
. O
[]

The O
free B-outcome ['Physiological-Clinical']
radicals I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
, O
respectively O
, O
21 O
, O
14 O
, O
10 O
and O
9 O
% O
at O
10 O
min O
, O
1 O
, O
2 O
and O
24 O
h O
after O
reperfusion O
. O
['Physiological-Clinical']

Systemic B-outcome ['Physiological-Clinical']
administration I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
antibiotics I-outcome ['Physiological-Clinical']
, O
e.g O
. O
['Physiological-Clinical']

RESULTS O
In O
the O
combined O
spinal-epidural O
group O
, O
the O
onset O
of O
analgesia O
was O
faster O
( O
5 O
vs. O
15 O
min O
, O
P O
< O
0.001 O
) O
, O
the O
consumption O
of O
bupivacaine O
was O
lower O
( O
7.5 O
vs. O
11.3 O
mg O
h O
( O
-1 O
) O
, O
P O
= O
0.003 O
) O
and O
there O
was O
less O
unilateral B-outcome ['Physiological-Clinical']
analgesia I-outcome ['Physiological-Clinical']
( O
14.8 O
% O
vs. O
40.7 O
% O
, O
P O
= O
0.002 O
) O
than O
in O
the O
epidural O
group O
. O
['Physiological-Clinical']

Enrollment O
was O
stratified O
1:2 O
by O
age O
( O
50 O
to O
59 O
years O
and O
> O
or O
=60 O
years O
) O
. O
[]

Within O
the O
placebo O
group O
, O
less O
carotid B-outcome ['Physiological-Clinical']
IMT I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
was O
found O
for O
high O
supplementary O
vitamin O
E O
users O
when O
compared O
with O
low O
vitamin O
E O
users O
( O
0.008 O
versus O
0.023 O
mm/y O
, O
P O
= O
.03 O
) O
. O
['Physiological-Clinical']

Homeopaths O
and O
the O
conventional O
medical O
provider O
rated O
their O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
( O
CGI B-outcome ['Physiological-Clinical']
) O
of O
the O
severity B-outcome ['Physiological-Clinical']
of O
illness B-outcome ['Physiological-Clinical']
( O
1 O
= O
normal O
; O
7 O
= O
among O
the O
most O
extremely O
ill O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

An O
Eastern O
Cooperative O
Oncology O
Group O
study O
. O
[]

CONCLUSION O
Incidence O
of O
[]

BACKGROUND O
Examination O
of O
families O
represents O
an O
important O
priority O
in O
health O
research O
. O
[]

The O
open O
anterior O
approach O
to O
the O
groin O
was O
associated O
with O
demonstrable O
nerve B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
, O
and O
laparoscopic O
TAPP O
repair O
was O
the O
most O
effective O
approach O
in O
the O
hands O
of O
an O
experienced O
surgeon O
. O
['Physiological-Clinical']

Concentrations O
of O
fluid-phase B-outcome ['Physiological-Clinical']
complement I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
products I-outcome ['Physiological-Clinical']
and O
microparticles B-outcome ['Physiological-Clinical']
were O
similar O
in O
patients O
whether O
or O
not O
retransfused O
with O
pericardial O
blood O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Valproate O
1000 O
mg O
or O
placebo O
was O
given O
daily O
, O
each O
for O
a O
minimum O
of O
13 O
days O
. O
[]

[ O
A O
comparison O
of O
2 O
methods O
of O
plastic O
cast O
fixation O
in O
treatment O
of O
loco O
classico O
radius O
fracture O
. O
[]

The O
analysis O
confirmed O
OPN O
as O
a O
prognostic O
marker O
. O
[]

Patients O
were O
randomized O
by O
stratification O
to O
receive O
a O
low-dose O
monophasic O
pill O
, O
a O
high-dose O
monophasic O
pill O
, O
a O
multiphasic O
pill O
or O
no O
therapy O
. O
[]

On O
sheath O
removal O
, O
hemostasis O
was O
obtained O
using O
the O
TR O
band O
with O
a O
plethysmography-guided O
patent O
hemostasis O
technique O
. O
[]

It O
is O
unknown O
whether O
small-molecule O
agents O
confer O
similar O
benefits O
. O
[]

Thirty-nine O
percent O
of O
303 O
pretreatment O
gonococcal O
isolates O
had O
one O
or O
more O
types O
of O
antimicrobial O
resistance O
; O
the O
efficacy O
of O
all O
three O
regimens O
was O
independent O
of O
the O
resistance O
pattern O
. O
[]

Scored O
end O
points O
were O
rectal O
bleeding O
, O
high O
stool O
frequency O
, O
and O
fecal O
incontinence O
. O
[]

Each O
volunteer O
made O
five O
parachute O
jumps O
, O
for O
a O
total O
of O
3,674 O
jumps O
. O
[]

Middle-preference O
stimuli O
functioned O
as O
reinforcers O
for O
2 O
clients O
, O
but O
only O
when O
compared O
with O
low-preference O
stimuli O
. O
[]

In O
the O
GeparTrio O
trial O
, O
patients O
were O
not O
treated O
with O
any O
anti-HER2 O
therapy O
, O
as O
this O
was O
not O
standard O
therapy O
at O
this O
time O
. O
[]

Recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
comparable O
between O
groups O
. O
['Mortality']

Pregabalin O
versus O
naltrexone O
in O
alcohol O
dependence O
: O
a O
randomised O
, O
double-blind O
, O
comparison O
trial O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
mechanics I-outcome ['Physiological-Clinical']
, O
however O
, O
were O
not O
significantly O
improved O
and O
delayed B-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
was O
observed O
in O
one O
patient O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
relative O
contributions O
of O
medication O
adherence O
and O
AA O
meeting O
attendance O
to O
abstinent O
outcome O
for O
chronic O
alcoholics O
. O
[]

Among O
children O
whose O
medications O
were O
stepped O
up O
at O
any O
time O
during O
the O
12-month O
study O
period O
, O
those O
in O
the O
intervention O
group O
experienced O
22.1 O
% O
fewer O
symptom O
days O
and O
37.9 O
% O
fewer O
school O
days O
missed O
. O
[]

OBJECTIVE O
As O
part O
of O
a O
prospective O
study O
of O
possible O
effects O
of O
early-life O
otitis O
media O
on O
speech O
, O
language O
, O
cognitive O
, O
and O
psychosocial O
development O
, O
we O
tested O
relationships O
between O
children O
's O
cumulative O
duration O
of O
middle O
ear O
effusion O
( O
MEE O
) O
in O
their O
first O
3 O
years O
of O
life O
and O
their O
scores O
on O
measures O
of O
language B-outcome ['Life-Impact']
, O
speech B-outcome ['Life-Impact']
sound I-outcome ['Life-Impact']
production I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact']

Despite O
the O
shortened B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
, O
the O
incidence O
of O
infections O
and O
the O
rate O
of O
remission O
were O
not O
affected O
. O
['Physiological-Clinical']

BEACOPP O
in O
baseline O
dose O
contains O
all O
drug O
dosages O
of O
COPP/ABVD O
( O
except O
vincristine O
and O
procarbazine O
) O
rearranged O
in O
a O
shorter O
, O
3-week O
cycle O
. O
[]

EMLA O
analgesia O
was O
only O
effective O
in O
the O
skin B-outcome ['Physiological-Clinical']
, O
and O
had O
to O
be O
supplemented O
as O
the O
incision O
reached O
subcutaneous O
tissue O
. O
['Physiological-Clinical']

Instructions O
also O
had O
no O
significant O
effect O
on O
saliva B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
of O
caffeine O
. O
['Physiological-Clinical']

The O
superficial O
needle O
insertion O
into O
the O
skin O
overlaying O
the O
right O
thenar O
muscle O
caused O
a O
pronounced O
balanced O
increase O
in O
both O
the O
sympathetic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
parasympathetic I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
during O
the O
post O
stimulation O
period O
of O
60 O
min O
( O
P O
< O
0.01 O
) O
while O
no O
changes O
were O
observed O
during O
the O
stimulation O
period O
. O
['Physiological-Clinical']

Effect O
of O
mild O
endurance O
exercise O
training O
and O
pravastatin O
on O
peripheral O
vasodilatation O
of O
forearm O
resistance O
vessels O
in O
patients O
with O
coronary O
artery O
disease O
. O
[]

The O
percent O
of O
total O
magnesium O
that O
was O
ionized B-outcome ['Physiological-Clinical']
( O
% O
IMg2+ O
) O
was O
low O
in O
both O
the O
hemodialysis O
and O
CAPD O
patients O
( O
55.6 O
+/- O
0.93 O
and O
59.2 O
+/- O
1.05 O
) O
compared O
with O
that O
of O
control O
subjects O
( O
72 O
+/- O
0.61 O
; O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Instent B-outcome ['Physiological-Clinical']
restenoses I-outcome ['Physiological-Clinical']
were O
significantly O
more O
common O
in O
the O
CAS O
group O
( O
4.6 O
% O
vs O
2.2 O
% O
, O
odds O
ratio O
2.14 O
, O
95 O
% O
CI O
1.10-4.18 O
) O
. O
['Physiological-Clinical']

One-half O
of O
the O
patients O
received O
100 O
units O
BTX-A O
, O
diluted O
in O
1 O
ml O
saline O
, O
while O
the O
other O
half O
received O
just O
saline O
( O
1 O
ml O
) O
. O
[]

Subjects O
wore O
removable O
palatal O
appliances O
with O
insets O
of O
human O
enamel O
containing O
demineralized O
subsurface O
lesions O
and O
chewed O
the O
gum O
for O
20 O
min O
4 O
times O
per O
day O
for O
14 O
days O
. O
[]

SUBJECTS O
AND O
METHODS O
Recruited O
249 O
adults O
from O
Washington O
State O
aged O
55 O
to O
75 O
with O
a O
doctor-confirmed O
diagnosis O
of O
osteoarthritis O
to O
participate O
in O
aquatic O
classes O
. O
[]

SETTING O
Seventy-three O
general O
practices O
in O
Nottingham O
, O
North O
Nottinghamshire O
, O
Southern O
Derbyshire O
, O
North O
Lincolnshire O
and O
North O
Leicestershire O
. O
[]

Gefitinib O
was O
well O
tolerated B-outcome ['Life-Impact']
, O
as O
in O
previous O
studies O
. O
['Life-Impact']

Quadruple O
therapy O
, O
which O
appear O
highly O
efficacious O
as O
a O
second O
line O
therapy O
, O
is O
associated O
with O
a O
significantly O
higher O
incidence O
of O
side O
effects O
when O
compared O
to O
first-line O
treatment O
. O
[]

Sedation O
of O
moderate O
depth O
was O
achieved O
with O
intravenous O
midazolam O
. O
[]

SETTING O
AND O
PARTICIPANTS O
Participants O
included O
87 O
newly O
postmenopausal O
women O
with O
status O
post O
chemotherapy O
, O
recruited O
from O
a O
breast O
cancer O
clinic O
in O
an O
academic O
medical O
center O
. O
[]

RESULTS O
At O
12 O
months O
, O
differences O
in O
MMR O
and O
complete B-outcome ['Physiological-Clinical']
cytogenetic I-outcome ['Physiological-Clinical']
response O
( O
CCyR B-outcome ['Physiological-Clinical']
) O
rates O
were O
not O
statistically O
significant O
( O
MMR O
, O
46 O
% O
v O
40 O
% O
; O
P O
= O
.2035 O
; O
CCyR O
, O
70 O
% O
v O
66 O
% O
; O
P O
= O
.3470 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Maximum O
isometric B-outcome ['Physiological-Clinical']
single-joint I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
multi-joint I-outcome ['Physiological-Clinical']
arm O
strength B-outcome ['Physiological-Clinical']
was O
observed O
in O
two O
body O
orientations O
( O
sitting O
and O
supine O
) O
while O
maintaining O
identical O
head/neck/trunk/extremity O
joint O
configurations O
in O
order O
to O
identify O
bulbospinal O
contributions O
to O
maximum O
joint O
torque O
generation O
in O
11 O
individuals O
with O
stroke O
and O
10 O
individuals O
without O
stroke O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
study O
took O
place O
at O
the O
Paediatric O
Intensive O
Care O
Unit O
of O
Padua O
Hospital O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
investigate O
myocardial B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
radical I-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
during O
reperfusion O
with O
and O
without O
allopurinol O
treatment O
in O
coronary O
artery O
bypass O
grafting O
patients O
randomized O
into O
allopurinol O
( O
n O
= O
14 O
) O
or O
placebo O
( O
n O
= O
13 O
) O
groups O
. O
['Physiological-Clinical']

Hemodynamic B-outcome ['Physiological-Clinical']
data O
were O
first O
obtained O
after O
intravenous O
administration O
of O
0.75 O
mg/kg O
of O
enoximone O
; O
data O
were O
again O
obtained O
after O
12 O
weeks O
of O
therapy O
with O
either O
oral O
enoximone O
( O
150 O
mg O
3 O
times O
daily O
) O
or O
placebo O
. O
['Physiological-Clinical']

Further O
research O
should O
address O
how O
health O
care O
providers O
can O
support O
families O
in O
making O
decisions O
about O
CAM O
use O
. O
[]

On O
continual O
treatment O
there O
were O
21 O
bleedings B-outcome ['Physiological-Clinical']
on O
weekly O
injections O
of O
36 O
U O
factor O
VIII O
per O
kg O
, O
14 O
on O
twice O
weekly O
18 O
U/kg O
and O
none O
on O
12 O
U/kg O
, O
three O
times O
weekly O
. O
['Physiological-Clinical']

In O
the O
sequential O
arm O
, O
29 O
of O
53 O
evaluable O
patients O
( O
55 O
% O
; O
95 O
% O
confidence O
interval O
, O
41 O
% O
-68 O
% O
) O
had O
a O
complete O
response O
. O
[]

The O
therapeutic O
course O
was O
8 O
weeks O
. O
[]

Signal-to-noise O
ratio O
( O
SNR O
) O
and O
[]

Prophylactic O
cranial O
irradiation O
for O
patients O
with O
small-cell O
lung O
cancer O
in O
complete O
remission O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
analgesic B-outcome ['Resource-use']
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
codeine O
phosphate O
versus O
hydrocodone O
bitartrate O
in O
combination O
with O
acetaminophen O
in O
the O
relief O
of O
cancer-related O
pain O
. O
['Resource-use', 'Life-Impact']

The O
incidence O
of O
tremor B-outcome ['Physiological-Clinical']
was O
similar O
with O
the O
two O
medications O
. O
['Physiological-Clinical']

Operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
with O
Steri-Strip O
S O
for O
breast O
was O
2.0 O
minutes O
( O
SD O
= O
1.1 O
) O
versus O
suture O
closure O
at O
4.6 O
minutes O
( O
SD O
= O
1.5 O
; O
p O
< O
0.001 O
) O
. O
['Life-Impact']

OBJECTIVE O
To O
observe O
the O
efficacy O
of O
encephalopathy O
therapeutic O
tongue O
acupoint O
apparatus O
( O
ETTAA O
) O
in O
the O
treatment O
of O
autism O
. O
[]

Mean O
reciprocal B-outcome ['Physiological-Clinical']
bactericidal I-outcome ['Physiological-Clinical']
titers I-outcome ['Physiological-Clinical']
were O
measured O
1 O
and O
6 O
h O
after O
administration O
. O
['Physiological-Clinical']

In O
a O
controlled O
randomized O
strictly O
double-blind O
trial O
with O
164 O
patients O
the O
effectiveness O
of O
homeopathically O
prepared O
Galphimia O
D6 O
, O
a O
conventional O
Galphimia O
dilution O
10 O
( O
-6 O
) O
and O
a O
placebo O
was O
investigated O
for O
the O
therapy O
of O
pollinosis O
. O
[]

Pilot O
study O
of O
the O
effectiveness O
of O
weighted O
vests O
. O
[]

A O
total O
of O
25 O
subjects O
( O
17.5 O
% O
) O
were O
still O
using O
smokeless O
tobacco O
after O
6 O
months O
. O
[]

Acamprosate O
appears O
to O
decrease O
alcohol B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
in O
weaned O
alcoholics O
. O
['Life-Impact']

There O
were O
two O
3-week O
study O
periods O
with O
a O
4-week O
wash-out O
period O
in O
between O
. O
[]

A O
low O
proportion O
( O
37 O
% O
) O
of O
the O
eligible O
population O
of O
hospitalized O
patients O
agreed O
to O
participate O
. O
[]

The O
outcome O
was O
measured O
by O
using O
Conners O
abbreviated O
parent O
and O
teacher O
questionnaires O
and O
by O
determining O
the O
number O
of O
daily O
performance O
tasks O
completed O
by O
the O
child O
at O
school O
. O
[]

Acute O
intervention O
studies O
in O
patients O
with O
myocardial O
infarction O
using O
atenolol O
, O
propranolol O
, O
oxprenolol O
and O
disopyramide O
phosphate O
. O
[]

busulfan O
( O
Bu O
) O
and O
fludarabine O
( O
Flu O
) O
is O
a O
safe O
, O
reduced-toxicity O
conditioning O
program O
for O
acute O
myelogenous O
leukemia/myelodysplastic O
syndromes O
( O
AML/MDS O
) O
, O
recurrent O
leukemia O
posttransplantation O
remains O
a O
problem O
. O
[]

In O
addition O
, O
melatonin O
enhanced O
the O
activation O
in O
the O
left B-outcome ['Physiological-Clinical']
parahippocampus I-outcome ['Physiological-Clinical']
in O
an O
autobiographic O
memory O
task O
. O
['Physiological-Clinical']

Corresponding O
figures O
for O
fibrin B-outcome ['Physiological-Clinical']
deposition I-outcome ['Physiological-Clinical']
were O
64.9+/-4.8 O
% O
and O
18.3+/-9.7 O
% O
, O
respectively O
( O
58 O
% O
reduction O
; O
95 O
% O
CI O
, O
45-67 O
% O
; O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Performance B-outcome ['Life-Impact']
is O
close O
to O
that O
of O
a O
human O
expert O
examining O
the O
images O
for O
the O
presence O
of O
red O
lesions O
. O
['Life-Impact']

In O
order O
to O
better O
understand O
the O
effect O
of O
breast O
cancer O
screening O
on O
mortality O
, O
we O
use O
the O
theory O
of O
competing O
risks O
to O
analyse O
deaths O
from O
the O
long-term O
follow-up O
of O
the O
HIP O
breast O
cancer O
screening O
trial O
. O
[]

Only O
3 O
patients O
, O
2 O
from O
the O
water O
group O
and O
1 O
from O
the O
land O
group O
, O
had O
exercise-induced B-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
after O
10 O
weeks O
. O
['Physiological-Clinical']

Effects O
of O
a O
combination O
of O
evening O
primrose O
oil O
( O
gamma O
linolenic O
acid O
) O
and O
fish O
oil O
( O
eicosapentaenoic O
+ O
docahexaenoic O
acid O
) O
versus O
magnesium O
, O
and O
versus O
placebo O
in O
preventing O
pre-eclampsia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

These O
4 O
are O
included O
on O
an O
'intention-to-treat O
' O
basis O
. O
[]

From O
these O
data O
we O
conclude O
that O
the O
intermittent O
cyclic O
regimen O
of O
6MP O
and O
MTX O
may O
be O
more O
effective O
as O
compared O
to O
the O
continuous O
administration O
of O
these O
drugs O
in O
the O
maintenance O
chemotherapy O
. O
[]

Maximum O
standardized O
uptake O
value O
( O
SUVmax O
) O
reductions O
from O
baseline O
were O
used O
to O
measure O
metabolic O
response O
. O
[]

Patients O
fulfilling O
the O
selection O
criteria O
were O
randomly O
assigned O
to O
receive O
urokinase O
900,000 O
units O
via O
intravenous O
or O
intra-arterial O
routes O
. O
[]

Recovery B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
in O
group O
F O
was O
significantly O
shorter O
than O
in O
group O
E O
( O
p O
< O
0.001 O
) O
, O
and O
after O
the O
injection O
of O
flumazenil O
, O
RSS B-outcome ['Physiological-Clinical']
in O
group O
F O
significantly O
decreased O
than O
in O
group O
E. O
There O
were O
no O
significant O
differences O
in O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Of O
55 O
families O
, O
71 O
% O
completed O
the O
program O
consisting O
of O
eight O
lessons O
. O
[]

After O
2 O
weeks O
on O
placebo O
the O
patients O
were O
assigned O
at O
random O
to O
4 O
groups O
: O
group O
P O
-- O
placebo O
, O
group O
L O
-- O
0.1 O
mg. O
, O
group O
M O
-- O
0.2 O
mg. O
and O
group O
H O
-- O
0.4 O
mg. O
of O
YM617 O
. O
[]

The O
percentages O
of O
echo-types B-outcome ['Physiological-Clinical']
were O
calculated O
, O
and O
the O
maximum O
tendon B-outcome ['Life-Impact']
thickness I-outcome ['Life-Impact']
was O
measured O
. O
['Physiological-Clinical', 'Life-Impact']

Assays O
in O
male O
adolescents O
and O
in O
Caco-2 O
cells O
. O
[]

PATIENTS O
AND O
METHODS O
Three O
hundred O
two O
patients O
with O
no O
previous O
chemotherapy O
for O
MBC O
were O
randomized O
to O
receive O
nab-paclitaxel O
300 O
mg/m O
( O
2 O
) O
q3w O
, O
nab-paclitaxel O
100 O
mg/m O
( O
2 O
) O
or O
150 O
mg/m O
( O
2 O
) O
the O
first O
3 O
of O
4 O
weeks O
( O
qw O
3/4 O
) O
, O
or O
docetaxel O
100 O
mg/m O
( O
2 O
) O
q3w O
. O
[]

This O
study O
examined O
the O
effect O
of O
m-chlorophenylpiperazine O
( O
m-CPP O
) O
on O
repetitive O
behaviours O
and O
prolactin O
response O
in O
11 O
adults O
with O
autism O
or O
Aspergers O
disorder O
and O
8 O
age- O
and O
gender-matched O
healthy O
controls O
via O
randomized O
double-blind O
, O
m-CPP O
and O
placebo O
challenges O
. O
[]

Forty-five O
patients O
posted O
for O
coronary O
artery O
bypass O
graft O
surgery O
were O
randomised O
to O
receive O
either O
short-term O
pulmonary O
rehabilitation O
( O
group O
I O
) O
or O
no O
such O
programme O
( O
group O
II O
) O
. O
[]

CONCLUSIONS O
No O
clear B-outcome ['Physiological-Clinical']
benefit O
in O
terms O
of O
response O
rates O
, O
median O
['Physiological-Clinical']

However O
, O
the O
pattern O
of O
modulation O
during O
arm O
swing O
was O
not O
exactly O
the O
same O
as O
that O
during O
walking O
. O
[]

Complete B-outcome ['Physiological-Clinical']
above-knee I-outcome ['Physiological-Clinical']
stripping I-outcome ['Physiological-Clinical']
was O
unsuccessful O
in O
seven O
of O
41 O
patients O
. O
['Physiological-Clinical']

0.5 O
Nm/BW O
) O
. O
[]

DASH O
scores O
were O
lower O
in O
the O
operative O
group O
throughout O
the O
first O
6 O
months O
and O
2 O
years O
after O
trauma O
, O
with O
a O
significant O
difference O
during O
the O
first O
18 O
weeks O
. O
[]

Reported O
are O
the O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
in O
165 O
patients O
and O
the O
recurrence B-outcome ['Physiological-Clinical']
rate O
of I-outcome ['Physiological-Clinical']
tumors I-outcome ['Physiological-Clinical']
in O
308 O
patients O
after O
a O
follow-up O
period O
of O
twelve O
months O
. O
['Adverse-effects', 'Physiological-Clinical']

Oral O
NAC O
was O
well O
tolerated B-outcome ['Life-Impact']
with O
limited O
side O
effects O
. O
['Life-Impact']

CONCLUSIONS O
TE O
supplementation O
was O
associated O
with O
higher O
circulating O
plasma O
and O
skin O
tissue O
contents O
of O
selenium O
and O
zinc O
and O
improved O
antioxidant O
status O
. O
[]

The O
mean O
birth B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
was O
770 O
g O
in O
the O
vitamin O
A O
group O
and O
769 O
g O
in O
the O
control O
group O
, O
and O
the O
respective O
gestational O
ages O
were O
26.8 O
and O
26.7 O
weeks O
. O
['Physiological-Clinical']

No O
differences O
between O
diets O
were O
found O
for O
cortisol O
, O
corticosteroid-binding O
globulin O
, O
and O
catecholamine O
concentrations O
in O
plasma O
and O
for O
GR O
binding O
in O
hippocampus O
and O
hypothalamus O
in O
piglets O
at O
PND O
1 O
and O
27 O
. O
[]

OBJECTIVES O
To O
examine O
the O
impact O
of O
including O
a O
'no O
active O
intervention O
' O
arm O
( O
called O
'conservative O
management O
' O
) O
in O
a O
randomised O
controlled O
trial O
comparing O
treatments O
( O
including O
surgery O
) O
for O
men O
with O
lower O
urinary O
tract O
symptoms O
related O
to O
benign O
prostatic O
enlargement O
. O
[]

The O
other O
22 O
patients O
showed O
an O
acceleration B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
transit I-outcome ['Physiological-Clinical']
on O
response O
to O
cisapride O
. O
['Physiological-Clinical']

RESEARCH O
DESIGN O
AND O
METHODS O
This O
was O
a O
randomized O
, O
placebo-controlled O
, O
multi-center O
, O
phase O
III O
trial O
, O
conducted O
in O
opioid-tolerant O
male O
and O
female O
patients O
( O
aged O
> O
or O
=17 O
years O
) O
with O
BTcP O
. O
[]

The O
spectrum O
and O
frequency O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
with O
esomeprazole O
were O
similar O
to O
those O
with O
placebo O
. O
['Adverse-effects']

The O
uptake O
of O
the O
photosensitizers O
in O
tumor O
( O
fibrosarcoma O
) O
and O
adjacent O
normal O
tissue O
biopsies O
was O
quantified O
by O
tissue O
solubilization O
technique O
and O
fluorimetry O
. O
[]

d O
) O
Occurrence O
of O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
in O
the O
two O
treatment O
groups O
. O
['Adverse-effects']

Efficacy O
of O
azithromycin O
for O
the O
treatment O
of O
feline O
chlamydophilosis O
. O
[]

The O
European O
Myocardial O
Infarction O
Project O
was O
a O
European O
Economic O
Community-supported O
double-blind O
study O
designed O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
pre-hospital O
early O
thrombolytic O
treatment O
in O
patients O
with O
suspected O
myocardial O
infarction O
compared O
with O
the O
same O
treatment O
given O
later O
in O
a O
hospital O
setting O
. O
[]

The O
unsuccessful B-outcome ['Life-Impact']
first-time I-outcome ['Life-Impact']
intubations I-outcome ['Life-Impact']
with O
a O
0 O
degree O
orientation O
were O
frequently O
converted O
to O
successful B-outcome ['Life-Impact']
intubations I-outcome ['Life-Impact']
with O
the O
-90 O
degrees O
position O
at O
a O
second O
attempt O
. O
['Life-Impact', 'Life-Impact']

Limited O
data O
characterize O
pharmacokinetic O
interactions O
between O
cephalexin O
and O
ranitidine O
, O
and O
no O
data O
exist O
for O
an O
interaction O
with O
proton O
pump O
inhibitors O
. O
[]

After O
3 O
months O
, O
pyrosis B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
noted O
by O
seven O
women O
in O
group O
A O
( O
28 O
% O
) O
, O
three O
in O
group O
B O
( O
12 O
% O
) O
and O
two O
in O
group O
C O
( O
8 O
% O
) O
; O
nausea B-outcome ['Physiological-Clinical']
: O
by O
one O
woman O
in O
group O
B O
; O
and O
headache B-outcome ['Physiological-Clinical']
by O
one O
patient O
in O
each O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

On O
each O
randomized O
study O
day O
, O
the O
subjects O
inhaled O
five O
serial O
doses O
of O
either O
LTD4 O
( O
mean O
cumulative O
concentration O
: O
95.7 O
microM O
) O
or O
methacholine O
( O
mean O
cumulative O
concentration O
: O
542 O
mM O
) O
or O
five O
doses O
of O
their O
respective O
diluents O
( O
PBS/ethanol O
or O
PBS O
) O
. O
[]

Risperidone O
improved O
global B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
responsiveness I-outcome ['Life-Impact']
while O
reducing O
hyperactivity B-outcome ['Life-Impact']
and O
aggression B-outcome ['Life-Impact']
in O
children O
with O
autism O
and O
was O
well O
tolerated O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
urine O
concentration O
of O
8-iso-PGF O
( O
2? O
) O
[ O
geometric O
mean O
( O
95 O
% O
CI O
) O
] O
was O
greater O
after O
the O
iTFA O
[ O
0.54 O
( O
0.48 O
, O
0.60 O
) O
nmol/mmol O
creatinine O
] O
and O
the O
CLA O
[ O
1.2 O
( O
1.1 O
, O
1.3 O
) O
nmol/mmol O
creatinine O
] O
diet O
periods O
than O
after O
the O
control O
period O
[ O
0.45 O
( O
0.41 O
, O
0.50 O
) O
nmol/mmol O
creatinine O
; O
P O
< O
0.05 O
] O
. O
[]

This O
was O
followed O
by O
a O
domiciliary O
assessment O
by O
a O
community O
pharmacist O
. O
[]

Therefore O
, O
the O
data O
of O
the O
prospective O
INTACT O
study O
( O
International O
Nifedipine O
Trial O
on O
Antiatherosclerotic O
Therapy O
) O
were O
reviewed O
. O
[]

A O
comparative O
study O
of O
ofloxacin O
and O
cefixime O
for O
treatment O
of O
typhoid O
fever O
in O
children O
. O
[]

PEG O
( O
Sachs-Vine O
) O
and O
OG O
( O
Stamm O
) O
were O
done O
using O
local O
anesthesia O
. O
[]

In O
conclusion O
, O
the O
adjusted O
mortality O
was O
similar O
between O
patients O
with O
and O
without O
previous O
CABG O
, O
despite O
a O
significantly O
different O
risk O
of O
target O
lesion O
revascularization O
. O
[]

METHODOLOGY/PRINCIPAL O
FINDINGS O
Sixty O
chronic O
pancreatitis O
patients O
were O
compared O
to O
15 O
healthy O
controls O
. O
[]

OBJECTIVES O
To O
determine O
the O
efficacy O
and O
safety O
of O
citalopram O
hydrobromide O
therapy O
for O
repetitive O
behavior O
in O
children O
with O
autism O
spectrum O
disorders O
. O
[]

PURPOSE O
Recently O
, O
new O
custom-fit O
pin O
guides O
in O
total O
knee O
arthroplasty O
( O
TKA O
) O
have O
been O
introduced O
. O
[]

hemoglobin O
, O
p O
= O
0.011 O
) O
. O
[]

Comparison O
of O
remifentanil O
with O
fentanyl O
for O
deep B-outcome ['Physiological-Clinical']
sedation I-outcome ['Physiological-Clinical']
in O
oral O
surgery O
. O
['Physiological-Clinical']

Apolipoprotein B-outcome ['Physiological-Clinical']
A-1 I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
decreased O
in O
the O
control O
group O
( O
0 O
vs. O
8 O
week O
, O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Daytime B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
sympathetic I-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MSNA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
elevated O
in O
HF O
patients O
with O
coexisting O
OSA O
. O
['Physiological-Clinical']

The O
opioid O
hypothesis O
suggests O
that O
childhood O
autism O
may O
result O
from O
excessive O
brain O
opioid O
activity O
during O
neonatal O
period O
which O
may O
constitutionally O
inhibit O
social O
motivation O
, O
yielding O
autistic O
isolation O
and O
aloofness O
( O
Panksepp O
, O
1979 O
) O
. O
[]

There O
were O
no O
differences O
in O
the O
tolerability B-outcome ['Life-Impact']
of O
the O
two O
antiemetic O
therapy O
modalities O
. O
['Life-Impact']

Children O
were O
prospectively O
randomised O
into O
two O
equal O
groups O
: O
potassium O
titanyl O
phosphate O
laser O
tonsillectomy O
and O
bipolar O
radiofrequency O
tonsillectomy O
. O
[]

Patients O
were O
stratified O
prospectively O
for O
platinum O
sensitivity O
and O
for O
the O
presence O
or O
absence O
of O
bulky O
disease O
. O
[]

A O
persistent B-outcome ['Physiological-Clinical']
fibronecrotic I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
was O
found O
in O
150 O
patients O
( O
20 O
% O
) O
and O
did O
not O
influence O
the O
relapse B-outcome ['Physiological-Clinical']
rate O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
six O
months O
of O
NHT O
therapy O
the O
proportion O
of O
patients O
with O
pathological B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
( O
67 O
% O
vs. O
36 O
% O
, O
respectively O
) O
and O
negative O
margins B-outcome ['Physiological-Clinical']
was O
greater O
than O
after O
3 O
months O
( O
92 O
% O
vs. O
42 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
some O
wearers O
this O
may O
interfere O
with O
activities O
where O
excellent O
vision O
is O
crucial O
, O
such O
as O
driving O
a O
car O
. O
[]

After O
starting O
estrogen O
treatment O
, O
the O
decrease O
in O
height B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
( O
HV O
) O
changed O
significantly O
to O
a O
stable O
HV O
, O
without O
affecting O
bone B-outcome ['Physiological-Clinical']
maturation I-outcome ['Physiological-Clinical']
( O
change O
in O
bone O
age/change O
in O
chronological O
age O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
Children O
aged O
5-15 O
years O
( O
without O
prior O
use O
of O
montelukast O
) O
with O
acute O
moderate O
to O
severe O
asthma O
exacerbation O
, O
as O
defined O
using O
Modified B-outcome ['Physiological-Clinical']
Pulmonary I-outcome ['Physiological-Clinical']
Index O
Score O
( O
MPIS B-outcome ['Physiological-Clinical']
) O
> O
or O
=9 O
, O
were O
enrolled O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thus O
, O
three O
groups O
were O
formed O
( O
n O
= O
10 O
) O
according O
to O
the O
adhesive O
system O
employed O
: O
All-Bond O
2 O
( O
TE3 O
) O
+ O
resin O
cement O
post O
( O
rcp O
) O
+ O
Duo-link O
( O
Dl O
) O
; O
One-Step O
Plus O
( O
TE2 O
) O
+ O
rcp O
+ O
Dl O
; O
Tyrian/One-Step O
Plus O
( O
SE O
) O
+ O
rcp O
+ O
Dl O
. O
[]

Time O
to O
intubate O
was O
also O
measured O
. O
[]

INTRODUCTION O
This O
study O
examined O
whether O
( O
1 O
) O
postmenopausal O
breast O
cancer O
survivors O
( O
BCS O
) O
with O
bone O
loss O
taking O
24 O
months O
of O
risedronate O
, O
calcium O
, O
and O
vitamin O
D O
had O
increased O
bone O
mineral O
density O
( O
BMD O
) O
at O
the O
total O
hip O
, O
femoral O
neck O
, O
L1-L4 O
spine O
, O
total O
radius O
and O
33 O
% O
radius O
, O
and O
decreased O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
; O
( O
2 O
) O
subjects O
who O
also O
participated O
in O
strength/weight O
training O
( O
ST O
) O
exercises O
had O
greater O
increases O
in O
BMD B-outcome ['Physiological-Clinical']
and O
greater O
decreases O
in O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
; O
and O
( O
3 O
) O
subjects O
who O
also O
exercised O
were O
more O
likely O
to O
preserve O
( O
at O
least O
maintain O
) O
BMD B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Seven O
children O
were O
assigned O
to O
a O
control O
group O
, O
receiving O
no O
intervention O
. O
[]

DISCUSSION O
Along O
with O
a O
technique O
to O
improve O
health B-outcome ['Life-Impact']
workers I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
on O
the O
protocol O
, O
the O
study O
will O
generate O
evidence O
on O
the O
research O
gap O
on O
the O
effectiveness O
of O
the O
simplified O
neonatal O
resuscitation O
protocol O
on O
intrapartum O
outcome O
and O
early O
neonatal O
['Life-Impact']

Seventy-one O
alcohol-dependent O
subjects O
were O
detoxified O
and O
subsequently O
randomised O
into O
two O
groups O
, O
receiving O
50 O
mg O
of O
NAL O
or O
150-450 O
mg O
of O
PRE O
. O
[]

They O
were O
treated O
immediately O
with O
intravenous O
heparin O
( O
10,000 O
units O
) O
and O
oral O
aspirin O
( O
325 O
mg O
) O
and O
randomized O
to O
treatment O
with O
placebo O
or O
streptokinase O
( O
1.5 O
M O
units O
) O
administered O
intravenously O
over O
30 O
minutes O
. O
[]

Inclusion O
criteria O
include O
left O
ventricular O
systolic O
dysfunction O
, O
the O
presence O
of O
New O
York O
Heart O
Association O
Class O
III O
symptoms O
, O
sinus O
rhythm O
, O
and O
QRS O
width O
less O
than O
120 O
milliseconds O
. O
[]

CONCLUSIONS O
Single-incision O
laparoscopic O
surgery O
appendectomy O
resulted O
in O
more O
pain O
and O
longer O
operative O
times O
without O
improving O
short-term O
recovery O
or O
complications O
. O
[]

BACKGROUND O
Recurrent O
or O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
( O
SCCHN O
) O
is O
associated O
with O
poor O
survival O
. O
[]

RE-LY O
is O
the O
largest O
AF O
stroke O
prevention O
trial O
yet O
undertaken O
. O
[]

AIMS/HYPOTHESIS O
Macrovascular O
disease O
is O
an O
important O
cause O
of O
the O
increased O
morbidity O
and O
mortality O
rates O
associated O
with O
type O
1 O
diabetes O
, O
and O
this O
vascular O
impairment O
begins O
in O
childhood O
. O
[]

These O
echocardiographic O
data O
of O
functional O
and O
morphological B-outcome ['Physiological-Clinical']
parameters O
indicate O
that O
there O
was O
no O
effect O
on O
various O
measurements O
of O
diastolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
after O
chemotherapy O
with O
or O
without O
mediastinal O
radiation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Forty-one O
children O
and O
youths O
between O
5 O
months O
and O
21 O
years O
with O
prior O
NRTI O
and O
no O
prior O
NNRTI O
or O
protease O
inhibitor O
experience O
received O
either O
nelfinavir O
( O
NFV O
) O
30 O
mg/kg O
twice O
daily O
( O
bid O
) O
, O
ritonavir O
( O
RTV O
) O
400 O
mg/m O
bid O
and O
buffered O
didanosine O
( O
ddI O
) O
240 O
mg/m O
daily O
( O
arm O
A O
) O
or O
NFV O
50-55 O
mg/kg O
bid O
, O
nevirapine O
( O
NVP O
) O
120 O
mg/m O
bid O
and O
stavudine O
( O
d4T O
) O
1 O
mg/kg O
bid O
( O
arm O
B O
) O
. O
[]

RESULTS O
Of O
the O
653 O
patients O
included O
in O
the O
trial O
, O
360 O
produced O
positive O
baseline O
mycologic O
cultures O
and O
were O
included O
in O
the O
efficacy O
assessment O
. O
[]

When O
determining O
whether O
an O
image O
contains O
red B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
the O
system O
achieves O
a O
sensitivity B-outcome ['Physiological-Clinical']
of O
100 O
% O
at O
a O
specificity O
of O
87 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
incidence O
of O
fever B-outcome ['Physiological-Clinical']
was O
also O
less O
in O
the O
sublingual O
group O
. O
['Physiological-Clinical']

Safety O
was O
assessed O
through O
adverse O
event O
monitoring O
. O
[]

The O
overall O
mean O
daily B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief O
score O
was O
significantly O
greater O
in O
the O
HI2 O
group O
( O
2.25+/-0.89 O
) O
than O
in O
the O
HI1 O
group O
( O
1.98+/-0.87 O
) O
( O
P O
= O
0.003 O
) O
or O
the O
CA O
group O
( O
1.85+/-0.96 O
) O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

The O
other O
12 O
received O
4 O
sessions O
of O
'associative O
therapy O
' O
, O
a O
presumably O
inert O
treatment O
that O
controls O
for O
therapist O
attention O
, O
followed O
by O
8 O
sessions O
of O
in O
vivo O
exposure O
that O
was O
framed O
in O
common O
behavioral O
terms O
. O
[]

Stimulation O
of O
the O
ear O
induced O
a O
significant O
increase O
in O
the O
parasympathetic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
during O
the O
stimulation O
period O
of O
25 O
min O
( O
P O
< O
0.05 O
) O
and O
during O
the O
post-stimulation O
period O
of O
60 O
min O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

SS O
discharged O
immediately O
( O
mean O
18 O
days O
) O
for O
standard O
Health O
Service O
care O
at O
home O
for O
6 O
months O
plus O
high-energy O
supplement O
( O
3.31 O
MJ O
with O
20.6 O
g O
protein O
daily O
) O
for O
first O
3 O
months O
. O
[]

The O
levels O
of O
opioid O
physical O
dependence O
in O
a O
group O
of O
long-term O
heroin O
addicts O
were O
ascertained O
by O
measuring O
the O
severity O
of O
the O
opioid B-outcome ['Physiological-Clinical']
withdrawal I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
before O
and O
after O
pharmacological O
challenge O
with O
either O
0.4 O
mg O
naloxone O
or O
placebo O
. O
['Physiological-Clinical']

CONCLUSION O
Prolonged O
subclinical O
hyperthyroidism O
leads O
to O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
, O
which O
is O
reversible O
after O
restoration O
of O
euthyroidism O
. O
['Physiological-Clinical']

African O
Americans O
have O
a O
disproportionate O
burden O
of O
inflammation-associated O
chronic O
diseases O
such O
as O
cancer O
and O
lower O
circulating O
levels O
of O
25-hydroxyvitamin O
D O
[ O
25 O
( O
OH O
) O
D O
] O
. O
[]

Of O
these O
, O
80.0 O
to O
96.8 O
% O
, O
depending O
on O
the O
question O
, O
expressed O
satisfaction O
with O
their O
child O
's O
research O
participation O
regardless O
of O
treatment O
outcome O
or O
assignment O
to O
active O
drug O
or O
placebo O
. O
[]

OBJECTIVE O
This O
study O
aimed O
to O
investigate O
the O
effect O
of O
adding O
amantadine O
to O
risperidone O
for O
treatment O
of O
autism O
. O
[]

Mecamylamine O
reduces O
some O
EEG B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
nicotine O
chewing O
gum O
in O
humans O
. O
['Physiological-Clinical']

RESULTS O
The O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
was O
11.8 O
% O
( O
6/51 O
) O
in O
the O
S O
group O
, O
14.8 O
% O
( O
8/54 O
) O
in O
the O
M O
group O
, O
1.9 O
% O
( O
1/52 O
) O
in O
the O
S+M O
group O
, O
and O
38 O
% O
( O
19/50 O
) O
in O
the O
CTR O
group O
. O
['Physiological-Clinical']

The O
CTRS-R O
: O
S O
Hyperactivity O
subscore O
also O
improved O
significantly O
for O
atomoxetine O
compared O
with O
placebo O
, O
but O
not O
the O
other O
CTRS-R O
: O
S O
subscores O
. O
[]

Fifty O
sedentary O
males O
were O
randomly O
divided O
into O
five O
groups O
. O
[]

From O
January O
2008 O
to O
June O
2010 O
, O
80 O
consecutive O
children O
undergoing O
correction O
of O
TOF O
were O
enrolled O
and O
randomly O
assigned O
to O
either O
a O
postconditioning O
group O
( O
three O
cycles O
of O
30 O
seconds O
of O
ischemia O
and O
30 O
seconds O
of O
reperfusion O
using O
re-clamping O
and O
de-clamping O
starting O
30 O
seconds O
after O
the O
initial O
de-clamping O
of O
the O
aorta O
, O
n O
= O
41 O
) O
or O
a O
control O
group O
( O
n O
= O
39 O
) O
. O
[]

In O
conclusion O
, O
there O
was O
an O
additive O
effect O
of O
sevelamer O
for O
the O
treatment O
of O
hyperphosphatemia O
with O
CC O
. O
[]

In O
group O
2 O
, O
however O
, O
the O
level O
of O
serum B-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
did O
not O
change O
after O
three O
and O
6 O
months O
. O
['Physiological-Clinical']

Clofibrate B-outcome ['Resource-use']
and O
diabetes B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
in O
patients O
treated O
with O
oral O
hypoglycaemic O
agents O
. O
['Resource-use', 'Physiological-Clinical']

The O
non-recurrence B-outcome ['Physiological-Clinical']
rates O
in O
the O
THP O
group O
and O
control O
group O
were O
54.1 O
% O
versus O
37.6 O
% O
at O
1 O
year O
and O
40.4 O
% O
versus O
26.8 O
% O
at O
2 O
years O
, O
respectively O
( O
P O
= O
0.086 O
) O
. O
['Physiological-Clinical']

A O
randomized O
double-blind O
study O
of O
atomoxetine O
versus O
placebo O
for O
attention-deficit/hyperactivity O
disorder O
symptoms O
in O
children O
with O
autism O
spectrum O
disorder O
. O
[]

Attendance O
at O
Alcoholics O
Anonymous O
( O
AA O
) O
meetings O
was O
also O
associated O
with O
medication O
adherence O
. O
[]

This O
study O
was O
designed O
to O
examine O
the O
levels O
of O
plasma B-outcome ['Physiological-Clinical']
plasminogen I-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PAI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
serum B-outcome ['Physiological-Clinical']
ACE I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
during O
the O
course O
of O
2 O
weeks O
in O
40 O
patients O
with O
AMI O
within O
12 O
hours O
after O
the O
onset O
of O
the O
symptom O
and O
who O
randomly O
received O
early O
treatment O
with O
either O
the O
ACE O
inhibitor O
imidapril O
or O
a O
placebo O
( O
20 O
patients O
in O
the O
imidapril O
group O
and O
20 O
in O
the O
placebo O
group O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

At O
the O
end O
of O
the O
study O
, O
significantly O
fewer O
subjects O
in O
the O
active O
group O
( O
n O
= O
1 O
) O
had O
new B-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
infarcts I-outcome ['Physiological-Clinical']
compared O
with O
the O
placebo O
group O
( O
n O
= O
8 O
; O
p O
= O
0.018 O
) O
. O
['Physiological-Clinical']

This O
study O
assesses O
the O
efficacy O
of O
current O
physiotherapy O
strategies O
. O
[]

With O
increasing O
trends O
of O
cardiovascular O
disease O
and O
increasing O
costs O
of O
care O
, O
development O
of O
cost-effective O
strategies O
is O
vital O
. O
[]

METHODS O
In O
this O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
, O
Japanese O
women O
were O
randomized O
to O
1 O
of O
4 O
groups O
to O
receive O
IV O
administration O
of O
propofol O
0.5 O
mg/kg O
, O
droperidol O
20 O
microg/kg O
, O
metoclopramide O
0.2 O
mg/kg O
, O
or O
placebo O
( O
isotonic O
saline O
) O
immediately O
after O
skin O
suture O
. O
[]

An O
excellent O
correlation O
between O
ultrasound O
and O
CT O
was O
observed O
( O
r O
= O
0.98 O
) O
. O
[]

INTERVENTION O
Participants O
were O
randomized O
to O
receive O
1 O
year O
of O
daily O
supplementation O
with O
71 O
g O
of O
LP O
( O
282 O
kcal O
) O
, O
50 O
g O
of O
FS O
( O
FS50 O
) O
( O
256 O
kcal O
) O
, O
or O
25 O
g O
of O
FS O
( O
FS25 O
) O
( O
130 O
[ O
corrected O
] O
kcal O
) O
. O
[]

Patients O
were O
followed O
up O
for O
2 O
months O
, O
and O
data O
concerning O
patients O
' O
age O
and O
gender O
; O
tooth O
position O
, O
angulation O
, O
and O
depth O
; O
date O
and O
site O
of O
surgery O
; O
and O
occurrence O
of O
late O
mandibular O
fracture O
were O
recorded O
and O
statistically O
analyzed O
. O
[]

These O
results O
provide O
insight O
into O
the O
nature O
of O
multisensory O
processing O
while O
also O
revealing O
a O
continuum O
over O
which O
perceptual O
abilities O
correlate O
with O
symptoms O
of O
autism O
and O
that O
this O
continuum O
is O
not O
just O
specific O
to O
clinical O
populations O
but O
is O
present O
within O
the O
general O
population O
. O
[]

CONCLUSION O
Our O
results O
strongly O
suggest O
that O
there O
is O
no O
relevant O
radiotherapy B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
effect O
in O
the O
range O
between O
20 O
Gy O
and O
40 O
Gy O
in O
IF/BF O
and O
EF/IF O
after O
4 O
months O
of O
modern O
polychemotherapy O
in O
patients O
with O
intermediate-stage O
HD O
. O
['Life-Impact']

In O
the O
controlgroup O
, O
income B-outcome ['Life-Impact']
generated O
was O
11.35 O
pounds O
per O
immunisation O
, O
for O
each O
additional O
immunisation O
in O
the O
intervention O
group O
the O
income O
was O
5.20 O
pounds O
. O
['Life-Impact']

Attempts O
have O
been O
made O
to O
remove O
endotoxin O
, O
the O
main O
cause O
of O
sepsis O
, O
from O
the O
circulation O
using O
polymyxin O
B O
immobilized O
fiber O
, O
charcoal O
hemoperfusion O
, O
and O
plasma O
or O
whole O
blood O
exchange O
. O
[]

Mean O
age O
at O
walking B-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
was O
19.2 O
, O
21.4 O
, O
and O
23.9 O
months O
for O
the O
HI O
, O
LG O
, O
and O
C O
groups O
respectively O
. O
['Life-Impact']

Values O
are O
given O
as O
n O
( O
% O
) O
. O
( O
[]

PURPOSE O
To O
evaluate O
the O
antitumor B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
safety O
of O
the O
epothilone O
B O
analog O
, O
ixabepilone O
, O
with O
or O
without O
estramustine O
phosphate O
( O
EMP O
) O
, O
in O
chemotherapy-naive O
patients O
with O
progressive O
castrate O
metastatic O
prostate O
cancer O
. O
['Physiological-Clinical']

POPULATION O
Two O
hundred O
and O
eighty-four O
out-patients O
with O
SAR O
, O
who O
were O
symptomatic O
during O
the O
ragweed O
season O
, O
volunteered O
for O
enrolment O
( O
243 O
randomized O
) O
. O
[]

Patients O
who O
had O
been O
referred O
for O
investigation O
and O
treatment O
of O
their O
snoring O
were O
randomly O
allocated O
to O
receive O
either O
UPPP O
or O
LAUP O
. O
[]

The O
preliminary O
data O
suggest O
that O
serotonergic O
agents O
may O
play O
a O
role O
in O
the O
effective O
treatment O
of O
methamphetamine B-outcome ['Physiological-Clinical']
abuse I-outcome ['Physiological-Clinical']
and O
dependence B-outcome ['Physiological-Clinical']
within O
the O
context O
of O
other O
effective O
behavioral O
interventions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
6-mercaptopurine O
has O
been O
a O
standard O
component O
of O
long-term O
continuing O
treatment O
for O
childhood O
lymphoblastic O
leukaemia O
, O
whereas O
6-thioguanine O
has O
been O
mainly O
used O
for O
intensification O
courses O
. O
[]

There O
is O
no O
effect O
on O
the O
early B-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
study O
is O
to O
investigate O
modulation O
of O
the O
soleus B-outcome ['Physiological-Clinical']
H-reflex I-outcome ['Physiological-Clinical']
during O
rhythmic O
arm O
swing O
in O
humans O
. O
['Physiological-Clinical']

Significant O
improvements O
were O
seen O
in O
performance O
on O
theory O
of O
mind O
tasks O
in O
both O
trained O
groups O
, O
whilst O
the O
control O
group O
showed O
no O
improvement O
. O
[]

At O
the O
conclusion O
of O
the O
study O
, O
ultrasonic B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
was O
greatest O
for O
TT O
steers O
( O
11.4 O
? O
['Physiological-Clinical']

Measurements O
of O
American O
Urological B-outcome ['Physiological-Clinical']
Association O
symptom B-outcome ['Physiological-Clinical']
score O
, O
peak O
urine B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
prostate B-outcome ['Physiological-Clinical']
specific I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
biofeedback O
treatment O
of O
white-coat O
hypertension O
. O
['Physiological-Clinical']

Dizziness B-outcome ['Physiological-Clinical']
was O
the O
most O
common O
adverse O
event O
with O
alfuzosin O
treatment O
( O
5 O
vs O
0 O
% O
with O
placebo O
) O
, O
with O
other O
adverse O
events O
reported O
with O
comparable O
frequency O
in O
both O
treatment O
groups O
. O
['Physiological-Clinical']

A O
study O
in O
Kerman O
, O
Islamic O
Republic O
of O
Iran O
in O
2002 O
compared O
the O
effectiveness O
of O
fennel O
and O
mefenamic B-outcome ['Resource-use']
acid I-outcome ['Resource-use']
on O
pain O
relief O
in O
primary O
dysmenorrhoea O
. O
['Resource-use']

Double-blind O
comparison O
of O
the O
efficacy O
and O
safety O
of O
trandolapril O
2 O
mg O
and O
hydrochlorothiazide O
25 O
mg O
in O
patients O
with O
mild-to-moderate O
essential O
hypertension O
. O
[]

Evoked O
V-wave O
, O
H-reflex O
, O
and O
M-wave O
recruitment O
curves O
, O
maximal O
voluntary O
contraction O
( O
MVC O
) O
, O
and O
time-to-task-failure O
( O
isometric O
contraction O
at O
40 O
% O
MVC O
) O
of O
the O
plantar O
flexors O
were O
recorded O
before O
and O
after O
training O
. O
[]

Short-term O
fluoxetine O
monotherapy O
for O
bipolar O
type O
II O
or O
bipolar O
NOS O
major O
depression O
- O
low O
manic O
switch O
rate O
. O
[]

In O
conclusion O
, O
in O
clinical O
practice O
, O
major O
and O
minor O
bleeding O
event O
rates O
associated O
with O
prasugrel O
therapy O
are O
comparable O
to O
those O
reported O
in O
controlled O
randomized O
trials O
. O
[]

A O
direct O
link O
model O
with O
an O
effect O
compartment O
was O
used O
in O
the O
population O
pharmacokinetic-pharmacodynamic O
analysis O
. O
[]

All O
patients O
received O
a O
left O
internal O
thoracic O
artery O
to O
the O
left O
anterior O
descending O
, O
and O
the O
randomized O
conduit O
was O
used O
to O
graft O
the O
second O
largest O
target O
. O
[]

With O
dosages O
of O
1 O
mg/kg/day O
, O
we O
observed O
an O
immediate O
reduction O
of O
hyperactivity B-outcome ['Life-Impact']
, O
self-injurious B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
and O
aggressiveness B-outcome ['Life-Impact']
, O
while O
attention B-outcome ['Life-Impact']
improved O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Isolated O
overt O
TL O
occurred O
in O
four O
( O
2.0 O
% O
) O
and O
all O
remained O
in O
CCR O
22+ O
to O
60+ O
months O
after O
re-treatment O
. O
[]

In O
this O
main O
study O
the O
thromboprophylactic B-outcome ['Physiological-Clinical']
effect O
of O
the O
LMW-heparin O
( O
Logiparin O
) O
in O
a O
dose O
of O
35 O
XaI O
mu/kg O
b.w O
. O
['Physiological-Clinical']

No O
significant O
alteration O
in O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
or O
any O
other O
adverse O
effects O
were O
observed O
. O
['Physiological-Clinical']

Results O
provide O
preliminary O
evidence O
that O
a O
modified O
version O
of O
the O
Coping O
Cat O
program O
may O
be O
a O
feasible O
and O
effective O
program O
for O
reducing O
clinically O
significant O
levels O
of O
anxiety O
in O
children O
with O
high-functioning O
ASD O
. O
[]

Twenty-one O
attention O
deficit O
disorder O
with O
hyperactivity O
and O
seven O
autistic O
children O
were O
randomly O
exposed O
to O
negatively O
ionized O
and O
ambient O
atmospheres O
under O
rigorously O
controlled O
experimental O
conditions O
. O
[]

We O
assigned O
a O
total O
of O
578 O
adult O
ambulatory O
surgery O
patients O
to O
either O
a O
control O
group O
that O
was O
given O
two O
folded O
, O
warmed O
cotton O
blankets O
or O
a O
treatment O
group O
that O
was O
given O
a O
warmed O
, O
unfolded O
cotton O
sheet O
and O
cotton O
blanket O
. O
[]

Increase O
over O
the O
baseline O
treadmill B-outcome ['Life-Impact']
exercise I-outcome ['Life-Impact']
test O
was O
similar O
in O
the O
treatment O
groups O
at O
each O
stage O
of O
the O
trial O
for O
all O
the O
main O
efficacy O
parameters O
: O
total O
treadmill O
exercise O
test O
duration O
; O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
anginal I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
except O
for O
a O
-13 O
s O
difference O
in O
favour O
of O
placebo O
at O
week O
24 O
; O
P=0.040 O
) O
; O
time O
to O
['Life-Impact', 'Physiological-Clinical']

In O
contrast O
to O
previous O
understanding O
, O
mepivacaine O
produces O
significantly O
longer O
anesthesia O
and O
recovery O
times O
and O
may O
not O
be O
optimal O
for O
outpatient O
epidural O
use O
. O
[]

The O
treatment O
protocol O
and O
baseline O
characteristics O
of O
480 O
subjects O
with O
a O
history O
of O
repeated O
parasuicide O
recruited O
in O
five O
centres O
to O
a O
randomised O
therapeutic O
trial O
of O
manual O
assisted O
cognitive-behaviour O
therapy O
( O
MACT O
) O
and O
treatment O
as O
usual O
( O
TAU O
) O
are O
described O
. O
[]

Ferrokinetic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
RBC I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
determinations I-outcome ['Physiological-Clinical']
were O
made O
at O
3-month O
intervals O
in O
iron-replete O
hemodialysis O
patients O
randomized O
to O
a O
control O
group O
or O
to O
nandrolone O
decanoate O
therapy O
. O
['Physiological-Clinical']

After O
eight O
1/2-hour O
sessions O
the O
WR O
and O
CR O
demonstrated O
a O
significant O
difference O
in O
temperature B-outcome ['Life-Impact']
change I-outcome ['Life-Impact']
, O
but O
there O
were O
no O
significant O
main O
effects O
in O
reported O
subjective B-outcome ['Life-Impact']
relaxation I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

During O
the O
other O
treatment O
period O
volunteers O
ate O
a O
standard O
supper O
, O
snacks O
, O
breakfast O
and O
lunch O
. O
[]

The O
2-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rate O
was O
21.5 O
% O
in O
the O
control O
group O
and O
29 O
% O
in O
the O
treatment O
group O
( O
relative O
risk O
= O
0.83 O
; O
P O
= O
.14 O
) O
. O
['Mortality']

Preliminary O
examination O
of O
a O
cartoon-based O
hostile B-outcome ['Life-Impact']
attributional I-outcome ['Life-Impact']
bias O
measure O
for O
urban O
African O
American O
boys O
. O
['Life-Impact']

RESULTS O
Multiple O
regression O
analysis O
showed O
a O
significant O
correlation O
between O
LVMI O
and O
ROS O
formation O
by O
monocytes O
and O
between O
LVMI O
and O
CRP O
. O
[]

Subsequent O
dose O
reduction O
to O
20 O
mg O
once O
daily O
led O
to O
a O
stable O
fraction O
of O
time O
with O
pH O
> O
3 O
of O
72 O
% O
. O
[]

Shear O
bond O
values O
of O
the O
ceramic O
brackets O
were O
higher O
than O
those O
of O
the O
metal O
brackets O
independent O
of O
HFLCS O
application O
( O
P O
< O
0.001 O
) O
. O
[]

The O
testings O
of O
the O
related O
as O
well O
as O
the O
independent O
samples O
show O
differentiated O
program O
effects O
. O
[]

The O
primary O
endpoint O
was O
empirical O
treatment O
with O
antifungal B-outcome ['Resource-use']
drugs I-outcome ['Resource-use']
in O
the O
26 O
weeks O
after O
enrolment O
( O
for O
the O
biomarker-based O
diagnostic O
strategy O
, O
a O
single O
postive O
galactomannan O
or O
PCR O
result O
was O
deemed O
insufficient O
to O
confirm O
invasive O
aspergillosis O
, O
so O
treatment O
in O
this O
context O
was O
classified O
as O
empirical O
) O
. O
['Resource-use']

OBJECTIVE O
This O
study O
was O
done O
to O
compare O
percutaneous O
laser O
ablation O
( O
PLA O
) O
and O
radiofrequency O
thermoablation O
( O
RFA O
) O
for O
the O
treatment O
of O
hepatocellular O
carcinoma O
( O
HCC O
) O
? O
[]

These O
results O
suggest O
that O
individuals O
with O
autism O
over-process O
information O
needed O
for O
the O
successful O
differentiation O
of O
target O
and O
novel O
stimuli O
. O
[]

The O
hippocampal O
component O
contributes O
by O
recalling O
studied O
details O
. O
[]

Women O
who O
had O
prolonged B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
were O
more O
likely O
to O
discontinue O
depot O
medroxyprogesterone O
injections O
. O
['Physiological-Clinical']

The O
course O
of O
misoprostol O
was O
repeated O
if O
the O
woman O
did O
not O
abort O
within O
24 O
hours O
. O
[]

Furthermore O
, O
TCM O
, O
histological O
grading O
of O
myeloma O
cells O
, O
degree O
of O
bone O
marrow O
infiltration O
, O
haemoglobin O
, O
platelet O
counts O
, O
calcium O
, O
creatinine O
, O
albumin O
, O
beta O
2M O
, O
and O
Bence O
Jones O
proteinuria O
correlated O
to O
both O
OAS O
and O
TRS O
. O
[]

CONCLUSION O
At O
this O
time O
, O
the O
evidence O
is O
insufficient O
to O
state O
whether O
catheter O
washout O
with O
saline O
or O
Contisol O
is O
more O
effective O
than O
usual O
care O
with O
no O
washout O
in O
preventing O
blocking O
. O
[]

1.3 O
mSv O
; O
amount O
of O
contrast O
agent:57.1 O
? O
[]

No O
patient O
developed O
clinical O
significant O
DVT B-outcome ['Physiological-Clinical']
, O
wound B-outcome ['Physiological-Clinical']
haematoma I-outcome ['Physiological-Clinical']
or O
intra-abdominal B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mean O
change O
of O
quantitative B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
testing O
sum O
scores O
was O
the O
primary O
study O
outcome O
measure O
. O
['Physiological-Clinical']

There O
were O
no O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
and O
the O
therapies O
were O
well O
accepted O
without O
any O
compliance O
issue O
. O
['Adverse-effects']

A O
non-significant O
increase O
in O
the O
number O
of O
Actinomyces B-outcome ['Physiological-Clinical']
viscosus/naeslundii I-outcome ['Physiological-Clinical']
was O
noted O
after O
treatment O
with O
chlorhexidine O
and O
fluoride O
varnish O
. O
['Physiological-Clinical']

Unlike O
with O
controls O
, O
in O
uremic O
patients O
GHRH-stimulated O
GH O
and O
TRH-stimulated O
PRL/GH B-outcome ['Physiological-Clinical']
peaks I-outcome ['Physiological-Clinical']
were O
dispersed O
throughout O
the O
120 O
min O
period O
. O
['Physiological-Clinical']

Dual-task-related O
gait O
changes O
in O
transitionally O
frail O
older O
adults O
: O
the O
type O
of O
the O
walking-associated O
cognitive O
task O
matters O
. O
[]

Objective B-outcome ['Physiological-Clinical']
roentgenographic I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
accompanied O
by O
improved O
survival B-outcome ['Mortality']
in O
squamous O
cell O
carcinoma O
, O
but O
not O
in O
the O
other O
three O
cell O
types O
. O
['Physiological-Clinical', 'Mortality']

PURPOSE O
The O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
resistance O
and O
endurance O
training O
on O
serum O
adiponectin O
and O
insulin O
resistance O
index O
( O
SI O
) O
in O
healthy O
men O
. O
[]

CONCLUSIONS O
The O
addition O
of O
an O
HPV O
test O
to O
the O
Pap O
test O
to O
screen O
women O
in O
their O
mid-30s O
for O
cervical O
cancer O
reduces O
the O
incidence O
of O
grade O
2 O
or O
3 O
cervical O
intraepithelial O
neoplasia O
or O
cancer O
detected O
by O
subsequent O
screening O
examinations O
. O
( O
[]

In O
the O
weight O
maintenance O
phase O
, O
the O
MR O
group O
lost O
0.70 O
+/- O
0.40 O
kg O
and O
the O
RCD O
group O
lost O
0.90 O
+/- O
0.40 O
kg O
( O
P O
= O
.60 O
) O
. O
[]

Exploratory O
translational O
endpoints O
included O
crypt O
length O
( O
which O
was O
significantly O
shorter O
in O
normal-appearing O
mucosa O
in O
the O
RS O
group O
over O
time O
) O
and O
laboratory O
measures O
of O
proliferation O
( O
including O
Ki67 O
) O
. O
[]

and O
67 O
% O
N2O O
in O
O2 O
. O
[]

OBJECTIVE O
To O
evaluate O
long-term O
effects O
of O
continuous O
glucose O
monitoring O
( O
CGM O
) O
in O
intensively O
treated O
adults O
with O
type O
1 O
diabetes O
. O
[]

Based O
on O
t O
tests O
, O
in O
weeks O
2 O
and O
8 O
, O
patients O
treated O
with O
fluoxetine O
plus O
zinc O
had O
significantly O
lower O
scores O
than O
those O
treated O
with O
fluoxetine O
plus O
placebo O
. O
[]

In O
the O
IB O
group O
, O
BCVA B-outcome ['Physiological-Clinical']
had O
improved O
by O
0.31 O
, O
0.32 O
, O
0.30 O
, O
and O
0.31 O
logMAR B-outcome ['Physiological-Clinical']
and O
CMT B-outcome ['Physiological-Clinical']
had O
decreased O
by O
59.5 O
% O
, O
59 O
% O
, O
60 O
% O
, O
and O
60.3 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
Sleep O
disturbances O
are O
common O
in O
patients O
with O
gastroesophageal O
reflux O
disease O
( O
GERD O
) O
. O
[]

Brief O
Report O
: O
social B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
in O
autism O
spectrum O
disorder O
: O
results O
from O
Research O
Units O
on O
Pediatric O
Psychopharmacology O
( O
RUPP O
) O
Autism O
Network O
trials O
. O
['Life-Impact']

We O
conclude O
that O
some O
, O
but O
not O
all O
, O
of O
the O
breast O
cancer O
cases O
detected O
early O
as O
a O
result O
of O
screening O
realized O
a O
benefit O
in O
terms O
of O
elimination O
of O
the O
risk O
of O
breast B-outcome ['Mortality']
cancer I-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality']

The O
overall O
mortality B-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
were O
not O
markedly O
influenced O
by O
PCP O
. O
['Mortality', 'Physiological-Clinical']

Preliminary O
findings O
and O
methodological O
challenges O
. O
[]

Augmented O
soft O
tissue O
mobilization O
vs O
natural O
history O
in O
the O
treatment O
of O
lateral O
epicondylitis O
: O
a O
pilot O
study O
. O
[]

However O
, O
among O
OC O
users O
, O
nonsmokers O
had O
significantly O
greater O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
presents O
the O
results O
of O
a O
30-week O
double-blind O
, O
placebo-controlled O
trial O
exploring O
the O
effectiveness O
of O
ascorbic O
acid O
( O
8g/70kg/day O
) O
as O
a O
supplemental O
pharmacological O
treatment O
for O
autistic O
children O
in O
residential O
treatment O
. O
[]

The O
cumulative B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
morphine I-outcome ['Life-Impact']
by O
PCA O
for O
each O
group O
was O
used O
as O
the O
end-point O
of O
the O
study O
. O
['Life-Impact']

Sham O
device O
v O
inert O
pill O
: O
randomised O
controlled O
trial O
of O
two O
placebo O
treatments O
. O
[]

Evaluation O
included O
performance B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
or O
number O
of O
completed O
tasks O
within O
a O
given O
time O
frame O
. O
['Life-Impact']

SETTING O
The O
Resolute O
'All-Comers O
' O
stent O
trial O
. O
[]

CONCLUSIONS O
Continuous O
subcutaneous O
insulin O
infusion O
improves O
glycemic O
control O
and O
some O
aspects O
of O
health-related O
quality O
of O
life O
in O
patients O
with O
a O
history O
of O
long-term O
poor O
glycemic O
control O
. O
[]

VAS O
pain B-outcome ['Physiological-Clinical']
scores O
decreased O
by O
32 O
% O
in O
the O
splinting O
group O
and O
increased O
by O
17 O
% O
in O
the O
control O
group O
. O
['Physiological-Clinical']

Placebo O
did O
not O
induce O
any O
significant O
effect O
. O
[]

The O
influence O
of O
nonhandicapped O
peers O
on O
the O
social B-outcome ['Life-Impact']
interactions I-outcome ['Life-Impact']
of O
children O
with O
a O
pervasive O
development O
disorder O
. O
['Life-Impact']

PATIENTS O
AND O
METHODS O
This O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
compared O
gemcitabine O
+ O
tipifarnib O
versus O
gemcitabine O
+ O
placebo O
in O
patients O
with O
advanced O
pancreatic O
adenocarcinoma O
previously O
untreated O
with O
systemic O
therapy O
. O
[]

Patients O
in O
the O
IV O
group O
were O
slightly O
more O
sedated B-outcome ['Physiological-Clinical']
than O
the O
IM O
group O
5 O
and O
10 O
min O
after O
morphine O
. O
['Physiological-Clinical']

8.3 O
, O
P O
< O
0.0001 O
) O
also O
after O
adjustment O
for O
age O
, O
GFR O
and O
BMI O
. O
[]

Only O
recently O
have O
psychotherapeutic O
interventions O
for O
complicated O
grief O
been O
developed O
and O
evaluated O
in O
randomized O
controlled O
trials O
. O
[]

We O
conducted O
a O
randomized O
crossover O
study O
whether O
or O
not O
brief O
bright O
light O
( O
BL O
) O
exposure O
on O
workday O
mornings O
can O
improve O
health O
, O
performance O
and O
safety O
in O
nurses O
with O
rapidly O
rotating O
shifts O
. O
[]

The O
absolute O
decreases O
within O
the O
hormone O
replacement O
therapy O
group O
were O
3 O
to O
10 O
% O
. O
[]

There O
was O
a O
non-significant O
trend O
for O
SULP O
and O
LEGO O
groups O
to O
improve O
more O
than O
the O
no-intervention O
group O
in O
communication B-outcome ['Life-Impact']
and O
socialisation B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

2.7 O
g/kg O
crude O
protein O
) O
purified O
diets O
were O
prepared O
with O
graded O
levels O
( O
0 O
, O
10 O
, O
50 O
, O
100 O
and O
200 O
mg/kg O
diet O
) O
of O
PN O
. O
[]

CHF O
STAT O
Investigators O
. O
[]

We O
aimed O
to O
explore O
observer O
variation O
in O
the O
assessment O
of O
outcome O
in O
a O
recently O
completed O
trial O
of O
dexanabinol O
in O
head O
injury O
and O
to O
consider O
steps O
to O
reduce O
such O
variation O
. O
[]

Ramsay O
sedation B-outcome ['Physiological-Clinical']
scale O
scores O
were O
between O
3 O
and O
4 O
in O
all O
patients O
and O
there O
were O
no O
significant O
differences O
. O
['Physiological-Clinical']

Treatment O
did O
not O
affect O
the O
proportion O
of O
cows O
exhibiting O
ovarian B-outcome ['Physiological-Clinical']
luteal I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
before O
the O
start O
of O
the O
breeding O
season O
( O
67 O
% O
) O
or O
pregnancy O
rate O
( O
91 O
% O
) O
. O
['Physiological-Clinical']

INTERVENTIONS O
According O
to O
a O
computer-generated O
randomization O
schedule O
, O
patients O
were O
allocated O
to O
one O
of O
two O
groups O
. O
[]

Selamectin O
was O
administered O
to O
a O
total O
of O
673 O
dogs O
and O
347 O
cats O
having O
an O
age O
range O
of O
6 O
weeks O
to O
19 O
years O
( O
3954 O
doses O
) O
. O
[]

The O
results O
obtained O
with O
the O
three O
Na+ O
modeling O
programs O
were O
similar O
. O
[]

The O
primary O
endpoint O
was O
clinical B-outcome ['Physiological-Clinical']
response O
on O
day O
7 O
after O
the O
start O
of O
treatment O
. O
['Physiological-Clinical']

PURPOSE O
Alterations O
in O
the O
RAS-RAF-MAP2K O
( O
MEK O
) O
-MAPK O
signaling O
pathway O
are O
major O
drivers O
in O
colorectal O
carcinogenesis O
. O
[]

The O
intervention O
group O
will O
receive O
14 O
training O
sessions O
, O
each O
1 O
hour O
long O
, O
with O
a O
physiotherapist O
over O
6 O
weeks O
and O
will O
be O
encouraged O
to O
practice O
independently O
for O
1 O
hour/day O
to O
give O
a O
total O
of O
56 O
hours O
of O
training O
time O
per O
participant O
. O
[]

METHODS O
This O
retrospective O
cohort O
study O
involved O
152 O
patients O
with O
ALI O
enrolled O
in O
the O
Fluid O
and O
Catheter O
Treatment O
Trial O
( O
FACTT O
) O
from O
five O
NHLBI O
ARDS O
( O
Acute O
Respiratory O
Distress O
Syndrome O
) O
Network O
sites O
. O
[]

and O
oral O
administration O
of O
Yizhi O
Jiannao O
Granules O
; O
the O
Chinese O
herb O
group O
was O
treated O
with O
Yizhi O
Jiannao O
Granules O
, O
and O
the O
western O
medicine O
group O
with O
oral O
administration O
of O
Aricept O
. O
[]

Bestatin O
is O
shown O
to O
be O
a O
clinically O
useful O
drug O
for O
immunotherapy O
of O
adult O
ANLL O
, O
since O
it O
has O
prolonged O
survival B-outcome ['Mortality']
and O
remission B-outcome ['Physiological-Clinical']
especially O
in O
elderly O
patients O
, O
with O
few O
side-effects B-outcome ['Adverse-effects']
. O
['Mortality', 'Physiological-Clinical', 'Adverse-effects']

In O
vivo O
study O
was O
conducted O
according O
to O
a O
single-center O
, O
randomized O
, O
single-dose O
, O
laboratory-blinded O
, O
2 O
Way O
, O
Cross-Over O
Study O
with O
a O
washout O
period O
of O
10 O
days O
. O
[]

CONCLUSIONS O
These O
results O
indicate O
that O
short-term O
combination O
of O
an O
angiotensin-converting O
enzyme O
inhibitor O
and O
an O
angiotensin O
receptor O
blocker O
is O
safe O
and O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
in O
patients O
with O
moderate O
chronic O
renal O
failure O
. O
['Life-Impact']

According O
to O
these O
results O
, O
the O
probability O
that O
phenytoin O
has O
the O
originally O
hypothesized O
effect O
of O
reducing O
the O
rate O
of O
early B-outcome ['Physiological-Clinical']
posttraumatic I-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
by O
12.5 O
% O
is O
0.0053 O
. O
['Physiological-Clinical']

Clomipramine O
was O
associated O
with O
a O
higher O
incidence O
of O
overall O
and O
treatment-related O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

In O
contrast O
to O
previous O
studies O
we O
did O
n't O
find O
obvious O
indication O
for O
nonlinear O
formation O
of O
DMU O
at O
therapeutic O
concentration O
range O
. O
[]

PRINCIPAL O
FINDINGS O
Largely O
because O
the O
program O
increased O
consumers O
' O
ability O
to O
get O
the O
authorized O
amount O
of O
paid O
care O
, O
expenditures O
for O
personal B-outcome ['Resource-use']
care/waiver I-outcome ['Resource-use']
services I-outcome ['Resource-use']
were O
higher O
for O
the O
treatment O
group O
than O
for O
the O
control O
group O
in O
each O
state O
and O
age O
group O
, O
except O
among O
the O
elderly O
in O
Florida O
. O
['Resource-use']

Furthermore O
, O
systemic O
side O
effects O
observed O
with O
formoterol O
are O
of O
a O
similar O
duration O
but O
less O
pronounced O
than O
with O
short-acting O
beta O
( O
2 O
) O
-agonists O
. O
[]

Angiotensin O
II O
, O
one O
of O
the O
main O
effectors O
of O
this O
system O
, O
contributes O
to O
the O
pathogenesis O
of O
hypertension O
and O
plays O
an O
important O
role O
in O
monocyte O
, O
platelet O
, O
and O
endothelium O
interactions O
. O
[]

OBJECTIVE O
To O
observe O
the O
effect O
of O
acupuncture O
on O
rehabilitation O
training O
for O
children O
's O
autism O
. O
[]

SETTING O
Churches O
and O
community-based O
organizations O
. O
[]

SUBJECTS O
AND O
METHODS O
A O
population-based O
crosssectional O
survey O
was O
conducted O
in O
Qingdao O
, O
China O
in O
2006 O
with O
6100 O
Chinese O
aged O
35-74 O
yr O
invited O
and O
5355 O
who O
attended O
; O
3357 O
subjects O
, O
1562 O
urban O
( O
46.5 O
% O
) O
and O
1795 O
rural O
residents O
( O
53.5 O
% O
) O
met O
the O
inclusion O
criteria O
for O
the O
current O
data O
analysis O
. O
[]

The O
results O
indicate O
that O
the O
initial O
cortical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
the O
magnocellular O
afferents O
is O
weaker O
at O
low O
contrast O
in O
the O
high O
autistic O
tendency O
group O
and O
that O
a O
second-order O
response O
, O
reflecting O
magnocellular O
activity O
, O
demonstrated O
a O
delay B-outcome ['Physiological-Clinical']
for O
high O
versus O
low O
scorers O
when O
the O
parvocellular O
pathway O
was O
also O
active O
in O
response O
to O
a O
high O
contrast O
stimulus O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Similar O
responses O
were O
observed O
in O
subjects O
who O
were O
baseline O
seronegative O
and O
seropositive O
based O
on O
serum O
hemagglutination O
inhibition O
antibody O
titers O
. O
[]

Following O
the O
induction O
of O
general O
anesthesia O
, O
a O
small O
change O
in O
bladder B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
was O
noted O
. O
['Physiological-Clinical']

32.7 O
mm? O
at O
baseline O
vs O
42.5 O
? O
[]

The O
conclusion O
is O
that O
children O
with O
isolated O
CNS O
leukemia O
can O
achieve O
prolonged O
survival B-outcome ['Mortality']
with I-outcome ['Mortality']
aggressive I-outcome ['Mortality']
therapy I-outcome ['Mortality']
, O
and O
that O
CSpRT B-outcome ['Physiological-Clinical']
is O
possibly O
less O
toxic B-outcome ['Adverse-effects']
and O
more O
likely O
than O
is O
CRT O
+ O
ITC O
to O
prevent O
subsequent O
BM B-outcome ['Physiological-Clinical']
and O
testicular B-outcome ['Physiological-Clinical']
relapse B-outcome ['Physiological-Clinical']
( O
P O
less O
than O
0.02 O
) O
, O
but O
not O
subsequent O
['Mortality', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
efficacy O
endpoint O
was O
change O
from O
baseline O
in O
6-min O
walk O
distance O
( O
6MWD O
) O
at O
week O
18 O
. O
[]

After O
practice O
, O
half O
of O
the O
participants O
were O
immediately O
tested O
and O
the O
other O
half O
were O
tested O
after O
a O
7-day O
delay O
. O
[]

RESULTS O
A O
total O
of O
143 O
patients O
received O
30 O
% O
perioperative O
oxygen O
and O
148 O
received O
80 O
% O
perioperative O
oxygen O
. O
[]

Eighty-six O
male O
patients O
, O
doing O
their O
obligatory O
military O
service O
, O
ranging O
between O
19 O
and O
24 O
years O
of O
age O
( O
mean O
20 O
) O
, O
were O
randomly O
treated O
: O
29 O
with O
clarithromycin O
500 O
mg O
12-hourly O
, O
30 O
with O
roxithromycin O
150 O
mg O
12-hourly O
, O
and O
27 O
with O
erythromycin O
stearate O
500 O
mg O
6-hourly O
, O
each O
course O
being O
administered O
for O
10 O
days O
. O
[]

Time-varying O
smoking O
abstinence O
predicts O
lower O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
following O
smoking O
cessation O
treatment O
. O
['Life-Impact']

Children O
's O
step O
counts O
were O
measured O
for O
five O
consecutive O
days O
during O
school O
hours O
at O
baseline O
and O
follow-up O
. O
[]

All O
patients O
received O
BLT O
for O
15 O
days O
in O
the O
morning O
, O
30 O
min O
daily O
. O
[]

SETTING O
Laboratory O
of O
a O
Department O
of O
Physical O
Therapy O
. O
[]

Finasteride O
was O
found O
to O
be O
a O
potent O
inhibitor O
of O
both O
C19 B-outcome ['Physiological-Clinical']
androgen I-outcome ['Physiological-Clinical']
and O
C21 B-outcome ['Physiological-Clinical']
5 I-outcome ['Physiological-Clinical']
alpha-steroid I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
affecting O
both O
hepatic B-outcome ['Physiological-Clinical']
and O
peripheral B-outcome ['Physiological-Clinical']
5 I-outcome ['Physiological-Clinical']
alpha-metabolism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

FINDINGS O
197 O
patients O
underwent O
aneurysm O
repair O
( O
47 O
assigned O
no O
intervention O
) O
and O
80 O
% O
of O
patients O
adhered O
to O
protocol O
. O
[]

Injection O
sclerotherapy O
versus O
electrocoagulation O
in O
the O
management O
outcome O
of O
early O
haemorrhoids O
. O
[]

The O
efficacy O
of O
conventional O
PCNL O
and O
two O
modifications O
to O
standard O
procedure O
. O
[]

Each O
subject O
was O
studied O
twice O
: O
during O
a O
weight O
maintenance O
diet O
and O
during O
ad O
libitum O
food O
intake O
. O
[]

Even O
so O
, O
there O
has O
been O
little O
research O
into O
the O
prevalence O
of O
the O
problem O
or O
effective O
intervention O
procedures O
. O
[]

PATIENTS O
AND O
METHODS O
From O
July O
1996 O
through O
December O
1997 O
, O
201 O
evaluable O
children O
ages O
6 O
months O
to O
10 O
years O
( O
35 O
% O
< O
1 O
year O
; O
70 O
% O
< O
3 O
years O
) O
presenting O
with O
acute O
invasive O
diarrhea O
at O
the O
Pediatric O
Emergency O
Room O
were O
randomized O
to O
receive O
either O
ciprofloxacin O
suspension O
( O
10 O
mg/kg O
twice O
a O
day O
+ O
im O
placebo O
; O
n O
= O
95 O
) O
or O
im O
ceftriaxone O
( O
50 O
mg/kg/day O
+ O
placebo O
suspension O
; O
n O
= O
106 O
) O
for O
3 O
days O
in O
a O
double O
blind O
manner O
. O
[]

Overweight O
patients O
who O
underwent O
LA O
had O
longer O
operating B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
anesthesia I-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
than O
their O
OA O
counterparts O
( O
55 O
vs O
40 O
min O
, O
p O
< O
0.001 O
; O
and O
125 O
vs O
100 O
min O
, O
p O
< O
0.001 O
, O
respectively O
) O
. O
['Life-Impact']

DESIGN O
A O
prospective O
, O
randomized O
trial O
. O
[]

Reduced O
albuminuria O
with O
sarpogrelate O
is O
accompanied O
by O
a O
decrease O
in O
monocyte O
chemoattractant O
protein-1 O
levels O
in O
type O
2 O
diabetes O
. O
[]

HR B-outcome ['Physiological-Clinical']
also O
increased O
; O
SV B-outcome ['Physiological-Clinical']
decreased O
in O
patients O
receiving O
eltanolone O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Blockade O
of O
endogenous O
growth O
hormone-releasing O
hormone O
receptors O
dissociates O
nocturnal B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
and O
slow-wave B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTERVENTION O
Children O
received O
montelukast O
( O
5-12 O
years O
: O
5 O
mg O
and O
> O
12 O
years O
: O
10 O
mg O
) O
or O
placebo O
orally O
in O
addition O
to O
the O
standard O
therapy O
. O
[]

Treatment O
group O
patients O
( O
n O
= O
22 O
) O
were O
administered O
various O
assessments O
of O
complicated O
grief O
indicators O
, O
including O
the O
Impact O
of O
Event O
Scale O
, O
the O
anxiety B-outcome ['Life-Impact']
and O
depression B-outcome ['Life-Impact']
subscales O
of O
the O
Brief O
Symptom B-outcome ['Life-Impact']
Inventory O
, O
and O
the O
SF-12 O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

There O
were O
no O
instances O
of O
tissue B-outcome ['Physiological-Clinical']
orientation I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
the O
scalpel O
or O
marker O
arms O
, O
nor O
were O
there O
any O
visible B-outcome ['Physiological-Clinical']
score O
mark B-outcome ['Physiological-Clinical']
scars B-outcome ['Physiological-Clinical']
at O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
authors O
conducted O
a O
multicenter O
, O
prospective O
, O
randomized O
trial O
of O
the O
ALL-2 O
regimen O
compared O
with O
a O
standard O
4-drug O
induction O
( O
the O
L-20 O
regimen O
) O
. O
[]

The O
trainee O
radiologists O
evaluated O
the O
degree O
of O
stenosis B-outcome ['Physiological-Clinical']
on O
each O
coronary B-outcome ['Physiological-Clinical']
segment I-outcome ['Physiological-Clinical']
, O
and O
overall O
accuracy B-outcome ['Physiological-Clinical']
was O
calculated O
on O
a O
per-segment O
, O
pervessel O
and O
per-patient O
basis O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
and O
placebo-controlled O
study O
. O
[]

Pain B-outcome ['Physiological-Clinical']
intensity O
measurements O
during O
early O
and O
late O
labor O
revealed O
the O
degree O
of O
analgesia B-outcome ['Resource-use']
to O
be O
the O
same O
in O
both O
groups O
. O
['Physiological-Clinical', 'Resource-use']

Although O
at O
the O
4-week O
follow-up O
the O
intervention O
group O
indicated O
that O
they O
were O
very O
likely O
to O
have O
an O
annual O
clinical O
breast O
examination O
more O
frequently O
than O
controls O
, O
no O
differences O
were O
detected O
at O
6 O
months O
. O
[]

eEF2 B-outcome ['Physiological-Clinical']
phosphorylation I-outcome ['Physiological-Clinical']
decreased O
at O
1 O
and O
2 O
h O
postexercise O
to O
a O
similar O
extent O
in O
both O
groups O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

No O
effect O
was O
seen O
on O
plasma B-outcome ['Physiological-Clinical']
triglycerides I-outcome ['Physiological-Clinical']
, O
cholesterol B-outcome ['Physiological-Clinical']
, O
HDL-cholesterol B-outcome ['Physiological-Clinical']
and O
gamma-glutamyltranspeptidase B-outcome ['Physiological-Clinical']
at O
any O
stage O
of O
the O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

It O
is O
possible O
that O
the O
children O
who O
did O
not O
improve O
have O
difficulties O
that O
are O
of O
a O
more O
complex O
type O
which O
require O
more O
specialist O
therapy O
to O
meet O
their O
need O
. O
[]

Even O
moderate O
increases O
in O
blood O
glucose O
are O
associated O
with O
poor O
surgical O
outcome O
. O
[]

Group O
3 O
received O
propofol O
2 O
mg/kg O
i.v. O
, O
followed O
by O
propofol O
50 O
to O
160 O
micrograms/kg/min O
i.v O
. O
[]

Analysis O
followed O
the O
intention-to-treat O
principle O
. O
[]

Antisaccade O
, O
no-saccade O
, O
visually O
guided O
saccade O
and O
smooth O
pursuit O
tasks O
were O
carried O
out O
and O
the O
effects O
of O
practice O
and O
drugs O
measured O
. O
[]

METHODS O
Non-and-low O
response O
infants O
born O
in O
2004 O
2005 O
administered O
3 O
doses O
of O
HepB O
at O
0 O
, O
1 O
, O
6 O
months O
in O
Guangzhou O
, O
Beijing O
and O
Zhejiang O
were O
divided O
into O
4 O
groups O
randomly O
, O
and O
boosted O
3 O
dose O
of O
4 O
different O
types O
of O
HepB O
at O
0 O
, O
1 O
, O
6 O
months O
. O
[]

After O
6 O
months O
, O
the O
patients O
treated O
with O
L-tiroxine O
exhibited O
a O
reduction O
of O
QT B-outcome ['Physiological-Clinical']
dispersion I-outcome ['Physiological-Clinical']
and O
an O
increase O
of O
['Physiological-Clinical']

14.4? O
) O
compared O
to O
no O
PFOA O
( O
mean O
? O
[]

Stimuli O
were O
presented O
via O
headphones O
and O
consisted O
of O
common O
facts O
( O
Group O
A O
, O
29 O
patients O
) O
, O
or O
familiar O
or O
unfamiliar O
full O
names O
of O
fictitious O
people O
( O
GRoup O
B O
, O
29 O
patients O
) O
. O
[]

LX4211 O
, O
a O
dual O
inhibitor O
of O
SGLT1 O
and O
SGLT2 O
, O
reduces O
glucose O
absorption O
from O
the O
GI O
tract O
and O
enhances O
urinary O
glucose O
excretion O
. O
[]

We O
compared O
the O
impact O
of O
an O
annual O
community-wide O
single-dose O
treatment O
with O
diethylcarbamazine O
alone O
or O
with O
ivermectin O
on O
rate O
and O
intensity O
of O
microfilaraemia O
, O
and O
transmission O
intensity O
in O
an O
area O
of O
Papua O
New O
Guinea O
endemic O
for O
intense O
W O
bancrofti O
transmission O
. O
[]

Regarding O
the O
antioxidant O
defense O
system O
, O
it O
was O
found O
that O
both O
total O
antioxidant B-outcome ['Physiological-Clinical']
status B-outcome ['Physiological-Clinical']
( O
P=.014 O
) O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Presence O
and O
predictability O
of O
temporal O
and O
spatial O
cues O
. O
[]

As O
a O
novel O
source O
of O
evidence O
, O
we O
documented O
how O
participants O
autonomously O
sequenced O
the O
seven O
murmurs O
during O
initial O
and O
delayed O
practice O
sessions O
. O
[]

Patients O
were O
excluded O
from O
the O
study O
if O
they O
did O
not O
have O
a O
histological O
diagnosis O
for O
AK O
, O
if O
they O
were O
older O
than O
85 O
years O
, O
or O
if O
they O
did O
not O
comply O
with O
the O
protocol O
. O
[]

Both O
the O
anesthesiologists O
and O
the O
recovery O
room O
nurses O
rated O
remifentanil O
better O
with O
respect O
to O
level O
of O
consciousness B-outcome ['Life-Impact']
. O
['Life-Impact']

Further O
studies O
are O
needed O
to O
assess O
the O
optimal O
treatment O
strategy O
for O
hypertension O
in O
the O
elderly O
. O
[]

Changes O
in O
total O
cholesterol B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

A O
preplanned O
Bayesian O
analysis O
will O
be O
performed O
to O
interpret O
the O
CV O
event O
distribution O
, O
given O
the O
limited O
number O
of O
events O
expected O
in O
this O
study O
. O
[]

METHODS O
A O
controlled O
, O
multiple O
indexes O
study O
was O
conducted O
in O
56 O
old O
subjects O
randomized O
into O
3 O
groups O
. O
[]

METHODS O
28 O
patients O
with O
a O
clinical O
diagnosis O
of O
actinic O
keratosis O
were O
randomized O
to O
receive O
diclofenac O
sodium O
or O
5-Fluorouracil O
and O
were O
clinically O
assessed O
before O
and O
after O
treatment O
as O
well O
as O
8 O
weeks O
after O
the O
end O
of O
treatment O
. O
[]

Despite O
this O
reduced O
saliency O
and O
processing O
of O
other O
faces O
, O
recognition O
of O
their O
own O
face O
is O
reported O
to O
be O
more O
typical O
in O
nature O
. O
[]

We O
tested O
the O
efficacy O
of O
polydioxanone O
( O
PDS O
) O
suture O
in O
sternal B-outcome ['Physiological-Clinical']
closure I-outcome ['Physiological-Clinical']
and O
in O
prevention O
of O
complications B-outcome ['Adverse-effects']
in O
comparison O
to O
steel O
wires O
in O
high-risk O
individuals O
. O
['Physiological-Clinical', 'Adverse-effects']

Measurements O
were O
made O
after O
run-in O
and O
after O
both O
randomized O
treatments O
. O
[]

CGM-derived B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hypoglycemia I-outcome ['Physiological-Clinical']
were O
used O
to O
predict O
episodes O
of O
SH O
over O
a O
24-h O
time O
horizon O
. O
['Physiological-Clinical']

A O
randomised O
group O
comparison O
controlled O
trial O
of O
'preschoolers O
with O
autism O
' O
: O
a O
parent O
education O
and O
skills O
training O
intervention O
for O
young O
children O
with O
autistic O
disorder O
. O
[]

Field B-outcome ['Life-Impact']
placement I-outcome ['Life-Impact']
errors I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
FPEs I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
were O
calculated O
by O
comparing O
field O
centres O
of O
each O
film O
with O
a O
designated O
point O
of O
interest O
. O
['Life-Impact']

GTR O
provided O
complete O
closure B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
furcation I-outcome ['Physiological-Clinical']
defect I-outcome ['Physiological-Clinical']
in O
two O
sites O
and O
superior O
horizontal O
clinical O
attachment O
level O
gain O
( O
GTR O
: O
2.27 O
mm O
; O
OFD O
: O
1.01 O
mm O
, O
P O
= O
0.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
Changes O
in O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
over O
time O
between O
the O
two O
groups O
were O
significantly O
different O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

The O
mean O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
intraoperative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
number O
of O
retrieved B-outcome ['Physiological-Clinical']
lymph I-outcome ['Physiological-Clinical']
nodes I-outcome ['Physiological-Clinical']
were O
greater O
in O
the O
extended O
group O
, O
but O
the O
other O
operative O
results O
were O
comparable O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Prospective O
randomized O
multicenter O
trial O
of O
sevelamer O
hydrochloride O
and O
calcium O
carbonate O
for O
the O
treatment O
of O
hyperphosphatemia B-outcome ['Physiological-Clinical']
in O
hemodialysis O
patients O
in O
Japan O
. O
['Physiological-Clinical']

78 O
% O
of O
the O
digoxin B-outcome ['Resource-use']
administered O
was O
absorbed O
from O
the O
tablets O
and O
76 O
% O
from O
the O
solution O
. O
['Resource-use']

Values O
for O
serum B-outcome ['Physiological-Clinical']
total O
cholesterol B-outcome ['Physiological-Clinical']
, O
LDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
, O
and O
plasma B-outcome ['Physiological-Clinical']
apolipoprotein I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
4.2 O
% O
( O
0.22 O
mmol/L O
; O
P O
= O
0.04 O
) O
, O
7.1 O
% O
( O
0.23 O
mmol/L O
; O
P O
= O
0.004 O
) O
, O
and O
3.4 O
% O
( O
P O
= O
0.03 O
) O
higher O
, O
respectively O
, O
with O
DHA O
treatment O
than O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
intervention O
group O
received O
manual O
prompts O
of O
immunizations O
due O
. O
[]

The O
reason O
for O
this O
has O
remained O
unclear O
. O
[]

Life O
expectancy O
beyond O
the O
trial O
was O
estimated O
from O
the O
Saskatchewan O
Health O
Database O
. O
[]

Changes O
were O
evaluated O
after O
one O
year O
. O
[]

At O
week O
48 O
, O
EVG/COBI/FTC/TDF O
was O
noninferior O
to O
EFV/FTC/TDF O
( O
88 O
% O
vs O
84 O
% O
, O
difference O
+3.6 O
% O
, O
95 O
% O
confidence O
interval O
: O
-1.6 O
% O
to O
8.8 O
% O
) O
. O
[]

AAAs O
were O
diagnosed O
by O
CT O
in O
116 O
patients O
( O
80 O
% O
) O
. O
[]

The O
most O
noteworthy O
group O
difference O
was O
observed O
for O
cerebrovascular B-outcome ['Physiological-Clinical']
end I-outcome ['Physiological-Clinical']
points I-outcome ['Physiological-Clinical']
( O
strokes B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
transient I-outcome ['Physiological-Clinical']
ischemic I-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
) O
, O
with O
an O
incidence O
of O
8.2 O
% O
( O
9 O
patients O
) O
in O
the O
drug O
treatment O
group O
and O
19.0 O
% O
( O
23 O
patients O
) O
in O
the O
placebo O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Emerging O
research O
has O
suggested O
that O
children O
with O
autism O
might O
also O
have O
deficits O
in O
basic O
perceptual O
abilities O
including O
multisensory O
processing O
( O
e.g. O
, O
simultaneously O
processing O
visual O
and O
auditory O
inputs O
) O
. O
[]

Endoscopic O
versus O
operative O
gastrostomy O
: O
final O
results O
of O
a O
prospective O
randomized O
trial O
. O
[]

There O
were O
a O
number O
of O
significant O
differences O
between O
the O
two O
interventions O
to O
suggest O
parent O
involvement O
as O
beneficial O
. O
[]

Children O
with O
higher O
scores O
on O
the O
CYBOCS-PDD O
had O
higher O
levels O
of O
maladaptive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
lower O
adaptive B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Side O
effects O
were O
few O
in O
all O
groups O
, O
but O
involuntary B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
hypertonus I-outcome ['Physiological-Clinical']
occurred O
in O
23 O
% O
of O
the O
patients O
in O
the O
eltanolone O
and O
in O
3 O
% O
in O
the O
thiopental O
groups O
( O
n.s O
) O
. O
['Physiological-Clinical']

1 O
. O
[]

To O
evaluate O
the O
effect O
of O
metformin O
on O
insulin O
sensitivity O
and O
to O
further O
examine O
the O
relationship O
between O
insulin O
resistance O
, O
sympathetic O
nerve O
activity O
and O
blood O
pressure O
, O
6 O
obese O
insulin O
resistant O
, O
normoglycemic O
hypertensive O
men O
were O
investigated O
( O
age O
49 O
+/- O
2 O
years O
, O
BMI O
27.6 O
+/- O
1.2 O
, O
mean O
+/- O
SEM O
) O
. O
[]

METHODS O
AND O
RESULTS O
Forty-five O
HF O
patients O
( O
New O
York O
Heart O
Association O
class O
II-III O
) O
were O
randomly O
assigned O
to O
placebo O
or O
sildenafil O
( O
50 O
mg O
three O
times O
per O
day O
) O
for O
1 O
year O
, O
with O
assessment O
( O
6 O
months O
and O
1 O
year O
) O
of O
LV O
ejection O
fraction O
, O
diastolic O
function O
, O
geometry O
, O
cardiopulmonary O
exercise O
performance O
, O
and O
quality O
of O
life O
. O
[]

Survival O
rates O
were O
also O
compared O
. O
[]

Results O
showed O
a O
significant O
treatment O
effect O
of O
FPI O
on O
responsive B-outcome ['Life-Impact']
parental I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
. O
['Life-Impact']

Two O
readers O
evaluated O
the O
NCE O
4D O
MRA O
data O
for O
the O
diagnosis O
of O
DAVF O
and O
its O
type O
with O
consensus O
. O
[]

Asthma O
medications O
were O
stepped O
up O
when O
indicated O
after O
46.0 O
% O
of O
these O
visits O
in O
the O
intervention O
group O
compared O
with O
35.6 O
% O
in O
the O
control O
group O
, O
and O
when O
asthma O
symptoms O
warranted O
a O
step O
up O
in O
therapy O
, O
medication O
changes O
occurred O
earlier O
among O
the O
intervention O
children O
. O
[]

A O
total O
of O
106 O
patients O
were O
treated O
with O
PTCA O
. O
[]

In O
this O
study O
we O
evaluated O
the O
effects O
of O
anxiety B-outcome ['Life-Impact']
visibility I-outcome ['Life-Impact']
on O
patients O
and O
controls O
using O
feedback O
of O
veridical O
heart O
sounds O
. O
['Life-Impact']

This O
was O
a O
phase O
II/III O
, O
multicenter O
, O
randomized O
, O
open-label O
, O
parallel O
group O
study O
of O
841 O
women O
at O
risk O
for O
pregnancy O
. O
[]

Main O
variables O
were O
safety O
, O
tolerability B-outcome ['Life-Impact']
and O
pharmacokinetics B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

A O
randomized O
controlled O
trial O
of O
R-salbutamol O
for O
topical O
treatment O
of O
discoid O
lupus O
erythematosus O
. O
[]

Radial O
pulse O
wave O
recordings O
were O
performed O
in O
all O
the O
patients O
before O
the O
active O
treatments O
were O
given O
and O
at O
the O
end O
of O
the O
study O
. O
[]

CONCLUSION O
Imiquimod O
improved O
excision B-outcome ['Physiological-Clinical']
results I-outcome ['Physiological-Clinical']
relative O
to O
vehicle O
when O
used O
for O
treating O
basal O
cell O
carcinoma O
before O
Mohs O
micrographic O
surgery O
. O
['Physiological-Clinical']

CONCLUSION O
Acupuncture O
combined O
with O
scientific O
and O
effective O
rehabilitation O
training O
has O
a O
better O
therapeutic O
effect O
than O
that O
of O
the O
simple O
rehabilitation O
training O
for O
child O
's O
autism O
. O
[]

At O
month O
6 O
, O
plasma O
EBV O
( O
+ O
) O
patients O
( O
n O
= O
7 O
) O
had O
inferior O
FFS O
compared O
with O
plasma O
EBV O
( O
- O
) O
patients O
( O
n O
= O
125 O
) O
, O
log-rank O
P O
= O
.007 O
. O
[]

On O
the O
basis O
of O
diet O
intervention O
, O
the O
observation O
group O
was O
treated O
with O
electroacupuncture O
at O
local O
points O
combined O
with O
blood-letting O
puncture O
and O
cupping O
, O
and O
the O
control O
group O
with O
oral O
administration O
of O
Probenecid O
. O
[]

BACKGROUND O
This O
randomized O
study O
compared O
the O
efficacy O
and O
safety O
of O
fludarabine-mitoxantrone O
( O
FM O
) O
with O
mini-CHVP O
( O
cyclophosphamide O
, O
doxorubicin O
, O
vindesine O
, O
prednisone O
) O
in O
elderly O
patients O
with O
advanced O
, O
low-grade O
non-Hodgkin O
's O
lymphoma O
. O
[]

Specimens O
were O
sectioned O
longitudinally O
in O
the O
bucco-lingual O
direction O
, O
in O
slices O
of O
1 O
mm O
thick O
. O
[]

A O
priori O
the O
facial O
affect O
recognition O
test O
had O
shown O
good O
psychometric O
properties O
in O
a O
normative O
sample O
( O
internal O
consistency O
: O
rtt=.91-.95 O
; O
retest O
reliability O
: O
rtt=.89-.92 O
) O
. O
[]

RESULTS O
Primiparous O
women O
reported O
unspecified O
UI B-outcome ['Physiological-Clinical']
at O
3 O
months O
postpartum O
more O
often O
( O
17.9 O
% O
) O
in O
the O
VB O
group O
than O
in O
the O
CS O
group O
( O
6.4 O
% O
) O
. O
['Physiological-Clinical']

These O
variables O
included O
physician O
information O
status O
, O
patient O
gender O
, O
and O
drinking O
disorder O
severity O
and O
recency O
. O
[]

During O
the O
run-in O
and O
treatment O
periods O
, O
symptoms B-outcome ['Life-Impact']
were O
evaluated O
in O
a O
daily O
diary O
using O
a O
0 O
( O
best O
) O
to O
3 O
( O
worst O
) O
scale O
. O
['Life-Impact']

OBJECTIVE O
We O
tested O
the O
hypothesis O
that O
biotin O
supplementation O
significantly O
decreases O
3-HIA O
excretion O
in O
pregnant O
women O
with O
abnormally O
increased O
3-HIA O
excretion O
. O
[]

Kaliuresis B-outcome ['Physiological-Clinical']
was O
similar O
during O
the O
two O
treatment O
periods O
, O
despite O
the O
striking O
differences O
observed O
in O
natriuresis O
. O
['Physiological-Clinical']

BACKGROUND O
Prenatal O
exposure O
to O
alcohol O
is O
a O
major O
, O
preventable O
cause O
of O
neurobehavioral O
dysfunction O
in O
children O
worldwide O
. O
[]

Twenty-four O
patients O
, O
with O
a O
biopsy-proven O
laryngeal O
or O
hypopharyngeal O
carcinoma O
, O
received O
as O
an O
adjunct O
to O
their O
primary O
treatment O
( O
surgery O
and/or O
radiotherapy O
) O
, O
levamisole O
( O
150 O
mg O
daily O
during O
three O
consecutive O
days O
, O
every O
fortnight O
) O
or O
placebo O
, O
following O
a O
single-blind O
, O
but O
randomized O
method O
. O
[]

Soaring O
obesity O
rates O
in O
the O
United O
States O
demand O
comprehensive O
health O
intervention O
strategies O
that O
simultaneously O
address O
dietary O
patterns O
, O
physical O
activity O
, O
psychosocial O
factors O
and O
the O
food O
environment O
. O
[]

Analysis O
of O
prevention O
program O
effectiveness O
with O
clustered O
data O
using O
generalized O
estimating O
equations O
. O
[]

Clinicians O
were O
assessed O
for O
skill O
level O
at O
post-workshop O
, O
at O
post-training O
, O
and O
3 O
months O
later O
; O
learning O
was O
assessed O
using O
the O
MI O
Treatment O
Integrity O
instrument O
. O
[]

The O
ALS O
CNTF O
Treatment O
Study O
( O
ACTS O
) O
Phase O
I-II O
Study O
Group O
. O
[]

Parent O
and O
teacher O
data O
from O
the O
[]

OBJECTIVES O
A O
temporal O
association O
between O
non-rapid O
eye O
movement O
( O
NREM O
) O
sleep O
stages O
3 O
and O
4 O
and O
nocturnal O
augmentation O
of O
GH O
release O
was O
found O
long O
ago O
, O
yet O
the O
precise O
mechanism O
for O
this O
association O
has O
not O
been O
identified O
. O
[]

METHODS O
Seventy-nine O
children O
( O
aged O
15-196 O
months O
) O
undergoing O
liver O
transplantation O
at O
Birmingham O
Children O
's O
Hospital O
between O
October O
1998 O
and O
October O
2000 O
were O
studied O
. O
[]

10.32 O
?g/L O
, O
32.00 O
? O
[]

Tetrahydrobiopterin O
in O
the O
treatment O
of O
children O
with O
autistic O
disorder O
: O
a O
double-blind O
placebo-controlled O
crossover O
study O
. O
[]

Blind O
versus O
open O
approach O
to O
laparoscopic O
cholecystectomy O
: O
a O
randomized O
study O
. O
[]

The O
intensity O
of O
pain B-outcome ['Physiological-Clinical']
was O
assessed O
daily O
by O
a O
100-mm O
visual O
analog O
scale O
. O
['Physiological-Clinical']

The O
functional O
index O
did O
not O
differ O
between O
any O
group O
of O
patients O
. O
[]

Factors O
significantly O
associated O
with O
late O
attendance O
for O
the O
first O
test O
were O
the O
same O
as O
for O
non-attendance O
, O
plus O
current O
smoking O
and O
having O
children O
. O
[]

RESULTS O
Both O
groups O
showed O
significant O
reduction O
in O
GI O
scores O
at O
6 O
months O
( O
ps O
< O
0.005 O
) O
. O
[]

[ O
Effect O
of O
alanyl-glutamine O
in O
postoperative O
total O
parenteral O
nutrition O
on O
postoperative O
immunosuppression B-outcome ['Physiological-Clinical']
and O
morbidity B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Each O
tooth O
was O
then O
placed O
in O
a O
capped O
vial O
containing O
2 O
X O
2 O
inch O
gauze O
pads O
saturated O
with O
distilled O
water O
, O
and O
the O
sealer O
was O
allowed O
to O
set O
at O
37 O
degrees O
C O
in O
the O
humidor O
for O
48 O
hours O
. O
[]

A O
randomized O
controlled O
pilot O
trial O
of O
oral O
N-acetylcysteine O
in O
children O
with O
autism O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
impact O
of O
prior O
antipsychotic O
exposure O
( O
PAE O
) O
on O
safety O
and O
tolerability B-outcome ['Life-Impact']
outcomes O
in O
pediatric O
subjects O
receiving O
aripiprazole O
treatment O
. O
['Life-Impact']

Group O
1 O
received O
conventional O
working O
aids O
( O
paper-based O
documents O
) O
to O
support O
the O
task O
processing O
. O
[]

In O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
study O
of O
minocycline O
in O
60 O
HD O
patients O
, O
the O
authors O
determined O
that O
over O
8 O
weeks O
, O
minocycline O
at O
100 O
and O
200 O
mg/day O
was O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
and O
safe O
in O
HD O
patients O
. O
['Life-Impact']

Safety O
measures O
: O
morning B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
cortisol B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
, O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

The O
perioperative O
use O
of O
glucocorticoids O
has O
been O
advocated O
as O
a O
method O
to O
improve O
postoperative O
outcomes O
. O
[]

Only O
children O
treated O
with O
carvedilol O
showed O
a O
significant O
decrease O
in O
systolic B-outcome ['Physiological-Clinical']
SI I-outcome ['Physiological-Clinical']
( O
P O
B O
0.0001 O
) O
, O
diastolic B-outcome ['Physiological-Clinical']
SI I-outcome ['Physiological-Clinical']
( O
P O
B O
0.0001 O
) O
, O
and O
TEI B-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
( O
P O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
end O
point O
was O
mean O
change O
from O
baseline O
in O
seated B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
SeDBP B-outcome ['Physiological-Clinical']
) O
at O
week O
8 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Between O
July O
1999 O
and O
December O
2000 O
, O
140 O
patients O
undergoing O
anal O
sphincterotomy O
were O
randomized O
into O
two O
groups O
to O
have O
their O
fibrous O
polyps O
and O
hypertrophied O
anal O
papillae O
either O
removed O
by O
radiofrequency O
surgery O
or O
left O
intact O
. O
[]

Conventional O
in O
vitro O
fertilization O
versus O
intracytoplasmic O
sperm O
injection O
in O
patients O
with O
borderline O
semen O
: O
a O
randomized O
study O
using O
sibling O
oocytes O
. O
[]

Side O
effects O
were O
less O
in O
the O
diamorphine O
group O
than O
the O
control O
, O
or O
the O
bupivacaine O
group O
. O
[]

Amantadine-sulfate O
has O
been O
used O
for O
several O
decades O
to O
treat O
acute O
influenza O
A O
, O
Parkinson O
's O
disease O
( O
PD O
) O
, O
and O
acute O
or O
chronic O
drug-induced O
dyskinesia O
. O
[]

Variables O
indicating O
the O
quality O
of O
life O
of O
the O
two O
groups O
were O
compared O
. O
[]

Initial O
protocol O
dosing O
achieved O
target O
plasma O
levels O
of O
trimethoprim O
( O
3 O
to O
8 O
micrograms/ml O
) O
or O
gentamicin O
( O
4 O
to O
10 O
micrograms/ml O
) O
in O
57 O
of O
68 O
( O
84 O
per O
cent O
) O
C-T/S O
trials O
compared O
to O
21 O
of O
60 O
( O
35 O
per O
cent O
) O
C-G O
trials O
. O
[]

A O
joint O
clinical O
prospective O
study O
between O
SUMS O
and O
Lund O
university O
was O
reported O
. O
[]

Flu O
with O
i.v O
. O
[]

Addition O
of O
atorvastatin O
to O
quinapril O
, O
but O
not O
quinapril O
to O
the O
statin O
, O
enhanced O
the O
anticoagulant O
effects O
. O
[]

This O
superiority O
proved O
to O
be O
independent O
of O
risk O
group O
. O
[]

This O
study O
was O
designed O
to O
determine O
the O
effect O
of O
a O
once-daily O
administration O
of O
mometasone O
furoate O
administered O
via O
a O
dry O
powder O
inhaler O
( O
MF-DPI O
) O
on O
treatment O
adherence O
compared O
with O
a O
twice-daily O
administration O
. O
[]

The O
patients O
were O
randomly O
allocated O
to O
two O
treatment O
groups O
: O
one O
to O
receive O
800 O
microg O
inhaled O
budesonide O
per O
day O
and O
the O
other O
to O
receive O
200 O
microg O
inhaled O
budesonide O
per O
day O
. O
[]

These O
findings O
confirm O
that O
pitch B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
is O
enhanced O
in O
high-functioning O
autism O
. O
['Life-Impact']

Six O
months O
after O
the O
end O
of O
treatment O
, O
the O
overall O
response O
rate O
( O
complete B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
partial I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
) O
was O
70 O
% O
: O
57 O
and O
82 O
% O
for O
patients O
receiving O
interferon O
alpha-2b O
( O
IM O
and O
subcutaneously O
) O
and O
diathermocoagulation O
, O
respectively O
, O
and O
8 O
% O
for O
the O
control O
group O
. O
['Physiological-Clinical']

Memantine O
as O
adjunctive O
treatment O
to O
risperidone O
in O
children O
with O
autistic O
disorder O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

The O
cancer B-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

This O
measurement O
has O
historically O
been O
performed O
utilizing O
axial O
computed O
tomography O
( O
CT O
) O
. O
[]

BACKGROUND O
This O
study O
was O
conducted O
to O
compare O
the O
effects O
of O
two O
contraceptive O
pills O
with O
different O
doses O
of O
the O
same O
components O
, O
on O
plasma B-outcome ['Physiological-Clinical']
androgen I-outcome ['Physiological-Clinical']
levels O
and O
female B-outcome ['Life-Impact']
sexual I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
among O
women O
without O
previous O
sexual I-outcome ['Life-Impact']
dysfunction O
. O
['Physiological-Clinical', 'Life-Impact']

PATIENTS O
AND O
METHODS O
Women O
with O
invasive O
breast O
cancer O
were O
eligible O
if O
there O
were O
one O
to O
three O
positive O
lymph O
nodes O
or O
if O
the O
node-negative O
tumor O
was O
greater O
than O
1 O
cm O
. O
[]

Central O
venous O
catheters O
were O
placed O
into O
the O
right O
IJV O
by O
the O
Seldinger O
technique O
. O
[]

METHODS O
Patients O
( O
n=766 O
) O
, O
aged O
18 O
to O
65 O
years O
inclusive O
, O
with O
current O
manic O
or O
mixed O
episodes O
were O
initially O
randomized O
( O
4:1 O
) O
to O
flexibly-dosed O
paliperidone O
ER O
( O
3-12 O
mg/day O
) O
or O
olanzapine O
( O
5-20 O
mg/day O
; O
3-week O
acute O
treatment O
phase O
) O
; O
responders O
continued O
the O
same O
treatment O
( O
12-week O
continuation O
phase O
) O
. O
[]

RESULTS O
Among O
ZrO O
( O
2 O
) O
copings O
, O
Lava O
( O
0.3 O
mm O
and O
0.5 O
mm O
thick O
) O
showed O
the O
highest O
( O
P O
< O
.05 O
) O
values O
of O
translucency B-outcome ['Physiological-Clinical']
measured O
as O
light O
flow O
units O
( O
3.572 O
+ O
or O
- O
018 O
x O
10 O
( O
3 O
) O
lx O
and O
3.181 O
+ O
or O
- O
0.13 O
x O
10 O
( O
3 O
) O
lx O
, O
respectively O
) O
. O
['Physiological-Clinical']

Similar O
findings O
were O
observed O
in O
the O
duodenum O
. O
[]

Steers O
were O
blocked O
by O
arrival O
at O
the O
feed O
yard O
, O
genotyped O
for O
the O
leptin O
SNP O
, O
allotted O
to O
genotype-specific O
pens O
( O
90 O
steers/pen O
) O
, O
and O
assigned O
randomly O
within O
genotype O
and O
block O
to O
0 O
or O
21 O
d O
of O
dietary O
ZH O
. O
[]

Adverse O
effects O
within O
2 O
weeks O
after O
TAI O
were O
evaluated O
by O
subjective O
signs O
and O
symptoms O
such O
as O
fever B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
maximum I-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
the O
frequency O
of O
shaking B-outcome ['Physiological-Clinical']
chills I-outcome ['Physiological-Clinical']
and O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
by O
biochemical O
parameters O
such O
as O
albumin O
, O
prothrombin O
time O
, O
and O
aspartate O
and O
alanine O
aminotransferases O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Yet O
, O
the O
effects O
of O
MECC O
on O
the O
intraoperative O
microvascular O
perfusion O
in O
comparison O
with O
conventional O
extracorporeal O
circulation O
( O
CECC O
) O
have O
not O
been O
studied O
so O
far O
. O
[]

One O
hundred O
three O
consecutive O
patients O
( O
53 O
women O
; O
mean O
age O
64+/-17 O
years O
) O
entered O
the O
study O
. O
[]

Serum O
leptin O
was O
correlated O
with O
BCS O
( O
P O
< O
0.0001 O
; O
r O
= O
0.35 O
) O
at O
initiation O
of O
the O
feeding O
period O
and O
was O
correlated O
with O
BCS O
( O
P O
= O
0.02 O
; O
r O
= O
0.12 O
) O
and O
weight O
( O
P O
< O
0.01 O
; O
r O
= O
0.14 O
) O
at O
the O
completion O
of O
the O
supplement O
period O
, O
but O
it O
was O
not O
correlated O
with O
initial O
BW O
or O
interim O
BCS O
. O
[]

CONCLUSIONS O
An O
adaptive O
low-pass O
filtered O
speech O
test O
such O
as O
the O
UCAST-FW O
is O
sensitive O
to O
maturational B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
auditory I-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
ability I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Cross-over O
effects O
of O
a O
dopamine O
agonist O
and O
an O
antagonist O
] O
. O
[]

METHODS O
AND O
MATERIALS O
Fifty O
patients O
were O
randomized O
to O
receive O
conventional O
radiotherapy O
( O
RT O
) O
( O
2-Gy O
fractions O
, O
5 O
days O
weekly O
, O
to O
a O
total O
of O
60-74 O
Gy O
, O
depending O
on O
the O
tumor O
localization O
and O
TNM O
classification O
) O
and O
carboplatin O
( O
90 O
mg/m O
( O
2 O
) O
infusion O
once O
per O
week O
before O
RT O
) O
. O
[]

aminophylline O
and O
corticosteroids O
. O
[]

PROCEDURES O
Intensive O
care O
unit O
cages O
were O
sprayed O
with O
sDAP O
solution O
or O
sham O
treated O
with O
the O
carrier O
used O
in O
the O
solution O
20 O
minutes O
prior O
to O
use O
. O
[]

Outcomes O
on O
play B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
were O
mixed O
, O
with O
improvement O
of O
symbolic B-outcome ['Life-Impact']
play I-outcome ['Life-Impact']
for O
the O
CMM O
group O
and O
no O
change O
in O
functional B-outcome ['Life-Impact']
play I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
shear-induced B-outcome ['Physiological-Clinical']
hemostasis I-outcome ['Physiological-Clinical']
was O
monitored O
by O
the O
in O
vitro O
bleeding O
test O
( O
Thrombostat O
) O
, O
which O
mimics O
bleeding O
through O
an O
injured O
arteriole O
. O
['Physiological-Clinical']

The O
primary O
efficacy O
parameter O
of O
the O
study O
was O
the O
control O
of O
serum B-outcome ['Physiological-Clinical']
phosphorus I-outcome ['Physiological-Clinical']
levels O
( O
< O
or O
=1.8 O
mmol/l O
[ O
< O
or O
= O
5.6 O
mg/dl O
] O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
further O
explore O
the O
effects O
of O
sodium O
oxybate O
( O
SXB O
) O
administration O
on O
nocturnal B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
in O
narcolepsy O
patients O
during O
a O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
conducted O
with O
228 O
adult O
patients O
with O
narcolepsy/cataplexy O
in O
the O
United O
States O
, O
Canada O
, O
and O
Europe O
. O
['Physiological-Clinical']

Our O
results O
indicate O
that O
short-term O
strength O
training O
increases O
basal O
femoral O
blood O
flow O
and O
vascular O
conductance O
in O
healthy O
middle-aged O
and O
older O
adults O
. O
[]

We O
studied O
40 O
children O
younger O
than O
4 O
yr O
having O
elective O
abdominal O
surgery O
under O
general O
anaesthesia O
supplemented O
with O
either O
systemic O
opioids O
or O
extradural O
bupivacaine O
. O
[]

Comorbid O
anxiety O
is O
common O
among O
children O
with O
Autism O
Spectrum O
Disorder O
( O
ASD O
) O
, O
and O
parents O
of O
children O
with O
ASD O
are O
more O
likely O
to O
have O
anxiety O
disorders O
. O
[]

Studies O
support O
load O
theory O
's O
prediction O
that O
working O
memory O
load O
will O
lead O
to O
larger O
distractor B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
; O
however O
, O
these O
studies O
used O
secondary O
tasks O
that O
required O
only O
verbal O
working O
memory O
and O
the O
central O
executive O
. O
['Life-Impact']

The O
participants O
' O
self-control O
was O
measured O
by O
three O
neuropsychological B-outcome ['Physiological-Clinical']
tests O
and O
parental B-outcome ['Life-Impact']
rating I-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
standardized I-outcome ['Life-Impact']
questionnaires I-outcome ['Life-Impact']
, O
and O
the O
underlying O
neural O
mechanism O
was O
assessed O
by O
the O
participants O
' O
brain O
EEG O
activity O
during O
an O
inhibitory-control O
task O
before O
and O
after O
intervention O
. O
['Physiological-Clinical', 'Life-Impact']

Self-reports O
were O
also O
used O
to O
determine O
adherence O
. O
[]

CONCLUSIONS O
EE30/LNG150 O
decreased O
plasma O
androgen O
levels O
, O
but O
there O
was O
no O
impairment O
in O
sexual O
desire O
, O
on O
the O
other O
hand O
, O
sexual O
desire O
score O
increased O
with O
EE20/LNG100 O
formulation O
. O
[]

anova O
and O
Dunnett O
's O
test O
showed O
that O
groups O
A-D O
did O
not O
differ O
statistically O
from O
the O
control O
group O
E O
but O
differed O
from O
the O
control O
group O
F. O
The O
lowest O
mean O
value O
was O
found O
for O
group O
F. O
Regression O
analysis O
was O
unable O
to O
show O
salivary O
effect O
on O
dentine B-outcome ['Physiological-Clinical']
wear I-outcome ['Physiological-Clinical']
reduction O
. O
['Physiological-Clinical']

All O
patients O
received O
a O
standard O
preoperative O
regimen O
of O
cyclopentolate O
( O
2 O
% O
) O
and O
phenylephrine O
hydrochloride O
( O
2.5 O
% O
) O
. O
[]

Analysis O
will O
be O
on O
an O
intention O
to O
treat O
basis O
. O
[]

Prophylactic O
amnioinfusion O
was O
assessed O
in O
term O
and O
post-dates O
pregnancies O
with O
decreased O
amniotic O
fluid O
volume O
. O
[]

RESULTS O
No O
differences O
with O
regard O
to O
wives O
' O
general B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
or O
cancer-specific B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
were O
noted O
. O
['Life-Impact', 'Life-Impact']

The O
goal O
of O
this O
pilot O
study O
was O
to O
evaluate O
the O
effects O
of O
an O
antimicrobial O
additive O
( O
Microban O
) O
to O
toothbrushes O
on O
residual O
retention O
of O
periodontal B-outcome ['Physiological-Clinical']
pathogens I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

One O
subject O
( O
10 O
mg/kg O
) O
experienced O
a O
mild O
hypersensitivity O
reaction O
. O
[]

Results O
were O
not O
materially O
affected O
by O
adjustment O
for O
basline O
values O
or O
changes O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Main O
outcome O
measures O
included O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
, O
estimated O
red B-outcome ['Physiological-Clinical']
reflex I-outcome ['Physiological-Clinical']
, O
postsurgical B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
, O
corneal B-outcome ['Physiological-Clinical']
clarity I-outcome ['Physiological-Clinical']
, O
posterior B-outcome ['Physiological-Clinical']
synechias I-outcome ['Physiological-Clinical']
, O
iris B-outcome ['Physiological-Clinical']
capture I-outcome ['Physiological-Clinical']
, O
IOL B-outcome ['Physiological-Clinical']
position O
, O
capsulectomy B-outcome ['Physiological-Clinical']
size O
, O
glaucoma B-outcome ['Physiological-Clinical']
, O
cystoid B-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
edema I-outcome ['Physiological-Clinical']
, O
retinal B-outcome ['Physiological-Clinical']
tear O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Twenty-four O
patients O
were O
treated O
with O
sclerotherapy O
and O
25 O
with O
band O
ligation O
. O
[]

Primary O
outcomes O
were O
fatigue B-outcome ['Physiological-Clinical']
( O
measured O
by O
Chalder O
fatigue B-outcome ['Physiological-Clinical']
questionnaire O
score O
) O
and O
physical B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
( O
measured O
by O
short O
form-36 O
subscale O
score O
) O
up O
to O
52 O
weeks O
after O
randomisation O
, O
and O
safety O
was O
assessed O
primarily O
by O
recording O
all O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
including O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Adverse-effects', 'Adverse-effects']

Participants O
assigned O
to O
3CM O
also O
received O
telephone O
care O
management O
. O
[]

The O
effect O
of O
halothane O
and O
isoflurane O
on O
plasma B-outcome ['Physiological-Clinical']
cytokine I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

The O
most O
common O
type O
of O
histologic B-outcome ['Physiological-Clinical']
conversion B-outcome ['Physiological-Clinical']
was O
from O
NLPD O
to O
diffuse O
histiocytic B-outcome ['Physiological-Clinical']
lymphoma B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
cumulative O
postoperative O
fatigue B-outcome ['Physiological-Clinical']
scores O
were O
lower O
in O
BCAA O
group O
than O
that O
in O
the O
control O
group O
at O
the O
4th O
, O
5th O
and O
7th O
day O
after O
operation O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Given O
the O
lack O
of O
significant O
complications O
for O
the O
4-hour O
group O
and O
similar O
comfort B-outcome ['Life-Impact']
levels O
for O
both O
study O
groups O
, O
these O
findings O
suggest O
the O
feasibility O
of O
reducing O
the O
standard O
period O
of O
postcatheterization O
bed O
rest O
from O
6 O
hours O
to O
4 O
hours O
, O
thereby O
possibly O
lowering O
the O
cost B-outcome ['Resource-use']
of I-outcome ['Resource-use']
the I-outcome ['Resource-use']
outpatient I-outcome ['Resource-use']
procedure I-outcome ['Resource-use']
. O
['Life-Impact', 'Resource-use']

The O
main O
outcome O
was O
completion B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
any I-outcome ['Life-Impact']
CRC I-outcome ['Life-Impact']
screening I-outcome ['Life-Impact']
. O
['Life-Impact']

We O
have O
compared O
the O
efficacy O
of O
0.25 O
% O
S O
( O
- O
) O
-bupivacaine O
with O
0.25 O
% O
RS-bupivacaine O
in O
providing O
epidural B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
for O
labour O
in O
a O
randomized O
, O
multicentre O
, O
double-blind O
study O
. O
['Resource-use']

Preliminary O
findings O
of O
the O
minimally-invasive O
surgery O
plus O
rtPA O
for O
intracerebral B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
evacuation I-outcome ['Physiological-Clinical']
( O
MISTIE O
) O
clinical O
trial O
. O
['Physiological-Clinical']

Trial O
design O
challenges O
when O
combining O
medication O
and O
parent O
training O
in O
children O
with O
pervasive O
developmental O
disorders O
. O
[]

However O
, O
in O
the O
amantadine-treated O
group O
there O
were O
statistically O
significant O
improvements O
in O
absolute O
changes O
in O
clinician-rated O
ABC-CVs O
for O
hyperactivity B-outcome ['Life-Impact']
( O
amantadine O
-6.4 O
versus O
placebo O
-2.1 O
; O
p O
= O
.046 O
) O
and O
inappropriate B-outcome ['Life-Impact']
speech I-outcome ['Life-Impact']
( O
-1.9 O
versus O
0.4 O
; O
p O
= O
.008 O
) O
. O
['Life-Impact', 'Life-Impact']

This O
report O
describes O
a O
secondary O
outcome O
measurement O
from O
this O
trial O
, O
EEG B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Biological O
links O
between O
compulsions O
and O
stereotyped O
, O
repetitive O
behaviors O
in O
autistic O
disorder O
should O
be O
explored O
. O
[]

After O
an O
exactly O
controlled O
6-month O
treatment O
hypertensives O
with O
additionally O
recommended O
far-reaching O
CNT O
showed O
an O
economization O
of O
medicaments O
by O
scarcely O
the O
half O
in O
comparison O
to O
the O
reference O
group O
. O
[]

PURPOSE O
This O
randomized O
group O
experiment O
compared O
the O
efficacy O
of O
2 O
communication O
interventions O
( O
Responsive O
Education O
and O
Prelinguistic O
Milieu O
Teaching O
[ O
RPMT O
] O
and O
the O
Picture O
Exchange O
Communication O
System O
[ O
PECS O
] O
) O
on O
spoken O
communication O
in O
36 O
preschoolers O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
. O
[]

Terry O
Beirn O
Community O
Programs O
for O
Clinical O
Research O
on O
AIDS O
. O
[]

The O
skin O
sites O
were O
then O
treated O
epidermally O
with O
45 O
% O
alcohol/onion O
extract O
and O
45 O
% O
ethanol O
under O
occlusion O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
evolution O
of O
GMT O
values O
for O
the O
two O
groups O
. O
[]

PATIENTS O
AND O
METHODS O
In O
the O
WHI O
trial O
, O
women O
were O
randomly O
assigned O
to O
daily O
CEE O
0.625 O
mg O
or O
placebo O
. O
[]

TRIAL O
REGISTRATION O
ClinicalTrials.gov O
Identifier O
: O
NCT01260597 O
. O
[]

Adult O
asthma O
patients O
undergoing O
treatment O
with O
budesonide O
400 O
microg O
b.i.d O
. O
[]

Blood B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
taken O
in O
fasting O
state O
from O
all O
subjects O
. O
['Physiological-Clinical']

There O
were O
a O
total O
of O
three O
deaths B-outcome ['Mortality']
in O
the O
therapy O
group O
and O
eight O
deaths B-outcome ['Mortality']
in O
the O
control O
group O
. O
['Mortality', 'Mortality']

Plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
midazolam I-outcome ['Physiological-Clinical']
were O
measured O
at O
the O
time O
of O
each O
measurement O
of O
CBF O
. O
['Physiological-Clinical']

Participants O
were O
randomly O
assigned O
to O
a O
computerized O
training O
program O
involving O
either O
faces O
or O
houses O
. O
[]

CONCLUSION O
Yufeining O
could O
improve O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
decrease O
['Physiological-Clinical']

The O
first O
flow O
measurements O
were O
performed O
approximately O
1 O
h O
after O
induction O
of O
anaesthesia O
. O
[]

While O
there O
have O
been O
several O
decision O
aids O
( O
DAs O
) O
developed O
and O
tested O
, O
very O
few O
have O
included O
an O
exercise O
to O
help O
men O
clarify O
their O
values O
and O
preferences B-outcome ['Life-Impact']
about O
PCa O
screening O
. O
['Life-Impact']

Pulsed O
wave O
doppler O
echocardiography O
was O
used O
to O
measure O
mean O
pulmonary O
artery O
pressure O
, O
cardiac O
output O
and O
hence O
pulmonary B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PVR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
contrast O
to O
the O
control O
group O
who O
deteriorated O
, O
language B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
the O
intervention O
group O
remained O
stable O
. O
['Life-Impact']

The O
efficacy O
and O
safety O
of O
three O
oral O
fluoroquinolones O
( O
lomefloxacin O
, O
levofloxacin O
, O
and O
ciprofloxacin O
) O
for O
the O
treatment O
of O
chronic O
osteomyelitis O
were O
analyzed O
. O
[]

Right O
ventricular O
( O
RV O
) O
blood O
pool-derived O
isovolumic O
relaxation O
time O
( O
IVRT O
) O
correlates O
well O
with O
systolic O
pulmonary O
arterial O
pressure O
( O
PAP O
) O
. O
[]

Continued O
treatment O
with O
belatacept O
was O
associated O
with O
a O
consistent O
safety O
profile O
and O
sustained O
improvement O
in O
renal O
function O
versus O
CsA O
over O
time O
. O
[]

We O
conclude O
that O
auscultation O
of O
epigastrium O
, O
right O
and O
left O
axilla O
, O
are O
recommended O
. O
[]

Neither O
hyperamylasemia B-outcome ['Physiological-Clinical']
nor O
pancreatitis B-outcome ['Physiological-Clinical']
was O
preventable O
when O
glucagon O
was O
used O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
received O
fluticasone O
propionate O
powder O
50 O
micrograms O
, O
100 O
micrograms O
, O
250 O
micrograms O
, O
or O
placebo O
via O
a O
breath-actuated O
inhalation O
device O
, O
the O
Diskhaler O
, O
twice O
daily O
for O
12 O
weeks O
. O
[]

RESULTS O
No O
patient O
taking O
dirithromycin O
alone O
( O
n O
= O
6 O
) O
or O
in O
combination O
with O
omeprazole O
( O
n O
= O
26 O
) O
achieved O
cure B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
their I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSION O
The O
treatment O
with O
probucol O
can O
improve O
oxidative B-outcome ['Physiological-Clinical']
stress O
in O
hypertension B-outcome ['Physiological-Clinical']
patients O
, O
resulting O
in O
reduced O
serum B-outcome ['Physiological-Clinical']
MDA I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

3.6 O
) O
, O
( O
26.2 O
? O
[]

Each O
operator O
performed O
stone O
extraction O
of O
2 O
, O
5 O
and O
8 O
mm O
calculi O
( O
size O
determined O
by O
digital O
caliper O
with O
3 O
repetitions O
of O
each O
basket O
. O
[]

MAIN O
OUTCOME O
MEASURE O
Insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
( O
rate O
of O
glucose B-outcome ['Physiological-Clinical']
infusion I-outcome ['Physiological-Clinical']
per O
kg O
fat O
free O
body O
mass O
and O
minute O
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

Procedures O
and O
maps O
from O
the O
mapping O
activity O
( O
two-stage O
conversational O
mapping O
) O
are O
described O
. O
[]

During O
aortic O
cross-clamping O
the O
intramucosal B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
value I-outcome ['Physiological-Clinical']
decreased O
in O
Group O
I O
patients O
, O
but O
did O
not O
change O
in O
Group O
II O
patients O
. O
['Physiological-Clinical']

METHODS O
A O
total O
of O
517 O
HALT-C O
patients O
received O
peginterferon O
alfa-2a O
( O
90 O
microg/week O
) O
; O
532 O
received O
no O
additional O
treatment O
for O
3.5 O
years O
. O
[]

A O
prospective O
comparison O
of O
the O
multiplane O
probe O
with O
the O
biplane O
probe O
in O
structure O
visualization B-outcome ['Physiological-Clinical']
and O
Doppler B-outcome ['Resource-use']
examination I-outcome ['Resource-use']
during O
transesophageal O
echocardiography O
. O
['Physiological-Clinical', 'Resource-use']

There O
was O
a O
non-significant O
tendency O
for O
hours B-outcome ['Life-Impact']
worked I-outcome ['Life-Impact']
to O
be O
reduced O
and O
for O
annual O
incomes B-outcome ['Life-Impact']
to O
be O
greater O
for O
those O
exposed O
to O
atole O
from O
0 O
to O
2 O
years O
. O
['Life-Impact', 'Life-Impact']

Results O
showed O
that O
tirasemtiv O
was O
well O
tolerated B-outcome ['Life-Impact']
, O
with O
dizziness B-outcome ['Physiological-Clinical']
the O
most O
common O
adverse O
event O
. O
['Life-Impact', 'Physiological-Clinical']

Anxiety O
was O
screened O
by O
The O
Screen O
for O
Child O
Anxiety O
Related O
Emotional O
Disorders O
( O
SCARED O
) O
questionnaire O
. O
[]

Feeding O
ZH O
decreased O
DMI O
in O
steers O
with O
increased O
frequency O
of O
the O
T O
allele O
( O
9.67 O
, O
9.53 O
, O
and O
9.28 O
kg/d O
for O
CC O
, O
CT O
, O
and O
TT O
, O
respectively O
) O
, O
but O
DMI O
increased O
with O
the O
frequency O
of O
the O
T O
allele O
( O
9.68 O
, O
9.90 O
, O
and O
10.1 O
kg O
for O
CC O
, O
CT O
, O
and O
TT O
, O
respectively O
) O
when O
ZH O
was O
not O
fed O
( O
leptin O
genotype O
? O
[]

A O
maximum O
of O
150 O
mg/day O
clozapine O
or O
placebo O
equivalent O
was O
given O
for O
a O
period O
of O
31 O
days O
. O
[]

Eight O
male O
children O
( O
8.1 O
+/- O
2.8 O
years O
) O
with O
autistic O
disorder O
, O
diagnosed O
by O
DSM-III-R O
criteria O
, O
completed O
a O
placebo-controlled O
, O
double-blind O
crossover O
trial O
of O
clonidine O
. O
[]

Monitoring O
of O
anti-Xa B-outcome ['Physiological-Clinical']
levels O
in O
this O
situation O
is O
usually O
not O
required O
. O
['Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

No O
association O
was O
found O
between O
costs B-outcome ['Resource-use']
and O
baseline O
status B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

There O
were O
no O
statistically O
significant O
differences O
in O
time O
to O
the O
development O
of O
progressive B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
or O
survival B-outcome ['Mortality']
between O
the O
ER O
positive O
and O
ER O
unknown O
patients O
or O
between O
the O
tamoxifen O
and O
tamoxifen O
plus O
CMF O
groups O
. O
['Physiological-Clinical', 'Mortality']

The O
CRQ B-outcome ['Physiological-Clinical']
total O
and O
['Physiological-Clinical']

Cognitive O
behavioral O
therapies O
( O
CBT O
) O
are O
frequently O
used O
with O
success O
for O
children O
with O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

METHODS O
The O
study O
was O
done O
in O
51 O
centres O
in O
nine O
countries O
. O
[]

In O
analogy O
, O
a O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
model O
and O
, O
as O
a O
supplement O
, O
a O
best O
case/worst O
case O
analysis O
are O
performed O
for O
further O
statistical O
evaluation O
. O
['Mortality']

The O
primary O
end O
point O
was O
angiographic B-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Follow-up O
survey O
of O
6-36 O
months O
showed O
that O
the O
VAS O
score O
and O
the O
lumbar B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
range I-outcome ['Physiological-Clinical']
in O
the O
needle-knife O
group O
were O
superior O
to O
those O
in O
the O
physiotherapy O
group O
. O
['Physiological-Clinical']

Urea-N B-outcome ['Physiological-Clinical']
replaced O
50 O
% O
of O
SBM-N O
in O
the O
SBM-U O
diet O
. O
['Physiological-Clinical']

SUBJECTS/METHOD O
In O
total O
140 O
patients O
( O
36 O
men O
, O
104 O
women O
) O
, O
aged O
18-60 O
years O
and O
body O
mass O
index O
> O
30 O
kg/m O
( O
2 O
) O
were O
randomized O
and O
93 O
patients O
( O
27 O
men O
, O
66 O
women O
) O
completed O
the O
study O
. O
[]

Treatment O
of O
Wilms O
' O
tumor O
. O
[]

In O
this O
work O
, O
we O
analysed O
the O
frequency O
of O
peripheral O
blood O
lymphocyte O
subsets O
in O
10 O
Chinese O
patients O
with O
histologically O
proven O
CAHB O
and O
seven O
healthy O
Chinese O
individuals O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Twenty-six O
sedentary O
but O
healthy O
middle-aged O
and O
older O
subjects O
were O
randomly O
assigned O
to O
either O
a O
whole O
body O
strength O
training O
intervention O
group O
( O
52 O
+/- O
2 O
yr O
, O
3 O
men O
, O
10 O
women O
) O
who O
underwent O
three O
supervised O
resistance O
training O
sessions O
per O
week O
for O
13 O
wk O
or O
a O
control O
group O
( O
53 O
+/- O
2 O
yr O
, O
4 O
men O
, O
9 O
women O
) O
who O
participated O
in O
a O
supervised O
stretching O
program O
. O
[]

The O
goal O
of O
our O
study O
was O
to O
investigate O
whether O
reaction O
time O
( O
RT O
) O
, O
error O
rate O
, O
post-error O
RT O
change O
, O
ERN O
, O
and O
Pe O
will O
show O
positive O
changes O
following O
12-week O
long O
slow O
frequency O
repetitive O
TMS O
( O
rTMS O
) O
over O
dorsolateral O
prefrontal O
cortex O
( O
DLPFC O
) O
in O
high O
functioning O
children O
with O
ASD O
. O
[]

Safety O
and O
efficacy O
of O
sitaxsentan O
50 O
and O
100 O
mg O
in O
patients O
with O
pulmonary O
arterial O
hypertension O
. O
[]

Data O
analyzed O
in O
platinum-sensitive O
patients O
demonstrated O
a O
statistically O
significant O
benefit O
from O
PLD O
for O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
=.037 O
) O
, O
with O
medians O
of O
28.9 O
for O
PLD O
versus O
23.3 O
weeks O
for O
topotecan O
. O
['Mortality']

Forty-two O
patients O
with O
migraine O
without O
aura O
underwent O
the O
test O
before O
and O
2 O
months O
after O
antimigraine O
therapy O
. O
[]

After O
debonding O
, O
the O
teeth O
and O
the O
brackets O
were O
examined O
under O
a O
stereomicroscope O
( O
model O
SMZ-1B O
, O
Nikon O
, O
Osaka O
, O
Japan O
) O
at O
20-times O
magnification O
to O
assess O
the O
residual O
adhesive O
on O
the O
tooth O
surfaces O
. O
[]

Muscle O
biopsies O
were O
taken O
before O
and O
immediately O
after O
exercise O
and O
after O
1 O
and O
4 O
h O
of O
postexercise O
recovery O
to O
determine O
4E-BP1 O
, O
S6K1 O
( O
both O
T O
( O
421 O
) O
/S O
( O
424 O
) O
and O
T O
( O
389 O
) O
) O
, O
and O
S6 O
phosphorylation O
status O
. O
[]

RESULTS O
Laser-assisted O
topical O
anesthesia O
demonstrated O
significantly O
lower O
mean O
pain B-outcome ['Physiological-Clinical']
scores O
than O
topical O
anesthesia O
alone O
. O
['Physiological-Clinical']

Further O
, O
powerful O
and O
controlled O
studies O
are O
needed O
to O
elucidate O
the O
best O
treatment O
strategies O
for O
H. O
pylori O
eradication O
in O
this O
age O
group O
. O
[]

The O
results O
were O
evaluated O
by O
preference O
in O
a O
sequential O
procedure O
. O
[]

Major B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
coronary B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
death B-outcome ['Mortality']
( O
n=3 O
per O
group O
) O
, O
['Adverse-effects', 'Physiological-Clinical', 'Mortality']

Patients O
of O
the O
intervention O
group O
were O
more O
likely O
to O
show O
reduction O
in O
body O
mass O
index O
and O
sodium B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
to O
stop B-outcome ['Life-Impact']
smoking I-outcome ['Life-Impact']
, O
as O
compared O
with O
the O
control O
group O
. O
['Life-Impact', 'Life-Impact']

Recently O
, O
several O
phototherapeutic O
modalities O
, O
most O
notably O
pulsed-dye O
laser O
( O
PDL O
) O
treatment O
, O
have O
been O
introduced O
, O
but O
the O
published O
results O
- O
albeit O
promising O
- O
are O
controversial O
. O
[]

In O
this O
multicenter O
, O
double-blind O
trial O
; O
130 O
nonsteroid-dependent O
patients O
were O
randomized O
to O
receive O
one O
of O
the O
two O
treatments O
concomitantly O
with O
their O
regular O
asthma O
medications O
. O
[]

However O
, O
the O
Usual O
Care O
group O
did O
not O
represent O
existing O
practice O
and O
is O
not O
a O
useful O
comparator O
for O
decision O
making O
. O
[]

The O
total O
number O
of O
episodes B-outcome ['Physiological-Clinical']
of O
GER B-outcome ['Physiological-Clinical']
in O
the O
placebo O
and O
ranitidine O
groups O
was O
16 O
and O
1 O
, O
respectively O
( O
P O
= O
0.002 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
study O
population O
included O
403 O
of O
the O
original O
479 O
patients O
in O
the O
trial O
who O
had O
completed O
six O
days O
of O
blinded O
therapy O
without O
refractory O
angina O
or O
myocardial O
infarction O
. O
[]

RESULTS O
The O
primary O
end O
point O
occurred O
in O
185 O
of O
2654 O
patients O
receiving O
cangrelor O
( O
7.0 O
% O
) O
and O
in O
210 O
of O
2641 O
patients O
receiving O
placebo O
( O
8.0 O
% O
) O
( O
odds O
ratio O
in O
the O
cangrelor O
group O
, O
0.87 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.71 O
to O
1.07 O
; O
P=0.17 O
) O
( O
modified O
intention-to-treat O
population O
adjusted O
for O
missing O
data O
) O
. O
[]

CONCLUSIONS O
The O
bioavailability O
of O
oral O
GCV O
in O
transplant O
patients O
was O
similar O
to O
that O
observed O
in O
human O
immunodeficiency O
virus-infected O
patients O
. O
[]

Baseline O
and O
postcatheterization O
serum B-outcome ['Physiological-Clinical']
Cr I-outcome ['Physiological-Clinical']
levels O
were O
analyzed O
in O
a O
longitudinal O
fashion O
, O
allowing O
for O
differences O
in O
the O
time O
between O
blood O
draws O
, O
to O
determine O
the O
different O
critical O
trajectories O
of O
serum O
Cr O
. O
['Physiological-Clinical']

Effect O
of O
resistance O
exercise O
contraction O
mode O
and O
protein O
supplementation O
on O
members O
of O
the O
STARS O
signalling O
pathway O
. O
[]

0.1 O
kg O
) O
were O
used O
in O
a O
randomized O
complete O
block O
experiment O
to O
determine O
the O
effects O
of O
Aspergillus O
oryzae O
extract O
, O
Amaferm O
( O
AMF O
) O
supplementation O
( O
1 O
g/d O
) O
in O
an O
85 O
% O
concentrate O
diet O
on O
growth O
and O
carcass O
characteristics O
. O
[]

METHODS O
Adults O
aged O
> O
or O
=18 O
yr O
with O
nocturia O
( O
> O
or O
=2 O
voids/night O
) O
received O
desmopressin O
tablets O
( O
0.1 O
, O
0.2 O
, O
or O
0.4 O
mg O
) O
during O
a O
3-wk O
dose-titration O
period O
. O
[]

2.92 O
and O
11.27 O
? O
[]

Specifically O
, O
perceptual O
load O
should O
lead O
to O
efficient O
distractor O
rejection O
, O
whereas O
working O
memory O
load O
( O
dual-task O
coordination O
) O
should O
hinder O
distractor B-outcome ['Life-Impact']
rejection I-outcome ['Life-Impact']
. O
['Life-Impact']

Intranasal O
administration O
of O
the O
neuropeptide O
oxytocin O
improved O
performance B-outcome ['Life-Impact']
in O
a O
facial B-outcome ['Life-Impact']
emotion B-outcome ['Life-Impact']
recognition B-outcome ['Life-Impact']
task O
in O
individuals O
with O
AS O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Results O
indicated O
that O
all O
six O
participants O
increased O
their O
imitation B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
to O
varying O
degrees O
in O
both O
conditions O
, O
and O
imitation O
maintained O
and O
generalized O
at O
higher O
than O
baseline O
levels O
post O
treatment O
. O
['Life-Impact']

CONCLUSIONS O
Global B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
specific I-outcome ['Physiological-Clinical']
health-related I-outcome ['Physiological-Clinical']
QoL I-outcome ['Physiological-Clinical']
data O
similar O
in O
both O
treatment O
groups O
with O
no O
statistically O
significant O
difference O
. O
['Physiological-Clinical']

Specifically O
, O
21 O
out O
of O
24 O
( O
87.5 O
% O
) O
treatment O
group O
participants O
acquired B-outcome ['Life-Impact']
employment I-outcome ['Life-Impact']
while O
1 O
of O
16 O
( O
6.25 O
% O
) O
of O
control O
group O
participants O
acquired O
employment O
. O
['Life-Impact']

METHODS O
A O
limited O
montage O
sleep O
study O
was O
recorded O
from O
2300 O
to O
0700 O
h O
during O
each O
admission O
. O
[]

RESULTS O
The O
median O
age O
of O
the O
patients O
was O
74 O
years O
and O
43 O
% O
of O
participants O
were O
females O
. O
[]

The O
participants O
consisted O
of O
60 O
unfit O
male O
university O
undergraduate O
students O
with O
no O
previous O
training O
in O
stress O
management O
who O
were O
randomly O
and O
evenly O
assigned O
to O
engage O
in O
one O
of O
four O
treatments O
over O
10 O
weeks O
: O
( O
a O
) O
moderate O
aerobic O
exercise O
, O
( O
b O
) O
progressive O
relaxation O
, O
( O
c O
) O
a O
placebo O
group O
that O
engaged O
in O
group O
discussion O
but O
did O
experience O
acute O
stress O
, O
and O
( O
d O
) O
a O
nonintervention O
control O
group O
that O
did O
not O
experience O
stress O
while O
performing O
the O
motor O
task O
. O
[]

Using O
more O
ecologically O
valid O
stimulus O
situations O
than O
the O
traditional O
LED O
in O
the O
dark O
, O
we O
performed O
two O
experiments O
. O
[]

CONCLUSIONS O
Comparable O
prediction O
models O
were O
obtained O
with O
LKB O
, O
RS O
, O
and O
logistic O
NTCP O
models O
. O
[]

Mean O
time O
between O
upper O
and O
lower O
hemi-body O
irradiation O
was O
69 O
days O
( O
range O
35-294 O
) O
. O
[]

Side O
effects O
were O
reported O
by O
three O
patients O
, O
which O
were O
the O
patients O
with O
the O
highest O
AUC O
. O
[]

The O
participants O
in O
the O
intervention O
group O
met O
every O
6 O
months O
during O
the O
5-year O
study O
for O
clinical O
examination O
and O
for O
dietary O
and O
smoking B-outcome ['Resource-use']
counselling I-outcome ['Resource-use']
. O
['Resource-use']

We O
therefore O
suggest O
routine O
pretreatment O
with O
thiopental O
0.5 O
mg/kg O
along O
with O
venous O
occlusion O
for O
1 O
min O
for O
prevention O
of O
pain B-outcome ['Physiological-Clinical']
associated O
with O
propofol O
injection O
. O
['Physiological-Clinical']

Communication B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
were O
analysed O
according O
to O
the O
Cancer O
Research O
Campaign O
Workshop O
Evaluation O
Manual O
. O
['Life-Impact']

EORTC O
protocols O
in O
prostatic O
cancer O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
during O
PGE1 O
infusion O
; O
the O
pre-ejection O
period O
and O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
period O
were O
shortened O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
therapeutic B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
for O
the O
brachytherapy O
group O
was O
significantly O
longer O
, O
83 O
days O
compared O
to O
36 O
days O
for O
the O
laser O
group O
( O
p O
= O
0.026 O
) O
. O
['Physiological-Clinical']

The O
Obstetrics O
and O
Gynecology O
Adhesion O
Prevention O
Committee O
. O
[]

This O
analysis O
confirms O
that O
the O
ESRA-C O
application O
for O
collecting O
symptom O
and O
quality O
of O
life O
information O
is O
easy O
for O
patients O
to O
use O
and O
acceptable O
across O
a O
range O
of O
user O
characteristics O
. O
[]

Leading B-outcome ['Physiological-Clinical']
edge I-outcome ['Physiological-Clinical']
voltage I-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
and O
shock B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
were O
also O
decreased O
with O
the O
dual-coil O
configuration O
, O
although O
peak O
current O
was O
increased O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
also O
demonstrated O
that O
selamectin O
provided O
the O
highest O
level O
of O
residual O
activity B-outcome ['Life-Impact']
on O
cats O
against O
the O
Kansas O
1 O
flea O
strain O
. O
['Life-Impact']

A O
parent-mediated O
intervention O
to O
increase O
responsive B-outcome ['Life-Impact']
parental I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
child B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
in O
children O
with O
ASD O
: O
a O
randomized O
clinical O
trial O
. O
['Life-Impact', 'Life-Impact']

Our O
findings O
support O
the O
potential O
for O
daclizumab O
HYP O
to O
offer O
an O
additional O
treatment O
option O
for O
relapsing-remitting O
disease O
. O
[]

BACKGROUND O
Some O
evidence O
suggests O
an O
increased O
risk O
of O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
and O
dysrhythmia B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
associated O
with O
beta O
( O
2 O
) O
-agonist O
use O
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Fluvoxamine O
is O
more O
effective O
than O
placebo O
in O
the O
short-term O
treatment O
of O
the O
symptoms O
of O
autistic O
disorder O
in O
adults O
. O
[]

We O
, O
however O
, O
recommend O
closely O
monitoring O
cyclosporin O
blood O
levels O
when O
prescribing O
ticlopidine O
. O
[]

For O
three O
themes O
, O
the O
proportion O
of O
responses B-outcome ['Physiological-Clinical']
that O
recalled O
the O
theme O
was O
significantly O
greater O
in O
the O
narrative O
arm O
compared O
to O
the O
summary O
arm O
, O
with O
the O
differences O
ranging O
from O
20 O
% O
to O
51 O
% O
. O
['Physiological-Clinical']

The O
incidence O
of O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
1.8 O
% O
( O
6 O
of O
334 O
patients O
) O
in O
the O
warfarin O
group O
and O
2.1 O
% O
( O
7 O
of O
336 O
patients O
) O
in O
the O
enoxaparin O
group O
( O
P O
> O
0.2 O
) O
. O
['Physiological-Clinical']

The O
effect O
of O
clinical O
and O
supratherapeutic O
doses O
of O
vilazodone O
on O
cardiac O
repolarization O
was O
determined O
in O
healthy O
volunteers O
. O
[]

The O
difference O
in O
the O
number O
of O
occlusions B-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
was O
not O
statistically O
significant O
. O
['Physiological-Clinical']

Human O
sensitivity O
to O
second-order O
modulations O
is O
well O
described O
by O
a O
filter-rectify-filter O
( O
FRF O
) O
model O
, O
with O
first- O
and O
second-order O
filters O
selective O
for O
orientation O
and O
SF O
. O
[]

SETTING O
Thirty-eight O
bedded O
acute O
trauma O
ward O
in O
a O
teaching O
hospital O
. O
[]

Postoperative O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
tests O
showed O
no O
important O
changes O
from O
preoperative O
values O
, O
although O
reductive O
metabolites O
of O
halothane O
were O
not O
measured O
. O
['Physiological-Clinical']

PURPOSE O
Breast O
cancer O
patients O
with O
treatment-induced O
menopause O
experience O
frequent O
and O
severe B-outcome ['Physiological-Clinical']
hot I-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Treatment O
with O
10 O
g/day O
of O
MF101 O
reduces O
the O
frequency O
of O
hot O
flushes O
. O
[]

A O
comparison O
of O
the O
laryngeal O
tube-S O
and O
Proseal O
laryngeal O
mask O
during O
outpatient O
surgical O
procedures O
. O
[]

Two O
and O
4 O
months O
after O
treatment O
withdrawal O
, O
most O
subjects O
with O
a O
negative O
response O
to O
the O
post-treatment O
test O
maintained O
treatment O
benefit O
, O
whereas O
benefit O
was O
lost O
in O
patients O
with O
an O
[]

Denosumab O
compared O
with O
zoledronic O
acid O
for O
the O
treatment O
of O
bone O
metastases O
in O
patients O
with O
advanced O
breast O
cancer O
: O
a O
randomized O
, O
double-blind O
study O
. O
[]

CONCLUSION O
Our O
results O
suggest O
that O
statin O
treatment O
produces O
a O
multidirectional O
effect O
on O
coagulation O
and O
fibrinolysis O
in O
patients O
with O
isolated O
hypertriglyceridemia O
and O
that O
this O
treatment O
may O
bring O
some O
benefits O
to O
patients O
with O
elevated O
triglyceride O
levels O
. O
[]

The O
patients O
' O
evaluation O
was O
significant O
for O
the O
first B-outcome ['Physiological-Clinical']
attack I-outcome ['Physiological-Clinical']
( O
p O
= O
0.002 O
) O
. O
['Physiological-Clinical']

This O
therapy O
, O
combined O
with O
traditional O
Chinese O
medicine O
and O
Western O
Medicine O
, O
is O
worth O
of O
clinical O
application O
in O
the O
treatment O
of O
knee O
osteoarthritis O
. O
[]

Patients O
' O
visual O
assessment O
of O
linear B-outcome ['Physiological-Clinical']
scars I-outcome ['Physiological-Clinical']
rating O
of O
breasts B-outcome ['Physiological-Clinical']
was O
3.8 O
( O
SD O
= O
2.9 O
) O
for O
Steri-Strip O
S O
and O
better O
at O
2.6 O
( O
SD O
= O
2.9 O
) O
for O
suture O
( O
p O
= O
0.008 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CLINICAL O
IMPLICATIONS O
Hard-tissue O
cutting O
lasers O
are O
being O
introduced O
for O
use O
in O
operative O
dentistry O
. O
[]

CONCLUSIONS O
The O
effectiveness O
of O
i.v O
. O
[]

There O
was O
a O
significant O
reduction O
in O
the O
number O
of O
lesions B-outcome ['Physiological-Clinical']
in O
['Physiological-Clinical']

Ototoxicity B-outcome ['Physiological-Clinical']
also O
occurred O
less O
frequently O
in O
the O
netilmicin-treated O
patients O
( O
3 O
% O
versus O
10 O
% O
, O
P O
= O
0.4 O
) O
. O
['Physiological-Clinical']

The O
awakening B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
however O
, O
was O
shorter O
with O
use O
of O
the O
index O
in O
those O
aged O
from O
1 O
to O
6 O
years O
. O
['Physiological-Clinical']

Simple O
clinical O
tests O
, O
like O
Romberg O
's O
test O
or O
a O
walking O
test O
, O
have O
proved O
to O
be O
inadequate O
guidelines O
for O
safe B-outcome ['Life-Impact']
discharge I-outcome ['Life-Impact']
after O
outpatient O
anaesthesia O
. O
['Life-Impact']

Combining O
individual-subject O
fMRI O
analyses O
with O
a O
scrambling O
method O
that O
manipulated O
musical O
structure O
, O
we O
provide O
evidence O
of O
brain B-outcome ['Physiological-Clinical']
regions I-outcome ['Physiological-Clinical']
sensitive I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
musical I-outcome ['Physiological-Clinical']
structure I-outcome ['Physiological-Clinical']
bilaterally O
in O
the O
temporal O
lobes O
, O
thus O
reconciling O
the O
neuroimaging O
and O
patient O
findings O
. O
['Physiological-Clinical']

Inclusion O
criteria O
were O
: O
1 O
) O
pain O
raising O
suspicion O
of O
ACS O
and O
2 O
) O
pain O
score O
?4 O
. O
[]

Erectile O
dysfunction O
( O
ED O
) O
is O
one O
of O
the O
major O
health O
concerns O
affects O
the O
quality O
of O
life O
among O
Thai O
male O
. O
[]

The O
most O
important O
prognostic O
feature O
at O
presentation O
was O
the O
quality O
of O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

No O
significant O
changes O
were O
seen O
in O
left O
ventricular O
ejection O
time O
( O
LVET O
) O
, O
LV O
dimensions O
, O
[]

Gefitinib O
versus O
placebo O
in O
completely O
resected O
non-small-cell O
lung O
cancer O
: O
results O
of O
the O
NCIC O
CTG O
BR19 O
study O
. O
[]

CONCLUSIONS O
The O
results O
of O
this O
study O
provide O
preliminary O
evidence O
that O
omega-3 O
fatty O
acids O
may O
be O
an O
effective O
treatment O
for O
children O
with O
autism O
. O
[]

The O
order O
of O
the O
experiments O
was O
randomized O
between O
sham O
( O
60 O
min O
of O
seated O
upright O
rest O
) O
and O
exercise O
( O
60 O
min O
of O
upright O
cycling O
at O
60 O
% O
peak O
aerobic O
capacity O
) O
. O
[]

[ O
Clinical O
observation O
on O
different O
acupuncture O
and O
moxibustion O
therapies O
for O
treatment O
of O
postsurgical O
gastroparesis O
syndrome O
] O
. O
[]

OBJECTIVES O
Ponezumab O
is O
a O
humanized O
antiamyloid O
beta O
( O
A? O
) O
monoclonal O
antibody O
designed O
to O
treat O
Alzheimer O
disease O
( O
AD O
) O
. O
[]

STUDY O
OBJECTIVE O
To O
compare O
the O
intraoperative O
conditions O
and O
postoperative O
recovery O
of O
patients O
following O
the O
use O
of O
either O
propofol-nitrous O
oxide O
( O
N2O O
) O
or O
enflurane-N2O O
for O
maintenance O
of O
outpatient O
anesthesia O
. O
[]

This O
enables O
one O
to O
differentiate O
between O
the O
curable B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
IIc I-outcome ['Physiological-Clinical']
and O
the O
stage B-outcome ['Physiological-Clinical']
III I-outcome ['Physiological-Clinical']
, O
showing O
the O
beginning O
of O
breakdown O
of O
the O
femoral B-outcome ['Physiological-Clinical']
head I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

123 O
patients O
were O
enrolled O
. O
[]

METHOD O
The O
authors O
conducted O
a O
multisite O
, O
two-part O
study O
of O
risperidone O
in O
children O
ages O
5 O
to O
17 O
years O
with O
autism O
accompanied O
by O
severe O
tantrums O
, O
aggression O
, O
and/or O
self-injurious O
behavior O
who O
showed O
a O
positive O
response O
in O
an O
earlier O
8-week O
trial O
. O
[]

However O
, O
the O
age O
of O
the O
subjects O
was O
found O
to O
be O
an O
intervening O
variable O
: O
The O
older O
subjects O
of O
both O
groups O
demonstrated O
a O
gradual O
but O
not O
significant O
decline O
in O
hypertonus O
, O
whereas O
the O
younger O
adults O
demonstrated O
a O
significant O
decline O
in O
hypertonus O
over O
a O
6-week O
period O
. O
[]

Simple O
mastoidectomies O
, O
radical O
mastoidectomies O
and O
tympano O
plastics O
were O
carried O
out O
in O
49 O
patients O
under O
the O
following O
randomised O
anaesthetic O
procedures O
: O
Group O
1 O
halothane O
anaesthesia O
and O
retroauricular O
infiltration O
anaesthesia O
with O
lidocaine O
and O
ornipressin O
( O
n O
= O
14 O
) O
, O
Group O
2 O
fentanyl O
anaesthesia O
and O
retroauricular O
anaesthesia O
with O
lidocaine O
and O
ornipressin O
( O
n O
= O
10 O
) O
, O
Group O
3 O
fentanyl O
anaesthesia O
and O
retroauricular O
infiltration O
anaesthesia O
with O
lidocaine O
and O
epinephrine O
( O
n O
= O
14 O
) O
, O
and O
Group O
4 O
retroauricular O
infiltration O
anaesthesia O
with O
prilocaine O
and O
epinephrine O
( O
n O
= O
14 O
) O
. O
[]

In O
addition O
, O
few O
students O
wore O
a O
hat O
with O
a O
wide O
brim O
when O
outside O
but O
not O
at O
school O
. O
[]

Extended O
surgery O
was O
often O
required O
. O
[]

5 O
. O
[]

We O
used O
multiple O
linear O
and O
logistic O
models O
to O
regress O
lesion O
risk O
and O
intima-media O
thickness O
on O
work-related B-outcome ['Life-Impact']
stress O
scores O
from O
a O
questionnaire O
administered O
at O
an O
18-month O
follow-up O
examination O
. O
['Life-Impact']

The O
treadmill O
exercise O
tests O
and O
subjective O
feelings O
were O
also O
assessed O
at O
day O
0 O
and O
day O
90 O
. O
[]

Patients O
in O
the O
splinting O
group O
received O
a O
prefabricated O
wrist O
working O
splint O
and O
were O
instructed O
to O
use O
this O
splint O
as O
much O
as O
possible O
during O
the O
day O
. O
[]

The O
two-dose O
regimen O
of O
POIO O
was O
the O
least O
amount O
necessary O
for O
effective O
results O
. O
[]

OBJECTIVE O
Restless O
legs O
syndrome O
( O
RLS O
) O
is O
a O
common O
neurologic O
condition O
characterized O
by O
uncomfortable O
and O
unpleasant O
sensations O
in O
the O
legs O
, O
occurring O
primarily O
at O
rest O
, O
which O
are O
usually O
worse O
in O
the O
evening O
and O
are O
alleviated O
by O
movement O
. O
[]

Thirteen O
cases O
were O
clinically O
controlled O
, O
with O
11 O
markedly O
effective O
, O
6 O
effective O
, O
and O
1 O
ineffective O
in O
the O
treatment O
group O
, O
while O
5 O
cases O
were O
clinically O
controlled O
, O
with O
11 O
markedly O
effective O
, O
10 O
effective O
, O
and O
4 O
ineffective O
in O
the O
control O
group O
. O
( O
[]

Blood O
samples O
were O
drawn O
at O
baseline O
, O
10 O
, O
20 O
, O
40 O
, O
and O
80 O
minutes O
, O
and O
histamine O
and O
the O
histamine-degrading O
enzyme O
diamine O
oxidase O
( O
DAO O
) O
were O
determined O
. O
[]

The O
TEF O
was O
2 O
% O
greater O
after O
the O
HP O
than O
after O
the O
LP O
meal O
at O
baseline O
( O
P O
< O
0.01 O
) O
and O
0.8 O
% O
greater O
at O
week O
16 O
( O
P=0.35 O
) O
. O
[]

Apparent B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
( O
afebrile O
at O
the O
end O
of O
therapy O
) O
occurred O
in O
all O
patients O
and O
parasitological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
in O
96 O
( O
100 O
% O
) O
, O
92 O
( O
96 O
% O
) O
and O
84 O
( O
88 O
% O
) O
patients O
respectively O
in O
groups O
A O
, O
B O
and O
C. O
Ultimate B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
( O
no O
relapse O
in O
six O
months O
of O
follow O
up O
) O
occurred O
in O
95 O
( O
99 O
% O
) O
, O
87 O
( O
91 O
% O
) O
and O
79 O
( O
82 O
% O
) O
patients O
in O
groups O
A O
, O
B O
and O
C O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Intraocular O
pressure O
changes O
with O
propofol O
( O
'Diprivan O
' O
) O
: O
comparison O
with O
thiopentone O
. O
[]

Double O
contrast O
arthrography O
of O
the O
knee O
. O
[]

Also O
, O
the O
arterial-jugular O
venous O
lactate O
difference O
increased O
from-0.03?0.01 O
mM O
at O
rest O
to O
3.2?0.9 O
mM O
( O
P O
< O
0.05 O
) O
and O
3.4?1.4 O
mM O
( O
P O
< O
0.05 O
) O
following O
the O
Sal O
and O
Bicarb O
trials O
, O
respectively O
. O
[]

SUBJECTS/SETTING O
Participants O
were O
625 O
fourth- O
through O
sixth-grade O
, O
low-income O
children O
living O
in O
San O
Antonio O
, O
Texas O
, O
and O
enrolled O
in O
the O
control O
arm O
of O
the O
Bienestar O
Diabetes O
Prevention O
Program O
's O
cluster O
randomized O
trial O
. O
[]

Sex B-outcome ['Physiological-Clinical']
hormones I-outcome ['Physiological-Clinical']
- I-outcome ['Physiological-Clinical']
17beta-estradiol I-outcome ['Physiological-Clinical']
, O
luteinizing B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( O
LH B-outcome ['Physiological-Clinical']
) O
, O
follicle-stimulating B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( O
FSH B-outcome ['Physiological-Clinical']
) O
, O
prolactin B-outcome ['Physiological-Clinical']
, O
testosterone B-outcome ['Physiological-Clinical']
, O
and O
dehydroepiandrosterone B-outcome ['Physiological-Clinical']
sulfate I-outcome ['Physiological-Clinical']
- O
were O
measured O
and O
the O
patients O
completed O
a O
neuropsychological O
test O
in O
the O
last O
two O
active O
drug O
and/or O
placebo O
phases O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
drug O
was O
well O
tolerated O
and O
there O
were O
no O
adverse B-outcome ['Adverse-effects']
side-effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

We O
found O
no O
evidence O
that O
the O
proportion O
of O
patients O
with O
events O
increased O
as O
the O
number O
of O
injections B-outcome ['Resource-use']
increased O
. O
['Resource-use']

CONCLUSIONS O
Stapled O
hemorrhoidectomy O
is O
a O
safe O
and O
effective O
day-care O
procedure O
for O
the O
treatment O
of O
grade O
III O
and O
grade O
IV O
hemorrhoids O
. O
[]

The O
measurement O
instruments O
were O
the O
visual O
analogue O
scale O
( O
VAS O
) O
and O
the O
aberrant B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
checklist O
( O
ABC O
) O
. O
['Life-Impact']

An O
economic O
analysis O
was O
performed O
, O
considering O
the O
cost O
of O
repeating O
studies O
in O
cases O
with O
faulty O
or O
inconclusive O
home O
studies O
( O
these O
patients O
should O
undergo O
polysomnography O
as O
a O
second O
step O
) O
. O
[]

The O
study O
was O
stopped O
after O
34 O
patients O
were O
included O
. O
[]

BACKGROUND O
Ropivacaine O
is O
a O
relatively O
new O
long-acting O
amide O
local O
anesthetic O
. O
[]

Some O
question O
whether O
they O
do O
not O
remove O
too O
much O
tooth O
substance O
. O
[]

The O
gel O
was O
applied O
directly O
to O
the O
calculus O
and O
subgingivally O
to O
the O
area O
to O
be O
scaled O
. O
[]

The O
long O
intracellular O
half-life O
of O
abacavir O
( O
ABC O
) O
supports O
its O
once-daily O
use O
, O
and O
this O
would O
be O
expected O
to O
simplify O
treatment O
if O
ABC O
could O
be O
given O
as O
part O
of O
a O
complete O
once-daily O
regimen O
. O
[]

Each O
communicative O
act O
is O
scored O
according O
to O
its O
form O
, O
function O
, O
role O
and O
complexity O
. O
[]

In O
30 O
patients O
with O
follow-up O
data O
the O
rate O
of O
change O
in O
hip B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
over O
a O
year O
was O
also O
determined O
by O
both O
methods O
. O
['Physiological-Clinical']

RESULTS O
Immediately O
after O
placement O
, O
the O
self-etching O
adhesive O
and O
its O
respective O
cement O
resulted O
in O
more O
suppression O
of O
cold B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
than O
no O
treatment O
( O
control O
) O
; O
with O
Linkmax O
treatment O
, O
the O
temperature O
at O
which O
teeth O
responded O
was O
reduced O
by O
8.4 O
degrees O
C. O
The O
conventionally O
etched O
adhesive O
and O
its O
cement O
reduced O
the O
temperature O
at O
which O
teeth B-outcome ['Physiological-Clinical']
responded I-outcome ['Physiological-Clinical']
by O
9.4 O
degrees O
C. O
After O
1 O
week O
, O
these O
temperature B-outcome ['Physiological-Clinical']
reductions I-outcome ['Physiological-Clinical']
were O
7.0 O
degrees O
C O
and O
4.3 O
degrees O
C O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

To O
achieve O
the O
accrual O
goal O
of O
140 O
subjects O
in O
this O
single O
institution O
study O
, O
the O
Wisconsin O
Cancer B-outcome ['Physiological-Clinical']
Reporting O
System O
( O
WCRS O
) O
, O
a O
population-based O
cancer O
registry O
, O
was O
used O
. O
['Physiological-Clinical']

BACKGROUND O
From O
2005 O
to O
2007 O
the O
Australian O
Government O
funded O
a O
multicentre O
, O
clustered O
randomized O
controlled O
trial O
to O
determine O
the O
clinical O
effectiveness O
, O
cost-effectiveness O
, O
satisfaction O
and O
safety O
of O
point O
of O
care O
testing O
( O
PoCT O
) O
in O
general O
practice O
( O
GP O
) O
. O
[]

The O
primary O
outcome O
was O
the O
between-group O
difference O
in O
improvement O
in O
pain B-outcome ['Physiological-Clinical']
at O
2 O
hours O
following O
the O
most O
recent O
ingestion O
of O
the O
study O
drug O
, O
relative O
to O
the O
time O
of O
phone O
contact O
after O
ED O
discharge O
. O
['Physiological-Clinical']

The O
rates O
of O
acute B-outcome ['Physiological-Clinical']
kidney I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
, O
gastrointestinal B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Eighteen O
months O
after O
cessation O
of O
therapy O
, O
the O
proportion O
of O
patients O
with O
Grade O
2 O
[]

In O
Group O
A O
, O
the O
MMC O
group O
received O
bolus O
intravenous O
injections O
of O
20 O
mg O
MMC O
on O
the O
day O
of O
operation O
and O
10 O
mg O
the O
next O
day O
, O
followed O
by O
10 O
mg O
every O
4 O
weeks O
until O
a O
total O
of O
100 O
mg O
had O
been O
administered O
. O
[]

MATERIAL O
AND O
METHODS O
This O
randomized O
open-label O
clinical O
trial O
was O
conducted O
to O
assess O
the O
effect O
of O
pravastatin O
20 O
mg O
on O
kidney O
function O
and O
urinary O
protein O
excretion O
in O
patients O
with O
ADPKD O
. O
[]

Our O
findings O
are O
consistent O
with O
a O
model O
, O
wherein O
the O
5-HT4R B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
adjusts O
to O
changes O
in O
the O
extracellular O
5-HT O
tonus O
. O
['Physiological-Clinical']

After O
the O
first O
interim O
analysis O
, O
the O
predicted O
probability O
of O
LTA O
having O
a O
significantly O
better O
overall O
survival O
than O
TH O
at O
the O
final O
analysis O
was O
only O
3.65 O
% O
, O
and O
the O
trial O
was O
closed O
immediately O
. O
[]

Oral B-outcome ['Physiological-Clinical']
mucositis B-outcome ['Physiological-Clinical']
was O
analyzed O
using O
the O
unadjusted O
chi-square O
test O
, O
and O
time O
to O
first B-outcome ['Physiological-Clinical']
episode I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
reproducibility O
of O
measurements O
under O
baseline O
was O
high O
, O
no O
changes O
were O
observed O
after O
systemically O
effective O
doses O
of O
phenylephrine O
or O
sodium O
nitroprusside O
. O
[]

Three O
products O
that O
promote O
a O
moist O
wound O
environment O
( O
polyurethane O
, O
hydrocolloid O
, O
hydrogel O
) O
and O
two O
standard O
plasters O
were O
randomly O
allocated O
to O
the O
test O
areas O
. O
[]

No O
significant O
differences O
were O
found O
in O
bond O
failure O
modes O
in O
the O
4 O
groups O
. O
[]

BACKGROUND O
Acne O
vulgaris O
is O
the O
most O
common O
skin O
disease O
and O
can O
pose O
a O
substantial O
therapeutic O
challenge O
. O
[]

Major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
more O
common O
in O
the O
aspirin O
group O
than O
in O
the O
placebo O
group O
( O
230 O
patients O
[ O
4.6 O
% O
] O
vs. O
188 O
patients O
[ O
3.8 O
% O
] O
; O
hazard O
ratio O
, O
1.23 O
; O
95 O
% O
CI O
, O
1.01 O
, O
to O
1.49 O
; O
P=0.04 O
) O
. O
['Physiological-Clinical']

TC=2297 O
( O
Archived O
by O
WebCite O
at O
http O
: O
//www.webcitation.org/65TkwoESp O
) O
. O
[]

We O
investigated O
the O
effects O
of O
statins O
upon O
development O
of O
brain B-outcome ['Physiological-Clinical']
infarct I-outcome ['Physiological-Clinical']
by O
performing O
a O
post-hoc O
analysis O
of O
the O
Regression O
of O
Cerebral O
Artery O
Stenosis O
( O
ROCAS O
) O
study O
. O
['Physiological-Clinical']

Using O
the O
chi2-test O
for O
overall O
association O
, O
this O
difference O
was O
statistically O
highly O
significant O
( O
p O
= O
0.002 O
) O
. O
[]

FINDINGS O
EMIAT O
enrolled O
1486 O
patients O
( O
743 O
in O
the O
amiodarone O
group O
, O
743 O
in O
the O
placebo O
group O
) O
. O
[]

CONCLUSIONS O
In O
undernourished O
older O
people O
, O
combined O
treatment O
with O
testosterone O
and O
nutritional O
supplementation O
reduced O
the O
number O
of O
people O
hospitalized O
and O
the O
duration O
of O
hospital O
admissions O
, O
which O
are O
important O
endpoints O
in O
this O
group O
. O
[]

For O
hypnosis O
, O
synergistic O
interaction O
was O
found O
( O
P O
less O
than O
0.01 O
) O
, O
the O
combination O
having O
1.44 O
times O
the O
potency O
of O
the O
individual O
agents O
. O
[]

METHODS O
Pregnant O
women O
with O
WHO O
stage O
1 O
, O
2 O
, O
or O
3 O
HIV-1 O
infection O
who O
had O
CD4 O
cell O
counts O
of O
200-500 O
cells O
per O
?L O
were O
enrolled O
at O
five O
study O
sites O
in O
Burkina O
Faso O
, O
Kenya O
, O
and O
South O
Africa O
to O
start O
study O
treatment O
at O
28-36 O
weeks O
' O
gestation O
. O
[]

The O
effect O
of O
systemic O
lidocaine O
on O
pain B-outcome ['Physiological-Clinical']
and O
secondary B-outcome ['Resource-use']
hyperalgesia I-outcome ['Resource-use']
associated O
with O
the O
heat/capsaicin O
sensitization O
model O
in O
healthy O
volunteers O
. O
['Physiological-Clinical', 'Resource-use']

Piritramide B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
was O
identical O
in O
both O
groups O
( O
19.7 O
+/- O
16 O
mg O
vs. O
19.8 O
+/- O
19 O
mg O
) O
. O
['Resource-use']

RESULTS O
Thirty-six O
patients O
were O
evaluable O
for O
efficacy O
assessment O
. O
[]

To O
evaluate O
efficacy O
and O
safety O
of O
levosulpiride O
in O
short-term O
treatment O
, O
1298 O
patients O
were O
enrolled O
in O
a O
double-blind O
multicentric O
study O
carried O
out O
in O
45 O
Italian O
Gastroenterology O
Departments O
. O
[]

Gastric O
ulcer O
treatment O
with O
intravenous O
human O
epidermal O
growth O
factor O
: O
a O
double-blind O
controlled O
clinical O
study O
. O
[]

Between O
1981 O
and O
1987 O
, O
533 O
patients O
from O
9 O
institutions O
have O
been O
entered O
in O
a O
randomized O
trial O
to O
assess O
the O
value O
of O
adjuvant O
portal O
infusion O
( O
5-Fluorouracil O
, O
Mitomycin O
C O
) O
compared O
to O
radical O
surgery O
alone O
. O
[]

Phase O
III O
trial O
of O
induction O
gemcitabine O
or O
paclitaxel O
plus O
carboplatin O
followed O
by O
paclitaxel O
consolidation O
in O
ovarian O
cancer O
. O
[]

The O
study O
was O
repeated O
when O
the O
patients O
were O
in O
the O
euthyroid O
state O
. O
[]

Acupuncture O
is O
becoming O
a O
common O
technique O
within O
the O
physiotherapy O
profession O
as O
a O
treatment O
modality O
for O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
; O
however O
, O
few O
randomised O
controlled O
trials O
have O
been O
undertaken O
to O
assess O
the O
effectiveness O
of O
acupuncture O
, O
particularly O
in O
the O
treatment O
of O
osteoarthritis O
( O
OA O
) O
of O
the O
hip O
. O
['Physiological-Clinical']

The O
results O
of O
the O
study O
say O
that O
prostamol O
Uno O
in O
a O
dose O
320 O
mg/day O
can O
prevent O
PA O
progression O
without O
side O
effects O
. O
[]

The O
MTLC O
component O
can O
not O
support O
recall O
, O
but O
one O
can O
extract O
a O
scalar O
familiarity O
signal O
from O
MTLC O
that O
tracks O
how O
well O
a O
test O
item O
matches O
studied O
items O
. O
[]

Pupil O
diameter O
was O
greater O
than O
7 O
mm O
in O
all O
patients O
( O
100 O
% O
) O
. O
[]

On O
D28 O
, O
the O
[]

There O
was O
no O
difference O
between O
the O
treatment O
regimens O
in O
antibiotic B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
, O
and O
serious B-outcome ['Physiological-Clinical']
superinfection I-outcome ['Physiological-Clinical']
occurred O
only O
in O
group O
2 O
patients O
( O
21 O
per O
cent O
of O
trials O
) O
, O
equally O
divided O
between O
treatment O
arms O
. O
['Adverse-effects', 'Physiological-Clinical']

Children O
with O
National O
Cancer O
Institute O
standard-risk O
ALL O
were O
randomly O
assigned O
in O
a O
2 O
x O
2 O
factorial O
design O
to O
receive O
dexamethasone O
( O
6 O
mg/m O
( O
2 O
) O
/d O
) O
for O
28 O
days O
in O
induction O
, O
plus O
taper O
, O
compared O
with O
prednisone O
( O
40 O
mg/m O
( O
2 O
) O
/d O
) O
. O
[]

RESULTS O
In O
all O
, O
80 O
% O
of O
children O
had O
achieved O
functional B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
of O
spoken O
language B-outcome ['Life-Impact']
with O
baseline O
play O
level O
predicting O
spoken O
language O
at O
the O
5-year O
follow-up O
. O
['Life-Impact', 'Life-Impact']

Erythropoietin B-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
was O
approximately O
ten O
times O
greater O
for O
IV O
dosing O
than O
for O
subcutaneous O
dosing O
. O
['Physiological-Clinical']

The O
effect O
on O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
tended O
to O
be O
greater O
than O
the O
effect O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Study O
and O
Control O
groups O
were O
equivalent O
in O
gender O
distribution O
, O
mean O
academic O
ability O
, O
pre-test O
performance O
and O
time O
studying O
leukaemia O
during O
the O
trial O
. O
[]

Promoting O
physical O
activity O
in O
patients O
with O
colon O
adenomas O
: O
a O
randomized O
pilot O
intervention O
trial O
. O
[]

However O
, O
a O
recent O
randomized O
trial O
showed O
that O
sulindac O
, O
when O
compared O
with O
placebo O
, O
failed O
to O
prevent O
the O
development O
of O
adenomatous O
polyps O
in O
genotypically O
positive O
but O
phenotypically O
negative O
FAP O
patients O
. O
[]

RESULTS O
Overall O
, O
58 O
% O
of O
the O
36 O
patients O
assigned O
to O
AMB O
successfully O
completed O
prophylaxis O
compared O
with O
80 O
% O
of O
the O
41 O
patients O
assigned O
to O
FLU O
( O
< O
0.05 O
) O
. O
[]

All O
outcomes O
were O
assessed O
by O
a O
blinded O
outcomes O
researcher O
using O
a O
standardised O
outcomes O
measurement O
tool O
developed O
specifically O
for O
this O
population O
. O
[]

After O
excavation O
, O
the O
cavities O
were O
analyzed O
using O
: O
( O
a O
) O
the O
tactile B-outcome ['Physiological-Clinical']
method I-outcome ['Physiological-Clinical']
, O
( O
b O
) O
caries-detection B-outcome ['Physiological-Clinical']
dye I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
stain I-outcome ['Physiological-Clinical']
demineralized I-outcome ['Physiological-Clinical']
dentin I-outcome ['Physiological-Clinical']
, O
as O
proposed O
by O
Smales O
& O
Fang O
, O
and O
( O
c O
) O
Demineralized O
Tissue B-outcome ['Physiological-Clinical']
Removal I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
, O
as O
proposed O
in O
this O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
Western O
countries O
, O
numerous O
reports O
are O
available O
in O
effectiveness O
studies O
, O
which O
are O
related O
to O
olanzapine O
and O
risperidone O
primarily O
, O
whereas O
evidence O
for O
other O
second-generation O
antipsychotics O
( O
SGAs O
) O
is O
poor O
. O
[]

The O
individuals O
in O
the O
control O
group O
( O
n O
= O
29 O
) O
continued O
their O
usual O
care O
. O
[]

APC O
was O
also O
used O
to O
measure O
the O
effects O
of O
treatment O
on O
hepatic B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Findings O
indicate O
IBD O
patients O
may O
benefit O
from O
relaxation O
training O
in O
their O
holistic O
care O
. O
[]

No O
major O
side O
effects O
were O
noted O
in O
any O
of O
the O
groups O
either O
. O
[]

A O
total O
of O
63 O
patients O
were O
randomized O
into O
two O
groups O
, O
the O
THP O
group O
and O
the O
control O
group O
. O
[]

BACKGROUND O
Seborrhoeic O
dermatitis O
is O
a O
chronic O
inflammatory O
disease O
with O
remissions O
and O
exacerbations O
, O
characterized O
by O
erythema O
, O
scaling O
and O
pruritus O
primarily O
on O
the O
face O
, O
scalp O
and O
chest O
. O
[]

A O
report O
on O
the O
first O
600 O
cases O
in O
a O
cooperative O
programme O
to O
carry O
out O
a O
systematic O
study O
( O
1974-1977 O
) O
( O
author O
's O
transl O
) O
] O
. O
[]

Linking O
organized O
medical O
care O
with O
complementary O
community-based O
interventions O
may O
be O
a O
promising O
direction O
for O
research O
and O
practice O
. O
[]

CONCLUSIONS O
Interventions O
focusing O
on O
reducing O
EE O
and O
[]

Evaluation O
of O
an O
intervention O
to O
change O
benzodiazepine-prescribing O
behavior O
in O
a O
prepaid O
group O
practice O
setting O
. O
[]

We O
hypothesized O
that O
initiating O
oral O
nutrition O
with O
a O
low-fat O
solid O
diet O
( O
LFSD O
) O
after O
mild O
pancreatitis O
would O
be O
well O
tolerated O
and O
would O
result O
in O
a O
shorter O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
( O
LOH O
) O
. O
['Resource-use']

The O
objective O
response O
rate O
to O
FAC O
was O
46 O
% O
versus O
44 O
% O
to O
FEC O
. O
[]

Development O
of O
renal O
disease O
in O
people O
at O
high O
cardiovascular O
risk O
: O
results O
of O
the O
HOPE O
randomized O
study O
. O
[]

Effect O
of O
daily O
etidronate O
on O
the O
osteolysis O
of O
multiple O
myeloma O
. O
[]

AIM O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
impact O
on O
pain O
and O
anxiety O
of O
the O
combination O
of O
an O
anxiolytic O
and O
an O
analgesic O
as O
compared O
with O
an O
analgesic O
alone O
in O
the O
prehospital O
setting O
of O
suspected O
ACS O
. O
[]

RESULTS O
Immunogenicity B-outcome ['Physiological-Clinical']
and O
protective B-outcome ['Physiological-Clinical']
rate O
of O
vaccine O
were O
still O
kept O
well O
11 O
years O
after O
immunization O
with O
a O
protective B-outcome ['Physiological-Clinical']
rate O
against O
HBV O
infection O
of O
73.5 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Recommending O
snacks O
or O
not O
between O
meals O
does O
not O
influence O
1-year O
weight O
[]

Sequential O
therapy O
versus O
standard O
triple-drug O
therapy O
for O
Helicobacter O
pylori O
eradication O
: O
a O
randomized O
study O
. O
[]

Secretin O
, O
a O
gastrointestinal O
( O
GI O
) O
hormone O
, O
was O
reported O
in O
a O
preliminary O
study O
to O
improve O
language B-outcome ['Life-Impact']
and O
behavior B-outcome ['Life-Impact']
in O
children O
with O
autism/pervasive O
developmental O
disorder O
( O
PDD O
) O
and O
chronic O
diarrhea O
. O
['Life-Impact', 'Life-Impact']

Effects O
of O
flumazenil O
on O
cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
oxygen B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
after O
midazolam O
anaesthesia O
for O
craniotomy O
. O
['Physiological-Clinical', 'Resource-use']

The O
progression B-outcome ['Physiological-Clinical']
rates O
were O
not O
different O
between O
the O
topical O
therapies O
, O
but O
were O
significantly O
higher O
in O
grade O
3 O
than O
in O
grade O
2 O
cases O
. O
['Physiological-Clinical']

Primary O
non-resectable O
liver O
malignancies O
show O
the O
best O
results O
after O
chemoembolisation O
( O
Frankfurt O
method O
) O
. O
[]

717 O
N O
) O
than O
for O
NHL O
( O
2710 O
? O
[]

Renal O
function O
was O
studied O
in O
18 O
patients O
with O
Type O
1 O
diabetes O
mellitus O
. O
[]

Data O
on O
162 O
women O
( O
90 O
premenopausal O
and O
72 O
postmenopausal O
) O
with O
metastatic O
breast O
cancer O
randomized O
to O
receive O
cyclophosphamide O
, O
Adriamycin O
( O
doxorubicin O
) O
and O
5-fluorouracil O
( O
CAF O
) O
on O
two O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
protocols O
were O
analyzed O
. O
[]

We O
measured O
the O
concentration O
of O
extracellular B-outcome ['Physiological-Clinical']
glycerol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EGC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
adipose I-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
in O
response O
to O
( O
1 O
) O
pharmacologic O
stimulation O
with O
isoprenaline O
( O
1 O
and O
10 O
micromol/L O
) O
in O
situ O
, O
( O
2 O
) O
stimulation O
with O
intravenous O
infusion O
of O
epinephrine O
( O
0.0375 O
microg/min/kg O
body O
weight O
) O
, O
and O
( O
3 O
) O
submaximal O
aerobic O
exercise O
( O
50 O
% O
V*O2max O
, O
60-minute O
duration O
) O
. O
['Physiological-Clinical']

Untoward O
effects O
of O
fenfluramine O
in O
autistic O
children O
. O
[]

The O
program O
was O
designed O
to O
be O
easy O
to O
use O
, O
require O
little O
provider O
or O
family O
time O
, O
effectively O
reduce O
negative O
behaviors B-outcome ['Life-Impact']
, O
and O
increase O
blood B-outcome ['Life-Impact']
draw I-outcome ['Life-Impact']
compliance I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

2 O
neurotoxicity O
was O
40 O
% O
and O
45 O
% O
, O
respectively O
( O
p O
= O
0.22 O
) O
. O
[]

Both O
drugs O
exhibited O
comparable O
and O
significant O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
['Physiological-Clinical']

Holter O
monitoring O
could O
not O
be O
used O
as O
an O
early O
predictor O
of O
late O
coronary O
restenosis O
. O
[]

OBJECTIVE O
We O
postulated O
that O
asymptomatic O
ongoing O
allergen O
exposure O
could O
drive O
airway O
inflammation O
as O
well O
as O
changes O
in O
the O
extracellular O
matrix O
( O
ECM O
) O
, O
and O
that O
inhaled O
steroids O
could O
prevent O
this O
. O
[]

Individuals O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
have O
pervasive O
impairments O
in O
social O
functioning O
, O
which O
may O
include O
problems O
with O
processing O
and O
remembering O
faces O
. O
[]

Changes O
in O
metabolic B-outcome ['Physiological-Clinical']
variables O
did O
not O
differ O
between O
the O
groups O
, O
except O
for O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
that O
increased O
in O
the O
3M O
group O
but O
not O
in O
3+3M O
group O
( O
P O
< O
0.033 O
for O
group O
difference O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Induction O
of O
anaesthesia O
was O
followed O
by O
a O
fall O
in O
oxygen B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
( O
NA O
group O
from O
221 O
to O
163 O
ml O
X O
min-1 O
; O
epidural O
group O
from O
230 O
to O
189 O
ml O
X O
min-1 O
) O
which O
appears O
to O
be O
delayed O
in O
the O
epidural O
group O
, O
with O
a O
short O
lasting O
statistically O
significant O
difference O
between O
the O
groups O
after O
eventration O
of O
the O
gut O
( O
NA O
group O
: O
162 O
ml O
X O
min-1 O
less O
than O
epidural O
group O
184 O
ml O
X O
min-1 O
) O
. O
['Physiological-Clinical']

They O
were O
then O
given O
750 O
ml O
of O
stored O
plasma O
, O
750 O
ml O
of O
fresh O
frozen O
plasma O
, O
and O
then O
an O
infusion O
of O
angiotensin O
II O
, O
in O
random O
order O
on O
successive O
days O
. O
[]

Isometric O
back O
extensor O
strength O
, O
spinal O
range O
of O
motion O
, O
and O
scores O
for O
quality O
of O
life O
were O
evaluated O
at O
baseline O
and O
4 O
months O
. O
[]

Basal O
levels O
of O
9-cis O
beta-carotene O
in O
plasma O
, O
PLT O
, O
and O
MN O
were O
low O
and O
found O
as O
one-tenth O
, O
one-fifth O
, O
and O
one-fifth O
of O
all-trans O
beta-carotene O
, O
which O
increased O
three- O
, O
two- O
, O
and O
1.5-fold O
the O
baseline O
, O
respectively O
. O
[]

The O
effect O
of O
a O
combined O
intervention O
including O
MP O
plus O
a O
nursing O
telephone O
intervention O
( O
NTI O
) O
was O
also O
assessed O
. O
[]

74 O
patients O
were O
availble O
to O
be O
analysis O
. O
[]

Each O
coronary O
segment O
was O
evaluated O
for O
image B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
on O
a O
4-point O
scale O
. O
['Life-Impact']

BACKGROUND O
Ventricular O
arrhythmias O
are O
a O
major O
cause O
of O
death O
after O
myocardial O
infarction O
, O
especially O
in O
patients O
with O
poor O
left-ventricular O
function O
. O
[]

INTERVENTION O
( O
S O
) O
Performing O
IVF O
and O
ICSI O
on O
sibling O
oocytes O
. O
[]

However O
, O
this O
could O
not O
be O
confirmed O
using O
estimates O
from O
the O
Bergman O
Minimal O
Model O
, O
perhaps O
because O
of O
our O
small O
sample O
size O
. O
[]

Five O
patients O
had O
a O
relapse B-outcome ['Physiological-Clinical']
: O
four O
of O
these O
were O
in O
the O
group O
with O
no O
further B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

CONCLUSION O
The O
CPRV O
allows O
reliable B-outcome ['Physiological-Clinical']
cuff I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
at O
various O
pressure O
levels O
and O
reliably O
prevents O
cuff B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
increases O
caused O
by O
N2O O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Both O
groups O
received O
similar O
doses O
of O
midazolam O
( O
4.2 O
+/- O
2.7 O
mg O
vs O
4.4 O
+/- O
2.8 O
mg O
, O
P O
= O
NS O
) O
and O
both O
reported O
a O
similar O
discomfort B-outcome ['Physiological-Clinical']
score O
in O
( O
0.9 O
+/- O
1.3 O
vs O
1.1 O
+/- O
1.8 O
, O
P O
= O
NS O
) O
. O
['Physiological-Clinical']

Vilazodone O
had O
no O
significant O
effect O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
PR B-outcome ['Physiological-Clinical']
, O
or O
QRS B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

min O
( O
-1 O
) O
) O
were O
randomised O
to O
no-exercise O
or O
to O
a O
bout O
of O
treadmill O
exercise O
at O
45 O
% O
, O
55 O
% O
, O
65 O
% O
or O
75 O
% O
[ O
Vdot O
] O
O O
( O
2 O
) O
max O
in O
a O
crossover O
design O
. O
[]

Subjects O
are O
randomly O
assigned O
to O
either O
the O
treatment O
group O
or O
to O
the O
control O
group O
. O
[]

The O
anti-stigma O
program O
improved O
the O
knowledge O
and O
attitudes O
, O
but O
not O
the O
behavioural O
intentions O
of O
participants O
towards O
their O
peers O
with O
autism O
. O
[]

Between O
September O
1993 O
and O
February O
1996 O
, O
56 O
eligible O
and O
evaluable O
patients O
were O
entered O
: O
27 O
were O
randomised O
to O
receive O
FAMTX O
before O
surgery O
and O
29 O
to O
undergo O
surgery O
only O
. O
[]

Groups O
II O
, O
III O
and O
IV O
were O
comparable O
with O
regards O
to O
duration O
of O
postoperative B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
and O
total O
analgesic B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
( O
P O
> O
0.05 O
) O
. O
['Resource-use', 'Resource-use']

Relatives O
of O
the O
project O
group O
patients O
were O
significantly O
more O
satisfied B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
than O
control O
group O
relatives O
. O
['Life-Impact']

RESULTS O
After O
a O
mean O
follow-up O
of O
31 O
months O
, O
46 O
% O
of O
patients O
included O
in O
Group O
I O
versus O
18 O
% O
of O
patients O
included O
in O
Group O
II O
restarted O
sinus B-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
( O
p O
= O
0.06 O
) O
. O
['Physiological-Clinical']

The O
hazard O
ratio O
for O
hospitalization B-outcome ['Resource-use']
was O
1.50 O
for O
the O
dialysis O
group O
( O
95 O
% O
CI O
, O
1.11 O
to O
2.01 O
; O
P O
< O
0.01 O
) O
. O
['Resource-use']

Sexually O
abstinent O
women O
applied O
gel O
once O
or O
twice O
daily O
and O
sexually O
active O
women O
used O
gel O
once O
daily O
. O
[]

The O
antiischemic B-outcome ['Physiological-Clinical']
effects O
were O
documented O
by O
relief B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
reduction O
of O
ST-depression B-outcome ['Physiological-Clinical']
, O
improvement O
of O
impaired O
myocardial B-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
, O
decrease O
to O
normalization O
of O
pathologically B-outcome ['Physiological-Clinical']
elevated I-outcome ['Physiological-Clinical']
filling I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
amelioration O
of O
coronary B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
as O
evidenced O
by O
myocard O
scintigraphy O
and O
washout O
time O
of O
an O
intracoronarily O
injected O
echo-contrast O
medium O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Secondary O
end O
points O
were O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
, O
overall O
survival B-outcome ['Mortality']
( O
OS B-outcome ['Mortality']
) O
, O
and O
safety O
. O
['Mortality', 'Mortality', 'Mortality']

Metoprolol O
CR/XL O
improves O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
chronic O
heart O
failure O
. O
['Physiological-Clinical']

From O
September O
1993 O
to O
November O
1995 O
, O
57 O
patients O
were O
recruited O
and O
randomized O
to O
either O
video-assisted O
thoracoscopic O
talc O
insufflation O
under O
general O
anesthesia O
( O
n O
= O
28 O
) O
or O
talc O
slurry O
by O
the O
bedside O
( O
n O
= O
29 O
) O
. O
[]

BACKGROUND O
Ketorolac O
is O
a O
parenteral O
nonsteroidal O
antiinflammatory O
drug O
( O
NSAID O
) O
. O
[]

RESULTS O
In O
the O
early-pregnancy O
group O
, O
3-HIA B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
decreased O
( O
P O
< O
0.006 O
) O
by O
11.7 O
+/- O
3.6 O
mmol/mol O
creatinine O
( O
mean O
+/- O
SEM O
) O
in O
the O
5 O
women O
who O
received O
biotin O
supplements O
, O
whereas O
3-HIA B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
increased O
by O
1.6 O
+/- O
0.6 O
mmol/mol O
creatinine O
in O
the O
5 O
women O
who O
received O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Despite O
this O
, O
recent O
trends O
in O
modern O
life-styles O
have O
raised O
obstacles O
to O
successful O
lactation O
. O
[]

A O
single O
pegfilgrastim O
dose O
( O
> O
or O
=6 O
mg O
) O
could O
be O
substituted O
for O
daily O
filgrastim O
in O
[]

Assessment O
did O
not O
moderate O
intervention O
effects O
. O
[]

Only O
hoarseness B-outcome ['Physiological-Clinical']
was O
more O
frequent O
in O
the O
LTS O
group O
. O
['Physiological-Clinical']

The O
Social O
Communication O
Intervention O
Project O
: O
a O
randomized O
controlled O
trial O
of O
the O
effectiveness O
of O
speech O
and O
language O
therapy O
for O
school-age O
children O
who O
have O
pragmatic O
and O
social O
communication O
problems O
with O
or O
without O
autism O
spectrum O
disorder O
. O
[]

These O
differences O
persisted O
even O
after O
controlling O
for O
condition O
severity O
, O
personal O
characteristics O
, O
and O
insurance O
status O
. O
[]

The O
five O
countries O
sampled O
lie O
on O
an O
axis O
from O
northern O
to O
southern O
Europe O
with O
a O
steep O
gradient O
in O
terms O
of O
premature O
heart O
disease O
. O
[]

There O
were O
30 O
patients O
in O
each O
group O
: O
Group O
1 O
, O
physiological O
saline O
30 O
mL O
; O
Group O
2 O
, O
bupivacaine O
0.25 O
% O
30 O
mL O
; O
Group O
3 O
, O
bupivacaine O
0.25 O
% O
30 O
mL O
plus O
morphine O
2 O
mg O
. O
[]

Adverse O
events O
such O
as O
line O
/ O
filter O
coagulation O
, O
rupture O
and O
bleeding O
were O
also O
investigated O
and O
compared O
due O
to O
frequency O
and O
severity O
between O
the O
2 O
groups O
. O
[]

The O
question O
of O
which O
is O
the O
optimum O
technique O
to O
intubate O
the O
trachea O
in O
a O
patient O
who O
may O
have O
a O
cervical O
( O
C O
) O
-spine O
injury O
remains O
unresolved O
. O
[]

The O
antihypertensive O
effects O
of O
the O
oral O
converting O
enzyme O
inhibitor O
captopril O
and O
of O
propranolol O
were O
evaluated O
in O
a O
single-blind O
trial O
of O
12 O
weeks O
in O
19 O
ambulatory O
men O
with O
moderated O
essential O
hypertension O
( O
supine B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
DPB I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
, O
100 O
to O
120 O
mm O
Hg O
after O
receiving O
placebo O
for O
two O
weeks O
) O
whose O
sodium O
intake O
was O
unrestricted O
. O
['Physiological-Clinical']

Pregnancy O
rate O
, O
time O
to O
conception O
, O
and O
rate O
of O
endometrioma O
recurrence O
was O
similar O
in O
the O
2 O
study O
groups O
. O
[]

A O
total O
of O
204 O
patients O
with O
probable O
Alzheimer O
's O
disease O
were O
included O
in O
the O
study O
. O
[]

Using O
backward O
elimination O
, O
we O
derived O
a O
risk O
scoring O
algorithm O
( O
range O
0-63 O
) O
from O
the O
final O
reduced O
model O
. O
[]

After O
a O
minimum O
of O
4 O
yr O
of O
GH O
treatment O
, O
at O
a O
mean O
age O
of O
12.7 O
+/- O
0.7 O
yr O
, O
low O
dose O
micronized O
17beta-estradiol O
was O
given O
orally O
. O
[]

The O
interventions O
that O
have O
been O
tested O
with O
health O
care O
professionals O
and O
published O
have O
several O
limitations O
that O
must O
be O
surpassed O
( O
i.e O
. O
[]

Different O
therapeutic O
modalities O
for O
treatment O
of O
melasma O
. O
[]

At O
24 O
weeks O
, O
pain B-outcome ['Physiological-Clinical']
remained O
['Physiological-Clinical']

The O
tailored O
materials O
had O
a O
significant O
effect O
on O
overall B-outcome ['Life-Impact']
sun-protection I-outcome ['Life-Impact']
habits I-outcome ['Life-Impact']
, O
the B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
hats I-outcome ['Life-Impact']
, O
the B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
sunglasses I-outcome ['Life-Impact']
, O
and O
the B-outcome ['Life-Impact']
recency B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
skin I-outcome ['Life-Impact']
self-examination I-outcome ['Life-Impact']
. O
['Life-Impact']

In O
this O
single-center O
study O
, O
patients O
who O
experienced O
a O
total O
of O
247 O
febrile O
episodes O
were O
prospectively O
randomized O
to O
receive O
either O
our O
standard O
regimen O
, O
ceftazidime O
3 O
g/day O
( O
1 O
g O
t.i.d O
. O
) O
[]

Genome-wide O
association O
has O
identified O
groups O
of O
genomic O
markers O
associated O
with O
successful O
quitting O
, O
allowing O
us O
to O
develop O
a O
v1.0 O
quit-success O
genotype O
score O
. O
[]

There O
was O
no O
difference O
in O
patients O
' O
subjective O
evaluation O
of O
satisfaction O
and O
discomfort O
between O
the O
early O
or O
delayed O
reinfusion O
groups O
as O
determined O
by O
blinded O
interview O
on O
days O
1 O
, O
3 O
, O
5 O
, O
and O
7 O
postoperatively O
. O
( O
[]

However O
, O
for O
some O
specific O
working O
tasks O
, O
advantages O
in O
process O
optimisation O
and O
operator O
support O
were O
observed O
. O
[]

Conversely O
, O
plasma B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
increased O
and O
blood B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
used O
a O
randomized O
controlled O
trial O
to O
evaluate O
the O
efficacy O
of O
RIT O
on O
elicited O
and O
spontaneous O
imitation B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
21 O
young O
children O
with O
autism O
. O
['Life-Impact']

This O
post O
hoc O
analysis O
evaluated O
the O
secondary O
endpoint O
of O
CV B-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
and O
the O
clinical B-outcome ['Physiological-Clinical']
benefit O
of O
dronedarone O
on O
the O
number O
and O
duration O
of O
CV B-outcome ['Resource-use']
hospitalizations I-outcome ['Resource-use']
in O
patients O
with O
atrial O
fibrillation O
( O
AF O
) O
. O
['Resource-use', 'Physiological-Clinical', 'Resource-use']

There O
were O
significantly O
more O
treatment O
failures O
for O
active B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
using O
EL O
( O
42 O
% O
vs. O
0 O
% O
; O
P O
=.027 O
) O
and O
esophageal B-outcome ['Physiological-Clinical']
stricture I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
in O
the O
ES-treated O
patients O
( O
19.4 O
% O
vs. O
2.9 O
% O
; O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
in O
terms O
of O
neuropsychological B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
indicated O
by O
computed O
tomography O
brain O
scans O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
objective O
of O
this O
research O
was O
to O
explore O
the O
effects O
of O
risperidone O
on O
cognitive B-outcome ['Life-Impact']
processes I-outcome ['Life-Impact']
in O
children O
with O
autism O
and O
irritable O
behavior O
. O
['Life-Impact']

RESULTS O
Uveitis B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
was O
reduced O
in O
implanted O
eyes O
from O
62 O
% O
( O
during O
the O
1-year O
preimplantation O
period O
) O
to O
4 O
% O
, O
10 O
% O
, O
and O
20 O
% O
during O
the O
1- O
, O
2- O
, O
and O
3-year O
postimplantation O
periods O
, O
respectively O
, O
for O
the O
0.59-mg O
dose O
group O
( O
P O
< O
.01 O
) O
and O
from O
58 O
% O
to O
7 O
% O
, O
17 O
% O
, O
and O
41 O
% O
, O
respectively O
, O
for O
the O
2.1-mg O
dose O
group O
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical']

The O
experimental O
group O
( O
n O
= O
15 O
) O
received O
ASTM O
twice O
a O
week O
for O
5 O
weeks O
. O
[]

Interindividual O
BP O
variability O
during O
treatment O
shows O
marked O
quantitative O
differences O
with O
intraindividual O
BP O
variability O
questioning O
whether O
its O
use O
can O
accurately O
reflect O
individual O
BP O
variations O
from O
one O
visit O
to O
another O
. O
[]

Citalopram O
was O
well O
tolerated O
, O
the O
few O
side-effects O
being O
mild O
and O
transient O
. O
[]

Throughout O
the O
study O
smokers O
were O
more O
likely O
to O
dropout O
than O
non-smokers O
. O
[]

The O
treatment O
ratios O
of O
AUC O
and O
associated O
90 O
% O
confidence O
intervals O
( O
CIs O
) O
for O
risperidone O
active O
moiety O
, O
defined O
as O
risperidone O
plus O
9-hydroxyrisperidone O
( O
ratio O
= O
110.2 O
% O
; O
90 O
% O
CI O
= O
103.7-117.2 O
) O
, O
and O
for O
donepezil O
( O
ratio O
= O
97.1 O
% O
; O
90 O
% O
CI O
= O
90.0-103.6 O
) O
were O
within O
the O
80 O
% O
to O
125 O
% O
of O
bioequivalence O
range O
. O
[]

One O
of O
3 O
levels O
of O
lactoferrin O
was O
supplemented O
from O
3 O
to O
56 O
d O
in O
either O
whole O
milk O
or O
water O
to O
produce O
3 O
dietary O
treatments O
: O
1 O
) O
0 O
g/d O
, O
2 O
) O
0.5 O
g/d O
, O
and O
3 O
) O
1 O
g/d O
. O
[]

Both O
peripheral O
and O
central O
mechanisms O
have O
been O
proposed O
. O
[]

To O
sort O
out O
this O
heterogeneity O
in O
autism O
, O
we O
investigated O
whether O
specific B-outcome ['Physiological-Clinical']
neurobiological I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
vary O
in O
parallel O
to O
core B-outcome ['Physiological-Clinical']
symptomatology I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
subjects O
ingested O
rye O
bran O
enriched O
breads O
equivalent O
to O
approximately O
10.2 O
mg O
ferulic O
acid O
per O
day O
. O
[]

Three O
experiments O
compared O
the O
timing O
performance O
of O
humans O
on O
a O
modified O
temporal O
generalization O
task O
with O
1 O
, O
3 O
, O
or O
5 O
presentations O
of O
the O
standard O
duration O
. O
[]

Culturally O
and O
linguistically O
appropriate O
interventions O
are O
necessary O
to O
increase O
hepatitis B-outcome ['Life-Impact']
B I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
, O
serologic B-outcome ['Physiological-Clinical']
testing O
, O
and O
vaccination B-outcome ['Resource-use']
among O
Cambodian O
Americans O
. O
['Life-Impact', 'Physiological-Clinical', 'Resource-use']

The O
Autism O
Research O
Units O
on O
Pediatric O
Psychopharmacology O
( O
RUPP O
Autism O
Network O
) O
resolved O
some O
of O
these O
problems O
during O
the O
design O
of O
a O
risperidone O
RCT O
in O
children/adolescents O
. O
[]

METHODS O
Patients O
undergoing O
mini-incision O
thyroidectomy O
under O
local O
anesthesia O
were O
prospectively O
randomized O
for O
either O
nerve O
monitoring O
of O
the O
EBSLN O
( O
group O
1 O
) O
or O
no O
nerve O
monitoring O
( O
group O
2 O
) O
. O
[]

Chemotherapy O
for O
patients O
with O
non-small O
cell O
lung O
cancer O
: O
the O
surgical O
setting O
of O
the O
Big O
Lung O
Trial O
. O
[]

3 O
. O
[]

In O
addition O
, O
after O
its O
first O
use O
, O
acceptance O
of O
this O
new B-outcome ['Life-Impact']
medium I-outcome ['Life-Impact']
rose O
dramatically O
. O
['Life-Impact']

Low O
power O
Ga-Al-As O
laser O
treatment O
of O
painful B-outcome ['Physiological-Clinical']
osteoarthritis I-outcome ['Physiological-Clinical']
of O
the O
knee O
. O
['Physiological-Clinical']

Similar O
effects O
of O
rofecoxib O
and O
indomethacin O
on O
the O
incidence O
of O
heterotopic O
ossification O
after O
hip O
arthroplasty O
. O
[]

RESULTS O
Risperidone O
led O
to O
a O
significant O
greater O
reduction O
on O
CGI O
scale O
. O
[]

Continuous O
epidural O
anesthesia O
with O
C O
, O
L O
or O
M O
appears O
safe O
and O
effective O
for O
outpatient O
surgical O
procedures O
such O
as O
ESWL O
. O
[]

The O
median O
effect O
size O
in O
this O
trial O
was O
-0.015 O
( O
seizure O
rate O
increased O
by O
1.5 O
% O
in O
the O
phenytoin O
group O
) O
, O
95 O
% O
probability O
interval O
-0.127 O
to O
0.091 O
( O
12.7 O
% O
higher O
rate O
of O
posttraumatic B-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
to O
a O
9.1 O
% O
lower O
rate O
of O
posttraumatic O
seizures O
with O
phenytoin O
) O
. O
['Physiological-Clinical']

Thirteen O
patients O
( O
5 O
in O
group O
A O
and O
8 O
in O
group O
B O
) O
died B-outcome ['Mortality']
before O
day O
120 O
( O
p=0.3 O
) O
. O
['Mortality']

A O
pilot O
study O
to O
improve O
venipuncture B-outcome ['Life-Impact']
compliance I-outcome ['Life-Impact']
in O
children O
and O
adolescents O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

In O
both O
groups O
plasma O
levels O
of O
fibrinogen O
and O
factor O
VII O
increased O
while O
the O
capacity O
of O
coagulation O
inhibition O
was O
affected O
by O
increased O
protein B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
and O
decreased O
protein B-outcome ['Physiological-Clinical']
S I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
pancreatic B-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
median O
survival B-outcome ['Mortality']
on O
the O
mitomycin O
limb O
was O
19 O
weeks O
as O
compared O
to O
17 O
weeks O
on O
the O
methyl-CCNU O
program O
. O
['Physiological-Clinical', 'Mortality']

However O
, O
the O
incidence O
of O
premature B-outcome ['Physiological-Clinical']
LH I-outcome ['Physiological-Clinical']
surge I-outcome ['Physiological-Clinical']
remains O
too O
high O
, O
and O
modification O
will O
be O
necessary O
before O
the O
application O
of O
cetrorelix O
to O
IVF O
treatment O
. O
['Physiological-Clinical']

For O
dentine O
at O
day O
10 O
, O
many O
specimens O
exceeded O
the O
50 O
microm O
set O
limit O
of O
the O
profilometer O
and O
only O
day O
5 O
data O
were O
considered O
. O
[]

After O
applying O
the O
above O
criteria O
, O
11 O
patients O
were O
excluded O
due O
to O
disease O
progression O
before O
PBSCT O
( O
n O
= O
6 O
) O
or O
a O
low O
number O
of O
harvested O
cells O
( O
n O
= O
5 O
) O
, O
leaving O
63 O
patients O
for O
analysis O
; O
32 O
patients O
in O
the O
treatment O
group O
( O
300 O
microg/m2 O
of O
G-CSF O
intravenously O
over O
1 O
hour O
from O
day O
1 O
of O
PBSCT O
) O
and O
31 O
in O
the O
control O
group O
without O
treatment O
. O
[]

Our O
data O
confirm O
the O
presence O
and O
similarity O
of O
emboli B-outcome ['Physiological-Clinical']
generation I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
both I-outcome ['Physiological-Clinical']
methods I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
intramedullary I-outcome ['Physiological-Clinical']
nailing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Patients O
received O
remote O
conditioning O
during O
transport O
to O
hospital O
, O
and O
primary O
percutaneous O
coronary O
intervention O
in O
hospital O
. O
[]

In O
our O
opinion O
, O
PKRP O
makes O
a O
promising O
treatment O
for O
BPH O
with O
its O
advantages O
, O
such O
as O
early O
removal O
of O
postoperative O
urethral O
catheter O
, O
a O
shorter O
hospital O
stay O
and O
the O
absence O
of O
TUR O
syndrome O
risk O
. O
[]

NHT O
) O
before O
RP O
was O
performed O
, O
whereas O
58 O
and O
33 O
had O
been O
treated O
for O
three O
and O
six O
months O
, O
respectively O
. O
[]

AIMS O
There O
is O
evidence O
that O
plasma O
coenzyme B-outcome ['Physiological-Clinical']
Q I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
10 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CoQ I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
10 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
decrease O
in O
patients O
with O
advanced O
chronic O
heart O
failure O
( O
CHF O
) O
. O
['Physiological-Clinical']

However O
, O
our O
ability O
to O
identify O
those O
at O
risk O
for O
SCD O
in O
the O
general O
population O
is O
poor O
, O
and O
more O
specific O
markers O
are O
needed O
. O
[]

Weight O
gain O
, O
increased O
appetite B-outcome ['Physiological-Clinical']
, O
anxiety B-outcome ['Life-Impact']
, O
and O
fatigue B-outcome ['Physiological-Clinical']
were O
the O
most O
frequently O
reported O
side O
effects O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

These O
preliminary O
data O
demonstrated O
no O
statistically O
significant O
difference O
between O
the O
two O
arms O
with O
regard O
to O
toxicity O
and O
recurrence O
of O
tumors O
. O
[]

There O
were O
no O
significant O
differences O
( O
P O
= O
0.3626 O
) O
in O
the O
prevaccination B-outcome ['Physiological-Clinical']
anti-Hib I-outcome ['Physiological-Clinical']
geometric O
mean O
concentration O
( O
GMC B-outcome ['Physiological-Clinical']
) O
among O
the O
three O
Hib O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
, O
and O
almost O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
mild O
and O
improved O
without O
specific O
treatment O
. O
['Adverse-effects', 'Adverse-effects']

Outcome O
measures O
included O
histologic B-outcome ['Physiological-Clinical']
assessment I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
biopsies I-outcome ['Physiological-Clinical']
and O
assessment O
of I-outcome ['Physiological-Clinical']
serologic B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IBD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
fecal B-outcome ['Physiological-Clinical']
calprotectin O
levels O
, O
and O
polymorphisms O
in O
immune-related B-outcome ['Physiological-Clinical']
genes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
evaluated O
a O
new O
prognostic O
classification O
incorporating O
additional O
information O
from O
inflammatory O
markers O
. O
[]

Cross-sectional O
study O
design O
including O
patients O
with O
JIA O
aged O
between O
8 O
and O
17 O
years O
and O
healthy O
controls O
was O
used O
. O
[]

Overall O
, O
one-third O
of O
women O
for O
whom O
mammography O
had O
been O
recommended O
had O
not O
been O
screened O
within O
1 O
year O
of O
follow-up O
. O
[]

Of O
18 O
patients O
12 O
were O
evaluable O
for O
their O
response O
to O
therapy O
. O
[]

The O
30-day O
mortality O
did O
not O
differ O
between O
group O
A O
( O
17.3 O
% O
) O
and O
group O
B O
( O
13.4 O
% O
; O
p=0.78 O
) O
. O
[]

Epidural O
supplementation O
was O
administered O
in O
three O
patients O
( O
12 O
% O
) O
in O
Group O
1 O
and O
one O
patient O
( O
3 O
% O
) O
in O
Group O
2 O
when O
the O
sensory O
block O
regressed O
to O
L-1 O
with O
surgery O
expected O
to O
last O
longer O
than O
15 O
min O
. O
[]

This O
study O
was O
conducted O
to O
determine O
the O
long-term O
effect O
of O
flosequinan O
, O
a O
new O
orally O
administered O
arterial O
and O
venous O
dilator O
, O
on O
the O
clinical O
course O
of O
patients O
with O
moderate O
to O
severe O
congestive O
heart O
failure O
. O
[]

All O
volunteers O
received O
ASA O
81 O
mg O
once O
daily O
for O
5 O
days O
prior O
to O
the O
study O
( O
pre-screen O
) O
. O
[]

To O
date O
, O
no O
prospective O
study O
has O
addressed O
the O
possible O
health O
implications O
of O
silicone O
breast O
implant O
rupture O
. O
[]

Samples O
of O
blood O
and O
urine O
were O
collected O
at O
baseline O
, O
week O
4 O
, O
and O
week O
8 O
and O
then O
every O
8 O
weeks O
from O
310 O
patients O
entering O
a O
controlled O
trial O
of O
prophylaxis O
with O
valaciclovir O
versus O
acyclovir O
. O
[]

They O
had O
regular O
sexual O
lives O
. O
[]

CDI B-outcome ['Physiological-Clinical']
was O
calculated O
using O
the O
interval O
from O
day O
1 O
of O
the O
first O
course O
to O
hematologic O
recovery O
after O
the O
fifth O
course O
( O
100 O
% O
CDI O
= O
105-day O
interval O
) O
. O
['Physiological-Clinical']

The O
limit O
to O
exercise O
tolerance O
in O
humans O
: O
mind O
over O
muscle O
? O
[]

A O
significant O
increase O
in O
total O
procedure B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
noted O
in O
the O
rotational O
angiography O
arm O
. O
['Life-Impact']

Physiotherapy O
and O
placebo O
interventions O
were O
applied O
by O
10 O
physiotherapists O
in O
private O
practices O
for O
12 O
weeks O
. O
[]

4 O
cm O
, O
in O
patients O
with O
liver O
cirrhosis O
. O
[]

A O
comparative O
study O
of O
netilmicin-cefoxitin O
and O
gentamicin-cefoxitin O
in O
surgical O
patients O
with O
serious O
systemic O
infection O
. O
[]

SETTING O
A O
private O
medical O
centre O
, O
without O
university O
affiliation O
, O
in O
rural O
Quebec O
. O
[]

RESULTS O
The O
mean O
( O
+/-SD O
) O
of O
reported O
fish O
meals O
per O
week O
was O
4.3 O
+/- O
0.4 O
, O
4.7 O
+/- O
1.1 O
and O
0.6 O
+/- O
0.4 O
in O
the O
groups O
, O
respectively O
. O
[]

No O
correlation O
was O
found O
between O
the O
numbers O
of O
CD19+ B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( O
range O
, O
5 O
% O
to O
51 O
% O
) O
and O
PCR O
estimates O
of O
the O
number O
of O
clonal O
cells O
in O
the O
peripheral O
blood O
( O
range O
, O
.009 O
% O
to O
3.6 O
% O
) O
. O
['Physiological-Clinical']

RESULTS O
Oral B-outcome ['Physiological-Clinical']
hygiene I-outcome ['Physiological-Clinical']
around O
both O
test O
and O
control O
implants O
was O
improved O
at O
3 O
and O
6 O
months O
compared O
with O
baseline O
. O
['Physiological-Clinical']

BACKGROUND O
This O
study O
tested O
the O
hypothesis O
that O
, O
for O
colonoscopy O
, O
analgesia/sedation O
with O
remifentanil O
and O
propofol O
might O
be O
more O
effective O
compared O
with O
anesthesia O
by O
intravenous O
administration O
of O
midazolam O
, O
fentanyl O
, O
and O
propofol O
. O
[]

Efficacy O
of O
topical O
azithromycin O
ophthalmic O
solution O
1 O
% O
in O
the O
treatment O
of O
posterior O
blepharitis O
. O
[]

The O
eradication B-outcome ['Physiological-Clinical']
rates O
in O
those O
allocated O
to O
OCT O
were O
as O
follows O
: O
intention-to-treat O
, O
710 O
out O
of O
1161 O
( O
61 O
% O
; O
95 O
% O
confidence O
interval O
: O
58-64 O
% O
) O
; O
evaluable O
710 O
out O
of O
967 O
( O
73 O
% O
; O
95 O
% O
CI O
: O
71-76 O
% O
) O
; O
took O
all O
medication O
645 O
out O
of O
769 O
( O
84 O
% O
; O
95 O
% O
CI O
: O
81-87 O
% O
) O
. O
['Physiological-Clinical']

[ O
Perioperative O
teicoplanin O
prophylaxis O
in O
patients O
undergoing O
breast O
reconstruction O
with O
the O
abdominal O
wall O
. O
[]

Significant O
shorter O
procedure O
and O
fluoroscopy O
times O
compared O
with O
a O
primary O
4:1 O
ablation O
mode O
during O
repeat O
PVI O
are O
mainly O
attributed O
to O
a O
lower O
incidence O
of O
acutely O
reconnected O
PVs O
within O
the O
first O
30 O
min O
. O
[]

Overall O
improvement O
in O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
at O
1 O
and O
6 O
months O
follow-up O
, O
as O
measured O
with O
the O
30-item O
General O
Health B-outcome ['Physiological-Clinical']
Questionnaire O
and O
the O
['Life-Impact', 'Physiological-Clinical']

Overall O
, O
the O
correct O
treatment O
decision B-outcome ['Life-Impact']
was O
established O
in O
87 O
% O
of O
the O
consultations O
. O
['Life-Impact']

BACKGROUND O
Unsedated O
transnasal O
endoscopy O
( O
TNE O
) O
may O
be O
safer O
and O
less O
expensive O
than O
standard O
endoscopy O
( O
SE O
) O
for O
detecting O
Barrett O
's O
esophagus O
( O
BE O
) O
. O
[]

The O
IT O
group O
demonstrated O
significant O
improvements O
with O
medium O
to O
large O
effect O
sizes O
in O
their O
responsiveness B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
joint I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
diversity I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
functional I-outcome ['Life-Impact']
play I-outcome ['Life-Impact']
acts I-outcome ['Life-Impact']
after O
the O
intervention O
with O
maintenance O
of O
these O
skills O
1 O
year O
post-intervention O
. O
['Life-Impact']

Mean O
terminal O
half-life O
was O
approximately O
6 O
weeks O
. O
[]

They O
were O
randomly O
assigned O
( O
2:1 O
) O
with O
a O
central O
randomisation O
schedule O
to O
receive O
intravenous O
ganitumab O
12 O
mg O
per O
kg O
bodyweight O
or O
placebo O
in O
combination O
with O
open-label O
intramuscular O
fulvestrant O
( O
500 O
mg O
on O
day O
1 O
, O
then O
250 O
mg O
on O
days O
15 O
, O
29 O
, O
and O
every O
28 O
days O
) O
or O
oral O
exemestane O
( O
25 O
mg O
once O
daily O
) O
on O
a O
28-day O
cycle O
. O
[]

After O
the O
addition O
of O
VR B-outcome ['Physiological-Clinical']
, O
77 O
% O
of O
all O
patients O
improved O
. O
['Physiological-Clinical']

The O
current O
study O
was O
designed O
to O
determine O
whether O
the O
inclusion O
of O
a O
disclaimer O
( O
i.e. O
, O
Retouched O
photograph O
aimed O
at O
changing O
a O
person O
's O
physical O
appearance O
. O
) O
[]

They O
were O
randomly O
distributed O
into O
three O
groups O
. O
[]

Of O
the O
11 O
recurrent O
infections O
, O
7 O
were O
detected O
in O
urine O
obtained O
after O
prostatic O
massage O
. O
[]

Multivariate O
statistical O
models O
adjusting O
for O
these O
factors O
confirmed O
the O
statistically O
significant O
RFS B-outcome ['Mortality']
benefit O
of O
HDI O
versus O
Obs O
but O
did O
not O
demonstrate O
a O
significant O
OS B-outcome ['Mortality']
benefit O
in O
the O
pooled O
populations O
. O
['Mortality', 'Mortality']

Thirty-four O
children O
, O
with O
autism O
spectrum O
disorders O
, O
ages O
4-14 O
years O
, O
were O
matched O
and O
randomly O
assigned O
to O
one O
of O
two O
conditions O
for O
learning B-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
novel I-outcome ['Life-Impact']
juice-making I-outcome ['Life-Impact']
task I-outcome ['Life-Impact']
and O
producing B-outcome ['Life-Impact']
two I-outcome ['Life-Impact']
novel I-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
event I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

A O
comparative O
controlled O
study O
] O
. O
[]

There O
was O
an O
initial O
increase O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
the O
nicardipine O
group O
, O
but O
the O
rise O
was O
only O
moderate O
( O
3 O
beats/min O
supine O
p O
= O
0.3219 O
, O
and O
7 O
beats/min O
standing O
, O
p O
= O
0.0203 O
) O
at O
the O
end O
of O
the O
24 O
weeks O
. O
['Physiological-Clinical']

We O
report O
a O
double-blind O
comparison O
of O
liquid O
antacid O
vs O
placebo O
in O
the O
treatment O
of O
reflux O
esophagitis O
in O
32 O
patients O
with O
chronic O
heartburn O
. O
[]

We O
have O
shown O
that O
manikin-only O
training O
in O
the O
emergency O
technique O
for O
LMA O
insertion O
is O
as O
effective O
as O
live O
patient O
training O
. O
[]

NaCl O
is O
an O
appropriate O
first-line O
treatment O
, O
but O
for O
subjects O
with O
fluorescein-staining O
punctuations O
, O
lubrication O
with O
PVP O
is O
preferable O
. O
[]

intravenously O
. O
[]

Heifers O
treated O
with O
SG+IVPO O
consumed O
more O
DM O
, O
had O
greater O
ADG O
, O
were O
[]

METHODS O
We O
prospectively O
enrolled O
264 O
patients O
who O
were O
scheduled O
for O
cardiovascular O
procedures O
and O
had O
a O
baseline O
creatinine O
level O
> O
1.2 O
mg/dL O
. O
[]

Data O
on O
the O
influence O
of O
calcium O
antagonists O
on O
glucose B-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
in O
humans O
are O
conflicting O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Cost-effectiveness O
of O
cognitive-behavioral O
group O
therapy O
for O
dysfunctional O
fear O
of O
progression O
in O
cancer O
patients O
. O
['Resource-use']

The O
behavioural O
improvement O
was O
accompanied O
by O
alterations O
in O
the O
distribution O
of O
the O
major O
lymphocyte O
subsets O
, O
with O
a O
significant O
increase O
of O
the O
T-helper-inducers B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CD4+CD8- I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
a O
significant O
reduction O
of O
the O
T-cytotoxic-suppressor B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CD4-CD8+ I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
resulting O
in O
a O
normalization O
of O
the O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratio O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Recurrence B-outcome ['Physiological-Clinical']
is O
a O
major O
challenge O
for O
CA O
treatment O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Fifty O
patients O
aged O
22 O
to O
83 O
( O
mean O
age O
61.8 O
) O
with O
primary O
( O
n O
= O
26 O
, O
52 O
% O
) O
and O
recurrent O
( O
n O
= O
24 O
, O
48 O
% O
) O
urethral O
strictures O
0.3 O
to O
2.4 O
cm O
long O
qualified O
for O
the O
study O
. O
[]

Randomized O
controlled O
trial O
of O
education O
and O
feedback O
for O
implementation O
of O
guidelines O
for O
acute O
low O
back O
pain O
. O
[]

CONCLUSIONS O
No O
evidence O
of O
a O
threshold O
of O
calcium O
absorption O
was O
found O
with O
a O
serum O
25 O
( O
OH O
) O
D O
range O
from O
40 O
to O
130 O
nmol/L O
. O
[]

The O
application O
of O
80 O
mg O
tobramycin O
four O
times O
a O
day O
as O
an O
aerosol O
was O
well O
tolerated B-outcome ['Life-Impact']
by O
the O
patients O
. O
['Life-Impact']

OBJECTIVE O
To O
evaluate O
two O
solutions O
, O
lactated O
Ringer O
's O
( O
LR O
) O
and O
a O
balanced O
salt O
solution O
( O
BSS O
Plus O
, O
Alcon O
Laboratories O
, O
Ft. O
Worth O
, O
TX O
) O
, O
compared O
with O
normal O
saline O
solution O
( O
NSS O
) O
, O
for O
ocular O
irrigation O
in O
healthy O
adult O
volunteers O
with O
and O
without O
the O
Morgan O
therapeutic O
lens O
( O
MTL O
) O
. O
[]

Positive O
results O
are O
reported O
from O
a O
double-blind O
study O
of O
estrogen O
therapy O
administered O
to O
severely O
depressed O
, O
inpatient O
women O
who O
had O
failed O
to O
respond O
to O
various O
conventional O
treatments O
of O
depression O
. O
[]

Twenty-four-hour O
urinary B-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
( O
24-h O
NE O
) O
was O
used O
as O
an O
estimate O
of O
sympathetic B-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Prospective O
studies O
comparing O
the O
two O
methods O
in O
Asian O
people O
are O
few O
. O
[]

To O
evaluate O
the O
efficacy O
and O
safety O
of O
two O
1-week O
low-dose O
triple-therapy O
drug O
regimens O
involving O
antisecretory O
drugs O
for O
Helicobacter O
pylori O
infection O
, O
99 O
patients O
with O
H. O
pylori O
infection O
were O
treated O
with O
either O
lansoprazole O
( O
LPZ O
) O
or O
ranitidine O
( O
RNT O
) O
used O
together O
with O
clarithromycin O
( O
CAM O
) O
and O
metrinidazole O
( O
MTZ O
) O
. O
[]

Two O
distinct O
disease-oriented O
high-dose O
regimens O
without O
total O
body O
irradiation O
consisted O
of O
the O
MCVAC O
regimen O
using O
ranimustine O
( O
MCNU O
, O
450 O
mg/m2 O
) O
, O
cytosine O
arabinoside O
( O
16 O
g/m2 O
) O
, O
etoposide O
( O
1.6 O
g/m2 O
) O
, O
and O
cyclophosphamide O
( O
100 O
mg/kg O
) O
for O
patients O
with O
ALL O
, O
and O
the O
Hi-MEC O
regimen O
using O
melphalan O
( O
180 O
mg/m2 O
) O
, O
etoposide O
( O
1.6 O
g/m2 O
) O
, O
and O
carboplatinum O
( O
1.6 O
g/m2 O
) O
for O
those O
with O
solid O
tumors O
. O
[]

once O
daily O
for O
7 O
days O
to O
10 O
patients O
undergoing O
total O
hip O
replacement O
( O
THR O
) O
in O
a O
pilot O
study O
. O
[]

The O
results O
of O
that O
open-label O
study O
demonstrated O
significant O
within-group O
improvement O
in O
both O
depressive O
symptoms O
( O
including O
suicidal O
ideations O
) O
and O
level O
of O
drinking O
. O
[]

Canadian O
HIV O
Trials O
Network O
Protocol O
010 O
Study O
Group O
. O
[]

Echocardiographic B-outcome ['Physiological-Clinical']
, O
hemodynamic B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

The O
control O
group O
children O
were O
not O
, O
at O
this O
stage O
, O
screened O
, O
yet O
their O
parents O
received O
the O
same O
questionnaire O
assessing O
dental B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
over O
the O
2-month O
period O
. O
['Life-Impact']

Low O
molecular O
weight O
dextran O
and O
heparin O
were O
given O
during O
the O
procedure O
and O
heparin O
was O
continued O
for O
24 O
hours O
in O
all O
patients O
. O
[]

A O
prospective O
randomized O
study O
of O
amoxycillin O
and O
omeprazole O
with O
and O
without O
metronidazole O
in O
the O
eradication O
treatment O
of O
Helicobacter O
pylori O
. O
[]

METHODS O
& O
DESIGN O
This O
paper O
describes O
the O
development O
and O
evaluation O
protocol O
of O
a O
web-based O
out-of-school O
smoking O
prevention O
programme O
for O
primary O
school O
children O
( O
age O
10-13 O
years O
) O
entitled O
'Fun O
without O
Smokes O
' O
. O
[]

No O
significant O
differences O
were O
found O
in O
meconium B-outcome ['Physiological-Clinical']
passage I-outcome ['Physiological-Clinical']
, O
1- O
or O
5-minute O
Apgar B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
< O
7 O
, O
neonatal B-outcome ['Physiological-Clinical']
resuscitations I-outcome ['Physiological-Clinical']
, O
or O
admissions B-outcome ['Resource-use']
to O
the O
neonatal O
intensive O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

We O
conducted O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
trial O
in O
40 O
patients O
to O
evaluate O
the O
need O
for O
antibiotics O
in O
acute O
exacerbations O
of O
chronic O
bronchitis O
. O
[]

The O
objectives O
were O
to O
compare O
the O
two O
devices O
with O
regard O
to O
their O
safety O
and O
acceptability O
and O
to O
determine O
whether O
the O
probability O
of O
pregnancy B-outcome ['Physiological-Clinical']
among O
FemCap O
users O
was O
no O
worse O
than O
that O
of O
the O
diaphragm O
( O
meaning O
not O
more O
than O
6 O
percentage O
points O
higher O
) O
. O
['Physiological-Clinical']

Just O
after O
delivery O
, O
2.5 O
mg O
droperidol O
was O
given O
intravenously O
to O
groups O
2 O
and O
5 O
, O
and O
5 O
mg O
was O
given O
to O
groups O
3 O
and O
6 O
. O
[]

Patients O
completed O
the O
EORTC O
QLQ O
C30 O
and O
the O
Prostate O
Cancer O
Index O
( O
PCI O
) O
before O
treatment O
and O
at O
1.5 O
, O
3 O
, O
6 O
, O
12 O
, O
18 O
, O
24 O
, O
and O
36 O
months O
post-treatment O
. O
[]

Similarly O
, O
Kaplan-Meier O
curves O
for O
the O
probability O
of O
premature O
discontinuation O
from O
the O
study O
for O
any O
reason O
were O
similar O
across O
the O
treatment O
groups O
. O
[]

B-type O
natriuretic O
peptide O
in O
the O
evaluation O
and O
management O
of O
dyspnoea O
in O
primary O
care O
. O
[]

MRA O
was O
performed O
to O
identify O
the O
hepatofugal O
supply O
vein O
selectively O
for O
esophageal O
varices O
. O
[]

This O
study O
confirms O
the O
positive O
results O
obtained O
by O
a O
previous O
DIR O
pilot O
study O
( O
Solomon O
et O
al. O
, O
2007 O
) O
. O
[]

significantly O
improved O
erectile B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
men O
with O
lower O
urinary O
tract O
symptoms/ O
benign O
prostatic O
hypertrophy O
and O
had O
no O
adverse O
effect O
on O
ejaculatory O
function O
. O
['Physiological-Clinical']

Changes O
in O
logarithm O
of O
minimum B-outcome ['Physiological-Clinical']
angle I-outcome ['Physiological-Clinical']
of O
resolution I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
logMAR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
best-corrected I-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BCVA I-outcome ['Physiological-Clinical']
) O
, O
central B-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CMT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
shown O
by O
optical B-outcome ['Physiological-Clinical']
coherence O
tomography-3 O
were O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
serum B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
was O
lower O
( O
p O
< O
0.001 O
) O
in O
both O
groups O
at O
36 O
weeks O
' O
gestation O
than O
at O
presentation O
but O
higher O
( O
p O
= O
0.04 O
) O
in O
the O
hematinic O
group O
than O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

Twelve O
patients O
( O
seven O
females O
and O
five O
males O
) O
with O
a O
mean O
age O
of O
14.8 O
+/- O
0.3 O
years O
were O
treated O
with O
banded O
RPE O
and O
11 O
patients O
( O
six O
females O
and O
five O
males O
) O
with O
a O
mean O
age O
of O
15.1 O
+/- O
0.7 O
years O
with O
bonded O
RPE O
. O
[]

Nature O
, O
onset B-outcome ['Physiological-Clinical']
, O
intensity O
as O
well O
as O
outcome O
of O
each O
adverse O
reaction O
were O
recorded O
. O
['Physiological-Clinical']

PURPOSE O
We O
compare O
the O
contrast O
sensitivity B-outcome ['Physiological-Clinical']
obtained O
with O
an O
anterior O
surface O
modified O
prolate O
intraocular O
lens O
with O
the O
contrast O
sensitivity O
obtained O
with O
a O
standard O
spherical O
intraocular O
lens O
. O
['Physiological-Clinical']

Boosting O
uptake B-outcome ['Physiological-Clinical']
of O
influenza O
immunisation O
: O
a O
randomised O
controlled O
trial O
of O
telephone O
appointing O
in O
general O
practice O
. O
['Physiological-Clinical']

Double-blind O
trial O
comparing O
the O
effectiveness O
of O
the O
homeopathic O
preparation O
Galphimia O
potentiation O
D6 O
, O
Galphimia O
dilution O
10 O
( O
-6 O
) O
and O
placebo O
on O
pollinosis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
examined O
the O
learning B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
transfer I-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
classified I-outcome ['Life-Impact']
as I-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
length I-outcome ['Life-Impact']
, O
consistency O
, O
and O
complexity O
of O
['Life-Impact']

Effect O
of O
nitric-oxide-generating O
system O
on O
microcirculatory B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
in O
skin O
of O
patients O
with O
severe O
Raynaud O
's O
syndrome O
: O
a O
randomised O
trial O
. O
['Physiological-Clinical']

METHOD O
Bipolar O
patients O
were O
studied O
who O
had O
at O
least O
one O
episode O
per O
year O
in O
the O
previous O
2 O
years O
despite O
ongoing O
prophylaxis O
. O
[]

OBJECTIVE O
The O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
long-term O
treatment O
with O
atomoxetine O
for O
symptoms O
of O
attention-deficit/hyperactivity B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
ADHD I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
in O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
has O
not O
been O
established O
. O
['Life-Impact', 'Life-Impact']

Six- O
to O
13-year-olds O
( O
N O
= O
126 O
) O
viewed O
a O
sad O
film O
and O
were O
instructed O
to O
reappraise O
the O
importance O
, O
reappraise O
the O
outcome O
, O
or O
ruminate O
about O
the O
sad O
events O
; O
another O
group O
received O
no O
regulation O
instructions O
. O
[]

All O
patients O
tolerated O
the O
treatment O
well O
and O
reported O
relief O
from O
compressive B-outcome ['Physiological-Clinical']
and O
cosmetic O
complaints I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Twenty-seven O
of O
50 O
patients O
( O
54 O
% O
) O
in O
the O
prostaglandin O
E2 O
group O
were O
admitted O
for O
labor O
during O
the O
dosing O
interval O
compared O
with O
10 O
placebo-treated O
patients O
( O
20 O
% O
, O
p O
= O
0.001 O
) O
. O
[]

METHODS O
Patients O
with O
inoperable O
carcinoma O
of O
the O
oesophagus O
were O
randomised O
to O
receive O
either O
endoscopic O
Nd O
: O
YAG O
laser O
therapy O
alone O
, O
or O
laser O
followed O
by O
brachytherapy O
. O
[]

With O
oral O
administration O
of O
the O
drug O
over O
a O
period O
of O
one O
week O
antiischemic B-outcome ['Physiological-Clinical']
effects O
could O
also O
be O
documented O
with O
Holter B-outcome ['Physiological-Clinical']
monitoring I-outcome ['Physiological-Clinical']
as O
well O
as O
during O
exercise O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODOLOGY O
This O
multi-centric O
, O
randomised O
placebo O
controlled O
double O
blind O
clinical O
trial O
intended O
to O
investigate O
equivalent O
efficacy O
of O
placebo O
and O
amoxicillin O
and O
was O
conducted O
in O
ambulatory O
care O
settings O
in O
eight O
government O
hospitals O
in O
India O
. O
[]

0.5 O
vs. O
6.4 O
? O
[]

No O
side O
effects O
were O
observed O
during O
the O
trial O
or O
afterwards O
( O
observation O
period O
6 O
months O
) O
. O
[]

No O
subjects O
withdrew O
from O
the O
study O
because O
of O
MTX O
complications O
. O
[]

RESULTS O
ADS O
quartiles O
differed O
on O
age O
, O
other O
demographics O
, O
and O
prior O
treatment O
episodes O
. O
[]

AIM O
The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
amantadine O
reduces O
deterioration O
of O
quality B-outcome ['Life-Impact']
of O
life B-outcome ['Life-Impact']
in O
patients O
with O
chronic O
hepatitis O
C O
during O
and O
after O
treatment O
with O
interferon-alpha O
( O
IFN-alpha O
) O
and O
ribavirin O
. O
['Life-Impact', 'Life-Impact']

The O
treatment O
protocol O
was O
divided O
into O
3 O
stages O
: O
Stage O
1 O
is O
a O
single O
dose O
treatment O
where O
12 O
patients O
were O
divided O
randomly O
into O
2 O
groups O
of O
6 O
each O
. O
[]

Effectiveness O
and O
safety O
of O
the O
Levitan O
FPS O
Scope? O
for O
tracheal O
intubation O
under O
general O
anesthesia O
with O
a O
simulated O
difficult O
airway O
. O
[]

A O
single-blind O
placebo O
baseline O
was O
followed O
by O
double-blind O
nizatidine O
CR O
( O
150 O
and O
300 O
mg O
) O
in O
randomized O
sequence O
, O
2 O
to O
5 O
days O
apart O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
were O
randomly O
assigned O
to O
receive O
ixabepilone O
( O
35 O
mg/m O
( O
2 O
) O
) O
by O
intravenous O
infusion O
every O
3 O
weeks O
with O
or O
without O
EMP O
280 O
mg O
orally O
three O
times O
daily O
on O
days O
1 O
to O
5 O
. O
[]

Since O
the O
insula O
is O
implicated O
in O
nicotine O
dependence O
, O
we O
hypothesized O
that O
SZ O
smokers O
will O
have O
greater O
dysfunction O
in O
smoking-related O
insular O
and O
dACC O
circuits O
than O
normal O
control O
smokers O
( O
NC O
) O
independent O
of O
smoking O
severity O
, O
consistent O
with O
an O
inherent O
disease-related O
weakening O
of O
smoking-related O
circuits O
. O
[]

Following O
a O
12 O
hour O
fast O
, O
heart O
rate O
, O
arterial O
blood O
pressure O
, O
light O
reflex O
plethysmography O
of O
the O
finger O
, O
resting O
blood O
flow O
volume O
in O
the O
lower O
arm O
and O
leg O
and O
peripheral B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
were O
measured O
at O
10 O
min O
. O
['Physiological-Clinical']

Patients O
were O
then O
randomized O
double-blind O
to O
oral O
treatment O
. O
[]

In O
a O
double-blind O
and O
randomized O
manner O
, O
18 O
male O
and O
female O
junior O
competitive O
swimmers O
supplemented O
their O
diets O
with O
21 O
g.day-1 O
of O
creatine O
monohydrate O
( O
Cr O
) O
or O
a O
maltodextrin O
placebo O
( O
P O
) O
for O
9 O
days O
during O
training O
. O
[]

The O
infusion O
was O
started O
with O
an O
initial O
dose O
given O
over O
10 O
min O
before O
the O
induction O
of O
anesthesia O
; O
at O
induction O
the O
maintenance O
rate O
was O
begun O
and O
continued O
until O
closure O
of O
the O
abdominal O
fascia O
. O
[]

Patients O
were O
given O
the O
drugs O
intravenously O
for O
a O
minimum O
of O
three O
days O
followed O
by O
oral O
preparations O
for O
the O
next O
seven O
to O
ten O
days O
. O
[]

CONCLUSION O
The O
logMAR O
crowded O
Kay O
picture O
test O
is O
a O
useful O
tool O
in O
clinical O
practice O
. O
[]

Anesthesia O
was O
induced O
with O
thiopental O
sodium O
5 O
mg/kg O
, O
followed O
by O
rocuronium O
1.0 O
mg/kg O
. O
[]

METHODS O
This O
was O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
parallel O
design O
study O
conducted O
in O
DM O
patients O
with O
stable O
coronary O
artery O
disease O
receiving O
DAPT O
. O
[]

METHODS O
AND O
RESULTS O
In O
a O
randomized O
, O
unblinded O
multicenter O
study O
of O
209 O
men O
and O
124 O
women O
with O
uncomplicated O
gonorrhea O
, O
we O
compared O
three O
single-dose O
treatment O
regimens O
: O
400 O
mg O
or O
800 O
mg O
of O
cefixime O
, O
administered O
orally O
, O
and O
250 O
mg O
of O
ceftriaxone O
administered O
intramuscularly O
. O
[]

Participants O
performed O
three O
tasks O
: O
one O
in O
which O
they O
decided O
whether O
a O
letter O
string O
was O
a O
word O
or O
a O
non-word O
( O
lexical O
decision O
) O
and O
two O
affective O
classification O
tasks O
in O
which O
they O
judged O
whether O
words O
were O
1 O
) O
neutral O
or O
unpleasant O
, O
or O
2 O
) O
neutral O
or O
pleasant O
. O
[]

Smoking B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
with O
smokeless O
tobacco O
and O
group O
therapy O
: O
an O
open O
, O
randomized O
, O
controlled O
trial O
. O
['Life-Impact']

The O
effects O
of O
esmolol O
, O
an O
ultrashort-acting O
beta O
blocker O
, O
and O
verapamil O
were O
compared O
in O
controlling O
ventricular B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
45 O
patients O
with O
atrial O
fibrillation O
or O
atrial O
flutter O
, O
in O
a O
randomized O
, O
parallel O
, O
open-label O
study O
. O
['Physiological-Clinical']

In O
a O
two-stage O
screening O
procedure O
using O
the O
Edinburgh O
Postnatal O
Depression O
Scale O
( O
EPDS O
) O
at O
8 O
and O
12 O
weeks O
postpartum O
and O
the O
Montgomery-Asberg O
Depression O
Rating O
Scale O
( O
MADRS O
) O
and O
DSM-III-R B-outcome ['Physiological-Clinical']
at O
about O
13 O
weeks O
postpartum O
, O
41 O
women O
identified O
as O
depressed O
were O
randomly O
allocated O
to O
a O
study O
and O
a O
control O
group O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
action O
of O
the O
oscillating/rotating/pulsating O
toothbrushes O
( O
Oral-B O
ProfessionalCare O
7000 O
and O
Oral-B O
3D O
Excel O
) O
was O
more O
effective O
in O
plaque O
removal O
than O
the O
high-frequency O
toothbrush O
( O
Sonicare O
Advance O
) O
. O
[]

IgG1 B-outcome ['Physiological-Clinical']
increased O
significantly O
in O
all O
active O
groups O
compared O
to O
placebo O
. O
['Physiological-Clinical']

The O
most O
significant O
determinant O
of O
LA O
was O
time B-outcome ['Life-Impact']
spent I-outcome ['Life-Impact']
breast-feeding I-outcome ['Life-Impact']
( O
min/d O
) O
, O
which O
was O
in O
turn O
negatively O
associated O
( O
P O
= O
0.06 O
) O
with O
the O
infant O
's O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
from O
complementary O
foods O
in O
regression O
analyses O
. O
['Life-Impact', 'Life-Impact']

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
influence O
of O
quadriceps O
muscle O
fatigue O
on O
exercise O
tolerance O
and O
ventilatory O
response O
during O
constant-workrate O
cycling O
exercise O
testing O
( O
CWT O
) O
in O
patients O
with O
COPD O
and O
healthy O
subjects O
. O
[]

Clonidine O
also O
reduces O
the O
induction O
dose O
of O
IV O
anesthetics O
. O
[]

From O
the O
health-care O
sector O
perspective O
, O
the O
intervention O
will O
most O
likely O
lead O
to O
no O
additional B-outcome ['Resource-use']
cost I-outcome ['Resource-use']
. O
['Resource-use']

A O
study O
was O
conducted O
to O
assess O
the O
effect O
of O
thermal O
, O
nutritional O
and O
combined O
stresses O
( O
thermal O
and O
nutritional O
) O
on O
the O
growth O
, O
oestradiol O
and O
progesterone O
levels O
during O
oestrus O
cycles O
in O
Malpura O
ewes O
. O
[]

No O
treatment O
effect O
was O
detected O
for O
clomipramine O
in O
either O
live B-outcome ['Physiological-Clinical']
or O
videotape B-outcome ['Physiological-Clinical']
ratings O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
short-course O
pretreatment O
with O
metformin O
decreased O
hyperandrogenism B-outcome ['Physiological-Clinical']
and O
insulin B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
and O
improved O
cervical B-outcome ['Physiological-Clinical']
sores I-outcome ['Physiological-Clinical']
, O
ovulation B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
pregnancy B-outcome ['Physiological-Clinical']
rate O
among O
women O
with O
CC-resistant O
PCOS O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Primary O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
has O
become O
an O
alternative O
to O
thrombolytic O
therapy O
as O
a O
reperfusion O
strategy O
for O
ST-elevation O
acute O
myocardial O
infarction O
( O
AMI O
) O
. O
[]

Patients O
returned O
every O
3 O
weeks O
for O
follow-up O
with O
the O
pharmacist O
, O
for O
a O
total O
of O
13 O
visits O
. O
[]

Inclusion O
criteria O
were O
: O
age O
18-70 O
years O
, O
active O
participation O
in O
sports O
, O
and O
tendon O
pain O
localised O
at O
2-7 O
cm O
from O
distal O
insertion O
. O
[]

A O
profile O
for O
bipolar O
states O
emerged O
. O
[]

METHOD O
AND O
MATERIALS O
Three O
types O
of O
PMMA O
surfaces O
were O
tested O
: O
( O
1 O
) O
polished O
, O
( O
2 O
) O
polished O
and O
coated O
with O
bonding O
agent O
, O
and O
( O
3 O
) O
polished O
and O
coated O
with O
light-cured O
liquid O
polish O
. O
[]

OBJECTIVE O
The O
objective O
of O
the O
study O
was O
to O
compare O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
biofeedback O
treatment O
( O
BF O
) O
effects O
between O
white-coat O
hypertension O
and O
essential O
hypertension O
. O
['Physiological-Clinical']

Secondary O
endpoints O
are O
quality O
of O
life O
measured O
by O
validated O
questionnaires O
and O
[]

Teacher O
and O
child O
predictors O
of O
achieving O
IEP O
goals O
of O
children O
with O
autism O
. O
[]

The O
renal B-outcome ['Physiological-Clinical']
haemodynamic I-outcome ['Physiological-Clinical']
and O
natriuretic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
angiotensin O
II O
, O
indomethacin O
and O
their O
combination O
were O
not O
qualitatively O
different O
from O
those O
observed O
in O
the O
pre-frusemide O
phase O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
pregnancy B-outcome ['Physiological-Clinical']
rate O
within O
one O
year O
after O
laparoscopic O
surgery O
was O
higher O
in O
the O
test O
group O
than O
in O
the O
control O
group O
[ O
61.33 O
% O
( O
46/75 O
) O
vs O
45.45 O
% O
( O
25/55 O
) O
] O
, O
showing O
significant O
difference O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Actometer B-outcome ['Physiological-Clinical']
readings I-outcome ['Physiological-Clinical']
improved O
in O
two O
children O
who O
were O
very O
active O
at O
baseline O
. O
['Physiological-Clinical']

Phase O
III O
study O
of O
the O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
2597 O
) O
: O
induction O
chemotherapy O
followed O
by O
either O
standard O
thoracic O
radiotherapy O
or O
hyperfractionated O
accelerated O
radiotherapy O
for O
patients O
with O
unresectable O
stage O
IIIA O
and O
B O
non-small-cell O
lung O
cancer O
. O
[]

Seventy-two O
oncology O
nurses O
were O
randomly O
assigned O
to O
a O
24-h O
P.T.P O
. O
[]

There O
was O
no O
difference O
in O
antibody B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
either O
influenza O
A O
or O
B O
in O
64 O
patients O
who O
received O
GM-CSF O
at O
vaccination O
, O
compared O
with O
the O
53 O
who O
did O
not O
. O
['Physiological-Clinical']

The O
dose O
per O
treatment O
was O
22.5 O
joule O
. O
[]

CONCLUSION O
Dietetic O
or O
nutrition O
assistants O
are O
being O
introduced O
in O
units O
across O
the O
UK O
. O
[]

No O
allergic B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
, O
increased O
respiratory B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
the O
study O
was O
to O
analyse O
the O
basal B-outcome ['Physiological-Clinical']
diurnal I-outcome ['Physiological-Clinical']
and O
total O
secretion B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
salivary I-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
in O
short- O
and O
long-term O
aspects O
of O
tactile O
massage O
( O
TM O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Gastric O
carcinoma O
: O
expression O
of O
c-erbB-2/neu B-outcome ['Physiological-Clinical']
oncoprotein I-outcome ['Physiological-Clinical']
, O
epidermal B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor O
receptor B-outcome ['Physiological-Clinical']
, O
cathepsin B-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
, O
progesterone B-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
and O
tumor B-outcome ['Physiological-Clinical']
associated O
glycoprotein-72 B-outcome ['Physiological-Clinical']
in O
different O
histological O
types O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
success B-outcome ['Physiological-Clinical']
rate O
in O
the O
imidapril O
group O
was O
66 O
compared O
with O
68 O
per O
cent O
in O
the O
benazepril O
group O
. O
['Physiological-Clinical']

Especially O
important O
is O
the O
fact O
that O
the O
thalamus O
is O
activated O
by O
nicotine O
. O
[]

NT-proBNP B-outcome ['Physiological-Clinical']
was O
higher O
in O
patients O
with O
more O
severe O
symptoms O
and O
older O
patients O
but O
not O
in O
women O
, O
although O
differences O
in O
NT-proBNP O
may O
have O
been O
confounded O
by O
differences O
in O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
high O
carbohydrate O
( O
HC O
) O
and O
high O
fat O
( O
HF O
) O
meal O
ingestion O
on O
the O
CV O
responses O
to O
simulated O
orthostatic O
stress O
( O
using O
graded O
lower O
body O
subatmospheric O
pressure O
( O
LBSP O
) O
) O
was O
assessed O
in O
nine O
healthy O
young O
volunteers O
. O
[]

Participants O
were O
18 O
sedentary O
, O
overweight O
( O
BMI?85th O
percentile O
) O
8- O
to O
11-year-old O
children O
( O
94 O
% O
Black O
) O
, O
randomly O
assigned O
to O
either O
an O
aerobic O
exercise O
( O
n=10 O
) O
or O
sedentary O
attention O
control O
group O
( O
n=8 O
) O
. O
[]

DESIGN O
Comprehensive O
cohort O
study O
( O
CCS O
) O
with O
a O
nested O
randomized O
controlled O
trial O
. O
[]

Reductions O
in O
allodynia B-outcome ['Physiological-Clinical']
area O
and O
severity O
, O
and O
overall O
pain B-outcome ['Physiological-Clinical']
relief O
, O
were O
also O
greater O
with O
gabapentin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
It O
is O
feasible O
to O
extend O
the O
original O
STRokE O
DOC O
trial O
protocol O
to O
a O
new O
state O
and O
establish O
an O
operational O
single-hub O
, O
multispoke O
rural O
hospital O
telestroke O
research O
network O
in O
Arizona O
. O
[]

This O
clinical O
trial O
is O
the O
largest O
ever O
conducted O
in O
the O
setting O
of O
FAP O
and O
found O
a O
trend O
of O
reduced O
polyp O
load O
( O
number O
and O
size O
) O
with O
600 O
mg O
of O
aspirin O
daily O
. O
[]

A O
real-time O
polymerase O
chain O
reaction O
assay O
was O
developed O
, O
permitting O
the O
comparative O
determination O
of O
hASH1 B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
levels O
in O
triplicate O
in O
a O
double-blind O
pilot O
study O
including O
24 O
frozen O
cases O
of O
esthesioneuroblastoma O
and O
poorly O
differentiated O
tumors O
. O
['Physiological-Clinical']

Analysis O
of O
patients O
who O
subsequently O
relapsed O
compared O
with O
those O
still O
in O
remission O
after O
18 O
months O
of O
treatment O
indicated O
that O
the O
former O
, O
on O
average O
, O
had O
slightly O
lower O
neutrophil B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

diltiazem O
in O
a O
standard O
, O
weight-based O
dose O
. O
[]

To O
evaluate O
bone O
biochemical O
markers O
as O
predictors O
of O
the O
efficacy O
of O
a O
hormone O
replacement O
therapy O
( O
HRT O
) O
, O
we O
studied O
the O
bone O
changes O
induced O
by O
the O
cessation O
and O
return O
of O
ovarian O
function O
in O
28 O
patients O
treated O
for O
6 O
months O
with O
a O
GnRH O
agonist O
. O
[]

However O
, O
further O
study O
is O
needed O
to O
clarify O
the O
moderate B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
seen O
during O
intubation O
in O
some O
cases O
as O
well O
as O
to O
elucidate O
any O
patient O
population O
differences O
. O
['Physiological-Clinical']

Between O
March O
2001 O
and O
November O
2001 O
, O
87 O
patients O
with O
99 O
lesions O
were O
enrolled O
in O
this O
study O
and O
were O
treated O
with O
12 O
and O
16 O
mm O
long O
iridium-oxide O
coated O
Lunar O
stents O
. O
[]

Acceptability B-outcome ['Life-Impact']
data O
were O
explored O
with O
respect O
to O
whether O
any O
differences O
may O
be O
attributed O
to O
demographics O
and O
symptom O
and O
quality-of-life B-outcome ['Life-Impact']
levels O
, O
such O
as O
depression B-outcome ['Life-Impact']
and O
cognitive O
and O
emotional B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
results O
show O
that O
the O
antihypertensive B-outcome ['Resource-use']
effect O
of O
the O
two O
drugs O
was O
the O
same O
( O
both O
caused O
a O
more O
than O
10 O
% O
decrease O
in O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
) O
. O
['Resource-use', 'Physiological-Clinical']

Fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
samples O
were O
taken O
before O
treatment O
, O
and O
after O
cycles O
3 O
and O
6 O
, O
between O
the O
18th O
and O
the O
22nd O
day O
of O
the O
cycle O
. O
['Physiological-Clinical']

No O
association O
between O
estrogen B-outcome ['Physiological-Clinical']
and O
spatial B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
was O
found O
; O
however O
, O
in O
an O
additional O
exploratory O
data O
analysis O
, O
high O
levels O
of O
testosterone O
, O
LH B-outcome ['Physiological-Clinical']
, O
and O
FSH B-outcome ['Physiological-Clinical']
correlated O
significantly O
with O
performance O
in O
the O
flexibility B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
closure I-outcome ['Life-Impact']
task O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Ondansetron O
has O
similar O
clinical B-outcome ['Physiological-Clinical']
efficacy O
against O
both O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
intraoperative O
elevations O
of O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
cortisol B-outcome ['Physiological-Clinical']
were O
seen O
in O
the O
EA O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
lacking O
both O
risk O
factors O
displayed O
50 O
% O
survival B-outcome ['Mortality']
times I-outcome ['Mortality']
of O
46 O
months O
in O
stage O
III O
and O
88 O
months O
in O
stage O
II O
. O
['Mortality']

CONCLUSIONS O
There O
were O
no O
differences O
in O
arch B-outcome ['Physiological-Clinical']
dimensions I-outcome ['Physiological-Clinical']
after O
1-phase O
or O
2-phase O
treatment O
of O
Class O
II O
malocclusion O
. O
['Physiological-Clinical']

Post O
hoc O
analyses O
revealed O
a O
significant O
difference O
between O
prestimulation O
and O
poststimulation O
in O
the O
anodal O
stimulation O
group O
but O
not O
in O
the O
sham O
stimulation O
group O
. O
[]

Patients O
received O
dofequidar O
( O
900 O
mg O
PO O
) O
30 O
minutes O
before O
each O
dose O
of O
doxorubicin O
. O
[]

PURPOSE O
The O
aim O
of O
this O
prospective O
randomised O
double-blind O
study O
is O
to O
investigate O
the O
effect O
of O
magnesium O
added O
to O
local O
anaesthetics O
on O
postoperative O
VAS O
scores O
, O
total O
opioid O
consumption O
, O
time O
to O
first O
mobilisation O
, O
patient O
satisfaction O
and O
rescue O
analgesic O
requirements O
in O
arthroscopic O
ACL O
reconstruction O
surgery O
. O
[]

All O
patients O
underwent O
a O
clinic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
evaluation O
with O
an O
automatic O
sphygmomanometer O
and O
a O
24-h B-outcome ['Physiological-Clinical']
ambulatory I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
monitoring I-outcome ['Physiological-Clinical']
, O
at O
baseline O
and O
after O
3 O
months O
of O
aspirin O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
61 O
ASA O
physical O
status O
I O
and O
II O
, O
healthy O
female O
outpatients O
undergoing O
laparoscopic O
surgery O
. O
[]

These O
findings O
demonstrated O
that O
medication O
of O
penbutolol O
over O
a O
three-day O
period O
has O
no O
influence O
on O
the O
baseline O
blood O
sugar O
profile O
and O
insulin O
consumption O
or O
on O
insulin O
consumption O
after O
food O
intake O
during O
rest O
and O
physical O
exercise O
. O
[]

Amplitude O
changes O
were O
significant O
for O
APAP/pl O
vs. O
pl/pl O
at O
t150 O
: O
-44 O
% O
( O
95 O
% O
CI O
-58 O
to O
-30 O
) O
vs. O
-27 O
% O
( O
95 O
% O
CI O
-37 O
to O
-17 O
; O
P O
< O
0.05 O
) O
but O
not O
vs. O
APAP/Nal O
. O
[]

Moist O
Exposed O
Burn O
Ointment O
( O
MEBO O
) O
in O
partial O
thickness O
burns O
- O
a O
randomized O
, O
comparative O
open O
mono-center O
study O
on O
the O
efficacy O
of O
dermaheal O
( O
MEBO O
) O
ointment O
on O
thermal O
2nd O
degree O
burns O
compared O
to O
conventional O
therapy O
. O
[]

The O
relationship O
between O
masticatory O
performance O
and O
chewing O
experience O
has O
not O
yet O
been O
explored O
for O
patients O
with O
implant-retained O
overdentures O
. O
[]

Eight O
volunteers O
were O
enrolled O
in O
this O
four-arm O
, O
double-blind O
, O
cross-over O
, O
randomized O
study O
. O
[]

Given O
the O
importance O
of O
imitation O
in O
social O
interaction O
we O
speculate O
that O
difficulties O
with O
the O
modulation O
of O
imitation O
may O
contribute O
to O
the O
social O
problems O
characteristic O
of O
ASC O
. O
[]

Mean O
? O
[]

The O
New O
Jersey O
Risk O
Assessment O
was O
used O
to O
calculate O
the O
preoperative O
estimated O
surgical B-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality']

Several O
gains O
were O
also O
generalized O
to O
interactions O
with O
an O
unfamiliar B-outcome ['Life-Impact']
nonhandicapped I-outcome ['Life-Impact']
peer I-outcome ['Life-Impact']
, O
to O
interactions O
with O
another O
child B-outcome ['Physiological-Clinical']
with O
PDD B-outcome ['Life-Impact']
, O
and O
to O
the O
large O
school B-outcome ['Life-Impact']
setting I-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

CONCLUSIONS O
In O
this O
study O
of O
anemic O
critically O
ill O
patients O
treated O
with O
epoetin O
alfa O
, O
all O
dosing O
regimens O
were O
well O
tolerated B-outcome ['Life-Impact']
and O
appeared O
to O
effect O
reticulocytosis B-outcome ['Physiological-Clinical']
, O
with O
a O
peak O
at O
day O
11 O
or O
15 O
in O
most O
patients O
. O
['Life-Impact', 'Physiological-Clinical']

For O
comparison O
, O
a O
matched O
sample O
of O
ten O
non-ASD O
children O
was O
also O
assessed O
, O
but O
received O
no O
treatment O
. O
[]

International O
Nifedipine O
Trial O
on O
Antiatherosclerotic O
Therapy O
. O
[]

STUDY O
OBJECTIVES O
To O
characterize O
the O
effects O
of O
infusing O
fat O
emulsion O
during O
neonatal O
extracorporeal O
membrane O
oxygenation O
( O
ECMO O
) O
by O
comparing O
results O
from O
patients O
receiving O
fat O
emulsion O
through O
the O
ECMO O
circuit O
with O
those O
receiving O
fat O
emulsion O
through O
separate O
intravenous O
access O
. O
[]

Trough O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
measured O
in O
duplicate O
with O
the O
patient O
in O
the O
sitting O
position O
at O
each O
clinic O
visit O
( O
baseline O
[ O
week O
0 O
] O
and O
weeks O
4 O
and O
8 O
of O
treatment O
) O
; O
mean O
values O
were O
calculated O
and O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
ASSURE O
, O
310 O
patients O
with O
angiographic O
coronary O
artery O
disease O
and O
low O
HDL-C O
levels O
will O
be O
randomized O
to O
receive O
RVX-208 O
100 O
mg O
bid O
or O
placebo O
for O
26 O
weeks O
. O
[]

Secondary O
end O
points O
included O
pain B-outcome ['Physiological-Clinical']
, O
analgesic B-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
and O
quality O
of O
life O
. O
['Physiological-Clinical', 'Resource-use']

BACKGROUND O
The O
efficacy O
of O
conventional O
treatment O
with O
surgery O
and O
radiation O
for O
cancer O
of O
the O
esophagus O
is O
limited O
. O
[]

These O
results O
are O
in O
accordance O
with O
the O
hypothesis O
that O
the O
nephrotoxic O
effect O
of O
cyclosporin O
A O
results O
from O
a O
preferential O
constriction O
of O
afferent O
glomerular O
vessels O
. O
[]

Five O
days O
later O
, O
we O
only O
found O
single-labelled B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
sensory I-outcome ['Physiological-Clinical']
neurons I-outcome ['Physiological-Clinical']
in O
the O
normal O
and O
end-to-end O
coaptation O
groups O
, O
while O
some O
dual-labelled O
neurons O
can O
be O
identified O
in O
end-to-side O
coaptation O
groups O
. O
['Physiological-Clinical']

DESIGN O
Prospective O
, O
randomized O
, O
double-blind O
, O
controlled O
clinical O
trial O
. O
[]

METHODS O
Eight O
male O
volunteers O
were O
treated O
with O
nitroglycerin O
( O
0.1 O
microgram/kg O
per O
min O
) O
combined O
with O
N-acetylcysteine O
( O
2 O
g O
intravenously O
, O
followed O
by O
5 O
mg/kg O
per O
h O
) O
or O
placebo O
for O
23 O
h O
in O
a O
double-blind O
, O
randomized O
, O
crossover O
study O
. O
[]

A O
randomized O
study O
on O
hormone-resistant O
prostatic O
cancer O
: O
estramustine O
phosphate O
versus O
low O
dose O
epirubicin O
with O
or O
without O
medroxyprogesterone O
acetate O
. O
[]

The O
carotenoid O
zeaxanthin O
is O
concentrated O
within O
the O
macula O
. O
[]

In O
this O
group O
of O
severely O
affected O
patients O
with O
RA O
both O
cyclosporin O
and O
azathioprine O
were O
effective O
therapies O
. O
[]

Patients O
randomized O
to O
arm O
B O
received O
simple O
drainage O
only O
to O
presacral O
space O
; O
while O
those O
patients O
in O
arm O
A O
received O
continuous O
irrigation O
in O
addition O
to O
simple O
drainage O
. O
[]

The O
study O
shows O
that O
limiting O
treatment O
to O
four O
courses O
of O
chemotherapy O
alone O
is O
associated O
with O
inferior O
survival O
, O
but O
this O
is O
not O
the O
case O
if O
chemotherapy O
is O
given O
at O
relapse O
. O
[]

Seven O
healthy O
subjects O
immersed O
a O
hand O
in O
random O
order O
in O
either O
warm O
water O
or O
in O
cold O
water O
at O
5 O
degrees O
C O
for O
2 O
min O
, O
after O
taking O
orally O
a O
single O
dose O
of O
120 O
mg O
of O
propranolol O
or O
a O
placebo O
in O
a O
double O
blind O
fashion O
. O
[]

From O
the O
postintervention O
to O
long-term O
follow-up O
, O
adherence O
in O
the O
group O
condition O
( O
immediate O
intervention O
) O
improved O
in O
comparison O
with O
adherence O
in O
the O
individual O
condition O
( O
delayed O
intervention O
; O
? O
( O
[]

They O
were O
randomly O
assigned O
to O
one O
of O
three O
3-day O
conditions O
. O
[]

DTkid O
: O
interactive O
simulation O
software O
for O
training O
tutors O
of O
children O
with O
autism O
. O
[]

The O
primary O
end O
point O
is O
a O
composite O
of O
incident O
or O
recurrent B-outcome ['Physiological-Clinical']
CVD I-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
, O
that O
is O
, O
coronary B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
, O
cerebrovascular B-outcome ['Physiological-Clinical']
, O
or O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Based O
on O
the O
5-year O
follow-up O
data O
, O
there O
is O
strong O
evidence O
that O
surgical O
manipulation O
of O
one O
or O
more O
migraine O
trigger O
sites O
can O
successfully O
eliminate B-outcome ['Physiological-Clinical']
or O
reduce O
['Physiological-Clinical']

The O
primary O
outcome O
measure O
was O
the O
change O
in O
FMD B-outcome ['Physiological-Clinical']
after O
8 O
weeks O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
postoperative O
magnesium O
infusion O
on O
duration O
of O
block O
, O
sedation B-outcome ['Physiological-Clinical']
and O
analgesic B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
after O
spinal O
anaesthesia O
. O
['Physiological-Clinical', 'Resource-use']

Whereas O
Group O
I O
patients O
did O
not O
receive O
a O
dopexamine O
infusion O
. O
[]

Norasept O
II O
Study O
Investigators O
. O
[]

Grade O
3/4 O
toxicity B-outcome ['Adverse-effects']
was O
seen O
in O
8 O
patients O
( O
20 O
% O
) O
. O
['Adverse-effects']

The O
proportion O
of O
vaccine B-outcome ['Resource-use']
high O
responders O
was O
higher O
in O
the O
experimental O
group O
( O
n O
= O
48 O
) O
than O
among O
controls O
( O
n O
= O
49 O
; O
48.8 O
% O
vs O
25.0 O
% O
; O
P O
= O
.02 O
) O
at O
9 O
months O
. O
['Resource-use']

The O
incidence O
of O
and O
time O
to O
symptomatic B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
were O
calculated O
for O
any O
mood O
episode O
, O
and O
for O
depressive O
, O
manic O
, O
hypo-manic O
, O
and O
mixed O
mood O
episodes O
. O
['Physiological-Clinical']

Endurance O
physical O
activity O
, O
diet O
and O
fibrinolysis O
. O
[]

RESULTS O
Median O
uterine B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
was O
400 O
g O
in O
both O
LAVH O
and O
TAH O
group O
. O
['Physiological-Clinical']

Transcutaneous O
electrical O
nerve O
stimulation O
for O
postoperative O
pain O
relief O
after O
total O
knee O
arthroplasty O
. O
[]

Low-dose O
intravenous O
midazolam O
reduces O
etomidate-induced O
myoclonus O
: O
a O
prospective O
, O
randomized O
study O
in O
patients O
undergoing O
elective O
cardioversion O
. O
[]

DESIGN O
A O
randomised O
unblinded O
controlled O
trial O
. O
[]

BACKGROUND O
Maximum O
lactate O
steady O
state O
( O
MLSS O
) O
is O
defined O
as O
the O
highest O
steady O
state O
exercise O
level O
one O
can O
maintain O
while O
also O
maintaining O
an O
equilibrium O
between O
the O
elimination O
of O
blood O
lactate O
and O
the O
diffusion O
of O
lactate O
into O
the O
blood O
. O
[]

All O
groups O
demonstrated O
a O
decrease O
( O
P O
< O
.05 O
) O
from O
baseline O
values O
in O
fibularis B-outcome ['Physiological-Clinical']
longus I-outcome ['Physiological-Clinical']
( O
10-30 O
min O
post-intervention O
) O
and O
soleus B-outcome ['Physiological-Clinical']
( O
30 O
min O
post-intervention O
) O
H/M B-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Risperidone O
has O
shown O
safety O
and O
efficacy O
for O
aggressive O
and O
destructive O
behaviors O
in O
short-term O
studies O
. O
[]

No O
association O
between O
dinucleotide O
repeat O
polymorphism O
in O
intron O
1 O
of O
the O
epidermal O
growth O
factor O
receptor O
gene O
EGFR O
and O
risk O
of O
lung O
cancer O
. O
[]

First-generation O
trainees O
scored O
significantly O
higher O
than O
second-generation O
trainees O
on O
both O
skills B-outcome ['Life-Impact']
and O
knowledge B-outcome ['Life-Impact']
assessments I-outcome ['Life-Impact']
( O
p O
= O
0.003 O
) O
. O
['Life-Impact', 'Life-Impact']

Those O
assigned O
to O
PACT O
were O
also O
given O
treatment O
as O
usual O
. O
[]

METHODS/RESULTS O
In O
order O
to O
evaluate O
the O
impact O
of O
vagus O
nerve O
stimulation O
, O
an O
international O
multi-center O
randomized O
clinical O
trial O
( O
INOVATE-HF O
) O
has O
been O
designed O
to O
assess O
safety O
and O
efficacy O
of O
vagus O
nerve O
stimulation O
in O
symptomatic O
patients O
with O
heart O
failure O
on O
optimal O
medical O
therapy O
using O
the O
CardioFit O
System O
( O
BioControl O
Medical O
, O
Yehud O
, O
Israel O
) O
. O
[]

OBJECTIVES O
Soluble O
intercellular O
adhesion O
molecule-1 O
( O
sICAM-1 O
) O
is O
thought O
to O
be O
released O
by O
a O
variety O
of O
cells O
at O
sites O
of O
inflammation O
, O
and O
their O
serum O
levels O
have O
been O
used O
as O
markers O
of O
inflammatory O
and O
immune O
activity O
. O
[]

We O
randomly O
assigned O
101 O
patients O
with O
cirrhosis O
of O
the O
liver O
and O
bleeding O
esophageal O
varices O
to O
undergo O
either O
emergency O
sclerotherapy O
( O
n O
= O
50 O
) O
or O
staple O
transection O
of O
the O
esophagus O
( O
n O
= O
51 O
) O
. O
[]

GERA O
group O
participants O
meet O
with O
a O
nurse O
, O
decide O
whether O
to O
have O
a O
GERA O
blood O
test O
( O
a O
combination O
of O
genetic O
polymorphism O
and O
folate O
) O
, O
and O
, O
if O
tested O
, O
receive O
GERA O
feedback O
. O
[]

CONCLUSIONS O
Depressive O
patients O
are O
able B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
follow I-outcome ['Life-Impact']
prescribed I-outcome ['Life-Impact']
lifestyle I-outcome ['Life-Impact']
recommendations I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
short-term I-outcome ['Life-Impact']
. O
['Life-Impact']

METHODS O
Eighteen O
subjects O
, O
six O
males O
and O
12 O
females O
, O
mean O
age O
: O
32.2 O
years O
, O
were O
evaluated O
. O
[]

METHODS O
Multiple O
n-of-1 O
randomized O
, O
double-blind O
, O
crossover O
trials O
switched O
outpatients O
( O
N O
= O
7 O
) O
between O
a O
generic O
warfarin O
formulation O
( O
Apo-warfarin O
) O
and O
Coumadin O
over O
30 O
weeks O
. O
[]

The O
results O
indicated O
that O
amprenavir B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
decreased O
by O
saquinavir O
soft O
gel O
capsule O
( O
by O
32 O
% O
for O
area O
under O
the O
concentration-time O
curve O
at O
steady B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
[ O
AUC O
( O
ss O
) O
] O
and O
37 O
% O
for O
peak O
plasma O
concentration O
at O
steady B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
[ O
C O
( O
max O
, O
ss O
) O
] O
) O
and O
increased O
by O
indinavir O
( O
33 O
% O
for O
AUC O
( O
ss O
) O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Laparoscopically O
assisted O
vaginal O
hysterectomy O
versus O
abdominal O
hysterectomy O
in O
stage O
I O
endometrial O
cancer O
. O
[]

In O
the O
absence O
of O
obesity O
or O
overweight O
, O
the O
presence O
of O
fasting B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
?100 O
mg/dL O
, O
HOMA-IR O
index O
?3 O
, O
triglyceride O
levels O
?150 O
mg/dL O
and/or O
systolic O
and O
diastolic O
blood O
pressure O
?140 O
and O
90 O
mmHg O
defined O
the O
presence O
of O
the O
MONW O
phenotype O
. O
['Physiological-Clinical']

A O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
was O
conducted O
. O
[]

This O
randomized O
controlled O
trial O
looked O
at O
the O
effect O
of O
a O
new O
computer O
program O
designed O
to O
teach O
people O
with O
autistic O
spectrum O
disorders O
to O
better O
recognize O
and O
predict O
emotional O
responses O
in O
others O
. O
[]

We O
aimed O
to O
evaluate O
platelet O
activation O
and O
fibrinolyis O
in O
acute O
atherosclerotic O
ischemic O
stroke O
patients O
to O
clarify O
the O
relationship O
between O
them O
. O
[]

[ O
Efficacy O
of O
naftopidil O
in O
patients O
with O
overactive O
bladder O
associated O
with O
benign O
prostatic O
hyperplasia O
: O
prospective O
randomized O
controlled O
study O
to O
compare O
differences O
in O
efficacy O
between O
morning O
and O
evening O
medication O
] O
. O
[]

At O
12 O
months O
, O
patients O
receiving O
tamoxifen O
had O
a O
significantly O
higher O
mean O
hot B-outcome ['Physiological-Clinical']
flash I-outcome ['Physiological-Clinical']
score O
( O
P O
= O
.03 O
) O
, O
with O
daily O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
increasing O
from O
baseline O
by O
33 O
% O
compared O
with O
a O
7 O
% O
increase O
from O
baseline O
with O
exemestane O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
While O
the O
benefits O
of O
planned O
replacement O
of O
soft O
contact O
lenses O
have O
been O
investigated O
, O
the O
question O
of O
whether O
there O
are O
any O
clinical O
benefits O
to O
planned O
replacement O
of O
rigid O
gas O
permeable O
( O
RGP O
) O
lenses O
does O
not O
appear O
to O
have O
been O
addressed O
experimentally O
. O
[]

For O
example O
, O
subjects O
may O
be O
uncommunicative O
and O
extremely O
heterogeneous O
in O
problem O
presentation O
, O
and O
current O
pharmacological O
treatments O
are O
not O
likely O
to O
alter O
most O
core O
features O
of O
autism O
. O
[]

Mean O
blood B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
through O
the O
brachial O
artery O
was O
1680+/-156 O
and O
1450+/-221 O
mL/min O
three O
months O
after O
surgery O
for O
the O
PTFE O
and O
the O
BB-AVF O
group O
, O
respectively O
. O
['Physiological-Clinical']

APPLICATIONS O
Prestudy O
chemical O
validation O
of O
menus O
and O
continuous O
sampling O
and O
assay O
of O
diets O
throughout O
the O
study O
are O
essential O
to O
standardize O
experimental O
diets O
and O
to O
ensure O
that O
nutrient O
target O
goals O
are O
met O
and O
maintained O
throughout O
a O
controlled O
multicenter O
feeding O
study O
. O
[]

There O
are O
four O
core O
musculoskeletal O
topics O
. O
[]

CONCLUSION O
The O
smooth O
, O
cohesive O
HA O
gel O
with O
preincorporated O
lidocaine O
increased O
subject B-outcome ['Life-Impact']
comfort I-outcome ['Life-Impact']
during O
treatment O
and O
improved O
the O
injection B-outcome ['Physiological-Clinical']
experience I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

BACKGROUND O
In O
recent O
years O
some O
studies O
have O
been O
published O
supporting O
the O
efficacy O
of O
light O
exposure O
, O
physical O
activity O
, O
sleep O
control O
and O
a O
Mediterranean O
diet O
pattern O
on O
the O
improvement O
or O
prevention O
of O
depression O
. O
[]

Pain B-outcome ['Physiological-Clinical']
outcomes O
were O
assessed O
, O
including O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
( O
1-10 O
visual-analogue O
scale O
) O
and O
the O
use O
of O
hydrocodone O
bitartrate O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
significant O
difference O
between O
the O
groups O
regarding O
the O
detection O
thresholds O
( O
electrical O
and O
heat O
) O
. O
[]

Patients O
in O
tamoxifen O
group O
received O
wedge O
mastectomy O
if O
there O
was O
sign O
of O
local O
progression O
. O
[]

All O
urodynamic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
significantly O
improved O
in O
group O
1 O
. O
['Physiological-Clinical']

A O
randomized O
, O
double-masked O
, O
placebo-controlled O
parallel O
study O
of O
loteprednol O
etabonate O
0.2 O
% O
in O
patients O
with O
seasonal O
allergic O
conjunctivitis O
. O
[]

Approximately O
0.5 O
tablet O
per O
day O
less O
analgesic B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
was O
taken O
by O
the O
amiprilose O
group O
( O
P O
less O
than O
0.05 O
at O
weeks O
6 O
and O
12 O
) O
. O
['Resource-use']

By O
contrast O
, O
the O
combination O
of O
verapamil O
plus O
lithium O
was O
highly O
efficacious O
. O
[]

Body O
weight O
was O
reduced O
by O
2.3-3.7 O
% O
among O
participants O
, O
whereas O
values O
increased O
by O
0.5-1.7 O
% O
in O
non-intervened O
subjects O
with O
impaired O
glucose O
tolerance O
and O
in O
normal O
control O
subjects O
( O
p O
less O
than O
0.0001 O
) O
; O
maximal B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
( O
ml.min-1.kg-1 O
) O
was O
increased O
by O
10-14 O
% O
vs O
decreased O
by O
5-9 O
% O
, O
respectively O
( O
p O
less O
than O
0.0001 O
) O
. O
['Physiological-Clinical']

Medication O
side O
effects O
were O
mild O
in O
the O
majority O
of O
subjects O
. O
( O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
pentoxifylline O
for O
the O
treatment O
of O
recurrent O
aphthous O
stomatitis O
. O
[]

Fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
samples O
were O
collected O
before O
and O
after O
12-month O
treatment O
for O
determinations O
of O
fibrinogen B-outcome ['Physiological-Clinical']
, O
prothrombin O
fragment O
1+2 O
( O
F1+2 O
) O
, O
plasma O
D-dimer O
, O
soluble B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
, O
tissue B-outcome ['Physiological-Clinical']
plasminogen I-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
tPA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
, O
tPA B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
plasminogen B-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
type-1 I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PAI-1 I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
serum O
D-dimer O
as O
a O
global O
test O
of O
fibrinolytic O
activity O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Both O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
significantly O
lower O
after O
administration O
of O
captopril O
25 O
mg O
, O
whereas O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
unaffected O
by O
enalapril O
compared O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
in O
the O
brain B-outcome ['Physiological-Clinical']
was O
longer O
in O
the O
combined-modality O
group O
( O
P=.005 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Levamisole O
versus O
placebo O
as O
an O
adjunct O
to O
primary O
therapy O
of O
laryngopharyngeal O
epidermoid O
carcinoma O
. O
[]

RESULTS O
Of O
84 O
patients O
initially O
enrolled O
, O
16 O
( O
19 O
percent O
) O
were O
found O
to O
have O
silent O
, O
persistent O
infection O
on O
the O
basis O
of O
cultures O
that O
became O
positive O
after O
entry O
into O
the O
study O
; O
7 O
other O
patients O
were O
lost O
to O
follow-up O
shortly O
after O
entry O
. O
[]

The O
maximum O
observed O
plasma B-outcome ['Physiological-Clinical']
acetaminophen I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
actual O
C O
( O
max O
) O
) O
and O
time B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
actual I-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
actual I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
determined O
, O
and O
pharmacokinetic O
modeling O
was O
used O
to O
calculate O
model O
C O
( O
max O
) O
and O
model O
T O
( O
max O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Additional O
evaluations O
performed O
at O
baseline O
and O
at O
each O
maximal O
administered O
dose O
regimen O
included O
tear O
and O
saliva O
quantitation O
, O
24 O
hour O
electrocardiogram O
( O
ECG O
) O
, O
exercise O
testing O
and O
programmed O
ventricular O
stimulation O
. O
[]

There O
were O
no O
differences O
in O
the O
number O
of O
attempts B-outcome ['Life-Impact']
at I-outcome ['Life-Impact']
esophageal I-outcome ['Life-Impact']
intubation I-outcome ['Life-Impact']
, O
the O
amount O
of O
sedation B-outcome ['Life-Impact']
used O
, O
and O
the O
['Life-Impact', 'Life-Impact']

Azimilide O
decreases O
recurrent B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
tachyarrhythmias I-outcome ['Physiological-Clinical']
in O
patients O
with O
implantable O
cardioverter O
defibrillators O
. O
['Physiological-Clinical']

Fondaparinux O
was O
investigated O
in O
phase O
2 O
studies O
for O
the O
treatment O
of O
acute O
coronary O
syndromes O
, O
including O
acute B-outcome ['Physiological-Clinical']
ST-segment I-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PENTALYSE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
unstable B-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PENTUA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Vitamin O
C O
was O
measured O
in O
plasma O
and O
vitamin O
E O
and O
carotenoids O
were O
measured O
in O
serum O
by O
high-performance O
liquid O
chromatography O
( O
HPLC O
) O
. O
[]

1.98 O
?g/mL O
after O
25 O
min O
of O
reperfusion O
in O
Group O
I O
vs. O
10.19 O
? O
[]

Line-item O
analysis O
of O
the O
Aberrant O
Behavior O
Checklist O
: O
results O
from O
two O
studies O
of O
aripiprazole O
in O
the O
treatment O
of O
irritability O
associated O
with O
autistic O
disorder O
. O
[]

Under O
the O
conditions O
of O
this O
study O
, O
lactoferrin O
supplementation O
was O
not O
beneficial O
. O
[]

There O
was O
no O
penalty O
for O
an O
incorrect O
answer O
. O
[]

It O
made O
no O
difference O
whether O
motion B-outcome ['Life-Impact']
discrimination I-outcome ['Life-Impact']
was O
accomplished O
by O
saccades B-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
verbal I-outcome ['Life-Impact']
responses I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

These O
findings O
are O
discussed O
in O
the O
context O
of O
the O
increasingly O
central O
role O
of O
service O
user O
outcomes O
in O
providing O
evidence O
for O
an O
intervention O
. O
[]

Hemostasis O
by O
bipolar O
coagulation O
versus O
suture O
after O
surgical O
stripping O
of O
bilateral O
ovarian O
endometriomas O
: O
a O
randomized O
controlled O
trial O
. O
[]

INTERPRETATION O
Eltrombopag O
is O
effective O
for O
management O
of O
chronic O
immune O
thrombocytopenia O
, O
and O
could O
be O
particularly O
beneficial O
for O
patients O
who O
have O
not O
responded O
to O
splenectomy O
or O
previous O
treatment O
. O
[]

In O
complex O
regional O
pain O
syndrome O
( O
CRPS1 O
) O
initiated O
by O
wrist O
fracture O
, O
a O
motor O
imagery O
program O
( O
MIP O
) O
, O
consisting O
of O
hand O
laterality O
recognition O
followed O
by O
imagined O
movements O
and O
then O
mirror O
movements O
, O
reduces O
pain B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
, O
but O
the O
mechanism O
of O
effect O
is O
unclear O
. O
['Physiological-Clinical', 'Life-Impact']

They O
were O
randomly O
assigned O
in O
a O
2 O
: O
1 O
order O
to O
either O
statin O
therapy O
( O
pravastatin O
, O
40 O
mg O
daily O
) O
or O
exercise O
training O
therapy O
( O
mild O
endurance O
exercise O
three O
or O
more O
times O
a O
week O
) O
. O
[]

Blood B-outcome ['Physiological-Clinical']
purification I-outcome ['Physiological-Clinical']
for O
critical O
care O
medicine O
: O
endotoxin O
adsorption O
. O
['Physiological-Clinical']

A O
controlled O
trial O
of O
intravenous O
immune O
globulin O
to O
reduce O
nosocomial B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
very-low-birth-weight O
infants O
. O
['Physiological-Clinical']

BACKGROUND O
Because O
intercellular O
adhesion O
molecule O
( O
ICAM O
) O
1 O
and O
recruitment O
of O
eosinophils O
are O
crucial O
in O
supporting O
allergic O
inflammation O
, O
their O
down-regulation O
may O
bring O
additional O
benefits O
in O
patients O
' O
recovery O
. O
[]

In O
one O
patient O
loculation B-outcome ['Physiological-Clinical']
was O
observed O
, O
but O
only O
250 O
ml O
of O
normal O
saline O
was O
infused O
with O
Tc-99m O
SC O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
attempt O
at O
leak O
compensation O
largely O
feeds O
the O
leakage O
itself O
and O
only O
results O
in O
a O
marginal O
increase O
of O
tidal O
volume O
. O
[]

We O
estimated O
annual O
income O
, O
hours O
worked O
, O
and O
average O
hourly O
wages O
from O
all O
economic O
activities O
. O
[]

Randomized O
controlled O
trial O
for O
early O
intervention O
for O
autism O
: O
a O
pilot O
study O
of O
the O
Autism O
1-2-3 O
Project O
. O
[]

Secondary O
endpoints O
were O
mean O
changes O
from O
baseline O
in O
post-bronchodilator B-outcome ['Physiological-Clinical']
forced I-outcome ['Physiological-Clinical']
expired I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
s I-outcome ['Physiological-Clinical']
( O
FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
) O
and O
CCQ B-outcome ['Physiological-Clinical']
scores O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Hyperglycaemia O
was O
reported O
by O
12 O
of O
106 O
( O
11 O
% O
) O
patients O
in O
the O
ganitumab O
group O
( O
with O
six O
patients O
having O
grade O
3 O
or O
4 O
hyperglycaemia O
) O
and O
none O
of O
49 O
in O
the O
placebo O
group O
. O
[]

Chumnguh O
thleum O
: O
understanding O
liver O
illness O
and O
hepatitis O
B O
among O
Cambodian O
immigrants O
. O
[]

It O
may O
aggravate O
[]

METHODS O
The O
following O
pain O
models O
were O
applied O
: O
( O
1 O
) O
pain O
thresholds O
to O
single O
and O
repeated O
cutaneous O
and O
intramuscular O
electrical O
stimulation O
( O
temporal O
summation O
to O
5 O
stimuli O
delivered O
at O
2 O
Hz O
) O
; O
( O
2 O
) O
stimulus-response O
function O
relating O
pain O
intensity O
scores O
( O
visual O
analog O
scale O
, O
VAS O
) O
to O
increasing O
current O
intensities O
for O
electrical O
skin O
and O
muscle O
stimuli O
( O
single O
and O
repeated O
, O
determined O
at O
baseline O
) O
; O
and O
( O
3 O
) O
the O
pain O
intensity O
( O
VAS O
) O
and O
pain O
areas O
after O
intramuscular O
injection O
of O
hypertonic O
saline O
. O
[]

114 O
patients O
were O
clinical O
stage O
B O
whereas O
41 O
were O
clinical O
stage O
C. O
After O
three O
months O
of O
total O
androgen O
ablation O
, O
pathological B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
was O
more O
prevalent O
among O
patients O
with O
clinical O
B O
tumours O
, O
compared O
with O
untreated O
patients O
( O
57 O
% O
in O
treated O
patients O
vs. O
36 O
% O
in O
untreated O
) O
. O
['Physiological-Clinical']

A O
surveillance O
system O
, O
including O
CCD O
cameras O
and O
pulse O
oximeters O
, O
will O
be O
set O
up O
to O
evaluate O
the O
intervention O
. O
[]

This O
benefit O
increased O
with O
2 O
years O
additional O
follow-up O
( O
P=0.006 O
, O
hazard O
ratio=1.68 O
( O
1.16-2.44 O
) O
) O
, O
with O
2-year O
survival B-outcome ['Mortality']
of O
5 O
% O
and O
18 O
% O
respectively O
. O
['Mortality']

A O
randomized O
controlled O
trial O
of O
nonlinear O
frequency O
compression O
versus O
conventional O
processing O
in O
hearing O
aids O
: O
speech O
and O
language O
of O
children O
at O
three O
years O
of O
age O
. O
[]

In O
the O
second O
group O
these O
reductions O
were O
38.5 O
% O
( O
P O
< O
0.001 O
) O
, O
46.2 O
% O
( O
P O
< O
0.001 O
) O
, O
and O
26.78 O
% O
( O
P O
< O
0.001 O
) O
, O
respectively O
, O
and O
the O
increase O
in O
HDL B-outcome ['Physiological-Clinical']
was O
7.8 O
% O
( O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical']

The O
respective O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
85 O
% O
, O
74 O
% O
, O
55 O
% O
and O
84 O
% O
, O
71 O
% O
, O
40 O
% O
( O
P O
= O
0.64 O
) O
. O
['Mortality']

Outcome O
measurement O
tools O
included O
monthly O
Global B-outcome ['Life-Impact']
Behaviour I-outcome ['Life-Impact']
Rating O
Scales O
, O
Additional O
Rating O
Scales O
of O
other O
symptoms O
by O
parents O
and O
therapists O
, O
and O
monthly O
completion O
of O
the O
Rescorla O
Language B-outcome ['Physiological-Clinical']
Development I-outcome ['Physiological-Clinical']
Survey O
. O
['Life-Impact', 'Physiological-Clinical']

Patients O
in O
the O
two O
treatment O
groups O
did O
not O
differ O
at O
entry O
in O
biochemical B-outcome ['Physiological-Clinical']
measures I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
histological I-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Neonates O
scheduled O
for O
cardiac O
surgery O
were O
randomly O
assigned O
to O
receive O
either O
2-dose O
( O
8 O
hours O
preoperatively O
and O
operatively O
, O
n O
= O
39 O
) O
or O
single-dose O
( O
operatively O
, O
n O
= O
37 O
) O
methylprednisolone O
( O
30 O
mg/kg O
per O
dose O
) O
in O
a O
prospective O
double-blind O
trial O
. O
[]

In O
group O
2 O
, O
hemodilution O
( O
hematocrit O
30 O
+/- O
3 O
% O
) O
resulted O
in O
a O
steeper O
increase O
in O
the O
albumin B-outcome ['Physiological-Clinical']
diffusion I-outcome ['Physiological-Clinical']
space I-outcome ['Physiological-Clinical']
( O
p O
< O
.05 O
) O
and O
a O
progressive O
decrease O
in O
the O
body B-outcome ['Physiological-Clinical']
electrical I-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
( O
p O
< O
.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

1.88 O
?g/mL O
, O
respectively O
, O
in O
Group O
II O
) O
. O
[]

Negative O
dromotropic B-outcome ['Physiological-Clinical']
effects O
of O
Gallopamil O
could O
be O
abolished O
by O
Enoximone O
. O
['Physiological-Clinical']

[ O
Hemostatic O
balance O
during O
treatment O
with O
the O
newest O
contraceptives O
] O
. O
[]

LIMITATIONS O
An O
imbalance O
existed O
in O
the O
number O
of O
patients O
with O
the O
clinical O
outcome O
unable O
to O
determine O
( O
15 O
retapamulin O
, O
2 O
cephalexin O
) O
, O
mainly O
because O
of O
their O
failure O
to O
attend O
the O
study O
visit O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
tetrahydrobiopterin O
( O
BH4 O
) O
reduced O
core O
symptoms O
of O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

The O
dud O
effect O
: O
adding O
highly O
dissimilar O
fillers O
increases O
confidence O
in O
lineup O
identifications O
. O
[]

Dopexamine O
has O
no O
additional O
benefit O
in O
high-risk O
patients O
receiving O
goal-directed O
fluid O
therapy O
undergoing O
major O
abdominal O
surgery O
. O
[]

The O
aim O
of O
the O
present O
project O
was O
to O
investigate O
different O
types O
of O
ear O
plugs O
and O
their O
effect O
on O
speech O
intelligibility O
in O
helicopter O
noise O
. O
[]

In O
the O
treatment O
group O
there O
was O
a O
mean O
relative O
reduction O
of I-outcome ['Physiological-Clinical']
postoperative B-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
thigh I-outcome ['Physiological-Clinical']
by O
3.27 O
cm O
( O
p O
less O
than O
0.001 O
) O
and O
of O
the O
calf O
by O
1.55 O
cm O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
splinting O
teeth O
on O
the O
results O
of O
periodontal O
reconstructive O
surgery O
using O
a O
specific O
carbonate O
bone O
replacement O
graft O
( O
BRG O
) O
material O
. O
[]

MAIN O
OUTCOME O
MEASURE O
Weight O
changes O
. O
[]

This O
study O
is O
registered O
, O
number O
ISRCTN54469112 O
. O
[]

Tobacco O
use O
prevention O
and O
cessation O
( O
TUPAC O
) O
counselling O
guidelines O
recommend O
that O
healthcare O
providers O
ask O
about O
each O
patient O
's O
tobacco O
use O
, O
assess O
the O
patient O
's O
readiness O
and O
willingness O
to O
stop O
, O
document O
tobacco O
use O
habits O
, O
advise O
the O
patient O
to O
stop O
, O
assist O
and O
help O
in O
quitting O
, O
and O
arrange O
monitoring O
of O
progress O
at O
follow-up O
appointments O
. O
[]

This O
phase O
of O
depression B-outcome ['Life-Impact']
partially O
overlapped O
the O
phase O
of O
depression O
of O
the O
soleus O
H-reflex O
during O
walking O
. O
['Life-Impact']

BACKGROUND O
Depressive O
disorder O
is O
currently O
one O
of O
the O
most O
burdensome O
disorders O
worldwide O
. O
[]

Following O
a O
pre-test O
on O
leukaemia O
administered O
to O
both O
groups O
, O
the O
Study O
group O
was O
provided O
with O
access O
to O
the O
new O
e-learning O
module O
, O
while O
the O
Control O
group O
was O
directed O
to O
existing O
online O
resources O
. O
[]

In O
addition O
, O
the O
effectiveness O
of O
a O
2-g O
single O
dose O
of O
metronidazole O
was O
compared O
with O
a O
seven-day O
course O
of O
500 O
mg O
of O
metronidazole O
twice O
a O
day O
in O
patients O
with O
bacterial O
vaginosis O
. O
[]

One O
hundred O
and O
eighty-one O
patients O
in O
the O
CA O
group O
versus O
175 O
in O
the O
placebo O
group O
completed O
the O
three-month O
study O
. O
[]

In O
a O
subgroup O
( O
N O
= O
23 O
) O
, O
manual O
motor B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
was O
tested O
with O
tasks O
of O
graded O
dexterous O
demand O
. O
['Life-Impact']

The O
addition O
of O
MTP O
to O
chemotherapy O
improved O
6-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
from O
70 O
% O
to O
78 O
% O
( O
P O
= O
.03 O
) O
. O
['Mortality']

The O
data O
are O
in O
line O
with O
recent O
experimental O
studies O
showing O
a O
beneficial O
metabolic O
effect O
of O
captopril O
in O
Type O
II O
diabetes O
. O
[]

Cryotherapy O
does O
not O
affect O
peroneal O
reaction O
following O
sudden O
inversion O
. O
[]

Drug O
therapy O
will O
be O
continued O
for O
all O
patients O
throughout O
the O
entire O
study O
unless O
adverse O
reactions O
occur O
that O
necessitate O
individualized O
treatment O
. O
[]

Raters O
' O
[]

METHODS O
We O
prospectively O
compared O
the O
results O
of O
520 O
patients O
with O
osteoarthritis O
who O
underwent O
computer-navigated O
total O
knee O
arthroplasty O
for O
one O
knee O
and O
conventional O
total O
knee O
arthroplasty O
for O
the O
other O
. O
[]

Major B-outcome ['Physiological-Clinical']
bleeds I-outcome ['Physiological-Clinical']
occurred O
in O
1.6 O
% O
( O
10/635 O
) O
and O
0.2 O
% O
( O
1/650 O
) O
of O
fondaparinux-treated O
and O
placebo-treated O
patients O
, O
respectively O
( O
P O
= O
0.006 O
) O
, O
none O
being O
fatal O
or O
involving O
a O
critical O
organ O
. O
['Physiological-Clinical']

The O
influence O
of O
dietary O
fibre O
source O
and O
gender O
on O
the O
postprandial B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
lipid B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
healthy O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
other O
drugs O
, O
such O
as O
dopaminergic O
agonists O
or O
antagonists O
, O
have O
therapeutic O
effects O
. O
[]

Cardiac B-outcome ['Physiological-Clinical']
safety O
of O
formoterol O
12 O
microg O
twice O
daily O
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
. O
['Physiological-Clinical']

There O
was O
no O
difference O
between O
postoperatively O
irradiated O
patients O
and O
patients O
treated O
with O
surgery O
only O
. O
[]

All O
participants O
received O
progressive O
exercise O
training O
. O
[]

Neither O
was O
subjective O
improvement O
significant O
, O
with O
29.2 O
% O
vs. O
27.3 O
% O
of O
the O
women O
reporting O
improvement O
in O
the O
amount O
of O
urinary B-outcome ['Physiological-Clinical']
leakage I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Magnetic O
resonance O
angiography O
for O
monitoring O
prophylactic O
endoscopic O
treatment O
of O
high O
risk O
esophageal O
varices O
. O
[]

RESULTS O
Nineteen O
patients O
were O
randomized O
in O
group O
I O
and O
17 O
patients O
in O
group O
II O
. O
[]

The O
primary O
outcomes O
is O
the O
mortality B-outcome ['Mortality']
rate O
at O
6 O
months O
follow-up O
. O
['Mortality']

A O
special O
education O
teacher O
provided O
40 O
visits O
over O
12 O
months O
working O
with O
the O
families O
to O
help O
generalize O
skills O
to O
the O
home O
environment O
and O
assist O
with O
their O
concerns O
. O
[]

There O
was O
no O
placebo O
control O
group O
. O
[]

CONCLUSION O
A O
quality O
improvement O
intervention O
that O
can O
be O
widely O
disseminated O
by O
using O
Internet-based O
information O
technology O
significantly O
improved O
the O
quality O
of O
ADHD O
care O
in O
community-based O
pediatric O
settings O
. O
[]

Previous O
intervention O
studies O
have O
been O
limited O
by O
size O
or O
design O
and O
have O
shown O
mixed O
results O
. O
[]

Venographic O
assessment O
of O
clot B-outcome ['Physiological-Clinical']
size O
evolution O
between O
day O
0 O
and O
day O
10 O
showed O
a O
statistically O
significant O
superiority O
( O
P O
< O
.002 O
) O
of O
enoxaparin O
over O
the O
reference O
treatment O
with O
UFH O
. O
['Physiological-Clinical']

A O
double-blind O
comparison O
of O
oral O
ketoprofen O
'controlled O
release O
' O
and O
indomethacin O
suppository O
in O
the O
treatment O
of O
rheumatoid O
arthritis O
with O
special O
regard O
to O
morning O
stiffness O
and O
pain O
on O
awakening O
. O
[]

Patients O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O
[]

RESULTS O
After O
a O
learning O
curve O
of O
27 O
basket O
retrievals O
, O
there O
was O
no O
significant O
difference O
in O
stone B-outcome ['Physiological-Clinical']
capture I-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
between O
novice O
( O
38 O
+/- O
54 O
seconds O
) O
and O
expert O
operators O
( O
32 O
+/- O
49 O
seconds O
, O
p O
= O
0.174 O
) O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
is O
to O
prospectively O
compare O
the O
local O
control O
rate O
, O
toxicity O
profiles O
, O
and O
overall O
survival O
( O
OS O
) O
between O
patients O
received O
different O
target O
volumes O
irradiation O
after O
induction O
chemotherapy O
. O
[]

They O
were O
randomly O
classified O
into O
two O
groups O
. O
[]

RESULTS O
Parent O
follow-in O
comments O
and O
follow-in O
directives O
predicted O
spoken O
vocabulary O
after O
controlling O
for O
child O
engagement O
. O
[]

Compared O
to O
the O
control O
group O
, O
the O
fitness B-outcome ['Physiological-Clinical']
level O
increased O
( O
p O
< O
0.01 O
) O
and O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
decreased O
in O
the O
I O
group O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Despite O
the O
high O
rates O
of O
Internet O
access O
, O
actual O
reach O
by O
Web-based O
interventions O
is O
often O
disappointingly O
low O
, O
and O
differences O
in O
use O
between O
demographic O
subgroups O
are O
present O
. O
[]

Information O
on O
eating B-outcome ['Life-Impact']
patterns I-outcome ['Life-Impact']
, O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
weight O
and O
metabolic B-outcome ['Physiological-Clinical']
variables O
was O
collected O
at O
baseline O
and O
after O
1 O
year O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

RESULTS O
Compared O
with O
baseline O
values O
, O
the O
mean O
inhibition O
of O
total O
platelet B-outcome ['Physiological-Clinical']
deposition I-outcome ['Physiological-Clinical']
was O
63.9+/-5.9 O
% O
with O
clopidogrel O
plus O
acetylsalicylic O
acid O
, O
compared O
with O
18.4+/-5.6 O
% O
for O
extended-release O
dipyridamole O
plus O
acetylsalicylic O
acid O
( O
67 O
% O
reduction O
; O
95 O
% O
CI O
, O
49-79 O
% O
; O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Study O
retention B-outcome ['Life-Impact']
rates O
were O
excellent O
, O
with O
95 O
% O
of O
both O
support O
persons O
and O
smokers O
completing O
the O
week O
26 O
assessment O
. O
['Life-Impact']

Efficacy O
and O
safety O
relative O
to O
placebo O
of O
an O
oral O
formulation O
of O
cetirizine O
and O
sustained-release O
pseudoephedrine O
in O
the O
management O
of O
nasal B-outcome ['Physiological-Clinical']
congestion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Metformin O
was O
given O
1500 O
mg O
daily O
for O
4 O
weeks O
. O
[]

However O
, O
the O
delta-PVR O
response O
to O
hypoxaemia B-outcome ['Physiological-Clinical']
was O
not O
significantly O
altered O
by O
frusemide O
compared O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
BMD O
of O
lumbar B-outcome ['Physiological-Clinical']
vertebrae I-outcome ['Physiological-Clinical']
and O
femur O
in O
observation O
group O
increased O
obviously O
than O
that O
before O
treatment O
( O
P O
< O
0.01 O
, O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Aspirin O
in O
patients O
undergoing O
noncardiac O
surgery O
. O
[]

Efficacy O
of O
this O
compound O
would O
support O
the O
usefulness O
of O
the O
model O
in O
prophylactic O
antimigraine O
drug O
development O
. O
[]

BACKGROUND O
Breast O
cancer O
surgery O
performed O
with O
the O
patient O
under O
general O
anesthesia O
has O
been O
associated O
with O
a O
relatively O
high O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
vomiting I-outcome ['Physiological-Clinical']
( O
PONV B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Couples O
reviewed O
videotapes O
of O
the O
episodes O
and O
completed O
measures O
of O
responsibility O
, O
struggle O
, O
and O
cooperation O
. O
[]

A O
double-blind O
, O
placebo-controlled O
study O
of O
fluvoxamine O
in O
adults O
with O
autistic O
disorder O
. O
[]

INTERVENTIONS O
After O
placement O
of O
catheters O
in O
the O
pulmonary O
artery O
, O
radial O
artery O
, O
peripheral O
and O
right O
hepatic O
vein O
, O
one O
hour O
postoperatively O
either O
enflurane O
or O
isoflurane O
was O
applied O
at O
different O
minimum O
alveolar O
concentration O
( O
MAC O
) O
of O
0.5 O
, O
1.0 O
, O
and O
1.5 O
in O
a O
randomized O
order O
. O
[]

For O
two O
matched O
chemotherapy O
treatments O
, O
one O
pre-test O
and O
two O
post-test O
measures O
were O
employed O
. O
[]

SETTING O
Four O
district O
general O
hospitals O
in O
the O
West O
Midlands O
. O
[]

Four O
patients O
( O
8 O
eyes O
) O
had O
bilateral O
zone O
1 O
disease O
. O
[]

mCIT O
has O
shown O
efficacy O
in O
all O
stages O
poststroke O
. O
[]

Both O
drugs O
were O
ineffective O
as O
sole O
analgesic B-outcome ['Resource-use']
agents O
in O
half O
of O
their O
respective O
groups O
. O
['Resource-use']

DESIGN O
Randomized O
clinical O
trial O
. O
[]

Erythrocyte B-outcome ['Physiological-Clinical']
deformability I-outcome ['Physiological-Clinical']
was O
reduced O
in O
the O
cyclosporin-treated O
patients O
and O
returned O
to O
normal O
values O
after O
supplementation O
of O
either O
oil O
. O
['Physiological-Clinical']

Group O
I O
consisted O
of O
15 O
patients O
with O
Forrest O
IB O
and O
Group O
II O
consisted O
of O
30 O
patients O
with O
Forrest O
II O
. O
[]

RESULTS O
After O
anesthesia O
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
HR B-outcome ['Physiological-Clinical']
measurements O
were O
not O
significantly O
changed O
in O
both O
groups O
compared O
with O
the O
baseline O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
investigate O
the O
effects O
of O
810-nm O
diode O
laser O
treatment O
on O
hair O
and O
on O
the O
biophysical O
properties O
of O
skin O
by O
using O
various O
non-invasive O
techniques O
on O
various O
parameters O
, O
including O
hair O
analysis O
, O
surface O
color O
changes O
, O
integrity O
of O
skin O
barrier O
, O
sebum O
production O
rate O
and O
pH O
level O
. O
[]

METHOD O
In O
a O
parallel O
groups O
design O
, O
12 O
children O
with O
DSM-IV O
autistic O
disorder O
( O
mean O
age O
7.8+/-2.1 O
years O
) O
were O
randomized O
to O
6 O
weeks O
of O
open O
treatment O
with O
olanzapine O
or O
haloperidol O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
use O
of O
beta B-outcome ['Resource-use']
blockers I-outcome ['Resource-use']
or O
the O
incidence O
of O
coronary B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
disease B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Results O
showed O
no O
significant O
differences O
between O
barrier O
cream O
and O
vehicle O
. O
[]

There O
was O
no O
suppression O
of O
early B-outcome ['Physiological-Clinical']
morning I-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
in O
either O
treatment O
group O
. O
['Physiological-Clinical']

In O
addition O
, O
multiple O
assessments O
of O
insulin O
sensitivity O
were O
conducted O
. O
[]

The O
participants O
, O
children O
aged O
6 O
weeks O
to O
15 O
months O
, O
admitted O
with O
first-time O
wheezing O
, O
were O
eligible O
if O
their O
oxygen O
saturation O
was O
less O
than O
95 O
% O
on O
admission O
to O
the O
hospital O
and O
their O
Respiratory B-outcome ['Physiological-Clinical']
Distress I-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
Instrument I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RDAI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
score O
was O
greater O
than O
6 O
. O
['Physiological-Clinical']

RESULTS O
Visit-to-visit O
24-h O
SBP/DBP O
variabilities O
were O
20-25 O
% O
smaller O
than O
, O
and O
loosely O
correlated O
with O
clinic O
BP O
variability O
( O
r O
( O
2 O
) O
< O
0.022 O
) O
. O
[]

Of O
21 O
patients O
with O
bladder O
recurrence O
, O
17 O
had O
recurrent B-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
around I-outcome ['Physiological-Clinical']
cystotomy I-outcome ['Physiological-Clinical']
or O
in O
the O
bladder B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
compromised O
by O
the O
urethral O
catheter O
, O
supporting O
the O
notion O
that O
tumor O
cells O
seeded O
in O
the O
injured O
urothelium O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
test O
the O
hypothesis O
that O
an O
equivalent O
GVR O
might O
be O
obtained O
by O
an O
absorbed O
thyroid O
dose O
well O
below O
what O
has O
been O
used O
previously O
. O
[]

Treatment O
of O
whiplash O
associated O
neck O
pain O
[ O
corrected O
] O
with O
botulinum O
toxin-A O
: O
a O
pilot O
study O
. O
[]

Multisensory O
temporal O
integration O
in O
autism O
spectrum O
disorders O
. O
[]

State-Trait B-outcome ['Life-Impact']
Anxiety I-outcome ['Life-Impact']
Inventory O
( O
STAI O
) O
and O
the O
Short O
Form-36 O
( O
SF-36 O
) O
were O
administered O
at O
study O
inclusion O
, O
after O
1 O
, O
6 O
months O
. O
['Life-Impact']

The O
overall O
major O
response O
rate O
was O
13 O
% O
( O
three O
complete O
responders O
and O
three O
partial O
responders O
among O
47 O
evaluable O
patients O
) O
and O
was O
the O
same O
on O
both O
arms O
. O
[]

RESULTS O
A O
hundred O
and O
one O
eligible O
patients O
were O
analyzed O
. O
[]

Forty-five O
patients O
were O
randomly O
treated O
with O
a O
periodontal O
surgery O
approach O
. O
[]

A O
controlled O
trial O
with O
diclofensine O
, O
a O
new O
psychoactive O
drug O
, O
in O
the O
treatment O
of O
depression O
. O
[]

On O
Days O
-2 O
, O
7 O
, O
14 O
, O
21 O
, O
and O
28 O
, O
each O
cat O
was O
infested O
with O
100 O
adult O
C. O
felis O
from O
the O
Kansas O
1 O
flea O
strain O
. O
[]

Thrombolysis O
is O
an O
efficient O
and O
safe O
treatment O
, O
and O
may O
be O
first-line O
therapy O
if O
there O
is O
no O
contraindication O
. O
[]

This O
study O
investigated O
the O
effect O
of O
chewing O
on O
alertness O
and O
cognitive O
performance O
across O
one O
night O
without O
sleep O
as O
well O
as O
the O
possible O
mediating O
role O
of O
cardiac O
autonomic O
activity O
. O
[]

Comparing O
across O
programs O
tiotropium O
Respimat O
Soft O
Mist O
inhaler O
was O
at O
least O
as O
efficacious O
as O
tiotropium O
HandiHaler O
, O
however O
, O
concerns O
have O
been O
raised O
about O
tiotropium O
's O
safety O
when O
given O
via O
Respimat O
. O
[]

The O
effects O
on O
platelet B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
endothelial I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
either O
by O
angiotensin O
converting O
enzyme O
inhibitors O
or O
angiotensin O
receptor O
antagonists O
, O
are O
still O
not O
well O
understood O
. O
['Physiological-Clinical']

In O
the O
expectant O
management O
group O
, O
40 O
women O
( O
32 O
% O
) O
conceived B-outcome ['Physiological-Clinical']
, O
of O
which O
34 O
pregnancies O
were O
ongoing O
( O
27 O
% O
) O
( O
relative O
risk O
: O
0.85 O
; O
95 O
% O
CI O
: O
0.63-1.1 O
) O
. O
['Physiological-Clinical']

Eye-closure O
led O
to O
an O
increase O
in O
correct O
cued-recall O
, O
with O
no O
increase O
in O
incorrect B-outcome ['Life-Impact']
responses I-outcome ['Life-Impact']
. O
['Life-Impact']

BACKGROUND O
Enteral O
feeding O
is O
known O
to O
be O
effective O
on O
the O
development O
of O
gut O
hormone O
secretion O
and O
pancreatic O
exocrine O
function O
. O
[]

Little O
change O
in O
eGFR B-outcome ['Physiological-Clinical']
occurred O
over O
1 O
year O
in O
the O
atorvastatin O
10-mg O
group O
, O
whereas O
eGFR O
improved O
in O
the O
80-mg O
group O
by O
1.48 O
ml/min/1.73 O
m O
( O
2 O
) O
( O
95 O
% O
confidence O
interval O
1.29 O
to O
1.67 O
, O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

First O
results O
of O
randomized O
prospective O
trial O
. O
[]

Incremental O
cost-effectiveness O
of O
pharmacotherapy O
and O
two O
brief O
cognitive-behavioral O
therapies O
compared O
with O
usual O
care O
for O
panic B-outcome ['Physiological-Clinical']
disorder I-outcome ['Physiological-Clinical']
and O
noncardiac O
chest O
pain O
. O
['Resource-use', 'Physiological-Clinical']

The O
effect O
of O
body O
positioning O
upon O
maximal O
oxygenation O
of O
patients O
with O
unilateral O
lung O
pathology O
. O
[]

With O
this O
in O
mind O
, O
we O
aimed O
to O
determine O
the O
efficacy O
and O
safety O
of O
perianal-intrarectal O
( O
PI O
) O
lidocaine O
gel O
, O
lidocaine-ketorolac O
gel O
, O
and O
lidocaine-prilocaine O
cream O
in O
relieving B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
during O
TPB O
. O
['Physiological-Clinical']

Further O
research O
could O
assess O
whether O
these O
gains O
generalized O
into O
real O
life O
or O
improved O
performance O
on O
theory O
of O
mind O
measures O
. O
[]

Infants O
less O
than O
1500 O
g O
( O
24 O
treated O
, O
15 O
control O
) O
received O
10 O
( O
9 O
) O
LGG O
orally O
twice O
daily O
for O
21 O
days O
. O
[]

Mean O
bactericidal B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
CSF I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
the O
ceftriaxone O
than O
in O
the O
conventional O
treatment O
group O
at O
the O
beginning O
and O
end O
of O
therapy O
. O
['Physiological-Clinical']

PURPOSE O
To O
assess O
any O
changes O
in O
the O
Functional O
Communicative O
Profile O
( O
FCP O
) O
and O
in O
the O
Social O
Cognitive O
Performance O
( O
SCP O
) O
of O
children O
with O
Autism O
Spectrum O
Disorders O
, O
based O
on O
two O
short O
periods O
of O
intervention O
. O
[]

These O
findings O
suggest O
that O
an O
individualized O
, O
comprehensive O
, O
home-based O
cardiac O
rehabilitation O
program O
improves O
risk O
factor O
profiles O
and O
work B-outcome ['Life-Impact']
resumption I-outcome ['Life-Impact']
patterns I-outcome ['Life-Impact']
for O
patients O
following O
PCI O
. O
['Life-Impact']

Toxic B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
and O
health-related B-outcome ['Physiological-Clinical']
and O
menopause-specific B-outcome ['Life-Impact']
qualities I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
were O
measured O
. O
['Adverse-effects', 'Physiological-Clinical', 'Life-Impact']

METHODS O
Patients O
were O
eligible O
if O
they O
had O
stage O
I-IIIB O
NSCLC O
, O
unsuitable O
for O
curative O
therapy O
, O
or O
stage O
IV O
with O
a O
PET-detected O
extracranial O
solitary O
metastasis O
. O
[]

Six O
of O
the O
patients O
were O
also O
studied O
with O
0.1 O
mM/kg O
gadopentetate O
dimeglumine O
. O
[]

METHODS O
STEMI O
patients O
undergoing O
emergency O
PCI O
in O
affiliated O
hospital O
of O
Beihua O
University O
between O
October O
2006 O
and O
January O
2009 O
were O
randomly O
divided O
into O
two O
groups O
: O
the O
control O
group O
( O
n O
= O
34 O
) O
without O
any O
intervention O
after O
PTCA O
, O
and O
the O
postconditioning O
group O
( O
n O
= O
30 O
) O
with O
ischemia O
postconditioning O
within O
first O
minutes O
of O
reflow O
by O
3 O
episodes O
of O
30-second O
inflation O
and O
30-second O
deflation O
with O
the O
angioplasty O
balloon O
. O
[]

Patients O
treated O
in O
the O
current O
study O
with O
rhGM-CSF O
plus O
either O
rHuEPO O
or O
with O
placebo O
had O
a O
higher O
incidence O
of O
rash B-outcome ['Physiological-Clinical']
than O
seen O
in O
our O
historical O
experience O
using O
rhGM-CSF O
. O
['Physiological-Clinical']

RESULTS O
Groups O
were O
well O
matched O
for O
birthweight O
, O
gestation O
and O
CRIB O
scores O
. O
[]

Continuous O
sustained O
quitters O
cost B-outcome ['Resource-use']
less O
than O
their O
matched O
community- O
dwelling O
smokers O
in O
almost O
every O
quarter O
observed O
. O
['Resource-use']

There O
was O
no O
significant O
difference O
in O
the O
maximal B-outcome ['Physiological-Clinical']
percent I-outcome ['Physiological-Clinical']
fall I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
FEV1 I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
baseline I-outcome ['Physiological-Clinical']
between O
LTD4 O
( O
mean O
+/- O
SEM O
, O
49.5 O
+/- O
4.4 O
% O
fall O
) O
and O
methacholine O
( O
mean O
+/- O
SEM O
, O
55.9 O
+/- O
3.4 O
% O
fall O
) O
( O
p O
= O
0.11 O
) O
. O
['Physiological-Clinical']

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
graded O
according O
to O
the O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
v. O
3.0 O
( O
CTCAE O
v3.0 O
) O
. O
['Adverse-effects']

RESULTS O
Good O
mydriasis O
was O
achieved O
in O
both O
groups O
with O
no O
significant O
differences O
in O
pupil B-outcome ['Physiological-Clinical']
size O
or O
blood O
pressure O
( O
systolic O
, O
diastolic O
, O
or O
mean O
arterial O
pressures O
) O
over O
starting O
baseline O
values O
. O
['Physiological-Clinical']

However O
, O
overall O
, O
it O
had O
only O
minimal O
impact O
on O
postoperative B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
. O
['Resource-use']

The O
decreasing O
level O
of O
both O
ABC O
scores O
and O
the O
increasing O
level O
of O
the O
IQ B-outcome ['Life-Impact']
scores O
were O
negatively O
correlated O
with O
age O
, O
and O
the O
decreasing O
level O
of O
ABC O
scores O
was O
in O
line O
regression O
( O
positive O
correlation O
) O
with O
base O
IQ O
. O
['Life-Impact']

Also O
, O
the O
school-age O
group O
, O
in O
pre- O
and O
posttesting O
, O
demonstrated O
that O
the O
SCRPA O
curriculum O
increased O
knowledge B-outcome ['Life-Impact']
and O
skills B-outcome ['Life-Impact']
in O
the O
study O
group O
, O
changes O
not O
found O
in O
the O
control O
group O
. O
['Life-Impact', 'Life-Impact']

Glucose B-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
, O
GH B-outcome ['Physiological-Clinical']
, O
cortisol B-outcome ['Physiological-Clinical']
, O
ketones B-outcome ['Physiological-Clinical']
and O
catecholamines B-outcome ['Physiological-Clinical']
were O
measured O
at O
04.00 O
h O
and O
regularly O
from O
07.00 O
to O
12.00 O
h. O
Insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
was O
assessed O
by O
HOMA B-outcome ['Physiological-Clinical']
and O
hypoglycaemia B-outcome ['Physiological-Clinical']
defined O
as O
a O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
( O
BG O
) O
< O
/= O
3.3 O
mmol/l O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Coadministration O
of O
temafloxacin O
did O
not O
have O
any O
effect O
on O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
['Physiological-Clinical']

This O
study O
shows O
that O
in O
hypertensive O
patients O
receiving O
treatment O
with O
diuretics O
, O
the O
addition O
of O
enalapril O
should O
be O
undertaken O
with O
caution O
. O
[]

BACKGROUND O
AND O
OBJECTIVES O
Pelvic O
lymphocysts O
have O
been O
reported O
mainly O
following O
pelvic O
lymphadenectomy O
for O
cervical O
cancer O
. O
[]

Postoperative O
pain O
relief O
following O
laparoscopic O
tubal O
sterilization O
with O
silastic O
bands O
. O
[]

A O
total O
of O
360 O
films O
were O
taken O
and O
assessed O
by O
an O
experienced O
practitioner O
not O
apprised O
of O
the O
bitewing O
technique O
used O
. O
[]

According O
to O
cognitive O
behavioural O
models O
of O
social O
phobia O
, O
bodily O
symptoms O
are O
the O
main O
source O
of O
information O
concerning O
social B-outcome ['Life-Impact']
evaluation I-outcome ['Life-Impact']
for O
social O
phobics O
. O
['Life-Impact']

Oropharyngeal B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
was O
less O
severe O
in O
the O
Tac/Sir O
arm O
( O
peak O
Oral B-outcome ['Physiological-Clinical']
Mucositis I-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
Scale O
score O
0.70 O
vs O
0.96 O
, O
P O
< O
.001 O
) O
, O
but O
otherwise O
toxicity B-outcome ['Adverse-effects']
was O
similar O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

METHODS O
Data O
are O
obtained O
from O
in-person O
, O
structured O
, O
closed-end O
interviews O
with O
the O
caretakers O
of O
children O
aged O
4-12 O
years O
with O
persistent O
asthma O
living O
in O
households O
with O
incomes O
less O
than O
200 O
% O
of O
poverty O
. O
[]

BACKGROUND/AIMS O
Intravenous O
lipid O
emulsions O
may O
contribute O
to O
the O
development O
of O
total O
parenteral O
nutrition O
( O
TPN O
) O
-- O
induced O
hepatobiliary O
complications O
. O
[]

These O
changes O
were O
related O
mainly O
to O
the O
expenditure O
of O
energy O
, O
calculated O
from O
the O
food O
consumption O
, O
and O
appeared O
to O
be O
mediated O
through O
changed O
insulin O
sensitivity O
and O
decreased O
body O
fat O
mass O
. O
[]

The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
cardiac B-outcome ['Physiological-Clinical']
safety I-outcome ['Physiological-Clinical']
profile O
of O
tegaserod O
through O
analysis O
of O
electrocardiographic O
data O
from O
clinical O
studies O
conducted O
in O
patients O
with O
IBS O
and O
a O
study O
conducted O
in O
healthy O
male O
subjects O
. O
['Physiological-Clinical']

The O
volume O
of O
injected O
fluid O
was O
recorded O
. O
[]

Two O
parallel O
prospective O
randomized O
studies O
have O
been O
undertaken O
by O
the O
EORTC O
Urological O
Group O
in O
previously O
untreated O
patients O
with O
prostatic O
cancer O
in O
order O
to O
compare O
low O
dose O
Stilboestrol O
versus O
Cyproterone O
acetate O
versus O
Medroxyprogesterone O
acetate O
in O
the O
first O
trial O
, O
and O
Stilboestrol O
versus O
Estracyt O
in O
the O
second O
trial O
. O
[]

We O
evaluated O
portal O
hemodynamics O
using O
magnetic O
resonance O
angiography O
( O
MRA O
) O
in O
these O
two O
forms O
of O
treatment O
. O
[]

At O
12 O
weeks O
after O
injection O
, O
a O
two-point O
decrease O
in O
[]

We O
did O
not O
find O
any O
parameters O
of O
predictive O
value O
for O
the O
risk O
of O
developing O
an O
encephalopathic B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
based O
on O
the O
symptoms O
and O
signs O
before O
treatment O
initiation O
. O
['Physiological-Clinical']

Immunogenicity B-outcome ['Physiological-Clinical']
and O
safety O
were O
evaluated O
for O
up O
to O
10 O
months O
. O
['Physiological-Clinical']

A O
home-based O
exercise O
program O
to O
improve O
function B-outcome ['Life-Impact']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
in O
patients O
with O
Stage O
IV O
lung O
and O
colorectal O
cancer O
: O
a O
randomized O
controlled O
trial O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

This O
criterion O
was O
however O
in O
retrospect O
found O
to O
predict O
cardiovascular B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
in O
only O
67 O
of O
the O
126 O
patients O
getting O
one O
or O
several O
of O
these O
complications O
. O
['Physiological-Clinical']

RESULTS O
sICAM-1 B-outcome ['Physiological-Clinical']
levels O
were O
significantly O
higher O
in O
primary O
biliary O
cirrhosis O
patients O
than O
healthy O
subjects O
and O
fell O
by O
a O
median O
of O
20 O
% O
after O
12 O
months O
' O
therapy O
with O
ursodeoxycholic O
acid O
( O
P O
< O
0.0004 O
) O
. O
['Physiological-Clinical']

Terbinafine O
is O
the O
current O
treatment O
of O
choice O
for O
toenail O
onychomycosis O
. O
[]

The O
participants O
reported O
their O
daily B-outcome ['Life-Impact']
emotional I-outcome ['Life-Impact']
experiences I-outcome ['Life-Impact']
, O
by O
completing O
questionnaires O
relating O
to O
sensory B-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
pleasure I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Images O
of O
24 O
cardiac O
structures O
and O
nine O
Doppler B-outcome ['Physiological-Clinical']
signals I-outcome ['Physiological-Clinical']
were O
graded O
prospectively O
on O
a O
three-grade O
system O
. O
['Physiological-Clinical']

Serious B-outcome ['Adverse-effects']
late I-outcome ['Adverse-effects']
radiation I-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
was O
minimal O
( O
3 O
% O
in O
the O
RT O
group O
, O
0 O
% O
in O
the O
radiation O
therapy O
plus O
chemotherapy O
group O
) O
. O
['Adverse-effects']

Pain O
ratings O
were O
recorded O
immediately O
after O
perineorrhaphy O
, O
30 O
minutes O
, O
and O
1 O
, O
2 O
, O
6 O
, O
12 O
and O
24 O
hours O
after O
first O
dose O
on O
a O
10-cm O
visual O
analogue O
scale O
. O
['Physiological-Clinical']

in O
97 O
patients O
( O
aged O
31-83 O
years O
) O
belonging O
to O
NYHA O
class O
II O
and O
III O
with O
congestive O
heart O
failure O
of O
different O
aetiology O
, O
but O
without O
any O
complex O
ventricular O
arrhythmias O
in O
basal O
conditions O
( O
couplets O
with O
R'-R O
less O
than O
or O
equal O
to O
400 O
msec O
, O
ventricular O
tachycardia O
, O
R O
on O
T O
phenomena O
) O
. O
[]

Topical O
beta-blockade O
with O
intrinsic O
sympathomimetic O
activity O
offers O
no O
advantage O
for O
the O
respiratory O
and O
cardiovascular O
function O
of O
elderly O
people O
. O
[]

Additionally O
, O
the O
79 O
DES-exposed O
offspring O
were O
compared O
to O
an O
age-matched O
control O
population O
( O
group O
III O
) O
. O
[]

The O
current O
study O
will O
investigate O
the O
efficacy O
of O
group-based O
CBT O
for O
adults O
with O
ASD O
. O
[]

After O
the O
subsequent O
dose O
reduction O
, O
the O
mean O
pH B-outcome ['Physiological-Clinical']
decreased O
to O
6.1-6.2 O
. O
['Physiological-Clinical']

ORs O
for O
predicting O
wrist O
fracture O
were O
: O
previous B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
, O
2.29 O
( O
95 O
% O
CI O
1.56-3.34 O
) O
; O
and O
a O
fall O
in O
the O
last O
12 O
months O
, O
1.60 O
( O
95 O
% O
CI O
1.10-2.31 O
) O
. O
['Physiological-Clinical']

Patients O
given O
neoton O
in O
acute O
period O
of O
MI O
had O
no O
increase O
in O
the O
end B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
and O
diastolic I-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricle I-outcome ['Physiological-Clinical']
in O
the O
course O
of O
the O
first O
months O
after O
MI O
onset O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
double-blind O
comparison O
of O
intramuscular O
2 O
and O
4 O
mg. O
butorphanol O
and O
80 O
mg. O
meperidine O
was O
used O
. O
[]

An O
analysis O
of O
covariance O
discerned O
the O
effect O
of O
proactive B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
and O
post-hypnotic B-outcome ['Life-Impact']
suggestion I-outcome ['Life-Impact']
on O
test B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
, O
while O
controlling O
for O
the O
variance O
introduced O
by O
scholastic B-outcome ['Life-Impact']
aptitude I-outcome ['Life-Impact']
as O
measured O
by O
the O
ACT O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
acupuncture O
group O
will O
receive O
MSAT O
and O
the O
NSAID O
injection O
group O
will O
receive O
an O
intramuscular O
injection O
of O
diclofenac O
. O
[]

RESULTS O
There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
with O
regard O
to O
the O
temporospatial O
variables O
of O
velocity B-outcome ['Physiological-Clinical']
, O
cadence O
, O
step B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
, O
and O
stride B-outcome ['Life-Impact']
length I-outcome ['Life-Impact']
at O
any O
tested O
time O
point O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Two O
randomized O
studies O
demonstrate O
the O
efficacy O
and O
safety O
of O
dapsone O
gel O
, O
5 O
% O
for O
the O
treatment O
of O
acne O
vulgaris O
. O
[]

Rate O
of O
healing B-outcome ['Physiological-Clinical']
of O
the I-outcome ['Physiological-Clinical']
epithelial I-outcome ['Physiological-Clinical']
defects B-outcome ['Physiological-Clinical']
were O
measured O
as O
percentage O
decrease O
from O
the O
baseline O
parameter O
at O
each O
subsequent O
follow O
up O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
Combined-modality O
treatment O
is O
standard O
treatment O
for O
patients O
with O
clinical O
stage O
I/II O
Hodgkin O
lymphoma O
( O
HL O
) O
. O
[]

RESULTS O
At O
follow-up O
, O
adjusted O
prescription O
rates O
within O
30 O
days O
after O
discharge O
were O
similar O
in O
the O
early O
vs O
late O
groups O
( O
for O
beta-blockers O
, O
odds O
ratio O
[ O
OR O
] O
, O
1.06 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.82-1.37 O
; O
for O
angiotensin-converting O
enzyme O
inhibitors O
, O
OR O
, O
1.17 O
; O
95 O
% O
CI O
, O
0.90-1.52 O
; O
for O
lipid-lowering O
drugs O
, O
OR O
, O
1.14 O
; O
95 O
% O
CI O
, O
0.86-1.50 O
; O
and O
for O
aspirin O
, O
OR O
, O
1.05 O
; O
95 O
% O
CI O
, O
0.84-1.33 O
) O
. O
[]

There O
ws O
no O
reduction O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
or O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
in O
the O
group O
treated O
with O
beta-adrenoreceptor O
blocking O
agents O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
clinically O
significant O
changes O
were O
found O
on O
the O
lab O
tests O
. O
[]

Patients O
were O
evaluated O
monthly O
for O
blood O
pressure O
, O
fasting O
serum O
glucose O
, O
and O
adverse O
events O
. O
[]

Randomisation O
was O
by O
a O
computer-generated O
randomisation O
code O
, O
and O
researchers O
, O
clinicians O
, O
participants O
, O
and O
parents O
were O
masked O
to O
the O
identity O
of O
the O
solutions O
. O
[]

Subjects O
due O
for O
CRC O
screening O
were O
randomized O
within O
each O
practice O
to O
1 O
of O
4 O
groups O
: O
( O
1 O
) O
usual O
care O
; O
( O
2 O
) O
physician O
chart O
reminder O
; O
( O
3 O
) O
physician O
chart O
reminder O
, O
mailed O
education O
, O
CRC O
reminder O
magnet O
, O
and O
fecal O
immunochemical O
test O
( O
FIT O
) O
( O
mailed O
education/FIT O
) O
; O
or O
( O
4 O
) O
all O
the O
preceding O
plus O
a O
structured O
telephone O
call O
to O
the O
patient O
from O
project O
staff O
to O
provide O
education O
, O
assess O
interest O
in O
screening O
, O
explain O
the O
screening O
tests O
, O
and O
address O
barriers O
( O
mailed O
education/FIT O
plus O
phone O
call O
) O
. O
[]

On O
the O
ward O
, O
i.m O
. O
[]

Cost O
effectiveness O
of O
training O
incontinent O
elderly O
in O
nursing O
homes O
: O
a O
randomized O
clinical O
trial O
. O
[]

A O
total O
of O
4,444 O
patients O
with O
angina O
pectoris O
or O
previous O
myocardial O
infarction O
and O
serum O
cholesterol O
levels O
of O
213-310 O
mg/dl O
( O
5.5-8.0 O
mmol/liter O
) O
while O
treated O
with O
a O
lipid-lowering O
diet O
were O
randomly O
assigned O
to O
double-blind O
treatment O
with O
simvastatin O
or O
placebo O
. O
[]

Improved O
acidosis O
correction O
and O
recovery O
of O
mesothelial O
cell O
mass O
with O
neutral-pH O
bicarbonate O
dialysis O
solution O
among O
children O
undergoing O
automated O
peritoneal O
dialysis O
. O
[]

Selenium O
supplementation O
and O
secondary O
prevention O
of O
nonmelanoma O
skin O
cancer O
in O
a O
randomized O
trial O
. O
[]

DESIGN O
Randomised O
clinical O
trial O
. O
[]

Findings O
suggest O
that O
the O
peer O
mentor O
model O
is O
applicable O
in O
an O
older O
adult O
exercise O
program O
and O
may O
be O
as O
effective O
as O
a O
program O
mentored O
by O
young O
professionals O
. O
[]

Generalized O
estimating O
equations O
( O
GEEs O
) O
were O
used O
to O
test O
for O
intervention O
effect O
. O
[]

Self-reported O
medication B-outcome ['Life-Impact']
adherence I-outcome ['Life-Impact']
was O
high O
in O
both O
groups O
. O
['Life-Impact']

It O
is O
concluded O
that O
pindolol O
does O
not O
negatively O
influence O
blood B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
as O
the O
thiazide-type O
diuretic O
clopamide O
does O
, O
and O
that O
when O
both O
drugs O
are O
used O
together O
, O
the O
beta-blocker O
can O
probably O
counterbalance O
the O
diuretic-induced O
negative O
effects O
on O
blood B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Therefore O
, O
a O
study O
using O
a O
repeated O
measures O
design O
was O
used O
to O
measure O
effects O
of O
a O
1-year O
group O
leisure O
programme O
intended O
to O
facilitate O
interaction O
with O
media O
, O
engagement O
in O
exercise O
, O
playing O
games O
and O
doing O
crafts O
, O
attending O
events O
, O
and O
participating O
in O
other O
recreation O
activities O
on O
quality O
of O
life O
and O
stress O
of O
37 O
participants O
( O
22 O
male O
, O
15 O
female O
) O
, O
ages O
17-39 O
( O
M O
= O
31.49 O
) O
years O
at O
the O
beginning O
of O
the O
programme O
) O
diagnosed O
with O
an O
ASD O
and O
a O
group O
of O
34 O
adults O
with O
ASD O
as O
control O
group O
( O
waiting O
list O
) O
( O
19 O
male O
, O
15 O
female O
) O
, O
ages O
24-38 O
( O
M O
= O
30 O
at O
programme O
initiation O
) O
years O
. O
[]

Hair O
analysis O
and O
biophysical O
properties O
of O
the O
skin O
were O
assessed O
before O
treatment O
and O
at O
weeks O
2 O
, O
4 O
and O
6 O
after O
the O
therapy O
. O
[]

systolic O
versus O
diastolic O
) O
, O
84 O
% O
of O
DSRL O
participants O
implemented O
a O
location-based O
approach O
( O
i.e O
. O
[]

The O
incidence O
of O
morbidity O
as O
measured O
by O
the O
Postoperative O
Morbidity O
Survey O
on O
day O
5 O
was O
55 O
% O
in O
the O
control O
group O
versus O
47 O
% O
in O
the O
dopexamine O
group O
( O
P O
= O
0.14 O
) O
. O
[]

Complex O
clinical O
features O
associated O
with O
aging O
seem O
to O
have O
obscured O
the O
difference O
in O
effect O
between O
the O
two O
treatments O
. O
[]

The O
rate O
of O
[]

METHOD O
We O
randomized O
162 O
first-year O
medical O
students O
into O
four O
groups O
that O
received O
different O
lead-in O
statements O
before O
measuring O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
on O
a O
manikin O
simulator O
. O
['Physiological-Clinical']

Hypertension B-outcome ['Physiological-Clinical']
with O
the O
ensuing O
increase O
in O
myocardial B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
demand I-outcome ['Physiological-Clinical']
is O
a O
major O
factor O
in O
the O
aetiology O
of O
perioperative O
myocardial B-outcome ['Physiological-Clinical']
ischaemia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
suggest O
significant O
variability O
in O
implementation O
of O
evidence-based O
practices O
, O
even O
with O
supports O
, O
and O
also O
suggest O
the O
need O
to O
address O
challenging O
issues O
related O
to O
implementation O
measurement O
in O
community O
settings O
. O
[]

These O
images O
were O
then O
scanned O
and O
measured O
. O
[]

There O
were O
10 O
cerebral B-outcome ['Physiological-Clinical']
infarctions I-outcome ['Physiological-Clinical']
and O
1 O
intracerebral B-outcome ['Physiological-Clinical']
hematoma I-outcome ['Physiological-Clinical']
in O
the O
standard-care O
group O
, O
as O
compared O
with O
1 O
infarction B-outcome ['Physiological-Clinical']
in O
the O
transfusion O
group O
-- O
a O
92 O
percent O
difference O
in O
the O
risk O
of O
stroke O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
group O
, O
the O
mean O
plasma B-outcome ['Physiological-Clinical']
level O
of O
prilocaine O
at O
2 O
minutes O
was O
1.22 O
micrograms/ml O
, O
maximum O
2.12 O
micrograms/ml O
. O
['Physiological-Clinical']

Epigallocatechin-3-gallate O
( O
EGCG O
) O
is O
the O
main O
polyphenol O
component O
of O
green O
tea O
. O
[]

However O
, O
FEV1 B-outcome ['Physiological-Clinical']
continued O
to O
decline O
in O
the O
INB+ O
group O
at O
24 O
hours O
to O
lower O
than O
the O
INB- O
group O
although O
pain B-outcome ['Physiological-Clinical']
scores O
were O
similar O
beyond O
4 O
hours O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
this O
prospective O
randomized O
study O
of O
initial O
chemotherapy O
for O
advanced O
measurable O
metastatic O
large O
bowel O
carcinoma O
, O
the O
response O
rate O
was O
6/32 O
( O
19 O
% O
) O
for O
FU O
+ O
HU O
and O
5/32 O
( O
16 O
% O
) O
for O
MOF-Strep O
; O
the O
estimated O
median O
survival B-outcome ['Mortality']
is O
43 O
weeks O
for O
both O
treatments O
. O
['Mortality']

OBJECTIVES O
To O
compare O
dietary O
patterns O
of O
urban O
and O
rural O
cancer O
survivors O
and O
to O
examine O
associations O
of O
dietary B-outcome ['Life-Impact']
patterns I-outcome ['Life-Impact']
with O
body O
mass O
index O
( O
BMI O
) O
. O
['Life-Impact']

Distinction O
of O
high-grade O
esthesioneuroblastomas O
from O
other O
poorly O
differentiated O
tumors O
arising O
in O
the O
nasal O
cavity O
is O
an O
important O
diagnostic O
challenge O
because O
it O
determines O
patient O
management O
and O
prognosis O
. O
[]

Effect O
of O
simvastatin O
on O
hemostasis O
in O
patients O
with O
isolated O
hypertriglyceridemia O
. O
[]

This O
clinical O
study O
indicates O
BBOS O
1.5 O
% O
effectively O
and O
safely O
treated O
ocular B-outcome ['Physiological-Clinical']
itching I-outcome ['Physiological-Clinical']
in O
a O
natural O
exposure O
allergy O
study O
and O
is O
a O
useful O
treatment O
option O
for O
the O
management O
of O
ocular O
itching O
associated O
with O
AC O
. O
( O
['Physiological-Clinical']

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effectiveness O
and O
endocrine B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
of O
oral O
contraceptive O
ovarian O
suppression O
followed O
by O
clomiphene O
citrate O
in O
patients O
who O
previously O
were O
clomiphene O
citrate O
resistant O
. O
['Physiological-Clinical']

A O
comparative O
study O
of O
the O
effects O
of O
local O
estrogen O
with O
or O
without O
local O
testosterone O
on O
vulvovaginal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
sexual I-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
. O
['Physiological-Clinical']

These O
outcomes O
were O
also O
examined O
24 O
months O
posttreatment O
. O
[]

Patients O
on O
paliperidone O
ER O
who O
achieved O
remission O
during O
this O
phase O
were O
randomized O
( O
1:1 O
) O
to O
fixed-dose O
paliperidone O
ER O
( O
n=152 O
) O
or O
placebo O
( O
n=148 O
) O
; O
those O
on O
olanzapine O
continued O
to O
receive O
that O
at O
fixed O
dose O
( O
n=83 O
) O
( O
maintenance O
phase O
) O
. O
[]

The O
majority O
of O
younger O
subjects O
with O
high O
blood O
pressure O
had O
low O
risk O
, O
but O
in O
those O
aged O
45-54 O
this O
had O
already O
risen O
to O
a O
medium O
risk O
. O
[]

Approximately O
50 O
% O
of O
patients O
with O
migraine O
could O
be O
recommended O
for O
preventive O
therapies O
, O
yet O
only O
3 O
% O
to O
5 O
% O
of O
patients O
receive O
them O
. O
[]

Higher O
baseline O
[]

Thirty-two O
patients O
undergoing O
six O
courses O
of O
paclitaxel-based O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
either O
chemotherapy O
with O
vitamin O
E O
( O
300 O
mg O
twice O
a O
day O
, O
Group O
I O
) O
or O
chemotherapy O
without O
vitamin O
E O
supplementation O
( O
Group O
II O
) O
. O
[]

Maximal B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
questionnaire O
scores O
also O
reflected O
decreased O
anticholinergic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
presence O
of O
pyridostigmine O
compared O
with O
placebo O
: O
101.9 O
+/- O
2.2 O
versus O
104.6 O
+/- O
2.8 O
, O
respectively O
( O
p O
less O
than O
0.005 O
) O
. O
['Adverse-effects', 'Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
pure-cut O
current O
reduces O
the O
risk O
of O
pancreatitis B-outcome ['Physiological-Clinical']
compared O
with O
blend O
current O
. O
['Physiological-Clinical']

It O
was O
designed O
to O
result O
in O
fewer O
dislodgments O
and O
less O
pressure O
on O
the O
urethra O
than O
the O
cervical O
cap O
and O
diaphragm O
, O
respectively O
, O
and O
to O
require O
less O
clinician O
time O
for O
fitting O
. O
[]

Anesthesia O
was O
carried O
out O
using O
the O
standard O
procedure O
. O
[]

FINDINGS O
29 O
infants O
were O
assigned O
to O
receive O
sucrose O
and O
30 O
to O
sterilised O
water O
; O
20 O
and O
24 O
infants O
, O
respectively O
, O
were O
included O
in O
the O
analysis O
of O
the O
primary O
outcome O
measure O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
One O
hundred O
forty O
opioid-addicted O
IDUs O
were O
referred O
to O
the O
medical O
clinic O
for O
AOD O
. O
[]

Patients O
in O
the O
control O
group O
will O
receive O
standard O
care O
. O
[]

At O
end O
of O
the O
study O
, O
patients O
initiated O
with O
V/HCTZ O
required O
less O
titration B-outcome ['Life-Impact']
steps I-outcome ['Life-Impact']
compared O
with O
the O
initial O
valsartan O
monotherapy O
groups O
( O
63 O
vs O
86 O
% O
required O
titration O
by O
study O
end O
, O
respectively O
) O
and O
reached O
the O
target O
BP B-outcome ['Physiological-Clinical']
goal I-outcome ['Physiological-Clinical']
of O
< O
140/90 O
mm O
Hg O
in O
a O
shorter O
period O
of O
time O
( O
2.8 O
weeks O
) O
( O
P O
< O
0.0001 O
) O
vs O
V-low O
( O
4.3 O
weeks O
) O
and O
V-high O
( O
3.9 O
weeks O
) O
. O
['Life-Impact', 'Physiological-Clinical']

These O
symptoms O
have O
to O
be O
attributed O
to O
a O
neuronal O
degeneration O
. O
[]

Risperidone O
treatment O
of O
autistic O
disorder O
: O
longer-term O
benefits O
and O
blinded O
discontinuation O
after O
6 O
months O
. O
[]

In O
the O
early O
postoperative O
period O
, O
hypothermic O
patients O
had O
abnormally O
high B-outcome ['Physiological-Clinical']
systemic I-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
reduced I-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
compared O
with O
the O
normothermic B-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
At O
3-month O
, O
6-month O
, O
and O
12-month O
follow-up O
, O
in O
both O
study O
groups O
, O
postsurgical B-outcome ['Physiological-Clinical']
AMH I-outcome ['Physiological-Clinical']
levels O
were O
significantly O
lower O
and O
basal B-outcome ['Physiological-Clinical']
FSH I-outcome ['Physiological-Clinical']
levels O
were O
significantly O
higher O
than O
before O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Poor O
sleep O
quality O
across O
the O
first O
17 O
weeks O
post-delivery O
increases O
the O
risk O
for O
recurrent O
PPMD O
among O
women O
with O
a O
history O
of O
MDD O
. O
[]

Additionally O
, O
total O
knee O
range O
of O
motion O
was O
significantly O
lower O
for O
patients O
with O
moderate/severe O
PFOA O
( O
mean O
? O
[]

BACKGROUND O
Biotin O
deficiency O
is O
teratogenic O
in O
several O
mammalian O
species O
. O
[]

However O
, O
in O
5 O
subjects O
with O
acute O
increases O
in O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
levels O
, O
serum B-outcome ['Physiological-Clinical']
creatine I-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
levels O
were O
significantly O
elevated O
as O
well O
, O
suggesting O
that O
myocyte O
toxicity O
may O
have O
been O
responsible O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
undertook O
a O
multicentre O
randomised O
trial O
to O
test O
the O
effect O
of O
diet O
supplementation O
with O
calcium O
and O
fibre O
on O
adenoma O
recurrence O
. O
[]

The O
data O
showed O
that O
Xuezhikang O
therapy O
resulted O
in O
significant O
reductions O
in O
total O
cholesterol B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TC I-outcome ['Physiological-Clinical']
, O
19 O
% O
) O
, O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LDL-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( O
26 O
% O
) O
, O
and O
triglycerides B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TG I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
compared O
with O
baseline O
( O
16 O
% O
, O
p O
< O
0.01 O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Ambulatory B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
of O
children O
with O
cerebral O
palsy O
: O
which O
characteristics O
are O
important O
? O
['Life-Impact']

Follow-up O
assessments O
also O
included O
the O
Barthel O
Index O
( O
BI O
) O
and O
the O
NIH O
Stroke O
Scale O
( O
NIHSS O
) O
at O
4-7 O
days O
after O
the O
end O
of O
the O
last O
infusion O
and O
at O
30 O
days O
after O
the O
onset O
of O
stroke O
. O
[]

The O
prolactinemia O
, O
reflecting O
the O
DA O
action O
, O
has O
been O
also O
measured O
. O
[]

Radioiodine O
whole O
body O
scans O
were O
concordant O
between O
the O
recombinant B-outcome ['Physiological-Clinical']
TSH-stimulated I-outcome ['Physiological-Clinical']
and O
thyroid B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
withdrawal I-outcome ['Physiological-Clinical']
phases I-outcome ['Physiological-Clinical']
in O
195 O
of O
220 O
( O
89 O
% O
) O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
further O
improvement O
in O
defibrillation B-outcome ['Physiological-Clinical']
efficacy O
is O
desirable O
to O
allow O
for O
smaller O
pulse O
generators O
with O
a O
reduced O
maximal O
output O
. O
['Physiological-Clinical']

In O
conclusion O
, O
a O
low O
dose O
of O
amantadine O
is O
sufficient O
in O
modulating O
human B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
cortex I-outcome ['Physiological-Clinical']
excitability I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Effects O
of O
a O
low-salt O
diet O
and O
of O
acute O
salt O
loading O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
intralymphocytic B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
in O
young O
subjects O
with O
borderline O
hypertension O
. O
['Physiological-Clinical', 'Physiological-Clinical']

MATERIALS O
AND O
METHODS O
The O
study O
was O
performed O
on O
90 O
ASA O
class O
I-II O
urologic O
patients O
during O
extracorporeal O
shock O
wave O
lithotripsy O
. O
[]

Mean O
SUVmax O
reductions O
for O
pCR O
and O
non-pCR O
, O
respectively O
, O
were O
54.3 O
% O
versus O
32.8 O
% O
at O
week O
2 O
( O
P O
= O
0.02 O
) O
and O
61.5 O
% O
versus O
34.1 O
% O
at O
week O
6 O
( O
P O
= O
0.02 O
) O
. O
( O
[]

Serum B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
25OHD2 I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
25OHD3 I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
1,25 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
2D I-outcome ['Physiological-Clinical']
were O
unchanged O
in O
group O
B O
( O
without O
triple-treatment O
) O
, O
whereas O
in O
group O
A O
25OHD2 B-outcome ['Physiological-Clinical']
increased O
enormously O
, O
25OHD3 B-outcome ['Physiological-Clinical']
was O
suppressed O
possibly O
by O
substrate O
competition O
for O
hydroxylation O
in O
the O
liver O
and O
1,25 O
( O
OH O
) O
2D O
was O
halved O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
randomly O
assigned O
665 O
patients O
with O
a O
history O
of O
colorectal O
adenomas O
to O
three O
treatment O
groups O
, O
in O
a O
parallel O
design O
: O
calcium O
gluconolactate O
and O
carbonate O
( O
2 O
g O
elemental O
calcium O
daily O
) O
, O
fibre O
( O
3.5 O
g O
ispaghula O
husk O
) O
, O
or O
placebo O
. O
[]

This O
indicated O
the O
beneficial O
effect O
on O
ulcers O
of O
oral O
administration O
of O
EGF O
with O
agents O
allowing O
it O
to O
remain O
at O
high O
levels O
in O
the O
stomach O
, O
whereas O
most O
reports O
suggested O
less O
effect O
of O
oral O
EGF O
on O
healing O
of O
gastroduodenal O
ulcers O
. O
[]

Episodes O
of O
fever B-outcome ['Physiological-Clinical']
and O
neutropenia B-outcome ['Physiological-Clinical']
were O
not O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

By O
Week O
5 O
, O
52.2 O
% O
of O
the O
patients O
in O
the O
control O
group O
experienced O
Grade O
4 O
mucositis B-outcome ['Physiological-Clinical']
compared O
with O
4.5 O
% O
in O
the O
amifostine-treated O
group O
( O
p O
= O
0.0006 O
) O
. O
['Physiological-Clinical']

The O
treatment O
group O
was O
treated O
with O
the O
modified O
CRP O
technique O
until O
the O
nystagmus O
disappeared O
. O
[]

CONCLUSIONS O
Special-effect O
contact O
lenses O
were O
associated O
with O
a O
reduction O
of O
many O
visual B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
, O
including O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
and O
contrast O
sensitivity B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
One O
hundred O
and O
twenty-six O
patients O
fulfilled O
the O
eligibility O
criteria O
( O
type O
1 O
diabetes O
for O
> O
1 O
year O
; O
on O
conventional O
insulin O
therapy O
( O
CIT O
) O
; O
aged O
between O
8 O
and O
18 O
years O
) O
, O
of O
whom O
92 O
enrolled O
. O
[]

METHODS O
An O
online O
randomized O
controlled O
trial O
among O
321 O
women O
aged O
38-45 O
years O
was O
conducted O
. O
[]

BACKGROUND O
Low O
Back O
Pain O
is O
a O
major O
public O
health O
problem O
all O
over O
the O
western O
world O
. O
[]

Such O
findings O
suggest O
that O
self-disclosure O
by O
the O
therapist O
may O
improve O
both O
the O
quality O
of O
the O
therapeutic B-outcome ['Physiological-Clinical']
relationship I-outcome ['Physiological-Clinical']
and O
the O
outcome O
of O
treatment O
. O
['Physiological-Clinical']

Dysfunctional O
attitudes O
as O
a O
moderator O
of O
pharmacotherapy O
and O
psychotherapy O
for O
chronic O
depression O
. O
[]

AIM O
To O
investigate O
the O
effectiveness O
of O
pre-medication O
with O
the O
proteolytic O
enzyme O
, O
pronase O
, O
before O
endoscopic O
ultrasonography O
. O
[]

UNLABELLED O
The O
purpose O
of O
this O
randomized O
crossover O
trial O
was O
to O
determine O
the O
effects O
on O
autonomic O
responses O
in O
preterm O
infants O
of O
longer O
Kangaroo O
Care O
( O
30 O
minutes O
, O
KC30 O
) O
and O
shorter O
KC O
( O
15 O
minutes O
, O
KC15 O
) O
before O
and O
throughout O
heel O
stick O
compared O
with O
incubator O
care O
( O
IC O
) O
. O
[]

No O
invasive O
procedures O
were O
canceled O
due O
to O
study O
drug O
accumulation O
. O
[]

Hypertrophic B-outcome ['Physiological-Clinical']
or O
keloidal B-outcome ['Physiological-Clinical']
scars I-outcome ['Physiological-Clinical']
were O
less O
frequent O
in O
the O
treated O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
this O
study O
, O
a O
potential O
distribution O
of O
Skp2 O
in O
LSCC O
and O
its O
clinical O
implications O
was O
investigated O
by O
an O
immunohistochemical O
study O
. O
[]

PATIENTS O
AND O
METHODS O
Eighty O
patients O
with O
CD20 O
( O
+ O
) O
lymphoma O
and O
resolved O
hepatitis O
B O
were O
randomly O
assigned O
to O
receive O
either O
prophylactic O
entecavir O
( O
ETV O
) O
before O
chemotherapy O
to O
3 O
months O
after O
completing O
chemotherapy O
( O
ETV O
prophylactic O
group O
, O
n O
= O
41 O
) O
or O
to O
receive O
therapeutic O
ETV O
at O
the O
time O
of O
HBV O
reactivation O
and O
hepatitis O
B O
surface O
antigen O
( O
HBsAg O
) O
reverse O
seroconversion O
since O
chemotherapy O
( O
control O
group O
, O
n O
= O
39 O
) O
. O
[]

Most O
intervention O
mothers O
( O
78.0 O
% O
) O
received O
the O
full O
PSE O
course O
. O
[]

A O
new O
atrial B-outcome ['Physiological-Clinical']
enlargement I-outcome ['Physiological-Clinical']
took O
place O
in O
those O
patients O
who O
remained O
with O
atrial O
fibrillation O
( O
+16.8 O
% O
left O
auricular O
volume O
in O
Group O
I O
vs. O
+8.4 O
% O
in O
Group O
II O
; O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

OUTCOME O
MEASURES O
Rates O
of O
: O
communicative B-outcome ['Life-Impact']
initiations I-outcome ['Life-Impact']
, O
use B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
PECS I-outcome ['Life-Impact']
, O
and O
speech B-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
classroom I-outcome ['Life-Impact']
; O
Autism O
Diagnostic O
Observation O
Schedule-Generic O
( O
ADOS-G O
) O
domain O
scores O
for O
Communication B-outcome ['Life-Impact']
and O
Reciprocal B-outcome ['Life-Impact']
Social I-outcome ['Life-Impact']
Interaction O
; O
scores O
on O
formal B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
tests O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
total O
power O
output O
used O
for O
RF O
was O
lower O
in O
group O
1 O
than O
in O
group O
2 O
( O
median O
271 O
vs. O
1,045 O
W.m O
) O
. O
[]

Down O
syndrome O
children O
with O
Autism O
Spectrum O
Disorder O
displayed O
more O
restricted O
repetitive O
and O
stereotyped B-outcome ['Life-Impact']
patterns I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
interests B-outcome ['Life-Impact']
and O
activities B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Patients O
were O
assessed O
for O
safety O
and O
efficacy O
and O
followed O
up O
until O
death O
. O
[]

Physiological O
pacing O
improves O
symptoms O
and O
increases O
exercise O
capacity O
in O
the O
elderly O
patient O
. O
[]

Analysis O
of O
variance O
indicated O
no O
difference O
in O
the O
REEDA B-outcome ['Physiological-Clinical']
score O
before O
or O
two O
hours O
after O
treatment O
. O
['Physiological-Clinical']

During O
a O
run O
, O
the O
adaptor O
was O
presented O
at O
a O
constant O
velocity O
( O
-200 O
degrees O
to O
+200 O
degrees/sec O
) O
, O
while O
probes O
with O
velocities O
varying O
from O
-10 O
degrees O
to O
+10 O
degrees/sec O
were O
presented O
in O
a O
random O
order O
. O
[]

injection O
of O
depot O
MPA O
500 O
mg O
on O
days O
1 O
, O
14 O
and O
28 O
, O
or O
oral O
megestrol O
acetate O
40 O
mg O
daily O
for O
6 O
weeks O
. O
[]

The O
outcomes O
assessed O
were O
time B-outcome ['Life-Impact']
taken I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
complete I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
endometrial I-outcome ['Life-Impact']
polypectomy I-outcome ['Life-Impact']
, O
defined O
as O
the O
time O
from O
insertion O
to O
removal O
of O
vaginal O
instrumentation O
, O
completeness O
of O
polyp B-outcome ['Physiological-Clinical']
removal I-outcome ['Physiological-Clinical']
, O
acceptability B-outcome ['Life-Impact']
, O
and O
pain B-outcome ['Physiological-Clinical']
measured O
on O
a O
100-mm O
visual O
analog O
scale O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

METHODS O
Data O
from O
diet O
diaries O
of O
children O
( O
3-8 O
years O
) O
with O
ASD O
( O
n O
= O
62 O
) O
were O
analyzed O
by O
a O
registered O
pediatric O
dietician O
to O
compare O
to O
RDA O
standards O
for O
total O
calories O
, O
protein O
, O
carbohydrate O
, O
and O
fat O
. O
[]

As O
the O
number O
of O
pathological O
gamblers O
has O
increased O
recently O
, O
the O
need O
for O
effective O
treatment O
has O
become O
more O
evident O
. O
[]

Amiodarone O
is O
a O
powerful O
antiarrhythmic O
drug O
with O
several O
potentially O
beneficial O
actions O
, O
and O
has O
shown O
benefit O
in O
several O
small-scale O
studies O
. O
[]

The O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
Breast O
Cancer O
Prevention O
Trial O
( O
BCPT O
) O
is O
the O
only O
clinical O
trial O
that O
provides O
data O
to O
assess O
the O
cardiovascular B-outcome ['Physiological-Clinical']
effects O
of O
tamoxifen O
in O
women O
with O
and O
without O
CHD O
. O
['Physiological-Clinical']

Masticatory O
performance O
and O
chewing O
experience O
with O
implant-retained O
mandibular O
overdentures O
. O
[]

Patients O
randomised O
to O
arm O
A O
were O
given O
1000 O
mg/m O
( O
2 O
) O
cytarabine O
on O
day O
1 O
preceding O
for O
6 O
h O
cisplatin O
infusion O
, O
30 O
mg/m O
( O
2 O
) O
/24 O
h O
cisplatin O
intravenous O
( O
i.v O
. O
) O
[]

Generally O
, O
there O
are O
two O
types O
of O
RPE O
appliances O
: O
banded O
and O
bonded O
expanders O
. O
[]

This O
effect O
was O
reversible O
among O
patients O
who O
returned O
from O
bicarbonate O
to O
lactate O
fluid O
. O
[]

The O
incremental O
cost-effectiveness O
ratio O
[ O
95 O
% O
CI O
] O
amounts O
to O
minus O
< O
euro O
> O
78,741.66 O
[ O
-154,987.20 O
; O
110,486.32 O
] O
for O
an O
additional O
unit O
of O
effect O
. O
['Resource-use']

7 O
% O
) O
. O
[]

The O
median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
time O
was O
approximately O
20 O
months O
and O
the O
median O
overall O
survival O
( O
OS O
) O
time O
was O
approximately O
49 O
months O
. O
['Mortality']

Comparison O
of O
endotracheal O
and O
peripheral O
intravenous O
adrenaline O
in O
cardiac O
arrest O
. O
[]

The O
fictional O
narrative O
was O
constructed O
to O
match O
the O
summary O
in O
content O
and O
length O
. O
[]

Thromboembolic O
diseases O
can O
occur O
in O
the O
venous O
or O
arterial O
sides O
of O
the O
circulatory O
system O
. O
[]

CONCLUSION O
The O
fat O
content O
of O
a O
challenge O
vehicle O
has O
a O
profound O
effect O
on O
the O
reaction O
experienced O
after O
allergen O
ingestion O
. O
[]

In O
group O
I O
( O
halothane O
) O
, O
light O
general O
anaesthesia O
was O
induced O
with O
thiopental O
3-5 O
mg/kg O
and O
maintained O
with O
halothane O
. O
[]

The O
study O
group O
comprise O
41 O
patients O
with O
SSc O
. O
[]

BACKGROUND O
5-Fluorouracil O
( O
5-FU O
) O
, O
doxorubicin O
and O
methotrexate O
( O
FAMTX O
) O
and O
cisplatin O
, O
epirubicin O
, O
leucovorin O
and O
5-FU O
( O
PELF O
) O
have O
both O
been O
reported O
to O
be O
superior O
to O
the O
combination O
5-FU O
, O
doxorubicin O
and O
mitomycin O
C O
( O
FAM O
) O
in O
advanced O
gastric O
carcinoma O
. O
[]

SETTING O
Southeast O
region O
of O
Sweden O
. O
[]

There O
was O
also O
a O
control O
group O
that O
just O
filled O
in O
the O
study O
questionnaire O
but O
did O
not O
receive O
an O
educational O
intervention O
. O
[]

After O
a O
4-week O
, O
single-blind O
placebo O
run-in O
, O
patients O
were O
randomized O
to O
receive O
16 O
weeks O
of O
trandolapril O
2 O
mg/day O
( O
68 O
patients O
) O
, O
hydrochlorothiazide O
( O
HCTZ O
) O
25 O
mg/day O
( O
68 O
patients O
) O
, O
or O
the O
combination O
( O
69 O
patients O
) O
. O
[]

The O
perception B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
susceptibility I-outcome ['Life-Impact']
increased O
with O
age O
. O
['Life-Impact']

At O
week O
24 O
, O
intent-to-treat O
: O
exposed O
( O
missing O
= O
failure O
) O
analyses O
showed O
no O
statistically O
significant O
differences O
in O
the O
percentage O
of O
patients O
with O
HIV-1 B-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
< O
400 O
copies/mL O
( O
95 O
% O
[ O
QD O
] O
vs. O
90 O
% O
[ O
BID O
] O
) O
or O
< O
50 O
copies/mL O
( O
82 O
% O
[ O
QD O
] O
vs. O
81 O
% O
[ O
BID O
] O
) O
or O
in O
the O
median O
change O
from O
baseline O
in O
CD4 B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
( O
+42 O
cells/mm O
( O
3 O
) O
[ O
QD O
] O
vs. O
+22 O
cells/mm O
( O
3 O
) O
[ O
BID O
] O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Five O
pairs O
of O
human O
radii O
were O
used O
for O
the O
control O
in O
the O
pilot O
study O
. O
[]

MAIN O
OUTCOME O
MEASURES O
The O
primary O
outcome O
was O
the O
proportion O
of O
eyes O
with O
complete B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of O
SRF B-outcome ['Physiological-Clinical']
without O
rescue O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PARTICIPANTS O
A O
total O
of O
182 O
six-month-old O
infants O
. O
[]

For O
both O
diets O
an O
increased O
shortage O
of O
70 O
g O
of O
CHO B-outcome ['Physiological-Clinical']
was O
found O
at O
16 O
months O
compared O
with O
4 O
months O
, O
and O
an O
increase O
in O
fat B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
of O
33 O
g O
during O
the O
same O
time O
period O
in O
the O
obese O
subjects O
, O
indicating O
that O
CHO B-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
had O
increased O
with O
12 O
months O
endurance O
training O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
12 O
months O
the O
group O
on O
free O
diet O
showed O
a O
significant O
increase O
of O
intralymphocytic B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
but O
no O
change O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
noted O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Densitometry O
and O
roentgenographic O
scoring O
of O
callus O
formation O
after O
12 O
weeks O
in O
propranolol-treated O
rats O
revealed O
increased O
callus B-outcome ['Physiological-Clinical']
and O
bone B-outcome ['Physiological-Clinical']
union I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Implants O
with O
reported O
mechanical O
and/or O
mucosal O
problems O
or O
placed O
more O
apically O
in O
relation O
to O
the O
adjacent O
teeth O
did O
not O
present O
more O
bone O
loss O
as O
compared O
with O
implants O
with O
no O
problems O
or O
placed O
more O
coronally O
, O
respectively O
( O
p O
> O
.05 O
) O
. O
[]

These O
findings O
have O
implications O
for O
public O
health O
programmes O
intended O
for O
long-term O
care O
and O
support O
of O
children O
living O
in O
resource O
poor O
AIDS-impacted O
communities O
. O
[]

These O
results O
contribute O
to O
the O
debate O
as O
to O
whether O
a O
strict O
distinction O
between O
skin O
care O
and O
skin O
protection O
products O
is O
justified O
. O
[]

Co-administration O
of O
pethidine O
0.75 O
mg O
kg-1 O
and O
clonidine O
75 O
micrograms O
intrathecally O
provided O
good O
intraoperative O
anaesthesia O
for O
total O
hip O
replacement O
, O
similar O
to O
that O
obtained O
using O
0.5 O
% O
isobaric O
bupivacaine O
. O
[]

A O
randomized O
, O
controlled O
trial O
was O
performed O
to O
assess O
the O
efficacy O
and O
safety O
of O
vitamin O
E O
supplementation O
for O
prophylaxis O
against O
paclitaxel-induced B-outcome ['Physiological-Clinical']
peripheral I-outcome ['Physiological-Clinical']
neuropathy I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PIPN I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Modeling O
hippocampal O
and O
neocortical O
contributions O
to O
recognition B-outcome ['Life-Impact']
memory O
: O
a O
complementary-learning-systems O
approach O
. O
['Life-Impact']

The O
aim O
of O
this O
study O
was O
to O
test O
whether O
low- O
and O
high-scoring O
individuals O
on O
the O
Autism O
Spectrum O
Quotient O
differ O
on O
a O
measure O
of O
local B-outcome ['Physiological-Clinical']
and O
global B-outcome ['Physiological-Clinical']
processing O
, O
motion O
processing O
and O
visual O
pathway O
integrity O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Recent O
guidelines O
have O
recommended O
the O
use O
of O
aspirin O
and O
prasugrel O
in O
patients O
with O
acute O
coronary O
syndromes O
undergoing O
percutaneous O
coronary O
intervention O
. O
[]

infusion O
over O
35 O
minutes O
and O
the O
placebo O
group O
received O
normal O
saline O
infusion O
in O
the O
same O
dose O
and O
at O
the O
same O
rate O
. O
[]

Only O
scopolamine O
induced O
sedation B-outcome ['Physiological-Clinical']
in O
this O
study O
. O
['Physiological-Clinical']

Testing O
the O
efficacy O
of O
an O
HIV B-outcome ['Life-Impact']
stigma I-outcome ['Life-Impact']
reduction O
intervention O
with O
medical O
students O
in O
Puerto O
Rico O
: O
the O
SPACES O
project O
. O
['Life-Impact']

Acupressure O
at O
the O
extra O
1 O
significantly O
reduced O
the O
low B-outcome ['Physiological-Clinical']
frequency/high O
frequency O
ratio O
of O
HRV B-outcome ['Physiological-Clinical']
responding I-outcome ['Physiological-Clinical']
to O
needle B-outcome ['Resource-use']
insertion I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Forty-five O
patients O
were O
treated O
with O
HFX O
RT O
alone O
and O
fifty-six O
patients O
also O
received O
CDDP O
. O
[]

Double-blind O
comparison O
of O
doxepin O
versus O
bupropion O
in O
outpatients O
with O
a O
major O
depressive O
disorder O
. O
[]

Intercostal O
nerve O
blocks O
( O
INB O
) O
and O
subarachnoid O
morphine O
( O
SM O
) O
act O
on O
different O
portions O
of O
the O
pain O
pathway O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Before O
the O
patients O
were O
enrolled O
in O
the O
study O
and O
on O
completion O
of O
treatment O
, O
lymphocyte B-outcome ['Physiological-Clinical']
cell-surface I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
determined O
by O
flow O
cytometry O
( O
n O
= O
14 O
patients O
) O
; O
mitogen-stimulated B-outcome ['Physiological-Clinical']
interferon-gamma I-outcome ['Physiological-Clinical']
and O
interleukin-2 B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
were O
measured O
by O
enzyme-linked O
immunosorbent O
assay O
( O
n O
= O
19 O
patients O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Supporting O
families O
in O
challenging O
contexts O
: O
the O
CAPEDP O
project O
. O
[]

This O
study O
compared O
the O
safety O
and O
the O
immunogenicity B-outcome ['Physiological-Clinical']
of O
a O
refrigerator-stable O
formulation O
( O
Zostavax O
refrigerated O
) O
with O
those O
of O
the O
current O
formulation O
( O
Zostavax O
frozen O
) O
in O
subjects O
> O
or O
=50 O
years O
of O
age O
. O
['Physiological-Clinical']

Separate O
linear O
regressions O
were O
conducted O
for O
each O
standardized O
and O
observational O
measure O
at O
each O
time O
point O
. O
[]

It O
is O
unknown O
whether O
ST O
, O
with O
or O
without O
concurrent O
endurance O
training O
, O
would O
have O
a O
similar O
effect O
in O
older O
adults O
with O
reduced O
baseline O
arterial B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
relation O
was O
independent O
of O
treatment O
effect O
or O
change O
in O
low-density O
lipoprotein O
cholesterol O
level O
at O
1 O
year O
. O
[]

OBJECTIVE O
To O
assess O
the O
risk O
of O
developing O
multiple B-outcome ['Physiological-Clinical']
sclerosis I-outcome ['Physiological-Clinical']
( O
MS B-outcome ['Physiological-Clinical']
) O
after O
optic O
neuritis O
and O
the O
factors O
predictive O
of O
high O
and O
low O
risk O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Cancer O
information O
and O
anxiety B-outcome ['Life-Impact']
: O
applying O
the O
extended O
parallel O
process O
model O
. O
['Life-Impact']

However O
, O
in O
combination O
with O
the O
results O
of O
the O
larger O
trial O
, O
the O
data O
suggest O
that O
radiographic O
quality O
at O
an O
early O
time O
point O
might O
be O
a O
sensitive O
variable O
, O
perhaps O
better O
than O
time O
to O
cortical O
continuity O
. O
[]

No O
difference O
in O
efficacy O
was O
seen O
among O
patients O
who O
received O
montelukast O
and O
the O
group O
given O
a O
placebo O
. O
[]

METHODS O
This O
study O
was O
a O
prospective O
, O
double-blinded O
, O
8-wk O
trial O
. O
[]

G-CSF O
and/or O
EPO O
were O
employed O
as O
needed O
. O
[]

However O
, O
on O
a O
new O
test O
of O
executive O
function O
( O
selection O
between O
stimulus-oriented O
and O
stimulus-independent O
thought O
) O
, O
the O
ASD O
group O
exhibited O
significantly O
greater O
signal-change O
in O
medial B-outcome ['Physiological-Clinical']
rostral I-outcome ['Physiological-Clinical']
prefrontal I-outcome ['Physiological-Clinical']
cortex I-outcome ['Physiological-Clinical']
( O
especially O
Brodmann O
Area O
10 O
) O
in O
the O
comparison O
of O
stimulus-oriented O
versus O
stimulus-independent O
attention O
. O
['Physiological-Clinical']

Operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
longer O
( O
93.6 O
+/- O
23.8 O
min O
) O
and O
hospitalization B-outcome ['Resource-use']
time I-outcome ['Resource-use']
significantly O
shorter O
( O
22.4 O
+/- O
6.6 O
h O
) O
in O
the O
laparoscopy O
group O
. O
['Life-Impact', 'Resource-use']

Serum O
for O
rabies O
antibody O
determination O
and O
F O
( O
ab O
' O
) O
2 O
concentration O
was O
collected O
at O
hours O
( O
H O
) O
0 O
, O
6 O
and O
12 O
, O
and O
on O
day O
( O
D O
) O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
10 O
, O
12 O
and O
15 O
. O
[]

After O
the O
induction O
of O
DOMS B-outcome ['Physiological-Clinical']
, O
the O
participants O
were O
randomly O
divided O
into O
an O
experimental O
condition O
( O
HVPC O
) O
or O
a O
placebo O
condition O
. O
['Physiological-Clinical']

Adults O
with O
systolic O
BP O
120-159 O
mm O
Hg O
and O
diastolic O
BP O
80-95 O
mm O
Hg O
were O
randomly O
assigned O
to O
receive O
the O
DASH O
diet O
or O
a O
typical O
American O
( O
control O
) O
diet O
, O
consuming O
three O
different O
sodium O
intakes O
( O
higher=142 O
mmol/d O
, O
intermediate=107 O
mmol/d O
, O
and O
lower=65 O
mmol/d O
) O
for O
30 O
days O
each O
. O
[]

RESULTS O
Three O
patients O
were O
lost O
to O
follow-up O
. O
[]

Gum O
elastic O
bougie-guided O
insertion O
of O
the O
ProSeal O
Laryngeal O
Mask O
Airway O
. O
[]

at O
a O
rate O
of O
0.3 O
ml O
min O
( O
-1 O
) O
kg O
( O
-1 O
) O
during O
another O
2 O
h O
urine O
collection O
. O
[]

Chemotherapy O
was O
given O
if O
the O
WBC O
count O
was O
> O
or O
= O
3 O
x O
10 O
( O
9 O
) O
/L O
and O
platelet O
count O
> O
or O
= O
100 O
x O
10 O
( O
9 O
) O
/L O
. O
[]

CONCLUSION O
Treatment O
of O
VVC O
should O
be O
individualized O
, O
and O
women O
with O
complicated O
VVC O
achieve O
superior O
mycologic B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
by O
a O
6 O
day O
miconazole O
course O
. O
['Physiological-Clinical']

In O
this O
article O
the O
authors O
compare O
the O
relative O
importance O
of O
parameters O
contributing O
to O
the O
between-subject O
variability O
in O
estimated O
hydrogen O
ion O
dose O
to O
the O
lower O
airways O
( O
H+LAW O
) O
, O
based O
on O
analysis O
of O
variance O
. O
[]

METHODS O
A O
randomized O
controlled O
pilot O
study O
of O
Helping O
HAND O
, O
a O
6-month O
intervention O
, O
targeted O
children O
with O
body O
mass O
index O
85-99 O
% O
tile O
and O
their O
parents O
. O
[]

Practices O
vary O
across O
the O
UK O
on O
the O
use O
of O
topical O
preparation O
prior O
to O
flexible O
fibreoptic O
nasendoscopy O
. O
[]

PATIENTS O
AND O
METHODS O
SR O
patients O
( O
localized O
tumors O
, O
volume O
< O
100 O
mL O
) O
were O
randomly O
assigned O
to O
receive O
four O
courses O
of O
vincristine O
, O
dactinomycin O
, O
ifosfamide O
, O
and O
doxorubicin O
( O
VAIA O
) O
induction O
therapy O
followed O
by O
10 O
courses O
of O
either O
VAIA O
or O
vincristine O
, O
dactinomycin O
, O
cyclophosphamide O
, O
and O
doxorubicin O
( O
VACA O
; O
cyclophosphamide O
replacing O
ifosfamide O
) O
. O
[]

LA O
also O
abolished O
some O
of O
the O
negative O
effects O
that O
overweight O
had O
on O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
with O
the O
open O
technique O
. O
['Life-Impact', 'Resource-use', 'Life-Impact']

The O
primary O
efficacy O
endpoint O
was O
the O
sum O
of O
pain B-outcome ['Physiological-Clinical']
intensity O
difference O
( O
SPID O
) O
over O
30 O
min O
post-administration O
. O
['Physiological-Clinical']

The O
study O
was O
designed O
to O
reveal O
an O
additive O
response O
rate O
when O
the O
drugs O
were O
combined O
. O
[]

RESULTS O
Both O
groups O
showed O
a O
decrease O
in O
the O
mean O
Yale-Brown O
Obsessive-Compulsive B-outcome ['Life-Impact']
Scale O
score O
. O
['Life-Impact']

Patients O
in O
group O
A O
received O
2 O
weeks O
of O
daily O
GM-CSF O
, O
at O
which O
time O
zidovudine O
was O
restarted O
if O
the O
ANC O
was O
greater O
than O
1,000/microL O
; O
if O
the O
ANC O
was O
less O
than O
1,000/microL O
, O
the O
dose O
of O
GM-CSF O
was O
increased O
to O
3.0 O
micrograms/kg O
, O
and O
at O
2-week O
intervals O
either O
zidovudine O
was O
restarted O
or O
the O
dose O
of O
GM-CSF O
was O
increased O
to O
5 O
micrograms/kg O
and O
then O
10 O
micrograms/kg O
, O
to O
maintain O
the O
ANC O
greater O
than O
1,000/microL O
. O
[]

There O
were O
no O
significant O
differences O
in O
the O
number O
of O
patients O
receiving O
rescue O
analgesia O
after O
surgery O
. O
[]

Inappropriate O
myocardial O
protection O
is O
considered O
one O
of O
the O
main O
causes O
of O
mortality O
and O
morbidity O
in O
the O
correction O
of O
tetralogy O
of O
Fallot O
( O
TOF O
) O
. O
[]

Eicosanoids O
and O
free O
radicals O
are O
thought O
to O
be O
among O
the O
reasons O
for O
this O
effect O
. O
[]

Nizatidine O
versus O
ranitidine O
in O
the O
treatment O
of O
peptic O
ulcer O
disease O
: O
report O
on O
the O
Dutch O
investigation O
as O
part O
of O
a O
European O
multicentre O
trial O
. O
[]

Twenty-six O
patients O
with O
relapsed O
Hodgkin O
's O
disease O
were O
included O
in O
the O
study O
. O
[]

The O
rescue B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
['Resource-use']

Itraconazole O
has O
a O
broader O
spectrum O
of O
activity O
but O
the O
capsules O
give O
erratic O
bioavailability O
in O
neutropenic O
patients O
. O
[]

Several O
additional O
items O
measuring O
tantrum-like B-outcome ['Life-Impact']
['Life-Impact']

The O
goal O
of O
this O
project O
was O
to O
design O
a O
telehealth O
intervention O
to O
address O
such O
isolation O
, O
develop O
patient O
self-efficacy O
, O
and O
improve O
symptom O
management O
during O
the O
treatment O
experience O
. O
[]

By O
the O
end O
of O
the O
study O
the O
mean O
levodopa O
SR O
dosage O
was O
190 O
mg/d O
and O
the O
mean O
ropinirole O
dosage O
was O
1.45 O
mg/d O
. O
[]

days O
1-5 O
, O
plus O
mitoxantrone O
( O
10 O
mg/m O
( O
2 O
) O
i.v O
. O
) O
, O
[]

Using O
the O
geometry O
parameters O
as O
the O
input O
, O
the O
3D O
shape O
of O
another O
21 O
femora O
was O
built O
and O
meshed O
, O
separating O
a O
cortical O
and O
trabecular O
compartment O
. O
[]

OBJECTIVE O
Little O
is O
known O
about O
the O
neuropsychological O
effects O
of O
risperidone O
in O
children O
with O
pervasive O
developmental O
disorders O
. O
[]

BACKGROUND O
A O
combination O
of O
S-1 O
and O
cisplatin O
has O
been O
shown O
to O
be O
effective O
with O
acceptable O
safety O
for O
the O
first-line O
treatment O
of O
far-advanced O
gastric O
cancer O
in O
Japan O
. O
[]

Further O
studies O
will O
be O
needed O
with O
new O
formulations O
of O
cyclosporin O
or O
when O
using O
the O
full O
dosage O
of O
ticlopidine O
. O
[]

Elastic O
stable O
intramedullary O
nailing O
versus O
nonoperative O
treatment O
of O
displaced O
midshaft O
clavicular O
fractures-a O
randomized O
, O
controlled O
, O
clinical O
trial O
. O
[]

At O
seroconversion O
, O
the O
traditional O
schedule O
presented O
a O
higher O
percentage O
of O
children O
with O
serum O
HBs-Ag O
concentrations O
over O
100 O
mIU/ml O
than O
the O
accelerated O
schedule O
. O
[]

All O
children O
were O
evaluated O
at O
weeks O
1 O
, O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
with O
standardized O
assessments O
of O
language B-outcome ['Life-Impact']
, O
behavior B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact']

The O
third O
positive O
control O
group O
( O
n O
= O
17 O
) O
received O
E O
+ O
L O
( O
E O
( O
+ O
) O
L O
( O
+ O
) O
: O
10 O
mg/d O
+ O
50 O
mg/d O
) O
and O
the O
fourth O
negative O
control O
group O
( O
n O
= O
18 O
) O
received O
no O
medication O
( O
E O
( O
- O
) O
: O
L O
( O
- O
) O
) O
. O
[]

In O
this O
design O
, O
however O
, O
lithium/early O
morning O
sleep O
deprivation O
was O
no O
faster O
than O
either O
of O
the O
two O
desipramine/sleep O
deprivation O
conditions O
in O
inducing B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

MBCT O
appears O
to O
be O
a O
valid O
form O
of O
intervention O
for O
children O
with O
autism O
. O
[]

CONCLUSIONS O
No O
significant O
difference O
in O
response O
rate O
or O
response O
duration O
was O
observed O
in O
this O
study O
. O
[]

This O
trial O
evaluated O
the O
efficacy O
and O
long-term O
tolerability O
of O
a O
sublingual O
formulation O
of O
the O
fast-acting O
opioid O
fentanyl O
, O
for O
the O
treatment O
of O
BTcP O
in O
opioid-tolerant O
patients O
with O
cancer O
. O
[]

Other O
models O
of O
pulmonary O
rehabilitation O
, O
including O
home-based O
programs O
, O
have O
been O
proposed O
in O
order O
to O
improve O
access O
to O
this O
important O
treatment O
. O
[]

In O
classrooms O
with O
moderate O
fidelity B-outcome ['Physiological-Clinical']
, O
students O
in O
Structured O
Teaching O
experienced O
a O
greater O
gain O
than O
students O
in O
Strategies O
for O
Teaching O
based O
on O
Autism O
Research O
( O
10.1 O
vs. O
4.4 O
points O
) O
. O
['Physiological-Clinical']

METHODS O
Forty O
patients O
with O
esophageal O
cancer O
( O
without O
serious O
hypertension O
, O
heart O
disease O
, O
or O
respiratory O
function O
impairment O
, O
including O
34 O
men O
and O
6 O
women O
aged O
46 O
to O
70 O
years O
) O
scheduled O
for O
oesophagectomy O
via O
left O
thoracotomy O
were O
randomly O
divided O
into O
control O
group O
( O
n=20 O
) O
and O
UTI O
group O
( O
n=20 O
) O
. O
[]

Performances O
of O
all O
staging O
systems O
were O
rather O
disappointing O
. O
[]

In O
one O
patient O
, O
mannitol O
treatment O
was O
necessary O
to O
prevent O
dural B-outcome ['Physiological-Clinical']
tightness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Each O
dose O
and O
placebo O
was O
given O
three O
times O
in O
a O
randomized O
block O
sequence O
. O
[]

PATIENTS O
AND O
METHODS O
Forty O
five O
patients O
with O
melasma O
were O
randomly O
assigned O
into O
three O
groups O
of O
fifteen O
patients O
each O
. O
[]

BACKGROUND O
Patients O
with O
chronic O
heart O
failure O
complain O
of O
breathlessness O
and O
fatigue O
on O
exercise O
. O
[]

In O
the O
G-CSF O
group O
, O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
was O
significantly O
shorter O
and O
the O
frequency O
of O
documented O
infection O
was O
significantly O
decreased O
. O
['Physiological-Clinical']

This O
is O
a O
prospective O
, O
double-blind O
, O
placebo-controlled O
trial O
to O
determine O
the O
effect O
of O
antiarrhythmic O
drug O
therapy O
on O
mortality B-outcome ['Mortality']
in O
patients O
with O
congestive O
heart O
failure O
and O
ventricular O
arrhythmia O
. O
['Mortality']

This O
prospective O
, O
randomized O
study O
compares O
, O
for O
the O
first O
time O
, O
measured O
blood O
loss O
at O
conization O
and O
within O
24 O
hours O
after O
using O
either O
the O
cold O
knife O
technique O
or O
the O
carbon O
dioxide O
laser O
scalpel O
. O
[]

We O
found O
a O
significant O
reduction O
of O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
TC B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

Efficacy O
was O
assessed O
using O
a O
six-minute O
walking O
test O
, O
the O
New O
York O
Heart O
Association O
( O
NYHA O
) O
class O
, O
a O
functional O
lifescale O
( O
FLS O
) O
questionnaire O
and O
the O
cardiothoracic O
ratio O
( O
CTR O
) O
-at O
study O
entry O
and O
at O
the O
end O
of O
the O
maintenance O
phase O
. O
[]

Response O
status O
further O
improved O
in O
18 O
% O
randomized O
to O
continue O
tamoxifen O
alone O
vs O
31 O
% O
in O
whom O
CMF O
was O
added O
to O
tamoxifen O
. O
[]

The O
authors O
used O
tactile B-outcome ['Physiological-Clinical']
and O
cold B-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
and O
a O
visual O
analog O
scale O
to O
evaluate O
participants O
' O
pain O
at O
baseline O
, O
immediately O
after O
powder O
application O
and O
at O
one O
week O
, O
two O
weeks O
and O
four O
weeks O
after O
powder O
application O
. O
['Physiological-Clinical']

Unlike O
cimetidine O
, O
healing O
by O
sucralfate O
was O
unaffected O
by O
cigarette O
smoking O
, O
reluctance O
to O
give O
up O
smoking O
, O
habitual O
use O
of O
alcohol O
, O
high O
maximal O
acid O
output O
, O
and O
large O
ulcer O
diameter O
. O
[]

At O
24 O
h O
, O
1 O
week O
, O
and O
6 O
months O
after O
PCI O
, O
MCE O
was O
performed O
by O
Sonovue O
, O
and O
real-time O
imaging O
was O
performed O
by O
contrast O
pulse O
sequencing O
technology O
. O
[]

A O
total O
of O
288 O
events O
in O
which O
the O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
exceeded O
a O
predetermined O
trigger O
value O
were O
observed O
. O
['Physiological-Clinical']

All O
costs B-outcome ['Resource-use']
( I-outcome ['Resource-use']
medical I-outcome ['Resource-use']
and O
non-medical O
) O
were O
measured O
during O
follow-up O
. O
['Resource-use']

Erythropoiesis O
after O
therapy O
with O
recombinant O
human O
erythropoietin O
: O
a O
dose-response O
study O
in O
anemic O
cancer O
surgery O
patients O
. O
[]

OBJECTIVE O
To O
assess O
the O
effectiveness O
of O
visual O
laser O
ablation O
treatment O
with O
neodymium-doped O
yttrium O
aluminum O
garnet O
( O
Nd O
: O
YAG O
) O
laser O
in O
male O
patients O
with O
urethral O
strictures O
and O
to O
compare O
the O
effects O
with O
those O
obtained O
in O
patients O
treated O
with O
Sachse O
's O
optical O
urethrotomy O
. O
[]

A O
post-test O
and O
an O
evaluation O
questionnaire O
were O
administered O
to O
both O
groups O
at O
the O
end O
of O
the O
trial O
period O
. O
[]

term O
= O
landa O
& O
rank O
= O
3 O
. O
[]

During O
in-patient O
rehabilitation O
, O
the O
results O
of O
a O
comprehensive O
neuropsychological O
test O
battery O
improved O
significantly O
in O
all O
three O
groups O
, O
and O
no O
specific O
intervention O
effects O
were O
identified O
. O
[]

OBJECTIVE O
To O
evaluate O
whether O
long-term O
supplementation O
with O
vitamin O
E O
decreases O
the O
risk O
of O
cancer B-outcome ['Physiological-Clinical']
, O
cancer B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
and O
major B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

One O
screening O
center O
had O
a O
major O
special O
recruitment O
effort O
for O
blacks O
and O
another O
center O
had O
a O
major O
special O
recruitment O
effort O
for O
Hispanics O
. O
[]

Several O
reports O
indicate O
that O
children O
with O
ASD O
show O
reduced O
error O
processing B-outcome ['Life-Impact']
and O
deficient O
behavioral B-outcome ['Life-Impact']
correction I-outcome ['Life-Impact']
after O
an O
error O
is O
committed O
. O
['Life-Impact', 'Life-Impact']

SETTING O
Outpatient O
clinic O
. O
[]

Oedema O
formation O
was O
clinically O
estimated O
according O
to O
an O
arbitrary O
scale O
and O
skin O
thickness O
measured O
with O
a O
calliper O
. O
[]

Patients O
in O
the O
CEF O
+ O
GM-CSF O
group O
received O
chemotherapy O
at O
a O
median O
interval O
of O
16 O
days O
compared O
with O
20 O
days O
in O
the O
control O
group O
. O
[]

Indeed O
, O
42 O
% O
of O
the O
enriched O
group O
and O
only O
7 O
% O
of O
the O
control O
group O
had O
what O
we O
considered O
to O
be O
a O
clinically O
significant O
improvement O
of O
5 O
points O
on O
that O
scale O
. O
[]

Taken O
together O
, O
the O
findings O
of O
Study O
1 O
suggest O
that O
the O
TOM O
test O
is O
a O
valid O
measure O
. O
[]

Falls B-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
without I-outcome ['Life-Impact']
loss I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
consciousness I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
were O
reduced O
by O
two-thirds O
: O
controls O
reported O
669 O
falls O
( O
mean O
9.3 O
; O
range O
0 O
to O
89 O
) O
, O
and O
paced O
patients O
216 O
falls O
( O
mean O
4.1 O
; O
range O
0 O
to O
29 O
) O
. O
['Life-Impact']

PNES O
diagnosis O
was O
established O
by O
video-EEG O
telemetry O
for O
most O
patients O
. O
[]

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
L-1 I-outcome ['Physiological-Clinical']
regression I-outcome ['Physiological-Clinical']
was O
significantly O
longer O
in O
Group O
2 O
( O
146 O
+/- O
28 O
min O
in O
Group O
1 O
versus O
159 O
+/- O
19 O
min O
in O
Group O
2 O
) O
. O
['Physiological-Clinical']

The O
tolfenamic O
acid-caffeine O
combination O
proved O
the O
most O
effective O
as O
judged O
by O
duration O
and O
intensity O
of O
attacks B-outcome ['Physiological-Clinical']
, O
working O
ability O
, O
vigilance O
, O
and O
['Physiological-Clinical']

Flavonoids O
, O
such O
as O
troxerutin O
, O
have O
been O
shown O
to O
be O
safe O
and O
effective O
agents O
for O
the O
treatment O
of O
chronic O
venous O
insufficiency O
. O
[]

Second O
, O
an O
extensive O
number O
of O
new O
features O
are O
added O
to O
those O
proposed O
by O
Spencer-Frame O
. O
[]

Rumination O
did O
not O
lead O
to O
differences O
in O
memory B-outcome ['Life-Impact']
from O
the O
other O
instructions O
. O
['Life-Impact']

Notwithstanding O
the O
metabolic O
effects O
of O
the O
additional O
therapy O
have O
induced O
a O
positive O
change O
of O
atherogenic B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Active O
approaches O
including O
exercise O
in O
the O
treatment O
of O
low O
back O
pain O
results O
in O
better O
outcomes O
for O
patients O
, O
but O
it O
is O
not O
known O
exactly O
which O
types O
of O
back O
exercises O
are O
most O
beneficial O
or O
whether O
general O
physical O
activity O
provide O
similar O
benefits O
. O
[]

The O
interaction O
in O
the O
field O
trial O
showed O
a O
trend O
( O
p=0.138 O
) O
toward O
a O
beneficial O
treatment O
effect O
when O
the O
individual O
ODR O
values O
, O
measured O
in O
late O
lactation O
and O
using O
Svanovir O
( O
? O
) O
, O
[]

The O
single O
and O
combination O
groups O
comprised O
14 O
and O
13 O
patients O
, O
respectively O
, O
and O
there O
was O
no O
significant O
difference O
between O
the O
background O
of O
both O
groups O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
modelled O
according O
to O
a O
two-compartment O
open O
model O
with O
first-order O
absorption O
and O
elimination O
. O
['Physiological-Clinical']

In O
patients O
remaining O
in O
the O
study O
, O
significantly O
less O
pain B-outcome ['Physiological-Clinical']
was O
experienced O
by O
the O
HA O
group O
during O
the O
6 O
month O
follow-up O
period O
. O
['Physiological-Clinical']

SUBJECTS O
AND O
SETTING O
Adults O
with O
long-term O
indwelling O
catheters O
that O
required O
changing O
every O
3 O
weeks O
or O
less O
, O
living O
in O
the O
community O
, O
and O
requiring O
supportive O
or O
continuing O
care O
were O
recruited O
. O
[]

Biochemical B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
except O
urinary B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
hydroxyproline I-outcome ['Physiological-Clinical']
measured O
at O
6 O
months O
were O
positively O
correlated O
with O
the O
BMD B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
lumbar I-outcome ['Physiological-Clinical']
spine I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
median O
follow-up O
was O
18 O
months O
. O
[]

In O
the O
first O
group O
, O
17 O
patients O
, O
a O
through O
drainage O
with O
sterile O
physiologic O
solution O
was O
applied O
, O
while O
in O
the O
second O
group O
, O
16 O
patients O
, O
antibiotic O
was O
added O
to O
the O
sterile O
physiologic O
solution O
. O
[]

METHODS O
Sixty-one O
patients O
with O
depressive O
disorders O
who O
were O
already O
in O
therapy O
in O
an O
outpatient O
mental O
health O
institution O
were O
randomly O
assigned O
to O
either O
eight O
group O
sessions O
of O
COMET O
in O
addition O
to O
their O
regular O
therapy O
( O
COMET O
+ O
therapy O
as O
usual O
[ O
TAU O
] O
: O
the O
experimental O
group O
) O
or O
to O
8 O
weeks O
of O
ongoing O
regular O
therapy O
( O
TAU O
only O
: O
the O
control O
group O
) O
. O
[]

CONCLUSIONS O
Tegaserod O
is O
devoid O
of O
electrocardiographic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
and O
is O
not O
expected O
to O
adversely O
influence O
cardiac B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ten O
patients O
were O
randomly O
assigned O
to O
receive O
4.4 O
mL O
of O
2 O
% O
lidocaine O
with O
1:80,000 O
epinephrine O
as O
a O
local O
anesthetic O
and O
10 O
were O
given O
4.4 O
mL O
of O
3 O
% O
prilocaine O
with O
0.03 O
IU/mL O
felypressin O
. O
[]

Morphology O
of O
the O
postoperative O
blebs O
suggests O
that O
increased O
filtration O
results O
in O
lower O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
the O
5-FU O
group O
. O
['Physiological-Clinical']

All O
available O
baseline O
and O
6-month O
echocardiograms O
from O
Pediatric O
Carvedilol O
Trial O
( O
PCT O
) O
participants O
( O
carvedilol O
n O
= O
161 O
; O
placebo O
n O
= O
55 O
) O
were O
reviewed O
. O
[]

Fourteen O
young O
healthy O
men O
( O
height O
: O
177.0 O
? O
[]

Dietary O
lignan O
and O
proanthocyanidin O
consumption O
and O
colorectal B-outcome ['Physiological-Clinical']
adenoma I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
in O
the O
Polyp O
Prevention O
Trial O
. O
['Physiological-Clinical']

Nutritional O
support O
was O
initiated O
within O
12 O
hours O
postoperatively O
in O
both O
groups O
, O
and O
infused O
at O
a O
rate O
sufficient O
to O
render O
the O
patients O
in O
positive O
nitrogen O
balance O
. O
[]

Patients O
with O
arteriographically O
proven O
coronary O
artery O
disease O
are O
considered O
for O
the O
trial O
if O
the O
participating O
cardiologist O
and O
surgeon O
agree O
that O
equivalent O
revascularisation O
could O
be O
achieved O
by O
either O
treatment O
method O
. O
[]

For O
11 O
implants O
( O
11 O
percent O
) O
in O
10 O
women O
, O
the O
authors O
observed O
progression O
of O
silicone B-outcome ['Physiological-Clinical']
seepage I-outcome ['Physiological-Clinical']
, O
either O
as O
a O
conversion O
from O
intracapsular O
into O
extracapsular O
rupture O
( O
n O
= O
7 O
) O
, O
as O
progression O
of O
extra-capsular O
silicone O
( O
n O
= O
3 O
) O
, O
or O
as O
increasing O
herniation O
of O
the O
silicone O
within O
the O
fibrous O
capsule O
( O
n O
= O
1 O
) O
; O
however O
, O
in O
most O
cases O
, O
these O
changes O
were O
minor O
. O
['Physiological-Clinical']

Effect O
of O
ozone O
application O
on O
the O
resin-dentin B-outcome ['Physiological-Clinical']
microtensile I-outcome ['Physiological-Clinical']
bond I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
most O
common O
treatment-related O
grade O
3/4 O
AEs O
were O
fatigue B-outcome ['Physiological-Clinical']
( O
9 O
% O
v O
1 O
% O
) O
, O
asthenia B-outcome ['Physiological-Clinical']
( O
8 O
% O
v O
2 O
% O
) O
, O
and O
hand-foot B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
( O
7 O
% O
v O
0 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
the O
subjects O
were O
evaluated O
at O
enrolment O
and O
after O
6 O
months O
. O
[]

Significantly O
fewer B-outcome ['Physiological-Clinical']
ties I-outcome ['Physiological-Clinical']
were O
required O
during O
liver O
transection O
in O
the O
TL O
group O
than O
in O
the O
BP O
group O
( O
15.8 O
+/- O
4.8 O
versus O
22.8 O
+/- O
7.9 O
ties O
; O
P O
= O
0.023 O
) O
. O
['Physiological-Clinical']

METHODS O
Patients O
were O
studied O
first O
in O
their O
homes O
with O
the O
limited O
sleep-recording O
device O
. O
[]

BACKGROUND O
Autism O
spectrum O
disorder O
( O
ASD O
) O
is O
associated O
with O
altered O
face O
processing O
and O
decreased O
activity O
in O
brain O
regions O
involved O
in O
face O
processing O
. O
[]

A O
significant O
reduction O
in O
drain B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
seen O
in O
the O
POIO O
, O
IOPO O
, O
and O
POIOPO O
groups O
whereas O
total O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
in O
the O
POIO O
, O
POIOPO O
, O
and O
LA O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Aliquots O
were O
stained O
with O
a O
tumour-specific O
antibody O
against O
epithelial O
tissue O
( O
Ber O
EP4 O
) O
, O
verified O
as O
a O
good O
marker O
of O
SCLC O
cells O
by O
immunohistochemistry O
. O
[]

In O
period O
2 O
: O
ErSr O
urinary B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
was O
reduced O
by O
81.4 O
( O
SEM O
17.8 O
) O
mmol O
( O
mEq O
) O
/24 O
h O
and O
there O
was O
a O
weight O
loss B-outcome ['Physiological-Clinical']
of O
8.2 O
( O
SEM O
0.7 O
) O
kg O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
subjects O
were O
followed O
for O
1 O
year O
. O
[]

A O
parallel O
set O
of O
analyses O
was O
conducted O
on O
partners O
' O
depression B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
data O
. O
['Life-Impact', 'Life-Impact']

OBJECTIVES O
This O
study O
was O
designed O
to O
a O
) O
document O
the O
efficacy O
of O
a O
device O
intended O
to O
conserve O
blood O
in O
critically O
ill O
patients O
; O
b O
) O
determine O
the O
effect O
of O
this O
blood O
conservation O
on O
hemoglobin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
the O
need O
for O
blood O
transfusions O
; O
c O
) O
determine O
if O
the O
blood O
conservation O
device O
resulted O
in O
interference O
with O
arterial O
pressure O
waveforms O
; O
d O
) O
determine O
if O
use O
of O
the O
blood O
conservation O
device O
resulted O
in O
a O
difference O
in O
the O
number O
of O
accidental O
needle O
punctures O
suffered O
by O
healthcare O
workers O
. O
['Physiological-Clinical']

To O
investigate O
the O
effect O
of O
T O
( O
3 O
) O
-induced O
pulmonary O
hypertension O
on O
endothelin O
( O
ET O
) O
production O
and O
genes B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ET-1 I-outcome ['Physiological-Clinical']
, O
ET B-outcome ['Physiological-Clinical']
( O
A O
) O
and O
ET B-outcome ['Physiological-Clinical']
( O
B O
) O
receptors B-outcome ['Physiological-Clinical']
( O
ET B-outcome ['Physiological-Clinical']
( O
A O
) O
R O
and O
ET B-outcome ['Physiological-Clinical']
( O
B O
) O
R O
) O
during O
rearing O
, O
semiquantitative O
RT-PCR O
and O
enzyme O
immunometric O
assay O
were O
performed O
in O
the O
heart O
ventricles O
and O
serum O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
dose O
of O
risperidone O
was O
titrated O
between O
1 O
and O
2.0 O
mg/d O
, O
and O
the O
dose O
of O
amantadine O
was O
100 O
or O
150 O
mg/d O
for O
patients O
less O
than O
30 O
kg O
or O
more O
than O
30 O
kg O
, O
respectively O
. O
[]

PATIENTS O
AND O
METHODS O
Totally O
25 O
patients O
with O
a O
history O
of O
differentiated O
thyroid O
carcinoma O
on O
long-term O
TSH-suppressive O
levothyroxine O
( O
l-T O
( O
4 O
) O
) O
substitution O
were O
randomized O
to O
persistent O
TSH-suppressive O
l-T O
( O
4 O
) O
substitution O
( O
low-TSH O
group O
) O
or O
restoration O
of O
euthyroidism O
. O
[]

CONCLUSIONS O
Our O
results O
suggest O
humoral O
immunosuppression O
is O
better O
with O
Tac/MMF O
than O
with O
CsA/AZA O
during O
the O
first O
year O
of O
kidney O
transplantation O
. O
[]

Studies O
2 O
and O
3 O
were O
designed O
as O
cross-over O
studies O
intended O
to O
investigate O
drug B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
. O
['Resource-use']

administration O
, O
C O
is O
assumed O
to O
be O
absorption O
dependent O
since O
no O
sustained-release O
formulation O
was O
used O
. O
[]

Additional O
pain-reduction O
strategies O
are O
required O
. O
[]

DESIGN O
Patients O
in O
this O
randomized O
, O
double-blind O
, O
vehicle-controlled O
study O
applied O
5 O
% O
imiquimod O
cream O
or O
vehicle O
to O
AK B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
3 O
times O
per O
week O
for O
a O
maximum O
of O
12 O
weeks O
or O
until O
lesions O
had O
resolved O
. O
['Physiological-Clinical']

Fluoroscopic O
functional O
evaluation O
of O
bileaflet O
prostheses O
: O
effect O
of O
different O
intraoperative O
valve O
orientation O
. O
[]

Despite O
its O
high O
prevalence O
, O
medical O
teams O
often O
overlook O
malnutrition O
, O
and O
screening O
of O
these O
patients O
is O
not O
routine O
. O
[]

We O
have O
assessed O
whether O
it O
is O
possible O
to O
derive O
clinically O
useful O
information O
about O
total O
hip O
bone O
mineral O
density O
( O
BMD O
) O
from O
measurements O
at O
other O
hip O
sites O
. O
[]

The O
primary O
endpoint O
was O
pathological B-outcome ['Physiological-Clinical']
complete I-outcome ['Physiological-Clinical']
response O
( O
pCR O
) O
. O
['Physiological-Clinical']

Cruciferous O
vegetables O
( O
CVs O
) O
have O
been O
widely O
studied O
for O
their O
anticarcinogenic O
properties O
. O
[]

INTRODUCTION O
AND O
HYPOTHESIS O
Back-strengthening O
exercise O
is O
effective O
in O
increasing O
back B-outcome ['Physiological-Clinical']
extensor I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
and O
decreasing O
risk O
of O
vertebral B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
statistically O
significant O
differences O
were O
found O
when O
comparing O
the O
AT550 O
NCT O
with O
contact O
applanation O
tonometry O
( O
AT O
) O
( O
p O
> O
0.05 O
) O
, O
displaying O
the O
closest O
level O
of O
agreement B-outcome ['Life-Impact']
( O
as O
represented O
by O
the O
lowest O
mean O
difference O
['Life-Impact']

The O
aerosol O
was O
administered O
via O
a O
pneumatic O
nebulizer O
once O
a O
day O
for O
5 O
days O
. O
[]

With O
such O
long-term O
treatment O
, O
the O
safety O
profile O
of O
new O
agents O
will O
be O
of O
paramount O
importance O
. O
[]

In O
two O
years O
, O
control O
heifers O
( O
n O
= O
46 O
) O
grazed O
pasture O
and O
received O
0.9 O
kg O
of O
SBM O
supplement/d O
; O
LS O
( O
n O
= O
46 O
) O
heifers O
were O
self-fed O
a O
distiller O
's O
grain O
and O
soybean O
hull-based O
diet O
in O
drylot O
; O
and O
HS O
heifers O
( O
n O
= O
46 O
) O
were O
limited-fed O
a O
corn-based O
diet O
in O
drylot O
. O
[]

Short-term O
effects O
of O
prednisolone O
and O
dexamethasone O
on O
circulating B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
leptin I-outcome ['Physiological-Clinical']
and O
sex B-outcome ['Physiological-Clinical']
hormone-binding I-outcome ['Physiological-Clinical']
globulin I-outcome ['Physiological-Clinical']
in O
children O
being O
treated O
for O
acute O
lymphoblastic O
leukaemia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
in O
nonlinear O
models O
of O
absorption O
, O
in O
mechanisms O
involving O
recycling O
of O
drugs O
, O
and O
for O
drugs O
with O
long O
half-life O
, O
the O
use O
of O
total O
AUC O
( O
from O
zero O
to O
infinity O
) O
can O
give O
erroneous O
and O
clinically O
irrelevant O
results O
since O
the O
area O
is O
mostly O
determined O
by O
elimination O
phase O
or O
by O
recycling O
. O
[]

CONCLUSION O
The O
results O
of O
the O
study O
do O
not O
support O
the O
results O
of O
open O
studies O
, O
in O
which O
a O
reduction O
of O
social B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
social B-outcome ['Life-Impact']
avoidance I-outcome ['Life-Impact']
was O
reported O
in O
patients O
with O
social O
phobia O
treated O
with O
buspirone O
. O
['Life-Impact']

In O
conclusion O
, O
?-blocker O
therapy O
was O
well O
tolerated O
in O
patients O
with O
intermittent O
claudication O
and O
arterial O
hypertension O
during O
a O
treatment O
period O
of O
?1 O
year O
. O
[]

INTERVENTIONS O
After O
a O
6-hr-period O
of O
protective O
conventional O
mechanical O
ventilation O
, O
patients O
were O
submitted O
to O
three O
1-hr O
periods O
of O
high-frequency O
oscillatory O
ventilation O
( O
+5 O
, O
+10 O
, O
+15 O
) O
in O
a O
randomized O
order O
, O
with O
a O
mean O
airway O
pressure O
level O
determined O
by O
adding O
5 O
, O
10 O
, O
or O
15 O
cm O
H2O O
to O
the O
mean O
airway O
pressure O
recorded O
during O
conventional O
mechanical O
ventilation O
. O
[]

Maladaptive B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
decreased O
significantly O
more O
in O
the O
LEGO O
and O
SULP O
groups O
compared O
to O
the O
control O
group O
. O
['Life-Impact']

In O
addition O
, O
moving O
window O
analyses O
of O
text O
processing O
strategies O
indicated O
that O
differential O
strategies O
observed O
in O
previous O
studies O
when O
subjects O
listened O
to O
high O
vs O
low O
imagery O
text O
do O
not O
generalize O
to O
reading O
of O
the O
same O
materials O
. O
[]

CONCLUSIONS O
Medicaid B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
were O
generally O
higher O
under O
Cash O
and O
Counseling O
because O
those O
in O
the O
traditional O
system O
did O
not O
get O
the O
services O
they O
were O
entitled O
to O
. O
['Resource-use']

After O
screening O
, O
the O
patients O
were O
randomly O
allocated O
to O
receive O
, O
for O
a O
period O
of O
4 O
weeks O
, O
either O
a O
cocoa O
husk O
supplement O
or O
placebo O
plus O
standardized O
toilet O
training O
procedures O
. O
[]

On O
day O
4 O
, O
the O
effects O
of O
diphenhydramine O
did O
not O
reach O
significance O
. O
[]

The O
median O
( O
25-75 O
% O
) O
PBI O
was O
6 O
% O
( O
3-9 O
% O
) O
. O
[]

Comparison O
of O
yoga O
versus O
stretching O
for O
chronic B-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
: O
protocol O
for O
the O
Yoga O
Exercise O
Self-care O
( O
YES O
) O
trial O
. O
['Physiological-Clinical']

The O
Physiological O
Tension O
Scale O
detected O
significant O
increases O
in O
tension B-outcome ['Physiological-Clinical']
following O
tension O
inducement O
, O
whereas O
the O
Physical O
Assessment O
Scale O
and O
Cognitive O
Tension O
Scale O
detected O
increases O
in O
relaxation B-outcome ['Life-Impact']
following O
relaxation O
training O
. O
['Physiological-Clinical', 'Life-Impact']

FINDINGS O
Results O
of O
structural O
equation O
and O
hierarchical O
linear O
models O
did O
not O
support O
the O
hypothesis O
that O
bupropion O
SR O
treatment O
improves O
short-term O
abstinence B-outcome ['Life-Impact']
by O
reducing O
withdrawal O
distress O
or O
affecting O
the O
subjective O
effects O
of O
a O
lapse O
cigarette O
, O
but O
provided O
partial O
support O
for O
mediation O
by O
cigarette B-outcome ['Life-Impact']
craving I-outcome ['Life-Impact']
reduction I-outcome ['Life-Impact']
and O
enhanced O
positive O
affect O
. O
['Life-Impact', 'Life-Impact']

Therapy B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
obtained O
for O
38 O
patients O
with O
clinically O
evaluable O
disease O
after O
initial O
surgery O
. O
['Physiological-Clinical']

This O
study O
is O
registered O
with O
ClinicalTrials.gov O
, O
number O
NCT00919373 O
. O
[]

SICI B-outcome ['Physiological-Clinical']
was O
associated O
with O
significant O
changes O
with O
respect O
to O
treatment O
response O
. O
['Physiological-Clinical']

RESULTS O
The O
median O
follow-up O
was O
32 O
and O
35 O
months O
in O
the O
hypofractionation O
and O
conventional O
fractionation O
arms O
, O
respectively O
. O
[]

Generalization O
was O
assessed O
in O
a O
different O
room O
, O
to O
a O
new O
person O
, O
and O
to O
novel O
stimuli O
. O
[]

MATERIALS O
AND O
METHODS O
In O
a O
prospective O
, O
randomized O
clinical O
trial O
involving O
patients O
with O
dysfunctional O
, O
stenotic O
hemodialysis O
arteriovenous O
fistulas O
( O
AVFs O
) O
, O
patients O
were O
randomized O
to O
receive O
CBA O
or O
HPBA O
if O
conventional O
PTA O
had O
suboptimal O
results O
( O
ie O
, O
residual O
stenosis O
> O
30 O
% O
) O
. O
[]

AIM O
The O
present O
study O
investigated O
the O
effect O
of O
acarbose O
on O
insulin B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
and O
glycaemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
in O
patients O
with O
type O
2 O
diabetes O
receiving O
exogenous O
insulin O
due O
to O
secondary O
failure O
of O
maximum O
dose O
sulphonylurea O
therapy O
. O
['Resource-use', 'Physiological-Clinical']

We O
evaluated O
arterial B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation O
( O
SaO B-outcome ['Physiological-Clinical']
( O
2 O
) O
) O
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
acute O
stroke O
patients O
to O
determine O
whether O
routine O
positioning O
affected O
these O
physiological O
parameters O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mean O
data O
indicated O
that O
post-treatment O
VAS O
was O
significantly O
decreased O
and O
post-treatment B-outcome ['Physiological-Clinical']
PPT I-outcome ['Physiological-Clinical']
was O
significantly O
increased O
in O
the O
experimental O
group O
, O
not O
in O
the O
control O
group O
. O
['Physiological-Clinical']

Mortality B-outcome ['Mortality']
was O
similar O
in O
both O
groups O
. O
['Mortality']

The O
impact O
of O
schizophrenic O
patient O
functionality O
on O
service O
utilization O
and O
cost B-outcome ['Resource-use']
. O
['Resource-use']

METHODS O
A O
prospective O
randomized O
controlled O
trial O
was O
conducted O
in O
patients O
with O
curative O
resection O
of O
HCC O
; O
they O
were O
given O
either O
one O
intra-arterial O
dose O
of O
cisplatin/lipiodol O
, O
or O
received O
four O
doses O
, O
once O
every O
3 O
months O
. O
[]

However O
, O
glycerol O
provided O
significantly O
lower O
total O
ultrafiltration B-outcome ['Physiological-Clinical']
than O
glucose O
at O
each O
concentration O
, O
despite O
a O
higher O
initial O
osmotic O
pressure O
of O
the O
glycerol-based O
solutions O
. O
['Physiological-Clinical']

This O
study O
was O
designed O
to O
investigate O
the O
effects O
of O
conjugated O
linoleic O
acid O
( O
CLA O
) O
supplementation O
and O
endurance O
exercise O
training-induced O
changes O
on O
post-heparin O
lipoprotein O
lipase O
( O
PH-LPL O
) O
and O
butyrylcholinesterase B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BChE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
along O
with O
leptin O
, O
insulin O
and O
lipid O
levels O
in O
plasma O
by O
a O
randomized O
double O
blind O
experiment O
. O
['Physiological-Clinical']

BACKGROUND O
Hypothermia O
may O
be O
an O
effective O
treatment O
for O
stroke O
or O
acute O
myocardial O
infarction O
; O
however O
, O
it O
provokes O
vigorous O
shivering O
, O
which O
causes O
potentially O
dangerous O
haemodynamic O
responses O
and O
prevents O
further O
hypothermia O
. O
[]

This O
study O
examined O
the O
effects O
of O
MCT O
oil O
consumption O
, O
as O
part O
of O
a O
weight O
loss O
diet O
, O
on O
metabolic O
risk O
profile O
compared O
to O
olive O
oil O
. O
[]

Contrast O
ventriculography B-outcome ['Physiological-Clinical']
demonstrated O
improvement O
in O
immediate O
( O
54 O
+/- O
12 O
% O
) O
versus O
6-month O
( O
60 O
+/- O
15 O
% O
, O
p O
< O
0.05 O
) O
values O
for O
the O
overall O
group O
. O
['Physiological-Clinical']

The O
cardiovascular B-outcome ['Physiological-Clinical']
effects O
of O
tamoxifen O
in O
women O
with O
and O
without O
CHD O
are O
not O
known O
. O
['Physiological-Clinical']

Thrombus O
aspiration O
reduces O
microvascular B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
after O
primary O
coronary O
intervention O
: O
a O
myocardial O
contrast O
echocardiography O
substudy O
of O
the O
REMEDIA O
Trial O
. O
['Physiological-Clinical']

In O
addition O
, O
subjective O
assessment O
of O
nasal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
showed O
that O
cetirizine/PSE O
was O
significantly O
superior O
to O
placebo O
in O
both O
challenges O
for O
the O
sum B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
nasal I-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
scores O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
our O
recent O
randomized O
trial O
in O
HF O
, O
abolition O
of O
OSA O
by O
continuous O
positive O
airway O
pressure O
( O
CPAP O
) O
increased O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LVEF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
lowered O
morning B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIM O
To O
determine O
whether O
eradication O
of O
H. O
pylori O
might O
be O
of O
benefit O
in O
non-ulcer O
dyspepsia O
patients O
. O
[]

The O
main O
outcome O
was O
erectile B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
( O
International O
Index O
of O
Erectile O
Function-5 O
score O
) O
. O
['Physiological-Clinical']

Theta O
power O
in O
waking B-outcome ['Physiological-Clinical']
increased O
more O
in O
a O
frontal O
EEG O
derivation O
than O
in O
a O
posterior O
derivation O
. O
['Physiological-Clinical']

Pyridoxine O
has O
been O
reported O
as O
having O
an O
antilactogenic O
effect O
, O
presumably O
by O
suppressing O
prolactin B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

One O
group O
of O
patients O
was O
treated O
with O
implantation O
of O
a O
cardioverter-defibrillator O
; O
the O
other O
received O
class O
III O
antiarrhythmic O
drugs O
, O
primarily O
amiodarone O
at O
empirically O
determined O
doses O
. O
[]

The O
main O
measure O
in O
the O
intervention O
group O
is O
individual B-outcome ['Life-Impact']
dietary I-outcome ['Life-Impact']
advice I-outcome ['Life-Impact']
aimed O
at O
reducing O
weight O
and O
intake O
of O
saturated O
fat O
and O
increasing O
intake O
of O
dietary O
fibre O
. O
['Life-Impact']

Effect O
of O
ranitidine O
on O
the O
disposition B-outcome ['Life-Impact']
of O
orally O
and O
intravenously O
administered O
triazolam O
. O
['Life-Impact']

In O
the O
second O
group O
, O
CT O
colonography O
was O
performed O
after O
a O
reduced O
bowel O
preparation O
, O
with O
the O
oral O
contrast O
medium O
for O
residue O
tagging O
being O
administered O
only O
on O
the O
day O
of O
the O
investigation O
. O
[]

The O
use O
of O
vitamin O
E O
for O
the O
prevention O
of O
chemotherapy-induced O
peripheral O
neuropathy O
: O
results O
of O
a O
randomized O
phase O
III O
clinical O
trial O
. O
[]

After O
baseline O
measurements O
, O
CCM O
signals O
were O
delivered O
continuously O
for O
2 O
hours O
in O
dogs O
and O
for O
30 O
minutes O
in O
patients O
. O
[]

Airways O
resistance O
is O
increased O
and O
lung O
compliance O
is O
reduced O
in O
chronic O
heart O
failure O
patients O
. O
[]

Therefore O
, O
no O
significant O
pharmacokinetic B-outcome ['Physiological-Clinical']
differences O
occurred O
in O
either O
risperidone O
active O
moiety O
or O
donepezil O
when O
given O
alone O
or O
in O
combination O
. O
['Physiological-Clinical']

Results O
showed O
no O
significant O
difference O
in O
the O
apical O
seal O
produced O
by O
gutta-percha O
and O
the O
tested O
root O
canal O
sealers O
. O
( O
[]

METHOD O
Data O
were O
collected O
over O
a O
23-week O
period O
, O
from O
4:00 O
PM O
to O
midnight O
, O
and O
resulted O
in O
446 O
patients O
being O
recruited O
into O
the O
study O
( O
90 O
% O
of O
those O
who O
screened O
positive O
) O
and O
randomized O
to O
three O
conditions O
following O
a O
two-stage O
process O
: O
screened O
only O
( O
n O
= O
147 O
) O
, O
assessed O
( O
n O
= O
152 O
) O
, O
and O
received O
intervention O
( O
n O
= O
147 O
) O
. O
[]

A O
life-table O
comparison O
of O
the O
cumulative O
dose O
to O
the O
development O
of O
a O
cardiac O
event O
showed O
that O
mitoxantrone O
had O
significantly O
less O
[]

The O
susceptibility O
of O
LDL B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
was O
measured O
by O
challenging O
LDL O
with O
hemin O
and O
H2O2 O
and O
measuring O
the O
time B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
reach I-outcome ['Physiological-Clinical']
maximum I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Body-weight B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
significant O
( O
ENT O
0.8 O
( O
se O
0.3 O
) O
kg O
, O
P O
< O
0.05 O
; O
PLA O
1.3 O
( O
se O
0.3 O
) O
kg O
, O
P O
< O
0.001 O
) O
, O
but O
not O
different O
between O
treatments O
. O
['Physiological-Clinical']

Severe O
enteropathy O
among O
patients O
with O
stage O
II/III O
colon O
cancer O
treated O
on O
a O
randomized O
trial O
of O
bolus O
5-fluorouracil/leucovorin O
plus O
or O
minus O
oxaliplatin O
: O
a O
prospective O
analysis O
. O
[]

Parent-implemented O
enhanced O
milieu O
teaching O
with O
preschool O
children O
who O
have O
intellectual O
disabilities O
. O
[]

Field O
efficacy O
of O
an O
inactivated B-outcome ['Resource-use']
bivalent I-outcome ['Resource-use']
influenza I-outcome ['Resource-use']
vaccine I-outcome ['Resource-use']
in O
a O
multi-site O
swine O
production O
system O
during O
an O
outbreak O
of O
systemic O
porcine O
circovirus O
associated O
disease O
. O
['Resource-use']

In O
the O
group O
treated O
with O
calcium O
heparin O
2 O
cases O
of O
clinically O
and O
radiologically B-outcome ['Physiological-Clinical']
diagnosed I-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
and O
4 O
cases O
of O
DVT B-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
change O
of O
IIEF B-outcome ['Physiological-Clinical']
score O
from O
baseline O
for O
erectile O
function O
domain O
of O
Cappra O
( O
? O
) O
['Physiological-Clinical']

We O
therefore O
recommend O
use O
of O
the O
stabilization O
appliance O
in O
the O
treatment O
of O
TMD O
patients O
with O
myofascial B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Multiple O
regression O
analysis O
of O
EPA+DHA O
intake O
and O
RBC O
EPA O
+ O
DHA O
concentration O
indicated O
positive O
and O
significant O
correlations O
for O
oily O
fish O
( O
beta O
= O
0.44 O
, O
95 O
% O
CI O
0.16 O
, O
0.72 O
, O
P O
= O
0.0027 O
) O
, O
total O
fish O
( O
beta O
= O
0.42 O
, O
95 O
% O
CI O
0.19 O
, O
0.64 O
, O
P O
= O
0.0005 O
) O
and O
marine O
food O
products O
( O
beta O
= O
0.42 O
, O
95 O
% O
CI O
0.20 O
, O
0.64 O
, O
P O
= O
0.0003 O
) O
. O
[]

The O
most O
common O
treatment O
emergent O
[]

FUNDING O
Amgen O
. O
[]

The O
primary O
outcome O
was O
relief O
of O
nighttime B-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Group O
E O
specimens O
were O
only O
acid-eroded O
and O
those O
of O
group O
F O
were O
only O
brushed O
. O
[]

Effects O
of O
captopril O
and O
enalapril O
on O
electroencephalogram O
and O
cognitive B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
in O
healthy O
volunteers O
. O
['Physiological-Clinical']

Esmolol O
( O
0.3 O
mg. O
kg O
( O
-1 O
) O
. O
[]

The O
primary O
outcome O
variable O
was O
the O
incidence O
of O
clinical B-outcome ['Physiological-Clinical']
sepsis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Children O
with O
autism O
were O
randomly O
allocated O
to O
risperidone O
plus O
memantine O
or O
placebo O
plus O
risperidone O
for O
a O
10-wk O
, O
double-blind O
, O
placebo-controlled O
study O
. O
[]

Thereafter O
stepwise O
isobaric O
distensions O
were O
performed O
with O
ongoing O
peptide O
infusion O
, O
and O
gastric B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
was O
scored O
. O
['Physiological-Clinical']

The O
bronchodilator O
response O
to O
salbutamol O
was O
expressed O
as O
a O
percentage O
of O
initial B-outcome ['Physiological-Clinical']
FEV1 I-outcome ['Physiological-Clinical']
( O
deltaFEV1 O
% O
init O
) O
. O
['Physiological-Clinical']

Two O
groups O
of O
12 O
severe O
agoraphobics O
were O
treated O
with O
4 O
sessions O
of O
cognitive O
therapy O
followed O
by O
8 O
sessions O
of O
cognitive O
therapy O
combined O
with O
in O
vivo O
exposure O
. O
[]

The O
objectives O
of O
this O
trial O
are O
to O
determine O
whether O
tamoxifen O
is O
effective O
in O
1 O
) O
reducing O
the O
incidence O
of O
invasive B-outcome ['Physiological-Clinical']
breast I-outcome ['Physiological-Clinical']
cancer B-outcome ['Physiological-Clinical']
, O
2 O
) O
reducing O
breast B-outcome ['Mortality']
cancer I-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
3 O
) O
reducing O
deaths B-outcome ['Mortality']
from O
cardiovascular B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Mortality', 'Physiological-Clinical']

A O
control O
( O
C O
) O
group O
from O
another O
study O
, O
who O
did O
not O
receive O
treadmill O
training O
, O
served O
as O
the O
control O
( O
eight O
males O
, O
seven O
females O
; O
mean O
age O
10.4 O
mo O
[ O
SD O
2.2 O
mo O
] O
) O
. O
[]

Trainees O
with O
a O
high O
frequency O
of O
incontinence O
during O
baseline O
, O
relatively O
more O
cognitive O
residents O
, O
and O
residents O
with O
a O
normal O
bladder O
capacity O
responded O
better O
to O
this O
behavioral O
program O
. O
[]

The O
effects O
of O
different O
intensities O
and O
durations O
of O
the O
general O
warm-up O
on O
leg B-outcome ['Physiological-Clinical']
press I-outcome ['Physiological-Clinical']
1RM O
. O
['Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
alpha-tocopherol I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
lower O
in O
patients O
given O
standard O
PN O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Patients O
randomised O
to O
the O
RT O
group O
received O
50 O
Gy/25 O
fx/5 O
weeks O
of O
teletherapy O
followed O
1-2 O
weeks O
later O
with O
12 O
Gy/2 O
fx O
of O
high-dose-rate O
intra-lumenal O
brachytherapy O
spaced O
a O
week O
apart O
. O
[]

e O
) O
. O
[]

The O
absence O
of O
efficacy O
may O
relate O
to O
an O
effect O
of O
hyperglycaemia O
. O
[]

More O
research O
into O
effective O
methods O
of O
controlling O
demand O
and O
better O
identification O
of O
those O
who O
would O
benefit O
from O
access O
to O
specialist O
care O
is O
needed O
. O
[]

Using O
end-points O
of O
hypnosis B-outcome ['Life-Impact']
( O
loss O
of O
response O
to O
verbal O
command B-outcome ['Life-Impact']
) O
and O
anaesthesia B-outcome ['Resource-use']
( O
loss O
of O
response O
to O
a O
5-s O
transcutaneous O
tetanic O
stimulus O
) O
, O
we O
determined O
dose-response O
curves O
for O
propofol O
and O
midazolam O
alone O
and O
in O
combination O
. O
['Life-Impact', 'Life-Impact', 'Resource-use']

10 O
ng/mL O
or O
clinical O
pregnancy O
. O
[]

Using O
stepwise O
logistic O
regression O
we O
were O
able O
to O
accurately O
predict O
the O
left O
anterior O
descending O
( O
LAD O
) O
, O
right O
, O
or O
left O
circumflex O
( O
LC O
) O
coronary O
artery O
as O
the O
infarct-related O
artery O
using O
2 O
variables O
: O
( O
1 O
) O
the O
summation O
of O
the O
ST-segment O
elevation O
in O
leads O
V1 O
to O
V4 O
; O
and O
( O
2 O
) O
the O
summation O
of O
the O
T-wave O
negativity O
in O
leads O
I O
, O
aVL O
, O
and O
V5 O
. O
[]

A O
placebo-controlled O
, O
fixed-dose O
study O
of O
aripiprazole O
in O
children O
and O
adolescents O
with O
irritability O
associated O
with O
autistic O
disorder O
. O
[]

RESULTS O
No O
serious O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
observed O
. O
['Adverse-effects']

Thirty-three O
cases O
( O
77 O
% O
) O
in O
ozone O
therapy O
group O
vs. O
16 O
cases O
( O
38 O
% O
) O
in O
control O
group O
survived O
( O
?? O
= O
12.993 O
, O
P O
< O
0.01 O
) O
. O
[]

Iontophoretic O
administration O
of O
dexamethasone O
sodium O
phosphate O
for O
acute O
epicondylitis O
. O
[]

METHODS O
Forty O
patients O
after O
elective O
sphincter-saving O
low O
anterior O
resection O
were O
eligible O
for O
intraoperative O
randomization O
. O
[]

DISCUSSION O
We O
hypothesize O
that O
the O
value O
of O
these O
promising O
implementation O
strategies O
is O
additive O
and O
that O
incorporating O
all O
three O
strategies O
( O
CBP O
, O
PF O
, O
and O
P4P O
) O
will O
be O
superior O
to O
CBP O
alone O
and O
CBP O
+ O
PF O
in O
improving O
delivery O
of O
cessation O
assistance O
to O
smokers O
. O
[]

At O
baseline O
, O
the O
patients O
in O
the O
high O
magnesium O
group O
were O
older O
and O
had O
more O
severe O
functional O
and O
renal B-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
fluence O
, O
pain O
using O
the O
visual O
analog O
scale O
, O
time O
, O
laser O
spot O
spread B-outcome ['Physiological-Clinical']
with O
infrared O
images O
, O
and O
retinal B-outcome ['Physiological-Clinical']
sensitivity B-outcome ['Physiological-Clinical']
were O
compared O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
overall O
results O
of O
the O
first O
and O
second O
experimental O
trials O
did O
not O
reveal O
obvious O
differences O
in O
weight O
loss B-outcome ['Physiological-Clinical']
between O
the O
manual O
, O
ultrasonic O
or O
power-driven O
root O
treatments O
. O
['Physiological-Clinical']

The O
effect O
of O
salivary O
exposure O
time O
on O
the O
abrasive B-outcome ['Physiological-Clinical']
wear I-outcome ['Physiological-Clinical']
of O
acid-eroded O
dentine O
was O
evaluated O
in O
situ O
. O
['Physiological-Clinical']

Of O
52 O
protocol O
compliant O
placebo O
immunotherapy O
recipients O
in O
Wenzhou O
, O
37 O
were O
disease O
free O
at O
two O
months O
, O
and O
a O
further O
8 O
had O
> O
50 O
% O
disease O
reduction O
. O
[]

We O
conclude O
that O
concurrent O
rituximab O
plus O
infusional O
EPOCH O
is O
an O
effective O
regimen O
for O
HIV-associated O
lymphoma O
. O
[]

Abnormal O
spatial B-outcome ['Life-Impact']
orientation I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
body I-outcome ['Life-Impact']
postures I-outcome ['Life-Impact']
in O
children O
with O
autism O
often O
interfere O
with O
visual O
abilities O
to O
attend O
tasks O
and O
social O
interactions O
. O
['Life-Impact']

BACKGROUND O
Contrary O
to O
aerobic O
exercise O
, O
strength O
training O
( O
ST O
) O
is O
associated O
with O
decreased O
central B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
in O
young O
men O
. O
['Physiological-Clinical']

There O
effects O
on O
disability B-outcome ['Life-Impact']
['Life-Impact']

Efficacy O
parameters O
were O
assessed O
as O
follows O
: O
at O
baseline O
( O
T1 O
) O
, O
after O
the O
first O
administration O
( O
T2 O
; O
day O
of O
surgery O
) O
, O
the O
second O
day O
after O
the O
surgical O
procedure O
( O
T3 O
) O
, O
and O
the O
fifth O
day O
after O
the O
surgical O
procedure O
( O
T4 O
) O
; O
hemorrhoidal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
based O
on O
a O
visual O
analogue O
scale O
( O
VAS O
) O
: O
pain B-outcome ['Physiological-Clinical']
, O
discharge O
, O
bleeding O
, O
inflammation O
, O
and O
pruritus O
; O
analgesic O
intake O
, O
if O
any O
; O
time O
to O
restore O
a O
physiological O
defecation O
; O
edema O
evaluation O
( O
based O
on O
a O
four-point O
scale O
: O
0 O
= O
absent O
; O
1 O
= O
mild O
; O
2 O
= O
moderate O
; O
3 O
= O
severe O
) O
; O
camera O
pictures O
taken O
at O
T1 O
and O
T4 B-outcome ['Physiological-Clinical']
( O
in O
selected O
patients O
) O
; O
and O
blood B-outcome ['Physiological-Clinical']
coagulation I-outcome ['Physiological-Clinical']
tests O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Severe O
neurological O
involvement O
in O
systemic O
lupus O
erythematosus O
( O
NPSLE O
) O
is O
one O
of O
the O
most O
dreadful O
complications O
of O
the O
disease O
. O
[]

MAIN O
OUTCOME O
MEASURES O
The O
primary O
outcome O
measure O
was O
the O
teacher-rated O
hyperactivity B-outcome ['Life-Impact']
subscale O
of O
the O
Aberrant O
Behavior O
Checklist O
. O
['Life-Impact']

Warfarin O
for O
atrial O
fibrillation O
. O
[]

OBJECTIVES O
To O
assess O
the O
efficacy O
of O
an O
adjuvant O
PDL O
treatment O
when O
combined O
with O
a O
proven O
topical O
treatment O
[ O
fixed-combination O
clindamycin O
1 O
% O
-benzoyl O
peroxide O
5 O
% O
hydrating O
gel O
( O
C/BPO O
) O
] O
. O
[]

During O
the O
treatment O
with O
prednisolone O
, O
a O
significant O
increase O
in O
the O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
was O
observed O
in O
all O
treated O
patients O
. O
['Physiological-Clinical']

Ninety-eight O
percent O
of O
the O
patients O
considered O
to O
have O
been O
adequately O
informed O
on O
a O
context O
judged O
to O
be O
extraordinary O
( O
99.3 O
% O
) O
, O
96.6 O
% O
indicated O
the O
information O
as O
necessary O
, O
98.6 O
% O
appreciated O
the O
treatment O
of O
the O
intraoperative O
and O
postoperative O
( O
99.3 O
% O
) O
pain O
and O
99.3 O
% O
the O
anxiolytic O
treatment O
. O
[]

The O
therapeutic O
course O
for O
all O
was O
24 O
weeks O
. O
[]

Fluconazole O
( O
FLU O
) O
is O
a O
new O
antifungal O
agent O
that O
has O
been O
used O
successfully O
to O
treat O
Candida O
infections O
and O
has O
modest O
activity O
against O
aspergillosis O
in O
animal O
models O
. O
[]

Significant O
improvements B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
HbA1c I-outcome ['Physiological-Clinical']
over O
24 O
months O
were O
observed O
in O
both O
groups O
( O
VBC O
, O
8.3 O
to O
6.8 O
% O
vs O
EXB O
, O
8.2 O
to O
7.3 O
% O
) O
. O
['Physiological-Clinical']

Effects O
of O
congestive O
heart O
failure O
on O
plasma B-outcome ['Physiological-Clinical']
von I-outcome ['Physiological-Clinical']
Willebrand I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
and O
soluble B-outcome ['Physiological-Clinical']
P-selectin I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in O
patients O
with O
non-valvar O
atrial O
fibrillation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Craving B-outcome ['Life-Impact']
reduction I-outcome ['Life-Impact']
and O
improvement O
of O
psychiatric B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
were O
the O
secondary O
endpoints O
. O
['Life-Impact', 'Life-Impact']

Treatment O
of O
vaginal O
adenosis O
with O
the O
carbon O
dioxide O
laser O
did O
not O
significantly O
reduce O
the O
incidence O
of O
development O
of O
new B-outcome ['Physiological-Clinical']
dysplasia I-outcome ['Physiological-Clinical']
in O
the O
DES-exposed O
offspring O
. O
['Physiological-Clinical']

Parents O
were O
trained O
in O
monitoring O
untoward O
effects O
. O
[]

Structures O
with O
a O
decrease O
in O
regional B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
pepper I-outcome ['Physiological-Clinical']
minus O
nicotine B-outcome ['Physiological-Clinical']
) O
were O
the O
left O
insula O
and O
right O
inferior O
occipital O
gyrus O
, O
with O
Z O
scores O
> O
3.5 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
exercise O
group O
, O
there O
was O
an O
increase O
in O
the O
WHOQOL-BREF O
and O
shoulder B-outcome ['Physiological-Clinical']
ROM B-outcome ['Physiological-Clinical']
and O
decrease O
in O
BFI O
and O
pain B-outcome ['Physiological-Clinical']
score O
after O
radiotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Gamma B-outcome ['Physiological-Clinical']
camera I-outcome ['Physiological-Clinical']
images I-outcome ['Physiological-Clinical']
were O
obtained O
at O
meal O
completion O
, O
1- O
, O
2- O
, O
3- O
and O
4-hour O
postmeal O
. O
['Physiological-Clinical']

METHODS O
Two O
randomized O
, O
double-blind O
, O
4-week O
, O
multi-centre O
trials O
with O
identical O
methodology O
compared O
once-daily O
esomeprazole O
, O
40 O
mg O
( O
n O
= O
241 O
) O
or O
20 O
mg O
( O
n O
= O
234 O
) O
, O
with O
placebo O
( O
n O
= O
242 O
) O
for O
the O
rigorous O
end-point O
of O
complete B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Two O
hundred O
twenty-eight O
first-admission O
schizophrenic O
patients O
were O
randomly O
assigned O
to O
the O
following O
five O
treatments O
: O
psychotherapy O
alone O
, O
drug O
alone O
, O
psychotherapy O
plus O
drug O
, O
electroconvulsive O
therapy O
( O
ECT O
, O
and O
milieu O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
influence O
between O
prehydration O
with O
3 O
% O
hypertonic O
saline O
and O
with O
isotonic O
lactated O
Ringer O
's O
solution O
on O
the O
hemodynamic O
changes O
and O
serum O
electrolyte O
concentrations O
in O
patients O
undergoing O
spinal O
anesthesia O
. O
[]

There O
were O
no O
statistically O
significant O
differences O
between O
the O
two O
groups O
on O
any O
of O
the O
other O
study O
variables O
. O
[]

One-hundred O
and O
twenty O
bovine O
root O
dentine O
slabs O
were O
randomly O
assigned O
into O
six O
groups O
( O
A-F O
) O
and O
placed O
in O
intraoral O
palatal O
devices O
, O
which O
were O
worn O
by O
10 O
volunteers O
for O
4 O
d. O
On O
the O
first O
day O
, O
no O
erosive/abrasive O
procedures O
were O
carried O
out O
. O
[]

Overall O
, O
5.3 O
% O
of O
the O
non-brace O
group O
and O
4.6 O
% O
of O
the O
brace O
group O
experienced O
at O
least O
one O
injury O
. O
[]

A O
'tourniquet-release O
' O
dose O
of O
antibiotic O
increased O
drain B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
threefold O
. O
['Physiological-Clinical']

Peripheral O
arterial O
disease O
: O
therapeutic O
confidence O
of O
CT O
versus O
digital O
subtraction O
angiography O
and O
effects O
on O
additional O
imaging O
recommendations O
. O
[]

The O
use O
of O
TOSID O
though O
statistically O
insignificant O
compared O
to O
no O
dressing O
, O
could O
also O
be O
possible O
in O
reducing O
the O
risk O
and O
exaceration O
of O
deep O
incisional O
SSI O
. O
[]

In O
the O
first O
study O
388 O
patients O
with O
suspected O
acute O
myocardial O
infarction O
were O
randomly O
allocated O
to O
treatment O
with O
propranolol O
, O
atenolol O
, O
or O
placebo O
, O
and O
when O
analysed O
on O
an O
initial O
intention O
to O
treat O
basis O
there O
was O
no O
significant O
difference O
between O
the O
three O
groups O
in O
respect O
of O
the O
mortality B-outcome ['Mortality']
at O
one O
year O
. O
['Mortality']

Before O
and O
three O
months O
after O
AVF O
creation O
patients O
underwent O
an O
echocardiographic O
examination O
. O
[]

They O
either O
received O
40 O
mg O
frusemide O
daily O
or O
placebo O
for O
4 O
days O
and O
were O
then O
rendered O
hypoxaemic O
, O
by O
breathing O
an O
N2/O2 O
mixture O
for O
20 O
min O
to O
achieve O
an O
SaO2 O
of O
85-90 O
% O
adjusted O
for O
a O
further O
20 O
min O
to O
achieve O
an O
SaO2 O
of O
75-80 O
% O
. O
[]

Thirty O
social O
phobic O
patients O
( O
DSM-IV O
) O
were O
treated O
with O
either O
buspirone O
30 O
mg O
daily O
or O
placebo O
. O
[]

Vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
and O
its O
cellular O
receptor O
VEGFR-2 O
have O
been O
implicated O
as O
the O
main O
endothelial O
pathway O
required O
for O
tumor O
neovascularization O
. O
[]

At O
assessment O
of O
final O
outcome O
, O
it O
was O
found O
that O
43 O
of O
52 O
( O
82 O
% O
) O
assessable O
patients O
in O
the O
adjuvant O
interferon O
arm O
were O
controlled B-outcome ['Physiological-Clinical']
by O
a O
single B-outcome ['Physiological-Clinical']
laser I-outcome ['Physiological-Clinical']
ablation I-outcome ['Physiological-Clinical']
as O
compared O
with O
only O
17 O
of O
34 O
( O
50 O
% O
) O
in O
the O
5-fluorouracil O
group O
and O
13 O
of O
32 O
( O
40 O
% O
) O
in O
the O
laser O
alone O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Nonallergic B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
irritation I-outcome ['Physiological-Clinical']
was O
observed O
in O
less O
than O
3 O
% O
of O
all O
applications O
. O
['Physiological-Clinical']

METHODS O
Sixty O
children O
of O
autism O
were O
randomly O
divided O
into O
an O
electroacupuncture O
( O
EA O
) O
plus O
behavior O
therapy O
group O
and O
a O
behavior O
therapy O
group O
, O
30 O
cases O
in O
each O
group O
. O
[]

Doses O
were O
re-administered O
once O
daily O
on O
postoperative O
days O
1-4 O
. O
[]

Kallikrein O
inactivator O
units O
( O
KIU O
) O
on O
three O
occasions O
in O
the O
course O
of O
an O
OLT O
, O
whereas O
10 O
other O
patients O
were O
treated O
with O
continuous O
aprotinin O
infusion O
of O
0.1-0.4 O
Mill O
. O
[]

TRIAL O
REGISTRATION O
ClinicalTrials.gov O
identifier O
: O
NCT01227668 O
. O
[]

A O
low O
level O
of O
patient O
compliance O
must O
be O
considered O
when O
the O
outcome O
after O
treatment O
at O
home O
is O
interpreted O
. O
[]

Acetylsalicylic O
acid O
( O
ASA O
) O
inhibition O
of O
platelet O
aggregation O
as O
evaluated O
by O
collagen-induced O
14C-serotonin O
release O
, O
has O
been O
measured O
in O
12 O
healthy O
male O
subjects O
. O
[]

Time B-outcome ['Physiological-Clinical']
until I-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
for O
LTS O
and O
PLMA O
was O
24.5 O
+/- O
6.9 O
and O
28.8 O
+/- O
10.3 O
s. O
Fixation B-outcome ['Physiological-Clinical']
and O
manipulation B-outcome ['Physiological-Clinical']
time O
was O
54.9 O
+/- O
15.2 O
and O
73.2 O
+/- O
25 O
s O
, O
respectively O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
duration O
of O
postoperative B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
in O
Group O
I O
( O
5.1 O
+/- O
2.3 O
hr O
) O
was O
significantly O
shorter O
than O
in O
the O
other O
three O
groups O
( O
II O
-16.6 O
+/- O
4.9 O
hr O
; O
III O
- O
17.2 O
+/- O
5.5 O
hr O
; O
IV O
- O
17.0 O
+/- O
5.8 O
hr O
; O
P O
< O
0.05 O
) O
. O
['Resource-use']

METHODS O
This O
was O
a O
prospective O
, O
controlled O
study O
. O
[]

Overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
46 O
p. O
100 O
at O
5 O
years O
. O
['Mortality']

Each O
of O
the O
four O
drugs O
was O
given O
for O
5 O
days O
. O
[]

The O
organisms O
cultured O
and O
their O
sensitivities O
are O
discussed O
in O
detail O
. O
[]

Group O
1 O
patients O
also O
self-administered O
one O
drop O
of O
ketorolac O
three O
times O
a O
day O
for O
6 O
months O
. O
[]

Further O
research O
involving O
a O
larger O
, O
more O
heterogeneous O
sample O
is O
recommended O
. O
[]

[ O
Statins O
in O
the O
treatment O
of O
patients O
with O
arterial O
occlusive O
disease O
of O
the O
lower O
extremities O
] O
. O
[]

Diazoxide O
and O
labetalol O
in O
acute O
hypertension O
during O
haemodialysis O
. O
[]

RESULTS O
After O
3 O
doses O
of O
the O
OPV O
( O
HDC O
) O
vaccine O
, O
the O
systemic B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
were O
mild O
. O
['Physiological-Clinical']

The O
FemCap O
is O
a O
new O
silicone O
rubber O
barrier O
contraceptive O
shaped O
like O
a O
sailor O
's O
hat O
, O
with O
a O
dome O
that O
covers O
the O
cervix O
, O
a O
rim O
that O
fits O
into O
the O
fornices O
, O
and O
a O
brim O
that O
conforms O
to O
the O
vaginal O
walls O
around O
the O
cervix O
. O
[]

However O
, O
intraoperative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
postoperative B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
were O
not O
significantly O
different O
( O
Student O
t-test O
) O
. O
['Physiological-Clinical', 'Resource-use']

METHOD O
Using O
a O
quantitative O
Food B-outcome ['Life-Impact']
Frequency O
Questionnaire O
( O
FFQ O
) O
, O
we O
prospectively O
examined O
the O
nutritional O
intake O
of O
20 O
children O
with O
autism O
participating O
in O
a O
randomised O
placebo-controlled O
trial O
of O
risperidone O
for O
disruptive O
behaviours O
. O
['Life-Impact']

Multiple O
n-of-1 O
randomized O
, O
crossover O
trials O
. O
[]

A O
significant O
difference O
in O
the O
Fbg O
level O
was O
obtained O
between O
the O
2 O
groups O
. O
[]

There O
was O
a O
significant O
reduction O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
throughout O
maintenance O
therapy O
with O
propranolol O
, O
which O
continued O
through O
the O
tenth O
hospital O
day O
. O
['Physiological-Clinical']

CONCLUSION O
Undetectable O
HBV O
viral O
load O
before O
chemotherapy O
did O
not O
confer O
reactivation-free O
status O
. O
[]

The O
interval O
from O
calving O
to O
first O
ovulation O
tended O
( O
p=0.10 O
) O
to O
be O
lower O
and O
the O
diameter O
of O
the O
dominant B-outcome ['Physiological-Clinical']
follicle I-outcome ['Physiological-Clinical']
of O
the O
oestrous I-outcome ['Physiological-Clinical']
cycle O
at O
which O
cows O
conceived B-outcome ['Physiological-Clinical']
was O
greater O
( O
p=0.02 O
) O
in O
Control O
than O
High-N O
cows O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
this O
department O
a O
radioiodine O
ablation O
of O
thyroid O
remnants O
, O
by O
means O
of O
the O
treatment O
amount O
of O
radioiodine O
of O
a O
standard O
activity O
of O
3.7 O
GBq O
, O
was O
performed O
, O
and O
then O
a O
suppression O
and O
substitution O
therapy O
of O
thyroid O
hormones O
was O
started O
. O
[]

The O
blood O
conservation O
system O
did O
not O
alter O
or O
interfere O
with O
pressure B-outcome ['Physiological-Clinical']
waveforms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Couple-responsible O
therapy O
process O
: O
positive O
proximal B-outcome ['Physiological-Clinical']
outcomes O
. O
['Physiological-Clinical']

The O
estimated O
reduction O
in O
mean O
post-treatment B-outcome ['Physiological-Clinical']
eggs I-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
gram I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
feces I-outcome ['Physiological-Clinical']
relative O
to O
placebo O
was O
63 O
% O
( O
95 O
% O
CI O
30-81 O
% O
) O
for O
triple O
mebendazole O
, O
75 O
% O
( O
47-88 O
% O
) O
for O
single O
albendazole O
, O
and O
88 O
% O
( O
58-97 O
% O
) O
for O
triple O
albendazole O
. O
['Physiological-Clinical']

Both O
groups O
received O
24 O
months O
of O
1,200 O
mg O
of O
calcium O
and O
400 O
IU O
of O
vitamin O
D O
daily O
and O
35 O
mg O
of O
risedronate O
weekly O
, O
and O
the O
exercise O
group O
additionally O
had O
ST O
exercises O
twice O
weekly O
. O
[]

METHODS O
AND O
RESULTS O
Plasma O
macrophage-colony-stimulating O
factor O
( O
M-CSF O
) O
and O
C-reactive O
protein O
( O
CRP O
) O
were O
measured O
in O
100 O
patients O
with O
chronic O
CAD O
, O
60 O
of O
whom O
were O
chronic O
smokers O
. O
[]

Inflammatory O
markers O
were O
significantly O
increased O
at O
24 O
h O
in O
patients O
with O
< O
40 O
% O
TBSA O
burn O
. O
[]

Significant O
improvements O
were O
observed O
in O
all O
groups O
in O
all O
behavioral B-outcome ['Life-Impact']
factors O
and O
cognitive B-outcome ['Life-Impact']
and O
psychological B-outcome ['Life-Impact']
resources O
except O
for O
self-esteem B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
aim O
of O
this O
randomized O
, O
double-blind O
study O
with O
two O
parallel O
groups O
was O
to O
examine O
the O
safety O
, O
efficacy O
and O
tolerability O
of O
two O
combination O
eye O
drops O
containing O
0.5 O
% O
timolol O
and O
2 O
% O
pilocarpine O
( O
Fotil O
, O
Leiras O
, O
Finland O
, O
and O
Timpilo O
, O
MSD O
, O
USA O
) O
in O
patients O
with O
glaucoma O
or O
ocular O
hypertension O
. O
[]

BACKGROUND O
The O
Western O
Ontario O
and O
McMaster O
Universities O
( O
WOMAC O
) O
Osteoarthritis O
Index O
is O
a O
previously O
described O
self-administered O
questionnaire O
covering O
three O
domains O
: O
pain B-outcome ['Physiological-Clinical']
, O
stiffness B-outcome ['Physiological-Clinical']
and O
function B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

BACKGROUND O
Sublingual O
administration O
of O
allergens O
is O
a O
safe O
and O
effective O
alternative O
to O
subcutaneous O
immunotherapy O
in O
patients O
with O
respiratory O
allergies O
. O
[]

More O
women O
in O
the O
NETZ O
arm O
had O
clear B-outcome ['Physiological-Clinical']
histological I-outcome ['Physiological-Clinical']
margins I-outcome ['Physiological-Clinical']
( O
84.8 O
% O
vs O
75 O
% O
, O
( O
P= O
0.03 O
) O
. O
['Physiological-Clinical']

The O
range O
of O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
from O
the O
instillation O
of O
anti-cancer O
drug O
was O
3-365 O
days O
( O
average O
days O
) O
. O
['Mortality']

Forty-two O
patients O
had O
AML O
: O
14 O
were O
induction O
failures O
, O
8 O
in O
first O
chemotherapy-refractory O
relapse O
, O
7 O
in O
untreated O
relapse O
, O
3 O
in O
second O
or O
subsequent O
relapse O
, O
4 O
were O
in O
second O
complete O
remission O
( O
CR O
) O
, O
and O
3 O
in O
second O
CR O
without O
platelet O
recovery O
( O
CRp O
) O
, O
2 O
were O
in O
high-risk O
CR1 O
. O
[]

Gender O
differences O
of O
addictive B-outcome ['Life-Impact']
Internet I-outcome ['Life-Impact']
use O
were O
estimated O
with O
the O
regression O
model O
stratified O
by O
gender O
. O
['Life-Impact']

Body O
mass O
index O
, O
measured O
at O
31.5+/-2.05 O
kg/m2 O
in O
the O
placebo O
group O
, O
decreased O
to O
30.4+/-2.94 O
kg/m O
( O
2 O
) O
after O
12 O
wk O
( O
P=.07 O
) O
. O
[]

The O
reversibility O
of O
increased O
airways O
resistance O
in O
chronic O
heart O
failure O
measured O
by O
impulse O
oscillometry O
. O
[]

Rates O
were O
not O
significantly O
different O
between O
the O
arms O
. O
[]

Although O
several O
instruments O
are O
available O
for O
evaluation O
of O
the O
severity O
of O
PTS O
, O
including O
the O
Villalta-Prandoni O
scale O
( O
VPS O
) O
and O
Venous B-outcome ['Physiological-Clinical']
Clinical I-outcome ['Physiological-Clinical']
Severity I-outcome ['Physiological-Clinical']
Score O
( O
VCSS O
['Physiological-Clinical']

RESULTS O
The O
average O
of O
anginal B-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
, O
number O
of O
weekly O
sublingual B-outcome ['Resource-use']
nitrate I-outcome ['Resource-use']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
rest I-outcome ['Physiological-Clinical']
and O
at O
the O
end O
of O
diltiazem B-outcome ['Physiological-Clinical']
period I-outcome ['Physiological-Clinical']
were O
significantly O
lower O
( O
p O
< O
0.05 O
) O
regarding O
same O
periods O
on O
placebo O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
anti-proteinuric B-outcome ['Physiological-Clinical']
effect O
was O
even O
greater O
after O
9 O
months O
of O
therapy O
: O
losartan O
, O
44.2 O
% O
( O
p O
= O
0.02 O
) O
; O
enalapril O
, O
49.6 O
% O
( O
p O
= O
0.02 O
) O
; O
and O
combined O
therapy O
, O
51 O
% O
( O
p O
= O
0.003 O
) O
. O
['Physiological-Clinical']

To O
determine O
if O
CPX O
testing O
could O
distinguish O
between O
patients O
with O
HF O
with O
normal O
EFs O
( O
> O
50 O
% O
; O
i.e. O
, O
diastolic O
HF O
) O
and O
those O
with O
decreased O
EFs O
( O
> O
or O
=50 O
% O
; O
i.e. O
, O
systolic O
HF O
) O
, O
CPX O
responses O
were O
compared O
between O
185 O
patients O
with O
systolic O
HF O
( O
79 O
% O
men O
, O
mean O
age O
62.6 O
+/- O
10.9 O
years O
) O
and O
43 O
with O
diastolic O
HF O
( O
54 O
% O
men O
, O
mean O
age O
67.4 O
+/- O
9.8 O
years O
) O
enrolled O
in O
a O
phase O
II O
multicenter O
clinical O
trial O
. O
[]

It O
appears O
likely O
that O
the O
higher O
response O
of O
induction O
chemotherapy O
in O
patients O
with O
extensive O
disease O
made O
the O
salvage O
surgery O
more O
successful O
in O
group O
B O
than O
in O
group O
A O
. O
[]

Ursodeoxycholic O
acid O
has O
no O
influence O
on O
function O
after O
restorative O
proctocolectomy B-outcome ['Physiological-Clinical']
in O
ulcerative O
colitis O
. O
['Physiological-Clinical']

CONCLUSION O
The O
results O
of O
this O
study O
support O
the O
efficacy O
and O
tolerability O
of O
melatonin O
treatment O
for O
sleep O
problems O
in O
children O
with O
ASD O
and O
FXS O
. O
[]

RESULTS O
Overall O
, O
no O
differences O
were O
found O
on O
global O
improvement O
as O
measured O
with O
the O
CGI-I O
or O
CGI-S O
. O
[]

We O
failed O
to O
find O
any O
significant O
effect O
of O
active B-outcome ['Physiological-Clinical']
rTMS I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Overall O
, O
70 O
% O
( O
88/125 O
) O
of O
the O
AODs O
were O
successful O
, O
including O
42 O
% O
( O
24/57 O
) O
for O
clonidine O
and O
94 O
% O
( O
64/68 O
) O
for O
clonidine/naltrexone O
( O
p O
< O
0.001 O
) O
. O
[]

Statistical O
analysis O
was O
performed O
to O
compare O
the O
DNA O
copy O
numbers O
of O
the O
three O
groups O
. O
[]

23.15 O
) O
ml/min O
, O
t O
= O
4.78 O
, O
4.61 O
, O
P O
< O
0.01 O
) O
. O
[]

OBJECTIVE O
To O
assess O
efficacy O
, O
safety O
, O
predictability O
, O
stability B-outcome ['Physiological-Clinical']
, O
and O
changes O
in O
higher-order B-outcome ['Physiological-Clinical']
aberrations I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HOAs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
contrast O
sensitivity B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
after O
wavefront-guided O
and O
standard O
LASIK O
enhancement O
for O
the O
correction O
of O
residual O
refractive O
errors O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Results O
from O
the O
experimental O
acupuncture O
treatment O
group O
showed O
a O
decrease O
in O
mean O
monthly B-outcome ['Physiological-Clinical']
hot I-outcome ['Physiological-Clinical']
flush I-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
for O
site-specific O
acupuncture O
. O
['Physiological-Clinical']

CONCLUSION O
An O
intervention O
including O
patient O
education O
, O
a O
pain B-outcome ['Physiological-Clinical']
diary O
, O
and O
defining O
a O
procedure O
for O
therapeutic O
adjustments O
can O
be O
effective O
to O
improve O
pain B-outcome ['Physiological-Clinical']
relief O
in O
outpatients O
with O
cancer B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
added O
treatment O
group O
, O
the O
change O
in O
the O
B-type O
natriuretic O
peptide O
was O
significantly O
correlated O
with O
the O
change O
in O
the O
brachial B-outcome ['Physiological-Clinical']
PP I-outcome ['Physiological-Clinical']
( O
r O
= O
0.18 O
) O
, O
central B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
r O
= O
0.18 O
) O
, O
central B-outcome ['Physiological-Clinical']
PP I-outcome ['Physiological-Clinical']
( O
r O
= O
0.26 O
) O
, O
and O
PP B-outcome ['Physiological-Clinical']
amplification I-outcome ['Physiological-Clinical']
( O
r O
= O
-0.22 O
) O
even O
after O
adjusting O
for O
the O
confounding O
factors O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
was O
12 O
months O
for O
group O
A O
and O
9 O
for O
group O
B O
. O
['Physiological-Clinical']

The O
psychiatrist O
prescribed O
antidepressant O
medications O
for O
patients O
preferring O
or O
assessed O
to O
require O
medication O
. O
[]

Measurement O
of O
tissue B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
made O
on O
days O
5 O
and O
10 O
of O
each O
period O
using O
a O
profilometer O
. O
['Physiological-Clinical']

SETTING O
The O
study O
was O
conducted O
in O
air O
and O
land O
emergency O
medical O
services O
and O
2 O
trauma O
centers O
serving O
a O
population O
of O
4 O
million O
people O
. O
[]

DESIGN O
Prospective O
, O
randomized O
, O
clinical O
trial O
. O
[]

Four O
complications B-outcome ['Adverse-effects']
in O
the O
slotted O
nail O
group O
and O
three O
in O
the O
non-slotted O
nail O
group O
were O
considered O
to O
be O
independent O
of O
the O
choice O
of O
nail O
and O
did O
not O
affect O
the O
end O
result O
. O
['Adverse-effects']

Dobutamine O
stress O
echo O
provides O
potentially O
useful O
information O
on O
idiopathic O
dilated O
cardiomyopathy O
( O
IDC O
) O
. O
[]

The O
patients O
were O
randomly O
assigned O
to O
receive O
either O
rHuEPO O
( O
150 O
U/kg O
) O
or O
placebo O
subcutaneously O
three O
times O
a O
week O
for O
a O
maximum O
of O
12 O
weeks O
or O
until O
the O
hematocrit B-outcome ['Physiological-Clinical']
level O
increased O
to O
38 O
% O
-40 O
% O
. O
['Physiological-Clinical']

A O
treatment O
period O
of O
1 O
week O
, O
in O
which O
cetirizine/PSE O
was O
administered O
twice O
daily O
, O
was O
followed O
by O
a O
washout O
period O
of O
at O
least O
2 O
weeks O
and O
a O
further O
period O
of O
1 O
week O
in O
which O
the O
alternative O
treatment O
was O
given O
to O
each O
patient O
. O
[]

A O
prospective O
, O
randomized O
study O
. O
[]

The O
study O
consisted O
of O
23 O
patients O
( O
13 O
females O
and O
10 O
males O
) O
with O
a O
bilateral O
maxillary O
deficiency O
. O
[]

This O
study O
presents O
the O
results O
of O
a O
prospective O
randomized O
trial O
of O
SILS O
or O
3-port O
laparoscopic O
appendectomy O
. O
[]

As O
a O
result O
, O
no O
protective O
influence O
of O
Esberitox O
could O
be O
demonstrated O
. O
[]

Twenty-seven O
patients O
had O
documented O
infections O
with O
quinolone-sensitive O
organisms O
and O
received O
either O
lomefloxacin O
, O
levofloxacin O
, O
or O
ciprofloxacin O
. O
[]

METHODS O
We O
first O
did O
a O
pilot O
study O
, O
in O
which O
25 O
patients O
( O
group O
A O
) O
with O
unilateral O
ischaemia O
of O
the O
leg O
were O
injected O
with O
bone O
marrow-mononuclear O
cells O
into O
the O
gastrocnemius O
of O
the O
ischaemic O
limb O
and O
with O
saline O
into O
the O
less O
ischaemic O
limb O
. O
[]

Intervention O
farms O
received O
occupational O
health O
screenings O
, O
health O
and O
wellness O
screening O
, O
education O
, O
on-farm O
safety O
reviews O
, O
and O
performance O
incentives O
. O
[]

A O
simple O
way O
to O
study O
a O
histamine O
antagonist O
in O
man O
is O
to O
observe O
the O
effect O
it O
has O
on O
the O
magnitude O
of O
the O
skin O
reaction O
to O
intradermal O
histamine O
. O
[]

Participants O
were O
assigned O
to O
1 O
of O
4 O
conditions O
in O
this O
2 O
Intervention O
( O
Alcohol O
Feedback O
vs. O
Control O
) O
?2 O
Assessment O
( O
Motivational O
Assessment O
vs. O
No O
Motivational O
Assessment O
) O
between-subjects O
design O
. O
[]

METHODS O
In O
a O
prospective O
double-blind O
, O
randomized O
, O
placebo-controlled O
study O
, O
we O
investigated O
the O
analgesic O
effect O
of O
a O
single O
dose O
of O
parecoxib O
40 O
mg O
given O
at O
dural O
closure O
in O
82 O
patients O
undergoing O
elective O
craniotomies O
. O
[]

The O
benefits O
of O
ACE O
inhibitor O
therapy O
that O
were O
observed O
were O
likely O
due O
to O
a O
variety O
of O
mechanisms O
, O
not O
just O
a O
reduction O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

One O
patient O
was O
still O
alive O
at O
the O
time O
of O
this O
analysis O
. O
[]

A O
genetic B-outcome ['Physiological-Clinical']
interaction O
profile O
consisting O
of O
the O
TYMS O
enhancer O
region O
and O
VEGF O
+405G O
> O
C O
polymorphisms O
was O
significantly O
associated O
with O
PFS O
. O
['Physiological-Clinical']

The O
difficulties O
encountered O
in O
the O
conduct O
of O
RCTs O
for O
pre-school O
children O
with O
autism O
are O
discussed O
. O
[]

Serum B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
decreased O
significantly O
from O
4.2 O
+/- O
0.4 O
mmol/L O
to O
3.7 O
+/- O
0.6 O
mmol/L O
after O
hydrochlorothiazide O
therapy O
. O
['Physiological-Clinical']

RESULTS O
No O
dose-limiting O
toxicities O
were O
observed O
and O
ocular O
adverse O
events O
were O
mostly O
mild O
and O
transient O
. O
[]

Randomized O
, O
controlled O
trial O
of O
an O
intervention O
for O
toddlers O
with O
autism O
: O
the O
Early O
Start O
Denver O
Model O
. O
[]

The O
aim O
of O
this O
double-blind O
, O
placebo-controlled O
experimental O
pain O
study O
, O
conducted O
on O
20 O
healthy O
volunteers O
, O
was O
to O
examine O
the O
effect O
of O
a O
single O
dose O
of O
1200 O
mg O
gabapentin O
on O
multi-modal O
experimental O
cutaneous O
and O
muscle O
pain O
models O
. O
[]

Regarding O
safety O
after O
ESD O
, O
recovery B-outcome ['Physiological-Clinical']
was O
significantly O
better O
in O
the O
propofol O
group O
immediately O
after O
and O
at O
1 O
hour O
and O
2 O
hours O
after O
return O
to O
the O
ward O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

RESULTS O
The O
average O
number O
of O
sessions B-outcome ['Life-Impact']
per O
stone O
was O
1.92 O
and O
1.5 O
and O
the O
average O
number O
of O
shocks B-outcome ['Physiological-Clinical']
per O
stone O
was O
6295 O
and O
5300 O
for O
the O
first O
and O
second O
treatment O
groups O
respectively O
. O
['Life-Impact', 'Physiological-Clinical']

We O
found O
pronounced O
synergy O
between O
each O
nucleoside O
and O
the O
alkylator O
but O
even O
more O
enhanced O
cytotoxic O
synergy O
when O
the O
nucleoside O
analogs O
were O
combined O
prior O
to O
exposing O
the O
cells O
to O
Bu O
. O
[]

Subjects O
were O
randomly O
divided O
into O
two O
groups O
: O
a O
) O
NTI O
under O
CTSC O
guidance O
( O
G O
[ O
+ O
] O
group O
) O
. O
[]

LNH-84 O
regimen O
: O
a O
multicenter O
study O
of O
intensive O
chemotherapy O
in O
737 O
patients O
with O
aggressive O
malignant O
lymphoma O
. O
[]

RESULTS O
The O
9-month O
OS B-outcome ['Mortality']
rate O
was O
58 O
% O
in O
the O
RT-5-FU O
arm O
, O
52 O
% O
in O
the O
RT-GC O
arm O
, O
and O
45 O
% O
in O
the O
RT-GC+GC O
arm O
. O
['Mortality']

High-risk O
patients O
undergoing O
CABG O
surgery O
will O
be O
randomly O
assigned O
to O
receive O
either O
MC-1 O
( O
250 O
mg/d O
) O
or O
matching O
placebo O
immediately O
before O
and O
continuing O
for O
30 O
days O
after O
the O
procedure O
. O
[]

b O
) O
Acceptability B-outcome ['Life-Impact']
in O
the O
two O
treatment O
groups O
. O
['Life-Impact']

At O
Week O
6 O
, O
all O
COX-2 O
inhibitors O
provided O
significantly O
greater O
efficacy O
than O
acetaminophen O
. O
[]

Higher B-outcome ['Physiological-Clinical']
CSF I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
up O
to O
a O
median O
concentration O
of O
4.5 O
mug/ml O
, O
were O
observed O
in O
patients O
with O
CSF O
protein O
concentrations O
> O
/=75 O
mg/100 O
ml O
. O
['Physiological-Clinical']

The O
primary O
endpoints O
in O
the O
study O
were O
the O
duration O
of O
artificial B-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
and O
pulmonary B-outcome ['Physiological-Clinical']
oxygenation I-outcome ['Physiological-Clinical']
ability I-outcome ['Physiological-Clinical']
, O
and O
the O
secondary O
endpoints O
were O
mortality B-outcome ['Mortality']
and O
the O
concentrations O
of O
PMN-E O
, O
SP-D O
, O
TNF-alpha B-outcome ['Physiological-Clinical']
and O
IL-8 B-outcome ['Physiological-Clinical']
in O
blood B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Scores O
on O
learning B-outcome ['Life-Impact']
measures O
did O
not O
change O
across O
conditions O
. O
['Life-Impact']

Needle O
excision O
took O
longer B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
perform I-outcome ['Life-Impact']
( O
median O
treatment O
time O
210 O
vs O
90 O
seconds O
, O
P O
< O
0.0001 O
) O
and O
surgeons O
more O
often O
['Life-Impact']

SUBJECTS O
AND O
METHODS O
This O
two-arm O
randomized O
open-label O
study O
included O
35 O
HH O
women O
( O
aged O
25-36 O
yr O
) O
attending O
our O
Center O
. O
[]

OBJECTIVE O
To O
validate O
an O
FFQ O
for O
the O
assessment O
of O
dietary O
EPA B-outcome ['Physiological-Clinical']
and O
DHA B-outcome ['Physiological-Clinical']
against O
their O
relative B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
red I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RBC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Mood O
state O
and O
quality O
of O
life O
of O
female O
heroin O
addicts O
were O
poor O
. O
[]

Data O
on O
operation O
time O
, O
estimated O
blood O
loss O
, O
postoperative O
morbidities O
were O
collected O
and O
analysed O
with O
comparison O
between O
the O
two O
groups O
using O
chi O
square O
, O
Fischer O
's O
exact O
test O
and O
t-test O
as O
appropriate O
. O
[]

Cardiovascular O
follow-up O
was O
available O
for O
13 O
194 O
women O
, O
1048 O
of O
whom O
had O
prior O
clinical O
CHD O
. O
[]

Not O
Now O
! O
[]

CONCLUSIONS O
A O
hospital-based O
exercise O
class O
can O
produce O
a O
rapid O
recovery O
from O
a O
frozen O
shoulder O
with O
a O
minimum O
number O
of O
visits O
to O
the O
hospital O
and O
is O
more O
effective O
than O
individual O
physiotherapy O
or O
a O
home O
exercise O
program O
. O
[]

Comparison O
of O
neurocognitive B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
in O
children O
previously O
randomly O
assigned O
to O
intrathecal O
methotrexate O
compared O
with O
triple O
intrathecal O
therapy O
for O
the O
treatment O
of O
childhood O
acute O
lymphoblastic O
leukemia O
. O
['Life-Impact']

METHODS O
Thirty O
patients O
from O
the O
Heart O
Failure O
Clinic O
of O
the O
Instituto O
Nacional O
de O
Ciencias O
M?dicas O
y O
Nutrici?n O
Salvador O
Zubir?n O
underwent O
photoplethysmography O
using O
the O
hyperemia O
technique O
. O
[]

Findings O
indicate O
that O
persons O
in O
later O
stages O
of O
change O
reported O
higher O
participation O
levels O
. O
[]

PATIENTS O
AND O
METHODS O
A O
total O
of O
101 O
patients O
completed O
the O
QLQ-C30 O
on O
weeks O
1 O
, O
4 O
and O
7 O
of O
radical O
external-beam O
radiation O
therapy O
( O
RT O
) O
for O
localized O
cancer O
of O
the O
prostate O
. O
[]

Reductions O
in O
microalbuminuria B-outcome ['Physiological-Clinical']
occurred O
in O
both O
groups O
, O
with O
mean O
changes O
at O
1 O
year O
of O
-3.9 O
mg/mmol O
creatinine O
( O
95 O
% O
CI O
-5.3 O
, O
-2.5 O
) O
for O
manidipine/delapril O
( O
P O
< O
0.001 O
vs. O
baseline O
) O
and O
-2.7 O
mg/mmol O
creatinine O
( O
95 O
% O
CI O
-4.0 O
, O
-1.3 O
) O
for O
losartan/HCTZ O
( O
P O
< O
0.001 O
vs. O
baseline O
and O
P=0.199 O
between O
groups O
) O
. O
['Physiological-Clinical']

The O
active O
control O
group O
consists O
of O
two O
group O
sessions O
and O
four O
sessions O
by O
telephone O
, O
provided O
by O
a O
specialized O
nurse O
and O
physiotherapist O
. O
[]

Plasma O
A? O
( O
1-x O
) O
and O
A? O
( O
1-40 O
) O
increased O
dose O
dependently O
, O
and O
mean O
CSF O
A? O
( O
1-x O
) O
increased O
38 O
% O
from O
baseline O
with O
10 O
mg/kg O
( O
P O
= O
0.002 O
vs O
placebo O
) O
. O
[]

The O
oedema B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
during O
the O
late O
phase O
skin O
reaction O
was O
markedly O
depressed O
( O
P O
less O
than O
0.005 O
at O
2 O
h O
, O
P O
less O
than O
0.01 O
at O
4 O
and O
6 O
h O
, O
P O
less O
than O
0.02 O
at O
8 O
h O
) O
. O
['Physiological-Clinical']

Axillary B-outcome ['Physiological-Clinical']
metastases I-outcome ['Physiological-Clinical']
were O
found O
in O
16 O
% O
of O
the O
patients O
. O
['Physiological-Clinical']

SETTING O
University O
of O
Benin O
Teaching O
Hospital O
; O
a O
university-affiliated O
tertiary O
centre O
. O
[]

Among O
mothers O
assessed O
for O
eligibility O
, O
17.0 O
% O
declined O
participation O
. O
[]

A O
randomized O
experiment O
was O
conducted O
with O
a O
sample O
of O
618 O
women O
50 O
years O
or O
older O
with O
MBD O
greater O
than O
50 O
% O
of O
breast O
volume O
. O
[]

Since O
first O
Korotkoff O
sounds O
may O
already O
be O
heard O
after O
10-15 O
s O
when O
following O
recommended O
procedures O
, O
self-recorded B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
may O
be O
recorded O
as O
too O
high O
when O
subjects O
inflate O
their O
cuff O
at O
too O
low O
a O
pressure O
or O
deflate O
it O
too O
fast O
. O
['Physiological-Clinical']

On O
a O
different O
day O
, O
in O
all O
subjects O
we O
determined O
intraarterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
EKG B-outcome ['Physiological-Clinical']
and O
muscle B-outcome ['Physiological-Clinical']
sympathetic I-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
MSNA B-outcome ['Physiological-Clinical']
) O
both O
supine O
and O
during O
upright O
tilt O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Prevention O
of O
premature O
labor O
by O
17 O
alpha-hydroxyprogesterone O
caproate O
. O
[]

Twenty-two O
children O
( O
ages O
8-14 O
; O
IQ O
? O
[]

Indomethacin O
significantly O
attenuated O
the O
antihypertensive B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
of O
cilazapril O
. O
['Physiological-Clinical']

Neither O
the O
distribution O
of O
the O
patients O
among O
Lown B-outcome ['Physiological-Clinical']
classification O
nor O
the O
Final O
Score O
of O
the O
Italian O
['Physiological-Clinical']

RESULTS O
There O
was O
a O
significant O
difference O
in O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
delivered O
by O
one-handed O
( O
mean O
= O
694 O
mL O
, O
SD O
= O
111 O
) O
vs O
two-handed O
compressions O
( O
mean O
= O
827 O
mL O
, O
SD O
= O
113 O
) O
. O
['Physiological-Clinical']

The O
effect O
of O
indomethacin O
on O
the O
antihypertensive O
effect O
of O
cilazapril O
appears O
to O
depend O
upon O
the O
sequence O
of O
drug O
administration O
. O
[]

Enhanced O
small O
group O
instruction O
using O
choral O
responding O
and O
student O
interaction O
for O
children O
with O
autism O
and O
developmental O
disabilities O
. O
[]

Endogenous O
insulin O
secretion O
was O
assessed O
by O
measuring O
serum O
insulin O
and O
C-peptide O
before O
and O
6 O
min O
after O
iv O
administration O
of O
glucagon O
; O
insulin O
sensitivity O
was O
determined O
by O
measuring O
insulin O
binding O
to O
erythrocytes O
, O
and O
as O
the O
glucose O
disappearance O
rate O
( O
KITT O
) O
after O
i.v O
. O
[]

PATIENTS O
Sixteen O
consecutive O
patients O
within O
the O
first O
48 O
hrs O
of O
mainly O
pulmonary O
acute O
respiratory O
distress O
syndrome O
. O
[]

'piano O
' O
) O
than O
an O
unrelated O
prime O
( O
e.g O
. O
[]

Nurses O
without O
prior O
experience O
in O
the O
use O
of O
the O
laryngeal O
mask O
airway O
( O
LMA O
) O
were O
randomly O
allocated O
to O
one O
of O
two O
groups O
to O
be O
trained O
in O
the O
emergency O
technique O
of O
insertion O
of O
an O
LMA O
. O
[]

In O
both O
groups O
, O
ISDN-mediated B-outcome ['Physiological-Clinical']
dilation I-outcome ['Physiological-Clinical']
is O
unaffected O
by O
the O
treatment O
. O
['Physiological-Clinical']

Parenteral O
troxerutin O
and O
carbazochrome O
combination O
in O
the O
treatment O
of O
post-hemorrhoidectomy O
status O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
phase O
IV O
study O
. O
[]

Recurrent O
ulcer O
after O
successful O
treatment O
with O
cimetidine O
or O
antacid O
. O
[]

Dietary O
status O
and O
impact O
of O
risperidone O
on O
nutritional B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
in O
children O
with O
autism O
: O
a O
pilot O
study O
. O
['Physiological-Clinical']

Propofol O
was O
administered O
at O
300 O
, O
600 O
or O
1200 O
ml O
h-1 O
until O
loss B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
consciousness I-outcome ['Physiological-Clinical']
( O
as O
judged O
by O
loss O
of O
verbal B-outcome ['Life-Impact']
contact I-outcome ['Life-Impact']
with O
the O
patient O
) O
had O
been O
achieved O
. O
['Physiological-Clinical', 'Life-Impact']

The O
primary O
outcome O
measures O
were O
the O
score O
on O
the O
Irritability O
subscale O
of O
the O
Aberrant O
Behavior O
Checklist O
and O
the O
rating O
on O
the O
Clinical O
Global O
Impressions O
- O
Improvement O
( O
CGI-I O
) O
scale O
at O
eight O
weeks O
. O
[]

This O
impairment O
takes O
the O
form O
of O
mild O
to O
moderate O
shoulder O
pain O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
( O
Lp B-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
) O
is O
associated O
with O
atherogenesis O
and O
thrombogenesis O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
undertook O
the O
present O
analysis O
to O
evaluate O
the O
effect O
of O
NHT O
on O
pathologic B-outcome ['Physiological-Clinical']
stage B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
PCa I-outcome ['Physiological-Clinical']
and O
resection B-outcome ['Physiological-Clinical']
limit I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
in O
patients O
with O
prostate O
cancer O
and O
treated O
with O
total O
androgen O
ablation O
either O
for O
three O
or O
six O
months O
before O
RP O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Two O
weeks O
after O
SRP O
, O
mean O
PPD B-outcome ['Physiological-Clinical']
decreased O
from O
baseline O
by O
1.40 O
mm O
for O
the O
test O
group O
and O
0.60 O
mm O
for O
the O
control O
, O
and O
10 O
weeks O
after O
SRP O
by O
1.57 O
mm O
for O
the O
test O
group O
and O
0.58 O
mm O
for O
the O
control O
. O
['Physiological-Clinical']

Analysis O
of O
prognostic O
factors O
using O
optimized O
statistical O
models O
was O
based O
on O
data O
from O
patients O
in O
E1684 O
, O
E1690 O
, O
E1694 O
, O
and O
E2696 O
. O
[]

Early O
specific O
intervention O
to O
improve O
the O
autonomy B-outcome ['Life-Impact']
of O
elderly O
patients O
seems O
an O
attractive O
solution O
that O
could O
be O
assessed O
by O
randomized O
controlled O
trial O
. O
['Life-Impact']

Patients O
were O
randomized O
to O
bone-borne O
( O
n=25 O
) O
and O
tooth-borne O
( O
n=21 O
) O
groups O
. O
[]

Selamectin O
achieved O
a O
heartworm B-outcome ['Physiological-Clinical']
prevention I-outcome ['Physiological-Clinical']
rate O
of O
100 O
% O
, O
with O
all O
dogs O
testing O
negative O
for O
microfilariae O
and O
adult O
heartworm O
antigen O
on O
days O
180 O
and O
300 O
. O
['Physiological-Clinical']

In O
order O
to O
assess O
if O
the O
use O
of O
the O
laryngeal O
mask O
airway O
is O
associated O
with O
an O
increased O
risk O
of O
gastric O
regurgitation O
during O
mechanical O
ventilation O
, O
we O
studied O
50 O
patients O
allocated O
randomly O
to O
undergo O
anaesthesia O
with O
either O
artificial O
ventilation O
with O
isoflurane O
and O
nitrous O
oxide O
in O
oxygen O
and O
atracurium O
( O
group O
A O
) O
or O
spontaneous O
ventilation O
with O
isoflurane O
and O
nitrous O
oxide O
in O
oxygen O
( O
group O
B O
) O
. O
[]

RESULTS O
One O
year O
postoperatively O
, O
43/41 O
( O
surgical/endovascular O
) O
patients O
had O
good O
or O
moderate O
recovery B-outcome ['Physiological-Clinical']
, O
5/4 O
had O
severe B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
were I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
vegetative I-outcome ['Life-Impact']
state I-outcome ['Life-Impact']
, O
and O
9/7 O
had O
died B-outcome ['Mortality']
( O
NS O
) O
according O
to O
intention O
to O
treat O
. O
['Physiological-Clinical', 'Life-Impact', 'Mortality']

The O
relationship O
between O
histology B-outcome ['Physiological-Clinical']
and O
outcome O
in O
advanced O
and O
recurrent O
endometrial O
cancer O
patients O
participating O
in O
first-line O
chemotherapy O
trials O
: O
a O
Gynecologic O
Oncology O
Group O
study O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
planimetrically O
obtained O
prostate O
volume O
showed O
a O
more O
favorable O
agreement O
with O
the O
radical O
prostatectomy O
volume O
than O
the O
prolate O
ellipsoid O
volume O
. O
[]

These O
results O
suggest O
that O
none O
of O
the O
three O
beta-blockers O
tested O
nor O
disopyramide O
phosphate O
is O
likely O
to O
reduce O
the O
mortality B-outcome ['Mortality']
from I-outcome ['Mortality']
acute I-outcome ['Mortality']
myocardial I-outcome ['Mortality']
infarction I-outcome ['Mortality']
when O
given O
prophylactically O
, O
although O
disopyramide O
phosphate O
does O
reduce O
the O
incidence O
of O
'serious O
' O
ventriicular B-outcome ['Physiological-Clinical']
['Mortality', 'Physiological-Clinical']

After O
20 O
minutes O
( O
approximate O
time O
to O
peak O
nicotine O
levels O
) O
, O
echocardiograms O
and O
signal-averaged O
electrocardiograms O
( O
SAECG O
) O
were O
obtained O
. O
[]

The O
cure B-outcome ['Physiological-Clinical']
rate O
of O
H. O
pylori B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
88 O
% O
in O
the O
LCM O
group O
; O
95 O
% O
CI O
79-97 O
and O
92 O
% O
in O
the O
RCM O
group O
; O
95 O
% O
CI O
84-99 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
New O
antimalarial O
treatments O
are O
urgently O
needed O
in O
sub-Saharan O
Africa O
. O
[]

PlGF O
was O
measured O
at O
baseline O
( O
n O
= O
3,761 O
) O
and O
at O
four-months O
( O
n O
= O
3,369 O
) O
in O
patients O
randomized O
to O
atorvastatin O
80 O
mg O
or O
pravastatin O
40 O
mg O
after O
ACS O
in O
the O
PROVE O
IT-TIMI O
22 O
trial O
. O
[]

In O
vivo O
: O
there O
was O
no O
need O
to O
manually O
deflate O
the O
cuff O
in O
the O
CPRV O
group O
but O
, O
in O
every O
patient O
in O
the O
control O
group O
, O
three O
( O
two O
to O
seven O
) O
deflating O
manoeuvres O
were O
required O
within O
the O
first O
hour O
of O
anaesthesia O
( O
P O
< O
0.0001 O
) O
. O
[]

Combining O
weight-loss O
counseling O
with O
the O
weight O
watchers O
plan O
for O
obese O
breast O
cancer O
survivors O
. O
[]

OBJECTIVE O
To O
explore O
a O
new O
method O
for O
the O
management O
of O
patients O
with O
ocular O
burns O
. O
[]

Suboptimal B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
> O
MIC B-outcome ['Physiological-Clinical']
( O
90 O
) O
was O
observed O
for O
cephalexin O
irrespective O
of O
acid O
suppression O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Maintenance O
of O
pupillary B-outcome ['Physiological-Clinical']
dilatation I-outcome ['Physiological-Clinical']
is O
necessary O
for O
success O
of O
scleral O
buckling O
procedures O
. O
['Physiological-Clinical']

A O
statistically O
significant O
improvement O
was O
also O
noted O
on O
the O
ABC-Irritability O
subscale O
( O
p=0.048 O
) O
. O
['Life-Impact']

RESULTS O
Among O
355 O
randomly O
assigned O
women O
who O
average O
age O
was O
54.7 O
years O
, O
338 O
women O
( O
95 O
% O
) O
completed O
12-week O
assessments O
. O
[]

Male O
students O
( O
N=443 O
) O
were O
randomized O
to O
either O
a O
TC O
or O
TC O
+TSE O
information O
group O
or O
a O
no O
information O
control O
group O
, O
and O
assessed O
at O
three O
time O
points O
. O
[]

CONCLUSIONS O
Results O
support O
the O
use O
of O
adaptive O
devices O
and O
orofacial O
exercise O
to O
improve O
[]

A O
total O
of O
149 O
children O
and O
adolescents O
5 O
to O
17 O
years O
of O
age O
( O
mean O
[ O
SD O
] O
age O
, O
9.4 O
[ O
3.1 O
] O
years O
) O
from O
6 O
academic O
centers O
were O
randomly O
assigned O
to O
citalopram O
( O
n O
= O
73 O
) O
or O
placebo O
( O
n O
= O
76 O
) O
. O
[]

Whole O
mount O
sectioning O
of O
the O
complete O
RP O
specimens O
was O
adopted O
in O
each O
centre O
for O
accurately O
evaluating O
the O
pathologic B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
and O
resection B-outcome ['Physiological-Clinical']
limit I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
evaluated O
the O
effect O
of O
an O
easily O
implemented O
, O
low-intensity O
exercise O
program O
on O
the O
incidence O
of O
falls B-outcome ['Life-Impact']
and O
the O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
first I-outcome ['Life-Impact']
fall I-outcome ['Life-Impact']
among O
a O
clinically O
defined O
population O
of O
elderly O
men O
and O
women O
. O
['Life-Impact', 'Life-Impact']

Almost O
all O
influenza O
immunisation O
in O
the O
UK O
is O
done O
within O
general O
practice O
. O
[]

Chemotherapy-related B-outcome ['Physiological-Clinical']
toxicities I-outcome ['Physiological-Clinical']
were O
few O
and O
most O
of O
them O
related O
to O
cisplatin O
which O
was O
reduced O
to O
100 O
mg/m2 O
for O
35 O
patients O
. O
['Physiological-Clinical']

CONCLUSIONS O
Only O
one-fifth O
of O
the O
drug-treated O
hypertensives O
were O
well O
controlled O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Bayley O
Scales O
of O
Infant O
Development O
and O
Wechsler O
Preschool O
and O
Primary O
Scale O
of O
Intelligence O
Revised O
, O
Preschool O
Behaviour O
Checklist O
, O
Bayley O
Behaviour O
Rating O
Scale O
and O
Behaviour O
Screening O
Questionnaire O
. O
[]

Dose-response B-outcome ['Physiological-Clinical']
effect O
of O
flecainide O
in O
patients O
with O
symptomatic O
paroxysmal O
atrial O
fibrillation O
and/or O
flutter O
monitored O
with O
trans-telephonic O
electrocardiography O
: O
a O
multicenter O
, O
placebo-controlled O
, O
double-blind O
trial O
. O
['Physiological-Clinical']

[ O
Dexmedetomidine O
use O
for O
postoperative B-outcome ['Physiological-Clinical']
adrenergic I-outcome ['Physiological-Clinical']
analgesia I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
sedation I-outcome ['Physiological-Clinical']
in O
abdominal O
surgery O
] O
. O
['Physiological-Clinical']

Analgesia B-outcome ['Resource-use']
was O
supplemented O
whenever O
the O
pain B-outcome ['Physiological-Clinical']
score O
was O
> O
or O
= O
4 O
. O
['Resource-use', 'Physiological-Clinical']

AIM O
In O
high-risk O
hypertensive O
subjects O
( O
HTs O
) O
with O
incidental O
unilateral O
renal O
artery O
stenosis O
( O
RAS O
) O
, O
the O
effectiveness O
of O
percutaneous O
revascularization O
with O
stent O
( O
PR-STENT O
) O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
BP O
) O
and O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GFR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
not O
established O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
composite O
endpoint O
was O
cardiovascular B-outcome ['Physiological-Clinical']
death I-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
or O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Further O
, O
the O
results O
suggest O
significant O
improvements O
in O
parental B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
and O
conflict B-outcome ['Life-Impact']
about O
['Life-Impact', 'Life-Impact']

Lithium O
carbonate O
( O
mean O
dose O
, O
1,166 O
mg/day O
) O
adversely O
affected O
qualitative O
scores O
on O
the O
Porteus O
Maze O
test O
. O
[]

The O
most O
frequent O
minimal O
bleeding O
event O
was O
epistaxis O
. O
[]

RESULTS O
After O
controlling O
for O
body O
weight O
, O
there O
was O
a O
significant O
effect O
of O
time O
on O
fasting B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
( O
P O
= O
0.0177 O
) O
and O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
P O
= O
0.0386 O
) O
concentrations O
, O
and O
on O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
P O
= O
0.0413 O
) O
, O
with O
reductions O
in O
these O
variables O
occurring O
over O
time O
; O
there O
was O
no O
time-by-diet O
interaction O
for O
any O
of O
the O
parameters O
studied O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Combination O
of O
risperidone O
and O
celecoxib O
was O
superior O
to O
risperidone O
alone O
in O
treating O
irritability O
, O
social O
withdrawal O
, O
and O
stereotypy O
of O
children O
with O
autism O
. O
( O
[]

BACKGROUND O
We O
sought O
to O
determine O
the O
safety O
and O
preliminary O
efficacy O
of O
transcatheter O
intramyocardial O
administration O
of O
myoblasts O
in O
patients O
with O
heart O
failure O
( O
HF O
) O
. O
[]

SETTING O
Lung O
Health O
Study O
II O
, O
a O
clinical O
trial O
to O
assess O
the O
effect O
of O
ICS O
compared O
to O
placebo O
in O
1,116 O
participants O
in O
10 O
centers O
over O
> O
3.5 O
to O
4.5 O
years O
. O
[]

Similarly O
, O
nonsignificant O
changes O
were O
detected O
for O
the O
fibrinolytic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
plasminogen I-outcome ['Physiological-Clinical']
activator B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
tissue B-outcome ['Physiological-Clinical']
plasminogen I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
AND O
AIMS O
Studies O
investigating O
hyperbaric O
oxygen O
treatment O
( O
HBOT O
) O
to O
improve O
outcome O
in O
burns O
have O
been O
inconclusive O
. O
[]

A O
total O
of O
98.4 O
% O
of O
patients O
( O
63/64 O
) O
experienced O
a O
reduction O
in O
the O
frequency O
of O
angina B-outcome ['Physiological-Clinical']
attacks/week O
and O
91 O
% O
of O
patients O
( O
58/64 O
) O
had O
angina B-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
reduced O
to O
< O
or O
= O
2/week O
. O
['Physiological-Clinical', 'Physiological-Clinical']

14 O
day O
endoscopy O
study O
comparing O
risedronate O
and O
alendronate O
in O
postmenopausal O
women O
stratified O
by O
Helicobacter O
pylori O
status O
. O
[]

The O
primary O
end O
point O
was O
the O
subject O
's O
global O
assessment O
of O
therapy O
( O
SGAT O
; O
0-10 O
scale O
; O
0 O
= O
no O
response O
, O
10 O
= O
excellent O
response O
) O
. O
[]

A O
randomized O
, O
double-blinded O
, O
placebo-controlled O
trial O
of O
phenytoin O
for O
the O
prevention O
of O
early O
posttraumatic O
seizures O
in O
children O
with O
moderate O
to O
severe O
blunt O
head O
injury O
. O
[]

51 O
patients O
were O
divided O
into O
two O
groups O
: O
one O
in O
acupuncture O
treatment O
and O
the O
other O
without O
any O
treatment O
. O
[]

The O
Studies O
of O
Ocular O
Complications O
of O
AIDS O
Research O
Group O
. O
[]

Post-operative B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
and O
return O
to O
activity O
show O
statistically O
significant O
differences O
. O
['Life-Impact', 'Resource-use']

RESULTS O
FM O
therapy O
resulted O
in O
superior O
remission B-outcome ['Physiological-Clinical']
rates O
( O
OR O
81 O
% O
versus O
64 O
% O
, O
CR O
49 O
% O
versus O
17 O
% O
; O
P O
= O
0.0004 O
) O
. O
['Physiological-Clinical']

On O
the O
following O
3 O
d O
, O
erosive O
challenges O
were O
performed O
extraorally O
, O
two O
times O
per O
day O
, O
by O
immersing O
the O
device O
for O
90 O
s O
in O
a O
soft O
drink O
. O
[]

Two O
metropolitan O
and O
two O
rural O
regions O
were O
randomly O
allocated O
to O
intervention O
groups O
( O
n O
= O
70 O
) O
or O
control O
( O
n O
= O
35 O
) O
. O
[]

Serum B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cholestasis I-outcome ['Physiological-Clinical']
significantly O
( O
P O
less O
than O
0.01 O
) O
decreased O
after O
oral O
S-adenosylmethionine O
administration O
( O
1600 O
mg/day O
) O
, O
and O
their O
values O
were O
significantly O
( O
P O
less O
than O
0.01 O
) O
lower O
than O
the O
corresponding O
values O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

BACKGROUND O
The O
carbohydrate O
substitutes O
fructose O
, O
sorbitol O
and O
xylitol O
are O
gaining O
more O
and O
more O
importance O
in O
the O
production O
of O
dietary O
food O
. O
[]

RESULTS O
Alvimopan O
significantly O
increased O
the O
proportion O
of O
patients O
with O
GI-2 B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
and O
DCO B-outcome ['Physiological-Clinical']
written O
by O
each O
POD O
( O
P O
< O
0.001 O
for O
all O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Taking O
together O
all O
aspects O
assessed O
including O
the O
healing B-outcome ['Physiological-Clinical']
rate O
, O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
examination I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
, O
we O
judged O
the O
hEGF O
to O
be O
a O
useful O
and O
safe O
anticuler O
drug O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

14 O
nmol/L O
at O
baseline O
. O
[]

Four O
dual-task O
experiments O
are O
reported O
in O
which O
a O
short-term O
memory O
task O
is O
performed O
concurrently O
with O
a O
random O
interval O
repetition O
task O
, O
which O
was O
designed O
to O
interfere O
with O
functions O
normally O
attributed O
to O
the O
central O
executive O
in O
the O
working O
memory O
model O
of O
Baddeley O
and O
Hitch O
( O
1974 O
) O
. O
[]

The O
relative O
net O
leg O
release O
and O
uptake O
of O
individual O
FFA O
closely O
resembled O
their O
relative O
abundances O
in O
the O
plasma O
with O
approximately O
21 O
and O
41 O
% O
of O
net O
leg O
total O
FFA O
uptake O
during O
exercise O
accounted O
for O
by O
palmitate O
and O
oleate O
, O
respectively O
. O
[]

RESULTS O
32 O
cases O
with O
ischemic O
stroke O
and O
234 O
cases O
with O
bleeding O
in O
the O
analysis O
were O
matched O
in O
a O
4:1 O
ratio O
to O
122 O
and O
865 O
controls O
, O
respectively O
. O
[]

Each O
eye O
in O
the O
azithromycin O
group O
also O
received O
azithromycin O
solution O
( O
1 O
drop O
) O
twice O
daily O
for O
the O
first O
2 O
days O
followed O
by O
once O
daily O
for O
the O
next O
12 O
days O
. O
[]

Long-term O
therapy O
had O
no O
effect O
on O
the O
concentration O
of O
total O
, O
free B-outcome ['Physiological-Clinical']
and O
complex B-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
, O
testosterone B-outcome ['Physiological-Clinical']
( O
total O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Iodixanol O
caused O
significantly O
less O
discomfort B-outcome ['Physiological-Clinical']
than O
iohexol O
. O
['Physiological-Clinical']

The O
difference O
between O
the O
treatments O
( O
p O
= O
0.0395 O
) O
was O
the O
faster O
onset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of O
Antazolin/Tetryzolin O
30 O
minutes O
after O
administration O
of O
the O
first O
drop O
of O
trial O
medication O
. O
['Physiological-Clinical']

The O
latter O
finding O
is O
notable O
as O
it O
can O
be O
misinterpreted O
as O
pain B-outcome ['Physiological-Clinical']
when O
methadone O
is O
used O
as O
an O
analgesic O
. O
['Physiological-Clinical']

Patients O
receiving O
CMV O
hyperimmune O
globulin O
or O
control O
immune O
globulin O
were O
comparable O
with O
regard O
to O
age O
, O
diagnosis O
, O
pretransplant O
anti-CMV O
titer O
, O
incidence O
of O
graft-versus-host O
disease O
and O
transfusions O
. O
[]

Virtual O
reality O
( O
VR O
) O
shows O
promise O
as O
a O
non-pharmacological O
adjunct O
in O
reducing O
pain O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
rosiglitazone O
, O
a O
PPAR-? O
agonist O
, O
on O
cognition O
in O
clozapine-treated O
patients O
with O
schizophrenia O
. O
[]

Including O
additional O
self-care O
education O
by O
a O
professional O
, O
rather O
than O
leaving O
all O
the O
education O
to O
the O
mentor O
, O
could O
strengthen O
the O
peer O
support O
intervention O
trialed O
in O
this O
study O
. O
[]

Prospective O
comparison O
of O
nasal O
versus O
oral O
insertion O
of O
a O
thin O
video O
endoscope O
in O
healthy O
volunteers O
. O
[]

The O
number O
of O
patients O
who O
discontinued B-outcome ['Life-Impact']
treatment O
due O
to O
an O
unsatisfactory O
analgesic B-outcome ['Resource-use']
response O
was O
significantly O
less O
in O
the O
HI2 O
group O
( O
2 O
; O
1.3 O
% O
) O
than O
in O
the O
CA O
group O
( O
12 O
; O
7.5 O
% O
) O
( O
P O
= O
0.008 O
) O
. O
['Life-Impact', 'Resource-use']

We O
then O
evaluated O
the O
two O
groups O
for O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
( O
after O
surgery O
and O
6 O
months O
postoperatively O
) O
. O
['Adverse-effects']

Maintenance O
of O
response O
following O
stabilization O
of O
mixed O
index O
episodes O
with O
olanzapine O
monotherapy O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
of O
bipolar O
1 O
disorder O
. O
[]

DESIGN O
AND O
METHODS O
The O
HERA O
study O
( O
Hyperium O
Effect O
on O
the O
sympathetic O
Reflex O
activation O
and O
Adrenaline O
) O
is O
a O
randomised O
, O
double-blind O
, O
6-week O
cross-over O
trial O
, O
with O
a O
1-week O
placebo O
run-in O
period O
, O
two O
2-week O
active O
treatment O
intervals O
( O
rilmenidine O
1 O
mg O
bid O
, O
placebo O
) O
and O
intervening O
one O
week O
placebo O
wash-out O
. O
[]

DESIGN O
A O
randomized O
controlled O
trial O
was O
conducted O
as O
part O
of O
the O
population-based O
longitudinal O
study O
on O
outcomes O
of O
children O
with O
hearing O
impairment O
( O
LOCHI O
) O
. O
[]

Total O
control B-outcome ['Physiological-Clinical']
( O
no O
vomiting B-outcome ['Physiological-Clinical']
, O
no O
retching B-outcome ['Physiological-Clinical']
, O
no O
nausea B-outcome ['Physiological-Clinical']
, O
and O
no O
use B-outcome ['Life-Impact']
of O
antiemetic B-outcome ['Resource-use']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

e O
) O
Complications B-outcome ['Resource-use']
, O
given O
as O
n O
( O
% O
) O
. O
['Resource-use']

Problems O
with O
potency O
of O
CX516 O
in O
other O
studies O
have O
suggested O
dosing O
may O
have O
been O
inadequate O
for O
therapeutic O
effect O
and O
thus O
it O
remains O
unclear O
whether O
modulation O
of O
AMPA-mediated O
neurotransmission O
is O
a O
viable B-outcome ['Life-Impact']
therapeutic I-outcome ['Life-Impact']
strategy I-outcome ['Life-Impact']
for O
the O
treatment O
of O
FXS O
. O
['Life-Impact']

This O
trial O
protocol O
is O
aimed O
to O
test O
the O
SCION-PAIN O
program O
, O
a O
multi O
modular O
structured O
intervention O
to O
improve O
self O
management O
in O
cancer O
patients O
with O
pain O
. O
[]

Gastric B-outcome ['Physiological-Clinical']
contents I-outcome ['Physiological-Clinical']
and O
pH O
after O
oral O
premedication O
. O
['Physiological-Clinical']

Analysis O
comparing O
change O
between O
baseline O
and O
week O
8 O
of O
treatment O
for O
L-carnitine O
and O
the O
placebo O
showed O
that O
both O
parents/caregivers O
and O
medical O
follow-up O
detected O
improvements O
in O
the O
subjects O
' O
well-being B-outcome ['Life-Impact']
. O
['Life-Impact']

Also O
, O
this O
difference O
was O
mirrored O
by O
the O
action O
of O
caffeine O
. O
[]

Semi-structured O
interviews O
were O
conducted O
with O
6 O
specialists O
and O
16 O
GPs O
. O
[]

Monitoring O
acute O
effects O
on O
athletic O
performance O
with O
mixed O
linear O
modeling O
. O
[]

Moreover O
, O
the O
survival B-outcome ['Mortality']
and O
disease-free B-outcome ['Physiological-Clinical']
rate O
in O
the O
group O
of O
the O
combination O
therapy O
were O
higher O
than O
those O
in O
the O
group O
of O
Futraful O
alone O
, O
and O
the O
relapse B-outcome ['Physiological-Clinical']
rate O
was O
lower O
in O
the O
former O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

The O
volatile B-outcome ['Physiological-Clinical']
agent I-outcome ['Physiological-Clinical']
concentration O
in O
the O
blood B-outcome ['Physiological-Clinical']
was O
measured O
at O
30 O
min O
intervals O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thus O
, O
total O
hospital B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
of O
the O
noninvasive O
( O
$ O
16,073 O
+/- O
9,423 O
) O
and O
invasive O
approaches O
( O
$ O
16,949 O
+/- O
7,174 O
) O
were O
equivalent O
. O
['Resource-use']

expression O
was O
decreased O
in O
EGCG O
treated O
sites O
, O
such O
that O
28.4 O
% O
of O
the O
epidermis O
showed O
positive O
staining O
in O
vehicle O
treated O
vs. O
13.8 O
% O
in O
EGCG O
treated O
sites O
( O
p O
< O
0.001 O
) O
. O
[]

Seventy-three O
patients O
undergoing O
elective O
perianal O
surgery O
were O
randomly O
divided O
into O
a O
control O
group O
, O
a O
group O
who O
received O
a O
caudal O
injection O
of O
20 O
ml O
bupivacaine O
0.5 O
% O
plain O
and O
a O
group O
who O
received O
diamorphine O
2.5 O
mg O
in O
10 O
ml O
normal O
saline O
by O
caudal O
injection O
; O
a O
comparison O
was O
then O
made O
of O
postoperative O
analgesia O
requirements O
. O
[]

The O
present O
study O
compares O
the O
pharmacokinetics O
of O
azithromycin O
in O
plasma O
, O
lung O
tissue O
, O
and O
bronchial O
washing O
after O
oral O
administration O
of O
500 O
mg O
( O
standard O
dose O
) O
versus O
1000 O
mg O
daily O
for O
3 O
days O
. O
[]

Similarly O
, O
HR O
for O
all-cause B-outcome ['Mortality']
death I-outcome ['Mortality']
for O
GFR B-outcome ['Physiological-Clinical']
45-59 O
and O
< O
45 O
ml/min/1.73 O
m O
( O
2 O
) O
BSA O
were O
respectively O
1.03 O
( O
95 O
% O
CI O
, O
0.90-1.18 O
; O
P O
= O
0.651 O
) O
and O
1.70 O
( O
95 O
% O
CI O
, O
1.40-2.07 O
; O
P O
< O
0.0001 O
) O
. O
['Mortality', 'Physiological-Clinical']

The O
rarity O
of O
recurrent B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
ischemic I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
by O
Holter O
monitoring O
after O
PTCA O
negated O
any O
attempt O
at O
assessing O
the O
efficacy O
of O
intravenous O
isosorbide O
dinitrate O
in O
their O
prevention O
. O
['Physiological-Clinical']

Addition O
of O
epirubicin O
to O
adjuvant O
chemotherapy O
can O
provide O
important O
benefits O
for O
patients O
with O
early O
breast O
cancer O
, O
but O
the O
optimal O
dose O
remains O
unclear O
. O
[]

IFTC O
0702 O
randomized O
phase O
III O
study O
] O
. O
[]

Ninety-three O
women O
with O
FIGO O
stage O
II O
epithelial O
ovarian O
carcinoma O
underwent O
comprehensive O
surgical O
staging O
and O
were O
randomized O
prospectively O
to O
therapy O
consisting O
of O
either O
intraperitoneal O
radioactive O
phosphorus O
or O
oral O
melphalan O
. O
[]

52 O
male O
patients O
with O
postinfarction O
cardiosclerosis O
( O
PICS O
) O
who O
have O
developed O
CHF O
have O
been O
observed O
. O
[]

The O
morphology O
of O
the O
sting O
suggested O
little O
basis O
for O
this O
advice O
, O
which O
is O
likely O
to O
slow O
down O
removal O
of O
the O
sting O
. O
[]

PCA B-outcome ['Resource-use']
morphine I-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
in O
the O
2-CP O
, O
2-CP+Epi O
and O
Lido+Epi O
groups O
respectively O
was O
20.5 O
+/- O
24 O
, O
33.1.5 O
+/- O
27 O
and O
4.07 O
+/- O
( O
mean O
+/- O
SD O
) O
. O
['Resource-use']

For O
eyes O
undergoing O
retinotomy O
, O
silicone O
oil O
decreased O
the O
likelihood O
of O
hypotony B-outcome ['Physiological-Clinical']
( O
six O
months O
, O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
chronic O
effects O
of O
telmisartan O
and O
enalapril O
on O
proteinuria O
, O
urinary B-outcome ['Physiological-Clinical']
liver-type I-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid-binding I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
L-FABP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
endothelin B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ET I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
-1 I-outcome ['Physiological-Clinical']
levels O
in O
patients O
with O
mild O
CKD O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Overall O
, O
75 O
percent O
of O
patients O
receiving O
active O
drug O
had O
diastolic B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
less O
than O
or O
equal O
to O
90 O
mm O
Hg O
at O
the O
last O
treatment O
visit O
. O
['Physiological-Clinical']

The O
different O
Lp O
( O
a O
) O
behaviour O
in O
the O
two O
groups O
and O
in O
the O
presence O
of O
the O
same O
serum O
hormonal O
levels O
, O
seems O
to O
be O
dependent O
on O
the O
existence O
of O
a O
circadian O
rhythm O
of O
the O
hepatic O
responsiveness O
to O
estrogens O
, O
whose O
expression O
is O
higher O
during O
evening O
hours O
. O
[]

METHODS O
In O
a O
double-blind O
phase O
3 O
trial O
, O
patients O
with O
recurrent O
or O
metastatic O
SCCHN O
and O
no O
prior O
systemic O
therapy O
for O
metastatic O
disease O
were O
randomized O
to O
pemetrexed O
( O
500 O
mg/m O
( O
2 O
) O
) O
plus O
cisplatin O
( O
75 O
mg/m O
( O
2 O
) O
; O
n O
= O
398 O
) O
or O
placebo O
plus O
cisplatin O
( O
75 O
mg/m O
( O
2 O
) O
; O
n O
= O
397 O
) O
to O
assess O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
and O
secondary O
endpoints O
. O
['Mortality']

Households O
with O
young O
children O
and O
use O
of O
freely O
distributed O
bednets O
in O
rural O
Madagascar O
. O
[]

RESULTS O
Serum B-outcome ['Physiological-Clinical']
CETP I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
postmenopausal O
women O
compared O
with O
those O
in O
perimenopausal O
and O
premenopausal O
women O
( O
1.39+/-1.06 O
, O
2.36+/-1.50 O
and O
2.31+/-1.25 O
mg/l O
, O
respectively O
, O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

However O
, O
prasugrel O
use O
has O
been O
evaluated O
only O
in O
randomized O
trials O
. O
[]

All O
indices O
of O
efficacy O
showed O
similar O
results O
, O
all O
active O
treatments O
being O
associated O
with O
highly O
significant O
( O
P O
less O
than O
0.0001 O
) O
reductions O
in O
pain B-outcome ['Physiological-Clinical']
during O
the O
study O
period O
. O
['Physiological-Clinical']

Complement B-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
was O
present O
in O
all O
patients O
studied O
who O
had O
the O
syndrome O
( O
5 O
of O
27 O
) O
but O
also O
in O
many O
patients O
who O
did O
not O
meet O
our O
diagnostic O
criteria O
, O
suggesting O
a O
multifactorial O
cause O
. O
['Physiological-Clinical']

Clomipramine O
was O
equal O
to O
desipramine O
and O
both O
tricyclic O
agents O
were O
superior O
to O
placebo O
for O
amelioration O
of O
hyperactivity B-outcome ['Life-Impact']
. O
['Life-Impact']

In O
those O
with O
proven O
rhinovirus O
colds O
treated O
within O
24 O
h O
, O
the O
median O
duration O
was O
significantly O
longer O
in O
the O
20-MU O
group O
( O
9 O
days O
) O
than O
in O
the O
placebo O
group O
( O
6 O
days O
) O
. O
[]

Biochemical O
progression O
prompted O
a O
change O
of O
chemotherapy O
. O
[]

Treatment O
for O
head O
and O
neck O
cancer O
precipitates O
a O
myriad O
of O
distressing O
symptoms O
. O
[]

Postprandial O
increases O
in O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
and O
C-peptide B-outcome ['Physiological-Clinical']
were O
consistently O
lower O
in O
the O
acarbose-treated O
group O
than O
in O
the O
placebo O
group O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

There O
was O
no O
significant O
difference O
between O
the O
2 O
groups O
with O
respect O
to O
any O
of O
the O
measured O
variables O
. O
[]

A O
proof-of-principle O
study O
established O
that O
doses O
of O
heparin O
lower O
than O
what O
are O
used O
for O
anticoagulation O
but O
sufficient O
to O
block O
P-selectin O
improved O
microvascular B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
inpatients O
with O
SCD O
. O
['Physiological-Clinical']

Two-dose O
methylprednisolone O
was O
associated O
with O
a O
higher O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
( O
0.61 O
? O
['Physiological-Clinical']

Part O
B O
included O
20 O
asymptomatic O
porphobilinogen O
deaminase-deficient O
subjects O
and O
20 O
healthy O
subjects O
. O
[]

One O
patient O
on O
branched-chain O
amino O
acids O
and O
two O
on O
casein O
were O
lost O
to O
the O
study O
. O
[]

RESULTS O
A O
significant O
treatment O
effect O
was O
found O
for O
socially O
engaged O
imitation O
( O
p O
= O
.02 O
) O
, O
with O
more O
than O
doubling O
( O
17 O
% O
to O
42 O
% O
) O
of O
imitated O
acts O
paired O
with O
eye O
contact O
in O
the O
Interpersonal O
Synchrony O
group O
after O
the O
intervention O
. O
[]

METHODS O
Sixty O
boys O
with O
ADHD O
, O
Asperger O
syndrome/high-functioning O
autism O
( O
AS/HFA O
) O
, O
and O
reading O
and O
writing O
disorder O
( O
RD/WD O
) O
were O
allocated O
to O
participate O
in O
a O
service O
evaluation O
project O
. O
[]

Safety O
endpoints O
included O
occurrence O
of O
neutralizing B-outcome ['Physiological-Clinical']
anti-erythro I-outcome ['Physiological-Clinical']
poietin I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
, O
tolerability B-outcome ['Life-Impact']
, O
and O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Adverse-effects']

Voice B-outcome ['Physiological-Clinical']
and O
swallowing B-outcome ['Physiological-Clinical']
assessment O
were O
obtained O
by O
using O
the O
Voice B-outcome ['Physiological-Clinical']
Handicap I-outcome ['Physiological-Clinical']
Index-10 O
( O
VHI-10 O
) O
and O
the O
Reflux B-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Index O
questionnaires O
( O
RSI O
) O
before O
surgery O
and O
at O
3 O
weeks O
and O
3 O
months O
after O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
experienced O
some O
additional O
improvement O
in O
irritability O
and O
related O
behaviors O
. O
[]

Patients O
were O
stable O
for O
a O
mean O
of O
4 O
months O
( O
range O
1-13 O
) O
before O
entering O
the O
study O
. O
[]

For O
local O
treatment O
, O
substances O
from O
various O
groups O
of O
active O
ingredients O
are O
used O
as O
combinations O
and O
as O
single-agent O
drugs O
, O
e.g O
. O
[]

PBO-randomized O
patients O
were O
rescued O
with O
RTX O
as O
appropriate O
. O
[]

Infants O
in O
group O
TF O
had O
significantly O
greater O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
mean O
difference O
41.4 O
( O
95 O
% O
confidence O
interval O
9 O
, O
73.7 O
) O
kcal/kg O
p=0.02 O
; O
weight O
gain O
, O
130 O
( O
CI O
1 O
, O
250 O
) O
g O
p O
= O
0.02 O
; O
head B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
gain I-outcome ['Physiological-Clinical']
, O
mean O
difference O
0.7 O
( O
CI O
0.1 O
, O
1.3 O
) O
cm O
, O
p O
= O
0.04 O
; O
fewer O
episodes O
of O
culture B-outcome ['Physiological-Clinical']
confirmed I-outcome ['Physiological-Clinical']
sepsis I-outcome ['Physiological-Clinical']
, O
mean O
difference O
-0.7 O
( O
-1.3 O
, O
-0.2 O
) O
episodes O
, O
p O
= O
0.04 O
; O
less O
parenteral B-outcome ['Life-Impact']
nutrition I-outcome ['Life-Impact']
, O
mean O
difference O
-11.5 O
( O
CI O
-20 O
, O
-3 O
) O
days O
, O
p O
= O
0 O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Type-4a O
MI O
may O
not O
be O
a O
reliable O
component O
of O
the O
primary O
composite O
end O
point O
in O
coronary O
stent O
investigations O
which O
recruit O
patients O
with O
ACS O
. O
[]

Including O
clinical O
factors O
improved O
the O
predictive O
power O
of O
all O
models O
significantly O
. O
[]

The O
primary O
endpoint O
will O
be O
the O
percent O
change O
of O
coronary B-outcome ['Physiological-Clinical']
plaque I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSION O
Laparoscopic O
lymphadenectomy O
was O
associated O
with O
a O
significantly O
lower O
rate O
of O
major O
and O
minor B-outcome ['Adverse-effects']
postoperative I-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
and O
a O
better O
short O
term O
quality O
of O
life O
. O
['Adverse-effects']

Patients O
received O
iodixanol O
or O
iohexol O
containing O
either O
9 O
or O
12 O
g O
of O
iodine O
( O
gI O
) O
. O
[]

The O
duration O
of O
sensory B-outcome ['Resource-use']
anesthesia I-outcome ['Resource-use']
at O
the O
T O
10 O
dermatomal O
level O
was O
257 O
+/- O
102 O
, O
278 O
+/- O
67 O
, O
and O
191 O
+/- O
86 O
min O
for O
bupivacaine O
, O
ropivacaine O
, O
and O
etidocaine O
, O
respectively O
. O
['Resource-use']

BACKGROUND O
Among O
elderly O
persons O
, O
falls B-outcome ['Life-Impact']
account O
for O
87 O
% O
of O
all O
fractures O
and O
are O
contributing O
factors O
in O
many O
nursing O
home O
admissions O
. O
['Life-Impact']

Participants O
were O
followed O
for O
6 O
months O
. O
[]

Stepwise O
regression O
analysis O
showed O
that O
the O
association O
of O
B-ALP B-outcome ['Physiological-Clinical']
and O
D-Pyr B-outcome ['Physiological-Clinical']
measured O
at O
6 O
months O
explained O
40 O
% O
of O
BMD B-outcome ['Physiological-Clinical']
variance O
and O
the O
association O
of O
B-ALP B-outcome ['Physiological-Clinical']
, O
PTH B-outcome ['Physiological-Clinical']
, O
and O
estradiol B-outcome ['Physiological-Clinical']
56 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
nasal B-outcome ['Physiological-Clinical']
airflow I-outcome ['Physiological-Clinical']
was O
measured O
by O
anterior B-outcome ['Physiological-Clinical']
rhinomanometry I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Therefore O
, O
they O
would O
benefit O
from O
teaching O
procedures O
that O
minimize O
their O
difficulties O
in O
acquiring O
these O
relations O
. O
[]

An O
extensive O
evaluation O
was O
performed O
on O
a O
test O
set O
composed O
of O
images O
representative O
of O
those O
normally O
found O
in O
a O
screening O
set O
. O
[]

METHODS O
This O
is O
a O
prospective O
, O
randomized O
( O
1:1 O
) O
, O
single-blind O
, O
controlled O
trial O
comparing O
outcomes O
of O
patients O
with O
single O
de O
novo O
coronary O
lesions O
treated O
with O
ZES O
or O
PES O
. O
[]

Patients O
with O
involved O
axillary O
lymph O
nodes O
. O
[]

Rates O
of O
extrapyramidal O
disorder O
and O
drooling O
, O
but O
not O
akathisia O
or O
tremor O
, O
were O
marginally O
higher O
in O
AN O
subjects O
. O
[]

All O
the O
results O
are O
discussed O
with O
reference O
to O
the O
working O
memory O
model O
. O
[]

Enclosed O
were O
eyes O
with O
visual O
acuity O
of O
> O
or O
= O
0.1 O
and O
< O
or O
= O
0.6 O
revealing O
a O
juxta-subfoveal O
CNV O
either O
of O
the O
occult O
type O
( O
type O
1 O
) O
or O
the O
classic O
type O
( O
isolated O
or O
as O
part O
of O
a O
predominantly O
occult O
lesion O
) O
. O
[]

The O
counselor O
enhancement O
produced O
increased O
cessation B-outcome ['Life-Impact']
at O
12 O
months O
but O
not O
at O
18 O
months O
. O
['Life-Impact']

METHODS O
A O
randomised O
clinical O
trial O
was O
used O
to O
assign O
patients O
to O
receive O
the O
study O
medication O
( O
potassium O
) O
or O
placebo O
. O
[]

The O
Bath O
Ankylosing B-outcome ['Physiological-Clinical']
Spondylitis I-outcome ['Physiological-Clinical']
Disease I-outcome ['Physiological-Clinical']
Activity I-outcome ['Physiological-Clinical']
Index O
( O
BASDAI O
) O
score O
was O
the O
primary O
end O
point O
for O
clinical O
response O
. O
['Physiological-Clinical']

There O
is O
currently O
no O
effective O
treatment O
for O
these O
problems O
. O
[]

OBJECTIVE O
To O
demonstrate O
the O
comparative O
effects O
of O
MG O
+ O
MT O
, O
MT O
, O
and O
a O
control O
treatment O
( O
CT O
) O
on O
the O
outcomes O
of O
motor O
impairments O
, O
manual O
dexterity O
, O
ambulation O
function O
, O
motor O
control O
, O
and O
daily O
function O
. O
[]

These O
pregnancies O
were O
randomly O
allocated O
to O
a O
treatment O
group O
( O
AD O
and O
estimated O
weight O
reported O
) O
or O
to O
a O
control O
group O
( O
AD O
and O
estimated O
weight O
withheld O
) O
. O
[]

Prior O
disease O
duration O
was O
much O
shorter O
in O
Wenzhou O
subject O
( O
8.1 O
? O
[]

Somnolence O
, O
sedation O
and O
increased O
appetite O
occurred O
more O
frequently O
in O
high-versus O
low-dose O
groups O
. O
[]

No O
significant O
difference O
was O
found O
regarding O
dosages O
at O
the O
ages O
of O
4 O
months O
to O
1 O
year O
, O
and O
6 O
to O
15 O
years O
. O
[]

Nicotine O
challenge O
did O
not O
significantly O
alter O
rsFC B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
insula-dACC-striatal I-outcome ['Physiological-Clinical']
circuits I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Median O
serum B-outcome ['Physiological-Clinical']
IgG I-outcome ['Physiological-Clinical']
levels O
were O
similar O
in O
the O
2 O
groups O
. O
['Physiological-Clinical']

Then O
, O
subjects O
were O
randomized O
to O
receive O
D53 O
( O
n O
= O
6 O
) O
or O
its O
placebo O
( O
n O
= O
6 O
) O
by O
both O
oral O
and O
subcutaneous O
injection O
routes O
from O
day O
1 O
to O
day O
15 O
. O
[]

In O
the O
Primary O
Angioplasty O
in O
Myocardial O
Infarction O
trial O
, O
395 O
patients O
with O
acute O
myocardial O
infarction O
( O
AMI O
) O
were O
prospectively O
randomized O
to O
tissue O
plasminogen O
activator O
( O
tPA O
) O
or O
primary O
percutaneous O
transluminal O
coronary O
angioplasty O
( O
PTCA O
) O
. O
[]

Trained O
community O
health O
advisors O
, O
who O
were O
African-American O
male O
church O
members O
, O
led O
an O
educational O
session O
and O
distributed O
educational O
print O
materials O
. O
[]

A O
program O
of O
screening O
and O
prompting O
improves O
short-term O
physician O
counseling O
of O
dependent O
and O
nondependent O
harmful O
drinkers O
. O
[]

Intravenous O
thrombolytic O
treatment O
was O
used O
in O
30 O
% O
of O
the O
telemedicine O
and O
telephone O
consultations O
. O
[]

OBJECTIVE O
To O
observe O
the O
effect O
of O
Fuzheng O
Yiliu O
Granule O
( O
FZYLG O
) O
on O
cell O
cycle O
and O
nuclear O
transcription O
factor-kappa O
B O
( O
NF-kappa O
B O
) O
in O
tissue O
of O
esophageal-gastric O
carcinoma O
. O
[]

Torasemide O
in O
the O
treatment O
of O
patients O
with O
cirrhosis O
and O
ascites O
. O
[]

Severity B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
autism I-outcome ['Life-Impact']
, O
as O
assessed O
with O
the O
Childhood B-outcome ['Life-Impact']
Autism I-outcome ['Life-Impact']
Rating O
Scale O
, O
improved O
significantly O
in O
the O
enriched O
group O
compared O
to O
controls O
. O
['Life-Impact', 'Life-Impact']

Subjects O
were O
randomized O
either O
to O
paper O
format O
or O
computerized O
format O
first O
to O
balance O
possible O
order O
effects O
. O
[]

BACKGROUND O
Both O
standard O
and O
low-dose O
allergen O
provocations O
are O
an O
established O
tool O
in O
asthma O
research O
to O
improve O
our O
understanding O
of O
the O
pathophysiological O
mechanism O
of O
allergic O
asthma O
. O
[]

This O
exploratory O
study O
is O
a O
trial O
of O
the O
effects O
of O
the O
SSRI O
paroxetine O
versus O
placebo O
( O
in O
a O
double O
blind O
design O
) O
on O
craving O
and O
use O
in O
a O
population O
of O
methamphetamine O
users O
. O
[]

Pulsed O
azithromycin O
treatment O
is O
as O
effective O
and O
safe O
as O
2-week-longer O
daily O
doxycycline O
treatment O
of O
acne O
vulgaris O
: O
a O
randomized O
, O
double-blind O
, O
noninferiority O
study O
. O
[]

DESIGN O
Prospective O
, O
randomized O
. O
[]

This O
training O
adopted O
a O
cognitive O
mapping O
technique O
to O
help O
improve O
supervisor O
responsiveness O
. O
[]

Larger O
decreases O
in O
body B-outcome ['Physiological-Clinical']
weight O
, O
body B-outcome ['Physiological-Clinical']
mass O
index O
, O
waist O
circumference O
, O
body B-outcome ['Physiological-Clinical']
fat O
, O
total O
fat O
area O
and O
subcutaneous O
fat O
area O
in O
the O
abdomen O
and O
serum O
triglycerides O
, O
low-density O
lipoprotein O
cholesterol O
, O
apolipoprotein O
B O
, O
C2 O
, O
C3 O
and O
E O
were O
observed O
in O
male O
subjects O
in O
the O
MLCT O
group O
than O
those O
in O
the O
LCT O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Different O
aprotinin O
applications O
influencing O
hemostatic O
changes O
in O
orthotopic O
liver O
transplantation O
. O
[]

CONCLUSIONS O
The O
individualized O
nature O
of O
the O
educational O
intervention O
may O
have O
accounted O
for O
non-significant O
findings O
reported O
in O
outcomes O
between O
the O
two O
time O
points O
. O
[]

RESULTS O
The O
rate O
of O
malabsorption B-outcome ['Physiological-Clinical']
was O
84 O
% O
for O
sorbitol O
, O
36 O
% O
for O
fructose O
and O
12 O
% O
for O
xylitol O
( O
p O
< O
0.01 O
for O
sorbitol O
versus O
fructose O
and O
xylitol O
) O
. O
['Physiological-Clinical']

Four O
niacin O
treatment O
groups O
( O
daily O
doses O
of O
2000 O
, O
1500 O
, O
1250 O
, O
and O
1000 O
mg O
) O
were O
compared O
with O
placebo- O
and O
diet-treated O
controls O
to O
determine O
side-effect O
profile O
and O
optimal O
range O
of O
efficacy O
. O
[]

However O
, O
both O
regimens O
were O
significantly O
superior O
to O
treatment O
with O
VAC O
alone O
. O
[]

PURPOSE O
The O
purpose O
was O
to O
evaluate O
the O
activity B-outcome ['Life-Impact']
and O
toxicity B-outcome ['Adverse-effects']
of O
split-dose O
paclitaxel O
or O
docetaxel O
in O
combination O
with O
gemcitabine O
in O
patients O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
who O
had O
previously O
received O
anthracyclines O
. O
['Life-Impact', 'Adverse-effects']

Excluded O
were O
contaminated O
cases O
, O
operations O
with O
a O
transnasal-transsphenoidal O
approach O
, O
shunt-operations O
and O
patients O
with O
any O
other O
preoperative O
infection O
or O
antibiotic O
therapy O
. O
[]

BACKGROUND O
Although O
little O
empiric O
evidence O
has O
been O
published O
concerning O
the O
efficacy O
of O
blood O
donor O
recruitment O
materials O
, O
research O
suggests O
that O
simple O
attempts O
to O
enhance O
knowledge O
may O
not O
be O
sufficient O
to O
motivate B-outcome ['Life-Impact']
donation I-outcome ['Life-Impact']
. O
['Life-Impact']

Partly O
based O
on O
between-patient O
dispersion O
of O
BP O
values O
during O
treatment O
( O
interindividual O
variability O
) O
it O
has O
also O
been O
reported O
that O
long-term B-outcome ['Physiological-Clinical']
clinic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
is O
greater O
for O
?-blocker O
than O
for O
calcium O
antagonist O
and O
other O
types O
of O
treatment O
. O
['Physiological-Clinical']

Sustained B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
and O
verbal-semantic B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
played O
the O
main O
role O
for O
self-appraisal O
and O
in O
the O
designation O
as O
'neuropsychologically O
impaired O
' O
. O
['Life-Impact', 'Life-Impact']

Treatment O
with O
pronase O
significantly O
reduced O
( O
both O
at O
P O
< O
0.05 O
) O
the O
endoscopic B-outcome ['Resource-use']
ultrasonography I-outcome ['Resource-use']
score O
in O
the O
gastric O
cavity O
( O
score O
4 O
, O
34 O
% O
) O
in O
comparison O
with O
that O
found O
for O
treatments O
A O
( O
7 O
% O
) O
and O
B O
( O
0 O
% O
) O
. O
['Resource-use']

Protective O
effect O
of O
high-dose O
medroxyprogesterone O
acetate O
( O
HD-MPA O
) O
on O
hematological B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
induced O
by O
chemotherapy O
for O
advanced O
solid O
tumors O
: O
a O
multicentric O
controlled O
clinical O
trial O
. O
['Physiological-Clinical']

Wilcoxon O
signed-ranks O
test O
was O
used O
to O
pair O
pain O
scores O
. O
[]

The O
office O
measurements O
showed O
a O
similar O
trend O
, O
but O
the O
intertreatment O
differences O
did O
not O
reach O
statistical O
significance O
. O
[]

Each O
examination O
was O
rated O
as O
diagnostic O
or O
nondiagnostic O
and O
the O
image O
quality O
was O
noted O
. O
[]

3 O
Isoprenaline O
dose-response O
curves O
for O
decreases O
in O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
also O
showed O
shifts O
to O
the O
right O
after O
oral O
prizidilol O
, O
providing O
evidence O
of O
beta-adrenoceptor O
antagonism O
by O
this O
drug O
in O
peripheral O
resistance O
vessels O
. O
['Physiological-Clinical']

Practolol O
200 O
mg O
further O
attenuated O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
but O
also O
decreased O
the O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
responses O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Further O
studies O
are O
indicated O
to O
evaluate O
whether O
montelukast O
exhibits O
additive O
effects O
to O
ICS/long-acting O
beta2-adrenoceptor O
agonist O
combination O
inhalers O
upon O
clinically O
[]

40 O
micrograms O
ipratropium O
bromide O
( O
Atrovent O
MDI O
, O
20 O
micrograms/puff O
) O
plus O
2 O
puffs O
placebo O
; O
B O
. O
[]

Analysis O
was O
performed O
to O
detect O
differences O
between O
the O
intervention O
and O
control O
groups O
in O
baseline O
and O
quarterly B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
for O
one O
year O
post-study O
enrollment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Twenty-four O
women O
treated O
with O
ES O
and O
11 O
women O
treated O
with O
Kegel O
exercises O
completed O
the O
8-week O
study O
program O
. O
[]

Eligible O
participants O
in O
the O
study O
were O
51 O
patients O
with O
chronic O
schizophrenia O
with O
ages O
ranging O
from O
20 O
to O
45 O
years O
. O
[]

After O
a O
2-week O
wash-out O
period O
, O
the O
patients O
received O
the O
alternative O
mouthrinse O
. O
[]

Anthelmintic-treated O
sheep O
were O
drenched O
with O
fenbendazole O
against O
nematodes O
and O
with O
triclabendazole O
against O
trematodes O
. O
[]

In O
cycle O
1 O
, O
patients O
received O
carboplatin/paclitaxel O
on O
day O
1 O
, O
followed O
from O
day O
2 O
by O
pegfilgrastim O
6-18 O
mg O
or O
daily O
filgrastim O
( O
5 O
microg/kg/day O
for O
< O
or O
=14 O
days O
) O
as O
per O
randomization O
in O
cycle O
0 O
. O
[]

SIB O
delivered O
TV B-outcome ['Physiological-Clinical']
and O
MV B-outcome ['Physiological-Clinical']
over O
twice O
that O
delivered O
by O
VDMV O
and O
Neopuff O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Forty-eight O
patients O
completed O
the O
protocol O
; O
treatment O
was O
discontinued O
because O
of O
side O
effects O
in O
nine O
patients O
, O
and O
three O
patients O
dropped O
out O
of O
the O
study O
. O
[]

No O
evidence O
of O
nonlinearity O
was O
observed O
in O
the O
dose-response O
curve O
. O
[]

One O
way O
analysis O
of O
variance O
( O
ANOVA O
) O
and O
the O
Kruskal-Wallis O
test O
were O
applied O
for O
testing O
differences O
in O
scores O
between O
groups O
. O
[]

Improving O
and O
targeting O
nicotine O
replacement O
therapy O
( O
NRT O
) O
are O
cost-effective O
strategies O
for O
reducing O
adverse O
health O
consequences O
for O
smokers O
. O
[]

3.63 O
and O
-2.45 O
? O
[]

Gene O
expression O
is O
altered O
in O
piglet O
small O
intestine O
by O
weaning O
and O
dietary O
glutamine O
supplementation O
. O
[]

L-arginine O
and O
S-nitrosoglutathione O
reduce O
embolization B-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical']

[ O
Impact O
of O
CCND1 O
A870G O
polymorphism O
on O
acute B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
postoperative O
rectal O
cancer O
patients O
treated O
with O
adjuvant O
concurrent O
chemoradiotherapy O
] O
. O
['Adverse-effects']

This O
randomized O
controlled O
clinical O
trial O
compares O
the O
effectiveness O
of O
a O
biopsychosocial O
treatment O
with O
a O
solely O
conventional O
biomedical O
therapy O
in O
patients O
with O
subacute B-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
using O
parameters O
for O
pain O
intensity O
, O
functional O
status O
, O
depressive O
dysfunction O
and O
work O
performance O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
of O
oral O
amoxicillin O
in O
the O
treatment O
of O
pyoderma O
in O
Mali O
, O
by O
comparison O
with O
oral O
erythromycin O
. O
[]

To O
evaluate O
the O
effect O
of O
recombinant O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
GM-CSF O
) O
on O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
or O
AIDS-related O
complex O
( O
ARC O
) O
who O
were O
intolerant O
to O
zidovudine O
because O
of O
neutropenia O
, O
we O
performed O
a O
randomized O
, O
open-label O
study O
in O
which O
patients O
were O
assigned O
to O
one O
of O
two O
groups O
. O
[]

A O
controlled O
trial O
of O
cisapride O
in O
anorexia O
nervosa O
. O
[]

To O
date O
, O
no O
other O
double-blind O
, O
placebo-controlled O
studies O
involving O
substantial O
numbers O
of O
substance-abusing O
suicidal O
patients O
have O
been O
reported O
to O
either O
confirm O
or O
refute O
these O
findings O
. O
[]

BACKGROUND O
& O
AIMS O
Helicobacter O
pylori-infected O
gastric O
mucosa O
evolves O
through O
stages O
of O
chronic O
gastritis O
, O
intestinal O
metaplasia O
( O
IM O
) O
, O
glandular O
atrophy O
( O
GA O
) O
, O
and O
dysplasia O
before O
carcinoma O
develops O
. O
[]

Twenty-nine O
patients O
in O
the O
operated O
group O
and O
35 O
patients O
in O
the O
conservative O
group O
completed O
the O
study O
. O
[]

BACKGROUND O
Curettage O
and O
electrodesiccation O
( O
C O
& O
D O
) O
is O
a O
widely O
used O
method O
to O
treat O
nodular O
basal O
cell O
carcinoma O
( O
BCC O
) O
. O
[]

All O
predictors O
were O
significantly O
( O
P O
< O
.01 O
) O
associated O
with O
a O
hospitalization O
of O
32 O
days O
or O
longer O
; O
having O
a O
tracheostomy O
was O
the O
strongest O
predictor O
( O
odds O
ratio O
, O
4.74 O
) O
. O
[]

METHODS O
In O
this O
controlled O
trial O
, O
60 O
patients O
( O
mean O
age O
29 O
years O
) O
with O
myofascial O
pain O
were O
evaluated O
after O
10 O
weeks O
of O
treatment O
with O
either O
a O
stabilization O
appliance O
or O
a O
control O
appliance O
. O
[]

Patients O
who O
sustained O
an O
accidental O
dural O
puncture O
during O
establishment O
of O
epidural O
analgesia O
during O
labour O
or O
at O
caesarean O
delivery O
were O
randomly O
assigned O
to O
receive O
a O
prophylactic O
epidural O
blood O
patch O
or O
conservative O
treatment O
with O
a O
therapeutic O
epidural O
blood O
patch O
if O
required O
. O
[]

We O
found O
also O
a O
significant O
positive O
correlation O
between O
plasma O
levels O
of O
DOPEG O
and O
MOPEG O
. O
[]

Sixty O
Holstein O
calves O
( O
30 O
bulls O
, O
30 O
heifers O
) O
were O
used O
to O
examine O
the O
effects O
of O
supplemental O
lactoferrin O
on O
feed B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
growth B-outcome ['Physiological-Clinical']
, O
and O
health B-outcome ['Physiological-Clinical']
during O
the O
preweaning O
and O
postweaning O
periods O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Treatment O
group O
participants O
were O
better O
able O
to O
suggest O
appropriate O
emotion-management B-outcome ['Life-Impact']
strategies I-outcome ['Life-Impact']
for O
story O
characters O
at O
post-intervention O
than O
at O
pre-intervention O
, O
whereas O
control O
participants O
were O
not O
. O
['Life-Impact']

Comprehensive O
registry O
data O
were O
used O
to O
follow O
the O
women O
for O
a O
mean O
of O
4.1 O
years O
. O
[]

The O
cardiovascular O
parameters O
were O
measured O
at O
baseline O
and O
after O
6 O
months O
. O
[]

Treatment O
studies O
document O
the O
efficacy O
of O
precessation O
NRT O
and O
support O
important O
roles O
for O
level O
of O
nicotine O
dependence O
and O
precessation O
smoking O
reduction O
in O
successful O
quitting O
. O
[]

Based O
on O
the O
kinetics O
of O
the O
humoral O
immune O
responses O
, O
the O
vaccinees O
could O
be O
classified O
into O
fast O
, O
intermediate O
and O
slow/non-responders O
. O
[]

Posthoc O
testing O
of O
between O
group O
differences O
highlighted O
greater O
improvement O
at O
all O
post-operative O
assessments O
. O
[]

METHODS O
Patients O
( O
n=603 O
; O
mean O
age O
, O
73.9 O
years O
; O
55.2 O
% O
men O
) O
with O
probable O
( O
70.5 O
% O
) O
or O
possible O
( O
29.5 O
% O
) O
VaD O
, O
according O
to O
criteria O
of O
the O
National O
Institute O
of O
Neurological O
Disorders O
and O
Stroke O
( O
NINDS O
) O
and O
the O
Association O
Internationale O
pour O
la O
Recherche O
et O
l'Enseignement O
en O
Neurosciences O
( O
AIREN O
) O
, O
were O
randomized O
to O
24 O
weeks O
of O
treatment O
with O
donepezil O
5 O
mg/d O
( O
n=198 O
) O
, O
donepezil O
10 O
mg/d O
( O
5 O
mg/d O
for O
first O
28 O
days O
; O
n=206 O
) O
, O
or O
placebo O
( O
n=199 O
) O
. O
[]

In O
addition O
, O
body O
tetrapolar O
electrical O
impedance O
was O
used O
to O
assess O
extracellular O
fluid O
volume O
. O
[]

[ O
Improving O
wound B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
after O
nose O
surgery O
by O
combined O
administration O
of O
xylometazoline O
and O
dexpanthenol O
] O
. O
['Physiological-Clinical']

Repeated-measures O
multivariate O
analysis O
of O
variance O
performed O
on O
normalized O
relative O
area O
values O
revealed O
that O
ethanol O
had O
significant O
effects O
on O
EEG B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
anterior I-outcome ['Physiological-Clinical']
sites I-outcome ['Physiological-Clinical']
: O
frontal O
( O
F3 O
, O
F4 O
) O
and O
central O
( O
C3 O
, O
C4 O
) O
that O
presented O
as O
increased O
activity O
in O
the O
slow O
alpha O
frequency O
band O
. O
['Physiological-Clinical']

In O
all O
groups O
, O
children O
's O
serum O
retinol B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
improved O
. O
['Physiological-Clinical']

We O
observed O
no O
untoward B-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
in O
either O
of O
the O
groups O
. O
['Adverse-effects']

Surgical O
procedures O
, O
anesthesia O
, O
and O
recovery O
were O
conducted O
with O
standardized O
protocols O
. O
[]

Both O
studies O
included O
ASA O
Class O
I-III O
female O
patients O
about O
to O
undergo O
major O
abdominal O
gynaecological O
surgery O
or O
vaginal O
hysterectomy O
. O
[]

The O
efficacy O
of O
Rioprostil O
( O
a O
new O
prostaglandin O
E1 O
analogue O
) O
is O
compared O
with O
that O
of O
ranitidine O
in O
the O
recurrence O
prevention O
of O
duodenal O
ulcer O
( O
s O
) O
. O
[]

BACKGROUND O
The O
diagnostic O
yield O
of O
endobronchial O
ultrasonography O
( O
EBUS O
) O
-guided O
transbronchial O
needle O
aspiration O
( O
TBNA O
) O
for O
peripheral O
pulmonary O
lesions O
( O
PPLs O
) O
has O
not O
been O
evaluated O
. O
[]

Side-effects B-outcome ['Adverse-effects']
mainly O
consisted O
of O
constipation B-outcome ['Physiological-Clinical']
, O
headache B-outcome ['Physiological-Clinical']
, O
and O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Impact O
of O
disease O
severity O
on O
outcome O
of O
antiviral O
therapy O
for O
chronic O
hepatitis O
C O
: O
Lessons O
from O
the O
HALT-C O
trial O
. O
[]

Treating O
anxiety O
disorders O
in O
children O
with O
high O
functioning O
autism O
spectrum O
disorders O
: O
a O
controlled O
trial O
. O
[]

The O
difference O
between O
the O
two O
treatments O
was O
significant O
as O
indicated O
by O
the O
effect O
of O
group O
, O
and O
the O
between-subjects O
factor O
( O
F O
= O
4.17 O
, O
d.f O
. O
[]

BACKGROUND O
Heparin O
is O
an O
effective O
, O
widely O
used O
treatment O
for O
unstable O
angina O
. O
[]

Therefore O
, O
the O
purpose O
of O
our O
study O
was O
to O
evaluate O
the O
effect O
of O
the O
surgical O
technique O
on O
the O
development O
of O
parathyroid B-outcome ['Physiological-Clinical']
gland I-outcome ['Physiological-Clinical']
insufficiency I-outcome ['Physiological-Clinical']
in O
our O
group O
of O
patients O
. O
['Physiological-Clinical']

Treatment O
consisted O
of O
5 O
iCBT-based O
lessons O
, O
homework O
tasks O
, O
additional O
resources O
, O
weekly O
e-mail O
or O
telephone O
contact O
from O
a O
Clinical O
Psychologist O
, O
and O
automated O
e-mails O
. O
[]

Renal O
damage O
occurred O
in O
2 O
cases O
( O
5 O
% O
) O
in O
ozone O
therapy O
group O
, O
less O
than O
that O
in O
control O
group O
( O
9 O
cases O
, O
21 O
% O
) O
( O
?? O
= O
5.295 O
, O
P O
< O
0.05 O
) O
. O
[]

Combination O
of O
sotalol O
and O
magnesium O
prevents O
atrial O
fibrillation O
after O
coronary O
artery O
bypass O
grafting O
. O
[]

Two O
years O
after O
ESWT O
, O
pain O
during O
[]

CONCLUSIONS O
In O
patients O
with O
recurrent O
duodenal O
ulcer O
, O
eradication B-outcome ['Physiological-Clinical']
of O
H. O
pylori O
by O
a O
regimen O
that O
does O
not O
have O
any O
direct O
action O
on O
the O
mucosa O
is O
followed O
by O
a O
marked O
reduction O
in O
the O
rate O
of O
recurrence O
, O
suggesting O
a O
causal O
role O
for O
H. O
pylori O
in O
recurrent O
duodenal O
ulcer O
. O
['Physiological-Clinical']

The O
hASH1 O
mRNA O
level O
might O
represent O
a O
useful O
tool O
for O
distinguishing O
esthesioneuroblastoma O
from O
poorly O
differentiated O
tumors O
of O
the O
sinonasal O
region O
. O
[]

10 O
% O
. O
[]

INTERVENTIONS O
Each O
child O
was O
randomly O
assigned O
to O
receive O
a O
single O
dose O
of O
acetaminophen O
( O
10 O
mg/kg O
) O
, O
ibuprofen O
( O
7.5 O
or O
10 O
mg/kg O
) O
, O
or O
placebo O
. O
[]

Despite O
ongoing O
allergen O
exposure O
, O
steroid O
treatment O
decreases O
mucosal B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
while O
altering O
PG O
density O
. O
['Physiological-Clinical']

Differences O
were O
not O
statistically O
significant O
. O
[]

Each O
group O
( O
n=10 O
) O
received O
one O
of O
five O
interventions O
: O
normoxic O
( O
21 O
% O
O? O
) O
resting O
( O
N-C O
) O
, O
hypoxic O
( O
15 O
% O
O? O
) O
resting O
( O
H-C O
) O
, O
normoxic O
exercise O
( O
50 O
% O
W O
( O
max O
) O
under O
21 O
% O
O? O
, O
N-T O
) O
, O
hypoxic-relative O
exercise O
( O
50 O
% O
maximal O
heart O
rate O
reserve O
under O
15 O
% O
O? O
, O
H-RT O
) O
, O
or O
hypoxic-absolute O
exercise O
( O
50 O
% O
W O
( O
max O
) O
under O
15 O
% O
O? O
, O
H-AT O
) O
for O
30 O
min/day O
, O
5 O
days/week O
for O
4 O
weeks O
. O
[]

106 O
( O
79 O
% O
) O
patients O
in O
the O
eltrombopag O
group O
responded O
to O
treatment O
at O
least O
once O
during O
the O
study O
, O
compared O
with O
17 O
( O
28 O
% O
) O
patients O
in O
the O
placebo O
group O
. O
[]

Effect O
of O
secretin O
on O
children O
with O
autism O
: O
a O
randomized O
controlled O
trial O
. O
[]

However O
, O
the O
routine O
use O
of O
prophylactic O
antibiotics O
in O
the O
field O
of O
dental O
implantology O
continues O
to O
be O
controversial O
, O
and O
their O
utilization O
varies O
widely O
. O
[]

At O
the O
end O
of O
the O
treatment O
period O
, O
all O
patients O
were O
recalled O
. O
[]

The O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
the O
incidence O
rate O
of O
complications B-outcome ['Adverse-effects']
and O
the O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
were O
compared O
between O
E-PEG O
and O
ordinary O
pull-method O
PEG O
groups O
. O
['Life-Impact', 'Adverse-effects', 'Resource-use']

Effects O
on O
parental B-outcome ['Life-Impact']
mental I-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
of O
an O
education O
and O
skills O
training O
program O
for O
parents O
of O
young O
children O
with O
autism O
: O
a O
randomized O
controlled O
trial O
. O
['Life-Impact']

Headaches B-outcome ['Physiological-Clinical']
were O
more O
common O
in O
patients O
with O
active O
patches O
but O
were O
relieved O
by O
simple O
analgesics O
. O
['Physiological-Clinical']

However O
, O
severe B-outcome ['Physiological-Clinical']
anemia I-outcome ['Physiological-Clinical']
and O
febrile B-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
are O
statistically O
more O
frequent O
in O
the O
VNR/CDDP O
arm O
than O
in O
the O
DCT/CDDP O
one O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
In O
64 O
patients O
( O
8 O
% O
) O
, O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
was O
detected O
in O
one O
or O
more O
examinations O
. O
['Physiological-Clinical']

With O
the O
use O
of O
effectiveness O
measures O
that O
favored O
clozapine O
( O
extrapyramidal O
side O
effects O
, O
disruptiveness O
) O
, O
bootstrap O
techniques O
indicated O
that O
, O
even O
when O
a O
payer O
is O
unwilling O
to O
incur O
any O
additional O
cost O
for O
gains O
in O
effectiveness O
, O
the O
probability O
that O
clozapine O
is O
more O
cost-effective O
than O
usual O
care O
is O
at O
least O
0.80 O
. O
['Resource-use']

Most O
placebo O
patients O
discontinued O
by O
taking O
rescue B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
( O
ibuprofen O
200 O
mg O
) O
on O
the O
first O
day O
. O
['Resource-use']

Aripiprazole O
demonstrated O
significantly O
greater O
global O
improvements O
than O
placebo O
, O
as O
assessed O
by O
the O
mean O
CGI-I O
score O
from O
week O
1 O
through O
week O
8 O
; O
however O
, O
clinically O
significant O
residual O
symptoms B-outcome ['Physiological-Clinical']
may O
still O
persist O
for O
some O
patients O
. O
['Physiological-Clinical']

BACKGROUND O
Warfarin O
is O
a O
commonly O
used O
anticoagulant O
in O
North O
America O
. O
[]

For O
a O
subset O
of O
the O
participants O
( O
53 O
children O
ages O
5-16 O
) O
pre O
and O
post O
measurements O
of O
nutritional O
and O
metabolic O
status O
were O
also O
conducted O
. O
[]

In O
study O
II O
, O
normalized O
MEG-X O
test O
results O
( O
ranging O
from O
< O
or O
= O
4 O
to O
120 O
microg/L O
) O
were O
virtually O
identical O
to O
the O
standard O
test O
results O
( O
mean O
difference O
: O
-1.9 O
microg/L O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
: O
-5.3 O
; O
1.5 O
microg/L O
) O
. O
[]

7.6 O
% O
vs. O
29.0 O
? O
[]

However O
, O
research O
has O
failed O
to O
consistently O
demonstrate O
faster O
discharge O
times O
from O
the O
postanesthesia O
care O
unit O
following O
the O
use O
of O
desflurane O
. O
[]

Improvement O
with O
treatment O
was O
markedly O
greater O
for O
males O
than O
for O
females O
. O
[]

The O
lag O
times O
( O
mean O
42 O
( O
SD O
11 O
) O
s O
and O
44 O
( O
16 O
) O
s O
) O
, O
maximum B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
( O
99 O
( O
2 O
) O
% O
and O
98 O
( O
3 O
) O
% O
) O
and O
intubating B-outcome ['Life-Impact']
conditions I-outcome ['Life-Impact']
at O
60 O
s O
( O
good-to-excellent O
in O
86 O
% O
and O
84 O
% O
of O
patients O
) O
were O
similar O
for O
rapacuronium O
and O
rocuronium O
, O
respectively O
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
Patients O
in O
the O
CFNB O
group O
, O
the O
VAS O
scores O
at O
PO6-12 O
hr O
and O
tramadol O
IV O
requirement O
were O
significantly O
greater O
than O
the O
CEI O
group O
( O
VAS O
: O
PO6 O
hr O
p-value O
= O
0.001 O
, O
PO12 O
hr O
p-value O
= O
0.004 O
) O
. O
[]

Randomized O
controlled O
trial O
of O
melatonin O
for O
children O
with O
autistic O
spectrum O
disorders O
and O
sleep O
problems O
. O
[]

Responders O
were O
followed O
to O
assess O
maintenance O
of O
response O
( O
without O
further O
treatment O
) O
, O
which O
was O
significantly O
better O
with O
i.m O
. O
[]

It O
was O
found O
that O
after O
the O
parents O
added O
home-based O
DIR/Floortime? O
intervention O
at O
an O
average O
of O
15.2 O
hours/week O
for O
three O
months O
, O
the O
intervention O
group O
made O
significantly O
greater O
gains O
in O
all O
three O
measures O
employed O
in O
the O
study O
: O
Functional B-outcome ['Life-Impact']
Emotional I-outcome ['Life-Impact']
Assessment I-outcome ['Life-Impact']
Scale O
( O
FEAS O
) O
( O
F O
= O
5.1 O
, O
p O
= O
.031 O
) O
, O
Childhood O
Autism O
Rating O
Scale O
( O
F O
= O
2.1 O
, O
p O
= O
.002 O
) O
, O
and O
the O
Functional O
Emotional O
Questionnaires O
( O
F O
= O
6.8 O
, O
p O
= O
.006 O
) O
. O
['Life-Impact']

Treatment O
involved O
12 O
weekly O
group O
sessions O
and O
was O
compared O
with O
a O
waiting O
list O
condition O
. O
[]

PURPOSE O
This O
study O
was O
undertaken O
to O
compare O
the O
effectiveness O
of O
oral O
diazepam O
and O
midazolam O
in O
sedating O
autistic O
patients O
during O
dental O
treatment O
. O
[]

Psoriasis O
of O
the O
scalp O
treated O
with O
Grenz O
rays O
or O
topical O
corticosteroid O
combined O
with O
Grenz O
rays O
. O
[]

Both O
are O
currently O
Drug O
Enforcement O
Administration O
( O
DEA O
) O
Schedule O
III O
narcotics O
. O
[]

However O
, O
the O
published O
article O
concluded O
that O
both O
drugs O
were O
[]

H2-exhalation O
tests O
appear O
to O
be O
a O
reliable O
diagnostic O
tool O
to O
detect O
carbohydrate B-outcome ['Physiological-Clinical']
malabsorption I-outcome ['Physiological-Clinical']
and O
should O
find O
broader O
application O
in O
patients O
suffering O
from O
non-specific O
abdominal O
complaints O
. O
['Physiological-Clinical']

The O
effect O
of O
medication O
on O
each O
outcome O
variable O
was O
studied O
by O
using O
analysis O
of O
variance O
models O
in O
relation O
to O
patient O
, O
period O
and O
medication O
. O
[]

KEY O
RESULTS O
There O
were O
no O
differences O
between O
3CM O
and O
usual O
care O
in O
symptoms O
or O
functioning O
. O
[]

Two O
loading O
doses O
of O
3.5 O
mg/kg O
of O
AR-R15896AR O
over O
60 O
minutes O
, O
followed O
by O
a O
2.5 O
mg/kg O
infusion O
over O
the O
next O
120 O
minutes O
were O
given O
. O
[]

OBJECTIVE O
To O
observe O
therapeutic O
effect O
of O
picking O
therapy O
on O
Graves O
' O
disease O
( O
GD O
) O
and O
its O
effects O
on O
thyroid O
function O
. O
[]

Fifty-three O
patients O
were O
assigned O
to O
1 O
day O
of O
perioperative O
prophylaxis O
. O
[]

A O
neglegible O
incidence O
of O
subdural B-outcome ['Physiological-Clinical']
effusions I-outcome ['Physiological-Clinical']
in O
the O
DSV O
group O
compared O
to O
11 O
cases O
in O
the O
DP O
valve O
collective O
reflects O
the O
ability O
of O
the O
DSV O
to O
prevent O
overdrainage B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
study O
was O
a O
double O
blind O
, O
uncontrolled O
, O
noncrossover O
and O
randomized O
trial O
. O
[]

Quantifying O
the O
extent O
of O
osteonecrosis O
of O
the O
femoral O
head O
. O
[]

The O
difference O
between O
mean O
of O
dye B-outcome ['Physiological-Clinical']
penetration I-outcome ['Physiological-Clinical']
was O
statistically O
significant O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
Breast O
cancer O
patients O
with O
newly O
diagnosed O
bone O
metastases O
who O
were O
treated O
with O
zoledronic O
acid O
had O
a O
low O
incidence O
of O
SREs B-outcome ['Physiological-Clinical']
compared O
with O
patients O
who O
received O
placebo O
in O
randomized O
phase O
III O
trials O
, O
and O
pain O
was O
decreased O
from O
baseline O
. O
['Physiological-Clinical']

IMPLICATIONS O
Esmolol O
blunted O
the O
postoperative O
increase O
in O
cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
in O
neurosurgical O
patients O
. O
['Physiological-Clinical']

OBJECTIVES O
Evaluate O
the O
impact O
of O
an O
intensive O
insulin O
therapy O
and O
conventional O
glucose O
control O
protocol O
during O
staying O
in O
neurological O
intensive O
care O
unit O
( O
NICU O
) O
on O
infection B-outcome ['Physiological-Clinical']
rate O
, O
days B-outcome ['Resource-use']
in I-outcome ['Resource-use']
NICU I-outcome ['Resource-use']
, O
in-hospital B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
long-term B-outcome ['Physiological-Clinical']
neurological I-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
in O
severe O
traumatic O
brain O
injury O
( O
TBI O
) O
patients O
. O
['Physiological-Clinical', 'Resource-use', 'Mortality', 'Physiological-Clinical']

RESULTS O
Fever B-outcome ['Physiological-Clinical']
was O
reported O
in O
41 O
% O
of O
patients O
. O
['Physiological-Clinical']

Our O
results O
differ O
from O
previous O
studies O
done O
in O
Europe O
which O
show O
no O
difference O
between O
the O
courses O
. O
[]

Sustained B-outcome ['Physiological-Clinical']
response O
rates O
were O
10/19 O
( O
53 O
% O
) O
in O
the O
24 O
week O
group O
and O
13/18 O
( O
72 O
% O
) O
in O
the O
48 O
week O
group O
( O
p O
= O
0.31 O
) O
. O
['Physiological-Clinical']

Systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
DBP B-outcome ['Physiological-Clinical']
) O
, O
fasting B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
( O
FG B-outcome ['Physiological-Clinical']
) O
, O
lipid B-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
( O
total O
cholesterol B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
triglyceride B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TG I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LDL-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
high B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HDL-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) O
, O
and O
antioxidant O
enzymes O
activities O
( O
catalase O
( O
CAT O
) O
, O
superoxide O
dismutase O
( O
SOD O
) O
, O
and O
glutathione O
peroxidase O
( O
GPx O
) O
) O
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Following O
a O
one- O
to O
three-week O
washout O
phase O
and O
a O
four-week O
, O
open-label O
lanthanum O
carbonate O
dose-titration O
phase O
, O
male O
and O
female O
hemodialysis O
patients O
were O
randomized O
( O
1:1 O
) O
to O
receive O
either O
lanthanum O
carbonate O
or O
placebo O
for O
four O
weeks O
. O
[]

child B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
) O
was O
assessed O
with O
a O
self-report O
scale O
named O
visual O
analog O
scale O
( O
VAS O
) O
of O
pain O
. O
['Physiological-Clinical']

Thirteen O
GH-deficient O
adults O
( O
4 O
females O
, O
9 O
males O
; O
mean O
( O
SEM O
) O
age O
26.4 O
( O
1.7 O
) O
years O
) O
, O
who O
had O
completed O
4 O
months O
of O
GH O
therapy O
in O
a O
double-blind O
placebo-controlled O
cross-over O
study O
were O
followed O
, O
for O
further O
16.1 O
( O
0.8 O
) O
months O
of O
uninterrupted O
GH O
therapy O
in O
an O
open O
design O
. O
[]

OBJECTIVE O
To O
investigate O
whether O
hippotherapy O
( O
when O
applied O
by O
a O
simulator O
) O
improves O
postural O
control O
and O
balance O
in O
children O
with O
cerebral O
palsy O
. O
[]

However O
, O
more O
women O
in O
the O
vacuum O
extractor O
group O
were O
delivered O
vaginally O
( O
98 O
% O
) O
than O
in O
the O
forceps O
group O
( O
96 O
% O
) O
. O
[]

In O
the O
subgroup O
analysis O
of O
patients O
who O
had O
valve B-outcome ['Physiological-Clinical']
reoperations I-outcome ['Physiological-Clinical']
, O
lower O
blood O
transfusion O
requirements O
in O
the O
intensive O
care O
unit O
( O
p O
= O
0.013 O
) O
were O
found O
in O
the O
study O
group O
. O
['Physiological-Clinical']

PURPOSE O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
bupivacaine O
irrigated O
at O
the O
surgical O
bed O
on O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
laparoscopic O
cholecystectomy O
patients O
. O
['Physiological-Clinical']

The O
primary O
outcome O
measure O
was O
postoperative O
morbidity O
measured O
by O
the O
Postoperative O
Morbidity O
Survey O
. O
[]

DESIGN O
Randomized O
crossover O
trial O
. O
[]

A O
significantly O
greater O
proportion O
of O
bleeding O
suture O
line O
sites O
treated O
with O
the O
polymeric O
sealant O
achieved O
immediate B-outcome ['Physiological-Clinical']
sealing I-outcome ['Physiological-Clinical']
following O
reestablishment O
of O
blood O
flow O
compared O
with O
control-treated O
sites O
[ O
48 O
of O
59 O
( O
81 O
% O
) O
vs O
10 O
of O
27 O
( O
37 O
% O
) O
; O
P O
= O
0.002 O
] O
. O
['Physiological-Clinical']

PURPOSE O
The O
authors O
assessed O
the O
quality O
, O
diagnostic O
accuracy O
and O
patient O
acceptability O
of O
computed O
tomography O
( O
CT O
) O
colonography O
performed O
using O
a O
simplified O
bowel O
preparation O
and O
software O
for O
post-processing O
digital O
elimination O
of O
stool O
and O
fluid O
data O
from O
images O
compared O
with O
the O
examination O
obtained O
with O
conventional O
preparation O
. O
[]

All O
treatments O
were O
given O
as O
1 O
spray O
per O
nostril O
twice O
daily O
. O
[]

the O
area O
under O
the O
curve O
of O
hepatomegaly O
v. O
time O
, O
or O
AUC O
( O
hp O
) O
) O
and O
the O
half-life O
of O
the O
hepatomegaly O
( O
t O
( O
1/2hp O
) O
) O
were O
significantly O
lower O
in O
the O
CQCP O
group O
than O
in O
the O
other O
two O
groups O
. O
[]

Cephalic O
venous O
biomarkers O
of O
free O
radical-mediated O
lipid O
peroxidation O
( O
lipid O
hydroperoxides O
, O
LOOH O
) O
, O
nitrite O
( O
NO2- O
) O
and O
lipid O
soluble O
antioxidants O
were O
also O
obtained O
at O
rest O
. O
[]

Ranitidine O
improves O
lymphocyte O
function O
after O
severe O
head O
injury O
: O
results O
of O
a O
randomized O
, O
double-blind O
study O
. O
[]

METHODS O
Fourteen O
atopic O
patients O
with O
mild-to-moderate O
asthma O
( O
forced O
expiratory O
volume O
in O
1 O
second O
of O
76 O
% O
) O
completed O
a O
double-blind O
, O
randomized O
, O
crossover O
study O
consisting O
of O
3-week O
treatment O
blocks O
of O
either O
fluticasone O
propionate-salmeterol O
, O
250 O
microg O
twice O
daily O
, O
or O
fluticasone O
propionate O
alone O
, O
250 O
microg O
twice O
daily O
, O
in O
conjunction O
with O
either O
fexofenadine O
, O
180 O
mg O
once O
daily O
, O
or O
matched O
placebo O
. O
[]

INTERVENTIONS O
Transoesophageal O
Tissue O
Doppler O
echocardiographic O
examination O
of O
myocardial O
systolic O
and O
early O
diastolic O
velocities O
in O
both O
groups O
basally O
and O
60 O
s O
after O
coronary O
occlusion O
by O
the O
surgeon O
. O
[]

The O
present O
study O
examined O
the O
effects O
of O
pharmacological O
modulation O
of O
the O
norepinephrine O
system O
on O
the O
severity O
of O
such O
impairments O
. O
[]

Our O
results O
confirm O
previous O
reports O
that O
eye O
gaze O
cues O
as O
well O
as O
arrow O
cues O
result O
in O
automatic O
orienting O
of O
[]

We O
investigated O
whether O
the O
addition O
of O
chemotherapy O
to O
ASC O
improved O
survival B-outcome ['Mortality']
and O
quality O
of O
life O
. O
['Mortality']

and O
placebo O
b.i.d O
. O
[]

Extrapyramidal O
AEs O
were O
reported O
in O
6 O
( O
8 O
% O
) O
patients O
. O
[]

METHODS O
Of O
197 O
patients O
with O
differentiated O
papillary O
thyroid O
carcinoma O
, O
49 O
underwent O
total O
thyroidectomy O
alone O
, O
and O
148 O
underwent O
total O
thyroidectomy O
plus O
CND O
. O
[]

Infarct B-outcome ['Physiological-Clinical']
size O
( O
additional O
aim O
) O
, O
and O
safety O
. O
['Physiological-Clinical']

A O
significant O
increase O
in O
the O
duration O
of O
the O
motor B-outcome ['Physiological-Clinical']
response O
to O
levodopa B-outcome ['Resource-use']
was O
seen O
when O
200 O
mg O
entacapone O
was O
given O
with O
levodopa/carbidopa O
. O
['Physiological-Clinical', 'Resource-use']

A O
combined O
analysis O
of O
the O
VACT O
studies O
. O
[]

Both O
techniques O
provided O
acceptable O
analgesia O
, O
but O
the O
perioperative O
increases O
in O
adrenaline B-outcome ['Physiological-Clinical']
, O
glucose B-outcome ['Physiological-Clinical']
and O
ACTH B-outcome ['Physiological-Clinical']
were O
significantly O
greater O
in O
the O
opioid O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
showing O
evidence O
of O
impairment O
were O
randomly O
assigned O
to O
one O
of O
two O
training O
groups O
: O
individualized O
PC-supported O
training O
or O
neuropsychological O
group O
therapy O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
response O
and O
safety O
were O
assessed O
on O
Days O
1 O
, O
2 O
, O
3 O
, O
4 O
to O
5 O
and O
21 O
+/- O
5 O
. O
['Physiological-Clinical']

However O
, O
the O
incidence O
of O
low O
cardiac O
output O
syndrome O
was O
46 O
% O
( O
17/37 O
) O
in O
the O
single-dose O
and O
38 O
% O
( O
15/39 O
) O
in O
the O
2-dose O
methylprednisolone O
groups O
( O
P O
= O
.51 O
) O
. O
[]

Private O
physicians O
referred O
21 O
preschool O
children O
and O
38 O
school-age O
children O
into O
the O
program O
. O
[]

0.3 O
and O
3.4 O
? O
[]

The O
video O
analysis O
showed O
a O
significant O
interrater O
reliability O
. O
[]

Most O
importantly O
, O
the O
strength O
of O
perceptual B-outcome ['Physiological-Clinical']
binding I-outcome ['Physiological-Clinical']
of O
audiovisual I-outcome ['Physiological-Clinical']
speech B-outcome ['Life-Impact']
observed O
in O
individuals O
with O
ASD O
was O
strongly O
related O
to O
their O
low-level O
multisensory O
temporal O
processing O
abilities O
. O
['Physiological-Clinical', 'Life-Impact']

Consistent O
with O
hypothesis O
, O
AS O
was O
found O
to O
be O
a O
significant O
, O
incremental O
predictor O
of O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
over O
time O
, O
even O
after O
controlling O
for O
sex O
and O
negative O
affectivity O
. O
['Life-Impact']

RESULTS O
Eighty-five O
( O
56 O
% O
) O
men O
participated O
. O
[]

INTRODUCTION O
The O
laryngeal O
chemoreflex O
may O
explain O
why O
prone O
sleeping O
increases O
the O
risk O
of O
sudden O
infant O
death O
syndrome O
( O
SIDS O
) O
. O
[]

METHOD O
Two O
established O
hyperintensity O
rating O
systems O
were O
used O
to O
compare O
the O
MRI O
brain O
scans O
of O
48 O
elderly O
patients O
with O
depression O
diagnosed O
according O
to O
DSM-III-R O
with O
the O
scans O
of O
39 O
normal O
elderly O
subjects O
. O
[]

The O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
perindopril O
and O
its O
active O
metabolite O
perindoprilat O
and O
the O
time B-outcome ['Physiological-Clinical']
course I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
angiotensin I-outcome ['Physiological-Clinical']
converting I-outcome ['Physiological-Clinical']
enzyme I-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
were O
studied O
for O
72 O
h O
following O
the O
last O
dose O
of O
treatment O
in O
the O
two O
appropriate O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
A O
convenience O
sample O
of O
40 O
healthy O
adults O
was O
recruited O
: O
16 O
males O
, O
24 O
females O
, O
mean O
age O
22.9 O
( O
5.5 O
) O
years O
. O
[]

Although O
this O
practice O
is O
common O
, O
its O
effect O
on O
the O
pattern O
of O
breathing O
is O
not O
known O
. O
[]

Patients O
in O
the O
PlasmaKinetic O
and O
TURP O
groups O
were O
catheterized O
a O
mean O
of O
2.3 O
+/- O
0.7 O
( O
range O
2 O
to O
4 O
) O
and O
3.8 O
+/- O
0.7 O
days O
( O
range O
3 O
to O
5 O
) O
, O
respectively O
( O
p O
< O
0.05 O
) O
. O
[]

Recent O
anecdotal O
reports O
have O
touted O
the O
gastrointestinal O
( O
GI O
) O
hormone O
secretin O
as O
a O
treatment O
modality O
for O
autism O
, O
though O
there O
is O
little O
clinical O
evidence O
or O
literature O
to O
support O
its O
viability O
. O
[]

Naltrexone O
as O
compared O
with O
placebo O
did O
not O
demonstrate O
any O
significant O
change O
in O
motor B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
either O
group O
. O
['Life-Impact']

In O
addition O
, O
subjects O
performed O
three O
20-s O
arm O
ergometer O
maximal-effort O
sprint O
tests O
in O
the O
prone O
position O
with O
60 O
s O
rest/recovery O
between O
sprint O
tests O
. O
[]

However O
, O
the O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
significantly O
more O
in O
the O
DCS O
group O
( O
p=0.000 O
) O
. O
['Physiological-Clinical']

[ O
Pharmacological O
correction O
of O
free B-outcome ['Physiological-Clinical']
radical I-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
endotoxicosis I-outcome ['Physiological-Clinical']
in O
patients O
with O
diffuse O
peritonitis O
at O
the O
postoperative O
period O
] O
. O
['Physiological-Clinical']

There O
were O
two O
study O
injections O
, O
one O
with O
tetracaine O
and O
one O
with O
placebo O
. O
[]

Craving B-outcome ['Life-Impact']
( O
VAS O
; O
OCDS O
) O
, O
withdrawal B-outcome ['Life-Impact']
( O
CIWA-Ar O
) O
and O
psychiatric B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
( O
SCL-90-R O
) O
rating O
scales O
were O
applied O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Antisaccade O
and O
smooth O
pursuit O
eye O
movements O
in O
healthy O
subjects O
receiving O
sertraline O
and O
lorazepam O
. O
[]

HBV O
vaccine O
needs O
3 O
injections O
over O
6 O
months O
to O
induce O
immunity O
. O
[]

Cyclosporin O
versus O
cyclophosphamide O
for O
patients O
with O
steroid-dependent O
and O
frequently O
relapsing O
idiopathic O
nephrotic O
syndrome O
: O
a O
multicentre O
randomized O
controlled O
trial O
. O
[]

Octreotide-induced B-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
was O
fully O
explained O
by O
a O
reduction O
in O
parenchyma B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
from O
1506 O
+/- O
431 O
ml O
to O
1432 O
+/- O
403 O
ml O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Beneficial O
effects O
regarding O
the O
development O
of O
allergy O
have O
been O
suggested O
to O
come O
through O
probiotic O
supplementation O
. O
[]

The O
corresponding O
reductions O
in O
mortality B-outcome ['Mortality']
( O
with O
95 O
percent O
confidence O
limits O
) O
with O
the O
implantable O
defibrillator O
were O
39+/-20 O
percent O
, O
27+/-21 O
percent O
, O
and O
31+/-21 O
percent O
CONCLUSIONS O
Among O
survivors O
of O
ventricular O
fibrillation O
or O
sustained O
ventricular O
tachycardia O
causing O
severe O
symptoms O
, O
the O
implantable O
cardioverter-defibrillator O
is O
superior O
to O
antiarrhythmic O
drugs O
for O
increasing O
overall O
survival O
. O
['Mortality']

This O
effect O
was O
not O
observed O
in O
the O
control O
group O
. O
[]

Based O
on O
similar O
long-term O
outcomes O
, O
more O
rapid O
engraftment O
, O
and O
less O
oropharyngeal O
mucositis O
, O
the O
combination O
of O
Tac/Sir O
is O
an O
acceptable O
alternative O
to O
Tac/Mtx O
after O
MRD O
HCT O
. O
[]

At O
6 O
months O
, O
the O
mean O
decrease O
in O
SBP/DBP B-outcome ['Physiological-Clinical']
, O
as O
measured O
at O
home O
in O
the O
morning O
, O
was O
2.9/3.3 O
mm O
Hg O
in O
the O
intervention O
group O
relative O
to O
baseline O
( O
P O
= O
0.02 O
and O
P O
< O
0.0001 O
for O
SBP O
and O
DBP O
, O
respectively O
) O
. O
['Physiological-Clinical']

Verapamil O
's O
beneficial O
effect O
appeared O
to O
be O
related O
, O
in O
part O
, O
to O
a O
10 O
% O
reduction O
of O
the O
rate-pressure O
product O
at O
rest O
( O
p O
less O
than O
0.05 O
) O
and O
a O
12 O
% O
reduction O
during O
submaximal O
exercise O
( O
p O
less O
than O
0.001 O
) O
. O
[]

Results O
indicated O
four O
hundred O
and O
eighty-four O
infectious B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
occurred O
while O
giving O
305 O
infusions O
of O
IVIG O
200 O
mg/kg O
; O
205 O
infectious O
episodes O
while O
giving O
170 O
infusions O
of O
400 O
mg/kg O
and O
436 O
infectious O
episodes O
while O
giving O
247 O
infusions O
of O
600 O
mg/kg O
. O
['Physiological-Clinical']

The O
Treatment O
Group O
improved O
on O
the O
DSM-IV O
Criteria O
for O
Pathological O
Gambling B-outcome ['Life-Impact']
, O
but O
did O
not O
show O
a O
significant O
improvement O
on O
['Life-Impact']

All O
had O
prolonged O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
confirmed O
by O
actigraphy O
showing O
a O
mean O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
of O
30 O
minutes O
or O
more O
. O
['Physiological-Clinical', 'Physiological-Clinical']

About O
70 O
% O
in O
each O
active O
treatment O
group O
considered O
the O
overall O
pain B-outcome ['Physiological-Clinical']
relief O
to O
be O
some O
, O
a O
lot O
, O
or O
complete O
compared O
to O
only O
15 O
% O
on O
placebo O
. O
['Physiological-Clinical']

Adverse O
events O
were O
recorded O
. O
[]

A O
second B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
of O
fenoterol O
and O
of O
the O
combination O
regimen O
resulted O
in O
a O
further O
significant O
increase O
in O
FEV1 O
after O
120 O
min O
( O
p O
less O
than O
0.05 O
) O
. O
['Life-Impact']

We O
aimed O
to O
determine O
an O
effective O
and O
safe O
glucose-lowering B-outcome ['Physiological-Clinical']
adjuvant O
exenatide O
dose O
in O
adolescents O
with O
type O
1 O
diabetes O
. O
['Physiological-Clinical']

BACKGROUND O
This O
feasibility O
study O
is O
intended O
to O
assess O
the O
acceptability O
of O
home-based O
task-specific O
reach-to-grasp O
( O
RTG O
) O
training O
for O
people O
with O
stroke O
, O
and O
to O
gather O
data O
to O
inform O
recruitment O
, O
retention O
, O
and O
sample O
size O
for O
a O
definitive O
randomized O
controlled O
trial O
. O
[]

The O
detection O
of O
Helicobacter O
pylori O
( O
HP O
) O
in O
the O
stomach O
and O
duodenum O
was O
carried O
out O
with O
Giemsa O
( O
using O
standard O
visual O
analogue O
scale O
) O
, O
rapid O
urease O
test O
( O
standard O
Jatrox-HP O
test O
, O
Rohm O
Pharma O
, O
Germany O
) O
, O
and O
polymerase O
chain O
reaction O
( O
PCR O
) O
to O
detect O
the O
specific O
fragment O
of O
ureC O
HP O
gene O
( O
Helicopol O
II O
, O
Lytech O
, O
Russia O
) O
. O
[]

At O
baseline O
, O
DTCs O
were O
detected O
in O
26 O
of O
60 O
patients O
in O
the O
zoledronic O
acid O
group O
and O
28 O
of O
58 O
patients O
in O
the O
control O
group O
. O
[]

Doctors O
focused O
on O
the O
importance O
of O
improving O
patients O
' O
compliance O
and O
use O
of O
services O
. O
[]

Similar O
to O
patients O
with O
major O
depression O
, O
these O
results O
emphasize O
the O
impact O
of O
prior B-outcome ['Physiological-Clinical']
pharmacotherapy I-outcome ['Physiological-Clinical']
on O
treatment O
outcomes O
in O
patients O
with O
MDpsy O
. O
['Physiological-Clinical']

Overall O
, O
the O
differences O
in O
lipid B-outcome ['Physiological-Clinical']
, O
hemostatic B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
carbohydrate I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
were O
not O
significant O
between O
the O
two O
treatments O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Principal O
components O
analysis O
was O
used O
to O
construct O
a O
wealth O
and O
malaria O
knowledge O
index O
. O
[]

In O
cycle O
4 O
, O
63.8 O
% O
of O
cycles O
were O
normal O
in O
the O
LNG/EE O
group O
compared O
with O
41.9 O
% O
in O
the O
NETA/EE O
group O
( O
p O
< O
0.005 O
) O
. O
[]

AF B-outcome ['Physiological-Clinical']
occurred O
in O
7.14 O
% O
patients O
in O
group O
I O
, O
and O
in O
group O
II O
, O
28.57 O
% O
( O
P=0.035 O
) O
; O
ventricular B-outcome ['Physiological-Clinical']
tachycardia/fibrillation I-outcome ['Physiological-Clinical']
was O
observed O
in O
21.43 O
% O
patients O
in O
group O
I O
and O
46.43 O
% O
patients O
in O
group O
II O
( O
P=0.089 O
) O
after O
release O
of O
aortic O
clamp O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
effect O
of O
group O
was O
documented O
on O
the O
visual O
working O
memory O
tasks O
. O
[]

Smoothing O
affects O
the O
individualized O
net O
trough-to-peak O
ratios O
in O
an O
unpredictable O
way O
and O
should O
therefore O
be O
avoided O
. O
[]

No O
changes O
in O
menstrual B-outcome ['Physiological-Clinical']
cycle O
length B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
estrogen I-outcome ['Physiological-Clinical']
metabolite I-outcome ['Physiological-Clinical']
ratio O
of O
2-hydroxyestrone B-outcome ['Physiological-Clinical']
to O
16 B-outcome ['Physiological-Clinical']
alpha-hydroxyestrone I-outcome ['Physiological-Clinical']
were O
seen O
with O
soy O
feeding O
in O
the O
non-OC O
or O
the O
OC O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

High B-outcome ['Physiological-Clinical']
stool I-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
fits O
only O
benefitted O
significantly O
( O
p O
= O
0.003-0.006 O
) O
from O
the O
inclusion O
of O
the O
baseline O
toxicity O
score O
. O
['Physiological-Clinical']

We O
characterize O
pulmonary O
vein O
( O
PV O
) O
conduction O
at O
repeat O
ablation O
in O
patients O
with O
AF O
after O
an O
initial O
successful O
PVI O
using O
phased O
RF O
technology O
and O
analyze O
the O
effects O
of O
a O
primary O
2:1 O
ablation O
mode O
. O
[]

The O
mean O
time B-outcome ['Life-Impact']
needed I-outcome ['Life-Impact']
to O
administer O
ivermectin O
+ O
clorsulon O
( O
single O
injection O
) O
to O
five O
cattle O
was O
31 O
seconds O
, O
which O
was O
significantly O
less O
than O
the O
100 O
seconds O
needed O
for O
ivermectin O
+ O
closantel O
( O
two O
injections O
) O
and O
the O
126 O
seconds O
needed O
for O
levamisole O
+ O
triclabendazole O
( O
P O
< O
.001 O
) O
. O
['Life-Impact']

Veno-venous O
CRRT O
was O
administered O
to O
10 O
patients O
in O
the O
CRRT O
group O
whenever O
patients O
were O
determined O
to O
be O
septic O
. O
[]

Eighty-five O
ASA O
grade O
I O
or O
II O
patients O
( O
aged O
60-89 O
yr O
) O
for O
elective O
total O
hip O
replacement O
were O
randomized O
to O
receive O
500 O
mL O
crystalloid O
solution O
( O
Hartmanns O
, O
n O
= O
29 O
) O
, O
500 O
mL O
colloid O
( O
Haemaccel O
, O
n O
= O
28 O
) O
, O
or O
no O
prehydration O
( O
n O
= O
28 O
) O
over O
10 O
min O
prior O
to O
spinal O
anesthesia O
. O
[]

Fluoroscopic O
evaluation O
was O
considered O
appropriate O
when O
the O
prosthesis O
' O
tilting O
disk O
projection O
was O
obtained O
. O
[]

Patients O
were O
then O
randomly O
divided O
into O
two O
groups O
( O
Lottery O
method O
) O
. O
[]

Treatment O
of O
vasculogenic O
sexual O
dysfunction O
with O
pentoxifylline O
. O
[]

B1+B6 O
or O
B6 O
treatment O
both O
caused O
an O
increase O
in O
C-peptide B-outcome ['Physiological-Clinical']
( O
P=0.006 O
, O
P=0.004 O
) O
. O
['Physiological-Clinical']

Which O
women O
default O
from O
follow-up O
cervical O
cytology O
tests O
? O
[]

The O
treatment O
is O
usually O
with O
either O
phenobarbital O
or O
phenytoin O
, O
but O
the O
efficacy O
of O
the O
two O
drugs O
has O
not O
been O
compared O
directly O
. O
[]

speed O
) O
of O
movement O
in O
real O
time O
. O
[]

Theophylline B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
3-MX I-outcome ['Physiological-Clinical']
as O
well O
as O
to O
1-MU O
decreased O
with O
increasing O
dose O
but O
clearance O
to O
DMU O
remained O
unnaffected O
by O
the O
size O
of O
dose O
. O
['Physiological-Clinical']

There O
was O
no O
significant O
between-group O
difference O
in O
mean O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
or O
systolic B-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
at O
any O
of O
the O
time O
points O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
oxygen B-outcome ['Physiological-Clinical']
saturation O
, O
total O
amount B-outcome ['Resource-use']
of I-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
consumed O
and O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
also O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Adverse-effects']

The O
women O
in O
the O
study O
group O
received O
6 O
weekly O
, O
counselling O
visits O
by O
the O
Child O
Health O
Clinic O
nurse O
and O
the O
control O
group O
received O
routine O
primary O
care O
. O
[]

AN O
subjects O
were O
more O
likely O
to O
experience O
AEs O
related O
to O
somnolence O
. O
[]

There O
were O
19 O
serious O
bacterial B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
the O
trimethoprim-sulfamethoxazole O
group O
and O
38 O
in O
the O
pentamidine O
group O
. O
['Physiological-Clinical']

Thirty O
neurosurgical O
patients O
were O
included O
in O
a O
prospective O
, O
randomized O
, O
double-blinded O
study O
comparing O
esmolol O
, O
a O
short-acting O
beta-blocker O
, O
and O
a O
placebo O
. O
[]

Among O
patients O
without O
lesions O
on O
MRI O
, O
baseline O
factors O
associated O
with O
a O
substantially O
lower O
risk O
for O
MS B-outcome ['Physiological-Clinical']
included O
male O
sex O
, O
optic O
disc O
swelling O
, O
and O
certain O
atypical O
features O
of O
optic O
neuritis O
. O
['Physiological-Clinical']

Vaccination O
was O
carried O
out O
at O
six O
, O
10 O
and O
14 O
weeks O
of O
age O
based O
on O
the O
local O
Expanded O
Program O
of O
Immunization O
schedule O
. O
[]

Three O
hundred O
and O
eighteen O
( O
93 O
% O
) O
agreed O
to O
inclusion O
. O
[]

All O
patients O
underwent O
a O
clinical O
examination O
and O
a O
ramp O
pattern O
cycle O
exercise O
test O
before O
and O
after O
the O
observation O
period O
. O
[]

Part O
II O
: O
Effectiveness O
of O
a O
balance O
rehabilitation O
program O
with O
visual O
cue O
deprivation O
after O
stroke O
: O
a O
randomized O
controlled O
trial O
. O
[]

UNLABELLED O
Reports O
of O
transient O
neurological O
symptoms O
with O
the O
use O
of O
subarachnoid O
lidocaine O
has O
generated O
interest O
in O
alternate O
local O
anesthetics O
of O
intermediate O
duration O
, O
such O
as O
mepivacaine O
. O
[]

Families O
self-selected O
4.35 O
( O
SD O
1.75 O
) O
behaviours O
to O
target O
during O
the O
6-month O
programme O
and O
each O
of O
the O
seven O
behaviours O
was O
selected O
by O
45-80 O
% O
of O
the O
families O
. O
[]

A O
prospective O
, O
randomized O
study O
of O
5-fluorouracil O
and O
filtration O
surgery O
. O
[]

Pairwise O
comparisons O
revealed O
that O
iodixanol O
9 O
gI O
was O
significantly O
better O
than O
both O
iohexol O
9 O
gI O
( O
p O
= O
0.0005 O
) O
and O
12 O
gI O
( O
p O
= O
0.014 O
) O
. O
[]

To O
test O
the O
effects O
of O
paromomycin O
, O
10 O
patients O
with O
AIDS O
and O
cryptosporidiosis O
were O
randomized O
to O
paromomycin O
or O
placebo O
in O
a O
double-blind O
trial O
. O
[]

This O
lack O
of O
relationship O
between O
ability B-outcome ['Life-Impact']
and O
attention B-outcome ['Life-Impact']
to O
familiar O
faces O
may O
indicate O
that O
children O
across O
the O
autism O
spectrum O
are O
able O
to O
fixate O
these O
faces O
in O
a O
similar O
way O
. O
['Life-Impact', 'Life-Impact']

OBJECTIVE O
To O
elucidate O
the O
effect O
on O
blood O
pressure O
and O
blood O
lipids O
of O
an O
angiotensin O
converting O
enzyme O
inhibitor O
( O
captopril O
) O
, O
and O
a O
beta-receptor O
blocking O
agent O
( O
atenolol O
) O
, O
given O
alone O
or O
in O
combination O
with O
a O
cholesterol O
reducing O
drug O
, O
the O
beta-hydroxy-methylglutaryl-coenzyme O
A O
reductase O
inhibitor O
pravastatin O
, O
in O
patients O
who O
were O
also O
encouraged O
to O
improve O
their O
lifestyle O
. O
[]

Both O
short-term O
and O
long-term O
immunogenicity O
was O
assessed O
by O
determining O
diphtheria B-outcome ['Physiological-Clinical']
antitoxin I-outcome ['Physiological-Clinical']
levels O
four O
weeks O
after O
vaccination O
and O
after O
one O
and O
two O
years O
. O
['Physiological-Clinical']

EXPERIMENTAL O
DESIGN O
Genotyping O
was O
performed O
on O
seven O
established O
FMO3 O
polymorphisms O
previously O
shown O
to O
have O
functional O
relevance-M66I O
, O
P153L O
, O
E158K O
, O
V257M O
, O
E305X O
, O
E308G O
, O
and O
R492W-in O
21 O
and O
20 O
FAP O
patients O
, O
who O
received O
sulindac O
and O
placebo O
, O
respectively O
. O
[]

Surgical O
technique O
may O
have O
an O
influence O
on O
hematogenous O
tumor O
cell O
spread O
. O
[]

Social O
support O
and O
abstinence B-outcome ['Life-Impact']
from O
opiates O
and O
cocaine O
during O
opioid O
maintenance O
treatment O
. O
['Life-Impact']

Pain O
scores O
, O
the O
fentanyl O
doses O
required O
, O
plasma O
concentrations O
of O
fentanyl O
at O
18 O
hours O
, O
and O
the O
incidence O
and O
severity O
of O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
recorded O
. O
['Adverse-effects']

It O
is O
uncertain O
whether O
the O
negative O
finding O
was O
because O
of O
a O
lack O
of O
strength O
of O
the O
interventions O
or O
problems O
detecting O
intervention O
effects O
using O
individual-level O
closed-end O
surveys O
. O
[]

that O
tiotropium O
Respimat O
5 O
?g O
once O
daily O
is O
superior O
to O
HandiHaler O
in O
terms O
of O
time O
to O
first O
exacerbation O
. O
[]

Conversely O
, O
among O
men O
with O
the O
ff O
genotype O
, O
high B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
25 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
level O
( O
above O
versus O
below O
the O
median O
) O
was O
related O
to O
significant O
60 O
% O
approximately O
70 O
% O
lower O
risks O
of O
total O
and O
aggressive O
prostate O
cancer O
. O
['Physiological-Clinical']

Generalization O
was O
assessed O
in O
the O
families O
' O
homes O
at O
the O
end O
of O
treatment O
and O
a O
1-month O
follow-up O
. O
[]

Median O
follow-up O
was O
21 O
months O
. O
[]

As O
predicted O
, O
reappraisal O
strategies O
more O
effectively O
attenuated O
children B-outcome ['Physiological-Clinical']
's O
self-reported O
emotional B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

We O
performed O
cardiac O
magnetic O
resonance O
imaging O
and O
echocardiography O
and O
measured O
the O
ECV B-outcome ['Physiological-Clinical']
in O
42 O
patients O
treated O
with O
anthracyclines O
. O
['Physiological-Clinical']

The O
patients O
were O
randomized O
to O
group O
I O
( O
creatine O
phosphate O
) O
or O
group O
II O
( O
control O
) O
. O
[]

Citrated B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
was O
obtained O
before O
and O
after O
1 O
and O
2 O
weeks O
of O
exercise O
: O
tPA B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
was O
assessed O
by O
a O
10 O
min O
venous O
occlusion O
( O
VO O
) O
test O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
serious B-outcome ['Adverse-effects']
drug-related I-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
. O
['Adverse-effects']

CONCLUSIONS O
The O
inclusion O
of O
smoking-cessation O
therapy O
does O
not O
appear O
to O
raise O
short-term O
healthcare B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
['Resource-use']

Eligibility O
criteria O
included O
pathological O
proof O
of O
prostate O
cancer O
, O
documented O
progression O
despite O
prior O
hormonal O
manipulation O
, O
WHO O
PS O
0-2 O
, O
and O
no O
daily O
intake O
of O
narcotic O
analgesics O
. O
[]

Women O
who O
lead O
sedentary O
lifestyles O
may O
benefit O
from O
a O
structured O
exercise O
program O
that O
includes O
information O
and O
support O
related O
to O
exercise O
adherence O
strategies O
. O
[]

METHODS O
Participants O
were O
rigorously O
screened O
for O
cardiovascular O
disease O
and O
underwent O
pre-post O
testing O
for O
carotid B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
( O
via O
simultaneous O
ultrasound O
and O
applanation O
tonometry O
) O
, O
carotid-femoral O
pulse O
wave O
velocity O
, O
plasma O
endothelin-1 O
and O
angiotensin B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
and O
carotid B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
vasoreactivity I-outcome ['Physiological-Clinical']
( O
cold O
pressor O
test O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Dalcetrapib O
modulates O
cholesteryl O
ester O
transfer O
protein O
( O
CETP O
) O
activity O
to O
raise O
high-density O
lipoprotein O
cholesterol O
( O
HDL-C O
) O
. O
[]

Middle/deep O
dentin O
was O
exposed O
and O
bonded O
in O
accordance O
with O
the O
following O
treatments O
: O
( O
1D O
) O
ozone+Clearfil O
Protect O
Bond O
; O
( O
2D O
) O
Clearfil O
Protect O
Bond O
( O
control O
) O
; O
( O
3D O
) O
ozone+Xeno O
III O
( O
4D O
) O
Xeno O
III O
( O
control O
) O
. O
[]

METHODS O
Thirty-two O
patients O
on O
antihypertensive O
treatment O
completed O
the O
study O
. O
[]

0 O
microg/kg O
) O
. O
[]

Combined O
typhoid O
fever O
and O
hepatitis O
A O
vaccine O
: O
comparison O
of O
immunogenicity B-outcome ['Physiological-Clinical']
and O
safety O
to O
concomitant O
monovalent O
vaccine O
over O
3 O
years O
. O
['Physiological-Clinical']

Here O
we O
investigate O
the O
possible O
influence O
of O
a O
startling O
auditory O
stimulus O
( O
SAS O
) O
on O
postural B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

During O
training O
, O
serial O
CE O
discernibly O
( O
p O
< O
0.05 O
) O
increased O
cardiovascular O
adaptation O
in O
women O
, O
indicated O
by O
reduction O
( O
-5.7 O
% O
) O
in O
active B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
HR O
) O
( O
HR/aerobic O
exercise O
intensity O
) O
, O
whereas O
integrated O
CE O
discernibly O
reduced O
active B-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
women I-outcome ['Physiological-Clinical']
( O
-10.7 O
% O
) O
and O
men O
( O
-9.1 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Males O
( O
n O
= O
78 O
; O
7-31 O
years O
) O
meeting O
entry O
criteria O
were O
enrolled O
. O
[]

Fifth-graders O
reported O
more O
favorable O
cognitive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
behavioral I-outcome ['Life-Impact']
attitudes I-outcome ['Life-Impact']
when O
information O
was O
provided O
by O
extra-familial O
sources O
( O
i.e. O
, O
doctor O
) O
versus O
parent O
sources O
. O
['Life-Impact']

Many O
skin O
care O
instructions O
and O
various O
topical O
agents O
are O
recommended O
to O
help O
patients O
in O
the O
management O
of O
radiation O
skin O
reactions O
, O
but O
evidence O
to O
support O
the O
value O
of O
the O
topical O
treatments O
of O
the O
irradiated O
skin O
is O
lacking O
. O
[]

Intravenous O
lidocaine O
does O
not O
cause O
shivering-like B-outcome ['Physiological-Clinical']
tremor I-outcome ['Physiological-Clinical']
or O
alter O
thermoregulation B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

for O
4 O
consecutive O
days O
starting O
2 O
days O
before O
immunization O
) O
or O
placebo O
. O
[]

Patients O
who O
qualified O
for O
the O
prospective O
, O
randomized O
, O
double-masked O
, O
placebo-controlled O
trial O
were O
randomly O
divided O
into O
three O
groups O
: O
( O
1 O
) O
single O
dose O
of O
oral O
clindamycin O
administered O
preoperatively O
( O
single-dose O
group O
) O
; O
( O
2 O
) O
clindamycin O
administered O
preoperatively O
with O
continued O
therapy O
for O
5 O
days O
( O
5-day O
group O
) O
; O
and O
( O
3 O
) O
a O
placebo O
group O
. O
[]

Myelosuppression B-outcome ['Physiological-Clinical']
was O
greater O
with O
VIP O
. O
['Physiological-Clinical']

Hierarchical O
linear O
modeling O
was O
used O
to O
determine O
the O
effects O
of O
ethnic O
match O
on O
drinking B-outcome ['Life-Impact']
outcomes O
including O
volume O
per O
week O
, O
maximum O
amount O
, O
and O
frequency O
of O
5 O
or O
more O
drinks O
per O
occasion O
. O
['Life-Impact']

With O
the O
extended O
historical O
CK-based O
definition O
of O
MI O
, O
PMI B-outcome ['Physiological-Clinical']
was O
diagnosed O
in O
65/2121 O
patients O
( O
3.1 O
% O
) O
. O
['Physiological-Clinical']

The O
odds O
ratio O
in O
the O
control O
group O
for O
the O
rate O
of O
morbidity O
( O
cerebral O
infarction O
and O
reversible O
ischemic O
neurological O
deficits O
) O
during O
the O
first O
24 O
hours O
following O
the O
operation O
was O
3.2 O
compared O
with O
the O
NB O
group O
. O
[]

A O
randomized O
, O
open-label O
, O
multicenter O
study O
was O
undertaken O
to O
compare O
the O
effects O
of O
oral O
contraceptives O
( O
OC O
) O
containing O
100 O
micrograms O
levonorgestrel O
( O
LNG O
) O
/20 O
micrograms O
ethinyl O
estradiol O
( O
EE O
) O
( O
Aless/Loette O
) O
and O
1000 O
micrograms O
norethindrone O
acetate O
( O
NETA O
) O
/20 O
micrograms O
EE O
( O
Loestrin O
Fe O
1/20 O
) O
on O
menstrual O
cycle O
control O
over O
four O
cycles O
of O
use O
. O
[]

The O
total O
duration O
of O
sensory B-outcome ['Resource-use']
block I-outcome ['Resource-use']
was O
340 O
+/- O
103 O
min O
for O
bupivacaine O
, O
428 O
+/- O
65 O
min O
for O
ropivacaine O
and O
223 O
+/- O
62 O
min O
for O
etidocaine O
, O
respectively O
. O
['Resource-use']

BACKGROUND O
The O
aim O
of O
this O
paper O
is O
to O
present O
our O
experience O
concerning O
cooperation O
in O
the O
treatment O
of O
Slovak O
patients O
with O
differentiated O
thyroid O
cancer O
in O
Slovak O
and O
Czech O
hospitals O
. O
[]

A O
fat O
meal O
has O
also O
been O
found O
to O
decrease O
lower O
esophageal B-outcome ['Physiological-Clinical']
sphincter I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LESP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
normal O
subjects O
. O
['Physiological-Clinical']

The O
deep B-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
tests O
( O
expiration-inspiration B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
standard O
deviation O
, O
and O
mean O
circular B-outcome ['Physiological-Clinical']
resultant O
of O
R-R B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
) O
, O
postural B-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
, O
and O
postural B-outcome ['Physiological-Clinical']
hypotension B-outcome ['Physiological-Clinical']
were O
favorably O
affected O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
food O
on O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
BMS-181101 B-outcome ['Resource-use']
, O
a O
new O
anti-depressant O
under O
development O
, O
was O
investigated O
in O
12 O
healthy O
male O
volunteers O
at O
steady O
state O
. O
['Physiological-Clinical', 'Resource-use']

The O
accuracy O
of O
MCE O
was O
assessed O
for O
detection O
of O
segments O
and O
patients O
with O
moderate O
and O
severe O
sestamibi-SPECT O
defects O
, O
as O
well O
as O
for O
detection O
of O
patients O
with O
extensive O
perfusion O
defects O
( O
> O
12 O
% O
of O
left O
ventricle O
) O
. O
[]

RESULTS O
The O
following O
GCV B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
( O
mean O
+/-SD O
) O
were O
determined O
: O
with O
CrCl O
of O
> O
or O
=70 O
ml/min O
, O
the O
minimum O
steady-state O
concentration O
( O
Cmin O
) O
and O
maximum O
concentration O
( O
Cmax O
) O
were O
0.78+/-0.46 O
microg/ml O
and O
1.42+/-0.37 O
microg/ml O
, O
respectively O
, O
with O
a O
24-hr O
area O
under O
the O
concentration O
time O
curve O
( O
AUC0-24 O
) O
of O
24.7+/-7.8 O
microg O
x O
hr/ml O
; O
with O
CrCl O
of O
50-69 O
ml/min O
, O
the O
Cmin O
and O
Cmax O
were O
1.93+/-0.48 O
and O
2.57+/-0.39 O
microg/ml O
, O
respectively O
, O
with O
an O
AUC0-24 O
of O
52.1+/-10.1 O
microg O
x O
hr/ml O
; O
with O
CrCl O
of O
25-50 O
ml/min O
, O
the O
Cmin O
and O
Cmax O
were O
0.41+/-0.27 O
and O
1.17+/-0.32 O
microg/ml O
, O
respectively O
, O
with O
an O
AUC0-24 O
of O
14.6+/-7.4 O
microg O
x O
hr/ml O
. O
['Physiological-Clinical']

Lower O
extremity B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
blockade B-outcome ['Physiological-Clinical']
was O
increased O
with O
clonidine O
( O
return O
to O
baseline O
Bromage O
score O
: O
65 O
+/- O
13 O
min O
versus O
79 O
+/- O
19 O
min O
, O
P O
= O
0.004 O
; O
return O
to O
90 O
% O
gastrocnemius B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
: O
P O
= O
0.003 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
amount O
of O
gastric B-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
Group O
100 O
than O
in O
Group O
50 O
( O
P O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

Helicobacter O
pylori O
and O
gastric O
cancer O
: O
current O
status O
of O
the O
Austrain O
Czech O
German O
gastric O
cancer O
prevention O
trial O
( O
PRISMA O
Study O
) O
. O
[]

A O
randomized O
controlled O
trial O
. O
[]

BACKGROUND O
No O
study O
has O
yet O
assessed O
the O
impact O
of O
physicians O
' O
skills O
acquisition O
after O
a O
communication O
skills O
training O
programme O
on O
the O
evolution O
of O
patients O
' O
anxiety O
following O
a O
medical O
consultation O
. O
[]

Tracheal O
tube O
placement O
over O
a O
gum-elastic O
bougie O
. O
[]

However O
, O
based O
on O
discontinuations O
rates O
from O
AEs O
, O
overall O
tolerability O
was O
good O
for O
both O
AN O
and O
PAE O
groups O
. O
[]

hsCRP B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
compared O
in O
patients O
who O
suffered O
an O
adverse O
cardiac O
outcome O
within O
10 O
months O
of O
study O
entry O
and O
in O
patients O
who O
had O
no O
adverse O
event O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
in O
complete O
response O
rates O
between O
patients O
treated O
with O
RT O
alone O
or O
combined O
chemoradiotherapy O
. O
[]

The O
results O
indicate O
that O
MVA-BN O
has O
the O
potential O
to O
be O
developed O
as O
an O
efficient O
and O
safe O
alternative O
to O
the O
conventional O
smallpox O
vaccines O
such O
as O
Lister-Elstree O
or O
Dryvax O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

The O
target O
number O
of O
subjects O
was O
set O
at O
300 O
. O
[]

DISCUSSION O
To O
improve O
guideline O
adherence O
, O
the O
theoretical-domains O
approach O
could O
provide O
a O
comprehensive O
basis O
for O
assessing O
implementation O
difficulties O
, O
as O
well O
as O
designing O
and O
evaluating O
interventions O
. O
[]

RESULTS O
A O
positive O
MR O
angiogram O
of O
the O
hepatofugal O
left O
gastric O
vein O
as O
the O
supply O
vein O
was O
observed O
in O
41 O
patients O
. O
[]

CONCLUSION O
This O
randomized O
study O
failed O
to O
demonstrate O
a O
measurable O
effect O
for O
a O
community O
mobilization B-outcome ['Resource-use']
intervention I-outcome ['Resource-use']
. O
['Resource-use']

EXPERIMENTAL O
DESIGN O
prospective O
, O
randomized O
study O
. O
[]

During O
orthopaedic O
surgery O
of O
the O
limb O
, O
we O
performed O
a O
prospective O
, O
double O
blind O
controlled O
study O
on O
three O
parallel O
groups O
in O
30 O
patients O
to O
evaluate O
the O
pharmacokinetic O
and O
pharmacodynamic O
effect O
of O
infiltration O
of O
the O
iliac O
crest O
bone O
graft O
harvest O
site O
with O
20 O
ml O
of O
bupivacaine O
( O
100 O
mg O
) O
, O
ropivacaine O
( O
150 O
mg O
) O
or O
saline O
as O
control O
group O
( O
n O
= O
10 O
in O
each O
group O
) O
. O
[]

BBOS O
1.5 O
% O
was O
well O
tolerated B-outcome ['Life-Impact']
, O
and O
AEs B-outcome ['Adverse-effects']
were O
generally O
transient O
and O
mild O
. O
['Life-Impact', 'Adverse-effects']

At O
5 O
years O
, O
actuarial O
FFS B-outcome ['Mortality']
for O
patients O
treated O
with O
conventional O
chemotherapy O
was O
51 O
percent O
( O
95 O
percent O
CI O
: O
44-59 O
percent O
) O
compared O
to O
70 O
percent O
( O
95 O
percent O
CI O
: O
65-76 O
percent O
) O
in O
the O
intensive O
arm O
( O
p O
> O
0.01 O
) O
. O
['Mortality']

A O
paucity O
of O
data O
is O
available O
from O
large-scale O
studies O
evaluating O
the O
long-term O
outcomes O
of O
percutaneous O
coronary O
intervention O
in O
patients O
who O
had O
previously O
undergone O
coronary O
artery O
bypass O
grafting O
( O
CABG O
) O
in O
the O
drug-eluting O
stent O
era O
. O
[]

BACKGROUND O
Despite O
recent O
advances O
in O
interventional O
cardiology O
, O
including O
the O
introduction O
of O
drug-eluting O
stents O
for O
de O
novo O
coronary O
lesions O
, O
the O
treatment O
of O
in-stent O
restenosis O
( O
ISR O
) O
remains O
a O
challenging O
clinical O
issue O
. O
[]

High-frequency O
oscillatory O
ventilation O
did O
not O
improve O
oxygenation O
whatever O
the O
mean O
airway O
pressure O
level O
. O
[]

METHODS O
Combined O
data O
were O
analyzed O
on O
39 O
patients O
with O
delayed B-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
( O
DGE O
) O
from O
2 O
studies O
( O
n O
= O
84 O
) O
assessing O
the O
prokinetic O
effect O
of O
nizatidine O
CR O
. O
['Physiological-Clinical']

Antibiotic O
therapy O
of O
acute O
exacerbations O
of O
chronic O
bronchitis O
. O
[]

The O
half-life B-outcome ['Physiological-Clinical']
of O
radioactivity O
in O
plasma O
is O
39 O
h O
; O
16 O
% O
of O
C O
is O
excreted O
in O
urine O
in O
the O
form O
of O
metabolites O
and O
only O
0.3 O
% O
unchanged O
. O
['Physiological-Clinical']

Treatment O
with O
CsA O
yielded O
no O
improvement O
in O
treatment O
outcome O
as O
measured O
by O
the O
frequency O
of O
induction O
resistance B-outcome ['Physiological-Clinical']
( O
68 O
% O
vs O
53 O
% O
) O
, O
rate O
of O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
or O
restored B-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
phase I-outcome ['Physiological-Clinical']
( O
CR/CP O
, O
8 O
% O
vs O
30 O
% O
) O
, O
and O
survival B-outcome ['Mortality']
( O
3 O
vs O
5 O
months O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

A O
formula O
that O
provides O
12.5 O
mg/L O
of O
zinc O
permits O
positive O
zinc B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
and O
zinc B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
similar O
to O
in O
utero O
rates O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
It O
can O
be O
concluded O
that O
no O
significant O
difference O
was O
noted O
between O
the O
two O
types O
of O
enamel O
preparation O
when O
etching O
was O
performed O
. O
[]

Also O
, O
fewer O
subjects O
than O
the O
controls O
had O
significant O
painful O
episodes O
( O
50.0 O
% O
versus O
92.7 O
% O
) O
; O
febrile O
illness O
( O
46.6 O
% O
versus O
87.3 O
% O
) O
and O
admission O
rate O
( O
3.4 O
% O
versus O
34.5 O
% O
) O
( O
p O
< O
0.001 O
) O
. O
[]

CONCLUSION O
In O
a O
controlled O
setting O
, O
parents O
of O
young O
children O
with O
autism O
are O
unable O
to O
distinguish O
the O
[]

RESULTS O
Overall O
, O
the O
most O
frequent O
type O
of O
back O
pain O
experienced O
was O
lumbar B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
36 O
[ O
72.0 O
% O
] O
) O
. O
['Physiological-Clinical']

A O
cognitive O
battery O
was O
administered O
to O
2,166 O
elderly O
persons O
after O
a O
median O
of O
6.9 O
years O
of O
treatment O
. O
[]

Effect O
of O
the O
anesthesia O
procedure O
( O
NLA O
, O
thoracic O
continuous O
catheter O
peridural O
anesthesia O
) O
on O
circulation O
, O
respiration O
and O
metabolism O
. O
[]

Daily O
supplementation O
significantly O
increased O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
alpha-tocopherol I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
beta-carotene I-outcome ['Physiological-Clinical']
in O
the O
supplemented O
group O
( O
Delta O
14.4 O
( O
SE O
3.2 O
) O
and O
0.4 O
( O
se O
0.1 O
) O
micromol/l O
; O
P O
< O
0.001 O
and O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Assessment O
on O
the O
effectiveness O
and O
tolerability B-outcome ['Life-Impact']
as O
expressed O
separately O
by O
the O
physician O
and O
patient O
were O
positive O
in O
almost O
all O
cases O
of O
both O
treatments O
. O
['Life-Impact']

Effects O
of O
short-term O
isotonic O
& O
isometric O
training O
on O
cardiovascular B-outcome ['Physiological-Clinical']
& O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
GH O
treatment O
for O
short O
stature O
in O
Turner O
syndrome O
is O
an O
accepted O
treatment O
in O
many O
countries O
, O
which O
GH O
dosage O
to O
use O
and O
which O
age O
to O
start O
puberty O
induction O
are O
issues O
of O
debate O
. O
[]

In O
the O
first O
part O
a O
conventional O
roentgen O
unit O
was O
used O
, O
and O
in O
the O
second O
part O
a O
60Co O
unit O
, O
with O
considerably O
increased O
dosage O
and O
altered O
treatment O
plan O
. O
[]

Of O
40 O
subjects O
, O
23 O
( O
57.5 O
% O
) O
responded O
fully O
( O
50 O
% O
decrease O
in O
Aberrant O
Behavior O
Checklist-Community O
Irritability I-outcome ['Life-Impact']
subscale O
score O
) O
, O
while O
35 O
subjects O
( O
87.5 O
% O
) O
showed O
a O
25 O
% O
decrease O
. O
['Life-Impact']

All O
patients O
given O
interferon O
therapy O
complained O
of O
flu-like B-outcome ['Physiological-Clinical']
symptoms B-outcome ['Physiological-Clinical']
, O
which O
declined O
progressively O
after O
the O
first O
week O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

According O
to O
our O
data O
, O
rs3796863 O
mainly O
influences O
fusiform B-outcome ['Physiological-Clinical']
gyrus I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
, O
an O
area O
which O
has O
been O
widely O
discussed O
in O
ASD O
research O
. O
['Physiological-Clinical']

There O
was O
also O
no O
significant O
difference O
( O
P O
> O
0.05 O
) O
in O
these O
values O
between O
children O
with O
hyperparasitaemia O
( O
53.6 O
+/- O
11.1 O
and O
36.0 O
+/- O
17.0 O
h O
respectively O
) O
and O
those O
without O
hyperparasitaemia O
( O
49.1 O
+/- O
13.6 O
and O
31.8 O
+/- O
14.6 O
h O
respectively O
) O
. O
[]

This O
trial O
design O
was O
followed O
by O
an O
extended O
open-label O
maintenance O
on O
risperidone O
to O
confirm O
durability B-outcome ['Life-Impact']
of O
treatment O
effects O
and O
to O
monitor O
safety O
. O
['Life-Impact']

We O
compared O
rates O
of O
decline O
in O
ocular O
function O
in O
the O
DHA O
+ O
A O
vs O
control O
+ O
A O
groups O
among O
the O
subgroups O
defined O
by O
use O
or O
nonuse O
of O
vitamin O
A O
prior O
to O
entry O
. O
[]

CONCLUSIONS O
Caregivers O
found O
nurse O
counseling O
most O
helpful O
. O
[]

All O
patients O
were O
on O
100 O
mug O
or O
more O
T O
( O
4 O
) O
. O
[]

Clinical O
benefits O
of O
concurrent O
capecitabine O
and O
cisplatin O
versus O
concurrent O
cisplatin O
and O
5-flurouracil O
in O
locally O
advanced O
squamous O
cell O
head O
and O
neck O
cancer O
. O
[]

Junctional B-outcome ['Physiological-Clinical']
ectopic I-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
after O
congenital O
heart O
surgery O
in O
the O
current O
surgical O
era O
. O
['Physiological-Clinical']

In O
SARME O
, O
the O
widening O
achieved O
at O
dental O
level O
is O
stable O
after O
12 O
months O
. O
[]

OBJECTIVE O
There O
has O
been O
recent O
interest O
in O
the O
use O
of O
cognitive O
enhancing O
drugs O
, O
such O
as O
cholinesterase O
inhibitors O
, O
as O
a O
possible O
treatment O
for O
executive B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
( O
EF O
) O
deficits O
in O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
['Life-Impact']

The O
level O
of O
significance O
was O
set O
at O
p O
< O
or=0.05 O
. O
[]

PURPOSE O
We O
assessed O
the O
cardiovascular O
safety O
profile O
of O
degarelix O
, O
a O
new O
gonadotropin-releasing O
hormone O
antagonist O
. O
[]

At O
8 O
weeks O
, O
the O
proportion O
of O
patients O
with O
residual O
[]

Assessments O
were O
performed O
in O
the O
week O
before O
and O
at O
the O
last O
day O
of O
the O
trial O
. O
[]

Better O
emotional B-outcome ['Life-Impact']
coping I-outcome ['Life-Impact']
behaviours I-outcome ['Life-Impact']
were O
also O
revealed O
by O
some O
changes O
in O
personality O
traits O
in O
the O
intervention O
group O
. O
['Life-Impact']

METHODS O
The O
Transfusion O
Associated O
Complications O
= O
Transfusion O
Induced O
Complications O
? O
( O
[]

The O
experimental O
intervention O
led O
to O
a O
large O
increase O
in O
exclusive B-outcome ['Life-Impact']
breast-feeding I-outcome ['Life-Impact']
at O
3 O
mo O
( O
43.3 O
% O
vs. O
6.4 O
% O
, O
P O
< O
0.001 O
) O
and O
a O
significantly O
higher O
prevalence O
of O
any O
breast-feeding O
throughout O
infancy O
. O
['Life-Impact']

Although O
non-verbal O
IQ O
( O
NVIQ O
) O
for O
the O
group O
as O
a O
whole O
was O
stable O
across O
the O
3 O
assessments O
, O
this O
masked O
considerable O
individual O
instability O
. O
[]

We O
assessed O
a O
newer O
macrolide O
, O
dirithromycin O
, O
for O
the O
treatment O
of O
H. O
pylori O
in O
two O
separate O
studies O
. O
[]

RESULTS O
During O
follow-up O
, O
HBI O
had O
no O
impact O
on O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
( O
relative O
risk O
, O
1.04 O
; O
95 O
% O
confidence O
interval O
, O
0.80-1.35 O
) O
or O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
from O
death O
or O
unplanned B-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
( O
relative O
risk O
, O
1.03 O
; O
95 O
% O
confidence O
interval O
, O
0.86-1.24 O
) O
. O
['Mortality', 'Mortality', 'Resource-use']

Bone B-outcome ['Physiological-Clinical']
SOS I-outcome ['Physiological-Clinical']
decreased O
significantly O
in O
the O
control O
group O
( O
-108.1 O
+/- O
33.7 O
m/second O
, O
P O
< O
0.0001 O
) O
during O
the O
study O
period O
, O
while O
remaining O
stable O
in O
the O
exercise O
group O
( O
11.3 O
+/- O
22.8 O
m/second O
) O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
treatment O
conditions O
on O
the O
Purdue O
Pegboard O
( O
hand-eye B-outcome ['Life-Impact']
coordination I-outcome ['Life-Impact']
) O
task O
or O
the O
Analog O
Classroom O
Task O
( O
timed B-outcome ['Life-Impact']
math I-outcome ['Life-Impact']
test O
) O
. O
['Life-Impact', 'Life-Impact']

The O
age O
range O
was O
13-50 O
years O
( O
mean O
33.6 O
years O
) O
. O
[]

OBJECTIVE O
The O
primary O
objective O
of O
this O
three-way O
crossover-design O
study O
was O
to O
compare O
the O
pharmacokinetic O
( O
PK O
) O
parameters O
of O
two O
BDDrFVIII O
formulations O
( O
one O
reconstituted O
with O
5 O
mL O
of O
sterile O
water O
, O
the O
other O
reconstituted O
with O
4 O
mL O
sodium O
chloride O
0.9 O
% O
USP O
) O
with O
those O
of O
a O
plasma-derived O
, O
full-length O
FVIII O
preparation O
( O
Hemofil O
M O
) O
in O
patients O
with O
haemophilia O
A O
to O
determine O
bioequivalence O
. O
[]

Three O
individuals O
with O
mental O
retardation O
exhibited O
stimulus B-outcome ['Life-Impact']
overselectivity I-outcome ['Life-Impact']
in O
a O
delayed O
matching-to-sample O
task O
in O
which O
two O
sample O
stimuli O
were O
displayed O
on O
each O
trial O
. O
['Life-Impact']

There O
were O
40 O
controlled O
, O
7 O
partly O
controlled O
and O
13 O
uncontrolled O
visits O
. O
[]

Results O
of O
a O
prospective O
, O
randomized O
, O
clinical O
study O
] O
. O
[]

Patients O
underwent O
MRI O
every O
fourth O
week O
for O
32 O
weeks O
: O
twice O
during O
pretreatment O
, O
six O
times O
during O
treatment O
, O
and O
once O
after O
treatment O
. O
[]

This O
study O
showed O
that O
the O
two O
combinations O
of O
0.5 O
% O
timolol O
maleate O
and O
2 O
% O
pilocarpine O
HCl O
compared O
in O
this O
study O
were O
equally O
effective O
in O
reducing O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
comparison O
of O
dorsal O
and O
volar O
resting O
hand O
splints O
in O
the O
reduction O
of O
hypertonus O
. O
[]

With O
regard O
to O
the O
patients O
' O
overall O
assessment O
there O
was O
a O
clearly O
demonstrable O
positive O
effect O
of O
treatment O
in O
both O
groups O
. O
[]

The O
mean O
maximum O
tendon B-outcome ['Life-Impact']
thickness I-outcome ['Life-Impact']
was O
9.2 O
mm O
in O
the O
symptomatic O
group O
and O
6.8 O
mm O
in O
the O
asymptomatic O
group O
( O
p O
< O
0.001 O
) O
. O
['Life-Impact']

The O
concentration O
of O
prothrombin B-outcome ['Physiological-Clinical']
fragment I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
was O
reduced O
25 O
% O
( O
P O
< O
0.05 O
) O
after O
whale O
oil O
supplementation O
. O
['Physiological-Clinical']

Neither O
short-term O
clinical B-outcome ['Physiological-Clinical']
nor O
microbiological B-outcome ['Physiological-Clinical']
efficacy O
beyond O
that O
of O
a O
course O
of O
mechanical O
debridement O
alone O
was O
found O
by O
using O
systemic O
medication O
with O
doxycycline O
in O
patients O
with O
localized O
juvenile O
periodontitis O
. O
['Physiological-Clinical']

Patients O
were O
randomized O
to O
the O
following O
groups-arm O
A O
: O
40 O
Gy/20 O
fractions/4 O
weeks O
with O
concurrent O
weekly O
vinorelbine O
25 O
mg/m O
+ O
cisplatin O
20 O
mg/m O
or O
arm O
B O
: O
30 O
Gy/15 O
fractions/3 O
weeks O
with O
concurrent O
weekly O
gemcitabine O
200 O
mg. O
Primary O
end O
points O
were O
feasibility B-outcome ['Life-Impact']
, O
response O
rates O
, O
and O
toxicity B-outcome ['Adverse-effects']
. O
['Life-Impact', 'Adverse-effects']

The O
same O
AEs B-outcome ['Adverse-effects']
tended O
to O
recur O
through O
6 O
months O
of O
treatment O
, O
although O
often O
at O
reduced O
levels O
. O
['Adverse-effects']

41 O
outpatients O
who O
were O
long-term O
consumers O
of O
diazepam O
in O
therapeutic O
dosage O
were O
gradually O
withdrawn O
from O
the O
drug O
over O
3 O
months O
by O
stepwise O
reduction O
. O
[]

There O
are O
multiple O
design O
possibilities O
for O
VPs O
, O
however O
there O
is O
little O
formal O
evidence O
to O
support O
individual O
design O
features O
. O
[]

The O
mean O
follow-up O
was O
20.1 O
months O
. O
[]

Other O
measured O
variables O
included O
postoperative O
vomiting O
, O
additional O
analgesia O
requirement O
, O
and O
length O
of O
time O
spent O
in O
the O
recovery O
room O
. O
[]

Other O
associated O
symptom O
domains O
are O
also O
affected O
including O
impulsivity/aggression O
, O
self-injury O
, O
anxiety O
, O
and O
mood O
lability O
. O
[]

BACKGROUND O
Atrial O
fibrillation O
( O
AF O
) O
is O
a O
common O
complication O
reported O
in O
20 O
% O
to O
40 O
% O
of O
patients O
after O
coronary O
operations O
. O
[]

Five-year O
outcome O
of O
surgical O
treatment O
of O
migraine B-outcome ['Physiological-Clinical']
headaches I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

INTERVENTION O
After O
warfarin O
therapy O
was O
discontinued O
, O
participants O
were O
randomly O
assigned O
to O
either O
3 O
daily O
doses O
of O
tinzaparin O
( O
175 O
IU/kg O
) O
or O
dalteparin O
( O
200 O
IU/kg O
) O
, O
with O
2 O
intervening O
HD O
treatments O
between O
the O
first O
dose O
of O
study O
drug O
and O
their O
procedure O
. O
[]

On O
study O
days O
, O
at O
the O
beginning O
of O
the O
study O
and O
after O
2 O
and O
4 O
weeks O
, O
treatments O
were O
given O
in O
the O
office O
or O
laboratory O
and O
patients O
were O
monitored O
with O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
tests O
for O
eight O
hours O
. O
['Physiological-Clinical']

The O
effect O
of O
pravastatin O
was O
not O
limited O
by O
concurrent O
medication O
with O
captopril O
or O
atenolol O
. O
[]

CONCLUSIONS O
This O
study O
shows O
that O
ketorolac O
30 O
mg O
suppositories O
are O
effective O
in O
clinical O
conditions O
, O
such O
as O
after O
surgery O
, O
in O
which O
pain O
control O
must O
be O
achieved O
within O
the O
shortest O
time O
interval O
and O
maintained O
or O
improved O
by O
means O
of O
a O
single O
route O
of O
administration O
. O
[]

Additional O
stenting O
does O
not O
improve O
the O
long O
term O
outcome O
. O
[]

Few O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
noted O
. O
['Adverse-effects']

PURPOSE O
To O
evaluate O
the O
suppressive O
effect O
of O
intravenous O
dezocine O
on O
fentanyl-induced O
cough B-outcome ['Physiological-Clinical']
during O
the O
induction O
of O
general O
anesthesia O
. O
['Physiological-Clinical']

Thus O
, O
compared O
with O
tPA O
, O
primary O
PTCA O
in O
patients O
with O
anterior O
wall O
AMI O
results O
in O
significantly O
improved O
survival B-outcome ['Mortality']
, O
with O
lower O
rates O
of O
stroke B-outcome ['Physiological-Clinical']
, O
reinfarction B-outcome ['Physiological-Clinical']
, O
and O
recurrent B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
duration O
of O
this O
study O
was O
1 O
year O
. O
[]

RESULTS O
A O
statistically O
significant O
increase O
in O
knowledge B-outcome ['Life-Impact']
was O
found O
in O
all O
of O
the O
three O
investigated O
groups O
compared O
to O
the O
control O
group O
. O
['Life-Impact']

METHODS O
In O
this O
prospective O
, O
double-blind O
study O
, O
31 O
patients O
receiving O
pelvic O
radiotherapy O
were O
randomized O
to O
receive O
two O
sulfasalazine O
500-mg O
tablets O
twice O
daily O
or O
placebo O
, O
administered O
orally O
from O
the O
first O
day O
of O
irradiation O
. O
[]

CONCLUSION O
Pruritus B-outcome ['Physiological-Clinical']
caused O
by O
epidural O
use O
of O
2 O
or O
4 O
mg O
of O
morphine O
is O
inhibited O
by O
the O
intravenous O
use O
of O
2.5 O
mg O
droperidol O
but O
not O
by O
a O
larger O
dose O
. O
['Physiological-Clinical']

However O
, O
a O
significant O
interaction O
( O
P O
< O
0.001 O
) O
was O
found O
between O
the O
treatment O
and O
the O
number O
of O
invaded B-outcome ['Physiological-Clinical']
lymph I-outcome ['Physiological-Clinical']
nodes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Effects O
of O
coronary O
sinus O
occlusion O
on O
myocardial O
ischaemia O
in O
humans O
: O
role O
of O
coronary O
collateral O
function O
. O
[]

No O
statistically O
significant O
treatment O
effects O
were O
observed O
at O
1 O
and O
2 O
h O
after O
dosing O
, O
even O
after O
stratifying O
by O
baseline O
headache O
intensity O
. O
[]

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
significantly O
increased O
in O
the O
morning O
after O
a O
sleep-insufficient O
night O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Patients O
experiencing O
PDT O
with O
the O
Ciaglia O
PDT O
kit O
had O
a O
lower O
surgical B-outcome ['Adverse-effects']
complication I-outcome ['Adverse-effects']
rate I-outcome ['Adverse-effects']
( O
2 O
% O
vs. O
25 O
% O
) O
, O
less O
operative O
and O
postoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
and O
less O
overall B-outcome ['Life-Impact']
technical I-outcome ['Life-Impact']
difficulties I-outcome ['Life-Impact']
than O
did O
patients O
undergoing O
PDT O
with O
the O
Griggs O
PDT O
kit O
. O
['Adverse-effects', 'Physiological-Clinical', 'Life-Impact']

METHODS O
In O
all O
, O
360 O
diabetic O
patients O
with O
coronary O
artery O
disease O
were O
treated O
with O
pioglitazone O
or O
glimepiride O
for O
18 O
months O
in O
the O
PERISCOPE O
( O
Pioglitazone O
Effect O
on O
Regression O
of O
Intravascular O
Sonographic O
Coronary O
Obstruction O
Prospective O
Evaluation O
) O
study O
. O
[]

RESULTS O
The O
time O
taken O
for O
patients O
to O
achieve O
a O
degree O
of O
sedation B-outcome ['Physiological-Clinical']
that O
they O
thought O
was O
sufficient O
to O
tolerate O
the O
surgery O
was O
significantly O
longer O
when O
the O
increment O
interval O
was O
3 O
minutes O
( O
t O
= O
-4.8 O
; O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

Glibenclamide O
vs O
gliclazide O
in O
reducing O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
in O
patients O
of O
noninsulin O
dependent O
diabetes O
mellitus O
-- O
a O
double O
blind O
randomized O
study O
. O
['Physiological-Clinical']

Subjects O
received O
montelukast O
10 O
mg O
daily O
or O
placebo O
for O
2 O
weeks O
each O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Eleven O
of O
60 O
( O
18.3 O
% O
) O
patients O
in O
the O
prophylactic O
epidural O
blood O
patch O
group O
developed O
a O
post-dural B-outcome ['Physiological-Clinical']
puncture I-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
compared O
with O
39 O
of O
49 O
( O
79.6 O
% O
) O
in O
the O
therapeutic O
epidural O
blood O
patch O
group O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

We O
used O
the O
questionnaire O
( O
QLQ-C30 O
) O
developed O
by O
the O
European O
Organization O
of O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Study O
Group O
on O
Quality O
of O
Life O
. O
[]

After O
6 O
months O
, O
the O
HOA B-outcome ['Physiological-Clinical']
root I-outcome ['Physiological-Clinical']
mean O
square O
( O
RMS B-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
increased O
on O
average O
by O
a O
factor O
of O
1.44 O
for O
the O
Planoscan O
group O
( O
P O
= O
0.003 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Transfusion B-outcome ['Resource-use']
rate O
was O
higher O
( O
39 O
% O
versus O
8 O
% O
, O
p O
= O
0.0001 O
) O
and O
need O
for O
emergency O
coronary O
bypass O
surgery O
was O
greater O
( O
10.3 O
% O
versus O
1.6 O
% O
, O
p O
= O
0.03 O
) O
for O
the O
streptokinase-treated O
patients O
. O
['Resource-use']

Well O
, O
appropriate-for-gestational O
age O
, O
low-birth-weight O
infants O
were O
divided O
into O
three O
gestational O
age O
groups O
and O
assigned O
randomly O
within O
each O
age O
group O
to O
one O
of O
five O
feeding O
regimens O
: O
pooled O
human O
milk O
( O
BM O
) O
; O
formula O
1 O
( O
F1 O
) O
= O
1.5 O
gm/dl O
protein O
, O
60 O
parts O
bovine O
whey O
proteins O
: O
40 O
parts O
bovine O
caseins O
; O
F2 O
= O
3.0 O
gm/dl O
, O
60:40 O
; O
F3 O
= O
1.5 O
gm/dl O
, O
18:82 O
; O
F4 O
= O
3.0 O
gm/dl O
, O
18:82 O
. O
[]

BACKGROUND O
Because O
of O
the O
inaccessibility O
of O
mediastinal O
nodal O
metastases O
, O
the O
left O
thoracoabdominal O
approach O
( O
LTA O
) O
has O
often O
been O
used O
to O
treat O
gastric O
cancer O
of O
the O
cardia O
or O
subcardia O
. O
[]

A O
randomized O
study O
of O
fetal O
abdominal O
diameter O
and O
fetal O
weight O
estimation O
for O
detection O
of O
light-for-gestation O
infants O
in O
low-risk O
pregnancies O
. O
[]

We O
have O
previously O
shown O
that O
heparin O
attenuates O
the O
methacholine-induced O
bronchoconstriction O
in O
humans O
. O
[]

The O
predominant O
mechanism O
( O
s O
) O
accounting O
for O
the O
activity O
of O
SJW O
in O
vivo O
are O
, O
however O
, O
unclear O
. O
[]

CONCLUSIONS O
Obese O
patients O
with O
chronic O
osteoarthritis O
treated O
with O
a O
mixed O
diet O
supplemented O
with O
a O
commercial O
hypocaloric O
formula O
improved O
weight O
, O
fat B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
and O
HOMA B-outcome ['Physiological-Clinical']
in O
a O
better O
way O
than O
patients O
treated O
with O
a O
dietary O
counselling O
alone O
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
was O
shown O
that O
the O
imparting B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
is O
significantly O
improved O
when O
this O
learning O
system O
is O
employed O
. O
['Life-Impact']

Patients O
were O
randomly O
assigned O
to O
receive O
either O
a O
loading O
dose O
of O
intravenous O
aminophylline O
followed O
by O
a O
routine O
infusion O
( O
n O
= O
45 O
) O
or O
an O
equal O
volume O
of O
placebo O
as O
a O
loading O
dose O
and O
infusion O
( O
n O
= O
49 O
) O
. O
[]

RESULTS O
Change O
in O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
could O
be O
calculated O
in O
1,981 O
individuals O
, O
of O
whom O
399 O
individuals O
( O
20.2 O
% O
) O
were O
eligible O
for O
inclusion O
. O
['Physiological-Clinical']

Declining O
resting-state O
inhibition O
was O
associated O
with O
weakened O
event-related O
modulation O
of O
inhibition O
. O
[]

SETTING O
Recruitment O
of O
patients O
from O
hospitals O
, O
primary O
health O
care O
and O
advertisement O
, O
Oslo O
, O
Norway O
. O
[]

The O
substantial O
variations O
in O
the O
management O
of O
post-CABG O
AF O
across O
sites O
are O
likely O
because O
of O
definitive O
data O
on O
the O
most O
effective O
therapies O
, O
highlighting O
the O
need O
for O
clinical O
trials O
on O
rate O
versus O
rhythm O
control O
and O
on O
anticoagulation O
for O
AF O
in O
this O
setting O
. O
[]

SESSION O
C O
An O
acupuncture O
needle O
( O
Hwato O
, O
& O
emptyv O
; O
0.30x30 O
mm O
) O
was O
inserted O
perpendicular O
superficially O
into O
the O
skin O
overlying O
the O
Hegu O
point O
on O
the O
left O
hand O
. O
[]

The O
two O
patient O
groups O
were O
strictly O
comparable O
on O
D0 O
. O
[]

RESULTS O
Eighty-nine O
of O
100 O
patients O
in O
the O
treatment O
group O
underwent O
surgery O
, O
and O
79 O
were O
followed O
for O
5 O
years O
. O
[]

Systemic O
exposure O
to O
sirolimus O
was O
low O
, O
with O
blood O
concentrations O
below O
levels O
necessary O
for O
systemic O
immunosuppression O
. O
[]

The O
median O
follow-up O
was O
4.4 O
years O
. O
[]

These O
results O
provide O
early O
evidence O
of O
the O
effectiveness O
of O
online O
CME O
programs O
to O
improve O
physician B-outcome ['Life-Impact']
clinical I-outcome ['Life-Impact']
practice I-outcome ['Life-Impact']
. O
['Life-Impact']

In O
the O
second O
study O
473 O
patients O
with O
suspected O
acute O
myocardial O
infarction O
were O
randomly O
allocated O
to O
treatment O
with O
oxprenolol O
, O
disopyramide O
phosphate O
, O
or O
placebo O
. O
[]

Fluoroscopy O
is O
a O
reliable O
, O
easy O
, O
and O
readily O
available O
technique O
to O
follow-up O
prosthesis O
functioning O
after O
heart O
valve O
surgery O
. O
[]

We O
conclude O
that O
, O
whilst O
it O
may O
be O
possible O
to O
obtain O
reasonable O
point O
estimates O
of O
total O
hip B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
from O
other O
measures O
in O
the O
hip O
, O
these O
estimates O
are O
too O
imprecise O
to O
allow O
conclusions O
about O
['Physiological-Clinical']

METHOD O
Thirty-three O
mentally O
retarded O
adults O
with O
autism O
and/or O
SIB O
participated O
in O
double-blind O
, O
placebo-controlled O
crossover O
studies O
. O
[]

In O
summary O
, O
higher O
CD19+ B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
levels O
are O
a O
favorable O
prognostic O
sign O
with O
no O
apparent O
relationship O
to O
circulating O
tumor O
cells O
. O
['Physiological-Clinical']

Control O
subjects O
received O
day O
care O
alone O
. O
[]

During O
the O
first O
48 O
hours O
after O
operation O
the O
degree O
of O
pain B-outcome ['Physiological-Clinical']
was O
almost O
identical O
between O
the O
groups O
. O
['Physiological-Clinical']

At O
6 O
weeks O
the O
quality O
of O
life O
was O
better O
in O
patients O
who O
had O
laparoscopic O
lymphadenectomy O
( O
SF-12 O
) O
. O
[]

RESULTS O
The O
12-hour O
postoperative O
levels O
of O
serum O
hemoglobin O
were O
not O
significantly O
different O
in O
the O
centrifugation O
group O
as O
compared O
to O
the O
multiple-pass O
hemoconcentration O
group O
. O
[]

The O
probes O
consisted O
of O
auditory O
and O
visual O
stimuli O
, O
such O
as O
a O
loud O
spider O
crawling O
or O
a O
musical O
ball O
bouncing O
. O
[]

We O
performed O
a O
randomized O
, O
controlled O
study O
comparing O
the O
prophylactic O
effects O
of O
capsule O
forms O
of O
fluconazole O
( O
n O
= O
110 O
) O
and O
itraconazole O
( O
n O
= O
108 O
) O
in O
patients O
with O
acute O
myeloid O
leukemia O
( O
AML O
) O
or O
myelodysplastic O
syndromes O
( O
MDS O
) O
during O
and O
after O
chemotherapy O
. O
[]

A O
significant O
mean O
increase O
of O
1.3 O
cm O
in O
linear B-outcome ['Physiological-Clinical']
height I-outcome ['Physiological-Clinical']
was O
recorded O
, O
whereas O
body O
mass O
index O
remained O
unchanged O
. O
['Physiological-Clinical']

Patients O
and O
therapists O
were O
blinded O
to O
the O
type O
of O
TBS O
. O
[]

RESULTS O
Fifty-two O
patients O
were O
treated O
with O
cyclosporin O
and O
27 O
treated O
with O
tacrolimus O
. O
[]

People O
without O
and O
with O
diabetes O
who O
are O
at O
high O
risk O
for O
cardiovascular B-outcome ['Physiological-Clinical']
disease B-outcome ['Physiological-Clinical']
are O
also O
at O
risk O
for O
a O
progressive O
rise O
in O
albuminuria B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Immediately O
before O
first O
hemi-body O
irradiation O
, O
59 O
patients O
with O
relapsed O
multiple O
myeloma O
were O
randomised O
to O
receive O
or O
not O
to O
receive O
subsequent O
alpha-2b O
interferon O
maintenance O
. O
[]

Although O
no O
significant O
differences O
were O
found O
in O
the O
incidence O
of O
de O
novo B-outcome ['Physiological-Clinical']
adnexal I-outcome ['Physiological-Clinical']
adhesions I-outcome ['Physiological-Clinical']
, O
the O
lowest O
rate O
was O
found O
in O
the O
fibrin O
gel O
group O
, O
with O
4/32 O
patients O
( O
12.5 O
% O
) O
in O
the O
control O
group O
, O
2/29 O
patients O
( O
6.8 O
% O
) O
in O
the O
fibrin O
gel O
group O
and O
5/30 O
patients O
( O
16.7 O
% O
) O
in O
the O
fibrin O
sheet O
group O
. O
['Physiological-Clinical']

Parents O
learned B-outcome ['Life-Impact']
to O
use O
the O
intervention O
strategies O
and O
their O
children O
exhibited O
increases O
in O
spontaneous B-outcome ['Life-Impact']
imitation I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
?TBS O
values O
of O
Groups O
1 O
and O
4 O
were O
similar O
and O
higher O
than O
those O
of O
Group O
2 O
. O
[]

Estimated O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
increased O
similarly O
in O
both O
groups O
at O
12 O
months O
. O
['Physiological-Clinical']

VM B-outcome ['Physiological-Clinical']
and O
SOL B-outcome ['Physiological-Clinical']
H-reflexes B-outcome ['Physiological-Clinical']
were O
subsequently O
conducted O
on O
the O
involved O
lower O
extremity O
at O
1 O
and O
3 O
months O
post O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
prognostic O
value O
of O
testicular O
biopsy O
in O
childhood O
acute O
lymphoblastic O
leukemia O
: O
a O
report O
from O
the O
Childrens O
Cancer O
Study O
Group O
. O
[]

Endpoints O
were O
8 O
weeks O
( O
completion O
data O
) O
, O
3 O
or O
more O
catheter O
changes O
in O
the O
8-week O
period O
, O
or O
symptomatic B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
UTI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
requiring O
antibiotics O
. O
['Physiological-Clinical']

Recovery B-outcome ['Life-Impact']
was O
assessed O
by O
a O
research O
nurse O
blinded O
to O
the O
agent O
used O
. O
['Life-Impact']

Both O
groups O
showed O
significant O
improvement O
( O
P O
less O
than O
0.05 O
) O
in O
both O
frequency O
and O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Improvement O
from O
baseline O
to O
week O
18 O
in O
6MWD O
occurred O
with O
sitaxsentan O
100 O
but O
not O
50 O
mg O
; O
a O
strong O
placebo O
effect O
was O
observed O
. O
[]

The O
increased O
cost O
of O
care O
on O
the O
nursing-led O
inpatient O
unit O
was O
not O
a O
major O
factor O
in O
local O
management O
decisions O
about O
the O
future O
of O
the O
unit O
. O
[]

Twenty O
subjects O
, O
who O
have O
TMJ O
pain O
, O
were O
included O
for O
this O
study O
and O
randomly O
assigned O
to O
either O
the O
experimental O
group O
( O
n O
= O
10 O
) O
or O
the O
control O
group O
( O
n O
= O
10 O
) O
. O
[]

The O
patients O
in O
the O
two O
groups O
were O
treated O
with O
routine O
behavior O
, O
with O
EA O
at O
Baihui O
( O
GV O
20 O
) O
, O
Sishencong O
( O
EX-HN O
1 O
) O
, O
Shenting O
( O
GV O
24 O
) O
, O
Benshen O
( O
GB O
13 O
) O
, O
Yintang O
( O
EX-HN O
3 O
) O
, O
Naohu O
( O
GV O
17 O
) O
, O
Naokong O
( O
GB O
19 O
) O
, O
Neiguan O
( O
PC O
6 O
) O
and O
scalp O
acupuncture O
at O
Speech O
Areas O
I O
, O
II O
, O
III O
added O
for O
the O
EA O
plus O
behavior O
therapy O
group O
. O
[]

Microfilarial B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
had O
decreased O
1 O
year O
after O
treatment O
in O
all O
14 O
communities O
; O
this O
decrease O
was O
significantly O
higher O
in O
communities O
given O
combined O
therapy O
than O
in O
those O
given O
diethylcarbamazine O
alone O
( O
mean O
decreases O
57.5 O
% O
and O
30.6 O
% O
, O
respectively O
; O
p O
= O
0.0013 O
) O
. O
['Physiological-Clinical']

These O
children O
were O
randomly O
divided O
into O
two O
groups O
: O
Six O
were O
receiving O
both O
direct O
and O
indirect O
intervention O
( O
TG O
) O
, O
and O
five O
were O
receiving O
indirect O
intervention O
exclusively O
( O
OG O
) O
. O
[]

Patients O
with O
postoperative O
sepsis O
were O
hospitalized B-outcome ['Resource-use']
significantly O
longer O
than O
were O
patients O
without O
infection O
( O
13.8 O
vs. O
7.7 O
days O
, O
P O
less O
than O
0.0001 O
) O
. O
['Resource-use']

Physical O
activity O
for O
patients O
undergoing O
an O
allogeneic O
hematopoietic O
stem O
cell O
transplantation O
: O
benefits O
of O
a O
moderate O
exercise O
intervention O
. O
[]

PURPOSE O
To O
evaluate O
the O
efficacy O
of O
an O
antiherpetic O
vaccine O
in O
recurrent O
herpetic O
ocular O
infections O
. O
[]

RESULTS O
There O
were O
significant O
negative O
correlations O
between O
serum B-outcome ['Physiological-Clinical']
adiponectin I-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
percentage I-outcome ['Physiological-Clinical']
, O
waist-to-hip B-outcome ['Physiological-Clinical']
ratio O
, O
body B-outcome ['Physiological-Clinical']
mass O
index O
and O
the O
insulin B-outcome ['Resource-use']
resistance B-outcome ['Physiological-Clinical']
index O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

BACKGROUND O
AND O
PURPOSE O
Clinical O
observations O
suggest O
that O
patients O
with O
vascular O
dementia O
( O
VaD O
) O
may O
benefit O
from O
treatment O
with O
cholinesterase O
inhibitors O
. O
[]

CONCLUSIONS O
In O
stratum O
1 O
, O
the O
improved O
PFS O
with O
gefitinib O
plus O
tamoxifen O
met O
the O
protocol O
criteria O
to O
warrant O
further O
investigation O
of O
this O
strategy O
. O
[]

EEG O
showed O
long O
sequences O
of O
generalised O
irregular O
spike O
and O
slow O
waves O
. O
[]

CONCLUSIONS O
The O
results O
revealed O
that O
the O
efficacy O
and O
side O
effects O
of O
mitoxantrone O
were O
similar O
to O
those O
of O
doxorubicin O
. O
[]

CONCLUSIONS O
Intravenous O
histamine O
in O
the O
selected O
doses O
increased O
choroidal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
ApoA-I O
Synthesis O
Stimulation O
and O
Intravascular O
Ultrasound O
for O
Coronary O
Atheroma O
Regression O
Evaluation O
( O
ASSURE O
, O
NCT01067820 O
) O
study O
aims O
to O
evaluate O
the O
effect O
of O
RVX-208 O
on O
plaque O
burden O
. O
[]

Group O
C O
was O
treated O
with O
only O
rFSH O
. O
[]

A O
randomized O
, O
triple O
crossover O
study O
was O
carried O
out O
in O
24 O
elderly O
patients O
requiring O
chronic O
diuretic O
therapy O
to O
assess O
the O
different O
hypotensive O
effects O
of O
a O
fixed O
daily O
dose O
of O
5 O
mg O
bendrofluazide O
, O
1 O
mg O
bumetanide O
and O
40 O
mg O
xipamide O
. O
[]

Based O
on O
these O
findings O
, O
the O
use O
of O
VRE O
in O
the O
treatment O
of O
FOF O
was O
supported O
in O
this O
controlled O
study O
, O
suggesting O
that O
experiences O
in O
the O
virtual O
world O
can O
change O
experiences O
in O
the O
real O
world O
. O
[]

They O
were O
followed O
for O
6 O
months O
after O
allocation O
to O
either O
a O
control O
group O
or O
an O
added O
treatment O
group O
( O
doxazosin O
1-4 O
mg O
and O
atenolol O
when O
needed O
) O
. O
[]

CONCLUSIONS O
Administration O
of O
low-dose O
clonidine O
in O
patients O
undergoing O
noncardiac O
surgery O
did O
not O
reduce O
the O
rate O
of O
the O
composite O
outcome O
of O
death B-outcome ['Mortality']
or O
nonfatal B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
; O
it O
did O
, O
however O
, O
increase O
the O
risk O
of O
clinically B-outcome ['Physiological-Clinical']
important I-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
and O
nonfatal B-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
arrest I-outcome ['Physiological-Clinical']
. O
( O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
sCD44v6 B-outcome ['Physiological-Clinical']
was O
significantly O
positive O
correlated O
with O
the O
degree O
of O
cancer B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
differentiation I-outcome ['Physiological-Clinical']
, O
infiltration B-outcome ['Physiological-Clinical']
and O
lymph B-outcome ['Physiological-Clinical']
node I-outcome ['Physiological-Clinical']
metastasis I-outcome ['Physiological-Clinical']
; O
( O
2 O
) O
Level O
of O
sCD44v6 B-outcome ['Physiological-Clinical']
was O
the O
highest O
in O
patients O
of O
blood O
stasis O
type O
, O
as O
compared O
with O
that O
in O
the O
patients O
of O
Pi-deficiency O
type O
or O
of O
damp-heat O
type O
, O
the O
difference O
was O
significant O
; O
( O
3 O
) O
After O
ending O
treatment O
, O
level O
of O
sCD44v6 B-outcome ['Physiological-Clinical']
in O
the O
trial O
group O
was O
significantly O
lower O
than O
that O
in O
the O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Consumption O
of O
industrial O
trans O
fatty O
acids O
( O
iTFA O
) O
increases O
LDL O
cholesterol O
, O
decreases O
HDL O
cholesterol O
, O
and O
is O
strongly O
associated O
with O
a O
higher O
risk O
of O
cardiovascular O
disease O
( O
CVD O
) O
. O
[]

INTRODUCTION O
The O
question O
of O
whether O
abstinence O
during O
the O
months O
following O
a O
planned O
quit O
attempt O
exacerbates O
or O
improves O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
is O
an O
important O
clinical O
issue O
. O
['Life-Impact']

This O
study O
examined O
the O
effects O
of O
3 O
wk O
of O
either O
endurance O
or O
strength O
training O
on O
plasticity O
of O
the O
neural O
mechanisms O
involved O
in O
the O
soleus O
H O
reflex O
and O
V O
wave O
. O
[]

There O
was O
no O
statistical O
difference O
in O
outcome O
within O
the O
5-fluorouracil O
and O
laser O
only O
arms O
. O
[]

There O
were O
no O
statistically O
significant O
differences O
in O
death B-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
and O
stent B-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
according O
to O
the O
Academic O
Research O
Consortium O
criteria O
between O
the O
2 O
groups O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
One O
hundred-fifty O
dental O
patients O
were O
asked O
about O
the O
most O
appreciated O
information O
received O
in O
the O
preoperative O
visit O
on O
the O
anxiolytic O
technique O
, O
local O
anesthesia O
and O
treatment O
of O
the O
perioperative O
pain O
. O
[]

This O
subset O
appeared O
to O
have O
a O
larger O
area O
of O
viable B-outcome ['Physiological-Clinical']
but O
['Physiological-Clinical']

Prevention O
of O
venous O
thromboembolism O
after O
knee O
arthroplasty O
. O
[]

No O
adverse B-outcome ['Adverse-effects']
experiences I-outcome ['Adverse-effects']
were O
reported O
. O
['Adverse-effects']

On O
the O
basis O
of O
patient O
reports O
of O
comfort B-outcome ['Life-Impact']
and O
['Life-Impact']

Efficacy O
of O
treatment O
on O
clinical O
condition O
and O
some O
immune B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
( O
IgA B-outcome ['Physiological-Clinical']
, O
IgG B-outcome ['Physiological-Clinical']
, O
CD3 B-outcome ['Physiological-Clinical']
, O
CD4 B-outcome ['Physiological-Clinical']
) O
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Alternatively O
, O
the O
distinctiveness O
heuristic O
assumes O
that O
critical B-outcome ['Physiological-Clinical']
lures I-outcome ['Physiological-Clinical']
are O
actively O
withheld O
by O
the O
use O
of O
a O
retrieval O
strategy O
. O
['Physiological-Clinical']

Of O
7030 O
patients O
enrolled O
at O
these O
centers O
, O
916 O
were O
deceased O
at O
the O
beginning O
of O
the O
extension O
, O
1382 O
refused O
participation O
, O
3994 O
continued O
to O
take O
the O
study O
intervention O
, O
and O
738 O
agreed O
to O
passive O
follow-up O
. O
[]

Six O
families O
saw O
no O
difference O
after O
either O
infusion O
, O
and O
offered O
no O
guess O
. O
[]

Vecuronium O
permitted O
the O
most O
stable O
overall O
haemodynamic B-outcome ['Physiological-Clinical']
course O
at O
all O
measurement O
times O
. O
['Physiological-Clinical']

These O
studies O
will O
provide O
early O
evaluation O
of O
the O
effects O
of O
RVX-208 O
on O
lipids O
and O
atherosclerotic O
plaque O
. O
[]

Similarly O
, O
right B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
improved O
in O
40.9 O
% O
, O
deteriorated O
in O
25.0 O
% O
, O
and O
remained O
stable O
in O
34.1 O
% O
. O
['Physiological-Clinical']

Delayed B-outcome ['Physiological-Clinical']
alloimmunization I-outcome ['Physiological-Clinical']
using O
random O
single O
donor O
platelet O
transfusions O
: O
a O
prospective O
study O
in O
thrombocytopenic O
patients O
with O
acute O
leukemia O
. O
['Physiological-Clinical']

A O
loading O
dose O
and O
short-term O
administration O
of O
oral O
ribavirin O
significantly O
improved O
symptoms B-outcome ['Life-Impact']
and O
signs B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
influenza I-outcome ['Physiological-Clinical']
type O
A O
or O
B B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
in O
25 O
patients O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

AIM O
To O
determine O
whether O
telephone O
appointments O
offered O
bygeneral O
practice O
receptionists O
increase O
the O
uptake O
of O
irfluenza B-outcome ['Resource-use']
immunisation I-outcome ['Resource-use']
among O
the O
registered O
population O
aged O
over O
65 O
years O
in O
east O
London O
practices O
. O
['Resource-use']

Salmeterol O
plus O
fluticasone O
propionate O
versus O
fluticasone O
propionate O
plus O
montelukast O
: O
a O
randomised O
controlled O
trial O
investigating O
the O
effects O
on O
airway B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
in O
asthma O
. O
['Physiological-Clinical']

Minocycline O
is O
an O
antibiotic O
with O
anti-inflammatory O
and O
antiapoptotic O
properties O
that O
prolongs O
survival O
in O
a O
transgenic O
Huntington O
disease O
( O
HD O
) O
mouse O
model O
. O
[]

Funded O
by O
Vertex O
Pharmaceuticals O
and O
others O
; O
ClinicalTrials.gov O
number O
, O
NCT00457821 O
. O
) O
. O
[]

GH O
replacement O
therapy O
stimulates O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
in O
patients O
with O
GHD O
and O
in O
the O
long O
term O
such O
stimulation O
results O
in O
an O
increased O
BMD B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Omeprazole O
ameliorates O
aspirin-induced O
gastroduodenal O
injury O
. O
[]

Of O
the O
86 O
patients O
, O
62 O
finished O
the O
study O
without O
a O
change O
of O
dosage O
and O
their O
data O
were O
analyzed O
( O
group O
A O
, O
N=16 O
; O
group O
B O
, O
N=26 O
; O
group O
C O
, O
N=20 O
) O
. O
[]

Neonatal O
effects O
include O
respiratory O
depression O
and O
impaired O
feeding O
. O
[]

Conscious O
analgesia/sedation O
with O
remifentanil O
and O
propofol O
versus O
total O
intravenous O
anesthesia O
with O
fentanyl O
, O
midazolam O
, O
and O
propofol O
for O
outpatient O
colonoscopy O
. O
[]

Our O
aim O
with O
this O
pilot O
study O
was O
to O
evaluate O
if O
fiber O
supplementation O
is O
beneficial O
for O
the O
treatment O
of O
children O
with O
idiopathic B-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
constipation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
were O
no O
respiratory B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
, O
bradycardia B-outcome ['Physiological-Clinical']
, O
hypotension B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
and O
vomiting B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
whether O
a O
specific O
program O
of O
moderate-intensity O
step O
aerobics O
training O
may O
be O
sufficient O
to O
improve O
the O
exercise O
tolerance O
of O
patients O
with O
severe O
chronic O
heart O
failure O
. O
[]

Although O
this O
procedure O
provides O
long-term O
survival O
in O
a O
significant O
number O
of O
patients O
, O
50-75 O
% O
of O
the O
patients O
develop O
intra- O
and/or O
extrahepatic O
recurrence O
. O
[]

MATERIALS O
AND O
METHODS O
Twenty-four O
subjects O
, O
each O
requiring O
a O
nonmolar O
extraction O
and O
delayed O
implant O
placement O
, O
were O
randomly O
selected O
to O
receive O
ridge O
preservation O
treatment O
with O
either O
an O
allograft O
in O
an O
experimental O
putty O
carrier O
plus O
a O
calcium O
sulfate O
barrier O
( O
PUT O
) O
or O
a O
bovine-derived O
xenograft O
( O
BDX O
) O
plus O
a O
collagen O
membrane O
. O
[]

Twenty-three O
women O
who O
were O
exclusively O
breast-feeding O
their O
infants O
were O
randomly O
assigned O
to O
serially O
use O
several O
pumping O
methods O
, O
as O
well O
as O
infant O
suckling O
, O
with O
blood O
being O
taken O
at O
10-minute O
intervals O
to O
determine O
the O
hormonal O
responses O
. O
[]

Loss O
of O
autonomy O
among O
elderly O
patients O
after O
a O
stay O
in O
a O
medical O
intensive O
care O
unit O
( O
ICU O
) O
: O
a O
randomized O
study O
of O
the O
benefit O
of O
transfer O
to O
a O
geriatric O
ward O
. O
[]

Controlling O
for O
treatment O
arm O
, O
age O
, O
sex O
, O
presence O
of O
cirrhosis O
or O
hepatitis O
C O
virus O
viral O
load O
before O
treatment O
did O
not O
change O
these O
results O
. O
[]

Resource O
use O
of O
hematopoietic O
stem-cell O
transplant O
recipients O
during O
the O
first O
6 O
months O
posttransplant O
, O
both O
inpatient O
and O
ambulatory O
costs O
, O
in O
85 O
patients O
from O
five O
centers O
were O
collected O
prospectively O
and O
costed O
. O
[]

Those O
two O
groups O
meet O
the O
characteristics O
of O
childhood O
onset O
myoclonic-astatic O
epilepsy O
( O
MAE O
) O
with O
respectively O
, O
favourable O
and O
unfavourable O
outcome O
. O
( O
[]

The O
bootstrapped O
difference O
in O
QALYs O
was O
not O
statistically O
significant O
( O
0.06 O
; O
95 O
% O
UI O
: O
-0.024 O
to O
0.14 O
) O
. O
[]

OBJECTIVES O
In O
the O
present O
study O
the O
diet O
and O
the O
nutritional O
status O
of O
pregnant O
Pakistani O
immigrant O
women O
have O
been O
compared O
with O
a O
group O
of O
Norwegian O
women O
. O
[]

In O
a O
tamoxifen O
randomised O
patient O
material O
, O
absent O
YAP1 O
protein O
expression O
was O
associated O
with O
impaired O
tamoxifen O
response O
which O
was O
significant O
upon O
interaction O
analysis O
( O
p O
= O
0.042 O
) O
. O
[]

The O
evaluation O
using O
USHPS O
criteria O
revealed O
a O
significant O
decrease O
of O
alfa O
ratings O
over O
time O
with O
respect O
to O
criteria O
marginal B-outcome ['Physiological-Clinical']
adaptation I-outcome ['Physiological-Clinical']
and O
marginal B-outcome ['Physiological-Clinical']
discoloration I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Of O
note O
, O
when O
compared O
with O
omega-3 O
fatty O
acids O
, O
fenofibrate O
therapy O
decreased O
fasting B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
( O
P=0.023 O
) O
and O
increased O
plasma B-outcome ['Physiological-Clinical']
adiponectin I-outcome ['Physiological-Clinical']
( O
P=0.002 O
) O
and O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
( O
P=0.015 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
determine O
the O
optimal O
dose O
, O
safety O
, O
and O
efficacy O
of O
an O
estrogen O
receptor O
beta O
selective O
Chinese O
herbal O
extract O
, O
menopausal O
formula O
101 O
( O
MF101 O
) O
, O
for O
treating O
hot O
flushes O
. O
[]

Improved O
therapies O
should O
decrease O
failure B-outcome ['Physiological-Clinical']
rates O
in O
the O
short O
term O
, O
but O
their O
effect O
on O
incidence O
of O
subsequent O
episodes O
of O
malaria O
is O
little O
studied O
. O
['Physiological-Clinical']

Randomized O
comparison O
of O
two O
communication O
interventions O
for O
preschoolers O
with O
autism O
spectrum O
disorders O
. O
[]

Transmural B-outcome ['Physiological-Clinical']
dispersion O
of O
repolarisation B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TDR I-outcome ['Physiological-Clinical']
) O
was O
determined O
as O
Tpeak-Tend O
time O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Information O
about O
the O
trial O
will O
be O
provided O
to O
women O
in O
the O
antenatal O
period O
or O
in O
early O
labour O
. O
[]

METHODS O
A O
multicentre O
, O
double-blind O
, O
parallel O
group O
study O
was O
designed O
in O
which O
247 O
patients O
with O
CIU O
were O
randomised O
after O
a O
1-week O
placebo O
run-in O
period O
to O
10 O
mg O
daily O
mizolastine O
( O
n O
= O
88 O
) O
, O
10 O
mg O
daily O
loratadine O
( O
n O
= O
79 O
) O
, O
or O
placebo O
( O
n O
= O
80 O
) O
for O
a O
4-week O
treatment O
period O
. O
[]

Assessment O
of O
airway O
responsiveness O
by O
bronchoprovocation O
and O
bronchodilatation O
tests O
is O
important O
in O
the O
diagnostic O
work-up O
protocol O
of O
bronchial O
asthma O
and O
it O
would O
be O
convenient O
to O
undertake O
both O
tests O
on O
the O
same O
occasion O
. O
[]

BACKGROUND O
Breast O
cancer O
patients O
with O
prior O
response O
to O
endocrine O
therapy O
achieve O
subsequent O
benefit O
from O
additional O
endocrine O
therapies O
. O
[]

Infants O
were O
stratified O
by O
gestational O
age O
( O
< O
29 O
weeks O
or O
29-30 O
weeks O
) O
, O
then O
randomized O
into O
one O
of O
three O
intervention O
groups O
: O
postural O
support O
nappy O
, O
postural O
support O
nappy O
and O
postural O
support O
roll O
, O
or O
disposable O
nappy O
and O
postural O
support O
roll O
. O
[]

BACKGROUND O
L-carnitine O
was O
proposed O
as O
a O
potential O
treatment O
for O
patients O
diagnosed O
with O
an O
autism O
spectrum O
disorder O
to O
improve O
mitochondrial O
dysfunction O
, O
but O
no O
prior O
randomized O
controlled O
trials O
have O
been O
conducted O
. O
[]

CONCLUSION O
Rectal O
distention O
in O
patients O
with O
OAB O
symptoms O
significantly O
lowered O
bladder O
sensation O
volumes O
( O
normal O
desire O
, O
strong O
desire O
, O
and O
maximal O
capacity O
) O
. O
[]

Also O
access B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
was O
comparable O
at O
this O
time O
. O
['Physiological-Clinical']

Parent-child O
pairs O
were O
randomly O
assigned O
to O
either O
the O
RPMT O
group O
or O
a O
control O
group O
. O
[]

Both O
groups O
were O
given O
intravenous O
iron O
gluconate O
( O
125 O
mg O
) O
every O
day O
for O
15 O
days O
. O
[]

Epinephrine O
was O
effective O
for O
controlling O
induced B-outcome ['Physiological-Clinical']
or O
secondary B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
caused O
by O
puncture O
of O
the O
gastric O
varices O
with O
the O
sclerotherapy O
needle O
during O
intravariceal O
injections O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Prospective O
, O
randomised O
, O
blinded O
and O
placebo-controlled O
trial O
. O
[]

Randomized O
trial O
of O
tailored O
skin O
cancer O
prevention O
for O
children O
: O
the O
Project O
SCAPE O
family O
study O
. O
[]

The O
capability O
of O
the O
DSV O
to O
maintain O
the O
IVP B-outcome ['Physiological-Clinical']
within O
physiological O
limits O
after O
shunting O
, O
especially O
in O
the O
upright O
position O
, O
is O
documented O
by O
a O
comparison O
with O
possible B-outcome ['Physiological-Clinical']
unphysiological I-outcome ['Physiological-Clinical']
IVP I-outcome ['Physiological-Clinical']
variations I-outcome ['Physiological-Clinical']
in O
other O
valve O
constructions O
, O
which O
depend O
on O
the O
level O
of O
implantation B-outcome ['Physiological-Clinical']
, O
subcutaneous B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
CSF I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
through I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
valve I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Eberconazole O
1 O
% O
cream O
is O
an O
effective O
treatment O
for O
fungal O
infections O
produced O
by O
dermatophytes O
, O
with O
a O
good O
safety O
and O
tolerability B-outcome ['Life-Impact']
profile O
, O
and O
can O
be O
considered O
a O
good O
alternative O
for O
the O
treatment O
of O
dermatophytoses O
. O
['Life-Impact']

Subjective O
outcome O
variables O
were O
women O
's O
subjective O
assessment O
of O
change O
in O
urinary B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
based O
on O
the O
PRAFAB O
score O
. O
['Physiological-Clinical']

METHODS O
2x2 O
crossover O
randomised O
blinded O
study O
, O
comparing O
the O
effect O
of O
synthetic O
human O
secretin O
2 O
U/kg O
to O
placebo O
( O
saline O
) O
. O
[]

Twice-a-day O
versus O
four-times-a-day O
ofloxacin O
treatment O
of O
external O
ocular O
infection O
. O
[]

METHODS O
In O
this O
prospective O
, O
controlled O
trial O
, O
121 O
gastric O
cancer O
patients O
attending O
inpatient O
rehabilitation O
after O
surgical O
treatment O
received O
either O
the O
interactive O
intervention O
or O
lectures O
providing O
information O
. O
[]

Sensitivity O
analysis O
using O
a O
real-world O
scenario O
showed O
that O
in O
urban O
areas O
the O
average O
costs B-outcome ['Resource-use']
of O
the O
telemedicine O
and O
conventional O
consultations O
were O
about O
equal O
, O
while O
in O
rural O
areas O
the O
average O
cost O
of O
the O
telemedicine O
consultation O
was O
less O
than O
that O
of O
the O
conventional O
consultation O
. O
['Resource-use']

The O
duration O
of O
follow-up O
was O
two O
months O
. O
[]

In O
terms O
of O
therapeutic B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
, O
10 O
patients O
in O
the O
control O
group O
failed O
. O
['Physiological-Clinical']

11.51 O
, O
final O
18.81 O
? O
[]

Adverse O
effects O
spontaneously O
mentioned O
by O
the O
patients O
or O
elicited O
by O
direct O
questioning O
using O
a O
symptom O
check-list O
were O
recorded O
. O
[]

The O
?-blocker O
nebivolol O
possesses O
vasodilating O
, O
endothelium-dependent O
, O
NO-releasing O
properties O
that O
might O
be O
beneficial O
in O
peripheral O
arterial O
disease O
. O
[]

Lanthanum O
carbonate O
( O
Fosrenol O
) O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
in O
the O
treatment O
of O
hyperphosphatemic O
patients O
with O
end-stage O
renal O
disease O
. O
['Life-Impact']

MEASUREMENTS O
Interleukin-6 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IL-6 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
tumor B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor-alpha I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TNF-alpha I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
soluble B-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor-receptor-55 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
sTNF-R55 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
soluble B-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor-receptor-75 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
sTNF-R75 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
at O
enrollment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Randomised O
Phase O
I/II O
trial O
assessing O
the O
safety O
and O
efficacy O
of O
radiolabelled O
anti-carcinoembryonic O
antigen O
I O
( O
131 O
) O
KAb201 O
antibodies O
given O
intra-arterially O
or O
intravenously O
in O
patients O
with O
unresectable O
pancreatic O
adenocarcinoma O
. O
[]

Using O
data O
from O
a O
large O
randomized O
trial O
, O
we O
explored O
the O
prognostic O
value O
of O
clinical O
variables O
, O
measured O
at O
hospital O
admission O
for O
acute O
heart O
failure O
, O
to O
determine O
whether O
a O
few O
selected O
variables O
were O
inferior O
to O
an O
extended O
data O
set O
. O
[]

Secondary O
outcome O
measures O
include O
rhinoconjunctivitis B-outcome ['Physiological-Clinical']
quality O
of O
life O
questionnaire O
['Physiological-Clinical']

0.10 O
vs. O
1.97 O
? O
[]

Performance O
of O
the O
materials O
was O
evaluated O
using O
nine O
criteria O
at O
3 O
, O
6 O
, O
and O
12 O
months O
: O
physical B-outcome ['Life-Impact']
integrity I-outcome ['Life-Impact']
, O
surface O
detail O
, O
adhesion B-outcome ['Physiological-Clinical']
, O
color B-outcome ['Physiological-Clinical']
, O
odor B-outcome ['Physiological-Clinical']
, O
plaque B-outcome ['Physiological-Clinical']
accumulation I-outcome ['Physiological-Clinical']
, O
resilience B-outcome ['Life-Impact']
, O
hygiene B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

In O
mastectomy O
group O
[]

This O
study O
evaluated O
whether O
a O
single O
dose O
of O
intranasal O
oxytocin O
acutely O
improves O
social O
cognitive O
functioning O
in O
schizophrenia O
. O
[]

Using O
a O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
design O
, O
motor O
thresholds O
, O
recruitment O
curves O
, O
cortical O
stimulation-induced O
silent O
period O
( O
CSP O
) O
, O
short O
intracortical O
inhibition O
( O
ICI O
) O
, O
intracortical O
facilitation O
( O
ICF O
) O
, O
and O
late O
inhibition O
( O
L-ICI O
) O
in O
14 O
healthy O
subjects O
were O
investigated O
after O
oral O
doses O
of O
50 O
and O
100 O
mg O
amantadine O
with O
single O
and O
paired O
pulse O
TMS O
paradigms O
. O
[]

To O
evaluate O
earlier O
observations O
, O
including O
our O
own O
, O
showing O
usefulness O
of O
vitamin O
C O
for O
managing O
the O
common O
cold O
, O
we O
performed O
a O
double-blind O
trial O
of O
vitamin O
C O
versus O
placebo O
in O
868 O
children O
. O
[]

This O
paper O
aims O
to O
evaluate O
the O
cost B-outcome ['Resource-use']
, O
from O
the O
UK O
National O
Health O
Service O
perspective O
, O
of O
transfer O
to O
a O
nursing-led O
inpatient O
unit O
for O
intermediate O
care O
and O
to O
discuss O
the O
impact O
of O
these O
findings O
to O
the O
future O
development B-outcome ['Life-Impact']
and O
sustainability B-outcome ['Physiological-Clinical']
of O
the O
nursing-led O
inpatient O
unit O
. O
['Resource-use', 'Life-Impact', 'Physiological-Clinical']

If O
successful O
, O
these O
findings O
could O
be O
implemented O
broadly O
to O
promote O
safe O
and O
appropriate O
medication O
use O
and O
to O
support O
evidence-based O
standards O
in O
the O
development O
of O
labels O
. O
[]

After O
treatment O
, O
MPO B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

CONCLUSIONS O
Alpha O
dihidroergocriptine O
is O
effective O
in O
the O
treatment O
of O
fribrocystic O
breast O
disease O
with O
minimum O
adverse O
events O
when O
compared O
with O
similar O
drugs O
. O
[]

These O
results O
indicate O
that O
there O
is O
a O
significant O
effect O
of O
introducing O
foods O
at O
4 O
mo O
on O
the O
likelihood O
of O
amenorrhea O
at O
6 O
mo O
postpartum O
, O
but O
not O
thereafter O
, O
and O
that O
this O
effect O
is O
not O
seen O
in O
mothers O
who O
maintain O
breast-feeding O
frequency O
. O
[]

Dihydroergocryptine O
in O
the O
management O
of O
senile O
psycho-organic O
syndrome O
. O
[]

These O
were O
evaluated O
by O
parents O
and O
clinicians O
, O
both O
of O
whom O
were O
blinded O
to O
the O
actual O
exposure O
. O
[]

Some O
studies O
have O
reported O
the O
efficacy O
of O
cognitive-behavioral O
therapy O
( O
CBT O
) O
in O
improving O
emotion-regulation O
among O
children O
with O
ASD O
. O
[]

METHODS O
Umbilical O
cord O
serum O
or O
autologous O
serum O
drops O
were O
used O
to O
promote O
the O
healing O
of O
persistent B-outcome ['Physiological-Clinical']
epithelial I-outcome ['Physiological-Clinical']
defects I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Rescue O
treatment O
was O
available O
from O
month O
3 O
if O
the O
subretinal O
fluid O
( O
SRF O
) O
persisted O
or O
recurred O
after O
primary O
treatment O
; O
low-fluence O
PDT O
was O
given O
to O
the O
ranibizumab O
group O
and O
intravitreal O
ranibizumab O
to O
the O
low-fluence O
PDT O
group O
. O
[]

Importantly O
, O
adjusting O
for O
age O
did O
not O
change O
the O
magnitude O
of O
these O
effects O
. O
[]

Standard O
and O
high-pressure B-outcome ['Physiological-Clinical']
, O
rapid-inflation B-outcome ['Physiological-Clinical']
compression I-outcome ['Physiological-Clinical']
significantly O
increased O
the O
popliteal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
femoral I-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
velocities I-outcome ['Physiological-Clinical']
in O
healthy O
and O
post-thrombotic O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
operative O
findings O
consistent O
with O
our O
criteria O
were O
randomized O
into O
a O
radical O
resection O
group O
and O
a O
radiochemotherapy O
group O
( O
200 O
mg/m O
( O
2 O
) O
/day O
of O
intravenous O
5-fluorouracil O
and O
5040 O
cGy O
of O
radiotherapy O
) O
without O
resection O
. O
[]

Additional O
studies O
are O
necessary O
to O
assess O
whether O
there O
is O
any O
predictive O
role O
of O
BRAF O
mutation O
for O
irinotecan-based O
therapy O
. O
[]

Clinicians O
in O
10 O
systematically O
selected O
rural O
towns O
were O
involved O
in O
the O
subsequent O
intervention O
study O
. O
[]

Of O
the O
total O
cycles O
in O
the O
NETA/EE O
group O
, O
10 O
% O
were O
amenorrheic B-outcome ['Physiological-Clinical']
, O
compared O
with O
1.1 O
% O
in O
the O
LNG/EE O
group O
. O
['Physiological-Clinical']

Decisions O
about O
diet O
advancement O
and O
hospital O
discharge O
were O
at O
the O
discretion O
of O
the O
medical O
team O
, O
without O
input O
from O
study O
team O
members O
. O
[]

The O
present O
study O
demonstrated O
that O
the O
IL-6R B-outcome ['Physiological-Clinical']
gene I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
levels O
in O
skeletal O
muscle O
are O
increased O
in O
response O
to O
acute O
exercise O
, O
a O
response O
that O
is O
very O
well O
conserved O
, O
being O
affected O
by O
neither O
training B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
nor O
intramuscular B-outcome ['Physiological-Clinical']
glycogen I-outcome ['Physiological-Clinical']
levels O
, O
as O
opposed O
to O
IL-6 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Multiple O
correlation O
for O
the O
set O
of O
quantitative O
measures O
yielded O
R O
= O
0.614 O
( O
P O
< O
0.001 O
) O
with O
MAS O
scores O
and O
R O
= O
0.365 O
( O
P O
= O
0.045 O
) O
with O
TTT O
scores O
. O
[]

DESIGN O
Phase O
II O
, O
prospective O
, O
randomized O
, O
assessor-blind O
, O
multicenter O
, O
dose-finding O
, O
noninferiority O
study O
. O
[]

This O
study O
examined O
the O
effectiveness O
of O
imipramine O
, O
mexiletine O
, O
pirmenol O
, O
procainamide O
, O
propafenone O
, O
quinidine O
, O
and O
sotalol O
in O
patients O
with O
ventricular O
tachyarrhythmias O
who O
were O
enrolled O
in O
the O
Electrophysiologic O
Study O
versus O
Electrocardiographic O
Monitoring O
trial O
. O
[]

BACKGROUND O
Ketoconazole O
is O
a O
typical O
treatment O
available O
for O
pityriasis O
versicolor O
; O
tretinoin O
cream O
is O
effective O
, O
too O
. O
[]

Patients O
' O
views O
were O
obtained O
from O
written O
responses O
to O
a O
postal O
questionnaire O
( O
136 O
replies O
) O
. O
[]

There O
was O
no O
significant O
difference O
in O
survival B-outcome ['Mortality']
between O
limbs O
for O
either O
tumor O
. O
['Mortality']

However O
, O
a O
subgroup O
of O
26 O
% O
responded O
with O
more O
than O
25 O
% O
reduction O
of O
ADHD B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
a O
drop O
of O
CGI O
scores O
to O
the O
near-normal O
range O
. O
['Life-Impact']

In O
the O
control O
group O
, O
the O
volume B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
nodules I-outcome ['Physiological-Clinical']
did O
not O
significantly O
change O
over O
the O
30 O
week O
period O
of O
observation O
. O
['Physiological-Clinical']

METHODS O
In O
this O
randomized O
, O
parallel-group O
, O
double-blind O
, O
repeated-dose O
, O
active-comparator O
, O
4-week O
, O
multicenter O
study O
, O
469 O
patients O
were O
randomly O
assigned O
to O
receive O
a O
1-tablet O
( O
n O
= O
156 O
) O
or O
2-tablet O
( O
n O
= O
153 O
) O
dose O
of O
combination O
hydrocodone O
7.5 O
mg O
and O
ibuprofen O
200 O
mg O
( O
HI1 O
and O
HI2 O
, O
respectively O
) O
or O
a O
2-tablet O
dose O
of O
combination O
codeine O
30 O
mg O
and O
acetaminophen O
300 O
mg O
( O
CA O
, O
n O
= O
160 O
) O
, O
the O
active O
comparator O
, O
every O
6 O
to O
8 O
hours O
as O
needed O
for O
pain O
. O
[]

This O
study O
examined O
the O
feasibility O
and O
safety O
of O
deliberate O
mild O
hypothermia O
and O
rewarming O
. O
[]

Both O
propranolol O
and O
atenolol O
reduced O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
S-FFA B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
compared O
to O
placebo O
, O
and O
all O
patients O
showed O
measurable O
plasma O
concentrations O
of O
propranolol O
and O
atenolol O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
piloted O
a O
2-week O
Autism-1-2-3 O
early O
intervention O
for O
children O
with O
autism O
and O
their O
parents O
immediately O
after O
diagnosis O
that O
targeted O
at O
( O
1 O
) O
eye O
contact O
, O
( O
2 O
) O
gesture O
and O
( O
3 O
) O
vocalization/words O
. O
[]

Amyloid O
beta O
( O
Abeta O
) O
may O
play O
a O
central O
role O
in O
the O
pathogenesis O
of O
Alzheimer O
disease O
. O
[]

There O
were O
no O
differences O
in O
other O
plasma B-outcome ['Physiological-Clinical']
antioxidants I-outcome ['Physiological-Clinical']
between O
groups O
. O
['Physiological-Clinical']

Fourteen O
children O
( O
12 O
infantile O
autism O
full O
syndrome O
present O
, O
2 O
atypical O
pervasive O
developmental O
disorder O
) O
between O
5 O
and O
13 O
years O
of O
age O
participated O
in O
a O
double-blind O
placebo-controlled O
cross-over O
trial O
. O
[]

The O
results O
showed O
marked O
decreases O
in O
probing B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
and O
density B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
micro-organisms I-outcome ['Physiological-Clinical']
in O
both O
the O
RP O
and O
TC O
+ O
RP O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Plasma O
catecholamines O
( O
epinephrine O
and O
norepinephrine O
) O
increased O
significantly O
in O
Group O
4 O
( O
retroauricular O
infiltration O
anaesthesia O
) O
. O
[]

RESULTS O
At O
day O
+120 O
responses B-outcome ['Physiological-Clinical']
were O
classified O
as O
absent O
, O
partial O
, O
and O
complete O
in O
12 O
, O
22 O
, O
and O
4 O
patients O
in O
group O
A O
and O
in O
23 O
, O
7 O
, O
and O
9 O
patients O
in O
group O
B O
( O
p=0.001 O
) O
. O
['Physiological-Clinical']

Differences O
between O
the O
two O
groups O
were O
significant O
( O
p O
less O
than O
0.05 O
) O
. O
[]

MAIN O
RESULTS O
The O
12 O
patients O
treated O
with O
GM-CSF O
, O
when O
compared O
with O
placebo O
recipients O
, O
had O
shorter O
periods B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
( O
median O
duration O
of O
an O
absolute O
neutrophil O
count O
of O
less O
than O
1000 O
cells/mm3 O
, O
16 O
days O
compared O
with O
27 O
days O
; O
P O
= O
0.02 O
) O
, O
shorter O
periods O
of O
platelet-transfusion B-outcome ['Physiological-Clinical']
dependency I-outcome ['Physiological-Clinical']
( O
median O
duration O
, O
13.5 O
days O
compared O
with O
21 O
days O
; O
P O
= O
0.03 O
) O
, O
and O
shorter O
hospitalizations B-outcome ['Resource-use']
( O
median O
hospital O
stay O
, O
32 O
days O
compared O
with O
40.5 O
days O
; O
P O
= O
0.004 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Spinal O
anesthesia O
is O
often O
used O
in O
this O
institution O
, O
as O
well O
as O
many O
others O
, O
for O
this O
procedure O
. O
[]

The O
authors O
' O
study O
compared O
suture O
with O
a O
new O
coaptive O
film O
device O
, O
3M O
Steri-Strip O
S O
Surgical O
Skin O
Closure O
, O
on O
linear O
incisions O
. O
[]

Safety O
was O
assessed O
as O
deaths B-outcome ['Mortality']
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
and O
['Mortality', 'Adverse-effects']

This O
situation O
might O
represent O
an O
increased O
risk O
for O
both O
target B-outcome ['Physiological-Clinical']
organ I-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
and O
acute B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
diseases I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
use O
of O
two O
commonly O
used O
glutathione O
supplements O
in O
subjects O
diagnosed O
with O
an O
ASD O
to O
determine O
their O
efficacy O
in O
increasing O
blood B-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
levels O
in O
subjects O
diagnosed O
with O
an O
ASD O
. O
['Physiological-Clinical']

METHODS O
A O
consecutive O
series O
of O
100 O
patients O
undergoing O
thoracoscope-assisted O
thoracotomy O
were O
randomized O
into O
5 O
groups O
and O
received O
PCA O
with O
morphine O
doses O
at O
0 O
, O
5 O
, O
10 O
, O
15 O
, O
and O
20 O
mg O
given O
in O
200 O
ml O
saline O
( O
groups O
P O
( O
1 O
) O
, O
P O
( O
2 O
) O
, O
P O
( O
3 O
) O
, O
P O
( O
4 O
) O
, O
and O
P O
( O
5 O
) O
, O
respectively O
) O
. O
[]

AIMS O
Whether O
chronic O
dosing O
with O
montelukast O
confers O
benefit O
in O
patients O
with O
moderate O
to O
severe O
asthma O
remains O
to O
be O
fully O
established O
. O
[]

Wound B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
and O
general B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
were O
more O
frequent O
in O
the O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Significantly O
more O
patients O
receiving O
cetamolol O
than O
those O
receiving O
placebo O
showed O
a O
good O
response O
( O
a O
decrease O
in O
diastolic O
blood O
pressure O
of O
10 O
mm O
Hg O
or O
more O
or O
measuring O
less O
than O
90 O
mm O
Hg O
with O
a O
decrease O
of O
at O
least O
4 O
mm O
Hg O
) O
. O
( O
[]

CONCLUSION O
DST O
is O
effective O
on O
IgAN O
of O
deficiency O
of O
Yin O
with O
damp-heat O
symptom O
. O
[]

With O
the O
convenience O
of O
a O
subcutaneous O
injection O
and O
no O
requirement O
for O
renal O
monitoring O
, O
denosumab O
represents O
a O
potential O
treatment O
option O
for O
patients O
with O
bone O
metastases O
. O
[]

BACKGROUND O
To O
elucidate O
the O
most O
efficient O
topical O
therapy O
for O
carcinoma O
in O
situ O
of O
the O
bladder O
, O
the O
efficacy O
of O
intravesical O
mitomycin O
C O
plus O
doxorubicin O
therapy O
was O
compared O
with O
bacillus O
Calmette-Guerin O
( O
BCG O
) O
therapy O
. O
[]

RESULTS O
A O
large O
and O
highly O
significant O
treatment O
effect O
on O
wrist B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
found O
. O
['Physiological-Clinical']

HF B-outcome ['Physiological-Clinical']
frequency O
and O
severity B-outcome ['Physiological-Clinical']
, O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
quality O
of O
life O
and O
sexuality B-outcome ['Life-Impact']
were O
assessed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Life-Impact']

Two O
regimens O
of O
induction O
chemotherapy O
were O
studied O
in O
separate O
randomized O
, O
prospective O
trials O
over O
the O
last O
6 O
years O
. O
[]

MATERIALS O
AND O
METHODS O
We O
randomly O
assigned O
28 O
patients O
with O
refractory O
monosymptomatic O
nocturnal O
enuresis O
to O
2 O
equal O
groups O
. O
[]

The O
clinical O
significance O
of O
the O
theoretically O
more O
accurate O
measures O
of O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
produced O
with O
the O
new O
meter O
, O
and O
indeed O
of O
spirometry O
itself O
, O
needs O
further O
investigation O
. O
['Physiological-Clinical']

The O
incidence O
of O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
increased O
significantly O
over O
baseline O
in O
the O
10-mg O
group O
but O
not O
in O
the O
5-mg O
group O
. O
['Physiological-Clinical']

In O
addition O
, O
the O
conditioned O
pain O
modulation O
response O
to O
cold O
pressor O
task O
was O
determined O
. O
[]

The O
self-reported B-outcome ['Life-Impact']
alcohol I-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
was O
56.1 O
+/- O
3.6 O
( O
SEM O
) O
ml/day O
during O
the O
usual O
alcohol O
drinking O
period O
and O
26.1 O
+/- O
3.0 O
ml/day O
during O
the O
period O
of O
reduced O
alcohol O
consumption O
. O
['Life-Impact']

However O
, O
fluvoxamine O
was O
better O
tolerated B-outcome ['Life-Impact']
than O
clomipramine O
. O
['Life-Impact']

Thus O
, O
the O
Lightwand O
( O
Intubating O
Lighted O
Stylet O
) O
is O
associated O
with O
reduced O
C-spine B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
during O
endotracheal O
intubation O
compared O
with O
the O
Macintosh O
laryngoscope O
. O
['Physiological-Clinical']

Overall O
, O
after O
34 O
months O
( O
median O
posttreatment O
follow-up O
) O
, O
three O
patients O
were O
long O
term O
responders O
, O
whereas O
three O
showed O
a O
sustained O
remission B-outcome ['Physiological-Clinical']
after O
relapse O
. O
['Physiological-Clinical']

Enhancing O
the O
self-esteem B-outcome ['Life-Impact']
of O
inpatient O
alcoholics O
. O
['Life-Impact']

Six O
patients O
dropped O
out O
before O
the O
fifth O
postoperative O
day O
, O
leaving O
79 O
patients O
in O
the O
control O
group O
and O
81 O
patients O
in O
the O
study O
group O
. O
[]

Although O
ischaemic O
preconditioning O
had O
no O
effect O
on O
[]

Pharmacokinetic- O
pharmacodynamic O
analysis O
of O
the O
role O
of O
CYP2C19 O
genotypes O
in O
short-term O
rabeprazole-based O
triple O
therapy O
against O
Helicobacter O
pylori O
. O
[]

RESULTS O
Overall O
5-year O
cause B-outcome ['Mortality']
specific I-outcome ['Mortality']
survivals I-outcome ['Mortality']
were O
as O
follows O
: O
stage O
IA O
= O
100 O
% O
, O
stage O
IB O
= O
96 O
% O
, O
stage O
IIA O
= O
92 O
% O
, O
stage O
IIB O
= O
79 O
% O
, O
stage O
III O
= O
57 O
% O
, O
stage O
IV O
= O
27 O
% O
. O
['Mortality']

Toxicity B-outcome ['Adverse-effects']
was O
evaluated O
every O
treatment O
cycle O
; O
QOL O
and O
response O
6-weekly O
. O
['Adverse-effects']

Prophylaxis O
continued O
4 O
weeks O
longer O
. O
[]

A O
protective O
effect O
of O
induced O
iron O
reduction O
against O
cancer O
mortality O
has O
been O
confirmed O
in O
a O
recent O
trial O
( O
FeAST O
) O
with O
subjects O
randomized O
to O
iron O
reduction O
or O
observation O
. O
[]

We O
examined O
possible O
associations O
between O
a O
broad O
spectrum O
of O
circulating O
biomarkers O
of O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
risk O
of O
fibroadenomas O
. O
['Life-Impact']

Cardiopulmonary O
exercise O
testing O
was O
performed O
at O
baseline O
and O
after O
10 O
weeks O
. O
[]

Group-B O
streptococci O
were O
found O
in O
the O
urine O
of O
69 O
women O
. O
[]

However O
, O
it O
is O
not O
clear O
whether O
the O
effectiveness O
of O
reinforcement O
varies O
positively O
with O
the O
degree O
of O
preference O
( O
i.e. O
, O
whether O
the O
relative O
preference O
based O
on O
the O
results O
of O
a O
choice O
assessment O
predicts O
relative O
reinforcer O
effectiveness O
) O
. O
[]

A O
large O
body O
of O
evidence O
has O
been O
accumulated O
from O
studies O
of O
patients O
which O
suggests O
that O
such O
eye O
movement O
abnormalities O
may O
arise O
from O
frontal O
lobe O
dysfunction O
. O
[]

It O
is O
suggested O
that O
the O
mechanisms O
underlying O
opioid-immune O
interactions O
are O
altered O
in O
this O
population O
of O
autistic O
children O
and O
that O
an O
immunological O
screening O
may O
have O
prognostic O
value O
for O
the O
pharmacological O
therapy O
with O
opiate O
antagonists O
. O
[]

Grade O
3 O
and O
4 O
AEs B-outcome ['Adverse-effects']
occurring O
more O
commonly O
in O
panitumumab-treated O
patients O
included O
rash/acneiform B-outcome ['Physiological-Clinical']
dermatitis B-outcome ['Physiological-Clinical']
, O
diarrhea B-outcome ['Physiological-Clinical']
, O
dehydration B-outcome ['Physiological-Clinical']
, O
primarily O
resulting O
from O
diarrhea B-outcome ['Physiological-Clinical']
, O
hypokalemia B-outcome ['Physiological-Clinical']
, O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CHVP O
cycles O
comprised O
cyclophosphamide O
( O
750 O
mg/m O
( O
2 O
) O
i.v O
. O
[]

After O
adjusting O
the O
Mehran B-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
risk O
score O
, O
the O
risk O
of O
CIN B-outcome ['Physiological-Clinical']
significantly O
reduced O
with O
sodium O
bicarbonate O
compared O
with O
sodium O
chloride O
alone O
( O
adjusted O
risk O
ratio O
0.29 O
, O
P O
= O
.043 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Topical O
selamectin O
was O
found O
to O
be O
40.7-63.3 O
% O
effective O
( O
based O
on O
egg B-outcome ['Physiological-Clinical']
per O
gram O
method O
) O
in O
eliminating B-outcome ['Physiological-Clinical']
S. O
muris B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
statistically O
significant O
differences O
in O
the O
distribution O
of O
age O
, O
duration O
of O
injury O
, O
cause O
of O
injury O
, O
presence O
of O
neuropathic O
pain O
, O
presence O
of O
trigger O
pain O
, O
and O
degree O
of O
injury O
between O
the O
IAN O
and O
LN O
patient O
populations O
. O
[]

The O
result O
of O
the O
trial O
shows O
no O
advantage O
in O
terms O
of O
local O
control O
or O
survival O
for O
the O
experimental O
treatment O
arm O
of O
split O
course O
radiotherapy O
and O
concurrent O
chemotherapy O
with O
Mitomycin O
C O
and O
5 O
Fluorouracil O
compared O
to O
radiotherapy O
alone O
. O
[]

All O
five O
dogs O
in O
the O
placebo O
group O
developed O
fulminating B-outcome ['Physiological-Clinical']
enteritis I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
typical I-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and O
died B-outcome ['Mortality']
within O
10 O
days O
post-inoculation O
( O
or O
6 O
days O
post-treatment O
) O
. O
['Physiological-Clinical', 'Mortality']

Continuous O
event O
recorders O
( O
CERs O
) O
have O
proven O
to O
be O
successful O
in O
diagnosing O
causes O
of O
palpitations O
but O
may O
affect O
patient O
QoL B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Children O
wore O
an O
actigraphy O
device O
to O
record O
baseline O
sleep B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
, O
with O
the O
primary O
outcome O
variable O
being O
change O
in O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Previously O
, O
skin B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
, O
thermography B-outcome ['Physiological-Clinical']
, O
plethysmography B-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
changes O
have O
been O
used O
in O
evaluation O
of O
sympathetic O
nerve O
activity O
following O
acupuncture O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Increased O
upright B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
occurred O
in O
normals O
after O
the O
high O
fat O
( O
6.2 O
+/- O
2.1 O
% O
; O
mean O
+/- O
SE O
) O
compared O
with O
the O
low O
fat O
meal O
( O
1.5 O
+/- O
0.5 O
% O
; O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

METHODS O
A O
total O
of O
42 O
recently O
extracted O
upper O
incisors O
were O
randomly O
divided O
into O
3 O
groups O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
safety O
and O
efficacy O
of O
XS0601 O
in O
preventing O
restenosis O
following O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
[]

In O
order O
to O
verify O
hormone B-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
variations I-outcome ['Physiological-Clinical']
due O
to O
the O
antiestrogen O
, O
when O
possible O
a O
second O
biopsy B-outcome ['Resource-use']
was O
performed O
after O
the O
initial O
14 O
day O
cycle O
of O
TAM O
. O
['Physiological-Clinical', 'Resource-use']

The O
proportion O
of O
patients O
who O
were O
ELISPOT O
positive O
was O
higher O
in O
the O
groups O
treated O
with O
recombinant O
hepatitis O
B O
vaccine O
( O
including O
the O
dose O
of O
90 O
micrograms O
and O
60 O
micrograms O
) O
than O
that O
in O
the O
placebo O
group O
( O
P=0.0446 O
) O
. O
[]

Standard O
12-lead O
electrocardiograms O
were O
recorded O
at O
baseline O
and O
during O
treatment O
. O
[]

Early O
clinical O
outcomes O
and O
toxicity O
of O
intensity O
modulated O
versus O
conventional O
pelvic O
radiation O
therapy O
for O
locally O
advanced O
cervix O
carcinoma O
: O
a O
prospective O
randomized O
study O
. O
[]

Urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
melatonin I-outcome ['Physiological-Clinical']
also O
remained O
unchanged O
, O
as O
did O
GH B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Some O
patients O
were O
treated O
by O
means O
of O
a O
standard O
activity O
of O
7.4 O
GBq O
131I O
and O
after O
5 O
days O
whole O
body O
scintigraphy O
( O
WBS O
) O
was O
performed O
. O
[]

CONCLUSIONS O
Cortical O
bone O
reacts O
promptly O
to O
reinstitution O
of O
GH O
beyond O
the O
attainment O
of O
final O
height O
by O
increasing O
the O
cortical O
thickness O
through O
endosteal O
bone O
growth O
. O
[]

Lapatinib O
is O
approved O
in O
combination O
with O
capecitabine O
for O
treatment O
of O
patients O
with O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
-positive O
metastatic O
breast O
cancer O
( O
MBC O
) O
who O
have O
progressed O
on O
prior O
trastuzumab O
in O
the O
metastatic O
setting O
. O
[]

Patients O
were O
assigned O
to O
one O
of O
the O
two O
treatment O
groups O
by O
random O
sampling O
numbers O
. O
[]

Enhanced O
pitch O
sensitivity O
in O
individuals O
with O
autism O
: O
a O
signal O
detection O
analysis O
. O
[]

The O
study O
presents O
the O
results O
of O
prevention O
and O
treatment O
of O
infectious O
and O
inflammatory O
complications O
after O
oral O
surgery O
procedures O
. O
[]

RESULTS O
The O
[]

There O
was O
no O
statistically O
significant O
effect O
on O
the O
General O
Quality O
of O
Life O
[]

In O
15 O
children O
sleep O
normalized O
after O
5 O
weeks O
( O
range O
4 O
to O
6 O
weeks O
) O
. O
[]

Assessments O
will O
occur O
before O
therapy O
, O
after O
the O
8 O
week O
therapy O
program O
, O
and O
at O
3 O
and O
12 O
months O
after O
the O
intervention O
. O
[]

Dose-limiting B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
, O
consisting O
of O
febrile B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
in O
some O
patients O
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
nonproductive B-outcome ['Physiological-Clinical']
cough I-outcome ['Physiological-Clinical']
, O
was O
observed O
at O
a O
dose O
level O
of O
30 O
micrograms/kg O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
observed O
no O
between-group O
differences O
in O
four O
predefined O
quality-of-life B-outcome ['Life-Impact']
subscales O
( O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
, O
dyspnoea B-outcome ['Physiological-Clinical']
, O
and O
global B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
) O
at O
any O
of O
the O
assessments O
in O
the O
first O
6 O
months O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Fasting B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
was O
13 O
+/- O
3 O
and O
10 O
+/- O
2 O
mU/l O
and O
fasting O
glucose O
5.3 O
+/- O
0.2 O
and O
5.1 O
+/- O
0.1 O
mmol/l O
after O
placebo O
and O
metformin O
treatment O
, O
respectively O
( O
ns O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
are O
frequent O
in O
postmenopausal O
breast O
cancer O
patients O
, O
especially O
when O
treated O
with O
tamoxifen O
. O
['Physiological-Clinical']

Baseline O
demographic O
, O
smoking-related O
, O
disease-related O
, O
and O
psychological O
variables O
were O
examined O
as O
predictors O
of O
biochemically-confirmed O
point-prevalence O
abstinence O
. O
[]

Biodistribution O
of O
three O
photosensitizers O
in O
dogs O
with O
spontaneous O
tumors O
. O
[]

In O
Expt O
. O
[]

BACKGROUND O
Androgen O
deprivation O
therapy O
( O
ADT O
) O
is O
accompanied O
by O
a O
number O
of O
adverse O
side O
effects O
including O
reduced O
bone O
mass O
and O
increased O
risk O
for O
fracture O
, O
reduced O
lean O
mass O
and O
muscle O
strength O
, O
mood O
disturbance O
and O
increased O
fat O
mass O
compromising O
physical O
functioning O
, O
independence O
, O
and O
quality O
of O
life O
. O
[]

Although O
bright O
light O
therapy O
( O
BLT O
) O
suppresses O
melatonin O
release O
and O
is O
an O
established O
treatment O
for O
depression O
and O
sleep O
disturbances O
, O
it O
has O
not O
been O
evaluated O
in O
PD O
. O
[]

INTRODUCTION O
Exercise O
can O
increase O
bone B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
, O
but O
to O
be O
effective O
in O
reducing O
fracture B-outcome ['Physiological-Clinical']
risk O
, O
exercise O
must O
be O
feasible O
enough O
to O
be O
adopted O
into O
daily O
life O
and O
influence O
potentially O
vulnerable O
skeletal O
sites O
such O
as O
the O
superolateral O
cortex O
of O
the O
femoral O
neck O
, O
where O
thinning O
is O
associated O
with O
increased O
fracture B-outcome ['Physiological-Clinical']
risk O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Standardized O
IFT O
stimulation O
parameters O
were O
used O
: O
carrier O
frequency O
3.85 O
kHz O
; O
140 O
Hz O
constant O
; O
pulse O
duration O
130 O
micros O
; O
30 O
minutes O
' O
duration O
. O
[]

RESULTS O
fT O
( O
4 O
) O
and O
TSH O
showed O
a O
strong O
correlation O
with O
GHQ-12 O
scores O
( O
fT4 O
- O
b O
: O
-0.16 O
, O
P O
= O
0.005 O
; O
TSH O
- O
b O
: O
0.663 O
, O
P O
= O
0.04 O
) O
. O
[]

Involvement O
of O
the O
central O
nervous O
system O
at O
diagnosis O
was O
also O
more O
common O
in O
the O
youngest O
children O
( O
P O
=.01 O
) O
. O
[]

Cardiovascular O
and O
behavioral O
effects O
of O
aerobic O
exercise O
training O
in O
healthy O
older O
men O
and O
women O
. O
[]

[ O
Clinical O
study O
of O
feiyanqing O
rectum O
condensed O
liquid O
in O
treating O
36 O
cases O
of O
children O
syncytial O
viral O
pneumonia O
] O
. O
[]

The O
primary O
objective O
of O
the O
present O
randomized O
phase O
III O
trial O
was O
to O
compare O
the O
3-yr O
survival B-outcome ['Mortality']
rate O
of O
patients O
treated O
with O
standard O
fractionated O
radiotherapy O
( O
RT O
) O
alone O
or O
with O
the O
same O
RT O
concomitantly O
with O
cisplatin O
( O
DDP O
) O
or O
carboplatin O
( O
Cb O
) O
. O
['Mortality']

Endoscopic O
examinations O
were O
carried O
out O
before O
the O
start O
of O
treatment O
and O
14 O
days O
later O
. O
[]

The O
incidence O
of O
weight O
gain O
was O
not O
significantly O
different O
between O
treatment O
groups O
. O
[]

This O
study O
provides O
support O
for O
including O
an O
exercise B-outcome ['Life-Impact']
component I-outcome ['Life-Impact']
in O
SM O
interventions O
for O
cancer O
patients O
receiving O
chemotherapy O
( O
clinicaltrials.gov O
identifier O
: O
NCT00740038 O
) O
. O
['Life-Impact']

It O
was O
found O
to O
be O
a O
safe O
, O
effective O
and O
wall B-outcome ['Physiological-Clinical']
tolerated O
drug O
for O
the O
treatment O
of O
ureteral O
colic O
and O
is O
recommended O
in O
place O
of O
narcotics O
. O
['Physiological-Clinical']

Patients O
in O
CC O
( O
n O
= O
57 O
) O
received O
educational O
videotapes O
and O
pamphlets O
; O
pharmacotherapy O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
paroxetine O
; O
2 O
psychiatrist O
visits O
and O
2 O
telephone O
calls O
in O
the O
first O
8 O
weeks O
; O
and O
up O
to O
5 O
telephone O
calls O
between O
3 O
and O
12 O
months O
' O
follow-up O
. O
[]

The O
eprinomectin O
protocol O
employed O
in O
Study O
2 O
, O
consisting O
of O
four O
weekly O
topical O
administrations O
at O
the O
dose O
rate O
of O
500mug/kg O
of O
body O
weight O
, O
proved O
highly O
effective O
at O
reducing O
the O
Chorioptes B-outcome ['Physiological-Clinical']
mite I-outcome ['Physiological-Clinical']
burden I-outcome ['Physiological-Clinical']
in O
alpacas O
. O
['Physiological-Clinical']

Zero O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
, O
and O
follow-up O
for O
the O
primary O
outcome O
was O
100 O
% O
. O
['Adverse-effects']

Although O
the O
two O
groups O
were O
equally O
accurate O
in O
detecting O
targets O
, O
the O
ASD O
adults O
improve O
in O
their O
correct B-outcome ['Life-Impact']
elimination O
of O
['Life-Impact']

In O
addition O
, O
ORR O
was O
significantly O
higher O
with O
letrozole O
than O
tamoxifen O
in O
the O
human O
epidermal O
growth O
factor O
receptor O
HER1/HER2+ O
subgroup O
( O
P=0.0004 O
) O
. O
[]

The O
difference O
in O
thickness B-outcome ['Physiological-Clinical']
was O
most O
evident O
at O
1 O
month O
. O
['Physiological-Clinical']

Photodynamic O
therapy O
( O
PDT O
) O
has O
been O
considered O
a O
potential O
method O
for O
tumor O
eradication O
. O
[]

OBJECTIVES O
To O
analyze O
the O
effect O
of O
differing O
diet O
on O
the O
acid O
load O
content O
on O
bone B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
Little O
information O
is O
available O
on O
the O
effectiveness O
of O
lipid O
lowering O
in O
secondary O
prevention O
of O
coronary O
heart O
disease O
( O
CHD O
) O
in O
women O
; O
in O
particular O
, O
those O
with O
CHD O
and O
average O
cholesterol O
levels O
. O
[]

These O
findings O
may O
be O
of O
particular O
clinical O
importance O
when O
fetal B-outcome ['Physiological-Clinical']
distress I-outcome ['Physiological-Clinical']
or O
fetal B-outcome ['Physiological-Clinical']
hypoxemia I-outcome ['Physiological-Clinical']
is O
due O
to O
other O
perinatal O
events O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Four O
different O
doses O
of O
recombinant O
human O
porphobilinogen O
deaminase O
were O
studied O
( O
0.5 O
, O
1 O
, O
2 O
and O
4 O
mg/kg O
bodyweight O
) O
. O
[]

However O
, O
most O
studies O
demonstrating O
this O
advantage O
have O
employed O
simple O
, O
uncluttered O
images O
with O
fully O
visible O
targets O
. O
[]

No O
difference O
between O
membranes O
was O
observed O
for O
serum B-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
, O
high-sensitivity B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
, O
fibrinogen B-outcome ['Physiological-Clinical']
, O
IL-6 B-outcome ['Physiological-Clinical']
, O
triglycerides B-outcome ['Physiological-Clinical']
, O
HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
, O
LDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
, O
and O
lipoprotein B-outcome ['Physiological-Clinical']
( O
a O
) O
during O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

64.9 O
mm O
( O
3 O
) O
; O
p O
< O
0.001 O
) O
. O
[]

Three O
months O
after O
surgery O
, O
the O
patients O
were O
asked O
about O
symptomatic B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
and O
intervals O
between O
the O
operation O
and O
return O
to O
their O
daily O
activities O
and O
work O
, O
and O
examined O
for O
scar B-outcome ['Physiological-Clinical']
tenderness I-outcome ['Physiological-Clinical']
and O
esthetic O
outcome O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
high O
number O
of O
self-initiated B-outcome ['Life-Impact']
questions I-outcome ['Life-Impact']
during O
follow-up O
indicates O
that O
both O
groups O
maintained O
this O
skill O
. O
['Life-Impact']

Analgesia B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
, O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
and O
incidence O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Toxicity B-outcome ['Adverse-effects']
was O
mainly O
neutropenia B-outcome ['Physiological-Clinical']
and O
infection B-outcome ['Physiological-Clinical']
during O
the O
ACVB O
courses O
, O
with O
40 O
patients O
( O
5 O
% O
) O
dying O
from O
septic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
while O
responding O
to O
treatment O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Using O
the O
information O
given O
by O
the O
4 O
leads O
for O
each O
minute O
of O
recording O
the O
number O
of O
epochs B-outcome ['Physiological-Clinical']
which O
correspond O
to O
a O
stage O
A O
or O
non-A O
were O
determined O
. O
['Physiological-Clinical']

METHODS O
Sixty-five O
day-only O
patients O
with O
renal O
impairment O
( O
mean O
serum O
creatinine O
concentration O
0.16+/-0.03 O
mmol/l O
) O
due O
to O
undergo O
coronary O
or O
peripheral O
angiography O
and/or O
stenting O
were O
randomly O
assigned O
to O
IV O
NAC O
300 O
or O
600 O
mg O
immediately O
before O
and O
after O
the O
procedure O
or O
IV O
fluid O
alone O
. O
[]

Patient O
positioning O
influences O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
in O
the O
acute O
phase O
of O
stroke O
. O
['Physiological-Clinical']

Recognition B-outcome ['Life-Impact']
, O
awareness B-outcome ['Life-Impact']
, O
comprehension B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact']

BACKGROUND O
Teriparatide O
( O
parathyreoid O
hormone O
; O
PTH O
1-34 O
) O
increases O
skeletal O
mass O
in O
humans O
and O
improves O
fracture O
healing O
in O
animals O
. O
[]

OBJECTIVE O
To O
investigate O
the O
curative O
effect O
of O
early O
enteral O
nutrition O
( O
EN O
) O
supplemented O
with O
probiotics O
( O
bifidobacterium O
) O
in O
patients O
with O
severe O
acute O
pancreatitis O
( O
ASP O
) O
. O
[]

Biopsies O
of O
adipose O
tissue O
and O
synovial O
tissue O
were O
taken O
during O
surgery O
to O
evaluate O
the O
local B-outcome ['Physiological-Clinical']
penetration I-outcome ['Physiological-Clinical']
of O
the O
drug B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

Effects O
of O
nitric O
oxide O
synthase O
inhibition O
on O
cutaneous B-outcome ['Physiological-Clinical']
vasodilation I-outcome ['Physiological-Clinical']
in O
response O
to O
acupuncture O
stimulation O
in O
humans O
. O
['Physiological-Clinical']

Before O
the O
skin O
incision O
performed O
after O
anesthesia O
induction O
, O
we O
performed O
ilioinguinal O
iliohypogastric O
block O
( O
group O
C O
given O
saline O
and O
group O
P O
and O
DB O
given O
levobupivacaine O
) O
. O
[]

Above O
all O
, O
our O
results O
should O
also O
serve O
as O
a O
basis O
for O
further O
controlled O
randomized O
studies O
in O
this O
setting O
. O
[]

METHODS O
Thirty-six O
children O
with O
ASD O
, O
ages O
2 O
to O
10 O
years O
, O
were O
enrolled O
. O
[]

In O
this O
study O
, O
87 O
volunteers O
who O
wanted O
to O
quit O
cigarette O
smoking O
were O
assigned O
randomly O
to O
the O
experimental O
hypnosis O
group O
, O
the O
comparison O
relaxation O
group O
, O
and O
the O
waiting O
list O
control O
group O
. O
[]

In O
contrast O
, O
GH-secretagogues O
elevated O
leptin B-outcome ['Physiological-Clinical']
levels O
within O
12 O
h. O
Infusion O
of O
GHRP-2 O
alone O
induced O
a O
maximal O
leptin B-outcome ['Physiological-Clinical']
increase O
of O
+87 O
% O
after O
24 O
h O
, O
whereas O
GHRH O
+ O
GHRP-2 O
elevated O
leptin B-outcome ['Physiological-Clinical']
by O
up O
to O
+157 O
% O
after O
24 O
h. O
The O
increase O
in O
leptin B-outcome ['Physiological-Clinical']
within O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Neuropsychological O
deficits O
are O
potential O
side O
effects O
of O
hematopoietic O
stem O
cell O
therapy O
( O
HSCT O
) O
. O
[]

METHODS O
In O
a O
double-blind O
, O
multicenter O
study O
patients O
with O
symptoms O
of O
acute O
UC O
and O
a O
baseline O
Modified O
Mayo O
Disease O
Activity O
Index O
( O
MMDAI O
) O
score O
between O
6 O
and O
10 O
, O
inclusive O
, O
with O
a O
subscale O
rating O
of O
> O
or O
=2 O
for O
both O
rectal O
bleeding O
and O
mucosal O
appearance O
were O
randomized O
to O
receive O
3.3 O
g O
of O
balsalazide O
or O
placebo O
tablets O
twice O
daily O
for O
8 O
weeks O
. O
[]

OBJECTIVES O
To O
develop O
and O
validate O
a O
questionnaire O
for O
measuring O
satisfaction B-outcome ['Life-Impact']
with O
different O
forms O
of O
complex O
multidisciplinary O
care O
in O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
. O
['Life-Impact']

Resource B-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
, O
procedures B-outcome ['Resource-use']
, O
and O
direct B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
were O
calculated O
and O
analyzed O
in O
this O
post O
hoc O
retrospective O
study O
. O
['Resource-use', 'Resource-use', 'Resource-use']

Mean O
improvement O
in O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
irritability B-outcome ['Life-Impact']
subscale O
score O
was O
significantly O
greater O
with O
aripiprazole O
than O
with O
placebo O
from O
week O
1 O
through O
week O
8 O
. O
['Life-Impact', 'Life-Impact']

Clinical O
effects O
of O
buspirone O
in O
social O
phobia O
: O
a O
double-blind O
placebo-controlled O
study O
. O
[]

Major O
discrepancies O
exist O
between O
visit-to-visit O
BP O
variability O
as O
quantified O
by O
24-h O
vs. O
clinic O
BP O
, O
making O
investigation O
of O
which O
of O
these O
indices O
is O
clinically O
more O
relevant O
important O
. O
[]

Secondary O
outcomes O
included O
3 O
months O
of O
seizure B-outcome ['Physiological-Clinical']
freedom I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
6-month I-outcome ['Physiological-Clinical']
follow-up I-outcome ['Physiological-Clinical']
, O
measures O
of O
psychosocial B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
health B-outcome ['Resource-use']
service I-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
and O
employment B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Life-Impact']

were O
administered O
. O
[]

This O
multicenter O
international O
trial O
recruited O
205 O
patients O
from O
16 O
investigators O
. O
[]

In O
stratum O
2 O
, O
there O
was O
a O
numerical O
disadvantage O
for O
gefitinib O
; O
additional O
investigation O
after O
AI O
therapy O
is O
not O
warranted O
. O
[]

Data O
on O
LA O
were O
collected O
during O
and O
after O
a O
2-mo O
intervention O
trial O
in O
which O
low-income O
Honduran O
women O
who O
had O
breast-fed O
fully O
for O
4 O
mo O
were O
randomly O
assigned O
to O
one O
of O
three O
groups O
: O
continued O
full O
breast-feeding O
until O
6 O
mo O
( O
FBF O
, O
n O
= O
50 O
) O
, O
introduction O
of O
complementary O
foods O
at O
4 O
mo O
with O
ad O
libitum O
breast-feeding O
from O
4 O
to O
6 O
mo O
( O
SF O
, O
n O
= O
47 O
) O
, O
or O
introduction O
of O
complementary O
foods O
at O
4 O
mo O
with O
maintenance O
of O
baseline O
breast-feeding O
frequency O
from O
4 O
to O
6 O
mo O
( O
SF-M O
, O
n O
= O
44 O
) O
. O
[]

The O
proportions O
of O
patients O
who O
experienced O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
in O
the O
first O
24 O
h O
( O
30 O
% O
and O
27 O
% O
for O
the O
midazolam O
and O
ondansetron O
groups O
, O
respectively O
) O
were O
similar O
in O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
This O
was O
a O
phase O
III O
, O
randomized O
, O
open-label O
, O
dose-ranging O
6-month O
study O
. O
[]

METHODS O
Sixty-one O
mother-infant O
pairs O
were O
included O
, O
special O
emphasis O
being O
placed O
on O
the O
maternal O
allergic O
status O
. O
[]

[ O
Occupational O
exposure O
to O
nitrous O
oxide O
and O
sevoflurane O
during O
pediatric O
anesthesia O
: O
evaluation O
of O
an O
anesthetic B-outcome ['Resource-use']
gas I-outcome ['Resource-use']
extractor I-outcome ['Resource-use']
] O
. O
['Resource-use']

Double-blind O
, O
placebo-controlled O
study O
of O
azelastine O
and O
fluticasone O
in O
a O
single O
nasal O
spray O
delivery O
device O
. O
[]

Patients O
received O
adjuvant O
treatment O
with O
MSL-109 O
, O
60 O
mg O
intravenously O
every O
2 O
weeks O
, O
or O
placebo O
. O
[]

METHOD O
Examination O
to O
determine O
whether O
the O
improvements O
in O
oral B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
and O
oral B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
( O
use O
of O
toothbrush O
and O
dentifrice O
) O
, O
being O
unsupported O
, O
had O
been O
sustained O
since O
completion O
of O
the O
original O
study O
. O
['Physiological-Clinical', 'Life-Impact']

During O
a O
four-week O
titration O
period O
, O
the O
doses O
were O
increased O
weekly O
to O
a O
maximum O
of O
40 O
mg O
once O
daily O
until O
the O
treatment O
goal O
of O
diastolic O
blood O
pressure O
( O
BP O
) O
of O
less O
than O
90 O
mmHg O
was O
reached O
; O
treatment O
was O
then O
continued O
for O
four O
weeks O
. O
[]

Observational O
studies O
report O
lower O
serum O
ferritin O
values O
with O
regular O
aspirin O
use O
. O
[]

RESULTS O
Controlling O
for O
corresponding O
baseline O
alcohol O
measures O
, O
hierarchical O
linear O
regression O
analyses O
showed O
a O
significant O
interaction O
between O
intervention O
condition O
and O
baseline O
alcohol-related O
consequences O
. O
[]

Age O
and O
week O
relative O
to O
calving O
influenced O
leptin O
concentration O
. O
[]

A O
randomised O
comparison O
of O
UK O
genetic O
risk O
counselling O
services O
for O
familial O
cancer O
: O
psychosocial B-outcome ['Life-Impact']
outcomes O
. O
['Life-Impact']

However O
, O
pain B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
rest I-outcome ['Physiological-Clinical']
reported O
by O
the O
TENS O
group O
was O
significantly O
lower O
than O
that O
reported O
by O
the O
control O
group O
( O
treatment O
main O
effect O
; O
p O
< O
0.04 O
) O
, O
although O
no O
significant O
differences O
were O
observed O
between O
the O
TENS O
and O
placebo O
or O
between O
the O
placebo O
and O
control O
groups O
( O
p O
> O
0.05 O
) O
. O
['Physiological-Clinical']

Results O
indicate O
that O
, O
while O
individuals O
with O
autism O
may O
have O
the O
ability O
to O
think O
about O
reputation O
, O
a O
reduced O
expectation O
of O
reciprocal O
behavior O
from O
others O
may O
reduce O
the O
degree O
to O
which O
they O
engage O
in O
reputation O
management O
. O
[]

Phentolamine O
was O
given O
first O
to O
isolate O
the O
contribution O
of O
nitric O
oxide O
to O
postexercise O
hypotension O
by O
preventing O
reflex O
changes O
in O
sympathetic O
tone O
that O
result O
from O
systemic O
nitric O
oxide O
synthase O
inhibition O
and O
to O
control O
for O
alterations O
in O
resting O
sympathetic O
activity O
after O
exercise O
. O
[]

The O
Phase O
III O
trial O
therefore O
consists O
of O
two O
sub-protocols O
: O
one O
for O
patients O
with O
malignant O
conditions O
( O
four O
week O
protocol O
) O
and O
one O
for O
patients O
with O
non-malignant O
conditions O
( O
eight O
week O
protocol O
) O
. O
[]

METHODS O
186 O
patients O
received O
either O
indomethacin O
3 O
times O
daily O
, O
or O
rofecoxib O
twice O
, O
and O
1 O
placebo O
, O
daily O
for O
7 O
days O
. O
[]

Bridge O
plate O
osteosynthesis O
using O
dynamic O
condylar O
screw O
( O
DCS O
) O
or O
retrograde O
intramedullary O
supracondylar O
nail O
( O
RIMSN O
) O
in O
the O
treatment O
of O
distal O
femoral O
fractures O
: O
comparison O
of O
two O
methods O
in O
a O
prospective O
randomized O
study O
. O
[]

The O
effect O
of O
reinforcement O
or O
stimulus O
control O
to O
reduce O
sedentary B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
the O
treatment O
of O
pediatric O
obesity O
. O
['Life-Impact']

Airway O
pressures O
( O
surrogate O
for O
intrathoracic O
pressure O
) O
were O
measured O
with O
a O
pressure O
transducer O
. O
[]

As O
the O
comparatively O
few O
cases O
made O
it O
risky O
to O
associate O
certain O
predictors O
with O
certain O
time-points O
, O
we O
finally O
considered O
the O
predictors O
which O
were O
represented O
in O
at O
least O
3 O
follow-ups O
. O
[]

Moreover O
, O
the O
displaced O
upper O
canines O
showed O
an O
increase O
in O
vestibulo-oral B-outcome ['Physiological-Clinical']
dimension I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Subjects O
in O
the O
placebo O
group O
received O
normal O
saline O
solution O
. O
[]

Direct O
trocar O
use O
resulted O
in O
a O
decrease O
in O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
from O
9 O
minutes O
, O
40 O
seconds O
in O
the O
needle O
group O
to O
7 O
minutes O
, O
30 O
seconds O
in O
the O
trocar O
group O
. O
['Life-Impact']

Plasma B-outcome ['Physiological-Clinical']
renin I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
levels O
increased O
48 O
% O
with O
sodium O
nitroprusside O
and O
126 O
% O
with O
isoflurane O
. O
['Physiological-Clinical']

DESIGN O
A O
16 O
month O
exercise O
intervention O
study O
was O
executed O
, O
including O
a O
weight O
loss O
period O
with O
a O
very O
low O
energy O
diet O
( O
VLED O
) O
for O
2 O
months O
at O
the O
start O
of O
the O
study O
. O
[]

We O
compared O
the O
surgical O
outcomes O
between O
the O
two O
methods O
. O
[]

Patients O
received O
sildenafil O
25 O
mg O
twice O
a O
day O
or O
matching O
placebo O
for O
the O
first O
2 O
weeks O
and O
50 O
mg O
3 O
times O
a O
week O
for O
the O
remainder O
of O
the O
trial O
. O
[]

Scheffe O
post O
hoc O
tests O
were O
performed O
. O
[]

A O
sample O
of O
44 O
adults O
with O
severe O
disabilities O
completed O
a O
randomized O
single-blind O
cross-over O
study O
testing O
chlorhexidine O
swabbing O
under O
various O
conditions O
: O
with/without O
prior O
dental O
prophylaxis O
, O
reduced O
frequency O
of O
application O
( O
2 O
vs. O
5 O
times O
per O
week O
) O
, O
and O
prolonged O
use O
( O
42 O
weeks O
) O
. O
[]

Nutritive O
milk O
feeding O
was O
then O
introduced O
to O
both O
groups O
. O
[]

OBJECTIVE O
The O
main O
objective O
of O
the O
study O
was O
to O
determine O
the O
effects O
of O
three O
different O
infusion O
rates O
of O
fentanyl O
and O
remifentanil O
on O
the O
minimum O
alveolar O
concentration O
( O
MAC O
) O
of O
isoflurane O
in O
the O
rat O
. O
[]

RESULTS O
AGE-peptides B-outcome ['Physiological-Clinical']
were O
higher O
in O
the O
diabetic O
group O
with O
nephropathy O
than O
without O
nephropathy O
( O
P=0.005 O
) O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
expression O
of O
neu/c-erbB-2 B-outcome ['Physiological-Clinical']
oncoprotein I-outcome ['Physiological-Clinical']
, O
epidermal B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor O
receptor B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EGFR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
cathepsin B-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
catD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
progesterone B-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
( O
PR B-outcome ['Physiological-Clinical']
) O
and O
tumor-associated B-outcome ['Physiological-Clinical']
glycoprotein-72 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TAG-72 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
gastric O
carcinoma O
of O
these O
histological O
types O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
to O
etanercept O
or O
placebo O
, O
patients O
received O
standard O
therapy O
( O
glucocorticoids O
plus O
cyclophosphamide O
or O
methotrexate O
) O
. O
[]

The O
overall O
difference O
in O
the O
number O
of O
complications B-outcome ['Adverse-effects']
in O
the O
two O
groups O
was O
statistically O
significant O
( O
p O
< O
0.05 O
) O
. O
['Adverse-effects']

CONCLUSIONS O
In O
asymptomatic O
patients O
, O
the O
use O
of O
software O
for O
post-processing O
digital O
elimination O
of O
residue O
from O
images O
in O
conjunction O
with O
reduced O
bowel O
preparation O
does O
not O
reduce O
examination B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
or O
diagnostic B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
when O
compared O
with O
the O
conventional O
CT O
colonography O
technique O
and O
is O
more O
acceptable B-outcome ['Life-Impact']
to O
and O
better O
tolerated B-outcome ['Life-Impact']
by O
the O
patient O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

METHODS O
In O
a O
blinded O
experiment O
, O
we O
randomized O
99 O
African O
American O
patients O
with O
hypertension O
to O
perform O
a O
values-affirmation O
exercise O
or O
a O
control O
exercise O
before O
a O
visit O
with O
their O
primary O
care O
provider O
. O
[]

120 O
women O
were O
randomly O
assigned O
, O
using O
allocation O
concealment O
, O
to O
receive O
4 O
mg O
zoledronic O
acid O
intravenously O
every O
3 O
weeks O
( O
n=60 O
) O
, O
or O
no O
zoledronic O
acid O
( O
n=60 O
) O
, O
for O
1 O
year O
concomitant O
with O
four O
cycles O
of O
neoadjuvant O
epirubicin O
( O
75 O
mg/m O
( O
2 O
) O
) O
plus O
docetaxel O
( O
75 O
mg/m O
( O
2 O
) O
) O
and O
two O
cycles O
of O
adjuvant O
epirubicin O
plus O
docetaxel O
. O
[]

OBJECTIVE O
It O
was O
hypothesized O
that O
music O
or O
guided O
imagery O
versus O
usual O
care O
would O
result O
in O
less O
anxiety B-outcome ['Life-Impact']
and O
perceived B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
for O
colposcopy O
patients O
. O
['Life-Impact', 'Physiological-Clinical']

Such O
a O
pattern O
is O
consistent O
with O
the O
role O
of O
the O
left O
DLPFC O
in O
implementing O
top-down O
attentional O
control O
. O
[]

5 O
. O
[]

Paraesthesia O
during O
regional O
anaesthesia O
is O
an O
unpleasant O
sensation O
for O
patients O
and O
, O
more O
importantly O
, O
in O
some O
cases O
it O
is O
related O
to O
neurological O
injury O
. O
[]

RESULTS O
Both O
groups O
improved O
their O
knowledge B-outcome ['Life-Impact']
and O
QoL B-outcome ['Life-Impact']
during O
rehabilitation O
; O
however O
, O
knowledge B-outcome ['Life-Impact']
was O
significantly O
higher O
in O
the O
interactive O
group O
compared O
to O
the O
lecture O
group O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

By O
using O
power O
spectral O
analysis O
, O
the O
low O
frequency O
and O
high O
frequency O
components O
of O
heart O
rate O
variability O
can O
be O
calculated O
reflecting O
the O
sympathetic O
and O
parasympathetic O
activity O
. O
[]

Furthermore O
, O
LP O
mink O
had O
a O
higher B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
and O
lower O
body B-outcome ['Physiological-Clinical']
CP I-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
at O
50 O
weeks O
of O
age O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effectiveness O
of O
initiating O
treatment O
with O
valsartan/hydrochlorothiazide O
in O
patients O
with O
stage-1 O
or O
stage-2 O
hypertension O
. O
[]

CONCLUSIONS O
Rationing O
by O
delay O
was O
not O
detrimental O
to O
either O
mental O
or O
physical O
health O
and O
patients O
in O
both O
arms O
of O
the O
study O
showed O
significant O
and O
similar O
improvement O
in O
health O
by O
15 O
months O
. O
[]

The O
main O
effect O
is O
an O
increase O
of O
the O
professional B-outcome ['Life-Impact']
competence I-outcome ['Life-Impact']
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
interaction I-outcome ['Life-Impact']
, O
especially O
by O
the O
qualified O
staff O
members O
. O
['Life-Impact', 'Life-Impact']

Cervical O
spine O
motion O
: O
a O
fluoroscopic O
comparison O
during O
intubation O
with O
lighted O
stylet O
, O
GlideScope O
, O
and O
Macintosh O
laryngoscope O
. O
[]

Therefore O
, O
a O
randomised O
trial O
to O
compare O
the O
effectiveness O
of O
acupuncture O
with O
advice O
and O
exercises O
on O
the O
symptomatic O
treatment O
of O
OA O
of O
the O
hip O
was O
carried O
out O
. O
[]

AT O
strain B-outcome ['Physiological-Clinical']
was O
determined O
from O
kinematics O
and O
ultrasound O
images O
of O
medial O
gastrocnemius O
( O
50 O
Hz O
) O
. O
['Physiological-Clinical']

Randomized O
controlled O
trial O
of O
collaborative O
care O
management O
of O
depression O
among O
low-income O
patients O
with O
cancer O
. O
[]

METHODS O
AND O
RESULTS O
We O
performed O
an O
open O
labeled O
randomized O
prospective O
trial O
on O
78 O
drug-naive O
type O
2 O
diabetic O
patients O
whose O
HbA1c O
was O
less O
than O
6.5 O
% O
. O
[]

The O
total O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
LA I-outcome ['Resource-use']
did O
not O
differ O
significantly O
among O
groups O
. O
['Resource-use']

OBJECTIVES O
Certain O
GI O
prokinetic O
agents O
have O
been O
shown O
to O
affect O
cardiac O
repolarization O
, O
which O
may O
be O
associated O
with O
life-threatening O
arrhythmias O
. O
[]

The O
communication B-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
, O
compromising O
use O
of O
the O
patient O
as O
an O
informant O
, O
were O
addressed O
by O
several O
strategies O
, O
including O
careful B-outcome ['Life-Impact']
questioning I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
providers I-outcome ['Life-Impact']
, O
['Life-Impact', 'Life-Impact']

The O
resulting O
size O
of O
the O
occlusal O
opening O
was O
1.0 O
mm O
, O
1.4 O
mm O
, O
1.6 O
mm O
and O
1.8 O
mm O
for O
Groups O
A O
, O
B O
, O
C O
, O
and O
D O
, O
respectively O
. O
[]

Based O
on O
the O
findings O
, O
we O
suggest O
an O
approach O
utilising B-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
guidebook I-outcome ['Life-Impact']
to O
improve O
patient B-outcome ['Life-Impact']
participation I-outcome ['Life-Impact']
in O
disease O
management O
. O
['Life-Impact', 'Life-Impact']

The O
3-year O
survival B-outcome ['Mortality']
rate O
did O
not O
differ O
between O
sequential O
chemotherapy O
and O
autotransplantation O
, O
at O
71 O
% O
( O
95 O
% O
confidence O
interval O
, O
64 O
% O
to O
78 O
% O
) O
and O
69 O
% O
( O
95 O
% O
confidence O
interval O
, O
62 O
% O
to O
76 O
% O
) O
, O
respectively O
( O
P O
= O
.60 O
, O
relative O
risk O
= O
1.11 O
) O
. O
['Mortality']

OBJECTIVE O
Biofilm B-outcome ['Physiological-Clinical']
accumulation I-outcome ['Physiological-Clinical']
on O
provisional B-outcome ['Physiological-Clinical']
restorations I-outcome ['Physiological-Clinical']
may O
affect O
the O
surrounding O
tissues O
' O
integrity O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Basal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
posttreatment I-outcome ['Physiological-Clinical']
platelet I-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
in O
response O
to O
arachidonic O
acid O
( O
AA O
) O
and O
serum O
thromboxane O
( O
TX O
) O
B O
( O
2 O
) O
and O
AA-stimulated O
platelet O
TXB O
( O
2 O
) O
production O
were O
investigated O
. O
['Physiological-Clinical']

Side O
branch O
occlusion O
with O
everolimus-eluting O
and O
paclitaxel-eluting O
stents O
: O
three-year O
results O
from O
the O
SPIRIT O
III O
randomised O
trial O
. O
[]

The O
nicotine O
reduced O
both O
tone B-outcome ['Physiological-Clinical']
and O
activity B-outcome ['Life-Impact']
in O
all O
subjects O
, O
with O
reduction O
or O
abolition O
of O
the O
large O
contractions O
in O
UC O
. O
['Physiological-Clinical', 'Life-Impact']

Children O
at O
both O
grade O
levels O
showed O
less O
positive O
attitudes B-outcome ['Life-Impact']
toward O
the O
child O
in O
the O
two O
autism O
conditions O
. O
['Life-Impact']

Heparan O
sulfate O
in O
the O
treatment O
of O
intermittent O
claudication O
: O
results O
of O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
multicenter O
trial O
. O
[]

Recordings O
of O
total O
night-time B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
and O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
showed O
significant O
improvement O
of O
approximately O
30 O
min O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Compared O
to O
the O
placebo O
condition O
, O
the O
results O
showed O
a O
decrease O
in O
behavior B-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
at O
the O
1 O
1/2 O
and O
2 O
month O
assessment O
periods O
and O
a O
slight O
loss O
of O
these O
benefits O
at O
the O
3 O
and O
4 O
month O
assessment O
periods O
. O
['Life-Impact']

The O
RQLQ O
[]

INTERVENTIONS O
Autologous O
technetium-99m O
( O
99mTc O
) O
-labeled O
red O
blood O
cells O
and O
indium-oxine O
( O
( O
111 O
) O
In O
) O
-labeled O
human O
serum O
albumin O
were O
injected O
intravenously O
during O
anesthesia O
at O
T O
= O
0 O
min O
in O
the O
two O
groups O
for O
the O
determination O
of O
total O
blood O
volume O
and O
albumin O
diffusion O
space O
, O
respectively O
. O
[]

tablet O
formulation O
in O
patients O
with O
mild-to-moderately-active O
ulcerative O
colitis O
: O
a O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
. O
[]

Sixty-eight O
patients O
( O
44 O
men O
and O
24 O
women O
) O
with O
a O
mean O
age O
of O
44.3 O
( O
1.2 O
) O
yr O
and O
verified O
GH O
deficiency O
participated O
in O
a O
2-phase O
treatment O
trial O
with O
an O
initial O
randomized O
, O
double O
blind O
, O
placebo-controlled O
, O
6-month O
period O
, O
followed O
by O
an O
open O
treatment O
period O
, O
thereby O
ensuring O
all O
patients O
12 O
months O
of O
GH O
treatment O
. O
[]

Pharmacokinetic O
parameters O
indicate O
that O
the O
bioavailability B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cyclosporin I-outcome ['Physiological-Clinical']
A O
was O
not O
significantly O
modified O
by O
ticlopidine O
. O
['Physiological-Clinical']

More O
grade O
3 O
[]

After O
being O
matched O
, O
38 O
eyes O
were O
included O
in O
the O
study O
and O
were O
divided O
into O
2 O
equal O
groups O
for O
data O
analysis O
. O
[]

RESULTS O
Acidosis B-outcome ['Physiological-Clinical']
was O
evident O
in O
all O
infants O
between O
2 O
and O
5 O
days O
after O
birth O
. O
['Physiological-Clinical']

We O
evaluated O
the O
stone O
capture O
rate O
of O
9 O
commercially O
available O
tipless O
stone O
baskets O
in O
an O
in O
vitro O
model O
using O
novice O
and O
expert O
operators O
. O
[]

This O
is O
of O
obvious O
importance O
in O
countries O
where O
inactivated O
poliovirus O
vaccine O
is O
part O
of O
the O
routine O
infant O
immunization O
programs O
. O
[]

At O
12 O
months O
, O
the O
rate O
of O
eradication B-outcome ['Physiological-Clinical']
of O
H. O
pylori B-outcome ['Physiological-Clinical']
was O
69 O
% O
in O
the O
active-treatment O
group O
and O
18 O
% O
in O
the O
placebo O
group O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SUMMARY O
The O
effect O
of O
garlic O
and O
onion O
on O
alimentary O
hyperlipemia O
, O
induced O
by O
feeding O
100 O
g O
butter O
, O
has O
been O
studied O
in O
10 O
healthy O
subjects O
. O
[]

0.35 O
G/L O
vs. O
3.64 O
? O
[]

Lambs O
were O
allotted O
to O
12 O
pens O
( O
4 O
lambs O
per O
pen O
) O
, O
and O
blocked O
by O
sex O
and O
BW O
. O
[]

The O
CCR B-outcome ['Physiological-Clinical']
rates O
in O
Regimen O
A O
and O
B O
were O
75.1 O
% O
+/- O
5.8 O
% O
( O
mean O
+/- O
1 O
SE O
) O
and O
49.7 O
% O
+/- O
7.3 O
% O
( O
P O
less O
than O
0.01 O
) O
at O
4 O
years O
, O
and O
72.1 O
% O
+/- O
6.3 O
% O
and O
49.7 O
% O
+/- O
7.3 O
% O
( O
P O
less O
than O
0.05 O
) O
at O
5 O
years O
, O
respectively O
. O
['Physiological-Clinical']

The O
pre-treatment O
WOMAC O
scores O
in O
the O
two O
groups O
were O
similar O
( O
p=0.85 O
) O
. O
[]

The O
primary O
efficacy O
endpoint O
was O
the O
proportion O
of O
patients O
who O
achieved O
hemostasis B-outcome ['Physiological-Clinical']
at O
the O
primary O
treatment O
site O
within O
5 O
min O
, O
and O
maintained O
hemostasis O
until O
surgical O
closure O
. O
['Physiological-Clinical']

Following O
this O
practice O
will O
minimize O
the O
incidence O
of O
starting O
a O
practice O
or O
competition O
hypohydrated O
. O
[]

CONCLUSIONS O
The O
administration O
of O
L-arginine O
and O
citrulline O
has O
a O
beneficial O
effect O
on O
endothelial O
function O
as O
shown O
by O
the O
normalized O
MAT/TT O
index O
. O
[]

BACKGROUND O
Despite O
the O
potential O
benefits O
of O
genetic O
testing O
for O
hereditary O
nonpolyposis O
colorectal O
cancer O
( O
HNPCC O
) O
risk O
, O
individuals O
can O
find O
the O
genetic O
testing O
decision-making O
process O
complicated O
and O
challenging O
. O
[]

The O
ECM O
proteins O
in O
asthmatics O
were O
also O
compared O
with O
a O
normal O
control O
group O
. O
[]

So O
far O
, O
HER2 O
test O
accuracy O
of O
immunohistochemistry/in O
situ-hybridization O
techniques O
is O
still O
under O
debate O
, O
and O
more O
reliable O
and O
robust O
technologies O
are O
needed O
. O
[]

[ O
Prophylactic O
intraaortic O
balloon O
pumping O
in O
high-risk O
cardiac O
surgery O
patients O
] O
. O
[]

Forty-nine O
chemotherapy-naive O
patients O
were O
randomized O
to O
5-FU O
alone O
or O
to O
the O
combination O
. O
[]

The O
association O
from O
adolescent B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
peer I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
was O
significant O
only O
from O
7th O
to O
8th O
grade O
. O
['Life-Impact']

METHODS O
This O
study O
was O
a O
randomized O
controlled O
trial O
. O
[]

RESULTS O
After O
the O
treatment O
, O
liver O
function O
of O
the O
treatment O
group O
and O
the O
control O
group O
had O
more O
significant O
improvement O
. O
[]

No O
serious O
adverse O
events O
( O
including O
thromboembolic O
events O
) O
were O
reported O
. O
[]

RESULTS O
Both O
treatments O
were O
well O
tolerated O
. O
[]

METHODS O
We O
randomly O
allocated O
healthy O
children O
aged O
6 O
months O
to O
5 O
years O
to O
receive O
25 O
mg/kg O
sulfadoxine O
and O
1.25 O
mg/kg O
pyrimethamine O
plus O
either O
placebo O
, O
25 O
mg/kg O
amodiaquine O
, O
or O
12 O
mg/kg O
artesunate O
. O
[]

Ten O
subjects O
completed O
the O
study O
. O
[]

The O
subjective O
effects O
of O
diazepam O
( O
i.e O
. O
[]

BACKGROUND O
Inflammatory B-outcome ['Physiological-Clinical']
and O
structural O
changes O
of O
the O
airway B-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
are O
chronic O
features O
of O
asthma O
. O
['Physiological-Clinical', 'Physiological-Clinical']

By O
contrast O
these O
variables O
were O
sustained O
above O
baseline O
in O
the O
ONO-1078 O
group O
. O
[]

Group O
3 O
was O
too O
small O
to O
permit O
a O
meaningful O
comparison O
. O
[]

Those O
children O
treated O
with O
immunosuppression O
plus O
nifedipine O
developed O
gingival B-outcome ['Physiological-Clinical']
overgrowth I-outcome ['Physiological-Clinical']
, O
however O
, O
this O
was O
much O
less O
marked O
in O
the O
tacrolimus O
group O
. O
['Physiological-Clinical']

OBJECTIVE O
Our O
purpose O
was O
to O
determine O
whether O
pulse-dose O
terbinafine O
is O
as O
effective O
as O
standard O
continuous-dose O
terbinafine O
for O
treatment O
of O
toenail O
onychomycosis O
. O
[]

METHODS O
Twenty-four O
patients O
with O
perennial O
rhinitis O
due O
to O
house-dust-mite O
( O
HDM O
) O
allergy O
were O
recruited O
in O
this O
crossover O
study O
. O
[]

However O
, O
continuous O
intravenous O
prostacyclin O
infusion O
poses O
significant O
risks O
and O
challenges O
, O
particularly O
in O
children O
. O
[]

Thirteen O
individuals O
with O
impaired O
hearing O
were O
tested O
before O
and O
after O
6 O
months O
of O
hearing-aid O
use O
, O
and O
were O
compared O
with O
19 O
individuals O
who O
had O
worn O
hearing O
aids O
for O
many O
years O
. O
[]

The O
application O
of O
ozone O
decreased O
the O
?TBS O
of O
the O
dentin-composite O
resin O
interface O
. O
[]

A O
total O
of O
69 O
patients O
were O
followed O
up O
to O
6 O
months O
. O
[]

We O
discuss O
potential O
modification O
of O
current O
memory-based O
processing O
theories O
to O
account O
for O
these O
effects O
. O
[]

No O
changes O
in O
lung O
function O
were O
observed O
, O
but O
the O
aerosol O
bolus O
recovery O
technique O
revealed O
a O
statistically O
significant O
( O
p O
< O
.05 O
) O
decrease O
in O
the O
fraction O
of O
aerosol O
recovered O
following O
nitrogen O
dioxide O
exposure O
, O
which O
is O
suggestive O
of O
small O
obstructive O
changes O
induced O
by O
NO2 O
. O
[]

OBJECTIVE O
To O
assess O
outcomes O
of O
using O
a O
clinical O
pathway O
for O
managing O
patients O
with O
fractured O
neck O
of O
femur O
. O
[]

After O
the O
Mohs O
micrographic O
surgery O
excision O
, O
the O
tissue O
was O
evaluated O
histologically O
, O
and O
the O
excision O
area O
was O
measured O
. O
[]

Mean O
ddI O
plasma O
levels O
at O
day O
28 O
were O
0.0234 O
mg/L O
for O
group O
1 O
and O
0.0227 O
mg/L O
for O
group O
2 O
( O
P=0.96 O
) O
. O
[]

UNLABELLED O
In O
242 O
community-dwelling O
seniors O
, O
supplementation O
with O
either O
1000 O
mg O
of O
calcium O
or O
1000 O
mg O
of O
calcium O
plus O
vitamin O
D O
resulted O
in O
a O
decrease O
in O
the O
number O
of O
subjects O
with O
first O
falls O
of O
27 O
% O
at O
month O
12 O
and O
39 O
% O
at O
month O
20 O
. O
[]

RESULTS O
Participant O
evaluations O
indicated O
that O
the O
training O
video O
was O
clear O
in O
explaining O
and O
demonstrating O
the O
principles O
and O
skills O
of O
motivational O
interviewing O
. O
[]

CONCLUSIONS O
Both O
local O
anesthetics O
offer O
good O
surgical B-outcome ['Life-Impact']
conditions I-outcome ['Life-Impact']
with O
hemodynamic O
stability O
and O
few O
complications B-outcome ['Adverse-effects']
. O
['Life-Impact', 'Adverse-effects']

Nine O
hundred O
patient O
aged O
< O
80 O
, O
with O
diabetes O
of O
> O
or O
=1 O
year O
known O
duration O
, O
treated O
by O
either O
diet O
alone O
or O
diet O
and O
oral O
agents O
, O
will O
be O
recruited O
in O
15 O
centres O
and O
followed O
for O
4 O
years O
. O
[]

There O
was O
a O
marked O
difference O
between O
the O
Sedation O
and O
TIVA O
groups O
with O
respect O
to O
the O
time O
from O
the O
end O
of O
the O
procedure O
until O
the O
maximum O
MPADS O
score O
was O
reached O
: O
respectively O
, O
-6.9 O
( O
4.0 O
) O
versus O
25.7 O
( O
8.4 O
) O
minutes O
( O
p O
< O
0.001 O
) O
. O
[]

To O
increase O
statistical O
power O
, O
the O
data O
collected O
from O
this O
field O
trial O
was O
pooled O
with O
data O
from O
two O
other O
published O
field O
trials O
to O
form O
an O
individual O
patient O
data O
meta-analysis O
( O
IPDMA O
) O
. O
[]

Infants O
receive O
many O
painful O
immunizations O
before O
they O
are O
2 O
years O
old O
. O
[]

In O
people O
without O
diabetes O
it O
seems O
to O
be O
due O
to O
less O
glucose O
being O
produced O
and O
entering O
the O
circulation O
than O
the O
calculated O
theoretical O
amount O
. O
[]

We O
started O
a O
controlled O
clinical O
trial O
to O
evaluate O
the O
efficacy O
and O
toxicity B-outcome ['Adverse-effects']
of O
a O
conventional O
versus O
more O
intensive O
regimen O
of O
combined O
chemotherapy O
followed O
by O
radiotherapy O
to O
the O
mediastinum O
with O
the O
mantle O
technique O
. O
['Adverse-effects']

Menopausal B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
: O
RCT O
of O
yoga O
, O
exercise O
, O
and O
omega-3 O
supplements O
. O
['Life-Impact']

There O
were O
110 O
cases O
in O
MSCT O
and O
SAA O
combined O
group O
and O
115 O
cases O
in O
MSCT O
group O
. O
[]

Low B-outcome ['Physiological-Clinical']
alcoholism I-outcome ['Physiological-Clinical']
risk O
and O
employment B-outcome ['Life-Impact']
were O
identified O
as O
significant O
predictors O
of O
compliance O
with O
HBP O
medication-taking O
behavior O
. O
['Physiological-Clinical', 'Life-Impact']

Whenever O
possible O
, O
we O
give O
information O
on O
other O
forms O
of O
training O
for O
comparison O
. O
[]

if O
the O
C O
( O
2 O
) O
level O
was O
21-59 O
ng/mL O
or O
0.05 O
mg/kg O
b.d O
. O
[]

The O
clinical O
recovery O
with O
respect O
to O
the O
times O
to O
eye B-outcome ['Physiological-Clinical']
opening I-outcome ['Physiological-Clinical']
, O
to O
responding O
to O
command O
or O
to O
being O
fully O
awake O
did O
not O
differ O
between O
the O
two O
anaesthesia O
methods O
. O
['Physiological-Clinical']

BACKGROUND O
Measurement O
of O
objective O
response O
to O
chemotherapy B-outcome ['Resource-use']
using O
imaging B-outcome ['Resource-use']
modalities O
is O
sometimes O
difficult O
in O
pancreatic O
cancer O
( O
PC O
) O
. O
['Resource-use', 'Resource-use']

The O
experimental O
evidence O
above O
would O
possibly O
be O
a O
guide O
for O
such O
trial O
. O
[]

In O
contrast O
, O
in O
nine O
patients O
, O
with O
poor O
diabetes B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
clofibrate O
reduced O
24 O
h B-outcome ['Physiological-Clinical']
glycosuria I-outcome ['Physiological-Clinical']
and O
significantly O
improved O
the O
M-value B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
5 O
years O
of O
followup O
, O
38 O
patients O
( O
61.3 O
% O
) O
were O
cured B-outcome ['Physiological-Clinical']
( O
16 O
in O
group O
A O
and O
22 O
in O
group O
B O
) O
, O
and O
5 O
( O
8.1 O
% O
) O
were O
in O
remission O
without O
treatment O
but O
had O
not O
yet O
completed O
the O
cure-defining O
period O
of O
18 O
months O
( O
3 O
in O
group O
A O
and O
2 O
in O
group O
B O
) O
. O
['Physiological-Clinical']

Maintaining O
tissue O
orientation O
during O
mohs O
micrographic O
surgery O
: O
scalpel O
versus O
marker O
. O
[]

PI O
in O
the O
toe B-outcome ['Physiological-Clinical']
, O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
MAP B-outcome ['Physiological-Clinical']
) O
and O
toe B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
were O
all O
assessed O
at O
baseline O
and O
at O
5 O
, O
10 O
and O
20 O
min O
following O
epidural O
anesthesia O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
1233 O
patients O
were O
randomized O
. O
[]

After O
adjusting O
for O
confounders O
, O
the O
excess O
risk O
of O
death O
was O
no O
longer O
significant O
( O
hazard O
ratio O
0.99 O
, O
95 O
% O
confidence O
interval O
0.83 O
to O
1.18 O
, O
p O
= O
0.90 O
) O
, O
and O
the O
adjusted O
risk O
of O
target O
lesion O
revascularization O
was O
significantly O
higher O
in O
patients O
with O
previous O
CABG O
than O
in O
those O
without O
( O
hazard O
ratio O
1.25 O
, O
95 O
% O
confidence O
interval O
1.06 O
to O
1.47 O
, O
p O
= O
0.01 O
) O
. O
[]

Lessons O
learnt O
in O
conducting O
a O
clinical O
drug O
trial O
in O
children O
with O
Asperger O
Syndrome O
. O
[]

RESULTS O
For O
persons O
completing O
the O
study O
, O
8 O
( O
57 O
% O
) O
of O
14 O
patients O
treated O
with O
risperidone O
were O
categorized O
as O
responders O
( O
daily O
dose O
[ O
mean+/-SD O
] O
, O
2.9+/-1.4 O
mg O
) O
compared O
with O
none O
of O
16 O
in O
the O
placebo O
group O
( O
P O
< O
.002 O
) O
. O
[]

All O
patients O
were O
treated O
with O
CsA O
for O
the O
first O
10 O
days O
and O
then O
randomized O
to O
receive O
Evr O
in O
combination O
with O
CsA O
up O
to O
day O
30 O
, O
then O
either O
continued O
on O
Evr O
monotherapy O
( O
Evr O
group O
) O
or O
maintained O
on O
CsA O
with/without O
mycophenolate O
mofetil O
( O
CsA O
group O
) O
in O
case O
of O
chronic O
kidney O
disease O
( O
CKD O
) O
. O
[]

STUDY O
DESIGN O
Prospective O
, O
randomized O
, O
controlled O
trial O
. O
[]

All O
studies O
were O
conducted O
in O
a O
random O
fashion O
. O
[]

INTERVENTION O
The O
STG O
was O
instructed O
to O
perform O
strength O
training O
and O
both O
the O
STG O
and O
CG O
were O
instructed O
in O
the O
same O
stretching O
and O
stabilization O
exercises O
for O
12 O
months O
. O
[]

Study O
registration O
was O
in O
the O
UMIN O
Clinical O
Trial O
Registry O
( O
UMIN O
000001497 O
) O
, O
and O
the O
institutional O
trial O
number O
was O
KDOG O
0801 O
. O
[]

In O
this O
population O
, O
amlodipine O
maleate O
was O
not O
inferior O
to O
amlodipine O
besylate O
: O
the O
lower O
limit O
of O
the O
2-sided O
95 O
% O
CI O
for O
the O
treatment O
difference O
in O
SiDBP B-outcome ['Physiological-Clinical']
was O
greater O
than O
-4 O
mm O
Hg O
. O
['Physiological-Clinical']

Anxiety O
sensitivity O
as O
an O
incremental O
predictor O
of O
later O
anxiety O
symptoms O
and O
syndromes O
. O
[]

The O
findings O
revealed O
that O
women O
were O
more O
likely O
than O
men O
to O
attend B-outcome ['Resource-use']
aftercare I-outcome ['Resource-use']
. O
['Resource-use']

At O
52 O
weeks O
, O
patients O
receiving O
the O
implant O
with O
the O
postulated O
biomechanical O
advantage O
achieved O
116 O
% O
of O
the O
power O
output B-outcome ['Physiological-Clinical']
of O
['Physiological-Clinical']

This O
study O
was O
carried O
out O
on O
55 O
patients O
, O
who O
were O
either O
treated O
for O
six O
( O
n O
= O
16 O
) O
or O
18 O
months O
( O
n O
= O
39 O
) O
and O
followed O
up O
for O
an O
additional O
two-year O
period O
. O
[]

CONCLUSIONS O
Erosion O
increases O
the O
susceptibility B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
enamel I-outcome ['Physiological-Clinical']
to O
toothpaste B-outcome ['Physiological-Clinical']
abrasion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Serum O
liver O
function O
test O
results O
, O
PCIII O
, O
CIV O
, O
HA O
and O
liver O
biopsy O
results O
of O
these O
57 O
patients O
were O
simultaneously O
collected O
and O
analyzed O
before O
and O
after O
this O
intervention O
. O
[]

Naltrexone O
, O
1.0 O
mg/kg O
, O
or O
placebo O
was O
administered O
daily O
for O
2 O
weeks O
. O
[]

METHOD O
Sixteen O
dyads O
( O
preschoolers O
with O
ASD O
and O
the O
public O
school O
teachers O
who O
worked O
in O
the O
child O
's O
classroom O
) O
were O
randomly O
assigned O
to O
the O
6-week O
JASP/ER O
intervention O
or O
a O
control O
group O
. O
[]

One O
of O
the O
most O
efficacious O
treatments O
for O
cocaine O
abuse O
is O
contingency O
management O
( O
CM O
) O
, O
but O
little O
research O
has O
explored O
the O
impact O
of O
AD O
on O
abstinence B-outcome ['Life-Impact']
outcomes O
, O
particularly O
among O
patients O
in O
methadone O
maintenance O
. O
['Life-Impact']

Human O
achaete-scute O
homologue O
( O
hASH1 O
) O
mRNA O
level O
as O
a O
diagnostic O
marker O
to O
distinguish O
esthesioneuroblastoma O
from O
poorly O
differentiated O
tumors O
arising O
in O
the O
sinonasal O
tract O
. O
[]

CONCLUSION O
Hippotherapy O
with O
a O
simulator O
can O
improve O
sitting B-outcome ['Life-Impact']
balance I-outcome ['Life-Impact']
in O
cerebral O
palsy O
children O
who O
have O
higher O
levels O
of O
disability O
. O
['Life-Impact']

Double-blind O
placebo-controlled O
trial O
of O
pentoxifylline O
added O
to O
risperidone O
: O
effects O
on O
aberrant B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
children O
with O
autism O
. O
['Life-Impact']

OBJECTIVES O
We O
sought O
to O
assess O
the O
feasibility O
and O
accuracy O
of O
myocardial O
contrast O
echocardiography O
( O
MCE O
) O
using O
standard O
imaging O
approaches O
for O
the O
detection O
of O
perfusion O
defects O
in O
patients O
who O
had O
a O
myocardial O
infarction O
( O
MI O
) O
. O
[]

Other O
parameters O
showed O
a O
similar O
trend O
in O
favor O
of O
experienced O
by O
the O
HA O
group O
during O
the O
6 O
month O
follow-up O
period O
. O
[]

RESULTS O
Baseline O
prolactin B-outcome ['Physiological-Clinical']
levels O
were O
similar O
in O
the O
risperidone O
( O
N O
= O
42 O
) O
and O
placebo O
( O
N O
= O
36 O
) O
groups O
( O
9.3 O
+/- O
7.5 O
and O
9.3 O
+/- O
7.6 O
ng/ml O
, O
respectively O
) O
. O
['Physiological-Clinical']

No O
recurrences B-outcome ['Physiological-Clinical']
were O
observed O
over O
a O
12-month O
follow-up O
in O
both O
groups O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
injection O
pain O
of O
a O
HA O
gel O
with O
preincorporated O
lidocaine O
with O
that O
with O
a O
non-lidocaine O
formulation O
. O
[]

Valsartan O
( O
160 O
mg/day O
) O
lowered O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
significantly O
in O
African O
American O
patients O
on O
both O
low O
salt O
( O
-6.4/-4.8 O
mm O
Hg O
: O
P O
< O
.001 O
) O
and O
a O
high O
salt O
diet O
( O
-4.9/-3.8 O
mm O
Hg O
: O
P O
= O
.01 O
) O
. O
['Physiological-Clinical']

No O
significant O
differences O
were O
found O
between O
the O
sclerotherapy O
and O
ligation O
groups O
in O
arresting O
active B-outcome ['Life-Impact']
index O
bleeding B-outcome ['Physiological-Clinical']
( O
100 O
% O
each O
) O
and O
achieving B-outcome ['Life-Impact']
variceal B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
( O
91.7 O
% O
vs. O
96 O
% O
, O
P O
=.61 O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

However O
, O
the O
cumulative B-outcome ['Life-Impact']
doses I-outcome ['Life-Impact']
of O
metamizol O
were O
also O
lower O
in O
Group O
2 O
than O
in O
Groups O
1 O
and O
3 O
over O
the O
entire O
study O
( O
2025 O
+/- O
1044 O
mg O
vs. O
4925 O
+/- O
1238 O
and O
4125 O
+/- O
1276mg O
; O
P O
< O
0.05 O
) O
. O
['Life-Impact']

Symptomatic O
and O
functional O
improvement O
in O
employed O
depressed O
patients O
: O
a O
double-blind O
clinical O
trial O
of O
desvenlafaxine O
versus O
placebo O
. O
[]

There O
was O
a O
statistically O
significant O
positive O
relationship O
found O
between O
the O
sensory B-outcome ['Physiological-Clinical']
impairment B-outcome ['Life-Impact']
score O
and O
the O
['Physiological-Clinical', 'Life-Impact']

A O
1-year O
randomized O
clinical O
trial O
. O
[]

A O
falls O
calendar O
will O
be O
kept O
by O
each O
participant O
for O
12 O
months O
after O
outpatient O
therapy.Consistent O
with O
the O
recommendations O
of O
the O
Prevention O
of O
Falls O
Network O
Europe O
group O
, O
three O
falls B-outcome ['Life-Impact']
variables O
will O
be O
used O
as O
the O
primary O
outcome O
measures O
: O
the O
number O
of O
fallers B-outcome ['Physiological-Clinical']
, O
the O
number O
of O
multiple B-outcome ['Physiological-Clinical']
fallers I-outcome ['Physiological-Clinical']
and O
the O
falls B-outcome ['Life-Impact']
rate O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Feeding O
a O
LS O
or O
a O
HS O
diet O
for O
30 O
d O
before O
breeding O
may O
be O
inadequate O
to O
stimulate O
puberty B-outcome ['Physiological-Clinical']
in O
beef O
heifers O
, O
but O
feeding O
a O
diet O
with O
a O
greater O
amount O
of O
starch O
for O
60 O
d O
before O
breeding O
may O
increase O
the O
incidence O
of O
puberty B-outcome ['Physiological-Clinical']
during O
breeding O
of O
heifers O
that O
have O
inadequate O
yearling O
weight O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
simplified O
scores O
ranged O
from O
-5 O
to O
110 O
points O
and O
were O
categorized O
into O
3 O
classes O
of O
risk O
. O
[]

METHODS O
Two O
hundred O
children O
were O
randomized O
to O
receive O
S. O
boulardii O
in O
a O
granulated O
form O
in O
a O
daily O
dose O
of O
250 O
mg O
( O
S. O
boulardii O
group O
) O
or O
placebo O
( O
placebo O
group O
) O
for O
5 O
d. O
Clinical O
and O
demographic O
characteristics O
on O
admission O
were O
similar O
between O
the O
study O
groups O
. O
[]

Our O
findings O
suggest O
that O
intravesical O
THP O
instillation O
prior O
to O
TUR O
would O
be O
effective O
for O
patients O
with O
single B-outcome ['Physiological-Clinical']
, O
low O
grade O
['Physiological-Clinical']

After O
weaning O
from O
cardiopulmonary O
bypass O
, O
cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
increased O
and O
came O
close O
to O
the O
value O
after O
induction O
in O
all O
groups O
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
and O
leukapheresis B-outcome ['Physiological-Clinical']
products I-outcome ['Physiological-Clinical']
were O
assayed O
for O
hematopoietic O
progenitors O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Studies O
on O
the O
example O
of O
vecuronium O
] O
. O
[]

Is O
anti-Pseudomonas O
therapy O
warranted O
in O
acute O
respiratory B-outcome ['Physiological-Clinical']
exacerbations I-outcome ['Physiological-Clinical']
in O
children O
with O
cystic O
fibrosis O
? O
['Physiological-Clinical']

No O
clinically O
serious O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
observed O
in O
any O
of O
the O
groups O
. O
['Adverse-effects']

METHODS O
Multivariate O
logistic O
regression O
was O
used O
to O
establish O
socio-demographic O
characteristics O
of O
participants O
versus O
non-participants O
in O
the O
intervention O
arm O
. O
[]

Despite O
blinding O
, O
subjects O
' O
VAS O
scores O
improved O
from O
baseline O
to O
post-intervention O
for O
stress O
( O
5.5 O
vs. O
2.2 O
) O
, O
relaxation B-outcome ['Life-Impact']
( O
3.8 O
vs. O
8.8 O
) O
and O
peacefulness B-outcome ['Life-Impact']
( O
3.8 O
vs. O
9.0 O
, O
P O
< O
0.05 O
for O
all O
comparisons O
) O
. O
['Life-Impact', 'Life-Impact']

However O
, O
there O
are O
no O
reports O
on O
adapalene O
gel O
for O
the O
treatment O
of O
pityriasis O
versicolor O
. O
[]

Thirty-seven O
platinum-resistant O
and O
27 O
platinum-sensitive O
tumours O
were O
treated O
with O
carboplatin O
or O
cisplatin O
as O
second-line O
therapy O
. O
[]

Time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
recurrence I-outcome ['Life-Impact']
of O
any O
mood B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
was O
significantly O
longer O
with O
paliperidone O
ER O
than O
placebo O
( O
p=0.017 O
; O
based O
on O
weighted O
Z-test O
at O
0.0198 O
significance O
level O
; O
hazard O
ratio O
[ O
placebo O
: O
paliperidone O
ER O
; O
unweighted O
95 O
% O
confidence O
interval O
] O
: O
1.43 O
[ O
1.03 O
; O
1.98 O
] O
) O
; O
the O
difference O
was O
significant O
for O
preventing O
['Life-Impact', 'Life-Impact']

Treatment O
strategies O
targeting O
the O
PF O
joint O
may O
be O
warranted O
to O
mitigate O
the O
specific O
lower O
extremity O
impairments O
and O
functional O
problems O
present O
in O
this O
patient O
population O
. O
[]

The O
study O
dropout O
rate O
was O
high O
( O
43 O
% O
) O
. O
[]

SETTING O
A O
mixed-model O
health O
maintenance O
organization O
serving O
approximately O
110,000 O
enrollees O
in O
central O
Colorado O
. O
[]

Sinemet O
CR O
, O
a O
controlled O
release O
carbidopa/levodopa O
preparation O
, O
was O
compared O
to O
conventional O
carbidopa/levodopa O
in O
a O
double O
blind O
, O
placebo-controlled O
trial O
. O
[]

The O
epidural O
catheter O
was O
used O
only O
in O
the O
event O
the O
surgery O
outlasted O
the O
duration O
of O
surgical O
anesthesia O
with O
subarachnoid O
mepivacaine O
. O
[]

This O
study O
, O
therefore O
, O
tested O
the O
hypothesis O
that O
children O
with O
fetal O
alcohol O
spectrum O
disorder O
( O
FASD O
) O
will O
exhibit O
deficits O
in O
the O
accuracy O
of O
saccades O
. O
[]

Each O
CT O
scan O
was O
reconstructed O
at O
5 O
, O
2.5 O
and O
1.25 O
mm O
slice O
intervals O
during O
the O
image O
acquisition O
. O
[]

Electrophysiological O
data O
were O
affected O
according O
to O
the O
clinical O
and O
biochemical O
responsiveness O
to O
fenfluramine O
: O
the O
auditory O
evoked O
potential O
amplitude O
increased O
, O
and O
the O
single-trial O
potential O
variability O
decreased O
at O
each O
intensity O
level O
only O
in O
responders O
whose O
dopaminergic B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
was O
significantly O
modified O
by O
fenfluramine O
treatment O
. O
['Physiological-Clinical']

Glutamine O
did O
not O
affect O
psychometric B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
TIPS O
patients O
with O
or O
without O
LOLA O
. O
['Life-Impact']

The O
sample O
size O
requirement O
is O
406 O
women O
with O
data O
on O
primary O
outcomes O
. O
[]

Toxicity B-outcome ['Adverse-effects']
was O
low O
, O
with O
occasional B-outcome ['Physiological-Clinical']
gastroenteric I-outcome ['Physiological-Clinical']
discomfort I-outcome ['Physiological-Clinical']
in O
both O
groups O
. O
['Adverse-effects', 'Physiological-Clinical']

The O
modified O
scale O
( O
CYBOCS-PDD O
) O
, O
which O
contains O
only O
the O
five O
Compulsion O
severity O
items O
( O
range O
0-20 O
) O
, O
was O
administered O
to O
172 O
medication-free O
children O
( O
mean O
8.2 O
+/- O
2.6 O
years O
) O
with O
PDD O
( O
autistic O
disorder O
, O
n O
= O
152 O
; O
Asperger O
's O
disorder O
, O
n O
= O
6 O
; O
PDD O
not O
otherwise O
specified O
, O
n O
= O
14 O
) O
participating O
in O
RUPP O
clinical O
trials O
. O
[]

Somatization O
, O
anxiety O
, O
and O
depression O
were O
also O
measured O
. O
[]

Salmeterol O
, O
however O
, O
showed O
a O
flatter O
dose-response O
curve O
, O
and O
a O
significantly O
weaker O
maximal O
protective O
effect O
( O
2.8 O
doubling O
doses O
after O
250 O
micrograms O
) O
. O
[]

Rating O
individualized O
participant-chosen O
target O
symptoms O
seems O
a O
reliable O
, O
sensitive O
, O
efficient O
, O
and O
consumer-friendly O
way O
to O
assess O
treatment O
effect O
and O
might O
have O
clinical O
application O
. O
[]

INTERVENTIONS O
Four O
weeks O
of O
simvastatin O
( O
80 O
mg/day O
) O
or O
placebo O
. O
[]

BACKGROUND O
Photodynamic O
therapy O
( O
PDT O
) O
with O
topical O
5-aminolaevulinic O
acid O
( O
ALA O
) O
followed O
by O
irradiation O
with O
incoherent O
light O
( O
ALA-PDT O
) O
for O
recalcitrant O
warts O
have O
had O
beneficial O
results O
. O
[]

RESULTS O
In O
the O
portal O
venous O
phase O
, O
correlation O
coefficients O
for O
the O
correlation O
of O
change O
in O
CT B-outcome ['Physiological-Clinical']
number O
per O
gram B-outcome ['Physiological-Clinical']
of O
iodine O
with O
TBW B-outcome ['Physiological-Clinical']
for O
the O
aorta O
and O
liver O
were O
-0.71 O
and O
-0.79 O
, O
respectively O
, O
in O
the O
TBW O
group O
; O
-0.80 O
and O
-0.86 O
, O
respectively O
, O
in O
the O
LBW O
group O
; O
and O
-0.68 O
and O
-0.66 O
, O
respectively O
, O
in O
the O
BV O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
compared O
sub-Tenon O
's O
and O
retrobulbar O
anesthesia O
. O
[]

The O
safety O
was O
evaluated O
by O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

OBJECTIVE O
Analyze O
the O
relationship O
between O
tobacco B-outcome ['Life-Impact']
smoking I-outcome ['Life-Impact']
and O
intake O
of O
macro O
and O
micronutrients B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Analysis O
of O
CD19+ B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
in O
relationship O
to O
circulating O
clonal O
cells O
was O
done O
in O
13 O
myeloma O
patients O
using O
a O
clonotypic O
, O
quantitative O
allele-specific O
oligonucleotide-polymerase O
chain O
reaction O
( O
PCR O
) O
assay O
. O
['Physiological-Clinical']

To O
date O
, O
most O
of O
these O
risk O
factors O
have O
not O
been O
confirmed O
in O
a O
UK O
population O
. O
[]

150 O
patients O
will O
be O
included O
and O
randomized O
intraoperatively O
after O
surgical O
exploration O
just O
prior O
to O
resection O
. O
[]

These O
differences O
were O
variable O
, O
but O
consistent O
for O
each O
subject O
, O
thus O
those O
showing O
higher O
or O
lower O
changes O
with O
one O
tinted O
lens O
tended O
to O
show O
the O
same O
trend O
with O
the O
second O
lens O
( O
r O
( O
2 O
) O
= O
0.736 O
) O
. O
[]

RESULTS O
Direct B-outcome ['Physiological-Clinical']
palpation I-outcome ['Physiological-Clinical']
was O
associated O
with O
the O
highest O
accuracy O
for O
shape O
identification O
and O
was O
superior O
to O
both O
conventional O
instruments O
( O
p O
< O
0.001 O
) O
and O
laparoscopic O
instruments O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

This O
compound O
may O
be O
beneficial O
in O
patients O
with O
vasospastic B-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

To O
determine O
the O
efficacy O
and O
safety O
of O
endoscopic O
sclerotherapy O
and O
ligation O
, O
the O
2 O
methods O
were O
compared O
in O
a O
randomized O
control O
trial O
in O
49 O
children O
with O
extrahepatic O
portal O
venous O
obstruction O
who O
had O
proven O
bleeding O
from O
esophageal O
varices O
. O
[]

Marrow O
and O
blood O
( O
T O
cell O
) O
chimerism O
studies O
at O
day O
+100 O
revealed O
that O
both O
in O
the O
lower-dose O
Clo O
groups O
( O
groups O
1+2 O
) O
and O
the O
higher-dose O
Clo O
groups O
( O
groups O
3+4 O
) O
, O
the O
patients O
had O
a O
median O
of O
100 O
% O
donor O
( O
T O
cell O
) O
-derived O
DNA O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
1 O
) O
describe O
dietary O
intake O
of O
a O
cohort O
of O
children O
with O
ASD O
compared O
with O
normative O
data O
and O
2 O
) O
determine O
whether O
GI O
symptoms O
and O
stool O
consistency O
are O
related O
to O
dietary O
intake O
. O
[]

Formoterol O
dose-dependently O
protected O
against O
methacholine O
responsiveness O
( O
4.6 O
doubling O
doses O
after O
120 O
micrograms O
) O
. O
[]

Children O
were O
randomly O
assigned O
to O
one O
of O
three O
conditions O
: O
intervention O
for O
child O
only O
, O
intervention O
for O
child O
and O
parent O
, O
wait-list O
control O
. O
[]

The O
annualised O
relapse O
rate O
was O
lower O
for O
patients O
given O
daclizumab O
HYP O
150 O
mg O
( O
0?21 O
, O
95 O
% O
CI O
0?16-0?29 O
; O
54 O
% O
reduction O
, O
95 O
% O
CI O
33-68 O
% O
; O
p O
< O
0?0001 O
) O
or O
300 O
mg O
( O
0?23 O
, O
0?17-0?31 O
, O
50 O
% O
reduction O
, O
28-65 O
% O
; O
p=0?00015 O
) O
than O
for O
those O
given O
placebo O
( O
0?46 O
, O
0?37-0?57 O
) O
. O
[]

Enrollment O
of O
racial O
and O
ethnic O
minorities O
in O
the O
Prostate O
, O
Lung O
, O
Colorectal O
and O
Ovarian O
Cancer O
Screening O
Trial O
. O
[]

Because O
these O
cells O
may O
survive O
in O
transplant O
recipients O
for O
a O
long O
time O
, O
recipients O
of O
blood O
stem O
cells O
may O
be O
less O
immunocompromised O
than O
recipients O
of O
marrow O
. O
[]

ANIMALS O
Nine O
adult O
dogs O
( O
beagle O
and O
beagle O
cross O
breeds O
) O
, O
four O
males O
and O
five O
females O
. O
[]

Patients O
with O
obesity O
and/or O
diabetes O
were O
excluded O
. O
[]

Data O
was O
evaluated O
to O
calculate O
the O
overall O
treatment O
simulator O
differences O
, O
the O
number O
of O
error O
free B-outcome ['Resource-use']
treatments I-outcome ['Resource-use']
, O
and O
mean O
treatment-simulator O
position O
and O
to O
evaluate O
the O
['Resource-use']

Effects O
of O
levosimendan O
versus O
dobutamine O
on O
inflammatory O
and O
apoptotic O
pathways O
in O
acutely O
decompensated O
chronic O
heart O
failure O
. O
[]

BACKGROUND O
This O
study O
examines O
socio-demographic O
determinants O
of O
participation O
in O
a O
population-based O
randomized O
controlled O
trial O
that O
proved O
that O
oral O
visual O
inspection O
was O
effective O
in O
reducing O
oral B-outcome ['Mortality']
cancer I-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
high-risk O
individuals O
in O
India O
. O
['Mortality']

An O
alteration O
of O
dopaminergic B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
much O
more O
complex O
than O
simple O
hyperactivity O
has O
been O
evoked O
in O
infantile O
autism O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
From O
August O
1999 O
to O
December O
2004 O
, O
206 O
patients O
with O
locally O
advanced O
NPC O
were O
randomised O
with O
101 O
to O
cisplatin O
arm O
and O
105 O
to O
carboplatin O
arm O
. O
[]

Based O
on O
this O
study O
, O
a O
second O
study O
was O
implemented O
using O
both O
the O
estrogen-receptor O
( O
ER O
) O
content O
of O
the O
primary O
tumor O
and O
axillary O
nodal O
status O
to O
select O
therapy O
. O
[]

There O
were O
no O
significant O
differences O
in O
the O
changes O
occurring O
between O
volunteers O
treated O
with O
placebo O
and O
those O
on O
the O
steroid O
formulation O
. O
[]

This O
double-blind O
and O
placebo-controlled O
clinical O
trial O
in O
autistic O
children O
had O
three O
objectives O
: O
( O
a O
) O
to O
replicate O
earlier O
findings O
that O
haloperidol O
administration O
is O
associated O
with O
a O
significant O
reduction O
of O
behavioral B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
; O
( O
b O
) O
to O
further O
assess O
its O
safety O
when O
given O
on O
a O
short-term O
basis O
; O
and O
( O
c O
) O
to O
assess O
whether O
it O
has O
an O
effect O
on O
discrimination B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
effect O
of O
three O
times O
daily O
oral O
ondansetron O
in O
preventing O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
was O
investigated O
in O
two O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
multi-centre O
studies O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
incidence O
of O
ARDS B-outcome ['Physiological-Clinical']
due I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was I-outcome ['Physiological-Clinical']
higher O
in O
the O
G-CSF B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
A O
randomized O
, O
controlled O
trial O
of O
screening O
, O
brief O
intervention O
, O
and O
referral O
to O
treatment O
( O
SBIRT O
) O
for O
drinking O
and O
related O
problems O
among O
at-risk O
and O
dependent O
drinkers O
was O
conducted O
in O
an O
emergency O
department O
( O
ED O
) O
in O
Sosnowiec O
, O
Poland O
, O
among O
patients O
ages O
18 O
years O
and O
older O
. O
[]

METHODS O
Forty O
premenopausal O
women O
with O
large O
, O
symptomatic O
leiomyomata O
were O
randomized O
to O
receive O
either O
5 O
or O
10 O
mg O
of O
mifepristone O
daily O
for O
6 O
months O
in O
an O
open-label O
study O
. O
[]

In O
contrast O
to O
the O
CHO O
treatment O
( O
-4 O
+/- O
2 O
% O
) O
, O
S6K1 O
phosphorylation O
at O
T O
( O
389 O
) O
was O
higher O
following O
exercise O
in O
the O
CHO+PRO O
treatment O
only O
( O
+78 O
+/- O
2 O
% O
, O
P O
< O
0.01 O
) O
. O
[]

PATIENTS O
Twenty O
patients O
admitted O
with O
a O
Glasgow O
Coma O
Scale O
score O
of O
< O
10 O
who O
were O
enrolled O
as O
part O
of O
a O
prospective O
, O
multicenter O
trial O
to O
assess O
the O
impact O
of O
multiple O
risk O
factors O
and O
ranitidine O
prophylaxis O
on O
the O
development O
of O
stress-related O
upper O
gastrointestinal O
bleeding O
. O
[]

The O
similar O
effect O
of O
these O
drugs O
on O
the O
reactance O
can O
be O
explained O
by O
an O
increase O
in O
the O
capacitance O
of O
the O
respiratory B-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
, O
and O
in O
combination O
with O
a O
decrease O
in O
frequency O
dependence O
of O
resistance O
, O
by O
assuming O
a O
decrease O
in O
peripheral O
airway O
resistance O
. O
['Physiological-Clinical']

Of O
the O
43.6 O
% O
of O
the O
subjects O
who O
could O
not O
be O
located O
using O
either O
directory O
, O
the O
majority O
( O
73.5 O
% O
) O
were O
female O
. O
[]

CONCLUSIONS O
With O
the O
use O
of O
leukocyte O
reduction O
filters O
, O
we O
found O
significantly O
lower O
beta-glucuronidase O
levels O
in O
arterial O
and O
coronary O
sinus O
blood O
samples O
. O
[]

These O
results O
lend O
support O
to O
the O
feasibility O
of O
a O
cognitive-behavioral O
, O
school-based O
prevention O
program O
for O
students O
' O
distress-coping O
enhancement O
. O
[]

CONCLUSIONS O
With O
regard O
to O
gait O
kinematics O
in O
the O
early O
postoperative O
period O
( O
three O
months O
) O
, O
the O
present O
study O
showed O
no O
significant O
benefit O
for O
patients O
who O
underwent O
a O
total O
hip O
arthroplasty O
through O
a O
minimally O
invasive O
Watson-Jones O
approach O
in O
comparison O
with O
those O
who O
were O
managed O
with O
a O
standard O
transgluteal O
approach O
. O
[]

There O
were O
trends O
for O
BE O
levels O
to O
become O
reduced O
in O
the O
pentoxifylline O
group O
during O
the O
first O
4 O
weeks O
of O
treatment O
and O
for O
Addiction B-outcome ['Life-Impact']
Severity I-outcome ['Life-Impact']
Index O
( O
['Life-Impact']

Recruitment O
involved O
three O
steps O
: O
requesting O
the O
physician O
's O
consent O
to O
approach O
the O
melanoma O
case O
, O
approaching O
the O
case O
to O
request O
their O
participation O
and O
family O
contact O
information O
, O
and O
they O
approaching O
the O
FDRs O
and O
parents O
. O
[]

During O
induction O
and O
maintenance O
of O
anaesthesia O
body O
temperature O
fell O
( O
NA O
group O
from O
36.7 O
to O
35.3 O
degrees O
C O
; O
epidural O
group O
from O
36.7 O
to O
34.9 O
degrees O
C O
) O
but O
no O
statistically O
significant O
difference O
could O
be O
found O
between O
the O
groups O
, O
in O
spite O
of O
better O
surface B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
of O
the O
lower O
part O
of O
the O
body O
in O
the O
epidural O
group O
. O
['Physiological-Clinical']

Thirty-six O
patients O
also O
received O
CNS O
irradiation O
. O
[]

Forty O
percent O
( O
n O
= O
30 O
) O
of O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
obtained O
in O
the O
45-degree O
upright O
were O
greater O
than O
or O
equal O
to O
10 O
% O
less O
than O
those O
obtained O
in O
the O
supine O
flat O
position O
. O
['Physiological-Clinical']

There O
were O
24 O
gastrointestinal B-outcome ['Physiological-Clinical']
AEs I-outcome ['Physiological-Clinical']
in O
the O
treatment O
arm O
compared O
with O
1 O
AE O
in O
the O
placebo O
arm O
. O
['Physiological-Clinical']

Eight O
healthy O
subjects O
underwent O
parallel O
experiments O
on O
2 O
separate O
days O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
TE I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
significantly O
higher O
in O
the O
TE O
group O
. O
['Physiological-Clinical']

BACKGROUND O
Low O
heart O
rate O
ischemia O
, O
as O
detected O
by O
Holter O
ambulatory O
electrocardiographic O
monitoring O
, O
suggests O
that O
reduced O
coronary O
flow O
is O
the O
major O
factor O
leading O
to O
ischemia O
. O
[]

One O
PCC O
( O
RXU O
) O
debonded B-outcome ['Physiological-Clinical']
after O
11 O
months O
in O
situ O
, O
one O
PCC O
( O
RXU+E O
) O
fractured B-outcome ['Physiological-Clinical']
after O
12 O
months O
in O
situ O
. O
['Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Western O
Ontario O
and O
McMaster O
Universities O
Osteoarthritis O
Index O
( O
WOMAC O
) O
function O
scale O
, O
walking B-outcome ['Life-Impact']
speed I-outcome ['Life-Impact']
, O
muscle B-outcome ['Physiological-Clinical']
torque I-outcome ['Physiological-Clinical']
, O
and O
knee B-outcome ['Physiological-Clinical']
reposition I-outcome ['Physiological-Clinical']
error I-outcome ['Physiological-Clinical']
were O
assessed O
before O
and O
after O
intervention O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Rose O
geranium O
( O
Pelargonium O
graveolens O
, O
Geraniaceae O
) O
has O
anti-cancer O
and O
anti-inflammatory O
properties O
, O
and O
promotes O
wound O
healing O
. O
[]

Thus O
, O
the O
conventional O
pretask O
procedure O
can O
be O
replaced O
by O
a O
simple O
unweighted O
averaging O
to O
yield O
a O
scale O
of O
high O
sensitivity O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
We O
studied O
83 O
of O
86 O
individuals O
> O
or=25 O
years O
of O
age O
with O
type O
1 O
diabetes O
who O
used O
CGM O
as O
part O
of O
a O
6-month O
randomized O
clinical O
trial O
in O
a O
subsequent O
6-month O
extension O
study O
. O
[]

Free O
will O
and O
free O
wo O
n't O
. O
[]

In O
the O
intervention O
, O
teachers O
participated O
in O
eight O
weekly O
individualized O
1-h O
sessions O
with O
a O
researcher O
that O
emphasized O
embedding O
strategies O
targeting O
symbolic O
play O
and O
joint O
attention O
into O
their O
everyday O
classroom O
routines O
and O
activities O
. O
[]

The O
daily O
doses O
were O
given O
as O
a O
single O
oral O
dose O
of O
5 O
mg O
, O
20 O
mg O
, O
40 O
mg O
and O
80 O
mg O
tablets O
. O
[]

The O
effects O
of O
a O
six-week O
supervised O
multimodal O
exercise O
intervention O
during O
chemotherapy O
on O
cancer-related B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

s.e.m O
. O
[]

No O
significant O
differences O
were O
found O
for O
the O
other O
types O
of O
tumor O
, O
but O
the O
numbers O
in O
this O
population O
were O
very O
limited O
. O
[]

A O
transesophageal O
approach O
using O
light O
sedation O
has O
been O
proposed O
as O
a O
means O
of O
augmenting O
the O
success O
rate O
and O
avoiding O
the O
need O
for O
general O
anesthesia O
. O
[]

There O
were O
no O
significant O
demographic O
differences O
between O
the O
2 O
groups O
. O
[]

CONCLUSIONS O
This O
study O
suggests O
that O
women O
in O
an O
intensive O
behavioral O
intervention O
designed O
to O
increase O
mammography O
use O
may O
also O
increase O
Pap B-outcome ['Life-Impact']
test I-outcome ['Life-Impact']
completion I-outcome ['Life-Impact']
, O
similar O
to O
a O
minimal O
intervention O
focused O
only O
on O
increasing O
Pap B-outcome ['Life-Impact']
test I-outcome ['Life-Impact']
completion I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

For O
example O
, O
the O
mean O
increase O
in O
[]

The O
second O
study O
assessed O
the O
effects O
of O
GH O
( O
2 O
IU/day O
) O
on O
lipid O
oxidation O
and O
on O
protein O
metabolism O
using O
the O
whole O
body O
leucine O
turnover O
technique O
. O
[]

Inclusion O
criteria O
were O
one O
or O
more O
relapses O
in O
the O
year O
before O
entry O
and O
at O
least O
one O
gadolinium B-outcome ['Physiological-Clinical']
enhancing I-outcome ['Physiological-Clinical']
( O
GdE B-outcome ['Physiological-Clinical']
) O
lesion B-outcome ['Physiological-Clinical']
on O
screening O
MRI O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Epigastric O
impedance O
is O
a O
non-invasive O
method O
used O
to O
study O
gastric O
emptying O
time O
and O
gastric O
phasic O
activity O
. O
[]

After O
6 O
months O
all O
patients O
received O
GH O
. O
[]

OBJECTIVE O
It O
has O
been O
proposed O
that O
a O
deficit O
of O
adenosinergic O
activity O
could O
contribute O
to O
the O
pathophysiology O
of O
schizophrenia O
. O
[]

METHODS O
We O
conducted O
a O
noninferiority O
trial O
at O
48 O
institutions O
and O
randomly O
assigned O
872 O
patients O
with O
adenocarcinoma O
of O
the O
colon O
to O
undergo O
open O
or O
laparoscopically O
assisted O
colectomy O
performed O
by O
credentialed O
surgeons O
. O
[]

Thirty O
patients O
failed O
to O
achieve O
pain B-outcome ['Physiological-Clinical']
relief O
after O
the O
first O
injection O
( O
20 O
patients O
after O
S O
( O
- O
) O
-bupivacaine O
and O
10 O
after O
RS-bupivacaine O
; O
P O
= O
0.039 O
) O
. O
['Physiological-Clinical']

Most O
of O
these O
metabolic O
biomarkers O
improved O
to O
normal O
or O
near-normal O
levels.The O
supplement O
group O
had O
significantly O
greater O
improvements O
than O
the O
placebo O
group O
on O
the O
Parental B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions-Revised O
( O
PGI-R O
, O
Average O
Change O
, O
p O
= O
0.008 O
) O
, O
and O
on O
the O
subscores O
for O
Hyperactivity B-outcome ['Physiological-Clinical']
( O
p O
= O
0.003 O
) O
, O
Tantrumming B-outcome ['Life-Impact']
( O
p O
= O
0.009 O
) O
, O
Overall O
( O
p O
= O
0.02 O
) O
, O
and O
Receptive B-outcome ['Physiological-Clinical']
Language I-outcome ['Physiological-Clinical']
( O
p O
= O
0.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

To O
determine O
if O
6 O
courses O
of O
chemotherapy O
alone O
could O
achieve O
the O
same O
or O
better O
outcome O
than O
4 O
courses O
of O
chemotherapy O
followed O
by O
radiation O
therapy O
( O
chemoradiotherapy O
) O
in O
pediatric O
and O
adolescent O
patients O
with O
Hodgkin O
disease O
. O
[]

METHODS O
In O
a O
prospective O
, O
randomised O
setting O
the O
authors O
compared O
the O
short-term O
hepatic O
effects O
of O
medium-chain O
triglycerides/short-chain O
triglycerides O
( O
MCT/LCT O
) O
physical O
mixture O
with O
a O
four-component O
intravenous O
( O
i.v O
. O
) O
[]

The O
side O
effect O
[]

Twenty-nine O
of O
31 O
Treatment O
Group O
participants O
completed O
the O
5 O
lessons O
during O
the O
8-week O
program O
, O
and O
posttreatment O
and O
3-month O
follow-up O
data O
were O
collected O
from O
30/31 O
and O
29/31 O
participants O
, O
respectively O
. O
[]

No O
safety O
issues O
were O
observed O
with O
regard O
to O
intraocular O
pressure O
, O
visual O
acuity O
, O
or O
occurrence O
of O
adverse O
events O
. O
[]

METHODS O
This O
was O
a O
single-center O
, O
randomized O
, O
evaluator-blinded O
, O
parallel-group O
study O
. O
[]

Atrial B-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
occurred O
in O
13 O
patients O
( O
16.8 O
% O
) O
in O
Group O
1 O
, O
six O
patients O
( O
8.3 O
% O
) O
in O
Group O
2 O
and O
31 O
patients O
( O
33.6 O
% O
) O
in O
Group O
3 O
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION O
ClinicalTrials.gov O
Identifier O
: O
NCT00621608 O
. O
[]

Twenty O
( O
20 O
) O
metres O
[]

Aftermath O
of O
a O
clinical O
trial O
: O
evaluating O
the O
sustainability O
of O
a O
medical O
device O
intervention O
in O
Ghana O
. O
[]

Each O
treatment O
consisted O
of O
the O
application O
of O
ultrasound O
massage O
( O
1.0 O
MHz O
, O
0.8 O
to O
1.5 O
W/cm2 O
continuous O
output O
) O
for O
15 O
minutes O
to O
the O
painful O
temporomandibular O
joint O
. O
[]

In O
Experiment O
2 O
, O
20 O
healthy O
volunteers O
underwent O
quantitative O
sensory O
testing O
to O
determine O
heat O
and O
cold O
pain O
thresholds O
during O
the O
rubber O
hand O
illusion O
or O
during O
a O
control O
condition O
. O
[]

Because O
of O
the O
increasing O
resistance O
of O
enteric O
pathogens O
to O
commonly O
used O
oral O
antibiotics O
, O
intramuscular O
ceftriaxone O
has O
become O
the O
routine O
drug O
in O
the O
treatment O
of O
acute O
invasive O
diarrhea O
requiring O
an O
emergency O
visit O
in O
southern O
Israel O
. O
[]

The O
PFS O
technique O
was O
standardized O
, O
and O
all O
tracings O
were O
read O
by O
a O
single O
reader O
unaware O
of O
the O
treatment O
group O
. O
[]

Skin O
incision O
in O
the O
control O
group O
began O
at O
the O
distal O
border O
of O
the O
carpal O
ligament O
, O
followed O
the O
longitudinal O
crease O
of O
the O
palm O
, O
and O
crossed O
the O
base O
of O
the O
palm O
in O
a O
zigzag O
fashion O
. O
[]

During O
their O
hospitalization O
, O
48 O
% O
of O
patients O
in O
the O
rhAT O
group O
received O
fresh O
frozen O
plasma O
, O
compared O
with O
85 O
% O
of O
patients O
in O
the O
placebo O
group O
( O
P O
= O
0.009 O
) O
. O
[]

RESULTS O
Moderate/severe O
PFOA O
was O
associated O
with O
lower O
knee B-outcome ['Physiological-Clinical']
extension I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
( O
mean O
? O
['Physiological-Clinical']

CPAP O
was O
used O
for O
the O
first O
night O
, O
followed O
by O
a O
baseline O
day O
, O
and O
was O
then O
withdrawn O
for O
the O
two O
subsequent O
nights O
( O
nasal O
airflow O
monitored O
) O
. O
[]

CONCLUSIONS O
Remission O
by O
year O
3 O
in O
etanercept-treated O
( O
with O
and O
without O
methotrexate O
) O
patients O
with O
RA O
occurred O
in O
?35 O
% O
of O
patients O
in O
both O
an O
RCT O
( O
TEMPO O
) O
and O
a O
clinical O
practice O
setting O
( O
RADIUS O
II O
) O
, O
and O
more O
frequently O
in O
those O
with O
lower O
baseline O
disease O
severity O
. O
[]

Effect O
of O
sport-tinted O
contact O
lenses O
for O
contrast O
enhancement O
on O
retinal O
straylight O
measurements O
. O
[]

SETTING O
University O
research O
laboratory O
. O
[]

Preliminary O
findings O
from O
a O
prospective O
, O
randomized O
trial O
of O
two O
palatal O
operations O
for O
sleep-disordered O
breathing O
. O
[]

Both O
treatments O
were O
effective O
in O
reducing O
the O
BOP B-outcome ['Physiological-Clinical']
percentage I-outcome ['Physiological-Clinical']
which O
ranged O
from O
17-42 O
% O
at O
baseline O
by O
about O
40 O
% O
after O
10 O
days O
( O
mean O
BOP B-outcome ['Physiological-Clinical']
baseline O
: O
26 O
% O
, O
mean O
BOP B-outcome ['Physiological-Clinical']
after O
10 O
days O
: O
16 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
We O
conducted O
a O
prospective O
randomized O
controlled O
study O
to O
evaluate O
the O
effect O
of O
micronized O
flavonoid O
fractions O
( O
MFF O
) O
on O
pain B-outcome ['Physiological-Clinical']
after O
hemorrhoidectomy O
. O
['Physiological-Clinical']

CM O
was O
also O
significantly O
superior O
to O
EC O
during O
the O
first O
attack O
for O
complete B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
( O
20 O
vs. O
8 O
% O
, O
p O
= O
0.006 O
) O
, O
nausea B-outcome ['Physiological-Clinical']
( O
42 O
vs. O
63 O
% O
, O
p O
= O
0 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Fecal O
Bifidobacterium O
adolescentis O
and O
Bifidobacterium O
bifidum O
colonization O
frequencies O
and O
counts O
among O
mother-infant O
pairs O
correlated O
significantly O
( O
P=0.005 O
and O
0.02 O
for O
frequencies O
, O
respectively O
, O
and O
P=0.002 O
and O
0.01 O
for O
counts O
, O
respectively O
) O
. O
[]

Participants O
in O
the O
rosemary O
condition O
scored O
higher O
on O
measures O
of O
tension-anxiety B-outcome ['Life-Impact']
and O
confusion-bewilderment B-outcome ['Life-Impact']
relative O
to O
the O
lavender O
and O
control O
conditions O
. O
['Life-Impact', 'Life-Impact']

Modafinil O
effects O
during O
acute O
continuous O
positive O
airway O
pressure O
withdrawal O
: O
a O
randomized O
crossover O
double-blind O
placebo-controlled O
trial O
. O
[]

OBJECTIVE O
Primary O
prophylaxis O
against O
Pneumocystis O
carinii O
pneumonia O
( O
PCP O
) O
for O
patients O
with O
HIV O
infection O
has O
been O
recommended O
by O
the O
Centers O
for O
Disease O
Control O
and O
Prevention O
. O
[]

Patients O
were O
enrolled O
consecutively O
and O
assigned O
randomly O
to O
undergo O
deep O
sclerectomy O
without O
the O
use O
of O
mitomycin O
C O
( O
DS O
group O
) O
and O
deep O
sclerectomy O
with O
the O
application O
of O
mitomycin O
C O
( O
DSMMC O
group O
) O
in O
a O
concentration O
of O
0.2 O
mg/mL O
for O
2.5 O
minutes O
, O
before O
the O
superficial O
scleral O
flap O
formation O
. O
[]

Using O
a O
cutpoint O
of O
< O
6 O
, O
the O
sensitivity O
of O
the O
measure O
to O
identify O
patients O
with O
poor O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
was O
estimated O
to O
be O
93 O
% O
, O
and O
the O
specificity O
was O
53 O
% O
. O
['Physiological-Clinical']

RT O
consisted O
of O
arm O
1 O
( O
qdRT O
) O
, O
64 O
Gy O
( O
2 O
Gy/d O
) O
, O
versus O
arm O
2 O
( O
HART O
) O
, O
57.6 O
Gy O
( O
1.5 O
Gy O
tid O
for O
2.5 O
weeks O
) O
. O
[]

METHODS O
101 O
hemodialysis O
patients O
were O
randomized O
for O
each O
phosphate O
binder O
and O
submitted O
to O
multislice O
coronary O
tomographies O
and O
bone O
biopsies O
at O
entry O
and O
12 O
months O
. O
[]

HbA1c B-outcome ['Physiological-Clinical']
levels O
were O
significantly O
lower O
in O
the O
VBC O
group O
than O
in O
the O
EXB O
group O
after O
6 O
, O
9 O
, O
12 O
and O
24 O
months O
of O
the O
study O
. O
['Physiological-Clinical']

Reducing O
the O
risk O
of O
coronary O
events O
: O
evidence O
from O
the O
Scandinavian O
Simvastatin O
Survival O
Study O
( O
4S O
) O
. O
[]

Nonetheless O
, O
the O
empirical O
evidence O
for O
the O
effect O
of O
these O
interventions O
is O
limited O
. O
[]

Adverse O
events O
leading O
to O
withdrawal O
were O
few O
( O
n O
= O
0 O
perindopril O
, O
n O
= O
4 O
placebo O
) O
. O
[]

Neutrophil B-outcome ['Physiological-Clinical']
C3bi I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
significantly O
increased O
24 O
hours O
after O
the O
first O
dose O
of O
rhuGM-CSF O
at O
5.0 O
micrograms/kg O
once O
per O
day O
. O
['Physiological-Clinical']

Suppression O
of O
the O
hypothalamic-pituitary-adrenal O
( O
HPA O
) O
axis O
can O
occur O
after O
repeated O
application O
of O
topical O
corticosteroids O
. O
[]

Allopurinol O
use O
yields O
potentially O
beneficial O
effects O
on O
inflammatory O
indices O
in O
those O
with O
recent O
ischemic O
stroke O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Cognitive O
therapy O
did O
not O
potentiate O
exposure O
effects O
. O
[]

METHOD O
Thirty-eight O
children O
, O
ages O
5-17 O
years O
with O
autism O
and O
severe O
behavioral O
disturbance O
, O
were O
randomly O
assigned O
to O
risperidone O
( O
0.5 O
to O
3.5 O
mg/day O
) O
or O
placebo O
for O
8 O
weeks O
. O
[]

Exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
in O
atrial O
fibrillation O
: O
a O
substudy O
of O
the O
Sotalol-Amiodarone O
Atrial O
Fibrillation O
Efficacy O
Trial O
( O
SAFE-T O
) O
. O
['Life-Impact']

Ten O
females O
ran O
barefoot O
over O
a O
force O
plate O
in O
three O
conditions O
: O
no O
heel O
lifts O
( O
NHL O
) O
, O
with O
12 O
mm O
heel O
lifts O
( O
12HL O
) O
and O
with O
18 O
mm O
heel O
lifts O
( O
18HL O
) O
. O
[]

Six O
months O
later O
, O
however O
, O
improvement O
in O
APC O
( O
14 O
% O
; O
P O
< O
.05 O
) O
was O
evident O
among O
responders O
but O
not O
in O
those O
who O
had O
failed O
to O
respond O
to O
interferon O
. O
( O
[]

In O
the O
optimal O
LKB O
, O
RS O
, O
and O
logistic O
models O
for O
rectal O
bleeding O
and O
fecal O
incontinence O
, O
the O
first O
significant O
( O
p O
= O
0.011-0.013 O
) O
clinical O
factor O
was O
previous O
abdominal O
surgery O
. O
[]

Blacks O
and O
Hispanics O
were O
nonetheless O
underrepresented O
in O
PLCO O
compared O
to O
their O
levels O
among O
age-eligibles O
in O
the O
overall O
U.S. O
population O
or O
in O
the O
aggregate O
PLCO O
catchment O
areas O
. O
[]

In O
hypertensive O
patients O
, O
beta-endorphin O
decreased O
systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
, O
and O
plasma B-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
and O
endothelin-1 B-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
and O
raised O
circulating O
atrial O
natriuretic B-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
, O
GH B-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
, O
and O
IGF-I B-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
pretreatment O
EBV O
( O
+ O
) O
plasma O
( O
n O
= O
54 O
) O
had O
inferior O
failure-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
FFS I-outcome ['Mortality']
) I-outcome ['Mortality']
compared O
with O
those O
with O
pretreatment O
EBV O
( O
- O
) O
plasma O
( O
n O
= O
274 O
) O
, O
log-rank O
P O
= O
.009 O
. O
['Mortality']

Occult O
TL O
after O
3 O
years O
of O
CCR O
represents O
aggressive O
minimal-residual O
disease O
and O
carries O
a O
worse O
prognosis O
than O
absence O
of O
TL O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
find O
out O
how O
safe O
it O
would O
be O
to O
shorten O
the O
interval O
of O
increments O
of O
midazolam O
to O
1 O
minute O
in O
patient-controlled O
sedation O
. O
[]

Forty-four O
percent O
( O
24 O
of O
54 O
) O
of O
the O
CQ-treated O
patients O
were O
therapeutic B-outcome ['Physiological-Clinical']
failures I-outcome ['Physiological-Clinical']
, O
including O
7 O
early O
treatment O
failures B-outcome ['Physiological-Clinical']
( O
ETFs O
) O
and O
17 O
late O
treatment O
failures B-outcome ['Physiological-Clinical']
( O
LTFs O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
factorial O
analysis O
showed O
that O
both O
1000 O
mg O
acetaminophen O
and O
60 O
mg O
codeine O
made O
a O
statistically O
significant O
( O
P O
less O
than O
0.05 O
) O
contribution O
to O
the O
analgesic B-outcome ['Resource-use']
effectiveness O
of O
the O
combination O
on O
all O
measures O
of O
efficacy O
( O
sum O
of O
pain B-outcome ['Physiological-Clinical']
intensity O
differences O
, O
largest O
pain B-outcome ['Physiological-Clinical']
intensity O
difference O
, O
total O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
, O
largest O
pain B-outcome ['Physiological-Clinical']
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

While O
the O
study O
did O
not O
yield O
definitive O
data O
about O
the O
relative O
engagement O
potential O
of O
ESM O
alternatives O
, O
it O
does O
provide O
a O
foundation O
for O
future O
research O
, O
including O
guidance O
related O
to O
participant O
profiles O
, O
stimulus O
characteristics O
, O
and O
data O
coding O
challenges O
. O
[]

The O
bodyweight-corrected O
area O
under O
the O
curve O
( O
[]

Alternative O
medicine O
can O
be O
beneficial O
for O
the O
treatment O
of O
ED O
. O
[]

relapses/patient/year O
; O
cumulative B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
prednisone/patient I-outcome ['Life-Impact']
; O
laboratory B-outcome ['Physiological-Clinical']
investigations I-outcome ['Physiological-Clinical']
( O
kidney B-outcome ['Physiological-Clinical']
and O
liver B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
, O
haematological B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
) O
; O
incidence O
of O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
determine O
whether O
addition O
of O
the O
farnesyltransferase O
inhibitor O
tipifarnib O
( O
Zarnestra O
, O
R115777 O
; O
Johnson O
and O
Johnson O
Pharmaceutical O
Research O
and O
Development O
, O
Beerse O
, O
Belgium O
) O
to O
standard O
gemcitabine O
therapy O
improves O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
advanced O
pancreatic O
cancer O
. O
['Mortality']

Is O
the O
endotracheal O
route O
reliable O
? O
[]

The O
effect O
of O
perindopril O
and O
hydrochlorothiazide O
alone O
and O
in O
combination O
on O
blood O
pressure O
and O
on O
the O
renin-angiotensin O
system O
in O
hypertensive O
subjects O
. O
[]

No O
significant O
changes O
were O
observed O
in O
carotid B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
or O
carotid-femoral B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
following O
ST B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
ST+aerobic I-outcome ['Physiological-Clinical']
exercise B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

We O
instigated O
EVAR O
trial O
2 O
to O
identify O
whether O
EVAR O
improves O
survival B-outcome ['Mortality']
compared O
with O
no O
intervention O
in O
patients O
unfit O
for O
open O
repair O
of O
aortic O
aneurysm O
. O
['Mortality']

The O
use O
of O
Cmax B-outcome ['Physiological-Clinical']
or O
Tmax B-outcome ['Physiological-Clinical']
as O
a O
measure O
of O
rate O
of O
absorption O
, O
to O
correlate O
with O
clinical O
relevance O
, O
is O
widely O
criticized O
on O
logical O
, O
technical O
, O
and O
statistical O
grounds O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
investigate O
whether O
cell-derived O
microparticles O
play O
a O
role O
in O
complement B-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
in O
pericardial O
blood O
of O
patients O
undergoing O
cardiac O
surgery O
with O
cardiopulmonary O
bypass O
( O
CPB O
) O
and O
whether O
microparticles O
in O
pericardial O
blood O
contribute O
to O
systemic B-outcome ['Physiological-Clinical']
complement I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
upon O
retransfusion O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
compared O
two O
teaching O
procedures O
, O
an O
error O
prevention O
procedure O
and O
an O
error O
correction O
procedure O
, O
for O
teaching O
relations O
between O
objects O
and O
pictures O
. O
[]

Procedures O
were O
performed O
under O
general O
anaesthesia O
, O
using O
standard O
techniques O
for O
access O
and O
lithotomy O
. O
[]

This O
retrospective O
analysis O
from O
2 O
independent O
trials O
revealed O
that O
increased O
PTK2 O
expression O
is O
associated O
with O
improved O
outcomes O
for O
CLL O
patients O
treated O
with O
R-FC O
vs O
FC O
. O
[]

The O
most O
notable O
hematologic B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
was O
leukopenia B-outcome ['Physiological-Clinical']
; O
15 O
% O
and O
20 O
% O
of O
patients O
experienced O
grade O
4 O
in O
arm O
A O
and O
arm O
B O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Risperidone O
was O
superior O
to O
placebo O
in O
reducing O
symptoms B-outcome ['Physiological-Clinical']
of O
most O
concern O
to O
parents O
of O
autistic O
children O
with O
irritable B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Compared O
with O
placebo O
, O
secretin O
treatment O
was O
not O
associated O
with O
significant O
improvement O
of O
CSBS O
standard O
scores O
from O
baseline O
to O
2 O
or O
4 O
weeks O
post-infusion O
. O
[]

The O
intensive O
treatment O
group O
( O
7 O
with O
autism O
, O
8 O
with O
pervasive O
developmental O
disorder O
not O
otherwise O
specified O
-- O
NOS O
) O
averaged O
24.52 O
hours O
per O
week O
of O
individual O
treatment O
for O
one O
year O
, O
gradually O
reducing O
hours O
over O
the O
next O
1 O
to O
2 O
years O
. O
[]

The O
overall O
incidence O
was O
62 O
and O
67 O
% O
for O
air-O2 O
and O
N2O-O2 O
groups O
, O
respectively O
. O
[]

Treatment O
consisted O
of O
a O
16-week O
group O
intervention O
designed O
to O
teach O
appropriate O
social O
behavior O
. O
[]

METHODS O
We O
conducted O
a O
prospective O
, O
randomized O
, O
multicenter O
trial O
in O
which O
62 O
patients O
were O
randomly O
assigned O
to O
receive O
either O
prednisone O
plus O
cyclophosphamide O
( O
intravenous O
bolus O
) O
( O
group O
A O
; O
n O
= O
28 O
) O
or O
prednisone O
plus O
cyclophosphamide O
( O
intravenous O
bolus O
) O
plus O
plasma O
exchanges O
( O
group O
B O
; O
n O
= O
34 O
) O
as O
first-line O
treatment O
for O
severe O
PAN O
or O
CSS O
. O
[]

Moreover O
, O
the O
percentage O
of O
patients O
without O
induration B-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
the O
active O
group O
compared O
with O
the O
placebo O
group O
( O
P O
= O
0.013 O
) O
, O
and O
a O
statistically O
significantly O
greater O
decrease O
in O
the O
size O
of O
the O
lesional B-outcome ['Physiological-Clinical']
area O
was O
also O
seen O
in O
the O
overall O
analysis O
of O
the O
R-salbutamol-treated O
patients O
( O
P O
= O
0.0197 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
endpoint O
evaluated O
was O
SWI B-outcome ['Physiological-Clinical']
, O
which O
was O
defined O
as O
purulent O
drainage O
or O
active O
wound O
treatment O
. O
['Physiological-Clinical']

OBJECTIVE O
A O
previously O
published O
randomized O
clinical O
trial O
indicated O
that O
a O
developmental O
behavioral O
intervention O
, O
the O
Early O
Start O
Denver O
Model O
( O
ESDM O
) O
, O
resulted O
in O
gains O
in O
IQ O
, O
language O
, O
and O
adaptive O
behavior O
of O
children O
with O
autism O
spectrum O
disorder O
. O
[]

The O
most O
common O
adverse B-outcome ['Adverse-effects']
experience I-outcome ['Adverse-effects']
leading O
to O
withdrawal O
was O
rash B-outcome ['Physiological-Clinical']
, O
with O
approximately O
double O
the O
proportion O
of O
reports O
occurring O
in O
patients O
on O
CBZ O
600 O
( O
5.1 O
% O
) O
compared O
with O
lamotrigine O
( O
1.7 O
% O
on O
LTG O
100 O
and O
2.7 O
% O
on O
LTG O
200 O
) O
. O
['Adverse-effects', 'Physiological-Clinical']

METHODS O
We O
performed O
a O
blinded O
, O
randomized O
trial O
with O
a O
2-by-2 O
factorial O
design O
to O
allow O
separate O
evaluation O
of O
low-dose O
clonidine O
versus O
placebo O
and O
low-dose O
aspirin O
versus O
placebo O
in O
patients O
with O
, O
or O
at O
risk O
for O
, O
atherosclerotic O
disease O
who O
were O
undergoing O
noncardiac O
surgery O
. O
[]

Defibrillation B-outcome ['Physiological-Clinical']
or O
cardio B-outcome ['Physiological-Clinical']
version I-outcome ['Physiological-Clinical']
was O
needed O
in O
7.14 O
% O
patients O
in O
group O
I O
and O
28.57 O
% O
patients O
in O
group O
II O
( O
P=0.078 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Differences O
( O
95 O
% O
CI O
) O
versus O
placebo O
were O
40.5 O
% O
( O
32.4 O
% O
, O
48.5 O
% O
) O
and O
37.8 O
% O
( O
29.9 O
% O
, O
45.7 O
% O
) O
and O
were O
highly O
significant O
( O
p O
< O
0.0001 O
) O
. O
[]

Based O
on O
evidence O
that O
endothelial O
P-selectin O
is O
central O
to O
the O
abnormal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
SCD I-outcome ['Physiological-Clinical']
we O
provide O
results O
from O
four O
of O
our O
studies O
that O
are O
germane O
to O
microvascular O
blood O
flow O
in O
SCD O
. O
['Physiological-Clinical']

Breast O
cancer O
screening O
appears O
not O
to O
affect O
the O
rate O
of O
mortality B-outcome ['Mortality']
from O
causes O
of O
death O
other O
than O
breast O
cancer O
. O
['Mortality']

This O
study O
was O
undertaken O
to O
quantify O
and O
compare O
the O
time O
needed O
to O
treat O
commercial O
beef O
cattle O
with O
three O
fluke O
and O
worm O
combination O
products O
with O
different O
administration O
profiles O
. O
[]

The O
changes O
in O
neuropsychologic O
function O
were O
associated O
with O
an O
improvement O
in O
semiquantitative O
nitrogen O
balance O
, O
which O
became O
consistently O
positive O
in O
amino O
acid-treated O
subjects O
; O
there O
was O
also O
a O
mild O
improvement O
in O
nutritional O
parameters O
and O
in O
liver O
function O
tests O
. O
[]

Spontaneous O
pneumothorax O
( O
SP O
) O
is O
a O
disabling O
condition O
mostly O
affecting O
young O
, O
thin O
and O
otherwise O
healthy O
males O
. O
[]

Investigator-based O
Global O
Aesthetic O
Improvement O
Scale O
assessment O
at O
9 O
months O
after O
baseline O
indicated O
that O
Perlane O
was O
superior O
in O
48.8 O
percent O
of O
patients O
, O
whereas O
Zyplast O
was O
superior O
in O
14.0 O
percent O
of O
patients O
( O
p O
= O
0.0025 O
) O
. O
[]

Insecticide-treated O
bednets O
offer O
effective O
prevention O
, O
but O
it O
is O
unclear O
how O
well O
free O
bednet O
distribution O
programs O
reach O
young O
children O
. O
[]

The O
improvement O
of O
both O
Integral O
of O
Clinical B-outcome ['Physiological-Clinical']
Symptoms I-outcome ['Physiological-Clinical']
( O
ICS O
) O
and O
Bone B-outcome ['Physiological-Clinical']
Mineral I-outcome ['Physiological-Clinical']
Density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of O
two O
groups O
was O
observed O
after O
6 O
months O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Confirmatory O
statistical O
analysis O
was O
carried O
out O
according O
to O
Wilcoxon-Mann-Whitney-U O
two-sided O
at O
alpha O
< O
or O
= O
0.05 O
. O
[]

Measures O
included O
scintigraphic O
gastric O
emptying O
studies O
at O
0 O
, O
2 O
, O
4 O
, O
and O
8 O
weeks O
; O
subjective B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
during I-outcome ['Life-Impact']
meals I-outcome ['Life-Impact']
measured O
by O
visual O
analogue O
scales O
; O
self-rating O
of O
degree O
of O
global B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
associated O
with O
eating B-outcome ['Life-Impact']
at O
end O
of O
study O
; O
and O
weight O
measured O
weekly O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

The O
maternal O
and O
fetal O
metabolic O
effects O
of O
three O
commonly O
used O
intravenous O
fluids O
administered O
before O
regional O
anesthesia O
were O
studied O
in O
32 O
gravid O
women O
undergoing O
elective O
cesarean O
section O
at O
term O
. O
[]

No O
difference O
in O
complication B-outcome ['Adverse-effects']
rate O
between O
the O
tested O
methods O
was O
found O
. O
['Adverse-effects']

CONCLUSION O
Intravitreal O
bevacizumab O
injection O
improves O
[]

We O
found O
a O
significant O
negative O
correlation O
of O
the O
one-year O
CRP- O
( O
r O
= O
-0.44 O
, O
p O
< O
0.001 O
) O
or O
ESR B-outcome ['Physiological-Clinical']
differences O
( O
r O
= O
-0.45 O
, O
p O
< O
0.001 O
) O
with O
the O
corresponding O
osteocalcin O
differences O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
the O
patients O
who O
received O
the O
medical O
treatment O
and O
those O
who O
received O
the O
surgical O
treatment O
combined O
, O
the O
median O
survival O
times O
were O
1093 O
days O
in O
Group O
1 O
, O
222 O
days O
in O
Group O
2 O
, O
and O
37 O
days O
in O
Group O
3 O
( O
P O
less O
than O
or O
equal O
to O
0.01 O
) O
for O
all O
comparisons O
) O
. O
[]

Patients O
undergoing O
chemotherapy O
combined O
with O
electro-acupuncture O
showed O
obviously O
higher O
leukocyte B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
than O
that O
of O
the O
control O
group O
given O
no O
leukogenic O
drugs O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

In O
both O
groups O
a O
laryngeal O
mask O
airway O
was O
used O
. O
[]

One O
strategy O
to O
minimize O
the O
number O
of O
potential O
matches O
per O
true O
match O
is O
to O
first O
search O
by O
InfoSpace O
with O
the O
last O
name O
and O
first O
name O
, O
then O
by O
Canada411 O
with O
the O
last O
name O
and O
first O
name O
, O
and O
finally O
by O
InfoSpace O
with O
the O
last O
name O
and O
first O
initial O
. O
[]

MATERIALS O
AND O
METHODS O
Twelve O
healthy O
volunteers O
, O
six O
men O
and O
six O
women O
, O
mean O
age O
34.4 O
( O
range O
23-48 O
) O
participated O
in O
three O
balanced O
, O
randomly O
distributed O
sessions O
. O
[]

The O
side-effects B-outcome ['Adverse-effects']
were O
mild O
and O
transient O
in O
both O
the O
dihydroergocryptine O
and O
placebo O
groups O
and O
there O
were O
no O
alterations O
in O
blood B-outcome ['Physiological-Clinical']
chemistry I-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical']

Safety O
and O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
a O
glycoPEGylated O
recombinant O
activated O
factor O
VII O
derivative O
: O
a O
randomized O
first O
human O
dose O
trial O
in O
healthy O
subjects O
. O
['Physiological-Clinical']

When O
the O
group O
of O
healthy O
controls O
was O
included O
in O
the O
analyses O
, O
it O
is O
of O
note O
that O
group-by-time O
interaction O
showed O
a O
significant O
result O
for O
the O
frontal O
lobe O
at O
trend O
level O
( O
F O
( O
3,81 O
) O
=2.686 O
; O
P=0.052 O
) O
. O
[]

No O
clinically O
relevant O
effect O
of O
gemfibrozil O
on O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
observed O
in O
groups O
defined O
by O
baseline O
lipid B-outcome ['Physiological-Clinical']
levels O
, O
kidney B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
diabetic B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
or O
other O
components O
of O
the O
metabolic B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

To O
investigate O
adenosinergic O
mechanisms O
in O
these O
differences O
, O
we O
studied O
the O
effects O
of O
prolonged O
waking O
and O
the O
adenosine O
receptor O
antagonist O
caffeine O
on O
sustained O
vigilant O
attention O
and O
regional O
electroencephalogram O
( O
EEG O
) O
power O
in O
the O
ranges O
of O
theta O
activity O
( O
6.25-8.25 O
Hz O
) O
in O
waking O
and O
the O
slow O
oscillation O
( O
< O
1 O
Hz O
) O
in O
sleep O
. O
[]

The O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
was O
significantly O
smaller O
in O
both O
groups O
than O
predicted O
according O
to O
the O
patients O
' O
underlying O
risks O
( O
midazolam O
group O
: O
p O
= O
0.018 O
; O
ondansetron O
group O
: O
p O
= O
0.017 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
cases O
and O
all O
learning O
materials O
will O
be O
open O
access O
and O
available O
on O
a O
Creative O
Commons O
Attribution-Share-Alike O
license O
. O
[]

BACKGROUND O
Zeaxanthin O
is O
hypothesized O
to O
reduce O
the O
risk O
of O
age-related O
macular O
degeneration O
; O
however O
, O
kinetic O
information O
is O
limited O
. O
[]

Three O
consecutive O
weekly O
infusions O
followed O
by O
a O
1-week O
rest O
period O
represented O
1 O
chemotherapy O
cycle O
. O
[]

PURPOSE O
To O
test O
the O
effect O
of O
valacyclovir O
alone O
and O
with O
aspirin O
on O
the O
asymptomatic O
shedding O
of O
HSV-1 O
DNA O
in O
tears O
and O
saliva O
of O
healthy O
individuals O
. O
[]

PURPOSE O
To O
evaluate O
the O
safety O
and O
efficacy O
of O
initial O
treatment O
with O
imatinib O
mesylate O
800 O
mg/d O
( O
400 O
mg O
twice O
daily O
) O
versus O
400 O
mg/d O
in O
patients O
with O
newly O
diagnosed O
chronic O
myeloid O
leukemia O
in O
chronic O
phase O
. O
[]

In O
study O
I O
, O
MEG-X B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
rate O
was O
dose-independent O
in O
patients O
with O
severely O
impaired O
liver O
function O
. O
['Physiological-Clinical']

RESULTS O
There O
was O
a O
significant O
decrease O
in O
overall O
scores O
of O
stress O
levels O
for O
participants O
over O
the O
course O
of O
the O
study O
and O
there O
was O
a O
significant O
increase O
in O
the O
four O
factors O
of O
quality O
of O
life O
that O
were O
measured O
( O
satisfaction B-outcome ['Life-Impact']
, O
independence O
, O
competence B-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
interaction I-outcome ['Life-Impact']
) O
as O
well O
as O
the O
total O
score O
for O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
from O
baseline O
to O
the O
end O
of O
the O
intervention O
12 O
months O
later O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Diagnostic B-outcome ['Life-Impact']
accuracy I-outcome ['Life-Impact']
was O
improved O
from O
75 O
% O
to O
97 O
% O
. O
['Life-Impact']

Physical O
activity O
was O
measured O
via O
blinded O
pedometer O
and O
accelerometer O
at O
baseline O
and O
follow-up O
. O
[]

Postthrombotic B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
also O
occurred O
with O
less O
frequency O
in O
systemically O
treated O
patients O
versus O
controls O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

METHOD O
Thirty-eight O
patients O
received O
baseline O
MRIs O
as O
part O
of O
a O
larger O
12-week O
, O
randomized O
clinical O
trial O
comparing O
sertraline O
and O
nortriptyline O
in O
the O
treatment O
of O
late-life O
depression O
. O
[]

PURPOSE O
The O
purpose O
of O
this O
prospective O
, O
randomized O
, O
double-blind O
study O
was O
to O
compare O
injection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
postinjection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
of O
2 O
% O
lidocaine O
with O
1:100,000 O
epinephrine O
and O
3 O
% O
mepivacaine O
using O
the O
computer-assisted O
Wand O
Plus O
injection O
system O
to O
administer O
the O
palatal-anterior O
superior O
alveolar O
( O
P-ASA O
) O
injection O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
quality O
of O
the O
analgesia O
was O
assessed O
with O
a O
Numerical O
Pain O
Rating O
Scale O
( O
NRS O
) O
; O
recovery B-outcome ['Physiological-Clinical']
level O
and O
return O
of O
psychomotor B-outcome ['Life-Impact']
efficiency O
were O
evaluated O
with O
, O
respectively O
, O
the O
Aldrete O
scale O
and O
a O
Modified O
Post O
Anesthesia O
Discharge O
Scoring O
( O
MPADS O
) O
system O
. O
['Physiological-Clinical', 'Life-Impact']

MATERIALS O
AND O
METHODS O
Men O
50 O
years O
or O
older O
with O
an O
International O
Prostate O
Symptom O
Score O
of O
13 O
or O
greater O
and O
peak O
urinary O
flow O
rate O
of O
4 O
to O
15 O
ml O
per O
second O
received O
placebo O
or O
8 O
mg O
silodosin O
daily O
with O
breakfast O
for O
12 O
weeks O
. O
[]

We O
aimed O
to O
verify O
whether O
monitoring O
of O
serum B-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TMs I-outcome ['Physiological-Clinical']
) O
, O
namely O
carcinoembryonic B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
, O
CA19-9 B-outcome ['Physiological-Clinical']
, O
DUPAN-2 B-outcome ['Physiological-Clinical']
, O
SPan-1 B-outcome ['Physiological-Clinical']
, O
can O
facilitate O
earlier O
confirmation O
of O
treatment O
failure O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
results O
suggest O
that O
the O
hemodynamic B-outcome ['Physiological-Clinical']
effects O
of O
the O
3 O
drugs O
are O
similar O
within O
the O
first O
30 O
min O
. O
['Physiological-Clinical']

We O
conducted O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
to O
examine O
the O
efficacy O
of O
prophylactic O
ondansetron O
on O
post-operative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
vomiting I-outcome ['Physiological-Clinical']
( O
PONV B-outcome ['Physiological-Clinical']
) O
during O
opioid O
patient-controlled O
analgesia O
( O
PCA O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Hypoxemia O
during O
the O
induction O
of O
general O
anesthesia O
for O
the O
morbidly O
obese O
patient O
is O
a O
major O
concern O
of O
anesthesiologists O
. O
[]

This O
trial O
compared O
toxicity O
and O
efficacy O
of O
weekly O
versus O
daily O
CDA O
administration O
. O
[]

These O
sustained O
effects O
of O
CBSM O
on O
depressive O
symptoms O
were O
mediated O
by O
10-week O
increases O
in O
cognitive B-outcome ['Life-Impact']
coping B-outcome ['Life-Impact']
( O
i.e O
. O
['Life-Impact', 'Life-Impact']

In O
26 O
patients O
with O
chronic O
angina O
pectoris O
receiving O
acebutolol O
under O
double-blind O
, O
placebo-controlled O
conditions O
, O
gated O
( O
equilibrium O
) O
myocardial O
blood O
pool O
imaging O
using O
red O
blood O
cells O
labeled O
with O
technetium O
99m O
showed O
acebutolol O
to O
have O
no O
clinically O
significant O
negative O
effect O
on O
left O
ventricular O
performance O
at O
rest O
or O
during O
supine O
bicycle O
exercise O
. O
[]

Patients O
were O
regularly O
treated O
with O
salbutamol O
200 O
micrograms O
twice O
daily O
during O
the O
study O
period O
, O
to O
avoid O
variability O
in O
beta2-adrenoceptor B-outcome ['Life-Impact']
tolerance I-outcome ['Life-Impact']
. O
['Life-Impact']

Forearm B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMDprox I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
increased O
with O
2.94 O
% O
( O
p O
= O
0.006 O
) O
in O
women O
who O
were O
prescribed O
levonorgestrel O
, O
which O
was O
in O
contrast O
to O
stable O
values O
in O
those O
prescribed O
depot-medroxy-progesterone O
acetate O
; O
group O
difference O
at O
6 O
months O
for O
BMDprox O
3.4 O
% O
( O
95 O
% O
CI O
1.3 O
, O
5.5 O
; O
p O
= O
0.025 O
) O
and O
BMDdist O
4.1 O
% O
( O
95 O
% O
CI O
- O
1.3 O
, O
9.6 O
; O
p O
= O
0.077 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
the O
93 O
randomized O
patients O
, O
87 O
started O
treatment O
, O
41 O
received O
PUVA O
and O
46 O
received O
PUVA O
+ O
bexarotene O
. O
[]

Although O
classic O
IBD O
and O
ipilimumab-related O
gastrointestinal O
toxicity O
are O
both O
immune O
mediated O
, O
the O
observed O
pattern O
of O
biomarkers O
suggests O
ipilimumab-related O
gastrointestinal O
toxicity O
may O
be O
a O
distinct O
clinicopathologic O
entity O
. O
[]

Topical O
adrenaline O
in O
the O
control O
of O
intraoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
in O
adenoidectomy O
: O
a O
randomised O
, O
controlled O
trial O
. O
['Physiological-Clinical']

We O
also O
included O
a O
visual B-outcome ['Life-Impact']
working I-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
task O
. O
['Life-Impact']

After O
preventive O
central O
nervous O
system O
( O
CNS O
) O
therapy O
including O
18 O
Gy O
cranial O
irradiation O
and O
three O
doses O
of O
intrathecal O
methotrexate O
( O
MTX O
) O
, O
the O
patients O
were O
assigned O
randomly O
to O
the O
two O
maintenance O
chemotherapies O
, O
Regimen O
A O
and O
Regimen O
B O
. O
[]

Each O
experiment O
consisted O
of O
nine O
sessions O
: O
On O
the O
first O
four O
sessions O
subjects O
sampled O
two O
color-coded O
capsules O
on O
alternate O
sessions O
and O
on O
the O
following O
five O
sessions O
they O
chose O
and O
ingested O
the O
capsule O
they O
preferred O
. O
[]

Consistent O
with O
this O
hypothesis O
, O
Experiment O
1 O
showed O
that O
participants O
( O
N O
= O
81 O
) O
altered O
how O
frequently O
they O
admitted B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
criminal I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
unethical I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
during O
an O
interview O
to O
avoid O
a O
proximal O
consequence O
even O
though O
doing O
so O
increased O
their O
risk O
of O
incurring O
a O
distal B-outcome ['Life-Impact']
consequence I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

OBJECTIVE O
To O
compare O
the O
efficacy O
of O
an O
acupuncture O
regimen O
for O
persistent O
allergic O
rhinitis O
( O
PER O
) O
, O
aimed O
at O
improving O
a O
patient O
's O
mind O
or O
Shen O
in O
Traditional O
Chinese O
Medicine O
, O
to O
that O
of O
a O
second-generation O
Hi-receptor O
antagonist O
, O
cetirizine O
hydrochloride O
. O
[]

OBJECTIVE O
The O
primary O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
a O
ST O
program O
on O
central B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
in O
middle-aged O
and O
older O
adults O
. O
['Physiological-Clinical']

Ten O
of O
the O
20 O
long O
day O
care O
services O
will O
be O
randomly O
allocated O
to O
deliver O
the O
intervention O
with O
the O
remaining O
ten O
services O
allocated O
to O
a O
wait O
list O
control O
group O
. O
[]

All O
patients O
were O
intubated O
, O
received O
non-depolarising O
muscle O
relaxants O
, O
and O
were O
manually O
ventilated O
with O
nitrous O
oxide-oxygen O
( O
2:1.2 O
) O
. O
[]

Vildagliptin O
increased O
fasting O
GLP-1 B-outcome ['Physiological-Clinical']
levels O
in O
subjects O
taking O
metformin O
, O
but O
not O
those O
managed O
with O
diet O
, O
and O
raised O
active O
GIP O
levels O
slightly O
. O
['Physiological-Clinical']

Pupils O
in O
the O
intervention O
+ O
prompt O
condition O
will O
- O
in O
addition O
to O
the O
personalised O
feedback O
letters O
- O
receive O
e-mail O
and O
SMS O
messages O
prompting O
them O
to O
revisit O
the O
'Fun O
without O
Smokes O
' O
website O
. O
[]

The O
registrations O
were O
repeated O
after O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
and O
follow-up O
data O
were O
compared O
with O
baseline O
with O
aid O
of O
chi-square O
and O
paired O
t-tests O
. O
[]

A O
PSA-D O
threshold O
of O
0.15 O
ng/mL/cc O
would O
have O
avoided O
73.8 O
% O
of O
biopsies O
at O
the O
cost O
of O
not O
diagnosing O
43.8 O
% O
of O
detectable O
cancers O
. O
[]

Acetazolamide O
had O
no O
statistically O
significant O
effect O
( O
P=0.53 O
) O
on O
the O
improvement O
of O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
of O
patients O
over O
that O
of O
placebo O
( O
13 O
vs O
eight O
eyes O
) O
, O
nor O
on O
the O
deterioration O
of O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
( O
three O
vs O
11 O
eyes O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

3 O
months O
, O
daily O
mean O
voiding O
frequency O
( O
DMVF O
) O
? O
[]

Further O
studies O
are O
needed O
to O
demonstrate O
whether O
beta-carotene O
has O
a O
role O
as O
adjunct O
therapy O
in O
treatment O
of O
HIV-infected B-outcome ['Physiological-Clinical']
patients O
. O
['Physiological-Clinical']

SETTING O
Primary O
contact O
, O
college O
out-patient O
clinic O
. O
[]

These O
findings O
underscore O
the O
need O
for O
interventions O
targeting O
high-risk O
populations O
, O
such O
as O
those O
receiving O
high-intensity O
sun O
exposures O
at O
the O
beach O
. O
[]

The O
long-term O
efficacy O
in O
functional O
gain O
needs O
to O
be O
further O
explored O
. O
[]

METHODS O
Serum O
magnesium O
levels O
were O
measured O
in O
1,068 O
patients O
enrolled O
in O
a O
survival O
study O
of O
class O
III O
or O
IV O
heart O
failure O
at O
the O
time O
of O
double-blind O
randomization O
to O
milrinone O
, O
a O
phosphodiesterase O
inhibitor O
, O
or O
placebo O
. O
[]

As O
for O
cyclophosphamide O
versus O
radiotherapy O
, O
the O
differences O
are O
to O
uncertain O
for O
any O
conclusion O
to O
be O
drawn O
. O
[]

The O
percentages O
of O
the O
reduction O
ratio O
in O
plasma B-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
were O
measured O
as O
primary O
outcomes O
. O
['Physiological-Clinical']

Multicenter O
, O
double-blind O
, O
placebo-controlled O
crossover O
study O
to O
assess O
the O
acute B-outcome ['Physiological-Clinical']
prokinetic I-outcome ['Physiological-Clinical']
efficacy O
of O
nizatidine-controlled O
release O
( O
150 O
and O
300 O
mg O
) O
in O
patients O
with O
gastroesophageal O
reflux O
disease O
. O
['Physiological-Clinical']

Thirty-four O
healthy O
young O
women O
were O
allocated O
to O
12 O
consecutive O
cycles O
of O
treatment O
with O
monophasic O
combinations O
of O
: O
20 O
micrograms O
ethinyl O
estradiol O
and O
150 O
micrograms O
desogestrel O
( O
n O
= O
15 O
) O
or O
30 O
micrograms O
ethinyl O
estradiol O
and O
75 O
micrograms O
gestodene O
( O
n O
= O
19 O
) O
. O
[]

The O
modified O
Blalock-Taussig O
shunt O
was O
better O
among O
the O
4 O
% O
of O
subjects O
who O
were O
preterm O
with O
a O
patent O
aortic O
valve O
( O
P O
= O
.003 O
) O
. O
[]

The O
cumulative O
complication B-outcome ['Adverse-effects']
rate O
was O
significantly O
lower O
in O
group O
B O
than O
in O
group O
A O
. O
['Adverse-effects']

The O
3,583 O
men O
in O
the O
CARE O
trial O
also O
showed O
a O
reduction O
in O
risk O
, O
but O
the O
magnitude O
tended O
to O
be O
less O
. O
[]

BACKGROUND O
Animal O
studies O
have O
shown O
the O
effectiveness O
of O
AZ O
for O
therapy O
of O
supraventricular O
and O
ventricular O
tachycardia O
( O
VT O
) O
. O
[]

The O
increase O
in O
plasma B-outcome ['Physiological-Clinical']
6-keto-prostaglandin I-outcome ['Physiological-Clinical']
F1 I-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
associated O
with O
an O
increase O
in O
['Physiological-Clinical']

Lack O
of O
effect O
of O
a O
low-fat O
, O
high-fiber O
diet O
on O
the O
recurrence O
of O
colorectal B-outcome ['Physiological-Clinical']
adenomas I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Future O
studies O
need O
to O
examine O
the O
long-term O
effects O
of O
these O
early O
interventions O
on O
children O
's O
development O
. O
[]

A O
control O
group O
( O
n O
= O
99 O
) O
only O
had O
a O
standard O
disinfection O
procedure O
of O
the O
eye O
( O
including O
instillation O
of O
Terramycin O
cum O
polymyxin O
B O
cream O
in O
the O
conjunctival O
sac O
the O
evening O
before O
surgery O
) O
. O
[]

2.25 O
demonstrated O
?89 O
% O
sensitivity O
but O
?35 O
% O
specificity O
for O
VDI O
. O
[]

Eleven O
patients O
with O
12 O
traumatic O
femur O
fractures O
were O
randomized O
to O
reamed O
( O
7 O
fractures O
) O
and O
unreamed O
( O
5 O
fractures O
) O
groups O
. O
[]

METHODS O
Sixty-one O
patients O
with O
ovarian O
cancer O
or O
endometrial O
cancer O
who O
underwent O
retroperitoneal O
lymph O
node O
resection O
were O
assigned O
at O
random O
to O
a O
retroperitoneal O
partial O
no-closure O
group O
or O
a O
closure O
group O
. O
[]

STUDY O
DESIGN O
Randomized O
, O
double-blinded O
, O
placebo-controlled O
study O
. O
[]

Wound B-outcome ['Physiological-Clinical']
progress I-outcome ['Physiological-Clinical']
was O
recorded O
by O
nurses O
' O
perception O
of O
the O
progress O
of O
wound O
healing O
and O
by O
objective O
digital O
imaging O
. O
['Physiological-Clinical']

MATERIAL O
AND O
METHODS O
For O
all O
treatment O
groups O
anaesthesia O
was O
induced O
with O
5 O
% O
isoflurane O
in O
oxygen O
using O
an O
induction O
chamber O
. O
[]

The O
economic O
impact O
of O
esophageal O
variceal O
hemorrhage O
: O
cost-effectiveness O
implications O
of O
endoscopic O
therapy O
. O
[]

CONCLUSIONS O
N7-GP O
had O
a O
plasma O
half-life O
of O
15 O
h O
and O
a O
profile O
that O
makes O
it O
a O
potential O
candidate O
for O
prophylaxis O
in O
patients O
with O
hemophilia O
and O
inhibitors O
. O
[]

In O
the O
context O
of O
picture-to-object O
requesting O
, O
one O
group O
was O
taught O
using O
an O
error O
correction O
method O
and O
the O
other O
group O
with O
an O
error O
prevention O
method O
. O
[]

BACKGROUND O
Tissue O
injury O
following O
ischemia-reperfusion O
is O
mediated O
in O
part O
by O
free O
oxygen O
radicals O
. O
[]

At O
3 O
years O
, O
freedom O
from O
the O
composite O
end O
point O
of O
AMI O
, O
[]

A O
once-daily O
regimen O
might O
be O
more O
effective O
and O
less O
toxic O
. O
[]

Based O
on O
these O
studies O
, O
we O
decided O
to O
assess O
the O
effectiveness O
of O
Ginkgo O
biloba O
extract O
( O
Ginko O
T.D. O
, O
Tolidaru O
, O
Iran O
) O
as O
an O
adjunctive O
agent O
to O
risperidone O
in O
the O
treatment O
of O
autism O
. O
[]

However O
, O
little O
is O
known O
about O
how O
neuronal O
activity O
in O
visual O
cortex O
represents O
second-order B-outcome ['Physiological-Clinical']
modulations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
levels O
of O
NH2-terminal B-outcome ['Physiological-Clinical']
immunoreactivity I-outcome ['Physiological-Clinical']
in O
patients O
with O
a O
short O
ileal O
segment O
and O
in O
controls O
were O
lower O
than O
in O
patients O
with O
a O
long O
ileal O
segment O
. O
['Physiological-Clinical']

Positive O
effects O
of O
methylphenidate O
on O
social B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
self-regulation I-outcome ['Life-Impact']
in O
children O
with O
pervasive O
developmental O
disorders O
and O
hyperactivity O
. O
['Life-Impact']

SD O
. O
[]

Forty-eight O
women O
, O
equally O
divided O
between O
women O
using O
and O
not O
using O
HRT O
, O
participated O
in O
a O
double-blind O
crossover O
trial O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Questionnaire O
responses O
and O
recording O
of O
key O
variables O
extracted O
from O
the O
clinical O
records O
before O
and O
after O
the O
intervention O
. O
[]

Intraabdominal O
pressure O
and O
bladder O
compliance O
were O
recorded O
prior O
to O
the O
induction O
of O
anesthesia O
and O
immediately O
before O
the O
onset O
of O
the O
surgical O
procedure O
. O
[]

CONCLUSIONS O
Diuresis O
is O
a O
useful O
, O
inexpensive O
and O
safe O
adjunct O
to O
ESWL O
of O
ureteric O
stones O
. O
[]

The O
setting O
was O
at O
University O
Hospital O
, O
Out-patient O
Clinic O
. O
[]

A O
total O
of O
121 O
patients O
was O
studied O
; O
92 O
were O
clinically O
evaluable O
. O
[]

Inhaled O
treprostinil O
has O
been O
shown O
to O
be O
safe O
and O
efficacious O
in O
adults O
. O
[]

The O
results O
largely O
replicate O
other O
findings O
in O
this O
area O
and O
call O
into O
question O
advocacy O
efforts O
to O
label O
media O
images O
as O
a O
strategy O
to O
decrease O
women O
's O
identification O
with O
the O
stimuli O
. O
[]

Neither O
the O
active O
combination O
nor O
placebo O
affected O
blood B-outcome ['Physiological-Clinical']
coagulation I-outcome ['Physiological-Clinical']
tests O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURE O
Clinical B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
condylomata I-outcome ['Physiological-Clinical']
for O
six O
months O
following O
adjuvant B-outcome ['Resource-use']
chemotherapy I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

A O
total O
of O
54 O
patients O
met O
the O
study O
criteria O
for O
a O
stable B-outcome ['Physiological-Clinical']
PT I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
before O
hospital O
discharge O
( O
analog O
computer O
, O
n O
= O
20 O
; O
linear O
regression O
, O
n O
= O
15 O
; O
empiric O
dosing O
, O
n O
= O
19 O
) O
. O
['Physiological-Clinical']

There O
were O
no O
recognized O
signs O
or O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hypocalcemia I-outcome ['Physiological-Clinical']
in O
the O
sodium O
phosphate O
group O
. O
['Physiological-Clinical']

Identifiers O
: O
NCT00332241 O
and O
NCT00337571 O
. O
[]

CONCLUSION O
Although O
the O
difference O
in O
PCSK9 O
between O
2 O
groups O
was O
transient O
, O
that O
in O
both O
campesterol O
and O
lathosterol O
persisted O
until O
52 O
weeks O
. O
[]

In O
this O
study O
20 O
patients O
were O
prospectively O
randomized O
into O
2 O
groups O
, O
to O
undergo O
either O
standard O
femoral O
( O
group O
A O
) O
or O
direct O
aortic O
cannulation O
( O
group O
B O
) O
. O
[]

METHODS O
All O
patients O
with O
patellar O
instability O
who O
underwent O
both O
CT O
and O
MRI O
of O
the O
knee O
from O
2003 O
to O
2011 O
were O
included O
( O
n O
= O
59 O
knees O
in O
54 O
patients O
) O
. O
[]

RESULTS O
People O
with O
BBTW O
showed O
a O
significant O
improvement O
in O
the O
25-foot B-outcome ['Physiological-Clinical']
walk I-outcome ['Physiological-Clinical']
( O
P O
= O
.01 O
) O
over O
those O
with O
no O
weight O
, O
and O
the O
TUG B-outcome ['Physiological-Clinical']
( O
P O
= O
.01 O
) O
over O
those O
with O
standard O
weight O
placement O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
controlled O
study O
. O
[]

METHODS O
Fifty O
patients O
who O
had O
tennis O
elbow O
participated O
in O
the O
study O
and O
were O
randomised O
into O
two O
groups O
. O
[]

Anabolic O
steroids O
in O
athelics O
: O
crossover O
double-blind O
trial O
on O
weightlifters O
. O
[]

A O
global O
evaluation O
to O
assess O
the O
method O
of O
irrigation O
and O
the O
solutions O
used O
for O
irrigation O
was O
completed O
by O
both O
the O
physician O
blinded O
to O
the O
treatment O
groups O
and O
the O
volunteers O
. O
[]

Why O
were O
the O
results O
of O
the O
Heart O
Outcomes O
Prevention O
Evaluation O
( O
HOPE O
) O
trial O
so O
astounding O
? O
[]

Hypocalcemic B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
, O
and O
parathyroid B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PTH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
were O
compared O
among O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
test O
set O
, O
the O
sensitivity O
and O
specificity O
were O
97 O
% O
and O
95 O
% O
for O
LAD O
lesions O
, O
85 O
% O
and O
86 O
% O
for O
right O
lesions O
, O
and O
73 O
% O
and O
60 O
% O
for O
LC B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

leaves O
, O
on O
the O
levels O
of O
pro-oxidant-antioxidant B-outcome ['Physiological-Clinical']
equilibrium O
markers B-outcome ['Physiological-Clinical']
and O
anti- O
and O
proinflammatory B-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
in O
rowers O
subjected O
to O
exhaustive O
exercise O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
conclude O
that O
, O
in O
elderly O
patients O
undergoing O
elective O
procedures O
, O
withholding O
prehydration O
is O
not O
associated O
with O
any O
greater O
degree O
of O
[]

METHODS O
At O
baseline O
and O
after O
3 O
weeks O
, O
periodic B-outcome ['Physiological-Clinical']
limb I-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PLM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
sleep B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
were O
assessed O
by O
polysomnography B-outcome ['Resource-use']
, O
and O
patients O
self-assessed O
their O
sleep B-outcome ['Physiological-Clinical']
disturbance I-outcome ['Physiological-Clinical']
and O
overall O
RLS B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
using O
the O
international O
RLS O
study O
group O
rating O
scale O
( O
IRLS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

A O
day O
before O
scanning O
, O
participants O
undertook O
an O
active O
object O
location O
memory O
task O
within O
a O
virtual O
house O
in O
which O
each O
room O
was O
associated O
with O
a O
different O
schedule O
of O
task-irrelevant O
emotional O
events O
. O
[]

In O
light O
of O
the O
inhibitory O
effect O
of O
somatostatin O
on O
TSH O
secretion O
, O
we O
examined O
whether O
this O
condition O
is O
caused O
by O
an O
increased O
hypothalamic B-outcome ['Physiological-Clinical']
somatostatinergic I-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
in O
starving O
subjects O
. O
['Physiological-Clinical']

BACKGROUND O
Myocardial O
contrast O
echocardiography O
may O
be O
more O
versatile O
than O
perfusion O
scintigraphy O
for O
identifying O
the O
presence O
and O
extent O
of O
perfusion O
defects O
after O
MI O
. O
[]

SUBJECTS O
Nine O
neonates O
receiving O
ECMO O
who O
required O
intravenous O
nutrition O
. O
[]

The O
probable O
therapeutic O
mechanism O
of O
adapalene O
is O
also O
discussed O
. O
[]

Homogenous B-outcome ['Physiological-Clinical']
enhancement I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
deep I-outcome ['Physiological-Clinical']
veins I-outcome ['Physiological-Clinical']
was O
more O
assuredly O
achieved O
with O
protocol O
C. O
CONCLUSION O
With O
protocol O
C O
, O
qualitatively O
acceptable O
enhancement O
can O
be O
obtained O
in O
whole-body O
CT O
. O
['Physiological-Clinical']

It O
did O
not O
affect O
the O
[]

All O
subjects O
received O
therapeutic O
doses O
of O
10 O
mL O
0.12 O
% O
chlorhexidine O
gluconate O
( O
Peridex O
, O
Procter O
& O
Gamble O
) O
and O
10 O
mL O
0.05 O
% O
NaF O
applied O
with O
a O
Toothette O
( O
Sage O
Products O
) O
. O
[]

STUDY O
DESIGN O
AND O
SETTING O
A O
prospective O
randomized O
study O
was O
conducted O
on O
150 O
consecutive O
adult O
patients O
undergoing O
tonsillectomy O
. O
[]

Twenty-seven O
( O
48.2 O
% O
) O
and O
19 O
( O
35.2 O
% O
) O
patients O
experienced O
acute B-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
( O
placebo O
versus O
steroid O
, O
respectively O
; O
p O
= O
0.116 O
) O
. O
['Physiological-Clinical']

The O
scores O
for O
the O
bispectral O
index O
may O
not O
reflect O
correct O
values O
in O
children O
, O
but O
may O
be O
helpful O
during O
titration O
of O
sedatives O
such O
as O
midazolam O
and O
ketamine O
. O
[]

Primary O
prevention O
and O
health O
promotion O
have O
become O
salient O
topics O
in O
Canadian O
society O
and O
in O
nursing O
during O
the O
past O
two O
decades O
. O
[]

METHODS O
Randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
in O
the O
inpatient O
wards O
of O
a O
pediatric O
tertiary O
care O
hospital O
. O
[]

MR O
imaging O
of O
pituitary O
region O
lesions O
with O
gadodiamide O
injection O
. O
[]

RESULTS O
Between O
October O
1993 O
and O
August O
1995 O
, O
58 O
patients O
were O
randomly O
assigned O
to O
streptokinase O
( O
SK O
) O
and O
54 O
patients O
to O
primary O
PCI O
. O
[]

Major O
grade O
II-IV O
toxicities B-outcome ['Adverse-effects']
included O
: O
neutropenia B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
vomiting B-outcome ['Physiological-Clinical']
and O
alopecia B-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
value O
of O
calculated B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
at O
T O
= O
0 O
min O
did O
not O
shown O
any O
difference O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

Other O
prognostic O
features O
were O
much O
less O
important O
when O
account O
was O
taken O
of O
renal O
function O
and O
haemoglobin O
level O
. O
[]

Additional O
misoprostol O
was O
not O
given O
after O
either O
spontaneous O
rupture O
of O
membranes O
, O
adequate O
cervical O
ripening O
( O
Bishop O
score O
of O
> O
or O
= O
8 O
or O
cervical O
dilatation O
of O
> O
or O
= O
3 O
cm O
) O
, O
or O
beginning O
of O
active O
labor O
. O
[]

ZNS O
did O
not O
provide O
significant O
improvements O
in O
clinical B-outcome ['Physiological-Clinical']
rating O
scales O
at O
study O
endpoint O
compared O
to O
placebo O
and O
was O
only O
modestly O
well O
['Physiological-Clinical']

OBJECTIVES O
To O
verify O
non-inferiority O
of O
the O
clinical O
pregnancy O
rate O
of O
Early O
hCG O
administration O
( O
leading O
follicle O
sizes O
within O
16.0-16.9 O
mm O
in O
diameter O
) O
compared O
to O
Late O
hCG O
administration O
( O
leading O
follicle O
sizes O
within O
18.0-18.9 O
mm O
in O
diameter O
) O
. O
[]

Each O
regimen O
was O
well O
tolerated B-outcome ['Life-Impact']
with O
acceptable O
levels O
of O
myelosuppression B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Comparative O
efficacy O
of O
oral O
erythromycin O
versus O
oral O
tetracycline O
in O
the O
treatment O
of O
acne B-outcome ['Physiological-Clinical']
vulgaris I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Ambulatory O
activity O
outcome O
parameters O
served O
as O
dependent O
variables O
, O
and O
disease O
, O
personal O
, O
and O
environmental O
characteristics O
as O
independent O
variables O
. O
[]

A O
graph O
was O
used O
to O
demonstrate O
the O
treatment O
effect O
( O
the O
estimated O
difference O
of O
kg/cow/day O
of O
milk O
yield O
between O
the O
treated O
and O
placebo O
cows O
) O
, O
with O
95 O
% O
confidence O
intervals O
, O
as O
the O
ODR O
values O
increase O
. O
[]

In O
an O
eight-week O
double-blind O
, O
placebo-controlled O
pilot O
trial O
, O
clozapine-treated O
patients O
with O
schizophrenia O
were O
randomized O
to O
receive O
rosiglitazone O
( O
4mg/day O
) O
or O
placebo O
. O
[]

Abstinence O
or O
controlled O
drinking O
in O
clinical O
practice O
: O
indications O
at O
initial O
assessment O
. O
[]

Interferential O
therapy O
electrode O
placement O
technique O
in O
acute O
low O
back O
pain O
: O
a O
preliminary O
investigation O
. O
[]

The O
trial O
involved O
75 O
volunteers O
, O
aged O
45-58 O
with O
moderate O
to O
severe O
osteopenia O
( O
T-score O
lower O
than O
-2 O
SD O
) O
assessed O
by O
quantitative O
ultrasound O
. O
[]

Comparison O
of O
electromotive O
drug O
administration O
with O
ketorolac O
or O
with O
placebo O
in O
patients O
with O
pain B-outcome ['Physiological-Clinical']
from O
rheumatic O
disease O
: O
a O
double-masked O
study O
. O
['Physiological-Clinical']

Efficacy O
was O
based O
on O
the O
blinded O
subject O
's O
, O
evaluator O
's O
, O
and O
[]

Cognitive O
effects O
of O
lithium O
carbonate O
and O
haloperidol O
in O
treatment-resistant O
aggressive O
children O
. O
[]

In O
venous O
blood O
samples O
the O
serum O
levels O
of O
immunoreactive O
insulin O
, O
C-peptide O
and O
glucosamine O
were O
determined O
as O
well O
as O
binding O
of O
125I-insulin B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
erythrocyte I-outcome ['Physiological-Clinical']
receptors I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Death B-outcome ['Mortality']
or O
neurological B-outcome ['Physiological-Clinical']
deterioration I-outcome ['Physiological-Clinical']
at O
day O
10 O
was O
associated O
, O
both O
in O
unadjusted O
and O
adjusted O
analyses O
, O
with O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
( O
adjusted O
OR O
, O
1.02 O
; O
95 O
% O
CI O
, O
1.01-1.03 O
) O
, O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
OR O
, O
1.02 O
; O
95 O
% O
CI O
, O
1.01-1.04 O
) O
, O
pulse B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
OR O
, O
1.02 O
; O
95 O
% O
CI O
, O
1.01-1.03 O
) O
, O
and O
BP B-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
( O
OR O
, O
1.03 O
; O
95 O
% O
CI O
, O
1.01-1.05 O
) O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
study O
, O
electrocautery O
division O
of O
the O
thyroid B-outcome ['Physiological-Clinical']
isthmus I-outcome ['Physiological-Clinical']
during O
tracheostomy O
is O
faster O
and O
as O
safe O
as O
other O
techniques O
with O
respect O
to O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
, O
perioperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
and O
airway B-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical']

Impact O
of O
an O
encounter-based O
prompting O
system O
on O
resident B-outcome ['Life-Impact']
vaccine I-outcome ['Life-Impact']
administration I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
immunization B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

OBJECTIVE O
To O
assess O
the O
efficacy O
of O
exercise O
therapy O
on O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
in O
patients O
with O
acute O
low O
back O
pain O
. O
['Life-Impact']

A O
model O
combining O
baseline O
level O
, O
the O
change O
and O
the O
interaction O
between O
them O
gave O
the O
best O
prediction O
of O
outcome O
, O
however O
, O
insignificantly O
better O
than O
baseline O
level O
for O
all O
markers O
except O
CA242 O
. O
[]

Direct B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
, O
including O
['Resource-use']

Mean O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
( O
?SEM O
) O
was O
significantly O
lower O
( O
1.75 O
? O
['Physiological-Clinical']

BACKGROUND O
Despite O
curative O
resection O
, O
50 O
% O
-90 O
% O
of O
gastric O
cancer O
patients O
die O
of O
disease B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Sorafenib O
dose O
escalation O
is O
not O
uniformly O
associated O
with O
blood O
pressure O
elevations O
in O
normotensive O
patients O
with O
advanced O
malignancies O
. O
[]

antibiotics O
. O
[]

CONCLUSIONS O
These O
data O
suggest O
that O
significant O
improvements O
can O
be O
made O
in O
peer O
social O
connections O
for O
children O
with O
autism O
spectrum O
disorders O
in O
general O
education O
classrooms O
with O
a O
brief O
intervention O
, O
and O
that O
these O
gains O
persist O
over O
time O
. O
[]

In O
particular O
, O
the O
TC O
+ O
RP O
group O
was O
characterized O
by O
a O
decreased O
rate O
of O
bleeding B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
pocket I-outcome ['Physiological-Clinical']
probing I-outcome ['Physiological-Clinical']
and O
an O
increased O
probing B-outcome ['Physiological-Clinical']
attachment I-outcome ['Physiological-Clinical']
gain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
6-month O
follow-up O
rate O
was O
97 O
% O
in O
both O
groups O
. O
[]

Basal B-outcome ['Physiological-Clinical']
CRT I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
was O
0.643 O
( O
0.033 O
) O
s O
in O
non-TIPS O
and O
0.825 O
( O
0.076 O
) O
s O
in O
TIPS O
patients O
( O
p O
< O
0.02 O
) O
. O
['Physiological-Clinical']

METHODS O
The O
CCS O
included O
4292 O
women O
aged O
> O
70 O
years O
. O
[]

Clinical O
reactions O
and O
neutralizing O
antibody O
responses O
to O
six O
pre-exposure O
regimens O
of O
purified O
chick O
embryo O
cell O
culture O
rabies O
vaccine O
( O
PCECV O
) O
and O
human O
diploid O
cell O
strain O
rabies O
vaccine O
( O
HDCSV O
) O
were O
studied O
in O
177 O
volunteers O
. O
[]

Supplementing O
beef O
cows O
with O
whole O
corn O
germ O
had O
no O
effect O
on O
cow O
performance O
, O
calf O
performance O
, O
or O
serum O
leptin O
concentrations O
of O
cows O
. O
[]

The O
primary O
outcome O
parameter O
was O
the O
change O
of O
the O
five O
typical O
clinical O
symptoms O
, O
earache B-outcome ['Physiological-Clinical']
, O
itching B-outcome ['Physiological-Clinical']
, O
otorrhea B-outcome ['Physiological-Clinical']
, O
hearing B-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
, O
and O
clogged B-outcome ['Physiological-Clinical']
ear I-outcome ['Physiological-Clinical']
at O
Visit O
2 O
( O
Day O
7 O
) O
based O
on O
the O
initial O
examination O
on O
Day O
0 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Correlations O
with O
forced O
expiratory O
volume O
in O
one O
second O
( O
FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
) O
% O
predicted O
and O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate O
( O
PEFR O
) O
were O
low O
for O
both O
questionnaires O
but O
better O
for O
the O
SGRQ O
than O
for O
the O
CRQ O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Serum O
concentrations O
of O
hemoglobin O
levels O
, O
follicle-stimulating O
hormone O
, O
and O
liver O
enzymes O
were O
obtained O
, O
and O
endometrial O
samples O
, O
symptoms O
, O
and O
menstrual O
bleeding O
were O
also O
assessed O
. O
[]

Muscle O
contractions O
induced O
by O
functional O
electrical O
stimulation O
( O
FES O
) O
tend O
to O
result O
in O
rapid B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
, O
which O
greatly O
limits O
activities O
such O
as O
FES-assisted O
standing O
and O
walking O
. O
['Physiological-Clinical']

MATERIAL O
AND O
METHODS O
Fifty-seven O
patients O
scheduled O
for O
transurethral O
resection O
of O
the O
prostate O
or O
a O
vesical O
tumor O
. O
[]

This O
randomised O
monocentre O
study O
was O
done O
between O
December O
1995 O
and O
August O
1997 O
. O
[]

Enteral O
formulas O
were O
given O
orally O
as O
the O
sole O
source O
of O
nutrition O
to O
the O
subjects O
for O
6 O
days O
. O
[]

PATIENTS O
AND O
METHODS O
The O
study O
was O
carried O
out O
in O
50 O
cirrhotic O
patients O
. O
[]

[ O
A O
randomized O
trial O
of O
PVB O
, O
VAB-6 O
, O
BVP O
regimen O
versus O
PEB O
chemotherapy O
in O
patients O
with O
disseminated O
testicular O
tumors O
] O
. O
[]

Pulmonary O
function O
testing O
showed O
that O
O O
( O
3 O
) O
-induced O
reductions O
in O
FEV O
( O
1 O
) O
and O
FVC B-outcome ['Physiological-Clinical']
were O
30 O
% O
and O
24 O
% O
smaller O
, O
respectively O
, O
in O
the O
supplemented O
cohort O
. O
['Physiological-Clinical']

No O
women O
given O
metformin O
spontaneously B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

During O
the O
month O
following O
parenteral O
nutrition O
, O
weight O
, O
skinfold O
thickness O
, O
and O
mid-arm O
muscle O
circumference O
, O
but O
not O
MIP O
, O
decreased O
and O
arterial O
oxygen O
saturation O
returned O
to O
the O
initial O
value O
( O
P O
less O
than O
0.01 O
) O
. O
[]

They O
will O
be O
randomized O
in O
a O
2:2:1 O
ratio O
to O
receive O
12 O
weekly O
yoga O
classes O
, O
12 O
weekly O
conventional O
therapeutic O
exercise O
classes O
of O
comparable O
physical O
exertion O
, O
or O
a O
self-care O
book O
. O
[]

FINDINGS O
Of O
the O
120 O
patients O
initially O
enrolled O
, O
one O
withdrew O
after O
signing O
consent O
and O
one O
patient O
's O
baseline O
bone O
marrow O
was O
not O
available O
. O
[]

In O
these O
EEG-regulators O
, O
no O
statistically O
significant O
reductions O
of O
symptoms B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
ASD I-outcome ['Life-Impact']
were O
observed O
, O
but O
they O
showed O
significant O
improvement O
in O
cognitive B-outcome ['Life-Impact']
flexibility I-outcome ['Life-Impact']
as O
compared O
to O
participants O
who O
managed O
to O
regulate O
SC O
. O
['Life-Impact', 'Life-Impact']

Urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
6-beta-hydroxycortisol I-outcome ['Physiological-Clinical']
was O
augmented O
after O
treatment O
in O
the O
ticlopidine O
group O
compared O
with O
the O
placebo O
group O
, O
suggesting O
that O
induction O
of O
drug O
metabolism O
might O
have O
occurred O
. O
['Physiological-Clinical']

Quantitative O
coronary O
analysis O
was O
performed O
by O
an O
independent O
core O
lab O
. O
[]

There O
was O
no O
correlation O
between O
necessary O
injection O
volume O
and O
sex O
, O
body O
mass O
index O
, O
or O
knee O
circumference O
. O
[]

MATERIALS O
AND O
METHODS O
The O
shear O
bond O
strength O
test O
was O
conducted O
to O
assess O
adhesion O
on O
enamel O
( O
protocol O
1 O
) O
, O
while O
the O
microtensile O
bond O
strength O
test O
was O
performed O
on O
dentin O
( O
protocol O
2 O
) O
. O
[]

The O
first O
study O
targeted O
children O
with O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
( O
N=191 O
, O
mean O
age=10.1 O
) O
as O
screened O
with O
self O
, O
parent O
, O
and O
teacher-reports O
; O
the O
second O
study O
took O
a O
universal O
approach O
with O
full O
classrooms O
of O
children O
participating O
( O
N=253 O
, O
mean O
age=9.8 O
) O
. O
['Life-Impact']

Our O
visual O
system O
can O
link O
components O
of O
contours O
and O
segregate O
contours O
from O
complex O
backgrounds O
based O
on O
geometric O
grouping O
rules O
. O
[]

The O
median O
duration O
of O
progression-free B-outcome ['Physiological-Clinical']
survival B-outcome ['Mortality']
was O
10.6 O
months O
in O
the O
group O
given O
IFL O
plus O
bevacizumab O
, O
as O
compared O
with O
6.2 O
months O
in O
the O
group O
given O
IFL O
plus O
placebo O
( O
hazard O
ratio O
for O
disease O
progression O
, O
0.54 O
; O
P O
< O
0.001 O
) O
; O
the O
corresponding O
rates O
of O
response O
were O
44.8 O
percent O
and O
34.8 O
percent O
( O
P=0.004 O
) O
. O
['Physiological-Clinical', 'Mortality']

INTRODUCTION O
Recent O
ex O
vivo O
platelet O
aggregometry O
data O
indicate O
that O
clopidogrel O
75 O
mg/day O
plus O
acetylsalicylic O
acid O
( O
ASA O
) O
75 O
mg/day O
is O
a O
more O
potent O
antiplatelet O
regimen O
than O
the O
marketed O
combination O
of O
dipyridamole+ASA O
. O
[]

It O
also O
has O
been O
suggested O
that O
ENT O
may O
increase O
thermogenesis O
. O
[]

PATIENTS O
AND O
METHODS O
Forty-seven O
patients O
undergoing O
an O
allogeneic O
HSCT O
were O
randomly O
assigned O
to O
an O
exercise O
group O
( O
EG O
) O
or O
a O
control O
group O
( O
CG O
) O
. O
[]

Successful O
treatment O
of O
blepharitis O
with O
bibrocathol O
( O
Posiformin? O
2 O
% O
) O
. O
[]

Large-scale O
and O
long-term O
studies O
are O
indicated O
to O
evaluate O
the O
effects O
of O
inhaled O
steroid O
therapy O
on O
the O
inflammatory O
components O
in O
bronchiectasis O
. O
[]

RESULTS O
All O
H. O
pylori O
( O
+ O
) O
patients O
showed O
a O
rapid O
increase O
of O
intragastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
with O
a O
mean O
intragastric B-outcome ['Physiological-Clinical']
pH B-outcome ['Physiological-Clinical']
of O
6.7 O
during O
the O
second O
half O
of O
the O
first O
day O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
a O
1-year O
cessation O
trial O
of O
smokers O
with O
COPD O
, O
continuous O
abstinence B-outcome ['Life-Impact']
compared O
with O
continuous O
smoking O
significantly O
improved O
['Life-Impact']

Ventricular O
fibrillation O
durations O
greater O
than O
10 O
s O
may O
negatively O
affect O
the O
effectiveness O
of O
ICD B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
. O
['Resource-use']

Histologic B-outcome ['Physiological-Clinical']
examination I-outcome ['Physiological-Clinical']
revealed I-outcome ['Physiological-Clinical']
thinning I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cartilage I-outcome ['Physiological-Clinical']
, O
diffuse B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
chondrocytes I-outcome ['Physiological-Clinical']
, O
with O
the O
calcified B-outcome ['Physiological-Clinical']
zone I-outcome ['Physiological-Clinical']
intact I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

and O
19 O
patients O
with O
propranolol O
80 O
mg O
t.d.s O
. O
[]

The O
presenting O
features O
and O
outcomes O
of O
therapy O
in O
these O
children O
were O
compared O
by O
age O
. O
[]

Groups O
1 O
and O
2 O
received O
metal O
brackets O
, O
and O
groups O
3 O
and O
4 O
had O
ceramic O
brackets O
. O
[]

We O
compared O
the O
efficacy O
of O
amphotericin O
B O
and O
pentamidine O
isethionate O
in O
a O
prospective O
randomised O
trial O
in O
120 O
uncomplicated O
and O
parasitologically O
confirmed O
cases O
of O
antimony-unresponsive O
kala-azar O
. O
[]

The O
effect O
sizes O
( O
95 O
% O
confidence O
interval O
) O
for O
[]

The O
role O
of O
treatment O
fidelity O
on O
outcomes O
during O
a O
randomized O
field O
trial O
of O
an O
autism O
intervention O
. O
[]

If O
there O
is O
no O
special O
need O
to O
treat O
a O
specific B-outcome ['Physiological-Clinical']
nosocomial I-outcome ['Physiological-Clinical']
outbreak I-outcome ['Physiological-Clinical']
, O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cord I-outcome ['Physiological-Clinical']
attachment I-outcome ['Physiological-Clinical']
and O
satisfaction B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
staff I-outcome ['Life-Impact']
and O
parents B-outcome ['Physiological-Clinical']
can O
help O
clinicians O
decide O
on O
a O
cord O
care O
regimen O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Clinical O
measures O
were O
collected O
at O
entry O
( O
J0 O
) O
, O
once O
when O
subjects O
began O
to O
walk B-outcome ['Life-Impact']
( O
JM O
) O
and O
30 O
days O
later O
( O
JM O
+ O
30 O
) O
. O
['Life-Impact']

BACKGROUND O
Many O
infants O
admitted O
to O
hospital O
undergo O
repeated O
invasive O
procedures O
. O
[]

The O
nonsmoking O
participants O
, O
ages O
18-30 O
years O
, O
included O
42 O
women O
and O
31 O
men O
who O
reported O
demographic O
information O
and O
measures O
of O
external O
temperature O
and O
heart O
rate O
were O
taken O
prior O
to O
introduction O
of O
an O
anxiety-eliciting O
task O
and O
exposure O
to O
lavender O
, O
rosemary O
, O
or O
water O
scents O
. O
[]

Participating O
institutions O
were O
asked O
to O
send O
five O
full O
patient O
records O
with O
the O
chemotherapy O
charts O
, O
surgical O
and O
pathology O
reports O
, O
radiation O
treatment O
charts O
, O
treatment O
planning O
calculations O
, O
computed O
tomography O
( O
CT O
) O
scans O
, O
portal O
images O
and O
follow-up O
charts O
. O
[]

No O
clinically O
relevant O
changes O
in O
cardiac B-outcome ['Physiological-Clinical']
conduction I-outcome ['Physiological-Clinical']
( O
lead O
II O
ECG O
) O
were O
observed O
in O
any O
subject O
during O
any O
treatment O
period O
. O
['Physiological-Clinical']

Prior O
focal O
( O
n O
= O
31 O
) O
or O
panretinal O
( O
n O
= O
25 O
) O
laser O
coagulation O
was O
permitted O
. O
[]

Activator O
protein-1 O
( O
AP-1 O
) O
signalling O
in O
human O
atherosclerosis O
: O
results O
of O
a O
systematic O
evaluation O
and O
intervention O
study O
. O
[]

Results O
suggest O
GAS O
descriptions O
can O
be O
evaluated O
for O
equivalency O
, O
that O
teacher O
collected O
behavior O
samples O
are O
representative O
, O
and O
that O
varied O
sources O
of O
behavior O
samples O
can O
be O
reliably O
coded O
. O
[]

In O
patients O
receiving O
fentanyl O
, O
the O
trachea B-outcome ['Physiological-Clinical']
was O
extubated B-outcome ['Resource-use']
on O
average O
2 O
h O
later O
than O
in O
those O
receiving O
sufentanil O
and O
3 O
h O
later O
than O
in O
those O
receiving O
alfentanil O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Resource-use']

PATIENT O
( O
S O
) O
Infertile O
couples O
( O
n=52 O
) O
with O
a O
female O
partner O
less O
than O
42 O
years O
old O
with O
eight O
or O
more O
mature O
oocytes O
retrieved O
. O
[]

34 O
% O
) O
, O
and O
erythrocyte B-outcome ['Physiological-Clinical']
support I-outcome ['Physiological-Clinical']
( O
22 O
% O
vs O
. O
['Physiological-Clinical']

The O
PC O
7000 O
and O
3DE O
were O
equally O
more O
effective O
in O
plaque B-outcome ['Resource-use']
removal I-outcome ['Resource-use']
than O
the O
SA O
, O
at O
all O
tooth O
areas O
, O
reducing O
plaque B-outcome ['Physiological-Clinical']
by O
59.0 O
% O
, O
59.7 O
% O
and O
51.8 O
% O
, O
respectively O
on O
whole O
mouth O
surfaces O
, O
and O
by O
67.5 O
% O
, O
67.8 O
% O
and O
59.4 O
% O
, O
respectively O
on O
approximal O
surfaces O
. O
['Resource-use', 'Physiological-Clinical']

OBJECTIVE O
This O
5-year O
observational O
posthoc O
analysis O
of O
the O
REFLEX O
study O
and O
its O
open-label O
extension O
assessed O
clinical O
efficacy O
, O
radiographic O
response O
, O
and O
safety O
of O
rituximab O
( O
RTX O
) O
in O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
who O
had O
an O
inadequate O
response O
to O
tumor O
necrosis O
factor O
( O
TNF O
) O
inhibitors O
. O
[]

In O
Group O
S O
, O
mean O
bladder O
compliance O
was O
significantly O
( O
p O
= O
0.003 O
) O
higher O
and O
mean O
intraabdominal B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
significantly O
lower O
( O
p O
= O
0.007 O
) O
when O
compared O
to O
baseline O
preanesthetic O
values O
. O
['Physiological-Clinical']

Ciprofloxacin O
, O
lomefloxacin O
, O
or O
levofloxacin O
as O
treatment O
for O
chronic B-outcome ['Physiological-Clinical']
osteomyelitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

After O
randomization O
, O
patients O
were O
begun O
on O
subcutaneous O
GM-CSF O
at O
a O
dose O
of O
1.0 O
microgram/kg/d O
. O
[]

At O
week O
84 O
, O
HBV B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

One O
hundred O
and O
fifty-five O
patients O
were O
randomized O
, O
144 O
were O
evaluable O
for O
safety O
and O
142 O
for O
response O
. O
[]

This O
result O
revealed O
that O
acupuncture O
seemed O
to O
have O
more O
affect O
on O
OKT4+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
than O
on O
OKT8+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
ORG-2766 O
on O
brain O
event-related O
potentials O
of O
autistic O
children O
. O
[]

DISCUSSION O
This O
study O
, O
if O
successful O
, O
will O
provide O
a O
much-needed O
randomized O
comparison O
of O
the O
conventional O
strategy O
of O
primary O
RT O
vs. O
the O
novel O
strategy O
of O
primary O
TORS O
. O
[]

These O
findings O
suggest O
that O
perioperative O
treatment O
with O
indomethacin O
is O
an O
excellent O
treatment O
of O
intracranial O
hypertension O
during O
normocapnic O
isoflurane O
anesthesia O
for O
craniotomy O
. O
[]

In O
48 O
instances O
, O
parents O
based O
their O
guess O
on O
perceived O
improvement O
; O
in O
six O
cases O
, O
parents O
based O
their O
guess O
on O
perceived O
deterioration B-outcome ['Life-Impact']
. O
['Life-Impact']

Ten O
young O
, O
nonverbal O
children O
with O
autism O
were O
matched O
in O
pairs O
and O
randomized O
to O
treatment O
. O
[]

Exercise O
improved O
the O
maximal O
aerobic O
power O
and O
body O
composition O
equally O
when O
walking O
was O
performed O
in O
one O
or O
two O
daily O
bouts O
. O
[]

BACKGROUND O
Combinations O
of O
infero-temporal O
and O
either O
supero-nasal O
( O
'inferior-superior O
' O
) O
or O
medial O
percaruncular O
( O
'inferior-medial O
' O
) O
injections O
are O
popular O
double-injection O
techniques O
for O
establishing O
peribulbar O
block O
analgesia O
. O
[]

AIM O
To O
determine O
the O
proportion O
of O
patients O
achieving O
tacrolimus B-outcome ['Physiological-Clinical']
whole-blood I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
?10 O
ng/mL O
within O
3 O
days O
of O
kidney O
transplantation O
, O
after O
randomization O
either O
to O
standard O
dosing O
( O
control O
group O
) O
or O
post-transplantation O
dosing O
guided O
by O
a O
2-hour O
( O
C O
( O
2 O
) O
) O
level O
following O
a O
preoperative O
tacrolimus O
dose O
( O
T2 O
group O
) O
. O
['Physiological-Clinical']

The O
ewes O
were O
randomly O
allocated O
into O
four O
groups O
, O
viz. O
, O
GI O
( O
n=7 O
; O
control O
) O
, O
GII O
( O
n=7 O
; O
thermal O
stress O
) O
, O
GIII O
( O
n=7 O
; O
restricted O
feeding O
) O
and O
GIV O
( O
n=7 O
; O
combined O
stress O
) O
. O
[]

Overall O
, O
tolerability B-outcome ['Life-Impact']
of O
the O
study O
medications O
was O
generally O
good O
and O
similar O
. O
['Life-Impact']

After O
1 O
week O
, O
the O
pain B-outcome ['Physiological-Clinical']
score O
and O
number O
of O
intramuscular B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
injections I-outcome ['Resource-use']
given O
were O
significantly O
less O
in O
group O
1 O
( O
P O
= O
0.001 O
and O
P O
= O
0.021 O
) O
. O
['Physiological-Clinical', 'Resource-use']

RESULTS O
Comparison O
of O
the O
change O
in O
median O
visual O
analog O
scale O
scores O
for O
60 O
minutes O
demonstrated O
that O
octreotide O
was O
less O
effective O
at O
reducing O
pain B-outcome ['Physiological-Clinical']
( O
P O
= O
.03 O
) O
and O
producing O
clinical O
success O
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical']

PURPOSE O
To O
investigate O
the O
effect O
of O
two O
tinted O
contact O
lenses O
( O
CL O
) O
designed O
for O
outdoor O
sports O
activity O
on O
the O
psychometric O
determination O
of O
retinal O
straylight O
using O
the O
compensation O
comparison O
method O
. O
[]

CONCLUSIONS O
SH O
in O
the O
6 O
months O
prior O
to O
the O
study O
was O
the O
strongest O
predictor O
of O
SH O
during O
the O
study O
. O
[]

Evaluating O
a O
test O
protocol O
for O
predicting O
maximum B-outcome ['Physiological-Clinical']
lactate I-outcome ['Physiological-Clinical']
steady I-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

INTERVENTION O
LEAP O
was O
a O
comprehensive O
school-based O
intervention O
emphasizing O
changes O
in O
instruction O
and O
school O
environment O
designed O
to O
increase O
physical O
activity O
among O
black O
and O
white O
adolescent O
girls O
. O
[]

In O
group O
A O
, O
75 O
% O
passed O
the O
LMA O
successfully O
at O
the O
first O
attempt O
, O
22 O
% O
at O
the O
second O
attempt O
and O
3 O
% O
( O
one O
nurse O
) O
at O
the O
third O
attempt O
. O
[]

METHODS O
In O
this O
double-blinded O
randomized O
clinical O
trial O
, O
101 O
patients O
with O
acute O
anterior O
STEMI O
who O
were O
candidate O
for O
TLT O
, O
were O
enrolled O
and O
randomly O
assigned O
into O
treatment O
or O
control O
groups O
. O
[]

Treatment O
with O
enalapril O
significantly O
reduced O
plasma B-outcome ['Physiological-Clinical']
angiotensin I-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
levels O
and O
supine B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
compared O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
in O
the O
riluzole O
group O
also O
showed O
significantly O
greater O
improvement O
on O
the O
lethargy/social O
withdrawal O
( O
P O
= O
0.02 O
) O
, O
stereotypic O
behavior O
( O
P O
= O
0.03 O
) O
, O
and O
hyperactivity/non-compliance O
subscales O
( O
P O
= O
0.005 O
) O
, O
but O
not O
on O
the O
inappropriate O
speech O
subscale O
( O
P O
= O
0.20 O
) O
than O
patients O
in O
the O
placebo O
group O
. O
[]

However O
, O
the O
benefits O
of O
such O
a O
strategy O
remain O
uncertain O
. O
[]

The O
results O
of O
therapy O
with O
carbenicillin O
plus O
trimethoprim-sulfamethoxazole O
( O
C-T/S O
) O
were O
compared O
to O
those O
obtained O
with O
carbenicillin O
plus O
gentamicin O
( O
C-G O
) O
in O
a O
prospective O
double-blind O
study O
of O
empiric O
antibiotic O
therapy O
in O
granulocytopenic O
patients O
. O
[]

Twenty-four O
patients O
predicted O
to O
require O
artificial O
ventilation O
for O
at O
least O
48 O
h O
were O
entered O
into O
a O
randomised O
crossover O
study O
to O
monitor O
sedation B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
sedation I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Eight O
gas O
mixtures O
of O
oxygen O
and O
nitrogen O
( O
fractional O
inspired O
oxygen O
concentration O
( O
FiO2 O
) O
0.1 O
to O
1.0 O
) O
were O
administered O
. O
[]

PURPOSE O
To O
determine O
the O
reliability O
of O
TT-TG B-outcome ['Physiological-Clinical']
distance O
measurements O
on O
both O
MRI O
and O
CT O
and O
to O
determine O
whether O
the O
measurements O
are O
interchangeable O
with O
one O
another O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
examine O
further O
the O
relations O
of O
plasma B-outcome ['Physiological-Clinical']
von I-outcome ['Physiological-Clinical']
Willebrand I-outcome ['Physiological-Clinical']
factor O
( O
vWf B-outcome ['Physiological-Clinical']
, O
an O
index O
of O
endothelial B-outcome ['Physiological-Clinical']
damage B-outcome ['Physiological-Clinical']
and O
dysfunction B-outcome ['Physiological-Clinical']
) O
and O
soluble B-outcome ['Physiological-Clinical']
P-selectin I-outcome ['Physiological-Clinical']
( O
sP-sel B-outcome ['Physiological-Clinical']
, O
an O
index O
of O
platelet B-outcome ['Physiological-Clinical']
activation B-outcome ['Physiological-Clinical']
) O
concentrations O
to O
the O
presence O
and O
onset O
of O
clinical O
congestive O
heart O
failure O
( O
CHF O
) O
and O
the O
degree O
of O
left O
ventricular O
( O
LV O
) O
dysfunction O
in O
patients O
taking O
part O
in O
the O
SPAF O
( O
stroke O
prevention O
in O
atrial O
fibrillation O
) O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
significant O
differences O
in O
the O
logarithm O
of O
the O
[]

Patients O
who O
undergo O
major O
contaminated O
surgery O
of O
the O
head O
and O
neck O
benefit O
from O
perioperative O
antibiotic O
prophylaxis O
. O
[]

Restenosis B-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
from O
42.2 O
% O
to O
38.6 O
% O
and O
to O
22.1 O
% O
in O
the O
placebo O
, O
usual-dose O
, O
and O
high-dose O
sirolimus O
groups O
, O
respectively O
( O
P=0.005 O
) O
. O
['Physiological-Clinical']

The O
original O
results O
of O
these O
trials O
were O
reported O
in O
1991 O
and O
1992 O
. O
[]

MATERIALS O
AND O
METHODS O
Thirty O
patients O
with O
single O
HCC O
? O
[]

Development O
, O
description O
, O
and O
acceptability O
of O
a O
small-group O
, O
behavioral O
intervention O
to O
prevent O
HIV O
and O
hepatitis O
C O
virus O
infections O
among O
young O
adult O
injection O
drug O
users O
. O
[]

aureus O
exopolysaccharides O
; O
and O
inactivated O
, O
unencapsulated O
Staph O
, O
aureus O
and O
Streptococcus O
spp O
. O
[]

A O
selective O
angiotensin O
receptor O
antagonist O
, O
Valsartan O
, O
produced O
regression O
of O
left O
ventricular O
hypertrophy O
associated O
with O
a O
reduction O
of O
arterial O
stiffness O
. O
[]

Magnetic O
resonance O
imaging O
brain O
scans O
( O
1.5T O
) O
were O
obtained O
and O
images O
were O
analyzed O
by O
using O
BRAINS2 O
. O
[]

DESIGN O
Prospective O
, O
randomised O
, O
double-blind O
, O
placebo-controlled O
crossover O
study O
. O
[]

Serum B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Patient O
recruitment O
was O
stopped O
early O
, O
due O
to O
positive O
interim O
analysis O
results O
( O
significant O
at O
prespecified O
level O
, O
p O
< O
or O
= O
0.0414 O
) O
. O
[]

There O
was O
no O
difference O
in O
the O
duration O
of O
analgesia O
between O
groups O
( O
Mann-Whitney O
test O
P O
= O
0.27 O
, O
Mantel-Haentszel O
test O
P O
= O
0.17 O
) O
. O
[]

METHODS O
Lymph O
nodes O
from O
patients O
( O
n=94 O
) O
which O
were O
included O
in O
a O
randomized O
trial O
of O
lymph O
node O
sampling O
( O
LS O
, O
n=41 O
) O
versus O
radical O
systematic O
lymphadenectomy O
( O
LA O
, O
n=53 O
) O
were O
screened O
by O
immunohistochemistry O
for O
disseminated O
tumor O
cells O
using O
the O
antibody O
Ber-Ep4 O
. O
[]

The O
Tennessee O
Self-Concept O
Scale O
( O
TSCS O
) O
was O
administered O
to O
all O
subjects O
in O
both O
groups O
before O
and O
after O
the O
interventions O
. O
[]

The O
objective O
of O
the O
study O
was O
to O
evaluate O
the O
influence O
of O
GH B-outcome ['Physiological-Clinical']
on O
cortical B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
dimensions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
conducted O
a O
secondary O
analysis O
on O
the O
Aberrant O
Behavior O
Checklist O
Social B-outcome ['Life-Impact']
Withdrawal I-outcome ['Life-Impact']
subscale O
using O
data O
from O
two O
federally-funded O
, O
multi-site O
, O
randomized O
trials O
with O
risperidone O
. O
['Life-Impact']

To O
be O
eligible O
for O
inclusion O
, O
women O
had O
to O
be O
( O
i O
) O
under O
26 O
years O
old O
, O
( O
ii O
) O
less O
that O
27 O
weeks O
pregnant O
, O
( O
iii O
) O
sufficiently O
fluent O
in O
French O
to O
give O
truly O
informed O
consent O
to O
participate O
in O
the O
study O
and O
benefit O
from O
the O
intervention O
and O
( O
iv O
) O
presenting O
with O
one O
or O
more O
of O
the O
following O
social O
vulnerability O
factors O
: O
low O
income O
, O
low O
educational O
level O
, O
and/or O
intending O
to O
bring O
up O
the O
child O
without O
the O
child O
's O
father O
. O
[]

Preoperative O
use O
of O
flurbiprofen O
does O
not O
significantly O
decrease O
intraoperative B-outcome ['Physiological-Clinical']
miosis I-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
scleral I-outcome ['Physiological-Clinical']
buckling I-outcome ['Physiological-Clinical']
procedures I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

No O
statistical O
differences O
were O
seen O
in O
the O
demographic O
and O
baseline O
data O
among O
both O
groups O
. O
[]

A O
conventional O
medical O
provider O
independently O
evaluated O
patients O
with O
a O
standardized O
history O
and O
physical O
examination O
. O
[]

However O
, O
these O
differences O
between O
the O
two O
groups O
were O
not O
statistically O
significant O
. O
[]

PATIENTS O
The O
study O
population O
consisted O
of O
head O
injured O
, O
blunt O
trauma O
adult O
patients O
with O
a O
Glasgow O
Coma O
Scale O
of O
lower O
than O
9 O
. O
[]

During O
the O
two O
basal O
tilts O
, O
all O
the O
control O
subjects O
completed O
the O
study O
, O
whereas O
all O
the O
NMS O
patients O
developed O
syncope O
. O
[]

The O
metabolic O
responses O
to O
anticholinergic O
drugs O
have O
not O
been O
studied O
. O
[]

[ O
Opiate O
hypothesis O
in O
infantile O
autism O
? O
[]

After O
12 O
weeks O
of O
care O
, O
the O
proportion O
of O
wounds B-outcome ['Physiological-Clinical']
healed I-outcome ['Physiological-Clinical']
( O
defined O
as O
complete O
epithelialization O
without O
drainage O
) O
in O
the O
active O
ultrasound O
therapy O
device O
group O
was O
significantly O
higher O
than O
that O
in O
the O
sham O
control O
group O
( O
40.7 O
% O
versus O
14.3 O
% O
, O
P O
= O
0.0366 O
, O
Fisher O
's O
exact O
test O
) O
. O
['Physiological-Clinical']

Cryoprobe O
biopsy O
increases O
the O
diagnostic O
yield O
in O
endobronchial O
tumor O
lesions O
. O
[]

Both O
groups O
made O
significant O
progress B-outcome ['Physiological-Clinical']
after O
treatment O
. O
['Physiological-Clinical']

The O
number O
of O
patients O
with O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
similar O
in O
both O
treatment O
groups O
. O
['Adverse-effects']

INTRODUCTION O
The O
potential O
effect O
of O
strontium O
( O
Sr O
) O
on O
bone O
apatite O
crystals O
was O
investigated O
in O
paired O
biopsies O
of O
osteoporotic O
women O
treated O
with O
either O
strontium O
ranelate O
( O
SrRan O
) O
or O
a O
placebo O
for O
36 O
months O
. O
[]

In O
the O
sticking O
needling O
group O
, O
the O
manual O
sticking O
needling O
technique O
was O
adopted O
to O
stimulate O
the O
galea O
tendon-muscle O
node O
. O
[]

Twenty-seven O
adolescent O
basketball O
players O
( O
14.7+/-0.5 O
years O
; O
Tanner O
stage O
: O
3.5+/-0.5 O
) O
were O
randomly O
divided O
into O
a O
specialized O
basketball O
training O
group O
( O
SP O
, O
n=10 O
) O
, O
a O
mixed O
basketball O
plus O
conditioning O
training O
group O
( O
MX O
, O
n=10 O
) O
and O
a O
control O
group O
( O
n=7 O
) O
. O
[]

This O
trial O
compares O
two O
different O
strategies O
following O
thrombolysis O
: O
to O
transfer O
all O
patients O
for O
immediate O
coronary O
angiography O
and O
intervention O
, O
or O
to O
manage O
the O
patients O
more O
conservatively O
. O
[]

The O
updated O
survival O
analysis O
showed O
similar O
results O
. O
[]

Three O
sets O
of O
data O
were O
obtained O
with O
the O
program O
being O
conducted O
three O
times O
in O
a O
row O
. O
[]

Primary O
outcome O
measure O
was O
naturalistic B-outcome ['Life-Impact']
observation I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
in O
the O
classroom O
. O
['Life-Impact']

At O
4 O
weeks O
, O
98 O
% O
or O
more O
of O
the O
subjects O
in O
group O
1 O
had O
circulating B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
and O
D O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Prospective O
, O
randomized O
, O
and O
double-blind O
study O
of O
80 O
American O
Society O
of O
Anesthesiology O
grade O
I-II O
patients O
who O
underwent O
phacoemulsification O
with O
local O
anesthesia O
under O
sedation O
. O
[]

In O
the O
azithromycin O
group O
, O
MG B-outcome ['Physiological-Clinical']
plugging I-outcome ['Physiological-Clinical']
resolved O
completely O
in O
three O
patients O
and O
MG B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
returned I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
normal I-outcome ['Physiological-Clinical']
in O
two O
patients O
; O
no O
such O
results O
were O
seen O
in O
the O
compress O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
In O
patients O
with O
iron O
deficiency O
anemia O
due O
to O
heavy O
uterine O
bleeding O
, O
rapid O
IV O
administration O
of O
large O
doses O
of O
a O
new O
iron O
agent O
, O
ferric O
carboxymaltose O
, O
is O
more O
effective O
than O
oral O
iron O
therapy O
in O
correcting B-outcome ['Physiological-Clinical']
anemia I-outcome ['Physiological-Clinical']
, O
replenishing B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

These O
data O
confirm O
the O
complex O
relations O
among O
different O
fatty B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
pools I-outcome ['Physiological-Clinical']
after O
n-3 O
PUFA O
supplementation O
. O
['Physiological-Clinical']

METHODS O
Randomized O
, O
double-blind O
, O
placebo-controlled O
study O
. O
[]

However O
, O
the O
outcomes O
in O
poorer O
acuities O
should O
still O
be O
viewed O
with O
caution O
. O
[]

METHODS O
We O
designed O
a O
prospective O
, O
randomized O
study O
to O
compare O
video-assisted O
thoracoscopic O
talc O
insufflation O
with O
bedside O
talc O
slurry O
in O
the O
treatment O
of O
malignant O
pleural O
effusion O
. O
[]

Effectiveness O
of O
a O
brief O
cognitive-behavioural O
therapy O
intervention O
in O
the O
treatment O
of O
schizophrenia B-outcome ['Life-Impact']
. O
['Life-Impact']

PURPOSE O
This O
single O
centre O
, O
open O
labelled O
, O
randomised O
non-inferiority O
trial O
compared O
concurrent O
chemoradiotherapy O
with O
carboplatin O
versus O
standard O
concurrent O
chemoradiotherapy O
with O
cisplatin O
in O
patients O
with O
locoregionally O
advanced O
nasopharyngeal O
cancer O
( O
NPC O
) O
. O
[]

Serum B-outcome ['Physiological-Clinical']
hemoglobin I-outcome ['Physiological-Clinical']
was O
measured O
before O
and O
after O
surgery O
, O
and O
the O
following O
day O
. O
['Physiological-Clinical']

RESULTS O
Among O
patients O
not O
taking O
vitamin O
A O
prior O
to O
entry O
, O
those O
in O
the O
DHA O
+ O
A O
group O
had O
a O
slower O
decline O
in O
field B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
and O
electroretinogram B-outcome ['Physiological-Clinical']
amplitude I-outcome ['Physiological-Clinical']
than O
those O
in O
the O
control O
+ O
A O
group O
over O
the O
first O
2 O
years O
( O
P O
=.01 O
and O
P O
=.03 O
, O
respectively O
) O
; O
these O
differences O
were O
not O
observed O
in O
years O
3 O
and O
4 O
of O
follow-up O
or O
among O
patients O
taking O
vitamin O
A O
prior O
to O
entry O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Forty-seven O
patients O
with O
schizophrenia O
meeting O
criteria O
for O
deficit O
syndrome O
were O
randomized O
to O
D-cycloserine O
, O
50 O
mg/d O
( O
n=23 O
) O
or O
placebo O
( O
n=24 O
) O
added O
to O
their O
conventional O
neuroleptic O
for O
an O
8-week O
, O
double-blind O
trial O
. O
[]

Results O
showed O
significantly O
lower B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
assessment O
and O
opioid B-outcome ['Physiological-Clinical']
consumption I-outcome ['Physiological-Clinical']
, O
which O
should O
encourage O
further O
studies O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Bolus O
injection O
of O
contrast O
agents O
with O
various O
iodine O
concentrations O
and O
delivery O
rates O
for O
intracranial O
three-dimensional O
CT O
angiography O
: O
evaluation O
of O
intracranial B-outcome ['Physiological-Clinical']
arteriovenous I-outcome ['Physiological-Clinical']
contrast I-outcome ['Physiological-Clinical']
using O
a O
multidetector-row O
CT O
scanner O
. O
['Physiological-Clinical']

[ O
A O
randomized O
study O
of O
prophylactic O
intravesical O
instillation O
of O
pirarubicin O
( O
THP O
) O
prior O
to O
transurethral O
resection O
of O
superficial B-outcome ['Physiological-Clinical']
bladder I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
] O
. O
['Physiological-Clinical']

STUDY O
OBJECTIVE O
To O
investigate O
the O
effect O
of O
simultaneously O
administered O
didanosine O
( O
ddI O
) O
on O
the O
absorption O
of O
a O
single O
dose O
of O
itraconazole O
. O
[]

In O
the O
treatment O
group O
, O
we O
found O
significant O
improvements O
in O
the O
social B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
of O
the O
children O
with O
PDD O
. O
['Life-Impact']

In O
the O
OK-432 O
group O
intrapleural O
instillation O
of O
2 O
units O
of O
OK-432 O
was O
administered O
daily O
until O
disappearance O
of O
pleural O
effusion O
; O
thereafter O
, O
2 O
to O
5 O
units O
of O
OK-432 O
were O
administered O
intradermally O
every O
other O
day O
. O
[]

The O
most O
pronounced O
therapeutic O
effects O
of O
the O
drug O
were O
registered O
in O
respect O
of O
irritative O
symptoms O
of O
BPH O
. O
[]

Visual O
acuity O
is O
almost O
the O
same O
in O
both O
methods O
1 O
years O
after O
the O
operation O
. O
[]

Parents O
were O
also O
asked O
a O
series O
of O
questions O
to O
gather O
information O
about O
the O
pamphlet O
and O
its O
usefulness O
. O
[]

OBJECTIVES O
To O
document O
changes O
in O
toe-brachial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TBPI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
during O
the O
6 O
months O
following O
percutaneous O
transluminal O
angioplasty O
( O
PTA O
) O
and O
relate O
these O
changes O
to O
restenosis O
. O
['Physiological-Clinical']

Other O
aspects O
of O
therapy O
were O
constant O
. O
[]

Compliance O
with O
the O
recommended O
treatment O
, O
of O
at O
least O
four O
hours O
daily O
, O
is O
unknown O
. O
[]

There O
was O
a O
statistically O
significant O
difference O
in O
response O
rate O
and O
the O
median O
survival B-outcome ['Mortality']
between O
two O
groups O
. O
['Mortality']

Efficacy O
was O
evaluated O
through O
scores O
of O
erythema B-outcome ['Physiological-Clinical']
, O
scaling/hypertrophy B-outcome ['Physiological-Clinical']
and O
induration B-outcome ['Physiological-Clinical']
as O
well O
as O
pain B-outcome ['Physiological-Clinical']
and O
itching B-outcome ['Physiological-Clinical']
; O
general O
improvement O
scored O
by O
the O
investigator O
and O
global B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
scored O
by O
patients O
' O
assessment O
were O
also O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Intravenous O
L-arginine O
and O
GSNO O
attenuate O
Doppler B-outcome ['Physiological-Clinical']
embolic I-outcome ['Physiological-Clinical']
signals I-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical']

BACKGROUND O
A O
new O
aqueous O
gel O
formulation O
of O
dapsone O
has O
been O
developed O
that O
allows O
clinically-effective O
doses O
of O
dapsone O
to O
be O
administered O
topically O
with O
minimal O
systemic O
absorption O
. O
[]

METHODS O
In O
the O
surgery O
setting O
, O
a O
total O
of O
381 O
patients O
were O
randomised O
to O
chemotherapy O
( O
C O
, O
192 O
patients O
) O
or O
no O
chemotherapy O
( O
NoC O
, O
189 O
patients O
) O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
with O
bidimensionally O
measurable O
disease O
were O
randomised O
to O
topotecan O
( O
1.5 O
mg/m O
( O
2 O
) O
/day O
for O
5 O
days O
) O
or O
paclitaxel O
( O
175 O
mg/m O
( O
2 O
) O
/day O
as O
a O
3-h O
infusion O
) O
every O
21 O
days O
. O
[]

Symptoms O
of O
autism O
spectrum O
disorder O
( O
ASD O
) O
were O
assessed O
( O
Social O
Responsiveness O
Scale-Parent O
( O
SRS-P O
) O
; O
coded O
in-session O
behavior O
) O
in O
typically-developing O
, O
anxiety-disordered O
children O
( O
N O
= O
50 O
) O
treated O
with O
cognitive-behavioral O
therapy O
( O
CBT O
) O
. O
[]

Mean O
HbA B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1c I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Although O
fibric O
acid O
derivatives O
increase O
serum O
HDL-C O
levels O
and O
decrease O
triglyceride O
levels O
, O
their O
effects O
on O
renal O
function O
are O
largely O
unknown O
. O
[]

Although O
significantly O
more O
toxicity B-outcome ['Adverse-effects']
was O
noted O
in O
the O
CCRT O
arm O
, O
including O
leukopenia B-outcome ['Physiological-Clinical']
and O
emesis B-outcome ['Physiological-Clinical']
, O
compliance B-outcome ['Life-Impact']
with O
the O
combined O
treatment O
was O
good O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

A O
proof O
of O
concept O
study O
was O
performed O
evaluating O
putative O
benefits O
with O
montelukast O
in O
moderate O
persistent O
asthmatics O
who O
were O
taken O
off O
inhaled O
corticosteroids O
( O
ICS O
) O
and O
switched O
to O
salmeterol O
. O
[]

No O
statistically O
significant O
difference O
appeared O
between O
the O
number O
of O
preventive O
measures O
received O
by O
the O
control O
group O
and O
the O
form-letter O
group O
. O
[]

Our O
preliminary O
studies O
of O
the O
efficacy O
of O
lithium O
carbonate O
therapy O
for O
alcoholism O
under O
double-blind O
, O
placebo-controlled O
conditions O
demonstrated O
that O
alcoholics O
who O
took O
their O
assigned O
medication O
( O
lithium O
or O
placebo O
) O
for O
the O
first O
6 O
months O
after O
discharge O
from O
an O
inpatient O
rehabilitation O
program O
were O
more O
likely O
to O
abstain O
from O
any O
alcohol O
use O
for O
18 O
months O
following O
discharge O
than O
were O
alcoholics O
who O
took O
their O
medication O
erratically O
or O
not O
at O
all O
. O
[]

No O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
effect O
was O
seen O
with O
sarcalasin O
. O
['Physiological-Clinical']

Naltrexone O
in O
young O
autistic O
children O
: O
replication O
study O
and O
learning O
measures O
. O
[]

BACKGROUND O
AND O
STUDY O
AIMS O
Attempts O
have O
been O
made O
to O
improve O
patient O
's O
tolerance O
of O
upper O
gastrointestinal O
endoscopy O
and O
to O
decrease O
the O
need O
for O
sedation O
, O
using O
thinner O
endoscopes O
and O
a O
nasal O
introduction O
route O
. O
[]

MATERIALS O
AND O
METHODS O
Thirty O
CKD O
patients O
with O
mild O
to O
moderate O
renal O
insufficiency O
( O
20 O
men O
and O
10 O
women O
; O
mean O
age O
, O
37 O
years O
; O
estimated B-outcome ['Physiological-Clinical']
glomerular I-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
eGFR B-outcome ['Physiological-Clinical']
) O
> O
60 O
mL O
min O
( O
-1 O
) O
and O
blood O
pressure O
> O
130/85 O
mmHg O
) O
were O
included O
in O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Primary O
outcomes O
were O
differences O
in O
proportions O
and O
event O
rates O
of O
: O
any O
DSH O
; O
general O
hospital B-outcome ['Resource-use']
admission I-outcome ['Resource-use']
for O
DSH O
and O
any O
psychiatric B-outcome ['Resource-use']
admission I-outcome ['Resource-use']
; O
and O
mean O
difference O
in O
length O
of O
stay O
for O
any O
hospitalization O
. O
['Resource-use', 'Resource-use']

Therefore O
, O
the O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
motivational O
music O
( O
music O
that O
stimulates O
or O
inspires O
physical O
activity O
) O
during O
recovery O
from O
intense B-outcome ['Life-Impact']
exercise I-outcome ['Life-Impact']
, O
on O
activity B-outcome ['Life-Impact']
pattern I-outcome ['Life-Impact']
, O
rate O
of O
perceived B-outcome ['Life-Impact']
exertion I-outcome ['Life-Impact']
( O
RPE B-outcome ['Physiological-Clinical']
) O
, O
and O
blood B-outcome ['Physiological-Clinical']
lactate I-outcome ['Physiological-Clinical']
concentration O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Models O
were O
estimated O
separately O
for O
nonelderly O
and O
elderly O
adults O
in O
each O
state O
and O
for O
children O
in O
Florida O
. O
[]

Both O
regimens O
remain O
as O
reasonable O
treatment O
options O
. O
[]

With O
the O
use O
of O
a O
repeated O
measures O
design O
, O
30 O
subjects O
randomly O
received O
an O
inferior O
alveolar O
injection O
at O
three O
successive O
appointments O
. O
[]

During O
the O
first O
2 O
postoperative O
hours O
pain O
scores O
at O
rest O
and O
worst O
pain B-outcome ['Physiological-Clinical']
score O
( O
VAS O
0-100 O
mm O
) O
were O
significantly O
higher O
in O
the O
active O
placebo O
group O
compared O
to O
the O
gabapentin-treated O
patients O
. O
['Physiological-Clinical']

In O
hospitals O
that O
lack O
an O
efficient O
obstetric O
triage O
system O
, O
it O
is O
very O
difficult O
to O
regulate O
patient O
flow O
and O
wait O
times O
. O
[]

There O
is O
growing O
interest O
in O
measuring O
social B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
as O
a O
core O
element O
of O
autism O
spectrum O
disorders O
in O
medication O
trials O
. O
['Life-Impact']

Low-frequency O
rTMS O
minimized B-outcome ['Physiological-Clinical']
early I-outcome ['Physiological-Clinical']
cortical I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
irrelevant I-outcome ['Physiological-Clinical']
stimuli B-outcome ['Physiological-Clinical']
and O
increased O
responses B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
relevant I-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
have O
studied O
the O
effects O
of O
four O
doses O
of O
atenolol O
in O
11 O
patients O
with O
stable O
angina O
pectoris O
using O
a O
symptom-limited O
exercise O
test O
and O
angina O
diaries O
. O
[]

The O
median O
survival B-outcome ['Mortality']
was O
138 O
days O
for O
placebo O
and O
160 O
days O
for O
marimastat O
, O
with O
2-year O
survival O
of O
3 O
% O
and O
9 O
% O
respectively O
. O
['Mortality']

Death B-outcome ['Mortality']
( O
not O
due O
to O
pericarditis O
) O
occurred O
in O
two O
patients O
treated O
with O
indomethacin O
and O
one O
patient O
who O
received O
the O
placebo O
. O
['Mortality']

Two- O
and O
3-year O
survival B-outcome ['Mortality']
was O
44 O
% O
and O
34 O
% O
for O
HART O
, O
and O
24 O
% O
and O
14 O
% O
for O
qdRT O
, O
respectively O
. O
['Mortality']

CONCLUSIONS O
A O
brief O
course O
of O
oral O
dexamethasone O
( O
4 O
days O
) O
was O
significantly O
more O
effective O
than O
placebo O
within O
14 O
days O
for O
the O
treatment O
of O
depression O
in O
a O
randomized O
, O
double-blind O
study O
of O
depressed O
outpatients O
. O
[]

These O
results O
have O
implications O
for O
the O
design O
and O
evaluation O
of O
behavioral O
intervention O
studies O
. O
[]

Object B-outcome ['Life-Impact']
interest I-outcome ['Life-Impact']
in O
autism O
spectrum O
disorder O
: O
a O
treatment O
comparison O
. O
['Life-Impact']

These O
patients O
were O
compared O
to O
a O
group O
of O
22 O
children O
with O
similar O
pathologies O
who O
did O
not O
receive O
sildenafil O
( O
control O
group O
) O
. O
[]

METHODS O
The O
relationship O
between O
the O
changes O
of O
endogenous O
estrogen O
and O
the O
concentration O
of O
cholesteryl O
ester O
transfer O
protein O
( O
CETP O
) O
in O
the O
serum O
of O
Chinese O
women O
was O
investigated O
. O
[]

To O
evaluate O
the O
effect O
of O
treatment O
with O
L-thyroxine O
on O
QT O
dispersion O
and O
HRV O
, O
15 O
patients O
with O
SH O
were O
randomly O
assigned O
to O
receive O
therapy O
with O
L-thyroxine O
. O
[]

CONCLUSION O
Biological O
links O
between O
compulsions O
and O
stereotyped O
, O
repetitive O
behaviors O
in O
autistic O
disorder O
should O
be O
explored O
. O
[]

Direct O
measures O
of O
behavior B-outcome ['Life-Impact']
were O
compared O
across O
six O
matched O
pairs O
using O
a O
multiple O
baseline O
probe O
design O
. O
['Life-Impact']

Cost B-outcome ['Resource-use']
per O
quality-adjusted O
life O
year O
( O
QALY O
) O
gained O
was O
estimated O
using O
trial O
data O
. O
['Resource-use']

Optimization O
of O
acid O
suppression O
for O
patients O
with O
peptic O
ulcer O
bleeding O
: O
an O
intragastric O
pH-metry O
study O
with O
omeprazole O
. O
[]

BACKGROUND O
Allopurinol O
has O
been O
widely O
used O
for O
treatment O
of O
hyperuricemia O
, O
however O
, O
it O
may O
be O
associated O
with O
various O
adverse O
effects O
. O
[]

The O
Warfarin O
Re-Infarction O
Study O
. O
[]

DISCUSSION O
Losartan O
was O
very O
effective O
in O
reducing O
cardiovascular B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
as O
compared O
to O
atenolol O
. O
['Physiological-Clinical', 'Mortality']

Vaginal O
neutral O
sphingomyelinase O
activity O
was O
not O
modified O
in O
either O
group O
. O
[]

The O
secondary O
end O
point O
was O
the O
proportion O
of O
patients O
in O
whom O
pain O
was O
decreased O
( O
VAS O
score O
, O
< O
- O
3 O
cm O
) O
. O
[]

While O
the O
CT O
group O
( O
n O
= O
57 O
) O
consumed O
their O
habitual O
diet O
throughout O
, O
the O
HF O
( O
n O
= O
58 O
) O
and O
LF O
( O
n O
= O
59 O
) O
groups O
sequentially O
increased O
their O
daily O
F O
& O
V O
intake O
by O
an O
additional O
2 O
, O
4 O
and O
6 O
portions O
for O
6-week O
periods O
during O
the O
18-week O
study O
. O
[]

From O
October O
1990 O
to O
March O
1992 O
38 O
patients O
were O
recruited O
: O
20 O
patients O
in O
the O
antibiotic O
prophylaxis O
arm O
and O
18 O
patients O
in O
the O
control O
group O
. O
[]

METHOD O
Seven O
subjects O
, O
ages O
6-18 O
years O
, O
with O
autistic O
disorder O
completed O
a O
10-week O
double-blind O
, O
crossover O
trial O
of O
clomipramine O
and O
desipramine O
following O
a O
2-week O
single-blind O
, O
placebo O
phase O
. O
[]

Rate O
of O
progressive O
joint O
damage O
( O
PJD O
; O
change O
in O
mean O
Total O
Sharp O
Score O
) O
decreased O
over O
time O
in O
both O
PBO-randomized O
( O
n O
= O
79 O
) O
and O
RTX-randomized O
( O
n O
= O
105 O
) O
groups O
. O
[]

Excess O
paid B-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
home I-outcome ['Life-Impact']
management I-outcome ['Life-Impact']
loss I-outcome ['Life-Impact']
costs I-outcome ['Life-Impact']
were O
$ O
2,291 O
per O
patient O
per O
year O
( O
95 O
% O
CI O
, O
$ O
1847- O
$ O
2752 O
) O
. O
['Life-Impact']

Epidural O
fentanyl-bupivacaine O
compared O
with O
clonidine-bupivacaine O
for O
analgesia O
in O
labour O
. O
[]

An O
early O
regenerative O
response O
was O
apparent O
following O
acute B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Patients O
' O
satisfaction B-outcome ['Life-Impact']
and O
complications B-outcome ['Adverse-effects']
were O
evaluated O
. O
['Life-Impact', 'Adverse-effects']

RESULTS O
Three O
participants O
dropped O
out O
and O
seven O
died O
( O
five O
in O
the O
intervention O
and O
two O
in O
the O
control O
group O
, O
P=0.28 O
) O
. O
[]

Morbidity B-outcome ['Physiological-Clinical']
after O
elective O
open O
infrarenal O
aneurysm O
repair O
is O
as O
high O
as O
30 O
% O
; O
mortality B-outcome ['Mortality']
ranges O
up O
to O
10 O
% O
. O
['Physiological-Clinical', 'Mortality']

Chemotherapy O
of O
large O
bowel O
carcinoma O
-- O
fluorouracil O
( O
FU O
) O
+ O
hydroxyurea O
( O
HU O
) O
vs. O
methyl-CCNU O
, O
oncovin O
, O
fluorouracil O
, O
and O
streptozotocin O
( O
MOF-Strep O
) O
. O
[]

PURPOSE O
To O
compare O
the O
level O
of O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
with O
crowded O
and O
uncrowded O
versions O
of O
the O
logMAR O
acuity O
test O
and O
the O
Kay O
picture O
test O
in O
amblyopia O
. O
['Physiological-Clinical']

METHOD O
. O
[]

sedation O
) O
were O
similar O
across O
all O
three O
groups O
, O
but O
after O
amphetamine O
the O
AGE O
group O
showed O
greater O
stimulant O
effects O
. O
[]

The O
PVSG O
was O
organized O
in O
1967 O
to O
establish O
effective O
diagnostic O
criteria O
for O
polycythemia O
vera O
, O
to O
study O
the O
natural O
history O
of O
the O
disease O
and O
to O
define O
the O
optimal O
treatment O
. O
[]

Effect O
of O
prophylactic O
amiodarone O
in O
patients O
with O
rheumatic O
valve O
disease O
undergoing O
valve O
replacement O
surgery O
. O
[]

A O
few O
studies O
have O
been O
conducted O
that O
evaluate O
the O
effects O
of O
risperidone O
on O
destructive O
behavior O
; O
however O
, O
none O
of O
these O
studies O
have O
combined O
objective O
measures O
with O
rating O
scales O
to O
evaluate O
the O
effects O
of O
risperidone O
on O
destructive O
behavior O
across O
home O
and O
clinical O
settings O
. O
[]

However O
, O
there O
have O
been O
no O
pharmacokinetic/pharmacodynamic O
studies O
of O
diltiazem O
in O
these O
patients O
. O
[]

Family O
education O
for O
people O
with O
schizophrenia O
in O
Beijing O
, O
China O
: O
randomised O
controlled O
trial O
. O
[]

Two-hundred O
patients O
were O
randomized O
into O
2 O
groups O
to O
receive O
heparinized O
( O
group O
H O
, O
n O
= O
100 O
) O
or O
nonheparinized O
( O
group O
S O
, O
n O
= O
100 O
) O
flush O
solutions O
. O
[]

BACKGROUND O
Methylphenidate O
has O
been O
shown O
elsewhere O
to O
improve O
hyperactivity B-outcome ['Life-Impact']
in O
about O
half O
of O
treated O
children O
who O
have O
pervasive O
developmental O
disorders O
( O
PDD O
) O
and O
significant O
hyperactive-inattentive O
symptoms O
. O
['Life-Impact']

Randomisation O
was O
by O
use O
of O
minimisation O
of O
probability O
in O
the O
marginal O
distribution O
of O
treatment O
centre O
, O
age O
( O
< O
/=42 O
months O
or O
> O
42 O
months O
) O
, O
and O
autism O
severity O
( O
Autism O
Diagnostic O
Observation O
Schedule-Generic O
[ O
ADOS-G O
] O
algorithm O
score O
12-17 O
or O
18-24 O
) O
. O
[]

Thirty-four O
volunteer O
adult O
patients O
with O
traumatic O
brain O
injuries O
participated O
. O
[]

34.1 O
ng/L O
, O
67.8 O
? O
[]

BACKGROUND O
Extracorporeal O
circulation O
used O
during O
coronary O
artery O
bypass O
grafting O
triggers O
systemic O
inflammatory O
response O
with O
neutrophil O
activation O
which O
adversely O
affects O
ischaemic/reperfused O
myocardium O
. O
[]

BACKGROUND O
Beyond O
lipid O
lowering O
, O
various O
antiinflammatory O
properties O
have O
been O
ascribed O
to O
statins O
. O
[]

These O
included O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
( O
61.6 O
vs O
70.7 O
) O
, O
physical B-outcome ['Life-Impact']
role I-outcome ['Life-Impact']
limitations I-outcome ['Life-Impact']
( O
56.8 O
vs O
72.8 O
) O
, O
and O
bodily B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
60.0 O
vs O
71.7 O
) O
at O
baseline O
and O
6 O
months O
, O
respectively O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

RESULTS O
The O
total O
effective O
rate O
was O
96.6 O
% O
in O
the O
treatment O
group O
, O
higher O
than O
that O
of O
the O
control O
group O
( O
70.00 O
% O
, O
P O
< O
0.01 O
) O
. O
[]

This O
is O
one O
of O
the O
first O
demonstrations O
of O
a O
therapeutic O
benefit O
for O
a O
matrix O
metalloproteinase O
inhibitor O
in O
cancer O
patients O
. O
[]

A O
time O
delay O
procedure O
was O
used O
to O
teach O
3 O
children O
with O
autism O
to O
ask O
the O
question O
What O
's O
that O
? O
[]

Rescue B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
was O
required O
after O
the O
second O
injection O
in O
a O
mean O
of O
14 O
% O
of O
attacks O
. O
['Resource-use']

PATIENTS O
One O
hundred-sixty O
patients O
with O
septate O
uterus O
and O
a O
history O
of O
recurrent O
abortion O
or O
primary O
infertility O
undergoing O
hysteroscopic O
metroplasty O
from O
2001 O
to O
2005 O
. O
[]

BMD O
on O
the O
hemiplegic B-outcome ['Physiological-Clinical']
side I-outcome ['Physiological-Clinical']
increased O
by O
1.4 O
% O
in O
the O
etidronate O
group O
and O
decreased O
by O
2.2 O
% O
in O
the O
placebo O
group O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

RESULTS O
A O
total O
of O
121 O
of O
304 O
patients O
( O
39.8 O
% O
) O
met O
criteria O
for O
symptomatic B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
in O
the O
open-label O
treatment O
phase O
and O
were O
randomly O
assigned O
to O
olanzapine O
( O
n=76 O
) O
or O
placebo O
( O
n=45 O
) O
. O
['Physiological-Clinical']

The O
high O
subclinical O
frequency O
of O
deep O
vein O
thrombosis O
indicates O
the O
importance O
of O
improving O
thromboprophylaxis O
in O
order O
to O
further O
minimise O
the O
occurrence O
of O
deep O
vein O
thrombosis O
and O
the O
risk O
of O
thromboembolic O
complications O
. O
[]

Higher O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
associated O
with O
higher O
heart O
rate O
, O
lower O
calcium O
channel O
blocker O
and O
digoxin O
use O
and O
lower O
New O
York O
Heart O
Association O
functional O
class O
. O
['Physiological-Clinical']

All O
participants O
will O
also O
have O
a O
structured O
2 O
hour O
home O
practice O
program O
for O
each O
week O
during O
the O
8 O
week O
intervention O
phase O
. O
[]

METHODS O
Sixty O
patients O
were O
randomised O
to O
receive O
two O
single O
doses O
of O
cediranib O
in O
either O
fed/fasted O
or O
fasted/fed O
state O
( O
Part O
A O
) O
. O
[]

The O
task O
was O
found O
to O
interfere O
with O
supra-span O
serial O
recall O
and O
with O
backward B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
span I-outcome ['Life-Impact']
, O
but O
did O
not O
disrupt O
performance O
on O
a O
forward-memory-span B-outcome ['Life-Impact']
task O
. O
['Life-Impact', 'Life-Impact']

On O
the O
contrary O
, O
the O
gluten-free O
diet O
seemed O
to O
be O
another O
negative O
factor O
leading O
to O
further O
social B-outcome ['Life-Impact']
isolation I-outcome ['Life-Impact']
in O
this O
group O
of O
highly O
socially O
handicapped O
patients O
and O
families O
. O
['Life-Impact']

This O
study O
evaluated O
peginterferon O
alfa-2a O
for O
60 O
wk O
, O
alone O
or O
in O
combination O
with O
lamivudine O
. O
[]

BACKGROUND O
Psychosocial O
treatments O
are O
the O
mainstay O
of O
management O
of O
autism O
in O
the O
UK O
but O
there O
is O
a O
notable O
lack O
of O
a O
systematic O
evidence O
base O
for O
their O
effectiveness O
. O
[]

One O
potentially O
prolactin-related O
AE O
( O
irregular O
menstruation O
) O
was O
reported O
. O
[]

Specific O
immunoglobulin O
for O
treatment O
of O
whooping O
cough O
. O
[]

Nodules B-outcome ['Physiological-Clinical']
decreased O
significantly O
( O
p O
< O
0.0001 O
) O
by O
22 O
% O
after O
2 O
weeks O
( O
6.5 O
ml O
; O
range O
2.4-16.7 O
) O
and O
by O
44 O
% O
after O
30 O
weeks O
( O
4.6 O
ml O
; O
range O
0.69-14.2 O
) O
. O
['Physiological-Clinical']

Auditory O
ERPs O
were O
recorded O
before O
and O
5 O
h O
after O
drug O
administration O
on O
day O
1 O
( O
acute O
effect O
) O
and O
on O
day O
15 O
( O
subacute O
and O
superimposed O
effect O
) O
. O
[]

RESULTS O
There O
was O
statistically O
significant O
improvement O
from O
the O
baseline O
value O
in O
both O
the O
arms O
, O
i.e O
injection O
papaverine O
and O
oral O
sildenafil O
( O
p O
< O
0.001 O
, O
p O
< O
0.001 O
, O
respectively O
) O
for O
both O
penile B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
and O
circumference B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Evidence O
suggests O
that O
the O
elevation O
in O
plasma O
norepinephrine O
levels O
can O
be O
at O
least O
partly O
attributed O
to O
an O
increase O
in O
sympathetic O
nervous O
system O
activity O
. O
[]

However O
, O
there O
were O
no O
significant O
differences O
in O
the O
median O
improvement O
in O
FACIT-F O
fatigue O
between O
the O
MP O
and O
PL O
groups O
( O
5.5 O
v O
6.0 O
, O
respectively O
; O
P O
= O
.69 O
) O
and O
among O
all O
four O
groups O
( O
P O
= O
.16 O
) O
. O
[]

Thus O
a O
study O
of O
phenytoin O
prophylaxis O
was O
undertaken O
and O
is O
herein O
reported O
. O
[]

Overall O
median O
survival B-outcome ['Mortality']
was O
15 O
months O
for O
58 O
patients O
receiving O
tamoxifen O
and O
25 O
months O
for O
53 O
patients O
undergoing O
oophorectomy O
( O
P O
= O
.18 O
) O
. O
['Mortality']

RESULTS O
NPPV O
was O
feasible O
with O
negligible O
leak B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
, O
indicating O
optimal O
mask O
fitting O
during O
the O
daytime O
( O
setting O
I O
) O
. O
['Physiological-Clinical']

Tetracaine O
( O
ametop O
) O
compared O
to O
placebo O
for O
reducing O
pain O
associated O
with O
intramuscular O
injection O
of O
palivizumab O
( O
synagis O
) O
. O
[]

Dexmedetomidine O
was O
administered O
as O
a O
two-step O
infusion O
to O
rapidly O
achieve O
a O
steady-state O
plasma O
concentration O
. O
[]

Patients O
could O
not O
have O
visceral O
crisis O
. O
[]

The O
degree O
of O
protection B-outcome ['Physiological-Clinical']
by O
heparin O
against O
adenosine-induced O
bronchoconstriction O
was O
not O
correlated O
with O
that O
against O
methacholine-induced O
bronchoconstriction O
( O
r O
= O
0.60 O
, O
NS O
) O
. O
['Physiological-Clinical']

The O
primary O
end O
point O
was O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality']

OBJECTIVE O
The O
authors O
evaluated O
the O
efficacy O
, O
safety O
, O
and O
tolerability B-outcome ['Life-Impact']
of O
sertraline B-outcome ['Resource-use']
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
in O
the O
treatment O
of O
generalized O
social B-outcome ['Life-Impact']
phobia I-outcome ['Life-Impact']
. O
['Life-Impact', 'Resource-use', 'Life-Impact']

Events B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
anaemia I-outcome ['Physiological-Clinical']
, O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
jaundice B-outcome ['Physiological-Clinical']
and O
weight O
loss B-outcome ['Physiological-Clinical']
were O
more O
common O
in O
the O
placebo O
arm O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Differences O
in O
straylight O
with O
the O
clear O
CL O
compared O
with O
the O
grey-green O
CL O
were O
also O
statistically O
different O
from O
zero O
( O
p O
= O
0.002 O
) O
showing O
an O
increased O
straylight B-outcome ['Physiological-Clinical']
value I-outcome ['Physiological-Clinical']
for O
the O
tinted O
CL O
. O
['Physiological-Clinical']

The O
experimental O
group O
had O
significant O
gains O
in O
knowledge B-outcome ['Life-Impact']
related I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
anatomy I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
physiology I-outcome ['Life-Impact']
, O
diet B-outcome ['Life-Impact']
, O
and O
lifestyle B-outcome ['Life-Impact']
risk O
factors O
associated O
with O
the O
development O
of O
heart B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

The O
primary O
end O
point O
was O
overall B-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality']

Over O
a O
61-month O
follow-up O
1,582 O
deaths B-outcome ['Mortality']
( O
1,397 O
cardiovascular O
) O
occurred O
. O
['Mortality']

The O
CDAI O
does O
not O
contain O
an O
acute-phase O
reactant O
component O
. O
[]

RESULTS O
The O
data O
include O
223,135 O
person-years O
of O
observation O
. O
[]

4.9 O
) O
, O
( O
18.7 O
? O
[]

Progress O
was O
measured O
by O
patient O
's O
assessment O
on O
pain O
at O
rest B-outcome ['Life-Impact']
and O
on O
movement B-outcome ['Physiological-Clinical']
and O
by O
physician O
's O
assessment O
on O
functional O
impairment O
. O
['Life-Impact', 'Physiological-Clinical']

METHODS O
Applied O
with O
open-labeled O
, O
randomized O
, O
and O
clinical O
trial O
design O
, O
136 O
postmenopausal O
women O
were O
assigned O
into O
four O
groups O
: O
group O
A O
: O
estradiol O
valerate O
( O
E2 O
V O
) O
1 O
mg/d O
+ O
medroxyprogesterone O
acetate O
( O
MPA O
) O
2 O
mg/d O
; O
group O
B O
: O
conjugated O
equine O
estrogen O
0.45 O
mg/d O
+ O
MPA O
2 O
mg/d O
; O
group O
C O
: O
tibolone O
1.25 O
mg/d O
; O
group O
D O
: O
a O
Chinese O
formulated O
herbs O
product O
( O
Kuntai O
) O
4 O
# O
tid O
. O
[]

RESULTS O
NFT O
rates O
were O
significantly O
lower O
in O
the O
CRM-training O
group O
( O
31.4?6.1 O
% O
vs. O
36.3?6.6 O
% O
, O
p=0.014 O
) O
. O
[]

The O
relationship O
between O
cortical B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
changes O
and O
clinical B-outcome ['Physiological-Clinical']
and O
cognitive B-outcome ['Life-Impact']
outcome O
was O
also O
assessed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Those O
patients O
often O
had O
signs O
of O
a O
generalized O
disease O
such O
as O
fever B-outcome ['Physiological-Clinical']
( O
84 O
% O
) O
, O
headache B-outcome ['Physiological-Clinical']
( O
72 O
% O
) O
or O
bullous O
skin O
( O
8 O
% O
) O
reactions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
determine O
the O
safety O
, O
tolerability B-outcome ['Life-Impact']
, O
and O
['Life-Impact']

AIM O
To O
validate O
the O
WOMAC O
3.0 O
using O
a O
numerical O
rating O
scale O
in O
a O
computerized O
touch O
screen O
format O
allowing O
immediate O
evaluation O
of O
the O
questionnaire O
. O
[]

The O
effect O
of O
epidural O
anesthesia O
over O
time O
was O
assessed O
by O
repeated O
measures O
analysis O
of O
variance O
. O
[]

RESULTS O
The O
total O
effective O
rate O
was O
100 O
% O
in O
the O
treated O
group O
, O
which O
was O
better O
than O
that O
in O
the O
control O
group O
90.5 O
% O
, O
( O
P O
< O
0.05 O
) O
. O
[]

During O
the O
pentoxifylline O
treatment O
period O
, O
in O
contrast O
with O
the O
control O
period O
, O
nine O
men O
were O
able O
to O
reestablish B-outcome ['Life-Impact']
coital I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
and O
three O
had O
no O
improvement O
. O
['Life-Impact']

Impact B-outcome ['Life-Impact']
of O
a O
fixed O
combination O
of O
clindamycin O
phosphate O
1.2 O
% O
-benzoyl O
peroxide O
2.5 O
% O
aqueous O
gel O
on O
health-related O
quality O
of O
life O
in O
moderate O
to O
severe O
acne O
vulgaris O
. O
['Life-Impact']

Intravenous O
copper O
, O
selenium O
, O
and O
zinc O
( O
TE O
group O
) O
or O
vehicle O
( O
V O
group O
) O
was O
given O
with O
a O
saline O
solution O
for O
14-21 O
d. O
Blood O
and O
urine O
samples O
were O
collected O
until O
day O
20 O
, O
and O
skin O
biopsy O
specimens O
were O
collected O
on O
days O
3 O
, O
10 O
, O
and O
20 O
. O
[]

Use O
of O
ketorolac O
is O
associated O
with O
decreased O
pneumonia O
following O
rib O
fractures O
. O
[]

RESULTS O
Higher O
apparent O
temperature O
was O
associated O
with O
higher O
levels O
of O
BNP B-outcome ['Physiological-Clinical']
beginning O
with O
2-day O
moving O
averages O
and O
reached O
statistical O
significance O
for O
3- O
and O
4-day O
moving O
averages O
. O
['Physiological-Clinical']

Primary O
outcome O
was O
total O
sleep B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
( O
TST O
) O
recorded O
by O
actigraphy O
over O
each O
2-week O
period O
. O
['Physiological-Clinical']

These O
results O
indicate O
that O
propofol O
and O
clonidine O
act O
additively O
for O
loss B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
consciousness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
compare O
this O
technique O
with O
a O
conventional O
procedure O
for O
acute O
thrombosed O
circumferential O
prolapsed O
haemorrhoids O
. O
[]

Patients O
in O
the O
treatment O
group O
received O
an O
intravenous O
bolus O
injection O
of O
2.5 O
mg/kg O
of O
CsA O
immediately O
before O
TLT O
. O
[]

Studies O
of O
predictive O
biomarkers O
are O
needed O
to O
subset O
appropriate O
patients O
. O
[]

We O
then O
calculated O
end-systolic B-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
stress O
( O
ESWS B-outcome ['Physiological-Clinical']
) O
, O
shortening B-outcome ['Physiological-Clinical']
fraction O
( O
SF B-outcome ['Physiological-Clinical']
) O
, O
systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
( O
SVR B-outcome ['Physiological-Clinical']
) O
, O
velocity O
for O
circumferential B-outcome ['Physiological-Clinical']
fiber I-outcome ['Physiological-Clinical']
shortening B-outcome ['Physiological-Clinical']
corrected I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
Vcfc B-outcome ['Physiological-Clinical']
) O
, O
stroke B-outcome ['Physiological-Clinical']
volume B-outcome ['Physiological-Clinical']
, O
and O
cardiac B-outcome ['Physiological-Clinical']
output B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
compare O
tooth B-outcome ['Physiological-Clinical']
whitening I-outcome ['Physiological-Clinical']
with O
6 O
% O
hydrogen O
peroxide O
whitening O
strips O
and O
two O
whitening O
dentifrices O
in O
a O
12-week O
randomized O
controlled O
trial O
at O
a O
Belgian O
dental O
school O
. O
['Physiological-Clinical']

The O
median O
duration O
of O
response O
was O
11.4 O
months O
. O
[]

Leiomyoma-related B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
comparably O
reduced O
in O
both O
groups O
. O
['Physiological-Clinical']

Plasma O
maximum O
observed O
concentration O
increased O
approximately O
dose O
proportionally O
, O
and O
the O
area O
under O
the O
plasma O
concentration-time O
profile O
from O
time O
zero O
extrapolated O
to O
infinite O
time O
( O
AUC O
( O
inf O
) O
) O
increased O
slightly O
more O
than O
dose O
proportionally O
. O
[]

RESULTS O
Of O
the O
416 O
patients O
, O
362 O
were O
included O
in O
the O
analysis O
. O
[]

There O
were O
no O
differences O
in O
favour O
of O
group O
III O
compared O
to O
group O
II O
. O
[]

UNLABELLED O
We O
estimated O
the O
cost-effectiveness O
of O
hemiarthroplasty O
compared O
to O
internal O
fixation O
for O
elderly O
patients O
with O
displaced O
femoral O
neck O
fractures O
. O
['Resource-use']

Risperidone O
was O
superior O
to O
placebo O
in O
reducing O
repetitive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
( O
P O
< O
.001 O
) O
, O
aggression B-outcome ['Life-Impact']
( O
P O
< O
.001 O
) O
, O
anxiety B-outcome ['Life-Impact']
or O
nervousness B-outcome ['Life-Impact']
( O
P O
< O
.02 O
) O
, O
depression O
( O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

2 O
. O
[]

Net O
treatment O
effects O
were O
computed O
by O
subtracting O
the O
mean O
changes O
from O
baseline O
during O
placebo O
( O
n O
= O
133 O
) O
from O
those O
during O
active O
treatment O
( O
n O
= O
111 O
) O
. O
[]

Eighty O
patients O
treated O
all O
migraine O
attacks O
for O
6 O
months O
at O
home O
with O
a O
subcutaneous O
injection O
of O
sumatriptan O
6 O
mg. O
A O
second O
injection O
could O
be O
taken O
after O
1 O
to O
24 O
hours O
if O
relief O
was O
inadequate O
, O
or O
if O
the O
headache B-outcome ['Physiological-Clinical']
recurred O
, O
and O
rescue O
medication O
could O
be O
taken O
1 O
hour O
after O
the O
second O
injection O
. O
['Physiological-Clinical']

SETTING O
Clinical O
Research O
Unit O
, O
University O
of O
Wisconsin-Madison O
. O
[]

Bronchodilator O
response O
to O
salbutamol O
after O
spontaneous O
recovery O
from O
nonspecific O
bronchial O
provocation O
tests O
in O
asthma O
. O
[]

For O
apical O
leakage O
test O
, O
teeth O
were O
covered O
with O
nail O
varnish O
and O
sticky O
wax O
to O
within O
1 O
mm O
of O
the O
apical O
foramen O
and O
placed O
in O
2 O
% O
methylene O
blue O
for O
7 O
days O
. O
[]

SETTING O
A O
large O
senior O
center O
located O
in O
a O
northeast O
Seattle O
suburb O
. O
[]

There O
may O
be O
a O
steep O
dose-response O
curve O
, O
based O
on O
the O
significant O
correlation O
between O
myelosuppression B-outcome ['Physiological-Clinical']
and O
response O
. O
['Physiological-Clinical']

The O
goal O
of O
this O
randomized O
phase O
II O
study O
is O
to O
compare O
QOL B-outcome ['Life-Impact']
, O
functional B-outcome ['Life-Impact']
outcomes O
, O
toxicity B-outcome ['Adverse-effects']
profiles O
, O
and O
survival B-outcome ['Mortality']
following O
primary O
RT O
( O
? O
['Life-Impact', 'Life-Impact', 'Adverse-effects', 'Mortality']

Spironolactone O
for O
heart O
failure O
with O
preserved O
ejection O
fraction O
. O
[]

The O
other O
two O
underwent O
a O
Nissen O
fundoplication O
. O
[]

One O
examiner O
, O
blinded O
to O
the O
treatment O
sequence O
, O
performed O
all O
clinical O
measurements O
. O
[]

OBJECTIVE O
To O
determine O
the O
feasibility O
of O
primary B-outcome ['Physiological-Clinical']
care-based I-outcome ['Physiological-Clinical']
ambulatory I-outcome ['Physiological-Clinical']
opioid I-outcome ['Physiological-Clinical']
detoxification I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AOD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
using O
two O
protocols O
: O
clonidine O
and O
clonidine O
plus O
naltrexone O
. O
['Physiological-Clinical']

Estimated O
5-year O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
52 O
% O
and O
61 O
% O
respectively O
( O
hazard O
ratio O
1:0.75 O
; O
95 O
% O
confidence O
interval O
0.57-0.99 O
; O
p O
= O
0.046 O
) O
. O
['Mortality']

The O
effect O
of O
patient O
compliance O
on O
treatment O
parameters O
. O
[]

RESULTS O
Patients O
with O
high O
serum O
magnesium O
( O
defined O
as O
> O
or O
= O
1.9 O
mEq/liter O
, O
n O
= O
242 O
) O
were O
less O
likely O
to O
survive B-outcome ['Mortality']
than O
were O
patients O
with O
a O
normal O
magnesium O
level O
( O
n O
= O
627 O
) O
( O
p O
< O
0.05 O
, O
risk O
ratio O
= O
1.41 O
) O
. O
['Mortality']

Patients O
felt O
constrained O
by O
time O
limits O
and O
consultants O
did O
not O
actively O
encourage O
guidebook O
use O
. O
[]

AIMS O
To O
assess O
if O
raising O
concentrations O
of O
crude O
protein O
( O
CP O
) O
in O
pasture O
in O
spring O
by O
the O
frequent O
application O
of O
urea O
fertiliser O
would O
affect O
ovarian B-outcome ['Physiological-Clinical']
follicular I-outcome ['Physiological-Clinical']
dynamics I-outcome ['Physiological-Clinical']
, O
luteal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
onset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oestrus I-outcome ['Physiological-Clinical']
and O
reproductive B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
of O
dairy O
cows O
under O
farming O
conditions O
in O
New O
Zealand O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
more O
renal B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
, O
leucopenia B-outcome ['Physiological-Clinical']
, O
and O
anaemia B-outcome ['Physiological-Clinical']
in O
the O
cisplatin O
group O
, O
and O
more O
thrombocytopenia B-outcome ['Physiological-Clinical']
in O
the O
carboplatin O
arm O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
hemodynamic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
hormonal I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
beta-endorphin O
in O
hypertensive O
patients O
were O
significantly O
( O
P O
< O
0.0001 O
) O
greater O
than O
in O
controls O
but O
were O
annulled O
in O
all O
individuals O
when O
naloxone O
preceded O
beta-endorphin O
infusion O
. O
['Physiological-Clinical']

In O
pre-clinical O
studies O
, O
the O
SsWC O
vaccine O
was O
immunogenic O
and O
protected O
against O
S. O
sonnei-induced O
keratoconjunctivitis O
in O
the O
guinea O
pig O
model O
. O
[]

The O
average O
drop O
in O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
attributable O
to O
ALT O
was O
6.6 O
mmHg O
. O
['Physiological-Clinical']

This O
compares O
to O
an O
age-eligible O
population O
in O
the O
combined O
catchment O
areas O
of O
the O
PLCO O
centers O
that O
was O
14.0 O
% O
black O
, O
2.9 O
% O
Hispanic O
and O
5.4 O
% O
Asian O
, O
and O
an O
age-eligible O
population O
across O
the O
U.S. O
that O
was O
9.5 O
% O
black O
, O
6.5 O
% O
Hispanic O
and O
3.0 O
% O
Asian O
. O
[]

METHODS O
We O
did O
this O
phase O
2 O
trial O
in O
outpatient O
clinics O
and O
hospitals O
. O
[]

Seven O
of O
eight O
CPAP O
machines O
were O
functional O
, O
but O
five O
of O
eight O
oxygen O
concentrators O
and O
three O
of O
four O
electric O
generators O
were O
non-functional O
. O
[]

Currently O
available O
intravenous O
( O
IV O
) O
iron O
replacement O
therapies O
have O
either O
inconvenient O
regimens O
of O
administration O
or O
adverse O
event O
profiles O
that O
limit O
their O
utility O
in O
the O
outpatient O
setting O
. O
[]

Tibial O
bone O
marrow O
aspirates O
demonstrated O
a O
significant O
increase O
in O
the O
bone B-outcome ['Physiological-Clinical']
marrow I-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
storage I-outcome ['Physiological-Clinical']
pool I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BM I-outcome ['Physiological-Clinical']
NSP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
at O
5.0 O
micrograms/kg O
twice O
per O
day O
and O
10.0 O
micrograms/kg O
once O
per O
day O
. O
['Physiological-Clinical']

We O
studied O
the O
effect O
of O
hernia O
recurrence O
and O
complications O
on O
PRO O
for O
participants O
in O
the O
Veterans O
Affairs O
trial O
of O
Open O
or O
Laparoscopic O
Repair O
of O
Inguinal O
Hernia O
. O
[]

Urethral O
catheterization O
is O
a O
skilled O
procedure O
that O
nurses O
in O
hospital O
settings O
perform O
routinely O
. O
[]

Physicians O
evaluated O
their O
practice B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
quarterly O
and O
addressed O
underperforming B-outcome ['Life-Impact']
areas I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
results O
of O
a O
multicenter O
, O
randomized O
trial O
on O
the O
effect O
of O
intravenous O
administration O
of O
gamma O
globulin O
( O
IVGG O
) O
plus O
aspirin O
versus O
aspirin O
alone O
upon O
coronary O
aneurysm O
formation O
show O
a O
decrease O
in O
coronary B-outcome ['Physiological-Clinical']
aneurysm I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
from O
the O
usual O
20 O
% O
-30 O
% O
to O
3 O
% O
. O
['Physiological-Clinical']

INTRODUCTION O
Existing O
eye-tracking O
literature O
has O
shown O
that O
both O
adults O
and O
children O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
show O
fewer O
and O
slower O
fixations O
on O
faces O
. O
[]

The O
experimental O
intervention O
consist O
of O
six O
self-management O
group O
sessions O
provided O
by O
a O
multi-disciplinary O
team O
( O
occupational O
therapist O
, O
physiotherapist O
, O
dietician O
and O
specialized O
nurse O
) O
. O
[]

FINDINGS O
23 O
patients O
died O
, O
15 O
were O
lost O
to O
follow-up O
, O
45 O
refused O
repeat O
colonoscopy O
, O
and O
five O
developed O
severe B-outcome ['Adverse-effects']
contraindications I-outcome ['Adverse-effects']
to I-outcome ['Adverse-effects']
colonoscopy I-outcome ['Adverse-effects']
. O
['Adverse-effects']

Doses O
were O
titrated O
to O
the O
optimum O
. O
[]

Long-term O
decrease O
in O
bladder B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
with O
hexaminolevulinate O
enabled O
fluorescence O
cystoscopy O
. O
['Physiological-Clinical']

Multivariable O
analysis O
evaluated O
the O
association O
between O
costs B-outcome ['Resource-use']
and O
patient O
's O
pretransplant B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
and O
transplant-related B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
. O
['Resource-use', 'Physiological-Clinical', 'Adverse-effects']

In O
each O
group O
, O
the O
transfusion O
threshold O
levels O
decreased O
with O
improving O
clinical O
status O
. O
[]

Olanzapine O
versus O
haloperidol O
in O
children O
with O
autistic B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
: O
an O
open O
pilot O
study O
. O
['Life-Impact']

RESULTS O
In O
total O
, O
313 O
patients O
were O
randomized O
to O
receive O
epoetin O
zeta O
( O
n O
= O
155 O
) O
or O
epoetin O
alfa O
( O
n O
= O
158 O
) O
; O
146 O
and O
145 O
patients O
( O
respectively O
) O
switched O
treatment O
after O
12 O
weeks O
. O
[]

Sexual B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
was O
assessed O
using O
a O
standardized O
questionnaire O
[ O
Female O
Sexual O
Function O
Index O
( O
FSFI O
) O
] O
. O
['Life-Impact']

RESULTS O
The O
mean O
AUC O
for O
MTX O
was O
increased O
( O
p O
= O
0.005 O
) O
and O
the O
maximum O
MTX O
concentration O
( O
Cmax B-outcome ['Physiological-Clinical']
) O
decreased O
( O
p O
= O
0.025 O
) O
when O
MTX O
was O
coadministered O
with O
HCQ O
, O
compared O
to O
MTX O
administered O
alone O
. O
['Physiological-Clinical']

No O
electrocardiographic O
signs O
of O
ischemia O
were O
associated O
with O
the O
increasing O
muscle O
mass O
and O
only O
one O
patient O
developed O
symptoms O
that O
might O
relate O
to O
ischemia O
. O
[]

Eighteen O
patients O
were O
selected O
for O
semistructured O
interviews O
focusing O
on O
patients O
' O
clinical O
and O
psychosocial O
experiences O
with O
CVCs O
. O
[]

The O
study O
was O
designed O
as O
a O
large O
simple O
trial O
with O
a O
large O
number O
of O
centers O
( O
302 O
) O
in O
the O
United O
States O
and O
Canada O
, O
many O
of O
which O
were O
inexperienced O
in O
research O
. O
[]

Healing O
of O
anal B-outcome ['Physiological-Clinical']
fissure I-outcome ['Physiological-Clinical']
at O
6 O
weeks O
was O
used O
as O
the O
primary O
end-point O
. O
['Physiological-Clinical']

Sixteen O
schizophrenia O
patients O
with O
predominantly O
negative O
symptoms O
on O
stable O
antipsychotic O
medication O
were O
treated O
with O
20 O
Hz O
rTMS O
( O
90 O
% O
of O
motor O
threshold O
, O
2000 O
stimuli O
per O
session O
) O
over O
ten O
days O
within O
2 O
weeks O
with O
six O
weeks O
follow-up O
. O
[]

The O
orientation O
perpendicular O
to O
the O
ventricular O
septum O
greatly O
facilitates O
the O
postoperative B-outcome ['Life-Impact']
feasibility I-outcome ['Life-Impact']
and O
accuracy O
of O
fluoroscopy B-outcome ['Resource-use']
, O
and O
it O
is O
not O
detrimental O
to O
the O
valve O
's O
['Life-Impact', 'Resource-use']

SETTING O
General O
operating O
theaters O
of O
a O
university O
hospital O
. O
[]

Impact O
of O
vitamin O
D O
supplementation O
on O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
in O
African O
Americans O
: O
results O
of O
a O
four-arm O
, O
randomized O
, O
placebo-controlled O
trial O
. O
['Physiological-Clinical']

In O
addition O
, O
the O
data O
comparing O
their O
effects O
on O
the O
quality O
of O
life O
are O
lacking O
. O
[]

In O
a O
convenience O
subset O
of O
43 O
patients O
, O
clinic O
use O
for O
Z O
and O
P O
infusions O
was O
also O
measured O
by O
timing O
infusions O
and O
other O
procedures O
. O
[]

RESULTS O
In O
the O
current O
analysis O
, O
there O
was O
no O
evidence O
of O
interaction O
, O
and O
we O
were O
able O
to O
examine O
each O
intervention O
separately O
. O
[]

We O
randomized O
465 O
patients O
, O
222 O
in O
the O
2,000-IU O
group O
and O
243 O
in O
the O
5,000-IU O
group O
. O
[]

Seventy-two-hour O
metabolic O
balance O
studies O
were O
performed O
at O
an O
average O
postconceptual O
age O
of O
34 O
weeks O
and O
an O
average O
weight O
of O
1,549 O
g. O
All O
infants O
were O
in O
positive O
zinc B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
and O
nine O
of O
ten O
achieved O
the O
in O
utero B-outcome ['Physiological-Clinical']
accretion I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
zinc I-outcome ['Physiological-Clinical']
for O
a O
34-week O
gestation O
fetus O
( O
greater O
than O
or O
equal O
to O
0.432 O
mg/d O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
monitored O
every O
4 O
weeks O
with O
comprehensive O
physical O
and O
neurologic O
examinations O
and O
electrophysiologic O
studies O
of O
peripheral O
nerve O
function O
. O
[]

The O
incidence O
of O
side O
effects O
was O
20 O
% O
in O
the O
doxorubicin O
group O
and O
21.2 O
% O
in O
the O
mitoxantrone O
group O
. O
[]

The O
trial O
was O
conducted O
in O
collaboration O
with O
primary O
care O
providers O
of O
two O
large O
managed O
care O
organizations O
. O
[]

The O
percentage O
of O
patients O
who O
quit B-outcome ['Life-Impact']
on-demand O
therapy O
in O
the O
two O
groups O
and O
the O
cost-effectiveness O
of O
the O
treatment O
were O
evaluated O
as O
primary O
end O
points O
. O
['Life-Impact', 'Resource-use']

Thirty-six O
experienced O
practitioners O
gave O
positive O
pressure O
mask O
ventilation O
targeting O
acceptable O
chest O
wall O
movement O
with O
a O
rate O
of O
60 O
inflations/min O
and O
when O
pressures O
could O
be O
targeted O
or O
set O
, O
a O
peak O
inspiratory B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PIP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of O
18 O
cm O
water O
, O
positive O
end-expiratory B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PEEP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of O
5 O
cm O
water O
, O
for O
3 O
min O
with O
each O
of O
the O
four O
mask O
ventilation O
methods O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Multiple O
risk O
factor O
intervention O
reduces O
cardiovascular O
risk O
in O
hypertensive O
patients O
with O
echolucent O
plaques O
in O
the O
carotid O
artery O
. O
[]

Mean O
failure B-outcome ['Physiological-Clinical']
loads I-outcome ['Physiological-Clinical']
( O
kN O
) O
for O
the O
A1 O
, O
A2 O
, O
B1 O
and O
B2 O
Groups O
were O
: O
1.46 O
( O
S.D O
. O
['Physiological-Clinical']

Spinal O
anaesthesia O
was O
performed O
at O
L3-4 O
or O
L4-5 O
interspace O
with O
12.5 O
mg O
0.5 O
% O
heavy O
bupivacaine O
, O
using O
a O
25 O
G O
Quincke O
needle O
. O
[]

Median O
increase O
above O
baseline O
in O
CD4 B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Prospective O
, O
randomized O
trial O
of O
diclofenac O
and O
ketorolac O
after O
refractive O
surgery O
. O
[]

Effective O
antithrombotic O
agents O
may O
prevent O
or O
limit O
thrombus B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
and O
events B-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
use O
of O
a O
response O
surface O
modeling O
analysis O
indicated O
that O
there O
was O
an O
additive O
interaction B-outcome ['Life-Impact']
between O
measured O
arterial O
propofol O
and O
clonidine O
concentrations O
in O
relation O
to O
loss B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
consciousness I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

DESIGN O
Cross-sectional O
analysis O
of O
baseline O
data O
. O
[]

iTBS O
is O
a O
novel O
type O
of O
rTMS O
that O
may O
be O
more O
efficacious O
than O
conventional O
rTMS O
. O
[]

In O
addition O
, O
similar O
patterns O
were O
found O
using O
a O
subgroup O
of O
children O
with O
high-anxiety O
symptoms O
from O
both O
studies O
. O
[]

These O
data O
support O
the O
hypothesis O
that O
cumulus O
cells O
during O
vitrification O
represent O
an O
obstacle O
to O
cryoprotectant O
penetration O
more O
than O
having O
a O
protective O
role O
for O
the O
oocyte O
. O
[]

METHODS O
In O
DaVINCI O
, O
a O
randomised O
phase O
II O
trial O
, O
patients O
with O
advanced O
colorectal O
cancer O
were O
randomly O
allocated O
to O
: O
Combination O
therapy O
( O
FOLFIRI O
) O
, O
irinotecan O
( O
180 O
mg/m O
( O
2 O
) O
IV O
over O
90 O
min O
, O
day O
1 O
) O
, O
5-fluorouracil O
( O
400mg/m O
( O
2 O
) O
IV O
bolus O
and O
2400 O
mg/m O
( O
2 O
) O
by O
46-hour O
infusion O
from O
day O
1 O
) O
and O
folinic O
acid O
( O
20mg/m O
( O
2 O
) O
IV O
bolus O
, O
day O
1 O
) O
, O
2-weekly O
; O
or O
Single-agent O
, O
irinotecan O
( O
350 O
mg/m O
( O
2 O
) O
IV O
over O
90 O
min O
) O
, O
3-weekly O
. O
[]

Patients O
treated O
initially O
with O
a O
combination O
of O
DMARDs O
have O
less O
long-term O
radiologic O
damage O
than O
do O
those O
treated O
initially O
with O
DMARD O
monotherapy O
. O
[]

The O
statistically O
significant O
improvements O
from O
baseline O
in O
efficacy O
parameters O
observed O
for O
each O
tamsulosin O
group O
at O
the O
end O
of O
the O
13-week O
Phase O
III O
trial O
were O
maintained O
during O
the O
long-term O
extension O
phase O
. O
[]

No O
significant O
complications B-outcome ['Resource-use']
were O
noticed O
regarding O
sildenafil O
use O
. O
['Resource-use']

85 O
patients O
with O
advanced O
ovarian O
carcinomas O
were O
treated O
either O
intra-arterially O
with O
MTX O
and O
5-FU O
, O
later O
systemically O
with O
the O
CMFV-combination O
( O
therapy O
arm O
A O
) O
or O
only O
systemically O
( O
therapy O
arm O
B O
) O
after O
randomization O
. O
[]

Nevertheless O
, O
no O
difference O
was O
observed O
between O
both O
slopes O
and O
intercepts O
. O
[]

The O
injured O
colon O
: O
therapeutic O
considerations O
. O
[]

A O
comparison O
of O
the O
efficacy O
of O
heparinized O
and O
nonheparinized O
solutions O
for O
maintenance O
of O
perioperative B-outcome ['Physiological-Clinical']
radial I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
catheter I-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
and O
subsequent B-outcome ['Physiological-Clinical']
occlusion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
465 O
patients O
with O
primary O
and O
multiple O
or O
recurrent O
, O
stages O
Ta O
and O
T1 O
superficial O
bladder O
cancer O
were O
included O
in O
this O
randomized O
multicenter O
trial O
to O
compare O
the O
prophylactic O
effect O
by O
17 O
times O
instillation O
of O
40 O
mg O
doxorubicin O
or O
40 O
mg O
epirubicin O
with O
no O
instillation O
after O
transurethral O
resection O
of O
tumor O
( O
s O
) O
. O
[]

SETTING O
AND O
INTERVENTIONS O
Forty-five O
women O
and O
men O
, O
aged O
50-79 O
years O
, O
were O
recruited O
. O
[]

Participants O
can O
use O
any O
background O
treatment O
for O
COPD O
except O
inhaled O
anticholinergic O
agents O
. O
[]

Onset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of O
ciclesonide O
once O
daily O
in O
the O
treatment O
of O
seasonal O
allergic O
rhinitis O
. O
['Physiological-Clinical']

Twenty-three O
WL O
participants O
completed O
randomly O
assigned O
treatment O
following O
the O
waiting O
period O
. O
[]

49 O
mL O
, O
P O
= O
.05 O
) O
. O
[]

Randomised O
controlled O
trial O
of O
patient O
triggered O
and O
conventional O
fast O
rate O
ventilation O
in O
neonatal O
respiratory O
distress O
syndrome O
. O
[]

We O
investigated O
the O
necessary O
infusion O
rate O
of O
propofol O
to O
maintain O
anesthesia O
for O
short O
surgical O
procedures O
without O
loss O
of O
the O
evident O
advantages O
of O
this O
substance O
. O
[]

Weight-adjusted O
dalteparin O
for O
prevention O
of O
vascular B-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
in O
advanced O
pancreatic O
cancer O
patients O
decreases O
serum B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
factor O
and O
serum-mediated B-outcome ['Physiological-Clinical']
induction O
of O
cancer B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
invasion B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Osteocalcin O
in O
patients O
with O
rheumatoid O
arthritis O
. O
[]

The O
cream O
was O
applied O
to O
the O
face O
twice O
daily O
for O
one O
month O
. O
[]

The O
absolute O
risk O
difference O
was O
0.3 O
% O
in O
favor O
of O
warfarin O
( O
Cl O
, O
-2.4 O
% O
to O
1.8 O
% O
) O
. O
[]

The O
copings O
were O
prepared O
to O
allow O
for O
a O
40-mum O
cement O
layer O
and O
were O
of O
different O
thicknesses O
according O
to O
system O
specifications O
. O
[]

Women O
and O
men O
found O
the O
gel O
highly O
acceptable O
. O
[]

Ten O
variables O
were O
independently O
associated O
with O
1-year O
mortality O
: O
five O
used O
in-hospital O
data O
( O
[]

Severe O
pancreatitis O
patients O
showed O
lower O
pain B-outcome ['Physiological-Clinical']
thresholds I-outcome ['Physiological-Clinical']
than O
moderate O
pancreatitis O
patients O
or O
healthy O
volunteers O
. O
['Physiological-Clinical']

Heart O
rate O
and O
blood O
pressure O
were O
monitored O
until O
3 O
h O
after O
injection O
. O
[]

Children O
were O
randomly O
assigned O
to O
an O
intervention O
( O
n O
= O
28 O
) O
or O
control O
group O
( O
n O
= O
27 O
) O
. O
[]

CONCLUSIONS O
The O
postoperative O
pattern O
of O
CEA O
clearance O
is O
a O
useful O
prognostic O
determinant O
in O
patients O
with O
rectal O
cancer O
. O
[]

TIBC B-outcome ['Physiological-Clinical']
appeared O
to O
share O
a O
u O
-shaped O
relationship O
with O
GNCC B-outcome ['Physiological-Clinical']
( O
global O
P O
= O
0.033 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
explore O
associations O
between O
histology B-outcome ['Physiological-Clinical']
and O
outcome O
in O
advanced O
or O
recurrent O
endometrial O
cancer O
patients O
participating O
in O
Gynecologic O
Oncology O
Group O
chemotherapy O
trials O
. O
['Physiological-Clinical']

Weight O
loss B-outcome ['Physiological-Clinical']
and O
increase O
in O
['Physiological-Clinical']

We O
report O
findings O
of O
a O
pilot O
RCT O
for O
a O
parent O
training O
intervention O
with O
a O
focus O
on O
the O
development O
of O
joint O
attention O
skills O
and O
joint O
action O
routines O
. O
[]

PATIENTS O
AND O
METHODS O
The O
study O
was O
a O
controlled O
clinical O
trial O
at O
two O
tertiary O
care O
centres O
of O
patients O
with O
SLE O
according O
to O
the O
ACR O
criteria O
, O
with O
incident O
( O
no O
more O
than O
15 O
days O
) O
onset O
of O
severe O
NP O
manifestations O
such O
as O
seizures O
, O
optic O
neuritis O
, O
peripheral O
or O
cranial O
neuropathy O
, O
coma O
, O
brainstem O
disease O
, O
or O
transverse O
myelitis O
. O
[]

CONCLUSIONS O
Increases O
in O
enjoyment O
partially O
mediated O
the O
positive O
effect O
of O
the O
LEAP O
intervention O
. O
[]

OBJECTIVE O
We O
examined O
the O
incidence O
of O
perioperative O
fever O
and O
its O
relationship O
to O
outcome O
among O
patients O
enrolled O
in O
the O
Intraoperative O
Hypothermia O
for O
Aneurysm O
Surgery O
Trial O
. O
[]

RESULTS O
: O
The O
proportion O
of O
children O
with O
HIV-1 O
RNA O
< O
or O
=400 O
copies/mL O
and O
on O
randomized O
treatment O
at O
48 O
weeks O
was O
65 O
% O
among O
children O
assigned O
NFV O
+ O
RTV O
+ O
ddI O
versus O
28 O
% O
among O
those O
assigned O
NFV O
+ O
NVP O
+ O
d4T O
( O
P O
= O
0.039 O
) O
. O
[]

BACKGROUND O
As O
the O
proportion O
of O
the O
population O
that O
is O
older O
continues O
to O
rise O
, O
infection O
in O
older O
people O
has O
become O
an O
important O
healthcare O
problem O
. O
[]

Of O
12,812 O
patients O
who O
had O
undergone O
sirolimus-eluting O
stent O
implantation O
in O
the O
j-Cypher O
registry O
, O
919 O
( O
7.2 O
% O
) O
had O
a O
history O
of O
CABG O
and O
had O
significantly O
higher O
crude O
5-year O
mortality B-outcome ['Mortality']
( O
19.9 O
% O
vs O
14.0 O
% O
, O
p O
< O
0.001 O
) O
. O
['Mortality']

Blood B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
response O
to O
a O
given O
dietary O
intervention O
could O
be O
determined O
by O
the O
effect O
of O
diet O
, O
gene O
variants O
or O
gene-diet O
interactions O
. O
['Physiological-Clinical']

Prevention O
of O
type O
2 O
( O
non-insulin-dependent O
) O
diabetes O
mellitus O
by O
diet O
and O
physical O
exercise O
. O
[]

However O
, O
in O
the O
desloratadine/montelukast O
arm O
, O
the O
resulting O
improvement O
of O
combination O
therapy O
of O
sICAM-1 B-outcome ['Physiological-Clinical']
and O
the O
influx B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
was O
not O
statistically O
significant O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Ninety-nine O
eligible O
patients O
with O
T2 O
to O
T4b O
transitional O
cell O
bladder O
cancer O
participated O
, O
64 O
% O
with O
cT3b O
or O
cT4 O
. O
[]

RESULTS O
There O
were O
no O
significant O
difference O
in O
ELISPOT O
positive O
ratio O
among O
the O
3 O
groups O
on O
baseline O
detection O
. O
[]

Hypertension B-outcome ['Physiological-Clinical']
following O
coronary O
artery O
bypass O
grafting O
is O
a O
common O
problem O
that O
may O
result O
in O
postoperative B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infraction I-outcome ['Physiological-Clinical']
or O
bleeding B-outcome ['Physiological-Clinical']
, O
Hemodynamic B-outcome ['Physiological-Clinical']
effects O
were O
compared O
in O
45 O
hypertensive O
coronary O
bypass O
patients O
randomized O
to O
receive O
either O
diltiazem O
, O
nitroglycerin O
, O
or O
sodium O
nitroprusside O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

For O
the O
syncope O
unit O
and O
standard O
care O
patients O
, O
the O
presumptive B-outcome ['Physiological-Clinical']
diagnosis I-outcome ['Physiological-Clinical']
was O
established O
in O
34 O
( O
67 O
% O
) O
and O
5 O
( O
10 O
% O
) O
patients O
( O
P O
< O
0.001 O
) O
, O
respectively O
, O
hospital B-outcome ['Resource-use']
admission I-outcome ['Resource-use']
was O
required O
for O
22 O
( O
43 O
% O
) O
and O
51 O
( O
98 O
% O
) O
patients O
( O
P O
< O
0.001 O
) O
, O
and O
total O
patient-hospital B-outcome ['Resource-use']
days I-outcome ['Resource-use']
were O
reduced O
from O
140 O
to O
64 O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use']

Serum B-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
, O
epinephrine B-outcome ['Physiological-Clinical']
, O
dopamine B-outcome ['Physiological-Clinical']
and O
ACTH B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
before O
and O
after O
the O
examination O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
retrospective O
cohort O
study O
was O
conducted O
spanning O
January O
2003 O
to O
June O
2011 O
assessing O
pneumonia O
within O
30 O
days O
and O
potential O
adverse O
effects O
of O
ketorolac O
among O
all O
patients O
with O
rib O
fractures O
who O
received O
ketorolac O
< O
4 O
days O
after O
injury O
compared O
with O
a O
random O
sample O
of O
those O
who O
did O
not O
. O
[]

2 O
. O
[]

Chemotherapy O
significantly O
improves O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
for O
postmenopausal O
women O
with O
endocrine-responsive O
breast O
cancer O
, O
but O
the O
magnitude O
of O
the O
effect O
is O
substantially O
attenuated O
if O
ER O
levels O
are O
high O
. O
['Mortality']

BACKGROUND O
Increased O
conduit O
vessel O
stiffness O
increases O
pulse O
pressure O
and O
pulsatile O
load O
, O
potentially O
contributing O
to O
adverse O
outcomes O
in O
patients O
with O
left O
ventricular O
dysfunction O
. O
[]

By O
day O
10 O
, O
7 O
patients O
in O
the O
tobramycin O
group O
( O
35 O
% O
) O
had O
been O
extubated B-outcome ['Resource-use']
versus O
3 O
in O
the O
placebo O
group O
( O
18.5 O
% O
, O
p O
= O
0.18 O
) O
. O
['Resource-use']

One O
hundred O
patients O
aged O
5-88 O
years O
( O
56 O
patients O
with O
a O
history O
of O
chronic O
respiratory O
complaints O
and O
44 O
patients O
without O
) O
entered O
Phase O
1 O
, O
and O
100 O
patients O
aged O
6-82 O
years O
( O
62 O
patients O
with O
a O
history O
of O
chronic O
respiratory O
complaints O
and O
38 O
patients O
without O
) O
entered O
Phase O
2 O
. O
[]

The O
posttreatment O
Hamilton O
ratings O
of O
depression B-outcome ['Life-Impact']
were O
significantly O
reduced O
in O
the O
estrogen-treated O
group O
, O
but O
not O
in O
the O
placebo O
group O
. O
['Life-Impact']

We O
conclude O
that O
although O
interferon O
provides O
excellent O
palliation B-outcome ['Life-Impact']
, O
that O
most O
patients O
will O
eventually O
require O
further O
treatment O
with O
interferon B-outcome ['Physiological-Clinical']
or O
chemotherapy B-outcome ['Resource-use']
. O
['Life-Impact', 'Physiological-Clinical', 'Resource-use']

The O
difference O
was O
statistically O
significant O
( O
P O
= O
0.004 O
) O
. O
[]

Optimal B-outcome ['Physiological-Clinical']
cosmetic I-outcome ['Physiological-Clinical']
result I-outcome ['Physiological-Clinical']
was O
achieved O
with O
a O
smaller O
volume O
of O
Perlane O
than O
Zyplast O
( O
mean O
, O
1.2 O
ml O
versus O
2.1 O
ml O
) O
. O
['Physiological-Clinical']

The O
recovery O
rates O
of O
children O
with O
acute O
diarrhoea O
receiving O
GB O
( O
vs. O
control O
) O
were O
significantly O
more O
by O
day O
3 O
: O
79.9 O
% O
vs O
. O
[]

Is O
the O
effect O
of O
mobile O
phone O
radiofrequency O
waves O
on O
human O
skin O
perfusion O
non-thermal O
? O
[]

Irrigation O
with O
bupivacaine O
at O
the O
surgical O
bed O
for O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
after O
laparoscopic O
cholecystectomy O
. O
['Physiological-Clinical']

The O
type O
of O
second-line O
chemotherapy O
after O
initial O
adjuvant O
or O
neoadjuvant O
treatment O
with O
a O
platinum-based O
regimen O
remains O
largely O
undefined O
. O
[]

Two O
patients O
( O
one O
in O
each O
group O
) O
withdrew O
consent O
immediately O
after O
randomisation O
without O
any O
follow-up O
data O
and O
one O
patient O
( O
ablation O
group O
) O
was O
excluded O
because O
of O
a O
protocol O
violaton O
. O
[]

Cellular B-outcome ['Physiological-Clinical']
infiltration I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
molecule I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
were O
evaluated O
after O
immunohistochemical O
staining O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
effect O
of O
intravenous O
lidocaine O
on O
the O
ECG B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
induced O
by O
laryngoscopy O
and O
tracheal O
intubation O
. O
['Physiological-Clinical']

Of O
44 O
patients O
in O
the O
CRT O
group O
, O
12 O
( O
28 O
% O
) O
had O
had O
bowel O
obstruction O
compared O
with O
5 O
of O
33 O
( O
15 O
% O
) O
in O
the O
RT O
group O
( O
p O
= O
0.27 O
) O
. O
[]

They O
were O
then O
placed O
in O
the O
45-degree O
upright O
position O
, O
and O
after O
an O
additional O
5 O
minutes O
had O
cardiac O
output O
measurements O
performed O
. O
[]

Mean O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
comparable O
between O
the O
groups O
. O
['Physiological-Clinical']

CONCLUSIONS O
Although O
the O
patients O
in O
the O
levosimendan O
group O
were O
alive O
for O
more O
days O
and O
thus O
at O
risk O
of O
hospitalisation B-outcome ['Resource-use']
for O
longer O
, O
there O
was O
no O
increase O
in O
hospitalisation B-outcome ['Resource-use']
or O
hospitalisation B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
with O
levosimendan O
treatment O
. O
['Resource-use', 'Resource-use', 'Resource-use']

Both O
groups O
then O
engaged O
in O
a O
post-test O
roleplay O
similar O
to O
the O
pretest O
. O
[]

2-LTR O
circles O
were O
analyzed O
by O
droplet O
digital O
polymerase O
chain O
reaction O
at O
weeks O
0 O
, O
1 O
, O
2 O
, O
and O
8 O
. O
[]

Concluding O
that O
concomitant O
AS O
in O
AF O
is O
not O
cost-effective O
after O
a O
one-year O
follow-up O
compared O
to O
regular O
cardiac O
surgery O
. O
[]

Propranolol O
, O
a O
nonspecific O
beta-blocker O
has O
many O
physiologic O
effects O
. O
[]

METHODS O
AND O
RESULTS O
Sixty O
patients O
with O
stable O
coronary O
artery O
disease O
, O
a O
positive O
treadmill O
exercise O
test O
and O
asymptomatic O
ST O
segment O
depression O
on O
ambulatory O
electrocardiographic O
recording O
were O
assessed O
in O
a O
multicenter O
, O
double-blind O
, O
placebo-controlled O
, O
cross-over O
trial O
. O
[]

In O
Phase O
1 O
, O
the O
patients O
were O
randomly O
allocated O
to O
receive O
either O
CMZ O
( O
600 O
mg/d O
) O
or O
placebo O
during O
an O
SCS-free O
period O
of O
8 O
days O
. O
[]

Sexual B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
, O
SF-36 O
scores O
and O
symptoms O
were O
serially O
assessed O
by O
repeated-measures O
analyses O
of O
covariance O
. O
['Physiological-Clinical']

There O
was O
, O
however O
, O
a O
significantly O
greater O
reduction O
in O
anaerobic O
bacteria O
in O
the O
feces O
and O
colon O
contents O
of O
patients O
receiving O
metronidazole O
. O
[]

OBJECTIVE O
To O
study O
the O
effect O
of O
the O
addition O
of O
a O
single O
dose O
of O
oral O
montelukast O
to O
standard O
therapy O
in O
acute O
moderate O
to O
severe O
asthma O
. O
[]

Although O
there O
was O
a O
trend O
for O
more O
dropouts B-outcome ['Life-Impact']
by O
subjects O
taking O
desipramine O
, O
there O
were O
no O
significant O
differences O
among O
treatment O
groups O
regarding O
retention B-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
, O
craving B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
cocaine I-outcome ['Life-Impact']
, O
and O
decreased O
cocaine B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
confirmed O
by O
urine B-outcome ['Physiological-Clinical']
toxicology I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Once O
versus O
thrice O
daily O
gentamicin O
in O
patients O
with O
serious O
infections O
. O
[]

25 O
pairs O
were O
randomly O
selected O
. O
[]

The O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
the O
granisetron O
groups O
were O
similar O
to O
those O
in O
the O
control O
group O
. O
['Adverse-effects']

The O
present O
study O
was O
undertaken O
to O
evaluate O
the O
efficacy O
, O
safety O
, O
and O
patient B-outcome ['Life-Impact']
tolerability I-outcome ['Life-Impact']
of O
two O
antibiotic O
regimens O
for O
the O
treatment O
of O
brucellosis B-outcome ['Physiological-Clinical']
: O
rifampicin O
600 O
mg/day O
and O
doxycycline O
200 O
mg/day O
for O
45 O
days O
( O
group O
1 O
) O
, O
versus O
rifampicin O
600 O
mg/day O
and O
ciprofloxacin O
1 O
g/day O
for O
30 O
days O
( O
group O
2 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Metabolic O
responses O
to O
oral O
surgery O
under O
local O
anesthesia O
and O
sedation O
with O
intravenous O
midazolam O
: O
the O
effects O
of O
two O
different O
local O
anesthetics O
. O
[]

Clinical O
efficacy O
of O
fluvoxamine O
and O
functional O
polymorphism O
in O
a O
serotonin O
transporter O
gene O
on O
childhood O
autism O
. O
[]

In O
the O
future O
, O
surgical O
devices O
may O
have O
to O
prove O
superiority O
in O
randomised O
trials O
or O
be O
monitored O
in O
quality O
registers O
before O
they O
can O
be O
introduced O
into O
day O
to O
day O
surgical O
practice O
. O
[]

Moclobemide O
was O
better O
tolerated B-outcome ['Life-Impact']
than O
imipramine O
, O
and O
was O
almost O
comparable O
to O
placebo O
in O
this O
respect O
. O
['Life-Impact']

RESULTS O
Controlling O
for O
baseline O
age O
, O
developmental O
quotient O
( O
DQ O
) O
and O
language O
; O
rates O
of O
initiations O
and O
PECS O
usage O
increased O
significantly O
immediately O
post-treatment O
( O
Odds O
Ratio O
( O
OR O
) O
of O
being O
in O
a O
higher O
ordinal O
rate O
category O
2.72 O
, O
95 O
% O
confidence O
interval O
1.22-6.09 O
, O
p O
< O
.05 O
and O
OR O
3.90 O
( O
95 O
% O
CI O
1.75-8.68 O
) O
, O
p O
< O
.001 O
, O
respectively O
) O
. O
[]

BACKGROUND O
The O
safety O
and O
efficacy O
of O
paricalcitol O
injection O
have O
been O
well O
established O
for O
the O
prevention O
and O
treatment O
of O
secondary B-outcome ['Physiological-Clinical']
hyperparathyroidism I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SHPT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
patients O
with O
chronic O
kidney O
disease O
( O
CKD O
) O
stage O
5 O
. O
['Physiological-Clinical']

On O
the O
basis O
of O
this O
first O
study O
of O
women O
with O
untreated O
silicone O
breast O
implant O
rupture O
, O
the O
authors O
conclude O
that O
implant O
rupture O
is O
a O
relatively O
harmless O
condition O
, O
which O
only O
rarely O
progresses O
and O
gives O
rise O
to O
notable O
symptoms O
. O
[]

Parents O
from O
autism O
assessment O
services O
in O
the O
intervention O
regions O
were O
randomly O
allocated O
to O
parent O
education O
and O
behaviour O
management O
( O
n O
= O
35 O
) O
or O
parent O
education O
and O
counselling O
( O
n O
= O
35 O
) O
. O
[]

RESULTS O
Eighty O
patients O
were O
enrolled O
in O
the O
study O
. O
[]

Assessment O
of O
therapeutic B-outcome ['Physiological-Clinical']
response O
of O
Plasmodium O
falciparum O
to O
chloroquine O
and O
sulfadoxine-pyrimethamine O
in O
an O
area O
of O
low O
malaria O
transmission O
in O
Colombia O
. O
['Physiological-Clinical']

The O
cost O
per O
study O
of O
home O
study O
recordings O
was O
less O
expensive O
than O
that O
of O
polysomnography O
( O
143.86 O
euros O
) O
, O
either O
with O
( O
93.08 O
euros O
) O
or O
without O
( O
129.97 O
euros O
) O
intervention O
of O
the O
technician O
in O
the O
patient O
's O
home O
. O
[]

These O
findings O
suggest O
that O
men O
with O
greater O
[]

Evaluation O
of O
the O
effect O
of O
low O
level O
laser O
on O
prevention O
of O
chemotherapy-induced B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
was O
linked O
to O
increased O
left O
amygdala B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
in O
response O
to O
facial O
stimuli O
and O
increased O
['Physiological-Clinical']

One O
hundred O
twenty O
patients O
( O
54 O
men O
, O
66 O
women O
; O
mean O
age O
, O
64.1 O
years O
; O
range O
, O
19-88 O
years O
) O
who O
underwent O
multidetector O
CT O
of O
the O
upper O
abdomen O
were O
randomized O
into O
three O
groups O
of O
40 O
patients O
each O
: O
( O
a O
) O
TBW O
group O
( O
0.6 O
g O
of O
iodine O
per O
kilogram O
of O
TBW O
) O
, O
( O
b O
) O
LBW O
group O
( O
0.821 O
g O
of O
iodine O
per O
kilogram O
of O
LBW O
) O
, O
and O
( O
c O
) O
BV O
group O
( O
men O
, O
8.6 O
g O
of O
iodine O
per O
liter O
of O
BV O
; O
women O
, O
9.9 O
g O
of O
iodine O
per O
liter O
of O
BV O
) O
. O
[]

Similarly O
, O
post-operative O
increments O
in O
urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ammonia I-outcome ['Physiological-Clinical']
, O
creatinine B-outcome ['Physiological-Clinical']
and O
3-methylhistidine B-outcome ['Physiological-Clinical']
were O
not O
altered O
by O
addition O
of O
insulin O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Ginger O
also O
seemed O
to O
be O
tolerable B-outcome ['Life-Impact']
and O
safe O
. O
['Life-Impact']

Fifty-three O
rural O
breast O
cancer O
survivors O
were O
randomized O
to O
either O
an O
experimental O
( O
n O
= O
27 O
) O
or O
a O
wait-control O
arm O
( O
n O
= O
26 O
) O
. O
[]

CONCLUSIONS O
All O
patients O
in O
both O
groups O
had O
an O
increasing O
tendency O
to O
free O
radical O
production O
during O
early O
reperfusion O
. O
[]

Eighteen O
diabetic O
patients O
with O
foot B-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
were O
recruited O
through O
simple O
nonprobability O
sampling O
. O
['Physiological-Clinical']

A O
neuropsychological O
battery O
including O
the O
Digit O
Span O
subtest O
from O
the O
Wechsler O
Adult O
Intelligence O
Scale-III O
( O
WAIS-III O
) O
, O
the O
verbal O
fluency O
test O
, O
the O
Hopkins O
Verbal O
Learning O
Test O
( O
HVLT O
) O
, O
the O
Trail-Making O
Test O
( O
TMT O
) O
and O
the O
Wisconsin O
Card O
Sorting O
Test O
( O
WCST O
) O
was O
administered O
at O
baseline O
and O
week O
eight O
. O
[]

AIM O
To O
assess O
the O
effectiveness O
of O
expressed O
breast O
milk O
( O
EBM O
) O
in O
reducing O
pain B-outcome ['Physiological-Clinical']
due O
to O
venepuncture O
, O
in O
term O
neonates O
, O
as O
measured O
by O
behavioural O
and O
physiological O
observations O
. O
['Physiological-Clinical']

Sixty O
roots O
of O
maxillary O
central O
incisors O
were O
cleansed O
and O
shaped O
and O
randomly O
assigned O
to O
one O
of O
six O
groups O
of O
ten O
roots O
each O
. O
[]

METHODS O
In O
this O
8-week O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
, O
risperidone/placebo O
solution O
( O
0.01-0.06 O
mg/kg/day O
) O
was O
administered O
to O
79 O
children O
who O
were O
aged O
5 O
to O
12 O
years O
and O
had O
PDD O
. O
[]

We O
conclude O
that O
periarticularly O
administered O
morphine O
in O
arthroscopic O
subacromial O
decompression O
in O
the O
dosage O
applied O
in O
this O
study O
does O
exert O
no O
relevant O
analgesic B-outcome ['Resource-use']
effect O
. O
['Resource-use']

Impact O
of O
prior O
pharmacotherapy O
on O
remission O
of O
psychotic B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
in O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

RESULTS O
The O
59 O
knees O
had O
a O
mean O
TT-TG B-outcome ['Physiological-Clinical']
distance B-outcome ['Physiological-Clinical']
of O
16.9 O
mm O
( O
range O
, O
8.3-25.8 O
mm O
) O
by O
CT O
and O
14.7 O
mm O
( O
range O
, O
1.5-25.1 O
mm O
) O
by O
MRI O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Duration O
on O
treadmill O
and O
right O
ventricular O
ejection O
fraction O
post O
exercise O
increased O
, O
while O
diastolic O
and O
systolic O
artery O
pressure O
decreased O
significantly O
in O
both O
groups O
. O
[]

Single O
dose O
of O
intraoperative O
amiodarone O
may O
be O
used O
to O
decrease O
postoperative O
arrhythmia O
in O
open O
heart O
surgery O
. O
[]

During O
phase O
1 O
, O
egg B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
decreased O
linearly O
( O
P O
< O
0.05 O
) O
and O
feed B-outcome ['Life-Impact']
conversion I-outcome ['Life-Impact']
ratio O
( O
FCR O
) O
tended O
to O
increase O
linearly O
( O
P O
= O
0.057 O
) O
with O
increasing O
choline O
level O
in O
the O
diet O
. O
['Physiological-Clinical', 'Life-Impact']

Based O
on O
these O
findings O
, O
a O
prospective O
multicenter O
, O
double-blind O
, O
placebo-controlled O
trial O
was O
planned O
to O
assess O
whether O
oral O
S-adenosylmethionine O
is O
effective O
in O
cholestatic B-outcome ['Physiological-Clinical']
patients O
with O
chronic O
liver O
disease O
. O
['Physiological-Clinical']

Secondary O
outcomes O
were O
health B-outcome ['Physiological-Clinical']
utility I-outcome ['Physiological-Clinical']
and O
perceived B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
both O
measured O
with O
the O
EuroQol O
instrument O
, O
mental O
health O
measured O
with O
the O
Hospital O
Anxiety B-outcome ['Life-Impact']
and O
Depression B-outcome ['Life-Impact']
scale O
, O
disability B-outcome ['Life-Impact']
with O
the O
modified O
Health O
Assessment O
Questionnaire O
and O
economic O
costs O
measured O
from O
a O
societal O
perspective O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Plasma O
or O
serum O
samples O
were O
assayed O
for O
concentrations O
of O
cortisol O
, O
growth O
hormone O
, O
luteinising O
hormone O
, O
follicle O
stimulating O
hormone O
, O
prolactin O
, O
and O
thyroid O
stimulating O
hormone O
at O
multiple O
times O
for O
120 O
minutes O
. O
[]

Baseline O
demographic O
and O
donor O
characteristics O
were O
similar O
between O
groups O
. O
[]

Change O
from O
baseline O
in O
the O
levels O
of O
high-sensitivity B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
, O
CD40 B-outcome ['Physiological-Clinical']
ligand I-outcome ['Physiological-Clinical']
, O
P-selectin B-outcome ['Physiological-Clinical']
, O
and O
N-terminal B-outcome ['Physiological-Clinical']
pro-brain I-outcome ['Physiological-Clinical']
natriuretic I-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
at O
6 O
weeks O
was O
assessed O
to O
evaluate O
each O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Eighty O
healthy O
women O
beginning O
active O
labor O
( O
cervical O
dilation O
4 O
cm O
) O
at O
term O
were O
assigned O
to O
receive O
fentanyl O
intravenously O
by O
either O
patient-controlled O
administration O
( O
n=37 O
) O
or O
nurse O
administration O
on O
demand O
( O
n=43 O
) O
. O
[]

At O
the O
end O
of O
the O
study O
, O
the O
systolic/diastolic B-outcome ['Physiological-Clinical']
differences I-outcome ['Physiological-Clinical']
between I-outcome ['Physiological-Clinical']
ambulatory I-outcome ['Physiological-Clinical']
( O
n O
= O
46 O
) O
and O
home O
( O
n O
= O
52 O
) O
BP B-outcome ['Physiological-Clinical']
groups O
in O
home B-outcome ['Life-Impact']
, O
daytime B-outcome ['Physiological-Clinical']
ambulatory I-outcome ['Physiological-Clinical']
, O
night-time B-outcome ['Physiological-Clinical']
ambulatory I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Pharmacodynamic O
effects O
on O
biochemical B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
and O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
the O
cathepsin O
K O
inhibitor O
, O
ONO-5334 O
, O
in O
an O
ascending O
multiple-dose O
, O
phase O
1 O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
patients O
, O
114 O
adult O
subjects O
with O
chronic O
plantar O
fasciitis O
, O
recalcitrant O
to O
conservative O
therapies O
for O
at O
least O
6 O
months O
, O
were O
randomized O
to O
two O
groups O
. O
[]

By O
actuarial O
analysis O
, O
the O
median O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
granulocytopenia I-outcome ['Physiological-Clinical']
, O
less O
than O
1000/cu O
mm O
, O
was O
16.0 O
days O
in O
the O
lithium O
group O
and O
24.6 O
days O
in O
the O
no-lithium O
group O
, O
p O
= O
0.013 O
. O
['Physiological-Clinical']

Early O
gastric O
cancer O
or O
cardia O
carcinoma O
were O
excluded O
. O
[]

OBJECTIVE O
To O
observe O
clinical O
therapeutic B-outcome ['Physiological-Clinical']
effect O
of O
acupuncture O
combined O
with O
Yizhi O
Jiannao O
Granules O
for O
treatment O
of O
Alzheimer O
's O
disease O
and O
its O
effects O
on O
intelligence B-outcome ['Life-Impact']
, O
daily B-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
gases I-outcome ['Physiological-Clinical']
, O
spirometric B-outcome ['Physiological-Clinical']
tests O
, O
bacteriologic B-outcome ['Physiological-Clinical']
evaluation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sputum I-outcome ['Physiological-Clinical']
, O
and O
patient O
and O
physician O
evaluation O
of O
the O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
were O
assessed O
at O
the O
beginning O
and O
end O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Procedure B-outcome ['Life-Impact']
and O
fluoroscopy B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
were O
shorter O
in O
group O
B O
( O
108 O
? O
['Life-Impact']

SSA O
patients O
had O
a O
significantly O
shorter O
time O
to O
straight O
leg O
raising O
( O
3 O
+/- O
1 O
min O
versus O
9 O
+/- O
4 O
min O
; O
P O
< O
0.0001 O
) O
and O
to O
ambulation B-outcome ['Life-Impact']
( O
3 O
+/- O
0.9 O
min O
versus O
59 O
+/- O
16 O
min O
; O
P O
< O
0.0001 O
) O
compared O
with O
the O
DES O
group O
. O
['Life-Impact']

Data O
were O
collected O
at O
admission O
and O
at O
discharge O
, O
and O
then O
at O
3 O
and O
9 O
months O
after O
discharge O
. O
[]

Survival B-outcome ['Mortality']
and O
toxicity B-outcome ['Adverse-effects']
were O
similar O
in O
the O
two O
maintenance-treatment O
groups O
. O
['Mortality', 'Adverse-effects']

The O
estimated O
treatment O
difference O
for O
duration O
of O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
was O
-4 O
( O
90 O
% O
CI O
-13 O
, O
6 O
) O
min O
. O
['Physiological-Clinical']

Mending O
the O
rhythm O
does O
not O
improve O
prognosis O
in O
patients O
with O
persistent O
atrial O
fibrillation O
: O
a O
subanalysis O
of O
the O
RACE O
study O
. O
[]

The O
most O
common O
adverse O
events O
in O
double-blind O
, O
placebo-controlled O
studies O
of O
TPM O
in O
migraine O
prevention O
are O
paresthesia B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
anorexia B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
taste B-outcome ['Physiological-Clinical']
alteration I-outcome ['Physiological-Clinical']
, O
and O
diarrhea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PoCT O
device O
operators O
were O
provided O
with O
a O
colour-coded O
QC O
Result O
Sheet O
and O
QC O
Action O
Sheet O
for O
on-site O
recording O
and O
interpreting O
of O
their O
results O
. O
[]

METHODS O
One O
hundred O
forty O
patients O
received O
either O
a O
once O
daily O
220-microgram O
dose O
of O
triamcinolone O
acetonide O
aqueous O
nasal O
spray O
or O
placebo O
for O
2 O
weeks O
. O
[]

The O
influence O
of O
pre- O
and O
intraoperative O
positioning O
of O
the O
condyle O
in O
the O
centre O
of O
the O
articular O
fossa O
on O
the O
position O
of O
the O
disc O
in O
orthognathic O
surgery O
. O
[]

Training O
sessions O
in O
outcome O
assessment O
were O
held O
, O
and O
problems O
in O
assigning O
outcome O
were O
investigated O
. O
[]

For O
geometric O
mean O
titers O
( O
GMT O
) O
, O
antibody B-outcome ['Physiological-Clinical']
titers I-outcome ['Physiological-Clinical']
below O
the O
cutoff O
of O
the O
assay O
were O
given O
, O
arbitrarily O
, O
0.05 O
IU/mL O
. O
['Physiological-Clinical']

RESULTS O
No O
significant O
changes O
occurred O
in O
the O
hemodynamics O
during O
the O
preoperative O
periods O
. O
[]

A O
hybrid O
intervention O
of O
MT O
combined O
with O
MG O
( O
MT O
+ O
MG O
) O
may O
broaden O
aspects O
of O
treatment O
benefits O
. O
[]

METHODS O
One O
hundred O
and O
forty O
four O
patients O
with O
moderate O
or O
severe O
COPD O
were O
randomly O
assigned O
to O
receive O
three O
months O
of O
treatment O
with O
either O
salmeterol O
, O
salmeterol O
+ O
ipratropium O
bromide O
, O
or O
placebo O
. O
[]

However O
, O
25 O
of O
48 O
control O
patients O
have O
had O
a O
first B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
in O
the O
pelvis O
, O
compared O
with O
15 O
of O
51 O
cisplatin-treated O
patients O
( O
P O
= O
.036 O
) O
. O
['Physiological-Clinical']

There O
were O
no O
clinical O
characteristics O
that O
differentiated O
patients O
with O
and O
without O
an O
increase O
in O
the O
DFT B-outcome ['Resource-use']
. O
['Resource-use']

Effects O
of O
amlodipine O
and O
enalapril O
on O
platelet B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
mild O
to O
moderate O
hypertension O
. O
['Physiological-Clinical']

Thus O
, O
these O
pilot O
data O
emphasize O
the O
need O
for O
further O
research O
and O
implementation O
of O
classroom-based O
interventions O
targeting O
[]

Comparison O
of O
amantadine O
and O
desipramine O
combined O
with O
psychotherapy O
for O
treatment O
of O
cocaine O
dependence O
. O
[]

In O
conclusion O
, O
the O
parallel-group O
analysis O
proposed O
makes O
it O
possible O
for O
one O
to O
correct O
the O
trough-to-peak O
ratio O
for O
baseline O
as O
well O
as O
placebo O
, O
to O
account O
for O
interindividual O
variability O
, O
and O
to O
calculate O
a O
confidence O
interval O
for O
the O
net O
trough-to-peak O
ratio O
. O
[]

Cycles O
were O
repeated O
every O
3 O
weeks O
for O
four O
cycles O
. O
[]

Here O
, O
individuals O
with O
AS O
over-detected O
faux B-outcome ['Life-Impact']
pas I-outcome ['Life-Impact']
stories I-outcome ['Life-Impact']
, O
failed O
to O
provide O
correct B-outcome ['Life-Impact']
justifications I-outcome ['Life-Impact']
of O
the O
speaker O
's O
behavior B-outcome ['Life-Impact']
and O
were O
unaware O
of O
the O
mistaken B-outcome ['Life-Impact']
belief I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
resulting I-outcome ['Life-Impact']
emotional I-outcome ['Life-Impact']
impact I-outcome ['Life-Impact']
, O
whereas O
they O
appeared O
to O
be O
responsive O
to O
social O
rule O
violations O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
objective O
of O
this O
open-label O
, O
multiple-dose O
, O
controlled O
study O
was O
to O
examine O
the O
safety O
and O
efficacy O
of O
argatroban O
in O
patients O
undergoing O
elective O
PCI O
. O
[]

In O
the O
IFN-treated O
group O
, O
one O
animal O
died B-outcome ['Mortality']
on O
day O
2 O
after O
the O
treatment O
was O
started O
, O
whereas O
the O
other O
four O
dogs O
survived B-outcome ['Mortality']
the O
challenge O
and O
gradually O
recovered B-outcome ['Physiological-Clinical']
. O
['Mortality', 'Mortality', 'Physiological-Clinical']

In O
older O
children O
, O
the O
intervention O
was O
independently O
associated O
with O
reduction O
in O
situational B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
but O
not O
in O
pain B-outcome ['Physiological-Clinical']
intensity O
or O
in O
parental B-outcome ['Life-Impact']
perception I-outcome ['Life-Impact']
of O
pain O
distress O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Prospective O
study O
of O
short O
and O
ultrashort O
regimens O
of O
gonadotropin-releasing O
hormone O
agonist O
in O
an O
in O
vitro O
fertilization O
program O
. O
[]

We O
conducted O
a O
randomized O
unblinded O
parallel O
clinical O
trial O
to O
compare O
the O
effectiveness O
, O
side O
effects O
and O
tolerance O
between O
calcium O
acetate O
( O
CA O
) O
and O
calcium O
carbonate O
( O
CC O
) O
in O
80 O
stable O
chronic O
hemodialysis O
patients O
selected O
on O
the O
basis O
of O
their O
acceptable O
control O
of O
serum O
phosphorus O
( O
P O
) O
levels O
with O
aluminum O
hydroxide O
( O
AH O
) O
. O
[]

A O
total O
of O
34 O
patients O
undergoing O
assisted O
reproduction O
was O
divided O
in O
two O
groups O
according O
to O
different O
ovarian O
stimulation O
protocols O
: O
( O
i O
) O
flare-up O
gonadotrophin-releasing O
hormone O
analogue O
( O
GnRHa O
) O
plus O
elevated O
pure O
follicle O
stimulating O
hormone O
( O
pFSH O
) O
( O
n O
= O
17 O
) O
; O
and O
( O
ii O
) O
flare-up O
GnRHa O
plus O
elevated O
pFSH O
plus O
oral O
L-arginine O
( O
n O
= O
17 O
) O
. O
[]

This O
necessitates O
increased O
focus O
on O
the O
pregnancy O
and O
early O
post-natal O
periods O
, O
developing O
and O
scaling O
up O
appropriate O
models O
of O
community-based O
care O
, O
especially O
to O
reach O
the O
peri-urban O
poor O
. O
[]

METHOD O
The O
two O
interventions O
were O
crossed O
in O
a O
2 O
? O
[]

[ O
Prevention O
of O
vascular B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
following O
cerebral O
ischemia O
of O
arterial O
origin O
; O
the O
ESPRIT O
trial O
: O
mild O
anticoagulant O
therapy O
, O
combination O
treatment O
with O
acetylsalicylic O
acid O
plus O
dipyridamole O
or O
treatment O
with O
acetylsalicylic O
acid O
alone O
? O
] O
. O
['Physiological-Clinical']

Relief B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
appeared O
somewhat O
faster O
with O
ranitidine O
, O
but O
was O
more O
pronounced O
with O
lansoprazole O
. O
['Physiological-Clinical']

To O
conclude O
, O
dietary O
lignan O
and O
proanthocyanidin O
consumption O
were O
not O
generally O
related O
to O
colorectal B-outcome ['Physiological-Clinical']
adenoma I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
; O
however O
, O
high O
lignan O
intake O
may O
increase O
the O
risk O
of O
adenoma B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
in O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
proportion O
of O
mothers O
who O
exclusively O
breastfeed O
their O
babies O
up O
to O
6 O
months O
remains O
low O
. O
[]

BACKGROUND O
Cediranib O
( O
RECENTIN? O
) O
is O
an O
oral O
, O
highly O
potent O
VEGF O
inhibitor O
. O
[]

Coded O
behavior O
did O
not O
predict O
outcome O
. O
[]

Locoregional B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
overall O
survival O
were O
the O
main O
clinical O
endpoints O
. O
['Physiological-Clinical']

In O
addition O
, O
there O
was O
an O
inverse O
association O
between O
the O
grade O
of O
esthesioneuroblastomas B-outcome ['Physiological-Clinical']
and O
hASH1 O
mRNA O
levels O
. O
['Physiological-Clinical']

Midazolam O
was O
significantly O
more O
effective O
than O
diazepam O
in O
those O
portions O
of O
the O
procedure O
with O
increased O
stimulation O
. O
[]

Clinical O
evaluation O
of O
two O
adhesive O
composite O
cements O
for O
the O
suppression O
of O
dentinal B-outcome ['Physiological-Clinical']
cold I-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
The O
frequency O
of O
postoperative B-outcome ['Physiological-Clinical']
adhesions I-outcome ['Physiological-Clinical']
of O
the O
uterus B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
( O
p O
< O
0.05 O
) O
in O
the O
fibrin O
gel O
group O
, O
with O
20/32 O
( O
62.5 O
% O
) O
in O
the O
control O
group O
, O
10/29 O
( O
34.5 O
% O
) O
in O
the O
fibrin O
gel O
group O
and O
20/30 O
( O
67.7 O
% O
) O
in O
the O
fibrin O
sheet O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Therefore O
, O
we O
started O
the O
randomized O
EORTC/LYSA/FIL O
Intergroup O
H10 O
trial O
evaluating O
whether O
involved-node O
radiotherapy O
( O
IN-RT O
) O
could O
be O
omitted O
without O
compromising O
progression-free O
survival O
in O
patients O
attaining O
a O
negative O
early O
PET O
scan O
after O
two O
cycles O
of O
ABVD O
( O
doxorubicin O
, O
bleomycin O
, O
vinblastine O
, O
and O
dacarbazine O
) O
as O
compared O
with O
standard O
combined-modality O
treatment O
. O
[]

The O
patients O
were O
randomly O
assigned O
to O
take O
either O
fluconazole O
or O
placebo O
as O
maintenance O
therapy O
. O
[]

The O
purpose O
of O
the O
study O
was O
to O
explore O
a O
low-cost O
intervention O
that O
targets O
an O
increasingly O
common O
developmental O
disorder O
. O
[]

RESULTS O
The O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
taken O
at O
0 O
, O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
5 O
, O
6 O
, O
7 O
, O
8 O
, O
9 O
, O
10 O
, O
15 O
, O
20 O
, O
25 O
, O
and O
30 O
min O
after O
the O
injection O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
statistical O
difference O
according O
to O
clinical O
stage O
, O
age O
( O
greater O
than O
15 O
or O
less O
than O
15 O
years O
) O
, O
sex O
, O
or O
number O
of O
cycles O
of O
chemotherapy B-outcome ['Resource-use']
( O
six O
or O
three O
) O
. O
['Resource-use']

After O
3-6 O
months O
some O
patients O
were O
examined O
by O
means O
of O
diagnostic B-outcome ['Life-Impact']
whole I-outcome ['Life-Impact']
body I-outcome ['Life-Impact']
scintigraphy I-outcome ['Life-Impact']
after O
application O
of O
300 O
MBq O
131I O
. O
['Life-Impact']

OBJECTIVE O
To O
compare O
the O
antipyretic O
efficacy O
of O
ibuprofen O
, O
placebo O
, O
and O
acetaminophen O
. O
['Physiological-Clinical', 'Resource-use']

At O
3 O
months O
, O
109 O
bone-marrow O
samples O
were O
available O
for O
analysis O
. O
[]

CONCLUSION O
Our O
results O
indicated O
that O
the O
weighted O
vests O
were O
not O
effective O
in O
increasing O
time B-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
task I-outcome ['Life-Impact']
. O
['Life-Impact']

Experimentally O
induced O
pain O
can O
be O
attenuated O
by O
concomitant O
heterotopic O
nociceptive O
stimuli O
( O
counterirritation O
) O
. O
[]

In O
addition O
, O
in O
serum B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
asthmatic I-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
significant O
differences O
were O
shown O
between O
the O
treatment O
groups O
. O
['Physiological-Clinical']

Patients O
randomly O
received O
a O
7-day O
oral O
dose O
( O
28 O
capsules O
, O
500 O
mg O
each O
, O
to O
be O
taken O
every O
6 O
hours O
) O
of O
either O
penicillin O
or O
a O
placebo O
control O
in O
a O
double-blind O
manner O
. O
[]

Effects O
of O
two-month O
vocal O
exercising O
with O
and O
without O
spectral O
biofeedback O
on O
student O
actors O
' O
speaking O
voice O
. O
[]

CONCLUSION O
These O
results O
indicate O
that O
eye O
gaze O
attracted O
attention B-outcome ['Life-Impact']
more O
effectively O
than O
the O
arrow O
in O
typically O
developed O
children O
, O
while O
children O
with O
autism O
shifted O
their O
attention O
equally O
in O
response O
to O
eye O
gaze O
and O
arrow O
direction O
, O
failing O
to O
show O
preferential O
['Life-Impact']

METHODS O
A O
randomized O
, O
prospective O
study O
was O
undertaken O
with O
150 O
volunteers O
who O
performed O
management O
of O
a O
standardized O
simulated O
cardiac O
arrest O
in O
a O
manikin O
. O
[]

Prior O
to O
the O
first O
vaccination O
27 O
% O
of O
the O
subjects O
had O
a O
diphtheria B-outcome ['Physiological-Clinical']
antitoxin I-outcome ['Physiological-Clinical']
level O
below O
0.01 O
I.U./ml O
; O
after O
the O
first O
booster O
only O
5 O
% O
were O
unprotected O
. O
['Physiological-Clinical']

Groupe O
d'Etude O
des O
Lymphomes O
de O
l'Adulte O
. O
[]

7.07 O
?g/L O
vs. O
48.00 O
? O
[]

That O
looks O
familiar O
: O
attention O
allocation O
to O
familiar O
and O
unfamiliar O
faces O
in O
children O
with O
autism O
spectrum O
disorder O
. O
[]

The O
development B-outcome ['Life-Impact']
for O
the O
group O
of O
children O
on O
diet O
was O
significantly O
better O
than O
for O
the O
controls O
. O
['Life-Impact']

A O
CC O
enhanced O
the O
use O
of O
EH O
alone O
and O
was O
the O
only O
treatment O
to O
reduce O
symptoms O
to O
baseline O
within O
1 O
hour O
of O
antigenic O
challenge O
. O
[]

As O
measures O
of O
mental O
health O
functioning O
, O
both O
hopelessness B-outcome ['Life-Impact']
and O
depression B-outcome ['Life-Impact']
have O
long-term O
negative O
psychosocial O
and O
developmental O
impacts O
on O
children O
. O
['Life-Impact', 'Life-Impact']

Importance O
of O
preventive O
pharmacological O
strategies O
in O
elderly O
patients O
and O
associated O
costs B-outcome ['Resource-use']
. O
['Resource-use']

RESULTS O
Both O
the O
subjective O
and O
objective O
symptoms B-outcome ['Physiological-Clinical']
and O
signs B-outcome ['Physiological-Clinical']
improved O
during O
the O
one O
week O
of O
treatment O
statistically O
significantly O
more O
rapidly O
under O
the O
test O
preparation O
as O
compared O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
30-month O
longitudinal O
study O
of O
the O
effects O
of O
some O
oral O
hygiene O
measures O
on O
Streptococcus B-outcome ['Physiological-Clinical']
mutans I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
approximal I-outcome ['Physiological-Clinical']
dental I-outcome ['Physiological-Clinical']
caries I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
Stages O
to O
Healthy O
Eating O
Patterns O
Study O
( O
STEPs O
) O
was O
an O
intervention O
study O
, O
in O
middle-aged O
adults O
with O
cardiovascular O
risk O
factors O
, O
to O
examine O
the O
effectiveness O
of O
printed O
, O
tailored O
, O
iterative O
dietary O
feedback O
delivered O
by O
mail O
in O
improving O
short-term O
dietary O
behaviour O
in O
the O
areas O
of O
saturated O
fat O
, O
fruit O
, O
vegetable O
and O
grain O
and O
cereal O
intake O
. O
[]

Participants O
in O
the O
intervention O
group O
received O
a O
rechargeable O
, O
powered O
Oral-B? O
oscillating-rotating-pulsating O
toothbrush O
and O
a O
Reach? O
Access? O
Flosser O
that O
has O
a O
toothbrush-like O
handle O
. O
[]

cells O
. O
[]

Prospectively O
randomized O
toxicity B-outcome ['Adverse-effects']
study O
of O
high-dose O
versus O
low-dose O
treatment O
strategies O
for O
lymphoblastoid O
interferon O
. O
['Adverse-effects']

Carbon O
dioxide O
laser O
treatment O
of O
vaginal O
adenosis O
in O
DES-exposed O
offspring O
: O
a O
prospective O
study O
. O
[]

We O
examined O
serial O
changes O
in O
spirometry O
and O
Clinical O
COPD O
Questionnaire O
( O
CCQ O
) O
scores O
( O
measuring O
respiratory O
symptoms O
and O
health-related O
quality O
of O
life O
) O
in O
COPD O
participants O
by O
smoking O
status O
during O
a O
smoking O
cessation O
trial O
. O
[]

Randomization O
compliance O
was O
96 O
% O
( O
109/113 O
) O
. O
[]

The O
overall B-outcome ['Life-Impact']
tolerability I-outcome ['Life-Impact']
was O
higher O
in O
the O
TM-PEG O
4L O
group O
than O
in O
the O
PEG O
4L O
group O
( O
P O
= O
0.036 O
) O
. O
['Life-Impact']

This O
study O
demonstrates O
that O
losartan O
reduces O
t-PA B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
levels O
in O
white O
, O
but O
not O
African-American O
hypertensive O
individuals O
. O
['Physiological-Clinical']

METHODS O
In O
all O
, O
239 O
children O
were O
enrolled O
by O
25 O
family O
practitioners O
in O
an O
open-label O
study O
. O
[]

DESIGN O
All O
patients O
completed O
2 O
face-to-face O
interviews O
, O
which O
were O
2 O
weeks O
apart O
. O
[]

CONCLUSIONS O
In O
this O
sample O
, O
there O
was O
a O
high O
rate O
of O
reported O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
despite O
lack O
of O
medical O
causes O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
investigate O
the O
sensitivity O
, O
specificity O
and O
predictive O
value O
of O
endocervical O
sampling O
in O
women O
with O
abnormal O
cervical O
smears O
. O
[]

There O
was O
no O
difference O
in O
microcystic B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
tarsal I-outcome ['Physiological-Clinical']
conjunctiva I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
lens B-outcome ['Physiological-Clinical']
comfort I-outcome ['Physiological-Clinical']
, O
refractive B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
, O
or O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
long-term O
neurotoxicities O
of O
these O
two O
IT O
strategies O
have O
not O
yet O
been O
directly O
compared O
. O
[]

13.0? O
) O
. O
[]

Stone B-outcome ['Physiological-Clinical']
fragmentation I-outcome ['Physiological-Clinical']
rate O
was O
47/54 O
( O
87 O
% O
) O
and O
50/52 O
( O
96.2 O
% O
) O
and O
the O
stone B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
rate O
was O
47/54 O
( O
87 O
% O
) O
and O
48/52 O
( O
92.3 O
% O
) O
for O
the O
first O
and O
the O
second O
groups O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Angiotensin O
converting O
enzyme O
inhibition O
does O
not O
affect O
the O
response O
to O
exogenous O
angiotensin O
II O
in O
the O
human O
forearm O
. O
[]

RESULTS O
The O
overall O
breastfeeding B-outcome ['Physiological-Clinical']
rate O
at O
8-12 O
weeks O
postpartum O
was O
67 O
% O
. O
['Physiological-Clinical']

Significant O
improvement O
was O
recorded O
for O
all O
symptoms O
at O
days O
10 O
and O
28 O
in O
all O
groups O
( O
p O
< O
0.001 O
) O
, O
but O
levosulpiride O
was O
significantly O
( O
p O
< O
0.01 O
) O
superior O
to O
domperidone O
, O
metoclopramide O
and O
placebo O
both O
in O
the O
overall O
clinical O
improvement O
scale O
as O
well O
as O
in O
a O
subgroup O
of O
symptoms O
( O
postprandial B-outcome ['Physiological-Clinical']
bloating I-outcome ['Physiological-Clinical']
, O
epigastric B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
heartburn B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Ninety-six O
patients O
were O
evaluable O
for O
response O
and O
toxicity B-outcome ['Adverse-effects']
and O
additional O
12 O
patients O
for O
toxicity B-outcome ['Adverse-effects']
only O
. O
['Adverse-effects', 'Adverse-effects']

HYPOTHESIS O
This O
study O
was O
designed O
to O
investigate O
the O
efficacy O
of O
low-dose O
dopamine O
( O
2 O
micrograms/kg/min O
) O
as O
a O
renal-protective O
agent O
during O
vigorous O
diuresis O
for O
congestive O
heart O
failure O
( O
CHF O
) O
associated O
with O
mild O
or O
moderate O
renal O
insufficiency O
. O
[]

Between O
1977 O
and O
1983 O
the O
Southwest O
Oncology O
Group O
( O
SWOG O
) O
evaluated O
chemotherapy O
alone O
( O
cyclophosphamide O
, O
doxorubicin O
, O
vincristine O
, O
prednisone O
; O
CHOP O
) O
or O
chemoimmunotherapy O
( O
CHOP-levamisole O
or O
CHOP-levamisole-BCG O
) O
in O
a O
randomized O
prospective O
clinical O
trial O
involving O
715 O
eligible O
patients O
with O
all O
types O
of O
malignant O
lymphoma O
( O
ML O
) O
. O
[]

An O
insufficient O
bacteriological O
response O
( O
persistent B-outcome ['Physiological-Clinical']
positive O
cultures B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

These O
surveys O
suggested O
that O
engaging O
supervisors O
in O
a O
dialogue O
about O
tolerance O
might O
improve O
their O
willingness B-outcome ['Life-Impact']
to O
use O
the O
EAP O
. O
['Life-Impact']

DESIGN O
Prospective O
, O
multicenter O
, O
randomized O
, O
parallel O
group O
, O
double-blind O
placebo-controlled O
12-week O
trial O
. O
[]

Following O
stratification O
by O
site O
and O
endoscopic O
appearance O
of O
their O
lesions O
, O
the O
patients O
were O
randomized O
to O
undergo O
brushing O
either O
before O
or O
after O
forceps O
biopsy O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
booster B-outcome ['Physiological-Clinical']
immunization I-outcome ['Physiological-Clinical']
effect O
to O
non-and-low O
response O
children O
after O
3 O
doses O
HepB O
immunization O
. O
['Physiological-Clinical']

A O
sixty-day O
feeding O
trial O
was O
carried O
out O
to O
elucidate O
the O
effect O
of O
dietary O
pyridoxine O
( O
PN O
) O
on O
hemato-immunological B-outcome ['Physiological-Clinical']
parameters O
in O
Labeo O
rohita O
fingerlings O
exposed O
to O
an O
elevated O
temperature O
( O
ET O
) O
of O
33 O
?C O
. O
['Physiological-Clinical']

METHODS O
This O
was O
a O
multicenter O
, O
52-week O
, O
double-blind O
, O
parallel-group O
trial O
. O
[]

METHODS O
To O
investigate O
the O
effect O
of O
exposure O
to O
nitrogen O
dioxide O
( O
NO2 O
) O
on O
nasal O
airways O
resistance O
( O
NAR O
) O
and O
inflammatory O
mediators O
in O
nasal O
lavage O
fluid O
, O
eight O
subjects O
with O
a O
history O
of O
seasonal O
allergic O
rhinitis O
, O
who O
were O
tested O
out O
of O
season O
, O
were O
exposed O
in O
a O
randomized O
single-blind O
, O
crossover O
study O
to O
either O
air O
or O
400 O
ppb O
NO2 O
for O
6 O
hours O
. O
[]

The O
incidence O
of O
[]

Immunologic O
and O
hemodynamic O
effects O
of O
low-dose O
hydrocortisone O
in O
septic O
shock O
: O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
, O
crossover O
study O
. O
[]

Most O
children O
had O
poor O
, O
single O
mothers O
who O
had O
completed O
12 O
or O
fewer O
years O
of O
school O
and O
who O
lived O
in O
older O
, O
poorly O
maintained O
residences O
. O
[]

Accuracy O
and O
feasibility O
of O
contrast O
echocardiography O
for O
detection O
of O
perfusion O
defects O
in O
routine O
practice O
: O
comparison O
with O
wall O
motion O
and O
technetium-99m O
sestamibi O
single-photon O
emission O
computed O
tomography O
. O
[]

The O
interindividual O
variability O
resulted O
in O
the O
highest O
values O
for O
the O
reactance O
, O
followed O
by O
Raw O
and O
FEV1 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
We O
first O
measured O
the O
basal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
sugar I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
amylase I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

METHODS O
Patients O
with O
standard O
ICD O
indications O
undergo O
defibrillation O
threshold O
testing O
( O
DFT O
) O
at O
the O
time O
of O
ICD O
implant O
, O
with O
reconfirmation O
of O
lowest O
successful O
energy O
twice O
( O
DFT++ O
) O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effect O
of O
chronic O
cigarette O
smoking O
, O
acute O
nicotine O
administration O
, O
and O
OC O
use O
on O
cardiovascular B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS/DESIGN O
Children O
aged O
between O
4 O
; O
0 O
and O
6 O
; O
11 O
years O
who O
are O
diagnosed O
with O
autism O
spectrum O
disorder O
will O
be O
randomly O
assigned O
to O
one O
of O
three O
conditions O
. O
[]

An O
additional O
26 O
patients O
were O
treated O
in O
an O
identical O
fashion O
, O
but O
were O
not O
part O
of O
the O
randomized O
trial O
because O
of O
contraindications O
to O
chemotherapy O
, O
refusal O
to O
enter O
the O
randomized O
trial O
, O
or O
because O
they O
were O
treated O
before O
1977 O
in O
a O
trial O
in O
which O
all O
patients O
received O
chemotherapy O
. O
[]

METHODS O
In O
a O
randomized O
study O
, O
biliary O
and O
serum O
bile O
acid O
analyses O
were O
performed O
at O
entry O
and O
after O
2 O
yr O
of O
UDCA O
or O
placebo O
. O
[]

STUDY O
DESIGN O
Multivariate O
logistic O
regression O
analysis O
was O
used O
to O
evaluate O
the O
association O
between O
the O
results O
of O
generic O
discharge O
administered O
by O
the O
PROs O
and O
two O
patient O
outcomes O
: O
mortality O
and O
readmission O
within O
30 O
days O
. O
[]

The O
purpose O
of O
this O
pilot O
study O
was O
to O
test O
the O
efficacy O
of O
a O
personalized O
informed O
consent O
generated O
through O
an O
electronic O
health O
record O
( O
EHR O
) O
at O
one O
dental O
school O
and O
its O
role O
in O
patient O
decision O
making O
. O
[]

UICC O
[ O
20 O
] O
stage O
distribution O
of O
patients O
was O
as O
follows O
: O
stage O
IA O
= O
4 O
, O
stage O
IB O
= O
33 O
, O
stage O
IIA O
= O
18 O
, O
stage O
IIB O
= O
38 O
, O
stage O
III O
= O
57 O
, O
stage O
IV O
= O
15 O
. O
[]

No O
ventricular B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
supraventricular I-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
was O
observed O
. O
['Physiological-Clinical']

In O
comparison O
with O
the O
placebo O
group O
, O
fasting B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
( O
p O
< O
0.04 O
) O
, O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
and O
Apo B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
( O
p O
< O
0.008 O
) O
concentrations O
decreased O
more O
in O
the O
metformin O
group O
in O
the O
BIGPRO O
1 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Differences O
were O
not O
statistically O
significant O
. O
[]

Other O
adverse O
events O
were O
monitored O
through O
28 O
to O
35 O
days O
after O
dose O
2 O
. O
[]

The O
overall B-outcome ['Mortality']
progression-free I-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
similar O
between O
the O
two O
arms O
( O
P O
=.095 O
) O
. O
['Mortality']

Predictors O
of O
postdischarge O
outcomes O
from O
information O
acquired O
shortly O
after O
admission O
for O
acute O
heart O
failure O
: O
a O
report O
from O
the O
Placebo-Controlled O
Randomized O
Study O
of O
the O
Selective O
A1 O
Adenosine O
Receptor O
Antagonist O
Rolofylline O
for O
Patients O
Hospitalized O
With O
Acute O
Decompensated O
Heart O
Failure O
and O
Volume O
Overload O
to O
Assess O
Treatment O
Effect O
on O
Congestion O
and O
Renal O
Function O
( O
PROTECT O
) O
Study O
. O
[]

Basal B-outcome ['Physiological-Clinical']
TSH I-outcome ['Physiological-Clinical']
levels O
were O
similar O
in O
control O
and O
obese O
men O
. O
['Physiological-Clinical']

The O
patients O
were O
stratified O
according O
to O
whether O
they O
had O
not O
been O
taking O
aspirin O
before O
the O
study O
( O
initiation O
stratum O
, O
with O
5628 O
patients O
) O
or O
they O
were O
already O
on O
an O
aspirin O
regimen O
( O
continuation O
stratum O
, O
with O
4382 O
patients O
) O
. O
[]

BACKGROUND O
Omega-3 O
fatty O
acids O
and O
fenofibrate O
are O
both O
used O
to O
treat O
patients O
with O
hypertriglyceridemia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

We O
conducted O
a O
randomized O
, O
double-masked O
, O
dose-response O
study O
of O
the O
ocular B-outcome ['Physiological-Clinical']
hypotensive I-outcome ['Physiological-Clinical']
effect O
of O
the O
beta-adrenergic O
blocker O
, O
levobunolol O
. O
['Physiological-Clinical']

MAIN O
OUTCOMES O
MEASURE O
( O
S O
) O
Survival B-outcome ['Mortality']
rates O
and O
maintenance O
of O
meiotic O
spindle O
observed O
immediately O
after O
warming O
and O
3 O
hours O
after O
incubation O
. O
['Mortality']

BACKGROUND O
Heparin-coated O
circuits O
in O
cardiopulmonary O
bypass O
have O
been O
shown O
to O
decrease O
the O
systemic O
inflammatory O
responses O
associated O
with O
cardiopulmonary O
bypass O
. O
[]

INTERPRETATION O
This O
is O
a O
post O
hoc O
subgroup O
analysis O
of O
an O
outcome O
variable O
, O
which O
was O
not O
in O
the O
official O
protocol O
. O
[]

Adverse O
effects O
were O
more O
frequent O
. O
[]

PURPOSE O
To O
evaluate O
the O
additional O
therapeutic O
effect O
of O
single O
intravitreal O
bevacizumab O
injection O
on O
standard O
laser O
treatment O
in O
the O
management O
of O
proliferative O
diabetic O
retinopathy O
. O
[]

The O
children O
presented O
with O
a O
chief O
complaint O
of O
severely O
disruptive O
symptoms O
related O
to O
autistic O
disorder O
. O
[]

Ten O
patients O
with O
writer O
's O
cramp O
were O
enrolled O
in O
a O
double-blind O
, O
randomized O
, O
crossover O
study O
in O
which O
the O
effects O
of O
transcutaneous O
electrical O
stimulation O
( O
TENS O
) O
and O
placebo O
treatment O
were O
compared O
. O
[]

From O
pharmacokinetic O
and O
in O
vitro O
studies O
perspectives O
, O
1 O
FDC O
tablet O
demonstrated O
similar O
relative O
bioavailability O
with O
the O
2 O
individual O
-reference O
tablets O
. O
[]

Wind-up O
to O
the O
2 O
Hz O
train O
increased O
in O
the O
UO B-outcome ['Physiological-Clinical']
( O
wind-up O
ratio O
1.4 O
( O
0.1 O
) O
to O
1.6 O
( O
0.1 O
) O
; O
p=0.03 O
) O
but O
not O
in O
the O
hand O
( O
wind-up O
ratio O
1.3 O
( O
0.1 O
) O
and O
1.3 O
( O
0.1 O
) O
; O
p=0.3 O
) O
CONCLUSION O
Enhanced O
wind-up O
after O
secondary O
oesophageal O
hyperalgesia O
suggests O
that O
visceral O
pain O
hypersensitivity O
induced O
by O
central O
sensitisation O
results O
from O
increased O
central O
neuronal O
excitability O
. O
['Physiological-Clinical']

Determinants O
of O
post-intervention O
serum O
retinol O
concentration O
included O
baseline O
serum O
retinol O
concentration O
, O
caregiver O
's O
education O
, O
receipt O
of O
high-dose O
vitamin O
A O
capsule O
, O
interaction O
between O
consumption O
of O
vitamin O
A-fortified O
cooking O
oil O
and O
of O
other O
vitamin O
A-rich O
foods O
, O
and O
between O
households O
purchasing O
cooking O
oil O
and O
food O
expenditure O
. O
[]

Patient-rated O
outcome O
was O
assessed O
at O
baseline O
and O
after O
6 O
weeks O
and O
3 O
months O
using O
a O
visual O
analog O
scale O
and O
the O
Patient-Rated O
Tennis O
Elbow O
Evaluation O
. O
[]

Bacterial O
species O
found O
at O
least O
in O
50 O
% O
of O
the O
patients O
and O
comprising O
on O
average O
5 O
% O
or O
more O
of O
the O
cultivable O
flora O
were O
included O
in O
the O
analysis O
. O
[]

All O
episodes O
of O
PONV O
during O
the O
first O
24 O
hours O
after O
anesthesia O
administration O
were O
recorded O
by O
an O
investigator O
who O
was O
blinded O
to O
treatment O
assignment O
. O
[]

A O
2-year O
randomized O
, O
controlled O
trial O
. O
[]

METHODS O
A O
prospective O
randomized O
paired-eye O
trial O
was O
studied O
. O
[]

Research O
detailing O
the O
normal O
vascular O
adaptions O
to O
high O
altitude O
is O
minimal O
and O
often O
confounded O
by O
pathology O
( O
e.g. O
, O
chronic O
mountain O
sickness O
) O
and O
methodological O
issues O
. O
[]

Further O
studies O
are O
necessary O
to O
assess O
the O
effectiveness O
of O
hormone O
adjuvant O
treatment O
in O
FIGO O
stage O
I O
endometrial O
carcinoma O
with O
myometrial O
invasion O
. O
[]

PURPOSE O
Postoperative O
radiotherapy O
for O
breast O
cancer O
has O
a O
number O
of O
associated O
complications O
. O
[]

Patients O
receiving O
aromatherapy O
massage O
also O
described O
greater O
improvement O
in O
self-reported O
anxiety B-outcome ['Life-Impact']
at O
both O
6 O
and O
10 O
weeks O
postrandomization O
( O
OR O
, O
3.4 O
; O
95 O
% O
CI O
, O
0.2 O
to O
6.7 O
; O
P O
= O
.04 O
and O
OR O
, O
3.4 O
; O
95 O
% O
CI O
, O
0.2 O
to O
6.6 O
; O
P O
= O
.04 O
) O
, O
respectively O
. O
['Life-Impact']

OBJECTIVE O
To O
model O
the O
pharmacokinetic B-outcome ['Physiological-Clinical']
and O
pharmacodynamic B-outcome ['Physiological-Clinical']
relationship O
of O
bilastine O
, O
a O
new O
histamine O
H O
( O
1 O
) O
receptor O
antagonist O
, O
from O
single- O
and O
multiple-dose O
studies O
in O
healthy O
adult O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
Early O
Detection O
and O
Intervention O
Programme O
of O
the O
German O
Research O
Network O
on O
Schizophrenia O
( O
GRNS O
) O
investigates O
the O
initial O
prodromal O
phase O
of O
psychosis O
in O
a O
multidimensional O
approach O
. O
[]

The O
TM O
components O
migrated O
less O
than O
the O
Ti O
components O
at O
1 O
year O
( O
p O
= O
0.01 O
) O
and O
2 O
years O
( O
p O
= O
0.004 O
) O
. O
[]

In O
order O
to O
question O
the O
value O
of O
both O
glycol O
metabolites O
as O
peripheral O
indices O
of O
central B-outcome ['Physiological-Clinical']
noradrenergic I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
a O
comparative O
study O
of O
plasma O
DOPEG O
and O
MOPEG O
( O
measured O
by O
HPLC O
) O
related O
to O
depression O
, O
sex O
, O
age O
and O
diagnostic O
categories O
( O
DSM-III O
) O
was O
carried O
out O
on O
depressed O
and O
control O
subjects O
. O
['Physiological-Clinical']

The O
factors O
from O
univariate O
analyzes O
with O
a O
p-value O
of O
at O
most O
.10 O
were O
included O
. O
[]

Multitomographic O
radiographs O
were O
taken O
before O
( O
T0 O
) O
and O
at O
the O
end O
( O
T1 O
) O
of O
expansion O
while O
the O
patients O
were O
wearing O
an O
acrylic O
mandibular O
appliance O
in O
which O
ball O
bearings O
and O
bars O
were O
embedded O
. O
[]

Patients O
with O
stage O
III O
in O
the O
OK-432 O
group O
survived B-outcome ['Mortality']
significantly O
longer O
than O
those O
in O
the O
control O
group O
( O
P O
less O
than O
0.05 O
) O
, O
but O
there O
was O
no O
significance O
between O
in O
patients O
with O
stage O
IV O
of O
both O
treatment O
groups O
. O
['Mortality']

This O
finding O
would O
indicate O
that O
the O
chance O
of O
developing O
cicatricial O
ectropion O
with O
any O
of O
the O
tested O
combinations O
of O
TCA O
should O
be O
very O
remote O
. O
[]

RESULTS O
Intervention-group O
participants O
who O
attended O
over O
half O
of O
the O
Working O
Well O
sessions O
reported O
significantly O
lower O
rates O
of O
limitation B-outcome ['Life-Impact']
from O
secondary O
conditions O
over O
the O
1-year O
study O
span O
, O
F O
( O
1 O
, O
124 O
) O
= O
4.11 O
, O
p O
= O
.004 O
. O
['Life-Impact']

Stepwise O
hook O
extension O
technique O
for O
radiofrequency O
ablation O
therapy O
of O
hepatocellular O
carcinoma O
. O
[]

EEG O
showed O
long O
sequences O
of O
slow O
spike-wave O
activity O
and O
half O
the O
patients O
had O
spike O
and O
slow O
wave O
foci O
. O
[]

RESULTS O
Under O
treatment O
with O
levodopa O
SR O
, O
1 O
patient O
presented O
severe B-outcome ['Physiological-Clinical']
vomiting I-outcome ['Physiological-Clinical']
, O
leading O
to O
study O
discontinuation O
. O
['Physiological-Clinical']

RESULTS O
At O
month O
12 O
, O
biopsy-confirmed B-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
rejections I-outcome ['Physiological-Clinical']
were O
reported O
for O
15.2 O
% O
( O
induction O
) O
and O
30.4 O
% O
( O
noninduction O
) O
of O
patients O
( O
P=0.001 O
) O
. O
['Physiological-Clinical']

SETTING O
Neurologic O
and O
ophthalmologic O
examinations O
at O
13 O
clinical O
sites O
. O
[]

OBJECTIVE O
To O
assess O
the O
effectiveness O
of O
a O
weighted-blanket O
intervention O
in O
treating O
severe O
sleep O
problems O
in O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

As O
seen O
from O
the O
parents O
' O
logs O
, O
the O
median O
time B-outcome ['Physiological-Clinical']
needed I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
children I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
fall I-outcome ['Physiological-Clinical']
asleep I-outcome ['Physiological-Clinical']
decreased O
from O
15 O
minutes O
( O
range O
15 O
to O
60 O
minutes O
) O
to O
10 O
minutes O
( O
range O
10 O
to O
15 O
minutes O
, O
P O
= O
.001 O
) O
. O
['Physiological-Clinical']

There O
was O
a O
main O
effect O
of O
stimulus O
temperature O
on O
pain O
ratings O
, O
but O
no O
main O
effect O
of O
condition O
( O
p O
= O
0.32 O
) O
, O
nor O
a O
condition O
x O
temperature O
interaction O
( O
p O
= O
0.31 O
) O
. O
[]

RESULTS O
The O
incidence O
of O
reperfusion B-outcome ['Physiological-Clinical']
arrhythmias-frequent I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

This O
double-blind O
and O
randomized O
study O
showed O
no O
differences O
between O
these O
two O
populations O
with O
regard O
to O
the O
three O
parameters O
. O
[]

PATIENTS O
AND O
METHODS O
Within O
a O
multi-centre O
, O
randomised O
phase O
II O
trial O
, O
95 O
patients O
with O
LAPC O
were O
assigned O
to O
three O
different O
chemoradiotherapy O
( O
CRT O
) O
regimens O
: O
patients O
received O
conventionally O
fractionated O
radiotherapy O
of O
50 O
Gy O
and O
were O
randomised O
to O
concurrent O
5-fluorouracil O
( O
350 O
mg O
m O
( O
-2 O
) O
per O
day O
on O
each O
day O
of O
radiotherapy O
, O
RT-5-FU O
arm O
) O
, O
concurrent O
gemcitabine O
( O
300 O
mg O
m O
( O
-2 O
) O
) O
, O
and O
cisplatin O
( O
30 O
mg O
m O
( O
-2 O
) O
) O
on O
days O
1 O
, O
8 O
, O
22 O
, O
and O
29 O
( O
RT-GC O
arm O
) O
, O
or O
the O
same O
concurrent O
treatment O
followed O
by O
sequential O
full-dose O
gemcitabine O
( O
1000 O
mg O
m O
( O
-2 O
) O
) O
and O
cisplatin O
( O
50 O
mg O
m O
( O
-2 O
) O
) O
every O
2 O
weeks O
( O
RT-GC+GC O
arm O
) O
. O
[]

Progression-free B-outcome ['Physiological-Clinical']
and O
cancer-specific B-outcome ['Mortality']
survivals I-outcome ['Mortality']
were O
determined O
by O
the O
Kaplan-Meier O
method O
. O
['Physiological-Clinical', 'Mortality']

The O
effect O
of O
a O
single O
oral O
dose O
on O
the O
responses O
of O
heart O
rate O
and O
blood O
pressure O
to O
isoprenaline O
infusion O
has O
been O
studied O
in O
healthy O
volunteers O
. O
[]

Neonates O
, O
especially O
those O
of O
very O
low O
birthweight O
( O
VLBW O
) O
, O
have O
an O
increased O
risk O
of O
nosocomial O
infections O
secondary O
to O
deficiencies O
in O
development O
. O
[]

Twenty O
children O
with O
autism O
( O
mean O
age O
, O
5 O
years O
) O
were O
recruited O
for O
the O
study O
from O
a O
school O
for O
children O
with O
autism O
. O
[]

RESULTS O
Results O
showed O
that O
using O
a O
triage O
room O
and/or O
standing O
orders O
did O
not O
significantly O
decrease O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
. O
['Resource-use']

An O
equivalence O
trial O
of O
maintenance O
therapy O
was O
carried O
out O
in O
children O
with O
B O
non-Hodgkin O
lymphoma O
, O
and O
serves O
as O
an O
illustration O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
a O
2-dimensional O
, O
handheld O
ultrasound O
device O
and O
a O
newly O
developed O
ultrasound O
volume O
scanner O
( O
based O
on O
bladder O
scan O
technology O
) O
with O
computed O
tomography O
( O
CT O
) O
for O
diagnosing O
AAA O
. O
[]

SETTING O
Urban O
teaching O
hospital O
clinical O
research O
center O
. O
[]

All O
of O
the O
most O
widely-cited O
studies O
for O
the O
prediction O
of O
maximum B-outcome ['Physiological-Clinical']
exercise I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
have O
utilized O
either O
volunteers O
or O
referred O
subjects O
. O
['Physiological-Clinical']

The O
aim O
of O
the O
present O
study O
was O
to O
examine O
the O
safety O
and O
tolerability O
of O
a O
new O
and O
higher O
dosage O
regimen O
that O
would O
enable O
acute O
stroke O
patients O
to O
achieve O
and O
maintain O
neuroprotective O
plasma O
concentrations O
. O
[]

n O
= O
758 O
) O
. O
[]

RESULTS O
Both O
the O
hep/hc O
and O
filter O
groups O
were O
similar O
in O
terms O
of O
phlebitis B-outcome ['Physiological-Clinical']
incidence I-outcome ['Physiological-Clinical']
and O
i.v O
. O
['Physiological-Clinical']

In O
addition O
, O
analysis O
of O
brachial B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
flow-mediated I-outcome ['Physiological-Clinical']
vasodilatation I-outcome ['Physiological-Clinical']
and O
24-hour B-outcome ['Physiological-Clinical']
ambulatory I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
monitoring I-outcome ['Physiological-Clinical']
were O
performed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Also O
the O
urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
melatonin I-outcome ['Physiological-Clinical']
was O
of O
similar O
magnitude O
at O
these O
two O
occasions O
. O
['Physiological-Clinical']

Gradual O
withdrawal O
of O
diazepam O
after O
long-term O
therapy O
. O
[]

A O
randomized O
protocol O
was O
used O
to O
study O
the O
effect O
of O
intraumbilical O
prostaglandin O
F2 O
alpha O
( O
Hembate O
, O
Upjohn O
) O
and O
oxytocin O
injection O
in O
women O
with O
retained O
placenta O
. O
[]

At O
TI2 O
, O
previous O
to O
the O
allergen O
challenge O
, O
the O
active O
group O
showed O
higher O
values O
of O
both O
FEV1 B-outcome ['Physiological-Clinical']
and O
Mth-PD20 B-outcome ['Physiological-Clinical']
and O
lower O
values O
of O
Mth-DRS B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Adrenergic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
following O
infusions O
of O
yohimbine O
or O
normal O
saline O
was O
evaluated O
in O
9 O
control O
subjects O
, O
8 O
patients O
suffering O
from O
a O
major O
depressive O
episode O
( O
MDE O
) O
, O
and O
12 O
patients O
suffering O
from O
concurrent O
MDE O
and O
panic O
disorder O
( O
MDE O
+ O
P O
) O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVES O
Both O
larger O
molecule O
removal O
and O
dialyzer O
biocompatibility O
have O
been O
implicated O
in O
the O
high-flux O
hemodialysis O
( O
HD O
) O
-associated O
favorable O
outcome O
. O
[]

INTRODUCTION O
Stigma B-outcome ['Life-Impact']
associated O
with O
HIV O
has O
been O
documented O
as O
a O
barrier O
for O
accessing O
quality O
health-related O
services O
. O
['Life-Impact']

RESULT O
Compared O
with O
the O
placebo O
group O
, O
the O
scores O
for O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
and O
excessive B-outcome ['Physiological-Clinical']
sweating I-outcome ['Physiological-Clinical']
were O
significantly O
reduced O
after O
3 O
months O
, O
and O
the O
scores O
for O
weakness B-outcome ['Physiological-Clinical']
, O
palpitations B-outcome ['Physiological-Clinical']
, O
limb B-outcome ['Physiological-Clinical']
paresthesia I-outcome ['Physiological-Clinical']
, O
and O
total O
symptoms B-outcome ['Physiological-Clinical']
after O
6 O
months O
, O
in O
the O
EP O
group O
only O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Individual O
group O
comparisons O
after O
5 O
and O
11 O
wk O
of O
intervention O
on O
all O
three O
main O
outcome O
measures O
did O
not O
reveal O
any O
clear O
clinically O
important O
or O
statistically O
significant O
differences O
. O
[]

The O
results O
of O
the O
study O
indicate O
that O
a O
psychotherapeutic O
element O
in O
the O
treatment O
of O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
appears O
to O
positively O
influence O
pain B-outcome ['Physiological-Clinical']
, O
functional B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
and O
work B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
when O
conducted O
at O
an O
early O
stage O
of O
chronification O
and O
helps O
in O
the O
achievement O
of O
a O
better O
outcome O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Few O
RCT O
exercise O
intervention O
studies O
have O
included O
cancer O
patients O
undergoing O
chemotherapy O
. O
[]

OBJECTIVE O
To O
determine O
the O
extent O
to O
which O
the O
estrogen-induced O
changes O
in O
lipids O
and O
markers O
of O
carbohydrate O
metabolism O
explain O
the O
beneficial O
effect O
of O
estrogen O
therapy O
on O
the O
progression O
of O
carotid B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
intima-media I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IMT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
feasibility O
of O
a O
prehospital O
trial O
comparing O
hypertonic O
saline O
and O
dextran O
( O
HSD O
) O
with O
normal O
saline O
( O
NS O
) O
in O
blunt O
head O
injury O
patients O
. O
[]

BACKGROUND O
Despite O
enthusiasm O
for O
the O
use O
of O
mild O
hypothermia O
during O
neurosurgical O
procedures O
, O
this O
therapy O
has O
not O
been O
evaluated O
systematically O
. O
[]

All O
children O
were O
followed O
up O
three O
, O
six O
and O
12 O
months O
after O
the O
initial O
treatment O
, O
morbidity B-outcome ['Physiological-Clinical']
being O
clinically O
evaluated O
at O
the O
six- O
and O
12-month O
follow-ups O
. O
['Physiological-Clinical']

Currently O
ongoing O
is O
the O
UK O
Collaborative O
Trial O
of O
Ovarian O
Cancer O
Screening O
( O
UKCTOCS O
) O
, O
which O
utilizes O
the O
risk O
of O
ovarian O
cancer O
algorithm O
( O
ROCA O
) O
, O
a O
statistical O
tool O
that O
considers O
current O
and O
past O
CA125 O
values O
to O
determine O
ovarian O
cancer O
risk O
. O
[]

The O
toxic/adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
were O
milder O
in O
the O
treatment O
group O
than O
in O
the O
control O
group O
( O
P O
< O
0.01 O
) O
. O
['Adverse-effects']

Enhancing O
the O
application O
and O
evaluation O
of O
a O
discrete O
trial O
intervention O
package O
for O
eliciting O
first O
words O
in O
preverbal O
preschoolers O
with O
ASD O
. O
[]

CONCLUSIONS O
Implementation O
of O
an O
education O
and O
feedback-supported O
acute O
low O
back O
pain O
care O
guideline O
for O
primary O
care O
clinicians O
was O
associated O
with O
an O
increase O
in O
guideline-consistent O
behavior O
. O
[]

There O
is O
a O
strong O
association O
between O
premature B-outcome ['Mortality']
coronary I-outcome ['Mortality']
heart I-outcome ['Mortality']
disease I-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
men O
and O
the O
mean O
levels O
of O
8-oxo-dG O
for O
the O
five O
countries O
( O
r O
= O
0.95 O
, O
P O
< O
0.01 O
) O
. O
['Mortality']

The O
protective O
effects O
of O
angiotensin O
II O
blockade O
with O
olmesartan O
medoxomil O
on O
resistance O
vessel O
remodeling O
( O
The O
VIOS O
study O
) O
: O
rationale O
and O
baseline O
characteristics O
. O
[]

RESULTS O
Twenty O
patients O
completed O
the O
study O
. O
[]

Results O
were O
analysed O
using O
a O
Student O
's O
t O
test O
analysis O
. O
[]

Artificial O
tear O
instillation O
alone O
or O
CC O
combined O
with O
ATs O
or O
EH O
significantly O
reduced O
the O
temperature O
( O
P O
< O
0.05 O
) O
. O
[]

The O
VISA-A O
score O
significantly O
improved O
in O
both O
groups O
; O
in O
the O
eccentric O
group O
from O
50.1 O
to O
68.8 O
( O
p O
= O
0.001 O
) O
and O
in O
the O
night O
splint O
group O
from O
49.4 O
to O
67.0 O
( O
p O
< O
0.001 O
) O
. O
[]

Both O
drugs O
were O
well O
tolerated B-outcome ['Life-Impact']
, O
with O
pioglitazone O
associated O
with O
more O
peripheral B-outcome ['Physiological-Clinical']
edema I-outcome ['Physiological-Clinical']
( O
number O
of O
treatment-emergent O
cases O
: O
35/121 O
[ O
28.9 O
% O
] O
vs O
17/123 O
[ O
13.8 O
% O
] O
; O
P O
= O
0.005 O
) O
and O
fewer O
hypoglycemic B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
( O
19 O
[ O
15.7 O
% O
] O
vs O
38 O
[ O
30.9 O
% O
] O
; O
P O
= O
0.024 O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
outcome O
measure O
was O
the O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental B-outcome ['Life-Impact']
Disorders I-outcome ['Life-Impact']
, O
4 O
( O
th O
) O
edition O
( O
DSM-IV O
) O
ADHD B-outcome ['Life-Impact']
subscale O
of O
the O
Conners O
' O
Parent O
Rating O
Scale-Revised O
( O
CPRS-R-DSM-IV-ADHD O
) O
. O
['Life-Impact', 'Life-Impact']

It O
is O
devoid O
of O
any O
behavioural O
activity O
in O
animals O
, O
except O
at O
very O
high O
doses O
. O
[]

The O
two O
groups O
were O
comparable O
in O
terms O
of O
baseline O
characteristics O
. O
[]

METHOD O
Two O
hundred O
eighteen O
children O
and O
adolescents O
( O
aged O
6-17 O
years O
) O
with O
a O
diagnosis O
of O
autistic O
disorder O
, O
and O
with O
behaviors O
such O
as O
tantrums O
, O
aggression O
, O
self-injurious O
behavior O
, O
or O
a O
combination O
of O
these O
symptoms O
, O
were O
randomized O
1:1:1:1 O
to O
aripiprazole O
( O
5 O
, O
10 O
, O
or O
15 O
mg/day O
) O
or O
placebo O
in O
this O
8-week O
double-blind O
, O
randomized O
, O
placebo-controlled O
, O
parallel-group O
study O
. O
[]

METHODS O
Five O
adult O
male O
long-term O
survivors O
of O
childhood O
brain O
tumours O
( O
median O
age O
21.8 O
years O
( O
18.4-26.7 O
) O
; O
13.7 O
years O
( O
11.4-15.7 O
) O
post-radiotherapy O
, O
> O
30Gy O
) O
and O
five O
matched O
controls O
were O
studied O
. O
[]

However O
OC O
use O
among O
nonsmoking O
women O
is O
associated O
with O
greater O
[]

Advanced O
age O
and O
diabetes B-outcome ['Physiological-Clinical']
increased O
susceptibility O
to O
the O
composite O
outcome O
. O
['Physiological-Clinical']

The O
Bypass O
Angioplasty O
Revascularization O
Investigation O
( O
BARI O
) O
Investigators O
. O
[]

Those O
patients O
were O
treated O
only O
with O
arthroscopic O
debridment O
. O
[]

METHODS O
A O
random O
, O
blind O
and O
control O
trial O
, O
1200 O
healthy O
children O
of O
2-5 O
months O
old O
in O
Jiangsu O
province O
were O
administered O
OPV O
( O
HDC O
) O
vaccine O
and O
control O
vaccines O
. O
[]

This O
randomized O
field O
trial O
comparing O
Strategies O
for O
Teaching O
based O
on O
Autism O
Research O
and O
Structured O
Teaching O
enrolled O
educators O
in O
33 O
kindergarten-through-second-grade O
autism O
support O
classrooms O
and O
119 O
students O
, O
aged O
5-8 O
years O
in O
the O
School O
District O
of O
Philadelphia O
. O
[]

OBJECTIVE O
Forceps O
biopsy O
is O
the O
standard O
method O
to O
obtain O
specimens O
in O
endoscopically O
visible O
lesions O
. O
[]

RESULTS O
Of O
patients O
receiving O
ME-609 O
, O
42 O
% O
did O
not O
develop O
an O
ulcerative B-outcome ['Physiological-Clinical']
lesion I-outcome ['Physiological-Clinical']
compared O
with O
35 O
% O
of O
patients O
receiving O
acyclovir O
in O
ME-609 O
vehicle O
( O
P O
= O
.014 O
) O
and O
26 O
% O
of O
patients O
receiving O
placebo O
( O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical']

In O
a O
double O
blind O
study O
40 O
patients O
were O
allocated O
specific O
immunotherapy O
( O
hyposensitization O
) O
with O
partially O
purified O
timothy O
extract O
or O
two O
timothy O
major O
allergens O
19 O
, O
25 O
. O
[]

Stepping O
Stones O
Triple O
P O
: O
an O
RCT O
of O
a O
parenting O
program O
with O
parents O
of O
a O
child O
diagnosed O
with O
an O
autism O
spectrum O
disorder O
. O
[]

Results O
differed O
significantly O
between O
centres O
for O
doctor O
's O
satisfaction O
with O
the O
provision O
of O
referral O
criteria O
and O
prescribing O
information O
. O
[]

In O
conclusion O
, O
there O
were O
relatively O
few O
significant O
differences O
in O
psychosocial B-outcome ['Life-Impact']
outcomes O
between O
centres O
, O
considering O
the O
wide O
variation O
in O
service O
organisation O
and O
activity O
. O
['Life-Impact']

For O
patients O
with O
ED O
at O
baseline O
, O
a O
marginal O
improvement O
in O
erectile B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
demonstrated O
with O
alfuzosin O
treatment O
( O
P=0.09 O
vs O
placebo O
) O
. O
['Physiological-Clinical']

GMFRs O
after O
LAIV O
in O
years O
1 O
and O
2 O
ranged O
from O
1.2 O
to O
6.2 O
, O
compared O
with O
0.5-2.2 O
among O
placebo O
recipients O
. O
[]

Sub-Tenon O
's O
anesthesia O
involved O
direct O
transconjunctival O
infiltration O
of O
the O
same O
local O
anesthetic O
directly O
into O
the O
sub-Tenon O
's O
space O
, O
in O
the O
inferior-nasal O
quadrant O
, O
using O
a O
blunt O
23-gauge O
cannula O
. O
[]

RESULTS O
The O
score O
of O
symptom B-outcome ['Physiological-Clinical']
was O
lower O
in O
titanoreine O
group O
( O
4.4 O
) O
than O
that O
in O
the O
control O
group O
( O
6.1 O
) O
24 O
hours O
after O
PPH O
( O
P O
< O
0.05 O
) O
, O
but O
no O
significant O
difference O
in O
symptom B-outcome ['Physiological-Clinical']
grade I-outcome ['Physiological-Clinical']
was O
found O
between O
the O
two O
groups O
6 O
days O
and O
12 O
days O
after O
PPH O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Twenty-four O
patients O
( O
77 O
% O
) O
complained O
of O
pain B-outcome ['Physiological-Clinical']
in O
the O
group O
pretreated O
with O
normal O
saline O
as O
compared O
with O
12 O
( O
39 O
% O
) O
, O
10 O
( O
32 O
% O
) O
, O
and O
1 O
( O
3 O
% O
) O
in O
the O
groups O
pretreated O
with O
lidocaine O
40 O
mg O
, O
thiopental O
0.25 O
mg/kg O
, O
and O
thiopental O
0.5 O
mg/kg O
, O
respectively O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Efficacy O
measures O
, O
overall O
response O
rate O
, O
time-to-progression B-outcome ['Physiological-Clinical']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
were O
equivalent O
in O
both O
arms O
. O
['Physiological-Clinical', 'Mortality']

The O
primary O
outcome O
measure O
was O
cardiovascular B-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality']

Of O
the O
27 O
patients O
who O
received O
room O
temperature O
irrigation O
fluid O
, O
15 O
( O
55.6 O
% O
) O
had O
a O
decrease O
in O
body B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Seventy-five O
patients O
with O
an O
abdominal O
trauma O
index O
( O
ATI O
) O
greater O
than O
15 O
and O
less O
than O
40 O
were O
randomized O
at O
initial O
laparotomy O
to O
receive O
either O
TEN O
( O
Vivonex O
TEN O
) O
or O
TPN O
( O
Freamine O
HBC O
6.9 O
% O
and O
Trophamine O
6 O
% O
) O
; O
both O
regimens O
contained O
2.5 O
% O
fat O
, O
33 O
% O
branched O
chain O
amino O
acids O
, O
and O
had O
a O
calorie O
to O
nitrogen O
ratio O
of O
150:1 O
. O
[]

These O
were O
initial O
level O
of O
depression B-outcome ['Life-Impact']
, O
disability B-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
, O
beliefs O
about O
the O
consequences B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
arthritis I-outcome ['Physiological-Clinical']
and O
coping B-outcome ['Life-Impact']
strategies I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Changes O
in O
quality O
of O
life O
were O
assessed O
by O
self-report O
questionnaires O
administered O
at O
baseline O
and O
16 O
weeks O
. O
[]

Rectal B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
significantly O
less O
in O
the O
patients O
who O
received O
anesthesia O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
describe O
in O
detail O
the O
resources B-outcome ['Resource-use']
used O
and O
costs B-outcome ['Resource-use']
incurred I-outcome ['Resource-use']
in O
the O
clinical O
management O
of O
patients O
with O
insulin-dependent O
diabetes O
mellitus O
( O
IDDM O
) O
in O
the O
Diabetes O
Control O
and O
Complications O
Trial O
( O
DCCT O
) O
. O
['Resource-use', 'Resource-use']

Three O
hundred O
four O
patients O
entered O
the O
LTE O
( O
n O
= O
104 O
MI O
; O
n O
= O
113 O
LI O
; O
n O
= O
87 O
CsA O
) O
, O
and O
260 O
continued O
treatment O
through O
year O
5 O
( O
n O
= O
91 O
MI O
; O
n O
= O
100 O
LI O
; O
n O
= O
69 O
CsA O
) O
. O
[]

RESULTS O
Among O
the O
113 O
children O
with O
SCA O
studied O
in O
two O
hospitals O
, O
the O
58 O
receiving O
lime O
treatment O
had O
lower O
rates O
of O
significant B-outcome ['Physiological-Clinical']
painful I-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
than O
the O
55 O
without O
lime O
( O
37 O
versus O
83 O
crises O
in O
6 O
months O
, O
and O
0.64?0.11 O
versus O
1.51?0.34 O
average O
rates O
per O
child O
, O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

At O
this O
point O
, O
there O
was O
a O
significant O
improvement O
to O
mean O
diet O
group O
scores O
( O
time*treatment O
interaction O
) O
on O
sub-domains O
of O
[]

[ O
Pilot O
results O
of O
using O
tamsulone-FS O
in O
patients O
with O
prostatic O
adenoma O
according O
to O
the O
results O
of O
a O
randomized O
multicenter O
comparative O
trial O
] O
. O
[]

Sequential O
alternate O
administration O
of O
tamoxifen O
and O
medroxyprogesterone O
acetate O
in O
advanced O
breast O
cancer O
: O
clinical-biological O
randomized O
study O
. O
[]

Allelic B-outcome ['Physiological-Clinical']
imbalance I-outcome ['Physiological-Clinical']
in O
the O
clonal O
evolution O
of O
prostate O
carcinoma O
. O
['Physiological-Clinical']

Hyperoxia O
increases O
the O
level O
of O
exhaled O
NO O
, O
which O
indicates O
increased O
NO O
production O
. O
[]

More O
patients O
sensitized O
at O
baseline O
became O
non-sensitized O
at O
M12 O
with O
Tac/MMF O
than O
with O
CsA/AZA O
. O
[]

Also O
, O
the O
pediatric O
nurse O
must O
educate O
parents O
and O
children O
about O
this O
disease O
to O
prepare O
them O
for O
discharge O
and O
long-term O
follow-up O
care O
. O
[]

The O
only O
independent O
determinant O
of O
left O
ventricular O
thrombosis O
is O
the O
extent O
of O
the O
akinetic-dyskinetic O
area O
detected O
on O
echocardiography O
between O
24-48 O
hours O
from O
symptom O
onset O
. O
[]

These O
effect O
sizes O
were O
large O
. O
[]

A O
single O
experienced O
operator O
, O
blinded O
to O
the O
study O
drug O
, O
subjectively O
determined O
the O
presence O
of O
spasm B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

At O
3 O
months O
, O
17 O
of O
56 O
patients O
receiving O
zoledronic O
acid O
versus O
25 O
of O
53 O
patients O
who O
did O
not O
receive O
zoledronic O
acid O
had O
detectable O
DTCs O
( O
p=0.054 O
) O
. O
[]

In O
conclusion O
, O
lisinopril O
administration O
reduces O
arterial B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
and O
improves B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
in O
elderly O
hypertensive O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Although O
our O
encouraging O
preliminary O
results O
must O
be O
validated O
by O
double-blind O
histological O
trials O
, O
UDCA O
may O
be O
an O
alternative O
treatment O
for O
patients O
who O
fail O
to O
respond O
to O
interferon O
therapy O
. O
[]

In O
1987 O
, O
we O
designed O
a O
randomized O
study O
to O
evaluate O
the O
potential O
benefit O
of O
a O
high-dose O
regimen O
containing O
cyclophosphamide O
, O
carmustine O
, O
and O
etoposide O
( O
CBV O
) O
followed O
by O
autotransplantation O
over O
a O
consolidative O
sequential O
chemotherapy O
( O
ifosfamide O
, O
etoposide O
, O
asparaginase O
, O
and O
cytarabine O
) O
in O
patients O
in O
first O
complete O
remission O
with O
intermediate- O
and O
high-grade O
non-Hodgkin O
's O
lymphoma O
. O
[]

Serum O
selenium O
concentration O
and O
antioxidant O
activity O
in O
cervical O
cancer O
patients O
before O
and O
after O
treatment O
. O
[]

Heparin O
resistance O
was O
diagnosed O
when O
the O
activated O
clotting O
time O
was O
less O
than O
480 O
s O
after O
400 O
U/kg O
heparin O
. O
[]

had O
marginally O
significant O
further O
increase O
in O
12-h O
mean O
DBP O
( O
P O
= O
0.053 O
) O
, O
but O
group O
B O
( O
600 O
mg O
b.i.d O
. O
) O
[]

Fracture B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
was O
measured O
by O
applying O
point O
force O
at O
130 O
degrees O
to O
the O
long O
axis O
of O
the O
teeth O
on O
an O
universal O
testing O
machine O
. O
['Physiological-Clinical']

The O
pharmacokinetics B-outcome ['Physiological-Clinical']
and O
safety O
of O
hyperimmune O
anti-human O
immunodeficiency O
virus O
( O
HIV O
) O
intravenous O
immunoglobulin O
( O
HIVIG O
) O
were O
evaluated O
in O
the O
first O
28 O
maternal-infant O
pairs O
enrolled O
in O
a O
randomized O
, O
intravenous O
immunoglobulin O
( O
IVIG O
) O
-controlled O
trial O
of O
HIVIG O
maternal-infant O
HIV O
transmission O
prophylaxis O
. O
['Physiological-Clinical']

Comparable O
patencies O
of O
the O
radial O
artery O
and O
right O
internal O
thoracic O
artery O
or O
saphenous O
vein O
beyond O
5 O
years O
: O
results O
from O
the O
Radial O
Artery O
Patency O
and O
Clinical O
Outcomes O
trial O
. O
[]

The O
flexion O
group O
had O
the O
knee O
flexed O
to O
30? O
during O
this O
period O
. O
[]

Multiple O
measures O
of O
cigarette O
smoking O
, O
subjective O
effect O
and O
physiological O
effect O
were O
collected O
during O
90-min O
test O
sessions O
in O
normal O
volunteers O
. O
[]

OBJECTIVE O
To O
investigate O
whether O
artificial O
tears O
and O
cold O
compress O
alone O
or O
in O
combination O
provide O
a O
treatment O
benefit O
and O
whether O
they O
were O
as O
effective O
as O
or O
could O
enhance O
topical O
antiallergic O
medication O
. O
[]

We O
aimed O
to O
compare O
the O
response O
to O
once O
daily O
eltrombopag O
versus O
placebo O
in O
patients O
with O
chronic O
immune O
thrombocytopenia O
during O
a O
6-month O
period O
. O
[]

Echocardiography O
is O
used O
to O
measure O
the O
therapeutic O
effectiveness O
of O
heart O
failure O
therapy O
in O
adults O
and O
children O
. O
[]

Range O
of O
motion B-outcome ['Life-Impact']
, O
Constant O
score O
, O
Oxford O
Shoulder B-outcome ['Physiological-Clinical']
Score O
, O
Short O
Form O
36 O
, O
and O
Hospital O
Anxiety B-outcome ['Life-Impact']
and O
Disability O
Scale O
( O
HADS O
) O
outcome O
measures O
were O
performed O
at O
baseline O
, O
6 O
weeks O
, O
6 O
months O
, O
and O
1 O
year O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Local O
and O
systemic O
reactions O
were O
recorded O
for O
28 O
days O
postvaccination O
. O
[]

Two O
preplanned O
comparisons O
were O
made O
: O
( O
a O
) O
Spinal O
manipulative O
therapy O
( O
SMT O
) O
combined O
with O
trunk O
strengthening O
exercises O
( O
TSE O
) O
vs. O
SMT O
combined O
with O
trunk O
stretching O
exercises O
, O
and O
( O
b O
) O
SMT O
combined O
with O
TSE O
vs. O
nonsteroidal O
anti-inflammatory O
drug O
( O
NSAID O
) O
therapy O
combined O
with O
TSE O
. O
[]

It O
was O
the O
aim O
of O
this O
double-blind O
study O
to O
compare O
the O
PBSC-mobilizing O
efficacy O
of O
recombinant O
human O
G-CSF O
and O
GM-CSF O
when O
administered O
post-chemotherapy O
. O
[]

OBJECTIVE O
To O
compare O
the O
effects O
of O
a O
pill O
containing O
drospirenone O
with O
those O
of O
a O
combined O
contraceptive O
vaginal O
ring O
on O
the O
lipid O
and O
carbohydrate O
metabolism O
and O
on O
the O
surrogate O
markers O
of O
arterial O
function O
. O
[]

[ O
Clinical O
observation O
on O
acupuncture O
for O
treatment O
of O
male O
osteoporosis O
] O
. O
[]

RESULTS O
At O
6 O
months O
, O
both O
groups O
showed O
a O
significant O
improvement O
in O
best-corrected B-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
( O
both O
, O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Furthermore O
, O
a O
consistent O
increase O
in O
[]

No O
significant O
dose O
related O
changes O
were O
observed O
in O
the O
renal B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
3-MX I-outcome ['Physiological-Clinical']
, O
1-MU O
and O
DMU O
, O
indicating O
linear O
urinary O
excretion O
kinetics O
of O
the O
metabolites O
. O
['Physiological-Clinical']

Drug O
efficacy O
was O
measured O
by O
ventricular B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
and O
conversion B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
sinus I-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Basal B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
TCr I-outcome ['Physiological-Clinical']
content O
was O
lower O
( O
P O
< O
0.05 O
) O
in O
VEG O
compared O
with O
NVEG O
. O
['Physiological-Clinical']

In O
only O
one O
case O
there O
was O
heartburn B-outcome ['Physiological-Clinical']
and O
this O
was O
corrected O
with O
alkalines O
. O
['Physiological-Clinical']

Human O
maxillary O
central O
incisors O
( O
n O
= O
70 O
) O
were O
instrumented O
with O
a O
rotary O
NiTi O
system O
and O
filled O
. O
[]

At O
4 O
months O
postextraction O
, O
a O
trephine O
core O
was O
obtained O
for O
histologic B-outcome ['Physiological-Clinical']
analysis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Neridronate O
is O
an O
effective O
treatment O
in O
preventing O
bone B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
the O
hip O
and O
lumbar O
spine O
in O
men O
receiving O
ADT O
for O
prostate O
cancer O
. O
['Physiological-Clinical']

RESULTS O
Reductions O
in O
lung O
impedance B-outcome ['Physiological-Clinical']
during O
suctioning O
were O
less O
for O
CS O
than O
for O
OS O
( O
mean O
difference O
, O
-905 O
impedance O
units O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
-1234 O
to O
-587 O
; O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

[ O
Treating O
rheumatoid O
arthritis O
patients O
of O
Shen O
deficiency O
and O
cold O
invading O
syndrome O
by O
bushen O
quhan O
zhiwang O
decoction O
combined O
methotrexate O
: O
an O
evaluation O
of O
clinical O
efficacy O
and O
safety O
] O
. O
[]

Placebo-controlled O
pilot O
trial O
of O
mecamylamine O
for O
treatment O
of O
autism B-outcome ['Life-Impact']
spectrum O
disorders B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

In O
the O
second-line O
treatment O
of O
advanced O
breast O
carcinoma O
, O
fulvestrant O
was O
shown O
previously O
to O
be O
as O
effective O
as O
the O
third-generation O
aromatase O
inhibitor O
, O
anastrozole O
, O
in O
terms O
of O
time O
to O
disease O
progression O
and O
objective O
response O
rates O
. O
[]

In O
the O
first O
visit O
, O
electible O
patients O
after O
written O
informed O
consent O
were O
randomized O
to O
receive O
HT O
plus O
local O
estriol O
or O
placebo O
. O
[]

RESULTS O
The O
concentration O
of O
[]

Ovulation O
was O
defined O
as O
a O
midluteal O
phase O
serum O
P O
level O
? O
[]

In O
contrast O
to O
its O
effect O
on O
the O
pulmonary O
vasculature O
prior O
treatment O
with O
frusemide O
did O
not O
significantly O
alter O
systemic B-outcome ['Physiological-Clinical']
haemodynamic I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
either O
at O
baseline O
or O
during O
hypoxia O
. O
['Physiological-Clinical']

This O
technique O
requires O
several O
orthogonal O
projections O
. O
[]

Patients O
rated O
their O
change O
in O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
emotional B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
functioning B-outcome ['Life-Impact']
, O
and O
overall/global B-outcome ['Life-Impact']
quality O
of O
life O
( O
QOL B-outcome ['Life-Impact']
) O
by O
completing O
a O
seven-category O
SSQ O
at O
weeks O
4 O
and O
7 O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
proposed O
dosing O
algorithm O
resulted O
in O
adequate O
levels O
for O
patients O
with O
CrCl O
greater O
than O
50 O
ml/min O
and O
for O
patients O
on O
dialysis O
. O
[]

As O
part O
of O
an O
ongoing O
study O
of O
mechanisms O
of O
interferon O
action O
, O
we O
have O
evaluated O
toxicity O
in O
a O
two-arm O
protocol O
in O
which O
patients O
were O
randomly O
assigned O
to O
receive O
lymphoblastoid O
interferon O
by O
either O
a O
low-dose O
treatment O
strategy O
( O
2 O
X O
10 O
( O
6 O
) O
units/m2 O
daily O
X O
28 O
days O
then O
daily O
X O
5 O
days O
every O
other O
week O
by O
im O
injection O
) O
or O
a O
high-dose O
treatment O
strategy O
( O
5 O
X O
10 O
( O
6 O
) O
units/m2 O
by O
continuous O
iv O
infusion O
over O
24 O
hours O
, O
escalating O
by O
5 O
X O
10 O
( O
6 O
) O
units/m2/day O
as O
tolerated O
over O
10 O
days O
, O
repeated O
every O
28 O
days O
) O
. O
[]

Patients O
were O
classed O
into O
four O
groups O
: O
Group O
F O
, O
16 O
cases O
who O
received O
a O
single O
administration O
of O
5-fluorouracil O
( O
5-FU O
) O
; O
Group O
C O
, O
15 O
cases O
who O
received O
a O
single O
administration O
of O
cis-diamminedichloroplatinum O
( O
CDDP O
; O
cisplatin O
) O
; O
Group O
FC O
, O
16 O
cases O
who O
received O
both O
5-FU+CDDP O
; O
and O
a O
Control O
group O
, O
16 O
cases O
who O
did O
not O
receive O
chemotherapy O
. O
[]

The O
primary O
efficacy O
measures O
were O
response O
latencies O
to O
visually O
presented O
stimuli O
requiring O
two O
different O
types O
of O
attention-controlled B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
, O
i.e. O
, O
focused B-outcome ['Life-Impact']
and O
divided B-outcome ['Life-Impact']
attention B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Data O
were O
analyzed O
using O
software O
that O
digitized O
the O
TEE O
images O
and O
quantified O
the O
area O
of O
embolic O
particles O
in O
each O
frame O
. O
[]

RESULTS O
With O
respect O
to O
operation O
time O
, O
the O
DCS O
group O
presented O
significantly O
better O
results O
than O
the O
RIMSN O
group O
( O
p=0.000 O
) O
. O
[]

UNLABELLED O
We O
conducted O
a O
randomized O
, O
sham-controlled O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rTMS O
) O
study O
in O
chronic O
schizophrenia O
in-patients O
( O
n=35 O
) O
to O
evaluate O
the O
therapeutic O
efficacy O
of O
10 O
Hz O
stimulation O
. O
[]

The O
role O
of O
platelet O
glycoprotein O
IIb/IIIa O
inhibitor O
therapy O
in O
patients O
with O
mild O
renal O
impairment O
is O
not O
well O
characterized O
. O
[]

MEASUREMENTS O
Urine B-outcome ['Physiological-Clinical']
benzoylecgonine I-outcome ['Physiological-Clinical']
( O
BE B-outcome ['Physiological-Clinical']
) O
concentrations B-outcome ['Physiological-Clinical']
, O
self-report O
of O
cocaine B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
and O
global B-outcome ['Physiological-Clinical']
impression I-outcome ['Physiological-Clinical']
scores O
served O
as O
primary O
outcome O
measures O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

No O
other O
marine O
food O
products O
significantly O
predicted O
RBC O
EPA O
+ O
DHA O
concentration O
. O
[]

When O
BMS-181101 O
was O
administered O
with O
food O
, O
Cmax B-outcome ['Physiological-Clinical']
was O
reduced O
by O
about O
25 O
% O
and O
['Physiological-Clinical']

The O
best O
clinical O
responders O
exhibited O
the O
clearest O
normalization O
of O
the O
elevated O
plasma B-outcome ['Physiological-Clinical']
chemistries I-outcome ['Physiological-Clinical']
, O
especially O
in O
C-terminal-beta-endorphin O
and O
serotonin O
. O
['Physiological-Clinical']

Sixty O
children O
participated O
from O
56 O
classrooms O
in O
30 O
schools O
. O
[]

No O
statistically O
significant O
differences O
in O
response O
rates O
between O
the O
two O
groups O
were O
observed O
: O
20 O
% O
in O
the O
control O
group O
( O
95 O
% O
CI O
: O
9 O
% O
-36 O
% O
) O
, O
25 O
% O
in O
the O
PC O
group O
( O
95 O
% O
CI O
: O
13 O
% O
-41 O
% O
, O
P O
= O
0.59 O
) O
. O
[]

SETTING O
Hysteroscopy O
units O
in O
two O
university O
hospitals O
and O
in O
a O
private O
center O
. O
[]

Circulating O
concentrations O
of O
pro- O
and O
anti-inflammatory O
mediators O
were O
measured O
before O
and O
after O
the O
1-year O
intervention O
. O
[]

The O
comparison O
acupuncture O
treatment O
consisted O
of O
a O
treatment O
designated O
as O
a O
general O
tonic O
specifically O
designed O
to O
benefit O
the O
flow O
of O
Ch'i O
( O
energy O
) O
. O
[]

In O
the O
trimethoprim-sulfamethoxazole O
arm O
, O
7 O
of O
17 O
women O
( O
41 O
% O
) O
with O
a O
trimethoprim-sulfamethoxazole-nonsusceptible O
isolate O
had O
a O
clinical O
cure O
compared O
with O
84 O
% O
of O
women O
with O
a O
trimethoprim-sulfamethoxazole-susceptible O
isolate O
( O
P O
< O
.001 O
) O
. O
[]

Response O
was O
defined O
as O
much O
improved O
or O
very O
much O
improved O
on O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions I-outcome ['Physiological-Clinical']
Improvement O
item O
coupled O
with O
considerable O
reductions O
in O
the O
parent-rated O
and/or O
teacher-rated O
Aberrant O
Behavior O
Checklist O
hyperactivity B-outcome ['Life-Impact']
subscale O
score O
. O
['Physiological-Clinical', 'Life-Impact']

Neuropsychological B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
after O
psychosocial O
intervention O
for O
depression O
in O
Parkinson O
's O
disease O
. O
['Physiological-Clinical']

Teachers O
of O
the O
intervention O
classes O
led O
a O
10 O
min O
activity O
break O
in O
the O
classroom O
each O
day O
( O
Bizzy O
Break O
! O
) O
. O
[]

The O
drug O
and O
placebo O
were O
administered O
in O
a O
double-blind O
crossover O
design O
over O
17 O
weeks O
. O
[]

Adults O
with O
a O
history O
of O
reflux O
symptoms O
, O
a O
negative O
endoscopy O
, O
and O
> O
or O
= O
3 O
days O
of O
moderate O
to O
very O
severe O
heartburn O
in O
the O
7 O
days O
before O
enrollment O
( O
N O
= O
535 O
) O
entered O
4 O
weeks O
of O
open-label O
, O
acute O
treatment O
with O
rabeprazole O
10 O
mg O
once O
daily O
. O
[]

INTERVENTION O
An O
IV O
injection O
of O
either O
17 O
mL O
of O
ferumoxytol O
or O
saline O
placebo O
over O
17 O
seconds O
on O
day O
0 O
and O
the O
alternate O
agent O
on O
day O
7 O
. O
[]

Following O
treatment O
with O
ORG O
2766 O
gaze O
and O
[]

The O
trial O
will O
monitor O
cause-specific O
mortality O
and O
major O
clinical O
events O
associated O
with O
each O
treatment O
. O
[]

Effectiveness O
of O
cetrorelix O
for O
the O
prevention O
of O
premature B-outcome ['Physiological-Clinical']
luteinizing I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
surge I-outcome ['Physiological-Clinical']
during O
controlled O
ovarian O
stimulation O
using O
letrozole O
and O
gonadotropins O
: O
a O
randomized O
trial O
. O
['Physiological-Clinical']

CONCLUSIONS O
Our O
results O
reveal O
the O
existence O
of O
a O
specific O
[]

Subgingival B-outcome ['Physiological-Clinical']
bacterial I-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
taken O
with O
curettes O
from O
the O
same O
sites O
. O
['Physiological-Clinical']

OBJECTIVES O
Current O
guidelines O
for O
the O
initial O
treatment O
of O
bipolar O
type O
II O
( O
BP O
II O
) O
major O
depressive O
episode O
( O
MDE O
) O
recommend O
using O
either O
a O
mood O
stabilizer O
alone O
or O
a O
combination O
of O
a O
mood O
stabilizer O
plus O
a O
selective O
serotonin O
re-uptake O
inhibitor O
( O
SSRI O
) O
. O
[]

BACKGROUND O
Inhibition O
of O
neointimal O
tissue O
growth O
has O
been O
demonstrated O
in O
preliminary O
human O
feasibility O
studies O
with O
a O
stent-based O
polymer O
sleeve O
delivering O
7-hexanoyltaxol O
. O
[]

Before O
the O
ISDN O
treatment O
, O
GTN O
reduced O
exercise O
PAWP B-outcome ['Physiological-Clinical']
to O
13.9 O
+/- O
5.27 O
mmHg O
and O
MAP O
to O
119 O
+/- O
11.2 O
mmHg O
, O
whereas O
after O
4 O
weeks O
ISDN O
treatment O
, O
the O
addition O
of O
GTN O
did O
not O
reduce O
exercise O
PAWP B-outcome ['Physiological-Clinical']
and O
MAP B-outcome ['Physiological-Clinical']
to O
the O
same O
low O
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
efficacy O
parameter O
will O
be O
the O
percentage O
change O
in O
HDL-C B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

All O
subjects O
underwent O
assessment O
of O
levels O
for O
creatinine B-outcome ['Physiological-Clinical']
, O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
, O
average O
pressure B-outcome ['Physiological-Clinical']
, O
total O
cholesterol B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
triglyceride I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
fasting I-outcome ['Physiological-Clinical']
homocysteine I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Early O
treatment O
of O
cold O
sores O
with O
topical O
ME-609 O
decreases O
the O
frequency O
of O
ulcerative B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
patient-initiated O
clinical O
trial O
. O
['Physiological-Clinical']

All O
side O
effects O
resolved O
spontaneously O
after O
termination O
of O
treatment O
. O
[]

Effect O
of O
sensory O
stimulation O
( O
acupuncture O
) O
on O
sympathetic O
and O
parasympathetic O
activities O
in O
healthy O
subjects O
. O
[]

To O
assess O
the O
antiviral O
efficacy O
, O
HIV-1 O
RNA O
was O
determined O
at O
baseline O
, O
day O
3 O
, O
day O
7 O
and O
weekly O
thereafter O
. O
[]

There O
was O
also O
a O
statistically O
significant O
difference O
between O
treatments O
in O
the O
number O
of O
participants O
whose O
changes O
in O
Visual O
Analog O
Scale O
scores O
met O
the O
study O
definition O
of O
success O
at O
both O
6 O
weeks O
and O
3 O
months O
posttreatment O
; O
and O
between O
treatment O
groups O
in O
the O
change O
from O
baseline O
to O
3 O
months O
posttreatment O
in O
the O
Roles O
and O
Maudsley O
Score O
. O
[]

colchicine O
. O
[]

HRs O
( O
three-class O
vs O
combined O
two-class O
) O
for O
AIDS B-outcome ['Physiological-Clinical']
or O
death B-outcome ['Mortality']
were O
similar O
for O
participants O
with O
baseline O
CD4 O
cell O
counts O
of O
200 O
cells O
per O
mm3 O
or O
less O
and O
of O
more O
than O
200 O
cells O
per O
mm3 O
( O
p=0.38 O
for O
interaction O
) O
, O
and O
for O
participants O
with O
baseline O
HIV O
RNA O
concentrations O
less O
than O
100 O
000 O
copies O
per O
mL O
and O
100,000 O
copies O
per O
mL O
or O
more O
( O
p=0.26 O
for O
interaction O
) O
. O
['Physiological-Clinical', 'Mortality']

The O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
vitamin I-outcome ['Physiological-Clinical']
A I-outcome ['Physiological-Clinical']
supplementation I-outcome ['Physiological-Clinical']
prior O
to O
entry O
was O
inversely O
related O
to O
rate O
of O
decline O
in O
electroretinogram O
amplitude O
( O
P O
=.008 O
) O
. O
['Physiological-Clinical']

Multicyclic O
, O
dose-intensive O
chemotherapy O
supported O
by O
sequential O
reinfusion O
of O
hematopoietic O
progenitors O
in O
whole O
blood O
. O
[]

B-vitamins O
reduce O
plasma B-outcome ['Physiological-Clinical']
levels O
of O
beta O
amyloid O
. O
['Physiological-Clinical']

Mean O
change O
from O
baseline O
in O
peak O
urinary B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate O
( O
ml O
per O
second O
) O
2 O
to O
6 O
hours O
after O
initial O
dose O
was O
greater O
( O
p O
< O
0.0001 O
) O
with O
silodosin O
( O
2.8 O
+/- O
3.4 O
) O
than O
placebo O
( O
1.5 O
+/- O
3.8 O
) O
. O
['Physiological-Clinical']

However O
, O
group O
I O
exhibited O
a O
tendency O
toward O
a O
better O
stroke-work B-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
( O
135 O
+/- O
18 O
% O
vs. O
102 O
+/- O
5 O
% O
recovery O
15 O
minutes O
after O
bypass O
and O
145 O
+/- O
16 O
% O
vs. O
119 O
+/- O
11 O
% O
recovery O
105 O
min O
after O
bypass O
) O
. O
['Physiological-Clinical']

TIMI B-outcome ['Physiological-Clinical']
grade O
3 O
flow B-outcome ['Physiological-Clinical']
after O
primary O
PCI O
was O
obtained O
in O
85 O
% O
of O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

16.04 O
kg O
) O
were O
used O
to O
test O
the O
interactive O
effects O
, O
if O
any O
, O
of O
leptin O
R25C O
genotypes O
( O
CC O
, O
CT O
, O
or O
TT O
) O
and O
zilpaterol O
hydrochloride O
( O
ZH O
) O
feeding O
duration O
on O
growth O
performance O
and O
carcass O
traits O
. O
[]

2 O
patients O
in O
each O
group O
died O
with O
uncontrolled O
infection O
. O
[]

The O
mean O
change O
from O
baseline O
to O
11 O
years O
in O
Larsen B-outcome ['Physiological-Clinical']
score I-outcome ['Physiological-Clinical']
was O
17 O
( O
95 O
% O
CI O
, O
12 O
to O
26 O
) O
in O
the O
FIN-RACo O
group O
and O
27 O
( O
95 O
% O
CI O
, O
22 O
to O
33 O
) O
in O
the O
SINGLE O
group O
( O
P=0.037 O
) O
. O
['Physiological-Clinical']

The O
scalp B-outcome ['Physiological-Clinical']
distribution O
of O
ERP B-outcome ['Physiological-Clinical']
maxima O
changes O
slightly O
with O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Randomised O
, O
crossover O
, O
double O
blind O
, O
and O
placebo O
controlled O
trial O
of O
a O
single O
intravenous O
dose O
of O
human O
synthetic O
secretin O
( O
HSS O
) O
2 O
CU/kg O
. O
[]

Although O
participants O
were O
more O
likely O
to O
recommend B-outcome ['Physiological-Clinical']
TKR I-outcome ['Physiological-Clinical']
when O
completing O
the O
implicit O
association O
test O
before O
the O
decision O
, O
patient O
race O
was O
not O
significant O
in O
the O
association O
( O
P O
= O
.960 O
) O
. O
['Physiological-Clinical']

SETTING O
An O
oral O
medicine O
specialist O
referral O
center O
in O
Manchester O
. O
[]

OBJECTIVE O
To O
determine O
the O
effect O
of O
nonlinear O
frequency O
compression O
( O
NLFC O
) O
on O
children O
's O
development O
of O
speech O
and O
language O
at O
three O
years O
of O
age O
. O
[]

BACKGROUND O
It O
is O
known O
that O
the O
bifidobacteria O
flora O
play O
important O
roles O
in O
mucosal O
host O
defense O
and O
can O
prevent O
infectious O
diseases O
. O
[]

The O
nature O
and O
importance O
of O
changes O
in O
toe-brachial O
pressure O
indices O
following O
percutaneous O
transluminal O
angioplasty O
for O
leg O
ischaemia O
. O
[]

The O
pharmacokinetic O
parameters O
Cmax O
, O
AUC0-t O
, O
AUC0-? O
, O
tmax O
, O
and O
t1/2 O
were O
determined O
from O
plasma O
concentration-time O
profiles O
. O
[]

A O
controlled O
study O
was O
designed O
to O
clarify O
the O
indications O
for O
antibiotic O
therapy O
in O
children O
with O
advanced O
cystic O
fibrosis O
hospitalized O
with O
respiratory O
exacerbations O
. O
[]

RESULTS O
127 O
patients O
were O
randomised O
to O
either O
desmopressin O
( O
n=61 O
) O
or O
placebo O
( O
n=66 O
) O
. O
[]

Low-dose O
, O
vaginally O
administered O
estrogens O
may O
enhance O
local O
benefits O
of O
systemic O
therapy O
in O
the O
treatment O
of O
urogenital O
atrophy O
in O
postmenopausal O
women O
on O
hormone O
therapy O
. O
[]

There O
was O
a O
statistically O
significant O
correlation O
between O
the O
incidence O
of O
cardiovascular B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
and O
a O
history O
of O
previous O
cardiovascular O
disease O
. O
['Physiological-Clinical']

After O
3 O
months O
, O
11/19 O
( O
57.9 O
% O
) O
PPI-treated O
patients O
had O
a O
complete O
resolution B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
; O
6/8 O
nonresponders O
were O
treated O
with O
PPI O
for O
another O
3 O
months O
and O
became O
all O
symptom-free B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
AND O
PURPOSE O
Elevated O
serum O
uric O
acid O
level O
is O
associated O
with O
poor O
outcome O
and O
increased O
risk O
of O
recurrent O
events O
after O
stroke O
. O
[]

BACKGROUND O
Having O
a O
'theory O
of O
mind O
' O
, O
or O
having O
the O
ability O
to O
attribute O
mental O
states O
to O
oneself O
or O
others O
, O
is O
considered O
one O
of O
the O
most O
central O
domains O
of O
impairment O
among O
children O
with O
an O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

After O
2 O
years O
of O
treatment O
the O
mean O
( O
S.E O
. O
) O
[]

infusion O
of O
Ringer O
's O
solution O
25 O
ml O
kg-1 O
over O
30 O
min O
in O
15 O
healthy O
male O
volunteers O
( O
mean O
age O
31 O
yr O
) O
and O
over O
30 O
, O
45 O
and O
80 O
min O
in O
six O
females O
( O
mean O
age O
32 O
yr O
) O
. O
[]

In O
conclusion O
, O
the O
HI O
treadmill O
intervention O
significantly O
promoted O
earlier O
walking B-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
and O
elicited O
more O
advanced O
gait B-outcome ['Life-Impact']
patterns I-outcome ['Life-Impact']
( O
particularly O
in O
stride O
length O
) O
in O
infants O
with O
DS O
. O
['Life-Impact', 'Life-Impact']

We O
found O
that O
both O
increased O
gradually O
with O
motion B-outcome ['Life-Impact']
coherence O
and O
viewing B-outcome ['Life-Impact']
time O
, O
but O
discrimination B-outcome ['Life-Impact']
was O
systematically O
leading O
awareness O
, O
reaching O
a O
plateau B-outcome ['Physiological-Clinical']
much O
earlier O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Safety O
, O
clinical B-outcome ['Physiological-Clinical']
efficacy O
, O
survival B-outcome ['Mortality']
on I-outcome ['Mortality']
treatment I-outcome ['Mortality']
, O
and O
radiographic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
were O
evaluated O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
influence O
of O
diabetes O
on O
9-month O
outcomes O
of O
patients O
undergoing O
PCI O
in O
the O
current O
era O
. O
[]

Influence O
of O
the O
size O
of O
the O
antacid O
dose O
and O
of O
anticholinergics O
. O
[]

Eradication B-outcome ['Physiological-Clinical']
of O
H. O
pylori B-outcome ['Physiological-Clinical']
in O
the O
omeprazole-amoxycillin B-outcome ['Resource-use']
group O
was O
50 O
% O
and O
in O
the O
omeprazole O
placebo O
group O
0 O
% O
four O
weeks O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

METHOD O
Parent O
verbal O
utterances O
were O
coded O
from O
videotapes O
of O
naturalistic O
parent-child O
play O
sessions O
using O
interval O
and O
event-based O
coding O
. O
[]

A O
controlled O
trial O
of O
trimethoprim-sulfamethoxazole O
or O
aerosolized O
pentamidine O
for O
secondary O
prophylaxis O
of O
Pneumocystis O
carinii O
pneumonia O
in O
patients O
with O
the O
acquired O
immunodeficiency O
syndrome O
. O
[]

In O
a O
survival O
analysis O
of O
treatment O
compliance O
, O
a O
significant O
difference O
was O
found O
between O
groups O
T O
and O
C. O
At O
the O
6- O
and O
12-month O
follow-ups O
, O
a O
significant O
reduction O
in O
myofascial B-outcome ['Physiological-Clinical']
pain O
, O
as O
measured O
on O
a O
visual O
analog O
scale O
, O
was O
found O
in O
all O
three O
groups O
. O
['Physiological-Clinical']

Furthermore O
, O
training O
significantly O
improved O
contour B-outcome ['Life-Impact']
detection I-outcome ['Life-Impact']
, O
increasing O
the O
critical B-outcome ['Physiological-Clinical']
spacing I-outcome ['Physiological-Clinical']
of O
line O
elements O
beyond O
which O
contours O
were O
no O
longer O
detectable O
. O
['Life-Impact', 'Physiological-Clinical']

OBJECTIVES O
The O
rapid O
and O
accurate O
diagnosis O
of O
heart O
failure O
in O
primary O
care O
is O
a O
major O
unmet O
clinical O
need O
. O
[]

A O
selective O
induction O
test O
then O
examined O
context-dependent O
responding O
in O
a O
more O
complex O
matching O
task O
. O
[]

HIV B-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
at O
week O
4 O
and O
thereafter O
was O
significantly O
decreased O
from O
the O
baseline O
value O
in O
both O
groups O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Administration O
with O
40 O
% O
alcohol O
did O
not O
affect O
overall B-outcome ['Life-Impact']
morphine I-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
but O
was O
associated O
with O
a O
2-fold O
increase O
in O
C B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
reduction O
of O
t O
( O
max O
) O
from O
9 O
to O
4 O
hours O
versus O
MS-sNT O
taken O
with O
water O
. O
['Life-Impact', 'Physiological-Clinical']

High-pressure O
, O
rapid-inflation O
pneumatic O
compression O
improves O
venous O
hemodynamics O
in O
healthy O
volunteers O
and O
patients O
who O
are O
post-thrombotic O
. O
[]

The O
study O
was O
conducted O
as O
a O
single-blinded O
, O
parallel-cell O
trial O
. O
[]

After O
6 O
months O
, O
femoral B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
both O
in O
subjects O
treated O
with O
clodronate O
, O
both O
cyclically O
and O
continuously O
( O
P O
< O
.01 O
) O
, O
compared O
with O
controls O
. O
['Physiological-Clinical']

This O
study O
examined O
temporal O
changes O
in O
neurohormones B-outcome ['Physiological-Clinical']
related O
to O
cardiac O
remodeling O
and O
prognosis O
in O
patients O
with O
systolic O
dysfunction O
and O
heart O
failure O
receiving O
therapeutic O
inhibition O
of O
the O
renin-angiotensin-aldosterone O
system O
. O
['Physiological-Clinical']

Measurements O
of O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
, O
and O
visual B-outcome ['Physiological-Clinical']
fields I-outcome ['Physiological-Clinical']
were O
performed O
throughout O
the O
five O
years O
, O
with O
the O
clinician O
masked O
to O
the O
treatment O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Because O
this O
treatment O
did O
not O
prevent O
some O
radiographic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
, O
other O
approaches O
( O
e.g. O
, O
step-up O
approach O
) O
may O
be O
more O
appropriate O
in O
early O
RA O
. O
['Physiological-Clinical']

There O
is O
circumstantial O
evidence O
for O
an O
association O
between O
falls B-outcome ['Life-Impact']
and O
the O
syndrome O
. O
['Life-Impact']

Mood B-outcome ['Life-Impact']
and O
employment B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
showed O
no O
change O
. O
['Life-Impact', 'Life-Impact']

For O
them O
the O
sound-producing O
voice O
prosthesis O
improves B-outcome ['Physiological-Clinical']
voice I-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
and O
increases O
the O
average O
pitch B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
voice I-outcome ['Physiological-Clinical']
, O
without O
decreasing O
intelligibility O
or O
necessitating B-outcome ['Physiological-Clinical']
other O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
present O
study O
examined O
long-term O
efficacy O
outcomes O
in O
a O
subgroup O
of O
postmenopausal O
, O
estrogen O
receptor-positive O
Japanese O
breast O
cancer O
patients O
from O
the O
Pre-Operative O
Arimidex O
Compared O
with O
Tamoxifen O
trial O
, O
following O
pre-operative O
( O
3 O
months O
) O
and O
post-operative O
( O
5 O
years O
) O
adjuvant O
treatment O
with O
either O
anastrozole O
or O
tamoxifen O
. O
[]

RESULTS O
Over O
half O
of O
the O
carers O
reported O
some O
MH B-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
and O
a O
minority O
( O
5.4 O
% O
) O
were O
experiencing O
considerable O
difficulties O
. O
['Physiological-Clinical']

All O
three O
studied O
drugs O
resulted O
in O
a O
significant O
increase O
in O
the O
reactance B-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.01 O
) O
and O
decrease O
in O
resonant B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
The O
effect O
of O
thoracic O
peridural O
analgesia O
on O
the O
cortisol B-outcome ['Physiological-Clinical']
and O
glucose B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
surgery O
of O
the O
abdominal O
aorta O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Virtual O
reality O
exposure O
therapy O
and O
standard O
( O
in O
vivo O
) O
exposure O
therapy O
in O
the O
treatment O
of O
fear O
of O
flying O
. O
[]

Current O
equations O
for O
estimating O
water O
requirements O
in O
sheep O
do O
not O
differentiate O
between O
shorn O
and O
unshorn O
sheep O
. O
[]

METHODS O
Fifty-two O
patients O
with O
NTG O
( O
average O
age O
57.7 O
years O
) O
with O
an O
IOP O
that O
was O
consistently O
less O
than O
15 O
mmHg O
were O
randomly O
assigned O
to O
receive O
oral O
brovincamine O
( O
20 O
mg O
three O
times O
daily O
) O
or O
to O
an O
untreated O
control O
group O
. O
[]

Hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
longer O
for O
overweight O
patients O
than O
for O
normal-weight O
patients O
undergoing O
OA O
( O
3.0 O
vs O
2.0 O
, O
p O
< O
0.01 O
) O
. O
['Resource-use']

UNLABELLED O
The O
school O
dental O
screening O
programme O
has O
been O
in O
existence O
from O
the O
beginning O
of O
the O
20th O
century O
yet O
its O
value O
in O
encouraging O
attendance O
among O
children O
with O
a O
dental O
health O
need O
is O
not O
fully O
established O
. O
[]

They O
were O
randomly O
allocated O
to O
one O
of O
three O
groups O
( O
n O
= O
40 O
for O
each O
) O
: O
saline O
( O
as O
a O
control O
) O
, O
granisetron O
20 O
micrograms/kg O
, O
and O
granisetron O
40 O
micrograms/kg O
. O
[]

on O
days O
0 O
, O
7 O
and O
21 O
, O
but O
when O
given O
on O
days O
0 O
, O
28 O
and O
56 O
the O
responses O
were O
comparable O
. O
[]

The O
effects O
of O
physical O
and O
emotional O
status O
on O
adherence O
to O
a O
low-fat O
dietary O
pattern O
in O
the O
Women O
's O
Health O
Initiative O
. O
[]

When O
compared O
to O
the O
control O
group O
, O
time B-outcome ['Resource-use']
to I-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
need I-outcome ['Resource-use']
was O
increased O
and O
total O
analgesic B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
was O
reduced O
in O
the O
magnesium O
group O
( O
meperidine O
consumption O
60.0 O
+/- O
73.1 O
mg O
control O
group O
, O
31.8 O
+/- O
30.7 O
mg O
magnesium O
group O
, O
P O
= O
0.02 O
) O
. O
['Resource-use', 'Resource-use']

Application O
of O
ambulatory O
blood O
pressure O
monitoring O
to O
clinical O
therapeutic O
decisions O
in O
hypertension O
. O
[]

A O
total O
of O
84 O
evaluable O
women O
provided O
274 O
cycles O
of O
exposure O
in O
the O
LNG/EE O
group O
, O
and O
89 O
women O
provided O
289 O
cycles O
of O
exposure O
in O
the O
NETA/EE O
group O
. O
[]

Intraoperative O
suture O
line O
bleeding O
was O
subjectively O
evaluated O
by O
observing O
bleeding O
at O
3 O
and O
4 O
minutes O
following O
carotid O
cross-clamp O
removal O
and O
then O
objectively O
weighing O
the O
sponge O
used O
to O
tamponade O
bleeding O
during O
these O
time O
intervals O
. O
[]

Consequently O
, O
various O
adjunctive O
therapies O
have O
been O
investigated O
to O
improve O
clinical O
outcome O
. O
[]

Thus O
, O
the O
present O
study O
first O
examined O
the O
relationship O
of O
alexithymia O
to O
several O
other O
emotion B-outcome ['Life-Impact']
regulation I-outcome ['Life-Impact']
measures I-outcome ['Life-Impact']
and O
then O
investigated O
the O
impact O
of O
alexithymia O
on O
attrition O
and O
alcohol O
treatment O
outcomes O
in O
men O
and O
women O
( O
N=77 O
) O
enrolled O
in O
a O
12-week O
cognitive-behavioral O
intervention O
for O
alcohol O
dependence O
. O
['Life-Impact']

This O
induction O
regimen O
does O
not O
offer O
any O
advantages O
over O
standard O
treatment O
. O
[]

To O
study O
the O
regulation O
of O
the O
human O
immune O
response O
to O
hepatitis O
B O
surface O
antigen O
( O
HBsAg O
) O
we O
have O
carefully O
monitored O
the O
in O
vivo O
humoral O
and O
in O
vitro O
cellular O
immune O
responses O
to O
HBsAg O
in O
50 O
subjects O
receiving O
four O
doses O
of O
hepatitis O
B O
vaccine O
according O
to O
a O
0 O
, O
1 O
, O
2 O
, O
12 O
month O
vaccination O
scheme O
. O
[]

Both O
groups O
had O
definitive O
screw-retained O
metal-ceramic O
crowns O
placed O
in O
occlusion O
8 O
weeks O
later O
. O
[]

METHODS O
A O
total O
of O
121 O
HIV-infected O
patients O
with O
CD4+ O
cell O
counts O
< O
or O
= O
200 O
x O
10 O
( O
6 O
) O
/l O
or O
an O
AIDS O
diagnosis O
were O
enrolled O
in O
a O
controlled O
study O
of O
aerosolized O
pentamidine O
as O
primary O
PCP O
prophylaxis O
. O
[]

The O
present O
investigation O
was O
designed O
as O
a O
12-week O
, O
single-center O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
evaluating O
the O
effects O
of O
sildenafil O
on O
mean O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
primary O
endpoint O
) O
in O
patients O
with O
left O
systolic O
heart O
failure O
. O
['Physiological-Clinical']

KEY O
RESULTS O
Throughout O
extended O
wakefulness O
, O
the O
carriers O
of O
haplotype O
HT4 O
performed O
faster O
on O
the O
PVT O
than O
carriers O
of O
non-HT4 O
haplotype O
alleles O
. O
[]

This O
finding O
offers O
surgeons O
, O
for O
now O
, O
enhanced O
flexibility O
in O
planning O
revascularization O
. O
[]

Eligible O
patients O
were O
randomized O
to O
ALVAC O
followed O
by O
chemotherapy O
and O
booster O
vaccination O
( O
group O
1 O
) O
, O
ALVAC O
and O
tetanus O
toxoid O
followed O
by O
chemotherapy O
( O
group O
2 O
) O
, O
or O
chemotherapy O
alone O
followed O
by O
ALVAC O
in O
patients O
without O
disease O
progression O
( O
group O
3 O
) O
. O
[]

CIU O
patients O
with O
treatment O
failure O
under O
fexofenadine O
at O
180 O
mg O
q.d O
. O
[]

The O
effects O
of O
fluoride O
and O
chlorhexidine O
varnishes O
on O
the O
microflora O
of O
dental O
root O
surfaces O
and O
on O
the O
progression O
of O
root-surface O
caries O
were O
studied O
. O
[]

Closed O
suction O
( O
CS O
) O
minimizes O
lung O
volume O
loss O
during O
suction O
, O
and O
therefore O
, O
volumes O
are O
presumed O
to O
recover O
more O
quickly O
postsuctioning O
. O
[]

Although O
group O
differences O
were O
small O
, O
BLT O
led O
to O
significant O
improvement O
of O
tremor O
, O
UPDRS O
I O
, O
II O
, O
and O
[]

We O
investigated O
the O
direct O
effect O
of O
a O
nutrition O
intervention O
in O
early O
childhood O
on O
adult O
economic O
productivity O
. O
[]

Recurrence O
of O
atrial B-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
was O
documented O
by O
electrocardiogram O
. O
['Physiological-Clinical']

Further O
, O
only O
one O
DA O
has O
utilized O
an O
interactive O
web-based O
format O
, O
which O
allows O
for O
an O
expansion O
and O
customization O
of O
the O
material O
. O
[]

Coronary O
flow O
in O
the O
infarct-related O
artery O
was O
defined O
using O
the O
TIMI O
criteria O
. O
[]

Follow-up O
was O
conducted O
for O
( O
13+/-7 O
) O
( O
3-24 O
) O
months O
to O
observe O
the O
necrosis B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
, O
size O
of O
tumor B-outcome ['Physiological-Clinical']
, O
local B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
, O
and O
survival B-outcome ['Mortality']
of I-outcome ['Mortality']
patient I-outcome ['Mortality']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Duration O
of O
treatment O
is O
6 O
months O
. O
[]

We O
studied O
the O
correlation O
between O
response O
to O
fluvoxamine O
and O
serotonin O
transporter O
gene O
promoter O
region O
polymorphism O
( O
5-HTTLPR O
) O
. O
[]

The O
aim O
of O
the O
study O
was O
to O
investigate O
efficacy O
, O
safety O
and O
tolerability O
of O
bibrocathol O
( O
Posiformin? O
2 O
% O
) O
eye O
ointment O
in O
patients O
diagnosed O
with O
blepharitis O
. O
[]

Dose-dependent O
effects O
of O
the O
CRF O
( O
1 O
) O
receptor O
antagonist O
R317573 O
on O
regional O
brain O
activity O
in O
healthy O
male O
subjects O
. O
[]

The O
study O
included O
60 O
patients O
with O
A O
degree O
of O
ERD O
, O
consistently O
received O
in-patient O
treatment O
in O
the O
Municipal O
KGVV O
, O
mean O
age O
79.0 O
+/- O
6.8 O
years O
. O
[]

Intervention O
for O
ineffective O
airway B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
in O
asthmatic O
children O
: O
a O
controlled O
and O
randomized O
clinical O
trial O
. O
['Physiological-Clinical']

We O
have O
evaluated O
the O
effects O
of O
orally O
administered O
enalapril O
on O
angiotensin O
II O
induced O
vasoconstriction O
in O
the O
human O
forearm O
. O
[]

Irrespective O
of O
MIC O
and O
dose O
of O
mefloquine O
, O
parasitaemia O
cleared O
in O
all O
subjects O
in O
96 O
h O
or O
less O
. O
( O
[]

Randomized O
study O
of O
continuous O
infusion O
fluorouracil O
versus O
fluorouracil O
plus O
cisplatin O
in O
patients O
with O
metastatic O
colorectal O
cancer O
. O
[]

INTERPRETATION O
ACE O
inhibitors O
did O
not O
enhance O
the O
effect O
of O
exercise O
training O
on O
physical O
function O
in O
functionally O
impaired O
older O
people O
. O
[]

The O
low-dose O
MEG-X O
test O
gives O
almost O
identical O
results O
to O
the O
standard O
MEG-X O
test O
and O
is O
associated O
with O
fewer O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
which O
occur O
less O
often O
in O
individuals O
with O
more O
severely O
compromised O
liver O
function O
. O
['Adverse-effects']

Patients O
with O
preoperative O
CEA O
levels O
< O
5.0 O
ng/ml O
were O
excluded O
. O
[]

1773 O
( O
30 O
% O
of O
5997 O
) O
untreated O
subjects O
had O
a O
blood O
pressure O
of O
140/90 O
or O
above O
; O
16 O
% O
in O
the O
low- O
, O
62 O
% O
in O
the O
medium- O
, O
8 O
% O
in O
the O
high- O
, O
and O
14 O
% O
in O
the O
very-high-risk O
group O
. O
[]

RESULTS O
A O
statistically O
significant O
difference O
( O
P O
< O
0.0001 O
) O
was O
observed O
between O
Er O
: O
YAG O
laser O
prepared O
and O
etched O
specimens O
and O
those O
in O
the O
other O
groups O
. O
[]

A O
significant O
increase O
in O
endometritis B-outcome ['Physiological-Clinical']
and O
a O
trend O
toward O
an O
increase O
in O
neonatal B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
cesarean I-outcome ['Physiological-Clinical']
section I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
were O
noted O
with O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eligibility O
criteria O
included O
WHO O
performance O
status O
0-2 O
, O
documented O
inoperable O
stage O
IIIA O
and O
IIIB O
, O
IV O
, O
no O
brain O
metastasis O
, O
no O
prior O
chemotherapy O
and O
adequate O
renal O
and O
hepatic O
function O
. O
[]

CONCLUSION O
MDD O
patients O
were O
able O
to O
utilize B-outcome ['Life-Impact']
predictive I-outcome ['Life-Impact']
context I-outcome ['Life-Impact']
in O
order O
to O
facilitate O
processing O
of O
deterministic O
targets O
, O
however O
, O
this O
ability B-outcome ['Life-Impact']
was O
limited O
compared O
to O
controls O
, O
as O
demonstrated O
by O
context-dependent O
P3b O
deficits O
. O
['Life-Impact', 'Life-Impact']

For O
the O
variables O
reported O
, O
the O
visit O
schedules O
studied O
are O
similar O
in O
their O
clinical O
effectiveness O
. O
[]

Secondary O
outcomes O
included O
blood B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
, O
fasting B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
and O
insulin B-outcome ['Resource-use']
levels O
and O
side B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
elevated I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
increased O
dietary B-outcome ['Life-Impact']
fiber I-outcome ['Life-Impact']
intake B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Twenty-six O
women O
were O
randomized O
to O
a O
10-week O
exercise O
program O
and O
24 O
were O
randomized O
as O
controls O
. O
[]

A O
statistical O
comparison O
of O
the O
pharmacokinetic O
parameters O
did O
not O
demonstrate O
bioequivalence O
of O
the O
two O
products O
. O
['Physiological-Clinical']

Patients O
on O
antihistamines O
with O
or O
without O
doxepin O
had O
the O
highest O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
although O
more O
of O
these O
patients O
reported O
a O
greater O
degree O
of O
relief B-outcome ['Physiological-Clinical']
than O
patients O
on O
pentoxifylline O
. O
['Adverse-effects', 'Physiological-Clinical']

Experiments O
1 O
and O
2 O
exposed O
groups O
of O
participants O
either O
to O
DTkid O
training O
or O
to O
a O
control O
task O
. O
[]

Pain B-outcome ['Physiological-Clinical']
was O
measured O
with O
a O
visual O
analogue O
scale O
score O
, O
scale O
ranges O
from O
0 O
( O
no O
pain O
) O
to O
10 O
( O
unbearable O
pain O
) O
. O
['Physiological-Clinical']

After O
eight O
chemotherapy O
cycles O
, O
initial O
bulky O
and O
residual O
disease O
is O
irradiated O
. O
[]

Instead O
of O
the O
ends O
of O
the O
cuts O
being O
squared O
, O
the O
ends O
were O
beveled O
or O
rounded O
. O
[]

After O
baseline O
screening O
, O
subjects O
with O
FXS O
( O
n O
= O
49 O
) O
underwent O
a O
1-week O
placebo O
lead-in O
and O
then O
were O
randomized O
to O
study O
drug O
or O
placebo O
for O
a O
4-week O
period O
. O
[]

Controlled O
studies O
of O
fluvoxamine O
and O
other O
potent O
and O
selective O
serotonin O
uptake O
inhibitors O
seem O
warranted O
in O
children O
and O
adolescents O
with O
autism O
. O
[]

Means O
and O
standard O
deviations O
were O
calculated O
, O
and O
data O
were O
analyzed O
using O
a O
series O
of O
t-tests O
( O
paired O
and O
unpaired O
) O
and O
Wilcoxon O
matched-pairs O
signed-rank O
test O
. O
[]

RESULTS O
Intranasal O
oxytocin O
enabled O
the O
participants O
to O
make O
NVJs B-outcome ['Physiological-Clinical']
more O
frequently O
( O
P O
= O
.03 O
) O
with O
shorter O
response O
time O
( O
P O
= O
.02 O
) O
. O
['Physiological-Clinical']

RESULTS O
The O
medians O
of O
the O
average O
stool B-outcome ['Physiological-Clinical']
frequency O
after O
the O
second O
day O
of O
the O
treatment O
were O
significantly O
lower O
in O
the O
S. O
boulardii O
group O
than O
in O
the O
placebo O
group O
( O
p O
= O
0.003 O
) O
. O
['Physiological-Clinical']

Interventions O
Five O
hundred O
ninety-six O
community O
clusters O
( O
study O
sectors O
) O
were O
randomized O
for O
pregnant O
women O
to O
receive O
weekly O
, O
from O
the O
first O
trimester O
through O
12 O
weeks O
postpartum O
, O
7000 O
?g O
of O
retinol O
equivalents O
as O
retinyl O
palmitate O
, O
42 O
mg O
of O
all-trans O
beta O
carotene O
, O
or O
placebo O
. O
[]

The O
aim O
of O
the O
study O
was O
to O
compare O
psychosocial B-outcome ['Life-Impact']
outcomes O
for O
50 O
new O
clinic O
attendees O
, O
referred O
for O
cancer O
genetic O
counselling O
to O
five O
UK O
centres O
. O
['Life-Impact']

Serum B-outcome ['Physiological-Clinical']
IgG I-outcome ['Physiological-Clinical']
anti-IgG I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
were O
determined O
after O
dithiothreitol O
treatment O
. O
['Physiological-Clinical']

Subjective O
responses O
were O
measured O
with O
visual O
analog O
scale O
( O
VAS O
) O
. O
[]

RESULTS O
A O
total O
of O
60 O
patients O
were O
treated O
. O
[]

Tracheostomy B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
not O
associated O
with O
either O
anticoagulant O
therapy O
or O
an O
abnormal O
clotting O
profile O
. O
['Physiological-Clinical']

Adverse O
side O
effects O
and O
changes O
in O
laboratory O
data O
were O
all O
slight O
and O
disappeared O
when O
the O
second O
tests O
were O
performed O
. O
[]

Parents O
in O
the O
treatment O
group O
increased O
their O
use O
of O
comments O
that O
: O
described O
their O
child B-outcome ['Physiological-Clinical']
's O
focus B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
; O
interpreted O
or O
expanded O
child B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
acts I-outcome ['Life-Impact']
; O
and O
prompted O
child B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
intervention O
, O
during O
October O
2000 O
, O
was O
a O
telephone O
call O
from O
the O
practice O
receptionist O
to O
intervention O
group O
households O
, O
offering O
an O
appointment O
for O
influenza O
immunisation O
at O
a O
nurse-run O
. O
[]

This O
study O
did O
demonstrate O
that O
many O
outcome O
measures O
were O
reproducible O
in O
this O
test-retest O
setting O
for O
the O
FXS O
population O
, O
yet O
some O
were O
too O
difficult O
or O
variable O
. O
[]

However O
, O
small O
non-sedative O
doses O
of O
methotrimeprazine O
potentiated O
the O
analgesic B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
morphine I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

More O
patients O
on O
CBZ O
600 O
reported O
adverse B-outcome ['Adverse-effects']
experiences I-outcome ['Adverse-effects']
, O
66 O
% O
versus O
53 O
% O
( O
LTG O
100 O
) O
and O
58 O
% O
( O
LTG O
200 O
) O
, O
and O
of O
these O
a O
greater O
proportion O
were O
attributed O
to O
CBZ O
600 O
treatment O
, O
53 O
% O
versus O
23 O
% O
( O
LTG O
100 O
) O
and O
28 O
% O
( O
LTG O
200 O
) O
. O
['Adverse-effects']

Steroid O
boluses O
were O
given O
in O
the O
first O
2 O
days O
and O
tapered O
thereafter O
from O
20 O
mg/day O
to O
5 O
mg/day O
. O
[]

OBJECTIVE O
To O
compare O
holmium O
laser O
enucleation O
of O
the O
prostate O
( O
HoLEP O
) O
with O
transurethral O
resection O
of O
the O
prostate O
( O
TURP O
) O
for O
treatment O
of O
men O
with O
bladder O
outflow O
obstruction O
( O
BOO O
) O
secondary O
to O
benign O
prostatic O
hyperplasia O
with O
a O
minimum O
of O
24-month O
follow-up O
. O
[]

In O
the O
untreated O
historical O
control O
group O
the O
incidence O
of O
heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
was O
65 O
% O
( O
Brooker O
Score O
I O
: O
26 O
% O
; O
II O
: O
15 O
% O
; O
III O
: O
19 O
% O
; O
IV O
: O
5 O
% O
) O
. O
['Physiological-Clinical']

Analyses O
of O
predictors O
of O
relapse O
and O
response O
are O
now O
needed O
to O
improve O
the O
therapeutic O
value O
of O
this O
modality O
. O
[]

The O
same O
warming O
system O
was O
used O
for O
10 O
minutes O
in O
patients O
with O
leukaemia O
. O
[]

The O
effect O
of O
CEE O
on O
mammographic B-outcome ['Physiological-Clinical']
percent I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
was O
determined O
over O
1 O
and O
2 O
years O
in O
a O
stratified O
random O
sample O
of O
435 O
racially O
and O
ethnically O
diverse O
participants O
from O
15 O
of O
40 O
WHI O
clinics O
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION O
NUMBER O
http O
: O
//www.ClinicalTrials.gov O
; O
Unique O
identifier O
: O
NCT00617084 O
. O
[]

DISCUSSION O
In O
this O
study O
, O
an O
American O
model O
to O
enhance O
care O
for O
patients O
with O
a O
depressive O
disorder O
, O
the O
collaborative O
care O
model O
, O
will O
be O
evaluated O
for O
effectiveness O
in O
the O
primary O
care O
setting O
. O
[]

DESIGN O
Randomized O
, O
single-blind O
study O
. O
[]

Data O
of O
hepatic B-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
functions O
were O
normal O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DISCUSSION O
Older O
women O
with O
the O
clinical O
risk O
factors O
identified O
in O
this O
study O
should O
be O
investigated O
for O
osteoporosis O
or O
offered O
preventive O
treatment O
. O
[]

Cognitive O
function O
was O
recorded O
on O
the O
day O
of O
surgery O
using O
the O
Mini-Mental O
State O
Examination O
( O
MMSE O
) O
and O
24 O
and O
48 O
hours O
postoperatively O
using O
the O
Telephone O
Interview O
of O
Cognitive B-outcome ['Life-Impact']
Status I-outcome ['Life-Impact']
( O
TICS O
) O
. O
['Life-Impact']

The O
combined O
study O
sample O
showed O
improvement O
on O
all O
parent O
measures O
and O
on O
Teacher O
CGI O
and O
SE-Restlessness O
compared O
with O
baseline O
and O
placebo O
. O
['Life-Impact']

At O
3 O
months O
of O
follow-up O
, O
only O
27 O
% O
of O
patients O
in O
the O
study O
group O
experienced O
Grade O
2 O
xerostomia B-outcome ['Physiological-Clinical']
compared O
with O
73.9 O
% O
in O
the O
control O
group O
( O
p O
= O
0.0001 O
) O
. O
['Physiological-Clinical']

RESULTS O
The O
intention-to-treat O
analysis O
showed O
a O
survival B-outcome ['Mortality']
rate O
of O
63.6 O
per O
cent O
in O
the O
PC O
group O
and O
65.3 O
per O
cent O
in O
the O
LD O
group O
( O
P O
= O
0.69 O
) O
, O
with O
recurrence B-outcome ['Physiological-Clinical']
rates O
of O
27.8 O
and O
27.9 O
per O
cent O
respectively O
. O
['Mortality', 'Physiological-Clinical']

All O
performances B-outcome ['Life-Impact']
were O
videotaped O
and O
evaluated O
for O
unsuccessful B-outcome ['Life-Impact']
attempts I-outcome ['Life-Impact']
and O
unwanted B-outcome ['Adverse-effects']
interactions I-outcome ['Adverse-effects']
of I-outcome ['Adverse-effects']
instruments I-outcome ['Adverse-effects']
. O
['Life-Impact', 'Life-Impact', 'Adverse-effects']

These O
intrinsic O
muscles O
of O
the O
neck O
contribute O
to O
stabilization O
and O
protection O
of O
the O
cervical O
spine O
and O
are O
critical O
for O
the O
control O
of O
both O
intervertebral O
motion O
and O
the O
cervical O
lordosis O
. O
[]

Changes O
in O
the O
volume O
of O
the O
fluid O
space O
expanded O
by O
i.v O
. O
[]

There O
were O
significantly O
more O
cases O
of O
proven O
aspergillosis B-outcome ['Physiological-Clinical']
in O
flu O
than O
itra O
( O
six O
versus O
nil O
, O
P O
= O
0.038 O
, O
5/6 O
cases O
were O
fatal O
) O
if O
those O
occurring O
outside O
the O
study O
period O
are O
included O
. O
['Physiological-Clinical']

Changes O
in O
their O
anthropometric B-outcome ['Physiological-Clinical']
, O
nutritional B-outcome ['Physiological-Clinical']
, O
and O
hormonal B-outcome ['Physiological-Clinical']
biomarkers I-outcome ['Physiological-Clinical']
from O
early O
follicular O
phase O
were O
analyzed O
at O
baseline O
and O
post-intervention O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
significant O
difference O
in O
VAS O
score O
between O
two O
groups O
after O
treatment O
. O
[]

The O
10-hook O
electrode O
of O
LeVeen O
needle O
was O
deployed O
in O
four O
steps O
to O
full O
extension O
during O
ablation O
in O
group O
1 O
, O
and O
full O
extension O
at O
start O
of O
treatment O
in O
group O
2 O
. O
[]

The O
Study O
to O
COmpare O
REstenosis O
rate O
between O
QueST O
and O
QuaDS-QP2 O
( O
SCORE O
) O
trial O
is O
a O
human O
, O
randomized O
, O
multicenter O
trial O
comparing O
7-hexanoyltaxol O
( O
QP2 O
) O
-eluting O
stents O
( O
qDES O
) O
with O
bare O
metal O
stents O
( O
BMS O
) O
in O
the O
treatment O
of O
de O
novo O
coronary O
lesions O
. O
[]

Objectively O
maximum O
active O
extension O
, O
flexion O
and O
abduction O
of O
the O
shoulder O
, O
and O
subjectively O
pain O
stiffness O
movement O
and O
function O
were O
measured O
at O
0 O
and O
2 O
weeks O
. O
[]

In O
cultured O
human O
EPCs O
, O
TZD O
increased O
EPC B-outcome ['Physiological-Clinical']
numbers O
and O
migration B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical', 'Physiological-Clinical']

Activity O
of O
the O
supplementary O
motor O
area O
may O
be O
inferred O
from O
movement-related O
potentials O
( O
MRPs O
) O
which O
are O
associated O
with O
the O
preparation O
and O
execution O
of O
voluntary O
, O
or O
internally O
determined O
movements O
. O
[]

The O
teeth O
were O
divided O
into O
two O
groups O
of O
25 O
teeth O
and O
the O
remaining O
five O
teeth O
served O
as O
control O
. O
[]

Weight O
gain O
was O
observed O
more O
frequently O
in O
the O
haloperidol O
group O
at O
week O
24 O
. O
[]

Radiographs O
were O
taken O
biweekly O
to O
evaluate O
bony O
fusion O
. O
[]

CONCLUSIONS O
This O
study O
suggests O
prophylactic B-outcome ['Physiological-Clinical']
effects O
of O
add-on O
phenytoin O
in O
BP O
illness O
. O
['Physiological-Clinical']

Ibopamine O
is O
a O
dopaminergic O
and O
adrenergic O
receptor O
agonist O
, O
which O
is O
active O
in O
the O
treatment O
of O
congestive O
heart O
failure O
. O
[]

Students O
( O
n=2453 O
) O
in O
the O
seven O
middle O
schools O
in O
one O
school O
district O
were O
assessed O
at O
school O
at O
the O
beginning O
and O
end O
of O
the O
sixth O
, O
seventh O
, O
eighth O
grade O
and O
beginning O
of O
the O
9th O
grade O
. O
[]

Changes O
in O
organ O
function O
and O
outcome O
were O
also O
recorded O
at O
the O
same O
time O
points O
. O
[]

BACKGROUND O
Administration O
of O
PUFA O
reduces O
the O
risk O
of O
life-threatening O
arrhythmias O
in O
patients O
surviving O
myocardial O
infarction O
. O
[]

This O
report O
is O
restricted O
to O
7674 O
participants O
with O
albuminuria O
data O
at O
baseline O
and O
at O
follow-up O
. O
[]

The O
utilisation O
of O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
may O
be O
used O
for O
definition O
of O
insulin O
resistance O
in O
type O
II O
diabetes O
mellitus O
. O
['Physiological-Clinical']

Our O
aim O
was O
to O
determine O
the O
effect O
of O
therapy O
with O
ursodeoxycholic O
acid O
alone O
and O
in O
combination O
with O
azathioprine O
and O
prednisone O
on O
serum B-outcome ['Physiological-Clinical']
sICAM-1 I-outcome ['Physiological-Clinical']
levels O
in O
primary O
biliary O
cirrhosis O
. O
['Physiological-Clinical']

RESULTS O
Both O
pimecrolimus O
and O
betamethasone O
were O
highly O
effective O
in O
the O
treatment O
of O
seborrhoeic O
dermatitis O
. O
[]

In O
our O
patients O
pericarditis O
encompassed O
a O
wide O
spectrum O
ranging O
from O
a O
mild B-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
several I-outcome ['Physiological-Clinical']
days O
duration B-outcome ['Physiological-Clinical']
to O
a O
painful O
and O
debilitating B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
transient B-outcome ['Physiological-Clinical']
deterioration I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
was O
observed O
despite O
unchanged O
levels O
of O
insulin B-outcome ['Resource-use']
after O
treatment O
with O
both O
compounds O
for O
3 O
months O
. O
['Physiological-Clinical', 'Resource-use']

However O
, O
exploratory O
analyses O
suggested O
that O
vinorelbine O
merits O
further O
investigation O
. O
[]

UNLABELLED O
Cerebral B-outcome ['Physiological-Clinical']
hyperemia I-outcome ['Physiological-Clinical']
has O
been O
demonstrated O
during O
emergence O
from O
anesthesia O
in O
neurosurgical O
patients O
, O
but O
its O
mechanism O
is O
speculative O
. O
['Physiological-Clinical']

SUBJECTS O
251 O
patients O
aged O
over O
15 O
years O
who O
were O
taking O
anti-epileptic O
drugs O
or O
had O
a O
diagnosis O
of O
epilepsy O
and O
an O
attack O
in O
the O
past O
two O
years O
who O
met O
specified O
inclusion O
criteria O
and O
had O
responded O
to O
a O
questionnaire O
. O
[]

Mean O
uterine B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
shrank I-outcome ['Physiological-Clinical']
by O
48 O
% O
( O
P O
< O
.001 O
) O
in O
the O
5-mg O
group O
and O
49 O
% O
( O
P O
< O
.001 O
) O
in O
the O
10-mg O
group O
, O
a O
nonsignificant O
difference O
. O
['Physiological-Clinical']

This O
study O
compared O
measurements O
taken O
by O
a O
new O
portable O
Fleisch O
pneumotachograph O
spirometer O
( O
known O
as O
the O
Escort O
) O
with O
those O
of O
the O
commonly O
used O
mini-Wright O
peak O
flow O
meter O
and O
the O
Micromed O
Pocket O
turbine O
spirometer O
. O
[]

Colonoscopic O
miss O
rates O
of O
adenomas O
determined O
by O
back-to-back O
colonoscopies O
. O
[]

METHODS O
The O
present O
clinical O
trial O
compared O
GnRH O
antagonist O
( O
cetrorelix O
) O
and O
GnRH O
agonist O
( O
buserelin O
) O
protocols O
during O
COH O
of O
112 O
infertile O
PCOS O
patients O
entering O
assisted O
reproduction O
cycles O
. O
[]

Autism O
symptoms O
were O
monitored O
periodically O
. O
[]

Testosterone O
and O
gonadotropins O
but O
not O
estrogen O
associated O
with O
spatial B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
in O
women O
suffering O
from O
schizophrenia O
: O
a O
double-blind O
, O
placebo-controlled O
study O
. O
['Life-Impact']

The O
final O
analysis O
will O
reveal O
whether O
this O
finding O
is O
maintained O
over O
time O
. O
[]

This O
study O
examines O
the O
impact O
of O
a O
preadmission O
telephone O
intervention O
on O
anxiety B-outcome ['Life-Impact']
, O
knowledge B-outcome ['Life-Impact']
, O
and O
readiness B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
discharge I-outcome ['Life-Impact']
for O
patients O
attending O
a O
preadmission O
teaching O
program O
prior O
to O
cardiac O
surgery O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

MATERIAL O
AND O
METHODS O
106 O
males O
with O
Q-MI O
entered O
the O
study O
. O
[]

Improved O
intraoperative B-outcome ['Life-Impact']
management I-outcome ['Life-Impact']
of O
anastomotic B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
during O
aortic O
reconstruction O
: O
results O
of O
a O
randomized O
controlled O
trial O
. O
['Life-Impact', 'Physiological-Clinical']

Valsartan O
but O
not O
amlodipine O
reduced O
CRP B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

Learning O
through O
interaction O
in O
children O
with O
autism O
: O
preliminary O
data O
from O
asocial-communication-based O
intervention O
. O
[]

Comparison O
of O
three O
solutions O
of O
ropivacaine/fentanyl O
for O
postoperative O
patient-controlled O
epidural O
analgesia O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effectiveness O
of O
a O
GnRH O
antagonist O
in O
preventing O
premature B-outcome ['Physiological-Clinical']
LH I-outcome ['Physiological-Clinical']
surge I-outcome ['Physiological-Clinical']
under O
a O
letrozole O
and O
gonadotropin O
protocol O
. O
['Physiological-Clinical']

Progress O
was O
measured O
at O
15 O
days O
, O
1 O
month O
, O
3 O
months O
, O
6 O
months O
and O
a O
year O
. O
[]

Among O
men O
, O
Sexual B-outcome ['Physiological-Clinical']
Health I-outcome ['Physiological-Clinical']
scores O
were O
significantly O
worse O
in O
treated O
patients O
and O
in O
those O
with O
a O
clinical O
outcome O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
results O
can O
provide O
information O
on O
potential O
directions O
for O
future O
family O
recruitment O
. O
[]

They O
were O
assessed O
and O
analyzed O
by O
positive O
and O
negative O
symptoms O
scales O
( O
PANSS O
) O
, O
social O
disability O
screening O
schedule O
( O
SDSS O
) O
and O
treatment O
emergent O
symptom O
scale O
( O
TESS O
) O
at O
baseline O
, O
6 O
( O
th O
) O
weekend O
and O
12 O
( O
th O
) O
weekend O
. O
[]

The O
3 O
year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
77.7 O
% O
and O
79.2 O
% O
for O
cisplatin O
and O
carboplatin O
groups O
, O
respectively O
( O
p=0.9884 O
) O
( O
HR O
0.83 O
, O
95 O
% O
CI O
: O
0.63-1.010 O
) O
. O
['Mortality']

A O
total O
of O
33 O
tumour O
samples O
( O
73 O
% O
) O
had O
detectable O
sequence B-outcome ['Physiological-Clinical']
alterations I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
TP53 I-outcome ['Physiological-Clinical']
gene I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Future O
therapeutic O
directions O
for O
selective O
factor O
Xa O
inhibition O
in O
the O
management O
of O
other O
thrombotic O
diseases O
are O
discussed O
. O
[]

Intraperitoneal O
CT O
was O
delivered O
mainly O
through O
intraperitoneal O
catheters O
( O
Port-a-Cath O
61 O
% O
and O
Tenckhoff O
25 O
% O
) O
. O
[]

RESULTS O
Neu B-outcome ['Physiological-Clinical']
, O
EGFR B-outcome ['Physiological-Clinical']
, O
catD B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effects O
of O
a O
10-week O
aerobic O
exercise O
and O
progressive O
relaxation O
training O
program O
on O
somatic O
, O
emotional O
, O
and O
behavioral O
responses O
to O
acute O
stress O
, O
as O
determined O
by O
quality O
of O
motor O
performance O
and O
affect O
, O
were O
examined O
. O
[]

The O
average O
of O
the O
maximum O
pressure B-outcome ['Physiological-Clinical']
rises O
above O
the O
preoperative O
level O
over O
the O
24 O
hour O
period O
was O
greatest O
for O
the O
group O
receiving O
acetazolamide O
only O
at O
8.9 O
mm O
Hg O
; O
for O
the O
acetylcholine O
group O
the O
average O
maximum O
rise O
was O
6.3 O
mm O
Hg O
; O
while O
the O
combined O
treatment O
group O
showed O
a O
decrease O
of O
0.7 O
mm O
Hg O
. O
['Physiological-Clinical']

METHODS O
Of O
7788 O
patients O
in O
the O
Digitalis O
Investigation O
Group O
trial O
, O
3527 O
had O
CKD O
, O
defined O
by O
an O
estimated O
glomerular O
filtration O
rate O
( O
GFR O
) O
< O
60 O
ml/min/1.73 O
m O
( O
2 O
) O
body O
surface O
area O
( O
BSA O
) O
. O
[]

Homeostatic O
mechanisms O
, O
including O
activation O
of O
the O
renin-aldosterone O
system O
, O
may O
counteract O
the O
effects O
of O
sodium O
restriction O
. O
[]

PATIENTS O
AND O
METHODS O
Two O
hundred O
patients O
with O
untreated O
advanced O
gastric O
carcinoma O
were O
randomised O
to O
receive O
PELF O
or O
FAMTX O
for O
a O
maximum O
of O
six O
cycles O
or O
until O
disease O
progression O
. O
[]

Unique O
identifier O
: O
NCT00433966 O
. O
[]

The O
following O
results O
were O
obtained O
: O
Arm O
A O
: O
84 O
patients O
were O
included O
, O
74 O
were O
evaluable O
for O
activity O
; O
RESPONSE O
complete B-outcome ['Physiological-Clinical']
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
8 O
( O
11 O
% O
) O
, O
partial B-outcome ['Physiological-Clinical']
response O
( O
PR O
) O
40 O
( O
54 O
% O
) O
, O
stable B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( O
SD O
) O
11 O
( O
15 O
% O
) O
, O
progressive B-outcome ['Physiological-Clinical']
disease B-outcome ['Physiological-Clinical']
( O
PD O
) O
15 O
( O
20 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

SETTING O
Eight O
sites O
, O
heterogeneous O
for O
sociodemographic O
and O
health O
care O
use O
. O
[]

At O
this O
age O
measures O
of O
rate O
of O
non-verbal O
communication O
might O
be O
more O
informative O
than O
scores O
on O
standard O
psychometric O
tests O
. O
[]

The O
decrease O
of O
ICF B-outcome ['Physiological-Clinical']
and O
increase O
of O
L-ICI B-outcome ['Physiological-Clinical']
may O
reflect O
glutamatergic O
modulation O
or O
a O
polysynaptic O
interaction O
of O
glutamatergic O
and O
GABA-ergic O
circuits O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Dedicated O
glucometer O
measurement O
of O
arterial O
glucose O
values O
was O
calibrated O
daily O
to O
values O
measured O
in O
the O
laboratory O
. O
[]

Twenty-seven O
patients O
receiving O
a O
standard O
cytosine O
arabinoside O
and O
daunorubicin O
regimen O
as O
induction O
of O
reinduction O
therapy O
of O
acute O
myelogenous O
leukemia O
were O
randomly O
assigned O
to O
receive O
lithium O
carbonate O
, O
300 O
mg O
t.i.d. O
, O
or O
no O
lithium O
. O
[]

Effect O
of O
n-3 O
polyunsaturated O
fatty O
acid O
intake O
on O
phospholipid O
fatty O
acid O
composition O
in O
plasma O
and O
erythrocytes O
. O
[]

During O
the O
4-year O
follow-up O
period O
there O
were O
no O
significant O
differences O
in O
the O
progression B-outcome ['Physiological-Clinical']
rates O
( O
appearance B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
metastases I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
scan I-outcome ['Physiological-Clinical']
) O
between O
the O
therapy O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
this O
study O
, O
open-label O
T3 O
was O
administered O
to O
68 O
high-risk O
patients O
undergoing O
open O
heart O
surgery O
. O
[]

Intervention O
effectiveness O
will O
be O
measured O
via O
child B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
levels O
during O
attendance O
at O
long B-outcome ['Resource-use']
day I-outcome ['Resource-use']
care I-outcome ['Resource-use']
. O
['Life-Impact', 'Resource-use']

CONCLUSIONS O
No O
correlation O
was O
found O
between O
[]

Effects O
of O
hydraulic O
circuit O
training O
on O
cardiovascular O
function O
. O
[]

The O
risk O
of O
mortality B-outcome ['Mortality']
was O
high O
in O
this O
group O
( O
52 O
% O
) O
. O
['Mortality']

INTERPRETATION O
The O
present O
data O
do O
not O
provide O
any O
evidence O
that O
LMWH O
is O
superior O
to O
aspirin O
for O
the O
treatment O
of O
acute O
ischaemic O
stroke O
in O
patients O
with O
atrial O
fibrillation O
. O
[]

Fentanyl O
( O
15 O
, O
30 O
, O
60 O
micro O
g O
kg-1 O
hour-1 O
) O
or O
remifentanil O
( O
60 O
, O
120 O
, O
240 O
micro O
g O
kg-1 O
hour-1 O
) O
were O
infused O
intravenously O
into O
a O
previously O
cannulated O
tail O
vein O
. O
[]

The O
development O
and O
evaluation O
of O
a O
computer-based O
program O
to O
test O
and O
to O
teach O
the O
recognition O
of O
facial B-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
. O
['Life-Impact']

RESULTS O
Mean O
MVD O
in O
the O
suburethral O
portion O
of O
prostate O
was O
significantly O
lower O
in O
patients O
treated O
with O
finasteride O
when O
compared O
with O
controls O
( O
9.08 O
+/- O
5.6 O
and O
13.94 O
+/- O
5.90 O
, O
respectively O
, O
p O
< O
0.05 O
) O
. O
[]

In O
2 O
experiments O
with O
134 O
young O
adult O
women O
, O
6 O
variables O
were O
explored O
that O
might O
influence O
such O
risk O
perception B-outcome ['Life-Impact']
persistence O
. O
['Life-Impact']

As O
of O
June O
1984 O
the O
median O
follow-up O
was O
82 O
months O
( O
range O
, O
49 O
to O
145 O
months O
) O
, O
the O
actuarial O
probabilities O
for O
survival B-outcome ['Mortality']
and O
freedom B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
for O
all O
patients O
being O
91.6 O
% O
and O
87.6 O
% O
, O
respectively O
. O
['Mortality', 'Physiological-Clinical']

The O
dosage O
of O
moclobemide O
( O
25 O
patients O
) O
was O
300 O
mg O
daily O
for O
the O
first O
5 O
days O
, O
after O
which O
it O
could O
be O
increased O
to O
600 O
mg. O
Imipramine O
( O
25 O
patients O
) O
was O
given O
in O
a O
dosage O
starting O
with O
33 O
mg O
and O
gradually O
increased O
to O
100 O
mg/day O
in O
the O
first O
5 O
days O
, O
after O
which O
it O
could O
be O
further O
increased O
; O
25 O
patients O
received O
placebo O
. O
[]

METHODS O
Renal O
transplant O
patients O
were O
prospectively O
randomized O
into O
an O
intervention O
group O
or O
a O
control O
group O
. O
[]

RESULTS O
Among O
the O
417 O
patients O
with O
adequate O
venograms O
, O
109 O
of O
211 O
warfarin O
recipients O
( O
51.7 O
% O
) O
had O
deep B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
compared O
with O
76 O
of O
206 O
enoxaparin O
recipients O
( O
36.9 O
% O
) O
( O
P O
= O
0.003 O
) O
. O
['Physiological-Clinical']

This O
study O
examined O
children O
's O
ratings O
of O
attitudes B-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
intentions I-outcome ['Life-Impact']
toward O
a O
peer O
presented O
with O
or O
without O
autistic O
behaviors O
. O
['Life-Impact']

METHODS O
ERPs O
were O
recorded O
during O
an O
auditory O
selective O
attention O
task O
( O
SAT O
) O
that O
involved O
detecting O
infrequent O
long-duration O
target O
tones O
presented O
among O
short-duration O
tones O
that O
varied O
in O
location O
( O
left O
vs. O
right O
ear O
) O
and O
pitch O
( O
low O
vs. O
high O
) O
. O
[]

METHODS O
A O
double-blind O
crossover O
study O
with O
nine O
healthy O
normotensive O
volunteers O
( O
age O
27 O
+/- O
3 O
y O
, O
BMI O
23.3 O
+/- O
2.0 O
kg O
m O
( O
-2 O
) O
; O
mean O
+/- O
SD O
) O
-randomly O
assigned O
to O
a O
3-day O
treatment O
of O
either O
5 O
mg O
enalapril O
or O
placebo O
. O
[]

We O
therefore O
made O
a O
blinded O
qualitative O
scoring O
of O
the O
callus O
at O
5 O
weeks O
in O
our O
27 O
patients O
. O
[]

BACKGROUND O
AND O
AIM O
OF O
THE O
STUDY O
Non-obstructive O
prosthetic O
valve O
thrombosis O
( O
PVT O
) O
is O
a O
unique O
subset O
that O
features O
clinical O
presentation O
without O
heart O
failure O
, O
and O
may O
be O
asymptomatic O
. O
[]

Eight O
of O
the O
children O
were O
comatose O
. O
[]

METHODS O
Forty O
patients O
were O
randomly O
assigned O
to O
receive O
either O
fentanyl O
( O
10 O
micrograms/mL O
) O
or O
a O
fentanyl/bupivacaine O
( O
0.1 O
% O
) O
mixture O
epidurally O
corresponding O
to O
the O
dermatome O
of O
the O
surgical O
incision O
in O
a O
double-blind O
fashion O
for O
the O
first O
18 O
hours O
after O
major O
abdominal O
surgery O
. O
[]

Venous B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
samples O
were O
obtained O
for O
determination O
of O
serum B-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
including I-outcome ['Physiological-Clinical']
interleukin-1beta I-outcome ['Physiological-Clinical']
( O
IL-1beta B-outcome ['Physiological-Clinical']
) O
, O
tumor B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor-alpha I-outcome ['Physiological-Clinical']
( O
TNF-alpha B-outcome ['Physiological-Clinical']
) O
, O
RANKL B-outcome ['Physiological-Clinical']
, O
osteoprotegerin B-outcome ['Physiological-Clinical']
, O
and O
markers B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
and O
resorption B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
controlled O
trial O
. O
[]

Long O
term O
follow O
up O
of O
patients O
treated O
for O
Helicobacter B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Findings O
indicated O
that O
high-BP O
individuals O
showed O
heightened B-outcome ['Life-Impact']
['Life-Impact']

After O
initial O
preparation O
, O
the O
defects O
were O
randomly O
assigned O
in O
each O
patient O
to O
either O
GTR-group O
or O
OFD-group O
. O
[]

Parameters O
of O
liver B-outcome ['Physiological-Clinical']
function B-outcome ['Life-Impact']
, O
taste B-outcome ['Life-Impact']
acuity I-outcome ['Life-Impact']
, O
dark O
adaptation O
and O
of O
zinc B-outcome ['Physiological-Clinical']
and O
vitamin B-outcome ['Physiological-Clinical']
A I-outcome ['Physiological-Clinical']
metabolism B-outcome ['Physiological-Clinical']
were O
followed O
for O
six O
weeks O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Ninety-eight O
patients O
were O
randomly O
assigned O
to O
receive O
placebo O
( O
n O
= O
51 O
) O
or O
aripiprazole O
( O
n O
= O
47 O
) O
. O
[]

A O
cohort O
of O
111 O
patients O
who O
fulfilled O
the O
same O
inclusion O
criteria O
in O
the O
subsequent O
trial O
HD5 O
( O
1988 O
to O
1993 O
) O
were O
treated O
with O
30 O
Gy O
. O
[]

Both O
preparations O
were O
found O
to O
possess O
good O
anti-inflammatory B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
analgesic I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
, O
comparable O
clinically O
and O
statistically O
. O
['Physiological-Clinical']

Among O
the O
predictive O
markers O
studied O
, O
p16 O
( O
INK4a O
) O
has O
been O
suggested O
to O
be O
of O
some O
value O
in O
monitoring O
the O
diagnosis O
of O
CIN2 O
. O
[]

Discrimination O
attained O
on O
haloperidol O
was O
retained O
when O
the O
children O
were O
switched O
to O
placebo O
. O
[]

In O
those O
patients O
who O
had O
received O
a O
minimum O
of O
90 O
million O
units O
per O
m2 O
total O
dose O
over O
12 O
weeks O
, O
a O
negative O
anti-human B-outcome ['Physiological-Clinical']
immunodeficiency I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.001 O
) O
, O
chronic B-outcome ['Physiological-Clinical']
active I-outcome ['Physiological-Clinical']
hepatitis I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
biopsy I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.005 O
) O
, O
high O
AST B-outcome ['Physiological-Clinical']
level O
( O
p O
less O
than O
0.001 O
) O
, O
low O
hepatitis B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
level O
( O
p O
less O
than O
0.001 O
) O
and O
a O
history O
of O
acute B-outcome ['Physiological-Clinical']
hepatitis I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.005 O
) O
were O
all O
associated O
with O
an O
increased O
likelihood O
of O
response O
on O
univariate O
analysis O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
, O
crossover O
, O
double-blind O
, O
controlled O
trial O
. O
[]

[ O
Efficacy O
of O
immunomodulating O
treatment O
in O
patients O
with O
different O
degrees O
of O
immunosuppression O
] O
. O
[]

Effects O
of O
clonidine O
on O
postoperative O
nausea O
and O
vomiting O
in O
breast O
cancer O
surgery O
. O
[]

With O
increasing O
Na O
intake O
, O
T1/2 B-outcome ['Physiological-Clinical']
increased O
in O
both O
whites O
and O
blacks O
; O
at O
the O
400 O
mmol/d O
intake O
, O
the O
T1/2 O
for O
whites O
was O
2.88 O
days O
and O
for O
blacks O
was O
5.81 O
days O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Its O
toxicity O
has O
previously O
been O
correlated O
to O
the O
formation O
of O
an O
active O
metabolite O
, O
N-acetyl-amonafide O
. O
[]

Mefloquine O
pharmacokinetics O
were O
compared O
in O
a O
randomized O
clinical O
trial O
in O
Thailand O
among O
patients O
with O
malaria O
and O
healthy O
volunteers O
. O
[]

RESULTS O
The O
physical O
activity O
group O
improved O
in O
sleep O
quality O
on O
the O
global O
PSQI O
( O
p O
< O
.0001 O
) O
, O
sleep O
latency O
( O
p=.049 O
) O
, O
sleep O
duration O
( O
p=.04 O
) O
, O
daytime O
dysfunction O
( O
p=.027 O
) O
, O
and O
sleep O
efficiency O
( O
p=.036 O
) O
PSQI O
sub-scores O
compared O
to O
the O
control O
group O
. O
[]

The O
rates O
of O
favorable O
response O
were O
89 O
% O
in O
patients O
receiving O
clindamycine O
alone O
and O
78 O
% O
in O
patients O
receiving O
cefoxitin O
alone O
. O
[]

Multitomographic O
evaluation O
of O
the O
dental B-outcome ['Physiological-Clinical']
effects O
of O
two O
different O
rapid O
palatal O
expansion O
appliances O
. O
['Physiological-Clinical']

For O
women O
who O
underwent O
exercise O
and O
omega-3 O
therapy O
compared O
with O
control O
subjects O
, O
improvements O
in O
baseline O
to O
12-week O
total O
MENQOL O
scores O
were O
not O
observed O
. O
[]

Response O
was O
obtained O
by O
75 O
and O
67 O
% O
of O
patients O
receiving O
MPA O
or O
megestrol O
, O
respectively O
( O
P O
= O
0.5 O
) O
. O
[]

Teniposide O
120 O
mg/m O
( O
2 O
) O
was O
given O
intravenously O
three O
times O
a O
week O
, O
every O
3 O
weeks O
. O
[]

Parameters O
are O
calculated O
both O
in O
uni- O
and O
bipolar O
configuration O
at O
implant O
and O
at O
follow-up O
after O
1 O
, O
5 O
, O
15 O
, O
30 O
, O
90 O
, O
180 O
, O
and O
360 O
days O
. O
[]

A O
placebo O
controlled O
crossover O
trial O
of O
liquid O
fluoxetine O
on O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
childhood O
and O
adolescent O
autism O
. O
['Life-Impact']

SETTING O
Emergency O
department O
and O
inpatient O
units O
of O
a O
large O
, O
metropolitan O
, O
university-based O
, O
children O
's O
hospital O
in O
Michigan O
. O
[]

The O
exclusive B-outcome ['Physiological-Clinical']
breastfeeding I-outcome ['Physiological-Clinical']
rate O
was O
27.4 O
% O
. O
['Physiological-Clinical']

The O
number O
of O
patients O
developing O
abnormal O
liver O
function O
tests O
( O
including O
clinically O
significant O
elevation O
) O
, O
hemoglobin O
, O
and O
creatinine O
clearance O
was O
significantly O
higher O
in O
the O
oral O
diclofenac O
group O
. O
[]

The O
vascular O
femoral O
head O
necrosis O
is O
a O
serious O
illness O
, O
especially O
when O
appearing O
in O
patients O
aged O
30 O
to O
50 O
years O
. O
[]

Experimental O
and O
clinical O
studies O
have O
suggested O
that O
statins O
may O
slow O
the O
progression O
of O
chronic B-outcome ['Physiological-Clinical']
kidney I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
in O
general O
and O
ADPKD O
specifically O
. O
['Physiological-Clinical']

DESIGN O
Double O
blind O
, O
placebo O
controlled O
study O
. O
[]

The O
strength O
of O
resin O
core O
material O
can O
be O
increased O
by O
hot-press O
methods O
. O
[]

Financial O
and O
quality-of-life O
burden O
of O
dysfunctional O
uterine O
bleeding O
among O
women O
agreeing O
to O
obtain O
surgical O
treatment O
. O
[]

The O
usefulness O
of O
intravenous O
dexmedetomidine O
infusion O
for O
maintenance O
of O
anesthesia O
was O
studied O
in O
patients O
anesthetized O
with O
thiopental O
, O
fentanyl O
, O
nitrous O
oxide O
, O
and O
oxygen O
. O
[]

These O
results O
provide O
some O
preliminary O
evidence O
for O
the O
effectiveness O
of O
multi-session O
anti-stigma O
programs O
incorporating O
combined O
information O
for O
adolescent O
students O
in O
inclusive O
educational O
environments O
. O
[]

Brief O
report O
: O
imitation O
effects O
on O
children O
with O
autism O
. O
[]

Accuracy O
of O
noninvasive O
haemoglobin B-outcome ['Physiological-Clinical']
measurement O
by O
pulse O
oximetry O
depends O
on O
the O
type O
of O
infusion O
fluid O
. O
['Physiological-Clinical']

The O
rehabilitation B-outcome ['Life-Impact']
indices O
and O
duration O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
are O
comparable O
in O
both O
groups O
. O
['Life-Impact', 'Resource-use']

Supplementation O
with O
n3 O
fatty O
acid O
ethyl O
esters O
increases O
large O
and O
small O
artery O
elasticity B-outcome ['Physiological-Clinical']
in O
obese O
adults O
on O
a O
weight O
loss O
diet O
. O
['Physiological-Clinical']

The O
DCCT O
proved O
that O
intensive O
treatment O
reduced O
the O
risks O
of O
retinopathy B-outcome ['Physiological-Clinical']
, O
nephropathy B-outcome ['Physiological-Clinical']
, O
and O
neuropathy B-outcome ['Physiological-Clinical']
by O
35 O
% O
to O
90 O
% O
compared O
with O
conventional O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Statistical O
analysis O
was O
done O
by O
the O
Mann-Whitney O
test O
, O
with O
P O
less O
than O
0.05 O
considered O
significant O
. O
[]

Randomized O
trial O
of O
a O
decision O
aid O
for O
individuals O
considering O
genetic O
testing O
for O
hereditary O
nonpolyposis O
colorectal O
cancer O
risk O
. O
[]

Sequential O
pre-operative/post-operative O
treatment O
with O
anastrozole O
resulted O
in O
lower O
recurrence B-outcome ['Physiological-Clinical']
and O
death B-outcome ['Mortality']
rates O
, O
compared O
with O
tamoxifen O
. O
['Physiological-Clinical', 'Mortality']

This O
study O
is O
a O
prospective O
, O
randomized O
, O
open-label O
study O
with O
blinded O
assessment O
of O
endpoints O
to O
compare O
the O
2-year O
effect O
of O
strict O
treatment O
to O
maintain O
systolic O
blood O
pressure O
below O
140 O
mmHg O
with O
that O
of O
mild O
treatment O
to O
maintain O
systolic O
blood O
pressure O
below O
160 O
but O
at O
or O
above O
140 O
mmHg O
in O
elderly O
hypertensive O
patients O
. O
[]

The O
mean O
dose O
of O
Mo O
was O
5.3 O
mg O
in O
Mi+Mo O
and O
6.0 O
mg O
in O
Mo O
alone O
( O
p O
< O
0.0001 O
) O
. O
[]

PURPOSES O
Fluorescence O
diagnosis O
induced O
by O
5-aminolevulinic O
acid O
enables O
more O
thorough O
transurethral O
resection O
of O
superficial O
bladder O
carcinoma O
compared O
with O
conventional O
white O
light O
. O
[]

Detection O
rates O
of O
cancer B-outcome ['Physiological-Clinical']
, O
high O
grade O
PIN B-outcome ['Physiological-Clinical']
and O
atypical B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
suspicious I-outcome ['Physiological-Clinical']
for O
cancer B-outcome ['Physiological-Clinical']
in O
the O
European O
Randomized O
Study O
of O
Screening O
for O
Prostate O
Cancer O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
the O
end O
of O
the O
operation O
, O
when O
nitrous O
oxide O
had O
been O
turned O
of O
, O
the O
[]

The O
present O
study O
demonstrated O
a O
significant O
reduction O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
and O
lipid B-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
and O
an O
increase O
in O
antioxidant B-outcome ['Physiological-Clinical']
enzymes I-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
in O
subjects O
with O
MS O
after O
WGP O
supplementation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
A O
total O
of O
32 O
929 O
subjects O
were O
invited O
to O
attend O
, O
8407 O
were O
evaluable O
, O
and O
2329 O
( O
28 O
% O
) O
of O
these O
were O
H. O
pylori-positive B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

34 O
+/- O
2.24 O
and O
-1.73 O
+/- O
3.25 O
% O
at O
the O
lumbar B-outcome ['Physiological-Clinical']
spine I-outcome ['Physiological-Clinical']
and O
the O
femoral B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

ERCP O
began O
after O
studied O
subjects O
were O
randomly O
premedicated O
with O
either O
1 O
mg O
glucagon O
( O
n O
= O
38 O
) O
or O
40 O
mg O
hyoscine O
N-butyl O
bromide O
( O
n O
= O
36 O
) O
intravenously O
. O
[]

bolus O
dose O
of O
240 O
mg O
, O
followed O
by O
a O
continuous O
i.v O
. O
[]

In O
inhaler-use O
technique O
, O
we O
could O
not O
find O
significant O
changes O
neither O
in O
the O
intervention O
nor O
in O
the O
control O
group O
. O
[]

No O
significant O
differences O
were O
found O
between O
the O
two O
treatment O
groups O
with O
regard O
to O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
or O
side O
effects O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Women O
with O
bone O
metastases O
( O
N O
= O
228 O
) O
were O
randomly O
assigned O
to O
receive O
4 O
mg O
zoledronic O
acid O
( O
n O
= O
114 O
) O
or O
placebo O
( O
n O
= O
114 O
) O
via O
15-minute O
infusions O
every O
4 O
weeks O
for O
1 O
year O
. O
[]

Stroke O
team O
remote O
evaluation O
using O
a O
digital O
observation O
camera O
in O
Arizona O
: O
the O
initial O
mayo O
clinic O
experience O
trial O
. O
[]

Mean O
distance O
walked B-outcome ['Life-Impact']
was O
significantly O
higher O
in O
atrioventricular O
synchronous O
than O
in O
ventricular O
pacing O
( O
360 O
+/- O
65 O
m O
vs. O
327 O
+/- O
69 O
m O
; O
P O
< O
0.01 O
) O
. O
['Life-Impact']

The O
mean O
numbers O
of O
doses B-outcome ['Life-Impact']
of O
droperidol B-outcome ['Resource-use']
were O
0.8+/-0.9 O
and O
0.3+/-0.6 O
( O
P O
< O
.05 O
) O
, O
respectively O
. O
['Life-Impact', 'Resource-use']

During O
one O
period O
the O
subjects O
relaxed O
with O
eyes O
closed O
, O
in O
the O
other O
period O
they O
performed O
a O
math O
task O
with O
eyes O
open O
. O
[]

The O
62 O
subjects O
( O
3-8 O
years O
) O
were O
assigned O
to O
group O
1 O
( O
saline O
placebo/HSS O
) O
or O
group O
2 O
( O
HSS/saline O
placebo O
) O
. O
[]

METHODS O
Of O
20 O
study O
patients O
( O
mean O
age O
74.3 O
+/- O
15 O
years O
) O
with O
severe O
CHF O
, O
10 O
( O
Group O
A O
) O
were O
randomized O
to O
a O
treatment O
strategy O
of O
intravenous O
bumetanide O
( O
1 O
mg O
b.i.d O
. O
) O
[]

DESIGN O
Randomized O
, O
open-label O
, O
multicenter O
, O
28-day O
clinical O
trial O
. O
[]

Concomitantly O
, O
we O
found O
that O
intervention O
with O
prednisone O
significantly O
impaired O
the O
induction O
of O
T B-outcome ['Physiological-Clinical']
regulatory I-outcome ['Physiological-Clinical']
lymphocytes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Ethanol-induced O
alterations O
in O
electroencephalographic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
adult O
males O
. O
['Physiological-Clinical']

Quantitative O
myocardial O
dye O
intensity O
measurement O
revealed O
a O
significantly O
higher O
grade O
of O
myocardial B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
perfusion B-outcome ['Physiological-Clinical']
( O
1 O
/0-9.25/ O
vs O
0 O
/0-3.0/ O
grey O
pixel O
unit O
, O
p=0.048 O
) O
in O
Group O
1 O
before O
pPCI O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Younger O
participants O
, O
aged O
< O
34 O
years O
, O
reported O
more O
confusion B-outcome ['Life-Impact']
( O
p= O
.013 O
) O
at O
T2 O
than O
at O
T1 O
and O
T4 O
. O
['Life-Impact']

The O
results O
show O
a O
significant O
training O
effect O
on O
attitudes B-outcome ['Life-Impact']
( O
P O
= O
0.05 O
) O
, O
especially O
on O
those O
related O
to O
['Life-Impact']

CONCLUSIONS O
Remifentanil O
is O
a O
suitable O
alternative O
to O
fentanyl O
in O
supratentorial O
craniotomy O
. O
[]

DESIGN O
Randomized O
, O
controlled O
clinical O
trial O
. O
[]

We O
collected O
ERP B-outcome ['Life-Impact']
responses I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
familiar I-outcome ['Life-Impact']
repeated I-outcome ['Life-Impact']
face I-outcome ['Life-Impact']
( O
Familiar B-outcome ['Life-Impact']
) O
, O
an O
unfamiliar B-outcome ['Life-Impact']
repeated I-outcome ['Life-Impact']
face I-outcome ['Life-Impact']
( O
Other O
) O
and O
novel B-outcome ['Life-Impact']
faces I-outcome ['Life-Impact']
( O
Novels B-outcome ['Life-Impact']
) O
in O
29 O
high-functioning O
adults O
with O
ASD O
and O
matched O
controls O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Twenty-eight O
newly O
diagnosed O
patients O
with O
small O
cell O
lung O
cancer O
were O
randomized O
to O
receive O
either O
high-dose O
or O
standard-dose O
cyclophosphamide O
, O
vincristine O
, O
and O
semustine O
in O
a O
trial O
where O
the O
dose O
of O
induction O
chemotherapy O
was O
the O
sole O
treatment O
variable O
. O
[]

OBJECTIVES O
The O
aim O
of O
the O
study O
was O
to O
determine O
whether O
cardiac O
pacing O
reduces O
falls B-outcome ['Life-Impact']
in O
older O
adults O
with O
cardioinhibitory O
carotid O
sinus O
hypersensitivity O
( O
CSH O
) O
. O
['Life-Impact']

METHODOLOGY O
Twenty O
patients O
had O
one O
side O
of O
their O
mouths O
brushed O
with O
a O
toothbrush O
containing O
the O
antimicrobial O
agent O
( O
experimental O
side O
) O
, O
and O
the O
other O
side O
with O
a O
toothbrush O
containing O
no O
agent O
( O
control O
) O
. O
[]

Data O
on O
TOD O
were O
not O
available O
. O
[]

During O
pre- O
and O
post-tests O
, O
submaximal O
exercise O
was O
performed O
on O
a O
stationary O
wheelchair O
ergometer O
at O
fixed O
levels O
of O
power O
output O
. O
[]

No O
time O
x O
training O
group O
effect O
was O
found O
for O
any O
of O
the O
vertical B-outcome ['Life-Impact']
jump I-outcome ['Life-Impact']
and O
Agility-15m O
variables O
( O
p B-outcome ['Physiological-Clinical']
> O
0.05 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

The O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
declined O
with O
esmolol O
from O
139 O
to O
100 O
beats/min O
( O
p O
less O
than O
0.001 O
) O
and O
with O
verapamil O
from O
142 O
to O
97 O
beats/min O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical']

SETTING O
Multiple O
sites O
of O
care O
in O
San O
Francisco O
, O
California O
. O
[]

We O
performed O
the O
following O
interventions O
: O
( O
1 O
) O
weekly O
90-minute O
yoga O
classes O
with O
daily O
at-home O
practice O
, O
( O
2 O
) O
individualized O
facility-based O
aerobic O
exercise O
training O
3 O
times/week O
, O
and O
( O
3 O
) O
0.615 O
g O
omega-3 O
supplement O
, O
3 O
times/day O
. O
[]

Ten O
weeks O
following O
SRP O
, O
mean O
PPD B-outcome ['Physiological-Clinical']
decreases O
were O
0.77 O
mm O
for O
the O
test O
group O
and O
0.13 O
mm O
for O
the O
control O
, O
and O
mean O
BI B-outcome ['Physiological-Clinical']
reductions O
were O
0.14 O
for O
the O
test O
group O
and O
0.00 O
for O
the O
control O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
rates O
of O
retinitis B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
, O
as O
evaluated O
in O
a O
masked O
fashion O
, O
were O
3.04/person-year O
in O
the O
MSL-109-treated O
group O
and O
3.05/person-year O
in O
the O
placebo-treated O
group O
( O
P=.98 O
; O
Wald O
test O
) O
; O
the O
median O
times O
to O
progression O
were O
67 O
days O
in O
the O
MSL-109-treated O
group O
and O
65 O
days O
in O
the O
placebo-treated O
group O
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION O
ISRCTN O
ISRCTN58280620 O
. O
[]

TYPE O
OF O
THE O
STUDY O
Prospective O
randomized O
study O
. O
[]

Two O
sprays O
of O
IB O
at O
a O
dose O
of O
42 O
micrograms/spray O
( O
0.06 O
% O
) O
, O
or O
saline O
, O
were O
administered O
intranasally O
twice O
daily O
for O
two O
weeks O
, O
after O
which O
time O
the O
participants O
were O
given O
another O
nasal O
spray O
( O
either O
IB O
or O
saline O
) O
for O
the O
crossover O
portion O
of O
the O
study O
. O
[]

The O
GAI-Estimate B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GAI-E I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
algorithms I-outcome ['Physiological-Clinical']
accounted O
for O
58 O
% O
to O
82 O
% O
of O
the O
variance O
. O
['Physiological-Clinical']

The O
association O
of O
change O
in O
year-1 O
eGFR O
and O
subsequent O
HF O
hospitalization O
was O
examined O
using O
Cox O
regression O
models O
. O
[]

Setting O
Emergency O
room/outpatient O
paediatric O
services O
of O
a O
tertiary O
care O
hospital O
. O
[]

The O
open O
flap O
debridement O
( O
OFD O
) O
was O
used O
as O
the O
control O
. O
[]

The O
passive O
drain O
group O
reported O
less O
nausea B-outcome ['Physiological-Clinical']
than O
the O
suction O
drain O
groups O
. O
['Physiological-Clinical']

METHODS O
A O
cluster O
randomised O
controlled O
trial O
consisting O
of O
two O
study O
arms O
, O
a O
treatment O
condition O
( O
n=179 O
) O
and O
a O
control O
condition O
( O
n=118 O
) O
, O
was O
used O
to O
examine O
the O
impact O
of O
the O
family O
economic O
empowerment O
intervention O
on O
children O
's O
levels O
of O
hopelessness O
and O
depression O
. O
[]

The O
serum B-outcome ['Physiological-Clinical']
LDL I-outcome ['Physiological-Clinical']
level O
decreased O
by O
6.2 O
% O
and O
11.8 O
% O
, O
respectively O
. O
['Physiological-Clinical']

We O
compared O
the O
safety O
and O
feasibility B-outcome ['Life-Impact']
of O
early O
and O
late O
delivery O
of O
stem O
cells O
with O
combined O
therapy O
approaches O
. O
['Life-Impact']

Study O
patients O
took O
each O
drug O
for O
five O
3-week O
periods O
, O
with O
international O
normalized O
ratio O
( O
INR B-outcome ['Physiological-Clinical']
) O
measurements O
taken O
twice O
per O
period O
. O
['Physiological-Clinical']

3 O
. O
[]

Participants O
were O
mothers O
of O
122 O
young O
children O
( O
mean O
age O
, O
34 O
months O
) O
who O
recently O
received O
a O
diagnosis O
of O
ASD O
. O
[]

At O
week O
8 O
Ca B-outcome ['Physiological-Clinical']
was O
not O
significantly O
changed O
in O
group O
A O
, O
whereas O
a O
significant O
increase O
occurred O
in O
groups O
B O
and O
C. O
Side-effects B-outcome ['Adverse-effects']
with O
sevelamer O
administration O
occurred O
in O
34 O
of O
the O
86 O
patients O
and O
24 O
dropped O
out O
of O
the O
study O
, O
with O
a O
high O
frequency O
in O
group O
A O
( O
13/29 O
; O
44.8 O
% O
) O
. O
['Physiological-Clinical', 'Adverse-effects']

RESULTS O
We O
found O
a O
significant O
decrease O
in O
pulmonary O
function O
, O
an O
increased O
use O
of O
salbutamol O
and O
the O
development O
of O
a O
late O
asthmatic O
response O
and O
bronchial O
hyperresponsiveness O
, O
as O
well O
as O
a O
significant O
induction O
of O
eNO O
, O
eosinophils O
, O
and O
Th-2 O
cytokines O
. O
[]

STUDY O
DESIGN O
Forty-eight O
patients O
from O
a O
private O
tertiary O
infertility O
clinic O
were O
assigned O
randomly O
prospectively O
to O
either O
group O
1 O
( O
oral O
contraceptive/clomiphene O
citrate O
) O
, O
which O
received O
continuous O
oral O
contraceptives O
followed O
by O
clomiphene O
citrate O
, O
or O
to O
group O
2 O
( O
control O
) O
received O
no O
treatment O
in O
the O
cycle O
before O
clomiphene O
citrate O
treatment O
. O
[]

Zoledronic O
acid O
significantly O
delayed B-outcome ['Physiological-Clinical']
time-to-first I-outcome ['Physiological-Clinical']
SRE I-outcome ['Physiological-Clinical']
( O
median O
not O
reached O
v O
364 O
days O
; O
Cox O
regression O
; O
P O
= O
.007 O
) O
and O
reduced O
the O
risk O
of O
SREs O
by O
41 O
% O
in O
multiple O
event O
analysis O
( O
risk O
ratio O
= O
0.59 O
; O
P O
= O
.019 O
) O
compared O
with O
placebo O
. O
['Physiological-Clinical']

Relief O
of O
periorbital O
pain O
after O
acute O
angle O
closure O
glaucoma O
attack O
by O
botulinum O
toxin O
type O
A O
. O
[]

RESULTS O
Both O
groups O
were O
similar O
regarding O
age O
( O
p O
= O
0.06 O
, O
Mann-Whitney O
test O
) O
. O
[]

This O
suggests O
a O
greater O
development O
pattern O
during O
the O
studied O
period O
for O
this O
group O
. O
[]

These O
changes O
in O
interaction O
were O
clinically O
relevant O
. O
[]

Asthma O
and O
the O
home O
environment O
of O
low-income O
urban O
children O
: O
preliminary O
findings O
from O
the O
Seattle-King O
County O
healthy O
homes O
project O
. O
[]

Furthermore O
, O
significant O
improvements O
were O
observed O
in O
CARS O
score O
( O
P O
= O
0.04 O
) O
in O
raw O
CM O
group O
only O
. O
[]

Results O
were O
analyzed O
with O
paired O
t-tests O
. O
[]

CONCLUSIONS O
Phased O
RF O
energy O
applied O
by O
a O
2:1 O
bipolar/unipolar O
mode O
seems O
safe O
and O
effective O
in O
redo-PVI O
procedures O
, O
resulting O
in O
a O
mid-term O
freedom O
from O
AF O
in O
86.4 O
% O
. O
[]

Outcome O
variables O
assessed O
were O
pain B-outcome ['Physiological-Clinical']
, O
additional B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
, O
and O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

The O
Eastern O
Cooperative O
Oncology O
Group O
experience O
with O
cyclophosphamide O
, O
adriamycin O
, O
and O
5-fluorouracil O
( O
CAF O
) O
in O
patients O
with O
metastatic O
breast O
cancer O
. O
[]

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
safety O
of O
induction O
treatment O
with O
antithymocyte O
globulins O
( O
ATG O
) O
followed O
by O
tacrolimus O
therapy O
with O
immediate O
tacrolimus O
therapy O
in O
renal O
transplant O
recipients O
. O
[]

In O
addition O
, O
the O
amount O
of O
narcotic B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
in O
the O
PACU O
was O
less O
in O
the O
fentanyl O
group O
( O
P O
< O
0.005 O
) O
. O
['Life-Impact']

Twenty-four O
participants O
with O
type O
2 O
diabetes O
( O
mean O
age O
58 O
years O
; O
14 O
women O
and O
10 O
men O
) O
were O
randomly O
assigned O
to O
one O
of O
the O
two O
possible O
sequence O
permutations O
to O
receive O
an O
ad O
libitum O
diet O
enriched O
with O
56 O
g O
( O
366 O
kcal O
) O
walnuts/day O
and O
an O
ad O
libitum O
diet O
without O
walnuts O
for O
8 O
weeks O
. O
[]

Visual O
analog O
scale O
pain B-outcome ['Physiological-Clinical']
scores O
at O
rest O
, O
with O
cough B-outcome ['Physiological-Clinical']
, O
and O
with O
movement B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
ipsilateral I-outcome ['Physiological-Clinical']
arm O
, O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
second I-outcome ['Physiological-Clinical']
( O
FEV1 B-outcome ['Physiological-Clinical']
) O
, O
and O
forced B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
( O
FVC B-outcome ['Physiological-Clinical']
) O
were O
measured O
at O
4 O
, O
24 O
, O
48 O
, O
and O
72 O
hours O
after O
the O
operation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
, O
prospective O
study O
. O
[]

The O
onset B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
of O
rapacuronium O
was O
shorter O
than O
rocuronium O
( O
87 O
( O
20 O
) O
vs O
141 O
( O
65 O
) O
s O
, O
P O
< O
0.001 O
) O
, O
and O
the O
degree O
of O
block O
at O
60 O
s O
was O
greater O
( O
69 O
( O
26 O
) O
vs O
50 O
( O
27 O
) O
% O
, O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
( O
1 O
) O
Intravenous O
diltiazem O
was O
effective O
on O
the O
improvement O
of O
symptom B-outcome ['Physiological-Clinical']
and O
electrocardiogram B-outcome ['Resource-use']
, O
and O
its O
effects O
were O
similar O
to O
intravenous O
nitroglycerin O
. O
( O
['Physiological-Clinical', 'Resource-use']

Cefprozil O
versus O
penicillin O
V O
in O
treatment O
of O
streptococcal O
tonsillopharyngitis O
. O
[]

After O
the O
intervention O
( O
age O
48 O
to O
77 O
months O
) O
, O
EEG B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
event-related I-outcome ['Physiological-Clinical']
potentials I-outcome ['Physiological-Clinical']
and O
spectral B-outcome ['Physiological-Clinical']
power O
) O
was O
measured O
during O
the O
presentation O
of O
faces O
versus O
objects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Results O
of O
the O
study O
show O
that O
primary O
closure O
is O
a O
safe O
and O
reiable O
method O
of O
management O
when O
rigid O
criteria O
are O
incorporated O
in O
an O
ongoing O
protocol O
. O
[]

OBJECTIVE O
It O
has O
been O
demonstrated O
that O
colon O
operation O
combined O
with O
fast-track O
( O
FT O
) O
surgery O
and O
laparoscopic O
technique O
can O
shorten O
the O
length O
of O
hospital B-outcome ['Resource-use']
stay B-outcome ['Resource-use']
, O
accelerate O
recovery B-outcome ['Physiological-Clinical']
of O
intestinal B-outcome ['Physiological-Clinical']
function B-outcome ['Life-Impact']
, O
and O
reduce O
the O
occurrence O
of O
post-operative B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

RESULTS O
No O
serious O
vaccine-related O
AEs O
occurred O
. O
[]

At O
1 O
year O
, O
H. O
pylori O
was O
eradicated O
in O
226 O
subjects O
assigned O
to O
OAC O
. O
[]

The O
mean O
lead-time B-outcome ['Physiological-Clinical']
was O
similar O
, O
6-7 O
years O
, O
at O
ages O
50-64 O
years O
, O
but O
close O
to O
8 O
years O
among O
men O
aged O
65-74 O
years O
. O
['Physiological-Clinical']

BACKGROUND O
Quick O
change O
( O
QC O
) O
and O
double O
pumping O
( O
DP O
) O
are O
common O
methods O
of O
substituting O
the O
infusion O
of O
inotropes O
given O
through O
intravenous O
pump O
. O
[]

The O
two O
periods O
were O
separated O
by O
a O
wash-out O
period O
( O
20 O
days O
) O
. O
[]

2 O
. O
[]

The O
incidence O
of O
[]

Periodontal O
probing O
depth O
( O
PPD O
) O
, O
clinical O
probing O
attachment O
level O
( O
CPAL O
) O
, O
and O
tooth O
mobility O
were O
measured O
using O
desmodontometry O
( O
DDM O
) O
and O
periotest O
( O
PTV O
) O
with O
reproducible O
methods O
before O
surgery O
and O
at O
various O
periods O
up O
to O
1 O
year O
afterwards O
. O
[]

Betamethasone O
reduced O
all O
three O
parameters O
, O
erythema B-outcome ['Physiological-Clinical']
, O
scaling O
and O
pruritus B-outcome ['Physiological-Clinical']
, O
faster O
than O
pimecrolimus O
, O
but O
the O
differences O
in O
reduction O
were O
not O
statistically O
significant O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
group O
1 O
, O
placental B-outcome ['Physiological-Clinical']
expulsion I-outcome ['Physiological-Clinical']
occurred O
in O
all O
patients O
and O
the O
duration O
of O
the O
placental B-outcome ['Physiological-Clinical']
expulsion I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
prostaglandin I-outcome ['Physiological-Clinical']
F2 I-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
was O
6.8 O
+/- O
1.36 O
( O
mean O
+/- O
SE O
) O
min O
: O
in O
group O
2 O
, O
six O
placental B-outcome ['Physiological-Clinical']
expulsions I-outcome ['Physiological-Clinical']
occurred O
after O
13.3 O
+/- O
1.97 O
min O
( O
mean O
+/- O
SE O
) O
; O
and O
in O
group O
3 O
, O
no O
effect O
was O
recorded O
after O
intraumbilical O
saline O
injection O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
P-selectin I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
, O
tissue O
plasminogen O
activator O
( O
tPA O
) O
antigen O
and O
activity O
, O
and O
plasminogen B-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
inhibitor-1 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PAI-1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
determined O
in O
60 O
acute O
atherosclerotic O
stroke O
patients O
and O
matched O
control O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
received O
premedication O
and O
opioids O
consistent O
with O
institutional O
practice O
, O
and O
inhalation O
agents O
were O
titrated O
to O
effect O
during O
anesthetic O
maintenance O
. O
[]

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
examine O
the O
effect O
of O
aging O
on O
circulating O
levels O
of O
the O
proinflammatory O
cytokines O
in O
a O
large O
cohort O
of O
septic O
shock O
patients O
. O
[]

On O
a O
subsequent O
day O
, O
we O
measured O
neural B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
while O
participants O
were O
shown O
static O
images O
of O
the O
previously O
learned O
virtual O
environment O
, O
now O
in O
the O
absence O
of O
any O
affective O
stimuli O
. O
['Physiological-Clinical']

Wade O
, O
& O
T. O
Charman O
, O
2007 O
) O
. O
[]

Of O
119 O
eligible O
patients O
, O
115 O
( O
96.6 O
% O
) O
attained O
complete O
remission O
by O
treatment O
with O
prednisone O
( O
PRD O
) O
plus O
vincristine O
( O
VCR O
) O
or O
vindesine O
( O
VDS O
) O
. O
[]

RESULTS O
Disability B-outcome ['Life-Impact']
, O
depression B-outcome ['Life-Impact']
, O
and O
visual O
analog O
scale O
scores O
decreased O
significantly O
after O
both O
treatments O
. O
['Life-Impact', 'Life-Impact']

Interviewers O
masked O
to O
participants O
' O
treatment O
group O
will O
assess O
outcomes O
at O
baseline O
and O
6 O
, O
12 O
and O
26 O
weeks O
after O
randomization O
. O
[]

Significantly O
better O
survival B-outcome ['Mortality']
rates O
were O
obtained O
in O
those O
cases O
with O
disseminating O
peritoneal O
metastasis O
, O
hepatic O
metastasis O
and O
stage O
V O
cancer O
in O
the O
MMC O
+ O
HCFU O
group O
as O
when O
compared O
with O
the O
MMC O
only O
group O
. O
['Mortality']

Patients O
received O
CEF O
( O
cyclophosphamide O
600 O
mg O
m-2 O
, O
epidoxorubicin O
60 O
mg O
m-2 O
and O
fluorouracil O
600 O
mg O
m-2 O
) O
i.v O
. O
[]

Noradrenergic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
intravenous O
yohimbine O
in O
patients O
with O
depression O
and O
comorbidity O
of O
depression O
and O
panic O
. O
['Physiological-Clinical']

Compared O
with O
dexibuprofen O
, O
ibuprofen O
arginate O
demonstrated O
a O
45 O
% O
higher O
maximum O
concentration O
( I-outcome ['Physiological-Clinical']
C B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) O
, O
and O
a O
time O
to O
peak O
concentration O
['Physiological-Clinical']

In O
the O
first O
study O
, O
40 O
specimens O
were O
randomly O
assigned O
to O
four O
groups O
of O
treatment O
: O
combined O
use O
of O
ultrasonic O
scaler O
and O
Periopolisher O
diamond-coated O
inserts O
( O
US-POL O
) O
, O
hand O
instruments O
( O
MANUAL O
) O
, O
Perioplaner-Periopolisher O
system O
( O
PPL-POL O
) O
and O
Periokit O
ultrasonic-designed O
scalers O
( O
PERIOKIT O
) O
. O
[]

In O
general O
, O
products O
that O
promote O
a O
moist O
wound O
environment O
produced O
better O
results O
than O
those O
that O
promote O
a O
dry O
wound O
environment O
, O
with O
an O
earlier O
onset O
of O
[]

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
of O
aripiprazole O
in O
the O
treatment O
of O
discrete O
symptoms O
of O
irritability O
associated O
with O
autistic O
disorder O
, O
as O
well O
as O
other O
symptoms O
captured O
on O
the O
Aberrant O
Behavior O
Checklist O
( O
ABC O
) O
. O
[]

Five O
of O
10 O
patients O
showed O
abnormalities O
of O
the O
hypothalamic-pituitary-adrenal B-outcome ['Physiological-Clinical']
axis I-outcome ['Physiological-Clinical']
, O
including O
borderline B-outcome ['Physiological-Clinical']
or O
increased O
UFC B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
in O
4 O
of O
them O
accompanied O
by O
blunted O
ACTH O
in O
2 O
cases O
and O
failure O
of O
cortisol O
to O
suppress O
after O
dexamethasone O
in O
1 O
; O
the O
fifth O
patient O
displayed O
low O
ACTH O
and O
resistance O
to O
dexamethasone O
suppression O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
s I-outcome ['Physiological-Clinical']
( O
FEV1 B-outcome ['Physiological-Clinical']
) O
and O
forced B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
( O
FVC B-outcome ['Physiological-Clinical']
) O
were O
recorded O
in O
37 O
non-atopic O
patients O
referred O
for O
intravenous O
urography O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
cross-sectional O
observations O
at O
7 O
years O
showed O
negative O
correlations O
between O
all O
OPs B-outcome ['Physiological-Clinical']
and O
age O
( O
p O
< O
0.0001-0.003 O
) O
, O
and O
between O
OP-3 B-outcome ['Physiological-Clinical']
and O
duration O
( O
p O
= O
0.003 O
) O
and O
counts O
of O
microaneurysms B-outcome ['Physiological-Clinical']
( O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
Barthel O
indexes O
were O
81.5+/-30.4 O
in O
the O
geriatric O
management O
arm O
and O
70.5+/-33.4 O
in O
the O
standard O
management O
arm O
( O
p=0.4 O
) O
. O
[]

An O
observational O
study O
. O
[]

1.6 O
vs O
3.5 O
? O
[]

Pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
after O
the O
initial O
dose O
of O
diclofenac-K O
( O
2 O
x O
12.5 O
mg O
) O
was O
superior O
to O
placebo O
( O
P O
< O
.01 O
for O
all O
efficacy O
outcomes O
) O
and O
comparable O
to O
paracetamol O
( O
2 O
x O
500 O
mg O
) O
. O
['Physiological-Clinical']

The O
mean O
maternal B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
erythropoietin I-outcome ['Physiological-Clinical']
was O
higher O
( O
p O
< O
0.05 O
) O
in O
the O
placebo O
group O
than O
in O
the O
hematinic O
group O
after O
24 O
weeks O
' O
gestation O
. O
['Physiological-Clinical']

RESULTS O
At O
6 O
months O
, O
6.2 O
% O
of O
patients O
died B-outcome ['Mortality']
, O
12.1 O
% O
had O
MI B-outcome ['Physiological-Clinical']
, O
and O
15.7 O
% O
suffered O
death B-outcome ['Mortality']
or O
MI B-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

Ambient B-outcome ['Physiological-Clinical']
nitrous I-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
exceeded O
25 O
parts O
per O
million O
in O
37 O
% O
of O
cases O
with O
uncuffed O
tubes O
and O
in O
0 O
% O
of O
cases O
with O
cuffed O
tubes O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

CONCLUSION O
Use O
of O
CEE O
results O
in O
a O
modest O
but O
statistically O
significant O
increase O
in O
mammographic B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
that O
is O
sustained O
over O
at O
least O
a O
2-year O
period O
. O
['Physiological-Clinical']

Analysis O
modalities O
and O
clinical O
applicability O
of O
QoL B-outcome ['Life-Impact']
in O
randomized O
phase O
II O
trial O
in O
a O
digestive O
oncology O
. O
['Life-Impact']

With O
resistant O
, O
progressive O
or O
relapsing O
disease O
, O
patients O
originally O
treated O
with O
MPH-P O
for O
induction O
received O
combination O
chemotherapy O
and O
vice O
versa O
. O
[]

The O
benefits O
of O
including O
clinical O
factors O
in O
rectal O
normal O
tissue O
complication O
probability O
modeling O
after O
radiotherapy O
for O
prostate O
cancer O
. O
[]

The O
CTnI B-outcome ['Physiological-Clinical']
level O
was O
statistically O
significantly O
lower O
in O
the O
IP O
group O
( O
p O
= O
0.043 O
) O
, O
and O
IP O
patients O
tended O
to O
have O
a O
smaller O
CK-MB B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
after O
surgery O
( O
not O
significant O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
failure-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
FFS B-outcome ['Mortality']
) O
and O
overall O
survival B-outcome ['Mortality']
( O
OS O
) O
had O
statistical O
differences O
. O
['Mortality', 'Mortality', 'Mortality']

CETP B-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
increased O
with O
escalating O
dose O
, O
leading O
to O
elevations O
of O
HDL-C O
of O
16 O
% O
to O
91 O
% O
. O
['Physiological-Clinical']

Moreover O
, O
in O
the O
D53-treated O
group O
, O
the O
optimal B-outcome ['Physiological-Clinical']
LPS I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
ie O
, O
LPS O
concentration O
that O
induced O
maximal O
IL-1 O
production O
) O
was O
significantly O
lower O
on O
day O
15 O
( O
mean O
+/- O
SD O
: O
11 O
+/- O
7 O
mg/L O
) O
than O
on O
day O
1 O
( O
16 O
+/- O
7 O
mg/L O
; O
p O
less O
than O
0.05 O
Wilcoxon O
W O
test O
) O
. O
['Physiological-Clinical']

AIM O
The O
aim O
of O
this O
retrospective O
trial O
was O
to O
investigate O
differences O
in O
mesiodistal O
and O
vestibulo-oral O
crown O
sizes O
of O
naturally O
, O
fully-erupted O
permanent O
maxillary O
teeth O
between O
patients O
with O
and O
without O
palatal O
canine O
displacement O
. O
[]

In O
the O
intervention O
group O
, O
the O
primary O
end O
point O
composite O
of O
death B-outcome ['Mortality']
or O
unplanned B-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
was O
reduced O
( O
hazard O
ratio O
, O
0.64 O
; O
confidence O
interval O
, O
0.43 O
to O
0.88 O
; O
P=0.008 O
) O
, O
driven O
by O
reduction O
in O
hospitalization B-outcome ['Resource-use']
. O
['Mortality', 'Resource-use', 'Resource-use']

RESULTS O
We O
found O
a O
significant O
decrease O
in O
PMN B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
in O
filtered O
blood B-outcome ['Physiological-Clinical']
cardioplegic I-outcome ['Physiological-Clinical']
solution I-outcome ['Physiological-Clinical']
during O
its O
first O
administration O
( O
0.27 O
? O
['Physiological-Clinical', 'Physiological-Clinical']

One O
hundred O
and O
eighty-seven O
13-year-old O
individuals O
with O
high O
levels O
of O
salivary O
S. O
mutans B-outcome ['Physiological-Clinical']
( O
greater O
than O
10 O
( O
6 O
) O
/mL O
) O
were O
selected O
. O
['Physiological-Clinical']

Prognostic O
factor O
analysis O
in O
patients O
with O
advanced O
prostate O
cancer O
treated O
by O
castration O
plus O
anandron O
or O
placebo O
: O
a O
final O
update O
. O
[]

OBJECTIVE O
To O
study O
the O
effect O
of O
crystalloid O
and O
colloid O
fluid O
on O
the O
accuracy O
( O
bias O
) O
and O
precision O
of O
pulse O
oximetry O
haemoglobin B-outcome ['Physiological-Clinical']
estimation O
to O
indicate O
the O
venous O
haemoglobin O
concentration O
in O
volunteers O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
in O
terms O
of O
cumulative O
rate O
of O
union B-outcome ['Physiological-Clinical']
( O
p=0.855 O
) O
, O
range O
of O
motion B-outcome ['Physiological-Clinical']
of O
the O
knee B-outcome ['Physiological-Clinical']
( O
p=0.727 O
) O
, O
overall O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
comparative O
analysis O
of O
the O
effects O
of O
the O
fixed O
combination O
of O
timolol O
and O
dorzolamide O
versus O
latanoprost O
plus O
timolol O
on O
ocular B-outcome ['Physiological-Clinical']
hemodynamics I-outcome ['Physiological-Clinical']
and O
visual B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
primary O
open-angle O
glaucoma O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
is O
the O
first O
placebo-controlled O
trial O
of O
olanzapine O
in O
the O
treatment O
of O
children O
and O
adolescents O
with O
PDD O
. O
[]

There O
was O
a O
significant O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
and O
analgesic B-outcome ['Resource-use']
intake I-outcome ['Resource-use']
in O
both O
active O
and O
sham O
TENS O
groups O
when O
compared O
with O
the O
control O
group O
( O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical', 'Resource-use']

RESULTS O
Lymphocysts B-outcome ['Physiological-Clinical']
appeared O
in O
23/61 O
patients O
( O
38 O
% O
) O
in O
total O
. O
['Physiological-Clinical']

ARIX O
: O
a O
randomised O
trial O
of O
acupuncture O
v O
oral O
care O
sessions O
in O
patients O
with O
chronic O
xerostomia O
following O
treatment O
of O
head O
and O
neck O
cancer O
. O
[]

The O
impact O
on O
outcome O
of O
the O
addition O
of O
all-trans O
retinoic O
acid O
to O
intensive O
chemotherapy O
in O
younger O
patients O
with O
nonacute O
promyelocytic O
acute O
myeloid O
leukemia O
: O
overall O
results O
and O
results O
in O
genotypic O
subgroups O
defined O
by O
mutations O
in O
NPM1 O
, O
FLT3 O
, O
and O
CEBPA O
. O
[]

Effect O
of O
facial O
sensory O
re-training O
on O
sensory O
thresholds O
. O
[]

Thus O
, O
the O
severity O
of O
a O
specific B-outcome ['Life-Impact']
behavioral I-outcome ['Life-Impact']
dimension I-outcome ['Life-Impact']
in O
autism O
( O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
) O
parallels B-outcome ['Life-Impact']
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
the O
rates O
of O
in B-outcome ['Physiological-Clinical']
vitro I-outcome ['Physiological-Clinical']
oocyte I-outcome ['Physiological-Clinical']
maturation I-outcome ['Physiological-Clinical']
, O
fertilization B-outcome ['Physiological-Clinical']
and O
cleavage B-outcome ['Physiological-Clinical']
, O
as O
well O
as O
implantation B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
pregnancy B-outcome ['Physiological-Clinical']
rate O
, O
could O
be O
improved O
by O
low-dose O
priming O
with O
FSH O
in O
vivo O
before O
retrieval O
of O
immature O
oocytes O
in O
patients O
with O
polycystic O
ovary O
syndrome O
( O
PCOS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Combined O
administration O
of O
nitric O
oxide O
gas O
and O
iloprost O
during O
cardiopulmonary O
bypass O
reduces O
platelet O
dysfunction O
: O
a O
pilot O
clinical O
study O
. O
[]

The O
current O
study O
investigated O
perceptual B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
in O
two O
optimal O
conditions O
: O
conversational O
speech O
( O
Experiment O
1 O
) O
versus O
clear O
speech O
( O
Experiment O
2 O
) O
, O
and O
three O
adverse O
conditions O
: O
noise O
( O
Experiment O
3a O
) O
versus O
two O
cognitive O
loads O
( O
Experiments O
4a O
and O
4b O
) O
. O
['Life-Impact']

The O
decrease O
in O
bronchial B-outcome ['Physiological-Clinical']
hyperresponsiveness I-outcome ['Physiological-Clinical']
was O
, O
however O
, O
more O
marked O
in O
the O
high O
dose O
budesonide O
group O
, O
reaching O
a O
borderline O
significance O
( O
P=0.10 O
high O
vs. O
low O
dose O
budesonide O
) O
. O
['Physiological-Clinical']

The O
patients O
with O
abnormal O
spaces O
, O
coagulopathy O
, O
infection O
, O
pre-eclampsia/eclampsia O
or O
obesity O
were O
excluded O
. O
[]

Beneficial O
effects O
on O
serum B-outcome ['Physiological-Clinical']
triglyceride I-outcome ['Physiological-Clinical']
, O
HDL-cholesterol B-outcome ['Physiological-Clinical']
and O
apo B-outcome ['Physiological-Clinical']
A1 I-outcome ['Physiological-Clinical']
levels O
were O
also O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

On O
the O
third O
day O
of O
GnRH-a O
administration O
, O
119 O
patients O
were O
randomized O
in O
three O
groups O
to O
receive O
daily O
fixed O
doses O
of O
300 O
IU O
of O
rFSH O
( O
group O
A O
, O
n O
= O
38 O
) O
, O
or O
450 O
IU O
of O
rFSH O
( O
group O
B O
, O
n O
= O
39 O
) O
, O
or O
600 O
IU O
of O
rFSH O
( O
group O
C O
, O
n O
= O
42 O
) O
. O
[]

To O
improve O
guideline O
implementation O
, O
it O
is O
essential O
to O
understand O
factors O
influencing O
it O
and O
find O
effective O
ways O
to O
influence O
those O
factors O
. O
[]

OBJECTIVE O
To O
determine O
the O
clinical O
manifestations O
of O
vulvovaginal O
candidiasis O
( O
VVC O
) O
and O
to O
study O
the O
mycologic B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
rate O
of O
different O
miconazole O
treatment O
courses O
for O
VVC O
. O
['Physiological-Clinical']

SETTING O
Three O
university O
teaching O
hospitals O
in O
Hamilton O
, O
Ontario O
, O
Canada O
. O
[]

Serum B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
leptin I-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
, O
cortisol B-outcome ['Physiological-Clinical']
, O
T4 B-outcome ['Physiological-Clinical']
, O
T3 B-outcome ['Physiological-Clinical']
, O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor O
( O
IGF B-outcome ['Physiological-Clinical']
) O
-I O
, O
IGF-binding B-outcome ['Physiological-Clinical']
protein-3 I-outcome ['Physiological-Clinical']
and O
the O
acid-labile B-outcome ['Physiological-Clinical']
subunit O
( O
ALS O
) O
were O
measured O
at O
0900 O
h O
, O
2100 O
h O
, O
and O
0600 O
h O
on O
each O
of O
the O
2 O
study O
days O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
During O
a O
median O
follow O
up O
of O
818 O
days O
, O
21 O
patients O
received O
one O
dose O
and O
19 O
received O
four O
doses O
, O
with O
10 O
( O
47.6 O
% O
) O
and O
eight O
( O
42.1 O
% O
) O
recurrences O
, O
respectively O
. O
[]

Using O
the O
cluster O
randomised O
controlled O
design O
, O
we O
aim O
to O
provide O
further O
evidence O
on O
intervention O
effects O
, O
as O
well O
as O
on O
the O
validity O
and O
feasibility O
of O
the O
theoretical-domain O
approach O
. O
[]

Results O
revealed O
that O
treated O
young O
adults O
reported O
significantly O
less O
loneliness B-outcome ['Life-Impact']
and O
improved O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
, O
while O
caregivers O
reported O
significant O
improvements O
in O
young O
adults O
' O
overall B-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
responsiveness I-outcome ['Life-Impact']
, O
empathy B-outcome ['Life-Impact']
, O
and O
frequency O
of O
get-togethers B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

STUDY O
DESIGN O
A O
total O
of O
28 O
patients O
with O
mandibular O
retrognathism O
had O
bilateral O
sagittal O
split O
osteotomies O
for O
mandibular O
advancement O
. O
[]

HYPOTHESIS O
Parenteral O
administration O
of O
erythromycin O
increases O
and O
gentamicin O
decreases O
the O
rate O
of O
abomasal B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Treatment O
of O
children O
with O
autism O
: O
a O
randomized O
controlled O
trial O
to O
evaluate O
a O
caregiver-based O
intervention O
program O
in O
community O
day-care O
centers O
. O
[]

These O
results O
confirm O
that O
relative-direction O
judgments O
do O
not O
require O
information O
about O
eye O
position O
. O
[]

Tests O
of O
upright B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
included O
: O
timed B-outcome ['Physiological-Clinical']
up I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
go I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TUG I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
sharpened B-outcome ['Physiological-Clinical']
Romberg I-outcome ['Physiological-Clinical']
, O
360-degree B-outcome ['Physiological-Clinical']
turns I-outcome ['Physiological-Clinical']
, O
25-foot B-outcome ['Physiological-Clinical']
walk I-outcome ['Physiological-Clinical']
, O
and O
computerized B-outcome ['Physiological-Clinical']
platform I-outcome ['Physiological-Clinical']
posturography I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Are O
PRO O
discharge O
screens O
associated O
with O
postdischarge O
adverse O
outcomes O
? O
[]

DESIGN O
Longitudinal O
follow-up O
of O
participants O
enrolled O
in O
a O
randomized O
clinical O
trial O
. O
[]

Thirty O
patients O
undergoing O
elective O
eye O
surgery O
had O
anaesthesia O
induced O
with O
sodium O
thiopentone O
, O
suxamethonium O
and O
d-tubocurarine O
chloride O
. O
[]

The O
vaginal O
insert O
was O
removed O
for O
spontaneous O
rupture O
of O
membranes O
, O
entry O
into O
active O
labor O
, O
adequate O
cervical O
ripening O
, O
or O
abnormality O
of O
uterine O
contractile O
pattern O
or O
fetal O
cardiac O
activity O
. O
[]

OBJECTIVE O
Risperidone O
is O
widely O
prescribed O
for O
aggression O
and O
self-injury O
in O
children O
, O
adolescents O
, O
and O
adults O
with O
mental O
retardation O
( O
MR O
) O
and O
pervasive O
developmental O
disorders O
( O
PDD O
) O
. O
[]

Patients O
were O
randomized O
to O
have O
respiratory O
acidosis O
corrected O
by O
THAM O
( O
pH-corrected O
group O
) O
, O
or O
not O
corrected O
( O
pH-uncorrected O
group O
) O
. O
[]

Bisphosphonates O
are O
now O
in O
the O
vanguard O
of O
osteoporosis O
treatment O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

The O
most O
common O
AEs O
in O
the O
C/A O
and O
H/A O
groups O
were O
constipation O
( O
36 O
% O
and O
29 O
% O
, O
respectively O
) O
, O
dizziness O
( O
24 O
% O
and O
19 O
% O
) O
, O
vomiting O
( O
24 O
% O
and O
16 O
% O
) O
, O
and O
dry O
mouth O
( O
15 O
% O
and O
18 O
% O
) O
, O
with O
no O
significant O
differences O
between O
groups O
. O
[]

Median O
followup O
in O
the O
white O
light O
and O
fluorescence O
groups O
was O
53.0 O
and O
55.1 O
months O
, O
and O
83 O
( O
31.8 O
% O
) O
and O
97 O
patients O
( O
38 O
% O
) O
remained O
tumor O
free O
, O
respectively O
. O
[]

8.5 O
% O
; O
p O
< O
0.001 O
) O
and O
total O
atheroma O
volume O
( O
174.6 O
? O
[]

During O
postoperative O
observation O
of O
up O
to O
two O
years O
, O
progressive O
improvement O
in O
hepatic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
has O
occurred O
. O
['Physiological-Clinical']

Different O
prognostic O
factors O
and O
SLN O
tumor O
burden O
were O
recorded O
. O
[]

BACKGROUND O
Although O
the O
DFT B-outcome ['Resource-use']
using I-outcome ['Resource-use']
monophasic I-outcome ['Resource-use']
waveforms I-outcome ['Resource-use']
has O
been O
shown O
to O
increase O
with O
VF O
duration O
in O
humans O
, O
the O
effect O
of O
VF O
duration O
on O
defibrillation O
efficacy O
using O
biphasic O
waveforms O
in O
humans O
is O
not O
known O
. O
['Resource-use']

DESIGN O
Randomized O
, O
open-label O
, O
dose-escalating O
phase O
I O
study O
. O
[]

BACKGROUND O
Sudden B-outcome ['Mortality']
cardiac I-outcome ['Mortality']
death I-outcome ['Mortality']
( I-outcome ['Mortality']
SCD I-outcome ['Mortality']
) I-outcome ['Mortality']
is O
an O
important O
cause O
of O
mortality O
even O
among O
apparently O
healthy O
populations O
. O
['Mortality']

Subjects O
in O
each O
group O
underwent O
3 O
1-hour O
exercise O
sessions O
per O
week O
for O
19 O
weeks O
. O
[]

RESULTS O
[]

METHODS O
Four O
hundred O
patients O
with O
stage O
II O
and O
III O
rectal O
cancer O
received O
postoperative O
CRT O
of O
capecitabine O
with O
or O
without O
oxaliplatin O
were O
accumulated O
and O
prostectively O
studied O
in O
this O
study O
. O
[]

Pain O
was O
reduced O
from O
a O
median O
of O
6 O
to O
4 O
and O
finally O
to O
3 O
in O
both O
groups O
. O
[]

All O
patients O
were O
dialyzed O
against O
the O
same O
calcium O
dialyzate O
( O
1.62 O
mmol/l O
) O
. O
[]

the O
patients O
had O
lesions O
greater O
than O
1.70 O
mm O
thick O
and O
TNM O
stage O
IB O
or O
stage O
II O
disease O
. O
[]

A O
prospective O
randomized O
trial O
of O
Duraflo O
II O
heparin-coated O
circuits O
in O
cardiac O
reoperations O
. O
[]

There O
was O
only O
one O
death B-outcome ['Mortality']
in O
JET O
group O
( O
1.8 O
% O
) O
with O
no O
significant O
difference O
compared O
with O
the O
control O
group O
. O
['Mortality']

METHOD O
The O
study O
was O
a O
single-blind O
, O
randomised O
, O
five-treatment O
cross-over O
design O
involving O
15 O
healthy O
volunteers O
. O
[]

A O
major O
cause O
of O
long-standing O
problems O
is O
adductor-related O
groin O
pain O
. O
[]

Clinical O
, O
radiological O
and O
patient-based B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
were O
recorded O
at O
1 O
and O
5 O
weeks O
after O
intervention O
. O
['Physiological-Clinical']

Sixty-one O
healthy O
adults O
consumed O
each O
of O
3 O
diets O
for O
3 O
wk O
, O
in O
random O
order O
. O
[]

For O
the O
positive O
feedback O
condition O
, O
increases O
in O
the O
index O
caused O
an O
increase O
in O
the O
array O
size O
( O
AS O
) O
while O
decreases O
caused O
a O
decrease O
in O
the O
array O
size O
. O
[]

Paired O
embryo O
transfers O
were O
accomplished O
by O
transferring O
one O
euploid O
embryo O
from O
each O
group O
. O
[]

PATIENTS O
Fifty-five O
patients O
suspected O
of O
having O
SAHS O
and O
living O
within O
30 O
km O
of O
our O
laboratory O
. O
[]

Statistically O
significant O
effects O
were O
seen O
on O
scaling/hypertrophy O
, O
induration O
, O
pain O
and O
itching O
as O
well O
as O
patient O
global O
assessment O
, O
suggesting O
that O
R-salbutamol O
could O
be O
a O
promising O
new O
topical O
therapy O
alternative O
for O
DLE O
. O
[]

After O
a O
placebo O
lead-in O
period O
, O
patients O
received O
either O
cetamolol O
5-10-15 O
mg/d O
( O
low O
dose O
) O
, O
cetamolol O
15-25-50 O
mg/d O
( O
high O
dose O
) O
, O
or O
placebo O
, O
once O
daily O
for O
four O
weeks O
. O
[]

After O
the O
initial O
clinical O
evaluation O
, O
including O
plain O
radiography O
and O
MRI O
, O
37 O
hips O
with O
early-stage O
osteonecrosis O
( O
ON O
) O
in O
33 O
patients O
were O
randomly O
assigned O
to O
a O
core-decompression O
group O
or O
a O
conservatively-treated O
group O
. O
[]

A O
major O
issue O
was O
that O
of O
adapting O
international O
best O
practice O
recommendations O
with O
regard O
to O
home-visiting O
programs O
to O
the O
particularities O
of O
the O
existing O
French O
social O
and O
health O
care O
system O
. O
[]

As O
to O
Lysholm O
score O
, O
there O
were O
significant O
differences O
in O
limp B-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
, O
swelling B-outcome ['Physiological-Clinical']
, O
stair B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
squat B-outcome ['Physiological-Clinical']
, O
but O
there O
were O
no O
significant O
differences O
in O
items O
of O
interlocking B-outcome ['Physiological-Clinical']
and O
instability B-outcome ['Physiological-Clinical']
between O
two O
groups O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Virtual O
Patients O
( O
VPs O
) O
are O
web-based O
representations O
of O
realistic O
clinical O
cases O
. O
[]

Adherence B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
lifestyle I-outcome ['Life-Impact']
recommendations I-outcome ['Life-Impact']
by O
patients O
with O
depression O
. O
['Life-Impact']

CONCLUSIONS O
The O
lower O
initial O
hospital B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
of O
the O
noninvasive O
approach O
are O
offset O
by O
greater O
follow-up O
costs O
. O
['Resource-use']

Effect O
of O
liquid-polish O
coating O
on O
in O
vivo B-outcome ['Physiological-Clinical']
biofilm I-outcome ['Physiological-Clinical']
accumulation I-outcome ['Physiological-Clinical']
on O
provisional O
restorations O
: O
part O
1 O
. O
['Physiological-Clinical']

Acid B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
of O
enamel O
subsurface O
lesions O
remineralized O
by O
a O
sugar-free O
chewing O
gum O
containing O
casein O
phosphopeptide-amorphous O
calcium O
phosphate O
. O
['Physiological-Clinical']

CONCLUSION O
In O
this O
prospective O
, O
randomized O
trial O
, O
the O
addition O
of O
a O
direct O
nitric O
oxide O
donor O
to O
nitroglycerin O
in O
an O
antispastic O
cocktail O
did O
not O
reduce O
the O
risk O
of O
spasm O
, O
and O
the O
use O
of O
nitroglycerin O
was O
found O
to O
be O
as O
effective O
as O
nitroprusside O
. O
[]

We O
examined O
the O
effects O
of O
open O
suction O
( O
OS O
) O
and O
CS O
on O
lung B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
loss O
during O
suctioning O
, O
and O
recovery O
of O
end-expiratory B-outcome ['Physiological-Clinical']
lung I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EELV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
up O
to O
30 O
minutes O
postsuction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
trained O
9 O
persons O
with O
heart O
failure O
to O
mentor O
other O
heart O
failure O
patients O
and O
tested O
the O
effectiveness O
of O
this O
approach O
in O
a O
randomized O
controlled O
clinical O
trial O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
combine O
two O
in O
situ O
protocols O
to O
study O
the O
interplay O
between O
erosion B-outcome ['Physiological-Clinical']
and O
abrasion B-outcome ['Physiological-Clinical']
of O
enamel B-outcome ['Physiological-Clinical']
and O
dentine B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Preschool O
based O
JASPER O
intervention O
in O
minimally O
verbal O
children O
with O
autism O
: O
pilot O
RCT O
. O
[]

Effects O
of O
strontium O
on O
the O
quality O
of O
bone B-outcome ['Physiological-Clinical']
apatite I-outcome ['Physiological-Clinical']
crystals I-outcome ['Physiological-Clinical']
: O
a O
paired O
biopsy O
study O
in O
postmenopausal O
osteoporotic O
women O
. O
['Physiological-Clinical']

However O
, O
the O
pharmacodynamic O
( O
PD O
) O
effects O
of O
the O
PDE O
inhibitor O
pentoxifylline O
on O
platelet B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
profiles O
in O
DM O
patients O
receiving O
DAPT O
are O
unknown O
. O
['Physiological-Clinical']

1 O
( O
TB1 O
, O
a O
prescription O
for O
reinforcing O
Kidney O
and O
Spleen O
, O
clearing O
up O
the O
bowel O
viscera O
to O
send O
Turbid O
downward O
and O
regulating O
Qi O
and O
blood O
) O
in O
retarding B-outcome ['Physiological-Clinical']
aging I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Here O
, O
we O
searched O
for O
activity O
correlating O
with O
temporal O
complexity O
, O
in O
terms O
of O
the O
number O
of O
different O
intervals O
produced O
in O
the O
sequence O
, O
using O
an O
overlearned O
tapping O
task O
. O
[]

BACKGROUND O
Cognitive O
difficulties O
have O
been O
reported O
after O
coronary O
artery O
bypass O
graft O
surgery O
using O
cardiopulmonary O
bypass O
. O
[]

PATIENTS O
AND O
METHODS O
Sixty-seven O
children O
with O
very O
high-risk O
ALL O
were O
randomized O
( O
slow O
early O
response O
to O
therapy O
, O
55 O
patients O
; O
translocation O
t O
( O
9 O
; O
22 O
) O
or O
t O
( O
4 O
; O
11 O
) O
, O
12 O
patients O
) O
. O
[]

We O
examined O
effects O
of O
BLT O
on O
motor B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
depression B-outcome ['Life-Impact']
, O
and O
sleep B-outcome ['Physiological-Clinical']
in O
PD O
in O
a O
randomized O
placebo-controlled O
double-blind O
study O
in O
36 O
PD O
patients O
, O
using O
Parkinson O
's O
Disease O
Rating O
Scale O
( O
UPDRS O
) O
I-IV O
, O
Beck O
's O
Depression O
Inventory O
, O
and O
Epworth O
Sleepiness B-outcome ['Physiological-Clinical']
Scale O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Study O
1 O
included O
52 O
subjects O
assigned O
to O
placebo O
and O
49 O
subjects O
to O
risperidone O
under O
double-blind O
conditions O
. O
[]

Nineteen O
women O
( O
mean O
age=38.0 O
years O
, O
SD=9.9 O
years O
) O
with O
schizophrenia O
hospitalized O
for O
the O
first O
time O
or O
repeatedly O
were O
included O
in O
the O
study O
. O
[]

Whole-brain O
radiotherapy O
( O
WBRT O
) O
gives O
symptomatic O
improvement O
in O
more O
than O
50 O
% O
of O
these O
patients O
. O
[]

Though O
the O
groups O
did O
not O
differ O
significantly O
on O
the O
social B-outcome ['Life-Impact']
cognition I-outcome ['Life-Impact']
composite O
score O
, O
oxytocin O
improved O
performance O
for O
the O
higher-level O
social B-outcome ['Life-Impact']
cognitive I-outcome ['Life-Impact']
tasks O
( O
Cohen O
's O
d=1.0 O
, O
p=0.045 O
) O
. O
['Life-Impact', 'Life-Impact']

The O
influence O
of O
amiloride O
on O
the O
therapeutic O
and O
metabolic O
effects O
of O
carbenoxolone O
in O
patients O
with O
gastric O
ulcer O
. O
[]

RESULTS O
Seventy O
patients O
completed O
the O
study O
( O
36 O
verum O
; O
34 O
placebo O
) O
. O
[]

BACKGROUND/AIMS O
The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
of O
somatostatin O
vs. O
ranitidine O
in O
controlling O
acute B-outcome ['Physiological-Clinical']
non-variceal I-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Risperidone O
therapy O
was O
associated O
with O
an O
average O
weight O
gain O
of O
2.7+/-2.9 O
kg O
, O
as O
compared O
with O
0.8+/-2.2 O
kg O
with O
placebo O
( O
P O
< O
0.001 O
) O
. O
[]

The O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
at O
3 O
, O
4 O
, O
5 O
, O
and O
6 O
min O
) O
of O
patients O
in O
the O
study O
group O
increased O
significantly O
less O
than O
that O
of O
patients O
in O
the O
control O
group O
. O
['Physiological-Clinical']

Laser-aided O
external O
drainage O
of O
subretinal O
fluid O
: O
prospective O
randomized O
comparison O
with O
needle O
drainage O
. O
[]

Each O
patient O
received O
single O
oral O
doses O
of O
30 O
mg O
nicorandil O
, O
10 O
mg O
nifedipine O
, O
and O
, O
on O
2 O
days O
, O
a O
placebo O
. O
[]

METHODS O
In O
this O
open-label O
, O
parallel-group O
, O
randomised O
controlled O
trial O
, O
eligible O
patients O
were O
adults O
undergoing O
allogeneic O
stem-cell O
transplantation O
or O
chemotherapy O
for O
acute O
leukaemia O
, O
with O
no O
history O
of O
invasive O
fungal O
disease O
. O
[]

14 O
( O
11.0 O
% O
) O
patients O
in O
the O
hydrotalcite O
group O
and O
six O
( O
4.8 O
% O
) O
in O
the O
esomeprazole O
group O
[]

Clinical O
trial O
: O
exposure O
to O
ribavirin O
predicts O
EVR O
and O
SVR O
in O
patients O
with O
HCV O
genotype O
1 O
infection O
treated O
with O
peginterferon O
alpha-2a O
plus O
ribavirin O
. O
[]

We O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
supplemental O
oral O
vitamin O
D O
( O
placebo O
, O
1,000 O
, O
2,000 O
, O
or O
4,000 O
IU/day O
of O
vitamin O
D3 O
orally O
for O
3 O
months O
) O
in O
328 O
African O
Americans O
( O
median O
age O
, O
51 O
years O
) O
of O
public O
housing O
communities O
in O
Boston O
, O
MA O
, O
who O
were O
enrolled O
over O
three O
consecutive O
winter O
periods O
( O
2007-2010 O
) O
. O
[]

Children O
in O
the O
intervention O
group O
showed O
improved O
performance O
in O
the O
recognition B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
anger I-outcome ['Life-Impact']
compared O
with O
the O
control O
group O
, O
with O
few O
improvements O
maintained O
at O
3-month O
follow-up O
. O
['Life-Impact']

OBJECTIVE O
This O
study O
evaluated O
the O
efficacy O
and O
safety O
of O
naltrexone O
, O
an O
opiate O
blocker O
, O
in O
the O
treatment O
of O
autism O
. O
[]

Single-needle O
acupuncture O
alleviates O
gag O
reflex O
during O
transesophageal O
echocardiography O
: O
a O
blinded O
, O
randomized O
, O
controlled O
pilot O
trial O
. O
[]

injection O
5 O
min O
before O
surgery O
and O
isotonic O
saline O
5 O
mL O
i.v O
. O
[]

Induction O
deaths B-outcome ['Mortality']
were O
comparable O
at O
9 O
% O
( O
ALL-2 O
) O
versus O
7 O
% O
( O
L-20 O
) O
. O
['Mortality']

Antipyretic O
treatment O
had O
no O
effect O
on O
fever B-outcome ['Physiological-Clinical']
clearance O
and O
therefore O
should O
be O
used O
cautiously O
in O
the O
treatment O
of O
malaria O
. O
['Physiological-Clinical']

Thirty-minute O
language O
groups O
were O
targeted O
to O
teach O
receptive O
and O
expressive O
skills O
using O
pictures O
and O
common O
objects O
across O
five O
categories O
( O
e.g. O
, O
household O
items O
, O
foods O
) O
. O
[]

RESULTS O
A O
significant O
difference O
in O
improvement O
of O
overall B-outcome ['Physiological-Clinical']
subjective I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
an O
intent-to-treat O
analysis O
between O
groups O
T O
and O
C O
was O
found O
at O
the O
follow-ups O
. O
['Physiological-Clinical']

PTK2 O
expression O
may O
be O
a O
useful O
biomarker O
for O
patient O
selection O
in O
future O
trials O
. O
[]

Thus O
, O
changes O
in O
the O
chain O
length O
of O
the O
alkyl O
substituent O
of O
synthetic O
PAF O
homologues O
and O
combination O
of O
these O
homologues O
, O
in O
ratios O
found O
in O
vivo O
or O
formed O
by O
leukocytes O
in O
vitro O
, O
did O
not O
alter O
the O
cutaneous O
[]

Outcome O
was O
correlated O
with O
biomarkers O
measured O
on O
the O
primary O
tumor O
. O
[]

AIDS O
Clinical O
Trials O
Group O
Protocol O
915 O
Team O
. O
[]

Effects O
of O
antihypertensive O
drugs O
on O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
adolescents O
. O
['Life-Impact']

The O
animals O
in O
group O
1 O
( O
RDN0 O
) O
were O
fed O
with O
ad O
libitum O
FMS O
. O
[]

However O
, O
individuals O
who O
participated O
in O
sheltered O
workshops O
earned B-outcome ['Life-Impact']
significantly O
less O
( O
US O
$ O
129.36 O
versus O
US O
$ O
191.42 O
per O
week O
) O
, O
and O
cost B-outcome ['Resource-use']
significantly O
more O
to O
serve O
( O
US O
$ O
6,065.08 O
versus O
US O
$ O
2,440.60 O
) O
, O
than O
their O
non-sheltered O
workshop O
peers O
. O
['Life-Impact', 'Resource-use']

However O
, O
fenofibrate O
therapy O
had O
substantially O
better O
effects O
on O
lipoprotein B-outcome ['Physiological-Clinical']
and O
metabolic B-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
in O
patients O
with O
hypertriglyceridemia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
results O
indicate O
that O
there O
is O
no O
contraindication O
to O
the O
use O
of O
zolmitriptan O
in O
patients O
treated O
concurrently O
with O
selective O
serotonin O
reuptake O
inhibitors O
and O
that O
no O
adjustment O
of O
the O
zolmitriptan O
dose O
is O
required O
in O
these O
circumstances O
. O
[]

In O
a O
double-blind O
, O
placebo O
, O
cross-over O
study O
, O
nine O
healthy O
volunteers O
were O
given O
intravenous O
lidocaine O
( O
or O
saline O
) O
to O
approximate O
the O
plasma O
levels O
of O
lidocaine O
achieved O
during O
epidural O
anesthesia O
for O
major O
abdominal O
surgery O
. O
[]

the O
production O
of O
the O
skin O
reaction O
. O
[]

METHODS O
Participants O
were O
578 O
children O
who O
were O
part O
of O
an O
ongoing O
population-based O
, O
case-control O
study O
of O
2- O
to O
5-year O
olds O
with O
ASD O
, O
DD O
, O
and O
the O
general O
population O
. O
[]

The O
experimental O
group O
received O
7 O
weeks O
wheelchair O
training O
( O
3 O
week O
( O
-1 O
) O
, O
70 O
min O
) O
at O
a O
low O
intensity O
( O
30 O
% O
of O
the O
heart O
rate O
reserve O
) O
, O
whereas O
the O
control O
group O
did O
not O
receive O
training O
. O
[]

[ O
Effect O
of O
dopexamine O
in O
splanchnic O
perfusion O
during O
surgery O
of O
the O
abdominal O
aorta O
] O
. O
[]

It O
induced O
more O
adverse O
effects O
and O
this O
should O
be O
considered O
before O
routinely O
using O
the O
combined O
spinal-epidural O
technique O
. O
[]

Sixty-three O
percent O
of O
5143 O
screen-positives O
complied O
with O
referral B-outcome ['Life-Impact']
. O
['Life-Impact']

This O
study O
examined O
the O
effect O
of O
vegetarianism O
on O
skeletal B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
total O
creatine B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TCr I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
content B-outcome ['Physiological-Clinical']
and O
creatine B-outcome ['Physiological-Clinical']
transporter I-outcome ['Physiological-Clinical']
( O
CreaT B-outcome ['Physiological-Clinical']
) O
gene B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
, O
prior O
to O
and O
during O
5 O
d O
of O
Cr O
supplementation O
( O
CrS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

After O
treatment O
, O
the O
Chinese B-outcome ['Physiological-Clinical']
medicine I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
scores O
, O
urinary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
red-cell I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
reduced O
significantly O
in O
the O
treatment O
group O
( O
P O
< O
0.05 O
or O
P O
< O
0.01 O
) O
and O
showed O
significant O
difference O
as O
compared O
with O
those O
in O
the O
control O
group O
( O
P O
< O
0.05 O
or O
P O
< O
0.01 O
) O
; O
while O
the O
endogenous B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
was O
changed O
insignificantly O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
We O
recruited O
609 O
postmenopausal O
women O
with O
a O
mean O
age O
of O
61 O
( O
sd O
6 O
years O
) O
, O
of O
whom O
113 O
( O
19 O
% O
) O
had O
VDI O
. O
[]

CONCLUSIONS O
In O
patients O
with O
atrial O
fibrillation O
, O
rivaroxaban O
was O
noninferior O
to O
warfarin O
for O
the O
prevention O
of O
stroke O
or O
systemic O
embolism O
. O
[]

If O
the O
DEA O
reclassifies O
hydrocodone O
as O
a O
Schedule O
II O
narcotic O
, O
as O
recently O
recommended O
by O
its O
advisory O
board O
, O
our O
data O
suggest O
that O
the O
codeine/acetaminophen O
may O
be O
a O
clinically O
reasonable O
Schedule O
III O
substitute O
for O
hydrocodone/acetaminophen O
at O
ED O
discharge O
. O
[]

There O
was O
no O
survival B-outcome ['Mortality']
benefit O
from O
FAM O
adjuvant O
chemotherapy O
. O
['Mortality']

Patients O
in O
the O
exercise O
group O
who O
had O
not O
reported O
sick O
at O
entry O
had O
more O
sickness B-outcome ['Life-Impact']
absences I-outcome ['Life-Impact']
during O
the O
follow-up O
year O
than O
patients O
in O
the O
usual O
care O
and O
placebo O
group O
. O
['Life-Impact']

To O
evaluate O
treatment O
withdrawal O
effects O
, O
12- O
and O
24-month O
post O
EOT O
BMD O
results O
are O
available O
for O
122 O
and O
126 O
patients O
, O
respectively O
. O
[]

Only O
patients O
with O
negative O
HCV O
RNA O
at O
week O
10 O
continued O
treatment O
. O
[]

The O
inappropriateness O
of O
the O
usual O
anchors O
for O
a O
Clinical O
Global O
Impression O
of O
Severity O
( O
CGI-S O
) O
was O
resolved O
by O
defining O
uncomplicated O
autism O
without O
secondary O
symptoms O
as O
a O
CGI-S O
of O
3 O
, O
mildly O
ill O
. O
[]

The O
secondary O
events O
during O
the O
first O
14 O
days O
also O
revealed O
no O
benefit O
of O
dalteparin O
compared O
with O
aspirin O
: O
symptomatic B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
haemorrhage I-outcome ['Physiological-Clinical']
6/224 O
versus O
4/225 O
; O
symptomatic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
asymptomatic I-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
haemorrhage I-outcome ['Physiological-Clinical']
26/224 O
versus O
32/225 O
; O
progression O
of O
symptoms B-outcome ['Physiological-Clinical']
within O
the O
first O
48 O
hours O
24/224 O
versus O
17/225 O
; O
and O
death O
21/224 O
versus O
16/225 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Intervention O
subjects O
received O
individual O
risk O
profiles O
and O
the O
REACH O
intervention O
through O
nine O
in-home O
and O
three O
telephone O
sessions O
over O
6 O
months O
. O
[]

Femoral-artery O
blood O
samples O
were O
taken O
for O
assay O
of O
adrenaline O
and O
noradrenaline O
. O
[]

no O
significant O
difference O
between O
the O
two O
toothpaste O
treatments O
) O
. O
[]

Vaccine O
was O
given O
at O
two O
, O
four O
, O
and O
18 O
months O
of O
age O
. O
[]

We O
studied O
the O
effects O
of O
a O
single O
dose O
of O
fenoterol O
on O
the O
relationship O
between O
inspiratory O
effort O
sensation O
( O
IES O
) O
and O
inspiratory O
muscle O
fatigue O
induced O
by O
inspiratory O
threshold O
loading O
in O
healthy O
subjects O
. O
[]

Thirty-three O
cases O
of O
acute O
hematogenous O
bone O
or O
joint O
infection O
in O
children O
were O
randomly O
treated O
with O
short-term O
( O
7 O
days O
for O
joint O
infection O
, O
10 O
days O
for O
bone O
infection O
) O
or O
long-term O
( O
14 O
days O
and O
21 O
days O
, O
respectively O
) O
intravenous O
antibiotics O
after O
surgical O
drainage O
. O
[]

A O
pilot O
study O
of O
a O
low-tilt O
biphasic O
waveform O
for O
transvenous O
cardioversion O
of O
atrial O
fibrillation O
: O
improved O
efficacy O
compared O
with O
conventional O
capacitor-based O
waveforms O
in O
patients O
. O
[]

However O
, O
the O
difference O
was O
not O
observed O
in O
indapamide O
group O
. O
[]

Piracetam O
had O
no O
significant O
effect O
on O
either O
mental B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
or O
rCBF O
. O
['Life-Impact']

Several O
quality O
of O
life O
scores O
improved O
significantly O
in O
the O
study O
group O
after O
6 O
months O
( O
p O
< O
0.05 O
) O
. O
[]

A O
fenbendazole O
oral O
drench O
in O
addition O
to O
an O
ivermectin O
pour-on O
reduces O
parasite B-outcome ['Physiological-Clinical']
burden I-outcome ['Physiological-Clinical']
and O
improves O
feedlot O
and O
carcass O
performance O
of O
finishing O
heifers O
compared O
with O
endectocides O
alone O
. O
['Physiological-Clinical']

One O
surgeon O
rated O
breast O
Steri-Strip O
S O
scars O
worse O
than O
suture O
scars O
( O
4.3 O
versus O
3.7 O
; O
p O
= O
0.014 O
) O
. O
[]

Counselor O
and O
stimulus O
control O
enhancements O
of O
a O
stage-matched O
expert O
system O
intervention O
for O
smokers B-outcome ['Life-Impact']
in O
a O
managed O
care O
setting O
. O
['Life-Impact']

It O
is O
planned O
to O
enroll O
4500 O
patients O
with O
a O
mean O
follow-up O
of O
three O
years O
. O
[]

The O
effect O
of O
polyvinylpyrrolidone-iodine O
as O
an O
disinfectant B-outcome ['Resource-use']
in O
eye O
surgery O
. O
['Resource-use']

MEASUREMENTS O
Control O
and O
MI O
subjects O
received O
identical O
research O
assessments O
at O
baseline O
, O
1 O
and O
6 O
months O
following O
study O
enrollment O
. O
[]

We O
present O
data O
regarding O
551 O
women O
who O
had O
colposcopy O
in O
Wales O
for O
a O
low-grade O
cytological O
abnormality O
and O
who O
were O
followed O
through O
Cervical O
Screening O
Wales O
for O
subsequent O
CIN O
. O
[]

All O
were O
significantly O
elevated O
after O
CPB O
. O
[]

Photosensitizers O
, O
such O
as O
porfimer O
sodium O
, O
tin O
ethyl O
etiopurpurin O
, O
and O
aluminum O
chlorophthalocyanine O
, O
were O
administered O
i.v O
. O
[]

ACL-implantation O
remains O
our O
method O
of O
choice O
for O
secondary O
implantation O
in O
patients O
with O
an O
intact O
iris O
diaphragm O
. O
[]

Blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
of O
volunteers O
were O
allowed O
to O
fall O
by O
10 O
% O
from O
fasting O
levels O
and O
were O
kept O
constant O
thereafter O
by O
employing O
a O
Biostator-based O
euglycemic O
glucose O
clamp O
. O
['Physiological-Clinical']

Mean O
( O
+/-SD O
) O
age O
was O
70 O
( O
+/-13 O
) O
years O
. O
[]

The O
evaluation O
of O
the O
signal O
intensity O
by O
the O
dynamic B-outcome ['Resource-use']
screening I-outcome ['Resource-use']
sequence I-outcome ['Resource-use']
is O
considered O
as O
an O
objective O
contribution O
for O
the O
staging O
of O
the O
femoral B-outcome ['Physiological-Clinical']
head I-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Fentanyl O
( O
1 O
mcg/kg O
iv O
) O
and O
ketorolac O
( O
30 O
mg O
im O
) O
were O
administered O
immediately O
following O
induction O
of O
anaesthesia O
. O
[]

RESULTS O
The O
incidence O
of O
conjunctival B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
from O
treating O
and O
control O
group O
were O
8 O
% O
and O
15 O
% O
respectively O
. O
['Physiological-Clinical']

Effect O
of O
CX516 O
, O
an O
AMPA-modulating O
compound O
, O
on O
cognition B-outcome ['Life-Impact']
and O
behavior B-outcome ['Life-Impact']
in O
fragile O
X O
syndrome O
: O
a O
controlled O
trial O
. O
['Life-Impact', 'Life-Impact']

Every O
other O
boy O
in O
each O
diagnostic O
group O
was O
randomly O
allocated O
to O
receive O
either O
( O
a O
) O
a O
special O
education O
program O
( O
clinical O
index O
group O
) O
or O
( O
b O
) O
follow-up O
without O
the O
special O
education O
program O
( O
clinical O
comparison O
group O
) O
. O
[]

Three O
patients O
experienced O
ocular O
adverse O
events O
considered O
possibly O
related O
to O
study O
drug O
: O
Conjunctival O
edema O
and O
reduced O
visual O
acuity O
were O
reported O
in O
1 O
SCJ O
patient O
each O
and O
iritis O
was O
reported O
in O
1 O
IVT O
patient O
. O
[]

The O
difference O
was O
significant O
in O
the O
proximal O
region O
as O
compared O
to O
the O
control O
group O
( O
Palacos O
) O
. O
[]

Young O
children O
with O
pervasive O
developmental O
disorder O
were O
randomly O
assigned O
to O
intensive O
treatment O
or O
parent O
training O
. O
[]

All O
the O
subjects O
had O
baseline O
studies O
, O
including O
medical O
history O
, O
physical O
examination O
, O
blood O
and O
urine O
analysis O
. O
[]

Varying O
robotic O
movement O
training O
to O
include O
practice O
of O
simpler O
, O
anatomically-isolated O
motions O
may O
enhance O
its O
efficacy O
. O
[]

Risperidone O
and O
haloperidol O
treatments O
were O
applied O
with O
a O
once O
daily O
dosage O
regimen O
as O
0.01-0.08 O
mg/kg/day O
. O
[]

Efficacy O
of O
intravenous O
acetaminophen O
and O
lidocaine O
on O
propofol O
injection O
pain O
. O
[]

ondansetron O
, O
droperidol O
, O
perphenazine O
, O
and O
metoclopramide O
was O
evaluated O
in O
a O
prospective O
, O
double-blind O
study O
of O
360 O
ASA O
physical O
status O
I-III O
patients O
undergoing O
total O
abdominal O
hysterectomy O
( O
TAH O
) O
. O
[]

Whether O
n3 O
fatty O
acid O
ethyl O
ester O
( O
FAEE O
) O
supplementation O
improves O
arterial O
stiffness O
in O
obese O
participants O
on O
a O
weight O
loss O
diet O
has O
not O
yet O
been O
investigated O
. O
[]

According O
to O
anticoagulation O
Methods O
, O
174 O
MARS O
treatment O
sessions O
for O
146 O
patients O
with O
liver O
failure O
and O
prothrombin O
time O
activity O
percentage O
( O
PTA O
) O
? O
[]

Pathology O
data O
on O
the O
intact O
extracted O
specimens O
were O
similar O
between O
the O
groups O
. O
[]

SETTING O
Neurosurgical O
unit O
and O
haematology O
ward O
of O
university O
hospital O
. O
[]

on O
days O
1 O
to O
4 O
. O
[]

CONCLUSIONS O
Hydration O
with O
sodium O
bicarbonate O
provides O
better O
protection O
against O
[]

This O
suggests O
a O
role O
for O
the O
use O
of O
errors O
in O
surgical O
technical O
skill O
instruction O
. O
[]

The O
primary O
outcome O
is O
change O
in O
providers O
' O
tobacco O
treatment O
practices O
and O
the O
secondary O
outcomes O
are O
cost O
per O
quit O
, O
use O
of O
tobacco O
cessation O
treatments O
, O
quit O
attempts O
, O
and O
smoking O
abstinence O
. O
[]

CONCLUSIONS O
In O
our O
study O
, O
the O
use O
of O
bupivacaine O
irrigated O
over O
the O
surgical O
bed O
was O
an O
effective O
method O
for O
reducing O
pain B-outcome ['Physiological-Clinical']
during O
the O
first O
postoperative O
hours O
after O
laparoscopic O
cholecystectomy O
. O
['Physiological-Clinical']

Additive O
IOP-reducing B-outcome ['Physiological-Clinical']
effect O
of O
latanoprost O
in O
patients O
insufficiently O
controlled O
on O
timolol O
. O
['Physiological-Clinical']

AIM O
OF O
THE O
STUDY O
The O
aim O
of O
this O
pilot O
study O
was O
to O
examine O
the O
effects O
of O
fatty O
fish O
and O
lean O
( O
white O
) O
fish O
on O
fatty B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
and O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
factors O
in O
subjects O
with O
CHD O
using O
multiple O
drugs O
for O
this O
condition O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Non-evaporative B-outcome ['Physiological-Clinical']
heat I-outcome ['Physiological-Clinical']
exchange I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
, O
-14.0 O
and O
-10.6 O
W.m-2 O
( O
p O
less O
than O
0.03 O
) O
, O
for O
the O
pyridostigmine-treated O
subjects O
. O
['Physiological-Clinical']

In O
a O
group O
of O
nonsurgical O
rats O
, O
propranolol O
treatment O
increased O
femoral B-outcome ['Physiological-Clinical']
torsional I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
on O
biomechanical O
testing O
. O
['Physiological-Clinical']

The O
children O
were O
then O
taught O
to O
ask O
the O
question O
within O
a O
less O
structured O
context O
. O
[]

Using O
health-plan O
data O
, O
we O
measured O
changes O
in O
antibiotics O
dispensed O
per O
person-year O
of O
observation O
among O
children O
who O
were O
aged O
3 O
to O
< O
72 O
months O
, O
resided O
in O
study O
communities O
, O
and O
were O
insured O
by O
a O
participating O
commercial O
health O
plan O
or O
Medicaid O
. O
[]

It O
has O
been O
suggested O
that O
for O
children O
with O
autism O
, O
imitation O
may O
be O
a O
prerequisite O
skill O
that O
can O
assist O
in O
the O
development O
of O
various O
skills O
. O
[]

The O
study O
supports O
the O
feasibility O
of O
this O
intervention O
to O
families O
and O
highlights O
challenges O
for O
future O
research O
in O
social O
skills O
intervention O
. O
[]

The O
shorter O
and O
simpler O
treatment O
schedule O
of O
azithromycin O
had O
similar O
efficacy O
and O
safety O
as O
doxycycline O
in O
the O
treatment O
of O
moderate O
acne O
vulgaris O
, O
confirming O
noninferiority O
of O
azithromycin O
as O
compared O
with O
doxycycline O
. O
[]

Study O
1 O
evaluated O
the O
analgesic O
efficacy O
of O
piroxicam O
20 O
mg O
compared O
with O
that O
of O
codeine O
sulfate O
60 O
mg O
and O
placebo O
. O
[]

A O
testing O
videotape O
was O
created O
consisting O
of O
24 O
performances O
of O
the O
skill O
that O
ranged O
in O
quality O
of O
the O
performance O
. O
[]

The O
risk O
of O
death B-outcome ['Mortality']
in O
the O
group O
treated O
with O
vitamin O
A O
was O
less O
than O
half O
that O
in O
the O
control O
group O
( O
relative O
risk O
, O
0.46 O
; O
95 O
percent O
confidence O
interval O
, O
0.30 O
to O
0.71 O
) O
. O
['Mortality']

Fifty-six O
patients O
with O
90 O
double O
lumen O
VACs O
were O
randomly O
chosen O
, O
and O
received O
either O
1- O
or O
2-week O
catheterizations O
from O
operators O
experienced O
in O
the O
placement O
of O
such O
catheters O
at O
three O
sites O
such O
as O
the O
internal O
jugular O
, O
subclavian O
, O
or O
femoral O
vein O
. O
[]

BACKGROUND O
AND O
DESIGN O
Pulsed O
low-intensity O
direct O
current O
( O
300 O
to O
600 O
microA O
) O
has O
been O
used O
in O
a O
double-blind O
placebo O
multicenter O
study O
in O
the O
treatment O
of O
stage B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
III I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
decubitus I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Twenty O
volunteers O
were O
given O
single O
doses O
of O
fluoxetine O
20 O
mg O
or O
an O
identical O
placebo O
daily O
for O
28 O
days O
prior O
to O
receiving O
a O
single O
10 O
mg O
oral O
dose O
of O
zolmitriptan O
. O
[]

Stage O
of O
change O
appears O
to O
be O
useful O
for O
understanding O
mediators O
of O
health O
promotion O
intervention O
effectiveness O
. O
[]

Fourteen O
healthy O
, O
non-smoking O
, O
Caucasian O
male O
volunteers O
took O
part O
. O
[]

OBJECTIVES O
The O
objective O
was O
to O
investigate O
the O
plasma B-outcome ['Physiological-Clinical']
kinetics I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
synthetic I-outcome ['Physiological-Clinical']
zeaxanthin I-outcome ['Physiological-Clinical']
after O
repeated O
oral O
doses O
and O
to O
assess O
the O
possible O
influence O
of O
other O
carotenoids O
on O
plasma B-outcome ['Physiological-Clinical']
zeaxanthin I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Studies O
were O
pooled O
using O
a O
random O
effect O
model O
, O
conducting O
secondary O
analyses O
for O
tuberculin O
skin O
test-positive O
and O
negative O
persons O
. O
[]

Twenty-one O
PEG O
patients O
required O
endoscopic B-outcome ['Resource-use']
tube I-outcome ['Resource-use']
change I-outcome ['Resource-use']
which O
raised O
their O
total O
cost B-outcome ['Resource-use']
to O
$ O
1574 O
. O
['Resource-use', 'Resource-use']

For O
phase O
2 O
, O
all O
subjects O
were O
then O
treated O
with O
full O
orthodontic O
appliances O
. O
[]

Enhancement O
values O
in O
the O
aorta O
, O
liver O
, O
and O
portal O
vein O
and O
tumor-liver O
contrast O
were O
measured O
at O
multiphase O
CT O
. O
[]

Effect O
of O
acupuncture O
on O
the O
T-lymphocyte B-outcome ['Physiological-Clinical']
and O
its O
subsets O
from O
the O
peripheral O
blood O
of O
patients O
with O
malignant O
neoplasm O
has O
been O
researched O
in O
this O
study O
. O
['Physiological-Clinical']

Blood O
pressure O
and O
blood O
chemistry O
tests O
, O
including O
a O
comprehensive O
metabolic O
panel O
and O
cell O
blood O
count O
, O
were O
conducted O
at O
the O
beginning O
of O
the O
trial O
and O
after O
4 O
and O
8 O
weeks O
of O
supplementation O
. O
[]

The O
mean O
maximal B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
elevation I-outcome ['Physiological-Clinical']
induced O
by O
interferon O
was O
significantly O
reduced O
( O
from O
102.1 O
to O
100.7 O
, O
P O
= O
0.0002 O
) O
by O
indomethacin O
, O
but O
the O
incidence O
and O
severity O
of O
interferon-related B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
, O
reduction O
in O
performance B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
headache B-outcome ['Physiological-Clinical']
, O
depression B-outcome ['Life-Impact']
, O
confusion B-outcome ['Life-Impact']
, O
elevations B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
tests I-outcome ['Physiological-Clinical']
, O
and O
myelosuppression B-outcome ['Physiological-Clinical']
were O
no O
different O
in O
either O
arm O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

No O
patient O
had O
gross O
residual O
disease O
at O
the O
time O
of O
randomization O
. O
[]

Advantages O
of O
cuffed O
endotracheal O
tubes O
include O
avoidance O
of O
repeated B-outcome ['Resource-use']
laryngoscopy I-outcome ['Resource-use']
, O
use O
of O
low B-outcome ['Physiological-Clinical']
fresh I-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
and O
reduction O
of O
the O
concentration O
of O
anesthetics B-outcome ['Resource-use']
detectable O
in O
['Resource-use', 'Physiological-Clinical', 'Resource-use']

Meglumine O
iothalamate O
( O
Conray O
Meglumin O
) O
, O
sodium-calcium-meglumine O
metrizoate O
( O
Isopaque O
Cerebral O
) O
and O
dimeglumine O
iocarmate O
( O
Dimerex O
) O
, O
each O
containing O
about O
280 O
mg O
I/ml O
, O
were O
compared O
in O
two O
series O
of O
double O
contrast O
knee O
arthrography O
, O
190 O
and O
184 O
patients O
each O
. O
[]

Multiple O
raters O
and O
rating O
scales O
were O
employed O
in O
a O
variety O
of O
conditions O
. O
[]

All O
isolates O
, O
incuding O
H. O
influenzae O
, O
were O
susceptible O
to O
CB O
and O
AMP O
. O
[]

SETTING O
An O
inner-city O
county O
trauma O
center O
with O
70,000 O
patient O
visits O
per O
year O
. O
[]

The O
actual O
advantage O
of O
barrier O
creams O
over O
bland O
emollients O
for O
skin O
protection O
is O
still O
hotly O
debated O
. O
[]

After O
the O
extension O
( O
i.e. O
, O
23 O
weeks O
post-SRP O
) O
, O
mean O
[]

At O
basal O
conditions O
and O
after O
30 O
, O
90 O
and O
180 O
days O
the O
maximum B-outcome ['Physiological-Clinical']
exercise I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
was O
evaluated O
using O
an O
exercise B-outcome ['Life-Impact']
tolerance O
test O
performed O
on O
an O
ergometer O
bicycle O
and O
the O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
was O
tested O
by O
means O
of O
bidimensional B-outcome ['Resource-use']
echocardiography I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

The O
study O
group O
received O
an O
additional O
treatment O
with O
Esberitox O
, O
the O
control O
group O
did O
not O
receive O
an O
additional O
treatment O
. O
[]

However O
, O
among O
patients O
with O
serious O
comorbidities O
( O
Charlson O
score O
> O
4 O
) O
, O
[]

Cost-effectiveness O
of O
collaborative O
care O
including O
PST O
and O
an O
antidepressant O
treatment O
algorithm O
for O
the O
treatment O
of O
major O
depressive O
disorder O
in O
primary O
care O
; O
a O
randomised O
clinical O
trial O
. O
['Resource-use']

Absence O
of O
central B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
in O
man O
of O
the O
benzodiazepine O
antagonist O
Ro O
15-1788 O
. O
['Physiological-Clinical']

Stool B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
also O
decreased O
more O
in O
those O
treated O
with O
drug O
( O
3.6 O
fewer O
vs. O
1.25 O
fewer/24 O
h O
, O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

Additional O
changes O
in O
BMD B-outcome ['Physiological-Clinical']
and O
bone B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

For O
the O
patients O
developing O
acute O
toxicity O
, O
no O
difference O
between O
the O
two O
fractionation O
groups O
was O
found O
in O
either O
severity O
or O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
or O
genitourinary B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
response-cost O
program O
was O
applied O
to O
reduce O
problem O
behaviors O
and O
foster O
skills O
acquisition O
. O
[]

Twenty-nine O
patients O
with O
mycologically O
proven O
tinea O
pedis O
were O
randomly O
allocated O
to O
oral O
treatment O
with O
either O
ketoconazole O
200 O
mg O
daily O
or O
griseofulvin O
1 O
g O
daily O
for O
a O
period O
of O
up O
to O
8 O
weeks O
. O
[]

AIMS O
We O
examined O
whether O
Dementia O
Care O
Mapping O
( O
DCM O
) O
or O
the O
VIPS O
practice O
model O
( O
VPM O
) O
is O
more O
effective O
than O
education O
of O
the O
nursing O
home O
staff O
about O
dementia O
( O
control O
group O
) O
in O
reducing O
agitation O
and O
other O
neuropsychiatric O
symptoms O
as O
well O
as O
in O
enhancing O
the O
quality O
of O
life O
among O
nursing O
home O
patients O
. O
[]

Results O
found O
that O
children O
in O
the O
treatment O
group O
made O
significantly O
more O
gains O
in O
elicited B-outcome ['Life-Impact']
and O
spontaneous B-outcome ['Life-Impact']
imitation I-outcome ['Life-Impact']
, O
replicating O
previous O
single-subject O
design O
studies O
. O
['Life-Impact', 'Life-Impact']

Three O
( O
2 O
% O
) O
patients O
receiving O
eltrombopag O
had O
thromboembolic O
events O
compared O
with O
none O
in O
patients O
on O
placebo O
. O
[]

A O
phase O
III O
study O
of O
laparoscopy-assisted O
versus O
open O
distal O
gastrectomy O
with O
nodal O
dissection O
for O
clinical O
stage O
IA/IB O
gastric O
Cancer O
( O
JCOG0912 O
) O
. O
[]

CONCLUSION O
EC O
, O
although O
more O
painful B-outcome ['Physiological-Clinical']
, O
is O
a O
safe O
, O
more O
effective O
and O
a O
highly O
satisfying B-outcome ['Life-Impact']
procedure O
for O
treating O
early O
hemorrhoids O
. O
['Physiological-Clinical', 'Life-Impact']

Participants O
randomised O
to O
receive O
an O
X-ray O
were O
not O
less O
worried B-outcome ['Life-Impact']
, O
or O
more O
reassured B-outcome ['Life-Impact']
about O
serious O
disease O
causing O
their O
low O
back O
pain O
. O
['Life-Impact', 'Life-Impact']

The O
most O
common O
( O
? O
[]

Effects O
of O
a O
chlorhexidine O
varnish O
on O
the O
gingival B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
of O
adolescents O
. O
['Physiological-Clinical']

OBJECTIVES O
This O
study O
was O
designed O
to O
determine O
whether O
reductions O
in O
morning B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
elicited O
by O
treatment O
of O
moderate O
to O
severe O
obstructive B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
apnea I-outcome ['Physiological-Clinical']
( O
OSA O
) O
in O
heart O
failure O
( O
HF O
) O
patients O
are O
associated O
with O
a O
reduction O
in O
sympathetic B-outcome ['Physiological-Clinical']
vasoconstrictor I-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

EEGs O
were O
reviewed O
for O
clinical O
abnormalities O
, O
including O
IEDs O
, O
by O
readers O
blinded O
to O
participants O
' O
behavioral O
symptoms O
. O
[]

Also O
patients O
with O
PPD O
negative O
skin O
reaction O
at O
the O
time O
of O
beginning O
of O
treatment O
in O
the O
OK-432 O
group O
survived O
significantly O
longer O
than O
those O
in O
the O
control O
group O
( O
P O
less O
than O
0.001 O
) O
, O
but O
there O
was O
no O
significance O
between O
both O
treatment O
groups O
in O
patients O
with O
PPD O
positive O
skin B-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
at O
the O
time O
of O
beginning O
of O
treatment O
. O
['Physiological-Clinical']

OBJECTIVE O
Previous O
studies O
have O
reported O
the O
link O
between O
residual O
microbial O
contamination O
of O
toothbrushes O
and O
periodontal O
diseases O
. O
[]

Blood B-outcome ['Physiological-Clinical']
glucose B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
every O
15 O
min O
during O
surgery O
, O
and O
hourly O
for O
6 O
h O
after O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
complete O
response O
rate O
was O
89 O
% O
, O
with O
a O
complete O
response O
and O
partial O
response O
rate O
of O
99.4 O
% O
. O
[]

At O
T3 O
and O
T4 O
, O
the O
double O
product O
was O
highest O
in O
group O
3 O
( O
group O
1 O
vs. O
3 O
, O
p O
< O
0.001 O
) O
. O
[]

Patients O
were O
randomly O
allocated O
to O
pentoxifylline+risperidone O
or O
placebo+risperidone O
for O
a O
10-week O
, O
double-blind O
, O
placebo-controlled O
study O
. O
[]

The O
treatment O
began O
on O
average O
26 O
days O
after O
the O
operation O
and O
was O
continued O
for O
one O
year O
. O
[]

The O
principal O
results O
on O
serum B-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
show O
neither O
order B-outcome ['Physiological-Clinical']
x O
treatment O
interaction B-outcome ['Life-Impact']
, O
nor O
order O
effect O
but O
a O
significant O
treatment O
effect O
( O
p O
< O
0.01 O
) O
: O
amisulpride O
increases O
serum B-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
whereas O
bromocriptine B-outcome ['Resource-use']
decreases O
according O
to O
the O
usual O
data O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Resource-use']

Gene O
expression O
of O
endothelin-1 O
and O
its O
receptors O
in O
the O
heart O
of O
broiler O
chickens O
with O
T O
( O
3 O
) O
-induced O
pulmonary O
hypertension O
. O
[]

Group O
LM O
was O
administered O
19 O
ml O
of O
0.25 O
% O
levobupivacaine O
and O
1 O
ml O
of O
15 O
% O
magnesium O
sulphate O
, O
while O
Group O
L O
was O
administered O
20 O
ml O
of O
0.25 O
% O
levobupivacaine O
for O
femoral O
blockade O
. O
[]

Armodafinil O
, O
the O
longer O
lasting O
R-isomer O
of O
racemic O
modafinil O
, O
improves O
wakefulness B-outcome ['Physiological-Clinical']
in O
patients O
with O
excessive O
sleepiness O
associated O
with O
shift O
work O
disorder O
( O
SWD O
) O
. O
['Physiological-Clinical']

METHODS/DESIGN O
In O
this O
randomized O
, O
single O
blind O
, O
clinical O
trial O
with O
active O
controls O
, O
we O
aim O
to O
include O
170 O
patients O
with O
GOA O
. O
[]

PATIENTS O
AND O
METHODS O
ED O
is O
common O
in O
men O
aged O
?40 O
years O
and O
impacts O
upon O
their O
overall O
health-related O
quality O
of O
life O
and O
that O
of O
their O
partners O
. O
[]

No O
significant O
changes O
in O
species B-outcome ['Physiological-Clinical']
number O
or O
quantitative O
counts O
were O
noted O
after O
LGG O
treatment O
in O
the O
infants O
weighing O
1500 O
to O
1999 O
g O
LGG O
was O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
in O
all O
infants O
. O
['Physiological-Clinical', 'Life-Impact']

BACKGROUND O
In O
a O
population O
of O
patients O
with O
manic O
and O
mixed O
mood O
episodes O
, O
olanzapine O
has O
proven O
effective O
in O
maintaining O
response O
, O
as O
compared O
to O
placebo O
. O
[]

The O
treatment O
group O
complete O
effective O
and O
partial O
effective O
were O
10 O
% O
and O
35 O
% O
difference O
. O
[]

Treatment O
efficacy O
was O
assessed O
on O
the O
basis O
of O
the O
percentage O
of O
effective O
response O
after O
4 O
weeks O
through O
mycologic O
and O
clinical O
assessment O
. O
[]

Patients O
who O
were O
taught O
about O
their O
health O
problems O
while O
waiting O
in O
the O
clinic O
( O
n O
= O
104 O
) O
were O
significantly O
more O
satisfied B-outcome ['Life-Impact']
with O
the O
education O
received O
during O
that O
visit O
than O
the O
control O
group O
( O
n O
= O
101 O
) O
. O
['Life-Impact']

The O
double-blind O
crossover O
design O
included O
nine O
measurement O
occasions O
, O
each O
involving O
rCBF B-outcome ['Physiological-Clinical']
measurement I-outcome ['Physiological-Clinical']
by O
the O
133-Xe O
inhalation O
method O
, O
ratings O
of O
symptoms O
of O
dementia O
, O
personality O
changes O
, O
and O
side O
effects O
, O
and O
a O
psychometric O
investigation O
. O
['Physiological-Clinical']

RESULTS O
Sodium O
nitroprusside O
, O
substance O
P O
and O
bradykinin O
produced O
dose-dependent O
increases O
in O
the O
blood B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
of O
infused O
forearm O
( O
analysis O
of O
variance O
[ O
ANOVA O
] O
, O
p O
< O
0.001 O
for O
all O
) O
. O
['Physiological-Clinical']

Quantitative O
side O
effects O
questionnaire O
scores O
were O
used O
to O
guide O
disopyramide O
administration O
in O
20 O
men O
with O
ventricular O
tachycardia O
. O
[]

In O
two O
prospective O
, O
randomized O
studies O
the O
frequency O
of O
headache B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
vomiting B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
LDL B-outcome ['Physiological-Clinical']
from O
the O
beta-carotene O
and O
placebo O
groups O
, O
as O
assessed O
by O
measuring O
the O
lag O
time B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
conjugated I-outcome ['Physiological-Clinical']
dienes I-outcome ['Physiological-Clinical']
; O
the O
rate O
of O
formation B-outcome ['Physiological-Clinical']
and O
the O
amount O
of O
conjugated B-outcome ['Physiological-Clinical']
dienes I-outcome ['Physiological-Clinical']
formed I-outcome ['Physiological-Clinical']
; O
the O
amount O
of O
lipid B-outcome ['Physiological-Clinical']
peroxides I-outcome ['Physiological-Clinical']
generated I-outcome ['Physiological-Clinical']
; O
and O
the O
relative O
electrophoretic B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
, O
at O
baseline O
and O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Several O
randomised O
controlled O
trials O
have O
been O
undertaken O
to O
evaluate O
the O
efficacy O
of O
alpha-interferon O
in O
the O
therapy O
of O
chronic O
hepatitis O
B O
. O
[]

Owing O
to O
the O
pharmacokinetic O
properties O
of O
physostigmine O
when O
administered O
by O
conventional O
routes O
, O
long-term O
cholinergic O
treatment O
of O
Alzheimer O
's O
disease O
is O
difficult O
to O
manage O
. O
[]

In O
the O
high-dose O
therapy O
arm O
the O
overall O
response O
rate O
was O
83 O
% O
with O
64 O
% O
in O
CR O
( O
difference O
between O
arms O
not O
significant O
) O
. O
[]

A O
Pearson O
r O
correlation O
indicated O
the O
REEDA O
score O
was O
associated O
with O
a O
[]

Overall O
, O
there O
were O
40 O
recurrences O
in O
the O
control O
group O
and O
25 O
in O
the O
ASI O
group O
. O
[]

RESULTS O
Results O
of O
the O
promoter O
methylation O
of O
MGMT O
genes O
showed O
that O
methylation O
rate O
was O
20.00 O
% O
in O
the O
treatment O
group O
and O
46.67 O
% O
in O
the O
control O
group O
( O
P O
< O
0.05 O
) O
. O
[]

The O
number O
of O
antenatal B-outcome ['Resource-use']
day I-outcome ['Resource-use']
admissions I-outcome ['Resource-use']
and O
ultrasound B-outcome ['Resource-use']
scans I-outcome ['Resource-use']
performed O
may O
also O
be O
reduced O
. O
['Resource-use', 'Resource-use']

There O
was O
no O
difference O
in O
estimated O
loss B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
Hb I-outcome ['Physiological-Clinical']
( O
3.6 O
g/dl O
vs. O
4.1 O
g/dl O
; O
n.s O
. O
) O
['Physiological-Clinical']

RESULTS O
There O
were O
no O
intraoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
and O
no O
postoperative B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
or O
revisions B-outcome ['Resource-use']
. O
['Adverse-effects', 'Physiological-Clinical', 'Resource-use']

The O
experiment O
was O
then O
repeated O
and O
brushing O
or O
not O
brushing O
crossed O
over O
. O
[]

There O
were O
no O
statistically O
significant O
differences O
in O
average O
percentage O
changes O
of O
total O
[]

Impact O
of O
pentoxifylline O
on O
platelet B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
profiles O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
and O
coronary O
artery O
disease O
on O
dual O
antiplatelet O
therapy O
with O
aspirin O
and O
clopidogrel O
. O
['Physiological-Clinical']

The O
volume O
of O
blood B-outcome ['Physiological-Clinical']
drawn O
and O
discarded B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
catheters I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
blood O
conservation O
group O
( O
blood O
conservation O
device O
: O
5.7 O
+/- O
7.5 O
mL O
; O
control O
: O
96.4 O
+/- O
88.5 O
mL O
; O
p O
< O
.0001 O
) O
, O
as O
was O
the O
total O
volume O
of O
blood B-outcome ['Physiological-Clinical']
discarded I-outcome ['Physiological-Clinical']
( O
blood O
conservation O
device O
: O
19.4 O
+/- O
47.4 O
mL O
; O
control O
: O
103.5 O
+/- O
99.9 O
mL O
; O
p O
< O
.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Aortic B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PWV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
augmentation B-outcome ['Physiological-Clinical']
index O
( O
AIx O
) O
are O
independent O
predictors O
of O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
and O
mortality B-outcome ['Mortality']
, O
but O
little O
is O
known O
about O
the O
effect O
of O
air O
temperature O
changes O
on O
these O
variables O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

The O
dropout O
rate O
due O
to O
side O
effects O
was O
only O
3.4 O
% O
and O
was O
coupled O
with O
good O
medication O
compliance O
. O
[]

Valid O
and O
reliable O
self-report O
measures O
of O
withdrawal B-outcome ['Life-Impact']
did O
not O
reveal O
gender O
differences O
in O
response O
['Life-Impact']

The O
median O
hospital O
stay O
was O
14 O
days O
in O
both O
groups O
. O
[]

Randomized O
controlled O
trial O
of O
the O
focus O
parent O
training O
for O
toddlers O
with O
autism O
: O
1-year O
outcome O
. O
[]

Children O
were O
assessed O
on O
objective B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
and O
on O
social B-outcome ['Life-Impact']
, O
neuropsychological B-outcome ['Physiological-Clinical']
, O
and O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

The O
main O
reasons O
for O
not O
participating O
were O
a O
lack O
of O
interest O
and O
time O
requirements O
. O
[]

under O
tocainide O
and O
7 O
under O
prajmalium O
bitartrate O
were O
responders O
. O
[]

However O
, O
the O
patients O
treated O
with O
aminophylline O
had O
significantly O
more O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
( O
p O
< O
0.05 O
) O
. O
['Adverse-effects']

These O
values O
represent O
71.7 O
% O
and O
63.9 O
% O
, O
respectively O
, O
of O
the O
glass-ceramic O
control O
group O
( O
4.98 O
x O
10 O
( O
3 O
) O
lx O
) O
. O
[]

The O
study O
population O
was O
broken O
down O
into O
five O
age O
groups O
as O
follows O
: O
less O
than O
50 O
years O
( O
group O
one O
) O
, O
50 O
to O
64 O
years O
( O
group O
two O
) O
, O
65 O
to O
74 O
years O
( O
group O
three O
) O
, O
75 O
to O
84 O
years O
( O
group O
four O
) O
, O
and O
85 O
or O
older O
( O
group O
five O
) O
. O
[]

Furthermore O
, O
chronic O
redox O
imbalance O
was O
also O
recently O
linked O
to O
this O
disorder O
. O
[]

A O
nonrandomized O
human O
milk/formula-fed O
cohort O
( O
n O
= O
81 O
) O
, O
was O
concurrently O
enrolled O
. O
[]

Integral O
part O
of O
the O
study O
was O
the O
monitoring O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
during O
the O
treatment O
. O
['Adverse-effects']

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer B-outcome ['Physiological-Clinical']
Quality O
of O
Life O
Questionnaire O
C30 B-outcome ['Physiological-Clinical']
was O
used O
to O
assess O
HRQOL O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Exercise O
therapy O
for O
patients O
with O
acute O
low O
back O
pain O
does O
not O
reduce O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
. O
['Life-Impact']

CONCLUSIONS O
Systemic O
thrombolytic O
treatment O
for O
acute O
DVT O
achieved O
a O
significantly O
better O
short- O
and O
long-term O
clinical O
outcome O
than O
conventional O
heparin/anticoagulation O
therapy O
but O
at O
the O
expense O
of O
a O
serious O
increase O
in O
major O
bleeding O
and O
pulmonary O
emboli O
. O
[]

Primary O
endpoints O
of O
the O
study O
were O
the O
number O
of O
CD34+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
harvested O
per O
kg O
body O
weight O
on O
the O
occasion O
of O
six O
consecutive B-outcome ['Physiological-Clinical']
leukaphereses I-outcome ['Physiological-Clinical']
and O
the O
time B-outcome ['Life-Impact']
needed I-outcome ['Life-Impact']
for O
hematological B-outcome ['Physiological-Clinical']
reconstitution B-outcome ['Physiological-Clinical']
following O
autografting B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Such O
an O
option O
would O
provide O
convincing O
evidence O
for O
the O
use O
of O
immunochemotherapy O
in O
a O
resource O
constrained O
setting O
. O
[]

Fractions O
of O
2 O
Gy O
or O
less O
are O
advisable O
. O
[]

The O
prospective O
multicentre O
study O
included O
171 O
patients O
with O
endoscopically O
confirmed O
duodenal O
ulcers O
. O
[]

Amisulpride O
versus O
bromocriptine O
in O
infantile O
autism O
: O
a O
controlled O
crossover O
comparative O
study O
of O
two O
drugs O
with O
opposite O
effects O
on O
dopaminergic O
function O
. O
[]

Questionnaires O
assessed O
demographic O
data O
, O
risk O
perception O
, O
mental O
health O
and O
use O
of O
health B-outcome ['Resource-use']
services I-outcome ['Resource-use']
pre-consultation O
and O
at O
1 O
and O
12 O
months O
follow-up O
. O
['Resource-use']

Due O
to O
differing O
disease O
trajectories O
, O
the O
service O
uses O
two O
broad O
service O
models O
: O
one O
for O
patients O
with O
malignant O
disease O
( O
intervention O
delivered O
over O
two O
weeks O
) O
and O
one O
for O
patients O
with O
non-malignant O
disease O
( O
intervention O
delivered O
over O
four O
weeks O
) O
. O
[]

The O
treatment O
arms O
were O
balanced O
in O
terms O
of O
pretreatment O
characteristics O
. O
[]

Eligible O
patients O
( O
1439 O
) O
were O
randomized O
according O
to O
stage O
( O
I-IV O
) O
and O
histology O
( O
favorable O
[ O
FH O
] O
or O
unfavorable O
[ O
UH O
] O
) O
, O
and O
contributed O
data O
to O
survival O
and O
relapse-free O
survival O
( O
RFS O
) O
analyses O
. O
[]

DISCUSSION O
This O
is O
the O
first O
evaluation O
of O
a O
breathlessness O
intervention O
for O
advanced O
disease O
to O
have O
followed O
the O
MRC O
framework O
and O
one O
of O
the O
first O
palliative O
care O
trials O
to O
use O
fast O
track O
methodology O
and O
single-blinding O
. O
[]

Earlier O
patient B-outcome ['Life-Impact']
mobilization I-outcome ['Life-Impact']
was O
also O
seen O
in O
the O
early O
reinfusion O
groups O
for O
the O
A/P O
and O
PSF O
groups O
. O
['Life-Impact']

We O
collected O
hospital O
and O
general O
practice O
data O
on O
at O
least O
91 O
and O
72 O
% O
of O
patients O
respectively O
at O
each O
follow-up O
point O
and O
interviewed O
between O
43 O
and O
90 O
% O
of O
the O
study O
subjects O
. O
[]

Only O
one O
patient O
in O
each O
of O
the O
combined O
therapy O
groups O
withdrew O
from O
the O
study O
because O
of O
hyperkalaemia B-outcome ['Physiological-Clinical']
and O
no O
patients O
were O
forced O
to O
withdraw O
because O
of O
an O
increase O
in O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
, O
acute B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
or O
hospitalization B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

I O
: O
Lifestyle O
intervention O
alone O
. O
[]

Helicobacter B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
was O
eradicated O
in O
all O
CYP2C19 O
PMs O
except O
in O
one O
patient O
infected O
by O
a O
resistant O
strain O
. O
['Physiological-Clinical']

DESIGN O
Open O
interventional O
crossover O
study O
. O
[]

Corrected B-outcome ['Physiological-Clinical']
TIMI I-outcome ['Physiological-Clinical']
frame O
count O
was O
furthermore O
lower O
in O
the O
nicorandil O
group O
( O
21.0+/-9.1 O
versus O
25.1+/-14.1 O
; O
P=0.0009 O
) O
. O
['Physiological-Clinical']

Three O
healthy B-outcome ['Physiological-Clinical']
singleton I-outcome ['Physiological-Clinical']
children I-outcome ['Physiological-Clinical']
have O
been O
born B-outcome ['Physiological-Clinical']
at O
term O
; O
the O
remaining O
pregnancies O
ended O
with O
spontaneous B-outcome ['Physiological-Clinical']
abortions I-outcome ['Physiological-Clinical']
in O
the O
first O
trimester O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
double-blind O
cross-over O
study O
in O
coronary O
care O
unit O
. O
[]

CONCLUSIONS O
The O
transdermal O
nicotine O
system O
used O
in O
this O
trial O
had O
a O
low O
contact O
sensitization O
incidence O
and O
was O
well O
tolerated B-outcome ['Life-Impact']
topically O
with O
minimal O
irritation O
. O
['Life-Impact']

The O
present O
study O
was O
undertaken O
to O
investigate O
whether O
Xuezhikang O
could O
modify O
endothelin-1 O
( O
ET-1 O
) O
, O
interleukin-6 O
( O
IL-6 O
) O
, O
high-sensitivity O
C-reactive O
protein O
( O
CRP O
) O
and O
exercise-induced O
ischemia O
in O
patients O
with O
cardiac O
syndrome O
X O
( O
CSX O
) O
. O
[]

The O
difference O
was O
significant O
( O
P O
less O
than O
0.02 O
) O
. O
[]

Both O
products O
were O
safe O
, O
with O
no O
serious O
adverse O
events O
, O
and O
in O
particular O
, O
no O
anaphylactic O
reactions O
or O
serum O
sickness O
was O
reported O
. O
[]

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
hypertensive O
patients O
was O
lowered O
by O
bed O
rest O
only O
, O
or O
by O
oxprenolol O
or O
methyldopa O
, O
but O
remained O
elevated O
. O
['Physiological-Clinical']

PATIENT O
( O
S O
) O
A O
total O
of O
274 O
oocytes O
obtained O
from O
46 O
couples O
undergoing O
infertility O
treatment O
. O
[]

We O
conclude O
that O
D53 O
immunostimulant O
in O
vivo O
primes O
AM O
to O
produce O
IL-1 B-outcome ['Physiological-Clinical']
following O
low B-outcome ['Physiological-Clinical']
LPS I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
stimulation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Intensive O
insulin O
therapy O
on O
infection O
rate O
, O
days O
in O
NICU O
, O
in-hospital B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
neurological B-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
in O
severe O
traumatic O
brain O
injury O
patients O
: O
a O
randomized O
controlled O
trial O
. O
['Mortality', 'Physiological-Clinical']

Twelve O
patients O
were O
randomly O
assigned O
to O
four O
groups O
with O
different O
rhG-CSF O
therapy O
schedules O
. O
[]

An O
increased O
erythrocyte O
membrane O
polyunsaturated O
fatty O
acid O
content O
might O
correct O
the O
lower O
erythrocyte O
deformability O
in O
cyclosporin O
treated O
patients O
. O
[]

RESULTS O
The O
ABC-C O
and O
the O
Childhood O
Autism B-outcome ['Physiological-Clinical']
Rating O
Scale O
scores O
improved O
with O
cyproheptadine O
. O
['Physiological-Clinical']

Both O
drugs O
had O
rather O
short O
biological O
elimination O
half-lives B-outcome ['Physiological-Clinical']
and O
a O
predominantly O
renal O
route O
of O
elimination O
. O
['Physiological-Clinical']

In O
all O
four O
groups O
, O
neither O
plasma B-outcome ['Physiological-Clinical']
adrenaline I-outcome ['Physiological-Clinical']
nor I-outcome ['Physiological-Clinical']
noradrenaline I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
changed O
. O
['Physiological-Clinical']

RESULTS O
During O
follow-up O
, O
the O
overall O
RQLQ O
( O
S O
) O
score O
for O
the O
entire O
grass O
pollen O
season O
was O
significantly O
improved O
in O
the O
active O
group O
( O
relative O
difference O
to O
placebo O
: O
23 O
% O
, O
P O
= O
0.004 O
) O
. O
[]

In O
40 O
CSF O
specimens O
obtained O
4-12 O
h O
after O
initiation O
of O
therapy O
, O
cultures B-outcome ['Physiological-Clinical']
were O
negative O
in O
57 O
% O
of O
the O
ceftriaxone O
patients O
and O
in O
42 O
% O
of O
the O
others O
. O
['Physiological-Clinical']

Twenty-eight O
women O
with O
severe O
endometriosis O
also O
had O
significantly O
more O
[]

A O
prospective O
double-blind O
, O
randomized O
clinical O
trial O
of O
levocarnitine O
to O
treat O
autism O
spectrum O
disorders O
. O
[]

CONCLUSIONS O
In O
this O
study O
, O
there O
was O
no O
statistically O
significant O
difference O
between O
aripiprazole O
and O
placebo O
in O
time O
to O
relapse O
during O
maintenance O
therapy O
. O
[]

Total O
mesorectal O
excision O
was O
scheduled O
4-6 O
weeks O
following O
completion O
of O
CRT O
. O
[]

STUDY O
DESIGN O
Subjects O
were O
randomly O
assigned O
to O
1 O
of O
2 O
diets O
: O
a O
high O
protein O
, O
low O
carbohydrate O
( O
20 O
g/d O
) O
diet O
( O
high O
protein O
, O
low O
carbohydrate O
, O
HPLC O
) O
or O
low O
fat O
( O
30 O
% O
of O
calories O
) O
regimen O
for O
13 O
weeks O
; O
close O
monitoring O
was O
maintained O
to O
evaluate O
safety O
. O
[]

METHODS O
In O
a O
prospective O
randomized O
study O
, O
100 O
consecutive O
endoscopic O
resections O
were O
performed O
in O
72 O
patients O
with O
early O
stage O
esophageal O
cancer O
. O
[]

There O
was O
no O
significant O
difference O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
between O
groups O
and O
no O
side O
effects O
occurred O
. O
['Physiological-Clinical']

Deep B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
after O
major O
reconstructive O
spinal O
surgery O
. O
['Physiological-Clinical']

PURPOSE O
Preoperative O
chemoradiotherapy O
( O
CRT O
) O
is O
superior O
to O
radiotherapy O
( O
RT O
) O
in O
locally O
advanced O
rectal O
cancer O
, O
but O
the O
survival B-outcome ['Mortality']
gain O
is O
limited O
. O
['Mortality']

Premedication O
with O
ranitidine O
significantly O
reduces O
, O
but O
does O
not O
eliminate O
, O
the O
incidence O
of O
this O
potentially O
life-threatening O
complication O
. O
[]

Irritability/aggression O
is O
a O
significant O
comorbid O
symptom O
in O
this O
population O
, O
which O
greatly O
impacts O
burden O
of O
care O
. O
[]

CONCLUSION O
RFA O
took O
longer O
to O
perform O
but O
resulted O
in O
a O
significantly O
better O
early O
outcome O
than O
conventional O
surgery O
in O
suitable O
patients O
with O
great O
saphenous O
varicose O
veins O
. O
[]

RESULTS O
Median O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
recurrence I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
any I-outcome ['Life-Impact']
mood I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
( O
primary O
endpoint O
) O
was O
: O
558 O
days O
( O
paliperidone O
ER O
) O
, O
283 O
days O
( O
placebo O
) O
and O
not O
observed O
with O
olanzapine O
( O
< O
50 O
% O
of O
patients O
experienced O
recurrence O
) O
. O
['Life-Impact']

IIT O
increased O
circulating B-outcome ['Physiological-Clinical']
GH B-outcome ['Physiological-Clinical']
( O
P O
= O
0.04 O
) O
and O
lowered O
bioavailable B-outcome ['Physiological-Clinical']
IGF-I B-outcome ['Physiological-Clinical']
( O
P O
= O
0.002 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
clinical B-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
remission B-outcome ['Physiological-Clinical']
rate O
was O
90.6 O
% O
( O
29/32 O
) O
in O
the O
TACE+HIFU O
group O
and O
70.8 O
% O
( O
28/38 O
) O
in O
the O
TACE O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Peri- O
and O
postmenopausal O
women O
, O
40-62 O
years O
old O
, O
were O
assigned O
randomly O
to O
yoga O
( O
n O
= O
107 O
) O
, O
exercise O
( O
n O
= O
106 O
) O
, O
or O
usual O
activity O
( O
n O
= O
142 O
) O
and O
also O
assigned O
randomly O
to O
a O
double-blind O
comparison O
of O
omega-3 O
( O
n O
= O
177 O
) O
or O
placebo O
( O
n O
= O
178 O
) O
capsules O
. O
[]

RESULTS O
In O
comparison O
with O
pre-treatment O
, O
the O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
at O
base O
line O
in O
sitting O
position O
and O
the O
average O
circadian B-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
and O
DBP I-outcome ['Physiological-Clinical']
monitored O
with O
24-hour O
ambulatory O
blood O
pressure O
monitoring O
( O
ABPM B-outcome ['Physiological-Clinical']
) O
was O
remarkably O
decreased O
in O
group O
A O
with O
statistical O
significance O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

arm O
( O
p=0.36 O
) O
. O
[]

The O
efficacy O
of O
the O
SI B-outcome ['Resource-use']
vaccine I-outcome ['Resource-use']
was O
assessed O
through O
its O
effect O
on O
average O
daily O
weight O
gain O
, O
and O
serological O
responses O
to O
SI O
over O
time O
. O
['Resource-use']

Since O
the O
long-term O
prognosis O
for O
patients O
with O
congestive O
heart O
failure O
remains O
very O
poor O
and O
the O
incidence O
of O
arrhythmic O
death O
is O
high O
, O
every O
new O
drug O
to O
be O
employed O
against O
this O
disease O
should O
be O
thoroughly O
tested O
in O
order O
to O
rule O
out O
any O
possible O
arrhythmogenic B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
unchanged O
drug O
following O
single O
oral O
administration O
at O
3-300 O
mg O
after O
a O
meal O
increased O
with O
increasing O
dose O
. O
['Physiological-Clinical']

INTERVENTIONS O
One O
of O
six O
dosing O
epoetin O
alfa O
regimens O
for O
15 O
days O
, O
as O
follows O
: O
40,000 O
IU O
once O
weekly O
, O
subcutaneously O
( O
group O
A O
) O
or O
intravenously O
( O
IV O
) O
( O
group O
B O
) O
; O
15,000 O
IU O
every O
other O
day O
, O
subcutaneously O
( O
group O
C O
) O
or O
IV O
( O
group O
D O
) O
; O
or O
40,000 O
IU O
day O
1 O
and O
3 O
, O
subcutaneously O
( O
group O
E O
) O
or O
IV O
( O
group O
F O
) O
, O
followed O
by O
15,000 O
IU O
once O
every O
other O
day O
on O
[ O
corrected O
] O
days O
5-15 O
[ O
corrected O
] O
MEASUREMENTS O
Serum B-outcome ['Physiological-Clinical']
erythropoietin I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
, O
absolute B-outcome ['Physiological-Clinical']
reticulocyte I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
and O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

METHODS O
Thirty O
adults O
with O
autistic O
disorder O
completed O
a O
12-week O
double-blind O
, O
placebo-controlled O
trial O
of O
the O
potent O
and O
selective O
serotonin O
uptake O
inhibitor O
fluvoxamine O
maleate O
. O
[]

RESULTS O
Of O
29 O
eligible O
and O
consenting O
patients O
, O
17 O
patients O
received O
tinzaparin O
and O
12 O
patients O
received O
dalteparin O
. O
[]

Untreated O
silicone O
breast O
implant O
rupture O
. O
[]

Ratios O
of O
strain-specific O
nasal O
IgA O
to O
total O
nasal O
IgA O
were O
calculated O
and O
prevaccination O
to O
postvaccination O
geometric O
mean O
fold-rises B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GMFRs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
evaluated O
. O
['Physiological-Clinical']

The O
authors O
tested O
the O
use O
of O
a O
thank O
you O
or O
reminder O
postcard O
as O
a O
method O
by O
which O
to O
stem O
the O
tide O
of O
declining O
response O
rates O
. O
[]

The O
first O
, O
run-in O
period O
was O
carried O
out O
to O
confirm O
the O
ability O
of O
the O
patients O
to O
maintain O
a O
daily O
record O
of O
symptoms O
. O
[]

During O
clamping O
of O
the O
aorta O
a O
moderate B-outcome ['Physiological-Clinical']
compensated I-outcome ['Physiological-Clinical']
acidosis I-outcome ['Physiological-Clinical']
developed O
in O
both O
groups O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
An O
open O
, O
longitudinal O
, O
randomized O
, O
parallel-group O
. O
[]

CONCLUSIONS O
The O
findings O
are O
discussed O
in O
terms O
of O
the O
efficacy O
of O
mindfulness O
training O
in O
reducing O
TBI-related B-outcome ['Life-Impact']
cognitive I-outcome ['Life-Impact']
deficits I-outcome ['Life-Impact']
. O
['Life-Impact']

Testing O
three O
different O
cancer O
genetics O
registry O
recruitment O
methods O
with O
Hispanic O
cancer O
patients O
and O
their O
family O
members O
previously O
registered O
in O
local O
cancer O
registries O
in O
Texas O
. O
[]

Ten O
patients O
were O
given O
flumazenil O
0.01 O
mg O
kg-1 O
and O
5 O
min O
later O
the O
second O
flow O
measurement O
was O
performed O
. O
[]

The O
most O
frequently O
reported O
drug-related O
events O
were O
diarrhoea B-outcome ['Physiological-Clinical']
( O
2.2 O
% O
versus O
2.9 O
% O
) O
, O
nausea/vomiting B-outcome ['Physiological-Clinical']
( O
1.5 O
% O
vs. O
0.7 O
% O
) O
, O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
0.7 O
% O
vs O
1.5 O
% O
) O
and O
skin B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
( O
1.5 O
% O
vs. O
1.1 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Regular O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
pattern I-outcome ['Life-Impact']
by O
questionnaire O
, O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
by O
anthropometry O
and O
dual O
energy O
X-ray O
absorptiometry O
( O
n O
= O
75 O
) O
and O
knee B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
by O
isokinetic O
dynamometry B-outcome ['Resource-use']
were O
also O
assessed O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

RESULTS O
Persons O
with O
one O
or O
two O
long O
( O
l O
) O
5HTTLPR O
alleles O
had O
CSF B-outcome ['Physiological-Clinical']
levels O
of O
the O
major O
serotonin O
metabolite O
, O
5HIAA O
, O
that O
were O
50 O
% O
higher O
than O
those O
of O
persons O
with O
the O
s/s O
5HTTLPR O
genotype O
. O
['Physiological-Clinical']

Prefrontal O
neuromodulation O
using O
rTMS O
improves O
error O
monitoring O
and O
correction O
function O
in O
autism O
. O
[]

Hormone B-outcome ['Physiological-Clinical']
assays I-outcome ['Physiological-Clinical']
were O
performed O
at O
baseline O
and O
after O
the O
sixth O
cycle O
. O
['Physiological-Clinical']

Kinematics O
for O
the O
right O
lower O
limb B-outcome ['Physiological-Clinical']
were O
collected O
( O
200 O
Hz O
) O
. O
['Physiological-Clinical']

In O
both O
cases O
this O
was O
followed O
by O
patient-controlled O
epidural O
analgesia O
with O
bupivacaine O
0.125 O
% O
( O
+ O
sufentanil O
0.25 O
microg O
mL O
( O
-1 O
) O
) O
. O
[]

Before O
aortic O
cross-clamping O
, O
effective B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ERPF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
131I-hippuran I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GFR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
99Tc-DTPA I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
significantly O
lower O
in O
the O
halothane O
group O
( O
118.4 O
+/- O
25.6 O
and O
19.7 O
+/- O
5.2 O
mL/min O
, O
respectively O
) O
than O
in O
the O
isoflurane O
group O
( O
253.4 O
+/- O
51.5 O
and O
44.9 O
+/- O
8.4 O
mL/min O
) O
( O
P O
less O
than O
0.05 O
for O
both O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
convergence O
of O
cervical O
and O
trigeminal O
afferents O
on O
second-order O
neurons O
in O
the O
trigeminocervical O
nucleus O
may O
refer O
pain O
from O
the O
upper O
cervical O
spine O
into O
the O
head O
and O
face O
. O
[]

The O
use O
of O
immunomodulatory O
drugs O
has O
proved O
useful O
in O
the O
prophylaxis O
of O
these O
complications O
, O
although O
the O
precise O
indications O
for O
each O
drug O
have O
not O
yet O
been O
clearly O
codified O
. O
[]

The O
median O
survival B-outcome ['Mortality']
was O
9.5 O
months O
for O
group O
A O
versus O
11.4 O
months O
for O
group O
B O
( O
P O
= O
0.16 O
) O
. O
['Mortality']

Patients O
were O
divided O
randomly O
into O
2 O
equal O
groups O
. O
[]

An O
antibody B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
detected O
in O
all O
subjects O
on O
day O
14 O
when O
the O
highest O
titres O
were O
found O
after O
two O
intramuscular O
( O
i.m O
. O
) O
['Physiological-Clinical']

For O
the O
208 O
patients O
evaluable O
for O
safety O
, O
the O
most O
common O
grade O
3/4 O
toxicity B-outcome ['Adverse-effects']
for O
each O
regimen O
was O
neutropaenia B-outcome ['Physiological-Clinical']
, O
with O
64 O
% O
, O
57 O
% O
, O
and O
68 O
% O
for O
GP1 O
, O
GP2 O
, O
and O
GD O
, O
respectively O
. O
['Adverse-effects', 'Physiological-Clinical']

Prespecified O
outcomes O
at O
30 O
days O
were O
death B-outcome ['Mortality']
or O
rehospitalization B-outcome ['Resource-use']
for I-outcome ['Resource-use']
any I-outcome ['Resource-use']
reason I-outcome ['Resource-use']
; O
death B-outcome ['Mortality']
or O
rehospitalization O
for O
cardiovascular B-outcome ['Physiological-Clinical']
or O
renal B-outcome ['Physiological-Clinical']
reasons O
; O
and O
, O
at O
both O
30 O
and O
180 O
days O
, O
all-cause O
mortality O
. O
['Mortality', 'Resource-use', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Diagnostic B-outcome ['Life-Impact']
accuracy I-outcome ['Life-Impact']
is O
shown O
in O
the O
table O
. O
[ O
['Life-Impact']

The O
results O
from O
94 O
patients O
treated O
with O
CBS O
coated O
tablets O
and O
95 O
patients O
treated O
with O
CBS O
chewing O
tablets O
were O
statistically O
evaluated O
. O
[]

Faculty O
raters O
receiving O
error O
training O
had O
a O
higher O
proportion O
of O
specific O
comments O
than O
the O
group O
that O
received O
no O
training O
although O
this O
difference O
was O
not O
statistically O
significant O
. O
[]

MAIN O
OUTCOME O
MEASURE O
( O
S O
) O
The O
21-item O
Hamilton O
Rating O
Scale O
for O
Depression O
( O
HRSD O
) O
, O
which O
is O
an O
instrument O
designed O
to O
assess O
depressive O
symptomatology O
. O
[]

A O
common O
variation O
in O
this O
gene O
( O
rs3796863 O
) O
was O
recently O
found O
to O
be O
associated O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
. O
[]

DESIGN O
Prospective O
, O
randomized O
, O
controlled O
trial O
. O
[]

Secondary O
efficacy O
variables O
included O
investigator-assessed O
shoulder B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
patient-assessed O
quality O
of O
life O
on O
the O
Short-Form-36 O
( O
SF-36 O
) O
Acute O
Health O
Survey O
and O
both O
patients O
' O
and O
investigators O
' O
overall O
assessment O
of O
efficacy O
. O
['Physiological-Clinical']

Motor B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
was O
significantly O
more O
common O
( O
30 O
vs. O
0 O
% O
) O
and O
more O
intense O
with O
the O
0.2 O
% O
ropivacaine-4 O
microg O
fentanyl O
solution O
. O
['Physiological-Clinical']

In O
summary O
, O
high O
OPN B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
indicated O
decreased O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
= O
.0002 O
) O
and O
OS O
( O
P O
= O
.001 O
) O
. O
['Physiological-Clinical', 'Mortality']

Body O
mass O
index O
( O
BMI O
) O
and O
waist B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
did O
not O
change O
in O
any O
groups O
except O
for O
the O
NETE-8 O
in O
which O
BMI O
increased O
significantly O
( O
p O
= O
0.02 O
) O
at O
the O
end O
of O
the O
treatment O
period O
. O
['Physiological-Clinical']

Four O
young O
patients O
participated O
in O
an O
open O
study O
and O
were O
given O
a O
gluten-free O
diet O
in O
six O
months O
. O
[]

Topiramate O
improves O
health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
when O
used O
to O
prevent O
migraine O
. O
['Life-Impact']

MAIN O
OUTCOMES O
MEASURES O
Changes O
in O
FIM O
and O
Tinetti O
scale O
scores O
, O
and O
dependence O
on O
walking O
aids O
. O
[]

Adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
occurred O
in O
77 O
% O
of O
patients O
on O
nicardipine O
and O
in O
63 O
% O
of O
those O
on O
propranolol O
, O
and O
there O
were O
no O
unexpected O
findings O
. O
['Adverse-effects']

A O
multiple O
logistic O
regression O
analysis O
was O
used O
to O
determine O
the O
factors O
associated O
with O
exclusive O
breastfeeding O
at O
8-12 O
weeks O
postpartum O
. O
[]

Significant O
declines O
in O
the O
sitting O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
of O
-19 O
+/- O
4 O
mm O
Hg O
( O
standard O
error O
) O
and O
-13 O
+/- O
2 O
mm O
Hg O
, O
respectively O
, O
were O
observed O
during O
this O
follow-up O
period O
. O
['Physiological-Clinical']

The O
high O
salt O
diet O
attenuated O
the O
antihypertensive B-outcome ['Resource-use']
effect O
slightly O
( O
1.6/1.3 O
mm O
Hg O
, O
P O
= O
not O
significant O
) O
. O
['Resource-use']

METHODS O
We O
did O
a O
single-blind O
, O
randomised O
, O
placebo O
controlled O
, O
cross-over O
study O
of O
the O
microcirculatory B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
topical O
application O
of O
a O
nitric-oxidegenerating O
gel O
in O
20 O
patients O
with O
severe O
Raynaud O
's O
syndrome O
, O
and O
ten O
healthy O
volunteers O
. O
['Physiological-Clinical']

Fat O
embolism O
prophylaxis O
with O
corticosteroids O
. O
[]

In O
a O
return O
to O
the O
baseline O
condition O
, O
when O
differential O
observing O
responses O
were O
no O
longer O
prompted O
, O
accuracy O
returned O
to O
intermediate O
levels O
. O
[]

METHODS O
AND O
RESULTS O
The O
trial O
used O
a O
randomized O
cross-over O
design O
consisting O
of O
2 O
16-week O
periods O
of O
open-label O
drug O
therapy O
. O
[]

For O
patients O
reporting O
'a O
little O
' O
change O
in O
[]

Physostigmine O
restored B-outcome ['Physiological-Clinical']
consciousness I-outcome ['Physiological-Clinical']
in O
9 O
of O
11 O
subjects O
, O
with O
concomitant O
increases O
in O
ASSR B-outcome ['Physiological-Clinical']
( O
0.38 O
+/- O
0.17 O
microV O
, O
P O
< O
0.01 O
) O
and O
BIS B-outcome ['Physiological-Clinical']
( O
75.3 O
+/- O
8.3 O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

An O
efficacy O
analysis O
was O
conducted O
in O
per-protocol O
patients O
and O
the O
safety O
analysis O
was O
conducted O
in O
all O
randomised O
patients O
. O
[]

Mild B-outcome ['Physiological-Clinical']
transitory I-outcome ['Physiological-Clinical']
contact I-outcome ['Physiological-Clinical']
dermatitis I-outcome ['Physiological-Clinical']
of O
the O
primary O
irritant O
type O
occurred O
in O
all O
the O
treatment O
groups O
and O
was O
apparently O
due O
to O
the O
detergent O
base O
. O
['Physiological-Clinical']

The O
findings O
suggest O
that O
in O
the O
presence O
of O
overt B-outcome ['Life-Impact']
emotional I-outcome ['Life-Impact']
disturbance I-outcome ['Life-Impact']
, O
of O
new B-outcome ['Physiological-Clinical']
psychological I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
psychophysiological I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
preceding I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
by O
up O
to O
a O
year O
, O
and O
of O
high O
motivation B-outcome ['Life-Impact']
for O
it O
, O
brief O
psychiatric O
treatment O
improves O
the O
outcome O
in O
eczema B-outcome ['Physiological-Clinical']
( O
the O
proportion O
clear O
at O
18 O
months O
was O
about O
doubled O
) O
, O
whereas O
in O
their O
absence O
such O
treatment O
may O
worsen O
it O
, O
especially O
in O
the O
short O
term O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

All O
38 O
subjects O
seroconverted O
in O
the O
groups O
receiving O
the O
highest O
dose O
( O
10 O
( O
8 O
) O
TCID50 O
) O
. O
[]

Each O
treatment O
period O
was O
followed O
by O
a O
2-week O
, O
drug-free O
washout O
period O
. O
[]

Hyperbaric O
oxygen O
attenuation O
of O
lipopolysaccharide-induced O
acute O
lung O
injury O
involves O
heme O
oxygenase-1 O
. O
[]

Measurements O
were O
recorded O
at O
the O
bedside O
non-invasively O
in O
five O
different O
positions O
assigned O
in O
random O
order O
each O
maintained O
for O
10 O
min O
. O
[]

Before O
28 O
weeks O
' O
gestation O
tocolysis O
was O
associated O
with O
a O
significant O
increase O
in O
[]

BACKGROUND O
Given O
the O
prevalence O
of O
cardiovascular O
disease O
and O
the O
high O
rates O
of O
depression O
among O
cardiac O
patients O
, O
there O
is O
a O
need O
to O
develop O
practical O
ways O
to O
identify O
this O
population O
and O
provide O
pragmatic O
general-practitioner-based O
interventions O
for O
managing O
depression O
as O
a O
comorbid O
condition O
. O
[]

The O
intervention O
group O
received O
individual O
skin O
screening O
by O
a O
dermatologist O
and O
participated O
in O
an O
education O
session O
. O
[]

The O
dose O
of O
risperidone O
was O
titrated O
up O
to O
3 O
mg/day O
, O
pentoxifylline O
was O
titrated O
to O
600 O
mg/day O
. O
[]

There O
were O
1038 O
girls O
in O
the O
control O
group O
and O
1049 O
girls O
in O
the O
experimental O
group O
. O
[]

The O
8-item O
medication O
adherence O
scale O
was O
reliable O
( O
alpha=.83 O
) O
and O
significantly O
associated O
with O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

Lansoprazole O
, O
omeprazole O
MUPS O
and O
esomeprazole O
were O
compared O
under O
doctor O
's O
office O
conditions O
. O
[]

Recovery O
profile O
after O
desflurane O
with O
or O
without O
ondansetron O
compared O
with O
propofol O
in O
patients O
undergoing O
outpatient O
gynecological O
laparoscopy O
. O
[]

RESULTS O
After O
treatment O
, O
the O
scores O
for O
MMSE O
and O
ADL B-outcome ['Physiological-Clinical']
were O
improved O
in O
the O
combined O
acupuncture O
and O
medication O
group O
, O
the O
Chinese O
herb O
group O
and O
the O
western O
medicine O
group O
, O
which O
were O
better O
in O
the O
combined O
acupuncture O
and O
medication O
group O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
parenchymal I-outcome ['Physiological-Clinical']
transection I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
speed I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
transection I-outcome ['Physiological-Clinical']
were O
the O
primary O
endpoints O
, O
whereas O
the O
degree O
of O
postoperative B-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
and O
morbidity B-outcome ['Physiological-Clinical']
were O
secondary O
endpoints O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
was O
undertaken O
to O
evaluate O
the O
efficacy O
of O
different O
r-hGH O
treatment O
schedules O
( O
67 O
microg/kg/day O
in O
a O
discontinuous O
or O
continuous O
regimen O
) O
during O
the O
second O
year O
of O
r-hGH O
treatment O
by O
comparing O
height B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
changes O
and O
total O
gain O
of O
height B-outcome ['Physiological-Clinical']
over O
a O
4-year O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
median O
time O
to O
the O
recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ascites I-outcome ['Physiological-Clinical']
in O
Group O
1 O
was O
4 O
months O
in O
medical O
patients O
, O
as O
compared O
with O
18 O
months O
in O
surgical O
patients O
( O
P O
= O
0.01 O
) O
; O
in O
Group O
2 O
it O
was O
3 O
months O
in O
medical O
patients O
as O
compared O
with O
12 O
months O
in O
surgical O
patients O
( O
P O
= O
0.04 O
) O
. O
['Physiological-Clinical']

The O
mean O
NRS O
pain B-outcome ['Physiological-Clinical']
score O
before O
the O
most O
recent O
dose O
of O
pain O
medication O
after O
ED O
discharge O
was O
7.6 O
NRS O
units O
for O
both O
groups O
. O
['Physiological-Clinical']

Lung B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
was O
higher O
5 O
minutes O
before O
bypass O
in O
group O
1 O
versus O
group O
5 O
( O
34 O
+/- O
13 O
mL/cm O
H O
( O
2 O
) O
O O
vs O
20 O
+/- O
9 O
mL/cm O
H O
( O
2 O
) O
O O
; O
P O
= O
0.048 O
) O
. O
['Physiological-Clinical']

In O
all O
others O
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
of O
transient O
nature O
and O
considered O
mild O
. O
['Adverse-effects']

The O
primary O
outcome O
was O
improvement O
in O
dry B-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Moreover O
, O
it O
allows O
operative O
procedures O
to O
be O
performed O
with O
the O
new O
bipolar O
instruments O
. O
[]

Of O
the O
958 O
subjects O
in O
the O
intervention O
group O
and O
the O
947 O
in O
the O
control O
group O
who O
completed O
the O
study O
, O
39.7 O
percent O
and O
39.5 O
percent O
, O
respectively O
, O
had O
at O
least O
one O
recurrent B-outcome ['Physiological-Clinical']
adenoma I-outcome ['Physiological-Clinical']
; O
the O
unadjusted B-outcome ['Physiological-Clinical']
risk O
ratio O
was O
1.00 O
( O
95 O
percent O
confidence O
interval O
, O
0.90 O
to O
1.12 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Recent O
studies O
have O
suggested O
that O
combined O
chemotherapy O
and O
radiation O
therapy O
may O
result O
in O
improved O
survival O
. O
[]

Group O
1 O
had O
significantly O
higher O
?TBS O
values O
than O
Group O
2 O
or O
3 O
. O
[]

In O
the O
normal O
men O
, O
insulin O
administration O
resulted O
in O
a O
significant O
decline O
of O
basal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
glucagon I-outcome ['Physiological-Clinical']
and O
C-peptide B-outcome ['Physiological-Clinical']
levels O
and O
in O
a O
clear-cut O
decrease O
in O
the O
arginine-induced B-outcome ['Physiological-Clinical']
glucagon I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
ScanBrit O
randomised O
, O
controlled O
, O
single-blind O
study O
of O
a O
gluten- O
and O
casein-free O
dietary O
intervention O
for O
children O
with O
autism O
spectrum O
disorders O
. O
[]

5 O
. O
[]

Immunogenicity B-outcome ['Physiological-Clinical']
was O
comparable O
for O
the O
diphtheria O
and O
tetanus O
components O
, O
but O
significantly O
superior O
for O
pertussis B-outcome ['Physiological-Clinical']
toxin I-outcome ['Physiological-Clinical']
, O
filamentous B-outcome ['Physiological-Clinical']
hemagglutinin I-outcome ['Physiological-Clinical']
, O
pertactin B-outcome ['Physiological-Clinical']
and O
polioviruses B-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
, O
2 O
and O
3 O
in O
the O
Pa O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Prospective O
, O
comparative O
, O
open-label O
clinical O
trial O
. O
[]

RESULTS O
Seven O
children O
completed O
the O
trial O
. O
[]

Iopamidol O
offers O
no O
advantage O
over O
sodium O
iothalamate O
with O
respect O
to O
ventilatory O
effects O
in O
non-atopic O
patients O
undergoing O
intravenous O
urography O
. O
[]

Furthermore O
, O
Latino O
health O
care O
professionals O
have O
been O
absent O
from O
these O
intervention O
efforts O
even O
though O
the O
epidemic O
has O
affected O
this O
population O
disproportionately O
. O
[]

STUDY O
OBJECTIVES O
To O
assess O
the O
stability O
of O
the O
multiple O
sleep O
latency O
test O
( O
MSLT O
) O
in O
primary B-outcome ['Physiological-Clinical']
insomnia I-outcome ['Physiological-Clinical']
and O
its O
relation O
to O
total O
sleep B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
decrease O
in O
the O
respiratory B-outcome ['Physiological-Clinical']
score I-outcome ['Physiological-Clinical']
was O
5.2 O
+/- O
1.8 O
, O
0.82 O
+/- O
2.4 O
and O
1.7 O
+/- O
1.3 O
in O
group O
I O
, O
II O
and O
III O
, O
respectively O
. O
['Physiological-Clinical']

Reported O
[]

[ O
Randomized O
clinical O
trial O
between O
nutritional O
counselling O
and O
commercial O
hypocaloric O
diet O
in O
weight O
loss O
in O
obese O
patients O
with O
chronic O
arthropathy O
] O
. O
[]

The O
postoperative B-outcome ['Resource-use']
antiemetic I-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
were O
consistently O
and O
significantly O
( O
P O
< O
0.01 O
) O
higher O
in O
the O
desflurane-only O
group O
compared O
to O
the O
other O
two O
groups O
. O
['Resource-use']

At O
the O
time O
of O
enrolment O
7/13 O
( O
54 O
% O
) O
and O
6/13 O
( O
46 O
% O
) O
of O
patients O
in O
the O
intervention O
and O
control O
groups O
, O
respectively O
, O
had O
sub B-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
hyperthyroidism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

For O
all O
patients O
, O
baseline O
TEI O
index O
was O
a O
predictor O
of O
worsened B-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
In O
our O
parallel-group O
randomised O
trial O
, O
patients O
meeting O
Oxford O
criteria O
for O
chronic O
fatigue O
syndrome O
were O
recruited O
from O
six O
secondary-care O
clinics O
in O
the O
UK O
and O
randomly O
allocated O
by O
computer-generated O
sequence O
to O
receive O
specialist O
medical O
care O
( O
SMC O
) O
alone O
or O
with O
adaptive O
pacing O
therapy O
( O
APT O
) O
, O
CBT O
, O
or O
GET O
. O
[]

Twenty O
families O
were O
randomly O
assigned O
to O
the O
treatment O
or O
waitlist O
group O
. O
[]

The O
carotid B-outcome ['Physiological-Clinical']
intima-media I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
at O
the O
end O
of O
1-year O
follow-up O
was O
significantly O
reduced O
in O
the O
nateglinide O
group O
compared O
with O
the O
untreated O
group O
( O
-0.017+/-0.054 O
mm/year O
versus O
0.024+/-0.066 O
mm/year O
, O
P=0.0064 O
) O
. O
['Physiological-Clinical']

None O
of O
the O
secondary O
outcomes O
varied O
significantly O
between O
the O
2 O
treatment O
groups O
. O
[]

5 O
alpha-metabolism O
in O
finasteride-treated O
subjects O
and O
male O
pseudohermaphrodites O
with O
inherited O
5 O
alpha-reductase O
deficiency O
. O
[]

The O
present O
prospective O
study O
was O
aimed O
at O
determining O
whether O
removal O
of O
hypertrophied O
anal O
papillae O
and O
fibrous O
anal O
polyps O
while O
dealing O
with O
chronic O
fissure O
in O
ano O
confers O
long-term O
benefit O
to O
patients O
. O
[]

In O
conclusion O
, O
initiating O
therapy O
with O
a O
combination O
of O
valsartan O
and O
low-dose O
HCTZ O
results O
in O
early O
, O
improved O
[]

CONCLUSIONS O
The O
results O
of O
this O
randomized O
trial O
strongly O
support O
the O
efficacy O
of O
just-in-time O
evidence-based O
reminders O
as O
a O
means O
of O
changing O
clinical O
practice O
among O
home O
health O
nurses O
who O
are O
geographically O
dispersed O
and O
spend O
much O
of O
their O
time O
in O
the O
field O
. O
[]

Implications O
for O
estimating O
GAI O
in O
patients O
with O
known O
or O
suspected O
neurological O
dysfunction O
is O
discussed O
and O
future O
research O
is O
proposed O
. O
[]

METHODS O
Some O
204 O
patients O
with O
mid O
and O
low O
rectal O
adenocarcinomas O
were O
allocated O
randomly O
to O
open O
( O
103 O
) O
or O
laparoscopic O
( O
101 O
) O
surgery O
. O
[]

Patients O
with O
a O
clinical O
outcome O
had O
significantly O
greater O
declines O
in O
all O
SF-36 O
and O
symptom O
scores O
. O
[]

The O
relation O
of O
the O
response O
to O
plasma O
oestradiol O
values O
was O
similar O
for O
each O
variable O
with O
an O
initial O
large O
reduction O
and O
little O
change O
in O
response O
to O
increases O
in O
the O
plasma O
oestradiol O
concentration O
above O
150 O
pmol/l O
( O
41 O
pg/ml O
) O
. O
[]

In O
this O
potentiation O
the O
primary O
substance O
is O
specially O
mixed O
with O
a O
carrier O
( O
typically O
90 O
% O
ethanol O
) O
in O
the O
ratio O
1:10 O
. O
[]

OBJECTlVE O
: O
To O
determine O
whether O
sulfasalazine O
can O
reduce O
the O
radiation-induced O
acute O
gastrointestinal O
complications O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
efficacy O
was O
determined O
by O
pneumatic O
otoscopy O
and O
tympanometric O
testing O
3 O
to O
5 O
, O
11 O
to O
14 O
, O
and O
22 O
to O
26 O
days O
after O
the O
initiation O
of O
therapy O
. O
['Physiological-Clinical']

All O
patients O
in O
the O
SSA O
group O
were O
awake O
and O
oriented O
at O
the O
end O
of O
surgery O
, O
whereas O
patients O
in O
the O
DES O
group O
required O
7 O
+/- O
2 O
min O
for O
extubation O
and O
orientation O
. O
[]

PVI O
was O
achieved O
in O
all O
patients O
without O
complications O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Assessing O
the O
effect O
of O
CT O
slice O
interval O
on O
unidimensional B-outcome ['Physiological-Clinical']
, O
bidimensional O
and O
volumetric O
measurements O
of O
solid O
tumours O
. O
['Physiological-Clinical']

In O
78 O
patients O
, O
there O
was O
fertilization O
after O
both O
IVF O
and O
ICSI O
( O
IVF+ O
group O
) O
; O
the O
fertilization O
rate O
was O
51 O
% O
for O
both O
the O
IVF- O
and O
ICSI-treated O
oocytes O
( O
271/528 O
oocytes O
and O
334/658 O
oocytes O
, O
respectively O
) O
. O
[]

Twelve O
months O
after O
primary O
vaccination O
, O
GMTs B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
PT I-outcome ['Physiological-Clinical']
in O
the O
freeze-dried O
, O
liquid O
ADPT O
groups O
and O
the O
WCDPT O
group O
have O
fallen O
from O
56.23 O
, O
62.63 O
and O
44.97 O
ELISA O
U/ml O
to O
6.08 O
, O
6.18 O
and O
11.30 O
ELISA O
U/ml O
, O
respectively O
. O
['Physiological-Clinical']

Patients O
were O
given O
insulin O
by O
continuous O
i.v O
. O
[]

These O
patients O
would O
not O
usually O
be O
referred O
for O
cardiovascular O
assessment O
. O
[]

Rifampicin O
plus O
isoniazid O
for O
the O
prevention O
of O
tuberculosis O
in O
an O
immigrant O
population O
. O
[]

The O
primary O
outcome O
will O
be O
the O
patient B-outcome ['Life-Impact']
's O
ability B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
correctly I-outcome ['Life-Impact']
demonstrate I-outcome ['Life-Impact']
dosing I-outcome ['Life-Impact']
instructions I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

However O
, O
identification O
of O
patients O
at O
risk O
for O
CI-AKI O
is O
challenging O
. O
[]

SETTING O
Primary O
health O
care O
, O
Kingston O
, O
Jamaica O
. O
[]

Liposome-encapsulated O
doxorubicin O
compared O
with O
conventional O
doxorubicin O
in O
a O
randomized O
multicenter O
trial O
as O
first-line O
therapy O
of O
metastatic O
breast O
carcinoma O
. O
[]

A O
secondary O
outcome O
was O
the O
frequency O
and O
nature O
of O
adverse O
events O
and O
the O
number O
of O
patients O
who O
withdrew O
from O
the O
study O
as O
a O
result O
. O
[]

Main O
outcome O
measure O
was O
BCVA O
at O
6 O
months O
, O
secondary O
was O
foveal B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Overall O
diet O
quality O
was O
determined O
by O
the O
Healthy O
Eating O
Index O
. O
[]

RESULTS O
Two O
hundred O
ninety-four O
patients O
who O
did O
not O
have O
brain O
metastases O
at O
the O
time O
of O
random O
assignment O
were O
analyzed O
. O
[]

Ninety-seven O
insulin-resistant O
PCOS O
patients O
undergoing O
ovulation O
induction O
using O
clomiphene O
citrate O
were O
randomly O
divided O
, O
by O
random O
number O
table O
, O
into O
two O
groups O
. O
[]

2 O
. O
[]

The O
efficacy O
and O
toxicity O
of O
once-daily O
( O
od O
) O
versus O
twice-daily O
( O
bd O
) O
dosing O
of O
vancomycin O
was O
compared O
in O
121 O
hospitalized O
patients O
. O
[]

Drinking O
and O
brushing O
times O
were O
around O
0900 O
, O
1100 O
, O
1300 O
and O
1500 O
h. O
Drinks O
were O
consumed O
as O
250 O
ml O
over O
10 O
min O
and O
brushing O
ex O
vivo O
for O
1 O
min O
to O
each O
specimen O
. O
[]

It O
is O
concluded O
that O
the O
use O
of O
an O
anal O
dilator O
improves O
the O
results O
of O
anal B-outcome ['Physiological-Clinical']
stretch I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
To O
assess O
safety O
and O
efficacy O
of O
sitaxsentan O
50 O
and O
100 O
mg O
in O
patients O
with O
pulmonary O
arterial O
hypertension O
( O
PAH O
) O
. O
[]

It O
has O
been O
suggested O
that O
, O
in O
view O
of O
the O
number O
of O
tablets O
to O
be O
taken O
( O
particularly O
in O
adults O
) O
, O
it O
may O
be O
possible O
to O
improve O
compliance B-outcome ['Life-Impact']
by O
allowing O
patients O
to O
divide O
the O
daily O
dose O
. O
['Life-Impact']

Modified O
constraint-induced O
therapy O
combined O
with O
mental O
practice O
: O
thinking O
through O
better O
motor O
outcomes O
. O
[]

INTERVENTIONS O
Patients O
were O
randomly O
allocated O
to O
one O
of O
4 O
groups O
. O
[]

Reliability O
was O
assessed O
by O
intraclass O
correlation O
coefficient O
( O
ICC O
) O
and O
internal O
consistency O
by O
Cronbach O
's O
alpha O
coefficient O
. O
[]

METHODS O
Seventy-nine O
patients O
with O
acute O
exacerbated O
COPD O
were O
randomly O
assigned O
to O
the O
treatment O
group O
( O
39 O
cases O
) O
and O
the O
control O
group O
( O
40 O
cases O
) O
. O
[]

Denopamine O
increased O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
patients O
with O
atrial O
fibrillation O
but O
had O
little O
effect O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
patients O
with O
sinus O
rhythm O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
response O
was O
defined O
as O
a O
reduction O
in O
diastolic B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
below I-outcome ['Physiological-Clinical']
90 I-outcome ['Physiological-Clinical']
mmHg I-outcome ['Physiological-Clinical']
or O
a O
fall O
of O
at O
least O
10 O
mmHg O
from O
baseline O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
A O
prospective O
, O
randomized O
controlled O
trial O
. O
[]

The O
influence O
of O
preoperative O
antibiotics O
on O
success B-outcome ['Physiological-Clinical']
of O
endosseous O
implants O
up O
to O
and O
including O
stage O
II O
surgery O
: O
a O
study O
of O
2,641 O
implants O
. O
['Physiological-Clinical']

This O
study O
analyses O
Internet-based O
training O
regarding O
acceptance O
and O
attrition O
in O
a O
trial O
on O
minimal-contact O
interventions O
for O
acute O
tinnitus O
. O
[]

The O
total O
number O
of O
inpatient B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
days I-outcome ['Resource-use']
during O
the O
study O
year O
was O
significantly O
less O
in O
the O
intervention O
group O
compared O
with O
controls O
( O
total O
days O
= O
33 O
vs O
116 O
, O
P O
= O
.049 O
) O
. O
['Resource-use']

Two O
symptomatic B-outcome ['Physiological-Clinical']
malunions I-outcome ['Physiological-Clinical']
required O
corrective O
osteotomy O
in O
the O
nonoperative O
group O
. O
['Physiological-Clinical']

The O
amount O
of O
memory B-outcome ['Life-Impact']
priming I-outcome ['Life-Impact']
, O
however O
, O
was O
positively O
related O
to O
one O
of O
two O
measures O
of O
preoperative O
anxiety B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

RESULTS O
No O
results O
available O
at O
this O
point O
. O
[]

At O
1 O
year O
, O
no O
differences O
in O
the O
resolution B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
observed O
between O
the O
2 O
groups O
, O
and O
over O
2 O
years O
, O
the O
overall O
incidence O
of O
complications B-outcome ['Adverse-effects']
was O
the O
same O
, O
specifically O
fecaloma B-outcome ['Physiological-Clinical']
( O
P O
= O
0.003 O
) O
in O
the O
MM O
group O
and O
external B-outcome ['Physiological-Clinical']
hemorrhoidal I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
( O
P O
= O
0.006 O
) O
in O
the O
SH O
group O
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Positive O
symptoms B-outcome ['Physiological-Clinical']
were O
not O
associated O
with O
cognitive B-outcome ['Life-Impact']
deficits I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Compared O
with O
the O
healthy O
volunteers O
, O
the O
patients O
who O
were O
post-thrombotic O
had O
a O
significantly O
attenuated O
velocity B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
at O
both O
the O
popliteal O
and O
the O
femoral O
vein O
levels O
. O
['Physiological-Clinical']

Double O
blind O
cross O
over O
study O
was O
performed O
comparing O
exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
, O
measuring O
distance O
walked O
on O
a O
6-min B-outcome ['Life-Impact']
walking I-outcome ['Life-Impact']
test O
and O
time B-outcome ['Life-Impact']
taken I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
climb I-outcome ['Life-Impact']
two I-outcome ['Life-Impact']
flights I-outcome ['Life-Impact']
of O
stairs B-outcome ['Life-Impact']
; O
and O
symptoms B-outcome ['Physiological-Clinical']
, O
evaluated O
by O
an O
activity O
of O
daily B-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
questionnaire O
, O
in O
atrioventricular O
synchronous O
and O
ventricular O
pacing O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

PN O
has O
been O
associated O
with O
shorter O
engraftment O
time O
and O
decreased O
mortality O
during O
HSCT O
, O
however O
, O
it O
is O
also O
linked O
with O
complications O
, O
including O
infections B-outcome ['Physiological-Clinical']
, O
liver B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
, O
and O
metabolic B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
examined O
the O
effects O
these O
same O
cardiac O
contractility O
modulating O
( O
CCM O
) O
electrical O
signals O
on O
myocardial B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
consumption I-outcome ['Physiological-Clinical']
( O
MVO B-outcome ['Physiological-Clinical']
( O
2 O
) O
) O
in O
both O
patients O
and O
dogs O
with O
chronic O
HF O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
prostate-specific I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
was O
4.4 O
months O
( O
95 O
% O
CI O
, O
3.1 O
to O
6.9 O
months O
) O
on O
the O
ixabepilone-alone O
arm O
and O
5.2 O
months O
( O
95 O
% O
CI O
, O
4.5 O
to O
6.8 O
months O
) O
on O
the O
combination O
arm O
. O
['Physiological-Clinical']

The O
least O
effective O
approach O
was O
adding O
benazepril O
20 O
mg/day O
to O
valsartan O
160 O
mg/day O
with O
no O
incremental O
reduction O
in O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
reduction O
of O
only O
1.7 O
mm O
Hg O
( O
P O
= O
not O
significant O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
Carbohydrate O
substitutes O
: O
comparative O
study O
of O
intestinal O
absorption O
of O
fructose O
, O
sorbitol O
and O
xylitol O
] O
. O
[]

This O
study O
provides O
preliminary O
support O
for O
the O
use O
of O
divalproex O
in O
treating O
[]

AIM O
The O
objective O
of O
this O
study O
was O
to O
evaluate O
diagnostic O
yield O
of O
TBLB O
using O
large O
modified O
flexible O
gastroenterological O
forceps O
( O
Jumbo O
forceps O
) O
compared O
with O
'normal O
' O
flexible O
forceps O
via O
rigid O
bronchoscopy O
in O
patients O
with O
diffuse O
parenchymal O
lung O
disease O
( O
DPLD O
) O
. O
[]

The O
primary O
end O
point O
was O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality']

These O
activities O
were O
continued O
for O
5 O
years O
. O
[]

[ O
Metastatic B-outcome ['Physiological-Clinical']
breast I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
: O
a O
comparative O
study O
of O
the O
efficacy O
of O
tamoxifen O
and O
the O
sequential O
administration O
of O
tamoxifen O
and O
medroxyprogesterone O
acetate O
] O
. O
['Physiological-Clinical']

Formation O
of O
ROS B-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
monocytes I-outcome ['Physiological-Clinical']
was O
reduced O
to O
a O
greater O
extent O
with O
valsartan O
than O
with O
amlodipine O
( O
28 O
% O
vs. O
2 O
% O
, O
n O
= O
50 O
, O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Those O
patients O
not O
responding O
to O
treatment O
were O
enrolled O
in O
the O
second O
part O
of O
the O
study O
, O
treated O
with O
an O
individualized O
combination O
of O
CRM O
and O
VR O
, O
and O
then O
reevaluated O
3 O
months O
later O
. O
[]

BACKGROUND O
Seizures O
occur O
in O
1 O
to O
2 O
percent O
of O
neonates O
admitted O
to O
an O
intensive O
care O
unit O
. O
[]

Using O
a O
population-based O
cancer O
registry O
for O
recruitment O
in O
a O
pilot O
cancer O
control O
study O
. O
[]

We O
hypothesized O
that O
perioperative O
micronutrient O
supplementation O
would O
augment O
antioxidant O
defenses O
, O
minimize O
muscle B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical']

We O
aimed O
to O
assess O
the O
efficacy O
and O
safety O
of O
triple O
antiretroviral O
compared O
with O
zidovudine O
and O
single-dose O
nevirapine O
prophylaxis O
in O
pregnant O
women O
infected O
with O
HIV O
. O
[]

Treatment-emergent O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs O
) O
were O
monitored O
during O
an O
8-week O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
risperidone O
( O
0.5-3.5 O
mg/day O
) O
in O
101 O
children O
and O
adolescents O
with O
a O
lifetime O
diagnosis O
of O
autistic O
disorder O
. O
['Adverse-effects']

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
an O
oral O
formulation O
of O
cetirizine O
5 O
mg O
with O
sustained-release O
pseudoephedrine O
( O
PSE O
) O
120 O
mg O
relative O
to O
placebo O
in O
patients O
with O
nasal B-outcome ['Physiological-Clinical']
congestion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
grade O
3/4 O
[]

METHODS O
Twenty-nine O
patients O
( O
6 O
type O
1 O
and O
23 O
type O
2 O
) O
with O
gastroparesis O
underwent O
assessments O
of O
: O
( O
i O
) O
gastric B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
of O
a O
solid/liquid O
meal O
using O
scintigraphy O
, O
( O
ii O
) O
glycaemic O
control O
( O
blood O
glucose O
at O
0 O
, O
30 O
, O
60 O
, O
90 O
and O
120 O
min O
during O
the O
gastric O
emptying O
measurement O
) O
and O
( O
iii O
) O
upper O
gastrointestinal O
and O
'meal-related O
' O
symptoms O
( O
questionnaire O
) O
, O
at O
baseline O
and O
after O
treatment O
with O
KC O
11458 O
in O
a O
dose O
of O
8 O
mg O
t.d.s. O
, O
or O
placebo O
for O
8 O
days O
. O
['Physiological-Clinical']

The O
effects O
of O
candesartan O
, O
with O
reduction O
in O
morphological B-outcome ['Physiological-Clinical']
parameters O
and O
lowering O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
might O
influence O
future O
treatment O
of O
glomerulopathy O
in O
type O
1 O
diabetes O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Contrast O
sensitivity B-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
in O
a O
photopic O
condition O
with O
and O
without O
glare O
and O
in O
a O
scotopic O
condition O
without O
glare O
. O
['Physiological-Clinical']

BACKGROUND O
Psychosocial O
stress O
may O
increase O
risk O
and O
worsen O
prognosis O
of O
coronary O
heart O
disease O
in O
women O
. O
[]

CONCLUSION O
This O
study O
will O
determine O
if O
a O
single O
intradermal O
SWI O
technique O
is O
no O
less O
effective O
than O
the O
routinely O
used O
four O
injection O
technique O
for O
lower O
back O
pain O
during O
labour O
. O
[]

Less O
is O
known O
about O
specific O
emotion O
regulation O
strategies O
that O
promote O
learning O
. O
[]

Conversely O
, O
a O
relatively O
low O
dose O
of O
recombinant O
interferon O
, O
used O
in O
combination O
with O
effective O
surgical O
deleulking O
, O
can O
markedly O
reduce O
the O
risk O
of O
postoperative B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Using O
current O
colonoscopic O
technology O
, O
there O
are O
significant O
miss O
rates O
for O
adenomas O
< O
1 O
cm O
even O
with O
meticulous O
colonoscopy O
. O
[]

We O
compared O
onset B-outcome ['Physiological-Clinical']
and O
offset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
and O
tracheal B-outcome ['Physiological-Clinical']
intubating I-outcome ['Physiological-Clinical']
conditions I-outcome ['Physiological-Clinical']
after O
rapacuronium O
and O
rocuronium O
in O
60 O
patients O
in O
a O
randomized O
, O
assessor-blinded O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Low-dose O
naltrexone O
effects O
on O
plasma O
chemistries O
and O
clinical O
symptoms O
in O
autism O
: O
a O
double-blind O
, O
placebo-controlled O
study O
. O
[]

CONCLUSIONS O
It O
can O
be O
suggested O
that O
0.6 O
and O
0.8 O
ml O
of O
4 O
% O
Ar O
+ O
1:100,000 O
Ep O
, O
delivered O
by O
CCLADS O
, O
offer O
high O
success O
rate O
and O
effective O
clinical O
parameters O
of O
ISA O
as O
a O
primary O
anesthesia O
. O
[]

METHODS O
The O
Atypical O
Squamous O
Cells O
of O
Undetermined O
Significance O
( O
ASCUS O
) O
and O
Low-Grade O
Squamous O
Intraepithelial O
Lesion O
( O
LSIL O
) O
Triage O
Study O
( O
ALTS O
) O
was O
a O
clinical O
trial O
to O
evaluate O
the O
best O
management O
strategies O
for O
women O
with O
equivocal O
( O
ASCUS O
) O
or O
mildly O
abnormal O
( O
LSIL O
) O
Pap O
tests O
. O
[]

RESULTS O
Response O
in O
Phase O
2 O
did O
not O
differ O
significantly O
between O
verapamil O
and O
continued-lithium O
. O
[]

The O
final O
outcome O
with O
or O
without O
inclusion O
of O
these O
10 O
patients O
was O
not O
statistically O
different O
. O
[]

PATIENTS O
A O
total O
of O
67 O
patients O
were O
enrolled O
who O
met O
defined O
criteria O
for O
acute O
lung O
injury/acute O
respiratory O
distress O
syndrome O
. O
[]

Tumours O
with O
marginal O
proliferation O
pattern O
showed O
a O
lower O
hazard O
ratio O
with O
CHART O
versus O
conventional O
for O
locoregional O
control O
( O
P O
= O
0.005 O
) O
. O
[]

Efficacy O
of O
a O
total O
occlusive O
ionic O
silver-containing O
dressing O
combination O
in O
decreasing O
risk O
of O
surgical B-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
: O
an O
RCT O
. O
['Physiological-Clinical']

We O
conclude O
that O
intramuscular O
administration O
of O
the O
fixed O
combination O
of O
troxerutin O
150 O
mg O
and O
carbazochrome O
1.5 O
mg O
is O
effective O
, O
well O
tolerated O
and O
superior O
to O
placebo O
in O
improving O
hemorrhoidal O
and O
post-surgical O
symptoms O
during O
the O
five O
days O
following O
surgery O
. O
[]

The O
results O
obtained O
with O
Defibrotide O
in O
a O
random O
and O
controlled O
clinical O
study O
versus O
calcium O
heparin O
involving O
211 O
patients O
of O
both O
sexes O
candidates O
to O
receive O
total O
hip O
arthroplasty O
and O
presenting O
at O
least O
one O
major O
thromboembolic O
risk O
factor O
are O
reported O
. O
[]

The O
cumulative O
proportions O
of O
the O
children O
with O
complete B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
their I-outcome ['Physiological-Clinical']
enlarged I-outcome ['Physiological-Clinical']
livers I-outcome ['Physiological-Clinical']
at O
48 O
, O
96 O
, O
168 O
or O
336 O
and O
504 O
h O
after O
commencement O
of O
treatment O
were O
significantly O
higher O
in O
those O
treated O
with O
CQ O
plus O
chlorpheniramine O
( O
CQCP O
) O
than O
in O
the O
other O
two O
treatment O
groups O
( O
with O
P-values O
of O
0.02 O
, O
0.001 O
, O
0.00000 O
and O
0.00002 O
, O
respectively O
) O
. O
['Physiological-Clinical']

Statistical O
analysis O
of O
the O
results O
from O
83 O
evaluable O
patients O
showed O
that O
the O
'controlled-release O
' O
tablet O
formulation O
of O
200 O
mg O
ketoprofen O
was O
equally O
as O
effective O
as O
the O
100 O
mg O
indomethacin B-outcome ['Resource-use']
suppository I-outcome ['Resource-use']
in O
the O
treatment O
of O
rheumatoid O
arthritis O
, O
especially O
with O
regard O
to O
pain B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
awakening I-outcome ['Physiological-Clinical']
and O
morning B-outcome ['Physiological-Clinical']
stiffness I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

One O
hundred O
thirteen O
patients O
were O
randomized O
to O
receive O
either O
oral O
sodium O
phosphate O
( O
Fleet O
Phospho-Soda O
) O
, O
lemon-flavored O
castor O
oil O
( O
Purge O
) O
, O
or O
standard O
polyethylene O
glycol-based O
lavage O
solution O
( O
GoLYTELY O
) O
before O
elective O
colonoscopy O
. O
[]

Following O
prehydration O
, O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
recorded O
and O
serum B-outcome ['Physiological-Clinical']
electrolyte I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Granisetron O
at O
both O
doses O
also O
was O
superior O
to O
the O
control O
for O
the O
prevention O
of O
nausea B-outcome ['Physiological-Clinical']
over O
the O
24-h O
study O
period O
( O
nausea B-outcome ['Physiological-Clinical']
visual O
analog O
scales O
at O
24-h O
postsurgery O
: O
49 O
mm O
, O
17 O
mm O
, O
and O
18 O
mm O
in O
the O
control O
, O
granisetron O
20 O
micrograms/kg O
, O
and O
granisetron O
40 O
micrograms/kg O
groups O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Computer-delivered O
tailored O
intervention O
improves O
colon B-outcome ['Life-Impact']
cancer I-outcome ['Life-Impact']
screening I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
and O
health O
beliefs O
of O
African-Americans O
. O
['Life-Impact']

METHODS O
A O
total O
of O
13 O
388 O
women O
at O
increased O
risk O
for O
breast O
cancer O
were O
randomly O
assigned O
in O
the O
BCPT O
to O
receive O
either O
tamoxifen O
( O
20 O
mg/day O
) O
or O
placebo O
. O
[]

The O
median O
survival O
time O
was O
3.5 O
months O
in O
the O
combined-modality O
arm O
and O
3.2 O
months O
in O
the O
teniposide-alone O
arm O
. O
[]

Four O
healthy O
volunteers O
with O
significant O
erythema O
and O
telangiectasia O
on O
the O
face O
applied O
EGCG O
cream O
to O
one O
side O
of O
the O
face O
, O
and O
vehicle O
control O
cream O
to O
the O
other O
, O
twice O
daily O
for O
six O
weeks O
. O
[]

To O
that O
end O
, O
participants O
completed O
two O
cooperative O
tasks O
with O
a O
confederate O
, O
which O
allowed O
us O
to O
measure O
linguistic B-outcome ['Life-Impact']
alignment I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
confederate I-outcome ['Life-Impact']
in O
terms O
of O
lexical B-outcome ['Life-Impact']
choice I-outcome ['Life-Impact']
, O
syntactic B-outcome ['Life-Impact']
structure O
and O
spatial B-outcome ['Life-Impact']
frame O
of O
reference B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Repeated-measures O
analysis O
of O
variance O
was O
used O
to O
evaluate O
treatment O
and O
time O
effects O
on O
mood O
and O
quality O
of O
life O
. O
[]

They O
had O
included O
416 O
and O
122 O
patients O
. O
[]

The O
incidence O
of O
acid B-outcome ['Physiological-Clinical']
GER I-outcome ['Physiological-Clinical']
in O
the O
placebo O
and O
ranitidine O
groups O
was O
28.2 O
% O
and O
2.5 O
% O
, O
respectively O
( O
P O
= O
0.006 O
) O
. O
['Physiological-Clinical']

5.2 O
% O
in O
the O
strength O
group O
( O
P O
< O
0.001 O
) O
, O
whereas O
time-to-task-failure O
was O
prolonged O
in O
the O
endurance O
group O
( O
22.7 O
? O
[]

OBJECTIVES O
to O
determine O
the O
effectiveness O
of O
a O
health O
information O
package O
in O
terms O
of O
empowering O
the O
pregnant O
women O
to O
modify O
their O
health-care O
behaviour O
and O
take O
appropriate O
action O
to O
combat O
anaemia O
in O
pregnancy O
. O
[]

Our O
first O
randomized O
trial O
in O
71 O
patients O
( O
1981-1983 O
) O
compared O
the O
association O
of O
CYC O
with O
corticosteroids O
( O
CS O
) O
and O
PE O
to O
CS O
and O
PE O
, O
in O
order O
to O
evaluate O
the O
efficacy O
of O
CYC O
given O
as O
the O
first-line O
treatment O
to O
control O
disease O
activity O
and O
subsequent O
survival B-outcome ['Mortality']
of O
PAN O
and O
CSS O
patients O
. O
['Mortality']

All O
rats O
were O
maintained O
for O
6 O
h O
and O
then O
sacrificed O
with O
a O
high-dose O
pentobarbital O
injection O
. O
[]

Clinic O
visit O
and O
waiting O
: O
patient B-outcome ['Life-Impact']
education I-outcome ['Life-Impact']
and O
satisfaction B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
self-report O
measure O
did O
not O
significantly O
differentiate O
between O
groups O
, O
but O
the O
REI O
group O
demonstrated O
significant O
pre- O
to O
follow-up O
changes O
. O
[]

RESULTS O
The O
median O
age O
was O
52 O
years O
( O
range O
: O
39-68 O
) O
and O
30 O
% O
of O
the O
participants O
were O
male O
. O
[]

This O
study O
confirms O
that O
mizolastine O
is O
a O
rapid O
and O
potent O
antihistamine B-outcome ['Physiological-Clinical']
; O
and O
its O
long-lasting O
effectiveness O
indicates O
that O
a O
once-daily O
regimen O
is O
acceptable O
for O
clinical O
use O
. O
['Physiological-Clinical']

Regarding O
comparison O
of O
the O
biophysical O
properties O
of O
the O
skin O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
the O
assessments O
, O
except O
for O
the O
increase O
determined O
during O
the O
second O
week O
in O
the O
erythema B-outcome ['Physiological-Clinical']
index O
in O
the O
laser-treated O
areas O
. O
['Physiological-Clinical']

The O
sample O
of O
the O
5 O
patients O
per O
institution O
was O
randomly O
selected O
at O
the O
EORTC O
Data O
Center O
. O
[]

This O
difference O
reaches O
statistical O
significance O
( O
p O
less O
than O
0.05 O
) O
. O
[]

However O
, O
little O
is O
known O
about O
the O
long-term O
outcomes O
of O
these O
treatments O
. O
[]

Fourteen O
subjects O
( O
three O
females O
and O
11 O
males O
) O
, O
who O
met O
the O
criteria O
for O
pathological O
gambling O
in O
accordance O
with O
the O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
IV O
, O
were O
randomly O
assigned O
to O
a O
Treatment O
Group O
( O
n=7 O
) O
or O
a O
waiting O
list O
Control O
Group O
( O
n=7 O
) O
. O
[]

METHODS O
This O
was O
an O
open-label O
continuation O
study O
of O
the O
randomized O
, O
double-blind O
, O
controlled O
trial O
of O
risperidone O
and O
haloperidol O
study O
for O
12 O
week O
in O
autistic O
children O
and O
adolescents O
. O
[]

Imiquimod O
, O
a O
topical O
immune O
response O
modifier O
that O
targets O
Toll-like O
receptor O
7 O
, O
is O
currently O
approved O
for O
superficial O
BCC O
. O
[]

2.25 O
mm O
; O
p O
= O
0.85 O
) O
, O
and O
with O
a O
fourfold O
AH O
dose O
some O
reduction O
of O
AS-induced O
wheal O
( O
3.79 O
? O
[]

Change O
in O
serum B-outcome ['Physiological-Clinical']
leptin I-outcome ['Physiological-Clinical']
levels O
after O
2 O
months O
was O
examined O
as O
a O
predictor O
of O
final O
weight O
gain O
in O
mixed O
regression O
models O
that O
controlled O
for O
site O
, O
gender O
, O
age O
, O
and O
risperidone O
dose O
. O
['Physiological-Clinical']

Ducks O
in O
the O
fluid O
resuscitation O
study O
received O
a O
5 O
mL/kg O
intravenous O
bolus O
of O
crystalloids O
, O
hetastarch O
( O
HES O
) O
, O
or O
a O
hemoglobin-based O
oxygen-carrying O
solution O
( O
HBOCS O
) O
. O
[]

Both O
experiments O
involved O
the O
localization O
of O
a O
target O
that O
appeared O
to O
the O
left O
or O
right O
of O
the O
fixation O
point O
. O
[]

RESULTS O
Regarding O
chemical B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

DNA O
fingerprinting O
was O
used O
as O
needed O
to O
determine O
the O
outcome O
for O
each O
embryo O
. O
[]

There O
were O
also O
no O
significant O
inter-group O
differences O
. O
[]

G-CSF O
was O
given O
after O
each O
course O
, O
and O
the O
next O
scheduled O
course O
was O
started O
as O
soon O
as O
neutrophil O
count O
was O
> O
1 O
x O
10 O
( O
9 O
) O
/L O
and O
platelet O
count O
was O
> O
100 O
x O
10 O
( O
9 O
) O
/L O
. O
[]

Routine O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
recorded O
before O
and O
after O
treatment O
. O
['Physiological-Clinical']

Why O
does O
lag O
affect O
the O
durability O
of O
memory-based B-outcome ['Life-Impact']
automaticity I-outcome ['Life-Impact']
: O
loss O
of O
memory O
strength O
or O
interference O
? O
['Life-Impact']

OBJECTIVE O
To O
compare O
the O
effect O
of O
400 O
mug O
of O
oral O
misoprostol O
with O
5 O
U O
of O
intravenous O
oxytocin O
in O
the O
reduction O
of O
postpartum B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
prevention O
of O
postpartum O
hemorrhage O
. O
['Physiological-Clinical']

Recent O
studies O
suggest O
that O
immediate O
restoration O
of O
single O
implants O
may O
be O
a O
viable O
treatment O
option O
. O
[]

The O
present O
study O
examined O
the O
feasibility B-outcome ['Life-Impact']
, O
acceptability B-outcome ['Life-Impact']
, O
and O
potential O
efficacy O
of O
a O
telephone-based O
intervention O
for O
nonsmoking O
support O
persons O
. O
['Life-Impact', 'Life-Impact']

Carbohydrate O
supplementation O
significantly O
increased O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
exhaustion I-outcome ['Physiological-Clinical']
( O
carbohydrate O
19.7 O
+/- O
4.6 O
min O
vs. O
placebo O
12.7 O
+/- O
3.1 O
min O
) O
, O
while O
the O
addition O
of O
protein O
enhanced O
the O
effect O
of O
the O
carbohydrate O
supplement O
( O
carbohydrate-protein O
26.9 O
+/- O
4.5 O
min O
, O
p O
< O
.05 O
) O
. O
['Physiological-Clinical']

A O
double-blind O
, O
randomized O
study O
of O
gentamicin O
and O
netilmicin O
, O
each O
in O
combination O
with O
cefoxitin O
, O
was O
done O
to O
compare O
their O
respective O
efficacy O
and O
toxicity B-outcome ['Adverse-effects']
in O
patients O
with O
serious O
systemic O
infection O
. O
['Adverse-effects']

Long-term O
follow-up O
of O
cytostatic O
intravesical O
instillation O
in O
patients O
with O
superficial O
bladder O
carcinoma O
. O
[]

No O
significant O
differences O
were O
observed O
in O
serum B-outcome ['Physiological-Clinical']
estrone I-outcome ['Physiological-Clinical']
, O
estradiol B-outcome ['Physiological-Clinical']
, O
sex B-outcome ['Physiological-Clinical']
hormone-binding I-outcome ['Physiological-Clinical']
globulin I-outcome ['Physiological-Clinical']
, O
dehydroepiandrosterone B-outcome ['Physiological-Clinical']
sulfate I-outcome ['Physiological-Clinical']
, O
prolactin B-outcome ['Physiological-Clinical']
, O
or O
progesterone B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
with O
soy O
feeding O
in O
the O
non-OC O
or O
the O
OC O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Topical O
imiquimod O
5 O
% O
cream O
as O
an O
effective O
treatment O
for O
external O
genital B-outcome ['Physiological-Clinical']
and O
perianal B-outcome ['Physiological-Clinical']
warts O
in O
different O
patient O
populations O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Eight O
normal O
male O
volunteers O
undergoing O
UGIE O
with O
sedation O
( O
0.1 O
mg/kg O
of O
midazolam O
) O
and O
without O
it O
( O
two O
endoscopies O
per O
volunteer O
in O
random O
order O
) O
were O
monitored O
throughout O
the O
procedure O
by O
means O
of O
electrocardiogram B-outcome ['Resource-use']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
peripheral O
oxygen O
saturation O
( O
SpO2 O
) O
. O
['Resource-use', 'Physiological-Clinical']

Controls O
showed O
significantly O
higher O
ventilation B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
end-exercise I-outcome ['Life-Impact']
dyspnea I-outcome ['Life-Impact']
scores O
in O
the O
fatigued O
condition O
, O
whereas O
, O
in O
COPD O
, O
fatigue O
did O
not O
influence O
ventilation O
or O
dyspnea O
during O
exercise O
. O
['Life-Impact']

Intensification O
also O
reduced O
the O
D-dimer O
level O
, O
a O
coagulation O
biomarker O
that O
is O
predictive O
of O
morbidity O
and O
mortality O
among O
patients O
receiving O
treatment O
for O
HIV O
infection O
. O
[]

Approximately O
50 O
% O
of O
pregnant O
women O
have O
an O
abnormally O
increased O
urinary O
excretion O
of O
3-hydroxyisovaleric B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
3-HIA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
which O
probably O
reflects O
decreased O
activity O
of O
the O
biotin-dependent O
enzyme O
methylcrotonyl-CoA O
carboxylase O
. O
['Physiological-Clinical']

The O
mean O
range O
of O
movement O
for O
plantar B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
improved O
from O
15.2 O
degrees O
( O
10.0 O
degrees O
to O
20.6 O
degrees O
) O
to O
18.7 O
degrees O
( O
10.0 O
degrees O
to O
33.0 O
degrees O
) O
and O
for O
dorsiflexion O
from O
12.3 O
degrees O
( O
7.4 O
degrees O
to O
19.4 O
degrees O
) O
to O
18.9 O
degrees O
( O
10.0 O
degrees O
to O
24.1 O
degrees O
) O
( O
both O
, O
p O
= O
0.0001 O
) O
when O
the O
first O
third O
of O
therapy O
was O
compared O
with O
the O
last O
third O
. O
['Physiological-Clinical']

Their O
aim O
was O
to O
test O
whether O
conscious O
versus O
unconscious O
processing O
influenced O
diagnosis O
of O
psychiatric O
cases O
. O
[]

Falls B-outcome ['Life-Impact']
and O
mobility B-outcome ['Life-Impact']
in O
Parkinson O
's O
disease O
: O
protocol O
for O
a O
randomised O
controlled O
clinical O
trial O
. O
['Life-Impact', 'Life-Impact']

We O
therefore O
compared O
the O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
a O
DA O
antagonist O
( O
amisulpride O
) O
and O
a O
DA O
agonist O
( O
bromocriptine O
) O
in O
a O
randomized O
, O
double-blind O
, O
crossover O
trial O
in O
9 O
children O
with O
autism O
, O
likely O
severely O
mentally O
retarded O
. O
['Physiological-Clinical']

Forty O
human O
third O
molars O
were O
divided O
into O
four O
groups O
: O
Group O
1 O
, O
not O
treated O
with O
ozone O
; O
Group O
2 O
, O
ozone O
application O
followed O
by O
acid O
etching O
; O
Group O
3 O
, O
acid O
etching O
followed O
by O
ozone O
application O
; O
and O
Group O
4 O
, O
ozone O
and O
application O
of O
sodium O
ascorbate O
. O
[]

Areas O
under O
the O
receiver O
operating O
characteristic O
( O
AUROC O
) O
curve O
assessed O
screening O
accuracy O
for O
DSM-IV O
physiological O
dependence O
( O
tolerance O
or O
withdrawal O
) O
or O
withdrawal O
alone O
. O
[]

A O
next O
generation O
fibrin O
sealant O
( O
TISSEEL O
VH O
S/D O
) O
has O
been O
developed O
in O
frozen O
, O
ready-to-use O
form O
with O
an O
added O
virus O
inactivation O
step O
( O
solvent/detergent O
[ O
S/D O
] O
treatment O
) O
to O
provide O
added O
safety O
and O
convenience O
to O
the O
currently O
licensed O
product O
. O
[]

in O
a O
5 O
1/2-year O
study O
, O
we O
randomly O
assigned O
299 O
men O
with O
alcoholic O
cirrhosis O
, O
who O
had O
persistent O
or O
recurrent O
severe O
ascites O
despite O
a O
standard O
medical O
regimen O
, O
to O
receive O
either O
intensive O
medical O
treatment O
or O
peritoneovenous O
( O
LeVeen O
) O
shunting O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
if O
topical O
tetracaine O
reduces O
the O
pain O
of O
intramuscular O
palivizumab O
compared O
to O
placebo O
. O
[]

Effects O
of O
electro-acupuncture O
on O
T O
cell B-outcome ['Physiological-Clinical']
subpopulations I-outcome ['Physiological-Clinical']
, O
NK B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
humoral B-outcome ['Physiological-Clinical']
immunity I-outcome ['Physiological-Clinical']
and O
leukocyte B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Sample O
size O
for O
larger O
future O
randomized O
clinical O
trial O
was O
116 O
participants O
. O
[]

However O
, O
few O
emotion O
training O
interventions O
have O
been O
trialled O
with O
young O
children O
with O
autism O
and O
co-morbid O
ID O
. O
[]

16 O
healthy O
patients O
requiring O
removal O
of O
bilateral O
symmetrically-impacted O
mandibular O
third O
molars O
participated O
in O
a O
double-blind O
randomised O
crossover O
trial O
to O
test O
the O
effectiveness O
of O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
using O
a O
long-acting O
anti-inflammatory O
agent O
( O
diflunisal O
) O
in O
combination O
with O
a O
long-acting O
local O
anaesthetic O
agent O
( O
bupivacaine O
) O
. O
['Physiological-Clinical']

CALLISTO O
was O
a O
12-month O
, O
prospective O
, O
multicenter O
, O
open-label O
study O
. O
[]

Exclusion O
criteria O
were O
diabetic O
ketoacidosis O
, O
severe O
hepatic O
failure O
or O
hepatic O
resection O
, O
pancreatitis O
, O
glucose O
of O
less O
than O
2.2 O
mmol/L O
on O
admission O
to O
hospital O
, O
insulin O
infusion O
on O
admission O
to O
ICU O
, O
planned O
withdrawal O
of O
life O
support O
, O
and O
inability O
to O
obtain O
informed O
consent O
. O
[]

During O
the O
trial O
, O
a O
process O
of O
central O
review O
was O
established O
to O
monitor O
performance O
. O
[]

Patients O
were O
stratified O
by O
clinical O
tumor O
stage O
and O
by O
radiation O
plan O
. O
[]

Thus O
, O
patients O
with O
acute O
myocardial O
infarction O
treated O
with O
emergency O
angioplasty O
had O
significantly O
less O
severe O
residual O
coronary B-outcome ['Physiological-Clinical']
stenosis B-outcome ['Physiological-Clinical']
and O
exercise-induced B-outcome ['Life-Impact']
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Anti-angiogenic B-outcome ['Physiological-Clinical']
effects O
of O
epigallocatechin-3-gallate O
in O
human O
skin O
. O
['Physiological-Clinical']

Urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
showed O
a O
significant O
increase O
at O
night O
during O
sleep O
deprivation O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

No O
patient O
experienced O
diarrhea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Forty-six O
patients O
with O
advanced O
gastric O
carcinoma O
( O
Stage O
IV O
) O
were O
evaluated O
in O
a O
prospective O
randomized O
comparison O
of O
two O
chemotherapy O
regimens O
( O
FAM O
versus O
5-FU O
plus O
BCNU O
) O
to O
identify O
therapeutic O
activity O
. O
[]

Following O
the O
task O
, O
participants O
completed O
the O
Profile O
of O
Mood O
States O
to O
assess O
mood B-outcome ['Life-Impact']
, O
and O
temperature B-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
reassessed O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
cecal B-outcome ['Life-Impact']
intubation I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
shorter O
in O
the O
CF-240I O
group O
( O
5.75 O
+/- O
3.18 O
vs O
6.26 O
+/- O
3.30 O
min O
, O
P O
= O
0.02 O
) O
. O
['Life-Impact']

Areas O
of O
secondary O
hyperalgesia O
, O
heat O
pain O
detection O
thresholds O
, O
and O
painfulness O
of O
stimulation O
with O
45 O
degrees O
C O
for O
1 O
min O
( O
long O
thermal O
stimulation O
) O
were O
quantified O
. O
[]

Peak O
concentrations O
of O
RU B-outcome ['Physiological-Clinical']
486 I-outcome ['Physiological-Clinical']
occurred O
on O
most O
occasions O
within O
2 O
h. O
Plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
at O
1 O
h O
and O
at O
24 O
h O
increased O
in O
proportion O
to O
log O
dose O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
total O
of O
102 O
patients O
were O
included O
in O
this O
experimental O
study O
at O
the O
POF O
Hospital O
, O
Wah O
Cantt O
from O
October O
2004 O
to O
June O
2005 O
. O
[]

No O
routine O
laboratory O
or O
physical O
findings O
reliably O
predicted O
the O
development O
of O
the O
fat B-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
except O
petechial B-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
, O
which O
occurred O
only O
in O
5 O
placebo-treated O
patients O
who O
developed O
the O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
the O
intervention O
, O
no O
clinical O
contact O
was O
made O
until O
follow-up O
measurements O
were O
obtained O
at O
24 O
and O
36 O
weeks O
from O
baseline O
. O
[]

DESIGN O
Multicenter O
, O
randomized O
, O
prospective O
, O
double-blind O
study O
of O
184 O
healthy O
post-menopausal O
women O
randomized O
to O
6 O
cycles O
of O
either O
estradiol O
( O
2mg O
) O
+trimegestone O
( O
0.5mg O
) O
( O
T-group O
) O
or O
estradiol O
( O
2mg O
) O
+dydrogesterone O
( O
10mg O
) O
( O
DYDR O
group O
) O
. O
[]

In O
both O
, O
the O
cumulative O
relapse B-outcome ['Physiological-Clinical']
rate O
was O
significantly O
greater O
in O
cigarette O
smokers O
than O
in O
nonsmokers O
, O
but O
smokers O
and O
nonsmokers O
treated O
with O
cimetidine O
relapsed B-outcome ['Physiological-Clinical']
( O
50 O
% O
at O
4 O
and O
8 O
mo O
, O
respectively O
) O
faster O
than O
the O
corresponding O
smokers O
and O
nonsmokers O
treated O
with O
sucralfate O
( O
50 O
% O
at O
8 O
and O
18 O
mo O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Blood O
pressure O
, O
lipids O
, O
and O
hyperinsulinaemia O
were O
reduced O
and O
early O
insulin O
responsiveness O
to O
glucose O
loading O
preserved O
. O
[]

= O
38 O
, O
P O
< O
0.0001 O
) O
. O
[]

Combination O
therapy O
with O
methotrexate O
and O
hydroxychloroquine O
for O
rheumatoid O
arthritis O
increases O
exposure O
to O
methotrexate O
. O
[]

On O
admission O
they O
were O
assigned O
to O
one O
of O
three O
groups O
: O
( O
a O
) O
monocomponent O
pertussis O
toxoid O
vaccine O
; O
( O
b O
) O
two-component O
acellular O
vaccine O
also O
containing O
filamentous O
haemagglutinin O
; O
or O
( O
c O
) O
20 O
% O
albumin O
solution O
( O
placebo O
) O
. O
[]

On O
average O
, O
parents O
' O
checklists O
and O
playroom O
data O
could O
not O
differentiate O
between O
naltrexone O
treatment O
and O
placebo O
treatment O
; O
however O
, O
teachers O
significantly O
favored O
naltrexone O
treatment O
. O
[]

Data O
will O
help O
us O
to O
decide O
the O
final O
details O
of O
the O
large O
multicenter O
trial O
. O
[]

Histological O
evaluation O
of O
human O
atherosclerosis O
showed O
minimal O
AP-1 O
activation O
in O
non-diseased O
arterial O
wall O
( O
i.e O
. O
[]

A O
total O
of O
56 O
patients O
were O
enrolled O
consecutively O
and O
randomised O
in O
a O
1:1 O
ratio O
to O
receive O
combination O
treatment O
with O
intravitreal O
ranibizumab O
and O
topical O
ketorolac O
( O
group O
1 O
) O
or O
ranibizumab O
alone O
( O
group O
2 O
) O
. O
[]

Primary O
glaucoma O
triple O
procedure O
in O
patients O
with O
primary O
open-angle O
glaucoma O
: O
the O
effect O
of O
mitomycin O
C O
in O
patients O
with O
and O
without O
prognostic O
factors O
for O
filtration O
failure O
. O
[]

Routine O
hemodynamic O
monitoring O
and O
biochemical O
measurements O
were O
registered O
according O
to O
the O
hospital O
practice O
. O
[]

These O
results O
challenge O
the O
long-standing O
assumption O
that O
muscle O
fatigue O
causes O
exhaustion O
during O
high-intensity O
aerobic O
exercise O
, O
and O
suggest O
that O
exercise O
tolerance O
in O
highly O
motivated O
subjects O
is O
ultimately O
limited O
by O
perception O
of O
effort O
. O
[]

Changes O
were O
accompanied O
by O
a O
reverse B-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
left B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
( O
from O
32.0 O
to O
29.0 O
and O
29.1 O
mL/m O
( O
2 O
) O
; O
P O
< O
0.01 O
) O
and O
LV B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
( O
from O
148.0 O
to O
130.0 O
and O
128.0 O
g/m O
( O
2 O
) O
; O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Our O
objective O
was O
to O
determine O
whether O
a O
questionnaire O
can O
identify O
individuals O
with O
vitamin B-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
insufficiency I-outcome ['Physiological-Clinical']
( O
VDI O
) O
. O
['Physiological-Clinical']

During O
the O
postpartum O
period O
, O
information O
was O
collected O
via O
a O
questionnaire O
about O
participants O
' O
levels O
of O
satisfaction O
with O
a O
variety O
of O
aspects O
of O
care O
provided O
during O
the O
antenatal O
, O
delivery O
and O
postpartum O
periods O
. O
[]

This O
study O
investigates O
the O
logic O
and O
robustness O
of O
the O
partial-area O
method O
in O
establishing O
bioequivalence O
. O
[]

Agreement O
between O
the O
home O
and O
laboratory O
study O
recordings O
was O
also O
assessed O
using O
receiver O
operating O
characteristic O
( O
ROC O
) O
curves O
and O
Bland-Altman O
analysis O
. O
[]

CONCLUSION O
On O
the O
basis O
of O
this O
analysis O
, O
combined-modality O
treatment O
resulted O
in O
fewer O
early O
progressions O
in O
clinical B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
I/II I-outcome ['Physiological-Clinical']
HL I-outcome ['Physiological-Clinical']
, O
although O
early O
outcome O
was O
excellent O
in O
both O
arms O
. O
['Physiological-Clinical']

CONCLUSIONS O
In O
this O
preliminary O
investigation O
, O
verapamil O
monotherapy O
did O
not O
demonstrate O
antimanic O
efficacy O
. O
[]

In O
a O
randomized O
controlled O
trial O
, O
the O
effectiveness O
of O
a O
polymeric O
surgical O
sealant O
( O
CoSeal O
) O
was O
compared O
to O
Gelfoam/thrombin O
for O
managing O
anastomotic B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
after O
implantation O
of O
Dacron O
grafts O
during O
aortic O
reconstruction O
for O
nonruptured O
aneurysms O
. O
['Physiological-Clinical']

The O
effect O
of O
a O
classroom-based O
activity O
break O
on O
in-school B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
levels O
of O
primary O
school O
children O
. O
['Life-Impact']

[ O
Prevention O
of O
stress O
ulcers O
with O
synthetic O
depot O
secretin O
] O
. O
[]

Postprandial B-outcome ['Physiological-Clinical']
triglyceride I-outcome ['Physiological-Clinical']
levels O
tended O
to O
be O
higher O
after O
all O
fibre-rich O
meals O
, O
but O
only O
significant O
for O
oat O
powder O
and O
the O
mixed O
meal O
when O
compared O
with O
the O
control O
meal O
. O
['Physiological-Clinical']

Patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
for O
PCA O
was O
scored O
at O
the O
end O
of O
the O
evaluation O
period O
. O
['Life-Impact']

Sensitivity O
to O
musical O
structure O
in O
the O
human O
brain O
. O
[]

Postprandial B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
with O
oral B-outcome ['Physiological-Clinical']
estrogen B-outcome ['Physiological-Clinical']
treatment O
, O
both O
before O
( O
P O
< O
0.05 O
) O
and O
during O
( O
P O
< O
0.05 O
) O
GH O
administration O
, O
compared O
with O
transdermal O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

They O
were O
given O
intramuscular O
atropine O
( O
15 O
micrograms/kg O
) O
, O
glycopyrrolate O
( O
8 O
micrograms/kg O
) O
, O
scopolamine O
( O
8 O
micrograms/kg O
) O
, O
and O
placebo O
in O
a O
random O
double-blind O
cross-over O
design O
. O
[]

Sine O
wave O
grating O
contrast O
sensitivity B-outcome ['Physiological-Clinical']
testing O
under O
mesopic O
and O
photopic O
conditions O
served O
as O
the O
principal O
outcome O
measure O
. O
['Physiological-Clinical']

At O
1 O
year O
43.4 O
% O
and O
at O
2 O
years O
41.8 O
% O
of O
the O
intervention O
subjects O
had O
achieved O
a O
weight O
reduction O
of O
at O
least O
5 O
kg O
, O
while O
the O
corresponding O
figures O
for O
the O
control O
subjects O
were O
14.0 O
and O
12.0 O
% O
( O
P O
< O
0.001 O
between O
the O
groups O
) O
. O
[]

Pain B-outcome ['Physiological-Clinical']
assessments O
were O
performed O
prior O
to O
, O
and O
at O
4 O
, O
6 O
, O
and O
8 O
hours O
after O
medication O
. O
['Physiological-Clinical']

Participants O
will O
be O
randomized O
in O
a O
1:1 O
ratio O
between O
Arm O
1 O
( O
RT O
? O
[]

In O
individual O
subjects O
, O
the O
baseline-adjusted O
trough-to-peak O
ratios O
were O
nonnormally O
distributed O
. O
[]

Early O
effects O
of O
continuous O
low-dosage O
all-norgestrel O
administered O
alone O
or O
with O
estrogen O
. O
[]

Evaluation O
of O
apical O
sealing O
ability O
and O
adaptation O
to O
dentine O
of O
two O
resin-based O
sealers O
. O
[]

Four O
weeks O
after O
the O
completion O
of O
therapy O
a O
repeat O
13C-urea O
breath O
test O
was O
done O
to O
assess O
for O
cure O
. O
[]

Clinical O
variables O
included O
baseline O
illness O
severity O
ratings O
( O
the O
Aberrant O
Behavior O
Checklist O
, O
the O
Child O
and O
Adolescent O
Symptom O
Inventory O
, O
the O
Vineland O
Adaptive O
Behavior O
Scales O
, O
the O
Repetitive O
Behavior O
Scale-Revised O
, O
and O
the O
Children O
's O
Yale-Brown O
Obsessive-Compulsive O
Scale O
) O
. O
[]

No O
beneficial O
effect O
of O
the O
interferon B-outcome ['Physiological-Clinical']
on O
the O
course O
of O
MS O
could O
be O
shown O
. O
['Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
triazolam I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
by O
modified O
high-performance O
liquid O
chromatography O
, O
and O
pharmacokinetic B-outcome ['Physiological-Clinical']
values O
were O
calculated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
In O
the O
DCCT O
, O
the O
annual O
cost B-outcome ['Resource-use']
of I-outcome ['Resource-use']
intensive I-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
( O
$ O
4,000 O
and O
$ O
5,800/year O
for O
multiple O
daily O
injections O
and O
continuous O
subcutaneous O
insulin O
infusion O
, O
respectively O
) O
was O
approximately O
three O
times O
the O
cost O
of O
conventional B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
( O
$ O
1,700/year O
) O
. O
['Resource-use', 'Resource-use']

Information O
easily O
obtained O
on O
the O
ECG O
can O
accurately O
predict O
the O
likelihood O
of O
the O
LAD O
, O
right O
, O
or O
LC O
artery O
as O
the O
infarct-related O
artery O
. O
[]

All O
subjects O
were O
randomized O
to O
single O
dose O
sumatriptan O
( O
6 O
mg O
SQ O
) O
and O
placebo O
challenges O
, O
separated O
by O
a O
1-week O
interval O
, O
and O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
was O
measured O
before O
and O
during O
the O
challenges O
. O
['Physiological-Clinical']

The O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
of O
E-PEG O
group O
was O
5-16 O
( O
mean O
+/- O
SD O
: O
10.3 O
+/- O
2.96 O
) O
min O
as O
compared O
to O
14-37 O
( O
mean O
+/- O
SD O
: O
26.9 O
+/- O
8.39 O
) O
min O
with O
pull-method O
PEG O
. O
['Life-Impact']

Our O
aim O
was O
to O
assess O
the O
prevalence O
of O
breastfeeding O
in O
Beirut O
and O
determine O
the O
factors O
that O
impact O
breastfeeding O
behavior O
in O
this O
population O
. O
[]

RESULTS O
Data O
were O
collected O
from O
thirty O
cats O
. O
[]

Until O
now O
no O
studies O
have O
been O
performed O
to O
investigate O
whether O
Nordic O
Walking O
has O
beneficial O
effects O
in O
relation O
to O
low O
back O
pain O
. O
[]

Blood O
samples O
were O
collected O
before O
and O
at O
the O
end O
of O
each O
period O
. O
[]

In O
those O
having O
pain O
reduction O
> O
50 O
% O
, O
we O
made O
the O
same O
comparison O
during O
a O
migraine O
attack O
. O
[]

In O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
study O
we O
showed O
that O
treatment O
of O
hypertensive O
patients O
with O
ascorbic O
acid O
lowers O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Thus O
, O
increased O
plasma B-outcome ['Physiological-Clinical']
tyrosine I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in O
low-birth-weight O
infants O
are O
related O
directly O
both O
to O
the O
quantity O
and O
to O
the O
quality O
of O
the O
protein O
in O
their O
diets O
. O
['Physiological-Clinical']

OBJECTIVE O
The O
purpose O
of O
this O
prospective O
, O
randomized O
, O
double-blind O
study O
was O
to O
determine O
the O
effect O
of O
penicillin O
on O
pain O
in O
untreated O
teeth O
diagnosed O
with O
irreversible O
pulpitis O
. O
[]

Endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
brachial I-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
flow-mediated I-outcome ['Physiological-Clinical']
dilation I-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
FMD I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
measured O
at O
baseline O
, O
after O
fat O
gain O
( O
8 O
weeks O
) O
, O
and O
after O
weight O
loss O
( O
16 O
weeks O
) O
for O
fat O
gainers O
and O
at O
baseline O
and O
follow-up O
( O
8 O
weeks O
) O
for O
weight O
maintainers O
. O
['Physiological-Clinical']

[ O
Comparison O
of O
complications B-outcome ['Adverse-effects']
after O
intra- O
and O
extracapsular O
cataract O
extraction O
with O
lens O
implantation O
. O
['Adverse-effects']

We O
used O
chi2 O
and O
t O
tests O
to O
assess O
the O
statistical O
significance O
of O
associations O
between O
DUB O
characteristics O
and O
the O
financial O
and O
quality-of-life O
burden O
. O
[]

Randomized O
trial O
of O
angiotensin O
II-receptor O
blocker O
vs. O
dihydropiridine O
calcium O
channel O
blocker O
in O
the O
treatment O
of O
paroxysmal O
atrial O
fibrillation O
with O
hypertension O
( O
J-RHYTHM O
II O
study O
) O
. O
[]

BACKGROUND O
This O
study O
aimed O
to O
investigate O
the O
role O
of O
the O
effectiveness O
of O
camel O
milk O
( O
CM O
) O
( O
raw O
and O
boiled O
) O
on O
thymus B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
activation-regulated I-outcome ['Physiological-Clinical']
chemokine I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TARC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
levels O
and O
childhood B-outcome ['Life-Impact']
autism I-outcome ['Life-Impact']
rating O
scale O
( O
CARS O
) O
score O
in O
subjects O
with O
autism O
and O
compared O
to O
placebo O
group O
( O
cow O
milk O
) O
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
Fifty-five O
subjects O
completed O
the O
study O
. O
[]

BACKGROUND O
Torso O
weighting O
has O
sometimes O
been O
effective O
for O
improving O
upright B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
in O
people O
with O
multiple O
sclerosis O
, O
but O
parameters O
for O
weighting O
have O
been O
inconsistent O
. O
['Physiological-Clinical']

The O
curved O
tip O
was O
directed O
ventrally O
. O
[]

Chloroprocaine O
and O
lidocaine O
decrease O
hospital O
stay O
and O
admission O
rate O
after O
outpatient O
epidural O
anesthesia O
. O
[]

On O
long-term O
follow-up O
, O
about O
5 O
% O
of O
6-thioguanine O
recipients O
have O
evidence O
of O
non-cirrhotic B-outcome ['Physiological-Clinical']
portal I-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
due O
to O
periportal O
liver O
fibrosis O
or O
nodular O
regenerative O
hyperplasia O
. O
['Physiological-Clinical']

The O
results O
show O
that O
postprandial O
levels O
of O
both O
intact O
neurotensin O
and O
NH2-terminal O
immunoreactivity O
are O
related O
to O
the O
length O
of O
the O
functioning O
ileum O
and O
that O
even O
a O
difference O
in O
length O
of O
25 O
cm O
is O
reflected O
in O
the O
circulating O
levels O
of O
neurotensin O
. O
[]

In O
prospective O
face-to-face O
interviews O
, O
data O
were O
obtained O
on O
socio-demographic O
and O
lifestyle O
characteristics O
, O
psychosocial O
factors O
and O
clinic-related O
variables O
. O
[]

We O
investigated O
the O
performance O
of O
a O
group O
of O
high-functioning O
participants O
with O
ASD O
( O
N=15 O
) O
and O
an O
age- O
and O
IQ-matched O
control O
group O
( O
N=18 O
) O
on O
two O
executive O
function O
tests O
, O
whilst O
undergoing O
functional O
magnetic O
resonance O
imaging O
( O
fMRI O
) O
. O
[]

39 O
patients O
( O
32 O
% O
) O
in O
the O
standard O
diagnosis O
group O
and O
18 O
( O
15 O
% O
) O
in O
the O
biomarker O
diagnosis O
group O
received O
empirical O
antifungal O
treatment O
( O
difference O
17 O
% O
, O
95 O
% O
CI O
4-26 O
; O
p=0?002 O
) O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
failures I-outcome ['Physiological-Clinical']
occurred O
in O
201 O
( O
24.0 O
% O
) O
on O
placebo O
and O
166 O
( O
19.9 O
% O
) O
on O
amoxycillin O
( O
risk O
difference O
4.2 O
% O
in O
favour O
of O
antibiotic O
, O
95 O
% O
CI O
: O
0.2 O
to O
8.1 O
) O
. O
['Physiological-Clinical']

The O
actuarial O
survival B-outcome ['Mortality']
curves O
were O
performed O
according O
to O
Kaplan O
and O
Meier O
. O
['Mortality']

METHODS O
The O
TIOSPIR O
trial O
( O
NCT01126437 O
) O
compares O
the O
safety O
and O
efficacy O
of O
tiotropium O
Respimat O
5 O
?g O
once O
daily O
( O
marketed O
) O
and O
2.5 O
?g O
once O
daily O
( O
investigational O
) O
with O
tiotropium O
HandiHaler O
18 O
? O
[]

The O
purpose O
of O
this O
study O
was O
to O
compare O
apical O
seal O
of O
five O
different O
root O
canal O
sealers O
. O
[]

CONCLUSIONS O
Endocervical O
sampling O
should O
not O
influence O
management O
when O
colposcopy O
is O
unsatisfactory O
. O
[]

RESULTS O
A O
total O
of O
13 O
test O
and O
15 O
control O
subjects O
completed O
the O
original O
three-month O
trial O
, O
of O
whom O
10 O
test O
and O
13 O
control O
subjects O
finished O
the O
three-month O
extension O
. O
[]

Peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
mononuclear I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
from O
seven O
Chinese O
control O
individuals O
comprised O
63 O
+/- O
3 O
% O
CD3+ O
cells O
, O
of O
which O
41 O
+/- O
4 O
% O
were O
of O
CD4+ O
and O
23 O
+/- O
2 O
% O
of O
CD8+ O
subsets O
. O
['Physiological-Clinical']

Outcome O
of O
children O
with O
centrally O
reviewed O
low-grade O
gliomas O
treated O
with O
chemotherapy O
with O
or O
without O
radiotherapy O
on O
Children O
's O
Cancer O
Group O
high-grade O
glioma O
study O
CCG-945 O
. O
[]

OBJECTIVES O
Because O
preventing O
disability B-outcome ['Life-Impact']
and O
falls B-outcome ['Life-Impact']
in O
older O
adults O
is O
a O
national O
priority O
, O
a O
randomized O
controlled O
trial O
was O
conducted O
to O
test O
a O
multicomponent O
intervention O
program O
. O
['Life-Impact', 'Life-Impact']

BACKGROUND O
To O
evaluate O
resource B-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
and O
direct B-outcome ['Resource-use']
economic I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
of O
care O
for O
patients O
treated O
with O
negative-pressure O
wound O
therapy O
( O
NPWT O
) O
, O
using O
the O
Vacuum-Assisted O
Closure O
( O
V.A.C O
. O
) O
['Resource-use', 'Resource-use']

The O
assignment O
of O
the O
knee O
to O
navigation O
or O
not O
was O
done O
randomly O
. O
[]

Results O
of O
the O
study O
showed O
that O
dexmedetomidine O
is O
more O
effective O
and O
safer O
than O
trimeperidine O
for O
analgesia B-outcome ['Resource-use']
and O
sedation B-outcome ['Physiological-Clinical']
in O
patients O
with O
spontaneous O
breathing O
after O
abdominal O
surgery O
. O
['Resource-use', 'Physiological-Clinical']

Subjects O
were O
instructed O
to O
lift O
their O
upper O
trunk O
from O
a O
prone O
position O
antigravity O
and O
maintain O
the O
neutral O
position O
. O
[]

Does O
a O
first O
trimester O
dating O
scan O
using O
crown O
rump O
length O
measurement O
reduce O
the O
rate O
of O
induction O
of O
labour B-outcome ['Physiological-Clinical']
for O
prolonged B-outcome ['Physiological-Clinical']
pregnancy B-outcome ['Physiological-Clinical']
? O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

STUDY O
DESIGN O
The O
study O
involved O
82 O
overweight O
adults O
participating O
in O
the O
Lifestyle O
Intervention O
Treatment O
Evaluation O
( O
LITE O
) O
follow-up O
study O
at O
Oulu O
University O
Hospital O
in O
northern O
Finland O
. O
[]

A O
pre-test-post-test O
randomized-groups O
design O
was O
conducted O
. O
[]

A O
Phase O
I O
trial O
was O
performed O
to O
investigate O
the O
safety O
and O
immunogenicity B-outcome ['Physiological-Clinical']
of O
the O
third O
generation O
smallpox O
vaccine O
MVA-BN O
( O
IMVAMUNE O
) O
, O
a O
highly O
attenuated O
clone O
derived O
from O
the O
Modified O
Vaccinia O
Virus O
Ankara O
strain O
571 O
, O
in O
naive O
and O
pre-immunized O
subjects O
. O
['Physiological-Clinical']

The O
ICT O
patients O
were O
in O
the O
hospital O
a O
mean O
time O
of O
7.5 O
( O
4 O
to O
15 O
) O
days O
and O
the O
VATS O
patients O
, O
5.3 O
( O
2 O
to O
7 O
) O
days O
( O
P O
< O
.05 O
) O
. O
[]

SETTING O
Outpatient O
with O
sleep O
laboratory O
assessments O
in O
months O
1 O
and O
8 O
of O
treatment O
. O
[]

CONCLUSIONS O
Basic O
treatment O
plus O
medical O
ozone O
therapy O
for O
patients O
with O
chronic O
severe O
hepatitis O
could O
decrease O
PRA O
, O
AII O
and O
ALD O
levels O
significantly O
increase O
renal O
blood O
flow O
, O
prevent O
renal O
damage O
to O
certain O
extent O
and O
improve O
survival O
rate O
of O
the O
patients O
. O
[]

Type O
of O
[]

If O
occult O
TR O
is O
identified O
during O
or O
at O
the O
end O
of O
planned O
therapy O
, O
a O
higher B-outcome ['Physiological-Clinical']
salvage I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
may O
require O
intensified O
alternate O
therapy O
. O
['Physiological-Clinical']

We O
conclude O
that O
an O
intervention O
that O
reduces O
rates O
of O
childhood B-outcome ['Physiological-Clinical']
diarrhea I-outcome ['Physiological-Clinical']
may O
not O
necessarily O
also O
improve O
nutritional B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Two O
hundred O
fifty-seven O
healthy O
female O
subjects O
, O
15 O
to O
49 O
years O
of O
age O
with O
moderate O
acne O
vulgaris O
, O
were O
enrolled O
in O
a O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
clinical O
trial O
. O
[]

Immune O
reconstitution O
was O
studied O
in O
115 O
patients O
randomly O
assigned O
to O
receive O
either O
allogeneic O
marrow O
or O
filgrastim-mobilized O
blood O
stem O
cell O
transplantation O
. O
[]

The O
mean O
rate O
of O
substitutions O
of O
calcium O
by O
strontium O
ions O
was O
4.5 O
% O
. O
[]

PARTICIPANTS O
100 O
neurosurgical O
patients O
and O
40 O
patients O
with O
leukaemia O
who O
required O
chemotherapy O
. O
[]

PARTICIPANTS O
Three O
hundred O
eighty-nine O
subjects O
with O
acute O
optic O
neuritis O
. O
[]

BACKGROUND O
Central O
nervous O
system O
adverse O
effects O
, O
such O
as O
sedation B-outcome ['Physiological-Clinical']
, O
often O
accompany O
the O
use O
of O
first-generation O
antihistamines O
. O
['Physiological-Clinical']

METHODS O
Twelve O
patients O
with O
RA O
entering O
a O
randomized O
clinical O
trial O
of O
human O
recombinant O
IL-1Ra O
underwent O
synovial O
biopsies O
before O
and O
after O
treatment O
. O
[]

INTERVENTION O
A O
targeted O
, O
multi-component O
disability O
prevention O
and O
disease O
self-management O
program O
led O
by O
a O
geriatric O
nurse O
practitioner O
( O
GNP O
) O
. O
[]

CONCLUSIONS O
Imidafenacin O
was O
non-inferior O
to O
fesoterodine O
in O
terms O
of O
efficacy O
, O
and O
showed O
no O
significant O
difference O
in O
terms O
of O
safety O
. O
[]

After O
a O
mean O
duration O
of O
GH B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
of O
8.6 O
+/- O
1.9 O
yr O
, O
FH O
was O
reached O
at O
a O
mean O
age O
of O
15.8 O
+/- O
0.9 O
yr. O
FH B-outcome ['Physiological-Clinical']
, O
expressed O
in O
centimeters O
or O
SD O
score O
, O
was O
157.6 O
+/- O
6.5 O
or O
-1.6 O
+/- O
1.0 O
in O
group O
A O
, O
162.9 O
+/- O
6.1 O
or O
-0.7 O
+/- O
1.0 O
in O
group O
B O
, O
and O
163.6 O
+/- O
6.0 O
or O
-0.6 O
+/- O
1.0 O
in O
group O
C. O
The O
difference O
in O
FH B-outcome ['Physiological-Clinical']
in O
centimeters O
, O
corrected O
for O
height O
SD O
score O
and O
age O
at O
start O
of O
treatment O
, O
was O
significant O
between O
groups O
A O
and O
B O
[ O
regression O
coefficient O
, O
4.1 O
; O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
1.4 O
, O
6.9 O
; O
P O
< O
0.01 O
] O
, O
and O
groups O
A O
and O
C O
( O
coefficient O
, O
5.0 O
; O
95 O
% O
CI O
, O
2.3 O
, O
7.7 O
; O
P O
< O
0.001 O
) O
, O
but O
not O
between O
groups O
B O
and O
C O
( O
coefficient O
, O
0.9 O
; O
95 O
% O
CI O
, O
-1.8 O
, O
3.6 O
) O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Six O
treatment O
groups O
were O
P10T26 O
( O
10 O
mg O
PN O
+ O
ambient O
temperature O
( O
26 O
?C O
) O
, O
P0T33 O
( O
0 O
mg O
PN O
+ O
ET O
) O
, O
P10T33 O
( O
10 O
mg O
PN O
+ O
ET O
) O
, O
P50T33 O
( O
50 O
mg O
PN O
+ O
ET O
) O
, O
P100T33 O
( O
100 O
mg O
PN O
+ O
ET O
) O
and O
P200T33 O
( O
200 O
mg O
PN O
+ O
ET O
) O
. O
[]

Contrary O
to O
expectations O
, O
findings O
revealed O
that O
patients O
characterized O
by O
more O
severe O
pretreatment O
trauma-related O
cognitions O
( O
and O
more O
severe O
pretreatment O
PTSD O
symptoms O
) O
fared O
slightly O
worse O
in O
treatment O
combining O
exposure O
and O
cognitive O
restructuring O
. O
[]

Indomethacin O
did O
not O
affect O
the O
cerebral B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
, O
the O
arteriovenous B-outcome ['Physiological-Clinical']
difference I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
lactate I-outcome ['Physiological-Clinical']
, O
or O
the O
lactate/oxygen B-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
, O
suggesting O
that O
indomethacin O
did O
not O
provoke O
global O
cerebral O
ischemia O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
conclusion O
, O
neither O
aprindine O
nor O
digoxin O
had O
a O
significant O
effect O
on O
preventing O
relapse B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptomatic I-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
; O
however O
, O
recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
occurred O
later O
with O
aprindine O
than O
with O
placebo O
or O
digoxin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
a O
randomized O
diltiazem-placebo-controlled O
therapeutic O
trial O
of O
non-Q-wave O
AMI O
confirmed O
by O
creatine O
kinase-MB O
( O
CK-MB O
) O
, O
126 O
of O
544 O
patients O
( O
23 O
% O
) O
exhibited O
LV O
hypertrophy O
using O
standard O
voltage O
criteria O
. O
[]

Antihypertensive B-outcome ['Resource-use']
efficacy O
of O
cetamolol O
: O
a O
dose-titrated O
study O
. O
['Resource-use']

There O
was O
no O
significant O
difference O
between O
PSA-D O
and O
PSA-T O
. O
[]

Short-term O
effects O
of O
systemic O
antibiotics O
during O
periodontal O
healing O
. O
[]

The O
rating O
scheme O
has O
good O
discriminatory O
power O
and O
reliability O
and O
shows O
promise O
as O
a O
broadly O
applicable O
and O
inexpensive O
tool O
for O
intervention O
needs O
assessment O
and O
effectiveness O
evaluation O
. O
[]

In O
the O
remaining O
patients O
from O
each O
group O
, O
DBP B-outcome ['Physiological-Clinical']
was O
not O
reduced O
by O
either O
drug O
given O
alone O
at O
maximum O
allowable O
dosages O
during O
dose-finding O
periods O
, O
nor O
by O
combined O
administration O
in O
following O
weeks O
. O
['Physiological-Clinical']

1.0 O
ml O
doses O
of O
a O
schedule O
of O
immunization O
on O
days O
0 O
, O
7 O
and O
21 O
. O
[]

Fifteen O
low-scoring O
individuals O
and O
14 O
high-scoring O
individuals O
derived O
from O
a O
normal O
population O
participated O
in O
the O
study O
. O
[]

The O
cardiovascular B-outcome ['Mortality']
death I-outcome ['Mortality']
in O
the O
therapy O
group O
was O
due O
to O
stroke O
. O
['Mortality']

This O
objective O
improvement O
was O
associated O
with O
a O
subjective O
improvement O
. O
[]

RT O
substantially O
reduced O
loco-regional B-outcome ['Physiological-Clinical']
recurrences I-outcome ['Physiological-Clinical']
among O
both O
pre- O
and O
postmenopausal O
patients O
( O
relative O
hazard O
RT O
versus O
CT O
: O
0.67 O
and O
0.43 O
, O
respectively O
) O
. O
['Physiological-Clinical']

Group O
B O
patients O
continued O
on O
full-dose O
( O
1,200 O
mg/d O
) O
zidovudine O
therapy O
while O
beginning O
GM-CSF O
therapy O
. O
[]

Seventy-five O
toddlers O
with O
autism O
spectrum O
disorder O
( O
65 O
autism O
, O
10 O
PDD-NOS O
, O
mean O
age O
= O
34.4 O
months O
, O
SD O
= O
6.2 O
) O
were O
enrolled O
. O
[]

The O
walking B-outcome ['Life-Impact']
pattern I-outcome ['Life-Impact']
was O
improved O
for O
both O
groups O
, O
with O
a O
significant O
increase O
of O
the O
duration O
of O
the O
paretic B-outcome ['Physiological-Clinical']
limb I-outcome ['Physiological-Clinical']
single I-outcome ['Physiological-Clinical']
stance I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

SETTING O
The O
trial O
was O
conducted O
in O
a O
15-bed O
medical-surgical O
university-affiliated O
intensive O
care O
unit O
( O
ICU O
) O
. O
[]

Twenty-five O
percent O
of O
the O
children O
with O
IIT O
experienced O
hypoglycemia O
, O
which O
may O
have O
evoked O
counterregulatory O
responses O
. O
[]

Bacteremia O
resulting O
from O
dental O
extraction O
is O
regarded O
as O
an O
important O
cause O
of O
bacterial O
endocarditis O
, O
and O
it O
is O
therefore O
recommended O
that O
patients O
undergoing O
tooth O
extraction O
be O
given O
prophylactic O
antibiotics O
. O
[]

Zeaxanthin O
bioavailability O
from O
the O
hot O
milk O
formulation O
was O
significantly O
higher O
( O
P O
< O
0.001 O
) O
than O
from O
the O
others O
. O
[]

Ambient O
levels O
of O
sevoflurane O
and O
N2O O
were O
measured O
in O
the O
breathing O
area O
around O
the O
anesthesiologist O
. O
[]

One O
hundred O
fifty-seven O
patients O
were O
screened O
for O
cognitive O
deficits O
following O
HSCT O
for O
malignant O
diseases O
at O
an O
in-patient O
oncologic O
rehabilitation O
clinic O
. O
[]

CONCLUSIONS O
Two O
weeks O
seems O
to O
be O
a O
sufficient O
duration O
to O
allow O
functional O
restoration O
across O
the O
ureteropelvic O
junction O
after O
endopyelotomy O
and O
decrease O
stent B-outcome ['Adverse-effects']
related I-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
. O
['Adverse-effects']

In O
the O
S-1+paclitaxel O
and O
S-1+cisplatin O
groups O
, O
RRs O
( O
52.3 O
% O
vs O
48.7 O
% O
; O
P=0.74 O
) O
and O
median O
PFS O
( O
9 O
vs O
6 O
months O
; O
P=0.50 O
) O
were O
similar O
. O
[]

The O
choice O
of O
VLASU O
as O
a O
method O
of O
treatment O
significantly O
decreased O
the O
probability O
of O
therapeutic B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
and O
recurrence O
of O
urethral B-outcome ['Physiological-Clinical']
strictures I-outcome ['Physiological-Clinical']
( O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

